<SEC-DOCUMENT>0001104659-23-004454.txt : 20230118
<SEC-HEADER>0001104659-23-004454.hdr.sgml : 20230118
<ACCEPTANCE-DATETIME>20230118074922
ACCESSION NUMBER:		0001104659-23-004454
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		56
FILED AS OF DATE:		20230118
DATE AS OF CHANGE:		20230118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sesen Bio, Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267891
		FILM NUMBER:		23532939

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-444-8550

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>tm2227887-13_s4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<html>
  <head>
    <title>tm2227887-13_s4a - block - 139.7037644s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:775.71pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">

          <div style="text-align:center; width:541.31pt; line-height:10.5pt;font-weight:bold;">
            <font style="letter-spacing:-0.17pt;">As filed with the Securities and Exchange Commission on January 18, 2023</font><font style="font-weight:normal;letter-spacing:0.17pt;"> </font>
          </div>

        <div style="margin-left:20pt; margin-top:0.7pt; text-align:right; width:521.31pt; line-height:10.5pt;font-weight:bold;font-size:8.8pt;">
          <font style="letter-spacing:-0.176pt;">Registration No. 333-267891</font>&#8203;</div>
        <div style="margin-top:4.333pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 4.33333333333333pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.7pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.7pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5.51pt; text-align:center; width:541.31pt; line-height:15.5pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">UNITED STATES</font>
          <br >
          <font style="letter-spacing:-0.28pt;">SECURITIES AND EXCHANGE COMMISSION </font>
          <br >
          <font style="font-size:9pt;letter-spacing:-0.18pt;">Washington, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>

          <div style="margin-top:1pt; text-align:center; width:541.31pt; line-height:10.5pt;font-weight:bold;font-size:8.8pt;">
            <font style="letter-spacing:-0.176pt;">Amendment No. 4</font>
            <br >
            <font style="letter-spacing:-0.176pt;">to</font><font style="font-weight:normal;letter-spacing:0.176pt;"> </font>
          </div>

        <div style="margin-top:1.7pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">FORM S-4</font>
        </div>
        <div style="margin-top:1.7pt; text-align:center; width:541.31pt; line-height:10.5pt;font-style:italic;font-weight:bold;font-size:8.8pt;">
          <font style="font-style:normal;letter-spacing:-0.176pt;">REGISTRATION STATEMENT</font>
          <br >
          <font style="letter-spacing:-0.176pt;">UNDER </font>
          <br >
          <font style="letter-spacing:-0.176pt;">THE SECURITIES ACT OF 1933</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.176pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">SESEN BIO, INC.</font>
        </div>
        <div style="margin-top:-1.3pt; text-align:center; width:541.31pt; line-height:10pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Exact name of registrant as specified in its charter)</font><font style="font-size:8.8pt;">&#8203;<font style="letter-spacing:0.176pt;"> </font></font>
        </div>
        <table style="width:541.31pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
          <tr style="line-height:9pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;font-weight:bold;font-size:8.5pt;">
                <font style="letter-spacing:-0.17pt;">Delaware</font>
              </div>
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">(State or other jurisdiction of</font>
                <br >
                <font style="letter-spacing:0.16pt;">incorporation or organization)</font><font style="font-size:8.5pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;font-weight:bold;font-size:8.5pt;">
                <font style="letter-spacing:-0.17pt;">2834</font>
              </div>
              <div style="text-align:center; line-height:8pt;">
                <font style="letter-spacing:0.16pt;">(Primary Standard Industrial</font>
                <br >
                <font style="letter-spacing:0.16pt;">Classification Code Number) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center;font-weight:bold;font-size:8.5pt;">
                <font style="letter-spacing:-0.17pt;">26-2025616</font>
              </div>
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">(I.R.S. Employer</font>
                <br >
                <font style="letter-spacing:0.16pt;">Identification Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.71pt; text-align:center; width:541.31pt; line-height:10.5pt;font-weight:bold;font-size:8.8pt;">
          <font style="letter-spacing:-0.176pt;">245 First Street, Suite 1800 </font>
          <br >
          <font style="letter-spacing:-0.176pt;">Cambridge, MA 02142</font>
          <br >
          <font style="letter-spacing:-0.176pt;">(617) 444-8550</font>
        </div>
        <div style="margin-top:1.7pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Address including zip code, and telephone number, including</font>
          <br >
          <font style="letter-spacing:0.16pt;">area code, of registrant&#8217;s principal executive offices)</font><font style="font-size:8.8pt;">&#8203;<font style="letter-spacing:0.176pt;"> </font></font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:541.31pt; line-height:10.5pt;font-weight:bold;font-size:8.8pt;">
          <font style="letter-spacing:-0.176pt;">Thomas R. Cannell, D.V.M.</font>
          <br >
          <font style="letter-spacing:-0.176pt;">President and Chief Executive Officer</font>
          <br >
          <font style="letter-spacing:-0.176pt;">Sesen Bio, Inc.</font>
          <br >
          <font style="letter-spacing:-0.176pt;">245 First Street, Suite 1800</font>
          <br >
          <font style="letter-spacing:-0.176pt;">Cambridge, MA 02142</font>
          <br >
          <font style="letter-spacing:-0.176pt;">(617) 444-8550</font>
        </div>
        <div style="margin-top:1.7pt; text-align:center; width:541.31pt; line-height:10pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font><font style="font-size:8.8pt;">&#8203;<font style="letter-spacing:0.176pt;"> </font></font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:541.31pt; line-height:10.5pt;font-style:italic;font-weight:bold;font-size:8.8pt;">
          <font style="letter-spacing:-0.176pt;">Copies to:</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.176pt;"> </font>
        </div>
        <table style="width:541.31pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
          <tr style="line-height:10.2pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">Steven J. Abrams</font>
                <br >
                <font style="letter-spacing:0.17pt;">Tiffany Posil</font>
                <br >
                <font style="letter-spacing:0.17pt;">Jessica A. Bisignano</font>
                <br >
                <font style="letter-spacing:0.17pt;">Hogan Lovells US LLP</font>
                <br >
                <font style="letter-spacing:0.17pt;">1735 Market Street, 23</font><font style=" position:relative; bottom:3.5pt;font-size:6.5pt;letter-spacing:0.13pt;">rd</font><font style="letter-spacing:0.17pt;"> Floor</font>
                <br >
                <font style="letter-spacing:0.17pt;">Philadelphia, PA 19103</font>
                <br >
                <font style="letter-spacing:0.17pt;">(267) 675-4600 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">Steven Kelly</font>
                <br >
                <font style="letter-spacing:0.17pt;">President and Chief Executive Officer</font>
                <br >
                <font style="letter-spacing:0.17pt;">CARISMA Therapeutics Inc.</font>
                <br >
                <font style="letter-spacing:0.17pt;">3675 Market Street, Suite 200</font>
                <br >
                <font style="letter-spacing:0.17pt;">Philadelphia, PA 19104</font>
                <br >
                <font style="letter-spacing:0.17pt;">(267) 491-6422 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:172.43pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.17pt;">Brian A. Johnson</font>
                <br >
                <font style="letter-spacing:0.17pt;">Hal J. Leibowitz</font>
                <br >
                <font style="letter-spacing:0.17pt;">Christopher D. Barnstable-Brown</font>
                <br >
                <font style="letter-spacing:0.17pt;">Wilmer Cutler Pickering Hale and Dorr LLP</font>
                <br >
                <font style="letter-spacing:0.17pt;">7 World Trade Center</font>
                <br >
                <font style="letter-spacing:0.17pt;">250 Greenwich Street</font>
                <br >
                <font style="letter-spacing:0.17pt;">New York, NY 10007</font>
                <br >
                <font style="letter-spacing:0.17pt;">(212) 230-8800</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.7pt; width:541.31pt; line-height:10.5pt;font-size:8.8pt;">
          <font style="font-weight:bold;letter-spacing:-0.176pt;">Approximate date of commencement of proposed sale of the securities to the public:</font><font style="letter-spacing:0.176pt;"> As soon as practicable after the effectiveness of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:10.5pt;font-size:8.8pt;">
          <font style="letter-spacing:0.176pt;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:10.5pt;font-size:8.8pt;">
          <font style="letter-spacing:0.176pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:10.5pt;font-size:8.8pt;">
          <font style="letter-spacing:0.176pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:10.5pt;font-size:8.8pt;">
          <font style="letter-spacing:0.176pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </font>
        </div>
        <table style="width:421.31pt;height:30.39pt;margin-left:60pt;margin-top:6pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
          <tr style="line-height:8.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:128.51pt;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Large accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:0.17pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:82.15pt;">&#8203;</td>
            <td style="padding:0pt; width:82.15pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:128.5pt;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:0.17pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 0.5pt 0pt; width:128.51pt;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Non-accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:0.17pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:82.15pt;">&#8203;</td>
            <td style="padding:0pt; width:82.15pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 0.5pt 0pt; width:128.5pt;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Smaller reporting company</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:0.17pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:128.51pt;">&#8203;</td>
            <td style="padding:0pt; width:82.15pt;">&#8203;</td>
            <td style="padding:0pt; width:82.15pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 0.5pt 0pt; width:128.5pt;white-space:normal;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Emerging growth company</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:0.17pt;">&#9744;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:-3.2pt; width:541.31pt; line-height:10.5pt;font-size:8.8pt;">
          <font style="letter-spacing:0.176pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744; </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; width:521.31pt; line-height:10.5pt;font-size:8.8pt;">
          <font style="letter-spacing:0.176pt;">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; width:521.31pt; line-height:10.5pt;font-size:8.8pt;">
          <font style="letter-spacing:0.176pt;">Exchange Act Rule&#160;13e-4(i) (Cross-Border Issuer Tender Offer) &#9744; </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; width:521.31pt; line-height:10.5pt;font-size:8.8pt;">
          <font style="letter-spacing:0.176pt;">Exchange Act Rule&#160;14d-1(d) (Cross-Border Third-Party Tender Offer) &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:10.5pt;font-weight:bold;font-size:8.8pt;">
          <font style="letter-spacing:-0.176pt;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</font><font style="font-weight:normal;letter-spacing:0.176pt;"> </font>
        </div>
        <div style="margin-top:4.433pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 4.43333333333339pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.8pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.79999999999995pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow-x:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.83pt;left:48.66pt;height:30.02pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">
          <font style="letter-spacing:-0.08pt;">The information in this proxy statement/prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.08pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:87.66pt;width:456pt;">

          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;color:#FC0014;">
            <font style="letter-spacing:-0.2pt;">Subject to completion, dated January 18, 2023</font><font style="font-weight:normal;color:#000000;letter-spacing:0.2pt;"> </font>
          </div>

        <table style="width:456pt;margin-top:5pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="height:96pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:222pt;">
              <div style="position:relative;text-align:center;">
                <img src="lg_sesenbio-4c.jpg" alt="[MISSING IMAGE: lg_sesenbio-4c.jpg]" height="117" width="197" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:36pt 0pt 20pt 0pt; width:222pt;text-align:left;vertical-align:bottom;">
              <div style="position:relative;text-align:center;">
                <img src="lg_carismatherapeutics-4c.jpg" alt="[MISSING IMAGE: lg_carismatherapeutics-4c.jpg]" height="53" width="200" >
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.7pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSED MERGER</font>
          <br >
          <font style="letter-spacing:-0.2pt;">YOUR VOTE IS VERY IMPORTANT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:3pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the stockholders of Sesen Bio, Inc. and CARISMA Therapeutics Inc.: </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio, Inc., a Delaware corporation, or Sesen Bio, and CARISMA Therapeutics Inc., a Delaware corporation, or Carisma, entered into an Agreement and Plan of Merger and Reorganization on September&#160;20, 2022, which was subsequently amended on December 29, 2022, collectively referred to herein as the Merger Agreement, pursuant to which a wholly-owned subsidiary of Sesen Bio will merge with and into Carisma, with Carisma surviving as a wholly-owned subsidiary of Sesen Bio, which transaction is referred to herein as the merger. We refer to the surviving corporation following the merger as the combined company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">At the effective time of the merger, each outstanding share of Carisma capital stock (including shares of Carisma common stock issued in connection with the Carisma pre-closing financing described below) will be converted into the right to receive a number of shares of Sesen Bio common stock equal to the exchange ratio described in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201; Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tTMAER">172</a> of the accompanying proxy statement/prospectus. Also at the effective time of the merger, each outstanding option to purchase shares of Carisma common stock will be assumed by Sesen Bio and will be converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the exchange ratio. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s capitalization as of December 29, 2022, the date the Merger Agreement Amendment was executed, the exchange ratio is estimated to be approximately 37.7924 shares of Sesen Bio common stock for each share of Carisma capital stock, which exchange ratio does not give effect to the proposed reverse stock split described in the accompanying proxy statement/prospectus. The final exchange ratio is subject to adjustment prior to the closing of the merger based on Sesen Bio&#8217;s net cash at the closing of the merger and the aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company.</font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Immediately prior to the consummation of the merger, certain investors have agreed to purchase shares of Carisma common stock, at a purchase price of $15.60 per share, for an aggregate purchase price of approximately $30.6&#160;million. We refer to this transaction as the Carisma pre-closing financing. The closing of the Carisma pre-closing financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the merger set forth in the Merger Agreement. The shares of Carisma common stock that are issued in the Carisma pre-closing financing will be converted into the right to receive a number of shares of Sesen Bio common stock equal to the exchange ratio described in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page&#160;<a href="#tTMAER">172</a> of the accompanying proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus.</font></div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Each share of Sesen Bio common stock, each option to purchase Sesen Bio common stock and each Sesen Bio restricted stock unit that is outstanding at the effective time of the merger will remain outstanding in accordance with its terms and such shares of common stock, options and restricted stock&#160;units, subject to the proposed reverse stock split, will be unaffected by the merger. Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 25.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, are expected to own approximately 74.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of closing of the merger being at least $75.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Additionally, at or prior to the effective time of the merger, Sesen Bio will enter into a Contingent Value Rights Agreement and, as provided in the Merger Agreement, Sesen Bio will declare a dividend payable to Sesen Bio stockholders of record as of a date agreed to by Sesen Bio and Carisma prior to the effective time of the merger with respect to the receipt of one contingent value right, or a CVR, for each outstanding share of Sesen Bio common stock held by such stockholders on such date. Each CVR will </font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">represent the contractual right to receive contingent cash payments upon the receipt by Sesen Bio of certain proceeds payable by F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., or collectively, Roche, if any, pursuant to the Asset Purchase Agreement by and among Sesen Bio and Roche, or the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, prior to the closing of the merger, Sesen Bio will, in addition to the CVRs, declare a special cash dividend to Sesen Bio stockholders of record prior to the merger, which would be contingent upon Sesen Bio stockholder approval of Proposal Nos. 1 and 2 and the satisfaction or waiver of other customary closing conditions to the merger. The amount of the special cash dividend will be the amount by which Sesen Bio&#8217;s estimated net cash as of the closing of the merger exceeds $75.0 million. </font>
        </div>

          <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio common stock is currently listed on the Nasdaq Capital Market under the symbol &#8220;SESN.&#8221; Sesen Bio has filed an initial listing application for the combined company with the Nasdaq Capital Market. After completion of the merger, Sesen Bio is expected to be renamed &#8220;Carisma Therapeutics Inc.&#8221; and to trade under the symbol &#8220;CARM.&#8221; On January 17, 2023, the last trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of Sesen Bio common stock was $0.6493 per share. </font>
          </div>


          <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio stockholders are cordially invited to attend the special meeting of Sesen Bio stockholders, or the Sesen Bio special meeting, which is being held in order to obtain the stockholder approvals necessary to complete the merger and related matters. The Sesen Bio special meeting will be held at 10:00 a.m., Eastern Time, on Thursday, March 2, 2023, unless postponed or adjourned to a later date, for the purpose of considering and voting upon the matters set forth in the Notice of Special Meeting of Stockholders and the accompanying proxy statement/prospectus. The Sesen Bio special meeting will be a virtual meeting held exclusively via live webcast. Sesen Bio stockholders will be able to attend the meeting online, vote during the meeting until polls are closed, and submit questions during the meeting by registering in advance at www.proxydocs.com/SESN. </font>
          </div>

        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described in the accompanying proxy statement/prospectus, certain Carisma stockholders (solely in their respective capacities as Carisma stockholders) holding approximately 97.23% of the outstanding shares of Carisma capital stock as of January 4, 2023 (subject to customary cutbacks in the event of certain triggering events) and certain Sesen Bio stockholders (solely in their respective capacities as Sesen Bio stockholders), are parties to support agreements with Carisma and Sesen Bio whereby such stockholders have agreed, subject to the effectiveness of the registration statement on Form&#160;S-4, to vote their shares in favor of the transactions contemplated therein, including, with respect to such Carisma stockholders, adoption of the Merger Agreement and approval of the merger and, with respect to such Sesen Bio stockholders, the issuance of Sesen Bio common stock in the merger pursuant to the Merger Agreement, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form S-4, of which the accompanying proxy statement/prospectus is a part, and pursuant to the Merger Agreement and the support agreements, Carisma stockholders holding a sufficient number of shares of Carisma capital stock to adopt the Merger Agreement and approve the merger and related transactions are expected to execute written consents providing for such adoption and approval, subject to the terms and limitations set forth in the support agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After careful consideration, each of the Sesen Bio and Carisma boards of directors have approved the Merger Agreement and have determined that it is advisable to consummate the merger. The Sesen Bio board of directors has approved the proposals described in the accompanying proxy statement/prospectus and unanimously recommends that its stockholders vote &#8220;FOR&#8221; the proposals described in the accompanying proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">More information about Sesen Bio, Carisma, the Merger Agreement and the transactions contemplated thereby and the proposals being considered at the Sesen Bio special meeting is contained in the accompanying proxy statement/prospectus. Sesen Bio urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER THE SECTION ENTITLED &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE&#160;<a href="#tRIFA">26</a> OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Carisma are excited about the opportunities the proposed merger brings to both Sesen Bio&#8217;s and Carisma&#8217;s stockholders, and thank you for your consideration and continued support. </font>
        </div>
        <table style="width:436pt;height:40pt;margin-left:20pt;margin-top:4.60000000000002pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">Steven Kelly </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">President and Chief Executive Officer</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">President and Chief Executive Officer</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">Sesen Bio, Inc. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">CARISMA Therapeutics Inc.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/</font>&#8203;<font style="letter-spacing:-0.2pt;">prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:3pt; width:456pt; line-height:11.5pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying proxy statement/prospectus is dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, and is first being mailed to Sesen Bio stockholders on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:3pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;text-align:center; width:456pt;">
          <img src="lg_sesenbio-4c.jpg" alt="[MISSING IMAGE: lg_sesenbio-4c.jpg]" height="117" width="197" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font>
          <br >
          <font style="letter-spacing:-0.2pt;">245 First Street, Suite 1800</font>
          <br >
          <font style="letter-spacing:-0.2pt;">Cambridge, MA 02142</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(617) 444-8550</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS</font>
            <br >
            <font style="letter-spacing:-0.2pt;">TO BE HELD ON MARCH 2, 2023</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dear stockholders of Sesen Bio, Inc.: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On behalf of the board of directors of Sesen Bio, Inc., a Delaware corporation, or Sesen Bio, we are pleased to deliver this proxy statement/prospectus for a special meeting of stockholders of Sesen Bio, including any adjournment or postponement thereof, or the Sesen Bio special meeting, and for the proposed transactions between Sesen Bio and CARISMA Therapeutics Inc., a Delaware corporation, or Carisma, pursuant to which Seahawk Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Sesen Bio, or Merger Sub, will merge with and into Carisma, with Carisma surviving as a wholly-owned subsidiary of Sesen Bio, or the merger. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Sesen Bio special meeting will be a virtual meeting held exclusively via live webcast on March 2, 2023 at 10:00 a.m. Eastern Time for the following purposes: </font>
          </div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock, $0.001 par value per share, or Sesen Bio common stock, to stockholders of Carisma pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated as of September&#160;20, 2022, or the Original Merger Agreement, and as amended by the First Amendment thereto, dated as of December 29, 2022, or the Merger Agreement Amendment and, together with the Original Merger Agreement, the Merger Agreement, by and among Sesen Bio, Merger Sub and Carisma, copies of which are attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex A-1</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex A-2</font><font style="letter-spacing:0.2pt;">, respectively, to the accompanying proxy statement/prospectus, and the change of control of Sesen Bio resulting from the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an amendment to the restated certificate of incorporation of Sesen Bio, as amended, or the Sesen Bio Certificate of Incorporation, to (a) effect a reverse stock split of the issued and outstanding shares of Sesen Bio common stock, at a ratio of 1-for-20, with the implementation and timing of the reverse stock split to be determined in the discretion of the Sesen Bio board of directors and as agreed to by Carisma at or prior to the closing of the merger, or in the sole discretion of the Sesen Bio board of directors if Proposal No. 1 is not approved, and (b) if and when the reverse stock split is effected, reduce the number of authorized shares of Sesen Bio common stock to 100,000,000, in the form attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex G</font><font style="letter-spacing:0.2pt;"> to the accompanying proxy statement/prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an amendment and restatement of the Sesen Bio, Inc. 2014 Stock Incentive Plan, as amended, or the 2014 Incentive Plan, to, among other things, (a)&#160;increase the number of shares of Sesen Bio common stock reserved for issuance under the 2014 Incentive Plan, and (b)&#160;extend the term of the 2014 Incentive Plan to the tenth (10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;">) anniversary of the closing of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">4.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an amendment to the Sesen Bio, Inc. 2014 Employee Stock Purchase Plan, as amended, or the 2014 ESPP, to increase the number of shares </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of Sesen Bio common stock reserved for issuance under the 2014 ESPP to 6,568,655 shares of Sesen Bio common stock; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">5.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an adjournment of the Sesen Bio special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">6.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to transact such other business as may properly come before the Sesen Bio special meeting or any adjournment or postponement thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors has fixed January 17, 2023 as the record date for the determination of Sesen Bio stockholders entitled to notice of, and to vote at, the Sesen Bio special meeting and any adjournment or postponement thereof, or the record date. Only holders of record of shares of Sesen Bio common stock at the close of business on the record date are entitled to notice of, and to vote at, the Sesen Bio special meeting. At the close of business on the record date, Sesen Bio had 202,759,043 shares of common stock outstanding and entitled to vote. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio special meeting will be a virtual meeting held exclusively via live webcast. You may attend the Sesen Bio special meeting, vote your shares and submit questions electronically during the Sesen Bio special meeting. Whether or not you expect to attend the Sesen Bio special meeting, you are respectfully requested to promptly either (i)&#160;sign, date and return the enclosed proxy card or voting instruction form, or (ii)&#160;vote via telephone or the internet by following the instructions provided on the enclosed proxy card or voting instruction form. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In order to attend the Sesen Bio special meeting, you must register in advance at www.proxydocs.com/SESN. After completing your registration, you will receive further instructions via email, including a unique link that will allow you to access the Sesen Bio special meeting and to vote and submit questions during the Sesen Bio special meeting. As part of the registration process, you must enter the control number located on your proxy card or voting instruction form. If you are a beneficial owner of shares registered in the name of a broker, bank or other nominee, you will also need to provide the registered name on your account and the name of your broker, bank or other nominee as part of the registration process. Please be sure to follow the instructions found on your proxy card or voting instruction form. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Your vote is important. The affirmative vote of a majority in voting power of the votes cast by the holders of all shares of Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting and entitled to vote on the matter is required for approval of Proposal Nos. 1, 3, 4 and 5. The affirmative vote of the holders of a majority of the outstanding shares of Sesen Bio common stock on the record date for the Sesen Bio special meeting entitled to vote on the matter is required for approval of Proposal No. 2.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposal No. 1 is conditioned upon the approval of Proposal No. 2, and the merger cannot be consummated without the approval of Proposal Nos. 1 and 2. Proposal Nos. 3 and 4 are conditioned upon the approval of Proposal Nos. 1 and 2. Proposal No. 2 is not conditioned on the approval of any other proposal.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if you plan to attend the Sesen Bio special meeting, Sesen Bio requests that you sign and return the enclosed proxy card or voting instruction form to ensure that your shares will be represented at the Sesen Bio special meeting if you are unable to attend.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE SESEN BIO BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, SESEN BIO AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE SESEN BIO BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT SESEN BIO STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By Order of the Sesen Bio Board of Directors, </font>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Mark Sullivan</font>
          <br >
          <font style="font-style:italic;letter-spacing:0.2pt;">General Counsel and Corporate Secretary</font>
          <br >
          <font style="letter-spacing:0.2pt;">Cambridge, Massachusetts</font>
          <br >
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2023 </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPLANATORY NOTE</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The issuance of all shares of Sesen Bio common stock in exchange for each outstanding share of Carisma capital stock, other than shares of Sesen Bio common stock issued in exchange for shares of Carisma common stock issued in connection with the Carisma pre-closing financing, is intended to be covered by this registration statement on Form S-4 of which the accompanying proxy statement/prospectus is a part. There is no difference between the Sesen Bio common stock that will be issued in exchange for each share of Carisma common stock issued in the pre-closing financing and the Sesen Bio common stock that will be issued in exchange for each other outstanding share of Carisma capital stock, except that the shares of Sesen Bio common stock that will be issued as transaction consideration in exchange for each share of Carisma common stock issued in the pre-closing financing will not be registered under the Securities Act of 1933, as amended, or the Securities Act, and will be subject to restrictions on resale. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">REFERENCES TO ADDITIONAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This proxy statement/prospectus incorporates important business and financial information about Sesen Bio that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission, or the SEC, website (www.sec.gov) or upon your written or oral request by contacting the Corporate Secretary of Sesen Bio, Inc., 245 First Street, Suite&#160;1800, Cambridge, MA 02142 or by calling (617) 444-8550. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">To ensure timely delivery of these documents, any request should be made no later than February 23, 2023 to receive them before the Sesen Bio special meeting.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For additional details about where you can find information about Sesen Bio, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Where You Can Find More Information</font><font style="letter-spacing:0.2pt;">&#8221; on page <a href="#tWYCF">404</a> of this proxy statement/prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROXY STATEMENT/PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This proxy statement/prospectus, which forms part of a registration statement on Form S-4 filed with the SEC by Sesen Bio (File No. 333-267891), constitutes a prospectus of Sesen Bio under Section&#160;5 of the Securities Act with respect to shares of Sesen Bio common stock to be issued pursuant to the Merger Agreement. This document also constitutes a notice of meeting and a proxy statement under Section&#160;14(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, with respect to the Sesen Bio special meeting at which Sesen Bio stockholders will be asked to consider and vote on, among other matters, a proposal to approve the issuance of shares of Sesen Bio common stock pursuant to the Merger Agreement. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">No one has been authorized to provide you with information that is different from that contained in, or incorporated by reference into, this proxy statement/prospectus. This proxy statement/prospectus is dated &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2023. The information contained in this proxy statement/prospectus is accurate only as of that date or, in the case of information in a document incorporated by reference, as of the date of such document, unless the information specifically indicates that another date applies. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">This proxy statement/prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The information concerning Sesen Bio contained in this proxy statement/prospectus or incorporated by reference has been provided by Sesen Bio, and the information concerning Carisma contained in this proxy statement/prospectus has been provided by Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All references in this proxy statement/prospectus to &#8220;Sesen Bio&#8221; and &#8220;Carisma&#8221; refer to Sesen Bio, Inc. and CARISMA Therapeutics Inc., respectively. All references in this proxy statement/prospectus to &#8220;Merger Sub&#8221; refer to Seahawk Merger Sub, Inc., a newly formed, wholly-owned subsidiary of Sesen Bio. All references in this proxy statement/prospectus to the &#8220;combined company&#8221; refer to Sesen Bio and its wholly-owned subsidiary, Carisma, following completion of the merger. Except as otherwise noted, references to &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to both Sesen Bio and Carisma. All references in this proxy statement/prospectus to &#8220;Sesen Bio common stock&#8221; refer to the common stock of Sesen Bio, $0.001 par value per share, and all references in this proxy statement/prospectus to &#8220;Carisma common stock&#8221; refer to the common stock of Carisma, $0.0001 par value per share.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:3.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:602.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:419.63pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tQAAA"><font style="letter-spacing:0.2pt;">QUESTIONS AND ANSWERS ABOUT THE MERGER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tQAAA">1</a></font> <a href="#tQAAA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">11</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMPAD"><font style="letter-spacing:0.2pt;">MARKET PRICE AND DIVIDEND INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMPAD">25</a></font> <a href="#tMPAD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">26</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tRRTT"><font style="letter-spacing:0.2pt;">Risks Related to the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRRTT">26</a></font> <a href="#tRRTT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tRRTT1"><font style="letter-spacing:0.2pt;">Risks Related to the Proposed Reverse Stock Split </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRRTT1">31</a></font> <a href="#tRRTT1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tRRTS"><font style="letter-spacing:0.2pt;">Risks Related to Sesen Bio </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRRTS">32</a></font> <a href="#tRRTS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tRRTC"><font style="letter-spacing:0.2pt;">Risks Related to Carisma </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRRTC">57</a></font> <a href="#tRRTC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSCF"><font style="letter-spacing:0.2pt;">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSCF">118</a></font> <a href="#tCSCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTSMO"><font style="letter-spacing:0.2pt;">THE SPECIAL MEETING OF SESEN BIO STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTSMO">121</a></font> <a href="#tTSMO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHME"><font style="letter-spacing:0.2pt;">THE MERGER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHME">125</a></font> <a href="#tTHME"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tBOTM"><font style="letter-spacing:0.2pt;">Background of the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBOTM">125</a></font> <a href="#tBOTM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tSBRF"><font style="letter-spacing:0.2pt;">Sesen Bio Reasons for the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSBRF">134</a></font> <a href="#tSBRF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCRFT"><font style="letter-spacing:0.2pt;">Carisma Reasons for the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCRFT">137</a></font> <a href="#tCRFT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tOOSB"><font style="letter-spacing:0.2pt;">Opinion of Sesen Bio&#8217;s Financial Advisor </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOOSB">139</a></font> <a href="#tOOSB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCUFP"><font style="letter-spacing:0.2pt;">Certain Unaudited Financial Projections </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCUFP">145</a></font> <a href="#tCUFP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tIOSB"><font style="letter-spacing:0.2pt;">Interests of Sesen Bio Directors and Executive Officers in the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOSB">148</a></font> <a href="#tIOSB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tIOCD"><font style="letter-spacing:0.2pt;">Interests of Carisma Directors and Executive Officers in the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCD">153</a></font> <a href="#tIOCD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tFOTM"><font style="letter-spacing:0.2pt;">Form of the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tFOTM">156</a></font> <a href="#tFOTM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tETOT"><font style="letter-spacing:0.2pt;">Effective Time of the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tETOT">156</a></font> <a href="#tETOT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tMCAE"><font style="letter-spacing:0.2pt;">Merger Consideration and Exchange Ratio </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMCAE">156</a></font> <a href="#tMCAE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tSBFN"><font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s Final Net Cash </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSBFN">158</a></font> <a href="#tSBFN"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tPFEC"><font style="letter-spacing:0.2pt;">Procedures for Exchanging Carisma Stock Certificates </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPFEC">159</a></font> <a href="#tPFEC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tREAP"><font style="letter-spacing:0.2pt;">Regulatory Approvals </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tREAP">160</a></font> <a href="#tREAP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tMUFI"><font style="letter-spacing:0.2pt;">Material U.S. Federal Income Tax Consequences of the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMUFI">160</a></font> <a href="#tMUFI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tMUFI1"><font style="letter-spacing:0.2pt;">Material U.S. Federal Income Tax Consequences of the Special Cash Dividend </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMUFI1">162</a></font> <a href="#tMUFI1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tNALI"><font style="letter-spacing:0.2pt;">Nasdaq Listing </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNALI">165</a></font> <a href="#tNALI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tAAT"><font style="letter-spacing:0.2pt;">Anticipated Accounting Treatment </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tAAT">166</a></font> <a href="#tAAT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tARAD"><font style="letter-spacing:0.2pt;">Appraisal Rights and Dissenters&#8217; Rights </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tARAD">166</a></font> <a href="#tARAD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tLRTM"><font style="letter-spacing:0.2pt;">Litigation Related to the Merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLRTM">169</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTMA"><font style="letter-spacing:0.2pt;">THE MERGER AGREEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTMA">171</a></font> <a href="#tTMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tARTT"><font style="letter-spacing:0.2pt;">AGREEMENTS RELATED TO THE MERGER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tARTT">192</a></font> <a href="#tARTT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCVAG"><font style="letter-spacing:0.2pt;">CVR Agreement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCVAG">192</a></font> <a href="#tCVAG"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tSAAW"><font style="letter-spacing:0.2pt;">Support Agreements and Written Consents </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSAAW">197</a></font> <a href="#tSAAW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tSUAG"><font style="letter-spacing:0.2pt;">Subscription Agreement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSUAG">198</a></font> <a href="#tSUAG"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tLOAG"><font style="letter-spacing:0.2pt;">Lock-Up Agreements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLOAG">199</a></font> <a href="#tLOAG"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMBST"><font style="letter-spacing:0.2pt;">MATTERS BEING SUBMITTED TO A VOTE OF SESEN BIO STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMBST">201</a></font> <a href="#tMBST"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:419.63pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <a href="#tPN1A"><font style="letter-spacing:0.2pt;">Proposal No. 1: Approval, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Merger Agreement and the change of control of Sesen Bio resulting from the merger </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPN1A">201</a></font> <a href="#tPN1A"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:650.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:419.63pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:419.63pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <a href="#tPN2A"><font style="letter-spacing:0.2pt;">Proposal No. 2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common&#160;stock </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPN2A">203</a></font> <a href="#tPN2A"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tPN3A"><font style="letter-spacing:0.2pt;">Proposal No. 3: Approval of an amendment and restatement of the 2014 Incentive Plan </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPN3A">212</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tPN4A"><font style="letter-spacing:0.2pt;">Proposal No. 4: Approval of an amendment to the 2014 ESPP </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPN4A">224</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tPN5A"><font style="letter-spacing:0.2pt;">Proposal No. 5: Approval of possible adjournment of the Sesen Bio special meeting </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPN5A">229</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSBB"><font style="letter-spacing:0.2pt;">SESEN BIO BUSINESS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSBB">230</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tOVE"><font style="letter-spacing:0.2pt;">Overview </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOVE">230</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCUST"><font style="letter-spacing:0.2pt;">Current Strategy </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCUST">230</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tSBHP"><font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s Historical Pipeline Product Candidates </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSBHP">231</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCOM"><font style="letter-spacing:0.2pt;">Competition </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCOM">233</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tSAM"><font style="letter-spacing:0.2pt;">Sales and Marketing </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSAM">234</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tMAN"><font style="letter-spacing:0.2pt;">Manufacturing </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMAN">234</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tINPR"><font style="letter-spacing:0.2pt;">Intellectual Property </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tINPR">234</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tSBOB"><font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s OUS Business Development Partnering </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSBOB">235</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tGORE"><font style="letter-spacing:0.2pt;">Government Regulation </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tGORE">236</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tEMP"><font style="letter-spacing:0.2pt;">Employees </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEMP">246</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCOIN"><font style="letter-spacing:0.2pt;">Corporate Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCOIN">246</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tLEPR"><font style="letter-spacing:0.2pt;">Legal Proceedings </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEPR">247</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCABU"><font style="letter-spacing:0.2pt;">CARISMA BUSINESS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCABU">249</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tOVE1"><font style="letter-spacing:0.2pt;">Overview </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOVE1">249</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCATE"><font style="letter-spacing:0.2pt;">Carisma&#8217;s Team </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCATE">252</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCAST"><font style="letter-spacing:0.2pt;">Carisma&#8217;s Strategy </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCAST">252</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tBAC"><font style="letter-spacing:0.2pt;">Background </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBAC">254</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tMAD"><font style="letter-spacing:0.2pt;">Manufacturing and Delivery </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMAD">286</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tINPR1"><font style="letter-spacing:0.2pt;">Intellectual Property </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tINPR1">287</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tCOM1"><font style="letter-spacing:0.2pt;">Competition </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCOM1">292</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tGORE1"><font style="letter-spacing:0.2pt;">Government Regulation </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tGORE1">293</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tEAHC"><font style="letter-spacing:0.2pt;">Employees and Human Capital Resources </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEAHC">309</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tFAC"><font style="letter-spacing:0.2pt;">Facilities </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tFAC">309</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tLEPR1"><font style="letter-spacing:0.2pt;">Legal Proceedings </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEPR1">309</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:419.63pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tSBMD"><font style="letter-spacing:0.2pt;">SESEN BIO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSBMD">310</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:419.63pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tCMDA"><font style="letter-spacing:0.2pt;">CARISMA MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCMDA">326</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMFTM"><font style="letter-spacing:0.2pt;">MANAGEMENT FOLLOWING THE MERGER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMFTM">342</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSBEC"><font style="letter-spacing:0.2pt;">SESEN BIO EXECUTIVE COMPENSATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSBEC">349</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCEC"><font style="letter-spacing:0.2pt;">CARISMA EXECUTIVE COMPENSATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCEC">360</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:419.63pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tRPTO"><font style="letter-spacing:0.2pt;">RELATED PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMBINED COMPANY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRPTO">368</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUPFC"><font style="letter-spacing:0.2pt;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUPFC">372</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOSB"><font style="letter-spacing:0.2pt;">DESCRIPTION OF SESEN BIO CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOSB">383</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tCORO"><font style="letter-spacing:0.2pt;">COMPARISON OF RIGHTS OF HOLDERS OF SESEN BIO STOCK AND CARISMA </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCORO">386</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:287.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:323.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:419.63pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPSOS"><font style="letter-spacing:0.2pt;">PRINCIPAL STOCKHOLDERS OF SESEN BIO </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPSOS">395</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPSOC"><font style="letter-spacing:0.2pt;">PRINCIPAL STOCKHOLDERS OF CARISMA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPSOC">397</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPSOT"><font style="letter-spacing:0.2pt;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPSOT">400</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA">LEGAL MATTERS</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">
              <a href="#tLEMA">&#8203;</a>
            </td>
            <td style="padding:0pt; width:6pt;">
              <a href="#tLEMA">&#8203;</a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">
              <a href="#tLEMA">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <a href="#tLEMA">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <a href="#tLEMA">403</a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">
              <a href="#tLEMA">&#8203;</a>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a href="#tLEMA">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP">EXPERTS </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">
              <a href="#tEXP">&#8203;</a>
            </td>
            <td style="padding:0pt; width:6pt;">
              <a href="#tEXP">&#8203;</a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">
              <a href="#tEXP">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <a href="#tEXP">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <a href="#tEXP">403</a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">
              <a href="#tEXP">&#8203;</a>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a href="#tEXP">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF">WHERE YOU CAN FIND MORE INFORMATION </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">
              <a href="#tWYCF">&#8203;</a>
            </td>
            <td style="padding:0pt; width:6pt;">
              <a href="#tWYCF">&#8203;</a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">
              <a href="#tWYCF">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <a href="#tWYCF">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <a href="#tWYCF">404</a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">
              <a href="#tWYCF">&#8203;</a>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a href="#tWYCF">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTRNO">TRADEMARK NOTICE </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">
              <a href="#tTRNO">&#8203;</a>
            </td>
            <td style="padding:0pt; width:6pt;">
              <a href="#tTRNO">&#8203;</a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">
              <a href="#tTRNO">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <a href="#tTRNO">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <a href="#tTRNO">405</a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">
              <a href="#tTRNO">&#8203;</a>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a href="#tTRNO">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOTMA"><font style="letter-spacing:0.2pt;">OTHER MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOTMA">406</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fISCF"><font style="letter-spacing:0.2pt;">Index to Sesen Bio&#8217;s Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fISCF">F-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fISCS"><font style="letter-spacing:0.2pt;">Index to Carisma&#8217;s Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fISCS">F-70</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tAAPM"><font style="letter-spacing:0.2pt;">Annex A-1&#8201;&#8211;&#8201;Agreement and Plan of Merger and Reorganization </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tAAPM">A-1-1</a></font> <a href="#tAAPM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tFAAP"><font style="letter-spacing:0.2pt;">Annex A-2&#8201;&#8211;&#8201;First Amendment to Agreement and Plan of Merger and Reorganization </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tFAAP">A-2-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tANNB"><font style="letter-spacing:0.2pt;">Annex B&#8201;&#8211;&#8201;Opinion of SVB Securities LLC, dated December 29, 2022 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tANNB">B-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tANNC"><font style="letter-spacing:0.2pt;">Annex C&#8201;&#8211;&#8201;Form of Carisma Support Agreement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tANNC">C-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tANND"><font style="letter-spacing:0.2pt;">Annex D&#8201;&#8211;&#8201;Form of Sesen Bio Support Agreement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tANND">D-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tANNE"><font style="letter-spacing:0.2pt;">Annex E&#8201;&#8211;&#8201;Form of Lock-Up Agreement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tANNE">E-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tANNF"><font style="letter-spacing:0.2pt;">Annex F&#8201;&#8211;&#8201;Form of Contingent Value Rights Agreement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tANNF">F-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#AnnexG"><font style="letter-spacing:0.2pt;">Annex G&#8201;&#8211;&#8201;Certificate of Amendment for the Reverse Stock Split </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#AnnexG">G-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tANNH"><font style="letter-spacing:0.2pt;">Annex H&#8201;&#8211;&#8201;Appraisal Rights (Section&#160;262 of the Delaware General Corporation Law) </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tANNH">H-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tAnnexI"><font style="letter-spacing:0.2pt;">Annex I &#8201;&#8211;&#8201; Amended and Restated 2014 Stock Incentive Plan</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tAnnexI">I-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.63pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tAnnexJ"><font style="letter-spacing:0.2pt;">Annex J&#8201;&#8211;&#8201;Amendment No. 2 to the 2014 Employee Stock Purchase Plan</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tAnnexJ">J-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tQAAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">QUESTIONS AND ANSWERS ABOUT THE MERGER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in the section entitled &#8220;Matters Being Submitted to a Vote of Sesen Bio Stockholders&#8201;&#8212;&#8201;Proposal No. 2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common stock&#8221; beginning on page <a href="#tPN2A">203</a> of this proxy statement/prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following section provides answers to frequently asked questions about the merger. This section, however, provides only summary information. For a more complete response to each of these questions and for additional information, refer to the cross-referenced sections in this proxy statement/prospectus. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What is the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio, Inc., or Sesen Bio, Seahawk Merger Sub, Inc., or Merger Sub, and CARISMA Therapeutics Inc., or Carisma, entered into an Agreement and Plan of Merger and Reorganization, or the Original Merger Agreement, on September&#160;20, 2022, and entered into the First Amendment thereto on December&#160;29, 2022, or the Merger Agreement Amendment, and together with the Original Merger Agreement, the Merger Agreement. The Merger Agreement contains the terms and conditions of the proposed business combination of Sesen Bio and Carisma. Under the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma surviving as a wholly-owned subsidiary of Sesen Bio, or the merger. After the completion of the merger, Sesen Bio will change its corporate name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; as contemplated by the Merger Agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the effective time of the merger, or the effective time, each outstanding share of Carisma common stock and Carisma preferred stock, or collectively, Carisma capital stock, including shares of Carisma common stock issued in connection with the Carisma pre-closing financing as defined below, will be converted into the right to receive a number of shares of Sesen Bio common stock equal to an exchange ratio, or the exchange ratio, described in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Merger Consideration</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tTMA">171</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Also at the effective time, each outstanding option to purchase shares of Carisma common stock, or a Carisma option, will be assumed by Sesen Bio and will be converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the exchange ratio. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each share of Sesen Bio common stock, each option to purchase Sesen Bio common stock, or a Sesen Bio option, and each Sesen Bio restricted stock unit convertible into Sesen Bio common stock (including both time-based restricted stock&#160;units and performance-based restricted stock&#160;units), or a Sesen Bio RSU, that is outstanding at the effective time will remain outstanding in accordance with its terms and such shares of Sesen Bio common stock, Sesen Bio options and Sesen Bio RSUs, subject to the proposed reverse stock split, will be unaffected by the merger. Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 25.2% of the outstanding shares of capital stock of the combined company, and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, or the Carisma convertible note, are expected to own approximately 74.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of closing of the merger being at least $75.0 million. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Why are the two companies proposing to merge?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Carisma believe that the merger will provide Carisma with substantial capital resources, positioning it to become a pre-eminent clinical-stage biopharmaceutical company focused on advancement of Carisma&#8217;s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and other serious disorders. For a discussion of Sesen Bio&#8217;s and Carisma&#8217;s reasons for the merger, see the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Sesen Bio Reasons for the Merger</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Carisma Reasons for the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on pages&#160;<a href="#tSBRF">134</a> and <a href="#tCRFT">137</a>, respectively, of this proxy statement/prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Why am I receiving this proxy statement/prospectus?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">You are receiving this proxy statement/prospectus because you have been identified as a Sesen Bio stockholder as of the record date and you are entitled to vote at the Sesen Bio special meeting to approve the matters set forth herein. This document serves as: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a proxy statement of Sesen Bio used to solicit proxies for the Sesen Bio special meeting to vote on the matters set forth herein; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a prospectus of Sesen Bio used to offer shares of Sesen Bio common stock in exchange for shares of Carisma capital stock (excluding shares of Sesen Bio common stock issued as transaction&#160;consideration in exchange for shares of Carisma common stock issued in the Carisma pre-closing financing) in the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What is the Carisma pre-closing financing?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, immediately prior to the execution and delivery of the Original Merger Agreement, Carisma entered into a subscription agreement with certain investors named therein, or, as subsequently amended and restated, the subscription agreement, pursuant to which such investors agreed to purchase shares of Carisma common stock at an aggregate purchase price of approximately $30.6&#160;million, or the Carisma pre-closing financing. Immediately after the merger, the shares of Carisma common stock issued in the Carisma pre-closing financing are expected to represent approximately&#160;8.4% of the outstanding shares of capital stock of the combined company. The closing of the Carisma pre-closing financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the merger set forth in the Merger Agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What will Sesen Bio stockholders receive in the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">At the effective time, Sesen Bio stockholders will continue to own and hold their existing shares of Sesen Bio common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All outstanding and unexercised Sesen Bio options granted (i)&#160;pursuant to the Sesen Bio, Inc. 2014 Stock Incentive Plan, as amended, or the 2014 Incentive Plan, or the Eleven Biotherapeutics, Inc. 2009 Stock Incentive Plan, as amended and restated, or the 2009 Incentive Plan, or (ii)&#160;as an inducement grant under Nasdaq Listing Rule&#160;5635(c)(4) will remain in effect pursuant to their terms and will be unaffected by the merger. All outstanding and unvested Sesen Bio RSUs granted pursuant to the 2014 Incentive Plan or the 2009 Incentive Plan will remain in effect pursuant to their terms and will be unaffected by the merger. All outstanding and unexercised warrants to purchase Sesen Bio common stock, or Sesen Bio warrants, immediately prior to the effective time (other than certain Sesen Bio warrants that Sesen Bio may be required to repurchase at such warrant holder&#8217;s option as of a result of the merger) will remain in effect pursuant to their terms and will be unaffected by the merger. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, at or prior to the effective time, Sesen Bio will enter into a Contingent Value Rights Agreement, or the CVR Agreement, and, as provided in the Merger Agreement, Sesen Bio intends to declare a dividend payable to Sesen Bio stockholders of record as of a date agreed to by Sesen Bio and Carisma prior to the effective time with respect to the receipt of one contingent value right, or a CVR, for each outstanding share of Sesen Bio common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive contingent cash payments upon the receipt by Sesen Bio of certain proceeds payable by F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., or Roche, if any, pursuant to the Asset Purchase Agreement by and among Sesen Bio and Roche, or the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes. For a more detailed description of the CVRs and the CVR Agreement, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCVAG">192</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, prior to the closing of the merger, Sesen Bio will, in addition to the CVRs, declare a special cash dividend, or the special cash dividend, to Sesen Bio stockholders of record prior to the merger, which would be contingent upon Sesen Bio stockholder approval of Proposal Nos. 1 and 2 and the satisfaction </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">or waiver of other customary closing conditions to the merger. The amount of the special cash dividend will be the amount by which Sesen Bio&#8217;s estimated net cash as of the closing of the merger exceeds $75.0 million. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What will Carisma stockholders and Carisma optionholders receive in the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Carisma stockholders will receive shares of Sesen Bio common stock, and Carisma optionholders will receive options to purchase Sesen Bio common stock. Applying the exchange ratio, immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 25.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of the Carisma convertible note, are expected to own approximately 74.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of the closing of the merger being at least $75.0&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the merger, each outstanding and unexercised Carisma option will be assumed by Sesen Bio and converted into an option to purchase Sesen Bio common stock, with the number of shares and exercise price being appropriately adjusted to reflect the exchange ratio between Sesen Bio common stock and Carisma common stock determined in accordance with the Merger Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For a more complete description of what Carisma stockholders and optionholders will receive in the merger, see the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Merger Consideration</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; beginning on pages <a href="#tTMA">171</a> and <a href="#tTMAER">172</a>, respectively, of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. For a description of the effect of the Carisma pre-closing financing on current Sesen Bio and Carisma stockholders, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;Subscription Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tSUAG">198</a> of this proxy statement/prospectus. </font></div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What will happen to Sesen Bio if, for any reason, the merger does not close?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">If, for any reason, the merger does not close, the Sesen Bio board of directors may elect to, among other things, review and evaluate another strategic transaction like the merger, attempt to sell or otherwise dispose of the various assets of Sesen Bio, resume its research and development activities and continue to operate the business of Sesen Bio or dissolve and liquidate its assets. If Sesen Bio decides to dissolve and liquidate its assets, Sesen Bio would be required to pay all of its debts and contractual obligations, and to set aside certain reserves for potential future claims. There can be no assurances as to the amount or timing of available cash left, if any, to distribute to Sesen Bio stockholders after paying the debts and other obligations of Sesen Bio and setting aside funds for reserves. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What is required to consummate the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of the Merger Agreement, in order for the merger to close, the following proposals must be approved by the requisite vote of Sesen Bio stockholders at the Sesen Bio special meeting: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Proposal No. 1:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;to consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Original Merger Agreement, as amended by the Merger Agreement Amendment, copies of which are attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex A-1</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex A-2</font><font style="letter-spacing:0.2pt;">, respectively, to this proxy statement/prospectus, and the change of control of Sesen Bio resulting from the merger; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Proposal No. 2:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;to consider and vote upon a proposal to approve an amendment to the Sesen Bio Certificate of Incorporation, to (a) effect a reverse stock split of the issued and outstanding shares of Sesen Bio common stock at a ratio of 1-for-20, with the implementation and timing of the reverse stock split to be determined in the discretion of the Sesen Bio board of directors and as agreed to by Carisma at or prior to the closing of the merger, or in the sole discretion of the Sesen Bio board of directors if Proposal No. 1 is not approved, and (b) if and when the reverse stock split is effected, reduce the number of authorized shares of Sesen Bio common stock to 100,000,000, in the form attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex G</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma stockholders must adopt the Merger Agreement, thereby approving the merger and the related transactions. The adoption of the Merger Agreement and the approval of the merger and related transactions by the Carisma stockholders requires the affirmative vote (or written consent) of the holders of a majority of the Carisma capital stock, voting together as a single class, (ii)&#160;at least two-thirds of the Carisma Series&#160;A preferred stock, Carisma special voting preferred stock, Carisma Series&#160;B preferred stock and Carisma Series&#160;B special voting preferred stock, voting together as a single class, (iii)&#160;a majority of the Carisma Series&#160;A preferred stock and Carisma special voting preferred stock, voting together as a single class and (iv)&#160;at least two-thirds of the Carisma Series&#160;B preferred stock and Carisma Series&#160;B special voting preferred stock, voting together as a single class. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, certain Carisma stockholders (solely in their respective capacities as Carisma stockholders) holding approximately 97.23% of the outstanding shares of Carisma capital stock (subject to customary cutbacks in the event of certain triggering events) are parties to support agreements with Sesen Bio and Carisma, whereby such stockholders have agreed, subject to the effectiveness of the registration statement on Form S-4, to vote their shares in favor of, among other things, the adoption or approval of the Merger Agreement and the transactions contemplated therein, subject to the terms of the support agreements. In addition, following the effectiveness of the registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, and pursuant to the conditions of the Merger Agreement and the support agreements, Carisma stockholders who are party to the support agreements will each execute written consents approving the merger and related transactions, subject to the terms and limitations set forth in the support agreements. Therefore, holders of a sufficient number of shares of Carisma common stock required to adopt the Merger Agreement, thereby approving the merger, have agreed to adopt the Merger Agreement via written consent, subject to the terms and limitations set forth in the support agreements. Carisma stockholders, including those who are parties to support agreements, are being requested to execute written consents providing such approvals. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the requirement of obtaining the stockholder approvals described above, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived. For a more complete description of the closing conditions under the Merger Agreement, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Conditions to the Completion of the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page&#160;<a href="#tCCM5">176</a> of this proxy statement/prospectus. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What stockholder votes are required to approve the proposals at the Sesen Bio special meeting?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
            <br >
          </div>
          <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Approval of Proposal Nos. 1, 3, 4 and 5 each requires the affirmative vote of a majority in voting power of the votes cast by the holders of all shares of Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting and entitled to vote thereon. Approval of Proposal No. 2 requires the affirmative vote of the holders of a majority of the outstanding shares of Sesen Bio common stock on the record date, January 17, 2023, for the Sesen Bio special meeting, or the record date, entitled to vote on the matter. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Votes will be counted by the inspector of election appointed for the Sesen Bio special meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221; votes, abstentions and broker non-votes. Abstentions and broker non-votes will be treated as shares of Sesen Bio common stock present for the purpose of determining the presence of a quorum for the transaction of business at the Sesen Bio special meeting. Abstentions and broker non-votes will have the same effect as &#8220;AGAINST&#8221; votes for Proposal No. 2, but will have no effect on the outcome of Proposal Nos. 1, 3, 4 and 5. Proposal Nos. 2 and 5 are matters on which Sesen Bio expects brokers, banks or other nominees to have authority to vote uninstructed shares and, therefore, broker non-votes are not expected with respect to these proposals. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who will be the directors of the combined company following the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Immediately following completion of the merger, the combined company&#8217;s board of directors is expected to be composed of seven directors, consisting of six directors designated by Carisma and one director designated by Sesen Bio. It is anticipated that Thomas R. Cannell will be the Sesen Bio designated director following the closing of the merger, and that all other current Sesen Bio directors will resign as of the closing of the merger. Carisma will appoint the remaining directors to the Sesen Bio board of directors to fill the resulting vacancies. It is anticipated that Sanford Zweifach, Regina </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Hodits, Briggs Morrison, Bj&#246;rn Odlander, Chidozie Ugwumba and Steven Kelly will be appointed to the board of directors of the combined company by Carisma. Sanford Zweifach is expected to be appointed as chair of the board of the directors of the combined company. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The staggered structure of the Sesen Bio board of directors will remain in place for the combined company following the completion of the merger. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who will be the executive officers of the combined company immediately following the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Immediately following completion of the merger, the combined company&#8217;s executive management team is expected to consist of the members of Carisma&#8217;s executive management team prior to the merger, including: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:436pt;height:53.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:212pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:212pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">Steven Kelly </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">President and Chief Executive Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">Richard Morris </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:212pt;">
              <font style="letter-spacing:0.2pt;">Chief Scientific Officer</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What are the material U.S. federal income tax consequences of the merger to Sesen Bio stockholders?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio stockholders will not sell, exchange or dispose of any shares of Sesen Bio common stock as a result of the merger. Thus, there will be no material U.S. federal income tax consequences to Sesen Bio stockholders as a result of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What are the material U.S. federal income tax consequences of the merger to Carisma U.S. holders?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Subject to the qualifications and limitations set forth in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Merger,</font><font style="letter-spacing:0.2pt;">&#8221; in the opinion of Wilmer Cutler Pickering Hale and Dorr LLP, or WilmerHale, and Hogan Lovells US LLP, or Hogan Lovells, the merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended, or the Code, and a Carisma U.S. holder (as defined on page <a href="#tUSHCA">161</a>) will not recognize gain or loss for U.S. federal income tax purposes upon the receipt of shares of Sesen Bio common stock in exchange for shares of Carisma capital stock in the merger, except to the extent such a Carisma U.S. holder receives cash in lieu of a fractional share of Sesen Bio common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tMUFI">160</a> of this proxy statement/prospectus for a more complete description of the material U.S. federal income tax consequences of the merger to Carisma U.S. holders. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What are the material U.S. federal income tax consequences of the receipt of CVRs to Sesen Bio U.S. holders?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The U.S. federal income tax treatment of Sesen Bio U.S. holders&#8217; (as defined on page <a href="#tMUFI3">193</a>) receipt of the CVRs is unclear. Sesen Bio intends to report the issuance of the CVRs to Sesen Bio U.S. holders under the terms expressed in the form of the CVR Agreement included in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex F</font><font style="letter-spacing:0.2pt;"> to this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus as a distribution of property with respect to Sesen Bio common stock. In such case, each Sesen Bio U.S. holder will be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Sesen Bio U.S. holder on the date of the issuance. This distribution should be treated first as a taxable dividend to the extent of the Sesen Bio U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes and after taking into account the special cash dividend paid to Sesen Bio U.S. holders, if any, as described below), then as a non-taxable return of capital to the extent of the Sesen Bio U.S. holder&#8217;s basis in its Sesen Bio common stock, and finally as capital gain from the sale or exchange of Sesen Bio common stock with respect to any remaining value. Sesen Bio currently has negative accumulated earnings and profits and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Sesen Bio expects most or all of this distribution to be treated as other than a dividend for U.S. federal income tax purposes. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCVAG">192</a> of this proxy statement/prospectus for a more complete description of the </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">material U.S. federal income tax consequences of the receipt of CVRs to Sesen Bio U.S. holders, including possible alternative treatments. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The tax consequences to you of the receipt of CVRs will depend on your particular facts and circumstances. You should consult your tax advisors as to the specific tax consequences to you. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What are the material U.S. federal income tax consequences of the special cash dividend that Sesen Bio will declare and pay to Sesen Bio U.S. holders?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">In connection with the merger, the Sesen Bio board of directors will declare and pay a special cash dividend to Sesen Bio stockholders of record prior to the effective time consisting of Sesen Bio&#8217;s available cash in an aggregate amount expected to be approximately $70.0&#160;million, assuming Sesen Bio&#8217;s net cash as of the closing of the merger (after taking into account the proposed cash dividend) is $75.0&#160;million. The U.S. federal income tax consequences of the Sesen Bio U.S. holders&#8217; receipt of a special cash dividend generally should be treated first as a taxable dividend to the extent of the Sesen Bio U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Sesen Bio U.S. holder&#8217;s basis in its Sesen Bio common stock, and finally as capital gain from the sale or exchange of Sesen Bio common stock with respect to any remaining amount. Sesen Bio currently has negative accumulated earnings and profits and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Sesen Bio expects most or all of the special cash dividend to be treated as other than a dividend for U.S. federal income tax purposes. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Special Cash Dividend</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tMUFI1">162</a> of this proxy statement/prospectus for a general description of the tax consequences of the special cash dividend that Sesen Bio may pay. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The tax consequences to you of the special cash dividend will depend on your particular facts and circumstances. You should consult your tax advisors as to the specific tax consequences to you. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What are the material U.S. federal income tax consequences of the proposed reverse stock split to Sesen Bio U.S. holders?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio intends to report the proposed reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code. In general, and subject to the qualifications and limitations set forth in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Proposal No. 2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common stock&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#MUIT6">209</a> of this proxy statement/prospectus, if the proposed reverse stock split qualifies as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code, a Sesen Bio U.S. holder should not recognize gain or loss upon the proposed reverse stock split, except to the extent a Sesen Bio U.S. holder receives cash in lieu of a fractional share of Sesen Bio common stock. As discussed in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Proposal No. 2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common stock&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="letter-spacing:0.2pt;">&#8221; on page&#160;<a href="#MUIT6">209</a> of this proxy statement/prospectus, these consequences assume that distribution of the CVRs and any cash distributed pursuant to a special cash dividend will be treated for U.S. federal income tax purposes as separate and distinct from the proposed reverse stock split. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Proposal No.&#160;2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common stock&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page&#160;<a href="#MUIT6">209</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus for a more complete description of the material U.S. federal income tax consequences of the proposed reverse stock split to Sesen Bio U.S. holders. </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The tax consequences to you of the proposed reverse stock split will depend on your particular facts and circumstances. You should consult your tax advisors as to the specific tax consequences to you. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">As a Sesen Bio stockholder, how does the Sesen Bio board of directors recommend that I vote?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">After careful consideration, the Sesen Bio board of directors unanimously recommends that Sesen Bio stockholders vote &#8220;FOR&#8221; all of the proposals described in this proxy statement/prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What risks should I consider in deciding whether to vote in favor of the merger?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">You should carefully review the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Risk Factors</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tRIFA">26</a> of this proxy statement/prospectus which sets forth certain risks and uncertainties related to the merger, risks and uncertainties to which the combined company&#8217;s business will be subject, and risks and uncertainties to which each of Sesen Bio and Carisma, as independent companies, are subject. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who can vote at the Sesen Bio special meeting?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:8.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
            <br >
          </div>
          <div style=" margin-top:8.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Only Sesen Bio stockholders of record at the close of business on the record date will be entitled to vote at the Sesen Bio special meeting. The Sesen Bio board of directors has fixed January 17, 2023 as the record date for the Sesen Bio special meeting. As of the record date, there were 202,759,043 shares of Sesen Bio common stock outstanding and entitled to vote. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Stockholder of Record: Shares Registered in Your Name</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If, at the close of business on the record date, your shares of Sesen Bio common stock were registered directly in your name with Sesen Bio&#8217;s transfer agent, Computershare Trust Company, Inc., then you are a Sesen Bio stockholder of record. As a Sesen Bio stockholder of record, you may vote virtually at the Sesen Bio special meeting or vote by proxy. Whether or not you plan to attend the Sesen Bio special meeting, please vote as soon as possible by completing and returning the enclosed proxy card or vote by proxy over the telephone or on the internet as instructed on the proxy card to ensure your vote is counted. </font>
        </div>

          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio stockholders are invited to attend the special meeting, which will be a virtual meeting held exclusively via live webcast. In order to attend the Sesen Bio special meeting, you must register in advance at www.proxydocs.com/SESN. After completing your registration, you will receive further instructions via email, including a unique link that will allow you to access the Sesen Bio special meeting and to vote and submit questions during the Sesen Bio special meeting. As part of the registration process, you must enter the control number located on your proxy card. </font>
          </div>

        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Similar Organization</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If, at the close of business on the record date, your shares of Sesen Bio common stock were not held in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in &#8220;street name&#8221; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Sesen Bio special meeting. As a beneficial owner, you have the right to direct your broker or other agent how to vote the shares in your account. </font>
        </div>

          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">You are also invited to attend and vote at the Sesen Bio special meeting. After completing your registration in advance at www.proxydocs.com/SESN, you will receive further instructions via email, including a unique link to access the Sesen Bio special meeting. As part of the registration process, you must enter the control number located on your voting instruction form. You will also need to provide the registered name on your account and the name of your broker, bank or other nominee as part of the registration process. You may be instructed to obtain a legal proxy from your broker, bank or other nominee and to submit a copy in advance of the meeting. Further instructions will be provided to you as part of your registration process. </font>
          </div>

        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How many votes do I have?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">On each matter to be voted upon, you have one vote for each share of Sesen Bio common stock you own as of the record date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What is the quorum requirement?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
            <br >
          </div>
          <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">A quorum of Sesen Bio stockholders is necessary to hold a valid meeting. A quorum will be present if Sesen Bio stockholders holding at least a majority in voting power of the shares of Sesen Bio common stock outstanding and entitled to vote at the Sesen Bio special meeting are present or represented by proxy at the Sesen Bio special meeting. As of the record date, there were 202,759,043 shares of Sesen Bio common stock outstanding and entitled to vote. Your shares of Sesen Bio common stock will be counted toward the quorum at the Sesen Bio special meeting only if you attend the Sesen Bio special meeting or are represented by proxy at the Sesen Bio special meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:7.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What are &#8220;broker non-votes?&#8221;</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">If you hold shares beneficially in &#8220;street name&#8221; and do not provide your broker, bank or other nominee with voting instructions, your shares may constitute &#8220;broker non-votes.&#8221; Broker non-votes occur on a matter when banks, brokers and other nominees are not permitted to vote on certain non-discretionary matters without instructions from the beneficial owner and instructions are not given. These matters are referred to as &#8220;non-routine&#8221; matters. Proposal Nos. 1, 3 and 4 are anticipated to be non-routine matters, and Proposal Nos. 2 and 5 are anticipated to be routine matters. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If my shares of Sesen Bio common stock are held in &#8220;street name,&#8221; will my broker, bank or other nominee vote my shares for me?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Unless your broker, bank or other nominee has discretionary authority to vote on certain matters, your broker will not be able to vote your shares of Sesen Bio common stock on matters without instructions from you. If you do not give instructions to your broker, your broker can vote your shares of Sesen Bio common stock with respect to discretionary, routine items but not with respect to non-discretionary, non-routine items. Brokers are not expected to have discretionary authority to vote for any of the proposals other than Proposal Nos. 2 and 5. To make sure that your vote is counted, you should instruct your broker to vote your shares, following the procedures provided by your broker. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How can I view the list of Sesen Bio stockholders eligible to vote at the Sesen Bio special meeting?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The list of Sesen Bio stockholders of record entitled to vote at the Sesen Bio special meeting will be made available for ten days prior to the Sesen Bio special meeting, at the Sesen Bio offices at 245 First Street, Suite 1800, Cambridge, MA 02142. Please contact Sesen Bio&#8217;s Corporate Secretary at (617) 444-8550 if you wish to inspect the list of stockholders eligible to vote at the Sesen Bio special meeting prior to the Sesen Bio special meeting. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">When do you expect the merger to be consummated?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Carisma currently anticipate that the merger will close in the first quarter of 2023, but the companies cannot predict the exact timing. For more information, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Conditions to the Completion of the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCCM5">176</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What do I need to do now?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio urges you to read this proxy statement/prospectus carefully, including its annexes, and to consider how the merger affects you. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are a Sesen Bio stockholder of record, you may provide your proxy instructions in one of three ways prior to the Sesen Bio special meeting: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Over the internet.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;You may vote your shares over the internet by following the instructions in the enclosed proxy card. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">By telephone.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;You may vote your shares by telephone by following the instructions in the enclosed proxy card. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">By mail.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;You may vote your shares by completing, dating and signing the proxy card and promptly mailing it in the postage-paid envelope provided. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Please provide your proxy instructions only once, unless you are revoking a previously delivered proxy instruction, and as soon as possible so that your shares can be voted at the Sesen Bio special meeting. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">When and where is the Sesen Bio special meeting and may I vote in person?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:8.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
            <br >
          </div>
          <div style=" margin-top:8.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The Sesen Bio special meeting will be a virtual meeting held exclusively via live webcast at 10:00 a.m., Eastern Time, on March 2, 2023. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In order to attend the Sesen Bio special meeting, you must register in advance at www.proxydocs.com/SESN. After completing your registration, you will receive further instructions via email, including a unique link that will allow you to access the Sesen Bio special meeting and to vote and submit questions during the Sesen Bio special meeting. As part of the registration process, you must enter the control number located on your proxy card. </font>
          </div>


          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">If your shares are held in &#8220;street name&#8221; by a broker, bank or other nominee, you are also invited to attend and vote your shares at the Sesen Bio special meeting. After completing your registration in advance at www.proxydocs.com/SESN, you will receive further instructions via email, including a unique link to access the Sesen Bio special meeting. As part of the registration process, you must enter the control number located on your voting instruction form. You will also need to provide the registered name on your account and the name of your broker, bank or other nominee as part of the registration process. You may be instructed to obtain a legal proxy from your broker, bank or other nominee and to submit a copy in advance of the meeting. Further instructions will be provided to you as part of your registration process. </font>
          </div>

        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if you plan to attend the Sesen Bio special meeting, Sesen Bio requests that you sign and return the enclosed proxy card or voting instruction form to ensure that your shares will be represented at the Sesen Bio special meeting if you become unable to attend. Please be sure to follow the instructions found on your proxy card or voting instruction form. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What if I have technical difficulties or trouble accessing the Sesen Bio special meeting?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Technical assistance will be available one hour prior to and during the Sesen Bio special meeting. Information related to technical assistance will be provided in the email you receive with your unique link that will allow you to access the Sesen Bio special meeting. We recommend that you log in at least 15 minutes before the Sesen Bio special meeting to ensure you are logged in when the Sesen Bio special meeting starts. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What happens if I do not return a proxy card or otherwise provide proxy instructions, as applicable?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">If you are a Sesen Bio stockholder of record, the failure to return your proxy card or otherwise provide proxy instructions will have the same effect as voting &#8220;AGAINST&#8221; Proposal No. 2, and will have no effect with respect to Proposal Nos. 1, 3, 4, and 5. If your shares of Sesen Bio common stock are held in &#8220;street name,&#8221; and you do not provide voting instructions, your broker, bank or other nominee may still vote your shares of Sesen Bio common stock with respect to discretionary, routine items, but may not vote your shares of Sesen Bio common stock with respect to non-discretionary, non-routine items. Brokers are not expected to have discretionary authority to vote for any of the proposals other than Proposal Nos. 2 and 5. To make sure that your vote is counted, you should instruct your broker to vote your shares, following the procedures provided by your broker. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">May I change or revoke my vote after I have submitted a proxy or provided proxy instructions?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio stockholders of record may change or revoke their vote at any time before their proxy is voted at the Sesen Bio special meeting by doing any one of the following things: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">submitting a new proxy via the internet or telephone by following the instructions on the enclosed proxy card; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">signing another proxy card and arranging for delivery of that proxy card by mail by 11:59 p.m., Eastern Time, the day before the Sesen Bio special meeting; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:63pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">giving Sesen Bio&#8217;s Corporate Secretary a written notice before the Sesen Bio special meeting that you want to revoke your proxy; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">voting during the Sesen Bio special meeting. Your attendance at the Sesen Bio special meeting alone will not revoke a previously submitted proxy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a Sesen Bio stockholder who owns shares of Sesen Bio common stock in &#8220;street name&#8221; has instructed a broker to vote its shares of Sesen Bio common stock, the stockholder must follow directions received from its broker to change those instructions. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Your vote will be counted in accordance with the last instruction received prior to the closing of the polls, whether your instruction is received by internet, telephone, mail or at the Sesen Bio special meeting. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who is paying for this proxy solicitation?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Carisma will share equally the cost of printing and filing this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus and the proxy card. Sesen Bio also may be required to reimburse banks, brokers and other custodians, nominees and fiduciaries or their respective agents for reasonable expenses incurred in forwarding proxy materials to beneficial owners of Sesen Bio common stock. </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio has engaged MacKenzie Partners, Inc., or MacKenzie Partners, to assist in the solicitation of proxies and provide related advice and informational support. Sesen Bio will pay the fees of MacKenzie Partners, which Sesen Bio expects to be approximately $20,000, plus reimbursement of out-of-pocket expenses. </font>
          </div>

        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Q:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who can help answer my questions?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">A:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">If you would like to request documents from Sesen Bio or Carisma, please send a request in writing or by telephone to either Sesen Bio or Carisma at the following addresses: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;margin-bottom:5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:202pt;">
              <div style="text-align:center;">
                <font style="font-weight:bold;letter-spacing:-0.2pt;">Sesen Bio, Inc.</font>
                <br >
                <font style="letter-spacing:0.2pt;">245 First Street, Suite 1800</font>
                <br >
                <font style="letter-spacing:0.2pt;">Cambridge, Massachusetts 02142</font>
                <br >
                <font style="letter-spacing:0.2pt;">Telephone: (617) 444-8550</font>
                <br >
                <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary</font>
                <br >
                <font style="letter-spacing:0.2pt;">Email: ir@sesenbio.com </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:202pt;">
              <div style="text-align:center;">
                <font style="font-weight:bold;letter-spacing:-0.2pt;">CARISMA Therapeutics Inc</font><font style="letter-spacing:0.2pt;">.</font>
                <br >
                <font style="letter-spacing:0.2pt;">3675 Market Street, Suite 200</font>
                <br >
                <font style="letter-spacing:0.2pt;">Philadelphia, PA 19104</font>
                <br >
                <font style="letter-spacing:0.2pt;">Telephone: (267) 491-6422</font>
                <br >
                <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary</font>
                <br >
                <font style="letter-spacing:0.2pt;">Email: info@carismatx.com</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you are a Sesen Bio stockholder and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the merger, including the procedures for voting your shares, you should contact Sesen Bio&#8217;s proxy solicitor: </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_mackenziepartners-bw.jpg" alt="[MISSING IMAGE: lg_mackenziepartners-bw.jpg]" height="57" width="192" >
        </div>
        <div style="margin-top:13pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">MacKenzie Partners, Inc. </font>
          <br >
          <font style="letter-spacing:0.2pt;">1407 Broadway, 27th Floor </font>
          <br >
          <font style="letter-spacing:0.2pt;">New York, New York 10018 </font>
          <br >
          <font style="letter-spacing:0.2pt;">(800) 322-2885 </font>
          <br >
          <font style="letter-spacing:0.2pt;">proxy@mackenziepartners.com</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the merger, the proposals being considered at the Sesen Bio special meeting, you should read this entire proxy statement/prospectus carefully, including the Original Merger Agreement, attached as Annex A-1, the Merger Agreement Amendment, attached as Annex&#160;A-2, the opinion of SVB Securities LLC, or SVB Securities, attached as Annex B and the other annexes to which you are referred herein. For more information, see the section entitled &#8220;Where You Can Find More Information&#8221; on page <a href="#tWYCF">404</a> of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in the section entitled &#8220;Matters Being Submitted to a Vote of Sesen Bio Stockholders&#8201;&#8212;&#8201;Proposal No. 2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common stock&#8221; beginning on page <a href="#tPN2A">203</a> of this proxy statement/prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Companies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Sesen Bio, Inc.</font> <br ><font style="letter-spacing:0.2pt;">245 First Street, Suite 1800</font> <br ><font style="letter-spacing:0.2pt;">Cambridge, MA 02142</font> <br ><font style="letter-spacing:0.2pt;">(617) 444-8550 </font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio is a late-stage clinical company focused on targeted fusion protein therapeutics for the treatment of patients with cancer. Sesen Bio&#8217;s most advanced product candidate, Vicineum&#8482;, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer, or NMIBC. On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase&#160;3 clinical trial, following Sesen Bio&#8217;s discussions with the United States Food and Drug Administration, or FDA. Sesen Bio has turned its primary focus to consummating a strategic transaction with the goal of maximizing shareholder value. As a result of such decision and Sesen Bio&#8217;s subsequent decision to enter into the proposed merger with Carisma, Sesen Bio no longer plans to pursue regulatory approval of Vicineum for NMIBC in the European Union, or the E.U., and has started to wind down certain of its manufacturing operations and business development partnerships. Additionally, Sesen Bio is seeking a partner for the further development of Vicineum and has engaged a financial advisor for the potential sale of Vicineum. If the merger is consummated, the combined company does not expect to pursue further development of Vicineum.</font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CARISMA Therapeutics Inc.</font> <br ><font style="letter-spacing:0.2pt;">3675 Market Street, Suite 200</font> <br ><font style="letter-spacing:0.2pt;">Philadelphia, Pennsylvania 19104</font> <br ><font style="letter-spacing:0.2pt;">(267) 491-6422 </font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Carisma is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor macrophages for the treatment of solid tumors. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Seahawk Merger Sub, Inc.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Merger Sub is a wholly-owned subsidiary of Sesen Bio, formed solely for the purposes of carrying out the merger. </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">The Merger</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tTHME">125</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If the merger is completed, Merger Sub will merge with and into Carisma, with Carisma surviving as a wholly-owned subsidiary of Sesen Bio. After the completion of the merger, Sesen Bio will change its corporate name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; as contemplated by the Merger Agreement. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">At the effective time, each outstanding share of Carisma capital stock will be converted into the right to receive a number of shares of Sesen Bio common stock equal to the exchange ratio described in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tTMAER">172</a> of this proxy statement/prospectus. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s capitalization as of December 29, 2022, the date the Merger Agreement was executed, the exchange ratio is estimated to be approximately 37.7924 shares of Sesen Bio common stock for each share of Carisma capital stock, which exchange ratio does not give effect to the proposed reverse stock split. The final exchange ratio is subject to adjustment prior to the closing of the merger based on Sesen Bio&#8217;s net cash at the closing of the merger and the aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company.</font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Also at the effective time, each outstanding Carisma option will be assumed by Sesen Bio and will be converted into an option to purchase shares of Sesen Bio common stock, with the number of shares and exercise price being appropriately adjusted to reflect the exchange ratio between Sesen Bio common stock and Carisma common stock determined in accordance with the Merger Agreement. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Each share of Sesen Bio common stock, each Sesen Bio option and each Sesen Bio RSU that is outstanding at the effective time will remain outstanding in accordance with its terms and each such share of Sesen Bio common stock, Sesen Bio option and Sesen Bio RSU, subject to the proposed reverse stock split, will be unaffected by the merger. Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 25.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of the Carisma convertible note, are expected to own approximately 74.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of the closing of the merger being at least $75.0 million. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Reasons for the Merger</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tSBRF">134</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">After consideration and consultation of its senior management, consultants and advisors, outside legal counsel and financial advisor, the Sesen Bio board of directors unanimously determined that the Merger Agreement, the merger and other transactions contemplated thereby are advisable and in the best interests of Sesen Bio and Sesen Bio stockholders. The Sesen Bio board of directors considered various reasons to reach its determination. For example: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the financial condition and prospects of Sesen Bio and the risks associated with continuing to operate Sesen Bio on a stand-alone basis, particularly in light of Sesen Bio&#8217;s July&#160;2022 decision to voluntarily pause further development of Vicineum for the treatment of NMIBC and reduce its workforce, which was based on a thorough reassessment of Vicineum following FDA feedback on the requirements for an additional Phase&#160;3 clinical trial, the evolving competitive landscape and the resulting financial analysis; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">that the Sesen Bio board of directors and its financial advisor undertook a comprehensive and thorough process of reviewing and analyzing potential strategic alternatives and merger partner candidates and Sesen Bio board of directors&#8217; view that no alternatives to the merger, including a liquidation and dissolution of Sesen Bio and the distribution of any available cash, were reasonably likely to create greater value to Sesen Bio stockholders; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; conclusion that the merger would provide existing Sesen Bio stockholders a significant opportunity to participate in the potential growth of the combined company following the merger, which will focus on Carisma&#8217;s product pipeline, while also potentially receiving certain cash payments following the closing of the merger on account of the CVR Agreement and the special cash dividend; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; belief, after a thorough review of strategic alternatives and discussions with Sesen Bio&#8217;s senior management, outside legal counsel and financial advisor, that the merger is more favorable to Sesen Bio stockholders than the potential value that might have resulted </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">from other strategic alternatives available to Sesen Bio, including a liquidation and dissolution of Sesen Bio and the distribution of any available cash; </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; belief, after thorough discussion with Sesen Bio management and Sesen Bio&#8217;s consultants and advisors, that a potential liquidation and dissolution was not reasonably likely to create greater value for Sesen Bio stockholders than a strategic alternative transaction based on, among other things, the need to hold back a meaningful amount of the Company&#8217;s current cash balance to cover current and potential future liabilities, including those triggered by a liquidation strategy; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; belief that, as a result of arm&#8217;s length negotiations with Carisma, Sesen Bio and its representatives negotiated the highest exchange ratio to which Carisma was willing to agree, and that the other terms of the Merger Agreement include the most favorable terms to Sesen Bio in the aggregate to which Carisma was willing to agree; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; positive view, based on the scientific, regulatory and technical due diligence conducted by Sesen Bio management and advisors, of the regulatory pathway for, and potential significant market opportunity of, Carisma&#8217;s product candidates, which will be the focus of the combined company. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">After consideration and consultation with Carisma senior management, its financial advisors and legal counsel, and consideration of a wide variety of factors, the Carisma board of directors concluded that a merger with Sesen Bio, together with the additional financing committed from the Carisma pre-closing financing, was the best option to generate capital resources to support the advancement of Carisma&#8217;s pipeline and fund a combined organization. The Carisma board of directors considered various reasons to reach its determination. For example: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the merger will provide current Carisma stockholders with greater liquidity by owning publicly-traded stock, and expanding both the access to capital for Carisma and the range of investors potentially available as a public company, compared to the investors Carisma could otherwise gain access to if it continued to operate as a privately-held company;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the potential benefits from increased public market awareness of Carisma and its pipeline;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the historical and current information concerning Carisma&#8217;s business, including its financial performance and condition, operations, management and pre-clinical and clinical data;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the competitive nature of the industry in which Carisma operates;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the Carisma board of directors&#8217; fiduciary duties to Carisma stockholders;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the Carisma board of directors&#8217; belief that no alternatives to the merger were reasonably likely to create greater value for Carisma stockholders, after reviewing the various financing and other strategic alternatives that were considered by the Carisma board of directors; and</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the projected financial position, operations, management structure, operating plans, and anticipated cash burn rate of the combined company, including the ability to support the combined company&#8217;s current and planned clinical trials and operations), as further discussed in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Carisma Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8201;&#8212;&#8201;Liquidity and Capital Resources&#8201;&#8212;&#8201;Funding Requirements</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tFUNDRE1">335</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus.</font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="font-style:normal;letter-spacing:0.2pt;">For additional information, see the sections entitled &#8220;</font><font style="letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Sesen Bio Reasons for the Merger</font><font style="font-style:normal;letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Carisma Reasons for the Merger</font><font style="font-style:normal;letter-spacing:0.2pt;">&#8221; in this proxy statement/prospectus. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Opinion of Sesen Bio&#8217;s Financial Advisor</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tOOSB">139</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio retained SVB Securities as its financial advisor in connection with the merger and the other transactions contemplated by the Merger Agreement. On December 29, 2022, SVB Securities rendered to the Sesen Bio board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion to the Sesen Bio board of directors dated December 29, 2022 that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">undertaken by SVB Securities in preparing its opinion, the exchange ratio proposed to be paid by Sesen Bio pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to Sesen Bio. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
            <font style="font-weight:normal;letter-spacing:0.2pt;">The full text of the written opinion of SVB Securities, dated December 29, 2022, which describes the assumptions made and the qualifications and limitations upon the review undertaken by SVB Securities in preparing its opinion, is attached as </font><font style="font-style:italic;font-weight:normal;letter-spacing:0.2pt;">Annex B</font><font style="font-weight:normal;letter-spacing:0.2pt;"> to this proxy statement/prospectus and is incorporated herein by reference. </font><font style="letter-spacing:-0.2pt;">SVB Securities&#8217; financial advisory services and opinion were provided for the information and assistance of Sesen Bio board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of the Sesen Bio board of directors&#8217; consideration of the merger and the opinion of SVB Securities addressed only the fairness, from a financial point of view, as of the date thereof, to Sesen Bio of the exchange ratio proposed to be paid by Sesen Bio pursuant to the terms of the Merger Agreement. The opinion of SVB Securities did not address any other term or aspect of the Merger Agreement or the merger and does not constitute a recommendation to any stockholder of Sesen Bio as to whether or how such holder should vote with respect to the merger or otherwise act with respect to the merger or any other matter.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The full text of the written opinion of SVB Securities should be read carefully in its entirety for a description of the assumptions made and the qualifications and limitations upon the review undertaken by SVB Securities in preparing its opinion.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview of the Merger Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Merger Consideration </font><font style="letter-spacing:0.2pt;">(see page <a href="#tTMA">171</a>)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the effective time, each outstanding share of Carisma capital stock will be converted into the right to receive a number of shares of Sesen Bio common stock equal to the exchange ratio described in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tTMAER">172</a> of this proxy statement/prospectus. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s capitalization as of December 29, 2022, the date the Merger Agreement was executed, the exchange ratio is estimated to be approximately 37.7924 shares of Sesen Bio common stock for each share of Carisma capital stock, which exchange ratio does not give effect to the proposed reverse stock split. The final exchange ratio is subject to adjustment prior to the closing of the merger based on Sesen Bio&#8217;s net cash at the closing of the merger and the aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company.</font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Also at the effective time, each outstanding Carisma option will be assumed by Sesen Bio and will be converted into an option to purchase shares of Sesen Bio common stock, with the number of shares and exercise price being appropriately adjusted to reflect the exchange ratio between Sesen Bio common stock and Carisma common stock determined in accordance with the Merger Agreement. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 25.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, are expected to own approximately 74.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of the closing of the merger being at least $75.0 million. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-style:normal;letter-spacing:0.2pt;">For a more complete description of the merger consideration, see the sections entitled &#8220;</font><font style="letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Merger Consideration</font><font style="font-style:normal;letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="font-style:normal;letter-spacing:0.2pt;">&#8221; in this proxy statement/</font>&#8203;<font style="font-style:normal;letter-spacing:0.2pt;">prospectus. </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Treatment of Sesen Bio Equity Awards and Warrants </font><font style="letter-spacing:0.2pt;">(see page <a href="#tTMAER7">174</a>)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Sesen Bio Equity Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">At the effective time, all outstanding and unexercised Sesen Bio options granted pursuant to the 2014 Incentive Plan or the 2009 Incentive Plan or as an inducement grant under Nasdaq Listing Rule&#160;5635(c)(4) </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">will remain in effect pursuant to their terms and will be unaffected by the merger. The number of shares of Sesen Bio common stock underlying the Sesen Bio options and the exercise prices for such Sesen Bio options will be appropriately adjusted to reflect the proposed reverse stock split, if approved and implemented. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the effective time, all outstanding Sesen Bio RSUs granted pursuant to the 2014 Incentive Plan or the 2009 Incentive Plan will remain in effect pursuant to their terms and will be unaffected by the merger. The number of shares of Sesen Bio common stock underlying the Sesen Bio RSUs will be appropriately adjusted to reflect the proposed reverse stock split, if approved and implemented. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Sesen Bio Warrants</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the effective time, all Sesen Bio warrants (other than certain Sesen Bio warrants that Sesen Bio may be required to repurchase at such warrant holder&#8217;s option as of a result of the merger) will remain in effect pursuant to their terms and will be unaffected by the merger. The number of shares of Sesen Bio common stock underlying such Sesen Bio warrants and the exercise prices for such Sesen Bio warrants will be appropriately adjusted to reflect the proposed reverse stock split, if approved. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Treatment of Carisma Options and Carisma Plan </font><font style="letter-spacing:0.2pt;">(see page <a href="#tTMAER9">174</a>)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the effective time, Sesen Bio will assume the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan, as amended, or the Carisma Plan, and each Carisma option in accordance with the terms of the Carisma Plan and the terms of the stock option agreement by which such Carisma option is evidenced but with such changes to such documents as Carisma and Sesen Bio mutually agree are appropriate to reflect the substitution of each Carisma option for a Sesen Bio option. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the effective time, each Carisma option outstanding and unexercised immediately prior to the effective time, whether or not vested, will be converted into a Sesen Bio option. From and after the effective time, each Carisma option assumed by Sesen Bio may be exercised for such number of shares of Sesen Bio common stock as is determined by multiplying the number of shares of Carisma common stock subject to the Carisma option, as in effect immediately prior to the effective time, by the exchange ratio and rounding that result down to the nearest whole number of shares of Sesen Bio common stock. The per share exercise price of the converted Carisma option will be determined by dividing the per share exercise price of the Carisma option, as in effect prior to the effective time, by the exchange ratio and rounding that result up to the nearest whole cent. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Conditions to the Completion of the Merger </font><font style="letter-spacing:0.2pt;">(see page <a href="#tCCM5">176</a>)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">To complete the merger, Sesen Bio stockholders must approve Proposal Nos. 1 and 2 and Carisma stockholders must adopt the Merger Agreement and approve the merger and the related transactions. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived (including Sesen Bio having net cash as of the closing of the merger greater than or equal to $75.0&#160;million). </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">No Solicitation</font><font style="letter-spacing:0.2pt;">(see page <a href="#tNSON">179</a>)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Each of Sesen Bio and Carisma agreed that during the period commencing on the date of the Original Merger Agreement and continuing until the earlier to occur of the termination of the Merger Agreement and the effective time, or the pre-closing period, except as described below, Sesen Bio and Carisma will not, nor will either party authorize any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any &#8220;acquisition proposal&#8221; or &#8220;acquisition inquiry&#8221; &#8203;(each as defined in the Merger Agreement) or take any action that could reasonably be expected to lead to an acquisition proposal or acquisition inquiry; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">furnish any non-public information regarding the party and its subsidiaries to any person in connection with or in response to an acquisition proposal or acquisition inquiry; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">approve, endorse or recommend an acquisition proposal; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any &#8220;acquisition transaction&#8221; as defined below (other than a confidentiality agreement permitted by the Merger Agreement); or </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">publicly propose to do any of the above. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Termination of the Merger Agreement </font><font style="letter-spacing:0.2pt;">(see page <a href="#tTMAER10">188</a>)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Either Sesen Bio or Carisma can terminate the Merger Agreement under certain circumstances, which would prevent the merger from being consummated. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Termination Fees</font><font style="letter-spacing:0.2pt;">(see page <a href="#tTERFEE123">190</a>)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If the Merger Agreement is terminated under certain circumstances, Sesen Bio may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million, and Carisma may be required to pay Sesen Bio a termination fee of $5.49&#160;million and/or reimburse Sesen Bio&#8217;s expenses up to a maximum of $1.75&#160;million. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">CVR Agreement</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tCVAG">192</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement and the CVR Agreement, Sesen Bio stockholders of record as of a date agreed to by Sesen Bio and Carisma prior to the effective time will receive one CVR for each share of Sesen Bio common stock held of record as of immediately prior to the effective time. Each CVR will represent the right to receive contingent cash payments (i) upon the occurrence of a certain triggering event, entitling CVR holders to a pro rata portion of the $30.0 million milestone payment to be made by Roche to Sesen Bio upon Roche&#8217;s initiation of a Phase 3 clinical trial with legacy IL-6 antagonist antibody technology previously owned by Sesen Bio for a certain indication if initiated prior to December 31, 2026, pursuant to the Roche Asset Purchase Agreement, less certain permitted deductions and (ii) from proceeds from any sale of Sesen Bio&#8217;s non-cash assets, subject to certain customary deductions, including for expenses and taxes.</font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The sole right of the holders of the CVRs is to receive cash from Sesen Bio, if any, through the rights agent in accordance with the CVR Agreement. The CVRs are not transferable, except in certain limited circumstances, will not be certificated or evidenced by any instrument and will not be registered with the SEC or listed for trading on any exchange. The CVRs will not have any voting or dividend rights, will not represent any equity or ownership interest in Sesen Bio or its subsidiaries, and interest will not accrue on any amounts payable on the CVRs. The CVR Agreement will be effective prior to the closing of the merger and will continue in effect until the earlier of March&#160;31, 2027 or the payment of all amounts payable thereunder, unless and until earlier termination of the Merger Agreement. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Support Agreements and Written Consents</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tSAAW">197</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In order to induce Sesen Bio to enter into the Merger Agreement, certain stockholders of Carisma (solely in their respective capacities as Carisma stockholders) are parties to a support agreement with Sesen Bio and Carisma pursuant to which, among other things, each such stockholder has agreed (a)&#160;to vote all of his, her or its shares of Carisma capital stock (subject to customary cutbacks in the event of certain triggering events) in favor of (i)&#160;adoption and approval of the Merger Agreement and the transactions contemplated thereby; (ii)&#160;adoption and approval of an amendment to Carisma&#8217;s certificate of incorporation, or the Carisma Certificate of Incorporation, to increase the authorized shares of Carisma common stock; (iii)&#160;acknowledgement that the approval given thereby is irrevocable and that the stockholder is aware of the stockholder&#8217;s rights to demand appraisal for its shares pursuant to Section&#160;262 of the Delaware General Corporation Law, or the DGCL; and (iv)&#160;acknowledgement that by the stockholder&#8217;s approval of the merger, the stockholder is (a)&#160;waiving its appraisal rights under the DGCL with respect to its shares, and (b)&#160;waiving any notice that may have been or may be required relating to the merger or any other transactions contemplated thereby. Additionally, each such signatory has agreed, solely in his, her or its capacity as a </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Carisma stockholder, to vote against (subject to customary cutbacks in the event of certain triggering events) any such competing acquisition proposal and any action in furtherance of any competing acquisition proposal. These signatories have also granted an irrevocable proxy to Carisma and its designee to vote their respective shares of Carisma common stock in accordance with the support agreements. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition, in order to induce Carisma to enter into the Merger Agreement, certain stockholders of Sesen Bio (solely in their respective capacities as Sesen Bio stockholders) are parties to a support agreement with Sesen Bio and Carisma pursuant to which, among other things, each such stockholder has agreed, to vote all of his, her or its shares of Sesen Bio common stock in favor of (i)&#160;adoption and approval of the Merger Agreement and the transactions contemplated thereby; (ii)&#160;the issuance of shares of Sesen Bio common stock to Carisma stockholders in connection with the Merger Agreement and the transactions contemplated thereby; (iii)&#160;the change of control of Sesen Bio resulting from the merger pursuant to Nasdaq rules; (iv)&#160;the approval of the equity plan amendment proposals; and (v)&#160;a waiver of any notice that may have been or may be required relating to the merger or any other transactions contemplated thereby. Additionally, each such signatory has agreed, solely in his, her or its capacity as a Sesen Bio stockholder, to vote against any competing acquisition proposal and any action in furtherance of any such competing acquisition proposal. These signatories have also granted an irrevocable proxy to Sesen Bio and its designee to vote their respective shares of Sesen Bio common stock in accordance with the support agreements. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Lock-Up Agreements</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tLOAG">199</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As a condition to the closing of the merger, certain stockholders of each of Sesen Bio and Carisma and their affiliates have entered into lock-up agreements, pursuant to which such parties have agreed not to, except in limited circumstances, and among other restrictions, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of or lend, directly or indirectly, any shares of Sesen Bio common stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive Sesen Bio common stock (including, Sesen Bio common stock or such other securities which may be deemed to be beneficially owned by the signatory in accordance with the rules and regulations of the SEC and securities of Sesen Bio which may be issued upon exercise of a Sesen Bio option, Sesen Bio RSU or Sesen Bio warrant) during the period commencing at the effective time and continuing until the date that is 180&#160;days after the effective time. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Certain directors and executive officers of both Sesen Bio and Carisma are party to a lock-up agreement. Carisma stockholders who have executed lock-up agreements, as of January 4, 2023, beneficially owned in the aggregate approximately 97.23% of the outstanding shares of Carisma capital stock on an as converted to Carisma common stock basis. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Subscription Agreement</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tSUAG">198</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, immediately prior to the execution and delivery of the Original Merger Agreement, Carisma entered into a subscription agreement with certain investors named therein, pursuant to which such investors have agreed to purchase shares of Carisma common stock at an aggregate purchase price of approximately $30.6&#160;million. The subscription agreement contains customary representations and warranties of Carisma and also contains customary representations and warranties of the purchasers party thereto. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The subscription agreement may not be changed, waived, amended or modified, except by an instrument in writing executed by Carisma and the purchasers then committed to purchase a majority of the shares to be sold in the Carisma pre-closing financing. The subscription agreement will terminate upon the earlier to occur of (i)&#160;such date and time that the Merger Agreement is terminated in accordance with its terms, (ii)&#160;upon the mutual written agreement of Carisma and the purchasers then committed to purchase a majority of the shares to be sold in the Carisma pre-closing financing (provided that Carisma and a purchaser may terminate the commitment of the applicable purchaser without the consent of any other party), and (iii)&#160;if the closing of the merger has not occurred on or before January&#160;31, 2023 (as such date may be extended in the event that a request for additional information is made by any governmental body or in the event that the SEC has not declared the registration statement on Form S-4, of which this proxy statement/prospectus is a </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">part, effective under the Securities Act by the date which is 60&#160;days prior to the end date), other than as a result of a willful breach of a purchaser&#8217;s obligations under the subscription agreement. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">On December 29, 2022, immediately prior to the execution and delivery of the Merger Agreement Amendment, Carisma entered into an amended and restated subscription agreement with the investors party to the original subscription agreement, pursuant to which the parties thereto clarified that shares of Carisma common stock issued in the pre-closing financing will not be registered under the Securities Act and will be subject to restrictions on resale and agreed, among other things, to enter into a registration rights agreement to provide for the registration of the resale of the shares of common stock purchased by such investors in connection with the Carisma pre-closing financing.</font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Nasdaq Stock Market Listing</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tNALI">165</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio has filed an initial listing application for the combined company with Nasdaq. If such application is accepted, Sesen Bio anticipates that the combined company&#8217;s common stock will be listed on the Nasdaq Capital Market following the closing of the merger under the trading symbol &#8220;CARM.&#8221; </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Management Following the Merger</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tMFTM">342</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">The following table lists the names, ages as of January 4, 2023 and positions of the individuals who are expected to serve as executive officers and directors of the combined company following completion of the merger. </font>
          </div>
          <table style="width:456pt;height:173.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:198pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:36pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Age </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:198pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Position </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:-0.2pt;">Executive Officers</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:198pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Steven Kelly </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">57 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">President and Chief Executive Officer </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Richard Morris </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">49 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Chief Financial Officer </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D. </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">33 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Chief Scientific Officer </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;text-align:center;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:198pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Sanford Zweifach </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">66 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Director, Chair of the Board </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">61 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D. </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">53 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D. </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">63 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D., Ph.D. </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">64 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;text-align:center;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">40 </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:198pt;">
                <font style="letter-spacing:0.2pt;">Director</font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:12.5pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Interests of Sesen Bio Directors and Executive Officers in the Merger</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tIOSB">148</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In considering the recommendation of the Sesen Bio board of directors with respect to issuing shares of Sesen Bio common stock as contemplated by the Merger Agreement and the other matters to be acted upon by Sesen Bio stockholders at the Sesen Bio special meeting, Sesen Bio stockholders should be aware that certain members of the Sesen Bio board of directors and certain Sesen Bio executive officers have interests in the merger that may be different from, or in addition to, the interests of Sesen Bio stockholders, including, among others, severance benefits, the acceleration of equity vesting, continued indemnification and the potential ability to sell an increased number of shares of common stock of the combined company in accordance with Rule&#160;144 under the Securities Act. As of January 4, 2023, Sesen Bio&#8217;s directors, executive officers and affiliates of Sesen Bio&#8217;s directors and executive officers, owned, in the aggregate, less than 1% of the shares of Sesen Bio common stock, which for purposes of this subsection excludes any Sesen Bio common stock issuable upon exercise of Sesen Bio options or vesting of Sesen Bio RSUs held by such individual. As of January 4, 2023, Sesen Bio&#8217;s directors and current executive officers owned, in the aggregate, (i)&#160;unvested Sesen Bio options covering 3,499,202 shares of Sesen Bio common stock and vested Sesen Bio options covering 8,215,261 shares of Sesen Bio common stock and (ii)&#160;unvested Sesen Bio RSUs covering 3,559,892 shares of Sesen Bio common stock. Each of Sesen Bio&#8217;s executive officers and directors have </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">also entered into a support agreement in connection with the merger, whereby such executive officers and directors have agreed to vote their shares in favor of the proposals described in this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. </font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Further, Thomas R. Cannell, D.V.M., Sesen Bio&#8217;s President and Chief Executive Officer and a member of the Sesen Bio board of directors, is expected to continue as a member of the combined company&#8217;s board of directors following the merger. The compensation arrangements with Sesen Bio&#8217;s directors and executive officers are discussed in greater detail in the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Interests of Sesen Bio Directors and Executive Officers in the Merger</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Sesen Bio Executive Compensation</font><font style="letter-spacing:0.2pt;">&#8221; in this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Interests of Carisma Directors and Executive Officers in the Merger</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tIOCD">153</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In considering the recommendation of the Carisma board of directors with respect to approving the merger and related transactions, Carisma stockholders should be aware that certain members of the Carisma board of directors and certain Carisma executive officers have interests in the merger that may be different from, or in addition to, the interests of Carisma stockholders. As of January 4, 2023, Carisma&#8217;s current directors and executive officers owned, in the aggregate, approximately 2.36% of the outstanding shares of Carisma capital stock, excluding, for this purpose any Carisma shares issuable upon exercise or settlement of Carisma stock options held by such individuals. Each of Carisma&#8217;s executive officers and the majority of Carisma&#8217;s directors have also entered into a support agreement in connection with the merger, whereby such executive officers and directors have agreed to vote their shares in favor of adoption of the Merger Agreement and approval of the merger. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Further, certain Carisma directors and executive officers are expected to become directors and executive officers of the combined company following the merger. The compensation arrangements with Carisma&#8217;s directors and executive officers are discussed in greater detail in the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Interests of Carisma Directors and Executive Officers in the Merger</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Carisma Executive Compensation</font><font style="letter-spacing:0.2pt;">&#8221; in this proxy statement/prospectus. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of the Merger</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tMUFI">160</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Subject to the qualifications and limitations set forth in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Merger</font><font style="letter-spacing:0.2pt;">,&#8221; in the opinion of WilmerHale and Hogan Lovells, the merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code, and a Carisma U.S. holder will not recognize gain or loss for U.S. federal income tax purposes upon the receipt of shares of Sesen Bio common stock in exchange for shares of Carisma capital stock in the merger, except to the extent such a Carisma U.S. holder receives cash in lieu of a fractional share of Sesen Bio common stock. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If the merger does not qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, then each Carisma U.S. holder would recognize gain or loss upon the exchange of shares of Carisma capital stock for Sesen Bio common stock in the merger equal to the difference between the fair market value of the shares of Sesen Bio common stock received in exchange for the shares of Carisma capital stock (plus any cash received in lieu of a fractional share) and such Carisma U.S. holder&#8217;s adjusted tax basis in the shares of Carisma capital stock surrendered. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Since the Sesen Bio stockholders will not sell, exchange or dispose of any shares of Sesen Bio common stock as a result of the merger, there will be no material U.S. federal income tax consequences to Sesen Bio stockholders as a result of the merger. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Merger</font><font style="letter-spacing:0.2pt;">&#8221; for a more complete description of the material U.S. federal income tax consequences of the merger to U.S. holders of Carisma capital stock. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of Receipt of CVRs</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tARTT">192</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The U.S. federal income tax treatment of the Sesen Bio U.S. holders&#8217; receipt of the CVRs is unclear. Sesen Bio intends to report the issuance of the CVRs to Sesen Bio U.S. holders under the terms expressed in the form of the CVR Agreement included in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex F</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus as a distribution </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">of property with respect to Sesen Bio common stock. In such case, each Sesen Bio U.S. holder will be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Sesen Bio U.S. holder on the date of the issuance. This distribution should be treated first as a taxable dividend to the extent of the Sesen Bio U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes after taking into account the special cash dividend as described below), then as a non-taxable return of capital to the extent of the Sesen Bio U.S. holder&#8217;s basis in its Sesen Bio common stock, and finally as capital gain from the sale or exchange of Sesen Bio common stock with respect to any remaining value. Sesen Bio currently has negative accumulated earnings and profits and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Sesen Bio expects most or all of this distribution to be treated as other than a dividend for U.S. federal income tax purposes. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page&#160;<a href="#tARTT">192</a> of this proxy statement/prospectus for a more complete description of the material U.S. federal income tax consequences of the receipt of CVRs to Sesen Bio U.S. holders, including possible alternative treatments. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The tax consequences to you of the receipt of CVRs will depend on your particular facts and circumstances. You should consult your tax advisors as to the specific tax consequences to you. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of Receipt of the Special Cash Dividend</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tMUFI1">162</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In connection with the merger, the Sesen Bio board of directors will declare and pay a special cash dividend to Sesen Bio stockholders of record prior to the effective time consisting of Sesen Bio&#8217;s available cash in an aggregate amount expected to be approximately $70.0&#160;million, assuming Sesen Bio&#8217;s net cash as of closing of the merger is $75.0&#160;million. The U.S. federal income tax consequences of the Sesen Bio U.S. holders&#8217; receipt of such special cash dividend generally should be treated first as a taxable dividend to the extent of the Sesen Bio U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Sesen Bio U.S. holder&#8217;s basis in its Sesen Bio common stock, and finally as capital gain from the sale or exchange of Sesen Bio common stock with respect to any remaining amount. Sesen Bio currently has negative accumulated earnings and profits and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Sesen Bio expects most or all of the special cash dividend to be treated as other than a dividend for U.S. federal income tax purposes. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Special Cash Dividend</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tMUFI1">162</a> of this proxy statement/prospectus for a general description of the tax consequences of the special cash dividend that Sesen Bio will pay in connection with the consummation of the merger, subject to Sesen Bio having net cash as of the closing of the merger greater than or equal to $75.0&#160;million. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The tax consequences to you of the special cash dividend will depend on your particular facts and circumstances. You should consult your tax advisors as to the specific tax consequences to you. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="letter-spacing:0.2pt;"> (see page <a href="#MUIT6">209</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio intends to report the proposed reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code. In general, and subject to the qualifications and limitations set forth in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Proposal No. 2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common stock&#160;&#8212; Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#MUIT6">209</a> of this proxy statement/prospectus, if the proposed reverse stock split qualifies as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code, a Sesen Bio U.S. holder should not recognize gain or loss upon the proposed reverse stock split, except to the extent a Sesen Bio U.S. holder receives cash in lieu of a fractional share of Sesen Bio common stock. As discussed in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Proposal No. 2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common stock &#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="letter-spacing:0.2pt;">&#8221; on page <a href="#MUIT6">209</a> of this proxy statement/prospectus, these consequences assume that distribution of the CVRs and any cash distributed pursuant to a special cash </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">dividend will be treated for U.S. federal income tax purposes as separate and distinct from the proposed reverse stock split. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Proposal No. 2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common stock&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#MUIT6">209</a> of this proxy statement/prospectus for a more complete description of the material U.S. federal income tax consequences of the proposed reverse stock split to Sesen Bio U.S. holders. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The tax consequences to you of the proposed reverse stock split will depend on your particular facts and circumstances. You should consult your tax advisors as to the specific tax consequences to you. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Risk Factors</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tRIFA">26</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Both Sesen Bio and Carisma are subject to various risks associated with their businesses and their industries. In addition, the merger poses a number of risks to each company and its respective stockholders, including the possibility that the merger may not be completed and the following risks: </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to the Merger</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The exchange ratio will not change or otherwise be adjusted based on the market price of Sesen Bio common stock as the exchange ratio depends on the Sesen Bio net cash at the closing of the merger and not the market price of Sesen Bio common stock, so the merger consideration at the closing of the merger may have a greater or lesser value than at the time the Merger Agreement was signed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio stockholders and Carisma stockholders may not realize a benefit from the merger commensurate with the ownership dilution they will experience in connection with the merger and the Carisma pre-closing financing and the conversion of the Carisma convertible note. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Failure to complete the merger may result in either Sesen Bio or Carisma paying a termination fee to the other party and could significantly harm the market price of Sesen Bio common stock and negatively affect the future business and operations of each company. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The issuance of Sesen Bio common stock to Carisma stockholders pursuant to the Merger Agreement and the resulting change in control from the merger must be approved by Sesen Bio stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Carisma stockholders. Failure to obtain these approvals would prevent the closing of the merger. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Some Sesen Bio and Carisma executive officers and directors have interests in the merger that are different from the Sesen Bio stockholders and Carisma stockholders and that may influence them to support or approve the merger without regard to the interests of the Sesen Bio stockholders and Carisma stockholders. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If the conditions to the merger are not satisfied or waived, the merger will not occur. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Sesen Bio</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If the merger is not completed, the Sesen Bio board of directors may decide to pursue a liquidation and dissolution of Sesen Bio. In such an event, there can be no assurances as to the amount or timing of available cash left, if any, to distribute to Sesen Bio stockholders after paying its debts and other obligations and setting aside funds for reserves. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio stockholders may not receive any payment on the CVRs from the proceeds related to either the Roche Asset Purchase Agreement or any sale of Sesen Bio&#8217;s non-cash assets and therefore the CVRs may expire valueless, result in lower returns than anticipated or none at all. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio is substantially dependent on its remaining employees to facilitate the consummation of the merger. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio has incurred significant losses since its inception and anticipates that it will continue to incur losses for the foreseeable future if the merger is not completed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">With the exception of specified regulatory, development and commercial milestones under the Roche Asset Purchase Agreement, Sesen Bio currently has no potential source of revenue and may never become profitable. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If the merger is not completed and Sesen Bio resumes clinical development of Vicineum, Sesen Bio will need substantial additional funding. If Sesen Bio is unable to raise capital when needed, Sesen Bio could be forced to delay, reduce or eliminate its product development programs or commercialization efforts. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If Sesen Bio is unable to regain compliance with the listing requirements of the Nasdaq Capital Market, Sesen Bio common stock may be delisted from the Nasdaq Capital Market which could have a material adverse effect on Sesen Bio&#8217;s business and could make it more difficult for Sesen Bio stockholders to sell their shares of Sesen Bio common stock. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Carisma</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Carisma has incurred significant losses since its inception. Carisma expects to continue to incur significant expenses and operating losses for the foreseeable future and may never achieve or maintain profitability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Carisma has never generated revenue from product sales and may never achieve or maintain profitability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Carisma is heavily dependent on the success of its lead product candidate, CT-0508, which will require significant clinical testing before it can seek marketing approval and potentially launch commercial sales. If CT-0508 does not receive marketing approval or is not successfully commercialized, or if there is significant delay in doing so, Carisma&#8217;s business will be harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Carisma will need substantial additional funding for its continuing operations. If Carisma is unable to raise capital when needed or on acceptable terms, it could be forced to delay, reduce or eliminate its discovery or product development programs or commercialization efforts. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Cell therapy is a rapidly evolving area of science, and the approach Carisma is taking to discover and develop product candidates by utilizing genetically modified macrophages is novel and may never lead to approved or marketable products. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Even if any of Carisma&#8217;s product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of its product candidates, if approved, may be smaller than it estimates. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Carisma relies, and expects to continue to rely, on third parties to conduct its clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay Carisma&#8217;s ability to seek or obtain marketing approval for or commercialize its product candidates or otherwise harm its business. If Carisma is not able to maintain these third-party relationships or if these arrangements are terminated, it may have to alter its development and commercialization plans and its business could be adversely affected. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If Carisma is unable to obtain, maintain and enforce patent protection for its technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, its competitors could develop and commercialize technology and products similar or identical to Carisma&#8217;s, and its ability to successfully develop and commercialize its technology and product candidates may be adversely affected and Carisma may not be able to compete effectively in its market. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to the Ownership of the Common Stock of the Combined Company</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the combined company&#8217;s common stock may drop following the merger. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The combined company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Once the combined company is no longer a &#8220;smaller reporting company&#8221; or otherwise no longer qualifies for applicable exemptions, the combined company will be subject to additional laws and regulations affecting public companies that will increase the combined company&#8217;s costs and the demands on management and could harm the combined company&#8217;s operating results. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company, which may be beneficial to its stockholders, more difficult and may prevent attempts by its stockholders to replace or remove its management. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">These risks and other risks are discussed in greater detail under the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Risk Factors</font><font style="letter-spacing:0.2pt;">&#8221; in this proxy statement/prospectus. Sesen Bio and Carisma both encourage you to read and consider all of these risks carefully. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Regulatory Approvals</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tREAP">160</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In the U.S., Sesen Bio must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of Sesen Bio common stock and the filing of this proxy statement/prospectus with the SEC. Sesen Bio does not intend to seek any regulatory approval from antitrust authorities to consummate the transactions. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Anticipated Accounting Treatment</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tAAT">166</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The merger is expected to be accounted for as a reverse recapitalization under U.S. generally accepted accounting principles, or U.S. GAAP, because the primary assets of Sesen Bio are cash, cash equivalents and marketable securities. For financial reporting purposes, Carisma has been determined to be the accounting acquirer based upon the terms of the merger including: (i)&#160;Carisma stockholders and holders of securities convertible into Carisma common stock are expected to own approximately 66% of the combined company (based on estimates made at the time of signing the Original Merger Agreement), (ii)&#160;Carisma will hold the majority (six of seven) of board seats of the combined company and (iii)&#160;Carisma management will hold all key positions in the management of the combined company. Accordingly, the merger is expected to be treated as the equivalent of Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the merger, the net assets of Sesen Bio will be recorded at their acquisition-date fair value in the consolidated financial statements of Carisma and the reported operating results prior to the merger will be those of Carisma. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Unaudited Pro Forma Condensed Combined Financial Information</font><font style="letter-spacing:0.2pt;">&#8221; in this proxy statement/prospectus for additional information. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Appraisal Rights and Dissenters&#8217; Rights</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tAAT">166</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Holders of Sesen Bio common stock are not entitled to appraisal rights in connection with the merger under Delaware law. Holders of Carisma capital stock are entitled to appraisal rights in connection with the merger under Delaware law. For more information about such rights, see the provisions of Section&#160;262 of the DGCL attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex H</font><font style="letter-spacing:0.2pt;"> and the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Appraisal Rights and Dissenters&#8217; Rights</font><font style="letter-spacing:0.2pt;">&#8221; in this proxy statement/prospectus. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Comparison of Stockholder Rights</font><font style="letter-spacing:0.2pt;"> (see page <a href="#tCORO">386</a>) </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Both Sesen Bio and Carisma are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the DGCL. If the merger is completed, Carisma stockholders will become stockholders of Sesen Bio, and their rights will be governed by the DGCL, Sesen Bio&#8217;s amended and restated bylaws, or the Sesen Bio Bylaws, and the Sesen Bio Certificate of Incorporation, as may be further amended by Proposal No. 2 if approved by the Sesen Bio stockholders at the Sesen Bio special meeting. The rights of Sesen Bio stockholders contained in the Sesen Bio Certificate of Incorporation and Sesen Bio Bylaws differ from the rights of Carisma stockholders under the Carisma Certificate of Incorporation, and Carisma&#8217;s bylaws, or the Carisma Bylaws, as more fully described under the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Comparison of Rights of Holders of Sesen Bio Stock and Carisma Stock</font><font style="letter-spacing:0.2pt;">&#8221; in this proxy statement/prospectus. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Litigation Related to the Merger</font><font style="letter-spacing:0.2pt;"> (see page&#160;<a href="#tLRTM">169</a>)</font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio received two letters on October 21, 2022 and one letter on November 4, 2022 on behalf of purported stockholders demanding that Sesen Bio amend this proxy statement/prospectus to provide </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">additional disclosures that such stockholders allege were improperly omitted from this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, including information regarding the financial projections with respect to Carisma, the financial analyses performed by SVB Securities in support of its fairness opinion, and the background and process leading to the execution of the Merger Agreement. In addition, Sesen Bio received a books and records demand, dated November 18, 2022, on behalf of a purported stockholder of Sesen Bio, seeking access to certain relevant books and records of Sesen Bio, pursuant to Section 220 of the DGCL, in connection with the merger and the securities and derivative litigations arising out of the CRL that Sesen Bio received from the FDA. Further, on November 28, 2022, a purported Sesen Bio stockholder filed a complaint in the U.S. District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Keller v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:22-cv-10085 (S.D.N.Y.). Subsequently, on December 20, 2022, the purported stockholder voluntarily dismissed the complaint and on December 21, 2022, filed a new complaint as a putative class action in the Court of Chancery for the State of Delaware, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Keller v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 2022-1186 (Del. Ch. Dec. 21, 2022). The demand letters assert claims against Sesen Bio and the Sesen Bio board of directors under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements. The putative class action asserts claims against Sesen Bio and the Sesen Bio board of directors for breach of fiduciary duty based on the same allegedly false and misleading statements. Sesen Bio believes that the allegations in these stockholder demands and the complaint are without merit. At this time, no assessment can be made as to the likely outcomes or whether the outcomes will be material to Sesen Bio. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement &#8212; Litigation Relating to the Merger</font><font style="letter-spacing:0.2pt;">&#8221; in this proxy statement/prospectus for additional information.</font></div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMPAD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:212pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MARKET PRICE AND DIVIDEND INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio common stock is listed on the Nasdaq Capital Market under the symbol &#8220;SESN.&#8221; Carisma is a private company and shares of Carisma common stock are not publicly traded. The closing price of Sesen Bio common stock on September&#160;20, 2022, the last trading day prior to the public announcement of the merger, was $0.6692 per share, and the closing price of Sesen Bio common stock on January 17, 2023, the last practicable trading day prior to the date of this proxy statement/prospectus, was $0.6493 per share, each as reported on the Nasdaq Capital Market. Because the market price of Sesen Bio common stock is subject to fluctuation, the market value of the shares of Sesen Bio common stock that Carisma stockholders will be entitled to receive in the merger may increase or decrease. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Assuming stockholder approval of Proposal Nos. 1 and 2 and successful application for initial listing on the Nasdaq Capital Market, following the consummation of the merger, the Sesen Bio common stock will trade on the Nasdaq Capital Market under the new name, &#8220;Carisma Therapeutics Inc.,&#8221; and new trading symbol &#8220;CARM.&#8221; </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As of January 17, 2023, the record date for the Sesen Bio special meeting, there were approximately 25&#160;</font> <font style="letter-spacing:0.2pt;">holders of record of Sesen Bio common stock. As of January 17, 2023, there were 32 holders of record of Carisma capital stock. This number does not include stockholders for whom shares were held in &#8220;street name.&#8221; For detailed information regarding the beneficial ownership of certain Sesen Bio stockholders upon consummation of the merger, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Stockholders of the Combined Company</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tPSOT">400</a> of this proxy statement/prospectus. </font></div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has never declared or paid any cash dividends on the Sesen Bio common stock and does not anticipate paying cash dividends on the Sesen Bio common stock for the foreseeable future, other than the special cash dividend that Sesen Bio will pay to Sesen Bio stockholders in connection with the consummation of the merger, subject to Sesen Bio having net cash as of the closing of the merger greater than or equal to $75.0 million. Carisma has never declared or paid any cash dividends on the Carisma common stock and does not anticipate paying cash dividends on the Carisma common stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the merger will be at the discretion of the combined company&#8217;s then-current board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a><a name="tRRTT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained in this proxy statement/prospectus, you should carefully consider the material risks described below and those described in the section entitled &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221; beginning on page <a href="#tCSCF">118</a> of this proxy statement/prospectus before deciding how to vote your shares of Sesen Bio common stock.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The exchange ratio will not change or otherwise be adjusted based on the market price of Sesen Bio common stock as the exchange ratio depends on the Sesen Bio net cash at the closing of the merger and not the market price of Sesen Bio common stock, so the merger consideration at the closing of the merger may have a greater or lesser value than at the time the Merger Agreement was signed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement has set the calculation of the exchange ratio for the Carisma capital stock, and the exchange ratio is based on the fully-diluted capitalization of Carisma and Sesen Bio, in each case immediately prior to the closing of the merger (after giving effect to the Carisma pre-closing financing) as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tTMAER">172</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The closing price of Sesen Bio common stock on September 20, 2022, the last trading day prior to the public announcement of the merger, was $0.6692 per share. The Merger Agreement does not include a price-based termination right. Therefore, if before the completion of the merger the market price of Sesen Bio common stock declines from the market price on the date of the Original Merger Agreement, then Carisma stockholders could receive merger consideration with substantially lower value than the value of such merger consideration on the date of the Original Merger Agreement. Similarly, if before the completion of the merger the market price of Sesen Bio common stock increases from the market price of Sesen Bio common stock on the date of the Original Merger Agreement, then Carisma stockholders could receive merger consideration with substantially greater value than the value of such merger consideration on the date of the Original Merger Agreement. Because the exchange ratio does not adjust as a direct result of changes in the market price of Sesen Bio common stock, changes in the market price of Sesen Bio common stock will change the value of the total merger consideration payable to Carisma stockholders pursuant to the Original Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Stock price changes may result from a variety of factors, including changes in Sesen Bio&#8217;s or Carisma&#8217;s respective businesses, operations and prospects, reductions or changes in U.S. government spending or budgetary policies, market assessments of the likelihood that the merger will be completed, interest rates, federal, state and local legislation, governmental regulation, legal developments in the industry segments in which Sesen Bio or Carisma operate, the timing of the merger, and general market, industry and economic conditions, including pandemics and other public health emergencies. Recent events surrounding the global economy, geopolitics and the COVID-19 pandemic continue to evolve and have introduced unusually high levels of volatility into financial and stock markets, and may affect the value of Sesen Bio common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio stockholders and Carisma stockholders may not realize a benefit from the merger commensurate with the ownership dilution they will experience in connection with the merger and the Carisma pre-closing financing and the conversion of the Carisma convertible note.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the merger, Sesen Bio stockholders and Carisma stockholders will have experienced substantial dilution of their ownership interests in their respective companies, including as a result of the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the merger and the Carisma pre-closing financing. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Failure to complete the merger may result in either Sesen Bio or Carisma paying a termination fee to the other party and could significantly harm the market price of Sesen Bio common stock and negatively affect the future business and operations of each company.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not completed and the Merger Agreement is terminated under certain circumstances, Sesen Bio may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million, and Carisma may be required to pay Sesen Bio a termination fee of $5.49&#160;million and/or reimburse Sesen Bio&#8217;s expenses up to a maximum of $1.75&#160;million. Even if a termination fee or reimbursement of expenses of the other party are not payable in connection with a termination of the Merger Agreement, each of Sesen Bio and Carisma will have incurred significant fees and expenses, which must be paid whether or not the merger is completed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, if the Merger Agreement is terminated and the Sesen Bio board of directors or Carisma board of directors determines to seek another business combination, there can be no assurance that either Sesen Bio or Carisma will be able to find a partner and close an alternative transaction on terms that are as favorable or more favorable than the terms set forth in the Merger Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The issuance of Sesen Bio common stock to Carisma stockholders pursuant to the Merger Agreement and the resulting change in control from the merger must be approved by Sesen Bio stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Carisma stockholders. Failure to obtain these approvals would prevent the closing of the merger.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before the merger can be completed, the Sesen Bio stockholders must approve, among other things, the issuance of Sesen Bio common stock to Carisma stockholders pursuant to the Merger Agreement and the resulting change in control from the merger, and Carisma stockholders must adopt the Merger Agreement and approve the merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the merger. Any delay in completing the merger may materially adversely affect the timing and benefits that are expected to be achieved from the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The merger may be completed even though certain events occur prior to the closing of the merger that materially and adversely affect Sesen Bio or Carisma.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement provides that either Sesen Bio or Carisma can refuse to complete the merger if there is a material adverse change affecting the other party between September&#160;20, 2022, the date of the Original Merger Agreement, and the closing of the merger. However, certain types of changes do not permit either party to refuse to complete the merger, even if such change could be said to have a material adverse effect on Sesen Bio or Carisma, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">general business, economic or political conditions or conditions generally affecting the industries in which Sesen Bio or Carisma, as applicable, operates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any natural disaster, epidemic, pandemic (including COVID-19), certain COVID-19 measures or responses, any acts of war, armed hostilities or terrorism; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">with respect to Sesen Bio, any change in the trading price or trading volume of Sesen Bio common stock, excluding any underlying effect that may have caused such change, unless such effect is otherwise exempt from causing a material adverse effect under the Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any change in, or any compliance with or action taken for the purpose of complying with, applicable laws or U.S. GAAP, or interpretations thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">with respect to any product or product candidate of Sesen Bio or its subsidiaries or Carisma or its subsidiaries, as applicable, the request of the FDA to refile, amend, or temporarily delay making any regulatory application or filing related to such product or product candidate or the protocol for any clinical trial relating to such product or product candidate, unless in the event of repeated or continued adverse decisions with respect to the applicable party&#8217;s product or product candidates by the FDA; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the taking of any action or failure to take action by Sesen Bio or Carisma, as applicable, expressly required to comply with the terms of the Merger Agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If adverse changes occur and Sesen Bio and Carisma still complete the merger, the market price of the combined company&#8217;s common stock may suffer. This in turn may reduce the value of the merger to the Sesen Bio stockholders, Carisma stockholders or both. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Some Sesen Bio and Carisma executive officers and directors have interests in the merger that are different from the Sesen Bio stockholders and Carisma stockholders and that may influence them to support or approve the merger without regard to the interests of the Sesen Bio stockholders and Carisma stockholders.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain executive officers and directors of Sesen Bio and Carisma participate in arrangements that provide them with interests in the merger that are different from the interests of the Sesen Bio stockholders and Carisma stockholders, including, among others, severance benefits, the acceleration of equity vesting, continued indemnification and the potential ability to sell an increased number of shares of common stock of the combined company in accordance with Rule&#160;144 under the Securities Act. Further, Thomas R. Cannell, D.V.M., Sesen Bio&#8217;s President and Chief Executive Officer and a current member of the Sesen Bio board of directors, is expected to continue as a member of the combined company&#8217;s board of directors following the merger. The compensation arrangements with Sesen Bio&#8217;s executive officers and directors are discussed in greater detail in the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Interests of Sesen Bio Directors and Executive Officers in the Merger</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Sesen Bio Executive Compensation&#8201;&#8212;&#8201;Director Compensation</font><font style="letter-spacing:0.2pt;">&#8221; beginning on pages&#160;<a href="#tIOSB">148</a> and 16, respectively, of this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These interests, among others, may influence the executive officers and directors of Sesen Bio and Carisma to support or approve the merger. For more information concerning the interests of Sesen Bio&#8217;s and Carisma&#8217;s respective executive officers and directors, see the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Interests of Sesen Bio Directors and Executive Officers in the Merger&#8221;</font><font style="letter-spacing:0.2pt;"> and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Interests of Carisma Directors and Executive Officers in the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on pages <a href="#tIOSB">148</a> and <a href="#tIOCD">153</a>, respectively, of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The market price of the combined company&#8217;s common stock following the merger may decline as a result of the merger.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The market price of the combined company&#8217;s common stock may decline as a result of the merger for a number of reasons, including if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">investors react negatively to the prospects of the combined company&#8217;s product candidates, business and financial condition following the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effect of the merger on the combined company&#8217;s business and prospects is not consistent with the expectations of financial or industry analysts; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the combined company does not achieve the perceived benefits of the merger as rapidly or to the extent anticipated by financial or industry analysts. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.02pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio stockholders and Carisma stockholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing of the merger as compared to their current ownership and voting interest in the respective companies.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the merger is completed, the current Sesen Bio stockholders and Carisma stockholders will own a smaller&#160;percentage of the combined company than their ownership in their respective companies prior to the merger. Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 25.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, are expected to own approximately 74.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including Sesen Bio&#8217;s net cash as of closing being $75.0 million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Raising additional capital may cause dilution to the combined company&#8217;s stockholders, restrict its operations or require it to relinquish rights to its technologies or product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Until such time, if ever, as the combined company, operating as Carisma, can generate substantial revenues from product sales, Carisma expects to finance its cash needs through a combination of public and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">private equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although Carisma may receive future payments under its collaboration with Moderna&#160;Inc., or Moderna, Carisma does not currently have any other committed external source of funds. The terms of any financing may adversely affect the holdings or the rights of the combined company&#8217;s stockholders and the issuance of additional securities, whether equity or debt, by the combined company, or the possibility of such issuance, may cause the market price of the combined company&#8217;s shares of common stock to decline. To the extent that the combined company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of the combined company&#8217;s stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect the rights of such stockholders. Debt financing and preferred equity financing, if available, would increase the combined company&#8217;s fixed payment obligations and may involve agreements that include covenants limiting or restricting the combined company&#8217;s operations and ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing the combined company&#8217;s assets, making capital expenditures, redeeming its stock, making certain investments, declaring dividends or other operating restrictions that could adversely impact the combined company&#8217;s ability to conduct its business. The combined company could also be required to meet certain milestones in connection with debt financing and the failure to achieve such milestones by certain dates may force the combined company to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to the combined company which could have a material adverse effect on the combined company&#8217;s business, operating results and prospects. The combined company also could be required to seek funds through arrangements with collaborators or otherwise at an earlier stage than otherwise would be desirable. If the combined company raises funds through additional collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, the combined company may have to relinquish valuable rights to its intellectual property, future revenue streams, discovery programs or product candidates, grant licenses on terms that may not be favorable to the combined company or grant rights to develop and market product candidates that the combined company would otherwise prefer to develop and market itself, any of which may have a material adverse effect on the combined company&#8217;s business, operating results and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">During the pendency of the merger, Sesen Bio and Carisma may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Covenants in the Merger Agreement impede the ability of Sesen Bio and Carisma to make acquisitions during the pendency of the merger, subject to specified exceptions. As a result, if the merger is not completed, the parties may be at a disadvantage to their competitors during such period. In addition, while the Merger Agreement is in effect, each party is generally prohibited from soliciting, initiating or knowingly encouraging, inducing or facilitating any inquiries, indications of interest, proposals or offers that constitute or may reasonably be expected to lead to certain transactions involving a third party, including a merger, sale of assets or other business combination, subject to specified exceptions. Any such transactions could be favorable to such party&#8217;s stockholders, but the parties may be unable to pursue them. For more information, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;No Solicitation</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tNSON">179</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The terms of the Merger Agreement prohibit each of Sesen Bio and Carisma from soliciting alternative takeover proposals or cooperating with persons making unsolicited takeover proposals, except in limited circumstances when the Sesen Bio board of directors or the Carisma board of directors, as applicable, determines in good faith that an unsolicited alternative takeover proposal is or is reasonably likely to result in a superior takeover proposal and that failure to cooperate with the proponent of the proposal is reasonably likely to be inconsistent with the applicable board&#8217;s fiduciary duties. Any such transactions could be favorable to Sesen Bio stockholders or Carisma stockholders, as applicable. In addition, if Sesen Bio terminates the Merger Agreement under certain circumstances, including terminating because of a decision of Sesen Bio to enter into a definitive agreement with respect to a superior offer, Sesen Bio would be required to pay a termination fee of $7.6&#160;million to Carisma and/or reimburse Carisma&#8217;s expenses up to a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">maximum of $1.75&#160;million. This termination fee described above may discourage third parties from submitting alternative takeover proposals to Sesen Bio stockholders, and may cause the Sesen Bio board of directors to be less inclined to recommend an alternative takeover proposal. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Because the lack of a public market for Carisma common stock makes it difficult to evaluate the value of Carisma common stock, the Carisma stockholders may receive shares of Sesen Bio common stock in the merger that have a value that is less than, or greater than, the fair market value of Carisma common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The outstanding common stock of Carisma is privately held and is not traded in any public market. The lack of a public market makes it extremely difficult to determine the fair market value of Carisma. Because the&#160;percentage of Sesen Bio common stock to be issued to Carisma stockholders was determined based on negotiations between the parties, it is possible the value of Sesen Bio common stock to be received by Carisma stockholders will be less than the fair market value of Carisma, or the value of Sesen Bio&#8217;s common stock to be received by Carisma stockholders may be more than the aggregate fair market value for Carisma. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If the conditions to the merger are not satisfied or waived, the merger will not occur.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if the transactions contemplated by the Merger Agreement are approved by Sesen Bio stockholders and Carisma stockholders, certain other specified conditions set forth in the Merger Agreement must be satisfied, to the extent permitted by applicable law, or waived to complete the merger, including approval from Nasdaq to maintain the listing of the Sesen Bio common stock on the Nasdaq Capital Market following the merger and the listing of the shares of Sesen Bio common stock being issued in the merger and the conversion of the Carisma convertible note. These conditions are set forth in the Merger Agreement and each material condition to the completion of the merger is described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Conditions to the Completion of the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCCM5">176</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. Sesen Bio and Carisma cannot assure you that all of the conditions will be satisfied or waived. If the conditions are not satisfied or waived, the merger will not occur or will be delayed, and Sesen Bio and Carisma each may lose some or all of the intended benefits of the merger. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The merger may fail to qualify as a &#8220;reorganization&#8221; for U.S. federal income tax purposes, resulting in recognition of taxable gain or loss by Carisma stockholders in respect of their Carisma capital stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Carisma intend for the merger to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tMUFI">160</a> of this proxy statement/prospectus. In the event that the merger does not qualify as a &#8220;reorganization,&#8221; the merger would result in taxable gain or loss for each Carisma stockholder, with the amount of such gain or loss determined by the amount that each Carisma stockholder&#8217;s adjusted tax basis in the Carisma capital stock surrendered is less or more than the fair market value of the Sesen Bio common stock and any cash in lieu of a fractional share received in exchange therefor. Each Carisma stockholder is urged to consult with his, her or its own tax advisor with respect to the tax consequences of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If existing Sesen Bio stockholders and Carisma stockholders sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public market after the merger, the trading price of the common stock of the combined company could decline. Based on shares outstanding as of December 29, 2022, the date the Merger Agreement Amendment was executed, and taking into account the consummation of the Carisma pre-closing financing, the conversion of Carisma&#8217;s $35.0 million outstanding convertible note and an assumed exchange ratio of 37.7924, the combined company is expected to have outstanding a total of approximately 883,803,409 shares of common stock (prior to giving effect to the proposed reverse stock split) immediately following the completion of the merger. Not all shares of Sesen Bio common stock will be freely tradable, without restriction, in the public market. For example, an aggregate of 265,069,468 shares of the combined company&#8217;s common stock will be subject to the lock-up agreements required under the Merger Agreement as of the closing of the merger. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRRTT1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The historical unaudited pro&#160;forma condensed combined financial information may not be representative of the combined company&#8217;s results after the merger.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The historical unaudited pro&#160;forma condensed combined financial information included elsewhere in this proxy statement/prospectus has been presented for informational purposes only and is not necessarily indicative of the financial position or results of operations that actually would have occurred had the merger been completed as of the date indicated, nor is it indicative of future operating results or financial position. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lawsuits have been filed, and additional lawsuits may be filed in the future, against Sesen Bio, the members of the Sesen Bio board of directors, Carisma and/or the members of the Carisma board of directors arising out of the merger, which may delay or prevent the merger.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additional putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against Sesen Bio, the Sesen Bio board of directors, Carisma, and/or the Carisma board of directors in connection with the transactions contemplated by the Merger Agreement. For example, in December 2022, a complaint was filed in the Court of Chancery for the State of Delaware against Sesen Bio and the members of its board of directors. The outcome of litigation is uncertain, and Sesen Bio and Carisma may not be successful in defending against any such future claims. Lawsuits that may be filed against Sesen Bio, the Sesen Bio board of directors, Carisma, and/or the Carisma board of directors could delay or prevent the merger, divert the attention of the management teams and employees of Sesen Bio and Carisma from day-to-day business and otherwise adversely affect the business and financial condition of Sesen Bio, Carisma or the combined company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to the Proposed Reverse Stock Split</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The proposed reverse stock split may not increase the combined company&#8217;s stock price over the long-term.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">One of the purposes of the proposed reverse stock split is to increase the per-share market price of the Sesen Bio common stock. It cannot be assured, however, that the proposed reverse stock split will accomplish this objective for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of Sesen Bio common stock will proportionally increase the per-share market price of Sesen Bio common stock, it cannot be assured that the proposed reverse stock split will increase the per-share market price of Sesen Bio common stock by a multiple of the proposed reverse stock split ratio, or result in any permanent or sustained increase in the per-share market price of Sesen Bio common stock, which is dependent upon many factors, including the combined company&#8217;s business and financial performance, general market conditions and prospects for future success. Thus, while the stock price of the combined company might meet the continued listing requirements for the Nasdaq Capital Market initially, it cannot be assured that it will continue to do so. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The proposed reverse stock split may decrease the liquidity of the combined company&#8217;s common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although the Sesen Bio board of directors believes that the anticipated increase in the per-share market price of the combined company&#8217;s common stock as a result of the proposed reverse stock split could encourage interest in the combined company&#8217;s common stock and possibly promote greater liquidity for stockholders of the combined company, such liquidity could also be adversely affected by the reduced number of shares outstanding after the proposed reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the combined company&#8217;s common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Should the market price of the combined company&#8217;s common stock decline after the proposed reverse stock split, the&#160;percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the proposed reverse stock split. The proposed reverse stock split may be viewed negatively by the market and, consequently, may lead to a decrease in the combined company&#8217;s overall market capitalization. If the per-share market price does not increase in proportion to the exact ratio of the proposed reverse stock split, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some cases, the per-share market price of companies that have effected reverse stock splits subsequently declined back to pre-reverse split levels, and accordingly, it cannot be assured that the total market value of the combined company&#8217;s common stock will remain the same after the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRRTS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">proposed reverse stock split is effected, or that the proposed reverse stock split will not have an adverse effect on the price of the combined company&#8217;s common stock due to the reduced number of outstanding shares after the proposed reverse stock split. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Sesen Bio</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If the merger is not completed, the Sesen Bio board of directors may decide to pursue a liquidation and dissolution of Sesen Bio. In such an event, there can be no assurances as to the amount or timing of available cash left, if any, to distribute to Sesen Bio stockholders after paying its debts and other obligations and setting aside funds for reserves.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While Sesen Bio has entered into the Merger Agreement with Carisma, the closing of the merger may be delayed or may not occur at all and there can be no assurance that the merger will deliver the anticipated benefits Sesen Bio expects or enhance stockholder value. If the merger is not completed and the Merger Agreement is terminated under certain circumstances, Sesen Bio may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million. Even if a termination fee is not payable in connection with a termination of the Merger Agreement, Sesen Bio will have incurred significant fees and expenses, which must be paid whether or not the merger is completed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If, for any reason, the merger does not close, the Sesen Bio board of directors may elect to, among other things, attempt to complete another strategic transaction like the merger, attempt to sell or otherwise dispose of the various assets of Sesen Bio, resume its research and development activities and continue to operate the business of Sesen Bio. Any of these alternatives would be costly and time-consuming and would require that Sesen Bio obtain additional funding. Sesen Bio expects that it would be difficult to secure financing in a timely manner, on favorable terms or at all. Sesen Bio can make no assurances that it would be able to obtain additional financing or find a partner and close an alternative transaction on terms that are as favorable or more favorable than the terms set forth in the Merger Agreement or that any such alternatives are possible or would be successful, if pursued. To the extent that Sesen Bio seeks and is able to raise additional capital through the sale of equity or convertible debt securities, Sesen Bio stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect their rights as a common stockholder. Debt financing or preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Sesen Bio&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Sesen Bio raises funds through strategic transactions or marketing, distribution, or licensing arrangements with third parties, Sesen Bio may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to it. Even if Sesen Bio is able to pursue such alternatives, the failure to complete the merger may result in negative publicity and/or a negative impression of Sesen Bio in the investment community, could significantly harm the market price of Sesen Bio common stock and may affect Sesen Bio&#8217;s relationship with employees and other partners in the business community. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not completed, the Sesen Bio board of directors may decide that it is in the best interests of the Sesen Bio stockholders to dissolve the company and liquidate its assets. In that event, the amount of cash available for distribution to the Sesen Bio stockholders would depend heavily on the timing of such decision and, ultimately, such liquidation since the amount of cash available for distribution continues to decrease as Sesen Bio funds its operations and incurs fees and expenses related to the merger. In addition, if the Sesen Bio board of directors were to approve and recommend, and the Sesen Bio stockholders were to approve, a dissolution of Sesen Bio, it would be required under the DGCL to pay its outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to the Sesen Bio stockholders. As a result of this requirement, a portion of Sesen Bio&#8217;s assets may need to be reserved pending the resolution of such obligations. In addition, Sesen Bio may be subject to litigation or other claims related to a liquidation and dissolution of the company. If a liquidation and dissolution were pursued, the Sesen Bio board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, the Sesen Bio stockholders could lose all or a significant portion of their investment in the event of a liquidation and dissolution of Sesen Bio. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio stockholders may not receive any payment on the CVRs from the proceeds related to either the Roche Asset Purchase Agreement or any sale of Sesen Bio&#8217;s non-cash assets and therefore the CVRs may expire valueless, result in lower returns than anticipated or none at all.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The right of Sesen Bio stockholders to receive future payment on the CVRs from the proceeds related to the Roche Asset Purchase Agreement will be contingent upon the occurrence of a certain triggering event, entitling CVR holders to a pro rata portion of the $30.0 million milestone payment to be made by Roche to Sesen Bio upon Roche&#8217;s initiation of a Phase 3 clinical trial with legacy IL-6 antagonist antibody technology previously owned by Sesen Bio for a certain indication if initiated prior to December 31, 2026, pursuant to the Roche Asset Purchase Agreement, less certain permitted deductions. Sesen Bio may not receive any future payment pursuant to the Roche Asset Purchase Agreement after the closing of the merger. If this milestone is not achieved for any reason within the time period specified in the CVR Agreement or the consideration received is not greater than the amounts permitted to be retained or deducted by Sesen Bio, no payments will be made under the CVRs from the proceeds related to the Roche Asset Purchase Agreement, resulting in a lower return for Sesen Bio stockholders with respect to the CVRs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The right of Sesen Bio stockholders to receive future payment on the CVRs from the proceeds from any sale of Sesen Bio&#8217;s non-cash assets (net of customary deductions) existing as of the date of the Original Merger Agreement is dependent on Sesen Bio finding a partner to which, it can sell, transfer, license, assign or otherwise divest such non-cash assets. The Sesen Bio board of directors may elect not to divest any of Sesen Bio&#8217;s non-cash assets, resulting in a lower return for Sesen Bio stockholders with respect to the CVRs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, if Sesen Bio does not receive any future payment pursuant to the Roche Asset Purchase Agreement and it does not divest any of its non-cash assets, Sesen Bio stockholders will not receive any payments on the CVRs and the CVRs will expire valueless.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, the CVRs will be unsecured obligations of the combined company and all payments under the CVRs, all other obligations under the CVR Agreement and the CVRs and any rights or claims relating thereto will be subordinated in right of payment to the prior payment in full of all current or future senior obligations of the combined company. For more information about the CVR Agreement, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCVAG">192</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The U.S. federal income tax treatment of the CVRs is unclear and there can be no assurance that the Internal Revenue Service would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The U.S. federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments on, the CVRs, and there can be no assurance that the Internal Revenue Service, or the IRS, would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As discussed in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs,</font><font style="letter-spacing:0.2pt;">&#8221; Sesen Bio intends to treat the issuance of the CVRs as a distribution of property with respect to its stock. However, there is no authority directly addressing whether contingent value rights with characteristics similar to the CVRs should be treated as a distribution of property with respect to the corporation&#8217;s stock, a distribution of equity, a &#8220;debt instrument&#8221; or an &#8220;open transaction&#8221; for U.S. federal income tax purposes. Although Sesen Bio will estimate the value of the CVRs for purposes of reporting on Form 1099 to Sesen Bio stockholders, the value of the CVRs is uncertain and the IRS or a court could determine that the value of the CVRs at the time of issuance was higher. In such case, the Sesen Bio stockholders could be treated as having additional income or gain upon receipt of the CVRs as described further in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page&#160;<a href="#tCVAG">192</a> of this proxy statement/prospectus. Further, notwithstanding Sesen Bio&#8217;s position that the receipt of CVRs, the receipt of any cash distributed pursuant to a special cash dividend and the proposed reverse stock split are appropriately treated as separate transactions, it is possible that the IRS or a court could </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">determine that the Sesen Bio stockholders&#8217; receipt of the CVRs, the receipt of any cash distributed pursuant to a special cash dividend and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to Sesen Bio&#8217;s position, which could result in adverse U.S. federal income tax consequences to holders of the CVRs. The tax consequences of such alternative treatments are described below under the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs,</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCVAG">192</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio is substantially dependent on its remaining employees to facilitate the consummation of the merger.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, Sesen Bio had 17 full-time employees. Sesen Bio&#8217;s ability to successfully complete the merger depends in large part on its ability to retain certain remaining personnel. Despite Sesen Bio&#8217;s efforts to retain these employees, one or more may terminate their employment with Sesen Bio on short notice. The loss of the services of certain employees could potentially harm Sesen Bio&#8217;s ability to consummate the merger, to run its day-to-day business operations, as well as to fulfill its reporting obligations as a public company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio has never paid and, other than in connection with the merger, does not intend to pay any cash dividends in the foreseeable future.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has never paid cash dividends on any of its capital stock. Pursuant to the terms of the Merger Agreement, Sesen Bio will, in addition to the CVRs, declare and pay a special cash dividend to its stockholders of record prior to the merger, which would be contingent upon Sesen Bio stockholder approval of Proposal Nos. 1 and 2 and the satisfaction or waiver of other customary closing conditions to the merger. The amount of the special cash dividend will be the amount by which Sesen Bio&#8217;s estimated net cash as of the closing of the merger exceeds $75.0 million. Other than such special cash dividend in connection with the closing of the merger, Sesen Bio does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio may not be able to enter into a transaction with a suitable acquiror or licensee for Vicineum or any transaction entered into may not be on terms that are favorable to Sesen Bio.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July 15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the United States. As a result of such decision, the primary paths available to derive value from the Vicineum asset are to find a suitable acquiror or licensee for the asset. Supporting diligence activities conducted by potential acquirors or licensees and negotiating the financial and other terms of an agreement or license are typically long and complex processes, and the results of such processes cannot be predicted. There can be no assurance that Sesen Bio will enter into any transaction as a result of this effort or that any transaction entered into will be on terms that are favorable to Sesen Bio. Furthermore, if Sesen Bio enters into and completes a transaction relating to Vicineum, Sesen Bio cannot predict the impact that such transaction might have on its stock price. Sesen Bio also cannot predict the impact on its stock price if Sesen Bio fails to enter into and complete a transaction relating to Vicineum.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">In connection with Sesen Bio&#8217;s strategic decision to voluntarily pause further development of Vicineum in the United States, Sesen Bio may become involved in disagreements or disputes with its licensees, licensors and other counterparties relating to the development and/or commercialization of Vicineum, which may be time consuming, costly and could divert its efforts and attention from consummating the merger and harm Sesen Bio&#8217;s efforts to seek a partner to continue development of Vicineum.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has entered into various agreements and licenses with licensees, licensors and other counterparties related to the development and/or commercialization of Vicineum. These agreements and licenses impose a variety of obligations on Sesen Bio and the counterparties to such agreements and licenses. On July 15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the United States. As a result of such decision and Sesen Bio&#8217;s subsequent decision to enter into the Merger Agreement, Sesen Bio has begun the process of winding down its operations relating to Vicineum, Sesen Bio is seeking a partner for the further development of Vicineum and has engaged a financial </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">advisor for the potential sale of Vicineum. In addition, on December 23, 2022, Sesen Bio terminated the Qilu License Agreement, upon which Sesen Bio regained the rights to develop, manufacture and commercialize Vicineum in Greater China. However, Sesen Bio does not plan to develop or commercialize Vicineum in that region or any other, as it is pursuing the merger with Carisma. Disagreements and disputes between Sesen Bio and certain counterparties have arisen related to such wind-down efforts and additional disagreements or disputes may arise in the future between Sesen Bio and its counterparties regarding each parties&#8217; obligations under the respective agreement or license relating to Vicineum.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any such disagreement or dispute could become time consuming, costly and could divert Sesen Bio&#8217;s efforts and attention from consummating the merger and could harm its efforts to seek a partner to continue development of Vicineum. Any disagreements or disputes with such parties that lead to litigation, arbitration or similar proceedings will result in Sesen Bio incurring significant legal expenses, as well as potential significant legal liability.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, any disagreements or disputes over Sesen Bio&#8217;s obligations or intellectual property that it has licensed or acquired may prevent or impair its ability to maintain its current arrangements on acceptable terms. If Sesen Bio fails to meet its obligations under these agreements or licenses in a material respect, the respective counterparty may have the right to terminate the respective agreement or license and to re-obtain the related technology as well as aspects of any intellectual property controlled by Sesen Bio and developed during the period the agreement or license was in force that relates to the applicable technology. While Sesen Bio would expect to exercise its rights and remedies available to it in the event Sesen Bio fails to meet its obligations under such agreement or license in any material respect and otherwise seek to preserve its rights under the technology licensed to or acquired by it, Sesen Bio may not be able to do so in a timely manner, at an acceptable cost or at all. Any uncured, material breach under any agreement or license relating to Vicineum could result in Sesen Bio&#8217;s loss of rights and may lead to a complete termination of the respective agreement or license. Termination of one of these agreements or licenses for any reason could prevent Sesen Bio from completing a transaction to sell or license Vicineum.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Sesen Bio&#8217;s Financial Position and Need for Additional Capital if the Merger is Not Completed </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio has incurred significant losses since its inception and anticipates that it will continue to incur losses for the foreseeable future if the merger is not completed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is a specialty pharmaceutical company with a limited operating history. Over the past few&#160;years, Sesen Bio has focused primarily on developing its lead product candidate, Vicineum for the treatment of NMIBC. On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the U.S. to conserve cash while considering strategic alternatives. Since its inception, Sesen Bio has received no revenues from sales of its products, has incurred significant operating losses and expects to continue to incur operating losses for the foreseeable future. Sesen Bio had net losses of $0.3&#160;million, $22.4&#160;million and $107.5&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. Sesen Bio incurred negative cash flows from operating activities of $68.9&#160;million, $30.8&#160;million and $37.5&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. As of September&#160;30, 2022, Sesen Bio had cash, cash equivalents and marketable securities of $184.9&#160;million, net working capital (current assets less current liabilities) of $157.7&#160;million and an accumulated deficit of $328.6&#160;million. Sesen Bio has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering, its follow-on public offerings, sales effected in at-the-market, or ATM offerings, and its out-licensing and outside the U.S., or OUS, business development partnership agreements. The majority of Sesen Bio&#8217;s revenue to date has been from milestone payments received under its out-licensing and OUS business development partnership agreements. If the merger is not completed and Sesen Bio does not pursue a liquidation and dissolution or alternative strategic transaction and despite the 2022 restructuring plan, as defined below, Sesen Bio expects to continue to incur significant expenses and operating losses for the foreseeable future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio expects to incur losses for the foreseeable future, and Sesen Bio expects these losses to continue as it: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">addresses its ongoing securities litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintains, expands and protects its intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduces its personnel and incurs related severance and employee-related costs in connection with the restructuring plan announced following the decision to pause further development of Vicineum in the U.S., or the 2022 restructuring plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">winds down activities with its contract manufacturing organizations, or CMOs; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">explores, evaluates and pursues a liquidation and dissolution or alternative strategic transaction if the merger is not completed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">With the exception of specified regulatory, development and commercial milestones under the Roche Asset Purchase Agreement, Sesen Bio currently has no potential source of revenue and may never become profitable.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is a late-stage clinical company with a limited operating history. Sesen Bio&#8217;s ability to become and remain profitable depends on its ability to generate revenue. Although Sesen Bio may be entitled to certain payments under the Roche Asset Purchase Agreement, Sesen Bio has not commercialized any of its product candidates. On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development in the U.S. of Vicineum. This decision enables Sesen Bio to conserve cash while it prepares to consummate the merger. There can be no guarantee that the merger will be completed within the anticipated timing or at all. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, it does not expect to generate significant revenue unless and until Sesen Bio or one of its business development partners, if any, obtains marketing approval for, and commercializes, Vicineum for the treatment of NMIBC. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Sesen Bio&#8217;s ability to generate revenue from Vicineum will depend on a number of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s ability to obtain regulatory approval for, and successfully commercialize, Vicineum for the treatment of NMIBC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s ability to complete and submit applications to, and obtaining regulatory approval from, non-U.S. regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the size of the markets in the territories for which Sesen Bio or its business development partners, if any, gain regulatory approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s ability to find a suitable contract sales organization, or CSO, to help it market and promote Vicineum, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s ability to develop and maintain effective medical affairs, sales, marketing and distribution to market and sell Vicineum, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s ability to enter into and maintain commercially reasonable agreements with wholesalers, distributors and other third parties in its supply chain; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s success in establishing a commercially viable price for Vicineum, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s success in defending against potential competition and other developments in its market generally; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s ability to manufacture commercial quantities of Vicineum at acceptable cost levels; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s ability to obtain coverage and adequate reimbursement from third-party payors, including government payors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s or any business development partners&#8217; ability to successfully complete development activities, including necessary clinical trials, for Vicineum for the treatment of NMIBC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC and Vicineum is approved for commercial sale, Vicineum may not gain market acceptance or achieve commercial success. If Sesen Bio&#8217;s addressable market is not as significant as Sesen Bio estimates, the indication approved by regulatory authorities is narrower than Sesen Bio expects or the treatment population is narrowed by competition, physician choice or clinical practice guidelines, Sesen Bio may not generate significant revenue from sales of Vicineum. In addition, if Sesen Bio resumes clinical development of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Vicineum for the treatment of NMIBC, Sesen Bio would anticipate incurring significant costs associated with commercializing Vicineum, if approved. Sesen Bio may not achieve profitability soon after generating product sales from Vicineum, if ever. If Sesen Bio is unable to generate product revenues from Vicineum, Sesen Bio may not become profitable and may be unable to continue operations without continued funding. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if Sesen Bio achieves profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. Its failure to become and remain profitable would depress the value of Sesen Bio and could impair its ability to raise capital, expand its business, maintain its development efforts, obtain drug approvals, diversify its offerings or continue its operations. A decline in the value of Sesen Bio could also cause you to lose all or part of your investment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If the merger is not completed and Sesen Bio resumes clinical development of Vicineum, Sesen Bio will need substantial additional funding. If Sesen Bio is unable to raise capital when needed, Sesen Bio could be forced to delay, reduce or eliminate its product development programs or commercialization efforts.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has devoted substantial financial resources to clinical trial for Vicineum for the treatment of NMIBC and functions associated with operating as a public company. If the merger is not completed, Sesen Bio expects to continue to spend substantial amounts if it were to continue the clinical development of Vicineum for the treatment of NMIBC, and, if approved, commercialize Vicineum. Accordingly, Sesen Bio would need to obtain substantial additional funding in connection with its continuing operations if the merger is not completed. If Sesen Bio is unable to raise capital when needed or on attractive terms, Sesen Bio could be forced to delay, reduce or eliminate its research and development programs or any future commercialization efforts. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s future capital requirements will depend on many factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of continuing the clinical development of Vicineum for the treatment of NMIBC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success of its commercialization of Vicineum for the treatment of NMIBC, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the outcome, timing and cost of the regulatory approval process for Vicineum for the treatment of NMIBC by the FDA and comparable non-U.S. regulatory authorities, including the potential for the FDA to require that Sesen Bio perform more studies and clinical trials than those Sesen Bio currently expects; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of the implementation of commercial-scale manufacturing activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s ability to establish and maintain commercial arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for Vicineum for the treatment of NMIBC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing Sesen Bio&#8217;s intellectual property rights and defending any intellectual property-related claims; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s obligation to make milestone, royalty and other payments to third-party licensors under its in-licensing agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which Sesen Bio in-license or acquire rights to other products, product candidates or technologies; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effect of competing technological and market developments. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio cannot be certain that additional funding will be available when needed on acceptable terms, or at all. If Sesen Bio is unable to raise additional capital in sufficient amounts, when required or on acceptable terms, Sesen Bio also could be required to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seek out-licensing or commercialization partners to assist in the clinical development or commercialization of Vicineum for the treatment of NMIBC in the U.S. and other markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delay, limit, reduce or terminate the clinical development of Vicineum for the treatment of NMIBC; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">significantly curtail Sesen Bio&#8217;s operations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Clinical Development and Regulatory Approval of Vicineum if the Merger is Not Completed</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio has been dependent on its lead product candidate, Vicineum for the treatment of NMIBC. If Sesen Bio resumes clinical development of Vicineum and is unable to obtain marketing approval for or successfully commercialize its lead product candidate, either alone or through an out-license or OUS business development partnership, or experiences significant delays in doing so, its business could be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio currently has no products approved for sale and has invested a significant portion of its efforts and financial resources in the development of Vicineum. On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the U.S. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase&#160;3 clinical trial, following Sesen Bio&#8217;s discussions with the FDA. As a result of this decision, Sesen Bio no longer plans to pursue regulatory approval of Vicineum for NMIBC in the E.U. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not completed and even if Sesen Bio resumes clinical development of Vicineum for NMIBC, Sesen Bio may be unable to address the issues identified in the complete response letter, or CRL, from the FDA or resubmit a biologics license application, or BLA, for Vicineum, or address the concerns identified in the European Medicines Agency, or EMA, Withdrawal Assessment Report or resubmit its marketing authorization application, or MAA, for Vysyneum, including because of a lack of capital or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if the issues identified in the CRL or the concerns identified in the EMA Withdrawal Assessment Report are resolved to the satisfaction of the FDA or the EMA, respectively, the FDA and the European Commission retain the right not to approve a BLA or MAA, respectively, or to require additional information, or to raise additional issues with regard to regulatory approval, which could further delay or prevent its approval or limit product labelling claims. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not completed and Sesen Bio resumes clinical development, Sesen Bio&#8217;s prospects would be substantially dependent on its ability to obtain marketing approval for and commercialize Vicineum for the treatment of NMIBC. In addition, either the substance of the issues identified by the FDA in the CRL, or the CRL itself, or the concerns identified in the EMA Withdrawal Assessment Report could have an adverse impact on future efforts to obtain marketing authorization for Vicineum from other non-U.S. regulatory authorities, or on Sesen Bio&#8217;s future efforts to commercialize Vicineum and gain acceptance of Vicineum from third-party payors. The success of Vicineum would depend on several factors, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successfully completing the clinical development of Vicineum for the treatment of NMIBC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">addressing the issues identified in the CRL that Sesen Bio received from the FDA and the concerns identified in the EMA Withdrawal Assessment Report; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">receiving marketing approvals from the FDA, the European Commission or comparable non-U.S. regulatory authorities, including Sesen Bio&#8217;s ability to address the issues identified by the FDA in the CRL or the EMA Withdrawal Assessment Report; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developing and maintaining the commercial manufacturing supply and distribution chain for Vicineum; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">performance of future out-licensing or OUS business development partners (if any); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the U.S. and internationally; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">protecting Sesen Bio&#8217;s rights in its intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">launching commercial sales, if and when marketing approval is received; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">demonstrating an acceptable safety profile prior to and following any marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining marketplace acceptance, if approved, by patients, the medical community and third-party payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establishing and maintaining pricing sufficient to realize a meaningful return on Sesen Bio&#8217;s investment; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">competition with other therapies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio is unable to develop, receive marketing approval for, or successfully commercialize Vicineum or experience delays as a result of any of these factors or otherwise, its business could be materially harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If additional clinical trials of Vicineum for the treatment of NMIBC fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other non-U.S. regulatory authorities or do not otherwise produce favorable results, Sesen Bio will be unable to complete the development and potential commercialization of Vicineum for the treatment of NMIBC. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC and additional clinical trials of Vicineum fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other non-U.S. regulatory authorities or do not otherwise produce favorable results, Sesen Bio will be unable to complete the development and potential commercialization of Vicineum for the treatment of NMIBC.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before obtaining marketing approval from regulatory authorities for the sale of Vicineum for the treatment of NMIBC, Sesen Bio must complete pre-clinical development and conduct extensive clinical trials to demonstrate the safety and efficacy of Vicineum in humans. In order to address the issues identified in the CRL that Sesen Bio received from the FDA for the BLA for Vicineum and the concerns identified in the EMA Withdrawal Assessment Report, Sesen Bio would need to complete one or more additional clinical trials. Such trials would require Sesen Bio to incur substantial additional costs and would delay the potential commercialization of Vicineum for the treatment of NMIBC. Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. Further, the outcome of pre-clinical studies and early clinical trials may not be predictive of the success of later clinical trials, and preliminary results of a clinical trial do not necessarily predict final results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if such clinical trials are successfully completed as planned, the results may not support approval of Vicineum for the treatment of NMIBC under the laws and regulations of the FDA, the European Commission or comparable non-U.S. regulatory authorities. Even if Sesen Bio resumes clinical development of Vicineum, Sesen Bio cannot be certain that additional clinical data will demonstrate Vicineum is both safe and effective for its intended uses to the satisfaction of the FDA, the EMA or comparable non-U.S. regulatory authorities. Pre-clinical and clinical data and analyses are often able to be interpreted in different ways. Even if Sesen Bio views its results favorably, it may be unable to demonstrate safety and efficacy of Vicineum for the treatment of NMIBC to the satisfaction of the FDA, the EMA or other non-U.S. regulatory authorities. If a regulatory authority has a different view, Sesen Bio may still fail to obtain regulatory approval of Vicineum. This, in turn, would prevent Sesen Bio from commercializing Vicineum and its ability to generate revenues in the future would be materially impaired. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC and Sesen Bio experiences delays or difficulties in the enrollment of patients in clinical trials, its receipt of necessary regulatory approvals could be delayed or prevented.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Sesen Bio may not be able to initiate or continue clinical trials for Vicineum if Sesen Bio is unable to locate and enroll a sufficient number of patients to participate in these trials as required by the FDA or similar non-U.S. regulatory authorities. Sesen Bio has previously experienced difficulties with clinical trial enrollment and retention, which led to the early termination of its Phase&#160;3 trial of Vicineum for the treatment of squamous </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">cell carcinoma of the head and neck, or SCCHN, in 2008, and Sesen Bio may experience difficulties in patient enrollment in its clinical trials in the future for a variety of reasons. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject enrollment is affected by a number of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the severity of the disease under investigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the eligibility criteria for the clinical trial in question; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the size of the patient population for the disease; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the size of the patient population required for statistically significant analysis of the clinical trial&#8217;s primary endpoints; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the design of the clinical trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the clinicians&#8217; and patients&#8217; perceived risks and benefits of the product candidate under study, including relative to alternative treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the efforts to facilitate timely enrollment in clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the patient referral practices of physicians; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any ongoing clinical trials conducted by competitors for the same indication; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability to monitor patients adequately during and after treatment; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the proximity and availability of clinical trial sites for prospective patients. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, Sesen Bio&#8217;s ability to successfully initiate, enroll and complete a clinical trial in any country outside of the U.S., should Sesen Bio decide to do so, is subject to numerous risks unique to conducting business in such countries, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">difficulty in establishing or managing relationships with contract research organizations, or CROs, and physicians; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">different or additional standards for the conduct of clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">absence in some countries of established groups with sufficient regulatory expertise for review of the protocols associated with Vicineum; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ensuring that clinical trial quality is sufficient to meet the standards of the FDA or other regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s inability to locate qualified local consultants, physicians and partners; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential burden of complying with a variety of non-U.S. laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, Sesen Bio&#8217;s clinical trials would compete with other clinical trials for other product candidates that are in the same therapeutic areas as Vicineum, and this competition will reduce the number and types of patients available to Sesen Bio, because some patients who might have opted to enroll in Sesen Bio&#8217;s trials may instead opt to enroll in a trial being conducted by one of its competitors. Since the number of qualified clinical investigators is limited, Sesen Bio expects to conduct some of its clinical trials at the same clinical trial sites that some of its competitors use, which will reduce the number of patients who are available for Sesen Bio&#8217;s clinical trials in such clinical trial site. Moreover, because Vicineum represents a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in any of Sesen Bio&#8217;s clinical trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s inability to enroll a sufficient number of patients for its clinical trials would result in significant delays, could require Sesen Bio to abandon one or more clinical trials altogether and could delay or prevent its receipt of necessary regulatory approvals. Enrollment delays in its clinical trials may result </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">in increased development costs for its product candidates, which would cause the value of the company to decline and limit its ability to obtain additional financing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Vicineum for the treatment of NMIBC may cause undesirable side effects, serious adverse events or have other properties that could delay or halt clinical trials, delay or prevent its regulatory approval, limit the commercial profile of its labeling, if approved, or result in significant negative consequences following any marketing approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, undesirable side effects or serious adverse events caused by Vicineum for the treatment of NMIBC could cause Sesen Bio or regulatory authorities to interrupt, delay or halt respective clinical trials and could result in a restrictive label or the delay or denial of regulatory approval by the FDA or other comparable non-U.S. regulatory authorities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There were no Grade 4 or Grade 5 serious adverse events that were considered by the clinical investigators to be related to Vicineum during the Phase&#160;1 and Phase&#160;2 clinical trials of Vicineum for the treatment of bacillus Calmette-Gu&#233;rin, or BCG, unresponsive NMIBC. There was one Grade 5 serious adverse event, or death, which was determined by the clinical investigator to be unrelated to Vicineum. The most common reported treatment-related adverse events were an abnormally frequent passage of small amounts of urine, blood in the urine and painful urination, the majority of which were considered to be mild or moderate in severity. No patients discontinued treatment due to a Vicineum-related adverse event during the Phase&#160;1 and Phase&#160;2 clinical trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the May&#160;29, 2019 data cutoff date, in patients across all cohorts (n=133) of Sesen Bio&#8217;s Phase&#160;3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%)&#8201;&#8212;&#8201;all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, side effects and serious adverse events or further safety or toxicity issues that Sesen Bio may experience in its clinical trials or in post-marketing experience, if approved, could lead to the FDA&#8217;s or other comparable non-U.S. regulatory authority&#8217;s imposition of a risk evaluation and mitigation strategy, or REMS, or other post-marketing obligations, which could hinder Sesen Bio from generating revenues or achieving profitability. Results of Sesen Bio&#8217;s clinical trials could reveal an unacceptably high severity and prevalence of side effects or serious adverse events. As a result, Sesen Bio&#8217;s clinical trials could be suspended or terminated, and the FDA or comparable non-U.S. regulatory authorities could order Sesen Bio to cease further development or deny approval of Vicineum for the treatment of NMIBC. The related drug-side effects or serious adverse events in Sesen Bio&#8217;s clinical trials could affect clinical trial patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, even if Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC and receives marketing approval, and Sesen Bio or others later identify undesirable side effects or serious adverse events caused by Vicineum, a number of potentially significant negative consequences could result, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio may suspend or be forced to suspend marketing of Vicineum for the treatment of NMIBC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio may be obliged to conduct a product recall or product withdrawal; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may suspend, vary, or withdraw their approvals of Vicineum for the treatment of NMIBC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may order the seizure or recall of Vicineum; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may require additional warnings on the label or a REMS or other post-marketing obligations that could diminish the usage or otherwise limit the commercial success of Vicineum for the treatment of NMIBC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio may be required to conduct post-marketing studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio could be sued and held liable for harm caused to patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio could be required to pay fines and face other administrative, civil and criminal penalties; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s reputation may suffer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any of these events could prevent Sesen Bio from achieving or maintaining market acceptance of Vicineum for the treatment of NMIBC, if approved. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The marketing approval process is expensive, time-consuming and uncertain. As a result, even if Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, it cannot predict when or if it, or any licensees or partners, if any, will obtain marketing approval to commercialize Vicineum for the treatment of NMIBC.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Securing marketing approval requires the submission of extensive pre-clinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s quality, safety, and efficacy. The process of obtaining marketing approvals, both in the U.S. and abroad, is expensive and may take many&#160;years, especially if additional clinical trials are required, if approval is obtained at all. On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the U.S. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase&#160;3 clinical trial, following its discussions with the FDA. As a result of this decision, Sesen Bio no longer plans to pursue regulatory approval of Vysyneum for the treatment of NMIBC in the E.U. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, the FDA or other comparable non-U.S. regulatory authorities may determine that Vicineum is not safe, effective or of appropriate quality, is only moderately effective or has undesirable or unintended side effects, toxicities or other characteristics that preclude Sesen Bio obtaining marketing approval or prevent or limit commercial use. Any marketing approval Sesen Bio ultimately obtains may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The different requirements and expectations of the non-U.S. regulatory authorities compared with the FDA may lengthen the regulatory review process, require Sesen Bio to conduct additional studies or clinical trials, increase its development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post approval limitations or restrictions. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC and experiences delays in obtaining regulatory approvals, the commercial prospects for its product candidates may be harmed and its ability to generate revenues will be materially impaired. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, failure to obtain marketing approval in non-U.S. jurisdictions would prevent Vicineum for the treatment of NMIBC from being marketed abroad, and any approval Sesen Bio may be granted for Vicineum for the treatment of NMIBC in the U.S. would not assure approval of product candidates in non-U.S. jurisdictions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to market and sell any product candidate that Sesen Bio may develop outside of the U.S., Sesen Bio or its third-party licensees or commercialization partners, if any, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">outside the U.S. it is required that the product be approved for reimbursement before the product can be sold in that country. Sesen Bio or these third parties may not obtain approvals from regulatory authorities outside the U.S. on a timely basis, if at all. For example, on March&#160;5, 2021, Sesen Bio submitted its MAA to the EMA for Vicineum for the treatment of BCG-unresponsive NMIBC under the EMA&#8217;s centralized procedure. On August&#160;20, 2021, Sesen Bio withdrew its MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC. Additionally, on October&#160;20, 2021, the EMA issued its Withdrawal Assessment Report relating to Sesen Bio&#8217;s MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the U.S. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase&#160;3 clinical trial, following its discussions with the FDA. As a result of this decision, Sesen Bio no longer plans to pursue regulatory approval of Vysyneum for the treatment NMIBC in the E.U. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the U.S. does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Sesen Bio may not be able to file for marketing approvals and may not receive necessary approvals to commercialize its products in any market. If Sesen Bio is unable to obtain approval of its product candidates by regulatory authorities in other jurisdictions, the commercial prospects of its product candidates may be significantly diminished, and its business prospects could decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Sesen Bio would face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than Sesen Bio does.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The development and commercialization of new biologics products is highly competitive. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Sesen Bio would face competition from both large and small pharmaceutical, biopharmaceutical and biotechnology companies, academic institutions and other research organizations. There are a number of large pharmaceutical, biopharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of NMIBC. For instance, in January&#160;2020, the FDA approved Merck &amp; Co., Inc.&#8217;s Keytruda (pembrolizumab) as a systemic monotherapy to treat patients with BCG-unresponsive NMIBC with non-muscle invasive carcinoma in situ, or CIS, with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. In addition, FerGene Inc. is developing Adstiladrin (nadofaragene firadenovec (rAd-IFN/Syn3) for BCG-unresponsive NMIBC for the U.S. market. On May&#160;17, 2020, the FDA issued a CRL that indicated outstanding questions regarding chemistry, manufacturing and controls, or CMC, issues of Adstiladrin. In September&#160;2020, CG Oncology (CG0070, a recombinant adenovirus type&#160;5, same type as Adstiladrin) initiated a Phase&#160;3 study for the treatment of BCG-unresponsive patients with expected primary and study completion dates of December&#160;2022 and December&#160;2024, respectively. A combination trial with CG0070 and pembrolizumab was initiated in December&#160;2020 (active not recruiting) with a primary completion date of June&#160;2023. In December&#160;2020, ImmunityBio (Anktiva/N-803 in combination with BCG) released preliminary Phase&#160;2 data for the CIS cohort and filed its BLA with the FDA in May&#160;2022. However, the Phase&#160;2 trial did not include a BCG only control arm. The BLA for Anktiva was accepted by the FDA in July&#160;2022 and a PDUFA date of May&#160;23, 2023 has been set. In May&#160;2020, the preliminary results of the Phase&#160;2 study of Tecentriq for the treatment of BCG-unresponsive CIS patients were presented at American Society of Clinical Oncology, or ASCO, by the National Cancer Institute, or the NCI, which sponsored the trial. The data showed that the trial did not meet its primary endpoint and further development of Tecentriq remains uncertain. Finally, another route of administration for checkpoint inhibitors is currently being evaluated by Pfizer with the subcutaneous administration of Sasanlimab (PF-06801591) for the treatment of BCG-unresponsive NMIBC patients. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and antibody fragment and immuno-oncology therapeutics fields. Some of these competitive products and therapies are based on scientific </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">approaches that are similar to Sesen Bio&#8217;s approach, and others are based on entirely different approaches, including the emerging use of generic intravesical chemotherapy agents, such as mytomycin-C, Gemcytabine and Gemcytobine + Docetaxel. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, its commercial opportunity could be reduced or eliminated if its competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than product candidates that Sesen Bio may develop. Sesen Bio&#8217;s competitors also may obtain FDA or other regulatory approval for their products more rapidly than Sesen Bio may obtain approval for Vicineum, which could result in its competitors establishing a strong market position before Sesen Bio is able to enter the market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, Sesen Bio&#8217;s ability to compete may be affected in many cases by insurers or other third-party payors, particularly Medicare, seeking to encourage the use of generic drug products. Generic products are currently being used as part of the standard of care for the indications that Sesen Bio has been pursuing, and additional products are expected to become available on a generic basis over the coming&#160;years. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC and Vicineum achieves marketing approval, Sesen Bio expects that it will be priced at a significant premium over competitive generic products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">More established companies may have a competitive advantage over Sesen Bio due to their greater size, cash resources and institutional experience. Compared to Sesen Bio, many of its competitors may have significantly greater financial, technical and human resources. As a result of these factors, its competitors may obtain regulatory approval of their product candidates before Sesen Bio is able to, which may limit its ability to develop or commercialize its product candidates. Sesen Bio&#8217;s competitors may also develop drugs that are safer, more effective, more widely used and less expensive than Sesen Bio&#8217;s and may also be more successful than Sesen Bio in manufacturing and marketing their products. These appreciable advantages could render Vicineum obsolete or non-competitive before Sesen Bio can recover the expenses of development and commercialization. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Sesen Bio&#8217;s Dependence on Third Parties if the Merger is Not Completed</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio has historically relied on third parties to conduct its pre-clinical studies and clinical trials. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC and if these third parties do not successfully carry out their contractual duties or meet expected deadlines, Sesen Bio may not be able to obtain regulatory approval for or commercialize Vicineum for the treatment of NMIBC.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio relies on domestic and international third-party CROs to monitor and manage data for its pre-clinical and clinical programs. Sesen Bio relies on these parties for execution of its pre-clinical studies and clinical trials, and Sesen Bio controls only some aspects of their activities. Nevertheless, Sesen Bio is responsible for ensuring that each of its pre-clinical studies and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and its reliance on the CROs does not relieve Sesen Bio of its regulatory responsibilities. Sesen Bio also relies on third parties to assist in conducting its pre-clinical studies in accordance with the FDA&#8217;s current Good Laboratory Practice, or GLP, and the Animal Welfare Act requirements. Sesen Bio and its CROs are required to comply with U.S.&#160;federal regulations and current Good Clinical Practices, or GCP, which are international standards meant to protect the rights and health of patients and assure the credibility of clinical trial data that are enforced by the FDA and comparable non-U.S. regulatory authorities for all of its product candidates in clinical development. Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If Sesen Bio or any of its CROs fail to comply with applicable GCP, the clinical data generated in its clinical trials may be deemed unreliable and the FDA or comparable non-U.S. regulatory authorities may require Sesen Bio to perform additional clinical trials before approving its marketing applications. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;27, 2021, the FDA published a Warning Letter, or the FDA Warning Letter, issued to a former clinical investigator in Sesen Bio&#8217;s VISTA trial for Vicineum arising from a 2021 FDA inspection related to the review of Sesen Bio&#8217;s BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. Sesen Bio discontinued use of the clinical site and the clinical investigator over four&#160;years ago when it learned of professional misconduct by the clinical investigator that was unrelated to the VISTA trial. The FDA Warning Letter indicated that the clinical investigator did not comply with applicable statutory requirements and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">applicable regulations regarding conduct of clinical investigations. The clinical investigator&#8217;s medical license was temporarily suspended on May&#160;29, 2017, due to inaccurate recordkeeping, which was unassociated with Sesen Bio and the patients in the VISTA trial. Sesen Bio notified the FDA of the misconduct at that time. There was no evidence found that patients were harmed by the clinical investigator&#8217;s actions. Sesen Bio included the corresponding patient data from the clinical site in the BLA submission to the FDA, which were thoroughly analyzed and discussed during the BLA review. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of its clinical trials comply with GCP requirements. In addition, its clinical trials must be conducted with product produced under current good manufacturing process, or cGMP, requirements. Failure to comply with these regulations may require Sesen Bio to repeat pre-clinical studies and clinical trials, which would delay the regulatory approval process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s CROs are not its employees, and except for remedies available to Sesen Bio under its agreements with such CROs, Sesen Bio cannot control whether or not they devote sufficient time and resources to its ongoing clinical, non-clinical and pre-clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to its protocols, regulatory requirements or for other reasons, its pre-clinical studies and clinical trials may be extended, delayed or terminated and Sesen Bio may not be able to obtain regulatory approval for or successfully commercialize its product candidates. As a result, its results of operations and the commercial prospects for its product candidates would be harmed, its costs could increase and its ability to generate revenues could be delayed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because Sesen Bio relied, and will continue to rely, on third parties, its internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to its standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires Sesen Bio to disclose its proprietary information to these parties, which could increase the risk that this information will be misappropriated. Sesen Bio currently has a small number of employees, which limits the internal resources Sesen Bio has available to identify and monitor its third-party providers. To the extent Sesen Bio is unable to identify and successfully manage the performance of third-party service providers in the future, its business may be adversely affected. Though Sesen Bio carefully manages its relationships with its CROs, there can be no assurance that Sesen Bio will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on its business, financial condition and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Sesen Bio would likely be dependent on third-party manufacturers, as well as third parties for Sesen Bio&#8217;s supply chain, which would expose Sesen Bio to a number of risks that may delay development, regulatory approval and commercialization or result in higher product costs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with Sesen Bio&#8217;s decision to voluntarily pause further development of Vicineum, Sesen Bio terminated its agreements with its CMOs and requested that such manufacturers cease all work under the respective agreements and refrain from incurring any additional costs or expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Sesen Bio would likely be dependent on third-party manufacturers, as well as third parties for Sesen Bio&#8217;s supply chain. Sesen Bio&#8217;s reliance on third-party manufacturers would expose it to certain risks that it would not be subject to if Sesen Bio manufactured Vicineum itself, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">It may be difficult or impossible for Sesen Bio to find replacement manufacturers on acceptable terms quickly, or at all. Identifying alternate manufacturers may be difficult because the number of potential manufacturers that have the necessary expertise to produce biologics is limited. Additionally, the FDA must approve any alternative manufacturer before Sesen Bio may use the alternative manufacturer to produce clinical supply of Vicineum. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The development of manufacturing capabilities to produce clinical supply of Vicineum may require Sesen Bio&#8217;s third-party manufacturers to invest substantial additional funds and to hire and retain </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">technical personnel who have the necessary manufacturing experience. Sesen Bio&#8217;s third-party manufacturers may fail to devote sufficient time and resources to develop the capabilities to manufacture Vicineum. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Because of the complex nature of Vicineum, Sesen Bio&#8217;s third-party manufacturers, or other third parties it relies on, may encounter difficulties in achieving the volume of production needed to satisfy its clinical supply demands, may not be able to achieve such volume at an acceptable cost, may experience technical issues that impact comparability, quality, or compliance with applicable regulations governing the manufacture of biological products, and may experience shortages of qualified personnel to adequately staff production operations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s third-party manufacturers could default on their agreements with Sesen Bio to meet its requirements for supply of Vicineum, or they may terminate or decide not to renew their agreements with Sesen Bio, based on their own business priorities, at a time that is costly or damaging to Sesen Bio. If Sesen Bio&#8217;s third-party manufacturers were to terminate its arrangements or fail to meet its manufacturing demands, Sesen Bio may be delayed in its ability to obtain and maintain regulatory approval of Vicineum for the treatment of NMIBC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">If any third-party manufacturer makes improvements in the manufacturing process for Vicineum, Sesen Bio may not own, or may have to share, the intellectual property rights to such improvements. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A third-party manufacturer may gain knowledge from working with Sesen Bio that could be used to supply one of its competitors with a product that competes with Sesen Bio&#8217;s. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s reliance on third-party manufacturers reduces its control over production and supply of Vicineum but does not relieve Sesen Bio of its responsibility to ensure compliance with applicable legal and regulatory standards. The FDA and other non-U.S. regulatory authorities require that Sesen Bio&#8217;s product candidates and any products that it may eventually commercialize be manufactured according to cGMP and similar non-U.S. standards. Methods of manufacture as well as validation of manufacturing procedures and quality control systems are reviewed by regulatory authorities, such as the FDA and other comparable non-U.S. regulatory authorities, to determine their effect on the quality, purity and potency of product candidates. All such manufacturing procedures, validation programs and quality assessment activities must be properly documented in accordance with regulatory requirements. Any failure by Sesen Bio&#8217;s third-party manufacturers to comply with cGMP or similar non-U.S. standards, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in or failure to obtain regulatory approval of Vicineum for the treatment of NMIBC if Sesen Bio resumes clinical development of Vicineum. For example, Sesen Bio may be unable to resolve the issues raised in the CRL pertaining to a recent pre-approval inspection and product quality. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, a failure by Sesen Bio&#8217;s third-party manufactures to comply with cGMP or similar non-U.S. standards could be the basis for the FDA or any other non-U.S. regulatory authorities to issue a warning or untitled letter, withdraw approvals for product candidates previously granted to Sesen Bio or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of products, injunction, imposing administrative or civil penalties or pursuing criminal prosecution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC and if Sesen Bio or its third-party manufacturers fail to comply with environmental, health and safety laws and regulations, Sesen Bio could become subject to fines or penalties or incur significant costs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMBIC and engages third-party manufacturers, such manufacturers would be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Any such operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may produce hazardous waste products. Historically, Sesen Bio has generally contracted with third parties for the disposal of these materials and wastes. Sesen Bio cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from its use of hazardous materials, Sesen Bio could be held </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">liable for any resulting damages and any liability could exceed its resources. Sesen Bio also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although Sesen Bio maintains workers&#8217; compensation insurance to cover it for costs and expenses it may incur due to injuries to its employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. Sesen Bio does not maintain insurance for environmental liability or toxic tort claims that may be asserted against it in connection with its storage or disposal of biological, hazardous or radioactive materials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, if Sesen Bio resumes clinical development of Vicineum, Sesen Bio may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair its research, development or production efforts. Sesen Bio&#8217;s failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, with respect to the operations of third-party contract manufacturers, if any, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with its products, Sesen Bio could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of its product candidates or products. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Sesen Bio&#8217;s Intellectual Property if the Merger is Not Completed</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC and is unable to obtain and maintain patent protection for its technology or products, or if its licensors are unable to obtain and maintain patent protection for the technology or products that Sesen Bio licenses from them, or if the scope of the patent protection obtained is not sufficiently broad, Sesen Bio&#8217;s competitors could develop and commercialize technology and products similar or identical to theirs, and its ability to successfully commercialize it technology and products may be impaired.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Sesen Bio&#8217;s success depends in large part on the ability of both it and its licensors&#8217; to obtain and maintain patent protection in the U.S. and other countries with respect to Vicineum and its other proprietary technology and product candidates. Sesen Bio and its licensors have sought to protect Sesen Bio&#8217;s proprietary position by filing patent applications in the U.S. and abroad related to its novel technologies and product candidates. The patent prosecution process is expensive and time-consuming, and Sesen Bio may not be able to file and prosecute all necessary or desirable patent applications in jurisdictions of interest at a reasonable cost or in a timely manner. It is also possible that Sesen Bio will fail to identify patentable aspects of its research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, Sesen Bio does not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that it licenses from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of Sesen Bio&#8217;s business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights Sesen Bio has licensed may be reduced or eliminated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of Sesen Bio&#8217;s and its licensors&#8217; patent rights are highly uncertain. Sesen Bio&#8217;s and its licensors&#8217; pending and future patent applications may not result in patents being issued which protect its technology or products or which effectively prevent others from commercializing competitive technologies and products. In addition, the laws of non-U.S. countries may not protect Sesen Bio&#8217;s rights to the same extent as the laws of the U.S. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, Sesen Bio cannot know with certainty whether it or its licensors were the first to make the inventions claimed in its owned or licensed patents or pending patent applications, or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">that Sesen Bio or its licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of Sesen Bio&#8217;s owned or licensed patent rights are highly uncertain. Sesen Bio&#8217;s pending and future patent applications may not result in patents being issued which protect its technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. In particular, during prosecution of any patent application, the issuance of any patents based on the application may depend upon Sesen Bio&#8217;s ability to generate additional pre-clinical or clinical data that support the patentability of its proposed claims. Sesen Bio may not be able to generate sufficient additional data on a timely basis, or at all. Moreover, changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of Sesen Bio&#8217;s patents or narrow the scope of Sesen Bio&#8217;s patent protection. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, Sesen Bio may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging its patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, Sesen Bio&#8217;s patent rights, allow third parties to commercialize its technology or products and compete directly with Sesen Bio, without payment to it, or result in Sesen Bio&#8217;s inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by Sesen Bio&#8217;s patents and patent applications is threatened, it could dissuade companies from collaborating with Sesen Bio to license, develop or commercialize current or future product candidates. In addition, invalidation of Sesen Bio&#8217;s patent rights by third parties could jeopardize the anticipated revenue streams from current licensees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if Sesen Bio&#8217;s owned and licensed patent applications issue as patents, they may not issue in a form that will provide Sesen Bio with any meaningful protection, prevent competitors from competing with Sesen Bio or otherwise provide Sesen Bio with any competitive advantage. Sesen Bio&#8217;s competitors may be able to circumvent Sesen Bio&#8217;s owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and Sesen Bio&#8217;s owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit Sesen Bio&#8217;s ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of its technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, Sesen Bio&#8217;s owned and licensed patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Sesen Bio&#8217;s. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio may not be able to protect its intellectual property rights throughout the world.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, filing, prosecuting and defending patents on Vicineum and Sesen Bio&#8217;s other product candidates and technologies throughout the world would be prohibitively expensive, and Sesen Bio&#8217;s or its licensors&#8217; intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws and practices of countries outside the U.S. do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Moreover, the intellectual property laws of the U.S. change over time. For example, several United States Supreme Court cases have redefined what is considered to be patentable subject matter. Consequently, if Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, Sesen Bio and its licensors may not be able to prevent third parties from practicing Sesen Bio&#8217;s and its licensors&#8217; inventions in all countries inside or outside the U.S., or from selling or importing products made using Sesen Bio&#8217;s and its licensors&#8217; inventions in and into the U.S. or other jurisdictions. Competitors may use Sesen Bio&#8217;s technologies in jurisdictions where it has not obtained patent protection to develop their own products and may export infringing products to territories where Sesen Bio or its licensors have patent protection, but where enforcement is not as strong as in the U.S. These products may compete with Sesen Bio&#8217;s products in jurisdictions where it does not have any issued patents and Sesen Bio&#8217;s patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in non-U.S. jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for Sesen Bio to stop the infringement of Sesen Bio&#8217;s or its licensor&#8217;s patents or marketing of competing products in violation of Sesen Bio&#8217;s proprietary rights generally in those countries. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, proceedings to enforce Sesen Bio&#8217;s patent rights in non-U.S. jurisdictions could result in substantial cost and divert its efforts and attention from other aspects of its business, could put Sesen Bio&#8217;s and its licensors&#8217; patents at risk of being invalidated or being interpreted narrowly and put Sesen Bio&#8217;s and its licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against Sesen Bio or its licensors. Sesen Bio or its licensors may not prevail in any lawsuits that Sesen Bio or its licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The laws of certain countries outside of the U.S. may not protect Sesen Bio&#8217;s rights to the same extent as the laws of the U.S., and such laws may also be subject to change. For example, methods of treatment and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic and/or biosimilar product manufacturers or other competitors may challenge the scope, validity or enforceability of Sesen Bio&#8217;s or its licensors&#8217; patents, requiring Sesen Bio or its licensors to engage in complex, lengthy and costly litigation or other proceedings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Generic or biosimilar product manufacturers may develop, seek approval for, and generic versions or biosimilar versions, respectively, of Sesen Bio&#8217;s products. The FDA has published several guidance documents on biosimilar product development. If a biosimilar product is also found to be interchangeable with a reference product, it may be substituted for the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, and if Vicineum is approved by the FDA, the approval of a biologic product biosimilar to or interchangeable with Vicineum could have a material impact on Sesen Bio&#8217;s business. In particular, a biosimilar could be significantly less costly to bring to market and priced significantly lower than Sesen Bio&#8217;s products, if approved by the FDA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Many countries, including E.U. countries, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties. In those countries, Sesen Bio and its licensors may have limited remedies if patents are infringed or if Sesen Bio or its licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit Sesen Bio&#8217;s potential revenue opportunities. Accordingly, Sesen Bio&#8217;s and its licensors&#8217; efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that Sesen Bio owns or licenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio has been dependent on its license agreements with the University of Zurich, or Zurich, Micromet AG, or Micromet, and XOMA Ireland Limited, or XOMA, and if Sesen Bio cannot meet the requirements under the agreements, it could lose important rights to Vicineum, which could have material adverse effect on Sesen Bio&#8217;s business if it resumes clinical development of Vicineum for the treatment of NMIBC.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has an exclusive license agreement with Zurich, or the Zurich License Agreement. Pursuant to the Zurich License Agreement, Sesen Bio was granted an exclusive license, with the right to sublicense, under certain patents primarily relating, in part, to Sesen Bio&#8217;s targeting agents, EpCAM chimera and immunoconjugates (including aspects of Vicineum for the treatment of NMIBC and Vicineum for the treatment of SCCHN) and methods of use, to make, use, sell and import products that would otherwise infringe such patents in the field of the treatment, stasis and palliation of disease in humans. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, and if Sesen Bio fails to meet its obligations under the Zurich License Agreement, Zurich may have the right to terminate Sesen Bio&#8217;s license, and upon the effective date of such termination, Sesen Bio&#8217;s right to use the licensed Zurich patent rights would end. To the extent such licensed technology or patent rights relate to Sesen Bio&#8217;s product candidates, Sesen Bio would expect to exercise all rights and remedies available to it, including attempting to cure any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">breach by Sesen Bio, and otherwise seek to preserve its rights under the patent rights licensed to Sesen Bio, but it may not be able to do so in a timely manner, at an acceptable cost to Sesen Bio or at all. Any uncured, material breach under the Zurich License Agreement could result in Sesen Bio&#8217;s loss of rights to practice the patent rights licensed to it under the Zurich License Agreement, and to the extent such patent rights and other technology relate to its product candidates or other of its compounds, it could have a material adverse effect on Sesen Bio&#8217;s ability to complete a sale of its Vicineum asset to a potential partner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio also has a license agreement with Micromet, or the Micromet License Agreement, which grants it non-exclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, and if Sesen Bio fails to meet its obligations under the Micromet License Agreement, Micromet may have the right to terminate Sesen Bio&#8217;s license, and upon the effective date of such termination, Sesen Bio&#8217;s right to use the licensed Micromet patent rights would end. To the extent such licensed technology or patent rights relate to Sesen Bio&#8217;s product candidates, Sesen Bio would expect to exercise all rights and remedies available to it, including attempting to cure any breach by Sesen Bio, and otherwise seek to preserve its rights under the patent rights licensed to it, but Sesen Bio may not be able to do so in a timely manner, at an acceptable cost to Sesen Bio or at all. Any uncured, material breach under the Micromet License Agreement could result in Sesen Bio&#8217;s loss of rights to practice the patent rights licensed to it under the Micromet License Agreement, and to the extent such patent rights and other technology relate to its product candidates or other of its compounds, it could have a material adverse effect on Sesen Bio&#8217;s ability to complete a sale of its Vicineum asset to a potential partner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio also has a license agreement with XOMA, or the XOMA License Agreement, which grants Sesen Bio non-exclusive rights, with certain sublicense rights, to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, and if Sesen Bio&#8217;s fails to meet its obligations under the XOMA License Agreement, XOMA may have the right to terminate Sesen Bio&#8217;s license, and upon the effective date of such termination, Sesen Bio&#8217;s right to use the licensed XOMA patent rights and related know-how would end. To the extent such licensed technology or patent rights relate to Sesen Bio&#8217;s product candidates, Sesen Bio would expect to exercise all rights and remedies available to it, including attempting to cure any breach by Sesen Bio, and otherwise seek to preserve its rights under the patent rights licensed to it, but Sesen Bio may not be able to do so in a timely manner, at an acceptable cost to Sesen Bio or at all. Any uncured, material breach under the XOMA License Agreement could result in Sesen Bio&#8217;s loss of rights to practice the patent rights licensed to it under the XOMA License Agreement, and to the extent such patent rights and other technology relate to Sesen Bio&#8217;s product candidates or other of its compounds, it could have a material adverse effect on Sesen Bio&#8217;s ability to complete a sale of its Vicineum asset to a potential partner. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio may become involved in lawsuits to protect or enforce its patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not completed and Sesen Bio does not pursue a liquidation and dissolution or alternative strategic transaction, competitors may infringe Sesen Bio&#8217;s issued patents or other intellectual property. To counter infringement or unauthorized use, Sesen Bio may be required to file infringement claims, which can be expensive and time consuming. Any claims Sesen Bio asserts against perceived infringers could provoke these parties to assert counterclaims against it alleging that Sesen Bio infringes their patents, trademarks or other intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of Sesen Bio&#8217;s is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that Sesen Bio&#8217;s patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of Sesen Bio&#8217;s patents at risk of being invalidated or interpreted narrowly. In a trademark infringement proceeding, Sesen Bio could be enjoined from continued use of a trademark deemed to be infringing and forced to rebrand product packaging, product inserts, market and advertising materials, resulting in a loss of sales and established goodwill in that name or mark. In addition, Sesen Bio could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if it is found to have willfully infringed a trademark. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Sesen Bio&#8217;s confidential information could be compromised by disclosure during this type of litigation. Even if resolved in Sesen Bio&#8217;s favor, litigation or other legal proceedings relating to intellectual property claims may cause Sesen Bio to incur significant expenses and could distract its technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of Sesen Bio&#8217;s common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Third parties may initiate legal proceedings alleging that Sesen Bio is infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of Sesen Bio&#8217;s business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s only prospective revenue streams currently depends upon the ability of Roche to develop, manufacture, market and/or sell certain of Sesen Bio&#8217;s legacy technology without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. Sesen Bio or Roche may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to Sesen Bio&#8217;s current or former products and technology, including interference or derivation proceedings before the USPTO. The risks of being involved in such litigation and proceedings may increase as Sesen Bio gains the greater visibility associated with seeking strategic alternatives. Third parties may assert infringement claims against Sesen Bio or Roche based on existing patents or patents that may be granted in the future. Sesen Bio may not be aware of all such intellectual property rights potentially relating to its former product candidates and their uses. Thus, Sesen Bio does not know with certainty that any product candidate, or commercialization thereof, does not and will not infringe or otherwise violate any third party&#8217;s intellectual property. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio or Roche are found to infringe a third party&#8217;s intellectual property rights, Sesen Bio could be required to obtain a license from such third party to continue developing and marketing Sesen Bio&#8217;s products and technology. However, Sesen Bio may not be able to obtain any required license on commercially reasonable terms or at all. Even if Sesen Bio were able to obtain a license, it could be non-exclusive, thereby giving its competitors access to the same technologies licensed to Sesen Bio. Sesen Bio or Roche could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, Sesen Bio or Roche could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if Sesen Bio or Roche is found to have willfully infringed a patent. A finding of infringement could prevent Roche from commercializing Sesen Bio&#8217;s former product candidates. Claims that Sesen Bio has misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on Sesen Bio&#8217;s ability to profit from the Roche Asset Purchase Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Regulatory Compliance if the Merger is Not Completed</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio&#8217;s failure to comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against Sesen Bio, and adversely impact its operating results.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The regulatory environment surrounding information security, data collection, and privacy is increasingly demanding. In the U.S., Sesen Bio is subject to a number of data protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal and state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent&#160;years there has been an increasing focus on privacy and data security issues. Numerous federal and state laws, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, such as Section&#160;5 of the Federal Trade Commission Act, govern the collection, use, and disclosure of health-related and other personal information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, Sesen Bio may obtain health information from third parties that are subject to privacy and security requirements in the U.S. under the Health Insurance Portability and Accountability Act, or HIPAA. Although Sesen Bio is not directly subject to HIPAA&#8201;&#8212;&#8201;other than potentially with respect to providing certain employee benefits&#8201;&#8212;&#8201;Sesen Bio could be subject to criminal penalties if Sesen Bio knowingly obtains, uses or discloses individually identifiable health information maintained by a HIPAA-covered entity in a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">manner that is not authorized or permitted by HIPAA. Finally, a data breach affecting sensitive personal information, including health information, could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on Sesen Bio&#8217;s business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to U.S. data protection laws and regulations, Sesen Bio also may be subject to European and other international data protection requirements, such as the E.U. General Data Protection Regulation. Sesen Bio failures to comply with data privacy and security laws and regulations, or changes in the way in which these laws are implemented, could lead to unfavorable outcomes, including increased compliance costs, delays or impediments in the development of new products, increased operating costs, diversion of management time and attention, regulatory liability as a result of government enforcement actions and significant penalties against Sesen Bio, civil liability as a result of claims initiated by data subjects (including claims initiated as class actions) contracting parties or other third parties as a result of non-compliance with data protection laws and/or contractual obligations, and adverse publicity that could negatively affect Sesen Bio&#8217;s operating results, financial condition and Sesen Bio&#8217;s overall and business. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys, including class action attorneys, have been and will likely continue to be active in this space. Such liabilities could adversely impact Sesen Bio&#8217;s results of operations, financial condition and its overall business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, laws and regulations governing any international operations Sesen Bio may have in the future may preclude Sesen Bio from developing, manufacturing and selling certain products outside of the U.S. and require Sesen Bio to develop and implement costly compliance programs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not consummated and Sesen Bio does not decide to pursue a liquidation and dissolution or alternative strategic transaction, Sesen Bio must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which Sesen Bio operates. The Foreign Corrupt Practices Act, or the FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any non-U.S. official, political party or candidate for the purpose of influencing any act or decision of the non-U.S. entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring Sesen Bio to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered non-U.S. officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If the merger is not consummated and Sesen Bio does not decide to pursue a liquidation and dissolution or alternative strategic transaction, and if Sesen Bio expands its presence outside of the U.S., it will require Sesen Bio to dedicate additional resources to comply with these laws, and these laws may preclude Sesen Bio from developing, manufacturing, or selling certain products and product candidates outside of the U.S., which could limit Sesen Bio&#8217;s growth potential and increase its development costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not consummated and Sesen Bio does not decide to pursue a liquidation and dissolution or alternative strategic transaction, Sesen Bio&#8217;s employees may engage in misconduct or other improper </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for Sesen Bio and harm its reputation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not consummated and Sesen Bio does not decide to pursue a liquidation and dissolution or alternative strategic transaction, Sesen Bio could be exposed to the risk of employee fraud or other misconduct, including intentional failure to comply with FDA regulations or similar regulations of comparable non-U.S. regulatory authorities, failure to provide accurate information to the FDA or comparable non-U.S. regulatory authorities, including the competent authorities of the E.U. member states, failure to comply with manufacturing standards Sesen Bio has established, if any, failure to comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-U.S. regulatory authorities, and failure to report financial information or data accurately or disclose unauthorized activities to Sesen Bio. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to Sesen Bio&#8217;s reputation. It is not always possible to identify and deter employee misconduct, and the precautions Sesen Bio takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Sesen Bio from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against Sesen Bio, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business and results of operations, including the imposition of significant fines or other sanctions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Sesen Bio&#8217;s Business if the Merger is Not Completed</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio relies significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could materially adversely affect its business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the ordinary course of business, Sesen Bio relies on information technology networks and systems, some of which are provided, hosted or managed by third parties, to collect, store, process and transmit electronic data. In addition, Sesen Bio handles certain data, including proprietary business information and personal information that is subject to data protection laws and regulations. Despite the implementation of security measures, Sesen Bio&#8217;s internal computer systems and those of third parties with which it contracts are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in Sesen Bio&#8217;s operations and could result in a material disruption of its clinical and commercialization activities, if Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of clinical trial data could result in delays in Sesen Bio&#8217;s regulatory approval efforts, if Sesen Bio resumes clinical development of Vicineum for the treatment of NMIBC, and significantly increase its costs to recover or reproduce the data. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although Sesen Bio has implemented processes, procedures, and controls to help mitigate the risks associated with a cyber security incident, there can be no assurance that these measures will be sufficient for all possible situations. Even security measures that are appropriate, reasonable, and/or in accordance with applicable legal requirements may not be able to protect the networks, systems and information that Sesen Bio maintains and those of third parties with which Sesen Bio contracts. Unauthorized parties, whether within or outside Sesen Bio, may disrupt or gain access to its systems, or those of third parties with whom Sesen Bio does business, through human error, misfeasance, fraud, trickery or other forms of deceit, including break-ins, use of stolen credentials, social engineering, phishing, ransomware, computer viruses or other malicious codes, and similar means of unauthorized and destructive tampering. Even the most well-protected information, networks, systems and facilities remain potentially vulnerable because the techniques used in such attempted cyber security incidents evolve and generally are not recognized until launched against a target. Accordingly, Sesen Bio may be unable to anticipate these techniques or to implement adequate security barriers or other preventative measures, making it impossible for Sesen Bio to entirely mitigate this risk. While Sesen Bio has experienced, and expects to continue to experience, threats and disruptions to its information technology infrastructure, none of them to date has had a material impact on its business or operations. To the extent that any disruption or security breach were to result in a loss of, or damage to, its data or applications, or inappropriate disclosure of confidential or proprietary information, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">its clinical development of Vicineum for the treatment of NMIBC could be delayed if Sesen Bio resumes such clinical development, or Sesen Bio could be subject to regulatory and other government investigations, enforcement actions, or incur liability, substantial fines or costs, any of which could materially adversely affect its business, its reputation, results of operations and financial condition. Although Sesen Bio maintains insurance coverage for various cyber security risks, there can be no guarantee that all costs or losses incurred will be fully insured. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio and certain of its officers have been named as defendants in three pending securities class action lawsuits. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert Sesen Bio management&#8217;s time and attention from Sesen Bio&#8217;s business, and have a material adverse effect on Sesen Bio&#8217;s results of operations. These lawsuits, and any other lawsuits to which Sesen Bio is subject, will be costly to defend and are uncertain in their outcome.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;19, 2021, August&#160;31, 2021, and October&#160;7, 2021, three substantially identical securities class action lawsuits captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Bibb v. Sesen Bio, Inc., et. al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:21-cv-07025, </font><font style="font-style:italic;letter-spacing:0.2pt;">Cizek v. Sesen Bio, Inc., et.&#160;al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:21-cv-07309 and </font><font style="font-style:italic;letter-spacing:0.2pt;">Markman v. Sesen Bio, Inc. et al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:21-cv-08308 were filed against Sesen Bio and certain of its officers in the U.S. District Court for the Southern District of New York. The three complaints alleged violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder based on statements made by Sesen Bio concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October&#160;29, 2021, the court consolidated the three cases under the caption </font><font style="font-style:italic;letter-spacing:0.2pt;">In re Sesen Bio, Inc. Securities Litigation</font><font style="letter-spacing:0.2pt;">, Master File No. 1:21-cv-07025-AKH, or the Securities Litigation, and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj as the lead plaintiffs, or collectively, the Lead Plaintiffs, under the Private Securities Litigation Reform Act. On November&#160;1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. On November&#160;24, 2021, defendants filed a motion to transfer venue to the U.S. District Court for the District of Massachusetts. That motion was fully briefed as of December&#160;13, 2021, but the court has not ruled on that motion. On December&#160;6, 2021, the Lead Plaintiffs filed an amended class action complaint, or the Amended Complaint. The Amended Complaint alleges the same violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March&#160;7, 2022, and that motion was fully briefed on May&#160;6, 2022. On June&#160;3, 2022, before the court ruled on the motion to dismiss, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. On June&#160;30, 2022 and July&#160;6, 2022, Sesen Bio and the plaintiffs engaged in mediation sessions in an attempt to resolve the Securities Litigation and continued to discuss a potential settlement over the following weeks. On July&#160;19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, Sesen Bio and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to Sesen Bio and the individual defendants. On August&#160;3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which was filed with the court on August&#160;17, 2022. The Stipulation and Agreement of Settlement related to the Securities Litigation provides for a settlement payment of $21.0&#160;million to the class and the dismissal of all claims against Sesen Bio and the other defendants. The settlement payment is being funded by Sesen Bio and its insurance carriers. On September&#160;1, 2022, the U.S. District Court for the Southern District of New York issued an order denying the motions to appoint a different lead plaintiff. On September&#160;28, 2022, the court issued an order granting preliminary approval of the proposed settlement of the Securities Litigation. The court has set a final settlement approval hearing for January&#160;23, 2023 at 10:00&#160;a.m. local time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio, the Sesen Bio board of directors and the individual defendants continue to deny all allegations of any wrongdoing, but are seeking to settle the Securities Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio may be the target of similar litigation in the future. The market price of its common stock has experienced and may continue to experience volatility, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities litigation. Any future litigation could result in substantial costs and divert Sesen Bio management&#8217;s attention from other business concerns, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">which could seriously harm its business. Sesen Bio maintains liability insurance; however, if any costs or expenses associated with the pending lawsuits or any other litigation exceed Sesen Bio&#8217;s insurance coverage, Sesen Bio may be forced to bear some or all costs and expenses directly, which could adversely affect its business, financial condition, results of operations or stock price. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Ownership of Sesen Bio Common Stock if the Merger is Not Completed</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio is unable to regain compliance with the listing requirements of the Nasdaq Capital Market, Sesen Bio common stock may be delisted from the Nasdaq Capital Market which could have a material adverse effect on Sesen Bio&#8217;s business and could make it more difficult for Sesen Bio stockholders to sell their shares of Sesen Bio common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio common stock is listed on the Nasdaq Capital Market, and Sesen Bio is therefore subject to Nasdaq&#8217;s continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholders&#8217; equity, among others, and requirements relating to board and committee independence. If Sesen Bio fails to satisfy one or more of the requirements, it may be delisted from the Nasdaq Capital Market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;24, 2022, Sesen Bio received notice from Nasdaq that it was not currently in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule&#160;5450(a)(1). The Nasdaq notice indicated that, consistent with Nasdaq Listing Rule&#160;5810(c)(3)(A), Sesen Bio had 180 calendar days, or until July&#160;25, 2022, to regain compliance with the minimum bid price requirement by having the closing bid price of Sesen Bio common stock meet or exceed $1.00 per share for at least ten consecutive business days. On July&#160;26, 2022, Sesen Bio received approval to transfer the listing of Sesen Bio common stock from the Nasdaq Global Market to the Nasdaq Capital Market. As a result, Sesen Bio was granted a second 180-day grace period, or until January&#160;23, 2023, to regain compliance with the minimum bid price requirement. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">If Sesen Bio does not regain compliance by January&#160;23, 2023, it will receive notification from Nasdaq that Sesen Bio common stock is subject to delisting. At that time, Sesen Bio plans to appeal the delisting determination to a Nasdaq hearings panel. Such notification will have no immediate effect on Sesen Bio&#8217;s listing on the Nasdaq Capital Market, nor will it have an immediate effect on the trading of Sesen Bio common stock pending such hearing. However, there can be no assurance that Sesen Bio will be able to regain compliance with Nasdaq&#8217;s minimum bid price requirement. If Sesen Bio regains compliance with Nasdaq&#8217;s minimum bid price requirement, there can be no assurance that Sesen Bio will be able to maintain compliance with the continued listing requirements for the Nasdaq Capital Market or that Sesen Bio common stock will not be delisted from the Nasdaq Capital Market in the future. In addition, Sesen Bio may be unable to meet other applicable listing requirements of the Nasdaq Capital Market, including maintaining minimum levels of stockholders&#8217; equity or market values of Sesen Bio common stock in which case, Sesen Bio common stock could be delisted notwithstanding Sesen Bio&#8217;s ability to demonstrate compliance with the minimum bid price requirement. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Delisting from the Nasdaq Capital Market would adversely affect Sesen Bio&#8217;s ability to consummate the merger and may adversely affect Sesen Bio&#8217;s ability to raise additional financing through the public or private sale of equity securities, significantly affect the ability of investors to trade Sesen Bio common stock, or negatively affect the value and liquidity of Sesen Bio common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio is delisted from Nasdaq and Sesen Bio is not able to list Sesen Bio common stock on another exchange, Sesen Bio common stock could be quoted on the OTC Bulletin Board or in the &#8220;pink sheets.&#8221; As a result, Sesen Bio could face significant adverse consequences including, among others: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a limited availability of market quotations for Sesen Bio common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a determination that Sesen Bio common stock is a &#8220;penny stock&#8221; which will require brokers trading in Sesen Bio common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for Sesen Bio&#8217;s securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a limited amount of news and little or no analyst coverage for Sesen Bio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio would no longer qualify for exemptions from state securities registration requirements, which may require Sesen Bio to comply with applicable state securities laws; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3) or obtain additional financing in the future. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio common stock becomes subject to the penny stock rules, it would become more difficult to trade shares of Sesen Bio common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If Sesen Bio does not retain its listing on Nasdaq and if the price of Sesen Bio common stock is less than $5.00, Sesen Bio common stock may be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive: (i)&#160;the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure statement; (ii)&#160;a written agreement to transactions involving penny stocks; and (iii)&#160;a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for Sesen Bio common stock, and therefore stockholders may have difficulty selling their shares of Sesen Bio common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Provisions in the Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws and under Delaware law could make an acquisition of Sesen Bio, which may be beneficial to Sesen Bio stockholders, more difficult and may prevent attempts by Sesen Bio stockholders to replace or remove Sesen Bio&#8217;s current management.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Provisions in the Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws may discourage, delay or prevent a merger, acquisition or other change in control of Sesen Bio that Sesen Bio stockholders may consider favorable, including transactions in which Sesen Bio stockholders might otherwise receive a premium for their shares of Sesen Bio common stock. These provisions could also limit the price that investors might be willing to pay in the future for shares of Sesen Bio common stock, thereby depressing the market price of Sesen Bio common stock. In addition, because the Sesen Bio board of directors is responsible for appointing the members of Sesen Bio&#8217;s management team, these provisions may frustrate or prevent any attempts by Sesen Bio stockholders to replace or remove Sesen Bio&#8217;s current management by making it more difficult for Sesen Bio stockholders to replace members of the Sesen Bio board of directors. Among other things, these provisions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establish a classified board of directors such that only one of three classes of directors is elected each year; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">allow the authorized number of directors to be changed only by resolution of the Sesen Bio board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">limit the manner in which stockholders can remove directors from the Sesen Bio board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to the Sesen Bio board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">require that Sesen Bio stockholder actions must be affected at a duly called stockholder meeting and prohibit actions by Sesen Bio stockholders by written consent; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">limit who may call stockholder meetings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">authorize the Sesen Bio board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the Sesen Bio board of directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRRTC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">require the approval of the holders of at least 75% of the votes that all Sesen Bio stockholders would be entitled to cast to amend or repeal specified provisions of the Sesen Bio Certificate of Incorporation or Sesen Bio Bylaws. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, because Sesen Bio is incorporated in Delaware, Sesen Bio is governed by the provisions of Section&#160;203 of the DGCL, which prohibits a person who owns in excess of 15% of Sesen Bio&#8217;s outstanding voting stock from merging or combining with Sesen Bio for a period of three&#160;years after the date of the transaction in which the person acquired in excess of 15% of Sesen Bio&#8217;s outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Carisma</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Carisma&#8217;s Financial Position and Need for Additional Capital</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma has incurred significant losses since its inception. Carisma expects to continue to incur significant expenses and operating losses for the foreseeable future and may never achieve or maintain profitability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since inception, Carisma has incurred significant operating losses. Carisma&#8217;s net losses were $40.8&#160;million for the year ended December&#160;31, 2021 and $28.3&#160;million for the year ended December&#160;31, 2020. As of September&#160;30, 2022, Carisma had $70.6&#160;million in cash, cash equivalents and marketable securities and an accumulated deficit of $141.5&#160;million. To date, Carisma has not yet commercialized any products or generated any revenue from product sales and has financed its operations primarily with proceeds from sales of Carisma&#8217;s preferred stock, proceeds from Carisma&#8217;s collaboration with Moderna, research tax credits and convertible debt financing. Carisma has devoted substantially all of its financial resources and efforts to pursuing discovery, research and development of its product candidates. Carisma is still in the early stages of development of its lead product candidate, CT-0508, and initiated its first clinical trial in 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma expects to continue to incur significant expenses and operating losses for the foreseeable future. Upon the closing of the merger, Carisma will also incur additional costs associated with operating as a public company. Carisma anticipates that its expenses will increase substantially if and as it: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">enhances the capabilities of its CAR-M platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conducts its ongoing Phase&#160;1 clinical trial of CT-0508; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prepares for, initiates and conducts a planned clinical trial utilizing CT-0508 in combination with pembrolizumab; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">develops other CT-0508 combination studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">advances CT-0508 for additional indications or any other product candidate into clinical development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prepares for, initiates and conducts a planned clinical trial of CT-0525 for solid tumors that overexpress HER2;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prepares for, initiates and conducts a planned clinical trial of CT-1119 for advanced mesothelin-positive solid tumors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prepares for, initiates and conducts a planned clinical trial of CT-0729 for PSMA positive castrate resistant prostate cancer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conducts discovery and pre-clinical testing of the development of </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M therapeutics for up to twelve oncology targets, as well as multiple other targets and indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conducts discovery and pre-clinical testing of its autologous cell therapy pipeline to gather information to apply to the development of off-the-shelf engineered macrophage therapeutics; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">develops iPSC-derived iCAR-M, or iCAR-M, and other macrophage therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">develops </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> reprogrammed LNP/mRNA CAR-M therapies for cancer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">develops viral vectors to effectively engineer human monocytes and macrophages, including the Vpx lentiviral vector and Carisma&#8217;s Ad5f35 vector; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conducts discovery and pre-clinical testing of other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seeks marketing approval for CT-0508 or any other product candidate if it successfully completes clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">scales up its external manufacturing capabilities and capabilities to support clinical trials of CT-0508 or any other product candidates and for commercialization of any product candidate for which it may obtain marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establishes a sales, marketing and distribution infrastructure to commercialize any product candidate for which it may obtain marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in-licenses or acquires additional technologies or product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">makes any payments under its existing or future strategic collaboration agreements, global exclusive rights licensing agreements or sponsored research agreements, including with Moderna, University of Pennsylvania and New York University; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintains, expands, enforces and protects its intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">hires additional clinical, regulatory, manufacturing, quality control, development and scientific personnel; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adds operational, financial and management information systems and personnel, including personnel to support its discovery, product development and planned future commercialization efforts and its operations as a public company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, Carisma is unable to accurately predict the timing or amount of increased expenses or when, or if, it will be able to achieve or maintain profitability. Carisma&#8217;s expenses could increase beyond its expectations if, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma is required by regulatory authorities in the United States, Europe or other jurisdictions to perform trials or studies in addition to, or different than, those that it currently expects; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">there are any delays in establishing appropriate manufacturing arrangements for or completing the development of any of Carisma&#8217;s product candidates; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">there are any third-party challenges to Carisma&#8217;s intellectual property or Carisma needs to defend against any intellectual property-related claim. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if Carisma obtains marketing approval for and is successful in commercializing one or more of its product candidates, Carisma expects to incur substantial additional discovery and product development and other expenditures to develop and market additional product candidates or to expand the approved indications of any marketed product. Carisma may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect its business. The size of Carisma&#8217;s future net losses will depend, in part, on the rate of future growth of its expenses and Carisma&#8217;s ability to generate revenue. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma has never generated revenue from product sales and may never achieve or maintain profitability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma only recently initiated clinical development of its lead product candidate, CT-0508, and is in the pre-clinical testing stages for its other product candidates. Carisma expects that it will be a number of&#160;years, if ever, before it has a product candidate ready for commercialization. To become and remain profitable, Carisma must succeed in completing development of, obtaining marketing approval for and eventually commercializing, one or more products that generate significant revenue. The ability to achieve this success will require Carisma to be effective in a range of challenging activities, including completing clinical development of CT-0508, completing discovery, pre-clinical testing and clinical development of CT-0508 in the combination setting and for additional indications, timely filing and receiving acceptance of its Investigational New Drug applications, or INDs, in order to commence its planned or future clinical trials, including for CT-0525, CT-1119 and, CT-0729, successfully enrolling subjects in, and completing, its ongoing and planned clinical trials, scaling up its manufacturing processes and capabilities to support clinical trials </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of CT-0508 or of other product candidates, obtaining marketing approval for CT-0508 or any other product candidates, manufacturing, marketing and selling any products for which Carisma may obtain marketing approval and maintaining a continued acceptable safety profile of its products following approval. Carisma may never succeed in these activities and, even if it does, may never generate revenues that are significant enough to achieve profitability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if Carisma does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. Carisma&#8217;s failure to become and remain profitable would depress the value of its company and could impair its ability to raise capital, expand its business, maintain its discovery and product development efforts, diversify its pipeline of product candidates or even continue its operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma is heavily dependent on the success of its lead product candidate, CT-0508, which will require significant clinical testing before it can seek marketing approval and potentially launch commercial sales. If CT-0508 does not receive marketing approval or is not successfully commercialized, or if there is significant delay in doing so, Carisma&#8217;s business will be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma only recently initiated its first clinical trial, has no products that are approved for commercial sale and may never be able to develop marketable products. Carisma expects that a substantial portion of its efforts and expenditures for the foreseeable future will be devoted to CT-0508 and related combination sub-studies of the synergistic potential and utility of CT-0508. Carisma&#8217;s business currently depends heavily on the successful development, marketing approval and commercialization of CT-0508 and the success of related combination sub-studies. Carisma cannot be certain that CT-0508 or any combination therapy will achieve success in ongoing or future clinical trials, receive marketing approval or be successfully commercialized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Carisma were required to discontinue development of CT-0508, or if CT-0508 does not receive marketing approval for one or more of the indications Carisma pursues, fails to achieve significant market acceptance, or fails to receive adequate reimbursement, Carisma may be delayed by many&#160;years in its ability to achieve profitability, if ever, and may not be able to generate sufficient revenue to continue its business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma will need substantial additional funding for its continuing operations. If Carisma is unable to raise capital when needed or on acceptable terms, it could be forced to delay, reduce or eliminate its discovery or product development programs or commercialization efforts.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma expects to devote substantial financial resources to its ongoing and planned activities, particularly as it conducts its ongoing clinical trial of CT-0508 and pursues related combination strategies, prepares for, initiates and conducts its planned clinical trials of CT-0525, CT-1119 and CT-0729 and advances its discovery programs and continues its product development efforts. Carisma expects its expenses to increase substantially in connection with its ongoing activities, particularly as it advances its pre-clinical activities and clinical trials. In addition, if Carisma obtains marketing approval for CT-0508 or any other product candidate it is developing or develops in the future, it expects to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, upon the closing of the merger, it expects to incur additional costs associated with operating as a public company. Accordingly, Carisma will need to obtain substantial additional funding in connection with its continuing operations. If Carisma is unable to raise capital or obtain adequate funds when needed or on acceptable terms, it may be required to delay, limit, reduce or terminate its discovery and product development programs or any future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself. In addition, attempting to secure additional financing may divert the time and attention of Carisma management from day-to-day activities and distract from its discovery and product development efforts. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s future capital requirements will depend on many factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the progress, costs and results of its ongoing clinical trial of CT-0508 and other planned and future clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, costs and results of pre-clinical testing and clinical trials of CT-0508 for additional combinations, targets and indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of and development requirements for additional indications for CT-0508 or for any other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success of its collaborations with Moderna or others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its ability to scale up its manufacturing processes and capabilities to support clinical trials of CT-0508 and other product candidates it is developing and develops in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs, timing and outcome of regulatory review of CT-0508 and other product candidates it is developing and may develop in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential changes in the regulatory environment and enforcement rules; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the payment of license fees and other costs of its technology license arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for CT-0508 and other product candidates it is developing and may develop in the future for which it may receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its ability to obtain and maintain acceptance of any approved products by patients, the medical community and third-party payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amount and timing of revenue, if any, received from commercial sales of CT-0508 and any other product candidates it is developing or develops in the future for which it receives marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential changes in pharmaceutical pricing and reimbursement infrastructure; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of raw materials for use in production of its product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property and proprietary rights and defending any intellectual property-related claims; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which it in-licenses or acquires additional technologies or product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma management has concluded that there is substantial doubt about Carisma&#8217;s ability to continue as a going concern. As a result, Carisma management has included disclosures in Note 2 of the consolidated financial statements and Carisma&#8217;s independent auditor included an explanatory paragraph in its report on Carisma&#8217;s consolidated financial statements as of and for the year ended December&#160;31, 2021 with respect to this uncertainty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2022, Carisma had cash, cash equivalents and marketable securities of $70.6&#160;million. Immediately prior to the consummation of the merger, certain investors have agreed to purchase shares of Carisma common stock for an aggregate purchase price of approximately $30.6&#160;million. Carisma believes that following consummation of the pre-closing financing and the merger, it will have cash, cash equivalents and marketable securities sufficient to sustain its operating expenses and capital expenditure requirements at least through the end of 2024. However, Carisma has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to Carisma. In addition, changing circumstances could cause Carisma to consume capital significantly faster than it currently anticipates, and Carisma may need to spend more than currently expected because of circumstances beyond its control. As a result, Carisma could deplete its capital resources sooner than it currently expects. In addition, because the successful development of CT-0508, CT-0525, CT-1119, CT-0729 and any combination studies or other product candidates that it pursues is highly uncertain, at this time Carisma cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of any product candidate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Identifying potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and Carisma may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, Carisma&#8217;s product candidates, if approved, may not achieve commercial success. Carisma will not generate </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">commercial revenues unless and until it can achieve sales of products, which it does not anticipate for a number of&#160;years, if at all. Accordingly, Carisma will need to obtain substantial additional financing to achieve its business objectives. Adequate additional financing may not be available to Carisma on acceptable terms, or at all, and may be impacted by the economic climate and market conditions. For example, market volatility resulting from the COVID-19 pandemic, any other future infectious diseases, epidemics or pandemics or general U.S. or global economic or market conditions could also adversely impact Carisma&#8217;s ability to access capital as and when needed. Alternatively, Carisma may seek additional capital due to favorable market conditions or strategic considerations, even if it believes it has sufficient funds for its current or future operating plans. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s limited operating history may make it difficult for you to evaluate the success of Carisma&#8217;s business to date and to assess the combined company&#8217;s future viability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma was formed as Carma Therapeutics LLC, a Pennsylvania limited liability company, in April&#160;2016 and converted to a Delaware corporation in May&#160;2017. Carisma is a clinical-stage cell therapy company with a limited operating history. Cell therapy product development is a highly speculative undertaking and involves a substantial degree of risk. Carisma&#8217;s operations to date have been limited to organizing and staffing its company, business planning, capital raising, establishing and maintaining its intellectual property portfolio, building its pipeline of product candidates, conducting drug discovery activities, undertaking pre-clinical studies, manufacturing process development studies, conducting early-stage clinical trials, and providing general and administrative support for these operations. Carisma&#8217;s prospects must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered by companies in their early stages of operations. Carisma has not yet demonstrated its ability to successfully develop any product candidate, obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on its behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about the combined company&#8217;s future success or viability may not be as accurate as they could be if Carisma had a longer operating history or a history of successfully developing, obtaining marketing approval for and commercializing products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, as Carisma&#8217;s business grows, Carisma may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles. Carisma will need to transition at some point from a company with a discovery and pre-clinical and clinical focus to a company capable of supporting commercial activities. Carisma may not be successful in such a transition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As Carisma continues to build its business, Carisma expects its financial condition and operating results to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond Carisma&#8217;s control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The COVID-19 pandemic may affect Carisma&#8217;s pre-clinical studies and clinical trials, disrupt regulatory activities, disrupt Carisma&#8217;s manufacturing and supply chain or have other adverse effects on Carisma&#8217;s business and operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The COVID-19 pandemic has caused many governments to implement measures to slow the spread of the virus through quarantines, travel restrictions, heightened border scrutiny and other measures. The pandemic and government measures taken in response have also had a significant impact, both directly and indirectly, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The future progression of the pandemic and its effects on Carisma&#8217;s business and operations are uncertain. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma and the third-party manufacturers and clinical research organizations that it engages may face disruptions that could affect Carisma&#8217;s ability to initiate and complete pre-clinical studies or clinical trials, including disruptions in procuring items that are essential for Carisma&#8217;s discovery and product development activities, such as, for example, raw materials used in the manufacturing of its product candidates, laboratory </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">supplies for its ongoing and planned pre-clinical studies and clinical trials, or animals that are used for pre-clinical testing, in each case, for which there may be shortages because of ongoing efforts to address the pandemic, or disruptions in Carisma&#8217;s ability to obtain necessary site approvals or other delays at clinical trial sites. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result of the COVID-19 pandemic, Carisma may experience further disruptions that could severely impact Carisma&#8217;s business, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">disruptions related to Carisma&#8217;s ongoing and planned clinical trials or future clinical trials arising from delays in completing pre-clinical studies required to begin clinical development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">manufacturing disruptions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the inability to obtain necessary site approvals or other delays at clinical trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as Carisma&#8217;s clinical trial sites and hospital staff supporting the conduct of Carisma&#8217;s clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by foreign, federal or state governments, employers and others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption or delays in the operations of the FDA, or other regulatory authorities, which may impact review and approval timelines; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">limitations on employee resources that would otherwise be focused on the conduct of Carisma&#8217;s pre-clinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">difficulties recruiting or retaining patients for Carisma&#8217;s clinical trials if patients are affected by the virus or are fearful of visiting or traveling to clinical trial sites because of the virus; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risk that participants enrolled in its clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events and refusal of the FDA, to accept data from clinical trials in these affected geographies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The response to the COVID-19 pandemic may redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact its ability to pursue marketing approvals and protect its intellectual property. In addition, Carisma may face impediments to regulatory meetings and potential approvals due to measures intended to limit in-person interactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, third parties, including manufacturers, medical institutions, clinical investigators, contract research organizations and consultants with whom Carisma conducts business, are similarly adjusting their operations and assessing their capacity in light of the COVID-19 pandemic. If these third parties continue to experience shutdowns or business disruptions, Carisma&#8217;s ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively impacted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The COVID-19 pandemic continues to evolve and has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact Carisma&#8217;s ability to raise additional funds through public offerings and may also impact the volatility of Carisma&#8217;s stock price and trading in its stock. Moreover, it is possible the pandemic will further significantly impact economies worldwide, which could result in adverse effects on Carisma&#8217;s business and operations. Carisma cannot be certain what the overall impact of the COVID-19 pandemic will be on its business, and it has the potential to materially and adversely affect Carisma&#8217;s business, financial condition, results of operations and prospects. To the extent the COVID-19 pandemic adversely affects Carisma&#8217;s business, financial condition and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in tax law may adversely affect Carisma or its investors.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect Carisma or holders of Carisma&#8217;s common stock. In recent&#160;years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in Carisma&#8217;s or its stockholders&#8217; tax liability or require changes in the manner in which Carisma operates in order to minimize or mitigate any adverse effects of changes in tax law. Prospective investors should consult their tax advisors regarding the potential consequences of changes in tax law on Carisma&#8217;s business and on the ownership and disposition of Carisma common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s ability to use its net operating loss carryforwards, or NOLs, and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma has a history of cumulative losses and anticipates that it will continue to incur significant losses in the foreseeable future. As a result, Carisma does not know whether or when it will generate taxable income necessary to utilize its NOLs or research and development tax credit carryforwards. As of December&#160;31, 2021, Carisma had federal, state and local NOLs of $76.4&#160;million, $76.4&#160;million and $71.2&#160;million, respectively, and federal research and development tax credit carryforwards totaling $3.9&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, under Section&#160;382 of the Code and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50&#160;percentage point change (by value) in its equity ownership by certain stockholders over a three year period, is subject to limitations on its ability to utilize its pre-change NOLs and research and development tax credit carryforwards to offset future taxable income. Carisma has not conducted a study to assess whether any such ownership changes have occurred. Carisma may have experienced such ownership changes in the past and may experience such ownership changes in the future (which may be outside its control). As a result, if and to the extent Carisma earns net taxable income, its ability to use its pre-change NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Carisma&#8217;s Discovery Programs and Research and Development of Carisma&#8217;s Product Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cell therapy is a rapidly evolving area of science, and the approach Carisma is taking to discover and develop product candidates by utilizing genetically modified macrophages is novel and may never lead to approved or marketable products.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cell therapy has yet to be broadly applied to solid tumors, inflammatory disease, fibrotic disease or neurodegeneration. The discovery, research and development of engineered macrophages to treat disease is an emerging field and Carisma&#8217;s CAR-M platform, which is the first CAR-M to be evaluated in a human clinical trial, is a relatively new technology. Carisma&#8217;s future success depends on the successful development of this novel therapeutic approach. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Carisma has only preliminary results from its Phase&#160;1 clinical trial of CT-0508 and expects clinical updates in the next 18&#160;months. As such, there may be adverse effects or limited favorable results from treatment with any of Carisma&#8217;s current or future product candidates that it cannot predict at this time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s success also depends on its successful application of its proprietary macrophage engineering platform in the combination setting and to other indications by reprogramming the target specificity of its CAR-M cell product and developing product candidates against a plethora of tumor associated antigens, including in therapeutic areas beyond oncology. However, Carisma&#8217;s macrophage engineering platform may not allow it to generate new INDs to expand its pipeline on Carisma&#8217;s anticipated timeline or in a cost-efficient manner or at all, which could cause the potential value of Carisma&#8217;s business to decline and materially harm Carisma&#8217;s business prospects. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result of these factors, it is more difficult for Carisma to predict the time and cost of product candidate development, and Carisma cannot predict whether the application of macrophage engineering platform will result in the development and marketing approval of any products. Any development problems Carisma experiences in the future related to its macrophage engineering platform or any of its discovery programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent Carisma from completing its clinical trials or pre-clinical studies or commercializing any product candidates it may develop on a timely or profitable basis, if at all. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma is early in its development efforts. If Carisma is unable to commercialize its product candidates or experiences significant delays in doing so, its business will be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is early in its development efforts. Carisma initiated its first Phase&#160;1 clinical trial of CT-0508 in 2021 and expects to evaluate a combination of CT-0508 with pembrolizumab in an upcoming Phase&#160;1 clinical trial. Carisma expects to submit INDs for CT-0525 in the third quarter of 2023 and for CT-1119 in 2025. CT-0729 is still in the discovery stage. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s ability to generate revenues from product sales, which it does not expect will occur for a number of&#160;years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of CT-0508, including in the combination setting, or one or more of its other product candidates, which may never occur. The success of CT-0508 and Carisma&#8217;s other product candidates will depend on several factors, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successfully completing pre-clinical studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successfully initiating future clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successfully enrolling patients in and completing clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">scaling up manufacturing processes and capabilities to support clinical trials of CT-0508 and any other product candidate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">applying for and receiving marketing approvals from applicable regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining and maintaining intellectual property protection and regulatory exclusivity for CT-0508 and any other product candidates it is developing or may develop in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">making arrangements with third-party manufacturers, or establishing commercial manufacturing capabilities, for both clinical and commercial supplies of its product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establishing sales, marketing and distribution capabilities and launching commercial sales of its products, if and when approved, whether alone or in collaboration with others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acceptance of CT-0508 and any other product candidates, if and when approved, by patients, the medical community and third-party payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">effectively competing with other therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintaining, enforcing, defending and protecting its rights in its intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintaining a continued acceptable safety profile of its products following receipt of any marketing approvals. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Carisma does not achieve one or more of these factors in a timely manner or at all, it could experience significant delays or an inability to successfully develop and commercialize its product candidates, which would materially harm Carisma&#8217;s business. As a company, Carisma has limited experience in clinical development, having only recently advanced CT-0508 into an early-stage clinical trial. Any predictions </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">about the future success or viability of CT-0508 or any product candidates Carisma is developing or may develop in the future may not be as accurate as they could be if Carisma had a history of conducting clinical trials. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Drug development involves a lengthy and expensive process, with an uncertain outcome. The results of pre-clinical studies and early clinical trials may not be predictive of future results. Carisma may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of CT-0508 or its other product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma only recently initiated its first clinical trial of CT-0508 and its other product candidates are in pre-clinical development. The risk of failure for CT-0508 and Carisma&#8217;s other product candidates is high. It is impossible to predict when or if CT-0508 or any of Carisma&#8217;s other product candidates will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of a product candidate, Carisma must complete pre-clinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Clinical trials may fail to demonstrate that CT-0508 or any of Carisma&#8217;s other product candidates are safe for humans and effective for indicated uses. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before Carisma can commence clinical trials for a product candidate, it must complete extensive pre-clinical testing and studies, manufacturing process development studies, and analytical development studies that support its planned INDs and other applications to regulatory authorities in the United States or similar applications in other jurisdictions. Carisma cannot be certain of the timely completion or outcome of its pre-clinical testing and studies and cannot predict if the outcome of its pre-clinical testing and studies will ultimately support the further development of its current or future product candidates or whether regulatory authorities will accept its proposed clinical programs. As a result, Carisma may not be able to submit applications to initiate clinical development of product candidates on the timelines Carisma expects, if at all, and the submission of these applications may not result in regulatory authorities allowing clinical trials to begin. Furthermore, product candidates are subject to continued pre-clinical safety studies, which may be conducted concurrently with Carisma&#8217;s clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact Carisma&#8217;s ability to continue to conduct its clinical trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and is uncertain as to the outcome. Carisma cannot guarantee that any of its clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, among other things, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of Carisma&#8217;s product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of its other product candidates or cause regulatory authorities to require additional testing before approving any of its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent its ability to receive marketing approval or commercialize any product candidates, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulators or institutional review boards, or IRBs, may not authorize Carisma or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulators may determine that the planned design of Carisma&#8217;s clinical trials is flawed or inadequate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinical trials of Carisma&#8217;s product candidates may produce negative or inconclusive results, and Carisma may decide, or regulators may require Carisma, to conduct additional clinical trials or abandon product development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may be unable to establish clinical endpoints that applicable regulatory authorities consider clinically meaningful, or, if Carisma seeks accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities consider likely to predict clinical benefit; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">pre-clinical testing may produce results based on which Carisma may decide, or regulators may require Carisma, to conduct additional pre-clinical studies before it proceeds with certain clinical trials, limits the scope of its clinical trials, halt ongoing clinical trials or abandon product development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of patients required for clinical trials of Carisma&#8217;s product candidates may be larger than it anticipates, enrollment in these clinical trials may be slower than Carisma anticipates or participants may drop out of these clinical trials at a higher rate than Carisma anticipates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to Carisma in a timely manner, or at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may decide, or regulators or IRBs may require Carisma, to suspend or terminate clinical trials of its product candidates for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulators or IRBs may require Carisma to perform additional or unanticipated clinical trials to obtain approval or Carisma may be subject to additional post-marketing testing requirements to maintain marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulators may revise the requirements for approving Carisma&#8217;s product candidates, or such requirements may not be as it anticipates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of clinical trials of Carisma&#8217;s product candidates may be greater than it anticipates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the supply or quality of Carisma&#8217;s product candidates or other materials necessary to conduct clinical trials of its product candidates may be insufficient or inadequate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s product candidates may have undesirable side effects or other unexpected characteristics, causing Carisma or its clinical investigators, regulators or IRBs to suspend or terminate the trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulators may withdraw their approval of a product or impose restrictions on its distribution; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">business interruptions resulting from the COVID-19 pandemic may result in adverse effects on Carisma&#8217;s business and operations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Carisma is required to conduct additional clinical trials or other testing of its product candidates beyond those that it currently contemplates, if Carisma is unable to successfully complete clinical trials of its product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if Carisma determines that the observed safety or efficacy profile would not be competitive in the marketplace, it may: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">incur unplanned costs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be delayed in obtaining marketing approval for its product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not obtain marketing approval at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtain marketing approval in some countries and not in others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtain approval for indications or patient populations that are not as broad as intended or desired; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be subject to additional post-marketing testing requirements; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">have the product removed from the market after obtaining marketing approval. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s product development costs will also increase if it experiences delays in pre-clinical studies or clinical trials or in obtaining marketing approvals. Carisma does not know whether any of its pre-clinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Carisma may also determine to change the design or protocol of one or more of its clinical trials, including to add additional patients or arms, which could result in increased costs and expenses or delays. Significant pre-clinical study or clinical trial delays also could shorten any periods during which Carisma may have the exclusive right to commercialize its product candidates or allow its competitors to bring products to market before Carisma does and impair Carisma&#8217;s ability to successfully commercialize its product candidates and may harm Carisma&#8217;s business and results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for second-line or third-line use. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. For any of Carisma&#8217;s products that prove to be sufficiently beneficial, Carisma would expect to seek approval potentially as a first-line therapy, but any product candidates Carisma develops, even if approved, may not be approved for first-line therapy, and, prior to any such approvals, Carisma may have to conduct additional clinical trials. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The results of early-stage clinical trials and pre-clinical studies may not be predictive of future results. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary or interim results of a clinical trial do not necessarily predict final results. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. In particular, the small number of patients in Carisma&#8217;s ongoing early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results of Carisma&#8217;s Phase&#160;1 clinical trial of CT-0508 may not be predictive of the results of further clinical trials of CT-0508 or any of Carisma&#8217;s other product candidates. Carisma&#8217;s product candidates may also fail to show the desired safety and efficacy in clinical development despite positive results in pre-clinical studies or having successfully advanced through initial clinical trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Carisma&#8217;s current or future clinical trials may not ultimately be successful or support further clinical development of any of its product candidates and Carisma cannot assure you that any clinical trials that it may conduct will demonstrate consistent or adequate efficacy and safety to support marketing approval. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials even after achieving promising results in pre-clinical testing and earlier-stage clinical trials, and Carisma cannot be certain that it will not face similar setbacks. Any such setbacks in Carisma&#8217;s clinical development could materially harm Carisma&#8217;s business and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interim and preliminary results from Carisma&#8217;s clinical trials that it announces or publishes from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, Carisma may announce or publish interim or preliminary results from its clinical trials, including its Phase&#160;1 clinical trial of CT-0508. Interim results from clinical trials that Carisma may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available. Carisma also makes assumptions, estimations, calculations, and conclusions as part of its analyses of data, and Carisma may not have received or had the opportunity to fully evaluate all data. Preliminary or interim results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data Carisma previously published. As a result, interim and preliminary data should be viewed with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm Carisma&#8217;s reputation and business prospects and may cause the trading price of Carisma common stock to fluctuate significantly. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma experiences delays or difficulties in the enrollment of patients in its clinical trials for CT-0508 or any of its other product candidates, its receipt of necessary marketing approvals could be delayed or prevented.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Identifying and qualifying patients to participate in clinical trials for CT-0508 and any other product candidates in the future is critical to Carisma&#8217;s success. Successful and timely completion of clinical trials will require that Carisma enroll a sufficient number of patients who remain in the trial until its conclusion. Carisma may not be able to initiate or continue clinical trials for its product candidates if it is unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. In particular, group 2 for Carisma&#8217;s Phase&#160;1 clinical trial of CT-0508 is currently open for enrollment with an additional nine patients to be dosed in the study and Carisma is preparing to advance other products into clinical development. In addition, some of Carisma&#8217;s competitors have ongoing clinical trials for product candidates that treat the same indications as Carisma&#8217;s product candidates, and patients who would otherwise be eligible for Carisma&#8217;s clinical trials may instead enroll in clinical trials of Carisma&#8217;s competitors&#8217; product candidates. Carisma cannot predict how successful it will be at enrolling subjects in future clinical trials. Patient enrollment is affected by a variety of other factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prevalence and severity of the disease under investigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the eligibility criteria for the trial in question; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the perceived risks and benefits of the product candidate under trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the requirements of the trial protocols; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of existing treatments for the indications for which Carisma is conducting clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability to recruit clinical trial investigators with the appropriate competencies and experience; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the efforts to facilitate timely enrollment in clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability to identify specific patient populations based on specific genetic mutations or other factors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the patient referral practices of physicians; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability to monitor patients adequately during and after treatment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s ability to obtain and maintain patient consents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the proximity and availability of clinical trial sites for prospective patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the conduct of clinical trials by competitors for product candidates that treat the same indications or address the same patient populations as Carisma&#8217;s product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost to, or lack of adequate compensation for, prospective patients; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of the ongoing COVID-19 pandemic. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s inability to locate and enroll a sufficient number of patients for its clinical trials would result in significant delays, could require it to abandon one or more clinical trials altogether and could delay or prevent its receipt of necessary marketing approvals. Enrollment delays in Carisma&#8217;s clinical trials may result in increased development costs for its product candidates, which could cause the value of Carisma&#8217;s business to decline and limit its ability to obtain additional financing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of CT-0508 or any of Carisma&#8217;s other product candidates, Carisma may need to abandon or limit its further clinical development of those product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Enrollment in group 1 of Carisma&#8217;s first in human Phase&#160;1 clinical trial of CT-0508 has been completed with nine patients successfully dosed and group 2 is currently open for enrollment with nine additional </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">patients to be dosed in the trial. If CT-0508 or any other product candidate is associated with serious adverse events or undesirable side effects in clinical trials or have characteristics that are unexpected in clinical trials or pre-clinical testing, Carisma may need to abandon development of such product candidate or limit development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects or unexpected characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In pharmaceutical development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that delay or prevent further development of the compound. For example, while CT-0508 has been generally well tolerated based on preliminary clinical results from Carisma&#8217;s Phase&#160;1 clinical trial, such results may not be predictive or indicative of the successful development, marketing approval and eventual commercialization of CT-0508. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, if results of Carisma&#8217;s clinical trials reveal undesirable side effects, Carisma, regulatory authorities or the IRBs at the institutions in which Carisma&#8217;s studies are conducted could suspend or terminate its clinical trials, regulatory authorities could order Carisma to cease clinical trials or deny approval of its product candidates for any or all targeted indications or Carisma could be forced to materially modify the design of its clinical trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of Carisma&#8217;s clinical trials or result in potential liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Carisma elects or is forced to suspend or terminate any clinical trial of its product candidates, the commercial prospects of such product candidate will be harmed, and Carisma&#8217;s ability to generate revenues from sales of such product candidate will be delayed or eliminated. Any of these occurrences could materially harm Carisma&#8217;s business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If any of Carisma&#8217;s product candidates receives marketing approval and Carisma, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, Carisma&#8217;s ability to market the drug could be compromised.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma only recently initiated clinical development of its lead product candidate, CT-0508, and is in the pre-clinical testing stages for its other product candidates. Clinical trials will be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that Carisma&#8217;s clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of Carisma&#8217;s product candidates receives marketing approval, and Carisma, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">withdrawal or limitation by regulatory authorities of approvals of such product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seizure of the product by regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">recall of the product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on the marketing of the product or the manufacturing process for any component thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">requirement by regulatory authorities of additional warnings on the label; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">requirement that Carisma implement a risk evaluation and mitigation strategy or create a medication guide outlining the risks of such side effects for distribution to patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the product may become less competitive; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">initiation of regulatory investigations and government enforcement actions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">initiation of legal action against Carisma to hold it liable for harm caused to patients; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">harm to Carisma&#8217;s reputation and resulting harm to physician or patient acceptance of its products. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any of these events could prevent Carisma from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm Carisma&#8217;s business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because Carisma has limited financial and managerial resources, it focuses on discovery programs and product candidates that it identifies for specific indications. As a result, Carisma may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Carisma&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Carisma&#8217;s spending on current and future discovery and product development programs and product candidates for specific indications may not yield any commercially viable products. If Carisma does not accurately evaluate the commercial potential or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for Carisma to retain sole development and commercialization rights to such product candidate. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on Carisma&#8217;s business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may develop CT-0508 in combination with other drugs. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, revoke their approval of such drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs Carisma chooses to evaluate in combination with CT-0508, Carisma may be unable to obtain approval of CT-0508 or market CT-0508.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2022, Carisma submitted a clinical protocol amendment to the CT-0508 IND for a CAR-M / anti-PD-1 (CT-0508 and pembrolizumab) combination strategy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma did not develop or obtain marketing approval for, nor has Carisma manufactured or sold, any of the currently approved drugs that it may study in combination with CT-0508. If the FDA or similar regulatory authorities outside of the United States revoke their approval of any drug or drugs in combination with which Carisma determines to develop CT-0508, Carisma will not be able to market CT-0508 in combination with such revoked drugs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If safety or efficacy issues arise with any of these drugs, Carisma could experience significant regulatory delays, and the FDA or similar regulatory authorities outside of the United States may require Carisma to redesign or terminate the applicable clinical trials. If the drugs Carisma uses are replaced as the standard of care for the indications it chooses for CT-0508, the FDA or similar regulatory authorities outside of the United States may require Carisma to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs with which Carisma determines to combine with CT-0508, it may not be able to complete clinical development of CT-0508 on its current timeline or at all. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if CT-0508 were to receive marketing approval or be commercialized for use in combination with other existing drugs, Carisma would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the drug used in combination with CT-0508 or that safety, efficacy, manufacturing or supply issues could arise with these existing drugs. Combination therapies are commonly used for the treatment of cancer, and Carisma would be subject to similar risks if it develops any of its other product candidates for use in combination with other drugs or for indications other than cancer. This could result in Carisma&#8217;s own products being removed from the market or being less successful commercially. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may not be successful in its efforts to identify or discover additional potential product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A key element of Carisma&#8217;s strategy is to apply its macrophage engineering platform to address a broad array of indications and targets to generate next-generation therapeutics, including three programs for indications outside of oncology. The discovery efforts that Carisma is conducting may not be successful in identifying product candidates that are useful in treating cancer or other diseases. Carisma&#8217;s discovery </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">engine may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential product candidates may not be effective in treating their targeted diseases. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Discovery programs to identify new product candidates require substantial technical, financial and human resources. Carisma may choose to focus its efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. If Carisma is unable to identify additional suitable product candidates for pre-clinical and clinical development, it will limit its potential to obtain revenues from sale of products in future periods, which likely would result in significant harm to Carisma&#8217;s financial position and adversely impact its stock price. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Adverse public perception of genetic medicine, and gene therapy in particular, may negatively impact regulatory approval of, or demand for, Carisma&#8217;s potential products.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The clinical and commercial success of Carisma&#8217;s potential products will depend in part on public acceptance of the use of gene therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy is unsafe, unethical, or immoral, and, consequently, Carisma&#8217;s products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact Carisma&#8217;s ability to enroll clinical trials. Moreover, Carisma&#8217;s success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates that Carisma may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to the Commercialization of Carisma&#8217;s Product Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if any of Carisma&#8217;s product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of its product candidates, if approved, may be smaller than it estimates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any of Carisma&#8217;s product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as chemotherapy and radiation therapy, are well established in the medical community and doctors may continue to rely on these and similar treatments. Efforts to educate the medical community and third-party payors on the benefits of Carisma&#8217;s product candidates may require significant resources and may not be successful. If Carisma&#8217;s product candidates do not achieve an adequate level of acceptance, Carisma may not generate significant revenues from product sales and it may not become profitable. The degree of market acceptance of Carisma&#8217;s product candidates, if approved for commercial sale, will depend on a number of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the efficacy and potential advantages of Carisma&#8217;s product candidates compared to the advantages and relative risks of alternative treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effectiveness of sales and marketing efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s ability to offer its products, if approved, for sale at competitive prices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the clinical indications for which the product is approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of treatment in relation to alternative treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the convenience and ease of administration compared to alternative treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the strength of marketing and distribution support; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing of market introduction of competitive products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of third-party coverage and adequate reimbursement, and patients&#8217; willingness to pay out of pocket for required co-payments or in the absence of third-party coverage or adequate reimbursement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prevalence and severity of any side effects; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">support from patient advocacy groups; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any restrictions on the use of Carisma&#8217;s products, if approved, together with other medications. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s assessment of the potential market opportunity for its product candidates is based on industry and market data that it obtained from industry publications, research, surveys and studies conducted by third parties and Carisma&#8217;s analysis of these data, research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While Carisma believes these industry publications and third-party research, surveys and studies are reliable, it has not independently verified such data. Carisma&#8217;s estimates of the potential market opportunities for its product candidates include a number of key assumptions based on its industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While Carisma believes that its internal assumptions are reasonable, no independent source has verified such assumptions. If any of Carisma&#8217;s assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for any of its product candidates may be smaller than it expects, and as a result Carisma&#8217;s revenues from product sales may be limited and it may be more difficult for Carisma to achieve or maintain profitability. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma is unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, it may not be successful in commercializing its product candidates if and when they are approved.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma does not have a sales or marketing infrastructure and has no experience as a company in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial success for any product for which Carisma may obtain marketing approval, it will need to establish a sales, marketing and distribution organization, either itself or through collaborations or other arrangements with third parties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma currently expects that it would build its own focused, specialized sales and marketing organization to support the commercialization in the United States of product candidates for which it receives marketing approval and that can be commercialized with such capabilities. There are risks involved with Carisma establishing its own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which Carisma recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, Carisma would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and Carisma&#8217;s investment would be lost if it cannot retain or reposition its sales and marketing personnel. In general, the cost of establishing and maintaining a sales and marketing organization may exceed the cost-effectiveness of doing so. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Factors that may inhibit Carisma&#8217;s efforts to commercialize its products on its own include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs and other support personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its inability to equip sales personnel with effective materials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its inability to effectively manage a geographically dispersed sales and marketing team; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the inability to price its products at a sufficient price point to ensure an adequate and attractive level of profitability; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restricted or closed distribution channels that make it difficult to distribute its products to segments of the patient population; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the lack of complementary products to be offered by sales personnel, which may put Carisma at a competitive disadvantage relative to companies with more extensive product lines; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma is unable to establish its own sales, marketing and distribution capabilities and it enters into arrangements with third parties to perform these services, Carisma&#8217;s revenues from product sales and its profitability, if any, are likely to be lower than if it were to market, sell and distribute any products that it develops itself. In addition, Carisma may not be successful in entering into arrangements with third parties to sell, market and distribute its product candidates or may be unable to do so on terms that are acceptable to Carisma. Carisma likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market its products effectively. If Carisma does not establish sales, marketing and distribution capabilities successfully, either on its own or in collaboration with third parties, it will not be successful in commercializing its product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than it does, thus rendering Carisma&#8217;s products non-competitive, obsolete or reducing the size of its market.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The biopharmaceutical industry, and in particular the cell therapy field, is characterized by intense investment and competition aimed at rapidly advancing new technologies. Carisma&#8217;s platform and therapeutic product candidates are expected to face substantial competition from multiple technologies, marketed products and numerous other therapies being developed by third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small molecule inhibitors. The competition is likely to come from multiple sources, including biopharmaceutical companies, academic research institutions, governmental agencies and private research institutions that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The competition is likely to come from multiple sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is aware of a number of companies generally pursuing the development of myeloid cell therapies, including, among others Myeloid Therapeutics, Shoreline Biosciences, Inceptor Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, Sirpant Therapeutics, and others. Carisma is also facing competition from companies pursuing autologous T-cell therapies, allogenic T-cell therapies, NK and other cell therapies, direct </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> reprogrammed cell therapies and other macrophage-targeted oncology therapeutics. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Many of the companies against which Carisma is competing or against which it may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than Carisma does. These competitors also compete with Carisma in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, its development programs. Carisma&#8217;s commercial opportunity could be reduced or eliminated if its competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that Carisma may develop. Carisma&#8217;s competitors also may obtain FDA or other marketing approval for their products more rapidly than Carisma may obtain approval for its products, which could result in Carisma&#8217;s competitors establishing a strong market position </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">before Carisma is able to enter the market. In addition, Carisma&#8217;s ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that Carisma is pursuing, and additional products are expected to become available on a generic basis over the coming&#160;years. If Carisma&#8217;s product candidates are approved, it expects that they will be priced at a significant premium over competitive generic products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Technology in the biopharmaceutical industry has undergone rapid and significant change, and Carisma expects that it will continue to do so. Any products or processes that Carisma develops may become obsolete or uneconomical before it recovers any expenses incurred in connection with their development. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of Carisma&#8217;s competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with Carisma in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, Carisma&#8217;s programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma has pursued and may in the future pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. However, Carisma may be unable to in-license or acquire any additional technologies or product candidates from third parties. The acquisition and licensing of technologies and product candidates is a competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that Carisma may consider attractive. These established companies may have a competitive advantage over Carisma due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive Carisma to be a competitor may be unwilling to assign or license rights to Carisma. Carisma also may be unable to in-license or acquire the relevant technology or product candidate on terms that would allow Carisma to make an appropriate return on its investment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if Carisma is able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm its business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, Carisma may be required to conduct a clinical trial that compares the cost effectiveness of its product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, Carisma might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay its commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, Carisma is able to generate from the sale of the product in that country. Adverse pricing limitations may hinder Carisma&#8217;s ability to recoup its investment in one or more product candidates, even if its product candidates obtain marketing approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products, including Carisma&#8217;s product candidates. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, government authorities and third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that Carisma commercializes and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which it obtains marketing approval. Obtaining and maintaining adequate reimbursement for Carisma&#8217;s products may be difficult. Carisma may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, Carisma may not be able to successfully commercialize any product candidate for which it obtains marketing approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers its costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover Carisma&#8217;s costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Carisma&#8217;s inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that it develops could have a material adverse effect on its operating results, its ability to raise capital needed to commercialize products and its overall financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require Carisma to provide scientific and clinical support for the use of its product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and Carisma believes that changes in these rules and regulations are likely. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There can be no assurance that Carisma&#8217;s product candidates, even if they are approved for sale in the United States, in the European Union or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect Carisma&#8217;s ability to sell its product candidates profitably. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Clinical trial and product liability lawsuits against Carisma could divert its resources and could cause Carisma to incur substantial liabilities and to limit commercialization of any products that it may develop.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma faces an inherent risk of clinical trial and product liability exposure related to the testing of its product candidates in human clinical trials and will face an even greater risk if it commercially sells any products that it may develop. While Carisma currently has no products that have been approved for commercial sale, the ongoing, planned and future use of product candidates by Carisma in clinical trials, and the sale of any approved products in the future, may expose Carisma to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If Carisma cannot successfully defend itself against claims that its product candidates or products caused injuries, it will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">decreased demand for any product candidates or products that it may develop; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">termination of clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">withdrawal of marketing approval, recall, restriction on the approval or a &#8220;black box&#8221; warning or contraindication for an approved drug; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">withdrawal of clinical trial participants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">significant costs to defend any related litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">substantial monetary awards to trial participants or patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">loss of revenue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">injury to Carisma&#8217;s reputation and significant negative media attention; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduced resources of Carisma management to pursue its business strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">distraction of management&#8217;s attention from Carisma&#8217;s primary business; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the inability to commercialize any products that Carisma may develop. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma currently holds $10.0&#160;million in product liability insurance coverage in the aggregate, with a per incident limit of $10.0&#160;million, which may not be adequate to cover all liabilities that it may incur. Carisma may need to increase its insurance coverage as it expands its clinical trials or if it commences commercialization of its product candidates. Insurance coverage is increasingly expensive. Carisma may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against Carisma for uninsured liabilities or in excess of insured liabilities, its assets may not be sufficient to cover such claims and its business operations could be impaired. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Carisma&#8217;s Dependence on Third Parties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma relies, and expects to continue to rely, on third parties to conduct its clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay Carisma&#8217;s ability to seek or obtain marketing approval for or commercialize its product candidates or otherwise harm its business. If Carisma is not able to maintain these third-party relationships or if these arrangements are terminated, it may have to alter its development and commercialization plans and its business could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma relies, and expects to continue to rely, on third-party clinical research organizations, in addition to other third parties such as research collaboratives, clinical data management organizations, medical institutions and clinical investigators, to conduct its ongoing Phase&#160;1 clinical trial of CT-0508 and related combinations studies, its planned clinical trials of CT-0525, CT-1119 and CT-0729 and any other clinical trials it conducts. Carisma does not plan to independently conduct clinical trials of its product candidates or any other product candidates that it may develop. These contract research organizations and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. These third-party arrangements might terminate for a variety of reasons, including a failure to perform by the third parties. If Carisma needs to enter into alternative arrangements, its product development activities might be delayed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s reliance on these third parties for discovery and product development activities reduces its control over these activities but does relieve Carisma of its responsibilities. For example, Carisma will remain responsible for ensuring that each of its clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires Carisma to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities in Europe and other jurisdictions have similar requirements. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If Carisma or any of its contract research organizations or trial sites fail to comply with applicable GCPs, the clinical data generated in its clinical </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require Carisma to perform additional clinical trials before approving its marketing applications. Carisma is also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct Carisma&#8217;s clinical trials in accordance with regulatory requirements or Carisma&#8217;s stated protocols, Carisma will not be able to obtain, or may be delayed in obtaining, marketing approvals for its product candidates and will not be able to, or may be delayed in its efforts to, successfully develop and commercialize its product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be Carisma&#8217;s competitors. In addition, principal investigators for Carisma&#8217;s clinical trials may serve as scientific advisors or consultants to Carisma from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application Carisma submits to the FDA. Any such delay or rejection could prevent Carisma from commercializing its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If any of Carisma&#8217;s relationships with these third parties terminate, it may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional contract research organizations, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new contract research organization commences work. As a result, delays can occur, which could materially impact Carisma&#8217;s ability to meet its desired clinical development timelines. The COVID-19 pandemic and government measures taken in response have also had a significant impact on many contract research organizations. Although Carisma plans to carefully manage its relationships with its contract research organizations, investigators and other third parties, it may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on Carisma&#8217;s business, financial condition and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma relies on third-party contract manufacturing organizations for the manufacture of both drug substance and finished drug product of its product candidates for pre-clinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that Carisma will not have sufficient quantities of its product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair Carisma&#8217;s development or commercialization efforts.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma does not own or operate, and currently has no plans to establish, any manufacturing facilities. Carisma relies, and expects to continue to rely, on third-party contract manufacturing organizations for both drug substance and finished drug product, as well as for commercial manufacture if any of its product candidates receive marketing approval. Carisma also currently relies on these third parties for the manufacture of plasmid and viral vectors, patient leukapheresis material logistics, as well as packaging, labeling, sterilization, storage, distribution and other production logistics. This reliance on third parties increases the risk that Carisma will not have sufficient quantities of its product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair Carisma&#8217;s development or commercialization efforts. Carisma may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if Carisma is able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reliance on the third party for regulatory compliance and quality assurance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the possible breach of the manufacturing agreement by the third party; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential failure to manufacture Carisma&#8217;s product candidate or product according to its specifications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential failure to manufacture Carisma&#8217;s product candidate or product according to its schedule or at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the possible misappropriation of Carisma&#8217;s proprietary information, including its trade secrets and know-how; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for Carisma. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma or its third-party manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredients necessary to produce Carisma&#8217;s product candidates in the quantities needed for its clinical trials or, if its product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or active pharmaceutical ingredients, including shortages caused by the purchase of such raw materials or active pharmaceutical ingredients by its competitors or others. The failure of Carisma or its third-party manufacturers to obtain the raw materials or active pharmaceutical ingredients necessary to manufacture sufficient quantities of its product candidates, may have a material adverse effect on Carisma&#8217;s business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s third-party manufacturers are subject to inspection and approval by regulatory authorities before Carisma can commence the manufacture and sale of any of its product candidates, and thereafter subject to ongoing inspection from time to time. Third-party manufacturers may not be able to comply with cGMP, regulations or similar regulatory requirements outside of the United States. Carisma&#8217;s failure, or the failure of its third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on Carisma, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Carisma&#8217;s products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s product candidates and any products that it may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, Carisma may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for Carisma. Any performance failure on the part of Carisma&#8217;s existing or future manufacturers could delay clinical development or marketing approval. Carisma does not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If any of Carisma&#8217;s current contract manufacturers cannot perform as agreed, it may be required to replace such manufacturers. Although Carisma believes that there are several potential alternative manufacturers who could manufacture its product candidates, it may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer. In addition, the COVID-19 pandemic may impact Carisma&#8217;s ability to procure sufficient supplies for the development of its product candidates. The extent of this impact will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s current and anticipated future dependence upon others for the manufacture of its product candidates or products may adversely affect its future profit margins and its ability to commercialize any products that receive marketing approval on a timely and competitive basis. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma expects to depend on collaborations with third parties for the research, development and commercialization of certain of its product candidates. If Carisma&#8217;s collaborations are not successful, it may not be able to capitalize on the market potential of these product candidates and its business could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma anticipates seeking third-party collaborators for the research, development and commercialization of certain of its product candidates. For example, Carisma entered into a strategic collaboration with Moderna in January&#160;2022 focused on the development of </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M therapeutics for up to twelve product candidates. In collaboration with Moderna, Carisma has established a myeloid tropic LNP/mRNA </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M platform for oncology targets, which enables an off-the-shelf approach wherein the patient&#8217;s own myeloid cells are engineered directly within their body via the administration of a myeloid-tropic LNP encapsulating macrophage reprogramming mRNA CAR constructs, removing the requirement for </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> cell manufacturing entirely. As part of the collaboration, Carisma received a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">$45.0&#160;million up-front cash payment from Moderna, in addition to future research funding, milestone payments and royalties. Concurrent with entering into the collaboration agreement, Moderna made an investment in Carisma in the form of a $35.0&#160;million convertible note. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies and biotechnology companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any such arrangements with third parties will likely limit Carisma&#8217;s control over the amount and timing of resources that its collaborators dedicate to the development or commercialization of its product candidates Carisma may seek to develop with them. Carisma&#8217;s ability to generate revenues from these arrangements will depend on its collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Carisma cannot predict the success of any collaboration that it enters into. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Collaborations involving Carisma&#8217;s discovery programs or any product candidates it may develop, including its collaboration with Moderna, pose the following risks to Carisma: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; for example, Carisma&#8217;s collaboration with Moderna is managed by a joint steering committee, which is comprised of representatives from Carisma and Moderna, with Moderna having final decision-making authority, subject to specified limitations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators may not perform their obligations as expected; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators may not pursue development of Carisma&#8217;s product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that divert resources or create competing priorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators may not pursue development and commercialization of any product candidates that achieve marketing approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that may divert resources or create competing priorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform its stockholders about the status of such product candidates on a discretionary basis; for example, data, results and know-how generated in the performance of the Moderna collaboration is deemed the confidential information of Moderna, which Carisma may not disclose except under limited circumstances; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Carisma&#8217;s product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than Carisma&#8217;s; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product candidates discovered in collaboration with Carisma may be viewed by Carisma&#8217;s collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of Carisma&#8217;s product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a collaborator may seek to renegotiate or terminate their relationship with Carisma due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a collaborator with marketing and distribution rights to one or more of Carisma&#8217;s product candidates that achieve marketing approval may not commit sufficient resources to the marketing and distribution of such product or products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for Carisma with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may lose certain valuable rights under circumstances identified in its collaborations, including if it undergoes a change of control; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators may not properly obtain, maintain, enforce, defend or protect Carisma&#8217;s intellectual property or proprietary rights or may use its proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate its intellectual property or proprietary information or expose Carisma to potential litigation; for example, Moderna has the first right to prosecute, enforce or defend certain patent rights under its agreement with Carisma, and although Carisma may have the right to assume the prosecution, enforcement or defense of such patent rights if Moderna does not, Carisma&#8217;s ability to do so may be compromised by Moderna&#8217;s actions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">disputes may arise with respect to the ownership of intellectual property developed pursuant to Carisma&#8217;s collaborations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose Carisma to litigation and potential liability; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborations may be terminated, and, if terminated, Carisma could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates; for example, Moderna has the right to terminate its agreement with Carisma for convenience in its entirety or with respect to a specific product or target on ninety days&#8217; prior notice, in connection with a material breach of the agreement by Carisma that remains uncured for a specified period of time or in the event of specified insolvency events involving Carisma; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If a present or future collaborator of Carisma&#8217;s were to be involved in a business combination, the continued pursuit and emphasis on its product development or commercialization program under such collaboration could be delayed, diminished or terminated. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If any collaborations that Carisma enters into do not result in the successful development and commercialization of products or if one of Carisma&#8217;s collaborators terminates its agreement with it, Carisma may not receive any future research funding or milestone or royalty payments under the collaboration. If Carisma does not receive the funding it expects under these agreements, its development of its product candidates could be delayed and it may need additional resources to develop its product candidates. All of the risks relating to product development, marketing approval and commercialization described in this proxy statement/prospectus also apply to the activities of Carisma&#8217;s collaborators. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma may in the future decide to collaborate with biopharmaceutical companies for the development and potential commercialization of any product candidates it may develop. These relationships, or those like them, may require Carisma to incur non-recurring and other charges, increase Carisma&#8217;s near- and long-term expenditures, issue securities that dilute Carisma&#8217;s existing stockholders, or disrupt Carisma&#8217;s management and business. In addition, Carisma could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Carisma&#8217;s ability to reach a definitive collaboration agreement will depend, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If Carisma licenses rights to any product candidates it or its collaborators may develop, Carisma may not be able to realize the benefit of such transactions if it is unable to successfully integrate them with its existing operations and company culture. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may seek to establish additional collaborations. If Carisma is not able to establish or maintain additional collaborations, on commercially reasonable terms, it may have to alter its development and commercialization plans and its business could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To realize the full potential of Carisma&#8217;s macrophage engineering platform and accelerate the development of additional macrophage engineering programs, Carisma plans to continue to selectively pursue collaborations with leading biopharmaceutical companies with particular experience, including development and commercial expertise and capabilities. Carisma faces significant competition in attracting appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that it considers attractive. These established companies may have a competitive advantage over Carisma due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Carisma to be a competitor may be unwilling to assign or license rights to Carisma. Whether Carisma reaches a definitive agreement for a collaboration will depend, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to Carisma&#8217;s ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with Carisma for its product candidate. Carisma may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration Carisma may enter into may limit its ability to enter into future agreements on particular terms or covering similar target indications with other potential collaborators. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma is unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, it may have to curtail the development of a product candidate, reduce or delay its development program or one or more of Carisma&#8217;s other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase its expenditures and undertake development or commercialization activities at its own expense. If Carisma elects to fund and undertake development or commercialization activities on its own, it may need to obtain additional expertise and additional capital, which may not be available to Carisma on acceptable terms or at all. If Carisma fails to enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, it may not be able to further develop its product candidates or bring them to market and generate revenue from product sales, which could have an adverse effect on its business, prospects, financial condition and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma has a number of academic collaborations to supplement its internal discovery and product development program. If any such collaborator decides to discontinue or devote less resources to such research, Carisma&#8217;s discovery programs could be diminished.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s discovery engine is supplemented by academic collaborations to expand its platform, which Carisma relies upon to advance its development and commercialization plans for its product candidates. In August&#160;2020, Carisma entered into a scientific research and licensing agreement with Nathaniel R. Landau, Ph.D. and NYU Langone Health through which it obtained exclusive rights to develop their Vpx lentiviral vector globally for all indications. Carisma also has an ongoing discovery program in neurodegeneration being pursued through a sponsored research agreement with Dr.&#160;Saar Gill, Associate Professor of Medicine at the University of Pennsylvania and co-founder of Carisma, to develop CAR macrophages and microglia targeted against protein aggregates associated with neurodegenerative disease pathology. In addition, Carisma from time to time may enter into academic research collaborations to explore the development of new technologies and indications. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While these academic institutions have contractual obligations to Carisma, they are independent entities and are not under Carisma&#8217;s control or the control of Carisma&#8217;s officers or directors. Carisma&#8217;s research and licensing agreements with academic collaborators generally provide academic collaborators with license maintenance fees, development and regulatory milestone payments, royalties on net sales of products and a portion of sublicense income that Carisma receives. Upon the scheduled expiration of any academic collaboration, Carisma may not be able to renew the related agreement or any renewal could be on terms less favorable to Carisma than those contained in the existing agreement. Furthermore, either Carisma or the academic institution generally may terminate the sponsored research agreement for convenience following a specified notice period. If any of these academic institutions decides to not renew or to terminate the related agreement or decides to devote fewer resources to such activities, Carisma&#8217;s discovery efforts would be diminished, while its royalty obligations, if any, would continue unmodified. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Any acquisitions or in-license transactions that Carisma completes could disrupt its business, cause dilution to its stockholders or reduce its financial resources.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma has licensed three patent families from the University of Pennsylvania and one patent family from New York University and may enter into transactions to in-license or acquire other businesses, intellectual property, technologies, product candidates or products. If Carisma determines to pursue a particular transaction, it may not be able to complete the transaction on favorable terms, or at all. Any in-licenses or acquisitions Carisma completes may not strengthen its competitive position, and these transactions may be viewed negatively by customers or investors. Carisma may decide to incur debt in connection with an in-license or acquisition or issue its common stock or other equity securities to the stockholders of the target company, which would reduce the&#160;percentage ownership of its existing stockholders. Carisma could incur losses resulting from undiscovered liabilities that are not covered by the indemnification it may obtain from the seller. In addition, Carisma may not be able to successfully integrate the acquired personnel, technologies and operations into its existing business in an effective, timely and nondisruptive manner. In-license and acquisition transactions may also divert management attention from day-to-day responsibilities, increase its expenses and reduce its cash available for operations and other uses. Carisma cannot predict the number, timing or size of additional future in-licenses or acquisitions or the effect that any such transactions might have on its operating results. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Carisma&#8217;s Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma is unable to obtain, maintain and enforce patent protection for its technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, its competitors could develop and commercialize technology and products similar or identical to Carisma&#8217;s, and its ability to successfully develop and commercialize its technology and product candidates may be adversely affected and Carisma may not be able to compete effectively in its market.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s commercial success depends in part on its ability to obtain, maintain and enforce protection of the intellectual property it may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates. Carisma seeks to protect its proprietary position by filing patent applications in the United States and abroad related to its technologies and product candidates that are important to its business and by in-licensing intellectual property related to such technologies and product candidates. If Carisma is unable to obtain, maintain or enforce patent protection with respect to any proprietary technology or product candidate, its business, financial condition, results of operations and prospects could be materially harmed. Any disclosure to or misappropriation by third parties of Carisma&#8217;s confidential proprietary information could enable competitors to quickly duplicate or surpass Carisma&#8217;s technological achievements, thus eroding Carisma&#8217;s competitive position in its market. Moreover, the patent applications Carisma owns, co-owns or licenses may fail to result in issued patents in the United States or in other foreign countries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The patent prosecution process is expensive, time-consuming and complex, and Carisma may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that Carisma will fail to identify patentable aspects of its research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, Carisma does not have the right to control the preparation, filing and prosecution of patent </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">applications, or to maintain, enforce and defend the patents, covering technology that Carisma licenses from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of its business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect Carisma&#8217;s rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. With respect to both owned and in-licensed patent rights, Carisma cannot predict whether the patent applications Carisma and its licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, Carisma may not be aware of all third-party intellectual property rights potentially relating to its product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not published at all. Therefore, neither Carisma nor its licensors can know with certainty whether either Carisma or its licensors were the first to make the inventions claimed in the patents and patent applications Carisma owns or in-licenses now or in the future, or that either Carisma or its licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of its patent rights are highly uncertain. Moreover, its owned or in-licensed pending and future patent applications may not result in patents being issued which protects its technology and product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of its patents and its ability to obtain, protect, maintain, defend and enforce its patent rights, narrow the scope of its patent protection and, more generally, could affect the value or narrow the scope of its patent rights. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, Carisma or its licensors may be subject to a third-party preissuance submission of prior art to the USPTO or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or interference proceedings challenging its patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, its patent rights, allow third parties to commercialize its technology or product candidates and compete directly with it, without payment to it, or result in its inability to manufacture or commercialize products without infringing third-party patent rights. If the breadth or strength of protection provided by its patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with it to license, develop or commercialize current or future product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s owned or licensed patent estate includes patent applications, many of which are at an early stage of prosecution. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if its owned or in-licensed patent applications issue as patents, they may not issue in a form that will provide it with any meaningful protection, prevent competitors from competing with it or otherwise provide it with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and its owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit its ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of its technology and product candidates. Such proceedings also may result in substantial cost and require significant time from its management and employees, even if the eventual outcome is favorable to Carisma. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, its competitors may be able to circumvent its owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, its patent portfolio may not provide it with sufficient rights to exclude others from commercializing technology and products similar or identical to any of its technology and product candidates. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent terms may be inadequate to protect Carisma&#8217;s competitive position with respect to its current or future product candidates for an adequate amount of time.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but there is no assurance that any such extensions will be obtained, and the life of a patent, and the protection it affords, is limited. Even if patents covering Carisma&#8217;s current or future product candidates are obtained, once the patent life has expired, it may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, its patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Carisma&#8217;s. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">In the United States, patent term can also be adjusted due to delays that occur during examination of patent applications, which may extend the term of a patent beyond 20&#160;years. There is a risk that Carisma may take action that detracts from any accrued patent term adjustment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">It is necessary to pay certain maintenance fees, also referred to as annuities or renewal fees in some countries, throughout the lifetime of a patent at regular intervals. Failure to pay these fees can cause a granted patent to prematurely expire, without an opportunity for revival. There is a risk that Carisma may be unable to maintain patent protection for certain patents in all markets due to finite availability of resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma is unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with its obligations under such agreements, its business could be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It may be necessary for it to use the patented or proprietary technology of third parties to commercialize its products, in which case Carisma would be required to obtain a license from these third parties. If Carisma is unable to license such technology, or if Carisma is forced to license such technology on unfavorable terms, its business could be materially harmed. If Carisma is unable to obtain a necessary license, Carisma may be unable to develop or commercialize the affected product candidate(s), which could materially harm its business and the third parties owning such intellectual property rights could seek either an injunction prohibiting its sales or an obligation on its part to pay royalties and/or other forms of compensation. Even if Carisma is able to obtain a license, it may be non-exclusive, thereby giving its competitors access to the same technologies licensed to it. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma is unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights Carisma has, Carisma may be required to expend significant time and resources to redesign its technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Carisma is unable to do so, Carisma may be unable to develop or commercialize the affected technology and product candidates, which could harm its business, financial condition, results of operations and prospects significantly. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, if Carisma fails to comply with its obligations under any license agreements, its counterparties may have the right to terminate these agreements, in which event Carisma might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of its rights under these agreements, or restrictions on its ability to freely assign or sublicense its rights under such agreements when it is in the interest of its business to do so, may result in it having to negotiate new or restated agreements with less favorable terms, cause it to lose its rights under these agreements, including its rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma does not obtain patent term extension for any product candidates it may develop, its business may be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, the term of a patent that covers an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1984, or the Hatch-Waxman Act, as compensation for the loss of a patent term during the FDA regulatory review process for a drug product subject to the provisions of the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five&#160;years, but patent extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when its product candidates receive FDA approval, Carisma expects to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities, including the FDA, will agree with its assessment of whether such extensions should be granted, and even if granted, the length of such extensions. Carisma may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than requests. If Carisma is unable to obtain any patent term extension or the term of any such extension is less than it requests, its competitors may obtain approval of competing products following the expiration of its patent rights, and its business, financial condition, results of operations and prospects could be materially harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing its ability to protect its products.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of its owned or in-licensed patent applications and the maintenance, enforcement or defense of its owned or in-licensed issued patents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and wakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on Carisma&#8217;s patent rights and its ability to protect, defend and enforce its patent rights in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken Carisma&#8217;s ability to obtain new patents or to enforce patents that Carisma owns or has licensed or that Carisma may obtain in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The federal government retains certain rights in inventions created using its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights&#8221;. March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. Carisma collaborates with a number of universities with respect to certain of its research and development. Carisma cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, Carisma co-owns or in-licenses technology which is critical to its business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, its ability to enforce or otherwise exploit patents covering such technology may be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Although Carisma or its licensors are not currently involved in any litigation, Carisma may become involved in lawsuits to protect or enforce its patent, the patents of its licensors or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Competitors and other third parties may infringe, misappropriate or otherwise violate Carisma&#8217;s or its licensor&#8217;s issued patents, the patents of its licensors or other intellectual property. It may be difficult to detect </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s product. To counter infringement or misappropriation, Carisma or its licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming and can distract its management and scientific personnel. There can be no assurance that Carisma will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for&#160;years before they are concluded. Any claims Carisma asserts against perceived infringers could provoke such parties to assert counterclaims against it, alleging that it infringes, misappropriates or otherwise violates their intellectual property. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in a patent infringement proceeding, such parties could counterclaim that the patents Carisma or its licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness, enablement, or written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Similarly, if Carisma or its licensors assert trademark infringement claims, a court may determine that the marks Carisma or its licensors have asserted are invalid or unenforceable, or that the party against whom Carisma or its licensors have asserted trademark infringement has superior rights to the marks in question. In this case, Carisma could ultimately be forced to cease use of such trademarks, which could materially harm its business and negatively affect its position in the marketplace. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An adverse result in any such proceeding could put one or more of its owned or in-licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put any of its owned or in-licensed patent applications at risk of not yielding an issued patent, and could limit its or its licensor&#8217;s ability to assert those patents against those parties, or other competitors, and curtail or preclude its ability to exclude third parties from developing and commercializing similar or competitive products. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that its owned or in-licensed patents do not cover such technology. Even if Carisma establishes infringement, a court may not order the third party to stop using the technology at issue and instead award only monetary damages to Carisma, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of its confidential information or trade secrets could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of its common stock. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on its business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Interference or derivation proceedings provoked by third parties or brought by Carisma or declared by the USPTO may be necessary to determine the priority of inventions with respect to its patents or patent applications. An unfavorable outcome could require it to cease using the related technology or to attempt to license rights to it from the prevailing party. Carisma&#8217;s business could be harmed if the prevailing party does not offer it a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and its competitors gain access to the same technology. Its defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract its management, technical personnel and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on its ability to raise the funds necessary to continue its clinical trials, continue its research programs, license necessary technology from third parties, or enter into development partnerships that would help it bring its product candidates to market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any such litigation or proceedings could substantially increase Carisma&#8217;s operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of Carisma&#8217;s competitors may be able to sustain the costs of such litigation or proceedings more effectively than Carisma can because of their greater financial resources in one or more aspects, or for other reasons. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise Carisma&#8217;s ability to compete in the marketplace. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of Carisma&#8217;s products. It may be necessary for it to use the patented or proprietary technology of a third party to commercialize its own technology or products, in which case it would be required to obtain a license from such third party. A license to such intellectual property may not be available or may not be available on commercially reasonable terms, which could have a material adverse effect on Carisma&#8217;s business and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than Carisma, may also be pursuing strategies to license or acquire third-party intellectual property rights that it may consider necessary or attractive in order to commercialize its product candidates. More established companies may have a competitive advantage over Carisma due to their larger size and cash resources or greater clinical development and commercialization capabilities. Carisma may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellect al property surrounding the additional product candidates that it may seek to acquire. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Third parties may initiate legal proceedings alleging that Carisma is infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of its business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s commercial success depends upon its ability and the ability of its collaborators to develop, manufacture, market and sell its product candidates and use its proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the biopharmaceutical industry. Carisma may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to its technology and product candidates, including interference proceedings, post grant review, </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions, such as opposition proceedings before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which Carisma is pursuing development candidates. As the biopharmaceutical industry expands and more patents are issued, the risk increases that its technologies or product candidates that Carisma may identify may be subject to claims of infringement of the patent rights of third parties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The legal threshold for initiating litigation or contested proceedings is low, so even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and its adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than Carisma can. The risks of being involved in such litigation and proceedings may increase if and as its product candidates near commercialization and as Carisma gains the greater visibility associated with being a public company. Third parties may assert infringement claims against it based on existing patents or patents that may be granted in the future, regardless of merit. Even if Carisma diligently searches third-party patents for potential infringement by its products or product candidates, it may not successfully find patents its products or product candidates may infringe. Carisma may not be aware of all such intellectual property rights potentially relating to its technology and product candidates and their uses, or Carisma may incorrectly conclude that third-party intellectual property is invalid or that its activities and product candidates do not infringe such intellectual property. Thus, Carisma does not know with certainty that its technology and product candidates, or its development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Third parties may assert that Carisma is employing its proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates that Carisma may identify or related to its technologies. Because patent applications can take many&#160;years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that Carisma may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of its technologies infringe upon these patents. Moreover, as noted above, there may be existing patents that Carisma is not aware of or that Carisma has incorrectly concluded are invalid or not infringed by its activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that Carisma may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block its ability to commercialize such product candidate unless Carisma obtained a license under the applicable patents, or until such patents expire. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Parties making claims against it may obtain injunctive or other equitable relief, which could effectively block its ability to further develop and commercialize the product candidates that Carisma may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from its business. In the event of a successful claim of infringement against us, Carisma may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign its infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma may choose to take a license or, if it is found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, it could also be required to obtain a license from such third party to continue developing, manufacturing and marketing its technology and product candidates. However, it may not be able to obtain any required license on commercially reasonable terms or at all. Even if it is able to obtain a license, it could be non-exclusive, thereby giving its competitors and other third parties access to the same technologies licensed to it and could require it to make substantial licensing and royalty payments. Carisma could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, Carisma could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if Carisma is found to have willfully infringed a patent or other intellectual property right, it could be forced to indemnify its customers or collaborators. A finding of infringement could prevent it from commercializing its product candidates or force it to cease some of its business operations, which could materially harm its business. In addition, Carisma may be forced to redesign its product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements. Claims that Carisma has misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on its business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If its trademarks and trade names are not adequately protected, then Carisma may not be able to build name recognition in its markets of interest and its business may be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While Carisma seeks to protect the trademarks and trade names it uses in the United States and in other countries, it may be unsuccessful in obtaining registrations or otherwise protecting these trademarks and trade names, which it needs to build name recognition in its markets of interest and among potential partners or customers. Carisma relies on both registration and common law protection for its trademarks. Its registered or unregistered trademarks or trade names may be challenged, infringed, diluted or declared generic, or determined to be infringing on other marks. At times, competitors may adopt trademarks and trade names similar to ours, or collaborators may fail to use Carisma&#8217;s trade names or trademarks, thereby impeding its ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of its registered or unregistered trademarks. If Carisma is unable to protect its rights to trademarks and trade names, Carisma may be prevented from using such marks and names unless Carisma enters into appropriate royalty, license or coexistence agreements, which may not be available or may not be available on commercially reasonable terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During trademark registration proceedings, Carisma may receive rejections. Although Carisma would be given an opportunity to respond to those rejections, it may be unable to overcome such rejections. In </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against its trademarks, and its trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which its products are made available. Any name Carisma proposes to use for its products in the United States must be approved by the FDA, regardless of whether Carisma has registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of its proposed product names, Carisma may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. If Carisma is unable to establish name recognition based on its trademarks and trade names, Carisma may not be able to compete effectively and its business may be adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma may license its trademarks and trade names to third parties, such as distributors and collaborators. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of or failure to use our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks, and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect Carisma&#8217;s business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause it to spend substantial resources and distract its personnel from their normal responsibilities.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if resolved in its favor, litigation or other legal proceedings relating to intellectual property claims may cause it to incur significant expenses and could distract its technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of its common stock. Such litigation or proceedings could substantially increase its operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Carisma may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of its competitors may be able to sustain the costs of such litigation or proceedings more effectively than Carisma can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise its ability to compete in the marketplace. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and its patent protection could be reduced or eliminated for non-compliance with these requirements.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of its patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, Carisma relies on its licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to its patents, Carisma relies on an annuity service, outside firms and outside counsel to remind it of the due dates and to make payment after Carisma instructs them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If Carisma or its licensors fail to maintain the patents and patent applications covering its product candidates, it would have a material adverse effect on its business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma fails to comply with its obligations in its current and future intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to its business relationships with its licensors, Carisma could lose intellectual property rights that are important to its business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is party to a number license and research agreements. Some of these agreements provide Carisma with the intellectual property rights required for the development of its product candidates, including the license agreement with the University of Pennsylvania. These licenses and research agreements and similar agreements in the future may impose diligence, development and commercialization timelines, and milestone payment, royalty, insurance and other obligations on Carisma. If Carisma fails to comply with such obligations, the parties to these agreements may decide to terminate the agreements or require Carisma to grant them certain rights, in which Carisma may not be able to develop, manufacture, or market any products without the rights granted to it by these agreements and may face other penalties. Any such occurrences could adversely affect the value of any product candidate being developed, including CT-0508. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For a variety of purposes, Carisma will likely enter into additional licensing and funding arrangements with third parties that may impose similar obligations on Carisma. Termination of these agreements or reduction or elimination of its rights under these agreements may result in it having to negotiate new or restated agreements with less favorable terms, or cause it to lose its rights under these agreements, including its rights to important intellectual property or technology, which would have a material adverse effect on its business, financial condition, results of operations and prospects. While Carisma still faces all of the risks described herein with respect to such agreements, Carisma cannot prevent third parties from also accessing those technologies. In addition, its licenses may place restrictions on its future business opportunities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the above risks, intellectual property rights that Carisma licenses in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of its licensors may therefore affect its rights to use its sublicensed intellectual property, even if Carisma is in compliance with all of the obligations under its license agreements. Should its licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to Carisma, or should such agreements be terminated or amended, its ability to develop and commercialize its product candidates may be materially harmed. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope of rights granted under the license agreement and other interpretation related issues; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which its technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the sublicensing of patent and other rights under its collaborative development relationships; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its diligence obligations under the license agreement and what activities satisfy those diligence obligations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by its licensors and it and its partners; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the payment obligations with respect to licensed technology. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the agreements under which Carisma currently licenses intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what Carisma believes to be the scope of its rights to the relevant intellectual property or technology or increase what Carisma believes to be its financial or other obligations under the relevant agreement, either of which could have a material adverse effect on its business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that Carisma has licensed prevent or impair its ability to maintain its current licensing arrangements on commercially acceptable terms, Carisma may be unable to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on its business, financial conditions, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, licensors could retain the right to prosecute and defend the intellectual property rights licensed to Carisma, in which case Carisma would depend on its licensors to control the prosecution, maintenance and enforcement of all of its licensed and sublicensed intellectual property, and even when it does have such rights, Carisma may require the cooperation of its licensors and upstream licensors, which may not be forthcoming. Licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than Carisma would. Its business could be adversely affected if Carisma or its licensors are unable to prosecute, maintain and enforce its licensed and sublicensed intellectual property effectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that its licensors are not the sole and exclusive owners of the patents and patent applications Carisma in-licenses. If other third parties have ownership rights to patents or patent applications Carisma in-licenses, they may be able to license such patents to its competitors, and its competitors could market competing products and technology. This could have a material adverse effect on its competitive position, business, financial conditions, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In spite of its best efforts, its licensors might conclude that Carisma has materially breached its license agreements and might therefore terminate the license agreements, thereby removing its ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to its. This could have a material adverse effect on its competitive position, business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may not be able to protect its intellectual property and proprietary rights throughout the world.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect its rights to the same extent as the laws of the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, Carisma may not be able to prevent third parties from practicing its inventions in all countries outside the United States, or from selling or importing products made using its inventions in and into the United States or other jurisdictions. Competitors may use its technologies in jurisdictions where Carisma has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where Carisma has patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with its products, and its patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for it to stop the infringement of its patents or marketing of competing products in violation of its intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Proceedings to enforce its intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert its efforts and attention from other aspects of its business, could put its patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put its patent applications at risk of not issuing, and could provoke third parties to assert claims against Carisma. Carisma may not prevail in any lawsuits that Carisma initiates, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, its efforts to enforce its intellectual property and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that Carisma develops or licenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If Carisma or any of its licensors are forced to grant a license to third parties with respect to any patents relevant to its business, its competitive position may be impaired, and its business, financial condition, results of operations and prospects may be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma or its licensors may be subject to claims that former employees, collaborators or other third parties have an interest in its owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, Carisma or its licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing its product candidates. Although it is Carisma&#8217;s policy to require its employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, Carisma may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that Carisma regards as its own, and Carisma cannot be certain that its agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which Carisma may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or its or its licensors&#8217; ownership of its owned or in-licensed patents, trade secrets or other intellectual property. If Carisma or its licensors fail in defending any such claims, in addition to paying monetary damages, Carisma may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to its product candidates. Even if Carisma is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on its business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may be subject to claims by third parties asserting that its employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, including of their current or former employers or claims asserting Carisma has misappropriated their intellectual property, or is claiming ownership of what Carisma regards as its own intellectual property.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many of Carisma&#8217;s employees, consultants and contractors have been previously employed at universities or other biopharmaceutical companies, including its competitors or potential competitors. Although Carisma tries to ensure that its employees, consultants and contractors do not use the proprietary information or know-how of others in their work for Carisma, Carisma may be subject to claims that these individuals or Carisma have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma fails in prosecuting or defending any such claims, in addition to paying monetary damages, Carisma may lose valuable intellectual property rights or personnel, which could have a material adverse effect on its competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and Carisma could be required to obtain a license from such third party to commercialize its technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if Carisma is successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to its management and employees. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to seeking patents for some of its technology and product candidates, Carisma also relies on trade secrets and confidentiality agreements to protect its unpatented know-how, technology and other </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">proprietary information, to maintain its competitive position. Carisma seeks to protect its trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as its employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. Carisma may have also entered into confidentiality and invention or patent assignment agreements with its employees and consultants, but Carisma cannot guarantee that it has entered into such agreements with each party that may have or has had access to its trade secrets or proprietary technology. To the extent Carisma becomes involved in litigation that may require discovery of its trade secrets, know-how and other proprietary technology, Carisma will seek to secure protective orders from the court that bind the parties with access to the discovered information. Despite these efforts, any of these parties may breach the agreements and disclose its proprietary information, including its trade secrets, and Carisma may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. In addition, Carisma cannot be certain that proprietary technical information and related confidential documents that Carisma has shared with its collaborators and/or submitted to governmental agencies, including regulatory agencies for evaluation and supervision of pharmaceutical products, will be kept confidential. If any of its trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, Carisma would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with Carisma. If any of its trade secrets were to be disclosed to or independently developed by a competitor or other third party, its competitive position would be materially and adversely harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property rights do not necessarily address all potential threats to Carisma.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The degree of future protection afforded by Carisma&#8217;s intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect its business or permit it to maintain its competitive advantage. For example: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may be able to make product candidates that are similar to Carisma&#8217;s but that are not covered by the claims of the patents that it owns or licenses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma, or its license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that it licenses or may own in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma, or its license partners or current or future collaborators, might not have been the first to file patent applications covering its inventions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may independently develop similar or alternative technologies or duplicate any of its technologies without infringing its owned or in-licensed intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">it is possible that its owned or in-licensed pending patent applications or those Carisma may own or in-license in the future will not lead to issued patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">claims of issued patents that Carisma holds rights to may be held invalid or unenforceable, including as a result of legal challenges by its competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its competitors might conduct research, development, testing or commercialization activities in countries where Carisma does not have patent rights and then use the information learned from such activities to develop competitive products for sale in its major commercial markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma cannot ensure that any of its patents, or any of its pending patent applications, if issued, or those of its licensors, will include claims having a scope sufficient to protect its product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma cannot ensure that any patents issued to it or its licensors will provide a basis for an exclusive market for its commercially viable product candidates or will provide it with any competitive advantages; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the U.S. Supreme Court, other federal courts, Congress, the USPTO or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, Carisma&#8217;s or its licensors&#8217; patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patent terms may be inadequate to protect its competitive position on its product candidates for an adequate amount of time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma cannot ensure that its commercial activities or product candidates will not infringe upon the patents of others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma cannot ensure that it will be able to successfully commercialize its product candidates on a substantial scale, if approved, before the relevant patents that it owns or licenses expire; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may not develop additional proprietary technologies that are patentable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the patents of others may harm its business; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Should any of these events occur, they could have a material adverse effect on its business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Regulatory Approval and Other Legal Compliance Matters</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if Carisma is ultimately unable to obtain marketing approval for its product candidates, its business will be substantially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The time required to obtain approval by the FDA is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. Carisma has not obtained marketing approval for any product candidate and it is possible that none of its existing product candidates, or any product candidates it may seek to develop in the future will ever obtain marketing approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s product candidates could fail to receive marketing approval for many reasons, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA may disagree with the design or implementation of Carisma&#8217;s clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">results of clinical trials may not meet the level of statistical significance required by the FDA for approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA may disagree with Carisma&#8217;s interpretation of data from pre-clinical studies or clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">data collected from clinical trials of Carisma&#8217;s product candidates may not be sufficient to support the submission of an NDA to the FDA or other submission or to obtain marketing approval in the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which Carisma contracts for clinical and commercial supplies; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the approval policies or regulations of the FDA may significantly change in a manner rendering Carisma&#8217;s clinical data insufficient for approval. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in Carisma failing to obtain marketing approval to market any of its product candidates, which would significantly harm its business, results of operations and prospects. The FDA has substantial discretion in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the approval process and determining when or whether marketing approval will be obtained for any of Carisma&#8217;s product candidates. Even if Carisma believes the data collected from clinical trials of its product candidates are promising, such data may not be sufficient to support approval by the FDA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, even if Carisma were to obtain approval, regulatory authorities may approve any of Carisma&#8217;s product candidates for fewer or more limited indications than it requests, may not approve the price it intends to charge for its products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for Carisma&#8217;s product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if Carisma completes the necessary pre-clinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent Carisma from obtaining approvals for the commercialization of some or all of its product candidates. If Carisma is not able to obtain, or if there are delays in obtaining, required regulatory approvals, it will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by the EMA and other regulatory authorities outside of the United States. Failure to obtain marketing approval for a product candidate will prevent Carisma from commercializing the product candidate. Carisma has not submitted an application for or received marketing approval for any of its product candidates in the United States or in any other jurisdiction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma has only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical research organizations or other third-party consultants or vendors to assist it in this process. Securing marketing approval requires the submission of extensive pre-clinical and clinical data and supporting information, including manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Carisma&#8217;s product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Carisma obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many&#160;years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that Carisma&#8217;s data is insufficient for approval and require additional pre-clinical, clinical or other studies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval Carisma ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma experiences delays in obtaining approval or if it fails to obtain approval of its product candidates, the commercial prospects for its product candidates may be harmed and its ability to generate revenues will be materially impaired. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Failure to obtain marketing approval in foreign jurisdictions would prevent Carisma&#8217;s product candidates from being marketed in such jurisdictions, which, in turn, would materially impair Carisma&#8217;s ability to generate revenue. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to market and sell its products in the European Union and many other foreign jurisdictions, Carisma and its collaborators must obtain separate marketing approvals and comply with numerous and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Carisma or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The failure to obtain approval in one jurisdiction may negatively impact Carisma&#8217;s ability to obtain approval elsewhere. Carisma may not be able to file for marketing approvals and may not receive necessary approvals to commercialize its products in any jurisdiction, which would materially impair its ability to generate revenue. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, Carisma could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and European Union Customs Union. As of January&#160;1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations&#160;2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has been incorporated into the domestic law of the body of European Union law instruments governing medicinal products that pre-existed prior to the United Kingdom&#8217;s withdrawal from the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force Carisma to restrict or delay efforts to seek regulatory approval in the United Kingdom for its product candidates, which could significantly and materially harm Carisma&#8217;s business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma expects that it will be subject to additional risks in commercializing any of its product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of Carisma&#8217;s business may rely, which could negatively impact its business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect Carisma&#8217;s business. In addition, government funding of the SEC and other government agencies on which Carisma&#8217;s operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect Carisma&#8217;s business. For example, over the last several&#160;years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process Carisma&#8217;s regulatory submissions, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">which could have a material adverse effect on Carisma&#8217;s business. Further, future government shutdowns could impact Carisma&#8217;s ability to access the public markets and obtain necessary capital in order to properly capitalize and continue Carisma&#8217;s operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Separately, in response to the COVID-19 pandemic, a number of companies announced in 2021 receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Following a period of false starts and temporary suspensions due to the omicron variant, the FDA resumed domestic inspections in February&#160;2022 and indicated that it would conduct foreign inspections beginning in April&#160;2022 on a prioritized basis. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process Carisma&#8217;s regulatory submissions, which could have a material adverse effect on its business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact Carisma&#8217;s business by delaying review of its public filings, to the extent such review is necessary, and Carisma&#8217;s ability to access the public markets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Regulatory requirements governing gene therapy products are periodically updated and may continue to change in the future.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has established the Office of Tissues and Advanced Therapies, or the OTAT, within the Center for Biologics Evaluation and Research, or the CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the U.S. National Institutes of Health, or the NIH, also are potentially subject to review by the Office of Biotechnology Activities&#8217; Recombinant DNA Advisory Committee, or the RAC; however, the NIH announced that the RAC will only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks. Although the FDA decides whether individual gene therapy protocols may proceed, the RAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND on a clinical hold even if the RAC has provided a favorable review or an exemption from in-depth, public review. If Carisma were to engage an NIH-funded institution to conduct a clinical trial, that institution&#8217;s institutional biosafety committee, or IBC, as well as its IRB would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of Carisma&#8217;s product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has issued various guidance documents regarding gene therapies, including final guidance documents released in January&#160;2020 relating to chemistry, manufacturing and controls information for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, Carisma believes that its compliance with them is likely necessary to gain approval for any gene therapy product candidate that Carisma may develop. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper pre-clinical assessment of gene therapies; the chemistry, manufacturing, and control information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five&#160;years of annual examinations followed by 10&#160;years of annual queries, either in person or by questionnaire. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, for a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with good tissue practices, or GTP. These standards are found in FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue based products, or HCT/Ps, which are human cells or tissue intended </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finally, ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations or prohibiting the processes that Carisma may use. Federal and state agencies, congressional committees and foreign governments have expressed their intentions to further regulate biotechnology. More restrictive regulations or claims that Carisma&#8217;s product candidates are unsafe or pose a hazard could prevent Carisma from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of Carisma&#8217;s product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As Carisma advances its product candidates through clinical development, it will be required to consult with these regulatory and advisory groups, and comply with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require Carisma to perform additional studies, increase Carisma&#8217;s development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of Carisma&#8217;s product candidates or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease Carisma&#8217;s ability to generate sufficient product revenue. </font>
        </div>
        <div style="margin-top:9.72pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if Carisma, or any collaborators, obtains marketing approvals for its product candidates, the terms of approvals and ongoing regulation of its products may limit how Carisma, or any collaborators, manufacture and market its products, which could materially impair Carisma&#8217;s ability to generate revenue.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. Carisma, and any collaborators, must therefore comply with requirements concerning advertising and promotion for any of its product candidates for which Carisma or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, Carisma, and any collaborators will not be able to promote any products developed for indications or uses for which they are not approved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. Carisma, its third-party manufacturers, any collaborators and their third-party manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, assuming Carisma, or any collaborators, receive marketing approval for one or more of their product candidates, Carisma, and any collaborators, and Carisma and any collaborators&#8217; respective third-party manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma and such collaborators are not able to comply with post-approval regulatory requirements, Carisma and such collaborators could have the marketing approvals for their products withdrawn by regulatory authorities and Carisma or such collaborators&#8217;, ability to market any future products could be limited, which could adversely affect Carisma&#8217;s ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on Carisma&#8217;s business, operating results, financial condition and prospects. </font>
        </div>
        <div style="margin-top:9.62pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may seek certain designations for its product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, but it might not receive such designations, and even if it does, such designations may not lead to a faster development or regulatory review or approval process.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma may seek certain designations for one or more of its product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma may also seek a priority review designation for one or more of its product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six&#160;months, rather than the standard review period of ten&#160;months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These designations are within the discretion of the FDA. Accordingly, even if Carisma believes that one of its product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if Carisma receives a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA, including the Fast Track designation Carisma received for CT-0508. In addition, even if one or more of Carisma&#8217;s product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma, or its collaborators, may seek approval from the FDA or comparable foreign regulatory authorities to use accelerated development pathways for its product candidates. If Carisma, or its collaborators, are not able to use such pathways, Carisma, or they, may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if Carisma, or they, receive them at all. In addition, even if an accelerated approval pathway is available to Carisma, or its collaborators, it may not lead to expedited approval of Carisma&#8217;s product candidates, or approval at all.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Federal Food, Drug, and Cosmetic Act and implementing regulations, the FDA may grant accelerated approval to a product candidate to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies, upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. Prior to seeking such accelerated approval, Carisma, or its collaborators, will continue to seek feedback from the FDA or comparable foreign regulatory agencies and otherwise evaluate Carisma&#8217;s, or their, ability to seek and receive such accelerated approval. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There can be no assurance that the FDA or foreign regulatory agencies will agree with Carisma&#8217;s, or its collaborators&#8217;, surrogate endpoints or intermediate clinical endpoints in any of Carisma&#8217;s, or their, clinical trials, or that Carisma, or its collaborators, will decide to pursue or submit any additional application for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from the FDA or comparable foreign regulatory agencies, Carisma, or its collaborators, will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval. Furthermore, for any submission of an application for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or at all. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A failure to obtain accelerated approval or any other form of expedited development, review or approval for Carisma&#8217;s product candidates, or withdrawal of a product candidate, would result in a longer time period until commercialization of such product candidate, could increase the cost of development of such product candidate and could harm Carisma&#8217;s competitive position in the marketplace. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma may not be able to obtain orphan drug exclusivity for any product candidates it may develop, and even if it does, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven&#160;years in the United States and ten&#160;years in the European Union. The exclusivity period in the European Union can be reduced to six&#160;years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order for the FDA to grant orphan drug exclusivity to one of Carisma&#8217;s products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which Carisma seeks orphan drug exclusivity does not meet this standard. Even if Carisma obtains orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA and comparable foreign regulatory authorities such as the EMA can subsequently approve the same product for the same condition if the FDA or such other authorities conclude that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2017, the Congress passed the FDA Reauthorization Act of 2017, or the FDARA. The FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under omnibus legislation signed by former President Trump in December&#160;2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by the FDA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">1</font><font style="letter-spacing:0.2pt;">1th Circuit in September&#160;2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Carisma does not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">changes might affect Carisma&#8217;s business. Depending on what changes the FDA may make to its orphan drug regulations and policies, Carisma&#8217;s business could be adversely impacted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma is unable to successfully develop companion diagnostics for its product candidates and secure clearance or approval of such devices by the FDA and other regulatory authorities, or Carisma experiences significant delays in doing so, Carisma may not realize the full commercial potential of its therapeutics.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma believes that its success will depend, in part, on its ability to develop companion diagnostics, which are assays or tests to identify an appropriate patient population for these product candidates. Carisma has little experience in the development of diagnostics and may not be successful in developing appropriate diagnostics to pair with any of its therapeutic product candidates that receive marketing approval. Companion diagnostics are subject to regulation by the FDA and similar regulatory authorities outside the United States as medical devices and require separate regulatory approval prior to commercialization. Given Carisma&#8217;s limited experience in developing diagnostics, it relies and expects to continue to rely in part or in whole on third parties for their design and manufacture. Carisma also may in the future depend on other third parties for the development of other companion diagnostics for its therapeutic product candidates. If Carisma or its collaborators are unable to successfully develop companion diagnostics for Carisma&#8217;s therapeutic product candidates, or experience delays in doing so: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the development of Carisma&#8217;s therapeutic product candidates may be adversely affected if Carisma is unable to appropriately select patients for enrollment in its clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s therapeutic product candidates may not receive marketing approval if safe and effective use of a therapeutic product candidate depends on an in vitro diagnostic; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma may not realize the full commercial potential of any therapeutics that receive marketing approval if, among other reasons, Carisma is unable to appropriately select patients who are likely to benefit from therapy with its medicines. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result of any of these events, Carisma&#8217;s business would be harmed, possibly materially. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Any product candidate for which Carisma, or any collaborators, obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and Carisma, or any collaborators, may be subject to substantial penalties if Carisma, or any collaborators, fail to comply with regulatory requirements or if Carisma, or any collaborators, experience unanticipated problems with its products when and if any of them are approved.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any product candidate for which Carisma, or any collaborators, obtain marketing approval, as well as the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a risk evaluation and mitigation strategy. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed. If any of Carisma&#8217;s product candidates receives marketing approval, the accompanying label may limit the approved use of its drug in this way, which could limit sales of the product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product, including the adoption and implementation of risk evaluation and mitigation strategies. The FDA and other regulatory agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA, DOJ and other regulatory agencies impose stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if Carisma does not market its products for their approved indications, it may be subject to enforcement action for off-label marketing by the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">FDA and other federal and state enforcement agencies. Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, later discovery of previously unknown side effects or other problems with Carisma&#8217;s products or its manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on such products, manufacturers or manufacturing processes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions and warnings on the labeling or marketing of a product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on product distribution or use; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">requirements to conduct post-marketing studies or clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">receipt of warning letters or untitled letters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">withdrawal of the products from the market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refusal to approve pending applications or supplements to approved applications that Carisma submits; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">recall of products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fines, restitution or disgorgement of profits or revenues; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspension or withdrawal of marketing approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspension of any ongoing clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">damage to relationships with any potential collaborators; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">unfavorable press coverage and damage to Carisma&#8217;s reputation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refusal to permit the import or export of Carisma&#8217;s products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product seizure; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">injunctions or the imposition of civil or criminal penalties; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">litigation involving patients using Carisma&#8217;s products. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs applicable to drug manufacturers or quality assurance standards applicable to medical device manufacturers, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. Carisma, any contract manufacturers it may engage in the future, its collaborators and their contract manufacturers will also be subject to other regulatory requirements, including submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements regarding the distribution of samples to clinicians, recordkeeping, and costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product such as the requirement to implement a risk evaluation and mitigation strategy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose Carisma to civil, criminal and administrative sanctions, contractual damages, reputational harm and diminished future profits and earnings.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any drugs for which Carisma obtains marketing approval. Carisma&#8217;s future arrangements with third-party payors, healthcare providers and physicians may expose it to broadly applicable state and federal fraud and abuse and other healthcare laws and regulations that may constrain the business or financial </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">arrangements and relationships through which Carisma markets, sells and distributes any drugs for which it obtains marketing approval. These include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Anti-Kickback Statute,</font><font style="letter-spacing:0.2pt;"> which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">False Claims Act &#8212;</font><font style="letter-spacing:0.2pt;"> the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">HIPAA &#8212;</font><font style="letter-spacing:0.2pt;"> the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and apply regardless of the payor (e.g., public or private); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">HIPAA and HITECH &#8212;</font><font style="letter-spacing:0.2pt;"> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose obligations on HIPAA covered entities and their business associates, including mandatory contractual terms and required implementation of administrative, physical and technical safeguards to maintain the privacy and security of individually identifiable health information; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Transparency Requirements &#8212;</font><font style="letter-spacing:0.2pt;"> the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the Affordable Care Act, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Analogous State, Local and Foreign Laws &#8212;</font><font style="letter-spacing:0.2pt;"> analogous state, local and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader than similar federal laws, can apply to claims involving healthcare items or services regardless of payor, and are enforced by many different federal and state agencies as well as through private actions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Efforts to ensure that Carisma&#8217;s business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that Carisma&#8217;s business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If Carisma&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to Carisma, it may be subject to significant civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if Carisma becomes subject to a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of its operations. If any of the physicians or other healthcare providers or entities with whom Carisma expects to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union Member States. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to Carisma or inhibit its ability to collect and process data globally, and the failure to comply with such requirements could subject Carisma to significant fines and penalties, which may have a material adverse effect on its business, financial condition or results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which Carisma operates has established its own data security and privacy frameworks with which it must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the E.U. General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May&#160;2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases Carisma&#8217;s obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four&#160;percent of global revenues or 20.0&#160;million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Similar actions are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to Carisma&#8217;s activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act, or CCPA, which went into effect on January&#160;1, 2020, is creating similar risks and obligations as those created by the GDPR, though CCPA does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose Carisma to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if Carisma is not determined to have violated these laws, government investigations </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">104</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm Carisma&#8217;s reputation and business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Given the breadth and depth of changes in data protection obligations, preparing for and complying with such requirements is rigorous and time intensive and requires significant resources and a review of Carisma&#8217;s technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from Carisma&#8217;s clinical trials, could require Carisma to change its business practices and put in place additional compliance mechanisms, may interrupt or delay its development, regulatory and commercialization activities and increase its cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against Carisma and could have a material adverse effect on its business, financial condition or results of operations. Similarly, failure to comply with federal and state laws regarding privacy and security of personal information could expose Carisma to fines and penalties under such laws. Even if Carisma is not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm Carisma&#8217;s reputation and business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Current and future legislation may increase the difficulty and cost for Carisma and any collaborators to obtain marketing approval of and commercialize product candidates and affect the prices Carisma, or any collaborators, may obtain.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of Carisma&#8217;s product candidates, restrict or regulate post-approval activities, impact pricing and reimbursement and affect Carisma&#8217;s ability, or the ability of any collaborators, to profitably sell or commercialize any product candidates for which Carisma, or any collaborators, obtain marketing approval. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that Carisma, or any collaborators, may receive for any FDA approved products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for prescription drugs purchased through a pharmacy by the elderly and disabled and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this statute provides authority for limiting the number of drugs that will be covered in any therapeutic class, subject to certain exceptions. Cost reduction initiatives and other provisions of this statute could decrease the coverage and price that Carisma receives for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2010, then-President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April&#160;2013 and will remain in effect through 2031 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">105</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">recover overpayments to providers from three to five&#160;years. Further, with passage of the Inflation Reduction Act in August&#160;2022, Congress extended the expansion of the Patient Protection and Affordable Care Act premium tax credits through 2025. Those subsidies were originally extended through 2022 under the American Rescue Plan&#160;Act of 2021. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices Carisma may obtain for any of its product candidates for which it may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts for Jobs Act, or TCJA, in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December&#160;14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case on November&#160;10, 2020 and on June&#160;17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January&#160;28, 2021, however, President Biden rescinded those orders and issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access. Under this Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents. This Executive Order also directs the U.S. Department of Health and Human Services to create a special enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma expects that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that Carisma receives for any approved product and/or the level of reimbursement physicians receive for administering any approved product it might bring to market. Reductions in reimbursement levels may negatively impact the prices Carisma receives or the frequency with which its products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that Carisma may successfully develop and for which it may obtain marketing approval and may affect Carisma&#8217;s overall financial condition and ability to develop or commercialize product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices Carisma obtains for its drug products, if and when approved.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">106</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">nation model for prices that would tie Medicare Part&#160;B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January&#160;1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December&#160;29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part&#160;B pharmaceuticals and improve beneficiaries&#8217; access to evidence-based care. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in October&#160;2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section&#160;804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January&#160;1, 2022 to January&#160;1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which has been delayed until January&#160;1, 2026 by the Infrastructure Investment and Jobs Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">More recently, with passage of the Inflation Reduction Act in August&#160;2022, Congress authorized Medicare beginning in 2026 to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars. This provision is limited in terms of the number of pharmaceuticals whose prices can be negotiated in any given year and it only applies to drug products that have been approved for at least 9&#160;years and biologics that have been licensed for 13&#160;years. Drugs and biologics that have been approved for a single rare disease or condition are categorically excluded from price negotiation. Further, the new legislation provides that if pharmaceutical companies raise prices in Medicare faster than the rate of inflation, they must pay rebates back to the government for the difference. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for Carisma&#8217;s products, once approved, or put pressure on its product pricing. Carisma expects that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for its product candidates or additional pricing pressures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In other countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, Carisma, or its collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of its drug to other available therapies. If reimbursement of Carisma&#8217;s drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, its business could be materially harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma is subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing its operations. If Carisma fails to comply with these laws, it could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect its business, results of operations and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s operations are subject to anti-corruption laws, including the FCPA, the Bribery Act, and other anticorruption laws that apply in countries where Carisma does business and may do business in the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">107</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">future. The FCPA, the Bribery Act, and these other laws generally prohibit Carisma, its officers and its employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. Carisma may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and it may participate in collaborations and relationships with third parties whose actions could potentially subject Carisma to liability under the FCPA, the Bribery Act, or local anti-corruption laws. In addition, Carisma cannot predict the nature, scope or effect of future regulatory requirements to which its international operations might be subject or the manner in which existing laws might be administered or interpreted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is also subject to other laws and regulations governing its international operations, including regulations administered by the governments of the United States, United Kingdom, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which is collectively referred to as Trade Control Laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is no assurance that Carisma will be completely effective in ensuring its compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements, including Trade Control Laws. If Carisma is not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade Control Laws, it may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on its business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Likewise, any investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by the United States, the United Kingdom or other authorities could also have an adverse impact on Carisma&#8217;s reputation, business, results of operations and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma is subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject Carisma to significant fines and penalties, which may have a material adverse effect on Carisma&#8217;s business, financial condition or results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, the European Union and the United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect Carisma&#8217;s business. Failure to comply with any of these laws and regulations could result in an enforcement action against Carisma, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to Carisma&#8217;s reputation and loss of goodwill, any of which could have a material adverse effect on Carisma&#8217;s business, financial condition, results of operations or prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and Carisma&#8217;s contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of Carisma&#8217;s business activities now or in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma is unable to properly protect the privacy and security of protected health information, it could be found to have breached its contracts. Further, if Carisma fails to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, it could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">108</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. Carisma cannot be sure how these regulations will be interpreted, enforced or applied to its operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, Carisma&#8217;s ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to its policies, procedures and systems. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2018, California passed into law the California Consumer Privacy Act, or the CCPA, which took effect on January&#160;1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the General Data Protection Regulation, or the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November&#160;2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which will significantly expand the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. Most CPRA provisions will take effect on January&#160;1, 2023, though the obligations will apply to any personal information collected after January&#160;1, 2022. These provisions may apply to some of Carisma&#8217;s business activities. In addition, other states, including Virginia and Colorado, already have passed state privacy laws. Other states will be considering these laws in the future. These laws may impact Carisma&#8217;s business activities, including Carisma&#8217;s identification of research subjects, relationships with business partners and ultimately the marketing and distribution of its products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area, or EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May&#160;2018 and which imposes obligations on companies that operate in Carisma&#8217;s industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If Carisma&#8217;s or its partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, Carisma may be subject to litigation, regulatory investigations, enforcement notices requiring it to change the way it uses personal data and/or fines of up to 20.0&#160;million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The GDPR places restrictions on the cross-border transfer of personal data from the European Union to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the European Union to other countries. In July&#160;2020, the Court of Justice of the European Union, or the CJEU invalidated the European Union-United States Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. While Carisma is not self-certified under the Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States, generally, and increase Carisma&#8217;s costs of compliance with data privacy legislation as well as its costs of negotiating appropriate privacy and security agreements with its vendors and business partners. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following the withdrawal of the United Kingdom from the European Union, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. As with other issues related to Brexit, there are open </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">109</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">questions about how personal data will be protected in the United Kingdom and whether personal information can transfer from the European Union to the United Kingdom. Following the withdrawal of the United Kingdom from the European Union, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the Data Protection Act of 2018 in the United Kingdom that &#8220;implements&#8221; and complements the GDPR, has achieved Royal Assent on May&#160;23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under GDPR. The U.K. government has already determined that it considers all European Union and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union/EEA remain unaffected. In addition, a recent decision from the EC appears to deem the United Kingdom as being &#8220;essentially adequate&#8221; for purposes of data transfer from the European Union to the United Kingdom, although this decision may be re-evaluated in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact Carisma&#8217;s ability to conduct its business activities, including both its clinical trials and any eventual sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While Carisma continues to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and Carisma&#8217;s efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with Carisma&#8217;s practices. Carisma must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose Carisma to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if Carisma is found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose Carisma to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that Carisma change its practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect Carisma&#8217;s business. Even if Carisma is not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm Carisma&#8217;s business, financial condition, results of operations or prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma employees, independent contractors, consultants, collaborators and vendors engage in misconduct or other improper activities, including non-compliance with regulatory standards and/or requirements and insider trading, Carisma could sustain significant liability and harm to its reputation.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is exposed to the risk of fraud or other misconduct by its employees, independent contractors, consultants, collaborators and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to Carisma. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to Carisma&#8217;s reputation. This could include violations of HIPAA, other U.S. federal and state laws, and requirements of foreign jurisdictions, including the GDPR. Carisma is also exposed to risks in connection with any insider trading violations by employees or others affiliated with Carisma. It is not always possible to identify and deter employee or third-party misconduct, and the precautions that Carisma takes to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting Carisma from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against Carisma, and Carisma is not </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">110</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">successful in defending itself or asserting its rights, those actions could have a significant impact on its business and results of operations, including the imposition of significant fines or other sanctions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Carisma or any third-party manufacturer it engages now or in the future fails to comply with environmental, health and safety laws and regulations, Carisma could become subject to fines or penalties or incur costs or liabilities that could significantly harm its business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma and third-party manufacturers it engages now are, and any third-party manufacturer it may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, Carisma&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although Carisma contracts with third parties for the disposal of these materials and waste products, it cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of Carisma&#8217;s hazardous materials, Carisma could be held liable for any resulting damages, and any liability could exceed its resources. Carisma also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma maintains general liability insurance as well as workers&#8217; compensation insurance to cover costs and expenses it may incur due to injuries to its employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. Carisma does not maintain insurance for environmental liability or toxic tort claims that may be asserted against it. In addition, Carisma may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair Carisma&#8217;s research, development or production efforts, which could adversely affect its business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Employee Matters and Managing Growth</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s future success depends on its ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is highly dependent on the research and development, clinical, financial, operational and other business expertise of its executive officers, as well as the other principal members of its management, scientific and clinical teams. Although Carisma has entered into employment agreements with certain of its executive officers, each of them may terminate their employment with Carisma at any time. Carisma does not maintain &#8220;key person&#8221; insurance for any of its executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to Carisma&#8217;s success. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The loss of the services of Carisma&#8217;s executive officers or other key employees, including temporary loss due to illness, could impede the achievement of its discovery programs, development and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in Carisma&#8217;s industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and Carisma may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous biopharmaceutical companies for similar personnel. Carisma also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, Carisma relies on consultants and advisors, including scientific and clinical advisors, to assist it in formulating its discovery, research and development and commercialization strategy. Carisma&#8217;s consultants and advisors may be employed by employers other than Carisma and may have commitments under consulting or advisory contracts with other entities that may limit their availability to Carisma. Failure to succeed in clinical trials may make it even more challenging to recruit and retain qualified scientific personnel. Carisma&#8217;s success as a public company </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">111</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">also depends on implementing and maintaining internal controls and the accuracy and timeliness of its financial reporting. If Carisma is unable to continue to attract and retain high quality personnel, its ability to pursue its growth strategy will be limited. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma expects to expand its development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, it may encounter difficulties in managing its growth, which could disrupt its operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma expects to experience significant growth in the number of its employees and the scope of its operations, particularly as it functions as a public company and in the areas of product development, clinical, regulatory affairs, manufacturing and quality control and, if any of its product candidates receives marketing approval, sales, marketing and distribution. To manage Carisma&#8217;s anticipated future growth, it must continue to implement and improve its managerial, operational and financial systems, expand its facilities and continue to recruit and train additional qualified personnel. Future growth will impose significant added responsibilities on members of management, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">identifying, recruiting, integrating, maintaining and motivating additional employees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">managing its internal development efforts effectively, including the clinical and regulatory review process for CT-0508 and other product candidates Carisma is developing or may develop in the future, while complying with its contractual obligations to contractors and other third parties; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">improving its operational, financial and management controls, reporting systems and procedures. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s future financial performance and its ability to advance development of and, if approved, commercialize CT-0508 and any other product candidate Carisma is developing or may develop in the future will depend, in part, on Carisma&#8217;s ability to effectively manage any future growth. Due to Carisma&#8217;s limited financial resources and the limited experience of its management team in managing a company with such anticipated growth, Carisma may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel. If Carisma does not effectively manage the expansion of its operations, Carisma could experience weaknesses in its infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The expansion of Carisma&#8217;s operations also could lead to significant costs and may divert Carisma&#8217;s management and business development resources. Any inability to manage growth could delay the execution of Carisma&#8217;s business plans or disrupt its operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many of the biopharmaceutical companies, and in particular cell therapy companies, that Carisma competes against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than Carisma does. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what Carisma has to offer. If Carisma is unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which Carisma can develop product candidates and operate its business will be limited. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s internal computer systems, or those of its collaborators, vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of Carisma&#8217;s product development programs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s internal computer systems and those of any collaborators, vendors, suppliers, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by Carisma&#8217;s employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or email fraud to cause payments or information to be transmitted to an unintended recipient. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">112</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma experiences any material system failure, accident, cyber-attack or security that causes interruptions in its operations, it could result in a material disruption of Carisma&#8217;s development programs and its business operations, whether due to a loss of its trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in Carisma&#8217;s marketing approval efforts and significantly increase its costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, Carisma&#8217;s data or applications, or inappropriate disclosure of confidential or proprietary information, Carisma could incur liability, its competitive position could be harmed and the further development and commercialization of its product candidates could be delayed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s employees, independent contractors, including principal investigators, consultants and vendors and any third parties it may engage in connection with discovery programs, research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could cause significant liability for Carisma and harm its reputation.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is exposed to the risk of fraud or other misconduct by its employees, independent contractors, including principal investigators, consultants and vendors and any other third parties it engages. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that include failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide complete and accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state data privacy, security, fraud and other healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report complete financial information or data accurately or disclose unauthorized activities to Carisma. Misconduct by employees and other third parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to Carisma&#8217;s reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive. Carisma is also exposed to risks in connection with any insider trading violations by employees or others affiliated with Carisma. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions Carisma takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Carisma from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. Additionally, Carisma is subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against Carisma, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on Carisma&#8217;s business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of Carisma&#8217;s operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to the Ownership of the Common Stock of the Combined Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the combined company&#8217;s common stock may drop following the merger.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The market price of the combined company&#8217;s common stock following the merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the combined company&#8217;s common stock to fluctuate include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">results of clinical trials and pre-clinical studies of the combined company&#8217;s product candidates, or those of the combined company&#8217;s competitors or the combined company&#8217;s existing or future collaborators; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">failure to meet or exceed financial and development projections the combined company may provide to the public; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">113</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">failure to meet or exceed the financial and development projections of the investment community; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if the combined company does not achieve the perceived benefits of the merger as rapidly or to the extent anticipated by financial or industry analysts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">actions taken by regulatory agencies with respect to the combined company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company&#8217;s ability to obtain patent protection for its technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">additions or departures of qualified scientific and management personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">significant lawsuits, including patent or stockholder litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes in the market valuations of similar companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">general market or macroeconomic conditions or market conditions in the biopharmaceutical sector; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">sales of securities by the combined company or its stockholders in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if the combined company fails to raise an adequate amount of capital to fund its operations and continued development of its product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">trading volume of the combined company&#8217;s common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adverse publicity relating to product candidates, including with respect to other products in such markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the introduction of technological innovations or new therapies that compete with the products and services of the combined company; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">period-to-period fluctuations in the combined company&#8217;s financial results. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect the combined company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the combined company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the combined company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on the combined company&#8217;s operating results and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The combined company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The combined company will incur significant legal, accounting and other expenses as a public company that Carisma did not incur as a private company, including costs associated with public company reporting obligations under the Exchange Act. The combined company&#8217;s management team will consist of the executive officers of Carisma prior to the merger, some of whom have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">114</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">regulations to ensure that the combined company complies with all of these requirements. Any changes the combined company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the combined company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Once the combined company is no longer a &#8220;smaller reporting company&#8221; or otherwise no longer qualifies for applicable exemptions, the combined company will be subject to additional laws and regulations affecting public companies that will increase the combined company&#8217;s costs and the demands on management and could harm the combined company&#8217;s operating results.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The combined company will be subject to the reporting requirements of the Exchange Act, which requires, among other things, that the combined company file with the SEC annual, quarterly and current reports with respect to the combined company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as defined in Item&#160;10(f)(1) of Regulation&#160;S-K, the combined company may take advantage of certain exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2022 and reduced disclosure obligations regarding executive compensation in the combined company&#8217;s periodic reports and proxy statements. Once the combined company no longer qualifies as a smaller reporting company or otherwise no longer qualifies for these exemptions, the combined company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If the combined company is not able to comply with the requirements in a timely manner or at all, the combined company&#8217;s financial condition or the market price of the combined company&#8217;s common stock may be harmed. For example, if the combined company or its independent auditor identifies deficiencies in the combined company&#8217;s internal control over financial reporting that are deemed to be material weaknesses, then the combined company could face additional costs to remedy those deficiencies, the market price of the combined company&#8217;s stock could decline or the combined company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company, which may be beneficial to its stockholders, more difficult and may prevent attempts by its stockholders to replace or remove its management.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the merger is completed, the Sesen Bio Bylaws and the Sesen Bio Certificate of Incorporation, as amended by the amendment thereto attached to this proxy statement/prospectus as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex G</font><font style="letter-spacing:0.2pt;">, assuming Proposal No. 2 is approved by Sesen Bio stockholders at the Sesen Bio special meeting, will become the combined company&#8217;s certificate of incorporation and bylaws. Provisions that will be included in the combined company&#8217;s certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the combined company that stockholders may consider favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the combined company&#8217;s common stock, thereby depressing the market price of its common stock. In addition, because the combined company&#8217;s board of directors will be responsible for appointing the members of the combined company&#8217;s management team, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of the combined company&#8217;s board of directors. Among other things, these provisions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establish a classified board of directors such that only one of three classes of directors is elected each year; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">allow the authorized number of the combined company&#8217;s directors to be changed only by resolution of its board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">115</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">limit the manner in which stockholders can remove directors from the combined company&#8217;s board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and for nominations to the combined company&#8217;s board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">limit who may call stockholder meetings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prohibit actions by the combined company&#8217;s stockholders by written consent; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">require that stockholder actions be effected at a duly called stockholders meeting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">authorize the combined company&#8217;s board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the combined company&#8217;s board of directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">require the approval of the holders of at least 75% of the votes that all combined company stockholders would be entitled to cast to amend or repeal certain provisions of the combined company&#8217;s certificate of incorporation or bylaws. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, because the combined company is incorporated in Delaware, it is governed by the provisions of Section&#160;203 of the DGCL which prohibits a person who owns 15% or more of the combined company&#8217;s outstanding voting stock from merging or combining with the combined company for a period of three&#160;years after the date of the transaction in which the person acquired 15% or more of the combined company&#8217;s outstanding voting stock, unless the merger or combination is approved in a manner prescribed by the statute. For more information about provisions that will be included in the combined company&#8217;s certificate of incorporation and bylaws, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Comparison of Rights of Holders of Sesen Bio Stock and Carisma Stock</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCORO">386</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to the merger, there had been no public market for shares of Carisma capital stock. An active trading market for the combined company&#8217;s shares of common stock may never develop or be sustained. If an active market for the combined company&#8217;s common stock does not develop or is not sustained, it may be difficult for its stockholders to sell their shares at an attractive price or at all. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">After completion of the merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of the merger, and giving effect to the issuance of the shares of common stock of Carisma prior to the closing of the merger pursuant to the Carisma pre-closing financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately 56.94% of the combined company&#8217;s outstanding shares of common stock, subject to certain assumptions, including, but not limited to, Sesen Bio&#8217;s net cash as of closing being at least $75.0&#160;million. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the combined company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the combined company on terms that other stockholders may desire. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The trading market for the combined company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect not </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">116</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:112pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to provide research coverage of the combined company&#8217;s common stock after the completion of the merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts or the content and opinions included in their reports. The price of the combined company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company as well as the proceeds from the Carisma pre-closing financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The combined company will have broad discretion over the use of the cash and cash equivalents of the combined company and the proceeds from the Carisma pre-closing financing. You may not agree with the combined company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The combined company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the combined company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence the combined company&#8217;s decisions on how to use its cash resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If Sesen Bio fails to consummate a strategic transaction with respect to Vicineum, the combined company will be responsible for unwinding related contractual relationships, which may adversely impact the business, financial condition and results of operations of the combined company following the merger.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July 15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the U.S. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following Sesen Bio&#8217;s discussions with the FDA. If the merger is consummated, the combined company does not expect to pursue further development of Vicineum for the treatment of NMIBC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">Although Sesen Bio is seeking to consummate a strategic transaction with respect to Vicineum and has engaged a financial advisor for the potential sale of Vicineum, in the event that a transaction is delayed or does not occur, the combined company will be responsible for unwinding contractual relationships related to Vicineum, which could divert the attention of the management teams and employees of the combined company from day-to-day business, result in liability, impose additional costs and otherwise adversely affect the business and financial condition of the combined company. The combined company may also experience the same risks related to disagreements and disputes with certain licensees, licensors and other counterparties as discussed above in &#8220;</font><font style="letter-spacing:0.2pt;">Risk Factors&#8201;&#8212;&#8201;Risks Related to the Merger&#8201;&#8212;&#8201;In connection with Sesen Bio&#8217;s strategic decision to voluntarily pause further development of Vicineum in the United States, Sesen Bio may become involved in disagreements or disputes with its licensees, licensors and other counterparties relating to the development and/or commercialization of Vicineum, which may be time consuming, costly and could divert its efforts and attention from consummating the merger and harm Sesen Bio&#8217;s efforts to seek a partner to continue development of Vicineum</font><font style="font-style:normal;letter-spacing:0.2pt;">.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">117</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCSCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This proxy statement/prospectus contains forward-looking statements (including within the meaning of Section&#160;21E of the Exchange Act and Section&#160;27A of the Securities Act) concerning, among other things, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the expected benefits of, and potential value created by, the merger for the Sesen Bio stockholders and Carisma stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the likelihood of the satisfaction of certain conditions to the completion of the merger and whether and when the merger will be completed and the listing of the Sesen Bio common stock to be issued on the Nasdaq Capital Market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the expected amount of the Sesen Bio net cash on the anticipated closing date or the merger, or the closing date, and Sesen Bio&#8217;s ability to control and correctly estimate its operating expenses and its expenses associated with the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the expected number of Sesen Bio securities included in the fully diluted number of outstanding shares of Sesen Bio common stock for purposes of calculating the exchange ratio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any statements regarding the CVRs to be granted to Sesen Bio stockholders, pursuant to the Merger Agreement and the CVR Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any statements regarding the special cash dividend that Sesen Bio may pay to Sesen Bio stockholders in connection with the completion of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any statements of the plans, strategies and objectives of management for future operations, including the execution of integration plans and the anticipated timing of filings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any statements of plans to develop and commercialize additional products candidates, including planned pre-clinical, clinical, regulatory and manufacturing activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any statements concerning the attraction and retention of highly qualified personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any statements concerning the ability to protect and enhance the combined company&#8217;s product candidates and intellectual property; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any statements concerning developments and projections relating to the combined company&#8217;s competitors or industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any statements concerning the combined company&#8217;s projected financial performance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any statements regarding expectations concerning Sesen Bio&#8217;s or Carisma&#8217;s relationships and actions with third parties; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">future regulatory, judicial and legislative changes in Sesen Bio&#8217;s or Carisma&#8217;s industry. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These forward-looking statements should not be relied upon as predictions of future events as Sesen Bio and Carisma cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. You can identify forward-looking statements by the use of forward-looking terminology including &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro&#160;forma,&#8221; &#8220;estimates,&#8221; or &#8220;anticipates&#8221; or the negative of these words and phrases or other variations of these words and phrases or comparable terminology. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The events and circumstances reflected in forward-looking statements may not be achieved or occur and actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio stockholders and Carisma stockholders may not realize a benefit from the merger commensurate with the ownership dilution they will experience in connection with the merger, including the Carisma pre-closing financing, and the conversion of the Carisma convertible note; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the merger consideration may have greater or lesser value at the closing of the merger than at the time the Merger Agreement is signed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">118</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">failure to complete the merger may result in either party paying a termination fee or expenses to the other party and could harm the future business and operations of the applicable company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if the conditions to the merger are not met, including failure to obtain stockholder approval for the merger, or failure to comply with the listing standards of Nasdaq, the merger may not occur; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing of the consummation of the merger is uncertain as is the ability of each of Sesen Bio and Carisma to consummate the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the merger may be completed even though material adverse changes may occur; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio may not be able to correctly estimate its operating expenses and its expenses associated with the merger and may have a significantly lower net cash on the anticipated closing date than currently estimated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio may not be able to maintain its Nasdaq listing until the closing of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">as a result of any adjustments in the exchange ratio, Sesen Bio stockholders or Carisma stockholders may own less of the combined company after the closing of the merger than is currently anticipated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">executive officers and directors of each company have interests in the merger that are different from yours, which may cause them to support or approve the merger without regard to your interests; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the market price of combined company&#8217;s common stock may decline following the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conditions to payment under the CVRs may not be met and the CVRs may never deliver any value to the Sesen Bio stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions in the Merger Agreement may prevent Sesen Bio and Carisma from entering into a business combination with another party at a favorable price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Carisma stockholders may receive consideration in the merger that is greater or less than the fair market value of the Carisma shares due to the lack of a public market for Carisma shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if the merger does not qualify as a tax-free reorganization for U.S. federal income tax purposes, the receipt of Sesen Bio common stock pursuant to the merger could be fully taxable to all Carisma stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the combined company may never earn a profit; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the combined company will be subject to the uncertainties associated with the clinical development and regulatory approval of its product candidates including potential delays in the commencement, enrollment and completion of clinical trials and that the results of prior clinical trials may not be predictive of future results; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the combined company will be required to raise additional funds to finance its operations and remain a going concern and may be required to do so sooner than it expects; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the combined company may not be able to raise additional funds when necessary, and/or on acceptable terms; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the combined company&#8217;s small public float, low market capitalization, limited operating history, and lack of revenue may make it difficult and expensive for the combined company to raise additional funds; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the pro&#160;forma combined financial statements may not be an indication of the combined company&#8217;s financial condition or results of operations following the completion of the merger and the transactions contemplated thereby; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Carisma may not be able to protect their respective intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">there may be changes in expected or existing competition for the combined company&#8217;s product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">119</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:16pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the merger will result in changes to the combined company&#8217;s board of directors that may affect the combined company&#8217;s business strategy and operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">both companies expect that the price of the combined company&#8217;s common stock may be volatile and may fluctuate substantially following the merger and the transactions contemplated thereby; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if the combined company were to be delisted from Nasdaq, it could reduce the visibility, liquidity and price of its common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a significant portion of the combined company&#8217;s total outstanding shares of common stock may be sold into the public market at any point, which could cause the market price of the combined company&#8217;s common stock to drop significantly, even if the combined company is doing well; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">there may be adverse reactions or changes in business relationships resulting from announcement or completion of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the combined company will have broad discretion in the use of its cash reserves and may not use them effectively; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the combined company expects to continue to incur increased costs as a result of operating as a public company, and its management will be required to devote substantial time to compliance initiatives and corporate governance practices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the combined company does not anticipate paying any cash dividends on its capital stock in the foreseeable future, other than the special cash dividend that Sesen Bio may pay to Sesen Bio stockholders in connection with the consummation of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provisions in the combined company&#8217;s certificate of incorporation, its bylaws or Delaware law might discourage, delay or prevent a change in control of the company or changes in its management, which may depress the price of its common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the COVID-19 pandemic may have an adverse effect on the business of Sesen Bio, Carisma and the combined company, the medical community and the global economy; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">securities analysts&#8217; published reports could cause a decline in the price of the combined company&#8217;s stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foregoing risks should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere. Sesen Bio and Carisma can give no assurance that the conditions to the merger will be satisfied. For further discussion of the factors that may cause Sesen Bio, Carisma or the combined company&#8217;s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, or for a discussion of risks associated with the ability of Sesen Bio and Carisma to complete the merger and the effect of the merger on the business of Sesen Bio, Carisma and the combined company, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Risk Factors</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tRIFA">26</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC by Sesen Bio. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Where You Can Find More Information</font><font style="letter-spacing:0.2pt;">&#8221; on page <a href="#tWYCF">404</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of operations of Sesen Bio, Carisma or the combined company could differ materially from the forward-looking statements. All forward-looking statements in this proxy statement/prospectus are current only as of the date of this proxy statement/prospectus. Sesen Bio and Carisma do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made, the occurrence of unanticipated events or any new information that becomes available in the future.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">120</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTSMO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE SPECIAL MEETING OF SESEN BIO STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Date, Time and Place</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The Sesen Bio special meeting will be held on March 2, 2023, at www.proxydocs.com/SESN commencing at 10:00 a.m., Eastern Time, which will be a virtual meeting held exclusively via live webcast. Sesen Bio is sending this proxy statement/prospectus to Sesen Bio stockholders in connection with the solicitation of proxies by the Sesen Bio board of directors for use at the Sesen Bio special meeting and any adjournments or postponements of the Sesen Bio special meeting. This proxy statement/prospectus is first being furnished to Sesen Bio stockholders on or about &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2023. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purposes of the Sesen Bio Special Meeting</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The purposes of the Sesen Bio special meeting are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Original Merger Agreement, as amended by the Merger Agreement Amendment, copies of which are attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annexes A-1 and A-2</font><font style="letter-spacing:0.2pt;">, respectively, to this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, and the change of control of Sesen Bio resulting from the merger; </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:7.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an amendment to the Sesen Bio Certificate of Incorporation, to (a) effect a reverse stock split of the issued and outstanding shares of Sesen Bio common stock at a ratio of 1-for-20, with the implementation and timing of the reverse stock split to be determined in the discretion of the Sesen Bio board of directors and as agreed to by Carisma at or prior to the closing of the merger, or in the sole discretion of the Sesen Bio board of directors if Proposal No. 1 is not approved, and (b) if and when the reverse stock split is effected, reduce the number of authorized shares of Sesen Bio common stock, in the form attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex G</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an amendment and restatement of the 2014 Incentive Plan to, among other things, (a)&#160;increase the number of shares of Sesen Bio common stock reserved for issuance under the 2014 Incentive Plan, and (b)&#160;extend the term of the 2014 Incentive Plan to the tenth (10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;">) anniversary of the closing of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">4.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an amendment to the 2014 ESPP to increase the number of shares of Sesen Bio common stock reserved for issuance under the 2014 ESPP to 6,568,655 shares of Sesen Bio common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">5.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to consider and vote upon a proposal to approve an adjournment of the Sesen Bio special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 or 2; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">6.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to transact such other business as may properly come before the Sesen Bio special meeting or any adjournment or postponement thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recommendation of the Sesen Bio Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors has determined and believes that it is fair to, advisable and in the best interests of Sesen Bio and Sesen Bio stockholders to approve, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Merger Agreement and has approved such proposal. The Sesen Bio board of directors unanimously recommends that Sesen Bio stockholders vote &#8220;FOR&#8221; Proposal No.&#160;1 to approve, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders in connection with the merger pursuant to the terms of the Merger Agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors has determined and believes that it is fair to, advisable and in the best interests of Sesen Bio and Sesen Bio stockholders to approve the amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the authorized shares of Sesen </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">121</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Bio common stock, as described in this proxy statement/prospectus and has approved the amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and has approved such proposal. The Sesen Bio board of directors unanimously recommends that Sesen Bio stockholders vote &#8220;FOR&#8221; Proposal No. 2 to approve the amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split, as described in this proxy statement/prospectus. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors has determined and believes that it is fair to, advisable and in the best interests of Sesen Bio and Sesen Bio stockholders to approve the amendment and restatement of the 2014 Incentive Plan, as described in this proxy statement/prospectus. The Sesen Bio board of directors unanimously recommends that Sesen Bio stockholders vote &#8220;FOR&#8221; Proposal No. 3 to approve the amendment and restatement of the 2014 Incentive Plan, as described in this proxy statement/prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors has determined and believes that it is fair to, advisable and in the best interests of Sesen Bio and Sesen Bio stockholders to approve the amendment to the 2014 ESPP, as described in this proxy statement/prospectus. The Sesen Bio board of directors unanimously recommends that Sesen Bio stockholders vote &#8220;FOR&#8221; Proposal No. 4 to approve the amendment to the 2014 ESPP, as described in this proxy statement/prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors has determined and believes that it is fair to, advisable, and in the best interests of Sesen Bio and Sesen Bio stockholders to approve the adjournment of the Sesen Bio special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 or 2 and has approved such proposal. The Sesen Bio board of directors unanimously recommends that Sesen Bio stockholders vote &#8220;FOR&#8221; Proposal No. 5 to adjourn the Sesen Bio special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 or 2. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Record Date and Voting Power</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Only holders of record of Sesen Bio common stock at the close of business on the record date, January&#160;17, 2023, are entitled to notice of, and to vote at, the Sesen Bio special meeting. There were 25&#160;</font> <font style="letter-spacing:0.2pt;">holders of record of Sesen Bio common stock at the close of business on the record date. At the close of business on the record date, 202,759,043 shares of Sesen Bio common stock were issued and outstanding. Each share of Sesen Bio common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval. </font></div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting and Revocation of Proxies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The proxy accompanying this proxy statement/prospectus is solicited on behalf of the Sesen Bio board of directors for use at the Sesen Bio special meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are the &#8220;record holder&#8221; of your shares, meaning that you own your shares in your own name and not through a broker, bank or other nominee, you may vote in one of three ways prior to the Sesen Bio special meeting: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">You may vote over the internet.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;You may vote your shares by following the instructions in the enclosed proxy card. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">You may vote by telephone.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;You may vote your shares by following the instructions in the enclosed proxy card. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">You may vote by mail.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;You may vote by completing, dating and signing the enclosed proxy card and promptly mailing it in the postage-paid envelope provided. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">You may also vote during the Sesen Bio special meeting. To be admitted to the Sesen Bio special meeting and vote your shares, you must register in advance at www.proxydocs.com/SESN and provide the control number as set forth on the proxy card. After completing your registration, you will receive further instructions via email, including a unique link to access the Sesen Bio special meeting. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All proxies that are executed or are otherwise submitted over the internet or by telephone will be voted on the matters set forth in this proxy statement in accordance with the stockholders&#8217; instructions. However, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">122</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">if no choice is specified on a proxy as to one or more of the proposals, the proxy will be voted in accordance with the Sesen Bio board of directors&#8217; recommendations on such proposals as set forth in this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">After you have submitted a proxy, you may still change your vote and revoke your proxy by doing any one of the following things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">submitting a new proxy via the internet or telephone by following the instructions on the enclosed proxy card; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">signing another proxy card and arranging for delivery of that proxy card by mail by 11:59&#160;p.m., Eastern Time, the day before the Sesen Bio special meeting; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">giving Sesen Bio&#8217;s Corporate Secretary a written notice before the Sesen Bio special meeting that you want to revoke your proxy; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">voting during the Sesen Bio special meeting. Your attendance at the Sesen Bio special meeting alone will not revoke a previously submitted proxy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio will count your vote in accordance with the last instruction Sesen Bio receives from you prior to the closing of the polls, whether your instruction is received by internet, telephone, mail, or at the Sesen Bio special meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shares Held in &#8220;Street Name&#8221;</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">If the shares of Sesen Bio common stock you own are held in &#8220;street name&#8221; by a broker, bank or other nominee, then that broker, bank or other nominee, as the record holder of your shares of Sesen Bio common stock, is required to vote your shares of Sesen Bio common stock according to your instructions. In order to vote your shares of Sesen Bio common stock, change your vote or revoke your instructions, you will need to follow the directions your broker, bank or other nominee provides you. Many brokers, banks or other nominees also offer the option of providing for voting over the internet or by telephone, instructions for which, if available, would be provided by such broker, bank or other nominee on the voting instruction form that it delivers to you. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you do not give instructions to your broker, bank or other nominee, such nominee can vote your shares of Sesen Bio common stock with respect to &#8220;discretionary&#8221; items but not with respect to &#8220;non-discretionary&#8221; items. Discretionary items are proposals considered routine under certain rules applicable to brokers and on which your broker may vote shares of Sesen Bio common stock held in &#8220;street name&#8221; in the absence of your voting instructions. On non-discretionary items for which you do not give your broker instructions, your shares of Sesen Bio common stock will be treated as broker non-votes. It is anticipated that Proposal Nos. 1, 3 and 4 will be non-discretionary. To make sure that your vote is counted, you should instruct your broker to vote your shares, following the procedures provided by the institution that holds your shares. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If your shares are held in &#8220;street name,&#8221; you are also invited to attend and vote your shares of Sesen Bio common stock at the Sesen Bio special meeting live via webcast. After completing your registration in advance at www.proxydocs.com/SESN, you will receive further instructions via email, including a unique link to access the Sesen Bio special meeting. As part of the registration process, you must enter the control number located on your voting instruction form. You will also need to provide the registered name on your account and the name of your broker, bank or other nominee as part of the registration process. You may be instructed to obtain a legal proxy from your broker, bank or nominee and to submit a copy in advance of the meeting. Further instructions will be provided to you as part of your registration process. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If your shares of Sesen Bio common stock are held in &#8220;street name,&#8221; you must follow the instructions provided by your broker, bank or other nominee to revoke your voting instructions, or, if you have obtained a legal proxy to vote your shares of Sesen Bio common stock at the Sesen Bio special meeting, by attending the Sesen Bio special meeting and voting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Required Vote</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The presence, in person or represented by proxy, of Sesen Bio stockholders holding at least a majority in voting power of the shares of Sesen Bio common stock issued and outstanding and entitled to vote at the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">123</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:176pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio special meeting is necessary to constitute a quorum at the Sesen Bio special meeting. Abstentions and broker non-votes will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the Sesen Bio special meeting. Approval of Proposal Nos. 1, 3, 4 and 5 requires the affirmative vote of a majority in voting power of the votes cast by the holders of all shares of Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting and entitled to vote on the matter. Approval of Proposal No. 2 requires the affirmative vote of the holders of a majority of the outstanding shares of Sesen Bio common stock entitled to vote on the record date for the Sesen Bio special meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Votes will be counted by the inspector of election appointed for the Sesen Bio special meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221; votes, abstentions and broker non-votes. Abstentions will have the same effect as a vote &#8220;AGAINST&#8221; Proposal No. 2, but will have no effect on the outcome of Proposal Nos.&#160;1, 3, 4 and 5. Proposal Nos. 2 and 5 are matters on which Sesen Bio expects brokers, banks or other nominees to have discretionary authority to vote uninstructed shares and, therefore, broker non votes are not expected with respect to these proposals. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Proposal No. 1 is conditioned upon the approval of Proposal No. 2, and the merger cannot be consummated without the approval of Proposal Nos. 1 and 2. Proposal Nos. 3 and 4 are conditioned upon Proposal Nos. 1 and 2. Proposal No. 2 is not conditioned on the approval of any other proposal. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Solicitation of Proxies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition to solicitation by mail, the directors, officers, employees and agents of Sesen Bio and Carisma may solicit proxies from Sesen Bio stockholders by personal interview, telephone or otherwise. Sesen Bio and Carisma will share equally the cost of printing and filing this proxy statement/prospectus and the proxy card. Sesen Bio also may be required to reimburse brokers, banks and other custodians, nominees and fiduciaries or their respective agents for reasonable expenses incurred in forwarding proxy materials to beneficial owners of Sesen Bio common stock. Sesen Bio has engaged MacKenzie Partners to assist in the solicitation of proxies and provide related advice and informational support. Sesen Bio will pay the fees of MacKenzie Partners, which Sesen Bio expects to be approximately $20,000, plus reimbursement of out-of-pocket expenses. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Matters</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this proxy statement/prospectus, the Sesen Bio board of directors does not know of any business to be presented at the Sesen Bio special meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the Sesen Bio special meeting, it is intended that the shares of Sesen Bio common stock represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">124</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHME">&#8203;</a><a name="tBOTM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE MERGER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">This section and the section entitled &#8220;The Merger Agreement&#8221; in this proxy statement/prospectus describe the material aspects of the merger, including the Merger Agreement. While Sesen Bio and Carisma believe that this description covers the material terms of the merger and the Merger Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus for a more complete understanding of the merger and the Merger Agreement, including the Original Merger Agreement, as amended by the Merger Agreement Amendment, attached as Annexes A-1 and A-2, respectively, the opinion of SVB Securities attached as Annex B, and the other documents to which you are referred herein. See the section entitled &#8220;Where You Can Find More Information&#8221; on page <a href="#tWYCF">404</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Background of the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In an effort to enhance stockholder value, the Sesen Bio board of directors, in consultation with members of the Sesen Bio management team, regularly reviews and discusses Sesen Bio&#8217;s near and long-term operating and strategic priorities. Among other things, these reviews and discussions focus on the opportunities and risks associated with Sesen Bio&#8217;s development programs, financial condition and its strategic relationships and potential long-term strategic options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;22, 2022, the Sesen Bio board of directors held a meeting at which members of Sesen Bio management, Michael O&#8217;Donnell, M.D., regulatory consultant to Sesen Bio, Neal D. Shore, M.D., FACS, clinical consultant to Sesen Bio, and a representative of Hogan Lovells, Sesen Bio&#8217;s outside legal counsel, were present. During the meeting, Dr.&#160;O&#8217;Donnell and Dr.&#160;Shore reviewed, among other things, the potential trial size scenarios for an additional Phase&#160;3 clinical trial for Vicineum, which the FDA previously confirmed would be required for a potential resubmission of a BLA. A discussion ensued regarding Sesen Bio&#8217;s cash runway and potential financing needs and the commercial viability of Vicineum if Sesen Bio conducted a successful clinical trial. Sesen Bio management discussed strategic alternatives for Sesen Bio, including conducting an additional Phase&#160;3 clinical trial for Vicineum, exploring a potential strategic transaction, and acquiring a new product. Monica Forbes, Sesen Bio&#8217;s Chief Financial Officer, discussed the estimated financial impacts of an additional Phase&#160;3 clinical trial for Vicineum, including the estimated time to achieve profitability and the need for additional financing to achieve profitability, with the estimated growth in Sesen Bio value barely outpacing the estimated dilution to existing stockholders. A discussion ensued regarding the process and timeline for conducting an additional Phase&#160;3 clinical trial for Vicineum, the financial impacts of the additional Phase&#160;3 clinical trial and whether other companies would be interested in a strategic acquisition of Vicineum. Following discussion, the Sesen Bio board of directors authorized and directed Sesen Bio management to continue planning for an additional Phase&#160;3 clinical trial for Vicineum and indicated that it would evaluate whether to conduct an additional Phase&#160;3 clinical trial in the third quarter of 2022 following an anticipated June&#160;2022 meeting with the FDA. Erin Clark, Sesen Bio&#8217;s Vice President of Corporate Strategy and Investor Relations, reviewed next steps for exploring a potential strategic alternative transaction, including the engagement of a financial advisor, and a possible timeline for a strategic alternative review process. Ms.&#160;Clark also discussed that Sesen Bio management would assess the feasibility of acquiring a new product and prepare a recommendation for the Sesen Bio board of directors to consider. Following further discussion, the Sesen Bio board of directors authorized Sesen Bio management to evaluate potential strategic alternatives, including (i)&#160;conducting an additional Phase&#160;3 clinical trial for Vicineum, (ii)&#160;exploring a potential strategic transaction, and (iii)&#160;acquiring a new product, in order to maximize value for Sesen Bio&#8217;s stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following the April&#160;22, 2022 board meeting, Sesen Bio management thoroughly evaluated four highly-qualified financial advisors, including SVB Securities. Sesen Bio management provided a summary of its evaluation and made a recommendation to the Sesen Bio board of directors. On May&#160;2, 2022, the Sesen Bio board of directors authorized by unanimous written consent the engagement of SVB Securities to serve as Sesen Bio&#8217;s financial advisor in connection with a process to review potential strategic alternative transactions based on, among other factors, the qualifications, professional reputation and industry expertise of SVB Securities. This engagement was memorialized in an engagement letter, dated May&#160;6, 2022, between Sesen Bio and SVB Securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On May&#160;3, 2022, following the approval of the Sesen Bio board of directors to engage SVB Securities to serve as Sesen Bio&#8217;s financial advisor in connection with a process to review potential strategic alternative </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">125</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">transactions, Sesen Bio announced that it initiated a process to evaluate potential strategic alternatives with the goal of maximizing stockholder value. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On May&#160;9, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of SVB Securities and Hogan Lovells were present. During the meeting, Dr.&#160;Rachelle Dillon, Ph.D., Sesen Bio&#8217;s Executive Director of Clinical Operations, provided a summary of Sesen Bio&#8217;s activities in planning for an additional Phase&#160;3 clinical trial for Vicineum. In addition, at the meeting, representatives of SVB Securities reviewed potential strategic alternative transactions for Sesen Bio. Representatives of SVB Securities and Ms.&#160;Clark reviewed the status of the identification of potential counterparties for a strategic transaction, the proposed timeline for a potential strategic transaction and estimated wind-down costs in the event of a strategic transaction. A discussion ensued regarding potential strategic alternatives for Sesen Bio. Sesen Bio management discussed with the Sesen Bio board of directors potential ways to monetize potential milestone payments remaining under a 2016 license agreement with Roche, pursuant to which Sesen Bio had granted Roche an exclusive, worldwide license to develop and commercialize all patent rights and know-how related to the legacy IL-6 program, or the Roche licensed intellectual property, and had received $42.5&#160;million in milestone payments to date. The Sesen Bio board of directors authorized Sesen Bio management to pursue a potential transaction with Roche related to the Roche licensed intellectual property. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On May&#160;11, 2022, Sesen Bio management updated the Sesen Bio board of directors on discussions with senior management at Roche, who requested a formal proposal for a potential transaction related to the Roche licensed intellectual property. Sesen Bio management provided proposed terms for a potential transaction with Roche for the Sesen Bio board of directors&#8217; review and consideration. Subsequently, Sesen Bio management engaged in negotiations with Roche for a potential transaction related to the Roche licensed intellectual property. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On May&#160;25, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells were present. Members of Sesen Bio management provided an update on Sesen Bio&#8217;s activities in planning for an additional Phase&#160;3 clinical trial. Members of Sesen Bio management also provided an overview of the strategic alternative review process, including the proposed selection methodology and key evaluation criteria for identifying potential counterparties for a strategic transaction. A discussion ensued regarding strategic considerations for pursuing the additional Phase&#160;3 clinical trial or a strategic alternative transaction. Sesen Bio&#8217;s non-employee directors also met in executive session with a representative of Hogan Lovells to discuss a potential conflict of interest of a Sesen Bio director affiliated with a potential counterparty for a strategic transaction. All non-employee directors, including the director with a potential conflict of interest, agreed that the director would be recused from discussions of the strategic alternative review process until the potential conflict of interest no longer exists. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During May&#160;2022, at the direction of Sesen Bio following approvals from the Sesen Bio board of directors at the meeting held on April&#160;22, 2022 and by unanimous written consent of the Sesen Bio board of directors on May&#160;2, 2022, SVB Securities contacted 130 companies to determine the level of interest in a potential strategic transaction with Sesen Bio. Of those companies, 62 expressed interest in the strategic alternative review process and, at the direction of Sesen Bio, SVB Securities requested that such companies submit non-binding indications of interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From May&#160;18, 2022 to June&#160;7, 2022, 42 companies submitted non-binding indications of interest with respect to a potential strategic transaction with Sesen Bio based on publicly available information, including indications from Carisma and the companies referred to as Party A, Party B, Party C and Party D, as described below: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The indication of interest from Carisma proposed a reverse merger transaction with an ascribed value of Sesen Bio of $110.0&#160;million (assuming closing net cash of $100.0&#160;million) and an ascribed value of Carisma of $196.0&#160;million, with an implied ownership interest in the combined company of approximately 30.0% for existing Sesen Bio stockholders. Carisma&#8217;s proposal also contemplated a concurrent financing of $30.0&#160;million committed by existing Carisma investors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The indication of interest from Party A, a privately held company, proposed a reverse merger transaction with an ascribed value of Sesen Bio of $150.0&#160;million (assuming closing net cash of </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">126</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">$100.0&#160;million) and an ascribed value of Party A of $249.0&#160;million, with an implied ownership interest in the combined company of approximately 40.0% for existing Sesen Bio stockholders. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The indication of interest from Party B, a privately held company, proposed a reverse merger transaction with an ascribed value of Sesen Bio of $100.0&#160;million (assuming closing net cash of $100.0&#160;million) and an ascribed value of Party B of $200.0&#160;million, with an implied ownership interest in the combined company of approximately 33.0% for existing Sesen Bio stockholders. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The indication of interest from Party C, a privately held company, proposed a reverse merger transaction with an ascribed value of Sesen Bio of $130.0&#160;million (assuming closing net cash of $100.0&#160;million) and an ascribed value of Party C of $310.0&#160;million, with an implied ownership interest in the combined company of approximately 30.0% for existing Sesen Bio stockholders. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The indication of interest from Party D, a privately held company, proposed a reverse merger transaction with an ascribed value of Sesen Bio of $106.0&#160;million (assuming closing net cash of $100.0&#160;million) and an ascribed value of Party D of $159.0&#160;million, with an implied ownership interest in the combined company of approximately 40.0% for existing Sesen Bio stockholders. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Also during this period, Sesen Bio entered into confidentiality agreements with 18 of the companies that submitted indications of interest. 17 of the 18 confidentiality agreements, including those of Carisma, Party A, Party B, Party C and Party D, contained standstill provisions that expired 24 months after their execution. The remaining confidentiality agreement contained a standstill provision that expires 12&#160;months after its execution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From May&#160;20, 2022 to June&#160;7, 2022, members of Sesen Bio management and representatives of SVB Securities analyzed the 42 indications of interest using the following key evaluation criteria discussed by the Sesen Bio board of directors at a meeting on May&#160;25, 2022: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">business assessment, including each company&#8217;s proof of concept data generated to date, clinical development stage, pipeline depth, magnitude of potential clinical impact, existing standard of care, potential competitors, commercial potential, intellectual property, platform technology or drug discovery capabilities, scientific personnel and manufacturing capabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">management and board quality, including prior public company executive experience, and investor quality, including duration of investment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">public company readiness, including analysis of existing potential public company infrastructure and existing audited financials and/or retention of an independent registered public accounting firm; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ability/need to raise contingent financing with consideration given for any existing investor commitments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">material inflection points, including meaningful clinical data readouts or regulatory submissions for programs in the relative near term; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ability to reach inflection points with pro&#160;forma cash; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">current Sesen Bio stockholder ownership post-transaction. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on this analysis, members of Sesen Bio management identified 15 potential counterparties, including Carisma, Party A, Party B, Party C and Party D, to present to Sesen Bio management and/or the Sesen Bio board of directors. Since the company affiliated with the Sesen Bio director who had a potential conflict of interest was not one of the 15 potential counterparties identified, such director was able to resume full participation in discussions of the strategic alternative review process because the potential for a conflict of interest no longer existed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;15 and 16, 2022, the Sesen Bio board of directors held a meeting in person and by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells and SVB Securities were present. Sesen Bio&#8217;s directors met in executive session with Ms.&#160;Clark and a representative of Hogan Lovells present. Dr.&#160;Thomas Cannell, Sesen Bio&#8217;s President and Chief Executive Officer, provided an update on recent changes in the NMIBC landscape and the strategic alternative review process. A discussion ensued regarding strategic considerations for an additional Phase&#160;3 clinical trial and a strategic </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">127</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">alternative transaction. Sesen Bio&#8217;s directors then met in executive session with a representative of Hogan Lovells present to further discuss, among other things, the potential alternatives for Sesen Bio, which included conducting an additional Phase&#160;3 clinical trial for Vicineum, exploring a potential strategic transaction, acquiring a new product, and liquidation. During this executive session, the Sesen Bio board of directors considered the cost, infrastructure needs, and time that would be involved in acquiring a new product and developing it for commercialization and determined not to pursue that strategic alternative at this time. Members of Sesen Bio management team and representatives of SVB Securities rejoined the meeting at which time Ms.&#160;Clark provided an update on the strategic alternative review process. Ms.&#160;Clark discussed the potential benefits of a reverse merger transaction for Sesen Bio stockholders, reviewed the proposed timeline and estimated wind-down costs in the event of a strategic transaction. Ms.&#160;Clark also discussed that Sesen Bio was exploring the potential sale of the Vicineum asset in the event the Sesen Bio board of directors determined to cease further development of Vicineum. A discussion ensued among the members of the Sesen Bio board of directors. Representatives of SVB Securities (i)&#160;reviewed the selection methodology and key evaluation criteria that members of Sesen Bio management, with the assistance of SVB Securities, used to analyze the 42 indications of interest received by Sesen Bio to identify 15 potential counterparties to present to the Sesen Bio board of directors and/or Sesen Bio management, (ii)&#160;provided perspectives on each of the 15 potential counterparties, (iii)&#160;discussed next steps in the strategic alternative review process, and (iv)&#160;reviewed the timeline for a potential strategic transaction. Members of Sesen Bio management and representatives of SVB Securities responded to questions regarding the key evaluation criteria. Following discussion, the Sesen Bio board of directors authorized SVB Securities to move forward with presentations, with the five potential counterparties meeting the most key evaluation criteria, including Party A, Party B and Party C, to present to the full Sesen Bio board of directors and the remaining ten potential counterparties identified based on the key evaluation criteria, including Carisma and Party D, to present first to Sesen Bio management and then, if warranting further consideration, to the full Sesen Bio board of directors. Dr.&#160;Dillon joined the meeting and provided an update on Sesen Bio&#8217;s activities in planning for an additional Phase&#160;3 clinical trial, including the projected timeline and next steps for evaluating whether to pursue an additional Phase&#160;3 clinical trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Over the course of June and July&#160;2022, ten potential counterparties presented to Sesen Bio management and five potential counterparties, including two (Carisma and Party D) that first presented to Sesen Bio management, presented to the full Sesen Bio board of directors about their respective businesses. Prior to the commencement of the presentations, two of the initial five potential counterparties that were identified to present to the Sesen Bio board of directors voluntarily withdrew from the process. At the direction of the Sesen Bio board of directors, SVB Securities informed the other potential counterparties that had submitted indications of interest that they were not advancing to the next stage of discussions based on determinations by the Sesen Bio board of directors, informed by the perspectives of Sesen Bio management and SVB Securities, that each such counterparty was not reasonably likely to provide the best opportunity to maximize value for Sesen Bio&#8217;s current stockholders based on most of the key evaluation criteria. Following these presentations, the Sesen Bio board of directors further evaluated its initial business assessment of the five potential counterparties that presented to the Sesen Bio board of directors and provided feedback to Sesen Bio management in advance of the July&#160;25, 2022 board meeting to facilitate robust discussions before selecting the lead counterparties. During this period, Sesen Bio management also engaged in discussions with Roche about the possibility of Roche purchasing the Roche licensed intellectual property. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;13, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and a representative of Hogan Lovells were present. Dr.&#160;Cannell provided an update on the negotiations of an asset purchase agreement between Sesen Bio and Roche, pursuant to which Roche would purchase the Roche licensed intellectual property for up to $70.0&#160;million, including a $40.0&#160;million payment to Sesen Bio upon execution of the agreement and an additional $30.0&#160;million payment to Sesen Bio upon the achievement by Roche of a specified milestone. A discussion ensued regarding, among other things, the associated proceeds having the potential to increase the range and attractiveness of strategic alternatives for Sesen Bio to consider and create the opportunity for a CVR that could provide enhanced value to Sesen Bio&#8217;s stockholders. Following discussion, the Sesen Bio board of directors unanimously approved and authorized Sesen Bio management to execute the Roche Asset Purchase Agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">128</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and a representative of Hogan Lovells were present. Dr.&#160;Cannell provided an update on Sesen Bio&#8217;s July&#160;11, 2022 meeting with the FDA to discuss an additional Phase&#160;3 clinical trial for Vicineum, including the required design elements of an additional Phase&#160;3 clinical trial confirmed by the FDA. Dr.&#160;Cannell discussed that based on the agreed upon design elements and resulting trial size, estimated timing for enrollment and timing of sufficient data for BLA resubmission, a U.S. launch was projected between mid-2030 to mid-2033 with total trial cost estimated between $200.0&#160;million and $243.0&#160;million (assuming an approximately 1,000-patient trial). Ms.&#160;Forbes reviewed the estimated financial impact of an additional Phase&#160;3 clinical trial for Vicineum, including the estimated time to achieve profitability, the need for significant additional financing to achieve profitability, the anticipated negative return with dilution to existing stockholders outpacing the estimated growth in Sesen Bio&#8217;s value, and that the current cash runway was projected to run out before the first major inflection point of data disclosure was projected to occur. Ms.&#160;Forbes also reviewed the total estimated, risk-adjusted valuation of Sesen Bio, timing of first inflection point and cash runway in the case of an additional Phase&#160;3 clinical trial and in the case of a strategic alternative transaction. Members of management discussed the estimated impact of a potential liquidation, including that a meaningful amount of Sesen Bio&#8217;s current cash balance would need to be held back to cover current liabilities and future potential liabilities triggered by a liquidation strategy. Based on the FDA feedback on the requirements for an additional Phase&#160;3 clinical trial, the evolving competitive landscape and the resulting financial analysis for an additional Phase&#160;3 clinical trial, as well as the view that liquidation was not reasonably likely to create greater value for Sesen Bio stockholders than a strategic alternative transaction, Sesen Bio management recommended pausing further development of Vicineum in the U.S. and pursuing a strategic alternative transaction. Ms.&#160;Forbes also reviewed estimated wind-down costs in the event of a strategic transaction and possible next steps if the Sesen Bio board of directors were to approve pausing further development of Vicineum and pursue a strategic alternative transaction. Following discussion, the Sesen Bio board of directors unanimously approved pausing further development of Vicineum in the U.S., pursuing a strategic alternative transaction and implementing a restructuring plan to reduce operating expenses and to better align its workforce with the needs of its business following the decision to pause further development of Vicineum in the U.S. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;18, 2022, Sesen Bio announced that it made the strategic decision to voluntarily pause further development of Vicineum in the U.S. based on discussions with the FDA and a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase&#160;3 clinical trial for Vicineum for the treatment of NMIBC. Sesen Bio also announced that it would turn its primary focus to the assessment of strategic alternatives and that it intended to seek a partner with larger infrastructure for the further development of Vicineum. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Also on July&#160;18, 2022, Sesen Bio announced that it had entered into the Roche Asset Purchase Agreement following execution of such agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;25, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells were present. Ms.&#160;Clark reviewed management&#8217;s proposed corporate strategy for 2022, including pursuing a potential strategic alternative transaction or, in the event a strategic alternative transaction is not completed, a liquidation and dissolution. Ms.&#160;Clark then reviewed the five remaining potential counterparties, Carisma, Party A, Party B, Party C and Party D, the presentations made by each potential counterparty and the due diligence conducted to date on each of the potential counterparties, including their respective business, management, board and investor quality, public company readiness, ability/need to raise contingent financing, material near-term inflection points, and ability to reach inflection points with pro&#160;forma cash. Following discussion, the Sesen Bio board of directors determined to prioritize discussions with Carisma, Party A and Party B based on the business assessment of each such counterparty after the presentations to the Sesen Bio board of directors, the terms of each such counterparty&#8217;s proposed indication of interest, and the results of due diligence conducted to date, and authorized and directed Sesen Bio management and SVB Securities to move forward with Carisma, Party A and Party B into a technical due diligence process, including a comprehensive business, regulatory, intellectual property, legal and financial analysis of all three potential counterparties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the period from July&#160;25, 2022 through August&#160;19, 2022, members of Sesen Bio management and representatives of SVB Securities engaged in deep technical due diligence activities with each of Carisma, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">129</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Party A and Party B, and, at the direction of the Sesen Bio board of directors, SVB Securities informed the other remaining counterparties that Sesen Bio was prioritizing discussions with other parties. On August&#160;4, 2022, at the direction of the Sesen Bio board of directors, Sesen Bio management terminated diligence activities and discussions with Party B based on the due diligence and business discussions conducted to date, particularly the potential regulatory risks related to Party B&#8217;s lead program that were discussed by the Sesen Bio board of directors in the July&#160;25, 2022 meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;11, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells were present. Ms.&#160;Clark provided an update on the strategic alternative review process, including an overview of the due diligence process and possible timeline for the two remaining potential counterparties. A discussion ensued, including about the possibility that based on Sesen Bio&#8217;s estimated cash balance, Sesen Bio could issue a special cash dividend of up to $25.0 million in the aggregate to Sesen Bio stockholders to deliver additional value to Sesen Bio stockholders as a result of the payment received by Sesen Bio pursuant to the Roche APA and careful management of operating expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the period from August&#160;11, 2022 through August&#160;18, 2022, members of Sesen Bio management and representatives of SVB Securities engaged in additional due diligence activities with each of Carisma and Party A. Also during this period, Sesen Bio management proposed to Carisma that Sesen Bio be permitted to issue a special cash dividend of up to $25.0 million to Sesen Bio stockholders.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based on the key evaluation criteria and the technical and other due diligence activities undertaken to date by Sesen Bio management on each of Carisma and Party A, the Sesen Bio board of directors and Sesen Bio management conducted an additional due diligence call with key opinion leaders about Carisma&#8217;s proprietary cell therapy platform on August&#160;19, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Later on August&#160;19, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells were present. During the meeting, a representative of Hogan Lovells reviewed the fiduciary duties of the Sesen Bio board of directors in the context of considering a potential reverse merger transaction. Ms.&#160;Clark reviewed the key evaluation criteria that Sesen Bio management, with the assistance of SVB Securities, used to analyze the potential counterparties and the technical and other due diligence activities undertaken to date by Sesen Bio management and Sesen Bio&#8217;s consultants and advisors on each of Carisma and Party A. Based on the thorough assessment performed by Sesen Bio management and Sesen Bio&#8217;s consultants and advisors, including technical due diligence, and the belief that a transaction with Carisma would provide value to Sesen Bio stockholders with significant upside potential, Sesen Bio management proposed that Sesen Bio pursue a reverse merger transaction with Carisma. Following discussion, the Sesen Bio board of directors approved and authorized Sesen Bio management to enter into negotiations with Carisma. In determining to pursue a reverse merger transaction with Carisma, the Sesen Bio board of directors considered that, in its judgment, Carisma provided the best opportunity to maximize value for Sesen Bio&#8217;s current stockholders, including after considering the potential advantages of Carisma over Party A with respect to the potential breadth and application of Carisma&#8217;s scientific platform, the potential value inflection milestones during the anticipated cash runways for the two parties, and a comparison of the potential risks regarding regulatory approval of each. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;19, 2022, Sesen Bio delivered a counterproposal to Carisma representing a $20&#160;million premium to Sesen Bio&#8217;s estimated cash balance at closing. Also on August&#160;19, 2022, representatives of Hogan Lovells delivered a first draft of the proposed merger agreement for the transaction to representatives of WilmerHale, Carisma&#8217;s outside legal counsel. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the period from August&#160;19, 2022 through September&#160;20, 2022, representatives of Sesen Bio, including Hogan Lovells, and representatives of Carisma, including WilmerHale, completed confirmatory due diligence on each other and negotiated the terms of the merger agreement, including the definition of net cash, the calculation of the exchange ratio, the representations and warranties and operating covenants of each party, the amount of the termination fees and the expense reimbursement cap, and the terms of the forms of CVR Agreement, support agreement, and lock-up agreement. In evaluating and negotiating the exchange ratio, Sesen Bio considered Carisma&#8217;s valuation based on its last financing round along with other factors that favored increasing the Sesen Bio valuation, including a decline in general market conditions </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">130</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and limited opportunities available for privately-held biotechnology companies to access the capital markets for financing through an initial public offering. Also during this period, Carisma engaged in discussions with potential investors for an equity financing in Carisma that would close immediately prior to the closing of Sesen Bio&#8217;s transaction with Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;23, 2022, Carisma delivered a revised proposal with a stated value for Sesen Bio of $140.0&#160;million, which represented a $15.0&#160;million premium to Sesen Bio&#8217;s estimated cash balance at closing, and agreeing to a $125.0&#160;million cash minimum and permitting Sesen Bio to issue a special cash dividend of excess cash and subject to the minimum net cash condition. On August&#160;24, 2022, Sesen Bio requested more information on Carisma&#8217;s revised proposal. On August 26, 2022, Sesen Bio and Carisma agreed to a $100.0 million cash minimum and to permit Sesen Bio to issue a special cash dividend of an aggregate amount of up to $25.0 million subject to the $100.0 million cash minimum. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;14, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells were present. Dr.&#160;Cannell and Ms.&#160;Clark provided an update on the negotiations with Carisma, the anticipated timing of Carisma&#8217;s pre-closing financing and the anticipated timeline for a potential transaction with Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells and SVB Securities were present. Sesen Bio&#8217;s directors met in executive session with representatives of Hogan Lovells to discuss, among other things, the potential benefits and risks of the proposed transaction with Carisma. Following the executive session, Ms.&#160;Clark reviewed the anticipated timeline and next steps for the proposed transaction with Carisma and the estimated wind-down costs if the proposed transaction with Carisma were completed. Representatives of SVB Securities reviewed SVB Securities&#8217; financial analysis of the proposed transaction with Carisma. Following discussion with the directors, SVB Securities then rendered to the Sesen Bio board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion dated September&#160;20, 2022, that, as of such date and based upon and subject to the assumptions made, and the qualifications and limitations upon the review undertaken by SVB Securities in preparing its opinion, the exchange ratio to be paid by Sesen Bio pursuant to the terms of the Original Merger Agreement was fair, from a financial point of view, to Sesen Bio. During the meeting, a representative from Hogan Lovells again reviewed the fiduciary duties of the Sesen Bio board of directors in connection with the proposed transaction with Carisma and reviewed the material terms of the Original Merger Agreement. The Sesen Bio board of directors discussed various considerations with respect to the proposed transaction with Carisma, as summarized in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Sesen Bio Reasons for the Merger.</font><font style="letter-spacing:0.2pt;">&#8221; Following discussion, the Sesen Bio board of directors unanimously (i)&#160;determined that the merger and other transactions contemplated by the Original Merger Agreement are advisable and in the best interests of Sesen Bio and its stockholders, (ii)&#160;approved and declared advisable the Merger Agreement, the merger and the other transactions contemplated by the Merger Agreement, and (iii)&#160;resolved to recommend that the Sesen Bio stockholders approve the issuance of shares of Sesen Bio common stock to Carisma stockholders in the merger and the other proposals contemplated by the Original Merger Agreement. Later on September&#160;20, 2022, Sesen Bio and Carisma executed the Original Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;21, 2022, Sesen Bio and Carisma issued a joint press release announcing the execution of the Original Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Between September&#160;29, 2022 and November&#160;17, 2022, the Sesen Bio board of directors held three meetings by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells were present. At each meeting, Ms.&#160;Clark provided an update on preparation for the Sesen Bio special meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;18, 2022, Bradley L. Radoff and Michael Torok and their affiliates, collectively referred to as the Investor Group, filed a Schedule&#160;13D with the SEC disclosing their beneficial ownership of 5.7% of the outstanding shares of Sesen Bio common stock and their intent to vote against the merger and the transactions related thereto. On December&#160;1, 2022, the Investor Group amended the Schedule&#160;13D to disclose beneficial ownership of 7.4% of the outstanding shares of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Between November&#160;18, 2022 and December&#160;17, 2022, representatives of SVB Securities and representatives of Sesen Bio engaged with the Investor Group regarding their views on the merger. During </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">131</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">this time, representatives of SVB Securities and representatives of Sesen Bio also engaged with other Sesen Bio stockholders regarding their views on the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Between December&#160;13, 2022 and December&#160;17, 2022, members of Sesen Bio management and members of Carisma management discussed the Investor Group&#8217;s Schedule&#160;13D filings and opposition to the merger, engagement with the Investor Group and feedback received from the Investor Group on the amount of a potential special cash dividend to Sesen Bio stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;17, 2022, Sesen Bio entered into a confidentiality agreement with the Investor Group to facilitate the sharing of certain information with the Investor Group. The confidentiality agreement required Sesen Bio to notify the Investor Group, by the earlier of December&#160;29, 2022 or two business days following the Investor Group&#8217;s agreement to vote in favor of the merger, that the information shared with the Investor Group does not constitute material, non-public information as of such date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Between December&#160;17, 2022 and December&#160;23, 2022, representatives of Sesen Bio and Carisma and their respective advisors engaged with the Investor Group and Olshan Frome Wolosky LLP, or Olshan, the Investor Group&#8217;s outside legal counsel, regarding the merger and the transactions related thereto. During such discussions, the Investor Group demanded, among other things, an approximate $100.0&#160;million special cash dividend to Sesen Bio stockholders and an expanded CVR to include Sesen Bio&#8217;s legacy assets, including Vicineum. During this time, representatives of Sesen Bio also engaged with other Sesen Bio stockholders regarding their views on the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Between December&#160;20, 2022 and December&#160;21, 2022, members of Sesen Bio management and members of Carisma management discussed the status of engagement with the Investor Group, including the Investor Group&#8217;s demands for an approximate $100.0&#160;million special cash dividend to Sesen Bio stockholders and an expanded CVR to include Sesen Bio&#8217;s legacy assets, net cash for funding the combined company&#8217;s operations and Sesen Bio&#8217;s expected net cash as of immediately prior to the closing of the merger. Members of Sesen Bio management and members of Carisma management discussed that a $100.0 million special cash dividend to Sesen Bio stockholders would make the merger unfeasible (including that Carisma advised that such special cash dividend would be unacceptable) and potentially introduce significant risk to Sesen Bio. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;21, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells were present. Ms.&#160;Clark provided an update on engagement with the Investor Group, including the demand for an approximate $100.0&#160;million special cash dividend to Sesen Bio stockholders instead of the potential special cash dividend to Sesen Bio stockholders of up to $25.0&#160;million as set forth in the Original Merger Agreement. Members of Sesen Bio management reviewed with the Sesen Bio board of directors the estimated wind-down costs for Sesen Bio through March&#160;1, 2023 and that estimated net cash at the closing of the merger based on such wind-down costs was approximately $145.0 million, or approximately $75.0 million after a $70.0 million special cash dividend to Sesen Bio stockholders in connection with the merger. Ms.&#160;Clark reviewed with the Sesen Bio board of directors that in the event the merger is not completed, a court-managed liquidation would likely provide greater value to Sesen Bio stockholders compared to other potential strategic alternatives available to Sesen Bio due to the additional time, costs and associated risks to pursue other potential strategic alternatives, such as starting a new strategic review process, in-licensing or acquiring a new asset in a new disease and/or therapeutic area. Ms.&#160;Clark also provided an update on the anticipated timeline for the Sesen Bio special meeting. A discussion ensued among the Sesen Bio directors and others in attendance regarding a court-managed liquidation process, the Investor Group&#8217;s opposition to the merger, stockholder feedback Sesen Bio had received to date regarding the merger, and the potential size of an increased special cash dividend and related considerations, including that a $100.0 million special cash dividend to Sesen Bio stockholders would make the merger unfeasible (including that Carisma advised that such special cash dividend would be unacceptable) and potentially introduce significant risk to Sesen Bio. Based on the estimated wind-down costs through March&#160;1, 2023 and estimated net cash at the closing of the merger, members of Sesen Bio management recommended that the Sesen Bio board of directors authorize an increase of the amount of the potential special cash dividend in connection with the merger up to $75.0 million. Following discussion and management&#8217;s recommendation, the Sesen Bio board of directors authorized an increase of the amount of the potential special cash dividend in connection with the merger up to $75.0&#160;million, subject to agreement with Carisma. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">132</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;23, 2022, members of Carisma management advised members of Sesen Bio management that the Carisma board of directors had authorized a decrease to the minimum net cash requirement from $100.0&#160;million to $75.0&#160;million, which members of Carisma management advised that it believed was a sufficient amount to operate the combined company&#8217;s business as currently contemplated following the closing, with authorization for any excess cash above $75.0&#160;million to be part of a special cash dividend paid to Sesen Bio stockholders in connection with the merger, which was estimated to be approximately $70.0&#160;million. Members of Sesen Bio management and members of Carisma management discussed amending the CVR to also include potential proceeds from any sale of Sesen Bio&#8217;s legacy assets (including Vicineum). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;23, 2022, representatives of Sesen Bio and Carisma and their respective advisors continued engaging with the Investor Group regarding the merger and the transactions related thereto. During such discussions, representatives of SVB Securities and representatives of Evercore Group L.L.C., or Evercore, Carisma&#8217;s financial advisor, communicated that Sesen Bio and Carisma had determined to significantly increase the amount of the special cash dividend by $45.0&#160;million to approximately $70.0&#160;million and amend the CVR Agreement to also include potential proceeds from any sale of Sesen Bio&#8217;s legacy assets (including Vicineum), which would increase the value paid to Sesen Bio stockholders upon completion of the merger. Representatives of SVB Securities and representatives of Evercore communicated that a special cash dividend of approximately $70.0&#160;million would leave the combined company with net cash of $75.0&#160;million to fund its operations, based on Sesen Bio&#8217;s expected net cash of approximately $145.0&#160;million as of immediately prior to the closing of the merger and prior to the issuance of the special cash dividend. In response, the Investor Group reiterated to representatives of SVB Securities and representatives of Evercore its demand for an approximate $100.0&#160;million special cash dividend to Sesen Bio stockholders and intent to vote against the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;23, 2022, representatives of Hogan Lovells and representatives of WilmerHale negotiated the terms of the merger agreement amendment and form of CVR Agreement, which would increase the amount of the special cash dividend to be paid to Sesen Bio stockholders from up to $25.0&#160;million to the amount of cash available after Sesen Bio meets the $75.0&#160;million net cash minimum and amend the form of CVR Agreement to also include potential proceeds from any sale of Sesen Bio&#8217;s legacy assets (including Vicineum). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;29, 2022, the Sesen Bio board of directors held a meeting by videoconference at which members of Sesen Bio management and representatives of Hogan Lovells and SVB Securities were present. Sesen Bio&#8217;s directors met in executive session with representatives of Hogan Lovells to review, among other things, the Sesen Bio board of directors&#8217; previous evaluation of strategic alternatives, including liquidation, that the Sesen Bio board of directors conducted before approving the merger. The Sesen Bio board of directors confirmed that it continues to believe such transaction maximizes stockholder value and is in the best interest of the Sesen Bio stockholders. Following the executive session, Ms.&#160;Clark provided an update on engagement with the Investor Group, including the Investor Group&#8217;s continued demand for an approximate $100.0 million special cash dividend to Sesen Bio stockholders, which the Sesen Bio board of directors agreed would make the merger unfeasible (including that Carisma advised that such special cash dividend would be unacceptable) and potentially introduce significant risk to Sesen Bio. Ms.&#160;Clark then reviewed the draft merger agreement amendment which would (i)&#160;reduce the minimum net cash of Sesen Bio required at the closing of the merger from $100.0&#160;million to $75.0&#160;million, (ii)&#160;increase the amount of the special cash dividend to be paid to Sesen Bio stockholders to the amount of cash available after Sesen Bio meets the $75.0&#160;million net cash minimum as of the closing of the merger, which was estimated to be approximately $70.0&#160;million, and (iii)&#160;amend the form of CVR Agreement to also include potential proceeds from any sale of Sesen Bio&#8217;s legacy assets (including Vicineum), in addition to any proceeds from the milestone payment under the Roche Asset Purchase Agreement, as part of the CVR. Representatives of SVB Securities reviewed SVB Securities&#8217; financial analysis of the proposed transaction with Carisma pursuant to the terms of the Merger Agreement. Following discussion with the Sesen Bio directors, SVB Securities then rendered to the Sesen Bio board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion dated December&#160;29, 2022, that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by SVB Securities in preparing its opinion, the exchange ratio to be paid by Sesen Bio pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to Sesen Bio. Ms.&#160;Clark reviewed with the Sesen </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">133</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSBRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Bio board of directors the prior discussions from December&#160;21, 2022 that in the event the merger is not completed, a court-managed liquidation would likely provide greater value to Sesen Bio stockholders compared to other potential strategic alternatives available to Sesen Bio. Ms.&#160;Clark reviewed that, if the Sesen Bio board of directors were to approve and recommend, and Sesen Bio stockholders were to approve, a liquidation of Sesen Bio, Sesen Bio would be required under Delaware corporate law to notify potential claimants and pay its outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, which may be sizeable, prior to making any distributions in liquidation to Sesen Bio stockholders. Ms.&#160;Clark noted that as a result of such requirement, a portion of Sesen Bio&#8217;s assets would need to be reserved pending the resolution of such obligations, the timing of any such resolution would be uncertain, and Sesen Bio may become subject to litigation or other claims related to a dissolution and liquidation of Sesen Bio. Representatives of Hogan Lovells reviewed with the Sesen Bio board of directors the Investor Group&#8217;s Schedule&#160;13D filings and opposition to the merger, engagement with the Investor Group to date and other matters related to the Investor Group, including potential responses and related considerations. A discussion ensued regarding engagement with the Investor Group, the terms of the Merger Agreement Amendment and the potential for a court-managed liquidation in the event the merger is not completed. Following discussion, the Sesen Bio board of directors unanimously (i)&#160;determined that the Merger Agreement Amendment and the transactions contemplated thereby are advisable and in the best interests of Sesen Bio and its stockholders, and (ii)&#160;approved and declared advisable the Merger Agreement Amendment and the transactions contemplated by the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Later on December&#160;29, 2022, Sesen Bio and Carisma executed the Merger Agreement Amendment and issued a joint press release announcing the execution of the Merger Agreement Amendment and providing an update on engagement with the Investor Group. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;3, 2023, the Investor Group issued a press release reiterating their intent to vote against the merger notwithstanding the increase to the amount of the expected special cash dividend in connection with the merger up to $70.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;4, 2023, Sesen Bio issued a press release reiterating its confidence in the merger, detailing the terms of the Merger Agreement Amendment and correcting certain factual errors made by the Investor Group in its January&#160;3, 2023 press release. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;5, 2023, the Investor Group issued an open letter to the Sesen Bio board of directors regarding their intent to vote against the merger and further amended their Schedule&#160;13D to disclose beneficial ownership of 8.4% of the outstanding shares of Sesen Bio common stock. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Between January&#160;10 and January&#160;12, 2023, representatives of Sesen Bio and its legal and financial advisors engaged in discussions with the Investor Group and their legal counsel regarding the Investor Group&#8217;s views on the merger. In addition, between January&#160;11 and January&#160;16, 2023, representatives of Sesen Bio engaged in discussions with other Sesen Bio stockholders regarding their views on the merger. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio Reasons for the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the course of its evaluation of the Merger Agreement and the transactions contemplated by the Merger Agreement, the Sesen Bio board of directors held numerous meetings, consulted with Sesen Bio&#8217;s senior management, Sesen Bio&#8217;s consultants and advisors, outside legal counsel and financial advisor, and reviewed and assessed a significant amount of information. In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, the Sesen Bio board of directors considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the financial condition and prospects of Sesen Bio and the risks associated with continuing to operate Sesen Bio on a stand-alone basis, particularly in light of Sesen Bio&#8217;s July&#160;2022 decision to voluntarily pause further development of Vicineum for the treatment of NMIBC and reduce its workforce, which was based on a thorough reassessment of Vicineum following FDA feedback on the requirements for an additional Phase&#160;3 clinical trial, the evolving competitive landscape and the resulting financial analysis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">134</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">that the Sesen Bio board of directors and its financial advisor undertook a comprehensive and thorough process of reviewing and analyzing potential strategic alternatives and merger partner candidates and Sesen Bio board of directors&#8217; view that no alternatives to the merger, including a liquidation and dissolution of Sesen Bio and the distribution of any available cash, were reasonably likely to create greater value to Sesen Bio stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; conclusion that the merger would provide existing Sesen Bio stockholders a significant opportunity to participate in the potential growth of the combined company following the merger, which will focus on Carisma&#8217;s product pipeline, while also potentially receiving certain cash payments following the closing of the merger on account of the CVR Agreement and the special cash dividend; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; belief, after a thorough review of strategic alternatives and discussions with Sesen Bio&#8217;s senior management, outside legal counsel and financial advisor, that the merger is more favorable to Sesen Bio stockholders than the potential value that might have resulted from other strategic alternatives available to Sesen Bio, including a liquidation and dissolution of Sesen Bio and the distribution of any available cash; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; belief, after thorough discussion with Sesen Bio management and Sesen Bio&#8217;s consultants and advisors, that a potential liquidation and dissolution was not reasonably likely to create greater value for Sesen Bio stockholders than a strategic alternative transaction based on, among other things, the need to hold back a meaningful amount of the Company&#8217;s current cash balance to cover current and potential future liabilities, including those triggered by a liquidation strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; belief that, as a result of arm&#8217;s length negotiations with Carisma, Sesen Bio and its representatives negotiated the highest exchange ratio to which Carisma was willing to agree, and that the other terms of the Merger Agreement include the most favorable terms to Sesen Bio in the aggregate to which Carisma was willing to agree; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; positive view, based on the scientific, regulatory and technical due diligence conducted by Sesen Bio management and advisors, of the regulatory pathway for, and potential significant market opportunity of, Carisma&#8217;s product candidates, which will be the focus of the combined company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; consideration of the expected cash balances of the combined company as of the closing of the merger resulting from the approximately $75.0 million of net cash expected to be held by Sesen Bio upon completion of the merger together with the cash Carisma currently holds and the $30.6&#160;million of expected gross proceeds from the Carisma pre-closing financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; view, following a review with Sesen Bio&#8217;s management and advisors of Carisma&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the merger, or have access to sufficient resources, to fund continued development of Carisma&#8217;s product pipeline through upcoming value inflection points; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic transaction with Sesen Bio based on the scientific, technical and other due diligence conducted by Sesen Bio&#8217;s management and advisors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors&#8217; view that the combined company will be led by an experienced senior management team from Carisma and a board of directors with representation from each of the current boards of directors of Carisma and Sesen Bio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the current financial market conditions and historical market prices, volatility and trading information with respect to Sesen Bio common stock; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the opinion of SVB Securities, rendered orally to the Sesen Bio board of directors on December&#160;29, 2022 (and subsequently confirmed in writing as of December&#160;29, 2022) that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">135</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">review undertaken by SVB Securities in preparing its opinion, the exchange ratio was fair, from a financial point of view, to Sesen Bio, as more fully described below in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Opinion of Sesen Bio&#8217;s Financial Advisor</font><font style="letter-spacing:0.2pt;">,&#8221; beginning on page <a href="#tOOSB">139</a> in this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors also reviewed the terms of the Merger Agreement and related transaction documents, including those described below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were reasonable under the circumstances: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the calculation of the exchange ratio, closing net cash and the estimated number of shares of Sesen Bio common stock to be issued in the merger, including that the valuation of Sesen Bio under the Merger Agreement would be reduced to the extent that Sesen Bio&#8217;s closing net cash is less than $75.0 million and increased to the extent Sesen Bio&#8217;s closing net cash exceeds $75.0 million, which would result in a decrease or increase, as applicable, in the ownership of the pre-merger Sesen Bio stockholders in the combined company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and nature of the conditions to Sesen Bio&#8217;s and Carisma&#8217;s respective obligations to complete the merger and the likelihood that the merger will be completed on a timely basis, as more fully described below under the caption &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Conditions to the Completion of the Merger</font><font style="letter-spacing:0.2pt;">,&#8221; beginning on page <a href="#tCCM5">176</a> in this proxy statement/prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the respective rights of, and limitations on, Sesen Bio and Carisma under the Merger Agreement to consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of directors of each party to change its recommendation in favor of the merger, as more fully described below under the caption &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;No Solicitation</font><font style="letter-spacing:0.2pt;">,&#8221; beginning on page <a href="#tNSON">179</a> in this proxy statement/prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential termination fee of $7.6&#160;million, in the case of the fee payable by Sesen Bio, or $5.49&#160;million, in the case of the fee payable by Carisma, and related reimbursement of certain transaction expenses of up to $1.75&#160;million, which could become payable by either Sesen Bio or Carisma to the other party if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Termination Fee</font><font style="letter-spacing:0.2pt;">,&#8221; beginning on page <a href="#tTERFEE123">190</a> in this proxy statement/prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the lock-up agreements, pursuant to which certain stockholders of Carisma and Sesen Bio, respectively, have, subject to certain exceptions, agreed not to transfer their shares of the combined company common stock during the period of 180&#160;days following the completion of the merger, as more fully described below under the caption &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;Lock-Up Agreements</font><font style="letter-spacing:0.2pt;">,&#8221; beginning on page <a href="#tLOAG">199</a> in this proxy statement/prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the support agreements, pursuant to which certain stockholders of Carisma and Sesen Bio, respectively, have agreed, solely in their capacities as stockholders, to vote their shares of Carisma common stock or Sesen Bio common stock, respectively, in favor of the proposals submitted to them in connection with the merger and against any alternative acquisition proposals, as more fully described below under the caption &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;Support Agreements and Written Consents</font><font style="letter-spacing:0.2pt;">,&#8221; beginning on page <a href="#tSAAW">197</a> in this proxy statement/prospectus; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the CVR Agreement, pursuant to which Sesen Bio stockholders of record as of a date agreed to by Sesen Bio and Carisma prior to the effective time will receive a CVR for each outstanding share of Sesen Bio common stock held by such Sesen Bio stockholders representing the contractual right to receive contingent cash payments upon the receipt of Sesen Bio of certain proceeds payable by Roche during a certain period following closing or of proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, as more fully described below under the caption &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement</font><font style="letter-spacing:0.2pt;">,&#8221; beginning on page <a href="#tCVAG">192</a> in this proxy statement/prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the course of its deliberations, the Sesen Bio board of directors also considered a variety of risks and other countervailing factors related to entering into the merger, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the $7.6&#160;million termination fee payable by Sesen Bio and Sesen Bio&#8217;s expense reimbursement obligations upon the occurrence of certain events and the potential effect of such termination fee in </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">136</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCRFT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">deterring other potential acquirors from proposing an alternative acquisition that may be more advantageous to Sesen Bio stockholders; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the substantial expenses to be incurred by Sesen Bio in connection with the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prohibition on Sesen Bio to solicit alternative acquisition proposals during the pendency of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the possible volatility of the trading price of Sesen Bio common stock resulting from the announcement, pendency or completion of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the risk that the merger might not be consummated in a timely manner or at all and the potential effect of the public announcement of the merger or the failure to complete the merger on the reputation of Sesen Bio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scientific, technical, regulatory and other risks and uncertainties associated with development and commercialization of Carisma&#8217;s product pipeline; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the various other risks associated with the combined company and the proposed transaction, including those described in the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Risk Factors</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Cautionary Statement Concerning Forward-Looking Statements</font><font style="letter-spacing:0.2pt;">&#8221; beginning on pages <a href="#tRIFA">26</a> and <a href="#tCSCF">118</a>, respectively, in this proxy statement/prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foregoing information and factors considered by the Sesen Bio board of directors are not intended to be exhaustive but are believed to include all of the material factors considered by the Sesen Bio board of directors. In view of the wide variety of factors considered in connection with its evaluation of the merger and the complexity of these matters, the Sesen Bio board of directors did not find it useful to attempt, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the Sesen Bio board of directors may have given different weight to different factors. The Sesen Bio board of directors conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, Sesen Bio&#8217;s senior management team, outside legal counsel and financial advisor, and considered the factors overall to be favorable to, and to support, its determination. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma Reasons for the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the course of reaching its decision to approve the merger, the Carisma board of directors held numerous meetings, consulted with Carisma&#8217;s senior management, its financial advisors and legal counsel, and considered a wide variety of factors. Ultimately, the Carisma board of directors concluded that a merger with Sesen Bio, together with the additional financing committed from the Carisma pre-closing financing, was the best option to generate capital resources to support the advancement of Carisma&#8217;s pipeline and fund a combined organization. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additional factors that the Carisma board of directors considered included the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the merger will provide current Carisma stockholders with greater liquidity by owning publicly-traded stock, and expanding both the access to capital for Carisma and the range of investors potentially available as a public company, compared to the investors Carisma could otherwise gain access to if it continued to operate as a privately-held company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential benefits from increased public market awareness of Carisma and its pipeline; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the historical and current information concerning Carisma&#8217;s business, including its financial performance and condition, operations, management and pre-clinical and clinical data; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the competitive nature of the industry in which Carisma operates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Carisma board of directors&#8217; fiduciary duties to Carisma stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Carisma board of directors&#8217; belief that no alternatives to the merger were reasonably likely to create greater value for Carisma stockholders, after reviewing the various financing and other strategic alternatives that were considered by the Carisma board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">137</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the projected financial position, operations, management structure, operating plans, and anticipated cash burn rate of the combined company, including the ability to support the combined company&#8217;s current and planned clinical trials and operations), as further discussed in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Carisma Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Liquidity and Capital Resources &#8212; Funding Requirements</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tFUNDRE1">335</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus; </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the business, history, operations, financial resources, assets, technology and credibility of Sesen Bio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of appraisal rights under the DGCL to holders of Carisma&#8217;s capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Carisma capital stock as determined by the Delaware Court of Chancery; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the terms and conditions of the Merger Agreement, including the following: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="font-family:Times New Roman, Times, serif;">&#9702;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">the determination that the expected relative&#160;percentage ownership of Sesen Bio stockholders and Carisma stockholders in the combined company was appropriate, based on the Carisma board of directors&#8217; judgment and assessment of the approximate valuations of Sesen Bio (including the value of the net cash Sesen Bio is expected to provide to the combined company) and Carisma;</font><font style="font-family:Times New Roman, Times, serif;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="font-family:Times New Roman, Times, serif;">&#9702;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">the expectation that the merger will be treated as a reorganization for U.S. federal income tax purposes, with the result that in the merger Carisma stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes;</font><font style="font-family:Times New Roman, Times, serif;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif;">&#9702;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;font-family:Times New Roman, Times, serif;">
          <font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;">the limited number and nature of the conditions of the obligation of Sesen Bio to complete the merger;</font> </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif;">&#9702;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;font-family:Times New Roman, Times, serif;">
          <font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;">the condition to Carisma&#8217;s obligation to complete the merger based on a minimum amount of net cash of Sesen Bio as of the closing of the merger;</font> </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif;">&#9702;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;font-family:Times New Roman, Times, serif;">
          <font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;">the right of Carisma under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Carisma receive a superior proposal;</font> </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="font-family:Times New Roman, Times, serif;">&#9702;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">the conclusion of the Carisma board of directors that the potential termination fees payable by Sesen Bio or Carisma to the other party, and the circumstances when such fee may be payable, were reasonable; and</font><font style="font-family:Times New Roman, Times, serif;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="font-family:Times New Roman, Times, serif;">&#9702;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction;</font><font style="font-family:Times New Roman, Times, serif;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the shares of Sesen Bio common stock issued to Carisma stockholders in connection with the merger will be registered on a Form&#160;S-4 registration statement and will become freely tradable for Carisma stockholders who are not affiliates of Carisma and who are not parties to lock-up agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability to obtain a Nasdaq listing and the change of the combined company&#8217;s name to &#8220;Carisma Therapeutics Inc.&#8221; upon the closing of the merger; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the likelihood that the merger will be completed on a timely basis. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Carisma board of directors also considered a number of uncertainties and risks in its deliberations concerning the merger and the other transactions contemplated by the Merger Agreement, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the possibility that the merger might not be completed and the potential adverse effect of the public announcement of the merger on the reputation of Carisma and the ability of Carisma to obtain financing in the future in the event the merger is not completed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the risk that future sales of common stock by existing Sesen Bio stockholders may cause the price of Sesen Bio common stock to fall, thus reducing the potential value of Sesen Bio common stock received by Carisma stockholders following the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">138</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tOOSB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the exchange ratio used to establish the number of shares of Sesen Bio common stock to be issued to Carisma stockholders in the merger is fixed, except for adjustments including due to Sesen Bio&#8217;s net cash and the respective companies&#8217; outstanding capital stock at closing, and thus the relative&#160;percentage ownership of Sesen Bio stockholders and Carisma stockholders in the combined organization immediately following the completion of the merger is similarly fixed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the termination fee payable by Carisma to Sesen Bio upon the occurrence of certain events, and the potential effect of such termination fee in deterring other potential acquirers from proposing an alternative transaction that may be more advantageous to Carisma stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential reduction of Sesen Bio&#8217;s net cash prior to the closing of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the possibility that Sesen Bio could, under certain circumstances, consider unsolicited acquisition proposals if superior to the merger or change its recommendation to approve the merger upon certain events; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the risk that the merger might not be completed in a timely manner or at all, for a variety of reasons, such as the failure of Sesen Bio to obtain the required stockholder vote, and the potential adverse effect on the reputation of Sesen Bio and the ability of Sesen Bio to obtain financing in the future in the event the merger is not completed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs involved in connection with completing the merger, the time and effort of Carisma senior management required to complete the merger, the related disruptions or potential disruptions to Carisma&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Carisma, and related administrative challenges associated with combining the companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the additional expenses and obligations to which Carisma&#8217;s business will be subject following the merger that Carisma has not previously been subject to, and the operational changes to Carisma&#8217;s business, in each case that may result from being a public company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the fact that the representations and warranties in the Merger Agreement do not survive the closing of the merger and the potential risk of liabilities that may arise post-closing; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">various other risks associated with the combined organization and the merger, including the risks described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Risk Factors</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tRIFA">26</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The foregoing information is not intended to be exhaustive, but summarizes the material factors considered by the Carisma board of directors in its consideration of the Merger Agreement and the transactions contemplated. The Carisma board of directors concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. After considering these and other factors, the Carisma board of directors unanimously approved the Merger Agreement, the merger and the other transactions contemplated by the Merger Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion of Sesen Bio&#8217;s Financial Advisor</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Introduction</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio retained SVB Securities as its financial advisor in connection with the merger and the other transactions contemplated by the Merger Agreement. In connection with this engagement, the Sesen Bio board of directors requested that SVB Securities evaluate the fairness, from a financial point of view, to Sesen Bio of the exchange ratio proposed to be paid by Sesen Bio pursuant to the terms of the Merger Agreement. On December&#160;29, 2022, SVB Securities rendered to the Sesen Bio board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion dated December&#160;29, 2022, that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by SVB Securities in preparing its opinion, the exchange ratio proposed to be paid by Sesen Bio pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to Sesen Bio. In providing its opinion, SVB Securities noted that the exchange ratio is subject to certain adjustments set forth in the Merger Agreement, and SVB Securities expressed no opinion as to any such adjustments. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">139</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="font-weight:normal;letter-spacing:0.2pt;">The full text of the written opinion of SVB Securities, dated December&#160;29, 2022, which describes the assumptions made and the qualifications and limitations upon the review undertaken by SVB Securities in preparing its opinion, is attached as </font><font style="font-style:italic;font-weight:normal;letter-spacing:0.2pt;">Annex B</font><font style="font-weight:normal;letter-spacing:0.2pt;"> to this proxy statement/prospectus and is incorporated herein by reference. The summary of the written opinion of SVB Securities set forth below is qualified in its entirety by the full text of the written opinion attached hereto as </font><font style="font-style:italic;font-weight:normal;letter-spacing:0.2pt;">Annex B</font><font style="font-weight:normal;letter-spacing:0.2pt;">. </font><font style="letter-spacing:-0.2pt;">SVB Securities&#8217; financial advisory services and opinion were provided for the information and assistance of the Sesen Bio board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of the Sesen Bio board of directors&#8217; consideration of the merger and the opinion of SVB Securities addressed only the fairness, from a financial point of view, as of the date thereof, to Sesen Bio of the exchange ratio proposed to be paid by Sesen Bio pursuant to the terms of the Merger Agreement. The opinion of SVB Securities did not address any other term or aspect of the Merger Agreement or the merger and does not constitute a recommendation to any stockholder of Sesen Bio as to whether or how such holder should vote with respect to the merger or otherwise act with respect to the merger or any other matter.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The full text of the written opinion of SVB Securities should be read carefully in its entirety for a description of the assumptions made and the qualifications and limitations upon the review undertaken by SVB Securities in preparing its opinion.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with rendering the opinion described above and performing its related financial analyses, SVB Securities reviewed, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Original Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a draft of the Merger Agreement Amendment, dated December&#160;29, 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a draft of the form of CVR Agreement to be entered into prior to the closing of the merger by Sesen Bio and a rights agent, dated December&#160;29, 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed by Sesen Bio with the SEC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s Quarterly Reports on Form 10-Q for the quarterly periods ended March&#160;31, 2022, June&#160;30, 2022 and September 30, 2022 (including any amendments thereto), as filed by Sesen Bio with the SEC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">certain Current Reports on Form 8-K (including any amendments thereto), as filed by Sesen Bio with, or furnished by Sesen Bio to, the SEC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">certain internal information, primarily related to expense forecasts, relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of Sesen Bio, as furnished to SVB Securities by the management of Sesen Bio; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">certain internal information relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of Carisma, including the Financial Projections (as defined below), and furnished to, and approved for use by, SVB Securities by Sesen Bio for purposes of SVB Securities&#8217; analysis, as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Certain Unaudited Financial Projections</font><font style="letter-spacing:0.2pt;">,&#8221; which are referred to in this summary of the opinion of SVB Securities as the &#8220;Financial Projections,&#8221; and which are collectively referred to in this summary of the opinion of SVB Securities as the &#8220;Internal Data&#8221;. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities also conducted discussions with members of the senior management of Sesen Bio and Carisma and their respective advisors and representatives regarding the Internal Data as well as the past and current business, operations, financial condition and prospects of each of Sesen Bio and Carisma. In addition, SVB Securities reviewed certain financial data for Carisma and compared that data to similar publicly available market, financial and other data for certain other companies, the securities of which are publicly traded, that SVB Securities believed to be comparable in certain respects to Carisma. SVB Securities also conducted such other financial studies and analyses and took into account such other information as SVB Securities deemed appropriate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax, accounting and other information supplied to, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">140</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">discussed with, or reviewed by SVB Securities for purposes of its opinion and, with Sesen Bio&#8217;s consent, SVB Securities relied upon such information as being complete and accurate. In that regard, SVB Securities was advised by Sesen Bio, and assumed, at Sesen Bio&#8217;s direction, that the Internal Data (including, without limitation, the Financial Projections) were reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of Sesen Bio and Carisma as to the matters covered thereby and SVB Securities relied, at Sesen Bio&#8217;s direction, on the Internal Data for purposes of SVB Securities&#8217; analysis and its opinion. SVB Securities expressed no view or opinion as to the Internal Data (including, without limitation, the Financial Projections) or the assumptions on which they were based. The Sesen Bio board of directors was aware that the management of Sesen Bio did not provide SVB Securities with, and SVB Securities did not otherwise have access to, financial forecasts regarding Sesen Bio&#8217;s business, other than the expense forecasts described above. Accordingly, SVB Securities did not perform a discounted cash flow analysis or any multiples-based analysis with respect to Sesen Bio. In addition, at Sesen Bio&#8217;s direction, SVB Securities did not make any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, off-balance-sheet or otherwise) of Sesen Bio or Carisma, nor was SVB Securities furnished with any such evaluation or appraisal, and SVB Securities was not asked to conduct, and did not conduct, a physical inspection of the properties or assets of Sesen Bio or Carisma. Furthermore, at Sesen Bio&#8217;s direction, SVB Securities ascribed no value to the contingent value rights issuable pursuant to the CVR Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities assumed, at Sesen Bio&#8217;s direction, that the final executed Merger Agreement would not differ in any respect material to SVB Securities&#8217; analysis or its opinion from the last draft of the Merger Agreement reviewed by SVB Securities. SVB Securities also assumed, at Sesen Bio&#8217;s direction, that the representations and warranties made by Carisma and Sesen Bio and Merger Sub in the Merger Agreement and the related agreements were and would continue to be true and correct in all respects material to SVB Securities&#8217; analysis. Furthermore, SVB Securities assumed, at Sesen Bio&#8217;s direction, that the merger would be consummated on the terms set forth in the Merger Agreement and in accordance with all applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be material to SVB Securities&#8217; analysis or SVB Securities&#8217; opinion and that, in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers for the merger, no delay, limitation, restriction, condition or other change would be imposed, the effect of which would be material to SVB Securities&#8217; analysis or SVB Securities&#8217; opinion. SVB Securities did not evaluate and did not express any opinion as to the solvency or fair value of Sesen Bio or Carisma, or their respective abilities to pay their obligations when they come due, or as to the impact of the merger on such matters, under any state, federal or other laws relating to bankruptcy, insolvency, or similar matters. SVB Securities is not a legal, regulatory, tax or accounting advisor, and SVB Securities expressed no opinion as to any legal, regulatory, tax or accounting matters. SVB Securities expressed no view or opinion as to the price or range of prices at which the shares of stock or other securities or instruments of Sesen Bio or any third party may trade at any time, including subsequent to the announcement or consummation of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The opinion of SVB Securities expressed no view as to, and did not address, Sesen Bio&#8217;s underlying business decision to proceed with or effect the merger, or the relative merits of the merger as compared to any alternative business strategies or transactions that might be available to Sesen Bio or in which Sesen Bio might engage. The opinion of SVB Securities was limited to and addressed only the fairness, from a financial point of view, as of the date of its opinion, to Sesen Bio of the exchange ratio proposed to be paid by Sesen Bio pursuant to the terms of the Merger Agreement. SVB Securities was not asked to, nor did it express any view on, and its opinion did not address, any other term or aspect of the Merger Agreement or the other transactions contemplated by the Merger Agreement, including, without limitation, the structure or form of the merger or the other transactions contemplated by the Merger Agreement, or any other agreements or arrangements contemplated by the Merger Agreement or entered into in connection with or otherwise contemplated by the merger or the other transactions contemplated by the Merger Agreement, including, without limitation, the fairness of the merger or any other term or aspect of the merger to, or any consideration to be received in connection therewith by, or the impact of the merger on, the holders of any class of securities, creditors or other constituencies of Sesen Bio or any other party. In addition, SVB Securities expressed no view or opinion as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors or employees of Sesen Bio or any other party, or class of such persons in connection with the merger or the other </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">141</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">transactions contemplated by the Merger Agreement, whether relative to the exchange ratio to be paid by Sesen Bio pursuant to the terms of the Merger Agreement or otherwise. The opinion of SVB Securities was necessarily based on financial, economic, monetary, currency, market and other conditions and circumstances as in effect on, and the information made available to SVB Securities as of, the date of its written opinion, and SVB Securities does not have any obligation or responsibility to update, revise or reaffirm its opinion based on circumstances, developments or events occurring after the date of its opinion. SVB Securities&#8217; opinion does not constitute a recommendation to any stockholder of Sesen Bio as to whether or how such stockholder should vote with respect to the merger or otherwise act with respect to the merger or the other transactions contemplated by the Merger Agreement or any other matter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities&#8217; financial advisory services and its opinion were provided for the information and assistance of the Sesen Bio board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the merger and the other transactions contemplated by the Merger Agreement. SVB Securities&#8217; opinion was authorized by the SVB Securities LLC Fairness Opinion Review Committee. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary of Financial Analyses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of the material financial analyses prepared by SVB Securities and reviewed with the Sesen Bio board of directors in connection its opinion, which was delivered orally to the Sesen Bio board of directors on December&#160;29, 2022 and subsequently confirmed in its written opinion, dated December&#160;29, 2022. For purposes of the analyses described below, SVB Securities was directed to rely upon the Internal Data, including the Financial Projections. The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the opinion of, SVB Securities, nor does the order of the analyses described below represent the relative importance or weight given to those analyses by SVB Securities. The preparation of a fairness opinion is a complex analytical process involving various determinations as to the most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances and, therefore, a fairness opinion is not readily susceptible to summary description. In arriving at its opinion, SVB Securities did not draw, in isolation, conclusions from or with regard to any factor or analysis that it considered. Accordingly, SVB Securities believes that its analyses must be considered as a whole and that selecting portions of such analyses and factors without considering all analyses and factors, could create a misleading or incomplete view of the processes underlying SVB Securities&#8217; financial analyses and its opinion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities may have deemed various assumptions more or less probable than other assumptions, so the reference ranges resulting from any particular portion of the analyses summarized below should not be taken to be the view of SVB Securities as to the actual value of Carisma. Some of the summaries of the financial analyses set forth below include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary, as the tables alone do not constitute a complete description of the financial analyses performed by SVB Securities. In its analyses, SVB Securities made numerous assumptions with respect to industry performance, general business and economic conditions and other matters, many of which are beyond the control of Sesen Bio or any other parties to the merger and the other transactions contemplated by the Merger Agreement. None of Sesen Bio, Carisma, Merger Sub, SVB Securities or any other person assumes responsibility if future results are materially different from those discussed. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of Sesen Bio or Carisma do not purport to be appraisals or reflect the prices at which these companies may actually be sold. Accordingly, the assumptions and estimates used in, and the results derived from, the financial analyses are inherently subject to substantial uncertainty. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before December&#160;29, 2022 and is not necessarily indicative of current market conditions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities&#8217; financial analyses and opinion were only one of many factors taken into consideration by the Sesen Bio board of directors in its evaluation of the merger, as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Sesen Bio Reasons for the Merger</font><font style="letter-spacing:0.2pt;">.&#8221; Consequently, the analyses described below should not be viewed as determinative of the views of the Sesen Bio board of directors or management of Sesen Bio </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">142</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with respect to the exchange ratio or as to whether the Sesen Bio board of directors would have been willing to determine that a different exchange ratio was fair. The exchange ratio, as well as the type of consideration payable in the merger, was determined through arm&#8217;s-length negotiations between Sesen Bio and Carisma and was approved by the Sesen Bio board of directors. SVB Securities provided advice to Sesen Bio during these negotiations. However, SVB Securities did not recommend any specific exchange ratio or other financial terms to Sesen Bio or the Sesen Bio board of directors or that any specific exchange ratio or other financial terms constituted the only appropriate consideration for the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In preparing its analysis, SVB Securities took into account that the exchange ratio contained in the Merger Agreement is calculated by attributing equity values of $90.0&#160;million and $196.0&#160;million to Sesen Bio and Carisma, respectively, subject to certain adjustments set forth in the Merger Agreement and before giving effect to the Carisma pre-closing financing. SVB Securities expressed no opinion as to any such adjustments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Valuation Analysis&#8201;&#8212;&#8201;Discounted Cash Flow</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A discounted cash flow analysis is a traditional valuation methodology used to derive a valuation of an asset or set of assets by calculating the &#8220;present value&#8221; of estimated future cash flows of the asset or set of assets. &#8220;Present value&#8221; refers to the current value of future cash flows or amounts and is obtained by discounting those future cash flows or amounts by a discount rate that takes into account assumptions and estimates of risk, the opportunity cost of capital, expected returns and other appropriate factors, and then adding the present value equivalent of the terminal value of the business at the end of the applicable projection period. SVB Securities performed a discounted cash flow analysis to calculate the estimated present value of the stand-alone, unlevered, after-tax free cash flows that Carisma was forecasted to generate from January&#160;1, 2023 through December&#160;31, 2041, which unlevered, after-tax free cash flows were derived from the Financial Projections on which SVB Securities relied. The time period of the Financial Projections was determined by Sesen Bio assuming U.S. approval and launch of CT-0508 in fiscal year 2027 with a 12-year exclusivity period (ending in fiscal year 2038), which Sesen Bio believes is consistent with current exclusivity for biological products, and includes a 3-year drop off period to account for the anticipated gradual decline in sales once generic competition is projected to enter the market in fiscal year 2039. Sesen Bio advised SVB Securities that it believed it was reasonable to forecast revenues through this projection period. SVB Securities estimated the net present value of unlevered, after-tax free flows after fiscal year 2041 by assuming an annual decline ranging from 10% to 30% of such cash flows in perpetuity, at the direction of Sesen Bio management, which range was determined by Sesen Bio management after taking into account (i)&#160;the uncertainty of the future regulatory pathway for generic cellular therapies, (ii) the potential for market entry of competing therapeutic products following the loss of exclusivity for CT-0508 and (iii) that revenue from the Moderna partnership is expected to begin declining after 2041. These cash flows were discounted to present value as of January&#160;1, 2023, using a discount rate ranging from 11% to 13%, derived from a weighted average cost of capital calculation for Carisma, which SVB Securities performed utilizing the capital asset pricing model with inputs that SVB Securities determined were relevant based on publicly available data and SVB Securities&#8217; professional judgment, including target capital structure, levered and unlevered betas for certain companies deemed by SVB Securities to be comparable to Carisma, size and equity market risk premiums and yields for U.S. treasury bonds, and adjusted for an estimated net cash balance of $9.0 million as of December&#160;31, 2022, as provided by management of Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This analysis resulted in an implied equity value for Carisma of approximately $225.0 million to $335.0&#160;million and a corresponding implied exchange ratio of approximately 43.4142x to 64.3783x. The implied equity value for Carisma and corresponding exchange ratio derived from the discounted cash flow analysis performed by SVB Securities in connection with the opinion delivered by SVB Securities with respect to the Original Merger Agreement were approximately $210 million to $320 million and 26.4261x to 40.0919x, respectively. The differences are attributable to a revised estimated cash balance for Carisma as of December 31, 2022 as provided by management of Carisma of $9.0 million as compared to an estimated cash balance of ($6.0) million as provided by management of Carisma reflected in the discounted cash flow analysis performed by SVB Securities in connection with the opinion delivered by SVB Securities on September&#160;20, 2022, resulting in an increase in the implied value of Carisma of $15 million, and a reduction in the equity value attributed to Sesen Bio for purposes of the exchange ratio pursuant to the Merger </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">143</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Agreement Amendment from $140 million to $90 million which, together with the revised implied equity value for Carisma, results in an increase to the implied exchange ratio derived from SVB Securities&#8217; analysis. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Additional Factors Observed by SVB Securities&#8201;&#8212;&#8201;Carisma Valuation Analysis&#8201;&#8212;&#8201;Selected Public Companies </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As additional factors not part of its financial analysis but noted for reference purposes, SVB Securities reviewed publicly available information relating to the market capitalization of certain U.S.-listed publicly traded biopharmaceutical companies focused on cellular-based therapeutics whose lead products at the time of this analysis were (1)&#160;being developed for the treatment of oncology targets and (2)&#160;in early clinical development, selected based on SVB Securities&#8217; professional judgment and experience. These companies, which are referred to as the Selected Companies, were: </font>
        </div>
        <table style="width:456pt;height:80.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:154.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Company </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:73.77pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Lead Relevant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Program </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:79.78pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in millions) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Enterprise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in millions) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Adjusted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in millions) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:154.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Arcellx, Inc. </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:73.77pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">CART-ddBCMA </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:79.78pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Multiple Myeloma </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,579</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,298</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,089</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:154.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Celularity Inc. </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:73.77pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">CYNK-001 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:79.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">AML </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">164</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">161</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">142</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:154.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adicet Bio, Inc. </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:73.77pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">ADI-001 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:79.78pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">NHL </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">350</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">67</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">63</td>
            <td style="padding:0pt;padding-left:5.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities noted that although such companies had certain financial and operating characteristics that could be considered similar to those of Carisma, none of the companies had the same management, make-up, technology, size or mix of businesses as Carisma and, accordingly, there were inherent limitations on the applicability of such companies to the valuation analysis of Carisma. In selecting the Selected Companies, based on its professional judgment and expertise, SVB Securities excluded numerous companies meeting the selection criteria described above. These companies were excluded because either (i) the company used technology that, in SVB Securities&#8217; judgment, differed significantly from Carisma&#8217;s autologous CAR-M immunotherapy technology, (ii) in SVB Securities&#8217; judgment, a substantial portion of the company&#8217;s market value was attributable to non-cell therapy assets or other platform technologies, or (iii) the company traded at a negative enterprise value. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities calculated the aggregate enterprise value of each of the Selected Companies based upon the closing price of the common stock of each Selected Company on December 28, 2022 and the fully-diluted number of shares outstanding, using the treasury stock method. Using the 25</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> and 75</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> percentile of the Selected Companies, SVB Securities derived an enterprise value range for Carisma and then added Carisma&#8217;s estimated net cash for year ending December&#160;31, 2022 of $9.0 million to derive adjusted equity values for Carisma. SVB Securities then applied a 20% illiquidity discount to the derived adjusted equity values for Carisma. The results of this analysis are summarized as follows: </font>
        </div>
        <table style="width:416pt;height:56.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:350.67pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Adjusted Equity </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in millions) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:350.67pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">25</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> Percentile </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">105</td>
            <td style="padding:0pt;padding-left:16.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.67pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">75</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> Percentile </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">615</td>
            <td style="padding:0pt;padding-left:16.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities compared these adjusted equity valuations to the proposed Carisma valuation of $196.0&#160;million based on the proposed valuation and ownership ratio in the Merger Agreement and also compared the resulting implied exchange ratio range of approximately 19.6579x to 117.9667x to the exchange ratio. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The foregoing analysis differs from the selected companies analysis performed by SVB Securities in connection with the opinion delivered by SVB Securities with respect to the Original Merger Agreement, which resulted in a range of adjusted equity values of approximately $205 million (25</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> percentile) to $715&#160;million (75</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> percentile) and a resulting implied exchange ratio range of approximately 25.8592x to 89.5943x. These differences are attributable to: (1) changes in closing stock prices between September 19, 2022 and December 28, 2022; (2) the exclusion of Lyell Immunopharma, Inc. and Nkarta, Inc. from SVB Securities&#8217; Selected Companies analysis in connection with its opinion with respect to the Merger Agreement Amendment because the companies traded at a negative enterprise value; (3) the revised estimated cash </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">144</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCUFP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">balance for Carisma as of December 31, 2022 of $9 million as provided by management of Carisma; and (4) the reduction in the equity value attributed to Sesen Bio for purposes of the exchange ratio pursuant to the Merger Agreement Amendment from $140 million to $90 million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities is a full-service securities firm engaged in securities trading and brokerage activities as well as investment banking and financial advisory services. In the ordinary course of business, SVB Securities and its affiliates currently are providing and may in the future provide investment banking and commercial banking services to Sesen Bio, Carisma or their respective affiliates and would expect to receive customary fees for the rendering of such services. In the past two years, SVB Securities has not received any fees for investment banking services from Carisma. In the ordinary course of business, SVB Securities and its affiliates have in the past and may in the future hold positions, for their own account or the accounts of their customers, in equity, debt or other securities of Sesen Bio, Carisma or their respective affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Consistent with applicable legal and regulatory requirements, SVB Securities has adopted policies and procedures to establish and maintain the independence of its research department and personnel. As a result, SVB Securities&#8217; research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Sesen Bio and the merger and other participants in the merger that differ from the views of SVB Securities&#8217; investment banking personnel. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors selected SVB Securities to act as Sesen Bio&#8217;s financial advisor in connection with the merger based on SVB Securities&#8217; qualifications, reputation, experience and expertise in the biopharmaceutical industry, its knowledge of and involvement in recent transactions in the biopharmaceutical industry and its relationship and familiarity with Sesen Bio and its business. SVB Securities is an internationally recognized investment banking firm that has substantial experience in transactions similar to the merger and the other transactions contemplated by the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with SVB Securities&#8217; services as financial advisor to Sesen Bio, Sesen Bio has agreed to pay SVB Securities an aggregate fee of $2.5&#160;million, $750,000 of which became payable upon the rendering by SVB Securities of the opinion on September&#160;20, 2022 with respect to the Original Merger Agreement and the remainder of which is payable contingent upon consummation of the merger. Sesen Bio has agreed to pay SVB Securities a fee of $500,000 in connection with its opinion with respect to the Merger Agreement Amendment, which fee is not creditable against the $2.5 million fee described above. In addition, Sesen Bio has agreed to reimburse certain of SVB Securities&#8217; expenses arising, and to indemnify SVB Securities against certain liabilities that may arise, out of SVB Securities&#8217; engagement. The terms of the fee arrangement between SVB Securities and Sesen Bio, which are customary in transactions of this nature, were negotiated at arm&#8217;s length between SVB Securities and Sesen Bio, and the Sesen Bio board of directors was aware of the arrangement, including the fact that a significant portion of the fee payable to SVB Securities is contingent upon the completion of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain Unaudited Financial Projections</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a matter of course, Sesen Bio does not publicly disclose long-term projections of future financial results due to the inherent unpredictability and subjectivity of underlying assumptions and estimates. However, in connection with the Sesen Bio board of directors&#8217; evaluation of the merger, Carisma management provided to Sesen Bio management certain financial information relating to Carisma, and Sesen Bio management then, on the basis of various assumptions made by Sesen Bio management, prepared certain financial projections with respect to Carisma, such projections referred to herein as the Financial Projections. The Financial Projections were furnished to, and approved for use by, SVB Securities by Sesen Bio for purposes of SVB Securities&#8217; analyses, as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Opinion of Sesen Bio&#8217;s Financial Advisor</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tOOSB">139</a> of this proxy statement/prospectus, and made available to the Sesen Bio board of directors. A summary of the Financial Projections is set forth below.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The inclusion of the Financial Projections should not be deemed an admission or representation by Sesen Bio, SVB Securities, Carisma or any of their respective officers, directors, affiliates, advisors, or other representatives with respect to such Financial Projections. The Financial Projections are not included to influence your views on the merger and are summarized in this proxy statement/prospectus solely to provide </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">145</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">stockholders access to certain non-public information provided to and considered by the Sesen Bio board of directors in connection with its evaluation of the merger and provided to Sesen Bio&#8217;s financial advisor, SVB Securities, to assist with its financial analyses, as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Opinion of Sesen Bio&#8217;s Financial Advisor</font><font style="letter-spacing:0.2pt;">&#8221;. The information from the Financial Projections should be evaluated, if at all, in conjunction with the historical financial statements and other information regarding Carisma in this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Financial Projections were not prepared with a view toward public disclosure, nor were they prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information, or GAAP. Neither the independent registered public accounting firm of Sesen Bio nor Carisma nor any other independent accountant has audited, reviewed, compiled, examined or performed any procedures with respect to the accompanying unaudited prospective financial information for the purpose of its inclusion herein, and accordingly, neither the independent registered public accounting firm of Sesen Bio nor Carisma nor any other independent accountant expresses an opinion or provides any form of assurance with respect thereto for the purpose of this proxy statement/prospectus. The reports of Ernst &amp; Young LLP and KPMG LLP included in this proxy statement/prospectus relate to the consolidated financial statements of Sesen Bio and Carisma, respectively. The reports do not extend to the Financial Projections and should not be read to do so. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Financial Projections include unlevered free cash flow, total adjusted revenue and earnings before interest and taxes, which are &#8220;non-GAAP financial measures&#8221; and which are financial performance measures that are not calculated in accordance with GAAP. Non-GAAP financial measures should not be viewed as a substitute for GAAP financial measures and may be different from non-GAAP financial measures used by other companies. Furthermore, there are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly, non-GAAP financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP. The SEC rules that would otherwise require a reconciliation of a non-GAAP financial measure to a GAAP financial measure do not apply to non-GAAP financial measures provided to a board of directors or a financial advisor in connection with a proposed business combination transaction such as the merger if the disclosure is included in a document such as this proxy statement/prospectus. In addition, reconciliations of non-GAAP financial measures to a GAAP financial measure were not provided to or relied upon by SVB Securities in connection with rendering its fairness opinion with respect to the merger, as further described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Opinion of Sesen Bio&#8217;s Financial Advisor</font><font style="letter-spacing:0.2pt;">&#8221;. Accordingly, Sesen Bio has not provided a reconciliation of the financial measures included in the Financial Projections to the relevant GAAP financial measures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The financial projections prepared by Carisma and supplied to Sesen Bio were prepared solely for internal use as part of Carisma&#8217;s ongoing strategic planning processes and are subjective in many respects. As a result, the Financial Projections, are susceptible to multiple interpretations and periodic revisions based on actual experience and business developments. Although Carisma and Sesen Bio believe their respective assumptions to be reasonable, all financial projections are inherently uncertain, and Carisma and Sesen Bio expect that differences will exist between actual and projected results. Although presented with numerical specificity, the Financial Projections reflect numerous variables, estimates, and assumptions made by Carisma&#8217;s and Sesen Bio&#8217;s respective management at the time the initial financial projections were prepared by Carisma and prepared by Sesen Bio, and also reflect general business, economic, market, and financial conditions and other matters, all of which are difficult to predict and many of which are beyond Carisma&#8217;s and Sesen Bio&#8217;s control. In addition, the Financial Projections cover an extended period of time, and this information by its nature becomes subject to greater uncertainty with each successive year. Accordingly, there can be no assurance that the estimates and assumptions made in preparing the Financial Projections will prove accurate or that any of the Financial Projections will be realized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Financial Projections included certain assumptions relating to, among others things, Carisma&#8217;s and Sesen Bio&#8217;s respective expectations, which may not prove to be accurate, relating to the business, earnings, cash flow, assets, liabilities and prospects of Carisma, industry metrics and the regulatory and commercial probability of success and revenue and expenses adjusted on the basis thereof. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">146</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Financial Projections were prepared using the following material assumptions: (i) risk-adjusted sales of CT-0508 only for the treatment of breast cancer and gastric cancer</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">1</font><font style="letter-spacing:0.2pt;"> in the U.S., the E.U. Five (France, Germany, Italy, Spain and the United Kingdom) and Japan beginning with U.S. approval and launch in fiscal year 2027, E.U. Five approval and launch in fiscal year 2028, and Japan approval and launch in fiscal year 2029, with projected peak market share to be achieved five years post-launch in each region in the range of 0.6% to 50% depending on line of treatment and the anticipated competitive landscape (which includes the possibility of new competitive products); (ii) product exclusivity for a period of 12 years, which Sesen Bio believes is consistent with current exclusivity for biological products; (iii) a decline in sales after loss of exclusivity by 30% in the first year, 55% in the second year, and 75% in the third year; (iv) an estimated 75% market access; (v) an estimated 97% compliance/adherence to treatment; (vi) net annual price per patient of approximately $342,000 in the U.S. in fiscal year 2027, $262,000 in the E.U. Five in fiscal year 2028, and $267,000 in Japan in fiscal year 2029, each increasing 2% annually; (vii) costs associated with CT-0508 would include clinical development costs (including $50.0 million for a pivotal trial beginning in fiscal year 2024), technology transfer costs, cost of goods sold at approximately $75,000 per patient, other supporting research and development and general and administrative costs, as well as milestone and royalty obligations associated with the Penn License Agreement; and (viii) risk-adjusted estimated development, regulatory, and commercial milestone income and royalties on net sales of products that are commercialized and associated with Carisma&#8217;s strategic partnership with Moderna. The risk adjustment applied to projected cash flows associated with CT-0508 and the Moderna partnership was based upon phase success rates for CAR-T therapies from Phase 1 to approval, as reported in &#8220;Clinical Development Success Rates and Contributing Factors 2011-2020,&#8221; or the CDSR Report, a study of clinical drug development success rates published by Biotechnology Innovation Organization, Informa Pharma Intelligence and QLS Advisors LLC in February 2021. CAR-T is currently the closest analog against which to compare new CAR-M therapies.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Financial Projections are subject to many risks and uncertainties and you are urged to review the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Risk Factors</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tRIFA">26</a> of this proxy statement/prospectus for a description of risk factors relating to the merger and Carisma&#8217;s business. You should also read the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Cautionary Statement Concerning Forward-Looking Statements</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCSCF">118</a> of this proxy statement/prospectus for additional information regarding the risks inherent in forward-looking information such as the Financial Projections. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The inclusion of the Financial Projections herein should not be regarded as an indication that Sesen Bio, SVB Securities, Carisma or any of their respective affiliates or representatives considered or consider the Financial Projections to be necessarily indicative of actual future events, and the Financial Projections should not be relied upon as such. The Financial Projections do not take into account any circumstances or events occurring after the date they were prepared. Sesen Bio and the combined company do not intend to, and disclaim any obligation to, update, correct, or otherwise revise the Financial Projections to reflect circumstances existing or arising after the date the Financial Projections were generated or to reflect the occurrence of future events, even in the event that any or all of the assumptions or other information underlying the Financial Projections are shown to be in error. Furthermore, the Financial Projections do not take into account the effect of any failure of the merger to be consummated and should not be viewed as accurate or continuing in that context. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">In light of the foregoing factors and the uncertainties inherent in financial projections, stockholders are cautioned not to place undue reliance, if any, on the Financial Projections.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table, which is subject to the financial projection statements above, presents (in millions) a summary of the Financial Projections prepared by the management of Sesen Bio solely for use by SVB Securities in connection with the rendering of its fairness opinion and performing related financial analysis and made available to the Sesen Bio board of directors. The time period of the Financial Projections was </font>
        </div>
      </div>
      <div style="margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">1</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The Financial Projections include monotherapy only in breast cancer and gastric cancer as initial market opportunities, and does not include potential upside from expansion into other HER-2 positive solid tumors such as colon, bladder, and liver, or heme malignancy in mono or combo therapy with a checkpoint inhibitor, as well as non-oncology indications such as liver fibrosis, neurodegeneration, and autoimmune disorders.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:1.99000000000001pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">147</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIOSB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">determined by Sesen Bio assuming U.S. approval and launch of CT-0508 in fiscal year 2027 with a 12-year exclusivity period (ending in fiscal year 2038), which Sesen Bio believes is consistent with current exclusivity for biological products, and includes a 3-year drop off period to account for the anticipated gradual decline in sales once generic competition is projected to enter the market in fiscal year 2039. Sesen Bio management and the Sesen Bio board of directors believed the time period of the Financial Projections was reasonable, particularly for the use and preparation of financial forecasts in the biotechnology industry given the anticipated timing for the initiation of commercial sales and the anticipated period of patent term exclusivity for CT-0508.</font>
        </div>
        <table style="width:456pt;height:67pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:172.65pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="58">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Projected Financial Information for Carisma on a Risk-Adjusted Basis </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:172.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">($ in millions) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2026E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2027E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2028E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2029E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2030E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2031E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2032E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:172.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total Adjusted Revenue</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">38</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">73</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">104</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">130</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">151</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">159</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Earnings Before Interest and Taxes</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">($</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">82<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">($</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">($</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">($</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">38</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">62</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">85</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">110</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:172.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unlevered Free Cash Flow</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">($</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">86<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">($</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">14<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">($</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">($</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:3.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">48</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">66</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">79</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">88</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:79pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:155.98pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="52">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Projected Financial Information for Carisma on a Risk-Adjusted Basis </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:155.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">($ in millions) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2033E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2034E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2035E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2036E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2037E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2038E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2039E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2040E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2041E </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:155.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total Adjusted Revenue</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">165</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">169</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">188</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">201</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">213</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">221</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">202</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">167</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">128</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:155.98pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Earnings Before Interest and Taxes</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">115</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">119</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">137</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">149</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">161</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">169</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">167</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">143</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">112</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:155.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unlevered Free Cash Flow</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">92</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">95</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">108</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">118</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">126</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">132</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">134</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">116</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Equal to total risk-adjusted revenue. The risk adjustment applied to projected cash flows associated with CT-0508 (probability of success factor of 17%) and the Moderna partnership (cumulative probability of success factor of 6%) was based upon phase success rates for CAR-T therapies from Phase I to approval, as reported in the CDSR Report. CAR-T is currently the closest analog against which to compare new CAR-M therapies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Earnings before interest and taxes is defined as total adjusted revenue less cost of goods sold, outbound milestones and royalties, research and development expense, sales and marketing expense, general and administrative expense and depreciation expense. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Unlevered free cash flow is defined as earnings before interest and taxes, less tax expense (if profitable), plus depreciation and amortization, less capital expenditures, and less change in net working capital. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.81pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interests of Sesen Bio Directors and Executive Officers in the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In considering the recommendation of the Sesen Bio board of directors with respect to issuing shares of Sesen Bio common stock as contemplated by the Merger Agreement and the other matters to be acted upon by Sesen Bio stockholders at the Sesen Bio special meeting, Sesen Bio stockholders should be aware that certain members of the Sesen Bio board of directors and certain Sesen Bio executive officers have interests in the merger that may be different from, or in addition to, the interests of Sesen Bio stockholders. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of the Sesen Bio board of directors and the Carisma board of directors were aware of these potential conflicts of interest and considered them, among other matters, in reaching their respective decisions to approve the Merger Agreement and the merger, and to recommend, as applicable, that Sesen Bio stockholders approve the proposals to be presented to Sesen Bio stockholders for consideration at the Sesen Bio special meeting as contemplated by this proxy statement/prospectus, and that Carisma stockholders sign and return the written consent as contemplated by this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Ownership Interests</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January&#160;4, 2023, Sesen Bio&#8217;s directors and current executive officers owned, in the aggregate, less than one&#160;percent of the shares of Sesen Bio common stock, which for purposes of this subsection excludes any Sesen Bio common stock issuable upon (i)&#160;exercise of Sesen Bio options held by such individual or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">148</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&#160;vesting of Sesen Bio RSUs held by such individual. The affirmative vote of a majority in voting power of the votes cast by the holders of Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting and entitled to vote on the matter is required for approval of Proposal Nos. 1, 3, 4 and 5. The affirmative vote of the holders of a majority of the outstanding shares of Sesen Bio common stock on the record date for the Sesen Bio special meeting and entitled to vote on the matter is required for approval of Proposal No. 2. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Stockholders of Sesen Bio</font><font style="letter-spacing:0.2pt;">&#8221; on page <a href="#tPSOS">395</a> of this proxy statement/prospectus for a description of the beneficial ownership of Sesen Bio&#8217;s directors and officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Effect of the Merger on Sesen Bio Options</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January&#160;4, 2023, Sesen Bio&#8217;s directors and current executive officers owned, in the aggregate, unvested Sesen Bio options covering 3,499,202 shares of Sesen Bio common stock and vested Sesen Bio options covering 8,215,261 shares of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All outstanding and unexercised Sesen Bio options granted pursuant to the 2014 Incentive Plan or the 2009 Incentive Plan or as an inducement grant under Nasdaq Listing Rule&#160;5635(c)(4) will remain in effect pursuant to their terms and will be unaffected by the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents certain information concerning the outstanding Sesen Bio options held by Sesen Bio&#8217;s directors and current executive officers as of January&#160;4, 2023. All of the Sesen Bio options in the table below were out-of-the-money as of January&#160;4, 2023, on which date the closing price per share of Sesen Bio common stock was $0.6340. The number of shares of Sesen Bio common stock underlying such Sesen Bio options will be adjusted appropriately to reflect the proposed reverse stock split. </font>
        </div>
        <table style="width:456pt;height:233.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:264.57pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Vested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Vested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unvested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unvested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Executive Officers</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,346,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.62</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,453,125</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.46</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Monica Forbes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,028,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.64</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">531,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.18</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Glen MacDonald, Ph.D </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">952,739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.68</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">235,937</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.34</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Minori Rosales, M.D., Ph.D </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">623,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.73</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mark R. Sullivan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">735,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.45</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">285,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.13</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jay S. Duker, M.D </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">321,287</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.29</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">32,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.79</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrie L. Bourdow </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">295,444</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.40</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">39,056</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.80</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Peter K Honig, M.D., M.P.H </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">119,861</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.03</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">130,139</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.09</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael A.S. Jewett, M.D., F.R.C.S.C., F.A.C.S </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">119,861</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.03</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">130,139</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.09</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jason A. Keyes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">295,444</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.40</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">39,056</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.80</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.51pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Effect of the Merger on Sesen Bio RSUs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, Sesen Bio&#8217;s directors and current executive officers owned, in the aggregate, unvested Sesen Bio RSUs covering 3,559,892 shares of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All outstanding Sesen Bio RSUs granted pursuant to the 2014 Incentive Plan or the 2009 Incentive Plan will remain in effect pursuant to their terms and will be unaffected by the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents certain information concerning the outstanding Sesen Bio RSUs held by Sesen Bio&#8217;s directors and current executive officers as of January 4, 2023. All of the Sesen Bio RSUs in the table below were unvested as of January 4, 2023 and the value of such RSUs was calculated based on the closing price per share of Sesen Bio common stock on January 4, 2023, which was $0.6340. The number of shares of Sesen Bio common stock underlying such Sesen Bio RSUs will be adjusted appropriately to reflect the proposed reverse stock split. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">149</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTOESBEO123">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:224.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:313.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unvested</font>
                <br >
                <font style="letter-spacing:-0.16pt;">RSUs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Value of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">RSUs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Executive Officers</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,213,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">769,422</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Monica Forbes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">913,375</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">579,080</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Glen MacDonald, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">595,217</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">377,368</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Minori Rosales, M.D., Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mark R. Sullivan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">637,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">404,302</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jay S. Duker, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">25,360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrie L. Bourdow </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">25,360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Peter K Honig, M.D., M.P.H. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">25,360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael A.S. Jewett, M.D., F.R.C.S.C., F.A.C.S. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">25,360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jason A. Keyes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">25,360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Positions Following the Merger</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M., Sesen Bio&#8217;s President and Chief Executive Officer and a member of the Sesen Bio board of directors, is expected to remain a member of the board of directors of the combined company and will receive compensation to be paid to directors of the combined company. For a description of Sesen Bio&#8217;s non-employee director compensation policy and the amounts paid to Sesen Bio&#8217;s non-employee directors in 2021, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Sesen Bio Executive Compensation&#8201;&#8212;&#8201;Director Compensation</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 16 of this proxy statement/prospectus. Pursuant to the terms of the Merger Agreement, effective upon the effective time, all other then-current Sesen Bio directors will resign. Upon the resignation of such directors, all unvested Sesen Bio options and Sesen Bio RSUs held by such directors will be vested in full. All out-of-the money Sesen Bio options will be canceled for no consideration. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Termination of Existing Sesen Bio Executive Officers Following the Merger and Related Severance Payments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has entered into employment agreements with each of its executive officers providing that (i)&#160;upon the termination of each such executive officer&#8217;s employment without &#8220;cause&#8221; or (ii)&#160;if such executive officer terminates his or her employment with Sesen Bio for &#8220;good reason,&#8221; in each case within 12&#160;months (or 18&#160;months for Dr.&#160;Cannell) following a &#8220;change in control transaction,&#8221; as each such term is defined in the respective employment agreements, Sesen Bio is obligated to, among other things, (w)&#160;pay the executive officer an amount equal to his or her base salary for 12&#160;months (24&#160;months for Dr.&#160;Cannell), payable in accordance with Sesen Bio&#8217;s then-current payroll practices, (x)&#160;pay Dr.&#160;Cannell an amount equal to two times his target bonus payment for the year in which the termination of employment occurs, (y)&#160;continue, to the extent allowed by applicable law and the applicable plan documents, to provide the executive officer and certain of his or her dependents with group health and dental insurance for a period of up to 12&#160;months (24&#160;months for Dr.&#160;Cannell), and (z)&#160;accelerate in full the vesting of all outstanding equity awards held by such executive officer. For a description of the employment agreements of Sesen Bio&#8217;s named executive officers, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Sesen Bio Executive Compensation&#8201;&#8212;&#8201;Summary Compensation Table&#8201;&#8212;&#8201;Narrative to Summary Compensation Table</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page 1 of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of the Merger Agreement, effective immediately after the effective time, Sesen Bio will terminate the employment of all then-current Sesen Bio executive officers and each such termination will be deemed to be an involuntary termination without &#8220;cause&#8221; after a &#8220;change in control transaction.&#8221; Accordingly, all such executive officers will be entitled to the benefits afforded to each such executive officer in the event of his or her termination without &#8220;cause&#8221; within the period provided for under such executive officer&#8217;s employment agreement following a &#8220;change in control transaction.&#8221; Pursuant to the terms of the Merger Agreement, any severance payments or benefits payable to such executive officers pursuant to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">150</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">their respective employment agreements will, to the maximum extent permitted by Section&#160;409A of the Code, be paid in a lump sum as soon as practicable following the effective time, provided that the executive officer consents to his or her severance being paid in a lump sum (to the extent such consent is required). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s obligation to pay the severance payments to Dr.&#160;Cannell, Ms.&#160;Forbes, Dr.&#160;MacDonald, Dr.&#160;Rosales and Mr.&#160;Sullivan pursuant to their respective employment agreements is contingent upon the executive&#8217;s execution and non-revocation of a release of claims in favor of Sesen Bio. In addition, Sesen Bio&#8217;s obligation to pay such severance payments is subject to the executive&#8217;s compliance with certain restrictive covenants, including non-competition and non-solicitation (of employees and customers) covenants, which run for one year following the executive&#8217;s termination of employment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Taxation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that any severance or other compensation payment to Dr.&#160;Cannell, Ms.&#160;Forbes, Dr.&#160;Rosales and Mr.&#160;Sullivan pursuant to his or her employment agreement or any other agreement constitutes an &#8220;excess parachute payment&#8221; within the meaning of Sections&#160;280G and 4999 of the Code, then he or she will receive the full amount of such severance and other payments, or a reduced amount intended to avoid the application of Sections&#160;280G and 4999 of the Code, whichever provides the executive with the highest amount on an after-tax basis. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">2022 Retention Program</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to a retention program that was approved by the Sesen Bio board of directors and the Sesen Bio compensation committee on August&#160;28, 2022, certain employees of Sesen Bio, including Ms.&#160;Forbes, Dr.&#160;MacDonald and Mr.&#160;Sullivan, received a cash bonus award, which vests in full upon the earlier of the completion of a potential strategic transaction and the employee&#8217;s termination of employment without cause, subject to the employee&#8217;s continued employment through that time. Pursuant to the retention program, Ms.&#160;Forbes was awarded a cash bonus of $199,894, Dr.&#160;MacDonald was awarded a cash bonus of CAD&#160;$121,153 and Mr.&#160;Sullivan was awarded a cash bonus of $191,013. The foregoing cash bonuses will vest and be paid in connection with the closing of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Golden Parachute Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This section sets forth the information required by Item&#160;402(t) of Regulation&#160;S-K regarding the compensation that is based on or otherwise relates to the merger and that is payable or may become payable to Sesen Bio&#8217;s named executive officers. This compensation is referred to as &#8220;golden parachute&#8221; compensation by the applicable SEC disclosure rules. For purposes of calculating these amounts, Sesen Bio has assumed: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effective time occurred on January 4, 2023; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a price per share of Sesen Bio common stock of $0.40, which represents the average closing market price of Sesen Bio common stock over the first five business days following the public announcement on September&#160;21, 2022 of the entry into the Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the employment of the named executive officer will be terminated on such date in a manner that entitles the named executive officer to receive the severance payments and benefits under the terms of the employment agreement with the named executive officer (as described above). The employment of the named executive officer is expected to be terminated effective immediately after the closing of the merger; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the named executive officer does not enter into a new agreement or otherwise becomes legally entitled to, prior to the effective time, additional compensation or benefits. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The amounts set forth in the table are estimates based on multiple assumptions that may or may not actually occur, including assumptions described below and elsewhere in this proxy statement/prospectus and in the footnotes to the table. Furthermore, the amounts set forth in the table do not reflect any reductions in payments or benefits that could result from the operation of Section&#160;280G of the Code modified cutback provision that is in the employment agreements of Dr.&#160;Cannell and Ms.&#160;Forbes, as described above. As a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">151</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">result, the actual amounts, if any, that Sesen Bio&#8217;s named executive officers will receive, may materially differ from the amounts set forth in the table. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">For a narrative description of the terms and conditions applicable to the payments quantified in the table below, see the section entitled &#8220;</font><font style="letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Interests of Sesen Bio Directors and Executive Officers in the Merger&#8201;&#8212;&#8201;Termination of Existing Sesen Bio Executive Officers Following the Merger and Related Severance Payments</font><font style="font-style:normal;letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tTOESBEO123">150</a> of this proxy statement/prospectus. </font>
        </div>

          <table style="width:456pt;height:80.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:228.35pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Cash</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Equity</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Health </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Benefits </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Continuation </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(3)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Total</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:228.35pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,729,688</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,066,690</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.35pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:5.35pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,796,378</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228.35pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Monica Forbes </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">599,681</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">577,850</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.35pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">33,344</td>
              <td style="padding:0pt;padding-left:5.35pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,210,875</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228.35pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Mark Sullivan</font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">573,038 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">369,080 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.35pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">33,344 </td>
              <td style="padding:0pt;padding-left:5.35pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">975,462</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The amounts listed in this column represent (i)&#160;cash severance amounts payable to the named executive officer pursuant to his or her employment agreement equal to 12&#160;months (24&#160;months for Dr.&#160;Cannell) of base salary continuation ($1,153,125 for Dr.&#160;Cannell; $399,788 for Ms.&#160;Forbes; and $382,025 for Mr.&#160;Sullivan), which amounts are payable to the executive in installments over 12&#160;months (24&#160;months for Dr.&#160;Cannell) following the executive&#8217;s termination of employment; (ii)&#160;a cash severance amount payable to Dr.&#160;Cannell equal to two times his annual target bonus payment for calendar year 2022 ($576,563), payable in a lump sum following Dr.&#160;Cannell&#8217;s termination of employment, and (iii)&#160;a cash retention bonus payable to each of Ms.&#160;Forbes ($199,894) and Mr.&#160;Sullivan ($191,013) in a lump sum in connection with the closing of the merger. The cash severance payments payable to Dr.&#160;Cannell, Ms.&#160;Forbes and Mr.&#160;Sullivan pursuant to their respective employment agreements are a double-trigger benefit in that they will be paid only if the executive experiences a qualifying termination of employment within 12&#160;months (18&#160;months for Dr.&#160;Cannell) following the closing of the merger. The cash retention bonuses payable to Ms.&#160;Forbes and Mr.&#160;Sullivan are a single-trigger benefit in that they will be paid upon the consummation of the merger. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The amounts listed in this column represent (i)&#160;the value of the full acceleration of vesting of the unvested stock options held by the named executive officer ($581,250 for Dr.&#160;Cannell; $212,500 for Ms.&#160;Forbes; and $114,000 for Mr.&#160;Sullivan), and (ii)&#160;the value of the full acceleration of vesting of the unvested restricted stock&#160;units held by the named executive officer ($485,440 for Dr.&#160;Cannell; $365,350 for Ms.&#160;Forbes; and $255,080 for Mr.&#160;Sullivan;). The acceleration of vesting of the named executive officers&#8217; unvested equity awards is a double-trigger benefit in that it will occur only if the executive experiences a qualifying termination of employment within 12&#160;months (18&#160;months for Dr.&#160;Cannell) following the closing of the merger. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The amounts listed in this column represent the value of continued group health and dental insurance benefits to be provided to the named executive officer (and his or her eligible dependents) pursuant to their respective employment agreements for a period of up to 24&#160;months for Dr.&#160;Cannell and up to 12&#160;months for each of Ms.&#160;Forbes and Mr.&#160;Sullivan. This is a double-trigger benefit in that it will be provided only if the executive experiences a qualifying termination of employment within 12&#160;months (18&#160;months for Dr.&#160;Cannell) following the closing of the merger. As of the date of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, Dr.&#160;Cannell is not enrolled in Sesen Bio&#8217;s group health and dental insurance benefits and, therefore, would not receive any health benefit continuation payments in connection with his qualifying termination of employment. </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification and Insurance</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement, from the effective time through the sixth anniversary of the date on which the effective time occurs, each of Sesen Bio and the surviving corporation is required to indemnify and hold harmless each person who is or has served as a director or officer of Sesen Bio or Carisma against all claims, all claims, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements and investigation costs incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, or any other actual, threatened or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">152</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIOCD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">completed proceeding arising out of or pertaining to the fact that such person is or was a director or officer of Sesen Bio, to the fullest extent permitted under the DGCL for directors or officers of Delaware corporations. In addition, each such director and officer, or former director and officer, is entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement, the provisions of the Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Sesen Bio will not be amended, modified or repealed for a period of six&#160;years from the effective time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the effective time, were officers or directors of Sesen Bio, unless such modification is required by applicable law. The Carisma Certificate of Incorporation and Carisma Bylaws, as the surviving corporation in the merger, shall contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers than those that are presently set forth in the Sesen Bio Certificate of Incorporation and Sesen Bio Bylaws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement also provides that Sesen Bio shall maintain directors&#8217; and officers&#8217; liability insurance policies commencing at the closing of the merger, on commercially available terms and conditions with coverage limits customary for U.S. public companies similarly situated to Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interests of Carisma Directors and Executive Officers in the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In considering the recommendation of the Carisma board of directors with respect to approving the merger, stockholders should be aware that certain members of the Carisma board of directors and certain Carisma executive officers have interests in the merger that may be different from, or in addition to, the interests of Carisma stockholders. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of the Sesen Bio board of directors and the Carisma board of directors were aware of these potential conflicts of interest and considered them, among other matters, in reaching their respective decisions to approve the Merger Agreement and the merger, and to recommend, as applicable, that Sesen Bio stockholders approve the proposals to be presented to Sesen Bio stockholders for consideration at the Sesen Bio special meeting as contemplated by this proxy statement/prospectus, and that Carisma stockholders sign and return the written consent as contemplated by this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Ownership Interests</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, Carisma&#8217;s directors and current executive officers owned, in the aggregate approximately 2.36% of the outstanding shares of Carisma capital stock, which for purposes of this subsection excludes any shares of Carisma common stock issuable upon exercise or settlement of Carisma options held by each such individual. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Stockholders of Carisma</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page&#160;<a href="#tPSOC">397</a> of this proxy statement/prospectus for a description of the beneficial ownership of Carisma&#8217;s directors and officers.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain Carisma stockholders affiliated with Carisma directors also currently hold shares of Carisma capital stock. The table below sets forth the ownership of Carisma capital stock by affiliates of Carisma&#8217;s directors as of January 4, 2023. These Carisma stockholders have also agreed to purchase shares in the Carisma pre-closing financing, which is conditioned upon the satisfaction and waiver of the conditions to the merger as well as certain other conditions. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Related Party Transactions of Directors and Executive Officers of the Combined Company &#8212; Carisma Transactions &#8212; Carisma Pre-Closing Financing</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCARPREC123">369</a> of this proxy statement/prospectus for a description of such relationships. </font>
        </div>
        <table style="width:456pt;height:86.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:379.59pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Stockholder</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Capital Stock Held</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:379.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AbbVie Biotechnology Ltd</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,204,160</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:379.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">HealthCap VII L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,485,912</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:379.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SymBiosis II, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">961,492</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:379.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wellington Life Sciences V GmbH &amp; Co. KG</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">998,079</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">153</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;947,762 shares of Carisma common stock issuable upon conversion of the Carisma Series A preferred stock and (ii) 256,398 shares of Carisma common stock issuable upon conversion of the Carisma Series B preferred stock held by AbbVie Biotechnology Ltd. AbbVie Biotechnology Ltd. holds voting and investment control over the shares. The Board of Directors of AbbVie Biotechnology Ltd. consists of Lindsey Bristow, Jonathan C. Clipper, Stephen Muldoon and Arthur Price. Each of Ms. Bristow and each of Messrs. Clipper, Muldoon and Price may be deemed to share voting and investment power with respect to the shares held by AbbVie Biotechnology Ltd. and disclaim beneficial ownership of all shares held by AbbVie Biotechnology Ltd., except to the extent of their pecuniary interest therein, if any. Margarita Chavez is employed as a Managing Director of AbbVie Ventures and is a member of the Carisma board of directors. Ms. Chavez disclaims beneficial ownership of all shares held by AbbVie Biotechnology Ltd. except to the extent of her pecuniary interest therein, if any. The business address of AbbVie Biotechnology Ltd. is Thistle House, 4 Burnaby Street, Hamilton HM 11, Bermuda.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i) 250,647 shares of Carisma common stock issuable upon conversion of the Carisma Series A preferred stock, (ii)&#160;937,501 shares of Carisma common stock issuable upon the conversion of the Carisma special voting preferred stock and (iii)&#160;297,764 shares of Carisma common stock issuable upon the conversion of the Carisma Series B special voting preferred stock held by HealthCap VII, L.P. HealthCap VII GP SA, a Swiss registered L.C.C., is the sole general partner of HealthCap VII, L.P. and has voting and investment control over the shares. HealthCap VII GP SA disclaims beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of its pecuniary interest therein. Fabrice Bernhard is the General Manager of HealthCap VII GP SA. Dag Richter, Daniel Schafer and Frans Wuite are each Directors of HealthCap VII GP SA. Each of Messrs. Bernhard, Richter, Schafer and Wuite may be deemed to share voting and investment power with respect to the shares held by HealthCap VII L.P. and disclaim beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of their pecuniary interest therein. Bj&#246;rn Odlander is a Managing Partner of HealthCap and is a member of the Carisma board of directors. Dr. Odlander disclaims beneficial ownership of all shares held by HealthCap VII L.P. except to the extent of his pecuniary interest therein, if any. The business address of HealthCap VII L.P. is c/o HealthCap VII GP SA, Avenue Villamont 23, CH 1005&#160;Lausanne Switzerland.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 961,492 shares of Carisma common stock issuable upon conversion of the Carisma Series B preferred stock held by SymBiosis II, LLC, which exercises voting and investment control of the shares. Chidozie Ugwumba is the Managing Partner of Symbiosis II, LLC and as such has sole voting and investment control over the shares. Mr. Ugwumba is also a member of the Carisma board of directors. The business address of Symbiosis II, LLC is 609 S.W. 8th Street, Suite 365, Bentonville, Arkansas&#160;72712.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;798,072 shares of Carisma common stock issuable upon conversion of the Carisma Series A preferred stock and (ii)&#160;200,007 shares of Carisma common stock issuable upon conversion of the Carisma Series B preferred stock held by Wellington Life Sciences V GmbH &amp; Co. KG, or the Wellington Fund. The Wellington Fund is represented by Wellington Life Sciences Venture Capital Consulting GmbH, or the Wellington General Partner. The Wellington General Partner holds voting and investment control over the shares. Dr.&#160;Regina Hodits and Dr. Rainer Strohmenger, in their functions as managing directors of the Wellington General Partner, have individual signatory power as well as voting and/or investment control over the shares. Dr.&#160;Regina Hodits is a member of the Carisma board of directors. Dr.&#160;Regina Hodits disclaims beneficial ownership of all shares held by the Wellington Fund except to the extent of her pecuniary interest therein, if any. The business address of the Wellington Fund and the Wellington General Partner is Tuerkenstrasse 5, 80333 Munich, Germany.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Effect of the Merger on Carisma Options</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, Carisma&#8217;s directors and current executive officers owned, in the aggregate, unvested Carisma options covering 328,143 shares of Carisma common stock and vested Carisma options covering&#160;672,186 shares of Carisma common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Merger Agreement, each option to purchase shares of Carisma common stock that is outstanding and unexercised immediately prior to the effective time under the Carisma Plan and that, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">154</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">following assumption by Sesen Bio at the effective time, will be eligible to be registered on Form S-8, whether or not vested, will be converted into and become an option to purchase shares of Sesen Bio common stock. Sesen Bio will assume the Carisma Plan and each such outstanding Carisma option in accordance with the terms (as in effect as of the date of the Original Merger Agreement) of the Carisma Plan and the terms of the stock option agreement by which such Carisma option is evidenced. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents certain information concerning the outstanding Carisma options held by Carisma directors and current executive officers as of January 4, 2023. The number of shares of Carisma common stock underlying such Carisma options and the exercise price of such Carisma options will be adjusted appropriately to reflect the exchange ratio. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement &#8212; Treatment of Carisma Options</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tTMAER7">174</a> of this proxy statement/prospectus for a more detailed description of the treatment of Carisma options in the merger. </font>
        </div>
        <table style="width:456pt;height:218.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:217.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Vested Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Vested Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unvested Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unvested </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Executive Officers</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Steven Kelly </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">445,814</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.59</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">102,657</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.77</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard Morris </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">69,004</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.77</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">105,322</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.77</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">101,343</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.38</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">27,657</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.77</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Directors</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Margarita Chavez </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">29,700</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.76</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">21,632</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.86</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D., Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sanford Zweifach </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">26,325</td>
            <td style="padding:0pt;padding-left:8.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.77</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">70,875</td>
            <td style="padding:0pt;padding-left:12.93pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.77</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.81pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Support Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of Carisma&#8217;s executive officers and the majority of Carisma&#8217;s directors have also entered into a support agreement in connection with the merger, whereby such executive officers and directors have agreed to vote their shares in favor of adoption of the Merger Agreement and approval of the merger. For a more detailed discussion of the support agreements, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;Support Agreements and Written Consents</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tSAAW">197</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Management Following the Merger</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Management Following the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tMFTM">342</a> of this proxy statement/prospectus, certain members of the Carisma board of directors and Carisma executive officers are expected to become the directors and executive officers of the combined company upon the closing of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification and Insurance</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement, from the effective time through the sixth anniversary of the date on which the effective time occurs, each of Sesen Bio and the surviving corporation in the merger is required to indemnify and hold harmless each person who is or has served as a director or officer of Sesen Bio or Carisma against all claims, all claims, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements and investigation costs incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, or any other actual, threatened or completed proceeding arising out of or pertaining to the fact that such person is or was a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">155</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tFOTM">&#8203;</a><a name="tETOT">&#8203;</a><a name="tMCAE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">director or officer of Sesen Bio, to the fullest extent permitted under the DGCL for directors or officers of Delaware corporations. In addition, each such director and officer, or former director and officer, is entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement, the provisions of the Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Sesen Bio will not be amended, modified or repealed for a period of six&#160;years from the effective time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the effective time, were officers or directors of Sesen Bio, unless such modification is required by applicable law. The Carisma Certificate of Incorporation and the Carisma Bylaws, as the surviving corporation in the merger, shall contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers than those that are presently set forth in the Sesen Bio Certificate of Incorporation and Sesen Bio Bylaws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement also provides that Sesen Bio shall maintain directors&#8217; and officers&#8217; liability insurance policies commencing at the closing of the merger, on commercially available terms and conditions with coverage limits customary for U.S. public companies similarly situated to Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form of the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement provides that at the effective time, Merger Sub will be merged with and into Carisma, with Carisma surviving as a wholly-owned subsidiary of Sesen Bio. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After completion of the merger, Sesen Bio will change its corporate name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; as contemplated by the Merger Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Effective Time of the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement requires the parties to consummate the merger as promptly as practicable (and in any event within two business days) after all of the conditions to the consummation of the merger contained in the Merger Agreement are satisfied or waived. The merger will become effective upon the filing of a certificate of merger with the Secretary of State of the State of Delaware or at such later time as is agreed by Sesen Bio and Carisma and specified in the certificate of merger. Neither Sesen Bio nor Carisma can predict the exact timing of the consummation of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Merger Consideration and Exchange Ratio</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Merger Consideration</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the effective time, upon the terms and subject to the conditions set forth in the Merger Agreement, each outstanding share of Carisma&#8217;s capital stock (including shares of Carisma capital stock sold in the Carisma pre-closing financing but excluding (i)&#160;shares of Carisma capital stock to be canceled pursuant to the Merger Agreement and (ii)&#160;Carisma common stock held by holders of Carisma common stock who have exercised and perfected appraisal rights or dissenters&#8217; rights) will be automatically converted solely into the right to receive a number of shares of Sesen Bio common stock and each outstanding Carisma option will become exercisable for shares of Sesen Bio common stock, in each case, equal to the exchange ratio described in more detail below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No fractional shares of Sesen Bio common stock will be issued in connection with the merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of Sesen Bio common stock resulting from the conversion of Carisma capital stock will receive cash (without interest and subject to applicable tax withholding) in an amount equal to such fractional part of a share of Sesen Bio common stock multiplied by the last reported sale price of Sesen Bio common stock at 4:00&#160;p.m., Eastern Time, end of regular trading hours on Nasdaq on the last day prior to the effective time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exchange Ratio</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The exchange ratio is calculated using a formula intended to allocate existing Sesen Bio and Carisma stockholders a&#160;percentage of the combined company. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">156</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">capitalization as of December 29, 2022, the date the Merger Agreement Amendment was executed, the exchange ratio is estimated to be approximately 37.7924 shares of Sesen Bio common stock. This estimate is subject to adjustment prior to the closing of the merger for net cash at the cash determination time and aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing (and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on the estimates set forth above, and certain other assumptions, Sesen Bio stockholders would own approximately 25.2% of the common stock of the combined company post-merger, and Carisma stockholders would own approximately 74.8% of the common stock of the combined company post-merger, of which the shares issued in the Carisma pre-closing financing and the shares issued upon the conversion of the Carisma convertible note are expected to represent approximately 8.4% and 11.3%, respectively, of the common stock of the combined company post-merger. For more information on the Carisma pre-closing financing, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;Subscription Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tSUAG">198</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The exchange ratio formula is the quotient obtained (rounded to four decimal places) by dividing the number of Carisma merger shares (defined below) by the Carisma outstanding shares (defined below), in which: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Aggregate valuation&#8221; means the sum of the (i)&#160;Carisma valuation plus (ii)&#160;the Sesen Bio valuation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Carisma allocation&#160;percentage&#8221; means the quotient (expressed as a&#160;percentage with the&#160;percentage rounded to four decimal places) determined by dividing (i)&#160;the Carisma valuation by (ii)&#160;the aggregate valuation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Carisma merger shares&#8221; means the product determined by multiplying (i)&#160;the post-closing Sesen Bio shares by (ii)&#160;the Carisma allocation&#160;percentage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Carisma outstanding shares&#8221; means the total number of shares of Carisma capital stock outstanding immediately prior to the effective time expressed on a fully-diluted and as-converted to Carisma common stock basis and assuming, without limitation or duplication, (i)&#160;the exercise of all Carisma options outstanding as of immediately prior to the effective time, (ii)&#160;the closing of the Carisma pre-closing financing, and (iii)&#160;the issuance of shares of Carisma common stock issuable in respect of all other outstanding options, restricted stock awards, warrants or rights to receive such shares, whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or associated with the consummation of the Merger. Carisma outstanding shares shall also include all shares of the Carisma issued in the Carisma pre-closing financing prior to the effective time and excludes any shares issued upon the conversion of the Carisma convertible note. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Carisma valuation&#8221; means (i)&#160;$196.0&#160;million, plus (ii)&#160;the amount of gross proceeds from the Carisma pre-closing financing prior to the effective time. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Sesen Bio allocation&#160;percentage&#8221; means the quotient (expressed as a&#160;percentage with the&#160;percentage rounded to four decimal places) determined by dividing (i)&#160;the Sesen Bio valuation by (ii)&#160;the aggregate valuation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Sesen Bio outstanding shares&#8221; means the total number of shares of Sesen Bio common stock outstanding immediately prior to the effective time expressed on a fully-diluted and as converted to Sesen Bio common stock basis, assuming, without limitation or duplication, the issuance of shares of Sesen Bio common stock in respect of all Sesen Bio options, Sesen Bio RSUs, Sesen Bio warrants and other outstanding options, warrants or rights to receive such shares, in each case, outstanding as of immediately prior to the effective time. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Sesen Bio valuation&#8221; means $140.0&#160;million, minus the amount by which net cash at the cash determination time is less than $125.0&#160;million, plus the amount by which net cash at the cash determination time is greater than $125.0&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Post-closing Sesen Bio shares&#8221; mean the quotient determined by dividing (i)&#160;the Sesen Bio outstanding shares by (ii)&#160;the Sesen Bio allocation&#160;percentage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">157</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSBFN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio&#8217;s Final Net Cash</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of the Merger Agreement, Sesen Bio&#8217;s &#8220;final net cash&#8221; means, as of the cash determination time (which is as of 8:00&#160;p.m. Eastern Time on the last business day prior to the anticipated closing date) the sum (without duplication) of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">cash and cash equivalents, marketable securities and other short-term investments of Sesen Bio and its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s accounts receivable (including any tax refund claims pending as of the date of the Original Merger Agreement), deposits and interest; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Seen Bio&#8217;s deposits, prepaid expenses and other prepaid assets which are reflected on the most recent balance sheet and do not constitute restricted cash of Sesen Bio and its subsidiaries; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">50% of the cost of settling any transaction litigation to the extent actually paid in cash by Sesen Bio prior to the closing date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;font-style:italic;letter-spacing:0.2pt;">minus</font><font style="letter-spacing:0.2pt;">, the sum (without duplication) of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any unpaid transaction expenses of Sesen Bio or its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any unpaid indebtedness of Sesen Bio and/or its subsidiaries outstanding as of the closing date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any accounts payable, accrued expenses or short or long term liabilities that are or will become payable in cash, including any such accounts payable, accrued expenses or short or long term liabilities under any Sesen Bio contracts that were in effect prior to the effective time or associated with the termination of any Sesen Bio contracts which were in effect prior to the effective time, or the termination before, at or after the effective time, of all current or former employees of Sesen Bio and its subsidiaries (even if the applicable expenses or amounts are due and payable after the effective time); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any unpaid employer portion of payroll or employment taxes incurred in connection with the grant, exercise, conversion, settlement or cancellation of Sesen Bio RSUs, Sesen Bio options, equity compensation and other change in control or severance payments (including bonuses payable) due under the Merger Agreement or CVRs issued to holders of Sesen Bio RSUs or Sesen Bio options or otherwise as compensation (either incurred prior to or at the time of the Merger, and for the avoidance of doubt, not calculated as of the close of business on the business day prior to the closing date) in each case, incurred in connection with the merger by Sesen Bio at or prior to the effective time (even if payable after the effective time); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any pre-payment, termination, &#8220;end of term&#8221; or similar fee or charge payable to any lender in connection with the repayment of indebtedness by Sesen Bio at or prior to the effective time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amount of any cash dividend declared (or to be declared) but not yet paid as part of the pre-closing dividend; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to the extent unpaid at closing, the cost and/or premium of the directors&#8217; and officer&#8217;s &#8220;tail policy&#8221;; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to the extent unpaid at closing, the cost of settling any legal proceeding or other dispute existing as of the date of the Original Merger Agreement, as well as the unpaid deductible amount under Sesen Bio&#8217;s insurance reasonably expected to be payable in connection with legal proceedings existing as of the date of the Original Merger Agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each component of net cash, to the extent applicable, shall be determined in accordance with U.S. GAAP, applied on a basis consistent with the application of U.S. GAAP in the preparation of Sesen Bio&#8217;s most recent audited or reviewed financial statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Not more than ten nor less than five calendar days prior to the anticipated closing date, Sesen Bio will deliver to Carisma a schedule, or the net cash schedule, setting forth, in reasonable detail, Sesen Bio&#8217;s good faith estimated calculation of its net cash at the cash determination time, prepared and certified by Sesen Bio&#8217;s Chief Executive Officer and Chief Financial Officer (or if there is no chief financial officer at such time, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">158</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPFEC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the principal financial and accounting officer of Sesen Bio) together with the work papers and back-up materials used or useful in preparing the net cash schedule, as reasonably requested by Carisma. Within three business days after delivery of the net cash schedule (the last day of such period referred to as the response date), Carisma will have the right to dispute all or any part of the net cash schedule by delivering a written notice to that effect to Sesen Bio (referred to herein as a dispute notice). Any dispute notice will identify in reasonable detail to the extent then known, the nature and amounts of any proposed revisions to Sesen Bio&#8217;s net cash calculation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma disputes the net cash schedule prior to 8:00&#160;pm Eastern Time on the response date, the parties will promptly, and in no event later than one calendar day after the response date, meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of net cash. If the parties are unable to negotiate an agreed-upon determination of net cash thereof within two calendar days after the delivery of a dispute notice (or such other period as Sesen Bio and Carisma may mutually agree upon in writing), then any remaining disagreements as to the calculation of net cash will be referred to Deloitte &amp; Touche LLP or another independent auditor of recognized national standing mutually agreed upon by Sesen Bio and Carisma. The determination of the amount of net cash made by such auditor shall be final and binding on Sesen Bio and Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s net cash balance is subject to numerous factors, some of which are outside of Sesen Bio&#8217;s control. The actual amount of net cash will depend significantly on the timing of the closing of the merger. In addition, the closing of the merger could be delayed if Sesen Bio and Carisma are not able to agree upon the amount of Sesen Bio&#8217;s net cash as of the cash determination time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Procedures for Exchanging Carisma Stock Certificates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement provides that, at the effective time, Sesen Bio will deposit with an exchange agent acceptable to Sesen Bio and Carisma evidence of book-entry shares representing the shares of Sesen Bio common stock issuable to Carisma stockholders and a sufficient amount of cash to make payments in lieu of fractional shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement provides that, promptly after the effective time, the exchange agent will mail to each record holder of Carisma capital stock immediately prior to the effective time a letter of transmittal and instructions for surrendering and exchanging Carisma stock certificates or transfer of book-entry shares held by such record holder in exchange for book-entry shares of Sesen Bio common stock. Upon surrender of a Carisma stock certificate or transfer of book-entry shares for exchange to the exchange agent, together with a duly signed letter of transmittal and such other documents as the exchange agent or Sesen Bio may reasonably require, the Carisma stock certificate or book-entry share surrendered will be cancelled and the holder of such Carisma stock certificate or book-entry share will be entitled to receive the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">book-entry shares representing the number of whole shares of Sesen Bio common stock that such holder has the right to receive pursuant to the provisions of the Merger Agreement, and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">cash in lieu of any fractional share of Sesen Bio common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From and after the effective time, until it is surrendered, each certificate or book-entry share that previously evidenced shares of Carisma capital stock will be deemed to represent only the right to receive shares of Sesen Bio common stock, and cash in lieu of any fractional share of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If any Carisma stock certificate has been lost, stolen or destroyed, Sesen Bio may, in its discretion, and as a condition precedent to the delivery of any book-entry shares of Sesen Bio common stock, require the owner of such lost, stolen or destroyed certificate to provide an affidavit claiming such certificate has been lost, stolen or destroyed and, at Sesen Bio&#8217;s discretion, may also require such owner to indemnify Sesen Bio against any claim suffered by Sesen Bio related to the lost, stolen or destroyed certificate or any Sesen Bio common stock issued in exchange thereof as Sesen Bio may reasonably request. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio will not pay dividends or other distributions on any shares of Sesen Bio common stock to be issued in exchange for shares of Carisma capital stock represented by any unsurrendered Carisma stock certificate or book-entry share until such Carisma stock certificate is surrendered, or book-entry share transferred, as provided in the Merger Agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">159</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tREAP">&#8203;</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Regulatory Approvals</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the U.S., Sesen Bio must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of Sesen Bio common stock and the filing of this proxy statement/prospectus with the SEC. Sesen Bio does not intend to seek any regulatory approval from antitrust authorities to consummate the transactions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following discussion is a summary of the material U.S. federal income tax consequences of the merger to Carisma U.S. holders (as defined below), but does not purport to be a complete analysis of all potential tax consequences that may be relevant to Carisma U.S. holders. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Carisma U.S. holder. Carisma has not sought and does not intend to seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a position contrary to that discussed below regarding the tax consequences of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This discussion is limited to Carisma U.S. holders that hold Carisma capital stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences that may be relevant to a Carisma U.S. holder&#8217;s particular circumstances, including the impact of the alternative minimum tax, the Medicare contribution tax on net investment income or the rules related to &#8220;qualified small business stock&#8221; within the meaning of Section&#160;1202 of the Code. In addition, it does not address consequences relevant to Carisma U.S. holders subject to special rules, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">U.S. expatriates and former citizens or long-term residents of the U.S.; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">U.S. holders whose functional currency is not the U.S. dollar; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons holding Carisma capital stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">banks, insurance companies and other financial institutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">real estate investment trusts or regulated investment companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">brokers, dealers or traders in securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">S corporations, partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-exempt organizations or governmental organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons deemed to sell Carisma capital stock under the constructive sale provisions of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons who hold or received Carisma capital stock pursuant to the exercise of any employee stock option or otherwise as compensation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-qualified retirement plans. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an entity treated as a partnership for U.S. federal income tax purposes holds Carisma capital stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Carisma capital stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">160</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUSHCA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the following discussion does not address: (a)&#160;the tax consequences of transactions effectuated before, after or at the same time as the merger, whether or not they are in connection with the merger, including, without limitation, transactions in which shares of Carisma capital stock are acquired or disposed of other than in exchange for shares of Sesen Bio common stock in the merger, (b)&#160;the tax consequences to holders of convertible notes or options or warrants of Carisma, or (c)&#160;the tax consequences of the ownership of shares of Sesen Bio common stock following the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">IT IS RECOMMENDED THAT HOLDERS CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE MERGER ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this discussion, a &#8220;Carisma U.S. holder&#8221; is a beneficial owner of Carisma capital stock that, for U.S. federal income tax purposes, is or is treated as: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an individual who is a citizen or resident of the U.S.; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a corporation created or organized under the laws of the U.S., any state thereof, or the District of Columbia; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a trust that (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; &#8203;(within the meaning of Section&#160;7701(a)(30) of the Code) over all of its substantial decisions or (ii)&#160;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Tax Characterization of the Merger</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the opinion of WilmerHale and Hogan Lovells, the merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code and the material U.S. federal income tax consequences of the merger to Carisma U.S. holders are as described below under the heading &#8220;&#8212; </font><font style="font-style:italic;letter-spacing:0.2pt;">Tax Treatment of Carisma U.S.&#160;Holders in the Merger</font><font style="letter-spacing:0.2pt;">.&#8221; These opinions are based on facts and representations contained in representation letters provided to WilmerHale and Hogan Lovells by Sesen Bio, Merger Sub and Carisma and certain assumptions, including that the merger is completed in the manner set forth in the Merger Agreement and the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part. The accuracy of such facts, representations and assumptions, could affect the conclusions set forth in such opinions. The opinions will not be binding on the IRS or the courts.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the merger does not qualify as a tax-free &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code (including if the IRS successfully challenges the qualification of the merger as such), then each Carisma U.S. holder generally would recognize gain or loss on the exchange of Carisma capital stock for Sesen Bio common stock in the merger equal to the difference between (x)&#160;the fair market value of the shares of Sesen Bio common stock received in exchange for the Carisma capital stock plus any cash received in lieu of a fractional share and (y)&#160;such Carisma U.S. holder&#8217;s adjusted tax basis in the shares of Carisma capital stock surrendered. The remainder of this discussion assumes that the merger will be treated as a tax-free &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code in accordance with the opinions referred to above. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Tax Treatment of Carisma U.S. Holders in the Merger</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The material U.S. federal income tax consequences to a U.S. holder of Carisma capital stock as a result of the merger will be as follows: (i)&#160;except as described below with respect to the receipt of cash in lieu of a fractional share of Sesen Bio common stock, a Carisma U.S. holder generally will not recognize gain or loss upon the exchange of the holder&#8217;s Carisma capital stock for Sesen Bio common stock, (ii)&#160;a Carisma U.S. holder generally will obtain an aggregate adjusted tax basis in the Sesen Bio common stock the holder receives in the merger equal to the holder&#8217;s adjusted tax basis in the Carisma capital stock exchanged therefor, reduced by the basis allocable to any fractional share of Sesen Bio common stock for which cash is received, and (iii)&#160;the holding period of the shares of Sesen Bio common stock received by a Carisma U.S. holder in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">161</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the merger will include the holding period of the shares of Carisma capital stock surrendered in exchange therefor. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Carisma capital stock surrendered to the shares of Sesen Bio common stock received. Carisma U.S. holders of shares of Carisma capital stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash in Lieu of Fractional Share</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A Carisma U.S. holder that receives cash in lieu of a fractional share of Sesen Bio common stock generally will be treated as having received such fractional share and then as having received such cash in redemption of the fractional share. A Carisma U.S. holder generally will recognize gain or loss equal to the difference between the amount of cash received in lieu of the fractional share of Sesen Bio common stock and the portion of the U.S. holder&#8217;s aggregate adjusted tax basis in the shares of Carisma capital stock allocable to the fractional share. Such gain or loss generally will be capital gain or loss and will be long-term capital gain or loss if the Carisma U.S. holder&#8217;s holding period for the Carisma capital stock surrendered in the merger exceeds one year at the effective time. Long-term capital gains of certain non-corporate holders of Carisma capital stock, including individuals, are generally taxed at preferential rates. The deductibility of capital losses is subject to limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Reporting Requirements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each Carisma U.S. holder who receives shares of Sesen Bio common stock in the merger is required to retain permanent records pertaining to the merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and the fair market value of the Carisma capital stock exchanged and the amount of Sesen Bio common stock and cash received in exchange therefor. Carisma U.S. holders who owned immediately before the merger at least one&#160;percent (by vote or value) of the total outstanding stock of Carisma are required to attach a statement to their tax returns for the year in which the merger is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368-3(b). Such statement must include the Carisma U.S. holder&#8217;s tax basis in such holder&#8217;s Carisma capital stock surrendered in the merger, the fair market value of such stock, the date of the merger and the name and employer identification number of each of Carisma and Sesen Bio. Carisma U.S. holders are urged to consult with their tax advisors to comply with these rules. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Backup Withholding and Information Reporting</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A Carisma U.S. holder may, under certain circumstances, be subject to information reporting and backup withholding on any payments of cash in lieu of fractional shares, unless such holder properly establishes an exemption or provides its correct tax identification number and otherwise complies with the applicable requirements of the backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be refunded or credited against a payee&#8217;s U.S.&#160;federal income tax liability, if any, so long as such payee furnishes the required information to the IRS in a timely manner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The foregoing summary is of a general nature only and is not intended to be, and should not be construed to be, legal, business or tax advice to any particular Carisma stockholder. This summary does not take into account your particular circumstances and does not address consequences that may be particular to you. Therefore, you should consult your tax advisor regarding the particular consequences of the merger to you.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of the Special Cash Dividend</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following discussion is a summary of the material U.S. federal income tax consequences of receipt of the special cash dividend to Sesen Bio stockholders, but does not purport to be a complete analysis of all potential tax consequences that may be relevant to a Sesen Bio stockholder. The effects of other U.S.&#160;federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Sesen Bio stockholder. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">162</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has not sought and does not intend to seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a position contrary to that discussed below regarding the tax consequences of receipt of the special cash dividend. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion is limited to Sesen Bio stockholders that hold Sesen Bio common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences that may be relevant to a Sesen Bio stockholder&#8217;s particular circumstances, including the impact of the alternative minimum tax, the Medicare contribution tax on net investment income or the rules related to &#8220;qualified small business stock&#8221; within the meaning of Section&#160;1202 of the Code . In addition, it does not address consequences relevant to Sesen Bio stockholders subject to special rules, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">U.S. expatriates and former citizens or long-term residents of the U.S.; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio U.S. holders whose functional currency is not the U.S. dollar; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons holding Sesen Bio common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">banks, insurance companies and other financial institutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">real estate investment trusts or regulated investment companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">brokers, dealers or traders in securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">S corporations, partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-exempt organizations or governmental organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Sesen Bio common stock being taken into account in an &#8220;applicable financial statement&#8221; &#8203;(as defined in the Code); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons deemed to sell Sesen Bio common stock under the constructive sale provisions of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons who hold or received Sesen Bio common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-qualified retirement plans. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If an entity treated as a partnership for U.S. federal income tax purposes holds Sesen Bio common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Sesen Bio common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this discussion, a &#8220;Sesen Bio non-U.S. holder&#8221; means a beneficial owner of Sesen Bio common stock that is neither a Sesen Bio U.S. holder (which, for purposes of this discussion, has the same meaning as in &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font><font style="letter-spacing:0.2pt;">&#8221;) nor a partnership (or other entity treated as a partnership) for U.S. federal income tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">IT IS RECOMMENDED THAT SESEN BIO STOCKHOLDERS CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE SPECIAL CASH DIVIDEND ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The discussion below assumes that the distribution of CVRs and the special cash dividend will be treated for U.S. federal income tax purposes as transactions that are separate and distinct from the proposed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">163</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">reverse stock split. However, it is possible that the IRS or a court could determine that the proposed reverse stock split and the receipt of CVRs or the special cash dividend constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. If the proposed reverse stock split and the special cash dividend and the receipt of the CVRs are treated as a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes, then a Sesen Bio stockholder generally should recognize gain (but not loss) equal to the lesser of (i)&#160;the amount of the special cash dividend received plus the fair market value of the CVRs received (assuming the receipt of CVRs is treated as a distribution of property as described in &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font><font style="letter-spacing:0.2pt;">&#8221;), and (ii)&#160;the excess (if any) of (A)&#160;the sum of (1)&#160;the amount of the special cash dividend received plus the fair market value of the CVRs and (2)&#160;the fair market value of the Sesen Bio shares received in the proposed reverse stock split over (B)&#160;the Sesen Bio stockholder&#8217;s adjusted tax basis in the Sesen Bio common stock surrendered in the proposed reverse stock split. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Consequences to Sesen Bio U.S. Holders</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The U.S. federal income tax consequences of a Sesen Bio U.S. holder&#8217;s receipt of a special cash dividend generally should be treated first as a taxable dividend to the extent of the Sesen Bio U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Sesen Bio U.S. holder&#8217;s basis in its Sesen Bio common stock, and finally as capital gain from the sale or exchange of Sesen Bio common stock with respect to any remaining amount. Sesen Bio currently has negative accumulated earnings and profits and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Sesen Bio expects most or all of the special cash dividend to be treated as other than a dividend for U.S. federal income tax purposes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Consequences to Sesen Bio Non-U.S. Holders</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The U.S. federal income tax consequences of a Sesen Bio non-U.S. holder&#8217;s receipt of a special cash dividend generally should be treated first as a taxable dividend to the extent of the Sesen Bio non-U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Sesen Bio non-U.S. holder&#8217;s basis in its Sesen Bio common stock, and finally as capital gain from the sale or exchange of Sesen Bio common stock with respect to any remaining amount. Sesen Bio currently has negative accumulated earnings and profits and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Sesen Bio expects most or all of any special cash dividend to be treated as other than a dividend for U.S. federal income tax purposes. However, if Sesen Bio cannot determine at the time of the special cash dividend whether or not such special cash dividend will exceed current and accumulated earnings and profits, Sesen Bio or the applicable withholding agent is expected to withhold on the special cash dividend at the rate applicable to dividends, as described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Taxable Dividends. Dividend payments to a Sesen Bio non-U.S. holder will generally be subject to withholding at a 30% rate. If a Sesen Bio non-U.S. holder is eligible for a lower treaty rate, then withholding will be at the lower treaty rate only if such Sesen Bio non-U.S. holder provides a valid IRS Form W-8BEN or W-8BEN-E (or applicable successor form) certifying such Sesen Bio non-U.S. holder&#8217;s qualification for the reduced rate. If a Sesen Bio non-U.S. holder holds the stock through a financial institution or other intermediary, the Sesen Bio non-U.S. holder will be required to provide appropriate documentation to the intermediary, which then will be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. Sesen Bio non-U.S. holders who do not timely provide the applicable withholding agent with the required certification, but who qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussion below regarding backup withholding, if the special cash dividend is effectively connected with a Sesen Bio non-U.S. holder&#8217;s conduct of a trade or business within the U.S. (and, if required by an applicable income tax treaty, the Sesen Bio non-U.S. holder maintains a permanent establishment in the U.S. to which the special cash dividend is attributable), the Sesen Bio non-U.S. holder will be exempt from U.S. federal withholding tax and the special cash dividend generally will be subject to U.S. federal income tax on a net income basis in the same manner as if such Sesen Bio non-U.S. holder were a U.S. holder. To </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">164</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tNALI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">claim the exemption, the Sesen Bio non-U.S. holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI (or applicable successor form), certifying that the special cash dividend is effectively connected with the Sesen Bio non-U.S. holder&#8217;s conduct of a trade or business within the United States. A Sesen Bio non-U.S. holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) of all or a portion of its effectively connected earnings and profits for the taxable year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Non-Dividend Distributions. To the extent that the distribution is treated as capital gain from the sale or exchange of Sesen Bio common stock, such gain generally will not be subject to U.S. federal income tax unless (i)&#160;such gain is effectively connected with the conduct by a Sesen Bio non-U.S. holder of a trade or business in the United States (and, if an income tax treaty applies, the gain is generally attributable to a U.S. permanent establishment maintained by such Sesen Bio non-U.S. holder), (ii)&#160;in the case of gain realized by a Sesen Bio non-U.S. holder that is an individual, such Sesen Bio non-U.S. holder is present in the United States for 183&#160;days or more in the taxable year of the sale and certain other conditions are met or (iii)&#160;Sesen Bio is or has been a United States real property holding corporation, or a USRPHC, for U.S. federal income tax purposes and, if the shares are &#8220;regularly traded on an established securities market,&#8221; such Sesen Bio non-U.S. holder owned, directly or indirectly, at any time during the five-year period ending on the date of the distribution, more than 5% of the shares of Sesen Bio common stock and such Sesen Bio non-U.S. holder is not eligible for any treaty exemption. The shares will be considered &#8220;regularly traded&#8221; if they are traded on an established securities market located in the United States and are regularly quoted by brokers or dealers making a market in the shares. Sesen Bio believes it is not, and has not been, a USRPHC for U.S. federal income tax purposes. In addition, although not free from doubt, Sesen Bio believes that Sesen Bio common shares currently should be considered to be regularly traded. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A Sesen Bio non-U.S. holder should consult its tax advisor regarding its entitlement to benefits and the various rules under applicable tax treaties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Information Reporting and Backup Withholding</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, the special cash dividend received by Sesen Bio U.S. holders will be reported to the IRS unless the holder is an exempt recipient. Backup withholding, currently at a rate of 24%, may apply unless the Sesen Bio U.S. holder (1)&#160;is an exempt recipient or (2)&#160;provides a certificate (generally on an IRS Form&#160;W-9) containing the Sesen Bio U.S. holder&#8217;s name, address, correct federal taxpayer identification number and statement that the Sesen Bio U.S. holder is a U.S. person and is not subject to backup withholding. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A Sesen Bio non-U.S. holder will not be subject to backup withholding with respect to the special cash dividend, provided the Sesen Bio Non-U.S. holder certifies its non-U.S. status, such as by providing a valid IRS Form W-8BEN or W-8ECI or W-8BEN-E, or otherwise establishes an exemption. However, information returns will be filed with the IRS in connection with the special cash dividend, regardless of whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of a specific treaty or agreement to the tax authorities of the country in which the Sesen Bio non-U.S. holder resides or is established. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against a Sesen Bio U.S. holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nasdaq Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio common stock currently is listed on Nasdaq under the symbol &#8220;SESN.&#8221; Sesen Bio has agreed to use commercially reasonable efforts to (i)&#160;maintain its existing listing on Nasdaq through the closing of the merger, (ii)&#160;prepare and submit a Nasdaq notification form for the listing of the shares of Sesen Bio common stock to be issued in connection with the merger, and to cause such shares to be approved for listing (subject to official notice of issuance), (iii)&#160;effect the proposed reverse stock split and (iv)&#160;file an initial listing application for the Sesen Bio common stock on Nasdaq and to cause such application to be approved prior to the effective time. In addition, under the Merger Agreement, each party&#8217;s obligation to complete the merger is subject to the satisfaction or waiver by each of the parties prior to the closing of the merger of various conditions, including that the existing shares of Sesen Bio common stock must have been continually </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">165</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tAAT">&#8203;</a><a name="tARAD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">listed on Nasdaq, and Sesen Bio must have caused the shares of Sesen Bio common stock to be issued in the merger to be approved for listing on Nasdaq as of the closing of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has filed an initial listing application with Nasdaq pursuant to Nasdaq &#8220;business combination&#8221; rules. If such application is accepted, Sesen Bio anticipates that the shares of Sesen Bio common stock will be listed on Nasdaq following the closing of the merger under the trading symbol &#8220;CARM.&#8221; In order to meet the requirements for listing on Nasdaq, the post-merger combined company will be required to satisfy Nasdaq&#8217;s initial listing requirements, including the financial and liquidity requirements for the applicable Nasdaq market tier upon which the post-merger combined company&#8217;s shares will trade following the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anticipated Accounting Treatment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The merger is expected to be accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Sesen Bio are cash, cash equivalents and marketable securities. For financial reporting purposes, Carisma has been determined to be the accounting acquirer based upon the terms of the merger including: (i)&#160;Carisma stockholders and holders of securities convertible into Carisma common stock are expected to own approximately 74.8% of the combined company (based on estimates made at the time of the signing of the Merger Agreement), (ii)&#160;Carisma will hold the majority (six of seven) of board seats of the combined company and (iii)&#160;Carisma management will hold all key positions in the management of the combined company. Accordingly, the merger is expected to be treated as the equivalent of Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the merger, the net assets of Sesen Bio will be recorded at their acquisition-date fair value in the consolidated financial statements of Carisma and the reported operating results prior to the merger will be those of Carisma. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Unaudited Pro Forma Condensed Combined Financial Information</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tUPFC">372</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus for additional information. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Appraisal Rights and Dissenters&#8217; Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the merger is completed, Carisma stockholders who do not deliver a written consent approving the merger are entitled to appraisal rights under Section&#160;262 of the DGCL, or Section&#160;262, provided that they comply with the conditions established by Section&#160;262. Holders of Sesen Bio common stock are not entitled to appraisal rights under Delaware law in connection with the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The discussion below is not a complete summary regarding a Carisma stockholder&#8217;s appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which is attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex H</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus. Carisma stockholders intending to exercise appraisal rights should carefully review </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex H</font><font style="letter-spacing:0.2pt;">. Failure to follow precisely any of the statutory procedures set forth in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex H</font><font style="letter-spacing:0.2pt;"> may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that Carisma stockholders exercise their appraisal rights under Delaware law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under Section&#160;262, where a merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&#160;228 of the DGCL, either the constituent corporation before the effective date of the merger, or the surviving corporation within 10&#160;days after the effective date of the merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of the merger, the effective date of the merger and that appraisal rights are available. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the merger is completed, within 10&#160;days after the effective date Carisma will notify Carisma stockholders that the merger has been approved, the effective date and that appraisal rights are available to any Carisma stockholder who has not approved the merger. Carisma stockholders who desire to exercise their appraisal rights must deliver a written demand for appraisal to Carisma within 20&#160;days after the date of mailing of that notice, and that Carisma stockholder must not have delivered a written consent approving the merger. A demand for appraisal must reasonably inform Carisma of the identity of the Carisma stockholder and that such Carisma stockholder intends thereby to demand appraisal of the shares of Carisma common stock held by such Carisma stockholder. Failure to deliver a written consent approving the merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&#160;262. All demands for appraisal should be addressed to CARISMA Therapeutics Inc., 3675 Market </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">166</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Street, Suite 200, Philadelphia, PA 19104, Attention: Corporate Secretary, Email: legal@carismatx.com, and should be executed by, or on behalf of, the record holder of shares of Carisma capital stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ALL DEMANDS MUST BE RECEIVED BY CARISMA WITHIN 20 DAYS AFTER THE DATE CARISMA MAILS A NOTICE TO CARISMA STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY CARISMA STOCKHOLDER WHO HAS NOT APPROVED THE MERGER.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are a Carisma stockholder, and fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the merger consideration for your shares of Carisma capital stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of Carisma capital stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To be effective, a demand for appraisal by a Carisma stockholder must be made by, or in the name of, the registered stockholder, fully and correctly, as the Carisma stockholder&#8217;s name appears on the Carisma stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may exercise appraisal rights directly, rather than relying on the record owner of their shares of Carisma capital stock to demand appraisal on their behalf. In order for a beneficial owner to assert appraisal rights with respect to any shares, such owner must maintain continuous beneficial ownership of such shares through the effective date of the merger and provide documentary evidence of such ownership, as more fully described in Section&#160;262(d)(3) of the DGCL. If shares of Carisma capital stock are owned of record or beneficially in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares of Carisma capital stock are owned of record or beneficially by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a Carisma stockholder; however, the agent must identify the record/</font>&#8203;<font style="letter-spacing:0.2pt;">beneficial owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record/beneficial owner. A record owner, such as a broker, who holds shares of Carisma capital stock as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares of Carisma capital stock held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares of Carisma capital stock as to which appraisal is sought. Where no number of shares of Carisma capital stock is expressly mentioned, the demand will be presumed to cover all shares of Carisma capital stock held in the name of the record owner. In addition, the Carisma stockholder must hold the shares of Carisma capital stock continuously through the effective time and on the date of making a demand. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you hold your shares of Carisma capital stock in a brokerage account or in other custodian form and you do not wish to exercise appraisal rights directly as a beneficial owner, you should consult with your broker, bank or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At any time within 60&#160;days after the effective time, any Carisma stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such Carisma stockholder&#8217;s demand and accept the terms of the merger by delivering a written withdrawal to Carisma. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section&#160;262, you will have the right to receive the merger consideration for your shares of Carisma capital stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Within 120&#160;days after the effective time, any Carisma stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares of Carisma capital stock not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares of Carisma capital stock. This written statement will be mailed to the requesting Carisma stockholder within 10&#160;days after the Carisma stockholder&#8217;s written request is received by the surviving corporation or within 10&#160;days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120&#160;days after the effective time, either the surviving corporation or any Carisma stockholder who has delivered a demand for appraisal in accordance </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">167</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">with Section&#160;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares of Carisma capital stock held by all such Carisma stockholders. Upon the filing of the petition by a Carisma stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting Carisma stockholders, and Sesen Bio, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a Carisma stockholder to file a petition within the period specified could nullify the Carisma stockholder&#8217;s previously written demand for appraisal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a petition for appraisal is duly filed by a Carisma stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20&#160;days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all Carisma stockholders who have demanded an appraisal of their shares of Carisma capital stock and with whom agreements as to the value of their shares of Carisma capital stock have not been reached by the surviving corporation. After notice to dissenting Carisma stockholders who demanded appraisal of their shares of Carisma capital stock, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those Carisma stockholders who have complied with Section&#160;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the Carisma stockholders who have demanded appraisal for their shares of Carisma capital stock to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any Carisma stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that Carisma stockholder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After determination of the Carisma stockholders entitled to appraisal of their shares of Carisma capital stock, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares of Carisma capital stock owned by those Carisma stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the Carisma stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares of Carisma capital stock. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each Carisma stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&#160;the difference, if any, between the amount so paid and the fair value of the shares of Carisma capital stock subject to appraisal as determined by the Delaware Court of Chancery and (ii)&#160;interest theretofore accrued, unless paid at that time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In determining fair value, and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In </font><font style="font-style:italic;letter-spacing:0.2pt;">Weinberger v. UOP, Inc.</font><font style="letter-spacing:0.2pt;">, the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; In </font><font style="font-style:italic;letter-spacing:0.2pt;">Cede &amp; Co. v. Technicolor, Inc.</font><font style="letter-spacing:0.2pt;">, the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In Weinberger, the Delaware Supreme Court construed Section&#160;262 to mean that &#8220;elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You should be aware that the fair value of your shares of Carisma capital stock as determined under Section&#160;262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the Carisma stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">168</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLRTM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">deems equitable in the circumstances. Upon the application of a Carisma stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any Carisma stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro&#160;rata against the value of all shares of Carisma capital stock entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any Carisma stockholder who had demanded appraisal rights will not, after the effective time, be entitled to vote shares of Carisma capital stock subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares of Carisma capital stock, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120&#160;days after the effective time, or if the Carisma stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the merger within 60&#160;days after the effective time, then the right of that Carisma stockholder to appraisal will cease and that Carisma stockholder will be entitled to receive the merger consideration for shares of his or her Carisma capital stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more than 60&#160;days after the effective time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Failure to follow the steps required by Section&#160;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&#160;262, Carisma stockholders who may wish to dissent from the merger and pursue appraisal rights should consult their legal advisors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Litigation Related to the Merger</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio received (a) one demand letter on October 21, 2022, attaching a draft complaint, sent on behalf of Thomas Budzinski, a purported stockholder of Sesen Bio (the &#8220;Budzinski Demand&#8221;), (b) one demand letter on October 21, 2022, sent on behalf of Derick Passmore, a purported stockholder of Sesen Bio (the &#8220;Passmore Demand&#8221;) and (c) one demand letter on November&#160;4, 2022, sent on behalf of Ryan McKinley, a purported stockholder of Sesen Bio (the &#8220;McKinley Demand&#8221; and together with the Budzinski Demand and the Passmore Demand, the &#8220;Demand Letters&#8221;). In addition, Sesen Bio received a books and records demand, dated November&#160;18, 2022 (the &#8220;Section 220 Demand&#8221;), on behalf of a purported stockholder of Sesen Bio seeking access to certain relevant books and records of Sesen Bio pursuant to Section 220 of the DGCL in connection with the merger and the securities and derivative litigations arising out of the CRL that Sesen Bio received from the FDA.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each of the Budzinski Demand, the Passmore Demand and the McKinley Demand alleges omissions of material information with respect to the merger from this proxy statement/prospectus, including information regarding the financial projections with respect to Carisma, the financial analyses performed by SVB Securities in support of its fairness opinion, and the background and process leading to the execution of the Merger Agreement, and demands that Sesen Bio promptly provide stockholders with additional disclosure. In addition, the Budzinski Demand includes a draft complaint, which asserts claims against Sesen Bio and the Sesen Bio board of directors under Section 14(a) of the Exchange Act and Rule&#160;14a-9 promulgated thereunder for allegedly false and misleading statements in this proxy statement/prospectus and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements. The Section 220 Demand states that the purpose of the demand is to, among other things, investigate purported questions of director independence and disinterestedness and the possibility of wrongdoing, mismanagement, and/or material non-disclosure related to the Sesen Bio board&#8217;s approval of the merger and the other transactions contemplated thereby and to determine whether suit should be brought in connection therewith.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, on November 28, 2022, a purported Sesen Bio stockholder filed a complaint in the U.S. District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Keller v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No.&#160;1:22-cv-10085 (S.D.N.Y.) (the &#8220;Original Keller Complaint&#8221;). The Original Keller Complaint made assertions similar to the Demand Letters and sought, among other relief, an order enjoining the merger and an award for plaintiffs&#8217; fees and costs. On December&#160;20, 2022, the purported stockholder voluntarily dismissed his complaint and on December&#160;21, 2022, filed a new complaint as a putative class action in the Court of Chancery for the State of Delaware, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Keller v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 2022-1186 (Del. Ch. Dec. 21, 2022) (the &#8220;New Keller </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">169</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:444pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Complaint&#8221;). Along with the complaint, the purported stockholder filed motions for expedited proceedings and for a preliminary injunction to enjoin the Sesen Bio special meeting. The New Keller Complaint and associated filings contain substantially the same assertions as the Original Keller Complaint and the Demand Letters.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio believes that the claims asserted in the Demand Letters, the Section 220 Demand and the New Keller Complaint are without merit.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio stockholders and Carisma stockholders may serve additional demands and/or file additional lawsuits challenging the merger, which may name Sesen Bio, Carisma, members of the Sesen Bio board of directors, members of the Carisma board of directors and/or others as defendants. No assurance can be made as to the outcome of such additional demands, lawsuits, the Demand Letters, the Section 220 Demand or the Keller Complaint, including the amount of costs associated with defending, settling, or any other liabilities that may be incurred in connection with the litigation or settlement of, such claims. If any additional demands are served and/or any additional lawsuits filed, absent new or different allegations that are material, Sesen Bio will not necessarily announce such additional demands and/or complaints.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">170</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTMA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE MERGER AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following is a summary of the material terms of the Merger Agreement. Copies of the Original Merger Agreement and the Merger Agreement Amendment are attached as Annexes A-1 and A-2, respectively, to this proxy statement/prospectus and are incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about Sesen Bio, Carisma or Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the merger and the terms and conditions of the Merger Agreement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement contains representations and warranties that Sesen Bio and Merger Sub, on the one hand, and Carisma, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the Merger Agreement. While Sesen Bio and Carisma do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Sesen Bio and Carisma because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Sesen Bio, Merger Sub and Carisma and are modified by the disclosure schedules. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Structure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Merger Sub was formed as a wholly-owned subsidiary of Sesen Bio for the sole purpose of completing the merger transaction. Under the Merger Agreement at the effective time, Merger Sub will merge with and into Carisma, with Carisma surviving as the wholly-owned subsidiary of Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Completion and Effectiveness of the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The consummation of the merger will take place as promptly as practicable, but in no event later than the second business day after all of the conditions to completion of the merger are satisfied or waived, including certain approvals by the stockholders of Sesen Bio and Carisma. Sesen Bio and Carisma are working to complete the merger and expect that the merger will be completed in the first quarter of 2023, after the Sesen Bio special meeting of stockholders. However, Sesen Bio and Carisma cannot predict the completion of the merger or the exact timing of the completion of the merger because it is subject to various conditions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Merger Consideration</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the effective time, upon the terms and subject to the conditions set forth in the Merger Agreement, each outstanding share of Carisma&#8217;s capital stock (including shares of Carisma capital stock sold in the Carisma pre-closing financing but excluding (i)&#160;shares of Carisma capital stock to be canceled pursuant to the Merger Agreement and (ii)&#160;Carisma common stock held by holders of Carisma common stock who have exercised and perfected appraisal rights or dissenters&#8217; rights) will be automatically converted solely into the right to receive a number of shares of Sesen Bio common stock and each outstanding Carisma option will become exercisable for shares of Sesen Bio common stock, in each case, equal to the exchange ratio described in more detail below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No fractional shares of Sesen Bio common stock will be issued in connection with the merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of Sesen Bio common stock resulting from the conversion of Carisma capital stock will receive cash (without interest and subject to applicable tax withholding) in an amount equal to such fractional part of a share of Sesen Bio common stock multiplied by the last reported sale price of Sesen Bio common stock at 4:00&#160;p.m., Eastern Time, end of regular trading hours on Nasdaq on the last day prior to the effective time. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">171</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTMAER">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exchange Ratio</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The exchange ratio is calculated using a formula intended to allocate existing Sesen Bio and Carisma stockholders a&#160;percentage of the combined company. Based on Sesen Bio&#8217;s capitalization and Carisma&#8217;s capitalization as of December 29, 2022, the date the Merger Agreement was executed, the exchange ratio is estimated to be approximately 37.7924 shares of Sesen Bio common stock. This estimate is subject to adjustment prior to the closing of the merger for net cash at the cash determination time and aggregate proceeds from the sale of Carisma common stock in the Carisma pre-closing financing (and, as a result, Sesen Bio stockholders could own more, and Carisma stockholders (including, for this purpose, investors in the Carisma pre-closing financing) could own less, or vice versa, of the combined company). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on the estimates set forth above, and certain other assumptions, Sesen Bio stockholders would own approximately 25.2% of the common stock of the combined company post-merger, and Carisma stockholders would own approximately 74.8% of the common stock of the combined company post-merger, of which the shares issued in the Carisma pre-closing financing and the shares issued upon the conversion of the Carisma convertible note are expected to represent approximately 8.4% and 11.3%, respectively, of the common stock of the combined company post-merger. For more information on the Carisma pre-closing financing, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;Subscription Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tSUAG">198</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The exchange ratio formula is the quotient obtained (rounded to four decimal places) by dividing the number of Carisma merger shares (defined below) by the Carisma outstanding shares (defined below), in which: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Aggregate valuation&#8221; means the sum of the (i)&#160;Carisma valuation plus (ii)&#160;the Sesen Bio valuation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Carisma allocation&#160;percentage&#8221; means the quotient (expressed as a&#160;percentage with the&#160;percentage rounded to four decimal places) determined by dividing (i)&#160;the Carisma valuation by (ii)&#160;the aggregate valuation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Carisma merger shares&#8221; means the product determined by multiplying (i)&#160;the post-closing Sesen Bio shares by (ii)&#160;the Carisma allocation&#160;percentage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Carisma outstanding shares&#8221; means the total number of shares of Carisma capital stock outstanding immediately prior to the effective time expressed on a fully-diluted and as-converted to Carisma common stock basis and assuming, without limitation or duplication, (i)&#160;the exercise of all Carisma options outstanding as of immediately prior to the effective time, (ii)&#160;the closing of the Carisma pre-closing financing, and (iii)&#160;the issuance of shares of Carisma common stock issuable in respect of all other outstanding options, restricted stock awards, warrants or rights to receive such shares, whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or associated with the consummation of the Merger. Carisma outstanding shares shall also include all shares of the Carisma issued in the Carisma pre-closing financing prior to the effective time and excludes any shares issued upon the conversion of the Carisma convertible note. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Carisma valuation&#8221; means (i)&#160;$196.0&#160;million, plus (ii)&#160;the amount of gross proceeds from the Carisma pre-closing financing prior to the effective time. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Sesen Bio allocation&#160;percentage&#8221; means the quotient (expressed as a&#160;percentage with the&#160;percentage rounded to four decimal places) determined by dividing (i)&#160;the Sesen Bio valuation by (ii)&#160;the aggregate valuation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Sesen Bio outstanding shares&#8221; means the total number of shares of Sesen Bio common stock outstanding immediately prior to the effective time expressed on a fully-diluted and as converted to Sesen Bio common stock basis, assuming, without limitation or duplication, the issuance of shares of Sesen Bio common stock in respect of all Sesen Bio options, Sesen Bio RSUs, Sesen Bio warrants and other outstanding options, warrants or rights to receive such shares, in each case, outstanding as of immediately prior to the effective time. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Sesen Bio valuation&#8221; means $140.0&#160;million, minus the amount by which net cash at the cash determination time is less than $125.0&#160;million, plus the amount by which net cash at the cash </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">172</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">determination time is greater than $125.0&#160;million. However, and pursuant to the terms of the Merger Agreement Amendment, Sesen Bio expects to only have approximately $75.0 million of net cash at the cash determination time. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Post-closing Sesen Bio shares&#8221; mean the quotient determined by dividing (i)&#160;the Sesen Bio outstanding shares by (ii)&#160;the Sesen Bio allocation&#160;percentage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Calculation of Sesen Bio&#8217;s Final Net Cash</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of the Merger Agreement, Sesen Bio&#8217;s &#8220;final net cash&#8221; means, as of the cash determination time (which is as of 8:00&#160;p.m. Eastern Time on the last business day prior to the anticipated closing date) the sum (without duplication) of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">cash and cash equivalents, marketable securities and other short-term investments of Sesen Bio and its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s accounts receivable (including any tax refund claims pending as of the date of the Original Merger Agreement), deposits and interest; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Seen Bio&#8217;s deposits, prepaid expenses and other prepaid assets which are reflected on the most recent balance sheet and do not constitute restricted cash of Sesen Bio and its subsidiaries; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">50% of the cost of settling any transaction litigation to the extent actually paid in cash by Sesen Bio prior to the closing date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;font-style:italic;letter-spacing:0.2pt;">minus</font><font style="letter-spacing:0.2pt;">, the sum (without duplication) of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any unpaid transaction expenses of Sesen Bio or its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any unpaid indebtedness of Sesen Bio and/or its subsidiaries outstanding as of the closing date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any accounts payable, accrued expenses or short or long term liabilities that are or will become payable in cash, including any such accounts payable, accrued expenses or short or long term liabilities under any Sesen Bio contracts that were in effect prior to the effective time or associated with the termination of any Sesen Bio contracts which were in effect prior to the effective time or the termination before, at or after the effective time, of all current or former employees of Sesen Bio and its subsidiaries (even if the applicable expenses or amounts are due and payable after the effective time); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any unpaid employer portion of payroll or employment taxes incurred in connection with the grant, exercise, conversion, settlement or cancellation of Sesen Bio RSUs, Sesen Bio options, equity compensation and other change in control or severance payments (including bonuses payable) due under the Merger Agreement or CVRs issued to holders of Sesen Bio RSUs or Sesen Bio options or otherwise as compensation (either incurred prior to or at the time of the Merger, and for the avoidance of doubt, not calculated as of the close of business on the business day prior to the closing date) in each case, incurred in connection with the merger by Sesen Bio at or prior to the effective time (even if payable after the effective time); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any pre-payment, termination, &#8220;end of term&#8221; or similar fee or charge payable to any lender in connection with the repayment of indebtedness by Sesen Bio at or prior to the effective time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amount of any cash dividend declared (or to be declared) but not yet paid as part of the pre-closing dividend; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to the extent unpaid at closing, the cost and/or premium of the directors&#8217; and officer&#8217;s &#8220;tail policy&#8221;; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to the extent unpaid at closing, the cost of settling any legal proceeding or other dispute existing as of the date of the Original Merger Agreement, as well as the unpaid deductible amount under Sesen Bio&#8217;s insurance reasonably expected to be payable in connection with legal proceedings existing as of the date of the Original Merger Agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each component of net cash, to the extent applicable, shall be determined in accordance with U.S. GAAP, applied on a basis consistent with the application of U.S. GAAP in the preparation of Sesen Bio&#8217;s most recent audited or reviewed financial statements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">173</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTMAER7">&#8203;</a><a name="tTMAER9">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Not more than ten nor less than five calendar days prior to the anticipated closing date, Sesen Bio will deliver to Carisma the net cash schedule setting forth, in reasonable detail, Sesen Bio&#8217;s good faith estimated calculation of its net cash at the cash determination time, prepared and certified by Sesen Bio&#8217;s Chief Executive Officer and Chief Financial Officer (or if there is no chief financial officer at such time, the principal financial and accounting officer) together with the work papers and back-up materials used or useful in preparing the net cash schedule, as reasonably requested by Carisma. Within three business days after delivery of the net cash schedule (the last day of such period referred to as the response date), Carisma will have the right to dispute all or any part or parts of the net cash schedule by delivering a written notice to that effect to Sesen Bio (referred to herein as a dispute notice). Any dispute notice will identify in reasonable detail to the extent then known, the nature and amounts of any proposed revisions to Sesen Bio&#8217;s net cash calculation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma disputes the net cash schedule prior to 8:00&#160;pm Eastern Time on the response date, the parties shall promptly, and in no event later than one calendar day after the response date, meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of net cash. If the parties are unable to negotiate an agreed-upon determination of net cash within two calendar days after the delivery of the dispute notice (or such other period as Sesen Bio and Carisma may mutually agree upon in writing), then any remaining disagreements as to the calculation of net cash will be referred to Deloitte &amp; Touche LLP or another independent auditor of recognized national standing mutually agreed upon by Sesen Bio and Carisma. The determination of the amount of net cash made by such auditor shall be final and binding on Sesen Bio and Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s net cash balance is subject to numerous factors, some of which are outside of Sesen Bio&#8217;s control. The actual amount of net cash will depend significantly on the timing of the closing of the merger. In addition, the closing of the merger could be delayed if Sesen Bio and Carisma are not able to agree upon the amount of Sesen Bio&#8217;s net cash as of the cash determination time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Treatment of Sesen Bio Equity Awards and Warrants</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio Equity Awards</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the effective time, all outstanding and unexercised Sesen Bio options granted pursuant to the 2014 Incentive Plan or the 2009 Incentive Plan or as an inducement grant under Nasdaq Listing Rule 5635(c)(4) will remain in effect pursuant to their terms and will be unaffected by the merger. The number of shares of Sesen Bio common stock underlying the Sesen Bio options and the exercise prices for such Sesen Bio options will be appropriately adjusted to reflect the proposed reverse stock split, if approved and implemented.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the effective time, all outstanding Sesen Bio RSUs granted pursuant to the 2014 Incentive Plan or the 2009 Incentive Plan will remain in effect pursuant to their terms and will be unaffected by the merger. The number of shares of Sesen Bio common stock underlying the Sesen Bio RSUs will be appropriately adjusted to reflect the proposed reverse stock split, if approved and implemented.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio Warrants</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the effective time, all Sesen Bio warrants (other than certain Sesen Bio warrants that Sesen Bio may be required to repurchase at such warrant holder&#8217;s option as of a result of the merger) will remain in effect pursuant to their terms and will be unaffected by the merger. The number of shares of Sesen Bio common stock underlying such Sesen Bio warrants and the exercise prices for such Sesen Bio warrants will be appropriately adjusted to reflect the proposed reverse stock split, if approved.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Treatment of Carisma Options</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Merger Agreement, each Carisma option that is outstanding and unexercised immediately prior to the effective time under the Carisma Plan and that, following assumption by Sesen Bio at the effective time, will be eligible to be registered on Form S-8, whether or not vested, will be converted into and become an option to purchase Sesen Bio common stock. Sesen Bio will assume the Carisma Plan and each such Carisma option in accordance with the terms (as in effect as of the date of the Original Merger Agreement) of the Carisma Plan and the terms of the stock option agreement by which such Carisma option </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">174</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">is evidenced (but with changes to such documents as Sesen Bio and Carisma mutually agree are appropriate to reflect the substitution of the Carisma options for an option to purchase shares of Sesen Bio common stock). All other Carisma options that are outstanding and unexercised as of immediately prior to the effective time shall be canceled immediately prior to the effective time. All rights with respect to Carisma common stock subject to Carisma options assumed by Sesen Bio shall thereupon be converted into rights with respect to Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, from and after the effective time: (i)&#160;each Carisma option assumed by Sesen Bio may be exercised solely for shares of Sesen Bio common stock; (ii)&#160;the number of shares of Sesen Bio common stock subject to each Carisma option assumed by Sesen Bio shall be determined by multiplying (A)&#160;the number of shares of Carisma common stock that were subject to such Carisma option, as in effect immediately prior to the effective time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of Sesen Bio common stock; (iii)&#160;the per share exercise price for the Sesen Bio common stock issuable upon the exercise of each Carisma option assumed by Sesen Bio shall be determined by dividing (A)&#160;the per share exercise price of Carisma common stock subject to such Carisma option, as in effect immediately prior to the effective time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent; and (iv)&#160;any restriction on the exercise of any Carisma option assumed by Sesen Bio shall continue in full force and effect and the term, exercisability, vesting schedule and other provisions of such Carisma option shall otherwise remain unchanged. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">However, to the extent provided under the terms of a Carisma option and the Carisma Plan, such Carisma option may be further adjusted as necessary to reflect Sesen Bio&#8217;s substitution of the Carisma options with options to purchase Sesen Bio common stock (such as by making any change in control or similar definition related to Sesen Bio and having any provision that provides for the adjustment of Carisma options upon the occurrence of certain corporate events related to corporate events that relate to Sesen Bio and/or Sesen Bio common stock); and (y)&#160;the Sesen Bio board of directors or a committee thereof shall succeed to the authority and responsibility of the Carisma board of directors or any committee thereof with respect to each Carisma option assumed by Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Treatment of Carisma Convertible Note</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Merger Agreement, as of immediately after the effective time, the Carisma convertible note shall convert into shares of Sesen Bio common stock in accordance with the convertible note conversion agreement, as amended or supplemented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Directors and Officers of Sesen Bio Following the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement, each of the current directors who will not continue as directors of Sesen Bio or the combined company following the consummation of the merger will resign effective as of the closing of the merger. Additionally, pursuant to the Merger Agreement, the employment and service of each officer of Sesen Bio will terminate. Effective as of the effective time, the Sesen Bio board of directors is expected to be comprised of seven directors, to serve in the class assigned to director. Pursuant to the terms of the Merger Agreement, one such director will be designated by Sesen Bio, and six such directors will be designated by Carisma. It is anticipated that Thomas R. Cannell will be the Sesen Bio designated director following the closing of the merger, and that all other current Sesen Bio directors will resign as of the closing of the merger. Carisma will appoint the remaining directors to the Sesen Bio board of directors to fill the resulting vacancies. It is anticipated that Sanford Zweifach, Regina Hodits, Briggs Morrison, Bj&#246;rn Odlander, Chidozie Ugwumba, and Steven Kelly will be appointed to the board of directors of the combined company by Carisma. Sanford Zweifach is expected to be appointed as chair of the board of directors of the combined company. It is anticipated that Sesen Bio&#8217;s executive officers upon the closing of the merger will be Steven Kelly, Richard Morris and Michael Klichinsky. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendments to the Sesen Bio Certificate of Incorporation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Stockholders of record of Sesen Bio common stock on the record date will also be asked to approve Proposal No. 2, which include a series of alternative amendments to the Sesen Bio Certificate of Incorporation to effect the proposed reverse stock split in connection with consummation of the merger, which requires </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">175</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCCM5">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the affirmative vote of the holders of a majority of the outstanding shares of Sesen Bio common stock entitled to vote on the record date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has agreed to amend the Sesen Bio Certificate of Incorporation to change its name to &#8220;Carisma Therapeutics Inc.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Potentially Transferable Assets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is entitled, but under no obligation, to sell, transfer, license, assign or otherwise divest any of its non-cash assets existing as of the date of the Original Merger Agreement, in a transaction or series of transactions; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that any such sale, transfer, license or other disposition, each, an asset disposition, must be expressly approved by the Sesen Bio board of directors. Pursuant to the Merger Agreement, Sesen Bio shall keep Carisma reasonably apprised of any developments related to an asset disposition. Without limiting the foregoing, Sesen Bio shall provide Carisma with notice of Sesen Bio&#8217;s intention to enter into any definitive written agreement providing for the consummation of an asset disposition or otherwise to consummate an asset disposition, at least ten business days prior to the execution or such definitive written agreement or to otherwise consummate an asset disposition. Sesen Bio shall not enter into a definitive written agreement or otherwise consummate an asset disposition that would result in a material continuing obligation without first obtaining the prior written consent of Carisma, such consent not to be unreasonably withheld, delayed or conditioned. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conditions to the Completion of the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following contains a description of all material conditions to the completion of the merger. Each party&#8217;s obligation to effect the merger and otherwise consummate the other transactions contemplated by the Merger Agreement at the closing of the merger, is subject to the satisfaction or, the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the closing of the merger, of various conditions, which include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">no temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the transactions contemplated by the Merger Agreement shall have been issued by any court of competent jurisdiction or other governmental body of competent jurisdiction and remain in effect and there shall not be any law which has the effect of making the transactions contemplated by the Merger Agreement illegal; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma shall have obtained the &#8220;required Carisma stockholder vote,&#8221; whereby the affirmative vote (or written consent) of (i)&#160;the holders of a majority of the Carisma capital stock, voting together as a single class, (ii)&#160;the holders of at least two-thirds of the Carisma Series&#160;A Preferred Stock, Carisma Special Voting Preferred Stock, Carisma Series&#160;B Preferred Stock and Carisma Series&#160;B Special Voting Preferred Stock, voting together as a single class, (iii)&#160;the holders of a majority of the Carisma Series&#160;A Preferred Stock and Carisma Special Voting Preferred Stock, voting together as a single class, and (iv)&#160;the holders of at least two-thirds of the Carisma Series&#160;B Preferred Stock and Carisma Series&#160;B Special Voting Preferred Stock, voting together as a single class, must have (x)&#160;adopted and approved the Merger Agreement and the transactions contemplated by the Merger Agreement, (y)&#160;acknowledged that the approval given thereby is irrevocable and that the Carisma stockholders are aware of their rights to demand appraisal for their respective shares and (z)&#160;acknowledged that by their approval of the merger they are not entitled to appraisal rights with respect to their shares in connection with the merger and thereby waive any rights to receive payment of the fair value of their capital stock under the DGCL; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio shall have obtained the &#8220;required Sesen Bio stockholder vote,&#8221; whereby the affirmative vote of (i)&#160;the holders of a majority of the outstanding shares of Sesen Bio common stock entitled to vote on the record date for the Sesen Bio special meeting must have approved Proposal No. 2 and (ii)&#160;the holders of a majority in voting power of the votes cast by the holders of all Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting and entitled to thereon must have approved Proposal No. 1; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the existing shares of Sesen Bio common stock must have been continually listed on Nasdaq as of and from the date of the Original Merger Agreement through the closing date, the approval of the </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">176</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">listing of additional shares of Sesen Bio common stock on Nasdaq must have been obtained, and the shares of Sesen Bio common stock to be issued in the merger and the conversion pursuant to the Merger Agreement must have been approved for listing on Nasdaq; and </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the registration statement on Form S-4, of which this proxy statement/prospectus is a part, must have become effective in accordance with the Securities Act and must not be subject to any stop order or proceeding (or any proceeding threatened by the SEC) seeking a stop order with respect to such registration statement that has not been withdrawn. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the obligation of Sesen Bio and Merger Sub to effect the merger and otherwise consummate the other transactions contemplated by the Merger Agreement at the closing of the merger is further subject to the satisfaction or written waiver by Sesen Bio of the following conditions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the representations and warranties of Carisma regarding certain matters related to due organization, authority, vote required, non-contravention, and financial advisors in the Merger Agreement must be true and correct in all material respects on and as of the closing date with the same force and effect as if made on and as of such date, representations and warranties regarding the capitalization of Carisma and absence of a Carisma material adverse effect in the Merger Agreement must be true and correct in all respects, except for de minimis inaccuracies in the case of capitalization, on and as of the closing date with the same force and effect as if made on and as of such date, and the remaining representations and warranties of Carisma in the Merger Agreement shall be true and correct on and as of the closing date with the same force and effect as if made on and the closing date, except where the failure to be true and correct would not have a Carisma material adverse effect (in all cases, except to the extent such representations and warranties are specifically made as of a particular date, in which case as of such date); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma shall have performed or complied in all material respects with the agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the effective time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio shall have received a certificate executed by the Chief Executive Officer or Chief Executive Officer of Carisma certifying that certain closing conditions have been duly satisfied and that the information set forth in an allocation certificate delivered by Carisma is true and accurate in all respects as of the closing date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio shall have received (i)&#160;an original signed statement from Carisma that the Carisma common stock is not a &#8220;United States real property interest,&#8221; as defined in Section&#160;897(c) of the Code, conforming to the requirements of Treasury Regulations&#160;Section&#160;1.1445-2(c)(3) and 1.897-2(h), and (ii)&#160;an original signed notice to be delivered to the IRS by Sesen Bio in accordance with the provisions of Treasury Regulations&#160;Section&#160;1.897-2(h)(2), together with written authorization for Sesen Bio to deliver such notice to the IRS on behalf of Carisma following the closing of the merger, each dated as of the closing date, duly executed by an authorized officer of Carisma, and in form and substance reasonably acceptable to Sesen Bio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">certain investor agreements between Carisma and its stockholders must have been terminated; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Carisma lock-up agreements will continue to be in full force and effect as of immediately following the effective time. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the obligation of Carisma to effect the merger and otherwise consummate the transactions to be consummated at the closing of the merger is further subject to the satisfaction or written waiver by Carisma of the following conditions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the representations and warranties of Parent and Merger Sub regarding certain matters related to due organization, authority, vote required, non-contravention, and financial advisors in the Merger Agreement must be true and correct in all material respects on and as of the closing date with the same force and effect as if made on and as of such date, representations and warranties regarding the capitalization of Sesen Bio and Merger Sub and absence of a Sesen Bio material adverse effect in the Merger Agreement must be true and correct in all respects, except for de minimis inaccuracies in the case of capitalization, on and as of the closing date with the same force and effect as if made on and as of such date, and the remaining representations and warranties of Sesen Bio and Merger Sub in </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">177</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the Merger Agreement shall be true and correct on and as of the closing date with the same force and effect as if made on and as of the closing date, except where the failure to be true and correct would not have a Sesen Bio material adverse effect (in all cases, except to the extent such representations and warranties are specifically made as of a particular date, in which case as of such date); </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Merger Sub shall have performed or complied in all material respects with the agreements and covenants required to be performed or complied with by each of them under the Merger Agreement at or prior to the effective time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma shall have received (i)&#160;a certificate by the Chief Executive Officer or Chief Financial Officer of Sesen Bio certifying that certain closing conditions have been duly satisfied, (ii)&#160;a copy of the CVR Agreement duly executed by Sesen Bio and the rights agent (as defined therein) and (iii)&#160;a written resignation, in form reasonably satisfactory to Carisma, dated as of the closing date and effective as of the closing, executed by each of the officers and directors, from their positions as such, of Sesen Bio who are not to continue as directors or officers (as applicable) of Sesen Bio after the closing of the merger, which such resignations not affecting such officer&#8217;s or director&#8217;s status as an employee (if applicable) including any characterization of their cessation from employment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio lock-up agreements will continue to be in full force and effect as of immediately following the effective time; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s final net cash shall have been determined to be greater than or equal to $75.0&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Representations and Warranties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement contains customary representations and warranties of Sesen Bio and Carisma for a transaction of this type relating to, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">corporate organization and power, and similar corporate matters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">organizational documents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">authority to enter into the Merger Agreement and the related agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">votes required for completion of the merger and approval of the proposals that will come before the Sesen Bio special meeting and that will be the subject of the Carisma stockholder written consent; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">except as otherwise specifically disclosed in the Merger Agreement, the fact that the consummation of the merger would not contravene the organizational documents, certain laws, governmental authorization or certain contracts of the parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">result in any encumbrance on the parties&#8217; assets or require the consent of any third party; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">capitalization; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">financial statements and with respect to Sesen Bio, documents filed with the SEC and the accuracy of information contained in those documents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">material changes or events; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">liabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">title to assets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ownership of real property and leasehold interests; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">intellectual property; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">privacy and data security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the validity of material contracts to which the parties or their subsidiaries are a party and any violation, default or breach to such material contracts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory compliance, permits and restrictions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">178</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tNSON">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">legal proceedings and orders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.89pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax matters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">employee and labor matters and benefit plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.89pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">environmental matters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">insurance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.89pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any brokerage or finder&#8217;s fee or other fee or commission in connection with the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">certain transactions or relationships with affiliates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.89pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">compliance with anti-bribery laws; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">with respect to Sesen Bio, the valid issuance in the merger of Sesen Bio common stock and the opinion of SVB Securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The representations and warranties are, in many respects, qualified by materiality and knowledge and will not survive the merger, but their accuracy forms the basis of one of the conditions to the obligations of Sesen Bio and Carisma to complete the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-Closing Dividend</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the effective time, Sesen Bio will declare a dividend to its common stockholders of record consisting of (a)&#160;one CVR for each outstanding share of Sesen Bio common stock held by such stockholder as of such date, representing the right to receive contingent payments upon the occurrence of certain events as well as proceeds from any sale of Sesen Bio&#8217;s non-cash assets, as set forth in, and subject to and in accordance with the terms and conditions of, the CVR Agreement, in the form attached hereto as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex F</font><font style="letter-spacing:0.2pt;">, and (b)&#160;cash in an amount expected to be approximately $70.0&#160;million in the aggregate, subject to Sesen Bio&#8217;s estimated net cash as of the closing of the merger being greater than or equal to $75.0 million and subject to the satisfaction of certain obligations of Sesen Bio under the Merger Agreement. The record date for the pre-closing dividend shall be a date agreed upon by Carisma and Sesen Bio prior to the day on which the effective time occurs and the payment date for which shall be three business days after the effective time; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the payment of such dividend may be conditioned upon the occurrence of the effective time. In connection with the pre-closing dividend, Sesen Bio shall cause the CVR Agreement to be duly authorized, executed and delivered by Sesen Bio and a rights agent selected by Sesen Bio with Carisma&#8217;s prior approval (such approval not to be unreasonably withheld, delayed or conditioned). For more information related to the CVRs, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page&#160;<a href="#tCVAG">192</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Solicitation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as expressly permitted by the Merger Agreement, each of Sesen Bio and Carisma agreed that during the pre-closing period, except as described below, Sesen Bio and Carisma will not, nor will either party authorize any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any acquisition proposal or acquisition inquiry (each as defined below) or take any action that could reasonably be expected to lead to an acquisition proposal or acquisition inquiry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">furnish any non-public information regarding the party and its subsidiaries to any person in connection with or in response to an acquisition proposal or acquisition inquiry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.89pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approve, endorse or recommend an acquisition proposal; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">179</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any acquisition transaction, as defined below (other than a confidentiality agreement permitted under the Merger Agreement); or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">publicly propose to do any of the above. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement also provides that each of Carisma and Sesen Bio will immediately cease and cause to be terminated any existing discussions, negotiations and communications with any person that relate to any acquisition proposal or acquisition inquiry as of the date of the Original Merger Agreement and request the destruction or return of any non-public information of Sesen Bio or Carisma and their respective subsidiaries, as applicable, provided to such person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An &#8220;acquisition inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Carisma or any of its affiliates, on the one hand, or Sesen Bio or any of its affiliates, on the other hand, to the other party) that could reasonably be expected to lead to an acquisition proposal, other than (i)&#160;with respect to Sesen Bio, solely with respect to an asset disposition and (ii)&#160;with respect to Carisma, solely with respect to the Carisma pre-closing financing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An &#8220;acquisition proposal&#8221; means, with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Carisma or any of its affiliates, on the one hand, or by or on behalf of Sesen Bio or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to any acquisition transaction with such party, other than (i)&#160;with respect to Sesen Bio, solely with respect to an asset disposition and (ii)&#160;with respect to Carisma, solely with respect to the Carisma pre-closing financing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An &#8220;acquisition transaction&#8221; means any transaction or series of related transactions (other than the asset disposition) involving: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (A)&#160;in which a party is a constituent entity; (B)&#160;in which a person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of persons directly or indirectly acquires beneficial or record ownership of securities representing more than 15% of the outstanding securities of any class of voting securities of a party or any of its subsidiaries; or (C)&#160;in which a party or any of its subsidiaries issues securities representing more than 15% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that in the case of Carisma, to the extent the Carisma pre-closing financing is effected in accordance with the terms and conditions of the Merger Agreement, the Carisma pre-closing financing shall not constitute an acquisition transaction; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 15% or more of the consolidated book value or the fair market value of the assets of Sesen Bio or Carisma and their respective subsidiaries, as applicable, taken as a whole. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the foregoing, before obtaining the applicable approvals of the stockholders of Sesen Bio or Carisma required to consummate the merger, as applicable, each party may furnish non-public information regarding such party and its subsidiaries to, and enter into discussions or negotiations with, any person in response to a bona fide written unsolicited acquisition proposal by such person, which such party&#8217;s board of directors determines in good faith, after consultation with such party&#8217;s outside legal counsel and financial advisors, constitutes or is reasonably likely to result in a &#8220;superior offer,&#8221; &#8203;(as defined below) (and is not withdrawn) if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">neither such party nor any of its representative has breached the no solicitation provisions of the Merger Agreement in any material respects; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">such party&#8217;s board of directors concludes in good faith, after consultation with such party&#8217;s outside legal counsel, that the failure to take such action is reasonably likely to be inconsistent with the fiduciary duties of such party&#8217;s board of directors under applicable law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">180</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">at least two business days&#8217; prior to initially furnishing any such nonpublic information to, or entering into discussions with, such person, such party gives the other party written notice of the identity of such person and of that party&#8217;s intention to furnish non-public information to, or enter into discussions with, such person ; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">such party receives from the person an executed confidentiality agreement containing provisions (including nondisclosure provisions, use restrictions, non-solicitation provisions and no hire provisions) at least as favorable to such party as those contained in the confidentiality agreement between Sesen Bio and Carisma; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">at least two business days prior to furnishing any non-public information to such person, such party furnishes the same non-public information to the other party (to the extent such information has not been previously furnished). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A &#8220;superior offer&#8221; means an unsolicited bona fide written acquisition proposal (with all references to 15% in the definition of acquisition transaction being treated as references to 70% for these purposes) that: (a)&#160;was not obtained or made as a direct or indirect result of a breach of (or in violation of) the Merger Agreement; (b)&#160;is on terms and conditions that the Sesen Bio board of directors or the Carisma board of directors, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof, the financing terms thereof, any termination or break-up fees and conditions to consummation), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable to Sesen Bio stockholders or Carisma stockholders, as applicable, than the terms of the transaction contemplated by the Merger Agreement; (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the person); and (d)&#160;is reasonably capable of being completed on the terms proposed without unreasonable delay. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement also provides that each party will promptly advise the other in writing of such acquisition proposal or acquisition inquiry (including the identity of the person making or submitting such acquisition proposal or acquisition inquiry (subject to any confidentiality restrictions that may be in place between the applicable party and such person as of the date of the Original Merger Agreement), and a copy of the acquisition proposal or acquisition inquiry, or if the acquisition proposal or acquisition inquiry is not written, the terms thereof, and the material terms thereof). Each party shall keep the other party reasonably informed with respect to the status and terms of any such acquisition proposal or acquisition inquiry and any material modification or proposed material modification thereto. In addition to the foregoing, each party shall provide the other party with reasonable advance written notice of a meeting of the Sesen Bio board of directors or Carisma board of directors, as applicable, (or any committee thereof) at which such board of directors (or any committee thereof) is reasonably expected to consider an acquisition proposal or acquisition inquiry it has received. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in Board Recommendation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described above, and subject to the provisions described below, (i)&#160;the Sesen Bio board of directors recommends that Sesen Bio stockholders vote &#8220;FOR&#8221; all of the proposals described in this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus and (ii)&#160;the Carisma board of directors recommends that Carisma stockholders execute the written consent to approve the merger, the Merger Agreement, and the transactions contemplated therein, substantially in accordance with the terms of the Merger Agreement and the other agreements contemplated by the Merger Agreement. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Merger Agreement, subject to certain exceptions described below, Sesen Bio agreed that the Sesen Bio board of directors may not take any of the following actions, each of which are referred to in this proxy statement/prospectus as a Sesen Bio board of directors adverse recommendation change: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) Sesen Bio board of directors&#8217; recommendation in favor of the proposals described in this proxy statement/prospectus in a manner adverse to Carisma; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">resolve, or have any committee of the Sesen Bio board of directors resolve, to withhold, amend, withdraw or modify the Sesen Bio board of directors&#8217; recommendation in favor of the proposals described in this proxy statement/prospectus in a manner adverse to Carisma; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">181</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any acquisition proposal shall be adopted or proposed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">However, notwithstanding the foregoing, at any time prior to the approval of the proposals to be considered at the Sesen Bio special meeting by the required Sesen Bio stockholder vote, if Sesen Bio has received a bona fide written superior offer, the Sesen Bio board of directors may make a Sesen Bio board of directors adverse recommendation change if, but only if, following the receipt of and on account of such superior offer: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Sesen Bio board of directors recommendation would constitute a violation of the Sesen Bio board of directors&#8217; fiduciary duties under applicable law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has, and has caused its financial advisors and outside legal counsel to, during the required four business day notice period, or the required notice period, negotiate with Carisma in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such acquisition proposal ceases to constitute a superior offer; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if after Carisma shall have delivered to Sesen Bio a written offer to alter the terms or conditions of the Merger Agreement during the required notice period, the Sesen Bio board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Sesen Bio board of directors recommendation would constitute a violation of the Sesen Bio board of directors&#8217; fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement); </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that (x)&#160;Carisma receives written notice from Sesen Bio confirming that the Sesen Bio board of directors has determined to change its recommendation during the required notice period, which notice shall include a description in reasonable detail of the reasons for such Sesen Bio board of directors adverse recommendation change, and written copies of any relevant transaction with any party making a potential superior offer, (y)&#160;during any required notice period, Carisma shall be entitled to deliver to Sesen Bio one or more counterproposals to such acquisition proposal and Sesen Bio will, and will cause its representatives to, negotiate with Carisma in good faith (to the extent Carisma desires to negotiate) to make such adjustments in the terms and conditions of the Merger Agreement so that the applicable acquisition proposal ceases to constitute a superior offer, and (z)&#160;in the event of any material amendment to any superior offer (including any revision in the amount, form or mix of consideration the Sesen Bio stockholders would receive as a result of such potential superior offer), Sesen Bio shall be required to provide Carisma with notice of such material amendment and the required notice period shall be extended, if applicable, to ensure that at least two business days remain in the required notice period following such notification during which the parties shall comply again with the requirements in this provision and the Sesen Bio board of directors shall not make a Sesen Bio board of directors adverse recommendation change prior to the end of such notice period so extended (it being understood that there may be multiple extensions). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Merger Agreement, subject to certain exceptions described below, Carisma agreed that the Carisma board of directors may not take any of the following actions, each of which are referred to in this proxy statement/prospectus as a Carisma board of directors adverse recommendation change: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">withdraw or modify (or publicly propose to withdraw or modify) the Carisma board of directors recommendation in a manner adverse to Sesen Bio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">resolve or have any committee of the Carisma board of directors withdraw or modify the Carisma board of directors recommendation in a manner adverse to Sesen; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any acquisition proposal shall be adopted or proposed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">However, notwithstanding the foregoing, at any time prior to the approval and adoption of the Merger Agreement by the required Carisma stockholder vote, if Carisma has received a bona fide written superior offer, the Carisma board of directors may make a Carisma board of directors adverse recommendation change if, but only if, following the receipt of and on account of such superior offer: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">182</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Carisma board of directors determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Carisma board of directors recommendation would constitute a violation of the Carisma board of directors&#8217; fiduciary duties under applicable law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma has, and has caused its financial advisors and outside legal counsel to, during the required notice period, negotiate with Sesen Bio in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such acquisition proposal ceases to constitute a superior offer; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if after Sesen Bio shall have delivered to Carisma a written offer to alter the terms or conditions of the Merger Agreement during the required notice period, the Carisma board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Carisma board of directors recommendation would constitute a violation of the Carisma board of directors&#8217; fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement); </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that (x)&#160;Sesen Bio receives written notice from Carisma confirming that the Carisma board of directors has determined to change its recommendation at least four business days in advance of the Carisma board of directors adverse recommendation change, which notice shall include a description in reasonable detail of the reasons for such Carisma board of directors adverse recommendation change, and written copies of any relevant transaction agreements with any party making a potential superior offer, (y)&#160;during any required notice period, Sesen Bio shall be entitled to deliver to Carisma one or more counterproposals to such acquisition proposal and Carisma will, and cause its representatives to, negotiate with Sesen Bio in good faith (to the extent Sesen Bio desires to negotiate) to make such adjustments in the terms and conditions of the Merger Agreement so that the applicable acquisition proposal ceases to constitute a superior offer, and (z)&#160;in the event of any material amendment to any superior offer (including any revision in the amount, form or mix of consideration Carisma stockholders would receive as a result of such potential superior offer), Carisma shall be required to provide Sesen Bio with notice of such material amendment and the required notice period shall be extended, if applicable, to ensure that at least two business days remain in the notice period following such notification during which the parties shall comply again with the requirements in this provision and the Carisma board of directors shall not make a Carisma board of directors adverse recommendation change prior to the end of such notice period as so extended (it being understood that there may be multiple extensions). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Meetings of Sesen Bio stockholders; Consent of Carisma stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is obligated under the Merger Agreement to call, give notice of and hold the Sesen Bio special meeting for the purposes of considering the approval of, among the other items noted herein, the amendment of the Sesen Bio Certificate of Incorporation to effect the proposed reverse stock split, the issuance of shares of Sesen Bio common stock to Carisma stockholders in connection with the transactions contemplated under the Merger Agreement and change of control of Sesen Bio resulting therefrom, and the equity plan amendment proposals. Carisma is obligated under the Merger Agreement to obtain the written consent of its stockholders sufficient to adopt the Merger Agreement and approve the merger and related transactions and deliver to Sesen Bio such written consent within five business days following the registration statement on Form S-4, of which this proxy statement/prospectus is a part, being declared effective by the SEC. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Covenants; Conduct of Business Pending the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as expressly permitted by the Merger Agreement, as required by applicable law, in connection with any COVID-19 measures of COVID-19 response, or unless Carisma shall have otherwise consented in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the pre-closing period, Sesen Bio will and will cause its subsidiaries to, (i)&#160;use commercially reasonable efforts to conduct its business and operations in the ordinary course of business and (ii)&#160;conduct its business and operations in compliance in all material respects with all applicable laws, including timely making all filings required by the SEC, and the requirements of certain material contracts. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">183</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has also agreed that, except as expressly permitted by the Merger Agreement, as required by applicable law, in connection with the asset disposition and the pre-closing dividend, in connection with any COVID-19 measures or COVID-19 response, or for certain limited exceptions with the prior written consent of Carisma (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the pre-closing period, it will not, nor shall it cause or permit its subsidiaries to, do any of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except in connection with the payment of the exercise price and/or withholding taxes incurred upon the exercise of any Sesen Bio option or vesting of Sesen Bio RSUs in accordance with the terms of such award in effect on the date of the Original Merger Agreement); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">sell, issue, grant, pledge, or otherwise dispose of or encumber or authorize the issuance of: any capital stock or other security of Sesen Bio (except for Sesen Bio common stock issued upon the valid exercise or settlement of outstanding Sesen Bio options, Sesen Bio warrants or the vesting of Sesen Bio RSUs, as applicable, in accordance with their terms as in effect as of the date of the Original Merger Agreement); any option, warrant or right to acquire any capital stock or any other security; or any other instrument convertible into or exchangeable for any capital stock or other security of Sesen Bio or any of its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">amend the organizational documents of Sesen Bio or any of its subsidiaries, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split, or similar transaction except, for the avoidance of doubt, the transactions contemplated under the Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">form any subsidiary or acquire any equity interest, or other interest in any other entity, or enter into any joint venture with any other entity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">(A) lend money to any person, (B)&#160;incur or guarantee any indebtedness for borrowed money, issue or sell any debt securities or options, warrants, call or other rights to acquire any debt securities, (C)&#160;guarantee any debt securities of others, or (D)&#160;make any capital expenditure or commitment in excess of $250,000; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">other than as required by applicable law or by the terms of a Sesen Bio employee plan as in effect on the date of the Original Merger Agreement and disclosed in certain sections of the confidential disclosure schedules, adopt, terminate, establish or enter into any Sesen Bio employee plan; cause or permit any Sesen Bio employee plan to be amended in any material respect; pay any bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, benefits or other compensation or remuneration payable to, any current or former employee, independent contractor, officer or director of Sesen Bio or any of its subsidiaries; or increase or otherwise modify the severance, retention or change of control benefits offered to any current or former employee, independent contractor, officer or director of Sesen Bio or any of its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">enter into any contract with a labor union, labor organization, or similar person except as otherwise required by applicable law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">(A) hire or engage, or offer to hire, any director, officer, employee or consultant, or (B)&#160;enter into, amend or extend the term of any employment or consulting agreement with any current or former employee, independent contractor, officer or director of Sesen Bio or any of its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">enter into any material transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its material assets or properties, or grant any encumbrance with respect to such assets or properties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">make, change or revoke any material tax election, file any material amended tax return, settle or compromise any income or other material tax liability, enter into any tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the ordinary course of business the principal subject matter of which is not </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">184</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material taxes (other than pursuant to an extension of time to file any tax return granted in the ordinary course of business of not more than six&#160;months), or change any material accounting method in respect of taxes; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">(A) sell, assign, transfer, allow to lapse or expire, pledge, abandon, discontinue, fail to maintain or otherwise dispose of any right, title or interest of Sesen Bio or any of its subsidiaries in any material Sesen Bio intellectual property, or (B)&#160;license, sublicense or otherwise encumber (other than pursuant to a non-exclusive license granted to contract research organizations, including clinical trial sites and clinical trial services provides, or contract manufacturing organizations, in each case, (x)&#160;with whom Sesen Bio or any of its subsidiaries has previously entered into contracts prior to the effective time and (y)&#160;who are engaged to provide services directly related to clinical studies and manufacturing of any product candidate of Sesen Bio, </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that the scope of any such non-exclusive license grant is limited to only the extent necessary for such persons to perform their obligations under the respective contracts) any right, title or interest of Sesen Bio or any of its subsidiaries in any material Sesen Bio intellectual property; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">enter into, amend or terminate certain material contracts (or any contract that would have been a material contract if in effect on or prior to the date of the Original Merger Agreement); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">(A) materially change pricing or royalties or other payments set or charged by Sesen Bio or any of its subsidiaries to its customers or licensees or (B)&#160;agree to materially change pricing or royalties or other payments set or charged by persons who have licensed intellectual property rights to Sesen Bio or any of its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">make any expenditures, incur any liabilities or discharge or satisfy any liabilities, in each case, other than those expenditures or liabilities that will not survive the closing of the merger, are discharged or satisfied prior to the closing of the merger, and/or are taken into account in the calculation of net cash; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">waive, settle or compromise any pending or threatened legal proceeding against Sesen Bio or any of its subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $75,000 individually or in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not (1)&#160;impose any restriction on the operations or business of Sesen Bio or its subsidiaries (nor on Carisma or any of its subsidiaries, from and after the closing of the merger), (2)&#160;involve any equitable relief and (3)&#160;do not involve admission of any wrongdoing by Sesen Bio or any of its subsidiaries; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">agree, resolve, or commit to do any of the foregoing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the generality of the foregoing, nothing set forth above shall restrict (i)&#160;Sesen Bio or any of its subsidiaries from taking or not taking any action, including the establishment of any policy, procedure or protocol, in response to COVID-19 or any COVID-19 measures or otherwise take any COVID-19 response and (ii)&#160;Sesen Bio&#8217;s right to effectuate one or more asset dispositions or the pre-closing dividend, each on the on the terms and subject to the applicable limitations set forth in the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma has agreed that, except as expressly permitted by the Merger Agreement, as required by applicable law, in connection with any COVID-19 measures or COVID-19 response, or unless Sesen Bio shall have otherwise consented in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the pre-closing period, each of Carisma and its subsidiaries will (i)&#160;use commercially reasonable efforts to conduct its respective business and operations in the ordinary course of business and (ii)&#160;conduct its business and operations in compliance in all material respects with all applicable laws and the requirements of certain material contracts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma has also agreed that, except (i)&#160;as expressly permitted in the Merger Agreement, as required by applicable law, in connection with any COVID-19 measures or COVID-19 response, or with the prior written consent of Sesen Bio (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the pre-closing period, it will not, nor will it cause or permit any of its subsidiaries to, do any of the following: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">185</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except in connection with the payment of the exercise price and/or withholding taxes incurred upon the exercise of any Carisma option in accordance with the terms of such award in effect on the date of the Original Merger Agreement); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">except as contemplated by the Carisma pre-closing financing or the conversion of the Carisma convertible note, sell, issue, grant, pledge, or otherwise dispose of or encumber or authorize the issuance of: any capital stock or other security of Carisma or any of its subsidiaries (except for shares of outstanding Carisma common stock issued upon the valid exercise or settlement of Carisma options in accordance with their terms as in effect as of the date of the Original Merger Agreement); any option, warrant or right to acquire any capital stock or any other security, other than options grants to employees and service providers in the ordinary course of business; or any other instrument convertible into or exchangeable for any capital stock or any other security of Carisma or its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">amend the organizational documents of Carisma or its subsidiaries, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split, or similar transaction except, for the avoidance of doubt, the transactions contemplated under the Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">form any subsidiary or acquire any equity interest, or other interest in any other entity or enter into a joint venture with any other entity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">(A) lend money to any person (except for the advancement of reasonable expenses to employees, directors and consultants in the ordinary course of business), (B)&#160;incur or guarantee any indebtedness for borrowed money, other than in the ordinary course of business, (C)&#160;guarantee any debt securities of others or (D)&#160;except as contemplated by Carisma&#8217;s capital expenditure budget and operating budget made available to Sesen Bio, make any capital expenditure or commitment in excess of $350,000; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its material assets or properties, or grant any encumbrance with respect to such assets or properties, except in the ordinary course of business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">sell, assign, license, sublicense, transfer, allow to lapse or expire, pledge abandon, discontinue, fail to maintain or otherwise dispose of any right, title or interest of Carisma or any of its subsidiaries in any material Carisma intellectual property rights (other than pursuant to a non-exclusive license in the ordinary course of business); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">make, change or revoke any material tax election, file any material amended tax return, settle or compromise any income or other material tax liability, enter into any tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the ordinary course of business the principal subject matter of which is not taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material taxes (other than pursuant to an extension of time to file any tax return granted in the ordinary course of business of not more than six&#160;months), or change any material accounting method in respect of taxes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">enter into, materially amend or terminate any Carisma material contract (or any contract that would have been a Carisma material contract if in effect on or prior to the date of the Original Merger Agreement) other than in the ordinary course of business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">waive, settle or compromise any pending or threatened legal proceeding against Carisma or any of its subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $75,000 individually or in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not (1)&#160;impose any material restriction on the operations or business of Carisma or its subsidiaries (nor, following the closing of the merger, on Sesen Bio or any of its subsidiaries), (2)&#160;involve any equitable relief and (3)&#160;involve admission of any wrongdoing by Carisma or any of its subsidiaries; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">186</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">agree, resolve or commit to do any of the foregoing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the generality of the foregoing, nothing set forth above shall restrict Carisma or any of its subsidiaries from taking or not taking any action, including the establishment of any policy, procedure or protocol, in response to COVID-19 or any COVID-19 measures or otherwise take any COVID-19 response. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of Sesen Bio and Carisma has agreed to use its commercially reasonable efforts to cause to be taken all actions necessary to consummate the merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">file or otherwise submit all applications and notices required to be filed in connection with the merger and the other transactions contemplated by the Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">use reasonable best efforts to lift any injunction prohibiting, or any other legal bar to, the merger or the other transactions contemplated by the Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">use commercially reasonable efforts to resolve the matters set forth on a schedule without any material continuing obligation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement, Sesen Bio and Carisma have further agreed that Sesen Bio will use its commercially reasonable efforts to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintain its existing listing of its common stock on Nasdaq and to obtain approval for listing of the combined company on Nasdaq; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if required by the rules and regulations of Nasdaq, to prepare and submit to Nasdaq a notification form for the listing of the shares of Sesen Bio common stock to be issued in connection with the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prepare and timely submit to Nasdaq a notification form of the proposed reverse stock split and to submit a copy of the amendment to Sesen Bio&#8217;s certificate of incorporation to effect the proposed reverse stock split, certified by the Secretary of State of the State of Delaware to Nasdaq on the date of closing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if required by Nasdaq Listing Rule&#160;5110, to file an initial listing application for Sesen Bio common stock on Nasdaq and to cause such listing application to be approved; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in the event of receipt of a Nasdaq delisting determination, Sesen Bio will request a hearing to appeal the delisting determination and will pay the appropriate fee to Nasdaq to appeal the delisting determination. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification and Insurance for Directors and Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Merger Agreement, from the effective time through the sixth anniversary of the date on which the effective time occurs, each of Sesen Bio and the surviving corporation will, jointly and severally, indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Original Merger Agreement, or who becomes prior to the effective time, a director, officer, fiduciary or agent of Sesen Bio or Carisma and their respective subsidiaries, respectively, the indemnified parties, against all claims, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements and investigation costs, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, or any other actual, threatened or completed proceeding arising out of or pertaining to the fact that the indemnified party is or was an indemnified party, whether asserted or claimed prior to, at or after the effective time, in each case, to the fullest extent permitted under applicable law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each indemnified party will also be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Sesen Bio and the surviving corporation, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">187</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTMAER10">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">jointly and severally, upon receipt by Sesen Bio or the surviving corporation from the indemnified party of a request therefor; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that any such person to whom expenses are advanced provides an undertaking to Sesen Bio, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement also provides that the provisions of Sesen Bio&#8217;s organizational documents with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Sesen Bio that are presently set forth in the Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws shall not be amended, modified or repealed for a period of six&#160;years from the effective time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the effective time, were officers or directors of Sesen Bio, unless such modification is required by applicable law. The certificate of incorporation and bylaws of the surviving corporation shall contain, and Sesen Bio shall cause the certificate of incorporation and bylaws of the surviving corporation to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the Carisma Certificate of Incorporation and the Carisma Bylaws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From and after the effective time, (i)&#160;the surviving corporation shall fulfill and honor, and Sesen Bio shall cause the surviving corporation to fulfill and honor, in all respects the obligations of Carisma to its indemnified parties as of immediately prior to the closing of the merger pursuant to any indemnification provisions under Carisma&#8217;s organizational documents and pursuant to any indemnification agreements between Carisma and such indemnified parties, with respect to claims arising out of matters occurring at or prior to the effective time and (ii)&#160;Sesen Bio shall fulfill and honor in all respects the obligations of Sesen Bio to its indemnified parties as of immediately prior to the closing of the merger pursuant to any indemnification provisions under Sesen Bio&#8217;s organizational documents and pursuant to any indemnification agreements between Sesen Bio and such indemnified parties, with respect to claims arising out of matters occurring at or prior to the effective time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From and after the effective time, Sesen Bio will maintain director and officers&#8217; liability insurance policies, with an effective date as of the date of closing, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Sesen Bio. In addition, prior to the effective time, Sesen Bio will secure and purchase a six-year prepaid &#8220;tail policy&#8221; through Sesen Bio&#8217;s recognized broker of record for the non-cancellable extension on Sesen Bio&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with limits of liability no less than $20.0&#160;million, in each case. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Termination</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement may be terminated at any time prior to the effective time (whether before or after the required Carisma stockholder vote and the required Sesen Bio stockholder vote) have been obtained, unless otherwise specified below: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">by mutual written consent of Sesen Bio and Carisma; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">by either Sesen Bio or Carisma if the transactions contemplated by the Merger Agreement shall not have been consummated by January&#160;31, 2023 (subject to possible extension as provided in the Merger Agreement), or the end date</font><font style="font-style:italic;letter-spacing:0.2pt;">; provided</font><font style="letter-spacing:0.2pt;">, however, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the transactions contemplated by the Merger Agreement to occur on or before the end date and such action or failure to act constitutes a breach of the Merger Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, further, however, that, in the event that a request for additional information has been made by any governmental body, or in the event that the SEC has not declared effective under the Securities Act the registration statement by the date which is 60&#160;days prior to the end date, then either Carisma or Sesen Bio shall be entitled to extend the end date to the date that is 60&#160;days after the date that the SEC has declared effective the registration statement under the Securities Act, but in any event no more than 60&#160;days after the original end date, by written notice to the other party; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(c)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">by either Sesen Bio or Carisma if a court of competent jurisdiction or other governmental body has issued a final and non-appealable order, decree or ruling or has taken any other action, having </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">188</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the effect of permanently restraining, enjoining or otherwise prohibiting the merger or any of the other transactions contemplated by the Merger Agreement; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(d)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">by Sesen Bio if Carisma stockholder written consent evidencing the required Carisma stockholder vote has not been obtained within ten business days of the registration statement, of which this proxy statement/prospectus is a part, becoming effective; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however,</font><font style="letter-spacing:0.2pt;"> that once such vote has been obtained, Sesen Bio may not terminate the Merger Agreement pursuant to this provision; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(e)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">by either Sesen Bio or Carisma if the Sesen Bio special meeting shall have been held and completed and the Sesen Bio stockholders shall have taken a final vote and shall not have approved Proposal Nos. 1 and 2 at the Sesen Bio special meeting; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, however, that the right to terminate the Merger Agreement pursuant to this provision will not be available to Sesen Bio if Sesen Bio&#8217;s actions or failure to act has been a principal cause of the failure to obtain the required Sesen Bio stockholder vote and such action or failure to act constitutes a breach by Sesen Bio of the Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(f)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">by Carisma, at any time prior to the required Sesen Bio stockholder vote being obtained, if any of the following circumstances shall occur, each of the following, a Sesen Bio triggering event: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has failed to include in the proxy statement/prospectus the Sesen Bio board of directors recommendation or has made a Sesen Bio adverse recommendation change; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors, or any committee thereof, had publicly approved, endorsed or recommended any acquisition proposal; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has entered into any letter of intent or similar document relating to any acquisition proposal (other than a confidentiality agreement permitted under the Merger Agreement); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(g)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">by Sesen Bio, at any time prior to the required Carisma stockholder vote being obtained, if any of the following circumstances shall occur, each a Carisma triggering event: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">the Carisma board of directors has made a Carisma board of directors adverse recommendation change; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">the Carisma board of directors, or any committee thereof, has publicly approved, endorsed or recommended any acquisition proposal; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">Carisma has entered into any letter of intent or similar document relating to any acquisition proposal; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(h)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">by Carisma, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement by Parent or Merger Sub or if any representation or warranty of Sesen Bio or Merger Sub has become inaccurate, in either case such that certain closing conditions would not be satisfied as of time of such breach or inaccuracy; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that Carisma is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, that if such breach or inaccuracy is curable by the end date by Parent or Merger Sub, then the Merger Agreement will not terminate pursuant to this provision as a result of such particular breach or inaccuracy until the expiration of a 30-day period commencing upon delivery of written notice from Carisma to Sesen Bio or Merger Sub of such breach or inaccuracy and Carisma&#8217;s intention to terminate pursuant to this provision (it being understood that the Merger Agreement will not terminate pursuant to this provision as a result of such particular breach or inaccuracy if such breach by Sesen Bio or Merger Sub is cured prior to such termination becoming effective); or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">by Sesen Bio, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement by Carisma or if any representation or warranty of Carisma has become inaccurate, in either case such that certain closing conditions would not be satisfied as of time of such breach or inaccuracy; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that Sesen Bio is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, further</font><font style="letter-spacing:0.2pt;">, that if such breach or inaccuracy is curable by the end date by Carisma, then the Merger Agreement will not terminate pursuant to this provision as a result of a particular breach or inaccuracy until </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">189</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTERFEE123">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the expiration of a 30-day period commencing upon delivery of written notice from Sesen Bio to Carisma of such breach or inaccuracy and Sesen Bio&#8217;s intention to terminate pursuant to this provision (it being understood that the Merger Agreement will not terminate pursuant to this provision as a result of such particular breach or inaccuracy if such breach by Carisma is cured prior to such termination becoming effective). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Termination Fee</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fee payable by Sesen Bio</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio must pay Carisma a termination fee of $7.6&#160;million if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the Merger agreement is terminated by Sesen Bio or Carisma pursuant to clause (b)&#160;above (and the required Sesen Bio stockholder vote has not been obtained by Sesen Bio) or clause (e)&#160;above; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">at any time after the date of the Original Merger Agreement and prior to the Sesen Bio special meeting, an acquisition proposal with respect to Sesen Bio shall have been publicly announced or disclosed or otherwise communicated to Sesen Bio or the Sesen Bio board of directors (and shall not have been withdrawn); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">within 12&#160;months after the date of such termination, Sesen Bio consummates any subsequent transaction that is an acquisition transaction; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the Merger Agreement is terminated by Carisma pursuant to clause (f)&#160;above. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the Merger Agreement is terminated pursuant to clause (iv)&#160;above by Carisma, then Sesen Bio will pay the termination fee to Carisma within two business days of such termination. If the Merger Agreement is terminated by either Carisma or Sesen Bio pursuant to clause (e)&#160;above or by Carisma pursuant to clauses (f)&#160;or (h)&#160;above, then Sesen Bio shall reimburse Carisma for all reasonable out of pocket fees and expenses incurred by Carisma in connection with the Merger Agreement and the transactions contemplated thereby, up to a maximum of $1.75&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fee payable by Carisma</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma must pay Sesen Bio a termination fee of $5.49&#160;million if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the Merger agreement is terminated by Sesen Bio pursuant to clause (b)&#160;above (and the required Carisma stockholder vote has not been obtained by Carisma) or clause (d)&#160;above; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">at any time after the date of the Original Merger Agreement and before obtaining the required Carisma stockholder vote, an acquisition proposal with respect to Carisma shall have been publicly announced or disclosed or otherwise communicated to Carisma or the Carisma board of directors (and shall not have been withdrawn); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">within 12&#160;months after the date of such Merger Agreement termination, Carisma consummates any subsequent transaction that is an acquisition transaction; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the Merger Agreement is terminated by Sesen Bio pursuant to clause (g)&#160;above. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the Merger Agreement is terminated pursuant to clause (iv)&#160;above by Sesen Bio, then Carisma will pay the termination fee to Sesen Bio within two business days of such termination. If the Merger Agreement is terminated by Sesen Bio pursuant to clauses (d), (g), or (i)&#160;above, then Carisma shall reimburse Sesen Bio for all reasonable out of pocket fees and expenses incurred by Sesen Bio in connection with the Merger Agreement and the transactions contemplated thereby, up to a maximum of $1.75&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement may be amended by the parties at any time if such amendment is in writing, is approved by the boards of directors of each party to the Merger Agreement and is signed by each party to the Merger Agreement; provided, however, that after any approval of the Merger Agreement by a party&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">190</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:440pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">stockholders, no amendment will be made which by law requires further approval by such stockholders without the further approval of such stockholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fees and Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement provides all fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby shall be paid by the party incurring such expenses, except as described above in the section entitled &#8220;&#8212; </font><font style="font-style:italic;letter-spacing:0.2pt;">Termination Fee</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tTERFEE123">190</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus, and except that Sesen Bio and Carisma will share equally in any fees and expenses, other than attorneys&#8217; and accountants&#8217; fees and expenses, incurred in relation to the filings by the parties to the Merger Agreement under any filing requirement under antitrust or merger control laws applicable to the Merger Agreement and the transactions contemplated therein. Sesen Bio and Carisma shall also share equally all fees and expenses incurred in relation to (i)&#160;the printing and filing with the SEC of the registration statement on Form S-4, of which this proxy statement/prospectus is a part, and any amendments or supplements thereto and paid to a financial printer or the SEC and (ii)&#160;those filings with Nasdaq contemplated by the Merger Agreement. </font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">191</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tARTT">&#8203;</a><a name="tCVAG">&#8203;</a><a name="tMFIT5">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AGREEMENTS RELATED TO THE MERGER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CVR Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the effective time, Sesen Bio will enter into the CVR Agreement with a rights agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement and the CVR Agreement, for each share of Sesen Bio common stock held after giving effect to the proposed reverse stock split if approved and implemented, Sesen Bio stockholders of record as of a date agreed to by Sesen Bio and Carisma prior to the effective time will receive one CVR. Each CVR will entitle such Sesen Bio stockholder to receive (i) a pro&#160;rata portion of the $30.0&#160;million milestone payment to be made by Roche to Sesen Bio upon Roche&#8217;s initiation of a Phase&#160;3 clinical trial with legacy IL-6 antagonist antibody technology previously owned by Sesen Bio for a certain indication if initiated prior to December&#160;31, 2026, pursuant to the Roche Asset Purchase Agreement, less certain permitted deductions and (ii) a pro rata portion of the proceeds from any sale of Sesen Bio&#8217;s non-cash assets existing as of the date of the Original Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The CVR Agreement also provides that neither Sesen Bio, nor its affiliates, may, without the prior written consent of holders of at least 33% of the then-outstanding CVRs: (i)&#160;amend, restate, supplement, terminate or otherwise modify the Roche Asset Purchase Agreement in a manner materially adversely affecting the holders&#8217; rights under the CVR Agreement; (ii)&#160;in the event that Roche fails to make the milestone payment at the time rightfully due and payable, take action with respect to, or unreasonably waive or fail to enforce, the right to receive the applicable payments which are rightfully due and payable under the Roche Asset Purchase Agreement, in a manner materially adversely affecting the holders&#8217; rights under the CVR Agreement; or (iii)&#160;agree to any of the foregoing. Further, during the period between signing the CVR Agreement and December 31, 2023, Sesen Bio agreed to use commercially reasonable efforts to effectuate a disposition of any and all assets, tangible and intangible related to Vicineum</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">TM</font><font style="letter-spacing:0.2pt;">, including the negotiation and execution of a sale agreement and completion of the transactions contemplated thereby. Further, Sesen Bio agreed not to take any actions for the primary purpose of frustrating the payment of CVR payments. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The sole right of the holders of the CVRs is to receive cash from Sesen Bio, if any, through the rights agent in accordance with the CVR Agreement. The CVRs are not transferable, except in certain limited circumstances, will not be certificated or evidenced by any instrument and will not be registered with the SEC or listed for trading on any exchange. The CVRs will not have any voting or dividend rights, will not represent any equity or ownership interest in Sesen Bio or its subsidiaries, and interest will not accrue on any amounts payable on the CVRs. The CVR Agreement will be effective prior to the closing of the merger and will continue in effect until the earlier of (i) March&#160;31, 2027 for the Roche payments or December 31, 2023 for the payment of any proceeds from the sale of Sesen Bio&#8217;s legacy assets and (ii) the payment of all amounts payable thereunder, unless and until earlier terminated upon termination of the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foregoing description of the CVR Agreement does not purport to be complete and is qualified in its entirety by the full text of the form of CVR Agreement, which is included in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex F</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following discussion is a summary of the material U.S. federal income tax consequences of the receipt of CVRs to Sesen Bio stockholders who receive CVRs with respect to Sesen Bio common stock, but this discussion does not purport to be a complete analysis of all potential tax consequences that may be relevant to a Sesen Bio stockholder. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Sesen Bio U.S. holder. Sesen Bio has not sought and does not intend to seek any opinions of counsel or rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a position contrary to that discussed below regarding the tax consequences of the receipt of CVRs. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">192</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI3">&#8203;</a><a name="tSBUH">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion is limited to Sesen Bio U.S. holders that hold Sesen Bio common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Sesen Bio U.S. holder&#8217;s particular circumstances, including the impact of the alternative minimum tax or the Medicare contribution tax on net investment income or the rules related to &#8220;qualified small business stock&#8221; within the meaning of Section&#160;1202 of the Code. In addition, it does not address consequences relevant to Sesen Bio U.S. holders subject to special rules, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">U.S. expatriates and former citizens or long-term residents of the U.S.; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio U.S. holders whose functional currency is not the U.S. dollar; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons holding Sesen Bio common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">banks, insurance companies, and other financial institutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">real estate investment trusts or regulated investment companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">brokers, dealers or traders in securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">S corporations, partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-exempt organizations or governmental organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Sesen Bio common stock being taken into account in an &#8220;applicable financial statement&#8221; &#8203;(as defined in the Code); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons deemed to sell Sesen Bio common stock under the constructive sale provisions of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons who hold or received Sesen Bio common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-qualified retirement plans. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an entity treated as a partnership for U.S. federal income tax purposes holds Sesen Bio common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Sesen Bio common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">IT IS RECOMMENDED THAT HOLDERS CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE RECEIPT OF CVRs ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this discussion, a &#8220;Sesen Bio U.S. holder&#8221; is a beneficial owner of Sesen Bio common stock that, for U.S. federal income tax purposes, is or is treated as: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an individual who is a citizen or resident of the U.S.; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a corporation created or organized under the laws of the U.S., any state thereof, or the District of Columbia; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a trust that (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; &#8203;(within the meaning of Section&#160;7701(a)(30) of the Code) over all of its </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">193</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tALTERT3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">substantial decisions or (ii)&#160;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this discussion, a &#8220;Sesen Bio non-U.S. holder&#8221; means a beneficial owner of Sesen Bio common stock that is neither a Sesen Bio U.S. holder nor a partnership (or other entity treated as a partnership) for U.S. federal income tax purposes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Alternative Treatment of the Receipt of CVRs and the Proposed Reverse Stock Split as a Single Recapitalization </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio intends to report the proposed reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code that is separate from Sesen Bio&#8217;s distribution of the CVRs and the special cash dividend. Notwithstanding that Sesen Bio will report the receipt of CVRs, the receipt of the special cash dividend, and the proposed reverse stock split as separate transactions, it is possible that the IRS or a court could determine that the receipt of the CVRs or the special cash dividend, and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. In such case, the tax consequences of the receipt of CVRs and the proposed reverse stock split would differ from those described below and would depend in part on many of the same considerations described below, including whether the CVRs should be treated as property, equity or debt instruments or should be subject to the &#8220;open transaction&#8221; doctrine. In general, if the CVRs are treated as property and are not subject to the &#8220;open transaction&#8221; doctrine, and the receipt of the CVRs, the special cash dividend, and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes, then a Sesen Bio stockholder should recognize gain (but not loss) equal to the lesser of (i)&#160;the fair market value of the CVRs received plus the amount of the special cash dividend, and (ii)&#160;the excess (if any) of (A)&#160;the sum of (1)&#160;the fair market value of the CVRs received plus the amount of the special cash dividend and (2)&#160;the fair market value of the Sesen Bio shares received in the proposed reverse stock split over (B)&#160;the Sesen Bio stockholder&#8217;s adjusted tax basis in the Sesen Bio common stock surrendered in the proposed reverse stock split. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Receipt of CVRs by Sesen Bio U.S. holders</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion assumes that the distribution of CVRs and the special cash dividend to Sesen Bio U.S. holders will be treated for U.S. federal income tax purposes as transactions that are separate and distinct from the proposed reverse stock split. If, contrary to that assumption, the distribution of CVRs to Sesen Bio U.S. holders were integrated for tax purposes with the proposed reverse stock split, this could affect the calculation of the extent to which the distribution constitutes a taxable dividend or capital gain. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is substantial uncertainty as to the tax treatment of the CVRs. Specifically, there is no authority directly addressing whether contingent value rights with characteristics similar to the CVRs should be treated as a distribution of property with respect to Sesen Bio common stock, a distribution of equity, a &#8220;debt instrument&#8221; or an &#8220;open transaction&#8221; for U.S. federal income tax purposes. As a result, it is not possible to express a definitive conclusion as to the U.S. federal income tax treatment of receipt of the CVRs or receipt of any payments pursuant to the CVRs. Based on the specific characteristics of the CVRs, Sesen Bio intends to treat the issuance of the CVRs as a distribution of property with respect to its stock. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any description of the intended tax consequences summarized below. No opinion of counsel or ruling has been or will be sought from the IRS regarding the tax treatment of the CVRs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Provided that the issuance of the CVRs is treated as a distribution of property with respect to Sesen Bio common stock, each Sesen Bio U.S. holder should be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Sesen Bio U.S. holder on the date of the issuance. This distribution should be treated first as a taxable dividend to the extent of the Sesen Bio U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes and after taking into account the special cash dividend as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Special Cash Dividend</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tMUFI1">162</a> of this proxy statement/prospectus), then as a non-taxable return of capital to the extent of the Sesen Bio U.S. holder&#8217;s basis in its Sesen Bio common stock, and finally as capital gain from the sale or exchange of Sesen Bio common stock with respect to any remaining value. Sesen Bio currently has negative accumulated earnings and profits and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Sesen Bio expects most or all of this distribution to be treated as other </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">194</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">than a dividend for U.S. federal income tax purposes. Sesen Bio U.S. holders will receive a Form 1099-DIV notifying them of the portion of the CVR value that is treated as a non-dividend distribution (or a dividend to the extent of Sesen Bio&#8217;s earnings and profits) for U.S. federal income tax purposes. Although Sesen Bio will estimate the value of the CVRs for purposes of reporting on Form 1099 to Sesen Bio U.S. holders, the value of the CVRs is uncertain and the IRS or a court could determine that the value of the CVRs at the time of issuance was higher. In such case the Sesen Bio U.S. holders could be treated as having additional income or gain upon receipt of the CVRs as described above. A Sesen Bio U.S. holder&#8217;s initial tax basis in such holder&#8217;s CVRs should equal the fair market value of such CVRs on the date of their issuance. The holding period of such CVRs should begin on the day after the date of issuance. Future payments received by a Sesen Bio U.S. holder with respect to a CVR would likely be treated as a non-taxable return of such Sesen Bio U.S. holder&#8217;s adjusted tax basis in the CVR to the extent thereof, and payments in excess of such amount would likely be treated as ordinary income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">However, the treatment of the future payments, if any, pursuant to the CVRs is uncertain and alternative treatments are possible, although not expected. One such possible treatment is that the CVRs could be treated as one or more &#8220;debt instruments.&#8221; If that were to be the case, then the payments, if any, received with respect to the CVRs would likely be treated as payments in retirement of a &#8220;debt instrument,&#8221; except to the extent interest is imputed under complex rules under the Code. In such a case, a Sesen Bio U.S. holder would be required to include any such interest in income on an annual basis, whether or not currently paid. As discussed above, Sesen Bio does not intend to report the issuance of the CVRs as a distribution of a &#8220;debt instrument&#8221; for U.S. federal income tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is also possible that the issuance of the CVRs could be treated as a distribution of equity for U.S. federal income tax purposes, in which case Sesen Bio U.S. holders should not recognize gain or loss as a result of the issuance of the CVRs. Each Sesen Bio U.S. holder&#8217;s tax basis in such holder&#8217;s Sesen Bio common stock would be allocated between such holder&#8217;s Sesen Bio common stock and such holder&#8217;s CVRs. The holding period of such CVRs should include the Sesen Bio U.S. holder&#8217;s holding period of such holder&#8217;s Sesen Bio common stock. The future payments, if any, on a CVR received by a Sesen Bio U.S. holder could be treated as dividends to the extent of the Sesen Bio U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits at the time of such payments (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Sesen Bio U.S. holder&#8217;s basis in the CVR, and finally as capital gain from the sale or exchange of the CVR with respect to any remaining amount. As discussed above, Sesen Bio does not intend to report the issuance of the CVRs as a distribution of equity for U.S. federal income tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is also possible that the issuance of the CVRs could be treated as subject to the &#8220;open transaction&#8221; doctrine if the value of the CVRs at closing cannot be &#8220;reasonably ascertained.&#8221; If the receipt of CVRs were treated as an &#8220;open transaction&#8221; for U.S. federal income tax purposes, each Sesen Bio U.S. holder should not immediately take the CVRs into account in determining whether such holder must recognize income or gain, if any, on the receipt of the CVRs and such holder would not take any tax basis in the CVRs. Rather, the Sesen Bio U.S. holder&#8217;s U.S. federal income tax consequences would be determined in line with the discussion above based on whether the CVRs are treated as a distribution of property or of equity at the time the payments, if any, with respect to the CVRs is received or deemed received in accordance with the Sesen Bio U.S. holder&#8217;s regular method of accounting. As discussed above, Sesen Bio does not intend to report the issuance of the CVRs as an open transaction for U.S. federal income tax purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The CVRs should generally be treated as capital assets for U.S. federal income tax purposes once issued. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Receipt of CVRs by Sesen Bio Non-U.S. Holders</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Provided that the issuance of the CVRs is treated as a distribution of property with respect to Sesen Bio common stock, each Sesen Bio non-U.S. holder should be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Sesen Bio non-U.S. holder on the date of the issuance. This distribution should be treated first as a taxable dividend to the extent of the Sesen Bio non-U.S. holder&#8217;s pro&#160;rata share of Sesen Bio&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes and after taking into account the special cash dividend as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8212;Material U.S. Federal Income Tax Consequences of the Special Cash </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">195</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividend</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tMUFI1">162</a> of this proxy statement/prospectus), then as a non-taxable return of capital to the extent of the Sesen Bio non-U.S. holder&#8217;s basis in its Sesen Bio common stock, and finally as capital gain from the sale or exchange of Sesen Bio common stock with respect to any remaining amount. Sesen Bio currently has negative accumulated earnings and profits and expects no or a small amount of current earnings and profits for the relevant taxable year. Thus, Sesen Bio expects most or all of the distribution of the CVRs to be treated as other than a dividend for U.S. federal income tax purposes. However, if Sesen Bio cannot determine at the time of the distribution of the CVRs whether or not the amount of such distribution will exceed current and accumulated earnings and profits, Sesen Bio or the applicable withholding agent may withhold (potentially by utilizing cash that otherwise would be distributed to such holder with respect to the special cash dividend or other property of such Sesen Bio non-U.S. holder held in an account with the applicable withholding agent) at the rate applicable to dividends, as described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Taxable Dividends. Dividend payments will generally be subject to withholding at a 30% rate. If a Sesen Bio non-U.S. holder is eligible for a lower treaty rate, withholding will be at such lower treaty rate only if such Sesen Bio non-U.S. holder provides a valid IRS Form W-8BEN or W-8BEN-E (or applicable successor form) certifying such Sesen Bio non-U.S. holder&#8217;s qualification for the reduced rate. If a Sesen Bio non-U.S. holder holds the stock through a financial institution or other intermediary, the Sesen Bio non-U.S. holder will be required to provide appropriate documentation to the intermediary, which then will be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. Sesen Bio non-U.S. holders who do not timely provide the applicable withholding agent with the required certification, but who qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussions below regarding backup withholding, if the issuance of the CVRs is effectively connected with a Sesen Bio non-U.S. holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Sesen Bio non-U.S. holder maintains a permanent establishment in the United States to which the special cash dividend is attributable), the Sesen Bio non-U.S. holder will be exempt from U.S. federal withholding tax and the distribution of the CVRs generally will be subject to U.S. federal income tax on a net income basis in the same manner as if such Sesen Bio non-U.S. holder were a U.S. holder. To claim the exemption, the Sesen Bio non-U.S. holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI (or applicable successor form), certifying that the distribution is effectively connected with the Sesen Bio non-U.S. holder&#8217;s conduct of a trade or business within the United States. A Sesen Bio non-U.S. holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) of all or a portion of its effectively connected earnings and profits for the taxable year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any withholding required by Sesen Bio or other applicable withholding agents may be satisfied by Sesen Bio or such agent by withholding a portion of the issued CVRs, from the special cash dividend or from other property of the Sesen Bio non-U.S. holder held in an account with the applicable withholding agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Non-Dividend Distributions. To the extent that the issuance of the CVRs is treated as capital gain from the sale or exchange of Sesen Bio common stock, such gain generally will not be subject to U.S. federal income tax unless (i)&#160;such gain is effectively connected with the conduct by a Sesen Bio non-U.S. holder of a trade or business in the United States (and, if an income tax treaty applies, the gain is generally attributable to a U.S. permanent establishment maintained by such Sesen Bio non-U.S. holder), (ii)&#160;in the case of gain realized by a Sesen Bio non-U.S. holder that is an individual, such Sesen Bio non-U.S. holder is present in the United States for 183&#160;days or more in the taxable year of the sale and certain other conditions are met or (iii)&#160;Sesen Bio is or has been a USRPHC for U.S. federal income tax purposes and, if the shares are &#8220;regularly traded on an established securities market,&#8221; such Sesen Bio non-U.S. holder owned, directly or indirectly, at any time during the five-year period ending on the date of the distribution, more than 5% of the shares of Sesen Bio common stock and such Sesen Bio non-U.S. holder is not eligible for any treaty exemption. The shares will be considered &#8220;regularly traded&#8221; if they are traded on an established securities market located in the United States and are regularly quoted by brokers or dealers making a market in the shares. Sesen Bio believes it is not, and has not been, a USRPHC for U.S. federal income tax purposes. In addition, although not free from doubt, Sesen Bio believes that Sesen Bio common shares currently should be considered to be regularly traded. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">196</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSAAW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A Sesen Bio non-U.S. holder should consult its tax advisor regarding its entitlement to benefits and the various rules under applicable tax treaties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Information Reporting and Backup Withholding</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, the issuance of the CVRs to Sesen Bio U.S. holders will be reported to the IRS unless the holder is an exempt recipient. Backup withholding, currently at a rate of 24%, may apply unless the Sesen Bio U.S. holder (1)&#160;is an exempt recipient or (2)&#160;provides a certificate (generally on an IRS Form W-9) containing the Sesen Bio U.S. holder&#8217;s name, address, correct federal taxpayer identification number and statement that the Sesen Bio U.S. holder is a U.S. person and is not subject to backup withholding. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A Sesen Bio non-U.S. holder will not be subject to backup withholding with respect to the issuance of the CVRs, provided the Sesen Bio non-U.S. holder certifies its non-U.S. status, such as by providing a valid IRS Form W-8BEN or W-8ECI or W-8BEN-E, or otherwise establishes an exemption. However, information returns will be filed with the IRS in connection with the issuance of the CVRs, regardless of whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of a specific treaty or agreement to the tax authorities of the country in which the Sesen Bio non-U.S. holder resides or is established. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against a holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLEASE CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE PROPER CHARACTERIZATION OF THE RECEIPT OF THE CVRs.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Support Agreements and Written Consents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to induce Sesen Bio to enter into the Merger Agreement, certain stockholders of Carisma are parties to a support agreement with Sesen Bio and Carisma pursuant to which, among other things, each such stockholder has agreed, solely in his, her or its capacity as a stockholder of Carisma, to vote all of his, her or its shares of Carisma capital stock (subject to customary cutbacks in the event of certain triggering events) in favor of (i)&#160;adoption and approval of the Merger Agreement and the transactions contemplated thereby; (ii)&#160;adoption and approval of an amendment to the Carisma Certificate of Incorporation to increase the authorized shares of Carisma common stock; (iii)&#160;acknowledgement that the approval given thereby is irrevocable and that the stockholder is aware of the stockholder&#8217;s rights to demand appraisal for its shares pursuant to Section&#160;262 of the DGCL; and (iv)&#160;acknowledgement that by the stockholder&#8217;s approval of the merger, the stockholder is (a)&#160;waiving its appraisal rights under the DGCL with respect to its shares; and (b)&#160;waiving any notice that may have been or may be required relating to the merger or any other transactions contemplated thereby. Additionally, each such signatory has agreed, solely in his, her or its capacity as a Carisma stockholder, to vote against (subject to customary cutbacks in the event of certain triggering events) any such competing acquisition proposal and any action in furtherance of any competing acquisition proposal. These signatories have also granted an irrevocable proxy to Carisma and its designee to vote their respective shares of Carisma common stock in accordance with the support agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, in order to induce Carisma to enter into the Merger Agreement, certain stockholders of Sesen Bio are parties to a support agreement with Sesen Bio and Carisma pursuant to which, among other things, each such stockholder has agreed, solely in his or her capacity as a stockholder of Sesen Bio (if applicable), to vote all of his or her shares of Sesen Bio common stock in favor of (i)&#160;adoption and approval of the Merger Agreement and the transactions contemplated thereby; (ii)&#160;the issuance of shares of Sesen Bio common stock to Carisma stockholders in connection with the Merger Agreement and the transactions contemplated thereby; (iii)&#160;the change of control of Sesen Bio resulting from the Merger pursuant to Nasdaq rules; (iv)&#160;the approval of the equity plan amendment proposals; and (v)&#160;a waiver of any notice that may have been or may be required relating to the Merger or any other transactions contemplated thereby. Additionally, each such signatory has agreed, solely in his, her or its capacity as a Sesen Bio stockholder, to vote against any competing acquisition proposal and any action in furtherance of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">197</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSUAG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">any such competing acquisition proposal. These signatories have also granted an irrevocable proxy to Sesen Bio and its designee to vote their respective shares of Sesen Bio common stock in accordance with the support agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, the Carisma stockholders who are party to a support agreement (including any affiliated entities) owned an aggregate of 97.23% of the outstanding shares of Carisma common stock. Following the effectiveness of the registration statement of which this proxy statement/prospectus is a part and pursuant to the Merger Agreement, these stockholders will execute a written consent providing for such adoption and approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under these support agreements, subject to certain exceptions, such stockholders have also agreed not to sell or transfer the shares of Carisma capital stock subject to the support agreement held by them, or any voting rights with respect thereto, until the effective time. To the extent that any such sale or transfer is permitted pursuant to the exceptions included in the support agreement, each person to which any shares of Carisma capital stock subject to the support agreement are so sold or transferred shall be bound by the terms and provisions of the support agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The foregoing descriptions of the support agreements do not purport to be complete and are qualified in their entirety by the full text of the forms of support agreements, which are attached in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex C</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex&#160;D</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Subscription Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, immediately prior to the execution and delivery of the Original Merger Agreement, Carisma entered into a subscription agreement with certain investors named therein, pursuant to which the investors have agreed to purchase shares of Carisma common stock at an aggregate purchase price of approximately $30.6&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The shares of Carisma common stock issued in the Carisma pre-closing financing will be converted into shares of Sesen Bio common stock in the merger in accordance with the exchange ratio. The consummation of the transactions contemplated by the subscription agreement is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement. All shares of Sesen Bio common stock issued in exchange for shares of Carisma common stock issued in the Carisma pre-closing financing will be subject to restrictions on resale following the closing of the merger. On December 29, 2022, immediately prior to the execution and delivery of the Merger Agreement Amendment, Carisma entered into an amended and restated subscription agreement with the investors party to the original subscription agreement, pursuant to which the parties thereto clarified that shares of Carisma common stock issued in the pre-closing financing will not be registered under the Securities Act and will be subject to restrictions on resale and agreed, among other things, to enter into a registration rights agreement to provide for the registration of the resale of the shares of common stock purchased by such investors in connection with the Carisma pre-closing financing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The subscription agreement contains customary representations and warranties of Carisma and also contains customary representations and warranties of the purchasers party thereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each purchaser&#8217;s obligation to purchase shares of Carisma common stock from Carisma pursuant to the subscription agreement is subject to the satisfaction or waiver of certain conditions, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s representations and warranties in the subscription agreement being true and correct in all material respects as of the closing date for the Carisma pre-closing financing, subject to certain exceptions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma having performed and complied in all material respects with all covenants, agreements, obligations and conditions required to be performed or complied with by it on or prior to the closing date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma having filed the charter amendment with the Secretary of State of the State of Delaware; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the delivery of a compliance certificate by the Chief Executive Officer or the Chief Financial Officer of Carisma; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">198</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLOAG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the satisfaction or waiver of all conditions to the closing of the merger set forth in the Merger Agreement (other than the condition regarding the Carisma pre-closing financing and other than those conditions which, by their nature, are to be satisfied at the closing of the merger) and the closing of merger being set to occur substantially concurrently with the closing of the Carisma pre-closing financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">all authorizations, approvals or permits, if any, required under applicable state securities laws having been obtained; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the delivery of a fully executed registration rights agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s obligation to sell shares of Carisma common stock to each purchaser pursuant to the subscription agreement is subject to the satisfaction or waiver of certain conditions, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the representations and warranties made by such purchaser being true and correct in all material respects as of the closing date of the Carisma pre-closing financing, subject to certain exceptions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">such purchaser having performed and complied with all covenants, agreements, obligations and conditions required to be performed or complied with by it on or prior to the closing date; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the satisfaction or waiver of all conditions to the closing of the merger set forth in the Merger Agreement (other than the condition regarding the Carisma pre-closing financing and other than those conditions which, by their nature, are to be satisfied at the closing of the merger) and the closing of merger being set to occur substantially concurrently with the closing of the Carisma pre-closing financing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The subscription agreement may not be changed, waived, amended or modified, except by an instrument in writing executed by Carisma and the purchasers then committed to purchase a majority of the shares to be sold in the Carisma pre-closing financing. The subscription agreement will terminate upon the earlier to occur of (i)&#160;such date and time that the Merger Agreement is terminated in accordance with its terms, (ii)&#160;upon the mutual written agreement of Carisma and the purchasers then committed to purchase a majority of the shares to be sold in the Carisma pre-closing financing (provided that Carisma and a purchaser may terminate the commitment of the applicable purchaser without the consent of any other party), and (iii)&#160;if the closing of the merger has not occurred on or before January&#160;31, 2023 (as such date may be extended in the event that a request for additional information is made by any governmental body or in the event that the SEC has not declared the registration statement effective under the Securities Act by the date which is 60&#160;days prior to the end date), other than as a result of a willful breach of a purchaser&#8217;s obligations under the subscription agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lock-Up Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a condition to the closing of the merger, certain stockholders of each of Sesen Bio and Carisma and their affiliates, have entered into lock-up agreements, pursuant to which such parties have agreed not to, except in limited circumstances and among other restrictions, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of or lend, directly or indirectly, any shares of Sesen Bio common stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive Sesen Bio common stock (including without limitation, Sesen Bio common stock or such other securities which may be deemed to be beneficially owned by the signatory in accordance with the rules and regulations of the SEC and securities of Sesen Bio which may be issued upon exercise of a Sesen Bio option, Sesen Bio RSU or Sesen Bio warrant), during the period commencing at the effective time and continuing until the date that is 180&#160;days after the effective time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The foregoing description of the lock-up agreements do not purport to be complete and are qualified in their entirety by the full text of the form of lock-up agreement, which is attached in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex E</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain directors and executive officers of both Sesen Bio and Carisma are party to a lock-up agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain Carisma stockholders party to Carisma support agreements are also party to lock-up agreements. Carisma stockholders who have executed lock-up agreements, as of January 4, 2023, beneficially </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">199</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:464pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">owned in the aggregate approximately 97.23% of the outstanding shares of Carisma capital stock on an as converted to Carisma common stock basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has filed an initial listing application with Nasdaq pursuant to the Nasdaq Stock Market LLC &#8220;business combination&#8221; rules. If such application is accepted, Sesen Bio anticipates that Sesen Bio common stock will be listed on Nasdaq following the closing of the merger under the trading symbol &#8220;CARM.&#8221; In order to meet the requirements for listing on Nasdaq, the post-merger combined company will be required to satisfy Nasdaq&#8217;s initial listing requirements, including the financial and liquidity requirements for the applicable Nasdaq market tier upon which the post-merger combined company&#8217;s shares will trade following the merger. Certain Nasdaq market tiers and standards require companies seeking to list to demonstrate a minimum &#8220;Market Value of Unrestricted Publicly Held Shares&#8221; as of the effective time of the closing of a business combination. Per current Nasdaq Listing Rules, the &#8220;Market Value of Unrestricted Publicly Held Shares&#8221; may not include the value of any securities subject to resale restrictions, including the types of restrictions set forth in the Sesen Bio and Carisma lock-up agreements.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">200</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMBST">&#8203;</a><a name="tPN1A">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MATTERS BEING SUBMITTED TO A VOTE OF SESEN BIO STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposal No. 1: Approval, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock to Carisma stockholders pursuant to the terms of the Merger Agreement and the change of control of Sesen Bio resulting from the merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">At the Sesen Bio special meeting, Sesen Bio stockholders will be asked to consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule&#160;5635(a) and (b), the issuance of shares of Sesen Bio common stock pursuant to the terms of the Merger Agreement and the change of control of Sesen Bio resulting from the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Immediately after the merger, pre-merger Sesen Bio stockholders are expected to own approximately 25.2% of the outstanding shares of capital stock of the combined company and pre-merger Carisma stockholders, after taking into account shares of Carisma common stock purchased in connection with the Carisma pre-closing financing and the conversion of the Carisma convertible note, are expected to own approximately 74.8% of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including, Sesen Bio&#8217;s net cash as of closing being at least $75.0 million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The terms of, reasons for and other aspects of the Merger Agreement, the merger and the issuance of Sesen Bio common stock in the merger are described in detail in the other sections in this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus. A copy of the Original Merger Agreement and the Merger Agreement Amendment are attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annexes A-1</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">A-2</font><font style="letter-spacing:0.2pt;">, respectively, to this proxy statement/prospectus. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Nasdaq Listing Rule&#160;5635(a) requires a company listed on Nasdaq to obtain stockholder approval prior to the issuance of common stock (or other securities convertible into or exercisable for common stock) in connection with the acquisition of the stock or assets of another company, if such securities are not issued in a public offering and (i)&#160;the common stock has, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such securities, or (ii)&#160;the number of shares of common stock to be issued is or will be equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance of such securities. The potential issuance of the shares of Sesen Bio common stock in the merger will exceed the 20% threshold under the Nasdaq Listing Rules. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a), Sesen Bio must obtain the approval of Sesen Bio stockholders for the issuance of these shares of Sesen Bio common stock in the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Nasdaq Listing Rule&#160;5635(b) requires a company listed on Nasdaq to obtain stockholder approval prior to an issuance of securities that will result in a &#8220;change of control&#8221; of the company. Although Nasdaq has not adopted any rule as to what constitutes a &#8220;change of control&#8221; for purposes of Rule&#160;5635(b), Nasdaq has previously indicated that the acquisition of, or right to acquire, by a single investor or affiliated investor group, as little as 20% of the common stock (or securities convertible into or exercisable for common stock) or voting power of an issuer could constitute a change of control. In addition, the staff of Nasdaq has advised Sesen Bio that Nasdaq deems the merger to be a &#8220;change of control.&#8221; Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(b), Sesen Bio must obtain the approval of Sesen Bio stockholders for the potential change in control of Sesen Bio resulting from the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The terms of, reasons for and other aspects of the Merger Agreement, the merger, the issuance of shares of Sesen Bio common stock pursuant to the terms of the Merger Agreement and the resulting change of control are described in detail in the other sections in this proxy statement/prospectus. A copy of the Original Merger Agreement and the Merger Agreement Amendment are attached as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annexes A-1</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">A-2 to</font><font style="letter-spacing:0.2pt;"> this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Vote Required</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The affirmative vote of a majority in voting power of the votes cast by the holders of Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting and entitled to vote on the matter is required for approval of Proposal No. 1. Abstentions will have no effect on Proposal No. 1. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">201</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:524pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Recommendation of Sesen Bio Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">THE SESEN BIO BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT SESEN BIO STOCKHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL NO. 1 TO APPROVE, FOR PURPOSES OF NASDAQ LISTING RULE 5635(a) and (b), THE ISSUANCE OF SHARES OF SESEN BIO COMMON STOCK PURSUANT TO THE TERMS OF THE MERGER AGREEMENT AND THE CHANGE OF CONTROL OF SESEN BIO RESULTING FROM THE MERGER. PROPOSAL NO. 1 IS CONDITIONED UPON THE APPROVAL OF PROPOSAL NO. 2, AND THE MERGER CANNOT BE CONSUMMATED WITHOUT THE APPROVAL OF PROPOSAL NOS. 1 AND 2. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">202</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPN2A">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposal No. 2: Approval of an amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split and reduce the number of authorized shares of Sesen Bio common stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the Sesen Bio special meeting, Sesen Bio stockholders will be asked to consider and vote upon a proposal to approve an amendment to the Sesen Bio Certificate of Incorporation to effect the proposed reverse stock split and reduce the authorized shares of Sesen Bio common stock. Upon the effectiveness of the amendment to the Sesen Bio Certificate of Incorporation effecting the reverse stock split, or the split effective time, the issued and outstanding shares of Sesen Bio common stock immediately prior to the split effective time will be reclassified into a smaller number of shares of Sesen Bio common stock, at a ratio of 1-for-20. If the merger is not consummated, then the implementation and timing of the reverse stock split would be in the Sesen Bio board of directors&#8217; sole discretion. If and when the reverse stock split is effected, the amendment to the Sesen Bio Certificate of Incorporation will also reduce the number of authorized shares of Sesen Bio common stock from 400,000,000 to 100,000,000. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors may determine to effect the reverse stock split, if it is approved by the Sesen Bio stockholders, even if Proposal No. 1 is not approved and the merger is not consummated. If the Sesen Bio stockholders approve Proposal No. 2, and the Sesen Bio board of directors decides to implement it, the reverse stock split will become effective on the date of the filing of the amendment to the Sesen Bio Certificate of Incorporation with the Secretary of State of the State of Delaware. The form of amendment to the Sesen Bio Certificate of Incorporation set forth in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex G</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus has been approved by the Sesen Bio board of directors. By approving the reverse stock split, Sesen Bio stockholders also will be approving the form of amendment to the Sesen Bio Certificate of Incorporation set forth in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex G</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purpose</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors approved Proposal No.&#160;2 approving the amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split for the following reasons: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The reverse stock split may be necessary to increase Sesen Bio&#8217;s stock price to meet Nasdaq&#8217;s $4.00 minimum bid price requirement upon the closing of the merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors believes effecting the reverse stock split may be necessary to raise the per share trading price of Sesen Bio&#8217;s common stock to regain compliance with the Nasdaq Listing Rules to remain listed on the Nasdaq Capital Market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the reverse stock split and the related amendment to the Sesen Bio Certificate of Incorporation will be required in order to make sufficient shares of Sesen Bio common stock available for issuance to Carisma stockholders pursuant to the Merger Agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Sesen Bio board of directors believes a higher stock price may help generate investor interest in Sesen Bio and help Sesen Bio attract and retain employees; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if the reverse stock split successfully increases the per share price of Sesen Bio common stock, the Sesen Bio board of directors believes this increase may increase trading volume in Sesen Bio common stock and facilitate future financings by Sesen Bio. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reasons for the Reverse Stock Split</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Requirements for Listing on Nasdaq</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio common stock is quoted on the Nasdaq Capital Market under the symbol &#8220;SESN,&#8221; and Sesen Bio is therefore subject to its continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share and minimum stockholder&#8217;s equity, among others, and requirements relating to board and committee independence. If Sesen Bio fails to satisfy one or more of the requirements, Sesen Bio may be delisted from Nasdaq. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">203</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio has filed an initial listing application with Nasdaq to seek listing of the combined company on the Nasdaq Capital Market upon the closing of the merger. According to Nasdaq Listing Rule&#160;5110, an issuer must apply for initial listing in connection with a transaction whereby the issuer combines with a non-Nasdaq entity, resulting in a change of control of the issuer and potentially allowing the non-Nasdaq entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require Sesen Bio to have, among other things, a $4.00 per share minimum bid price upon the closing of the merger. As of January&#160;17, 2023 the closing price of Sesen Bio common stock was $0.6493 per share. If Sesen Bio stockholders do not approve Proposal No. 2, the merger will not be able to occur because continued listing on Nasdaq is a condition to the closing of the merger. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Requirements for Continued Listing on Nasdaq</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent the merger is not completed, the primary objective for the reverse stock split will be to raise the per share trading price of Sesen Bio&#8217;s common stock to regain compliance with the Nasdaq Listing Rules to remain listed on the Nasdaq Capital Market. The reverse stock split will have the immediate effect of increasing the bid price of the Sesen Bio common stock, which should help ensure a share price high enough to regain compliance with the $1.00 per share minimum bid price requirement. However, there can be no assurance that the trading price of Sesen Bio common stock would be maintained at such level or that Sesen Bio will be able to maintain the listing of Sesen Bio common stock on the Nasdaq Capital Market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As previously disclosed, on January&#160;24, 2022, Sesen Bio received written notice from Nasdaq indicating that Sesen Bio was not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule&#160;5450(a)(1). Sesen Bio was given until July&#160;25, 2022, to regain compliance with the minimum bid price requirement. In response, Sesen Bio submitted an application to transfer the listing of the Sesen Bio common stock from the Nasdaq Global Market to the Nasdaq Capital Market. On July&#160;26, 2022, Sesen Bio received approval from Nasdaq to transfer the listing of Sesen Bio common stock from the Nasdaq Global Market to the Nasdaq Capital Market. As a result, Sesen Bio has been granted a second 180-day grace period, or until January&#160;23, 2023, to regain compliance with the minimum bid price requirement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio common stock was transferred to the Nasdaq Capital Market effective at the opening of business on July&#160;28, 2022. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and requires that listed companies meet certain financial and liquidity requirements and comply with Nasdaq&#8217;s corporate governance requirements. To regain compliance with the minimum bid price requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Sesen Bio common stock must be at least $1.00 for at least ten consecutive business days during the second 180-day grace period. If Sesen Bio does not regain compliance during this second grace period, its common stock would be subject to delisting by Nasdaq. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Potential Increased Investor Interest</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">To the extent the merger is not completed, another principal reason for the reverse stock split would be to generate investor interest in Sesen Bio common stock. On January&#160;17, 2023, Sesen Bio common stock closed at $0.6493 per share. An investment in Sesen Bio common stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a&#160;percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower priced stocks. Also, Sesen Bio believes that most investment funds are reluctant to invest in lower priced stocks. Accordingly, the Sesen Bio board of directors believes that a higher stock price may generate investor interest in Sesen Bio common stock. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Criteria to be Used for Determining Whether to Implement the Reverse Stock Split</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In determining whether to implement the reverse stock split following receipt of Sesen Bio stockholder approval of Proposal No. 2, Sesen Bio and/or Carisma (solely in connection with the merger) may consider, among other things, various factors, such as: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the historical trading prices and trading volume of Sesen Bio common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">204</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s capitalization (including the number of shares of Sesen Bio common stock issued and outstanding); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the then-prevailing trading price and trading volume of the Sesen Bio common stock and the anticipated or actual impact of the reverse stock split on the trading price and trading volume of Sesen Bio common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability of Sesen Bio to continue its listing on the Nasdaq Capital Market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential devaluation of Sesen Bio common stock as a result of the reverse stock split; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the anticipated impact of a particular ratio on Sesen Bio&#8217;s ability to reduce administrative and transactional costs; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prevailing general market and economic conditions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event the Sesen Bio board of directors determines to implement the reverse stock split in connection with the merger, the total number of issued and outstanding shares of Sesen Bio common stock after the consummation of the transactions contemplated by the Merger Agreement, together with the total number of shares of Sesen Bio common stock then reserved for issuance or obligated to be issued by Sesen Bio pursuant to any agreement or arrangement or otherwise, including the Merger Agreement, will not exceed the total number of shares of Sesen Bio common stock then authorized under the Sesen Bio Certificate of Incorporation, as amended. Sesen Bio currently estimates that it will issue a maximum of 660,858,446 shares of Sesen Bio common stock (before giving effect to the reverse stock split) in connection with the transactions related to the merger (including to investors in the Carisma pre-closing financing and upon conversion of the Carisma convertible note). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Principal Effects of the Reverse Stock Split</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A reverse stock split refers to a reduction in the number of outstanding shares of a class of a corporation&#8217;s capital stock, which may be accomplished, as in this case, by reclassifying and combining all of the outstanding shares of Sesen Bio common stock into a proportionately smaller number of shares of Sesen Bio common stock. If the Sesen Bio board of directors decides to implement a 1-for-20 reverse stock split of Sesen Bio common stock, then a Sesen Bio stockholder holding 10,000 shares of Sesen Bio common stock before the reverse stock split would instead hold 500 shares of Sesen Bio common stock immediately after the reverse stock split. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If approved and implemented, the principal effects of the reverse stock split would include the following, all of which have been considered by the Sesen Bio board of directors in approving the reverse stock split: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The number of outstanding shares of Sesen Bio common stock will be reduced and each Sesen Bio stockholder will own fewer shares of Sesen Bio common stock than they currently own. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of Sesen Bio common stock reserved and available for issuance under Sesen Bio&#8217;s equity-based compensation plans and the number of shares of Sesen Bio common stock issuable upon the exercise of outstanding Sesen Bio options and Sesen Bio warrants, or upon the conversion of outstanding Sesen Bio RSUs, will be reduced proportionately based on the ratio selected by the Sesen Bio board of directors, and the exercise price of all outstanding Sesen Bio options and Sesen Bio warrants will be increased proportionately. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Except for adjustments that may result from the treatment of fractional shares resulting from the reverse stock split, which are explained below under the section entitled &#8220;&#8212; </font><font style="font-style:italic;letter-spacing:0.2pt;">Fractional Shares</font><font style="letter-spacing:0.2pt;">,&#8221; each Sesen Bio stockholder will hold the same&#160;percentage of Sesen Bio common stock immediately following the reverse stock split as the stockholder held immediately prior to the reverse stock split. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The voting rights, rights to dividends and distributions and other rights of Sesen Bio common stock will not be changed as a result of the reverse stock split. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The reverse stock split will not affect the number of authorized shares of Sesen Bio preferred stock or the par value of Sesen Bio common stock or preferred stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">205</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The number of authorized shares of Sesen Bio common stock will be reduced from 400,000,000 to 100,000,000. Authorized shares represent the number of shares of Sesen Bio common stock that Sesen Bio is permitted to issue under the Sesen Bio Certificate of Incorporation. Therefore, Proposal No. 2 would have the effect of reducing the number of shares of Sesen Bio common stock available for future issuance after giving effect to the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The reverse stock split will not affect Sesen Bio continuing to be subject to the periodic reporting requirements of the Exchange Act. The reverse stock split is not intended as, and will not have the effect of, a &#8220;going private transaction&#8221; covered by Rule&#160;13e-3 under the Exchange Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The reverse stock split will be effected simultaneously for all outstanding shares of Sesen Bio common stock. The reverse stock split will affect all Sesen Bio stockholders uniformly and will not affect any Sesen Bio stockholder&#8217;s&#160;percentage interest in Sesen Bio, except for immaterial adjustments that may result from the treatment of fractional shares as described below. Shares of Sesen Bio common stock issued pursuant to the reverse stock split will remain fully paid and nonassessable. The reverse stock split does not affect the total proportionate ownership of Sesen Bio following the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table, which is for illustrative purposes only, illustrates the effects of a 1-for-20 reverse stock split (without giving effect to the treatment of fractional shares): </font>
        </div>
        <table style="width:456pt;height:65.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:185.65pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Issued</font>
                <br >
                <font style="letter-spacing:-0.16pt;">and</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Authorized</font>
                <br >
                <font style="letter-spacing:-0.16pt;">and</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Reserved for</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Issuance</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Authorized</font>
                <br >
                <font style="letter-spacing:-0.16pt;">and</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unreserved for</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Issuance</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:185.65pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">As of January 4, 2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">202,759,043</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">27,017,998</td>
            <td style="padding:0pt;padding-left:7.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">170,222,959</td>
            <td style="padding:0pt;padding-left:5.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">400,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">1-for-20 Reverse Split </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">10,137,952</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,350,899</td>
            <td style="padding:0pt;padding-left:7.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">8,511,147</td>
            <td style="padding:0pt;padding-left:5.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">100,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">These estimates do not reflect the potential effects of the treatment of fractional shares that may result from the proposed reverse stock split. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Includes outstanding 186,600 Sesen Bio warrants, 15,304,313 Sesen Bio options, 4,695,007 Sesen Bio RSUs, 4,532,078 shares of Sesen Bio common stock reserved for future issuance under the 2014 Incentive Plan and 2,300,000 shares of Sesen Bio common stock reserved for future issuance under the 2014 ESPP as of January 4, 2023. Does not include any shares of Sesen Bio common stock issuable upon the exercise or conversion of securities that may have been issued since January 4, 2023 or any shares of Sesen Bio common stock reserved or to be reserved in connection with the Carisma pre-closing financing and the conversion of the Carisma convertible note. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain Risks Associated with the Reverse Stock Split</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are risks associated with the reverse stock split, which have been considered by the Sesen Bio board of directors in recommending to Sesen Bio stockholders the reverse stock split for approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">One of the effects of the reverse stock split will be to effectively increase the number of authorized shares of Sesen Bio common stock which are unissued relative to shares of Sesen Bio common stock which are issued. This could result in the Sesen Bio board of directors being able to issue more shares of Sesen Bio common stock without further stockholder approval. Therefore, the Sesen Bio board of directors has determined, if the reverse stock split is effected, to reduce the number of authorized shares of Sesen Bio common stock from 400,000,000 to 100,000,000. For example, before the reverse stock split, Sesen Bio estimates as of January 4, 2023, that Sesen Bio&#8217;s authorized but unallocated shares of Sesen Bio common stock immediately prior to the closing of the merger would be approximately 170,222,959 compared to issued and outstanding shares of Sesen Bio common stock of approximately 202,759,043. If Sesen Bio effects the reverse stock split using a 1-for-20 ratio, the authorized but unallocated shares of Sesen Bio common stock immediately prior to the closing of the merger would be approximately 88,511,149 compared to issued and outstanding shares of Sesen Bio common stock of approximately 10,137,952. Sesen Bio currently estimates that it will issue a maximum of 660,858,446 shares of Sesen Bio common stock (before giving effect to the reverse stock split) in connection with the transactions related to the merger (including to investors in the Carisma pre-closing financing and upon conversion of the Carisma convertible note). With respect to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">206</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">authorized but unallocated shares of Sesen Bio common stock available after the consummation of the merger, the combined company could use such shares that are available for issuance in future equity financing transactions, which could result in additional dilution to the stockholders of the combined company, or to oppose a hostile takeover attempt or delay or prevent future changes in control or changes in or removal of management, including transactions that are favored by a majority of such stockholders or in which such stockholders might otherwise receive a premium for their shares of the combined company&#8217;s common stock over then-current market prices or benefit in some other manner. Sesen Bio currently has no plans to issue shares of Sesen Bio common stock, other than in connection with the merger and to satisfy obligations under the Sesen Bio warrants, Sesen Bio options and Sesen Bio RSUs from time to time as such Sesen Bio warrants, Sesen Bio options and Sesen Bio RSUs are exercised, or vested and settled, for shares of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio cannot predict whether the reverse stock split will increase the market price for Sesen Bio common stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the market price per share of Sesen Bio common stock after the reverse stock split will rise in proportion to the reduction in the number of shares of Sesen Bio common stock outstanding before the reverse stock split; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks or promote greater liquidity for Sesen Bio stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the bid price per share will exceed the $1.00 minimum bid price as required by Nasdaq for continued listing on the Nasdaq Capital Market; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">that Sesen Bio will otherwise meet the requirements of Nasdaq for initial listing on the Nasdaq Capital Market, including the $4.00 minimum bid price upon the closing of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The market price of Sesen Bio common stock will also be based on the performance of Sesen Bio and other factors, some of which are unrelated to the number of outstanding shares of Sesen Bio common stock. If the reverse stock split is effected and the market price of Sesen Bio common stock declines, the&#160;percentage decline as an absolute number and as a&#160;percentage of the overall market capitalization of Sesen Bio may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of Sesen Bio common stock could be adversely affected by the reduced number of shares of Sesen Bio common stock that would be outstanding after the reverse stock split. In addition, there can be no assurance that Sesen Bio common stock will not be delisted due to a failure to meet other listing requirements even if the market price per share of Sesen Bio common stock after reverse stock split is in excess of the minimum bid price requirement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since the reverse stock split will decrease the number of shares of Sesen Bio common stock held by Sesen Bio stockholders, the reverse stock split may increase the number of Sesen Bio stockholders who hold less than a &#8220;round lot,&#8221; or 100 shares of Sesen Bio common stock. Typically, the transaction costs to stockholders selling &#8220;odd lots&#8221; are higher on a per share basis. Consequently, the reverse stock split could increase the transaction costs to existing Sesen Bio stockholders in the event they wish to sell all or a portion of their shares of Sesen Bio common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Procedure for Effecting the Reverse Stock Split and Exchange of Stock Certificates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio stockholders approve the amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split, and if the Sesen Bio board of directors still believes that a reverse stock split is in the best interests of Sesen Bio and Sesen Bio stockholders, Sesen Bio will file the amendment to the Sesen Bio Certificate of Incorporation with the Secretary of State of the State of Delaware at such time as the Sesen Bio board of directors has determined to be the appropriate split effective time. Beginning at the split effective time, each certificate representing pre-split shares of Sesen Bio common stock will be deemed for all corporate purposes to evidence ownership of post-split shares of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The form of amendment to the Sesen Bio Certificate of Incorporation set forth in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex G</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus has been approved by the Sesen Bio board of directors. By approving the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">207</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">reverse stock split, Sesen Bio stockholders also will be approving the form of amendment to the Sesen Bio Certificate of Incorporation set forth in </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex G</font><font style="letter-spacing:0.2pt;"> to this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As soon as practicable after the split effective time, Sesen Bio stockholders will be notified that the reverse stock split has been effected. Sesen Bio expects that the Sesen Bio transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates, if any. Holders of pre-split shares of Sesen Bio common stock holding all of their shares electronically in book-entry form with Sesen Bio&#8217;s transfer agent do not need to take any action to receive post-split shares. Holders of pre-split shares of Sesen Bio common stock held in certificated form will be asked to surrender to the exchange agent certificates representing pre-split shares of Sesen Bio common stock in exchange for certificates representing post-split shares of Sesen Bio common stock in accordance with the procedures to be set forth in a letter of transmittal to be sent by Sesen Bio. Upon receipt of the holder&#8217;s pre-split certificate(s) and the properly completed and executed letter of transmittal, the holder will be issued the appropriate number of shares of Sesen Bio common stock electronically in book-entry form under the Direct Registration System. No new shares in book-entry form will be reflected until the holder surrenders the holder&#8217;s outstanding pre-split certificate(s), together with the properly completed and executed letter of transmittal, to the exchange agent. Any pre-split shares of Sesen Bio common stock submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post-split shares of Sesen Bio common stock. </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Sesen Bio stockholders should not destroy any stock certificate(s) and should not submit any certificate(s) unless and until requested to do so.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fractional Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No fractional shares of Sesen Bio common stock will be issued in connection with the reverse stock split. Sesen Bio stockholders of record who otherwise would be entitled to receive a fractional share of Sesen Bio common stock because they hold a number of pre-split shares of Sesen Bio common stock not evenly divisible by the number of pre-split shares to be reclassified into one post-split share, will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the Sesen Bio stockholder would otherwise be entitled multiplied by the closing price of Sesen Bio common stock on Nasdaq on the date of the split effective time; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, holders of certificated shares must first surrender to the exchange agent the certificates representing such pre-split shares of Sesen Bio common stock. The ownership of a fractional interest will not give the holder thereof any voting, dividend, or other rights except to receive payment therefor as described herein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By approving the amendment to the Sesen Bio Certificate of Incorporation to effect the reverse stock split, Sesen Bio stockholders will be approving the combination of 20 outstanding shares of Sesen Bio common stock into one share of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio stockholders should be aware that, under the escheat laws of the various jurisdictions where Sesen Bio stockholders reside, where Sesen Bio is domiciled, and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the split effective date of the reverse stock split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by Sesen Bio or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, Sesen Bio stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Accounting Consequences</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The par value per share of Sesen Bio common stock will remain unchanged at $0.001 per share after the reverse stock split. As a result, at the split effective time of the reverse stock split, the stated capital on Sesen Bio&#8217;s balance sheet attributable to Sesen Bio common stock will be reduced proportionately based on the ratio, from its present amount, and the additional paid-in capital account will be increased for the amount by which the stated capital is reduced. After the reverse stock split (and disregarding the impact of shares of Sesen Bio common stock issued in the merger), net income or loss per share, and other per share amounts will be increased because there will be fewer shares of Sesen Bio common stock outstanding. In future financial statements, net loss per share and other per share amounts for periods ending before the reverse stock split will be restated to give retroactive effect to the reverse stock split. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">208</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="MUIT6">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Potential Anti-Takeover Effect</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although the increased proportion of unissued authorized shares of Sesen Bio common stock to issued shares of Sesen Bio common stock could, under certain circumstances, have an anti-takeover effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Sesen Bio board of directors or contemplating a tender offer or other transaction for the combination of Sesen Bio with another company, the reverse stock split is not being proposed in response to any effort of which Sesen Bio is aware to accumulate shares of Sesen Bio common stock or obtain control of Sesen Bio, other than in connection with the merger, nor is it part of a plan by management to recommend a series of similar amendments to the Sesen Bio board of directors and Sesen Bio stockholders. Other than the proposals being submitted to Sesen Bio stockholders for their consideration at the Sesen Bio special meeting, the Sesen Bio board of directors does not currently contemplate recommending the adoption of any other actions that could be construed to affect the ability of third parties to take over or effect a change of control of Sesen Bio. For more information, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Description of Sesen Bio Capital Stock&#8201;&#8212;&#8201;Anti-Takeover Effect of Sesen Bio&#8217;s Certificate of Incorporation and Bylaw Provisions</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tANTIT">384</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following discussion is a summary of the material U.S. federal income tax consequences of the reverse stock split to Sesen Bio U.S. holders (which, for purposes of this discussion, has the same meaning as in &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font><font style="letter-spacing:0.2pt;">&#8221;), but does not purport to be a complete analysis of all potential tax consequences that may be relevant to Sesen Bio U.S. holders. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Sesen Bio U.S. holder. Sesen Bio has not sought and does not intend to seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a position contrary to that discussed below regarding the tax consequences of the reverse stock split. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This discussion is limited to Sesen Bio U.S. holders that hold Sesen Bio common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences that may be relevant to a Sesen Bio U.S. holder&#8217;s particular circumstances, including the impact of the alternative minimum tax or the Medicare contribution tax on net investment income or the rules related to &#8220;qualified small business stock&#8221; within the meaning of Section&#160;1202 of the Code. In addition, it does not address consequences relevant to Sesen Bio U.S. holders subject to special rules, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">U.S. expatriates and former citizens or long-term residents of the U.S.; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio U.S. holders whose functional currency is not the U.S. dollar; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons holding Sesen Bio common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">banks, insurance companies, and other financial institutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">real estate investment trusts or regulated investment companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">brokers, dealers or traders in securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">S corporations, partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-exempt organizations or governmental organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">209</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Sesen Bio common stock being taken into account in an &#8220;applicable financial statement&#8221; &#8203;(as defined in the Code); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons deemed to sell Sesen Bio common stock under the constructive sale provisions of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons who hold or received Sesen Bio common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-qualified retirement plans. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If an entity treated as a partnership for U.S. federal income tax purposes holds Sesen Bio common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Sesen Bio common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">IT IS RECOMMENDED THAT SESEN BIO STOCKHOLDERS CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio intends to report the reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code. In general, and subject to the qualifications set forth below, if the reverse stock split qualifies as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code, a Sesen Bio U.S. holder should not recognize gain or loss upon the reverse stock split, except to the extent a Sesen Bio U.S. holder receives cash in lieu of a fractional share of Sesen Bio common stock. In addition, provided that the reverse stock split qualifies as a &#8220;recapitalization,&#8221; a Sesen Bio U.S. holder&#8217;s aggregate tax basis in the shares of Sesen Bio common stock received pursuant to the reverse stock split should equal the aggregate tax basis of the shares of Sesen Bio common stock surrendered excluding any portion of such basis that is allocated to any fractional share of Sesen Bio common stock, and such Sesen Bio U.S. holder&#8217;s holding period in the shares of Sesen Bio common stock received should include the holding period in the shares of Sesen Bio common stock surrendered. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Sesen Bio common stock surrendered, for the shares of Sesen Bio common stock received pursuant to the reverse stock split. Holders of shares of Sesen Bio common stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares of Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A Sesen Bio U.S. holder that receives cash in lieu of a fractional share of Sesen Bio common stock pursuant to the reverse stock split should recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the Sesen Bio U.S. holder&#8217;s tax basis in the shares of Sesen Bio common stock surrendered that is allocated to such fractional share of Sesen Bio common stock. Such capital gain or loss should be long-term capital gain or loss if the Sesen Bio U.S. holder&#8217;s holding period for Sesen Bio common stock surrendered exceeded one year at the effective time of the reverse stock split. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion assumes that the distribution of CVRs and the special cash dividend to Sesen Bio U.S. holders will be treated for U.S. federal income tax purposes as transactions that are separate and distinct from the reverse stock split. However, it is possible that the IRS or a court could determine that the reverse stock split and the receipt of CVRs or the special cash dividend constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. For a discussion of such treatment with respect to the CVRs or the special cash dividend, see the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs&#8201;&#8212;&#8201;Alternative Treatment of the Receipt of CVRs and the Proposed Reverse Stock Split as a Single Recapitalization</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tALTERT3">194</a> of this proxy statement/prospectus and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Special Cash Dividend</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tMUFI1">162</a> of this proxy statement/prospectus. If the reverse stock split, the special cash dividend, and receipt of CVRs are treated as a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes, then a Sesen Bio U.S. holder generally should recognize gain (but not loss) equal to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">210</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:316pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the lesser of (i)&#160;the amount of the special cash dividend received plus the fair market value of the CVRs received (assuming the receipt of CVRs is treated as a distribution of property as described in &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font><font style="letter-spacing:0.2pt;">&#8221;), and (ii)&#160;the excess (if any) of (A)&#160;the sum of (1)&#160;the amount of the special cash dividend received plus the fair market value of the CVRs received and (2)&#160;the fair market value of the Sesen Bio shares received in the reverse stock split over (B)&#160;the Sesen Bio U.S. holder&#8217;s adjusted tax basis in the Sesen Bio common stock surrendered in the reverse stock split. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reservation of Right to Abandon Reverse Stock Split</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding approval of this Proposal No.&#160;2 by Sesen Bio stockholders, the Sesen Bio board of directors may, in its sole discretion, abandon the proposed amendments and determine prior to the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the reverse stock split, as permitted under Section 242(c) of the Delaware General Corporation Law. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Vote Required</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The affirmative vote of the holders of a majority of the outstanding shares of Sesen Bio common stock on the record date for the Sesen Bio special meeting entitled to vote on the matter is required for approval of Proposal No. 2. Abstentions will have the same effect as votes &#8220;AGAINST&#8221; Proposal No. 2. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recommendation of Sesen Bio Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE SESEN BIO BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT SESEN BIO STOCKHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL NO. 2 TO APPROVE AN AMENDMENT TO THE SESEN BIO CERTIFICATE OF INCORPORATION TO EFFECT THE REVERSE STOCK SPLIT. THE APPROVAL OF PROPOSAL NO. 2 IS REQUIRED TO CONSUMMATE THE MERGER. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">211</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPN3A">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposal No. 3: Approval of an amendment and restatement of the 2014 Incentive Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Why Sesen Bio is Requesting Sesen Bio Stockholder Approval of the Amendment and Restatement of the 2014 Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is asking the Sesen Bio stockholders to approve the amendment and restatement of the 2014 Incentive Plan, or the Amended and Restated Plan. The Sesen Bio board of directors believes that the combined company&#8217;s growth and success will depend, in large part, on its ability to maintain a competitive position by attracting, retaining and motivating key employees with experience and ability to advance the combined company&#8217;s clinical and business objectives, thereby creating value for all of the combined company&#8217;s stakeholders. Central to these objectives will be a stock-based compensation program. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The 2014 Incentive Plan was originally adopted by the Sesen Bio board of directors in December&#160;2013 and approved by the Sesen Bio stockholders in January&#160;2014. The 2014 Incentive Plan was amended by the Sesen Bio board of directors on April&#160;19, 2019 and approved by the Sesen Bio stockholders on June&#160;19, 2019 and was further amended by the Sesen Bio board of directors on March&#160;12, 2021 and approved by the Sesen Bio stockholders on May&#160;3, 2021. On January&#160;17, 2023, the Sesen Bio board of directors adopted, subject to stockholder approval, the amendment and restatement of the 2014 Incentive Plan. At the Sesen Bio special meeting, Sesen Bio stockholders will be asked to consider and vote upon a proposal to approve the amendment and restatement of the 2014 Incentive Plan to (i)&#160;increase the number of shares of Sesen Bio common stock reserved for future issuance under the 2014 Incentive Plan by a number of shares of Sesen Bio common stock equal to 12.79% of the fully diluted capitalization of Sesen Bio, determined as of immediately following the closing of the merger, minus the number of shares that remain available for the grant of awards under the 2014 Incentive Plan as of the closing of the merger, (ii)&#160;establish a maximum aggregate number of shares of Sesen Bio common stock that may be granted as incentive stock options, (iii)&#160;extend the term of the 2014 Incentive Plan to the tenth (10th) anniversary of the closing of the merger, and (iv)&#160;revise certain provisions in the 2014 Incentive Plan to address certain changes in law and accounting relating to (1)&#160;the Sesen Bio board of directors&#8217; ability to delegate authority to make awards under the Amended and Restated Plan, (2)&#160;the satisfaction of withholding taxes with shares of Sesen Bio common stock, and (3)&#160;the effect on awards outstanding under the Amended and Restated Plan of any clawback policy that Sesen Bio has in effect or may adopt after the effective date of the Amended and Restated Plan. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Amended and Restated Plan will be used, following the closing of the merger, to grant equity awards to the combined company&#8217;s projected employees, officers, non-employee directors, consultants and advisors. The number of shares remaining available for issuance under the 2014 Incentive Plan is insufficient to meet these needs and would thus impede the combined company&#8217;s ability to properly compensate, motivate, incentivize and retain key talent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors determined the requested number of shares for the Amended and Restated Plan, in consultation with Carisma, based on projected annual equity awards to eligible participants, projected employee recognition and promotion awards and anticipated new-hire awards. If Sesen Bio stockholders approve the Amended and Restated Plan then, subject to adjustment in the event of stock splits and other similar events, including the proposed reverse stock split, awards may be made under the Amended and Restated Plan for up to the sum of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a number of shares of Sesen Bio common stock equal to 12.79% of the fully diluted capitalization of Sesen Bio, determined as of immediately following the closing of the merger, minus the number of shares of Sesen Bio common stock that remain available for the grant of awards under the 2014 Incentive Plan as of the closing of the merger; plus </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">25,313,283 shares of Sesen Bio common stock; plus</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of shares as is equal to the sum of (x)&#160;the number of shares of common stock reserved for issuance under the 2009 Incentive Plan, or the prior plan, that remained available for grant under the prior plan immediately prior to Sesen Bio&#8217;s initial public offering and (y)&#160;the number of shares of Sesen Bio common stock subject to (I)&#160;outstanding Sesen Bio awards granted under the prior plan and (II)&#160;stock options assumed by Sesen Bio in the merger, or, the awards described in the foregoing clauses (I)&#160;and (II)&#160;together, the Outstanding Awards, in each case which Outstanding Awards expire, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">212</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">terminate or are otherwise surrendered, canceled, forfeited or repurchased by Sesen Bio at their original issuance price pursuant to a contractual repurchase right. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Up to 252,000,000 of the shares of Sesen Bio common stock available for issuance under the Amended and Restated Plan may be issued as incentive stock options under the Amended and Restated Plan, subject to adjustment under the terms of the Amended and Restated Plan, including in the event the proposed reverse stock split occurs. The Amended and Restated Plan will have a term of ten&#160;years following the closing of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The proposed Amended and Restated Plan includes several features that are consistent with protecting the interests of Sesen Bio stockholders and sound corporate governance practices, as described below. If Sesen Bio stockholders do not approve the Amended and Restated Plan, the 2014 Incentive Plan will remain in effect pursuant to its terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table includes information regarding (i) all of Sesen Bio&#8217;s outstanding equity awards as of January 4, 2023 (under all of Sesen Bio&#8217;s equity-based compensation plans or arrangements under which shares of Sesen Bio common stock may be issued, including inducement grants made by Sesen Bio but excluding the 2014 ESPP) before giving effect to any equitable adjustments that may be made in connection with the distribution of the CVRs and any special cash dividend, including outstanding stock options granted under the Carisma equity incentive plan, which Sesen Bio will assume as part of the merger on an as-converted basis (assuming the merger was consummated as of January 4, 2023 at an assumed exchange ratio of 37.7924 shares of Sesen Bio common stock for each share of Carisma capital stock), (ii) shares available for future awards under the 2014 Incentive Plan as of January 4, 2023 and (iii)&#160;the number of shares of Sesen Bio common stock outstanding as of January 4, 2023 (including the number of shares of Sesen Bio common stock that will be issued in the merger (based on shares outstanding as of January 4, 2023 and taking into account the consummation of the Carisma pre-closing financing and the conversion of the Carisma convertible note and an assumed exchange ratio of 37.7924), prior to giving effect to the proposed reverse stock split): </font>
        </div>
        <table style="width:456pt;height:256pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:388.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of outstanding Sesen Bio options under Sesen Bio equity incentive plans and inducement grants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">15,304,313</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:388.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted average exercise price of outstanding Sesen Bio options under Sesen Bio equity incentive plans and inducement grants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">1.82</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:388.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted average remaining contractual term of outstanding Sesen Bio options under Sesen Bio equity incentive plans and inducement grants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">7.175</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:388.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Number of outstanding Sesen Bio RSUs under Sesen Bio equity incentive plans </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">4,695,007</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:388.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Sesen Bio remaining shares of Sesen Bio common stock available under the 2014 Incentive Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">4,532,078</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:388.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Estimated number of outstanding Carisma options under Carisma equity incentive plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">1,802,246</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:388.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted average exercise price of Carisma options under Carisma equity incentive plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">1.92</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:388.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted average remaining contractual term of outstanding Carisma options under Carisma equity incentive plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">7.666</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:388.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Estimated number of shares requested for approval under the Amended and </font>
                <br >
                <font style="letter-spacing:0.2pt;">Restated Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">79,902,694</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:388.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Total number of shares of Sesen Bio common stock authorized for issuance under the 2014 </font>
                <br >
                <font style="letter-spacing:0.2pt;">Incentive Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">25,313,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:388.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Estimated number of shares of Sesen Bio common stock outstanding following the closing </font>
                <br >
                <font style="letter-spacing:0.2pt;">of the merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">656,865,489</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.51pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, there were no outstanding shares of restricted stock, no stock appreciation rights, or SARs, nor any other stock-based awards under the 2014 Incentive Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio expects that the proposed share pool under the Amended and Restated Plan will allow the combined company to continue to grant market-competitive equity awards for approximately 3 years, but the actual duration of the share pool may vary based on changes in participation and the combined company&#8217;s stock price. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">213</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the Amended and Restated Plan is not approved by Sesen Bio stockholders, the combined company will not be able to make long-term equity incentive awards that are sufficient to meet its needs. The inability to make competitive equity awards to retain talented employees in a highly competitive market could have an adverse impact on the combined company&#8217;s business and future prospects. Further, if the Amended and Restated Plan is not approved, the combined company could be forced to increase cash compensation, which will reduce the resources the combined company intends to allocate to meeting its clinical and business needs and objectives. Therefore, the approval of the Amended and Restated Plan is vital to the combined company&#8217;s future success. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Highlights of the Amended and Restated Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Amended and Restated Plan includes several features that are consistent with protecting the interests of Sesen Bio stockholders and sound corporate governance practices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">No Evergreen.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Amended and Restated Plan does not include an &#8220;evergreen&#8221; or other provision that provides for automatic increases in the number of shares available for grant under the Amended and Restated Plan. Therefore, stockholders of the combined company will have a say in the combined company&#8217;s equity compensation programs because any increase to the maximum share reserve in the Amended and Restated Plan is subject to approval by the combined company&#8217;s stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Clawback Policy</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In accepting an award granted under the Amended and Restated Plan, a participant agrees to be bound by any clawback policy that Sesen Bio has in effect or may adopt in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">No Automatic Vesting of Awards on a Change in Control Event</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Amended and Restated Plan does not provide for the automatic vesting of awards in connection with a change in control event. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Limits on Liberal Share Recycling</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Amended and Restated Plan prohibits the re-granting of (i)&#160;Sesen Bio shares withheld or delivered to satisfy the exercise price of an award or to satisfy tax withholding obligations and (ii)&#160;Sesen Bio shares that were subject to a SAR and were not issued upon the net settlement or net exercise of such award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">No Repricing of Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Amended and Restated Plan prohibits the direct or indirect repricing of stock options or SARs without stockholder approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">No Discounted Options or SARs</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All options and SARs must have an exercise or measurement price that is at least equal to the fair market value of the underlying Sesen Bio common stock on the date of grant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Material Amendments Require Stockholder Approval</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Stockholder approval is required prior to an amendment of the Amended and Restated Plan that would (i)&#160;materially increase the number of Sesen Bio&#8217;s shares authorized (other than as provided under the Amended and Restated Plan with respect to certain corporate events or substitute awards), (ii)&#160;expand the types of awards that may be granted, or (iii)&#160;materially expand the class of participants eligible to participate in the Amended and Restated Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reasons Sesen Bio&#8217;s Stockholders Should Approve the Amended and Restated Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Incentivizes, Retains and Motivates Talent</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;It is critical to the combined company&#8217;s success that it incentivizes, retains and motivates the best talent in what is a tremendously competitive labor market. The combined company&#8217;s equity-based compensation program will be a key component in its ability to pay market-competitive compensation to its employees and other service providers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Aligns with a Pay-for-Performance Compensation Philosophy</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Sesen Bio believes that equity-based compensation is fundamentally performance-based. As the value of Sesen Bio common stock appreciates, its employees and other service providers receive greater compensation while Sesen Bio stockholders receive a greater return on their investment. Conversely, if the stock price does not appreciate following the grant of an equity award, then employees would not realize any compensation benefit in respect of stock options and would receive lower than intended compensation in respect of Sesen Bio RSUs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Aligns Employee and Director Interests with Stockholder Interests</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Providing employees and non-employee directors with compensation in the form of equity directly aligns the interests of those employees and directors with the interests of the combined company&#8217;s stockholders. If the Amended and Restated Plan </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">214</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">is approved by Sesen Bio stockholders, the combined company will be able to continue fostering this alignment between its employees and non-employee directors and stockholders by granting meaningful equity-based incentives. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Consistent with Stockholder Interests and Sound Corporate Governance</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;As described under the heading above entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Highlights of the Amended and Restated Plan</font><font style="letter-spacing:0.2pt;">&#8221; and more thoroughly below, the Amended and Restated Plan purposefully includes features that are consistent with the interests of the stockholders of the combined company and sound corporate governance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Description of the Amended and Restated Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Types of Awards; Shares Available for Awards; Share Counting Rules</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Amended and Restated Plan provides for the grant of incentive stock options intended to qualify under Section&#160;422 of the Code, nonstatutory stock options, SARs, restricted stock, RSUs, and other stock-based awards, or collectively, the awards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to adjustment in the event of stock splits, stock dividends and other similar events, including the proposed reverse stock split, awards may be made under the Amended and Restated Plan for up to the sum of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a number of shares of Sesen Bio common stock equal to 12.79% of the fully diluted capitalization of Sesen Bio, determined as of immediately following the closing of the merger, minus the number of shares that remain available for the grant of awards under the 2014 Incentive Plan as of the closing of the merger; plus </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">25,313,283 shares of Sesen Bio common stock; plus</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of shares of Sesen Bio common stock as is equal to the sum of (x)&#160;the number of shares of Sesen Bio common stock reserved for issuance under the prior plan that remained available for grant under the prior plan immediately prior to Sesen Bio&#8217;s initial public offering and (y)&#160;the number of shares of Sesen Bio common stock subject to Outstanding Awards, which Outstanding Awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by Sesen Bio at their original issuance price pursuant to a contractual repurchase right. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Up to 252,000,000 of the shares of Sesen Bio common stock available for issuance under the Amended and Restated Plan may be issued as incentive stock options under the Amended and Restated Plan, subject to adjustment under the terms of the Amended and Restated Plan, including in the event the proposed reverse stock split occurs. Shares of Sesen Bio common stock issued under the Amended and Restated Plan may consist in whole or in part of authorized but unissued shares or treasury shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For purposes of counting the number of shares available for the grant of awards under the Amended and Restated Plan, all shares of common stock covered by SARs will be counted against the number of shares available for the grant of awards. However, SARs that may be settled only in cash will not be so counted. In addition, if Sesen Bio grants a SAR in tandem with an option for the same number of shares of Sesen Bio common stock and provides that only one such award may be exercised, or the tandem SAR, only the shares covered by the option, and not the shares covered by the tandem SAR, will be so counted, and the expiration of one in connection with the other&#8217;s exercise will not restore shares to the Amended and Restated Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Shares covered by awards under the Amended and Restated Plan that expire or are terminated, surrendered, or cancelled without having been fully exercised or are forfeited in whole or in part (including as the result of shares subject to such award being repurchased by Sesen Bio at the original issuance price pursuant to a contractual repurchase right) or that result in any shares not being issued (including as a result of a SAR that was settleable either in cash or in stock actually being settled in cash) will again be available for the grant of awards under the Amended and Restated Plan (subject, in the case of incentive stock options, to any limitations under the Code). In the case of the exercise of a SAR, the number of shares counted against the shares available for the grant of awards under the Amended and Restated Plan will be the full number of shares subject to the SAR multiplied by the&#160;percentage of the SAR actually exercised, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">215</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">regardless of the number of shares actually used to settle the SAR upon exercise, and the shares covered by a tandem SAR will not again become available for grant upon the expiration or termination of the tandem SAR. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Shares of Sesen Bio common stock that are delivered (by actual delivery, attestation, or net exercise) to Sesen Bio by a participant to purchase shares of Sesen Bio common stock upon exercise of an award or to satisfy tax withholding obligations (including shares retained from the award creating the tax obligation) will not be added back to the number of shares available for the future grant of awards under the Amended and Restated Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with a merger or consolidation of an entity with Sesen Bio or Sesen Bio&#8217;s acquisition of property or stock of an entity, the Sesen Bio board of directors may grant awards under the Amended and Restated Plan in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof on such terms as the Sesen Bio board of directors determines appropriate in the circumstances, notwithstanding any limitation on awards contained in the Amended and Restated Plan. No such substitute awards shall count against the overall share limit, except as required by reason of Section&#160;422 and related provisions of the Code. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Descriptions of Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A participant who is awarded an option receives the right to purchase a specified number of shares of Sesen Bio common stock at a specified exercise price and subject to the other terms and conditions that are specified in connection with the award agreement. An option that is not intended to be an &#8220;incentive stock option&#8221; is a &#8220;nonstatutory stock option.&#8221; Options may not be granted at an exercise price that is less than 100% of the fair market value of Sesen Bio common stock on the date of grant. If the Sesen Bio board of directors approves the grant of an option with an exercise price to be determined on a future date, the exercise price may not be less than 100% of the fair market value of Sesen Bio common stock on that future date. Under present law, incentive stock options may not be granted at an exercise price less than 110% of the fair market value in the case of stock options granted to participants who hold more than 10% of the total combined voting power of all classes of Sesen Bio&#8217;s stock or any of Sesen Bio&#8217;s subsidiaries. Under the terms of the Amended and Restated Plan, options may not be granted for a term in excess of ten&#160;years (and, under present law, five&#160;years in the case of incentive stock options granted to participants who hold greater than 10% of the total combined voting power of all classes of Sesen Bio&#8217;s stock or any of Sesen Bio&#8217;s subsidiaries). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Amended and Restated Plan permits participants to pay the exercise price of options using one or more of the following manners of payment: (i)&#160;payment by cash or by check, (ii)&#160;except as may otherwise be provided in the applicable award agreement or approved by the Sesen Bio board of directors, in connection with a &#8220;cashless exercise&#8221; through a broker, (iii)&#160;to the extent provided in the applicable award agreement or approved by the Sesen Bio board of directors, and subject to certain conditions, by delivery to Sesen Bio (either by actual delivery or attestation) of shares of common stock owned by the participant valued at their fair market value, (iv)&#160;to the extent provided in an applicable nonstatutory stock option award agreement or approved by the Sesen Bio board of directors, by delivery of a notice of &#8220;net exercise&#8221; as a result of which Sesen Bio will retain a number of shares of Sesen Bio common stock otherwise issuable pursuant to the stock option equal to the aggregate exercise price for the portion of the option being exercised divided by the fair market value of Sesen Bio common stock on the date of exercise, (v)&#160;to the extent permitted by applicable law and provided for in the applicable award agreement or approved by the Sesen Bio board of directors, by any other lawful means as the Sesen Bio board of directors may determine, or (vi)&#160;by any combination of these forms of payment. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On January 17, 2023, the closing sale price of Sesen Bio common stock on Nasdaq was $0.6493 per share.</font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stock Appreciation Rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A participant who is awarded a SAR receives, upon exercise, a number of shares of Sesen Bio common stock, or cash (or a combination of shares of Sesen Bio common stock and cash) determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of Sesen Bio common stock over the measurement price. The Amended and Restated Plan provides that the measurement price of a SAR may not be less than 100% of the fair market value of Sesen Bio </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">216</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">common stock on the date the SAR is granted (provided, however, that if the Sesen Bio board of directors approves the grant of a SAR effective as of a future date, the measurement price will not be less than 100% of the fair market value on such future date) and that SARs may not be granted with a term in excess of 10&#160;years. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Limitation on Repricing of Options or SARs.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;With respect to options and SARs, unless such action is approved by Sesen Bio stockholders or otherwise permitted under the terms of the Amended and Restated Plan in connection with certain changes in capitalization and reorganization events, Sesen Bio may not (1)&#160;amend any outstanding option or SAR granted under the Amended and Restated Plan to provide an exercise price or measurement price per share that is lower than the then-current exercise price or measurement price per share of such outstanding option or SAR, (2)&#160;cancel any outstanding option or SAR (whether or not granted under the Amended and Restated Plan) and grant in substitution for such awards new awards under the Amended and Restated Plan (other than certain substitute awards issued in connection with a merger or consolidation of an entity with Sesen Bio or an acquisition by Sesen Bio, described above) covering the same or a different number of shares of Sesen Bio common stock and having an exercise price or measurement price per share lower than the then-current exercise price or measurement price per share of the canceled option or SAR, (3)&#160;cancel in exchange for a cash payment any outstanding option or SAR with an exercise price or measurement price per share above the then-current fair market value of Sesen Bio common stock, or (4)&#160;take any other action under the Amended and Restated Plan that constitutes a &#8220;repricing&#8221; within the meaning of the rules of the Nasdaq Stock Market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;A participant who is granted an award of restricted stock is entitled to acquire shares of Sesen Bio common stock, subject to Sesen Bio&#8217;s right to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) in the event that the conditions specified in the applicable award are not satisfied prior to the end of the applicable restriction period established for such award. Unless otherwise provided in the applicable award agreement, any dividends (whether paid in cash, stock or property) declared and paid by Sesen Bio with respect to shares of restricted stock will be paid to the participant only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock Unit Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;A participant who is granted an RSU award is entitled to receive shares of Sesen Bio common stock, or cash equal to the fair market value of such shares or a combination of cash and shares, to be delivered at the time such award vests or on a deferred basis pursuant to the terms and conditions established by the Sesen Bio board of directors. The Sesen Bio board of directors may provide that settlement of RSUs will be deferred, on a mandatory basis or at the election of the participant, in a manner that complies with Section&#160;409A of the Code. A participant has no voting rights with respect to any RSU. An RSU award agreement may provide the applicable participant with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Sesen Bio common stock. Any such dividend equivalents may be settled in cash and/or shares of Sesen Bio common stock and may be subject to the same restrictions on transfer and forfeitability as the RSUs with respect to which such dividend equivalents are awarded, in each case to the extent provided in the applicable award agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Other Stock-Based Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the Amended and Restated Plan, the Sesen Bio board of directors may grant other awards of shares of Sesen Bio common stock, and other awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Sesen Bio common stock or other property, having such terms and conditions as the Sesen Bio board of directors may determine. Sesen Bio refers to these types of awards as other stock-based awards. Other stock-based awards may be available as a form of payment in settlement of other awards granted under the Amended and Restated Plan or as payment in lieu of compensation to which a participant is otherwise entitled. Other stock-based awards may be paid in shares of Sesen Bio common stock or in cash, as the Sesen Bio board of directors may determine. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Eligibility to Receive Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All employees, officers or directors of the combined company or an affiliate of the combined company, and consultants or advisors to the combined company or an affiliate of the combined company are eligible to participate in the Amended and Restated Plan. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">217</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, following the closing of the merger, approximately 94 employees, 6 non-employee directors and 1 non-employee consultant of the combined company will be eligible to participate in the Amended and Restated Plan.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Transferability of Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Awards may not be sold, assigned, transferred, pledged or otherwise encumbered by a participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an incentive stock option, pursuant to a qualified domestic relations order. During the life of the participant, awards are exercisable only by the participant. However, the Sesen Bio board of directors may permit or provide in an award for the gratuitous transfer of the award by the participant to or for the benefit of any immediate family member, family trust or other entity established for the benefit of the participant and/or an immediate family member thereof if Sesen Bio would be eligible to use a Form S-8 under the Securities Act for the registration of the sale of the common stock subject to such award to the proposed transferee. Further, Sesen Bio is not required to recognize any such permitted transfer until such time as the permitted transferee has, as a condition to the transfer, delivered to Sesen Bio a written instrument in form and substance satisfactory to Sesen Bio confirming that such transferee will be bound by all of the terms and conditions of the award. None of the restrictions described in this paragraph prohibit a transfer from the participant to Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">No Rights as a Stockholder; Clawback</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the provisions of the applicable award, no participant or designated beneficiary will have any rights as a Sesen Bio stockholder with respect to any shares of Sesen Bio common stock to be distributed with respect to an award granted under the Amended and Restated Plan until becoming a record holder of such shares of Sesen Bio common stock. In accepting an award granted under the Amended and Restated Plan, a participant agrees to be bound by any clawback policy that Sesen Bio has in effect or may adopt in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Effective Date</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The effective date of the 2014 Incentive Plan was February&#160;11, 2014, which was immediately prior to the closing of the initial public offering of Sesen Bio common stock on the Nasdaq Global Market. The Amended and Restated Plan will be effective as of the date of the closing of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Amended and Restated Plan will terminate automatically on the tenth (10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;">) anniversary of the closing of the merger (but any awards previously granted under the Amended and Restated Plan may extend beyond such date) unless it is earlier terminated by the Sesen Bio board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">New Plan Benefits</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because the grant of awards under the Amended and Restated Plan is within the discretion of the Sesen Bio board of directors and the Sesen Bio compensation committee, Sesen Bio cannot determine the dollar value or number of shares of Sesen Bio common stock that will in the future be received by or allocated to any participant in the Amended and Restated Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Amended and Restated Plan will be administered by the Sesen Bio board of directors. The Sesen Bio board of directors has the authority to grant awards and to adopt, amend and repeal the administrative rules, guidelines and practices relating to the Amended and Restated Plan and to construe and interpret the terms of the Amended and Restated Plan and any award agreements entered into under the Amended and Restated Plan. The Sesen Bio board of directors may correct any defect, supply any omission or reconcile any inconsistency in the Amended and Restated Plan or any award under the Amended and Restated Plan in the manner and to the extent it deems expedient, and it is the sole and final judge of such expediency. All decisions by the Sesen Bio board of directors are made in its sole discretion and are final and binding on all persons having or claiming any interest in the Amended and Restated Plan or in any award under the Amended and Restated Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of the Amended and Restated Plan, the Sesen Bio board of directors may delegate any or all of its powers under the Amended and Restated Plan to one or more committees or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">218</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">subcommittees of the Sesen Bio board of directors. The Sesen Bio board of directors has authorized the Sesen Bio compensation committee to administer certain aspects of the Amended and Restated Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to any requirements of applicable law, the Sesen Bio board of directors may, by resolution, delegate to one or more persons (including Sesen Bio&#8217;s officers) or bodies, which Sesen Bio refers to as &#8220;delegated persons,&#8221; the power to grant awards (subject to any limitations under the Amended and Restated Plan) to eligible service providers of Sesen Bio to exercise such other powers under the Amended and Restated Plan as the Sesen Bio board of directors may determine, provided that the Sesen Bio board of directors must fix (i)&#160;the maximum number of awards, and the maximum number of shares issuable upon exercise of those awards, that may be issued by the delegated persons, (ii)&#160;the time period during which those awards, and during which the shares issuable upon exercise of those awards, may be issued, and (iii)&#160;the minimum amount of consideration (if any) for which awards may be issued, and a minimum amount of consideration for the shares issuable upon exercise of those awards. Further, no delegated person will be authorized to grant awards to any &#8220;executive officer&#8221; &#8203;(as defined by Rule&#160;3b-7 under the Exchange Act) or to any &#8220;officer&#8221; of Sesen Bio (as defined by Rule&#160;16a-1 under the Exchange Act). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to applicable limitations contained in the Amended and Restated Plan, the Sesen Bio board of directors, the Sesen Bio compensation committee, or any other committee or subcommittee of the Sesen Bio board of directors or delegated person to whom the Sesen Bio board of directors has delegated authority pursuant to the Amended and Restated Plan, as the case may be, selects the recipients of awards and determines (i)&#160;the number of shares of Sesen Bio common stock, cash or other consideration covered by awards and the terms and conditions of such awards, including the dates upon which such awards become exercisable or otherwise vest, (ii)&#160;the exercise or measurement price of awards, if any, and (iii)&#160;the duration of awards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise provided in the Amended and Restated Plan, each award under the Amended and Restated Plan may be made alone or in addition or in relation to any other award. The terms of each award need not be identical, and the Sesen Bio board of directors need not treat participants uniformly. The Sesen Bio board of directors will determine the effect on an award of the disability, death, termination or other cessation of employment or service, authorized leave of absence or other change in the employment or other service status of a participant, and the extent to which, and the period during which, the participant (or the participant&#8217;s legal representative, conservator, guardian or designated beneficiary) may exercise rights or receive any benefits under an award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors may at any time provide that any award will become immediately exercisable in whole or in part, free from some or all restrictions or conditions or otherwise realizable in whole or in part, as the case may be. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Sesen Bio common stock other than an ordinary cash dividend, Sesen Bio is required by the Amended and Restated Plan to make equitable adjustments (or make substitute awards, if applicable), in a manner determined by the board of directors, to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and class of securities available under the Amended and Restated Plan and the number and class of securities available for issuance as incentive stock options under the Amended and Restated Plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the share counting rules under the Amended and Restated Plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and class of securities and exercise price per share of each outstanding Sesen Bio option; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the share and per-share provisions and measurement price of each outstanding SAR; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of shares and the repurchase price per share subject to each outstanding restricted stock award or Sesen Bio RSU award; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the share and per-share related provisions and purchase price, if any, of any outstanding other stock-based award. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">219</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event Sesen Bio effects a split of Sesen Bio common stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then a participant who exercises an option between the record date and the distribution date for such stock dividend will be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Sesen Bio common stock acquired upon such option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio will indemnify and hold harmless each director, officer, employee or agent to whom any duty or power relating to the administration or interpretation of the Amended and Restated Plan has been or will be delegated against any cost or expense (including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Sesen Bio board of director&#8217;s approval) arising out of any act or omission to act concerning the Amended and Restated Plan unless arising out of such person&#8217;s own fraud or bad faith. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise provided under the Amended and Restated Plan with respect to repricing outstanding stock options or SARs and with respect to actions requiring stockholder approval, the Sesen Bio board of directors may amend, modify or terminate any outstanding award, including but not limited to, substituting for the award another award of the same or a different type, changing the date of exercise or realization, and converting an incentive stock option to a nonstatutory stock option. The participant&#8217;s consent to any such action will be required unless the Sesen Bio board of directors determines that the action, taking into account any related action, does not materially and adversely affect the participant&#8217;s rights under the Amended and Restated Plan or the change is otherwise permitted under the terms of the Amended and Restated Plan in connection with certain corporate events. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Reorganization Events</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Amended and Restated Plan contains provisions addressing the consequences of any reorganization event. A reorganization event is defined under the Amended and Restated Plan as (a)&#160;any merger or consolidation of Sesen Bio with or into another entity as a result of which all of Sesen Bio common stock is converted into or exchanged for the right to receive cash, securities or other property, or is canceled, (b)&#160;any transfer or disposition of all of Sesen Bio common stock for cash, securities or other property pursuant to a share exchange or other transaction or (c)&#160;Sesen Bio&#8217;s liquidation or dissolution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Provisions Applicable to Awards Other than Restricted Stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the Amended and Restated Plan, if a reorganization event occurs, the Sesen Bio board of directors may take any one or more of the following actions as to all or any (or any portion of) outstanding awards other than restricted stock on such terms as the Sesen Bio board of directors determines (except to the extent specifically provided otherwise in an applicable award agreement or another agreement between a participant and Sesen Bio): (1)&#160;provide that such awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (2)&#160;upon written notice to a participant, provide that all of the participant&#8217;s unvested and/or exercised awards will terminate immediately prior to the consummation of the reorganization event unless exercised by the participant (to the extent then exercisable) within a specified period following the date of such notice, (3)&#160;provide that outstanding awards will become exercisable, realizable, or deliverable, or restrictions applicable to an award will lapse, in whole or in part prior to or upon such reorganization event, (4)&#160;in the event of a reorganization event under the terms of which holders of Sesen Bio common stock will receive upon consummation of the reorganization event a cash payment for each share surrendered in the reorganization event, which Sesen Bio refers to as the &#8220;Acquisition Price&#8221;, make or provide for a cash payment to participants with respect to each award held by a participant equal to (A)&#160;the number of shares of Sesen Bio common stock subject to the vested portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by (B)&#160;the excess, if any, of (I)&#160;the Acquisition Price over (II)&#160;the exercise, measurement or purchase price of such award and any applicable tax withholdings, in exchange for the termination of such award, (5)&#160;provide that, in connection with Sesen Bio&#8217;s liquidation or dissolution, awards will convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (6)&#160;any combination of the foregoing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors is not obligated to treat all awards, all awards held by a participant, or all awards of the same type, identically. Certain RSU awards that are subject to Section&#160;409A of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">220</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Code will be settled in accordance with the terms of the applicable award agreement or as otherwise specified in the Amended and Restated Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Provisions Applicable to Restricted Stock</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Upon the occurrence of a reorganization event other than Sesen Bio&#8217;s liquidation or dissolution, Sesen Bio&#8217;s repurchase and other rights with respect to outstanding restricted stock will inure to the benefit of Sesen Bio&#8217;s successor and will, unless the Sesen Bio board of directors determines otherwise, apply to the cash, securities or other property which Sesen Bio common stock is converted into or exchanged for pursuant to such reorganization event in the same manner and to the same extent as they applied to such restricted stock. However, the Sesen Bio board of directors may either provide for termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any restricted stock or any other agreement between a participant and Sesen Bio, either initially or by amendment. Upon the occurrence of a reorganization event involving Sesen Bio&#8217;s liquidation or dissolution, except to the extent specifically provided to the contrary in the instrument evidencing any award of restricted stock or any other agreement between the participant and Sesen Bio, all restrictions and conditions on all restricted stock then outstanding will automatically be deemed terminated or satisfied. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Provisions for Foreign Participants</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors may establish one or more sub-plans under the Amended and Restated Plan to satisfy applicable securities, tax or other laws of various jurisdictions. The Sesen Bio board of directors will establish such sub-plans by adopting supplements to the Amended and Restated Plan containing any limitations on the board of director&#8217;s discretion under the Amended and Restated Plan and any additional terms and conditions not otherwise inconsistent with the Amended and Restated Plan as the Sesen Bio board of directors deems necessary or desirable. All supplements adopted by the Sesen Bio board of directors will be deemed to be part of the Amended and Restated Plan, but each supplement will only apply to participants within the affected jurisdiction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Withholding</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The participant must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations before Sesen Bio will deliver stock certificates or otherwise recognize ownership of Sesen Bio common stock under an award. Sesen Bio may elect to satisfy the withholding obligations through additional withholding on salary or wages. If Sesen Bio elects not to or cannot withhold from other compensation, the participant must pay Sesen Bio the full amount, if any, required for withholding or have a broker tender to Sesen Bio cash equal to the withholding obligations. Payment of withholding obligations is due before Sesen Bio will issue any shares on exercise, vesting or release from forfeiture of an award or at the same time as payment of the exercise or purchase price, unless Sesen Bio determines otherwise. If provided for in an award or approved by the Sesen Bio board of directors, a participant may satisfy the tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Sesen Bio common stock, including shares retained from the award creating the tax obligation, valued at their fair market value. However, except as otherwise provided by the Sesen Bio board of directors, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed Sesen Bio&#8217;s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income), except that, to the extent that Sesen Bio is able to retain shares of Sesen Bio common stock having a fair market value that exceeds the statutory minimum applicable withholding tax without financial accounting implications or Sesen Bio is withholding in a jurisdiction that does not have a statutory minimum withholding tax, Sesen Bio may retain such number of shares (up to the number of shares having a fair market value equal to the maximum individual statutory rate of tax) as Sesen Bio will determine to be necessary to satisfy the tax liability associated with any award. Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Amendment or Termination</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Sesen Bio receives stockholder approval of the Amended and Restated Plan, no award may be granted under the Amended and Restated Plan after the tenth (10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;">) anniversary of the closing of the merger, but awards previously granted may extend beyond that date. The Sesen Bio board of directors may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">221</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">amend, suspend or terminate the Amended and Restated Plan or any portion of the Amended and Restated Plan at any time, except that (i)&#160;no amendment may be made to the plan to permit an option or SAR to be repriced without stockholder approval and (ii)&#160;no amendment that would require stockholder approval under the rules of the Nasdaq Stock Market may be made effective unless and until such amendment has been approved by Sesen Bio stockholders. If at any time the approval of Sesen Bio stockholders is required as to any other modification or amendment under Section&#160;422 of the Code or any successor provision with respect to incentive stock options, the Sesen Bio board of directors may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to the Amended and Restated Plan adopted in accordance with the procedures described above will apply to, and be binding on the holders of, all awards outstanding under the Amended and Restated Plan at the time the amendment is adopted, provided that the Sesen Bio board of directors determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of participants under the Amended and Restated Plan. No award will be made that is conditioned on stockholder approval of any amendment to the Amended and Restated Plan unless the award provides that (i)&#160;it will terminate or be forfeited if stockholder approval of such amendment is not obtained within no more than 12&#160;months from the date the award was granted and (ii)&#160;it may not be exercised or settled (or otherwise result in the issuance of shares of Sesen Bio common stock) prior to the receipt of such Sesen Bio stockholder approval. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Federal Income Tax Consequences</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following summarizes the federal income tax consequences of awards that may be granted under the Amended and Restated Plan. This summary is based on the federal tax laws in effect as of the date of this proxy statement/prospectus. In addition, this summary assumes that all awards are exempt from, or comply with, the rules under Section&#160;409A of the Code regarding nonqualified deferred compensation. Changes to these laws could alter the tax consequences described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Incentive Stock Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;An optionee who is granted an incentive stock option does not recognize taxable income at the time the option is granted or upon its exercise, although the exercise may subject the optionee to the alternative minimum tax. Upon a disposition of the shares more than two&#160;years after grant of the option and one year after exercise of the option, any gain or loss is treated as long-term capital gain or loss. If these holding periods are not satisfied, the optionee recognizes ordinary income at the time of disposition equal to the difference between the exercise price and the lower of (i)&#160;the fair market value of the shares at the date of the option exercise or (ii)&#160;the sale price of the shares. Any gain or loss recognized on such a premature disposition of the shares to the extent not recognized as taxable income as provided above, will be long-term or short-term capital gain or loss, depending on the holding period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Nonstatutory Stock Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;An optionee does not recognize taxable income at the time the option is granted. Upon exercise, the optionee recognizes taxable income generally measured by the excess of the then fair market value of the shares over the exercise price. Any taxable income recognized in connection with an option exercise by an employee of the combined company is subject to tax withholding by Sesen Bio. Upon a disposition of such shares by the optionee, any difference between the sale price and the optionee&#8217;s exercise price, to the extent not recognized as taxable income as provided above, is treated as long-term or short-term capital gain or loss, depending on the holding period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stock Appreciation Rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A holder of a SAR does not recognize taxable income at the time a SAR is granted. Upon exercise, the participant will recognize ordinary income in an amount equal to the amount of cash received and the fair market value of the shares received, and if granted to an employee, tax withholding is generally due. Any additional gain or loss recognized upon any later disposition of the shares would be capital gain or loss, depending on the holding period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A participant will not have income upon the grant of restricted stock unless an election under Section&#160;83(b) of the Code is made within 30&#160;days of the date of grant. If a timely 83(b) election is made, then a participant will have ordinary income equal to the fair market value of the stock on the date of grant less the purchase price, if any. When the stock is sold, the participant will have capital gain or loss equal to the difference between the sales proceeds and the fair market value of the stock on the date of grant. If the participant does not make an 83(b) election, then when the stock vests the participant will have ordinary income equal to the fair market value of the stock on the vesting date less the purchase price, if any. When the stock is sold, the participant will have capital gain or loss equal to the sales proceeds </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">222</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:240pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">less the value of the stock on the vesting date. Any capital gain or loss will be long-term if the participant held the stock for more than one year, and otherwise will be short-term. If the participant is an employee, any ordinary income generally is subject to withholding of income and employment taxes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock Units</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A participant generally will recognize no income upon the grant of a restricted stock unit. Upon the settlement and/or payment of Sesen Bio RSUs, participants normally will recognize ordinary income in the year of receipt in an amount equal to the cash received and the fair market value of any nonrestricted shares received. If the participant is an employee, such ordinary income generally is subject to withholding taxes. Upon the sale of any shares received, any gain or loss, based on the difference between the sale price and the fair market value on the settlement date, will be taxed as short term or long term capital gain or loss, depending on the holding period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Other Stock-Based Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The tax consequences associated with any other stock-based award granted under the Amended and Restated Plan will vary depending on the specific terms of such award. Among the relevant factors are whether or not the award has a readily ascertainable fair market value, whether or not the award is subject to forfeiture provisions or restrictions on transfer, the nature of the property to be received by the participant under the award, and the participant&#8217;s holding period and tax basis for the award or underlying common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Tax Consequences to Sesen Bio</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;There will be no tax consequences to Sesen Bio except that Sesen Bio will be entitled to a deduction when a participant has ordinary income, subject to the limitations of Section&#160;162(m) of the Code. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Vote Required</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The affirmative vote of a majority in voting power of the votes cast by the holders of Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting and entitled to vote on the matter is required for approval of Proposal No. 3. Abstentions will have no effect on Proposal No. 3. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recommendation of Sesen Bio Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE SESEN BIO BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT SESEN BIO STOCKHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL NO. 3 TO APPROVE THE AMENDED AND RESTATED PLAN. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">223</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPN4A">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposal No. 4: Approval of an amendment to the 2014 ESPP</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the Sesen Bio special meeting, Sesen Bio stockholders will be asked to consider and vote upon a proposal to approve an amendment to the 2014 ESPP to increase, subject to adjustment in the event of stock splits and other similar events, including the proposed reverse stock split, the number of shares of Sesen Bio common stock reserved for issuance under the 2014 ESPP to 6,568,655 shares of Sesen Bio common stock, referred to in Proposal No.&#160;4 as the ESPP Increase. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2014 ESPP was adopted by the Sesen Bio board of directors on December&#160;18, 2013 and approved by Sesen Bio stockholders on January&#160;14, 2014. The 2014 ESPP was amended on May&#160;3, 2021 to increase the number of shares of Sesen Bio common stock available for issuance under the 2014 ESPP. On November&#160;17, 2022, the Sesen Bio board of directors adopted, subject to stockholder approval and the closing of the merger, Amendment No. 2 to the 2014 ESPP to increase the number of shares of Sesen Bio common stock reserved for issuance under the 2014 ESPP. The 2014 ESPP, as amended by the ESPP Increase, will provide eligible employees with the opportunity to purchase, subject to adjustment in the event of stock splits and other similar events, including the proposed reverse stock split, up to an aggregate of 6,568,655 shares of Sesen Bio common stock. As of January 4, 2023, 2.3&#160;million shares of Sesen Bio common stock had been reserved for issuance under the 2014 ESPP. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio believes that the availability of an adequate reserve of shares of Sesen Bio common stock for issuance under the 2014 ESPP will benefit the combined company by providing employees with an opportunity to acquire shares of Sesen Bio common stock, and will enable the combined company to attract, retain and motivate key employees with experience and ability. Further, Sesen Bio believes it is in the best interest of the combined company to encourage stock ownership by its employees. Therefore, Sesen Bio considers approval of the ESPP Increase vital to the future success of the combined company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Description of the 2014 ESPP</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All of the combined company&#8217;s employees, including directors who are employees, and all employees of any of the combined company&#8217;s subsidiaries designated by the Sesen Bio board of directors from time to time, are eligible to participate in the 2014 ESPP provided that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">such person is customarily employed by Sesen Bio or a designated subsidiary of Sesen Bio for more than 20 hours a week and for more than five&#160;months in a calendar year; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">such person has been employed by Sesen Bio or a designated subsidiary of Sesen Bio for at least six&#160;months prior to enrolling in the 2014 ESPP; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">such person was an employee of Sesen Bio or a designated subsidiary of Sesen Bio on the first day of the applicable plan period. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No employee is eligible to receive an option to purchase Sesen Bio common stock that would result in the employee owning 5% or more of the total combined voting power or value of Sesen Bio&#8217;s capital stock or the capital stock of any of Sesen Bio&#8217;s subsidiaries immediately after the grant of such option. For purposes of determining stock ownership of an employee, certain attribution rules under the Code will apply, and all Sesen Bio capital stock which the employee has a contractual right to purchase will be treated as stock owned by the employee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has made, and it expects the combined company to continue to make one or more offerings to its eligible employees to purchase Sesen Bio common stock under the 2014 ESPP. Each offering consists of a six-month offering period during which payroll deductions are made and held for the purchase of Sesen Bio common stock at the end of the offering period. The Sesen Bio board of directors may, in its discretion, choose a different plan period of no more than 12&#160;months for offerings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">With respect to any offering under the 2014 ESPP, an employee may authorize a payroll deduction in any dollar amount up to a maximum of 15% of the compensation such employee receives during the plan period (or during such shorter period during which payroll deductions are made). Compensation is defined under the 2014 ESPP to mean the amount of money reportable on the employee&#8217;s federal income tax </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">224</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">withholding statement, excluding overtime, shift premium, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances for travel expenses, income or gains associated with the grant or vesting of restricted stock, income or gains on the exercise of stock options or SARs, and similar items, but including, in the case of salespersons, sales commissions to the extent determined by the Sesen Bio board of directors. The Sesen Bio board of directors may, in its discretion, designate a lower maximum contribution rate, and a minimum payroll deduction may be established from time to time by the Sesen Bio board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On the first day of each plan period, Sesen Bio will grant to each eligible employee who is then a participant in the 2014 ESPP an option to purchase up to a number of shares of Sesen Bio common stock determined by dividing (a)&#160;the product of $2,083 and the number of full&#160;months in the plan period by (b)&#160;the closing price of a share of Sesen Bio common stock on the first day of the plan period (as determined under the 2014 ESPP). No employee may be granted an option under the 2014 ESPP that permits his or her rights to purchase Sesen Bio common stock under the 2014 ESPP and any other employee stock purchase plans of Sesen Bio or a subsidiary of Sesen Bio to accrue at a rate that exceeds $25,000 of the fair market value of Sesen Bio common stock (determined on the date the option is granted) for each calendar year in which the option is outstanding at any time. Further, the Sesen Bio board of directors may, in its discretion, set a fixed maximum number of shares of Sesen Bio common stock that each eligible employee may purchase per plan period, so long as that number is not greater than the number of shares of Sesen Bio common stock determined by using the formula described above and is subject to $25,000 limitation described above. Each employee who continues to be a participant in the 2014 ESPP on the last business day of the plan period (referred to as the exercise date) is deemed to have exercised the option at the option price on such date and will be deemed to have purchased from Sesen Bio the number of whole shares of Sesen Bio common stock reserved for purposes of the 2014 ESPP that such employee&#8217;s accumulated payroll deductions on the exercise date will pay for, up to the maximum number determined as set forth above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the 2014 ESPP, the option price will be determined by the Sesen Bio board of directors for each plan period and the option price will be at least 85% of the applicable closing price of Sesen Bio common stock (determined as provided under the 2014 ESPP). If the Sesen Bio board of directors does not make a determination of the option price, the option price will be 85% of the lesser of the closing price of Sesen Bio common stock (determined as provided under the 2014 ESPP) on either (a)&#160;the first business day of the plan period or (b)&#160;the exercise date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any balance remaining in an employee&#8217;s payroll deduction account at the end of a plan period will be automatically refunded to the employee, except that any balance that is less than the purchase price of one share of Sesen Bio common stock will be carried forward for the following offering, unless the employee elects not to participate in the following offering, in which case the balance in the employee&#8217;s account will be refunded. An employee may withdraw the balance accumulated in such employee&#8217;s account and withdraw from participation in an offering at any time prior to the close of business on the fifteenth business day prior to the end of the plan period. Any employee who so withdraws may not begin participating again during the remainder of the plan period but may participate in any subsequent offering in accordance with the terms and conditions established by the Sesen Bio board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any employee&#8217;s employment ends before the last business day of a plan period, the employee&#8217;s account balance will be refunded to the employee (without any reductions for payroll deductions). In the event of the employee&#8217;s death before the last business day of a plan period, Sesen Bio will, upon notification of such death, pay the balance of the employee&#8217;s account to the executor or administrator of the employee&#8217;s estate, or if no executor or administrator has been appointed to Sesen Bio&#8217;s knowledge, to any other person Sesen Bio designate in its discretion. If, before the last business day of a plan period, a designated subsidiary in which an employee is employed ceases to be a subsidiary of Sesen Bio, or if the employee is transferred to a subsidiary that is not a designated subsidiary, the employee will be deemed to have terminated employment for purposes of the 2014 ESPP. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Options under the 2014 ESPP are not transferable by a participating employee other than by will or the laws of descent and distribution, and are exercisable during the employee&#8217;s lifetime only by the employee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All funds received or held by Sesen Bio under the 2014 ESPP may be combined with other corporate funds and may be used for any corporate purposes. Shares of Sesen Bio common stock may be issued upon </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">225</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">exercise of an option from authorized but unissued shares of Sesen Bio common stock, from shares held in Sesen Bio&#8217;s treasury, or from any other proper source. In the event the total number of shares of Sesen Bio common stock specified in elections to be purchased under any offering plus the number of shares of Sesen Bio common stock purchased under previous offerings under the 2014 ESPP exceeds the maximum number of shares of Sesen Bio common stock issuable under the 2014 ESPP, the Sesen Bio board of directors will allot the shares of Sesen Bio common stock then available on a pro-rata basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2014 ESPP will be administered by the Sesen Bio board of directors or by a committee appointed by the Sesen Bio board of directors. The Sesen Bio board of directors or such committee has the authority to make rules and regulations for the administration of the 2014 ESPP and its interpretation and decisions with regard thereto will be final and conclusive. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the ESPP Increase is approved, up to 6,568,655 shares of Sesen Bio common stock will be available for issuance under the 2014 ESPP. Sesen Bio will be required to make equitable adjustments in the manner determined by the Sesen Bio board of directors to the number and class of securities available under the 2014 ESPP and the option price to reflect stock splits, reverse stock splits, stock dividends, recapitalizations, combinations of shares, reclassifications of shares, spin-offs and other similar changes in capitalization or any distribution to holders of Sesen Bio common stock other than an ordinary cash dividend. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the occurrence of a reorganization event (as defined below), the Sesen Bio board of directors is authorized to take any one or more of the following actions as to outstanding options under the 2014 ESPP: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that options will be assumed, or substantially equivalent options will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">upon written notice to employees, provide that all outstanding options will be terminated immediately prior to the consummation of the reorganization event and that all such outstanding options will become exercisable to the extent of accumulated payroll deductions as of a date specified by the Sesen Bio board of directors in such notice, which date will not be less than 10&#160;days preceding the effective date of the reorganization event; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">upon written notice to employees, provide that all outstanding options will be cancelled as of a date prior to the effective date of the reorganization event and that all accumulated payroll deductions will be returned to participating employees on such date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">upon the occurrence of a reorganization event in which holders of Sesen Bio common stock will receive a cash payment for each share surrendered in the reorganization event, or the acquisition price, change the last day of the plan period to be the date of the consummation of the reorganization event and make or provide for a cash payment to each employee equal to the acquisition price times the number of shares of Sesen Bio common stock that the employee&#8217;s accumulated payroll deductions as of immediately prior to the reorganization event could purchase at the option price, where the acquisition price is treated as the fair market value of the common stock and where the number of shares of Sesen Bio common stock that could be purchased is subject to the limitations set forth in the 2014 ESPP, minus the result of multiplying such number of shares of Sesen Bio common stock by the option price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that, in connection with a liquidation or dissolution of Sesen Bio, options will convert into the right to receive liquidation proceeds (net of the option price); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any combination of the foregoing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A &#8220;reorganization event&#8221; is defined under the 2014 ESPP as (i)&#160;any merger or consolidation of Sesen Bio with or into another entity as a result of which all of Sesen Bio common stock is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (ii)&#160;a transfer or disposition of all of Sesen Bio common stock for cash, securities or other property pursuant to a share exchange or other transaction, or (iii)&#160;Sesen Bio&#8217;s liquidation or dissolution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to comply with the laws of any foreign jurisdiction, Sesen Bio may grant options to employees or employees of designated subsidiaries who are citizens or residents of such foreign jurisdiction with terms that are less favorable (but not more favorable) than the terms of options granted under the 2014 ESPP to employees who are residents of the United States. Sesen Bio&#8217;s employees or employees of Sesen Bio&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">226</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">designated subsidiaries who are citizens or residents of a foreign jurisdiction may be excluded from eligibility under the 2014 ESPP if the grant of an option under the 2014 ESPP to a citizen or resident of the foreign jurisdiction is prohibited under the laws of such jurisdiction or if compliance with the laws of the foreign jurisdiction would cause the 2014 ESPP to violate the terms of Section&#160;423 of the Code. Sesen Bio may add one or more appendices to the 2014 ESPP describing the operation of the 2014 ESPP in those foreign jurisdictions in which employees are excluded from participation or granted less favorable options. The Sesen Bio board of directors may from time to time establish one or more sub-plans under the 2014 ESPP with respect to one or more of Sesen Bio&#8217;s designated subsidiaries, provided such sub-plan complies with Section&#160;423 of the Code. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors may at any time, and from time to time, amend or suspend the 2014 ESPP or any portion of the 2014 ESPP. Sesen Bio is required under the 2014 ESPP to obtain stockholder approval for any amendment if such approval is required by Section&#160;423 of the Code. Further, the Sesen Bio board of directors may not make any amendment that would cause the 2014 ESPP to fail to comply with Section&#160;423 of the Code. The Sesen Bio board of directors may terminate the 2014 ESPP at any time. Upon termination, Sesen Bio will refund all amounts in the accounts of participating employees. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Federal Income Tax Consequences</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following generally summarizes the United States federal income tax consequences that will arise with respect to participation in the 2014 ESPP and with respect to the sale of Sesen Bio common stock acquired under the 2014 ESPP. This summary is based on the tax laws in effect as of the date of this proxy statement/prospectus. Changes to these laws could alter the tax consequences described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Tax Consequences to Participants</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A participant will not have income upon enrolling in the 2014 ESPP or upon purchasing stock at the end of a plan period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A participant may have both ordinary income and a capital gain or loss upon the sale of Sesen Bio common stock that was acquired under the 2014 ESPP. The amount of each type of income and loss will depend on when the participant sells the stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the participant sells the Sesen Bio common stock more than two&#160;years after the commencement of the 2014 ESPP period during which the Sesen Bio common stock was purchased and more than one year after the date that the participant purchased the stock, at a profit (the sales proceeds exceed the purchase price), then the participant will have ordinary income equal to the lesser of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">15% of the value of the Sesen Bio common stock on the day the plan period commenced; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the participant&#8217;s profit. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any excess profit will be long-term capital gain. If the participant sells the Sesen Bio common stock at a loss (if sales proceeds are less than the purchase price) after satisfying these waiting periods, then the loss will be a long-term capital loss. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the participant sells the Sesen Bio common stock prior to satisfying these waiting periods, then he or she will have engaged in a disqualifying disposition. Upon a disqualifying disposition, the participant will have ordinary income equal to the value of the Sesen Bio common stock on the day he or she purchased the stock less the purchase price. The participant also will have a capital gain or loss equal to the difference between the sales proceeds and the value of the Sesen Bio common stock on the day he or she purchased the Sesen Bio common stock. This capital gain or loss will be long-term if the participant has held the Sesen Bio common stock for more than one year and otherwise will be short-term. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Tax Consequences to Sesen Bio.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;There will be no tax consequences to Sesen Bio except that Sesen Bio will be entitled to a deduction when a participant has ordinary income upon a disqualifying disposition. Any such deduction will be subject to the limitations of Section&#160;162(m) of the Code. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">227</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:388pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">New Plan&#160;Benefits</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Participation in the 2014 ESPP is discretionary. The benefits received by any individual under the 2014 ESPP are dependent upon the individual&#8217;s decision to participate in the 2014 ESPP, the amount that the individual decides to contribute to the 2014 ESPP and the fair market value of Sesen Bio common stock on the exercise date. As a result, it is not possible to determine the benefits that will be received under the 2014 ESPP by Sesen Bio named executive officers, other executive officers and other employees if the ESPP Increase is approved by the Sesen Bio stockholders. Non-employee directors, consultants and advisors are not eligible to participate in the 2014 ESPP.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Vote Required</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The affirmative vote of a majority in voting power of the votes cast by the holders of Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting and entitled to vote on the matter is required for approval of Proposal No. 4. Abstentions will have no effect on Proposal No. 4. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recommendation of Sesen Bio Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE SESEN BIO BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT SESEN BIO STOCKHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL NO. 4 TO APPROVE AN AMENDMENT TO THE 2014 ESPP. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">228</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPN5A">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:300pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposal No. 5: Approval of possible adjournment of the Sesen Bio special meeting</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the Sesen Bio special meeting, Sesen Bio stockholders will be asked to consider and vote upon a proposal to approve one or more adjournments of the Sesen Bio special meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the number of shares of Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting voting in favor of Proposal Nos. 1 or 2 is insufficient to approve such proposal at the time of the Sesen Bio special meeting, then Sesen Bio may move to adjourn the Sesen Bio special meeting in order to enable the Sesen Bio board of directors to solicit additional proxies in respect of such proposals. In that event, Sesen Bio stockholders will be asked to vote only upon the adjournment proposal, Proposal No. 5, and not on any other proposal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio currently does not intend to propose adjournment at the Sesen Bio special meeting if there are sufficient votes to approve Proposal Nos. 1 and 2. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Vote Required</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The affirmative vote of a majority in voting power of the votes cast by the holders of Sesen Bio common stock present or represented by proxy at the Sesen Bio special meeting and entitled to vote on the matter is required for approval of Proposal No. 5. Abstentions will have no effect on Proposal No. 5. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recommendation of Sesen Bio Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE SESEN BIO BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT SESEN BIO STOCKHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL NO. 5 TO APPROVE THE ADJOURNMENT OF THE SESEN BIO SPECIAL MEETING, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSAL NOS. 1 OR 2.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">229</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSBB">&#8203;</a><a name="tOVE">&#8203;</a><a name="tCUST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is a late-stage clinical company that was previously focused on advancing targeted fusion protein therapeutics, or TFPTs, for the treatment of patients with cancer. Sesen Bio&#8217;s most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule, or EpCAM, antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of NMIBC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the U.S. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase&#160;3 clinical trial, following Sesen Bio&#8217;s discussions with the FDA, which are further described below. Sesen Bio has turned its primary focus to consummating a strategic transaction with the goal of maximizing shareholder value. Additionally, Sesen Bio is seeking a partner for the further development of Vicineum and has engaged a financial advisor for the potential sale of Vicineum. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, Sesen Bio approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to pause further development of Vicineum in the U.S. The 2022 restructuring plan includes an incremental reduction in Sesen Bio&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the merger and while Sesen Bio seeks a potential partner for the further development of Vicineum. The 2022 restructuring plan is expected to be substantially completed in connection with the closing of the merger, which is expected to occur in the first quarter of 2023.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Current Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Merger</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In May&#160;2022, Sesen Bio announced that it had commenced a process to explore and evaluate strategic alternatives to enhance stockholder value, and had engaged a financial advisor to assist Sesen Bio in this process. Sesen Bio then commenced an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic acquisition or other transaction as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Background of the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tBOTM">125</a> of this proxy statement/prospectus. On September&#160;21, 2022, Sesen Bio announced that it had entered into the Original Merger Agreement, which was subsequently amended on December 29, 2022. Although Sesen Bio has entered into the Original Merger Agreement and the Merger Agreement Amendment and intends to consummate the merger, there is no assurance that it will be able to successfully consummate the merger on a timely basis, or at all. If, for any reason, the merger does not close, the Sesen Bio board of directors may elect to, among other things, attempt to complete another strategic transaction like the merger, attempt to sell or otherwise dispose of the various assets of Sesen Bio, resume its research and development activities and continue to operate the business of Sesen Bio or dissolve and liquidate its assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not completed, the Sesen Bio board of directors may decide that it is in the best interests of the Sesen Bio stockholders to dissolve the company and liquidate its assets. In that event, the amount of cash available for distribution to the Sesen Bio stockholders would depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as Sesen Bio funds its operations and incurs fees and expenses related to the merger. In addition, if the Sesen Bio board of directors were to approve and recommend, and the Sesen Bio stockholders were to approve, a dissolution of Sesen Bio, it would be required under Delaware law to pay its outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to the Sesen Bio stockholders. As a result of this requirement, a portion of Sesen Bio&#8217;s assets may need to be reserved pending the resolution of such obligations. In addition, Sesen Bio may be subject to litigation or other claims related to a liquidation and dissolution of the company. If a liquidation and dissolution were pursued, the Sesen Bio board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">230</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSBHP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">amount to reserve. Accordingly, the Sesen Bio stockholders could lose all or a significant portion of their investment in the event of a liquidation and dissolution of Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio&#8217;s Historical Pipeline Product Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TFPT Platform</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s historical product candidates are based on its proprietary TFPT platform and are focused on addressing areas of unmet medical need in cancer. Sesen Bio&#8217;s novel TFPTs have been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates, or ADCs, and were being developed for both local and systemic-administration. Sesen Bio&#8217;s TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its proprietary recombinant one-step, microbial manufacturing process. Sesen Bio&#8217;s TFPT platform uses protein binding antibody fragments, which include Fabs, single chain variable domains, and non-covalent scFv dimers, derived from the domains of antibodies that confer antigen recognition. Sesen Bio selects antibody fragments for its product candidates depending upon the target therapeutic indication. Sesen Bio targets tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and that also have limited expression in normal cells. For local administrations, Sesen Bio utilizes an immunogenic cytotoxic protein payload designed to both target cancer cells and promote a heightened local immune response against the tumor. For systemic-administrations, Sesen Bio uses deBouganin, a plant-derived, protein payload of reduced immunogenic potential that Sesen Bio believes can be repeatedly administered via infusion without the generation of an efficacy-limiting immune response against the payload. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Locally-administered TFPTs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio utilizes its TFPTs with immunogenic cytotoxic protein payloads for tumors that can be targeted locally rather than systemically. Local administration allows for the TFPT to reach the tumor without being cleared by the immune system, which enables Sesen Bio to maximize the concentration of TFPTs directly to tumors. Sesen Bio&#8217;s locally-administered TFPT Vicineum, which has been its lead product candidate in development for the treatment of NMIBC, contains a targeting antibody binding domain that is designed to bind to EpCAM, a protein over-expressed in many cancers. This binding domain is genetically fused to a truncated form of exotoxin A, or ETA, which is an immunogenic cytotoxic protein payload that is produced by the bacterial species Pseudomonas. This product candidate is designed to bind to EpCAM on the surface of cancer cells. The TFPT-EpCAM complex is subsequently internalized into the cell and, once inside the cell, the TFPT is cleaved by a cellular enzyme to release the cytotoxic protein payload, thus enabling cancer cell killing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio also believes that its TFPTs designed for local administration may not only directly kill cancer cells through targeted delivery of a cytotoxic protein payload, but also potentiate an anti-cancer therapeutic immune response. This immune response is believed to be triggered by the immunogenic cell death of the cancer cells due to the payload&#8217;s mechanism of action and the subsequent release of tumor antigens and the immunologically active setting created by the nature of the cytotoxic protein payloads. Sesen Bio believes that this immune response may also enhance the action of checkpoint inhibitors, that require a pre-existing immune response for maximum efficacy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s most advanced locally-administered TFPT product candidate is Vicineum, in development for the treatment of NMIBC and recurrent, locally advanced or metastatic EpCAM-expressing SCCHN. This TFPT is not, however, suitable for systemic-administration over multiple doses because the body&#8217;s immune system would recognize and eliminate foreign proteins, such as ETA, prior to their reaching targeted cancer cells. Sesen Bio has deferred further development of Vicineum for the treatment of SCCHN in order to focus its efforts and resources on development and, if approved, the commercialization of Vicineum for the treatment of NMIBC. Sesen Bio had also been exploring collaborations for the development of Vicineum for the treatment of SCCHN. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Vicineum for the treatment of NMIBC</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio completed the follow-up stage of its single-arm, multi-center, open-label Phase&#160;3 clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC, or the VISTA Trial in May&#160;2022. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">231</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The VISTA Trial completed enrollment in April&#160;2018 with a total of 133 patients. In December&#160;2020, Sesen Bio submitted its completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February&#160;2021. The FDA granted Priority Review for the BLA and set a target Prescription Drug User Fee Act, or PDUFA, date for a decision on the BLA of August&#160;18, 2021. On August&#160;13, 2021, Sesen Bio received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On August&#160;20, 2021, Sesen Bio withdrew its MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the E.U. until there was more clarity from the FDA on next steps for Vicineum in the U.S. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the E.U. In October&#160;2021, the EMA issued its Withdrawal Assessment Report relating to its MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. As a result of Sesen Bio&#8217;s decision on July&#160;15, 2022 to pause further development of Vicineum in the U.S., Sesen Bio no longer plans to pursue regulatory approval of Vysyneum for NMIBC in the E.U. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2021 and December&#160;2021, Sesen Bio participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase&#160;3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March&#160;2022, Sesen Bio participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of Sesen Bio&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase&#160;3 clinical trial. On July&#160;11, 2022, Sesen Bio participated in a Type B meeting with the FDA to discuss outstanding items related to Sesen Bio&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase&#160;3 clinical trial. As discussed above, on July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the U.S. If the merger is consummated, the combined company does not expect to pursue further development of Vicineum. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Systemically-administered TFPTs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio also utilizes its TFPTs with a de-immunized payload where systemic-administration is required. Sesen Bio&#8217;s systemically-administered TFPTs are built around deBouganin. Since the body&#8217;s immune system naturally recognizes and attempts to eliminate foreign proteins, Sesen Bio designed its systemically-administered TFPTs with a deBouganin payload to avoid inducing an immunogenic response. DeBouganin is constructed by mutating the immunogenic T-cell epitopes from bouganin so that they are not recognized as foreign by the immune system. However, Sesen Bio also believes that deBouganin may enhance the action of checkpoint inhibitors as a result of the promotion of a local tumor immune response following the death of cancer cells. Sesen Bio&#8217;s systemically-administered product candidate is VB6-845d for the treatment of multiple types of EpCAM-positive solid tumors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sale of EBI-031 Legacy Technology to Roche</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2016, Sesen Bio entered into a license agreement with Roche, or the Roche License Agreement, pursuant to which Sesen Bio granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to its monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by Sesen Bio, or collectively, the Licensed Intellectual Property. Under the Roche License Agreement, Roche was required to continue developing, at its cost, EBI-031 and any other product made from the Licensed Intellectual Property that contains an IL-6 antagonist monoclonal antibody, or the Roche Licensed Product, and pursue ongoing patent prosecution, at its cost. At the time of the Roche License Agreement, EBI-031, which was derived using Sesen Bio&#8217;s previous AMP-Rx platform, was in pre-clinical development as an intravitreal injection for diabetic macular edema and uveitis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, Sesen Bio executed the Roche Asset Purchase Agreement pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by Sesen Bio for up to $70.0&#160;million. As a result of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">232</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCOM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40.0&#160;million payment to Sesen Bio upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30.0&#160;million payable to Sesen Bio upon Roche&#8217;s initiation of a Phase&#160;3 clinical trial with EBI-031 for a certain indication if initiated prior to December&#160;31, 2026. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The pharmaceutical industry is highly competitive, subject to rapid and significant technological change and has a strong emphasis on developing proprietary products. While Sesen Bio believes that its next generation TFPT platform, knowledge, experience and scientific resources provide Sesen Bio with competitive advantages, Sesen Bio faces competition from both large and small pharmaceutical and biotechnology companies, academic institutions and other research organizations; specifically with companies, institutions and organizations that are actively researching and developing products that attach proprietary cell-killing payloads to antibodies for targeted delivery to cancer cells. Sesen Bio&#8217;s competitors include, but are not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">NMIBC: Merck &amp; Co., Inc. (Keytruda/pembrolizumab and BCG) (approved drugs), Endo Pharmaceuticals Inc. (Valstar/valrubicin) (approved drug), FerGene Inc. (Adstiladrin/nadofaragene firadenovec (rAd-IFN/Syn3)), Medical Enterprises Ltd. (Synergo RITE plus mitomycin C), Aadi, LLC (ABI-009), ImmunityBio (Anktiva/N-803 in combination with BCG), CG Oncology. (CG0070), Theralase Technologies Inc. (TLD-1433 photodynamic compound), Bristol-Myers Squibb (Opdivo/nivolumab with or without BCG or BMS-986205), F. Hoffmann-La Roche AG (Tecentriq/Atezolizumab), AstraZeneca (Imfinzi/durvalumab with or without BCG or External Beam Radiotherapy), Eli Lilly and Company (Gemcitabine) and Telormedix SA (Vesimune); Pfizer, Inc. (Sasanlimab) as well as the emerging use of generic intravesical chemotherapy agents, such as mytomycin-C, Gemcytabine and Gemcytobine + Docetaxel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">SCCHN: Bristol-Myers Squibb Company (Opdivo/nivolumab) (approved drug), Eli Lilly and Company, and Merck (Erbitux, pembrolizumab) (approved drugs); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Multiple types of solid tumors: Amgen Inc. (Panitumumab) (approved drug), Bayer AG and Onyx Pharmaceuticals (Sorafenib) (approved drug), Bristol-Myers Squibb Company, Eli Lilly and Company, and Merck (Erbitux) (approved drug), F. Hoffmann-La Roche AG (Bevacizumab) (approved drug), Genentech, Inc. (Bevacizumab, Erlotinib and Trastuzumab) (approved drugs), Pfizer, Inc. (Sunitinib) and Trion Research GmbH (Removab); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">In addition to competition from alternative treatments, Sesen Bio may also face competition from products that are biosimilar to, and possibly interchangeable with, its product candidates. Biosimilar products are expected to become available over the coming&#160;years. Even if Sesen Bio&#8217;s product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then and insurers or other third-party payors may encourage or even require the use of lower priced biosimilar products. Even if Sesen Bio treatments receive market authorization, they may not be listed on the formularies of payors (public or private insurers) or reimbursed. This may impact the uptake of the drug as a treatment option for patients and/or the price at which the drug can be sold at. Further, if the drug is reimbursed it may be at a narrower indication than the full scope of market authorization. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many of Sesen Bio&#8217;s competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical studies, conducting clinical trials, obtaining regulatory approval and marketing than Sesen Bio does. These competitors are also active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Moreover, specialized biologics, biopharmaceutical and biotechnology companies may prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s commercial opportunity could be substantially limited in the event that its competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or cheaper </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">233</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSAM">&#8203;</a><a name="tMAN">&#8203;</a><a name="tINPR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">than its comparable products. In geographies that are critical to Sesen Bio&#8217;s commercial success, competitors may also obtain regulatory approvals before Sesen Bio, resulting in its competitors building a strong market position in advance of its product&#8217;s entry. Sesen Bio believes the factors determining the success of its programs will be the drug design, effectiveness against multi-drug resistance mechanisms, efficacy, safety, price and convenience of its product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sales and Marketing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio does not currently have the sales and marketing infrastructure in place that would be necessary to sell and market products. Sesen Bio has no current plans to build the infrastructure that would be needed to successfully market and sell any successful drug candidate on its own, and would therefore need to seek strategic alliances and partnership with third parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Manufacturing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio previously leased a 31,100 square foot manufacturing, laboratory, warehouse and office facility in Winnipeg, Manitoba, with classified fermentation suite and post-production processing capabilities that were dedicated to producing its pre-clinical study and clinical trial batches of Vicineum. In September&#160;2017, Sesen Bio completed the manufacturing of all Vicineum necessary for its Phase&#160;3 VISTA Trial and for its Cooperative Research and Development Agreement, or CRADA, with the NCI. In conjunction with this achievement, Sesen Bio ended its manufacturing activities at its facility in Winnipeg and completed the technology transfer process to outsource future Vicineum clinical and commercial manufacturing to third-party manufacturers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2018, Sesen Bio entered into a Master Bioprocessing Services Agreement with Fujifilm Diosynth Biotechnologies U.S.A., Inc., or the Fujifilm MSA, for the manufacturing process and technology transfer of Vicineum drug substance production. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2019, Sesen Bio entered into a Commercial Manufacturing and Supply Agreement with Baxter, or the Baxter CMSA, for the manufacturing process and technology transfer of Vicineum drug product production. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2021, Sesen Bio entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with Sesen Bio&#8217;s decision to voluntarily pause further development of Vicineum, Sesen Bio commenced the process to wind down its manufacturing operations by terminating the Fujifilm MSA and Baxter CMSA on July&#160;17, 2022 and July&#160;20, 2022, respectively. Sesen Bio requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. As a result of the termination, and in accordance with the terms of the Fujifilm MSA, Sesen Bio has the responsibility to pay Fujifilm for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum. In addition, Sesen Bio terminated its Global Supply Agreement with Qilu on December 23, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio currently owns or exclusively licenses approximately 13 families of patents and applications, which generally relate to its TFPT-based product candidates and evolving its platform of targeting agents, cytotoxins (such as deBouganin) and linker technologies. As Sesen Bio&#8217;s product candidates evolve through clinical development, the company continues to monitor advancements and bolster patent coverage where possible. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio exclusively license two families under the Zurich License Agreement, which, among other things, include composition of matter claims directed to EpCAM antibody chimeras, EpCAM antibody chimera-cytotoxin conjugates, and their potential use in treating bladder and head and neck cancer. These families claim all or portions of Vicineum, as well as methods of treating bladder and head and neck cancer consist of issued patents in the U.S., Europe, Canada, China, Israel and Japan and also include pending applications in the U.S. The expiry dates of the patents in this family are April&#160;2024 and June&#160;2025, subject </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">234</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSBOB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to any applicable patent term adjustment or extension that may be available on a jurisdictional basis. See the section entitled &#8220;Our Vicineum License Agreements&#8221; in Sesen Bio&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 for additional information. In addition to the Zurich portfolio, Sesen Bio owns two issued U.S. patents related to Vicineum. The expiry date of these patents is February&#160;2029, subject to any applicable patent term extension that may be available on a jurisdictional basis. In addition, Sesen Bio has patent families relating to treatment regimens using Vicineum that include issued patents in the U.S., Australia and Japan and patent applications in Canada and Europe. These patents will expire in 2036. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, Sesen Bio has a license agreement with Micromet AG, or Micromet, or the Micromet License Agreement, now part of Amgen, Inc., which grants Sesen Bio non-exclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents (which are now expired) cover some key aspects of Vicineum. Under the terms of the License Agreement with Micromet, as of December 31, 2021, even though the patents have expired, Sesen Bio may be obligated to pay up to &euro;2.4 million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.7 million at exchange rates in effect on December 31, 2021). Sesen Bio is also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, Sesen Bio is required to pay to Micromet an annual license maintenance fee of &euro;50,000 (approximately $56,625 at exchange rates in effect as of December 31, 2021), which can be credited towards any royalty payment Sesen Bio owes to Micromet. Sesen Bio recorded an expense of &euro;0.7 million ($0.9 million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of its BLA for Vicineum with the FDA in December 2020. Sesen Bio recorded an expense of &euro;0.5 million ($0.6 million) related to the submission of the MAA to the EMA for Vysyneum in the first quarter of 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio also has a license agreement with XOMA Ireland Limited, or XOMA, or the XOMA License Agreement, which grants Sesen Bio non-exclusive rights, with certain sublicense rights, to certain XOMA patent rights (which are now expired) and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. Under the terms of the License Agreement with XOMA, even though the patents have expired, Sesen Bio is required to pay up to $0.25 million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Sesen Bio is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. Sesen Bio has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio&#8217;s OUS Business Development Partnering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with Sesen Bio&#8217;s decision to voluntarily pause further development of Vicineum, Sesen Bio has commenced the process to wind down its OUS business development partnerships in the Middle East and North Africa region, or MENA, and Turkey by providing notice of termination for its exclusive license agreements in these respective regions on July&#160;20, 2022. In connection with the termination of the exclusive license agreement with Sesen Bio&#8217;s partner in MENA, Sesen Bio was required to refund the $3.0&#160;million upfront payment paid to the company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Greater China</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;30, 2020, Sesen Bio and its wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which Sesen Bio granted Qilu an exclusive, sublicensable, royalty-bearing </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">235</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tGORE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">license, under certain intellectual property owned or exclusively licensed by Sesen Bio, to develop, manufacture and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan, or Greater China. Sesen Bio also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by Sesen Bio to develop, manufacture and commercialize Vicineum in Greater China. Sesen Bio retains (i)&#160;development and commercialization rights in the rest of the world excluding Greater China and (ii)&#160;manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During 2020, Sesen Bio received a total of $10.0&#160;million in net proceeds associated with the Qilu License Agreement. Sesen Bio is also entitled to receive up to an additional $23.0&#160;million upon the achievement of certain technology transfer, development and regulatory milestones, as well as a 12% royalty based upon annual net sales of Vicineum in Greater China. The royalties are payable upon the first commercial sale of Vicineum in a region and continuing until the latest of (i)&#160;twelve&#160;years after the first commercial sale of Vicineum in such region, (ii)&#160;the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of Vicineum in such region, and (iii)&#160;the expiration of regulatory or data exclusivity for Vicineum in such region. The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers Vicineum in a particular region or no data or regulatory exclusivity of Vicineum in a particular region. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The IND for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January&#160;2021 and approved in March&#160;2021, resulting in a $3.0&#160;million milestone payment from Qilu, the first milestone payment out of the $23.0&#160;million in potential milestone payments. Sesen Bio recorded $2.8&#160;million (net of value-added tax, or VAT) as license revenue during the three-month period ended March&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as &#8220;Technology Transfer&#8221;. An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, Sesen Bio recorded $0.9&#160;million of revenue during the three&#160;months ended June&#160;30, 2021, for additional purchase price resulting from Qilu&#8217;s obligation to pay Sesen Bio an amount equal to its recovery of VAT. Sesen Bio will not be subject to VAT on future potential milestone payments to Qilu. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;20, 2021 Sesen Bio and Qilu announced the enrollment of the first patient in China in a Phase&#160;3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ, or CIS, with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) and the recurrence-free rate (for papillary patients) at six&#160;months, with the complete response rate and the recurrence-free rate at three&#160;months, safety and tolerability as the secondary endpoints. Based on the Qilu License Agreement, the trial is being run at the sole cost of Qilu. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December 23, 2022, Sesen Bio terminated the Qilu License Agreement. In connection with the termination of the Qilu License Agreement, Sesen Bio will make a one-time aggregate payment to Qilu of $1,400,000, which consists of a $1,200,000 termination fee payable upon the termination of the Qilu License Agreement and a $200,000 payment payable upon Sesen Bio&#8217;s receipt of certain clinical data and chemistry, manufacturing, and controls data from Qilu. As a result of the termination of the Qilu License Agreement, all rights to Vicineum in China, Hong Kong, Macau and Taiwan have reverted to Sesen Bio. Sesen Bio currently retains all global rights to Vicineum. Sesen Bio is seeking a partner for the further development of Vicineum and has engaged a financial advisor for the potential sale of Vicineum. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a clinical-stage biologics company, Sesen Bio is subject to extensive regulation by the FDA, and other national, supranational, state, provincial and local regulatory agencies. Sesen Bio is also subject to extensive regulation by similar governmental authorities in other countries in which it operates. In the United States, the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA and their implementing regulations set forth, among other things, requirements for the research, testing, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">236</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">development, manufacture, quality control, safety, effectiveness, approval, post-approval monitoring and reporting, labeling, storage, record keeping, distribution, import, export, advertising and promotion of Sesen Bio&#8217;s product candidates. Although the discussion below focuses on regulation in the United States, Sesen Bio may seek marketing approval in other countries were it to resume development of Vicineum. Generally, Sesen Bio&#8217;s activities in other countries will be subject to regulation that is similar in nature and scope to that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in the E.U. are addressed in a centralized way through the European Commission following the opinion of the EMA, but country-specific regulation in the individual European Union Member States, or E.U. Member States, remains essential in many respects. The process of obtaining regulatory marketing approvals and the subsequent compliance with appropriate supranational, federal, state, provincial, local and non-U.S. statutes and regulations require the expenditure of substantial time and financial resources, and Sesen Bio may not be successful in any given jurisdiction were it to resume development of Vicineum. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">U.S. Government Regulation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, drug products are regulated by the FDA under the FDCA and other laws, including, in the case of biologics, the PHSA. Drug products are also subject to other federal, state and local statutes and regulations. A failure to comply with any applicable requirements during the product development, approval, or post-approval periods may lead to administrative or judicial sanctions, including, among other things, the imposition by the FDA or an institutional review board, or IRB, of a hold on clinical trials, refusal to approve pending marketing applications or supplements, withdrawal of approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, or administrative, civil and/or criminal investigation, penalties or prosecution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Were Sesen Bio to resume development of Vicineum, the FDA would regulate Vicineum in the United States as a biologic. Biologics require the submission of a BLA and approval by the FDA prior to being marketed in the United States. Manufacturers of biologics may also be subject to state and local regulation. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The steps required before a biologic may be marketed in the United States generally include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">completion of pre-clinical studies, animal studies and formulation studies, some in compliance with the FDA&#8217;s current Good Laboratory Practices, or GLP, regulations, and the Animal Welfare Act administered and enforced by the United States Department of Agriculture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">submission to the FDA of an IND to support human clinical testing, which must become effective before human clinical trials may commence; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approval by an IRB before each trial may be initiated at each clinical site; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">performance of adequate and well-controlled clinical trials under protocols submitted to the FDA and reviewed and approved by each IRB, conducted in accordance with federal regulations and current Good Clinical Practices, or GCP, to establish the safety, purity and potency of the biologic for each targeted indication; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">submission of a BLA to the FDA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of an FDA Advisory Committee review, if applicable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of an FDA inspection of the manufacturing facilities at which the biologic is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">FDA review and approval of a BLA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pre-clinical Studies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pre-clinical studies include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the pre-clinical studies must comply with federal regulations and requirements, including, as applicable, GLP and the Animal Welfare Act. The results of the pre-clinical studies, together with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">237</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA evaluates the IND to determine whether there is an adequate basis for starting the product candidate in initial clinical trials, and the IND must become effective before human clinical trials may be commenced. Additional pre-clinical studies may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If during this 30-day period the FDA does not raise any concerns or issues that must be addressed prior to the commencement of clinical trials or does not impose a clinical hold, the IND becomes effective 30&#160;days following the FDA&#8217;s receipt of the IND and the clinical trial proposed in the IND may begin. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Clinical Trials</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators. Clinical trials are subject to extensive regulation and must be conducted in compliance with (i)&#160;federal regulations, (ii)&#160;GCP standards, which set safeguards to protect the rights and health of patients and establish standards for conducting, recording data from, and reporting results of clinical trials, and (iii)&#160;protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if any. Non-U.S. studies conducted under an IND generally must meet the same requirements that apply to studies being conducted in the United States. The informed written consent of each study patient must be obtained before the patient may begin participation in the clinical trial. The study protocol, study plan, and informed consent forms for each clinical trial must be reviewed and approved by an IRB for each clinical site, and the study must be conducted under the auspices of an IRB for each trial site. Investigators and IRBs must also comply with FDA regulations and guidelines, including those regarding oversight of study patient informed consent, complying with the study protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The clinical trial program for a product candidate is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The three phases are as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;1.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Phase&#160;1 involves the initial introduction of a product candidate into humans. Phase&#160;1 clinical trials are typically conducted in healthy human subjects, but in some situations are conducted in patients with the target disease or condition. These clinical trials are generally designed to evaluate the safety, metabolism, pharmacokinetic, or PK, properties and pharmacologic actions of the product candidate in humans, the side effects associated with increasing doses and, if possible, to gain early evidence of effectiveness. During Phase&#160;1 clinical trials, sufficient information about the product candidate&#8217;s PK properties and pharmacological effects may be obtained to inform and support the design of Phase&#160;2 clinical trials. The total number of participants included in Phase&#160;1 clinical trials varies, but is generally in the range of 20 to 80; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;2.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Phase&#160;2 includes the controlled clinical trials conducted to obtain initial evidence of effectiveness of the product candidate for a particular indication(s) in patients with the target disease or condition, to determine dosage tolerance and optimal dosage, and to gather additional information on possible adverse side effects and safety risks associated with the product candidate. Phase&#160;2 clinical trials are typically well-controlled, closely monitored, and conducted in a limited patient population, usually involving no more than several hundred participants; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;3.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Phase&#160;3 clinical trials are clinical trials conducted in an expanded patient population at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the product candidate has been obtained and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the product candidate and to provide an adequate basis for regulatory approval. Phase&#160;3 clinical trials usually involve several hundred to several thousand participants. In most cases, the FDA requires two adequate and well controlled Phase&#160;3 clinical trials to demonstrate the efficacy of the product candidate, although a single Phase&#160;3 clinical trial with other confirmatory evidence may be sufficient in certain instances. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The decision to suspend or terminate development of a product candidate may be made by either a health authority body, such as the FDA, by an IRB, or by a company for various reasons and during any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">238</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">phase of clinical trials. The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. In some cases, clinical trials are overseen by a data safety monitoring board, or DSMB, which is an independent group of qualified experts organized by the trial sponsor to evaluate at designated points in time whether or not a trial may move forward and/or should be modified. These decisions are based on unblinded access to data from the ongoing trial and generally involve determinations regarding the benefit-risk ratio for study patients and the scientific integrity and validity of the clinical trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, there are requirements for the registration of certain clinical trials of product candidates on public registries, such as www.clinicaltrials.gov, and the submission of certain information pertaining to these trials, including clinical trial results, after trial completion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, a sponsor submits extensive information about the product candidate to the FDA in the form of a BLA to request marketing approval for the product candidate in specified indications. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Biologics License Applications</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to obtain approval to market a biologic in the United States, a marketing application must be submitted to the FDA that provides data establishing the safety and effectiveness of the product candidate for the proposed indication. The application includes all relevant data available from pertinent pre-clinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a product candidate, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the product candidate to the satisfaction of the FDA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Prescription Drug User Fee Act, the fees payable to the FDA for reviewing an original BLA, as well as annual program fees for approved products, can be substantial, subject to certain limited deferrals, waivers and reductions that may be available. The FDA has 60&#160;days from receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. The FDA may refuse to accept for filing any BLA that it deems incomplete or not properly reviewable at the time of submission, in which case the BLA will have to be updated and resubmitted. The FDA&#8217;s PDUFA review goal is to review 90% of priority BLA applications within six&#160;months of filing and 90% of standard applications within 10&#160;months of filing, but the FDA can and frequently does extend this review timeline to consider certain later-submitted information or information intended to clarify or supplement information provided in the initial submission. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may not complete its review or approve a BLA within these established goal review times. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure, and potent for its intended use, and whether the product is being manufactured in compliance with cGMP. The FDA may also refer applications for novel product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured or the facilities that are significantly involved in the product development and distribution process and will not approve the product candidate unless cGMP compliance is satisfactory. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Under the Pediatric Research Equity Act, certain BLAs must include an assessment, generally based on clinical trial data, of the safety and effectiveness of the biological product in relevant pediatric populations. The FDA may waive or defer the requirement for a pediatric assessment, either at a company&#8217;s request or by its own initiative, including waivers for certain products not likely to be used in a substantial </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">239</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">number of pediatric patients. Products with orphan drug designation are exempt from these requirements for orphan-designated indications with no formal waiver process required. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or a CRL. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. On August&#160;13, 2021, Sesen Bio received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. If Sesen Bio were to resume development of Vicineum, it would be required to address these deficiencies to the FDA&#8217;s satisfaction in a resubmission of a BLA. The FDA&#8217;s PDUFA review goal is to review such resubmissions within two or six&#160;months of receipt, depending on the type of information included. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval and deny approval of a resubmitted BLA. FDA approval of any application may include many delays or never be granted. An approval letter authorizes commercial marketing of the product candidate with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include Medication Guides, communication plans for healthcare professionals, and also may include elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the biologic. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the biologic&#8217;s safety, purity, or potency, which can be costly. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or a supplemental BLA before the change can be implemented. A supplemental BLA for a new indication typically requires clinical data similar to that in the original application, and the FDA generally uses the same procedures and actions in reviewing a supplemental BLA as it does in reviewing a new BLA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if safety or manufacturing problems occur following initial marketing. For example, quality control and manufacturing procedures must conform, on an ongoing basis, to cGMP requirements, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to spend time, money and effort to maintain cGMP compliance. In addition, new or modified government requirements, including from new legislation, may be established that could delay or prevent regulatory approval of Sesen Bio&#8217;s product candidates under development or affect its ability to maintain product approvals it has obtained. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Biosimilars and Market Exclusivity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Biologics Price Competition and Innovation Act of 2009, or BPCIA, the FDA can approve products that are biosimilar to (but not generic copies of) innovative biologics on the basis of less extensive data than is required by a full BLA. To be biosimilar, a biological product must be highly similar to an already-licensed FDA biological product, or reference product and can have no clinically meaningful differences in safety, purity and potency from the reference product. An interchangeable biosimilar product must meet additional standards for interchangeability and, if approved, may be substituted for the reference product. At this juncture, it is unclear whether any biosimilar product deemed &#8220;interchangeable&#8221; by the FDA, in fact, will be readily substituted by pharmacies, which are governed by state pharmacy law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After an innovator has marketed its product for four&#160;years, a manufacturer may file an application for approval of a &#8220;biosimilar&#8221; version of the innovator product. However, although an application for approval of a biosimilar may be filed four&#160;years after approval of the innovator product, qualified innovative biological products receive 12&#160;years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12&#160;years after the innovative biological product was first approved by the FDA under the PHSA. The BPCIA also provides a mechanism for innovators to enforce the patents that protect </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">240</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">innovative biological products and for biosimilar applicants to challenge the patents. Such patent litigation may begin as early as four&#160;years after the innovative biological product is first approved by the FDA. Although the patents for the reference biologic may be challenged by the biosimilar applicant during that time period pursuant to the BPCIA statutory patent challenge framework, no biosimilar or interchangeable product will be licensed by the FDA until the end of the exclusivity period. The first biologic product candidate submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against any other determinations of interchangeability to the reference product for the lesser of (i)&#160;one year after first commercial marketing of the interchangeable biosimilar product, (ii)&#160;18&#160;months after approval of the interchangeable biosimilar product if there is no legal challenge, (iii)&#160;18&#160;months after the resolution in the interchangeable biosimilar product applicant&#8217;s favor of a lawsuit challenging the reference product&#8217;s patents, and (iv)&#160;42&#160;months after approval of the interchangeable biosimilar product if a lawsuit is ongoing within the 42-month period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The objectives of the BPCIA are conceptually similar to those of the Hatch-Waxman Act, which established abbreviated pathways for the approval of generic drugs. The FDA has published several guidance documents providing direction on developing and obtaining approval of biosimilar product candidates. The guidance documents to date explain, among other things, that the FDA will approve a biosimilar product if there are no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency. A determination of biosimilarity may be based upon: (1)&#160;analytical studies showing that the biological product is highly similar to, with no clinically meaningful differences from, the reference product, (2)&#160;animal studies, including toxicity assessments, and/or (3)&#160;a clinical trial or trials (including assessment of immunogenicity and PKs) that are sufficient to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is licensed and for which licensure is sought for the biological product. The FDA recommends that sponsors use a stepwise approach to developing the data and information needed to support biosimilarity. At each step, the sponsor should evaluate the extent of residual uncertainty of biosimilarity that remains and incorporate the FDA&#8217;s advice for additional studies to address remaining uncertainty. To meet the higher standard for interchangeability the sponsor must demonstrate, in addition to biosimilarity, that the proposed biological product can be expected to produce the same clinical result and, if administered more than once to any given patient, the safety risk and potential for diminished efficacy associated with switching between the proposed biological product and the reference product is not greater than continuing to use the reference product. A biological product that is determined to be interchangeable may be substituted for the reference product without the intervention of the prescribing healthcare provider. In March&#160;2015, the FDA approved the first biosimilar product under the BPCIA, and it has approved other biosimilar products since then. If Sesen Bio were to resume development of Vicineum and obtain approval by the FDA, the approval of a biosimilar to Vicineum could have a material impact on Sesen Bio. In particular, a biosimilar could be significantly less costly to bring to market and priced significantly lower than Vicineum, if approved by the FDA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The &#8220;Purple Book,&#8221; first published by the FDA in September&#160;2014, lists biological products, including any biosimilar and interchangeable biological products licensed by the FDA under the PHSA. The lists include the date a biological product was licensed under Section&#160;351(a) of the PHSA and whether the FDA evaluated the biological product for reference product exclusivity under Section&#160;351(k)(7) of the PHSA. The Purple Book will also enable a user to see whether a biological product licensed under Section&#160;351(k) of the PHSA has been determined by the FDA to be biosimilar to or interchangeable with a reference biological product. Biosimilar and interchangeable biological products licensed under Section&#160;351(k) of the PHSA will be listed under the reference product to which biosimilarity or interchangeability was demonstrated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Advertising and Promotion</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA and other federal regulatory agencies closely regulate the marketing and promotion of biologics through standards and regulations for, among other things, direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the internet. A biologic cannot be promoted before it is approved. After approval, promotion of a biologic can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">241</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Healthcare providers are permitted, however, to prescribe products for unapproved uses (also known as &#8220;off-label&#8221; uses)&#8201;&#8212;&#8201;that is, uses not approved by the FDA and therefore not described in the product&#8217;s labeling&#8201;&#8212;&#8201;because the FDA does not regulate the practice of medicine. However, the FDA restricts manufacturers&#8217; communications regarding unapproved uses. Broadly speaking, a manufacturer may not promote a product for an unapproved use, but may engage in non-promotional, balanced communication regarding unapproved uses under specified conditions. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the United States Department of Justice, or DOJ, or the Office of Inspector General of the United States Department of Health and Human Services, or HHS, as well as state authorities. Such enforcement action could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Post-approval Regulation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After regulatory approval of a product is obtained, a company is required to comply with a number of post-approval requirements. For example, as a condition of BLA approval, the FDA may require post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. Regulatory approval of oncology products often requires that patients in clinical trials be followed for long periods to determine the overall survival benefit of the product. In addition, as a holder of an approved BLA, a company would be required to report adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements concerning advertising and promotional labeling for any of its products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The manufacturing of Sesen Bio&#8217;s product candidates is required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s cGMP regulations. Biologic manufacturers and other entities involved in the manufacture and distribution of approved biologics are also required to register their establishments and list any products they make with the FDA and to comply with related requirements in certain states. The FDA and certain state agencies periodically inspect manufacturing facilities to assess compliance with cGMP and other laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Discovery of problems with a product after approval may result in serious and extensive restrictions on a product or the manufacturer or holder of an approved BLA, as well as lead to potential market disruptions. These restrictions may include suspension of product manufacturing until the FDA is assured that quality standards can be met, continuing oversight of manufacturing by the FDA under a &#8220;consent decree,&#8221; which frequently includes the imposition of costs and continuing inspections over a period of many&#160;years, as well as possible withdrawal of the product from the market. Other potential consequences include interruption of production, issuance of warning letters or other enforcement letters, refusal to approve pending BLAs or supplements to approved BLAs, product seizure or detention, and injunctions or imposition of civil and/or criminal penalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation, correction, and reporting of any deviations from cGMP and impose reporting and documentation requirements upon a company and any third-party manufacturers that a company may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures, such as additional post-market clinical trials to assess new safety risks or distribution-related or other restrictions under a REMS. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Patent Term Extension</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Were Sesen Bio to resume development of Vicineum, depending upon the timing, duration and specifics of the FDA approval, some of its U.S. patents may be eligible for limited patent term extension. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">242</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The provisions of the Hatch-Waxman Act permit a patent term extension of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, were Sesen Bio to resume development of Vicineum, Sesen Bio may apply for patent term extension for one of its currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many other countries also provide for patent term extensions or similar extensions of patent protection for biologic products. For example, in Japan, it may be possible to extend the patent term for up to five&#160;years and in Europe, it may be possible to obtain a supplementary patent certificate that would effectively extend patent protection for up to five&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The Foreign Corrupt Practices Act</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FCPA prohibits any United States individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any non-U.S. official, political party or candidate for the purpose of influencing any act or decision of the non-U.S. entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring such companies to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">European Union and other International Government Regulation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to regulations in the United States, Sesen Bio will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its product candidates. Whether or not Sesen Bio obtains FDA approval for a product candidate, it must obtain the requisite approvals from regulatory authorities in countries outside of the United States prior to the commencement of clinical trials or marketing of a product in those countries should Sesen Bio resume development of Vicineum. Some countries outside of the United States have a similar process that requires the submission of a CTA much like the IND prior to the commencement of human clinical trials. In the E.U., for example, a CTA must be submitted to the competent authorities of the E.U. Member States where the clinical trial is conducted and to an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Marketing Authorization Application for Biologic Medicinal Products</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Should Sesen Bio resume development of Vicineum and seek regulatory approval under E.U. regulatory systems, it must submit a marketing authorization application. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the E.U., a marketing authorization for a medicinal product can be obtained through a centralized, mutual recognition, decentralized procedure, or national procedure (single country). The centralized procedure is mandatory for certain medicinal products, including orphan medicinal products and certain biologic products and optional for certain other products, including medicinal products that are a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public or animal health. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In accordance with the centralized procedure, the applicant can submit a single application for marketing authorization to the EMA which will provide a positive opinion regarding the application if it meets certain quality, safety, and efficacy requirements. Based on the opinion of the EMA, the European </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">243</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Commission takes a final decision to grant a centralized marketing authorization which permits the marketing of a product in all 27 E.U. Member States and three of the four European Free Trade Association States&#8201;&#8212;&#8201;Iceland, Liechtenstein and Norway. Under the centralized procedure in the E.U., the maximum timeframe for the evaluation of a marketing authorization application is 210&#160;days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the EMA CHMP. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For other countries outside of the E.U., such as the United Kingdom and countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCPs, applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origin in the Declaration of Helsinki. If Sesen Bio fails to comply with applicable non-U.S. regulatory requirements, it may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Advertising, Promotion and Compliance</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the E.U., the advertising and promotion of Sesen Bio&#8217;s products will also be subject to E.U. laws and E.U. Member States&#8217; national laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. Other E.U. Member State national legislation may also apply to the advertising and promotion of medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. The SmPC forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion and is prohibited in the E.U. The applicable laws at the E.U. level and in the individual E.U. Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations of the rules governing the promotion of medicinal products in the E.U. could be penalized by administrative measures, fines and imprisonment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During all phases of development (pre- and post-marketing), failure to comply with applicable regulatory requirements may result in administrative or judicial sanctions. These penalties could include the imposition of a clinical hold on trials, refusal to approve pending applications, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Orphan Drug Designation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may grant Orphan Drug Designation to biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States or a disease or condition that affects more than 200,000 individuals in the United States but there is no reasonable expectation that the cost of developing and making the biologic would be recovered from sales in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax credits for certain research and user fee waivers under certain circumstances. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to seven&#160;years of market exclusivity, which means the FDA may not approve any other application for a biologic for the same indication for a period of seven&#160;years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. The FDA can revoke a product&#8217;s orphan drug exclusivity under certain circumstances, including when the product sponsor is unable to assure the availability of sufficient quantities of the product to meet patient needs. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same biologic for a different disease or condition. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">244</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the E.U., medicinal products: (a)&#160;that are used to diagnose, treat or prevent life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the E.U.; or (b)&#160;that are used to treat or prevent life-threatening, seriously debilitating or serious and chronic conditions and that, for economic reasons, would be unlikely to be developed without incentives; and (c)&#160;where no satisfactory method of diagnosis, prevention or treatment of the condition concerned exists, or, if such a method exists, the medicinal product would be of significant benefit to those affected by the condition, may be granted an orphan designation in the E.U. The application for orphan designation must be submitted to the EMA and approved by the European Commission before an application is made for marketing authorization for the product. Once designated, Orphan medicinal product designation also entitles a party to financial incentives such as reduction of fees or fee waivers. Moreover, ten&#160;years of market exclusivity is granted following marketing authorization, if the product continues to be designated as an orphan medicinal product upon grant of the marketing authorization. During this ten-year period, with a limited number of exceptions, neither the competent authorities of the E.U. Member States, the EMA, or the European Commission are permitted to accept applications or grant marketing authorization for other similar medicinal products with the same therapeutic indication. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the ten-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this latter product is demonstrated to be safer, more effective or otherwise clinically superior to the original orphan medicinal product. This period of market exclusivity may be reduced to six&#160;years, at the end of the fifth year, if the orphan designation criteria are no longer met, including where it can be demonstrated on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Orphan drug designation must be requested before submission of an application for marketing approval or marketing authorization. Orphan drug designation does not convey any advantage in, nor shorten the duration of the regulatory review and approval process. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Expedited Programs in the United States and Other Jurisdictions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States, a product may be granted Fast Track designation if it is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to address unmet medical needs for such condition. With Fast Track designation, the sponsor may be eligible for more frequent opportunities to obtain the FDA&#8217;s feedback, and the FDA may initiate review of sections of a BLA before the application is complete. This Rolling Review is available if the applicant provides, and the FDA approves, a schedule for the remaining information. Even if a product receives Fast Track designation, the designation can be rescinded and provides no assurance that a product will be reviewed or approved more expeditiously than would otherwise have been the case, or that the product will be approved at all. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">FDA may designate a product candidate as a breakthrough therapy if it finds that the product candidate is intended, alone or in combination with one or more other product candidates or approved products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates designated as breakthrough therapies, more frequent interaction and communication between the FDA and the sponsor can help to identify the most efficient path for clinical development. Product candidates designated as breakthrough therapies by the FDA may also be eligible for Priority Review. The receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and, in any event, does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a breakthrough therapy, the FDA may later decide that the product candidate no longer meets the conditions for designation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accelerated approval under FDA regulations allows a product designed to treat a serious or life-threatening disease or condition that provides a meaningful therapeutic advantage over available therapies to be approved on the basis of either an intermediate clinical endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit. Approvals of this kind typically include requirements for </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">245</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEMP">&#8203;</a><a name="tCOIN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">confirmatory clinical trials to be conducted with due diligence to validate the surrogate endpoint or otherwise confirm clinical benefit and for all promotional materials to be submitted to the FDA for review prior to dissemination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA may grant Priority Review designation to a product candidate, which sets the target date for FDA action on the application at six&#160;months from FDA filing, or eight&#160;months from the sponsor&#8217;s submission. Priority Review may be granted where a product is intended to treat a serious or life-threatening disease or condition and, if approved, has the potential to provide a safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in safety or efficacy compared to available therapy. If criteria are not met for Priority Review, the standard FDA review period is ten&#160;months from FDA filing or 12&#160;months from sponsor submission. Priority Review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Centralized Procedure in the E.U., the maximum timeframe for the evaluation of a marketing authorization application is 210&#160;days (excluding &#8220;clock stops,&#8221; when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Accelerated evaluation might be granted by CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, which should be justified and assessed on a case-by-case basis. In this circumstance, EMA ensures that the opinion of CHMP is given within 150&#160;days. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Environmental and Safety Laws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is subject to a variety of federal, provincial and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. Sesen Bio&#8217;s operations involve such hazardous materials and produce such hazardous waste products. Although Sesen Bio believes that its safety procedures for handling and disposing of these materials comply with the standards prescribed by federal, provincial and local regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. Radioactive materials in Canada come under federal jurisdiction. Canada&#8217;s Nuclear Safety and Control Act 1997 c.9 contains a general prohibition against any activity, including possession of radioactive material, except in accordance with the terms and conditions set out in a federal license issued by the Canadian Nuclear Safety Commission. The Nuclear Substances and Radiation Devices Regulation does however, exempt licensing requirements for small quantities of radioactive substances that either meet concentrations set out in a schedule to the Regulation or, for radioactive substances not set out in the schedule, that meet certain regulatory criteria. Sesen Bio&#8217;s operations do not currently require a federal license issued by the Canadian Nuclear Safety Commission. Sesen Bio&#8217;s operations in Canada may be subject to license approvals, notification requirements and investigation and enforcement for air and water and waste matters. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employees</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, Sesen Bio employed 17 individuals, all of whom are full-time employees. Sesen Bio has never had a work stoppage, and none of its employees are represented by a labor organization or covered by collective bargaining arrangements. Sesen Bio considers its relationship with its employees to be good. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is a Delaware corporation formed in February&#160;2008. Sesen Bio&#8217;s principal executive offices are located in Cambridge, Massachusetts. Sesen Bio&#8217;s website address is www.sesenbio.com. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Acquisition of Viventia</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2016, Sesen Bio entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada, the shareholders of Viventia named therein, collectively, the selling shareholders, and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada, or Clairmark, pursuant to which Sesen Bio agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders, or the Viventia Acquisition. In </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">246</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tLEPR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">connection with the closing of the Viventia Acquisition, Sesen Bio issued 4.0&#160;million shares of Sesen Bio common stock to the selling shareholders according to their pro&#160;rata share of Viventia&#8217;s then-outstanding shares of common stock, which represented approximately 19.9% of Sesen Bio voting power as of immediately prior to the issuance of such shares of common stock. Clairmark is an affiliate of Leslie L. Dan, who served on the Sesen Bio board of directors until his retirement in July&#160;2019. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Viventia Acquisition, Sesen Bio is obligated to pay to the selling shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i)&#160;a one-time milestone payment of $12.5&#160;million payable upon the first sale of Vicineum, in the United States; (ii)&#160;a one-time milestone payment of $7.0&#160;million payable upon the first sale of Vicineum in any one of certain specified European countries; (iii)&#160;a one-time milestone payment of $3.0&#160;million payable upon the first sale of Vicineum in Japan; and (iv)&#160;and quarterly earn-out payments equal to 2% of net sales of Vicineum during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i)&#160;December&#160;31, 2033, and (ii)&#160;fifteen&#160;years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Share Purchase Agreement, Sesen Bio, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven&#160;years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize Vicineum in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio makes available free of charge annual reports on Form 10-K, quarterly reports on Form&#160;10-Q, current reports on Form 8-K and amendments to those reports, as soon as reasonably practicable after they are electronically filed or furnished to the SEC, on Sesen Bio&#8217;s website at www.sesenbio.com or by contacting Sesen Bio at (617) 444-8850. The SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov. The inclusion of any website address in this proxy statement/prospectus is an inactive textual reference only, and information contained on or accessible through these websites is not a part of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Description of Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s corporate headquarters are currently located in Cambridge, Massachusetts and consists of approximately 150 square feet, where Sesen Bio occupies office space under a lease that was executed in October&#160;2016. The initial term of the lease expired in July&#160;2017, with the lease now continuing on a month-to-month basis unless terminated by either party with the requisite notice. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio also has office space in Philadelphia, Pennsylvania, where Sesen Bio occupies office space under a lease executed in December&#160;2017. The initial term of the lease expired in May&#160;2018, which now continues on a month-to-month basis unless terminated by either party with the requisite notice. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Proceedings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;19, 2021, August&#160;31, 2021, and October&#160;7,2021, three substantially identical securities class action lawsuits captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Bibb v. Sesen Bio, Inc., et. al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:21-cv-07025, </font><font style="font-style:italic;letter-spacing:0.2pt;">Cizek v. Sesen Bio, Inc., et.&#160;al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:21-cv-07309 and </font><font style="font-style:italic;letter-spacing:0.2pt;">Markman v. Sesen Bio, Inc. et al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:21-cv-08308 were filed against Sesen Bio and certain of its officers in the U.S. District Court for the Southern District of New York. The three complaints alleged violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder based on statements made by Sesen Bio concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October&#160;29, 2021, the court consolidated the three cases under the caption </font><font style="font-style:italic;letter-spacing:0.2pt;">In re Sesen Bio, Inc. Securities Litigation</font><font style="letter-spacing:0.2pt;">, Master File No. 1:21-cv-07025-AKH, and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj as the Lead Plaintiffs under the Private </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">247</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:128pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Securities Litigation Reform Act. On November&#160;1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. On November&#160;24, 2021, defendants filed a motion to transfer venue to the U.S. District Court for the District of Massachusetts. That motion was fully briefed as of December&#160;13, 2021, but the court has not ruled on that motion. On December&#160;6, 2021, the Lead Plaintiffs filed the Amended Complaint. The Amended Complaint alleges the same violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March&#160;7, 2022, and that motion was fully briefed on May&#160;6, 2022. On June&#160;3, 2022, before the court ruled on the motion to dismiss, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. On June&#160;30, 2022 and July&#160;6, 2022, Sesen Bio and the plaintiffs engaged in mediation sessions in an attempt to resolve the Securities Litigation and continued to discuss a potential settlement over the following weeks. On July&#160;19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, Sesen Bio and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to Sesen Bio and the individual defendants. On August&#160;3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which was filed with the court on August&#160;17, 2022. The Stipulation and Agreement of Settlement related to the Securities Litigation provides for a settlement payment of $21.0&#160;million to the class and the dismissal of all claims against Sesen Bio and the other defendants. The settlement payment is being funded by Sesen Bio and its insurance carriers. On September&#160;1, 2022, the U.S. District Court for the Southern District of New York issued an order denying the motions to appoint a different lead plaintiff. On September&#160;28, 2022, the court issued an order granting preliminary approval of the proposed settlement of the Securities Litigation. The court has set a final settlement approval hearing for January&#160;23, 2023 at 10:00&#160;a.m. Eastern Time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On November 28, 2022, a purported Sesen Bio stockholder filed a complaint in the U.S. District Court for the Southern District of New York against Sesen Bio and the Sesen Bio board of directors, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Keller v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 1:22-cv-10085 (S.D.N.Y.). The Original Keller Complaint asserts claims against Sesen Bio and the Sesen Bio board of directors under Section 14(a) of the Exchange Act and Rule&#160;14a-9 promulgated thereunder for allegedly false and misleading statements in this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the merger and an award for plaintiffs&#8217; fees and costs. On December 20, 2022, the purported stockholder voluntarily dismissed his complaint and on December&#160;21, 2022, filed a new complaint as a putative class action in the Court of Chancery for the State of Delaware, captioned </font><font style="font-style:italic;letter-spacing:0.2pt;">Keller v. Sesen Bio, Inc., et al.</font><font style="letter-spacing:0.2pt;">, Case No. 2022-1186 (Del. Ch. Dec. 21, 2022). Along with the complaint, the purported stockholder filed motions for expedited proceedings and for a preliminary injunction to enjoin the Sesen Bio special meeting. The New Keller Complaint and associated filings contain substantially the same assertions as the Original Keller Complaint and the Demand Letters. Sesen Bio believes that the claims asserted in the Demand Letters, the Section&#160;220 Demand and the New Keller Complaint are without merit. At this time, no assessment can be made as to the likely outcome or whether the outcome will be material to Sesen Bio.</font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">248</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCABU">&#8203;</a><a name="tOVE1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is a clinical stage cell therapy company focused on utilizing Carisma&#8217;s proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. Carisma has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. Macrophages and monocytes are part of the innate immune system and can detect and degrade harmful substances through a process referred to as phagocytosis, in which the harmful substance is engulfed and destroyed and in turn leads to the activation of a broad immune response. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To harness the powerful immunologic functions of macrophages against cancer, Carisma has developed a proprietary Chimeric Antigen Receptor Macrophage, or CAR-M, platform technology. Chimeric antigen receptors, or CARs, are synthetically engineered receptors that are designed to bestow immune cells with the ability to target specific antigens on the surface of cancer cells. By introducing CARs into macrophage and monocyte cells, Carisma aims to redirect their potent innate immune functions against cancer. Carisma&#8217;s CAR-M platform technology incorporates proprietary tumor targeting constructs, vectors to deliver CARs to macrophages and monocytes and novel manufacturing processes. Carisma&#8217;s CAR-M therapeutics are designed to infiltrate the solid tumor microenvironment, kill cancer cells via targeted phagocytosis, and activate other immune cells, such as T-cells, to initiate a robust anti-tumor immune response. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s lead product candidate CT-0508, the first CAR-M to be evaluated in a human clinical trial, is an </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> autologous cell therapy product candidate, wherein immune cells from blood drawn from a patient are engineered outside of the body and reinfused into the same patient. CT-0508 is intended to treat solid tumors that overexpress HER2, a protein that is overexpressed on the surface of a variety of solid tumors, including breast cancer, gastric cancer, esophageal cancer, salivary gland cancer, and numerous others. Carisma has completed enrollment of the first group of patients in a Phase&#160;1 clinical trial of CT-0508, with nine patients having been successfully dosed. In November 2022, Carisma presented preliminary clinical results from the first group of patients. CT-0508 was successfully manufactured using macrophages obtained from heavily pre-treated, advanced solid tumor patients and has shown high CAR expression, viability, and purity. In addition, CT-0508 has been generally well-tolerated after infusion with no dose-limiting toxicities reported to date from the nine patients enrolled in the first group. While the results from this early clinical trial data are both preliminary and limited, Carisma believes the results indicate that CT-0508 can be detected within the tumor microenvironment, or TME, lead to remodeling and activation of the TME, and potentially induce anti-tumor adaptive immunity. Carisma anticipates providing multiple clinical data updates over the next 18&#160;months. In the combination setting, Carisma has observed the synergistic potential of CT-0508 with a PD1 blocking T-cell checkpoint inhibitor in pre-clinical models, enabling a combination trial with pembrolizumab. Carisma submitted a clinical protocol amendment to the FDA in September&#160;2022 to allow Carisma to treat patients with the co-administration of CT-0508 and pembrolizumab. The FDA has granted &#8220;Fast Track&#8221; status to CT-0508 for the treatment of patients with HER2 overexpressing solid tumors and Carisma plans to prioritize development for this indication. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Beyond CT-0508, Carisma has a broad pipeline of cell therapy assets in various stages of pre-clinical development. In addition to the development of </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> CAR-M cell therapies, Carisma is also developing </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M gene therapies, wherein immune cells are directly engineered within the patient&#8217;s body. To advance its </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M therapeutics, Carisma established a strategic collaboration with ModernaTX, Inc., or Moderna, focused on the development and potential commercialization of up to 12 product candidates, of which four have already been nominated. In collaboration with Moderna, Carisma has established an approach that uses Moderna&#8217;s myeloid cell specific lipid nanoparticle/mRNA, or LNP/mRNA, technology, together with Carisma&#8217;s CAR-M platform technology, to create novel </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> oncology gene therapies. Carisma believes this approach has the potential to enable a series of off-the-shelf product candidates to target a patient&#8217;s own myeloid cells against cancer cells directly within their body. As part of the agreement with Moderna, Carisma received a $45.0&#160;million up-front cash payment and an investment by Moderna in the form of a $35.0&#160;million convertible note, in addition to future research funding and the opportunity for milestone payments and royalties. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">249</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:125.43pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Through its robust internal discovery engine, Carisma is building upon its platform to enhance and expand the utility of macrophage cell and gene therapies, leading to the creation of multiple product candidates with the potential to treat cancer and other serious diseases. By replacing the targeting domain of the CAR, Carisma can reprogram the target antigen specificity of the CAR-M cell product and develop candidates against a range of cancer indications and therapeutic areas beyond oncology. As a result, Carisma believes the flexibility of its macrophage and monocyte cell engineering platform will allow Carisma to generate new product candidates suitable for clinical development in a cost-efficient manner to expand its pipeline. In addition to acting as a first line of defense in the innate immune system, macrophages are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses, and tissue regeneration. Using its macrophage and monocyte </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> engineering platform, Carisma is pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology, including liver fibrosis, neurodegeneration, and other immunologic and inflammatory diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">By investing in early platform research and accessing key enabling technologies, Carisma is enhancing and expanding its platform capabilities and reinforcing its leadership position in the engineered macrophage field. Carisma has developed proprietary CAR-M platform enhancements directed toward key product parameters that are important for efficacy, safety, and patient access to its CAR-M therapies. Carisma plans to apply these technology enhancements to future CAR-M product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s Pipeline Programs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Using its proprietary CAR-M platform technology, Carisma is developing a broad pipeline of product candidates, with a strong initial focus in oncology. Carisma&#8217;s </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> autologous CAR-M product candidates are summarized in the table below. </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d8-tbl_pipelin4c.jpg" alt="[MISSING IMAGE: tm2227887d8-tbl_pipelin4c.jpg]" height="244" width="578" >
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">250</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is also advancing discovery-stage candidates across a range of therapeutic areas, as summarized in the following table. </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2227887d8-tbl_oncolog4c.jpg" alt="[MISSING IMAGE: tm2227887d8-tbl_oncolog4c.jpg]" height="347" width="578" >
        </div>
        <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s lead product candidate, CT-0508, is an </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> autologous cell therapy product candidate intended to treat solid tumors that overexpress HER2, a protein that is overexpressed on the surface of a variety of solid tumors including breast cancer, gastric cancer, esophageal cancer, salivary gland cancer and numerous others. CT-0508 is produced by engineering a patient&#8217;s own monocyte-derived macrophages from blood drawn from the patient with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2 CAR. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma has completed enrollment of the first group of patients in a Phase&#160;1 clinical trial, with nine patients successfully dosed. The second group is currently open for enrollment, with nine additional patients to be dosed. In November 2022, Carisma presented preliminary clinical results from the first group of patients. CT-0508 was successfully manufactured using macrophages obtained from heavily pre-treated, advanced solid tumor patients and has shown high CAR expression, viability, and purity. In addition, CT-0508 has been generally well-tolerated after infusion with no dose-limiting toxicities reported to date from the nine patients enrolled in the first group. While the results from this early clinical trial data are both preliminary and limited, Carisma believes the results indicate that CT-0508 can be detected within the TME, lead to remodeling and activation of the TME, and potentially induce anti-tumor adaptive immunity. Carisma anticipates providing multiple clinical data updates over the next 18&#160;months. In the combination setting, Carisma has observed the synergistic potential of CT-0508 with a PD1 blocking T-cell checkpoint inhibitor in pre-clinical models, enabling a combination trial with pembrolizumab. Carisma submitted a clinical protocol amendment to the FDA in September&#160;2022 to allow it to treat patients with the co-administration of CT-0508 and pembrolizumab. The FDA has granted &#8220;Fast Track&#8221; status to CT-0508 for the treatment of patients with HER2 overexpressing solid tumors and Carisma plans to prioritize development for this indication. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is currently in the pre-clinical stage for another product candidate, CT-0525, which is also intended to treat solid tumors that overexpress HER2. By leveraging its discovery engine and preliminary clinical data from its Phase&#160;1 clinical trial of CT-0508, Carisma is building upon its CAR-M platform to generate next-generation therapeutics that may increase potential efficacy and patient access. Notably, Carisma has developed a novel approach to CAR-M therapy to accelerate the manufacturing process, increase the cell yield, and improve upon the potential anti-tumor effect by engineering patients&#8217; monocytes directly, without </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> differentiation into macrophages, as Carisma currently does for CT-0508. Carisma refers to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">251</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCATE">&#8203;</a><a name="tCAST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">this CAR-Monocyte approach as CAR-Mono. By increasing the cell yield, the CAR-Mono approach enables a larger potential dose, which may improve tumor control. The CAR-Mono approach reduces manufacturing time and leverages an automated, closed-system manufacturing process. CT-0525 is Carisma&#8217;s first CAR-Mono product candidate and is currently in the pre-clinical process development stage. Carisma expects to submit an IND to the FDA for CT-0525 in the third quarter of 2023 and initiate clinical development shortly thereafter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is also expanding its pipeline to include multiple tumor targets, encompassing diverse solid tumor indications with significant unmet medical needs, including the following product candidates: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CT-1119:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;CT-1119 is a mesothelin targeted CAR-M that Carisma plans to evaluate in patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. Carisma has identified a lead construct for CT-1119 and expects to submit an IND to the FDA in 2025. In November 2022, Carisma presented preliminary and limited data demonstrating that CT-1119 can mediate phagocytosis, tumor cell killing, and pro-inflammatory cytokine release and control tumor growth in pre-clinical lung cancer models. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CT-0729:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;CT-0729 is a prostate-specific membrane antigen, or PSMA, targeted CAR-M that Carisma plans to evaluate in patients with advanced, PSMA positive metastatic castrate resistant prostate cancer. CT-0729 is in the discovery stage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s current CAR-M cell therapy pipeline is informing the discovery and pre-clinical development of off-the-shelf engineered macrophage therapeutics. Carisma is developing </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> reprogrammed LNP/mRNA CAR-M therapies for cancer through its collaboration with Moderna. In addition, Carisma is establishing an </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> allogeneic, induced pluripotent stem cell, or iPSC, derived macrophage and monocyte platform with the potential to develop iPSC-derived CAR-M and other macrophage therapies for indications in oncology and beyond, including indications such as liver fibrosis, neurodegeneration and auto-immunity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s Team</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma was founded in 2016 by leading cell therapy experts from the University of Pennsylvania. Dr.&#160;Saar Gill is a co-inventor of the CAR-M technology and a co-founder of Carisma. He is an Associate Professor of Medicine in the Division of Hematology-Oncology at the University of Pennsylvania. Dr.&#160;Michael Klichinsky, Pharm.D., Ph.D., is a co-inventor of the CAR-M technology, a scientific co-founder of Carisma, and Carisma&#8217;s current Chief Scientific Officer. Dr.&#160;Carl June, a co-inventor of the CAR-M technology, is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania. He also is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, and Scientific Advisor to Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s executive team has decades of experience in business operations, discovery, development, and manufacturing of advanced therapeutics for the treatment of serious diseases. Steven Kelly, Carisma&#8217;s Chief Executive Officer, brings over 35&#160;years of experience in the biopharmaceutical industry at all phases of the business across multiple therapeutic categories. Carisma&#8217;s Chief Technology and Development Officer, Dr.&#160;Daniel Cushing, Ph.D., brings over 30&#160;years of experience in the biopharmaceutical industry and is responsible for product development at Carisma. Richard Morris, Carisma&#8217;s Chief Financial Officer, has more than 25&#160;years of experience in building and growing successful biotechnology organizations, with a focus on capital fundraising (including initial public offerings), financial strategy and operations execution, and business development efforts. Carisma&#8217;s Chief Business Officer, Tom Wilton, has over 25&#160;years of biopharmaceutical industry experience, including corporate strategy, business development, research and development operations, and marketing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s vision is to become a leading cell therapy company, developing and ultimately commercializing macrophage-based cell therapies that positively transform the treatment of cancer and other serious diseases. To achieve its vision, Carisma has developed its macrophage engineering platform, a pipeline of assets spanning numerous indications with unmet medical needs, a robust discovery engine, broad CAR-M </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">252</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">intellectual property, robust manufacturing capabilities, and a dedicated executive team with extensive experience in cell therapy and drug development, manufacturing and commercialization and leading scientific expertise in the field. The key components of Carisma&#8217;s strategy are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Advance Carisma&#8217;s lead product candidate, CT-0508, through clinical development for the treatment of HER2 overexpressing solid tumors.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;CT-0508 is an </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> gene-modified autologous CAR-M cell therapy product candidate intended to treat solid tumors that overexpress HER2. Carisma has completed enrollment of the first group of patients in a Phase&#160;1 clinical trial, with nine patients successfully dosed. The second group is currently open for enrollment, with nine additional patients to be dosed. In November 2022, Carisma presented preliminary clinical results from the first group of patients. CT-0508 was successfully manufactured using macrophages obtained from heavily pre-treated, advanced solid tumor patients and has shown high CAR expression, viability, and purity. In addition, CT-0508 has been generally well-tolerated after infusion with no dose-limiting toxicities reported to date from the nine patients enrolled in the first group. While the results from this early clinical trial data are both preliminary and limited, Carisma believes the results indicate that CT-0508 can be detected within the TME, lead to remodeling and activation of the TME, and potentially induce anti-tumor adaptive immunity. Additionally, the FDA granted &#8220;Fast Track&#8221; status to CT-0508 for the treatment of patients with HER2 overexpressing solid tumors and Carisma plans to prioritize development for this indication. Carisma also plans to initiate multiple sub-studies to expand the utility of CT-0508, including combination therapy with a PD1 blocking T-cell checkpoint inhibitor in pre-clinical models, enabling a combination trial with pembrolizumab. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Invest in Carisma&#8217;s CAR-Mono platform technology to further extend its leadership position in macrophage and monocyte based cellular therapy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As part of its ongoing platform enhancement effort, Carisma has developed its CAR-Mono approach, which significantly reduces manufacturing time and leverages an automated, closed-system manufacturing process. Carisma is currently in the pre-clinical process development stage for CT-0525, Carisma&#8217;s first anti-HER2 CAR-Mono product candidate, and expects to submit an IND in the third quarter of 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Advance Carisma&#8217;s pre-clinical CAR-M oncology pipeline candidates to clinical development stage.</font><font style="letter-spacing:0.2pt;"> Beyond its initial HER2 target, Carisma is expanding its pipeline into multiple tumor targets and constructs. CT-1119 is a mesothelin targeted CAR-M that Carisma plans to evaluate in patients with advanced mesothelin-positive solid tumors, with an IND expected to be submitted in 2025. In November 2022, Carisma presented preliminary and limited data demonstrating that CT-1119 can mediate phagocytosis, tumor cell killing, and pro-inflammatory cytokine release and control tumor growth in pre-clinical lung cancer models. Additionally, CT-0729 is a PSMA targeted CAR-M intended for use against metastatic castrate resistant prostate cancer and is currently in the discovery stage. Carisma is also developing product candidates targeting other cancer antigens. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Build next-generation technologies to expand the scope and capabilities of Carisma&#8217;s platform.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Beyond its CAR-M and CAR-Mono technologies, Carisma is pursuing multiple platform enhancements for its CAR constructs, editing technologies and therapeutic delivery vehicles. Further, Carisma is actively developing a gene edited iPSC-derived macrophage platform and leveraging delivery technologies for its mRNA-based </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M platform for oncology. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Harness the potential of Carisma&#8217;s platform to develop novel product candidates to address therapeutic areas beyond oncology.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;While Carisma has initially been an oncology focused company, Carisma believes the breadth of the myeloid engineering platform enables significant opportunities outside of oncology. Based on early data related to Carisma&#8217;s novel therapeutic approach, Carisma believes its platform has significant potential across multiple therapeutic areas, including fibrosis, neurodegeneration, autoimmunity, and chronic inflammation, which are currently in the discovery stage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Selectively enter into strategic partnerships and collaborations to maximize the potential of Carisma&#8217;s platform.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Given the breadth of opportunities enabled by Carisma&#8217;s platform, Carisma may opportunistically enter into strategic collaborations intended to advance and accelerate its development programs, expand into new therapeutic areas and enhance the capabilities of its platform. Carisma currently has a broad strategic collaboration with Moderna focused on the development of </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M therapeutics for up to 12 oncology targets, of which four have already been nominated. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">253</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tBAC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Background</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cellular Immunotherapy</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cellular immunotherapy is a type of immuno-oncology approach whereby human immune cells are utilized to recognize and destroy cancer cells in a targeted manner. To date, cellular immunotherapy has focused on the transfer of T-cells or natural killer, or NK, cells. For example, T-cells with intrinsic tumor reactivity, such as tumor infiltrating lymphocytes, have been utilized, as well as T-cells genetically engineered with tumor targeting T-cell receptors, or TCRs, or CARs, have been tested in a variety of hematologic malignancies and solid tumors. The only FDA approved genetically modified cellular immunotherapies for cancer are CAR T-cell therapies for B cell hematologic malignancies expressing CD19 or multiple myeloma expressing B-cell maturation antigen, or BCMA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Despite the incredible promise shown by cell therapies for hematologic malignancies, the success has not been replicated in the solid tumor setting. There are numerous challenges impacting T and NK cell immunotherapy in patients with solid tumors, such as the inability of cells to appropriately access the tumor microenvironment, overcome immunosuppression in the tumor microenvironment and overcome target antigen heterogeneity. Importantly, there have been challenges in targeting solid tumors with CAR T-cells without inducing toxicities against normal tissues or inducing severe systemic cytokine release syndrome, or CRS. To date, no CAR therapies for the treatment of solid tumors have received marketing approval. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Macrophages and Monocytes and the Tumor Microenvironment</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Macrophages play a vital role in the innate immune system, the body&#8217;s first line of defense against foreign pathogens. Macrophages are highly plastic innate cells that mediate a multitude of protective and homeostatic functions, including elimination of pathogens through phagocytosis, clearance of cellular debris, induction or regulation of inflammation, antigen presentation, and tissue remodeling. Macrophages can arise from circulating bone marrow-derived monocytes or embryonic precursors and are found in all tissues in the human body. Depending on the environmental cues, macrophages can actively adopt distinct activation states, or phenotypes, to either initiate or terminate immune responses. While macrophage activation states are complex, they can be categorized into two general subsets: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Classically activated (M1):</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;M1 macrophages are pro-inflammatory and are associated with anti-tumoral functions. They initiate or enhance immune responses by recruiting T-cells, upregulating antigen processing machinery and co-stimulatory ligands, and secreting pro-inflammatory factors cytokines and chemokines, and ultimately promote T-cell responses. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Alternatively activated (M2):</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;M2 macrophages are immunosuppressive and are associated with pro-tumoral functions. They accelerate tumor invasion and metastasis and promote angiogenesis (or formation of new blood vessels) by secreting inhibitory cytokines and upregulating immunosuppressive cell surface molecules, and ultimately inhibit T-cell responses. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Macrophages are typically the most abundant immune cell in the TME of most cancers, where they generally adopt an M2 phenotype and are therefore associated with poor prognostic outcomes and increased intratumoral immunosuppression. For example, numerous studies have shown that patients with more M2 macrophages in their tumors have reduced responses to immune checkpoint inhibitors such as pembrolizumab. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Given the generally negative role of M2 macrophages in the TME, there have been numerous therapeutic approaches focused on inhibiting tumor associated macrophage, or TAM, infiltration or survival. Other approaches have sought to convert TAMs from an M2 to an M1 phenotype. While numerous studies have shown that TAM infiltration is typically associated with poor prognostic outcome, macrophages have been shown to have potent anti-tumor capabilities if appropriately activated and targeted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Opportunity for Engineered Macrophages in Treating Cancer</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma believes macrophage and monocyte cell therapies hold promise in addressing the limitations of other cell types and transforming the cell therapy treatment paradigm for solid tumors. The inherent biology of macrophages and monocytes offers several potential advantages that directly apply to current barriers for cell therapy efficacy in the solid tumor context. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">254</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Macrophages and monocytes are actively recruited into solid tumors, while other immune cells such as T-cells are often actively excluded. Macrophages are professional phagocytic cells capable of directly killing tumor cells through this unique mechanism. In addition to direct killing, macrophages can secrete pro-inflammatory factors that convert the immunosuppressive TME into an environment that promotes immunity. Importantly, macrophages and monocytes are professional antigen presenting cells, meaning they can directly present tumor-derived antigens to T-cells leading to anti-tumor T-cell responses, a phenomenon known as epitope spreading. Epitope spreading enables activity against tumor cells which either lack or lose expression of the initial antigen targeted by the CAR&#8201;&#8212;&#8201;a key challenge for cell therapies&#8201;&#8212;&#8201;and ultimately enables macrophages and monocytes to overcome target antigen heterogeneity within the patient&#8217;s cancer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma believes an approach which harnesses the direct effector functions of macrophages or monocytes, optimizes their activation status toward an inflammatory M1 phenotype, and redirects phagocytosis with molecular specificity would represent a major advance in cancer immunotherapy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s Novel Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CAR-M have the potential to address the key challenges involved in treating solid tumors: </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d8-fc_problem4c.jpg" alt="[MISSING IMAGE: tm2227887d8-fc_problem4c.jpg]" height="367" width="597" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">CAR-M have the ability to infiltrate solid tumors, phagocytose and destroy tumor cells directly, and present tumor-derived antigens leading to activation of the adaptive immune system. CAR-M mount anti-tumor immunity in numerous ways. First, CAR-M leverage the natural tumor-homing ability of macrophages and monocytes, the naturally most abundant immune cells in the TME, to traffic to both primary tumors and metastases, enabling engineered macrophages to act as a &#8220;Trojan horse,&#8221; tricking the tumor into recruiting engineered, anti-tumor CAR-M as if they were normal monocytes or macrophages. Once within the tumor, CAR-M directly kill antigen-expressing tumor cells through phagocytosis and secretion of cytotoxic factors. CAR-M secrete inflammatory cytokines and chemokines that promote a pro-inflammatory environment and lead to the recruitment of T-cells and other leukocytes. Finally, CAR-M serve as professional antigen-presenting cells for T-cells, inducing epitope spreading, systemic anti-tumor immunity, and immune memory against tumor antigens, expanding anti-tumor immunity to target negative tumor cells and potentially preventing antigen negative relapse. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">255</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-pht_tumor4c.jpg" alt="[MISSING IMAGE: tm2227887d1-pht_tumor4c.jpg]" height="245" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Historically, macrophages have been challenging to genetically engineer due to their inherent resistance to most commonly used genetic manipulation methods. Furthermore, controlling the activation state of macrophages has been a long-standing challenge. Carisma believes that it has overcome these challenges with its proprietary platform that efficiently engineers macrophage-based cell therapies and enables control of their activation state. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s proprietary platform enables the therapeutic use of engineered macrophages and monocytes for the treatment of cancer and other serious diseases and disorders. In its first application, solid tumors that overexpress HER2, the CAR-M platform is designed to identify and eradicate HER2 overexpressing tumor cells. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Currently, CAR-M are an individualized therapy that begin with the isolation of monocytes, the pre-cursor cell to macrophages, from blood drawn from a patient through a process called apheresis. The cells are purified, cultured, differentiated, and engineered with a CAR which bestows the macrophage with the ability to identify and eradicate cancer cells. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To enable its proprietary CAR-M therapy, Carisma had to overcome several key technical challenges, which are summarized by its platform capabilities: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Gene Delivery</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Carisma has identified Ad5f35, a chimeric adenoviral vector, as a highly efficient vector for introducing genes such as CARs into primary human macrophages and monocytes. Carisma has further developed additional proprietary technologies for </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> macrophage engineering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Activation State</font><font style="font-weight:bold;letter-spacing:-0.2pt;">:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Carisma demonstrated that Ad5f35 transduction leads to M1 polarization of human macrophages and monocytes and renders them resistant to conversion to M2 by immunosuppressive environments. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Tumor targeting</font><font style="font-weight:bold;letter-spacing:-0.2pt;">:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Carisma demonstrated that macrophage function can be harnessed against tumors in a targeted fashion via CARs. Carisma&#8217;s CARs enable antigen specific activation of macrophages and monocytes, antigen specific cancer cell phagocytosis and killing, and antigen specific release of pro-inflammatory cytokines and chemokines. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">T-cell activation</font><font style="font-weight:bold;letter-spacing:-0.2pt;">:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;By appropriately engineering and polarizing CAR-M, Carisma has demonstrated that they are able to recruit and activate T-cells&#8201;&#8212;&#8201;a key aspect to solid tumor immunotherapy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Cell manufacturing processes</font><font style="font-weight:bold;letter-spacing:-0.2pt;">:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Carisma has developed manufacturing processes that enable the production of genetically engineered macrophages or monocytes for therapeutic use. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the case of Carisma&#8217;s lead product, CT-0508, a chimeric adenoviral vector, or Ad5f35, is used to deliver an anti-HER2 CAR which enables the macrophages to detect, phagocytose, kill, release inflammatory mediators, and initiate an immune reaction in response to HER2 overexpressing tumor cells. The resulting CAR-M, which are adenovirally transduced and locked into a pro-inflammatory M1 phenotype during the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">256</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">manufacturing process, are cryopreserved and shipped back to the patient for reinfusion. Reinfused CAR-M rapidly egress from peripheral blood and infiltrate tumor sites. Once in the tumor, CAR-M are activated by tumor-associated antigen engagement with the CAR, signaling via an intracellular signaling domain to phagocytose the tumor cell and release pro-inflammatory cytokines and chemokines that &#8220;warm up&#8221; the TME. They produce locally acting mediators that reprogram the TME, drawing in T-cells and NK cells, activating nearby antigen presenting cells, or APCs, such as dendritic cells, or DCs, and repolarizing immunosuppressive TAMs toward an M1 phenotype. In addition to direct phagocytosis of tumor cells, CAR-M present a patient&#8217;s unique array of tumor antigens to T-cells, leading to a broad adaptive immune response that has the potential to generate broad anti-tumor immunity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-clinical Data</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma evaluated its CAR-M platform in a variety of pre-clinical </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> model systems and published its foundational data in Nature Biotechnology in March&#160;2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">First, Carisma found that Ad5f35 led to the efficient transduction of human macrophages and could be utilized to produce human CAR-M. CAR-M mediated potent antigen-specific phagocytosis and tumor killing in a targeted fashion. CAR-M took on an activated M1 phenotype, expressed pro-inflammatory cytokines and chemokines, converted bystander M2 macrophages toward an M1 phenotype, recruited T-cells, and increased antigen presentation to activate T-cells. Enhanced anti-tumor T-cell responses mediated by CAR-M were noted in humanized murine models and the findings are summarized below. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Human CAR-M Anti-Tumoral Function </font><font style="font-style:italic;letter-spacing:-0.2pt;">In Vitro</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.2pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-lc_human4c.jpg" alt="[MISSING IMAGE: tm2227887d1-lc_human4c.jpg]" height="159" width="599" >
        </div>
        <div style="margin-top:9.4pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">* SKOV3 = Human HER2+ ovarian cancer cell line </font>
          <br >
          <font style="letter-spacing:0.2pt;">* UTD = Untransduced </font>
          <br >
          <font style="letter-spacing:0.2pt;">* CAR = Anti-HER2 human CAR-M </font>
          <br >
          <font style="letter-spacing:0.2pt;">* Delta</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">Z</font><font style="letter-spacing:0.2pt;"> = CAR-M with a non-signaling control CAR </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CAR-M were able to traffic to established tumors and co-localized with metastatic foci in the lung after intravenous administration without a pre-conditioning regimen. CAR-M treatment induced significant reduction in tumor burden and improved overall survival compared to mice treated with control macrophages in multiple mouse tumor models. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Transduction of macrophages with Ad5f35 led to the induction of a durable M1 phenotype. Despite the purported plasticity of macrophage phenotype, Ad5f35 transduced macrophages did not convert to M2 upon stimulation. CAR-M maintained a pro-inflammatory M1 state within the TME, while control macrophages were converted to M2. Additionally, CAR-M induced a pro-inflammatory signature in the surrounding TME. Given that solid tumors are rich in TAMs, Carisma evaluated the bidirectional interaction of CAR-M and M2 macrophages. While M2 macrophages failed to convert CAR-M from M1 to M2, CAR-M converted M2 macrophages to M1. Additionally, the presence of M2 macrophages did not impact the tumor killing capacity of CAR-M, highlighting their resistance to the immunosuppressive components of the TME. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Finally, CAR-M were shown to interact with cells of the adaptive immune system. CAR-M upregulated antigen presentation pathways and demonstrated heightened T-cell stimulation capacity as compared to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">257</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">control macrophages. Notably, CAR-M were able to present antigens to T-cells following phagocytosis. In addition, CAR-M were able to directly recruit various subtypes of T-cells. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To further its understanding of CAR-M, Carisma sought to model their function in fully immunocompetent mouse models which have an intact TME and immune system, enabling recapitulation of the complex immunological environment in human cancer patients. Toward that goal, Carisma developed a murine surrogate CAR-M to demonstrate the mechanism of action of CAR-M </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> in mice which have a fully intact immune system. First, Carisma validated comparability between human and murine CAR-M. Carisma demonstrated that the same vector utilized in its clinical pipeline, Ad5f35, could be used to engineer primary murine macrophages, and confirmed that T-cells were viable, expressed CAR, and were similarly polarized to an M1 phenotype. Functional studies showed CAR-M mediated tumor killing of target cancer cells and enhanced the </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> function of T-cells. Furthermore, murine CAR-M released pro-inflammatory cytokines similarly to human CAR-M. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pre-clinical immunocompetent solid tumor models were established via subcutaneous, or SC, injection and engraftment of the murine colorectal cancer cell line, or CT26, engineered to express human HER2. In this model, intratumoral, or IT, CAR-M monotherapy significantly reduced tumor growth and prolonged overall survival compared to untransduced macrophages (macrophages not expressing a CAR). By rechallenging complete responders several&#160;months post tumor clearance with the same tumor cells lacking HER2 expression, Carisma was able to demonstrate that CAR-M therapy leads to epitope spreading and immune memory which confers protection against antigen-negative relapse. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAR-M Control Tumor Progression, Improve Survival and Induce Long-Term Protection against Antigen-negative Relapse</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.6pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_contrl4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_contrl4c.jpg]" height="249" width="593" >
        </div>
        <div style="margin-top:8.21pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">* UTD-M = Untransduced macrophage </font>
        </div>
        <div style="margin-top:10.1pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(A)</font>
          <br >
        </div>
        <div style=" margin-top:7.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">CT26-HER2+ tumors were implanted subcutaneously in immunocompetent syngeneic mice. After 15&#160;days, mice were treated with intratumoral CAR-M, UTD-M, or left untreated. CAR-M significantly reduced tumor progression. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(B)</font>
          <br >
        </div>
        <div style=" margin-top:3.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">CAR-M significantly increased long term survival compared to control groups. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(C)</font>
          <br >
        </div>
        <div style=" margin-top:3.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mice achieving complete responses, or CR, post CAR-M therapy were re-challenged with HER2-negative CT26-Wt tumors to model antigen negative relapse. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(D)</font>
          <br >
        </div>
        <div style=" margin-top:3.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Na&#239;ve mice succumbed to disease within 35&#160;days, while 100% of the mice from the CAR-M treatment group survived, indicating long-term tumor protection against antigen negative relapse. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(E)</font>
          <br >
        </div>
        <div style=" margin-top:3.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">T-cell depletion reversed CAR-M induced protection against antigen negative relapse, indicating that CAR-M treatment led to epitope spreading and anti-tumor T-cell memory. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Analysis of the tumor microenvironment of mice receiving CAR-M therapy demonstrated the ability of Carisma&#8217;s therapy to recruit additional immune cells, including T-cells, into the tumor. CAR-M led to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">258</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:50.58pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">immune activation in the TME associated with T-cell expansion, activation, and modulation of the overall T-cell repertoire of tumor infiltrating lymphocytes&#8201;&#8212;&#8201;suggesting the induction of a broad anti-tumor immune response. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAR-M Reprogram the TME and Prime T-cells</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_reprogra4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_reprogra4c.jpg]" height="397" width="547" >
        </div>
        <div style="margin-top:7.19pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(A)</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Immunohistochemistry assessment showed that CAR-M treatment increased tumor CD8+ T-cell infiltration in the CT26-HER2+ model indicating activation of the TME. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(B)</font>
          <br >
        </div>
        <div style=" margin-top:5.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Flow cytometric analysis showed increased tumor infiltration of T-cells, NK cells, activated CD86+ DCs and tumor associated antigen specific CD8 T-cells (gp70 Tet+) in CAR-M treated mice, suggesting epitope spreading. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Combined, these results demonstrate that CAR-M have the potential to overcome some of the key challenges cell therapies encounter in the solid tumor setting and represent a novel immunotherapeutic platform that can be broadly applied to diverse tumor antigen targets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is applying its CAR-M platform to a broad pipeline of product candidates, and Carisma intends to build a fully integrated immunotherapy company spanning autologous cell therapy, allogeneic cell therapy, and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> macrophage gene therapy. Carisma currently owns all rights to its product candidates and programs outside of its Moderna collaboration, which is limited to direct </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> reprogrammed CAR-M in the field of oncology. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">259</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Macrophage and Monocyte Engineering Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-pht_macrop4clr.jpg" alt="[MISSING IMAGE: tm2227887d1-pht_macrop4clr.jpg]" height="332" width="608" >
        </div>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Gene Delivery</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the core of Carisma&#8217;s platform are its proprietary viral and non-viral approaches for delivering different payloads into macrophages and monocytes and engineering them into a variety of phenotypes depending on the disease which they are intended to treat. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For its initial solid tumor programs, Carisma&#8217;s adenoviral vector enables Carisma to generate an abundant supply of CAR-M cells and engineer the cells to be locked into an M1 phenotype. Carisma selected Ad5f35 after testing commonly utilized viral and non-viral approaches and demonstrating Ad5f35&#8217;s high efficiency in transducing primary human monocytes and macrophages. Ad5f35 can transduce macrophages with high efficiency, viability and reproducibility amongst donors. In addition to being highly efficient, transduction with Ad5f35 polarizes and locks macrophages into an M1 phenotype. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to Ad5f35, Carisma&#8217;s platform includes two other proprietary methods for delivering genes into macrophages. The first is a modified lentiviral vector, or Vpx-LV, which carries viral protein X. Vpx-LV depletes SAMHD1 and permits lentiviral transduction of primary human monocytes, macrophages, and dendritic cells. Vpx-LV was developed by Dr.&#160;Nathaniel Landau at New York University, and Carisma holds a global exclusive license to develop this vector. Unlike Ad5f35, which induces a potent M1 phenotype upon transduction, Vpx-LV has minimal impact on macrophage phenotype and can be utilized as a flexible tool to generate M0, M1, or M2 polarized myeloid cell therapies with durable gene expression. Additionally, Carisma has developed a proprietary non-viral mRNA-based approach to transiently engineered macrophage and a companion method to induce a durable pro-inflammatory M1 phenotype. Carisma has successfully generated M1-primed non-viral CAR-M using a research manufacturing process consisting of mRNA transfection to deliver the CAR transgene followed by IFN&beta; priming to polarize the cells to an M1 anti-tumoral phenotype. Non-viral CAR-M demonstrated high viability, high CAR expression, M1 polarization and anti-tumoral function </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> similar to Ad5f35 engineered CAR-M. Additionally, in partnership with Moderna, Carisma is developing a myeloid tropic LNP/mRNA platform to program CAR-M directly </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Approach to Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s proprietary technology and engineering capabilities enabled it to pioneer the CAR-M field and conduct the first in human CAR-M clinical trial, establishing its leading position in the engineered </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">260</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">macrophage space. Carisma&#8217;s goal is to advance </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> autologous cell therapies and off-the-shelf therapies including allogeneic cell therapies and direct </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> reprogramming approaches in oncology and other indications: </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Expansion: Building Upon the Learnings of Autologous Cell Therapy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.2pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-tbl_exvivo4c.jpg" alt="[MISSING IMAGE: tm2227887d1-tbl_exvivo4c.jpg]" height="255" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:13.39pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While the first iteration of its platform is the CAR macrophage, Carisma has expanded its capabilities to include multiple myeloid cell types (monocytes, macrophages, and dendritic cells), multiple gene delivery modalities (Ad5f35, Vpx-LV, and mRNA), various phenotypes (M1, M2, and subtypes thereof), and a broad variety of payloads including CARs, immune ligands, secreted or tethered cytokines, transcription factors, and other genes that enhance efficacy. Importantly, Carisma has expanded its platform to enable </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> engineering of myeloid cells directly within the patient&#8217;s body. Additionally, Carisma has established a robust process to edit the genome of human myeloid cells by utilizing tools such as CRISPR/Cas9, enabling gene edited macrophages with inhibitory pathways such as SIRP&alpha; genetically removed from the cell product. Carisma&#8217;s engineered macrophage platform enables fine tuning the activation state of the engineered macrophage or monocyte. Finally, Carisma has established a novel Engineered Myeloid Microenvironment Converter, or EM-C, platform that utilizes proprietary synthetic cytokine switch receptors to generate engineered macrophages that respond to M2 cytokines with M1 responses (for oncology applications) or to generate engineered macrophages that respond to M1 cytokines with M2 responses, for auto-immune or chronic inflammatory diseases. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma&#8217;s Pipeline of Product Candidates and Discovery Programs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Using its proprietary CAR-M platform, Carisma is developing a broad pipeline of product candidates, with an initial focus in oncology. </font>
        </div>
        <div style="position:relative;margin-top:10.1pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-tbl_pipelin4c.jpg" alt="[MISSING IMAGE: tm2227887d4-tbl_pipelin4c.jpg]" height="203" width="466" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">261</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lead Product Candidate: CT-0508</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CT-0508 is a cell product comprised of autologous, peripheral blood monocyte-derived, pro inflammatory macrophages, transduced with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2 CAR. The anti-HER2 CAR is a first-generation CAR composed of a fully human single-chain variable fragment, or scFv, derived from the monoclonal antibody trastuzumab, which is specific for human HER2. The anti-HER2 scFv is fused to a CAR backbone containing a cluster of differentiation CD8 hinge, CD8 transmembrane domain, and a CD3&#950; intracellular domain. The CAR is cloned into an adenoviral vector backbone and transduced into monocyte-derived macrophages. Based on the pre-clinical data generated to date, CT-0508 CAR-M are able to specifically recognize HER2 overexpressing tumor cells, which triggers both direct killing of tumor cells and phagocytosis. Additionally, CAR engagement by HER2 on tumor cells results in the secretion of a broad array of pro-inflammatory cytokines and chemokines, which contribute to the recruitment and activation of additional immune cells to the TME, including effector T-cells and other antigen presenting cells. CT-0508 CAR-M are antigen presenting cells, and after phagocytosing tumor cells they process tumor-derived antigens and present them to T-cells, leading to T-cell immunity against tumor antigens. This additional activation of the adaptive immune system amplifies anti-tumor immune response and can lead to long term immune memory not only against HER2, the primary target, but other tumor specific neoantigens as well. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Phase&#160;1 clinical trial of CT-0508 is currently ongoing. As of September&#160;1, 2022, five clinical sites were open for screening and enrollment: (i)&#160;the University of Pennsylvania Abramson Cancer Center, (ii)&#160;the University of North Carolina Lineberger Comprehensive Cancer Center, (iii)&#160;the City of Hope National Medical Center, (iv)&#160;the MD Anderson Cancer Center, and (v)&#160;the Sarah Cannon Cancer Research Institute. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November 2022, Carisma presented preliminary clinical results from the first group of patients. CT-0508 was successfully manufactured using macrophages obtained from heavily pre-treated, advanced solid tumor patients and has shown high CAR expression, viability, and purity. In addition, CT-0508 has been generally well-tolerated after infusion with no dose-limiting toxicities reported to date from the nine patients enrolled in the first group. While the results from this early clinical trial data are both preliminary and limited, Carisma believes the results indicate that CT-0508 can be detected within the TME, lead to remodeling and activation of the TME, and potentially induce anti-tumor adaptive immunity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA has granted &#8220;Fast Track&#8221; status to CT-0508 for the treatment of patients with HER2 overexpressing solid tumors. The components of CT-0508 cells are shown below: </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Key Components of First-Generation CAR Construct</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.4pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-pht_key4c.jpg" alt="[MISSING IMAGE: tm2227887d1-pht_key4c.jpg]" height="137" width="277" >
        </div>
        <div style="text-indent:20pt; margin-top:13.79pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Figure Legend: CT-0508 is an autologous monocyte derived macrophage cell product engineered with the adenoviral vector Ad5f35 to express an anti-HER2 CAR. The CAR is comprised of a single chain variable fragment derived from a humanized anti-HER2 antibody which provides specificity against the target antigen. The scFv is linked to a hinge domain derived from the human CD8 protein, which enables extension and flexibility from the cell membrane surface. The hinge is linked to a CD8 transmembrane, or TM, domain which spans the cell membrane, linking the extracellular portion of the CAR to the intracellular portion of the CAR, which is comprised of CD3&#950;. CD3&#950; signaling is activated when the CAR binds to the target antigen, leading to macrophage activation, phagocytosis, tumor cell killing, and release of pro-inflammatory factors such as cytokines and chemokines. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">262</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0508 Therapy for HER2+ Solid Tumors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While therapies targeting solid tumors that overexpress HER2 have led to improved survival in breast and gastric or gastro-esophageal junction cancers, there remains an unmet need in patients with advanced HER2 positive, or HER2+, cancers and HER2 expressing cancers, including metastatic lung, ovarian, colon, bladder, and other cancers for which there are no HER2 targeted agents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Approximately 20% of breast cancers overexpress HER2, a protein that is overexpressed on the surface of a variety of solid tumors. In addition to breast, gastric, and gastroesophageal junction cancers, HER2 is also overexpressed in a number of solid tumor indications including but not limited to bladder cancer, ovarian cancer, lung cancer and colon cancer. </font>
        </div>
        <table style="width:376pt;margin-left:40pt;margin-top:9.99999999999999pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-left:0.75pt solid #000000; border-right:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.5pt 0pt 2.25pt 0pt; width:0pt;" colspan="5">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">HER2 Positivity Frequencies Across Tumor Types </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">Tumor type </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">HER2 positivity (%) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Bladder cancer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8&#8201;&#8211;&#8201;70 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Breast cancer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">11.0&#8201;&#8211;&#8201;25.0 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Cervical cancer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2.8&#8201;&#8211;&#8201;3.9 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Colorectal cancer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1.6&#8201;&#8211;&#8201;5.0 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Esophageal cancer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">12.0&#8201;&#8211;&#8201;14.0 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Extrahepatic Cholangiocarcinoma </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6.3&#8201;&#8211;&#8201;9.0 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Gallbladder cancer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">9.8&#8201;&#8211;&#8201;12.8 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Gastric adenocarcinoma </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">7.0&#8201;&#8211;&#8201;34.0 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Ovarian cancer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">26 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Salivary duct carcinoma </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">30&#8201;&#8211;&#8201;40 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Salivary mucoepidermoid carcinomas </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">17.6 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Testicular cancer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2.4 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Uterine cancer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:179.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.0</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.29pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0508 Clinical Study Design&#8201;&#8212;&#8201;Study 101</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ongoing Phase&#160;1 clinical trial of CT-0508 is a single-arm, open-label study of systemic intravenous administration of CT-0508. This study is intended to evaluate safety, tolerability, cell trafficking, cell-manufacturing feasibility, and preliminary evidence of efficacy in approximately 18 subjects with locally advanced or metastatic solid tumors overexpressing HER2 who have failed available therapies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A summary of the clinical trial design, dosing regimen, sample collection regimen, and primary and secondary objectives are shown below: </font>
        </div>
        <div style="position:relative;margin-top:10.2pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-org_clinic4c.jpg" alt="[MISSING IMAGE: tm2227887d1-org_clinic4c.jpg]" height="232" width="579" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">263</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Filgrastim, or recombinant G-CSF, is administered to patients five days prior to apheresis to mobilize monocytes into the peripheral blood, increasing the available circulating monocyte count prior to collection by apheresis. The CT-0508 cell product is then prepared, cryopreserved, and released following quality control testing. The first three participants in the study were hospitalized for eight days after the first infusion of CT-0508 (Day 1 to Day 8) as part of the pre-determined study design. There is no preparative chemotherapy prior to the cell product infusion. The first group of nine patients have been treated with an intra-participant dose escalation regimen consisting of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Day 1:</font><font style="letter-spacing:0.2pt;"> Up to 0.5 &#215; 10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">9</font><font style="letter-spacing:0.2pt;"> cells; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Day 3:</font><font style="letter-spacing:0.2pt;"> Up to 1.5 &#215; 10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">9</font><font style="letter-spacing:0.2pt;"> cells; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Day 5:</font><font style="letter-spacing:0.2pt;"> Up to 3.0 &#215; 10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">9</font><font style="letter-spacing:0.2pt;"> cells. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">AE reporting begins at the start of mobilization and continues until any toxicities resolve or are deemed irreversible. Participants are continually reassessed for evidence of acute and/or cumulative toxicity. Approximately nine participants in the second group of patients will receive up to 5.0 &#215; 10</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">9</font><font style="letter-spacing:0.2pt;"> total manufactured CT-0508 cells in a single infusion on Day 1. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">HER2 has several advantages as a target antigen for CAR-M. In addition to being expressed in a variety of solid tumor types with significant unmet medical needs, HER2 is not shed or internalized and is only expressed at low levels in non-tumor tissues. As HER2 expression is typically maintained over the course of disease, CT-0508 may be developed for treatment of metastatic disease, for example, in the liver and lung, as well as primary tumors. Additionally, HER2 is typically not lost after patients with metastatic cancer progress on available HER2 targeted therapies, rendering HER2 refractory patients potentially eligible for CT-0508 therapy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Participants enrolled in Study 101 undergo one pre-treatment and two on-treatment biopsies to assess CT-0508 trafficking, impact on the TME, induction of anti-tumor T-cell immunity, and other biomarkers. Blood samples are also collected over a period of 52 weeks for evaluation of pharmacokinetics and biomarkers associated with safety and efficacy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based upon clinical data, Carisma may seek Regenerative Medicine Advanced Therapy, or RMAT, and PRIority MEdicine, or PRIME, designations for CT-0508, which provide an expedited developmental and approval pathway, in the United States and the European Union, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0508 Clinical Data&#8201;&#8212;&#8201;Study 101</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Enrollment of the first group of nine patients in the Phase&#160;1 clinical trial of CT-0508 has been completed and enrollment in the second group is currently ongoing. Carisma successfully generated CT-0508 product for all participants enrolled in the first group of the study with an average cell viability of 89%, an average purity of 85%, and an average CAR transduction of 81%. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma has reported on the safety, clinical response, and correlative studies for the first nine patients dosed in the first group of the clinical trial. Of such patients, two had HER2 overexpression levels of 2+ by immunohistochemistry staining, or IHC, with additional fluorescent in-situ hybridization FISH confirmation; and seven had levels of HER2 3+ by IHC. HER2 grading was performed based on the ASCO/</font>&#8203;<font style="letter-spacing:0.2pt;">CAP guidelines. Patients in the trial had three median prior therapies with a range of two to 11. Patients had a median of two prior HER2 targeted therapies, with a range of zero to nine. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CT-0508 was well tolerated with no dose-limiting toxicities. The majority (55.5%) of subjects with treatment-emergent adverse events, or TEAEs, by maximum severity were Grades 1 and 2. One subject experienced an unrelated Grade 4 TEAE (related to progression of disease of the patient&#8217;s cancer). For subjects with TEAEs considered related to CT-0508, the majority (66.6%) were Grades 1 and 2, and none were Grades 4 or 5 severity. With respect to TEAEs of special interest, six patients experienced CRS, and all of these were Grades 1 and 2. There were no episodes of immune cell therapy associated neurotoxic syndrome, or ICANS, reported. No patients had severe CRS. No AEs, or SAEs, led to CT-0508 dose modification or discontinuation. No major organ toxicity was observed. The majority of AEs, regardless of relatedness, were Grades 1 and 2. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">264</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:22.0599999999999pt;margin-left:69.66pt;width:456pt;">
        <table style="width:376pt;margin-left:40pt;margin-top:0pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-left:0.75pt solid #000000; border-right:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.5pt 0pt 2.25pt 0pt; width:0pt;" colspan="5">
              <font style="letter-spacing:-0.2pt;">Overview of Subjects with Treatment-Emergent Adverse Events (Safety Population) </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:297.75pt;">
              <font style="letter-spacing:0.2pt;">Category </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:60.75pt;">
              <font style="letter-spacing:0.2pt;">n = 9 (%) </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:297.75pt;">
              <font style="letter-spacing:0.2pt;">Treatment-Emergent Adverse Event (TEAE) </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:60.75pt;">
              <font style="letter-spacing:0.2pt;">9 (100.0) </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:297.75pt;">
              <font style="letter-spacing:0.2pt;">TEAE, Related to CT-0508 </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:60.75pt;">
              <font style="letter-spacing:0.2pt;">8 (88.9) </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:297.75pt;">
              <font style="letter-spacing:0.2pt;">TEAE, Serious AE </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:60.75pt;">
              <font style="letter-spacing:0.2pt;">4 (44.4) </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:297.75pt;">
              <font style="letter-spacing:0.2pt;">TEAE, Serious AE Related to CT-0508 </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:60.75pt;">
              <font style="letter-spacing:0.2pt;">2 (22.2) </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 2.25pt 0pt; width:297.75pt;">
              <font style="letter-spacing:0.2pt;">TEAE, AEs of Special Interest</font>
            </td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 2.25pt 0pt; width:60.75pt;">
              <font style="letter-spacing:0.2pt;">7 (77.8)</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; width:297.75pt;">
              <div style=" float:left; margin-left:30pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif;">&#9702;<br ></div>
              <div style=" line-height:10pt; text-align:left; margin-left:40pt;font-family:Times New Roman, Times, serif;">
                <font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;">Grade 1</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; width:60.75pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">3 (33.3)</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; width:297.75pt;">
              <div style=" float:left; margin-left:30pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif;">&#9702;<br ></div>
              <div style=" line-height:10pt; text-align:left; margin-left:40pt;font-family:Times New Roman, Times, serif;">
                <font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;">Grade 2</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; width:60.75pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">4 (44.4)</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; width:297.75pt;">
              <div style=" float:left; margin-left:30pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif;">&#9702;<br ></div>
              <div style=" line-height:10pt; text-align:left; margin-left:40pt;font-family:Times New Roman, Times, serif;">
                <font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;">Grade 3</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; width:60.75pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">0 (0.0) </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; width:297.75pt;">
              <div style=" float:left; margin-left:30pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif;">&#9702;<br ></div>
              <div style=" line-height:10pt; text-align:left; margin-left:40pt;font-family:Times New Roman, Times, serif;">
                <font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;">Grade 4</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:5.75pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt; width:60.75pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">0 (0.0) </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2.25pt 0pt; width:297.75pt;">
              <div style=" float:left; margin-left:30pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif;">&#9702;<br ></div>
              <div style=" line-height:10pt; text-align:left; margin-left:40pt;font-family:Times New Roman, Times, serif;">
                <font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;">Grade 5 </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2.25pt 0pt; width:60.75pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">0 (0.0)</font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:297.75pt;">
              <font style="letter-spacing:0.2pt;">Discontinued CT-0508 due to TEAE </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.25pt 0pt; width:60.75pt;">
              <font style="letter-spacing:0.2pt;">0 (0.0)</font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.19pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary of AEs by Preferred Term and by Severity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-bc_adverse4c.jpg" alt="[MISSING IMAGE: tm2227887d4-bc_adverse4c.jpg]" height="271" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The best overall response was stable disease per RECIST 1.1 criteria. A best overall response of stable disease was observed in five out of nine patients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Transient and low-grade fever was observed in seven out of nine patients post CT-0508 infusion. All fevers resolved within 48 hours. In concordance with clinical observations, a transient increase in serum&#160;IL-6, a pro-inflammatory cytokine, was observed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma evaluated the pharmacokinetics, or PK, of CT-0508 in the peripheral blood and the tumor. Similar peripheral blood PK was observed for all nine participants with CT-0508 detectable only on infusion days for four to eight hours post-infusion, consistent with rapid migration of CAR-M from the blood to tissues following infusion. CT-0508 was detected within the TME of eight out of nine evaluable patients assessed to date using RNAscope&#8482; technology as shown below. These data suggest that CT-0508 rapidly egresses from the peripheral blood and successfully traffic to the biopsied tumor mass. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">265</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:109.58pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0508 Rapidly Migrates Out of the Blood and is Detected within the TME of 8/9 Participants Evaluated</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_rapidly4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_rapidly4c.jpg]" height="170" width="578" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To evaluate the mechanism of action of CT-0508, single cell RNA sequencing, or scRNAseq, analysis was performed on fresh tumor biopsy to investigate changes within the TME following CT-0508 infusion. Analysis of screening (n=5), Day 8 post-infusion (n=5) and Week 4 post-infusion (n=3) biopsies revealed increases in CD8 T-cells, macrophages, and neutrophils on treatment consistent with inflammation and activation of an immune response. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">These increases were also associated with reprogramming of the infiltrating macrophages toward an M1 phenotype by Week 4. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Single Cell RNAseq Analysis Demonstrates Remodeling of the Tumor Immune Landscape Following CT-0508 Infusion</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-bc_single4clr.jpg" alt="[MISSING IMAGE: tm2227887d1-bc_single4clr.jpg]" height="181" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To evaluate whether CT-0508 was able to initiate anti-tumor adaptive immunity, TCR repertoire analysis was performed utilizing the Adaptive Biotechnologies&#8482; TCR sequencing platform. The analysis was performed on peripheral blood and tumor tissue. Peripheral blood TCR repertoire analysis revealed an expansion of T-cell clones in the blood of participants post CT-0508 infusion, indicative of the initiation of an adaptive immune response. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">266</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:53.11pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Early Expansion of T-cells in the Periphery Following CT-0508 Infusion</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-bc_mostpreva4c.jpg" alt="[MISSING IMAGE: tm2227887d4-bc_mostpreva4c.jpg]" height="293" width="581" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Based on scRNAseq analysis, the frequency of effector T-cells increased in all three participants with available screening and Week 4 biopsies (shown below). Furthermore, Carisma evaluated T-cell subtypes and found that Participant 1 demonstrated an increase in proliferating and effector memory CD8 T-cells, Participant 2 demonstrated an increase of all subsets except for activated CD8 T-cells, and Participant 4 demonstrated an increase in activated CD4, activated CD8 and effector memory CD8 T-cells. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Frequency of effector T-cells in TME</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-bc_frequen4c.jpg" alt="[MISSING IMAGE: tm2227887d4-bc_frequen4c.jpg]" height="228" width="437" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Differential gene expression analysis performed on biopsies collected at Week 4 post-CT-0508 infusion demonstrated an increased expression of genes associated with cytotoxic CD8 T-cell activation when compared to pre-treatment expression TME samples from six patients analyzed by RNA sequencing. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">267</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Increased T-Cell Activation in the TME</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.2pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-tbl_selct4c.jpg" alt="[MISSING IMAGE: tm2227887d4-tbl_selct4c.jpg]" height="174" width="571" >
        </div>
        <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">TCR repertoire analysis of the TME revealed that newly expanded peripheral clones accumulated over time within the TME, suggesting that these clones are tumor reactive. Expanding T-cell clonotypes from patient 1, 2 and 4 at Week 4 post-infusion clustered with cells expressing high levels of CD8&alpha;, perforin, granzyme B, Ki67, IFN&#947;, and PD1 demonstrated their activated and/or proliferating CD8 cytotoxic T lymphocyte phenotype. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Peripherally Expanded T-cell Clones Accumulate in the TME and Adopt a Cytotoxic Phenotype</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.2pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_pt4comp4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_pt4comp4c.jpg]" height="168" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:12.61pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While preliminary, the clinical data to date confirmed that CT-0508 is successfully manufactured from heavily pre-treated solid tumor patients, has been well tolerated, traffics to the tumor, activates the TME, and may initiate anti-tumor adaptive immunity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional CT-0508 Studies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0508 and Pembrolizumab combination sub study</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This open-label sub study will assess the safety and feasibility of co-administering CT-0508 in combination with the PD-1 inhibitor, pembrolizumab. The target population for this sub study are subjects at least 18&#160;years of age who meet inclusion criteria per the main protocol and have HER2 over-expressing solid tumors and meet the sub study specific eligibility criteria. Carisma expects to report clinical data for this sub study in the second half of 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0508 Intraperitoneal administration sub study</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This sub study has been designed to assess the safety and feasibility of CT-0508 via regional administration into the peritoneal cavity. The target population for this sub study are subjects at least 18&#160;years of age who meet inclusion criteria per the main protocol, that have HER2 over-expressing gynecological cancers including but not limited to ovarian, fallopian tube, primary peritoneal, and endometrial cancers, who have disease spread mainly within the peritoneal cavity that meet the sub study specific eligibility criteria. Subjects will be enrolled at select clinical sites participating in Study 101 that have the capability to enroll and adequately treat subjects with intraperitoneal administration of CT-0508. Carisma expects to report clinical data for this sub study in the second half of 2023. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">268</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:5.95000000000005pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0508 Biodistribution sub study</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">This open-label sub study is designed to evaluate the whole body biodistribution of CT-0508 after intravenous administration using radiolabeled CT-0508 and longitudinal PET/CT imaging. This sub study includes </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">89</font><font style="letter-spacing:0.2pt;">Zr-oxine radiolabeling a fraction of the CT-0508 cell product, followed by administration on Day&#160;1 and PET/CT imaging approximately on Day 1, 4, 8, 15, and 28 to assess trafficking and biodistribution of CT-0508. The target population for this sub study are subjects at least 18&#160;years of age that meet inclusion criteria per the main protocol. Subjects will be enrolled at specific sites in Study 101 that have the capability to perform </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">89</font><font style="letter-spacing:0.2pt;">Zr-oxine labeling, administration, and routine PET/CT analysis. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Synergistic Potential of CAR-M Therapy with T-Cell Checkpoint Inhibitors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Blocking the immune checkpoint molecule programmed cell death 1, or PD-1, has revolutionized cancer treatment for patients with a multitude of solid tumor indications. Pembrolizumab is a potent humanized immunoglobulin G4, or IgG4, monoclonal antibody, or mAb, with high specificity of binding to the PD-1 receptor, inhibiting its interaction with programmed cell death ligand 1, or PD-L1, and programmed cell death ligand 2, or PD-L2. While pembrolizumab is currently indicated for the treatment of patients across several solid tumor indications, the majority of patients have either primary or secondary resistance to immune checkpoint blockade and may benefit from combinatorial therapy that could overcome immune cell exclusion, poor antigen presentation, low T-cell infiltration, high TAM infiltration, a lack of productive co-stimulation, low mutational burden, IT immunosuppression, and a low frequency of tumor reactive T-cell clones. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Based on the data generated during pre-clinical development, CT-0508 cell product is able to specifically recognize, cancer cells through the binding of the CAR to HER2 expressed on the surface of these cells. This interaction triggers activation of the CAR-macrophages and results in direct anti-tumor effect by killing and phagocytosis of the tumor cells. In addition, CT-0508 recruits T-cells, activates the TME, and as professional antigen presenting cells, can process and present tumor associated antigen and/or neoantigens expressed by the tumor cells, leading to T-cell immunity against these specific antigens. However, this indirect anti-tumor effect involves the engagement of T-cells that may be actively suppressed, or exhausted, within the tumor micro-environment by a variety of factors including secreted immune-modulatory factors and inhibitory ligands expressed on both immune and tumor cells. Additionally, several studies have demonstrated that patients with low mutational burden, low MHC expression, defective antigen presentation, low CD8+&#160;T-cell infiltration, or minimal Th1 cytokine signatures tend to be unresponsive to PD-1 blockade. Therefore, based on the mechanism of action of CT-0508 and the limitations of PD-1 blockade, the combination of CAR-M therapy with PD-1 blockade therapy may be beneficial by enhancing antigen presentation (innate immunity) to initiate a robust anti-tumor T-cell response (adaptive immunity). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAR-M and PD-1 blockade combination therapy: Pre-clinical Development</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To model the combination of CT-0508 cell therapy with anti-PD-1 inhibitors, Carisma used a murine colorectal cancer cell line engineered to overexpress human HER2. Tumors were established in the flank of the immune competent mice and 14&#160;days post tumor inoculation, mice were randomized and received either murine CAR-M alone (IV), murine PD-1 blockade alone (IP) or a combination of both treatments. Using a regimen where CAR-M was injected first when the tumor was well established, followed by the anti-PD-1 inhibitor a few days later, neither murine CAR-M (Anti-HER2 muCAR-Mac) nor murine anti-PD1 monotherapy had a significant effect on tumor growth and overall survival. However, when co-administered the combination of both therapies resulted in significant tumor growth delay associated with prolonged survival of the mice (all mice in the combination group survived until the end of the study). All mice treated with the combination of Anti-HER2 muCAR-Mac and anti-PD1 mAb completely cleared their tumors (below). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">269</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:61.5599999999999pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Assessment of Tumor Burden and overall survival in a Syngeneic Mouse Model of Colon Carcinoma in response to treatment with IV CAR-M and Anti-PD-1 Therapy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-lc_asses4c.jpg" alt="[MISSING IMAGE: tm2227887d1-lc_asses4c.jpg]" height="489" width="608" >
        </div>
        <div style="margin-top:7.19pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Anti-HER2 muCAR-Mac are murine CAR-M and muUTD-Mac are untransduced murine CAR-M. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To determine the impact of Anti-HER2 muCAR-Mac and anti-PD-1 mAb combination therapy on tumor burden, tumor volumes were recorded during the treatment period (depicted in the left panel above) and mice were monitored for survival (depicted in the right panel above). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the IV CAR-M alone and in combination with anti-PD-1 therapy study described above, Carisma has performed studies with IT administered murine CAR-M. In this study, anti-PD-1 therapy was administered four times, at 3-day intervals starting 14&#160;days post tumor inoculation (CAR-M therapy initiated on Day 15). IT murine CAR-M and anti-PD-1 therapy improved tumor control and significantly improved survival probability. Cumulative survival for all groups: 0% CR CTRL, 8.3% CR anti-PD-1, 38.9% CR CAR-M and 66.7% CR CAR-M and anti-PD-1: </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">270</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">IT CAR-M and Anti-PD-1 Combination Therapy Improves Survival in the CT26-HER2 Model</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-lc_itcar4c.jpg" alt="[MISSING IMAGE: tm2227887d1-lc_itcar4c.jpg]" height="245" width="513" >
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Analysis of immune cell populations in the TME showed that macrophages were more abundant in the CAR-M samples while other myeloid cells and DCs showed the greatest infiltration in the combination group. A significant increase in total tumor infiltrating T-cells, and in particular helper T-cells, was noted in the combination therapy. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Profound TME Modulation in Response to IT CAR-M and CAR-M +Anti-PD-1 Combination Therapy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-pht_profnd4clr.jpg" alt="[MISSING IMAGE: tm2227887d1-pht_profnd4clr.jpg]" height="441" width="579" >
        </div>
        <div style="text-indent:20pt; margin-top:12.01pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Analysis of the TCR repertoire demonstrated that IT administration of CAR-M in combination with a PD-1 blocking monoclonal antibody led to increased frequency of T-cells in the periphery and significantly modulated the TCR repertoire in the TME suggesting enhanced adaptive anti-tumor immunity. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">271</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:38.55pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Based on these data, CAR-M and pembrolizumab represent a potentially synergistic immunotherapeutic combination regimen that combines CAR-M to infiltrate the TME, degrade the tumor via phagocytosis, and recruit and prime T-cells and pembrolizumab to prevent or reverse T-cell exhaustion. Patients with HER2 overexpressing tumors, such as metastatic breast cancer, gastric cancer, ovarian cancer, esophageal cancer, and others are generally poor responders to pembrolizumab. Carisma plans to evaluate CT-0508 in combination with pembrolizumab in an upcoming Phase&#160;1 clinical trial. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional Pipeline Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s additional pipeline candidates are CAR-M therapies that incorporate all of the core elements of its macrophage cell engineering platform, along with certain new platform enhancements that Carisma is currently developing. The CT-1119 product candidate targets the mesothelin tumor associated antigen that is found on lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and numerous other solid tumors. The CT-0729 product candidate targets the PSMA tumor associated antigen that is found on prostate cancer. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-1119 (Anti-Mesothelin CAR-M)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Mesothelin is a well validated tumor associated antigen. Mesothelin has been shown to be aberrantly expressed on the surface of tumor cells and plays an important role in promoting cancer invasion and proliferation. Mesothelin has been demonstrated to be expressed at high levels in mesothelioma, lung cancer, ovarian cancer, pancreatic cancer, and other solid tumors with limited expression in normal tissue, though recent data suggests inflammation may induce expression. There are no approved anti-mesothelin agents and no approved cell therapies targeting any of the solid tumor types that overexpress mesothelin. Mesothelin positive solid tumors represent a significant unmet medical need. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">While there are no mesothelin targeted approved agents, numerous clinical trials have been conducted targeting mesothelin and safety has been established with a variety of modalities including monoclonal antibodies, antibody drug conjugates, and CAR-T-cells. Targeting mesothelin enables a similar strategy to Carisma&#8217;s CT-0508 HER2 Phase&#160;1 trial in that it enables (i)&#160;a basket trial design that includes patients with diverse tumor types and (ii)&#160;separate arms for systemic and regional administration. There is a significant opportunity for regional administration of CT-1119, including intraperitoneal administration for mesothelin positive ovarian cancer with peritoneal metastasis and intrapleural administration for patients with malignant mesothelioma and lung tumors. There is also a significant opportunity for patients with mesothelin positive solid tumors with systemic metastasis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To develop a mesothelin targeted CAR-M, Carisma has screened anti-mesothelin scFv&#8217;s using mRNA to identify humanized anti-mesothelin binders. Carisma obtained exclusive rights to a humanized anti-mesothelin scFv from the University of Pennsylvania. Carisma demonstrated that human CAR-M engineered with an Ad5f35 vector show high viability and efficiently express an anti-mesothelin (meso) CAR. Similar to CT-0508, CT-1119 adopts an M1 macrophage activation state. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">CT-1119 effectively phagocytose mesothelin positive lung cancer (A549) and ovarian cancer (MesOV) cells as shown by two independent phagocytosis assays. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To evaluate the effector function of CT-1119, Carisma utilized mesothelin positive lung adenocarcinoma (A549) and ovarian cystadenocarcinoma (MesOV) cell lines. </font><font style="font-style:italic;letter-spacing:0.2pt;">In vitro</font><font style="letter-spacing:0.2pt;">, CT-1119 shows robust killing of lung cancer cells expressing mesothelin and CAR engagement induces the release of the pro-inflammatory cytokine TNF-&alpha; following stimulation with mesothelin expressing but not wild type (Wt) cell lines: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">272</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-1119 Kill and Produce Cytokine in Response to Biologically Relevant Targets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.01pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-bc_119ct4c.jpg" alt="[MISSING IMAGE: tm2227887d1-bc_119ct4c.jpg]" height="301" width="547" >
        </div>
        <div style="text-indent:20pt; margin-top:12.2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to evaluate the direct anti-tumor activity of CT-1119 in a relevant animal model, Carisma engrafted immunodeficient NSG-S mice with A549 lung adenocarcinoma cells expressing mesothelin by intravenous administration, which creates a lung metastasis model. CT1119 demonstrated the ability to reduce tumor progression and reduced the number of metastatic tumor nodules. </font>
        </div>
        <div style="position:relative;margin-top:9.4pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_ct1119a5494c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_ct1119a5494c.jpg]" height="304" width="361" >
        </div>
        <div style="text-indent:20pt; margin-top:12.21pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These findings demonstrate that CT-1119, an autologous human anti-mesothelin CAR-M, can effectively phagocytose and kill target tumor cells as well as initiate pro-inflammatory cytokine production in response to mesothelin. Carisma believes that CAR-M is a feasible approach for the treatment of mesothelin expressing solid tumors and is advancing the development of this program toward a clinical trial. The IND is expected to be submitted in 2025. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0729 (PSMA CAR-M)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prostate-specific membrane antigen, or PSMA, is highly specific to prostate cancer cells. </font><font style="font-style:italic;letter-spacing:0.2pt;">In vitro</font><font style="letter-spacing:0.2pt;"> studies have been conducted demonstrating that Carisma can: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">273</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Express anti-PSMA CARs on human macrophages </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Mediate phagocytosis of PSMA overexpressing tumor cells </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Induce killing of PSMA overexpressing tumor cells </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Initiate cytokine release in a PSMA specific manner </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Generate M1 polarized anti-PSMA CAR-M </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CT-0729 is in the discovery stage and a lead construct has not yet been nominated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAR-Mono: Pre-clinical Development</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Currently, the CAR-M platform requires differentiation of circulating monocytes into macrophage </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> prior to transduction with Ad5f35 to express the CAR. </font><font style="font-style:italic;letter-spacing:0.2pt;">Ex vivo</font><font style="letter-spacing:0.2pt;"> differentiation takes approximately one week and is associated with the loss of a fraction of cells during the differentiation process. Carisma hypothesized that monocytes could be directly engineered to express CARs, shortening the </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> manufacturing process from approximately eight days to approximately one to two days. By bypassing </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> differentiation, CAR monocytes will be administered to patients, wherein they will traffic to and enter tumor tissue, differentiating into macrophages </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> rather than </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo.</font><font style="letter-spacing:0.2pt;"> CAR-Mono are a precursor to the CAR macrophage. Carisma further hypothesized that CAR-Mono may have improved tumor trafficking potential, given their smaller size and increased chemokine receptor expression. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To determine the feasibility of generating CAR monocytes, or CAR-Mono, Carisma conducted </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> time course studies to assess cell viability and CAR expression compared to untransduced monocytes. Following transduction with Ad5f35, CAR expression and cell viability were tracked </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> for 28&#160;days. Viability was high (&gt;90%) and CAR expression was high (&gt;80%), and both stayed high for the entire 28&#160;days of culture. Durable CAR expression is critical to enable the cells to (a)&#160;retain CAR expression while trafficking to the tumor, (b)&#160;retain CAR expression during differentiation into CAR macrophages, and (c)&#160;to enable sustained anti-tumor activity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s first CAR-Mono program is CT-0525, an autologous anti-HER2 CAR-Mono. CT-0525 is an advanced pre-clinical program, and Carisma plans to submit an IND for CT-0525 in the third quarter of 2023, followed by initiation of a Phase&#160;1 clinical trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The M1 phenotype of Carisma&#8217;s CAR-M platform is an important aspect of the mechanism of action. As monocytes are the precursors to macrophages, differentiation and cell morphology was evaluated after two days and seven days of culture. After seven days in culture, CAR-Mono showed a progressively increasing M1 phenotype (high CD80 and CD86 expression) and expressed CAR. Compared to untransduced monocytes cultured for two or seven days </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;">, Ad5f35 transduced CAR-Mono upregulated M1 markers CD80 and CD86, confirming that Ad5f35 transduction similarly induces an M1 macrophage phenotype when added at the monocyte stage. Importantly, CAR-Mono-derived CAR-M had a similar morphology to CAR-M generated using the standard method&#8201;&#8212;&#8201;confirming morphologically that CAR-Mono differentiate into CAR-M. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To confirm that CAR-Mono differentiate into CAR-M and take on an M1 phenotype </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;">, NSG-S mice were engrafted with NCI-H2444 (Non-Small Cell Lung Cancer). NSG-S mice are highly immunodeficient mice that express human Interleukin (IL)-3, human GM-CSF, and human stem cell factor. These animals support enhanced engraftment of myeloid cells compared to NOD/SCID Il2rg-/- (NSG) mice, they are ideal for studies investigating the adoptive transfer of myeloid cells. Untransduced control or CAR-Mono were intratumorally injected (N=3 donors) and tumors were harvested seven days post injection. Human immune cells were enriched using flow sorting and processed for scRNA sequencing. By comparing the gene expression of </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> differentiated untransduced and CAR monocytes, Carisma&#8217;s data suggest that the monocytes have the potential to differentiate into macrophages and adopt an M1 like phenotype. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CAR-M are able to directly kill tumor cells via phagocytosis and release of cytotoxic mediators such as TNF&alpha;. Carisma evaluated the direct tumor killing capacity of CAR-Mono at Day 2 (monocyte phase) and Day 7 (macrophage phase). AU565, a HER2+ breast cancer cell line, was utilized as the target tumor cell. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">274</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s data show that CAR-Mono mediated effective killing at Day 2 and that fully differentiated CAR-Mono-derived CAR-M (Day 7) also efficiently cleared tumor cells. When comparing CAR-Mono-derived CAR-M (Day 7) to CT-0508, Carisma found that CAR-Mono led to improved tumor killing and inflammatory cytokine production. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAR-Mono-derived CAR-M Show Robust Tumor Killing Activity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-lc_carmno4c.jpg" alt="[MISSING IMAGE: tm2227887d1-lc_carmno4c.jpg]" height="284" width="578" >
        </div>
        <div style="margin-top:18.69pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAR-Mono-derived CAR-M Cocultures Show Robust Proinflammatory Cytokine Production</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-bc_cyto4c.jpg" alt="[MISSING IMAGE: tm2227887d1-bc_cyto4c.jpg]" height="258" width="591" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma previously demonstrated that CT-0508 CAR-M are locked into an M1 phenotype by Ad5f35 transduction, and resist M2 conversion by immunosuppressive cytokines. Carisma evaluated whether CAR-Mono similarly resisted M2 environments by culturing the cells for seven days in the presence of M-CSF (differentiation factor) or M-CSF plus the immunosuppressive cytokines IL-10 and TGF-&beta; during differentiation. CAR-Mono showed resistance to polarization and continued to express CD86 (M1) and not CD163 (M2) as demonstrated by flow cytometry and bulk RNA sequencing of untransduced and CAR-Mono-derived CAR-M. Additionally, untransduced monocytes but not CAR-Mono significantly upregulated CD163 in response to IL-10 and TGF-&beta;. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">275</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAR-Mono Are Protected Against M2 Polarization</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.6pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-lc_polar4c.jpg" alt="[MISSING IMAGE: tm2227887d1-lc_polar4c.jpg]" height="219" width="578" >
        </div>
        <div style="text-indent:20pt; margin-top:13.99pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">An important element to Carisma&#8217;s cell therapies is the long-term expression of its engineered CAR payloads by human myeloid cells. To evaluate persistence </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;">, monocytes were engineered with a modified Ad5f35 vector that induces the co-expression of CAR and luciferase under a single promoter by using a ribosomal skip site. This approach enables the ability to track luciferase using bioluminescent imaging and infer not only the viable persistence but also the CAR expression of human monocytes in mice. Ad5f35 engineered CAR-Luciferase Mono was injected intravenously into NSG or NSG-S mice and imaged for 180&#160;days. While both NSG and NSG-S mice are immunodeficient, only NSG-S mice constitutively express human cytokines that promote myeloid cell survival (GM-CSF, IL3, and SCF). Carisma found that human CAR-Mono persisted for at least 180&#160;days </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;">, independent of cytokine support. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0525 Show Long Term Persistence </font><font style="font-style:italic;letter-spacing:-0.2pt;">In Vivo</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.5pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_persis4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_persis4c.jpg]" height="327" width="576" >
        </div>
        <div style="text-indent:20pt; margin-top:14pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To determine whether CAR-Mono are able to control tumor growth in xenograft models, Carisma utilized a SKOV3 HER2+ ovarian cancer intraperitoneal carcinomatosis model. Anti-HER2 CAR-Mono significantly suppressed tumor growth and prolonged survival up to 120&#160;days post treatment, while mice that received untransduced control monocytes or mice that were left untreated only survived for &lt;60&#160;days. Carisma is currently evaluating CAR-Mono in immunocompetent models. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">276</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:9.62pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT-0525 Suppress Tumor Growth </font><font style="font-style:italic;letter-spacing:-0.2pt;">In Vivo</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_tumor4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_tumor4c.jpg]" height="220" width="578" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In summary, CAR-Mono were successfully generated with high efficiency and viability in a rapid, one-to-two day manufacturing process. CAR-Mono demonstrated stable CAR expression and viability </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;">, and persisted for at least six&#160;months </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo.</font><font style="letter-spacing:0.2pt;"> CAR-Mono differentiated into CAR-M efficiently and adopted an M1 macrophage phenotype, and resisted conversion to M2 in immunosuppressive environments. CAR-Mono were able to kill tumors cells in the monocyte phase and the macrophage phase. CAR-Mono controlled tumor growth in a xenograft mouse model of cancer. Based on the pre-clinical data to date, Carisma believes that CAR-Mono represents a potentially promising approach for cancer immunotherapy, while meaningfully expanding Carisma&#8217;s proprietary platform. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Next Generation Constructs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s discovery team is developing a next generation CAR-M platform utilizing enhanced CAR constructs to increase potency and functionality of the engineered cells. This includes optimization of each element of the CAR itself&#8201;&#8212;&#8201;the binder (which gives the CAR specificity to a target antigen), the hinge (which connects the binder to the transmembrane domain and gives the CAR length and flexibility), the transmembrane domain (which spans the cell membrane), and the intracellular signaling domains (which are responsible for activation of immune cell function). It is well accepted in the immunology field that T-cells require multiple signals for activation&#8201;&#8212;&#8201;signal 1 deriving from the TCR, and signal 2 deriving from co-stimulatory receptors such as CD28 or 4-1BB. Thus, all approved CAR-T products are second generation CARs, incorporating CD3&#950; as a primary signaling domain and either 4-1BB or CD28 as co-stimulatory domains. Third generation CARs, incorporating three signaling domains, have also been evaluated in T-cells. Unlike T-cells, macrophages do </font><font style="font-style:italic;letter-spacing:0.2pt;">not</font><font style="letter-spacing:0.2pt;"> require co-stimulation for activation and can be activated through a single signal, such as through an Fc receptor. However, multiple signaling pathways have the ability to enhance the macrophage response and may improve targeT-cell killing, cytokine/chemokine release, and macrophage activation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Next Generation CAR-M Constructs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma has been routinely developing and evaluating novel CAR-M constructs. Carisma&#8217;s well-established CAR-M assays enable a distinct opportunity to identify improved constructs in an efficient manner. Based on Carisma&#8217;s early findings, CD3&#950; is a potent activator of macrophage function and induces phagocytosis, cytokine release, chemokine release, killing, and activation of pro-inflammatory genes. Given this finding, Carisma has been evaluating the addition of other innate immune receptors such as Toll-like receptors, CD40, MyD88, Dectin-1, to CD3&#950; to improve upon CAR-M functionality. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">277</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-fc_antibody4c.jpg" alt="[MISSING IMAGE: tm2227887d4-fc_antibody4c.jpg]" height="276" width="370" >
        </div>
        <div style="margin-top:13.52pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Next Generation Construct: Pre-clinical Development</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s preliminary data assessing tumor cell killing activity with CAR variants at a low &#8220;stress test&#8221; dose shows increased potency at low effector (macrophage) to target (tumor cell) ratios. CD40 is an activating receptor found on antigen presenting cells including macrophages that is activated after binding to CD40-Ligand, typically expressed on activated T-cells. CD40 signals through numerous second messengers leading to the activation of NF-&#1008;B and other transcription factors that induce a potent M1 phenotype and activate antigen presenting cells. MyD88 is expressed in macrophages and acts as an adaptor that plays a pivotal role in the signaling of Toll-like receptors. Carisma has found that addition of MyD88 and CD40 to CD3&#950; CAR-M, in a specific sequence with a specific hinge domain, leads to a significant improvement to macrophage anti-tumor activity. </font>
        </div>
        <div style="margin-top:11.02pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Addition of the MyD88/CD40 pathway significantly increases CAR-M potency</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.11pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-lc_poten4c.jpg" alt="[MISSING IMAGE: tm2227887d1-lc_poten4c.jpg]" height="269" width="480" >
        </div>
        <div style="text-indent:20pt; margin-top:10.32pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further testing of the M88-CD40-CD3&#950; CAR and other novel CAR-M are ongoing. Leading second/</font>&#8203;<font style="letter-spacing:0.2pt;">third generation CAR candidates may be incorporated into future autologous, allogeneic, or </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> LNP programs. </font></div>
        <div style="margin-top:10.92pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Novel Modalities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is applying learnings from its autologous CAR-M data, tools, and processes to establish off-the-shelf engineered macrophage therapeutics. To broaden the application of CAR myeloid cell therapy, Carisma </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">278</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">is actively seeking to develop a gene edited iPSC-derived macrophage platform. The goal is to establish a process to generate allogeneic, iPSC-derived M1, M2, or CAR myeloid cells. One approach is using allogeneic iPSC myeloid cells manufactured using the following summary process: </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">iPSC-Derived Myeloid Cells: Summary</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-pht_ipsc4clr.jpg" alt="[MISSING IMAGE: tm2227887d1-pht_ipsc4clr.jpg]" height="412" width="547" >
        </div>
        <div style="text-indent:20pt; margin-top:11.31pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Initial </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> studies show that iPSCs can be converted to monocytes or macrophages, skewed to an M1 or M2 phenotype with cytokine culture, and can be engineered with Carisma&#8217;s proprietary vectors to express tumor targeting CARs. In addition to offering an allogeneic, universal donor platform, iPSCs are expandable cells&#8201;&#8212;&#8201;unlike primary human monocytes or macrophages which are terminally differentiated. In the first 15&#160;days of the process, Carisma noted &gt;1,000x expansion. It took approximately 15&#160;days to generate iPSC-derived monocytes and approximately 20&#160;days to generate iPSC-derived macrophages. The process is currently being performed in a non-GMP research environment at research scale but has the potential to be developed into a commercial scale, GMP process in the future. The macrophages generated with this process express canonical macrophage markers, appear macrophage-like with Giemsa staining and microscopic evaluation, and importantly demonstrate cell-to-cell uniformity in morphology. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">iCAR-M Production</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-bc_icar4c.jpg" alt="[MISSING IMAGE: tm2227887d1-bc_icar4c.jpg]" height="180" width="516" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">279</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">iCAR-M Anti-Tumor Activity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to confirm that iPSC-derived macrophages are effectively redirected against tumor associated antigens, Carisma introduced the anti-HER2 CAR into iPSC-derived macrophages using Ad5f35. Engineered iPSC-derived macrophages efficiently expressed CAR, upregulated M1 markers, and demonstrated an acceptable viability. To evaluate anti-tumor function, Carisma conducted an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> killing assay in which AU565 HER2+ breast cancer cells were cultured alone, together with iPSC-derived control macrophages, or iPSC-derived CAR-M. As shown below, while the control iPSC macrophages had minimal anti-tumor effect (orange), the iPSC-derived CAR-M cleared tumor cells over approximately 72 hours. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">iPSC-Derived CAR-M Exert Potent Anti-Tumor Activity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_ipscmacs4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_ipscmacs4c.jpg]" height="315" width="502" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While iCAR-M appear to be able to exert direct anti-tumor functionality, there are inherent complexities that will be critical to inform the ultimate allogeneic macrophage strategy. CAR-M exert anti-tumor immunity through tumor infiltration, phagocytosis, cytokine/chemokine release, TME activation, T-cell recruitment, and antigen presentation. To enable an allogeneic off-the-shelf iCAR-M program, the cells will inherently be either MHC mismatched or MHC-edited (for example, MHC-I and MHC-II may be deleted using CRISPR/</font>&#8203;<font style="letter-spacing:0.2pt;">Cas9 editing to generate universally accepted macrophages), and thus may have limited direct antigen presentation potential. However, iCAR-M are expected to maintain the other mechanisms of action, as summarized below. Future studies will evaluate whether allogeneic CAR-M are capable of inducing epitope spreading, as indirect mechanisms of antigen presentation have not been ruled out. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Importantly, the iPSC-derived myeloid cell platform, combined with Carisma&#8217;s gene engineering capabilities, has the potential to be produced in multiple ways. First, iPSC-derived myeloid cells can be expanded, qualified, and banked prior to being used as a master cell bank source for the production of engineered myeloid cell therapies. In this example, iPSC-derived myeloid cells would be engineered with Carisma&#8217;s proprietary methods (Ad5f35, Vpx-LV, modified mRNA, or other) after differentiation into the desired myeloid cell subtype. Alternatively, Carisma is optimizing methods to introduce the CAR (or other genetic payload) at the iPSC stage using targeted integration into desired genomic loci, isolating iPSC clones with integrated genes and additional potential genetic edits, and differentiating these cells into monocytes or macrophages, and skewing them to an M1 phenotype using Carisma&#8217;s proprietary polarization processes. For this approach, care must be taken to ensure that the CAR (or other payload) is not epigenetically downregulated or lost during the myeloid differentiation process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While the current focus of Carisma&#8217;s discovery efforts is to ultimately generate iCAR-M, the platform is expected to be readily adaptable to either develop (a)&#160;myeloid cells engineered with other anti-tumor </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">280</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:323.47pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">payloads, or (b)&#160;myeloid cells engineered with payloads designed to ameliorate disease outside of oncology. Notably, Carisma has early non-oncology programs in liver fibrosis, neurodegeneration, and auto-immunity/</font>&#8203;<font style="letter-spacing:0.2pt;">chronic inflammation which can be combined with the iPSC-derived myeloid cell platform. Currently, Carisma&#8217;s pipeline is focused on autologous approaches and direct </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> reprogramming, and the allogeneic iPSC-derived platform is at the pre-clinical discovery stage. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LNP/mRNA Platform (Moderna Collaboration)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In collaboration with Moderna, Carisma is developing an mRNA based </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M platform for oncology. This approach is highly differentiated in the cell therapy space&#8201;&#8212;&#8201;not only because it relies on myeloid cells as the engineered effectors, but also because it utilizes direct </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> reprogramming of a patients&#8217; own cells with a well-validated LNP/mRNA platform. By engineering a patients&#8217; own cells directly within their body, </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> autologous or allogeneic cell manufacturing is entirely bypassed&#8201;&#8212;&#8201;significantly increasing the commercial potential of the therapy. Importantly, while this approach enables an off-the-shelf therapy, the engineered cells are autologous, as it is the patients&#8217; own cells being engineered into CAR-M </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;">, or directly within their body. This strategic partnership enables Carisma to apply the learnings gleaned from autologous CAR-M development to expand its pipeline to up to 12 additional oncology candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Studies with the myeloid tropic LNP have shown mRNA delivery is specific for myeloid cells (monocytes, macrophages, dendritic cells). Based on clinical data using other (non-CAR) payloads, Moderna has previously demonstrated that the LNP was well-tolerated after systemic administration and could furthermore be re-dosed. Preliminary data have demonstrated that the LNP is efficient in transfecting myeloid cells </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;">. In addition, preliminary data confirms high CAR expression, viability, and CAR-M function, and availability of pre-clinical data is expected mid-2023. The platform summary for the </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M approach is shown below: </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">281</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Myeloid Tropic LNP/mRNA Platform (Moderna Collaboration)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-pht_myloid4clr.jpg" alt="[MISSING IMAGE: tm2227887d1-pht_myloid4clr.jpg]" height="658" width="456" >
        </div>
        <div style="margin-top:18.69pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">LNP/mRNA Pre-clinical Data (Moderna Collaboration): Pre-clinical Development</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">In vitro</font><font style="letter-spacing:0.2pt;"> pre-clinical studies with the myeloid tropic LNP/mRNA platform have shown efficient transfection. Carisma has optimized conditions for </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> LNP/mRNA delivery to human and murine monocytes/macrophages, as well as primary murine myeloid cells to establish various relevant murine tumor models. Carisma&#8217;s goal was to establish a platform with high viability (&gt;70%), high transfection efficiency (&gt;70%), and significantly increased CAR-M killing activity compared to untransfected control macrophages. Key data for the anti-HER2 CAR constructs CTX_001 and CTX_219 are shown in the figures below: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">282</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LNP Transfection is Well Tolerated by Human Macrophages</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_lnp4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_lnp4c.jpg]" height="209" width="544" >
        </div>
        <div style="margin-top:18.69pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LNP Engineering leads to Dose Dependent CAR Expression</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_2lnp4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_2lnp4c.jpg]" height="200" width="544" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to CAR expression and viability, Carisma has shown that one day post transfection, CTX001 and CTX219 mediate potent killing activity against target AU565 cells. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LNP Engineered CAR-M Display Effective Killing Function</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_3lnp4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_3lnp4c.jpg]" height="223" width="533" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Statistical analysis was determined using Two-way ANOVA, * p&lt;0.5 **** p&lt;0.0001. The data were generated from N=3 donors (3 technical replicates per donor). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">283</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LNP Transfection is Well Tolerated by Human Monocytes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.7pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_4lnp4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_4lnp4c.jpg]" height="231" width="565" >
        </div>
        <div style="margin-top:17.39pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LNP Engineering leads to Dose Dependent CAR Expression in Monocytes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.7pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_5lnp4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_5lnp4c.jpg]" height="215" width="559" >
        </div>
        <div style="text-indent:20pt; margin-top:13.4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to CAR expression and viability, Carisma has shown that monocytes engineered with LNP/mRNA encoding the CARs CTX001 and CTX219 mediate potent killing activity against target AU565 breast cancer cells. These findings demonstrate similarity between LNP engineered macrophage and monocyte effector function. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LNP Engineered CAR-Mono Display Effective Killing Function</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.8pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-lc_6lnp4c.jpg" alt="[MISSING IMAGE: tm2227887d4-lc_6lnp4c.jpg]" height="229" width="533" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">284</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Statistical analysis was determined using Two-way ANOVA, * p&lt;0.5 **** p&lt;0.0001. The data were generated from N=3 donors (three technical replicates per donor). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To model direct reprogramming of TAMs to CAR-M, Carisma generated tumor spheroids comprised of HER2+ breast cancer cells and human TAMs.&#160;Carisma confirmed that the macrophages embedded within these spheroids adopted an M2, TAM-like phenotype. Carisma added LNPs (containing CAR mRNA and an M1 polarizing gene) directly to the tumor spheroids and found that the reprogrammed TAMs mediated tumor spheroid shrinking over a 72-hour period. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Directly Reprogramming Myeloid Cells </font><font style="font-style:italic;letter-spacing:-0.2pt;">within Tumors</font><font style="letter-spacing:-0.2pt;"> with LNP/mRNA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-pht_reprobw.jpg" alt="[MISSING IMAGE: tm2227887d1-pht_reprobw.jpg]" height="201" width="517" >
        </div>
        <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The first four indications have been nominated by Moderna, spanning both solid tumors and hematologic malignancies. Pre-clinical platform optimization, as well as target discovery and CAR development, are ongoing in parallel. Early </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> proof of concept is expected in 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EM-C: A novel platform for regulation of inflammation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cytokines in tissue microenvironments regulate the balance between pro- and anti-inflammatory signaling. Dysregulated cytokine expression causes deleterious immunosuppression or inflammation, underpinning the pathophysiology of numerous diseases. As examples, anti-inflammatory cytokines in solid tumors suppress immune activation and safeguard the tumor, whereas pro-inflammatory cytokines in rheumatoid arthritis drive chronic inflammation. Rebalancing inflammation/immunosuppression by targeting aberrant cytokine signaling offers a generalizable approach to treating many diseases, but systemic cytokine blockade carries risks such as increased risk of serious infection. Cellular immunotherapies may offer a localized platform that could activate in response to cytokines then proportionately remodel the microenvironment&#8217;s inflammatory state as needed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Macrophages are tissue infiltrating homeostatic regulators responsible for the initiation and resolution of inflammation. Carisma leveraged the ability of macrophages to regulate inflammation by generating macrophages that express genetically engineered, synthetic cytokine switch receptors (SR). Carisma termed this platform EM-C and evaluated its modular ability to convert immunosuppressive M2 signals into pro-inflammatory M1 responses for solid tumor microenvironment conversion, or vice versa for the conversion of pro-inflammatory M1 signals into immunosuppressive M2 responses for auto-immune or inflammatory diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EM-Cs were generated by expressing SRs in primary human macrophages. First, Carisma generated SRs that convert immunosuppressive signals into inflammatory signals&#8201;&#8212;&#8201;focusing on IL-10. To convert IL-10 (a cytokine well known to polarize macrophages toward an M2 phenotype) in the TME into a pro-inflammatory signal, an IL-10 SR was designed by fusing the extracellular domain of the IL-10 receptor to an engineered portion of the IFN&#955; receptor. The </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> response of IL-10 EM-Cs to IL-10 was monitored by the expression of M1 and M2 markers. While control untransduced or CAR (a control irrelevant construct) expressing macrophages responded to IL-10 through the downregulation of M1 markers and upregulation of M2 markers, IL10-SR EM-Cs upregulated M1 markers and downregulated M2 markers. These data and others demonstrate that Carisma&#8217;s IL10-SR EM-Cs can induce an inflammatory response when exposed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">285</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tMAD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to immunosuppressive conditions. Carisma has generated numerous additional EM-Cs that respond to other immunosuppressive factors, such as TGF&beta;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Conversely, Carisma sought to develop EM-Cs that can convert inflammatory cytokines into anti-inflammatory responses. As myeloid cells are recruited to sites of inflammation. This approach would enable a myeloid cell therapy that accumulates at inflammatory sites and locally shuts down inflammation. This approach may have broad utility in autoimmunity, chronic inflammation, fibrosis, transplant, and graft versus host disease. Carisma generated EM-Cs targeting IFN-&#947; and demonstrated that while control untransduced or CAR (an irrelevant payload) macrophages respond to IFN-&#947; by upregulating M1 markers and downregulating M2 markers, IFN-&#947; SR EM-Cs responded to IFN-&#947; by downregulating M1 markers and upregulating M2 markers. These data demonstrate that Carisma&#8217;s proprietary EM-C platform can be broadly utilized to generate engineered macrophages with the ability to control the inflammatory nature of environments, and act as living converters, with broad potential applicability to oncology, autoimmunity, chronic inflammation, and other indications. This platform offers broad opportunity for strategic partnership. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Macrophages Expressing Cytokine Switch Receptors Can Invert</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pro- or Anti-Inflammatory Signals</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.2pt; text-align:center; width:456pt;">
          <img src="tm2227887d1-lc_macro4c.jpg" alt="[MISSING IMAGE: tm2227887d1-lc_macro4c.jpg]" height="267" width="570" >
        </div>
        <div style="margin-top:17.39pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indications Beyond Oncology</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While Carisma is an oncology focused company, the macrophage engineering platform Carisma has established offers broad opportunity to develop cell therapies for indications beyond oncology. Carisma has numerous early-stage research programs designed to produce development candidates for liver fibrosis, neurodegenerative disease, and autoimmunity/chronic inflammation. Carisma&#8217;s new product candidates will incorporate all the core elements of its macrophage cell engineering platform, plus certain indication specific modifications uniquely designed to address the pathology of each indication. While autologous cell therapy may be utilized for proof of concept, these indications have the potential to be combined with Carisma&#8217;s allogeneic or off-the-shelf therapeutic approaches. Indications beyond oncology offer opportunities for strategic partnerships to accelerate the development of these programs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Manufacturing and Delivery</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma does not own or operate, and currently has no plans to establish, any manufacturing facilities. Carisma currently relies on and expects to continue to rely on third-party contract development manufacturing organizations, or CDMOs, for the manufacturing and release testing of viral vectors and cell drug products. Carisma also currently relies on third parties for patient leukapheresis material logistics as well as to package, label, store, and distribute the cell drug products. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">286</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tINPR1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma has established and will continue to establish arrangements with contract manufacturers to supply clinical materials and manufacturing capabilities for Carisma&#8217;s clinical trials. Carisma currently obtains its supplies from these manufacturers on a purchase order basis and does not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to Carisma for any reason, Carisma believes that there are several potential replacements, although Carisma may incur some delay in identifying and qualifying such replacements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma also plans to continue to expand the scope and number of its collaborations to further develop its manufacturing capabilities and to minimize manufacturing risk. As Carisma scales to commercialization, it expects to increase its capacity with its current suppliers and evaluate other options to secure commercial scale capacity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Manufacturing Process for CT-0508</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A CDMO is used to produce cGMP lots of viral vector. The CT-0508 drug substance process begins by isolating the monocyte population from a single fresh patient leukopak mobilized by donor pretreatment with filgrastim. The resulting monocytes are cultured in the presence of a cytokine and other factors to induce differentiation into macrophages. The resulting macrophages are then transduced with the Ad5f35 vector encoding an anti-HER2 CAR. The resulting cells are then harvested as drug substance. Macrophages derived from a single leukopak from one patient comprise one batch of CT-0508. Final formulation is performed and transferred into freezing bags to generate drug product. The drug product is carefully frozen in a controlled process and then placed into secured storage and maintained at a temperature of &gt;-135&#8304; Celsius. Safety and specification tests are performed and if found acceptable the product is released and shipped to clinical trial sites. The current process from receipt of leukopak to drug product and cryopreservation is eight days. </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2227887d4-fc_carm4c.jpg" alt="[MISSING IMAGE: tm2227887d4-fc_carm4c.jpg]" height="218" width="605" >
        </div>
        <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma plans to continue to invest in process improvements to reduce the overall manufacturing process time and improve costs for the viral vector and cell drug product. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma strives to protect and enhance its proprietary technology, inventions and improvements that Carisma believes are commercially important to the development of its business, including through seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Carisma also intends to rely on trade secrets related to its proprietary technology platform and its know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain its proprietary position in the fields of cancer and other indications including those related to neurodegeneration, liver fibrosis and autoimmune disease, which may be important for the development of Carisma&#8217;s business. Carisma additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions, where available. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s commercial success may depend, in part, on its ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">287</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">its business, defend, and enforce its patents, preserve the confidentiality of its trade secrets and operate without infringing the valid enforceable patents and proprietary rights of third parties. Carisma&#8217;s ability to stop third parties from making, using, selling, offering to sell or importing its products may depend on the extent to which it has rights under valid and enforceable licenses, patents or trade secrets that cover these activities. With respect to both Carisma&#8217;s owned and licensed intellectual property, Carisma cannot be sure that patents will be granted with respect to any of its pending patent applications or with respect to any patent applications filed by Carisma in the future, nor can it be sure that any of its existing patents or any patents that may be granted to Carisma in the future will be commercially useful in protecting its commercial products and methods of manufacturing such products, as well as being held valid if challenged. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma currently controls over 15 granted patents and over 41 patent applications pending in several jurisdictions, including the United States, Europe, Australia, Brazil, Canada, China, Israel, Japan, Korea, Mexico, New Zealand, and Singapore. Intellectual property is a critical component of Carisma&#8217;s business plan for maximizing return on its investments. Carisma is actively developing intellectual property and will continue to maintain and defend United States and international patent rights for its products, technology, and development and improvement of its discovery platforms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To maintain its competitive position in the market, Carisma has spent considerable effort securing intellectual property rights, including several patent rights related to its proprietary CAR technology and myeloid cell engineering technology. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exclusively Licensed Intellectual Property&#8201;&#8212;&#8201;UPenn</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma has exclusive rights to three patent families, and non-exclusive rights to related know-how by virtue of a license agreement with the University of Pennsylvania. These patent families are directed to, among other things, methods of efficiently expressing CARs in myeloid cells, including monocytes, macrophages, and dendritic cells and enhancing effector activity, as well as the modified cells and compositions including such modified cells for use in several indications including various oncology targets. The applications will have an expiration date of no earlier than 2036. This licensed patent portfolio includes:</font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A patent family that includes eight issued U.S. patents and three pending U.S. patent applications relating to modified macrophages, monocytes and dendric cells comprising CARs. These U.S. patents are expected to expire in 2036, absent any term adjustments or extensions. Corresponding foreign applications have been filed and are pending in Australia, Brazil, Canada, China, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Russia, Singapore, Thailand and South Africa.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A patent family that includes one pending U.S. patent application relating to modified macrophages, monocytes and dendric cells in protein aggregate-associated disorders. Patent applications in this family are expected to expire in 2039, absent any term adjustments or extensions. Corresponding foreign applications have been filed and are pending in Australia, Canada, China, Europe, Israel, Japan, Korea, New Zealand, and Singapore.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A patent family that includes one pending U.S. patent application relating to activation of antigen presenting cells. Patent applications in this family are expected to expire in 2040, absent any term adjustments or extensions. A corresponding foreign application has been filed in Europe.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exclusively Licensed Intellectual Property&#8201;&#8212;&#8201;NYU</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma has exclusive rights to one patent family, and non-exclusive rights to related know-how by virtue of a license agreement with New York University, or NYU. The rights granted under the NYU license are to all indications for human use. This licensed patent portfolio includes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A patent family that includes one U.S. patent relating to a chimeric HIV-1 vector with an SIV minimal Vpx packaging domain and method of making virions with enhanced infectivity for macrophages and dendric cells. The U.S. patent is expected to expire in 2033, absent any term adjustments or extensions.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">288</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma Owned Intellectual Property</font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma currently owns four U.S. patent families. This owned patent portfolio includes:</font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A patent family that includes one issued U.S. patent and two pending U.S. patent applications relating to macrophages, monocytes and dendric cells comprising novel CAR constructs. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A patent family that includes one pending Patent Cooperation Treaty, or PCT, application relating to mRNA transfection of macrophages, monocytes and dendric cells comprising CARs. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A patent family that includes one pending PCT application relating to modified immune cells for fibrosis and inflammation. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A patent family that includes one pending PCT application relating to self-polarizing immune cells. Patent applications in this family are expected to expire in 2042, absent any term adjustments or extensions.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma will also seek to generate additional intellectual property that covers enhancements to all aspects of the platform, including novel CARs, combinations, gene editing and manufacturing improvements. Where appropriate, Carisma will also look to in-license relevant technology from third parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent Term and Patent Term Extensions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20&#160;years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug, biological product or medical device approved pursuant to a pre-market approval may also be eligible for patent term extension, or PTE, when FDA approval is granted, provided statutory and regulatory requirements are met. The length of the PTE is related to the length of time the drug is under regulatory review while the patent is in force. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five&#160;years beyond the expiration date set for the patent. Patent extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent applicable to each regulatory review period may be granted an extension and only those claims regarding the approved drug are extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Trademarks</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s trademark portfolio currently includes registered U.S. trademarks for Carisma in the United States, Europe, Great Britain and Japan. In order to supplement the protection of its brand, Carisma also has a registered internet domain name. Going forward, Carisma will consider additional trademarks to enhance its brand and support its products. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Trade Secrets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma relies, in some circumstances, on trade secrets to protect its unpatented technology. However, trade secrets can be difficult to protect in certain circumstances. Carisma seeks to protect its trade secrets and proprietary technology and processes, including through confidentiality agreements with its employees, consultants, scientific advisors and contractors. Carisma also seeks to preserve the integrity and confidentiality of its data and trade secrets by maintaining physical security of its premises and physical and electronic security of its information technology systems. While Carisma has confidence in these individuals, organizations and systems, agreements or security measures may be breached. Carisma may not have adequate remedies for any breach and could lose its trade secrets through such a breach. In addition, Carisma&#8217;s trade secrets may otherwise become known or be independently discovered by competitors. To the extent </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">289</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">that its consultants, contractors or collaborators use intellectual property owned by others in their work for Carisma, disputes may arise as to the rights in related or resulting trade secrets, know-how and inventions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Moderna Collaboration Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, Carisma entered into a Collaboration and License Agreement with Moderna providing for a broad strategic partnership to discover, develop and commercialize </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> engineered CAR-M therapeutics for up to 12 oncology programs. Carisma refers to this agreement as the Moderna Collaboration Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In collaboration with Moderna, Carisma has established an approach that uses Moderna&#8217;s LNP/</font>&#8203;<font style="letter-spacing:0.2pt;">mRNA technology, together with Carisma&#8217;s CAR-M platform technology, to create novel </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> oncology medications. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Moderna Collaboration Agreement, the parties initiate research programs during a research term, focused on the discovery and research of products directed to biological targets. Either party may nominate a target for inclusion in a research program, subject to certain exclusions. Carisma refers to a target included in a research program pursuant to designated procedures as a research target. Moderna may replace research targets pursuant to designated procedures. The first four research targets have been nominated and all programs are currently in the discovery phase at Carisma. Moderna funds the cost of Carisma&#8217;s activities in accordance with an agreed research budget.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moderna has the right to designate up to 12 research targets as development targets during a specified development target nomination period upon payment of a development target designation milestone payment. Moderna can replace development targets with research targets during a specified period of time. If Moderna exercises its right to designate a development target, Moderna will have a worldwide, exclusive license under patents and know-how controlled by Carisma to develop and commercialize products directed to the applicable development target, subject to certain diligence obligations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Commencing a specified time after the effective date of the Moderna Collaboration Agreement, Moderna will have the right to nominate targets relating to diseases outside the field of oncology for inclusion in research programs in specified circumstances. Such right is subject to the same exclusions as Moderna&#8217;s right to nominate other targets for inclusion in research programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the term of the Moderna Collaboration Agreement, Carisma and its affiliates are subject to various exclusivity obligations under which Carisma is not permitted to research, develop or commercialize particular products outside of the collaboration, including products for use as </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> therapies in the field of oncology, products directed to any target included in the collaboration, or products containing a polypeptide provided by Carisma to Moderna in connection with a research program that are directed to any development target. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Moderna Collaboration Agreement, Carisma received a $45.0&#160;million up-front cash payment. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, Carisma is also eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. In addition, Carisma is eligible to receive mid to high single digit tiered royalties on net sales of any products that are commercialized under the agreement, which may be subject to reductions. Moderna has also agreed to cover the cost of certain milestone payments and royalties Carisma owes to a licensor under one of its intellectual property in-license agreements that Carisma is sublicensing to Moderna under the Moderna Collaboration Agreement, which royalties Moderna may deduct in part from any royalties owed to Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless earlier terminated, the Moderna Collaboration Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Moderna Collaboration Agreement will expire on a country-by-country basis upon the later of (1)&#160;the expiration of the last-to-expire valid patent claim of specified patents, (2)&#160;the expiration of regulatory-based exclusivity for such product in such country or (3)&#160;ten years after the first commercial sale with respect to such product in such country. Moderna has the right to terminate the Moderna Collaboration Agreement for convenience in its entirety or with respect to a specific product or target on ninety days&#8217; prior notice. Either Carisma or Moderna may terminate the Moderna Collaboration Agreement in its entirety if the other party is in material </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">290</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tUNPLA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">breach and such breach is not cured within the specified cure period, except in the case of Moderna&#8217;s breach of its diligence obligations, termination by Carisma is limited to the applicable target and product. In addition, either Carisma or Moderna may terminate the Moderna Collaboration Agreement in the event of specified insolvency events involving the other party. As an alternative to termination in the event of Carisma&#8217;s uncured material breach of certain sections of the agreement, Moderna has the option to continue the collaboration under the agreement with reduced payment obligations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">University of Pennsylvania License Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2017, Carisma entered into a license agreement with the Trustees of the University of Pennsylvania, or Penn, which was amended in February&#160;2018, January&#160;2019, March&#160;2020 and June&#160;2021. Carisma refers to this agreement as the Penn License Agreement. Pursuant to the Penn License Agreement, Penn granted Carisma (1)&#160;an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s interest in specified patents related to CAR macrophages, monocytes or dendritic cells, which Carisma refers to collectively as CAR-M, (2)&#160;an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s interest in specified patents related to CAR-M directed to mesothelin, and (3)&#160;a nonexclusive, worldwide license under Penn&#8217;s interest in specified know-how related to CAR-M, with limited rights to sublicense only in combination with specified products or patents. These licensed patents and know-how arose primarily from research conducted by Dr.&#160;Saar Gill and Dr.&#160;Michael Klichinsky at the University of Pennsylvania, co-founders of Carisma. The foregoing licenses are subject to rights retained by Penn for specified non-commercial uses and rights retained by the United States government. Under the Penn License agreement, Carisma is obligated to use commercially reasonable efforts to pursue development and commercialization of at least one CAR-M product in oncology and non-oncology fields. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is responsible for paying Penn an annual license maintenance fee in the low tens of thousands of dollars, payable until Carisma&#8217;s first payment of a royalty. Carisma is required to pay Penn up to $10.9&#160;million per product in development and regulatory milestone payments, up to $30.0&#160;million per product in commercial milestone payments, and up to an additional $1.7&#160;million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. While the agreement remains in effect, Carisma is required to pay Penn low to mid-single digit&#160;percentage tiered royalties on annual net sales of licensed products, which may be subject to reductions. Penn is guaranteed a minimum royalty payment amount in the low hundreds of thousands of dollars for each year after the first commercial sale of a licensed product. Carisma must also pay Penn a&#160;percentage in the mid-single digits to low double digits of certain types of income Carisma receives from sublicensees. In addition, Carisma is required to pay Penn an annual alliance management fee in the low tens of thousands of dollars, ending after several&#160;years, unless Carisma provides funding to Penn for research and development activities that extend beyond a specified date, in which case Carisma will continue to owe the alliance management fee for each year in which Carisma continues to fund such activities. Carisma also paid Penn an upfront fee in the low hundreds of thousands of dollars for the license to the patents related to the mesothelin binder that is incorporated into the CAR design for Carisma&#8217;s mesothelin product candidate. Carisma is responsible for a pro&#160;rata share of costs relating to the prosecution and maintenance of the licensed patents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The royalty period for each licensed product will expire on a product-by-product basis upon the later of (1) the expiration of the last-to-expire valid patent claim of the licensed patents covering such product in the country of sale or in the country of manufacture, or (2) the expiration of regulatory-based exclusivity for such product in the country of sale. The license agreement remains in effect until the later of (1)&#160;expiration or abandonment of the last licensed patent or (2)&#160;loss of regulatory exclusivity. Carisma may terminate the agreement for convenience upon thirty days&#8217; prior notice. Penn may terminate the agreement for Carisma&#8217;s material breach, subject to a specified cure period, except for certain breaches for which Penn may terminate immediately. Penn may also terminate if Carisma becomes the subject of a specified insolvency event. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">New York University License Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In July&#160;2020, Carisma entered into a license agreement with NYU. Carisma refers to this agreement as the NYU License Agreement. Pursuant to the NYU License Agreement, NYU granted Carisma (1)&#160;an exclusive, worldwide license, with specified rights to sublicense, under NYU&#8217;s interest in specified patents related to the Vpx-LV and (2)&#160;a nonexclusive, worldwide license, with specified rights to sublicense, under </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">291</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCOM1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">NYU&#8217;s interest in specified know-how related to the Vpx-LV, in each case to develop, manufacture, use and sell products developed using the Vpx-LV, which Carisma refers to as Licensed Products. The foregoing licenses are subject to rights retained by NYU to use, and to permit other non-commercial entities to use, the licensed patents and licensed know-how for educational and research purposes, as well as rights retained by the United States government. Under the NYU License Agreement, Carisma is obligated to use reasonable diligence to carry out a specified development plan and to obtain regulatory approval for Licensed Products in the U.S. and each of the other countries in which Carisma or its sublicensees intend to produce, use, and/or sell Licensed Products, as well as to begin the regular commercial production, use, and sale of the Licensed Products in good faith in accordance with the development plan and to continue diligently thereafter to commercialize the Licensed Products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is required to pay NYU an annual license maintenance fee in the mid tens of thousands of dollars; up to $1,685,000 per Licensed Product in development and regulatory milestone payments; and low single digit&#160;percentage tiered royalties on annual net sales of Licensed Products on a country-by-country basis until the later of (1)&#160;12&#160;years after first commercial sale of a Licensed Product in such country or (2)&#160;expiration of the last to expire licensed patent. Carisma must also pay NYU a&#160;percentage in the low single digits to low double digits of certain types of income Carisma receives from sublicensees or assignees of the agreement. Carisma is also responsible for all costs relating to the prosecution, maintenance, and defense of the licensed patents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The NYU License Agreement remains in effect until the expiration of all royalty terms in all countries. Either party may terminate the NYU License Agreement for the other party&#8217;s uncured material breach or insolvency or bankruptcy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The biopharmaceutical industry, and in particular the cell therapy field, is characterized by intense investment and competition aimed at rapidly advancing new technologies, intense competition, and a strong emphasis on intellectual property and proprietary products. Carisma&#8217;s platform and therapeutic product candidates are expected to face substantial competition from multiple technologies, marketed products, and numerous other therapies being developed by other biopharmaceutical companies, academic research institutions, governmental agencies, and public and private research institutions. Many of Carisma&#8217;s potential competitors have substantially greater financial, technical, and other resources, such as larger research and development staff, established manufacturing capabilities and facilities, and experienced marketing organizations with well-established sales forces, and any product candidates that Carisma successfully develops and commercializes will compete with existing therapies and new therapies that may become available in the future. In addition, there is substantial patent infringement litigation in the biopharmaceutical industry, and, in the future, Carisma may bring or defend such litigation against its competitors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The key competitive factors affecting the success of Carisma&#8217;s product candidates, if approved, are likely to be their efficacy, safety, convenience and price, the level of competition, and the availability of coverage and adequate reimbursement from third-party payors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unlike other cell therapy approaches, Carisma&#8217;s CAR-M platform is based on engineering macrophages and monocytes with proprietary vectors, constructs, and processes, enabling a differentiated platform from other cell therapy competitors that primarily focus on T or NK cells. While Carisma believes that its scientific expertise, novel technology, and intellectual property position offer competitive advantages, Carisma faces competition from multiple other cell therapy technologies and companies. Other companies developing engineered myeloid cell therapies include, among others, Myeloid Therapeutics, Shoreline Biosciences, Inceptor Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, Sirpant Therapeutics, and others. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Due to the broad promise of cell therapies, and the potential of myeloid cell-based approaches to expand cell therapy efficacy into solid tumors, Carisma expects increasing competition from new and existing companies across several fronts, which include, among others: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Myeloid cell therapies:</font><font style="letter-spacing:0.2pt;"> Myeloid Therapeutics, Shoreline Biosciences, Inceptor Bio, Thunder Bio, CellOrigin, Deverra </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">292</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tGORE1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Autologous T-cell therapies:</font><font style="letter-spacing:0.2pt;"> Adaptimmune Therapeutics, Autolus Therapeutics, Bluebird, Bristol Myers Squibb, Kite/Gilead, Novartis, Gracell, TCR2, Poseida, Vor, TMunity, among others </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Allogeneic T-cell therapies:</font><font style="letter-spacing:0.2pt;"> Allogene, Atara, Century, Cellectis, Celyad, CRISPR, Fate, Gracell, Kite/</font>&#8203;<font style="letter-spacing:0.2pt;">Gilead, Legend, Poseida, Precision Bio, Sana, Vor, among others </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">NK and other cell therapies:</font><font style="letter-spacing:0.2pt;"> Artiva, Celularity, Century, Editas, Fate, Fortress, ImmunityBio, Nkarta, NKGen, Takeda, Adicet, Gamida Cell, among others </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Direct in vivo reprogrammed cell therapies:</font><font style="letter-spacing:0.2pt;"> Umoja, Ensoma, Interius, Tidal/Sanofi, BioNTech </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to competition from other cell therapy companies, any products that Carisma develops may also face competition from other types of therapies. Other companies developing non-cell therapies, including gene therapies, include Gilead, ALX Oncology, Trillium, Five-Prime, Immune-Onc, Pionyr, Infinity, NextCure, OncoResponse, Curis, Faron, Apexigen, Pfizer, Dren, and multiple biotechnology and pharmaceutical companies developing other directly competitive technologies such as small molecules, immune agonists, antibodies, bi/tri specific antibodies, antibody drug conjugates, and other solid tumor therapeutics. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma also competes with third parties for retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, its programs. Carisma may pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. The acquisition and licensing of technologies and product candidates is a competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that Carisma may consider attractive. These established companies may have a competitive advantage over Carisma due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive Carisma to be a competitor may be unwilling to assign or license rights to Carisma. Carisma also may be unable to in-license or acquire the relevant technology or product candidate on terms that would allow it to make an appropriate return on its investment.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s commercial opportunity could be reduced or eliminated if its competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that it may develop. Carisma&#8217;s competitors also may obtain FDA or other regulatory approval for their products more rapidly than it may obtain approval for Carisma&#8217;s, which could result in its competitors establishing a strong market position before it is able to enter the market. In addition, Carisma&#8217;s ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Licensure and Regulation of Biologics in the United States</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States, Carisma&#8217;s product candidates are regulated as biological products, or biologics, under the PHSA and the FDCA, and its implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable U.S. requirements at any time during the product development process, including pre-clinical testing, clinical testing, the approval process, or post-approval process, may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">293</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">subject a sponsor to delays in the conduct of the study, regulatory review, and approval, and/or administrative or judicial sanctions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A sponsor seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">pre-clinical laboratory tests, animal studies, and formulation studies all performed in accordance with the FDA&#8217;s GLP regulations and standards and other applicable regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">design of a clinical protocol and submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">performance of adequate and well-controlled human clinical trials to establish the safety, potency, and purity of the product candidate for each proposed indication, in accordance with current GCP; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">preparation and submission to the FDA of a BLA for a biologic product requesting marketing for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">review of the product by an FDA advisory committee, where appropriate or if applicable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the product&#8217;s identity, strength, quality, and purity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of any FDA audits of the pre-clinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">payment of user PDUFA, securing FDA approval of the BLA and licensure of the new biologic product; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">compliance with any post-approval requirements, including the potential requirement to implement a or REMS and any post-approval studies or other post-marketing commitments required by the FDA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pre-clinical Studies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before testing any biologic product candidate in humans, the product candidate must undergo pre-clinical testing. Pre-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. The conduct of the pre-clinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture&#8217;s Animal Welfare Act, if applicable. The results of the pre-clinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investigational New Drug Application</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">294</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">concerns before the clinical trials can begin or recommence. As a result, submission of the IND may result in the FDA not allowing the trials to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">If the FDA raises concerns or questions either during this initial 30-day period, or at any time during the IND process, it may choose to impose a partial or complete clinical hold. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, pre-clinical, and/or chemistry, manufacturing, and controls. This order issued by the FDA would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. This could cause significant delays or difficulties in completing Carisma&#8217;s planned clinical trial or future clinical trials in a timely manner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence. Occasionally, clinical holds are imposed due to manufacturing issues that may present safety issues for the clinical study subjects. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Expanded Access to an Investigational Drug for Treatment Use</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st Century Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it evaluates and responds to expanded access requests, sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase&#160;2 or Phase&#160;3 clinical trial, or 15&#160;days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to and separate from expanded access, on May&#160;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase&#160;1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Human Clinical Trials in Support of a BLA</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">295</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements, including GCP requirements, of the FDA in order to use the trial as support for an IND or application for marketing approval. The GCP requirements encompass both ethical and data integrity standards for clinical trials. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign trials are conducted in a manner comparable to that required for clinical trials in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB. This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB has access. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;1</font><font style="letter-spacing:0.2pt;"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;2</font><font style="letter-spacing:0.2pt;"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase&#160;2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase&#160;3 clinical trials. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;3</font><font style="letter-spacing:0.2pt;"> clinical trials proceed if the Phase&#160;2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase&#160;3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase&#160;3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase&#160;3 studies are referred to as &#8220;pivotal.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase&#160;4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase&#160;4 clinical trial requirement or to request a change </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">296</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">in the product labeling. The failure to exercise due diligence with regard to conducting Phase&#160;4 clinical trials could result in withdrawal of approval for products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase&#160;3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Generally, pivotal trials are Phase&#160;3 trials, but they may be Phase&#160;2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Finally, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Both NIH and the FDA have recently signaled the government&#8217;s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors. The failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Regulations and Guidance Governing Gene Therapy Products</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA has defined a gene therapy product as one that mediates its effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and which is administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> or transferred to cells </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> prior to administration to the recipient. Within the FDA, the Center for Biologics Evaluation and Research, or CBER, regulates gene therapy products. Within CBER, the review of gene therapy and related products is consolidated in the OTAT, and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its reviews. CBER works closely with the Local Biosafety Board, a federal advisory committee, in reviewing proposed and ongoing gene therapy protocols and engaging in a public discussion of scientific, safety, ethical, and societal issues related to those protocols. The NIH and the Recombinant DNA Advisory Committee, or RAC, a federal advisory committee, also advise the FDA on gene therapy issues and other issues related to emerging technologies. The FDA and the NIH have published guidance documents with respect to the development and submission of gene therapy protocols. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA has issued various guidance documents regarding gene therapies, including final guidance documents released in January&#160;2020 relating to chemistry, manufacturing and controls information for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders, as well as draft guidance in January&#160;2021 for Human Gene Therapy for Neurodegenerative Diseases. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, Carisma believes that its compliance with them is likely necessary to gain approval for any gene therapy product candidate Carisma may develop. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper pre-clinical assessment of gene therapies; the chemistry, manufacturing, and control information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five&#160;years of annual examinations followed by 10&#160;years of annual queries, either in person or by questionnaire. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, to facilitate adverse event reporting and dissemination of additional information about gene therapy trials, the FDA and the NIH established the Genetic Modification Clinical Research Information System, or GeMCRIS. Investigators and sponsors of human gene transfer trials can utilize this web-based system to report serious adverse events and to provide annual reports. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">297</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Finally, for a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with good tissue practices, or GTP. These standards are found in FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure thatT-cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pediatric Studies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are completed. The FDA is required to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Compliance with cGMP Requirements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with its review of a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. The FDA&#8217;s regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the sponsor and any third-party manufacturers involved in producing the approved product. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">298</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Submission and Filing of a BLA</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The results of product candidate development, pre-clinical testing, and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting license to market the product. The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs is subject to an application user fee, which for federal fiscal year 2022 is $3,117,218 for an application requiring clinical data. The sponsor of a licensed BLA is also subject to an annual program fee, which for federal fiscal year 2022 is $369,413. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following submission of a BLA, the FDA has 60&#160;days to conduct a preliminary review of the application and it must inform the sponsor within that period of time whether the BLA is sufficiently complete to permit substantive review. In the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. The FDA may request additional information and studies, and the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has ten&#160;months in which to complete its initial review of a standard application and respond to the sponsor, and six&#160;months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by three&#160;months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three&#160;months before the PDUFA goal date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA may also refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The FDA&#8217;s Decision on a BLA</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure, and potent, and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. Specifically, the FDA must determine that the expected benefits of the proposed product outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the proposed product in the BLA. On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of pre-clinical and clinical trial sites to assure compliance with GCPs, the FDA may issue a complete response letter, or CRL, or an approval letter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the application is not approved, the FDA will issue a CRL, which will contain the conditions that must be met in order to secure final approval of the application and will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a CRL may submit to the FDA information that represents a complete response to the issues identified by the FDA, withdraw the application or request a hearing. The FDA will not approve an application until issues identified in the CRL have been addressed. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six-month extension to respond. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. The FDA may limit the approved indication(s) for use of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">299</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase&#160;4 clinical trials, to further assess the product&#8217;s efficacy and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Expedited Review Programs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA is authorized to expedite the review of applications in several ways. None of these expedited programs changes the standards for approval but each may help expedite the development or approval process governing product candidates. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Fast Track designation.&nbsp;&nbsp;&nbsp;The sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if </font><font style="font-style:italic;letter-spacing:0.2pt;">they</font><font style="letter-spacing:0.2pt;"> are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Breakthrough therapy designation.&nbsp;&nbsp;&nbsp;To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Priority review.&nbsp;&nbsp;&nbsp;A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six&#160;months as opposed to 10&#160;months for standard review. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Accelerated approval.&nbsp;&nbsp;&nbsp;Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Regenerative advanced therapy.&nbsp;&nbsp;&nbsp;With passage of the Cures Act, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">300</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Post-Approval Regulation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency, and effectiveness of pharmaceutical products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fines, warning letters or holds on post-approval clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product seizure or detention, or refusal to permit the import or export of products; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">injunctions or the imposition of civil or criminal penalties. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. In September&#160;2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a biologic product. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">301</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Orphan Drug Designation and Exclusivity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven&#160;years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same indication for seven&#160;years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The period of exclusivity begins on the date that the marketing application is approved by the FDA. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Under Omnibus legislation enacted in December&#160;2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by FDA. In addition, the FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> Circuit in September&#160;2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pediatric Exclusivity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pediatric exclusivity is another type of non-patent exclusivity in the United States and for biologics, if granted, provides for the attachment of an additional six&#160;months of regulatory exclusivity to the term of any existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">302</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity that cover the product are extended by six&#160;months. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Biosimilars and Exclusivity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The 2010 Patient Protection and Affordable Care Act, which was signed into law in March&#160;2010, included a subtitle called the BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an existing FDA-licensed &#8220;reference product.&#8221; As of January&#160;1, 2021, the FDA has approved 29 biosimilar products for use in the United States. To date, the FDA has approved a number of biosimilars, and the first interchangeable biosimilar product was approved on July&#160;30, 2021, and a second product previously approved as a biosimilar was designated as interchangeable in October&#160;2021. The FDA has also issued numerous guidance documents outlining its approach to reviewing and licensing biosimilars and interchangeable biosimilars under the PHSA, including a draft guidance issued in November&#160;2020 that seeks to provide additional clarity to manufacturers of interchangeable biosimilars. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12&#160;years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Federal and State Data Privacy and Security Laws</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under HIPAA, the U.S. Department of Health and Human Services has issued regulations to protect the privacy and security of protected health information used or disclosed by covered entities including certain healthcare providers, health plans, and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes, and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their regulations, including the omnibus final rule published on January&#160;25, 2013, also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that are applicable to Carisma&#8217;s business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Accordingly, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. New laws and regulations governing privacy and security may be adopted in the future as well. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">303</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States, the CCPA. The CCPA creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January&#160;1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. The CCPA could impact Carisma&#8217;s business activities depending on how it is interpreted and exemplifies the vulnerability of Carisma&#8217;s business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of Carisma&#8217;s current or future business activities, including certain clinical research, sales, and marketing practices and the provision of certain items and services to Carisma&#8217;s customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If Carisma&#8217;s operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to Carisma, or any other laws that apply to Carisma, Carisma may be subject to penalties, including potentially significant criminal, civil, and administrative penalties, damages, fines, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, and/or oversight if Carisma becomes subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of Carisma&#8217;s operations, any of which could adversely affect Carisma&#8217;s ability to operate its business and its results of operations. To the extent that any of Carisma&#8217;s product candidates, once approved, are sold in a foreign country, Carisma may be subject to similar foreign laws. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Patent Term Restoration and Extension</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five&#160;years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND clearing clinical studies and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&#160;years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">FDA Approval of Companion Diagnostics</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July&#160;2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> companion diagnostic device on issues related to co-development of the products. The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">304</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2020, the FDA issued additional guidance which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple biological oncology products, when appropriate. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the FDCA, </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA previously has required </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> companion diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several&#160;years or longer. It involves a rigorous premarket review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. For federal fiscal year 2022, the standard fee is $374,858 and the small business fee is $93,714. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Coverage, Pricing, and Reimbursement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which Carisma may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates Carisma may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any product candidates Carisma may develop are approved, sales of such product candidates will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates Carisma may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on Carisma&#8217;s sales, results of operations and financial condition. Additionally, a payor&#8217;s decision </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">305</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be available to enable Carisma to maintain price levels sufficient to realize an appropriate return on Carisma&#8217;s investment in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to any companion diagnostics. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Outside the United States, ensuring adequate coverage and payment for any product candidates Carisma may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require Carisma to conduct a clinical trial that compares the cost effectiveness of any product candidates Carisma may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in Carisma&#8217;s commercialization efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of Carisma&#8217;s products, if approved in those countries. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthcare Law and Regulation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to physicians and teaching physicians and patient privacy laws and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">306</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">regulations and other healthcare laws and regulations that may constrain Carisma&#8217;s business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Foreign Corrupt Practices Act, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal transparency requirements under the ACA, which require certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the CMS within the U.S. Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. In addition, certain state and local laws require drug manufacturers to register pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If Carisma&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to Carisma, Carisma may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of Carisma&#8217;s operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthcare Reform</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few&#160;years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government healthcare programs. Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which will remain in effect through 2031 pursuant to the Coronavirus Aid, Relief and Economic Security Act or CARES Act. The American Taxpayer Relief Act of 2012, which was enacted in January&#160;2013, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers, and cancer treatment centers, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">307</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. Further, with passage of the Inflation Reduction Act in August&#160;2022, Congress extended the expansion of ACA premium tax credits through 2025. Those subsidies were originally extended through 2022 under the American Rescue Plan&#160;Act of 2021. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices Carisma may obtain for any of Carisma&#8217;s product candidates for which Carisma may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the TCJA, which was signed by President Trump on December&#160;22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019 Further, on December&#160;14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the PPACA is an essential and inseverable feature of the ACA and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case on November&#160;10, 2020 and, on June&#160;17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although the previous administration took executive actions to undermine or delay implementation of the ACA, those actions were rescinded with issuance of an Executive Order on January&#160;28, 2021, by President Biden which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access. Under this Executive Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part&#160;B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January&#160;1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December&#160;29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part&#160;B pharmaceuticals and improve beneficiaries&#8217; access to evidence-based care. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in October&#160;2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section&#160;804 Importation Program, or SIP, to import certain prescription products from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of products from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January&#160;1, 2022 to January&#160;1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which has been delayed until January&#160;1, 2026, by the Infrastructure Investment and Jobs Act. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">308</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEAHC">&#8203;</a><a name="tFAC">&#8203;</a><a name="tLEPR1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">More recently, with passage of the Inflation Reduction Act in August&#160;2022, Congress authorized Medicare beginning in 2026 to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars. This provision is limited in terms of the number of pharmaceuticals whose prices can be negotiated in any given year and it only applies to drug products that have been approved for at least 9&#160;years and biologics that have been licensed for 13&#160;years. Drugs and biologics that have been approved for a single rare disease or condition are categorically excluded from Medicare price negotiations. Further, the new legislation provides that if pharmaceutical companies raise prices in Medicare faster than the rate of inflation, they must pay rebates back to the government for the difference. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals. The Order directs HHS to create a plan within 45&#160;days to combat &#8220;excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.&#8221; On September&#160;9, 2021, HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a)&#160;make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b)&#160;improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars, and increase transparency; and (c)&#160;foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require pharmaceutical manufacturers and other entities in the supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for Carisma&#8217;s products, once approved, or put pressure on Carisma&#8217;s product pricing. Carisma expects that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for Carisma&#8217;s product candidates or additional pricing pressures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employees and Human Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January 4, 2023, Carisma had 94 full-time employees, including a total of 33 employees with M.D. or Ph.D. degrees. Of these full-time employees, 85 are engaged in research and development activities. None of Carisma&#8217;s employees are represented by labor unions or covered by collective bargaining agreements. Carisma considers its relationship with its employees to be good. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s human capital objectives are focused on attracting, developing, and retaining talent. Cash compensation plans and equity grants are designed to attract, retain and to motivate employees, directors, and select consultants to achieve our corporate objectives. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Facilities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s principal facilities consist of office and laboratory space in Philadelphia, Pennsylvania. Carisma occupies approximately 4,369 square feet of office space under a lease that is expected to expire in January&#160;2030 and approximately 3,600 square feet of laboratory space under a lease that expires in October&#160;2023. Carisma believes that its facilities are sufficient to meet its current needs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Proceedings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is currently not a party to any material legal proceedings.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">309</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSBMD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</font>
          <br >
          <font style="letter-spacing:-0.2pt;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following discussion and analysis should be read in conjunction with Sesen Bio&#8217;s financial statements and related notes included elsewhere in this proxy statement/prospectus. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Sesen Bio&#8217;s actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set out under the section entitled &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">26</a> of this proxy statement/prospectus and elsewhere in this proxy statement/prospectus. See also the section entitled &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221; beginning on page&#160;<a href="#tCSCF">118</a> of this proxy statement/prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is a late-stage clinical company that was previously focused on advancing TFPTs for the treatment of patients with cancer. Sesen Bio&#8217;s most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an EpCAM antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of NMIBC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the U.S. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase&#160;3 clinical trial, following Sesen Bio&#8217;s discussions with the FDA, which are further described below. Sesen Bio no longer plans to pursue regulatory approval of Vicineum for NMIBC in the E.U. and has started to wind down certain of its manufacturing operations and business development partnerships. Sesen Bio has turned its primary focus to consummating a strategic transaction with the goal of maximizing shareholder value. Additionally, Sesen Bio is seeking a partner for the further development of Vicineum and has engaged a financial advisor for the potential sale of Vicineum. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Current Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Merger</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In May&#160;2022, Sesen Bio announced that it had commenced a process to explore and evaluate strategic alternatives to enhance stockholder value, and had engaged a financial advisor to assist Sesen Bio in this process. Sesen Bio then commenced an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic acquisition or other transaction as described in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger&#8201;&#8212;&#8201;Background of the Merger</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tBOTM">125</a> of this proxy statement/prospectus. On September&#160;21, 2022, Sesen Bio announced that it had entered into the Merger Agreement. Although Sesen Bio has entered into the Merger Agreement and intends to consummate the merger, there is no assurance that it will be able to successfully consummate the merger on a timely basis, or at all. If, for any reason, the merger does not close, the Sesen Bio board of directors may elect to, among other things, attempt to complete another strategic transaction like the merger, attempt to sell or otherwise dispose of the various assets of Sesen Bio, resume its research and development activities and continue to operate the business of Sesen Bio or dissolve and liquidate its assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the merger is not completed, the Sesen Bio board of directors may decide that it is in the best interests of the Sesen Bio stockholders to dissolve the company and liquidate its assets. In that event, the amount of cash available for distribution to the Sesen Bio stockholders would depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as Sesen Bio funds its operations and incurs fees and expenses related to the merger. In addition, if the Sesen Bio board of directors were to approve and recommend, and the Sesen Bio stockholders were to approve, a dissolution of Sesen Bio, it would be required under Delaware corporate law to pay its outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to the Sesen Bio stockholders. As a result of this requirement, a portion of Sesen Bio&#8217;s assets may need to be reserved pending the resolution of such obligations. In addition, Sesen Bio may be subject to litigation or other claims related to a liquidation and dissolution of the company. If a liquidation and dissolution were pursued, the Sesen Bio board of directors, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">310</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, the Sesen Bio stockholders could lose all or a significant portion of their investment in the event of a liquidation and dissolution of Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Recent Events</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">2022 Restructuring Plan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, Sesen Bio approved the 2022 restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the United States. Execution of the 2022 restructuring plan is expected to be substantially completed in connection with the closing of the merger with Carisma, which is expected to occur in the first quarter of 2023. The 2022 restructuring plan includes an incremental reduction in Sesen Bio&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the merger with Carisma and while Sesen Bio seeks a potential partner for the further development of Vicineum. Sesen Bio has also incurred one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 restructuring plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Sale of Legacy Technology to Roche</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, Sesen Bio executed the Roche Asset Purchase Agreement pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by Sesen Bio for up to $70&#160;million. As a result of the Roche Asset Purchase Agreement, the exclusive license agreement between Roche and Sesen Bio was terminated resulting in no further diligence, milestone or royalty payment obligations under such license agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40&#160;million payment to Sesen Bio upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30&#160;million payable to Sesen Bio upon Roche&#8217;s initiation of a Phase&#160;3 clinical trial with EBI-031 for a defined indication if initiated prior to December&#160;31, 2026. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">2022 Retention Program</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;28, 2022, the Sesen Bio board of directors and the Sesen Bio compensation committee approved a retention program for certain employees pursuant to which Sesen Bio will provide a cash incentive designed to retain such employees. Pursuant to this retention program, certain of Sesen Bio&#8217;s employees, including certain executive officers, will receive a cash bonus award, which vests in full upon the earlier of the completion of a strategic transaction and termination without cause, subject to continued employment through that time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Components of Sesen Bio&#8217;s Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">License and Related Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">License revenue consists of revenue recognized pursuant to Sesen Bio&#8217;s OUS business development partnership agreements, including the Qilu License Agreement, and the Roche Asset Purchase Agreement, which is assessed under ASC Topic 606, Revenue. Sesen Bio has terminated all of its OUS business development partnership agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses consist primarily of costs incurred for the development of Vicineum for the treatment of NMIBC, which include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">employee-related expenses, including salaries, benefits, travel and share-based compensation expense; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expenses incurred under agreements with CROs and investigative sites that conduct Sesen Bio&#8217;s clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expenses associated with developing manufacturing capabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">311</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expenses associated with transferring manufacturing capabilities to CMOs for commercial-scale production; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expenses associated with regulatory activities; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expenses associated with license milestone fees. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio expenses research and development costs as incurred. Sesen Bio recognizes external development costs based on an evaluation of the progress to completion of specific tasks using information and data provided to Sesen Bio by its vendors and its clinical sites. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio allocates direct research and development expenses, consisting principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with its clinical trials, costs related to manufacturing or purchasing clinical trial materials and technology transfer and license milestone fees, to specific product programs. Sesen Bio does not allocate employee and contractor-related costs, costs associated with its platform and facility expenses, including depreciation or other indirect costs, to specific product programs because these costs may be deployed across multiple product programs under research and development and, as such, are separately classified. The table below provides research and development expenses incurred for Vicineum for the treatment of NMIBC and other expenses by category. Sesen Bio expects to significantly reduce its research and development expenses during the pendency of the proposed merger with Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio did not allocate research and development expenses to any other specific product program during the periods presented (in thousands): </font>
        </div>
        <table style="width:456pt;height:183pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Programs: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vicineum for the treatment of NMIBC </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">813</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">2,989</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">29,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,888</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total direct program expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">813</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">2,989</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">29,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,888</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Personnel and other expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Employee and contractor-related expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,840</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,732</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">6,920</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,392</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Platform-related lab expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">133</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Facility expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">150</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">124</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">428</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">392</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">123</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">103</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">483</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">468</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total personnel and other expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">2,118</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">1,978</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">7,931</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">7,385</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:284.84pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:-0.2pt;">Total Research and Development</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">2,931</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">4,967</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">37,636</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">18,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and Administrative</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses consist primarily of salaries and related costs for personnel, including share-based compensation and benefits, in executive, operational, finance, legal, business development and human resource functions. Other general and administrative expenses include facility-related costs, professional fees for legal, estimated payments to settle litigation, insurance, investment banking fees, patent, consulting and accounting services, and pre-commercial United States market research. Sesen Bio expects its general and administrative expenses to increase due to increases in professional and advisory fees during the pendency of the proposed merger with Carisma. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Change in Fair Value of Contingent Consideration</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Viventia Acquisition in September&#160;2016, Sesen Bio recorded contingent consideration pertaining to the amounts potentially payable to Viventia&#8217;s shareholders pursuant to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">312</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">terms of the Share Purchase Agreement among Sesen Bio, Viventia and the other signatories thereto and are based on regulatory approval in certain markets and future revenue levels. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized in earnings (or loss) for the period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Income, Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other income, net consists primarily of interest income earned on cash and cash equivalents and, to a lesser extent, any gains or losses on foreign exchange. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Provision for Income Taxes</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Benefit for income taxes is driven by the intangible impairment charge, changing the value of deferred tax liabilities. Provision for income taxes consists of income taxes incurred to non-U.S. jurisdictions pursuant to Sesen Bio&#8217;s OUS business development partnership agreements, including the Qilu License Agreement, which was terminated on December 23, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio&#8217;s Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the three&#160;months ended September&#160;30, 2022 and 2021</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:288.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:259.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Increase/(Decrease) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:259.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Dollars </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:259.97pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:259.97pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">License and related revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:259.97pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,931</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,967</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(2,036<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(41<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">8,141</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8,699</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(558<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restructuring charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">10,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,522</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,425</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">98<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(31,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(1,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(114,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">112,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(98<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">20,219</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(63,112<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">83,331</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(132<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Income from Operations </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">19,781</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">63,112</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(43,331<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(69<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:259.97pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">676</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">675</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">67,500<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Income Before Taxes</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">20,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">63,113</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(42,656<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(68<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:259.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Benefit from income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">8,561</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:259.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net Income After Taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">20,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">71,674</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(51,217<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(71<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:4.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.3pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Revenue for the three&#160;months ended September&#160;30, 2022 was $40.0&#160;million, which was due to the execution of the Roche Asset Purchase Agreement for EBI-031 and all other IL-6 antagonist monoclonal antibody technology. Sesen Bio did not record any revenue for the three&#160;months ended September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $2.9&#160;million for the three&#160;months ended September&#160;30, 2022, compared to $5.0&#160;million for the three&#160;months ended September&#160;30, 2021. The decrease of $2.0&#160;million was </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">313</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">primarily due to a decrease in costs associated with manufacturing ($1.9&#160;million) and a decrease in other R&amp;D related costs ($0.1&#160;million), driven by the strategic decision to voluntarily pause further development of Vicineum in the U.S. in the third quarter of 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $8.1&#160;million for the three&#160;months ended September&#160;30, 2022, compared to $8.7&#160;million for the three&#160;months ended September&#160;30, 2021. The decrease of $0.6&#160;million was primarily due to a decrease in marketing and commercialization expenses, which were incurred in the third quarter of 2021 in preparation for potential commercial launch of Vicineum but were discontinued as a result of the Complete Response Letter from the FDA received in August&#160;2021 ($2.3&#160;million) and a decrease in professional fees for accounting services ($0.4&#160;million). This was partially offset by an increase in legal expense ($1.3&#160;million), driven by legal fees associated with Sesen Bio&#8217;s assessment of strategic alternatives incurred in the third quarter of 2022 ($2.2&#160;million), partially offset by a decrease in legal fees associated with the internal review completed in February 2022 ($0.4&#160;million) and other legal expenses ($0.5&#160;million). Additionally, financial advisor fees increased due to financial advisor fees associated with Sesen Bio&#8217;s assessment of strategic alternatives incurred in the third quarter of 2022 ($0.8&#160;million). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Restructuring Charge</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Restructuring charges were $10.9&#160;million for the three&#160;months ended September&#160;30, 2022 compared to $5.5&#160;million for the three&#160;months ended September&#160;30, 2021. The expense for the third quarter of 2022 consisted of severance and other employee-related costs ($6.9&#160;million) and termination of certain contracts and other associated costs ($4.0&#160;million) associated with the 2022 restructuring plan following the decision to voluntarily pause further development of Vicineum in the United States. The expense for the third quarter of 2021 consisted of severance and other employee-related costs ($2.8&#160;million) and termination of certain contracts ($2.7&#160;million) associated with the restructuring plan Sesen Bio approved on August&#160;30, 2021 to reduce operating expenses and better align its workforce with the needs of its business following the receipt of the CRL in August&#160;2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Intangibles impairment</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Intangibles impairment charge for the three&#160;months ended September&#160;30, 2022 was zero compared to $31.7&#160;million in the three&#160;months ended September&#160;30, 2021. In August&#160;2021, Sesen Bio received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. As a result an impairment analysis was conducted, which concluded that the carrying value of its intangible asset of Vicineum U.S. rights was fully impaired as of September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of Contingent Consideration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The non-cash change in fair value of contingent consideration was a gain of $1.8&#160;million for the three&#160;months ended September&#160;30, 2022, compared to a gain of $114.0&#160;million for the three&#160;months ended September&#160;30, 2021. The decrease in the fair value of contingent consideration of $1.8&#160;million for the three&#160;months ended September&#160;30, 2022 was due to Sesen Bio&#8217;s conclusion that it no longer expects to owe any future earnout payments related to the Greater China region since Qilu has informed Sesen Bio that it no longer intends to commercialize Vicineum in the Greater China region. Accordingly, Sesen Bio reduced its remaining $1.8&#160;million of contingent consideration liabilities to zero as of September&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The change in fair value of contingent consideration was a gain of $114.0&#160;million for the three&#160;months ended September&#160;30, 2021. This was primarily driven by the receipt of a CRL from the FDA, in which the FDA determined that it cannot approve the BLA for Vicineum in its present form. Due to the inherent uncertainty in the path forward for Vicineum at the time, Sesen Bio reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of contingent consideration was based. The most significant and impactful assumptions in Sesen Bio&#8217;s revenue projection models are timing of product launch and probabilities of clinical and regulatory success, or POS; Sesen Bio expected delays in the start of commercialization and estimated lower POS as a direct result of the CRL. Sesen Bio anticipated needing to conduct an additional clinical trial, which would lead to delays in the start of commercialization globally. Sesen Bio had assessed a range of commercialization timeline assumptions and applied a probability to each </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">314</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">outcome based on management&#8217;s best estimate. In addition, Sesen Bio assumed a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. The milestone payments constitute debt-like obligations, and the high-yield debt index rate applied to the milestones in order to determine the estimated fair value was 7.5% as of September&#160;30, 2021. The discount rate applied to the 2% earnout payment due on forecasted Vicineum revenues was derived from Sesen Bio&#8217;s estimated weighted-average cost of capital, or WACC, and this WACC-derived discount rate was 8.6% as of September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Benefit (Provision) from Income Taxes</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio did not record a benefit or loss for the three&#160;months ended September&#160;30, 2022. In the third quarter of 2021, Sesen Bio determined that the fair value of the Vicineum U.S. rights was zero, which resulted in an impairment charge of $31.7&#160;million. In connection with this impairment charge, in the third quarter of 2021, Sesen Bio reduced the associated deferred tax liability which resulted in an $8.6&#160;million income tax benefit. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Net income</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the three&#160;months ended September&#160;30, 2022, net income was $20.5&#160;million, compared to $71.7&#160;million for the three&#160;months ended September&#160;30, 2021. In the third quarter of 2022, Sesen Bio recorded revenue of $40.0&#160;million related to the execution of the Roche Asset Purchase Agreement and non-cash income of $1.8&#160;million related to changes in the fair value of contingent consideration, partially offset by operating expenses of $22.0&#160;million. In the third quarter of 2021, Sesen Bio recorded net non-cash income of $90.9&#160;million, which includes changes in the fair value of contingent consideration, income tax benefit and intangible impairment charge. Additionally, Sesen Bio recorded R&amp;D, G&amp;A and restructuring charges of $19.2&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the nine&#160;months ended September&#160;30, 2022 and 2021</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:273.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Increase/(Decrease) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Dollars </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:266.64pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:266.64pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">License and related revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">33,456</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">511<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">33,456</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">511<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:266.64pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">37,636</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">18,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">19,363</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">106<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">32,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">20,797</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,908</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">57<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restructuring charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,522</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,425</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">98<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">27,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(3,936<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(52,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(52,240<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">240</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">57,052</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">24,052</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">33,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">137<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Loss from Operations </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,052<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,508<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">456</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(3<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(45<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">912</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,027<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Loss Before Taxes</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,185<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,553<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,368</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:266.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Benefit from income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">3,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(4,398<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(53<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:266.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net Loss After Taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(3,030<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.81pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Revenue for the nine&#160;months ended September&#160;30, 2022 was $40.0&#160;million, which was due to the execution of the Roche Asset Purchase Agreement. Revenue for the nine&#160;months ended September&#160;30, 2021 </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">315</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">was $6.5&#160;million, which was due to achieving the IND milestone in China pursuant to the Qilu License Agreement, clinical supply revenue resulting from the delivery of drug product to Qilu and license revenue for additional purchase price due to the recovery of VAT by Qilu. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $37.6&#160;million for the nine&#160;months ended September&#160;30, 2022, compared to $18.3&#160;million for the nine&#160;months ended September&#160;30, 2021. The increase of $19.4&#160;million was primarily due to the expense of prepaid balances related to consumables and manufacturing reservations as the balances were deemed to have no future value ($25.2&#160;million) in the second quarter of 2022. Additionally, employee-related compensation increased, primarily due to the retention programs implemented in the fourth quarter of 2021 and third quarter of 2022 ($2.6&#160;million). The increase was partially offset by decreased costs associated with manufacturing ($6.1&#160;million), clinical and manufacturing related consulting fees ($2.0&#160;million), and other individually immaterial R&amp;D costs ($0.3&#160;million), driven by the strategic decision to voluntarily pause further development of Vicineum in the U.S. in the third quarter of 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $32.7&#160;million for the nine&#160;months ended September&#160;30, 2022, compared to $20.8&#160;million for the nine&#160;months ended September&#160;30, 2021. The increase of $11.9&#160;million was primarily due to an increase in legal expense ($14.6&#160;million) driven by the preliminary settlements of the securities and derivative litigation net of expected insurance recovery ($8.2&#160;million) and legal fees associated with Sesen Bio&#8217;s assessment of strategic alternatives ($2.6&#160;million). Additionally, legal fees related to the internal review ($2.8&#160;million), securities litigation counseling ($0.9&#160;million) and other legal expenses ($0.1&#160;million) increased during the nine&#160;months ended September&#160;30, 2022. In addition, employee-related compensation increased, primarily driven by the retention programs implemented in the fourth quarter of 2021 and third quarter of 2022 ($1.3&#160;million). This was partially offset by decreases in marketing and commercial expenses ($4.0&#160;million), which were incurred during the first half of 2021 in preparation for potential commercial launch of Vicineum but were discontinued as a result of the CRL received in August&#160;2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Restructuring Charge</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Restructuring charges were $10.9&#160;million for the nine&#160;months ended September&#160;30, 2022 compared to $5.5&#160;million for the nine&#160;months ended September&#160;30, 2021. The expense for the nine&#160;months ended September&#160;30, 2022 consisted of severance and other employee-related costs ($6.9&#160;million) and termination of certain contracts and other associated costs ($4.0&#160;million) following the decision to pause further development of Vicineum in the U.S. The expense for the nine&#160;months ended September&#160;30, 2021 consisted of severance and other employee-related costs ($2.8&#160;million) and termination of certain contracts ($2.7&#160;million) following the receipt of the CRL in August&#160;2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of Contingent Consideration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The non-cash change in fair value of contingent consideration was a gain of $52.0&#160;million for the nine&#160;months ended September&#160;30, 2022, compared to a gain of $52.2&#160;million for the nine&#160;months ended September&#160;30, 2021. The decrease in the fair value of contingent consideration of $52.0&#160;million for the nine&#160;months ended September&#160;30, 2022 was driven by Sesen Bio&#8217;s strategic decision to voluntarily pause further development of Vicineum in the U.S. and its conclusion that Sesen Bio no longer expects to owe any future earnout payments related to the Greater China region since Qilu has informed Sesen Bio that it no longer intends to commercialize Vicineum in the Greater China region. The decision was based on a thorough reassessment of Vicineum following recent discussions with the FDA, which had implications for the size, timeline and costs for an additional Phase&#160;3 clinical trial for the treatment of NMIBC. Additionally, during the second quarter of 2022, Sesen Bio observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. Sesen Bio continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, is seeking a partner that can execute further development to realize the full potential of Vicineum. Sesen Bio </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">316</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:55.9400000000001pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">expects that any partner who acquires Vicineum from Sesen Bio will be obligated to make any payments to the former shareholders of Viventia under the Share Purchase Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The change in fair value of contingent consideration was a gain of $52.2&#160;million for the nine&#160;months ended September&#160;30, 2021. This was primarily driven by the receipt of a CRL in August&#160;2021, in which the FDA determined that it could not approve the BLA for Vicineum in its present form. Due to the inherent uncertainty in the path forward for Vicineum at the time, Sesen Bio reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in Sesen Bio&#8217;s revenue projection models are timing of product launch and POS; Sesen Bio expected delays in the start of commercialization and estimate lower POS as a direct result of the CRL. Sesen Bio anticipated needing to conduct an additional clinical trial, which would lead to delays in the start of commercialization globally. Sesen Bio had assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, Sesen Bio assumed a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. The milestone payments constitute debt-like obligations, and the high-yield debt index rate applied to the milestones in order to determine the estimated fair value was 7.5% as of September&#160;30, 2021. The discount rate applied to the 2% earnout payment due on forecasted Vicineum revenues was derived from Sesen Bio&#8217;s estimated WACC, and this WACC-derived discount rate was 8.6% as of September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Provision for Income Taxes</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For the nine&#160;months ended September&#160;30, 2022, Sesen Bio recorded a benefit from income taxes of $3.9&#160;million. In the second quarter of 2022, Sesen Bio determined that the fair value of the Vicineum E.U. rights was zero, which resulted in an impairment charge of $14.7&#160;million. In connection with this impairment charge, in the second quarter of 2022, Sesen Bio reduced the associated deferred tax liability to zero, which resulted in a $4.0&#160;million income tax benefit, partially offset by $0.1&#160;million income tax paid to foreign jurisdictions pursuant to the Qilu License Agreement. Please refer to Note 8, &#8220;Intangible Assets and Goodwill,&#8221; in the Notes to Condensed Consolidated Financial Statements in Sesen Bio&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2022 for further information regarding the impairment charge. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For the nine&#160;months ended September&#160;30, 2021, Sesen Bio recorded a benefit from income taxes of $8.3&#160;million. In the third quarter of 2021, Sesen Bio determined that the fair value of the Vicineum United States rights were zero, which resulted in an impairment charge of $31.7&#160;million. In connection with this impairment charge, in the third quarter of 2021, Sesen Bio reduced the associated deferred tax liability which resulted in an $8.6&#160;million income tax benefit. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Net Loss</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For the nine&#160;months ended September&#160;30, 2022 net loss was $12.3&#160;million, compared to net loss of $9.3&#160;million, for the nine&#160;months ended September&#160;30, 2021. The increase of $3.0&#160;million was due to an increase in operating expense ($33.0&#160;million), primarily driven by the reduction of Sesen Bio&#8217;s prepaid balances related to consumables and manufacturing reservations in the second quarter of 2022 ($25.2&#160;million) and the preliminary settlements of the securities and derivative litigation net of expected insurance recovery ($8.2&#160;million). Additionally, the benefit from income taxes decreased ($4.4&#160;million) in 2022 compared to 2021. This was partially offset by increased revenue ($33.5&#160;million) primarily driven by the execution of the Roche Asset Purchase agreement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">317</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Years Ended December&#160;31, 2021 and December&#160;31, 2020</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:261.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Increase/(Decrease) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Dollars </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:263.19pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:263.19pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">License and related revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">26,544</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,236</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">15,308</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">136<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">26,544</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,236</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">15,308</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">136<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:263.19pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">25,312</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">29,191</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(3,879<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(13<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">29,393</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,302</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">15,091</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">106<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restructuring charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,528</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">5,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(56,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(45,660<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">408<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">35,093</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">32,313</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">2,780</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Loss from Operations </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(8,549<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(21,077<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">12,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(59<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:263.19pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other (expense) income: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other (expense) income, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(185<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(148<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:263.19pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net Loss and Comprehensive Loss Before Taxes</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(8,609<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,952<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">12,343</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(59<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:263.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Benefit (provision) for income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,445<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">9,718</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(673<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:263.19pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net Loss and Comprehensive Loss After Taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(336<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(22,397<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0300000000000011pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">22,061</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(98<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:9.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:15.41pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Revenue for the year ended December&#160;31, 2021 was $26.5&#160;million, primarily due to the $20.0&#160;million milestone achieved pursuant to the Roche License Agreement upon initiating a Phase&#160;II clinical trial, $5.0&#160;million related to the Qilu License Agreement (achievement of the IND milestone, clinical supply revenue, and license revenue for additional purchase price due to the recovery of VAT), and $1.5&#160;million upfront milestone revenue achieved pursuant to the MENA License Agreement. Revenue for the year ended December&#160;31, 2020 was $11.2&#160;million, which was due to the recognition of revenue pursuant to the Qilu License Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $25.3&#160;million for the year ended December&#160;31, 2021, compared to $29.2&#160;million for the year ended December&#160;31, 2020. The decrease of $3.9&#160;million was primarily due to lower costs associated with technology transfer and manufacturing ($7.4&#160;million). This was partially offset by increases in employee-related compensation driven by increased headcount as part of the commercial build and the retention program implemented after receipt of the CRL in August&#160;2021 ($2.1&#160;million), regulatory and clinical consulting fees ($1.0&#160;million) and certain other R&amp;D expense, none of which were individually material ($0.5&#160;million). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $29.4&#160;million for the year ended December&#160;31, 2021, compared to $14.3&#160;million for the year ended December&#160;31, 2020. The increase of $15.1&#160;million was primarily due to increases in employee-related compensation ($5.0&#160;million), legal costs ($4.8&#160;million), and marketing and commercial expenses ($4.1&#160;million) driven by preparation for the commercial launch of Vicineum prior to the issuance of the CRL in August&#160;2021. Additionally, increases in accounting services ($0.4&#160;million), insurance expenses ($0.4&#160;million), IT expenses ($0.3&#160;million) and others ($0.1&#160;million) contributed to the increase. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Restructuring Charge</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;30, 2021, Sesen Bio approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">318</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, or the 2021 restructuring plan. The 2021 restructuring plan included a reduction in Sesen Bio&#8217;s workforce by 18 positions (or approximately 35% of its workforce) as well as additional cost-saving initiatives intended to preserve capital while it continued development of Vicineum. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Restructuring expenses were $5.5&#160;million for the year ended December&#160;31, 2021, compared to no restructuring expenses for the year ended December&#160;31, 2020. The increase was due to one-time costs associated with the 2021 restructuring plan implemented in response to the CRL for severance and other employee-related costs ($2.8&#160;million) and termination of certain contracts ($2.7&#160;million). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Intangibles Impairment Charge</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio recorded an intangibles impairment charge of $31.7&#160;million during the year ended December&#160;31, 2021. Sesen Bio did not record any impairment charges during the year ended December&#160;31, 2020. In August&#160;2021, Sesen Bio received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The impairment charge of $31.7&#160;million for the year ended December&#160;31, 2021 relates to the full impairment of its U.S. in-process research and development asset due to expected delays in the start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the U.S. market at this time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of Contingent Consideration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The non-cash change in fair value of contingent consideration was income of $56.8&#160;million for the year ended December&#160;31, 2021, compared to income of $11.2&#160;million for the year ended December&#160;31, 2020. The decrease in the fair value of contingent consideration of $45.7&#160;million from the year ended December&#160;31, 2020 to the year ended December&#160;31, 2021, was driven by the receipt of a CRL from the FDA, regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. Due to the inherent uncertainty in the path forward for Vicineum, Sesen Bio reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of the contingent consideration is based. The most significant and impactful assumptions in Sesen Bio&#8217;s revenue projection models are timing of product launch and probabilities of clinical and regulatory success POS; Sesen Bio expects delays in the start of commercialization and estimate lower POS as a direct result of the CRL and its withdrawal of the MAA. Sesen Bio will need to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. Sesen Bio has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, Sesen Bio assumed a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Sesen Bio participated in Type A Meetings with the FDA on October&#160;29, 2021 and December&#160;8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped Sesen Bio determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The change in fair value of contingent consideration was income of $11.2&#160;million for the year ended December&#160;31, 2020. This was primarily attributable to significantly higher discount rates as a result of financial market conditions as of the year ended December&#160;31, 2020, offset by changes to the competitive landscape. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other (expense) income, net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other expense, net was $0.1&#160;million for the year ended December&#160;31, 2021, compared to other income of $0.1&#160;million for the year ended December&#160;31, 2020. The change of $0.2&#160;million was due primarily to lower interest income. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Provision for Income Taxes</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the twelve&#160;months ended December&#160;31, 2021, Sesen Bio recorded a benefit from income taxes of $8.3&#160;million. In the third quarter of 2021, Sesen Bio determined that the fair value of the Vicineum U.S. in-process research and development asset was zero, which resulted in an impairment charge of $31.7&#160;million. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">319</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with this impairment charge, in the third quarter of 2021, Sesen Bio wrote-down the associated deferred tax liability by $8.6&#160;million as a benefit. See Note 8, &#8220;Intangibles and Goodwill,&#8221; to Sesen Bio&#8217;s audited annual consolidated financial statements for the fiscal year ended December&#160;31, 2021 for further information regarding the impairment charge. For the twelve&#160;months ended December&#160;31, 2020, Sesen Bio recorded a provision for income taxes of $1.4&#160;million. This provision consisted of income taxes paid to non-U.S. jurisdictions pursuant to Sesen Bio&#8217;s commercialization partnership agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2022, Sesen Bio had cash, cash equivalents and marketable securities of $184.9&#160;million, net working capital of $157.7&#160;million and an accumulated deficit of $328.6&#160;million. Sesen Bio incurred cash flows from operating activities of $22.2&#160;million for the nine&#160;months ended September&#160;30, 2022, compared to negative cash flows of $56.3&#160;million for the nine&#160;months ended September&#160;30, 2021. Sesen Bio believes that, based on its current operating plans and financial forecasts, its cash, cash equivalents and marketable securities of $184.9&#160;million as of September&#160;30, 2022, are sufficient to fund Sesen Bio&#8217;s current operating plan for at least twelve&#160;months from the date of Sesen Bio&#8217;s Form 10-Q filing on November&#160;7, 2022 for the fiscal quarter ended September&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on September&#160;20, 2022, Sesen Bio entered into the Merger Agreement with Carisma and Merger Sub, pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as its wholly-owned subsidiary and the surviving corporation of the merger. The Sesen Bio board of directors unanimously approved the Merger Agreement and resolved to recommend that Sesen Bio stockholders approve the proposals described in the Merger Agreement. If the merger is completed, the business of Carisma will continue as the business of the combined company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The merger is expected to close in the first quarter of 2023. Consummation of the merger is subject to certain closing conditions, including, among other things, (a)&#160;approval by Sesen Bio stockholders of the proposals described in the Merger Agreement, (b)&#160;approval by Carisma&#8217;s stockholders of, among other things, the adoption of the Merger Agreement, (c)&#160;Nasdaq&#8217;s approval of the listing of the shares of Sesen Bio common stock to be issued in connection with the merger, (d)&#160;the effectiveness of a registration statement on Form S-4 to register the shares of Sesen Bio common stock to be issued in connection with the merger, and (e)&#160;Sesen Bio having net cash as of closing of the merger greater than or equal to $75.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement contains certain termination rights of each of Sesen Bio and Carisma. Upon termination of the Merger Agreement under specified circumstances, Sesen Bio may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million, and Carisma may be required to pay Sesen Bio a termination fee of $5.49&#160;million and/or reimburse Sesen Bio expenses up to a maximum of $1.75&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s future operations are highly dependent on the success of the merger and there can be no assurances that the merger will be successfully consummated. In the event that Sesen Bio does not complete the merger with Carisma, Sesen Bio may continue to explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a liquidation and dissolution of Sesen Bio. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since Sesen Bio&#8217;s inception, Sesen Bio has received no revenue from sales of its products, and Sesen Bio anticipates that operating losses will continue for the foreseeable future. Sesen Bio has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its IPO, follow-on public offerings, sales effected in ATM offerings, its OUS business development partnerships and license agreements, sale of assets, and, to a lesser extent, from a collaboration. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has entered into an Open Market Sale Agreement with Jefferies LLC, or Jefferies, dated November&#160;29, 2019, as amended by Amendment No. 1 dated October&#160;30, 2020, Amendment No. 2 dated February&#160;17, 2021 and Amendment No. 3, dated June&#160;1, 2021, or as amended, the Sale Agreement, under </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">320</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">which Sesen Bio may issue and sell shares of Sesen Bio common stock from time to time through Jefferies, or the ATM Offering. In June and July&#160;2021, Sesen Bio filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of Sesen Bio common stock pursuant to the Sale Agreement of which $97.8&#160;million of common shares remain available for future issuance as of September&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule&#160;415(a)(4) of the Securities Act of 1933, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for Sesen Bio common stock. Sesen Bio may sell shares of Sesen Bio common stock efficiently from time to time but have no obligation to sell any of Sesen Bio common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell Sesen Bio common stock from time to time, as the sales agent, based upon Sesen Bio&#8217;s instructions, which include a prohibition on sales below a minimum price set by Sesen Bio from time to time. Sesen Bio has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of Sesen Bio common stock under the Sale Agreement. Sesen Bio did not sell any shares of common stock pursuant to the Sale Agreement during the nine&#160;months ended September&#160;30, 2022. Sesen Bio raised $175.0&#160;million of net proceeds from the sale of 56.9&#160;million shares of Sesen Bio common stock at a weighted-average price of $3.17 per share during the nine&#160;months ended September&#160;30, 2021, including $38.2&#160;million of net proceeds from the sale of 9.8&#160;million shares of Sesen Bio common stock at a weighted-average price of $4.01 per share during the three&#160;months ended September&#160;30, 2021. Share issue costs, including sales agent commissions, related to the ATM Offering totaled $1.2&#160;million and $5.4&#160;million for the three and nine&#160;months ended September&#160;30, 2021, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Funding Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s future funding requirements will depend on the outcome of the proposed merger with Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is subject to a number of risks similar to other clinical companies that have determined to focus primarily on pursuing a strategic transaction, including, but not limited to, those which are described under in the section entitled &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">26</a> of the proxy statement/prospectus. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio will incur substantial expenses if and as Sesen Bio: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">addresses its ongoing securities litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintains, expands and protects its intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduces personnel and incur related severance and employee-related costs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">winds down activities with its CMOs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">terminates its property leases; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">explores, evaluates and pursues any strategic alternatives if the merger is not completed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s future capital requirements will depend on many factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the outcome and the timing of the proposed merger with Carisma; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the outcome and timing of any pending or future litigation involving Sesen Bio or its business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of maintaining and enforcing Sesen Bio&#8217;s intellectual property rights and defending any intellectual property-related claims; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s obligation to make milestone, royalty and other payments to third-party licensors under its licensing agreements. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Until such time, if ever, as Sesen Bio can generate substantial revenues, Sesen Bio expects to finance its cash needs through a combination of equity offerings, debt financings, or government or other third-party funding. To the extent that Sesen Bio raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing Sesen Bio stockholders. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">321</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting Sesen Bio&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Sesen Bio is unable to raise additional funds when needed, Sesen Bio may be required to delay, limit, reduce or terminate its assessment of strategic alternatives. If Sesen Bio does not successfully consummate the proposed merger with Carisma, the Sesen Bio board of directors may decide to explore other strategic alternatives, including, without limitation, another strategic transaction and/or a liquidation and dissolution of Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contractual and Other Obligations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For information related to Sesen Bio&#8217;s cash requirements from known contractual and other obligations, see the description of Contingent Consideration in Note 5 &#8220;Fair Value Measurement and Financial Instruments,&#8221; the information in Note 10 &#8220;Commitments and Contingencies&#8221;, Sesen Bio&#8217;s leases in Note&#160;11&#160;&#8220;Leases&#8221;, and the description of Sesen Bio&#8217;s license agreements in Note 17, &#8220;License Agreements&#8221; of &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Financial Statements&#8201;&#8212;&#8201;Notes to Condensed Consolidated Financial Statements</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tNTCC">F-48</a> of this proxy statement/prospectus.. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash Flows</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary of Sesen Bio&#8217;s cash flows for the nine&#160;months ended September&#160;30, 2022 and 2021 (in thousands): </font>
        </div>
        <table style="width:456pt;height:91.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:353.26pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:353.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Cash Provided by (Used in) Operating Activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">22,214</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(56,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Cash Used in Investing Activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(113,733<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Cash Provided by Financing Activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">176,129</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(91,519<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">119,847</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:15.51pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Net Cash Used in Operating Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by operating activities was $22.2&#160;million for the nine&#160;months ended September&#160;30, 2022 and consisted primarily of a net loss of $12.3&#160;million, adjusted for non-cash items including, a decrease in the fair value of contingent consideration ($52.0&#160;million), intangible impairment charge ($27.8&#160;million), share-based compensation ($5.9&#160;million), and a net increase in operating assets and liabilities ($52.9&#160;million). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities was $56.3&#160;million for the nine&#160;months ended September&#160;30, 2021 and consisted primarily of a net loss of $9.3&#160;million, which includes $6.5&#160;million of revenue recognized pursuant to certain of Sesen Bio&#8217;s out-license agreements, adjusted for non-cash items, including share-based compensation ($3.4&#160;million), a decrease in the fair value of contingent consideration ($52.2&#160;million), increase in impairment charge ($31.7&#160;million), and a net decrease in operating assets and liabilities of ($29.9&#160;million). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Net Cash Used in Investing activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities was $113.7&#160;million for the nine&#160;months ended September&#160;30, 2022 and consisted of marketable security purchases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities consisted of de minimis purchases and sales or property and equipment during the nine&#160;months ended September&#160;30, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Net Cash Provided by Financing activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities was zero for the nine&#160;months ended September&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities was $176.1&#160;million for the nine&#160;months ended September&#160;30, 2021 and consisted primarily of $175.0&#160;million net proceeds from the sale of common stock under the ATM Offering. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">322</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Critical Accounting Policies and Use of Estimates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of Sesen Bio&#8217;s condensed consolidated financial statements in accordance with U.S.&#160;GAAP and the rules and regulations of the SEC require the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Sesen Bio&#8217;s critical accounting policies are those policies which involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on Sesen Bio&#8217;s financial condition or results of operations. Sesen Bio&#8217;s management has determined that Sesen Bio&#8217;s most critical accounting policies are those relating to the fair value of indefinite-lived intangible assets, goodwill; contingent consideration; revenue recognition; development and regulatory milestone payments and other costs; and research and development costs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fair Value of Indefinite-Lived Intangible Assets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s intangible assets consist of indefinite-lived, acquired IPR&amp;D worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. Sesen Bio recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, Sesen Bio performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the second quarter of 2022, Sesen Bio observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. Sesen Bio has also experienced a sustained decline in share price and a resulting decrease in its market capitalization. On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following recent discussions with the FDA, which had implications on the size, timeline and costs of an additional Phase&#160;3 clinical trial for the treatment of NMIBC. Sesen Bio management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of its intangible asset of Vicineum E.U. rights. Sesen Bio concluded that the carrying value of its intangible asset of Vicineum E.U. rights of $14.7&#160;million was fully impaired as of June&#160;30, 2022 and was reduced to zero in the second quarter of 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Goodwill</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Goodwill on Sesen Bio&#8217;s condensed consolidated balance sheets is the result of its acquisition of Viventia in September&#160;2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. Sesen Bio recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit&#8217;s carrying value, including goodwill. Sesen Bio has only one reporting unit. In addition, on a quarterly basis, Sesen Bio performs a qualitative review of its business operations to determine whether events </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">323</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the second quarter of 2022, Sesen Bio observed continued trends in its market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. Sesen Bio identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of its typical annual assessment date of October&#160;1. Sesen Bio reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Sesen Bio updated its revenue forecast models based on further expected launch delays in both U.S. and OUS regions. Sesen Bio also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. Sesen Bio also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, Sesen Bio concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June&#160;30, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contingent Consideration</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Contingent consideration on Sesen Bio&#8217;s condensed consolidated balance sheets is the result of Sesen Bio&#8217;s acquisition of Viventia in September&#160;2016 and represents the discounted present value of future commercial launch milestones and net sales earnout payments due to the former shareholders of Viventia pursuant to the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level&#160;3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are unpredictable and inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The estimated fair value of Sesen Bio&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales were expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the U.S., Europe, Japan, China and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December&#160;2033. The discount rate applied to the 2% earnout was derived from Sesen Bio&#8217;s estimated weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following recent discussions with the FDA, which had implications on the size, timeline and costs of an additional Phase&#160;3 clinical trial for the treatment of NMIBC. Sesen Bio continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, Sesen Bio is seeking a partner for the further development of Vicineum. Accordingly, during the second quarter of 2022, Sesen Bio concluded that it was no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to the Greater China region since those territory rights had been out-licensed. Qilu held the exclusive license to develop Vicineum in the Greater China region, and accordingly, the $1.8&#160;million estimated earnout payment in the Greater China region remained as long-term contingent consideration as of June&#160;30, 2022. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">324</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:24pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Qilu has informed Sesen Bio that it no longer intends to commercialize Vicineum in the Greater China region. Therefore, Sesen Bio terminated the Qilu License Agreement, upon which Sesen Bio regained the rights to develop, manufacture and commercialize Vicineum in Greater China. However, Sesen Bio does not plan to develop or commercialize Vicineum in that region or any other, as Sesen Bio is pursuing the merger with Carisma. Sesen Bio is also seeking to sell or out-license Vicineum and all the related obligations related to Vicineum. Sesen Bio expects that any partner who acquires or licenses Vicineum from Sesen Bio will be obligated to make any payments, including those related to sales in the Greater China region (if any), that become payable to the former shareholders of Viventia under the Share Purchase Agreement. If a sale or license of Vicineum has not occurred at the time the merger is completed, Carisma has indicated it may continue to seek a sale or license of Vicineum and has no plans to develop Vicineum. Accordingly, as of September&#160;30, 2022, Sesen Bio concluded that it no longer expects to owe any future earnout payments related to the Greater China region and reduced its remaining $1.8&#160;million of contingent consideration liabilities to zero as of September&#160;30, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income Taxes</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. Sesen Bio recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Sesen Bio recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its condensed consolidated statements of operations. As of September&#160;30, 2022 and December&#160;31, 2021, Sesen Bio did not have any uncertain tax positions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Costs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In certain circumstances, Sesen Bio is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Issued Accounting Standards</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Recently issued accounting standards are discussed in of &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Financial Statements&#8201;&#8212;&#8201;Notes to Condensed Consolidated Financial Statements</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tNTCC">F-48</a> of this proxy statement/prospectus.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">325</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCMDA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF </font>
          <br >
          <font style="letter-spacing:-0.2pt;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following discussion and analysis of Carisma&#8217;s financial condition and results of operations should be read in conjunction with Carisma&#8217;s consolidated financial statements and the related notes included elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to Carisma&#8217;s plans and strategy for its business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set out under the section entitled &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">26</a> of this proxy statement/prospectus, Carisma&#8217;s actual results could differ materially from the results described in or implied by these forward-looking statements. See also the section entitled &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221; beginning on page <a href="#tCSCF">118</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is a clinical stage cell therapy company focused on utilizing Carisma&#8217;s proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. Carisma has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. Macrophages and monocytes are part of the innate immune system and can detect and degrade harmful substances through a process referred to as phagocytosis, in which the harmful substance is engulfed and destroyed and in turn leads to the activation of a broad immune response. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To harness the powerful immunologic functions of macrophages against cancer, Carisma has developed a proprietary Chimeric Antigen Receptor Macrophage, or CAR-M, platform technology. Chimeric antigen receptors, or CARs, are synthetically engineered receptors that are designed to bestow immune cells with the ability to target specific antigens on the surface of cancer cells. By introducing CARs into macrophage and monocyte cells, Carisma aims to redirect their potent innate immune functions against cancer. Carisma&#8217;s CAR-M platform technology incorporates proprietary tumor targeting constructs, vectors to deliver CARs to macrophages and monocytes and novel manufacturing processes. Carisma&#8217;s CAR-M therapeutics are designed to infiltrate the solid tumor microenvironment, kill cancer cells via targeted phagocytosis, and activate other immune cells, such as T-cells, to initiate a robust anti-tumor immune response. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Beyond CT-0508, Carisma has a broad pipeline of cell therapy assets in various stages of pre-clinical development. In addition to the development of </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> CAR-M cell therapies, Carisma is also developing </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M gene therapies, wherein immune cells are directly engineered within the patient&#8217;s body. To advance its </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> CAR-M therapeutics, Carisma established a strategic collaboration with Moderna focused on the development and potential commercialization of up to 12 product candidates, of which four have already been nominated. In collaboration with Moderna, Carisma has established an approach that uses Moderna&#8217;s LNP/mRNA technology, together with Carisma&#8217;s CAR-M platform technology, to create novel </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> oncology gene therapies. Carisma believes this approach has the potential to enable a series of off-the-shelf product candidates to target a patient&#8217;s own myeloid cells against cancer cells directly within their body. As part of the agreement with Moderna, Carisma received a $45.0&#160;million up-front cash payment and an investment by Moderna in the form of a $35.0&#160;million convertible note, in addition to future research funding and the opportunity for milestone payments and royalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Through its robust internal discovery engine, Carisma is building upon its platform to enhance and expand the utility of macrophage cell and gene therapies, leading to the creation of multiple product candidates with the potential to treat cancer and other serious diseases. By replacing the targeting domain of the CAR, Carisma can reprogram the target antigen specificity of the CAR-M cell product and develop candidates against a range of cancer indications and therapeutic areas beyond oncology. As a result, Carisma believes the flexibility of its macrophage and monocyte cell engineering platform will allow Carisma to generate new product candidates suitable for clinical development in a cost-efficient manner to expand its pipeline. In addition to acting as a first line of defense in the innate immune system, macrophages are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses and tissue regeneration. Using its macrophage and monocyte </font><font style="font-style:italic;letter-spacing:0.2pt;">ex vivo</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> engineering </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">326</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">platform, Carisma is pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology, including liver fibrosis, neurodegeneration, and other immunologic and inflammatory diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">By investing in early platform research and accessing key enabling technologies, Carisma is enhancing and expanding its platform capabilities and reinforcing its leadership position in the engineered macrophage field. Carisma has developed proprietary CAR-M platform enhancements directed toward key product parameters that are important for efficacy, safety and patient access to its CAR-M therapies. Carisma plans to apply these technology enhancements to future CAR-M product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma was formed as Carma Therapeutics LLC, a Pennsylvania limited liability company, in April&#160;2016 and converted to a Delaware corporation in May&#160;2017. To date, Carisma has not yet commercialized any products or generated any revenue from product sales and has financed its operations primarily with proceeds from sales of Carisma&#8217;s preferred stock, proceeds from Carisma&#8217;s collaboration with Moderna, research tax credits and convertible debt financing. Carisma&#8217;s operations to date have been limited to organizing and staffing its company, business planning, capital raising, establishing and maintaining its intellectual property portfolio, building its pipeline of product candidates, conducting drug discovery activities, undertaking pre-clinical studies, manufacturing process development studies, conducting early-stage clinical trials, and providing general and administrative support for these operations. Carisma has devoted substantially all of its financial resources and efforts to pursuing discovery, research and development of its product candidates. Carisma only recently initiated clinical development of its lead product candidate, CT-0508, and is in the pre-clinical testing stages for its other product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s net losses were $40.8&#160;million for the year ended December&#160;31, 2021 and $28.3&#160;million for the year ended December&#160;31, 2020. As of September&#160;30, 2022, Carisma had $70.6&#160;million in cash, cash equivalents and marketable securities and an accumulated deficit of $141.5&#160;million. Carisma expects to devote substantial financial resources to its ongoing and planned activities, particularly as it conducts its ongoing clinical trial of CT-0508 and pursues related combination strategies, prepares for, initiates and conducts its planned clinical trials of CT-0525, CT-1119 and CT-0729 and advances its discovery programs and continues its product development efforts. In addition, if Carisma obtains marketing approval for CT-0508 or any other product candidate it is developing or develops in the future, it expects to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, upon the closing of the merger, it expects to incur additional costs associated with operating as a public company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, Carisma will need to obtain substantial additional funding in connection with its continuing operations. If Carisma is unable to raise capital or obtain adequate funds when needed or on acceptable terms, it may be required to delay, limit, reduce or terminate its discovery and product development programs or any future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself. In addition, attempting to secure additional financing may divert the time and attention of Carisma management from day-to-day activities and distract from its discovery and product development efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, Carisma is unable to accurately predict the timing or amount of increased expenses or when, or if, it will be able to achieve or maintain profitability. Carisma may never succeed in these activities and, even if it does, may never generate revenues that are significant enough to achieve profitability. Even if Carisma does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. Carisma&#8217;s failure to become and remain profitable would depress the value of its company and could impair its ability to raise capital, expand its business, maintain its discovery and product development efforts, diversify its pipeline of product candidates or even continue its operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Moderna Collaboration and License Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, Carisma entered into the Moderna Collaboration Agreement, which provides for a broad strategic partnership with Moderna to discover, develop and commercialize </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> engineered CAR-M therapeutics for up to 12 oncology programs. Under the Moderna Collaboration Agreement, the parties initiate research programs during a research term, focused on the discovery and research of products directed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">327</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to biological targets. Either party may nominate a target for inclusion in a research program, subject to certain exclusions. Carisma refers to a target included in a research program pursuant to designated procedures as a research target. Moderna may replace research targets pursuant to designated procedures. The first four research targets have been nominated and all programs are currently in the discovery phase at Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In collaboration with Moderna, Carisma has established an approach that uses Moderna&#8217;s LNP/mRNA technology, together with Carisma&#8217;s CAR-M platform technology, to create novel </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> oncology gene therapies. Carisma believes this approach has the potential to enable a series of off-the-shelf product candidates to target a patient&#8217;s own myeloid cells against cancer cells directly within their body. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The collaboration is managed by a joint steering committee, or JSC, which is comprised of representatives from Carisma and Moderna. Decisions of the JSC are made by consensus, with each party having one vote. If the JSC is unable to agree, and the parties&#8217; executives are not able to resolve the dispute, then Moderna has final decision-making authority, subject to specified limitations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Moderna Collaboration Agreement, Carisma received a $45.0&#160;million up-front cash payment. Assuming Moderna develops and commercializes 12 products, each directed to a different Development Target, Carisma is also eligible to receive up to between $247.0&#160;million and $253.0&#160;million per product in development target designation, development, regulatory and commercial milestone payments. In addition, Carisma is eligible to receive mid to high single digit tiered royalties on net sales of any products that are commercialized under the agreement, which may be subject to reductions. Moderna has also agreed to cover the cost of certain milestone payments and royalties Carisma owes to a licensor under one of its intellectual property in-license agreements that Carisma is sublicensing to Moderna under the Moderna Collaboration Agreement, which royalties Moderna may deduct in part from any royalties owed to Carisma. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impact of the COVID-19 Pandemic</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is carefully monitoring the COVID-19 pandemic which continues to evolve worldwide. The continued spread of COVID-19 and the measures taken by governmental authorities, and any future epidemic disease outbreaks, could cause difficulties recruiting or retaining patients for Carisma&#8217;s clinical trials, disrupt the supply chain and the manufacture or shipment of pre-clinical materials, delay, limit or prevent Carisma&#8217;s employees and third parties from continuing research and development activities which could delay Carisma&#8217;s pre-clinical studies, and increase its development costs and/or have a material adverse effect on Carisma&#8217;s business, financial condition and results of operations. The effect of the COVID-19 pandemic on Carisma&#8217;s development timelines is difficult to assess or predict. The future impact of the COVID-19 pandemic on Carisma&#8217;s industry, the healthcare system and Carisma&#8217;s current and future operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financial Operations Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenues</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To date, Carisma has not generated any revenue from product sales and does not expect to generate any revenue from the sale of products for the foreseeable future. Carisma&#8217;s revenues to date have been generated from the Moderna Collaboration Agreement. Moderna reimburses Carisma for all costs incurred by it in connection with its research and development activities under the Moderna Collaboration Agreement plus a reasonable margin for the respective services performed. Carisma expects that its revenue for at least the next several&#160;years will be derived primarily from Moderna Collaboration Agreement, other current collaboration agreements and any additional collaborations that it may enter into in the future. To date, Carisma has not received any royalties under the Moderna Collaboration Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and development expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses consist primarily of costs incurred for Carisma&#8217;s research activities, including discovery efforts and the development of product candidates, and include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expenses incurred to conduct the necessary pre-clinical studies and clinical trials required to obtain regulatory approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">328</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs of funding research performed by third parties, including pursuant to agreements with CROs, as well as investigative sites and consultants that conduct Carisma&#8217;s pre-clinical studies and clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expenses incurred under agreements with CMOs, including manufacturing scale-up expenses and the cost of acquiring and manufacturing pre-clinical study and clinical trial materials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs of laboratory supplies and acquiring materials for pre-clinical studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">facility-related expenses, which include direct depreciation costs of equipment and expenses for rent and maintenance of facilities and other operating costs; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">third-party licensing fees. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development activities are central to Carisma&#8217;s business model. Product candidates in later stages of clinical development will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Carisma expects its research and development expenses to increase significantly over the next several&#160;years as it increases personnel costs, including stock-based compensation, conducts ongoing and planned clinical trials for CT-0508, conducts research and development activities under the Moderna Collaboration Agreement and conducts other clinical and pre-clinical activities for other product candidates and prepares regulatory filings for any of its product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The successful development of Carisma&#8217;s current or future product candidates is highly uncertain. At this time, Carisma cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of any product candidates. The success of CT-0508 and Carisma&#8217;s other product candidates will depend on several factors, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successfully completing pre-clinical studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successfully initiating future clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successfully enrolling patients in and completing clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">scaling up manufacturing processes and capabilities to support clinical trials of CT-0508 and any other product candidate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">applying for and receiving marketing approvals from applicable regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining and maintaining intellectual property protection and regulatory exclusivity for CT-0508 and any other product candidates it is developing or may develop in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">making arrangements with third-party manufacturers, or establishing commercial manufacturing capabilities, for both clinical and commercial supplies of its product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establishing sales, marketing and distribution capabilities and launching commercial sales of its products, if and when approved, whether alone or in collaboration with others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acceptance of CT-0508 and any other product candidates, if and when approved, by patients, the medical community and third-party payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">effectively competing with other therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintaining, enforcing, defending and protecting its rights in its intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">329</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintaining a continued acceptable safety profile of its products following receipt of any marketing approvals. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A change in the outcome of any of these variables with respect to the development, manufacture or commercialization activities of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if Carisma is required to conduct additional clinical trials or other testing of its product candidates beyond those that it currently contemplates, if Carisma is unable to successfully complete clinical trials of its product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if Carisma determines that the observed safety or efficacy profile would not be competitive in the marketplace, it could be required to expend significant additional financial resources and time on the completion of clinical development. Product commercialization will take several&#160;years, and Carisma expects to spend a significant amount in development costs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and administrative expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expense consists primarily of personnel expenses, including salaries, benefits and stock-based compensation expense for employees in executive, finance, accounting, business development and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation and maintenance, and costs not otherwise included in research and development expense, legal fees related to intellectual property and corporate matters as well as fees for accounting and consulting services. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma expects that its general and administrative expense will increase in the future to support its continued research and development activities, potential commercialization efforts and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. Increased costs associated with being a public company will also include expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the SEC, insurance and investor relations costs. If any of Carisma&#8217;s current or future product candidates obtains marketing approval, Carisma expects that it would incur significantly increased expenses associated with sales and marketing efforts. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interest expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interest expense consists of interest on the Carisma convertible note that was entered into concurrently with the Moderna Collaboration Agreement including non-cash interest expense associated with the amortization of the debt discount. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Change in fair value of derivative liability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Change in fair value of the derivative liability for the redemption feature of the Carisma convertible note reflects the non-cash charge for changes in the fair value of the derivative liability that is subject to re-measurement at each balance sheet date until Carisma&#8217;s obligations under the Carisma convertible note are satisfied. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income tax provision</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since inception, Carisma has incurred significant net losses. As of December&#160;31, 2021, Carisma had net operating loss carryforwards, or NOLs, for federal and state income tax purposes of $76.4&#160;million. Carisma has provided a valuation allowance against the full amount of its deferred tax assets since, in the opinion of Carisma management, based upon its historical and anticipated future losses, it is more likely than not that the benefits will not be realized. As of September&#160;30, 2022, Carisma remained in a full valuation allowance position. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s utilization of its NOLs may be subject to a substantial annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections&#160;382 and 383 of the Code, respectively, as well as similar state </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">330</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">provisions. Carisma has recorded a valuation allowance on all of its deferred tax assets, including its deferred tax assets related to its NOLs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:11.01pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Nine Months Ended September&#160;30, 2022 and 2021</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes Carisma&#8217;s results of operations for the nine&#160;months ended September&#160;30, 2022 and 2021 (in thousands): </font>
        </div>
        <table style="width:416pt;height:159pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:288.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:288.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Collaboration revenues </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,103</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">38,536</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">24,597</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,407</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">3,852</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">46,943</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">28,449</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,449<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in fair value of derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,369<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest (expense) income, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.5pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Collaboration Revenues</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Collaboration revenues were $6.1&#160;million for the nine&#160;months ended September&#160;30, 2022, which related to the research and development activities completed under the Moderna Collaboration Agreement that Carisma executed in January&#160;2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma tracks outsourced development, outsourced personnel costs and other external research and development costs of its CT-0508 program. Carisma does not track its internal research and development costs on a program-by-program basis. The following table summarizes Carisma&#8217;s research and development expenses for the nine&#160;months ended September&#160;30, 2022 and 2021 (in thousands): </font>
        </div>
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:288.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:288.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">CT-0508 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,044</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,965</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Personnel costs, including stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,178</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,676</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other clinical and pre-clinical development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,541</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,822</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Facilities and other expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">15,773</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">8,134</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:288.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">38,536</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">24,597</td>
            <td style="padding:0pt;padding-left:9.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses for the nine&#160;months ended September&#160;30, 2022 were $38.5&#160;million, compared to $24.6&#160;million for the nine&#160;months ended September&#160;30, 2021. The increase of $13.9&#160;million was primarily attributable to a $7.6&#160;million increase in facilities and other expenses primarily due to the additional leases entered into during the nine&#160;months ended September&#160;30, 2022, a $5.5&#160;million increase in Carisma&#8217;s personnel costs attributable to an increase in its research and development employee headcount, and a $0.7&#160;million increase in the pre-clinical discovery work associated with the Moderna Collaboration Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes Carisma&#8217;s general and administrative expenses for the nine&#160;months ended September&#160;30, 2022 and 2021 (in thousands): </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">331</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:288.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:288.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal and professional fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,209</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,016</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Personnel costs, including stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,080</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,958</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Facilities and supplies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">471</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">586</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:288.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">647</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">292</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:288.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total general and administrative expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,407</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,852</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10.41pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses for the nine&#160;months ended September&#160;30, 2022 were $8.4&#160;million, compared to $3.9&#160;million for the nine&#160;months ended September&#160;30, 2021. The increase of $4.6&#160;million was primarily attributable to a $4.2&#160;million increase in legal and professional fees in support of Carisma&#8217;s patent portfolio, expanding infrastructure in preparation to operate as a public company and an increase legal fees incurred in connection with the merger, a $0.1&#160;million increase in personnel costs attributable to an increase in employee headcount and a $0.4&#160;million increase in other expenses attributable to the increase in travel and public relations in preparation to operate as a public company. </font>
        </div>
        <div style="margin-top:10.32pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest (Expense) Income, net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma recognized $2.3&#160;million in interest (expense) income, net for the nine&#160;months ended September&#160;30, 2022, which was attributable primarily to the outstanding principal balance associated with the Carisma convertible note issued to Moderna in January&#160;2022 including non-cash interest expense associated with the amortization of the debt discount partially offset by interest income of $0.3&#160;million. </font>
        </div>
        <div style="margin-top:10.32pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of Derivative Liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma recognized a $1.4&#160;million non-cash charge for the increase in fair value of the derivative liability associated with the redemption feature of the Carisma convertible note with Moderna. The increase was attributable to the timing in which Carisma estimates a settlement event for the derivative to occur. </font>
        </div>
        <div style="margin-top:10.32pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Years Ended December&#160;31, 2021 and 2020</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:128.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">34,387</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">23,292</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,407</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,086</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">40,794</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">28,378</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,794<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,378<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.33pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes Carisma&#8217;s research and development expenses for the year ended December&#160;31, 2021 and 2020 (in thousands): </font>
        </div>
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">CT-0508 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,570</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,225</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Personnel costs, including stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,490</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,850</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other clinical and pre-clinical development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,035</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,812</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Facilities and other expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,292</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,405</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:317.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">34,387</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">23,292</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">332</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:15.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses for the year ended December&#160;31, 2021 were $34.4&#160;million, compared to $23.3&#160;million for the year ended December&#160;31, 2021. The increase of $11.1&#160;million was primarily due to an increase in Carisma&#8217;s personnel costs of $3.6&#160;million attributable to an increase in Carisma&#8217;s research and development employee headcount and higher stock-based compensation and $3.9&#160;million increase attributable to an increase in facilities and supplies due to increased use of lab spaces and increased lab supplies as Carisma continued increasing its clinical and pre-clinical work. Carisma also had a $3.3&#160;million increase in its direct costs associated with CT-0508 as it initiated its Phase&#160;1 clinical trial in early 2021, and an increase in other clinical and pre-clinical development expenses of $0.2&#160;million as Carisma continues to further discover and develop earlier stage product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes Carisma&#8217;s general and administrative expenses for the year ended December&#160;31, 2021 and 2020 (in thousands): </font>
        </div>
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Personnel costs, including stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,446</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,479</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal and professional fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,321</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,300</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Facilities and supplies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">869</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">641</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">771</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">666</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:317.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total general and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6,407</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,086</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses for the year ended December&#160;31, 2021 were $6.4&#160;million, compared to $5.1&#160;million for the year ended December&#160;31, 2020. The increase of $1.3&#160;million was primarily attributable to a $1.0&#160;million increase in legal and professional fees in support of Carisma&#8217;s patent portfolio and expanding infrastructure in preparation to operate as a public company as well as a $0.2&#160;million increase in facilities and supplies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sources of Liquidity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2022, Carisma had $70.6&#160;million in cash, cash equivalents and marketable securities and an accumulated deficit of $141.5&#160;million. To date, Carisma has not yet commercialized any products or generated any revenue from product sales and has financed its operations primarily with proceeds from sales of Carisma&#8217;s preferred stock, proceeds from Carisma&#8217;s collaboration with Moderna, research tax credits and convertible debt financing. Since June&#160;2018, Carisma has sold convertible preferred stock, raising aggregate gross proceeds of $122.2&#160;million. In January&#160;2022, Carisma received $80.0&#160;million from Moderna comprised of an upfront non-refundable payment of $45.0&#160;million in connection with the Moderna Collaboration Agreement and $35.0&#160;million in connection with the Carisma convertible note. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Carisma Convertible Note</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If not earlier converted or repaid, the Carisma convertible note is payable on demand beginning in July&#160;2023 and accrues interest at an annual rate beginning at 0.33% through March&#160;2022 and then increases by 0.767% each month thereafter, capped at an annual rate of 8.0% in January&#160;2023. Upon the completion of a qualified financing event, the outstanding principal and accrued interest under the Carisma convertible note will automatically convert into shares of Carisma issued in connection with the qualified financing at a conversion price equal to the lesser of (a)&#160;90% of the purchase price paid by other investors in such qualified financing and (b)&#160;$21.06 per share on an as converted to common stock basis. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">333</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash Flows</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows a summary of Carisma&#8217;s cash flows for the periods indicated (in thousands): </font>
        </div>
        <table style="width:456pt;height:97.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:230.22pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:230.22pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:230.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Cash provided by (used in) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:230.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11,984</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,207<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(37,328<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(27,012<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:230.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(46,369<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,526<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,871<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(440<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:230.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">34,777</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">15,962</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">15,962</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">72,258</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:230.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net change in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">392</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(13,771<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,237<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">44,806</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash Flows from Operating Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2022, Carisma provided $12.0&#160;million of net cash in operating activities. Cash provided by operating activities reflected Carisma&#8217;s net loss of $44.5&#160;million that was offset by $7.9&#160;million of non-cash charges related to depreciation and amortization expense, stock-based compensation, reductions in the operating right of use, or ROU, assets, amortization of the debt discount on the Carisma convertible note, change in fair value of the derivative liability, and non-cash interest on the finance liability from the failed sale-leaseback and the accretion on marketable securities and a $48.6&#160;million net change in Carisma&#8217;s operating assets and liabilities, which was primarily attributable to the upfront non-refundable payment received from Moderna pursuant to the Moderna Collaboration Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2021, Carisma used $28.2&#160;million of net cash in operating activities. Cash used in operating activities reflected Carisma&#8217;s net loss of $28.4&#160;million that was offset by $1.2&#160;million of non-cash charges related to depreciation and amortization expense, stock-based compensation and reductions in the operating ROU assets and a $1.0&#160;million net reduction in Carisma&#8217;s operating assets and liabilities attributable to the timing in which Carisma makes payments to its vendors for research and development activities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2021, Carisma used $37.3&#160;million of net cash in operating activities. Cash used in operating activities reflected Carisma&#8217;s net loss of $40.8&#160;million that was offset by $2.0&#160;million of non-cash charges related to depreciation and amortization expense, stock-based compensation and reductions in the operating ROU assets and a $1.5&#160;million net change in Carisma&#8217;s operating assets and liabilities attributable to the timing in which Carisma pays its vendors for research and development activities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2020, Carisma used $27.0&#160;million of net cash in operating activities. Cash used in operating activities reflected Carisma&#8217;s net loss of $28.3&#160;million that was offset by $1.8&#160;million of non-cash charges related to depreciation and amortization expense, stock-based compensation and reductions in the operating ROU assets and a $0.5&#160;million net change in Carisma&#8217;s operating assets and liabilities attributable to the timing in which Carisma pays its vendors for research and development activities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash Flows from Investing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2022, Carisma used $46.4&#160;million of net cash in investing activities. Cash used in investing activities reflected purchases of marketable securities of $84.0&#160;million offset by $42.0&#160;million of proceeds from the sale of marketable securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2022 and 2021 and for the&#160;years ended December&#160;31, 2021 and 2020, Carisma used $4.3&#160;million, $1.5&#160;million, $1.9&#160;million and $0.4&#160;million, respectively, for the purchase of property and equipment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash Flows from Financing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2022, Carisma received $34.8&#160;million of net cash from financing activities, primarily attributable to the $35.0&#160;million in proceeds from the Carisma convertible </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">334</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tFUNDRE1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">note, partially offset by $0.8&#160;million in payments made on financing leases. Immediately prior to completion of the merger, the outstanding principal and unpaid interest of the Carisma convertible note will convert into shares of Carisma capital stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2021 and for the year ended December&#160;31, 2021, Carisma received $16.0&#160;million of net cash from financing activities, primarily attributable to the net proceeds from the sale of its Series&#160;B convertible preferred stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2020, Carisma received $72.3&#160;million of net cash from financing activities attributable from the sale of its Series&#160;A and Series&#160;B convertible preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Funding Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma expects to devote substantial financial resources to its ongoing and planned activities, particularly as it conducts its ongoing clinical trial of CT-0508 and pursues related combination strategies, prepares for, initiates and conducts its planned clinical trials of CT-0525, CT-1119 and CT-0729 and advances its discovery programs and continues its product development efforts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma expects its expenses to increase substantially in connection with its ongoing activities, particularly as it advances its pre-clinical activities and clinical trials. In addition, if Carisma obtains marketing approval for CT-0508 or any other product candidate it is developing or develops in the future, it expects to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, upon the closing of the merger, it expects to incur additional costs associated with operating as a public company. Accordingly, Carisma will need to obtain substantial additional funding in connection with its continuing operations. If Carisma is unable to raise capital or obtain adequate funds when needed or on acceptable terms, it may be required to delay, limit, reduce or terminate its discovery and product development programs or any future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself. In addition, attempting to secure additional financing may divert the time and attention of Carisma management from day-to-day activities and distract from its discovery and product development efforts. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s future capital requirements will depend on many factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the progress, costs and results of its ongoing clinical trial of CT-0508 and other planned and future clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, costs and results of pre-clinical testing and clinical trials of CT-0508 for additional combinations, targets and indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of and development requirements for additional indications for CT-0508 or for any other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success of its collaborations with Moderna or others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its ability to scale up its manufacturing processes and capabilities to support clinical trials of CT-0508 and other product candidates it is developing and develops in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs, timing and outcome of regulatory review of CT-0508 and other product candidates it is developing and may develop in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential changes in the regulatory environment and enforcement rules; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the payment of license fees and other costs of its technology license arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for CT-0508 and other product candidates it is developing and may develop in the future for which it may receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">its ability to obtain and maintain acceptance of any approved products by patients, the medical community and third-party payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">335</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amount and timing of revenue, if any, received from commercial sales of CT-0508 and any other product candidates it is developing or develops in the future for which it receives marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential changes in pharmaceutical pricing and reimbursement infrastructure; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of raw materials for use in production of its product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property and proprietary rights and defending any intellectual property- related claims; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which it in-licenses or acquires additional technologies or product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2022, Carisma had cash, cash equivalents and marketable securities of $70.6&#160;million. Immediately prior to the consummation of the merger, certain investors have agreed to purchase shares of Carisma common stock for an aggregate purchase price of approximately $30.6&#160;million. The closing of the Carisma pre-closing financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the merger set forth in the Merger Agreement. Carisma believes that following consummation of the pre-closing financing and the merger, it will have cash, cash equivalents and marketable securities sufficient to sustain its operating expenses and capital expenditure requirements at least through the end of 2024. However, Carisma has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to Carisma. In addition, changing circumstances could cause Carisma to consume capital significantly faster than it currently anticipates, and Carisma may need to spend more than currently expected because of circumstances beyond its control. As a result, Carisma could deplete its capital resources sooner than it currently expects. In addition, because the successful development of CT-0508, CT-0525, CT-1119, CT-0729 and any combination studies or other product candidates that it pursues is highly uncertain, at this time Carisma cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of any product candidate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma currently anticipates that it will use the expected cash balances of the combined company as of the closing of the merger resulting from the net cash expected to be provided by Sesen Bio upon completion of the merger, together with Carisma&#8217;s existing cash resources and the expected gross proceeds from the Carisma pre-closing financing, as follows:</font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approximately $44.0 million to $55.0 million for the advancement of CT-0508 for treatment of solid tumors that overexpress HER2, including completion of its ongoing Phase 1 clinical trial and related combination studies;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approximately $28.0 million to $35.0 million for the advancement of CT-0525 for treatment of solid tumors that overexpress HER2, including submission of an IND to the FDA in the third quarter of 2023 and the initiation of clinical development shortly thereafter; and</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the remainder for preclinical studies for research stage programs, working capital and other general corporate purposes.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This expected use of anticipated funds available to the combined company following the closing of the merger represents Carisma&#8217;s intentions based upon its current plans for the combined company and business conditions. The amounts and timing of the combined company&#8217;s actual expenditures may vary significantly depending on numerous factors, including the progress of the combined company&#8217;s development efforts, the status of and results from clinical trials and preclinical studies, the timing of regulatory submissions, as well as any collaborations that the combined company may enter into with third parties for its product candidates, and any unforeseen cash needs. As a result, the combined company&#8217;s management will retain broad discretion over the allocation of the anticipated funds available to the combined company following the closing of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on Carisma&#8217;s planned use of the anticipated funds available to the combined company following the closing of the merger, Carisma estimates that such funds will be sufficient to enable the combined company to complete its ongoing Phase 1 clinical trial of CT-0508 and the related sub study evaluating the combination of CT-0508 and pembrolizumab, and initiate a Phase 1 clinical trial of CT-0525 following </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">336</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">submission of an IND to the FDA. Carisma has based these estimates on assumptions that may prove to be wrong, and the combined company could use its capital resources sooner than Carisma currently expects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Identifying potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and Carisma may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, Carisma&#8217;s product candidates, if approved, may not achieve commercial success. Carisma will not generate commercial revenues unless and until it can achieve sales of products, which it does not anticipate for a number of&#160;years, if at all. Accordingly, Carisma will need to obtain substantial additional financing to achieve its business objectives. Adequate additional financing may not be available to Carisma on acceptable terms, or at all, and may be impacted by the economic climate and market conditions. For example, market volatility resulting from the COVID-19 pandemic, any other future infectious diseases, epidemics or pandemics or general U.S. or global economic or market conditions could also adversely impact Carisma&#8217;s ability to access capital as and when needed. Alternatively, Carisma may seek additional capital due to favorable market conditions or strategic considerations, even if it believes it has sufficient funds for its current or future operating plans. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Until such time, if ever, as the combined company, operating as Carisma, can generate substantial revenues from product sales, Carisma expects to finance its cash needs through a combination of public and private equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that Carisma raises additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect your rights as a holder of Carisma common stock. Debt financing and preferred equity financing, if available, would increase Carisma&#8217;s fixed payment obligations and may involve agreements that include covenants limiting or restricting Carisma&#8217;s operations and ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing Carisma&#8217;s assets, making capital expenditures, redeeming its stock, making certain investments, declaring dividends or other operating restrictions that could adversely impact Carisma&#8217;s ability to conduct its business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Carisma raises funds through additional collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, Carisma may have to relinquish valuable rights to its intellectual property, future revenue streams, discovery programs or product candidates, grant licenses on terms that may not be favorable to Carisma or grant rights to develop and market product candidates that Carisma would otherwise prefer to develop and market itself, any of which may have a material adverse effect on Carisma&#8217;s business, operating results and prospects. If Carisma is unable to raise capital or obtain adequate funds when needed or on acceptable terms, it may be required to delay, limit, reduce or terminate its discovery and product development programs or any future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contractual Obligations and Commitments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes Carisma&#8217;s contractual obligations and commitments at September&#160;30, 2022 (in thousands): </font>
        </div>
        <table style="width:456pt;height:93pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:216.91pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Less than</font>
                <br >
                <font style="letter-spacing:-0.16pt;">1 Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">1 to 3 Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">4 to 5 Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">More than</font>
                <br >
                <font style="letter-spacing:-0.16pt;">5 Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:216.91pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Contractual obligations: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.91pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease commitments</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,907</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,539</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">654</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">469</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">245</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.91pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance lease commitments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,137</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">763</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:216.91pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Convertible promissory note</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">37,338</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">37,338</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:216.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total contractual obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">46,145</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">44,014</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,417</td>
            <td style="padding:0pt;padding-left:5.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">469</td>
            <td style="padding:0pt;padding-left:9.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">245</td>
            <td style="padding:0pt;padding-left:7.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects obligations pursuant to Carisma&#8217;s office and laboratory leases in Philadelphia, Pennsylvania. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects principal and interest payments pursuant to the Carisma convertible note issued to Moderna in January&#160;2022. The table above assumes cash settlement at the contractual maturity date in July&#160;31, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">337</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2023. Settlement may be through the conversion of outstanding principal and interest into shares of Carisma capital stock that may be issued in connection with a qualified or unqualified financing event and prior to maturity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Carisma&#8217;s contracts with CMOs, CROs and other third parties for the manufacture of its product candidates and to support pre-clinical research studies and clinical testing are generally cancelable by Carisma upon prior notice and do not contain any minimum purchase commitments. Payments due upon cancellation consisting only of payments for services provided or expenses incurred, including noncancelable obligations of Carisma&#8217;s service providers, up to the date of cancellation are not included in the table above as the amount and timing of such payments are not known. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table above does not include any potential milestone or royalty payments that Carisma may be required to make under license agreement with Penn and under licensing agreements with other third parties not considered material. Carisma excluded these milestone and royalty payments given that the timing and likelihood of any such payments cannot be reasonably estimated at this time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">University of Pennsylvania License</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2017, Carisma entered into a license agreement with Penn for certain intellectual property licenses, which was amended in February&#160;2018, January&#160;2019, March&#160;2020 and June&#160;2021. Carisma is responsible for paying Penn an annual license maintenance fee in the low tens of thousands of dollars, payable until Carisma&#8217;s first payment of a royalty. Carisma is required to pay Penn up to $10.9&#160;million per product in development and regulatory milestone payments, up to $30.0&#160;million per product in commercial milestone payments, and up to an additional $1.7&#160;million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. While the license agreement remains in effect, Carisma is required to pay Penn low to mid-single digit&#160;percentage tiered royalties on annual net sales of licensed products, which may be subject to reductions. Penn is guaranteed a minimum royalty payment amount in the low hundreds of thousands of dollars for each year after the first commercial sale of a licensed product. Carisma must also pay Penn a&#160;percentage in the mid-single digits to low double digits of certain types of income Carisma receives from sublicensees. In addition, Carisma is required to pay Penn an annual alliance management fee in the low tens of thousands of dollars, ending after several&#160;years, unless Carisma provides funding to Penn for research and development activities that extend beyond a specified date, in which case Carisma will continue to owe the alliance management fee for each year in which Carisma continues to fund such activities. Carisma also paid Penn an upfront fee in the low hundreds of thousands of dollars for the license to the patents related to the mesothelin binder that is incorporated into the CAR design for Carisma&#8217;s mesothelin product candidate. Carisma is responsible for a pro&#160;rata share of costs relating to the prosecution and maintenance of the licensed patents. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Critical Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma management&#8217;s discussion and analysis of its financial condition and results of operations are based on its consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of the consolidated financial statements requires Carisma to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements. On an ongoing basis, Carisma evaluates its estimates and judgments, including those related to accrued expenses, fair value of Carisma common stock and stock-based compensation. Carisma bases its estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While Carisma&#8217;s significant accounting policies are described in more detail in Note 3 to its audited consolidated financial statements included elsewhere in this proxy statement/prospectus, Carisma believes </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">338</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the following accounting policies are the most critical to the judgments and estimates used in the preparation of its consolidated financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenues from Contracts</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma accounts for its revenue in accordance with Accounting Standards Codification, or ASC, 606, </font><font style="font-style:italic;letter-spacing:0.2pt;">Revenue from Contracts with Customers</font><font style="letter-spacing:0.2pt;">, or ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps at inception of the agreement or upon material modification of the agreement: (i)&#160;identifies the contract(s) with a customer; (ii)&#160;identifies the performance obligations in the contract; (iii)&#160;determines the transaction price, including variable consideration, if any; (iv)&#160;allocates the transaction price to the performance obligations in the contract; and (v)&#160;recognizes revenue when (or as) the entity satisfies a performance obligation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma considers the pattern of satisfaction of the performance obligations under step (v)&#160;above to be a critical accounting estimate. More specifically, the determination of the level of achievement of research and development service performance obligations, whose pattern of satisfaction is measured using costs incurred to date as compared to total costs incurred and expected to be incurred in the future is driven by a critical accounting estimate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In estimating the costs expected to be incurred in the future, Carisma management uses its most recent budget and long-range plan, adjusted for any pertinent information. While this is Carisma&#8217;s best estimate as of the reporting period, costs expected to be incurred in the future require management&#8217;s judgment as the scope and timing of research and development activities may change significantly over time. Carisma may adjust the scope of its research and development activities based on several factors, such as additional work needed to support advancement of product candidate or change in the number of patients in trials. Further, research and development services may no longer be within the scope of a collaboration agreement, as has been the case with certain of Carisma&#8217;s programs. The timing of when research and development costs are expected to be incurred may change as a result of external factors, such as delays caused by manufacturing or supply chain, or difficulty in enrolling patients; or internal factors, such as prioritization of programs. Carisma&#8217;s estimate of the scope and timing of research and development services performed relative to the actual scope and timing may have a significant impact on revenue recognition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Accruals</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses consist primarily of costs incurred in connection with the development of Carisma&#8217;s product candidates. Carisma expenses research and development costs as incurred. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma accrues expenses for pre-clinical studies and activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with third parties. Carisma determines the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with its internal clinical personnel and external service providers as to the progress or stage of completion of activities or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including Carisma&#8217;s clinical development plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, Carisma will adjust the accrual accordingly. Non-refundable advance payments for goods and services, including fees for process development or manufacturing and distribution of pre-clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">339</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Milestone payments within Carisma&#8217;s licensing and collaboration arrangements are recognized when achievement of the milestone is deemed probable to occur. To the extent products are commercialized and future economic benefit has been established, commercial milestones that become probable are capitalized and amortized over the estimated remaining useful life of the intellectual property. In addition, Carisma accrues royalty expense and sublicense non-royalty payments, as applicable, for the amount it is obligated to pay, with adjustments as sales are made. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock-Based Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma measures compensation expense for all stock-based awards based on the estimated fair value of the award on the grant date. Carisma uses the Black-Scholes option pricing model to value its stock option awards. Carisma recognizes compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. Carisma has not issued awards where vesting is subject to a market or performance condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Black-Scholes option pricing model requires the use of subjective assumptions that include the expected stock price volatility and the fair value of the underlying common stock on the date of grant. See Note 8 to Carisma&#8217;s audited consolidated financial statements and Note 8 to Carisma&#8217;s unaudited interim consolidated financial statements included elsewhere in this proxy statement/prospectus for information concerning certain of the specific assumptions Carisma used in applying the Black-Scholes option pricing model to determine the estimated fair value of its stock options granted during the&#160;years ended December&#160;31, 2021 and 2020 and for the nine&#160;months ended September&#160;30, 2022 and 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Estimating the fair value of common stock</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma is required to estimate the fair value of Carisma common stock underlying its stock-based awards. Because Carisma common stock is not currently publicly traded, the fair value of Carisma common stock has been estimated on each grant date by the Carisma board of directors, with input from Carisma management, considering its most recently available third-party valuation of Carisma common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Carisma board of directors considered various objective and subjective factors to estimate the estimated fair value of Carisma common stock, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the estimated value of all classes of securities outstanding; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the anticipated capital structure that will directly impact the value of the currently outstanding securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s results of operations and financial position; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the status of Carisma&#8217;s research and development efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the composition of, and changes to, Carisma&#8217;s management team and the Carisma board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the lack of liquidity of Carisma common stock as a private company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carisma&#8217;s stage of development and business strategy and the material risks related to its business and industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">external market conditions affecting the life sciences and biotechnology industry sectors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the likelihood of achieving a liquidity event for the holders of Carisma common stock, such as an initial public offering, or a sale of the company, given the prevailing market conditions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the market value and volatility of comparable companies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In estimating the fair value of Carisma common stock, the Carisma board of directors considered the subjective factors discussed above in conjunction with the most recent valuations of Carisma common stock that were prepared by an independent third party. The independent valuation prepared as of February&#160;28, 2022 was utilized by the Carisma board of directors when estimating the fair value of Carisma common stock for the awards granted after such date and through September&#160;30, 2022. The independent valuation prepared as of April&#160;1, 2021 was utilized by the Carisma board of directors when estimating the fair value </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">340</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:200pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of Carisma common stock for the awards granted after such date and through December&#160;31, 2021. These third-party valuations resulted in an estimated fair value of Carisma common stock of $2.68 and $2.77 per share as of February&#160;28, 2022 and April&#160;1, 2021, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Redemption feature</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The redemption feature of the Carisma convertible note with Moderna is marked-to-market each reporting period with the changes in fair value recorded to other expense in the consolidated statements of operations until the obligations under the Carisma convertible note are satisfied. The fair value of the redemption feature of the Carisma convertible note is estimated by using a discounted cash flow method in conjunction with assuming the probability of completing a qualified financing. During the nine&#160;months ended September&#160;30, 2022, the discount factor used was 12% and a 90% probability of completing a qualified financing prior to the maturity date of the Carisma convertible note was assumed. The estimated time of conversion ranged from three to twelve&#160;months. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Accounting Pronouncements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See Note 3 to Carisma&#8217;s unaudited interim consolidated financial statements included elsewhere in this proxy statement/prospectus for a description of recent accounting pronouncements applicable to its consolidated financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Off-Balance Sheet Arrangements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma does not have any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. Carisma does not engage in off-balance sheet financing arrangements. In addition, Carisma does not engage in trading activities involving non-exchange traded contracts. Carisma therefore believes that it is not materially exposed to any financing, liquidity, market or credit risk that could arise if it had engaged in these relationships. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Qualitative and Quantitative Disclosures About Market Risk</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma is exposed to market risks in the ordinary course of its business. These risks primarily include interest rate sensitivities. Carisma&#8217;s interest-earning assets consist of cash, cash equivalents and marketable securities. Interest income earned on these assets was de minimis for the&#160;years ended December&#160;31, 2021 and 2020 and for the nine&#160;months ended September&#160;30, 2022 and 2021.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">341</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tMFTM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT FOLLOWING THE MERGER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:11.02pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Officers and Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The combined company&#8217;s board of directors will initially be fixed at seven members, consisting of six directors designated by Carisma and one director designated by Sesen Bio. The staggered structure of the current Sesen Bio board of directors will remain in place for the combined company&#8217;s board of directors following the completion of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the name, age as of January 4, 2023 and position of each of the individuals who are expected to serve as executive officers and directors of the combined company. </font>
        </div>
        <table style="width:456pt;height:173.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:204pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:24pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:204pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:-0.2pt;">Executive Officers</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Steven Kelly </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">57 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">President and Chief Executive Officer, Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Richard Morris </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">49 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">33 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Chief Scientific Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Sanford Zweifach </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">66 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Director, Chair </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">61 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">53 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">63 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D., Ph.D. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">64 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">40 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204pt;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.51pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Officers</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Steven Kelly</font><font style="letter-spacing:0.2pt;"> has served as Carisma&#8217;s President and Chief Executive Officer and as a member of the Carisma board of directors since February&#160;2018. Prior to joining Carisma, Mr.&#160;Kelly served as Chief Executive Officer of Pinteon Therapeutics, a biotechnology company, from April&#160;2014 to July&#160;2015 and as the Chief Executive Officer of Theracrine, Inc., a biopharmaceutical company, from June&#160;2011 to August&#160;2012. Mr.&#160;Kelly currently serves on the board of directors of Artelo Biosciences, Inc. (Nasdaq: ARTL). Mr.&#160;Kelly received a B.S. from the University of Oregon and an M.B.A. from Cornell University. Carisma believes Mr.&#160;Kelly is qualified to serve as a member of the combined company&#8217;s board of directors because of his extensive knowledge of Carisma based on his current role as its President and Chief Executive Officer, as well as his significant biopharmaceutical industry and management experience. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Richard Morris</font><font style="letter-spacing:0.2pt;"> has served as Carisma&#8217;s Chief Financial Officer since June&#160;2021. Prior to joining Carisma, Mr.&#160;Morris served as Chief Financial Officer of Passage Bio, Inc., a genetic medicines company, from October&#160;2019 to May&#160;2021 and as Executive Vice President and Chief Financial Officer of Context Therapeutics, LLC, a biopharmaceutical company, or Context, from November&#160;2017 to July&#160;2019. Prior to Context, Mr. Morris served as Chief Financial Officer of Vitae Pharmaceuticals Incorporated, a biopharmaceutical company, from 2014 to October 2016, and held several senior financial roles over 12 years at ViroPharma Incorporated, a biopharmaceutical company, including Chief Accounting Officer and Vice President, Financial and Strategic Planning. Mr.&#160;Morris received a B.S. in Accounting from Saint Joseph&#8217;s University and has been a CPA since 1999. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Michael Klichinsky,</font><font style="letter-spacing:0.2pt;"> </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Pharm.D., Ph.D.</font><font style="letter-spacing:0.2pt;"> has served as Carisma&#8217;s Chief Scientific Officer since April&#160;2022. He co-founded Carisma in 2016 and served as Vice President of Discovery of Carisma from October 2018 to April 2021 and as Senior Vice President of Research of Carisma from April 2021 to April&#160;2022. Dr.&#160;Klichinsky received a Doctor of Pharmacy from the University of Sciences in Philadelphia and a Ph.D. in Pharmacology from the University of Pennsylvania. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Sanford Zweifach</font><font style="letter-spacing:0.2pt;"> has served as a member and Chair of the Carisma board of directors since November&#160;2021. Mr.&#160;Zweifach has served as the Founder and President of Pelican Consulting Group, a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">342</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">biotechnology consulting firm, since December&#160;2019. Mr.&#160;Zweifach founded and served as Chief Executive Officer of Nuvelution Pharma, Inc., a pharmaceutical company, from June&#160;2015 to November&#160;2019. Mr.&#160;Zweifach currently serves on the boards of directors of Essa Pharma Inc. (Nasdaq: EPIX) and Compugen Ltd. (Nasdaq: CGEN). Mr.&#160;Zweifach received a B.A. in Biology from University of California San Diego and a M.S. in Human Physiology from University of California Davis. Carisma believes Mr.&#160;Zweifach is qualified to serve as Chair of the combined company&#8217;s board of directors because of his extensive experience in the biopharmaceutical industry and service on the boards of other public and private biopharmaceutical companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Thomas R. Cannell, </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">D.V.M.</font><font style="letter-spacing:0.2pt;">, has served as Sesen Bio&#8217;s President and Chief Executive Officer and a member of the Sesen Bio board of directors since August&#160;2018. Prior to joining Sesen Bio, Dr.&#160;Cannell served as Orexigen Therapeutics, Inc.&#8217;s Chief Operating Officer &amp; President of Global Commercial Products from July&#160;2016 to July&#160;2018, and as its Chief Commercial Officer from March&#160;2015 to June&#160;2016. Prior to Orexigen, Dr.&#160;Cannell spent 27&#160;years with Merck &amp; Co., Inc., where he held senior leadership positions in global commercialization, consumer marketing, and sales operations and management for both development-stage programs and approved marketed products. Dr.&#160;Cannell received a D.V.M. from Washington State University. Carisma believes Dr.&#160;Cannell is qualified to serve as a member of the combined company&#8217;s board of directors because of his extensive industry experience and scientific background. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Regina Hodits</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">, Ph.D.,</font><font style="letter-spacing:0.2pt;"> has served as a member of the Carisma board of directors since June 2018. Dr.&#160;Hodits has served as a Managing Partner at Wellington Partners, a venture capital firm investing in companies mainly in areas of technology, life sciences and digital media, since 2010. Prior to that, Dr.&#160;Hodits served as Partner of Atlas Ventures from 2004 to 2010. She currently serves on the board of directors of Onward Medical. Dr.&#160;Hodits received a Master&#8217;s degree in Chemical Engineering and a Ph.D. in biochemistry from Technical University of Vienna, Austria. Carisma believes Dr.&#160;Hodits is qualified to serve as a member of the combined company&#8217;s board of directors because of her scientific background and training in biochemistry, extensive experience with biopharmaceutical companies and service on the boards of other biopharmaceutical companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Briggs Morrison</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">, M.D.,</font><font style="letter-spacing:0.2pt;"> has served as a member of the Carisma board of directors since July&#160;2020. Dr.&#160;Morrison has served as President, Head of Research and Development of Syndax Pharmaceuticals Inc., a biopharmaceutical company, since February 2022; he was previously Chief Executive Officer of Syndax Pharmaceuticals Inc. from June&#160;2015. Dr.&#160;Morrison currently serves on the boards of directors of Repare Therapeutics Inc. (Nasdaq: RPTX), Werewolf Therapeutics Inc. (Nasdaq: HOWL), Arvinas, Inc. (Nasdaq: ARVN) and Syndax Pharmaceuticals Inc. (Nasdaq: SNDX). Dr.&#160;Morrison received an M.D. from the University of Connecticut and a B.S. in Biology from Georgetown University. Carisma believes Dr.&#160;Morrison is qualified to serve as a member of the combined company&#8217;s board of directors due to his extensive executive leadership experience, medical background and training, and extensive service on the boards of other public and private biopharmaceutical companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Bj&#246;rn Odlander,</font><font style="letter-spacing:0.2pt;"> </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">M.D., Ph.D.</font><font style="letter-spacing:0.2pt;"> has served as a member of the Carisma board of directors since February&#160;2022. Dr.&#160;Odlander is a co-founder of HealthCap, a family of venture capital funds investing globally in life sciences, where he has been a Managing Partner since 1996. Dr.&#160;Odlander received a M.D. and Ph.D. from Karolinska Institute. Dr.&#160;Odlander is qualified to serve as a member of the combined company&#8217;s board of directors with his medical background and training, industry background and extensive experience of investments in the life-science sector. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Chidozie Ugwumba</font><font style="letter-spacing:0.2pt;"> has served as a member of the Carisma board of directors since December 2020. Mr.&#160;Ugwumba has served as Managing Partner of SymBiosis, a venture capital firm focused on investments in biotherapeutics, since August&#160;2021. Prior to SymBiosis, Mr.&#160;Ugwumba served as a Managing Director and the Co-Head of the Direct and Impact Investment Group of WIT, LLC, an investment management entity affiliated with Walton Enterprises, from 2018 to 2021 and on the Private Credit and Infrastructure teams at Partners Group, a global private investment manager, from 2015 to 2018. Mr.&#160;Ugwumba currently serves on the board of directors of Clene, Inc. (Nasdaq: CLNN). Mr.&#160;Ugwumba received an M.B.A. from Cornell University and a B.A. in Political Science from Amherst College. Carisma believes Mr.&#160;Ugwumba is qualified to serve as a member of the combined company&#8217;s board of directors because of his significant experience and expertise in biopharmaceutical investments and his overall industry knowledge. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">343</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Independence</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Applicable Nasdaq Listing Rules require that the combined company&#8217;s board of directors be comprised of a majority of independent directors. Based upon information requested from and provided by each proposed director concerning his or her background, employment and affiliations, including family relationships, Carisma expects that the combined company&#8217;s board of directors will determine that each member of the combined company&#8217;s board of directors, except Mr.&#160;Kelly, Carisma&#8217;s current President and Chief Executive Officer, who will serve as President and Chief Executive Officer of the combined company, and Dr.&#160;Cannell, Sesen Bio&#8217;s current President and Chief Executive Officer, will qualify as an &#8220;independent director&#8221; as defined under applicable Nasdaq Listing Rules. In making such determination, the combined company&#8217;s board of directors will consider the current and prior relationships that each director has with Carisma and Sesen Bio and all other facts and circumstances that the company&#8217;s board of directors deems relevant in determining the independence of each director, including the interests of each director in the merger, any relevant related party transactions and the beneficial ownership of Carisma or Sesen Bio common stock by each director. See the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Interests of Carisma Directors and Executive Officers in the Merger</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Related Party Transactions of Directors and Executive Officers of the Combined Company</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Stockholders of Carisma</font><font style="letter-spacing:0.2pt;">&#8221; beginning on pages <a href="#tIOCD">153</a>, <a href="#tRPTO">368</a> and <a href="#tPSOC">397</a>, respectively, of this proxy statement/prospectus for additional information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, Nasdaq Listing Rules require that, subject to specified exceptions, each member of the combined company&#8217;s audit, compensation and nominating and corporate governance committees be independent under the Exchange Act. Audit committee members must also satisfy the independence criteria set forth in Rule&#160;10A-3 under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule&#160;10C-1 under the Exchange Act. Under applicable Nasdaq Listing Rules, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of the combined company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule&#160;10A-3, a member of an audit committee of the combined company may not, other than in his or her capacity as a member of the audit committee, the combined company&#8217;s board of directors, or any other committee of the combined company&#8217;s board of directors, accept, directly or indirectly, any consulting, advisory or other compensatory fee from the combined company or any of its subsidiaries or otherwise be an affiliated person of the combined company or any of its subsidiaries. In order to be considered independent for purposes of Rule&#160;10C-1, the board of directors must consider, for each member of a compensation committee of the combined company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&#160;the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director; and (2)&#160;whether the director is affiliated with the company or any of its subsidiaries or affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are no family relationships among any of the proposed directors or officers of the combined company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Composition of the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors currently consists of six members divided into three staggered classes, with one class elected at each annual meeting to serve for a three-year term. The staggered structure of the current Sesen Bio board of directors will remain in place for the combined company&#8217;s board of directors following the completion of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Committees of the Board of Directors Following the Merger</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors has an established audit committee, compensation committee, nominating and corporate governance committee and science committee, each of which operate pursuant to a charter adopted by the Sesen Bio board of directors. After completion of the merger, the combined company&#8217;s board of directors will continue to have such standing committees. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">344</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The responsibilities of the Sesen Bio audit committee include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">appointing, approving the compensation of, and assessing the independence of, Sesen Bio&#8217;s registered public accounting firm; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing the work of the independent registered public accounting firm, including through the receipt and consideration of reports and other communications from such firm; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and discussing with management and the independent registered public accounting firm&#160;(x)&#160;the annual and quarterly financial statements and related disclosures (including any interim financial statements to be included in Sesen Bio&#8217;s periodic disclosures filed with the SEC); (y)&#160;earnings press releases; and (z)&#160;litigation or other legal matters that could have a significant impact on Sesen Bio&#8217;s financial results; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">monitoring internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing Sesen Bio&#8217;s internal audit function; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">working with Sesen Bio&#8217;s Chief Compliance Officer to evaluate and define the goals of Sesen Bio&#8217;s ethics and compliance programs, evaluate the adequacy of Sesen Bio&#8217;s internal controls over compliance and develop proposals for improving Sesen Bio&#8217;s internal controls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing Sesen Bio&#8217;s risk assessment and risk management policies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">meeting independently with Sesen Bio&#8217;s internal audit advisor, if applicable, and the independent registered public accounting firm and management; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving or ratifying any related person transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">preparing the audit committee report required by SEC rules; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conducting a periodic self-assessment of the committee and its charter. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The audit committee of the combined company is expected to retain these duties and responsibilities following the completion of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the closing of the merger, the combined company&#8217;s board of directors is expected to select members of the audit committee. Sesen Bio and Carisma believe that, following the completion of the merger, the composition of the audit committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The responsibilities of the Sesen Bio compensation committee include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving, or making recommendations to the Sesen Bio board of directors with respect to, the compensation of the chief executive officer and other executive officers, taking into consideration the executive officer&#8217;s performance as it relates to both legal compliance and compliance with Sesen Bio&#8217;s internal policies and procedures; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving termination benefits and separation pay to executive officers, taking into consideration the circumstances surrounding the particular executive officer&#8217;s departure and performance as it relates to both legal compliance and compliance with Sesen Bio&#8217;s internal policies and procedures; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing an evaluation of Sesen Bio&#8217;s senior executives, including the establishment of corporate goals and objectives applicable to the chief executive officer and other executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving, or making recommendations to the Sesen Bio board of directors with respect to, the terms of any binding offer letters, employment agreements, termination agreements or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">345</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">arrangements, change-in-control agreements, severance agreements, indemnification agreements or other material compensatory agreements with the chief executive officer or the other executive officers; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and making recommendations to the Sesen Bio board of directors with respect to incentive-compensation and equity-based plans that are subject to approval by the Sesen Bio board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing and administering Sesen Bio stock option, stock incentive, employee stock purchase and other equity-based plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">retaining the services, following the determination of independence under applicable Nasdaq Listing Rules and Exchange Act rules, of Sesen Bio&#8217;s compensation consultant, as well as overseeing and considering the recommendations of the compensation consultant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and making recommendations to the Sesen Bio board of directors with respect to director compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establishing, if deemed advisable by the Sesen Bio board of directors, and monitoring compliance with, stock ownership guidelines for the chief executive officer, directors and other executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and discussing annually with management the compensation disclosure required by SEC rules; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">preparing the compensation committee report required by SEC rules; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conducting a periodic self-assessment of the committee and its charter. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The compensation committee of the combined company is expected to retain these duties and responsibilities following completion of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the closing of the merger, the combined company&#8217;s board of directors is expected to select members of the compensation committee. Sesen Bio and Carisma believe that, following the completion of the merger, the composition of the compensation governance committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nominating and Corporate Governance Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The responsibilities of the Sesen Bio nominating and corporate governance committee include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">identifying individuals qualified to become members of the Sesen Bio board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">recommending to the Sesen Bio board of directors the persons to be nominated for election as directors and to each of the board committees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and making recommendations to the Sesen Bio board of directors with respect to board leadership structure; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and making recommendations to the Sesen Bio board of directors with respect to management succession planning; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and making recommendations to the Sesen Bio board of directors with respect to the adequacy of the Sesen Bio Certificate of Incorporation and Sesen Bio Bylaws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developing and recommending corporate governance guidelines to the Sesen Bio board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing a periodic evaluation of the Sesen Bio board of directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conducting a periodic self-assessment of the committee and its charter. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The nominating and corporate governance committee of the combined company is expected to retain these duties and responsibilities following completion of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the closing of the merger, the combined company&#8217;s board of directors is expected to select members of the nominating and corporate governance committee. Sesen Bio and Carisma believe that, following the completion of the merger, the composition of the nominating and corporate governance committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">346</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Science Committee</font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The responsibilities of the Sesen Bio science committee include:</font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and advising on the overall strategy, direction and effectiveness of Sesen Bio&#8217;s research and development, or R&amp;D, initiatives, programs and related investments, and on Sesen Bio&#8217;s progress in achieving our long-term strategic R&amp;D goals and objectives, including preclinical studies and clinical trial design;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and advising on opportunities and risks associated with Sesen Bio&#8217;s R&amp;D initiatives, programs and related investments;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and advising on Sesen Bio&#8217;s significant medical affairs strategies and initiatives;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and advising on trends and innovation in research and development to enhance Sesen Bio&#8217;s R&amp;D capabilities; and</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conducting a periodic self-assessment of the science committee and its charter. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The science committee of the combined company is expected to retain these duties and responsibilities following completion of the merger.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the closing of the merger, the combined company&#8217;s board of directors is expected to select members of the science committee. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee Interlocks and Insider Participation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the closing of the merger, the combined company&#8217;s board of directors is expected to select members of the compensation committee. None of the proposed executive officers of the combined company serve, or in the past year has served, as a member of the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers who is proposed to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Code of Business Conduct and Ethics</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The combined company will adopt a written code of business conduct and ethics, substantially in the form of Sesen Bio&#8217;s current Code of Business Conduct and Ethics, that applies to its directors, officers and employees, including the principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, of the combined company. The combined company will post a current copy of the code on its website, www.carismatx.com. In addition, the combined company intends to post on its website all disclosures that are required by law or Nasdaq Listing Rules concerning any amendments to, or waivers from, any provision of the code of business conduct and ethics. The information contained on, or that can be accessed through, the website is not a part of this prospectus. The website address is included in this prospectus solely as an inactive textual reference. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to the merger, Carisma did not have a formal policy to provide any cash or equity compensation to its non-employee directors for their service on the Carisma board of directors or committees of the Carisma board of directors. In connection with Mr.&#160;Zweifach&#8217;s election as a member and Chair of the Carisma board of directors in November&#160;2021, the Carisma board of directors authorized an annual cash retainer of $75,000 to be paid to Mr.&#160;Zweifach in equal quarterly installments and a grant to Mr.&#160;Zweifach of options to purchase 97,200 shares of Carisma common stock. In connection with Mr.&#160;Morrison&#8217;s election as a member of the Carisma board of directors in July&#160;2020, the Carisma board of directors authorized a grant to Mr.&#160;Morrison of options to purchase 33,332 shares of Carisma common stock. For additional information on compensation paid to directors of Carisma, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Carisma Executive Compensation&#8201;&#8212;&#8201;Carisma Director Compensation</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCADCT">367</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the closing of the merger and the transition of the board of directors, the combined company expects to evaluate Sesen Bio&#8217;s director compensation practices and finalize the combined company&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">347</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:568pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">non-employee director compensation program, pursuant to which non-employee directors will be eligible to receive compensation for service on the board of directors of the combined company and its committees. The board of directors of the combined company expects to review director compensation periodically to ensure that director compensation remains competitive such that the combined company is able to recruit and retain qualified directors. </font>
          </div>

      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">348</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSBEC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
            <font style="letter-spacing:-0.2pt;">SESEN BIO EXECUTIVE COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s named executive officers for 2022 are Thomas R. Cannell, D.V.M., its President and Chief Executive Officer, Monica Forbes, its Chief Financial Officer, and Mark Sullivan, its General Counsel, Chief Compliance Officer and Corporate Secretary. </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
            <font style="letter-spacing:-0.2pt;">Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">The following table sets forth information regarding compensation awarded to, earned by or paid to each of Sesen Bio&#8217;s named executive officers for the&#160;years ended December&#160;31, 2022 and 2021. </font>
          </div>


          <table style="width:456pt;height:168.14pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:135.9pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name and Principal Position</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Year</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Salary</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Bonus </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Stock </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Awards ($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(4)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">awards</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(5)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Non-equity </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">incentive </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">plan </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">compensation </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(6)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">All other</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">compensation</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(7)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Total</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.48999999999998pt;height:6.89pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
              <td style="padding:3.267pt 0pt 1.14pt 0pt; width:135.9pt;text-align:left;" rowspan="2">
                <div style="margin-left:9.5pt; text-indent:-9.5pt; text-align:justify; line-height:11.39pt; padding-bottom:0.63pt;">
                  <font style="letter-spacing:0.19pt;">Thomas R. Cannell, D.V.M.</font><font style=" position:relative; bottom:4pt;font-size:6pt;letter-spacing:0.14pt;">&#65279;(1)</font> <br ><font style="letter-spacing:0.19pt;">President and Chief Executive </font><br ><font style="letter-spacing:0.19pt;">Officer</font></div>
              </td>
              <td style="padding:0pt; width:2.5pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:18pt; text-align:right; white-space:nowrap;">2022 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:27.75pt; text-align:right; white-space:nowrap;">574,345 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:27.75pt; text-align:right; white-space:nowrap;">813,112 </td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,000 </td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.267pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,391,457 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:11.39pt;height:22.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">2021 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">558,362 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,123,086 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">236,250 </td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,000 </td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,921,698 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.48999999999998pt;height:6.64pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
              <td style="padding:3.517pt 0pt 1.14pt 0pt; width:135.9pt;white-space:normal;text-align:left;" rowspan="2">
                <div style="margin-left:9.5pt; text-indent:-9.5pt; text-align:justify; line-height:11.39pt; padding-bottom:0.63pt;">
                  <font style="letter-spacing:0.19pt;">Monica Forbes</font><font style=" position:relative; bottom:4pt;font-size:6pt;letter-spacing:0.14pt;">&#65279;(2)</font> <br ><font style="letter-spacing:0.19pt;">Chief Financial Officer and Treasurer</font></div>
              </td>
              <td style="padding:0pt; width:2.5pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:18pt; text-align:right; white-space:nowrap;">2022 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:27.75pt; text-align:right; white-space:nowrap;">388,785 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:27.75pt; text-align:right; white-space:nowrap;">484,229 </td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,000 </td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.517pt 0pt 1.633pt 0pt; line-height:11.39pt; min-width:33.75pt; text-align:right; white-space:nowrap;">877,015 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:11.39pt;height:22.77pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">2021 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">377,958 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">148,778 </td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,195,695 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">145,447 </td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,000 </td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.25pt 0pt 9.13pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,871,878 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:11.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">
              <td style="padding:2.26pt 0pt 9.13pt 0pt; width:135.9pt;white-space:normal;text-align:left;">
                <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                  <font style="letter-spacing:0.19pt;">Mark Sullivan</font><font style=" position:relative; bottom:4pt;font-size:6pt;letter-spacing:0.14pt;">&#65279;(3)</font> <br ><font style="letter-spacing:0.19pt;">General Counsel, Chief Compliance Officer and Corporate Secretary</font></div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">2022 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">380,129 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:5.455pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">303,196 </td>
              <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.005pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,000 </td>
              <td style="padding:0pt;padding-left:11.755pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.26pt 0pt 9.13pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">687,325</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.55pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Dr.&#160;Cannell&#8217;s base salary was increased from $562,500 to $576,563, effective March&#160;1, 2022. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Ms.&#160;Forbes&#8217; base salary was increased from $380,750 to $399,788, effective March&#160;1, 2022. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Mr.&#160;Sullivan&#8217;s base salary was $382,025 effective March&#160;1, 2022. Mr.&#160;Sullivan was not a named executive officer for fiscal year 2021. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(4)</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">The amounts reported in the &#8220;Stock awards&#8221; column reflect the aggregate grant date fair value of performance-based restricted stock&#160;units and restricted stock&#160;units awarded during the year computed in accordance with the provisions of Financial Accounting Standards Board Accounting Standard Codification, or ASC, Topic 718. See Note 14 to Sesen Bio&#8217;s financial statements appearing at the end of Sesen Bio&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 regarding assumptions underlying the valuation of equity awards. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(5)</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">The amounts reported in the &#8220;Option awards&#8221; column reflect the aggregate grant date fair value of stock options awarded during the year computed in accordance with the provisions of Financial Accounting Standards Board Accounting Standard Codification, or ASC, Topic 718. See Note 14 to Sesen Bio&#8217;s financial statements appearing at the end of Sesen Bio&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 regarding assumptions underlying the valuation of equity awards. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="margin-left:20pt; margin-top:2.09pt; width:436pt; line-height:11.5pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">For the year ended December&#160;31, 2022, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model: </font>
          </div>


          <table style="width:436pt;height:116.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:378.41pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Year ended</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">2022</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 0.5pt 0pt; width:378.41pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Fair market value </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.72 </td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:378.41pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Grant exercise price </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.72 </td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:378.41pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Expected term (in&#160;years) </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.9 </td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:378.41pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Risk-free interest rate </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.11<font style="position:absolute;">% </font></td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:378.41pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Expected volatility </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">71.77<font style="position:absolute;">% </font></td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:378.41pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Dividend yield </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">349</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(6)</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The amounts reported in the &#8220;Non-equity incentive plan compensation&#8221; column reflect bonuses that were earned by Sesen Bio&#8217;s executive officers in the fiscal year ending December&#160;31, 2021 based on the achievement of pre-established performance goals that were previously communicated to Sesen Bio&#8217;s executive officers. See &#8220;Bonus Compensation&#8221; below for additional information. As of the date of this proxy statement/prospectus, the determination of performance-based bonuses for the fiscal year ending December&#160;31, 2022 has not yet been made. It is anticipated that these amounts will be determined in the first quarter of 2023, at which time Sesen Bio will disclose the amounts of such bonuses. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(7)</font>
            <br >
          </div>
          <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">For Dr.&#160;Cannell and Ms.&#160;Forbes, for the fiscal&#160;years 2022 and 2021, and Mr.&#160;Sullivan, for the fiscal year 2022, the amounts reported reflect discretionary 401(k) matching contributions contributed to Sesen Bio&#8217;s 401(k) retirement plan as approved by the Sesen Bio compensation committee. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Narrative to Summary Compensation Table</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Employment Agreements with Named Executive Officers</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On August&#160;7, 2018, Sesen Bio entered into an employment agreement with Dr.&#160;Cannell, which provides that his employment will continue until either Sesen Bio or Dr.&#160;Cannell provides notice of termination in accordance with the terms of the agreement. In addition, Sesen Bio entered into a non-competition, non-solicitation, confidentiality and assignment agreement with Dr.&#160;Cannell, which prohibits him from competing with Sesen Bio, soliciting Sesen Bio&#8217;s employees and customers and disclosing confidential information during the term of his employment and for one year following the conclusion of his service with Sesen Bio. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to Dr.&#160;Cannell&#8217;s employment agreement, he is entitled to receive an annual base salary, which will be reviewed at least annually and will be subject to increase (but not decrease) from time to time, as determined by the Sesen Bio board of directors. In February&#160;2022, the Sesen Bio compensation committee approved an increase in Dr.&#160;Cannell&#8217;s annual base salary to $576,563, effective March&#160;1, 2022. In addition, pursuant to his employment agreement, Dr.&#160;Cannell is eligible to receive an annual cash bonus, which is based on the achievement of individual and corporate performance objectives, calculated as a&#160;percentage of his annual base salary, and which will be determined by the Sesen Bio board of directors, in its sole discretion. Dr.&#160;Cannell&#8217;s target annual bonus for 2021 and 2022 was 50% of his annual base salary. </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Monica Forbes</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On August&#160;26, 2019, Sesen Bio entered into an employment agreement with Ms.&#160;Forbes in connection with her appointment as Sesen Bio&#8217;s Chief Financial Officer and Treasurer. Ms.&#160;Forbes&#8217; employment agreement provides that her employment will continue until either Sesen Bio or Ms.&#160;Forbes provides notice of termination in accordance with the terms of the agreement. In addition, Sesen Bio entered into a non-competition, non-solicitation, confidentiality and assignment agreement with Ms.&#160;Forbes, which prohibits her from competing with Sesen Bio, soliciting Sesen Bio&#8217;s employees and customers and disclosing confidential information during the term of her employment and for one year following the conclusion of her service with Sesen Bio. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to Ms.&#160;Forbes&#8217; employment agreement, she is entitled to receive an annual base salary, which will be reviewed at least annually and will be subject to increase (but not decrease) from time to time, as determined by the Sesen Bio board of directors. In February&#160;2022, the Sesen Bio compensation committee approved an increase in Ms.&#160;Forbes&#8217; annual base salary to $400,000, effective March&#160;1, 2022. In addition, pursuant to her employment agreement, Ms.&#160;Forbes is eligible to receive an annual cash bonus based on the achievement of individual and corporate performance objectives, calculated as a&#160;percentage of her annual base salary, and which will be determined by the Sesen Bio board of directors, in its sole discretion. Ms.&#160;Forbes&#8217; annual target bonus for 2021 and 2022 was 40% of her annual base salary. </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Mark Sullivan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On July&#160;26, 2019, Sesen Bio entered into an employment agreement with Mr.&#160;Sullivan. Mr.&#160;Sullivan&#8217;s employment agreement provides that his employment will continue until either Sesen Bio or Mr.&#160;Sullivan </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">350</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">provides notice of termination in accordance with the terms of the agreement. In addition, Sesen Bio entered into a non-competition, non-solicitation, confidentiality and assignment agreement with Mr.&#160;Sullivan, which prohibits him from competing with Sesen Bio, soliciting Sesen Bio&#8217;s employees and customers and disclosing confidential information during the term of his employment and for one year following the conclusion of his service with Sesen Bio. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to Mr.&#160;Sullivan&#8217;s employment agreement, he is entitled to receive an annual base salary, which will be reviewed at least annually and will be subject to increase (but not decrease) from time to time, as determined by the Sesen Bio board of directors. In February&#160;2022, the Sesen Bio compensation committee approved an increase in Mr.&#160;Sullivan&#8217;s annual base salary to $382,025, effective March&#160;1, 2022. In addition, pursuant to his employment agreement, Mr.&#160;Sullivan is eligible to receive an annual cash bonus based on the achievement of individual and corporate performance objectives, calculated as a&#160;percentage of his annual base salary, and which will be determined by the Sesen Bio board of directors, in its sole discretion. Mr.&#160;Sullivan&#8217;s annual target bonus for 2021 and 2022 was 40% of his annual base salary. </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Equity Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Although Sesen Bio does not have a formal policy with respect to the grant of equity incentive awards to its executive officers, or any formal equity ownership guidelines applicable to them, Sesen Bio believes that equity grants provide its executives with a strong link to its long-term performance, create an ownership culture and help to align the interests of its executives and Sesen Bio stockholders. In addition, Sesen Bio believes that equity grants with a time-based vesting feature promote executive retention by incentivizing its executive officers to remain in Sesen Bio&#8217;s employment during the vesting period. Accordingly, the Sesen Bio board of directors periodically reviews the equity incentive compensation of its executive officers and from time to time may grant equity incentive awards to them, including in the form of Sesen Bio options and Sesen Bio RSUs (both time-based RSUs and performance-based RSUs, or Sesen Bio PSUs). </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On February&#160;18, 2022, Sesen Bio granted Dr.&#160;Cannell an award of 606,800 RSUs. Each Sesen Bio RSU represents a contingent right to receive one share of Sesen Bio common stock. The Sesen Bio RSU award vests annually in equal amounts over a four year period following the grant date, subject to Dr.&#160;Cannell&#8217;s continued service with Sesen Bio on the applicable vesting date. On February&#160;18, 2022, Sesen Bio also granted Dr.&#160;Cannell an award of 606,800 Sesen Bio PSUs. Each Sesen Bio PSU represents a contingent right to receive one share of Sesen Bio common stock upon the satisfaction of pre-determined performance criteria related to completing patient enrollment for the new clinical trial. Subject to continued employment, such Sesen Bio PSUs vest upon the determination by the Sesen Bio compensation committee of the level of achievement of a clinical trial milestone. On February&#160;19, 2021, Sesen Bio granted Dr.&#160;Cannell options to purchase 2,000,000 shares of Sesen Bio common stock at an exercise price of $3.17 per share. These options vest 6.25% every three&#160;months over four&#160;years commencing on February&#160;19, 2021, subject to Dr.&#160;Cannell&#8217;s continued service with Sesen Bio on the applicable vesting date. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On February&#160;18, 2022, Sesen Bio granted Ms.&#160;Forbes an award of 542,250 RSUs. Each Sesen Bio RSU represents a contingent right to receive one share of Sesen Bio common stock. The Sesen Bio RSU award vests annually in equal amounts over a four year period following the grant date, subject to Ms.&#160;Forbes&#8217;s continued service with Sesen Bio on the applicable vesting date. On February&#160;18, 2022, Sesen Bio also granted Ms.&#160;Forbes an award of 180,750 Sesen Bio PSUs. Each Sesen Bio PSU represents a contingent right to receive one share of Sesen Bio common stock upon the satisfaction of pre-determined performance criteria related to completing patient enrollment for the new clinical trial. Subject to continued employment, such Sesen Bio PSUs vest upon the determination by the Sesen Bio compensation committee of the level of achievement of a clinical trial milestone. On February&#160;19, 2021, Sesen Bio granted Ms.&#160;Forbes options to purchase 580,000 shares of Sesen Bio common stock at an exercise price of $3.17 per share. These options vest 6.25% every three&#160;months over four&#160;years commencing on February&#160;19, 2021, subject to Ms.&#160;Forbes&#8217; continued service with Sesen Bio on the applicable vesting date. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On February&#160;18, 2022, Sesen Bio granted Mr.&#160;Sullivan an award of 339,525 RSUs. Each Sesen Bio RSU represents a contingent right to receive one share of Sesen Bio common stock. The Sesen Bio RSU award vests annually in equal amounts over a four year period following the grant date, subject to Mr.&#160;Sullivan&#8217;s continued service with Sesen Bio on the applicable vesting date. On February&#160;18, 2022, Sesen Bio also granted Mr.&#160;Sullivan an award of 113,175 Sesen Bio PSUs. Each Sesen Bio PSU represents a contingent </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">351</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">right to receive one share of Sesen Bio common stock upon the satisfaction of pre-determined performance criteria related to completing patient enrollment for the new clinical trial. Subject to continued employment, such Sesen Bio PSUs vest upon the determination by the Sesen Bio compensation committee of the level of achievement of a clinical trial milestone. On February&#160;19, 2021, Sesen Bio granted Mr.&#160;Sullivan options to purchase 300,000 shares of Sesen Bio common stock at an exercise price of $3.17 per share. These options vest 6.25% every three&#160;months over four&#160;years commencing on February&#160;19, 2021, subject to Mr.&#160;Sullivan&#8217;s continued service with Sesen Bio on the applicable vesting date. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In addition, on September&#160;9, 2021, the Sesen Bio board of directors and Sesen Bio compensation committee approved a retention program, or the 2021 retention program, for all current employees, except for the Chief Executive Officer, pursuant to which Sesen Bio has provided certain incentives designed to retain such employees. Pursuant to the 2021 retention program and effective as of October&#160;1, 2021, Sesen Bio&#8217;s executive officers, except for the Chief Executive Officer, were granted a Sesen Bio PSU award equal to the value of approximately fifty&#160;percent of the executive officer&#8217;s then-current base salary. Under the 2021 retention program, Ms.&#160;Forbes was granted an award of 190,375 Sesen Bio PSUs and Mr.&#160;Sullivan was granted an award of 185,000 Sesen Bio PSUs. Each Sesen Bio PSU represents a contingent right to receive one share of Sesen Bio common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September&#160;30, 2023 upon the determination by the Sesen Bio compensation committee of the level of achievement of certain key milestones consisting of a clinical trial milestone (weighted 50%), an employee retention milestone (weighted 30%) and a cash management milestone (weighted 20%). </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Bonus Compensation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio prepares a detailed set of overall corporate objectives for each fiscal year for use under the Sesen Bio annual bonus plan. These corporate objectives are initially prepared by management, reviewed (and revised, if determined appropriate) by the Sesen Bio compensation committee, and then presented to the full Sesen Bio board of directors for approval. The Sesen Bio compensation committee assigns weighting to the corporate objectives, but uses its judgment to determine a&#160;percentage that it believes fairly represents Sesen Bio&#8217;s achievement level for the applicable year. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">With respect to the fiscal year ended December&#160;31, 2021, each of Sesen Bio&#8217;s named executive officers was eligible to receive a performance-based bonus based on the achievement of corporate objectives and individual objectives. Since Sesen Bio&#8217;s Chief Executive Officer is responsible for the overall performance of Sesen Bio&#8217;s business, his annual bonus was based solely on Sesen Bio&#8217;s overall performance in achieving corporate objectives. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In February&#160;2022, the Sesen Bio compensation committee reviewed Sesen Bio&#8217;s 2021 corporate performance against Sesen Bio&#8217;s corporate objectives and noted that while Sesen Bio made substantial progress on Sesen Bio regulatory and financial goals during 2021, Sesen Bio had certain corporate setbacks as well. Further, the Sesen Bio compensation committee and the Sesen Bio board of directors determined to modify certain corporate objectives related to commercialization, which were determined to be no longer applicable in light of the CRL, as further described below. The weighting of the remaining corporate objectives was adjusted accordingly. Such objectives and outcomes included the following: </font>
          </div>


          <table style="width:456pt;height:143.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:144pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2021 Corporate Objective</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:192pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Outcome</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:48pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Weighting</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:36pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Score</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">Achieve FDA acceptance of the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC after 1Q 2021</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:192pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">Sesen Bio exceeded the target for this objective. The BLA for Vicineum was accepted with Priority Review during Q1 2021, which was earlier than the target.</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:48pt;white-space:nowrap;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">22%</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;white-space:nowrap;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">24</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:144pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">Receive FDA approval of the BLA in the second half of 2021</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:192pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">Sesen Bio did not meet this objective. The FDA issued a Complete Response Letter regarding Sesen Bio&#8217;s BLA for Vicineum.</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:48pt;white-space:nowrap;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">22%</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:36pt;white-space:nowrap;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">0</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:144pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">Submit the MAA for Vysyneum for the treatment of BCG-unresponsive NMIBC to the</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:192pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">Sesen Bio did not meet this objective. While Sesen Bio submitted the MAA earlier than its target date, Sesen Bio withdrew the MAA</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:48pt;white-space:nowrap;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">6%</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:36pt;white-space:nowrap;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">0</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">352</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:188.5pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:144pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2021 Corporate Objective</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:192pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Outcome</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:48pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Weighting</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:36pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Score</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 0.5pt 0pt; width:144pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">EMA after Q1 2021</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 0.5pt 0pt; width:192pt;white-space:normal;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">in order to pause its plans to pursue regulatory approval of Vysyneum in the E.U. until there is more clarity from the FDA on next steps for Vicineum in the U.S.</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:48pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:144pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">Strengthen balance sheet and extend cash runway by finishing fiscal 2021 with $40.0&#160;million -$50.0&#160;million</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:192pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">Sesen Bio exceeded the target for this objective by ending fiscal 2021 with a strong balance sheet of $163.0&#160;million in cash and cash equivalents. The strength of Sesen Bio&#8217;s balance sheet will be critical to supporting Sesen Bio&#8217;s business going forward, including future clinical development of Vicineum.</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:48pt;white-space:nowrap;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">50%</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:36pt;white-space:nowrap;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">60</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:8.5pt 0pt 0.5pt 0pt; width:144pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.2pt;">Total</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:192pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:8.5pt 0pt 0.5pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.2pt;">100%</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:8.5pt 0pt 0.5pt 0pt; width:36pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.2pt;">84</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:16pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As a result, and as noted in the table below, the Sesen Bio compensation committee and the Sesen Bio board of directors approved 2021 performance cash bonus payments to Sesen Bio&#8217;s named executive officers based on an assessment of corporate performance during 2021. </font>
          </div>


          <table style="width:456pt;height:70pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:193.35pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Target</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:193.35pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Annual </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Base Salary ($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Annual </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Bonus (%)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Annual </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Bonus ($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Company </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Scorecard </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Result</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Final </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Award</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:193.35pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.305pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">562,500 </td>
              <td style="padding:0pt;padding-left:9.305pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.865pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">50<font style="position:absolute;">% </font></td>
              <td style="padding:0pt;padding-left:15.865pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.509999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">281,250 </td>
              <td style="padding:0pt;padding-left:0.509999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.58pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">84<font style="position:absolute;">% </font></td>
              <td style="padding:0pt;padding-left:11.58pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">236,250 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:193.35pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Monica Forbes </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.305pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">380,750 </td>
              <td style="padding:0pt;padding-left:9.305pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.865pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">40<font style="position:absolute;">% </font></td>
              <td style="padding:0pt;padding-left:15.865pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.509999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">152,300 </td>
              <td style="padding:0pt;padding-left:0.509999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.58pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">84<font style="position:absolute;">% </font></td>
              <td style="padding:0pt;padding-left:11.58pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">145,447</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">2021 target annual bonus opportunity was a&#160;percentage of 2021 base salary. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">It is anticipated that the Sesen Bio compensation committee will review Sesen Bio&#8217;s 2022 corporate performance against Sesen Bio&#8217;s corporate objectives in the first quarter of 2023 in order to determine 2022 performance cash bonus payments to Sesen Bio&#8217;s named executive officers, at which time Sesen Bio will disclose the amounts of such bonuses. </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Outstanding Equity Awards at December&#160;31, 2022</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following table sets forth information regarding all outstanding equity awards held by each of Sesen Bio&#8217;s named executive officers as of December&#160;31, 2022. </font>
          </div>

      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">353</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:27.16pt;width:541pt;">

          <table style="width:541pt;height:363.83pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:130.71pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option Awards</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Stock Awards</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:130.71pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Number of</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">securities</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">underlying</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">unexercised</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">options</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(#)</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">exercisable</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Number of</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">securities</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">underlying</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">unexercised</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">options</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(#)</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">unexercisable</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">exercise</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">price</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">expiration</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">date</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Number of </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">shares or&#160;</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">units of </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">stock that </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">have not </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">vested </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(#)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Market </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">value of </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">shares of&#160;</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">units of </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">stock that </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">have not </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">vested</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Equity </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">incentive plan </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">awards: </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Number of </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">unearned </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">shares, units </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">or other rights </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">that have not </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">vested</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(#)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Equity </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">incentive plan </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">awards: </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Market or </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">payout value </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">of unearned </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">shares, units </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">or other </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">rights that </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">have not </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">vested</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:6.53pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:3.27pt 0pt 0.5pt 0pt; width:130.71pt;text-align:left;" rowspan="5">
                <div style="white-space:nowrap; line-height:10.8pt; padding-bottom:-0.0100000000000004pt;">
                  <font style="letter-spacing:0.18pt;">Thomas R. Cannell, D.V.M. </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;" rowspan="5">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:32.25pt; text-align:right; white-space:nowrap;">1,350,000 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(1)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1.60 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:33.75pt; text-align:right; white-space:nowrap;">8/7/2028 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.27pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:14.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">937,500 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">62,500<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(2)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0.8285 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2/21/2029 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:14.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">996,875 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">453,125<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(3)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0.8911 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2/13/2030 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.53pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:14.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">875,000 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">1,125,000<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(4)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3.17 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2/19/2031 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:14.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">606,800<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(7)</font> </font></td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">370,148<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(16)</font> </font></td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">606,800<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(8)</font> </font></td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">370,148<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(16)</font> </font></td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:6.28pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:3.54pt 0pt 0.5pt 0pt; width:130.71pt;text-align:left;" rowspan="6">
                <div style="white-space:nowrap; line-height:10.8pt; padding-bottom:-0.0100000000000099pt;">
                  <font style="letter-spacing:0.18pt;">Monica Forbes </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;" rowspan="6">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:32.25pt; text-align:right; white-space:nowrap;">195,000 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:29.25pt; text-align:right; white-space:nowrap;">45,000 <font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(5)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1.16 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:33.75pt; text-align:right; white-space:nowrap;">8/1/2029 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.54pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:14.28pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">227,500 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">52,500<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(6)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1.13 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">8/26/2029 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:14.28pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">316,250 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">143,750<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(3)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0.8911 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2/13/2030 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.55pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:14.28pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">253,750 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">326,250<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(4)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3.17 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2/19/2031 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.97pt;height:14.28pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">542,250<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(9)</font> </font></td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">330,773<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(16)</font> </font></td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">190,375<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(10)</font> </font></td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.56pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">116,129<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(16)</font> </font></td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.96999999999997pt;height:14.28pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">180,750<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(11)</font> </font></td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">110,258<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(16)</font> </font></td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.96999999999997pt;height:6.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:3.57pt 0pt 0.5pt 0pt; width:130.71pt;text-align:left;" rowspan="6">
                <div style="white-space:nowrap; line-height:10.8pt; padding-bottom:-0.0100000000000099pt;">
                  <font style="letter-spacing:0.18pt;">Mark Sullivan </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;" rowspan="6">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:32.25pt; text-align:right; white-space:nowrap;">243,750 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:29.25pt; text-align:right; white-space:nowrap;">16,250<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(12)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1.00 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2/27/2029 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; line-height:10.8pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.96999999999997pt;height:14.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">162,500 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">37,500<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(5)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1.16 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">8/1/2029 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.57pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.96999999999997pt;height:14.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">178,750 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">81,250<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(3)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">0.8911 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2/13/2030 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.96999999999997pt;height:14.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">131,250 </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">168,750<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(4)</font> </font></td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3.17 </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2/19/2031 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.58pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.96999999999997pt;height:14.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">339,525<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(13)</font> </font></td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">207,110<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(16)</font> </font></td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">185,000<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(14)</font> </font></td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">112,850<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(16)</font> </font></td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.96999999999997pt;height:18.28pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.814999999999998pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:8.31pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0.535pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:3.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:1.77pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">113,175<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(15)</font> </font></td>
              <td style="padding:0pt;padding-left:8.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.59pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">69,037<font style="position:absolute;"><font style=" position:relative; bottom:2.55357142857143pt;font-size:5.5pt;">(16)</font></font></td>
              <td style="padding:0pt;padding-left:7.7pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Option vests over four&#160;years, with 25% of the shares underlying the option vesting on August&#160;7, 2019, the first anniversary of the grant date, and 6.25% of the shares underlying the option vesting quarterly thereafter until the fourth anniversary of the grant date. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Option vests over four&#160;years, with 6.25% of the shares underlying the option vesting at the end of each successive three-month period beginning on February&#160;21, 2019. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Option vests over four&#160;years, with 6.25% of the shares underlying the option vesting at the end of each successive three-month period beginning on February&#160;13, 2020. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(4)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Option vests over four&#160;years, with 6.25% of the shares underlying the option vesting at the end of each successive three-month period beginning on February&#160;19, 2021. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(5)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Option vests over four&#160;years, with 25% of the shares underlying the option vesting on August&#160;1, 2020, the first anniversary of the grant date, and 6.25% of the shares underlying the option vesting quarterly thereafter until the fourth anniversary of the grant date. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(6)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Option vests over four&#160;years, with 6.25% of the shares underlying the option vesting at the end of each successive three-month period beginning on August&#160;26, 2019. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(7)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Restricted stock&#160;units granted on February&#160;18, 2022 vest annually in equal amounts over a four year period following the grant date, subject to continued employment. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">(8)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">Performance-based restricted stock&#160;units granted on February&#160;18, 2022 vest upon the determination by the Sesen Bio compensation committee of the level of achievement of a clinical trial milestone, subject to continued employment, as described above under &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Narrative to Summary Compensation Table&#8201;&#8212;&#8201;Equity Awards</font><font style="letter-spacing:0.2pt;">&#8221; above. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">354</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(9)</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Restricted stock&#160;units granted on February&#160;18, 2022 vest annually in equal amounts over a four year period following the grant date, subject to continued employment. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(10)</font>
            <br >
          </div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Performance-based restricted stock&#160;units granted on October&#160;1, 2021 vest on September&#160;30, 2023 upon the determination by the Sesen Bio compensation committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and a cash management milestone, subject to continued employment, as described above under &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Narrative to Summary Compensation Table&#8201;&#8212;&#8201;Equity Awards</font><font style="letter-spacing:0.2pt;">&#8221; above. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(11)</font>
            <br >
          </div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Performance-based restricted stock&#160;units granted on February&#160;18, 2022 vest upon the determination by the Sesen Bio compensation committee of the level of achievement of a clinical trial milestone, subject to continued employment, as described above under &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Narrative to Summary Compensation Table&#8201;&#8212;&#8201;Equity Awards</font><font style="letter-spacing:0.2pt;">&#8221; above. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(12)</font>
            <br >
          </div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Option vests over four&#160;years, with 6.25% of the shares underlying the option vesting at the end of each successive three-month period beginning on February&#160;27, 2019. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(13)</font>
            <br >
          </div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Restricted stock&#160;units granted on February&#160;18, 2022 vest annually in equal amounts over a four year period following the grant date, subject to continued employment. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(14)</font>
            <br >
          </div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Performance-based restricted stock&#160;units granted on October&#160;1, 2021 vest on September&#160;30, 2023 upon the determination by the Sesen Bio compensation committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and a cash management milestone, subject to continued employment, as described above under &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Narrative to Summary Compensation Table&#8201;&#8212;&#8201;Equity Awards</font><font style="letter-spacing:0.2pt;">&#8221; above. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(15)</font>
            <br >
          </div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Performance-based restricted stock&#160;units granted on February&#160;18, 2022 vest upon the determination by the Sesen Bio compensation committee of the level of achievement of a clinical trial milestone, subject to continued employment, as described above under &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Narrative to Summary Compensation Table&#8201;&#8212;&#8201;Equity Awards</font><font style="letter-spacing:0.2pt;">&#8221; above. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(16)</font>
            <br >
          </div>
          <div style=" margin-top:3.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Based on the per share closing market price of the Sesen Bio common stock on December&#160;31, 2022 of $0.61. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Potential Payments to Named Executive Officers Upon Termination or Change in Control Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to their respective employment agreements with Sesen Bio, upon execution and effectiveness of a release of claims, each of Dr.&#160;Cannell, Ms.&#160;Forbes and Mr.&#160;Sullivan will be entitled to severance payments if his or her employment is terminated under specified circumstances. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;letter-spacing:0.2pt;">Dr.&#160;Cannell.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If Sesen Bio terminates Dr.&#160;Cannell&#8217;s employment without cause, as defined in his employment agreement, or if Dr.&#160;Cannell terminates his employment with Sesen Bio for good reason, as defined in his employment agreement, absent a change in control transaction, as defined in his employment agreement, Sesen Bio is obligated to (i)&#160;pay Dr.&#160;Cannell&#8217;s base salary for a period of 12&#160;months, payable in accordance with Sesen Bio&#8217;s then-current payroll practices, (ii)&#160;pay Dr.&#160;Cannell an amount equal to his target bonus payment for the year in which the termination of employment occurs, prorated for the portion of the year in which he was employed, and (iii)&#160;continue, to the extent allowed by applicable law and the applicable plan documents, to provide Dr.&#160;Cannell and certain of his dependents with group health and dental insurance for a period up to 12&#160;months. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If Sesen Bio terminates Dr.&#160;Cannell&#8217;s employment without cause or if Dr.&#160;Cannell terminates his employment with Sesen Bio for good reason, in each case within 18&#160;months following a change in control transaction, as defined in his employment agreement, Sesen Bio is obligated to (i)&#160;pay Dr.&#160;Cannell an amount equal to his base salary for 24&#160;months, payable in accordance with Sesen Bio&#8217;s then-current payroll practices, (ii)&#160;pay Dr.&#160;Cannell an amount equal to two times his target bonus payment for the year in which the termination of employment occurs, (iii)&#160;accelerate in full the vesting of all of Dr.&#160;Cannell&#8217;s outstanding equity awards, and (iv)&#160;continue, to the extent allowed by applicable law and the applicable plan documents, to provide Dr.&#160;Cannell and certain of his dependents with group health and dental insurance for a period of up to 24&#160;months. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;letter-spacing:0.2pt;">Ms.&#160;Forbes.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If Sesen Bio terminates Ms.&#160;Forbes&#8217; employment without cause, as defined in her employment agreement, or if Ms.&#160;Forbes terminates her employment with Sesen Bio for good reason, as </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">355</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">defined in her employment agreement, absent a change in control transaction, as defined in her employment agreement, Sesen Bio is obligated to (i)&#160;pay Ms.&#160;Forbes&#8217; base salary for a period of 12&#160;months, payable in accordance with Sesen Bio&#8217;s then-current payroll practices, and (ii)&#160;continue, to the extent allowed by applicable law and the applicable plan documents, to provide Ms.&#160;Forbes and certain of her dependents with group health and dental insurance for a period of up to 12&#160;months. In addition, if, prior to September&#160;30, 2023, Sesen Bio terminates Ms.&#160;Forbes&#8217; employment without cause, then each Sesen Bio PSU earned as of the time of such termination of employment based on the achievement of the applicable performance milestone, as determined by the Sesen Bio compensation committee in its sole discretion, will become vested as of the date of such termination of employment. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If Sesen Bio terminates Ms.&#160;Forbes employment without cause or if Ms.&#160;Forbes terminates her employment with Sesen Bio for good reason, in each case within 12&#160;months following a change in control transaction, as defined in her employment agreement, Sesen Bio is obligated to (i)&#160;pay Ms.&#160;Forbes&#8217; base salary for a period of 12&#160;months, payable in accordance with Sesen Bio&#8217;s then-current payroll practices, (ii)&#160;continue, to the extent allowed by applicable law and the applicable plan documents, to provide Ms.&#160;Forbes and certain of her dependents with group health and dental insurance for a period of 12&#160;months, and (iii)&#160;accelerate in full the vesting of all of Ms.&#160;Forbes&#8217; outstanding equity awards. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;letter-spacing:0.2pt;">Mr.&#160;Sullivan.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If Sesen Bio terminates Mr.&#160;Sullivan&#8217;s employment without cause, as defined in his employment agreement, or if Mr.&#160;Sullivan terminates his employment with Sesen Bio for good reason, as defined in his employment agreement, absent a change in control transaction, as defined in his employment agreement, Sesen Bio is obligated to (i)&#160;pay Mr.&#160;Sullivan&#8217;s base salary for a period of 12&#160;months, payable in accordance with Sesen Bio&#8217;s then-current payroll practices and (ii)&#160;continue, to the extent allowed by applicable law and the applicable plan documents, to provide Mr.&#160;Sullivan and certain of his dependents with group health and dental insurance for a period of up to 12&#160;months. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If Sesen Bio terminates Mr.&#160;Sullivan&#8217;s employment without cause or if Mr.&#160;Sullivan terminates his employment with Sesen Bio for good reason, in each case within 12&#160;months following a change in control transaction, as defined in his employment agreement, Sesen Bio is obligated to: (i)&#160;pay Mr.&#160;Sullivan&#8217;s base salary for a period of 12&#160;months, payable in accordance with Sesen Bio&#8217;s then-current payroll practices, (ii)&#160;continue, to the extent allowed by applicable law and the applicable plan documents, to provide Mr.&#160;Sullivan and certain of his dependents with group health and dental insurance for a period of 12&#160;months, and (iii)&#160;accelerate in full the vesting of all of Mr.&#160;Sullivan&#8217;s outstanding equity awards. In addition, if, prior to September&#160;30, 2023, Sesen Bio terminates Mr.&#160;Sullivan&#8217;s employment without cause, then each Sesen Bio PSU earned as of the time of such termination of employment based on the achievement of the applicable performance milestone, as determined by the Sesen Bio compensation committee in its sole discretion, will become vested as of the date of such termination of employment. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s obligation to pay the severance payments to Dr.&#160;Cannell, Ms.&#160;Forbes and Mr.&#160;Sullivan pursuant to their respective employment agreements, as described above, is contingent upon the executive&#8217;s execution and non-revocation of a release of claims in favor of Sesen Bio. In addition, Sesen Bio&#8217;s obligation to pay such severance payments is subject to such executive officer&#8217;s compliance with certain restrictive covenants, including non-competition and non-solicitation (of employees and customers) covenants, which run for one year following the executive&#8217;s termination of employment. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;letter-spacing:0.2pt;">Taxation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To the extent that any severance or other compensation payment to Dr.&#160;Cannell or Ms.&#160;Forbes pursuant to his or her employment agreement or any other agreement constitutes an &#8220;excess parachute payment&#8221; within the meaning of Sections&#160;280G and 4999 of the Code, then he or she will receive the full amount of such severance and other payments, or a reduced amount intended to avoid the application of Sections&#160;280G and 4999 of the Code, whichever provides the executive with the highest amount on an after-tax basis. </font>
          </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">401(k) Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio maintains a defined contribution 401(k) retirement plan for its employees in which substantially all of Sesen Bio&#8217;s full-time U.S. employees are eligible to participate, including its executive officers. Participants may contribute a&#160;percentage of their annual compensation to this plan, subject to statutory limitations. Sesen Bio made matching contributions of $45,517 to the plan for the year ended December&#160;31, 2022. </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">356</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:149.63pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Limitation of Liability and Indemnification</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s Certificate of Incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the DGCL and provides that no director will have personal liability to Sesen Bio or to Sesen Bio stockholders for monetary damages for breach of fiduciary duty as a director. However, these provisions do not eliminate or limit the liability of any of Sesen Bio&#8217;s directors: </font>
          </div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">for any breach of the director&#8217;s duty of loyalty to Sesen Bio or Sesen Bio stockholders; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">for voting for or assenting to unlawful payments of dividends, stock repurchases or other distributions; or </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">for any transaction from which the director derived an improper personal benefit. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Any amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to such amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of the Sesen Bio directors will be further limited to the greatest extent permitted by the DGCL. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">In addition, the Sesen Bio Certificate of Incorporation provides that Sesen Bio must indemnify its directors and officers and Sesen Bio must advance expenses, including attorneys&#8217; fees, to its directors and officers in connection with legal proceedings, subject to very limited exceptions. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio maintains a general liability insurance policy that covers specified liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. In addition, Sesen Bio has entered into indemnification agreements with all of its directors and executive officers. These indemnification agreements may require Sesen Bio, among other things, to indemnify each such director and executive officer for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of its directors or executive officers. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Some of Sesen Bio&#8217;s non-employee directors may, through their relationships with their employers, be insured or indemnified against specified liabilities incurred in their capacities as members of the Sesen Bio board of directors. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, executive officers or persons controlling Sesen Bio, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </font>
          </div>

      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">357</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Director Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s non-employee directors are compensated for their services on the Sesen Bio board of directors as follows: </font>
          </div>


          <table style="width:456pt;height:244pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:314.75pt;">
                <font style="letter-spacing:-0.2pt;">Compensation</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0.5pt 0.5pt 0pt; width:129.25pt;text-align:right;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.75pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Annual Board Cash Retainer </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:129.25pt;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$40,000</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.75pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Additional Retainer for Non-Executive Chair of the Board </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:129.25pt;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$30,000</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.75pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Additional Retainers for Committee Chairs </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0.5pt 0.5pt 0pt; width:129.25pt;text-align:right;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 1pt 0pt; width:314.75pt;">
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">&#8226;</font>
                  <br >
                </div>
                <div style=" line-height:10pt; text-align:left; margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Audit </font> </div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0.5pt 1pt 0pt; width:129.25pt;white-space:nowrap;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$15,000</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 1pt 0pt; width:314.75pt;">
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">&#8226;</font>
                  <br >
                </div>
                <div style=" line-height:10pt; text-align:left; margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Compensation </font> </div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0.5pt 1pt 0pt; width:129.25pt;white-space:nowrap;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$10,000</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 1pt 0pt; width:314.75pt;">
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">&#8226;</font>
                  <br >
                </div>
                <div style=" line-height:10pt; text-align:left; margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Nominating and Corporate Governance </font> </div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0.5pt 1pt 0pt; width:129.25pt;white-space:nowrap;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$8,000</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 1pt 0pt; width:314.75pt;">
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">&#8226;</font>
                  <br >
                </div>
                <div style=" line-height:10pt; text-align:left; margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Science </font> </div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0.5pt 1pt 0pt; width:129.25pt;white-space:nowrap;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$10,000</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:314.75pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Additional Retainers for Committee Members </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0.5pt 0.5pt 0pt; width:129.25pt;text-align:right;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 1pt 0pt; width:314.75pt;">
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">&#8226;</font>
                  <br >
                </div>
                <div style=" line-height:10pt; text-align:left; margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Audit </font> </div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0.5pt 1pt 0pt; width:129.25pt;white-space:nowrap;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$7,500</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 1pt 0pt; width:314.75pt;">
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">&#8226;</font>
                  <br >
                </div>
                <div style=" line-height:10pt; text-align:left; margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Compensation </font> </div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0.5pt 1pt 0pt; width:129.25pt;white-space:nowrap;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$5,000</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 1pt 0pt; width:314.75pt;">
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">&#8226;</font>
                  <br >
                </div>
                <div style=" line-height:10pt; text-align:left; margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Nominating and Corporate Governance </font> </div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0.5pt 1pt 0pt; width:129.25pt;white-space:nowrap;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$4,000</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 1pt 0pt; width:314.75pt;">
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style=" float:left; margin-left:10pt; line-height:10pt; text-align:left; width:10pt;white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">&#8226;</font>
                  <br >
                </div>
                <div style=" line-height:10pt; text-align:left; margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Science </font> </div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0.5pt 1pt 0pt; width:129.25pt;white-space:nowrap;text-align:right;">
                <div style="text-align:right;">
                  <font style="letter-spacing:0.2pt;">$5,000</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:314.75pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Annual Equity Award (non-employee directors) </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0.5pt 0.833pt 0pt; width:129.25pt;text-align:right;">
                <div style="margin-left:10pt; text-indent:-10pt; text-align:right;">
                  <font style="letter-spacing:0.2pt;">65,000 Sesen Bio options and</font>
                  <br >
                  <font style="letter-spacing:0.2pt;">40,000 Sesen Bio RSUs</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:314.75pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Initial Equity Award (non-employee directors) </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.167pt 0.5pt 0.833pt 0pt; width:129.25pt;text-align:right;">
                <div style="margin-left:10pt; text-indent:-10pt; text-align:right;">
                  <font style="letter-spacing:0.2pt;">130,000 Sesen Bio options and</font>
                  <br >
                  <font style="letter-spacing:0.2pt;">80,000 Sesen Bio RSUs</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:6.31pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The Sesen Bio compensation committee engages Radford, its independent compensation consultant, to provide advice on the competitiveness of Sesen Bio&#8217;s non-employee director compensation program and ensure that both cash and equity components of Sesen Bio&#8217;s non-employee director compensation program remain market competitive. In February&#160;2022, the Sesen Bio compensation committee and Sesen Bio board of directors, based on a market analysis prepared by Radford, approved annual board, chair and committee cash retainers, as well as a combination of options and Sesen Bio RSUs for both the initial and annual equity awards to non-employee directors. In its approvals, the Sesen Bio compensation committee and the Sesen Bio board of directors considered the time commitment and responsibilities of Sesen Bio&#8217;s directors as well as the size of the Sesen Bio board of directors. Consistent with the prior year, cash compensation aligns with the 50th&#160;percentile of the Radford market analysis and equity compensation aligns with the 75th&#160;percentile of the Radford market analysis. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The Sesen Bio options granted to Sesen Bio&#8217;s non-employee directors will have an exercise price equal to the fair market value of the Sesen Bio common stock on the date of grant and will expire ten&#160;years after the date of grant. The initial stock options granted to Sesen Bio&#8217;s non-employee directors will, subject to the director&#8217;s continued service on the Sesen Bio board of directors, vest monthly in equal amounts over a three-year period following the grant date. The annual stock options granted to Sesen Bio&#8217;s non-employee directors will, subject to the director&#8217;s continued service on Sesen Bio board of directors, vest monthly in equal amounts over a one-year period following the grant date. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The initial restricted stock&#160;units granted to Sesen Bio&#8217;s non-employee directors will vest annually in equal amounts over a three-year period following the grant date. The annual restricted stock&#160;units granted to Sesen Bio&#8217;s non-employee directors will vest on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of Sesen Bio&#8217;s common stock and is subject to continued service with Sesen Bio on the applicable vesting date. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Each annual cash fee will be payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of each payment will be prorated for any portion of a quarter that a director is not serving on the Sesen Bio board of directors. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Each member of the Sesen Bio board of directors will also be entitled to reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of the Sesen Bio board of directors and any committee on which he or she serves. </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">358</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:55pt;margin-left:69.66pt;width:456pt;">

          <div style="margin-left:20pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The table below shows all compensation to Sesen Bio&#8217;s non-employee directors during 2022. </font>
          </div>


          <table style="width:416pt;height:101.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:226.22pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Fees Earned or</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Paid in Cash ($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Stock</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Awards</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Awards</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Total ($) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:226.22pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Jay S. Duker, M.D. </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">93,000 </td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">31,560 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">33,079 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">157,639 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:226.22pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Jason A. Keyes </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">60,000 </td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">31,560 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">33,079 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">124,639 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:226.22pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Carrie L. Bourdow </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">51,500 </td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">31,560 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">33,079 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">116,139 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:226.22pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Peter K Honig, M.D. </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">52,500 </td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">31,560 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">33,079 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">117,139 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:226.22pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Michael A.S. Jewett, M.D. </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">59,000 </td>
              <td style="padding:0pt;padding-left:12.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">31,560 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">33,079 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">123,639</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">On June&#160;22, 2022, Dr.&#160;Duker, Mr.&#160;Keyes, Ms.&#160;Bourdow, Mr.&#160;Honig and Mr.&#160;Jewett each received 40,000 restricted stock&#160;units that vest on June&#160;23, 2023. The amounts reported in the &#8220;Stock Awards&#8221; column reflect the aggregate grant date fair value of restricted stock&#160;units awarded during the year computed in accordance with the provisions of Financial Accounting Standards Board Accounting Standard Codification, or ASC, Topic 718. See Note 14 to Sesen Bio&#8217;s financial statements appearing at the end of Sesen Bio&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 regarding assumptions underlying the valuation of equity awards. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Following the annual meeting of stockholders held on June&#160;22, 2022, Dr.&#160;Duker, Mr.&#160;Keyes, Ms.&#160;Bourdow, Mr.&#160;Honig and Mr.&#160;Jewett each received an option to purchase 65,000 shares of Sesen Bio common stock at an exercise price of $0.79 per share. These stock options vest over twelve&#160;months, with 1/12</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the shares underlying the option vesting at the end of each one-month period following June&#160;22, 2022. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The amounts reported in the &#8220;Option Awards&#8221; column reflect the aggregate grant date fair value of stock-based compensation awarded during the year computed in accordance with the provisions of Financial Accounting Standards Board ASC Topic 718. See footnote 6 to the &#8220;Summary Compensation Table&#8221; above and Note 14 to Sesen Bio&#8217;s financial statements appearing at the end of Sesen Bio&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 regarding assumptions underlying the valuation of equity awards. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">During 2022, Sesen Bio did not provide any additional compensation to Dr.&#160;Cannell, its President and Chief Executive Officer, for his service as a director. Dr.&#160;Cannell&#8217;s compensation as a named executive officer is set forth above under &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Executive Compensation&#8201;&#8212;&#8201;Summary Compensation Table</font><font style="letter-spacing:0.2pt;">&#8221; above. </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The table below shows all stock options held by each of Sesen Bio&#8217;s non-employee directors as of December&#160;31, 2022. </font>
          </div>


          <table style="width:416pt;height:101.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:356.1pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Stock Options</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Outstanding</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(#)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:356.1pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Jay S. Duker, M.D. </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">288,787 </td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:356.1pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Peter K Honig, M.D. </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">185,000 </td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:356.1pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Michael A.S. Jewett, M.D. </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">185,000 </td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:356.1pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Jason A. Keyes </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">269,500 </td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:356.1pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Carrie L. Bourdow </font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">269,500</td>
              <td style="padding:0pt;padding-left:7.595pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-left:10pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">359</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCEC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA EXECUTIVE COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">This section describes the material elements of compensation awarded to, earned by or paid to each of Carisma&#8217;s named executive officers in 2022. Carisma&#8217;s &#8220;named executive officers&#8221; for 2022 are (i)&#160;Steven Kelly, Carisma&#8217;s President and Chief Executive Officer, (ii)&#160;Richard Morris, Carisma&#8217;s Chief Financial Officer, and (iii)&#160;Michael Klichinsky, Carisma&#8217;s Chief Scientific Officer. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The following table sets forth information regarding compensation awarded to, earned by, or paid to each of Carisma&#8217;s named executive officers for the&#160;years ended December&#160;31, 2022 and 2021. </font>
          </div>


          <table style="width:456pt;height:107.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:237.46pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name and Principal Position </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Year </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Salary</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Bonus</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">awards</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Total </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;height:7.25pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:237.46pt;text-align:left;" rowspan="2">
                <div style="margin-left:10pt; text-indent:-10pt; text-align:justify; line-height:12pt; padding-bottom:0pt;">
                  <font style="letter-spacing:0.2pt;">Steven Kelly</font>
                  <br >
                  <font style="font-style:italic;letter-spacing:0.2pt;">President &amp; Chief Executive Officer</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:18pt; text-align:right; white-space:nowrap;">2022 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:27.75pt; text-align:right; white-space:nowrap;">440,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:33.75pt; text-align:right; white-space:nowrap;">440,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">2021 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">416,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">158,080 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">482,883 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1,057,111 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:237.46pt;text-align:left;" rowspan="2">
                <div style="margin-left:10pt; text-indent:-10pt; text-align:justify; line-height:12pt; padding-bottom:0pt;font-size:7.5pt;">
                  <font style="font-size:10pt;letter-spacing:0.2pt;">Richard Morris</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">3</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;)</font>
                  <br >
                  <font style="font-style:italic;font-size:10pt;letter-spacing:0.2pt;">Chief Financial Officer</font><font style="font-size:10pt;">&#8203;</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:18pt; text-align:right; white-space:nowrap;">2022 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:27.75pt; text-align:right; white-space:nowrap;">400,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:33.75pt; text-align:right; white-space:nowrap;">400,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">2021 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">227,500 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">73,255 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">606,630 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">907,385 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;height:7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:237.46pt;text-align:left;" rowspan="2">
                <div style="margin-left:10pt; text-indent:-10pt; text-align:justify; line-height:12pt; padding-bottom:0pt;font-size:7.5pt;">
                  <font style="font-size:10pt;letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">4</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;)</font>
                  <br >
                  <font style="font-style:italic;font-size:10pt;letter-spacing:0.2pt;">Chief Scientific Officer</font><font style="font-size:10pt;">&#8203;</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:18pt; text-align:right; white-space:nowrap;">2022 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:27.75pt; text-align:right; white-space:nowrap;">340,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:33.75pt; text-align:right; white-space:nowrap;">340,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;height:19pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">2021 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">300,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">87,750 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">163,430 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">551,180</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:6.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:6.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">As of the date of this proxy statement/prospectus, the Carisma board of directors has not yet determined the bonus amounts that its named executive officers are entitled to for 2022. It is anticipated that 2022 bonus amounts will be determined in the first quarter of 2023, at which time Carisma will disclose the amounts of such bonuses. See &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Narrative Disclosure to Summary Compensation Table&#8201;&#8212;&#8201;Bonus Compensation</font><font style="letter-spacing:0.2pt;">&#8221; below for information on how the amount of bonuses are determined by Carisma. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:2.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:2.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The amounts reported in the &#8220;Option awards&#8221; column reflect the grant date fair value of Carisma options awarded during the year computed in accordance with the provisions of Financial Accounting Standard Board, or FASB, Accounting Standards Codification, or ASC, Topic 718. See Note 3 to Carisma&#8217;s consolidated financial statements appearing at the end of this proxy/statement prospectus regarding assumptions underlying the valuation of option awards. These amounts reflect the accounting cost for these stock options and do not reflect the actual economic value that may be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options or the sale of the common stock underlying such stock options. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:2.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:2.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Mr.&#160;Morris was appointed as Carisma&#8217;s Chief Financial Officer on June&#160;1, 2021. His annual base salary for 2021 was $390,000. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:2.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(4)</font>
            <br >
          </div>
          <div style=" margin-top:2.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Dr.&#160;Klichinsky was appointed as Carisma&#8217;s Chief Scientific Officer in April 2022. Prior to that, he served as Senior Vice President of Research for Carisma. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-top:9.83pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Narrative Disclosure to Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Base Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma uses base compensation or salaries to recognize the experience, skills, knowledge and responsibilities required of its executive officers. None of the Carisma named executive officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base compensation or salary. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">For the year ended December&#160;31, 2022, Carisma paid Mr.&#160;Kelly, Mr.&#160;Morris and Dr.&#160;Klichinsky annual base compensation of $440,000, $400,000 and $340,000, respectively. For the year ended December 31, 2021, Carisma paid Mr. Kelly, Mr. Morris and Dr. Klichinsky annual base compensation of $416,000, $227,500 and $300,000, respectively. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Bonus Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Carisma board of directors may, in its discretion, award bonuses to the Carisma named executive officers from time to time. The Carisma named executive officers are eligible for annual performance-based </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">360</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:64pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">bonuses up to a specified&#160;percentage of their base compensation or salary, subject to approval by the Carisma board of directors. Performance-based bonuses, which are calculated as a&#160;percentage of base compensation or salary, are designed to motivate Carisma&#8217;s executive officers to achieve annual goals based on Carisma&#8217;s strategic, financial and operating performance objectives. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As of the date of this proxy statement/prospectus, the Carisma board of directors has not yet determined the bonus amounts that its named executive officers are entitled to for 2022. It is anticipated that 2022 bonus amounts will be determined in the first quarter of 2023, at which time the Company will disclose the amounts of such bonuses. With respect to 2021 performance, the Carisma board of directors awarded performance-based bonuses of $158,080, $73,255 and $87,750, respectively, to Mr.&#160;Kelly, Mr.&#160;Morris and Dr.&#160;Klichinsky. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Incentives</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although Carisma does not have a formal policy with respect to the grant of equity incentive awards to its executive officers, or any formal equity ownership guidelines applicable to them, Carisma believes that equity grants provide its executives with a strong link to Carisma&#8217;s long-term performance, create an ownership culture and help to align the interests of Carisma executive officers and Carisma stockholders. Accordingly, Carisma uses stock options to compensate its executive officers in the form of initial grants in connection with the commencement of employment and also at various other times, if Carisma or they have performed as expected or better than expected. In addition, Carisma believes that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes its executive officers to remain in Carisma&#8217;s employment during the vesting period. The option awards that Carisma has granted to its executive officers typically become exercisable as to 25% of the shares underlying the option on the first anniversary of the vesting commencement date and as to an additional 2.0833% of the original number of shares underlying the option monthly thereafter. Vesting rights cease upon termination of employment and exercise rights for previously vested stock options cease shortly after termination, though exercisability is extended in the case of death or disability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma executive officers are eligible to participate in the Carisma Plan. All Carisma options have been granted pursuant to the Carisma Plan. For a description of the Carisma Plan, see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">&#8212;&#8201;2017 Stock Incentive Plan</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tSTOIP">364</a> of this proxy statement/prospectus. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">None of the Carisma executive officers is currently party to an employment agreement that provides for the automatic award of stock options. To date, Carisma has not maintained a practice of granting additional equity on an annual basis, but has retained discretion to provide additional targeted grants in certain circumstances. Accordingly, the Carisma board of directors periodically reviews the equity incentive compensation of the Carisma executive officers, including the Carisma named executive officers, and from time to time may grant equity incentive awards to them in the form of stock options. Carisma did not grant stock option awards to the Carisma named executive officers during the year ended December&#160;31, 2022, but has done so in prior years, as described in more detail in the &#8220;Outstanding Equity Awards at December&#160;31, 2022&#8221; table below. </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the exercise of an option, the holder has no rights as a stockholder with respect to the shares subject to such option, including no voting rights and no right to receive dividends or dividend equivalents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma has historically granted stock options with exercise prices that are equal to the fair market value of Carisma common stock on the date of grant as determined by the Carisma board of directors, based on a number of objective and subjective factors. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">361</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Outstanding Equity Awards at December&#160;31, 2022</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The following table sets forth information regarding all outstanding equity awards held by each of Carisma&#8217;s named executive officers as of December&#160;31, 2022. </font>
          </div>


          <table style="width:456pt;height:163pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:144.47pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="19">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option Awards </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:144.47pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.16pt;">Name </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Number of securities</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">underlying</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">unexercised options (#)</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">exercisable </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Number of securities</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">underlying</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">unexercised options (#)</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">unexercisable </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option exercise</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">price ($) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:58.95pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option expiration</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">date </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:144.47pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Steven Kelly </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">329,471 </td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;"><font style="font-weight:bold;font-size:8.5pt;"></font><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(1)</font> </font></td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.18</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:58.95pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">9/18/2028 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:144.47pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">112,541 </td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">106,459<font style="position:absolute;"><font style="font-weight:bold;font-size:8.5pt;"></font><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(2)</font> </font></td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.77</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:58.95pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">3/31/2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:9.5pt 0pt 1.5pt 0pt; width:144.47pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Richard Morris </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">65,372 </td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">108,954<font style="position:absolute;"><font style="font-weight:bold;font-size:8.5pt;"></font><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(3)</font> </font></td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.77</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:9.5pt 0pt 1.5pt 0pt; width:58.95pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">5/31/2031 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:8.167pt 0pt 0.833pt 0pt; width:144.47pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D. </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:8.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:8.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">30,000</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:8.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:8.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;"><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(4)</font> </font></td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:8.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:8.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.19</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:8.167pt 0pt 0.833pt 0pt; width:58.95pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">11/01/2027 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:144.47pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">40,000 </td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;"><font style="font-weight:bold;font-size:8.5pt;"></font><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(5)</font> </font></td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.18</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:58.95pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">10/21/2028 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:144.47pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">30,319 </td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">28,681<font style="position:absolute;"><font style="font-weight:bold;font-size:8.5pt;"></font><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(6)</font> </font></td>
              <td style="padding:0pt;padding-left:21.935pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.77</td>
              <td style="padding:0pt;padding-left:16.855pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:58.95pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">3/31/2031</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">This Carisma option is fully vested. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">This Carisma option vests over four&#160;years, with 25% of the shares vested on April 1, 2022 and 2.0833% of the original number of shares vested thereafter in equal monthly installments through April 1, 2025, subject to continued service. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">This Carisma option vests over four&#160;years, with 25% of the shares vested on June&#160;1, 2022 and 2.0833% of the original number of shares vesting thereafter in equal monthly installments through June&#160;1, 2025, subject to continued service. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">This Carisma option is fully vested. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(5)</font>
            <br >
          </div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">This Carisma option is fully vested. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">This Carisma option vests over four years, with 25% of the shares vested on April 1, 2022 and 2.0833% of the original number of shares vested thereafter in equal monthly installments through April 1, 2025, subject to continued service. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employment Agreements with Named Executive Officers</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma has entered into written employment agreements with each of its executive officers. These agreements set forth the terms of the executive officer&#8217;s compensation, including base salary, annual discretionary bonus eligibility and severance benefits, among other matters. The employment agreements with the Carisma named executive officers are summarized below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Agreement with Steven Kelly</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;12, 2018, Carisma entered into an offer letter, or the Kelly Agreement, with Mr.&#160;Kelly in connection with his employment as Carisma&#8217;s President and Chief Executive Officer. Under the Kelly Agreement, Mr.&#160;Kelly is an at-will employee and his employment with Carisma can be terminated by Mr.&#160;Kelly or Carisma at any time and for any reason. Pursuant to the Kelly Agreement, Mr.&#160;Kelly&#8217;s annualized base salary may be adjusted from time to time in accordance with normal business practice and in the sole discretion of Carisma. He is eligible to receive an annual performance bonus of up to a specified&#160;percentage of his base salary for the applicable calendar year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Kelly Agreement, in the event of the termination of Mr.&#160;Kelly&#8217;s employment by Carisma without cause or by him for good reason, Mr.&#160;Kelly is entitled, subject to his execution of and compliance with a separation and release of claims agreement in Carisma&#8217;s favor and his continued compliance with certain restrictive covenants, to (i)&#160;continued payment of his base salary for a period of 12&#160;months following the date his release of claims becomes effective and (ii)&#160;payment of a pro-rated portion of his annual target discretionary bonus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">362</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">After the date of the Kelly Agreement, the Carisma board of directors approved increases to Mr.&#160;Kelly&#8217;s annualized base salary to $416,000 for 2021 and $440,000 for 2022. The Carisma board of directors has authorized an annual performance bonus&#160;percentage of 40% for Mr.&#160;Kelly. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Agreement with Richard Morris</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;15, 2021, Carisma entered into an offer letter, or the Morris Agreement, with Mr.&#160;Morris in connection with his employment as Carisma&#8217;s Chief Financial Officer. Under the Morris Agreement, Mr.&#160;Morris is an at-will employee, and his employment with Carisma can be terminated by Mr.&#160;Morris or Carisma at any time and for any reason. Pursuant to the Morris Agreement, Mr.&#160;Morris&#8217;s annualized base salary may be adjusted from time to time in accordance with normal business practice and in the sole discretion of Carisma. He is eligible to receive an annual performance bonus of up to a specified&#160;percentage of his base salary for the applicable calendar year. The Morris Agreement also provided for an initial grant of options to purchase 174,326 shares of Carisma common stock, subject to the approval of the Carisma board of directors, or the Morris Grant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Morris Agreement, in the event of the termination of Mr.&#160;Morris&#8217; employment by Carisma without cause or by him for good reason, Mr.&#160;Morris is entitled, subject to his execution of and compliance with a separation and release of claims agreement in Carisma&#8217;s favor and his continued compliance with certain restrictive covenants, to (i)&#160;continued payment of his base salary for a period of 12&#160;months following the date his release of claims becomes effective and (ii)&#160;payment of a pro-rated portion of his annual target discretionary bonus. In addition, in the event that Mr.&#160;Morris&#8217; employment is terminated by Carisma without cause or by Mr.&#160;Morris for good reason, within 12&#160;months following a change in control event (as defined in the Carisma Plan), then 100% of the unvested portion of the Morris Grant shall be accelerated and immediately vest and become exercisable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Morris Agreement, the Carisma board of directors approved an annualized base salary of $390,000 for 2021 and an annual performance bonus&#160;percentage of 35% for Mr.&#160;Morris. In 2022, the Carisma board of directors authorized an increase in Mr.&#160;Morris&#8217; annualized base salary to $400,000. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Agreement with Michael Klichinsky</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;18, 2018, Carisma entered into an offer letter, or the Klichinsky Agreement, with Dr.&#160;Klichinsky in connection with his employment as Carisma&#8217;s Vice President of Discovery Research. Under the Klichinsky Agreement, Dr.&#160;Klichinsky is an at-will employee, and his employment with Carisma can be terminated by Dr.&#160;Klichinsky or Carisma at any time and for any reason. Pursuant to the Klichinsky Agreement, Dr.&#160;Klichinsky&#8217;s annualized base salary may be adjusted from time to time in accordance with normal business practice and in the sole discretion of Carisma. He is eligible to receive an annual performance bonus of up to a specified&#160;percentage of his base salary for the applicable calendar year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Klichinsky Agreement, in the event of the termination of Dr.&#160;Klichinsky&#8217;s employment by Carisma without cause or by him for good reason, Dr.&#160;Klichinsky is entitled, subject to his execution of and compliance with a separation and release of claims agreement in Carisma&#8217;s favor and his continued compliance with certain restrictive covenants, to (i)&#160;continued payment of his base salary for a period of 12&#160;months following the date his release of claims becomes effective and (ii)&#160;payment of a pro-rated portion of his annual target discretionary bonus. </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">After the date of the Klichinsky Agreement, the Carisma board of directors approved an increase to Dr.&#160;Klichinsky&#8217;s annualized base salary to $300,000 for 2021. In 2022, Dr.&#160;Klichinsky was promoted to Chief Scientific Officer of Carisma, and the Carisma board of directors approved an increase to his annualized base salary to $340,000 and an increase of his annual performance bonus&#160;percentage to 35%. </font>
          </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employee Invention, Non-Disclosure, Non-Competition and Non-Solicitation Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each of Carisma&#8217;s executive officers has entered into standard forms of agreements with respect to proprietary and confidential information, developments, non-competition, and non-solicitation. Under these agreements, each executive officer has agreed to protect Carisma&#8217;s confidential and proprietary information during and after the executive officer&#8217;s employment with Carisma, not to compete with Carisma </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">363</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSTOIP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">during his or her employment and for a period generally lasting for one year after the termination of his or her employment, and not to solicit Carisma&#8217;s employees, consultants, clients or customers during his or her employment and for a period generally lasting for one year after the termination of his or her employment. In addition, under these agreements, each executive officer has agreed that Carisma owns all developments and inventions that are developed by such executive officer within the scope of and during the period of his or her employment with Carisma that are related to Carisma&#8217;s business or research and development conducted or planned to be conducted by Carisma at the time such development is created. Each executive officer has also agreed to provide Carisma with a non-exclusive, royalty-free, perpetual license to use any prior inventions that such executive officer incorporates into inventions assigned to Carisma under these agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2017 Stock Incentive Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Carisma board of directors adopted, and the Carisma stockholders approved, the Carisma Plan in September&#160;2017. The Carisma Plan was amended on June 22, 2018, December&#160;21, 2020, November&#160;9, 2021 and April&#160;7, 2022 to increase the number of shares of Carisma common stock available for issuance under the Carisma Plan. At the effective time of the merger, Sesen Bio will assume the Carisma Plan and each Carisma option in accordance with the terms of the Carisma Plan and the applicable stock option agreements evidencing by which such Carisma options but with such changes to such documents as Carisma and Sesen Bio mutually agree are appropriate to reflect the substitution of the Carisma option for a Sesen Bio option. The material terms of the Carisma Plan are summarized below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Carisma Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock&#160;units and other stock-based awards. Carisma&#8217;s employees, officers, directors, as well as its consultants and advisors, are eligible to receive awards under the Carisma Plan. Incentive stock options, however, may only be granted to Carisma employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Authorized Shares</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;As of January&#160;4, 2023, Carisma had reserved an aggregate of 2,664,018 shares of Carisma common stock for the issuance of awards under the Carisma Plan. As of January&#160;4, 2023, 1,802,246 stock options were issued and outstanding under the Carisma Plan to purchase shares of Carisma common stock at a weighted average exercise price of $1.92 per share and 748,753 shares of Carisma common stock remained available for the issuance of future awards under the Carisma Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Plan&#160;Administration.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Pursuant to the terms of the Carisma Plan, the Carisma board of directors (or a committee delegated by the Carisma board of directors) administers the Carisma Plan and, subject to any limitations in the Carisma Plan, selects the recipients of awards and determines: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of shares of Carisma common stock covered by options and the dates upon which the options become exercisable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the type of options to be granted; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the duration of options, which may not be in excess of ten&#160;years; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the exercise price of options, which must be at least equal to the fair market value of a share of Carisma common stock on the date of grant; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of shares of Carisma common stock subject to any stock appreciation rights, restricted stock awards, restricted stock&#160;units or other stock-based awards and the terms and conditions of such awards, including conditions for repurchase, issue price and repurchase price (though the measurement price of stock appreciation rights must be at least equal to the fair market value of a share of Carisma common stock on the date of grant and the duration of such awards may not be in excess of ten&#160;years). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Transferability of Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Carisma Plan prohibits awards from being sold, assigned, transferred, pledged, hypothecated or otherwise encumbered by the person to whom such awards are granted, either voluntarily or by operation of law, and, during the life of a participant in the Carisma Plan, awards are exercisable only by the participant, except that certain awards may be transferred to family members through gifts or domestic relations orders or to an executor or guardian upon the death or disability of the participant. Carisma is not required to recognize any such permitted transfer until such time as a permitted </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">364</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">transferee delivers to Carisma a written instrument, as a condition to such transfer, in form and substance satisfactory to Carisma confirming that such transferee shall be bound by all of the terms and conditions of the applicable award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Effect of Certain Changes in Capitalization.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Upon the occurrence of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Carisma common stock other than an ordinary cash dividend, under the terms of the Carisma Plan, Carisma is required to equitably adjust (or make substitute awards, if applicable), in the manner determined by the Carisma board of directors: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and class of securities available under the Carisma Plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and class of securities and exercise price per share of each outstanding option; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the share and per-share provisions and the measurement price of each outstanding stock appreciation right; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of shares subject to and the repurchase price per share subject to each outstanding award of restricted stock; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the share and per-share related provisions and the purchase price, if any, of each outstanding restricted stock unit award and each outstanding other stock-based award. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Effect of Certain Corporate Transactions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Upon the occurrence of a merger or other reorganization event (as defined in the Carisma Plan), the Carisma board of directors may, on such terms as the Carisma board of directors determines (except to the extent specifically provided otherwise in an applicable award agreement or other agreement between the participant and Carisma), take any one or more of the following actions pursuant to the Carisma Plan as to all or any (or any portion of) outstanding awards, other than awards of restricted stock: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that outstanding awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">upon written notice to a participant, provide that all of the participant&#8217;s unexercised and/or unvested awards will terminate immediately prior to the consummation of the reorganization event unless exercised by the participant (to the extent then exercisable) within a specified period following the date of the notice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon such reorganization event; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in the event of a reorganization event pursuant to which holders of shares of Carisma common stock will receive a cash payment for each share surrendered in the reorganization event, make or provide for a cash payment to participants with respect to each award held by a participant equal to (1)&#160;the number of shares of Carisma common stock subject to the vested portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by (2)&#160;the excess, if any, (A)&#160;of the cash payment for each share of Carisma common stock surrendered in the reorganization event, over (B)&#160;the exercise, measurement or purchase price of such award and any applicable tax withholdings, in exchange for the termination of such award; and/or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that, in connection with Carisma&#8217;s liquidation or dissolution, awards will convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Carisma board of directors is not obligated under the Carisma Plan to treat all awards, all awards held by a participant, or all awards of the same type, identically. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the case of certain restricted stock&#160;units, no assumption or substitution is permitted, and the restricted stock&#160;units will instead be settled in accordance with the terms of the applicable restricted stock unit agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">365</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the occurrence of a reorganization event other than Carisma&#8217;s liquidation or dissolution, Carisma&#8217;s repurchase and other rights with respect to outstanding awards of restricted stock will continue for the benefit of the succeeding company and will, unless the Carisma board of directors determines otherwise, apply to the cash, securities, or other property which the Carisma common stock was converted into or exchanged for pursuant to the reorganization event in the same manner and to the same extent as they applied to the shares of Carisma common stock subject to the restricted stock award. However, the Carisma board of directors may provide for the termination or deemed satisfaction of such repurchase or other rights under the restricted stock award agreement or in any other agreement between a participant and Carisma, either initially or by amendment, or provide for forfeiture of such restricted stock if issued at no cost. Upon Carisma&#8217;s liquidation or dissolution, except to the extent specifically provided to the contrary in the restricted stock award agreement or any other agreement between the participant and Carisma, all restrictions and conditions on all restricted stock awards then outstanding will automatically be deemed terminated or satisfied. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the provisions of the Carisma Plan described above related to reorganization events, except to the extent specifically provided to the contrary in the applicable award agreement or in any other agreement between a participant and Carisma: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each stock option granted under the Carisma Plan will be immediately exercisable in full if, on or prior to the first anniversary of the date of the consummation of the change in control event (as defined in the Carisma Plan), the participant&#39;s employment with Carisma or the acquiring or succeeding corporation is terminated for good reason (as defined in the Carisma Plan) by the participant or is terminated without cause (as defined in the Carisma Plan) by Carisma or the acquiring or succeeding corporation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each award of restricted stock or restricted stock units will immediately become free from all conditions or restrictions if, on or prior to the first anniversary of the date of the consummation of the change in control event, the participant&#39;s employment with Carisma or the acquiring or succeeding corporation is terminated for good reason by the participant or is terminated without cause by Carisma or the acquiring or succeeding corporation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Carisma board of directors may specify in an award agreement at the time of the grant the effect of a change in control event on any stock appreciation right or other stock-based award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acceleration.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;At any time, the Carisma board of directors may provide that any award under the Carisma Plan will become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Amendment of Plan and Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Carisma board of directors may amend, suspend, or terminate the Carisma Plan or any portion thereof at any time, however if approval of the Carisma stockholders as to any modification or amendment is required under the Internal Revenue Code of 1986, as amended, with respect to incentive stock options, the Carisma board of directors may not effect such modification or amendment without such approval. The Carisma board of directors may amend, modify or terminate any outstanding award, however the participant&#8217;s consent to such action is required unless the Carisma board of directors determines that the action, taking into account any related action, does not materially and adversely affect the participant&#8217;s rights under the Carisma Plan or the change is otherwise permitted by the Carisma Plan. Furthermore, the Carisma board of directors may amend any outstanding award granted under the Carisma Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such award or, without stockholder approval, cancel any outstanding award and grant in substitution therefor new awards under the Carisma Plan covering the same or a different number of shares of Carisma common stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Termination</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No award may be granted under the Carisma Plan on or after the date that is ten&#160;years following the earlier of (i)&#160;the date on which the Carisma Plan was adopted by the Carisma board of directors or (ii)&#160;the date the Carisma Plan was approved by the Carisma stockholders, but all awards previously granted may extend beyond such date. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">366</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCADCT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:207.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Potential Payments to Named Executive Officers Upon Termination or Change in Control</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Carisma named executive officers are entitled to certain payments upon termination or a change in control as set forth above under the sections entitled &#8220;&#8212; </font><font style="font-style:italic;letter-spacing:0.2pt;">Employment Agreements with Named Executive Officers</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;&#8212;&#160;</font><font style="font-style:italic;letter-spacing:0.2pt;">2017 Stock Incentive Plan&#8201;&#8212;&#8201;Effect of Certain Corporate Transactions</font><font style="letter-spacing:0.2pt;">&#8221;. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma Director Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The table below shows all compensation to non-employee directors of Carisma during the year ended December&#160;31, 2022. </font>
          </div>


          <table style="width:456pt;height:107.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.167pt 0pt; width:274.38pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Fees Earned or Paid </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">in Cash ($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Option Awards</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Total ($)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:274.38pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Margarita Chavez</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.38pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D. </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.38pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D. </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.38pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D., Ph.D. </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.38pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.38pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Sanford Zweifach </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">75,000<font style="position:absolute;"><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(3)</font> </font></td>
              <td style="padding:0pt;padding-left:19.655pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:19.875pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:9.43pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Ms. Chavez is not expected to serve as a director of the combined company. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">As of December 31, 2022, the aggregate number of shares of the Carisma common stock subject to outstanding option awards for each non-employee director was as follows: Mr. Morrison, 51,332 shares; and Mr. Zweifach, 97,200 shares. These amounts reflect the aggregate grant date fair value of Carisma options previously awarded, computed in accordance with the provisions of ASC Topic&#160;718. See Note 3 to Carisma&#8217;s consolidated financial statements appearing at the end of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus regarding assumptions underlying the valuation of option awards. </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">Represents fees paid in connection with Mr. Zweifach&#8217;s service as Chair of the Carisma board of directors for the year ended December&#160;31, 2022. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2022, Carisma did not provide any additional compensation to Mr.&#160;Kelly, its President and Chief Executive Officer, for his service as a director. Mr.&#160;Kelly&#8217;s compensation as a named executive officer is set forth above under &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Carisma Executive Compensation&#8201;&#8212;&#8201;Summary Compensation Table</font><font style="letter-spacing:0.2pt;">&#8221;. </font>
          </div>

      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">367</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tRPTO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RELATED PARTY TRANSACTIONS OF DIRECTORS AND</font>
          <br >
          <font style="letter-spacing:-0.2pt;">EXECUTIVE OFFICERS OF THE COMBINED COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Sesen Bio&#8217;s and Carisma&#8217;s directors and executive officers, including those discussed in the sections entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Management Following the Merger</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Sesen Bio Executive Compensation</font><font style="letter-spacing:0.2pt;">&#8221; and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Carisma Executive Compensation</font><font style="letter-spacing:0.2pt;">,&#8221; beginning on pages <a href="#tMFTM">342</a>, <a href="#tSBEC">349</a> and <a href="#tCEC">360</a>, respectively, of this proxy statement/prospectus, the following is a description of each transaction occurring since January&#160;1, 2019 and any currently proposed transactions in which: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">either Sesen Bio or Carisma was or is to be a participant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of Sesen Bio&#8217;s or Carisma&#8217;s the total assets at year end for the last two completed fiscal&#160;years; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any director, executive officer, holder of more than 5% of the voting securities of Sesen Bio, Carisma, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Manufacturing and Office Lease</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio leases a manufacturing, laboratory, and office facility in Winnipeg, Manitoba, from an affiliate of Leslie Dan, a former director of Sesen Bio who retired from the Sesen Bio board of directors in July&#160;2019, under a two-year renewable lease through September&#160;2022 with a right to renew the lease for one subsequent three-year term. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, Sesen Bio had a rent expense for this facility of $327,000, $301,000 and $320,000, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Protoden License</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is party to an intellectual property license agreement under which Sesen Bio pays fees to Protoden Technologies Inc., or Protoden, a company owned by an affiliate of Mr.&#160;Dan. Pursuant to the agreement, Sesen Bio has an exclusive, perpetual, irrevocable and non-royalty bearing license, with the right to sublicense, under certain patents and technology to make, use and sell products that utilize such patents and technology. The annual fee is $100,000. Beginning on January&#160;1, 2025, the licenses granted to Sesen Bio will require no further payments to Protoden. Sesen Bio paid $100,000 under this license agreement to Protoden in each of the&#160;years ended December&#160;31, 2021, 2020 and 2019. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Carisma Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Private Placements of Securities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Series&#160;A Convertible Preferred Stock Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2018, November&#160;2018 and March&#160;2020, Carisma and CARISMA Therapeutics S.&#224; r.l., a soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e organized under the laws of Luxembourg and a subsidiary of Carisma, or Carisma Europe, as applicable, issued and sold an aggregate of 5,201,017 shares of the Carisma Series&#160;A preferred stock, $0.0001 par value per share and an aggregate of 937,501 Class&#160;B Shares, with a nominal value of one tenth of one eurocent (EUR 0.001), of Carisma Europe, or the Class&#160;B exchangeable shares, of which (i)&#160;4,701,925 shares of Series&#160;A preferred stock and all of the Class&#160;B exchangeable shares were sold at a price per share of $10.40 in cash, for an aggregate purchase price of $58,650,030.40 and (ii)&#160;499,092 shares of Carisma Series&#160;A preferred stock were sold at a price per share of $8.06 against payment by cancellation or conversion of indebtedness of Carisma to the applicable purchaser, including interest. Carisma also issued one share of Special Voting Preferred Stock of Carisma, $0.0001 par value per share, to the holder of the Class&#160;B exchangeable shares, which share shall be automatically cancelled at such time as all Class&#160;B exchangeable shares have been exchanged for capital stock of Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the aggregate number of shares of the Carisma Series&#160;A preferred stock and Class&#160;B exchangeable shares that were issued and sold to Carisma directors, executive officers and holders </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">368</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCARPREC123">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of more than 5% of Carisma voting securities and their affiliates in the transactions and the aggregate amount of consideration for such shares: </font>
        </div>
        <table style="width:456pt;height:122.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:224.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Purchaser</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Series&#160;A</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Class&#160;B</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exchangeable Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:224.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AbbVie Biotechnology Ltd </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">947,762</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">8,500,003.20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:224.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">HealthCap VII L.P. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">250,647</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">937,501</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">11,000,017.60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:224.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with IPG </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">947,186</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">8,500,003.20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:224.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MRL Ventures Fund, LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">480,770</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">5,000,008.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:224.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Trustees of the University of Pennsylvania </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">309,594</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">2,750,009.60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:224.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">TPG Biotechnology Partners V, L.P </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">673,076</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">6,999,990.40</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:224.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wellington Life Sciences V GmbH &amp; Co. KG </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">798,072</td>
            <td style="padding:0pt;padding-left:14.375pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">8,299,948.80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">See section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Stockholders of Carisma</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tPSOC">397</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus for additional information about shares held by these entities. </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Series&#160;B Convertible Preferred Stock Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020 and February&#160;2021, Carisma and Carisma Europe, as applicable, issued and sold an aggregate of 3,499,866 shares of the Carisma Series&#160;B preferred stock, $0.0001 par value per share and an aggregate of 297,764 Class&#160;B-1 Shares, with a nominal value of one tenth of one eurocent (EUR 0.001), of Carisma Europe, or the Class&#160;B-1 exchangeable shares, all of which were sold at a price per share of $15.60 in cash, for an aggregate purchase price of $59,243,028.00. Carisma also issued one share of Carisma Series&#160;B special voting preferred stock, $0.0001 par value per share, to the holder of the Class&#160;B-1 exchangeable shares, which share shall be automatically cancelled at such time as all Class&#160;B-1 exchangeable shares have been exchanged for capital stock of Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the aggregate number of shares of the Carisma Series&#160;B preferred stock and Class&#160;B-1 exchangeable shares that were issued and sold to Carisma directors, executive officers and holders of more than 5% of Carisma voting securities and their affiliates in the transactions and the aggregate amount of consideration for such shares: </font>
        </div>
        <table style="width:456pt;height:152.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Purchaser</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Series&#160;B</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of Class&#160;B-1</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exchangeable Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AbbVie Biotechnology Ltd </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">256,398</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">3,999,808.80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Briggs Morrison </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">6,410</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">99,996.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">HealthCap VII L.P. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">297,764</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">4,645,118.40</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with IPG </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">577,120</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">9,003,072.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MRL Ventures Fund, LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">134,609</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">2,099,900.40</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SymBiosis II, LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">961,492</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">14,999,275.20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Trustees of the University of Pennsylvania </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">170,131</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">2,654,043.60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">TPG Biotechnology Partners V, L.P </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">168,681</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">2,631,423.60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:225.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wellington Life Sciences V GmbH &amp; Co. KG </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">200,007</td>
            <td style="padding:0pt;padding-left:14.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.875pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">3,120,109.20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">See section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Stockholders of Carisma</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tPSOC">397</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus for additional information about shares held by these entities. </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Carisma Pre-Closing Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, immediately prior to the execution and delivery of the Original Merger Agreement, Carisma entered into a subscription agreement with certain investors named therein in connection with the Carisma pre-closing financing. Pursuant to the Subscription Agreement, the investors agreed to purchase an aggregate of 1,964,101 shares of Carisma common stock, at a price of $15.60 per share, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">369</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">for aggregate gross proceeds of $30.6&#160;million. The closing of the Carisma pre-closing financing is conditioned upon the satisfaction or waiver of the conditions to the merger as well as certain other conditions. Seven of the investors or their affiliates are beneficial holders of more than 5% of Carisma&#8217;s capital stock, and the table below sets forth the number of shares of Carisma common stock expected to be purchased by such holders at the closing of the Carisma pre-closing financing: </font>
        </div>
        <table style="width:416pt;height:122.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:282.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Purchaser</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:282.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AbbVie Biotechnology Ltd </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">243,590</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">3,800,004.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">HealthCap VII L.P. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">303,205</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">4,729,998.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MRL Ventures Fund, LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">160,256</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">2,499,993.60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SymBiosis II, LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">205,128</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">3,199,996.80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Trustees of the University of Pennsylvania </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">179,487</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">2,799,997.20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">TPG Biotechnology Partners V, L.P </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">44,872</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">700,003.20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wellington Life Sciences V GmbH &amp; Co. KG </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">211,538</td>
            <td style="padding:0pt;padding-left:9.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">3,299,992.80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.2pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">See section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Stockholders of Carisma</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tPSOC">397</a> of this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus for additional information about shares held by these entities. </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma has agreed to enter into a registration rights agreement with the investors party to the subscription agreement to provide for the registration of the resale of the shares of common stock purchased by such investors in connection with the Carisma pre-closing financing. The registration rights agreement will also provide these investors rights to require Carisma to register additional shares held by such investors under specified circumstances and to participate in future registrations of securities by Carisma under specified circumstances. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Agreements with Carisma Stockholders</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investor Rights Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, Carisma and Carisma Europe entered into an amended and restated investor rights agreement, or the Investor Rights Agreement, with certain holders of Carisma common stock, the Series&#160;A preferred stock, Series&#160;B preferred stock, Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares, including certain holders of 5% of Carisma&#8217;s capital stock, and including certain affiliates of Carisma&#8217;s directors and their affiliates. The Investor Rights Agreement provides such holders with certain registration rights, including the right to demand that Carisma file a registration statement or request that their shares be covered by a registration statement that Carisma is otherwise filing. The Investor Rights Agreement also provides certain major investors with certain information and observer rights. The Investor Rights Agreement is expected to be terminated in connection with the closing of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Voting Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, Carisma and Carisma Europe entered into an amended and restated voting agreement, or the Voting Agreement, with certain holders of Carisma common stock, Series&#160;A preferred stock, Series&#160;B preferred stock, Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares, including certain holders of 5% of Carisma&#8217;s capital stock, and including certain of Carisma&#8217;s directors and their affiliates. Pursuant to the Voting Agreement, such holders party thereto agreed to vote their shares in favor of the election of certain directors and specified transactions approved by the requisite majority of the shares of voting capital stock held by such holders. The Voting Agreement is expected to be terminated in connection with the closing of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Right of First Refusal and Co-Sale Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, Carisma entered into an amended and restated right of first refusal and co-sale agreement, or the ROFR Agreement, with certain holders of Carisma common stock, the Series&#160;A preferred stock, Series&#160;B preferred stock, Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares, including </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">370</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:140pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">certain holders of 5% of its capital stock, and including certain of Carisma&#8217;s directors and their affiliates. Pursuant to the ROFR Agreement, Carisma has a right of first refusal in respect of certain sales of securities by certain holders of its capital stock. To the extent Carisma does not exercise such right in full, certain holders of its capital stock are granted certain rights of first refusal and co-sale in respect of such sales. The ROFR Agreement is expected to be terminated in connection with the closing of the merger. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Share Exchange and Voting Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, Carisma and Carisma Europe entered into an amended and restated share exchange and voting agreement, or the Share Exchange Agreement, with certain holders of the Series&#160;A preferred stock, Series&#160;B preferred stock, Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares, including certain holders of 5% of its capital stock, and including certain of Carisma&#8217;s directors and their affiliates. The Share Exchange Agreement provides for the exchange of the Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares for shares of Series&#160;A preferred stock and Series&#160;B preferred stock, respectively, either voluntarily or automatically, upon certain circumstances as set forth therein. In connection with the closing of the merger, the Class&#160;B exchangeable shares and Class&#160;B-1 exchangeable shares will be exchanged into Carisma preferred stock, and the Share Exchange Agreement will terminate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">License Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2017, Carisma entered into the Penn License Agreement with Penn. Pursuant to the Penn License Agreement, Carisma is responsible for paying Penn an annual license maintenance fee in the low tens of thousands of dollars, payable until Carisma&#8217;s first payment of a royalty. Carisma is required to pay Penn up to $10.9&#160;million per product in development and regulatory milestone payments, up to $30.0&#160;million per product in commercial milestone payments, and up to an additional $1.7&#160;million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Penn is a holder of 5% or more of the Carisma capital stock. For additional detail on the Penn License Agreement see the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Carisma Business&#8201;&#8212;&#8201;University of Pennsylvania License Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tUNPLA">291</a> of this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation provides that Carisma will provide indemnification, and advancement of expenses to, directors and officers to the fullest extent permitted by applicable law. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Policies for Approval of Related Party Transactions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Carisma does not have a written policy regarding the review and approval of related person transactions. Nevertheless, with respect to such transactions, it has been the practice of the Carisma board of directors to consider the nature of and business reasons for such transactions, how the terms of such transactions compared to those which might be obtained from unaffiliated third parties and whether such transactions were otherwise fair to and in the best interests of, or not contrary to, Carisma&#8217;s best interests.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">371</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tUPFC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, Sesen Bio, Merger Sub, and Carisma entered into the Original Merger Agreement (as amended by the Merger Agreement Amendment dated as of December&#160;29, 2022, the Merger Agreement) pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as a wholly-owned subsidiary of Sesen Bio and the surviving corporation of the merger. At the effective time of the merger, Sesen Bio will change its name to &#8220;Carisma Therapeutics Inc.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Immediately prior to the execution and delivery of the Original Merger Agreement, Carisma entered into a subscription agreement in connection with the Carisma pre-closing financing, pursuant to which certain investors agreed to purchase shares of Carisma common stock at an aggregate purchase price of $30.6&#160;million. The closing of the Carisma pre-closing financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the merger set forth in the Merger Agreement. The shares of Carisma common stock issued in the Carisma pre-closing financing will be converted into shares of Sesen Bio common stock in the merger in accordance with the exchange ratio. As of immediately after the effective time of the merger, the Carisma convertible note will automatically convert into a number of shares of Sesen Bio common stock calculated in accordance with the terms of the Carisma convertible note and based on the exchange ratio for the conversion of Carisma capital stock into Sesen Bio common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the effective time, Sesen Bio will enter into the CVR Agreement with a rights agent pursuant to which Sesen Bio stockholders of record as of a date agreed to by Sesen Bio and Carisma prior to the effective time will receive one CVR for each outstanding share of Sesen Bio common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive contingent cash payments upon the receipt by Sesen Bio of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes. The CVRs will not have any voting or dividend rights, will not represent any equity or ownership interest in Sesen Bio or its subsidiaries, and interest will not accrue on any amounts payable on the CVRs. Prior to the effective time, Sesen Bio will declare a pre-closing dividend to its common stockholders of record consisting of (a)&#160;one CVR for each outstanding share of Sesen Bio common stock held by such stockholder as of such date, representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the CVR Agreement and (b)&#160;a special cash dividend expected to be approximately $70.0&#160;million in the aggregate, subject to Sesen Bio&#8217;s estimated net cash as of the closing of the merger being greater than or equal to $75.0 million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the effective time of the merger, each outstanding share of Carisma capital stock, including shares of Carisma common stock issued in connection with the Carisma pre-closing financing, will be converted into the right to receive a number of shares of Sesen Bio common stock equal to the exchange ratio. The exchange ratio was estimated at the time of the execution of the Merger Agreement Amendment on December&#160;29, 2022 to be 37.7924 shares of Sesen Bio common stock for each share of Carisma capital stock and is subject to adjustment prior to the closing for, among other things, Sesen Bio&#8217;s net cash at the cash determination time. Because Sesen Bio&#8217;s final net cash will not be determined until the closing, and because the number of shares of Sesen Bio common stock issuable to Carisma stockholders is determined based on, among other things, Sesen Bio&#8217;s final net cash, Sesen Bio stockholders cannot be certain of the exact number of shares that will be&#160;issued to Carisma stockholders when Sesen Bio stockholders vote on the proposals at the Sesen Bio special meeting. The exchange ratio referenced above is an estimate only and the final exchange ratio will be determined pursuant to a formula described in more detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">The Merger Agreement&#8201;&#8212;&#8201;Merger Consideration</font><font style="letter-spacing:0.2pt;">&#8221; in this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following selected unaudited pro&#160;forma condensed combined financial data gives effect to the (i)&#160;merger, (ii)&#160;the Carisma pre-closing financing, (iii)&#160;the automatic conversion of the Carisma convertible note, and (iv)&#160;the pre-closing dividend. Additionally, the unaudited pro&#160;forma condensed combined balance sheet reflects the proceeds received by Sesen Bio in connection with the Roche Asset Purchase Agreement in July&#160;2022. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">372</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:40pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The merger is accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Sesen Bio are cash, cash equivalents, and marketable securities. For financial reporting purposes, Carisma has been determined to be the accounting acquirer based upon the terms of the merger and other factors including: (i)&#160;Carisma stockholders and other persons holding securities that are convertible into Carisma common stock are expected to own approximately 74.8% of the fully diluted closing Sesen Bio common stock immediately following the effective time of the merger (based on estimates made at the time of the execution of the Merger Agreement), (ii)&#160;Carisma will hold the majority (six of seven) of board seats of the combined company, and (iii)&#160;Carisma&#8217;s management will hold all key positions in the management of the combined company. The &#8220;fully diluted closing Sesen Bio common stock&#8221; as used herein means (x)&#160;the number of outstanding shares of Sesen Bio common stock, which amount excludes the shares of Sesen Bio common stock available for issuance under the 2014 Incentive Plan and the 2009 Incentive Plan, as well as inducement grants made outside of the Sesen Bio stockholder-approved plans and out-of-the-money Sesen Bio options, </font><font style="font-style:italic;letter-spacing:0.2pt;">plus</font><font style="letter-spacing:0.2pt;"> (y)&#160;the number of outstanding shares of Carisma common stock, which amount includes the shares of Carisma common stock available for issuance under the Carisma Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial information was prepared in accordance with Article&#160;11 of Regulation&#160;S-X. The Sesen Bio and Carisma unaudited pro&#160;forma condensed combined balance sheet data assume that the merger took place on September&#160;30, 2022, and combines the Sesen Bio and Carisma historical balance sheets at September&#160;30, 2022. The Sesen Bio and Carisma unaudited pro&#160;forma condensed combined statements of operations data assume that the merger took place as of January&#160;1, 2021 and combines the historical results of Sesen Bio and Carisma for the nine&#160;months ended September&#160;30, 2022 and the year ended December&#160;31, 2021. The historical financial statements of Sesen Bio and Carisma, which are included in this proxy statement/prospectus, have been adjusted to give pro&#160;forma effect to events that are (i)&#160;directly attributable to the merger, (ii)&#160;factually supportable, and (iii)&#160;with respect to the statements of operations, expected to have a continuing impact on the combined results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial statements are based on the assumptions and adjustments that are described in the accompanying notes. The unaudited pro&#160;forma condensed combined financial statements and pro&#160;forma adjustments have been prepared based on preliminary estimates of fair value of assets acquired and liabilities assumed. A final determination of these estimated fair values will be based on the actual net tangible assets of Sesen Bio that exist as of the date of completion of the merger. Differences between these preliminary estimates and the final fair value of assets and liabilities acquired may occur and these differences could have a material impact on the accompanying unaudited pro&#160;forma condensed combined financial statements and the combined company&#8217;s future results of operations and financial position. The actual amounts recorded as of the completion of the merger may differ materially from the information presented in these unaudited pro&#160;forma condensed combined financial statements as a result of the amount of cash used by Sesen Bio&#8217;s operations between the signing of the Merger Agreement and the closing of the merger; the timing of the closing of the merger; and other changes in Sesen Bio&#8217;s assets and liabilities that occur prior to the completion of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the merger. The unaudited pro&#160;forma condensed combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of operations in future periods or the results that actually would have been realized had Sesen Bio and Carisma been a combined company during the specified period. The unaudited pro&#160;forma condensed combined financial statements, including the notes thereto, should be read in conjunction with the separate historical audited financial statements of Sesen Bio and Carisma for the year ended December&#160;31, 2021 and the unaudited condensed financial statements of Sesen Bio and Carisma for the nine&#160;months ended September&#160;30, 2022 included elsewhere in this proxy statement/prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">373</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Unaudited Pro Forma Condensed Combined Balance Sheet </font>
          <br >
          <font style="letter-spacing:-0.2pt;">As of September&#160;30, 2022 </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:570.17pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:247.49pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.067pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.067pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.067pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transactions </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.067pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.067pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Combined </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.17pt 0pt 0.69pt 0pt; width:247.49pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">ASSETS</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.42pt 0pt 0.69pt 0pt; width:247.49pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Current assets</font><font style="font-weight:normal;letter-spacing:0.18pt;">: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.43pt 0pt 0.68pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">28,943</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">71,107</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(62,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">A</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">37,257</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.43pt 0pt 0.68pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Short-term marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">41,705</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">106,427</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">148,132</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.43pt 0pt 0.68pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.43pt 0pt 0.68pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Other receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">14,297</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.43pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">14,297</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.24pt 0pt 0.965pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.77pt; margin-bottom:-0.499999999999994pt;">
                <font style="letter-spacing:0.18pt;">Prepaid expenses and other current </font>
                <br >
                <font style="letter-spacing:0.18pt;">assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.24pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.24pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">2,290</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.24pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.24pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">527</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.24pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.24pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.24pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.24pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">2,817</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.18pt 0pt 0.68pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Total current assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">72,938</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">192,358</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.68pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(62,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.68pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.68pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">202,503</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.44pt 0pt 0.67pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.44pt 0pt 0.67pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,336</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,336</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.44pt 0pt 0.67pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8,677</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 0.67pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8,677</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.42pt 0pt 1.555pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Right of use assets&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.42pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.42pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">6,121</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.42pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.42pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.42pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.42pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.42pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.42pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">6,121</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.18pt 0pt 2.305pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:-0.18pt;">Total assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 1.555pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.18pt 0pt 1.555pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">87,736</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 1.555pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.18pt 0pt 1.555pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">199,724</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 1.555pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.18pt 0pt 1.555pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(62,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 1.555pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.18pt 0pt 1.555pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">224,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:247.49pt;white-space:normal;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt;">
                <font style="letter-spacing:-0.18pt;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLERS&#8217; EQUITY (DEFICIT)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.45pt 0pt 0.66pt 0pt; width:247.49pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Current liabilities</font><font style="font-weight:normal;letter-spacing:0.18pt;">: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.45pt 0pt 0.66pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,084</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">514</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,599</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.45pt 0pt 0.66pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8,997</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">33,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,871<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">B</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">39,926</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.45pt 0pt 0.66pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Deferred revenues </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,230</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.45pt 0pt 0.66pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,230</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.46pt 0pt 0.65pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,184</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.46pt 0pt 0.65pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Finance lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,006</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,006</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.46pt 0pt 0.65pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Convertible promissory notes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">33,175</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(33,175<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">C</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 0.65pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.44pt 0pt 1.555pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.44pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">157</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.44pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">381</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.44pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.44pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.44pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">538</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.22pt 0pt 0.64pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Total current liabilities</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.22pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.22pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">53,834</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.22pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.22pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">34,695</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.22pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.22pt 0pt 0.64pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(36,046<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.22pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.22pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">52,483</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.47pt 0pt 0.64pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.47pt 0pt 0.64pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Deferred revenues, noncurrent </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.47pt 0pt 0.64pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,189</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(5,189<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">C</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.47pt 0pt 0.64pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.48pt 0pt 0.63pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Operating lease liabilities, noncurrent </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,003</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,003</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.48pt 0pt 0.63pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Finance lease liabilities, noncurrent </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 0.63pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.46pt 0pt 1.555pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Other noncurrent liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.46pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">307</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.46pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.46pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.46pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.46pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">307</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.21pt 0pt 1.555pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.18pt;">Total liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">106,036</div>
            </td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">34,695</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(41,235<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">D</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.21pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">99,496</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.22pt 0pt 1.555pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.22pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.22pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">107,808</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.22pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.22pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.22pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.22pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(107,808<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.22pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.22pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.24pt 0pt 0.62pt 0pt; width:247.49pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Stockholders&#8217; equity (deficit):</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.49pt 0pt 0.62pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">202</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">596</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">E</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">798</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.49pt 0pt 0.62pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,141</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">493,629</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(225,920<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">E</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">268,850</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:2.49pt 0pt 0.62pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accumulated other comprehensive income (loss) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(235<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">E</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.62pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.48pt 0pt 1.555pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(141,484<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(328,567<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">325,734</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">E</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.48pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(144,317<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.05pt 0pt 0.5pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Total stockholders&#8217; equity (deficit) attributable to Carisma and </font>
                <br >
                <font style="letter-spacing:0.18pt;">Sesen Bio </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(140,503<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">165,029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">100,645</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">125,171</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.3pt 0pt 0.965pt 0pt; width:247.49pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.77pt; margin-bottom:-0.499999999999994pt;">
                <font style="letter-spacing:0.18pt;">Equity attributable to noncontrolling </font>
                <br >
                <font style="letter-spacing:0.18pt;">interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(14,395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.965pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.965pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">F</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.3pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.23pt 0pt 1.555pt 0pt; width:247.49pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.18pt;">Total stockholders&#8217; equity (deficit)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.23pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.23pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(126,108<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.23pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.23pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">165,029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.23pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.23pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">86,250</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.23pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.23pt 0pt 1.555pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">125,171</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:1.05pt 0pt 1.715pt 0pt; width:247.49pt;white-space:normal;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt; line-height:10.77pt; margin-bottom:-0.499999999999994pt;">
                <font style="letter-spacing:-0.18pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.41pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.05pt 0pt 0.41pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">87,736</td>
            <td style="padding:0pt;padding-left:2.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.41pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.41pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">199,724</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.41pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.05pt 0pt 0.41pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(62,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.05pt 0pt 0.41pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.05pt 0pt 0.41pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">224,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited pro&#160;forma condensed combined financial statements </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">374</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:218pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Pro Forma Condensed Combined Statements of Operations </font>
          <br >
          <font style="letter-spacing:-0.2pt;">For the Nine Months Ended September&#160;30, 2022 </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:339pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:176.53pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Other </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Transaction </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Combined </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Collaboration revenues </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,103</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:2.25pt; text-align:right; white-space:nowrap;">I</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">6,103</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">38,536</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">37,636</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">76,172</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">8,407</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">41,112</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restructuring charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">27,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">27,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:176.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(52,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(52,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">46,943</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">57,052</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">103,995</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(17,052<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(97,892<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Non-operating income (expense): </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of derivative </font>
                <br >
                <font style="letter-spacing:0.2pt;">liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,369<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,369</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">G</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,551</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">G</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss before income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(16,185<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,920</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">96,752</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">3,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">3,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">3,920</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">92,877</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(40.16<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.06<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:176.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted average common shares outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,108</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">199,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">596,215</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">H</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:2.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.78pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">797,124</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited pro&#160;forma condensed combined financial statements </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">375</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:245pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Pro Forma Condensed Combined Statements of Operations </font>
          <br >
          <font style="letter-spacing:-0.2pt;">For the Year Ended December&#160;31, 2021 </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except per share amounts)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:312pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:176.53pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Other </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Transaction </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Combined </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Collaboration revenues </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">26,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3pt; text-align:right; white-space:nowrap;">J</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">6,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating Expenses: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">34,387</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">25,312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">59,699</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,407</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">29,393</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">35,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restructuring charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:176.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(56,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(56,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">40,794</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">35,093</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">75,887</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,794<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,549<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(69,343<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Non-operating income (expense): </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss before income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,609<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(69,393<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(336<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(61,120<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:176.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(37.62<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.00<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.08<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:176.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted average common shares outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,084</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">182,323</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">607,511</td>
            <td style="padding:0pt;padding-left:1.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; white-space:nowrap;">H</td>
            <td style="padding:0pt;padding-left:5.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.515pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">790,918</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited pro&#160;forma condensed combined financial statements </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">376</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Description of Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Merger Transaction</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, Sesen Bio and Carisma entered into the Original Merger Agreement, as amended by the First Amendment thereto on December&#160;29, 2022, pursuant to which a wholly-owned subsidiary of Sesen Bio will merge with and into Carisma, with Carisma surviving as a wholly-owned subsidiary of Sesen Bio. After completion of the merger, Sesen Bio is expected to be renamed &#8220;Carisma Therapeutics Inc.&#8221; and to trade under the symbol &#8220;CARM.&#8221; As of October&#160;14, 2022, the Sesen Bio common stock is listed on the Nasdaq Capital Market under the symbol &#8220;SESN.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the effective time of the merger, each outstanding share of Carisma capital stock (including shares of Carisma common stock issued in connection with the Carisma pre-closing financing) will be converted into the right to receive shares of Sesen Bio common stock equal to the exchange ratio. Based on estimates made at the time of the Merger Agreement, the exchange ratio was initially estimated to be 37.7924 shares of Sesen Bio common stock for each share of Carisma capital stock and is subject to adjustment prior to the closing. Among other things, the exchange ratio will be adjusted to the extent that Sesen Bio&#8217;s net cash at closing is less than or greater than $75.0&#160;million and based on the amount of the Carisma pre-closing financing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio currently estimates, assuming the closing of the merger occurred on December&#160;31, 2022, that (i)&#160;it would have approximately $75.0&#160;million in net cash immediately prior to closing, (ii)&#160;the Carisma pre-closing financing amount will be $30.6&#160;million, (iii)&#160;the outstanding shares of Sesen Bio common stock, Sesen Bio RSUs, Sesen Bio options and Sesen Bio warrants as of the closing will be equal to 222,944,963 and (iv)&#160;the outstanding shares of Carisma capital stock as of the closing on a fully diluted and as-converted basis will be equal to 14,855,514. Accordingly, it is currently estimated that the exchange ratio at closing will be 37.7924 and, based solely on such exchange ratio, at closing: (a)&#160;Carisma stockholders as of immediately prior to the merger (not including the shares of Carisma common stock issued in the Carisma pre-closing financing) are expected to own approximately 66.4% of the fully diluted closing Sesen Bio common stock, (b)&#160;the shares of Carisma common stock issued in the Carisma pre-closing financing to Carisma stockholders as of immediately prior to the merger are expected to represent approximately 8.4% of the fully diluted closing Sesen Bio common stock, (c)&#160;the Sesen Bio stockholders as of immediately prior to the merger (excluding for this purpose certain out-of-the-money Sesen Bio options) are expected to own approximately 25.2% of the fully diluted closing Sesen Bio common stock, (d)&#160;the shares of Sesen Bio common stock issued upon the conversion of the Carisma convertible note are expected to represent approximately 11.3% of the fully diluted closing Sesen Bio common stock, and (e)&#160;the shares of Carisma capital stock available for issuance under the Carisma Plan as of immediately prior to the merger are expected to represent approximately 10.7% of the fully diluted closing Sesen Bio common stock, in each case, subject to adjustment of the exchange ratio as set forth in the Merger Agreement and described herein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because Sesen Bio&#8217;s final net cash will not be determined until the closing, Sesen Bio stockholders cannot be certain of the exact number of shares that will be issued to Carisma stockholders when Sesen Bio stockholders vote on the proposals at the Sesen Bio special meeting. The exchange ratio referenced above is an estimate only and the final exchange ratio will be determined pursuant to a formula described in more detail in the Merger Agreement and in this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the effective time of the merger, each Carisma option that is outstanding and unexercised immediately prior to the effective time granted under the Carisma Plan, or otherwise, whether or not vested, will be, along with the Carisma Plan, assumed by Sesen Bio and will become an option to purchase solely that number of shares of Sesen Bio common stock equal to the product obtained by multiplying (i)&#160;the number of shares of Carisma common stock by (ii)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of Sesen Bio common stock. The per share exercise price for Sesen Bio common stock issuable upon exercise of each Carisma option assumed shall be determined by dividing (a)&#160;the per share exercise price of Carisma common stock by (b)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Any restriction on the exercise of any Carisma option </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">377</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">assumed will continue in full force and effect and the term, exercisability, vesting schedule and other provisions of such Carisma option shall otherwise remain unchanged. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pre-Closing Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a condition of the Merger Agreement, certain investors have entered into the subscription agreement with Carisma pursuant to which such investors have agreed, subject to the terms and conditions of the subscription agreement, to purchase shares of Carisma common stock prior to closing for an aggregate purchase price of $30.6&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pre-Closing Dividend</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the effective time, Sesen Bio will declare a pre-closing dividend to its stockholders consisting of the right to receive contingent payments as discussed in greater detail in the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Agreements Related to the Merger&#8201;&#8212;&#8201;CVR Agreement</font><font style="letter-spacing:0.2pt;">&#8221; beginning on page <a href="#tCVAG">192</a> of this proxy statement/prospectus and a special cash dividend that is expected to be approximately $70.0&#160;million in the aggregate, subject to Sesen Bio&#8217;s estimated net cash as of the closing of the merger being greater than or equal to $75.0 million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Conversion of Carisma Convertible Note</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon completion of the merger, Carisma&#8217;s $35.0&#160;million convertible note and accrued interest will convert into shares of Sesen Bio common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Contingent Value Rights Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the effective time, Sesen Bio will enter into the CVR Agreement with a rights agent pursuant to which Sesen Bio stockholders will receive one CVR for each share of Sesen Bio common stock held. Each CVR will represent the contractual right to receive contingent cash payments upon the receipt by Sesen Bio of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as proceeds from any sale of Sesen Bio&#8217;s legacy assets, including Vicineum. The CVR will be recognized when the achievement of the milestone payment becomes probable. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Sesen Bio Sale of Legacy Technology to Roche</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, Sesen Bio executed the Roche Asset Purchase Agreement pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by Sesen Bio. Sesen Bio received an upfront payment from Roche of $40.0&#160;million upon execution of the Roche Asset Purchase Agreement. In addition, Sesen Bio is eligible to receive an additional $30.0&#160;million payment from Roche upon Roche&#8217;s initiation of a Phase&#160;3 clinical trial with EBI-031 for a defined indication if initiated prior to December&#160;31, 2026 which will be paid to Sesen Bio stockholders through the CVR Agreement. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis of Presentation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial statements were prepared in accordance with the regulations of the SEC. The unaudited pro&#160;forma condensed combined balance sheet as of September&#160;30, 2022 is presented as if the merger had been completed on September&#160;30, 2022. The unaudited pro&#160;forma condensed combined statements of operations for the nine&#160;months ended September&#160;30, 2022 and the year ended December&#160;31, 2021 assumes that the merger occurred on January&#160;1, 2021, and combines the historical results of Carisma and Sesen Bio. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, the unaudited pro&#160;forma condensed combined balance sheet and statements of operations data reflect the other transactions that will have occurred at or prior to the completion of the merger. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">378</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For accounting purposes, Carisma is considered to be the acquiring company and the merger will be accounted for as a reverse recapitalization of Sesen Bio by Carisma because at the closing of the merger, the primary pre-combination assets of Sesen Bio will be cash, cash equivalents and marketable securities. The final exchange ratio will be determined based on a net cash calculation prior to the closing. Sesen Bio currently estimates that it will have approximately $75.0&#160;million in net cash immediately prior to the closing of the merger, assuming for this purpose that the closing of the merger occurred on December&#160;31, 2022. The exchange ratio will be adjusted dollar-for-dollar by the amount that the net cash amount is less than $75.0&#160;million. The pro&#160;forma financial statements reflect Sesen Bio management&#8217;s estimates of the fair value of Sesen Bio&#8217;s net assets that will be contributed to Carisma as part of the merger. However, the actual exchange ratio will vary based on the net cash calculation prior to the closing as described above and that difference could be material. A 10% decrease in Sesen Bio&#8217;s net cash would increase the exchange ratio by 9.1%. A 10% increase in Sesen Bio&#8217;s net cash could decrease the exchange ratio by 7.7%. As such, the estimated exchange ratio reflected in these unaudited pro&#160;forma condensed combined financial statements does not purport to represent what the actual exchange ratio will be when the merger is completed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Under reverse recapitalization accounting, the assets and liabilities of Sesen Bio will be recorded, as of the completion of the merger, at their fair values which are expected to approximate book values because of the short-term nature of the instruments. No goodwill or intangible assets are expected to be recognized. The historical financial statements of Sesen Bio and Carisma, which are provided elsewhere in this proxy statement/prospectus, have been adjusted to give pro&#160;forma effect to events that are (i)&#160;directly attributable to the merger, (ii)&#160;factually supportable, and (iii)&#160;with respect to the statements of operations, expected to have a continuing impact on the combined results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Pro&#160;forma adjustments related to the Carisma pre-closing financing for aggregate cash proceeds of $30.6&#160;million and reflect the conversion of the Carisma convertible note into shares of Sesen Bio common stock effective as of immediately after the effective time of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The unaudited pro&#160;forma condensed combined financial statements also give effect to the other transactions that are not directly attributable to the merger but are deemed relevant to the pro&#160;forma financial position and operations of the combined companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent there are significant changes to the business following completion of the merger, the assumptions and estimates set forth in the unaudited pro&#160;forma condensed combined financial statements could change significantly. Accordingly, the pro&#160;forma adjustments are subject to further adjustments as additional information becomes available and as additional analyses are conducted following the completion of the merger. There can be no assurances that these additional analyses will not result in material changes to the estimates of fair value. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pro Forma Adjustments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The pro&#160;forma adjustments were based on the preliminary information available at the time of the preparation of the unaudited pro&#160;forma condensed combined financial information. The unaudited pro&#160;forma condensed combined financial information, including the notes thereto, are qualified in their entirety by reference to, and should be read in conjunction with, the separate historical audited financial statements of Sesen Bio and Carisma for the year ended December&#160;31, 2021 and the unaudited condensed financial statements of Sesen Bio and Carisma for the nine&#160;months ended September&#160;30, 2022 included elsewhere in this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Merger Transaction Adjustments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects (i)&#160;approximately $30.6&#160;million in proceeds from the Carisma pre-closing financing, (ii)&#160;payment of a $70.0&#160;million special cash dividend (iii)&#160;payment of total estimated unpaid transaction costs and (iv)&#160;payment of severance costs upon consummation of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">379</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:208pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:114pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.167pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:265.26pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from Carisma pre-closing financing, net of issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">30,640</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">30,640</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Special cash dividend payment to Sesen Bio stockholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(70,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(70,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of transaction costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(7,333<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(7,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,033<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of severance costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(8,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(8,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma adjustment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">23,307</td>
            <td style="padding:0pt;padding-left:4.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(86,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(62,793<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">B</font>
          <br >
        </div>
        <div style=" margin-top:11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Reflects payment of total estimated unpaid transaction costs as of September&#160;30, 2022 in connection with the merger and settlement of accrued interest upon conversion of the Carisma convertible note: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;height:72pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.167pt 0pt; width:271.71pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">CARISMA </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Therapeutics </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:271.71pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unpaid transaction costs as of September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(290<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,025<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,315<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:271.71pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued interest for Carisma convertible note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(556<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(556<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:271.71pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(846<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,025<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,871<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">C</font>
          <br >
        </div>
        <div style=" margin-top:11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Settlement of the Carisma convertible note and related derivative liability through the issuance of Sesen Bio common stock upon completion of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">D</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Conversion of Carisma convertible preferred stock into common stock of the combined company upon completion of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">E</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">To record the (i)&#160;exchange ratio adjustment to Carisma&#8217;s common stock outstanding, (ii)&#160;conversion of Carisma convertible preferred stock into common stock, (iii)&#160;the elimination of Carisma&#8217;s noncontrolling interest upon conversion of Carisma convertible preferred stock, (iv)&#160;sale of Carisma common stock, net of issuance costs, in connection with Carisma pre-closing financing, (v)&#160;automatic conversion of the Carisma convertible note, (vi)&#160;elimination of Sesen Bio&#8217;s historical equity carrying value, (vii)&#160;issuance of common stock upon the acceleration of unvested Sesen Bio RSUs and PSUs upon closing of the merger, (viii)&#160;special cash dividend payment to Sesen Bio stockholders, (ix)&#160;post-combination stock-based compensation expense for Sesen Bio options and Sesen Bio RSUs and (x)&#160;payment of transaction and severance costs: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">380</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;height:357pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:22.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:208.28pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">paid-in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">comprehensive</font>
                <br >
                <font style="letter-spacing:-0.16pt;">income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Noncontrolling</font>
                <br >
                <font style="letter-spacing:-0.16pt;">interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:208.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:208.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Adjustment to Carisma common stock outstanding in connection with the Exchange Ratio </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">42,422</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(43<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:208.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock upon conversion of Carisma convertible preferred shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">341,209</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">341</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">107,467</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">107,808</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:208.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock upon conversion of Carisma noncontrolling interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">34,301</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">14,361</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:208.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock upon completion of Pre-Closing Financing </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">74,228</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">75</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">30,565</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">30,640</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:208.28pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock upon settlement of </font>
                <br >
                <font style="letter-spacing:0.2pt;">Carisma convertible promissory note, accrued </font>
                <br >
                <font style="letter-spacing:0.2pt;">interest and related derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">98,068</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">40,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(1,825<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">38,920</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:208.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Elimination of Sesen Bio&#8217;s historical carrying values </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(328,802<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">328,567</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:208.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares of common stock of the continuing company to Sesen Bio shareholders</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,695</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:208.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Special dividend payment to Sesen Bio shareholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(70,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(70,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:208.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Post-combination stock-based compensation costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,008</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(1,008<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 0.5pt 0pt; width:208.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Payment of transaction costs and severance expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(21,118<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(21,118<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:208.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma Adjustment </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">594,923</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">596</td>
            <td style="padding:0pt;padding-left:2.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(225,920<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:13.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">325,734</td>
            <td style="padding:0pt;padding-left:2.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">86,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:12pt;margin-bottom:97.64pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">F</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Issuance of common stock upon conversion of Carisma noncontrolling interests. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">G</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Elimination of interest expense and change in fair value of derivative liability associated with the Carisma convertible note and related derivative, respectively, that were settled upon completion of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">H</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The pro&#160;forma combined basic and diluted earnings per share have been adjusted to reflect the pro&#160;forma net loss for the nine&#160;months ended September&#160;30, 2022 and the year ended December&#160;31, 2021. In addition, the number of shares used in calculating the pro&#160;forma combined basic and diluted net income per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company that would be outstanding as of the closing. The following table sets forth the calculation of the pro&#160;forma weighted average number of common shares outstanding&#8201;&#8212;&#8201;basic and diluted. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">381</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:353pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:180pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.167pt 0pt; width:262.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine&#160;months ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:262.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Effect of applying estimated exchange ratio to Carisma common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">40,758</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">39,886</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:262.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Conversion of Carisma preferred stock and noncontrolling interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">375,510</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">370,200</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:262.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock in connection with Carisma pre-closing financing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">74,228</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">74,228</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:262.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock upon settlement of Carisma convertible note, accrued interest and related derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">98,068</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">98,068</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:262.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of shares of common stock of the combined company to Sesen Bio stockholders </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">7,651</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">25,129</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:262.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">596,215</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">607,511</td>
            <td style="padding:0pt;padding-left:12.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Transaction Adjustments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">I</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Elimination of one time payments received in connection with the Roche Asset Purchase Agreement in July&#160;2022 of $40.0&#160;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">J</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Elimination of development milestone revenue received from Roche during the year ended December&#160;31, 2021 related to the assets sold to Roche in July&#160;2022.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">382</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOSB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF SESEN BIO CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following description of Sesen Bio&#8217;s capital stock is not complete and may not contain all the information you should consider before investing in Sesen Bio&#8217;s capital stock. This description is summarized from, and qualified in its entirety by reference to, the Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws, which have been publicly filed with the SEC. See the section entitled &#8220;Where You Can Find More Information&#8221; on page <a href="#tWYCF">404</a> of this proxy statement/prospectus. The following information does not give effect to the proposed reverse stock split described in Proposal No. 2 in this proxy statement/prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio is authorized to issue up to 400,000,000 shares of common stock with a par value of $0.001 per share. As of January&#160;4, 2023, there were 202,759,043 shares of common stock outstanding and no shares of preferred stock outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rights of Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Voting Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Holders of Sesen Bio common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. When a quorum is present at any meeting, a plurality of the votes properly cast for election to any office shall elect to such office and a majority of the votes properly cast upon any question other than an election to an office shall decide the question, except when a larger vote is required by law, by the Sesen Bio Certificate of Incorporation or by the Sesen Bio Bylaws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and Sesen Bio Bylaws do not provide for cumulative voting rights. Because of this, the holders of a majority of the shares of Sesen Bio common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividends</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to the preferences that may be applicable to any then outstanding preferred stock, the holders of outstanding Sesen Bio common stock are entitled to receive dividends, if any, as may be declared from time to time by the Sesen Bio board of directors out of legally available funds. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Liquidation Rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of Sesen Bio&#8217;s liquidation or dissolution, the holders of Sesen Bio common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any holders of then outstanding preferred stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Other Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The terms of Sesen Bio common stock do not include any preemptive, conversion or subscription rights, nor any redemption or sinking fund provisions. Sesen Bio common stock is not subject to future calls or assessments by Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio board of directors is authorized to issue up to 5,000,000 shares of preferred stock in one or more series, with such rights, preferences and privileges as shall be determined by the Sesen Bio board of directors. The rights, preferences and privileges of the holders of Sesen Bio common stock are subject to, and may be adversely affected by, the rights of shares of any series of preferred stock that Sesen Bio may classify and issue in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fully Paid and Nonassessable</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All of Sesen Bio&#8217;s outstanding shares of common stock are fully paid and nonassessable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio Options</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of September&#160;30, 2022, there were 16,202,254 shares of Sesen Bio common stock issuable upon the exercise of outstanding Sesen Bio options, at a weighted-average exercise price of $1.83 per share. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio Restricted Stock Units</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of September 30, 2022, there were 4,695,007 shares of Sesen Bio common stock issuable upon the vesting and settlement of outstanding Sesen Bio RSUs. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">383</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tANTIT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sesen Bio Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of September 30, 2022, there were 198,535 shares of Sesen Bio common stock issuable upon the exercise of outstanding warrants, with a weighted-average exercise price of $3.57 per share. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover Effect of Sesen Bio&#8217;s Certificate of Incorporation and Bylaw Provisions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws contain provisions that could make it more difficult to complete an acquisition of Sesen Bio by means of a tender offer, a proxy contest or otherwise or the removal and replacement of its incumbent officers and directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Staggered Board; Removal of Directors.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws divide the Sesen Bio board of directors into three classes with staggered three-year terms. In addition, The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws provide that directors may be removed only for cause and only by the affirmative vote of the holders of 75% of Sesen Bio common stock present in person or by proxy and entitled to vote. Under the Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws, any vacancy on the Sesen Bio board of directors, including a vacancy resulting from an enlargement of the Sesen Bio board of directors, may be filled only by vote of a majority of Sesen Bio directors then in office. Furthermore, the Sesen Bio Certificate of Incorporation provides that the authorized number of directors may be changed only by the resolution of the Sesen Bio board of directors. The classification of the Sesen Bio board of directors and the limitations on the ability of Sesen Bio stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of Sesen Bio. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stockholder Action; Special Meeting of stockholders; Advance Notice Requirements for stockholder Proposals and Director Nominations</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws provide that any action required or permitted to be taken by Sesen Bio stockholders at an annual meeting or special meeting of stockholders may only be taken if it is properly brought before such meeting and may not be taken by written action in lieu of a meeting. The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called by the chairman of the Sesen Bio board of directors, the Sesen Bio chief executive officer or the Sesen Bio board of directors. In addition, the Sesen Bio Bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to the Sesen Bio board of directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Sesen Bio board of directors, or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to the Sesen Bio corporate secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of Sesen Bio outstanding voting securities. These provisions also could discourage a third party from making a tender offer for Sesen Bio common stock because even if the third party acquired a majority of Sesen Bio&#8217;s outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Super-Majority Voting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater&#160;percentage. The Sesen Bio Bylaws may be amended or repealed by a majority vote of the Sesen Bio board of directors or the affirmative vote of the holders of at least 75% of the votes that all Sesen Bio stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all Sesen Bio stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of the Sesen Bio Certificate of Incorporation described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware Law.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Sesen Bio is subject to the provisions of Section&#160;203 of the DGCL. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">384</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:104pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (1)&#160;shares owned by persons who are directors and also officers and (2)&#160;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">on or subsequent to the consummation of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;203 defines a business combination to include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any merger or consolidation involving the corporation and the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio common stock is listed on the Nasdaq Capital Market under the symbol &#8220;SESN.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for Sesen Bio common stock is Computershare Trust Company, Inc. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">385</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCORO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">COMPARISON OF RIGHTS OF HOLDERS OF SESEN BIO STOCK AND CARISMA STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Both Sesen Bio and Carisma are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the DGCL. If the merger is completed, Carisma stockholders will become stockholders of Sesen Bio, and their rights will be governed by the DGCL, the Sesen Bio Bylaws and the Sesen Bio Certificate of Incorporation, as amended by the amendment thereto attached to this proxy statement/prospectus as </font><font style="font-style:italic;letter-spacing:0.2pt;">Annex G</font><font style="letter-spacing:0.2pt;">, assuming Proposal No. 2 is approved by Sesen Bio stockholders at the Sesen Bio special meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table below summarizes the material differences between the current rights of Carisma stockholders under the Carisma Certificate of Incorporation and the Carisma Bylaws, and the rights of Sesen Bio stockholders, post-merger, under the Sesen Bio Certificate of Incorporation and Sesen Bio Bylaws, each as amended, as applicable, and as in effect immediately following the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While Sesen Bio and Carisma believe that the summary tables cover the material differences between the rights of their respective stockholders prior to the merger and the rights of Sesen Bio stockholders following the merger, these summary tables may not contain all of the information that is important to you. These summaries are not intended to be a complete discussion of the respective rights of Sesen Bio stockholders and Carisma stockholders and are qualified in their entirety by reference to the DGCL and the various documents of Sesen Bio and Carisma that are referred to in the summaries. You should carefully read this entire proxy statement/prospectus and the other documents referred to in this proxy statement/</font>&#8203;<font style="letter-spacing:0.2pt;">prospectus for a more complete understanding of the differences between being a stockholder of Sesen Bio or Carisma before the merger and being a stockholder of Sesen Bio after the merger. Sesen Bio has filed copies of the Sesen Bio Certificate of Incorporation and Sesen Bio Bylaws with the SEC and will send copies of the documents referred to in this proxy statement/prospectus to you upon your request. Carisma will also send copies of its documents referred to in this proxy statement/prospectus to you upon your request. See the section entitled &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Where You Can Find More Information</font><font style="letter-spacing:0.2pt;">&#8221; on page <a href="#tWYCF">404</a> of this proxy statement/prospectus. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Current Carisma Rights Versus Post-Merger Sesen Bio Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carisma (Pre-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio (Post-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;" colspan="7">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">Elections; Voting; Procedural Matters</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Authorized Capital Stock </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation authorizes the issuance of up to 14,910,158 shares of common stock, par value $0.0001 per share, and 10,946,041 shares of preferred stock, par value of $0.0001 per share. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation authorizes the issuance of up to 400,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Number of Directors </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation and the Carisma Bylaws provide that the number of directors that constitute the Carisma board of directors is established by the Carisma stockholders or the Carisma board of directors. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws provide that the number of directors that constitute the Sesen Bio board of directors is established by the Sesen Bio board of directors. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Stockholder Nominations and Proposals </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Bylaws do not contain advance notice requirements for stockholder proposals. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Bylaws provide that in order for a stockholder to make a director nomination or propose business at an annual meeting of stockholders, the stockholder must give timely written notice to the Sesen Bio </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">386</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carisma (Pre-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio (Post-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Secretary, which must be received not less than 90&#160;days nor more than 120&#160;days prior to the first anniversary of the preceding year&#8217;s annual meeting (with certain adjustments if the date of the annual meeting is advanced by more than 20&#160;days, or delayed by more than 60&#160;days, from the first anniversary of the preceding year&#8217;s annual meeting). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Quorum </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Bylaws provide that the holders of a majority in voting power of the shares of the Carisma capital stock issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Carisma board of directors in its sole discretion, or represented by proxy, shall constitute a quorum for the transaction of business. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Bylaws provide that the holders of a majority in voting power of the shares of Sesen Bio capital stock issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Sesen Bio in its sole discretion, or represented by proxy, shall constitute a quorum for the transaction of business. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Structure of Board of Directors; Term of Directors; Election of Directors </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <div>
                <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation and the Carisma Bylaws provide that the directors shall be elected at the annual meeting of stockholders. Each director holds office until the next annual meeting of stockholders or until a successor is elected and qualified, or until such director&#8217;s earlier death resignation or removal.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">The holders of record of the Carisma Series&#160;B preferred stock and Series&#160;B Special Voting preferred stock, exclusively and as a separate class, shall be entitled to elect one director, and the holders of record of the Carisma Series&#160;A preferred stock and Special Voting preferred stock, exclusively and together as a single class, shall be entitled to elect three directors. The holders of record of Carisma capital stock, exclusively and voting together as a single class, shall be entitled to elect the balance of the total number of directors. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws provide for the division of the Sesen Bio board of directors into three staggered classes. Each director shall serve for a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected, provided, however, that the term of each director shall continue until the election and qualification of such director&#8217;s successor and be subject to such director&#8217;s earlier death, resignation or removal. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">387</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carisma (Pre-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio (Post-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Removal of Directors </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation and the Carisma Bylaws provide for the removal of any one or more or all the directors, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except that directors elected by the holders of a particular class or series of stock may be removed without cause only by the vote of the holders of a majority of the outstanding shares of such class or series. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws provide for the removal of any of its directors only for cause and requires the affirmative vote of the holders of at least seventy-five&#160;percent of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Special Meetings </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Bylaws provide that special meetings of stockholders may be called at any time by only the Carisma board of directors, the Chair of the Carisma board of directors, the Carisma Chief Executive Officer, or the Carisma President, and may not be called by any other person or persons. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws provide that a special meeting of stockholders may be called only by the Sesen Bio board of directors, the Chair of the Sesen Bio board of directors or the Sesen Bio Chief Executive Officer, and may not be called by any other person or persons. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Cumulative Voting </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation provides that there shall be no cumulative voting. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation provides that there shall be no cumulative voting. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Vacancies </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation and the Carisma Bylaws provide that, subject to the rights of holders of any series of Carisma preferred stock to elect directors, unless and until filled by the stockholders, any vacancy or newly-created directorship on the Carisma board of directors may be filled by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director. A vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series. A director elected to fill a vacancy shall be elected for the unexpired term of </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws provide that any vacancy occurring on the Sesen Bio board of directors shall be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director and shall not be filled by the stockholders. A director elected to fill a vacancy shall hold office until the next election of the class for which such director shall have been chosen, subject to the election and qualification of a successor and to such director&#8217;s earlier death, resignation or removal. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">388</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:5.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carisma (Pre-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio (Post-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:144pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">such director&#8217;s predecessor in office, and a director chosen to fill a position resulting from a newly-created directorship shall hold office until the next annual meeting of stockholders and until a successor is elected and qualified, or until such director&#8217;s earlier death, resignation or removal. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Voting Stock </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:144pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Under the Carisma Certificate of Incorporation and the Carisma Bylaws, each stockholder shall have one vote for each share of stock entitled to vote held of record by such stockholder.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Each holder of Carisma preferred stock shall be entitled to cast the number of votes equal to the number of whole shares of Carisma common stock into which such shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter; provided that each holder of the Carisma Special Voting preferred stock and Series&#160;B Special Voting preferred stock shall be entitled to cast the number of votes equal to the number of votes to which the holders of the Class&#160;B Exchangeable Shares and the Class&#160;B-1 Exchangeable Shares of CARISMA Therapeutics S.&#224; r.l., or Carisma Europe, respectively, would be entitled to cast if such exchangeable shares had, before the record date for such vote, been exchanged for shares of the applicable series of Carisma preferred stock pursuant to the terms of the Amended and Restated Share Exchange and Voting Agreement, dated December&#160;22, 2020, by and among Carisma, Carisma Europe and the holders of such exchangeable shares. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Under the Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws, each stockholder shall at every meeting of the stockholders be entitled to one vote for each share of stock held by such stockholder. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">389</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carisma (Pre-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio (Post-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Stockholder Action by Written Consent </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Under the Carisma Certificate of Incorporation and the Carisma Bylaws, any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on such action were present and voted. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and Sesen Bio Bylaws provide that stockholders may not take any action by written consent in lieu of a meeting. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Notice of Stockholder Meeting </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Under the Carisma Bylaws, notice of each meeting of stockholders shall be given not less than 10 or more than 60&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting. Without limiting the manner by which notice otherwise may be given to stockholders, any notice shall be effective if given by a form of electronic transmission consented to (in a manner consistent with the DGCL) by the stockholder to whom the notice is given. The notice of all meetings shall state the place, if any, date and time of the meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting. The notice of a special meeting shall state, in addition, the purpose or purposes for which the meeting is called. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Under the Sesen Bio Bylaws, notice of each stockholder meeting must specify the place, date and time of the meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose(s) for which the meeting is called. Notice shall be given not less than 10 nor more than 60&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting. Without limiting the manner by which notice otherwise may be given to stockholders, any notice shall be effective if given by a form of electronic transmission consented to (in a manner consistent with the DGCL) by the stockholder to whom the notice is given. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Conversion Rights and Protective Provisions </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation provides that holders of Carisma preferred stock have the right to convert such shares into shares of Carisma common stock at any time at a conversion rate in accordance with the terms of the Carisma Certificate of Incorporation. In addition, upon </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation does not provide that stockholders have preemptive, conversion or other protective rights. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">390</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carisma (Pre-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio (Post-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">either (i)&#160;the closing of the sale of shares of Carisma common stock in a firm-commitment underwritten public offering in which the price is at least $46.80 per share and which results in at least $50&#160;million of proceeds or (ii)&#160;the date and time, or the occurrence of an event, specified by vote or written consent in accordance with the terms of the Carisma Certificate of Incorporation, all outstanding shares of Carisma preferred stock will be converted into shares of Carisma common stock. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Right of First Refusal </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Pursuant to an Amended and Restated Right of First Refusal and Co-Sale Agreement, dated December&#160;22, 2020, or the ROFR Agreement, certain stockholders party to the ROFR Agreement, or a Key Holder, wishing to transfer any shares of Carisma capital stock must first provide Carisma with the right to purchase such shares. In such an event, if Carisma does not elect to exercise its right of first refusal in full, certain investors party to the ROFR Agreement, or the Investors, have a secondary right of first refusal to purchase all or any portion of the shares of Carisma common stock which are proposed for sale or transfer by the Key Holders. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Sesen Bio does not have a right of first refusal in place. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Right of Co-Sale </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Pursuant to the ROFR Agreement, each Investor has a right of co-sale with respect to any Carisma capital stock proposed to be transferred or sold by any Key Holder which is not earlier purchased by Carisma by exercise of its right of first refusal (as described above) or by any Investor by exercise of their secondary right of first refusal (as described above). </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Sesen Bio does not have a right of co-sale in place. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Right of First Offer </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Pursuant to an Amended and Restated Investor Rights Agreement, dated December&#160;22, </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Sesen Bio does not have a right of first offer place. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">391</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carisma (Pre-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio (Post-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">2020, or the Investor Rights Agreement, if Carisma or Carisma Europe proposes to offer or sell certain new securities, Carisma and/or Carisma Europe, as applicable, must first offer such new securities to certain investors party to the Investor Rights Agreement. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Forum Selection </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation provides that unless Carisma consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of Carisma, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Carisma to Carisma or Carisma stockholders, (iii)&#160;any action asserting a claim against Carisma, its directors, officers or employees arising pursuant to any provision of the DGCL or the Carisma Certificate of Incorporation or the Carisma Bylaws or (iv)&#160;any action asserting a claim against Carisma, its directors, officers or employees governed by the internal affairs doctrine. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws do not provide for a specific forum. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Registration Rights </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Under the Investor Rights Agreement, certain holders of Carisma capital stock that are party to the Investor Rights Agreement have certain registration rights, including the right to demand that Carisma file a registration statement, so called &#8220;demand&#8221; registration rights, or request that their shares be covered by a registration statement that Carisma is otherwise filing, so-called &#8220;piggyback&#8221; registration rights. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <div>
                <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws do not provide registration rights to holders of Sesen Bio common stock. </font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">In connection with the closing of the Carsima pre-closing financing, the combined company has agreed to enter into a registration rights agreement to provide for the registration of the resale of the shares of common stock purchased by the investors in connection with the Carisma pre-closing financing. </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">392</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carisma (Pre-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio (Post-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;" colspan="7">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">Indemnification of Officers and Directors and Advancement of Expenses; Limitation on Personal Liability</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Indemnification; Advancement of Expenses </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation provides that Carisma shall provide indemnification of (and advancement of expenses to) directors, officers, and agents of Carisma (and any other persons to which the DGCL permits Carisma to provide indemnification), to the fullest extent permitted by applicable law through bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&#160;145 of the DGCL. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <div>
                <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation provides that Sesen Bio shall indemnify its directors and officers if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Sesen Bio, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation provides that Sesen Bio will pay the expenses incurred by or on behalf of an indemnitee in defending an action, suit, proceeding or investigation or any appeal therefrom in advance of its final disposition, provided, however, that such payment of expenses in advance of the final disposition of the proceeding will be made only upon receipt of an undertaking by or on behalf of the indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision from which there is no further right to appeal that the indemnitee is not entitled to be indemnified. </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:0pt;" colspan="7">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">Dividends</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Declaration and Payment of Dividends </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation states that the dividend rights of the holders of Carisma common stock are subject to and qualified by the rights, powers, and preferences of the holders of the Carisma preferred stock. Carisma shall not declare, pay or set aside dividends on shares of any other class or series of Carisma capital stock (other than dividends on shares of Carisma common stock payable in shares of Carisma common stock) unless (in addition to obtaining any of the consents required in the Carisma </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation provides that holders of Sesen Bio common stock are entitled to receive dividends as may be lawfully declared from time to time by the Sesen Bio board of directors. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">393</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carisma (Pre-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Sesen Bio (Post-Merger) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Certificate of Incorporation) the holders of the Carisma Series&#160;A and Series&#160;B preferred stock receive certain dividends as set forth in the Carisma Certificate of Incorporation. The Carisma Special Voting preferred stock and Series&#160;B Special Voting preferred stock shall not be entitled to receive any dividends. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:0pt;" colspan="7">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">Amendments to Certificate of Incorporation or Bylaws</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">General Provisions </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Provisions of the Carisma Certificate of Incorporation may be amended, altered or repealed in the manner prescribed by the DGCL and the Carisma Certificate of Incorporation. The Carisma Certificate of Incorporation provides that the affirmative vote of the holders of at least two-thirds of the voting power represented by the outstanding shares of the Carisma preferred stock, voting together as a single class are required to authorize amend, waive, alter or repeal any provision of the Carisma Certificate of Incorporation or the Carisma Bylaws, in a manner that adversely affects the powers, preferences or rights of the Carisma preferred stock.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">The Carisma Certificate of Incorporation and the Carisma Bylaws provide that the Carisma Bylaws may be altered, amended or repealed, in whole or in part, or new bylaws may be adopted by the Carisma board of directors or by the affirmative vote of the holders of a majority of the shares of the Carisma capital stock issued and outstanding and entitled to vote at any annual meeting of stockholders, or at any special meeting of stockholders, provided notice of such alteration, amendment, repeal or adoption of new bylaws shall have been stated in the notice of such special meeting. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:144pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Provisions of the Sesen Bio Certificate of Incorporation may be amended, altered or repealed in the manner prescribed by the DGCL and the Sesen Bio Certificate of Incorporation.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation provides that the Sesen Bio board of directors has the power to amend, alter or repeal the Sesen Bio Bylaws by the affirmative vote of a majority of the directors present at any regular or special meeting of the Sesen Bio board of directors at which a quorum is present.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">The Sesen Bio Certificate of Incorporation provides that the stockholders have the power to amend, alter or repeal the Sesen Bio Bylaws by the affirmative vote of the holders of at least seventy-five&#160;percent of the votes that all the stockholders would be entitled to cast in any annual election of directors or class of directors.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">394</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tPSOS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRINCIPAL STOCKHOLDERS OF SESEN BIO</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except where specifically noted, the following information and all of the information in this proxy statement/prospectus does not give effect to the proposed reverse stock split. The table below sets forth the beneficial ownership of Sesen Bio common stock as of January&#160;4, 2023 by the following individuals or entities: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each of Sesen Bio&#8217;s directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each of Sesen Bio&#8217;s named executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">all of Sesen Bio&#8217;s current directors and executive officers as a group; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each person or entity known by Sesen Bio to own beneficially more than 5% of the outstanding shares of Sesen Bio common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The column entitled &#8220;Percentage&#8221; is based on a total of 202,759,043 shares of Sesen Bio common stock outstanding as of January&#160;4, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to Sesen Bio common stock. Shares of Sesen Bio common stock (i)&#160;subject to Sesen Bio options that are currently exercisable or exercisable within 60&#160;days after January&#160;4, 2023 and (ii)&#160;underlying Sesen Bio RSUs that are expected to vest and settle within 60&#160;days after January&#160;4, 2023 are considered outstanding and beneficially owned by the person holding such Sesen Bio option or Sesen Bio RSU, as applicable, for the purpose of calculating the&#160;percentage ownership of that person but not for the purpose of calculating the&#160;percentage ownership of any other person. Except as otherwise set forth below, the persons and entities in this table have sole voting and investment power with respect to all of the shares of Sesen Bio common stock beneficially owned by them, subject to applicable community property laws, where applicable. Except as otherwise set forth below, the address of each beneficial owner is c/o&#160;Sesen Bio, Inc., 245 First Street, Suite 1800, Cambridge, Massachusetts 02142. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as contemplated by the merger and the Carisma pre-closing financing, Sesen Bio does not know of any arrangements the operation of which may at a subsequent date result in a change in control of Sesen Bio. </font>
        </div>
        <table style="width:456pt;height:238pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:350.01pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Beneficially Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Directors and Named Executive Officers:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jay S. Duker, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">332,120</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Peter K Honing, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">140,972</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrie L. Bourdow</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">312,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jason A. Keyes</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">312,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael A.S. Jewett, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">140,972</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,437,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Monica Forbes</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,090,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Glen MacDonald, Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">969,926</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">All current executive officers and directors as a group (10 persons)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,672,906</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">4.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Greater than 5% stockholders:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Vanguard Group</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,366,756</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:350.01pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Bradley L. Radoff, The Radoff Family Foundation, JEC II Associates, LLC, The&#160;K. Peter Heiland 2008 Irrevocable Trust and Michael Torok</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,046,704</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">8.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Represents less than 1% of the issued and outstanding shares of Sesen Bio common stock as of January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 332,120 shares of Sesen Bio common stock issuable upon the exercise of Sesen Bio options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">395</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:4pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 140,972 shares of Sesen Bio common stock issuable upon the exercise of Sesen Bio options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 312,833 shares of Sesen Bio common stock issuable upon the exercise of Sesen Bio options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 312,833 shares of Sesen Bio common stock issuable upon the exercise of Sesen Bio options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 140,972 shares of Sesen Bio common stock issuable upon the exercise of Sesen Bio options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 4,437,500 shares of Sesen Bio common stock issuable upon the exercise of Sesen Bio options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 1,090,000 shares of Sesen Bio common stock issuable upon the exercise of Sesen Bio options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 969,926 shares of Sesen Bio common stock issuable upon the exercise of Sesen Bio options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 8,672,906 shares of Sesen Bio common stock issuable upon the exercise of Sesen Bio options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Holdings for The Vanguard Group are as of December&#160;31, 2021 and are based solely on information on Schedule&#160;13G filed on February&#160;10, 2022. As reported therein, The Vanguard Group reports sole voting power over 0 shares of Sesen Bio common stock, shared voting power over 343,061 shares of Sesen Bio common stock, sole dispositive power over 11,951,290 shares of Sesen Bio common stock and shared dispositive power over 415,466 shares of Sesen Bio common stock. The address of the principal business office of The Vanguard Group is 100 Vanguard Blvd., Malvern, PA 19355. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Based solely on information provided on an amended Schedule 13D filed jointly on January&#160;5, 2023 by Bradley&#160;L. Radoff, The Radoff Family Foundation, JEC II Associates, LLC, the K. Peter Heiland 2008 Irrevocable Trust and Michael Torok. As reported therein, as of January&#160;3, 2023, Mr. Radoff reports sole voting power over 8,641,865 shares of Sesen Bio common stock, shared voting power over 0 shares of Sesen Bio common stock, sole dispositive power over 8,641,865 shares of Sesen Bio common stock and shared dispositive power over 0 shares of Sesen Bio common stock. As reported therein, as of January&#160;3, 2023, the Radoff Family Foundation reports sole voting power over 1,879,344, shared voting power over 0 shares of Sesen Bio common stock, sole dispositive power over 1,879,344 shares of Sesen Bio common stock and shared dispositive power over 0 shares of Sesen Bio common stock. As reported therein, as of January&#160;3, 2023, JEC II Associates,&#160;LLC reports sole voting power over 6,379,839 shares of Sesen Bio common stock, shared voting power over 0 shares of Sesen Bio common stock, sole dispositive power over 6,379,839 shares of Sesen Bio common stock and shared dispositive power over 0 shares of Sesen Bio common stock. As reported therein, as of November&#160;29, 2022, the K.&#160;Peter Heiland 2008 Irrevocable Trust reports sole voting power over 1,000,000 shares of Sesen Bio common stock, shared voting power over 0 shares of Sesen Bio common stock, sole dispositive power over 1,000,000 shares of Sesen Bio common stock and shared dispositive power over 0 shares of Sesen Bio common stock. As reported therein, as of January&#160;3, 2023, Mr. Torok reports sole voting power over 8,404,839 shares of Sesen Bio common stock, shared voting power over 0 shares of Sesen Bio common stock, sole dispositive power over 8,404,839 shares of Sesen Bio common stock and shared dispositive power over 0 shares of Sesen Bio common stock. The address of the principal business office of Mr. Radoff and the Radoff Family Foundation is 2727 Kirby Drive, Unit 29L, Houston, Texas 77098. The address of the principal business office of each of JEC II Associates, LLC, the K. Peter Heiland 2008 Irrevocable Trust and Mr. Torok is 68 Mazzeo Drive, Randolph, Massachusetts 02368. Mr. Radoff, the Radoff Family Foundation, JEC II Associates, LLC, the K. Peter Heiland 2008 Irrevocable Trust and Mr. Torok may be deemed to beneficially own as a group the 17,046,704 shares of Sesen Bio common stock owned in the aggregate by all of them, constituting approximately 8.4% of the outstanding shares of Sesen Bio common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">396</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tPSOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRINCIPAL STOCKHOLDERS OF CARISMA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information with respect to the beneficial ownership of Carisma capital stock on an as converted basis as of January&#160;4, 2023 by: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each of Carisma&#8217;s directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each of Carisma&#8217;s named executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">all of Carisma&#8217;s directors and executive officers as a group; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each person or entity known by Carisma to beneficially own more than 5% of Carisma capital stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The&#160;percentage of beneficial ownership prior to the merger and the Carisma pre-closing financing in the table below is based on 11,089,167 shares outstanding as of January&#160;4, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Carisma has determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules require that Carisma includes shares of Carisma common stock issuable pursuant to the exercise of Carisma options that are either immediately exercisable or exercisable within 60&#160;days of January&#160;4, 2023. These shares of Carisma common stock are deemed to be outstanding and beneficially owned by the person holding those Carisma options for the purpose of calculating the&#160;percentage ownership of that person, but they are not treated as outstanding for the purpose of calculating the&#160;percentage ownership of any other person. Unless otherwise indicated, Carisma believes that the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, based on information provided to Carisma by such persons or entities, subject to applicable community property laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise set forth below, the address of each person or entity listed in the table is c/o&#160;CARISMA Therapeutics Inc., 3675 Market Street, Suite 200, Philadelphia, Pennsylvania 19104. </font>
        </div>
        <table style="width:456pt;height:310pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:355.01pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Beneficially Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Directors and Named Executive Officers:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Margarita Chavez </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Steven Kelly</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">454,939</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.94<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., PhD.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">358,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.21<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard Morris</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">76,268</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">38,249</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D., Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sanford Zweifach</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">30,375</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">All current executive officers and directors as a group (9 persons)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">958,632</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.45<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Greater than 5% stockholders:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AbbVie Biotechnology Ltd</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,204,160</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.86<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">HealthCap VII L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,485,912</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">13.40<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with IPG</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,524,306</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">13.75<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MRL Ventures Fund, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">615,379</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.55<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SymBiosis II, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">961,492</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.67<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Trustees of the University of Pennsylvania</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">969,725</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.74<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">TPG Biotechnology Partners V, L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">841,757</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7.59<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:355.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wellington Life Sciences V GmbH &amp; Co. KG</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(14)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">998,079</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">9.00<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Represents less than 1% of the issued and outstanding shares of Carisma common stock as of January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">397</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 454,939 shares of Carisma common stock issuable upon the exercise of Carisma options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;255,000 shares of Carisma common stock and (ii)&#160;103,801 shares of Carisma common stock issuable upon the exercise of Carisma options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 76,268 shares of Carisma common stock issuable upon the exercise of Carisma options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;6,410 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock and (ii)&#160;31,839 shares of Carisma common stock issuable upon the exercise of Carisma options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 30,375 shares of Carisma common stock issuable upon the exercise of Carisma options exercisable within 60 days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;255,000 shares of Carisma common stock, (ii)&#160;6,410 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock and (iii)&#160;697,222 shares of Carisma common stock issuable upon the exercise of Carisma options exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;947,762 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;A preferred stock and (ii)&#160;256,398 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock held by AbbVie Biotechnology Ltd. AbbVie Biotechnology Ltd. holds voting and investment control over the shares. The Board of Directors of AbbVie Biotechnology Ltd. consists of Lindsey Bristow, Jonathan C. Clipper, Stephen Muldoon and Arthur Price. Each of Ms. Bristow and each of Messrs. Clipper, Muldoon and Price may be deemed to share voting and investment power with respect to the shares held by AbbVie Biotechnology Ltd. and disclaim beneficial ownership of all shares held by AbbVie Biotechnology Ltd., except to the extent of their pecuniary interest therein, if any. Margarita Chavez is employed as a Managing Director of AbbVie Ventures and is a member of the Carisma board of directors. Ms.&#160;Chavez disclaims beneficial ownership of all shares held by AbbVie Biotechnology Ltd. except to the extent of her pecuniary interest therein, if any. The business address of AbbVie Biotechnology Ltd. is Thistle House, 4 Burnaby Street, Hamilton&#160;HM&#160;11, Bermuda. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;250,647 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;A preferred stock, (ii)&#160;937,501 shares of Carisma common stock issuable upon the conversion of the Carisma special voting preferred stock and (iii)&#160;297,764 shares of Carisma common stock issuable upon the conversion of the Carisma Series&#160;B special voting preferred stock held by HealthCap VII, L.P. HealthCap VII GP SA, a Swiss registered L.C.C., is the sole general partner of HealthCap VII, L.P. and has voting and investment control over the shares. HealthCap VII GP SA disclaims beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of its pecuniary interest therein. Fabrice Bernhard is the General Manager of HealthCap VII GP SA. Dag Richter, Daniel Schafer and Frans Wuite are each Directors of HealthCap VII GP SA. Each of Messrs. Bernhard, Richter, Schafer and Wuite may be deemed to share voting and investment power with respect to the shares held by HealthCap VII L.P. and disclaim beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of their pecuniary interest therein. Bj&#246;rn Odlander is a Managing Partner of HealthCap and is a member of the Carisma board of directors. Dr.&#160;Odlander disclaims beneficial ownership of all shares held by HealthCap VII L.P. except to the extent of his pecuniary interest therein, if any. The business address of HealthCap VII L.P. is c/o&#160;HealthCap VII GP SA, Avenue Villamont 23, CH&#160;1005&#160;Lausanne Switzerland. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;(a)&#160;947,186 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;A preferred stock and (b)&#160;237,376 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock held by IPG Cayman LP, (ii)&#160;141,026 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock held by IPG USA SCO LP and (iii)&#160;198,718 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock held by CT SPV Investment LP., or collectively, the IPG entities. IP Group, Inc. has voting and investment control over the shares held by the IPG entities. The business address of the IPG entities is c/o&#160;IP Group, Inc., 1 Righter Parkway, Suite 260, Wilmington, Delaware 19803. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">398</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;480,770 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;A preferred stock and (ii)&#160;134,609 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock held by MRL Ventures Fund, LLC. MRL Ventures Fund, LLC holds investment and voting control over the shares. Peter Dudek, Sunil Patel, Dean Li, Joe Miletich, Caroline Litchfield and George Adonna are members of the investment committee of MRL Ventures Fund, LLC. Each of Messrs. Dudek, Patel, Li, Miletich, Litchfield and Adonna may be deemed to share voting and investment power with respect to the shares held by MRL Ventures Fund, LLC and disclaim beneficial ownership of all shares held by MRL Ventures Fund, LLC, except to the extent of their pecuniary interest therein. The business address of MRL Ventures Fund, LLC is One Merck Drive, Whitehouse Station, New Jersey 08889. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 961,492 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock held by SymBiosis II, LLC, which exercises voting and investment control of the shares. Chidozie Ugwumba is the Managing Partner of Symbiosis II, LLC and as such has sole voting and investment control over the shares. Mr.&#160;Ugwumba is also a member of the Carisma board of directors. The business address of Symbiosis II, LLC is 609 S.W. 8th Street, Suite 365, Bentonville, Arkansas 72712. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;490,000 shares of Carisma common stock, (ii)&#160;309,594 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;A preferred stock and (iii)&#160;170,131 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock, held by The Trustees of the University of Pennsylvania. The Board of Trustees of the University of Pennsylvania has voting and dispositive power over the shares. The Board of Trustees of the University of Pennsylvania is comprised of more than three individuals who have authority over the voting and disposition of the share. A business address of The Trustees of the University of Pennsylvania is 2929 Walnut Street, Suite 300, Philadelphia, Pennsylvania 19104. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;673,076 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;A preferred stock and (ii)&#160;168,681 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock held by TPG Biotechnology Partners V, L.P., a Delaware limited partnership. The general partner of TPG Biotechnology Partners V, L.P. is TPG Biotechnology GenPar&#160;V, L.P., a Delaware limited partnership, whose general partner is TPG Biotech GenPar V Advisors, LLC, a Delaware limited liability company, whose sole member is TPG Operating Group I, L.P., a Delaware limited partnership, whose general partner is TPG Holdings I-A, LLC, a Delaware limited liability company, whose managing member is TPG GPCo, LLC, a Delaware limited liability company, whose managing member is TPG Inc., a Delaware corporation, whose shares of Class&#160;B common&#160;stock (which represent a majority of the combined voting power of the common stock) are held by TPG Group Holdings (SBS), L.P., a Delaware limited partnership, whose general partner is TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, whose managing member is TPG GP A, LLC, a Delaware limited liability company, which is owned by entities owned by David Bonderman, James G. Coulter and Jon Winkelried. Messrs. Bonderman, Coulter and Winkelried may therefore be deemed to share voting and investment power with respect to, and thus beneficially own the securities directly held by TPG Biotechnology Partners V, L.P. Messrs. Bonderman, Coulter and Winkelried disclaim beneficial ownership of the securities directly held by TPG Biotechnology Partners V, L.P. except to the extent of their pecuniary interest therein. The address of each of TPG GP A, LLC and Messrs. Bonderman, Coulter and Winkelried is 301 Commerce Street, Suite 3300, Fort Worth, Texas&#160;76102. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;798,072 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;A preferred stock and (ii)&#160;200,007 shares of Carisma common stock issuable upon conversion of the Carisma Series&#160;B preferred stock held by Wellington Life Sciences V GmbH &amp; Co. KG, or the Wellington Fund. The Wellington Fund is represented by Wellington Life Sciences Venture Capital Consulting GmbH, or the Wellington General Partner. The Wellington General Partner holds voting and investment control over the shares. Dr. Regina Hodits and Dr. Rainer Strohmenger, in their functions as managing directors of the Wellington General Partner, have individual signatory power as well as voting and/or investment control over the shares. Dr. Regina Hodits is a member of the Carisma board of directors. Dr.&#160;Regina Hodits disclaims beneficial ownership of all shares held by the Wellington Fund except to the extent of her pecuniary interest therein, if any. The business address of the Wellington Fund and the Wellington General Partner is Tuerkenstrasse 5, 80333 Munich, Germany. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">399</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tPSOT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:100.73pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Except where specifically noted, the following information and all of the information in this proxy statement/prospectus does not give effect to the proposed reverse stock split. The table below sets forth certain information with respect to the beneficial ownership of the common stock of the combined company upon consummation of the merger based on beneficial ownership of Sesen Bio common stock and Carisma common stock as of January&#160;4, 2023 (assuming the closing of the merger occurred on January&#160;24, 2023) by: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each director of the combined company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each named executive officer of the combined company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">all of the combined company&#8217;s directors and executive officers as a group; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each person or entity expected by Carisma and Sesen Bio to become the beneficial owner of more than 5% of the common stock of the combined company upon the consummation of the merger. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The table assumes effectiveness of the Carisma pre-closing financing, an exchange ratio of 37.7924, that the closing of the merger occurred on January&#160;4, 2023 and that the conversion of the Carisma convertible note occurred immediately after the effective time of the merger. Assuming a closing date of January&#160;4, 2023, immediately prior to the merger and after the closing of the Carisma pre-closing financing and conversion of the Carisma convertible note, Carisma is expected to have 15,689,808 shares of common stock outstanding and Sesen Bio is expected to have 202,759,043 shares of common stock outstanding. Upon the closing of the merger on the assumed date of January&#160;4, 2023, the 15,689,808 shares of Carisma common stock would be converted into the right to receive an aggregate of 591,720,707 shares of Sesen Bio common stock such that there would be a total of 794,479,750 shares of common stock of the combined company outstanding upon the closing of the merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio and Carisma have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include (a)&#160;shares of Sesen Bio common stock (i)&#160;subject to Sesen Bio options that are currently exercisable or exercisable within 60&#160;days after January&#160;4, 2023 and (ii)&#160;underlying Sesen Bio RSUs that are expected to vest and settle within 60&#160;days after January&#160;4, 2023 and (b)&#160;shares of Carisma common stock issuable pursuant to the exercise of Carisma options that are either immediately exercisable or exercisable within 60&#160;days of January&#160;4, 2023. Such shares of Sesen Bio common stock or Carisma common stock are, in each case, deemed to be outstanding and beneficially owned by the person holding such Sesen Bio option, Sesen Bio RSU or Carisma option, as applicable, for the purpose of calculating the&#160;percentage ownership of that person, but they are not treated as outstanding for the purpose of calculating the&#160;percentage ownership of any other person. Except as otherwise set forth below, Sesen Bio and Carisma believe that the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. Except as otherwise set forth below, the address of each person or entity listed in the table is c/o&#160;CARISMA Therapeutics Inc., 3675 Market Street, Suite 200, Philadelphia, Pennsylvania 19104. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">400</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:316pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:350.01pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Beneficially Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Directors and Named Executive Officers:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,437,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Regina Hodits, Ph.D </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Steven Kelly</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,193,237</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.12<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael Klichinsky, Pharm.D., Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">13,559,964</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.70<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard Morris</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,882,335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Briggs Morrison, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,445,515</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bj&#246;rn Odlander, M.D., Ph.D </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Chidozie Ugwumba </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sanford Zweifach</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,147,944</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">All current executive officers and directors as a group (9 persons)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">40,666,495</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.05<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Greater than 5% stockholders:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">AbbVie Biotechnology Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">54,713,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.88<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">HealthCap VII L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">67,615,025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.50<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with IPG</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">57,607,182</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7.24<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Moderna Biotech Ventures, LLC.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">99,641,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">12.52<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SymBiosis II, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">44,089,370</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.54<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Trustees of the University of Pennsylvania</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">43,431,480</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.46<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Wellington Life Sciences V GmbH &amp; Co. KG</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(14)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">45,714,330</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.75<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.935pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Represents less than 1% of the issued and outstanding shares of common stock of the combined company as of January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 4,437,500 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 17,193,237 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;9,637,062 shares of common stock of the combined company and (ii)&#160;3,922,902 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 2,882,335 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;242,249 shares of common stock of the combined company and (ii)&#160;1,203,266 shares of common stock issuable upon the exercise of options of the combined company exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 1,147,944 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;9,879,311 shares of common stock of the combined company and (ii)&#160;30,787,183 shares of common stock of the combined company issuable upon the exercise of options of the combined company exercisable within 60&#160;days after January&#160;4, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 54,713,947 shares of common stock of the combined company held by AbbVie Biotechnology Ltd. AbbVie Biotechnology Ltd. holds voting and investment control over the shares. The Board of Directors of AbbVie Biotechnology Ltd. consists of Lindsey Bristow, Jonathan C. Clipper, Stephen Muldoon and Arthur Price. Each of Ms.&#160;Bristow and each of Messrs. Clipper, Muldoon and Price may be deemed to share voting and investment power with respect to the shares held by AbbVie Biotechnology Ltd. and disclaim beneficial ownership of all shares held by AbbVie Biotechnology </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">401</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:8pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Ltd., except to the extent of their pecuniary interest therein, if any. Margarita Chavez is employed as a Managing Director of AbbVie Ventures and is a member of the Carisma board of directors. Ms.&#160;Chavez disclaims beneficial ownership of all shares held by AbbVie Biotechnology Ltd. except to the extent of her pecuniary interest therein, if any. The business address of AbbVie Biotechnology Ltd. is Thistle House, 4 Burnaby Street, Hamilton HM 11, Bermuda. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 67,615,025 shares of common stock of the combined company held by HealthCap VII, L.P. HealthCap VII GP SA, a Swiss registered L.C.C., is the sole general partner of HealthCap VII, L.P. and has voting and investment control over the shares. HealthCap VII GP SA disclaims beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of their pecuniary interest therein. Fabrice Bernhard is the General Manager of HealthCap VII GP SA. Dag Richter, Daniel Schafer and Frans Wuite are each Directors of HealthCap VII GP SA. Each of Messrs. Bernhard, Richter, Schafer and Wuite may be deemed to share voting and investment power with respect to the shares held by HealthCap VII L.P. and disclaim beneficial ownership of all shares held by HealthCap&#160;VII L.P., except to the extent of their pecuniary interest therein. Bj&#246;rn Odlander is a Managing Partner of HealthCap and is a member of the Carisma board of directors. Dr.&#160;Odlander disclaims beneficial ownership of all shares held by HealthCap VII L.P. except to the extent of his pecuniary interest therein, if any. The business address of HealthCap VII L.P. is c/o&#160;HealthCap VII GP&#160;SA, Avenue Villamont 23, CH 1005 Lausanne Switzerland. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;44,767,441 shares of common stock of the combined company held by IPG Cayman&#160;LP, (ii)&#160;5,329,711 shares of common stock of the combined company held by IPG USA SCO LP and (iii)&#160;7,510,030 shares of common stock of the combined company held by CT SPV Investment LP, or collectively, the IPG entities. IP Group, Inc. has voting and investment control over the shares held by the IPG entities. The business address of the IPG entities is c/o&#160;IP Group, Inc., 1 Righter Parkway, Suite&#160;260, Wilmington, Delaware 19803. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 99,641,170 shares of common stock of the combined company held by ModernaTX, Inc. ModernaTX, Inc. is wholly owned by Moderna, Inc., a publicly-traded company. The business address of ModernaTX, Inc. is 200 Technology Square, Cambridge, MA 02139. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 44,089,370 shares of common stock of the combined company held by SymBiosis II, LLC, which exercises voting and investment control of the shares. Chidozie Ugwumba is the Managing Partner of Symbiosis II, LLC and as such has sole voting and investment control over the shares. Mr.&#160;Ugwumba is also a member of the Carisma board of directors. The business address of Symbiosis&#160;II, LLC is 609 S.W. 8th Street, Suite 365, Bentonville, Arkansas 72712. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 43,431,480 shares of common stock of the combined company held by The Trustees of the University of Pennsylvania. The Board of Trustees of the University of Pennsylvania has voting and dispositive power over the shares. The Board of Trustees of the University of Pennsylvania is comprised of more than three individuals who have authority over the voting and disposition of the share. A business address of The Trustees of the University of Pennsylvania is 2929 Walnut Street, Suite 300, Philadelphia, Pennsylvania 19104. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 45,714,330 shares of common stock of the combined company held by Wellington Life Sciences V GmbH &amp; Co. KG, or the Wellington Fund. The Wellington Fund is represented by Wellington Life Sciences Venture Capital Consulting GmbH, or the Wellington General Partner. The Wellington General Partner holds voting and investment control over the shares. Dr.&#160;Regina Hodits and Dr.&#160;Rainer Strohmenger, in their functions as managing directors of the Wellington General Partner, have individual signatory power as well as voting and/or investment control over the shares. Dr.&#160;Regina Hodits is a member of the Carisma board of directors. Dr.&#160;Regina Hodits disclaims beneficial ownership of all shares held by the Wellington Fund except to the extent of her pecuniary interest therein, if any. The business address of the Wellington Fund and the Wellington General Partner is Tuerkenstrasse 5, 80333 Munich, Germany. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">402</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:376pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Hogan Lovells US LLP, Philadelphia, Pennsylvania, will pass on the validity of the Sesen Bio common stock offered by this proxy statement/prospectus. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Sesen Bio, Inc. at December&#160;31, 2021 and 2020, and for each of the three&#160;years in the period ended December&#160;31, 2021, included in the Proxy Statement of Sesen Bio,&#160;Inc., which is referred to and made part of this Prospectus and Registration Statement, have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of CARISMA Therapeutics Inc. as of December&#160;31, 2021 and 2020, and for the&#160;years then ended, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December&#160;31, 2021 consolidated financial statements contains an explanatory paragraph that states that CARISMA Therapeutics Inc.&#8217;s recurring losses and negative cash flows from operations raise substantial doubt about the entity&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">403</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:117pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio files annual, quarterly and current reports, proxy statements and other information with the SEC. Sesen Bio&#8217;s SEC filings are available to the public electronically at the SEC&#8217;s website at www.sec.gov. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio also makes available free of charge on or through its website at www.ir.sesenbio.com, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after Sesen Bio electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Sesen Bio are inactive textual references, and information on those websites are not part of this proxy statement/prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this proxy statement/prospectus, Sesen Bio has filed with the SEC a registration statement on Form S-4, of which this proxy statement/prospectus is a part, under the Securities Act to register the shares of Sesen Bio common stock that Sesen Bio will issue to Carisma stockholders in the merger. This proxy statement/prospectus is a part of that registration statement and constitutes a prospectus of Sesen Bio, as well as a proxy statement of Sesen Bio for its special meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has supplied all information contained in this proxy statement/prospectus relating to Sesen Bio, and Carisma has supplied all information contained in this proxy statement/prospectus relating to Carisma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you would like to request documents from Sesen Bio or Carisma, please send a request in writing or by telephone to either Sesen Bio or Carisma at the following addresses: </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="font-weight:bold;letter-spacing:-0.2pt;">Sesen Bio, Inc.</font>
                <br >
                <font style="letter-spacing:0.2pt;">245 First Street, Suite 1800</font>
                <br >
                <font style="letter-spacing:0.2pt;">Cambridge, Massachusetts 02142</font>
                <br >
                <font style="letter-spacing:0.2pt;">Telephone: (617) 444-8550</font>
                <br >
                <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary</font>
                <br >
                <font style="letter-spacing:0.2pt;">Email: ir@sesenbio.com </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="font-weight:bold;letter-spacing:-0.2pt;">CARISMA Therapeutics Inc</font><font style="letter-spacing:0.2pt;">.</font>
                <br >
                <font style="letter-spacing:0.2pt;">3675 Market Street, Suite 200</font>
                <br >
                <font style="letter-spacing:0.2pt;">Philadelphia, PA 19104</font>
                <br >
                <font style="letter-spacing:0.2pt;">Telephone: (267) 491-6422</font>
                <br >
                <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary</font>
                <br >
                <font style="letter-spacing:0.2pt;">Email: info@carismatx.com</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you are a Sesen Bio stockholder and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the merger, including the procedures for voting your shares, you should contact Sesen Bio&#8217;s proxy solicitor: </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_mackenziepartners-bw.jpg" alt="[MISSING IMAGE: lg_mackenziepartners-bw.jpg]" height="57" width="192" >
        </div>
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">MacKenzie Partners, Inc. </font>
          <br >
          <font style="letter-spacing:0.2pt;">1407 Broadway, 27th Floor </font>
          <br >
          <font style="letter-spacing:0.2pt;">New York, New York 10018 </font>
          <br >
          <font style="letter-spacing:0.2pt;">(800) 322-2885</font>
          <br >
          <font style="letter-spacing:0.2pt;">proxy@mackenziepartners.com </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">404</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tTRNO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:560pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">TRADEMARK NOTICE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">This proxy statement/prospectus contains trademarks, service marks and trade names of Sesen Bio, Inc. and CARISMA Therapeutics Inc., including their respective names and logos. Other trademarks, service marks and trade names referred to in this proxy statement/prospectus are the property of their respective owners. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">405</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tOTMA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">OTHER MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;16(a) Beneficial Ownership Reporting Compliance</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;16(a) of the Exchange Act requires Sesen Bio&#8217;s directors, certain officers and persons who own more than 10% of Sesen Bio common stock to file reports of ownership and reports of changes in ownership of Sesen Bio common stock and other equity securities of Sesen Bio with the SEC. Directors, certain officers and greater than 10% stockholders are required by SEC regulations to furnish Sesen Bio with copies of all Section&#160;16(a) forms they file. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To Sesen Bio&#8217;s knowledge, based solely on a review of the copies of reports furnished to Sesen Bio and the written representations of Sesen Bio&#8217;s directors and officers, Sesen Bio believes that during the year ended December&#160;31, 2021, Sesen Bio&#8217;s officers, directors and greater than 10% stockholders complied with all Section&#160;16(a) filing requirements, except for the following: a Form 3 for Elly Ryu reporting her beneficial ownership upon being named a Section&#160;16 officer was filed late on May&#160;10, 2021 and a Form 4 for Jane Henderson reporting one transaction was filed late on May&#160;10, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stockholder Proposals Pursuant to Rule&#160;14a-8</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stockholders of Sesen Bio may submit proposals on matters appropriate for stockholder action at meetings of Sesen Bio stockholders in accordance with Rule&#160;14a-8 promulgated under the Exchange Act. For such proposals to be included in Sesen Bio&#8217;s proxy materials relating to the 2023 annual meeting of stockholders, all applicable requirements of Rule&#160;14a-8 must be satisfied and such proposals must have been received at Sesen Bio&#8217;s principal offices no later than December&#160;29, 2022, the date that is 120&#160;days prior to the first anniversary of the date of the proxy statement was released to stockholders in connection with the 2022 annual meeting of stockholders. If, however, the Sesen Bio 2023 annual meeting of stockholders is not held within 30&#160;days from the anniversary of the 2022 annual meeting of stockholders, then the deadline will be a reasonable time prior to the time Sesen Bio begins to print and send its proxy materials. All such proposals must comply with all applicable requirements of Rule&#160;14a-8 and, prior to consummation of the merger, should be sent to Sesen Bio&#8217;s executive offices, 245 First Street, Suite 1800 Cambridge, MA 02142, Attention: Corporate Secretary by the close of business on the required deadline. After the consummation of the merger, such proposals should be sent to the combined company&#8217;s Corporate Secretary at CARISMA Therapeutics Inc., 3675 Market Street, Suite 200, Philadelphia, PA 19104, Attention: Corporate Secretary, Email: legal@carismatx.com, by the close of business on the required deadline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nominations and Stockholder Proposals Under the Sesen Bio Bylaws</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio Bylaws also establish an advance notice procedure for nominations for election to the Sesen Bio board of directors and other matters that stockholders wish to present for action at an annual meeting of stockholders other than those to be included in the proxy statement. In general, notice must be received at Sesen Bio&#8217;s principal offices at 245 First Street, Suite 1800 Cambridge, MA 02142, Attention:&#160;Corporate Secretary, not less than 90 calendar days before nor more than 120 calendar days before the one year anniversary of the previous year&#8217;s annual meeting of stockholders. Therefore, to be presented at Sesen Bio&#8217;s 2023 annual meeting, such a proposal must be received no earlier than February&#160;22, 2023 and no later than March&#160;24, 2023. However, if the date of the annual meeting of stockholders is more than 20&#160;days earlier or more than 60&#160;days later than such anniversary date, notice must be received no earlier than 120 calendar days prior to such annual meeting of stockholders and no later than the close of business on the later of (A)&#160;90&#160;days prior to such annual meeting of stockholders and (B)&#160;10&#160;days following the day on which notice of the date of such annual meeting of stockholders was mailed or public announcement of the date of such annual meeting of stockholders was first made, whichever first occurs. If the stockholder fails to give notice by these dates, then the persons named as proxies in the proxies solicited by the Sesen Bio board of directors for the 2023 annual meeting of stockholders may exercise discretionary voting power regarding any such proposal. Stockholders are advised to review the Sesen Bio Bylaws which also specify requirements as to the form and content of a stockholder&#8217;s notice. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to satisfying the foregoing advanced notice requirements under the Sesen Bio Bylaws, to comply with the universal proxy rules under the Exchange Act, shareholders who intend to solicit proxies in support of director nominees other than the Sesen Bio&#8217;s nominees must provide notice that sets forth the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">406</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:120pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">information required by Rule&#160;14a-19 under the Exchange Act no later than April&#160;23, 2023. These requirements are separate from, and in addition to, the SEC&#8217;s requirements that a stockholder must meet in order to have a stockholder proposal included in the proxy statement. A copy of the full text of these bylaw provisions may be obtained from Sesen Bio&#8217;s website at www.ir.sesenbio.com/corporate-governance. Proposals or nominations not meeting these requirements will not be entertained at the 2023 Annual Meeting of stockholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Communications with the Sesen Bio Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Stockholders who wish to communicate with the Sesen Bio board of directors may do so by writing to Dr.&#160;Jay S. Duker, Chair of the Sesen Bio board of directors, Sesen Bio, Inc., 245 First Street, Suite 1800, Cambridge, MA 02142. Communications will be forwarded to other directors if they relate to substantive matters that the Chair of the Sesen Bio board of directors, in consultation with Sesen Bio&#8217;s legal counsel, considers appropriate for attention by the other directors. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances or matters as to which Sesen Bio tends to receive repetitive or duplicative communications. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8220;Householding&#8221;&#8201;&#8212;&#8201;Stockholders Sharing the Same Address</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC has adopted rules that permit companies and intermediaries (such as brokers) to implement a delivery procedure called &#8220;householding.&#8221; Under this procedure, multiple stockholders who reside at the same address may receive a single copy of Sesen Bio&#8217;s proxy materials unless the affected stockholder has provided other instructions. This procedure reduces printing costs and postage fees, and helps protect the environment as well. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio expects that a number of brokers with account holders who are Sesen Bio stockholders will be &#8220;householding&#8221; Sesen Bio&#8217;s proxy materials. A single set of proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from one or more of the affected stockholders. Once you have received notice from your broker that it will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. Sesen Bio stockholders may revoke their consent at any time by contacting your broker. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon written or oral request, Sesen Bio will undertake to promptly deliver a separate copy of proxy materials to any stockholder at a shared address to which a single copy of any of those documents was delivered. To receive a separate copy of proxy materials now or in the future, you may write to Sesen Bio at Sesen Bio, Inc., 245 First Street, Suite 1800 Cambridge, MA 02142, Attention: Corporate Secretary, or by calling (617) 444-8550. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any stockholders who share the same address and currently receive multiple copies of Sesen Bio&#8217;s proxy materials who wish to receive only one copy in the future can contact their broker, bank or other holder of record to request information about &#8220;householding&#8221; or Sesen Bio&#8217;s Corporate Secretary at the address or telephone number listed above.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">407</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="TOC4">&#8203;</a><a name="fISCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:318.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO SESEN BIO&#8217;S CONSOLIDATED FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:272.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:424pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Audited Consolidated Financial Statements</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tROIR"><font style="letter-spacing:0.2pt;">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tROIR">F-2</a></font> <a href="#tROIR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCBS"><font style="letter-spacing:0.2pt;">Consolidated Balance Sheets </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCBS">F-5</a></font> <a href="#tCBS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOO"><font style="letter-spacing:0.2pt;">Consolidated Statements of Operations and Comprehensive Loss </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOO">F-6</a></font> <a href="#tCSOO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOC"><font style="letter-spacing:0.2pt;">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOC">F-7</a></font> <a href="#tCSOC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOC1"><font style="letter-spacing:0.2pt;">Consolidated Statements of Cash Flows </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOC1">F-8</a></font> <a href="#tCSOC1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tNTCF"><font style="letter-spacing:0.2pt;">Notes to Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNTCF">F-9</a></font> <a href="#tNTCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Unaudited Condensed Consolidated Financial Statements</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCCBS"><font style="letter-spacing:0.2pt;">Condensed Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCCBS">F-43</a></font> <a href="#tCCBS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tCCSO"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September&#160;30, 2022 and 2021 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCCSO">F-44</a></font> <a href="#tCCSO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tCCSO1"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">September&#160;30, 2022 and 2021 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCCSO1">F-45</a></font> <a href="#tCCSO1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tCCSO2"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity for the Three and Nine Months Ended September&#160;30, 2022 and 2021 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCCSO2">F-46</a></font> <a href="#tCCSO2"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tCCSO3"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September&#160;30, 2022 and 2021 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCCSO3">F-47</a></font> <a href="#tCCSO3"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tNTCC"><font style="letter-spacing:0.2pt;">Notes to Condensed Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNTCC">F-48</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tROIR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:52pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Report of Independent Registered Public Accounting Firm</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the Shareholders and the Board of Directors of Sesen Bio, Inc. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion on the Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have audited the accompanying consolidated balance sheets of Sesen Bio, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; (deficit) equity, and cash flows for each of the three&#160;years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the three&#160;years in the period ended December&#160;31, 2021, in conformity with U.S. generally accepted accounting principles. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February&#160;28, 2022 expressed an unqualified opinion thereon. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis for Opinion</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Critical Audit Matters</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1)&#160;relates to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-bottom:5pt;margin-top:0pt;border-collapse: collapse;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:72pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:372pt;">
              <font style="letter-spacing:-0.2pt;">Fair Value of Contingent Consideration</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:72pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Description of the Matter</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:372pt;">
              <font style="letter-spacing:0.2pt;">As discussed in Notes 3 and 5 to the consolidated financial statements under the caption &#8220;Contingent Consideration,&#8221; the Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. Fluctuations in the fair value of the liability result in a charge to earnings (or loss) during the period. As of December&#160;31, 2021, the Company estimated the fair value of the contingent consideration liability as $52.0&#160;million and recorded the change in fair value of $56.8&#160;million as operating income for the year ended December&#160;31, 2021. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:72pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:372pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Auditing the fair value of the contingent consideration liability required significant auditor judgment due to the high degree of subjectivity in evaluating certain assumptions used to estimate the fair value. In particular, the fair value measurement was sensitive to the significant assumptions underlying the projected commercial sales of Vicineum and probabilities of success and timing of certain milestone events and achievements. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.5pt 0pt; width:72pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">How We Addressed the Matter in Our Audit</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.5pt 0pt; width:372pt;">
              <font style="letter-spacing:0.2pt;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the development of the significant assumptions over the Company&#8217;s process to estimate the fair value of the contingent consideration liability. This included testing controls over management&#8217;s review of the significant estimation assumptions and methods used to develop the fair value estimate, the accuracy of the calculations included within the fair value model, and the underlying data used in the model. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:72pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:372pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">To test the estimated fair value of the contingent consideration liability, our audit procedures included, among others, assessing the terms of the arrangement, evaluating the methodology used and testing the key inputs and significant assumptions discussed above. We evaluated the significant assumptions in light of observable industry and economic trends and standards, external data sources, probability of success benchmarks, and regulatory factors. Our procedures included evaluating the data sources used by management in determining its significant assumptions and included an evaluation of available information that either corroborated or contradicted management&#8217;s conclusions. In addition, we involved our valuation professionals to assess the methodology used to determine the fair value of the contingent consideration liability, which included performing corroborative fair value calculations. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:72pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:372pt;">
              <font style="letter-spacing:-0.2pt;">Impairment Evaluation of Goodwill and Indefinite-Lived Intangible Assets</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:72pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Description of the Matter</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:372pt;">
              <font style="letter-spacing:0.2pt;">As discussed in Notes 3 and 8 to the consolidated financial statements under the captions &#8220;Indefinite-Lived Intangible Assets&#8221; and &#8220;Goodwill,&#8221; the Company&#8217;s intangible assets consist of indefinite-lived, acquired in-process research and development (IPR&amp;D) worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. Goodwill on the Company&#8217;s consolidated balance sheets is the result of the Company&#8217;s acquisition of Viventia in September&#160;2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of IPR&amp;D requires management to estimate the future discounted cash flows of the underlying asset. Impairment testing of goodwill requires management to estimate the future discounted cash flows of the Company&#8217;s one reporting unit. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:245pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:72pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:372pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Auditing management&#8217;s impairment assessments required significant auditor judgment due to the high degree of subjectivity in evaluating certain assumptions used to estimate the fair value of the reporting unit for and the IPR&amp;D. In particular, the fair value estimates of goodwill and of IPR&amp;D were sensitive to the significant assumptions underlying the projected commercial sales of Vicineum. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:72pt;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">How We Addressed the Matter in Our Audit</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:372pt;">
              <font style="letter-spacing:0.2pt;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the development of the significant assumptions over the Company&#8217;s goodwill and indefinite-lived intangible asset impairment review processes. This included testing controls over management&#8217;s review of the quantitative impairment analyses of goodwill and IPR&amp;D, including the significant estimation assumptions and methods used, the accuracy of the calculations included within the valuation models, and the underlying data used in those models. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:72pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:372pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">To test the impairment evaluations over goodwill and IPR&amp;D assets, our audit procedures included, among others, evaluating the methodology and valuation models used and testing the key inputs and significant assumptions discussed above. We evaluated the significant assumptions in light of observable industry and economic trends and standards, external data sources, probability of success benchmarks, and regulatory factors. Our procedures included evaluating the data sources used by management in determining its significant assumptions and included an evaluation of available information that either corroborated or contradicted management&#8217;s conclusions. In addition, we inspected the Company&#8217;s reconciliation of the fair value of the reporting unit to the market capitalization of the Company and assessed the results. We involved our valuation professionals to assess the methodology and valuation of the discounted cash flow models, including evaluating the reasonableness of certain significant assumptions.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ Ernst &amp; Young LLP </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have served as the Company&#8217;s auditor since 2010. </font> <br ><font style="letter-spacing:0.2pt;">Boston, Massachusetts </font> <br ><font style="letter-spacing:0.2pt;">February&#160;28, 2022</font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tCBS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED BALANCE SHEETS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(In thousands, except share and per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:581pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">162,636</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">52,389</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">21,011</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,482</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">18,476</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7,478</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restricted Cash </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">3,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">205,605</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">62,867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-current assets: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">123</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Intangible assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">14,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">46,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Goodwill </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">13,064</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">13,064</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Long term prepaid expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7,192</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">123</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">349</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:30pt;font-weight:normal;">
                <font style="letter-spacing:0.2pt;">Total non-current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">35,142</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">59,956</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 2.25pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:40pt;font-weight:normal;">
                <font style="letter-spacing:0.2pt;">Total Assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">240,747</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">122,823</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities and Stockholders&#8217; Equity (Deficit)</font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,853</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,102</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">8,255</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,973</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">8,985</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">460</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">489</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">11,568</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">18,049</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-current liabilities: </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">99,855</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred tax liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,969</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">12,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenue, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other non-current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">118</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total non-current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">57,469</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">114,001</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Total Liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">69,037</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">132,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Stockholders&#8217; Equity (Deficit): </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at </font>
                <br >
                <font style="letter-spacing:0.2pt;">December&#160;31, 2021 and 2020; no shares issued and outstanding at December&#160;31, </font>
                <br >
                <font style="letter-spacing:0.2pt;">2021 and 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common stock, $0.001 par value per share; 400,000,000 and 200,000,000 shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">authorized at December&#160;31, 2021 and 2020; 199,463,645 and 140,449,647 shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">issued and outstanding at December&#160;31, 2021 and 2020, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">487,768</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">306,554</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(316,257<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(315,921<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total Stockholders&#8217; Equity (Deficit) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">171,710</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(9,227<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:normal;">
                <font style="letter-spacing:0.2pt;">Total Liabilities and Stockholders&#8217; Equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">240,747</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">122,823</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tCSOO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:251pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(In thousands, except per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:310pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:303.55pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:303.55pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0pt;text-align:left;" colspan="13">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">License and related revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">26,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">11,236</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">26,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,236</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">25,312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">29,191</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">24,663</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">29,393</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">14,302</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restructuring charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(56,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(11,180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">71,620</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">35,093</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,313</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">108,491</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from Operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,549<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(21,077<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(108,491<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other (expense) income, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">991</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss Before Taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,609<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(20,952<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(107,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Benefit (provision) from income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(1,445<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Loss and Comprehensive Loss After Taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(336<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(22,397<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(107,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deemed dividend on adjustment of exercise price of certain warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(147<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss attributable to common stockholders&#8201;&#8211;&#8201;basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(336<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(22,544<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(107,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per common share&#8201;&#8211;&#8201;basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.19<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(1.18<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:303.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average common shares outstanding&#8201;&#8211;&#8201;basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">182,323</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">118,221</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">90,929</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tCSOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:93pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT) </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(In thousands, except share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:466pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:13.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:205.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid-in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217;</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity (Deficit)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:205.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2018</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">77,456,180</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">77</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">230,154</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(186,024<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">44,207</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(107,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(107,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,237</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,237</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:205.89pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of stock options and vesting of RSAs </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">89,812</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Sales of common stock under 2014 ESPP </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">10,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:205.89pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock and common stock warrants, net of issuance costs of $2.2&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">20,410,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">27,812</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">27,833</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of common stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">6,772,928</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">5,474</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,481</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:205.89pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock under ATM Offering, net of issuance costs of $0.2&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">2,062,206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">1,934</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1,936</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">106,801,409</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">266,717</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(293,524<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(26,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(22,397<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(22,397<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,757</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,757</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">12,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Sales of common stock under 2014 ESPP </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">28,186</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of common stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">238,110</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">131</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">131</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:205.89pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock under ATM Offering, net of issuance costs of $1.2&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">33,369,942</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">33</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">37,925</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">37,958</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">140,449,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">306,554</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(315,921<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(9,227<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(336<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(336<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">5,143</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,143</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">33,610</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of common stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">2,048,059</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,124</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,126</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:205.89pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock under ATM Offering, net of issuance costs of $5.4&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">56,932,329</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">174,905</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">174,962</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:205.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">199,463,645</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">487,768</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(316,257<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">171,710</td>
            <td style="padding:0pt;padding-left:5.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tCSOC1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(In thousands)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:582.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash Flows from Operating Activities:</font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(336<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(22,397<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(107,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Adjustments to reconcile net loss to net cash used in operating activities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">85</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">122</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">219</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">5,143</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,757</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,237</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(56,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(11,180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">71,620</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in operating assets and liabilities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable (net) </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(24,493<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(17,964<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(1,304<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(5,188<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(249<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">535</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses and other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(4,424<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(2,035<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,556</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(1,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">3,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(68,878<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(30,837<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(37,521<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash Flows from Investing Activities:</font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Purchases of equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(136<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 1.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(4<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(8<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(136<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash Flows from Financing Activities:</font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:317.22pt;white-space:normal;text-align:left;">
              <div style="margin-left:40pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from issuance of common stock and common stock warrants, net of issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">27,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from exercises of common stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,126</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">131</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,481</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:40pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from issuance of common stock under ATM Offering, net </font>
                <br >
                <font style="letter-spacing:0.2pt;">of issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">174,962</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">37,958</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,936</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from exercises of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from sale of common stock pursuant to ESPP </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">176,129</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">38,113</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">35,356</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net increase (decrease) in cash, cash equivalents and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">107,247</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">7,268</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(2,301<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents and restricted cash&#8201;&#8211;&#8201;beginning of period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">55,409</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">48,141</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">50,442</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents and restricted cash&#8201;&#8211;&#8201;end of period </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">162,656</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">55,409</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">48,141</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Reconciliation of cash, cash equivalents and restricted cash:</font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">162,636</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">52,389</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">48,121</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Short term restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Long term restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:50pt;font-weight:normal;">
                <font style="letter-spacing:0.2pt;">Total cash, cash equivalents and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">162,656</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">55,409</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">48,141</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Supplemental cash flow disclosure: </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Cash paid for amounts included in the measurement of lease </font>
                <br >
                <font style="letter-spacing:0.2pt;">liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">174</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">154</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Supplemental disclosure of non-cash operating activities: </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Right-of-use assets related to the adoption of ASC 842 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">236</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Right-of-use assets obtained in exchange for lease obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">290</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Supplemental disclosure of non-cash financing activities: </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:317.22pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Deemed Dividend on adjustment of exercise price on certain </font>
                <br >
                <font style="letter-spacing:0.2pt;">warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">147</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements.</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tNTCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1.&nbsp;&nbsp;&nbsp;DESCRIPTION OF BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio, Inc. (&#8220;Sesen&#8221; or the &#8220;Company&#8221;), a Delaware corporation formed in February&#160;2008, is a late-stage clinical company advancing targeted fusion protein therapeutics (&#8220;TFPTs&#8221;) for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">TM</font><font style="letter-spacing:0.2pt;">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (&#8220;EpCAM&#8221;) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with bacillus Calmette-Gu&#233;rin (&#8220;BCG&#8221;). The Company has an ongoing single-arm, multi-center, open-label Phase&#160;3 VISTA clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the &#8220;VISTA Trial&#8221;). The VISTA Trial completed enrollment in April&#160;2018 with a total of 133 patients. On December&#160;18, 2020, the Company submitted its completed Biologics License Application (the &#8220;BLA&#8221;) for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration (&#8220;FDA&#8221;). On February&#160;12, 2021, the FDA notified the Company that it has accepted for filing the BLA. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) date for a decision on the BLA of August&#160;18, 2021. On July&#160;13, 2021, the Company participated in a productive Late-Cycle Meeting with the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. In the meeting, the FDA confirmed that there was no Advisory Committee meeting planned at that time, and that no post-marketing requirements, including a confirmatory trial, had been identified at that time. Also in the meeting, the Company and the FDA discussed remaining questions related to manufacturing facilities inspection, product quality information requests and additional information related to chemistry, manufacturing and controls (&#8220;CMC&#8221;), and a timeline to submit additional supporting information was agreed upon. On August&#160;13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company participated in Type A Meetings with the FDA on October&#160;29, 2021 and December&#160;8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Viventia Acquisition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Viventia&#8221;), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0&#160;million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, a director of the Company until his retirement in July&#160;2019. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i)&#160;a one-time milestone payment of $12.5&#160;million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii)&#160;a one-time milestone payment of $7.0&#160;million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii)&#160;a one-time milestone payment of $3.0&#160;million payable upon the first sale of the Purchased Product in Japan; and (iv)&#160;quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i)&#160;December&#160;31, 2033, and (ii)&#160;fifteen&#160;years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven&#160;years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company&#8217;s board of directors. However, as of December&#160;31, 2021, none of these individuals are active employees or members of the Company&#8217;s board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2021, the Company had cash and cash equivalents of $162.6&#160;million and an accumulated deficit of $316.3&#160;million. The Company incurred negative cash flows from operating activities of $68.9&#160;million, $30.8&#160;million and $37.5&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. Since the Company&#8217;s inception, it has received no revenue from sales of its products, and the Company anticipates that operating losses will continue for the foreseeable future as it seeks to address the issues raised in the CRL it received for a BLA for Vicineum for the treatment of BCG unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, complete the follow-up stage of the ongoing Phase&#160;3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, complete any additional clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and seek marketing approval from the FDA and the European Commission and, if approved, commercialize Vicineum. The Company has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering (&#8220;IPO&#8221;), follow-on public offerings, sales effected in &#8220;at-the-market&#8221; &#8203;(&#8220;ATM&#8221;) offerings, commercialization partnership and out-license agreements. See &#8220;Note 12. Stockholders&#8217; Equity&#8221; below for information regarding the Company&#8217;s recently completed equity financings. Management believes that the Company&#8217;s cash and cash equivalents as of December&#160;31, 2021 will be sufficient to fund the Company&#8217;s current operating plan for at least the next twelve&#160;months from the date these consolidated financial statements were issued. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Funding Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s future success is dependent on its ability to develop, and if approved, commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and ultimately upon its ability to attain profitable operations. In order to commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the Company needs to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of its product candidates, raising additional capital, development and commercialization by its competitors of new technological innovations, protection of proprietary technology and market acceptance of its products. The successful discovery, development and, if approved, commercialization of product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, requires substantial working capital, and the Company expects to seek additional funds through equity or debt financings or through additional outside of United States (&#8220;OUS&#8221;) business development partnerships, collaborations, licensing transactions or other sources. The Company may be unable to obtain equity or debt financings or enter into additional OUS business development partnerships, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">collaborations or licensing transactions at favorable terms, or at all, and, if necessary, may be required to implement cost reduction strategies. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company will incur substantial expenses if and as it: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">addresses the issues identified in the CRL it received from the FDA for its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the European Medicines Agency&#8217;s (&#8220;EMA&#8221;) Withdrawal Assessment Report, which the Company expects will include the completion of an additional Phase&#160;3 clinical trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seeks marketing approvals for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establishes and implement sales, marketing and distribution capabilities and scale up and validate external manufacturing capabilities to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintains, expands and protects its intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">hires additional clinical, regulatory, quality control, scientific and management personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expands its operational, financial and management systems and personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conducts research and pre-clinical and clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and its other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seeks to discover and develop additional product candidates; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in-licenses or acquires the rights to other products, product candidates or technologies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s future capital requirements will depend on many factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, initiation, progress, timing, costs and results of laboratory testing and clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and its other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ongoing COVID-19 pandemic and its impact on the Company&#8217;s business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Company&#8217;s ability to establish additional OUS business development partnerships, collaborations or licensing arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for its product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of the implementation of commercial-scale manufacturing activities, including those associated with the manufacturing process and technology transfer to third-party manufacturers to facilitate such commercial-scale manufacturing of Vicineum; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of establishing and implementing sales, marketing and distribution capabilities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property rights and defending any intellectual property-related claims; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Company&#8217;s obligation to make milestone, royalty and other payments to third-party licensors under its licensing agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which the Company in-licenses or acquires rights to other products, product candidates or technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the outcome, timing and cost of regulatory review by the FDA, EMA and comparable non-US regulatory authorities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including the potential for the FDA, EMA or comparable non-US regulatory authorities to require that the Company perform more studies or clinical trials than those that it currently expects to perform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Company&#8217;s ability to achieve certain future regulatory, development and commercialization milestones under its out-license and OUS business development partnership agreements </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effect of competing technological and market developments; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the revenue, if any, received from commercial sales of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Until such time, if ever, as the Company can generate substantial product revenues from commercial sales, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic collaborations, OUS business development partnership agreements, partnerships, alliances, and licensing arrangements. The Company does not have any committed external source of funds other than the amounts payable under the license agreement with F.&#160;Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) and the license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;). To the extent the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting the Company&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises additional funds through government or other third-party funding, strategic OUS business development partnerships, collaborations, alliances or licensing arrangements, the Company may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. If the Company is unable to raise additional funds when needed, the Company may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The COVID-19 pandemic has negatively impacted the global economy, disrupted business operations and created significant volatility and disruption to financial markets. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on the Company&#8217;s operations, and on the global economy as a whole. The extent and duration of the pandemic could continue to disrupt global markets and may affect the Company&#8217;s ability to raise additional capital in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2.&nbsp;&nbsp;&nbsp;BASIS OF PRESENTATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates (&#8220;ASUs&#8221;), promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Principles of Consolidation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Currency Translation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The functional currency of the Company and each of its subsidiaries is the US dollar. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">3.&nbsp;&nbsp;&nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company&#8217;s primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company&#8217;s corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents and accounts receivable. As of December&#160;31, 2021 and 2020, the Company limited its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Property and Equipment</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of five&#160;years for lab equipment, four&#160;years for furniture and fixtures, three&#160;years for computer equipment and software and the lesser of five&#160;years or the remaining lease term for leasehold improvements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indefinite-Lived Intangible Assets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s intangible assets consist of indefinite-lived, acquired in-process research and development (&#8220;IPR&amp;D&#8221;) worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum&#8217;s commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of BCG-unresponsive NMIBC is not obtained, the Company will immediately expense the related capitalized cost. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/</font>&#8203;<font style="letter-spacing:0.2pt;">statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company&#8217;s marketing authorization application (&#8220;MAA&#8221;), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum US rights was fully impaired as of September&#160;30, 2021. The $31.7&#160;million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of the Company&#8217;s intangible asset of Vicineum EU rights, this asset was not impaired as of September&#160;30, 2021. At that time, management assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and probability of clinical and regulatory success (&#8220;POS&#8221;) assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#8217;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June&#160;30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company&#8217;s previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. The Company participated in Type A Meetings with the FDA on October&#160;29, 2021 and December&#160;8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Based upon the outcome of these meetings, the Company plans to conduct an additional Phase&#160;3 clinical trial. Also, during the Clinical Type A Meeting, the Company aligned with FDA to include patients with less than adequate BCG into its new clinical trial. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company did not recognize any impairment charges during the year ended December&#160;31, 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Goodwill</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Goodwill on the Company&#8217;s consolidated balance sheets is the result of the Company&#8217;s acquisition of Viventia in September&#160;2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit&#8217;s carrying value, including goodwill. The Company has only one reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021. While an impairment was recognized in one of the Company&#8217;s intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September&#160;30, 2021. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October and December&#160;2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase&#160;3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March&#160;28, 2022, in which we expect to discuss the study protocol for the additional Phase&#160;3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&#160;31, 2021. Management believes the Company has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. The Company will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contingent Consideration</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September&#160;2016. See &#8220;Note 1. Description of Business&#8221; for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level&#160;3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October and December&#160;2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase&#160;3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March&#160;28, 2022, in which we expect to discuss the study protocol for the additional Phase&#160;3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company&#8217;s revenue projection models are timing of product launch and probabilities of clinical and regulatory success (&#8220;POS&#8221;); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company plans to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December&#160;2033. The discount rate applied to the 2% earnout is derived from the Company&#8217;s estimated weighted-average cost of capital (&#8220;WACC&#8221;), which has fluctuated from 8.8% as of December&#160;31, 2020, to 7.8% as of March&#160;31, 2021, 6.8% as of June&#160;30, 2021, 8.6% as of September&#160;30, 2021, and 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&#160;31, 2020, to 7.4% as of March&#160;31, 2021, 6.6% as of June&#160;30, 2021, 7.5% as of September&#160;30, 2021, and 8.0% as of December&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Effective January&#160;1, 2019, the Company adopted ASC Topic 842, </font><font style="font-style:italic;letter-spacing:0.2pt;">Leases</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 842&#8221;) using the optional transition method outlined in ASU No. 2018-11, </font><font style="font-style:italic;letter-spacing:0.2pt;">Leases (Topic 842), Targeted Improvements</font><font style="letter-spacing:0.2pt;">. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. The reported results for the year ended December&#160;31, 2021, 2020 and 2019 reflect the application of ASC 842 guidance, while the reported results for priors were prepared in accordance with the previous ASC Topic 840, </font><font style="font-style:italic;letter-spacing:0.2pt;">Leases</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 840&#8221;) guidance. The adoption of ASC 842 resulted in the recognition of operating lease right-of-use assets and corresponding lease liabilities of $0.2&#160;million on the Company&#8217;s consolidated balance sheet as of January&#160;1, 2019. The adoption of this guidance did not have a material impact on the Company&#8217;s financial condition, results of operations or cash flows; however, the adoption did result in significant changes to the Company&#8217;s financial statement disclosures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As part of the adoption of ASC 842, the Company utilized certain practical expedients outlined in the guidance. These practical expedients include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Accounting policy election to use the short-term lease exception by asset class; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Election of the practical expedient package during transition, which includes: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8212;</font>
          <br >
        </div>
        <div style=" margin-top:7.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">An entity need not reassess whether any expired or existing contracts are or contain leases; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8212;</font>
          <br >
        </div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8212;</font>
          <br >
        </div>
        <div style=" margin-top:7.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">An entity need not reassess initial direct costs for any existing leases. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s lease portfolio as of the adoption date and as of December&#160;31, 2021 includes: a property lease for manufacturing, laboratory, warehouse and office space in Winnipeg, Manitoba, a property lease for its headquarters in Cambridge, MA, and a property lease for office space in Philadelphia, PA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#8217;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company&#8217;s consolidated balance sheet. The short-term and long-term liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#8217;s consolidated balance sheet. As of December&#160;31, 2021, the Company did not have any finance leases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. Existing leases in the Company&#8217;s lease portfolio as </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">of the adoption date were valued as of January&#160;1, 2019. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Costs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Share-Based Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives&#8217; stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#8217;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#8217;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The fair value of each grant of options during the&#160;years ended December&#160;31, 2021, 2020 and 2019 was determined using the following methods and assumptions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Due to the lack of historical exercise data and given the plain vanilla nature of the options granted by the Company, the expected term is determined using the &#8220;simplified&#8221; method, as prescribed in SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 107 (&#8220;SAB 107&#8221;), whereby the expected life equals the arithmetic average of the vesting term (generally four&#160;years) and the original contractual term (ten&#160;years) of the option, taking into consideration multiple vesting tranches. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-Free Interest Rate.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Volatility.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company&#8217;s own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividend Yield.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The dividend yield is 0% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income Taxes</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss (&#8220;NOL&#8221;) and research and development credit (&#8220;R&amp;D credit&#8221;) carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2021 and 2020, the Company did not have any uncertain tax positions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue Recognition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company records revenue from out-license agreements and OUS business development partnership agreements, including the License Agreement with Roche and its OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January&#160;1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1)</font>
          <br >
        </div>
        <div style=" margin-top:7.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Identification of the contract; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2)</font>
          <br >
        </div>
        <div style=" margin-top:7.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3)</font>
          <br >
        </div>
        <div style=" margin-top:7.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Measurement of the transaction price, including the constraint on variable consideration; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">4)</font>
          <br >
        </div>
        <div style=" margin-top:7.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Allocation of the transaction price to the performance obligations; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">5)</font>
          <br >
        </div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Recognition of revenue when or as the Company satisfies each performance obligation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Development and Regulatory Milestones and Other Payments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1)&#160;the terms of milestone and royalty payments relate specifically to the license and (2)&#160;allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase&#160;II clinical trial. The Company invoiced Roche $20&#160;million with payment terms of 30&#160;days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. Management evaluated the transaction under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company recorded $20&#160;million as license revenue and accounts receivables in the fourth quarter of 2021. In January&#160;2022, the payment of $20&#160;million was received. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.71pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognized $26.5&#160;million of license revenue related to the Roche, Qilu and MENA License Agreements during the year ended December&#160;31, 2021 and $11.2&#160;million of license revenue related to the Qilu License Agreement during the year ended December&#160;31, 2020. </font>
        </div>
        <div style="margin-top:10.71pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">4.&nbsp;&nbsp;&nbsp;RECENT ACCOUNTING PRONOUNCEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Adopted in 2021</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2019, the FASB issued ASU No. 2019-12, </font><font style="font-style:italic;letter-spacing:0.2pt;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font><font style="letter-spacing:0.2pt;"> (&#8220;ASU 2019-12&#8221;). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January&#160;1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows. </font>
        </div>
        <div style="margin-top:10.72pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">5.&nbsp;&nbsp;&nbsp;FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s consolidated balance sheets approximated their fair values as of December&#160;31, 2021 and 2020 due to their short-term nature. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.62pt; margin-bottom:0pt; text-align:left; width:41pt;white-space:nowrap;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Level&#160;1</font><font style="letter-spacing:0.2pt;">:</font>
          <br >
        </div>
        <div style=" margin-top:5.62pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:61pt;">
          <font style="letter-spacing:0.2pt;">Inputs are quoted prices for identical instruments in active markets, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.61pt; margin-bottom:0pt; text-align:left; width:41pt;white-space:nowrap;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Level&#160;2</font><font style="letter-spacing:0.2pt;">:</font>
          <br >
        </div>
        <div style=" margin-top:5.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:61pt;">
          <font style="letter-spacing:0.2pt;">Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.62pt; margin-bottom:0pt; text-align:left; width:41pt;white-space:nowrap;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Level&#160;3</font><font style="letter-spacing:0.2pt;">:</font>
          <br >
        </div>
        <div style=" margin-top:5.62pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:61pt;">
          <font style="letter-spacing:0.2pt;">Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.52pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following tables set forth the carrying amounts and fair values of the Company&#8217;s financial instruments measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020 (in thousands): </font>
        </div>
        <table style="width:456pt;height:146.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:214.14pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value Measurement Based on </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carrying </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Quoted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Prices in </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Active</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Markets</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;1) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Significant </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Other </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Observable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inputs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;2) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Significant </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unobservable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inputs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;3) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Money market funds (cash equivalents) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,382</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,382</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,382</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration&#8201;&#8211;&#8201;short term </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration&#8201;&#8211;&#8201;long term </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:158.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:214.14pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value Measurement Based on </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carrying </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Quoted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Prices in </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Active</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Markets</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;1) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Significant </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Other </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Observable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inputs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;2) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Significant </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unobservable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inputs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;3) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:214.14pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:214.14pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Money market funds (cash equivalents) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,374</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,374</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,374</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:214.14pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:214.14pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,985</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,985</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,985</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:214.14pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">99,855</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">99,855</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.125pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">99,855</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the year ended December&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contingent Consideration</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2025 to 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 8.0% to 9.3% as of December&#160;31, 2021 and 8.4% to 8.8% as of December&#160;31, 2020. There have been no changes to the valuation methods utilized during the year ended December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary by quarter of the change in the fair value of the Company&#8217;s contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:416pt;height:164pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">108,840</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value included in loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">48,160</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">157,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value included in loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">13,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at June&#160;30, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">170,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value included in loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(114,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at September&#160;30, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">56,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value included in loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(4,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at December&#160;31, 2021, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at December&#160;31, 2021, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary of the change in the fair value of the Company&#8217;s total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2021. </font>
        </div>
        <table style="width:416pt;height:55.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">108,840</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration&#8201;&#8211;&#8201;short term </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration&#8201;&#8211;&#8201;long term </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(47,855<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December&#160;2033. The discount rate applied to the 2% earnout is derived from the Company&#8217;s WACC, which has fluctuated from 8.8% as of December&#160;31, 2020, to 7.8% as of March&#160;31, 2021, 6.8% as of June&#160;30, 2021, 8.6% as of September&#160;30, 2021, and 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&#160;31, 2020, to 7.4% as of March&#160;31, 2021, 6.6% as of June&#160;30, 2021, 7.5% as of September&#160;30, 2021, and 8.0% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $56.8&#160;million for the year ended December&#160;31, 2021 was driven by the receipt of the CRL from the FDA, in which the FDA determined that it could not approve the BLA for Vicineum in its present form, and the Company&#8217;s withdrawal of its MAA with EMA. In October and December&#160;2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase&#160;3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March&#160;28, 2022, in which we expect to discuss the study protocol for the additional Phase&#160;3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Incorporating the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company&#8217;s revenue projection models are timing of commercial product launch and probabilities of clinical and regulatory success; the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL and the Company&#8217;s withdrawal of its MAA. The Company plans to conduct an additional Phase&#160;3 clinical trial in order to resubmit a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which will lead to delays in the start of commercialization globally. The Company has assessed a commercialization timeline assumption and applied a probability to each outcome based on management&#8217;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates as a result of these meetings, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">6.&nbsp;&nbsp;&nbsp;RECEIVABLES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The accounts receivable balance as of December&#160;31, 2021 is $21.0&#160;million, comprised primarily of a $20&#160;million milestone achieved in December&#160;2021 due to Roche initiating a Phase&#160;II clinical trial. The Company invoiced Roche $20&#160;million with payment terms of 30&#160;days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January&#160;2022 the payment of $20&#160;million was received. Additionally, in June&#160;2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a &#8220;Technology Transfer&#8221;. As such, the Company recorded $0.9&#160;million of revenue and accounts receivable for the additional purchase price resulting from Qilu&#8217;s obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The other receivable balance as of December&#160;31, 2021 is $3.5&#160;million. The Company recorded $3.4&#160;million to other receivables in the fourth quarter of 2021 for German VAT recovery related to drug substance sent to Baxter. The Company received a payment for $1.8&#160;million in January&#160;2022 and expects to collect the remaining balance. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accounts receivable and other receivable balances as of December&#160;31, 2020 were de minims. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7.&nbsp;&nbsp;&nbsp;PROPERTY AND EQUIPMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the composition of property and equipment, net as of December&#160;31, 2021 and 2020 (in thousands): </font>
        </div>
        <table style="width:416pt;height:143pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lab equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">569</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">570</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">99</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">97</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">32</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, gross </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,009</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,004</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Less: accumulated depreciation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(966<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(881<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total Property and Equipment, Net</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">123</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.71pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Depreciation expense was $0.1&#160;million, $0.1&#160;million and $0.2&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">8.&nbsp;&nbsp;&nbsp;INTANGIBLES AND GOODWILL</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intangibles</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Intangible assets on the Company&#8217;s consolidated balance sheet are the result of the Viventia Acquisition in September&#160;2016. The following table sets forth the composition of intangible assets as of December&#160;31, 2021 and 2020 (in thousands): </font>
        </div>
        <table style="width:416pt;height:82.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:326.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:326.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:326.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">IPR&amp;D intangible assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:326.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vicineum United States rights </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:326.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vicineum European Union rights </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">14,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">14,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:326.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total Intangibles</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">14,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">46,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.81pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The fair value of the acquired intangible assets for the US and EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August&#160;2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, the Company&#8217;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September&#160;30, 2021. The $31.7&#160;million of impairment charges as of September&#160;30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management&#8217;s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June&#160;30, 2019, wherein management determined that both the global market size </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company&#8217;s previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In October and December&#160;2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase&#160;3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March&#160;28, 2022, in which we expect to discuss the study protocol for the additional Phase&#160;3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum EU rights was not impaired as of December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company did not recognize any impairment charges during the year ended December&#160;31, 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Goodwill</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Goodwill on the Company&#8217;s consolidated balance sheet is the result of the Viventia Acquisition in September&#160;2016. Goodwill had a carrying value of $13.1&#160;million as of December&#160;31, 2021 and 2020. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, a quantitative impairment analysis was conducted during the third quarter of 2021, in advance of the Company&#8217;s typical annual assessment date of October&#160;1. While an impairment was recognized in one of its intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September&#160;30, 2021, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately 45%. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In October and December&#160;2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase&#160;3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March&#160;28, 2022, in which we expect to discuss the study protocol for the additional Phase&#160;3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&#160;31, 2021. The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in the Company&#8217;s current development profile (ranging from 45% to 55% globally) also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2020. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">9.&nbsp;&nbsp;&nbsp;ACCRUED EXPENSES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the composition of accrued expenses as of December&#160;31, 2021 and 2020 (in thousands): </font>
        </div>
        <table style="width:416pt;height:112.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,841</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,372</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payroll-related expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">2,967</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,892</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Restructuring charge related </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,497</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Professional fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,941</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">684</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Total Accrued Expenses</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">8,255</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,973</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.71pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">10.&nbsp;&nbsp;&nbsp;COMMITMENTS AND CONTINGENCIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Proceedings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;19, 2021, August&#160;31, 2021, and October&#160;7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints allege violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#8217; fees. On October&#160;29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November&#160;1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November&#160;24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December&#160;13, 2021, but the court has not yet ruled on that motion. On December&#160;6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder on the same theory as the prior complaints. Defendants&#8217; response to the Amended Complaint is due to be filed on March&#160;7, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2021 and September&#160;24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January&#160;12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers in the US District </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Court for the District of Massachusetts, with the Company named as nominal defendant, but no defendant has yet been served. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October&#160;18, 2021, the court consolidated the two federal cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December&#160;22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. Defendants intend to seek a similar stay of the state court derivative litigation in the event any defendant is served. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Employment Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has entered into employment agreements and offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">11.&nbsp;&nbsp;&nbsp;LEASES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company accounts for operating leases under ASC Topic 842, </font><font style="font-style:italic;letter-spacing:0.2pt;">Leases.</font><font style="letter-spacing:0.2pt;"> The Company&#8217;s lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September&#160;2020, the Company entered into an extension of this lease for an additional two&#160;years, through September&#160;2022, with a right to extend the lease for one subsequent three-year term. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,300 at exchange rates in effect on December&#160;31, 2021). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,300 at exchange rates in effect on December&#160;31, 2021). Operating lease cost under this lease, including the related operating costs, were $0.3&#160;million and $0.3&#160;million for the year ended December&#160;31, 2021 and $0.3&#160;million and $0.3&#160;million for the year ended December&#160;31, 2020, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within other assets on the Company&#8217;s consolidated balance sheets. The short-term lease liability is recorded in other current liabilities and the long-term lease liability is recorded in other liabilities on the Company&#8217;s consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the term of the lease. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every three&#160;months to six&#160;months and currently extend through June&#160;2022 and May&#160;2022, respectively. The minimum monthly rent for these office spaces is $2,100 and $18,400, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The components of lease cost for the&#160;years ended December&#160;31, 2021 and 2020 is as follows (in thousands): </font>
        </div>
        <table style="width:416pt;height:78pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:264.81pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:264.81pt;text-align:left;">
              <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Lease Cost:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:264.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease (including related operating costs) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">327</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">301</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:264.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Short term property leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">262</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">261</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:264.81pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total lease costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">589</div>
            </td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">562</div>
            </td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:62.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:264.81pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:264.81pt;">
              <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Supplemental Information:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average remaining lease term (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.75</td>
            <td style="padding:0pt;padding-left:22.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.75</td>
            <td style="padding:0pt;padding-left:22.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average discount rate&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">12<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:22.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">12<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:22.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.1pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the Company&#8217;s future minimum lease payments under non-cancelable leases as of December&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:416pt;height:78pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:340.41pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:340.41pt;">
              <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Minimum Lease Payments:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:340.41pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total future minimum lease payments (2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">129</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:340.41pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Less: Amounts representing present value adjustment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:340.41pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease liabilities, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">124</div>
            </td>
            <td style="padding:0pt;padding-left:21.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.1pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12.&nbsp;&nbsp;&nbsp;STOCKHOLDERS&#8217; EQUITY DEFICIT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Financings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">ATM Offering</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2019, the Company entered into an Open Market Sale Agreement </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">SM</font><font style="letter-spacing:0.2pt;"> (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time (the &#8220;ATM Offering&#8221;) for an aggregate sales price of up to $35&#160;million through Jefferies. In October&#160;2020 and February&#160;2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $50.0&#160;million and $34.5&#160;million, respectively. In June&#160;2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July&#160;2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement. Sales are made by any method that is deemed to be an ATM offering as defined in Rule&#160;415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for the Company&#8217;s common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company raised $175.0&#160;million of net proceeds from the sale of 56.9&#160;million shares of common stock at a weighted-average price of $3.17 per share during the year ended December&#160;31, 2021, compared to $38.0&#160;million of net proceeds from the sale of 33.4&#160;million shares of common stock at a weighted-average price of $1.17 per share during the year ended December&#160;31, 2020. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $5.4&#160;million and $1.2&#160;million during the year ended December&#160;31, 2021 and 2020, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">June&#160;2019 Financing</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2019, the Company raised $27.8&#160;million of net proceeds from the sale of 20.4&#160;million shares of common stock and accompanying warrants to purchase an additional 20.4&#160;million shares of common stock in an underwritten public offering (the &#8220;June&#160;2019 Financing&#8221;). The combined purchase price for each </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">share of common stock and accompanying warrant was $1.47. Subject to certain ownership limitations, the warrants issued in the June&#160;2019 Financing were exercisable immediately upon issuance at an exercise price of $1.47 per share, subject to adjustments as provided under the terms of such warrants, and had a one-year term that expired on June&#160;21, 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;), the Company is authorized to issue 5.0&#160;million shares of &#8220;blank check&#8221; preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company&#8217;s common stock. The Company had no preferred stock issued and outstanding as of December&#160;31, 2021 and 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Following approval by the Company&#8217;s stockholders on May&#160;3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which 199&#160;million and 140&#160;million shares were issued and outstanding as of December&#160;31, 2021 and 2020, respectively. In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2021 and 2020 (in thousands): </font>
        </div>
        <table style="width:456pt;height:142.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shares of common stock issued </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">199,464</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">140,450</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Shares of common stock reserved for issuance for: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,247</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">15,703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,147</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">RSUs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Shares available for grant under 2014 Stock Incentive Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">8,933</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,863</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Shares available for sale under 2014 Employee Stock Purchase Plan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">2,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total shares of common stock issued and reserved for issuance</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">229,640</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">157,707</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, </font><font style="letter-spacing:0.2pt;">Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Own Equity</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 815-40&#8221;)</font><font style="font-style:italic;letter-spacing:0.2pt;">.</font><font style="letter-spacing:0.2pt;"> The following table sets forth the Company&#8217;s warrant activity for the year ended December&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:456pt;height:108pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:114.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Issued </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:41.92pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Expiration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:20.74pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Issued </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Exercised) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:37.92pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Cancelled) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:114.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jun-2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.47</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:41.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Jun-2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:20.74pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:37.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mar-2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.55<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Mar-2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,705</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.74pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,573<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:37.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">132</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nov-2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.55<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Nov-2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">487</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.74pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(475<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:37.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">May-2015 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">11.83</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Nov-2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.74pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:37.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:114.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nov-2014 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:17.25pt; text-align:right; white-space:nowrap;">11.04</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:41.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Nov-2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.5pt 0pt 2.5pt 0pt; width:20.74pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.5pt 0pt 2.5pt 0pt; width:37.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:114.65pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:41.92pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">2,247</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3pt double #000000;padding:3.25pt 0pt 2.5pt 0pt; width:20.74pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,048<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3pt double #000000;padding:3.25pt 0pt 2.5pt 0pt; width:37.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.2pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Exercise price shown (i)&#160;reflects modification described below and (ii)&#160;subject to further adjustment based on down round provision added by amendment described below. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2021, the Company received proceeds of $1.1&#160;million from the exercises of 1.6&#160;million 2018 Warrants and 0.5&#160;million 2017 Warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrant Modifications</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2019, the Company entered into transactions with holders of its outstanding 2018 Warrants and 2017 Warrants to purchase the Company&#8217;s common stock. At such time, the 2018 Warrants and 2017 Warrants utilized the same form of warrant, which contained a prohibition on variable rate transactions (as defined therein). Warrant holders agreed to waive such prohibition in exchange for certain concessions from the Company. Management evaluated the warrants after modifications and determined that they continued to be equity-classified under the derivative scope exception of ASC 815-40. The warrants were revalued immediately before and immediately after the modifications to calculate the $1.1&#160;million incremental value of the modified warrants. The Company considers this incremental value to be akin to an offering cost since the modifications were directly related to enabling the ATM Offering and would not have otherwise been incurred. Therefore, in the fourth quarter of 2019, management initially capitalized the $1.1&#160;million to deferred financing cost asset, with an offsetting credit to additional paid-in capital, and then reclassified the deferred financing cost asset to reduce the ATM Offering proceeds within equity as proceeds were received from sales of common stock under the ATM Offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">2018 Warrants</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2019, the Company entered into transactions with the holders of its outstanding 2018 Warrants pursuant to which such holders either (i)&#160;exercised their warrants pursuant to a Warrant Exercise Agreement (the &#8220;2018 Warrant Exercise Agreements&#8221;) or (ii)&#160;amended their warrants pursuant to a Warrant Amendment Agreement (the &#8220;2018 Warrant Amendment Agreements&#8221;). As consideration for those holders executing the 2018 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $1.20 to $0.60 per share of the Company&#8217;s common stock, resulting in proceeds of $2.0&#160;million from the exercise of 3.4&#160;million warrants. Pursuant to the 2018 Warrant Amendment Agreements, the prohibition on certain variable rate transactions included in the 2018 Warrants was amended to exclude ATM offerings and the exercise price of the warrants was reduced from $1.20 to the lesser of (a)&#160;$0.95 per share of common stock and (b)&#160;the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2018 Warrant Amendment Agreements. During the second quarter of 2020, the anti-dilution provision was triggered to lower the exercise price of the warrants to $0.55; as such, the Company recognized a deemed dividend of approximately $0.1&#160;million which reduced the income available to common stockholders. As the Company has an accumulated deficit balance, there is no overall impact to additional paid-in capital, as the deemed dividend is recorded as offsetting debit and credit entries to additional paid-in capital. Therefore, the amounts were not presented on the Statement of Stockholders&#8217; (Deficit) Equity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the 2018 Warrant Exercise Agreements and 2018 Warrant Amendment Agreements, the Company entered into an amendment to the Securities Purchase Agreement dated March&#160;21, 2018 related </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to the March&#160;2018 Financing, by and among the Company and each purchaser identified on the signature pages thereto, with certain holders representing greater than 50.1% of the securities issued based on initial subscription amounts, pursuant to which the prohibition on variable rate transactions, including ATM offerings, was deleted in its entirety. </font>
        </div>
        <div style="margin-top:9.92pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">2017 Warrants</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2019, the Company entered into transactions with the holders of its outstanding 2017 Warrants pursuant to which such holders either (i)&#160;exercised their warrants pursuant to a Warrant Exercise Agreement (the &#8220;2017 Warrant Exercise Agreements&#8221;) or (ii)&#160;amended their warrants pursuant to a Warrant Amendment Agreement (the &#8220;2017 Warrant Amendment Agreements&#8221;). As consideration for those holders executing the 2017 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $0.80 to $0.55 per share of the Company&#8217;s common stock. Pursuant to the 2017 Warrant Amendment Agreements, the prohibition on certain variable rate transactions, including ATM offerings, included in the 2017 Warrants was deleted in its entirety and the exercise price of the warrants was reduced from $0.80 to the lesser of (a)&#160;$0.55 per share of common stock and (b)&#160;the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2017 Warrant Amendment Agreements. As of December&#160;31, 2021, there has been no adjustment to the exercise price of these warrants. </font>
        </div>
        <div style="margin-top:9.92pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">13.&nbsp;&nbsp;&nbsp;EARNINGS (LOSS) PER SHARE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and&#160;units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For periods with net income, diluted net earnings per share is calculated by either (i)&#160;adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii)&#160;the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The two-class method was not applied for the twelve&#160;months ended December&#160;31, 2021, 2020 and 2019 as the Company&#8217;s participating securities do not have any obligation to absorb net losses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following potentially dilutive securities outstanding as of December&#160;31, 2021, 2020 and 2019 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands): </font>
        </div>
        <table style="width:416pt;height:59.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:296.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,247</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">22,895</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 0.5pt 0pt; width:296.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stock options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">15,703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">10,147</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,236</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:296.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Total</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">15,902</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">12,394</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">29,131</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">14.&nbsp;&nbsp;&nbsp;SHARE-BASED COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the&#160;years ended December&#160;31, 2021, 2020 and 2019 (in thousands): </font>
        </div>
        <table style="width:416pt;height:67.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:296.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">973</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">188</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:296.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">4,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">1,407</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,049</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:296.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Total Share Based Compensation</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">5,143</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">1,757</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,237</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2014 Stock Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s 2014 Stock Incentive Plan, as amended (the &#8220;2014 Plan&#8221;), was adopted by its board of directors in December&#160;2013 and subsequently approved by its stockholders in January&#160;2014. The 2014 Plan became effective immediately prior to the closing of the Company&#8217;s IPO in February&#160;2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock&#160;units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant, to the Company&#8217;s employees, officers, directors, consultants and advisors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the Annual Meeting of the Company&#8217;s stockholders in June&#160;2019, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that (i)&#160;increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii)&#160;eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May&#160;2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 8.9&#160;million shares of common stock available for issuance under the 2014 Plan as of December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten&#160;years from the date of grant. There were approximately 12.8&#160;million stock options outstanding under the 2014 Plan as of December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October&#160;1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#8220;RSU&#8221;) award which vests in full on September&#160;30, 2022, subject to continued employment through September&#160;30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. The Company recorded an expense of $0.5&#160;million for retention-related RSUs for the year ended December&#160;31, 2021. Additionally, the Company expensed $0.6&#160;million in relation to the cash bonus portion of the retention program. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Also pursuant to the Retention Program and effective as of October&#160;1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately fifty&#160;percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September&#160;30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As none of the retention milestones were met in the year ended December&#160;31, 2021 and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:141.39pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">achievement was deemed not probable, the Company did not record expenses for retention-related PSUs. As of December&#160;31, 2021, the unrecognized compensation expense for the retention-related PSUs, granted on October&#160;1, 2021, was $0.4&#160;million. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A summary of the status of restricted stock&#160;units is presented below: </font>
        </div>
        <table style="width:416pt;height:87pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.03pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Restricted Stock </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Units</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:349.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.13pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.13pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted RSU </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.13pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,482</td>
            <td style="padding:0pt;padding-left:16.13pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted PSU </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.13pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">559</td>
            <td style="padding:0pt;padding-left:16.13pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.13pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">3,041</div>
            </td>
            <td style="padding:0pt;padding-left:16.13pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The weighted average remaining contractual life of unvested RSUs and PSUs as of December&#160;31, 2021 is 9.75&#160;years. The Company did not grant restricted stock&#160;units during the&#160;years ended December&#160;31, 2020 and 2019. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2009 Stock Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the &#8220;2009 Plan&#8221;), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock&#160;units, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February&#160;2014, the Company ceased granting awards under the 2009 Plan and all shares (i)&#160;available for issuance under the 2009 Plan at such time and (ii)&#160;subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten&#160;years from the date of grant. There were approximately 0.1&#160;million fully vested stock options outstanding under the 2009 Plan as of December&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Out-of-Plan&#160;Inducement Grants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) employment inducement grant exemption (Nasdaq Listing Rule&#160;5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee&#8217;s acceptance of employment with the Company. There were approximately 2.8&#160;million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of December&#160;31, 2021. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock Options</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the&#160;years ended December&#160;31, 2021, 2020 and 2019: </font>
        </div>
        <table style="width:456pt;height:268pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:241.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares under </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Life</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Intrinsic</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding at December&#160;31, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,942</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.12</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.14</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,986</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.02</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(90<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.10</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Canceled or forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1,602<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">1.78</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,236</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">1.52</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">8.83</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:17.25pt; text-align:right; white-space:nowrap;">358</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,044</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.87</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.13</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Canceled or forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(121<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">1.04</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,147</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">1.26</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">8.50</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:17.25pt; text-align:right; white-space:nowrap;">3,160</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.32</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(34<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.23</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:241.76pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Canceled or forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(2,683<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">3.70</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:241.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">15,703</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.93</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.03</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:241.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercisable at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">7,562</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.65</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.41</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">59</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognized share-based compensation expense of $5.1&#160;million for the year ended 2021. The stock option related expenses were $4.6&#160;million, $1.8&#160;million and $1.2&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. The RSU related expense was $0.5&#160;million for the year ended December&#160;31, 2021. The Company did not record RSU related expenses for the&#160;years ended December&#160;31, 2020 and 2019. As of December&#160;31, 2021, there was $10.4&#160;million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 2.7&#160;years. The weighted-average grant-date fair value of stock options granted during the year ended December&#160;31, 2021, 2020 and 2019 were $2.16, $0.56 and $1.02, respectively. The total intrinsic value of stock options exercised for the&#160;years ended December&#160;31, 2021, 2020 and 2019 was de minimis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model: </font>
        </div>
        <table style="width:456pt;height:112pt;margin-top:9.99999999999994pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:351.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:351.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:351.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair market value </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.32</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.87</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.02</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:351.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.32</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.87</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.02</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:351.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:351.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:351.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">74.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">71.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">78.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:351.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:0.330000000000041pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">15.&nbsp;&nbsp;&nbsp;EMPLOYEE BENEFIT PLANS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2014 Employee Stock Purchase Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s 2014 Employee Stock Purchase Plan (&#8220;2014 ESPP&#8221;) was adopted by its board of directors in December&#160;2013 and subsequently approved by its stockholders in January&#160;2014. The 2014 ESPP became effective immediately prior to the closing of the Company&#8217;s IPO in February&#160;2014 and established an initial reserve of 0.2&#160;million shares of the Company&#8217;s common stock for issuance to participating employees. At the Annual Meeting of the Company&#8217;s stockholders in May&#160;2021, the Company&#8217;s stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders&#8217; equity (deficit). As of December&#160;31, 2021, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company sold a de minimis number of shares under the ESPP for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Defined Contribution Plans</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">United States&#8201;&#8212;&#8201;401(k) Plan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The Company contributed a de minimis amount for each of the three&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Canada&#8201;&#8212;&#8201;Defined Contribution Plan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a&#160;percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The Company contributed a de minimis amount for each of the three&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">16.&nbsp;&nbsp;&nbsp;INCOME TAXES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the components of the Company&#8217;s loss before income taxes by country (in thousands): </font>
        </div>
        <table style="width:456pt;height:82.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Country </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">United States </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(32,757<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(35,529<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(27,468<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Canada </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">24,148</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">14,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(80,032<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:306.89pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total Loss Before Income Taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(8,609<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,952<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(107,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s tax benefit (provision) is comprised of the following components (in thousands): </font>
        </div>
        <table style="width:456pt;height:165pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.26pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:336.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current Tax Provision </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:336.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Federal </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:336.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">State </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:336.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">(286<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,445<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 1.5pt 0pt; width:336.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current (provision) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">(286<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,445<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:336.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred tax provision </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:336.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Federal </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:336.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">State </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:336.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">8,559</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:336.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total deferred benefit (provision) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">8,559</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:336.26pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:normal;">
                <font style="letter-spacing:0.2pt;">Total Tax Benefit (Provision) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,445<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company did not record current or deferred income tax or benefit for the year ended December&#160;31, 2019. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#8217;s effective income tax rate: </font>
        </div>
        <table style="width:456pt;height:163.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:355.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">United States federal statutory income tax rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">21.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">21.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">21.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Impact of foreign rate differential </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(15.9<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(4.2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">4.4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">State taxes, net of federal benefit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.3</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">2.0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.6</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stock option cancellations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(1.1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(0.2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">178.2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">14.4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(18.0<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General business credits and other credits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">6.6</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Permanent differences </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(1.4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(13.8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(2.1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(0.5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Foreign taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(3.3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(6.9<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:355.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(72.3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">(37.7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">(7.9<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:355.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Effective Income Tax Rate</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">96.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">(6.9<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company&#8217;s deferred tax assets and liabilities (in thousands): </font>
        </div>
        <table style="width:456pt;height:178.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred tax assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">NOL carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">63,381</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">57,935</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">50,727</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">R&amp;D credit carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,316</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,787</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,385</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accruals and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,058</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,464</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Capitalized start-up costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">53</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">70</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">91</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">41</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Gross deferred tax assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">71,849</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">65,631</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">57,724</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred tax liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">IPR&amp;D </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,969<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,528<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,528<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Gross deferred tax liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,969<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,528<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,528<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(71,849<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(65,631<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(57,724<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:-0.2pt;">Net Deferred Tax Liability</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,969<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,528<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,528<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In assessing the realizability of the Company&#8217;s deferred tax assets, management considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL and R&amp;D credit carryforwards. The Company has generated NOLs since its inception, and management believes that it is more likely than not that the Company&#8217;s deferred tax assets will not be realized. As a result, valuation allowances of $71.8&#160;million, $65.6&#160;million and $57.7&#160;million have been established as of December&#160;31, 2021, 2020 and 2019, respectively. The $6.2&#160;million increase in the valuation allowance was attributable to the NOL for the year ended December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The net deferred tax liability of $4.0&#160;million primarily relates to the potential future impairments or amortization associated with IPR&amp;D intangible assets, which is not deductible for tax purposes and cannot be considered as a source of income to realize deferred tax assets. As a result, the Company recorded the deferred tax liability with an offset to goodwill. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the Company&#8217;s NOL and R&amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2021 (in millions): </font>
        </div>
        <table style="width:456pt;height:179.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:322.77pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:41.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Expiration </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beginning in </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:28.18pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Through </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:322.77pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">United States: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:28.18pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.77pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Federal NOL carryforwards&#8201;&#8211;&#8201;indefinite </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">101.1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">None </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28.18pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">None </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.77pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Federal NOL carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">118.9</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2030 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28.18pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2038 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.77pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">State NOL carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">138.4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2030 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28.18pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2040 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.77pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Federal R&amp;D credit carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.5</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28.18pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2040 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.77pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">State R&amp;D credit carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28.18pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2040 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.77pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Canada: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:28.18pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322.77pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Federal non-capital loss carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">31.2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2035 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28.18pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2040 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:322.77pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Federal scientific research and experimental development expense carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:41.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2032 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:28.18pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2040 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:322.77pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Federal and provincial investment tax credit carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:41.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2032 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:28.18pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2040</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Tax Reform Act of 1986 (the &#8220;Act&#8217;), NOL and R&amp;D credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, and there are similar provisions in certain state and non-US tax laws. NOL and R&amp;D credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interests of significant shareholders over a three-year period in excess of 50&#160;percent, as defined in Sections&#160;382 and 383 of the Internal Revenue Code, respectively. This could limit the amount of tax attributes that can be utilized to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. Management completed a Section&#160;382 study through March&#160;31, 2016 and determined that it is more likely than not that the Company&#8217;s NOL carryforwards are subject to a material limitation. Accordingly, the Company reduced its NOL carryforward by $0.8&#160;million. The Company has continued to raise additional equity capital since March&#160;2016 but has not done any additional analysis to determine whether or not ownership changes, as defined in the Act, have occurred, which would result in additional limitations. There could be additional ownership changes in the future that could further limit the amount of NOL carryforwards that the Company can utilize. The Company has not yet conducted a study of its R&amp;D credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards; however, until a study is completed and any adjustment is known, no amount is being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s R&amp;D credit carryforwards, and, if an adjustment is required, it would be offset by an adjustment to the valuation allowance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five&#160;years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, we have no assurance that the provision will be repealed or otherwise modified. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s consolidated statements of operations. Due to NOL and R&amp;D credit carryforwards that remain unutilized, income tax returns filed in the United States, certain states within the United States and Canadian tax jurisdictions from the Company&#8217;s inception through 2020 remain subject to examination by the taxing jurisdictions. There are currently no audits in process in any of the Company&#8217;s tax filing jurisdictions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">17.&nbsp;&nbsp;&nbsp;LICENSE AGREEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">In-License Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Agreement with Zurich</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has a license agreement with the University of Zurich (&#8220;Zurich&#8221;) which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company&#8217;s targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. Upon the Company&#8217;s receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $0.5&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.5&#160;million and $0.3&#160;million related to achievement of a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December&#160;2020), in the year ended December&#160;31, 2021 and 2020, respectively, and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August&#160;2021), in the twelve&#160;months ended December&#160;31, 2021, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Agreement with Micromet</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has a License Agreement with Micromet AG (&#8220;Micromet&#8221;), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of December&#160;31, 2021, the Company may be obligated to pay up to &euro;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.7&#160;million at exchange rates in effect on December&#160;31, 2021). The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &euro;50,000 (approximately $56,625 at exchange rates in effect as of December&#160;31, 2021), which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &euro;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three&#160;months ended December&#160;31, 2020, due to the submission of the Company&#8217;s BLA </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">for Vicineum with the FDA in December&#160;2020. The Company recorded an expense of &euro;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Agreement with XOMA</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has a license agreement with XOMA Ireland Limited (&#8220;XOMA&#8221;) which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#8217;s clinical development pathway. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Out-License Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Roche License Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the &#8220;Roche Licensed Intellectual Property&#8221;). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Financial Terms</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company received from Roche an upfront license fee of $7.5&#160;million in August&#160;2016 upon the effectiveness of the Roche License Agreement following approval by the Company&#8217;s stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i)&#160;$72.5&#160;million in development milestones, the next of which is $30&#160;million for initiation of the first Phase&#160;III clinical trial, (ii)&#160;$50&#160;million in regulatory milestones and (iii)&#160;$75&#160;million in commercialization milestones. Additional amounts of up to $65&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September&#160;15, 2016. In December&#160;2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase&#160;II clinical trial. Management evaluated the milestone under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company invoiced Roche $20&#160;million with payment terms of 30&#160;days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $20&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January&#160;2022, the payment of $20&#160;million was received. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Buy-Out Options</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Roche License Agreement provides for two &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i)&#160;Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase&#160;2 study for a Roche Licensed Product until the day before Initiation of the first Phase&#160;3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30&#160;days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, or (ii)&#160;Roche may exercise a buy-out option following the day after Initiation of the first Phase&#160;3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within 30&#160;days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Termination</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve&#160;months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">OUS Business Development Partnership Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Qilu License Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#8220;Qilu License Agreement&#8221;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to develop, manufacture and commercialize Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan (&#8220;Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i)&#160;development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region (&#8220;MENA&#8221;) and Turkey and (ii)&#160;manufacturing rights with respect to Vicineum in the rest of the world excluding China. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax (&#8220;VAT&#8221;), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i)&#160;twelve&#160;years after the first commercial sale of such Qilu Licensed Product in such region, (ii)&#160;the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii)&#160;the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China (&#8220;NMPA&#8221;) for the Qilu Licensed Product has been obtained. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Qilu License Agreement is subject to the provisions of Accounting Standards Codification 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), which was adopted effective January&#160;1, 2018. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September&#160;30, 2020. As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September&#160;30, 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January&#160;2021 and approved in March&#160;2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March&#160;31, 2021. The Company received the payment in 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a &#8220;Technology Transfer&#8221;. An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three&#160;months ended June&#160;30, 2021 for additional purchase price resulting from Qilu&#8217;s obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MENA License Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, (&#8220;MENA License Agreement&#8221;). The Company retains development and commercialization rights in the rest </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December&#160;31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($1.5&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained and recorded as long-term deferred revenue as of December&#160;31, 2021. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March&#160;31, 2021; as such, revenue of $1.5&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of December&#160;31, 2021, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EIP License Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement). Under the terms of the License Agreement, the Company is entitled to receive an upfront payment of $1.5&#160;million. The Company is in the process of amending the license agreement to defer payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and is also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. The EIP License Agreement is subject to the provisions of ASC 606 and as of December&#160;31, 2021, none of these amounts have been received by the Company. No initial transaction price was estimated by management as of December&#160;31, 2021, as the upfront payment is subject to a refund if certain regulatory approvals in the US are not obtained. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of December&#160;31, 2021, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">18.&nbsp;&nbsp;&nbsp;RELATED-PARTY TRANSACTIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company leases its facility in Winnipeg, Manitoba from an affiliate of Leslie L. Dan, a director of the Company until his retirement in July&#160;2019. For each of the&#160;years ended December&#160;31, 2021, 2020 and 2019, the Company paid $0.3&#160;million of rent, which includes the related operating expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company pays fees under an intellectual property license agreement to Protoden Technologies Inc. (&#8220;Protoden&#8221;), a company owned by Clairmark, an affiliate of Mr.&#160;Dan. Pursuant to the agreement, the Company has an exclusive, perpetual, irrevocable and non-royalty bearing license, with the right to sublicense, to certain patents and technology to make, use and sell products that utilize such patents and technology. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The annual fee is $0.1&#160;million. Upon expiration of the term on December&#160;31, 2024, the licenses granted to the Company will require no further payments to Protoden. For each of the&#160;years ended December&#160;31, 2021, 2020 and 2019, the Company paid $0.1&#160;million under this license agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Due to his retirement in July&#160;2019, Mr.&#160;Dan was not deemed a related party during the twelve-month period ended December&#160;31, 2020 and 2021; as such, only payments made through the nine month period ended September&#160;30, 2019 are considered payments to a related party. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">19.&nbsp;&nbsp;&nbsp;RESTRUCTURING AND RELATED ACTIVITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Restructuring Plan included a reduction in the Company&#8217;s workforce by 18 positions (or approximately 35% of the Company&#8217;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the Restructuring Plan: </font>
        </div>
        <table style="width:416pt;height:122pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:357.69pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:357.69pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:357.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Severance and benefits costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,792</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Contract termination costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,736</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:357.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other restructuring costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:357.69pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total restructuring costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5,528</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:357.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash payments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,031<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:357.69pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Balance at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,497</td>
            <td style="padding:0pt;padding-left:7.635pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.19pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss in the year ended December&#160;31, 2021. The Company expects that substantially all of the accrued restructuring costs as of December&#160;31, 2021 will be paid in cash by the end of September&#160;2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">20.&nbsp;&nbsp;&nbsp;SUBSEQUENT EVENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;7, 2022, the FDA granted the Company&#8217;s request for a Type C Meeting (&#8220;Type C Meeting&#8221;) to discuss the study protocol for an additional Phase&#160;3 clinical trial that the Company plans to conduct for potential resubmission of a BLA for Vicineum&#8482; for the treatment of BCG-unresponsive NMIBC. The Type C Meeting has been scheduled for March&#160;28, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;24, 2022, the Company received written notice (the &#8220;Notice&#8221;) from Nasdaq indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule&#160;5450(a)(1). The Notice has no effect at this time on the listing of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;), which continues to trade on The Nasdaq Global Market under the symbol &#8220;SESN&#8221;. In accordance with Nasdaq Listing Rule&#160;5810(c)(3)(A), the Company has a period of 180 calendar days, or until July&#160;25, 2022, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company&#8217;s Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the Company is not in compliance by July&#160;25, 2022, the Company may qualify for a second 180 calendar day compliance period. If the Company does not qualify for, or fail to regain, compliance during the second compliance period, then Nasdaq will notify the Company of its determination to delist the Company&#8217;s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq hearings panel. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:452pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company intends to actively monitor the closing bid price of the Company&#8217;s common stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As previously announced, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) initiated an independent internal review conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the &#8220;Review&#8221;). The Review took place over the course of five&#160;months, involved full cooperation from the Company&#8217;s management team, a review of more than 600,000 documents, and 39 interviews of current and former employees and consultants. It is now complete. As a result of the Review, the Board continues to fully support the Company&#8217;s current management team and believes no changes or amendments relating to the Company&#8217;s prior disclosures to the SEC or the FDA relating to Vicineum, the Phase&#160;3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted. The Company intends to work cooperatively with the FDA in preparing for an additional Phase&#160;3 clinical trial for Vicineum.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tCCBS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(Unaudited; In thousands, except share and per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:577.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">71,107</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">162,636</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Short term marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">106,427</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">21,011</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">14,297</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,482</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">527</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">18,476</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">192,358</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">205,605</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-current assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7,336</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Intangible assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">14,700</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Goodwill </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">13,064</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Long term prepaid expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7,192</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">123</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total non-current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7,366</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">35,142</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 2.25pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:40pt;font-weight:normal;">
                <font style="letter-spacing:0.2pt;">Total Assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">199,724</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">240,747</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities and Stockholders&#8217; Equity</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">514</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,853</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">33,800</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">8,255</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">381</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">460</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">34,695</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">11,568</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-current liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred tax liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,969</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total non-current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">57,469</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Total Liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">34,695</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">69,037</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Stockholders&#8217; Equity: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:338.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at September&#160;30, 2022 and December&#160;31, 2021; no shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common stock, $0.001 par value per share; 400,000,000 shares authorized at </font>
                <br >
                <font style="letter-spacing:0.2pt;">September&#160;30, 2022 and December&#160;31, 2021; 202,757,012 and 199,463,645 </font>
                <br >
                <font style="letter-spacing:0.2pt;">shares issued and outstanding at September&#160;30, 2022 and December&#160;31, </font>
                <br >
                <font style="letter-spacing:0.2pt;">2021, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">202</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">493,629</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">487,768</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(235<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(328,567<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(316,257<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total Stockholders&#8217; Equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">165,029</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">171,710</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 2.25pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:normal;">
                <font style="letter-spacing:0.2pt;">Total Liabilities and Stockholders&#8217; Equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">199,724</td>
            <td style="padding:0pt;padding-left:3.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">240,747</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:15.5pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these condensed consolidated financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tCCSO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:187.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS)</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(Unaudited; In thousands, except per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:373.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:253.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:253.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">License and related revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">6,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">40,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">6,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,931</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,967</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">37,636</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">18,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,141</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8,699</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,797</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restructuring charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,522</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,522</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">27,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(1,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(114,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(52,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(52,240<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,219</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(63,112<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">57,052</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">24,052</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income (loss) from Operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,781</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">63,112</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(17,052<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(17,508<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">676</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(45<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income (loss) Before Taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">63,113</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(16,185<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(17,553<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Benefit from income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">8,561</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">3,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Income (loss) After Taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">20,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">71,674</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:253.84pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net income (loss) attributable to common stockholders&#8201;&#8211;&#8201; basic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,442</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">71,622</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:253.84pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net income (loss) attributable to common stockholders&#8201;&#8211;&#8201; diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,442</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">71,623</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net income (loss) per common share&#8201;&#8211;&#8201;basic </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">0.10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">0.36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.06<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.05<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average common shares outstanding&#8201;&#8211;&#8201;basic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">200,464</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">196,778</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">199,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">176,547</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net income (loss) per common share&#8201;&#8211;&#8201;diluted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">0.10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">0.36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.06<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.05<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:253.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average common shares outstanding&#8201;&#8211;&#8201;diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">200,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">199,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">176,547</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these condensed consolidated financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tCCSO1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:484.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(Unaudited; In thousands, except per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:76.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:275.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:275.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:275.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net income (loss) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">71,674</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:275.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unrealized (gain) loss on marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(46<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:275.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total comprehensive income (loss) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,503</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">71,674</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,545<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these condensed consolidated financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tCCSO2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(Unaudited; In thousands, except share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:230pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:31.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:154.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid-in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9.00000000000001pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Other </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Comprehensive </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Loss </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Investments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217;</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:154.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:154.89pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">199,463,645</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">487,768</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(316,257<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">171,710</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:154.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(807<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(807<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:154.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">1,894</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">1,894</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:154.89pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at March&#160;31, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">199,463,645</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">489,662</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(317,064<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">172,797</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:154.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(31,960<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(31,960<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:154.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,802</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,802</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:154.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Unrealized loss of investments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(281<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(281<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:154.89pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at June&#160;30, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">199,463,645</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">491,464</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(281<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(349,024<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">142,358</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:154.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net income </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">20,457</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,457</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:154.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">3,293,367</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,165</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,168</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:154.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Unrealized gain of investments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">46</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">46</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:154.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Balance at September&#160;30, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">202,757,012</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">202</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">493,629</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(235<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(328,567<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">165,029</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:359pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:13.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid-in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217;</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">140,449,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">306,554</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(315,921<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,227<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(55,512<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(55,512<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">958</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">958</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">30,610</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">39</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">39</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of common stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">852,840</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">468</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">469</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 0.5pt 0pt; width:192.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock under ATM Offering, net of issuance costs of $2.2&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">30,645,702</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">31</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">72,512</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">72,543</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:192.64pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at March&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">171,978,799</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">172</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">380,531</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(371,433<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">9,270</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(25,442<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(25,442<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,260</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,260</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 0.5pt 0pt; width:192.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock under ATM Offering, net of issuance costs of $2.0&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">16,482,152</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">64,245</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">64,261</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:192.64pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at June&#160;30, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">188,460,951</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">188</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">446,036</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(396,875<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">49,349</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">71,674</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">71,674</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,168</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,168</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">3,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:192.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercises of common stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:41.25pt; text-align:right; white-space:nowrap;">1,195,219</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">656</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">657</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 0.5pt 0pt; width:192.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock under ATM Offering, net of issuance costs of $1.2&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">9,804,475</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">38,147</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">38,157</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:192.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Balance at September&#160;30, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:41.25pt; text-align:right; white-space:nowrap;">199,463,645</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:3.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">486,010</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(325,201<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">161,008</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these condensed consolidated financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tCCSO3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:33pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(Unaudited; In thousands)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:528pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:353.26pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:353.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash Flows from Operating Activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Adjustments to reconcile net loss to net cash used in operating activities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">74</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Share-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,864</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(52,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(52,240<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Intangibles impairment charge </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">27,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">31,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in operating assets and liabilities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable (net) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">21,012</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(1,107<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Other receivables </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(10,816<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">17,949</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(23,665<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Long term prepaid expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,192</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Unrealized loss on marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(235<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">123</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(2,339<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">807</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses and other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">21,497</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(4,453<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(1,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(1,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Net cash provided by (used in) operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">22,214</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(56,278<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash Flows from Investing Activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Purchase of marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(113,763<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Disposal (purchase) of equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(113,733<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(4<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash Flows from Financing Activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from issuance of common stock under ATM Offering, net of</font>
                <br >
                <font style="letter-spacing:0.2pt;">issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">174,961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from exercises of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from exercises of common stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">1,126</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">176,129</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net (decrease) increase in cash, cash equivalents and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(91,519<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">119,847</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents and restricted cash&#8201;&#8211;&#8201;beginning of period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">162,656</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">55,409</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents and restricted cash&#8201;&#8211;&#8201;end of period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">71,137</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">175,256</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Supplemental cash flow disclosure: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:353.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash paid for amounts included in the measurement of lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">127</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">131</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these condensed consolidated financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a><a name="tNTCC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(Unaudited)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1.&nbsp;&nbsp;&nbsp;DESCRIPTION OF BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio, Inc. (&#8220;Sesen Bio&#8221; or the &#8220;Company&#8221;), a Delaware corporation formed in February&#160;2008, is a late-stage clinical company focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">TM</font><font style="letter-spacing:0.2pt;">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (&#8220;EpCAM&#8221;) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). On July&#160;15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following recent discussions with the United States Food and Drug Administration (&#8220;FDA&#8221;), which had implications on the size, timeline and costs of an additional Phase&#160;3 clinical trial, which the FDA previously confirmed would be required for a potential resubmission of a biologics license application (&#8220;BLA&#8221;) for Vicineum for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, intends to seek a partner that can execute further development to realize the full potential of Vicineum. As a result of this decision, the Company has&#160;turned its primary focus to the careful assessment of potential strategic alternatives with the goal of maximizing shareholder value. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anticipated Merger with CARISMA Therapeutics Inc.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on September&#160;20, 2022, Sesen Bio, Seahawk Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Sesen Bio (&#8220;Merger Sub&#8221;), and CARISMA Therapeutics Inc., a Delaware corporation (&#8220;Carisma&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as a wholly-owned subsidiary of Sesen Bio and the surviving corporation of the merger (the &#8220;Merger&#8221;). Sesen Bio&#8217;s board of directors unanimously approved the&#160;Merger Agreement and resolved to recommend that Sesen Bio&#8217;s stockholders approve the proposals described in the Merger Agreement. If the Merger is completed, the business of Carisma will continue as the business of the combined company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that Sesen Bio does not complete the Merger with Carisma, Sesen Bio may continue to review and evaluate a strategic alternatives, including, without limitation, another strategic transaction and/or pursue a liquidation and dissolution of Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Viventia Acquisition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Viventia&#8221;), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously&#160;completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0&#160;million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Agreement, including: (i)&#160;a one-time milestone payment of $12.5&#160;million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii)&#160;a one-time milestone payment of $7.0&#160;million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii)&#160;a one-time milestone payment of $3.0&#160;million payable upon the first sale of the Purchased Product in Japan; and (iv)&#160;quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i)&#160;December&#160;31, 2033, and (ii)&#160;fifteen&#160;years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven&#160;years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company&#8217;s board of directors. However, as of September&#160;30, 2022, none of these individuals are active employees of the Company or members of the Company&#8217;s board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2.&nbsp;&nbsp;&nbsp;BASIS OF PRESENTATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASUs&#8221;), promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interim Financial Statements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule&#160;10-01 of Regulation&#160;S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the nine&#160;months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February&#160;28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Principles of Consolidation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries Viventia and Seahawk Merger Sub, Inc. and its indirect subsidiary, Viventia Bio USA Inc. All intercompany transactions and balances have been eliminated in consolidation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Currency Translation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The functional currency of the Company and each of its subsidiaries is the US dollar. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">3.&nbsp;&nbsp;&nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s complete summary of significant accounting policies can be found in &#8220;Item&#160;15.&#160;Exhibits and Financial Statement Schedules&#8201;&#8212;&#8201;Note 3. Summary of Significant Accounting Policies&#8221; in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">4.&nbsp;&nbsp;&nbsp;RECENT ACCOUNTING PRONOUNCEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Adopted in 2022</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, the FASB issued ASU No. 2020-06, </font><font style="font-style:italic;letter-spacing:0.2pt;">Debt&#8201;&#8212;&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</font><font style="letter-spacing:0.2pt;"> (&#8220;ASU 2020-06&#8221;). ASU&#160;2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU&#160;also amends the diluted earnings per share (&#8220;EPS&#8221;) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January&#160;1, 2022 and it did not have an impact on the Company&#8217;s financial position, results of operations including per-share amounts, or cash flows. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">In May&#160;2021, the FASB issued ASU No. 2021-04, </font><font style="letter-spacing:0.2pt;">Earnings Per Share (Topic 260), Debt&#8201;&#8212;&#8201;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8201;&#8212;&#8201;Stock Compensation (Topic 718), and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</font><font style="font-style:normal;letter-spacing:0.2pt;"> (&#8220;ASU 2021-04&#8221;)</font><font style="letter-spacing:0.2pt;">.</font><font style="font-style:normal;letter-spacing:0.2pt;"> ASU&#160;2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal&#160;years, and interim&#160;periods within those fiscal&#160;years, beginning after December&#160;15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January&#160;1, 2022 and it did not have an impact on the Company&#8217;s financial position, results of operations including per-share amounts, or cash flows. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">5.&nbsp;&nbsp;&nbsp;FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of September&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:41pt;white-space:nowrap;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Level&#160;1</font><font style="letter-spacing:0.2pt;">:</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:61pt;">
          <font style="letter-spacing:0.2pt;">Inputs are quoted prices for identical instruments in active markets. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:41pt;white-space:nowrap;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Level&#160;2</font><font style="letter-spacing:0.2pt;">:</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:61pt;">
          <font style="letter-spacing:0.2pt;">Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:41pt;white-space:nowrap;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Level&#160;3</font><font style="letter-spacing:0.2pt;">:</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:61pt;">
          <font style="letter-spacing:0.2pt;">Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following tables set forth the carrying amounts and fair values of the Company&#8217;s financial instruments measured at fair value on a recurring basis as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:456pt;height:161.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:205.34pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:205.34pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">
                <font style="letter-spacing:-0.16pt;">Carrying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value Measurement Based on </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:49.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:205.34pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Quoted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Prices in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Active</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Markets</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;1) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Significant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Observable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inputs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;2) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Significant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unobservable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inputs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;3) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:205.34pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.34pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Marketable securities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.34pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Money market funds (cash equivalents) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,450</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,450</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,450</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.34pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">113,763</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">113,763</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">113,763</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.34pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.34pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:12.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:131.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:214.14pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value Measurement Based on </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:214.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Carrying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Quoted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Prices in</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Active</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Markets</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;1) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Significant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Observable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inputs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;2) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Significant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unobservable</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Inputs</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Level&#160;3) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:214.14pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:214.14pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Money market funds (cash equivalents) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,382</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,382</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,382</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:214.14pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:214.14pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:8.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:6.065pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no asset or liability transfers between fair value levels during the nine&#160;months ended September&#160;30, 2022 and the year ended December&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contingent Consideration</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level&#160;3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following recent discussions with the FDA, which had implications on the size, timeline and costs of an additional Phase&#160;3 clinical trial for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such intends to seek a partner for the further development of Vicineum. Additionally, during the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the bacillus Calmette-Gu&#233;rin (&#8220;BCG&#8221;) shortage. Accordingly, during the second quarter of 2022, the Company concluded that it no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to the Greater China region since those territory rights had been out-licensed pursuant to the exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) (the &#8220;Qilu License Agreement&#8221;) (as further&#160;described in Note 17. &#8220;License Agreements&#8221; below). As of June&#160;30, 2022, Qilu held the exclusive license to develop Vicineum in the Greater China region, and accordingly, the $1.8&#160;million estimated earnout payment in the Greater China region remained as long-term contingent consideration as of June&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company and Qilu are in the process of negotiating a termination of the Qilu License Agreement. Upon the termination of the Qilu License Agreement, the Company will regain the rights to develop, manufacture and commercialize Vicineum in Greater China. However, the Company does not plan to develop or commercialize Vicineum in that region or any other, as it is pursuing the Merger with Carisma. The Company is also seeking to sell or out-license Vicineum and all the related obligations related to Vicineum. The Company expects that any partner who acquires or licenses Vicineum from the Company will be obligated to make any payments, including those related to sales in the Greater China region (if any), that become payable to the former shareholders of Viventia under the Share Purchase Agreement. If a sale or license of Vicineum has not occurred at the time the Merger is completed, Carisma has indicated it may continue to seek a sale or license of Vicineum and has no plans to develop Vicineum. Accordingly, as of September&#160;30, 2022, the Company concluded that it no longer expects to owe any future earnout payments related to the Greater China region and reduced its remaining $1.8&#160;million of contingent consideration liabilities to zero as of September&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The contingent consideration balance as of December&#160;31, 2021 was $52.0&#160;million which was based upon projected world-wide net sales. The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 8.0% to 9.3% as of December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary of the change in the fair value of the Company&#8217;s contingent consideration liability, measured on a recurring basis at each reporting period (in thousands). </font>
        </div>
        <table style="width:416pt;height:40.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:367.96pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:367.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in fair value of contingent consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(52,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:367.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Balance at September&#160;30, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The fair value of the Company&#8217;s contingent consideration was determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">dependent on discount rates to estimate the fair value at each reporting period. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December&#160;2033. The discount rate applied to the 2% earnout was derived from the Company&#8217;s weighted-average cost of capital, which was 9.3% as of December&#160;31, 2021. As of December&#160;31, 2021, the balance also reflected potential milestone payments which constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $52.0&#160;million for the nine&#160;months ended September&#160;30, 2022 was driven by the Company&#8217;s decision to voluntarily pause further development of Vicineum in the United States and seek a partner to acquire or license the asset and assume all associated liabilities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">6.&nbsp;&nbsp;&nbsp;RECEIVABLES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accounts receivable balance as of December&#160;31, 2021 was $21.0&#160;million, comprised primarily of a $20&#160;million milestone achieved in December&#160;2021 due to F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) initiating a Phase&#160;II clinical trial in the fourth quarter of 2021. In January&#160;2022 the payment of $20&#160;million was received. Additionally, in June&#160;2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a &#8220;Technology Transfer&#8221;. As such, the Company recorded $0.9&#160;million of revenue and accounts receivable for the additional purchase price resulting from Qilu&#8217;s obligation to pay the Company an amount equal to its recovery of value-added tax (&#8220;VAT&#8221;). The accounts receivable balance as of September&#160;30, 2022 was zero. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The other receivables balance as of September&#160;30, 2022 was $14.3&#160;million compared to $3.5&#160;million as of December&#160;31, 2021. The increase of $10.8&#160;million was primarily driven by expected insurance recovery of $13.4&#160;million related to the preliminary settlements of the Securities Litigation and Derivative Litigation (as defined in Note 10. &#8220;Commitments and Contingencies&#8221; below). This amount was partially offset by the receipt of $2.4&#160;million for German VAT recovery in the first half of 2022, related to drug substance sent to Baxter in 2020 and 2019 and other individually immaterial changes of $0.2&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7.&nbsp;&nbsp;&nbsp;PREPAID EXPENSES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The prepaid expenses balance as of September&#160;30, 2022 was $0.5&#160;million compared to $25.7&#160;million as of December&#160;31, 2021. In light of the Company&#8217;s decision to voluntarily pause further development of Vicineum in the United States, the Company evaluated prepaid balances and determined that the prepayments for the manufacturing of Vicineum, including consumables, had no future economic benefit or value. Pursuant to ASC Topic 730, </font><font style="font-style:italic;letter-spacing:0.2pt;">Certain Nonrefundable Advance Payment</font><font style="letter-spacing:0.2pt;">, the Company expensed $25.2&#160;million of prepayments during the second quarter of 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">8.&nbsp;&nbsp;&nbsp;INTANGIBLE ASSETS AND GOODWILL</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intangibles</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Intangible assets on the Company&#8217;s condensed consolidated balance sheets are the result of the Viventia Acquisition in September&#160;2016. The following table sets forth the composition of intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:416pt;height:63pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:298.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">IPR&amp;D intangible assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vicineum European Union rights </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">14,700</div>
            </td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total Intangibles</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">14,700</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.1pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The fair value of the acquired intangible assets for the European Union (&#8220;EU&#8221;) rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. On July&#160;15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following recent discussions with the FDA, which had implications on the size, timeline and costs of an additional Phase&#160;3 clinical trial for the treatment of NMIBC. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of a potential partnering deal to conclude the fair value of the Company&#8217;s intangible asset of Vicineum EU rights. The Company concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum EU rights of $14.7&#160;million was fully impaired and was reduced to zero in the second quarter of 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Goodwill</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Goodwill on the Company&#8217;s condensed consolidated balance sheets is the result of the Viventia Acquisition in September&#160;2016. During the second quarter of 2022, the Company observed continued trends in the Company&#8217;s market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis, in advance of the Company&#8217;s typical annual assessment date of October&#160;1 and concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired and was reduced to zero in the second quarter of 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary of the change in goodwill as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands). </font>
        </div>
        <table style="width:416pt;height:40.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:367.96pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at December&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13,064</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:367.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Impairment loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(13,064<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:367.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Balance at September&#160;30, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.9pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">9.&nbsp;&nbsp;&nbsp;ACCRUED EXPENSES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the composition of accrued expenses as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:416pt;height:123pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:298.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,242</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,841</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payroll-related expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,043</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,967</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Restructuring charge related </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">6,365</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,497</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Professional fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">381</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">597</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal expenses, including preliminary litigation settlement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">23,720</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,344</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:298.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">49</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:298.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Total Accrued Expenses</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">33,800</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,255</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.9pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">10.&nbsp;&nbsp;&nbsp;COMMITMENTS AND CONTINGENCIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Proceedings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;19, 2021, August&#160;31, 2021, and October&#160;7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October&#160;29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (collectively, the &#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November&#160;1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. On November&#160;24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December&#160;13, 2021, but the court has not ruled on that motion. On December&#160;6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections&#160;10(b) and 20(a) of the Exchange Act and Rule&#160;10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March&#160;7, 2022, and that motion was fully briefed on May&#160;6, 2022. On June&#160;3, 2022, before the court ruled on the motion to dismiss, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. On June&#160;30, 2022 and July&#160;6, 2022, the Company and the plaintiffs engaged in mediation sessions in an attempt to resolve the Securities Litigation and continued to discuss a potential settlement over the following weeks. On July&#160;19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August&#160;3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which was filed with the court on August&#160;17, 2022. The Stipulation and Agreement of Settlement related to the Securities Litigation provides for a settlement payment of $21.0&#160;million to the class and the dismissal of all claims against the Company and the other defendants. The settlement payment is being funded by the Company and its insurance carriers. On September&#160;1, 2022, the US District Court for the Southern District of New York issued an order denying the motions to appoint a different lead plaintiff. On September&#160;28, 2022, the court issued an order granting preliminary approval of the proposed settlement of the Securities Litigation. The court has set a final settlement approval hearing for January&#160;23, 2023 at 10:00&#160;a.m. local time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2021 and September&#160;24, 2021, two substantially similar derivative lawsuits captioned&#160;Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as nominal defendant. On January&#160;12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers (the &#8220;State Derivative Litigation&#8221;). The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October&#160;18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December&#160;22, 2021, the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May&#160;1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May&#160;18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On July&#160;6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in mediation in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July&#160;19, 2002, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims (collectively, the &#8220;Derivative Litigation&#8221;). Pursuant to that agreement, the individual defendants will cause the Company to adopt certain enhancements to its corporate governance policies and procedures. In exchange, plaintiffs will dismiss the Derivative Litigation and, on behalf of the Company, provide broad customary releases to the individual defendants. On August&#160;22, 2002, the parties entered into a Stipulation of Settlement to settle the Derivative Litigation, which was filed with the court on August&#160;30, 2022. The Stipulation of Settlement related to the Derivative Litigation confirms that the Company previously adopted certain corporate governance enhancements in response to, among other things, the filing of the Derivative Litigation, and that, subject to final court approval, the Company will adopt additional corporate governance enhancements. The Stipulation of Settlement also provides for a $0.6&#160;million payment for plaintiffs&#8217; attorneys fees due to the benefits the corporate governance enhancements are intended to provide to the Company. The payment of plaintiffs&#8217; attorneys fees is being funded by the Company. On September&#160;2, 2022, the court issued an order granting preliminary approval of the Stipulation of Settlement related to the Derivative Litigation. The court has set a final settlement approval hearing for November&#160;8, 2022 at 2:00&#160;p.m. local time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the second quarter of 2022, the Company deemed the settlements of the Securities Litigation and the Derivative Litigation probable and amounts reasonably estimable and recorded $21.6&#160;million to litigation related liability. During the third quarter of 2022, the Company paid $0.6&#160;million to be held in escrow for the plaintiffs&#8217; attorneys fees and $21.0&#160;million remains as a litigation related liability as of September&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company, its board of directors and the individual defendants continue to deny all allegations of any wrongdoing but are seeking to settle the Securities Litigation and the Derivative Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subsequent to September&#160;30, 2022, on October&#160;21, 2022, the Company received two separate letters and on November&#160;4, 2022, the Company received one letter from purported stockholders demanding that the Company amend the Registration Statement filed with the SEC on October&#160;14, 2022 (the &#8220;Registration Statement&#8221;) to provide additional disclosures that such stockholders allege were improperly omitted from the Registration Statement, including information regarding the financial projections for Carisma, the financial analyses performed by the Company&#8217;s financial advisor in support of its fairness opinion, and the background and process leading to the execution of the Merger Agreement. The Company believes that these demands are without merit and intends to vigorously defend against them. See discussion in Note 19. &#8220;Subsequent Events.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Employment Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Termination Fees associated with the Anticipated Merger with Carisma</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Merger Agreement contains certain termination rights of each of the Company and Carisma. Upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million, and Carisma may be required to pay the Company a termination fee of $5.49&#160;million and/or reimburse the Company expenses up to a maximum of $1.75&#160;million. At this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">11.&nbsp;&nbsp;&nbsp;LEASES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the third quarter of 2022, the Company entered into a Lease Termination Agreement (the &#8220;Lease Termination Agreement&#8221;) pursuant to which the Company terminated its operating lease agreement for its 31,000 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse, and office space and agreed to end the lease by September&#160;30, 2022. As part of the execution of the Lease Termination Agreement, the Company paid the landlord the all-inclusive sum of CAD $1.2&#160;million (USD $0.9&#160;million). Operating lease costs under this lease, including the related operating costs, were $81,000 and $245,000 for the three and nine&#160;months ended September&#160;30, 2022, respectively, and $79,000 and $245,000 for the three and nine&#160;months ended September&#160;30, 2021, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The right of use asset total was zero as of September&#160;30, 2022 and $123,300 as of December&#160;31, 2021. As of December&#160;31, 2021, the asset component of the Company&#8217;s operating leases was recorded as operating lease right-of-use assets and reported within other assets on the Company&#8217;s condensed consolidated&#160;balance sheets. The short-term lease liability was zero as of September&#160;30, 2022 and $123,300 as of December&#160;31, 2021. As of December&#160;31, 2021, the short-term lease liability was recorded in other current liabilities on the Company&#8217;s condensed consolidated balance sheets. There was no long-term operating lease liability as of September&#160;30, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The Company intends to terminate both leases in connection with the closing of the anticipated Merger with Carisma. The short-term lease in Philadelphia is renewed on a month-to-month basis. The short-term lease in Cambridge ends in June&#160;2023. The minimum monthly rent for these office spaces is $2,500 and $17,200, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12.&nbsp;&nbsp;&nbsp;STOCKHOLDERS&#8217; EQUITY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Financings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">ATM Offering</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has entered into an Open Market Sale Agreement </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">SM</font><font style="letter-spacing:0.2pt;"> with Jefferies LLC (&#8220;Jefferies&#8221;), dated November&#160;29, 2019, as amended by Amendment No. 1 dated October&#160;30, 2020, Amendment No. 2 dated February&#160;17, 2021 and Amendment No. 3, dated June&#160;1, 2021 (as amended, the &#8220;Sale Agreement&#8221;), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time through Jefferies (the &#8220;ATM Offering&#8221;). In June and July&#160;2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement of which $97.8&#160;million of common stock remain available for future issuance as of September&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule&#160;415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for the Company&#8217;s common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the nine&#160;months ended September&#160;30, 2022. The Company raised $175.0&#160;million of net proceeds from the sale of 56.9&#160;million shares of common stock at a weighted-average price of $3.17 per share during the nine&#160;months ended September&#160;30, 2021. The Company raised $38.2&#160;million of net proceeds from the sale of 9.8&#160;million shares of common stock at a weighted-average price of $4.01 per share during the three&#160;months ended September&#160;30, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $1.2&#160;million and $5.4&#160;million during the three and nine&#160;months ended September&#160;30, 2021, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;), the Company is authorized to issue 5.0&#160;million shares of &#8220;blank check&#8221; preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company&#8217;s common stock. The Company had no preferred stock issued and outstanding as of September&#160;30, 2022 and 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following approval by the Company&#8217;s stockholders on May&#160;3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which approximately 203&#160;million and 199&#160;million shares were issued and outstanding as of September&#160;30, 2022 and December&#160;31, 2021, respectively. In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:456pt;height:138pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shares of common stock issued </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">202,757</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">199,464</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Shares of common stock reserved for issuance for: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">16,202</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">15,703</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Restricted stock&#160;units </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">4,695</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,041</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Shares available for grant under 2014 Stock Incentive Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">3,725</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,933</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Shares available for sale under 2014 Employee Stock Purchase Plan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">2,300</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">2,300</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total shares of common stock issued and reserved for issuance</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">229,878</td>
            <td style="padding:0pt;padding-left:7.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">229,640</td>
            <td style="padding:0pt;padding-left:6.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.01pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock, other than the CVR (as further described in Note 17. &#8220;License Agreements&#8221; below) and any special cash dividend that the Company may pay to its stockholders in connection with the consummation of the Merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, </font><font style="letter-spacing:0.2pt;">Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:42.72pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Own Equity</font><font style="letter-spacing:0.2pt;">. The following table sets forth the Company&#8217;s warrant activity for the three&#160;months ended September&#160;30, 2022 (in thousands): </font>
        </div>
        <table style="width:456pt;height:93pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:112.83pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Issued </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Expiration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Issued </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Exercised) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Cancelled) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:112.83pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mar-2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.55<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">Mar-2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">132</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">132</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:112.83pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nov-2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.55<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">Nov-2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:112.83pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">May-2015 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">11.83</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">Nov-2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:112.83pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nov-2014 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">11.04</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:30pt; text-align:right; white-space:nowrap;">Nov-2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:112.83pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.209999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:15.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:16.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.69pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Exercise price shown (i)&#160;reflects modification and (ii)&#160;is subject to further adjustment based on down round provision added by amendment described in &#8220;Item&#160;15. Exhibits and Financial Statement Schedules&#8201;&#8212;&#8201;Note 12. Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">13.&nbsp;&nbsp;&nbsp;EARNINGS (LOSS) PER SHARE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and&#160;units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For periods with net income, diluted net earnings per share is calculated by either (i)&#160;adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii)&#160;the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. Accordingly, the Company applied the two-class method to calculate basic and diluted net earnings per share of common stock for the three&#160;months ended September&#160;30, 2022 and September&#160;30, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:51.3099999999999pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table illustrates the determination of earnings (loss) per share for each period presented: </font>
        </div>
        <table style="width:456pt;height:402.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:273.17pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except per share amounts) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Basic Earnings (Loss) Per Share:</font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Numerator: </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net income (loss) </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">71,674</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: Income attributable to participating securities&#8201;&#8211;&#8201;basic </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(15<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(52<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:273.17pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net income (loss) attributable to common stockholders&#8201;&#8211;&#8201;</font>
                <br >
                <font style="letter-spacing:0.2pt;">basic </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">20,442</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">71,622</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Denominator: </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted average common shares outstanding&#8201;&#8211;&#8201;basic </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">200,464</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">196,778</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">199,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">176,547</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:273.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net income (loss) per share applicable to common stockholders&#8201;&#8211;&#8201;basic </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">0.10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">0.36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.06<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.05<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Dilutive Earnings (Loss) Per Share:</font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Numerator: </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net income (loss) </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,457</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">71,674</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: Income attributable to participating securities&#8201;&#8211;&#8201;diluted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(15<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(51<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:273.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net income (loss) attributable to common stockholders&#8201;&#8211;&#8201; diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">20,442</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">71,623</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(12,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Denominator: </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted average shares outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">200,464</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">196,778</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">199,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">176,547</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Dilutive impact from: </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stock options and employee stock purchase plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,239</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Restricted stock&#160;units &amp; performance based stock&#160;units </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">463</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:273.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted average common shares outstanding&#8201;&#8211;&#8201;diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">200,947</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">199,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">176,547</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.5pt 0pt; width:273.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net income (loss) per share applicable to common stockholders&#8201;&#8211;&#8201;diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">0.10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">0.36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.06<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(0.05<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following potentially dilutive securities outstanding as of September&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands): </font>
        </div>
        <table style="width:456pt;height:93pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:294.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:294.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:294.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">16,182</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">11,273</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">16,202</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">15,511</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:294.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">RSUs and PSUs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">4,232</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">4,695</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:294.84pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Total</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">20,469</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">11,328</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">21,096</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">15,710</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">14.&nbsp;&nbsp;&nbsp;SHARE-BASED COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and nine&#160;months ended September&#160;30, 2022 and 2021 (in thousands): </font>
        </div>
        <table style="width:456pt;height:76.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:294.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:294.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:294.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">863</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">152</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,838</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">536</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:294.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">1,305</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">1,016</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">4,026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,849</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:294.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Total Share Based Compensation</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">2,168</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">1,168</td>
            <td style="padding:0pt;padding-left:0.584999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">5,864</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,385</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.9pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2014 Stock Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s 2014 Stock Incentive Plan, as amended (the &#8220;2014 Plan&#8221;), was adopted by its board of directors in December&#160;2013 and subsequently approved by its stockholders in January&#160;2014. The 2014 Plan became effective immediately prior to the closing of the Company&#8217;s IPO in February&#160;2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock&#160;units (&#8220;RSU&#8221;), stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant, to the Company&#8217;s employees, officers, directors, consultants and advisors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the Annual Meeting of the Company&#8217;s stockholders in June&#160;2019, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that (i)&#160;increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii)&#160;eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May&#160;2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 3.7&#160;million shares of common stock available for issuance under the 2014 Plan as of September&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten&#160;years from the date of grant. There were approximately 13.0&#160;million stock options outstanding under the 2014 Plan as of September&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;9, 2021, the Company&#8217;s board of directors and the compensation committee of the board of directors (the &#8220;Compensation Committee&#8221;) approved a retention program for all then-current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;2021 Retention Program&#8221;). Pursuant to the 2021 Retention Program and effective as of October&#160;1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which vested in full on September&#160;30, 2022, subject to continued employment through September&#160;30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Also pursuant to the 2021 Retention Program and effective as of October&#160;1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately fifty&#160;percent of then-current base salary. The fair value of PSUs at the grant date was $0.4&#160;million. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September&#160;30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of September&#160;30, 2022, achievement was deemed probable for only the cash management milestone, representing $87,000, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">20% of the PSU awards. Therefore, $11,000 and $44,000 have been expensed during the three and nine&#160;months ended September&#160;30, 2022, respectively and $43,000 remains measured but unrecognized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2009 Stock Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the &#8220;2009 Plan&#8221;), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock&#160;units, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February&#160;2014, the Company ceased granting awards under the 2009 Plan and all shares (i)&#160;available for issuance under the 2009 Plan at such time and (ii)&#160;subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten&#160;years from the date of grant. There were approximately 0.1&#160;million fully vested stock options outstanding under the 2009 Plan as of September&#160;30, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Out-of-Plan&#160;Inducement Grants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with Nasdaq employment inducement grant exemption (Nasdaq Listing Rule&#160;5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee&#8217;s acceptance of employment with the Company. There were approximately 3.1&#160;million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of September&#160;30, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock Options</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary of the Company&#8217;s total stock option activity, including&#160;awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the nine&#160;months ended September&#160;30, 2022: </font>
        </div>
        <table style="width:456pt;height:146pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:228pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares under</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Life</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Intrinsic</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:228pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">15,703</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.93</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.03</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,510</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.72</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:228pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Canceled or forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1,011<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">2.10</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:228pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding at September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,202</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.81</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.41</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:12pt; text-align:right; white-space:nowrap;">DM</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:228pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercisable at September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,494</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.72</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.94</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:12pt; text-align:right; white-space:nowrap;">DM</td>
            <td style="padding:0pt;padding-left:11.59pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognized share-based compensation expense, related to stock options, of $1.0&#160;million and $3.5&#160;million for the three and nine&#160;months ended September&#160;30, 2022, respectively and $1.2&#160;million and $3.4&#160;million for the three and nine&#160;months ended September&#160;30, 2021, respectively. As of September&#160;30,&#160;2022, there was $6.4&#160;million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of 2.09&#160;years. The weighted-average grant-date fair value of stock options granted during the nine&#160;months ended September&#160;30, 2022 and 2021 were $0.46 and $2.20, respectively. No stock options were exercised during the nine&#160;months ended September&#160;30, 2022. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">For the nine&#160;months ended September&#160;30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model: </font>
        </div>
        <table style="width:416pt;height:107.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair market value </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.72</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.40</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.72</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.40</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.0</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.03</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">71.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">74.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Restricted Stock Units and Performance Stock Units</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary of the Company&#8217;s RSU and PSU activity for the nine&#160;months ended September&#160;30, 2022: </font>
        </div>
        <table style="width:416pt;height:117pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:284.34pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Restricted Stock </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Units</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average Grant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested at December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">3,041</td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.80</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted RSU </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,160</td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.68</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cancelled RSU </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">(217<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.75</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Released RSU </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">(3,293<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.76</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted PSU </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">1,004</td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">0.67</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:284.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested at September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">4,695</div>
            </td>
            <td style="padding:0pt;padding-left:14.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.68</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company did not grant any RSUs or PSUs during the nine&#160;months ended September&#160;30, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The share-based compensation expense related to RSUs and PSUs for the three and nine&#160;months ended September&#160;30, 2022 was $1.2&#160;million and $2.4&#160;million, respectively. There was no shared-based compensation expense related to RSUs and PSUs for the three and nine&#160;months ended September&#160;30, 2021. As of September&#160;30, 2022, there was $1.8&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">15.&nbsp;&nbsp;&nbsp;EMPLOYEE BENEFIT PLANS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2014 Employee Stock Purchase Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s 2014 Employee Stock Purchase Plan (&#8220;2014 ESPP&#8221;) was adopted by its board of directors in December&#160;2013 and subsequently approved by its stockholders in January&#160;2014. The 2014 ESPP became effective immediately prior to the closing of the Company&#8217;s IPO in February&#160;2014 and established an initial reserve of 0.2&#160;million shares of the Company&#8217;s common stock for issuance to participating employees. At the Annual Meeting of the Company&#8217;s stockholders in May&#160;2021, the Company&#8217;s stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders&#8217; equity (deficit). As of September&#160;30, 2022, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP during the nine&#160;months ended September&#160;30, 2022 and 2021. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Defined Contribution Plans</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">United States&#8201;&#8212;&#8201;401(k) Plan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The expenses incurred for the periods presented were de minimis amount for each of the nine&#160;months ended September&#160;30, 2022 and 2021, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Canada&#8201;&#8212;&#8201;Defined Contribution Plan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a&#160;percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the nine&#160;months ended September&#160;30, 2022 and 2021, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">16.&nbsp;&nbsp;&nbsp;INCOME TAXES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the components of the Company&#8217;s loss before income taxes by country (in thousands): </font>
        </div>
        <table style="width:456pt;height:91.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Country: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">United States </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(32,083<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(38,864<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Canada </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">15,898</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">21,311</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total loss before income taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,185<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,553<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s tax benefit (provision) is comprised of the following components (in thousands): </font>
        </div>
        <table style="width:456pt;height:106.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:376.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:376.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current tax benefit (provision) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Federal </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,559</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">State </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">3,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(286<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:376.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total current benefit</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">3,875</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s deferred tax liability is comprised of the following: </font>
        </div>
        <table style="width:456pt;height:63pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred tax liabilities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">IPR&amp;D </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,969<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total deferred tax liabilities</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:13.705pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,969<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the nine&#160;months ended September&#160;30, 2022, the Company recorded a benefit from income taxes of $3.9&#160;million. In the second quarter of 2022, the Company determined that the fair value of the Vicineum EU rights was zero, which resulted in an impairment charge of $14.7&#160;million. In connection with this </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">impairment charge, the Company reversed the associated deferred tax liability by $4.0&#160;million as an income tax benefit, partially offset by $0.1&#160;million income tax paid to foreign jurisdictions pursuant to the Qilu License Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2021, the Company recorded a benefit from income&#160;taxes of $8.3&#160;million. In the third quarter of 2021, the Company determined that the fair value of the Vicineum US rights was zero, which resulted in an impairment charge of $31.7&#160;million. In connection with this impairment charge, in the third quarter of 2021, the Company wrote-down the associated deferred tax liability by $8.6&#160;million as a benefit. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">17.&nbsp;&nbsp;&nbsp;LICENSE AGREEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">In-License Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Agreement with Zurich</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has a license agreement with the University of Zurich (&#8220;Zurich&#8221;) which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company&#8217;s targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. The Company&#8217;s receipt of the Complete Response Letter (&#8220;CRL&#8221;) regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $0.5&#160;million milestone payment to Zurich. Under the Zurich License Agreement, as of September&#160;30, 2022, the Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich&#160;may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3&#160;million and $0.5&#160;million related to meeting a development milestone, the submission of the Company&#8217;s BLA with the FDA in December&#160;2020, in the fourth quarter of 2020, and a regulatory milestone, the Company&#8217;s receipt of the CRL from the FDA in August&#160;2021, in the third quarter of 2021, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Agreement with Micromet</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has a License Agreement with Micromet AG (&#8220;Micromet&#8221;), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of September&#160;30, 2022, the Company may be obligated to pay up to &euro;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.4&#160;million at exchange rates in effect on September&#160;30, 2022). The Company is also&#160;required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to&#160;Micromet an annual license maintenance fee of &euro;50,000 (approximately $48,987 at exchange rates in effect as of September&#160;30, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &euro;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three&#160;months ended December&#160;31, 2020, due to the submission of the Company&#8217;s BLA for Vicineum with the FDA in December&#160;2020. The Company recorded an expense of &euro;0.5&#160;million ($0.6&#160;million) related to the submission of marketing authorization application (the &#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for Vysyneum&#8482; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the EU. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">License Agreement with XOMA</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has a license agreement with XOMA Ireland Limited (&#8220;XOMA&#8221;) which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Out-License Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Roche License Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the&#160;right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the &#8220;Roche Licensed Intellectual Property&#8221;). Under the Roche License Agreement, Roche was required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist monoclonal antibody and pursue ongoing patent prosecution, at its cost. For additional information regarding the Roche License Agreement, see Note 17. &#8220;License Agreements&#8221; in the Notes to Condensed Consolidated Financial Statements in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, the Company entered into an asset purchase agreement with Roche (the &#8220;Roche Asset Purchase Agreement&#8221;) pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement, which was recorded as license revenue in the third quarter of 2022. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30&#160;million payment to the Company upon Roche&#8217;s initiation of a Phase&#160;3 clinical trial with EBI-031 for a defined indication if initiated prior to December&#160;31, 2026. Pursuant to ASC 606, the variable consideration of $30&#160;million is constrained. Therefore, the amount was not recorded as revenue during the third quarter of 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, at or prior to the effective time of the Merger, the Company will enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a rights agent (&#8220;Rights Agent&#8221;) pursuant to which the Company intends to declare a dividend payable to the Company&#8217;s stockholders of record as of a date agreed to by the Company and Carisma prior to the effective time of the Merger with respect to the receipt of one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of the Company&#8217;s common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive contingent cash payments upon the receipt by the Company of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement, subject to certain customary deductions, including for expenses and taxes. The contingent payments under the CVR Agreement, if they become due, will be payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that any cash payment will be made or that any holders of CVRs will receive any amounts with respect thereto. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">OUS Business Development Partnership Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Qilu License Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;30, 2020, the Company and its wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to develop, manufacture and commercialize Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan (&#8220;Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i)&#160;development, and commercialization rights in the rest of the world, excluding Greater China and (ii)&#160;manufacturing rights with respect to Vicineum in the rest of the world, excluding China. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of VAT, which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Qilu Licensed Product in a region and continuing until the latest of (i)&#160;twelve&#160;years after the first commercial sale of such Qilu Licensed Product in such region, (ii)&#160;the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii)&#160;the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China (&#8220;NMPA&#8221;) for the Qilu Licensed Product has been obtained. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Qilu License Agreement is subject to the provisions of ASC Topic 606, </font><font style="font-style:italic;letter-spacing:0.2pt;">Revenue</font><font style="letter-spacing:0.2pt;">. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September&#160;30, 2020. As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September&#160;30, 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January&#160;2021 and approved in March&#160;2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March&#160;31, 2021. The Company received the payment in 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a &#8220;Technology Transfer&#8221;. An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three&#160;months ended June&#160;30, 2021 for additional purchase price resulting from Qilu&#8217;s obligation to pay Sesen Bio an amount equal to its recovery of VAT. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MENA License Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the Middle East and North Africa region (&#8220;MENA&#8221;) (the &#8220;MENA License Agreement&#8221;). In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;20, 2022, the Company provided notice of termination of the MENA License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EIP License Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement&#8221;). Under the terms of the EIP License Agreement, the Company was entitled to receive an upfront payment of $1.5&#160;million. The Company and EIP have amended the license agreement to defer EIP&#8217;s payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company would be eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and also to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;20, 2022, the Company provided notice of termination of the EIP License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. The EIP License Agreement was terminated on October&#160;20, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">18.&nbsp;&nbsp;&nbsp;RESTRUCTURING AND RELATED ACTIVITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the US (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2022 Restructuring Plan is expected to be substantially completed in connection with the closing of the Merger with Carisma, which is expected to occur approximately two to three&#160;months from the date of this Form 10-Q filing, November&#160;7, 2022. The 2022 Restructuring Plan includes an incremental reduction in the Company&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC4">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:228.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the Merger with Carisma and while the Company seeks a potential partner for the further development of Vicineum. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company also incurred one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan. The following is a summary of accrued restructuring costs related to the 2022 Restructuring Plan, (in thousands): </font>
        </div>
        <table style="width:456pt;height:84.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:363.36pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 Restructuring Plan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:363.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Severance and benefits costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,944</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:363.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Contract termination and other associated costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">4,003</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:363.36pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total restructurings costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,947</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:363.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash payments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(4,582<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:363.36pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance at September&#160;30, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,365</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company&#8217;s Condensed Consolidated Statements of Income (Operations) and Comprehensive Income (Loss) in the three&#160;months ended September&#160;30, 2022. The Company expects that substantially all of the accrued restructuring costs as of September&#160;30, 2022 will be paid in cash in connection with the closing of the Merger with Carisma, which is expected to occur approximately two to three&#160;months from the date of this Form 10-Q filing, November&#160;7, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">19.&nbsp;&nbsp;&nbsp;SUBSEQUENT EVENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;21, 2022, the Company received two separate letters and on November&#160;4, 2022, the Company received one letter from purported stockholders demanding that the Company amend the Registration Statement filed with the SEC on October&#160;14, 2022 to provide additional disclosures that such stockholders allege were improperly omitted from the Registration Statement, including information regarding the financial projections for Carisma, the financial analyses performed by the Company&#8217;s financial advisor in support of its fairness opinion, and the background and process leading to the execution of the Merger Agreement. The Company believes that these demands are without merit and intends to vigorously defend against them. At this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="TOC5">&#8203;</a><a name="fISCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:351.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO CARISMA&#8217;S CONSOLIDATED FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:239.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:424pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Audited Consolidated Financial Statements</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tROIR1"><font style="letter-spacing:0.2pt;">Report of Independent Registered Public Accounting Firm </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tROIR1">F-71</a></font> <a href="#tROIR1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCBS1"><font style="letter-spacing:0.2pt;">Consolidated Balance Sheets, December&#160;31, 2021 and 2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCBS1">F-72</a></font> <a href="#tCBS1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOO1"><font style="letter-spacing:0.2pt;">Consolidated Statements of Operations, Years Ended December&#160;31, 2021 and 2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOO1">F-73</a></font> <a href="#tCSOO1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tCSOC2"><font style="letter-spacing:0.2pt;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit, Years ended December&#160;31, 2021 and 2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOC2">F-74</a></font> <a href="#tCSOC2"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOC3"><font style="letter-spacing:0.2pt;">Consolidated Statements of Cash Flows, Years ended December&#160;31, 2021 and 2020 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOC3">F-75</a></font> <a href="#tCSOC3"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tNTTC"><font style="letter-spacing:0.2pt;">Notes to Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNTTC">F-76</a></font> <a href="#tNTTC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Unaudited Interim Consolidated Financial Statements</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUCBS"><font style="letter-spacing:0.2pt;">Consolidated Balance Sheets, September&#160;30, 2022 and December&#160;31, 2021 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUCBS">F-89</a></font> <a href="#tUCBS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tUCSO"><font style="letter-spacing:0.2pt;">Consolidated Statements of Operations and Comprehensive Loss, Nine Months Ended September&#160;30, 2022 and 2021 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUCSO">F-90</a></font> <a href="#tUCSO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tUCSO1"><font style="letter-spacing:0.2pt;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit, Nine Months Ended September&#160;30, 2022 and 2021 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUCSO1">F-91</a></font> <a href="#tUCSO1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUCSO2"><font style="letter-spacing:0.2pt;">Consolidated Statements of Cash Flows, Nine Months Ended September&#160;30, 2022 and 2021 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUCSO2">F-92</a></font> <a href="#tUCSO2"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tNTTI"><font style="letter-spacing:0.2pt;">Notes to Interim Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNTTI">F-93</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tROIR1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Report of Independent Registered Public Accounting Firm</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the Stockholders and Board of Directors</font> <br ><font style="letter-spacing:0.2pt;">CARISMA Therapeutics Inc.: </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Opinion on the Consolidated Financial Statements </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have audited the accompanying consolidated balance sheets of CARISMA Therapeutics Inc. and subsidiary (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, convertible preferred stock and stockholders&#8217; deficit, and cash flows for the&#160;years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with U.S. generally accepted accounting principles. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Going Concern </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred losses and negative cash flows from operations since inception that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Basis for Opinion </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Critical Audit Matters </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1)&#160;relate to accounts or disclosures that are material to the consolidated financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ KPMG LLP </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have served as the Company&#8217;s auditor since 2018. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Philadelphia, Pennsylvania</font> <br ><font style="letter-spacing:0.2pt;">October 14, 2022</font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tCBS1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:6.00999999999999pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consolidated Balance Sheets </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except share and per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:569pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:358.26pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:358.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">28,551</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">51,788</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">1,235</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,277</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">29,786</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">53,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,084</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,774</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Right of use assets&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,413</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">211</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">35,449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">58,463</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Deficit</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,322</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,471</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,573</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">898</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">813</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,691</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,679</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">1,734</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,632</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">9,425</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,311</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Commitments and Contingencies (Note 6) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Convertible preferred stock, $0.0001 par value: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;A convertible preferred stock, 6,138,518 shares authorized; 5,201,017 shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">issued and outstanding (liquidation value of $54,091 at December&#160;31, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Special voting preferred stock, 1 share authorized, issued and outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:358.26pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;B convertible preferred stock, 4,807,541 shares authorized, 3,499,866 and 2,453,170 shares issued and outstanding as of December&#160;31, 2021 and 2020, respectively (liquidation value of $54,598 at December&#160;31, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">54,231</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">38,054</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;B special voting preferred stock, 1 share authorized, issued and </font>
                <br >
                <font style="letter-spacing:0.2pt;">outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">107,808</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">91,631</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Stockholders&#8217; deficit: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common stock $0.0001 par value, 14,230,158 shares authorized, 1,084,082 shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">issued and outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">818</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(96,997<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(56,213<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total CARISMA Therapeutics Inc. stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(96,179<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(55,874<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Noncontrolling interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(81,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(41,479<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:358.26pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">35,449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">58,463</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tCSOO1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:381.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consolidated Statements of Operations </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except share and per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:177.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">34,387</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">23,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">6,407</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,086</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">40,794</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">28,378</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(40,794<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(28,378<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(40,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(28,349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Share information: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share of common stock, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(37.62<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(26.66<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares of common stock outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,084,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,063,309</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="min-height:579.31pt;page-break-after:always; width:775.7pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tCSOC2">&#8203;</a>
      </div>
      <div style="margin-top:61.66pt;margin-left:46.86pt;width:680pt;">
        <div style="width:680pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:115.5pt;margin-left:46.86pt;width:680pt;">
        <div style="margin-top:12pt; text-align:center; width:680pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:680pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except share and per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:680pt;height:253.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:152.33pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="46">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:23pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:152.33pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Series&#160;A </font>
                <br >
                <font style="letter-spacing:-0.16pt;">convertible </font>
                <br >
                <font style="letter-spacing:-0.16pt;">preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Special voting </font>
                <br >
                <font style="letter-spacing:-0.16pt;">preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Series&#160;B </font>
                <br >
                <font style="letter-spacing:-0.16pt;">convertible </font>
                <br >
                <font style="letter-spacing:-0.16pt;">preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Series&#160;B </font>
                <br >
                <font style="letter-spacing:-0.16pt;">special voting </font>
                <br >
                <font style="letter-spacing:-0.16pt;">preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.16pt;">paid-in </font>
                <br >
                <font style="letter-spacing:-0.16pt;">capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.16pt;">deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Noncontrolling </font>
                <br >
                <font style="letter-spacing:-0.16pt;">interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:152.33pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:152.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Balance, January&#160;1, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">2,910,151</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">29,752</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">1,042,187</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">157</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(27,864<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,250</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(23,457<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Issuance of Series&#160;A convertible preferred stock at $10.40 per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">2,290,866</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">23,825</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">5,500</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">5,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Issuance of Series&#160;B convertible preferred stock at $15.60 per share, net of issuance costs of $215 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">2,453,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">38,054</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,645</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">4,645</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">41,895</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">163</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">163</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:152.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(28,349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(28,349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:152.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Balance, December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">2,453,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">38,054</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">1,084,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">339</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(56,213<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(41,479<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:9pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Issuance of Series&#160;B convertible preferred stock at $15.60 per share, net of issuance costs of $151 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">1,046,696</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">16,177</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">479</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">479</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:152.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(40,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(40,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:152.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Balance, December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">3,499,866</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">54,231</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">1,084,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">818</td>
            <td style="padding:0pt;padding-left:8.455pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(96,997<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.415pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:10.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(81,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:1.99999999999997pt;height:12pt;margin-left:46.86pt;width:680pt;">
        <div style="text-align:center; width:680pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to consolidated financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:49.64pt;margin-left:168.89pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tCSOC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:83.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consolidated Statement of Cash Flows </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:475.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:357.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:357.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Cash flows from operating activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Adjustment to reconcile net loss to net cash used in operating activities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Depreciation and amortization expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">682</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">448</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">479</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">163</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Reduction in the operating right of use assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">834</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,179</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Changes in operating assets and liabilities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">253</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(936<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(974<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,282</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,995</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">353</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(813<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,152<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(37,328<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(27,012<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Cash flows from investing activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,871<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(440<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,871<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(440<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Cash flows from financing activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the sale of Series&#160;A convertible preferred stock and noncontrolling </font>
                <br >
                <font style="letter-spacing:0.2pt;">interests </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">29,325</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the sale of Series&#160;B convertible preferred stock and noncontrolling </font>
                <br >
                <font style="letter-spacing:0.2pt;">interests </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">16,328</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">42,914</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Payment of Series&#160;B offering costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(366<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">15,962</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">72,258</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net (decrease) increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(23,237<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">44,806</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents at beginning of the year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">51,788</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,982</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:357.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents at end of the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">28,551</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">51,788</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Supplemental disclosures of non-cash financing and investing activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;B issuance costs in accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">118</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;B issuance costs in accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">97</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment in accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">121</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the consolidated financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tNTTC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notes to the Consolidated Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:10.42pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(1)&nbsp;&nbsp;&nbsp;Background</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.42pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CARISMA Therapeutics Inc., a Delaware Corporation (the Company), is a clinical-stage biopharmaceutical company focused on utilizing the Company&#8217;s proprietary macrophage and monocyte cell engineering platform to develop transformative therapies to treat cancer and other serious disorders. Cell therapy enables the utilization of reprogrammed living cells to perform complex functions such as clearance of tumor cells or resolution of inflammation. The Company&#8217;s initial focus is its proprietary Chimeric Antigen Receptor Macrophage (CAR-M) platform, which redirects macrophages against specific tumor associate antigens and enables targeted anti-tumor immunity by utilizing genetically modifying myeloid cells (macrophages and monocytes) to express chimeric antigen receptors, or CARs, enabling the innate immune cells to recognize specific tumor associated antigens on the surface of tumor cells. The Company&#8217;s clinical lead product candidate CT-0508 is an ex vivo gene-modified autologous CAR-M cell therapy product intended to treat solid tumors that overexpress HER2. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company received an investigational new drug application, or IND, clearance for CT-0508 for the treatment of HER2-overexpressing solid tumors in July&#160;2020 and dosed the first patient in March&#160;2021. The Food and Drug Administration, or FDA, granted CT-0508 Fast Track Status in September&#160;2021. As of September&#160;1, 2022, enrollment in group 1 of the first in human study has been completed with 9 patients successfully dosed with CT-0508, and group 2 is currently open for enrollment with an additional 9 patients to be dosed in the study. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(2)&nbsp;&nbsp;&nbsp;Development-Stage Risks and Liquidity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.41pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $97.0&#160;million as of December&#160;31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. Management believes that cash and cash equivalents of $28.6&#160;million as of December&#160;31, 2021 and the $80.0&#160;million of cash proceeds received in January&#160;2022 from ModernaTX, Inc. (Moderna) related to the Collaboration and License Agreement and the Convertible Promissory Note (Note 11) are sufficient to sustain planned operations into the second quarter of 2023. As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include but are not limited to private placements of equity and/or debt, licensing and/or marketing arrangements, and public offerings of equity and/or debt securities. There is no assurance that such financing will be available when needed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(3)&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:10.32pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Principles of Consolidation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.31pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has a majority owned subsidiary in Luxembourg. The functional currency of the majority owned subsidiary is the US dollar. The consolidated financial statements include the accounts of the Company and its majority owned subsidiary. All intercompany transactions have been eliminated in consolidation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Significant areas that require management&#8217;s estimates include the fair value of the Company&#8217;s common stock and stock-based compensation assumptions, the estimated useful lives of property and equipment and accrued research and development expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fair Value of Financial Instruments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fair Value Measurements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;1 Inputs:&nbsp;&nbsp;&nbsp;Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;2 Inputs:&nbsp;&nbsp;&nbsp;Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;3 Inputs:&nbsp;&nbsp;&nbsp;Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cash equivalents of $5.2&#160;million and $0.2&#160;million are classified as Level&#160;1 assets as of December&#160;31, 2021 and 2020, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Concentration of credit risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Segment information</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash and Cash Equivalents</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. As of December&#160;31, 2021 and 2020, cash equivalents consisted of investments in a money market account. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Property and Equipment</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from two to five&#160;years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Long-lived Assets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company did not recognize any impairment of long-lived assets during the&#160;years ended December&#160;31, 2021, or 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, </font><font style="font-style:italic;letter-spacing:0.2pt;">Leases (ASC 842)</font><font style="letter-spacing:0.2pt;">, which requires lessees to recognize most leases on-balance sheet and disclose key information about leasing arrangements. The Company adopted ASC 842 effective as of January&#160;1, 2019 using the modified retrospective approach. The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has elected the &#8220;package of 3&#8221; practical expedients permitted under the transition guidance, which eliminated the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. In addition, the Company elected the practical expedient of hindsight in determining the lease term upon adoption of ASC 842. The Company also adopted an accounting policy which provides that leases with an initial term of 12&#160;months or less and without a purchase option that the Company is reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its consolidated balance sheet. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Noncontrolling Interest</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent that ownership interests in the Company&#8217;s subsidiary are held by entities other than the Company, management reports these as noncontrolling interests on the consolidated balance sheet. At December&#160;31, 2021 and 2020, an investor had outstanding Class&#160;B and Class&#160;B-1 shares in the Company&#8217;s Luxembourg subsidiary related to the sale of the Company&#8217;s Series&#160;A and Series&#160;B convertible preferred stock. The shares are nonvoting shares at the subsidiary entity level and presented as noncontrolling interests in the accompanying consolidated balance sheet. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Earnings or losses are attributed to noncontrolling interests under the hypothetical liquidation at book value (HLBV) method. The HLBV method is a point in time calculation that utilizes inputs to determine the amount that the Company and noncontrolling interest holders would receive upon a hypothetical liquidation at each balance sheet date based on the liquidation provisions of the respective articles of incorporation. Holders of the noncontrolling interests do not share in earnings or losses of the Luxembourg subsidiary. In addition and upon a liquidation event, as described in the Company&#8217;s articles of incorporation, holders of noncontrolling interests will automatically convert into the Company&#8217;s preferred securities for purposes of liquidation. As a result, no earnings or losses at the Company&#8217;s subsidiaries are allocated to noncontrolling interests. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Costs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock-Based Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company&#8217;s common stock, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The expected term of stock options for employees is estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Loss per Share Attributable to Common Stockholders</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive. The Company&#8217;s convertible preferred stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:79.0700000000001pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </font>
        </div>
        <table style="width:416pt;height:112.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A Convertible Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B Convertible Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,499,866</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,453,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Class&#160;B exchangeable shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">937,501</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">937,501</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Class&#160;B-1 exchangeable shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">297,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">297,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stock options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">1,869,438</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">965,912</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:306.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">11,805,586</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">9,855,364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Accounting guidance not yet adopted</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, the FASB issued ASU No. 2020-06, </font><font style="font-style:italic;letter-spacing:0.2pt;">Debt&#8201;&#8212;&#8201;Debt with Conversion and Other Options</font><font style="letter-spacing:0.2pt;"> (Subtopic 470-20) </font><font style="font-style:italic;letter-spacing:0.2pt;">and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity</font><font style="letter-spacing:0.2pt;"> (Subtopic 815-40)</font><font style="font-style:italic;letter-spacing:0.2pt;">: Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</font><font style="letter-spacing:0.2pt;"> (ASU 2020-06), which simplifies the accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if converted method. This standard is effective for the Company on January&#160;1, 2022, including interim periods within those fiscal&#160;years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company does not expect the adoption of this standard to have a material impact on the consolidated financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(4)&nbsp;&nbsp;&nbsp;Property and Equipment, net</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment, net consisted of the following (in thousands): </font>
        </div>
        <table style="width:416pt;height:143pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:333.26pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:333.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:333.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">214</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">108</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:333.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lab equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,694</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,821</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:333.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Office furniture </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">267</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">267</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:333.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">317</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">317</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:333.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Construction in progress </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:333.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,505</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,513</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:333.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: accumulated depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,421<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(739<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:333.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">3,084</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,774</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Depreciation and amortization expense was $0.7&#160;million and $0.4&#160;million for the&#160;years ended December&#160;31, 2021, and 2020, respectively. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(5)&nbsp;&nbsp;&nbsp;Accrued Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accrued expenses consisted of the following (in thousands): </font>
        </div>
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Compensation and related expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,563</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">985</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,352</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">361</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Professional fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">323</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">191</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:336.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">233</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:336.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,471</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,573</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(6)&nbsp;&nbsp;&nbsp;Commitments and Contingencies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has operating leases for its lab and office space. In April&#160;2019, the Company entered into a lease agreement for its headquarters in Philadelphia, Pennsylvania, which commenced in October&#160;2019 and has a termination date of September&#160;2029. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2018, the Company entered into a lease agreement for lab and office space in Philadelphia, Pennsylvania. This lease agreement commenced the same month and initially had a month-to-month lease term. As of January&#160;2019, upon adoption of ASC 842, the Company was reasonably certain the lease would be renewed for approximately five&#160;years based on certain economic factors at that time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s operating lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The elements of the lease costs were as follows (in thousands): </font>
        </div>
        <table style="width:416pt;height:37pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,129</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,129</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:14.19pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Lease term and discount rate information related to leases was as follows: </font>
        </div>
        <table style="width:416pt;height:82pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:358.41pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:358.41pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.41pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Weighted-average remaining lease term (in&#160;years) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.41pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">4.4</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">4.9</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.41pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Weighted-average discount rate </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.41pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">9.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">9.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:2.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:9.19pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Supplemental cash flow information (in thousands): </font>
        </div>
        <table style="width:416pt;height:52pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash paid for amounts included in the measurement of lease liabilities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating cash used in operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,108</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,103</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Future maturities of lease liabilities were as follows as of December&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:416pt;height:168.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:370.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Operating </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:370.17pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Fiscal year ending:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:370.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,114</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:370.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">892</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:370.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">213</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:370.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">219</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:370.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2026 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">226</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:370.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Thereafter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">657</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:370.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total future minimum payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,321</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:370.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Less imputed interest </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(689<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:370.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Present value of lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,632</td>
            <td style="padding:0pt;padding-left:3.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.9pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Licensing and Sponsored Research Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2017, the Company entered into a license agreement (Penn License Agreement) with The Trustees of the University of Pennsylvania (Penn) for certain intellectual property licenses. The Penn License Agreement specifies the Company will provide $5.5&#160;million of sponsored research as part of the research and development plan within the first three&#160;years of the agreement. The Company is required to make annual payments of $10,000 through 2021 and $25,000 in annual payments thereafter. Penn is eligible to receive up to $10.9&#160;million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0&#160;million per product in commercial milestones, and up to an additional $1.7&#160;million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contingencies</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(7)&nbsp;&nbsp;&nbsp;Convertible Preferred Stock, Noncontrolling Interests and Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2020, the Company sold 2,290,866 shares of its Series&#160;A convertible preferred stock (Series&#160;A) and 528,847 shares of Class&#160;B exchangeable shares issued by the Luxembourg subsidiary at an original issuance price of $10.40 per share. One special voting preferred stock share was also issued to the investor in the Luxembourg subsidiary. In December&#160;2020, the Company sold 2,453,170 shares of its Series&#160;B convertible preferred stock (Series&#160;B) and 297,764 shares of Class&#160;B-1 exchangeable shares issued by the Luxembourg subsidiary at an original issuance price of $15.60 per share. One Series&#160;B special voting preferred stock share was also issued to the investor in the Luxembourg subsidiary. The proceeds received associated with Luxembourg subsidiary securities are presented as noncontrolling interests in the Company&#8217;s consolidated financial statements. As of December&#160;31, 2021 and 2020, there were 937,501 and 297,764 Class&#160;B and Class&#160;B-1 exchangeable shares outstanding, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2021, the Company sold an additional 1,046,696 shares of Series&#160;B at an original issuance price of $15.60 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Class&#160;B and Class&#160;B-1 exchangeable shares (the Exchangeable Shares) are exchangeable into shares of Series&#160;A and Series&#160;B, respectively, on a one for one basis, at the option of the holder, or automatically upon an initial public offering or liquidation event. The Class&#160;B and Class&#160;B-1 exchangeable shares participate as Series&#160;A and Series&#160;B preferred shareholders, respectively, as it pertains to all rights and preferences held by the Company&#8217;s preferred shareholders. In addition, the Class&#160;B and Class&#160;B-1 exchangeable share investor </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">holds a share of special voting preferred stock and Series&#160;B special voting preferred stock that provides the investor with additional control relating voting matters for the Series&#160;A and Series&#160;B preferred shareholders, respectively. The following is a summary of the rights, preferences, and terms of the Series&#160;A and Series&#160;B (collectively, Convertible Preferred Stock): </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of the Convertible Preferred Stock are entitled to receive dividends payable when, as and if declared by the Board of Directors of the Company, with the holders of common stock, paid out of any assets or on the common stock of the Company, on an as-converted or as exchangeable to common stock basis. No dividends on common stock were declared or paid from inception through December&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of Convertible Preferred Stock, Special voting preferred stock and Series&#160;B special voting preferred stock are entitled to vote on any matter presented to the stockholders of the Company. Each holder of outstanding shares of Convertible Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of Convertible Preferred Stock are convertible or exchangeable. Holders of Series&#160;A and the holder of Special voting preferred stock, exclusively and together as a single class, are entitled to elect three directors of the corporation and Series&#160;B holders and the holder of Series&#160;B special voting preferred stock, exclusively and as a separate class, are entitled to elect one director of the corporation. The holders of record of common stock and Convertible Preferred Stock, together as a separate class, are entitled to elect the balance of the total directors of the corporation and on an as converted or exchangeable basis. As of December&#160;31, 2021, the Company had 7 directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidation Preference</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of any voluntary or involuntary liquidations, dissolution or winding up of the Company, the holders of Series&#160;B shall be entitled to be paid out of the consideration payable to stockholders before any payment shall be made to the holders of Series&#160;A or common stock, an amount equal to the greater of (i)&#160;Series&#160;B original issue price, plus any dividend declared but unpaid, or (ii)&#160;such amount per share as would have been payable had all shares of Series&#160;B been converted into common stock immediately prior to liquidation, dissolution or winding up. The holders of Series&#160;A shall be entitled to be paid out of the consideration payable to stockholders after any payment to the Series&#160;B but before any payment shall be made to the holders common stock, an amount equal to the greater of (i)&#160;Series&#160;A original issue price, plus any dividend declared but unpaid, or (ii)&#160;such amount per share as would have been payable had all shares of Series&#160;A been converted into common stock immediately prior to liquidation, dissolution or winding up. If exchanged as of December&#160;31, 2021, the Class&#160;B and Class&#160;B-1 exchangeable shares have a liquidation value of $9.8&#160;million and $4.6&#160;million, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conversion</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Convertible Preferred Stock is convertible into common stock based on the original issuance price of the security. The Convertible Preferred Stock automatically converts to common stock upon (1)&#160;an initial public offering totaling at least $50.0&#160;million in proceeds, or (2)&#160;the date and time, or the occurrence of an event, specified by vote or written consent of (i)&#160;the holders of a majority of the voting power represented by&#160;the outstanding shares of Series&#160;A, voting together as a single class and (ii)&#160;the holders of at least two-thirds&#160;(2/3) of the voting power represented by the outstanding shares of Series&#160;B, voting together as a single class (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Redemption</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Convertible Preferred Stock is subject to redemption under certain deemed liquidation events not solely within the control of the Company, as defined, and as such is considered contingently redeemable for accounting purposes. Accordingly, the Convertible Preferred Stock is classified outside of permanent stockholders&#8217; deficit. An adjustment of the carrying amount of the Convertible Preferred Stock is not </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">necessary until it is probable that the securities will become redeemable. At December&#160;31, 2021, the Company has determined that redemption of the Convertible Preferred Stock is not probable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. Unless required by law, there shall be no cumulative voting. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment of all preferential amounts required to be paid to the holders of shares of Convertible Preferred Stock, the remaining funds and assets available for distribution to the stockholders of the Company will be distributed among the holders of shares of common stock, pro&#160;rata based on the number of shares of common stock held by each such holder. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(8)&nbsp;&nbsp;&nbsp;Stock-based Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2017, the Company adopted the 2017 Stock Incentive Plan (the Plan) as amended that authorized the Company to grant up to 1,739,936 shares of common stock. In 2021, the Company amended the Plan and increased the total number of shares authorized under the Plan to 1,984,018. As of December&#160;31, 2021, there were 24,242 shares available to be granted. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over four&#160;years. The Company recorded stock-based compensation expense in the following expense categories in its accompanying consolidated statements of operations: </font>
        </div>
        <table style="width:416pt;height:67.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">185</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">67</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">294</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">96</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">479</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">163</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:14.19pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of stock option activity under the Plan: </font>
        </div>
        <table style="width:456pt;height:199.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:236.73pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">term (years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Intrinsic</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding as of January&#160;1, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">912,321</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.06</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">134,997</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.28</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(41,895<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.47</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(16,386<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.23</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expired </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(23,125<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">1.18</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.0000000000001pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding as of December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">965,912</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.11</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">903,526</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">2.63</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding as of December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,869,438</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.85</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">8.2</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,693</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercisable as of December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">828,821</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.24</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.2</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,270</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and expected to vest </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,869,438</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.85</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">8.2</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,693</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The weighted-average grant-date per share fair values of options granted in 2021 and 2020 were $1.43 and $0.66, respectively. The fair values in 2021 and 2020 were estimated using the Black-Scholes option-pricing model based on the following assumptions: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:97pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:307.43pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:307.43pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:62.28pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:62.28pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:307.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">0.89%&#8201;&#8211;&#8201;1.26%</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">0.4%&#8201;&#8211;&#8201;1.8%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:307.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">6&#160;years</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">6&#160;years</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:307.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">53.3%&#8201;&#8211;&#8201;54.2%</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">54.1%&#8201;&#8211;&#8201;55.5%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:307.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:307.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Estimated fair value of the Company&#8217;s common stock per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$2.77</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:62.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$1.28</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recorded stock-based compensation expense of $0.5&#160;million and $0.2&#160;million for the&#160;years ended December&#160;31, 2021, and 2020, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Future compensation cost for awards not vested as of December&#160;31, 2021, was $1.2&#160;million and will be expensed over a weighted-average period of 3&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(9)&nbsp;&nbsp;&nbsp;Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has incurred losses since inception and has not recorded current or deferred income taxes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows: </font>
        </div>
        <table style="width:416pt;height:127.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Federal tax benefit at statutory rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(21.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(21.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">State tax, net of federal benefit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(12.6<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(12.6<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Permanent differences </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.2</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.1</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(4.3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(4.3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">37.1</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">40.3</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Return to provision </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">0.6</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">(2.5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total provision </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:7.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.9pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for&#160;years in which differences are expected to reverse. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Significant components of the Company&#8217;s deferred tax assets for federal income taxes consisted of the following (in thousands): </font>
        </div>
        <table style="width:416pt;height:173.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:319.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:319.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:319.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Deferred tax assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:319.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net operating losses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">25,507</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">14,474</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:319.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development credits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,862</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,166</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:319.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Start-up costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,133</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,732</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:319.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Equity compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">65</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:319.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(35,374<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(20,299<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:319.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred tax assets, net of valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">193</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:319.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Deferred tax liabilities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:319.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(193<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(107<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:319.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net deferred tax assets and liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2021, the Company has net operating loss (NOL) carryforwards for federal income tax purposes of $76.4&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOL carryforwards of $1.1&#160;million will begin to expire in 2037, if not utilized. The post-2017 federal NOL carryforwards of $75.3&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $76.4&#160;million and $71.2&#160;million, respectively that are available to offset future taxable income. The state NOL carryforwards will begin to expire in 2037 while the local NOLs expire after three&#160;years with $4.1&#160;million expiring in 2021. As of December&#160;31, 2021, the Company also had federal research and development tax credit carryforwards of $3.9&#160;million that will begin to expire in 2038, unless previously utilized. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against all of the Company&#8217;s net deferred tax assets as of December&#160;31, 2021. The valuation allowance increased by $15.1&#160;million and $11.4&#160;million during the&#160;years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections&#160;382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits NOL utilization as a&#160;percentage of apportioned taxable income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s consolidated financial statements. Tax&#160;years from 2018 and after remain subject to examination by all of the taxing jurisdictions. The NOL and credit carryforwards remain subject to review until utilized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(10)&nbsp;&nbsp;&nbsp;Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has outstanding licensing and scientific research agreements with Penn, a significant shareholder (Note 6). The Company recognized $0.8&#160;million of research and development expense for each of the&#160;years ended December&#160;31, 2021 and 2020 related to the Penn License Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(11)&nbsp;&nbsp;&nbsp;Subsequent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has evaluated subsequent events from the balance sheet date through October&#160;14, 2022, the issuance date of these consolidated financial statements and has not identified any requiring disclosure except as noted below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Moderna Collaboration and License Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, the Company entered into a Collaboration and License Agreement with ModernaTX, Inc. (Moderna License Agreement), to develop and commercialize </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for different forms of cancer. The Moderna License Agreement allows Moderna to develop and commercialize product candidates for up to twelve research targets. The Company will be responsible for discovering and optimizing development candidates, and Moderna will be responsible for the clinical development thereafter. Pursuant to the Moderna License Agreement, the Company and Moderna will form a joint steering committee, or JSC, that will be responsible for the coordination and oversight of all research activities to which the Company is responsible for providing. The </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">JSC will be comprised of three representatives each from the Company and Moderna and with Moderna having final decision-making authority, subject to customary exclusions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the research term of the Moderna License Agreement, the Company has granted Moderna an exclusive worldwide royalty free license to the Company&#8217;s intellectual property associated with the product candidates that permits Moderna to conduct its research and development activities. Upon Moderna&#8217;s election of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon execution of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0&#160;million to the Company. Moderna also will reimburse the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0&#160;million in research and development costs over the first three&#160;years from execution of the Moderna License Agreement). In addition, assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0&#160;million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. The Company is also eligible to receive tiered mid-to-high single digit royalties of net product sales, subject to adjustment. In addition, Moderna will repay the Company for certain development, regulatory and commercial milestone payments and certain royalty payments pursuant to the Company&#8217;s license agreement with the University of Pennsylvania. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Moderna Convertible Promissory Note</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Concurrent with entering into the Moderna License Agreement, the Company issued and sold to Moderna a convertible promissory note in the aggregate principal amount of $35.0&#160;million (the Note). If not earlier converted or repaid, the Note is payable on demand beginning in July&#160;2023. The Note accrues interest at an annual rate beginning at 0.33% through March&#160;2022 and then increasing by 0.767% each month thereafter capping at an annual rate of 8.0% in January&#160;2023. Upon the completion of a qualified financing event, the outstanding principal and accrued interest under the Note will automatically convert into shares of the Company issued in connection with the qualified financing at a conversion price equal to the lesser of (a)&#160;90% of the purchase price paid by other investors in such qualified financing and (b)&#160;$21.06 per share on an as converted to common stock basis. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Office and Laboratory Space</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, the Company amended its October&#160;2018 lease to add additional lab and office spaces. The lease for the additional spaces commenced in April&#160;2022 and has a term of 18&#160;months. The total future minimum lease payments for these spaces are $3.6&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2022, the Company entered into another agreement to lease additional office and laboratory space in Philadelphia, Pennsylvania. This lease commenced in March&#160;2022 and has a term of 18&#160;months with an option for the Company to renew the lease for two additional terms of six&#160;months each at the end of lease term. The total future minimum lease payments for the lease are $3.3&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Merger with Seahawk Merger Sub, Inc.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, the Company entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Seahawk Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of Sesen Bio, Inc. (Sesen Bio). The Merger Agreement provides for the merger of the Company with Merger Sub, with the Company as the surviving entity and the Company continuing as a wholly-owned subsidiary of Sesen Bio (the Merger). Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, (a)&#160;each then outstanding share of the Company&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:444pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">common stock and preferred stock (collectively, the Company&#8217;s capital stock) (including shares of the Company&#8217;s common stock issued in connection with the pre-closing financing transaction described below) will be converted into the right to receive a number of shares of Sesen Bio common stock, and (b)&#160;each then outstanding stock option to purchase the Company&#8217;s common stock will be assumed by Sesen Bio, subject to adjustment as set forth in the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following the Merger, the shareholders of the Company are expected to hold 58.3% of the combined company, and the shareholders of Sesen Bio are expected to hold 41.7% of the combined company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties entered into agreements with the Company to purchase prior to the consummation of the Merger shares of the Company&#8217;s common stock for an aggregate purchase price of $30.6&#160;million (Pre-Closing Financing). Shares of the Company&#8217;s common stock issued pursuant to the Pre-Closing Financing transaction will be converted into shares of Sesen Bio common stock in the Merger. Upon completion of the merger, the outstanding principal and unpaid interest associated with the Notes will automatically convert into the shares of Sesen Bio common stock.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tUCBS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Unaudited Consolidated Balance Sheets </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except share and per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:592pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.16pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">28,943</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">28,551</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">41,705</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Prepaid expenses and other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">2,290</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,235</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:24pt;">
                <font style="letter-spacing:0.16pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">72,938</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">29,786</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">8,677</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,084</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Right of use assets&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">6,121</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,579</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:24pt;">
                <font style="letter-spacing:0.16pt;">Total assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">87,736</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">35,449</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Deficit</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.16pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">4,085</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,322</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">8,997</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,471</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,230</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">5,184</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">898</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Finance lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,006</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Convertible promissory note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">33,175</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">157</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:24pt;">
                <font style="letter-spacing:0.16pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">53,834</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">7,691</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Deferred revenues </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">5,189</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,003</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,734</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Finance lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Other long-term liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">307</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:16pt;">
                <font style="letter-spacing:0.16pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">106,036</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">9,425</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.16pt;">Commitments (Note 6) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.16pt;">Convertible preferred stock, $0.0001 par value: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:16pt; text-indent:-8pt;">
                <font style="letter-spacing:0.16pt;">Series&#160;A convertible preferred stock, 6,138,518 shares authorized; 5,201,017 shares issued and outstanding (liquidation value of $54,091 at September&#160;30, 2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Special voting preferred stock, 1 share authorized, issued and outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:16pt; text-indent:-8pt;">
                <font style="letter-spacing:0.16pt;">Series&#160;B convertible preferred stock, 4,807,541 shares authorized, 3,499,866 shares issued and outstanding (liquidation value of $54,598 at September&#160;30, 2022) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">54,231</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">54,231</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Series&#160;B special voting preferred stock, 1 share authorized, issued and outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:24pt;">
                <font style="letter-spacing:0.16pt;">Total convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">107,808</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">107,808</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <font style="letter-spacing:0.16pt;">Stockholders&#8217; deficit: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;white-space:normal;text-align:left;">
              <div style="margin-left:16pt; text-indent:-8pt;">
                <font style="letter-spacing:0.16pt;">Common stock $0.0001 par value, 14,910,158 shares authorized, 1,153,019 and 1,084,082 shares issued and outstanding as of September&#160;30, 2022 and December&#160;31, 2021, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,141</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">818</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Accumulated other comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(141,484<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(96,997<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:24pt;">
                <font style="letter-spacing:0.16pt;">Total CARISMA Therapeutics Inc. stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(140,503<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(96,179<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:8pt;">
                <font style="letter-spacing:0.16pt;">Noncontrolling interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:24pt;">
                <font style="letter-spacing:0.16pt;">Total stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(126,108<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(81,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:338.99pt;text-align:left;">
              <div style="margin-left:24pt;">
                <font style="letter-spacing:0.16pt;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">87,736</td>
            <td style="padding:0pt;padding-left:7.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">35,449</td>
            <td style="padding:0pt;padding-left:7.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited interim consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tUCSO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:273.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Consolidated Statements of Operations and Comprehensive Loss</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except share and per share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:285.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Collaboration revenues </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">6,103</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">38,536</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">24,597</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">8,407</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,852</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">46,943</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">28,449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(40,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(28,449<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in fair value of derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,369<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest (expense) income, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(28,436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Share information: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share of common stock, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(40.16<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(26.23<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares of common stock outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,107,792</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,084,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Comprehensive loss </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(28,436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Unrealized loss on marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(44,647<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(28,436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited interim consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tUCSO1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Unaudited Consolidated Statements of Convertible Preferred Equity and Stockholders&#8217; Deficit </font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands, except per share and share data)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:350.06pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;height:227.44pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.2pt;">
          <tr style="line-height:6.2pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.2pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:85.75pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3.07pt 0pt; width:0pt;" colspan="46">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3.07pt 0pt; width:0pt;" colspan="40">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.97pt;height:18.27pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.2pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:85.75pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.124pt;">Series&#160;A</font>
                <br >
                <font style="letter-spacing:-0.124pt;">convertible</font>
                <br >
                <font style="letter-spacing:-0.124pt;">preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center; line-height:6.96pt;">
                <font style="letter-spacing:-0.124pt;">Special voting</font>
                <br >
                <font style="letter-spacing:-0.124pt;">preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.124pt;">Series&#160;B</font>
                <br >
                <font style="letter-spacing:-0.124pt;">convertible</font>
                <br >
                <font style="letter-spacing:-0.124pt;">preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.124pt;">Series&#160;B</font>
                <br >
                <font style="letter-spacing:-0.124pt;">special voting</font>
                <br >
                <font style="letter-spacing:-0.124pt;">preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:6.97pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.124pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.124pt;">paid-in </font>
                <br >
                <font style="letter-spacing:-0.124pt;">capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:6.97pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.124pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.124pt;">other </font>
                <br >
                <font style="letter-spacing:-0.124pt;">comprehensive</font>
                <br >
                <font style="letter-spacing:-0.124pt;">loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:6.97pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.124pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.124pt;">deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:6.97pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.124pt;">Noncontrolling</font>
                <br >
                <font style="letter-spacing:-0.124pt;">interests </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.727pt 0pt 2.813pt 0pt;" colspan="4" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:6.97pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.124pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:6.2pt;height:12.84pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.2pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:85.75pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 3.07pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.124pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:3.24pt 0pt 2.01pt 0pt; width:85.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.13pt;">Balance, January&#160;1, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,499,866</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">54,231</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,084,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">818</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(96,997<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(81,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:3.49pt 0pt 2.01pt 0pt; width:85.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.13pt;">Exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">68,937</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">88</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">88</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:3.49pt 0pt 2.01pt 0pt; width:85.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.13pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:3.49pt 0pt 2.01pt 0pt; width:85.75pt;text-align:left;">
              <div style="margin-left:6.5pt; text-indent:-6.5pt;">
                <font style="letter-spacing:0.13pt;">Unrealized loss on marketable </font>
                <br >
                <font style="letter-spacing:0.13pt;">securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.49pt 0pt 2.75pt 0pt; width:85.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.13pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:3.24pt 0pt 3.5pt 0pt; width:85.75pt;text-align:left;">
              <div style="margin-left:6.5pt; text-indent:-6.5pt;">
                <font style="letter-spacing:0.13pt;">Balance at September&#160;30, </font>
                <br >
                <font style="letter-spacing:0.13pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">3,499,866</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">54,231</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">1,153,019</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">1,141</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(141,484<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(126,108<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:8.74pt 0pt 2.01pt 0pt; width:85.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.13pt;">Balance, January&#160;1, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,453,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">38,054</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,084,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">339</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(56,213<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:8.74pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(41,479<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:3.49pt 0pt 2.01pt 0pt; width:85.75pt;text-align:left;">
              <div style="margin-left:6.5pt; text-indent:-6.5pt;">
                <font style="letter-spacing:0.13pt;">Sale of Series&#160;B convertible </font>
                <br >
                <font style="letter-spacing:0.13pt;">preferred stock at $15.60 per </font>
                <br >
                <font style="letter-spacing:0.13pt;">share, net of issuance costs </font>
                <br >
                <font style="letter-spacing:0.13pt;">of $151 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,046,696</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">16,177</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:3.49pt 0pt 2.01pt 0pt; width:85.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.13pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">361</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.01pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">361</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.49pt 0pt 2.75pt 0pt; width:85.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.13pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(28,436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(28,436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:3.24pt 0pt 3.5pt 0pt; width:85.75pt;text-align:left;">
              <div style="margin-left:6.5pt; text-indent:-6.5pt;">
                <font style="letter-spacing:0.13pt;">Balance at September&#160;30, </font>
                <br >
                <font style="letter-spacing:0.13pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">53,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">3,499,866</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">54,231</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">1,084,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">700</td>
            <td style="padding:0pt;padding-left:4.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(84,649<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">14,395</td>
            <td style="padding:0pt;padding-left:8.615pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.75pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(69,554<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited interim consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tUCSO2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Unaudited Consolidated Statements of Cash Flows</font>
          <br >
          <font style="letter-spacing:-0.2pt;">(in thousands)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:572.38pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:362.1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.467pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.55pt 0pt 1.8pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.55pt 0pt 1.8pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.55pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <font style="letter-spacing:0.194pt;">Cash flows from operating activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.8pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,436<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.8pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Adjustment to reconcile net loss to net cash provided by (used in) operating activities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.8pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:19.4pt;">
                <font style="letter-spacing:0.194pt;">Depreciation and amortization expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,188</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">475</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.8pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:19.4pt;">
                <font style="letter-spacing:0.194pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">361</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.8pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:19.4pt;">
                <font style="letter-spacing:0.194pt;">Reduction in the operating right of use assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,895</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">408</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.8pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:19.4pt;">
                <font style="letter-spacing:0.194pt;">Amortization of debt discount </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,995</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.8pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:19.4pt;">
                <font style="letter-spacing:0.194pt;">Change in fair value of derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,369</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:19.4pt;">
                <font style="letter-spacing:0.194pt;">Non-cash interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">176</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:19.4pt;">
                <font style="letter-spacing:0.194pt;">Changes in operating assets and liabilities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:29.1pt;">
                <font style="letter-spacing:0.194pt;">Prepaid expenses and other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,055<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(81<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:29.1pt;">
                <font style="letter-spacing:0.194pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,794</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(952<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:29.1pt;">
                <font style="letter-spacing:0.194pt;">Accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,526</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">414</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:29.1pt;">
                <font style="letter-spacing:0.194pt;">Deferred revenues </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">46,230</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.79pt 0pt 1.45pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:29.1pt;">
                <font style="letter-spacing:0.194pt;">Operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.79pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,882<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.79pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(396<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.54pt 0pt 1.45pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:38.8pt;">
                <font style="letter-spacing:0.194pt;">Net cash provided by (used in) operating activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.54pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.54pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,984</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.54pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.54pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,207<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.54pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <font style="letter-spacing:0.194pt;">Cash flows from investing activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Purchase of marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(84,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Proceeds from the sale of marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">42,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.79pt 0pt 1.45pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.79pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(4,341<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.79pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,526<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.54pt 0pt 1.45pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:38.8pt;">
                <font style="letter-spacing:0.194pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.54pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.54pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(46,369<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.54pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.54pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,526<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.54pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <font style="letter-spacing:0.194pt;">Cash flows from financing activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Proceeds from the exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">88</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Payment of principal related to the finance lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(766<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.79pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Proceeds from failed sale-leaseback arrangement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">505</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.79pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.78pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Payment of finance liability from failed sale-leaseback arrangement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(50<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.78pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Proceeds from the sale of Series&#160;B convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">16,328</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.78pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Payment of Series&#160;B issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(366<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.78pt 0pt 1.45pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Proceeds from issuance of convertible promissory note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">35,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.53pt 0pt 1.45pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:38.8pt;">
                <font style="letter-spacing:0.194pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.53pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.53pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">34,777</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.53pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.53pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">15,962</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.69999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.53pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.194pt;">Net increase (decrease) in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.53pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.53pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">392</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.53pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.53pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(13,771<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.78pt 0pt 1.45pt 0pt; width:362.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.194pt;">Cash and cash equivalents at beginning of the period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">28,551</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">51,788</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.53pt 0pt 2.2pt 0pt; width:362.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.194pt;">Cash and cash equivalents at end of the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.53pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.53pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">28,943</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.53pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.53pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">38,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.70000000000005pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.03pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <font style="letter-spacing:0.194pt;">Supplemental disclosures of cash flow information: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.78pt 0pt 2.2pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Cash paid for interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(50<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.70000000000005pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.03pt 0pt 0.5pt 0pt; width:362.1pt;text-align:left;">
              <font style="letter-spacing:0.194pt;">Supplemental disclosures of non-cash financing and investing activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.78pt 0pt 2.2pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Property and equipment in accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">90</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.78pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">212</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.03pt 0pt 2.2pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Unrealized loss on marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.03pt 0pt 2.2pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Allocation of debt proceeds to derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">3,820</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:1.646pt 0pt 2.254pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:19.4pt; text-indent:-9.7pt; line-height:10.6999999999999pt; margin-bottom:-0.499999999999978pt;">
                <font style="letter-spacing:0.194pt;">Operating lease right of use assets obtained in exchange for operating lease </font>
                <br >
                <font style="letter-spacing:0.194pt;">liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.144pt 0pt 1.756pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.144pt 0pt 1.756pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,437</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.144pt 0pt 1.756pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.144pt 0pt 1.756pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9.7pt;">
            <td style="padding:2.03pt 0pt 2.2pt 0pt; width:362.1pt;text-align:left;">
              <div style="margin-left:9.7pt;">
                <font style="letter-spacing:0.194pt;">Operating lease right of use assets obtained in exchange for finance lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,471</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.03pt 0pt 1.45pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:20.62pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">See accompanying notes to the unaudited interim consolidated financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a><a name="tNTTI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notes to the Interim Consolidated Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(1)&nbsp;&nbsp;&nbsp;Background</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CARISMA Therapeutics Inc., a Delaware Corporation (the Company), is a clinical-stage biopharmaceutical company focused on utilizing the Company&#8217;s proprietary macrophage and monocyte cell engineering platform to develop transformative therapies to treat cancer and other serious disorders. Cell therapy enables the utilization of reprogrammed living cells to perform complex functions such as clearance of tumor cells or resolution of inflammation. The Company&#8217;s initial focus is its proprietary Chimeric Antigen Receptor Macrophage (CAR-M) platform, which redirects macrophages against specific tumor associate antigens and enables targeted anti-tumor immunity by utilizing genetically modifying myeloid cells (macrophages and monocytes) to express chimeric antigen receptors, or CARs, enabling the innate immune cells to recognize specific tumor associated antigens on the surface of tumor cells. The Company&#8217;s clinical lead product candidate CT-0508 is an ex vivo gene-modified autologous CAR-M cell therapy product intended to treat solid tumors that overexpress HER2. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company received an investigational new drug application, or IND, clearance for CT-0508 for the treatment of HER2-overexpressing solid tumors in July&#160;2020 and dosed the first patient in March&#160;2021. The Food and Drug Administration, or FDA, granted CT-0508 Fast Track Status in September&#160;2021. As of September&#160;1, 2022, enrollment in group 1 of the first in human study has been completed with 9 patients successfully dosed with CT-0508, and group 2 is currently open for enrollment with an additional 9 patients to be dosed in the study. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2022, the Company entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Seahawk Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of Sesen Bio, Inc. (Sesen Bio). The Merger Agreement provides for the merger of the Company with Merger Sub, with the Company as the surviving entity and the Company continuing as a wholly-owned subsidiary of Sesen Bio (the Merger). Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, (a)&#160;each then outstanding share of the Company&#8217;s common stock and preferred stock (collectively, the Company&#8217;s capital stock) (including shares of the Company&#8217;s common stock issued in connection with the pre-closing financing transaction described below) will be converted into the right to receive a number of shares of Sesen Bio common stock, and (b)&#160;each then outstanding stock option to purchase the Company&#8217;s common stock will be assumed by Sesen Bio, subject to adjustment as set forth in the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following the Merger, the shareholders of the Company are expected to hold 58.3% of the combined company, and the shareholders of Sesen Bio are expected to hold 41.7% of the combined company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties entered into agreements with the Company to purchase prior to the consummation of the Merger shares of the Company&#8217;s common stock for an aggregate purchase price of $30.6&#160;million (Pre-Closing Financing). Shares of the Company&#8217;s common stock issued pursuant to the Pre-Closing Financing transaction will be converted into shares of Sesen Bio common stock in the Merger. Upon completion of the Merger, the outstanding principal and unpaid interest associated with the $35.0&#160;million convertible promissory note will automatically convert into the shares of Sesen Bio common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(2)&nbsp;&nbsp;&nbsp;Development-Stage Risks and Liquidity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has incurred losses since inception and has an accumulated deficit of $141.5&#160;million as of September&#160;30, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. Management believes that cash, cash equivalents and marketable securities of $70.6&#160;million as of September&#160;30, 2022 are sufficient to sustain planned operations into the third quarter of 2023. As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the unaudited interim consolidated financial statements are issued. The accompanying unaudited interim consolidated financial statements have been prepared on a going-concern basis, which contemplates the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">realization of assets and satisfaction of liabilities in the normal course of business. The unaudited interim consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include but are not limited to private placements of equity and/or debt, licensing and/or marketing arrangements, and public offerings of equity and/or debt securities. There is no assurance that such financing will be available when needed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(3)&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The summary of significant accounting policies included in the Company&#8217;s annual consolidated financial statements that can be found elsewhere in this registration statement, have not materially changed, except as set forth below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interim Financial Statements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the opinion of management, the accompanying interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the consolidated financial statements) considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2022 and its results of operations for the nine&#160;months ended September&#160;30, 2022 and 2021. Operating results for the nine&#160;months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The interim consolidated financial statements, presented herein, do not contain the required disclosures under U.S. GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Significant areas that require management&#8217;s estimates include the fair value of the Company&#8217;s common stock, the derivative liability, stock-based compensation assumptions, the estimated useful lives of property and equipment and accrued research and development expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fair Value of Financial Instruments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">instruments. Due to the related-party relationship of the Convertible Promissory Note (Note 5), it is impractical to determine the fair value of the debt. The derivative liability is recorded at its estimated fair value. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Marketable Securities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s marketable securities consist of investments in U.S. Treasuries that are classified as available-for-sale. The securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, a component of stockholders&#8217; deficit. Realized gains and losses and declines in value determined to be other than temporary are included in the Company&#8217;s statements of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fair Value Measurements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;1 Inputs:&nbsp;&nbsp;&nbsp;Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;2 Inputs:&nbsp;&nbsp;&nbsp;Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;3 Inputs:&nbsp;&nbsp;&nbsp;Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </font>
        </div>
        <table style="width:456pt;height:172pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:329.19pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair value measurement at </font>
                <br >
                <font style="letter-spacing:-0.16pt;">reporting date using </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:329.19pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Level&#160;1) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Level&#160;2) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Level&#160;3) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:329.19pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">September&#160;30, 2022:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.19pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash equivalents&#8201;&#8211;&#8201;money markets accounts </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">575</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Marketable securities&#8201;&#8211;&#8201;U.S. Treasuries </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.19pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Derivative liability&#8201;&#8211;&#8201;redemption feature on convertible promissory note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,189</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:329.19pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">December&#160;31, 2021:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.19pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.19pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash equivalents&#8201;&#8211;&#8201;money markets accounts </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,182</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
            <td style="padding:0pt;padding-left:7.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:7.8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of the Company&#8217;s marketable securities as of September&#160;30, 2022. </font>
        </div>
        <table style="width:456pt;height:56.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.06pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amortized </font>
                <br >
                <font style="letter-spacing:-0.16pt;">costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.16pt;">unrealized </font>
                <br >
                <font style="letter-spacing:-0.16pt;">loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.06pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Available-for-sale marketable securities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.06pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">U.S. Treasury securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41,865</td>
            <td style="padding:0pt;padding-left:1.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(160<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">41,705</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company evaluated a redemption feature within the convertible promissory note issued in January&#160;2022 and determined bifurcation of the redemption feature was required. The redemption feature is </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">classified as a liability on the accompanying consolidated balance sheet and is marked-to-market each reporting period with the changes in fair value recorded in the accompanying statements of operations until it is triggered, terminated, reclassified or otherwise settled. The fair value of the derivative was determined based on an income approach that identified the cash flows using a &#8220;with-and-without&#8221; valuation methodology. The inputs used to determine the estimated fair value of the derivative instrument were based primarily on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2022, the discount factor used was 12% and a 90% probability of completing a qualified financing prior to the maturity date of the convertible promissory note was assumed. The estimated time of conversion ranged from three to twelve&#160;months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table presented below is a summary of the changes in fair value of the Company&#8217;s derivative liability (Level&#160;3 measurement): </font>
        </div>
        <table style="width:416pt;height:78pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.167pt 0pt; width:345.03pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair value of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:345.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at January&#160;1, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:345.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at issuance </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,820</td>
            <td style="padding:0pt;padding-left:15.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:345.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,369</td>
            <td style="padding:0pt;padding-left:15.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:345.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,189</td>
            <td style="padding:0pt;padding-left:15.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the nine&#160;months ended September&#160;30, 2022 and 2021, there were no transfers between Level&#160;1, Level&#160;2 and Level&#160;3. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue Recognition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes revenue in accordance with ASC Topic 606, </font><font style="font-style:italic;letter-spacing:0.2pt;">Revenue from Contracts with Customers</font><font style="letter-spacing:0.2pt;"> (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees; (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (i)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheet. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s consolidated balance sheet. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the changes in deferred revenue (in thousands): </font>
        </div>
        <table style="width:416pt;height:78pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine&#160;months ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at the beginning of the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferral of revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,333</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:338.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Recognition of unearned revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(6,103<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:338.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at the end of the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">46,230</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:12.1pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There was no deferred revenue as of December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The current portion of deferred revenue represents advanced payments received from ModernaTX, Inc. (Moderna) for costs expected to be incurred by the Company within the next twelve&#160;months. The noncurrent portion of deferred revenue represents the $45.0&#160;million upfront, non-refundable and non- creditable payment allocated to customer option right which is not expected to be recognized within the next 12&#160;months. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Upfront license fees</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Customer options</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and development services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:23pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Milestone payments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Loss per Share Attributable to Common Shareholders</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </font>
        </div>
        <table style="width:456pt;height:114pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:302.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,201,017</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,499,866</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,499,866</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Class&#160;B exchangeable shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">937,501</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">937,501</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Class&#160;B-1 exchangeable shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">297,764</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">297,764</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stock options to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,804,246</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,869,438</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:302.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Conversion of convertible promissory note </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">1,688,301</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:302.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">13,428,695</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">11,805,586</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The above table assumes outstanding principal and interest converted into shares of the Company&#8217;s common stock at $21.06 per share. Conversion of the promissory note and related interest may vary depending on the terms and conditions to upon conversion of the promissory note. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Accounting Pronouncements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, the FASB issued ASU No. 2020-06, </font><font style="font-style:italic;letter-spacing:0.2pt;">Debt&#8201;&#8212;&#8201;Debt with Conversion and Other Options</font><font style="letter-spacing:0.2pt;"> (Subtopic 470-20) </font><font style="font-style:italic;letter-spacing:0.2pt;">and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity</font><font style="letter-spacing:0.2pt;"> (Subtopic 815-40)</font><font style="font-style:italic;letter-spacing:0.2pt;">: Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</font><font style="letter-spacing:0.2pt;"> (ASU 2020-06), which simplifies the accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if converted method. The Company adopted the ASU effective January&#160;1, 2022 using the modified retrospective method of adoption. The Company applied this ASU to the convertible promissory note entered into in January&#160;2022 (see Note&#160;5). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(4)&nbsp;&nbsp;&nbsp;Property and Equipment, net</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:7.12pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment, net consisted of the following (in thousands): </font>
        </div>
        <table style="width:416pt;height:129.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:262.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:262.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">917</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">214</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:262.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lab equipment</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">9,749</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,694</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:262.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Office furniture </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">267</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">267</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:262.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">340</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">317</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:262.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Construction in progress </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:262.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,286</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,505</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:262.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: accumulated depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(2,609<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,421<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:262.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">8,677</td>
            <td style="padding:0pt;padding-left:16.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">3,084</td>
            <td style="padding:0pt;padding-left:16.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:6.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:6.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Lab equipment includes finance lease right of use (ROU) assets of $2.2&#160;million and are recorded net of accumulated amortization of $83,000 as of September&#160;30, 2022. There were no financial lease ROU assets as of December&#160;31, 2021. Lab equipment includes $0.6&#160;million resulting from a failed sale-leaseback (see Note&#160;6) and is recorded net of accumulated depreciation of $62,000 as of September&#160;30, 2022. There were no assets from failed sale-leasebacks as of December&#160;31, 2021.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Depreciation and amortization expense was $1.2&#160;million and $0.5&#160;million for the nine&#160;months ended September&#160;30, 2022 and 2021, respectively. </font>
        </div>
        <div style="margin-top:10.02pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(5)&nbsp;&nbsp;&nbsp;Convertible Promissory Note</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, concurrent with entering into the Moderna Collaboration and License Agreement (Note 8), the Company issued and sold to Moderna a convertible promissory note in the aggregate principal amount of $35.0&#160;million (the Note). If not earlier converted or repaid, the Note is payable on demand beginning in July&#160;2023. The Note accrues interest at an annual rate beginning at 0.33% through March&#160;2022 and then increasing by 0.767% each month thereafter capping at an annual rate of 8.0% in January&#160;2023. Upon the completion of a qualified financing event, the outstanding principal and accrued interest under the Note will automatically convert into shares of the Company issued in connection with the qualified financing at a conversion price equal to the lesser of (a)&#160;90% of the purchase price paid by other investors in such qualified financing and (b)&#160;$21.06 per share on an as converted to common stock basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.22pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since the Note is convertible into either (i)&#160;a variable number of shares of stock or (ii)&#160;a fixed conversion price, the Company evaluated the conversion provisions as a redemption feature and as a conversion feature, with the redemption feature evaluated as an embedded derivative and bifurcated from the proceeds of the Note due to the substantial premium paid upon redemption. Upon bifurcating the redemption feature, the Company recorded a debt discount of $3.8&#160;million which represents the initial fair value of the derivative liability that will be recognized as interest expense over the term of the Note. For the nine&#160;months ended September&#160;30, 2022, the Company recognized a change in fair value related to the redemption feature of $1.4&#160;million, which was included in the change in fair value of derivative liability on the consolidated statement of operations. For the nine&#160;months ended September&#160;30, 2022, the Company recognized interest expense of $2.6&#160;million of which $2.0&#160;million was related to the amortization of the debt discount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the carrying value of the Note at September&#160;30, 2022 (in thousands): </font>
        </div>
        <table style="width:416pt;height:40.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Principal amount of the Note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">35,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unamortized debt discount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1,825<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Carrying value of the Note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">33,175</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.92pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(6)&nbsp;&nbsp;&nbsp;Commitments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, the Company amended its October&#160;2018 lease to add additional lab and office spaces. The lease for the additional spaces commenced in April&#160;2022 and has a term of 18&#160;months. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2022, the Company entered into another agreement to lease additional office and laboratory space in Philadelphia, Pennsylvania. This lease commenced in March&#160;2022 and has a term of 18&#160;months with an option for the Company to renew the lease for two additional terms of six&#160;months each at the end of lease term. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2022, the Company entered into a purchase and sale agreement under which the Company sold lab equipment for a purchase price of $0.5&#160;million. Concurrent with the sale of the equipment, the Company entered into a three-year lease agreement, whereby the Company will lease back the equipment at an annual rental rate of $0.2&#160;million. The Company was considered to have continuing involvement, and thus, accounted for the transaction as a failed sale-leaseback, with the equipment remaining on the balance sheet and the sale proceeds recorded as a finance liability. No gain or loss was recorded on the failed sale-leaseback. The Company continues to carry the lab equipment as property and equipment, net on the accompanying consolidated balance sheet. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of September&#160;30, 2022, the Company had a $0.5&#160;million financing liability recorded in other liabilities and other noncurrent liabilities on the unaudited consolidated balance sheet. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company also has obligations under an arrangement for the use of certain lab equipment that are classified as finance leases that commenced in May&#160;2022 and have an end date of April&#160;2025. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The elements of the lease costs were as follows (in thousands): </font>
        </div>
        <table style="width:416pt;height:122pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine&#160;months ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,331</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">847</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.25pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Finance lease cost: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization of lease assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">264</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest on lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">50</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total finance lease cost </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">314</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,645</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">847</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Lease term and discount rate information related to leases was as follows: </font>
        </div>
        <table style="width:416pt;height:98.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Weighted-average remaining lease term (in&#160;years) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2.0</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2.4</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Weighted-average discount rate </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">9.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">9.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:26.35pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Supplemental cash flow information (in thousands): </font>
        </div>
        <table style="width:416pt;height:91pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine&#160;months ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.25pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash paid for amounts included in the measurement of lease liabilities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating cash used in operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,319</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">830</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating cash used for finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">50</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Financing cash used in finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">766</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Future maturities of lease liabilities were as follows as of September&#160;30, 2022 (in thousands): </font>
        </div>
        <table style="width:416pt;height:174.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Fiscal year ending:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2022 (remaining three&#160;months) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">110</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,430</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,137</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,161</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">437</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">213</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">216</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">219</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2026 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">226</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">233</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Thereafter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">425</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total future minimum payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,900</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,907</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Less imputed interest </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(191<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(720<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:289.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Present value of lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,709</td>
            <td style="padding:0pt;padding-left:9.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6,187</td>
            <td style="padding:0pt;padding-left:13.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(7)&nbsp;&nbsp;&nbsp;Stock-based Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2017, the Company adopted the 2017 Stock Incentive Plan (the Plan) as amended that authorized the Company to grant up to 1,739,936 shares of common stock. In 2022, the Company amended the Plan and increased the total number of shares authorized under the Plan to 2,664,018. As of September&#160;30, 2022, there were 631,560 shares available to be granted. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over four&#160;years. The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations: </font>
        </div>
        <table style="width:416pt;height:76.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.66pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.66pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:337.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">122</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">135</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">113</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">226</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:337.66pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">235</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">361</td>
            <td style="padding:0pt;padding-left:3.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:12.8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of stock option activity under the Plan: </font>
        </div>
        <table style="width:456pt;height:169pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:236.73pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">remaining </font>
                <br >
                <font style="letter-spacing:-0.16pt;">contractual </font>
                <br >
                <font style="letter-spacing:-0.16pt;">term (years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Intrinsic </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding as of January&#160;1, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,869,438</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.85</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">107,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.67</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(68,937<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.28</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">97</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(101,844<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.78</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expired </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,411<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">1.89</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding as of September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,804,246</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.92</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.6</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,441</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercisable as of September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,039,047</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.51</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6.9</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,243</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4pt 0pt 2.25pt 0pt; width:236.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and expected to vest at September&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,804,246</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.92</td>
            <td style="padding:0pt;padding-left:10.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.6</td>
            <td style="padding:0pt;padding-left:13.785pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,441</td>
            <td style="padding:0pt;padding-left:9.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The weighted-average grant-date per share fair values of options granted during the nine&#160;months ended September&#160;30, 2022 and 2021 was $1.46 and $1.44, respectively. The fair values during the nine&#160;months ended September&#160;30, 2022 and 2021 were estimated using the Black-Scholes option-pricing model based on the following assumptions: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:97pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:287.43pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nine Months Ended September&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:287.43pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:72.28pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:72.28pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:287.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">2.40%&#8201;&#8211;&#8201;3.05%</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">0.98%&#8201;&#8211;&#8201;1.19%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:287.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">6&#160;years</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">6&#160;years</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:287.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">54.54%&#8201;&#8211;&#8201;56.50%</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">53.27%&#8201;&#8211;&#8201;54.22%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:287.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:287.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Estimated fair value of the Company&#8217;s common stock per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$2.68</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:72.28pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$2.77</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.3pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Future compensation cost for awards not vested as of September&#160;30, 2022 was $0.9&#160;million and will be expensed over a weighted-average period of 2.5&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(8)&nbsp;&nbsp;&nbsp;Moderna Collaboration and License Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2022, the Company entered into a Collaboration and License Agreement with Moderna (Moderna License Agreement), to develop and commercialize </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for different forms of cancer. The Moderna License Agreement allows Moderna to develop and commercialize product candidates for up to twelve research targets. The Company is responsible for discovering and optimizing development candidates, and Moderna is responsible for the clinical development thereafter. Pursuant to the Moderna License Agreement, the Company and Moderna formed a joint steering committee, or JSC, that is responsible for the coordination and oversight of all research activities to which the Company is responsible for providing. The JSC is comprised of three representatives each from the Company and Moderna and with Moderna having final decision-making authority, subject to customary exclusions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the research term of the Moderna License Agreement, the Company has granted Moderna an exclusive worldwide royalty free license to the Company&#8217;s intellectual property associated with the product candidates that permits Moderna to conduct its research and development activities. Upon Moderna&#8217;s election of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon execution of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0&#160;million to the Company. Moderna also will reimburse the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0&#160;million in research and development costs over the first three&#160;years from execution of the Moderna License Agreement). In addition, assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0&#160;million and $253.0&#160;million per product in development target designation, development, regulatory and commercial milestone payments. The Company is also eligible to receive tiered mid-to-high single digit royalties of net product sales, subject to adjustment. In addition, Moderna will repay the Company for certain development, regulatory and commercial milestone payments and certain royalty payments pursuant to the Company&#8217;s license agreement with the University of Pennsylvania. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the JSC. The Company determined that there were two performance obligations comprised of (1)&#160;research and development services and (2)&#160;option rights. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC5">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:155pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the amendment. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided, using an input method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transaction price allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna elects to exercise or elects to not exercise its option right to license and commercialize the underlying research and development target. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company included the $45.0&#160;million upfront payment and $73.9&#160;million of variable consideration for expected research and development services to be performed during the five year contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the nine&#160;months ended September&#160;30, 2022, the Company recognized $6.1&#160;million of research and development services as collaboration revenues as the Company is the principal in providing such services. The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of September&#160;30, 2022 (in thousands): </font>
        </div>
        <table style="width:416pt;height:78pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:276.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction price </font>
                <br >
                <font style="letter-spacing:-0.16pt;">allocated </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Transaction price </font>
                <br >
                <font style="letter-spacing:-0.16pt;">unsatisfied </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:276.51pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Performance obligations: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">73,937</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">67,834</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:276.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Option rights </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:276.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total performance obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">118,937</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">112,834</td>
            <td style="padding:0pt;padding-left:10.015pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(9)&nbsp;&nbsp;&nbsp;Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has outstanding licensing and scientific research agreements with the University of Pennsylvania, a significant shareholder. The Company recognized $1.4&#160;million and $1.0&#160;million of research and development expense for the nine&#160;months ended September&#160;30, 2022 and 2021, respectively, related to the license agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(10)&nbsp;&nbsp;&nbsp;Subsequent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has evaluated subsequent events from the balance sheet date through November&#160;21, 2022, the issuance date of these unaudited interim consolidated financial statements and has not identified any requiring disclosure except as noted below.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tAAPM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX A-1</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AGREEMENT AND PLAN OF MERGER</font>
          <br >
          <font style="letter-spacing:-0.2pt;">AND REORGANIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">among:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.,</font>
          <br >
          <font style="letter-spacing:-0.2pt;">a Delaware corporation;</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SEAHAWK MERGER SUB, INC.,</font>
          <br >
          <font style="letter-spacing:-0.2pt;">a Delaware corporation; and</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.,</font>
          <br >
          <font style="letter-spacing:-0.2pt;">a Delaware corporation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dated as of September&#160;20, 2022</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="TOC6">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:620.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:414.63pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; text-align:left; width:51pt;white-space:nowrap;font-weight:bold;">
                <a href="#tS1OT"><font style="letter-spacing:-0.2pt;">Section&#160;1.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:51pt;font-weight:bold;">
                <a href="#tS1OT"><font style="letter-spacing:-0.2pt;">DESCRIPTION OF TRANSACTION</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tS1OT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tS1OT">A-1-2</a></font> <a href="#tS1OT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1MUT"><font style="letter-spacing:0.2pt;">1.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1MUT"><font style="font-weight:bold;letter-spacing:-0.2pt;">The Merger</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1MUT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1MUT">A-1-2</a></font> <a href="#t1MUT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1OTM"><font style="letter-spacing:0.2pt;">1.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1OTM"><font style="font-weight:bold;letter-spacing:-0.2pt;">Effects of the Merger</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1OTM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1OTM">A-1-2</a></font> <a href="#t1OTM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1ETU"><font style="letter-spacing:0.2pt;">1.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1ETU"><font style="font-weight:bold;letter-spacing:-0.2pt;">Closing; Effective Time</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1ETU">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1ETU">A-1-2</a></font> <a href="#t1ETU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1OIA"><font style="letter-spacing:0.2pt;">1.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1OIA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Certificate of Incorporation and Bylaws; Directors and Officers</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1OIA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1OIA">A-1-2</a></font> <a href="#t1OIA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1OS"><font style="letter-spacing:0.2pt;">1.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1OS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Conversion of Shares</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1OS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1OS">A-1-3</a></font> <a href="#t1OS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1OTC"><font style="letter-spacing:0.2pt;">1.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1OTC"><font style="font-weight:bold;letter-spacing:-0.2pt;">Closing of the Company&#8217;s Transfer Books</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1OTC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1OTC">A-1-4</a></font> <a href="#t1OTC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1OC"><font style="letter-spacing:0.2pt;">1.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1OC"><font style="font-weight:bold;letter-spacing:-0.2pt;">Surrender of Certificates</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1OC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1OC">A-1-4</a></font> <a href="#t1OC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t18RI"><font style="letter-spacing:0.2pt;">1.8</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t18RI"><font style="font-weight:bold;letter-spacing:-0.2pt;">Appraisal Rights</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t18RI">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t18RI">A-1-5</a></font> <a href="#t18RI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1AIA"><font style="letter-spacing:0.2pt;">1.9</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1AIA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Further Action</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1AIA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1AIA">A-1-5</a></font> <a href="#t1AIA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1TPA"><font style="letter-spacing:0.2pt;">1.10</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1TPA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Withholding</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1TPA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1TPA">A-1-6</a></font> <a href="#t1TPA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1ONC"><font style="letter-spacing:0.2pt;">1.11</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1ONC"><font style="font-weight:bold;letter-spacing:-0.2pt;">Calculation of Net Cash</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1ONC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1ONC">A-1-6</a></font> <a href="#t1ONC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; text-align:left; width:51pt;white-space:nowrap;font-weight:bold;">
                <a href="#tS2AW"><font style="letter-spacing:-0.2pt;">Section&#160;2.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:51pt;font-weight:bold;">
                <a href="#tS2AW"><font style="letter-spacing:-0.2pt;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tS2AW">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tS2AW">A-1-7</a></font> <a href="#tS2AW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2OS"><font style="letter-spacing:0.2pt;">2.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2OS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Due Organization; Subsidiaries</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2OS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2OS">A-1-7</a></font> <a href="#t2OS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2DTC"><font style="letter-spacing:0.2pt;">2.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2DTC"><font style="font-weight:bold;letter-spacing:-0.2pt;">Organizational Documents</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2DTC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2DTC">A-1-8</a></font> <a href="#t2DTC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2BNO"><font style="letter-spacing:0.2pt;">2.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2BNO"><font style="font-weight:bold;letter-spacing:-0.2pt;">Authority; Binding Nature of Agreement</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2BNO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2BNO">A-1-8</a></font> <a href="#t2BNO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2RTA"><font style="letter-spacing:0.2pt;">2.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2RTA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Vote Required</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2RTA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2RTA">A-1-8</a></font> <a href="#t2RTA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2CST"><font style="letter-spacing:0.2pt;">2.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2CST"><font style="font-weight:bold;letter-spacing:-0.2pt;">Non-Contravention; Consents</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2CST">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2CST">A-1-8</a></font> <a href="#t2CST"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t26C"><font style="letter-spacing:0.2pt;">2.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t26C"><font style="font-weight:bold;letter-spacing:-0.2pt;">Capitalization</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t26C">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t26C">A-1-9</a></font> <a href="#t26C"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t27ST"><font style="letter-spacing:0.2pt;">2.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t27ST"><font style="font-weight:bold;letter-spacing:-0.2pt;">Financial Statements</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t27ST">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t27ST">A-1-10</a></font> <a href="#t27ST"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2OCA"><font style="letter-spacing:0.2pt;">2.8</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2OCA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Absence of Changes</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2OCA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2OCA">A-1-11</a></font> <a href="#t2OCA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2OUL"><font style="letter-spacing:0.2pt;">2.9</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2OUL"><font style="font-weight:bold;letter-spacing:-0.2pt;">Absence of Undisclosed Liabilities</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2OUL">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2OUL">A-1-11</a></font> <a href="#t2OUL"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2TAE"><font style="letter-spacing:0.2pt;">2.10</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2TAE"><font style="font-weight:bold;letter-spacing:-0.2pt;">Title to Assets</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2TAE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2TAE">A-1-11</a></font> <a href="#t2TAE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2PLN"><font style="letter-spacing:0.2pt;">2.11</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2PLN"><font style="font-weight:bold;letter-spacing:-0.2pt;">Real Property; Leasehold</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2PLN">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2PLN">A-1-12</a></font> <a href="#t2PLN"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t21PR"><font style="letter-spacing:0.2pt;">2.12</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t21PR"><font style="font-weight:bold;letter-spacing:-0.2pt;">Intellectual Property</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t21PR">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t21PR">A-1-12</a></font> <a href="#t21PR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2CAC"><font style="letter-spacing:0.2pt;">2.13</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2CAC"><font style="font-weight:bold;letter-spacing:-0.2pt;">Agreements, Contracts and Commitments</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2CAC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2CAC">A-1-14</a></font> <a href="#t2CAC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2PR"><font style="letter-spacing:0.2pt;">2.14</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2PR"><font style="font-weight:bold;letter-spacing:-0.2pt;">Compliance; Permits; Restrictions</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2PR">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2PR">A-1-15</a></font> <a href="#t2PR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2PO"><font style="letter-spacing:0.2pt;">2.15</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2PO"><font style="font-weight:bold;letter-spacing:-0.2pt;">Legal Proceedings; Orders</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2PO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2PO">A-1-17</a></font> <a href="#t2PO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t21MA"><font style="letter-spacing:0.2pt;">2.16</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t21MA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Tax Matters</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t21MA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t21MA">A-1-18</a></font> <a href="#t21MA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2ALM"><font style="letter-spacing:0.2pt;">2.17</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2ALM"><font style="font-weight:bold;letter-spacing:-0.2pt;">Employee and Labor Matters; Benefit Plans</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2ALM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2ALM">A-1-19</a></font> <a href="#t2ALM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2MSJ"><font style="letter-spacing:0.2pt;">2.18</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2MSJ"><font style="font-weight:bold;letter-spacing:-0.2pt;">Environmental Matters</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2MSJ">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2MSJ">A-1-22</a></font> <a href="#t2MSJ"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2TCH"><font style="letter-spacing:0.2pt;">2.19</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2TCH"><font style="font-weight:bold;letter-spacing:-0.2pt;">Insurance</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2TCH">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2TCH">A-1-22</a></font> <a href="#t2TCH"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2FAN"><font style="letter-spacing:0.2pt;">2.20</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2FAN"><font style="font-weight:bold;letter-spacing:-0.2pt;">No Financial Advisors</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2FAN">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2FAN">A-1-23</a></font> <a href="#t2FAN"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2WAS"><font style="letter-spacing:0.2pt;">2.21</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2WAS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Transactions with Affiliates</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2WAS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2WAS">A-1-23</a></font> <a href="#t2WAS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2NOT"><font style="letter-spacing:0.2pt;">2.22</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2NOT"><font style="font-weight:bold;letter-spacing:-0.2pt;">Anti-Bribery</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2NOT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2NOT">A-1-23</a></font> <a href="#t2NOT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t2OOR"><font style="letter-spacing:0.2pt;">2.23</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t2OOR"><font style="font-weight:bold;letter-spacing:-0.2pt;">Disclaimer of Other Representations or Warranties</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t2OOR">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t2OOR">A-1-23</a></font> <a href="#t2OOR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; text-align:left; width:51pt;white-space:nowrap;font-weight:bold;">
                <a href="#tS3AW"><font style="letter-spacing:-0.2pt;">Section&#160;3.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:51pt;font-weight:bold;">
                <a href="#tS3AW"><font style="letter-spacing:-0.2pt;">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tS3AW">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tS3AW">A-1-23</a></font> <a href="#tS3AW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3OS"><font style="letter-spacing:0.2pt;">3.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3OS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Due Organization; Subsidiaries</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3OS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3OS">A-1-23</a></font> <a href="#t3OS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3DPH"><font style="letter-spacing:0.2pt;">3.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3DPH"><font style="font-weight:bold;letter-spacing:-0.2pt;">Organizational Documents</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3DPH">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3DPH">A-1-24</a></font> <a href="#t3DPH"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3BNO"><font style="letter-spacing:0.2pt;">3.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3BNO"><font style="font-weight:bold;letter-spacing:-0.2pt;">Authority; Binding Nature of Agreement</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3BNO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3BNO">A-1-24</a></font> <a href="#t3BNO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:647.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:414.63pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3RAT"><font style="letter-spacing:0.2pt;">3.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3RAT"><font style="font-weight:bold;letter-spacing:-0.2pt;">Vote Required</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3RAT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3RAT">A-1-25</a></font> <a href="#t3RAT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3CST"><font style="letter-spacing:0.2pt;">3.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3CST"><font style="font-weight:bold;letter-spacing:-0.2pt;">Non-Contravention; Consents</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3CST">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3CST">A-1-25</a></font> <a href="#t3CST"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t36C"><font style="letter-spacing:0.2pt;">3.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t36C"><font style="font-weight:bold;letter-spacing:-0.2pt;">Capitalization</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t36C">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t36C">A-1-26</a></font> <a href="#t36C"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3FFS"><font style="letter-spacing:0.2pt;">3.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3FFS"><font style="font-weight:bold;letter-spacing:-0.2pt;">SEC Filings; Financial Statements</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3FFS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3FFS">A-1-27</a></font> <a href="#t3FFS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3OCA"><font style="letter-spacing:0.2pt;">3.8</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3OCA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Absence of Changes</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3OCA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3OCA">A-1-29</a></font> <a href="#t3OCA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3OUL"><font style="letter-spacing:0.2pt;">3.9</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3OUL"><font style="font-weight:bold;letter-spacing:-0.2pt;">Absence of Undisclosed Liabilities</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3OUL">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3OUL">A-1-29</a></font> <a href="#t3OUL"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3TAE"><font style="letter-spacing:0.2pt;">3.10</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3TAE"><font style="font-weight:bold;letter-spacing:-0.2pt;">Title to Assets</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3TAE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3TAE">A-1-29</a></font> <a href="#t3TAE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3PLN"><font style="letter-spacing:0.2pt;">3.11</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3PLN"><font style="font-weight:bold;letter-spacing:-0.2pt;">Real Property; Leasehold</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3PLN">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3PLN">A-1-29</a></font> <a href="#t3PLN"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t31PR"><font style="letter-spacing:0.2pt;">3.12</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t31PR"><font style="font-weight:bold;letter-spacing:-0.2pt;">Intellectual Property</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t31PR">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t31PR">A-1-29</a></font> <a href="#t31PR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3CAC"><font style="letter-spacing:0.2pt;">3.13</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3CAC"><font style="font-weight:bold;letter-spacing:-0.2pt;">Agreements, Contracts and Commitments</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3CAC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3CAC">A-1-31</a></font> <a href="#t3CAC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t31PE"><font style="letter-spacing:0.2pt;">3.14</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t31PE"><font style="font-weight:bold;letter-spacing:-0.2pt;">Compliance; Permits</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t31PE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t31PE">A-1-33</a></font> <a href="#t31PE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3PO"><font style="letter-spacing:0.2pt;">3.15</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3PO"><font style="font-weight:bold;letter-spacing:-0.2pt;">Legal Proceedings; Orders</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3PO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3PO">A-1-35</a></font> <a href="#t3PO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t31MA"><font style="letter-spacing:0.2pt;">3.16</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t31MA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Tax Matters</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t31MA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t31MA">A-1-35</a></font> <a href="#t31MA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3ALM"><font style="letter-spacing:0.2pt;">3.17</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3ALM"><font style="font-weight:bold;letter-spacing:-0.2pt;">Employee and Labor Matters; Benefit Plans</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3ALM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3ALM">A-1-36</a></font> <a href="#t3ALM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3MSJ"><font style="letter-spacing:0.2pt;">3.18</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3MSJ"><font style="font-weight:bold;letter-spacing:-0.2pt;">Environmental Matters</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3MSJ">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3MSJ">A-1-39</a></font> <a href="#t3MSJ"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3PHM"><font style="letter-spacing:0.2pt;">3.19</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3PHM"><font style="font-weight:bold;letter-spacing:-0.2pt;">Insurance</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3PHM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3PHM">A-1-39</a></font> <a href="#t3PHM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3FAO"><font style="letter-spacing:0.2pt;">3.20</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3FAO"><font style="font-weight:bold;letter-spacing:-0.2pt;">No Financial Advisors</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3FAO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3FAO">A-1-40</a></font> <a href="#t3FAO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3WAE"><font style="letter-spacing:0.2pt;">3.21</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3WAE"><font style="font-weight:bold;letter-spacing:-0.2pt;">Transactions with Affiliates</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3WAE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3WAE">A-1-40</a></font> <a href="#t3WAE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3NPN"><font style="letter-spacing:0.2pt;">3.22</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3NPN"><font style="font-weight:bold;letter-spacing:-0.2pt;">Anti-Bribery</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3NPN">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3NPN">A-1-40</a></font> <a href="#t3NPN"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3ITP"><font style="letter-spacing:0.2pt;">3.23</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3ITP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Valid Issuance</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3ITP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3ITP">A-1-40</a></font> <a href="#t3ITP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3OFA"><font style="letter-spacing:0.2pt;">3.24</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3OFA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Opinion of Financial Advisor</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3OFA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3OFA">A-1-40</a></font> <a href="#t3OFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t3OOR"><font style="letter-spacing:0.2pt;">3.25</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t3OOR"><font style="font-weight:bold;letter-spacing:-0.2pt;">Disclaimer of Other Representations or Warranties</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t3OOR">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t3OOR">A-1-40</a></font> <a href="#t3OOR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; text-align:left; width:51pt;white-space:nowrap;font-weight:bold;">
                <a href="#tS4CO"><font style="letter-spacing:-0.2pt;">Section&#160;4.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:51pt;font-weight:bold;">
                <a href="#tS4CO"><font style="letter-spacing:-0.2pt;">CERTAIN COVENANTS OF THE PARTIES</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tS4CO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tS4CO">A-1-40</a></font> <a href="#tS4CO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t4OPB"><font style="letter-spacing:0.2pt;">4.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t4OPB"><font style="font-weight:bold;letter-spacing:-0.2pt;">Operation of Parent&#8217;s Business</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t4OPB">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t4OPB">A-1-40</a></font> <a href="#t4OPB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t4OTC"><font style="letter-spacing:0.2pt;">4.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t4OTC"><font style="font-weight:bold;letter-spacing:-0.2pt;">Operation of the Company&#8217;s Business</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t4OTC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t4OTC">A-1-43</a></font> <a href="#t4OTC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t4AI"><font style="letter-spacing:0.2pt;">4.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t4AI"><font style="font-weight:bold;letter-spacing:-0.2pt;">Access and Investigation</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t4AI">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t4AI">A-1-44</a></font> <a href="#t4AI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t44NO"><font style="letter-spacing:0.2pt;">4.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t44NO"><font style="font-weight:bold;letter-spacing:-0.2pt;">Parent Non-Solicitation</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t44NO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t44NO">A-1-45</a></font> <a href="#t44NO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t45NO"><font style="letter-spacing:0.2pt;">4.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t45NO"><font style="font-weight:bold;letter-spacing:-0.2pt;">Company Non-Solicitation</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t45NO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t45NO">A-1-46</a></font> <a href="#t45NO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t4OCM"><font style="letter-spacing:0.2pt;">4.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t4OCM"><font style="font-weight:bold;letter-spacing:-0.2pt;">Notification of Certain Matters</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t4OCM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t4OCM">A-1-47</a></font> <a href="#t4OCM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t4TA"><font style="letter-spacing:0.2pt;">4.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t4TA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Potentially Transferable Assets</font><font style="letter-spacing:0.2pt;">. </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t4TA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t4TA">A-1-48</a></font> <a href="#t4TA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; text-align:left; width:51pt;white-space:nowrap;font-weight:bold;">
                <a href="#tS5AO"><font style="letter-spacing:-0.2pt;">Section&#160;5.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:51pt;font-weight:bold;">
                <a href="#tS5AO"><font style="letter-spacing:-0.2pt;">ADDITIONAL AGREEMENTS OF THE PARTIES.</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tS5AO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tS5AO">A-1-48</a></font> <a href="#tS5AO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5SPS"><font style="letter-spacing:0.2pt;">5.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5SPS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Registration Statement; Proxy Statement/Prospectus</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5SPS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5SPS">A-1-48</a></font> <a href="#t5SPS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t52MA"><font style="letter-spacing:0.2pt;">5.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t52MA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Regulatory Matters</font><font style="letter-spacing:0.2pt;">. </font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t52MA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t52MA">A-1-49</a></font> <a href="#t52MA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5SM"><font style="letter-spacing:0.2pt;">5.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5SM"><font style="font-weight:bold;letter-spacing:-0.2pt;">Company Stockholder Matters</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5SM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5SM">A-1-50</a></font> <a href="#t5SM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5SM1"><font style="letter-spacing:0.2pt;">5.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5SM1"><font style="font-weight:bold;letter-spacing:-0.2pt;">Parent Stockholders&#8217; Meeting</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5SM1">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5SM1">A-1-51</a></font> <a href="#t5SM1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:12pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5OCC"><font style="letter-spacing:0.2pt;">5.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:12pt; text-align:left; margin-left:80pt;">
                <a href="#t5OCC"><font style="font-weight:bold;letter-spacing:-0.2pt;">Company Options, Company Convertible Note, Parent Warrants, and Parent Equity Awards</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5OCC">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5OCC">A-1-53</a></font> <a href="#t5OCC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5OOA"><font style="letter-spacing:0.2pt;">5.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5OOA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Indemnification of Officers and Directors</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5OOA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5OOA">A-1-54</a></font> <a href="#t5OOA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5AIA"><font style="letter-spacing:0.2pt;">5.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5AIA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Additional Agreements</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5AIA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5AIA">A-1-56</a></font> <a href="#t5AIA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5TIP"><font style="letter-spacing:0.2pt;">5.8</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5TIP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Disclosure</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5TIP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5TIP">A-1-56</a></font> <a href="#t5TIP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5DTP"><font style="letter-spacing:0.2pt;">5.9</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5DTP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Listing</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5DTP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5DTP">A-1-56</a></font> <a href="#t5DTP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t51MA"><font style="letter-spacing:0.2pt;">5.10</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t51MA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Tax Matters</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t51MA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t51MA">A-1-56</a></font> <a href="#t51MA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:647.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:414.63pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5PSB"><font style="letter-spacing:0.2pt;">5.11</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5PSB"><font style="font-weight:bold;letter-spacing:-0.2pt;">Legends</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5PSB">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5PSB">A-1-57</a></font> <a href="#t5PSB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5AOP"><font style="letter-spacing:0.2pt;">5.12</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5AOP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Directors and Officers</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5AOP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5AOP">A-1-57</a></font> <a href="#t5AOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5OCA"><font style="letter-spacing:0.2pt;">5.13</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5OCA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Termination of Certain Agreements and Rights</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5OCA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5OCA">A-1-57</a></font> <a href="#t5OCA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t51MP"><font style="letter-spacing:0.2pt;">5.14</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t51MP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;16 Matters</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t51MP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t51MP">A-1-57</a></font> <a href="#t51MP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5EPS"><font style="letter-spacing:0.2pt;">5.15</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5EPS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Cooperation</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5EPS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5EPS">A-1-58</a></font> <a href="#t5EPS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t51CE"><font style="letter-spacing:0.2pt;">5.16</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t51CE"><font style="font-weight:bold;letter-spacing:-0.2pt;">Allocation Certificates</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t51CE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t51CE">A-1-58</a></font> <a href="#t51CE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5FST"><font style="letter-spacing:0.2pt;">5.17</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5FST"><font style="font-weight:bold;letter-spacing:-0.2pt;">Company Financial Statements</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5FST">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5FST">A-1-58</a></font> <a href="#t5FST"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5SIA"><font style="letter-spacing:0.2pt;">5.18</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5SIA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Takeover Statutes</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5SIA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5SIA">A-1-58</a></font> <a href="#t5SIA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5LEP"><font style="letter-spacing:0.2pt;">5.19</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5LEP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Stockholder Litigation</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5LEP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5LEP">A-1-58</a></font> <a href="#t5LEP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t52BE"><font style="letter-spacing:0.2pt;">5.20</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t52BE"><font style="font-weight:bold;letter-spacing:-0.2pt;">Employee Benefits</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t52BE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t52BE">A-1-59</a></font> <a href="#t52BE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5DPT"><font style="letter-spacing:0.2pt;">5.21</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5DPT"><font style="font-weight:bold;letter-spacing:-0.2pt;">Pre-Closing Dividend</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5DPT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5DPT">A-1-59</a></font> <a href="#t5DPT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5RSP"><font style="letter-spacing:0.2pt;">5.22</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5RSP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Nasdaq Reverse Split</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5RSP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5RSP">A-1-59</a></font> <a href="#t5RSP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5SDF"><font style="letter-spacing:0.2pt;">5.23</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5SDF"><font style="font-weight:bold;letter-spacing:-0.2pt;">Parent SEC Documents</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5SDF">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5SDF">A-1-59</a></font> <a href="#t5SDF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t5OMS"><font style="letter-spacing:0.2pt;">5.24</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t5OMS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Obligations of Merger Sub</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t5OMS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t5OMS">A-1-60</a></font> <a href="#t5OMS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; text-align:left; width:51pt;white-space:nowrap;font-weight:bold;">
                <a href="#tS6PT"><font style="letter-spacing:-0.2pt;">Section&#160;6.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:51pt;font-weight:bold;">
                <a href="#tS6PT"><font style="letter-spacing:-0.2pt;">CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tS6PT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tS6PT">A-1-60</a></font> <a href="#tS6PT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t6RNT"><font style="letter-spacing:0.2pt;">6.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t6RNT"><font style="font-weight:bold;letter-spacing:-0.2pt;">No Restraints</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t6RNT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t6RNT">A-1-60</a></font> <a href="#t6RNT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t6AIP"><font style="letter-spacing:0.2pt;">6.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t6AIP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Stockholder Approval</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t6AIP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t6AIP">A-1-60</a></font> <a href="#t6AIP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t6TES"><font style="letter-spacing:0.2pt;">6.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t6TES"><font style="font-weight:bold;letter-spacing:-0.2pt;">Listing</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t6TES">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t6TES">A-1-60</a></font> <a href="#t6TES"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t6ORS"><font style="letter-spacing:0.2pt;">6.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t6ORS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Effectiveness of Registration Statement</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t6ORS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t6ORS">A-1-60</a></font> <a href="#t6ORS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:12pt; text-align:left; width:51pt;white-space:nowrap;">
                <a href="#tS7CP"><font style="letter-spacing:-0.2pt;">Section&#160;7.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:12pt; text-align:left; margin-left:51pt;">
                <a href="#tS7CP"><font style="letter-spacing:-0.2pt;">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tS7CP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">
                <font style="letter-spacing:0.2pt;"><a href="#tS7CP">A-1-60</a></font> <a href="#tS7CP"></a></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t7ORT"><font style="letter-spacing:0.2pt;">7.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t7ORT"><font style="font-weight:bold;letter-spacing:-0.2pt;">Accuracy of Representations</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t7ORT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t7ORT">A-1-60</a></font> <a href="#t7ORT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t7OCT"><font style="letter-spacing:0.2pt;">7.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t7OCT"><font style="font-weight:bold;letter-spacing:-0.2pt;">Performance of Covenants</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t7OCT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t7OCT">A-1-61</a></font> <a href="#t7OCT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t7CPS"><font style="letter-spacing:0.2pt;">7.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t7CPS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Closing Certificate</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t7CPS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t7CPS">A-1-61</a></font> <a href="#t7CPS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t7CPS1"><font style="letter-spacing:0.2pt;">7.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t7CPS1"><font style="font-weight:bold;letter-spacing:-0.2pt;">FIRPTA Certificate</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t7CPS1">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t7CPS1">A-1-61</a></font> <a href="#t7CPS1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t7OIA"><font style="letter-spacing:0.2pt;">7.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t7OIA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Termination of Investor Agreements</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t7OIA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t7OIA">A-1-61</a></font> <a href="#t7OIA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t7LAT"><font style="letter-spacing:0.2pt;">7.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t7LAT"><font style="font-weight:bold;letter-spacing:-0.2pt;">Company Lock-Up Agreements</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t7LAT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t7LAT">A-1-61</a></font> <a href="#t7LAT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:12pt; text-align:left; width:51pt;white-space:nowrap;">
                <a href="#tS8CP"><font style="letter-spacing:-0.2pt;">Section&#160;8.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:12pt; text-align:left; margin-left:51pt;">
                <a href="#tS8CP"><font style="letter-spacing:-0.2pt;">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tS8CP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">
                <font style="letter-spacing:0.2pt;"><a href="#tS8CP">A-1-61</a></font> <a href="#tS8CP"></a></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t8ORT"><font style="letter-spacing:0.2pt;">8.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t8ORT"><font style="font-weight:bold;letter-spacing:-0.2pt;">Accuracy of Representations</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t8ORT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t8ORT">A-1-61</a></font> <a href="#t8ORT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t8OCP"><font style="letter-spacing:0.2pt;">8.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t8OCP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Performance of Covenants</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t8OCP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t8OCP">A-1-62</a></font> <a href="#t8OCP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t8TCS"><font style="letter-spacing:0.2pt;">8.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t8TCS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Documents</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t8TCS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t8TCS">A-1-62</a></font> <a href="#t8TCS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t8LAT"><font style="letter-spacing:0.2pt;">8.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t8LAT"><font style="font-weight:bold;letter-spacing:-0.2pt;">Parent Lock-Up Agreements</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t8LAT">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t8LAT">A-1-62</a></font> <a href="#t8LAT"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t8PFN"><font style="letter-spacing:0.2pt;">8.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t8PFN"><font style="font-weight:bold;letter-spacing:-0.2pt;">Minimum Parent Final Net Cash</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t8PFN">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t8PFN">A-1-62</a></font> <a href="#t8PFN"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; text-align:left; width:51pt;white-space:nowrap;font-weight:bold;">
                <a href="#tSE9T"><font style="letter-spacing:-0.2pt;">Section&#160;9.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:51pt;font-weight:bold;">
                <a href="#tSE9T"><font style="letter-spacing:-0.2pt;">TERMINATION</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tSE9T">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSE9T">A-1-62</a></font> <a href="#tSE9T"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t9TAM"><font style="letter-spacing:0.2pt;">9.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t9TAM"><font style="font-weight:bold;letter-spacing:-0.2pt;">Termination</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t9TAM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t9TAM">A-1-62</a></font> <a href="#t9TAM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t9OTI"><font style="letter-spacing:0.2pt;">9.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t9OTI"><font style="font-weight:bold;letter-spacing:-0.2pt;">Effect of Termination</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t9OTI">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t9OTI">A-1-63</a></font> <a href="#t9OTI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t9TF"><font style="letter-spacing:0.2pt;">9.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t9TF"><font style="font-weight:bold;letter-spacing:-0.2pt;">Expenses; Termination Fees</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t9TF">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t9TF">A-1-64</a></font> <a href="#t9TF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; text-align:left; width:51pt;white-space:nowrap;font-weight:bold;">
                <a href="#tS1P"><font style="letter-spacing:-0.2pt;">Section&#160;10.</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:51pt;font-weight:bold;">
                <a href="#tS1P"><font style="letter-spacing:-0.2pt;">MISCELLANEOUS PROVISIONS</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#tS1P">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tS1P">A-1-65</a></font> <a href="#tS1P"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1ORA"><font style="letter-spacing:0.2pt;">10.1</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1ORA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Non-Survival of Representations and Warranties</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1ORA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1ORA">A-1-65</a></font> <a href="#t1ORA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1TAM"><font style="letter-spacing:0.2pt;">10.2</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1TAM"><font style="font-weight:bold;letter-spacing:-0.2pt;">Amendment</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1TAM">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1TAM">A-1-65</a></font> <a href="#t1TAM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-iv</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:214.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:143.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:414.63pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t103"><font style="letter-spacing:0.2pt;">10.3</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t103"><font style="font-weight:bold;letter-spacing:-0.2pt;">Waiver</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t103">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t103">A-1-65</a></font> <a href="#t103"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1ACE"><font style="letter-spacing:0.2pt;">10.4</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1ACE"><font style="font-weight:bold;letter-spacing:-0.2pt;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1ACE">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1ACE">A-1-65</a></font> <a href="#t1ACE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1LJW"><font style="letter-spacing:0.2pt;">10.5</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1LJW"><font style="font-weight:bold;letter-spacing:-0.2pt;">Applicable Law; Jurisdiction; Waiver of Jury Trial</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1LJW">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1LJW">A-1-66</a></font> <a href="#t1LJW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1TAS"><font style="letter-spacing:0.2pt;">10.6</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1TAS"><font style="font-weight:bold;letter-spacing:-0.2pt;">Assignability</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1TAS">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1TAS">A-1-66</a></font> <a href="#t1TAS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1ANA"><font style="letter-spacing:0.2pt;">10.7</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1ANA"><font style="font-weight:bold;letter-spacing:-0.2pt;">Notices</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1ANA">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1ANA">A-1-66</a></font> <a href="#t1ANA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1ATO"><font style="letter-spacing:0.2pt;">10.8</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1ATO"><font style="font-weight:bold;letter-spacing:-0.2pt;">Severability</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1ATO">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1ATO">A-1-67</a></font> <a href="#t1ATO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1RSP"><font style="letter-spacing:0.2pt;">10.9</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1RSP"><font style="font-weight:bold;letter-spacing:-0.2pt;">Other Remedies; Specific Performance</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1RSP">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1RSP">A-1-67</a></font> <a href="#t1RSP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t1TPB"><font style="letter-spacing:0.2pt;">10.10</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t1TPB"><font style="font-weight:bold;letter-spacing:-0.2pt;">No Third Party Beneficiaries</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t1TPB">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t1TPB">A-1-68</a></font> <a href="#t1TPB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:414.63pt;white-space:normal;text-align:left;">
              <div style=" float:left; margin-left:50pt; line-height:10pt; text-align:left; width:30pt;white-space:nowrap;">
                <a href="#t101"><font style="letter-spacing:0.2pt;">10.11</font>
                  <br >
                </a>
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:80pt;">
                <a href="#t101"><font style="font-weight:bold;letter-spacing:-0.2pt;">Construction</font></a>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">
                <a href="#t101">&#8203;</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#t101">A-1-68</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Schedules</font><font style="letter-spacing:0.2pt;">: </font> <br ><font style="letter-spacing:0.2pt;">Company Disclosure Schedule </font> <br ><font style="letter-spacing:0.2pt;">Parent Disclosure Schedule </font> <br ><font style="letter-spacing:0.2pt;">Schedule&#160;5.7&#8201;&#8211;&#8201;Additional Agreements </font> <br ><font style="letter-spacing:0.2pt;">Schedule&#160;5.12&#8201;&#8211;&#8201;Post-Closing Directors and Officers of Parent and the Surviving Corporation </font><br ><font style="letter-spacing:0.2pt;">Schedule&#160;N </font></div>
        <table style="width:456pt;height:160pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:60pt;">
              <font style="letter-spacing:-0.2pt;">Exhibits</font><font style="font-weight:normal;letter-spacing:0.2pt;">: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:384pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;A </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Definitions </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;B-1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Form of Company Stockholder Support Agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;B-2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Form of Parent Stockholder Support Agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;C-1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Form of Company Lock-Up Agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;C-2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Form of Parent Lock-Up Agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;D </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Form of Contingent Value Right Agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;E </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Net Cash Illustrative Calculations </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;F </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Form of Certificate of Merger </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;G </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Form of Company Stockholder Written Consent </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <font style="letter-spacing:0.2pt;">Exhibit&#160;H </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;">
              <font style="letter-spacing:0.2pt;">Exchange Ratio Calculation</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-v</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</font><font style="letter-spacing:0.2pt;"> (this &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) is made and entered into as of September&#160;20, 2022, by and among </font><font style="font-weight:bold;letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="letter-spacing:0.2pt;">, a Delaware corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221;), </font><font style="font-weight:bold;letter-spacing:-0.2pt;">SEAHAWK MERGER SUB, INC.</font><font style="letter-spacing:0.2pt;">, a Delaware corporation and wholly-owned subsidiary of Parent (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub</font><font style="letter-spacing:0.2pt;">&#8221;), and </font><font style="font-weight:bold;letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font><font style="letter-spacing:0.2pt;">, a Delaware corporation (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;). Certain capitalized terms used in this Agreement are defined in </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;A</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RECITALS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A.&nbsp;&nbsp;&nbsp;Parent and the Company intend to effect a merger of Merger Sub with and into the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger</font><font style="letter-spacing:0.2pt;">&#8221;) in accordance with this Agreement and the DGCL. Upon consummation of the Merger, Merger Sub will cease to exist and the Company will become a wholly-owned subsidiary of Parent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">B.&nbsp;&nbsp;&nbsp;The Parties intend that the Merger qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, and by executing this Agreement, the Parties intend to adopt this Agreement as a plan of reorganization within the meaning of Treasury Regulations&#160;Sections&#160;1.368-2(g) and 1.368-3. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">C.&nbsp;&nbsp;&nbsp;The Parent Board has (i)&#160;determined that the Contemplated Transactions, including the Merger, are fair to, advisable and in the best interests of Parent and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Common Stock to the stockholders of the Company pursuant to the terms of this Agreement, and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Parent Stockholder Matters. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">D.&nbsp;&nbsp;&nbsp;The Merger Sub Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">E.&nbsp;&nbsp;&nbsp;Parent, as the sole stockholder of Merger Sub, has adopted this Agreement and thereby approved the Contemplated Transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">F.&nbsp;&nbsp;&nbsp;The Company Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to approve the Company Stockholder Matters. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">G.&nbsp;&nbsp;&nbsp;Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, the officers, directors and stockholders of the Company listed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;A</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule (solely in their capacity as stockholders of the Company) (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Signatories</font><font style="letter-spacing:0.2pt;">&#8221;) are executing (a)&#160;support agreements in favor of Parent in substantially the form attached hereto as </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;B-1</font><font style="letter-spacing:0.2pt;"> (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Stockholder Support Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), pursuant to which the Company Signatories have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Common Stock in favor of the Company Stockholder Matters and against any proposals that compete with the Contemplated Transactions, and (b)&#160;lock-up agreements in substantially the form attached hereto as </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;C-1</font><font style="letter-spacing:0.2pt;"> (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Lock-Up Agreement</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">H.&nbsp;&nbsp;&nbsp;Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, the officers and directors of Parent listed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;A</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule (solely in their capacity as stockholders of Parent) (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Signatories</font><font style="letter-spacing:0.2pt;">&#8221;) are executing (a)&#160;support agreements in favor of the Company in substantially the form attached hereto as </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;B-2</font><font style="letter-spacing:0.2pt;"> (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Stockholder Support Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), pursuant to which the Parent Signatories have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of capital stock of Parent in favor of the Parent Stockholder Matters and against any proposals that compete with the Contemplated Transactions, and (b)&#160;lock-up agreements in substantially the form attached hereto as </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;C-2</font><font style="letter-spacing:0.2pt;"> (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Lock-Up Agreement</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="tS1OT">&#8203;</a><a name="t1MUT">&#8203;</a><a name="t1OTM">&#8203;</a><a name="t1ETU">&#8203;</a><a name="t1OIA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">I.&nbsp;&nbsp;&nbsp;It is expected that promptly after the Registration Statement is declared effective under the Securities Act (and in any event no later than five Business Days), the holders of shares of Company Capital Stock sufficient to adopt and approve the Company Stockholder Matters as required under the DGCL and the Company&#8217;s certificate of incorporation and bylaws will execute and deliver the Company Stockholder Written Consent evidencing the Required Company Stockholder Vote. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">J.&nbsp;&nbsp;&nbsp;In connection with the execution and delivery of this Agreement, the Company has entered into one or more Subscription Agreements with certain investors, pursuant to which such investors have agreed to purchase immediately prior to the Effective Time certain shares of the Company in connection with the Pre-Closing Financing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Parties, intending to be legally bound, agree as follows: </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;1.&nbsp;&nbsp;&nbsp;DESCRIPTION OF TRANSACTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">The Merger</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Upon the terms and subject to the conditions set forth in this Agreement and in accordance with the DGCL, at the Effective Time, Merger Sub shall be merged with and into the Company, and the separate existence of Merger Sub shall cease. Following the Effective Time, the Company will continue as the surviving corporation in the Merger (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Surviving Corporation</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Effects of the Merger</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Merger shall have the effects set forth in this Agreement, the Certificate of Merger and the applicable provisions of the DGCL. As a result of the Merger, the Company will become a wholly-owned subsidiary of Parent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Closing; Effective Time</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Unless this Agreement is earlier terminated pursuant to the provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1</font><font style="letter-spacing:0.2pt;">, and subject to the satisfaction or waiver of the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;">, the consummation of the Merger (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Closing</font><font style="letter-spacing:0.2pt;">&#8221;) shall take place remotely as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver (to the extent permitted by applicable Law) of the last to be satisfied or waived of the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;">, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Closing Date</font><font style="letter-spacing:0.2pt;">&#8221;. At the Closing, the Parties shall cause the Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, in the form attached hereto as </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;F</font><font style="letter-spacing:0.2pt;"> (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Certificate of Merger</font><font style="letter-spacing:0.2pt;">&#8221;). The Merger shall become effective at the time of such filing of the Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in the Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Effective Time</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Certificate of Incorporation and Bylaws; Directors and Officers</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;At the Effective Time: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;the certificate of incorporation of the Surviving Corporation shall be amended and restated in the Merger to read as set forth on Exhibit&#160;A to the Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;the certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Effective Time (which shall reflect the Nasdaq Reverse Split, if approved), until thereafter amended as provided by the DGCL and such certificate of incorporation; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that at the Effective Time Parent shall file an amendment to its certificate of incorporation, to change the name of Parent to &#8220;CARISMA Therapeutics Inc.&#8221;; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;the bylaws of the Surviving Corporation shall be amended and restated in their entirety to read identically to the bylaws of Merger Sub as in effect immediately prior to the Effective Time (except that the name of the Surviving Corporation in such bylaws shall reflect the name identified on Exhibit&#160;A to the Certificate of Merger), until thereafter amended as provided by the DGCL and such bylaws; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t1OS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;the directors and officers of Parent, each to hold office in accordance with the certificate of incorporation and bylaws of Parent, shall be as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.12</font><font style="letter-spacing:0.2pt;">; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;the directors and officers of the Surviving Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Corporation, shall be the directors and officers of Parent as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.12</font><font style="letter-spacing:0.2pt;"> or such other persons as shall be mutually agreed upon by Parent and the Company. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Conversion of Shares</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;At the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any stockholder of the Company or Parent: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;any shares of Company Capital Stock held as treasury stock or held or owned by the Company, Merger Sub or any Subsidiary of the Company immediately prior to the Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.5(c)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.8</font><font style="letter-spacing:0.2pt;">, each share of Company Capital Stock outstanding immediately prior to the Effective Time (including any shares of Company Capital Stock issued pursuant to the Pre-Closing Financing, and excluding shares to be canceled pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.5(a)(i)</font><font style="letter-spacing:0.2pt;"> and Dissenting Shares) shall be automatically converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Consideration</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;If any shares of Company Capital Stock outstanding immediately prior to the Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of Parent Common Stock issued in exchange for such shares of Company Capital Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Common Stock shall accordingly be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement in accordance with its terms. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;No fractional shares of Parent Common Stock shall be issued in connection with the Merger or the Conversion, and no certificates or scrip for any such fractional shares shall be issued. Notwithstanding any other provision of this Agreement, any holder of Company Capital Stock or the Company Convertible Note, as applicable, converted in connection with the Merger or the Conversion, as applicable, who would otherwise have been entitled to receive a fraction of a share of Parent Common Stock (after taking into account all Company Stock Certificates delivered or Book-Entry Shares transferred by such holder and the aggregate number of shares of Company Capital Stock represented thereby, as applicable) shall receive, in lieu thereof, cash (without interest and subject to applicable Tax withholding) in an amount equal to such fractional part of a share of Parent Common Stock multiplied by the last reported sale price of Parent Common Stock at the 4:00&#160;p.m., Eastern Time, end of regular trading hours on Nasdaq on the last trading day prior to the Effective Time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;All Company Options outstanding immediately prior to the Effective Time under the Company Plan shall be treated in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;The Company Convertible Note shall be treated in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(c)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;All Parent Warrants outstanding immediately prior to the Effective Time shall be treated in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(e)</font><font style="letter-spacing:0.2pt;"> and Parent RSUs and Parent Options outstanding immediately prior to the Effective Time shall be treated in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(f)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Each share of common stock, $0.0001 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.0001 par value per share, of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t1OTC">&#8203;</a><a name="t1OC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Surviving Corporation. Each stock certificate of Merger Sub, if any, evidencing ownership of any such shares shall, as of the Effective Time, evidence ownership of such shares of common stock of the Surviving Corporation. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;If, between the date of this Agreement and the Effective Time, any outstanding shares of Company Capital Stock or Parent Common Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to provide the holders of Company Capital Stock, Company Options, Parent Common Stock, Parent Options, Parent RSUs and Parent Warrants with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split), combination or exchange of shares or other like change; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Common Stock, respectively, that is prohibited by the terms of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Closing of the Company&#8217;s Transfer Books</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;At the Effective Time: (a)&#160;all shares of Company Capital Stock outstanding immediately prior to the Effective Time (including any shares of Company Capital Stock issued pursuant to the Pre-Closing Financing) shall be treated in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.5(a)</font><font style="letter-spacing:0.2pt;">, and all holders of (i)&#160;certificates representing shares of Company Capital Stock and (ii)&#160;book-entry shares representing shares of Company Capital Stock (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Book-Entry Shares</font><font style="letter-spacing:0.2pt;">&#8221;), in each case, that were outstanding immediately prior to the Effective Time shall cease to have any rights as stockholders of the Company; and (b)&#160;the stock transfer books of the Company shall be closed with respect to all shares of Company Capital Stock outstanding immediately prior to the Effective Time. No further transfer of any such shares of Company Capital Stock shall be made on such stock transfer books after the Effective Time. If, after the Effective Time, a valid certificate previously representing any shares of Company Capital Stock outstanding immediately prior to the Effective Time (a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Stock Certificate</font><font style="letter-spacing:0.2pt;">&#8221;) is presented to the Exchange Agent or to the Surviving Corporation, such Company Stock Certificate shall be canceled and shall be exchanged as provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;1.5</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">1.7</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Surrender of Certificates</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Prior to the Closing Date, Parent and the Company shall agree upon and select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Agent</font><font style="letter-spacing:0.2pt;">&#8221;). At the Effective Time, Parent shall deposit with the Exchange Agent: (i)&#160;evidence of book-entry shares representing the Parent Common Stock issuable pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.5(a)</font><font style="letter-spacing:0.2pt;"> in exchange for shares of Company Capital Stock and conversion of the Company Convertible Note; and (ii)&#160;cash sufficient to make payments in lieu of fractional shares in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.5(c)</font><font style="letter-spacing:0.2pt;">. The Parent Common Stock and cash amounts so deposited with the Exchange Agent, together with any dividends or distributions received by the Exchange Agent with respect to such shares, are referred to collectively as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Fund.</font><font style="letter-spacing:0.2pt;">&#8221; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Promptly after the Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of Company Capital Stock that were converted into the right to receive the Merger Consideration: (i)&#160;a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">LoT</font><font style="letter-spacing:0.2pt;">&#8221;) (including a provision confirming that delivery of Company Stock Certificates or transfer of Book-Entry Shares to the Exchange Agent shall be effected, and risk of loss and title thereto shall pass, only upon proper delivery of such Company Stock Certificates or transfer of the Book-Entry Shares to the Exchange Agent); and (ii)&#160;instructions for effecting the surrender of Company Stock Certificates or transfer of Book-Entry Shares in exchange for shares of Parent Common Stock. Upon surrender of a Company Stock Certificate or transfer of Book-Entry Share to the Exchange Agent for exchange, together with a duly executed LoT and such other documents as may be reasonably required by the Exchange Agent or Parent: (A)&#160;the holder of such Company Stock Certificate or Book-Entry Share shall be entitled to receive in exchange therefor book-entry shares representing the Merger Consideration (in a number of whole shares of Parent Common Stock) that such holder has the right to receive pursuant to the provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.5(a)</font><font style="letter-spacing:0.2pt;"> (and cash in lieu of any fractional share of Parent Common Stock pursuant to the provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.5(c)</font><font style="letter-spacing:0.2pt;">); </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t18RI">&#8203;</a><a name="t1AIA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and (B)&#160;the Company Stock Certificate or Book-Entry Share so surrendered or transferred, as the case may be, shall be canceled. Until surrendered or transferred as contemplated by this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.7(b)</font><font style="letter-spacing:0.2pt;">, each Company Stock Certificate or Book-Entry Share shall be deemed, from and after the Effective Time, to represent only the right to receive book-entry shares of Parent Common Stock representing the Merger Consideration (and cash in lieu of any fractional share of Parent Common Stock). If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of Parent Common Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;No dividends or other distributions declared or made with respect to Parent Common Stock with a record date on or after the Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate or Book-Entry Shares with respect to the shares of Parent Common Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or transfers such Book-Entry Share or provides an affidavit of loss or destruction in lieu thereof in accordance with this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.7</font><font style="letter-spacing:0.2pt;"> (at which time (or, if later, on the applicable payment date) such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Any portion of the Exchange Fund that remains unclaimed by holders of shares of Company Common Stock as of the first anniversary of the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates or Book-Entry Shares who have not theretofore surrendered their Company Stock Certificates or transferred their Book-Entry Shares in accordance with this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.7</font><font style="letter-spacing:0.2pt;"> shall thereafter look only to Parent for satisfaction of their claims for Parent Common Stock, cash in lieu of fractional shares of Parent Common Stock and any dividends or distributions with respect to shares of Parent Common Stock. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;No Party shall be liable to any holder of shares of any Company Capital Stock or to any other Person with respect to any shares of Parent Common Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Appraisal Rights</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the Effective Time and which are held by stockholders who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the DGCL (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Dissenting Shares</font><font style="letter-spacing:0.2pt;">&#8221;) shall not be converted into or represent the right to receive the Merger Consideration described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.5</font><font style="letter-spacing:0.2pt;"> attributable to such Dissenting Shares. Such stockholders shall be entitled to receive payment of the appraised value of such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders who shall have failed to perfect or who effectively shall have withdrawn or lost their right to appraisal of such shares of Company Capital Stock under the DGCL (whether occurring before, at or after the Effective Time) shall thereupon be deemed to be converted into and to have become exchangeable for, as of the Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;1.5</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">1.7</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Company shall give Parent prompt written notice of any demands by dissenting stockholders received by the Company, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with such demands. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Further Action</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;If, at any time after the Effective Time, any further action is determined by the Surviving Corporation to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the Surviving Corporation shall be fully authorized, and shall </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t1TPA">&#8203;</a><a name="t1ONC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">use their and its commercially reasonable efforts (in the name of the Company, in the name of Merger Sub, in the name of the Surviving Corporation and otherwise) to take such action. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Withholding</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Parties and the Exchange Agent and their respective agents shall be entitled to deduct and withhold from any amounts otherwise payable pursuant to this Agreement such amounts as such Party or the Exchange Agent is required to deduct and withhold under the Code or any other Tax Law with respect to the making of such payment and shall be entitled to request any reasonably appropriate Tax forms, including an IRS Form W-9 or the appropriate IRS Form W-8, as applicable, from any recipient of payments hereunder. The payor shall provide commercially reasonable notice to the payee upon becoming aware of any such withholding obligation (other than any withholding on amounts treated as compensation), and the Parties shall cooperate with each other and with such payee to the extent reasonable to obtain reduction of or relief from such withholding. To the extent that amounts are so deducted and withheld and paid to the appropriate taxing authority, such deducted and withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding was made. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Calculation of Net Cash</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Not more than ten nor less than five calendar days prior to the anticipated date for Closing (as mutually agreed in good faith by Parent and the Company) (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Anticipated Closing Date</font><font style="letter-spacing:0.2pt;">&#8221;), Parent will deliver to the Company a schedule (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Net Cash Schedule</font><font style="letter-spacing:0.2pt;">&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith estimated calculation of Net Cash (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Net Cash Calculation</font><font style="letter-spacing:0.2pt;">&#8221; and the date of delivery of such schedule, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Delivery Date</font><font style="letter-spacing:0.2pt;">&#8221;) as of 8:00&#160;p.m. Eastern Time on the last Business Day prior to the Anticipated Closing Date (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Cash Determination Time</font><font style="letter-spacing:0.2pt;">&#8221;), prepared and certified by Parent&#8217;s chief executive officer and chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer of Parent). Subject to the terms of the Confidentiality Agreement, Parent shall make available to the Company, its accountants and/or counsel, the work papers and back-up materials used or useful in preparing the Net Cash Schedule, as reasonably requested by the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Within three Business Days following the Delivery Date (the last day of such period, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Response Date</font><font style="letter-spacing:0.2pt;">&#8221;), the Company will have the right to dispute all or any part or parts of the Net Cash Calculation by delivering a written notice to that effect (a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Dispute Notice</font><font style="letter-spacing:0.2pt;">&#8221;) to Parent. Any Dispute Notice shall identify in reasonable detail to the extent then known the nature and amounts of any proposed revisions to the Net Cash Calculation. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;If (i)&#160;the Company notifies Parent in writing on or prior to the Response Date that it has no objections to the Net Cash Calculation or (ii)&#160;the Company has failed to deliver a Dispute Notice as provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11(b)</font><font style="letter-spacing:0.2pt;"> prior to 8:00&#160;p.m. Eastern Time on the Response Date, then the Net Cash Calculation as set forth in the Net Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Net Cash at the Cash Determination Time (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Final Net Cash</font><font style="letter-spacing:0.2pt;">&#8221;) for purposes of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;If the Company delivers a Dispute Notice prior to 8:00&#160;p.m. Eastern Time on the Response Date, then Representatives of Parent and the Company shall promptly, and in no event later than one calendar day after the Response Date, meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of the Net Cash, which agreed-upon Net Cash shall be deemed to have been finally determined for purposes of this Agreement and to represent the Final Net Cash for purposes of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;If Representatives of Parent and the Company are unable to negotiate an agreed-upon determination of Final Net Cash pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11(d)</font><font style="letter-spacing:0.2pt;"> within two calendar days after delivery of the Dispute Notice (or such other period as Parent and the Company may mutually agree upon in writing), then any remaining disagreements as to the calculation of Net Cash shall be referred to Deloitte &amp; Touche LLP or another independent auditor of recognized national standing mutually agreed upon by Parent and the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Accounting Firm</font><font style="letter-spacing:0.2pt;">&#8221;). Parent shall promptly deliver to the Accounting Firm all work papers and back-up materials used in preparing the Net Cash Schedule, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="tS2AW">&#8203;</a><a name="t2OS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">determination within five calendar days of accepting its selection. The Company and Parent shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that no such presentation or discussion shall occur without the presence of a Representative of each of the Company and Parent. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Net Cash made by the Accounting Firm shall be made in writing delivered to each of the Company and Parent, shall be final and binding on the Company and Parent and shall be deemed to have been finally determined for purposes of this Agreement and to represent the Final Net Cash for purposes of this Agreement, absent fraud or manifest error. The Parties shall delay the Closing until the resolution of the matters described in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11(e)</font><font style="letter-spacing:0.2pt;">. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Net Cash that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Net Cash and such portion of the costs and expenses of the Accounting Firm borne by Parent and any other fees, costs or expenses incurred by Parent following the Delivery Date in connection with the procedures set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11(e)</font><font style="letter-spacing:0.2pt;"> shall be deducted from the final determination of the amount of Net Cash. If this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11(e)</font><font style="letter-spacing:0.2pt;"> applies as to the determination of the Final Net Cash described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11(e)</font><font style="letter-spacing:0.2pt;">, upon resolution of the matter in accordance with this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11(e)</font><font style="letter-spacing:0.2pt;">, the Parties shall not be required to determine the Net Cash again even though the Closing Date may occur later than the Anticipated Closing Date, except that either Party may require a re-determination of Final Net Cash if the Closing Date is more than ten calendar days after the Anticipated Closing Date. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;2.&nbsp;&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.11(m)</font><font style="letter-spacing:0.2pt;">, except as set forth in the written disclosure schedule delivered by the Company to Parent (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Disclosure Schedule</font><font style="letter-spacing:0.2pt;">&#8221;), the Company represents and warrants to Parent and Merger Sub as follows: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Due Organization; Subsidiaries</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Company is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware and has all necessary corporate power and authority: (i)&#160;to conduct its business in the manner in which its business is currently being conducted; (ii)&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii)&#160;to perform its obligations under all material Contracts by which it is bound. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified would not have a Company Material Adverse Effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;The Company has no Subsidiaries, except for the Entities identified in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1(c)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule; and neither the Company nor any of the Company&#8217;s Subsidiaries owns any capital stock of, or any equity, ownership or profit sharing interest of any nature in, or controls, directly or indirectly, any other Entity other than the Entities identified in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1(c)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule. Each of the Company&#8217;s Subsidiaries is a corporation or other legal Entity duly incorporated or otherwise organized, validly existing and, if applicable, in good standing under the Laws of the jurisdiction of its incorporation or organization, as applicable, and has all necessary corporate or similar power and authority to conduct its business in the manner in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used, except where the failure to have such power or authority would not have a Company Material Adverse Effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is or has otherwise been a party to, or a member of, any partnership, joint venture or similar business Entity. Neither the Company nor any of its Subsidiaries has agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t2DTC">&#8203;</a><a name="t2BNO">&#8203;</a><a name="t2RTA">&#8203;</a><a name="t2CST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither the Company nor any of its Subsidiaries has, at any time, been a general partner of, or has otherwise been liable for, any of the debts or other obligations of, any general partnership, limited partnership or other Entity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Organizational Documents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company has made available to Parent accurate and complete copies of the Organizational Documents of the Company and each of its Subsidiaries&#8217; in effect as of the date of this Agreement. Neither the Company nor any of its Subsidiaries is in material breach or violation of its respective Organizational Documents. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Authority; Binding Nature of Agreement</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and, subject to receipt of the Required Company Stockholder Vote, to consummate the Contemplated Transactions. The Company Board (at a meeting or meetings duly called and held and at which all members were present) has unanimously (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of, the Company and its stockholders, (ii)&#160;authorized, approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to approve the Company Stockholder Matters. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Parent and Merger Sub, constitutes the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Vote Required</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The affirmative vote (or written consent) of (i)&#160;the holders of a majority of the Company Capital Stock, voting together as a single class, (ii)&#160;the holders of at least two-thirds of the Company Series&#160;A Preferred Stock, Company Special Voting Preferred Stock, Company Series&#160;B Preferred Stock and Company Series&#160;B Special Voting Preferred Stock, voting together as a single class, (iii)&#160;the holders of a majority of the Company Series&#160;A Preferred Stock and Company Special Voting Preferred Stock, voting together as a single class, and (iv)&#160;the holders of at least two-thirds of the Company Series&#160;B Preferred Stock and Company Series&#160;B Special Voting Preferred Stock, voting together as a single class, in the form attached hereto as </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;G</font><font style="letter-spacing:0.2pt;"> (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Stockholder Written Consent</font><font style="letter-spacing:0.2pt;">&#8221; and such vote thereon, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Required Company Stockholder Vote</font><font style="letter-spacing:0.2pt;">&#8221;), is the only vote (or written consent) of the holders of any class or series of Company Capital Stock necessary to adopt and approve the Company Stockholder Matters. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Non-Contravention; Consents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to obtaining the Required Company Stockholder Vote, the filing of the Certificate of Merger with the Secretary of State of the State of Delaware required by the DGCL and clearance of the Merger under any applicable Antitrust Laws, neither (x)&#160;the execution, delivery or performance of this Agreement by the Company, nor (y)&#160;the consummation by the Company of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time): </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation of any of the provisions of the Company&#8217;s Organizational Documents; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a material violation of, or, to the Knowledge of the Company, give any Governmental Body or other Person the right to successfully challenge the Contemplated Transactions or to successfully exercise any material remedy or obtain any material relief under, any Law or any order, writ, injunction, judgment or decree to which the Company or its Subsidiaries, or any of the assets owned or used by the Company or its Subsidiaries, is subject, except as would not reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or its Subsidiaries, except as would not reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (i)&#160;declare a default or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t26C">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">exercise any remedy under any Company Material Contract; (ii)&#160;any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract; (iii)&#160;accelerate the maturity or performance of any Company Material Contract; or (iv)&#160;cancel, terminate or modify any term of any Company Material Contract, except in each case under this clause (d), as would not reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole; or </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;result in the imposition or creation of any material Encumbrance upon or with respect to any material asset owned or used by the Company or its Subsidiaries (except for Permitted Encumbrances). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except for (i)&#160;any Consent set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.5</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule, (ii)&#160;the Required Company Stockholder Vote, (iii)&#160;the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL and the clearance of the Merger under any applicable Antitrust Laws, and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities Laws or, if not given or obtained, as would not reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole, or would not reasonably be expected to prevent or materially delay beyond the End Date the ability of the Company to consummate the Contemplated Transactions, neither the Company nor any of its Subsidiaries is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (A)&#160;the execution, delivery or performance by the Company of this Agreement, or (B)&#160;the consummation by the Company of the Contemplated Transactions. None of the Company nor any of its &#8220;affiliates&#8221; or &#8220;associates&#8221; directly or indirectly &#8220;owns,&#8221; beneficially or otherwise, and at all times during the three-year period prior to the date of this Agreement, none of its &#8220;affiliates&#8221; or &#8220;associates&#8221; directly or indirectly has &#8220;owned,&#8221; beneficially or otherwise, any of the outstanding Parent Common Stock, as those terms are defined in Section&#160;203 of the DGCL. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Capitalization</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The authorized Company Capital Stock as of the date of this Agreement consists of (i)&#160;14,910,158 shares of Company Common Stock, par value $0.0001 per share, of which 1,085,436 shares have been issued and are outstanding as of the date of this Agreement, and (ii)&#160;10,946,061 shares of Company Preferred Stock, par value $0.0001 per share, of which (a)&#160;6,138,518 shares have been designated as Company Series&#160;A Preferred Stock, of which 5,201,017 shares are issued and outstanding as of the date of this Agreement, (b)&#160;1 share has been designated as Company Special Voting Preferred Stock, of which 1 share is issued and outstanding as of the date of this Agreement, (c)&#160;4,807,541 shares have been designated as Company Series&#160;B Preferred Stock, of which 3,499,866 shares are issued and outstanding as of the date of this Agreement and (d)&#160;1 share has been designated as Company Series&#160;B Special Voting Preferred Stock, of which 1 share is issued and outstanding as of the date of this Agreement. As of the date of this Agreement, the Company does not hold any shares of its capital stock in treasury. </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.6(a)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule lists, as of the date of this Agreement (x)&#160;each record holder of issued and outstanding Company Capital Stock and the number and type of shares of Company Capital Stock held by such holder and (y)(A) the holder of the issued and outstanding convertible promissory note into Company Capital Stock (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Convertible Note</font><font style="letter-spacing:0.2pt;">&#8221;), (B)&#160;the date the Company Convertible Note was issued, (C)&#160;the type of securities subject to the Company Convertible Note, (D)&#160;the underlying principal amount and accrued interest of the Company Convertible Note, and (E)&#160;the maturity date of the Company Convertible Note. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;All of the outstanding shares of Company Capital Stock have been duly authorized and validly issued, and are fully paid and nonassessable. None of the outstanding shares of Company Capital Stock are entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Company Capital Stock are subject to any right of first refusal in favor of the Company, in each case under any Company Contract. Except as contemplated herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Company Capital Stock. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Company Capital Stock or other </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t27ST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">securities. None of the outstanding shares of Company Capital Stock held by current or former Company employees or other service providers are subject to any repurchase or forfeiture rights held by the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Except for the Company Plan (and awards granted thereunder), the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As of the date of this Agreement, the Company has reserved 2,664,018 shares of Company Common Stock for issuance under the Company Plan, of which 45,436 shares have been issued and are currently outstanding, 1,900,829 shares have been reserved for issuance upon the exercise of Company Options previously granted and are currently outstanding under the Company Plan, and 717,753 shares of Company Common Stock remain available for future issuance pursuant to the Company Plan. Only shares of Company Common Stock are subject to Company Options. </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.6(c)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule sets forth the following information with respect to each Company Option outstanding as of the date of this Agreement: (i)&#160;the name of the optionee; (ii)&#160;the number of shares of Company Common Stock subject to such Company Option at the time of grant; (iii)&#160;the number of shares of Company Common Stock subject to such Company Option as of the date of this Agreement; (iv)&#160;the exercise price of such Company Option; (v)&#160;the date on which such Company Option was granted; (vi)&#160;the applicable vesting schedule, including the number of vested and unvested shares as of the date of this Agreement and any acceleration provisions; (vii)&#160;the date on which such Company Option expires; and (viii)&#160;whether such Company Option is intended to constitute an &#8220;incentive stock option&#8221; &#8203;(as defined in the Code) or a non-qualified stock option. The Company has made available to Parent accurate and complete copies of the Company Plan and all forms of stock option and other award agreements evidencing outstanding options granted thereunder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Except for the Company Convertible Note and the Company Options set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.6(c)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule, there is no: (i)&#160;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of the Company or any of its Subsidiaries; or (ii)&#160;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company or any of its Subsidiaries. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company or any of its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;All outstanding shares of Company Capital Stock, Company Options, the Company Convertible Note, and other securities of the Company have been issued and granted in material compliance with (i)&#160;the Organizational Documents of the Company in effect as of the relevant time and all applicable securities Laws and other applicable Law, and (ii)&#160;all requirements set forth in applicable Contracts. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Financial Statements</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Company has made available to Parent true and complete copies of (i)&#160;the Company&#8217;s audited consolidated balance sheets at December&#160;31, 2021 and 2020, together with related audited consolidated statements of income, stockholders&#8217; equity and cash flows, and notes thereto, for the fiscal&#160;years then ended and (ii)&#160;the Company Unaudited Interim Balance Sheet, together with the unaudited consolidated statements of income, stockholders&#8217; equity and cash flows of the Company for the six-month period ended on the date of the Company Unaudited Interim Balance Sheet (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Financial Statements</font><font style="letter-spacing:0.2pt;">&#8221;). The Company Financial Statements were prepared in accordance with GAAP (except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material) and fairly present, in all material respects, the financial position and operating results of the Company and its consolidated Subsidiaries as of the dates and for the periods indicated therein. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Each of the Company and its Subsidiaries maintains a system of internal accounting controls designed to provide reasonable assurance that: (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorizations; (ii)&#160;transactions are recorded as necessary to permit preparation of the financial statements of the Company and its Subsidiaries in accordance with GAAP </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t2OCA">&#8203;</a><a name="t2OUL">&#8203;</a><a name="t2TAE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and to maintain accountability of the Company&#8217;s and its Subsidiaries&#8217; assets; (iii)&#160;access to the Company&#8217;s and its Subsidiaries&#8217; assets is permitted only in accordance with management&#8217;s general or specific authorization; (iv)&#160;the recorded accountability for the Company&#8217;s and its Subsidiaries&#8217; assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences; and (v)&#160;accounts, notes and other receivables are recorded accurately, and proper and adequate procedures are implemented to effect the collection thereof on a current and timely basis. The Company and each of its Subsidiaries maintains internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.7(c)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule lists, and the Company has made available to Parent accurate and complete copies of the documentation creating or governing, all securitization transactions and &#8220;off-balance sheet arrangements&#8221; &#8203;(as discussed in Item&#160;303 of Regulation&#160;S-K under the Exchange Act) effected by the Company or any of its Subsidiaries since January&#160;1, 2019. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof. As of the date of this Agreement, the Company nor its independent auditors have identified (i)&#160;any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company and its Subsidiaries, (ii)&#160;any fraud, whether or not material, that involves the Company, any of its Subsidiaries, the Company&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company and its Subsidiaries or (iii)&#160;any claim or allegation regarding any of the foregoing. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;The Company Financial Statements will be suitable for inclusion in the Registration Statement and prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on that basis will present fairly, in all material respects, the financial position and the results of operations, changes in stockholders&#8217; equity, and cash flows of the Company as of the dates of and for the periods referred to in the Company Financial Statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Absence of Changes</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;(a)&#160;Between the date of the Company Unaudited Interim Balance Sheet and the date of this Agreement, (i)&#160;the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and (ii)&#160;the Company has not taken any action that would have required the consent of Parent pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.2(b)</font><font style="letter-spacing:0.2pt;"> had such action taken place after the execution and delivery of this Agreement; and (b)&#160;since the date of the Company Unaudited Interim Balance Sheet, there has not been any Company Material Adverse Effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Absence of Undisclosed Liabilities</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has any liability, indebtedness, obligation or expense of any kind, whether accrued, absolute, contingent, matured or unmatured (whether or not required to be reflected in the financial statements in accordance with GAAP) (each a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Liability</font><font style="letter-spacing:0.2pt;">&#8221;), except for: (a)&#160;Liabilities disclosed, reflected or reserved against in the Company Unaudited Interim Balance Sheet; (b)&#160;Liabilities that have been incurred by the Company or its Subsidiaries since the date of the Company Unaudited Interim Balance Sheet in the Ordinary Course of Business; (c)&#160;Liabilities for performance of obligations of the Company or any of its Subsidiaries under Company Contracts (other than those arising as a result of a breach or default thereunder or as a result of failure to comply with applicable Law); (d)&#160;Liabilities for payment of fees and expenses incurred in connection with the Contemplated Transactions; (e)&#160;Liabilities which would not, individually or in the aggregate, reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole; and (f)&#160;Liabilities described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.9</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Title to Assets</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each of the Company and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t2PLN">&#8203;</a><a name="t21PR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">each case that are material to the Company and its Subsidiaries, taken as a whole, including: (a)&#160;all such tangible assets reflected on the Company Unaudited Interim Balance Sheet; and (b)&#160;all other such tangible assets reflected in the books and records of the Company or any of its Subsidiaries as being owned by the Company or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased by the Company or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Real Property; Leasehold</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries owns or has ever owned any real property. The Company has made available to Parent (a)&#160;an accurate and complete list of all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of, or occupied or leased by the Company or any of its Subsidiaries, and (b)&#160;copies of all leases under which any such real property is possessed, occupied or leased (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Real Estate Leases</font><font style="letter-spacing:0.2pt;">&#8221;), each of which is in full force and effect, with no existing material default by the Company or any Subsidiary thereunder. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.12&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Intellectual Property</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.12(a)(1)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule identifies, as of the date of this Agreement, each item of material Company IP that is owned or purported to be owned by or assigned to the Company or its Subsidiaries and that is the subject of a registration or application in any jurisdiction (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Registered IP</font><font style="letter-spacing:0.2pt;">&#8221;), including, with respect to each such patent and patent application: (i)&#160;the name of the applicant/registrant; (ii)&#160;the jurisdiction of application/registration; (iii)&#160;the application or registration number; and (iv)&#160;any other co-owners. </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.12(a)(2)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule identifies, as of the date of this Agreement, each license agreement under which the Company or its Subsidiaries exclusively license material Company IP from a third party. To the Knowledge of the Company, each of the patents and patent applications included in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.12(a)(1)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule properly identifies by name each and every inventor of the inventions claimed therein as determined in accordance with applicable Laws of the United States. To the Knowledge of the Company, as of the date of this Agreement, no cancellation, interference, opposition, reissue, reexamination or other proceeding of any nature (other than office actions or similar communications issued by any Governmental Body in the ordinary course of prosecution of any pending applications for registration) is pending or threatened in writing, in which the scope, validity, enforceability or ownership of any Company IP, other than such items with pending applications, is being or has been contested or challenged. To the Knowledge of the Company, each item of issued Company Registered IP is valid, enforceable and subsisting. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Except as would not have a Company Material Adverse Effect, the Company and its Subsidiaries collectively exclusively own, are the sole assignees of, or have exclusively licensed all material Company IP, free and clear of all Encumbrances other than Permitted Encumbrances (other than as disclosed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.12(b)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule). The Company IP and the Intellectual Property Rights licensed to the Company pursuant to a valid, enforceable written agreement constitute all Intellectual Property Rights used in, material to and otherwise necessary for the operation of the Company&#8217;s business as currently conducted. Each Company Associate involved in the creation or development of any material Company IP, pursuant to such Company Associate&#8217;s activities on behalf of the Company or its Subsidiaries, has signed a valid and enforceable written agreement containing an assignment of such Company Associate&#8217;s rights in such Company IP to the Company or its applicable Subsidiary. Each Company Associate who has or has had access to the Company&#8217;s trade secrets or confidential information has signed a valid and enforceable written agreement containing confidentiality provisions protecting the Company IP, trade secrets and confidential information. The Company and its Subsidiaries have taken commercially reasonable steps to protect and preserve the confidentiality of its trade secrets and confidential information. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;To the Knowledge of the Company, no funding, facilities or personnel of any Governmental Body or any university, college, research institute or other educational institution has been used to create material Company IP that is owned or purported to be owned by or assigned to the Company or its Subsidiaries, except for any such funding or use of facilities or personnel that does not result in such Governmental Body or institution obtaining ownership rights or a license to such Company IP (excluding confirmatory licenses to inventions made with government funding and for which the Company, its </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subsidiaries or either of their licensors has duly retained title under the Bayh-Dole Act) or the right to receive royalties for the practice of such Company IP. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.12(d)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule sets forth, as of the date of this Agreement, each license agreement pursuant to which the Company (i)&#160;is granted a license under any material Intellectual Property Right owned by any third party that is used by the Company or its Subsidiaries in its business as currently conducted (each a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company In-bound License</font><font style="letter-spacing:0.2pt;">&#8221;) or (ii)&#160;grants to any third party a license under any material Company IP or material Intellectual Property Right licensed to the Company or its Subsidiaries under a Company In-bound License (each a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Out-bound License</font><font style="letter-spacing:0.2pt;">&#8221;) (</font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that, Company In-bound Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, clinical trial agreements, agreements with Company Associates, services agreements, commercially available Software-as-a-Service offerings or off-the-shelf software licenses; and Company Out-bound Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, clinical trial agreements, services agreements, or non-exclusive outbound licenses). All Company In-bound Licenses and Company Out-bound Licenses are in full force and effect and are valid, enforceable and binding obligations of the Company or the applicable Subsidiary and, to the Knowledge of Company, each other party to such Company In-bound Licenses or Company Out-bound Licenses. Neither the Company or any of its Subsidiaries, nor to the Knowledge of the Company, any other party to such Company In-bound Licenses or Company Out-bound Licenses, is in material breach under any Company In-bound Licenses or Company Out-bound Licenses. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;To the Knowledge of the Company: (i)&#160;the operation of the businesses of the Company and its Subsidiaries as currently conducted does not infringe, misappropriate or otherwise violate any Intellectual Property Rights of any other Person; and (ii)&#160;no other Person is infringing, misappropriating or otherwise violating any Company IP. As of the date of this Agreement, no Legal Proceeding is pending (or, to the Knowledge of the Company, is threatened in writing) (A)&#160;against the Company or its Subsidiaries alleging that the operation of the businesses of the Company or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights of another Person or (B)&#160;by the Company or its Subsidiaries alleging that another Person has infringed, misappropriated or otherwise violated any of the Company IP or any Intellectual Property Rights exclusively licensed to the Company or its Subsidiaries. Between January&#160;1, 2019 and the date of this Agreement, neither the Company nor its Subsidiaries has received any written notice or other written communication alleging that the operation of the business of the Company or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another Person. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;None of the Company IP that is owned or purported to be owned by or assigned to the Company or its Subsidiaries and, to the Knowledge of the Company, no material Intellectual Property Rights exclusively licensed to the Company or its Subsidiaries is subject to any pending or outstanding injunction, directive, order, judgment or other disposition of dispute that adversely and materially restricts the use, transfer, registration or licensing by the Company or its Subsidiaries of any such Company IP that is owned or purported to be owned by or assigned to the Company or its Subsidiaries or material Intellectual Property Rights exclusively licensed to the Company or its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;To the Knowledge of the Company, the Company, its Subsidiaries and the operation of the Company&#8217;s and its Subsidiaries&#8217; business are in substantial compliance with all Laws pertaining to data privacy and data security of any personally identifiable information or sensitive business information (collectively, &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Sensitive Data</font><font style="letter-spacing:0.2pt;">&#8221;). Between January&#160;1, 2019 and the date of this Agreement, there have been (i)&#160;no losses or thefts of data or security breaches relating to Sensitive Data used in the business of the Company or its Subsidiaries, (ii)&#160;no material violations of any security policy of the Company regarding any such Sensitive Data used in the business of the Company or its Subsidiaries and (iii)&#160;no unauthorized access, unauthorized use or unintended or improper disclosure of any Sensitive Data used in the business of the Company or its Subsidiaries, except in each case as would not reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole. The Company has taken commercially reasonable steps and implemented reasonable disaster recovery and security plans and procedures to protect the information technology systems used in, material to and necessary for </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t2CAC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">operation of the Company&#8217;s business as currently conducted from unauthorized use or access. To the Knowledge of the Company, as of the date of this Agreement, there have been no material malfunctions or unauthorized intrusions or breaches of the information technology systems used in, material to and necessary for the operation of the Company&#8217;s business as currently conducted. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.13&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Agreements, Contracts and Commitments</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.13(a)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule lists the following Company Contracts in effect as of the date of this Agreement and under which the Company or any of its Subsidiaries has any remaining material rights or obligations (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Material Contract</font><font style="letter-spacing:0.2pt;">&#8221; and collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Material Contracts</font><font style="letter-spacing:0.2pt;">&#8221;): </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;each Company Contract containing (A)&#160;any covenant limiting the freedom of the Company, its Subsidiaries or the Surviving Corporation to engage in any line of business or compete with any Person, (B)&#160;any most-favored pricing arrangement, (C)&#160;any exclusivity provision, or (D)&#160;any non-solicitation provision, in each case, except for restrictions that would not materially affect the ability of the Company and its Subsidiaries to conduct its business; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $250,000 pursuant to its express terms and not cancelable without penalty; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $250,000, other than Company Contracts in which the applicable acquisition or disposition has been consummated and there are no material ongoing liabilities or obligations; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $250,000 or creating any material Encumbrances with respect to any assets of the Company or any of its Subsidiaries or any loans or debt obligations with officers or directors of the Company; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;each Company Contract requiring payment by or to the Company or its Subsidiaries after the date of this Agreement in excess of $250,000 pursuant to its express terms and constituting: (A)&#160;an exclusive distribution agreement; (B)&#160;an agreement involving provision of material services or products with respect to any pre-clinical or clinical development activities of the Company or its Subsidiaries; (C)&#160;a dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or similar agreement currently in force under which the Company or its Subsidiaries has continuing obligations to develop or market any product, technology or service, or an agreement pursuant to which the Company or its Subsidiaries has continuing obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by the Company or its Subsidiaries; or (D)&#160;a Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party relating to the manufacture or production of any product, service or technology of the Company or its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of the Company or its Subsidiaries, in each case under clauses (A)&#160;through (D), except for Company Contracts that are entered into in the Ordinary Course of Business; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(vii)&nbsp;&nbsp;&nbsp;each Company Contract with any financial advisor, broker, finder, investment banker or other similar Person, providing advisory services to the Company in connection with the Contemplated Transactions; </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(viii)&nbsp;&nbsp;&nbsp;each Company Real Estate Lease; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ix)&nbsp;&nbsp;&nbsp;each Company Contract that would be a material contract as defined in Item&#160;601(b)(10) of Regulation&#160;S-K as promulgated under the Securities Act if the Company were subject to such regulation; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t2PR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; text-indent:20pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(x)&nbsp;&nbsp;&nbsp;each Company Out-bound License and Company In-bound License, and each Company Contract containing a covenant not to sue or otherwise enforce any Intellectual Property Rights; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xi)&nbsp;&nbsp;&nbsp;each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company or any of its Subsidiaries; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xii)&nbsp;&nbsp;&nbsp;each (A)&#160;Company Contract, offer letter, employment agreement or other agreement with any employee that requires payment of base salary and target annual cash bonus in excess of $150,000 in any calendar year that (1)&#160;provides for employment by the Company or any of its Subsidiaries and is not immediately terminable at will by the Company without advance notice, severance, or other similar cost or liability (other than for accrued compensation, vacation or other amounts due upon any termination) or (2)&#160;provides for retention payments, change of control payments, severance, accelerated vesting or any payment or benefit that may or will become due as a result of the Merger (whether alone or in connection with any other event) and (B)&#160;each Company Contract, independent contractor agreement, or other agreement with any individual consultant or service provider requiring payment of fees in excess of $150,000 in any calendar year that (1)&#160;is not immediately terminable at will by the Company without more than 30&#160;days&#8217; prior notice, severance, or other cost or liability or (2)&#160;provides for retention payments, change of control payments, severance, accelerated vesting or any payment or benefit that may or will become due as a result of the Merger (whether alone or in connection with any other event); </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xiii)&nbsp;&nbsp;&nbsp;each Company Contract under which a third party would be entitled to receive a license or have any other rights in, any material Company IP; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xiv)&nbsp;&nbsp;&nbsp;each Company Contract entered into in settlement of any Legal Proceeding or other dispute; and </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xv)&nbsp;&nbsp;&nbsp;any other Company Contract that is not terminable at will (with no penalty or payment) by the Company or its Subsidiaries, as applicable, and (A)&#160;which involves payment or receipt by the Company or its Subsidiaries after the date of this Agreement under any such agreement, Contract or commitment of more than $250,000 in the aggregate, or obligations after the date of this Agreement in excess of $250,000 in the aggregate, or (B)&#160;that is material to the business or operations of the Company and its Subsidiaries, taken as a whole. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Company has made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto, in each case in effect on the date of this Agreement. There are no Company Material Contracts that are not in written form. Neither the Company nor any of its Subsidiaries has, nor to the Company&#8217;s Knowledge, as of the date of this Agreement, has any other party to a Company Material Contract, breached, violated or defaulted under, or as of the date of this Agreement received notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract in such manner as would permit any other party to cancel or terminate any such Company Material Contract, or would permit any other party to seek damages which would have a Company Material Adverse Effect. As to the Company and its Subsidiaries, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. As of the date of this Agreement, no Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract, and, as of the date of the Agreement, no Person has indicated in writing to the Company that it desires to renegotiate, modify, not renew or cancel any Company Material Contract. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.14&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Compliance; Permits; Restrictions</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Company and each of its Subsidiaries is, and since January&#160;1, 2019 has been, in compliance in all material respects with all applicable Laws, including the Federal Food, Drug and Cosmetic Act and regulations issued thereunder by the United States Food and Drug Administration (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">FDA</font><font style="letter-spacing:0.2pt;">&#8221;) (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">FDCA</font><font style="letter-spacing:0.2pt;">&#8221;), the Public Health Service Act and its implementing regulations (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">PHSA</font><font style="letter-spacing:0.2pt;">&#8221;) and any other similar Law administered or promulgated by the FDA or other comparable Governmental Body responsible for regulation of the research, development, pre-clinical and clinical </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">testing, manufacturing, storage, supply, approval, sale, marketing, distribution and importation or exportation of drug and biological products (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Drug Regulatory Agency</font><font style="letter-spacing:0.2pt;">&#8221;), except for any noncompliance, either individually or in the aggregate, which would not be material to the Company and its Subsidiaries, taken as a whole. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, no investigation, claim, suit, proceeding, audit or other action by any Governmental Body is pending or, to the Knowledge of the Company, threatened against the Company or any of its Subsidiaries. There is no judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of material property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently conducted, (ii)&#160;is reasonably likely to have an adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under this Agreement, or (iii)&#160;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;The Company and its Subsidiaries hold all required Governmental Authorizations to develop, test manufacture, store, label, package, distribute, import and export the respective current products or product candidates that are material to the operation of the business of the Company and its Subsidiaries as currently conducted (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Permits</font><font style="letter-spacing:0.2pt;">&#8221;). </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.14(c)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule identifies each Company Permit. Each such Company Permit is valid and in full force and effect, and each of the Company and its Subsidiaries is in material compliance with the terms of the Company Permits. As of the date of this Agreement, no Legal Proceeding is pending or, to the Knowledge of the Company, threatened, which seeks to revoke, limit, suspend, or materially modify any Company Permit. The rights and benefits of each Company Permit will be available to the Surviving Corporation or its Subsidiaries, as applicable, immediately after the Effective Time on terms substantially identical to those enjoyed by the Company and its Subsidiaries as of the date of this Agreement and immediately prior to the Effective Time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there has not been and is not now any Form FDA-483 observation, civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, untitled letter, or proceeding pending or in effect against the Company or its Subsidiaries or any of their respective officers and employees, and the Company has no liability for failure to comply with the FDCA, PHSA, or other similar Laws. There is no act, omission, event, or circumstance of which the Company has Knowledge that would reasonably be expected to give rise to or form the basis for any civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, untitled letter, proceeding or request for information or any liability (whether actual or contingent) for failure to comply with the FDCA, PHSA or other similar Laws. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company or its Subsidiaries, or of their respective current products or product candidates, were and, if still pending, are being conducted in all material respects with applicable regulations of any applicable Drug Regulatory Agency and other applicable Law, including the Good Clinical Practice (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">GCP</font><font style="letter-spacing:0.2pt;">&#8221;) regulations under 21 C.F.R. Parts 50, 54, 56 and 312 and Good Laboratory Practice (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">GLP</font><font style="letter-spacing:0.2pt;">&#8221;) regulations under 21 C.F.R. Part&#160;58. No preclinical study or clinical trial conducted by or on behalf of the Company or any of its Subsidiaries has been terminated or suspended prior to completion for safety or non-compliance reasons. Between January&#160;1, 2019 and the date of this Agreement, neither the Company nor any of its Subsidiaries has received any written notices, correspondence, or other written communications from any Drug Regulatory Agency requiring, or to the Knowledge of the Company, threatening to initiate, the termination or suspension of any clinical studies conducted by or on behalf of, or sponsored by, the Company or any of its Subsidiaries or of their respective current products or product candidates. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, neither the Company nor any of its Subsidiaries is the subject of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products or product candidates pursuant to the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September&#160;10, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t2PO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1991). To the Knowledge of the Company, neither the Company nor any of its Subsidiaries has committed any acts, made any statement, or failed to make any statement, in each case in respect of its business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Neither the Company nor its Subsidiaries, nor any of their respective officers, directors, employees or, to the Knowledge of the Company, agents has been, is, or is in anticipation of being (based on a conviction by the courts or a finding of fault by a regulatory authority): (a)&#160;debarred pursuant to the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;&#160;335a), as amended from time to time; (b)&#160;disqualified from participating in clinical trials pursuant to 21 C.F.R. &#167;312.70, as amended from time to time; (c)&#160;disqualified as a testing facility under 21 C.F.R. Part&#160;58, Subpart K, as amended from time to time; (d)&#160;excluded, debarred or suspended from or otherwise ineligible to participate in a &#8220;Federal Health Care Program&#8221; as that term is defined in 42 U.S.C. 1320a-7b(f), including under 42 U.S.C. &#167;&#160;1320a-7 or relevant regulations in 42 C.F.R. Part&#160;1001; (e)&#160;assessed or threatened with assessment of civil money penalties pursuant to 42 C.F.R. Part&#160;1003; or (f)&#160;included on the HHS/OIG List of Excluded Individuals/Entities, the General Services Administration&#8217;s System for Award Management, or the FDA Debarment List or the FDA Disqualified/Restricted List. Neither the Company nor its Subsidiaries, nor any of their respective officers, directors, employees or, to the Knowledge of the Company, agents has engaged in any activities that are prohibited, or are cause for civil penalties, or grounds for mandatory or permissive exclusion, debarment, or suspension pursuant to any of these authorities. Neither the Company nor its Subsidiaries are using, or have ever used, in any capacity any Person that has ever been, or to the Knowledge of Company, is the subject of a proceeding that could lead to the Persons becoming debarred, excluded, disqualified, restricted or suspended pursuant to any of these authorities. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;The Company and its Subsidiaries have materially complied with all applicable Laws relating to patient, medical or individual health information, including the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations promulgated thereunder, all as amended from time to time (collectively &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">HIPAA</font><font style="letter-spacing:0.2pt;">&#8221;), including the standards for the privacy of Individually Identifiable Health Information at 45 C.F.R. Parts 160 and 164, Subparts A and E, the standards for the protection of Electronic Protected Health Information set forth at 45 C.F.R. Part&#160;160 and 45 C.F.R. Part&#160;164, Subpart A and Subpart C, the standards for transactions and code sets used in electronic transactions at 45 C.F.R. Part&#160;160, Subpart A and Part&#160;162, and the standards for Breach Notification for Unsecured Protected Health Information at 45 C.F.R. Part&#160;164, Subpart D, all as amended from time to time. The Company and its Subsidiaries have entered into, where required, and are in compliance in all material respects with the terms of all Business Associate (as defined in HIPAA) agreements (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Business Associate Agreements</font><font style="letter-spacing:0.2pt;">&#8221;) to which the Company or any Subsidiary is a party or otherwise bound. The Company and its Subsidiaries where required, have (i)&#160;created and maintained written policies and procedures to protect the privacy of Protected Health Information in its possession or control, (ii)&#160;provided training to all employees and agents, and (iii)&#160;implemented security procedures, including physical, technical and administrative safeguards, to protect all Protected Health Information stored or transmitted in electronic form. As of the date of this Agreement, neither the Company nor any of its Subsidiaries has received written notice from the Office for Civil Rights for the U.S. Department of Health and Human Services or any other Governmental Body alleging a failure to comply with HIPAA or any other federal or state law or regulation applicable to the protection of individually identifiable health information or personally identifiable information. To the Knowledge of the Company, as of the date of this Agreement, there has been no Breach of Unsecured Protected Health Information, unpermitted disclosure of Personal Health Information, or breach of personally identifiable information with respect to information maintained or transmitted to the Company or any of its Subsidiaries that would require notice to a Governmental Body. All capitalized terms in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.14(h)</font><font style="letter-spacing:0.2pt;"> not otherwise defined in this Agreement shall have the meanings set forth under HIPAA. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.15&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Legal Proceedings; Orders</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there is no material pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i)&#160;that involves (A)&#160;the Company, (B)&#160;any of its Subsidiaries, (C)&#160;any Company Associate (in his or her </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t21MA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">capacity as such) or (D)&#160;any of the material assets owned or used by the Company or any of its Subsidiaries; or (ii)&#160;that challenges, or that would have the effect of preventing, delaying beyond the End Date, or making illegal, the Contemplated Transactions. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;There is no order, writ, injunction, judgment or decree to which the Company or any of its Subsidiaries is a party or any of the material assets owned or used by the Company or any of its Subsidiaries is subject. To the Knowledge of the Company, no officer or other Key Employee of the Company or any of its Subsidiaries is subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of the Company or any of its Subsidiaries or to any material assets owned or used by the Company or any of its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.16&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Tax Matters</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Company and each of its Subsidiaries has timely filed all income Tax Returns and other material Tax Returns that they were required to file under applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in material compliance with all applicable Law. No written claim has ever been made by any Governmental Body in any jurisdiction where the Company or any of its Subsidiaries does not file a particular Tax Return or pay a particular Tax that the Company or such Subsidiary is subject to taxation by that jurisdiction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;All income and other material Taxes due and owing by the Company or any of its Subsidiaries (whether or not shown on any Tax Return) have been fully paid. The unpaid Taxes of the Company and its Subsidiaries did not, as of the date of the Company Unaudited Interim Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax items) set forth on the face of the Company Unaudited Interim Balance Sheet. Since the date of the Company Unaudited Interim Balance Sheet, neither the Company nor any of its Subsidiaries has incurred any material Liability for Taxes outside the Ordinary Course of Business. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;All Taxes that the Company or any of its Subsidiaries are or were required by Law to withhold or collect from payments to employees, independent contractors, stockholders, lenders, customers or other third parties have been duly and timely withheld or collected in all material respects and, have been timely paid to the proper Governmental Body or properly set aside in accounts for this purpose. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;There are no Encumbrances for material Taxes (other than Permitted Encumbrances) upon any of the assets of the Company or any of its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;No deficiencies for income or other material Taxes with respect to the Company or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Body in writing other than any deficiency that has been resolved. There are no pending or ongoing, and to the Knowledge of the Company, threatened audits, assessments or other actions for or relating to any liability in respect of a material amount of Taxes of the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries (or any of their predecessors) has waived any statute of limitations in respect of any income or other material Taxes or agreed to any extension of time with respect to any income or other material Tax assessment or deficiency, which waiver is still in effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has, since January&#160;1, 2019, distributed stock of another Person, or had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code (or any similar provisions of state, local or foreign Law). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a &#8220;listed transaction&#8221; that is required to be reported to the IRS pursuant to Section&#160;6011 of the Code and applicable Treasury Regulations thereunder. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t2ALM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has taken or agreed to take any action or knows of any fact or circumstance that would reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is a party to any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement, other than customary commercial Contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i)&#160;change in method of accounting for Tax purposes filed on or prior to the Closing Date; (ii)&#160;use of an improper method of accounting for a Tax period ending on or prior to the Closing Date; (iii)&#160;&#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar provision of state, local or foreign Law) executed on or prior to the Closing Date; (iv)&#160;intercompany transaction or excess loss account described in Treasury Regulations under Section&#160;1502 of the Code (or any similar provision of state, local or foreign Law) as a result of a transaction on or prior to the Closing Date; (v)&#160;installment sale or open transaction disposition made on or prior to the Closing Date; or (vi)&#160;prepaid amount received outside of the Ordinary Course of Business on or prior to the Closing Date. The Company has not made any election under Section&#160;965(h) of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has ever been (i)&#160;a member of a consolidated, combined or unitary Tax group (other than such a group the common parent of which is the Company) or (ii)&#160;a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. Neither the Company nor any of its Subsidiaries has any Liability for any Taxes of any Person (other than the Company and any of its Subsidiaries) under Treasury Regulations&#160;Section&#160;1.1502-6 (or any similar provision of state, local, or foreign Law), or as a transferee or successor. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries (i)&#160;is a &#8220;controlled foreign corporation&#8221; as defined in Section&#160;957 of the Code; (ii)&#160;is a &#8220;passive foreign investment company&#8221; within the meaning of Section&#160;1297 of the Code; (iii)&#160;has ever had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed place of business in a country other than the country in which it is organized; or (iv)&#160;is or was a &#8220;surrogate foreign corporation&#8221; within the meaning of Section&#160;7874(a)(2)(B) or is treated as a U.S. corporation under Section&#160;7874(b) of the Code. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.17&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Employee and Labor Matters; Benefit Plans</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.17(a)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule is a list as of the date of this Agreement of all Company Benefit Plans, including each Company Benefit Plan that provides for retirement, change in control, stay or retention, deferred compensation, incentive compensation, severance or retiree medical or life insurance benefits. &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Benefit Plan</font><font style="letter-spacing:0.2pt;">&#8221; means each (i)&#160;&#8220;employee benefit plan&#8221; as defined in Section&#160;3(3) of ERISA (whether or not ERISA governs such plan) and (ii)&#160;other pension, retirement, deferred compensation, excess benefit, profit sharing, bonus, incentive, equity or equity-based (other than individual Company Options made pursuant to the Company&#8217;s standard forms, in which case only representative standard forms of such stock option agreements shall be scheduled), phantom equity, employment (other than individual employment agreements made pursuant to the Company&#8217;s standard forms, in which case only representative standard forms of such employment agreements shall be scheduled), offer letter (other than individual offer letters made pursuant to the Company&#8217;s standard forms, in which case only representative standard forms of such offers shall be scheduled), consulting, severance, change-of-control, retention, health, life, disability, group insurance, paid-time off, holiday, welfare and fringe benefit plan, program, agreement, Contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded and including any that have been frozen or terminated but only if the Company has continuing liabilities with respect thereto), in any case, maintained, contributed to, or required to be contributed to, by the Company or any of its Subsidiaries or Company ERISA Affiliates for the benefit of any current or former employee, director, officer or independent contractor of the Company or any of its Subsidiaries or under which </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the Company or any of its Subsidiaries has any Liability (including as the result of its being treated as a single employer under Code Section&#160;414 with any other person). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;As applicable with respect to each Company Benefit Plan, the Company has made available to Parent, true and complete copies of (i)&#160;each Company Benefit Plan, including all amendments thereto, and in the case of an unwritten Company Benefit Plan, a written description thereof, (ii)&#160;all current trust documents, investment management Contracts, custodial agreements, administrative services agreements and insurance and annuity Contracts relating thereto, (iii)&#160;the current summary plan description and each summary of material modifications thereto, (iv)&#160;the most recently filed annual reports with any Governmental Body (e.g., Form 5500 and all schedules thereto), (v)&#160;the most recent IRS determination, opinion or advisory letter, (vi)&#160;the most recent summary annual reports, nondiscrimination testing reports, actuarial reports, financial statements and trustee reports, (vii)&#160;all material records, notices and filings concerning IRS or Department of Labor or other Governmental Body audits or investigations, and (viii)&#160;any written reports constituting a valuation of the Company Common Stock for purposes of Section&#160;409A of the Code, whether prepared internally by the Company or by an outside, third-party valuation firm. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Each Company Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and any related documents or agreements and the applicable provisions of ERISA, the Code and all other Laws. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;The Company Benefit Plans that are &#8220;employee pension benefit plans&#8221; within the meaning of Section&#160;3(2) of ERISA and which are intended to meet the qualification requirements of Section&#160;401(a) of the Code have received determination, opinion, or advisory letters from the IRS to the effect that such plans are qualified under Section&#160;401(a) of the Code and the related trusts are exempt from federal income Taxes under Section&#160;501(a) of the Code, respectively, and to the Knowledge of the Company, nothing has occurred that would reasonably be expected to adversely affect the qualification of such Company Benefit Plan or the tax exempt status of the related trust. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Since January&#160;1, 2016, neither the Company nor any of its Subsidiaries maintained, contributed to, been required to contribute to, or had any liability with respect to, (i)&#160;any &#8220;employee pension benefit plan&#8221; &#8203;(within the meaning of Section&#160;3(2) of ERISA) that is subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii)&#160;any &#8220;multiemployer plan&#8221; &#8203;(within the meaning of Section&#160;3(37) of ERISA), (iii)&#160;any &#8220;multiple employer plan&#8221; &#8203;(within the meaning of Section&#160;413 of the Code) or (iv)&#160;any &#8220;multiple employer welfare arrangement&#8221; &#8203;(within the meaning of Section&#160;3(40) of ERISA). No Company Benefit Plan is sponsored by a professional employer organization. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there are no (i)&#160;pending audits or investigations by any Governmental Body involving any Company Benefit Plan, and (ii)&#160;pending or, to the Knowledge of the Company, threatened claims (except for individual claims for benefits payable in the normal operation of the Company Benefit Plans), suits or proceedings involving any Company Benefit Plan, any fiduciary thereof or service provider thereto. All contributions and premium payments required to have been made under any of the Company Benefit Plans or by applicable Law (without regard to any waivers granted under Section&#160;412 of the Code), have been timely made in all material respects and neither the Company nor any Company ERISA Affiliate has any material liability for any unpaid contributions with respect to any Company Benefit Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Neither the Company, any of its Subsidiaries nor any Company ERISA Affiliates, nor to the Knowledge of the Company, any fiduciary, trustee or administrator of any Company Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Company Benefit Plan which would subject any such Company Benefit Plan, the Company or any of its Subsidiaries or Parent to a material Tax, material penalty or material liability for a &#8220;prohibited transaction&#8221; under Section&#160;406 of ERISA or Section&#160;4975 of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;No Company Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service or retirement other than coverage mandated by Law and fully paid by the participant (except in connection with severance), and neither the Company nor any of its Subsidiaries or Company ERISA Affiliates has made a written or oral representation promising the same. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;Neither the execution of this Agreement nor the consummation of the Contemplated Transactions will either alone or in connection with any other event(s) (i)&#160;result in any payment becoming due to any current or former employee, director, officer, or independent contractor of the Company or any of its Subsidiaries, (ii)&#160;increase any amount of compensation or benefits otherwise payable under any Company Benefit Plan, (iii)&#160;result in the acceleration of the time of payment, funding or vesting of any benefits under any Company Benefit Plan, (iv)&#160;require any contribution or payment to fund any obligation under any Company Benefit Plan or (v)&#160;limit the right to merge, amend or terminate any Company Benefit Plan that is subject to ERISA. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;Neither the execution of this Agreement nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) will result in the receipt or retention by any Person who is a &#8220;disqualified individual&#8221; &#8203;(within the meaning of Code Section&#160;280G) with respect to the Company and its Subsidiaries of any payment or benefit under any Company Benefit Plan that is or could reasonably be expected to be characterized as a &#8220;parachute payment&#8221; &#8203;(within the meaning of Code Section&#160;280G). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;The exercise price of each Company Option granted to a U.S. taxpayer is not and never has been less than the fair market value of one share of Company Common Stock, as determined by the Company Board, as of the grant date of such Company Option. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;Each Company Benefit Plan providing for deferred compensation that constitutes a &#8220;nonqualified deferred compensation plan&#8221; &#8203;(as defined in Section&#160;409A(d)(1) of the Code and the regulations promulgated thereunder) is, and has been, established, administered and maintained in material compliance with the requirements of Section&#160;409A of the Code and the regulations promulgated thereunder in all material respects. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(m)&nbsp;&nbsp;&nbsp;No current or former employee, officer, director or independent contractor of the Company or any of its Subsidiaries has any &#8220;gross up&#8221; agreements with the Company or any of its Subsidiaries or other assurance of reimbursement by the Company or any of its Subsidiaries for any Taxes imposed under Code Section&#160;409A or Code Section&#160;4999. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(n)&nbsp;&nbsp;&nbsp;No Company Benefit Plan is maintained outside of the United States. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(o)&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has ever been a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union, labor organization, or similar Person representing any of its employees, and there is no labor union, labor organization, or similar Person representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company or its Subsidiaries, including through the filing of a petition for representation election. There is not and has not been in the past three&#160;years, nor is there or has there been in the past three&#160;years any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or, to the Knowledge of the Company, any union organizing activity, against the Company or any of its Subsidiaries. No event has occurred, and no condition or circumstance exists, that might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, any similar activity or dispute, or, to the Knowledge of the Company, any union organizing activity. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(p)&nbsp;&nbsp;&nbsp;The Company and each of its Subsidiaries is, and since January&#160;1, 2019 has been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, harassment and retaliation, equal employment opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health, payment of wages (including overtime wages), unemployment and workers&#8217; compensation, leaves of absence, and hours of work. Except as would not be reasonably likely to result in a material liability to the Company or any of its Subsidiaries, with respect to employees of the Company and its Subsidiaries, each of the Company and its Subsidiaries, since January&#160;1, 2019: (i)&#160;has withheld and reported all amounts required by Law or by agreement to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t2MSJ">&#8203;</a><a name="t2TCH">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&#160;is not liable for any arrears of wages (including overtime wages), severance pay or any Taxes or any penalty for failure to comply with any of the foregoing; and (iii)&#160;is not liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Body, with respect to unemployment compensation benefits, disability, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). As of the date of this Agreement, there are no Legal Proceedings, claims, or charges pending or, to the Knowledge of the Company, threatened or reasonably anticipated against the Company or its Subsidiaries relating to any employee, applicant for employment, consultant or employment agreement or otherwise relating to labor, employment, employment practices, or terms and conditions of employment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(q)&nbsp;&nbsp;&nbsp;Except as would not be reasonably likely to result in a material liability to the Company or any of its Subsidiaries, the Company and each of its Subsidiaries has accurately classified each individual service provider as an employee, independent contractor, or otherwise under all applicable Laws and, for each individual classified as an employee, the Company and each of its Subsidiaries has accurately classified him or her as exempt or non-exempt under all applicable Laws. Neither the Company nor any of its Subsidiaries has any material liability with respect to any misclassification of: (a)&#160;any Person as an independent contractor rather than as an employee; (b)&#160;any employee leased from another employer; or (c)&#160;any employee currently or formerly classified as exempt under all applicable Laws. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(r)&nbsp;&nbsp;&nbsp;Within the preceding five&#160;years, the Company has not implemented any &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; of employees that would reasonably be expected to require notification under the WARN Act or any similar state, local or foreign Law, and no such &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; will be implemented before the Closing Date without advance notification to and approval of Parent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.18&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Environmental Matters</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Since January&#160;1, 2019, the Company and each of its Subsidiaries have complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in such compliance that would not have a Company Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received between January&#160;1, 2019 and the date of this Agreement any written notice, whether from a Governmental Body or other Person, that alleges that the Company or any of its Subsidiaries is not in compliance with any Environmental Law and, to the Knowledge of the Company, there are no circumstances that would reasonably be expected to prevent or interfere with the Company&#8217;s or any of its Subsidiaries&#8217; compliance in any material respects with any Environmental Law, except where such failure to comply would not have a Company Material Adverse Effect. To the Knowledge of the Company, (i)&#160;no current or prior owner of any property leased or controlled by the Company or any of its Subsidiaries has received, between January&#160;1, 2019 and the date of this Agreement, any written notice relating to property owned or leased at any time by the Company or any of its Subsidiaries, whether from a Governmental Body or other Person, that alleges that such current or prior owner or the Company or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii)&#160;neither the Company nor any of its Subsidiaries has any material liability under any Environmental Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.19&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Insurance</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company has made available to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company and each of its Subsidiaries. Each of such insurance policies is in full force and effect and the Company and each of its Subsidiaries are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, between January&#160;1, 2019 and the date of this Agreement, neither the Company nor any of its Subsidiaries has received any written notice regarding any actual or possible: (a)&#160;cancellation or invalidation of any insurance policy; or (b)&#160;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. The Company and each of its Subsidiaries has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against the Company or any of its Subsidiaries for which the Company or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company or any of its Subsidiaries of its intent to do so. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t2FAN">&#8203;</a><a name="t2WAS">&#8203;</a><a name="t2NOT">&#8203;</a><a name="t2OOR">&#8203;</a><a name="tS3AW">&#8203;</a><a name="t3OS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.20&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">No Financial Advisors</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company or any of its Subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.21&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Transactions with Affiliates</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.21</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule describes any material transactions or relationships, between January&#160;1, 2019 and the date of this Agreement, between, on one hand, the Company or any of its Subsidiaries and, on the other hand, any (A)&#160;executive officer or director of the Company or, to the Knowledge of the Company, any of its Subsidiaries or any of such executive officer&#8217;s or director&#8217;s immediate family members, (B)&#160;owner of more than 5% of the voting power of the outstanding Company Capital Stock or (C)&#160;to the Knowledge of the Company, any &#8220;related person&#8221; &#8203;(within the meaning of Item&#160;404 of Regulation&#160;S-K under the Securities Act) of any such officer, director or owner (other than the Company or its Subsidiaries) in the case of each of (A), (B)&#160;or (C)&#160;that is of the type that would be required to be disclosed under Item&#160;404 of Regulation&#160;S-K under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.22&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Anti-Bribery</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;None of the Company or any of its Subsidiaries or any of their respective directors, officers, employees or, to the Company&#8217;s Knowledge, agents or any other Person acting on their behalf has, directly or indirectly, made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of the Foreign Corrupt Practices Act of 1977, or any other applicable anti-bribery or anti-corruption Law (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Anti-Bribery Laws</font><font style="letter-spacing:0.2pt;">&#8221;). To the Knowledge of the Company, neither the Company nor any of its Subsidiaries has been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.23&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Disclaimer of Other Representations or Warranties</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither Parent nor any of its Subsidiaries nor any other person on behalf of Parent or its Subsidiaries make any express or implied representation or warranty with respect to Parent or its Subsidiaries or with respect to any other information provided by the Company, any of the Company&#8217;s Subsidiaries or stockholder or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representation and warranties of Parent set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3</font><font style="letter-spacing:0.2pt;"> (in each case qualified and limited by the Parent Disclosure Schedule)), neither the Company, its Subsidiaries nor any of their respective Representatives or stockholders, has relied on such information including the accuracy or completeness thereof. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;3.&nbsp;&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.11(m)</font><font style="letter-spacing:0.2pt;">, except (a)&#160;as set forth in the written disclosure schedule delivered by Parent to the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Disclosure Schedule</font><font style="letter-spacing:0.2pt;">&#8221;) or (b)&#160;as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (but (i)&#160;without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (ii)&#160;excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being understood and agreed that any matter disclosed in the Parent SEC Documents (x)&#160;shall not be deemed disclosed for purposes of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.1</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.2</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.4</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.5</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.6</font><font style="letter-spacing:0.2pt;"> and (y)&#160;shall be deemed to be disclosed in a section of the Parent Disclosure Schedule only to the extent to which its relevance is readily apparent from a reading of such Parent SEC Documents, Parent and Merger Sub represent and warrant to the Company as follows: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Due Organization; Subsidiaries</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Parent is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware, and has all necessary corporate power and authority: (i)&#160;to conduct its business in the manner in which its business is currently being conducted; (ii)&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii)&#160;to perform its obligations under all material Contracts by which it is bound. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Parent is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t3DPH">&#8203;</a><a name="t3BNO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">requires such licensing or qualification other than in jurisdictions where the failure to be so qualified would not have a Parent Material Adverse Effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Other than Merger Sub, Parent has no Subsidiaries, except for the Entities identified in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.1(c)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule; and neither Parent nor any of Parent&#8217;s Subsidiaries owns any capital stock of, or any equity, ownership or profit sharing interest of any nature in, or controls, directly or indirectly, any other Entity other than the Entities identified in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.1(c)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule. Each of Parent&#8217;s Subsidiaries identified in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.1(c)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule is a corporation or other legal Entity duly incorporated or otherwise organized, validly existing and, if applicable, in good standing under the Laws of the jurisdiction of its incorporation or organization, as applicable, and has all necessary corporate or similar power and authority to conduct its business in the manner in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used, except where the failure to have such power or authority would not have a Parent Material Adverse Effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Merger Sub is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware. Merger Sub was formed solely for the purpose of engaging in the Contemplated Transactions. All of the issued and outstanding capital stock of Merger Sub, which consists of 100 shares of common stock, $0.0001 par value, is validly issued, fully paid and non-assessable and is owned, beneficially and of record, by Parent, free and clear of any Encumbrances with respect thereto. Except for obligations and liabilities incurred in connection with its incorporation and the Contemplated Transactions, Merger Sub has not, and will not have, incurred, directly or indirectly, any obligations or liabilities or engaged in any business activities or conducted any operations of any type or kind whatsoever or entered into any agreements or arrangements with any Person. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries is or has otherwise been a party to, or a member of, any partnership, joint venture or similar business Entity. Neither Parent nor any of its Subsidiaries has agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Neither Parent nor any of its Subsidiaries has, at any time, been a general partner of, or has otherwise been liable for, any of the debts or other obligations of, any general partnership, limited partnership or other Entity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Organizational Documents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent has made available to the Company accurate and complete copies of Parent&#8217;s and each of its Subsidiaries Organizational Documents in effect as of the date of this Agreement. Neither Parent nor any of its Subsidiaries is in material breach or violation of its respective Organizational Documents. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Authority; Binding Nature of Agreement</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Parent and each of its Subsidiaries has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Parent Board (at a meeting or meetings duly called and held and at which all members were present) has unanimously: (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders; (ii)&#160;authorized, approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Common Stock to the stockholders of the Company pursuant to the terms of this Agreement; and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Parent Stockholder Matters. The Merger Sub Board (by unanimous written consent) has: (A)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder; (B)&#160;authorized, approved and declared advisable this Agreement and the Contemplated Transactions; and (C)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions. Parent, in its capacity as the sole stockholder of Merger Sub, has by written consent duly approved votes adopting this Agreement and approving the Contemplated Transactions. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;This Agreement has been duly executed and delivered by each of Parent and Merger Sub and, assuming the due authorization, execution and delivery by the Company, constitutes the valid and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t3RAT">&#8203;</a><a name="t3CST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">binding obligation of Parent and Merger Sub, enforceable against each of Parent and Merger Sub in accordance with its terms, subject to the Enforceability Exceptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Vote Required</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;(a)&#160;The affirmative vote of the holders of a majority of the outstanding shares of Parent Common Stock entitled to vote on the record date for the Parent Stockholders&#8217; Meeting is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve the Nasdaq Reverse Split and (b)&#160;the affirmative vote of a majority in voting power of the votes cast by the holders of all shares of Parent Common Stock present or represented by proxy at the Parent Stockholders&#8217; Meeting and entitled to vote thereon is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve all other Parent Stockholder Matters (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Required Parent Stockholder Vote</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Non-Contravention; Consents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to obtaining the Required Parent Stockholder Vote, the filing of the Certificate of Merger with the Secretary of State of the State of Delaware required by the DGCL and clearance of the Merger under any applicable Antitrust Laws, neither (x)&#160;the execution, delivery or performance of this Agreement by Parent or Merger Sub, nor (y)&#160;the consummation by Parent and Merger Sub of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time): </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or Merger Sub; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a material violation of, or, to the Knowledge of Parent, give any Governmental Body or other Person the right to successfully challenge the Contemplated Transactions or to successfully exercise any material remedy or obtain any material relief under, any Law or any order, writ, injunction, judgment or decree to which Parent or its Subsidiaries, or any of the assets owned or used by Parent or its Subsidiaries, is subject, except as would not reasonably be expected to be material to Parent and its Subsidiaries, taken as a whole; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries, except as would not reasonably be expected to be material to Parent and its Subsidiaries, taken as a whole; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (i)&#160;declare a default or exercise any remedy under any Parent Material Contract; (ii)&#160;any material payment or payments, rebate, chargeback, penalty or change in delivery schedule under any Parent Material Contract; (iii)&#160;accelerate the maturity or performance of any Parent Material Contract; or (iv)&#160;cancel, terminate or modify any term of any Parent Material Contract, except in the case under this clause (d)&#160;as would not reasonably be expected to be material to Parent and its Subsidiaries, taken as a whole; or </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;result in the imposition or creation of any material Encumbrance upon or with respect to any material asset owned or used by Parent or its Subsidiaries (except for Permitted Encumbrances). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except for (i)&#160;any Consent set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.5</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule, (ii)&#160;the Required Parent Stockholder Vote, (iii)&#160;the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL and the clearance of the Merger under any applicable Antitrust Laws; and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities Laws or, if not given or obtained, as would not reasonably be expected to be material to Parent and its Subsidiaries, taken as a whole, or would not reasonably be expected to prevent or materially delay beyond the End Date the ability of Parent or the Merger Sub to consummate the Contemplated Transactions, neither Parent nor any of its Subsidiaries is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (A)&#160;the execution, delivery or performance by Parent and the Merger Sub of this Agreement, or (B)&#160;the consummation of the Contemplated Transactions. Assuming the accuracy of the representations and warranties of the Company in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.5</font><font style="letter-spacing:0.2pt;">, the Parent Board and the Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and the Parent Stockholder Support Agreements, and to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t36C">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">consummation of the Contemplated Transactions. No other state Takeover Statute or similar Law applies or purports to apply to the Merger, this Agreement, the Parent Stockholder Support Agreements or any of the Contemplated Transactions. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Capitalization</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The authorized capital stock of Parent as of the date of this Agreement consists of (i)&#160;400,000,000 shares of Parent Common Stock, par value $0.001 per share, of which 201,701,853 shares have been issued and are outstanding as of the date of this Agreement, and (ii)&#160;5,000,000 shares of preferred stock of Parent, par value $0.001 per share, of which no shares have been issued and are outstanding as of the date of this Agreement. As of the date of this Agreement, Parent does not hold any shares of its capital stock in its treasury. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable. None of the outstanding shares of Parent Common Stock are entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock are subject to any right of first refusal in favor of Parent, in each case under any Parent Contract. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. Parent is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. There are outstanding Parent Warrants to purchase 198,535 shares of Parent Common Stock. </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.6(b)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule accurately and completely lists all repurchase or forfeiture rights held by Parent with respect to shares of Parent Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable and, to the Knowledge of Parent, whether the holder of such shares of Parent Common Stock timely filed an election with the IRS under Section&#160;83(b) of the Code with respect to such shares. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Except for the Parent Stock Plans (and awards granted thereunder) and as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.6(c)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As of the date of this Agreement, 13,133,660 shares of Parent Common Stock have been reserved for issuance upon the exercise of Parent Options granted under the Parent Stock Plan that are outstanding as of the date of this Agreement, 3,068,594 shares of Parent Common Stock have been reserved for issuance upon the exercise of Parent Options granted outside of the Parent Stock Plans that are outstanding as of the date of this Agreement, 5,750,166 shares of Parent Common Stock have been reserved for issuance upon the settlement of Parent RSUs granted under the Parent Stock Plans that are outstanding as of the date of this Agreement, 0 shares of Parent Common Stock have been reserved for issuance upon the settlement of Parent RSUs granted outside of the Parent Stock Plans that are outstanding as of the date of this Agreement, 2,300,000 shares of Parent Common Stock have been reserved for issuance under the Parent ESPP, and 3,724,762 shares remain available for future issuance pursuant to the Parent Stock Plans. </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.6(c)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule sets forth the following information with respect to each Parent Option and Parent RSU outstanding as of the date of this Agreement: (i)&#160;the name of the holder; (ii)&#160;the number of shares of Parent Common Stock subject to such Parent Option or Parent RSU at the time of grant; (iii)&#160;the number of shares of Parent Common Stock subject to such Parent Option or Parent RSU as of the date of this Agreement; (iv)&#160;the exercise price of such Parent Option; (v)&#160;the date on which such Parent Option or Parent RSU was granted; (vi)&#160;the applicable vesting schedule, including the number of vested and unvested shares as of the date of this Agreement and any acceleration provisions; (vii)&#160;the date on which such Parent Option expires; and (viii)&#160;whether such Parent Option is intended to constitute an &#8220;incentive stock option&#8221; &#8203;(as defined in the Code) or a non-qualified stock option. Parent has made available to the Company accurate and complete copies of the Parent Stock Plans and all forms of the stock option and other award agreements evidencing outstanding awards granted thereunder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Except for the Parent Warrants, the Parent Options and the Parent RSUs, there is no: (i)&#160;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t3FFS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">acquire any shares of the capital stock or other securities of Parent or any of its Subsidiaries; or (ii)&#160;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent or any of its Subsidiaries. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent or any of its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;All outstanding shares of Parent Common Stock, Parent Options, Parent Warrants, Parent RSUs and other securities of Parent have been issued and granted in material compliance with (i)&#160;the Organizational Documents of Parent in effect as of the relevant time and all applicable securities Laws and other applicable Law, and (ii)&#160;all requirements set forth in applicable Contracts. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">SEC Filings; Financial Statements</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Parent has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and other documents required to be filed or furnished by Parent with the SEC under the Exchange Act or the Securities Act since January&#160;1, 2019 (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent SEC Documents</font><font style="letter-spacing:0.2pt;">&#8221;). As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and, as of the time they were filed, or if amended or superseded by a filing prior to the date of this Agreement, on the date of the last such amendment or superseding filing prior to the date of this Agreement, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i)&#160;Rule&#160;13a-14 or Rule&#160;15d-14(a) under the Exchange Act and (ii)&#160;18 U.S.C. &#167;1350 (Section&#160;906 of the Sarbanes-Oxley Act) relating to the Parent SEC Documents (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Certifications</font><font style="letter-spacing:0.2pt;">&#8221;) are accurate and complete and comply as to form and content with all applicable Laws. Parent meets the registration requirements for the use of Form S-3 under the Securities Act. As used in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.7</font><font style="letter-spacing:0.2pt;">, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is filed, furnished, supplied or otherwise made available to the SEC. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i)&#160;complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii)&#160;were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, except as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments) applied on a consistent basis unless otherwise noted therein throughout the periods indicated; and (iii)&#160;fairly present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof or have been permitted or required by any regulatory authority, there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with GAAP. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Parent SEC Documents fairly presents the information called for in all material respects and has been prepared in accordance with the SEC&#8217;s rules and guidelines applicable thereto. The books of accounts and other financial records of Parent and each of its Subsidiaries are true and complete in all material respects. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent&#8217;s independent registered accounting firm has at all times since its first date of service to Parent been: (i)&#160;a registered public accounting firm (as defined in Section&#160;2(a)(12) of the Sarbanes-Oxley Act); (ii)&#160;to the Knowledge of Parent, &#8220;independent&#8221; with respect to Parent within the meaning of Regulation&#160;S-X under the Exchange Act; and (iii)&#160;to the Knowledge of Parent, in compliance with subsections (g)&#160;through (l)&#160;of Section&#160;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.7(d)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from officials of Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq that has not been resolved, and Parent has made available to Company all such comments or correspondence (written or oral) with the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Between January&#160;1, 2019 and the date of this Agreement, there have been no formal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, principal accounting officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act and the applicable listing and other rules and regulations of Nasdaq and, except as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.7(f)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule, has not received any notice from Nasdaq asserting any noncompliance with such rules and regulations. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Parent maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i)&#160;that Parent maintains records that in reasonable detail accurately and fairly reflect Parent&#8217;s transactions and dispositions of assets, (ii)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)&#160;that receipts and expenditures are made only in accordance with authorizations of management and the Parent Board, (iv)&#160;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements, and (v)&#160;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Parent SEC Documents fairly presents the SEC&#8217;s rules and guidelines applicable thereto. Parent has evaluated the effectiveness of Parent&#8217;s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent&#8217;s auditors and audit committee (and made available to the Company a summary of the significant aspects of such disclosure) (A)&#160;all significant deficiencies and material weaknesses, if any, in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B)&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s or its Subsidiaries&#8217; internal control over financial reporting. Parent has not identified any material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;Parent maintains &#8220;disclosure controls and procedures&#8221; &#8203;(as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are reasonably designed to ensure that all information (both financial and non-financial) required to be disclosed by Parent in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods required by the SEC, and that all such information is accumulated and communicated to Parent&#8217;s management as appropriate to allow timely decisions regarding required disclosure and to make the Certifications. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;Between January&#160;1, 2019 and the date of this Agreement, (i)&#160;Parent has not received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of Parent&#8217;s internal accounting controls relating to periods after January&#160;1, 2019, including any material complaint, allegation, assertion or claim that Parent has engaged in questionable accounting or auditing practices (except for any of the foregoing after the date of this Agreement which have no reasonable basis), and (ii)&#160;no attorney representing Parent, whether or not employed by Parent, has </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t3OCA">&#8203;</a><a name="t3OUL">&#8203;</a><a name="t3TAE">&#8203;</a><a name="t3PLN">&#8203;</a><a name="t31PR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation, relating to periods after January&#160;1, 2019, by Parent or agents to the Parent Board or any committee thereof or, to the Knowledge of Parent, to any director or officer of Parent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Absence of Changes</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;(a)&#160;Between the date of the Parent Balance Sheet and the date of this Agreement, (i)&#160;Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and (ii)&#160;Parent has not taken any action that would have required the consent of the Company pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.1(b)</font><font style="letter-spacing:0.2pt;"> had such action taken place after the execution and delivery of this Agreement; and (b)&#160;since the date of the Parent Balance Sheet, there has not been any Parent Material Adverse Effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Absence of Undisclosed Liabilities</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries has any Liability, except for: (a)&#160;Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet; (b)&#160;Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business; (c)&#160;Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts (other than those arising as a result of a breach or default thereunder or as a result of failure to comply with applicable Law); (d)&#160;Liabilities for payment of fees and expenses incurred in connection with the Contemplated Transactions; (e)&#160;Liabilities which would not, individually or in the aggregate, reasonably be expected to be material to Parent and its Subsidiaries, taken as a whole; and (f)&#160;Liabilities described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.9</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Title to Assets</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, in each case, that are material to Parent and its Subsidiaries, taken as a whole, including: (a)&#160;all such tangible assets reflected on the Parent Balance Sheet; and (b)&#160;all other such tangible assets reflected in the books and records of Parent or any of its Subsidiaries as being owned by Parent or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased by Parent or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Real Property; Leasehold</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries owns or has ever owned any real property. Parent has made available to the Company (a)&#160;an accurate and complete list of all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of, or occupied or leased by Parent or any of its Subsidiaries, and (b)&#160;copies of all leases under which any such real property is possessed, occupied or leased (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Real Estate Leases</font><font style="letter-spacing:0.2pt;">&#8221;), each of which is in full force and effect, with no existing material default by Parent or any Subsidiary thereunder. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.12&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Intellectual Property</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.12(a)(1)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule identifies, as of the date of this Agreement, each item of material Parent IP that is owned or purported to be owned by or assigned to Parent or its Subsidiaries and that is the subject of a registration or application in any jurisdiction (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Registered IP</font><font style="letter-spacing:0.2pt;">&#8221;), including, with respect to each such patent and patent application: (i)&#160;the name of the applicant/registrant; (ii)&#160;the jurisdiction of application/registration; (iii)&#160;the application or registration number; and (iv)&#160;any other co-owners. </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.12(a)(2)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule identifies, as of the date of this Agreement, each license agreement under which Parent or its Subsidiaries exclusively licenses material Parent IP from a third party. To the Knowledge of Parent, each of the patents and patent applications included in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.12(a)(1)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule properly identifies by name each and every inventor of the inventions claimed therein as determined in accordance with applicable Laws of the United States. To the Knowledge of Parent, as of the date of this Agreement, no cancellation, interference, opposition, reissue, reexamination or other proceeding of any nature (other than office actions or similar communications issued by any Governmental Body in the ordinary course of prosecution of any pending applications for registration) is pending or threatened in writing, in which the scope, validity, enforceability or ownership of any Parent IP, other than such items with pending applications, is being or has been contested or challenged. To the Knowledge of Parent, each item of issued Parent Registered IP is valid and enforceable and subsisting. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Except as would not have a Parent Material Adverse Effect, Parent and its Subsidiaries collectively exclusively own, are the sole assignees of, or have exclusively licensed all material Parent IP, free and clear of all Encumbrances other than Permitted Encumbrances (other than as disclosed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.12(b)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule). The Parent IP and the Intellectual Property Rights licensed to Parent pursuant to a valid, enforceable written agreement constitute all Intellectual Property Rights used in, material to and otherwise necessary for the operation of Parent&#8217;s business as currently conducted. Each Parent Associate involved in the creation or development of any material Parent IP, pursuant to such Parent Associate&#8217;s activities on behalf of Parent or its Subsidiaries, has signed a valid and enforceable written agreement containing an assignment of such Parent Associate&#8217;s rights in such Parent IP to Parent or its applicable Subsidiary. Each Parent Associate who has or has had access to Parent&#8217;s trade secrets or confidential information has signed a valid and enforceable written agreement containing confidentiality provisions protecting the Parent IP, trade secrets and confidential information. Parent and its Subsidiaries have taken commercially reasonable steps to protect and preserve the confidentiality of its trade secrets and confidential information. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;To the Knowledge of Parent, no funding, facilities or personnel of any Governmental Body or any university, college, research institute or other educational institution has been used to create material Parent IP that is owned or purported to be owned by or assigned to Parent or its Subsidiaries, except for any such funding or use of facilities or personnel that does not result in such Governmental Body or institution obtaining ownership rights or a license to such Parent IP (excluding confirmatory licenses to inventions made with government funding and for which Parent, its Subsidiaries or either of their licensor has duly retained title under the Bayh-Dole Act) or the right to receive royalties for the practice of such Parent IP. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.12(d)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule sets forth, as of the date of this Agreement, each license agreement pursuant to which Parent (i)&#160;is granted a license under any material Intellectual Property Right owned by any third party that is used by Parent or its Subsidiaries in its business as currently conducted (each a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent In-bound License</font><font style="letter-spacing:0.2pt;">&#8221;) or (ii)&#160;grants to any third party a license under any material Parent IP or material Intellectual Property Right licensed to Parent or its Subsidiaries under a Parent In-bound License (each a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Out-bound License</font><font style="letter-spacing:0.2pt;">&#8221;) (</font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that, Parent In-bound Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, clinical trial agreements, agreements with Parent Associates, services agreements, commercially available Software-as-a-Service offerings or off-the-shelf software licenses; and Parent Out-bound Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, clinical trial agreements, services agreements, or non-exclusive outbound licenses). All Parent In-bound Licenses and Parent Out-bound Licenses are in full force and effect and are valid, enforceable and binding obligations of Parent or the applicable Subsidiary and, to the Knowledge of Parent, each other party to such Parent In-bound Licenses or Parent Out-bound Licenses. Neither Parent or any of its Subsidiaries, nor to the Knowledge of Parent, any other party to such Parent In-bound Licenses or Parent Out-bound Licenses, is in material breach under any Parent In-bound Licenses or Parent Out-bound Licenses. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;To the Knowledge of Parent: (i)&#160;the operation of the businesses of Parent and its Subsidiaries as currently conducted does not infringe, misappropriate or otherwise violate any Intellectual Property Rights of any other Person; and (ii)&#160;no other Person is infringing, misappropriating or otherwise violating any Parent IP. As of the date of this Agreement, no Legal Proceeding is pending (or, to the Knowledge of Parent, is threatened in writing) (A)&#160;against Parent or its Subsidiaries alleging that the operation of the businesses of Parent or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights of another Person or (B)&#160;by Parent or its Subsidiaries alleging that another Person has infringed, misappropriated or otherwise violated any of the Parent IP or any Intellectual Property Rights exclusively licensed to Parent or its Subsidiaries. Between January&#160;1, 2019 and the date of this Agreement, neither Parent nor its Subsidiaries has received any written notice or other written communication alleging that the operation of the business of Parent or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another Person. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;None of the Parent IP that is owned or purported to be owned by or assigned to Parent or its Subsidiaries and, to the Knowledge of Parent, no material Intellectual Property Rights exclusively </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t3CAC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">licensed to Parent or its Subsidiaries is subject to any pending or outstanding injunction, directive, order, judgment or other disposition of dispute that adversely and materially restricts the use, transfer, registration or licensing by Parent or its Subsidiaries of any such Parent IP that is owned or purported to be owned by or assigned to Parent or its Subsidiaries or material Intellectual Property Rights exclusively licensed to Parent or its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;To the Knowledge of Parent, Parent, its Subsidiaries and the operation of Parent&#8217;s and its Subsidiaries&#8217; business are in substantial compliance with all Laws pertaining to data privacy and data security of Sensitive Data. Between January&#160;1, 2019 and the date of this Agreement, there have been (i)&#160;no losses or thefts of data or security breaches relating to Sensitive Data used in the business of Parent, (ii)&#160;no material violations of any security policy of Parent regarding any such Sensitive Data used in the business of Parent or its Subsidiaries, (iii)&#160;no unauthorized access, unauthorized use or unintended or improper disclosure of any Sensitive Data used in the business of Parent or its Subsidiaries, except in each case as would not reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole. Parent has taken commercially reasonable steps and implemented reasonable disaster recovery and security plans and procedures to protect the information technology systems used in, material to and necessary for operation of Parent&#8217;s business as currently conducted from unauthorized use or access. To the Knowledge of Parent, as of the date of this Agreement, there have been no material malfunctions or unauthorized intrusions or breaches of the information technology systems used in, material to and necessary for the operation of Parent&#8217;s business as currently conducted. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.13&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Agreements, Contracts and Commitments</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.13(a)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule lists the following Parent Contracts in effect as of the date of this Agreement and under which Parent or any of its Subsidiaries has any remaining material rights or obligations (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Material Contract</font><font style="letter-spacing:0.2pt;">&#8221; and collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Material Contracts</font><font style="letter-spacing:0.2pt;">&#8221;): </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;a material Contract as defined in Item&#160;601(b)(10) of Regulation&#160;S-K as promulgated under the Securities Act; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;each Parent Contract containing (A)&#160;any covenant limiting the freedom of Parent or its Subsidiaries to engage in any line of business or compete with any Person, (B)&#160;any most-favored pricing arrangement, (C)&#160;any exclusivity provision, or (D)&#160;any non-solicitation provision, in each case, except for restrictions that would not materially affect the ability of Parent and its Subsidiaries to conduct its business; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $250,000 pursuant to its express terms and not cancelable without penalty; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $250,000, other than Parent Contracts in which the applicable acquisition or disposition has been consummated and there are no material ongoing liabilities or obligations; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $250,000 or creating any material Encumbrances with respect to any assets of Parent or any of its Subsidiaries or any loans or debt obligations with officers or directors of Parent; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vii)&nbsp;&nbsp;&nbsp;each Parent Contract requiring payment by or to Parent or its Subsidiaries after the date of this Agreement in excess of $250,000 pursuant to its express terms and constituting: (A)&#160;an exclusive distribution agreement; (B)&#160;an agreement involving provision of material services </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or products with respect to any pre-clinical or clinical development activities of Parent or its Subsidiaries; (C)&#160;a dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or similar agreement currently in force under which Parent or its Subsidiaries has continuing obligations to develop or market any product, technology or service, or an agreement pursuant to which Parent or its Subsidiaries has continuing obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by Parent or its Subsidiaries; or (D)&#160;a Parent Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to the manufacture or produce any product, service or technology of Parent or its Subsidiaries or any Parent Contract to sell, distribute or commercialize any products or service of Parent or its Subsidiaries, in each case under clauses (A)&#160;through (D), except for Parent Contracts that are entered into in the Ordinary Course of Business; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(viii)&nbsp;&nbsp;&nbsp;each Parent Contract with any financial advisor, broker, finder, investment banker or other similar Person, providing advisory services to Parent in connection with the Contemplated Transactions; </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ix)&nbsp;&nbsp;&nbsp;each Parent Real Estate Lease; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(x)&nbsp;&nbsp;&nbsp;each Parent Out-bound License and Parent In-bound License, and each Parent Contract containing a covenant not to sue or otherwise enforce any Intellectual Property Rights; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xi)&nbsp;&nbsp;&nbsp;each Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent or any of its Subsidiaries; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xii)&nbsp;&nbsp;&nbsp;each (A)&#160;Parent Contract, offer letter, employment agreement or other agreement with any employee that requires payment of base salary and target annual cash bonus in excess of $150,000 in any calendar year that (1)&#160;provides for employment by Parent or any of its Subsidiaries and is not immediately terminable at will by Parent without advance notice, severance, or other similar cost or liability (other than for accrued compensation, vacation, or other amounts due upon any termination), or (2)&#160;provides for or otherwise relates to any retention payments, change of control payments, severance, accelerated vesting or any payment or benefit that may or will become due as a result of the Merger (whether alone or in connection with any other event), and (B)&#160;Parent Contract, independent contractor agreement, or other agreement with any individual consultant or service provider requiring payment of fees in excess of $150,000 in any calendar year that (1)&#160;is not immediately terminable at will by the Company without more than 30&#160;days&#8217; prior notice, severance, or other similar cost or liability (other than for any accrued but unpaid fees) or (2)&#160;provides for retention payments, change of control payments, severance, accelerated vesting or any payment or benefit that may or will become due as a result of the Merger (whether alone or in connection with any other event); </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xiii)&nbsp;&nbsp;&nbsp;each Parent Contract under which a third party would be entitled to receive a license or have any other rights in any material Parent IP; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xiv)&nbsp;&nbsp;&nbsp;each Parent Contract entered into in settlement of any Legal Proceeding or other dispute; and </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xv)&nbsp;&nbsp;&nbsp;any other Parent Contract that is not terminable at will (with no penalty or payment) by Parent or any of its Subsidiaries, as applicable and (A)&#160;which involves payment or receipt by Parent or its Subsidiaries after the date of this Agreement under any such agreement, Contract or commitment of more than $250,000 in the aggregate, or obligations after the date of this Agreement in excess of $250,000 in the aggregate, or (B)&#160;that is material to the business or operations of Parent and its Subsidiaries, taken as a whole. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Parent has made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto, in each case in effect on the date of this Agreement. There are no Parent Material Contracts that are not in written form. Neither Parent nor any of its Subsidiaries has, nor, to Parent&#8217;s Knowledge, as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or as of the date of this </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t31PE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Agreement received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such manner as would permit any other party to cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would have a Parent Material Adverse Effect. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. As of the date of this Agreement, no Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract, and, as of the date of this Agreement, no Person has indicated in writing to Parent that it desires to renegotiate, modify, not renew or cancel any Parent Material Contract. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.14&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Compliance; Permits</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Parent and each of its Subsidiaries is, and since January&#160;1, 2019 has been, in compliance in all material respects with all applicable Laws, including the FDCA, PHSA and any other similar Law administered or promulgated by the FDA or other Drug Regulatory Agency, except for any noncompliance, either individually or in the aggregate, which would not be material to Parent and its Subsidiaries, taken as a whole. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, no investigation, claim, suit, proceeding, audit or other action by any Governmental Body is pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries. There is no judgment, injunction, order or decree binding upon Parent or any of its Subsidiaries which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii)&#160;is reasonably likely to have an adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this Agreement, or (iii)&#160;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent and its Subsidiaries hold all required Governmental Authorizations to develop, test, manufacture, store, label, package, distribute, import and export the respective current products or product candidates that are material to the operation of the business of Parent and its Subsidiaries as currently conducted (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Permits</font><font style="letter-spacing:0.2pt;">&#8221;). </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.14(c)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule identifies each Parent Permit. Each such Parent Permit is valid and in full force and effect, and each of Parent and its Subsidiaries is in material compliance with the terms of the Parent Permits. As of the date of this Agreement, no Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, limit, suspend, or materially modify any Parent Permit. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there has not been and is not now any Form FDA-483 observation, civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, untitled letter, or proceeding pending or in effect against Parent or its Subsidiaries or any of their respective officers and employees, and Parent has no liability for failure to comply with the FDCA, PHSA, or other similar Laws. There is no act, omission, event, or circumstance of which Parent has Knowledge that would reasonably be expected to give rise to or form the basis for any civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, untitled letter, proceeding or request for information or any liability (whether actual or contingent) for failure to comply with the FDCA, PHSA or other similar Laws. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Parent or its Subsidiaries, or of their respective current products or product candidates, were and, if still pending, are being conducted in all material respects with applicable regulations of any applicable Drug Regulatory Agency and other applicable Law, including the GCP regulations under 21 C.F.R. Parts 50, 54, 56 and 312 and GLP regulations under 21 C.F.R. Part&#160;58. No preclinical study or clinical trial conducted by or on behalf of Parent or any of its Subsidiaries has been terminated or suspended prior to completion for safety or non-compliance reasons. Between January&#160;1, 2019 and the date of this Agreement, neither Parent nor any of its Subsidiaries has received any written notices, correspondence, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">or other written communications from any Drug Regulatory Agency requiring, or to the Knowledge of Parent, threatening to initiate, the termination or suspension of any clinical studies conducted by or on behalf of, or sponsored by, Parent any of its Subsidiaries or of their respective current products or product candidates. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, neither Parent nor any of its Subsidiaries is the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its business or products or product candidates pursuant to the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September&#160;10, 1991). To the Knowledge of Parent, neither Parent nor any of its Subsidiaries has committed any acts, made any statement, or failed to make any statement, in each case in respect of its business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Neither Parent nor its Subsidiaries, nor any of their respective officers, directors, or employees has been, is, or is in anticipation of being (based on a conviction by the courts or a finding of fault by a regulatory authority): (a)&#160;debarred pursuant to the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;&#160;335a), as amended from time to time; (b)&#160;disqualified from participating in clinical trials pursuant to 21 C.F.R. &#167;312.70, as amended from time to time; (c)&#160;disqualified as a testing facility under 21 C.F.R. Part&#160;58, Subpart K, as amended from time to time; (d)&#160;excluded, debarred or suspended from or otherwise ineligible to participate in a &#8220;Federal Health Care Program&#8221; as that term is defined in 42 U.S.C. 1320a-7b(f), including under 42 U.S.C. &#167;&#160;1320a-7 or relevant regulations in 42 C.F.R. Part&#160;1001; (e)&#160;assessed or threatened with assessment of civil money penalties pursuant to 42 C.F.R. Part&#160;1003; or (f)&#160;included on the HHS/OIG List of Excluded Individuals/Entities, the General Services Administration&#8217;s System for Award Management, or the FDA Debarment List or the FDA Disqualified/</font>&#8203;<font style="letter-spacing:0.2pt;">Restricted List. Neither Parent nor its Subsidiaries, nor any of their respective officers, directors or employees has engaged in any activities that are prohibited, or are cause for civil penalties, or grounds for mandatory or permissive exclusion, debarment, or suspension pursuant to any of these authorities. Neither Parent nor its Subsidiaries are using, or have ever used, in any capacity any Person that has ever been, or to the Knowledge of Parent, is the subject of a proceeding that could lead to the Persons becoming debarred, excluded, disqualified, restricted or suspended pursuant to any of these authorities. </font></div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;Parent and its Subsidiaries have materially complied with all applicable Laws relating to patient, medical or individual health information, including HIPAA and the standards for the privacy of Individually Identifiable Health Information at 45 C.F.R. Parts 160 and 164, Subparts A and E, the standards for the protection of Electronic Protected Health Information set forth at 45 C.F.R. Part&#160;160 and 45 C.F.R. Part&#160;164, Subpart A and Subpart C, the standards for transactions and code sets used in electronic transactions at 45 C.F.R. Part&#160;160, Subpart A and Part&#160;162, and the standards for Breach Notification for Unsecured Protected Health Information at 45 C.F.R. Part&#160;164, Subpart D, all as amended from time to time. Parent and its Subsidiaries have entered into, where required, and are in compliance in all material respects with the terms of all Business Associate Agreements to which Parent or any Subsidiary is a party or otherwise bound. Parent and its Subsidiaries where required, have (i)&#160;created and maintained written policies and procedures to protect the privacy of Protected Health Information in its possession or control, (ii)&#160;provided training to all employees and agents, and (iii)&#160;implemented security procedures, including physical, technical and administrative safeguards, to protect all Protected Health Information stored or transmitted in electronic form. As of the date of this Agreement, neither Parent nor any of its Subsidiaries has received written notice from the Office for Civil Rights for the U.S. Department of Health and Human Services or any other Governmental Body alleging a failure to comply with HIPAA or any other federal or state law or regulation applicable to the protection of individually identifiable health information or personally identifiable information. To the Knowledge of Parent, as of the date of this Agreement, there has been no Breach of Unsecured Protected Health Information, unpermitted disclosure of Personal Health Information, or breach of personally identifiable information with respect to information maintained or transmitted to Parent or any of its Subsidiaries that would require notice to a Governmental Body. All capitalized terms in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.14(h)</font><font style="letter-spacing:0.2pt;"> not otherwise defined in this Agreement shall have the meanings set forth under HIPAA. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t3PO">&#8203;</a><a name="t31MA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.15&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Legal Proceedings; Orders</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there is no material pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i)&#160;that involves (A)&#160;Parent, (B)&#160;any of its Subsidiaries, (C)&#160;any Parent Associate (in his or her capacity as such) or (D)&#160;any of the material assets owned or used by Parent or any of its Subsidiaries; or (ii)&#160;that challenges, or that would have the effect of preventing, delaying beyond the End Date, or making illegal, the Contemplated Transactions. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;There is no order, writ, injunction, judgment or decree to which Parent or any of its Subsidiaries is a party or any of the material assets owned or used by Parent or any of its Subsidiaries is subject. To the Knowledge of Parent, no officer or Key Employee of Parent or any of its Subsidiaries is subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or to any material assets owned or used by Parent or any of its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.16&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Tax Matters</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Parent and each of its Subsidiaries have timely filed all income Tax Returns and other material Tax Returns that they were required to file under applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in material compliance with all applicable Law. No written claim has ever been made by any Governmental Body in any jurisdiction where Parent or its any of its Subsidiaries does not file a particular Tax Return or pay a particular Tax that Parent or such Subsidiary is subject to taxation by that jurisdiction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;All income and other material Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been fully paid. The unpaid Taxes of Parent and its Subsidiaries did not, as of the date of the Parent Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax items) set forth on the face of the Parent Balance Sheet. Since the Parent Balance Sheet Date, neither Parent nor any of its Subsidiaries has incurred any material Liability for Taxes outside the Ordinary Course of Business. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;All Taxes that Parent or any of its Subsidiaries are or were required by Law to withhold or collect from payments to employees, independent contractors, stockholders, lenders, customers or other third parties have been duly and timely withheld or collected in all material respects and, have been timely paid to the proper Governmental Body or properly set aside in accounts for this purpose. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;There are no Encumbrances for material Taxes (other than Permitted Encumbrances) upon any of the assets of Parent or any of its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;No deficiencies for income or other material Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Body in writing other than any deficiency that has been resolved. There are no pending or ongoing, and to the Knowledge of Parent, threatened audits, assessments or other actions for or relating to any liability in respect of a material amount of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries (or any of their predecessors) has waived any statute of limitations in respect of any income or other material Taxes or agreed to any extension of time with respect to any income or other material Tax assessment or deficiency which waiver is still in effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries has, since January&#160;1, 2019, distributed stock of another Person, or had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code (or any similar provisions of state, local or foreign Law). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries has participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a &#8220;listed transaction&#8221; that is required to be reported to the IRS pursuant to Section&#160;6011 of the Code and applicable Treasury Regulations thereunder. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t3ALM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries has taken or agreed to take any action or knows of any fact or circumstance that would reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries is a party to any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement, other than customary commercial Contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i)&#160;change in method of accounting for Tax purposes filed on or prior to the Closing Date; (ii)&#160;use of an improper method of accounting for a Tax period ending on or prior to the Closing Date; (iii)&#160;&#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar provision of state, local or foreign Law) executed on or prior to the Closing Date; (iv)&#160;intercompany transaction or excess loss account described in Treasury Regulations under Section&#160;1502 of the Code (or any similar provision of state, local or foreign Law) as a result of a transaction on or prior to the Closing Date; (v)&#160;installment sale or open transaction disposition made on or prior to the Closing Date; or (vi)&#160;prepaid amount received outside of the Ordinary Course of Business on or prior to the Closing Date. Parent has not made any election under Section&#160;965(h) of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries has ever been (i)&#160;a member of a consolidated, combined or unitary Tax group (other than such a group the common parent of which is Parent) or (ii)&#160;a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. Neither Parent nor its Subsidiaries has any Liability for any Taxes of any Person (other than Parent and any of its Subsidiaries) under Treasury Regulations&#160;Section&#160;1.1502-6 (or any similar provision of state, local, or foreign Law), or as a transferee or successor. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries (i)&#160;is a &#8220;controlled foreign corporation&#8221; as defined in Section&#160;957 of the Code; (ii)&#160;is a &#8220;passive foreign investment company&#8221; within the meaning of Section&#160;1297 of the Code; (iii)&#160;has ever had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed place of business in a country other than the country in which it is organized; or (iv)&#160;is or was a &#8220;surrogate foreign corporation&#8221; within the meaning of Section&#160;7874(a)(2)(B) or is treated as a U.S. corporation under Section&#160;7874(b) of the Code. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.17&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Employee and Labor Matters; Benefit Plans</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.17(a)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule is a list as of the date of this Agreement of all Parent Benefit Plans, including each Parent Benefit Plan that provides for retirement, change in control, stay or retention, deferred compensation, incentive compensation, severance or retiree medical or life insurance benefits. &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Benefit Plan</font><font style="letter-spacing:0.2pt;">&#8221; means each (i)&#160;&#8220;employee benefit plan&#8221; as defined in Section&#160;3(3) of ERISA (whether or not ERISA governs such plan) and (ii)&#160;other pension, retirement, deferred compensation, excess benefit, profit sharing, bonus, incentive, equity or equity-based (other than individual Parent Options or Parent RSUs made pursuant to Parent&#8217;s standard forms, in which case only representative standard forms of such stock option agreements and other award agreements shall be scheduled), phantom equity, employment (other than individual employment agreements made pursuant to Parent&#8217;s standard forms, in which case only representative standard forms of such employment agreements shall be scheduled), offer letter (other than individual offer letters made pursuant to Parent&#8217;s standard forms, in which case only representative standard forms of such offers shall be scheduled), consulting, severance, change-of-control, retention, health, life, disability, group insurance, paid-time off, holiday, welfare and fringe benefit plan, program, agreement, Contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded and including any that have been frozen or terminated but only if Parent has continuing liabilities with respect thereto), in any case, maintained, contributed to, or required to be contributed to, by Parent, any of its Subsidiaries or Parent ERISA Affiliates for the benefit of any current or former employee, director, officer or independent contractor of Parent or any of its Subsidiaries or under which Parent or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">any of its Subsidiaries has any Liability (including as the result of its being treated as a single employer under Code Section&#160;414 with any other person). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;As applicable with respect to each Parent Benefit Plan, Parent has made available to the Company, true and complete copies of (i)&#160;each Parent Benefit Plan, including all amendments thereto, and in the case of an unwritten Parent Benefit Plan, a written description thereof, (ii)&#160;all current trust documents, investment management Contracts, custodial agreements, administrative services agreements and insurance and annuity Contracts relating thereto, (iii)&#160;the current summary plan description and each summary of material modifications thereto, (iv)&#160;the most recently filed annual reports with any Governmental Body (e.g., Form 5500 and all schedules thereto), (v)&#160;the most recent IRS determination, opinion or advisory letter, (vi)&#160;the most recent summary annual reports, nondiscrimination testing reports, actuarial reports, financial statements and trustee reports, and (vii)&#160;all material records, notices and filings concerning IRS or Department of Labor or other Governmental Body audits or investigations. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Each Parent Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and any related documents or agreements and the applicable provisions of ERISA, the Code and all other Laws, including applicable pension Laws and, if applicable, the Income Tax Act (Canada) and the regulations thereunder. All filings and reports as to each Parent Plan required to have been submitted to the Internal Revenue Service, the Canada Revenue Agency, a Canadian Governmental Entity or to the Department of Labor, in each case to the extent applicable, have been timely submitted. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;The Parent Benefit Plans that are &#8220;employee pension benefit plans&#8221; within the meaning of Section&#160;3(2) of ERISA and which are intended to meet the qualification requirements of Section&#160;401(a) of the Code have received determination, opinion or advisory letters from the IRS to the effect that such plans are qualified under Section&#160;401(a) of the Code and the related trusts are exempt from federal income Taxes under Section&#160;501(a) of the Code, respectively, and to the Knowledge of Parent, nothing has occurred that would reasonably be expected to adversely affect the qualification of such Parent Benefit Plan or the tax exempt status of the related trust. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Since January&#160;1, 2016, neither Parent nor any of its Subsidiaries nor any Parent ERISA Affiliate has maintained, contributed to, been required to contribute to, or had any liability with respect to, (i)&#160;any &#8220;employee pension benefit plan&#8221; &#8203;(within the meaning of Section&#160;3(2) of ERISA) that is subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii)&#160;any &#8220;multiemployer plan&#8221; &#8203;(within the meaning of Section&#160;3(37) of ERISA), or (iii)&#160;any &#8220;multiple employer plan&#8221; &#8203;(within the meaning of Section&#160;413 of the Code). No Parent Benefit Plan is a self-funded group health plan that is a &#8220;multiple employer welfare arrangement&#8221; &#8203;(within the meaning of Section&#160;3(40) of ERISA). No Parent Benefit Plan is sponsored by a professional employer organization. Except as set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.17(e)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule, Parent has not maintained any Parent Benefit Plans outside the United States that are defined-benefit type plans. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there are no (i)&#160;pending audits or investigations by any Governmental Body involving any Parent Benefit Plan, and (ii)&#160;pending or, to the Knowledge of Parent, threatened claims (except for individual claims for benefits payable in the normal operation of the Parent Benefit Plans), suits or proceedings involving any Parent Benefit Plan, any fiduciary thereof or service provider thereto. All contributions and premium payments required to have been made under any of the Parent Benefit Plans or by applicable Law (without regard to any waivers granted under Section&#160;412 of the Code), have been timely made in all material respects and neither Parent nor any Parent ERISA Affiliate has any material liability for any unpaid contributions with respect to any Parent Benefit Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;Neither Parent, any of its Subsidiaries nor any Parent ERISA Affiliates, nor to the Knowledge of Parent, any fiduciary, trustee or administrator of any Parent Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Parent Benefit Plan which would subject any such Parent Benefit Plan, Parent or any of its Subsidiaries or Parent to a material Tax, material penalty or material liability for a &#8220;prohibited transaction&#8221; under Section&#160;406 of ERISA or Section&#160;4975 of the Code. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;No Parent Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service or retirement other than coverage mandated by Law and fully paid by the participant (except in connection with severance), and neither Parent, any of its Subsidiaries nor any Parent ERISA Affiliates has made a written or oral representation promising the same. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;Neither the execution of this Agreement nor the consummation of the Contemplated Transactions will either alone or in connection with any other event(s) (i)&#160;result in any payment becoming due to any current or former employee, director, officer, or independent contractor of Parent or any of its Subsidiaries, (ii)&#160;increase any amount of compensation or benefits otherwise payable under any Parent Benefit Plan, (iii)&#160;result in the acceleration of the time of payment, funding or vesting of any benefits under any Parent Benefit Plan, (iv)&#160;require any contribution or payment to fund any obligation under any Parent Benefit Plan or (v)&#160;limit the right to merge, amend or terminate any Parent Benefit Plan that is subject to ERISA. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;Neither the execution of this Agreement nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) will result in the receipt or retention by any Person who is a &#8220;disqualified individual&#8221; &#8203;(within the meaning of Code Section&#160;280G) with respect to Parent and its Subsidiaries of any payment or benefit under any Parent Benefit Plan that is or could reasonably be expected to be characterized as a &#8220;parachute payment&#8221; &#8203;(within the meaning of Code Section&#160;280G). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;The exercise price of each Parent Option granted to a U.S. taxpayer is not and never has been less than the fair market value, as determined by the Parent Board, of one share of Parent Common Stock as of the grant date of such Parent Option. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;Each Parent Benefit Plan providing for deferred compensation that constitutes a &#8220;nonqualified deferred compensation plan&#8221; &#8203;(as defined in Section&#160;409A(d)(1) of the Code and the regulations promulgated thereunder) is, and has been, established, administered and maintained in material compliance with the requirements of Section&#160;409A of the Code and the regulations promulgated thereunder in all material respects. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(m)&nbsp;&nbsp;&nbsp;No current or former employee, officer, director or independent contractor of Parent or any of its Subsidiaries has any &#8220;gross up&#8221; agreements with Parent or any of its Subsidiaries or other assurance of reimbursement by Parent or any of its Subsidiaries for any Taxes imposed under Code Section&#160;409A or Code Section&#160;4999. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(n)&nbsp;&nbsp;&nbsp;No Parent Benefit Plan is maintained outside of the United States. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(o)&nbsp;&nbsp;&nbsp;Parent has made available to the Company a true and correct list, as of the date of this Agreement, containing an anonymized list of all full-time, part-time or temporary employees and independent contractors (and indication as such), and, as applicable: (i)&#160;the annual dollar amount of all compensation (including wages, salary or fees, commissions, director&#8217;s fees, fringe benefits, bonuses, profit sharing payments, and other payments or benefits of any type) payable to each person; (ii), dates of employment or service; (iii)&#160;title; (iv)&#160;any eligibility to receive severance, retention payment, change of control payment, or other similar compensation; (v)&#160;visa status, if applicable; (vi)&#160;if any employee is an on approved leave, and the expected date of return, if known; and (vii)&#160;with respect to employees, a designation of whether they are classified as exempt or non-exempt for purposes of the Fair Labor Standards Act and any similar state or foreign law. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(p)&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries is and has never been a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union, labor organization, or similar Person representing any of its employees, and there is no labor union, labor organization, or similar Person representing or, to the Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent or its Subsidiaries, including through the filing of a petition for representation election. There is not and has not been in the past three&#160;years, nor is there or has there been in the past three&#160;years any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or, to the Knowledge of Parent, any union organizing activity, against Parent or any of its Subsidiaries. No event has occurred, and no condition or circumstance exists, that might directly or indirectly be likely to give rise </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t3MSJ">&#8203;</a><a name="t3PHM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, any similar activity or dispute, or, to the Knowledge of Parent, any union organizing activity. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(q)&nbsp;&nbsp;&nbsp;Parent and each of its Subsidiaries is, and since January&#160;1, 2019 has been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, harassment and retaliation, equal employment opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health, payment of wages (including overtime wages), unemployment and workers&#8217; compensation, leaves of absence, and hours of work. Except as would not be reasonably likely to result in a material liability to Parent or any of its Subsidiaries, with respect to employees of Parent and its Subsidiaries, each of Parent and its Subsidiaries, since January&#160;1, 2019: (i)&#160;has withheld and reported all amounts required by Law or by agreement to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees; (ii)&#160;is not liable for any arrears of wages (including overtime wages), severance pay or any Taxes or any penalty for failure to comply with any of the foregoing; and (iii)&#160;is not liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Body, with respect to unemployment compensation benefits, disability, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). As of the date of this Agreement, there are no Legal Proceedings, claims or charges pending or, to the Knowledge of Parent, threatened or reasonably anticipated against Parent or its Subsidiaries relating to any employee, applicant for employment, consultant, or employment agreement or otherwise relating to labor, employment, employment practices, or terms and conditions of employment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(r)&nbsp;&nbsp;&nbsp;Except as would not be reasonably likely to result in a material liability to Parent or any of its Subsidiaries, Parent and each of its Subsidiaries has accurately classified each individual service provider as an employee, independent contractor, or otherwise under all applicable Laws and, for each individual classified as an employee, Parent and each of its Subsidiaries has accurately classified him or her as exempt or non-exempt under all applicable Laws. Neither Parent nor any of its Subsidiaries has any material liability with respect to any misclassification of: (a)&#160;any Person as an independent contractor rather than as an employee; (b)&#160;any employee leased from another employer; or (c)&#160;any employee currently or formerly classified as exempt under all applicable Laws. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(s)&nbsp;&nbsp;&nbsp;Within the preceding five&#160;years, Parent has not implemented any &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; of employees that would reasonably be expected to require notification under the WARN Act or any similar state, local or foreign Law. No &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; will be implemented before the Closing Date without advance notification to and approval of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.18&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Environmental Matters</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Since January&#160;1, 2019, Parent and each of its Subsidiaries have complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in such compliance that would not have a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries have received between January&#160;1, 2019 and the date of this Agreement any written notice, whether from a Governmental Body or other Person, that alleges that Parent or any of its Subsidiaries is not in compliance with any Environmental Law and, to the Knowledge of Parent, there are no circumstances that would reasonably be expected to prevent or interfere with Parent&#8217;s or any of its Subsidiaries&#8217; compliance in any material respects with any Environmental Law, except where such failure to comply would not have a Parent Material Adverse Effect. To the Knowledge of Parent, (i)&#160;no current or prior owner of any property leased or controlled by Parent or any of its Subsidiaries has received, between January&#160;1, 2019 and the date of this Agreement, any written notice relating to property owned or leased at any time by Parent or any of its Subsidiaries, whether from a Governmental Body or other Person, that alleges that current or prior owners or Parent or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii)&#160;neither Parent nor any of its Subsidiaries has any material liability under any Environmental Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.19&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Insurance</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent has made available to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t3FAO">&#8203;</a><a name="t3WAE">&#8203;</a><a name="t3NPN">&#8203;</a><a name="t3ITP">&#8203;</a><a name="t3OFA">&#8203;</a><a name="t3OOR">&#8203;</a><a name="tS4CO">&#8203;</a><a name="t4OPB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">business, assets, liabilities and operations of Parent and each of its Subsidiaries. Each of such insurance policies is in full force and effect and Parent and each of its Subsidiaries are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, between January&#160;1, 2019 and the date of this Agreement, neither Parent nor any of its Subsidiaries has received any written notice regarding any actual or possible: (a)&#160;cancellation or invalidation of any insurance policy; or (b)&#160;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Parent and each of its Subsidiaries have provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against Parent or any of its Subsidiaries for which Parent or such Subsidiaries has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.20&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">No Financial Advisors</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Other than SVB Securities LLC, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent or any of its Subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.21&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Transactions with Affiliates</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since December&#160;31, 2021, no event has occurred that would be required to be reported by Parent pursuant to Item&#160;404 of Regulation&#160;S-K. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.22&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Anti-Bribery</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Neither Parent nor any of its Subsidiaries or any of their respective directors, officers, employees or, to Parent&#8217;s Knowledge, agents or any other Person acting on their behalf has, directly or indirectly, made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of Anti-Bribery Laws. To the Knowledge of Parent, neither Parent nor any of its Subsidiaries is or has been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.23&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Valid Issuance</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Parent Common Stock to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.24&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Opinion of Financial Advisor</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Parent Board has received an opinion of SVB Securities LLC to the effect that, as of the date of this Agreement and subject to the assumptions, qualifications, limitations and other matters set forth therein, the Exchange Ratio is fair, from a financial point of view, to Parent. It is agreed and understood that such opinion is for the benefit of the Parent Board and may not be relied upon by the Company or any other party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.25&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Disclaimer of Other Representations or Warranties</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company or any of its Subsidiaries makes any express or implied representation or warranty with respect to the Company or any of its Subsidiaries or with respect to any other information provided to Parent, Merger Sub or stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of the Company set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2</font><font style="letter-spacing:0.2pt;"> (in each case as qualified and limited by the Company Disclosure Schedule)) neither Parent, its Subsidiaries nor any of their respective Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof). </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;4.&nbsp;&nbsp;&nbsp;CERTAIN COVENANTS OF THE PARTIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Operation of Parent&#8217;s Business</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Except as expressly permitted by this Agreement, as required by applicable Law, in connection with any COVID-19 Measures or COVID-19 Response or unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9</font><font style="letter-spacing:0.2pt;"> and the Effective Time (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Pre-Closing Period</font><font style="letter-spacing:0.2pt;">&#8221;), Parent shall, and shall cause each of its Subsidiaries to, (x)&#160;use commercially reasonable efforts to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">conduct its business and operations in the Ordinary Course of Business and (y)&#160;conduct its business and operations in compliance in all material respects with all applicable Laws, including timely making all filings required by the SEC, and the requirements of all Contracts that constitute Parent Material Contracts. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Except (i)&#160;as expressly permitted by this Agreement, (ii)&#160;as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.1(b)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule, (iii)&#160;as required by applicable Law, (iv)&#160;in connection with an Asset Disposition, on the terms and subject to the limitations set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.7</font><font style="letter-spacing:0.2pt;">, (v)&#160;in connection with the Pre-Closing Dividend in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.21</font><font style="letter-spacing:0.2pt;">, (vi)&#160;in connection with any COVID-19 Measures or COVID-19 Response, or (vii)&#160;with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except in connection with the payment of the exercise price and/or withholding Taxes incurred upon the exercise of any Parent Option or vesting of Parent RSUs in accordance with the terms of such award in effect on the date of this Agreement); </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A)&#160;any capital stock or other security of Parent (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options, Parent Warrants or the vesting of Parent RSUs, as applicable, in accordance with their terms as in effect as of the date of this Agreement); (B)&#160;any option, warrant or right to acquire any capital stock or any other security; or (C)&#160;any other instrument convertible into or exchangeable for any capital stock or other security of Parent or any of its Subsidiaries; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;amend any of its or any of its Subsidiaries&#8217; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;form any Subsidiary or acquire any equity interest or other interest in any other Entity, or enter into a joint venture with any other Entity; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;(A) lend money to any Person, (B)&#160;incur or guarantee any indebtedness for borrowed money, issue or sell any debt securities or options, warrants, calls or other rights to acquire any debt securities, (C)&#160;guarantee any debt securities of others, or (D)&#160;make any capital expenditure or commitment in excess of $250,000; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;other than as required by applicable Law or by the terms of any Parent Benefit Plan as in effect on the date of this Agreement and disclosed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.17(a)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule: (A)&#160;adopt, terminate, establish or enter into any Parent Benefit Plan; (B)&#160;cause or permit any Parent Benefit Plan to be amended in any material respect; (C)&#160;pay any bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, benefits or other compensation or remuneration payable to, any Parent Associate; or (D)&#160;increase or otherwise modify the severance, retention or change of control benefits offered to any current or former or new Parent Associate; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(vii)&nbsp;&nbsp;&nbsp;enter into any Contract with a labor union, labor organization, or similar Person, except as otherwise required by applicable Law; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(viii)&nbsp;&nbsp;&nbsp;(A) hire or engage, or offer to hire, any director, officer, employee or consultant, or (B)&#160;enter into, amend or extend the term of any employment or consulting agreement with any Parent Associate; </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ix)&nbsp;&nbsp;&nbsp;enter into any material transaction; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(x)&nbsp;&nbsp;&nbsp;acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its material assets or properties, or grant any Encumbrance with respect to such assets or properties; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; text-indent:20pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xi)&nbsp;&nbsp;&nbsp;make, change or revoke any material Tax election, file any material amended Tax Return, settle or compromise any income or other material Tax liability, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial Contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than six&#160;months), or change any material accounting method in respect of Taxes; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xii)&nbsp;&nbsp;&nbsp;(A) sell, assign, transfer, allow to lapse or expire, pledge, abandon, discontinue, fail to maintain or otherwise dispose of any right, title or interest of Parent or any of its Subsidiaries in any material Parent IP, or (B)&#160;license, sublicense or otherwise encumber (other than pursuant to a non-exclusive license granted to contract research organizations, including clinical trial sites and clinical trial services provides, or contract manufacturing organizations, in each case, (x)&#160;with whom Parent or any of its Subsidiaries has previously entered into Contracts prior to the Effective Time and (y)&#160;who are engaged to provide services directly related to clinical studies and manufacturing of any product candidate of Parent, provided that the scope of any such non-exclusive license grant is limited to only the extent necessary for such Persons to perform their obligations under the respective Contracts) any right, title or interest of Parent or any of its Subsidiaries in any material Parent IP; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xiii)&nbsp;&nbsp;&nbsp;enter into, amend or terminate any Parent Material Contract (or any Contract that would have been a Parent Material Contract if in effect on or prior to the date of this Agreement); </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xiv)&nbsp;&nbsp;&nbsp;(A) materially change pricing or royalties or other payments set or charged by Parent or any of its Subsidiaries to its customers or licensees or (B)&#160;agree to materially change pricing or royalties or other payments set or charged by persons who have licensed Intellectual Property Rights to Parent or any of its Subsidiaries; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xv)&nbsp;&nbsp;&nbsp;make any expenditures, incur any Liabilities or discharge or satisfy any Liabilities, in each case, other than those expenditures or Liabilities that (A)&#160;will not survive the Closing, (B)&#160;are discharged or satisfied prior to the Closing, and/or (C)&#160;are taken into account in the calculation of Net Cash; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(xvi)&nbsp;&nbsp;&nbsp;waive, settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $75,000 individually or in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not (1)&#160;impose any restriction on the operations or business of Parent or its Subsidiaries (nor on the Company or any of its Subsidiaries, from and after the Closing), (2)&#160;involve any equitable relief and (3)&#160;do not involve admission of any wrongdoing by Parent or any of its Subsidiaries; or </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xvii)&nbsp;&nbsp;&nbsp;agree, resolve or commit to do any of the foregoing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding anything to the contrary contained herein, nothing herein shall prevent Parent or any of its Subsidiaries from taking or not taking any action, including the establishment of any policy, procedure or protocol, in response to COVID-19 or any COVID-19 Measures or otherwise take any COVID-19 Response and (a)&#160;no such actions or failure to take such actions or COVID-19 Responses shall be deemed to violate or breach this Agreement in any way, (b)&#160;all such actions or failures to take such actions or COVID-19 Responses shall be deemed to constitute an action taken in the Ordinary Course of Business and (c)&#160;no such actions or failures to take such actions or COVID-19 Responses shall serve as a basis for the Company to terminate this Agreement or assert that any of the conditions to the Closing contained herein have not been satisfied. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the generality of the foregoing, nothing set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.1</font><font style="letter-spacing:0.2pt;"> shall restrict Parent&#8217;s right to effectuate one or more Asset Dispositions, on the terms and subject to the limitations set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.7</font><font style="letter-spacing:0.2pt;">, or the Pre-Closing Dividend, on the terms and subject to the limitations set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.21</font><font style="letter-spacing:0.2pt;">, it being understood that </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.7</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.21</font><font style="letter-spacing:0.2pt;"> contains the parties&#8217; entire agreement </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t4OTC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">pertaining to Parent&#8217;s rights and obligations in connection with the preparation for, and negotiation and execution of, one or more Asset Dispositions prior to the Closing and the Pre-Closing Dividend. Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the Effective Time. Prior to the Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Operation of the Company&#8217;s Business</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.2(a)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule, as expressly permitted by this Agreement, as required by applicable Law, in connection with any COVID-19 Measures or COVID-19 Response or unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period, each of the Company and its Subsidiaries shall (i)&#160;use commercially reasonable efforts to conduct its respective business and operations in the Ordinary Course of Business and (ii)&#160;conduct its business and operations in compliance in all material respects with all applicable Laws and the requirements of all Contracts that constitute Company Material Contracts. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Except (i)&#160;as expressly permitted by this Agreement, (ii)&#160;as set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.2(b)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule, (iii)&#160;as required by applicable Law, (iv)&#160;in connection with any COVID-19 Measures or COVID-19 Response, or (v)&#160;with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except in connection with the payment of the exercise price and/or withholding Taxes incurred upon the exercise of any Company Option in accordance with the terms of such award in effect on the date of this Agreement); </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;except as contemplated by the Company Pre-Closing Financing or the Conversion in accordance with the Convertible Note Conversion Agreement, sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A)&#160;any capital stock or other security of the Company or any of its Subsidiaries (except for shares of outstanding Company Common Stock issued upon the valid exercise or settlement of Company Options in accordance with their terms as in effect as of the date of this Agreement); (B)&#160;any option, warrant or right to acquire any capital stock or any other security, other than options grants to employees and service providers in the Ordinary Course of Business; or (C)&#160;any other instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;amend any of its or its Subsidiaries&#8217; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;form any Subsidiary or acquire any equity interest or other interest in any other Entity, or enter into a joint venture with any other Entity; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;(A) lend money to any Person (except for the advancement of reasonable expenses to employees, directors and consultants in the Ordinary Course of Business), (B)&#160;incur or guarantee any indebtedness for borrowed money, other than in the Ordinary Course of Business, (C)&#160;guarantee any debt securities of others or (D)&#160;except as contemplated by the Company&#8217;s capital expenditure budget and operating budget made available to Parent, make any capital expenditure or commitment in excess of $350,000; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its material assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t4AI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; text-indent:20pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(vii)&nbsp;&nbsp;&nbsp;sell, assign, license, sublicense, transfer, allow to lapse or expire, pledge, abandon, discontinue, fail to maintain or otherwise dispose of any right, title or interest of the Company or any of its Subsidiaries in any material Company IP (other than pursuant to a non-exclusive license in the Ordinary Course of Business); </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(viii)&nbsp;&nbsp;&nbsp;make, change or revoke any material Tax election file any material amended Tax Return, settle or compromise any income or other material Tax liability, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial Contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than six&#160;months), or change any material accounting method in respect of Taxes; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ix)&nbsp;&nbsp;&nbsp;enter into, materially amend or terminate any Company Material Contract (or any Contract that would have been a Company Material Contract if in effect on or prior to the date of this Agreement) other than in the Ordinary Course of Business; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(x)&nbsp;&nbsp;&nbsp;waive, settle or compromise any pending or threatened Legal Proceeding against the Company or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $75,000 individually or in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not (1)&#160;impose any material restriction on the operations or business of the Company or its Subsidiaries (nor, following the Closing, on Parent or any of its Subsidiaries), (2)&#160;involve any equitable relief and (3)&#160;involve admission of any wrongdoing by the Company or any of its Subsidiaries; or </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(xi)&nbsp;&nbsp;&nbsp;agree, resolve or commit to do any of the foregoing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding anything to the contrary contained herein, nothing herein shall prevent the Company or any of its Subsidiaries from taking or not taking any action, including the establishment of any policy, procedure or protocol, in response to COVID-19 or any COVID-19 Measures or otherwise take any COVID-19 Response and (a)&#160;no such actions or failure to take such actions or COVID-19 Responses shall be deemed to violate or breach this Agreement in any way, (b)&#160;all such actions or failures to take such actions or COVID-19 Responses shall be deemed to constitute an action taken in the Ordinary Course of Business and (c)&#160;no such actions or failures to take such actions or COVID-19 Responses shall serve as a basis for Parent to terminate this Agreement or assert that any of the conditions to the Closing contained herein have not been satisfied. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the Effective Time. Prior to the Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Access and Investigation</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (i)&#160;provide the other Party and such other Party&#8217;s Representatives with reasonable access, upon reasonable notice and during normal business hours to such Party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries; (ii)&#160;provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request; (iii)&#160;permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the principal financial officer and other officers and managers of such </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t44NO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Party responsible for such Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary or appropriate; and (iv)&#160;make available to the other Party copies of unaudited financial statements and any material notice, report or other document filed with or sent to or received from any Governmental Body in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.3(a)</font><font style="letter-spacing:0.2pt;"> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party and to comply with applicable COVID-19 Measures and COVID-19 Responses. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, any Party may restrict the foregoing access to the extent that any Law applicable to such Party requires such Party to restrict or prohibit access to any such properties or information or if access would jeopardize protections afforded the Party under the attorney-client privilege or the attorney work product doctrine, violate applicable Law or breach such Party&#8217;s confidentiality obligations to a third party in effect as of the date of this Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that such Party shall use commercially reasonable efforts to allow for such access in a manner that does not violate any such applicable Law or jeopardize protections afforded the Party under the attorney-client privilege or the attorney work product doctrine, including by entering into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably required by the other Party in order that all such information may be provided to the other Party without causing such violation or waiver. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Parent Non-Solicitation</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Except as expressly permitted by this Agreement, Parent agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of its Representatives to (and shall use reasonable best efforts to cause such Representative not to), directly or indirectly: (i)&#160;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)&#160;furnish any non-public information regarding Parent to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii)&#160;engage in discussions (other than to inform any Person of the existence of the provisions contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.4</font><font style="letter-spacing:0.2pt;">) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv)&#160;approve, endorse or recommend any Acquisition Proposal (subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4</font><font style="letter-spacing:0.2pt;">); (v)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction (other than a confidentiality agreement permitted under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.4(a)</font><font style="letter-spacing:0.2pt;">); or (vi)&#160;publicly propose to do any of the foregoing; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that, notwithstanding anything contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.4</font><font style="letter-spacing:0.2pt;"> and subject to compliance with this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.4</font><font style="letter-spacing:0.2pt;">, prior to obtaining the Required Parent Stockholder Vote, Parent may furnish non-public information regarding Parent to, and enter into discussions or negotiations with, any Person in response to a </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> written unsolicited Acquisition Proposal by such Person, which the Parent Board determines in good faith, after consultation with Parent&#8217;s outside legal counsel and financial advisers, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A)&#160;neither Parent nor any of its Representatives shall have breached this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.4</font><font style="letter-spacing:0.2pt;"> in any material respect; (B)&#160;the Parent Board concludes in good faith, after consultation with Parent&#8217;s outside legal counsel, that the failure to take such action is reasonably likely to be inconsistent with the fiduciary duties of the Parent Board under applicable Law; (C)&#160;at least two Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such Person, Parent gives the Company written notice of the identity of such Person and of Parent&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person; (D)&#160;Parent receives from such Person an executed confidentiality agreement containing provisions (including nondisclosure provisions, use restrictions, non-solicitation provisions and no hire provisions) at least as favorable to Parent as those contained in the Confidentiality Agreement; and (E)&#160;at least two Business Days prior to furnishing any such nonpublic information to such Person, Parent furnishes such nonpublic information to the Company (to the extent such information has not been previously furnished by Parent to the Company). Without limiting the generality of the foregoing, Parent acknowledges and agrees that, in the event any Representative of Parent (whether or not such Representative is purporting to act on behalf of Parent) takes any action that, if taken by Parent, would constitute a breach of this </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t45NO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.4</font><font style="letter-spacing:0.2pt;">, the taking of such action by such Representative shall be deemed to constitute a breach of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.4</font><font style="letter-spacing:0.2pt;"> by Parent for purposes of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;If Parent or any Representative of Parent receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then Parent shall promptly (and in no event later than twenty-four hours after Parent becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the Company in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry (subject to any confidentiality restrictions that may be in place between Parent and such Person as of the date of this Agreement), and a copy of the Acquisition Proposal or Acquisition Inquiry, or if the Acquisition Proposal or Acquisition Inquiry is not written, the terms thereof, and the material terms thereof). Parent shall keep the Company reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or proposed material modification thereto. In addition to the foregoing, Parent shall provide the Company with reasonable advance (and in any event not less than 24 hours) written notice of a meeting of the Parent Board (or any committee thereof) at which the Parent Board (or any committee thereof) is reasonably expected to consider an Acquisition Proposal or Acquisition Inquiry it has received. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information of Parent provided to such Person. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Company Non-Solicitation</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Except as expressly permitted by this Agreement, the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of its Representatives to (and shall use reasonable best efforts to cause each such Representative not to), directly or indirectly: (i)&#160;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)&#160;furnish any non-public information regarding the Company or any of its Subsidiaries to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii)&#160;engage in discussions (other than to inform any Person of the existence of the provisions contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.5</font><font style="letter-spacing:0.2pt;">) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv)&#160;approve, endorse or recommend any Acquisition Proposal (subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3</font><font style="letter-spacing:0.2pt;">); (v)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction (other than a confidentiality agreement permitted under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.5(a)</font><font style="letter-spacing:0.2pt;">); or (vi)&#160;publicly propose to do any of the foregoing; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that, notwithstanding anything contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.5</font><font style="letter-spacing:0.2pt;"> and subject to compliance with this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.5</font><font style="letter-spacing:0.2pt;">, prior to obtaining the Required Company Stockholder Vote, the Company may furnish non-public information regarding the Company to, and enter into discussions or negotiations with, any Person in response to a </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> written unsolicited Acquisition Proposal by such Person, which the Company Board determines in good faith, after consultation with the Company&#8217;s outside legal counsel and financial advisers, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A)&#160;neither the Company nor any of its Representatives shall have breached this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.5</font><font style="letter-spacing:0.2pt;"> in any material respect; (B)&#160;the Company Board concludes in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to take such action is reasonably likely to be inconsistent with the fiduciary duties of the Company Board under applicable Law; (C)&#160;at least two Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such Person, the Company gives Parent written notice of the identity of such Person and of the Company&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person; (D)&#160;the Company receives from such Person an executed confidentiality agreement containing provisions (including nondisclosure provisions, use restrictions, non-solicitation provisions and no hire provisions), at least as favorable to the Company as those contained in the Confidentiality Agreement; and (E)&#160;at least two Business Days prior to furnishing any such nonpublic information to such Person, the Company furnishes such nonpublic information to Parent (to the extent such information has not been previously </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t4OCM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">furnished by the Company to Parent). Without limiting the generality of the foregoing, the Company acknowledges and agrees that, in the event any Representative of the Company (whether or not such Representative is purporting to act on behalf of the Company) takes any action that, if taken by the Company, would constitute a breach of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.5</font><font style="letter-spacing:0.2pt;">, the taking of such action by such Representative shall be deemed to constitute a breach of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.5</font><font style="letter-spacing:0.2pt;"> by the Company for purposes of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;If the Company or any Representative of the Company receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then the Company shall promptly (and in no event later than twenty-four hours after the Company becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise Parent in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry (subject to any confidentiality restrictions that may be in place between the Company and such Person as of the date of this Agreement), and a copy of the Acquisition Proposal or Acquisition Inquiry, or if the Acquisition Proposal or Acquisition Inquiry is not written, the terms thereof, and the material terms thereof). The Company shall keep Parent reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or proposed material modification thereto. In addition to the foregoing, the Company shall provide Parent with reasonable advance (and in any event not less than 24 hours) written notice of a meeting of the Company Board (or any committee thereof) at which the Company Board (or any committee thereof) is reasonably expected to consider an Acquisition Proposal or Acquisition Inquiry it has received. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;The Company shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information of the Company or any of its Subsidiaries provided to such Person. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Notification of Certain Matters</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;During the Pre-Closing Period, the Company shall promptly notify Parent (and, if in writing, furnish copies of) if any of the following occurs: (i)&#160;any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions; (ii)&#160;any Legal Proceeding against or involving or otherwise affecting the Company or its Subsidiaries is commenced, or, to the Knowledge of the Company, threatened against the Company or its Subsidiaries or, to the Knowledge of the Company, any director, officer or Key Employee of the Company or its Subsidiaries; (iii)&#160;the Company becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv)&#160;the failure of the Company to comply with any covenant or obligation of the Company; in the case of (iii)&#160;and (iv)&#160;that will or could reasonably be expected to result in the failure by the Company to satisfy any of the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7</font><font style="letter-spacing:0.2pt;">. No notification given to Parent pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.6(a)</font><font style="letter-spacing:0.2pt;"> shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations of the Company or any of its Subsidiaries contained in this Agreement or the Company Disclosure Schedule for purposes of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7</font><font style="letter-spacing:0.2pt;">, as applicable. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;During the Pre-Closing Period, Parent shall promptly notify the Company (and, if in writing, furnish copies of) if any of the following occurs: (i)&#160;any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions; (ii)&#160;any Legal Proceeding against or involving or otherwise affecting Parent or its Subsidiaries is commenced, or, to the Knowledge of Parent, threatened against Parent or its Subsidiaries or, to the Knowledge of Parent, any director, officer or Key Employee of Parent or its Subsidiaries; (iii)&#160;Parent becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv)&#160;the failure of Parent to comply with any covenant or obligation of Parent or Merger Sub; in the case of (iii)&#160;and (iv)&#160;that will or could reasonably be expected to result in the failure by Parent to satisfy any of the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;">. No notification given to the Company pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.6(b)</font><font style="letter-spacing:0.2pt;"> shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations of Parent contained in this Agreement or the Parent Disclosure Schedule for purposes of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8</font><font style="letter-spacing:0.2pt;">, as applicable. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t4TA">&#8203;</a><a name="tS5AO">&#8203;</a><a name="t5SPS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Potentially Transferable Assets</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Parent shall be entitled, but under no obligation, to sell, transfer, license, assign or otherwise divest Potentially Transferable Assets in a transaction or series of transactions; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that any such sale, transfer, license or other disposition must be expressly approved by the Parent Board (each, an &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Asset Disposition</font><font style="letter-spacing:0.2pt;">&#8221; and collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Asset Dispositions</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Parent shall keep the Company reasonably apprised of any developments related to the Asset Dispositions and any transactions undertaken pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.7</font><font style="letter-spacing:0.2pt;">. Without limiting the foregoing, Parent shall provide the Company with notice of Parent&#8217;s intention to enter into any definitive written agreement (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Sale Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) providing for the consummation of an Asset Disposition (such notice to include copies of the proposed execution form of such agreement) or otherwise to consummate an Asset Disposition, at least ten Business Days prior to the execution of such Sale Agreement or to otherwise consummate an Asset Disposition. Parent shall not enter into a Sale Agreement or otherwise consummate an Asset Disposition that would result in a Material Continuing Obligation without first obtaining the prior written consent of the Company, such consent not to be unreasonably withheld, delayed or conditioned (it being understood that if the Company does not notify Parent by the tenth Business Day following receipt of the applicable notice from Parent that the Company has not consented to the entry into such Sale Agreement, then the Company shall be deemed to have given its consent). </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;5.&nbsp;&nbsp;&nbsp;ADDITIONAL AGREEMENTS OF THE PARTIES.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Registration Statement; Proxy Statement/Prospectus</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;As promptly as practicable after the date of this Agreement (but in no event later than 30&#160;days following the date of this Agreement), Parent shall, in cooperation with the Company, prepare and cause to be filed with the SEC, the Registration Statement, in which the Proxy Statement/</font>&#8203;<font style="letter-spacing:0.2pt;">Prospectus will be included, in connection with the registration under the Securities Act of the shares of Parent Common Stock to be issued by virtue of the Merger or the Conversion. Each of Parent and the Company shall use their commercially reasonable efforts to cause the Registration Statement to become effective as promptly as practicable, and shall take all or any action required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Parent Common Stock pursuant to the Merger or the Conversion. Each of the Parties shall furnish all information concerning itself and their Affiliates, as applicable, to the other Parties as the other Parties may reasonably request in connection with such actions and the preparation of the Registration Statement and the Proxy Statement/Prospectus. </font></div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), will comply with applicable U.S. federal securities laws and the DGCL in all material respects, and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances in which they were made, not misleading. The Company covenants and agrees that the information supplied, or to be supplied, by or on behalf of the Company or any of its Subsidiaries to Parent for inclusion in the Registration Statement (including the Company Financial Statements) will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make such information, in light of the circumstances in which they were made, not misleading. Notwithstanding the foregoing, Parent makes no covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information furnished in writing by the Company or any of its Subsidiaries or any of their representations specifically for inclusion therein. The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. The Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), including any amendments thereto, shall be subject to the Company&#8217;s advance review and reasonable approval. Each of the Parties shall use commercially reasonable efforts to cause the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t52MA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Registration Statement, including the Proxy Statement/Prospectus, to comply with the applicable rules and regulations promulgated by the SEC, to respond promptly to any comments of the SEC or its staff and to have the Registration Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC. Each of the Parties shall use commercially reasonable efforts to cause the Proxy Statement/Prospectus to be mailed to holders of Parent Common Stock as promptly as practicable after the Registration Statement is declared effective under the Securities Act. If Parent, Merger Sub or the Company become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement/Prospectus, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in filing such amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to Parent&#8217;s stockholders. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;The Company will use commercially reasonable efforts to cause to be delivered to Parent a consent letter of the Company&#8217;s independent accounting firm, dated no more than two Business Days before the date on which the Registration Statement becomes effective, that is customary in scope and substance for consent letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Regulatory Matters</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, the Company and Parent shall use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary or desirable under applicable Laws to consummate the Merger as promptly as practicable, including in connection with (i)&#160;preparing and filing as promptly as practicable with any Governmental Body documentation to effect all necessary or desirable filings, notices, petitions, statements, registrations, submissions of information, applications and other documents and (ii)&#160;obtaining and maintaining all approvals, consents, registrations, permits, authorizations and other confirmations required to be obtained from any Governmental Body that are necessary or desirable to consummate the Merger as promptly as practicable. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;In furtherance and not in limitation of the foregoing, each of the Company and, solely to the extent required under applicable Law as mutually determined by Parent and the Company, Parent shall make, with respect to the Merger: (i)&#160;no later than 10 Business Days after the date hereof, a Notification and Report Form pursuant to the HSR Act, as applicable; and (ii)&#160;as promptly as practicable after the date hereof, all filings required pursuant to applicable Antitrust Laws as described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.2(b)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Each of the Company and Parent shall (i)&#160;respond as promptly as practicable to any inquiries or requests received from any Governmental Body, including in connection with any Antitrust Laws applicable to the Contemplated Transactions, (ii)&#160;supply as promptly as practicable any additional information and documentary material that may be requested by a Governmental Body, including pursuant to the HSR Act, as applicable, (iii)&#160;if any request for additional information and documents, including a &#8220;second request&#8221; under the HSR Act, as applicable, is received from any Governmental Body, then substantially comply with any such request at the earliest practicable date, (iv)&#160;not extend any waiting period or agree to refile under the HSR Act, as applicable, or any other Antitrust Law except with the prior consent of the other Party, and (v)&#160;take all other actions necessary or desirable to cause the expiration or termination of the applicable waiting periods under the HSR Act, as applicable, and any other Antitrust Laws, and obtain all other required consents, authorizations, orders and approvals from Governmental Bodies, as promptly as practicable. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;If any objections are asserted with respect to the Contemplated Transactions by any Governmental Body, including under the HSR Act, as applicable, or any other applicable Law (including applicable Antitrust Laws), or if any action is instituted or threatened by any Governmental Body or any private party challenging the transaction as violative of the HSR Act, as applicable, or any other applicable Law (including applicable Antitrust Laws), the Parties shall, and shall cause their respective Affiliates to, take any and all actions to resolve such objections as promptly as practicable and in any event prior to the End Date. The Company and Parent shall oppose, fully and vigorously, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t5SM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(A)&#160;any administrative or judicial action or proceeding that is initiated or threatened to be initiated challenging this Agreement or the consummation of the Contemplated Transactions and (B)&#160;any request for, the entry of, and seek to have vacated or terminated, any order that could restrain, prevent or delay the consummation of the transaction, including in the case of either (A)&#160;or (B)&#160;by defending through litigation any action asserted by any Person in any court or before any Governmental Body as may be required (x)&#160;by the applicable Governmental Body in order to resolve such objections as such Governmental Body may have to such transactions under the HSR Act, as applicable, or any other applicable Law (including any other applicable Antitrust Law) or (y)&#160;by any domestic or foreign court or other tribunal, in any action challenging the transaction as violative of the HSR Act, as applicable, or any other applicable Law (including other applicable Antitrust Law), in order to avoid the entry of, or to effect the dissolution, vacating, lifting, altering or reversal of, any order that has the effect of restricting, preventing or prohibiting the consummation of the transaction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Subject to applicable Law relating to the sharing of information, each Party shall (i)&#160;furnish the other Party with copies of all documents (except documents or portions thereof for which confidential treatment has been requested or given, which the Party may limit to sharing only with the external legal counsel of the other Party) and correspondence (A)&#160;prepared by or on behalf of such Party for any Governmental Body and affording the other Party the opportunity to comment and participate in responding, where appropriate; or (B)&#160;received by or on behalf of such Party from any Governmental Body, in each case in connection with the consents, authorizations, orders or approvals contemplated by this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.2</font><font style="letter-spacing:0.2pt;"> and (ii)&#160;use reasonable best efforts to consult with and keep the other Party informed as to the status of such matters. Further, no Party shall, nor shall it permit any of its Representatives to, meet or engage in substantive conversations with any Governmental Body or representative of such Governmental Body in connection with obtaining any such consent, authorization, order and approval unless it consults with the other Party in advance and, to the extent not precluded by applicable Law, offers the other Party the opportunity to participate in such meeting or conversation. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Company Stockholder Matters</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Promptly after the Registration Statement shall have been declared effective under the Securities Act, the Company shall prepare, with the cooperation of Parent, and cause to be mailed to its stockholders an information statement, which shall include a copy of the Proxy Statement/Prospectus, and the Company Stockholder Written Consent, in order to solicit the approval of the Company&#8217;s stockholders, including the Company&#8217;s stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to Section&#160;228 of the DGCL, for purposes of (i)&#160;adopting and approving this Agreement and the Contemplated Transactions, (ii)&#160;acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&#160;262 of the DGCL, a true and correct copy of which will be attached thereto, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (iii)&#160;acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Stockholder Matters</font><font style="letter-spacing:0.2pt;">&#8221;). Promptly following receipt of the duly executed Company Stockholder Written Consent from the stockholders representing the Required Company Stockholder Vote, the Company shall deliver a copy of the duly executed Company Stockholder Written Consent to Parent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Company agrees that, subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3(c)</font><font style="letter-spacing:0.2pt;">: (i)&#160;the Company Board shall recommend that the Company&#8217;s stockholders vote to approve the Company Stockholder Matters and shall use its reasonable best efforts to solicit such approval from each of the Company stockholders necessary to deliver the Company Stockholder Written Consent evidencing the Required Company Stockholder Vote within the time set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3(a)</font><font style="letter-spacing:0.2pt;"> (the recommendation of the Company Board that the Company&#8217;s stockholders vote to adopt and approve this Agreement being referred to as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Board Recommendation</font><font style="letter-spacing:0.2pt;">&#8221;); and (ii)&#160;the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t5SM1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (ii), collectively, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Board Adverse Recommendation Change</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary contained in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3(b)</font><font style="letter-spacing:0.2pt;"> and subject to compliance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.5</font><font style="letter-spacing:0.2pt;">, if at any time prior to the approval and adoption of this Agreement by the Required Company Stockholder Vote, the Company receives a bona fide written Superior Offer, the Company Board may make a Company Board Adverse Recommendation Change, if, but only if, following the receipt of and on account of such Superior Offer, (i)&#160;the Company Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would constitute a violation of the Company Board&#8217;s fiduciary duties under applicable Law; (ii)&#160;the Company has, and has caused its financial advisors and outside legal counsel to, during the Notice Period (as defined below), negotiate with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii)&#160;if after Parent shall have delivered to the Company a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would constitute a violation of the Company Board&#8217;s fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that (x)&#160;Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four Business Days in advance of the Company Board Adverse Recommendation Change (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Notice Period</font><font style="letter-spacing:0.2pt;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant transaction agreements with any party making a potential Superior Offer, (y)&#160;during any Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer, and (z)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Company&#8217;s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure that at least two Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3(c)</font><font style="letter-spacing:0.2pt;"> and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;The Company&#8217;s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3(a)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.3(b)</font><font style="letter-spacing:0.2pt;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or by any withdrawal or modification of the Company Board Recommendation. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Parent Stockholders&#8217; Meeting</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Promptly after the Registration Statement has been declared effective by the SEC under the Securities Act, Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock for the purpose of seeking approval of this Agreement and the Contemplated Transactions, including: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;the amendment of Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;the issuance of shares of Parent Common Stock to the Company&#8217;s stockholders in connection with the Contemplated Transactions pursuant to the terms of this Agreement; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; text-indent:20pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;the change of control of Parent resulting from the Merger pursuant to Nasdaq rules (the matters contemplated by </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;5.4(a)(i)</font><font style="letter-spacing:0.2pt;"> through </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">5.4(a)(iii)</font><font style="letter-spacing:0.2pt;"> are referred to as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Stockholder Matters,</font><font style="letter-spacing:0.2pt;">&#8221; and such meeting, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Stockholders&#8217; Meeting</font><font style="letter-spacing:0.2pt;">&#8221;); and </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;the approval of the Equity Plan&#160;Amendments. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Parent Stockholders&#8217; Meeting shall be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, and in any event no later than 45&#160;days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholders&#8217; Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholders&#8217; Meeting, or a date preceding the date on which the Parent Stockholders&#8217; Meeting is scheduled, Parent reasonably believes that (i)&#160;it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present or (ii)&#160;it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholders&#8217; Meeting, Parent may (and at the Company&#8217;s request, Parent shall) postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholders&#8217; Meeting as long as the date of the Parent Stockholders&#8217; Meeting is not postponed or adjourned more than an aggregate of 30 calendar days in connection with any postponements or adjournments in reliance on the preceding sentence. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent agrees that, subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4(d)</font><font style="letter-spacing:0.2pt;">: (i)&#160;the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters and shall use its reasonable best efforts to solicit such approval within the timeframe set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4(b)</font><font style="letter-spacing:0.2pt;">; (ii)&#160;the Proxy Statement/Prospectus shall include a statement to the effect that the Parent Board recommends that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board with respect to the Parent Stockholder Matters being referred to as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Board Recommendation</font><font style="letter-spacing:0.2pt;">&#8221;); and (iii)&#160;the Parent Board Recommendation shall not be withheld, amended, withdrawn or modified (and the Parent Board shall not publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company, and no resolution by the Parent Board or any committee thereof to withdraw of modify the Parent Board Recommendation in a manner adverse to the Company or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (iii), collectively, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Board Adverse Recommendation Change</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary contained in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4(c)</font><font style="letter-spacing:0.2pt;"> and subject to compliance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.4</font><font style="letter-spacing:0.2pt;">, if at any time prior to the approval of Parent Stockholder Matters by the Required Parent Stockholder Vote, Parent receives a bona fide written Superior Offer, the Parent Board may make a Parent Board Adverse Recommendation Change, if, but only if, following the receipt of and on account of such Superior Offer, (i)&#160;the Parent Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would constitute a violation of the Parent Board&#8217;s fiduciary duties under applicable Law; (ii)&#160;Parent has, and has caused its financial advisors and outside legal counsel to, during the Notice Period, negotiate with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii)&#160;if after the Company shall have delivered to Parent a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would constitute a violation of the Parent Board&#8217;s fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that (x)&#160;the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation during the Notice Period, which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant transaction with any party making a potential Superior Offer, (y)&#160;during any Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and will cause </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t5OCC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer, and (z)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Parent&#8217;s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure that at least two Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4(d)</font><font style="letter-spacing:0.2pt;"> and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Notice Period so extended (it being understood that there may be multiple extensions). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Parent&#8217;s obligation to solicit the consent of its stockholders to approve the Parent Stockholder Matters shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or by any withdrawal or modification of the Parent Board Recommendation. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i)&#160;complying with Rules 14d-9 and 14e-2(a) under the Exchange Act, (ii)&#160;issuing a &#8220;stop, look and listen&#8221; communication or similar communication of the type contemplated by Rule&#160;14d-9(f) under the Exchange Act or (iii)&#160;otherwise making any disclosure to Parent&#8217;s stockholders if, in the case of the foregoing clause (iii), the Parent Board determines in good faith, after consultation with its outside legal counsel, that failure to make such disclosure would be inconsistent with applicable Law, including its fiduciary duties under applicable Law; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that in no event shall Parent or the Parent Board make a Parent Board Adverse Recommendation Change except in accordance with the provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4(d)</font><font style="letter-spacing:0.2pt;"> above. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">5.5</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Company Options, Company Convertible Note, Parent Warrants, and Parent Equity Awards</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(d)</font><font style="letter-spacing:0.2pt;">, at the Effective Time, each Company Option that is outstanding and unexercised immediately prior to the Effective Time under the Company Plan and that, following assumption by Parent at the Effective Time, will be eligible to be registered on Form S-8, whether or not vested, shall be converted into and become an option to purchase Parent Common Stock, and Parent shall assume the Company Plan and each such Company Option in accordance with the terms (as in effect as of the date of this Agreement) of the Company Plan and the terms of the stock option agreement by which such Company Option is evidenced (but with changes to such documents as Parent and the Company mutually agree are appropriate to reflect the substitution of the Company Options for an option to purchase shares of Parent Common Stock). All other Company Options that are outstanding and unexercised as of immediately prior to the Effective Time shall be canceled immediately prior to the Effective Time. All rights with respect to Company Common Stock subject to Company Options assumed by Parent shall thereupon be converted into rights with respect to Parent Common Stock. Accordingly, from and after the Effective Time: (i)&#160;each Company Option assumed by Parent may be exercised solely for shares of Parent Common Stock; (ii)&#160;the number of shares of Parent Common Stock subject to each Company Option assumed by Parent shall be determined by multiplying (A)&#160;the number of shares of Company Common Stock that were subject to such Company Option, as in effect immediately prior to the Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Parent Common Stock; (iii)&#160;the per share exercise price for the Parent Common Stock issuable upon the exercise of each Company Option assumed by Parent shall be determined by dividing (A)&#160;the per share exercise price of Company Common Stock subject to such Company Option, as in effect immediately prior to the Effective Time, by (B)&#160;the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent; and (iv)&#160;any restriction on the exercise of any Company Option assumed by Parent shall continue in full force and effect and the term, exercisability, vesting schedule and other provisions of such Company Option shall otherwise remain unchanged; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that: (x)&#160;to the extent provided under the terms of a Company Option and the Company Plan, such Company Option may be further adjusted as necessary to reflect Parent&#8217;s substitution of the Company Options with options to purchase Parent Common Stock (such as by making any change in control or similar definition relate to Parent and having any provision that </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t5OOA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provides for the adjustment of Company Options upon the occurrence of certain corporate events relate to corporate events that relate to Parent and/or Parent Common Stock); and (y)&#160;the Parent Board or a committee thereof shall succeed to the authority and responsibility of the Company Board or any committee thereof with respect to each Company Option assumed by Parent. Notwithstanding anything to the contrary in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(a)</font><font style="letter-spacing:0.2pt;">, the conversion of each Company Option (regardless of whether such option qualifies as an &#8220;incentive stock option&#8221; within the meaning of Section&#160;422 of the Code) into an option to purchase shares of Parent Common Stock shall be made in a manner consistent with Treasury Regulation&#160;Section&#160;1.424-1, such that the conversion of a Company Option shall not constitute a &#8220;modification&#8221; of such Company Option for purposes of Section&#160;409A or Section&#160;424 of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Parent shall file with the SEC, promptly after the Effective Time, a registration statement on Form S-8 (or any successor or alternative form), relating to the shares of Parent Common Stock issuable with respect to Company Options assumed by Parent in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(d)</font><font style="letter-spacing:0.2pt;">, as of immediately after the Effective Time, the Company Convertible Note shall convert into shares of Parent Common Stock in accordance with the Convertible Note Conversion Agreement, as amended or supplemented. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Prior to the Effective Time, the Company shall take all actions that may be necessary (under the Company Plan and otherwise) to effectuate the provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(a)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5(c)</font><font style="letter-spacing:0.2pt;"> and to ensure that, from and after the Effective Time, holders of Company Options and the Company Convertible Note have no rights with respect thereto other than those specifically provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.5</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Prior to the Closing, Parent shall notify the holders of the Parent Warrants of the Contemplated Transactions in accordance with the terms of the applicable Parent Warrants and, at the Effective Time, each Parent Warrant that is outstanding and unexercised immediately prior to the Effective Time, shall survive the Closing and remain outstanding in accordance with its terms. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;Prior to the Effective Time, the Parent Board shall have the right, in its sole discretion, to adopt appropriate resolutions and take all other actions necessary and appropriate to provide that each Parent RSU and/or each Parent Option, to the extent unvested immediately prior to the Effective Time, be accelerated in full effective as of immediately prior to the Effective Time. At the Effective Time, each Parent RSU and/or each Parent Option that is outstanding and unexercised immediately prior to the Effective Time, whether or not vested, shall survive the Closing and remain outstanding in accordance with its terms. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Indemnification of Officers and Directors</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, each of Parent and the Surviving Corporation shall, jointly and severally, indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director, officer, fiduciary or agent of Parent or the Company and their respective Subsidiaries, respectively (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">D&amp;O Indemnified Parties</font><font style="letter-spacing:0.2pt;">&#8221;), against all claims, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements and investigation costs, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, or any other actual, threatened or completed proceeding arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director, officer, fiduciary or agent of Parent or of the Company or their respective Subsidiaries, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest extent permitted under applicable Law. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Corporation, jointly and severally, upon receipt by Parent or the Surviving Corporation from the D&amp;O Indemnified Party of a request therefor; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The provisions of Parent&#8217;s Organizational Documents with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Parent that are presently set forth in the certificate of incorporation and bylaws of Parent shall not be amended, modified or repealed for a period of six&#160;years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Parent, unless such modification is required by applicable Law. The certificate of incorporation and bylaws of the Surviving Corporation shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Corporation to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;From and after the Effective Time, (i)&#160;the Surviving Corporation shall fulfill and honor, and Parent shall cause the Surviving Corporation to fulfill and honor, in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#8217;s Organizational Documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii)&#160;Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;From and after the Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, prior to the Effective Time, Parent shall purchase a six-year prepaid &#8220;tail policy&#8221; through Parent&#8217;s recognized broker of record for the non-cancellable extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six&#160;years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time with terms, conditions, and retentions that are no less favorable than the coverage provided under Parent&#8217;s existing policies as of the date of this Agreement and with limits of liability no less than $20,000,000, in each case with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Parent by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time (including in connection with this Agreement or the Contemplated Transactions) (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">D&amp;O Tail Policy</font><font style="letter-spacing:0.2pt;">&#8221;). For clarity, the cost of any such D&amp;O Tail Policy, to the extent unpaid as of the Effective Time, shall reduce the amount of Net Cash. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;From and after the Effective Time, Parent shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by the persons referred to in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.6</font><font style="letter-spacing:0.2pt;"> in connection with their successful enforcement of the rights provided to such persons in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.6</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;The provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.6</font><font style="letter-spacing:0.2pt;"> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives. The obligations set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.6</font><font style="letter-spacing:0.2pt;"> shall not be terminated, amended or otherwise modified in any manner that adversely affects any D&amp;O Indemnified Party (and their heirs and Representatives) without the prior written consent of such affected D&amp;O Indemnified Party (or their heirs and Representatives), </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;In the event Parent or the Surviving Corporation or any of their respective successors or assigns (i)&#160;consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii)&#160;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Corporation, as the case may be, shall succeed to the obligations set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.6</font><font style="letter-spacing:0.2pt;">. Parent shall cause the Surviving Corporation to perform all of the obligations of the Surviving Corporation under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.6</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t5AIA">&#8203;</a><a name="t5TIP">&#8203;</a><a name="t5DTP">&#8203;</a><a name="t51MA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Additional Agreements</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In addition to each Party&#8217;s obligations in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.2</font><font style="letter-spacing:0.2pt;">, the Parties shall use commercially reasonable efforts to cause to be taken all actions necessary to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each Party: (a)&#160;shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions; (b)&#160;shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained by such Party in connection with the Contemplated Transactions pursuant to any applicable Law or any Contracts set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;5.7</font><font style="letter-spacing:0.2pt;">; (c)&#160;shall use reasonable best efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions; (d)&#160;in the case of Parent, commercially reasonable efforts to resolve the matters set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;N</font><font style="letter-spacing:0.2pt;">, either without any Material Continuing Obligation, except for obligations which would reduce Net Cash pursuant to the definition thereof; and (e)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Disclosure</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The initial press release relating to this Agreement shall be a joint press release issued by, and mutually acceptable to, the Company and Parent and thereafter Parent and the Company shall obtain the consent of the other before issuing any further press release(s) or otherwise making any public statement or making any announcement to Parent Associates or Company Associates (to the extent not previously issued or made in accordance with this Agreement) with respect to the Contemplated Transactions and shall not issue any such press release, public statement or announcement to Parent Associates or Company Associates without the other Party&#8217;s prior written consent (which shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing: (a)&#160;each Party may, without such consultation or consent, make any public statement in response to questions from the press, analysts, investors or those attending industry conferences, make internal announcements to employees and make disclosures in Parent SEC Documents, so long as such statements are consistent with previous press releases, public disclosures or public statements made jointly by the Parties (or individually, if approved by the other Party); (b)&#160;a Party may, without the prior consent of the other Party hereto but subject to giving advance notice to the other Party, issue any such press release or make any such public announcement or statement such Party has determined in good faith, upon the advice of outside legal counsel, is required by applicable Law; and (c)&#160;a Party need not consult with the any other Party in connection with such portion of any press release, public statement or filing to be issued or made pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4(e)</font><font style="letter-spacing:0.2pt;"> or with respect to any Acquisition Proposal, Parent Board Adverse Recommendation Change or Company Board Adverse Recommendation Change, as applicable, or with respect to Parent only, pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4(f)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Listing</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;During the Pre-Closing Period, Parent shall use its commercially reasonable efforts: (a)&#160;to maintain its existing listing on Nasdaq and to obtain approval of the listing of the combined corporation on Nasdaq; (b)&#160;to the extent required by the rules and regulations of Nasdaq, to prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions; (c)&#160;to prepare and timely submit to Nasdaq a notification form of the Nasdaq Reverse Split and to submit a copy of the amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split certified by the Secretary of State of the State of Delaware to Nasdaq on the Closing Date; (d)&#160;to the extent required by Nasdaq Listing Rule&#160;5110, to file an initial listing application for the Parent Common Stock on Nasdaq (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Nasdaq Listing Application</font><font style="letter-spacing:0.2pt;">&#8221;) and to cause such Nasdaq Listing Application to be approved; and (e)&#160;in the event of receipt of a Nasdaq delisting determination, Parent will request a hearing to appeal the delisting determination and will pay the appropriate fee to Nasdaq to appeal the delisting determination. Prior to the Effective Time, each Party will promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its Representatives. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Company will cooperate with Parent as reasonably requested by Parent with respect to the Nasdaq Listing Application and promptly furnish to Parent all information concerning the Company and its stockholders that may be required or reasonably requested in connection with any action contemplated by this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.9</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Tax Matters</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;For U.S. federal income Tax purposes, (i)&#160;the Parties intend that (A)&#160;the Merger qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, and (B)&#160;the Nasdaq Reverse Split qualify as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(e) of the Code (collectively, the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t5PSB">&#8203;</a><a name="t5AOP">&#8203;</a><a name="t5OCA">&#8203;</a><a name="t51MP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Intended Tax Treatment</font><font style="letter-spacing:0.2pt;">&#8221;), and (ii)&#160;this Agreement is intended to be, and is hereby adopted as, a &#8220;plan of reorganization&#8221; for purposes of Section&#160;354 and 361 of the Code and Treasury Regulations&#160;Section&#160;1.368-2(g) and 1.368-3(a), to which Parent, Merger Sub and the Company are parties under Section&#160;368(b) of the Code. The Parties shall treat and shall not take any tax reporting position inconsistent with the Intended Tax Treatment, unless otherwise required pursuant to a &#8220;determination&#8221; within the meaning of Section&#160;1313(a) of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Parties acknowledge and agree that each has relied upon the advice of its own tax advisors in connection with the Merger and the Contemplated Transactions and that none of the Company, on the one hand, and Parent and Merger Sub, on the other hand, makes any representation or warranty as to the Intended Tax Treatment, other than the representations and warranties contained in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;2.16(h)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.16(h)</font><font style="letter-spacing:0.2pt;">, respectively. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;The Parties shall use their respective commercially reasonable efforts to cause the Merger to qualify, and will not take any action or cause or permit any action to be taken which action would reasonably be expected to prevent the Merger from qualifying, for the Intended Tax Treatment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Parent shall prepare and file, or cause to be prepared and filed, any IRS Forms 8937 that are required to be filed in connection with the Contemplated Transactions. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;In the event that the SEC requests or requires a tax opinion in connection with the Contemplated Transactions, each of Parent and the Company shall use its commercially reasonable efforts to deliver a &#8220;Tax Representation Letter,&#8221; signed by an officer of Parent and/or the Company, as applicable, containing customary representations of Parent and Merger Sub or Company, as applicable, in each case, as shall be reasonably necessary or appropriate to enable legal counsel to provide an opinion relating to the Contemplated Transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Legends</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent shall be entitled to place appropriate legends on the book entries evidencing any shares of Parent Common Stock to be received in the Merger by equityholders of the Company who may be considered &#8220;affiliates&#8221; of Parent for purposes of Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for Parent Common Stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.12&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Directors and Officers</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent shall cause, effective as of the Effective Time, the Parent Board to be composed of seven members, to serve in the respective director class set forth opposite such member&#8217;s name on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;5.12</font><font style="letter-spacing:0.2pt;">, which shall consist of (a)&#160;one such member designated by Parent as set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;5.12</font><font style="letter-spacing:0.2pt;"> under the heading &#8220;Directors&#8221; &#8203;(the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Designee</font><font style="letter-spacing:0.2pt;">&#8221;), and (b)&#160;six such members designated by the Company as set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;5.12</font><font style="letter-spacing:0.2pt;"> under the heading &#8220;Directors&#8221; &#8203;(the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Designees</font><font style="letter-spacing:0.2pt;">&#8221;). Furthermore, the Parties shall take all necessary action so that the Persons listed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;5.12</font><font style="letter-spacing:0.2pt;"> under the headings &#8220;Officers&#8221; or &#8220;Directors&#8221;, as applicable, are elected or appointed, as applicable, to the positions of officers or directors of Parent and the Surviving Corporation, as set forth therein, to serve in such positions effective as of the Effective Time until the earlier of their resignation or removal or until their respective successors are duly elected or appointed and qualified, as the case may be. If any Person named in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;5.12</font><font style="letter-spacing:0.2pt;"> as a director is unable or unwilling to serve as a director of Parent after the Effective Time, as set forth therein, the Party appointing such Person shall designate a successor. Other than with respect to the Parent Designee, prior to the Closing, Parent shall deliver to the Company written resignations, in a form reasonably satisfactory to the Company, of each pre-Closing member of the Parent Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.13&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Termination of Certain Agreements and Rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company shall cause the Investor Agreements (excluding the Company Stockholder Support Agreements and the Company Lock-Up Agreements) to be terminated, contingent upon, and to take effect as of immediately prior to, the Effective Time, without any liability being imposed on the part of Parent or the Surviving Corporation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.14&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Section&#160;16 Matters</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Prior to the Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of Parent Common Stock (including derivative securities with respect to Parent Common Stock) in connection with the Contemplated Transactions, by each individual who is or is reasonably expected to become, subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Parent, to be exempt under Rule&#160;16b-3 under the Exchange Act. At least 30 calendar days prior to the Closing Date, the Company shall furnish the following information to Parent for each </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t5EPS">&#8203;</a><a name="t51CE">&#8203;</a><a name="t5FST">&#8203;</a><a name="t5SIA">&#8203;</a><a name="t5LEP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">individual who, immediately after the Effective Time, will become subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Parent: (a)&#160;the number of shares of Company Capital Stock owned by such individual and expected to be exchanged for shares of Parent Common Stock pursuant to the Merger; and (b)&#160;the number of other derivative securities (if any) with respect to Company Capital Stock owned by such individual and expected to be converted into shares of Parent Common Stock, restricted stock awards to acquire Parent Common Stock or derivative securities with respect to Parent Common Stock in connection with the Merger. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.15&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Cooperation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each Party shall cooperate reasonably with the other Party and shall provide the other Party with such assistance as may be reasonably requested for the purpose of facilitating the performance by each Party of its respective obligations under this Agreement and to enable the combined entity to continue to meet its obligations following the Effective Time. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.16&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Allocation Certificates</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Company will prepare and deliver to Parent at least two Business Days prior to the Closing Date a certificate signed by the Chief Executive Officer or Chief Financial Officer of the Company setting forth, as of immediately prior to the Effective Time, after giving effect to the Pre-Closing Financing: (i)&#160;each holder of Company Capital Stock and Company Options; (ii)&#160;such holder&#8217;s name and address; (iii)&#160;the number and type of Company Capital Stock held and/or underlying the Company Options as of immediately prior to the Effective Time for each such holder and the per share exercise price of each Company Option; and (iv)&#160;the number of shares of Parent Common Stock to be issued to such holder, or to underlie any Parent Option to be issued to such holder, pursuant to this Agreement in respect of the Company Capital Stock or Company Options held by such holder as of immediately prior to the Effective Time (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Allocation Certificate</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Parent will prepare and deliver to the Company at least two Business Days prior to the Closing Date a certificate signed by the Chief Executive Officer or Chief Financial Officer of Parent, setting forth (as of immediately prior to the Effective Time), the number of Parent Outstanding Shares and each component thereof (broken down by outstanding shares of Parent Common Stock, Parent Options, Parent RSUs and Parent Warrants). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.17&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Company Financial Statements</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company will furnish to Parent Company Financial Statements required to be included in the Registration Statement prior to the initial filing of such Registration Statement and in no event later than 15 calendar days after the date hereof; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that, for clarity, the final, signed audit opinion with respect to such Company Financial Statements shall not be provided until the date of filing of the Registration Statement. The Company shall also furnish to Parent unaudited interim financial statements for each interim period completed prior to Closing required to be included in the Registration Statement prior to the initial filing of such Registration Statement and in no event later than 15 calendar days after the date hereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.18&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Takeover Statutes</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;If any Takeover Statute is or may become applicable to the Contemplated Transactions, each of the Company, the Company Board, Parent and the Parent Board, as applicable, shall grant such approvals and take such actions as are necessary so that the Contemplated Transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such statute or regulation on the Contemplated Transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.19&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Stockholder Litigation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each Party shall give the other Party the opportunity to participate in the settlement or defense of any stockholder litigation brought or threatened against such Party or any of its directors and officers relating to or challenging this Agreement or the consummation of the Contemplated Transactions (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Transaction Litigation</font><font style="letter-spacing:0.2pt;">&#8221;), and no such settlement shall be agreed to without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. Without limiting in any way the Parties&#8217; obligations under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.19</font><font style="letter-spacing:0.2pt;">, each of Parent and the Company will cooperate, and cause its Subsidiaries to cooperate, and shall use its reasonable best efforts to cause its Representatives to cooperate, in the defense against any Transaction Litigation. All costs and expenses, including attorney&#8217;s fees and settlement costs, incurred in connection with any Transaction Litigation shall be treated in accordance with the definition of Net Cash. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t52BE">&#8203;</a><a name="t5DPT">&#8203;</a><a name="t5RSP">&#8203;</a><a name="t5SDF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.20&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Employee Benefits</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Immediately following the Effective Time, the employment and service, as applicable, of each employee, independent contractor or officer of Parent, subject to the exceptions listed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.20(a)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Terminated Parent Associate</font><font style="letter-spacing:0.2pt;">&#8221;) who remains employed or engaged immediately prior to the Effective Time shall automatically terminate. Each such termination shall be deemed to be an involuntary termination without &#8220;cause&#8221; after a &#8220;change in control transaction&#8221; or a &#8220;covered termination&#8221;, as applicable, and Parent shall comply with the terms of any employment, severance, retention, change of control, or similar Contract or Parent Benefit Plan specified in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.17(a)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that any Terminated Parent Associate who is an employee of Parent as of the Effective Time and is terminated in accordance with the immediately preceding sentence and is not otherwise party to such Contract or subject to such a Parent Benefit Plan, shall be paid severance by Parent equal to two weeks of base salary plus one week of base salary for each full or partial year of employment with Parent, but no less than a minimum of 12 weeks of base salary, subject to such releases of claims against Parent and the Company and their agents, representatives, and other customary releases as the Company shall require. Notwithstanding the forgoing, any severance pay or severance benefits payable, including payments to cover COBRA, to Terminated Parent Associates pursuant to any employment, severance, retention, change of control, or similar Contract or Parent Benefit Plan specified in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.17(a)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule as a result of the Effective Time, to the maximum extent permitted by Code Section&#160;409A, be paid in lump sum as soon as practicable following the Effective Time, </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that the Terminated Parent Associate consents to the lump sum severance payment (to the extent required). From time to time after the date hereof, Parent may update </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.20(a)</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule upon the prior written consent of the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Each Person, other than any Person who has previously entered into a Contract with Parent providing for the payment of severance benefits and/or is a Terminated Parent Associate, who is an employee of Parent as of the Effective Time and who is terminated by Parent following the Effective Time shall be entitled to severance benefits to be paid by Parent pursuant to Parent&#8217;s current severance practice, but in no event shall such severance benefits be less than two weeks of base salary plus one week of base salary for each full or partial year of employment with Parent, but no less than a minimum of 12 weeks of base salary, subject to such releases of claims against Parent and the Company and their agents, representatives, and other customary releasees as the Company shall require. For the avoidance of doubt, all such payments under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.20(b)</font><font style="letter-spacing:0.2pt;"> shall not be included in the calculation of Parent Transaction Expenses nor in the calculation of Net Cash. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.21&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Pre-Closing Dividend</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Prior to the Effective Time, Parent may (a)&#160;declare a dividend (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Pre-Closing Dividend</font><font style="letter-spacing:0.2pt;">&#8221;) to its common stockholders of record consisting of (i)&#160;the right to receive one contingent value right (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR</font><font style="letter-spacing:0.2pt;">&#8221;) for each outstanding share of Parent Common Stock held by such stockholder as of such date, each representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the Contingent Value Rights Agreement in the form attached hereto as </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;D</font><font style="letter-spacing:0.2pt;"> (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) and (ii)&#160;cash in an amount not to exceed $25,000,000 in the aggregate subject to satisfaction of Parent&#8217;s obligation set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.5</font><font style="letter-spacing:0.2pt;"> and (b)&#160;make any necessary equitable adjustment required under the Parent Stock Plans. The record date for the Pre-Closing Dividend shall be a date agreed by Parent and the Company prior to the Effective Time and the payment date for which shall be three Business Days after the Effective Time; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the payment of such dividend may be conditioned upon the occurrence of the Effective Time. In connection with the Pre-Closing Dividend, Parent shall cause the CVR Agreement to be duly authorized, executed and delivered by Parent and a rights agent selected by Parent with the Company&#8217;s prior approval (such approval not to be unreasonably withheld, delayed or conditioned). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.22&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Nasdaq Reverse Split</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent shall submit to Parent&#8217;s stockholders at the Parent Stockholders Meeting a proposal to approve and adopt an amendment to Parent&#8217;s certificate of incorporation to authorize the Parent Board to effect the Nasdaq Reverse Split, and shall take such other actions as shall be reasonably necessary to effectuate the Nasdaq Reverse Split. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.23&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Parent SEC Documents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;From the date of this Agreement until the Effective Time, Parent shall use commercially reasonable efforts to timely file with the SEC all Parent SEC Documents. As of its filing </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t5OMS">&#8203;</a><a name="tS6PT">&#8203;</a><a name="t6RNT">&#8203;</a><a name="t6AIP">&#8203;</a><a name="t6TES">&#8203;</a><a name="t6ORS">&#8203;</a><a name="tS7CP">&#8203;</a><a name="t7ORT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">date, or if amended after the date of this Agreement, as of the date of the last such amendment, each Parent SEC Document filed by Parent with the SEC shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">5.24&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Obligations of Merger Sub</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent will take all actions necessary to cause Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;6.&nbsp;&nbsp;&nbsp;CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable Law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">6.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">No Restraints</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Body of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">6.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Stockholder Approval</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;(i)&#160;Parent shall have obtained the Required Parent Stockholder Vote and (ii)&#160;the Company shall have obtained the Required Company Stockholder Vote. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">6.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Listing</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The existing shares of Parent Common Stock shall have been continually listed on Nasdaq as of and from the date of this Agreement through the Closing Date, the approval of the listing of additional shares of Parent Common Stock on Nasdaq shall have been obtained and the shares of Parent Common Stock to be issued in the Merger and the Conversion pursuant to this Agreement shall have been approved for listing on Nasdaq. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">6.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Effectiveness of Registration Statement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or proceeding (or threatened proceeding by the SEC) seeking a stop order with respect to the Registration Statement that has not been withdrawn. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.8pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;7.</font>
          <br >
        </div>
        <div style=" margin-top:11.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The obligations of Parent and Merger Sub to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">7.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Accuracy of Representations</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company Fundamental Representations shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct in all material respects as of such date). The Company Capitalization Representations shall be true and correct in all respects on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;for such inaccuracies which are </font><font style="font-style:italic;letter-spacing:0.2pt;">de minimis</font><font style="letter-spacing:0.2pt;">, individually or in the aggregate, or (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of the Company set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.8(b)</font><font style="letter-spacing:0.2pt;"> shall be true and correct in all respects on and as of the Closing Date with the same force and effect as if made on and as of such date. The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations, the Company Capitalization Representations and the representations and warranties of the Company set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.8(b)</font><font style="letter-spacing:0.2pt;">) shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date, except (a)&#160;in each case, or in the aggregate, where the failure to be true and correct would not have a Company Material Adverse Effect (without giving effect to any references therein to any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t7OCT">&#8203;</a><a name="t7CPS">&#8203;</a><a name="t7CPS1">&#8203;</a><a name="t7OIA">&#8203;</a><a name="t7LAT">&#8203;</a><a name="tS8CP">&#8203;</a><a name="t8ORT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Company Material Adverse Effect or other materiality qualifications), or (b)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">7.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Performance of Covenants</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company shall have performed or complied in all material respects with the agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the Effective Time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">7.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Closing Certificate</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent shall have received a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i)&#160;that the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;7.1</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.2</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.5</font><font style="letter-spacing:0.2pt;"> have been duly satisfied and (ii)&#160;that the information set forth in the Allocation Certificate delivered by the Company in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.16</font><font style="letter-spacing:0.2pt;"> is true and accurate in all respects as of the Closing Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">7.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">FIRPTA Certificate</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent shall have received (i)&#160;an original signed statement from the Company that the Company Common Stock is not a &#8220;United States real property interest,&#8221; as defined in Section&#160;897(c) of the Code, conforming to the requirements of Treasury Regulations&#160;Section&#160;1.1445-2(c)(3) and 1.897-2(h), and (ii)&#160;an original signed notice to be delivered to the IRS by Parent in accordance with the provisions of Treasury Regulations&#160;Section&#160;1.897-2(h)(2), together with written authorization for Parent to deliver such notice to the IRS on behalf of the Company following the Closing, each dated as of the Closing Date, duly executed by an authorized officer of the Company, and in form and substance reasonably acceptable to Parent. If Parent does not receive the certification and notice described above on or before the Closing Date, Parent&#8217;s sole remedy shall be to withhold from the payments to be made pursuant to this Agreement any required withholding Tax under Section&#160;1445 of the Code. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Termination of Investor Agreements</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Investor Agreements shall have been terminated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">7.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Company Lock-Up Agreements</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company Lock-Up Agreement will continue to be in full force and effect as of immediately following the Effective Time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;8.&nbsp;&nbsp;&nbsp;ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Accuracy of Representations</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Parent Fundamental Representations shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct in all material respects as of such date). The Parent Capitalization Representations shall be true and correct in all respects on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;for such inaccuracies which are </font><font style="font-style:italic;letter-spacing:0.2pt;">de minimis</font><font style="letter-spacing:0.2pt;">, individually or in the aggregate, or (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications set forth in the preceding clause (x), as of such particular date). The representations and warranties of Parent and Merger Sub set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.8(b)</font><font style="letter-spacing:0.2pt;"> shall be true and correct in all respects as of the Closing Date with the same force and effect as if made on and as of such date. The representations and warranties of Parent and Merger Sub contained in this Agreement (other than the Parent Fundamental Representations, the Parent Capitalization Representations or the representations and warranties of Parent and Merger Sub set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.8(b)</font><font style="letter-spacing:0.2pt;">) shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a)&#160;in each case, or in the aggregate, where the failure to be true and correct would not have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications), or (b)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t8OCP">&#8203;</a><a name="t8TCS">&#8203;</a><a name="t8LAT">&#8203;</a><a name="t8PFN">&#8203;</a><a name="tSE9T">&#8203;</a><a name="t9TAM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Performance of Covenants</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent and Merger Sub shall have performed or complied in all material respects with their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the Effective Time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Documents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company shall have received the following documents, each of which shall be in full force and effect: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;a certificate executed by the Chief Executive Officer of Parent confirming that the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;8.1</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">8.2</font><font style="letter-spacing:0.2pt;">, and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">8.5</font><font style="letter-spacing:0.2pt;"> have been duly satisfied; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;a copy of the CVR Agreement, duly executed by Parent and the Rights Agent (as defined therein); and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;a written resignation, in a form reasonably satisfactory to the Company, dated as of the Closing Date and effective as of the Closing, executed by each of the officers and directors, from their positions as such, of Parent who are not to continue as officers or directors (as applicable) of Parent after the Closing pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.12</font><font style="letter-spacing:0.2pt;">, such resignation not effecting such officer&#8217;s or directors&#8217; status as an employee (if applicable), including any characterization of their cessation from employment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Parent Lock-Up Agreements</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Parent Lock-Up Agreements will continue to be in full force and effect as of immediately following the Effective Time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Minimum Parent Final Net Cash</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Final Net Cash shall have been determined in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11</font><font style="letter-spacing:0.2pt;"> to be greater than or equal to $100,000,000. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;9.&nbsp;&nbsp;&nbsp;TERMINATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Termination</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement may be terminated prior to the Effective Time (whether before or after adoption of this Agreement by the Company&#8217;s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent&#8217;s stockholders, unless otherwise specified below): </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;by mutual written consent of Parent and the Company; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;by either Parent or the Company if the Contemplated Transactions shall not have been consummated by January&#160;31, 2023 (subject to possible extension as provided in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(b)</font><font style="letter-spacing:0.2pt;">, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">End Date</font><font style="letter-spacing:0.2pt;">&#8221;); </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that the right to terminate this Agreement pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(b)</font><font style="letter-spacing:0.2pt;"> shall not be available to the Company, on the one hand, or to Parent, on the other hand, if such Party&#8217;s action or failure to act has been a principal cause of the failure of the Contemplated Transactions to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that, in the event that a request for additional information has been made by any Governmental Body, or in the event that the SEC has not declared effective under the Securities Act the Registration Statement by the date which is 60&#160;days prior to the End Date, then either the Company or Parent shall be entitled to extend the End Date to the date that is 60&#160;days after the date that the SEC has declared effective the Registration Statement under the Securities Act, but in any event no more than 60&#160;days after the original End Date, by written notice to the other Party; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;by either Parent or the Company if a court of competent jurisdiction or other Governmental Body shall have issued a final and nonappealable order, decree or ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;by Parent if the Company Stockholder Written Consent evidencing the Required Company Stockholder Vote shall not have been obtained within ten Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t9OTI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">once the Company Stockholder Written Consent evidencing the Required Company Stockholder Vote has been obtained, Parent may not terminate this Agreement pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(d)</font><font style="letter-spacing:0.2pt;">; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;by either Parent or the Company if (i)&#160;the Parent Stockholders&#8217; Meeting (including, if applicable, following adjournments or postponements thereof as permitted or required pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.4(b)</font><font style="letter-spacing:0.2pt;">) shall have been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii)&#160;the Parent Stockholder Matters shall not have been approved at the Parent Stockholders&#8217; Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that the right to terminate this Agreement pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(e)</font><font style="letter-spacing:0.2pt;"> shall not be available to Parent if Parent&#8217;s actions or failure to act has been a principal cause of the failure of Parent to obtain the Required Parent Stockholder Vote and such action or failure to act constitutes a breach by Parent of this Agreement; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;by the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;by Parent (at any time prior to the Required Company Stockholder Vote being obtained) if a Company Triggering Event shall have occurred; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Sub or if any representation or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.1</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.2</font><font style="letter-spacing:0.2pt;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, that if such inaccuracy in Parent&#8217;s or Merger Sub&#8217;s representations and warranties or breach by Parent or Merger Sub is curable by the End Date by Parent or Merger Sub, then this Agreement shall not terminate pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(h)</font><font style="letter-spacing:0.2pt;"> as a result of such particular breach or inaccuracy until the expiration of a 30-day period commencing upon delivery of written notice from the Company to Parent or Merger Sub of such breach or inaccuracy and its intention to terminate pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(h)</font><font style="letter-spacing:0.2pt;"> (it being understood that this Agreement shall not terminate pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(h)</font><font style="letter-spacing:0.2pt;"> as a result of such particular breach or inaccuracy if such breach by Parent or Merger Sub is cured prior to such termination becoming effective); or </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.2</font><font style="letter-spacing:0.2pt;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the End Date by the Company then this Agreement shall not terminate pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(i)</font><font style="letter-spacing:0.2pt;"> as a result of such particular breach or inaccuracy until the expiration of a 30-day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(i)</font><font style="letter-spacing:0.2pt;"> (it being understood that this Agreement shall not terminate pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(i)</font><font style="letter-spacing:0.2pt;"> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Party desiring to terminate this Agreement pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1</font><font style="letter-spacing:0.2pt;"> (other than pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(a)</font><font style="letter-spacing:0.2pt;">) shall give notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefore described in reasonable detail. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Effect of Termination</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of the termination of this Agreement as provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1</font><font style="letter-spacing:0.2pt;">, this Agreement shall be of no further force or effect; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that (a)&#160;this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.2</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10</font><font style="letter-spacing:0.2pt;"> and the definitions of the defined terms in such Sections shall survive the termination of this Agreement and shall remain in full force and effect, and (b)&#160;the termination of this Agreement and the provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;"> shall not relieve any Party of any liability for fraud or for any willful and material breach of any covenant or other obligation contained in this Agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t9TF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Expenses; Termination Fees</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Except as set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;">, whether or not the Merger is consummated, (i)&#160;all Parent Transaction Expenses shall be paid by Parent (or on behalf of Parent) at or prior to the Closing and (ii)&#160;all Company Transaction Expenses shall be paid by the Company at or prior to the Closing; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that Parent and the Company shall share equally all fees and expenses, other than attorneys&#8217; and accountants&#8217; fees and expenses, incurred in relation to the filings by the Parties under any filing requirement under any Antitrust Law, to the extent applicable to this Agreement and the transactions contemplated hereby; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that Parent and the Company shall also share equally all fees and expenses incurred in relation to the printing and filing with the SEC of the Registration Statement (including any financial statements and exhibits) and any amendments or supplements thereto and paid to a financial printer or the SEC and the filings with Nasdaq pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;5.9(b)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(d)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;If (i)&#160;this Agreement is terminated by Parent or the Company pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(b)</font><font style="letter-spacing:0.2pt;"> (and the Required Parent Stockholder Vote has not been obtained by Parent) or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(e)</font><font style="letter-spacing:0.2pt;">, (ii)&#160;at any time after the date of this Agreement and prior to the Parent Stockholder Meeting, an Acquisition Proposal with respect to Parent shall have been publicly announced or disclosed or otherwise communicated to Parent or the Parent Board (and shall not have been withdrawn), and (iii)&#160;within 12&#160;months after the date of such termination, Parent consummates any Subsequent Transaction, then Parent shall pay to the Company, upon consummation of a Subsequent Transaction, a nonrefundable fee in an amount equal to $7,600,000 (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Termination Fee</font><font style="letter-spacing:0.2pt;">&#8221;). If this Agreement is terminated by the Company pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(f)</font><font style="letter-spacing:0.2pt;">, then Parent shall pay to the Company the Company Termination Fee within two Business Days of such termination. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;If (i)&#160;this Agreement is terminated by Parent pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(b)</font><font style="letter-spacing:0.2pt;"> (and the Required Company Stockholder Vote has not been obtained by the Company) or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(d)</font><font style="letter-spacing:0.2pt;">, (ii)&#160;at any time after the date of this Agreement and before obtaining the Required Company Stockholder Vote, an Acquisition Proposal with respect to the Company shall have been publicly announced or disclosed or otherwise communicated to the Company or the Company Board (and shall not have been withdrawn), and (iii)&#160;within 12&#160;months after the date of such termination, the Company consummates any Subsequent Transaction, then the Company shall pay to Parent, upon consummation of a Subsequent Transaction, a nonrefundable fee in an amount equal to $5,490,000 (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Termination Fee</font><font style="letter-spacing:0.2pt;">&#8221;). If this Agreement is terminated by Parent pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(g)</font><font style="letter-spacing:0.2pt;">, then the Company shall pay to Parent the Parent Termination Fee within two Business Days of such termination. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;If this Agreement is terminated by either the Company or Parent pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(e)</font><font style="letter-spacing:0.2pt;"> or by the Company pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(f)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(h)</font><font style="letter-spacing:0.2pt;">, then Parent shall reimburse the Company for all reasonable out of pocket fees and expenses incurred by the Company in connection with this Agreement and the Contemplated Transactions, up to a maximum of $1,750,000, by wire transfer of same day funds within five Business Days following the date on which the Company submits to Parent true and correct copies of reasonable documentation supporting such expenses. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;If this Agreement is terminated by Parent pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(d)</font><font style="letter-spacing:0.2pt;">, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(g)</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.1(i)</font><font style="letter-spacing:0.2pt;">, then the Company shall reimburse Parent for all reasonable out of pocket fees and expenses incurred by Parent in connection with this Agreement and the Contemplated Transactions, up to a maximum of $1,750,000, by wire transfer of same day funds within five Business Days following the date on which Parent submits to the Company true and correct copies of reasonable documentation supporting such expenses. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;If a Party fails to pay when due any amount payable by it under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;">, then (i)&#160;such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;"> and (ii)&#160;such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; &#8203;(as published in </font><font style="font-style:italic;letter-spacing:0.2pt;">The Wall Street Journal</font><font style="letter-spacing:0.2pt;"> or any successor thereto) in effect on the date such overdue amount was originally required to be paid. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="tS1P">&#8203;</a><a name="t1ORA">&#8203;</a><a name="t1TAM">&#8203;</a><a name="t103">&#8203;</a><a name="t1ACE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;The Parties agree that, subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.2</font><font style="letter-spacing:0.2pt;">, (i)&#160;payment of the fees and expenses in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;"> shall, in the circumstances in which they are owed in accordance with the terms of this Agreement, constitute the sole and exclusive remedy of each Party following the termination of this Agreement under the circumstances described in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;">, it being understood that in no event shall either Parent or the Company be required to pay the individual amounts payable pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;"> on more than one occasion and (ii)&#160;following the termination of this Agreement under the circumstances described in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;"> and the payment of the fees and expenses set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;"> by a Party, (A)&#160;such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (B)&#160;no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by any such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (C)&#160;all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;Each of the Parties acknowledges that (i)&#160;the agreements contained in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;"> are an integral part of the Contemplated Transactions, (ii)&#160;without these agreements, the Parties would not enter into this Agreement and (iii)&#160;any amount payable pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;"> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Party in the circumstances in which such amount is payable. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;10.&nbsp;&nbsp;&nbsp;MISCELLANEOUS PROVISIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">10.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Non-Survival of Representations and Warranties</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The representations and warranties of the Company, Parent and Merger Sub contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the Effective Time, and only the covenants that by their terms survive the Effective Time and this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10</font><font style="letter-spacing:0.2pt;"> shall survive the Effective Time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">10.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Amendment</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Sub and Parent at any time (whether before or after the adoption and approval of this Agreement by the Company&#8217;s stockholders or before or after obtaining the Required Parent Stockholder Vote); </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that after any such approval of this Agreement by a Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Sub and Parent. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Waiver</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Any provisions hereof may be waived (or the time for performance extended) by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any other Party. No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">10.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement and the other agreements referred to in this Agreement constitute the entire agreement and supersede all prior </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t1LJW">&#8203;</a><a name="t1TAS">&#8203;</a><a name="t1ANA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:24pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Applicable Law; Jurisdiction; Waiver of Jury Trial</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;This Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (i)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware, New Castle County, or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (ii)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i)&#160;of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.5</font><font style="letter-spacing:0.2pt;">; (iii)&#160;waives any objection to laying venue in any such action or proceeding in such courts; (iv)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party; and (v)&#160;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.7</font><font style="letter-spacing:0.2pt;"> of this Agreement. Nothing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;10.5</font><font style="letter-spacing:0.2pt;">, however, shall affect the right of any Person to serve legal process in any other manner permitted by law. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (i)&#160;ARISING UNDER THIS AGREEMENT OR (ii)&#160;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE CONTEMPLATED TRANSACTIONS, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Assignability</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Notices</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand, or (c)&#160;on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00&#160;p.m. New York time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t1ATO">&#8203;</a><a name="t1RSP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">if to Parent or Merger Sub: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">245 First Street, Suite 1800</font> <br ><font style="letter-spacing:0.2pt;">Cambridge, MA</font> <br ><font style="letter-spacing:0.2pt;">Attention: Chief Executive Officer</font> <br ><font style="letter-spacing:0.2pt;">Email: *****@*****.com </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to (which shall not constitute notice): </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Hogan Lovells US LLP</font> <br ><font style="letter-spacing:0.2pt;">1735 Market St, 23</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">rd</font><font style="letter-spacing:0.2pt;"> Floor</font> <br ><font style="letter-spacing:0.2pt;">Philadelphia, PA 19103</font> <br ><font style="letter-spacing:0.2pt;">Attention: Steve Abrams; Jessica A. Bisignano</font> <br ><font style="letter-spacing:0.2pt;">Email: *****@*****.com; *****@*****.com </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">if to the Company: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3675 Market Street, Suite 200</font> <br ><font style="letter-spacing:0.2pt;">Philadelphia, Pennsylvania 19104</font> <br ><font style="letter-spacing:0.2pt;">Attention: President and Chief Executive Officer</font> <br ><font style="letter-spacing:0.2pt;">Email: *****@*****.com </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to (which shall not constitute notice): </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Wilmer Cutler Pickering Hale and Dorr LLP</font> <br ><font style="letter-spacing:0.2pt;">7 World Trade Center</font> <br ><font style="letter-spacing:0.2pt;">250 Greenwich Street</font> <br ><font style="letter-spacing:0.2pt;">New York, NY 10007</font> <br ><font style="letter-spacing:0.2pt;">Attention: Brian A. Johnson; Hal Leibowitz; Christopher Barnstable-Brown</font><br ><font style="letter-spacing:0.2pt;">Email: *****@*****.com; *****@*****.com; *****@*****.com </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Severability</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Other Remedies; Specific Performance</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not perform the provisions of this Agreement (including failing to take such actions as are required of it hereunder to consummate the Contemplated Transactions) in accordance with its specified terms or otherwise breaches such provisions. Accordingly, the Parties acknowledge and agree that the Parties shall be entitled to an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance or other equitable relief is not an appropriate remedy for any reason at law or in equity. Any Party seeking an injunction or injunctions to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a><a name="t1TPB">&#8203;</a><a name="t101">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">prevent breaches of this Agreement shall not be required to provide any bond or other security in connection with any such order or injunction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">10.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">No Third Party Beneficiaries</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.6</font><font style="letter-spacing:0.2pt;">) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Construction</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;References to &#8220;cash,&#8221; &#8220;dollars&#8221; or &#8220;$&#8221; are to U.S. dollars. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;For purposes of this Agreement, whenever the context requires: (i)&#160;the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; (ii)&#160;the feminine gender shall include the masculine and neuter genders; and (iii)&#160;the neuter gender shall include masculine and feminine genders. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;The Parties have participated jointly in the negotiating and drafting of this Agreement and agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;As used in this Agreement, the words &#8220;hereof&#8221;, &#8220;hereto&#8221;, &#8220;hereby&#8221;, &#8220;herein&#8221; and &#8220;hereunder&#8221; and variations thereof refer to this Agreement as a whole and not to any particular provision of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;As used in this Agreement, the words &#8220;date hereof&#8221; refers to the date set forth in the initial caption of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;As used in this Agreement, the word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extended, and such phrase does not simply mean &#8220;if&#8221;. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;Except as otherwise indicated, all references in this Agreement to an &#8220;Article,&#8221; &#8220;Section,&#8221; &#8220;Recital,&#8221; &#8220;preamble,&#8221; &#8220;Annex,&#8221; &#8220;Exhibit&#8221; and &#8220;Schedule&#8221; are intended to refer to an Article, Section, Recital or preamble of, or an Annex, Exhibit or Schedule to, this Agreement, respectively. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;Any reference to a Person is also to its permitted successors and assigns. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;Any reference to legislation or to any provision of any legislation shall include any modification, amendment, re-enactment thereof, any legislative provision substituted therefore and all rules, regulations, and statutory instruments issued or related to such legislations. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;Any reference to a communication by a regulatory agency include a communication by the staff of such regulatory agency. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;The bold-faced headings and table of contents contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(m)&nbsp;&nbsp;&nbsp;The Parties agree that each of the Company Disclosure Schedule and the Parent Disclosure Schedule shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in this Agreement. The disclosures in any section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule shall only qualify other sections and subsections in this Agreement to the extent it is reasonably apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. The inclusion of any information in the Company Disclosure Schedule or the Parent Disclosure Schedule shall not be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:436pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">deemed to be an admission or acknowledgment, in and of itself, that such information is required by the terms hereof to be disclosed, is material, has resulted in or would result in a Company Material Adverse Effect or a Parent Material Adverse Effect or is outside the Ordinary Course of Business. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(n)&nbsp;&nbsp;&nbsp;Each of &#8220;delivered&#8221; or &#8220;made available&#8221; means, with respect to any documentation, that prior to 11:59&#160;p.m. (New York time) on the date that is one Business Days prior to the date of this Agreement (i)&#160;a copy of such material has been posted to and made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party or (ii)&#160;such material is disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly made available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(o)&nbsp;&nbsp;&nbsp;Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Saturday, Sunday, or any date on which banks in New York, New York are authorized or obligated by Law to be closed, the Party having such privilege or duty may exercise such privilege or discharge such duty on the next succeeding day which is a regular Business Day. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(</font><font style="font-style:italic;letter-spacing:0.2pt;">Remainder of page intentionally left blank</font><font style="letter-spacing:0.2pt;">) </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">IN WITNESS WHEREOF</font><font style="letter-spacing:0.2pt;">, the Parties have caused this Agreement to be executed as of the date first above written. </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <font style="letter-spacing:0.2pt;">/s/ Thomas R. Cannell, D.V.M.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Name:&nbsp;&nbsp;&nbsp;Thomas R. Cannell, D.V.M. </font>
          <br >
          <font style="letter-spacing:0.2pt;">Title:&nbsp;&nbsp;&nbsp;&#8199;&#8201;President &amp; Chief Executive Officer </font>
        </div>
        <div style="margin-left:220pt; margin-top:36pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SEAHAWK MERGER SUB, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <font style="letter-spacing:0.2pt;">/s/ Mark Sullivan</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Name:&nbsp;&nbsp;&nbsp;Mark Sullivan </font>
          <br >
          <font style="letter-spacing:0.2pt;">Title:&nbsp;&nbsp;&nbsp;&#8199;&#8201;President, Secretary &amp; Treasurer </font>
        </div>
        <div style="margin-left:220pt; margin-top:36pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <font style="letter-spacing:0.2pt;">/s/ Steven Kelly</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Name:&nbsp;&nbsp;&nbsp;Steven Kelly </font>
          <br >
          <font style="letter-spacing:0.2pt;">Title:&nbsp;&nbsp;&nbsp;&#8199;&#8201;Chief Executive Officer </font>
        </div>
        <div style="margin-top:144pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[</font><font style="font-style:italic;letter-spacing:0.2pt;">Signature Page to Agreement and Plan of Merger and Reorganization</font><font style="letter-spacing:0.2pt;">]</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT A</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CERTAIN DEFINITIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;For purposes of this Agreement (including this </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;A</font><font style="letter-spacing:0.2pt;">): </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquisition Inquiry</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to a Party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by the Company or any of its Affiliates, on the one hand, or Parent or any of its Affiliates, on the other hand, to the other Party) that could reasonably be expected to lead to an Acquisition Proposal, other than (i)&#160;with respect to Parent, solely with respect to the Asset Dispositions and (ii)&#160;with respect to the Company, solely with respect to the Pre-Closing Financing. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquisition Proposal</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party, other than (i)&#160;with respect to Parent, solely with respect to an Asset Disposition and (ii)&#160;with respect to the Company, solely with respect to the Pre-Closing Financing. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquisition Transaction</font><font style="letter-spacing:0.2pt;">&#8221; means any transaction or series of related transactions (other than the Asset Dispositions) involving: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (A)&#160;in which a Party is a constituent Entity; (B)&#160;in which a Person or &#8220;group&#8221; &#8203;(as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 15% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries; or (C)&#160;in which a Party or any of its Subsidiaries issues securities representing more than 15% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that in the case of the Company, to the extent the Pre-Closing Financing is effected in accordance with the terms and conditions of this Agreement, the Pre-Closing Financing shall not constitute an Acquisition Transaction; or </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 15% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Affiliate</font><font style="letter-spacing:0.2pt;">&#8221; shall have the meaning given to such term in Rule&#160;145 under the Securities Act. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Antitrust Laws</font><font style="letter-spacing:0.2pt;">&#8221; shall mean the Sherman Act, as amended, the Clayton Act, as amended, the HSR Act, the Federal Trade Commission Act, as amended, all applicable foreign anti-trust laws and all other applicable Laws issued by a Governmental Body that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening of competition. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Business Day</font><font style="letter-spacing:0.2pt;">&#8221; means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be closed. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Code</font><font style="letter-spacing:0.2pt;">&#8221; means the Internal Revenue Code of 1986, as amended. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Associate</font><font style="letter-spacing:0.2pt;">&#8221; means any current or former employee, independent contractor, officer or director of the Company or its Subsidiaries. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Board</font><font style="letter-spacing:0.2pt;">&#8221; means the board of directors of the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Capital Stock</font><font style="letter-spacing:0.2pt;">&#8221; means the Company Common Stock and the Company Preferred Stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Capitalization Representations</font><font style="letter-spacing:0.2pt;">&#8221; means the representations and warranties of the Company set forth in the first sentence of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;2.6(a)</font><font style="letter-spacing:0.2pt;"> and in Section </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.6(d)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Common Stock</font><font style="letter-spacing:0.2pt;">&#8221; means the common stock, $0.0001 par value per share, of the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Contract</font><font style="letter-spacing:0.2pt;">&#8221; means any Contract: (a)&#160;to which the Company or any of its Subsidiaries is a Party; (b)&#160;by which the Company or any of its Subsidiaries or any Company IP or any other asset of the Company or its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation; or (c)&#160;under which the Company or any of its Subsidiaries has or may acquire any right or interest. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Convertible Note</font><font style="letter-spacing:0.2pt;">&#8221; means the outstanding note convertible described in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.6(a)</font><font style="letter-spacing:0.2pt;"> of the Company Disclosure Schedule. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company ERISA Affiliate</font><font style="letter-spacing:0.2pt;">&#8221; means any corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with the Company or any of its Subsidiaries as a single employer within the meaning of Section&#160;414 of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Fundamental Representations</font><font style="letter-spacing:0.2pt;">&#8221; means the representations and warranties of the Company set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;2.1(a)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.1(b)</font><font style="letter-spacing:0.2pt;"> (Due Organization; Subsidiaries), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.3</font><font style="letter-spacing:0.2pt;"> (Authority; Binding Nature of Agreement), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.4</font><font style="letter-spacing:0.2pt;"> (Vote Required), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.5(a)</font><font style="letter-spacing:0.2pt;"> (Non-Contravention) and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.20</font><font style="letter-spacing:0.2pt;"> (No Financial Advisors). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company IP</font><font style="letter-spacing:0.2pt;">&#8221; means all Intellectual Property Rights that are owned or purported to be owned by, assigned to, or exclusively licensed by, the Company or its Subsidiaries that are necessary for or used in the operation of the business of the Company or its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Material Adverse Effect</font><font style="letter-spacing:0.2pt;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of the Company and its Subsidiaries, taken as a whole; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Company Material Adverse Effect: (a)&#160;the announcement of this Agreement or the pendency of the Contemplated Transactions; (b)&#160;general business, economic or political conditions or conditions generally affecting the industry in which the Company and its Subsidiaries operate; (c)&#160;hurricane, flood, tornado, earthquake or other natural disaster, changes in weather conditions, epidemic, plague, pandemic (including COVID-19) or any other outbreak of illness or other public health event or any other force majeure event, whether or not cause by any Person, or any national or international calamity or crises, or any law, regulation, statute, directive, pronouncement or guideline issued by a Governmental Body, the World Health Organization or industry group providing for business closures, &#8220;sheltering-in-place,&#8221; curfews or other restrictions that relate to, or arise out of, an epidemic, pandemic or disease outbreak (including COVID-19) or any change in such law, regulation, statute, directive, pronouncement or guideline or interpretation thereof or any worsening of such conditions; (d)&#160;any COVID-19 Measures or COVID-19 Responses; (e)&#160;any acts, threats or escalations of war, armed hostilities or terrorism anywhere in the world or any governmental or other response or reaction to any of the foregoing; (f)&#160;any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP); (g)&#160;with respect to any product or product candidate of the Company or any of its Subsidiaries, the request of the FDA to refile, amend, or temporarily delay making any regulatory application or filing related to such product or product candidate or the protocol for any clinical trial relating to such product or product candidate (provided that this clause (g)&#160;shall not apply in the event of repeated or continued adverse decisions with respect to the Company&#8217;s product or product candidates by the FDA); or (h)&#160;resulting from the taking of any action, or the failure to take any action, by the Company that is expressly required to be taken by this Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that, in the case of clauses (b), (c), (d), (e)&#160;and (f), solely to the extent the impact on the Company and its Subsidiaries, taken as a whole, is disproportionately adverse compared to the impact on similarly situated companies operating in the industries in which the Company and its Subsidiaries operate, the incrementally disproportionate impact </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">or impacts shall be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Options</font><font style="letter-spacing:0.2pt;">&#8221; means options or other rights to purchase shares of Company Common Stock issued by the Company. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Plan</font><font style="letter-spacing:0.2pt;">&#8221; means the 2017 Stock Incentive Plan, as amended from time to time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221; means, collectively, the Company Series&#160;A Preferred Stock, Company Special Voting Preferred Stock, Company Series&#160;B Preferred Stock and the Company Series&#160;B Special Voting Preferred Stock. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Series&#160;A Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221; means the Series&#160;A Preferred Stock, $0.0001 par value per share, of the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Series&#160;B Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221; means the Series&#160;B Preferred Stock, $0.0001 par value per share, of the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Series&#160;B Special Voting Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221; means the Series&#160;B Special Voting Preferred Stock, $0.0001 par value per share, of the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Special Voting Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221; means the Special Voting Preferred Stock, $0.0001 par value per share, of the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Transaction Expenses</font><font style="letter-spacing:0.2pt;">&#8221; means, as of the applicable time of determination and without duplication, the sum of (a)&#160;the cash cost of any accrued and unpaid retention payments or other bonuses, as well as any change of control payments or severance, termination or similar payments that are due or become due to any current or former employee, director or independent contractor of the Company or any of its Subsidiaries at or prior to the Effective Time or otherwise in connection with the Merger or the Contemplated Transactions, and (b)&#160;subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;">, all costs, fees and expenses incurred by the Company or its Subsidiaries at or prior to the Effective Time in connection with the negotiation, preparation and execution of this Agreement or any agreements, documents, certificate, opinions or other items contemplated hereby and the consummation of the Merger or the Contemplated Transactions and that are unpaid as of the Effective Time, including brokerage fees and commissions, finder&#8217;s fees, legal fees or financial advisory fees payable or otherwise incurred by such person at or prior to the Effective Time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Triggering Event</font><font style="letter-spacing:0.2pt;">&#8221; shall be deemed to have occurred if: (a)&#160;the Company shall have made a Company Board Adverse Recommendation Change; (b)&#160;the Company Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal; or (c)&#160;the Company shall have entered into any letter of intent or similar document relating to any Acquisition Proposal. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Unaudited Interim Balance Sheet</font><font style="letter-spacing:0.2pt;">&#8221; means the unaudited consolidated balance sheet of the Company and its consolidated Subsidiaries for the period ended June&#160;30, 2022 provided to Parent prior to the date hereof. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Confidentiality Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means that certain Confidentiality Agreement, dated as of June&#160;25, 2022, between the Company and Parent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Consent</font><font style="letter-spacing:0.2pt;">&#8221; means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Contemplated Transactions</font><font style="letter-spacing:0.2pt;">&#8221; means the Merger, the Nasdaq Reverse Split, and the other transactions and actions contemplated by this Agreement, including the CVR Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Contract</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to any Person, any written or oral agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, sublicense or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Conversion</font><font style="letter-spacing:0.2pt;">&#8221; means the conversion of the Company Convertible Note for shares of Parent Common Stock pursuant to the Convertible Note Conversion Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Convertible Note Conversion Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means that certain Conversion Agreement, dated as of September&#160;20, 2022, by and between the Company and the holder of the Company Convertible Note. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">COVID-19</font><font style="letter-spacing:0.2pt;">&#8221; means SARS-CoV-2 or the COVID-19 virus, and any evolutions or mutations thereof and any related or associated epidemics, pandemics or disease outbreaks. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">COVID-19 Measures</font><font style="letter-spacing:0.2pt;">&#8221; means any quarantine, &#8220;shelter in place,&#8221; &#8220;stay at home,&#8221; workforce reduction, social distancing, shut down, closure, sequester or any other law, regulation, rule, order, directive, guideline or recommendation of any Governmental Body or industry group in connection with or in response to COVID-19, including the Coronavirus Aid, Relief, and Economic Security Act. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">COVID-19 Responses</font><font style="letter-spacing:0.2pt;">&#8221; means any action or inaction, including the establishment of any policy, procedure or protocol, by a Party or any of its Subsidiaries that such Party or any of its Subsidiaries determines in its reasonable discretion is necessary, advisable or prudent in connection with (a)&#160;mitigating the adverse effects of COVID-19 or applicable COVID-19 Measures, (b)&#160;ensuring compliance by such Party or any of its Subsidiaries with COVID-19 Measures applicable to any of them and/or (c)&#160;in respect of COVID-19, protecting the health and safety of employees or other persons with whom such Party or any of its Subsidiaries and their personnel come into contact with during the course of business operations. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">DGCL</font><font style="letter-spacing:0.2pt;">&#8221; means the General Corporation Law of the State of Delaware. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Effect</font><font style="letter-spacing:0.2pt;">&#8221; means any effect, change, event, circumstance, or development. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Encumbrance</font><font style="letter-spacing:0.2pt;">&#8221; means any lien, pledge, hypothecation, charge, mortgage, security interest, exclusive license, easement, adverse title or similar restriction or encumbrance of any nature. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Enforceability Exceptions</font><font style="letter-spacing:0.2pt;">&#8221; means the (a)&#160;Laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (b)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Entity</font><font style="letter-spacing:0.2pt;">&#8221; means any corporation (including any non-profit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Environmental Law</font><font style="letter-spacing:0.2pt;">&#8221; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any Law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Equity Plan&#160;Amendments</font><font style="letter-spacing:0.2pt;">&#8221; means (a)&#160;an amendment to the Sesen Bio, Inc. 2014 Stock Incentive Plan to provide for (i)&#160;such number of shares of common stock of Parent as mutually agreed by Parent and the Company (such agreement not to be unreasonably withheld, conditioned or delayed), not to exceed 9.5% on a fully diluted basis to be available for grant or issuance thereunder, as calculated to be as of immediately following the Closing, (ii)&#160;an extension of the term of the Sesen Bio, Inc. 2014 Incentive Plan up to, in the Company&#8217;s discretion, the 10th anniversary of the effectiveness of the Equity Plan&#160;Amendments and (iii)&#160;any other amendments deemed necessary and advisable by the Company, and (b)&#160;an amendment to the Parent ESPP to provide for such number of shares of common stock of Parent equal to one&#160;percent (1.0%) on a fully diluted basis to be available for purchase thereunder, as calculated to be as of immediately following the Closing. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">ERISA</font><font style="letter-spacing:0.2pt;">&#8221; means the Employee Retirement Income Security Act of 1974, as amended. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221; means the Securities Exchange Act of 1934, as amended. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Ratio</font><font style="letter-spacing:0.2pt;">&#8221; means, subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.5(h)</font><font style="letter-spacing:0.2pt;">, the following ratio (rounded to four decimal places): the quotient obtained by dividing (a)&#160;the Company Merger Shares by (b)&#160;the Company Outstanding Shares, in which: </font>
        </div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Aggregate Valuation</font><font style="letter-spacing:0.2pt;">&#8221; means the sum of (i)&#160;the Company Valuation, plus (ii)&#160;the Parent Valuation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Allocation Percentage</font><font style="letter-spacing:0.2pt;">&#8221; means the quotient (expressed as a&#160;percentage with the&#160;percentage rounded to four decimal places) determined by dividing (i)&#160;the Company Valuation by (ii)&#160;the Aggregate Valuation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Merger Shares</font><font style="letter-spacing:0.2pt;">&#8221; means the product of (i)&#160;the Post-Closing Parent Shares multiplied by (ii)&#160;the Company Allocation Percentage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Outstanding Shares</font><font style="letter-spacing:0.2pt;">&#8221; means the total number of shares of Company Capital Stock outstanding immediately prior to the Effective Time expressed on a fully-diluted and as-converted to Company Common Stock basis and assuming, without limitation or duplication, (i)&#160;the exercise of all Company Options outstanding as of immediately prior to the Effective Time, (ii)&#160;the closing of the Pre-Closing Financing, and (iii)&#160;the issuance of shares of Company Common Stock issuable in respect of all other outstanding options, restricted stock awards, warrants or rights to receive such shares, whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or associated with the consummation of the Merger. Company Outstanding Shares shall also include all shares of the Company issued in the Pre-Closing Financing prior to the Effective Time and excludes any shares to be issued upon the conversion of the Company Convertible Note. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company Valuation</font><font style="letter-spacing:0.2pt;">&#8221; means (i)&#160;$196,000,000, plus (ii)&#160;the amount of gross proceeds from the Pre-Closing Financing prior to the Effective Time. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Allocation Percentage</font><font style="letter-spacing:0.2pt;">&#8221; means the quotient (expressed as a&#160;percentage, with the&#160;percentage rounded to four decimal places) determined by dividing (i)&#160;the Parent Valuation by (ii)&#160;the Aggregate Valuation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Outstanding Shares</font><font style="letter-spacing:0.2pt;">&#8221; means the total number of shares of Parent Common Stock outstanding immediately prior to the Effective Time expressed on a fully-diluted and as converted to Parent Common Stock basis, assuming, without limitation or duplication, the issuance of shares of Parent Common Stock in respect of all Parent Options, Parent RSUs, Parent Warrants and other outstanding options, warrants or rights to receive such shares, in each case, outstanding as of immediately prior to the Effective Time. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Valuation</font><font style="letter-spacing:0.2pt;">&#8221; means $140,000,000, minus the amount by which Final Net Cash as determined in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11</font><font style="letter-spacing:0.2pt;"> is less than $125,000,000 (if any), and plus the amount by which Final Net Cash as determined in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11</font><font style="letter-spacing:0.2pt;"> is greater than $125,000,000. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Post-Closing Parent Shares</font><font style="letter-spacing:0.2pt;">&#8221; means the quotient determined by dividing (i)&#160;the Parent Outstanding Shares by (ii)&#160;the Parent Allocation Percentage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An example of the calculation of the Exchange Ratio and its components is set forth on </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;H</font><font style="letter-spacing:0.2pt;"> for illustrative purposes only. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">GAAP</font><font style="letter-spacing:0.2pt;">&#8221; means generally accepted accounting principles and practices in effect from time to time within the United States applied consistently throughout the period involved. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Governmental Authorization</font><font style="letter-spacing:0.2pt;">&#8221; means any: (a)&#160;permit, license, certificate, certification, franchise, permission, approval, exemption, variance, exception, order, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Law; or (b)&#160;right under any Contract with any Governmental Body. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Governmental Body</font><font style="letter-spacing:0.2pt;">&#8221; means any: (a)&#160;nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b)&#160;federal, state, local, municipal, foreign or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">other government; (c)&#160;governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority); or (d)&#160;self-regulatory organization (including Nasdaq). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Hazardous Materials</font><font style="letter-spacing:0.2pt;">&#8221; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or by-products. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">HSR Act</font><font style="letter-spacing:0.2pt;">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Intellectual Property Rights</font><font style="letter-spacing:0.2pt;">&#8221; means and includes all intellectual property or other proprietary rights under the laws of any jurisdiction in the world, including, without limitation: (a)&#160;rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, software, databases, and mask works; (b)&#160;trademarks, service marks, trade dress, logos, trade names and other source identifiers, domain names and URLs and similar rights and any and all goodwill associated therewith; (c)&#160;rights associated with trade secrets, know how, inventions, invention disclosures, methods, processes, protocols, specifications, techniques and other forms of technology; (d)&#160;patents and industrial property rights; and (e)&#160;other similar proprietary rights in intellectual property of every kind and nature; (f)&#160;rights of privacy and publicity; and (g)&#160;all registrations, renewals, extensions, statutory invention registrations, provisionals, continuations, continuations-in-part, provisionals, divisions, or reissues of, and applications for, any of the rights referred to in clauses &#8220;(a)&#8221; through &#8220;(f)&#8221; above (whether or not in tangible form and including all tangible embodiments of any of the foregoing, such as samples, studies and summaries), along with all rights to prosecute and perfect the same through administrative prosecution, registration, recordation or other administrative proceeding, and all causes of action and rights to sue or seek other remedies arising from or relating to the foregoing, including for past, present or future infringement of any of the foregoing. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Investor Agreements</font><font style="letter-spacing:0.2pt;">&#8221; means each stockholders agreement, voting agreement, registration rights agreement, co-sale agreement or other similar Contract between the Company and any holders of Company Common Stock, including any such Contract granting any Person investor rights, rights of first refusal, rights of first offer, registration rights, director designation rights or similar rights. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">IRS</font><font style="letter-spacing:0.2pt;">&#8221; means the United States Internal Revenue Service. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Key Employee</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to the Company or Parent, an executive officer of such Party or any employee of such Party that reports directly to the board of directors of such Party or to the chief executive officer or chief accounting officer of such party. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Knowledge</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to the Company or the Parent, that an individual identified on Schedule&#160;A of the Company Disclosure Schedule or Schedule&#160;A of the Parent Disclosure Schedule, as applicable, was actually aware on the date of this Agreement of the relevant fact. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Law</font><font style="letter-spacing:0.2pt;">&#8221; means any federal, state, national, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of Nasdaq or the Financial Industry Regulatory Authority). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Legal Proceeding</font><font style="letter-spacing:0.2pt;">&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Material Continuing Obligation</font><font style="letter-spacing:0.2pt;">&#8221; shall mean (a)&#160;any non-competition obligation affecting any of the assets or business of the Company as they exist as of the date of this Agreement, or (b)&#160;any Liability </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or other obligation which would require Parent, Company or any of their respective Subsidiaries, to, after the Effective Time, make any cash payment or expenditure in excess of $250,000, which would not be offset by the receipt of a future payment or contingent consideration. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub Board</font><font style="letter-spacing:0.2pt;">&#8221; means the board of directors of Merger Sub. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Nasdaq</font><font style="letter-spacing:0.2pt;">&#8221; means the Nasdaq Stock Market, LLC, including the Nasdaq Capital Market or such other Nasdaq market on which shares of Parent Common Stock are then listed. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Nasdaq Reverse Split</font><font style="letter-spacing:0.2pt;">&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock at a reverse stock split ratio as mutually agreed to by Parent and the Company that is effected by Parent for the purpose of maintaining compliance with Nasdaq listing standards. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Net Cash</font><font style="letter-spacing:0.2pt;">&#8221; means, as of any applicable time of determination and without duplication, (A)&#160;the sum of (i)&#160;cash and cash equivalents, marketable securities and other short-term investments of Parent and its Subsidiaries, (ii)&#160;accounts receivable (including any Tax refund claims pending as of the date of this Agreement), deposits and interest, (iii)&#160;deposits, prepaid expenses and other prepaid assets which are reflected on the most recent balance sheet and do not constitute restricted cash of Parent and its Subsidiaries, and (iv)&#160;50% of the cost of settling any Transaction Litigation to the extent actually paid in cash by Parent prior to the Closing Date, minus (B)&#160;the sum of (1)&#160;any unpaid Parent Transaction Expenses, (2)&#160;any unpaid indebtedness of Parent and/or its Subsidiaries outstanding as of the Closing Date, (3)&#160;any accounts payable, accrued expenses or short or long term liabilities that are or will become payable in cash, including any such accounts payable, accrued expenses or short or long term liabilities under any Parent Contracts which were in effect prior to the Effective Time or associated with the termination of any Parent Contracts which were in effect prior to the Effective Time, or the termination before, at or after the Effective Time, of all current or former employees of Parent and its Subsidiaries (even if the applicable expenses or amounts are due and payable after the Effective Time) pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.20(a)</font><font style="letter-spacing:0.2pt;"> (including, for clarity, any amounts in respect of the matters set forth on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;N</font><font style="letter-spacing:0.2pt;"> if reasonably estimable by Parent in good faith), (4)&#160;any unpaid employer portion of payroll or employment Taxes incurred in connection with the grant, exercise, conversion, settlement or cancellation of Parent RSUs, Parent Options, equity compensation and other change in control or severance payments (including bonuses payable) to be paid pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.20(a)</font><font style="letter-spacing:0.2pt;"> or CVRs issued to holders of Parent RSUs or Parent Options or otherwise as compensation (either incurred prior to or at the time of the Merger, and for the avoidance of doubt, not calculated as of the close of business on the Business Day prior to the Closing Date) in each case with respect to this clause (4), incurred in connection with the Merger by Parent at or prior to the Effective Time (even if payable after the Effective Time), (5)&#160;any pre-payment, termination, &#8220;end of term&#8221; or similar fee or charge payable to any lender in connection with the repayment of indebtedness by Parent at or prior to the Effective Time, (6)&#160;the amount of any cash dividend declared (or to be declared) but not yet paid as part of the Pre-Closing Dividend, (7)&#160;to the extent unpaid at Closing, the cost and/or premium of the D&amp;O Tail Policy, and (8)&#160;to the extent unpaid at Closing, (A)&#160;the cost of settling any Legal Proceeding or other dispute existing as of the date of this Agreement, as well as the unpaid deductible amount under the Parent&#8217;s insurance reasonably expected to be payable in connection with Legal Proceedings existing as of the date of this Agreement, and (B)&#160;if reasonably estimable by Parent in good faith as of the Closing Date, 50% of the cost of settling any Transaction Litigation. Each component of Net Cash, to the extent applicable, shall be determined in accordance with GAAP, applied on a basis consistent with the application of GAAP in the preparation of Parent&#8217;s most recent audited or reviewed financial statements. Net Cash shall be calculated excluding the effects of any payments or liabilities (including attorney&#8217;s fees and settlement costs) in respect of Dissenting Shares or any Transaction Litigation (other than as set forth in clause (8)(B)) and any payments which become due and payable after the Effective Time, if any, under that certain Share Purchase Agreement, dated September&#160;20, 2016, by and among Eleven Biotherapeutics, Inc., Viventia Bio Inc. and the other parties thereto. Net Cash shall be increased as necessary to account for any payments made by Parent to cover expenses or fees that are required to be shared pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3(a)</font><font style="letter-spacing:0.2pt;">. A sample calculation of Net Cash and its components is set forth on </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;E</font><font style="letter-spacing:0.2pt;"> for illustrative purposes only. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Ordinary Course of Business</font><font style="letter-spacing:0.2pt;">&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its normal operations and consistent in all material respects </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">with its past practices, taking into account any acts or omissions that have been or may be taken to comply with COVID-19 Measures or in good faith response to the COVID-19 pandemic, or otherwise to the extent necessary to avoid, mitigate or remediate a material adverse effect on the Company, Parent or any of their respective Subsidiaries or their respective businesses as may result from the COVID-19 pandemic, and subject to any reasonable changes required to address any then current facts and circumstances (including requirements to comply with applicable Law and guidelines and to reasonably preserve the health and safety of current employees and other service providers of the Company, Parent or any of their respective Subsidiaries); </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that any actions taken or not taken by the Company, Parent and any of their respective Subsidiaries reasonably and in good faith to respond to any other extraordinary event that was not reasonably foreseeable as of the date of this Agreement and occurring after the date of this Agreement that is outside of the control of the Company, Parent or their respective Affiliates, as applicable, shall be deemed to have been taken or not taken, as applicable, in the &#8220;Ordinary Court of Business.&#8221; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Organizational Documents</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to any Person (other than an individual), (a)&#160;the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b)&#160;all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Associate</font><font style="letter-spacing:0.2pt;">&#8221; means any current or former employee, independent contractor, officer or director of Parent or any of its Subsidiaries. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Balance Sheet</font><font style="letter-spacing:0.2pt;">&#8221; means the unaudited balance sheet of Parent as of June&#160;30, 2022 (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Balance Sheet Date</font><font style="letter-spacing:0.2pt;">&#8221;), included in Parent&#8217;s Report on Form 10-Q for the quarterly period ended June&#160;30, 2022, as filed with the SEC. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Board</font><font style="letter-spacing:0.2pt;">&#8221; means the board of directors of Parent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Capitalization Representations</font><font style="letter-spacing:0.2pt;">&#8221; means the representations and warranties of Parent and Merger Sub set forth in the first sentence of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;3.6(a)</font><font style="letter-spacing:0.2pt;"> and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.6(d)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Common Stock</font><font style="letter-spacing:0.2pt;">&#8221; means the common stock, $0.001 par value per share, of Parent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Contract</font><font style="letter-spacing:0.2pt;">&#8221; means any Contract: (a)&#160;to which Parent or any of its Subsidiaries is a party; (b)&#160;by which Parent, any of its Subsidiaries or any Parent IP or any other asset of Parent or any of its Subsidiaries is or may become bound or under which Parent or any of its Subsidiaries has, or may become subject to, any obligation; or (c)&#160;under which Parent or any of its Subsidiaries has or may acquire any right or interest. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent ERISA Affiliate</font><font style="letter-spacing:0.2pt;">&#8221; means any corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with Parent or any of its Subsidiaries as a single employer within the meaning of Section&#160;414 of the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent ESPP</font><font style="letter-spacing:0.2pt;">&#8221; means the Sesen Bio, Inc. 2014 Employee Stock Purchase Plan, as amended from time to time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Fundamental Representations</font><font style="letter-spacing:0.2pt;">&#8221; means the representations and warranties of Parent and Merger Sub set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Sections&#160;3.1</font><font style="letter-spacing:0.2pt;"> (Due Organization; Subsidiaries), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.3</font><font style="letter-spacing:0.2pt;"> (Authority; Binding Nature of Agreement), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.4</font><font style="letter-spacing:0.2pt;"> (Vote Required), </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.5(a)</font><font style="letter-spacing:0.2pt;"> (Non-Contravention) and </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.20</font><font style="letter-spacing:0.2pt;"> (No Financial Advisors). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent IP</font><font style="letter-spacing:0.2pt;">&#8221; means all Intellectual Property Rights that are owned or purported to be owned by, assigned to, or exclusively licensed by, Parent or its Subsidiaries that are necessary for or used in the operation of the business of Parent and its Subsidiaries as presently conducted. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Material Adverse Effect</font><font style="letter-spacing:0.2pt;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of Parent and its Subsidiaries, taken as a whole; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a)&#160;the announcement of this Agreement or the pendency of the Contemplated Transactions; (b)&#160;general business, economic or political conditions or conditions generally affecting the industry in which Parent and its Subsidiaries operate; (c)&#160;hurricane, flood, tornado, earthquake or other natural disaster, changes in weather conditions, epidemic, plague, pandemic (including COVID-19) or any other outbreak of illness or other public health event or any other force majeure event, whether or not caused by any Person, or an national or international calamity or crises, or any law, regulation, statute, directive, pronouncement or guideline issued by a Governmental Body, the World Health Organization or industry group providing for business closures, &#8220;sheltering-in-place,&#8221; curfews or other restrictions that relate to, or arise out of, an epidemic, pandemic or disease outbreak (including COVID-19) or any change in such law, regulation, statute, directive, pronouncement or guideline or interpretation thereof or any worsening of such conditions; (d)&#160;any COVID-19 Measures or COVID-19 Responses; (e)&#160;any acts, threats or escalations of war, armed hostilities or terrorism anywhere in the world or any governmental or other response or reaction to any of the foregoing; (f)&#160;changes in the trading price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), or the suspension of trading in or delisting of Parent&#8217;s securities on Nasdaq; (g)&#160;any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP); (h)&#160;with respect to any product or product candidate of Parent or any of its Subsidiaries, the request of the FDA to refile, amend, or temporarily delay making any regulatory application or filing related to such product or product candidate or the protocol for any clinical trial relating to such product or product candidate (provided that this clause (h)&#160;shall not apply in the event of repeated or continued adverse decisions with respect to Parent&#8217;s product or product candidates by the FDA); or (i)&#160;resulting from the taking of any action or the failure to take any action, by Parent that is expressly required to be taken by this Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that, in the case of clauses (b), (c), (d), (e), and (h), solely to the extent the impact on Parent and its Subsidiaries, taken as a whole, is disproportionately adverse compared to the impact on similarly situated companies operating in the industries in which Parent and its Subsidiaries operate, the incrementally disproportionate impact or impacts shall be taken into account in determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse Effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Options</font><font style="letter-spacing:0.2pt;">&#8221; means options or other rights to purchase shares of Parent Common Stock issued by Parent other than Parent Warrants. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent RSUs</font><font style="letter-spacing:0.2pt;">&#8221; means restricted stock&#160;units issued by Parent, whether time-based or performance based vesting. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Stock Plans</font><font style="letter-spacing:0.2pt;">&#8221; means the Sesen Bio, Inc. 2014 Stock Incentive Plan and the Sesen Bio, Inc. 2009 Stock Incentive Plan, in each case, as amended from time to time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Transaction Expenses</font><font style="letter-spacing:0.2pt;">&#8221; means as of the applicable time of determination and without duplication, the sum of (a)&#160;the cash cost of any accrued and unpaid retention payments or other bonuses, as well as any change of control payments or severance, termination or similar payments that are due or become due to any current or former employee, director or independent contractor of Parent or any of its Subsidiaries at or prior to the Effective Time otherwise in connection with the Merger or the Contemplated Transactions (and, for the avoidance of doubt, shall exclude any payments under arrangements entered into by Parent after the Effective Time), and (b)&#160;subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;9.3</font><font style="letter-spacing:0.2pt;">, all costs, fees and expenses incurred by Parent or its Subsidiaries at or prior to the Effective Time in connection with the negotiation, preparation and execution of this Agreement or any agreements, documents, certificate, opinions or other items contemplated hereby and the consummation of the Merger or the Contemplated Transactions and that are unpaid as of the Effective Time, including brokerage fees and commissions, finder&#8217;s fees, legal fees or financial advisory fees payable or otherwise incurred by such person at or prior to the Effective Time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Triggering Event</font><font style="letter-spacing:0.2pt;">&#8221; shall be deemed to have occurred if: (a)&#160;Parent shall have failed to include in the Proxy Statement/Prospectus the Parent Board Recommendation or shall have made a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Parent Board Adverse Recommendation Change; (b)&#160;the Parent Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal; or (c)&#160;Parent shall have entered into any letter of intent or similar document relating to any Acquisition Proposal (other than a confidentiality agreement permitted pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.4</font><font style="letter-spacing:0.2pt;">). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Warrants</font><font style="letter-spacing:0.2pt;">&#8221; means the warrants to purchase capital stock of Parent listed in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;B</font><font style="letter-spacing:0.2pt;"> of the Parent Disclosure Schedule. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Party</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parties</font><font style="letter-spacing:0.2pt;">&#8221; means the Company, Merger Sub and Parent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Permitted Encumbrance</font><font style="letter-spacing:0.2pt;">&#8221; means: (a)&#160;any liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith and, in each case, for which adequate reserves have been made on the Company Unaudited Interim Balance Sheet or the Parent Balance Sheet, as applicable; (b)&#160;minor liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets or properties subject thereto or materially impair the use thereof or the operations of the Company or any of its Subsidiaries or Parent, as applicable; (c)&#160;statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements; (d)&#160;deposits or pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by Law in the Ordinary Course of Business; (e)&#160;non-exclusive licenses of Intellectual Property Rights granted by the Company or any of its Subsidiaries or Parent or any of its Subsidiaries, as applicable, in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the Intellectual Property Rights subject thereto; and (f)&#160;statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Person</font><font style="letter-spacing:0.2pt;">&#8221; means any individual, Entity or Governmental Body. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Potentially Transferable Assets</font><font style="letter-spacing:0.2pt;">&#8221; means the non-cash assets of Parent existing as of the date of this Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Pre-Closing Financing</font><font style="letter-spacing:0.2pt;">&#8221; means an acquisition of capital stock of the Company to be consummated immediately prior to the Closing pursuant to the Subscription Agreements. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proxy Statement/Prospectus</font><font style="letter-spacing:0.2pt;">&#8221; means the proxy statement/prospectus, which shall be included in the Registration Statement, to be sent to Parent&#8217;s stockholders in connection with the Parent Stockholders&#8217; Meeting. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Registration Statement</font><font style="letter-spacing:0.2pt;">&#8221; means the registration statement on Form S-4 (or any other applicable form under the Securities Act to register Parent Common Stock) to be filed with the SEC by Parent registering the public offering and sale of Parent Common Stock to holders of Company Capital Stock and the Company Convertible Note in the Merger or the Conversion, as applicable, as may be amended prior to the time it is declared effective by the SEC. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Representatives</font><font style="letter-spacing:0.2pt;">&#8221; means directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and representatives. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Sarbanes-Oxley Act</font><font style="letter-spacing:0.2pt;">&#8221; means the Sarbanes-Oxley Act of 2002. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">SEC</font><font style="letter-spacing:0.2pt;">&#8221; means the United States Securities and Exchange Commission. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Securities Act</font><font style="letter-spacing:0.2pt;">&#8221; means the Securities Act of 1933, as amended. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Subscription Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means any stock purchase agreement, as well as related investment agreements, entered into among the Company and the Person(s) named therein, pursuant to which such Persons have agreed to purchase immediately prior to the Effective Time the number of shares of capital stock of the Company set forth therein in connection with the Pre-Closing Financing. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Subsequent Transaction</font><font style="letter-spacing:0.2pt;">&#8221; means any Acquisition Transaction (with all references to 15% in the definition of Acquisition Transaction being treated as references to 50% for these purposes). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Subsidiary</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to a Person, another entity of which such Person directly or indirectly owns or purports to own, beneficially or of record, (a)&#160;an amount of voting securities or other interests that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body, or (b)&#160;at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Superior Offer</font><font style="letter-spacing:0.2pt;">&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 15% in the definition of Acquisition Transaction being treated as references to 70% for these purposes) that: (a)&#160;was not obtained or made as a direct or indirect result of a breach of (or in violation of) this Agreement; (b)&#160;is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof, the financing terms thereof, any termination or break-up fees and conditions to consummation), as well as any written offer by the other Party this Agreement to amend the terms of this Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable to Parent&#8217;s stockholders or the Company&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions; (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party); and (d)&#160;is reasonably capable of being completed on the terms proposed without unreasonable delay. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Takeover Statute</font><font style="letter-spacing:0.2pt;">&#8221; means any &#8220;fair price,&#8221; &#8220;moratorium,&#8221; &#8220;control share acquisition&#8221; or other similar anti-takeover Law. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Tax</font><font style="letter-spacing:0.2pt;">&#8221; means any federal, state, local, foreign or other tax, including any income, capital gain, gross receipts, capital stock, profits, transfer, estimated, registration, stamp, premium, escheat, unclaimed property, customs duty, ad valorem, occupancy, occupation, alternative, add-on, windfall profits, value added, severance, property, business, production, sales, use, license, excise, franchise, employment, payroll, social security, disability, unemployment, workers&#8217; compensation, national health insurance, withholding or other taxes, duties, fees, assessments or governmental charges in the nature of a tax, surtaxes or deficiencies thereof of any kind whatsoever, however denominated, and including any fine, penalty, addition to tax or interest imposed by a Governmental Body with respect thereto. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Tax Return</font><font style="letter-spacing:0.2pt;">&#8221; means any return (including any information return), report, statement, declaration, estimate, schedule, notice, notification, form, election, certificate or other document, and any amendment or supplement to any of the foregoing, filed with or submitted to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Treasury Regulations</font><font style="letter-spacing:0.2pt;">&#8221; means the United States Treasury regulations promulgated under the Code. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">WARN Act</font><font style="letter-spacing:0.2pt;">&#8221; means the Worker Adjustment and Retraining Notification Act of 1988, as amended, or any similar state or local plant closing mass layoff statute, rule or regulation. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Each of the following terms is defined in the Section set forth opposite such term: </font>
        </div>
        <table style="width:416pt;height:143.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Term </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:41pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Section </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting Firm </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.11(e) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">Agreement </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Preamble </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Allocation Certificate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.16(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Anti-Bribery Laws </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.22 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Anticipated Closing Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.11(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Asset Disposition </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">4.7(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Asset Dispositions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">4.7(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Book-Entry Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.6 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Business Associate Agreements </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.14(h) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:653.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Term </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:41pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Section </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash Determination Time </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.11(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Certificate of Merger </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.3 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">Certifications </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.7(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">Closing </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.3 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Closing Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.3 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">Company </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Preamble </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Benefit Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.17(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Board Adverse Recommendation Change </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.3(b) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Board Recommendation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.3(b) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Convertible Note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.6(a)</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Designees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.12 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Disclosure Schedule </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;2 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Financial Statements </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.7(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company In-bound License </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.12(d) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Lock-Up Agreement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Recitals </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Material Contract </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.13(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Material Contracts </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.13(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Out-bound License </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.12(d) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Permits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.14(c) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Real Estate Leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.11 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Registered IP </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.12(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Signatories </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Recitals </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Stock Certificate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.6 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Stockholder Matters </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.3(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Stockholder Support Agreement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Recitals </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Stockholder Written Consent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.4 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Company Termination Fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">9.3(b) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">CVR </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.21 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">CVR Agreement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.21 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">D&amp;O Indemnified Parties </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.6(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">D&amp;O Tail Policy </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.6(d) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Delivery Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.11(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dispute Notice </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.11(b) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dissenting Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.8(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Drug Regulatory Agency </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.14(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Effective Time </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.3 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">End Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">9.1(b) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange Agent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.7(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exchange Fund </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.7(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">FDA </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.14(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">FDCA </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.14(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Final Net Cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.11(c) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">GCP </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.14(e) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:653.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Term </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:41pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Section </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">GLP </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.14(e) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">HIPAA </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.14(h) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Intended Tax Treatment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.10(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">Liability </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.9 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">LoT </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.7(b) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">Merger </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Recitals </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Merger Consideration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.5(a)(ii) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Merger Sub </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Preamble </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nasdaq Listing Application </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.9 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Cash Calculation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.11(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net Cash Schedule </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.11(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Notice Period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.3(c) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">Parent </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Preamble </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Benefit Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.17(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Board Adverse Recommendation Change </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.4(c) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Board Recommendation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.4(c) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Designees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.12 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Disclosure Schedule </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Section&#160;3 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent In-bound License </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.12(d) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Lock-Up Agreement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Recitals </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Material Contract </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.13(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Material Contracts </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.13(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Out-bound License </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.12(d) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Permits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.14(c) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Real Estate Leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.11 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Registered IP </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.12(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent SEC Documents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.7(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Signatories </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Recitals </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Stockholder Matters </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.4(a)(iii) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Stockholder Support Agreement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">Recitals </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Stockholders&#8217; Meeting </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.4(a)(iii) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Parent Termination Fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">9.3(c) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <font style="letter-spacing:0.2pt;">PHSA </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.14(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pre-Closing Dividend </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.21 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pre-Closing Period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">4.1(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Required Company Stockholder Vote </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.4 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Required Parent Stockholder Vote </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">3.4 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Response Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.11(b) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sale Agreement </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">4.7(b) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sensitive Data </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">2.12(g) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Surviving Corporation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">1.1 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Terminated Parent Associate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.20(a) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:363pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Transaction Litigation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:41pt;">
              <font style="letter-spacing:0.2pt;">5.19</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1-83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT B-1</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Form of Company Stockholder Support Agreement </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT B-2</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Form of Parent Stockholder Support Agreement </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT C-1</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Form of Company Lock-Up Agreement </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT C-2</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Form of Parent Lock-Up Agreement </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT D</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Form of CVR Agreement </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT E</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Net Cash Illustrative Calculations </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT F</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Form of Certificate of Merger </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT G</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Form of Company Stockholder Written Consent </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT H</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Exchange Ratio Calculation </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Schedule&#160;5.7</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Additional Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">None. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Schedule&#160;5.12</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Post-Closing Directors and Officers of Parent and the Surviving Corporation </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC6">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Schedule&#160;N</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tFAAP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX A-2</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FIRST AMENDMENT TO </font>
          <br >
          <font style="letter-spacing:-0.2pt;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">THIS FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</font><font style="letter-spacing:0.2pt;"> (this &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">First Amendment</font><font style="letter-spacing:0.2pt;">&#8221;) is made and entered into and made as of December&#160;29, 2022, by and among </font><font style="font-weight:bold;letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="letter-spacing:0.2pt;">, a Delaware corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221;), </font><font style="font-weight:bold;letter-spacing:-0.2pt;">SEAHAWK MERGER SUB, INC.</font><font style="letter-spacing:0.2pt;">, a Delaware corporation and wholly-owned subsidiary of Parent (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub</font><font style="letter-spacing:0.2pt;">&#8221;), and </font><font style="font-weight:bold;letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font><font style="letter-spacing:0.2pt;">, a Delaware corporation (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;). Parent, Merger Sub and the Company are sometimes individually referred to herein as a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Party</font><font style="letter-spacing:0.2pt;">&#8221; or collectively referred to herein as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parties</font><font style="letter-spacing:0.2pt;">&#8221;. Unless otherwise defined herein, capitalized terms shall have the meanings set forth in the Merger Agreement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RECITALS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A.&nbsp;&nbsp;&nbsp;The Parties previously entered into that certain Agreement and Plan of Merger and Reorganization dated as of September&#160;20, 2022 (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Agreement</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B.&nbsp;&nbsp;&nbsp;Section&#160;10.2 of the Merger Agreement provides that the Merger Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Sub and Parent at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C.&nbsp;&nbsp;&nbsp;The Parties desire to amend the Merger Agreement pursuant to the terms and conditions of this First Amendment and the respective boards of directors of the Company, Merger Sub and Parent have each approved this First Amendment to be effective as of the date hereof. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Parties, intending to be legally bound, agree as follows: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.&nbsp;&nbsp;&nbsp;AMENDMENT TO SECTION 3.24 &#8220;Opinion of Financial Advisor&#8221;. Section&#160;3.24 &#8220;Opinion of Financial Advisor&#8221; of the Merger Agreement is hereby deleted in its entirety and replaced with the following: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Opinion of Financial Advisor</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Parent Board has received an opinion of SVB Securities LLC to the effect that, as of the date of this First Amendment and subject to the assumptions, qualifications, limitations and other matters set forth therein, the Exchange Ratio is fair, from a financial point of view, to Parent. It is agreed and understood that such opinion is for the benefit of the Parent Board and may not be relied upon by the Company or any other party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.&nbsp;&nbsp;&nbsp;AMENDMENT TO SECTION 5.21 &#8220;Pre-Closing Dividend&#8221;. Section&#160;5.21 &#8220;Pre-Closing Dividend&#8221; of the Merger Agreement is hereby deleted in its entirety and replaced with the following: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;5.21&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Pre-Closing Dividend</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Prior to the Effective Time, Parent shall (a)&#160;declare a dividend (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Pre-Closing Dividend</font><font style="letter-spacing:0.2pt;">&#8221;) to its common stockholders of record consisting of (i)&#160;the right to receive one contingent value right (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR</font><font style="letter-spacing:0.2pt;">&#8221;) for each outstanding share of Parent Common Stock held by such stockholder as of such date, each representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the Contingent Value Rights Agreement in the form attached hereto as </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Exhibit&#160;D</font><font style="letter-spacing:0.2pt;"> (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) and (ii)&#160;cash equal to or greater than $70,000,000 in the aggregate, subject to satisfaction of Parent&#8217;s obligation set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.5</font><font style="letter-spacing:0.2pt;"> (and, for clarity, such cash dividend shall be reduced by any excess amount necessary to cause Parent to satisfy its obligation set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;8.5</font><font style="letter-spacing:0.2pt;">) and (b)&#160;make any necessary equitable adjustment required under the Parent Stock Plans. The record date for the Pre-Closing Dividend shall be a date agreed by Parent and the Company prior to the Effective Time and the payment date for which shall be three Business Days after the Effective Time; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the payment of such dividend may be conditioned upon the occurrence of the Effective Time. In connection with the Pre-Closing Dividend, Parent shall cause the CVR Agreement to be duly authorized, executed and delivered by Parent and a rights agent selected by Parent with the Company&#8217;s prior approval (such approval not to be unreasonably withheld, delayed or conditioned).&#8221; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:156pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.&nbsp;&nbsp;&nbsp;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">AMENDMENT TO EXHIBIT D &#8220;Form of Contingent Value Right Agreement&#8221;.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Exhibit&#160;D to the Merger Agreement shall be deleted in its entirety and replaced with the form attached hereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.&nbsp;&nbsp;&nbsp;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">AMENDMENT TO SECTION 8.5 &#8220;Minimum Parent Final Net Cash&#8221;.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Section&#160;8.5 &#8220;Minimum Parent Final Net Cash&#8221; of the Merger Agreement is hereby deleted in its entirety and replaced with the following: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;8.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Minimum Parent Final Net Cash</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Final Net Cash shall have been determined in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;1.11</font><font style="letter-spacing:0.2pt;"> to be greater than or equal to $75,000,000.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.&nbsp;&nbsp;&nbsp;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">APPLICABLE LAW.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This First Amendment shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6.&nbsp;&nbsp;&nbsp;HEADINGS.&nbsp;&nbsp;&nbsp;The bold-faced headings contained in this First Amendment are for convenience of reference only, shall not be deemed to be a part of this First Amendment and shall not be referred to in connection with the construction or interpretation of this First Amendment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7.&nbsp;&nbsp;&nbsp;ASSIGNABILITY.&nbsp;&nbsp;&nbsp;This First Amendment shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that neither this First Amendment nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this First Amendment or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8.&nbsp;&nbsp;&nbsp;CONSTRUCTION.&nbsp;&nbsp;&nbsp;The terms of this First Amendment amend and modify the Merger Agreement as if fully set forth in the Merger Agreement. Upon the effectiveness of this First Amendment, all references in the Merger Agreement to &#8220;the Agreement&#8221; or &#8220;this Agreement,&#8221; as applicable, shall refer to the Merger Agreement, as modified by this First Amendment. If there is any conflict between the terms, conditions and obligations of this First Amendment and the Merger Agreement, this First Amendment&#8217;s terms, conditions and obligations shall control. All other provisions of the Merger Agreement not specifically modified by this First Amendment are expressly preserved. This First Amendment may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed First Amendment (in counterparts or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this First Amendment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.&nbsp;&nbsp;&nbsp;AUTHORITY.&nbsp;&nbsp;&nbsp;By their execution of this First Amendment, the undersigned Parties hereby confirm that they are duly authorized to execute this First Amendment and any necessary requisite approval has been obtained with respect to this First Amendment and all matters set forth herein. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(Remainder of page intentionally left blank)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">IN WITNESS WHEREOF</font><font style="letter-spacing:0.2pt;">, the Parties have caused this First Amendment to be executed as of the date first above written. </font>
        </div>
        <table style="width:456pt;height:233pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:-0.2pt;">SESEN BIO, INC. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:14.38pt;">
              <font style="letter-spacing:0.2pt;">By:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:208.81pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Thomas Cannell</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 208.81pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:14.38pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:208.81pt;white-space:normal;">
              <div style=" float:left; line-height:10pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Name:</font>
                <br >
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:36pt;">
                <font style="letter-spacing:0.2pt;">Thomas Cannell </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:14.38pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:208.81pt;white-space:normal;">
              <div style=" float:left; line-height:10pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Title:</font>
                <br >
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:36pt;">
                <font style="letter-spacing:0.2pt;">President and Chief Executive Officer </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.5pt 0pt 1.833pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:-0.2pt;">SEAHAWK MERGER SUB, INC. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:14.38pt;">
              <font style="letter-spacing:0.2pt;">By:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:208.81pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Mark Sullivan</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 208.81pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:14.38pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:208.81pt;white-space:normal;">
              <div style=" float:left; line-height:10pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Name:</font>
                <br >
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:36pt;">
                <font style="letter-spacing:0.2pt;">Mark Sullivan </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:14.38pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:208.81pt;white-space:normal;">
              <div style=" float:left; line-height:10pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Title:</font>
                <br >
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:36pt;">
                <font style="letter-spacing:0.2pt;">President, Secretary &amp; Treasurer </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.5pt 0pt 1.833pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:14.38pt;">
              <font style="letter-spacing:0.2pt;">By:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:208.81pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Steven Kelly</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 208.81pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:14.38pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:208.81pt;white-space:normal;">
              <div style=" float:left; line-height:10pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Name:</font>
                <br >
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:36pt;">
                <font style="letter-spacing:0.2pt;">Steven Kelly </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:208.81pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:14.38pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:208.81pt;white-space:normal;">
              <div style=" float:left; line-height:10pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Title:</font>
                <br >
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:36pt;">
                <font style="letter-spacing:0.2pt;">Chief Executive Officer</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[</font><font style="font-style:italic;letter-spacing:0.2pt;">Signature Page to First Amendment to Agreement and Plan of Merger and Reorganization</font><font style="letter-spacing:0.2pt;">] </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT D</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Form of CVR Agreement </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONTINGENT VALUE RIGHTS AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [&#8226;], 2023 (this &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), is entered into by and among Sesen Bio, Inc., a Delaware corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221;), and Computershare Inc. (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Computershare</font><font style="letter-spacing:0.2pt;">&#8221;) and its affiliate, Computershare Trust Company, N.A., together, as the Rights Agent. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RECITALS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, Parent, Seahawk Merger Sub, Inc., a Delaware corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub</font><font style="letter-spacing:0.2pt;">&#8221;), and CARISMA Therapeutics Inc., a Delaware corporation (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;), have entered into an Agreement and Plan of Merger and Reorganization, dated as of September&#160;20, 2022 (as it may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving the Merger as a subsidiary of Parent; and </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, pursuant to the Merger Agreement, Parent has agreed to provide to the holders of record of Parent&#8217;s common stock, par value $0.001 per share (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Common Stock</font><font style="letter-spacing:0.2pt;">&#8221;), immediately prior to the Effective Time, the right to receive certain contingent cash payments, on the terms and subject to the conditions hereinafter described. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">NOW, THEREFORE, in consideration of the foregoing and the consummation of the transactions referred to above, Parent and the Rights Agent agree, for the proportionate benefit of all Holders (as hereinafter defined), as follows: </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.&nbsp;&nbsp;&nbsp;DEFINITIONS; CERTAIN RULES OF CONSTRUCTION </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">1.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Definitions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Capitalized terms used but not otherwise defined herein will have the meanings ascribed to them in the Merger Agreement, unless expressly set forth otherwise herein. As used in this Agreement, the following terms will have the following meanings: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquiror</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquisition</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acting Holders</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3(d)</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Affiliate</font><font style="letter-spacing:0.2pt;">&#8221; of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term &#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Preamble. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Asset Disposition Proceeds</font><font style="letter-spacing:0.2pt;">&#8221; means, without duplication, any and all consideration of any kind that is paid to Parent, or is received by, Parent or any of its Affiliates during the period specified in clause (b)&#160;of the definition of CVR Term in respect of an Asset Disposition, if any. The value of any securities (whether debt or equity) or other non-cash property constituting Asset Disposition Proceeds shall be determined as follows: (A)&#160;the value of securities for which there is an established public market shall be equal to the volume weighted average of their closing market prices for the five (5)&#160;trading days ending the day prior to the date of payment to, or receipt by, Parent or its relevant Affiliate, and (B)&#160;the value of securities that have no established public market and the value of consideration that consists of other non-cash property, shall be the fair market value thereof as of the date of payment to, or receipt by, Parent or its relevant Affiliate. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Assignee</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Board of Directors</font><font style="letter-spacing:0.2pt;">&#8221; means the board of directors of Parent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Board Resolution</font><font style="letter-spacing:0.2pt;">&#8221; means a copy of the resolution(s) certified by the secretary or an assistant secretary (or other comparable officer) of Parent that have been duly adopted by the Board of Directors and are in full force and effect on the date of such approval, and delivered to the Rights Agent. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Business Day</font><font style="letter-spacing:0.2pt;">&#8221; means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be closed. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Recitals. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Computershare</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Preamble. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Payment</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Payment Amount</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to each Holder, an amount equal to (a)&#160;(i)&#160;the applicable Total Payment Amount, less (ii)&#160;applicable accrued and documented Permitted Deductions, as calculated in accordance with GAAP, divided by (b)&#160;the total number of CVRs and then multiplied by the total number of CVRs held by such Holder as reflected on the CVR Register (rounded down to the nearest whole cent). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Register</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.3(b)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Sale Assets</font><font style="letter-spacing:0.2pt;">&#8221; means any and all assets, tangible and intangible, including, without limitation, patents, patent applications, know-how, trade secrets and other intellectual property rights, data, documentation, agreements and licenses, inventory related to Vicineum</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">TM</font><font style="letter-spacing:0.2pt;">, also known as VB4-845, which Parent or any of its subsidiaries owned or had rights to, as of immediately prior to the Effective Time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Term</font><font style="letter-spacing:0.2pt;">&#8221; means (a)&#160;with respect to any Roche Payment Amount, the period beginning on the date hereof and ending on the earlier of (i)&#160;the CVR Payment being delivered to each Holder in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4</font><font style="letter-spacing:0.2pt;"> of this Agreement, and (ii)&#160;March&#160;31, 2027, and (b)&#160;with respect to any Disposition or Asset Disposition or otherwise in respect of Asset Disposition Proceeds, the period beginning on the date hereof and ending on December&#160;31, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVRs</font><font style="letter-spacing:0.2pt;">&#8221; means the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Disposition</font><font style="letter-spacing:0.2pt;">&#8221; means the sale, license, transfer, disposition or other monetizing event of any CVR Sale Assets, in each case (i)&#160;during the period set forth in clause (b)&#160;of the definition of CVR Term and (ii)&#160;in a transaction identified by Parent&#8217;s financial advisor who was engaged as of the Effective Time for the purpose of identifying and proposing a potential Disposition transaction to Parent. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">DTC</font><font style="letter-spacing:0.2pt;">&#8221; means The Depository Trust Company or any successor thereto. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Funds</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.9</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Holder</font><font style="letter-spacing:0.2pt;">&#8221; means a Person in whose name a CVR is registered in the CVR Register at the applicable time. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Agreement</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Recitals. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Recitals. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Officer&#8217;s Certificate</font><font style="letter-spacing:0.2pt;">&#8221; means a certificate signed by the chief executive officer, president, chief financial officer, any vice president, the controller, the treasurer or the secretary, in each case of Parent, in his or her capacity as such an officer, and delivered to the Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Preamble. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Common Stock</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Recitals. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Permitted Deductions</font><font style="letter-spacing:0.2pt;">&#8221; means the following costs or expenses, without duplication (as approved by the Board of Directors, including, if applicable, the Parent Designee (as defined in the Merger Agreement)): </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;any applicable Tax (including any unreimbursed applicable value added or sales tax) imposed on the Total Payment Amount and payable by Parent or any of its Affiliates to any tax authority and, without duplication, any income or other similar Taxes payable by Parent or any of its Affiliates that would not have been incurred by Parent or any of its Affiliates but for the Total Payment Amount; provided that, for purposes of calculating income Taxes incurred by Parent and its Affiliates in respect </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of the Total Payment Amount, any such income Taxes shall be computed after reduction for any net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries (owned prior to the Merger) as of the Closing Date that are available to the maximum extent permitted by law to offset such gain after taking into account any limits on the usability of such attributes, including under Section&#160;382 of the Code, in each case, as reasonably determined by a nationally recognized tax advisor (and for the sake of clarity such income taxes shall be calculated without taking into account any net operating losses or other Tax attributes generated by Parent or its subsidiaries after the Closing Date or any Tax attributes of the Company, whether generated before or after the Closing Date), assuming for this purpose that (i)&#160;the only item of gross income of Parent and its subsidiaries is the Total Payment Amount (for the avoidance of doubt, assuming that the Total Payment Amount is taxable in the hands of Parent or its subsidiaries no later than the taxable year that includes the corresponding CVR Payment), and (ii)&#160;the net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries shall only include any net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries (owned prior to the Merger) existing as of immediately prior to the Merger for U.S. federal income tax purposes and applicable state and local income tax purposes; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;any reasonable and documented out-of-pocket expenses incurred by Parent or any of its Affiliates in respect of its performance of this Agreement following the Effective Time, losses incurred and paid by Parent or any of its Affiliates following the Effective Time arising out of any Legal Proceeding relating to or in connection with (i)&#160;an Asset Disposition, (ii)&#160;Parent&#8217;s, Roche&#8217;s or any of their respective Affiliates&#8217; obligations under the Roche Agreement or (iii)&#160;otherwise with respect to the Total Payment Amount; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;any Liabilities that were ascertainable prior to or at the Effective Time which Parent reasonably and in good faith determines should have been, but were not, deducted from &#8220;Net Cash&#8221; &#8203;(as defined in the Merger Agreement), in connection with the Closing of the Merger, to the extent that deduction of such Liabilities would have resulted in a change in the Exchange Ratio under the Merger Agreement were such amounts properly deducted; </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">provided that no Permitted Deductions shall be deducted to the extent they were otherwise deducted from the calculation of Net Cash (as defined in the Merger Agreement). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Permitted Transfer</font><font style="letter-spacing:0.2pt;">&#8221; means a transfer of CVRs: (a)&#160;on death of a Holder by will or intestacy; (b)&#160;by instrument to an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (c)&#160;pursuant to a court order; (d)&#160;made by operation of law (including a consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (e)&#160;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner (through an intermediary if applicable) or from a nominee to another nominee for the same beneficial owner, to the extent allowable by DTC; (f)&#160;a transfer from a participant&#8217;s account in a tax-qualified employee benefit plan to the participant or to such participant&#8217;s account in a different tax-qualified employee benefit plan or to a tax-qualified individual retirement account for the benefit of such participant; (g)&#160;to Parent or its Affiliates for any or no consideration; or (h)&#160;as provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.6</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Person</font><font style="letter-spacing:0.2pt;">&#8221; means any natural person, corporation, limited liability company, trust, unincorporated association, partnership, joint venture or other entity. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Record Time</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.3(e)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Rights Agent</font><font style="letter-spacing:0.2pt;">&#8221; means the Rights Agent named in the Preamble, until a successor Rights Agent will have become such pursuant to the applicable provisions of this Agreement, and thereafter &#8220;Rights Agent&#8221; will mean such successor Rights Agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Roche</font><font style="letter-spacing:0.2pt;">&#8221; means the collective reference to F. Hoffman-La Roche Ltd and Hoffmann La Roche Inc. or its successors or any of its or their respective Affiliates; provided, that neither Chugai Pharmaceutical Co., Ltd, a Japanese corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Chugai</font><font style="letter-spacing:0.2pt;">&#8221;) nor its subsidiaries (if any) shall be deemed as Affiliates of Roche unless Roche provides written notice to Parent of its desire to include Chugai or its respective subsidiaries (as applicable) as Affiliate(s) of Roche. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">RocheAgreement</font><font style="letter-spacing:0.2pt;">&#8221; means that certain Asset Purchase Agreement, dated as of July&#160;15, 2022, by and among F. Hoffman-La Roche Ltd, Hoffmann La Roche Inc. and Parent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Roche Payment Amount</font><font style="letter-spacing:0.2pt;">&#8221; means the thirty million dollar ($30,000,000) milestone payment to be made by Roche to Parent upon the initiation of a phase III clinical study in diabetic macular disorder with the compound known as &#8220;EBI-031&#8221; during the CVR Term, as set forth in Section&#160;11.1 of the Roche Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Third Party</font><font style="letter-spacing:0.2pt;">&#8221; means any Person other than Parent, Rights Agent or their respective Affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Total Payment Amount</font><font style="letter-spacing:0.2pt;">&#8221; means, as of any applicable time of determination, any Asset Disposition Proceeds plus any Roche Payment Amounts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">1.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Rules of Construction</font><font style="letter-spacing:0.2pt;">. Except as otherwise explicitly specified to the contrary, (a)&#160;whenever the context requires, the singular number shall include the plural, and vice versa; (b)&#160;the masculine gender shall include the feminine gender and neuter genders, the feminine gender shall include the masculine and neuter genders, and the neuter genders shall include masculine and feminine genders; (c)&#160;the word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and does not simply mean &#8220;if&#8221;; (d)&#160;the word &#8220;including&#8221; &#8203;(in its various forms) means &#8220;including without limitation&#8221;; (e)&#160;references to a &#8220;Section&#8221; means a Section of this Agreement unless another agreement is specified; (f)&#160;references to a particular statute or regulation include all rules and regulations thereunder and any predecessor or successor statute, rules or regulation, in each case as amended or otherwise modified from time to time; (g)&#160;words in the singular or plural form include the plural and singular form, respectively; (h)&#160;references to a particular Person include such Person&#8217;s successors and assigns to the extent not prohibited by this Agreement; (i)&#160;the word &#8220;or&#8221; shall not be exclusive (i.e., &#8220;or&#8221; shall be deemed to mean &#8220;and/or&#8221;) unless the subject of the conjunction are mutually exclusive; and (j)&#160;all references to dollars or &#8220;$&#8221; refer to United States dollars. For clarity, the parties agree that the phrase &#8220;materially adverse&#8221; when used in this Agreement with respect to the Holders includes any amendment or other action, as applicable, that does or would be reasonably expected to reduce, eliminate, or materially delay the Roche Payment Amount. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.&nbsp;&nbsp;&nbsp;CONTINGENT VALUE RIGHTS </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">CVRs; Appointment of Rights Agent.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Each Holder is entitled to one CVR in the form of a dividend for each share of Parent Common Stock held by such Holder as of the Record Time. The CVRs represent the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement. The initial Holders will be the holders of Parent Common Stock as of immediately prior to the Effective Time, and a list of the initial Holders shall be furnished to the Rights Agent by or on behalf of Parent in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.1</font><font style="letter-spacing:0.2pt;"> hereof. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Parent hereby appoints the Rights Agent to act as rights agent for Parent as contemplated hereby in accordance with the express terms and conditions set forth in this Agreement (and no implied terms or conditions), and the Rights Agent hereby accepts such appointment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent intends to treat the issuance of the CVRs as a distribution of property by Parent to the holders of Parent Common Stock for U.S. federal income tax purposes. Consistent with such intended tax treatment, Parent will timely send Forms 1099-DIV to all Holders notifying them of the portion of the CVR value that is a nondividend distribution (or a dividend to the extent of Parent&#8217;s earnings and profits) for U.S. federal income tax purposes, and take all necessary steps to file its tax returns and any information statements consistent with such tax treatment. Parent will determine, in consultation with and with the consent of the Parent Designee, the fair market value of the CVRs in connection with the issuance and Parent will utilize such fair market value for purposes of all tax reporting (including on Forms 1099-DIV) with respect to the CVR. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Nontransferable</font><font style="letter-spacing:0.2pt;">. The CVRs shall not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. Any attempted sale, assignment, transfer, pledge, encumbrance, transfer or disposition, in whole or in part, that is not a Permitted Transfer will be void </font><font style="font-style:italic;letter-spacing:0.2pt;">ab initio</font><font style="letter-spacing:0.2pt;"> and of no effect. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Certificate; Registration; Registration of Transfer; Change of Address</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The CVRs will not be evidenced by a certificate or other instrument. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Rights Agent will create and keep a register (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Register</font><font style="letter-spacing:0.2pt;">&#8221;) for the purpose of identifying the Holders and registering CVRs and transfers of CVRs as permitted herein. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from Parent. The CVR Register will initially show one position for Cede &amp; Co. representing all the CVRs provided to the holders of shares of Parent Common Stock held as of immediately prior to the Effective Time. The Rights Agent will have no responsibility whatsoever directly to the street name holders or DTC participants with respect to transfers of CVRs unless and until such CVRs are transferred into the name of such street name holders or DTC participants in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;"> of this Agreement. With respect to any payments to be made under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;"> below, the Rights Agent will accomplish the payment to any former street name holders of shares of Parent Common Stock by sending one lump-sum payment to DTC. The Rights Agent will have no responsibilities whatsoever with regard to the distribution of payments by DTC to such street name holders. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Subject to the restrictions on transferability set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;">, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer and other reasonably requested documentation in form reasonably satisfactory to the Rights Agent, duly executed by the Holder thereof or the Holder&#8217;s attorney duly authorized in writing, personal representative or survivor and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form, notify Parent that it has received such written notice. Upon receipt of such notice from the Rights Agent, Parent shall determine whether the transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;">), and if it determines that it does so comply, Parent shall instruct the Rights Agent in writing to register the transfer of the CVRs in the CVR Register and notify Parent of the same. No service charge shall be made for any registration of transfer of a CVR; however Parent and the Rights Agent may require payment of a sum sufficient to cover any stamp or other tax or governmental charge that is imposed in connection with any such registration of transfer. The Rights Agent shall have no duty or obligation to take any action under any section of this Agreement that requires the payment by a Holder of applicable taxes or charges unless and until the Rights Agent is satisfied that all such taxes or charges have been paid or will be paid. All duly transferred CVRs registered in the CVR Register will be the valid obligations of Parent and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a CVR will be valid until registered in the CVR Register. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;A Holder may make a written request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written request, the Rights Agent is hereby authorized to promptly record the change of address in the CVR Register. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Parent will provide written instructions to the Rights Agent for the distribution of CVRs to holders of Parent Common Stock as of immediately prior to the Effective Time (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Record Time</font><font style="letter-spacing:0.2pt;">&#8221;). Subject to the terms and conditions of this Agreement and Parent&#8217;s prompt confirmation of the Effective Time, the Rights Agent shall effect the distribution of the CVRs, less any applicable tax withholding, to each holder of Parent Common Stock as of the Record Time by the mailing of a statement of holding reflecting such CVRs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.4</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Payment Procedures</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Within thirty (30) days after the receipt of any portion of the Total Payment Amount, Parent shall (i)&#160;deliver to the Rights Agent a certificate certifying to and specifying in reasonable detail (A)&#160;the amount of the applicable Total Payment Amount received by Parent or its Affiliates, (B)&#160;a calculation of the CVR Payment Amount and CVR Payment, and (C)&#160;the Permitted Deductions reflected in such CVR Payment Amount, (ii)&#160;deliver to the Rights Agent an amount equal to the aggregate CVR Payment Amount in immediately available funds (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Payment</font><font style="letter-spacing:0.2pt;">&#8221;) and (iii)&#160;instruct the Rights Agent to deliver the CVR Payment to the Holders. The Rights Agent will promptly, and in any event </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">within ten (10) Business Days after receipt of each applicable CVR Payment, pay to each Holder, by check mailed to the address of each Holder as reflected in the CVR Register as of the close of business on the date of the receipt of the CVR Payment statement, such Holder&#8217;s CVR Payment Amount less any applicable tax withholding. Until such certificate, CVR Payment and instructions are received by the Rights Agent, the Rights Agent may presume conclusively for all purposes that such portion of the Total Payment Amount has not been received. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;All payments by Parent to the Rights Agent under this Agreement shall be made in U.S. dollars. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent shall be entitled to deduct or withhold, or cause the Rights Agent to deduct or withhold from any CVR Payment Amount otherwise payable or otherwise deliverable pursuant to this Agreement, in each case directly or through an authorized payroll agent, such amounts as are reasonably determined to be required to be deducted or withheld therefrom under the Code or any other provision of any applicable federal, state, local or non-U.S. Tax Law as may be determined by Parent. To the extent such amounts are so deducted or withheld and paid over or deposited with the relevant Tax authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Holder(s) to whom such amounts would otherwise have been paid or delivered. Prior to making any such Tax withholdings or causing any such Tax withholdings to be made with respect to any Holder, Parent shall instruct the Rights Agent, to the extent practicable, to provide notice to the Holder of such potential withholding and a reasonable opportunity for the Holder to provide any necessary Tax forms (including an IRS Form W-9 or an applicable IRS Form W-8) in order to avoid or reduce such withholding amounts; provided, that the time period for payment of a CVR Payment Amount by the Rights Agent set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;"> shall be extended by a period equal to any delay caused by the Holder providing such forms; provided, further, that in no event shall such period be extended for more than ten (10) Business Days, unless otherwise requested by the Holder for the purpose of delivering such forms and agreed to by the Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Any portion of any CVR Payment that remains undistributed to any Holder six (6)&#160;months after such CVR Payment is received by the Rights Agent from Parent, provided, that the Rights Agent has fully complied with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;">, will be delivered by the Rights Agent to Parent, upon demand, and such Holder will thereafter look only to Parent for payment of its share of such returned CVR Payment, without interest. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Neither Parent nor the Rights Agent will be liable to any person in respect of any CVR Payment Amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law. If, despite Parent&#8217;s and/or the Rights Agent&#8217;s commercially reasonable efforts to deliver a CVR Payment Amount to the applicable Holder, such CVR Payment Amount has not been paid immediately prior to the date on which such CVR Payment Amount would otherwise escheat to or become the property of any Governmental Body, any such CVR Payment Amount will, to the extent permitted by applicable Law, become the property of Parent, free and clear of all claims or interest of any person previously entitled thereto. In addition to and not in limitation of any other indemnity obligation herein, Parent agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to Parent and such indemnification obligation shall survive the termination of this Agreement, the resignation, replacement or removal of the Rights Agent, and the payment, termination and the expiration of the CVRs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.5</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Voting, Dividends or Interest; No Equity or Ownership Interest in Parent</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable on the CVRs to any Holder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The CVRs will not represent any equity or ownership interest in Parent or in any constituent company to the Merger. The sole right of the Holders to receive property hereunder is the right to receive the CVR Payment in accordance with the terms hereof. It is hereby acknowledged and agreed that a CVR shall not constitute a security of Parent or any constituent company to the Merger. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Each Holder acknowledges and agrees that such Holder will not challenge or contest any action, inaction, determination or decision of Parent or the Rights Agent, except via written action of the Acting Holders, and will not threaten, bring, commence, institute, maintain, prosecute or voluntarily aid any action, which challenges the validity of or seeks to enjoin the operation of any provision of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.6</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Ability to Abandon CVR</font><font style="letter-spacing:0.2pt;">. A Holder may at any time, at such Holder&#8217;s option, abandon all of such Holder&#8217;s remaining rights in a CVR by transferring such CVR to Parent without consideration therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by Parent of such transfer and cancellation. Nothing in this Agreement is intended to prohibit Parent from offering to acquire CVRs, in a private transaction or otherwise, for consideration in its sole discretion. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.&nbsp;&nbsp;&nbsp;THE RIGHTS AGENT </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Certain Duties and Responsibilities</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Rights Agent will be authorized and protected and will not have any liability for or in respect of any actions taken, suffered or omitted to be taken by it in connection with its acceptance and administration of this Agreement and the exercise and performance of its duties hereunder, except to the extent of its own willful misconduct, bad faith or gross negligence (each as determined by a final non-appealable judgment of a court of competent jurisdiction). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Certain Rights of the Rights Agent</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied duties, covenants or obligations will be read into this Agreement against the Rights Agent. The Rights Agent shall not assume any obligations or relationship of agency or trust with any Holder. In addition: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;the Rights Agent may rely and will be protected by Parent in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in the absence of bad faith to be genuine and to have been signed or presented by the proper party or parties; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;whenever the Rights Agent will deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Rights Agent may request and rely upon an Officer&#8217;s Certificate with respect to such matter, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of gross negligence, bad faith or willful or intentional misconduct (each as determined by a final non appealable judgment of a court of competent jurisdiction) on its part, incur no liability and be held harmless by Parent for or in respect of any action taken, suffered or omitted to be taken by it in the absence of bad faith under the provisions of this Agreement in reliance upon such certificate; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;in the event the Rights Agent believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Rights Agent hereunder, the Rights Agent, may, in its sole discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to Parent, any Holder or any other person or entity for refraining from taking such action, unless the Rights Agent receives written instructions from the Parent which eliminates such ambiguity or uncertainty to the satisfaction of the Rights Agent; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;the Rights Agent may engage and consult with counsel of its selection (who may be legal counsel for the Rights Agent or the Parent or an employee of the Rights Agent) and the written advice of such counsel or any opinion of counsel will be full and complete authorization and protection to the Rights Agent and the Rights Agent shall be held harmless by Parent and shall incur no liability for or in respect of any action taken, suffered or omitted by it hereunder in the absence of bad faith and in reliance thereon; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;the permissive rights of the Rights Agent to do things enumerated in this Agreement will not be construed as a duty; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;the Rights Agent will not be required to give any note or surety in respect of the execution of such powers or otherwise in respect of the premises; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;the Rights Agent shall not be liable for or by reason of, and shall be held harmless by Parent with respect to any of the statements of fact or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Parent only and the Rights Agent will have no liability and shall be held harmless by Parent in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution and delivery hereof by the Rights Agent), nor shall the Rights Agent be responsible for any breach by Parent of any covenant or condition contained in this Agreement; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;Parent agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability, damage, judgment, fine, penalty, settlement, claim, demands, suits, cost or expense (including without limitation, the reasonable and documented fees and expenses of legal counsel) for any action taken, suffered or omitted to be taken by the Rights Agent or arising out of or in connection with the Rights Agent&#8217;s duties under this Agreement, including the reasonable and documented out-of-pocket costs and expenses of defending the Rights Agent against any claims, charges, demands, suits or loss arising therefrom, directly or indirectly, or enforcement of its rights hereunder, unless such loss has been determined by a final non-appealable judgment of a court of competent jurisdiction to be a result of the Rights Agent&#8217;s gross negligence, bad faith or willful or intentional misconduct; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;anything to the contrary notwithstanding, (i)&#160;any liability of the Rights Agent under this Agreement will be limited to the aggregate amount of the annual fees (but not reimbursed expenses) paid by Parent to the Rights Agent under this Agreement during the twelve&#160;months immediately preceding the event for which recovery is sought, and (ii)&#160;in no event shall the Rights Agent be liable for any special, punitive, indirect, consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits) arising out of any action taken, suffered or omitted to be taken by it, even if the Rights Agent has been advised of the likelihood of such loss or damage and regardless of the form of action; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;Parent agrees (i)&#160;to pay the fees and expenses of the Rights Agent in connection with the Rights Agent&#8217;s duties under this Agreement as agreed upon in writing by the Rights Agent and Parent on or prior to the date hereof, and (ii)&#160;to reimburse the Rights Agent for all taxes and governmental charges, reasonable and documented out-of-pocket expenses and other charges of any kind and nature incurred by the Rights Agent in the preparation, delivery, amendment and execution of this Agreement and the exercise and performance of its duties hereunder (other than taxes imposed on or measured by the Rights Agent&#8217;s net income and franchise or similar taxes imposed on it (in lieu of net income taxes)). The Rights Agent will also be entitled to reimbursement from Parent for all reasonable and documented out-of-pocket expenses paid or incurred by it in connection with the administration by the Rights Agent of its duties hereunder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;the Rights Agent shall not be deemed to have knowledge of any event of which it was supposed to receive notice thereof hereunder, and the Rights Agent shall be fully protected and shall incur no liability for failing to take action in connection therewith, unless and until it has received such notice in writing from the Parent and all notices or other instruments required by this Agreement to be delivered to the Rights Agent must, in order to be effective, be received by the Rights Agent as specified herein, and in the absence of such notice so delivered the Rights Agent may conclusively assume no such event or condition exists; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;the Rights Agent and any shareholder, affiliate, director, officer or employee of the Rights Agent may buy, sell or deal in any securities of the Parent or become peculiarly interested in any transaction in which the Parent may be interested, or contract with or lend money to the Parent or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement. Nothing herein shall preclude the Rights Agent from acting in any other capacity for the Parent or for any other Person; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(m)&nbsp;&nbsp;&nbsp;the Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent shall not be liable, answerable or accountable for any act, omission, default, neglect or misconduct of any such attorneys or agents or for any loss to the Parent, any Holder or any other person or entity </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">resulting from any such act, omission, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment thereof; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(n)&nbsp;&nbsp;&nbsp;no provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(o)&nbsp;&nbsp;&nbsp;the Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect to any action or default by the Parent or its Affiliates, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Parent; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(p)&nbsp;&nbsp;&nbsp;the Rights Agent shall neither be responsible for, nor chargeable with, knowledge of, nor have any requirements to comply with, the terms and conditions of any other agreement, instrument or document, including, without limitation, the Merger Agreement, nor shall the Rights Agent be required to determine if any person or entity has complied with any such agreements, instruments or documents, nor shall any additional obligations of the Rights Agent be inferred from the terms of such agreements, instruments or documents even though reference thereto may be made in this Agreement. In the event of any conflict between the terms and provisions of this Agreement and those of any other agreement, instrument or document, including but not limited to the Merger Agreement, the terms and conditions of this Agreement shall control as they relate to the Rights Agent; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(q)&nbsp;&nbsp;&nbsp;The provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.1</font><font style="letter-spacing:0.2pt;"> and this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.2</font><font style="letter-spacing:0.2pt;"> shall survive the termination of this Agreement, the resignation, replacement or removal of the Rights Agent, and the payment, termination and the expiration of the CVRs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Resignation and Removal; Appointment of Successor</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Rights Agent may resign at any time by giving written notice thereof to Parent specifying a date when such resignation will take effect, which notice will be sent at least thirty (30) days prior to the date so specified, and such resignation will become effective on the earlier of (i)&#160;the date so specified and (ii)&#160;the appointment of a successor Rights Agent. Parent has the right to remove the Rights Agent at any time by a Board Resolution specifying a date when such removal will take effect (or, if earlier, the appointment of the successor Rights Agent). Notice of such removal will be given by Parent to the Rights Agent, which notice will be sent at least thirty (30) days prior to the date so specified. Notwithstanding anything to the contrary contained herein, such replacement or removal of the Rights Agent shall not affect any of the provisions of this Agreement that expressly survive the termination of this Agreement, or the resignation, replacement or removal of the Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;If the Rights Agent provides notice of its intent to resign, is removed or becomes incapable of acting, Parent, by a Board Resolution, will as soon as is reasonably possible appoint a qualified successor Rights Agent, who shall be a stock transfer agent or national reputation or the corporate trust department of a commercial bank. The successor Rights Agent so appointed will, forthwith upon its acceptance of such appointment in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.4</font><font style="letter-spacing:0.2pt;">, become the successor Rights Agent. Notwithstanding the foregoing, if Parent shall fail to make such appointment within a period of thirty (30) days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent will give notice to each Holder of each resignation and each removal of a Rights Agent and each appointment of a successor Rights Agent by delivering a written notice of such event to the Holders as their names and addresses appear in the CVR Register in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;">. Each notice will include the name and address of the successor Rights Agent. If Parent fails to send such notice within ten (10) Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Parent. Failure to give </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">any notice provided for in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;">, however, and any defect therein, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;">, unless consented to in writing by, at the applicable time of determination, Holders of at least 33% of the then outstanding CVRs, as set forth in the CVR Register (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acting Holders</font><font style="letter-spacing:0.2pt;">&#8221;), Parent will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;The Rights Agent will reasonably cooperate with Parent and any successor Rights Agent in connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.4</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Acceptance of Appointment by Successor</font><font style="letter-spacing:0.2pt;">. Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and thereupon such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring Rights Agent will execute and deliver an instrument transferring to the successor Rights Agent all the rights (except such rights of the predecessor Rights Agent which survive pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;"> of this Agreement), powers and trusts of the retiring Rights Agent. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.&nbsp;&nbsp;&nbsp;COVENANTS </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">4.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">List of Holders</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent will furnish or cause to be furnished to the Rights Agent in such form as Parent receives from Parent&#8217;s transfer agent (or other agent performing similar services for Parent), the names and addresses of the Holders within ten (10) Business Days of the Effective Time. Until such initial list of Holders is furnished to the Rights Agent, the Rights Agent shall have no duties, responsibilities or obligations with respect to such Holders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">4.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Payment of CVR Payment Amounts</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;If a CVR Payment is due under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;">, Parent will deposit the CVR Payment with the Rights Agent for payment to the Holders in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">4.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Roche Agreements</font><font style="letter-spacing:0.2pt;">. Without the prior written consent of the Acting Holders, neither Parent nor any of its Affiliates shall (a)&#160;amend, restate, supplement, terminate or otherwise modify the Roche Agreement in a manner materially adversely affecting the Holders&#8217; rights under this Agreement, (b)&#160;in the event that Roche fails to make a payment of a Roche Payment at the time rightfully due and payable, take action with respect to, or unreasonably waive or fail to enforce, the right to receive the applicable payments which are rightfully due and payable under the Roche Agreement, in a manner materially adversely affecting the Holders&#8217; rights under this Agreement or (c)&#160;agree to any of the foregoing. Without limiting the foregoing, Parent and its Affiliates shall pursue their rights under the Roche Agreement in good faith, and not take any action (or fail to take any action) with the intention of avoiding, reducing or materially delaying any payment to the Holders hereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">4.4</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Records</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Parent shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to enable the Holders and their consultants or professional advisors to confirm (a)&#160;whether the Roche Payment Amount or the Asset Disposition Proceeds have been received by Parent or its successors or Affiliates and (b)&#160;the applicable CVR Payment Amount payable to each Holder hereunder in accordance with the terms specified in this Agreement. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.&nbsp;&nbsp;&nbsp;DISPOSITION </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">5.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;During the period specified in clause (b)&#160;of the definition of &#8220;CVR Term&#8221;, Parent will, and will cause its subsidiaries to, use commercially reasonable efforts to effectuate a Disposition, including the negotiation and execution of a Sale Agreement and completion of the transactions contemplated thereby. Further, Parent will not take any actions for the primary purpose of frustrating the payment of CVR Payments. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">5.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Holders acknowledge and agree that, except as expressly set forth in the foregoing Section&#160;5.1, (a)&#160;Parent has a fiduciary obligation to operate its business in the best interests of its stockholders, and any potential obligation to pay any potential Asset Disposition Proceeds or any other amounts will not create any express or implied obligation to operate its business in any particular manner in order to maximize any such CVR Payments, (b)&#160;the Holders are not relying on any representation of Parent or any other Person with regard to any Disposition or other action involving CVR Sale Assets following the Closing, and neither Parent nor any other Person has provided, or can provide, any assurance to the Holders that any potential Asset Disposition Proceeds or any other amounts will in fact be earned and paid, and (c)&#160;none of Parent or any of its Subsidiaries, officers or directors shall have any obligation or liability whatsoever to any Person relating to or in connection with any action, or failure to act, with respect to the sale of CVR Sale Assets. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6.&nbsp;&nbsp;&nbsp;AMENDMENTS </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">6.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Amendments without Consent of Holders</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Without the consent of any Holders, Parent, when authorized by a Board Resolution, at any time and from time to time, and the Rights Agent may enter into one or more amendments hereto, solely to evidence any successor to or permitted Assignee of Parent and the assumption by any such successor or permitted Assignee of the covenants of Parent herein as provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Without the consent of any Holders, Parent, when authorized by a Board Resolution, may, with the consent of the Rights Agent, which consent shall not be unreasonably withheld, conditioned or delayed, at any time and from time to time, enter into one or more amendments hereto, solely for any of the following purposes: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;to evidence the succession of another Person as a successor Rights Agent in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3</font><font style="letter-spacing:0.2pt;"> and the assumption by any successor of the covenants and obligations of the Rights Agent herein; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;to add to the covenants of Parent such further covenants, restrictions, conditions or provisions as Parent shall consider to be for the protection of the Holders; provided, that, in each case, such provisions do not adversely affect the interests of the Holders; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;to cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision herein, or to make any other provisions with respect to matters or questions arising under this Agreement; provided, that, in each case, such provisions do not adversely affect the interests of the Holders; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange Act or any applicable state securities or &#8220;blue sky&#8221; laws; provided, that, in each case, such provisions do not adversely affect the interests of the Holders; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;to cancel any CVRs (A)&#160;in the event that any Holder has abandoned its rights in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.6</font><font style="letter-spacing:0.2pt;">, or (B)&#160;following a transfer of such CVRs to Parent or its Affiliates in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.3</font><font style="letter-spacing:0.2pt;">; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;any other amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition, elimination or change is adverse to the interests of the Holders; or </font>
        </div>
        <div style="text-indent:60pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vii)&nbsp;&nbsp;&nbsp;as may be necessary or appropriate to ensure that Parent complies with applicable Law. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.1</font><font style="letter-spacing:0.2pt;">, Parent will transmit a notice thereof in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;"> to the Holders at their addresses as they appear on the CVR Register, setting forth in general terms the substance of such amendment. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">6.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Amendments with Consent of Holders</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.1</font><font style="letter-spacing:0.2pt;"> (which amendments pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.1</font><font style="letter-spacing:0.2pt;"> may be made without the consent of the Holders), with the consent of the Acting Holders, whether evidenced in writing or taken </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">at a meeting of such Holders, Parent, when authorized by a Board Resolution, and the Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, even if such addition, elimination or change is materially adverse to the interest of the Holders. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Promptly after the execution by Parent, and the Rights Agent of any amendment pursuant to the provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.2</font><font style="letter-spacing:0.2pt;">, Parent will transmit (or cause the Rights Agent to transmit) a notice thereof in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;"> to the Holders at their addresses as they appear on the CVR Register, setting forth in general terms the substance of such amendment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">6.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Execution of Amendments</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In executing any amendment permitted by this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;">, the Rights Agent will be entitled to receive, and will be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of such amendment is authorized or permitted by this Agreement. Notwithstanding anything contained herein, the Rights Agent may, but is not obligated to, enter into any such amendment that affects the Rights Agent&#8217;s own rights, privileges, covenants or duties under this Agreement or otherwise. No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">6.4</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Effect of Amendments</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Upon the execution of any amendment under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;">, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7.&nbsp;&nbsp;&nbsp;OTHER PROVISIONS OF GENERAL APPLICATION </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notices to Rights Agent and Parent</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Any notice or other communication required or permitted hereunder shall be in writing and shall be deemed given when delivered and received hereunder (a)&#160;one Business Day after being sent for next Business Day delivery, fee prepared, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand, or (c)&#160;on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00&#160;p.m. New York time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If to the Rights Agent, to it at: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Computershare Inc. and Computershare Trust Company, N.A. </font> <br ><font style="letter-spacing:0.2pt;">150 Royall Street, 2nd Floor </font> <br ><font style="letter-spacing:0.2pt;">Canton, MA 02021 </font> <br ><font style="letter-spacing:0.2pt;">Attention: Relationship Manager </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If to Parent, to it at: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio, Inc. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Telephone:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Email:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Attention:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Telephone:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Email:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Attention:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Rights Agent or Parent may specify a different address, email address by giving notice to each other in accordance with this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;"> and to the Holders in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.2</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notice to Holders</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Where this Agreement provides for notice to Holders, such notice will be sufficiently given (unless otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid or, if applicable, transmitted through the facilities of DTC in accordance with DTC&#8217;s procedures, to each Holder affected by such event, at the Holder&#8217;s address as it appears in the CVR Register, not later </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">than the latest date, and not earlier than the earliest date, if any, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder will affect the sufficiency of such notice with respect to other Holders. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Parent Successors and Assigns</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Parent may not assign this Agreement without the prior written consent of the Acting Holders. Notwithstanding the foregoing (i)&#160;Parent may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more direct or indirect wholly-owned subsidiaries of Parent for so long as they remain wholly-owned subsidiaries of Parent (each, an &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Assignee</font><font style="letter-spacing:0.2pt;">&#8221;) and the Assignee agrees to assume and be bound by all of the terms of this Agreement; provided, however, that in connection with any assignment to an Assignee, Parent shall, and shall agree to, remain liable for the performance by such Assignee of all obligations of Parent hereunder, with such Assignee substituted for Parent under this Agreement, and (ii)&#160;Parent may assign this Agreement in its entirety without the consent of any other party to its successor in interest in connection with the sale of all or substantially all of its assets or of its stock, or in connection with a merger, acquisition or similar transaction (such successor in interest, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquiror</font><font style="letter-spacing:0.2pt;">&#8221;, and such transaction, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquisition</font><font style="letter-spacing:0.2pt;">&#8221;). This Agreement will be binding upon, inure to the benefit of and be enforceable by Parent&#8217;s successors, acquirers and each Assignee. Each reference to &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221; in this Agreement shall be deemed to include Parent&#8217;s successors, acquirers and all Assignees. Each of Parent&#8217;s successors, acquirers and assigns shall expressly assume by an instrument supplemental hereto, executed and delivered to the Rights Agent, the due and punctual payment of the CVR Payments and the due and punctual performance and observance of all of the covenants and obligations of this Agreement to be performed or observed by Parent. Notwithstanding anything to the contrary contained herein, no assignment pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3</font><font style="letter-spacing:0.2pt;"> shall relieve Parent of its obligations and liabilities to the Rights Agent hereunder, unless specifically agreed to in writing by the Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or any Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto; provided, that such Person would be eligible for appointment as a successor Rights Agent under the provisions of this Agreement. The purchase of all or substantially all of the Rights Agent&#8217;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3(b)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.4</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Benefits of Agreement; Action by Acting Holders</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The holders shall be intended third-party beneficiaries hereof and shall be entitled to, solely by action by the written consent of the Acting Holders, specifically enforce the terms hereof; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that under no circumstances shall the rights of Holders as third-party beneficiaries pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.4</font><font style="letter-spacing:0.2pt;"> be enforceable by such Holders or any other Person acting for or on their behalf other than through the action of the Acting Holders, which Acting Holders shall have the sole power and authority to act on behalf of the Holders in enforcing any of their rights hereunder. Nothing in this Agreement, express or implied, will give to any Person (other than the Rights Agent, Parent, Parent&#8217;s successors and permitted assignees, and the Holders and their respective successors and permitted assignees) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the Rights Agent, Parent, Parent&#8217;s successors and permitted Assignees, and the Holders and their respective successors and permitted assignees. The rights of Holders are limited to those expressly provided in this Agreement and the Merger Agreement. Except for the rights of the Rights Agent set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder or other group of Holders will be entitled to exercise such rights. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.5</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Governing Law</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement, the CVRs and all claims and causes of action based upon, arising out of or in connection herewith shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without regard to Laws that may be applicable under conflicts of laws principles </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In any Legal Proceeding between any of the parties arising out of our relating to this Agreement, each of the parties hereby (i)&#160;irrevocably and unconditionally consent and submits, for itself and its property, to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware, New Castle County, or, if such court does not have jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware, (ii)&#160;agrees that any claim in respect of any such Legal Proceeding shall be heard and determined exclusively in accordance with clause (i)&#160;of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.5</font><font style="letter-spacing:0.2pt;">, (iii)&#160;waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such Legal Proceeding in any such court, (iv)&#160;waives, to the fullest extent permitted by Law, any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (v)&#160;agrees that service of process upon such party in any such Legal Proceeding shall be effective if notice is given in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;"> of this Agreement. Nothing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.5</font><font style="letter-spacing:0.2pt;">, however, shall affect the right of any Person to serve legal process in any manner permitted by Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.6</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Severability</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If any term or other provision of this Agreement is determined by a final judgement of a court of competent jurisdiction to be invalid or unenforceable, the parties agree that the court making such determination shall have the power to limit such term or provisions, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. Notwithstanding anything to the contrary herein, if any such excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to Parent. In the event such court does not exercise the power granted to it in the prior sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business or other purposes of such invalid or unenforceable term or provision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.7</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Counterparts and Signature</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement may be signed in any number of counterparts, including by electronic transmission, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.8</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Termination</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Agreement will expire and be of no force or effect, the parties hereto will have no liability hereunder (other than with respect to monies due and owing by Parent to the Rights Agent or any other rights of the Rights Agent which expressly survive the termination of this Agreement), and no additional payments will be required to be made, upon the later of (i)&#160;the conclusion of the CVR Term, and (ii)&#160;the payment of the full amount of all CVR Payments made to Parent on or prior to the end of the applicable CVR Term to the Rights Agent and the payment of the full amount of all CVR Payment Amounts to the Holders by the mailing by the Rights Agent of each applicable CVR Payment Amount to each Holder at the address reflected in the CVR Register; provided that, for clarity, the term &#8220;CVR Term&#8221; as used in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.8</font><font style="letter-spacing:0.2pt;"> shall be deemed to mean clause (a)&#160;of such definition with respect to any Roche Payment Amount, and shall be deemed to mean clause (b)&#160;of such definition with respect to any Asset Disposition Proceeds. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.9</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Funds</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All funds received by the Rights Agent under this Agreement that are to be distributed or applied by Computershare in the performance of services hereunder (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Funds</font><font style="letter-spacing:0.2pt;">&#8221;) shall be held by Computershare as agent for Parent and deposited in one or more bank accounts to be maintained by Computershare in its name as agent for Parent. Until paid pursuant to the terms of this Agreement, Computershare will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1&#160;billion or with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&#8217;s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall have no responsibility or liability for any diminution of the Funds that may result from any deposit made by the Rights Agent in accordance with this </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:256pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">paragraph, including any losses resulting from a default by any bank, financial institution or other Third Party. The Rights Agent may from time to time receive interest, dividends or other earnings in connection with such deposits. The Rights Agent shall not be obligated to pay such interest, dividends or earnings to Parent, any Holder or any other party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.10</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Entire Agreement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;As between Parent and the Holders, this Agreement and the Merger Agreement (including the schedules, annexes and exhibits thereto, the documents and instruments referred to therein and the documents delivered pursuant thereto) constitute the entire agreement of Parent and the Holders and supersede all prior agreements and undertakings, both written and oral, among Parent and the Holders, or any of them, with respect to the subject matter hereof and, except as otherwise expressly provided herein or therein, are not intended to confer upon any other Person any rights or remedies hereunder or thereunder. As between Parent and the Rights Agent, this Agreement (including the documents and instruments referred to herein (other than the Merger Agreement) and the documents delivered pursuant thereto) contains the entire understanding of the parties with reference to the transactions and matters contemplated hereby and thereby and supersedes all prior agreements, written or oral, among the parties with respect thereto. If and to the extent that any provision of this Agreement is inconsistent or conflicts with the Merger Agreement, this Agreement will govern and control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.11</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Waiver of Jury Trial</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (i)&#160;ARISING UNDER THIS AGREEMENT OR (ii)&#160;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[</font><font style="font-style:italic;letter-spacing:0.2pt;">Remainder of page intentionally left blank</font><font style="letter-spacing:0.2pt;">] </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above written. </font>
        </div>
        <table style="width:456pt;height:207pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:0.2pt;">SESEN BIO, INC. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.5pt 0pt 0.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.5pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">Name: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify; line-height:0pt;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">Title: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify; line-height:0pt;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.667pt 0pt 1.5pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:0.2pt;">COMPUTERSHARE INC. and </font>
              <br >
              <font style="letter-spacing:0.2pt;">COMPUTERSHARE TRUST</font>
              <br >
              <font style="letter-spacing:0.2pt;">COMPANY, N.A., jointly as RIGHTS </font>
              <br >
              <font style="letter-spacing:0.2pt;">AGENT </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.5pt 0pt 0.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.5pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">Name: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify; line-height:0pt;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">Title: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify; line-height:0pt;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;min-height:690.02pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tANNB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX B</font>&#8203;</div>
        <div style="position:relative;margin-top:8.71pt; width:456pt;">
          <img src="lg_svbsecurities-4c.jpg" alt="[MISSING IMAGE: lg_svbsecurities-4c.jpg]" height="51" width="224" >
        </div>
        <div style="margin-top:14.81pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">December&#160;29</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;">, 2022 </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board of Directors </font> <br ><font style="letter-spacing:0.2pt;">Sesen Bio, Inc. </font> <br ><font style="letter-spacing:0.2pt;">245 First Street, Suite 1800 </font> <br ><font style="letter-spacing:0.2pt;">Cambridge, MA 02142 </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Ladies and Gentlemen: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You have requested our opinion as to the fairness, from a financial point of view, to Sesen Bio, Inc., a Delaware corporation (&#8220;Parent&#8221;), of the Exchange Ratio (as defined below) proposed to be paid by Parent pursuant to the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Original Merger Agreement&#8221;) dated as of September&#160;20, 2022 by and among Parent, Sesen Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;Merger Sub&#8221;), and CARISMA Therapeutics Inc., a Delaware corporation (the &#8220;Company&#8221;), as proposed to be amended by the First Amendment to Agreement and Plan of Merger and Reorganization (the &#8220;First Amendment to Merger Agreement&#8221;) to be entered into by and among Parent, Merger Sub and the Company (the Original Merger Agreement, as proposed to be amended by the First Amendment to Merger Agreement, the &#8220;Amended Merger Agreement&#8221;). The Amended Merger Agreement provides for the acquisition by Parent of the Company through the merger of Merger Sub with and into the Company (the &#8220;Merger&#8221;), with the Company continuing as the surviving entity of the Merger and as a wholly-owned subsidiary of Parent. Capitalized terms used but not defined herein have the meanings set forth in the Amended Merger Agreement. At the effective time of the Merger (the &#8220;Effective Time&#8221;), after giving effect to the Nasdaq Reverse Split, if any, and the declaration of the Pre-Closing Dividend, by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any stockholder of the Company or Parent, among other things, each share of Company Capital Stock outstanding immediately prior to the Effective Time (excluding Excluded Shares (as defined below)) shall be converted solely into the right to receive a number of shares of the common stock, $0.001 par value per share, of Parent (the &#8220;Parent Common Stock&#8221;) equal to the Exchange Ratio. As used herein, (i)&#160;the &#8220;Exchange Ratio&#8221; is the number of shares of Parent Common Stock to be received by holders of Company Capital Stock, other than Excluded Shares, in the Merger, which is derived from the agreed relative valuations of the Company and Parent as set forth in the Amended Merger Agreement; and (ii)&#160;&#8220;Excluded Shares&#8221; means (a)&#160;any shares of Company Capital Stock held as treasury stock or held or owned by the Company, Merger Sub or any Subsidiary of the Company immediately prior to the Effective Time (which shares shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor); and (b)&#160;any shares of Company Capital Stock that are outstanding immediately prior to the Effective Time and which are held by stockholders who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the General Corporation Law of the State of Delaware. The Exchange Ratio is subject to certain adjustments set forth in the Amended Merger Agreement; we express no opinion as to any such adjustments. The Merger and the other transactions summarized above are collectively referred to herein as the &#8220;Transaction.&#8221; The terms and conditions of the Transaction are more fully set forth in the Amended Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have been engaged by Parent to act as its financial advisor in connection with the Transaction and we will receive a fee from Parent for providing such services, a portion of which was payable upon delivery of our opinion in connection with the Original Merger Agreement, another portion of which is payable upon delivery of this opinion in connection with the Amended Merger Agreement, and the remaining (and principal) portion of which is contingent upon consummation of the Transaction. In addition, Parent has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may arise, out of our engagement.</font>
        </div>
        <div style="position:relative;margin-top:12.21pt; width:456pt;">
          <img src="ft_svbsecurities-4c.jpg" alt="[MISSING IMAGE: ft_svbsecurities-4c.jpg]" height="42" width="594" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SVB Securities LLC is a full-service securities firm engaged in securities trading and brokerage activities as well as investment banking and financial advisory services. In the ordinary course of business, we and our affiliates have in the past provided, currently are providing and may in the future provide investment banking and commercial banking services to Parent, the Company or their respective affiliates and have received and would expect to receive customary fees for the rendering of such services. In the ordinary course of our business, we or our affiliates have in the past and may in the future hold positions, for our own account or the accounts of our customers, in equity, debt or other securities of Parent, the Company or their respective affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Consistent with applicable legal and regulatory requirements, we have adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Parent, the Company and the Transaction and other participants in the Transaction that differ from the views of our investment banking personnel. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with this opinion, we have reviewed, among other things: (i)&#160;the Original Merger Agreement; (ii)&#160;a draft of the First Amendment to Merger Agreement, dated December&#160;29</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;">, 2022; (iii)&#160;a draft of the form of Contingent Value Rights Agreement to be entered into at the closing of the Transaction by Parent and a rights agent (the &#8220;CVR Agreement&#8221;), dated December&#160;29</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;">, 2022; (iv)&#160;Parent&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed by Parent with the Securities and Exchange Commission (the &#8220;SEC&#8221;); (v)&#160;Parent&#8217;s Quarterly Reports on Form 10-Q for the quarterly periods ended March&#160;31, 2022, June&#160;30, 2022, and September&#160;30, 2022 (including any amendments thereto), as filed by Parent with the SEC; (vi)&#160;certain Current Reports on Form 8-K (including any amendments thereto), as filed by Parent with, or furnished by Parent to, the SEC; (vii)&#160;certain internal information, primarily related to expense forecasts, relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of Parent, as furnished to us by the management of Parent; and (viii)&#160;certain internal information relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of the Company, including certain financial forecasts, analyses and projections relating to the Company prepared by management of the Company, as modified by management of Parent and furnished to, and approved for use by, us by Parent for purposes of our analysis (the &#8220;Company Forecast&#8221;) (collectively, the &#8220;Internal Data&#8221;). We have also conducted discussions with members of the senior management of Parent and the Company and their respective advisors and representatives regarding such Internal Data as well as the past and current business, operations, financial condition and prospects of each of Parent and the Company. In addition, we reviewed certain financial data for the Company and compared that data to similar publicly available market, financial and other data for certain other companies, the securities of which are publicly traded, that we believe to be comparable in certain respects to the Company. We also conducted such other financial studies and analyses and took into account such other information as we deemed appropriate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by us for purposes of this opinion and have, with your consent, relied upon such&#160;information as being complete and accurate. In that regard, we have been advised by Parent, and have assumed, at your direction, that the Internal Data (including, without limitation, the Company Forecast) has been reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of Parent and the Company as to the matters covered thereby and we have relied, at your direction, on the Internal Data for purposes of our analysis and this opinion. We express no view or opinion as to the Internal Data (including, without limitation, the Company Forecast) or the assumptions on which it is based. As you are aware, Parent&#8217;s management did not provide us with, and we did not otherwise have access to, financial forecasts regarding Parent&#8217;s business, other than the expense forecasts described above. Accordingly, we did not perform a discounted cash flow analysis or any multiples-based analysis with respect to Parent. In addition, at your direction, we have not made any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, off-balance-sheet or otherwise) of Parent or the Company, nor have we been furnished with any such evaluation or appraisal, and we have not been asked to conduct, and did not conduct, a physical inspection of the properties or assets of Parent or the Company. Furthermore, at your direction, we have ascribed no value to the contingent value rights issuable pursuant to the CVR Agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have assumed, at your direction, that the final executed First Amendment to Merger Agreement will not differ in any respect material to our analysis or this opinion from the last draft of the First Amendment to Merger Agreement reviewed by us. We have also assumed, at your direction, that the representations and warranties made by the Company and Parent and Merger Sub in the Amended Merger Agreement and the related agreements are and will continue to be true and correct in all respects material to our analysis. Furthermore, we have assumed, at your direction, that the Transaction will be consummated on the terms set forth in the Amended Merger Agreement and in accordance with all applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be material to our analysis or this opinion and that, in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers for the Transaction, no delay, limitation, restriction, condition or other change will be imposed, the effect of which would be material to our analysis or this opinion. We have not evaluated and do not express any opinion as to the solvency or fair value of Parent or the Company, or their respective abilities to pay their obligations when they come due, or as to the impact of the Transaction on such matters, under any state, federal or other laws relating to bankruptcy, insolvency, or similar matters. We are not legal, regulatory, tax or accounting advisors, and we express no opinion as to any legal, regulatory, tax or accounting matters. We express no view or opinion as to the price or range of prices at which the shares of stock or other securities or instruments of Parent or any third party may trade at any time, including subsequent to the announcement or consummation of the Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We express no view as to, and our opinion does not address, Parent&#8217;s underlying business decision to proceed with or effect the Transaction, or the relative merits of the Transaction as compared to any alternative business strategies or transactions that might be available to Parent or in which Parent might engage. This opinion is limited to and addresses only the fairness, from a financial point of view, as of the date hereof, to Parent of the Exchange Ratio proposed to be paid by Parent pursuant to the terms of the Amended Merger Agreement. We have not been asked to, nor do we express any view on, and our opinion does not address, any other term or aspect of the Amended Merger Agreement or the Transaction, including, without limitation, the structure or form of the Transaction, or any other agreements or arrangements contemplated by the Amended Merger Agreement or entered into in connection with or otherwise contemplated by the Transaction, including, without limitation, the fairness of the Transaction or any other term or aspect of the Transaction to, or any consideration to be received in connection therewith by, or the impact of the Transaction on, the holders of any class of securities, creditors or other constituencies of Parent or any other party. In addition, we express no view or opinion as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors or employees of Parent or any other party, or class of such persons in connection with the Transaction, whether relative to the Exchange Ratio to be paid by Parent pursuant to the terms of the Amended Merger Agreement or otherwise. Our opinion is necessarily based on financial, economic, monetary, currency, market and other conditions and circumstances as in effect on, and the information made available to us as of, the date hereof, and we do not have any obligation or responsibility to update, revise or reaffirm this opinion based on circumstances, developments or events occurring after the date hereof. Our opinion does not constitute a recommendation to any stockholder of Parent as to whether or how such stockholder should vote with respect to the Merger or otherwise act with respect to the Transaction or any other matter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our financial advisory services and the opinion expressed herein are provided for the information and assistance of the Board of Directors of Parent (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transaction. This opinion has been authorized by our Fairness Opinion Review Committee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based upon and subject to the foregoing, including the various assumptions, qualifications and limitations set forth herein, it is our opinion that, as of the date hereof, the Exchange Ratio proposed to be paid by Parent pursuant to the terms of the Amended Merger Agreement is fair, from a financial point of view, to Parent. </font>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Very truly yours, </font>
        </div>
        <div style="margin-left:240pt; margin-top:12pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ SVB SECURITIES LLC</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">B-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tANNC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX C</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This STOCKHOLDER SUPPORT AGREEMENT (this &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Support Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) is entered into as of [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;], 2022, among CARISMA Therapeutics Inc., a Delaware corporation (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;), Sesen Bio, Inc., a Delaware corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221;), and the undersigned stockholder (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Stockholder</font><font style="letter-spacing:0.2pt;">&#8221;) of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, as of the date hereof, the Stockholder is the sole record owner of and has the sole power to vote (or to direct the voting of) the number of shares of common stock, par value $0.0001 per share, of the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Common Stock</font><font style="letter-spacing:0.2pt;">&#8221;), and/or the number of shares of preferred stock, $0.0001 par value per share of the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221;), set forth opposite the Stockholder&#8217;s name on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;I</font><font style="letter-spacing:0.2pt;"> hereto (such Common Stock and Preferred Stock, together with any other shares of the Company that are hereafter issued to or otherwise acquired or owned by, including upon exercise of options or securities convertible into or exercisable or exchangeable for Common Stock (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Shares</font><font style="letter-spacing:0.2pt;">&#8221;), the voting power of which is acquired by such Stockholder during the Voting Period (as defined below), are collectively referred to herein as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Subject Shares</font><font style="letter-spacing:0.2pt;">&#8221;); </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, the Company, Parent, and Seahawk Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub</font><font style="letter-spacing:0.2pt;">&#8221;), are concurrently entering into an Agreement and Plan of Merger and Reorganization, dated on or about the date hereof (as amended from time to time, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), pursuant to which Merger Sub shall be merged with and into the Company, with the Company continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger</font><font style="letter-spacing:0.2pt;">&#8221;); </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, the adoption of the Merger Agreement and the transactions contemplated thereby requires the written consent or affirmative vote of (i)&#160;the holders of a majority of the capital stock of the Company, voting together as a single class, (ii)&#160;the holders of a majority of the Series&#160;A Preferred Stock, $0.0001 par value per share, of the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Series&#160;A Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221;), and the Special Voting Preferred Stock, $0.0001 par value per share, of the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Special Voting Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221;), voting together as a single class, (iii)&#160;the holders of at least two-thirds of the Series&#160;B Preferred Stock, $0.0001 par value per share, of the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Series&#160;B Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221;), and the Series&#160;B Special Voting Preferred Stock, $0.0001 par value per share, of the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Series&#160;B Special Voting Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8221;), voting together as a single class, and (iv)&#160;the holders of at least two-thirds of the Series&#160;A Preferred Stock, Special Voting Preferred Stock, Series&#160;B Preferred Stock and Series&#160;B Special Voting Preferred Stock, voting together as a single class; and </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, as a condition and inducement to Parent&#8217;s willingness to enter into the Merger Agreement and consummate the transactions contemplated thereby, Parent and the Company have required the Stockholder to, as an inducement and in consideration therefor, and the Stockholder (in the Stockholder&#8217;s capacity as holder of the Subject Shares) has agreed to, enter into this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, the parties agree as follows: </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE I</font>
          <br >
          <font style="letter-spacing:-0.2pt;">DEFINITIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 1.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Capitalized Terms</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;For purposes of this Support Agreement, capitalized terms used and not defined herein shall have the respective meanings ascribed to them in the Merger Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Expiration Time</font><font style="letter-spacing:0.2pt;">&#8221; shall mean the earliest to occur of (i)&#160;the Effective Time, (ii)&#160;any amendment to the Merger Agreement that reduces the amount, or changes the form of any consideration payable to the Stockholder in the transaction, (iii)&#160;the date and time of the valid termination of the Merger Agreement in accordance with its terms and (iv)&#160;the End Date (as defined in the Merger Agreement in effect on the date hereof) provided that the Effective Time has not occurred on or before such date. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Voting Period</font><font style="letter-spacing:0.2pt;">&#8221; shall mean such period of time between the date hereof and the Expiration Time. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Recommendation Change Requirement</font><font style="letter-spacing:0.2pt;">&#8221; shall mean, with respect to the Stockholder, 35% of the Subject Shares held by such Stockholder. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE II</font>
          <br >
          <font style="letter-spacing:-0.2pt;">VOTING AGREEMENT AND IRREVOCABLE PROXY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 2.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Agreement to Vote.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Stockholder hereby agrees that, during the Voting Period, and at any duly called meeting of the stockholders of the Company (or any adjournment or postponement thereof), or in any other circumstances (including action by written consent of stockholders in lieu of a meeting) upon which a vote, adoption or other approval or consent with respect to the adoption of the Merger Agreement or the approval of the Merger and any of the transactions contemplated thereby is sought, the Stockholder: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;if no Company Board Adverse Recommendation Change has occurred in accordance with Section&#160;5.3(c) of the Merger Agreement, shall, if a meeting is held, appear at the meeting, in person or by proxy, and shall provide a written consent (a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Written Consent</font><font style="letter-spacing:0.2pt;">&#8221;) or vote (or cause to be voted), in person or by proxy, all of the Subject Shares, in each case (i)&#160;in favor of (A)&#160;any proposal to adopt and approve or reapprove the Merger Agreement and the transactions contemplated thereby, including (1)&#160;adoption and approval of the Merger Agreement and the Contemplated Transactions, (2)&#160;adoption and approval of an amendment of the Company&#8217;s certificate of incorporation to increase the authorized shares of the Common Stock, (3)&#160;acknowledgment that the approval given thereby is irrevocable and that the Stockholder is aware of the Stockholder&#8217;s rights to demand appraisal for its shares pursuant to Section&#160;262 of the DGCL, a true and correct copy of which will be attached thereto, and that the Stockholder has received and read a copy of Section&#160;262 of the DGCL, (4)&#160;acknowledgment that by the Stockholder&#8217;s approval of the Merger the Stockholder is (A)&#160;waiving its appraisal rights with respect to the Subject Shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of the Stockholder&#8217;s capital stock under the DGCL, and (B)&#160;waiving any notice that may have been or may be required relating to the Merger or any of the other Contemplated Transactions (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Stockholder Approval Matters</font><font style="letter-spacing:0.2pt;">&#8221;), and (ii)&#160;against any Acquisition Proposal and any action in furtherance of any such Acquisition Proposal; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;if a Company Board Adverse Recommendation Change has occurred in accordance with Section&#160;5.3(c) of the Merger Agreement, shall, if a meeting is held, appear at the meeting, in person or by proxy, and shall provide a Written Consent or vote (or caused to be voted), in person or by proxy, at least the Recommendation Change Requirement (rounded up to the nearest whole number of Subject Shares) of Subject Shares held by such Stockholder, in each case (i)&#160;in favor of the Stockholder Approval Matters, and (ii)&#160;against any proposals that compete with the Contemplated Transactions, including any Acquisition Proposal and any action in furtherance of any such Acquisition Proposal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 2.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Grant of Irrevocable Proxy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the event and to the extent that the Stockholder fails to vote the Subject Shares in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1</font><font style="letter-spacing:0.2pt;"> at any applicable meeting of the stockholders of the Company or pursuant to any applicable meeting of the stockholders of the Company or pursuant to any applicable written consent of the stockholders of the Company, the Stockholder hereby appoints the Company and any designee of the Company, and each of them individually, as the Stockholder&#8217;s proxy, with full power of substitution and re-substitution, to vote, including by executing written consents, during the Voting Period with respect to any and all of the Subject Shares solely on the matters and in the manner specified in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1</font><font style="letter-spacing:0.2pt;">; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that, for the avoidance of doubt, if a Company Board Adverse Recommendation Change in accordance with Section&#160;5.3(c) of the Merger Agreement has occurred the Stockholder shall only be deemed to have granted a proxy to the extent of the Recommendation Change Requirement. The Stockholder shall take all further action or execute such other instruments as may be necessary to effectuate the intent of any such proxy. The Stockholder affirms that the irrevocable proxy given by it hereby with respect to the Merger Agreement and the Contemplated Transactions is given to the Company by the Stockholder to secure the performance of the obligations of the Stockholder under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1</font><font style="letter-spacing:0.2pt;"> of this Support Agreement. It is agreed that the Company (and its designees) will use the irrevocable proxy that is granted by the Stockholder hereby only in accordance with applicable Laws and that, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to the extent the Company (and its designees) uses such irrevocable proxy, it will only vote (or sign written consents in respect of) the Subject Shares subject to such irrevocable proxy with respect to the matters specified in, and in accordance with the provisions of, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 2.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Nature of Irrevocable Proxy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The proxy granted pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;"> to the Company by the Stockholder shall be irrevocable during the term of this Support Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall revoke any and all prior proxies or powers of attorney granted by the Stockholder and no subsequent proxy or power of attorney shall be given or written consent executed (and if given or executed, shall not be effective) by the Stockholder with respect thereto. The proxy that may be granted hereunder shall terminate automatically, without any further action on the part of the Company, Stockholder or any other Person, upon the Expiration Time, but shall survive the death or incapacity of the Stockholder and any obligation of the Stockholder under this Support Agreement shall be binding upon the heirs, personal representatives and successors of the Stockholder. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE III</font>
          <br >
          <font style="letter-spacing:-0.2pt;">COVENANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Subject Shares.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Stockholder agrees that (i)&#160;from the date hereof until the Expiration Time, it shall not, and shall not commit or agree to, without the prior written consent of Parent and the Company, directly or indirectly, whether by merger, consolidation or otherwise, offer for sale, sell (including short sales), transfer, tender, pledge, encumber, assign or otherwise dispose of (including by gift or by operation of law) (any of the foregoing, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Transfer</font><font style="letter-spacing:0.2pt;">&#8221;), or enter into any contract, option, derivative, hedging or other agreement or arrangement or understanding (including any profit-sharing arrangement) with respect to, or consent to or permit, a Transfer of, any or all of the Subject Shares or any interest therein; and (ii)&#160;during the Voting Period, it shall not, and shall not commit or agree to, without the prior written consent of Parent and the Company, (A)&#160;grant any proxies or powers of attorney with respect to any or all of the Subject Shares or agree to vote (or sign written consents in respect of) the Subject Shares on any matter or divest itself of any voting rights in the Subject Shares that would conflict with the terms of this Support Agreement, or (B)&#160;take any action that would have the effect of preventing or disabling the Stockholder from performing its obligations under this Support Agreement. Notwithstanding the foregoing, the Stockholder may, at any time, Transfer its Subject Shares (1)&#160;by will or other testamentary document or by intestacy, (2)&#160;to any investment fund or other entity controlled or managed by the Stockholder or the investment adviser or general partner of the Stockholder, (3)&#160;to another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect Affiliate of the Stockholder, including any investment funds or other entities that controls or manages, or is under common control or management with, or is controlled or managed by, the Stockholder, (4)&#160;to any member of the Stockholder&#8217;s immediate family, (5)&#160;to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder or otherwise for estate planning purposes, (6)&#160;to stockholders, current or former partners (general or limited), members or managers of the Stockholder, as applicable, or to the estates of any of the foregoing, or (7)&#160;to the extent required by applicable Law; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the case of clauses (1)-(6), such permitted transferee shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Support Agreement. The Stockholder agrees that any Transfer of Subject Shares not permitted hereby shall be null and void and that any such prohibited Transfer shall be enjoined. If any voluntary or involuntary Transfer of any Subject Shares covered hereby shall occur (including a sale by the Stockholder&#8217;s trustee in bankruptcy, or a sale to a purchaser at any creditor&#8217;s or court sale), the permitted transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee) shall take and hold such Subject Shares subject to all of the restrictions, liabilities and rights under this Support Agreement, which shall continue in full force and effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;In the event of a stock dividend or distribution, or any change in the Subject Shares by reason of any stock dividend or distribution, split-up, recapitalization, combination, conversion, exchange of shares or the like, the term &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Subject Shares</font><font style="letter-spacing:0.2pt;">&#8221; shall be deemed to refer to and include the Subject Shares as well as all such stock dividends and distributions and any securities into which or for </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">which any or all of the Subject Shares may be changed or exchanged or which are received in such transaction. The Stockholder further agrees that, in the event the Stockholder purchases or otherwise acquires beneficial or record ownership of or an interest in, or acquires the right to vote or share in the voting of, any additional Shares, in each case after the execution of this Support Agreement and prior to the Expiration Time, the Stockholder shall deliver promptly to the Company and Parent written notice of such event, which notice shall state the number of additional Shares so acquired; provided, that no such notice shall be required with respect to any additional Shares acquired in connection with the Pre-Closing Financing. The Stockholder agrees that any such additional Shares shall constitute Subject Shares for all purposes of this Support Agreement and shall be subject to the terms of this Support Agreement, including all covenants, agreements, obligations, representations and warranties set forth herein as if those additional Shares were owned by the Stockholder on the date of this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stockholder&#8217;s Capacity.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;All agreements and understandings made herein shall be made solely in the Stockholder&#8217;s capacity as a holder of the Subject Shares and not in any other capacity, including not in the Stockholder&#8217;s capacity as a director or officer of the Company. Notwithstanding anything herein to the contrary, nothing herein shall in any way restrict a director of the Company (including any director who is an Affiliate of the Stockholder) in the taking of any actions (or failure to act) solely in his or her capacity as a director of the Company, or in the exercise of his or her fiduciary duties as a director of the Company, or prevent or be construed to create any obligation on the part of any director of the Company from taking any action in his or her capacity as such director, and no action taken solely in any such capacity as a director of the Company shall be deemed to constitute a breach of this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Other Offers.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except to the extent the Company is permitted to take such action pursuant to the Merger Agreement, the Stockholder (in the Stockholder&#8217;s capacity as such) shall not, and shall direct its Representatives not to, take any of the following actions: (a)&#160;solicit, initiate, knowingly encourage or knowingly facilitate an Acquisition Proposal; (b)&#160;furnish any non-public information regarding the Company to any Person in connection with or in response to an Acquisition Proposal (except as required by applicable Law, pursuant to applicable rules and regulations of any applicable national securities exchange or pursuant to a request by a Governmental Body); (c)&#160;engage in, enter into, continue or otherwise participate in any discussions or negotiations with any Person with respect to, or otherwise knowingly cooperate in any way with any Person (or any Representative thereof) with respect to, any Acquisition Proposal; (d)&#160;approve, endorse or recommend or publicly propose to approve, endorse or recommend, any Acquisition Proposal; or (e)&#160;enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or publicly proposing to approve, endorse or recommend, any Acquisition Transaction; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that none of the foregoing restrictions shall apply to the Stockholder&#8217;s and its Representatives&#8217; interactions with Parent, Merger Sub, the Company and their respective subsidiaries and Representatives; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, that nothing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;"> shall prevent the Stockholder from referring a Person to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;"> or to the Merger Agreement. Without limiting the foregoing, it is understood that any violation of the foregoing restrictions by any Representatives of the Stockholder shall be deemed to be a breach of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Communications.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;During the Voting Period, the Stockholder shall not, and shall direct its Representatives not to, make any press release, public announcement or other broad-based public communication that disparages this Support Agreement or the Merger Agreement or the Merger, without the prior written consent of Parent and the Company, except as may be required by applicable Law, including applicable rules and regulations of any national securities exchange applicable to Stockholder, in which circumstance such announcing party shall consult with the Company and Parent to the extent legally permissible prior to any such disclosure; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the foregoing shall not: (x)&#160;limit or affect any actions taken by the Stockholder (or any affiliated officer or director of Stockholder) that would be permitted to be taken by Stockholder pursuant to the Merger Agreement or (y)&#160;prohibit the Stockholder or its Representatives from communicating truthfully with any Governmental Body or from cooperating with any such Governmental Body, or testifying truthfully pursuant to subpoena, as required by valid legal process, in which circumstance such announcing party shall consult with the Company and Parent to the extent legally permissible prior to any such disclosure. The Stockholder hereby: (a)&#160;consents to and authorizes the publication and disclosure in all documents and schedules filed the with SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">with the Merger or any Contemplated Transaction of (i)&#160;the Stockholder&#8217;s identity, (ii)&#160;the Stockholder&#8217;s ownership of the Subject Shares, (iii)&#160;this Support Agreement and (iv)&#160;the nature of the Stockholder&#8217;s commitments, arrangements and understandings under this Support Agreement; and (b)&#160;agrees as promptly as practicable to notify Parent, Merger Sub and the Company of any required corrections with respect to any written information supplied by the Stockholder specifically for use in any such disclosure document. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Voting Trusts.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except for this Agreement and the Amended and Restated Voting Agreement of the Company, dated as of December&#160;22, 2020 (the &#8220;Voting Agreement&#8221;), the Stockholder agrees that it will not, nor will it permit any entity under its control to, deposit any of its Subject Shares in a voting trust or subject any of its Subject Shares to any arrangement with respect to the voting of such Subject Shares, in each case to the extent that such action would restrict the Stockholder from performing its obligations under this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Waiver of Appraisal Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Stockholder hereby irrevocably and unconditionally waives, and agrees not to assert, exercise or perfect (or attempt to exercise, assert or perfect) any rights of appraisal or rights to dissent from the Merger or quasi-appraisal rights that it may at any time have under applicable Laws, including Section&#160;262 of the DGCL. The Stockholder agrees not to commence, join in, facilitate, assist or encourage, and agrees to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against Parent, Merger Sub, the Company or any of their respective successors, directors or officers, (a)&#160;challenging the validity, binding nature or enforceability of, or seeking to enjoin the operation of, this Support Agreement or the Merger Agreement, or (b)&#160;alleging a breach of any fiduciary duty of any Person in connection with the evaluation, negotiation, entry into or consummation of transactions contemplated by the Merger Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that (i)&#160;the Stockholder may defend against, contest or settle any action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company and (ii)&#160;the foregoing shall not limit or restrict in any manner the Stockholder from enforcing the Stockholder&#8217;s rights under this Support Agreement and the other agreements entered into by the Stockholder in connection herewith, or otherwise in connection with the Merger, including the Stockholder&#8217;s right to receive the Merger Consideration pursuant to the terms of the Merger Agreement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE IV</font>
          <br >
          <font style="letter-spacing:-0.2pt;">REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Stockholder hereby represents and warrants to Parent and the Company as follows: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Due Authorization, etc.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Stockholder is a natural person, corporation, limited partnership or limited liability company. If the Stockholder is a corporation, limited partnership or limited liability company, the Stockholder is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, organized or constituted. The Stockholder has all necessary power and authority to execute and deliver this Support Agreement, perform the Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery by the Stockholder of this Support Agreement, the performance by the Stockholder&#8217;s of its obligations hereunder and the consummation by the Stockholder of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Stockholder and no other proceedings on the part of the Stockholder are necessary to authorize this Support Agreement, or to consummate the transactions contemplated hereby. This Support Agreement has been duly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by Parent and the Company) constitutes a valid and binding obligation of the Stockholder, enforceable against the Stockholder in accordance with its terms, except to the extent enforcement is limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors&#8217; rights and by general equitable principles. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Ownership of Shares.</font><font style="letter-spacing:0.2pt;"> </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;I</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;hereto sets forth opposite the Stockholder&#8217;s name the Shares over which the Stockholder has record ownership as of the date hereof. As of the date hereof, the Stockholder is the lawful record owner of the Shares denoted as being owned by the Stockholder on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;I</font><font style="letter-spacing:0.2pt;"> hereto, has the power to vote or cause to be voted such Shares and has the power to dispose of, or cause to be disposed, such Shares (other than, if the Stockholder is a partnership or a limited liability company, the rights and interest of Persons that own partnership interests or&#160;units in the Stockholder under </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the partnership agreement or operating agreement governing the Stockholder and applicable partnership or limited liability company law, or if the Stockholder is a married individual and resides in a state with community property laws, the community property interest of his or her spouse to the extent applicable under such community property laws, which spouse hereby consents to this Support Agreement by executing the spousal consent attached hereto as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exhibit&#160;A</font><font style="letter-spacing:0.2pt;">). The Stockholder has, and will at all times up until the Expiration Time have, good and valid title to the Shares denoted as being owned by the Stockholder on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;I</font><font style="letter-spacing:0.2pt;"> hereto, free and clear of any and all pledges, mortgages, liens, charges, proxies, voting agreements, encumbrances, adverse claims, options, security interests and demands of any nature or kind whatsoever, other than (a)&#160;those created by this Support Agreement, (b)&#160;those created by the Voting Agreement, (c)&#160;those created by the Amended and Restated Investors&#8217; Rights Agreement of the Company, dated as of December&#160;22, 2020, (d)&#160;those existing under applicable securities laws and (e)&#160;those that would not prevent or materially delay the Stockholder&#8217;s ability to perform its obligations under this Support Agreement. Without limiting the generality of the foregoing, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Shares denoted as being owned by the Stockholder on Schedule&#160;I hereto, and no such Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of such Shares except as provided hereunder and in the Voting Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Conflicts.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;(a)&#160;No filing with any Governmental Body, and no authorization, consent or approval of any other Person, is necessary for the execution of this Support Agreement by the Stockholder and (b)&#160;none of the execution and delivery of this Support Agreement by the Stockholder, the performance of the Stockholder&#8217;s obligations hereunder, the consummation by the Stockholder of the transactions contemplated hereby or compliance by the Stockholder with any of the provisions hereof shall (i)&#160;conflict with or result in any breach of the organizational documents of the Stockholder, (ii)&#160;result in, or give rise to, a violation or breach of or a default under any of the terms of any material Contract, understanding, agreement or other instrument or obligation to which the Stockholder is a party or by which the Stockholder or any of the Subject Shares or its assets may be bound or (iii)&#160;violate any applicable order, writ, injunction, decree, judgment, statute, rule or regulation, in each case except for any of the foregoing as would not reasonably be expected to prevent or materially delay the Stockholder&#8217;s ability to perform its obligations under this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Finder&#8217;s Fees.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;No investment banker, broker, finder or other intermediary is entitled, whether directly or indirectly, to a fee, commission or other benefit from Parent, Merger Sub or the Company in respect of this Support Agreement based upon any Contract made by or on behalf of the Stockholder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Reliance.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Stockholder has had the opportunity to review the Merger Agreement and this Support Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective Representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that Parent and the Company are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Litigation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As of the date of this Support Agreement, there is no Legal Proceeding pending or, to the knowledge of the Stockholder, threatened against the Stockholder that would reasonably be expected to prevent or materially delay the ability of the Stockholder to perform its obligations hereunder or consummate the transactions contemplated hereby. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE V</font>
          <br >
          <font style="letter-spacing:-0.2pt;">TERMINATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 5.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Termination.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This Support Agreement shall automatically terminate, and none of Parent, the Company or the Stockholder shall have any rights or obligations hereunder and this Support Agreement shall become null and void and have no effect upon the earliest to occur of: (a)&#160;the Effective Time; (b)&#160;the valid termination of the Merger Agreement in accordance with its terms; (c)&#160;any amendment to the Merger Agreement that reduces the amount, or changes the form of any consideration payable to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Stockholder in the Contemplated Transactions; (d)&#160;the time this Support Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent; and (e)&#160;the End Date (as defined in the Merger Agreement in effect on the date hereof) provided that the Effective Time has not occurred on or before such date. The parties acknowledge that upon termination of this Support Agreement as permitted under and in accordance with the terms of this Support Agreement, no party to this Support Agreement shall have the right to recover any claim with respect to any losses suffered by such party in connection with such termination, and no party shall have any further obligations or liabilities under this Support Agreement, subject to the following sentence. Notwithstanding anything to the contrary herein, (i)&#160;nothing set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.1</font><font style="letter-spacing:0.2pt;"> shall relieve any party from liability for any willful breach of this Support Agreement prior to termination hereof, and (ii)&#160;the provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;V</font><font style="letter-spacing:0.2pt;"> and of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;VI</font><font style="letter-spacing:0.2pt;"> (other than </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.1</font><font style="letter-spacing:0.2pt;">) shall survive the termination of this Support Agreement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE VI</font>
          <br >
          <font style="letter-spacing:-0.2pt;">MISCELLANEOUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Further Actions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to the terms and conditions set forth in this Support Agreement, the Stockholder agrees to take any and all actions and to do all things reasonably necessary to effectuate this Support Agreement. If the Stockholder is a married individual, his or her spouse shall deliver the spousal consent attached hereto as Exhibit&#160;A unless such Stockholder can demonstrate to Parent&#8217;s and the Company&#8217;s reasonable satisfaction that his or her spouse does not have any community property interests in the Subject Shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Fees and Expenses.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as otherwise specifically provided herein, each party shall bear its own fees and expenses in connection with this Support Agreement and the transactions contemplated hereby. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Amendments, Waivers, etc.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This Support Agreement may not be amended except by an instrument in writing signed by all the parties hereto and specifically referencing this Support Agreement. No failure on the part of any party to exercise any power, right privilege or remedy under this Support Agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under this Support Agreement, shall operate as a waiver of such power, right, privilege or remedy, and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No party shall be deemed to have waived any claim arising out of this Support Agreement, or any power, right, privilege or remedy under this Support Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notices.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand, or (c)&#160;on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00&#160;p.m. New York time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If to the Company, to </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Attn: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Email: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;] </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to (which shall not constitute notice): </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Attn: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Email: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;] </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If to Parent, to </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Attn: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Email: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;] </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to (which shall not constitute notice): </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Attn: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Email: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;] </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If to the Stockholder, to the address or electronic mail address set forth on the signature pages hereto or to such other Person or address as any party shall specify by written notice so given. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Interpretation; Construction.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Headings of the Articles and Sections of this Support Agreement are for convenience of the parties only, and shall be given no substantive or interpretive effect whatsoever. Except as otherwise indicated, all references in this Support Agreement to &#8220;Exhibits&#8221;, &#8220;Sections&#8221; or &#8220;Schedules&#8221; are intended to refer to Sections of this Support Agreement and the Exhibits or Schedules to this Support Agreement. Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Support Agreement. As used in this Support Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; For purposes of this Support Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Severability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Any term or provision of this Support Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Support Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Support Agreement is invalid or unenforceable, the parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Support Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Entire Agreement; Assignment.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This Support Agreement constitutes the entire agreement, and supersedes all other prior agreements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter hereof; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that, as between the Company and Parent, to the extent of any conflict between the Merger Agreement and this Support Agreement, the terms of the Merger Agreement shall control and supersede any such conflicting terms. This Support Agreement will be binding upon, inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns, and, in the case of Stockholder, such Persons to which record or beneficial ownership of the Stockholder&#8217;s Subject shares shall pass; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that neither this Support Agreement nor any of the rights, interests or obligations hereunder shall be assigned or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">delegated by any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of the other parties, except that, without consent, each of Parent and the Company may assign all or any of its rights and obligations hereunder to any of its Affiliates that assume the rights and obligations of such party under the Merger Agreement, and any attempted assignment or delegation of this Support Agreement or any of the rights, interests or obligations by any of the parties without the other parties prior written consent shall be void and of no effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Governing Law.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;THIS SUPPORT AGREEMENT AND ALL QUESTIONS RELATING TO THE INTERPRETATION OR ENFORCEMENT OF THIS SUPPORT AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAW OF THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF TO THE EXTENT THAT SUCH PRINCIPLES WOULD DIRECT A MATTER TO ANOTHER JURISDICTION. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Specific Performance.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The parties hereto acknowledge that any breach of this Support Agreement would give rise to irreparable harm for which monetary damages, even if applicable, would not be an adequate remedy, and would occur in the event that any party does not perform the provisions of this Support Agreement (including failing to take such actions as are required of it hereunder to consummate the transactions contemplated hereby) in accordance with its specified terms or otherwise breaches such provisions. Accordingly, the parties shall be entitled to a decree of specific performance, an injunction or other equitable relief to prevent breaches or threatened breaches of any of the provisions of this Support Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy to which they are entitled at law or in equity. Each of the parties agrees that it will not oppose the granting of specific performance, an injunction or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance or other equitable relief is not an appropriate remedy for any reason at law or in equity. Any party seeking an injunction or injunctions to prevent breaches of this Support Agreement shall not be required to provide any bond or other security in connection with any such order or injunction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Submission to Jurisdiction.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The parties hereby (a)&#160;irrevocably and unconditionally submit to the exclusive personal jurisdiction and venue of the Court of Chancery of the State of Delaware, New Castle County, or, if the Chancery Court declines jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware, (b)&#160;agree that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&#160;of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.10</font><font style="letter-spacing:0.2pt;">, (c)&#160;waive any objection to laying venue in any such action or proceeding in such courts, (d)&#160;waive any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (e)&#160;agree that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.4</font><font style="letter-spacing:0.2pt;"> of this Support Agreement. Nothing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.10</font><font style="letter-spacing:0.2pt;">, however, shall affect the right of any person to serve legal process in any other manner permitted by Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Waiver of Jury Trial.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (i)&#160;ARISING UNDER THIS SUPPORT AGREEMENT OR (ii)&#160;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS SUPPORT AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS SUPPORT AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS SUPPORT AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">C-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:548pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.12&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Counterparts</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Support Agreement may be executed in two or more counterparts (including by facsimile transmission or other means of electronic transmission, such as by electronic mail in &#8220;pdf&#8221; form), each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by facsimile or otherwise) to the other parties. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(Signature Page Follows)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">C-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">IN WITNESS WHEREOF, the Company, Parent and the Stockholder have caused this Support Agreement to be duly executed as of the day and year first above written. </font>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By:</font>
        </div>
        <div style="margin-left:240pt; margin-top:3.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Name: </font>
          <br >
          <font style="letter-spacing:0.2pt;">Title: </font>
        </div>
        <div style="margin-left:220pt; margin-top:24pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By:</font>
        </div>
        <div style="margin-left:240pt; margin-top:3.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Name: </font>
          <br >
          <font style="letter-spacing:0.2pt;">Title: </font>
        </div>
        <div style="margin-left:220pt; margin-top:24pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">STOCKHOLDER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By:</font>
        </div>
        <div style="margin-left:240pt; margin-top:3.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Name: </font>
          <br >
          <font style="letter-spacing:0.2pt;">Title: </font>
        </div>
        <div style="margin-left:240pt; margin-top:24pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Address: </font>
        </div>
        <div style="margin-left:240pt; margin-top:36pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Electronic Mail Address: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[</font><font style="font-style:italic;letter-spacing:0.2pt;">Signature Page to Stockholder Support Agreement</font><font style="letter-spacing:0.2pt;">]</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Exhibit&#160;A</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Form of Spousal Consent</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I acknowledge that I have read the Stockholder Support Agreement (to which this consent is attached) and that I know and understand, and have been fully advised by my attorney with respect to, its contents. As the spouse of the Stockholder, I hereby agree: (i)&#160;that all shares of capital stock, all options, all warrants and all additional securities of the Company held by the Stockholder, and all other rights with respect to the capital stock of the Company held by the Stockholder, and my interest in such shares, options, warrants, additional securities and other rights, if any, are subject to the provisions of the Stockholder Support Agreement and the Merger Agreement (as defined in the Stockholder Support Agreement), which I consent to; and (ii)&#160;that I will take no action at any time to hinder the operation of the Stockholder Support Agreement or the Merger Agreement. </font>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURE OF SPOUSE:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:220pt; margin-top:26.5pt; width:236pt;">
          <div style="margin-left: 0pt; width: 236pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="border-collapse:collapse;width:236pt;margin-top:19.5pt;margin-left:220pt;white-space:nowrap;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="vertical-align:baseline;">
            <td style="width:287.38pt;">
              <font style="letter-spacing:0.2pt;">Printed Name:&#8199;</font>
            </td>
            <td style="padding-left:0pt;text-align:right;max-width:168.62pt;">
              <div style="margin-left: 0pt; width: 168.62pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:normal;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Schedule&#160;I</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.2pt;">Ownership of Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:32.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Name and Address of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">[&#8226;]</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">[&#8226;]</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">[&#8226;]</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tANND">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX D</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This STOCKHOLDER SUPPORT AGREEMENT (this &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Support Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) is entered into as of [&#8199;&#8199;&#8199;], 2022, among CARISMA Therapeutics Inc., a Delaware corporation (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;), Sesen Bio, Inc., a Delaware corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221;), and the undersigned stockholder (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Stockholder</font><font style="letter-spacing:0.2pt;">&#8221;) of Parent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, as of the date hereof, the Stockholder is the sole record owner of and has the sole power to vote (or to direct the voting of) the number of shares of common stock, par value $0.001 per share, of Parent (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Common Stock</font><font style="letter-spacing:0.2pt;">&#8221;), set forth opposite the Stockholder&#8217;s name on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;I</font><font style="letter-spacing:0.2pt;"> hereto (such Common Stock, together with any other shares of Parent that are hereafter issued to or otherwise acquired or owned by, including upon exercise of options or securities convertible into or exercisable or exchangeable for Common Stock (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Shares</font><font style="letter-spacing:0.2pt;">&#8221;), the voting power of which is acquired by such Stockholder during the Voting Period (as defined below), are collectively referred to herein as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Subject Shares</font><font style="letter-spacing:0.2pt;">&#8221;); </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, the Company, Parent, and Seahawk Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub</font><font style="letter-spacing:0.2pt;">&#8221;), are concurrently entering into an Agreement and Plan of Merger and Reorganization, dated on or about the date hereof (as amended from time to time, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), pursuant to which Merger Sub shall be merged with and into the Company, with the Company continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger</font><font style="letter-spacing:0.2pt;">&#8221;); </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, the adoption of the Merger Agreement and the transactions contemplated thereby requires the written consent or affirmative vote of (i)&#160;the holders of a majority of the outstanding shares of Common Stock entitled to vote on the record date for the Parent Stockholders&#8217; Meeting and (ii)&#160;the holders of a majority in voting power of the votes cast by the holders of all shares of Common Stock present or represented by proxy at the Parent Stockholders&#8217; Meeting and entitled to vote thereon; and </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, as a condition and inducement to the Company&#8217;s willingness to enter into the Merger Agreement and consummate the transactions contemplated thereby, Parent and the Company have required the Stockholder to, as an inducement and in consideration therefor, and the Stockholder (in the Stockholder&#8217;s capacity as holder of the Subject Shares) has agreed to, enter into this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, the parties agree as follows: </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE I</font>
          <br >
          <font style="letter-spacing:-0.2pt;">DEFINITIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 1.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Capitalized Terms</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;For purposes of this Support Agreement, capitalized terms used and not defined herein shall have the respective meanings ascribed to them in the Merger Agreement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Expiration Time</font><font style="letter-spacing:0.2pt;">&#8221; shall mean the earliest to occur of (i)&#160;the Effective Time, (ii)&#160;any amendment to the Merger Agreement that reduces the amount, or changes the form of any consideration payable to the Stockholder in the transaction or otherwise materially and adversely affects the Stockholder and (iii)&#160;the date and time of the valid termination of the Merger Agreement in accordance with its terms. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Voting Period</font><font style="letter-spacing:0.2pt;">&#8221; shall mean such period of time between the date hereof and the Expiration Time. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE II</font>
          <br >
          <font style="letter-spacing:-0.2pt;">VOTING AGREEMENT AND IRREVOCABLE PROXY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 2.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Agreement to Vote.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Stockholder hereby agrees that, during the Voting Period, and at any duly called meeting of the stockholders of Parent (or any adjournment or postponement thereof), or in any other circumstances (including action by written consent of stockholders in lieu of a meeting) upon which a vote, adoption or other approval or consent with respect to the adoption of the Merger Agreement or the approval of the Merger and any of the transactions contemplated thereby is sought, the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">D-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stockholder, if a meeting is held, appear at the meeting, in person or by proxy, and shall provide a written consent (a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Written Consent</font><font style="letter-spacing:0.2pt;">&#8221;) or vote (or cause to be voted), in person or by proxy, all of the Subject Shares, in each case (i)&#160;in favor of (A)&#160;any proposal to adopt and approve or reapprove the Merger Agreement and the transactions contemplated thereby, including (1)&#160;adoption and approval of the Merger Agreement and the Contemplated Transactions, (2)&#160;the issuance of shares of Common Stock to the Company&#8217;s stockholders in connection with the Contemplated Transactions pursuant to the terms of the Merger Agreement, (3)&#160;the change of control of Parent resulting from the Merger pursuant to Nasdaq rules, (4)&#160;the approval of the Equity Plan&#160;Amendments, and (B)&#160;waiving any notice that may have been or may be required relating to the Merger or any of the other Contemplated Transactions (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Stockholder Approval Matters</font><font style="letter-spacing:0.2pt;">&#8221;), and (ii)&#160;against any Acquisition Proposal and any action in furtherance of any such Acquisition Proposal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 2.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Grant of Irrevocable Proxy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the event and to the extent that the Stockholder fails to vote the Subject Shares in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1</font><font style="letter-spacing:0.2pt;"> at any applicable meeting of the stockholders of Parent or pursuant to any applicable meeting of the stockholders of Parent or pursuant to any applicable written consent of the stockholders of Parent, the Stockholder hereby appoints Parent and any designee of Parent, and each of them individually, as the Stockholder&#8217;s proxy, with full power of substitution and re-substitution, to vote, including by executing written consents, during the Voting Period with respect to any and all of the Subject Shares on the matters and in the manner specified in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1</font><font style="letter-spacing:0.2pt;">. The Stockholder shall take all further action or execute such other instruments as may be necessary to effectuate the intent of any such proxy. The Stockholder affirms that the irrevocable proxy given by it hereby with respect to the Merger Agreement and the Contemplated Transactions is given to Parent by the Stockholder to secure the performance of the obligations of the Stockholder under this Support Agreement. It is agreed that Parent (and its designees) will use the irrevocable proxy that is granted by the Stockholder hereby only in accordance with applicable Laws and that, to the extent Parent (and its designees) uses such irrevocable proxy, it will only vote (or sign written consents in respect of) the Subject Shares subject to such irrevocable proxy with respect to the matters specified in, and in accordance with the provisions of, </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.1</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 2.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Nature of Irrevocable Proxy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The proxy granted pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;"> to Parent by the Stockholder shall be irrevocable during the term of this Support Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall revoke any and all prior proxies or powers of attorney granted by the Stockholder and no subsequent proxy or power of attorney shall be given or written consent executed (and if given or executed, shall not be effective) by the Stockholder with respect thereto. The proxy that may be granted hereunder shall terminate upon the termination of this Support Agreement, but shall survive the death or incapacity of the Stockholder and any obligation of the Stockholder under this Support Agreement shall be binding upon the heirs, personal representatives and successors of the Stockholder. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE III</font>
          <br >
          <font style="letter-spacing:-0.2pt;">COVENANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Subject Shares.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Stockholder agrees that (i)&#160;from the date hereof until the Expiration Time, it shall not, and shall not commit or agree to, without the prior written consent of Parent and the Company, directly or indirectly, whether by merger, consolidation or otherwise, offer for sale, sell (including short sales), transfer, tender, pledge, encumber, assign or otherwise dispose of (including by gift or by operation of law) (collectively, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Transfer</font><font style="letter-spacing:0.2pt;">&#8221;), or enter into any contract, option, derivative, hedging or other agreement or arrangement or understanding (including any profit-sharing arrangement) with respect to, or consent to or permit, a Transfer of, any or all of the Subject Shares or any interest therein; and (ii)&#160;during the Voting Period, it shall not, and shall not commit or agree to, without the prior written consent of Parent and the Company, (A)&#160;grant any proxies or powers of attorney with respect to any or all of the Subject Shares or agree to vote (or sign written consents in respect of) the Subject Shares on any matter or divest itself of any voting rights in the Subject Shares that would conflict with the terms of this Support Agreement, or (B)&#160;take any action that would have the effect of preventing or disabling the Stockholder from performing its obligations under this Support Agreement. Notwithstanding the foregoing, the Stockholder may, at any time, Transfer its Subject Shares (1)&#160;by will or other testamentary document or by intestacy, (2)&#160;to any investment fund or other entity controlled or managed by the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">D-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stockholder or the investment adviser or general partner of the Stockholder,, (3)&#160;to any member of the Stockholder&#8217;s immediate family, (4)&#160;to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder or otherwise for estate planning purposes or (5)&#160;to the extent required by applicable Law; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the case of clauses (1)-(4), such permitted transferee shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Support Agreement. The Stockholder agrees that any Transfer of Subject Shares not permitted hereby shall be null and void and that any such prohibited Transfer shall be enjoined. If any voluntary or involuntary Transfer of any Subject Shares covered hereby shall occur (including a sale by the Stockholder&#8217;s trustee in bankruptcy, or a sale to a purchaser at any creditor&#8217;s or court sale), the permitted transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee) shall take and hold such Subject Shares subject to all of the restrictions, liabilities and rights under this Support Agreement, which shall continue in full force and effect. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;In the event of a stock dividend or distribution, or any change in the Subject Shares by reason of any stock dividend or distribution, split-up, recapitalization, combination, conversion, exchange of shares or the like, the term &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Subject Shares</font><font style="letter-spacing:0.2pt;">&#8221; shall be deemed to refer to and include the Subject Shares as well as all such stock dividends and distributions and any securities into which or for which any or all of the Subject Shares may be changed or exchanged or which are received in such transaction. The Stockholder further agrees that, in the event the Stockholder purchases or otherwise acquires beneficial or record ownership of or an interest in, or acquires the right to vote or share in the voting of, any additional Shares, in each case after the execution of this Support Agreement and prior to the Expiration Time, the Stockholder shall deliver promptly to the Company and Parent written notice of such event, which notice shall state the number of additional Shares so acquired. The Stockholder agrees that any such additional Shares shall constitute Subject Shares for all purposes of this Support Agreement and shall be subject to the terms of this Support Agreement, including all covenants, agreements, obligations, representations and warranties set forth herein as if those additional Shares were owned by the Stockholder on the date of this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stockholder&#8217;s Capacity.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;All agreements and understandings made herein shall be made solely in the Stockholder&#8217;s capacity as a holder of the Subject Shares and not in any other capacity, including not in the Stockholder&#8217;s capacity as a director or officer of Parent. Notwithstanding anything herein to the contrary, nothing herein shall in any way restrict a director of Parent (including any director who is an Affiliate of the Stockholder) in the taking of any actions (or failure to act) solely in his or her capacity as a director of Parent, or in the exercise of his or her fiduciary duties as a director of Parent, or prevent or be construed to create any obligation on the part of any director of Parent from taking any action in his or her capacity as such director, and no action taken solely in any such capacity as a director of Parent shall be deemed to constitute a breach of this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Other Offers.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except to the extent Parent is permitted to take such action pursuant to the Merger Agreement, the Stockholder (in the Stockholder&#8217;s capacity as such) shall not, and shall instruct and cause its Representatives not to, take any of the following actions: (a)&#160;solicit, initiate, knowingly encourage or knowingly facilitate an Acquisition Proposal; (b)&#160;furnish any non-public information regarding Parent to any Person in connection with or in response to an Acquisition Proposal (except as required by applicable Law or pursuant to a request by a Governmental Body); (c)&#160;engage in, enter into, continue or otherwise participate in any discussions or negotiations with any Person with respect to, or otherwise knowingly cooperate in any way with any Person (or any representative thereof) with respect to, any Acquisition Proposal; (d)&#160;approve, endorse or recommend or publicly propose to approve, endorse or recommend, any Acquisition Proposal; or (e)&#160;enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or publicly proposing to approve, endorse or recommend, any Acquisition Transaction; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that none of the foregoing restrictions shall apply to the Stockholder&#8217;s and its Representatives&#8217; interactions with Parent, Merger Sub, the Company and their respective subsidiaries and Representatives; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">further</font><font style="letter-spacing:0.2pt;">, that nothing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;"> shall prevent the Stockholder from referring a Person to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;"> or to the Merger Agreement. Without limiting the foregoing, it is understood that any violation of the foregoing restrictions by any Representatives of the Stockholder shall be deemed to be a breach of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Communications.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;During the Voting Period, the Stockholder shall not, and shall use its reasonable best efforts to cause its Representatives, if any, not to, directly or indirectly, make any press </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">D-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">release, public announcement or other public communication that criticizes or disparages this Support Agreement or the Merger Agreement or any of the transactions contemplated hereby and thereby, without the prior written consent of Parent and the Company, except as may be required by applicable Law in which circumstance such announcing party shall consult with the Company and Parent to the extent legally permissible prior to any such disclosure; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the foregoing shall not limit or affect any actions taken by the Stockholder (or any affiliated officer or director of Stockholder) that would be permitted to be taken by Stockholder pursuant to the Merger Agreement. The Stockholder hereby: (a)&#160;consents to and authorizes the publication and disclosure in all documents and schedules filed the with SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger or any Contemplated Transaction of (i)&#160;the Stockholder&#8217;s identity, (ii)&#160;the Stockholder&#8217;s ownership of the Subject Shares, (iii)&#160;this Support Agreement and (iv)&#160;the nature of the Stockholder&#8217;s commitments, arrangements and understandings under this Support Agreement; and (b)&#160;agrees as promptly as practicable to notify Parent, Merger Sub and the Company of any required corrections with respect to any written information supplied by the Stockholder specifically for use in any such disclosure document. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Voting Trusts.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except for this Agreement, the Stockholder agrees that it will not, nor will it permit any entity under its control to, deposit any of its Subject Shares in a voting trust or subject any of its Subject Shares to any arrangement with respect to the voting of such Subject Shares that would restrict the Stockholder from performing its obligations under this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 3.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Waiver of Appraisal Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Stockholder hereby irrevocably and unconditionally waives, and agrees not to assert, exercise or perfect (or attempt to exercise, assert or perfect) any rights of appraisal or rights to dissent from the Merger or quasi-appraisal rights that it may at any time have under applicable Laws, including Section&#160;262 of the DGCL. The Stockholder agrees not to commence, join in, facilitate, assist or encourage, and agrees to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against Parent, Merger Sub, the Company or any of their respective successors, directors or officers, (a)&#160;challenging the validity, binding nature or enforceability of, or seeking to enjoin the operation of, this Support Agreement or the Merger Agreement, or (b)&#160;alleging a breach of any fiduciary duty of any Person in connection with the evaluation, negotiation, entry into or consummation of the Merger Agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that (i)&#160;the Stockholder may defend against, contest or settle any action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of Parent and (ii)&#160;the foregoing shall not limit or restrict in any manner the Stockholder from enforcing the Stockholder&#8217;s rights under this Support Agreement and the other agreements entered into by the Stockholder in connection herewith, or otherwise in connection with the Merger, including the Stockholder&#8217;s right to receive the Merger Consideration pursuant to the terms of the Merger Agreement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE IV</font>
          <br >
          <font style="letter-spacing:-0.2pt;">REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Stockholder hereby represents and warrants to Parent and the Company as follows: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Due Authorization, etc.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Stockholder is a natural person, corporation, limited partnership or limited liability company. If the Stockholder is a corporation, limited partnership or limited liability company, Stockholder is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, organized or constituted. The Stockholder has all necessary power and authority to execute and deliver this Support Agreement, perform the Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery by the Stockholder of this Support Agreement, the performance by the Stockholder&#8217;s of its obligations hereunder and the consummation by the Stockholder of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Stockholder and no other proceedings on the part of the Stockholder are necessary to authorize this Support Agreement, or to consummate the transactions contemplated hereby. This Support Agreement has been duly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by Parent and the Company) constitutes a valid and binding obligation of the Stockholder, enforceable against the Stockholder in accordance with its terms, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">D-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">except to the extent enforcement is limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors&#8217; rights and by general equitable principles. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Ownership of Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;I</font><font style="letter-spacing:0.2pt;"> hereto sets forth opposite the Stockholder&#8217;s name the Shares over which the Stockholder has record ownership as of the date hereof. As of the date hereof, the Stockholder is the lawful record owner of the Shares denoted as being owned by the Stockholder on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;I</font><font style="letter-spacing:0.2pt;"> hereto, has the power to vote or cause to be voted such Shares and has the power to dispose of, or cause to be disposed, such Shares (other than, if the Stockholder is a partnership or a limited liability company, the rights and interest of Persons that own partnership interests or&#160;units in the Stockholder under the partnership agreement or operating agreement governing the Stockholder and applicable partnership or limited liability company law, or if the Stockholder is a married individual and resides in a state with community property laws, the community property interest of his or her spouse to the extent applicable under such community property laws, which spouse hereby consents to this Support Agreement by executing the spousal consent attached hereto as </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exhibit&#160;A</font><font style="letter-spacing:0.2pt;">). The Stockholder has, and will at all times up until the Expiration Time have, good and valid title to the Shares denoted as being owned by the Stockholder on </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Schedule&#160;I</font><font style="letter-spacing:0.2pt;"> hereto, free and clear of any and all pledges, mortgages, liens, charges, proxies, voting agreements encumbrances, adverse claims, options, security interests and demands of any nature or kind whatsoever, other than (a)&#160;those created by this Support Agreement, (b)&#160;those existing under applicable securities laws and (c)&#160;those that would not adversely affect the Stockholder&#8217;s ability to perform its obligations under this Support Agreement. Without limiting the generality of the foregoing, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Shares, and no Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of the Shares except as provided hereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Conflicts.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;(a)&#160;No filing with any Governmental Body, and no authorization, consent or approval of any other Person, is necessary for the execution of this Support Agreement by the Stockholder and (b)&#160;none of the execution and delivery of this Support Agreement by the Stockholder, the performance of the Stockholder&#8217;s obligations hereunder, the consummation by the Stockholder of the transactions contemplated hereby or compliance by the Stockholder with any of the provisions hereof shall (i)&#160;conflict with or result in any breach of the organizational documents of the Stockholder, (ii)&#160;result in, or give rise to, a violation or breach of or a default under any of the terms of any material Contract, understanding, agreement or other instrument or obligation to which the Stockholder is a party or by which the Stockholder or any of the Subject Shares or its assets may be bound or (iii)&#160;violate any applicable order, writ, injunction, decree, judgment, statute, rule or regulation, except for any of the foregoing as would not reasonably be expected to impair the Stockholder&#8217;s ability to perform its obligations under this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Finder&#8217;s Fees.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;No investment banker, broker, finder or other intermediary is entitled, whether directly or indirectly, to a fee, commission or other benefit from Parent, Merger Sub or the Company in respect of this Support Agreement based upon any Contract made by or on behalf of the Stockholder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Reliance.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Stockholder has had the opportunity to review the Merger Agreement and this Support Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective Representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that Parent and the Company are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Support Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 4.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Litigation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As of the date of this Support Agreement, there is no Legal Proceeding pending or, to the knowledge of the Stockholder, threatened against the Stockholder that would reasonably be expected to impair the ability of the Stockholder to perform its obligations hereunder or consummate the transactions contemplated hereby. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">D-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE V</font>
          <br >
          <font style="letter-spacing:-0.2pt;">TERMINATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 5.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Termination.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This Support Agreement shall automatically terminate, and none of Parent, the Company or the Stockholder shall have any rights or obligations hereunder and this Support Agreement shall become null and void and have no effect upon the earliest to occur of: (a)&#160;the Effective Time; (b)&#160;the valid termination of the Merger Agreement in accordance with its terms; (c)&#160;any amendment to the Merger Agreement that reduces the amount, or changes the form of any consideration payable to the Stockholder in the Contemplated Transactions or otherwise materially and adversely affects the Stockholder; and (d)&#160;the time this Support Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent. The parties acknowledge that upon termination of this Support Agreement as permitted under and in accordance with the terms of this Support Agreement, no party to this Support Agreement shall have the right to recover any claim with respect to any losses suffered by such party in connection with such termination, and no party shall have any further obligations or liabilities under this Support Agreement, subject to the following sentence. Notwithstanding anything to the contrary herein, (i)&#160;nothing set forth in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;5.1</font><font style="letter-spacing:0.2pt;"> shall relieve any party from liability for any willful breach of this Support Agreement prior to termination hereof, and (ii)&#160;the provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;V</font><font style="letter-spacing:0.2pt;"> and of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Article&#160;VI</font><font style="letter-spacing:0.2pt;"> shall survive the termination of this Support Agreement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ARTICLE VI</font>
          <br >
          <font style="letter-spacing:-0.2pt;">MISCELLANEOUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.1&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Further Actions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to the terms and conditions set forth in this Support Agreement, the Stockholder agrees to take any all actions and to do all things reasonably necessary to effectuate this Support Agreement. If the Stockholder is a married individual, his or her spouse shall deliver the spousal consent attached hereto as Exhibit&#160;A unless such Stockholder can demonstrate to Parent&#8217;s and the Company&#8217;s reasonable satisfaction that his or her spouse does not have any community property interests in the Subject Shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.2&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Fees and Expenses.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as otherwise specifically provided herein, each party shall bear its own fees and expenses in connection with this Support Agreement and the transactions contemplated hereby. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.3&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Amendments, Waivers, etc.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This Support Agreement may not be amended except by an instrument in writing signed by all the parties hereto and specifically referencing this Support Agreement. No failure on the part of any party to exercise any power, right privilege or remedy under this Support Agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under this Support Agreement, shall operate as a waiver of such power, right, privilege or remedy, and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No party shall be deemed to have waived any claim arising out of this Support Agreement, or any power, right, privilege or remedy under this Support Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.4&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Notices.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand, or (c)&#160;on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00&#160;p.m. New York time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If to the Company, to </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Attn: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Email: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;] </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">D-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to (which shall not constitute notice): </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Attn: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Email: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;] </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If to Parent, to </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Attn: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Email: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;] </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to (which shall not constitute notice): </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Attn: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;]</font> <br ><font style="letter-spacing:0.2pt;">Email: [&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;] </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If to the Stockholder, to the address or electronic mail address set forth on the signature pages hereto or to such other Person or address as any party shall specify by written notice so given. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.5&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Interpretation; Construction.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Headings of the Articles and Sections of this Support Agreement are for convenience of the parties only, and shall be given no substantive or interpretive effect whatsoever. Except as otherwise indicated, all references in this Support Agreement to &#8220;Exhibits&#8221;, &#8220;Sections&#8221; or &#8220;Schedules&#8221; are intended to refer to Sections of this Support Agreement and the Exhibits or Schedules to this Support Agreement. Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Support Agreement. As used in this Support Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; For purposes of this Support Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.6&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Severability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Any term of provision of this Support Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Support Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Support Agreement is invalid or unenforceable, the parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Support Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.7&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Entire Agreement; Assignment.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This Support Agreement constitutes the entire agreement, and supersedes all other prior agreements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter hereof; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that, as between the Company and Parent, to the extent of any conflict between the Merger Agreement and this Support Agreement, the terms of the Merger Agreement shall control and supersede any such conflicting terms. This </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">D-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Support Agreement will be binding upon, inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns, and, in the case of Stockholder, such Persons to which record or beneficial ownership of the Stockholder&#8217;s Subject shares shall pass; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that neither this Support Agreement nor any of the rights, interests or obligations hereunder shall be assigned or delegated by any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of the other parties, except that, without consent, each of Parent and the Company may assign all or any of its rights and obligations hereunder to any of its Affiliates that assume the rights and obligations of such party under the Merger Agreement, and any attempted assignment or delegation of this Support Agreement or any of the rights, interests or obligations by any of the parties without the other parties prior written consent shall be void and of no effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.8&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Governing Law.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;THIS SUPPORT AGREEMENT AND ALL QUESTIONS RELATING TO THE INTERPRETATION OR ENFORCEMENT OF THIS SUPPORT AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAW OF THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF TO THE EXTENT THAT SUCH PRINCIPLES WOULD DIRECT A MATTER TO ANOTHER JURISDICTION. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.9&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Specific Performance.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The parties hereto acknowledge that any breach of this Support Agreement would give rise to irreparable harm for which monetary damages, even if applicable, would not be an adequate remedy, would occur in the event that any party does not perform the provisions of this Support Agreement (including failing to take such actions as are required of it hereunder to consummate the transactions contemplated hereby) in accordance with its specified terms or otherwise breaches such provisions. Accordingly, the parties shall be entitled to a decree of specific performance, an injunction or other equitable relief to prevent breaches or threatened breaches of any of the provisions of this Support Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy to which they are entitled at law or in equity. Each of the parties agrees that it will not oppose the granting of specific performance, an injunction or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance or other equitable relief is not an appropriate remedy for any reason at law or in equity. Any party seeking an injunction or injunctions to prevent breaches of this Support Agreement shall not be required to provide any bond or other security in connection with any such order or injunction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.10&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Submission to Jurisdiction.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The parties hereby (a)&#160;irrevocably and unconditionally submit to the exclusive personal jurisdiction and venue of the Court of Chancery of the State of Delaware, New Castle County, or, if the Chancery Court declines jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware, (b)&#160;agree that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&#160;of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.10</font><font style="letter-spacing:0.2pt;">, (c)&#160;waive any objection to laying venue in any such action or proceeding in such courts, (d)&#160;waive any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (e)&#160;agree that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.4</font><font style="letter-spacing:0.2pt;"> of this Support Agreement. Nothing in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.10</font><font style="letter-spacing:0.2pt;">, however, shall affect the right of any person to serve legal process in any other manner permitted by Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.11&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Waiver of Jury Trial.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (i)&#160;ARISING UNDER THIS SUPPORT AGREEMENT OR (ii)&#160;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS SUPPORT AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS SUPPORT AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS SUPPORT AGREEMENT WITH ANY COURT AS </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">D-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:516pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SECTION 6.12&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Counterparts</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;This Support Agreement may be executed in two or more counterparts (including by facsimile transmission or other means of electronic transmission, such as by electronic mail in &#8220;pdf&#8221; form), each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by facsimile or otherwise) to the other parties. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(Signature Page Follows)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">D-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">IN WITNESS WHEREOF, the Company, Parent and the Stockholder have caused this Support Agreement to be duly executed as of the day and year first above written. </font>
        </div>
        <table style="width:456pt;height:361pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt; width:0pt;" colspan="7">
              <font style="letter-spacing:-0.2pt;">CARISMA THERAPEUTICS INC. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:27.5pt 0pt 0.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:27.5pt 0pt 0.5pt 0pt; width:0pt;white-space:normal;" colspan="4">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:5pt 0pt 0.5pt 0pt; width:48pt;">
              <font style="letter-spacing:0.2pt;">Name: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:156pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:48pt;">
              <font style="letter-spacing:0.2pt;">Title:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:156pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:40pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:29.5pt 0pt 1.5pt 0pt; width:0pt;" colspan="7">
              <font style="letter-spacing:-0.2pt;">SESEN BIO, INC. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:27.5pt 0pt 0.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:27.5pt 0pt 0.5pt 0pt; width:0pt;white-space:normal;" colspan="4">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:5pt 0pt 0.5pt 0pt; width:48pt;">
              <font style="letter-spacing:0.2pt;">Name: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:156pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:48pt;">
              <font style="letter-spacing:0.2pt;">Title:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:156pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:40pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:29.5pt 0pt 1.5pt 0pt; width:0pt;" colspan="7">
              <font style="letter-spacing:-0.2pt;">STOCKHOLDER </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:27.5pt 0pt 0.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:27.5pt 0pt 0.5pt 0pt; width:0pt;white-space:normal;" colspan="4">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:5pt 0pt 0.5pt 0pt; width:48pt;">
              <font style="letter-spacing:0.2pt;">Name: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:156pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:48pt;">
              <font style="letter-spacing:0.2pt;">Title:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:156pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:17.5pt 0pt 0.5pt 0pt; width:48pt;">
              <font style="letter-spacing:0.2pt;">Address:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:156pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:39pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:202pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:28.5pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:0.2pt;">Electronic Mail Address:</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:255.56pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[</font><font style="font-style:italic;letter-spacing:0.2pt;">Signature Page to Stockholder Support Agreement</font><font style="letter-spacing:0.2pt;">] </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Exhibit&#160;A</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Form of Spousal Consent</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I acknowledge that I have read the Stockholder Support Agreement (to which this consent is attached) and that I know and understand, and have been fully advised by my attorney with respect to, its contents. As the spouse of the Stockholder, I hereby agree: (i)&#160;that all shares of capital stock, all options, all warrants and all additional securities of Parent held by the Stockholder, and all other rights with respect to the capital stock of Parent held by the Stockholder, and my interest in such shares, options, warrants, additional securities and other rights, if any, are subject to the provisions of the Stockholder Support Agreement and the Merger Agreement (as defined in the Stockholder Support Agreement), which I consent to; and (ii)&#160;that I&#160;will take no action at any time to hinder the operation of the Stockholder Support Agreement or the Merger Agreement. </font>
        </div>
        <table style="width:459pt;height:83pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:-0.2pt;">SIGNATURE OF SPOUSE: </font>
            </td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:17.167pt 0pt 14.833pt 0pt; width:0pt;white-space:normal;" colspan="4">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 237pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 14.833pt 0pt; width:63pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printed Name: </font>
              </div>
            </td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 14.833pt 0pt; width:171pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 171pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Schedule&#160;I</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Ownership of Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:32.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Name and Address of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">[&#8226;]</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.2pt;">[&#8226;]</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tANNE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX E</font>&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio, Inc.</font> <br ><font style="letter-spacing:0.2pt;">245 First Cambridge Street, Suite 1800 </font> <br ><font style="letter-spacing:0.2pt;">Cambridge, MA 02142 </font></div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lock-Up Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199; &#8199;&#8199;&#8199;&#8199;, 2022 </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This Lock-Up Agreement (this &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Lock-Up Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) is executed in connection with the Agreement and Plan of Merger and Reorganization (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) by and among Sesen Bio, Inc. (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221;), Seahawk Merger Sub, Inc. (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub</font><font style="letter-spacing:0.2pt;">&#8221;), and CARISMA Therapeutics Inc. (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;), dated as of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199; &#8199;&#8199;&#8199;&#8199;, 2022. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Merger Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with, and as an inducement to, each of the parties entering into the Merger Agreement and to consummate the transactions contemplated thereby and for other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned, by executing this Lock-Up Agreement, irrevocably agrees that, without the prior written consent of Parent, during the period commencing at the Effective Time and continuing until the end of the Lock-Up Period (as hereinafter defined), the undersigned will not: (i)&#160;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of or lend, directly or indirectly, any shares of Parent Common Stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive Parent Common Stock (including without limitation, Parent Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Parent which may be issued upon exercise of a stock option, restricted stock unit or warrant) whether now owned or hereafter acquired (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Securities</font><font style="letter-spacing:0.2pt;">&#8221;); (ii)&#160;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Parent Securities, whether any such transaction described in clause (i)&#160;or this clause (ii)&#160;is to be settled by delivery of Parent Common Stock or such other securities, in cash or otherwise; (iii)&#160;make any demand for or exercise any right with respect to, the registration of any Parent Common Stock or any security convertible into or exercisable or exchangeable for Parent Common Stock (other than such rights set forth in the Merger Agreement); (iv)&#160;except for any voting agreement entered into as of the date hereof by the undersigned with Parent and the Company, grant any proxies or powers of attorney with respect to any Parent Securities, deposit any Parent Securities into a voting trust or enter into a voting agreement or similar arrangement or commitment with respect to any Parent Securities; or (v)&#160;publicly disclose the intention to do any of the foregoing (each of the foregoing restrictions, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Lock-Up Restrictions</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the terms of the foregoing paragraph, the Lock-Up Restrictions shall automatically terminate and cease to be effective on the date that is one-hundred and eighty (180) days after the Effective Time. The period during which the Lock-Up Restrictions apply to the Parent Securities shall be deemed the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Lock-Up Period</font><font style="letter-spacing:0.2pt;">&#8221; with respect thereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned agrees that the Lock-Up Restrictions preclude the undersigned from engaging in any hedging or other transaction with respect to any then-subject Parent Securities which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of such Parent Securities even if such Parent Securities would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to such Parent Securities or with respect to any security that includes, relates to, or derives any significant part of its value from such Parent Securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the foregoing, the undersigned may transfer any of the Parent Securities: (i)&#160;if the undersigned is a natural person, (1)&#160;to any person related to the undersigned (or to an ultimate beneficial owner of the undersigned) by blood or adoption who is an immediate family member of the undersigned, or a family member by marriage or domestic partnership (a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Family Member</font><font style="letter-spacing:0.2pt;">&#8221;), (2)&#160;as a </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> gift or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">E-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">charitable contribution, (3)&#160;to any trust for the direct or indirect benefit of the undersigned or any Family Member of the undersigned, (4)&#160;to the undersigned&#8217;s estate, following the death of the undersigned, by will, intestacy or other operation of law, (5)&#160;by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement, or (6)&#160;to any partnership, corporation, limited liability company, investment fund or other entity which is controlled by the undersigned and/or by any Family Member of the undersigned; (ii)&#160;if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (1)&#160;to another corporation, partnership, limited liability company, trust or other business entity that controls, is controlled by or is under common control with the undersigned, or to direct or indirect affiliates (as defined in Rule&#160;405 promulgated under the Securities Act of 1933, as amended) of the undersigned, including any investment funds or other entities that controls or manages, or is under common control or management with, or is controlled or managed by, the undersigned, (2)&#160;to current or former partners (general or limited), members or managers, limited liability company members or stockholders of the undersigned or holders of similar equity interests in the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s stockholders) or to the estates of any of the foregoing, (3)&#160;as a </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> gift, donation or charitable contribution or otherwise to a trust or entity for the direct or indirect benefit of an immediate family member of a beneficial owner (as defined in Rule&#160;405 promulgated under the Securities Act of 1933, as amended) of the undersigned&#8217;s Parent Securities or (4)&#160;transfers of dispositions not involving a change in beneficial ownership; (iii)&#160;if the undersigned is a trust, to any grantors or beneficiaries of such trust; (iv)&#160;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under above clauses (i)&#160;through (iii); (v)&#160;to Parent in a transaction exempt from Section&#160;16(b) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221;) upon a vesting event of the Parent Securities or upon the exercise of options or warrants to purchase Parent Common Stock, including on a &#8220;cashless&#8221; or &#8220;net exercise&#8221; basis or to cover tax withholding obligations of the undersigned in connection with such vesting or exercise (but for the avoidance of doubt, excluding all manners of exercise that would involve a sale in the open market of any securities relating to such options or warrants, whether to cover the applicable aggregate exercise price, withholding tax obligations or otherwise); (vi)&#160;to Parent in connection with the termination of employment or other termination of a service provider and pursuant to agreements in effect as of the Effective Time whereby Parent has the option to repurchase such shares or securities; (vii)&#160;acquired by the undersigned in open market transactions or in a public offering by Parent after the Effective Time; (viii)&#160;pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#8217;s capital stock involving a change of control of Parent, </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Parent Securities shall remain subject to the restrictions contained in this Lock-Up Agreement; or (ix)&#160;pursuant to an order of a court or regulatory agency; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that in the case of clauses (i)-(iv), that (A)&#160;such transfer shall not involve a disposition for value and (B)&#160;the transferee shall have executed and delivered a Lock-Up Agreement with terms and in a form substantially identical to this Lock-Up Agreement with respect to the Parent Securities so transferred. For purposes of this Agreement, &#8220;change of control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold a majority of the outstanding voting securities of Parent (or the surviving entity). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the foregoing restrictions shall not apply to (i)&#160;the exercise of stock options granted pursuant to equity incentive plans existing immediately following the Effective Time, including the &#8220;net&#8221; or cashless exercise of such options in accordance with their terms and any related transfers of Parent Common Stock to Parent for purposes of paying the exercise price of such options or for paying taxes (including estimated taxes and withholding taxes) due as a result of such exercise; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that the restrictions set forth in this Lock-Up Agreement shall apply to any of the Parent Securities issued upon such exercise; or (ii)&#160;the establishment of any contract, instruction or plan (a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Plan</font><font style="letter-spacing:0.2pt;">&#8221;) that satisfies the requirements of Rule&#160;10b5-1 under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221;); </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that such Plan does not provide for the transfer of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock during the Lock-Up Period; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, further</font><font style="letter-spacing:0.2pt;">, that with respect to each of clauses (i)&#160;and (ii)&#160;above, no filing by any party under Section&#160;16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership of shares of Parent Common Stock or any securities convertible into or exercisable or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">E-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">exchangeable for Parent Common Stock in connection with such transfer or disposition during the Lock-Up Period (other than any exit filings) and if any filings under Section&#160;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common Stock in connection with such transfer or distribution, shall be legally required during the Lock-Up Period, such filing, report or announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to the Lock-Up Agreement, including a statement to the effect that no transfer of Parent Common Stock may be made under such Plan during the Lock-Up Period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Parent. In furtherance of the foregoing, the undersigned hereby agrees and consents to the entry of &#8220;stop transfer&#8221; instructions with Parent&#8217;s transfer agent and registrar relating to the transfer of the undersigned&#8217;s shares of Parent Common Stock in violation of this Lock-Up Agreement and further agrees that Parent and its transfer agent and registrar are hereby authorized to decline to make any transfer of shares of Parent Common Stock if such transfer would constitute a violation or breach of this Lock-Up Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Parent Common Stock: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the release of any Parent Common Stock from this Lock-Up Agreement, Parent will cooperate with the undersigned to facilitate the timely preparation and delivery of certificates or the establishment of book entry positions at the Parent&#8217;s transfer agent representing the Parent Common Stock without the restrictive legend above and the withdrawal of any stop transfer instructions at the Parent&#8217;s transfer agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement and that upon request, the undersigned will execute any additional documents reasonably necessary to ensure the validity or enforcement of this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event that during the Lock-Up Period any holder of Parent Securities that is subject to a substantially similar agreement entered into by such holder (such agreement, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Similar Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), other than the undersigned, is permitted by Parent or otherwise granted a release to sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases), the same&#160;percentage of shares of Parent Common Stock held by the undersigned on the date of such release or waiver as the&#160;percentage of the total number of outstanding shares of Parent Common Stock held by such holder on the date of such release or waiver that are subject to such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Pro-Rata Release</font><font style="letter-spacing:0.2pt;">&#8221;). Parent will notify the undersigned of any Pro-Rata Release within ten business days of such release. Upon the release of any Parent Securities from this Lock-Up Agreement, Parent will promptly cooperate with the undersigned to facilitate the timely preparation and delivery of evidence of book-entry shares representing the Parent Securities without the restrictive legend above or the withdrawal of any stop transfer instructions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This Lock-Up Agreement shall terminate automatically, and the undersigned shall automatically be released from all restrictions and obligations under this Lock-Up Agreement upon the earlier of (i)&#160;the expiration of the Lock-Up Period, (ii)&#160;if the Merger Agreement is terminated prior to the Effective Time pursuant to its terms, upon the date of such termination and (iii)&#160;the End Date (as defined in the Merger Agreement in effect on the date hereof) provided that the Effective Time has not occurred on or before such date. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">E-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:456pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This Lock-Up Agreement and any claim, controversy or dispute arising under or related to this Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to the conflict of laws principles thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This Lock-Up Agreement, and any certificates, documents, instruments and writings that are delivered pursuant hereto, constitutes the entire agreement and understanding of Parent, the Company and the undersigned in respect of the subject matter hereof and supersedes all prior understandings, agreements or representations by or among Parent, the Company and the undersigned, written or oral, to the extent they relate in any way to the subject matter hereof. This Lock-Up Agreement may be executed in counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by the undersigned by facsimile or electronic transmission in &#8220;.pdf&#8221; format shall be sufficient to bind the undersigned to the terms and conditions of this Lock-Up Agreement. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(</font><font style="font-style:italic;letter-spacing:0.2pt;">Signature Page Follows</font><font style="letter-spacing:0.2pt;">) </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">E-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The undersigned understands that Parent, Merger Sub and the Company are relying on this Lock-Up Agreement in entering into the Merger Agreement and proceeding toward consummation of the transactions contemplated thereby. The undersigned further understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned and the heirs, personal representatives, successors and assigns of the undersigned. </font>
        </div>
        <table style="width:456pt;height:149pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:228pt;">
              <font style="letter-spacing:0.2pt;">Very truly yours, </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:20.167pt 0pt 0.5pt 0pt; width:228pt;white-space:normal;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 228pt; margin-top: 17.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Printed Name of Holder </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:20.667pt 0pt 0.5pt 0pt; width:228pt;white-space:normal;">
              <div style="text-align:justify;">
                <div style="overflow:hidden;">
                  <div style="float:left;">
                    <font style="letter-spacing:0.2pt;">By:&#8199;</font>
                  </div>
                  <div style="overflow:hidden;line-height:10pt;border-bottom:0.5pt #000000 solid;">&#160;</div>
                </div>
              </div>
              <div style="margin-top:1.5pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:20.167pt 0pt 0.5pt 0pt; width:228pt;white-space:normal;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 228pt; margin-top: 17.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Printed Name of Person Signing</font>
                <br >
                <font style="letter-spacing:0.2pt;">(and indicate capacity of person signing if signing</font>
                <br >
                <font style="letter-spacing:0.2pt;">as custodian, trustee, or on behalf of an entity)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:431.88pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[</font><font style="font-style:italic;letter-spacing:0.2pt;">Lock-Up Agreement Signature Page]</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tANNF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX F</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONTINGENT VALUE RIGHTS AGREEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [&#8226;], 2023 (this &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), is entered into by and among Sesen Bio, Inc., a Delaware corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221;), and Computershare Inc. (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Computershare</font><font style="letter-spacing:0.2pt;">&#8221;) and its affiliate, Computershare Trust Company, N.A., together, as the Rights Agent. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RECITALS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, Parent, Seahawk Merger Sub, Inc., a Delaware corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub</font><font style="letter-spacing:0.2pt;">&#8221;), and CARISMA Therapeutics Inc., a Delaware corporation (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;), have entered into an Agreement and Plan of Merger and Reorganization, dated as of September&#160;20, 2022 (as it may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Agreement</font><font style="letter-spacing:0.2pt;">&#8221;), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving the Merger as a subsidiary of Parent; and </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WHEREAS, pursuant to the Merger Agreement, Parent has agreed to provide to the holders of record of Parent&#8217;s common stock, par value $0.001 per share (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Common Stock</font><font style="letter-spacing:0.2pt;">&#8221;), immediately prior to the Effective Time, the right to receive certain contingent cash payments, on the terms and subject to the conditions hereinafter described. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">NOW, THEREFORE, in consideration of the foregoing and the consummation of the transactions referred to above, Parent and the Rights Agent agree, for the proportionate benefit of all Holders (as hereinafter defined), as follows: </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.&nbsp;&nbsp;&nbsp;DEFINITIONS; CERTAIN RULES OF CONSTRUCTION </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">1.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Definitions.&nbsp;&nbsp;&nbsp;Capitalized terms used but not otherwise defined herein will have the meanings ascribed to them in the Merger Agreement, unless expressly set forth otherwise herein. As used in this Agreement, the following terms will have the following meanings: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquiror</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquisition</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acting Holders</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3(d)</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Affiliate</font><font style="letter-spacing:0.2pt;">&#8221; of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term &#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Agreement</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Preamble. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Asset Disposition Proceeds</font><font style="letter-spacing:0.2pt;">&#8221; means, without duplication, any and all consideration of any kind that is paid to Parent, or is received by, Parent or any of its Affiliates during the period specified in clause (b)&#160;of the definition of CVR Term in respect of an Asset Disposition, if any. The value of any securities (whether debt or equity) or other non-cash property constituting Asset Disposition Proceeds shall be determined as follows: (A)&#160;the value of securities for which there is an established public market shall be equal to the volume weighted average of their closing market prices for the five (5)&#160;trading days ending the day prior to the date of payment to, or receipt by, Parent or its relevant Affiliate, and (B)&#160;the value of securities that have no established public market and the value of consideration that consists of other non-cash property, shall be the fair market value thereof as of the date of payment to, or receipt by, Parent or its relevant Affiliate. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Assignee</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Board of Directors</font><font style="letter-spacing:0.2pt;">&#8221; means the board of directors of Parent. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Board Resolution</font><font style="letter-spacing:0.2pt;">&#8221; means a copy of the resolution(s) certified by the secretary or an assistant secretary (or other comparable officer) of Parent that have been duly adopted by the Board of Directors and are in full force and effect on the date of such approval, and delivered to the Rights Agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Business Day</font><font style="letter-spacing:0.2pt;">&#8221; means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be closed. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Recitals. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Computershare</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Preamble. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Payment</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Payment Amount</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to each Holder, an amount equal to (a)&#160;(i)&#160;the applicable Total Payment Amount, less (ii)&#160;applicable accrued and documented Permitted Deductions, as calculated in accordance with GAAP, divided by (b)&#160;the total number of CVRs and then multiplied by the total number of CVRs held by such Holder as reflected on the CVR Register (rounded down to the nearest whole cent). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Register</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.3(b)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Sale Assets</font><font style="letter-spacing:0.2pt;">&#8221; means any and all assets, tangible and intangible, including, without limitation, patents, patent applications, know-how, trade secrets and other intellectual property rights, data, documentation, agreements and licenses, inventory related to Vicineum</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">TM</font><font style="letter-spacing:0.2pt;">, also known as VB4-845, which Parent or any of its subsidiaries owned or had rights to, as of immediately prior to the Effective Time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Term</font><font style="letter-spacing:0.2pt;">&#8221; means (a)&#160;with respect to any Roche Payment Amount, the period beginning on the date hereof and ending on the earlier of (i)&#160;the CVR Payment being delivered to each Holder in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4</font><font style="letter-spacing:0.2pt;"> of this Agreement, and (ii)&#160;March&#160;31, 2027, and (b)&#160;with respect to any Disposition or Asset Disposition or otherwise in respect of Asset Disposition Proceeds, the period beginning on the date hereof and ending on December&#160;31, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVRs</font><font style="letter-spacing:0.2pt;">&#8221; means the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Disposition</font><font style="letter-spacing:0.2pt;">&#8221; means the sale, license, transfer, disposition or other monetizing event of any CVR Sale Assets, in each case (i)&#160;during the period set forth in clause (b)&#160;of the definition of CVR Term and (ii)&#160;in a transaction identified by Parent&#8217;s financial advisor who was engaged as of the Effective Time for the purpose of identifying and proposing a potential Disposition transaction to Parent. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">DTC</font><font style="letter-spacing:0.2pt;">&#8221; means The Depository Trust Company or any successor thereto. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Funds</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.9</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Holder</font><font style="letter-spacing:0.2pt;">&#8221; means a Person in whose name a CVR is registered in the CVR Register at the applicable time. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Agreement</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Recitals. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Sub</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Recitals. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Officer&#8217;s Certificate</font><font style="letter-spacing:0.2pt;">&#8221; means a certificate signed by the chief executive officer, president, chief financial officer, any vice president, the controller, the treasurer or the secretary, in each case of Parent, in his or her capacity as such an officer, and delivered to the Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Preamble. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent Common Stock</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in the Recitals. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Permitted Deductions</font><font style="letter-spacing:0.2pt;">&#8221; means the following costs or expenses, without duplication (as approved by the Board of Directors, including, if applicable, the Parent Designee (as defined in the Merger Agreement)): </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;any applicable Tax (including any unreimbursed applicable value added or sales tax) imposed on the Total Payment Amount and payable by Parent or any of its Affiliates to any tax authority and, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">without duplication, any income or other similar Taxes payable by Parent or any of its Affiliates that would not have been incurred by Parent or any of its Affiliates but for the Total Payment Amount; provided that, for purposes of calculating income Taxes incurred by Parent and its Affiliates in respect of the Total Payment Amount, any such income Taxes shall be computed after reduction for any net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries (owned prior to the Merger) as of the Closing Date that are available to the maximum extent permitted by law to offset such gain after taking into account any limits on the usability of such attributes, including under Section&#160;382 of the Code, in each case, as reasonably determined by a nationally recognized tax advisor (and for the sake of clarity such income taxes shall be calculated without taking into account any net operating losses or other Tax attributes generated by Parent or its subsidiaries after the Closing Date or any Tax attributes of the Company, whether generated before or after the Closing Date), assuming for this purpose that (i)&#160;the only item of gross income of Parent and its subsidiaries is the Total Payment Amount (for the avoidance of doubt, assuming that the Total Payment Amount is taxable in the hands of Parent or its subsidiaries no later than the taxable year that includes the corresponding CVR Payment), and (ii)&#160;the net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries shall only include any net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries (owned prior to the Merger) existing as of immediately prior to the Merger for U.S. federal income tax purposes and applicable state and local income tax purposes; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;any reasonable and documented out-of-pocket expenses incurred by Parent or any of its Affiliates in respect of its performance of this Agreement following the Effective Time, losses incurred and paid by Parent or any of its Affiliates following the Effective Time arising out of any Legal Proceeding relating to or in connection with (i)&#160;an Asset Disposition, (ii)&#160;Parent&#8217;s, Roche&#8217;s or any of their respective Affiliates&#8217; obligations under the Roche Agreement or (iii)&#160;otherwise with respect to the Total Payment Amount; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;any Liabilities that were ascertainable prior to or at the Effective Time which Parent reasonably and in good faith determines should have been, but were not, deducted from &#8220;Net Cash&#8221; &#8203;(as defined in the Merger Agreement), in connection with the Closing of the Merger, to the extent that deduction of such Liabilities would have resulted in a change in the Exchange Ratio under the Merger Agreement were such amounts properly deducted; </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">provided that no Permitted Deductions shall be deducted to the extent they were otherwise deducted from the calculation of Net Cash (as defined in the Merger Agreement). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Permitted Transfer</font><font style="letter-spacing:0.2pt;">&#8221; means a transfer of CVRs: (a)&#160;on death of a Holder by will or intestacy; (b)&#160;by instrument to an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (c)&#160;pursuant to a court order; (d)&#160;made by operation of law (including a consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (e)&#160;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner (through an intermediary if applicable) or from a nominee to another nominee for the same beneficial owner, to the extent allowable by DTC; (f)&#160;a transfer from a participant&#8217;s account in a tax-qualified employee benefit plan to the participant or to such participant&#8217;s account in a different tax-qualified employee benefit plan or to a tax-qualified individual retirement account for the benefit of such participant; (g)&#160;to Parent or its Affiliates for any or no consideration; or (h)&#160;as provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.6</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Person</font><font style="letter-spacing:0.2pt;">&#8221; means any natural person, corporation, limited liability company, trust, unincorporated association, partnership, joint venture or other entity. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Record Time</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.3(e)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Rights Agent</font><font style="letter-spacing:0.2pt;">&#8221; means the Rights Agent named in the Preamble, until a successor Rights Agent will have become such pursuant to the applicable provisions of this Agreement, and thereafter &#8220;Rights Agent&#8221; will mean such successor Rights Agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Roche</font><font style="letter-spacing:0.2pt;">&#8221; means the collective reference to F. Hoffman-La Roche Ltd and Hoffmann La Roche Inc. or its successors or any of its or their respective Affiliates; provided, that neither Chugai Pharmaceutical Co., </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Ltd, a Japanese corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Chugai</font><font style="letter-spacing:0.2pt;">&#8221;) nor its subsidiaries (if any) shall be deemed as Affiliates of Roche unless Roche provides written notice to Parent of its desire to include Chugai or its respective subsidiaries (as applicable) as Affiliate(s) of Roche. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">RocheAgreement</font><font style="letter-spacing:0.2pt;">&#8221; means that certain Asset Purchase Agreement, dated as of July&#160;15, 2022, by and among F. Hoffman-La Roche Ltd, Hoffmann La Roche Inc. and Parent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Roche Payment Amount</font><font style="letter-spacing:0.2pt;">&#8221; means the thirty million dollar ($30,000,000) milestone payment to be made by Roche to Parent upon the initiation of a phase III clinical study in diabetic macular disorder with the compound known as &#8220;EBI-031&#8221; during the CVR Term, as set forth in Section&#160;11.1 of the Roche Agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Third Party</font><font style="letter-spacing:0.2pt;">&#8221; means any Person other than Parent, Rights Agent or their respective Affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Total Payment Amount</font><font style="letter-spacing:0.2pt;">&#8221; means, as of any applicable time of determination, any Asset Disposition Proceeds plus any Roche Payment Amounts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">1.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Rules of Construction. Except as otherwise explicitly specified to the contrary, (a)&#160;whenever the context requires, the singular number shall include the plural, and vice versa; (b)&#160;the masculine gender shall include the feminine gender and neuter genders, the feminine gender shall include the masculine and neuter genders, and the neuter genders shall include masculine and feminine genders; (c)&#160;the word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and does not simply mean &#8220;if&#8221;; (d)&#160;the word &#8220;including&#8221; &#8203;(in its various forms) means &#8220;including without limitation&#8221;; (e)&#160;references to a &#8220;Section&#8221; means a Section of this Agreement unless another agreement is specified; (f)&#160;references to a particular statute or regulation include all rules and regulations thereunder and any predecessor or successor statute, rules or regulation, in each case as amended or otherwise modified from time to time; (g)&#160;words in the singular or plural form include the plural and singular form, respectively; (h)&#160;references to a particular Person include such Person&#8217;s successors and assigns to the extent not prohibited by this Agreement; (i)&#160;the word &#8220;or&#8221; shall not be exclusive (i.e., &#8220;or&#8221; shall be deemed to mean &#8220;and/or&#8221;) unless the subject of the conjunction are mutually exclusive; and (j)&#160;all references to dollars or &#8220;$&#8221; refer to United States dollars. For clarity, the parties agree that the phrase &#8220;materially adverse&#8221; when used in this Agreement with respect to the Holders includes any amendment or other action, as applicable, that does or would be reasonably expected to reduce, eliminate, or materially delay the Roche Payment Amount. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.&nbsp;&nbsp;&nbsp;CONTINGENT VALUE RIGHTS </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;CVRs; Appointment of Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Each Holder is entitled to one CVR in the form of a dividend for each share of Parent Common Stock held by such Holder as of the Record Time. The CVRs represent the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement. The initial Holders will be the holders of Parent Common Stock as of immediately prior to the Effective Time, and a list of the initial Holders shall be furnished to the Rights Agent by or on behalf of Parent in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;4.1</font><font style="letter-spacing:0.2pt;"> hereof. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Parent hereby appoints the Rights Agent to act as rights agent for Parent as contemplated hereby in accordance with the express terms and conditions set forth in this Agreement (and no implied terms or conditions), and the Rights Agent hereby accepts such appointment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent intends to treat the issuance of the CVRs as a distribution of property by Parent to the holders of Parent Common Stock for U.S. federal income tax purposes. Consistent with such intended tax treatment, Parent will timely send Forms 1099-DIV to all Holders notifying them of the portion of the CVR value that is a nondividend distribution (or a dividend to the extent of Parent&#8217;s earnings and profits) for U.S. federal income tax purposes, and take all necessary steps to file its tax returns and any information statements consistent with such tax treatment. Parent will determine, in consultation with and with the consent of the Parent Designee, the fair market value of the CVRs in connection with the issuance and Parent will utilize such fair market value for purposes of all tax reporting (including on Forms 1099-DIV) with respect to the CVR. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Nontransferable.&nbsp;&nbsp;&nbsp;The CVRs shall not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any attempted sale, assignment, transfer, pledge, encumbrance, transfer or disposition, in whole or in part, that is not a Permitted Transfer will be void </font><font style="font-style:italic;letter-spacing:0.2pt;">ab initio</font><font style="letter-spacing:0.2pt;"> and of no effect. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;No Certificate; Registration; Registration of Transfer; Change of Address. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The CVRs will not be evidenced by a certificate or other instrument. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The Rights Agent will create and keep a register (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Register</font><font style="letter-spacing:0.2pt;">&#8221;) for the purpose of identifying the Holders and registering CVRs and transfers of CVRs as permitted herein. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from Parent. The CVR Register will initially show one position for Cede &amp; Co. representing all the CVRs provided to the holders of shares of Parent Common Stock held as of immediately prior to the Effective Time. The Rights Agent will have no responsibility whatsoever directly to the street name holders or DTC participants with respect to transfers of CVRs unless and until such CVRs are transferred into the name of such street name holders or DTC participants in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;"> of this Agreement. With respect to any payments to be made under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;"> below, the Rights Agent will accomplish the payment to any former street name holders of shares of Parent Common Stock by sending one lump-sum payment to DTC. The Rights Agent will have no responsibilities whatsoever with regard to the distribution of payments by DTC to such street name holders. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Subject to the restrictions on transferability set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;">, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer and other reasonably requested documentation in form reasonably satisfactory to the Rights Agent, duly executed by the Holder thereof or the Holder&#8217;s attorney duly authorized in writing, personal representative or survivor and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form, notify Parent that it has received such written notice. Upon receipt of such notice from the Rights Agent, Parent shall determine whether the transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;">), and if it determines that it does so comply, Parent shall instruct the Rights Agent in writing to register the transfer of the CVRs in the CVR Register and notify Parent of the same. No service charge shall be made for any registration of transfer of a CVR; however Parent and the Rights Agent may require payment of a sum sufficient to cover any stamp or other tax or governmental charge that is imposed in connection with any such registration of transfer. The Rights Agent shall have no duty or obligation to take any action under any section of this Agreement that requires the payment by a Holder of applicable taxes or charges unless and until the Rights Agent is satisfied that all such taxes or charges have been paid or will be paid. All duly transferred CVRs registered in the CVR Register will be the valid obligations of Parent and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a CVR will be valid until registered in the CVR Register. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;A Holder may make a written request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written request, the Rights Agent is hereby authorized to promptly record the change of address in the CVR Register. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Parent will provide written instructions to the Rights Agent for the distribution of CVRs to holders of Parent Common Stock as of immediately prior to the Effective Time (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Record Time</font><font style="letter-spacing:0.2pt;">&#8221;). Subject to the terms and conditions of this Agreement and Parent&#8217;s prompt confirmation of the Effective Time, the Rights Agent shall effect the distribution of the CVRs, less any applicable tax withholding, to each holder of Parent Common Stock as of the Record Time by the mailing of a statement of holding reflecting such CVRs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.4</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Payment Procedures. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Within thirty (30) days after the receipt of any portion of the Total Payment Amount, Parent shall (i)&#160;deliver to the Rights Agent a certificate certifying to and specifying in reasonable detail (A)&#160;the amount of the applicable Total Payment Amount received by Parent or its Affiliates, (B)&#160;a calculation </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of the CVR Payment Amount and CVR Payment, and (C)&#160;the Permitted Deductions reflected in such CVR Payment Amount, (ii)&#160;deliver to the Rights Agent an amount equal to the aggregate CVR Payment Amount in immediately available funds (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">CVR Payment</font><font style="letter-spacing:0.2pt;">&#8221;) and (iii)&#160;instruct the Rights Agent to deliver the CVR Payment to the Holders. The Rights Agent will promptly, and in any event within ten (10) Business Days after receipt of each applicable CVR Payment, pay to each Holder, by check mailed to the address of each Holder as reflected in the CVR Register as of the close of business on the date of the receipt of the CVR Payment statement, such Holder&#8217;s CVR Payment Amount less any applicable tax withholding. Until such certificate, CVR Payment and instructions are received by the Rights Agent, the Rights Agent may presume conclusively for all purposes that such portion of the Total Payment Amount has not been received. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;All payments by Parent to the Rights Agent under this Agreement shall be made in U.S. dollars. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent shall be entitled to deduct or withhold, or cause the Rights Agent to deduct or withhold from any CVR Payment Amount otherwise payable or otherwise deliverable pursuant to this Agreement, in each case directly or through an authorized payroll agent, such amounts as are reasonably determined to be required to be deducted or withheld therefrom under the Code or any other provision of any applicable federal, state, local or non-U.S. Tax Law as may be determined by Parent. To the extent such amounts are so deducted or withheld and paid over or deposited with the relevant Tax authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Holder(s) to whom such amounts would otherwise have been paid or delivered. Prior to making any such Tax withholdings or causing any such Tax withholdings to be made with respect to any Holder, Parent shall instruct the Rights Agent, to the extent practicable, to provide notice to the Holder of such potential withholding and a reasonable opportunity for the Holder to provide any necessary Tax forms (including an IRS Form W-9 or an applicable IRS Form W-8) in order to avoid or reduce such withholding amounts; provided, that the time period for payment of a CVR Payment Amount by the Rights Agent set forth in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;"> shall be extended by a period equal to any delay caused by the Holder providing such forms; provided, further, that in no event shall such period be extended for more than ten (10) Business Days, unless otherwise requested by the Holder for the purpose of delivering such forms and agreed to by the Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Any portion of any CVR Payment that remains undistributed to any Holder six (6)&#160;months after such CVR Payment is received by the Rights Agent from Parent, provided, that the Rights Agent has fully complied with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;">, will be delivered by the Rights Agent to Parent, upon demand, and such Holder will thereafter look only to Parent for payment of its share of such returned CVR Payment, without interest. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;Neither Parent nor the Rights Agent will be liable to any person in respect of any CVR Payment Amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law. If, despite Parent&#8217;s and/or the Rights Agent&#8217;s commercially reasonable efforts to deliver a CVR Payment Amount to the applicable Holder, such CVR Payment Amount has not been paid immediately prior to the date on which such CVR Payment Amount would otherwise escheat to or become the property of any Governmental Body, any such CVR Payment Amount will, to the extent permitted by applicable Law, become the property of Parent, free and clear of all claims or interest of any person previously entitled thereto. In addition to and not in limitation of any other indemnity obligation herein, Parent agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to Parent and such indemnification obligation shall survive the termination of this Agreement, the resignation, replacement or removal of the Rights Agent, and the payment, termination and the expiration of the CVRs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.5</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;No Voting, Dividends or Interest; No Equity or Ownership Interest in Parent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable on the CVRs to any Holder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;The CVRs will not represent any equity or ownership interest in Parent or in any constituent company to the Merger. The sole right of the Holders to receive property hereunder is the right to receive </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the CVR Payment in accordance with the terms hereof. It is hereby acknowledged and agreed that a CVR shall not constitute a security of Parent or any constituent company to the Merger. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Each Holder acknowledges and agrees that such Holder will not challenge or contest any action, inaction, determination or decision of Parent or the Rights Agent, except via written action of the Acting Holders, and will not threaten, bring, commence, institute, maintain, prosecute or voluntarily aid any action, which challenges the validity of or seeks to enjoin the operation of any provision of this Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">2.6</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Ability to Abandon CVR. A Holder may at any time, at such Holder&#8217;s option, abandon all of such Holder&#8217;s remaining rights in a CVR by transferring such CVR to Parent without consideration therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by Parent of such transfer and cancellation. Nothing in this Agreement is intended to prohibit Parent from offering to acquire CVRs, in a private transaction or otherwise, for consideration in its sole discretion. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3.&nbsp;&nbsp;&nbsp;THE RIGHTS AGENT </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Certain Duties and Responsibilities.&nbsp;&nbsp;&nbsp;The Rights Agent will be authorized and protected and will not have any liability for or in respect of any actions taken, suffered or omitted to be taken by it in connection with its acceptance and administration of this Agreement and the exercise and performance of its duties hereunder, except to the extent of its own willful misconduct, bad faith or gross negligence (each as determined by a final non-appealable judgment of a court of competent jurisdiction). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Certain Rights of the Rights Agent.&nbsp;&nbsp;&nbsp;The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied duties, covenants or obligations will be read into this Agreement against the Rights Agent. The Rights Agent shall not assume any obligations or relationship of agency or trust with any Holder. In addition: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;the Rights Agent may rely and will be protected by Parent in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in the absence of bad faith to be genuine and to have been signed or presented by the proper party or parties; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;whenever the Rights Agent will deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Rights Agent may request and rely upon an Officer&#8217;s Certificate with respect to such matter, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of gross negligence, bad faith or willful or intentional misconduct (each as determined by a final non appealable judgment of a court of competent jurisdiction) on its part, incur no liability and be held harmless by Parent for or in respect of any action taken, suffered or omitted to be taken by it in the absence of bad faith under the provisions of this Agreement in reliance upon such certificate; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;in the event the Rights Agent believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Rights Agent hereunder, the Rights Agent, may, in its sole discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to Parent, any Holder or any other person or entity for refraining from taking such action, unless the Rights Agent receives written instructions from the Parent which eliminates such ambiguity or uncertainty to the satisfaction of the Rights Agent; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;the Rights Agent may engage and consult with counsel of its selection (who may be legal counsel for the Rights Agent or the Parent or an employee of the Rights Agent) and the written advice of such counsel or any opinion of counsel will be full and complete authorization and protection to the Rights Agent and the Rights Agent shall be held harmless by Parent and shall incur no liability for or in respect of any action taken, suffered or omitted by it hereunder in the absence of bad faith and in reliance thereon; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;the permissive rights of the Rights Agent to do things enumerated in this Agreement will not be construed as a duty; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;the Rights Agent will not be required to give any note or surety in respect of the execution of such powers or otherwise in respect of the premises; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;the Rights Agent shall not be liable for or by reason of, and shall be held harmless by Parent with respect to any of the statements of fact or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Parent only and the Rights Agent will have no liability and shall be held harmless by Parent in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution and delivery hereof by the Rights Agent), nor shall the Rights Agent be responsible for any breach by Parent of any covenant or condition contained in this Agreement; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;Parent agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability, damage, judgment, fine, penalty, settlement, claim, demands, suits, cost or expense (including without limitation, the reasonable and documented fees and expenses of legal counsel) for any action taken, suffered or omitted to be taken by the Rights Agent or arising out of or in connection with the Rights Agent&#8217;s duties under this Agreement, including the reasonable and documented out-of-pocket costs and expenses of defending the Rights Agent against any claims, charges, demands, suits or loss arising therefrom, directly or indirectly, or enforcement of its rights hereunder, unless such loss has been determined by a final non-appealable judgment of a court of competent jurisdiction to be a result of the Rights Agent&#8217;s gross negligence, bad faith or willful or intentional misconduct; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;anything to the contrary notwithstanding, (i)&#160;any liability of the Rights Agent under this Agreement will be limited to the aggregate amount of the annual fees (but not reimbursed expenses) paid by Parent to the Rights Agent under this Agreement during the twelve&#160;months immediately preceding the event for which recovery is sought, and (ii)&#160;in no event shall the Rights Agent be liable for any special, punitive, indirect, consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits) arising out of any action taken, suffered or omitted to be taken by it, even if the Rights Agent has been advised of the likelihood of such loss or damage and regardless of the form of action; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(j)&nbsp;&nbsp;&nbsp;Parent agrees (i)&#160;to pay the fees and expenses of the Rights Agent in connection with the Rights Agent&#8217;s duties under this Agreement as agreed upon in writing by the Rights Agent and Parent on or prior to the date hereof, and (ii)&#160;to reimburse the Rights Agent for all taxes and governmental charges, reasonable and documented out-of-pocket expenses and other charges of any kind and nature incurred by the Rights Agent in the preparation, delivery, amendment and execution of this Agreement and the exercise and performance of its duties hereunder (other than taxes imposed on or measured by the Rights Agent&#8217;s net income and franchise or similar taxes imposed on it (in lieu of net income taxes)). The Rights Agent will also be entitled to reimbursement from Parent for all reasonable and documented out-of-pocket expenses paid or incurred by it in connection with the administration by the Rights Agent of its duties hereunder. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(k)&nbsp;&nbsp;&nbsp;the Rights Agent shall not be deemed to have knowledge of any event of which it was supposed to receive notice thereof hereunder, and the Rights Agent shall be fully protected and shall incur no liability for failing to take action in connection therewith, unless and until it has received such notice in writing from the Parent and all notices or other instruments required by this Agreement to be delivered to the Rights Agent must, in order to be effective, be received by the Rights Agent as specified herein, and in the absence of such notice so delivered the Rights Agent may conclusively assume no such event or condition exists; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(l)&nbsp;&nbsp;&nbsp;the Rights Agent and any shareholder, affiliate, director, officer or employee of the Rights Agent may buy, sell or deal in any securities of the Parent or become peculiarly interested in any transaction in which the Parent may be interested, or contract with or lend money to the Parent or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement. Nothing herein shall preclude the Rights Agent from acting in any other capacity for the Parent or for any other Person; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(m)&nbsp;&nbsp;&nbsp;the Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">shall not be liable, answerable or accountable for any act, omission, default, neglect or misconduct of any such attorneys or agents or for any loss to the Parent, any Holder or any other person or entity resulting from any such act, omission, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment thereof; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(n)&nbsp;&nbsp;&nbsp;no provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(o)&nbsp;&nbsp;&nbsp;the Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect to any action or default by the Parent or its Affiliates, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Parent; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(p)&nbsp;&nbsp;&nbsp;the Rights Agent shall neither be responsible for, nor chargeable with, knowledge of, nor have any requirements to comply with, the terms and conditions of any other agreement, instrument or document, including, without limitation, the Merger Agreement, nor shall the Rights Agent be required to determine if any person or entity has complied with any such agreements, instruments or documents, nor shall any additional obligations of the Rights Agent be inferred from the terms of such agreements, instruments or documents even though reference thereto may be made in this Agreement. In the event of any conflict between the terms and provisions of this Agreement and those of any other agreement, instrument or document, including but not limited to the Merger Agreement, the terms and conditions of this Agreement shall control as they relate to the Rights Agent; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(q)&nbsp;&nbsp;&nbsp;The provisions of </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.1</font><font style="letter-spacing:0.2pt;"> and this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.2</font><font style="letter-spacing:0.2pt;"> shall survive the termination of this Agreement, the resignation, replacement or removal of the Rights Agent, and the payment, termination and the expiration of the CVRs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Resignation and Removal; Appointment of Successor. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;The Rights Agent may resign at any time by giving written notice thereof to Parent specifying a date when such resignation will take effect, which notice will be sent at least thirty (30) days prior to the date so specified, and such resignation will become effective on the earlier of (i)&#160;the date so specified and (ii)&#160;the appointment of a successor Rights Agent. Parent has the right to remove the Rights Agent at any time by a Board Resolution specifying a date when such removal will take effect (or, if earlier, the appointment of the successor Rights Agent). Notice of such removal will be given by Parent to the Rights Agent, which notice will be sent at least thirty (30) days prior to the date so specified. Notwithstanding anything to the contrary contained herein, such replacement or removal of the Rights Agent shall not affect any of the provisions of this Agreement that expressly survive the termination of this Agreement, or the resignation, replacement or removal of the Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;If the Rights Agent provides notice of its intent to resign, is removed or becomes incapable of acting, Parent, by a Board Resolution, will as soon as is reasonably possible appoint a qualified successor Rights Agent, who shall be a stock transfer agent or national reputation or the corporate trust department of a commercial bank. The successor Rights Agent so appointed will, forthwith upon its acceptance of such appointment in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.4</font><font style="letter-spacing:0.2pt;">, become the successor Rights Agent. Notwithstanding the foregoing, if Parent shall fail to make such appointment within a period of thirty (30) days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Parent will give notice to each Holder of each resignation and each removal of a Rights Agent and each appointment of a successor Rights Agent by delivering a written notice of such event to the Holders as their names and addresses appear in the CVR Register in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;">. Each notice will include the name and address of the successor Rights Agent. If Parent fails to send such notice within ten (10) Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Parent. Failure to give </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">any notice provided for in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;">, however, and any defect therein, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;">, unless consented to in writing by, at the applicable time of determination, Holders of at least 33% of the then outstanding CVRs, as set forth in the CVR Register (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acting Holders</font><font style="letter-spacing:0.2pt;">&#8221;), Parent will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;The Rights Agent will reasonably cooperate with Parent and any successor Rights Agent in connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">3.4</font><font style="letter-spacing:0.2pt;"> Acceptance of Appointment by Successor. Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and thereupon such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring Rights Agent will execute and deliver an instrument transferring to the successor Rights Agent all the rights (except such rights of the predecessor Rights Agent which survive pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3.3</font><font style="letter-spacing:0.2pt;"> of this Agreement), powers and trusts of the retiring Rights Agent. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.&nbsp;&nbsp;&nbsp;COVENANTS </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">4.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;List of Holders.&nbsp;&nbsp;&nbsp;Parent will furnish or cause to be furnished to the Rights Agent in such form as Parent receives from Parent&#8217;s transfer agent (or other agent performing similar services for Parent), the names and addresses of the Holders within ten (10) Business Days of the Effective Time. Until such initial list of Holders is furnished to the Rights Agent, the Rights Agent shall have no duties, responsibilities or obligations with respect to such Holders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">4.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Payment of CVR Payment Amounts. If a CVR Payment is due under </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;">, Parent will deposit the CVR Payment with the Rights Agent for payment to the Holders in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.4(a)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">4.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Roche Agreements.&nbsp;&nbsp;&nbsp;Without the prior written consent of the Acting Holders, neither Parent nor any of its Affiliates shall (a)&#160;amend, restate, supplement, terminate or otherwise modify the Roche Agreement in a manner materially adversely affecting the Holders&#8217; rights under this Agreement, (b)&#160;in the event that Roche fails to make a payment of a Roche Payment at the time rightfully due and payable, take action with respect to, or unreasonably waive or fail to enforce, the right to receive the applicable payments which are rightfully due and payable under the Roche Agreement, in a manner materially adversely affecting the Holders&#8217; rights under this Agreement or (c)&#160;agree to any of the foregoing. Without limiting the foregoing, Parent and its Affiliates shall pursue their rights under the Roche Agreement in good faith, and not take any action (or fail to take any action) with the intention of avoiding, reducing or materially delaying any payment to the Holders hereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">4.4</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Records. Parent shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to enable the Holders and their consultants or professional advisors to confirm (a)&#160;whether the Roche Payment Amount or the Asset Disposition Proceeds have been received by Parent or its successors or Affiliates and (b)&#160;the applicable CVR Payment Amount payable to each Holder hereunder in accordance with the terms specified in this Agreement. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.&nbsp;&nbsp;&nbsp;DISPOSITION </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">5.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;During the period specified in clause (b)&#160;of the definition of &#8220;CVR Term&#8221;, Parent will, and will cause its subsidiaries to, use commercially reasonable efforts to effectuate a Disposition, including the negotiation and execution of a Sale Agreement and completion of the transactions contemplated thereby. Further, Parent will not take any actions for the primary purpose of frustrating the payment of CVR Payments. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">5.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Holders acknowledge and agree that, except as expressly set forth in the foregoing Section&#160;5.1, (a)&#160;Parent has a fiduciary obligation to operate its business in the best interests of its stockholders, and any potential obligation to pay any potential Asset Disposition Proceeds or any other amounts will not create any express or implied obligation to operate its business in any particular manner in order to maximize any such CVR Payments, (b)&#160;the Holders are not relying on any representation of Parent or any other Person with regard to any Disposition or other action involving CVR Sale Assets following the Closing, and neither Parent nor any other Person has provided, or can provide, any assurance to the Holders that any potential Asset Disposition Proceeds or any other amounts will in fact be earned and paid, and (c)&#160;none of Parent or any of its Subsidiaries, officers or directors shall have any obligation or liability whatsoever to any Person relating to or in connection with any action, or failure to act, with respect to the sale of CVR Sale Assets. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6.&nbsp;&nbsp;&nbsp;AMENDMENTS </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">6.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Amendments without Consent of Holders. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Without the consent of any Holders, Parent, when authorized by a Board Resolution, at any time and from time to time, and the Rights Agent may enter into one or more amendments hereto, solely to evidence any successor to or permitted Assignee of Parent and the assumption by any such successor or permitted Assignee of the covenants of Parent herein as provided in </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Without the consent of any Holders, Parent, when authorized by a Board Resolution, may, with the consent of the Rights Agent, which consent shall not be unreasonably withheld, conditioned or delayed, at any time and from time to time, enter into one or more amendments hereto, solely for any of the following purposes: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;to evidence the succession of another Person as a successor Rights Agent in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3</font><font style="letter-spacing:0.2pt;"> and the assumption by any successor of the covenants and obligations of the Rights Agent herein; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;to add to the covenants of Parent such further covenants, restrictions, conditions or provisions as Parent shall consider to be for the protection of the Holders; provided, that, in each case, such provisions do not adversely affect the interests of the Holders; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;to cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision herein, or to make any other provisions with respect to matters or questions arising under this Agreement; provided, that, in each case, such provisions do not adversely affect the interests of the Holders; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iv)&nbsp;&nbsp;&nbsp;as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange Act or any applicable state securities or &#8220;blue sky&#8221; laws; provided, that, in each case, such provisions do not adversely affect the interests of the Holders; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(v)&nbsp;&nbsp;&nbsp;to cancel any CVRs (A)&#160;in the event that any Holder has abandoned its rights in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.6</font><font style="letter-spacing:0.2pt;">, or (B)&#160;following a transfer of such CVRs to Parent or its Affiliates in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.2</font><font style="letter-spacing:0.2pt;"> or </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;2.3</font><font style="letter-spacing:0.2pt;">; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(vi)&nbsp;&nbsp;&nbsp;any other amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition, elimination or change is adverse to the interests of the Holders; or </font>
        </div>
        <div style="text-indent:60pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(vii)&nbsp;&nbsp;&nbsp;as may be necessary or appropriate to ensure that Parent complies with applicable Law. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.1</font><font style="letter-spacing:0.2pt;">, Parent will transmit a notice thereof in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;"> to the Holders at their addresses as they appear on the CVR Register, setting forth in general terms the substance of such amendment. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">6.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Amendments with Consent of Holders. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Subject to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.1</font><font style="letter-spacing:0.2pt;"> (which amendments pursuant to </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.1</font><font style="letter-spacing:0.2pt;"> may be made without the consent of the Holders), with the consent of the Acting Holders, whether evidenced in writing or taken </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">at a meeting of such Holders, Parent, when authorized by a Board Resolution, and the Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, even if such addition, elimination or change is materially adverse to the interest of the Holders. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Promptly after the execution by Parent, and the Rights Agent of any amendment pursuant to the provisions of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6.2</font><font style="letter-spacing:0.2pt;">, Parent will transmit (or cause the Rights Agent to transmit) a notice thereof in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;"> to the Holders at their addresses as they appear on the CVR Register, setting forth in general terms the substance of such amendment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">6.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Execution of Amendments.&nbsp;&nbsp;&nbsp;In executing any amendment permitted by this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;">, the Rights Agent will be entitled to receive, and will be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of such amendment is authorized or permitted by this Agreement. Notwithstanding anything contained herein, the Rights Agent may, but is not obligated to, enter into any such amendment that affects the Rights Agent&#8217;s own rights, privileges, covenants or duties under this Agreement or otherwise. No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">6.4</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Effect of Amendments.&nbsp;&nbsp;&nbsp;Upon the execution of any amendment under this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;6</font><font style="letter-spacing:0.2pt;">, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7.&nbsp;&nbsp;&nbsp;OTHER PROVISIONS OF GENERAL APPLICATION </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.1</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Notices to Rights Agent and Parent.&nbsp;&nbsp;&nbsp;Any notice or other communication required or permitted hereunder shall be in writing and shall be deemed given when delivered and received hereunder (a)&#160;one Business Day after being sent for next Business Day delivery, fee prepared, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand, or (c)&#160;on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00&#160;p.m. New York time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If to the Rights Agent, to it at: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Computershare Inc. and Computershare Trust Company, N.A. </font> <br ><font style="letter-spacing:0.2pt;">150 Royall Street, 2nd Floor </font> <br ><font style="letter-spacing:0.2pt;">Canton, MA 02021 </font> <br ><font style="letter-spacing:0.2pt;">Attention: Relationship Manager </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If to Parent, to it at: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio, Inc. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Telephone:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Email:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Attention:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with a copy to: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Telephone:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Email:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:60pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Attention:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">[&#8226;] </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Rights Agent or Parent may specify a different address, email address by giving notice to each other in accordance with this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.1</font><font style="letter-spacing:0.2pt;"> and to the Holders in accordance with </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.2</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.2</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Notice to Holders.&nbsp;&nbsp;&nbsp;Where this Agreement provides for notice to Holders, such notice will be sufficiently given (unless otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid or, if applicable, transmitted through the facilities of DTC in accordance with DTC&#8217;s procedures, to each Holder affected by such event, at the Holder&#8217;s address as it appears in the CVR Register, not later </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">than the latest date, and not earlier than the earliest date, if any, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder will affect the sufficiency of such notice with respect to other Holders. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.3</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Parent Successors and Assigns. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;Parent may not assign this Agreement without the prior written consent of the Acting Holders. Notwithstanding the foregoing (i)&#160;Parent may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more direct or indirect wholly-owned subsidiaries of Parent for so long as they remain wholly-owned subsidiaries of Parent (each, an &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Assignee</font><font style="letter-spacing:0.2pt;">&#8221;) and the Assignee agrees to assume and be bound by all of the terms of this Agreement; provided, however, that in connection with any assignment to an Assignee, Parent shall, and shall agree to, remain liable for the performance by such Assignee of all obligations of Parent hereunder, with such Assignee substituted for Parent under this Agreement, and (ii)&#160;Parent may assign this Agreement in its entirety without the consent of any other party to its successor in interest in connection with the sale of all or substantially all of its assets or of its stock, or in connection with a merger, acquisition or similar transaction (such successor in interest, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquiror</font><font style="letter-spacing:0.2pt;">&#8221;, and such transaction, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquisition</font><font style="letter-spacing:0.2pt;">&#8221;). This Agreement will be binding upon, inure to the benefit of and be enforceable by Parent&#8217;s successors, acquirers and each Assignee. Each reference to &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Parent</font><font style="letter-spacing:0.2pt;">&#8221; in this Agreement shall be deemed to include Parent&#8217;s successors, acquirers and all Assignees. Each of Parent&#8217;s successors, acquirers and assigns shall expressly assume by an instrument supplemental hereto, executed and delivered to the Rights Agent, the due and punctual payment of the CVR Payments and the due and punctual performance and observance of all of the covenants and obligations of this Agreement to be performed or observed by Parent. Notwithstanding anything to the contrary contained herein, no assignment pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3</font><font style="letter-spacing:0.2pt;"> shall relieve Parent of its obligations and liabilities to the Rights Agent hereunder, unless specifically agreed to in writing by the Rights Agent. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or any Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto; provided, that such Person would be eligible for appointment as a successor Rights Agent under the provisions of this Agreement. The purchase of all or substantially all of the Rights Agent&#8217;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.3(b)</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.4</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Benefits of Agreement;&nbsp;&nbsp;&nbsp;Action by Acting Holders. The holders shall be intended third-party beneficiaries hereof and shall be entitled to, solely by action by the written consent of the Acting Holders, specifically enforce the terms hereof; </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that under no circumstances shall the rights of Holders as third-party beneficiaries pursuant to this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.4</font><font style="letter-spacing:0.2pt;"> be enforceable by such Holders or any other Person acting for or on their behalf other than through the action of the Acting Holders, which Acting Holders shall have the sole power and authority to act on behalf of the Holders in enforcing any of their rights hereunder. Nothing in this Agreement, express or implied, will give to any Person (other than the Rights Agent, Parent, Parent&#8217;s successors and permitted assignees, and the Holders and their respective successors and permitted assignees) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the Rights Agent, Parent, Parent&#8217;s successors and permitted Assignees, and the Holders and their respective successors and permitted assignees. The rights of Holders are limited to those expressly provided in this Agreement and the Merger Agreement. Except for the rights of the Rights Agent set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder or other group of Holders will be entitled to exercise such rights. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.5</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Governing Law.&nbsp;&nbsp;&nbsp;This Agreement, the CVRs and all claims and causes of action based upon, arising out of or in connection herewith shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without regard to Laws that may be applicable under conflicts of laws principles </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In any Legal Proceeding between any of the parties arising out of our relating to this Agreement, each of the parties hereby (i)&#160;irrevocably and unconditionally consent and submits, for itself and its property, to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware, New Castle County, or, if such court does not have jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware, (ii)&#160;agrees that any claim in respect of any such Legal Proceeding shall be heard and determined exclusively in accordance with clause (i)&#160;of this Section&#160;7.5, (iii)&#160;waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such Legal Proceeding in any such court, (iv)&#160;waives, to the fullest extent permitted by Law, any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (v)&#160;agrees that service of process upon such party in any such Legal Proceeding shall be effective if notice is given in accordance with Section&#160;7.1 of this Agreement. Nothing in this Section&#160;7.5, however, shall affect the right of any Person to serve legal process in any manner permitted by Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.6</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Severability.&nbsp;&nbsp;&nbsp;Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If any term or other provision of this Agreement is determined by a final judgement of a court of competent jurisdiction to be invalid or unenforceable, the parties agree that the court making such determination shall have the power to limit such term or provisions, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. Notwithstanding anything to the contrary herein, if any such excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to Parent. In the event such court does not exercise the power granted to it in the prior sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business or other purposes of such invalid or unenforceable term or provision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.7</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Counterparts and Signature.&nbsp;&nbsp;&nbsp;This Agreement may be signed in any number of counterparts, including by electronic transmission, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.8</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Termination.&nbsp;&nbsp;&nbsp;This Agreement will expire and be of no force or effect, the parties hereto will have no liability hereunder (other than with respect to monies due and owing by Parent to the Rights Agent or any other rights of the Rights Agent which expressly survive the termination of this Agreement), and no additional payments will be required to be made, upon the later of (i)&#160;the conclusion of the CVR Term, and (ii)&#160;the payment of the full amount of all CVR Payments made to Parent on or prior to the end of the applicable CVR Term to the Rights Agent and the payment of the full amount of all CVR Payment Amounts to the Holders by the mailing by the Rights Agent of each applicable CVR Payment Amount to each Holder at the address reflected in the CVR Register; provided that, for clarity, the term &#8220;CVR Term&#8221; as used in this </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;7.8</font><font style="letter-spacing:0.2pt;"> shall be deemed to mean clause (a)&#160;of such definition with respect to any Roche Payment Amount, and shall be deemed to mean clause (b)&#160;of such definition with respect to any Asset Disposition Proceeds. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.9</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Funds.&nbsp;&nbsp;&nbsp;All funds received by the Rights Agent under this Agreement that are to be distributed or applied by Computershare in the performance of services hereunder (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Funds</font><font style="letter-spacing:0.2pt;">&#8221;) shall be held by Computershare as agent for Parent and deposited in one or more bank accounts to be maintained by Computershare in its name as agent for Parent. Until paid pursuant to the terms of this Agreement, Computershare will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1&#160;billion or with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&#8217;s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall have no responsibility or liability for any diminution of the Funds that may result from any deposit made by the Rights Agent in accordance with this </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:256pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">paragraph, including any losses resulting from a default by any bank, financial institution or other Third Party. The Rights Agent may from time to time receive interest, dividends or other earnings in connection with such deposits. The Rights Agent shall not be obligated to pay such interest, dividends or earnings to Parent, any Holder or any other party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.10</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Entire Agreement.&nbsp;&nbsp;&nbsp;As between Parent and the Holders, this Agreement and the Merger Agreement (including the schedules, annexes and exhibits thereto, the documents and instruments referred to therein and the documents delivered pursuant thereto) constitute the entire agreement of Parent and the Holders and supersede all prior agreements and undertakings, both written and oral, among Parent and the Holders, or any of them, with respect to the subject matter hereof and, except as otherwise expressly provided herein or therein, are not intended to confer upon any other Person any rights or remedies hereunder or thereunder. As between Parent and the Rights Agent, this Agreement (including the documents and instruments referred to herein (other than the Merger Agreement) and the documents delivered pursuant thereto) contains the entire understanding of the parties with reference to the transactions and matters contemplated hereby and thereby and supersedes all prior agreements, written or oral, among the parties with respect thereto. If and to the extent that any provision of this Agreement is inconsistent or conflicts with the Merger Agreement, this Agreement will govern and control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">7.11</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Waiver of Jury Trial.&nbsp;&nbsp;&nbsp;EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (i)&#160;ARISING UNDER THIS AGREEMENT OR (ii)&#160;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.</font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[</font><font style="font-style:italic;letter-spacing:0.2pt;">Remainder of page intentionally left blank</font><font style="letter-spacing:0.2pt;">] </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above written. </font>
        </div>
        <table style="width:468pt;height:183pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:0.2pt;">SESEN BIO, INC. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.5pt 0pt 0.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.5pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">Name: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify; line-height:0pt;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">Title: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify; line-height:0pt;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.667pt 0pt 1.5pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:0.2pt;">COMPUTERSHARE INC. and COMPUTERSHARE TRUSTCOMPANY, N.A., jointly as RIGHTS AGENT </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.5pt 0pt 0.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.5pt 0pt 0.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">Name: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify; line-height:0pt;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:11.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; width:24pt;">
              <font style="letter-spacing:0.2pt;">Title:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; width:204pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">&#8199;</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify; line-height:0pt;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="AnnexG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:58pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX G</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FORM OF CERTIFICATE OF AMENDMENT </font>
          <br >
          <font style="letter-spacing:-0.2pt;">TO THE RESTATED CERTIFICATE OF INCORPORATION OF </font>
          <br >
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;) hereby certifies as follows: </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">FIRST:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;That the Board of Directors of the Corporation adopted resolutions setting forth the proposed amendment to the Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders in accordance with Section&#160;242 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). The resolution setting forth the proposed amendment is as follows: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">RESOLVED</font><font style="letter-spacing:0.2pt;">, the first paragraph of Article&#160;FOURTH shall be amended and restated to read in its entirety as follows: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The total number of shares of all classes of stock which the Corporation shall have authority to issue is 105,000,000 shares, consisting of (i)&#160;100,000,000 shares of Common Stock, $0.001 par value per share (&#8220;Common Stock&#8221;), and (ii)&#160;5,000,000 shares of Preferred Stock, $0.001 par value per share (&#8220;Preferred Stock&#8221;). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the filing and effectiveness (the &#8220;Effective Time&#8221;) of this Certificate of Amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, every 20&#160;shares of Common Stock issued and outstanding immediately prior to the Effective Time shall, automatically and without any action on the part of the Corporation or the respective holder thereof, be combined into one validly issued, fully paid and non-assessable share of Common Stock (the &#8220;Reverse Stock Split&#8221;). No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, the Corporation shall pay cash equal to such fraction multiplied by the fair market value per share of Common Stock immediately prior to the Effective Time, as determined by the Board of Directors of the Corporation. The Reverse Stock Split shall occur whether or not the certificates representing such shares of Common Stock are surrendered to the Corporation or its transfer agent.&#8221; </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">SECOND:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Certificate of Amendment to the Restated Certificate of Incorporation has been duly adopted in accordance with the provisions of Section&#160;242 of the DGCL. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">THIRD:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;That except as amended hereby, the provisions of the Restated Certificate of Incorporation shall remain in full force and effect. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">FOURTH:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This Certificate of Amendment shall be effective as of </font><font style=" white-space:pre; text-decoration:underline #000000 solid;letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;</font><font style="letter-spacing:0.2pt;">, </font><font style=" white-space:pre; text-decoration:underline #000000 solid;letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">IN WITNESS WHEREOF, I have signed this Certificate this </font><font style=" white-space:pre; text-decoration:underline #000000 solid;letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;</font><font style="letter-spacing:0.2pt;"> day of </font><font style=" white-space:pre; text-decoration:underline #000000 solid;letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;</font><font style="letter-spacing:0.2pt;">, </font><font style=" white-space:pre; text-decoration:underline #000000 solid;letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font>
        </div>
        <div style="margin-left:220pt; margin-top:2.5pt; width:236pt;">
          <div style="margin-left: 0pt; width: 236pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:220pt; margin-top:2pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font>
          <br >
          <font style="letter-spacing:0.2pt;">President and Chief Executive Officer</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">G-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tANNH">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX H</font>&#8203;</div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;262 of the Delaware General Corporation Law </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#167;&#160;262. Appraisal rights </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a) Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, or conversion, who has otherwise complied with subsection (d)&#160;of this section and who has neither voted in favor of the merger, consolidation or conversion nor consented thereto in writing pursuant to &#167;&#160;228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c)&#160;of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b) Appraisal rights shall be available for the shares of any class or series of stock of a constituent or converting corporation in a merger, consolidation or conversion to be effected pursuant to &#167;&#160;251 (other than a merger effected pursuant to &#167;&#160;251(g) of this title), &#167;&#160;252, &#167;&#160;254, &#167;&#160;255, &#167;&#160;256, &#167;&#160;257, &#167;&#160;258, &#167;&#160;263, &#167;&#160;264 or &#167;&#160;266 of this title (other than, in each case and solely with respect to a domesticated corporation, a merger, consolidation or conversion authorized pursuant to and in accordance with the provisions of &#167;&#160;388 of this title): </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1) Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167;&#160;228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for conversion (or, in the case of a merger pursuant to &#167;&#160;251(h) of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167;&#160;251(f) of this title. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(2) Notwithstanding paragraph (b)(1) of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent or converting corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, pursuant to &#167;&#8201;251, &#167;&#8201;252, &#167;&#8201;254, &#167;&#8201;255, &#167;&#8201;256, &#167;&#8201;257, &#167;&#8201;258, &#167;&#8201;263, &#167;&#8201;264 or &#167;&#8201;266 of this title to accept for such stock anything except: </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity if such entity is a corporation as a result of the conversion, or depository receipts in respect thereof; </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation or conversion will be either listed on a national securities exchange or held of record by more than 2,000 holders; </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">H-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(3) In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167;&#160;253 or &#167;&#160;267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(4) [Repealed.] </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c) Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167;&#160;266 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&#160;of this section, shall apply as nearly as is practicable. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d) Appraisal rights shall be perfected as follows: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1) If a proposed merger, consolidation or conversion for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20&#160;days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167;&#160;255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c)&#160;of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167;&#160;114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167;&#160;114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation or conversion, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation or conversion shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10&#160;days after the effective date of such merger, consolidation or conversion, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation or conversion, and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section, of the date that the merger, consolidation or conversion has become effective; or </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(2) If the merger, consolidation or conversion was approved pursuant to &#167;&#160;228, &#167;&#160;251(h), &#167;&#160;253, or &#167;&#160;267 of this title, then either a constituent or converting corporation before the effective date of the merger, consolidation or conversion, or the surviving, resulting or converted entity within 10&#160;days after such effective date, shall notify each stockholder of any class or series of stock of such constituent or converting corporation who is entitled to appraisal rights of the approval of the merger, consolidation or conversion and that appraisal rights are available for any or all shares of such class or series of stock of such constituent or converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167;&#160;114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167;&#160;114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation or conversion, shall, also notify such stockholders of the effective date of the merger, consolidation or conversion. Any stockholder entitled to appraisal rights may, within 20&#160;days after the date of giving such notice or, in the case of a merger approved pursuant to &#167;&#160;251(h) of this title, within the later of the consummation of the offer contemplated by &#167;&#160;251(h) of this title and 20&#160;days after the date of giving such notice, demand in writing from the surviving or resulting entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">H-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation or conversion, either (i)&#160;each such constituent corporation or the converting corporation shall send a second notice before the effective date of the merger, consolidation or conversion notifying each of the holders of any class or series of stock of such constituent or converting corporation that are entitled to appraisal rights of the effective date of the merger, consolidation or conversion or (ii)&#160;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10&#160;days after such effective date; provided, however, that if such second notice is sent more than 20&#160;days following the sending of the first notice or, in the case of a merger approved pursuant to &#167;&#160;251(h) of this title, later than the later of the consummation of the offer contemplated by &#167;&#160;251(h) of this title and 20&#160;days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting corporation may fix, in advance, a record date that shall be not more than 10&#160;days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation or conversion, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(3) Notwithstanding subsection (a)&#160;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1) or (2)&#160;of this section, as applicable; provided that (i)&#160;such beneficial owner continuously owns such shares through the effective date of the merger, consolidation or conversion and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&#160;of this section and (ii)&#160;the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f)&#160;of this section. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e) Within 120&#160;days after the effective date of the merger, consolidation or conversion, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&#160;and (d)&#160;of this section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60&#160;days after the effective date of the merger, consolidation or conversion, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion. Within 120&#160;days after the effective date of the merger, consolidation or conversion, any person who has complied with the requirements of subsections (a)&#160;and (d)&#160;of this section hereof, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation or conversion (or, in the case of a merger approved pursuant to &#167;&#160;251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167;&#160;251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167;&#160;251(h)(2) of this title)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3) of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10&#160;days after such person&#8217;s request </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">H-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">for such a statement is received by the surviving, resulting or converted entity or within 10&#160;days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section hereof, whichever is later. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f) Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20&#160;days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g) At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation or conversion the shares of the class or series of stock of the constituent or converting corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger, consolidation or conversion for such total number of shares exceeds $1&#160;million, or (3)&#160;the merger was approved pursuant to &#167;&#160;253 or &#167;&#160;267 of this title. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h) After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation or conversion, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation or conversion through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i) The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(j) The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">H-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:264pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro&#160;rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&#160;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&#160;of this section. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(k) From and after the effective date of the merger, consolidation or conversion, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d)&#160;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation or conversion); provided, however, that if no petition for an appraisal is filed within the time provided in subsection (e)&#160;of this section, or if a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&#160;of this section, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&#160;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion within 60&#160;days after the effective date of the merger, consolidation or conversion, as set forth in subsection (e)&#160;of this section. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(l) The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">H-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tAnnexI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX I</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font>
          <br >
          <font style="letter-spacing:-0.2pt;">AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:7.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Purpose</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The purpose of this Amended and Restated 2014 Stock Incentive Plan (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Plan</font><font style="letter-spacing:0.2pt;">&#8221;) of Sesen Bio, Inc., a Delaware corporation (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;), is to advance the interests of the Company&#8217;s stockholders by enhancing the Company&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company&#8217;s stockholders. The Plan amends and restates the 2014 Stock Incentive Plan (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Original Plan</font><font style="letter-spacing:0.2pt;">&#8221;) that was originally adopted by the board of directors of the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Board</font><font style="letter-spacing:0.2pt;">&#8221;) in December&#160;2013 and approved by the Company&#8217;s stockholders in January&#160;2014, was amended by the Board on April&#160;19, 2019 and approved by the Company&#8217;s stockholders on June&#160;19, 2019 and was amended by the Board on March&#160;12, 2021 and approved by the Company&#8217;s stockholders on May&#160;3, 2021. Except where the context otherwise requires, the term &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221; shall include any of the Company&#8217;s present or future parent or subsidiary corporations as defined in Sections&#160;424(e) or (f)&#160;of the Internal Revenue Code of 1986, as amended, and any regulations thereunder (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Code</font><font style="letter-spacing:0.2pt;">&#8221;) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Eligibility</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All of the Company&#8217;s employees, officers and directors, as well as consultants and advisors to the Company (as such terms consultants and advisors are defined and interpreted for purposes of Form S-8 under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Securities Act</font><font style="letter-spacing:0.2pt;">&#8221;) (or any successor form)) are eligible to be granted Awards under the Plan. Each person who is granted an Award under the Plan is deemed a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Participant</font><font style="font-style:italic;letter-spacing:0.2pt;">.</font><font style="letter-spacing:0.2pt;">&#8221; &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Award</font><font style="letter-spacing:0.2pt;">&#8221; means Options (as defined in Section&#160;5), SARs (as defined in Section&#160;6), Restricted Stock (as defined in Section&#160;7), Restricted Stock Units (as defined in Section&#160;7) and Other Stock-Based Awards (as defined in Section&#160;8). </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Administration and Delegation</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Administration by Board of Directors</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&#8217;s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Appointment of Committees</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Committee</font><font style="letter-spacing:0.2pt;">&#8221;). All references in the Plan to the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Board</font><font style="letter-spacing:0.2pt;">&#8221; shall mean the Board or a Committee of the Board or the Delegated Persons referred to in Section&#160;3(c) to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee or such Delegated Persons. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Delegation to Delegated Persons</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to any requirements of applicable law (including as applicable Sections&#160;152(b) and 157(c) of the General Corporation Law of the State of Delaware), the Board may, by resolution, delegate to one or more persons (including officers of the Company) or bodies (such persons or bodies, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Delegated Persons</font><font style="letter-spacing:0.2pt;">&#8221;) the power to grant Awards (subject to any limitations under the Plan) to eligible service providers of the Company and to exercise such other powers under the Plan as the Board may determine, provided that the Board shall fix: (i)&#160;the maximum number of Awards, and the maximum number of shares issuable upon exercise thereof, that may be issued by such Delegated Persons, (ii)&#160;the time period during which such Awards, and during which the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">shares issuable upon exercise thereof, may be issued, and (iii)&#160;the minimum amount of consideration (if any) for which such Awards may be issued, and a minimum amount of consideration for the shares issuable upon exercise thereof; and provided further, that no Delegated Person shall be authorized to grant Awards to itself; and provided further, that no Delegated Person shall be authorized to grant Awards to any &#8220;executive officer&#8221; of the Company (as defined by Rule&#160;3b-7 under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221;)) or to any &#8220;officer&#8221; of the Company (as defined by Rule&#160;16a-1(f) under the Exchange Act). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stock Available for Awards</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Number of Shares; Share Counting</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Authorized Number of Shares</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to adjustment under Section&#160;9, Awards may be made under the Plan for up to such number of shares of common stock, $0.001 par value per share, of the Company (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Common Stock</font><font style="letter-spacing:0.2pt;">&#8221;) as is equal to the sum of: </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;an aggregate number of shares of Common Stock equal to 12.79% of the fully-diluted capitalization of the Company as of immediately following the closing of the transactions contemplated by the Agreement and Plan of Merger and Reorganization between the Company, Seahawk Merger Sub Inc. and Carisma Therapeutics Inc. (as it may be amended from time to time, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Merger Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) minus the number of shares of Common Stock that remain available for the grant of Awards as of the closing of the transactions contemplated by the Merger Agreement; plus </font>
        </div>
        <div style="margin-left:80pt; margin-top:8pt; width:376pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;25,313,283 shares of Common Stock; plus</font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;such additional number of shares of Common Stock as is equal to the sum of (x)&#160;the number of shares of Common Stock reserved for issuance under the Company&#8217;s 2009 Stock Incentive Plan (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Prior Plan</font><font style="letter-spacing:0.2pt;">&#8221;) that remained available for grant under the Prior Plan immediately prior to the closing of the Company&#8217;s initial public offering and (y)&#160;the number of shares of Common Stock (I)&#160;that were subject to awards granted under the Prior Plan and (II)&#160;that are subject to stock options assumed by the Company pursuant to the Merger Agreement, as of the closing of the transactions contemplated by the Merger Agreement (the awards described in the foregoing clauses (I)&#160;and (II)&#160;together, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Outstanding Awards</font><font style="letter-spacing:0.2pt;">&#8221;) in each case which Outstanding Awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right (subject, however, in the case of Incentive Stock Options to any limitations of the Code). </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to adjustment under Section&#160;9, up to 252,000,000 of the shares of Common Stock available for issuance under the Plan may be issued as Incentive Stock Options (as defined in Section&#160;5(b)) under the Plan. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Share Counting</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;For purposes of counting the number of shares available for the grant of Awards under the Plan: </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;all shares of Common Stock covered by SARs shall be counted against the number of shares available for the grant of Awards under the Plan; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that (i)&#160;SARs that may be settled only in cash shall not be so counted and (ii)&#160;if the Company grants an SAR in tandem with an Option for the same number of shares of Common Stock and provides that only one such Award may be exercised (a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Tandem SAR</font><font style="letter-spacing:0.2pt;">&#8221;), only the shares covered by the Option, and not the shares covered by the Tandem SAR, shall be so counted, and the expiration of one in connection with the other&#8217;s exercise will not restore shares to the Plan; </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;if any Award (i)&#160;expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or (ii)&#160;results in any Common Stock </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:60pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">not being issued (including as a result of an SAR that was settleable either in cash or in stock actually being settled in cash), the unused Common Stock covered by such Award shall again be available for the grant of Awards; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that (1)&#160;in the case of Incentive Stock Options, the foregoing shall be subject to any limitations under the Code, (2)&#160;in the case of the exercise of an SAR, the number of shares counted against the shares available under the Plan shall be the full number of shares subject to the SAR multiplied by the&#160;percentage of the SAR actually exercised, regardless of the number of shares actually used to settle such SAR upon exercise and (3)&#160;the shares covered by a Tandem SAR shall not again become available for grant upon the expiration or termination of such Tandem SAR; and </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;shares of Common Stock delivered (either by actual delivery, attestation, or net exercise) to the Company by a Participant to (i)&#160;purchase shares of Common Stock upon the exercise of an Award or (ii)&#160;satisfy tax withholding obligations (including shares retained from the Award creating the tax obligation) shall not be added back to the number of shares available for the future grant of Awards. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Substitute Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section&#160;4(a), except as may be required by reason of Section&#160;422 and related provisions of the Code. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stock Options</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">General</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board may grant options to purchase Common Stock (each, an &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Option</font><font style="letter-spacing:0.2pt;">&#8221;) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Incentive Stock Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;An Option that the Board intends to be an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code (an &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Incentive Stock Option</font><font style="letter-spacing:0.2pt;">&#8221;) shall only be granted to employees of Sesen Bio, Inc., any of Sesen Bio, Inc.&#8217;s present or future parent or subsidiary corporations as defined in Sections&#160;424(e) or (f)&#160;of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be construed consistently with the requirements of Section&#160;422 of the Code. An Option that is not intended to be an Incentive Stock Option shall be designated a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Nonstatutory Stock Option.</font><font style="letter-spacing:0.2pt;">&#8221; The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock Option or if the Company converts an Incentive Stock Option to a Nonstatutory Stock Option. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercise Price</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board shall establish the exercise price of each Option and specify the exercise price in the applicable Option agreement. The exercise price shall be not less than 100% of the fair market value per share of Common Stock, as determined by (or in a manner approved by) the Board (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Fair Market Value</font><font style="letter-spacing:0.2pt;">&#8221;), on the date the Option is granted; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that if the Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not less than 100% of the Fair Market Value on such future date. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Duration of Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable option agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that no Option will be granted with a term in excess of 10&#160;years. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercise of Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Options may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with payment in full (in a manner specified in Section&#160;5(f)) of the exercise price for the number of shares for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable following exercise. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Payment Upon Exercise</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows: </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;in cash or by check, payable to the order of the Company; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;except as may otherwise be provided in the applicable Option agreement or approved by the Board, in its sole discretion, by (i)&#160;delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii)&#160;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(3)&nbsp;&nbsp;&nbsp;to the extent provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value, </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> (i)&#160;such method of payment is then permitted under applicable law, (ii)&#160;such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii)&#160;such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(4)&nbsp;&nbsp;&nbsp;to the extent provided for in the applicable Nonstatutory Stock Option agreement or approved by the Board in its sole discretion, by delivery of a notice of &#8220;net exercise&#8221; to the Company, as a result of which the Participant would receive (i)&#160;the number of shares underlying the portion of the Option being exercised, less (ii)&#160;such number of shares as is equal to (A)&#160;the aggregate exercise price for the portion of the Option being exercised divided by (B)&#160;the Fair Market Value on the date of exercise; </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(5)&nbsp;&nbsp;&nbsp;to the extent permitted by applicable law and provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by payment of such other lawful consideration as the Board may determine; or </font>
        </div>
        <div style="margin-left:60pt; margin-top:8pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(6)&nbsp;&nbsp;&nbsp;by any combination of the above permitted forms of payment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Limitation on Repricing</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Unless such action is approved by the Company&#8217;s stockholders, the Company may not (except as provided for under Section&#160;9): (1)&#160;amend any outstanding Option granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Option, (2)&#160;cancel any outstanding option (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section&#160;4(b)) covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled option, (3)&#160;cancel in exchange for a cash payment any outstanding Option with an exercise price per share above the then-current Fair Market Value, or (4)&#160;take any other action under the Plan that constitutes a &#8220;repricing&#8221; within the meaning of the rules of the Nasdaq Stock Market (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Nasdaq</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stock Appreciation Rights</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">General</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board may grant Awards consisting of stock appreciation rights (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">SARs</font><font style="letter-spacing:0.2pt;">&#8221;) entitling the holder, upon exercise, to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the Fair Market Value of a share of Common Stock over the measurement price established pursuant to Section&#160;6(b). The date as of which such appreciation is determined shall be the exercise date. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Measurement Price</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board shall establish the measurement price of each SAR and specify it in the applicable SAR agreement. The measurement price shall not be less than 100% of the Fair Market Value on the date the SAR is granted; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that if the Board approves the grant of an SAR effective as of a future date, the measurement price shall be not less than 100% of the Fair Market Value on such future date. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Duration of SARs</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable SAR agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that no SAR will be granted with a term in excess of 10&#160;years. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercise of SARs</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;SARs may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with any other documents required by the Board. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Limitation on Repricing</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Unless such action is approved by the Company&#8217;s stockholders, the Company may not (except as provided for under Section&#160;9): (1)&#160;amend any outstanding SAR granted under the Plan to provide a measurement price per share that is lower than the then-current measurement price per share of such outstanding SAR, (2)&#160;cancel any outstanding SAR (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section&#160;4(b)) covering the same or a different number of shares of Common Stock and having an exercise or measurement price per share lower than the then-current measurement price per share of the cancelled SAR, (3)&#160;cancel in exchange for a cash payment any outstanding SAR with a measurement price per share above the then-current Fair Market Value, or (4)&#160;take any other action under the Plan that constitutes a &#8220;repricing&#8221; within the meaning of the rules of Nasdaq. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Restricted Stock; Restricted Stock Units</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">General</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board may grant Awards entitling recipients to acquire shares of Common Stock (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Restricted Stock</font><font style="letter-spacing:0.2pt;">&#8221;), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling the recipient to receive shares of Common Stock or cash to be delivered at the time such Award vests (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Restricted Stock Units</font><font style="letter-spacing:0.2pt;">&#8221;) (Restricted Stock and Restricted Stock Units are each referred to herein as a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Restricted Stock Award</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Terms and Conditions for All Restricted Stock Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board shall determine the terms and conditions of a Restricted Stock Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Additional Provisions Relating to Restricted Stock</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Dividends</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Unless otherwise provided in the applicable Award agreement, any dividends (whether paid in cash, stock or property) declared and paid by the Company with respect to shares of Restricted Stock (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Accrued Dividends</font><font style="letter-spacing:0.2pt;">&#8221;) shall be paid to the Participant only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such shares. Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third month following the lapsing of the restrictions on transferability and the forfeitability provisions applicable to the underlying shares of Restricted Stock. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stock Certificates</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company may require that any stock certificates issued in respect of shares of Restricted Stock, as well as dividends or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to his or her Designated Beneficiary. &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Designated Beneficiary</font><font style="letter-spacing:0.2pt;">&#8221; means (i)&#160;the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#8217;s death or (ii)&#160;in the absence of an effective designation by a Participant, the Participant&#8217;s estate. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Additional Provisions Relating to Restricted Stock Units</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Settlement</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted Stock Unit, the Participant shall be entitled to receive from the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Company such number of shares of Common Stock or (if so provided in the applicable Award agreement) an amount of cash equal to the Fair Market Value of such number of shares of Common Stock as set forth in the applicable Award agreement. The Board may, in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section&#160;409A of the Code. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Voting Rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A Participant shall have no voting rights with respect to any Restricted Stock Units. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(3)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Dividend Equivalents</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Award agreement for Restricted Stock Units may provide Participants with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Dividend Equivalents</font><font style="letter-spacing:0.2pt;">&#8221;). Dividend Equivalents may be paid currently or credited to an account for the Participants, may be settled in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which paid, in each case to the extent provided in the applicable Award agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Other Stock-Based Awards</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">General</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property, may be granted hereunder to Participants (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Other Stock-Based-Awards</font><font style="letter-spacing:0.2pt;">&#8221;). Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Terms and Conditions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price applicable thereto. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Adjustments for Changes in Common Stock and Certain Other Events</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Changes in Capitalization</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i)&#160;the number and class of securities available under the Plan and the number and class of securities available for issuance as Incentive Stock Options under the Plan, (ii)&#160;the share counting rules set forth in Section&#160;4(a), (iii)&#160;the number and class of securities and exercise price per share of each outstanding Option, (iv)&#160;the share and per-share provisions and the measurement price of each outstanding SAR, (v)&#160;the number of shares subject to and the repurchase price per share subject to each outstanding Restricted Stock Award and (vi)&#160;the share and per-share-related provisions and the purchase price, if any, of each outstanding Other Stock-Based Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Reorganization Events</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Definition</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Reorganization Event</font><font style="letter-spacing:0.2pt;">&#8221; shall mean: (a)&#160;any merger or consolidation of the Company with or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b)&#160;any transfer or disposition of all of the Common Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c)&#160;any liquidation or dissolution of the Company. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:60pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Consequences of a Reorganization Event on Awards Other than Restricted Stock</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;In connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards other than Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise in an applicable Award agreement or another agreement between the Company and the Participant): (i)&#160;provide that such Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii)&#160;upon written notice to a Participant, provide that all of the Participant&#8217;s unvested and/or unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following the date of such notice, (iii)&#160;provide that outstanding Awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv)&#160;in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquisition Price</font><font style="letter-spacing:0.2pt;">&#8221;), make or provide for a cash payment to Participants with respect to each Award held by a Participant equal to (A)&#160;the number of shares of Common Stock subject to the vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by (B)&#160;the excess, if any, of (I)&#160;the Acquisition Price over (II)&#160;the exercise, measurement or purchase price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (v)&#160;provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (vi)&#160;any combination of the foregoing. In taking any of the actions permitted under this Section&#160;9(b)(2), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;Notwithstanding the terms of Section&#160;9(b)(2)(i), in the case of outstanding Restricted Stock Units that are subject to Section&#160;409A of the Code: (i)&#160;if the applicable Restricted Stock Unit agreement provides that the Restricted Stock Units shall be settled upon a &#8220;change in control event&#8221; within the meaning of Treasury Regulation&#160;Section&#160;1.409A-3(i)(5)(i), and the Reorganization Event constitutes such a &#8220;change in control event&#8221;, then no assumption or substitution shall be permitted pursuant to Section&#160;9(b)(2)(i)(i) and the Restricted Stock Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and (ii)&#160;the Board may only undertake the actions set forth in clauses (iii), (iv)&#160;or (v)&#160;of Section&#160;9(b)(2)(i) if the Reorganization Event constitutes a &#8220;change in control event&#8221; as defined under Treasury Regulation&#160;Section&#160;1.409A-3(i)(5)(i) and such action is permitted or required by Section&#160;409A of the Code; if the Reorganization Event is not a &#8220;change in control event&#8221; as so defined or such action is not permitted or required by Section&#160;409A of the Code, and the acquiring or succeeding corporation does not assume or substitute the Restricted Stock Units pursuant to clause (i)&#160;of Section&#160;9(b)(2)(i), then the unvested Restricted Stock Units shall terminate immediately prior to the consummation of the Reorganization Event without any payment in exchange therefor. </font>
        </div>
        <div style="margin-left:60pt; text-indent:20pt; margin-top:8pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;For purposes of Section&#160;9(b)(2)(i)(i), an Award (other than Restricted Stock) shall be considered assumed if, following consummation of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share of Common Stock subject to the Award immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:60pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(3)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Consequences of a Reorganization Event on Restricted Stock</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Upon the occurrence of a Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit of the Company&#8217;s successor and shall, unless the Board determines otherwise, apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to such Restricted Stock; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that the Board may provide for termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, either initially or by amendment. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">General Provisions Applicable to Awards</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transferability of Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option, pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that the Board may permit or provide in an Award for the gratuitous transfer of the Award by the Participant to or for the benefit of any immediate family member, family trust or other entity established for the benefit of the Participant and/or an immediate family member thereof if the Company would be eligible to use a Form S-8 under the Securities Act for the registration of the sale of the Common Stock subject to such Award to such proposed transferee; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided further</font><font style="letter-spacing:0.2pt;">, that the Company shall not be required to recognize any such permitted transfer until such time as such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. For the avoidance of doubt, nothing contained in this Section&#160;10(a) shall be deemed to restrict a transfer to the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Documentation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Board Discretion</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Termination of Status</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board shall determine the effect on an Award of the disability, death, termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Withholding</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Participant must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may decide to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price unless the Company determines otherwise. If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company&#8217;s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income), except that, to the extent that the Company is able to retain shares of Common Stock having a fair market value (determined or approved by the Company) that exceeds the statutory minimum applicable withholding tax without financial accounting implications or the Company is withholding in a jurisdiction that does not have a statutory minimum withholding tax, the Company may retain such number of shares of Common Stock (up to the number of shares having a fair market value equal to the maximum individual statutory rate of tax (determined or approved by, the Company)) as the Company shall determine to be necessary to satisfy the tax liability associated with any Award. Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Amendment of Award</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as otherwise provided in Sections&#160;5(g) and 6(e) with respect to repricings and Section&#160;11(d) with respect to actions requiring stockholder approval, the Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant&#8217;s consent to such action shall be required unless (i)&#160;the Board determines that the action, taking into account any related action, does not materially and adversely affect the Participant&#8217;s rights under the Plan or (ii)&#160;the change is permitted under Section&#160;9. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conditions on Delivery of Stock</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously issued or delivered under the Plan until (i)&#160;all conditions of the Award have been met or removed to the satisfaction of the Company, (ii)&#160;in the opinion of the Company&#8217;s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules and regulations, and (iii)&#160;the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Acceleration</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board may at any time provide that any Award shall become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11.&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Miscellaneous</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Right To Employment or Other Status</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No person shall have any claim or right to be granted an Award by virtue of the adoption of the Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">No Rights As Stockholder; Clawback</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp; Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of such shares. In accepting an Award made under the Plan on and after the Closing Date (as defined in Section&#160;11(c)), the Participant agrees to be bound by any clawback policy that the Company has in effect or may adopt in the future. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Effective Date and Term of Plan</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Original Plan became effective immediately prior to the closing of the Company&#8217;s initial public stock offering of its Common Stock on a U.S.-based stock exchange whereby the Company&#8217;s shares of Common Stock are offered for sale to the public. The Plan shall become effective on the closing of the transactions contemplated by the Merger Agreement (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Closing Date</font><font style="letter-spacing:0.2pt;">&#8221;). No Awards shall be granted under the Plan after the expiration of 10&#160;years from the Closing Date, but Awards previously granted may extend beyond that date. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(d)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Amendment of Plan</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board may amend, suspend or terminate the Plan or any portion thereof at any time provided that (i)&#160;to the extent required by Section&#160;162(m) of the Code, no Award granted to a Participant that is intended to comply with Section&#160;162(m) of the Code after the date of such amendment shall become exercisable, realizable or vested, as applicable to such Award, unless and until the Company&#8217;s stockholders approve such amendment in the manner required by Section&#160;162(m) of the Code; and (ii)&#160;no amendment that would require stockholder approval under the rules of the Nasdaq Stock Market may be made effective unless and until the Company&#8217;s stockholders approve such amendment. In addition, if at any time the approval of the Company&#8217;s stockholders is required as to any other modification or amendment under Section&#160;422 of the Code or any successor provision with respect to Incentive Stock Options, the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section&#160;11(d) shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of Participants under the Plan. No Award shall be made that is conditioned upon stockholder approval of any amendment to the Plan unless the Award provides that (i)&#160;it will terminate or be forfeited if stockholder approval of such amendment is not obtained within no more than 12&#160;months from the date of grant and (2)&#160;it may not be exercised or settled (or otherwise result in the issuance of Common Stock) prior to such stockholder approval. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(e)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Authorization of Sub-Plans (including Grants to non-U.S. Employees)</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to the Plan containing (i)&#160;such limitations on the Board&#8217;s discretion under the Plan as the Board deems necessary or desirable or (ii)&#160;such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-size:9.8pt;">
          <font style="font-size:10pt;letter-spacing:0.2pt;">(f)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;font-size:10pt;letter-spacing:0.2pt;">Compliance with Section&#160;409A of the Code</font><font style="font-size:10pt;letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;</font><font style="font-size:10pt;letter-spacing:0.196pt;">Except as provided in individual Award agreements initially or by amendment, if and to the extent (i)&#160;any portion of any payment, compensation or other benefit provided to a Participant pursuant to the Plan in connection with his or her employment termination constitutes &#8220;nonqualified deferred compensation&#8221; within the meaning of Section&#160;409A of the Code and (ii)&#160;the Participant is a specified employee as defined in Section&#160;409A(a)(2)(B)(i) of the Code, in each case as determined by the Company in accordance with its procedures, by which determinations the Participant (through accepting the Award) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six&#160;months plus one day after the date of &#8220;separation from service&#8221; &#8203;(as determined under Section&#160;409A of the Code) (the &#8220;</font><font style="font-style:italic;font-weight:bold;font-size:10pt;letter-spacing:-0.196pt;">New Payment Date</font><font style="font-size:10pt;letter-spacing:0.196pt;">&#8221;), except as Section&#160;409A of the Code may then permit. The aggregate of any payments that otherwise would have been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original schedule.</font><font style="font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under the Plan are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:408pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">determined to constitute nonqualified deferred compensation subject to Section&#160;409A of the Code but do not to satisfy the conditions of that section. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(g)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Limitations on Liability</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, employee, or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan, nor will such individual be personally liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as a director, officer, employee, or agent of the Company. The Company will indemnify and hold harmless each director, officer, employee, or agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Board&#8217;s approval) arising out of any act or omission to act concerning the Plan unless arising out of such person&#8217;s own fraud or bad faith. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(h)&nbsp;&nbsp;&nbsp;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Governing Law</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than the State of Delaware.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">I-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tAnnexJ">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:180pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:right; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ANNEX J</font>&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AMENDMENT NO. 2</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TO</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2014 EMPLOYEE STOCK PURCHASE PLAN</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Sesen Bio, Inc. 2014 Employee Stock Purchase Plan, as amended (the &#8220;Plan&#8221;), is hereby amended as follows: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1.&nbsp;&nbsp;&nbsp;The second sentence of the first paragraph of the Plan shall be deleted in its entirety and replaced with the following: </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Subject to adjustment under Section&#160;15 hereof, the number of shares of Common Stock that have been approved for this purpose is 6,568,655 shares of Common Stock.&#8221; </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2.&nbsp;&nbsp;&nbsp;The following sentence shall be added to the end of Section&#160;26 of the Plan: </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;The first amendment to the Plan took effect on May&#160;3, 2021. The second amendment to the Plan shall take effect as of the effective time of the merger contemplated by the Agreement and Plan of Merger and Reorganization, dated as of September&#160;20, 2022, by and between the Company, Seahawk Merger Sub Inc. and Carisma Therapeutics Inc., subject to approval by the shareholders of the Company as required by Section&#160;423 of the Code, which approval must occur within twelve&#160;months of the second amendment of the Plan by the Board.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as set forth above, the remainder of the Plan remains in full force and effect. For the avoidance of doubt and for purposes of the Plan, the &#8220;Board&#8221; shall mean the Board of Directors of the Company. </font>
        </div>
        <div style="margin-left:220pt; margin-top:24pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adopted by the Board of Directors on </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;] </font>
        </div>
        <div style="margin-left:220pt; margin-top:24pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Approved by the Stockholders on </font>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">[&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;]</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">J-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PART II</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INFORMATION NOT REQUIRED IN</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROXY STATEMENT/PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;20&#8201;&#8212;&#8201;Indemnification of Directors and Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Delaware General Corporation Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(a) of the DGCL empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person&#8217;s conduct was unlawful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(b) of the DGCL empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which the person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(c) of the DGCL provides that to the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (a)&#160;and (b)&#160;of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(d) of the DGCL states that any indemnification under subsections (a)&#160;and (b)&#160;of Section&#160;145 (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that indemnification of the present or former director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a)&#160;and (b)&#160;of Section&#160;145. Such determination shall be made with respect to a person who is a director or officer at the time of such determination (i)&#160;by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, (ii)&#160;by a committee of such directors designated by majority vote of such directors, even though less than a quorum, (iii)&#160;if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion or (iv)&#160;by the stockholders. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(f) of the DGCL states that the indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of Section&#160;145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official capacity and as to action in another capacity while holding such office. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(g) of the DGCL provides that a corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity or arising out of such person&#8217;s status as such, whether or not the corporation would have the power to indemnify such person against such liability under the provisions of Section&#160;145. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(j) of the DGCL states that the indemnification and advancement of expenses provided by, or granted pursuant to, Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;102(b)(7) of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision shall not eliminate or limit the liability of (i)&#160;a director or officer for any breach of the director&#8217;s or officer&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;a director under Section&#160;174 of the DGCL, (iv)&#160;a director or officer for any transaction from which the director or officer derived an improper personal benefit, or (v)&#160;an officer in any action by or in the right of the corporation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certificate of Incorporation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has adopted provisions in the Sesen Bio Certificate of Incorporation that provide for indemnification of Sesen Bio&#8217;s officers and directors to the maximum extent permitted under the DGCL. As authorized by the DGCL, the Sesen Bio Certificate of Incorporation limits the liability of Sesen Bio&#8217;s directors for monetary damages. The effect of this provision is to eliminate Sesen Bio&#8217;s rights and those of Sesen Bio&#8217;s stockholders to recover monetary damages against a director for breach of the fiduciary duty of care as a director except in certain limited situations. This provision does not limit or eliminate Sesen Bio&#8217;s rights or that of any stockholder to seek non-monetary relief such as an injunction or rescission in the event of a breach of a director&#8217;s duty of care. These provisions will not alter the liability of the Sesen Bio board of directors under federal securities laws. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Insurance Policy</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio maintains a general liability insurance policy that covers certain liabilities of Sesen Bio directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Indemnification Agreemen</font><font style="letter-spacing:0.2pt;">t </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sesen Bio has entered into indemnification agreements with its directors and executive officers. In general, these agreements provide that Sesen Bio will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or officer of Sesen Bio or in connection with their service at Sesen Bio&#8217;s request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the director or executive officer. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Merger Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, pursuant to the terms of the Merger Agreement, the provisions of the Sesen Bio Certificate of Incorporation and the Sesen Bio Bylaws with respect to indemnification, advancement of expenses and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">exculpation of present and former directors and officers of Sesen Bio, shall not be amended, modified or repealed for a period of six&#160;years from the effective time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the effective time, were officers or directors of Sesen Bio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;21&#8201;&#8212;&#8201;Exhibits and Financial Statement Schedules</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(a) Exhibit&#160;Index</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A list of exhibits filed with this registration statement on Form S-4 is set forth on the Exhibit&#160;Index and is incorporated herein by reference. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(b) Financial Statements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The financial statements filed with this registration statement on Form S-4 are set forth on the Financial Statement Index and are incorporated herein by reference. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;22&#8201;&#8212;&#8201;Undertakings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: if the registrant is subject to Rule&#160;430C, each prospectus filed pursuant to Rule&#160;424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:60pt; width:396pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </font>
        </div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <font style="letter-spacing:0.2pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(c)</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes as follows: that every prospectus (i)&#160;that is filed pursuant to paragraph (b)&#160;immediately preceding, or (ii)&#160;that purports to meet the requirements of Section&#160;10(a)(3) of the Securities Act of 1933 and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(d)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into this proxy statement/prospectus pursuant to Item&#160;4, 10(b), 11, or 13 of Form S-4, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(e)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(f)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(g)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:496pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO EXHIBITS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <table style="width:456pt;height:633.5pt;margin-top:6pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:42.39pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">EXHIBIT</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">NUMBER </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:401.61pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">DESCRIPTION OF DOCUMENT </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.417pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">2.1* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.417pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a href="#tAAPM">Agreement and Plan of Merger, dated as of September&#160;20, 2022, by and among Sesen Bio, Inc., Seahawk Merger Sub, Inc. and Carisma (included as Annex A-1 to the proxy statement/&#8203;prospectus forming a part of this Registration Statement).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">2.2*</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a href="#tFAAP">First Amendment to Agreement and Plan of Merger and Reorganization, dated as of December&#160;29, 2022, by and among Sesen Bio,&#160;Inc., Seahawk Merger Sub,&#160;Inc., and Carisma (included as Annex&#160;A-2 to the proxy statement/ prospectus forming a part of this Registration Statement).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">2.3* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a href="#tANNC">Form of Carisma Support Agreement, by and between the Sesen Bio, Inc., Carisma and certain stockholders of Carisma (included as Annex C to the proxy statement/prospectus forming a part of this Registration Statement).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">2.4* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a href="#tANND">Form of Sesen Bio Support Agreement, by and between the Sesen Bio, Inc., Carisma and certain stockholders of Sesen Bio, Inc. (included as Annex D to the proxy statement/&#8203;prospectus forming a part of this Registration Statement).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">2.5* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a href="#tANNE">Form of Lock-Up Agreement, by and between Sesen Bio, Inc., Carisma and certain stockholders of Sesen Bio, Inc. and Carisma (included as Annex E to the proxy statement/&#8203;prospectus forming a part of this Registration Statement).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">2.6* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a href="#tANNF">Form of Contingent Value Rights Agreement by and among Sesen Bio, Inc. and the Rights Agent (included as Annex F to the proxy statement/prospectus forming a part of this Registration Statement).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">2.7</font><font style="letter-spacing:0.2pt;">&#8224; </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312516715368/d261598dex21.htm">Share Purchase Agreement, effective as of September&#160;20, 2016, by and between Eleven Biotherapeutics, Inc., Viventia Bio Inc. and Clairmark Investments Ltd., as representative of the selling shareholders (incorporated by reference to Exhibit&#160;2.1 to the Registrant&#8217;s Current Report on Form 8-K filed on September&#160;21, 2016).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">3.1 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514056904/d679756dex31.htm">Restated Certificate of Incorporation of Sesen Bio, Inc. (incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on February&#160;18, 2014).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">3.2 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit31-ebioxcertificate.htm">Certificate of Amendment of Certificate of Incorporation of Sesen Bio, Inc. (incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on May&#160;17, 2018).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">3.3 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000103/ex33-certificateofamendm.htm">Certificate of Amendment of Certificate of Incorporation of Sesen Bio, Inc. (incorporated by reference to Exhibit&#160;3.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May&#160;10, 2021).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">3.4 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit32-elevenbiotherape.htm">Amended and Restated By-Laws of Sesen Bio, Inc. (incorporated by reference to Exhibit&#160;3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on May&#160;17, 2018).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">4.1 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex41.htm">Specimen Certificate for Sesen Bio, Inc.&#8217;s Common Stock, par value $.001 per share (incorporated by reference to Exhibit&#160;4.1 to the Registrant&#8217;s Registration Statement on Form&#160;S-1/A (File No. 333-193131), filed on January&#160;23, 2014).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">4.2 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514448885/d704357dex1023.htm">Eleven Biotherapeutics, Inc. Form of Warrant issued to Silicon Valley Bank and Life Science Loans, LLC dated November&#160;25, 2014 (incorporated by reference to Exhibit&#160;10.23 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-201176), filed on December&#160;19, 2014).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">4.3 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500317000132/ex41ebiopre-fundedwarrant1.htm">Form of Common Warrant (incorporated by reference to Exhibit&#160;4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on November&#160;3, 2017).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">4.4 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit41.htm">Form of Warrant (incorporated by reference to Exhibit&#160;4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on March&#160;23, 2018).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">4.5 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2017warrantamendmenta.htm">Form of 2017 Warrant Amendment Agreement (incorporated by reference to Exhibit&#160;4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on October&#160;29, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:0.5pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;height:625.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:42.39pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">EXHIBIT</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">NUMBER </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:401.61pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">DESCRIPTION OF DOCUMENT </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.417pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">4.6 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.417pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2018warrantamendmenta.htm">Form of 2018 Warrant Amendment Agreement (incorporated by reference to Exhibit&#160;4.4 to the Registrant&#8217;s Current Report on Form 8-K, filed on October&#160;29, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">5.1^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex5d1.htm">Opinion of Hogan Lovells US LLP as to the validity of shares of common stock to be issued to CARISMA Therapeutics Inc. </a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">8.1^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922127022/tm2227887d10_ex8-1.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP as to certain tax matters. </a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:10pt;letter-spacing:0.2pt;">8.2^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922127022/tm2227887d10_ex8-2.htm">Opinion of Hogan Lovells US LLP as to certain tax matters. </a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.1+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex101.htm">Eleven Biotherapeutics, Inc. Amended and Restated 2009 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-193131), filed on December&#160;30, 2013).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.2+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex102.htm">Form of Incentive Stock Option Agreement under the Eleven Biotherapeutics, Inc. Amended and Restated 2009 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-193131), filed on December&#160;30, 2013).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.3+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex103.htm">Form of Non-Statutory Stock Option Agreement under the Eleven Biotherapeutics, Inc. Amended and Restated 2009 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.3 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-193131), filed on December&#160;30, 2013).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.4+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000045/sesenbio-2014stockincentiv.htm">Sesen Bio, Inc. 2014 Stock Incentive Plan, as amended (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on June&#160;25, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.5+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex106.htm">Form of Incentive Stock Option Agreement under the Sesen Bio Inc. 2014 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.6 to the Registrant&#8217;s Registration Statement on Form&#160;S-1/A (File No. 333-193131), filed on January&#160;23, 2014).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.6+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex107.htm">Form of Non-Statutory Stock Option Agreement under the Sesen Bio, Inc. 2014 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.7 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-193131), filed on January&#160;23, 2014).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.7+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312515239156/d34817dex101.htm">Form of Restricted Stock Unit Agreement under the Sesen Bio, Inc. 2014 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on June&#160;29, 2015).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.8+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit108_formindemnifica.htm">Form of Indemnification Agreement by and between Sesen Bio, Inc. and Each of its Directors and Executive Officers (incorporated by reference to Exhibit&#160;10.8 to the Registrant&#8217;s Annual Report on Form 10-K, filed on February&#160;28, 2022).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.9+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex1013.htm">Eleven Biotherapeutics, Inc. 2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit&#160;10.13 to the Registrant&#8217;s Registration Statement on Form S-1/A (Reg. No. 333-193131), filed on January&#160;23, 2014).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.10&#9826; </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000120/sesnexhibit101micrometli.htm">Non-Exclusive Product License Agreement, effective as of October&#160;18, 2005, by and between Micromet AG and Viventia Biotech Inc. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November&#160;9, 2018).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.11&#9826; </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000120/sesnexhibit102xomanonexc.htm">Non-Exclusive License Agreement, effective as of November&#160;30, 2001, by and between XOMA Ireland Limited and Viventia Biotech Inc. (incorporated by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November&#160;9, 2018).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.12+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000105/exhibit101-tcannellemploym.htm">Employment Agreement, dated August&#160;7, 2018, by and between Sesen Bio, Inc. and Thomas R. Cannell, D.V.M. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on August&#160;13, 2018).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.13 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit101.htm">Form of Securities Purchase Agreement (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on March&#160;23, 2018).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:4.5pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;height:621.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:42.39pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">EXHIBIT</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">NUMBER </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:401.61pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">DESCRIPTION OF DOCUMENT </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.417pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.14 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.417pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-spaamendment.htm">Amendment to Securities Purchase Agreement, dated October&#160;28, 2019, by and among Sesen Bio, Inc. and the undersigned parties thereto (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on October&#160;29, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.15 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000015/ex1032sesn-tomcannellstock.htm">Stock Option Award Agreement, dated August&#160;7, 2018, by and between Sesen Bio, Inc. and Thomas R. Cannell, D.V.M (incorporated by reference to Exhibit&#160;10.32 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March&#160;1, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.16+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000029/glenmacdonaldebioemploym.htm">Employment Agreement, dated September&#160;20, 2016, by and between Eleven Biotherapeutics, Inc. and Glen Macdonald, as amended on February&#160;21, 2017 (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May&#160;10, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.17+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000070/sesenbio-monicaforbesemplo.htm">Employment Agreement, dated August&#160;26, 2019, by and between Monica Forbes and Sesen Bio, Inc. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, filed on August&#160;26, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.18+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000090/sesn-09302019x10qex101.htm">Employment Agreement, dated July&#160;26, 2019, by and between Mark R. Sullivan and Sesen Bio, Inc. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q, filed on November&#160;12, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.19+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000090/sesn-09302019x10qex103.htm">Stock Option Award Agreement, dated August&#160;1, 2019, by and between Sesen Bio, Inc. and Monica Forbes (incorporated by reference to Exhibit&#160;10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November&#160;12, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.20 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">Open Market Sale Agreement</a><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">SM</a></font><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">, dated November&#160;2019, by and between Sesen Bio, Inc. and Jefferies LLC (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on November&#160;29, 2019).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.21 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm">Amendment No. 1 to the Open Market Sale Agreement</a><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm">SM</a></font><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm">, dated October&#160;30, 2020, by and between Sesen Bio, Inc. and Jefferies LLC (incorporated by reference to Exhibit&#160;1.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on October&#160;30, 2020).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.22&#9826; </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000118/sesn-ex101qilulicensea.htm">Exclusive License Agreement, dated July&#160;30, 2020, by and among Sesen Bio, Inc., Viventia Bio, Inc. and Qilu Pharmaceutical Co., Ltd. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November&#160;9, 2020).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.23 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm">Amendment No. 2 to the Open Market Sale Agreement</a><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm">SM</a></font><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm">, dated February&#160;17, 2021, by and between Sesen Bio, Inc. and Jefferies LLC (incorporated by reference to Exhibit&#160;1.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on February&#160;17, 2021).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.24+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000088/exhibit101-amendmentno2t.htm">Amendment No. 2 to the Sesen Bio, Inc. 2014 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on May&#160;3, 2021).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.25+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000088/exhibit102-amendmentno1t.htm">Amendment No. 1 to the Sesen Bio, Inc. 2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on May&#160;3, 2021).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.26 </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000114/sesn-amendmentno3toatmsa.htm">Amendment No. 3 to the Open Market Sale Agreement</a><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000114/sesn-amendmentno3toatmsa.htm">SM</a></font><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000114/sesn-amendmentno3toatmsa.htm">, dated June&#160;1, 2021, by and between Sesen Bio, Inc. and Jefferies LLC (incorporated by reference to Exhibit&#160;1.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on June&#160;1, 2021).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.27+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit1030-rsuandcashrete.htm">Form of RSU Award Agreement for Retention Awards (incorporated by reference to Exhibit&#160;10.30 to the Registrant&#8217;s Annual Report on Form 10-K, filed on February&#160;28, 2022).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.28+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit1031-performancexba.htm">Form of PSU Award Agreement for Retention Awards (incorporated by reference to Exhibit&#160;10.31 to the Registrant&#8217;s Annual Report on Form 10-K, filed on February&#160;28, 2022).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.29&#9826; </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000063/sesn-ex101xzurichlicenseag.htm">License Agreement, effective January&#160;13, 2003, as amended and restated on October&#160;14, 2015, by and between The University of Zurich and Viventia Bio, Inc. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May&#160;9, 2022).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;height:645.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:42.39pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">EXHIBIT</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">NUMBER </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:401.61pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">DESCRIPTION OF DOCUMENT </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.417pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.30&#9826; </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.417pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000092/ex101-sesenrocheassetpur.htm">Asset Purchase Agreement, dated as of July&#160;15, 2022 by and among Sesen Bio, Inc., F.&#160;Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on July&#160;18, 2022).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.31+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000121/sesenbio_minorirosales-e.htm">Employment Agreement, dated January 5, 2022, by and between Sesen Bio, Inc. and Minori Rosales (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q/A, filed on August 25, 2022).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.32^&#9826; </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d32.htm">Collaboration and License Agreement, dated January&#160;7, 2022, by and between Carisma and Moderna Therapeutics Inc. </a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.33&#9826; </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d33.htm">License Agreement, dated as of November&#160;10, 2017, by and between Carisma and the Trustees of the University of Pennsylvania, as amended (incorporated by reference to Exhibit 10.33 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-267891), filed on October 14, 2022).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.34&#9826; </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d34.htm">License Agreement, dated as of July&#160;24, 2020, by and between Carisma and New York University (incorporated by reference to Exhibit 10.34 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-267891), filed on October 14, 2022).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.35</font><font style="letter-spacing:0.2pt;">^</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923002376/tm2227887d12_ex10-35.htm">Amended and Restated Subscription Agreement, dated as of December&#160;29, 2022, by and between Carisma and each of the purchasers listed on the signature pages thereto, severally and not jointly.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.36^+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d36.htm">Offer Letter, dated as of February 12, 2018, by and between Carisma and Steven Kelly.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.37^+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d37.htm">Offer Letter, dated as of October 18, 2018, by and between Carisma and Michael Klichinsky.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.38^+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d38.htm">Offer Letter, dated as of March 15, 2021, by and between Carisma and Richard Morris.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">10.39^+ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d39.htm">Carisma 2017 Stock Incentive Plan, as amended.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">21.1^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex21d1.htm">Subsidiaries of Sesen Bio, Inc.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">23.1* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2227887d14_ex23-1.htm">Consent of KPMG LLP.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">23.2^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex5d1.htm">Consent of Hogan Lovells US LLP (contained in Exhibit&#160;5.1). </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">23.3* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2227887d14_ex23-3.htm">Consent of Ernst &amp; Young, LLP.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">23.4^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922127022/tm2227887d10_ex8-1.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (contained in Exhibit 8.1).</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">23.5^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922127022/tm2227887d10_ex8-2.htm">Consent of Hogan Lovells US LLP (contained in Exhibit 8.2). </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">24.1^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xs4.htm#Signature">Power of Attorney.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.1*</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2227887d14_ex99-1.htm">Form of Proxy Card for Special Meeting of Stockholders of Registrant.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.2* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <a href="#AnnexG">Proposed Certificate of Amendment to the Restated Certificate of Incorporation of Registrant for the Sesen Bio, Inc. Reverse Stock Split (included as Annex G to the proxy statement/&#8203;prospectus forming a part of this Registration Statement).</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.3* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:401.61pt;white-space:normal;">
                <div style="letter-spacing:0.2pt;">
                  <a href="#tANNB">Opinion of SVB Securities LLC, financial advisor to Sesen Bio, Inc. (included as Annex B to the proxy statement/prospectus forming part of this Registration Statement).</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.4* </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="tm2227887d14_ex99-4.htm">Consent of SVB Securities LLC, financial advisor to Sesen Bio, Inc.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.5^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex99d5.htm">Consent of Sanford Zweifach to be named as a Director.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.6^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex99d6.htm">Consent of Regina Hodits, Ph.D. to be named as a Director.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.7^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex99d7.htm">Consent of Steven Kelly to be named as a Director. </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.8^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex99d8.htm">Consent of Briggs Morrison, M.D. to be named as a Director.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.9^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex99d9.htm">Consent of Bj&#246;rn Odlander to be named as a Director.</a>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="margin-left:5pt;letter-spacing:0.2pt;">99.10^ </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex99d10.htm">Consent of Chidozie Ugwumba to be named as a Director.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="letter-spacing:0.2pt;">101.INS </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <font style="letter-spacing:0.2pt;">XBRL Instance Document. </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:389.5pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;height:115.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0.167pt 0pt 2.667pt 0pt; width:42.39pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">EXHIBIT</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">NUMBER </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0.167pt 0pt 2.667pt 0pt; width:401.61pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">DESCRIPTION OF DOCUMENT </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.75pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="letter-spacing:0.2pt;">101.SCH </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.75pt 0pt 2pt 0pt; width:401.61pt;">
                <font style="letter-spacing:0.2pt;">XBRL Taxonomy Extension Schema Document. </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="letter-spacing:0.2pt;">101.CAL </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <font style="letter-spacing:0.2pt;">XBRL Taxonomy Extension Calculation Linkbase Document. </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="letter-spacing:0.2pt;">101.DEF </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <font style="letter-spacing:0.2pt;">XBRL Taxonomy Extension Definition Linkbase Document. </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="letter-spacing:0.2pt;">101.LAB </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <font style="letter-spacing:0.2pt;">XBRL Taxonomy Extension Label Linkbase Document. </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <font style="letter-spacing:0.2pt;">101.PRE </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;">
                <font style="letter-spacing:0.2pt;">XBRL Taxonomy Extension Presentation Linkbase Document. </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:42.39pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:0.2pt;">107^ </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:4pt 0pt 2pt 0pt; width:401.61pt;text-align:left;">
                <div style="letter-spacing:0.2pt;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xexfilingfees.htm">Filing Fee Table.</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Filed herewith. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">**</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">To be filed by amendment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">^</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Previously filed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">+</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Indicates management contract or compensatory plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8224;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Certain schedules and exhibits have been omitted pursuant to Item&#160;601 of Regulation&#160;S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9826;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:30.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the town of Cambridge, Commonwealth of Massachusetts, on January&#160;18, 2023. </font>
          </div>

        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SESEN BIO, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:240pt; line-height:12pt; margin-top:18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:260pt;">
          <font style="letter-spacing:0.2pt;">/s/ Thomas R. Cannell, D.V.M.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="white-space:nowrap; margin-left:260pt; margin-top:2.5pt; width:196pt;">
          <div style="margin-left: 0pt; width: 196pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-left:260pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:33pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Name:</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:293pt;">
          <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:260pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:33pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">Title:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:293pt;">
          <font style="letter-spacing:0.2pt;">President and Chief Executive Officer </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated. </font>
        </div>

          <table style="width:456pt;height:333.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;min-height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:180.43pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Signature </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:180.43pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Title </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:71.15pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Date </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;min-height:52.25pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:19.917pt 0pt 0.5pt 0pt; width:180.43pt;">
                <div>
                  <font style="letter-spacing:0.2pt;">/s/ Thomas R. Cannell, D.V.M.</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 180.43pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Thomas R. Cannell, D.V.M. </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:19.917pt 0pt 0.5pt 0pt; width:180.43pt;">
                <font style="letter-spacing:0.2pt;">Director, President and Chief Executive Officer (Principal Executive Officer) </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:19.917pt 0pt 0.5pt 0pt; width:71.15pt;white-space:nowrap;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;18, 2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;min-height:39pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;">
                <div>
                  <font style="letter-spacing:0.2pt;">*</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 180.43pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Monica Forbes </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;">
                <font style="letter-spacing:0.2pt;">Chief Financial Officer (Principal Financial Officer) </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:71.15pt;white-space:nowrap;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;18, 2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;min-height:39pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;">
                <div>
                  <font style="letter-spacing:0.2pt;">*</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 180.43pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Elly Ryu </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;">
                <font style="letter-spacing:0.2pt;">Corporate Controller (Principal Accounting Officer) </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:71.15pt;white-space:nowrap;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;18, 2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;min-height:39pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;white-space:normal;">
                <div>
                  <font style="letter-spacing:0.2pt;">*</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 180.43pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Jay S. Duker, M.D. </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;">
                <font style="letter-spacing:0.2pt;">Chair of the Board of Directors </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:71.15pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;18, 2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;min-height:39pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;white-space:normal;">
                <div>
                  <font style="letter-spacing:0.2pt;">*</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 180.43pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Carrie L. Bourdow </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:71.15pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;18, 2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;min-height:39pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;white-space:normal;">
                <div>
                  <font style="letter-spacing:0.2pt;">*</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 180.43pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Peter K. Honig, M.D. </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:71.15pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;18, 2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;min-height:44pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:12.167pt 0pt 0.5pt 0pt; width:180.43pt;white-space:normal;">
                <div>
                  <font style="letter-spacing:0.2pt;">*</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 180.43pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Michael A.S. Jewett, M.D. </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:12.167pt 0pt 0.5pt 0pt; width:180.43pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:12.167pt 0pt 0.5pt 0pt; width:71.15pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;18, 2023 </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;min-height:38pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;white-space:normal;">
                <div>
                  <font style="letter-spacing:0.2pt;">*</font>
                </div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 180.43pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt;">
                  <font style="letter-spacing:0.2pt;">Jason A. Keyes </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:180.43pt;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:7.167pt 0pt 0.5pt 0pt; width:71.15pt;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">January&#160;18, 2023</font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Thomas R. Cannell, by signing his name hereto, signs this registration statement on behalf of the officers and directors of the registrant above in front of whose name an asterisk appears pursuant to powers of attorney duly executed by such officers and directors and filed with the SEC.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By: /s/ Thomas R. Cannell, D.V.M.</font>
        </div>
        <div style="margin-top:1.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 192pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Attorney-in-fact</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>tm2227887d14_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We consent to the use of our report dated October
14, 2022, with respect to the consolidated financial statements of CARISMA Therapeutics Inc., included herein and to the reference to
our firm under the heading &#8220;Experts&#8221; in the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ KPMG LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philadelphia, Pennsylvania</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 18, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>3
<FILENAME>tm2227887d14_ex23-3.htm
<DESCRIPTION>EXHIBIT 23.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>EXHIBIT 23.3</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Consent of Independent Registered Public Accounting Firm</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">We consent to the reference to our firm under the caption &ldquo;Experts&rdquo; and to the use of our report
dated&nbsp;February 28, 2022, included in the Proxy Statement of Sesen Bio, Inc. that is made part of Amendment No. 4  to the
Registration Statement (Form S-4) and Prospectus of Sesen Bio, Inc. for the registration of shares of its common
stock.&NegativeThickSpace;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">/s/ Ernst &amp; Young LLP&NegativeThickSpace;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">Boston, Massachusetts</P>

<P STYLE="margin: 0pt">January 18, 2023</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tm2227887d14_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head></head><body link=blue lang="EN-US"><div><div align="center"><div align="right"><div style="position:relative; top:17px; right:64px; font-family:'Times New Roman'; font-size:10pt; font-weight:bold;">Exhibit 99.1</div><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img width="839" height="1085"src="tm2227887d14_ex99-1img001.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">YOUR VOTE IS IMPORTANT! PLEASE VOTE BY:Sesen Bio, Inc.Special Meeting of StockholdersFor Stockholders of record as of January 17, 2023THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTEDIDENTICAL TO THE BOARD OF DIRECTORS RECOMMENDATION. This proxy, when properly executed, will be voted in the manner directed herein.In their discretion, the Named Proxies are authorized to vote upon such other matters that may properly come before the meeting or any adjournment orpostponement thereof.You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote inaccordance with the Board of Directors' recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and returnthis card.PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDEP.O. BOX 8016, CARY, NC 27512-9903
INTERNETGo To: www.proxypush.com/SESN&#xB7; Cast your vote online&#xB7; Have your Proxy Card ready&#xB7; Follow the simple instructions to record your votePHONE   Call 1-866-221-8259&#xB7; Use any touch-tone telephone&#xB7; Have your Proxy Card ready&#xB7; Follow the simple recorded instructionsMAIL&#xB7; Mark, sign and date your Proxy Card&#xB7; Fold and return your Proxy Card in the postage-paidenvelope providedTo participate in the virtual Special Meeting ofStockholders, go to www.proxydocs.com/SESN
TIME:Thursday, March 2, 2023 10:00 AM, Eastern TimePLACE:Special Meeting to be held via live webcast - please visitwww.proxydocs.com/SESN for more details.This proxy is being solicited on behalf of the Board of DirectorsThe undersigned hereby appoints Thomas R. Cannell, D.V.M. (President and CEO) and Mark R. Sullivan (General Counsel, Chief Compliance Officerand Corporate Secretary), (collectively the "Named Proxies"), and each or either of them, as the true and lawful attorneys of the undersigned, with fullpower of substitution and revocation, and authorizes them, and each of them, to vote all the shares of common stock of Sesen Bio, Inc. which theundersigned is entitled to vote at the special meeting and any adjournment or postponement thereof upon the matters specified and upon such othermatters as may be properly brought before the special meeting or any adjournment or postponement thereof, conferring authority upon such true andlawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given.
</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img width="839" height="1085"src="tm2227887d14_ex99-1img002.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">Sesen Bio, Inc.Special Meeting of StockholdersTHE BOARD OF DIRECTORS RECOMMENDS A VOTE:FOR ON PROPOSALS 1, 2, 3, 4 AND 5
PROPOSALYOUR VOTEBOARD OFDIRECTORSRECOMMENDSFORAGAINSTABSTAIN#P1##P1#FOR#P2##P2#FOR3.To consider and vote upon a proposal to approve an amendment and restatement of the SesenBio, Inc. 2014 Stock Incentive Plan, as amended, or the 2014 Incentive Plan, to, among otherthings, (a) increase the number of shares of Sesen Bio common stock reserved for issuanceunder the 2014 Incentive Plan, and (b) extend the term of the 2014 Incentive Plan to the tenth(10th) anniversary of the closing of the merger;#P3##P3##P3#FOR4.To consider and vote upon a proposal to approve an amendment to the Sesen Bio, Inc. 2014Employee Stock Purchase Plan, as amended, or the 2014 ESPP, to increase the number ofshares of Sesen Bio common stock reserved for issuance under the 2014 ESPP to 6,568,655#P4##P4##P4#FOR5.To consider and vote upon a proposal to approve an adjournment of the Sesen Bio specialmeeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor ofProposal Nos. 1 and 2#P5##P5##P5#FOR
To participate in the virtual Special Meeting of Stockholders, go to www.proxydocs.com/SESNAuthorized Signatures - Must be completed for your instructions to be executed.Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc.,should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/VoteForm.Signature (and Title if applicable)
Proposal_Page - VIFLDateDate
Signature (if held jointly)
X
Please make your marks like this:
1.#P1#2.#P2#
To consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule 5635(a) and (b), the issuance of shares of Sesen Bio common stock, $0.001 par value per share, or Sesen Bio common stock, to stockholders of Carisma pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated as of September 20, 2022, as amended by the First Amendment thereto, dated December 29, 2022, by and among Sesen Bio, Merger Sub and Carisma, copies of which are attached as Annex A-1 and Annex A-2, respectively, to the accompanying proxy statement/prospectus, and the change of control of Sesen Bio resulting from the merger;To consider and vote upon a proposal to approve an amendment to the restated certificate of incorporation of Sesen Bio, as amended, to (a) effect a reverse stock split of the issued and outstanding shares of Sesen Bio common stock, at a ratio of 1-for-20, with such implementation and timing of the reverse stock split to be determined in the discretion of the Sesen Bio board of directors and as agreed to by Carisma at or prior to the closing of the merger, or in the sole discretion of the Sesen Bio board of directors if Proposal No. 1 is not approved, and (b) if and when the reverse stock split is effected, reduce the number of  authorized shares of Sesen Bio common stock to 100,000,000, in the form attached as Annex G to the accompanying proxy statement/prospectus;
shares of Sesen Bio common stock; and
</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:avoid;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>tm2227887d14_ex99-4.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF SVB SECURITIES LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the use of our opinion letter dated December
29, 2022 to the Board of Directors of Sesen Bio, Inc., included as Annex B to the proxy statement/prospectus which forms a part of
Amendment No. 4 to the Registration Statement on Form S-4 of Sesen Bio, Inc. to be filed on the date hereof, and to the references
to such opinion in such proxy statement/prospectus under the captions: &#8220;Prospectus Summary &#8211; Opinion of Sesen
Bio&#8217;s Financial Advisor,&#8221; &#8220;The Merger &#8211; Background of the Merger,&#8221; &#8220;The Merger &#8211; Sesen Bio
Reasons for the Merger&#8221; and &#8220;The Merger &#8211; Opinion of Sesen Bio&#8217;s Financial Advisor&#8221;. In giving such
consent, we do not admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act
of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder, nor do we thereby admit that
we are experts with respect to any part of such Registration Statement within the meaning of the term &#8220;expert&#8221; as used
in the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder.
Additionally, such consent does not cover any future amendments to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ SVB SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 18, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>lg_sesenbio-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_sesenbio-4c.jpg
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M%!04%!04%!3_P  1" %M F@# 1$  A$! Q$!_\0 R0 !  (# 0$! 0
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M("#6-P+L;/B=PGC=TSSL%-"1SZIO5)'G#>H_ LGC4\^R(9/&IYMD*W+I'0B
M@REGNS[?)W<I+J1Y]9O/I/E'\:QMVGSQF.[9</F3IG$_3/W-R8]LC0]A#F.&
MK7#B""M3,8=7$Q,9A^J$B @\U3<*2DX32#K^8WB[XO\ 6KUI-NREME:]V)GR
M)YU%-$&CL=(=3\0_UKWC1XL>W(\(;5B.XF96^V3VFW7BHHZ-LIG$5.1%ZT@
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M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @@;** VW(*^ETT9WIDC'9T2^NW3T Z+I=%_-KB7S7GZOTM]J^_\
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M_%B[;9G"7EJGB(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @("#X5E)3U]++1U3!)3SM+)&GR'^,=BM6TUG,//9
MKKLK-;=I07D-CJ<?N4E%/JZ/VZ>;3@^,\CZ>PKI-.V-E<P^<<SBVX^R:SV]D
M^,,4O9A" @((]W@MIJ\:CKV#5]!.USCY(Y?4=_M%BV'!OB^/%G\*^+X\4$K>
MMV("#Q7 \(QZ?XE,,C3[7A4LD0?:C;U540'S@?BXJM^TO37&;0V%8;9B @S&
M/1]53++V,9T_"X_]BQ]\]&3QXZS+8UALT0$&SX#B%3FV34EEBZFTI/>U\[?]
MW3,(ZSV\3[+?I$+&Y&Z-5)M]BMK8C*ZM-304=-#1TL8BIJ=C8H8F\&MC8 UK
M1Y@!HN0F9F<RP7U4 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @("##Y'C]+D5O=2S:,G9JZFGTU+'_ZCVA>^
MG=.NV88'-X=>3K\L]_9/@A*Y6VLM-9)0UT9CGC/P.'8YI[05T5+Q>,P^>;]%
M]-YI>,3#R*[Q$!!XKQ;8KQ:JRUS<&5<+XNH_)+AP=\!XJ^N_EM$^"]+>6T3X
M*L5%/+2U$M+4-+)X'NBE8>;7L/21\!"ZF)S&8=-$YC,/FI2(/'<!ZK'>0D?'
M_P"13#(TSUEX%+)$&0M,)=(Z8CU6CI'I/_8O';/3#*X]>N676.S1 0;/88.[
MHS*1QE<2/P6\!_&L+=.;,_1&*Y91>#W$']Q12SRL@A8Z2:1P9'&P%SG.<=
M!S)*B9P+?[38 S!L?'O30;]<0V6XO''HT!+(0?(S7CY7:]FBY7F<C]6_3M'9
MAWMYI;^L%YB @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @PN1XW0Y'2=S4?5U,>IIZEH]9A/8?*T]H61I
MWVU3F.S7\WA4Y-<3TF.TH9O%EK['5NI*^/I=Q,<@XLD:/E-/:%O]>VNR,PX#
MD\;9HOY;Q_\ +'KU8P@((,W<QQUNO#;Y3LTH[EPE('!M0P<?YP'5Z=5O.%M\
MU?+/>&ZX6WS5\L]X1TMBV @^51'WL3FCVN8](1>EL2Q*LSG],8Z1X8P:N<=
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M6'VNWA[6DYG-Q\E._MEX;-GLA8E:%C" @(" @(" @(" @(" @(" @(" @("
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M2.UQ'%Q\YXK6WV6O.;3EY3,RR"H@0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M07U<T'J\]*FEFA//L]?BL7EQG58AU9EEB@B?-,]L<,;2^21Y#6M:T:DDG@
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MP1P(XC@MY6T6C,=E7EI:6JKJF&BHH)*FLJ'MBIZ>%CI)9)'GI:UC6@ESB3H
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MTG>U-BK@9*8O/!SXR"'Q/([6'0_*#M%B[N-3;W[^)E<[;[QK[596V&DRGO\
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M-7$! 0$! 0:1O-^Y_<'_  U>?[!,O;1^Y7XQ^(X^KK%! 0=N5QJX@(" @("
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M)+7W&IBI*&G:7SU-0]L44;!S<Y[R !YR5,1,](%8=W_&IA6)PU%HVYZ,HR,
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M[J<EP'%<CK>-9=[/;[A4'E];54L<KN'I<N4VU\MYCPE=LB\P0$! 0$! 0$!
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M@6KIZ=.?FGHG*F]BLV0;@Y;26:WM?<,CO]9T-<[5SGSU#RY\CR = -7/>[L
M)*V]K12N9[0AV)QNR4^-8[:,<HSU4EGHJ:WP.TZ=8Z2)L33IQTX-7)6MYIF?
M%=DU4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$'+S*(O##_>6\^_U6>"N]^JO>1!36<Q=[WSNOH+IP>G7737
MCHNEI^OY8^G[U'YGE/X5)Z:U,Q*X930W$6ZD]]GIZ&DKJ<S]PSJ[^*HJZ4BH
MU_INYD,75KT)KG?U\V.__GL'GVWIO"]3W^A&<73*+E2F5O49[=26ZW#UO_I
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@%OEJ4B @(" @(" @(" @(" @(" @(" @(" @(" @_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>lg_carismatherapeutics-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_carismatherapeutics-4c.jpg
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M -(  0 " @,! 0             '" $& @0% PD! 0 " P$! 0
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MV UIFMW'@\X- '$TT!(WU4ZRJM&B:U- 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'%^ZJ"
MBW.7$W>)YDYYETPM%Y<NO+=Q^FAG/$TCQ&H54KZ\FB+#*>.Z]C+F;4^7R[6D
M6=M9BW<_H,LTC7!OCHPE2KS0O*URL5" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M2FNK7M,/=<-XW^=Q]QPLN6D#;YM3Q#PM)"G$ZH3&C<@0=RRBR@(" @("#B9
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MXEI\VTFG&O&'9['O%,OLY/9G]B8(Y&. <TAS2 01MJ"%X'0N9>!O0>+J/5N
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MS,N86NQ<7$/P\TK>*-HH=HZ74Z%;JJB%*<WFLSJ_.397(O?=Y6^D%&,!=M-
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MHW%I^@JUZ5.[CG#BN80L'N(@RUK);</096%LC#3K\TCRK,(VY+CMW!6*64!
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M_5%Q<S^*0JI>B);+R.ROZ+YF89Y-&73I+1_A[9A 'W5%F&+<EX!2@IN5BAE
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MC5=RV9$R"-L%! &@1A@HT-Z*4Z%S3ZE$1IP?0-HZM?(L,N2 @(" @(" @("
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MOVC>$B28UA>?#YK'9W&P9;$SLN[&Y:'Q2QN!!KT'J(Z0=RL4/2600$! 0$!
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MLHX &ROG-CXGGHC?7A?MW;CX%.)5364E![" 0X$':*%21<J@[D! 0$! 0$!
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M1''A"T')W2\^G--":^C,.1R+S/-"\4<Q@V,:>D&FWRKZ7V79S@P:VC2UN/\
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MN=[CGEM?<6>ECK;=CN[+H2WX3?W-_?.Z?PC(6'R-;7^,LZ,=<MFM>0_*JV:
M-/MD<-[I;FZ>3XP9:>\LZ0CU2@KO%Z6T]I7,8&UT]CXL?;S6T[Y60@^<X2,
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MA^6<TU;!P]E#Q#I< 22/!55Y-Y:T:1PA?MNQX<<ZV]J?V)<@ABMXV0P,$<+
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M#P=E"#Q22$@RR.^J>Z@J5ILF2UYUL[3!MZ8:]-(X/>4'H$! 0$! 0$! 0$!
M0$! 0$! 0$!!@CH015K[DSB]32393#/&.S+R72"GY/,[K<W>''K'N+VX-W;'
MPGC#1[_M-,_M5]FW[/I0#J'1.IM+2.;F+!\<3:#VE@[2 UW?A&U'NK:X\U+\
MI<?N=AFP^]7ZN+P-X5\/!XZ&XISY''4I4@ 5)W +.OI*UF>3>=+\I]7:G='(
MVU-A8.(XKFZ!C\T]+6'SG+QY-U2GCK+<;7M&;-QTZ8]*QFAM"X[0V/DL["6:
M>2X<)+F:9PHYX;2K6  -'O\ A6FRYIRSK+MMGLZ;:G375MPW!5/:(" @(" @
M("".>>.!DSW+;,Q0MXI[-K;^(#?^3.XG>7@XE&W)*O-1_P *K7+"=U[4P@RF
M3TG.^C;I@O;0'IDBHV1H\;2'>13A"RT55-4(" @(" @(" @(" @C;GGGWX#E
MMEY('%ES>".QB<-A'M#PUW\6JQ*4*1#=15KED.ZYI>)QRNKKEG%*QS;&Q)^E
M%"Z4CPFK0I55WE9935B @(" @(""K/>K^<&G?BEQZQBKLMIR0-8_U^T_'Q?#
M"PG+]'U:\X@("#B[=_EU(/SLU!^O\K\<N/6N53T):[L7S]N_D^7UD:S'-&_)
M;H;E8I90$! 0$! 0$! 00!WJ_FUI_P"47_V=RA993FJP=RKGDL7_ .7/S#TY
M\GV_JPKH42V=98$! 0$! 0$! 0$! 0$'"5@D86$<33L<TTH0?&@I5SUT3;Z,
MUHXX]@BQ>6C]LMXQZ,;R>&1@IT!VT> JN874E'-A>SXV^M<C:NX+FSECN(7=
M3XG!X/NA83?H9I_(MR^%L<HST+R".<?]HP._A5D//+TEE@0$'YXZL^=6<^4+
MOUSU4]'@DSNR_O(F^2KKUL"S"-^2X2L4B @(" @(" @H_P ]A_\ M3/_ &5O
M_9XU5/-?7D\[E'^\K3/QZ/Z*Q'-BW)?%7*1 0$! 0$! 05*[T/SUQWQ!OK'*
MN5U.2',-^N,?\9A]8U13?HNWT1X@KGF90$&B<XLZ_3W+O-7L)X9Y8O98G=3K
MD]G7W"5B4J\U%%4O6([KNF(+F\RVK+F(/=:\-C9./TKWCCE(\/#PCRE3K"J\
MK/*:L0$! 0$! 05>[U8_\WT[\7N?AL4++*(%Q?ZRLOQ\7PPH2M7V5BALA:"*
M="DB\W)8##YA@BRMC!>,I0=O&UY \!(J/(I5O->4Z*LF*E_>B)5NYV8'3FG<
MW86. LF6;GP.ENFQN>0XN< WS7$@4H=RW.TR6O$S:=7%=YP8L5ZQ2--8:SRZ
MP-OJ/6&-Q5VSM+-[W27$9J.*.-I<1LIOHKMQ?IQS,/!V[!&;/6MHX>*U^)TA
MIG!T=B<7;6LM-DL<8[3[HU/OK0VR6MSE]!Q[;%C]VL0]CLQUJ#T.5$&4! 0-
MO0@(" @(" @(" @(" @(" L3(!9! 08X0@^;H&/:6O'&QPHYK@"#7K2.#$QK
MP1-SET3@VZ/O,OC<=!;9"RDBF,T$;8W%A>&O!X:5%'57NVN6WQ(B9:#N^TI\
MO-JUB)CCPA6JM-O5M]Q;OPEPFNBY&D-.Z6CQ&-RV,Q-K;RW5M%.)61,XP9(P
MX^=2O2N<R7MK,3+Z=M\.+HK:M8C6(;2& $'J5+VLT090$! 0$! 0$!!\;J&*
MYMI;>9H?#,QT<C3M!:X4(]Q!0+7>FI-(ZMRF!<TB*VG<;9Q%.*!_G,(\A5,K
MXY.OI'45SI/4N-U#:5,EC,V1[!LXXCLD8?LFDA9-%^\)E[3.XNSR]@\26=["
MRXA<#7S9 #3QBM"K(4R]!98$! 0$! 0$! 0$!!!G>A>]NA\<UI\Q^3C#_$(9
M2/?4;)U5-5>BU<?NX,C'+>!S*<;KJX,GCXJ"OD5E55^:7E) 0$! 0$! 059[
MU9_]P:=^*7'K&*%EM.2!K'^OVGX^+X844YY/T?5KSB @(.+MW^74@_.S4'Z_
MROQRX]:Y5/0EKNQ?/R\^3Y?61K->:%^2W85BH0$! 0$! 0$! 00!WJ_FUI_Y
M1?\ V=RA993FJP=RKE8O_P N?F'IWY/M_5A70HELZRP(" @(" @(" @(" @(
M""N7>NCB]DTO,0.V$MXT'I+>&(T]U1LLHK,=R@M7YY7]I_A]ISM:\?L,-:[Z
M<.SWE9#SSS;:LL" =R#\\=6?.K.?*%WZYZJ>CP29W9?WD3?)5UZV!9A"_)<)
M6*A 0$! 0$! 04?Y[_O4S_V4']GC54\U]>3SN4?[RM,_'HOHI'-BW)?%6J1
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M@5D*)>DLL" @_/'5GSJSGRA=^N>JGH\$F=V7]Y$WR5=>M@680OR7"5BH0$!
M0$! 0$%'^>W[U,_]E!_9XU5/-?7D\[E'^\K3/QZ+Z*1S8MR7Q5JD0$! 0$!
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M3ZE(-^T[STKIWR?77B(R()L[N;IOTMFH]OLQMXG.'1Q\9 ]ZJUF_CA'FZO\
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M<_CI/AE=/3W7RG)[\^N?M62[OOS/N?CC_@M6EWOXCN>Q_E_IE+:\3?" @("
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MVVH<G-=LXBYEN7%L#"?J(V^:/<6-5D0[NAN7.I-?7XM<-;\%HW^L9"8.;;Q
M;=K@#4]30FFK$VT;CSNT#AN7UGI;%8IA?++'=OO;R2G:SR Q"KB -@J>$="S
M:-$:SJBFQ_K]I^/B^&U82E^CRM4" @(.+MQ\2#\[=0?K_*_'+CUKE4]"6>[%
M\_+SY.E]9&LU0NMT-RL5,H" @(" @(" @(( [U?S:P'RB_\ L[E"RRG-5@[B
MJUD+_P#+GYAZ<^3[?U85T*)YMG66! 0$!!XFJM+X?5V&GPF:M^VLY^D;'QO
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M$=3Z]U;K&8R9[)S7$1<7,M XLMF'ZV)M&BG72JQJGH^NBN7^H]>9!MEA;>D
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M#MV(/A-96ER VY@9,T;A(T/ \5:H.4=O!"T,BC;'&-S& -:/($'U0$! 0$!
M0$!!\I+6WF9V<T396?4R .'N%8T'&&SM+=O#;PLA:=[8VA@]P461]T! 0$!
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MT4'I<T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MF*#V20\+;J"9A:Z-[A6G$/-/D*T^7'..=)=GM-W3<5ZJ_2VH;@JWL$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M'-K2T4JL#DL@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M)9! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MYW:;R\$,.;E_1F5+0)0\'V=SZ;2U^V@)Z'+5Y=I>D\.,.PVO=\.6(BT]-O\
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M0$! 0$! 0$! 0$! 0$! 6)%5>>_[P[KXI;?!<M[LOP_I<'WS\Q_M_BL-R_\
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M(" @(" @(" L2*J<]Z_XAW7Q2V^"Y;S9?A_2X/OOYC_;'[UA^7_S)P'Q*#X
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M']MO'A"]6VS?#OQY-1W/9?,XM(]Z.,($Y<ZYN]!YMSIFN=B[DB+(6U/.'"2
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M,VF\#-,Z>7%VLD\CN)\KH6%Q<36M2*U4^NVG-3.&DSKI&KUF@ 4 I107,H"
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; @(" @(" @(" @(" @(" @(" @(" @("#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>lg_mackenziepartners-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_mackenziepartners-bw.jpg
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M%!04%!04%!3_P  1" "R E<# 1$  A$! Q$!_\0 H  !  ,! 0$! 0$
M      <("08%! ," 0$! 0$!                  (! Q   0,# @,% P<'
M!P<)!@<  0(#!  %!A$'(1((,4%A(A-1,A1Q0E(CE!46@6)RTE16&)&",W/3
M%PFA0V,D1-09L=&24X.3-"6EHK(UY3=GH\-%574F)Q$! 0$! 0$
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M3K3SO\);//V*,X$W/+)"+8@ ^<1$?725#CV%*4M*_K*$9G46)2I2@E()43H
M.))-!KCM-C5JV;V;L=JO;[-L9M, 3+]+DK2TVW*D:OR2M:CIHE:R@$]P \*(
M4XZBNKFYYY\7AFW#KULPM84S.N?F:F7%)X*2.Q33"APY?>6/>T!*:-D<)L-T
MU97O--;N4@.6; V5Z2[TXC13_*=%-1$J&BU]Q7[B._4^4FVM*<%P'%-M\?8Q
MK#[<W;[8SQ7R^9UYW0 NO.'S+6K3BI7R#0 "B'2T"@KWUE9Y^#MFIMJBN^G=
M,J>3:&0#YA&4"Y*5I]$MI](_U@HV,QJ+3)TMX(<^WIQ^(\SZUKLRS>[D"-4A
MJ"0IL*'80IXM((/<JC*U9H@H%!7;K0SS\([.R;+%=+=TRQ]%K:Y3HH14_6R5
M?(4)#2OZRC8S+HLH)AZ;=XGMGMPXUPF.*_"EWY(&0LC4@,*5Y) 'TF5'F]I3
MS)'O498U99>:D--OL.)=8=2%M.H(4A2%#4*21P(([#1#^Z!0<ANIFK.W>W>1
MYF\I(<M4)QR(E>G*N6L>G'0=?I.J0G\M!D+:;9=<MR*%:(?-*O5[F-QF>8DJ
M<DRW0@$GQ4KB:.C9+%,<@8AC-HQ:UC2WV:&Q!C\-"41VPCF/;Q5IS'QHYO7H
M% H*+]675 F<)^U6W4L_"I4J-DM\841ZI22E<1A0^9KY75_.]T>77F*D4JHI
M/'3ETY7?>:[B[78.V_;VWN@3YX'*Y*<3H3&C$CBH_/7V('CH*,M::V.QVC&K
M1#L-AAM6^SV]I+$.&PGE;;;3W#VD]I)XD\3QHAF)U;9Y^.=Z;TB.]ZMJQT)L
M<'3W=8A)D'V$E]3@U[T@47$&T:T9Z,\5AX#LM<=P+V4QC?EOW23(4-"W:[:E
M:&^;AV I>=_14*(J@V=97-SG,;YE\_42;S->F%LG7TT.+)0V/!".5 \!1;P6
MVW'G$--(+CKA"4(2"I2E*.@  XDDT&P>SV$-[<[9XSAX0$2;?";,_EX@S7]7
MI)U[P75KT\*.;N*!0*!0*!0*!05 Z],_^[,3LFW4-W25?7_O&Y(2>/P<(Z-)
M4/8MX\P\6J*B-.E3:K[]VUW3S.8QS+GV6X8U9BH:GG<BEY]:00>(46 E0'TA
M[:%5,HHH-).A>\_>.R[UN4?/9[Q+BI3_ *-YMF2#\A4ZK^2B*LS1CSK_ 'ZT
M8O99V0W^6B#9K:RJ1,ENG1*&T#4]FI)/8E(XJ/ <3092[\[SW;>G-'KV^%QL
M=A<\?'[8H_T,;F]]8!(]5W0*<(\$@D)%%R)WZ0>F[[Z>B;L9W#_\G84'L9M;
MZ?\ Q+J#J);B3_FT$?5)(\Y\WN@<QEJMN\>5?C;=/+<G2OU(\ZYR/A%ZZZQ6
M5>BQ_P#A(11L<11J[G^'YC&KN99HZ@>5,6SQ'._S%4B0/\C%$U>&B2@^*\7B
MV8_:IE[O4IN%:;>TN1,EO'E;;:;&JE$_)095[^[T7?>_-U36DNM8U!4J+C=J
MXE26E*T]5:4D@O/$ JTUTX)!/+J2Y'K[M["R-I-K,-OU]U3F&02Y"KK&).D5
MKT6UL1].PK1YRZKZ1Y1J$ZD:@RC5D.AZ0IG?%MM(!$BTSFE$]P!;<U'Y4"C*
MTMHA#_49O3%V8P5RXQBAW+;J5Q,>AKT(]8 <\A:>]MD$*/M44IX<VH-D967*
MY3[Q<)5VNLER9<IKJY$N4\HK<==<45*4HGM))HM]^)8M>,VR6UXIC[!D7B[2
M$1HK?<"KM6H]R$)!6M7<D$T&MNT^V%AVDPN#B-B2%ED>K<9Y2$N2YBP/4>7V
M]I&B4ZGE2 GNHYNWH% H% H,U>MK//Q5NW^&XK@7;,1C)@@)/,DS9&C\A0]A
M&K;2A[6Z+BME&NVVD>Q6%N#9;SFS_HXO97OO6>A*0XX_\$/5:CMM_/4\Z$-\
MOT222$@D&.MWTZBLNWJN)CODVG#(R^:WV%E9*21V.R5C3U7/9PY4?-'O%0D>
MCTI;;X/N=N6JR9NMUR/#AKN$*V(5Z;4UQAQ 4TZL'FY0E7/RHT*@#Q &A%:A
M0H,.VPV+?;H[<2!&0EJ/&80EMIMM T2E"4@  #L HA^] H%!F[UP9Z<FW59Q
M2*[SVW$8J8ZDCBGXZ8$OOJ'\ST4'Q2:*BLE%+_\ 03@@MN'WW<&6V1*OLD6^
M I0[(<'BM23[%NK*3_5T35OJ)*!09K];F>?BG=I.-172NVXC%3#Y0=4?&R='
MY"AXZ%IM7BBBXC:W[+9)=-F9^\4-*G+=;KD84B)R^8PTH3SRDGO2AU8;5IXG
ML2:&HSHTH-#^BC>;\68JYMG?I//D.--!5J6XKSR+5J$I2->TQR0C] H]AHBQ
M:ZC"@IMU\YY\%8<=VYANZ/W1U5VN:$GB(T75MA*A]%;BEJ^5NBHB'HCP/\4;
MLKR:4SZELQ&*J9S'BGXZ5JS'21[=/5<3XHHVM)Z(*!04MZL.J%5M,O:_;:<!
M/(4QDE]C*XL?-5$CK'^<[G5I/E]T>;7E*D44HI.G3AT\7/>B^&X73U8. VQP
M?><](*5R7!H?A8ZB-.<CWU?,3XE()EK3FQV.T8U:(=AL,-JWV>WM)8APV$\K
M;;:>X>TGM)/$GB>-$.?W5S5G;O;K(\R=4$N6J$XY$"M"%3'/JHR#K])U:$_E
MH,=GWWI3[LF0LNR'EJ<=<4=5*6LZJ)/M)-'1Z.+X_.RS)+3C%L3S7"\3&($;
M@2 N0X&PHZ=PUU/A0:'=5^10MJ]@(N!V)7H+NS<;'8"$^^FWQ6TE\_(6VPTK
M^LHB,W*+3-TL8)^/=Z<?BOM^I;+*LWRX<.8>G *5-A0[-%/%I!U[C1E:KT04
M"@4"@4"@4"@R;ZD<].X^\>0W:*X7K7#>%HM&FJ@8T$EH*1WZ..<[H_3HN-)-
MF< 9V]VJQW"WVDB2Q""KJG0#FF2]7I )';HM:D _1 HFLC;M!5:[I.MBSJN%
M(=C*/#M964'LX=U%ODH+O_X?%ZX9UCJS_P#M\]@?]^T[_P#ET35WB0 23H!V
MFB6<'5KU#_WCWA6!XA*YL%M#VLJ4TK5-RFMG3G!':RV>#?<H^?CY="I'G=+/
M3J_NO>DY5E#"F]O;2\ XD^4W&4CS?#H/_5IX>LKV>4<22DVU??=?(H^ ;4Y1
M?HB414VFU/IMS;8"&T/J;]&,A(&@ ]12$@"B&/='0H-1.CO&/PWL39'EHY)-
M]?E7=\:::^LYZ+1\=666S1%3S1A09Y]874&,SNKNV.'RN?$[4]_YS-95Y)TY
MH_T:2#YF62/D4OCV)225(]_HQZ?Q<9#&\&81=8,99.*0GD\''T'0S%)/:E!!
M#7YWF^:DD6NR_P 0".%8%BDOFT+5W6URZ=OJQ5JUU\.2A&?M%)WZ.9"6>H/&
M&RDDR&KDTDCN(M\AS4_]"C*U%4I*4E2B D#4D\  *(9-=16ZCV[.YUSO3+Q7
MCMO4;=C[>OD$-A1'J >UY7,Z3VZ$#L2*+B**-7JZ$-K&V(%SW:NK ,B4I=KQ
M\K3[K+9'Q+Z=?I*T:"AV<JQWT35TZ)*!0*!0>-EN1PL/Q>\Y5<3I!LT-^<\-
M="I,=LKY1XJTY1XF@QJOEXG9#>KC?[FOU;C=)3TV6Y])Z2X7%GC[2HT='P4'
M]+:=;2VMQ"DI=3SM*4" I(44ZIU[1JDCY10?S0=EM/FSNW.X^-YDA2@Q:YK:
MYJ4:\RX;GU4A T[U-*6!1C8AEYJ0TV^PL.,NI"VW$G5*DJ&H(([011#^Z!0>
M3E&00<3QN[9/<U<MOL\-^?)X@$HCMEPI&O>=-!XT&-.0WR?DU^N>171?J7*[
M2GITM?M=D.%Q6GAJKA1T>=06ZV_ZW(.WV%6+"[=MWZL:RQ&XOQ'WQZ9>=2-7
M7B@0%<I<65+(U/$]M$XZ3_B&_P#VX_\ 6_\ Y?0Q\#G7YEMQD-PK#@D,39*_
M1C-.3'I2EN.$);2$MM-%1U.F@[?"ABXT[)9>)[?2,MS<,-S[3;%W&],PN9+
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M"D:C7MY60Z#I],496A=$JG=4G5(U@[4K;S;R4ES,W$EJ[79HA2;:E0T+;9'
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MZI"/RT&/D6-=<FOC$-@+FWN\2T--@G5;TJ6X$C4GO4M5'1L=@^*PL'P^QXC
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M[$('%1\-2#&JFV^V^+;5XM%Q3%(OHPV?/(D+T,B5(( 6\\L <RU:?(!HE(
M%$.NH% H*-=?F>>I)QK;:([Y&0J^71L'7ZQ?,Q%!]A"?641^<#144GHI;WH*
MP/[SS"^;@RV@8MBC"WV]2A_MD[7G4@^U#*5)/@Y1-1QU=Y[^.-Z+O'C.^I:L
M:2FQP]/=YXQ)DG3V^NIQ.O>$BC8@FC6CW0Y@7X;VMDY=*:";CELI3S:B-%?
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M_9(7E:0H:]BW5<P\6J-B@E%)KZ6;M@&,[J1\MW#N[-IMMDBO/V\O(==]6<Z
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M)[J-BF['2[OY(;]1O")@3KIHX[&:5P_-6\D_Y**U\T[IKWVMX)?P6Y+T /\
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MPK[_ /[DR?M$/^WH:?PK[_\ [DR?M$/^WH:?PK[_ /[DR?M$/^WH:?PK[_\
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M V_=+?$G.MI]U*Y+"'2!X JHYO8H% H% H% H% H% H% H% H% H% H% H%
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MW458ZCJIZF,NVMS"UXA@3T1$I$/XR\N261((5(7HRV 2.4A*"L^T+%"1 O\
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M65?I)GW!"3_L4'W$J'L6\I*AXMT5'E]!>$LVS'\GW/N82R):_NJ#(<\H1$B
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MXDVBZQVY<-X<"6W4Z@*'<H=BD]H.HHAZE H,P^LC._QCO-/MD=SGM>*M(L[
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M3JDR/Z62K](.*](_H47%C^A/!_N+;6XYG);Y9F4S"F.H]\&W<S*".\:NJ?\
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M';9%F)B>J_(Y77%.H6>>0XXLZ\FOO45$(4:VSMLE4VW1)BN7FD,MO'D]W5Q
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EC8LM1A0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2227887d8-tbl_pipelin4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d8-tbl_pipelin4c.jpg
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M%!04%!04%!3_P  1" ,B!VP# 1$  A$! Q$!_\0 Y0 !   ' 0$
M      (#! 4&!P@!"0$!  (# 0$               $# @0%!@<0  $# @,#
M P@1#0H,!0,"!P ! @,$!1$&!R$Q$D$3"%'1(M,4%18783*2LG2DM.0U596E
M5F9V-QAQ@9&Q<M(C,Y.SE-170E)S-,5&1X<X2*%BPD,D1(3$176%-L&"XU2U
M4X,E\&.C)N(GX?&B$0$  0("! @*"@(# 0 # 0$  0(#$00QH1(3(4%1D>%2
M8A5A<8'!T3)R,Q0%\+$B@I*B0U,T%D)4TB,&8_$D1,+B_]H # ,!  (1 Q$
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M,6IX?*_7-ZG0Y]S2C,E0    *JU>RU+]5?.J5UMBTS4H7
M        "S67^.77T0OGG&4B\F(
M                                        %FG_ .Y:7T.O^69<0O)B
M                       "[YF]EW>AZ3U+$5V]"V[ZWTY%H+%0
M             !-C_%3?<IYY E*"
M                                          NUP]@[/_M/YQ#"GUI7
M5>K'E6DS4@                                       O\ _,G_ *I_
MNY5_GY%O^'E:>A\K]<WJ=#1N:49DJ    !56KV6I?JKYU2NML6F:E"X
M                  6:R_QRZ^B%\\XRD7DQ
M                                                  LT_P#W+2^A
MU_RS+B%Y,0                       7?,WLN[T/2>I8BNWH6W?6^G(M!8
MJ                      )L?XJ;[E//($I00
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MR+?\/*T]#Y7ZYO4Z&C<THS)4    "JM7LM2_57SJE=;8M,U*%P
M             LUE_CEU]$+YYQE(O)B
M                                            !9I_^Y:7T.O^69<0
MO)B                       "[YF]EW>AZ3U+$5V]"V[ZWTY%H+%0
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M.S_[3^<0PI]:5U7JQY5I,U(
M  +_ /S)_P"J?[N5?Y^1;_AY6GH?*_7-ZG0T;FE&9*@    55J]EJ7ZJ^=4K
MK;%IFI0N                       %FLO\<NOHA?/.,I%Y,0
M
M   +-/\ ]RTOH=?\LRXA>3$                       %WS-[+N]#TGJ6(
MKMZ%MWUOIR+06*@                     ";'^*F^Y3SR!*4$
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MG)F;$8QAH4MZ_L?Q>A*+_P"5B,J/Y?/]3&Y_$\D?7#DD[;@@
M               +M</8.S_[3^<0PI]:5U7JQY5I,U(
M                      +_ /S)_P"J?[N5?Y^1;_AY6GH?*_7-ZG0T;FE&
M9*@    55J]EJ7ZJ^=4KK;%IFI0N                       %FLO\<NOH
MA?/.,I%Y,0
M                       +-/\ ]RTOH=?\LRXA>3$
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M/8.S_P"T_G$,*?6E=5ZL>5:3-2
M     "__ ,R?^J?[N5?Y^1;_ (>5IZ'ROUS>IT-&YI1F2H    %5:O9:E^JO
MG5*ZVQ:9J4+@                      !9K+_'+KZ(7SSC*1>3$
M
M      "S3_\ <M+Z'7_+,N(7DQ                       !=\S>R[O0])
MZEB*[>A;=];Z<BT%BH                      FQ_BION4\\@2E!
M
M        7:X>P=G_ -I_.(84^M*ZKU8\JTF:D
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M2NML6F:E"X                       6:R_P <NOHA?/.,I%Y,0
M
M      +-/_W+2^AU_P LRXA>3$                       %WS-[+N]#TG
MJ6(KMZ%MWUOIR+06*@                     ";'^*F^Y3SR!*4$
M                 "^YD_%6/_ED/YR4KHX_&NN<7B6(L4@
M        $V'_ #GW"B4I00                       +M</8.S_P"T_G$,
M*?6E=5ZL>5:3-2                                       "__ ,R?
M^J?[N5?Y^1;_ (>5IZ'ROUS>IT-&YI1F2H    %5:O9:E^JOG5*ZVQ:9J4+@
M                      !9K+_'+KZ(7SSC*1>3$
M                                                      "S3_\
M<M+Z'7_+,N(7DQ                       !=\S>R[O0])ZEB*[>A;=];Z
M<BT%BH                      FQ_BION4\\@2E!
M      ON9/Q5C_Y9#^<E*Z./QKKG%XEB+%(                     !-A_
MSGW"B4I00                       +M</8.S_ .T_G$,*?6E=5ZL>5:3-
M2                                       "_\ \R?^J?[N5?Y^1;_A
MY6GH?*_7-ZG0T;FE&9*@    55J]EJ7ZJ^=4KK;%IFI0N
M        %FLO\<NOHA?/.,I%Y,0
M                                        +-/_ -RTOH=?\LRXA>3$
M                       %WS-[+N]#TGJ6(KMZ%MWUOIR+06*@
M             ";'^*F^Y3SR!*4$                       "^YD_%6/_
M )9#^<E*Z./QKKG%XEB+%(                     !-A_SGW"B4I00
M                   +M</8.S_[3^<0PI]:5U7JQY5I,U(
M                          +_ /S)_P"J?[N5?Y^1;_AY6GH?*_7-ZG0T
M;FE&9*@    55J]EJ7ZJ^=4KK;%IFI0N                       %FLO\
M<NOHA?/.,I%Y,0
M                           +-/\ ]RTOH=?\LRXA>3$
M          %WS-[+N]#TGJ6(KMZ%MWUOIR+06*@
M";'^*F^Y3SR!*4$                       "^YD_%6/\ Y9#^<E*Z./QK
MKG%XEB+%(                     !-A_SGW"B4I00
M      +M</8.S_[3^<0PI]:5U7JQY5I,U(
M             +__ #)_ZI_NY5_GY%O^'E:>A\K]<WJ=#1N:49DJ    !56K
MV6I?JKYU2NML6F:E"X                       6:R_P <NOHA?/.,I%Y,
M0
M              +-/_W+2^AU_P LRXA>3$                       %WS
M-[+N]#TGJ6(KMZ%MWUOIR+06*@                     ";'^*F^Y3SR!*
M4$                       "^YD_%6/_ED/YR4KHX_&NN<7B6(L4@
M                $V'_ #GW"B4I00                       +M</8.S
M_P"T_G$,*?6E=5ZL>5:3-2
M "__ ,R?^J?[N5?Y^1;_ (>5IZ'ROUS>IT-&YI1F2H    %5:O9:E^JOG5*Z
MVQ:9J4+@                      !9K+_'+KZ(7SSC*1>3$
M
M  "S3_\ <M+Z'7_+,N(7DQ                       !=\S>R[O0])ZEB*
M[>A;=];Z<BT%BH                      FQ_BION4\\@2E!
M              ON9/Q5C_Y9#^<E*Z./QKKG%XEB+%(
M    !-A_SGW"B4I00                       +M</8.S_ .T_G$,*?6E=
M5ZL>5:3-2                                       "_\ \R?^J?[N
M5?Y^1;_AY6GH?*_7-ZG0T;FE&9*@    55J]EJ7ZJ^=4KK;%IFI0N
M                %FLO\<NOHA?/.,I%Y,0
M                                                +-/_ -RTOH=?
M\LRXA>3$                       %WS-[+N]#TGJ6(KMZ%MWUOIR+06*@
M                     ";'^*F^Y3SR!*4$                       "
M^YD_%6/_ )9#^<E*Z./QKKG%XEB+%(                     !-A_SGW"B
M4I00                       +M</8.S_[3^<0PI]:5U7JQY5I,U(
M                                  +_ /S)_P"J?[N5?Y^1;_AY6GH?
M*_7-ZG0T;FE&9*@    55J]EJ7ZJ^=4KK;%IFI0N
M   %FLO\<NOHA?/.,I%Y,0
M                                   +-/\ ]RTOH=?\LRXA>3$
M                  %WS-[+N]#TGJ6(KMZ%MWUOIR+06*@
M        ";'^*F^Y3SR!*4$                       "^YD_%6/\ Y9#^
M<E*Z./QKKG%XEB+%(                     !-A_SGW"B4I00
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MYQE(O)B
M                    !9I_^Y:7T.O^69<0O)B
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M0T\W<*N?S&,]8RF5,<>+8CL?JG.C+Q-[=X\'0Z-5^8L[S!PWF&\2YAO]UO\
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M(NQ78;>!N+O(+KEZFC3.E3:L5W-$<#&2YK@    LUE_CEU]$+YYQE(O)B
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M]/)15145-J*BX*FU-ATJ:HJC&-#F5T33.$Z5"9,
M           LT_\ W+2^AU_RS+B%Y,1O.W=%34.YV^DN4%SLK8*R&.HB:^>J
M1Z,E8CT1R)2JF."[=ISIS]N)PPGZ>5TX^7W)C3&OT*6]=%S5*TTSZFG907;F
MVJ]T-!4.67!,55$;41P\2[-R;5Y":<_:F>.&-60NQ'%+3B4TR57<<C%BJ$DY
ME\<B*U6OXN%4<BIBBHN\W\>#%H;,XX,[U*T>S-I9%;ILP5=#4MN;IF4Z4$DT
MBM6!&*[CYV&+#'C3##$UK&9INXX8\#9OY:JU$3.'"U\;34
M   "[YF]EW>AZ3U+$5V]"V[ZWTY&U;%T7<_Y@LEMOU%<K.RCNE+!74[)IZIL
MK8JF-LK4>C:5R(Y$=MP5?JFG7GK=-4Q,3P?3E;E&0N54Q,3'#].1,N713U0H
M*=TU-);+D]J*[F*2ID;(N&&Q.Z(86XKR=D13G[<\L)GY?<CD:6K:*KMM9/;Z
M^!]-74LCH:BGE:K)(Y(UX7-<U=J*BH=")B8QASZJ9B<)2"6(    +MEG+];F
MO,%NRY;I(HJZY3-IX)*A7-B:]^Y7*QKU1/J-4PN5Q13-4\2RW;FNJ*8XV1YR
MTKS#D?-MKR;=JFBFN=VC@EII:625\#6U4[Z=G&Y\3'(J.8JK@U=A5;S%-=$U
M1CA"ZYEZJ*XHG#&34G2O,.EM3;Z7,%315,EQCDE@6@DED:C8E:U>+G8HL%[+
M9AB+&8INXX8\!?R]5K#'#A8,;#5 -@Z:Z/9FU3BN,V7ZNAIFVQT+*A*^2:-7
M+.CU;P<U#+CAP+CC@:M_,TVL,<>%MV,M5=B9C#@8#-&Z&62%V"NC<K'*F[%J
MX;#:AJS&$X( @   -B9TT9S1D7*ELSA=ZN@FMEUD@AIXJ629\[75,#ZAO&V2
M%C41&L5%P<NTU;69IN533&.,-R[E:K=,53APL C_ !4WW*>>0VFHE!   W?:
M.BSJ#>K307BEN5F92W"GAJX62SU22)'.Q)&HY&TKD141VW!5.?5G[=,S&$\'
MTY72I^7W)C'&/IY$-UZ*VJ-NIWU%.MMN;F-5W,4=2])%PY$2HBA157DVBG/V
MYY8)^7W(CBEK'+F3[OF7-=+DVG1E'>:J=]+PUO'$R*6)'*YLG"Q[DPX53RN\
MVZ[D4T[7$TZ+555>QQJK4#(5XTXO_@[?)Z:HK>8CJ><HGR/BX)5<B)C)'&N/
M8[>Q(LWHNT[4)O69M582Q8N4         #(\CY'ONH.8(<NY?8Q:N5KY))YE
M<VGAC8F*OE<QKU:W'!J=CM540JNW:;=.U*ZS9JNU80EYURC<LB9FKLJ7>6":
MXV_FN>EI'/?"O/PLG;PK(R-RX-D3'%J;2;5R+E,51QHNVYMU33.F%@+%0  O
MN9/Q5C_Y9#^<E*Z./QKKG%XEB+%(!F.G.FM]U/NU59[!44E-54E.M7(^N?)'
M&L:/;'@BQ1RKCB].0HO7Z;48RV;%BJ[,Q#92]$?4E$54N=D54Y$J*O;]FD-3
MO"WR3]/*VN[KG+&OT-<Y\TISIIPL#\RT36T52O!!74[TFIW28*O!Q)@K78)C
M@Y$QY#:M9BB[ZK6O9:NUZVA76G1O,]XT^JM2::KH&6.D9/))3R23)5JE,Y6N
MX6I"K-JIL_"&-69IIN;'#BRIRM55O;X,&O#::8         R#)^2LR9\N[;+
MEBB=5UG"LDKE5&111IO?(]V"-3[:[$Q4JN7:;<8U+K5JJY.%+9ETZ+&J%NM[
MJZ!;=<9&-XUHJ.HD6HW8JB)-%$Q53J(_ZAJ4Y^W,X<,-R?E]R(XI:6EBE@E?
M!.QT<T3E9)&]%:YKFK@J*B[45%.A$XN=,8( @ FP_P"<^X42E*"  !NRQ=%W
M/^8+);;]17*SLH[I2P5U.R:>J;*V*IC;*U'HVE<B.1';<%7ZISZ\];IJF)B>
M#Z<KHT9"Y53$Q,</TY$RY=%/5"@IW34TELN3VHKN8I*F1LBX8;$[HAA;BO)V
M1%.?MSRPF?E]R.1JRS92O%YS739,1C:&]U-5W"L=;QQ-BG15:J2<+7.3!4V]
MBINU7(IIVN)IT6JJJ]C1*XZBZ=7O3*]T]AOU12U%944K*YCZ%\DD212221(B
MK+'$O%C$O)U-IA9O4W:<897K-5JK"6(E[7         &V<F]'74;.EIAO=-'
M26NW5+$DI)+G*^)TT:[G-9%'*Y$7>BN1,4VILP-*YG+=$X:?$W[>2N5QCP1X
MV)Y[TVS;IS71469J-(F5".6DK(7<[33HS#BX'IAM3%,6N1')U-J%UJ_3=C&E
M1>L5VI^TQ(O:X  NUP]@[/\ [3^<0PI]:5U7JQY5I,U+8FA'SN96]%/_ #$A
MJYOW53<R?OJ?IQ,RZ3==5VS6"FN5!,ZGKJ2BHIZ:>-<'LEBDD<UR+U45,37R
M,1-K">66QGZIINQ,<CIW2K/=OU(RG19EB9&R[QL[DND343BBJ6(BO:G*C'['
MM\A4Y4.1?M3:JFGB=BQ=B[1%3F_H]YQMF6M5+]:[M.VF@OSY::FF>J-9W7%4
M*Z-CG+AAQ(KT3_&P3E.KG+<U6HF.)RLI<BF]5$\<ME7?*'2&J,^STUMS0^GR
M/4U;I8K@CJ97T])(Y7\WS3F<;GL3L$V8+L7'?AJ4W+$4<-/VFY5;OS7P5?9\
MC2^K-DS/?=1K=D*+-$F>+W$B4['NIXZ9*6>9V+X7+&YZ+P-:CY'?N=R[E.AE
MZJ:;<U[.S#G9FBJJY%&UM3]3?"YER1T<K3E?)$OX>JN4R2W:J8F#VLDQ9)62
M)M54XT:UC?WC5PVMV\W8KS,U5<GTP=+;HRT4T\OTQ:AZ2>E<>7[FF?LN1-7+
MEY>CJUD&V."KD[+C14Q3FYO+)R(['JM0WLEF-J-BK3#0SV7V9VXT3I;,L^7J
M_/O1=HLMY<=%/<ZFFACC:]Z,8DE+<6RR-<Y=RHD:[S4JKBWF9JJT=#<BB;F6
MBFGDAR'>[15Y?O-PL5?P]W6RIFHZG@558LE.]8W*U51,6JJ;%PW'<IJBJ(F.
M-P:Z9IJF)XG56@=!2Z;Z0WW4JZ,1)Z]DE7$UVQ74U&CHX(]RJBR2J[[+3BYN
M9NW8HCB=S)TQ:M37/'PL3^E_FOX/6[S<_P!\7]W4\LJ.\IZK/\Z21:Z:!^$M
M)3L9?*!'5Z4T79+'4T2N;41(J[<'Q\3FMY<6FM:_Z+^S.AM7?_V+&,:5ITD_
MLQYN]"7WU&IGF/Y-/W5=C^-/BJ:WZ*OSI?\ 3:KST9MY_P!UY6I\O]YY%VJ*
MB"EZ6:2U$B1Q+=61\;EP3CEI48Q/KN<B%<1CE?)YUDSAF_IR+GTI-/LQ3WJ?
M4*-D2Y<IJ.DIIG\?X5)5E='AP8=5[=N.'U]AAD+U,1L<>++/V:IG;XHA?M<_
M[.^3_P#H_J"0KRO\BKR_6NS?N(\BX=PPZ\:"VNS9?K88\Q65E(D]+*Y=E70Q
M.@X)%PQ:DK5<]CL%3DQV*8X_#WYF8X)98?$6(B)X?.PNT]':PY6R9>,RZP5L
ME#+38OI8K94QHYK&-7!G$^-[7R2N5$:U$ZG57"^K.55UQ3;CG:].2IHHF;FI
MDW0^P[QYIX4P;W938(NU<.;?R["KYCZU/B6_+O4GQL?Z'GLSFGT+2?G)"SYC
MHI5?+=-7D\ZFK.C5F&[Y^6Y66LHY\B5]:ZM9=&3->Z.F?*KW1\"8JZ1NUC<.
MQ5=ZMVX91G:8MX3'VL"<C5-S&)^SCBN_2+S9E>]:@9,R?6U#9;7::YDF97M<
MO!''530M?&Y4W.;$Q[G=3B3R2O)VZJ;=54:9C@9YRY3-=-,Z(GA9_K!9]8:Q
M+/;M(Y(Z3+?,<%2VAEIJ.2-R+@Q4>]6*D2,5.%(?)Q3<:V6JM1C-S2V<Q3=G
M"+>A8=;;;7P='RAI:BN[]5EMEH6W2YLE6H1\\;G0S/6155783.X%5VW'?M+,
MK5&_T88XJ\U3,6,,<<,'FG5HJ<Y]%_P8L3XI;M)%74O-O=P-;/W?).C'.PV*
MK'-5/JH3>JV,SM3HX/J18IV\MLQIX?K6CHW5[<EY@S1I5F.=E)?UG9-2(QR<
M,DK(U;*QCW(F+D;P.;LVIBO(9YV-NFFY3H89*=W55;JTKM9\D])"HS+-;[UG
M)]%EN)9>;O$/<LSY41%YK@@X4<BJN'$C^'!,=N['"J[E]G&*>'D64V\QM835
MP>1KC+^>8<L=(&*MS!FKPDMT+76>HS$^)E-'PR1JB;&.<U61RK@K^+!43BW&
MU7:VK&$4[/'@U*+NSF/M5;7%BRK67H_YNSCGZ7-&4NY)[9>FP.J722MA2GDC
MB9$KU3!>-CD:C\6<3L579N5:<MFZ:*-FK3"W,Y.JY7M4\:\ZX4-MM?1\M%JM
M-5'74%OFH*..LA5'1S+3-?$]Z*BJB\3FN785Y69F_,SQXKLU3%-C".+!Q^=U
MYX O_P#,G_JG^[E7^?D6_P"'E:>A\K]<WJ=#1N:49DJ    !56KV6I?JKYU2
MNML6F:E"X WYT1OG(NG_ ".H]5TAS?F'NX\?FET_EWO)\7GAM35S'/VD&;%3
M&2X94O=9LWX=P53D^MA2S&EE_P#KNT]J/KZ70S,;RU5X)^KH>:(HW(FD5@K)
M$1M?FJ]4Z,:J;52MJF4Z;?X")ST&:_[+L]F/IK,I&Q:CPS]?0UMTMXY)L_6*
M*)JOEDM3&,8U,7.<ZJF1$1$WJJFW\O\ 4GQM/YC&-=/B7&BT#TYR-EVDO>LF
M8):.NK43AH:9W"R-ZIQ.C1&1RR2N:BIQ.8B-1>JF"F$YNY<JPMPSIR=NW3C<
ME:L]Z"9<ERA+J!I1>'WBR4['3U-'*YLK^:C_ !CHWM:Q46--KHY&\6"+MQV&
M=K-U;>Q<C"5=[)TS1MVYQAC6B.B_C/FK+I=ZJ2@RM;7)%/-#PI--,J<:QL<]
M'-:C6JCGN5%PQ39MV79K,[K@C3*G*97>XS.B&T,FY!T2JL_VB;3;-4LM_LE4
ME346ZI222&IB@5><YF1T,:.<B=EBQST5.3#::=V[>BW.W3P2WK5JSO(V)X88
M=TD+7+>]::&SP2Q02UU'0T[9ZAZ1PQ\Y)(WC>Y=B-;O4OR56S9F?#+7SM&U>
MB.6%^KM+^CGDJ2DLN<<U5<]\J(F2OEA<]T6#U5$=A302MC:JIL21ZKAMW%<7
M\Q7PTT\"R<OE[>$53PL&UTT<H=,)[97V.NEK+%=N<9$RI5KIHI(D:[!7L1K7
M-<CNQ7A3=MZILY7,S=QB8X8:V;RL6L)C1+:FN?\ 9WR?_P!']02&EE?Y%7E^
MMO9OW$>1A/BPLGT>?&!WPN7?7N?G.X^Z4[@Q[OYC#F>#=P[?+;]IL;^?B-C"
M,.A1N(^'VL9T<K<NAU!D:#1ZHBLUPEGMU7$^7,\K^+BIZ^6@@2KC9C&WL6-P
MX<$=]530S4U[WACQ>+'@;N4BB+7!Y?'APM59&TJT4SWG&^Y>LMTN590T--35
MENJ8YFQK)&[L*A'))3M7L)%9AV*>6-R[F+UNB)F(:EO+V*ZIB&GJ#(=PJ=2(
MM/)<4K>^BVR>1J8\+(Y5;)*GD(Q%?]0WYNQ%O;\&+G19F;NQX65Z\9#R9IS?
M;=E[*\M7-6/IUJKBZKF9*C4D=PQ-:C(V8+@USEQ5=BH4Y2[7<IF:E^<M46YB
M*=+4QNN> 6:R_P <NOHA?/.,I%Y,0               W'T8/G:H?0E9^:4T
M,][IT?E_O?(R/7K+FI5RU1NE1ERU7NJM4D=(V">@@JWTRN2GC1W"^-O!L=CC
MMWE64KMQ;C:F,5V;INS<^SCAX,6V*6&_VGHX7:'4R1ZW-+57L<E6[G*AJ2H]
ME(Q[EXOPG$K$;CBJ+@B[4-*9IG,1L:,8Z6[$51EYV].$M3:4:#Y;U$TWGS#4
M5E327]:B>G@EYQJ4C$BX<'O9P*Y<$555.-,?(-W,9NJW<PXFEE\I1<MXSI8_
MJ5DK2:WVRTT.F5WJ,P9KJZYMODB9/',UW8X*Y6)&U<7O5B,5J\*[=^!;8NW9
MF9KC",%5^S:B(BW.-6.&EF_B)THT^M%%5:N9EEBNU<G8T]*Y61-<B(KFL9'%
M+*]&XX+)L;Y"&O\ %W;D_P#7' V(REJW'_9/"QS4S0:SVO*B:A:;75]YRLC4
MFJ(I7-DD9#CPK+'(Q&\36NV/:K4<WEW+A;8S<S5L5QA*J_DZ8IVZ)QA;M%-$
M*;4*CK,T9GK7V[*5 ]T2OB<R.6:2)J/D7CD16LC8U4XG*GD)A@JF6:S4VYV:
M8QEAE<I%R-JK0VAICDG1Q^H]LOFF&9Y:NNLB5+[A::ILB\Y#+3RTW'"^2&)5
MX7RMXL%<F'4Y=2_=O;N8N1I;EBU9WD3;GACB8/JG8*'-/27;EVY+(V@N4MOI
MZAT+D;(C'TL>/"JHY$7ZQL6*YHR^U'%BHOT17F8IG1+#]>-/;%IKF^BL67GU
M$E%46V*MD6K>V23G9)YXU1%8QB881MY"_*7JKM$S/*U<W9IM5Q%/(R3,ND&5
M;1H=;=1J66L6_P!7#122QOE8M,CJEZ-?@Q(T=N79V131F:IO31Q<+8N9:BFQ
MMQIPAYI9H=9;[E.?4/4.Z26C*4:/= R%6LDDCB<K'2N>YK^%O&G"UK6JYR]3
M9C-_-335L41C*,OE*:J=NN<(9,[0W2O4*P7&OT=O]14WBW8(M-5*Y(7O<BJU
MCVS0Q2,X^%4:_P K_P"%/Q5VW5$7(X)73E+5VF9MSPLCZ*%!E:GM-RJ:.KE=
MG&3\'>:%^/-PPQS/2%6]@B8NVX]FOUBK/S5,QCZO$MR%-,4SAZW&TGKA;=/K
M?F979&N4UPJ:B>LDOK9U=A#5\]M8WBBCV8J[=Q?5.AE:KDT_:C#1@Y^<IMQ5
M]F>'AQ:O-QH.@M<%;E;2W3C3Z-5;,E-WTKXMW#,K.5/)DGF^P<O*_;NUU^1U
M\W]BU10Y].HY#L^Y4EYK^BQ0TF7X*JIN\EMMG<T% R22I=PU<#G\#8D5RX-1
MRKAR8G IF(S,XZ,9>BJBJ<M&SIPC1Y&!='S+FKUOS_2U=VI+O;\M-CG2ZI=&
MSP12-6%Z1(UD_"KG)(K%3A39MY#9SE=J:,(PQ\#6R=-Z*\9QP\*7K#9[#F_I
M%VC+DKW]SUD=%1W=T#FMD25W&O8KPJB*D:Q[T4G+5549>:N8S%%->8BF>1D%
MZT!T:R==DDS?F2:@M-<UD-II)ZEC)G3-_&R/>D7E4Q:B=BC6_NEVX)53F[U<
M?9C&5M63LT3]J<(\;6^FNB5+J5F&]U5'6S6_3ZU5<L,-=)P254[$<JL8UW"U
MB.YO!SW<.#<4V+B;=_-3:IC'UI:=G*1=JF?\8EGE#I!T>LWU<N6,H9KJ5S+&
MU_-.25)D>Z-,7*B/AC9*B(BJO-/W;<<#6G,WZ(VJJ>!M1ELO7]FF>%I*\Z79
MGL^H$>G,D;);S43QPT<K55(9HIE["9%Y&<.UW[W!4WH="F_35;V^)S:LO53<
MV.-NF^:,Z$:?TE):,_9HK8,QUL/.)/%Q*B8JK>-D44$W SB1419%7'!=O4Y]
M.9OW)QHIC!T:LM8MQA7/#*V9WT"RGE'2*NSG372>Z7F!(9:2LAD8E#/3U5<R
M.)Z1\"N15@D;C^$5./<JH9VLW77=BG#".A7>RE%%J:M,]*=I]T?<I9UTIMV;
M:BXU-NO57S[ZBJDEC[BAAIJV2*1ZL5B+LAC5=LB)Q;U1"+V<KHNS3AC'0FQD
MZ+EJ*IT]+%<]Y$THDKLLV;3"_=V5UVJGTM?5UE4QU-3QQHS\++C'&K<>)78I
ML5&K@F)=:NW<*IN1H57;-J9IBW/#/A9K7:8='#*%73Y=S3FFLFO\K(UDD8Y_
M-HLJ=B[\!!(R-%WHCWJJ)@JKAM*(OYBN-JFG@;$Y?+T3LU3PM?:ZZ/TNEEQM
MLMIK):NR7=)N8;4\*SPR4_!Q-<YB-1R*CT5J\*<J+U5V<KF9NQ..F&IF\M%J
M8F-$M@5G1]T[H\EY>SE=;]4V6U2TM+6W^HG>V95;40-<D=,QD6/$Z1V"8\2X
M<BFM&<N37-,1C/$VZLG:BB*IG".-5R='?3;/65X[]I7F"9,)>;6IKG.?3N;&
MY$E21CHHY&/:U>)NS!=FS!>),?C+ENK"Y"9R=JY3C;E!EC1/0K/-)6V7*6::
MVNS%;XT=4UK45K4<JJU'I%)"QKX^+_Z;UY.RVXDUYJ_;F)JIC"4496Q<B8IG
M&8<U7NTU5AO-QL==AW;;:F:CJ.%<6\Y3R+&[!>5,6[#K4U15$3'&X]=,TU3$
M\2A,F               !9I_^Y:7T.O^69<0O)B.S-;;W>;!HAEJML5QJK96
MN?;(EJ:*>2FE6-U'(JM5\;FK@JHFS$X&5IBJ],3&.EZ/-U339QB<-#3VC&L6
M>://]EM=XOE;=[1>*J*WU--<)Y*K!U4Y(F/8Z57.:K7JU=F],<3?S.6HFB9B
M(B8<[*YFN*XB9QB5TZ465Z.UZBVR[4+.YTOT#)*I8\&XU4,G-ND3#<JM5F/5
M7:89&Y,VYB>)9GK<1<B8XTOI%Y#K<FTN7GU>:KQF3NR2J:QEXJ75*0\VD6*Q
MHY5P5W%V7U$)R=V*YG[,4^)&=L[$1]J9\:O9H+IYDRS6VOU@S746FY71CG14
M-"UJ<#V(U7,XEAJ%>K$<U'JC&IBOUUP^+N5S,6Z<8AE\';HB-Y5A,L;U.T7L
M66,JTF>\E9B;>LMU2MPCG5C:CFWNX&O8K>'G,'=B]O US5Y-^%UC-555;%48
M2JS&4IHHVZ)QA3Z1Z'S:AV^KS->[DECRC0JYLE8Y&\<JQ-XI%:KU1C&,3RTC
MMGD;\)S&:W<[,1C+'+93>1M53A#-7]'K3O-]KKIM*,X/N=VM[?PE+5OAE8^1
M<>%JNCCA5B/P5&NX7(:_QERB8WE.$2V?@K=<3NZL9:FT[TKS#J'FB?+5*B4'
M<'$MWJZAJJE*UCN!45B*BN>KDX6LQ3'JHB*J;M[,4VZ=K3CH:%G+57*IIT8:
M6YOH]Z.R5RY3BSY+X:M7FU@66D5O.IO9W/PH[B3]YSW$:'QE[#:V?L^5T?@K
M..SM</D:GO.EC\E:CVW)N=ZIT-FN$T;67BDP:UU/.[FVRISB*B<#OQC5W8+Y
M"F[3F-NW-5.F.)HU9;8N137HGC5&MND\>E=ZMU-05,U;:+E3NE@J:A&H_GXG
M\,L?8(B;$<QW_F(RN8WL3CIA.;R\6IC#1*\1Z,V2WZ,NU.S'<:JFN51$LENM
MT21HQZS2<W3H[C:KEXOQB\/[@K^)JF]L4QP+(RM,6=NJ9Q^F"XY)T$L;\H0Y
M\U2OSLO6&K:R2C@A6-DSHI4QC<Y\C7IB].R:QK'+P[3&[FZMO8MQC+.UDZ=C
M:N3A"EU!T+M-MRD[4#3>^^$.5H55:MDBL=/%&CD:KT?&C4=PJN#VJQJMW]7"
M;.;F:MBN,)8WLG$4;=$XPBTAT*MVIN2+KF%]QJ*6\4M7445%3LX$IWOCIH98
MUD5S7.1%=+@[#D&8S4VJXC#@,ME*;M$S,\.*\7;172&RI8[?-G:2MO-9<8;1
M=&T4]'(V&HG:_!RQ(CG0M:]O"[G'+]8KIS5VK&=G@PQXULY2S&$35PXX<3 =
M:M+8M+,Q4=NHJF:MM5?2I44]3.C4?SC7N9(Q>%$3L<&K]1R&UE;^]IQG3#4S
M67BU5$1HE?KEHQ8[!HS3:CWRXU4-\KXHWT5L:D:0O?52+S"8JU7?BOPKMJ<J
M%5.9JJO;$1P+JLK339VYF<6ECH.8N^9O9=WH>D]2Q%=O0MN^M].1UWG2MOUO
MZ->7:K+=15TMU;:[&D<UO?+%4(U884<B.A5'8*F\XEN*9S$[6C&7=N35&6C9
MQQPIT>1@_1VO&K]QSNWOW57BMRKS$R7&6ZOGF@8Y&+S7 ZH5<'\?#L8N.&/(
M;&<IM11P88^!KY*;TU_:QP\*CU'R=9<]])=N4WU#Z6&XT[%N$],C.<;/!0/G
M3#'%,5;''CBAE9N3;R^UR>EC?MTW,Q%/+'F76?HSZ>V*YU4.;,YK;J.I1K;%
M#)44E-52N1C5D>])FX/1'JK49&W'##LMIA&>N51]FG'E9SD+=,_:J\6A@&E^
MA\.>Z:Y9HNUU6SY#M\DS&5\B,;/,R'LG.[->&-K&X*][MF.Q$V+ALW\UN\*8
MC&J6M8RD7,:IG"EDUQZ/V2LT6*ONVCV:7WNLMB?A[=5.CD?([!7(Q'1QPJQ7
MHB\WQ,X7*F&.]4IC.5TU1%RG#%;5DJ*J9FW5C,-5:9Z:WG4S,?>*W/2D@@8L
MUQKI6JYE/$B\/E4PXG*NQK<4Q\A$53=OWXM4XRTK%B;M6&ANEG1_T;JKF_)]
M%GN=^=HU<Q].CZ9[.=C15>SF48B\3<.R9SW$F"XG/^,O1&U-/V70^#LS.S%7
M#Y&O\J9)N^GVO67LLWGA=/3W&!\-1'CS<\$F*LD9CR*F].1<4Y#:N78N6)JC
MD:UJU-J_%,LQZ2M,ZMUJRI1MFDIG5%!;X6U$*\,L:R7"I;QL=R.;CBB]4HR4
MX6:I\,_4NSL8WZ8\7UL;Z162ZO)MQL4-7F2ZYC=5P5#VRWBH=4NA1CV)PQJY
M5P1<=I;D[L5Q/!$>)5G;6QAPS/C93?>C3EFST5IOE7FEUKRV^)9[U7U_-8QJ
MYL:Q10-:C>)[U<Y-N[#<J[%IHSU54S&SC/$V*\A13A.UA'&ILS]'O)]7D6KS
MKIEF2:[P6^&6HG95.BE9*VF172HQT<<2QO:U%5&O:N/U\2:,Y7%>S7&&+"O)
M431M43BM_1TR)6YSI<PR4F:KQEM*.2E:]MGJ74S9N<;*J+)PJF*MX>Q^JIGG
M+L43'V8GQL<E9VXG[4QXI:XR%IU>-1\W/RW:I$B;&LDM=<)D5[88&/X5>Y$P
MXG*JHC6X[57D3%4VKMZ+5&U+4M6)NUS3#=3= -&GW3P.9GN=V=L59W.CZ96<
MXU,59S7!CQIAY3GN(Y_Q=[#:V?LNC\'9QV=K[7D:BO6C^:+/J-3Z;JC);C72
M,[WUFUD$M-)Q83\JHUJ-=QIMP5JIM-ZG,TS;VVA5E:HN;'*VU-H/HIE^OARS
MFK/53'FN9&-2&-\%-&CYL.#B8^*;AQQ14XI4V&E&;O51M4T\#>G)V:9V:JN'
MR-7:R:2U&E-XHZ9M;WPM%SCDDH:ES.;D185:DD;T153%O&U<47;CN0W,MF-[
M$\&$PTLUE]S,<.,2W9TB_F,R=Z+MG_QM0<_)>^J\OUNCG_=1XX^J7)T?XJ;[
ME//(=MPDH(  ':.IE?F&W='_ "U4Y9J:VDN?<UG:DUMDEBGYM:9.).*%4=@O
M*<"Q%,WYVL,.'2])?FJ+$;../!H8AT<+MJY<<WRK?ZF[UN55II.ZYKL^>6)L
MJ8<WS3ZA57CXMBHQ=V.)?G:;44<&&/@:V2F]-7VL</"IKLV@;TNJ/N'A3&H@
M6I1F"-Y]:#L]W+^^_P ;$FG'X7A^G"BK#XN,/IP,IUCT[R+>,^LS%J)FR.PV
MRHI(*6AH87-2LF=$KU>]5>QZ,8G%ACP+MZG+3EKU=-&S13C*[,V+=5>U75AP
M-1ZT:'TVG-NH<S9>N;KIEBOE; UTW Z6-TK%DB7G(L&R,>UKNR:UO^$WLMFI
MN3--482T,UE(M1M4SC"NR%H5E^MR9#J!J5F!UAR_5*BTD4/ R5T:N5C7.DD:
M]$5ZHO"QL;EPV^08W<W5%>Q1&,L[.3IFC;KG"%TS-T?LG5N2J_.VE^99;O16
MV*6>:"J6.7C;3-XY6H^-D2M>C>R1KH]NSJXF%&<KBN*;D88LZ\E1-$U6YQ8G
MI1HS39XLMSSCF>[I9,GVMSV35#$:Z5[HF))(O9;&M:UR;<%Q78B%V8S,VYBF
MF,9E1ELK%RF:JIPAF4&AFD>=*&O=IGG>:>Y6^+G)(KEP+'B[%&\7X&F<UBKV
M*O1'</\ @*)S5VB8VZ>!L1D[5<3L5<+3>3,@7W.V;690M;6,KD?(E7.]W%%!
M% [ADD<K<<41=B8;U5$Y3?NWJ:*-J7/M6*JZ]F&\I.C_ */17-N3),^3MST_
M!C8%6GYOG7)BC%AX,4<O(Q9^(YWQEW#:V?LNE\%9QV=K[7D:*S_D:\:=YEJ,
MM7GA?-$ULM/4QX\W/3R8\$C<=N"X*BIR*BH=&S=BY3M0YEZS-JK9EC!<H=I:
M9YWTJLV;+?IKI=0+4Q5J327.^NXD61U- ^1$XY$1\JXMPW-8W;PXXG OVKM5
M,UW)\CT=B[:BK8MM =(WYYLR_P"P_P#Q].=/)>YCR_6Y.=]]5Y/J:L-QI  "
M^YD_%6/_ )9#^<E*Z./QKKG%XEB+%(!T)T0_^^KU_P I=ZI@.7\Q]2/&ZWRW
MUI\2TZG9AU9BU+S#16"Z9A;1,KY&45+13UO,HQ,,&QLC=PX>0B&=BBUNXF8I
MT>!CF*KV\G9VL/*W1J0ZZS]&R:3/K49F1:.C=.DJ,25*ONF/@543#"16^7PV
M^6\E#0LX?$?8T8NA?Q^'^WIPUK?I'99LQ]&ZKL4$\5-+7MN,"5-0O##&CI78
MO>J8X-:FU3+,5;.8QY,&&6IVLOARXL1L/1\TJS=055ORGGN2Y9GHFHM1+%S+
MZ5%VMXD@1J/5BN_=-F5/LE]><NT3C53A"BG)6JXPIJQEIS+>F5_S'J"_3MBL
MI[I35$]/7U#NSBA92.5)9-F'$FSL?WRJF['$WZ[]--O;XG/HR]55S8;I;H1H
MA#=VY.J\\U;LY.>D"4[)*=C.?<B*C.!87X.7]YSN/)O.?\7>PVMG[+H?!V<=
MG:X?(U)J'I+=\D9[H\DT\S;G+=N86SSHWFEE2JE6%C7M551KD>U6KM\GE-ZS
MF(KHFK1AI:-[+31<BF.''0V;7Z':.Y&2EMNI6=JJFS#50-J$AHF)'$C7*YJJ
MB+3U#E9Q-5K7.5N."[.IIQFKMSAHIX&Y.4LT<%=7"P76#1^FTYBMMWLMZCO-
M@NJ)S#U5C:AG&WG&*J,<J/C>W:V1N"<F&['9RV9WF,3&$PULSE8M1$Q.,2OV
M0-!K1791;G[4N^+E[+4Z-DI(XUC9,^%ZX->Y\B/1O&OE&HQRNWE=[-S%>Q1&
M,K;.3B:-NN<(>9YT)LD&49L_:8W]<PY=I$<^LAEX'3QQQX<;D?&UB*K$7B>U
MT;51NT6LW5M[%R,)+N3IBC;MSC#1AT7+;5TGUH=I7;+O14MC97UMT<CTKW5'
M,NB6-BMC16<T]'-:JN=ABF.)I9C+;V8G'#!OY?-;F)C#'%G?1BNN?;_GVXW*
MLN-;6V+N:1]XDJ99)875$BIS*=FJISF.*IAN:B\AK9ZFBFB(B(QXFSD:[E5<
MS,S,-6ZVU5LK-5LTSVE&I1K6<"JQ45JSQQL9.Y%3]]*CU-W*Q,6J<6EFYB;M
M6# 39:@!-A_SGW"B4I00  .TLZ5M^M_1KR[59;J*NENK;78TCFM[Y8JA&K#"
MCD1T*H[!4WG MQ3.8G:T8R]%<FJ,M&SCCA3H\C!^CM>-7[CG=O?NJO%;E7F)
MDN,MU?/- QR,7FN!U0JX/X^'8Q<<,>0V,Y3:BC@PQ\#7R4WIK^UCAX4.<FT+
M>E?9NX\.=6IMZUG"B)^'YE-^'+P<&\6\?A9Q\*;F'Q48,RUOR!DF_9VM^8M0
M,U1V"S);HJ"FI8U;W942Q3SRR.3B:]&L:DK4XN!VW?ART96]731--%.,XKLS
M8HJKBJNK",&H-8]#*'(-DHLWY7NS[KEFMDCC3GN!TK$G8LD4C9(D:R1CT3>C
M6\F_'9O9;-3<JV:HPEH9G*1;IVJ9QA-T[T,LEVR<FH6HE^6PY8D<O<S8N!LK
MXT>L?&Y\B/1O$Y%:QJ,<J[R+V:JBO8HC&4V<I3-&W7.$+Y?.CYDF[Y.N&;]+
M,T376"VQS2205?-RI(ZF9SDD:/CCA5C^%<6HYBXXIN1<2NG.5Q7%-RG#%;5D
MJ*J)JMU8L'TAT>34:&Z7N[W-+/E6S)_IE6C4?(YS6<XY&\2HUJ-9V3GNQPV;
M%Y-C,YG=X1$8S+6RV5WN,S.$0SV@T1T7SJRKHM/<]5,MYHX'U$K:YK'Q<#<$
MXE;S%,O B^6<U788I]?6G-7J.&NG@;,92S7P45<+367M/,P9DSOX!T"1+=63
MRP5$Z/1]-&RG54DEXVXHK$1,45OEMF&U3?KO4TT;<Z&A18JJN;'&WA)T?]'Z
M*XQ9-N&>YF9ZFX&,@1U.V/G9&HK6+"K%5'.Q[%BSHY<4PWH<_P",NS&U%/V7
M1^#LQ.S-7VO(T?J+I_>--LRS9=N[FS=@V>CK(T5(ZBG>JHUZ(NU%Q16N;R*B
M[TP5>A9O1=IVH<V_9FU5A+%6.1CVO5J/1JHJL=CPKAR+@J+@OU2]1#=E;J-J
MIKC5VO*N5Z5EMJ+<Q]0ZEM-0M#"]D:QHU[N=E3!(MG"U'+OV(<^+-JQ$U5<.
M/*Z4W[N8F*:>##DEGO24OE#0:=Y:R->:QERSQ#W'45LC5XW-6"F=%+,]5VIS
MKW=BB^6VKR&KDJ)FY-<<%+9SU<1;BF>&KZ<+E0[3A@ "[7#V#L_^T_G$,*?6
ME=5ZL>5:3-2G4M754-0RKHIY*:JB7&.>%[HY&JJ88HYJHJ;%(F(G@EE$S$XP
MCKKC<+I/W3<JN:LJ>%&<]42.F?PIN3B>JK@F(BF(T%54U<,SBFV^]WFTMD;:
MKC54+95196TL\D*.5NY7<#DQPQ(JHIJTPRIKJIT3,*)[WR/=)(Y7/<JN<YRX
MJJKM5553)@R*/4#/<5 EKBS/=66Y&\"4K:ZH2)&88<*-1^'#_B[BK<T8X[,<
MR[?W,,-J>=9:.X5]NJ.Z[?534E7@J<_!(Z*3!V].)JHNTLFF)X)515,3C$O*
MVX5]SG6JN55-65*HC5FJ)'2R<*;DXGJJX((IB-!55-7#,XJJ7,-_FHN]LUUK
M)+<C&QI1OJ)70<#,.%O KN'!,$P3 QV*<<<(Q9;RK##&<$^RYNS5ER*6#+][
MK[5#.N,T=%4RT[7NPPQ5(W-151.7>15;IJTQ$IHNUTZ)F%JJ*B>KGDJJJ5\]
M3,Y9)II7*][WN7%7.<[%555WJI9$8*YF9G&59)?[[+0):Y;G5OMB-:Q*)T\C
MH.!BHK6\VKN'!%1,$P,=BG''#A9[RK##&<%O,E:XT-_OMK@=36RZ5=%3.<KW
M0TU1+"Q7*B(JJUCD3%41$Q,)HIG3"RFY53&$3,(8+Y>J6BDMM+<JJ&W2HYLM
M)'/(R%R2)@Y',1R-7B3?LVDS13,XX<)%=41A$S@DT-QN%KG[IMM7-1U/"K.>
MIY'0OX5WIQ,5%P7 F:8G2QIJFGAB<$%365=94NK*NHDJ*QZHY]1*]SY'.38B
MJYRJJKL$1$1A!-4S.,Z5VN6=<X7BWMM-VS!<:ZULX<*.IJYIH>P7%N+'O5%X
M>3%-AA3:HIG&(C%G5=KJC"9F8453?+U6TD=!67*JJ*&+AYJEFGDDA9P)PMX6
M.<J)@FQ,$,HHIB<8A$W*IC"9G!#:[Q=['5)6V6OJ;=6(BM2HHYI*>7!=Z<4:
MM7 54Q5&$QBBFNJG1."IO6:,RYD<Q^8+Q6W5T>/-=VU$M0C,?WJ2.5&[^0BF
MW33HB(37<JK]:9E(M]\O5I8^.U7*JH62*CI&TL\D*.5-B*J,<F)-5%,Z8*:Z
MJ=$S#>O15S'E[+MVS))F"[45JCGIZ9L#Z^HBI6O<U\BJC5E<W%4QVX'-S]%5
M41A$RZ7R^NFF:L9B-#4<^<LT6BONM+8+_7T-MJ:J=ZPT57-#!(CY'+Q81O1J
MXIR]0WHM4S$8Q&+2JNU15.S,X8\K&'.<]RO>JN>Y55SE7%55=ZJI<UU\ASKG
M*FMG>6GS#<HK/P\"4$=9.VGX?WO-H_AP\C# KFU1,XX1BMB]7$8;4X>-0-O=
MY;;^]+;C5):L%3N%)Y$I\%=QJG-\7#M=V6[>9;%...'"QVZL,,9P5%ES3F;+
M:RKEZ\5MJY],)DHJB6G1^&Q.)(W)CACLQW$56Z:M,1)1<JH]69A0U-?75E8^
MXUE5+47"1_.R5<LCI)G2?OE>Y5<J^3B91$1&$:&,U3,XS/"O59G[/-PH5ME=
MF6Z5-N5O ZEFK:A\3F?O7-<]45/(4KBS1$XQ3',LF_<F,)JGG8Z6J5[CSEFZ
M&U+8HK]<665R<*V]M7,E/P_O>;1W#AY&&!7NJ,<<(Q7;ZO##&<%#)>+O-0LM
M<UPJ9+9'AS=$^:1T#<-J81JO"F&/4,MF,<<.%A-=4QAC."B,F !?_P"9/_5/
M]W*O\_(M_P /*T]#Y7ZYO4Z&C<THS)4    "JM7LM2_57SJE=;8M,U*%P!OS
MHC?.1=/^1U'JND.;\P]W'C\TNG\N]Y/B\\-FZ5U]/=M0-8,@UZJZDN-;5U*1
M\G-R224M1L7JH^,T[\86[=<<C?L58W+E$\J/4FJAR_FK1K3JBDQ@H:^BGE8F
MQ%;2+'2P.P\G&4BS&U3<KGD3>G9JMT1R_4QS7BKH:#7C3VMN2M;04Z4$M2]_
ME&QMN,BJYWD-WJ792)FQ7$>'ZE.:F(O48_3A6[I?VN[+=\O7G@>^QI2R4K9$
M3&..JYQ7N1<-RO:K<,=_#Y!E\NJC"8XU?S*F>">)D?1MAGL6D^9KSF-CH\MS
M2U%5%%.JL8^GBID;,]JX^5?AP8HG[DJSL[5V(ITKLC$TVIFK0AT 8ZZZ#9LL
M]JVW>1]S@;$Q<9%FJ*)B1+PKAACBB)R+A]49O@OTS.C@^LR?#8F(T\+2F@=L
MNU1J[8&T44C):&:6:M7A5.:ACB>V1'XX88X\&WE7 Z&;JC=3BYV3IG?1X&Q]
M9LH.SYTAK1E-L_<S;C0P)+48<2LBA9/-(K47>[@8[A\DU<M<W=B:N26WFK>\
MS$4\L>EYG1VC>CE^9E>WY%DS/F2".*1U3=)W.A<^9$6-.!6O9)Y*-B:F.S'J
M+6^O4[4U;,>!-W<V)V8HVI7OI;<:Y7R@LL202<_-QPM\JQW,LQ:F'(FXK^7^
MM4L^8^I'C3M<_P"SOD__ */Z@D(RO\BKR_6G-^XCR']S_P#V3^51_P#U^7S'
M_P#+Y'O1S15T,SBB;56KN>"?]-IQG??4^*/K1D/=3XY^J'/ND^;ER/G^R7^1
M_!1-G2"OZBTE1^"E7R>%%XT\E#IYBWO+<PY>6N;NY$\3L*'3:"EUNK-3'HUE
MJ6TM?SRJUK6W!R+3O=]1*=F+EZKCA3?QL[''CJ__ "[T6,+VWX'&&HN:I,[9
MVO697*O,UM2Y:5KM[::/\'"U?)2-K<?)._9M[%$4O/7[F\KFIC!<H +-9?XY
M=?1"^><92+R8@              !N/HP?.U0^A*S\TIH9[W3H_+_ 'OD;'UD
MU[SYD74"XY:L?<7>VECIG1<_ LDF,T#)'8N1Z<KEY#5RV4HN6XJG'%MYG-UV
MZ]F,&C<]:N9YU$BBI<QUZ+;H7<Y'04S$@I^<PP1SFMVN5.3C5<.0Z-K+T6_5
MCA<V]F:[O!.AT#H]+)3]&G-4\2\,L5->WL=U'-I%5%.7F8QS%/D=7+SAEIGP
M2Y^T<JJ*BU1RK47!6MIDN$35<]<&M?)BR-57DP>K5.IF8F;56'(Y65F(NTXM
MF=+>V7>/.UKO$[7OLT]N934DW#^#9-%+*Z2/%/W6#T?MWHOD&G\OJC8F./%N
M?,:9VXGBP9QI'#/E_HX9DJ\RM6&WU<5SJ*2.?%G'2STS86(F.W"21'</5XMF
M\U\Q.UF(V? VLM&SEYVM'"@TU@EOG1=O%JL;%?=&PW.":./LWR2\;IN!&X>6
M=$YK41/_ !%^=G,Q,Z.!%B-K+3$:<):IZ,EON-3JU;ZFEC>M+04]7)<'HG8M
MC? ^)J.7DQD>S W<],1:EHY"F=[XF8YQ<C>EI;5<J(G=EL3%=FU:6-$*+?\
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M,O3RTW1"FDA=PO=0W&-53][+<IXW)]=KE0FN,<UY8^I%O^+Y)^N7.6F62TU
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MJZJNC)JBHE<KY))'JJN<Y5WJJFQF(B+4Q'(HRU4U7HF=.+.^ERYRZC6IBJO
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M -I_.(84^M*ZKU8\JTF:D
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M9JN<MQJ(D5L*/1L<4;5PQ1D<:-8W'!,<&[>4FW:IMQA3&"+EZNY.-4L?+5(
M LUE_CEU]$+YYQE(O)B
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M3U+$5V]"V[ZWTY%H+%0                     !-C_ !4WW*>>0)2@@
M                    7W,GXJQ_\LA_.2E=''XUUSB\2Q%BD
M           FP_YS[A1*4H(                       %VN'L'9_\ :?SB
M&%/K2NJ]6/*M)FI        .K,GSRTW10NE3 Y630K4R1O3>CF5K51?K*AQ;
MD8YJ/IQ.]9G#*X^/ZV8YMRI%J9?M)L]4\+74<DC*BX*G9-2%:?OA$QV_8CX7
MQ_5=@I1;N;JFY1].1?<MQ=JHK^G*RC)^8._FJNH=,Q_'36:"R6Z)4W<36UDT
MGUTDE<U?J%-RC9M4>''S++=>U=JCDP\[0_1E^>7-'_+J_P#^0ICI9WW-/CCZ
MI<[)^_J\OUJC*']K2Y>B[EZED(N?Q8\C*W_*GZ<2LS!EF@S9TK^]MTB;/;H8
MZ>LJ('HBMD2FH&2,:Y%V*U7HWB1=Z8H8T5S1E<8T]+*NW%>:X>1L#4JBZ0%9
MFMDFGL]-1Y7HF1=SQK)3M6>3A1TBRME1SE3%>!&[$P3J[35LS8BG[>ELWHOS
M5]B8P87TI\NT[K)E7.]QI&07=)XK==XX5Q<]LL3I^;XMRI&L<B-7_&-C(5SC
M53&CB:^?HC"FJ>5LK,ULO.HF6[17Z19T98[?3Q81P4K$YB1JM:C&/='V<2QH
MF'!PKY*)@:E%46ZIBY3BW*XJN4Q-NK!I/7&;6:ER;1V//MJMM?9:66+_ /F>
MB1\LSIV8M:Y[N)G-J]%P7&%J.ZN)T,K%F:\:)G'D<[-S>BC"J(F.5L?1K.69
M+CH5>[S65O.7*QPUU-:Y^:A;S,5!0QN@;PM8C7<"\KT55Y<35S-NF+T1$<$X
M?6V\M<JJLXSIC%@O1UIZS4S42]:A9RE;=+O9X*5(97Q11M2HF1T<4G-Q,8W%
MC(7(U>'?MWX*;&<F+5N**>"):N2QNUS75PS#'\U=);42'.]=-9:N*GR_15<D
M%-:GP1/CE@B?PXRO<U9.)Z-Q7A>G#C@F!;;R5O8C'2KN9ZY%R<-$3H9?TH+%
M:KUE#+>IM%3I!7U:P05#DV/DIJR!T\7'NQ6-6\*+O[+R$PHR-<TUS1*_/T1-
M$5PR_4'-]RR/H5EB^6-(X[V^CME%1USXV2/IN?I$=(^-'HJ<2M8K?KE%FW%R
M],3HX6Q?N3;LQ,:>!+Z/N;K]J?DS,=JSI4]\TCD6D[HD8Q)'4]9"J.8Y&M1%
MP5%P54QVX;D0G.6Z;5<33P(R=VJ[1.UPL8Z)>6*9+/F#.O<S*B[-G6VV]S\$
M5G-0MFD:U5\KSBRL15\CZI=\PKG&*>+2H^741LS5QZ&99 I.D-2YT;69YEIJ
MG*U7SJ5E-'+3JD&+%6-86L1';'(UJIBN*8XXKM->]-B:,*-+9M1?BO&O#!S5
MKQEJ@RKJA>K?:XVPV^=8JV"!B<+8^Z8VO>U$38B(]78(FY#K92N:[<3+CYRB
M*+LX<;6YMM(        O_P#,G_JG^[E7^?D6_P"'E:>A\K]<WJ=#1N:49DJ
M   !56KV6I?JKYU2NML6F:E"X                       6:R_QRZ^B%\\
MXRD7DQ
M                    LT__ '+2^AU_RS+B%Y,0
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MJ^=4KK;%IFI0N                       %FLO\<NOHA?/.,I%Y,0
M
M        +-/_ -RTOH=?\LRXA>3$                       %WS-[+N]#
MTGJ6(KMZ%MWUOIR+06*@                     ";'^*F^Y3SR!*4$
M                   "^YD_%6/_ )9#^<E*Z./QKKG%XEB+%(
M           !-A_SGW"B4I00                       +M</8.S_[3^<0
MPI]:5U7JQY5I,U(                                       +_ /S)
M_P"J?[N5?Y^1;_AY6GH?*_7-ZG0T;FE&9*@    55J]EJ7ZJ^=4KK;%IFI0N
M                       %FLO\<NOHA?/.,I%Y,0
M                                                       +-/\
M]RTOH=?\LRXA>3$                       %WS-[+N]#TGJ6(KMZ%MWUO
MIR+06*@                     ";'^*F^Y3SR!*4$
M      "^YD_%6/\ Y9#^<E*Z./QKKG%XEB+%(                     !-
MA_SGW"B4I00                       +M</8.S_[3^<0PI]:5U7JQY5I,
MU(                                       +__ #)_ZI_NY5_GY%O^
M'E:>A\K]<WJ=#1N:49DJ    !56KV6I?JKYU2NML6F:E"X
M         6:R_P <NOHA?/.,I%Y,0
M                                          +-/_W+2^AU_P LRXA>
M3$                       %WS-[+N]#TGJ6(KMZ%MWUOIR+06*@
M               ";'^*F^Y3SR!*4$                       "^YD_%6
M/_ED/YR4KHX_&NN<7B6(L4@                     $V'_ #GW"B4I00
M                     +M</8.S_P"T_G$,*?6E=5ZL>5:3-2
M                             "__ ,R?^J?[N5?Y^1;_ (>5IZ'ROUS>
MIT-&YI1F2H    %5:O9:E^JOG5*ZVQ:9J4+@                      !9
MK+_'+KZ(7SSC*1>3$
M                              "S3_\ <M+Z'7_+,N(7DQ
M             !=\S>R[O0])ZEB*[>A;=];Z<BT%BH
M    FQ_BION4\\@2E!                        ON9/Q5C_Y9#^<E*Z./
MQKKG%XEB+%(                     !-A_SGW"B4I00
M        +M</8.S_ .T_G$,*?6E=5ZL>5:3-2
M                "_\ \R?^J?[N5?Y^1;_AY6GH?*_7-ZG0T;FE&9*@
M55J]EJ7ZJ^=4KK;%IFI0N                       %FLO\<NOHA?/.,I%
MY,0
M                +-/_ -RTOH=?\LRXA>3$                       %
MWS-[+N]#TGJ6(KMZ%MWUOIR+06*@                     ";'^*F^Y3SR
M!*4$                       "^YD_%6/_ )9#^<E*Z./QKKG%XEB+%(
M                   !-A_SGW"B4I00                       +M</8
M.S_[3^<0PI]:5U7JQY5I,U(
M  +_ /S)_P"J?[N5?Y^1;_AY6GH?*_7-ZG0T;FE&9*@    55J]EJ7ZJ^=4K
MK;%IFI0N                       %FLO\<NOHA?/.,I%Y,0
M
M   +-/\ ]RTOH=?\LRXA>3$                       %WS-[+N]#TGJ6(
MKMZ%MWUOIR+06*@                     ";'^*F^Y3SR!*4$
M              "^YD_%6/\ Y9#^<E*Z./QKKG%XEB+%(
M      !-A_SGW"B4I00                       +M</8.S_[3^<0PI]:5
MU7JQY5I,U(                                       +__ #)_ZI_N
MY5_GY%O^'E:>A\K]<WJ=#1N:49DJ    !56KV6I?JKYU2NML6F:E"X
M                 6:R_P <NOHA?/.,I%Y,0
M                                                  +-/_W+2^AU
M_P LRXA>3$                       %WS-[+N]#TGJ6(KMZ%MWUOIR+06
M*@                     ";'^*F^Y3SR!*4$
M "^YD_%6/_ED/YR4KHX_&NN<7B6(L4@                     $V'_ #GW
M"B4I00                       +M</8.S_P"T_G$,*?6E=5ZL>5:3-2
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MKZ#NWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\
M'7WK]>#O+LZ^@[M[6KI/H;_'7WK]>#O+LZ^@[M[6KI/H;_'7WK]>#O+LZ^@[
MM[6KI/H;_'7WK]>#O+LZ^@[M[6KI/H;_ !U]Z_7@[R[.OH.[>UJZ3Z&_QU]Z
M_7@[R[.OH.[>UJZ3Z&_QU]Z_7@[R[.OH.[>UJZ3Z&_QU]Z_7@[R[.OH.[>UJ
MZ3Z&_P =?>OUX.\NSKZ#NWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\=?>OUX.
M\NSKZ#NWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\ '7WK]>#O+LZ^@[M[6KI/
MH;_'7WK]>#O+LZ^@[M[6KI:MTIZ/GAMFC4.S>$7<*95O,ELY_N+GNZ>":HCY
MSA[H9P?BL>'%V_?L-J]G-BFF</6C'2UK.3WDU1CZLX:.EM+Z&_QU]Z_7AJ]Y
M=G7T-GNWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\ '7WK]>#O+LZ^@[M[6KI/
MH;_'7WK]>#O+LZ^@[M[6KI/H;_'7WK]>#O+LZ^@[M[6KI/H;_'7WK]>#O+LZ
M^@[M[6KI/H;_ !U]Z_7@[R[.OH.[>UJZ3Z&_QU]Z_7@[R[.OH.[>UJZ3Z&_Q
MU]Z_7@[R[.OH.[>UJZ3Z&_QU]Z_7@[R[.OH.[>UJZ3Z&_P =?>OUX.\NSKZ#
MNWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\=?>O
MUX.\NSKZ#NWM:ND^AO\ '7WK]>#O+LZ^@[M[6KI/H;_'7WK]>#O+LZ^@[M[6
MKI/H;_'7WK]>#O+LZ^@[M[6KI/H;_'7WK]>#O+LZ^@[M[6KI/H;_ !U]Z_7@
M[R[.OH.[>UJZ3Z&_QU]Z_7@[R[.OH.[>UJZ3Z&_QU]Z_7@[R[.OH.[>UJZ3Z
M&_QU]Z_7@[R[.OH.[>UJZ3Z&_P =?>OUX.\NSKZ#NWM:ND^AO\=?>OUX.\NS
MKZ#NWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\
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MKZ#NWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\=?>OUX.\NSKZ#NWM:ND^AO\
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M6N7RJG]55IT\YZEOV?0YN4]>Y[7I=%G,=(
M                                               .7=3?[6^3?DP_
M\Y<CI4?Q:O:]#GU?R8]GTMKM.8Z*) (D)$2!":WD($:;R1,0":T":W<$IK.0
M(3F@3V!*<F\(3$W 3 A-;RDB8W>@$U-X'I"0"74-<^"5C4Q<YCD1/)5 *.RT
MT]);XX*AO!*U7*K<47>Y53:BJ@%P                       6NOI*B:Y4
M%1$SBAA5RRNQ1,,<.15Q4"Z                       (7HJL<B;U143[
M%OL=+/1T"0U+."5'.7AQ1=B^2BJ!<@                      %KN5)45%
M=;IH6<4<$CG2NQ1,$56]5=N[D N@                       !SIT1_8G4
M#Y55GG(SIY_33[+FY'15[3HLYCI
M       ^=/\ >$_K4_E0]+^A]SS/.?K??\[0)TFA $@    VST9OGSR=Z(G]
M23&GG?<U-K*>^I?3L\H].                       .=.C;\X6N7RJG]55
MIT\YZEOV?0YN4]>Y[7I=%G,=(
M                                      .7=3?[6^3?DP_\Y<CI4?Q:
MO:]#GU?R8]GTMKM.8Z*) (D)$2!":WD($:;R1,0":T":W<$IK.0(3F@3V!*<
MF\(3$W 3 A-;RDB8W>@$U-X'I"0"%[VQL<]WE6HKE^HFT"72U4-9"VH@571.
MQ1%5%3<N'*!.                       2)JRG@GAIY'*DL^*1I@JXX>2!
M/                       >*J-157<FU0)-)5P5L*3T[E=&JJF*HJ;4^J!
M/                       2)ZR"GEAAE<J25"JV),%7%4PZX$\
M                YTZ(_L3J!\JJSSD9T\_II]ES<CHJ]IT6<QT@
M                               ?.G^\)_6I_*AZ7]#[GF><_6^_YV@3
MI-" )    !MGHS?/GD[T1/ZDF-/.^YJ;64]]2^G9Y1Z<
M       <Z=&WYPM<OE5/ZJK3IYSU+?L^AS<IZ]SVO2Z+.8Z0
M
M <NZF_VM\F_)A_YRY'2H_BU>UZ'/J_DQ[/I;7:<QT42 1(2(D"$UO(0(TWDB
M8@$UH$UNX)36<@0G- GL"4Y-X0F)N F!":WE)$QN] )J;P/2$@$JJ_BTW\&[
M[2@6[+GL3%]T_P \H%V                       66Z>S%K^Z=_P" %Z
M                     0R_BW_<K]H"TY9]BV_=O^V!>
M        %EO/LE:/X5WVV 7H                        YTZ(_L3J!\JJ
MSSD9T\_II]ES<CHJ]IT6<QT@
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MP]D['<Y-^]:<W13&S5$8;48X+LK75.U3,X[,X8MT&BW0
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M5#*NWU;&RTU3$Y'1OC<F**BH>=JIFF<)TOI=NY3<IBJF<8E4F+,
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M+U4U317ZT:VX#2;@    /G3_ 'A/ZU/Y4/2_H?<\SSGZWW_.T"=)H0!(
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M&U*1-:U\K6NC19,.)RXX[D*,U$5TTW>LNRL[%55OJM^'/=
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M[%;N4W*8JIG&)5)BS         $,GXM_W*_: M>7'O?;&N>Y7.XW;57%0+L
M                      L]W>]MQM36N5$=([B1%P1=K-X%X
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M;BU51,4Y"FG)U51$[5/#X5]6<IIF8V:N#P-EW_/66LJY4\,LRU?>NS<S'/\
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M'A:UC55&1MXG<+,5PQWX8(E%Z_-S#@PB-$+K-F+>/#C,Z99^:[8
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MJJM.GG/4M^SZ'-RGKW/:]+HLYCI
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ME]G[KQ?S*Y;JKPITQIGS/NW_ )G+9BW9F;D_8J]6GS^")Y./3X]_G(>Q
M    /'KPL<Y.1%7[ %%::Z2X4:5,K4:Y7*W!N.&SZH%<
M       H*^ODI:NBIV-:YM4]6O5<<41%;N^R!7@
M  '.G1']B=0/E56><C.GG]-/LN;D=%7M.BSF.D
M                 #YT_P!X3^M3^5#TOZ'W/,\Y^M]_SM G2:$ 2    #;/
M1F^?/)WHB?U),:>=]S4VLI[ZE].SRCTX                       YTZ-O
MSA:Y?*J?U56G3SGJ6_9]#FY3U[GM>ET6<QT@#7&:+K59LSA!IM:)WP4%+&RX
M9LK8'*R1M.JHL5(QZ8*UTV**]47'@W<I(H+O6UMPUPRYER@J98K39;7-<*^E
MAD<R)RR\43&O8U41>%>:5,>J!LNZW"&TVNMNM1_%Z&GEJI?N(6*]W^!"!I;+
M%ZN]EZ/MVS5<Z^>:ZW".LJ(:B:5[I(GU,G<D/"YRJJ8.1KVHG5)%9E;1U;IE
MNTW.[YNS-%<ZVD@J:J*"XHV-DDS$>K6HZ)Z]CCAY91B,SRGIO1Y1N3[I%?[W
M='NA=!W/=:U*B!J.<UW&C$C9V2<."*J[E4#6F0,HU&J-->LWW7,M^H(:N[5;
M;=36ZNYB!*5%:YN#7L?N5RM3##<!49ML=STHJLMW7+V:[S<7W"[04%19[M5=
MV15$4V/$K6-8W!4P1N.&/9)@J+O#-L\T6=<Q9CM.5[-/4V;*DL+ZJ]WVC<UD
M[N%5:VFB?CQ,<N&*KA^ZY<%10QUT%TTUU"RM9;??J^[V',RU%/4VRZSK5RPO
MA:CDFB>J(K6XN3%/J[\>Q#<A TV^X9DU<S/=;38[M46'(%AE6CK+A0.X*NOJ
MV^79'+^Y8WR.14547B3AD>9@TXO^1Z),QZ:W>[5=VHWQK/9:RH6L@K(5<C7M
MYMS4[+!<<>ICPX+@!MCOE%!:.^]R3N"".G[JJVS+M@:C.-Z/5/WB8XD#GFVY
MGS3<<]Y6U$JZRII\LYDO%1:K;:'2.; E(D:4\+W1\7"KGO>Y5V>63%.0R&],
M\7A;!DZ^WACN&6CH:B2!=WX;FU2/;Y+U0Q&K<D:2OO\ E*SWN\YMS+#<;C3,
MJI8Z>X\$2),G&SA1\;W)V*MWN)Q%3:H+MD+5BQ9.HLQ7&]V*]T51-5T=VG[K
MFIE@9(]DC7(UJ-:YS.%,$3EQQV ;H('.FN&;+S09^MD5JKIZ:@R]24USN<<$
MLD;'I-6QQ*CT8J8I@L?ENJ3 Z#KJVEMM%47&NE;!14D;YZB9ZX-9'&U7.<OU
M$0@:%TSO^8<[ZNUM]K:JIAL[+>^MI+4LKTAABF<V&F:^-%X>)\2\]CAMQQ)&
MRKWJ]I_E^XRVJONW'74ZX54=+#-5)"J;^<="Q[45.5,<4Z@P&46:^6C,5MBN
M]DK(ZVVSHJQU$2XMV;T5%P5JIRHY,4(&(5.M6F=+7K;Y;ZQSVOYJ2HCAGDIF
MR+L1%F8Q6?71V'DDX#)[MFO+UC;;GW2OC@CNTJ0V^3!SV2.<WCQXF(Y&MX=J
MO<J-1-ZD"UVC4S(]\I;I76^[QNH+,K4N%9*V2&!G'CPJDDC6M=BJ*B<*K_A3
M$**TZP:>WJY0VJANZ)55+D91K/!/3Q3O5<.&.26-K57'8B8[>3$G 7^_9MR[
ME>2BCO\ 7LH77![HJ19$>K7.C;Q.5SFM5&-:FU7/5$3JD"TV#5+(N9KLMCL]
MU;+<U170PR130<\UJ*JK$LK&H_8BKV/)MW 8QJ7F!*3/V1[3)<UMELIWU-XO
M,JS+!%W/2M18TDP<G$USFN;PKO521E66M2\EYNN,MIL5RY^XQ,YWF)(9J=SX
MTP[-G/,9Q)MY/M$"/-&H^3<GU$=%?+DD=QE3CCH88Y*BH5J_NE9$URM3!%VN
MP K<L9RRUG*EDJ\N5[*QD#D941\+XY8G+N1\<B-<W'!<,4P7D M68-5<AY9N
M*VF[79K;A'MJ(8(IJE86]6586/1F'47:3@+M:<X9:OUPFM=GN#*VLIX(:N5(
M6O=&D%0B.C<DG#P+Q(NY'8D"P7+6/3JU7"6VU-Y1\].Y8ZI]/!/40PN1<,'R
MQ1N8FW9OV<I. R&\PP9ERK7PVZH22&YT,K:2KIWXHO/1+S;V.8O55%14(%ET
MFS!-F;3RPW6J>LE8L"T]2]RXN=)2O= KG>2[@XOKDR,T(
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M^T4]VHYKM'CSE!'41/J&\._&-'*Y,,.H5S15ACAP+-NG'#'A7,Q9
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M.UVVDLUMH[30,YNBH88Z:G9O5(XFHQN*\JX)O(%6
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M?VX^GD8_U^Y_L5Z_^1]'7,_[5+[]F;]:'>%/4CZ>0_K]S_8KU_\ (^CKF?\
M:I??LS?K0[PIZD?3R']>N?[%>O\ Y'T=<S_M3OOV9OUH=X4]2/IY#^O7/]BO
M7_R>?1TS-^U.^_9F_6AWA3U(^GD/Z]<_V*]?_(^CGF7]J=\^S-^M#O"GJ1]/
M(?UZY_L5Z_\ D\^CEF3]J5\^S-^M#O".I'T\B/Z[<_?K^GWGGT<,Q?M1O?\
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M: M.6?8MOW;_ +8%X                       66\^R5H_A7?;8!>@
M                   #G3HC^Q.H'RJK/.1G3S^FGV7-R.BKVG19S'2
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MB*J?44"(                       W[% A9''$W@B8C&_O6HB)_@ B
M                   0NCC>YKGL:YS-K%5$547R.H!$
M        <Z=$?V)U ^559YR,Z>?TT^RYN1T5>TZ+.8Z0              !B
M=JT\L-FSU?\ 4.D=4+?LQPTU/<&R2-=3HRDC9$SFV(U%1<(TQQ<I=5=JFB*.
M*%--J(KFOCEEA2N                      /G3_>$_K4_E0]+^A]SS/.?K
M??\ .T"=)H0!(    -L]&;Y\\G>B)_4DQIYWW-3:RGOJ7T[/*/3@
M              #G3HV_.%KE\JI_55:=/.>I;]GT.;E/7N>UZ719S'2
M
M        #EW4W^UODWY,/_.7(Z5'\6KVO0Y]7\F/9]+:[3F.BB0")"1$@0FM
MY"!&F\D3$ FM FMW!*:SD"$YH$]@2G)O"$Q-P$P(36\I(F-WH!-3>!Z0D E5
M2X4TRIOX'?:4"@R\YS[7$YZJYW$_:JXKY90+H
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MM>ET6<QT@
M                      Y=U-_M;Y-^3#_SER.E1_%J]KT.?5_)CV?2VNTY
MCHHD B0D1($)K>0@1IO)$Q )K0)K=P2FLY A.:!/8$IR;PA,3<!,"$UO*2)C
M=Z 34W@>D) (9&<Y&^-5P1[5;C]5, *>WT3:"E;3,<KVM55XEV+M7$"J
M                   4=30,J:NFJW/5KJ955K438N/5 K
M         'CDXFJWJIA]D"FM]"RWTR4S'J]J*KN)=B[0*H
M        !25= RKJ*6H<]6K2N5S6IN7'#?\ 8 JP
M   #G3HC^Q.H'RJK/.1G3S^FGV7-R.BKVG19S'2
M                  !\Z?[PG]:G\J'I?T/N>9YS];[_ )V@3I-" )    !M
MGHS?/GD[T1/ZDF-/.^YJ;64]]2^G9Y1Z<                       <Z=&
MWYPM<OE5/ZJK3IYSU+?L^AS<IZ]SVO2Z+.8Z0
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M3[+FY'15[3HLYCI                                        ^=/\
M>$_K4_E0]+^A]SS/.?K??\[0)TFA $@    VST9OGSR=Z(G]23&GG?<U-K*>
M^I?3L\H].                       .=.C;\X6N7RJG]55IT\YZEOV?0YN
M4]>Y[7I=%G,=(
M                          .7=3?[6^3?DP_\Y<CI4?Q:O:]#GU?R8]GT
MMKM.8Z*) (D)$2!":WD($:;R1,0":T":W<$IK.0(3F@3V!*<F\(3$W 3 A-;
MRDB8W>@$U-X'I"0"74-<^"5C4Q<YCD1/)5 **QT\U+;HX9V*R5%<JM7#E<J\
M@%Q                       6JX4M1-<[?/&Q710J[G';-F. %U
M                0R(JL<B;U143[ %NL5-/26]L-0Q62(YR\*X+L7Z@%S
M                     6NYTL\]=;98F*Z.&1SI7;.Q15;U@+H
M               <Z=$?V)U ^559YR,Z>?TT^RYN1T5>TZ+.8Z0
M                              /G3_>$_K4_E0]+^A]SS/.?K??\[0)T
MFA $@    VST9OGSR=Z(G]23&GG?<U-K*>^I?3L\H].
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MU7(R9&I@C7+P.XFMV;EP3'!*<S:IHPFG15&*[+7:JL8JTTS@VN:;;
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M>9YS];[_ )V@3I-" )    !MGHS?/GD[T1/ZDF-/.^YJ;64]]2^G9Y1Z<
M                    <Z=&WYPM<OE5/ZJK3IYSU+?L^AS<IZ]SVO2Z+.8Z
M0!H--)M3],[[<[EHA=K4[*]XJ'5M5D_,#)DI8*B7!'OII*=.)$ZC<6HB(B+Q
M8(=#?V[D1%R)QCCAS]Q<MS,VYC">*7M'I+J5J!FRT9IUONML=:LOS=UVC*5A
M;,M$ZJ;APRU#Y^R=@K<>'%^.[%J*YJIOV[=,TVXG&>.2+%RY5%5R8PCBAOLY
M[H-8:$Z<7S3#*%=E^_U%)4UE3=:NXQOH7R21)#4)&C4598XEXDX%Q['#R3;S
M-Z+M6,<C5RUJ;=.$\K9YJ-IK?5O3>YYWCL=]RK<(K3GO*E6M=8:^I8KZ=W.(
MC98)D:BNYN1&MXE1%W;C:L7HHQBJ,::M+6OV9KPFF<*J=#%&Z>ZKZB9HR[=-
M7)K+0Y9RM5-NE)8K$M1-W9<8D_!23NJ$P:R-=S4QQ17-7?B6[VW;IF+>.-7!
MC/(IW5RY5$W,,*>*.5=,_P"F></#VCU8TNKZ*FS=#1+:KI:[NV7N"X42NXT1
MSX<7L>U4;A@F"JUNU,%XL;5ZG8W=<<&G@XF=VS5M[=$\.CAXU':M-M1,XY[L
MV>M7:NV14N5U?+EW+5CYZ2G;528)W342SHU7/;PHK4:G(F[LD=-5ZBBB:;>/
MVM,RQILUUUQ5<PX-$0G9ET[U!R]J%<-2-)*FV/GS#!!3YFR_>N>CIIY:5."*
MIBD@151Z-V*B[-KEVJ[!(HNT5411<QX-$PFNU737-=O#ATQ*OTSTXS1;<U7O
M4S4>NHZW/5[@CH(J:V-D2AM]OB5')!"Z5$>[B<UJO5>5-ZXJIC>O4S3%%'JQ
MKEE9M515-=?K3J8Q9-.M8])9KE9M*JBQ7?(E;52UUOME^?50U-ODGVNBC?"B
MH^+8F&*X^0BXJMM5VU=PFO&*O!QJJ;5VUC%&$T^'B9=I/IC=LGUV8<X9RN<5
MYU S7-'+=JNE8YE+## WABIZ='HCN!B+AQ*B8HC4P['%:;]Z*XBFF,*:5UBS
M-$S55.-539YJMH
M         !SQI]\]>J7\/3_;>=F[[FV\9D_YN8\=/G;?--W90N $H>*0Q0!#
MQ21X2A H0\)0A4#Q24(0/%W$L4()0J2A"$/'$H>!#Q24(0/'$PQ0DDH5"'B[
M@(7$L92'F2J4AYE"F5._<IDKE3O,E-2FD,X52IW[E,E4J=QDIE(>90JJ2'F<
M*94[S)5*0\R5RIG\IDJE3OW&4*I4[MZF:J4AYE"F5._E)52IWF<*92)"855*
M20LA1*2_<3"JI2O+%$K;<Z"GN$+H)T\ECT\LUW50F:8F&%-R;=6,-Q:'ZX3V
MB>FT^U!J?P&R&QWR9=B)N;#,Y?W/(QZ^5W+LP5/+Y_(3$S71'CA]8_\ /?\
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M^AS<IZ]SVO2Z+.8Z0
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M>?1P              "&39&]4W\*_: M>79));:U\KU>[C=V3E55_P (%V
M                     6>[22,N-J:Q[FM?(Y'HBJB*F+-_5 O
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M8;1F:_T?A=54=,ZJIYYX8ZA]3-&USDYO%JHJN=@U.%,>0@9B
M        #GC3[YZ]4OX>G^V\[-WW-MXS)_S<QXZ?.V^:;NRA< )0\4AB@"'B
MDCPE"!0AX2A"H'BDH0@>+N)8H02A4E"$(>.)0\"'BDH0@>.)ABA))0J$/%W
M0N)8RD/,E4I#S*%,J=^Y3)7*G>9*:E-(9PJE3OW*9*I4[C)3*0\RA54D/,X4
MRIWF2J4AYDKE3/Y3)5*G?N,H52IW;U,U4I#S*%,J=_*2JE3O,X4RD2$PJJ4D
MA9"B4E^XF%52E>6*)4\F]?\ ]<IG#7J4DAG#6J4%RIZ6HI7I5JC8VIQ<YRM7
MJH8UQ$QPKLO7737&SI=-]&#-N=,Q9;JJ"_0NJK!:E;3VF]S.5)7\.^!47%7H
MQN&#\>Q\KMY/%?,;5NBO&G3/%YWW?_S6:S%ZS,7(^S3HJ\WAPY6^CDO7@
M          /')Q-5O514^R!2VVA2W4R4S7K(B*KN)4PW_9 JP
M           %'5T"5=325"O5JTKE<C<,>+'#[&X"L
M     .=.B/[$Z@?*JL\Y&=//Z:?9<W(Z*O:;TS377BVY<NM?EZ@6Z7ZGII7V
MVW\36)-4HU>;8JN<U$:KL.+;N.?1$35$3.$-^N9BF9B,9<LZ:0ZRY$K[GF>]
M:/U>:-0+S*^2XYFJ[U1PR\VY<&PP1\U)S,:-P14:_;A^]1K6]:]-JN(IBO9I
MCBPERK.]HF:IHQJGCQ;GJ+EGW4+2C/%#?<ER97S#5VRY6ZUVE]=#7.JG3T+V
MQN21C(FMXGOX,'?5Q-&(HMW*9BK:C&/K;LS7<MU1-.$X3]2]Z+V*[99TLRM8
M;[3.H[O0438:NE<K7.CD1SEP56*Y%W\BF&8JBJY,QH9Y>F:;<1.EB^<<GYDN
M72$TYSA14#YLMV6BN<-SKT<Q&0R5%+41QHK5<CEXG/:G8M7>6V[E,6*J9GAG
M!5<MU3>IJB.",6X7N5C'.1JN5J*J-;ABN'(F.!I-UR!9*?6J+42Y:F9QTCJ<
MTY@>_@R^R:[T=-2VFD:JJR.")63)QIC^,Q1<<5PQ557LU3:V(HIKV8X^#2XU
M,7=N:ZJ-J>+AT-[91S%G?4&"]6#4'3V7*-HJ*-\'/27*&O[I;4(L4D:-BB8K
M<&KCBN)H7**+>$T5;4^)OVZZ[F,54[,>-KS*%SUGTART[39F09\W.M+IH<LY
MAHJJ&*DJ*:61SXNZFR+Q1+'Q8+M39LY.-VS<IM7:MO:V<=,->W-VU3L;.UAH
ME=;+D[4;2K1"ZTF6J9+WJQ?*F:Y5KH'1\VRX7)[6R2HLJM:O,QM3#D<]-V"F
M%5RB[>C'@ICS,J;==JU.'#5/G81I9)JMI=:9(*31*KNF8[@Y9[[F.JOU)W97
M5#UXG.<JP/5K,=K6<2X;U5SE5RWW]W=GWF$<48*+.\MQ[O&>.<6SLVT>J^H.
MG%OO-DI:C(NH=KKVW&&P+<.<AJF4LCF]S5$T*1L?',W!_"Y.''!';,5-6W-N
MW<F)^U3,:<&U7%RY1$Q]FJ)T8L8SA?\ 6C5/+-1I[0Z=SY5J+RQM)>[Y=*N"
M6BIJ5RHDW,\WV4JN3L4X4W<G*EMNFU:JVYJVL-$*KE5V[3L13LXZ9;'K8,SZ
M=99R9EC(-D2_T='+0V>Y232-A=3VZ*-(Y*I<7-XG)PXJU.J:T33<JJJJG#C\
MK9F*K=---,8\381K-EIRZY/S)4=)BQYWAH'NRK2Y8?;JBY<3.!M6M14O2/A5
MW'CPO:N/#AM-VFY3\/-./#M-*JW5OXJPX-DT[R?F2S:UZHYGN= ^GL5][V]Z
M:QSF*V?N>%6R8(URN3A7]\B"[<IFU13$\,8EJW5%VNJ8X)P55+E3,$?21KLZ
MOH7)E>7*+;7'<>)G M:E?%+S7#Q<>/ U78\.'DD373N-GCVL=28HJW^UQ;/G
M8[I?IWFVVY4U;LMWH5M]7FB[WF6SK,]BLE@KH%CBE58W/P:JKR[?(++UVF:J
M)B?5B%=FU5%-<3&F98M09?U.O'1QO^E-RR54VS,%FHZ2@MCW5,$K+DY*OG)%
MBP5&MYMK45<7JCL=B["Z:[<7XKBK&)U*HIN38FB:<)C6N&?-/<YQKI'FVGRV
MW-E'DNW,I+[E"22))$F?21Q\\QLBK'(Z-[<<$Q7B8W>F*MQM7:/MTX[.U/!+
M*[:J^Q5AM;,<,*35FEU?U2LEG2Q9#FL>7K!=:6YK;:VIIF7.MEA<K6I'#&_F
MXXXVO>YW&_%RX8)L)L3:M3.-6,S'D8WXNW(C"G"(GRMC565<P2])"ASJRA>N
M5X\HK:Y+CQ,1B5BU\LW-<*NX\>!R.QX<#6BNG<;/'M8ZFS-%6_BKBV?.VE6T
MD%PHZB@J45U-51/@F:BX*K)6JUR8_44U(G"<6W,8Q@YZR14ZMZ)V)=.79%JL
MYVNW35'@U?;;501,EI9Y72L94LE[*)S7/7%5V(BX)BC<5Z5R+=Z=O:V9XX<Z
MW-RS&QL[4<4H;GI%JOF3(-%>[W>&2:M6S,'A;:**:;G:&D5KD<VVL?M1&(B8
M[%5O%V./#V0IOVZ:\(C[$QATDV+E5&,S]J)QZ$_.&8]:]3<L5>GUMTYGRO6W
MJ+N&\WRYUT#Z"EII.QG6-8L72\3<6)P(JX+C@I%NBU;JVYJVL-$)N5W;E.S%
M.&/&J\[:6WJDN>B%KRO1R7"RY'KHF7.LQC8L=/"VF9SSVN<BJKN;<Y49B8V[
M\3%R:M-4)N69B;<4Z*5YUOR?F3-&8]+JVPT#ZVFL.9Z.XW:1CF-2"DBEB<^1
M>-S55$1J[&XJ89:Y3337C.FEGF;=555&$:*C7W)^9,V^ /@[0/K^].:*&XW'
M@<QG-4D/%QR+QN;BB8[DQ496Y31M8SIIDS5NJO9PC14QO,MHU4RUKY==2<K9
M96_9:?9:>@K*5M1%!+4M1S5<E/QJOX6-S6NP<B(YO$B+BJ%M%5NJS%%4X3BK
MKIN4WIKIC&,%=9K#GO5+5*P:A9SRZ[*>5<F0U*6*T5DL<]=55U8U&232)'LC
M8U&MP1=N+45,<5PQJJHM6YHIG:FK2FFFN[<BNJ-F*="CLULU%T,S!F:DL.5)
M\Z:?YCN,MZMRVV>**MH*JIPYV&2*7!7,5&M1KFKA@WJN5$FJ:+],8U;-41AX
MT4Q79JG"-JF9Q\2]:;90SO?-2[OK+J%;F6&IJ+>RRY=RXDS:J:FHDD25TD\D
M?8H]SDQ1J?OW8HF"&%ZY13;BW1./#C,L[-NNJY-RN,.#"(;K-%O/G3_>$_K4
M_E0]+^A]SS/.?K??\[0)TFA $@    VST9OGSR=Z(G]23&GG?<U-K*>^I?3L
M\H].                       .=.C;\X6N7RJG]55IT\YZEOV?0YN4]>Y[
M7I=%G,=( U3HJO?U<TY^J,'UE^NLL4#\4=PT-&B,A8B[=B8JGDX(3(Q6CL>9
M,\ZLYVOF6\QNRZMG6"SI4LI65BR-:W"2-$>]B-PDAXE^J U.R_J'E;(]VNES
MU%FN5&L;:66W][8(.?;5O2%S.<25RM[%ZJJHFY )^I%!+9M&LJ9$I<&U]XFM
MEL<S;MD5$FD=AU.=:W[(&1T^1]9*6"*EI]18(X(&-CB8EGI,&L8G"B;6\B(!
M=ZB3-.3,@YCN>:[^V^72FIZB>CJF4T5&UGX%&Q1\,2)BJR?NEZH& :>Y6U<M
MVGEM7*UZME)2U5.M?24E12JZ95J?PJ<4CD<W%R*F"\.&& %7IU:*K4FMAS-G
MN^SW*\99JW1NRTL$='#15L2['2-C5><VMQ:[!-J8<BH!M+.&<[)DFV)<;Q(Y
M7RNYJBHH4XZFIF7='$SE5<=^Y.4@8CE/*V8\QYF@U(S[&E'5TT;X\O9=:O$V
MABE3!9)7;.*9R+MV;/(V-;(V55/DCIII(DXI6,<YC<,<7(BJB8)Y) U7T=(H
M4TXCK&NXZNNKJJ>MD5<7.FXT9B[R>%K29&QKYF*RY;IX:N^5C**GJ)FTL#Y,
M5XYI$56L1&HJXJC5(&K]>\YOM]JILD6Q\G?;,'8UKJ=CII8+:CL)7\#-J\>"
MMPY6HXF!@V?,XY3@ROE*@RQ17"E3*MSHJJ&2KHI8&<S CN-7/5/+.>K7+U5)
M&RM?[E)2Z<5%!2KC4WNJI;=3HW>Y9).=5$P_?-C5/KD0+->K5K?E#*G.6:]V
MVJI++3,:VBIJ+"=:6F8C<&<ZCD<K6ICAL5<-FW8!<-/[-;IJ-VK]RO55FR]S
M4,BPS<RV'N>*-KG24\--&KD;(BHYBHB[5W)M7$+C8-777Z\4=H;E"^T2U<G-
M]UU=+S<$:8*JN>['8B(@P&L\TV_PNKM9;XJ<3+734MMI7;T3N"1DTZ(OD.ID
M5?JDC.,W7^LSC:,KY"LDKFW#.%%3UMWJF;5IK.Z-KYGJJX[9-K&X[]J<I H-
M*EM%!<]1,W/>RAR_05++11U'[B&CM$2LQ:JH['%G-KA@N*]55$B@RJN5HZ*H
MGM&0;QFWOC++4RYBO5+1M6JYU57B26H<W"/#EX43EP L67\RW'+FA=ZNME1]
M#)>KW/3V"-'JO<L%4YC%:QR[N%&2\*IAV6TD;6AT9R4S)SLK/MU.ZIEIUCFO
M#H6/K%JG-VU"2.3BXD=V2)Q8?N=Q&(P[..6)+MF[3S3-UPGGI;51SUERK,>"
MHDI8VI"Q5<W:CG)&Z/B1<>RQ GYTRY9'YMRQI98:*&SV.\\=PS$VA8V!U334
M#7+%$]S,%5'*UZ*J[=R\@%5K/E7*E@T[J+O:;=36FZV:6DEM%911,@G9,D\;
M$1',1JKL557%5_?;T$"ESG;?#W4K).5;NJMIZ&V2WF\4[%X%=SW#&L2JB[G.
MCX7)CY55 CU,L-DRYF?3RXY8H*>VWR2]0T:-HHV4_.T;U:V9KVQM3%J(J-55
MW(Y>J!#7V"AU UTKX;HU9[+E6UT\-12HY4CFGJ%69C)$14XF82*KF[EX$1<4
MQ0"IAM-JAU]H:7+U!!;X+38I)[BE'&V!CW3R+&QKVQHC55$>QR;,?L 6Z&X9
M,N>;[WF.V9<O&?ZJ:1M-W>^EIY[;2I"BHL-*^98V[,=O8KLV\6U5<%%D>]-L
MV8=4,T4=E[QVZT44+Y+&CF+&E;#%([#"!58BN5BX\.[B RK2W(UEN>4X<SYJ
MHJ>]YBS,UU?<*VNB9.[@J%561L1Z*C&HS#8W#[&"(D:[L54N0\JZHYKL4CY&
MQ7%+!8:A[ED6&&GD6)BL<Y7*J1MF;P]7A0D9!EVVVZT9>;:+EI;=;I7U$:]]
M;E4P4DT]142)C(_G))E>F+E56X+L^KM(&?:.4>8+;D2CMN9()J:LHY9H:>&J
MVS-I4>JQ(Y<5QP1<$\A,!(M>K:+37S3J[;DAS%3TCG[D1M8G"N*KLW,$#7F;
MJFIS3G.WY_:Y76.R9IM5ALS47!LL<,CY*N5.1>*5&(UW[WZA(SBUU,6;-0+W
MGZM5'Y7R3%/;K,O[A]4UG'63ICL[%.P1=RI@O(0->34D<?1[EN-;2155[S3=
MGU-(LT;9'QU574<UQL5R*J.=%$[!6[>R)XQEVJ^6K;:LGY;T[R_34]#/F*Z4
M5%/)3PLBYQ(6HCYI.!$XG([@55=M(@>:R9.RM8-/8+39[33]^;E<*2BHJY[$
M?6OJ97\;I'SKV;G/:QR.55Y?J"!N^)BQQ,C5RO5C4:KW;7.P3#%?)4@1@
M               !SQI]\]>J7\/3_;>=F[[FV\9D_P";F/'3YVWS3=V4+@!*
M'BD,4 0\4D>$H0*$/"4(5 \4E"$#Q=Q+%""4*DH0A#QQ*'@0\4E"$#QQ,,4)
M)*%0AXNX"%Q+&4AYDJE(>90IE3OW*9*Y4[S)34II#.%4J=^Y3)5*G<9*92'F
M4*JDAYG"F5.\R52D/,E<J9_*9*I4[]QE"J5.[>IFJE(>90IE3OY254J=YG"F
M4B0F%52DD+(42DOW$PJJ4KRQ1*GDWK_^N4SAKU**>1D3'22.1K&XJYR[$1#/
M'!KS3,SA#)]+-*[IJY=$K*Q)*'(=#)A552)PR54C=O-18\O[YVYB>3@APL_G
MXMQA&GZ<,OH7_G?_ #U5^=NO@IC3/_\ F//+M6U6JW6.W4UHM%,RCMM&Q(J:
MFB3A8QC>1/MJJ[57:IY&JJ:IQG2^RVK5-NF**(PB-$*PQ6
M/'KPM<[J(J_8 H[57/N%(E2]B,<KE;PIM38!6@
M*"NKWTE514[6(YM4]6N<N],%;N^R!7@                       '.G1']
MB=0/E56><C.GG]-/LN;D=%7M.BSF.D
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MS1F3*%;'+ RQV&M?<:^*5S^>DF8C>8YMJ,5J\+D7BXG)O S8@
M         YXT^^>O5+^'I_MO.S=]S;>,R?\ -S'CI\[;YIN[*%P E#Q2&* (
M>*2/"4(%"'A*$*@>*2A"!XNXEBA!*%24(0AXXE#P(>*2A"!XXF&*$DE"H0\7
M<!"XEC*0\R52D/,H4RIW[E,E<J=YDIJ4TAG"J5._<IDJE3N,E,I#S*%520\S
MA3*G>9*I2'F2N5,_E,E4J=^XRA5*G=O4S52D/,H4RIW\I*J5.\SA3*1(3"JI
M22%D*)27[B855*5Y8HE25$C(F/EE<C(V)BYR[$1$,L<(4S$S.$+_ *7:6W35
MVZ]V5:24.0J&3"JJD[&2JD;MYJ+'E_?.W,3R<$.-G\_%N,(T_3AE[G_S_P#Y
MZ<Q5MU\%,:9\T>>7:=JM5NL=NIK1:*9E';:-B14U-$G"QC&\B?;55VJNU3R-
M54U3C.E]DM6J;=,441A$:(5ABL               (9$56.1-ZHJ)]@"W6*F
MGI+>V&H8K)$<Y>%<%V+]0"Y@                      +7<Z6>>NMLL3%=
M'#(YTKMG8HJMZP%T                        .=.B/[$Z@?*JL\Y&=//Z
M:?9<W(Z*O:=%G,=(                :PMVH]\J]>KMI=)3TB9?H,OLO,-2
MUDB5BU#IX(E:YZR*S@PE=L2-%W;3:FS$68KX\<&K%V9O31Q88MGFJV@#"-)M
M0V:I9+ILYPT*VZGK)ZF*&E>])7MCIYG1-5SD1J8N1N*HF[=MWE]^UNJ]G2HL
M7=[1M,W*%X                 ?.G^\)_6I_*AZ7]#[GF><_6^_YV@3I-"
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MHG455\DG$;&:U&HC6HB-1,$1-B(B$#T
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MEO\ WN7_ ++NU#?Y?M'P?S/_ .>L\#^DK_[VP?9=VHGXC+]H^#^9_P#SUO/
M[I*K_KM@^R[M0^(R_:1\%\S_ /GK0KDKI)KOK;!]E_:A\1E^TQ^!^9?_ #UH
M5R/TD5WUM@^R_M1/Q.7[2.[_ )E_\]:%<A](]=]98/-/[4/B<OVF/=WS'_YZ
MT"Z?](U=]98?-/[43\5E^TCNSYC_ //GE NG?2*7?66'S3^U$_%V.TQ[J^8?
M_/GE"NF_2(7?5V'S3^U$_&6.TQ[I^8?_ #YY0KIGTAE_UNQ>;?VH?&6.TQ[G
MS_8YY0KIATA%WU=B\V_M1/QMCPL>Y<_V.>4"Z6=()=]78O-O[43\=9\*.Y,]
MV.>4*Z4=(!=]58O-O[4/CK/A8]Q9[L<\H%TEU^7?56/\H_M)/Q]GPL>X<[V.
M>4*Z0:^+OJK'^4?VDGO"SX4?U_.]CGE NCFO2[ZJQ_E']I)[PL^%C_7LYV.>
M?0A71C7A?]:LGY1_:1WC:\+&?_.9SL<\^A NBNNR[ZJR?E7]I)[RM>%C_6LW
MV.>?0A71'71?]9LOY63M)/>5KPL9_P#,9OL<\^A NANN2[ZFR_E9.TD]YVO"
MQ_J^:[///H4\VB>M,<L<$M;96RS8\VWG9-N'_P!D=YVO"QG_ ,KFIZO//H1K
MH)K:N^ILWY:3M)/>EOP\S'^IYGL\\^A N@.MB[ZFS?EG]I)[UM^'F8S_ .1S
M,]7\4^A"O1\UI7_6;/\ EI.TD][6_#S,9_\ 'YCL_BGT*VQ]&7/5UO%)'GFX
M44.6XW<Y5LM\CWSRHW=&W&-J)Q?OE79U%4JO?-:9I^SCBW,E_P"0KINQ-R8B
MGCPG&?%' ZFM5JMUCMU-:+13,H[;1L2*FIHDX6,8WD3[:JNU5VJ><JJFJ<9T
MOI=JU3;IBBB,(C1"L,5@                \541%5=R;5 ET]3!5Q\]3O1\
M:JJ<28IM3ZH$T                      !)EJH()(HI7HV29>&)NWLE3#K
M@3@                       #G3HC^Q.H'RJK/.1G3S^FGV7-R.BKVG19S
M'2               .:K%E.BU]U%S[<M09*JLREE&[29=L67(JJ:EI&S42JV
M:H?W/(QZO<Y&N1<4WX;41$3J57)L44Q1IJC&9<RFB+]=4UZ*9PB%/IGDY^1N
ME-?K%'<:JXVQ,H+-:GUTJU%1#2/KJ1&P.D=M<V-S7M9CMX,$Y";US;R\3AA]
MKS2BS;V,Q,8_X^>%NS1:M%8LR9@GZ0F>(\QW^>MD[WV:DJ;AS%KHUX>:@;34
M"JYLC?W7%OV*J8XJN5%5W9C=4X1R\'#SL:Z;6U.]JQGDX>#F5&@-+9\Z,U2T
MS=67.X::T=3;7V."XOJ*:NAIZQ)I7,1SE9*QF,#.%-F*;?W2D9J9HV*^#:X<
M4Y6(KVZ.'9X,$71;R32TVC<^<\O3][L[7:EN5"RYU4LDM' L<[TBD6!SEC3@
M5C7+@W;AMWC.W)F[LSPTQ@9*W_U;4:9Q8M467HS-M3:'-F<:W-FJ,C'+-F&U
MU%TN-6M>_:YU,V#C@5&N\KQ[T3:I;%68QQIIV:>2<(5338PPJJVJN6,6[^C'
MF*\YGT8R_<K]5OKKBQ:JE=5S.5\KXZ>IDCCXW*JJY4:B-Q7:N&W::&<HBF[,
M0WLG7-5J)EMXTVX               ?.G^\)_6I_*AZ7]#[GF><_6^_YV@3I
M-" )="VWI,7;*6EUFT]TVMC;?=::ED=>;\Z-CI%F>YSGOAC:BIQ(WAQFDQ79
MY5,$<<R<E%=R:ZYX.*'4C.33;BFB.'!IKO/G;-LL]_[WW2^35<CG5-R2&HK'
M2S?NE=*C7<3NKBIO[5%'!C$-'8KK^UA,K3<+;<;34K1W6CGH:MJ(YU/4QOAD
M1KMJ*K7HBX*9Q5$Z%=5,T\$Q@I26+;/1F^?/)WHB?U),:>=]S4VLI[ZE].SR
MCTX                       YTZ-OSA:Y?*J?U56G3SGJ6_9]#FY3U[GM>
MET6<QT@#35UK<\YQU2O>5LLYGDR]:+#14SIY8Z6*K:ZIF1K^'!ZM7%4>NWB_
M<X8$BES='JIIG97YPDSJW,5#0S0)6VJJM\-*DL4LC8\&R,<]R+BY-V&S;R8
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MLN>Q,7W3_/*!=@                      %ENGLQ:_NG?^ %Z
M              0R_BW_ '*_: M.6?8MOW;_ +8%X
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M*R5JL<Y,'<?5Y"G-UTUW-JF>!=E**J+>S5#;9IMP               ^=/\
M>$_K4_E0]+^A]SS/.?K??\[0)TFA $NO+;5Y4T0Z,U)=EM,=SS;J52U-'42O
M5K'=SUD;VX*_A5R111<'X-/+2.QV8[.+5%5_,88X10[=,TV;$3AC-7G>Z3:L
M+I9T9JB\V>2WU69(+S(D5JK),7.BG?$QS^:CD9)@B8X+N(OV-[F,)QPP39N[
MO+[7TTJ3I026O4+2K3[6NDIVTMPKW):ZZ-,>)5ECED5F.W%L,M/,C5WX/^QE
MDL;=RJVKSN%=NFMR:=EQVV>C-\^>3O1$_J28T\[[FIM93WU+Z=GE'IP
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M57:O\F6=KIIIBW3Q.93K.2VST9OGSR=Z(G]23&GG?<U-K*>^I?3L\H].
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M\>6%<FR2"%RK/4-\ATG$C'=153D VD0
M              '+NIO]K?)OR8?^<N1TJ/XM7M>ASZOY,>SZ6UVG,=%$@$2$
MB) A-;R$"--Y(F(!-:!-;N"4UG($)S0)[ E.3>$)B;@)@0FMY21,;O0":F\#
MTA(!*J55*:947!48Y45/J*!09?D?):XGR.5[L7]DY55?++U0+H
M             L]RED9=K:QKW-8]7<34541=V] +P
M    ADV1O5-_"OV@+7EV226VM?*]7NXW=DY55?\ "!=@
M      %GNTDC+C:FL>YK7R.1Z(JHBIBS?U0+P
M <Z=$?V)U ^559YR,Z>?TT^RYN1T5>TZ+.8Z0
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M"4UG($)S0)[ E.3>$)B;@)@0FMY21,;O0":F\#TA(!!*SG(WQXX<;5;C]5,
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M_JJM.GG/4M^SZ'-RGKW/:]+HLYCI
M                                         !R[J;_:WR;\F'_G+D=*
MC^+5[7H<^K^3'L^EM=IS'11(!$A(B0(36\A C3>2)B 36@36[@E-9R!"<T">
MP)3DWA"8FX"8$)K>4D3&[T FIO ](2 03/6.*21$Q5C5<B?43$"FM=8ZOHV5
M+VHQSE<BM3=L7 "L                       4%77OIJZDI&L1S:E51SEW
MIAAN KP                      'CUX6N=U$5?L 4=JKGW"D2I>Q&.5RMX
M4VIL K0                      %!75[Z2JHJ=K$<VJ>K7.7>F"MW?9 KP
M                       #G3HC^Q.H'RJK/.1G3S^FGV7-R.BKVG19S'2
M                                      !\Z?[PG]:G\J'I?T/N>9YS
M];[_ )V@3I-" )=%:)](++^6\JSZ7ZJ6E;WD*=7]RN;&V=].DKED<Q\;U3B9
MQKQM<Q4>QV*ICLPYF9RE556W1.%3IY;-4TT[%>AL%MZZ"MF<V\T-!W=70JDK
M*%8;U/Q.QQX>:K%2G7#J.7A-;9SD\$^9L15E8G'TM)Z^:WSZPWNC;04;K9E*
MS,?%::!ZMYQ5DP1TTB,[%'.1K6HQJJC438JXJIOY7+;F.'AF6CFLSO9PC1#4
M!NM)MGHS?/GD[T1/ZDF-/.^YJ;64]]2^G9Y1Z<
M <Z=&WYPM<OE5/ZJK3IYSU+?L^AS<IZ]SVO2Z+.8Z0
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M]'D^IS,=5R&V>C-\^>3O1$_J28T\[[FIM93WU+Z=GE'IP
M       !SIT;?G"UR^54_JJM.GG/4M^SZ'-RGKW/:]+HLYCI
M
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MJ(TJLQ2        <Z=&WYPM<OE5/ZJK3IYSU+?L^AS<IZ]SVO2Z+.8Z0
M
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MVJ>"8TQR=')+-S5=4      !9;I[,6O[IW_@!>@
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MJKQIK]:EJYO+TT854Z):'.BYS;/1F^?/)WHB?U),:>=]S4VLI[ZE].SRCTX
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MUKLVN#8Q\K9M1<X=O#R,Y-=>
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MKMQXMJIPF&8HIFBFY3&&/$RR]=45U6ZIQPXV\30;X
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MR=')+.#5=4    %HN4TS+K;8V2.;&]7<;&JJ-=NWHF\"[@
M        (9%5(WJFQ41?M 6S+TTL]M:^:1TC^-R<3U5RX)Y*@74
M             !:+K--'<+6R.1S&22.21K55$<F+-Z)OW@7<
M            YTZ(_L3J!\JJSSD9T\_II]ES<CHJ]IT6<QT@
M                           ?.G^\)_6I_*AZ7]#[GF><_6^_YV@3I-"
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MQ:JBJ:Z_6JU-MFFW
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MYO$U6[L45,?J@4ELH>]U*E-SG.8.5W%AP[_(Q4"L
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MJJTZ><]2W[/H<W*>O<]KTNBSF.D
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M,SIGEZ.2&<&JZH    *&KN"TU;24B1HY*E5178X<.&'(!7
M         /'+PM<[J(J_8 H[77+<:1*ES$C57*WA1<=WV *T
M          !0UM>M)54=.C$<E4Y6J['#APX?L[P*X
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M.F>7HY(9P:KJ@     6FXP3276W2QQN='&KN<>B8HW'#>!=@
M          $,B*L;D3>J+A]@"VY?@FI[<V.=BQR<;EX7)@N"@70
M             !:;K!-+7VR2.-SV12.61R)BC456;_L 78
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MF72%JME)9;716>@9S=#;Z>*DI6;^&&!B1L3ZR-0YM4S,XRZ=,1$80JS%(
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M+T.5,L6K+L+D>VWT[(7R-V(^7#&1Z(N[B>KG?7(%Z
M            .7=3?[6^3?DP_P#.7(Z5'\6KVO0Y]7\F/9]+:[3F.BB0")"1
M$@0FMY"!&F\D3$ FM FMW!*:SD"$YH$]@2G)O"$Q-P$P(36\I(F-WH!-3>!Z
M0D E57\6F_@W?:4"W9<]B8ONG^>4"[                       ++=/9BU
M_=._\ +T                       AE_%O^Y7[0%IRS[%M^[?]L"\
M                  ++>?9*T?PKOML O0                       !SI
MT1_8G4#Y55GG(SIY_33[+FY'15[3HLYCI
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MK<>H!,                       %1%3!=R[P)<,$-.SFX&)''CCPM3!,5
MF                       )<D$,KXY)(VO?$N,;E3%6JO4^P!,
M                .=.B/[$Z@?*JL\Y&=//Z:?9<W(Z*O:=%G,=(
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M5/ZJK3IYSU+?L^AS<IZ]SVO2Z+.8Z0
M                                           <NZF_VM\F_)A_YRY'
M2H_BU>UZ'/J_DQ[/I;7:<QT42 1(2(D"$UO(0(TWDB8@$UH$UNX)36<@0G-
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M43-7K2T\WF(N813HAH\Z#GML]&;Y\\G>B)_4DQIYWW-3:RGOJ7T[/*/3@
M                   #G3HV_.%KE\JI_55:=/.>I;]GT.;E/7N>UZ719S'2
M
M             #EW4W^UODWY,/\ SER.E1_%J]KT.?5_)CV?2VNTYCHHD B0
MD1($)K>0@1IO)$Q )K0)K=P2FLY A.:!/8$IR;PA,3<!,"$UO*2)C=Z 34W@
M>D) ()6<[$^/'#C:K<=^&*8 4]MHN]](REX^<X55>/#A\LN.[%0*L
M               !155O[IK*6KYSA[F55X.''BQ\G%, *T
M        !XYO$U6[L45,?J@4ELH>]U*E-SG.8.5W%AP[_(Q4"L
M             459;^ZZFDJ.<X.Y7*_AX<>+'AY<4PW 5H
M         !SIT1_8G4#Y55GG(SIY_33[+FY'15[3HLYCI
M                         ^=/]X3^M3^5#TOZ'W/,\Y^M]_SM G2:$ 2
M   #;/1F^?/)WHB?U),:>=]S4VLI[ZE].SRCTX
M YTZ-OSA:Y?*J?U56G3SGJ6_9]#FY3U[GM>ET6<QT@
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M>O<]KTNBSF.D
M                         '+NIO\ :WR;\F'_ )RY'2H_BU>UZ'/J_DQ[
M/I;7:<QT42 1(2(D"$UO(0(TWDB8@$UH$UNX)36<@0G- GL"4Y-X0F)N F!"
M:WE)$QN] )J;P/2$@$JH174\K6IBY6.1$3E544"BL,,L%MCCF8L<B*[%KDP7
M:Y0+D                       M-Q@FDNMNECC<Z.-7<X]$Q1N.&\"[
M                    (9$58W(F]47#[ %MR_!-3VYL<[%CDXW+PN3!<% N
M@                      "TW6":6OMDD<;GLBD<LCD3%&HJLW_ & +L
M                     <Z=$?V)U ^559YR,Z>?TT^RYN1T5>TZ+.8Z0
M                                    /G3_ 'A/ZU/Y4/2_H?<\SSGZ
MWW_.T"=)H0!(    -L]&;Y\\G>B)_4DQIYWW-3:RGOJ7T[/*/3@
M             #G3HV_.%KE\JI_55:=/.>I;]GT.;E/7N>UZ719S'2
M
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M+.8Z0
M                  <NZF_VM\F_)A_YRY'2H_BU>UZ'/J_DQ[/I;7:<QT42
M 1(2(D"$UO(0(TWDB8@$UH$UNX)36<@0G- GL"4Y-X0F)N F!":WE)$QN] )
MJ;P/2$@$JJ_BTW\&[[2@6[+GL3%]T_SR@78                      !9;
MI[,6O[IW_@!>@                      $,OXM_P!ROV@+3EGV+;]V_P"V
M!>                       %EO/LE:/X5WVV 7H
M     YTZ(_L3J!\JJSSD9T\_II]ES<CHJ]IT6<QT@
M                    ?.G^\)_6I_*AZ7]#[GF><_6^_P"=H$Z30@"0
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M=&SL6R8-[-&[-J<N)1F+=,1373HJ7Y>Y5,U45::6VC3;@
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MGG/UOO\ G:!.DT( D    &V>C-\^>3O1$_J28T\[[FIM93WU+Z=GE'IP
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M+5=V2HS'E)S4T[FC#1PL<M%6^KQT\#I@Y;J
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M=7E>Q-V].QW>1SF3FS.,>K]3[)\E^=4YVG9JX+D?F\,>>&WSG/2@
M        !:;C/-'=;=%'(YL<BNYQB+@CL,-X%V
M 0R*J1N5-Z(N'V +;E^>:HMS9)WK))QN3B<N*X(!=
M    %INL\T5?;(XY',9+(Y)&HN".1%9O^R!=@
M#G3HC^Q.H'RJK/.1G3S^FGV7-R.BKVG19S'2
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M[.Q(Y:NLEWNX45W"QO[EG$N&U>4HO7MY.C"(T0V+-G=QIQF=,LZ-=>
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MV0*T                      !0UM M754=0CT:E*Y7*W#'BQX?L;@*X
M                     YTZ(_L3J!\JJSSD9T\_II]ES<CHJ]IT6<QT@
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M\SSGZWW_ #M G2:$ 2    #;/1F^?/)WHB?U),:>=]S4VLI[ZE].SRCTX
M                    YTZ-OSA:Y?*J?U56G3SGJ6_9]#FY3U[GM>ET6<QT
M@
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M35;FIMDA^T]-R.W=1/#9RQ%JO")X/J??ODV?KSEC:KIPF.#'BGPQYVRS2=P
M              HJJX=S5E+2<WQ=TJJ<?%APX>1@N(%:
M       \<[A:KM^"*N'U *2V5W?&E2IYOF\7*WAQXMWDX(!6
M           **LN'<E324_-\?=3E9Q<6'#AP\F"X[P*T
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MM-(]SHX:RCD<QR1-5>%B.C[)_#O7>!L(@
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M#DX>?JY=JHU%V\#<5PQVJJJNS'!*,Q>WD\$81&A=8L[N.&<9G2V*:S9
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M=3'!%W@190RI3VK5NS9:IW<\S)]DDK*^I7%5FNEQ7AFD<J[<7-E;PX[<&IU
M,GOC^ZM>\KTT/9/H+-65-3AN;'.LD3<?_,!M4@
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M&$1HA6&*P                2WSPQR,BDD:V23\6Q5P5V'4 F
M             "JB)BNY-X$N&>&H9SD#TDCQPXFKBF* 3
M        $N2>&)\<<DC6/E7"-JK@KE3J?9 F
M'.G1']B=0/E56><C.GG]-/LN;D=%7M.BSF.D
M               #YT_WA/ZU/Y4/2_H?<\SSGZWW_.T"=)H0!(    -L]&;Y
M\\G>B)_4DQIYWW-3:RGOJ7T[/*/3@                      #G3HV_.%K
ME\JI_55:=/.>I;]GT.;E/7N>UZ719S'2 -7Z#1NH<EU=AEQ2HL=VK[=,U<,4
M?'(CUQPW^7)D73).G\^7;+F*@NU5'6U^8ZVKK*NHC:Y&\-6Q&\&#M^"\2_7
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M(C1"L,5@                 66Z>S%K^Z=_X 7H
M  !#+^+?]ROV@+3EGV+;]V_[8%X                       66\^R5H_A7
M?;8!>@                       #G3HC^Q.H'RJK/.1G3S^FGV7-R.BKVG
M19S'2                                       !\Z?[PG]:G\J'I?T
M/N>9YS];[_G:!.DT( D    &V>C-\^>3O1$_J28T\[[FIM93WU+Z=GE'IP
M                    !SIT;?G"UR^54_JJM.GG/4M^SZ'-RGKW/:]+HLYC
MI %LMN7[7:*ZYW&WPK#47B9M37X.<K'3,8C.)&JN#55$[+#>NT"Y@
M                       %MOEBMV8J!;7=F.FM[WQR34Z/<QLJ1.1R,DX5
M3B8JHG$U=B\H%Q8QL;6L8U&L:B-:UJ8(B)L1$1 /0
M                 '+NIO\ :WR;\F'_ )RY'2H_BU>UZ'/J_DQ[/I;7:<QT
M42 1(2(D"$UO(0(TWDB8@$UH$UNX)36<@0G- GL"4Y-X0F)N F!":WE)$QN]
M )J;P/2$@'CFH]JM<F+7)@J>0H$$$$--&D,#$9&F.#4W;0)@
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M0YN4]>Y[7I=%G,=(
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M@%T                       6FZSS15]LCCD<QDLCDD:BX(Y$5F_[(%V
M                      .=.B/[$Z@?*JL\Y&=//Z:?9<W(Z*O:=%G,=(
M                                     'SI_O"?UJ?RH>E_0^YYGG/U
MOO\ G:!.DT( D    &V>C-\^>3O1$_J28T\[[FIM93WU+Z=GE'IP
M              !SIT;?G"UR^54_JJM.GG/4M^SZ'-RGKW/:]+HLYCI
M
M        !R[J;_:WR;\F'_G+D=*C^+5[7H<^K^3'L^EM=IS'11(!$A(B0(36
M\A C3>2)B 36@36[@E-9R!"<T">P)3DWA"8FX"8$)K>4D3&[T FIO ](2 02
MLYR)\:+AQM5N/U4P IK91+;Z-E*YZ/5JJO$B8>67$"L
M      4-7;UJ:VDJTD1J4RJJMPQXL<.4"N                       >.3
MB:YO514^R!1VNA6W4B4SGI(J.5W$B8;_ +(%:
MH:V@6KJJ.H1Z-2E<KE;ACQ8\/V-P%<                        <Z=$?V
M)U ^559YR,Z>?TT^RYN1T5>TZ+.8Z0
M         /G3_>$_K4_E0]+^A]SS/.?K??\ .T"=)H0!(    -L]&;Y\\G>B
M)_4DQIYWW-3:RGOJ7T[/*/3@                      #G3HV_.%KE\JI_
M55:=/.>I;]GT.;E/7N>UZ719S'2
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MM>ET6<QT@
M                      Y=U-_M;Y-^3#_SER.E1_%J]KT.?5_)CV?2VNTY
MCHHD B0D1($)K>0@1IO)$Q )K0)K=P2FLY A.:!/8$IR;PA,3<!,"$UO*2)C
M=Z 34W@>D) )52BNIYFM3%RL<B(F]5P4"AL$4L-LCCF8Z.1%?BUZ*U=KEY%
MN8                      "T7*&9]UMLC(W.C8KN-[456MW;U3<!=P
M                  $,B*L;T3:JHOV@+9EZ&6"VM9-&Z-_&Y>%Z*U<%\A0+
MJ                       M%UAFDN%K?'&Y[(Y'+(YJ*J-3%F]4W;@+N
M                      <Z=$?V)U ^559YR,Z>?TT^RYN1T5>TZ+.8Z0
M                                     /G3_>$_K4_E0]+^A]SS/.?K
M??\ .T"=)H0!(    -L]&;Y\\G>B)_4DQIYWW-3:RGOJ7T[/*/3@
M              #G3HV_.%KE\JI_55:=/.>I;]GT.;E/7N>UZ719S'2
M
M        #EW4W^UODWY,/_.7(Z5'\6KVO0Y]7\F/9]+:[3F.BB0")"1$@0FM
MY"!&F\D3$ FM FMW!*:SD"$YH$]@2G)O"$Q-P$P(36\I(F-WH!-3>!Z0D \<
MY&M5SEP:B8JJ]1 (89HJB-)87I)&NYS5Q38!&
MEOGACD9%)(ULDGXMBK@KL.H!,                       %5$3%=R;P)<,
M\-0SG('I)'CAQ-7%,4 F                       )<D\,3XXY)&L?*N$;
M57!7*G4^R!,                        .=.B/[$Z@?*JL\Y&=//Z:?9<W
M(Z*O:=%G,=(                                       'SI_O"?UJ?
MRH>E_0^YYGG/UOO^=H$Z30@"0    ;9Z,WSYY.]$3^I)C3SON:FUE/?4OIV>
M4>G                       '.G1M^<+7+Y53^JJTZ><]2W[/H<W*>O<]K
MTNBSF.D 4=RN]JLU/W7>*ZGM]+CAS]7,R"/'J<4BM0RBF9T0QFJ(TO+9>+1>
MZ=:NS5]-<:5%X5GHYHZB/BZG%&KDQ%5,TZ8(JB=$I%5F7+E%.^EK;O14]3&N
M$D,U3%'(U53':USD5-BDQ15/$B:Z8XTKPORG[?6[]+@^_&[JY)-Y3RPNT,T-
M1#'44\C98)6I)%+&J.8]CDQ1S538J*FU%0P9HE5&HKG*B-1,55=B(B 4U#<[
M;<V/DMM9!61QNX)'4\K)4:[?@JL5<%)FF8THB8G0]FN%!3/YJHJH8I,,>"21
MK78+Y"J@PDQA"RZ6R1[8XZV!\CU1K6ME8JJJ[$1$11LR;4(ZVOH+;#W3<:J&
MDI\4;SU1(V)G$NY.)ZHF*B(F=!,Q&E'3U-/60,J:29D]-*G%'-$Y'L<G51S5
M5%$Q@1.*36W6V6U8FW&M@I'3+PPI42LB5Z]1O&J8[^013,Z":HC2JR$@
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M+[I_GE NP                      "RW3V8M?W3O\ P O0
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ML8KG4W&[:K(EX4;CU5*LU&U13<XZM*W+3LUU6^*G0WR<]T
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M6O:K')BUR*BIY"@2Z>GAI8DAIV<$3<51J8KOV\H$T
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M*^5[\,'/Y]%<N&")QHB)U)S=<S;HB=.GR<2,K1$7*YC1H\O&Z4.6Z8
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M8K'I"0"74.5M/*YJX.1CE1?)1 *&Q3S5-MCEG>KY%5R*Y=^QRH!<@
M               %JN%3/%=+?#&]6Q2J[G&IN7##>!=0
M      $,BJD;E3>B+A]@"W6"HFJ;>V6=ZR2*]R<2[\$ N8
M        "U72IGAK[;%$]6QS2.21J;G(BMW_ &0+J
M     <Z=$?V)U ^559YR,Z>?TT^RYN1T5>TZ+.8Z0
M                    /G3_ 'A/ZU/Y4/2_H?<\SSGZWW_.T"=)H0!(
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M[ERJY5C5I;%NW31&%.A?RM8
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M1HN"O:K47ZJ8 4UKHW4%&RF>Y'N:KE5R;MJX@5@
M "@JZ!]374E6UZ-;3*JN:N]<<-P%>                       \>G$US>J
MBI]D"CM5"^WTB4SWH]R.5W$FQ-H%:                       H*Z@?5U5
M%4->C6TKU<YJ[UQ5N[[ %>                        <Z=$?V)U ^559Y
MR,Z>?TT^RYN1T5>TZ+.8Z0
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MB*JK@B;550)/=M&C6/6HBX)'I%&[C;@Z1VYB+CM<O4 G@
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M<*KCN7#?L J@                      %'4W!M-5TU(L:N6I541V.'#AY
M%8                       \<O"U7=1%7[ %+;:Y+C3)4M8L:*JMX57'=]
M@"K                       4=77I25-)3JQ7+5.5J.QPX<,/L[P*P
M                    YTZ(_L3J!\JJSSD9T\_II]ES<CHJ]IT6<QT@
M                                   ?.G^\)_6I_*AZ7]#[GF><_6^_
MYV@3I-" )    !MGHS?/GD[T1/ZDF-/.^YJ;64]]2^G9Y1Z<
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M9T\_II]ES<CHJ]IT6<QT@
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M1 SO+U#):[!:K9-ASU%1T]-)ANXH8FL7_"A N0
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M@                      "JB)BNQ$ @BFBG9QPR-D9NXF*CDQ3R4 C
M                   0/FAC<QDDC6/D7"-KE1%<OD(N_>!&
M            <Z=$?V)U ^559YR,Z>?TT^RYN1T5>TZ+.8Z0
M                           /G3_>$_K4_E0]+^A]SS/.?K??\[0)TFA
M$@    VST9OGSR=Z(G]23&GG?<U-K*>^I?3L\H].
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MRZC9]HZ-B))D[)=1W172[V55Z:F#(6\BI BXO\E5:I(V>0
M                              #EW4W^UODWY,/_ #ER.E1_%J]KT.?5
M_)CV?2VNTYCHHD B0D1($)K>0@1IO)$Q )K0)K=P2FLY A.:!/8$IR;PA,3<
M!,"$UO*2)C=Z 34W@>D) )55_%IOX-WVE MV7/8F+[I_GE NP
M           "RW3V8M?W3O\ P O0                      "&7\6_[E?M
M 6G+/L6W[M_VP+P                       LMY]DK1_"N^VP"]
M                 '.G1']B=0/E56><C.GG]-/LN;D=%7M.BSF.D
M                                #YT_WA/ZU/Y4/2_H?<\SSGZWW_.T
M"=)H0!(    -L]&;Y\\G>B)_4DQIYWW-3:RGOJ7T[/*/3@
M        #G3HV_.%KE\JI_55:=/.>I;]GT.;E/7N>UZ719S'2 ),5'203SU,
M,$<=34JU:F9C&M?*K$X6J]R)B[!-B8@3@                       "32T
M=)0P-IJ&".FIFJY6PPL;&Q%<JN<J-:B)M5550)P
M                       !R[J;_:WR;\F'_G+D=*C^+5[7H<^K^3'L^EM=
MIS'11(!$A(B0(36\A C3>2)B 36@36[@E-9R!"<T">P)3DWA"8FX"8$)K>4D
M3&[T FIO ](2 >.:U[58Y,6N145/(4"73T\-+$D-.S@B;BJ-3%=^WE F@
M                   ),E+!-+'/(Q'2PXK&[;LQ G
M     /%1%147<NQ0)=/304D?,T[$9&BJO"F*[5^J!-
M     29:6">2*65B.DA7BB=M[%5PZP$X                        YTZ(
M_L3J!\JJSSD9T\_II]ES<CHJ]IT6<QT@
M           ?.G^\)_6I_*AZ7]#[GF><_6^_YV@3I-" )    !MGHS?/GD[T
M1/ZDF-/.^YJ;64]]2^G9Y1Z<                       <Z=&WYPM<OE5/
MZJK3IYSU+?L^AS<IZ]SVO2Z+.8Z0
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MM1OL>WYVC3?:(
M
M
M
G                                                 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2227887d8-tbl_oncolog4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d8-tbl_oncolog4c.jpg
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M%!04%!04%!3_P  1" 1T!VP# 1$  A$! Q$!_\0 \  !  $% 0$
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M#_S?,T!%Y@M*\RJR<ZLR:@      &>RONJ_LF?Y31?G=E.9Z$UL@
M                Q%B_W[UR\RD9<Q
M
M,1:_=.Z_9Q_PC*1ES$                           KBWN^Q=]0)4!
M                         #,YH]TH/S=:_P"SJ<UX^;KGY6S)S]4?(PQL
M:P
M                           !LO\ =]_7+_E9R?[_ /+\[L_+_P WS.<H
MO,%I7F563G5F34       SV5]U7]DS_*:+\[LIS/0FMD
M        &(L7^_>N7F4C+F(
M                                                    !B+7[IW7
M[./^$92,N8@                          %<6]WV+OJ!*@(
M                  9G-'NE!^;K7_9U.:\?-US\K9DY^J/D88V-8
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M^(M?):L\T+/B>'ICQQ:.>?4TP6"L
M   ;+_=]_7+_ )6<G^__ "_.[/R_\WS.<HO,%I7F563G5F34       SV5]U
M7]DS_*:+\[LIS/0FMD                        &(L7^_>N7F4C+F(
M
M                          !B+7[IW7[./^$92,N8@
M           %<6]WV+OJ!*@(                            9G-'NE!^
M;K7_ &=3FO'S=<_*V9.?JCY&&-C6
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MK\0QUB(M$:2O?" _8KIQ_HZ+^ST,>#_O7Z_E9\;_ &:]7R.8"X48
M                          #9?[OOZY?\K.3_ '_Y?G=GY?\ F^9SE%Y@
MM*\RJR<ZLR:@      &>RONJ_LF?Y31?G=E.9Z$UL@
M      Q%B_W[UR\RD9<Q
M                                                  ,1:_=.Z_9Q
M_P (RD9<Q                           *XM[OL7?4"5 0
M                 S.:/=*#\W6O^SJ<UX^;KGY6S)S]4?(PQL:P
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MR6B>27/Q_+BK,<L:K3P@/V*Z<?Z.B_L]#+@_[U^OY4<;_9KU?(Y@+A1@
M                              -E_N^_KE_RLY/]_P#E^=V?E_YOF<Y1
M>8+2O,JLG.K,FH      !GLK[JO[)G^4T7YW93F>A-;(
M        ,18O]^]<O,I&7,0
M                                                    #$6OW3NO
MV<?\(RD9<Q                           *XM[OL7?4"5 0
M                  S.:/=*#\W6O^SJ<UX^;KGY6S)S]4?(PQL:P
M                           %4<DD3D?$]6/3<YJJB^2@3$S!)))*Y7RO
M5[UWN<JJODJ"9F5(0     !)%43P8\Q*^+B\UP.5N/CX>.1,:LHM,<R/?M7>
M2A)S\_-+!SK^87:L7$O!OQW;B-$ZSIHC)8@
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M7YW93F>A-;(                        ,18O]^]<O,I&7,0
M
M                   #$6OW3NOV<?\ ",I&7,0
M     "N+>[[%WU E0$                            ,SFCW2@_-UK_LZ
MG->/FZY^5LR<_5'R,,;&L                          "_A]Q*SUU2_R=
M28S]:/VZ&<?5G]NE8&3                           "6F_&8?LV_502F
M$00                            V7^[[^N7_ "LY/]_^7YW9^7_F^9SE
M%Y@M*\RJR<ZLR:@      &>RONJ_LF?Y31?G=E.9Z$UL@
M         Q%B_P!^]<O,I&7,0
M                                                      #$6OW3
MNOV<?\(RD9<Q                           *XM[OL7?4"5 0
M                    S.:/=*#\W6O^SJ<UX^;KGY6S)S]4?(PQL:P
M                     +^'W$K/75+_ "=28S]:/VZ&<?5G]NE8&3
M                     "6F_&8?LV_502F$00
M      V7^[[^N7_*SD_W_P"7YW9^7_F^9SE%Y@M*\RJR<ZLR:@      &>RO
MNJ_LF?Y31?G=E.9Z$UL@                        Q%B_W[UR\RD9<Q
M
M                            ,1:_=.Z_9Q_PC*1ES$
M             KBWN^Q=]0)4!                            #,YH]TH
M/S=:_P"SJ<UX^;KGY6S)S]4?(PQL:P                          +^'W
M$K/75+_)U)C/UH_;H9Q]6?VZ5@9,                           ):;\9
MA^S;]5!*81!                            #9?[OOZY?\K.3_?\ Y?G=
MGY?^;YG.47F"TKS*K)SJS)J       9[*^ZK^R9_E-%^=V4YGH36R
M                 #$6+_?O7+S*1ES$
M
M  Q%K]T[K]G'_",I&7,0                          "N+>[[%WU E0$
M                           ,SFCW2@_-UK_LZG->/FZY^5LR<_5'R,,;
M&L                          "_A]Q*SUU2_R=28S]:/VZ&<?5G]NE8&3
M                           "6F_&8?LV_502F$00
M            V7^[[^N7_*SD_P!_^7YW9^7_ )OF<Y1>8+2O,JLG.K,FH
M   !GLK[JO[)G^4T7YW93F>A-;(                        ,18O]^]<O
M,I&7,0
M                                   #$6OW3NOV<?\ ",I&7,0
M                     "N+>[[%WU E0$
M  ,SFCW2@_-UK_LZG->/FZY^5LR<_5'R,,;&L
M   "_A]Q*SUU2_R=28S]:/VZ&<?5G]NE8&3
M  "6F_&8?LV_502F$00                            V7^[[^N7_ "LY
M/]_^7YW9^7_F^9SE%Y@M*\RJR<ZLR:@      &>RONJ_LF?Y31?G=E.9Z$UL
M@                        Q%B_P!^]<O,I&7,0
M
M          #$6OW3NOV<?\(RD9<Q                           *XM[O
ML7?4"5 0                            S.:/=*#\W6O^SJ<UX^;KGY6S
M)S]4?(PQL:P                          +^'W$K/75+_ "=28S]:/VZ&
M<?5G]NE8&3                           "6F_&8?LV_502F$00
M                      V7^[[^N7_*SD_W_P"7YW9^7_F^9SE%Y@M*\RJR
M<ZLR:@      &>RONJ_LF?Y31?G=E.9Z$UL@
MQ%B_W[UR\RD9<Q
M                                            ,1:_=.Z_9Q_PC*1E
MS$                           KBWN^Q=]0)4!
M         #,YH]TH/S=:_P"SJ<UX^;KGY6S)S]4?(PQL:P
M            +^'W$K/75+_)U)C/UH_;H9Q]6?VZ5@9,
M           ):;\9A^S;]5!*81!                            #9?[O
MOZY?\K.3_?\ Y?G=GY?^;YG.47F"TKS*K)SJS)J       9[*^ZK^R9_E-%^
M=V4YGH36R                        #$6+_?O7+S*1ES$
M
M                  Q%K]T[K]G'_",I&7,0
M  "N+>[[%WU E0$                            ,SFCW2@_-UK_LZG->
M/FZY^5LR<_5'R,,;&L                          "_A]Q*SUU2_R=28S
M]:/VZ&<?5G]NE8&3                           "6F_&8?LV_502F$00
M                            V7^[[^N7_*SD_P!_^7YW9^7_ )OF<Y1>
M8+2O,JLG.K,FH      !GLK[JO[)G^4T7YW93F>A-;(
M       ,18O]^]<O,I&7,0
M                                                   #$6OW3NOV
M<?\ ",I&7,0                          "N+>[[%WU E0$
M                  ,SFCW2@_-UK_LZG->/FZY^5LR<_5'R,,;&L
M                   "_A]Q*SUU2_R=28S]:/VZ&<?5G]NE8&3
M                  "6F_&8?LV_502F$00
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M"!,1J^<+N+AP7BQPX>7'H 'L?&Y6/:K7IL5KDP5/H*"8T? @
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ML7$NU6(]N+4<J\.'BKCOX76F::>1IXO3)AB_EY'*Y<J(
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MLZG&    "_A]Q*SUU2_R=28S]:/VZ&<?5G]NE8&3     '4O@;_]:_\ I?\
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M+BB+BAU\+N]G&[S.+B]_M)WN=K\ZG(    #9?[OOZY?\K.3_ '_Y?G=GY?\
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M'VE)KTJW!D[.\6=%Z@Z6Y5UHO<.>\H9RH((JV*&.Y1S*CU;S2(QKT;Q-<Q_
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MRR4;96+.U$DFQQ8B\2;TY#+'6>\S.AEF.ZQU.;2V4@
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MR<T-2'<X     ;+_ '??UR_Y6<G^_P#R_.[/R_\ -\SG*+S!:5YE5DYU9DU
M      ,]E?=5_9,_RFB_.[*<ST)K9                 !M+22LT=M_.W#4
MF.JDNE'4LGMT4+9)*>5C6HO#(QB8+@Y-SEP7';L./B(S3R4YG?PTX8Y;\^JC
M6[55NJ.8Z>IH(9:;+]LB=#;H)\$D<Z14=)*YK5<C5?@U,$7<U!PO#]E7EYY8
M\7Q':VY.:&L#L<0   8BQ?[]ZY>92,N8@
M                         ="VG430W->3Z&PZA6!;7?*-D4<UVME+&V25
MT#4:DB30ISG3HG3L<U6X_0PJ[8<U+S-)UA<5SX,E8B\:2BS9JUIW8=.*W3;2
MJCK%IKFY_7MQK<6IPRJWG%3B7B<YS6HSS+41O14G'P^2V2+Y/(QR\3CKCFF/
MRN?RS5(                                 &(M?NG=?LX_X1E(RYB
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MFMD                        &(L7^_>N7F4C+F(
M
M           !B+7[IW7[./\ A&4C+F(                          !7%
MO=]B[Z@2H"                            &9S1[I0?FZU_V=3FO'S=<_
M*V9.?JCY&&-C6                          !?P^XE9ZZI?Y.I,9^M'[=
M#./JS^W2L#)@                          !+3?C,/V;?JH)3"((
M                       ;+_=]_7+_ )6<G^__ "_.[/R_\WS.<HO,%I7F
M563G5F34       SV5]U7]DS_*:+\[LIS/0FMD
M  &(L7^_>N7F4C+F(
M                                              !B+7[IW7[./^$9
M2,N8@                          %<6]WV+OJ!*@(
M            9G-'NE!^;K7_ &=3FO'S=<_*V9.?JCY&&-C6
M              !?P^XE9ZZI?Y.I,9^M'[=#./JS^W2L#)@
M             !+3?C,/V;?JH)3"((                            ;+
M_=]_7+_E9R?[_P#+\[L_+_S?,YRB\P6E>959.=69-0      #/97W5?V3/\
M*:+\[LIS/0FMD                        &(L7^_>N7F4C+F(
M
M                     !B+7[IW7[./^$92,N8@
M      %<6]WV+OJ!*@(                            9G-'NE!^;K7_9
MU.:\?-US\K9DY^J/D88V-8                          %_#[B5GKJE_D
MZDQGZT?MT,X^K/[=*P,F                           $M-^,P_9M^J@E
M,(@@                           !LO\ =]_7+_E9R?[_ /+\[L_+_P W
MS.<HO,%I7F563G5F34       SV5]U7]DS_*:+\[LIS/0FMD
M            &(L7^_>N7F4C+F(
M                                                        !B+7
M[IW7[./^$92,N8@                          %<6]WV+OJ!*@(
M                      9G-'NE!^;K7_9U.:\?-US\K9DY^J/D88V-8
M                       %_#[B5GKJE_DZDQGZT?MT,X^K/[=*P,F
M                      $M-^,P_9M^J@E,(@@
M      !LO]WW]<O^5G)_O_R_.[/R_P#-\SG*+S!:5YE5DYU9DU       ,]E
M?=5_9,_RFB_.[*<ST)K9                        !B+%_OWKEYE(RYB
M
M                             8BU^Z=U^SC_ (1E(RYB
M               5Q;W?8N^H$J @                           !F<T>
MZ4'YNM?]G4YKQ\W7/RMF3GZH^1AC8U@                          7\/
MN)6>NJ7^3J3&?K1^W0SCZL_MTK R8                           2TWX
MS#]FWZJ"4PB"                            &R_W??UR_P"5G)_O_P O
MSNS\O_-\SG*+S!:5YE5DYU9DU       ,]E?=5_9,_RFB_.[*<ST)K9
M                   !B+%_OWKEYE(RYB
M
M    8BU^Z=U^SC_A&4C+F(                          !7%O=]B[Z@2H
M"                            &9S1[I0?FZU_P!G4YKQ\W7/RMF3GZH^
M1AC8U@                          7\/N)6>NJ7^3J3&?K1^W0SCZL_MT
MK R8                           2TWXS#]FWZJ"4PB"
M               &R_W??UR_Y6<G^_\ R_.[/R_\WS.<HO,%I7F563G5F34
M      SV5]U7]DS_ "FB_.[*<ST)K9                        !B+%_O
MWKEYE(RYB
M                                       8BU^Z=U^SC_A&4C+F(
M                       !7%O=]B[Z@2H"
M    &9S1[I0?FZU_V=3FO'S=<_*V9.?JCY&&-C6
M     !?P^XE9ZZI?Y.I,9^M'[=#./JS^W2L#)@
M    !+3?C,/V;?JH)3"((                            ;+_ '??UR_Y
M6<G^_P#R_.[/R_\ -\SG*+S!:5YE5DYU9DU       ,]E?=5_9,_RFB_.[*<
MST)K9                        !B+%_OWKEYE(RYB
M
M              8BU^Z=U^SC_A&4C+F(                          !7
M%O=]B[Z@2H"                            &9S1[I0?FZU_V=3FO'S=<
M_*V9.?JCY&&-C6                          !?P^XE9ZZI?Y.I,9^M'[
M=#./JS^W2L#)@                          !+3?C,/V;?JH)3"((
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M7-*.QJ[V6[RAW_+L.X8MI\ES2CL:N]EN\H=_R[#N&+:?)<TH[&KO9;O*'?\
M+L.X8MI\ES2CL:N]EN\H=_R[#N&+:?)<TH[&KO9;O*'?\NP[ABVGR7-*.QJ[
MV6[RAW_+L.X8MHWP?--,S(VYUU%/%/P,IT935#HHTCIV-BC1&[=S6HAC3C,E
M8TU9WX+%:==#Y+FE'8U=[+=Y1EW_ "[&'<,6T^2YI1V-7>RW>4._Y=AW#%M/
MDN:4=C5WLMWE#O\ EV'<,6T^2YI1V-7>RW>4._Y=AW#%M/DN:4=C5WLMWE#O
M^78=PQ;3Y+FE'8U=[+=Y0[_EV'<,6T^2YI1V-7>RW>4._P"78=PQ;3Y+FE'8
MU=[+=Y0[_EV'<,6T^2YI1V-7>RW>4._Y=AW#%M/DN:4=C5WLMWE#O^78=PQ;
M3Y+FE'8U=[+=Y0[_ )=AW#%M/DN:4=C5WLMWE#O^78=PQ;3Y+FE'8U=[+=Y0
M[_EV'<,6T^2YI1V-7>RW>4._Y=AW#%M/DN:4=C5WLMWE#O\ EV'<,6T^2YI1
MV-7>RW>4._Y=AW#%M/DN:4=C5WLMWE#O^78=PQ;3Y+FE'8U=[+=Y0[_EV'<,
M6T^2YI1V-7>RW>4._P"78=PQ;3Y+FE'8U=[+=Y0[_EV'<,6T^2YI1V-7>RW>
M4._Y=AW#%M/DN:4=C5WLMWE#O^78=PQ;3Y+FE'8U=[+=Y0[_ )=AW#%M/DN:
M4=C5WLMWE#O^78=PQ;5/R>-,HI%RZVAG6CJ.&LDF6=RU'.1\3&HC^1J(J[,.
M53'ON7775GW+%NZ:*ODN:4=C5WLMWE&7?\NQAW#%M/DN:4=C5WLMWE#O^78=
MPQ;3Y+FE'8U=[+=Y0[_EV'<,6T^2YI1V-7>RW>4._P"78=PQ;3Y+FE'8U=[+
M=Y0[_EV'<,6T^2YI1V-7>RW>4._Y=AW#%M/DN:4=C5WLMWE#O^78=PQ;3Y+F
ME'8U=[+=Y0[_ )=AW#%M/DN:4=C5WLMWE#O^78=PQ;3Y+FE'8U=[+=Y0[_EV
M'<,6T^2YI1V-7>RW>4._Y=AW#%M/DN:4=C5WLMWE#O\ EV'<,6T^2YI1V-7>
MRW>4._Y=AW#%M/DN:4=C5WLMWE#O^78=PQ;3Y+FE'8U=[+=Y0[_EV'<,6T^2
MYI1V-7>RW>4._P"78=PQ;3Y+FE'8U=[+=Y0[_EV'<,6T^2YI1V-7>RW>4._Y
M=AW#%M/DN:4=C5WLMWE#O^78=PQ;3Y+FE'8U=[+=Y0[_ )=AW#%M/DN:4=C5
MWLMWE#O^78=PQ;3Y+FE'8U=[+=Y0[_EV'<,6T^2YI1V-7>RW>4._Y=AW#%M/
MDN:4=C5WLMWE#O\ EV'<,6U1+X-VEMHC6Y0453-+3X.9'45+I(E7'#IFX)CO
M(MQN68TU95X'%$ZZ*F>#'I55,;4NI*QCID2161U3FL:K]N#4PV(F.PF..RHG
M@<4R^_)<TH[&KO9;O*'?\NQ'<,6T^2YI1V-7>RW>4._Y=AW#%M/DN:4=C5WL
MMWE#O^78=PQ;3Y+FE'8U=[+=Y0[_ )=AW#%M/DN:4=C5WLMWE#O^78=PQ;3Y
M+FE'8U=[+=Y0[_EV'<,6T^2YI1V-7>RW>4._Y=AW#%M/DN:4=C5WLMWE#O\
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MD^_/S-NGF7J
M                                         -0:.?M1U>]?T'];/<S^
M%P_=]3P&3\7F\\-VIN.9M?0*R1]"%;=X$B$"IN\D2(!(T"5I"5:;R1,T(2-W
MA*=@$@0D;N D;N"%:$B1.0"1N\"1-X'TA(  M*RA2KDII%?P=;R)*B88XX*B
MX?2 NP                            +6W426^F2G1_.(BJ[B5,-X%T
M                         "U=1(ZX,K^/:R/FN##9O5<<?H@70
M                    (*VF2LI9*97<"2(B<2)CA@J*!)#'S44<2+CP-1N/
M1X4P K                           !P%^^I^L7X$]%^4ZGG_ ,UUN:"U
M5L 2       [7\!#W)SMZXM_H*@HO$^>O6N?#>:W4Z]*5<
M          !R3HA[J:E?I77^C4Y/'OK8_N+/_K_]O)]^?F;=/,O4
M
M                      :@T<_:CJ]Z_H/ZV>YG\+A^[ZG@,GXO-YX;M3<<
MS:^@5DCZ$*V[P)$(%3=Y(D0"1H$K2$JTWDB9H0D;O"4[ ) A(W<!(W<$*T)$
MB<@$C=X$B;P/I"0 !87&LFI9J)D6'#/,D;\4QZ551-GD@7X
M               %A:*R6NHTGFPXU<Y.E3!,$ OP
M       6#ZR5MWCH4PYET/.+LZ;BQ5-_T +\
M   %K<JB2DHIJB+#G&(BMXMJ;51 )J=[I:>*5WFGL:Y<-V*IB!(
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MNX(5H2)$Y )&[P)$W@?2$@ "QN%%+5S4<D:M1*>5)'\2JBJB*B[,$7H 7P
M                          %C::.6@HTIYE:YZ.5V+%54V^.B 7P
M                      +%]'*ZZQUR*WF60\VK<5XL<57H88;>B!?
M                       M;C3/JZ*6FC5$?(B(BNQ1-BHO(B@34\:Q011.
MP5S&-:JINQ1, )                            <!?OJ?K%^!/1?E.IY_
M\UUN:"U5L 2       [7\!#W)SMZXM_H*@HO$^>O6N?#>:W4Z]*5<
M                 !R3HA[J:E?I77^C4Y/'OK8_N+/_ *__ &\GWY^9MT\R
M]0U'X2O[)[CZYI/Y=I?>!?BX\T_(H/'OP=O/7Y8;<*%?M"Y3<MBSSK-:[1)S
M-##!'<8$B16)%52TTDCU9NX51SEW>=3 ]1Q/_LP<-:W/KIU:O,\+_P"OB.)K
M7FY)ZYCE6-SSEFJET>R+<Y;K6TE#<YF1YHS) U:FMIZ97NP<CEQ5%<J8<6&.
MQ$Y<%V8^%Q3QF6N[$S6/H5YHF6O)Q66O!XK3:8BVF_:.68AZ73Z19\S4M5D[
M45^:\JR0RI=[5>JGG[E'(B8Q20)S3'(WB7IN)K4P\]];Q\;&F*8RX>SOKR36
M-*[=>5U\%.N2)Q9NTII.]%IUMLTY(_>@L[,RZMYBS-6KF:Y6#*=AN,EGM=+9
M9&TLLTU,B+)++(K7*J+BU4:J;G8;,-N66<?!8Z1N5O>]=Z=[ETU\D,,7:<;D
MR3OVI2EMV(KR:S'/,SRH[[?]3L@92?9*ZLAN>8;I>H;)E.\2JUU0^GJN+AEG
MB:U45[$;ABN.UR8XX=-EAP\-Q.7?B)K6M)M>ODUCR1*,V;B>&P[MIBUK7BM+
M;)Z8Z8?,W9:SMIQER3/%ISO=;Q<K2C*BZ6ZZO;-0542N:V1L<2-18MBJJ=,[
MQ%1=HX;/@XK)V5L5:Q;FFO/'7Y3B<&?A<<YJY;6FO+,6TW9CR^3D9*JS3<[=
MJ1DV^+5U'<;GFW)2MH)9%=#37!S&S0N:S<UST5C-F]>(TUX>MN&R4TC?Q6UU
MZ:\TM]^(M3B<=M9[/+733HMSQZ>9)69HN%;JG>98:RH9E#(5H?476FIWKS53
M<)V.E1CT:J([@C1<$7'!S2*\/6O"UUB-_-;DU\E8_C^Y-N(M;BK:3.YBKR[;
M3R_NAKFSYUMV;+7)F'->JU9EW,=6Y\E'9K9(L-%1,:JMB9+%S3N=V(CG=.F.
MY=NTM\O"VPVW,>"+UCGM;GGITY>13XN+KGIVF3B)I:>:M9C2O1KR<NU>WG5;
M,UYT3CS)25BPYEMM[BM57643EB95.BP?Q(C.'!LK'LXFILQQPP38:L7AV+'Q
MNY,?0M3>B)\G_P"&W)XCEOP7:5GZ=;Q76/+R_/#.9LREJ)DW)MQS='G:YW:^
M6^2END]$YZQTG-P.5:J)&(Y46)6NXN'!$P9NV[.;AN)X?/FC'V5:UG6NOEY>
M:?/ZW3Q/#\1@PVRQDM:U=+:>3D^M'F]3/:C9QK+O8,I6C)M;)277/533=:5E
M.Y6RP4*(V>>1',VHK6JU';-W$<O \+6F3);+&L8HG6.F>:'5QO$S>F.N*=)R
MS&DQ[//,^AM:-B1QLC15<C$1J.<JN<N"88JJ[57Q2DF=5W#15Y5_7]UJM2=4
M),LU_7,B6RQV"X10MIZ1-L2RL2-99'+]=BU,>CMP3TV+ZM8P8.TC3EM:O//E
MTY=(>9R_6M.?/V<Z\E:VB-(\FO)K*PL6>\R730?.-W?>9:JY62LJ*"W7N/&&
MHD@BZW?'(JMP7B5)5VKMPW[3;FX3'3C\==W2+Q$S7R:\OJ:L'&Y+\#EMO:S2
M;1%O+,1II/[UU?K'GZ@T[=J4N=[HW,\%)%=76V-\:6EL+FM>L',*WIE:U?-N
M<O$J;4VFO#EX>W$=AV5=R9W=?M>?5LSXN(KP\Y^UMOQ&]IR;OFT^?5F,RYLS
M+FFX9%R58J]UCJ<T6YMYO=RI419X:5(4DYN!78\*O<CF\6]-G)B<^#A\6&N7
M+>-^,=MVL3S3.OE='$<1ERVQ8J3N=I&]:8YXC9YWG<V95O>6-2=-XJC,%=?[
M%+<WK2K=GMGK*>=&LXT69K6<3'HB*B*FS!3KX;B*9>&S3%(I;=Y=WDB8\SDX
MCA\F+B<$3>;UWI^MSQ.G3R.ACRCU347@[?W1O?Z07#ZD1?>-_P!ZOW*_.HO!
MO[5OOV^5!K)%'1YWTNO5,J175;[%;UD:BH]]+4O8V1JJGUJ(JI@OGE\4S\+F
M;8,])YMS7KAK\4C=S8+Q];?B.J>=@LU:@4=\U!O.7+WG6?)F5LOHRG8VWNZW
MKJZL>W&1W.\$G"R->EPPV[/'3IX?@IQ\/6],49;WY>7EBL>;DYW/Q'&UR<1;
M'?+V5*<G)R3:?/R\D)<CYPJ;[>\Q:8V[-TM_H:BV2UF7,S\3F5U/(JHQ8I9&
MM:KG,<Y'H[#<G05&ICQ?#1CI3B+8]R8MI:ODG;#+A.*G)DOP]<F_$UUK?RQY
M-)\W.R^6]3JNBT5N&8[W*YV9<MMJ+37<\J.D=<J=R11<>.]SE?&KL=J[31GX
M"+<;%*?4OI:/NSRS\[?@\0FO!3DO]?'K6?O1R?OY'G,P9MS#E++^1\CWC,TM
MGN]\@?7YFS-6*^:HIH5^^<U&KN+!ZJO-)@G2\*=%5.O#PV/-DRY:TWJTG2M8
MYIVS\KDS\3DP8\6*^3=M>-;WGR;(V^1%1ZAVO*6;<OQ9:S[5YQL%YJX[==K=
M=I>N:BF6=W#'412\W&J-:J],U$\G%,,K<%;-BOVF*,5JQK$UY(G3R3&LL:\;
M3!EI%,TY:WG=F)F)F->:8Y(9>Q9@CRKG#7#,<C$D2VI;JED3EX4?(RFJ.!BK
MR<3L&FC-A[;#PM/:WH_?#=AS1AS\5D]G=G_#*\L.1]0,UY7ILW5^?;K;\TW6
MG97T='2/9':J=)VI)%&^GX5XDX>'B7'H[^75FXOA\.6<<8JS2LZ3,_6G3GY6
MW#PO$9L49+9;5O:-=(TW8UYHT86[:DYOOVD^6LP6R=;?FU<P4MJK%CQ9#-/&
MZ1JH]K5VQR*C%>S=O3<=./@<./B[TM&M-R;1YO7#1DX[-DX2EZ_1OOQ6>C77
M3T2RF=K;G#2NQT^?J+-MSOC[=/!W0VZYR,DHZF&HD;$Y8(D:WF51[TX4:JX)
MXRXZ.$R8>,O.&<=:;T3NS7GC3EY9\K;Q=<W!XXS1DM?=F-Z)TTF)G3DCR+O-
M-1FG,6K]#E2P9@J[1E^MRY%<:Z2D_C$B2KE:KX4>BMCD?][9SG#BC?(,.'KB
MQ<).2](M:+Z1KYHY^F.?D9\1?+DXR,5+S6LX]Z=/O3S=$SR<K#VJWYV?J+>M
M*F9TN:Y<IJ:"[NNDSVRWEL;D8Q8(ZAS<&HYS\5=P?6[$3%V/1DO@[O7B.RKO
M3,UT^SY]&G'3/WBW#]K;<B(MK]OS:_P9#+F9[[D.YZCV*^W:IS#;,J44%UM=
M37NYRK5LT#I.:?(B8NQ7A;CN3?LQV:<_#TXBN&]*Q2<DS6=.;GYVS!Q&3A[9
MJ7M-ZXXBT:\_+$\CQMNS=07VR=T%[U>J[1G6K8M1#;:5_-VJD>[;'#)3I"[C
M1J(B/7B\GEL;\-;'?<IP\6QQR:S]:=NNJOQ\37)CW[<3-<D\ND:;L;--.7:S
M=WU/S/F'2/*V:;//UCF>6_4EOJ^:56P2S,=(U6N1J[8I,&.<W=MP.;'P&+%Q
M=\=HUIN3,=/D_?#IOQ^7+P>/)7DO-ZQ/1SZ>B5]G2VYQTQBL>;J7.=TO4S[E
M2T=YMUQ?&ZBFCJE5'+%$UJ)%MV(B8JF.**F!JX7)AXN;8YQUK]&9K,<\:=,^
M5MXG'FX7=R1EM;Z41:+::3KT<G(M\UY5?7^$':*=+]=J3K^U35B34M2R.2G2
M-TC>9@58UX8G<.+FKCM5=IGP_$;OA]IW*SI:(Y8Y]L\O.QXCAYMXA7Z=HUK,
M\D\VR.3F;^/+/3N;-%]1NYC*,]K[D\R7G"XU<O7MGMW7=+T[DZ7G.<;TR8;4
MP/7^*<#VN6+=I2OT8Y+6TGY'C_#>/['%->SR6^E;EK76.?SO5Y7HLTYYU5IM
M1KK8:G+-CL]N=;Z*FN"<%94R3+(JJZ/8K6MYQR[>@F_;AQ<1;%P_"S@K>,EK
M6UG3FC]M'?P]<O$<5&>U)QUK72->>==C%W1SFSW*KU*U4ERY>UGDZSLE@N$<
M<-+ F/-I)$V-99%Z.*-5>CT-V/FK&#!OUTY;7KSSY]=(:<O),SGXCL[:\E:V
MB-(\GDUE@I-1<V5>@%?F#VWEDO-LN[*"&[0JL$T]/'+$K5>K.%>F:_A7HIOV
MG5' XHX^*;OT;5UTY])TERSQV6?#[9-[6U;:;W-K&]'S,IG[(.::'3/,-\S+
MG2ZW"LEI8JRHM;7-BHV3JJ<<7 O']Z17^8;P^9131P?&8K<32F/'6(UTU\NG
M3YW1QO!Y:\+>U\MIG373R>;S)+TW,V3]+\@,RM?J^6[WN\6AD4M?,DS6)74+
MFMID1K6)UNU[6N2-V/BXD8NRS\5E[2D;M:WYHZ+<_P![:9NUX?AL,8[S-KWI
M'TMM>;R?1V+_ #7;<W:8UN6,Q4N<+K?(*Z[TMLO5ONDC'T\K*M78NA8UJ)%A
MPK@B8X8IMV8+JX>^'BXO2<=::5FU9KS\G3TMO$4S<+:EXR6O$VBMHMIIR]')
MR(<_9_AK-1JO)-TS;+DS+-EIX9JRJHEYJNK*NHC;*V-DO _@8UCT5=GCX[,,
MN#X.:\-&6N/M;VF=->:(C8QXSC8MQ,X;9.RK2(UF.>9G;YDFG.?XX=0NX6@S
M3)G++=RI7U=LN-6O.5U+4PXN?!+)PLXVJQJN1>'H8<ICQW!Z\/VTX^RO6=)B
M.:8Z83P/&1'$=C&3M:VC6)\L3'DGI8[2&V9\SY10YFNN=+E34%IN<D$-OB>K
MDJXX)4EDY][G=,CN/FD147!K3=XEDP</,XZXJS-J\_1KT?*U^&TS\1':6R6B
M*VGDCRZ3Y?D8>VYE=F*KN\.<=1[KD[/T57/#2699.L+53M8["%'(Z-6/:N&U
M5D1?'WKT7P=E%9Q8:Y,>D:VY[3T_MHYJ<1VMK1ES6Q9(F=*\U8Z.>.7TO3ZJ
MIFQV0]/&U%?25><5S+:TAN5(G.4<E4K*CF96HK6HYJKP*[I<%V\AQ>'=EV^;
M2)BG9VY)Y].36'7XEVO88=9B;]I3ECFUY=)29JMN;],:W+&8Z;.-TOL5?=Z6
MV7NWW-['4TK*Q78NAC:U$BPX5P1.+#%-NS;'#WP\7%Z3CK32LVK->?DZ>EGQ
M%,W"VI>,EKQ-HK:+::<O1R<CU=#=[H_7&ZV1]9,ZT19>AJ8Z%7KS#9W5*-61
M&;N)4V8G#?'6.!K?3Z6_,:]3NIEMWVU-?H[D3IMU>)TRL.<]0\JOO-\SM>*%
ML4U52VAMOG2-WWN9ZK+4N<CG3+Q+P-8JHB,;AXUCQ^;#PV7=IBK/)$VUC9S1
MT>M7<!BS<3BW[Y;1RVBNGGGEGIZ/,]UH_FJ\YBL5RMN99&SYCRU<JBRW"I8W
MA29U*J(DNS9BN*HN'0QY2M\3X>F*];8_JWK%HV:^18^&<3?+CM6_+;'::S/3
MIY6PRI6P                       U!HY^U'5[U_0?UL]S/X7#]WU/ 9/Q
M>;SPW:FXYFU] K)'T(5MW@2(0*F[R1(@$C0)6D)5IO)$S0A(W>$IV 2!"1NX
M"1NX(5H2)$Y )&[P)$W@?2$@ "TK:[K22FCYOCZYD2+''#AQ5$QW+CO NP
M                          +2VUWMA3)4<WS>*JWAQXMWBX(!=@
M                     M'5W#<66_F\>./G><QW;53###Q.B!=@
M                   MZVIZSI9*GAX^;1%X<<,<51-^"]$"6&3GH8Y<,.<:
MCL-^'$F(%8                           . OWU/UB_ GHORG4\_^:ZW-
M!:JV )       =K^ A[DYV]<6_T%047B?/7K7/AO-;J=>E*N
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M<>%$VKT57>FTI/$>*KFR1%/J4B*QU+KP[A;8,<[_ ->]IM;SR]X5:S
M                 &H-'/VHZO>OZ#^MGN9_"X?N^IX#)^+S>>&[4W',VOH%
M9(^A"MN\"1"!4W>2)$ D:!*TA*M-Y(F:$)&[PE.P"0(2-W 2-W!"M"1(G(!(
MW>!(F\#Z0D  8VZ4\T\] Z)BN;%.U\BIAL:BIM R0
M         &.L=/-2T"15#."1'.7A7!=B^,!D0
M    8Z2GF6]Q52,^\-@5BOV8<6+EP^F!D0
M 6=UADJ+?/#"WBD<B(UJ<O3(O*!/2L<RFA8],'-8UKDZ"HB(!*
M                 #@+]]3]8OP)Z+\IU//_ )KK<T%JK8 D      !VOX"'
MN3G;UQ;_ $%047B?/7K7/AO-;J=>E*N                         Y)T0
M]U-2OTKK_1J<GCWUL?W%G_U_^WD^_/S-NGF7J              &%S78JO,=
MFEM=%=ZNQU+WL>RXT#N"=G N*HFU,4<FQ3HX?-&*^]-8O'1+GXC%.6F[%II/
M3'.AR9D^U9'L45BM2R21M>^>HJJAW'/45$JXOED=LQ<[ZAEQ7$VXC)OV_A$=
M#'A>&KP^.*5],\\STR] <KJ                 #SF<<GT><Z.WT=;42T[+
M=<*:Z1NAX<724JN5K5XD7I5XMIU\+Q,X+3,1KK6:^ER\3PU<\1$SINVBWH>C
M.1U                          \YDC)]'D:P,L%!42U-.R::=)9^%'\51
M(LBITJ(F"*NPZ^+XF>(R;\QIR1^YR\+PU>'Q[E9UC69],ZO1G(Z@
M                U!HY^U'5[U_0?UL]S/X7#]WU/ 9/Q>;SPW:FXYFU] K)
M'T(5MW@2(0*F[R1(@$C0)6D)5IO)$S0A(W>$IV 2!"1NX"1NX(5H2)$Y )&[
MP)$W@?2$@ ""HJX:9\+)<>*=Z1QX)CTR]'R0)P
M      (*2KAK84G@55C553:F"XH!.                           "!:N
M%M6VB55Y]S.<1,-G#BJ;_H 3@                           BJ*B.EA?
M42X\VS:[!,5VK@!7&]LL;9&^9>B.;XRIB!4
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M6Z890U-P
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M0"YHT5*2!%V*D;,4_P#"@$P                           . OWU/UB_
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M/;])4,>+G7+9EP4:8:^9ZHY'8
M                        &H-'/VHZO>OZ#^MGN9_"X?N^IX#)^+S>>&[4
MW',VOH%9(^A"MN\"1"!4W>2)$ D:!*TA*M-Y(F:$)&[PE.P"0(2-W 2-W!"M
M"1(G(!(W>!(F\#Z0D  1R3PQ.8V5Z,=(O"Q%7#%W00"0
M            ".&:*=G.0O21F[B:N*8H!(
M "-9HDE2!7ISRIQ)'CTW#T< )                            4R21PL6
M25R,C;YISMB(!]:YKVHYJXM<F**FY44#Z
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M8Q,$1/&1"OF9F=9641$1I"0A(
M                        :@T<_:CJ]Z_H/ZV>YG\+A^[ZG@,GXO-YX;M3
M<<S:^@5DCZ$*V[P)$(%3=Y(D0"1H$K2$JTWDB9H0D;O"4[ ) A(W<!(W<$*T
M)$B<@$C=X$B;P/I"0 !B+S^,VSUPWZJ!++A
M   #$Y<]S&_9N RP                           ,3+_>*'ULOHG 98
M                         &/O?N74_8IZ) +FC_$Z?_1L]"@$X
M                    . OWU/UB_ GHORG4\_\ FNMS06JM@"0      ':_
M@(>Y.=O7%O\ 05!1>)\]>M<^&\UNIUZ4JX                        #D
MG1#W4U*_2NO]&IR>/?6Q_<6?_7_[>3[\_,VZ>9>H?'L9(QT<C4?&]%:]CDQ1
M478J*B[T4"BGIZ>DA934L3(*>).&.&)J,8UJ<C6MP1$)F9F=91$1$:0D(2BJ
M:6EK85IZR".HIW8*Z*9C9&*J+BF+7(J;%)BTQ.L,;5BT:3RI2&0
M    "B:&&HB=#/&V6%Z8/C>B.:Y.@J+L4F)F.9$Q$\DK:BM-JMKGNMU#3TCI
M/XQ:>)D2NY=O B8F5KVMSS,L:XZUYHB%X8,P   BCI*6&::IA@CCJ*CA6HE8
MQK7R*Q,&\;D3%V";$Q)FTS&C&*Q$ZZ<Z4AD
M                                   #4&CG[4=7O7]!_6SW,_A</W?4
M\!D_%YO/#=J;CF;7T"LD?0A6W>!(A J;O)$B 2- E:0E6F\D3-"$C=X2G8!(
M$)&[@)&[@A6A(D3D D;O D3>!](2  *71QO5JO8CE8N+55$7!>B@%0
M                      %+(XXF\,;48WSK41$^D!4
M          "GFXU>DBM3G$3!'X)Q8=#$"H
M 'Q[&/:K'M1S5WM<F*+Y(!$1J(UJ8(FQ$3=@!]
M     !P%^^I^L7X$]%^4ZGG_ ,UUN:"U5L 2       [7\!#W)SMZXM_H*@H
MO$^>O6N?#>:W4Z]*5<                        !R3HA[J:E?I77^C4Y/
M'OK8_N+/_K_]O)]^?F;=/,O4
M                                                      :@T<_:
MCJ]Z_H/ZV>YG\+A^[ZG@,GXO-YX;M3<<S:^@5DCZ$*V[P)$(%3=Y(D0"1H$K
M2$JTWDB9H0D;O"4[ ) A(W<!(W<$*T)$B<@$C=X$B;P/I"0 !B+S^,VSUPWZ
MJ!++A                            #$Y<]S&_9N RP
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M])]#MQ>,\%E^KFI/\T:^B7HVN:]J/8J.:Y,6N3:BHO*ARK:)U?0D
M  (5I8753:Q6_?VLYM'8KAPXJN[Z($P                           (Z
MB".IA=!,F,;]CD1<-RX\@%3&-C8V-FQK$1K4\1$P J
M         !P%^^I^L7X$]%^4ZGG_ ,UUN:"U5L 2       [7\!#W)SMZXM_
MH*@HO$^>O6N?#>:W4Z]*5<                        !S%X._X]J=^EM?
MZ)3/Q;GQ_=AGX1]6_P!^6\"C7@
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MGBIACC@=O&W[7A\>2T1O3,J+P+#'">(\1PV.9[.D4F(F==)F(GY_6W 4;WH
M         8R2:5+[% CUYE:=7+'CTO%Q.VX 9,
M     %E=Y)(;=/)$Y62-1.%S=BITR 3TKG/I8'.7%SHV*JKO55:@$P
M                     . OWU/UB_ GHORG4\_^:ZW-!:JV )       =K^
M A[DYV]<6_T%047B?/7K7/AO-;J=>E*N                         YB\
M'?\ 'M3OTMK_ $2F?BW/C^[#/PCZM_ORW@4:\
M
M       Y[TH_:WK)^<J'^MGI<OX?%YI^9Y>/Q&7SPW,FXXG4^@5DCZ$*V[P)
M$(%3=Y(D0"1H$K2$JTWDB9H0D;O"4[ ) A(W<!(W<$*T)$B<@$C=X$B;P/I"
M0 !:U=$VKDIY'/5JT\B2(B)O5%1</I 70
M %K043:"G2G8Y7M15=Q+L7:!=               :KRM^W'/GK2W?T> N,_X
M/%Y[?++Q/A__ #?%?=Q_Y:MJ%.]L          %JZB:ZO97\2\;(^:1G)ABJ
MX_3 N@                           05E,VLII*9SE:V1$17)O3!<0)(H
MTBB9$BXHQJ-1?L4P K                           !P%^^I^L7X$]%^4
MZGG_ ,UUN:"U5L 2       [7\!#W)SMZXM_H*@HO$^>O6N?#>:W4Z]*5<
M                      !S%X._X]J=^EM?Z)3/Q;GQ_=AGX1]6_P!^6\"C
M7@
M                               '/>E'[6]9/SE0_P!;/2Y?P^+S3\SR
M\?B,OGAN9-QQ.I] K)'T(5MW@2(0*F[R1(@$C0)6D)5IO)$S0A(W>$IV 2!"
M1NX"1NX(5H2)$Y )&[P)$W@?2$@ #'W&KFIIJ)D2HC9YDCDQ3'I55$_R@9
M                           "PL]7-6T23SJBR*YR;$P3! +\
M      #5>5OVXY\]:6[^CP%QG_!XO/;Y9>)\/_YOBONX_P#+5M0IWM@
M     L'U<S;Q'1(J<PZ'G%3#;Q8JF_Z %^
M "TN=1)2T,U1%@DC$16XIBFU40":F>Z6GBD=YI[&N=XZHB@2@
M                X"_?4_6+\">B_*=3S_YKK<T%JK8 D      !VOX"'N3G
M;UQ;_05!1>)\]>M<^&\UNIUZ4JX                        #F+P=_P >
MU._2VO\ 1*9^+<^/[L,_"/JW^_+>!1KP
M
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MP)$W@?2$@ "QKZ*2KEI)&.1J4\J2.1<=J(J+L\@"^
M          LK5124%(E/(Y'.1RNQ;CAM\<"]               U7E;]N.?/
M6EN_H\!<9_P>+SV^67B?#_\ F^*^[C_RU;4*=[8          +)]%(ZZ1UZ.
M3FV1<TK=O%CBJX_3 O0                           6UPIGUE'+3,5&N
MD1$17;MBHO(!+!&L4$43EQ5C&M54W8HF $@
M  . OWU/UB_ GHORG4\_^:ZW-!:JV )       =K^ A[DYV]<6_T%047B?/7
MK7/AO-;J=>E*N                         YB\'?\>U._2VO]$IGXMSX_
MNPS\(^K?[\MX%&O
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MXD:KTVJO#TV&"FR<-HUU81FK.FGE;!-+>
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MMJ%.]L          &.DI9W7J*K1G^SM@5BOQ3S6+EPPQQY0,B
M                "SND$M30300MXI7HB-;BB8[47>N $],QT=-#&],'L8UK
MDZ"HB(H$H                           . OWU/UB_ GHORG4\_\ FNMS
M06JM@"0      ':_@(>Y.=O7%O\ 05!1>)\]>M<^&\UNIUZ4JX
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MF7M1R8[\%3$"H                           ' 7[ZGZQ?@3T7Y3J>?\
MS76YH+56P!(      #M?P$/<G.WKBW^@J"B\3YZ]:Y\-YK=3KTI5P
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M<5=B[:[':J[54PC),3KY6<XZS&GD>I,&P
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M 2-W@2)O ^D)  &*N\;WU%N5C5<C:AJN5$5<$Q3:H&5
M            Q>7XY(K<ULC58[C=TKD5%^F!E               -5Y6_;CG
MSUI;OZ/ 7&?\'B\]OEEXGP__ )OBONX_\M6U"G>V          #%R1R+?X9$
M:O-I3JBOP7AQXG;,0,H                           "QO#'OMM0QC5<Y
M43!K4Q5>F3H 7%(BMI($5,%2-B*B[\>% )@
M  <!?OJ?K%^!/1?E.IY_\UUN:"U5L 2       [7\!#W)SMZXM_H*@HO$^>O
M6N?#>:W4Z]*5<                        !S%X._X]J=^EM?Z)3/Q;GQ_
M=AGX1]6_WY;P*->
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MJ(871ME>C72NX(T7E<O(!(                            !'!/#4Q\[
M]'QXX<2;L4 D               U7E;]N.?/6EN_H\!<9_P>+SV^67B?#_\
MF^*^[C_RU;4*=[8          (UGA29*=7IS[F\:,Y>'H_2 D
M                !1++'!&Z65R,C;YIR[D J:YKVH]JXM<B*U>BB@?0
M                       <!?OJ?K%^!/1?E.IY_P#-=;F@M5; $@
M.U_ 0]R<[>N+?Z"H*+Q/GKUKGPWFMU.O2E7
M<Q>#O^/:G?I;7^B4S\6Y\?W89^$?5O\ ?EO HUX
M
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MW^_+>!1KP
M                                      #GO2C]K>LGYRH?ZV>ER_A\
M7FGYGEX_$9?/#<R;CB=3Z!62/H0K;O D0@5-WDB1 )&@2M(2K3>2)FA"1N\)
M3L D"$C=P$C=P0K0D2)R 2-W@2)O ^D)  %#VQ.5BR-:KD7%G$B*J+XF/*!6
M                            !1&R)C>&%K6LZ#$1$Q^@!6
M    !JO*W[<<^>M+=_1X"XS_ (/%Y[?++Q/A_P#S?%?=Q_Y:MJ%.]L
M    %"LBYQ'JUO/(F".P3BP\??@!6                           "E[6
M.8K9$16+O1V"I],#ZU$1$1N"-1-B)NP ^@
M X"_?4_6+\">B_*=3S_YKK<T%JK8 D      !VOX"'N3G;UQ;_05!1>)\]>M
M<^&\UNIUZ4JX                        #F+P=_Q[4[]+:_T2F?BW/C^[
M#/PCZM_ORW@4:\
M                                            Y[TH_:WK)^<J'^MG
MI<OX?%YI^9Y>/Q&7SPW,FXXG4^@5DCZ$*V[P)$(%3=Y(D0"1H$K2$JTWDB9H
M0D;O"4[ ) A(W<!(W<$*T)$B<@$C=X$B;P/I"0 !B+S^,VSUPWZJ!++A
M                        #$Y<]S&_9N RP              &J\K?MQSY
MZTMW]'@+C/\ @\7GM\LO$^'_ /-\5]W'_EJVH4[VP          8F7^\4/K9
M?1. RP                           ,?>_<NI^Q3T2 7-'^)T_P#HV>A0
M"<                           ' 7[ZGZQ?@3T7Y3J>?_ #76YH+56P!(
M      #M?P$/<G.WKBW^@J"B\3YZ]:Y\-YK=3KTI5P
M      ',7@[_ (]J=^EM?Z)3/Q;GQ_=AGX1]6_WY;P*->
M
M               <]Z4?M;UD_.5#_6STN7\/B\T_,\O'XC+YX;F3<<3J?0*R
M1]"%;=X$B$"IN\D2(!(T"5I"5:;R1,T(2-WA*=@$@0D;N D;N"%:$B1.0"1N
M\"1-X'TA(  AFI8*AT3YF<3H7(^-<53!R<NQ0)@
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M%3>AWJ]\   .U_ 0]R<[>N+?Z"H*+Q/GKUKGPWFMU.O2E7
M           <Q>#O^/:G?I;7^B4S\6Y\?W89^$?5O]^6\"C7@
M
M                  '/>E'[6]9/SE0_UL]+E_#XO-/S/+Q^(R^>&YDW'$ZG
MT"LD?0A6W>!(A J;O)$B 2- E:0E6F\D3-"$C=X2G8!($)&[@)&[@A6A(D3D
M D;O D3>!](2  ,9=9I8JBWMB>K&R3M:]$7#%JJFQ0,F
M            !C+#-+/;VR3/61_&Y.)RXK@@&3               U7E;]N.
M?/6EN_H\!<9_P>+SV^67B?#_ /F^*^[C_P M6U"G>V          #&232I?8
MH$>O,K3JY8\>EXN)VW #)@                           LKO))#;IY(G
M*R1J)PN;L5.F0">E<Y]+ YRXN=&Q55=ZJK4 F
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M>!1KP
M                                  #GO2C]K>LGYRH?ZV>ER_A\7FGY
MGEX_$9?/#<R;CB=3Z!62/H0K;O D0@5-WDB1 )&@2M(2K3>2)FA"1N\)3L D
M"$C=P$C=P0K0D2)R 2-W@2)O ^D)  %M543*N2GD>Y6K3O21J)AM5%1=OD 7
M(                            %M0T4=!3I3QN5S4578NPQV^,!<@
M          :KRM^W'/GK2W?T> N,_P"#Q>>WRR\3X?\ \WQ7W<?^6K:A3O;
M         !;.HHW5S*]7+SC(^:1NSAPQ5<?I@7(
M      (:NF964\E,]5:V1$15;OV+CR@5Q1I%$R)%Q1C4:BKOP1, *P
M                     <!?OJ?K%^!/1?E.IY_\UUN:"U5L 2 ;LS9F'6S4
M'2V"^5D$E%I-EJ"BMC(Z=>8IIGP\W2L>]%=SD[N+AXG?Q;7;$P78<&.F''DT
MY[RL<E\N3'O<U87-@\$K5C,EBM>8K=[6>U]WI(*^DYVK<V3F:J)LK.)O-K@O
M"Y,4Q(OQ^.MIB=>1%>!R6B)C3E:;OUCN>6KS7Y?O,"TUUML\E+5P.V\,D3N%
M<%38J<J*FQ4VG=2T6B)CFEQ7I-+3$\\,<9, #M?P$/<G.WKBW^@J"B\3YZ]:
MY\-YK=3KTI5P                        ',7@[_CVIWZ6U_HE,_%N?']V
M&?A'U;_?EO HUX
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M=P0K0D2)R 2-W@2)O ^D)  &/N-7-3343(E1&SS)')BF/2JJ)_E R
M                      %A9ZN:MHDGG5%D5SDV)@F" 7X
M &J\K?MQSYZTMW]'@+C/^#Q>>WRR\3X?_P WQ7W<?^6K:A3O;          !
M8/JYFWB.B14YAT/.*F&WBQ5-_P! "_                           !:7
M.HDI:&:HBP21B(K<4Q3:J(!-3/=+3Q2.\T]C7.\=410)0
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MGX1]6_WY;P*->
M                                           >8R!E++-URXM=<K32
MU58^LK$?/+$U[U1M0]$Q5>@A4^%<#P^7!O7I%IWK<LQM7'C'B/$X>)W*9+5K
MNTY(G_QAGY<B9-3=8J)/_)9Y18V\,X7W=?0JZ^+<9[VWI6$V2LHM799:-/\
MR6^4:+>'<-[NOH=-?%.+]Y;TK&;)V54799Z1/_*;Y1HMX?P_L5]#IKXGQ7O+
M>E92Y3RRB;+32I_Y3?*-$\#@]B/0WU\1XGWEO2LI<KY=3=:Z9/\ RVG/;@\'
ML1Z'57C^(]NWI8JIR]8VX\-O@3QHT.6W"XO9AV4XW/[<^EBY[+:6^9HH4\9B
M'+?A\?LP[:<5EG[4^EBJJU4'"J1P-B?O;)&G"YJIN5%3H''?#3R1H[L?$7\L
MZ^=[C)6=7U,C+!?I$2Y(G#25:[&U+4W(O0D^KX^_U_A'B_:3&'-/T_)/M?Q^
M7SO#^.>!QCB<^"/H?:K[/_Q^3S<VPFGJWBU:;R1,T(2-WA*=@$@0D;N D;N"
M%:$B1.0"1N\"1-X'TA(  LJZB?5RTDC7(U*>5)'(O*B*BX)Y %Z
M                   !96NB=04B4[W(]R.5W$FQ-H%Z              !J
MO*W[<<^>M+=_1X"XS_@\7GM\LO$^'_\ -\5]W'_EJVH4[VP          63Z
M)SKG'7\2<#(N:5G+CBJX_3 O0                           6U?3.K*2
M6F:Y&ND1$1R[DP5% E@C6*".)5Q5C&M5?L4P D
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MV:DJ8V303,7%KXY&HYKD7H*BXB8T(G5,$@
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M3>!](2  +.NKG4DM+&C$<E1*D2JJX88JB8_3 O
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MU-W*:K;OD;*;VGTF?,6P
M             %CIA_=%OKVM_I+SG\%_#?S6_P SH\>_%_RT_P L/3S%K935
M8R?><UG7183[SFLZJL=-N.>SIHL)CFL[*\[#U7*<=W=1AZDXKN^C$5.Y3BNL
M,;#57*<-UAC86J7A7BQX7-7%KDV*BIN5%./).COQ\O(WYD"OOUQR_!47Z+AF
M793S.V230X=*][>15Z/UV_Q_JG@V;/EX>+9HY?)/EF.F?VY>=\;\>P<-AXJ:
MX)Y/+'DK/1'[<G,]:TNWGTC=X2G8!($)&[@)&[@A6A(D3D D;O D3>!](2
M,=<Z6>HGH7PLXFPS-?(N*)@U%3;M4#(@
M8ZRTL])0I#4,X)$<Y>'%%V+XRJ!D0              -5Y6_;CGSUI;OZ/ 7
M&?\ !XO/;Y9>)\/_ .;XK[N/_+5M0IWM@          L'TDSKO'6IAS+8>;7
M;MXL57=]$"_                           !9W2"6IH)H(6\4KT1&MQ1,
M=J+O7 ">F8Z.FAC>F#V,:UR=!41$4"4                           '
M7[ZGZQ?@3T7Y3J>?_-=;F@M5; $@'9%[R)1^$_IGD^_9&NE+3YURK01VB\6F
ML>YB+S;&HJ*K4<K>F:KXG</"YKL%5%;@4=,L\+DM%HY+3JO+XXXG'$UGEAYC
M(G@=9X9?::YZ@U-#9LKV^1M5<%94MEGDAA7C<UJM16,143IGO<G"FW!3=E\0
MINZ4UF9:L7 6BT3:8TAK;PCL^VK4356Z7JQ2)/9J6.&W454U%1)F4S5XI$Q^
MM<]SN%>5N!U<'BG'CB)YW+QF6+Y-8YH:G.QQ ':_@(>Y.=O7%O\ 05!1>)\]
M>M<^&\UNIUZ4JX                        #F+P=_Q[4[]+:_T2F?BW/C
M^[#/PCZM_ORW@4:\ -16#_Z_K[F:YK]]ILM6NFM<#]N#)JE4F7#Q47GF^2=%
MN3'$=+EKRY9GHA+K=<ZVA;EFFJ*^KM.3:ZN=#F2YT"N9-'%PM6)BO8BN:UZ\
M?$J=#EW##&NO3Y$YYTTZ/*U;FJATRNEZRA9<D4T]9!77FD@N>8)I:R:%6\2-
MZW8^I>K7/<CN)W FS8G*IOK-XB9MT.:\4F8BO3SMKV%OM[KEFBZNPDI\MVRC
MM%.[>C9*M>N'X>*F#VKY!SVY,<1TNFO+DF>B&(NUWH].]9[EF?-398,NYAMD
M%-0W9L3YH89H.!'0O5C7*G$L?%L3E3Q53*(W\>D<\,9MN9-9YIA%EW,4>HFN
M#+E2T\T%FRQ:9'4+JF-T,LTE8K6<[P/1'-:]DBJSB1%5J(O*3:NYCTZ916V_
MDU\D0\1D^ETORQ;;E9-3XZJCSC;:N=)XVU%QB6L8YV,<D+*:1K'<6Y%3?OQP
MVFV^_,ZUYFJD4K$Q;GZWI*Z@CL>BV<LRV_+DN7*R^QQQ+2RU53654E Z5L$;
MYUJ'O5CN;FDQ:GUN_P 37$ZY(C771G,:8YG335MC3>NLM=D>Q^T%0E5;:6DA
MHVS-8^-%?3,2-^Q[6KYIJXKAO.?)$Q:=73CF)K&CR.M&ISLEQ6[+]MK([=>+
MTJ\Y=)8WS,H:1'(UTW-L:]7N5<48B-7<OB&W#CWN66K/EW>2/*MM*<QZ06^I
MCR[E.\R77--V5TE97U%-5I5UDT;'2O=)++"U$1$1SD:KL/'5<59:WGEF.1&*
MV..2)Y6P<OYQLV9KC>[9:UE=46"IZRKW2,X8^?17M5&.Q7BP5BXFFU)B(F?*
MWUO%IF(\B?-B7[N:NBY8D2/,#*=[[<KFM>BS,3B:WA?BWIL.%,=FT5TUY>9-
M]=)TYVN+'KCD6HR[#09\JW4.8H8$IKY;*ZBFXG5#&\,JJQD2LP>J*O#R8X*B
M&ZV&VOT>9HKGKI]+G>9R/ENZ77+.I]5EF@FM>6<R1R-RO;YD6)9%2*5KW,8J
M](V3B:U.3DQP:;+VB)KKSQSM=*S,6TYIYF<RKK!DW+FG]JM4BRIFJUT,5O?E
MMM/*VL?7T[$B5G"C,$XWMXN+Q=NW886Q6FVOD9TS5K2(\O0\K/EBYVW+F1,F
M7]JMO&;\SNOEYIDPXF1LP=+&JICM1CF*[H+LY#9O1,S,>2&O=F(K6>>9U>SH
MZ>IS1K'G6KI9$1+%9(;'1S[%2.HK6K/BGBM=QHIKGZ-(VRVQ]+).R-&$TSU+
MRWDK3R++%RCFCSE9%JXJG+[89$J9)TFDEV+PJU&\+L7/<N#41<=B;<LF.;6U
M\DL,62*TTGGCR/7:!TDT>GD-VJD1*R_5E9=:C!,$XYI5C1?HMC137GGZ6G0V
M\/'T->EAM9+S;+;GC3KV^G6CL%)65-RJJMS'OC26F8Q8$PC:Y57B3#=]<98H
MF:VTYV&:T1:NO,BS)F*S6'76FNV<)UMEIHK"Z.S5,K)%BEJ99OOBHK6NVHQ[
MVJGB)XF,UK,X](Z2UHC+K/0HL5\;G;6V>_.IYJ2Q97LKG43ZJ-8GOZ[7^.<Q
MW3,22-[U9Q)BK$1<$Q%J[N/3RS**VWLFODB&0T7JFTF0;[GVX,P=>:^Y7R=Z
M['+#&KDPQY$18WX>.8YHUM%66&?HS;IUE1I3,_+&BU7FRI5$K:MEROU0KTP1
M9<7\'C\38F>23E^EDTZC%]''KUO$Q6"LL&F&FF99:66HMMKNL=^OS(F++)S%
M3)SK9U8F]&1\.WQ3;O:WM&S1IW=*5G;J];J#GJUZCV5,@:=S^W-UOCXHZRIA
MCD2GHJ-LB/?+,][6HF/#P\/C\O"BZL=)I.];R-N3)%XW:\NJ^R_015>M57#&
MWG*')67Z.U4[O.SU6$B.7D1RQ\3?&(M/_K\\IK&N3[L-NG.Z@
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MD2)R 2-W@2)O ^D)  %M4UL5(^".1'*M0](V<*(J(JJB;<53H@7(
M                    %O15D5? E1"CFL55;@]$1=GC*H%P
M  !JO*W[<<^>M+=_1X"XS_@\7GM\LO$^'_\ -\5]W'_EJVH4[VP
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MN7>JX<H0D"0
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M?\>U._2VO]$IGXMSX_NPS\(^K?[\MX%&O
M
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M (]J=^EM?Z)3/Q;GQ_=AGX1]6_WY;P*->
M
M   <]Z4?M;UD_.5#_6STN7\/B\T_,\O'XC+YX;F3<<3J?0*R1]"%;=X$B$"I
MN\D2(!(T"5I"5:;R1,T(2-WA*=@$@0D;N D;N"%:$B1.0"1N\"1-X'TA(  Q
M%Y_&;9ZX;]5 EEP@                           !B<N>YC?LW 98
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M_HE,_%N?']V&?A'U;_?EO HUX
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M',J+3,SK/.MR6(!VOX"'N3G;UQ;_ $%047B?/7K7/AO-;J=>E*N
M                YB\'?\>U._2VO]$IGXMSX_NPS\(^K?[\MX%&O
M
M                       .>]*/VMZR?G*A_K9Z7+^'Q>:?F>7C\1E\\-S)
MN.)U/H%9(^A"MN\"1"!4W>2)$ D:!*TA*M-Y(F:$)&[PE.P"0(2-W 2-W!"M
M"1(G(!(W>!(F\#Z0D  8B\_C-L]<-^J@2RX0
M    Q.7/<QOV;@,L              !JO*W[<<^>M+=_1X"XS_@\7GM\LO$^
M'_\ -\5]W'_EJVH4[VP     &,GOUMIYWT\LO#)&N#DP=O\ (-]<%[1K$.2_
M%XZSI,\I%?[9-*R&.7&1ZX-3A=O\@FW#WB-9A%>+QVG2)55=\MU#-S%3+PR;
M\,'+]1"*8+WC6(99.*QX[:6GE6[<TV=\C8FS8O<J-1.%V]5PZ!LGA,D1KHU1
MQ^&9TB>5-<+_ &VV.:RLEX%<G$FQR[/H(IACP7R?5AGFXO'B^M*R;G2P.<C4
MJ-J[/,/^Y-L\%ECR.>/$^'G[7RKVNOUNML,=15R\$<N' O"Y<<4QY$4T8\-\
MDZ5CE=.;B\>*L6M/)+'KGC+J;ZK[1_W)T]PS='R.2?%N&C[7[I]2^FS%:H+<
MRZR3843UP;)PNVKCANPQWFBO#WM?<B.5TWXS%7'VDS]%BWZ@Y:9OJ57_ ,#_
M +DZOT[/T?(XI\9X:/M?NE?PYIL\]HDOD<V-NB=P/EX7;%Q1-V&/UR<AS6X;
M)&3LYCZ3KKQ^&V*<L3]&&([YV4>S%_U<GW)U_I?$>S^^%=^O\'[?[I]3+VS-
M-GN])45M#,LE/3<2S.X7)@C&HY=Z)R*<N7ALF.T5M'+*PX?Q##GI-Z3K%>=B
M':G91:Y6K6+BBJB]))R?^$ZH\,XB?L_(X)\?X./M?NGU+^SYUL-]FDI[=.LD
MD;>-Z*UR=*B*O*B= T9^"RX8B;1HZN%\5X?B9F,<ZS#&SZHY0IY'Q2UBHYBJ
MUR<#]Z+AYTWU\+XBT:Q7Y');Q_@ZS,3;EC9*\L^?\N7VM;;[;4K)5/17-:K'
MIBB>.B&G/P.;#7>M&D.CA?%^&XB^YCMK*WK]3,IVVKEHJJK5M1$N#T1CUP7#
M'SILQ^&Y\E8M%>1JS>.<)BO-+6Y8\[[;=2LJW:MAM]%5J^JG<C(VJQZ8JNS>
MK1E\.SXZS:T<D>9.#QKA<UXI6VLSYTUYU!RU8:UUON52L=4Q$5S$8]<$7Q4:
MJ&&#@,V:N]6.1LXKQ?AN'ON7MI*QCU8R7(]K&UJ\3EP3[W)R_P#A-\^%<1$:
M[OR.:/\ L'!S/U_E9.^9YR]EV6*&Z5"Q23QI+&B,>[%CE5$78B]!3FX?@LN:
M)FD:Z.WBO$\'#3$9)TUC5BDU;R5V:O\ JY/N3J_2>(]G]\.+_P"P<'[7RLO=
ML[9?LE-2U=PJ5C@K$5:=W ]>)&[]S5P^B<F'@\N69BL:Z.[B/$L&"M;7G2+<
MS#KJWDI/]^7_ %<GW)U_I/$^S\CA_7^#]KY7KK7<Z2\4,-QH7\Y2SM1T;\%3
M%%3'<J(O*5F3';'::VYX7>'-7-2+UYI7AK;@ !C[W[EU/V*>B0"YH_Q.G_T;
M/0H!.                           #@+]]3]8OP)Z+\IU//\ YKK<T%JK
M8 D ZP\(+,]RR/I'I]IGEBGCH\J7VR05=SJ$B8_KJ1B0S*U'.1>%5D7GGN;T
MRJY-J)CC3<)2+Y;7MSQ*ZXN\X\=:5YIAI?1;4_-6F6;Z6HRTC9X;K/3TERMK
MHF2+50K)@D;7*U7L=B[I58J;<,<4V'?Q.&N2G+Y'!PV:V.\:>5ZCPM+%:[%K
M1=$M4;(67&FIKA50QHB-;4S-5)%P3<KU;QKXKL33P%IMBC7R-O'5B,G)Y8:/
M+!7@':_@(>Y.=O7%O]!4%%XGSUZUSX;S6ZG7I2KAK#PA\S7W)VCV9,QY:K'6
M^]T76/6M6QK'N9SU?3Q/P21KF[6/<W:G*=7"4B^6(GF_@Y>*O-,4S'/_ !>[
MRU53UN7+16U3UDJ:BBIIII%P17221-<Y=F";54T7C2TM])UK#1OA+:C:@9 O
M^GZY$>^;KM]UJKG:&L8]M;!;64L[HW*K5<F$:R_Q:H[;LQ7 [^#PTR5MO;/W
MZN'C,MZ6KN[?W-J4&>+;F[367/&5JG&FJK945=+)L5\,T<3\6/3:B/C>U6N3
MHH<DXYIDW;=+KC)%\>]7H:)JM4<^Q^"'0ZB,O4B9SEG<R2[<W#SBM2\2TV'!
MP<'\6U&^9^F=\8:=YW-.3^"OG-?NV_KR_P 7OY]*]:8X7R6_6>L6M8G% E19
MJ%\*O3:B/3%=B[MR^,NXYXSXO+C_ 'RZ)P9?)D_=#+Z$:AWS/^5[DW-4<+,U
MY;NE38[N^E16P32TO"J2L3<G$CL%1.5JK@B*B&'$XHQVC=YIC5GPV6<E9WN>
M)T>HU+S2F2L@9CS3Q<,UMH)Y:7'EJ7-X(&_^*1S&FK#3?O%>F6[-?<I-NB%W
MD>CO-!DZQ4F8ZJ6MS!'0T_MK4SKC(^K=&CI<?&>JHGB&.28FTZ<R<<3%8UYU
MI?-2\@Y:EN,-_P PT=NFM*T[;A'42<#XW5K'20-P7:Y7M8YR(W%<$4RKAO;3
M2.=%LU*ZZSS+)^L.E\>7(\VOS5;VY>EE6FBK%F3IIVIBL2,\VKT1>)6\..&W
M<3W?)O;NDZL>WQ[N]K&B2ZYUM5ZTXO\ FS)5W@KX:>VU\U'<*-[96LJ*>G>]
M,=^#FJB+PN3QT%<<QDBMH\L%LD32;5GR2U)IQE76+/>1K'F^75VOHI+O3)4N
MI&VNAE;&JN5.%'+PX[N@=F:^*EYKN1R;9<F*F6](MOSR[(9S3_-.H.7-6ZW2
M#/M[BS5#+:$OMFOK*:.CJ61I-S*PSQP]+R.7%<5V)MZ;9KRTI;%VE8W>7289
MXKWKD[.T[W)K$O&Z=ZZYGI-9<TY2SW4NGR;<,Q7*Q99N<K(V1TE=15#DCI%<
MQK=DD;V-17XKQ<.'UV&_+PU9Q1:O/I$RTXN)M&6:VYM9B&P=;\X9DROF/2ZB
ML->^BIK]F>CMUVC8UCDGI)98FOC7C:Y414<NUN"G-PV.MJWUCFJZ.)R6K:FD
M\]GJ]8,[IIWIQ?LTQN1*^GIUAMC=BJZNJ52&#!JHO%@]R.5/.HIIX?'VEXJW
M9\G9TFSQFA.;\YRW',VG&IE:M=G;+[Z:NCJWQLB6>WW"!CTP;&B-7FGJK7.3
MSR)O13?Q..FD7I]66CALEM9I?GANLX7<  .8O!W_ ![4[]+:_P!$IGXMSX_N
MPS\(^K?[\MX%&O
M                                            .>]*/VMZR?G*A_K9
MZ7+^'Q>:?F>7C\1E\\-S)N.)U/H%9(^A"MN\"1"!4W>2)$ D:!*TA*M-Y(F:
M$)&[PE.P"0(2-W 2-W!"M"1(G(!(W>!(F\#Z0D  134T$[HWRLXG1.XXUV['
M)R[ )0                            (J>GAI8^:IV<$>*KPIBNU?' E
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MA(0R  %$T,=1&Z&9O%&[8YJ\O+R 5,8UC&L8F#6HC6IT$38!]
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M7^B4S\6Y\?W89^$?5O\ ?EO HUX
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ME2N[6(90P9@',7@[_CVIWZ6U_HE,_%N?']V&?A'U;_?EO HUX
M
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MD D;O D3>!](2  +:IHHJM\$DBN1:=Z2,X51$545%VXHO0 N0
M                 +>BHXJ"!*>%7.8BJ[%ZHJ[?&1 +@              #
M5>5OVXY\]:6[^CP%QG_!XO/;Y9>)\/\ ^;XK[N/_ "U;4*=[8          +
M=U'$ZM;7*KN>8SFT;BG#ABJ]#'';T0+@                           $
M-53,JZ=]-(JHR1,%5N"+L7'E10*XHTBC9$W%6L:C45=^")@!6
M                #@+]]3]8OP)Z+\IU//\ YKK<T%JK8 D [TT6N7@X:<Y4
MMU9;LQVJESI7V^%]TN=;.R:LBJ9H6NDC3'!&,8]<.!F&.'38KM/.\1&?):=8
MG35Z'!.''7DF-?.\EG+).AF?[N^^9NUPEN5>[%&+)-2)'$Q?K(HVQHQC?$:B
M&['DS8XTKCT]+5DQXLDZVO\ OAS5JAE[*&5\VSVG(U\[H<OLAA?%<^)C^.1[
M<7MQC1$Z5=A:X+WM76T:2J\]*4MI6=8>--[G .U_ 0]R<[>N+?Z"H*+Q/GKU
MKGPWFMU.O2E7                         <Q>#O\ CVIWZ6U_HE,_%N?'
M]V&?A'U;_?EO HUX
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M_P";XK[N/_+5M0IWM@          Q[ZJ9MYCHT=]X="LBMP3'BQ<F_Z &0
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M/BG'>:O(FYH .U_ 0]R<[>N+?Z"H*+Q/GKUKGPWFMU.O2E7
M            <Q>#O^/:G?I;7^B4S\6Y\?W89^$?5O\ ?EO HUX
M
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MN"%:$B1.0"1N\"1-X'TA(  LJZB?5RTDC7(U*>5)'(O*B*BX)Y %Z
M                     !96NB=04B4[W(]R.5W$FQ-H%Z
M!JO*W[<<^>M+=_1X"XS_ (/%Y[?++Q/A_P#S?%?=Q_Y:MJ%.]L
M%D^B<ZYQU_$G R+FE9RXXJN/TP+T                           %M7TS
MJRDEIFN1KI$1$<NY,%10)8(UB@CB5<58QK57[%, )
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M'JKEGJFM>V/APP3I5=MQY#9--*Q/2U1?6TUZ'L#6V@
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M/_+5M0IWM@          LGUKFW..@X4X'Q<ZK^7'%4P^D!>@
M               MJ^I=1TDM2UJ.=&B*C5W+BJ(!+!(LL$<JI@KV-<J?9)B!
M(                           #@+]]3]8OP)Z+\IU//\ YKK<T%JK8 D
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MR<LQ"<6/DB9EN8YG6
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MO D3>!](2  ,=<J2>IFH7Q-Q;#,V21<43!J*G1\8#(@
M           8^S4LU'1)#4-X9$<Y<$5%V+XP&0               U7E;]N.
M?/6EN_H\!<9_P>+SV^67B?#_ /F^*^[C_P M6U"G>V          #'OI9G7F
M.L1OWAL*QJ[%,>+%R[OH@9                            %I<X)*F@F@
MA3&1Z(C45<-RHO*!-3,='3PQOV.8QK7)XJ(B 2@
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M=IIIKK,MJ4]/#24\5+3L2.G@8V**--S6,3A:B>,B'.Z$@2
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M^6K:A3O;          !;NK(FUK:%4=SSV<XCL$X<,53HXX[.@!<
M                   AJJEE)3OJ9$561IBJ-P5=JX<JH!7%(DL;)6XHU[4<
MB+OP5,0*P                           <!?OJ?K%^!/1?E.IY_\ -=;F
M@M5; $@      .U_ 0]R<[>N+?Z"H*+Q/GKUKGPWFMU.O2E7
M             <Q>#O\ CVIWZ6U_HE,_%N?']V&?A'U;_?EO HUX     !X/
M,&D64[_=ZB^\==:[G6(U*Z:UU3Z5*CAP1.<:F**N"8*J(F/C[3;7+:(T:+8:
MS.KTF6<KV3*%JCLU@I4I:%CED<F*O?)*[#BDD>Y55SEPVJOC;D0PM:;3K+96
ML5C2&8,68
M                             <]Z4?M;UD_.5#_6STN7\/B\T_,\O'XC
M+YX;F3<<3J?0*R1]"%;=X$B$"IN\D2(!(T"5I"5:;R1,T(2-WA*=@$@0D;N
MD;N"%:$B1.0"1N\"1-X'TA(  Q=VBEDJ+>Z-CGHR=KGJU%5&IBFU<-P&4
M                          Q=@BEAM[63,=&_C<O"]%:OD*!E
M       -5Y6_;CGSUI;OZ/ 7&?\ !XO/;Y9>)\/_ .;XK[N/_+5M0IWM@
M       Q<D4JWZ*9&.6%*=6K)@O"B\3MF.[$#*
M      L;Q&^6VU$<;5>]R)@UJ*JKTR<B 7%(U6TL#7(J.2-B*B[%14:@$P
M                         . OWU/UB_ GHORG4\_^:ZW-!:JV )
M =K^ A[DYV]<6_T%047B?/7K7/AO-;J=>E*N
M YB\'?\ 'M3OTMK_ $2F?BW/C^[#/PCZM_ORW@4:\
M
M           Y[TH_:WK)^<J'^MGI<OX?%YI^9Y>/Q&7SPW,FXXG4^@5DCZ$*
MV[P)$(%3=Y(D0"1H$K2$JTWDB9H0D;O"4[ ) A(W<!(W<$*T)$B<@$C=X$B;
MP/I"0 !%-4P0.C9*_A=*[@C3;M<O)L E
M BIZB&JCYVG?QQXJG$F*;4\<"4              #5>5OVXY\]:6[^CP%QG_
M  >+SV^67B?#_P#F^*^[C_RU;4*=[8          (EJ(4J$I5?\ ?W-XT9MQ
MX=V/T@)0                           4331T\;IIG<,;=KG+R<G(!4Q[
M7L:]BXM<B.:O11=H'T                           ' 7[ZGZQ?@3T7Y3
MJ>?_ #76YH+56P!(      #M?P$/<G.WKBW^@J"B\3YZ]:Y\-YK=3KTI5P
M                      ',7@[_ (]J=^EM?Z)3/Q;GQ_=AGX1]6_WY;P*-
M>
M                               <]Z4?M;UD_.5#_6STN7\/B\T_,\O'
MXC+YX;F3<<3J?0*R1]"%;=X$B$"IN\D2(!(T"5I"5:;R1,T(2-WA*=@$@0D;
MN D;N"%:$B1.0"1N\"1-X'TA(  Q%Y_&;9ZX;]5 EEP@
M           !B<N>YC?LW 98              #5>5OVXY\]:6[^CP%QG_!X
MO/;Y9>)\/_YOBONX_P#+5M0IWM@          Q,O]XH?6R^B<!E@
M                   8^]^Y=3]BGHD N:/\3I_]&ST* 3@
M              X"_?4_6+\">B_*=3S_ .:ZW-!:JV )       =K^ A[DYV
M]<6_T%047B?/7K7/AO-;J=>E*N                         YB\'?\>U.
M_2VO]$IGXMSX_NPS\(^K?[\MX%&O
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M6K:A3O;          !3C'QHBJG.8;$V<6 %0
M   /CU8C55ZHC.57;OI@$P5$5N[DPW8 ?0
M <!?OJ?K%^!/1?E.IY_\UUN:"U5L 2       [7\!#W)SMZXM_H*@HO$^>O6
MN?#>:W4Z]*5<                        !S%X._X]J=^EM?Z)3/Q;GQ_=
MAGX1]6_WY;P*->
M                                            <]Z4?M;UD_.5#_6S
MTN7\/B\T_,\O'XC+YX;F3<<3J?0*R1]"%;=X$B$"IN\D2(!(T"5I"5:;R1,T
M(2-WA*=@$@0D;N D;N"%:$B1.0"1N\"1-X'TA(  Q%Y_&;9ZX;]5 EEP@
M                        !B<N>YC?LW 98              #5>5OVXY\
M]:6[^CP%QG_!XO/;Y9>)\/\ ^;XK[N/_ "U;4*=[8          ,3+_>*'UL
MOHG 98                           &/O?N74_8IZ) +FC_$Z?_1L]"@$
MX                           . OWU/UB_ GHORG4\_\ FNMS06JM@"0
M     ':_@(>Y.=O7%O\ 05!1>)\]>M<^&\UNIUZ4JX
M      #F+P=_Q[4[]+:_T2F?BW/C^[#/PCZM_ORW@4:\
M
M              Y[TH_:WK)^<J'^MGI<OX?%YI^9Y>/Q&7SPW,FXXG4^@5DC
MZ$*V[P)$(%3=Y(D0"1H$K2$JTWDB9H0D;O"4[ ) A(W<!(W<$*T)$B<@$C=X
M$B;P/I"0 !%-303NC?*SB=$[CC7;L<G+L E
M    BIZ>&ECYJG9P1XJO"F*[5\<"4              #5>5OVXY\]:6[^CP%
MQG_!XO/;Y9>)\/\ ^;XK[N/_ "U;4*=[8          (EIX5J$JE9]_:W@1^
MW'AWX?3 E                           !1-#'41NAF;Q1NV.:O+R\@%3
M&-8QK&)@UJ(UJ=!$V ?0                           <!?OJ?K%^!/1?
ME.IY_P#-=;F@M5; $@      .U_ 0]R<[>N+?Z"H*+Q/GKUKGPWFMU.O2E7
M                        <Q>#O^/:G?I;7^B4S\6Y\?W89^$?5O\ ?EO
MHUX
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MX"1NX(5H2)$Y )&[P)$W@?2$@ #%7>1[*BW(QRM1U0U'(BJF*8IL4#*@
M                        8O+\DDMN:Z1RO=QNZ9RJJ_3 R@
M    &J\K?MQSYZTMW]'@+C/^#Q>>WRR\3X?_ ,WQ7W<?^6K:A3O;
M  !BY))$O\,:.7FUIU568KPX\3MN &4                           !8
MWA[V6VH>QRM<B)@YJX*G3)T +BD574D"JN*K&Q55=^/"@$P
M              . OWU/UB_ GHORG4\_^:ZW-!:JV )       =K^ A[DYV]
M<6_T%047B?/7K7/AO-;J=>E*N                         YB\'?\>U._
M2VO]$IGXMSX_NPS\(^K?[\MX%&O
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M  6U3115;X))%<BT[TD9PJB(JHJ+MQ1>@!<@
M    6]%1Q4$"4\*N<Q%5V+U15V^,B 7               &J\K?MQSYZTMW]
M'@+C/^#Q>>WRR\3X?_S?%?=Q_P"6K:A3O;          !;NHXG5K:Y5=SS&<
MVC<4X<,57H8X[>B!<                            AJJ9E73OII%5&2)
M@JMP1=BX\J*!7%&D4;(FXJUC4:BKOP1, *P
M  <!?OJ?K%^!/1?E.IY_\UUN:"U5L 2       [7\!#W)SMZXM_H*@HO$^>O
M6N?#>:W4Z]*5<                        !S%X._X]J=^EM?Z)3/Q;GQ_
M=AGX1]6_WY;P*->
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M6_WY;P*->
M                                       6.F']T6^O:W^DO.?P7\-_
M-;_,Z/'OQ?\ +3_+#T\Q:V4U6,GWG-9UT6$^\YK.JK'3;CGLZ:+"8YK.RO.P
M]5RG'=W48>I.*[OHQ%3N4XKK#&PU5RG#=88V)?#-4SQTM-&Z:IG<C(H6)BYS
MEW(B'+-+7M%:QK,\T.W?K2LVM.E8YY;[R+8*W+EBAH*^H=-4.<LKHL>*.'C_
M /EL7H)R\F..!]4\(X*_"X(I>=9Y]/)&R/VYWQOQOC\?&<3-\==(YM?+;;/[
M<SU32Y4*1N\)3L D"$C=P$C=P0K0D2)R 2-W@2)O ^D)  %G74+JN6ED1Z-2
MGE2545,<<%1</I 7@                            %G;*);?2I3J_G%1
MRNXD3#>!>               :KRM^W'/GK2W?T> N,_X/%Y[?++Q/A__ #?%
M?=Q_Y:MJ%.]L          %F^B5UR97\>QD7-<&&W>JXX_1 O
M                 6]=3+64DM,CN!9$1.)4QPP5% D@CYJ&.)5QX&M;CT>%
M, )                            <!?OJ?K%^!/1?E.IY_P#-=;F@M5;
M$@      .U_ 0]R<[>N+?Z"H*+Q/GKUKGPWFMU.O2E7
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M[CEJK6MHJ>9U-+-S4L+>=:B.5$YUC.+8Y%Z7HBU)KSE+Q:-89TQ9@
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MWM@          LGUKFW..@X4X'Q<ZK^7'%4P^D!>@
M        MJ^I=1TDM2UJ.=&B*C5W+BJ(!+!(LL$<JI@KV-<J?9)B!(
M                     #@+]]3]8OP)Z+\IU//_ )KK<T%JK8 D      !V
MOX"'N3G;UQ;_ $%047B?/7K7/AO-;J=>E*N
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M,1<,4:B)N1$3=XB(ARNM4$@
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M(5H2)$Y )&[P)$W@?2$@ #'W&DFJ9J)\2(K8)DDDQ7#I45%_R 9
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MT\,Z2N8L44=*S@:V)&L:J([8KN)SMN[ PF\S$1T,XI$6F>EGS%L
M                                              Y[TH_:WK)^<J'^
MMGI<OX?%YI^9Y>/Q&7SPW,FXXG4^@5DCZ$*V[P)$(%3=Y(D0"1H$K2$JTWDB
M9H0D;O"4[ ) A(W<!(W<$*T)$B<@$C=X$B;P/I"0 !;55:RDDIXWM5RU#TC:
MJ8;%543;Y(%R                            !;4-;'7TZ5$;5:U55N#L
M,=GC 7(           QN8++#F*SU5EJ*B>EAJVM:^HI'I%.SA<CL6.5KD3=T
M#;ARSCO%HB)TZ7'QG"UXG#;%:9K%O+6=)ZI:][P&2W[*BLNM2U?XQLM6BH]?
M\["-"S_5LWDBL=3RO_T[@I^M;);SV_@OZ#0W3.A5'K9UJI$W.J9YY$ZE'HW[
M4UW\4XBWVM.J'5A_ZGX;CY>SWO/:T_/H]S;;3:[-3)1VBB@H:1%Q2&FC;"S'
MHX,1$Q\4KKY+7G6TS,[7I,'#XL%=W'6*1T1&GR+PP=           6SJV-M<
MR@5J\X^/G4=LX<,53#Z0%R                           "&KJ64=/)4O
M17-C1%5&[]JX<H%<4B2Q,E1,$>U'(B[\%3$"L
M    ' 7[ZGZQ?@3T7Y3J>?\ S76YH+56P!(      #M?P$/<G.WKBW^@J"B\
M3YZ]:Y\-YK=3KTI5P                        ',7@[_CVIWZ6U_HE,_%
MN?']V&?A'U;_ 'Y;P*->      4OCCE;P2-1[,47A<B*F+5Q1<%Z"IB$*@D
M
M                    '/>E'[6]9/SE0_UL]+E_#XO-/S/+Q^(R^>&YDW'$
MZGT"LD?0A6W>!(A J;O)$B 2- E:0E6F\D3-"$C=X2G8!($)&[@)&[@A6A(D
M3D D;O D3>!](2  ,9=899:BWNB8KVQSM<]43'!J*FU0,F
M              !C+##+!;VQS,6-_&Y>%R8+@H&3
M       !C)(95OL4Z,7F4IU:LF'2\7$[9B!DP
M    65WCDFMT\<35?(Y$X6MVJO3(!/2M<RE@:Y,'-C8BHN]%1J 3
M                    X"_?4_6+\">B_*=3S_YKK<T%JK8 D      !VOX"
M'N3G;UQ;_05!1>)\]>M<^&\UNIUZ4JX                        #F+P=
M_P >U._2VO\ 1*9^+<^/[L,_"/JW^_+>!1KP
M
M     #GO2C]K>LGYRH?ZV>ER_A\7FGYGEX_$9?/#<R;CB=3Z!62/H0K;O D0
M@5-WDB1 )&@2M(2K3>2)FA"1N\)3L D"$C=P$C=P0K0D2)R 2-W@2)O ^D)
M $,U5!3NB9,_A=,Y&1I@JXN7DV(!,                            !#3
M54%7%SU._CC553BP5-J>.B 3                            A6J@;4MI
M%?\ [0YO&C,%\SM3''##D F                           !'//%31.GF
M=PQ,VN=@JX<FY,0*F/;(QLC%Q8]$<U>BB[4 J
M    !P%^^I^L7X$]%^4ZGG_S76YH+56P!(      #M?P$/<G.WKBW^@J"B\3
MYZ]:Y\-YK=3KTI5P                        ',7@[_CVIWZ6U_HE,_%N
M?']V&?A'U;_?EO HUX
M                                               !SWI1^UO63\Y4
M/];/2Y?P^+S3\SR\?B,OGAN9-QQ.I] K)'T(5MW@2(0*F[R1(@$C0)6D)5IO
M)$S0A(W>$IV 2!"1NX"1NX(5H2)$Y )&[P)$W@?2$@ #$7G\9MGKAOU4"67"
M                            &)RY[F-^S<!E@
M        8F7^\4/K9?1. RP                           ,?>_<NI^Q3
MT2 7-'^)T_\ HV>A0"<                           ' 7[ZGZQ?@3T7Y
M3J>?_-=;F@M5; $@      .U_ 0]R<[>N+?Z"H*+Q/GKUKGPWFMU.O2E7
M                      <Q>#O^/:G?I;7^B4S\6Y\?W89^$?5O]^6\"C7@
M
M                             '/>E'[6]9/SE0_UL]+E_#XO-/S/+Q^(
MR^>&YDW'$ZGT"LD?0A6W>!(A J;O)$B 2- E:0E6F\D3-"$C=X2G8!($)&[@
M)&[@A6A(D3D D;O D3>!](2  *'NB:K$D<U'*N#.)4157Q,>4"L
M                   "B-\3V\4+FN9T6*BIC] "L
M        %"OBYQ&*YO/*F*-Q3BP\;?@!6
M"E[F-8KI%1&)O5V")],#ZU45$5N"M5-BINP ^@
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MC=P0K0D2)R 2-W@2)O ^D)  &(O/XS;/7#?JH$LN$
M         ,3ESW,;]FX#+                            Q,O]XH?6R^B
M<!E@                           8^]^Y=3]BGHD N:/\3I_]&ST* 3@
M                          X"_?4_6+\">B_*=3S_ .:ZW-!:JV )
M   =K^ A[DYV]<6_T%047B?/7K7/AO-;J=>E*N
M   T#X+_ /B?^F5R_@ECQOV/NPK^#^W]Z6_BN6
M
M        '+>GW[:M:?SC;O05)8<3_:Q^:?F5_#_W<GGCYVV4W%<L7T"LD?0A
M6W>!(A J;O)$B 2- E:0E6F\D3-"$C=X2G8!($)&[@)&[@A6A(D3D D;O D3
M>!](2  (Y:>&9T;I6(YT3N.-5Y')R@2
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M@
M                              !RWI]^VK6G\XV[T%26'$_VL?FGYE?P
M_P#=R>>/G;93<5RQ?0*R1]"%;=X$B$"IN\D2(!(T"5I"5:;R1,T(2-WA*=@$
M@0D;N D;N"%:$B1.0"1N\"1-X'TA(  Q5WD>RHMR,<K4=4-1R(JIBF*;% RH
M                            &+R_))+;FND<KW<;NF<JJOTP,H
M                     #%R22)?X8T<O-K3JJLQ7AQXG;< ,H
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MV7.W7JWTUVM-5'6VRLC;-2U<#DDBDC>F*.:Y-BHISVK,3I+HB8F-879"0
M  - ^"__ (G_ *97+^"6/&_8^["OX/[?WI;^*Y8
M
M         <MZ??MJUI_.-N]!4EAQ/]K'YI^97\/_ '<GGCYVV4W%<L7T"LD?
M0A6W>!(A J;O)$B 2- E:0E6F\D3-"$C=X2G8!($)&[@)&[@A6A(D3D D;O
MD3>!](2  +>IHXJI\$DN/% ])&8+ATR;=OD 7
M      %O1T<5#"D$./ BJO3+BN*@7                            +=U
M'$ZL;7+CSS6<VFWI>'%5W?1 N                            15-/'5P
M/IY<>;>F#N'8NQ<0*XXVQ1LB;YEC4:F._!$P J
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M^"_M[-9;H.%V@     :!\%__ !/_ $RN7\$L>-^Q]V%?P?V_O2W\5RP
M
M                         XWT[RWJ9F2NS1GW+=[M]%57ZXNBNG7<*N=)
M)1<7 K6MC<UJ82KN+_/&*-VEHGDCIZ7AN!R\;EBV2MZQO3//7H>Y7*FO#?\
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M5;BF*)RH!-)64D53#123QLK*A'.@IW/:DCVQX<2M;CBJ-Q3%4W 3@
M
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M<7!SB(G%ACA@J+NQ3H 2PQ\S#'%CCS;4;CNQX4P K
M        !P%^^I^L7X$]%^4ZGG_S76YH+56P!(      #M?P$/<G.WKBW^@J
M"B\3YZ]:Y\-YK=3KTI5P    "Q;>K,Z[NR^VXTRWYD'7C[6DT:UB4O$C.>6'
MBXTCXE1O'PX8[#+=G373D8[T:Z:\I:;U9K_2+7V*XTUSH4>Z):FBFCJ8N<C7
M!S>.-SDXFKO3'8+5FLZ3&A6T6C6)U7QBR        +*.[VF:YSV6&OIY+S2Q
MLGJ;<R9CJF*&38Q[XD7C:UW(Y4P4RW9TUTY&.]&NFO*O3%D     !H'P7_\
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MFM8B(UW%).].)[N'!C$X=ZNV!NI,<-N_E
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M@                            +*U5LE?2)42-1KE<K<&XX;/' O0
M                       63ZV1MTCH$:G-OBYU7;>+'%4P^D!>@
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MI*]RU&+EWJJ->UNWH ;#
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M=P0K0D2)R 2-W@2)O ^D)  &/N-)-4S43XD16P3)))BN'2HJ+_D R
M                      %A9Z2:BHD@G1$D1SEV+BF"@7X
M              +!]),Z\1UJ(G,-AYM5QV\6*KN^B!?@
M           M+G3R55#-3Q8+(]$1N*X)L5% FIF.BIXHW>:8QK7>.B(@$H
M                         . OWU/UB_ GHORG4\_^:ZW-!:JV )
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ML[S.I.G68L].ZTR_59&H\FSW.1%=34-UHECE5DCTQ1C7\&#5W;7+N15-L_\
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M
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M88JF'T@+H                           $%94MHZ:2I<U7-C1%5J;UQ7
M"2*1)8F2HF"/:CD3[),0*P                           <!?OJ?K%^!/
M1?E.IY_\UUN:"U5L 2       [7\!#W)SMZXM_H*@HO$^>O6N?#>:W4Z]*5<
M  "UN-MMUWHY;==J."OM\Z(DU)51LGA>B+BB.8]%:NU.5"8F8G6$3$3&DL32
M9$R106Z>T4.6K52VFI<U]3004--'3RN8O$U7QM8C7*B[4Q0SG+>9UF9U\[",
M5(C2(C1E6VNV,N*W=E% V[.AZU=7I$Q*A:='([FEDPXN#%,>''#$PWITT\C/
M=C77REOM=LM-,M':J*"AI%<Z1:>FB9#&KW[7.X6(B8KRJ)M,\Y%8CF8NWY&R
M3:;DZ\VK+=JH;N]55]PI:&GAJ55V_&5C$<N/CF<Y;S&DS.C",=(G6(C5Y'4Z
MBU-2YVZZ9/H*+->5N8DILP9'N+J:G2J555T4T51/$]$<W'!S7NX=B;%WINPS
MCTF+3NSY):<T9-8FL;T>6'F<HY&SK?\ 46Q9YS3EN@R-EW*%-6PY>RQ0U$57
M,ZJN4?,SS2NI6MA:U6<C=N*)OWFW)EI6DUK,VFW//F:L>.]KQ:T16*\T>=MN
M^Y2RKFAL;<RV.WWEL/\ $I<:2"K1F/G>>8[#Z!QUR6KS3,.RU*VYXB5W#9K1
M36Q;)3V^FBLRQN@6W1PQMI5BD14<SFD1&<+D545N&"D;TZZZ\J=V---.1*V@
MH64*6ME+"VV-A2F;1)&U($@1O D:1X</!P]+PX88;"-9UU3I&FBEELML=O2T
MQT<#+4V/F&T+8F)3I#AAP)&B</#ALX<,!O3KKY32--/(QMDR5DW+4\E5ES+U
MLM%5,BMEGM]%3TLCT5<51SHF-5?HF=LEK<\S+"N.M>:(ADF6VW15TMTCI(67
M*=C8IZQL;$G?&S:UKI$3B5J<B*IAK.FC/2-=6+N61\EWFXLO%WRY:[A=HU18
MZ^KH:>>I:K=V$DC%<F&&S:9QDO$:1,Z,)QTF=9B-6>1$1,$V(FY#6V     T
M#X+_ /B?^F5R_@ECQOV/NPK^#^W]Z6_BN6
M
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MR)PM;M5>F0">E:YE+ UR8.;&Q%1=Z*C4 F
M !P%^^I^L7X$]%^4ZGG_ ,UUN:"U5L 2       [7\!#W)SMZXM_H*@HO$^>
MO6N?#>:W4Z]*5<                        !H'P7_ /$_],KE_!+'C?L?
M=A7\']O[TM_%<L
M                                            .6]/OVU:T_G&W>@J
M2PXG^UC\T_,K^'_NY//'SMLIN*Y8OH%9(^A"MN\"1"!4W>2)$ D:!*TA*M-Y
M(F:$)&[PE.P"0(2-W 2-W!"M"1(G(!(W>!(F\#Z0D  03U<-,^)DJJCIW)''
M@BKBY0)P                            (:6JAK(N>IW<4:JJ8JBIM3QP
M)@                           0K50MJFT:N^_N9SB-P7#AQ5-_T )@
M                         1U$\=-"Z>9<(V;7*B8[UPY *F/;(QLC-K7H
MCFKXBIB!4                           #@+]]3]8OP)Z+\IU//\ YKK<
MT%JK8 D      !VOX"'N3G;UQ;_05!1>)\]>M<^&\UNIUZ4JX
M             #0/@O\ ^)_Z97+^"6/&_8^["OX/[?WI;^*Y8
M
M                   <MZ??MJUI_.-N]!4EAQ/]K'YI^97\/_=R>>/G;93<
M5RQ?0*R1]"%;=X$B$"IN\D2(!(T"5I"5:;R1,T(2-WA*=@$@0D;N D;N"%:$
MB1.0"1N\"1-X'TA(  Q%Y_&;9ZX;]5 EEP@
M  !B<N>YC?LW 98                           &)E_O%#ZV7T3@,L
M                        #'WOW+J?L4]$@%S1_B=/_HV>A0"<
M                   ' 7[ZGZQ?@3T7Y3J>?_-=;F@M5; $@      .U_ 0
M]R<[>N+?Z"H*+Q/GKUKGPWFMU.O2E7                         :!\%_
M_$_],KE_!+'C?L?=A7\']O[TM_%<L
M                                                           .
M6]/OVU:T_G&W>@J2PXG^UC\T_,K^'_NY//'SMLIN*Y8OH%9(^A"MN\"1"!4W
M>2)$ D:!*TA*M-Y(F:$)&[PE.P"0(2-W 2-W!"M"1(G(!(W>!(F\#Z0D  4N
MDC8K4>]&J]<&HJHF*]! *@                            *621RMXHW(
M]OGFJBI]("H                           %/.1H](U<G.*F*,Q3BPZ.
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M85_!_;^]+?Q7+
M                                           #EO3[]M6M/YQMWH*D
ML.)_M8_-/S*_A_[N3SQ\[;*;BN6+Z!62/H0K;O D0@5-WDB1 )&@2M(2K3>2
M)FA"1N\)3L D"$C=P$C=P0K0D2)R 2-W@2)O ^D)  $<D$,KF.E8CW1KQ,54
MQP=T4 D                             CAAB@9S<+$C9OX6I@F*@2
M                         C6&)94G5B<\B<*28=-P]#$"0
M                %,D<<S%CE:CXW>::[:B@?6M:QJ-:F#6I@B)N1$ ^@
M                        X"_?4_6+\">B_*=3S_YKK<T%JK8 D      !
MVOX"'N3G;UQ;_05!1>)\]>M<^&\UNIUZ4JX                        #
M0/@O_P")_P"F5R_@ECQOV/NPK^#^W]Z6_BN6
M
M      '+>GW[:M:?SC;O05)8<3_:Q^:?F5_#_P!W)YX^=ME-Q7+%] K)'T(5
MMW@2(0*F[R1(@$C0)6D)5IO)$S0A(W>$IV 2!"1NX"1NX(5H2)$Y )&[P)$W
M@?2$@ #$WASFU%M1KE1%J&HN"X8IB@&6
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M_P"F5R_@ECQOV/NPK^#^W]Z6_BN6
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MS$QSHB8GF71"0        !H'P7_\3_TRN7\$L>-^Q]V%?P?V_O2W\5RP
M
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M ^D)  &-NE1-!/0-B>K6RSM9(B8;6JJ; ,D
M   !CK'4355 DM0_CD5SDXEP38GC 9$                           &.
MDJ)DO<5*C_O#H%>K-F'%BY,?I 9$                           %G=9I
M*>WSS0NX9&HBM<G)TR)R@3TKW/IH7O7%SF-<Y>BJHB@2@
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M]52OH:FJIXIYJ&7;)!)*Q'.B=L3IF*O"NPBT:3HFLZQJO#%D
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MFXN#G$1.+#'#!47=BG0 EACYF&.+''FVHW'=CPI@!6
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M[OTJ;MNF.9MX?3>^C?>KT3SMXG [P
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MFU43D5 )J>198(I78(Y[&N5$W8JF($@                           .
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M6F:^J])77"2A@=.LJ+BDBN5F*O\ \]>F\4VQFO$:;TZ-4X:3.ND:O4FIM
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M]W=B/WN@2N6(
M                  <^>#S_ '*N/YYK?J1EUQ?U^J'C?!OP_P#-;Y6U'G'"
MXE _<90PE \SAKE XR:Y02<IDURPM=RG156Y7FZWE.JJHS/.UV]3IJJ,KSE=
MN4ZJJ?,\;?JEC6LHF0K5UE8O,TU$Q%>^5[UP1$:F*[U-UKQ6LS+@Q\/?-DBM
M.=T5HID:]9&RNM+?*Q\E56O2I2V\7%#1XHN+&+MZ9V.+\%PQW<JKXOC,]<M]
M:Q_%]S\%X#)PF#=O;69Y=/)7S?/Y&SVG"O4C=X2G8!($)&[@)&[@A6A(D3D
MD;O D3>!](2  +"XT<U5-1/BPX8)DD?BN'2HJ+L\@"_
M            L+11RT-&D$V'&CG+TJXI@H%^
M   "P?1RNN\=<F',MAYM=O3<6*KN^B!?@
MM;E3R5=%-3Q8<X]$1O%L38J*!-3L=%3Q1.\TQC6KANQ1, )
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MV@            :!\%__ !/_ $RN7\$L>-^Q]V%?P?V_O2W\5RP
M
M                     Y\\'G^Y5Q_/-;]2,NN+^OU0\;X-^'_FM\K:CSCA
M<2@?N,H82@>9PUR@<9-<H).4R:Y86NY3HJK<KS=;RG5549GG:[>ITU5&5XK,
M=V9;FQP11NJ;G5.2*BHHT5TDLCEP1$1,5PQ4Z-Z*QK*MG%;):*UC69;6TFTH
M7+CDS7FM&U.;ZEN,<:X.CHHW)YAF]./!<'.3=N3E5?,<;QLY9W:_5^5]3\$\
M$KP==^\:Y)_P_P >F6W4WE8]2F:$)&[PE.P"0(2-W 2-W!"M"1(G(!(W>!(F
M\#Z0D  6E97)224T:LX^N)$B1<<,,51,?I@78
M     %K;JU+A3)4(SFT55;PJN.X"Z                           !:NK
M4;<&4'!M?'SO'CLWJF&'T +H                           $%;4I1TLE
M2K>-(T1>%%PQQ5$ DADYV*.5$PXVH[#H<28@5@
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MPK^#^W]Z6_BN6
M                                           '+FB6>,H9>RK<*"^7
MJDM]:MVK)4@J)6QOX'<"([!>1512^XG%>U]8B9Y(>$\*XO#CP[MKUK.];GF.
MEL9VJ>G*[LSV[V0SRSF[#)[,K.>/X?WE?ZH0NU1TZ7=F:W>R&>63V&3V98SQ
MW#^\K_5"!^I^GB[LRV_V0SRS.,-^B6N>.X?WE?ZH1.U-T^7_ *EM_P#KV>63
MV-^B6$\;@]NOIA"_4O("XX9DH/\ 7L\LR[*_1+">,P>W7TPQ-9J'D9^/!F"A
M7QIV>6;ZX[=$N#+Q.*?MU],,%5YYR>_'AO=&OC3-\LZ*UGH5>7+2?M1Z8>7O
MF=K-'"C;3.RZW*=R0TE%2KSCY)7K@U,&XKAB;XY(UE6V^G.E>69YHAL;2W2Z
M2QR]UV;N&JSA5-Q8Q<'1T,;D_BX]Z<>"X.<F[<G*JT'&<9.2=VOU?E?0O!O!
MHX6.TR<N2?\ #LCYY;::5;U"M-Y(F:$)&[PE.P"0(2-W 2-W!"M"1(G(!(W>
M!(F\#Z0D  8RZP333T#HF*YL<[72*G(U%3:H&3
M       QMB@FIJ!(IV*R3B<O"N_!0,D                           #&
MR03+?(JA&+S#8%8K^3BXG;/I@9(                           %E=HI)
M[=/%$U7R.1.%J;UZ9 +BE:YE-"QR8.;&U')T%1$ E
M        !P%^^I^L7X$]%^4ZGG_S76YH+56P!(!Z#*N><WY'JWUN4KU5VBHE
M1$FZUD5K)$3:B2,VM?A_G(IKR8J7CZ4:MN/+>GU9T>QN&M^K^>Y8,OWW.%:M
M!<9(J2HCITBI&NCD<C%1S:9D7$F"[47?RFB.&Q8^6*\SHCB<MYBLVYV-UETW
MBTISU4Y.AN+KHRG@@GZ\?$D"N6=B/PX$>_##'#S1EPV;M:;VFC#B<,8K;L/
M'2Y0#M?P$/<G.WKBW^@J"B\3YZ]:Y\-YK=3KTI5P 1SI,Z"5M.Y&3JQR1/=M
M1'JFQ5\9281+DO3BSP93MU1;\\:/7C-6KBU=4^IOU5;XKA0UL\D[EBE2XU3E
MBB;PJU'.\17;<<"WS6WYUK>*TZ-?F5&*N[&EJ3:_3I\ZZRSI?GJZ^#SJ-IW<
MK,ZVYJJ;W4U=#2K]ZIZGFIJ6J8M/(]$:L;W0NC8N.&[%4Q(OFI&>MXG6-/6R
MIAO.&U)C2=?4N]0<XZ@ZD:2W#(=GTSS#07Y]' R\5%RI>MZ)B4KV/>VC=Q*^
MI<]T:,8C6)L=Q+L12,6.F/)%IO&G[<_0G+DODQS6*3K^W-TO0:IV?,]OAT@S
M=;LOU][AR=*V2]6RV1<_<&MDI(F=)#BBN5%C<B]!<#5@M6=^LS$;W,V9JVC<
MM$3.[SI)'9ITZU+NNIU'E2ZWK)VH%OMTEXMUK@;/=K9<:.%&,22E1R.>G"YW
M'PKL<J]!$<^CDQQ3>B)K,\_-,)^ECR3?29BT1YX7N6*'-.H^K]#JA=+#6Y7R
MEEJVSV^R4=XCZWN5955BJDLKX.)5BC1BX8.V[M^*\.-YKCQ;D3O3,\NG,FD6
MR9=^8TB(Y->=X7+^DV=;KH#[30T$EMSO9,S2YCLE%7LYA9)J:=5C1>/#A1['
MOX7;L<.3:=%\](S:ZZUF-):*X+SATTTM$ZP]1G7/V>M2<G5NGV7M.<P6G,^8
M(?:ZXUEYINM;10PS8,J)$J^+"9$:KD9P-Q7?ACTJZ<>*F.V_-HF(Z.?T-N3+
M?)7=BLQ,]/,^W#)69](\WY:SOE"T3YLM%'ENEREF6V4*L2X<U0HQ(*R&-[DX
MU7FT:K$7<GBJJ(R5RUFMIW9UUCU$X[8K1:L;T::3ZV#ES!F?.'A*Z:76ZV"?
M+5FIZ.]>U5ON;HVW.1G64K)9YH8U>D2.<]C&,5ZKTCEY39N5I@O$3K/)YN=A
MO6OGI,QI'+Y^9F<GUN9M!JK,&4;GD^]YCRG67.INV6KMEND2XJV"L5'+33Q,
M<U8W,5NQR[%55W)@89(KGTM%HB=-)UY&>.;8-:S69C76-.4L.G.<LY6K5O-N
M9*'VBOFH]%[7V6QS2(LM)3T=))3TRU+DXD:Z158KVINP7E7!%LU*32L3K%.>
M2N*UXO:>2;\T,)#FS4.LT;?I#3Z:7^#-]/8'Y>JJZJIVQ6=((:1:9TT=5QKS
MKW1IBR.-JXO7!%7ES[.D9>TWXTUUVM<7O.+L]R==--C/PIG_ "GIEIM2/R=W
M395IK9%29XRPM(RHNK,(&I$Z*"9R-?P/QXV<..Q-R*JIK^A;)?Z6DZ\D^1L^
MG7'3Z.L:<L>5ALDY.BN.L]CSEIUD6Z:?96MM-6,S/+=*=UJ9<5GBX8(8:%7K
ML8]>)7(UK=F.]K<=F3)IBFM[1:9YM.73K88\>N6+4K-8CG\FO4Z;*I:   !H
M'P7_ /$_],KE_!+'C?L?=A7\']O[TM_%<L
M
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MW 2-W!"M"1(G(!(W>!(F\#Z0D  03U<-,^)DJJCIW)''@BKBY0)P
M                    (:6JAK(N>IW<4:JJ8JBIM3QP)@
M             0K50MJFT:N^_N9SB-P7#AQ5-_T )@
M         1U$\=-"Z>9<(V;7*B8[UPY *F/;(QLC-K7HCFKXBIB!4
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M]O[TM_%<L
M                                       .6]/OVU:T_G&W>@J2PXG^
MUC\T_,K^'_NY//'SMLIN*Y8OH%9(^A"MN\"1"!4W>2)$ D:!*TA*M-Y(F:$)
M&[PE.P"0(2-W 2-W!"M"1(G(!(W>!(F\#Z0D  8F\(JU-MP3'"H;CY* 98
M                          #$Y=16VUJ*F"\;MB@98
M            &)E1>Z&%<-G6R[>3S3@,L
M"PO2*MKJ$1,5P38GV2 7-'LI*=%]+9Z% )@
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M                        &@?!?_Q/_3*Y?P2QXW['W85_!_;^]+?Q7+
M
M                            #EO3[]M6M/YQMWH*DL.)_M8_-/S*_A_[
MN3SQ\[;*;BN6+Z!62/H0K;O D0@5-WDB1 )&@2M(2K3>2)FA"1N\)3L D"$C
M=P$C=P0K0D2)R 2-W@2)O ^D)  %#Y8HU:V1[6*]>%B.5$5R]!,=X%8
M                       %$<L4S>.%[9&;N)BHY/)0"L
M             %"RQ)(D*O:DRIQ)'BG$J='#?@!6
M       "E\C(F+)(Y&,;O<Y41$^BH'UKD<B.:J*U4Q14VHJ*!]
M                 !P%^^I^L7X$]%^4ZGG_ ,UUN:"U5L 2 =1^%%#>I<@:
M45EN5[\B-LE,R)8,5IVUBT\/!QX;$58L$CXN@[#E*C@9C?O$_6U7'':[E=/J
MM":<09FJ,]Y?9D])5S&E= Z@6''B:]KT57.5-S$3'CQV<...PL<TUBD[W-HK
ML$6G)&[SZMJ>&*^B=K96I2JU9V6^A;6\.])N;54XO%YM8_H8')X?KV76ZN/_
M +G4T&6*N .U_ 0]R<[>N+?Z"H*+Q/GKUKGPWFMU.O2E7
M          :!\%__ !/_ $RN7\$L>-^Q]V%?P?V_O2W\5RP
M
M                 Y;T^_;5K3^<;=Z"I+#B?[6/S3\ROX?^[D\\?.VRFXKE
MB^@5DCZ$*V[P)$(%3=Y(D0"1H$K2$JTWDB9H0D;O"4[ ) A(W<!(W<$*T)$B
M<@$C=X$B;P/I"0 !B+S^,VSUPWZJ!++A
M#$Y<]S&_9N RP                           ,3+_ 'BA];+Z)P&6
M                       !C[W[EU/V*>B0"YH_Q.G_ -&ST* 3@
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M!_;^]+?Q7+
M                                        #EO3[]M6M/YQMWH*DL.)
M_M8_-/S*_A_[N3SQ\[;*;BN6+Z!62/H0K;O D0@5-WDB1 )&@2M(2K3>2)FA
M"1N\)3L D"$C=P$C=P0K0D2)R 2-W@2)O ^D)  %#XHI%:Z1C7JQ>)BN1%5J
M]%,=P%8                            %$<44+>"%C8V;^%B(U/(0"L
M                         %"Q1+(DRL:LR)PI)@G$B=#'?@!6
M                   "E\;)6+'(U'L=O:Y$5%^@H'UK4:B-:B(U$P1$V(B(
M!]                           !P%^^I^L7X$]%^4ZGG_ ,UUN:"U5L 2
M =7ZWYAI]--%LF:1Y;MD#*#,]J@NE\KY&*KY9D6&97-5%3&1TK>)7.QX6HUJ
M;-U-PU.URVR3/-/(N>*MV6.*1'.U'H1JU<=*,W-JJ6A@N%NO#H:&ZP2,59UI
MEDV\R]%Z5V*XX*BH[!$5.4[>*P1EKS\SCX7/..VG2R?A290L^3=7[G1V*G92
M6ZX007)M)$G#'%)4(J2(QJ;$17M<Y$38F.";#'@<DWQ1KY&7&TBN3D\K3)W.
M  [7\!#W)SMZXM_H*@HO$^>O6N?#>:W4Z]*5<
M !H'P7_\3_TRN7\$L>-^Q]V%?P?V_O2W\5RP
M
M      Y;T^_;5K3^<;=Z"I+#B?[6/S3\ROX?^[D\\?.VRFXKEB^@5DCZ$*V[
MP)$(%3=Y(D0"1H$K2$JTWDB9H0D;O"4[ ) A(W<!(W<$*T)$B<@$C=X$B;P/
MI"0 !B;PJI4VW!<,:AN/DH!E@                            ,3EU5=;
M6JJXKQNVJ!E@                           8F55[H84QV=;+LY/-. RP
M                           +"]*J6NH5%P7!-J?9(!<T>VDIU7TMGH4
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ML?=A7\']O[TM_%<L
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M<                            ""DI(:*%(($5(T55VKBN*@3@
M                    @6DA=5MK51>?:SFT7'9PXJN[Z($X
M               (JBGCJH7T\N/-OV.P7!=BX@5QL;%&V-OF6(C6^,B8 5
M                          X"_?4_6+\">B_*=3S_ .:ZW-!:JV ) .FL
MOZE^"=26*U4=[T[N=7>X*2GBN-3'!"K):ID36RO:JW!JJCGHJITJ>,A4VP<3
M,SI>-/VV+:O$</I]7]T>MO7*VG&@.8\MS9MN.FTF5+!$Q)DJ\R<%"CX53'G$
M:VLE5K-J8.D1N/)B5]\V:MMV+[T[/_P[Z8\5HUFFGGT<8ZTU6GM7G^O=IA"R
M#*,;(HJ=(F2,C=+&W"5[$E7B5KG;E7>7O#1>*?3YU+Q4TF_T.9KXZ7( =K^
MA[DYV]<6_P!!4%%XGSUZUSX;S6ZG7I2K@    &@_"/@AS3>M,-,YVK+2YAS"
MVLN-.U517T%M9C.U>%<4163+Y&/(6'"3NQ>_1'RJ_BXWII3IGY'H_DS:%_\
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M:M,MU'"[@     - ^"__ (G_ *97+^"6/&_8^["OX/[?WI;^*Y8
M
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M$B;P/I"0 !C+K/-#/0-B>K6R3M;(B<K55-B@9,
M      #&V*>:IH$EG>KY.)R<2[\$ R0                           ,;
M)/,E\BIT>O,.@5ZLY.+B=M^D!D@                           65VED@
MMT\L3E9(U$X7)O3ID N*5SGTT+W+BYT;5<O1540"4
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M(R8[4G2T:)QY*WC6LZL^:VP
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MNX(5H2)$Y )&[P)$W@?2$@ "TK*%*N2FD5_!UO(DJ)ACC@J+A]("[
M                      M;=1);Z9*='\XB*KN)4PW@70
M             +5U$CK@ROX]K(^:X,-F]5QQ^B!=
M        @K:9*REDIE=P)(B)Q(F.&"HH$D,?-11Q(N/ U&X]'A3 "L
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M\>8[;3Q5M;1<W*G-T]0JI&_G%8D:XJFYKE7HF<TM%=[R2PB]9MN^6&9,&8
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M-N.EXS;TZ1K'-$_O;^*Y8
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M7P                            %C::R6OHTJ)D:UZN5N#$5$V>.J@7P
M                          +%]9*VZQT*(WF7P\XKL%XL<53HX8;.@!?
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M77QT3VODHZ*CIJU68;*A&*]454WJC7L1>ANY#E\/B8Q<O2Z./F)R=30Q8JX
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M*D,+(VM;''BU%X4Z"<B(@RYYO$5TB(CR0G%@BDS;769\LM@G,Z
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M12TT:HCY$1$5V*)L5%Y$4":GC6*"*)V"N8QK55-V*)@!(
M            #@+]]3]8OP)Z+\IU//\ YKK<T%JK8 D VYI1X16?])J5UIM3
MH+GEY[G2):K@CWQQ/?M<Z%['-<S'E3%6X[<,=IQ9^#IEG6>27;@XN^*-.>'0
M&8?" UGN6CLVJ5CH;!9;%+/UBCTDJJNZ1R\]S*O9')$V#S7GG.V<F)74X3%&
M7<F9F?W+&W$Y)Q;\1$0XKK:VLN59/<+A/)55U5(Z:IJ9G*^221Z\3G.<[%55
M57%54O8B(C2%':TS.LK<EB =K^ A[DYV]<6_T%047B?/7K7/AO-;J=>E*N
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M_!_;^]+?Q7+
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M:JX]<<?/\_AAS7#ACLW')_ZNU[3?C7SPZ]<G9=GN3^_IU:5O%CO67JYULO\
M;:JU7)C6O?1UT$E-.UKTQ:JQRM:Y$5-VP[ZVBT:Q.K@M6:SI,:+ R8@':_@(
M>Y.=O7%O]!4%%XGSUZUSX;S6ZG7I2K@        UUJ#E/4.NOMJS;IQF*&WW
M2W0R4M78;NM0^RU\4F*M=*R!V+9&*JX/:Q7>*B)@O3BR4B)K>.3ICGAS9:7F
M8M2>7HGFEB,LZ<9ZN6H%%J5JG=+9/=;+2ST>7[-88IFT-+UVW@FF=+4_?'O<
MQ5:J88?4,[YJ13<I$Z3SS+"F*\WW[S&L<T0VX<;L             T#X+_\
MB?\ IE<OX)8\;]C[L*_@_M_>EOXKE@
M                                                           !
MRWI]^VK6G\XV[T%26'$_VL?FGYE?P_\ =R>>/G;93<5RQ?0*R1]"%;=X$B$"
MIN\D2(!(T"5I"5:;R1,T(2-WA*=@$@0D;N D;N"%:$B1.0"1N\"1-X'TA(
MQMTIYIYZ!T3%<V*=KY%3#8U%3:!D@                            ,=8
MZ>:EH$BJ&<$B.<O"N"[%\8#(@                           QTE/,M[B
MJD9]X; K%?LPXL7+A],#(@                           L[K#)46^>&%
MO%(Y$1K4Y>F1>4">E8YE-"QZ8.:QK7)T%1$0"4
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MTM_%<L
M                                    .6]/OVU:T_G&W>@J2PXG^UC\
MT_,K^'_NY//'SMLIN*Y8OH%9(^A"MN\"1"!4W>2)$ D:!*TA*M-Y(F:$)&[P
ME.P"0(2-W 2-W!"M"1(G(!(W>!(F\#Z0D  05%7#3/A9+CQ3O2./!,>F7H^2
M!.                            !!25<-;"D\"JL:JJ;4P7% )P
M                     0+5PMJVT2JO/N9SB)ALX<53?] "<
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M7\']O[TM_%<L
M                                          .6]/OVU:T_G&W>@J2P
MXG^UC\T_,K^'_NY//'SMLIN*Y8OH%9(^A"MN\"1"!4W>2)$ D:!*TA*M-Y(F
M:$)&[PE.P"0(2-W 2-W!"M"1(G(!(W>!(F\#Z0D  8F\(JU-MP3'"H;CY* 9
M8                            #$Y=16VUJ*F"\;MB@98
M               &)E1>Z&%<-G6R[>3S3@,L
M   "PO2*MKJ$1,5P38GV2 7-'LI*=%]+9Z% )@
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MV%?P?V_O2W\5RP
M                                            Y;T^_;5K3^<;=Z"I
M+#B?[6/S3\ROX?\ NY//'SMLIN*Y8OH%9(^A"MN\"1"!4W>2)$ D:!*TA*M-
MY(F:$)&[PE.P"0(2-W 2-W!"M"1(G(!(W>!(F\#Z0D  1R3PQ.8V5Z,=(O"Q
M%7#%W00"0                            ".&:*=G.0O21F[B:N*8H!(
M                          "-9HDE2!7ISRIQ)'CTW#T< )
M                  4R21PL625R,C;YISMB(!]:YKVHYJXM<F**FY44#Z
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M4YV.( [7\!#W)SMZXM_H*@HO$^>O6N?#>:W4Z]*5<
M     !H'P7_\3_TRN7\$L>-^Q]V%?P?V_O2W\5RP
M
M          Y;T^_;5K3^<;=Z"I+#B?[6/S3\ROX?^[D\\?.VRFXKEB^@5DCZ
M$*V[P)$(%3=Y(D0"1H$K2$JTWDB9H0D;O"4[ ) A(W<!(W<$*T)$B<@$C=X$
MB;P/I"0 !B+S^,VSUPWZJ!++A                            #$Y<]S&
M_9N RP                           ,3+_>*'ULOHG 98
M               &/O?N74_8IZ) +FC_ !.G_P!&ST* 3@
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M4XBEYTB>5[DYV\      !H'P7_\ $_\ 3*Y?P2QXW['W85_!_;^]+?Q7+
M
M                           #EO3[]M6M/YQMWH*DL.)_M8_-/S*_A_[N
M3SQ\[;*;BN6+Z!62/H0K;O D0@5-WDB1 )&@2M(2K3>2)FA"1N\)3L D"$C=
MP$C=P0K0D2)R 2-W@2)O ^D)  %#XHI%:Z1C7JQ>)BN1%5J]%,=P%8
M                      %$<44+>"%C8V;^%B(U/(0"L
M            %"Q1+(DRL:LR)PI)@G$B=#'?@!6
M      "E\;)6+'(U'L=O:Y$5%^@H'UK4:B-:B(U$P1$V(B(!]
M                !P%^^I^L7X$]%^4ZGG_S76YH+56P!(!TUHYX)5WS;0TN
M;L_U#[1E6>%M92T%(G/7&K@<U'M=@U'I&U[5Q38YZ^=3%%*KB./BL[M.6?W+
M7!P,VY;\W0]WG/-NI66K0_(O@_Z7W?+6768LEOKK7.E;4*K>%7L:]BJUR^FR
MJZ3###@5#FQTQVG>RWB9Z-75DMDK&[BKI'2Y#S3:LSVB]5%/G&EK*3,$JI45
M;+DV1M4Y9NF1[^=Z95=OQ7>76.U9CZ/,I<E;1;Z7.PQL:@#M?P$/<G.WKBW^
M@J"B\3YZ]:Y\-YK=3KTI5P     !S?I9?60.UTUEFP6#VRJX*.5Z8\5-EZF>
ML>'B.:]B;-ZIAR%GGK_;Q[/E5F&W]S)M^1F-!<OVG3/0F/.553M6YU]LGS+>
M:V1$YV6)8GU,;5=ACP-BX<&[L5<O*IAQ5YR9MWR:Z0V<-6,>'>\NFK#:3,U-
MRAH;DZ3(.7*2_P!TO#JNZ71E;5,HHXHZN9TL*LQ<W'B8K=B&>?L[YK;TZ1#7
M@[2F&N[&LRN]68]0<T^#YF^IS[9*6PYBMTD5=;Z:AJ$K&I!0RP3K,KVJY$<J
M)*W#D1,2,&Y7-7=G6)99]^V&V]&DPGN5P;KKGW+V5H,)<AY7IJ+,N;%;CS-3
M<JJ)):&A7>BHU'<[(U55%3I5VH1$=A2;?:MR1YO+*9GMKQ7[,<L^?R0N\AT\
M&;M=]5K_ %"<]06NEH,J4V.U%8Z-9:MGB82L^F8Y9W,-(Z=9]2<4;^:\]&D>
MMK7)^9[Y'HK8]%,MSX9]N]WNN5DG1%XJ.WTU5)+6U;T3:B1Q2\#=R[=FUIU9
M*1VLY)^K$1/JAS8[SV48X^M,S'K>R@RI9%UYRAIBM.G<=D#*CKU9K?*B.CFN
M+ZIM-S\B;$>]$7G$<J+TZ*[E4T3>>QM?RVMI/F;HI';5IY*UUZV;UIDIZG5#
M1ZV6UJ.S4V]R5G'%BLT=IAB_VOBX5Q1CTZ.Q>%?%,.'_ +=YGFT_?Y&?$<N2
MD1SZ_N;Q.!W@      - ^"__ (G_ *97+^"6/&_8^["OX/[?WI;^*Y8
M
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M)$B<@$C=X$B;P/I"0 !B+S^,VSUPWZJ!++A
M   #$Y<]S&_9N RP                           ,3+_>*'ULOHG 98
M                         &/O?N74_8IZ) +FC_$Z?_1L]"@$X
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M3SY@O<R5-4VG:N/,P\+6,BCQV\+&^.JC)GF\;O)$=$(QX(I.]RS/3+WISN@
M     !H'P7_\3_TRN7\$L>-^Q]V%?P?V_O2W\5RP
M
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M^2WSOHZ]M+-'.M/51;'PRHQR\$C?KF.P5#*:S'/#&+1/-*^,60
M (9*JEB9/)+/&R.F:KZE[G-:V-J-XE5ZJO2IAMV\A.B-4=NN5NN]%!<K35PU
M]NJ6\=-64LC)X)&+LXF/8JM<GBHHF)B=)(F)C6%T0D
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MW!"M"1(G(!(W>!(F\#Z0D  8RZSS0ST#8GJULD[6R(G*U538H&3
M                    QMBGFJ:!)9WJ^3B<G$N_! ,D
M           #&R3S)?(J='KS#H%>K.3BXG;?I 9(
M       %E=I9(+=/+$Y62-1.%R;TZ9 +BE<Y]-"]RXN=&U7+T55$ E
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M;255"][8UECD1K%3![VMX=OCXHJ$9<$5K%ZSK$LL6:;6FEHTF&T3D=0
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M]^R/RW\_S'YG^3YVYCB=H
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MX                            %A:*R6NHTGFPXU<Y.E3!,$ OP
M                     6#ZR5MWCH4PYET/.+LZ;BQ5-_T +\
M                 %K<JB2DHIJB+#G&(BMXMJ;51 )J=[I:>*5WFGL:Y<-V
M*IB!(                           #@+]]3]8OP)Z+\IU//\ YKK<T%JK
M8 D      !VOX"'N3G;UQ;_05!1>)\]>M<^&\UNIUZ4JX6UPMMNNU');[K20
MUU!-P\]2U4;)H7\#D>WB8]%:N#D14Q3>3$S$ZPB8B8TE@N]SI[_VE9O>ZE_F
MS9VU_:GTM?94]F/0RK;!8F.M[F6ND:ZTM<RU.2"-%I&O:C7)!TOWM%1$1>##
M88;T\O+SL]V.3DYE[/!#4PR4U3&V:GF:Z.6*1J/8]CTP<US5Q145%P5%,8G1
ME,:L>N6LN.M#; ZST2V)JXMM:TT76B+QK)BD/#P>:7B\SOVF>_;777E8;E=-
M-.1E#!F 6C;5:VW-][;14Z7F2!*1]Q2)B53J9KE>D2RX<:L1RJY&XX8[3+>G
M33R(W8UU\J[,4K:*VVZ"MJ+E!20QW&K:QE55LC8V:5L28,1[T3B<C4\SBNPG
M6=-$:1KJIIK7;*.KJZ^DHH*>NKU8M=511,9+.L2*C%E>U$5_"BJC>)5P$VF8
MT(K$3JI99[1'U[S=!3,]LE5;CPPQIURKF\"K-@G3XMV=-CL)WIZ>9&['1SIJ
M*BH[=2Q4-OIXJ2B@;P0TU.QL43&]!K&(B(GC(1,S,ZRF(B.2$%59;/7UE+<:
MZWTU3<*%56BJYH8Y)H%7:JQO<U7,W?6J3%IB-(E$UB9UF%=%:[9;75+[=104
MCZR9U36.IXF1+-/)YJ216(G$]W*YVU2)M,\Z8K$<RFNL]HN<U)4W*@IJRHH)
M$GH9:B&.5\$J*BH^)ST56.Q:BXMP783%ICFE$UB>>'VBM-JMLM5/;J&GI)ZZ
M19ZV6GB9$^>5<55\BL1%>Y<5Z9VT3:9YR*Q',FJZ2EKZ:6BKH(ZFCG:L<]/,
MQLD4C')@K7-<BHJ+T%(B9CEA,QKSOE'1T=NI8J*WT\=+10-1D%- QL43&IN1
MK&HB(GB(@F9GEDB(CDA.0D T#X+_ /B?^F5R_@ECQOV/NPK^#^W]Z6_BN6"T
MN-KMEXI'T%WHH*^AD5%?2U43)XG*U<4562(J+@J8IL)BTQ.L(FL3&DKLA*RH
M;/:+9-55%MH*:CJ*Y_/5LM/#'$^>3%5XY',1%>[%5VNZ)E-IGGEC%8CFAC*[
M(>1[I<DO-RRS::R\(J.2X5%!335**FY>=?&KMGCF49;Q&D3.GG8SBI,ZS$:^
M9FZBFIJNGDI*J%D])*U8Y8)6H^-[')@K7-<BHJ*G(IA$Z,YC5A*'(F1[9324
M=MRS:J.CFD9/+3T]#30QOFB7%DCFLC1%<U5Z5R[4,YRWGEF9]+",5(YHAE4M
M=L;<77AM% EW=#ULZO2)G7*P<2.YM9<.+@XDQX<<,3#>G33R,]V-=?*INUFM
M%^HGVV^6^FN=ND5%DI*V&.IA<J;L62(YJ^036TUG6)T1:L6C28U167+U@RW2
MK19=M5':*)5XEIJ"GBI8E=T>")K4Q^@+7M;EF=2M*UY(C1;WC*&4LPU4%;?[
M#;KK64V'6U174<%3+%@N*<#I6.5NW;L)KDM7DB9A%L=;<LQ$LA1VVW6]U0^@
MHX*5]7(L]4Z"-D2RS.1$6216HG$Y</-+M,9F9YV41$<S$+D+(RW;V^7+%I6^
M\?.^V?6%-UWSB+CQ<]S?'CCR\1GVM]--9T\[#LJ:ZZ1KYGF]4*+4ITEHN>0X
M:.]VRF=/'F/)UQ6"*&YT\S42/@GEB?S;XW8KYI&KRXX<*[<,X^6+<D^2>AJS
M1DY)KR],=+Q-BR-GC-N>,K7[,&4K?I[DW)TM374=@HJJ"KJ:RX5#.;;(]:-K
M86,:B([SV]-O%TN^V6E*3$6F\V\K17'>]XF:Q6*^1N:^98RUF>%E-F2S4-YI
MXEXHX;C30U;&NZ*-F:Y$4XJWM7FF8=MJ5MSQJGH++9K5;TM%KMU-16E&N8E!
M30QPTZ-?L<G-L:C<%Y=A$VF9UF>5,5B(TB.1-2T%#0T<=NHJ6&FM\3>;BI(8
MVQPM9YUK&HC43Q,")F9G64Q$1&D**:U6NCMZ6FDHJ>GM36NC;0Q1,93HQZJK
MFI&U$;@N*XI@3-IF=?*16(C3R,99LD9+RY525V7LN6NTULJ*DM3045/2RN1=
MZ.?$QJKCXYE;)>T:3,RPKCI7EB(ADXK7;(:^>ZPT4$=TJ6MCJ:UD3&SRL9L:
MU\B)Q.1.1%788;TZ:>1GNQKKY5E?<I95S0V)N9K';[TV#'F$N-)!5HS'?P\\
MQV&/B&5<EJ_5F88VI6W/$2F@R]8*66BFI;51P36YCH;?)'3Q,=3QR8HYD*HU
M%8UV.U&X8D3>T^7G3%(CR*'Y8RU)=)+Y)9J%U[FC6":Y.IH5JGPN;PK&Z56\
M:M5$P5JKA@3OVTTUG1&Y7773E74-KME/;TM-/1016IK%A;0QQ,;3I&N]B1HG
M#PKCNP,=Z==?*RW8TT\C'67)F3\MSRU67<O6VT54Z833V^C@I9'HJX],Z)C5
M7Z)G;):W/,RPKCK7FB(9-MMMS:]]U;20I=)(DIWUJ1L2H="U>)(UDPXE:B[>
M''#$PUG33R,](UU\I[6V[VQ]M^M(?;;F>M.O^;9UQUOQ\YS7.8<7!Q=-PXX8
M[1K.FGD-(UU\JY(2
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M)$Y )&[P)$W@?2$@ "QKZ*2KEI)&.1J4\J2.1<=J(J+L\@"^
M                 LK5124%(E/(Y'.1RNQ;CAM\<"]
M          !9/HI'72.O1R<VR+FE;MXL<57'Z8%Z
M       "VN%,^LHY:9BHUTB(B*[=L5%Y )8(UB@BB<N*L8UJJF[%$P D
M                       !P%^^I^L7X$]%^4ZGG_S76YH+56P!(      #
MM?P$/<G.WKBW^@J"B\3YZ]:Y\-YK=3KTI5P                        &
M@?!?_P 3_P!,KE_!+'C?L?=A7\']O[TM_%<L
M
M      .,<CTFIM'F?.V0LJYG@M=-EBX,=4*^D@G9-+7)(O$Q9(GN3!(L%15+
M_/FQ16M[5UWHZ>AXCA?#.+K-L=,T5BL^S$\_G>Y]H]=7?]>TGO=3?S!R=ZP>
MQ/I=OZ9QWOX_HA2N7]<UWY\I/>ZF_F">]8/8GTGZ7QWOX_H@7+>N*[\^4GO=
M3?S!/>L/L3Z6/Z5QWOX_HA\[E];U_P"NZ3WOI_Y@GO>'V)]*/TGC??Q_1#YW
M):W.V+GND][Z?^9'?,/L3Z4?I'&^_C^B$3\BZS2^;SQ1K_P$*?4A,HX[%'V)
M]+7/@G%SSYH_HA;NTTU;E\WG2C7_ (*+^:,_U#''V9]+3/\ U[B)Y\T?TK:7
M13/-Y='1YCS;#-9WO:M9%34S8I7QM7%6HK6MW^+L\11/B5=.2O*PK_UB\VC?
MR:U\NE6[K1:K=8[=3VJU4[*6WTK$C@@C3!K6I]557:JKM5=JE+:TVG6>=[?%
MBKCK%:QI$,BTP;5:;R1,T(2-WA*=@$@0D;N D;N"%:$B1.0"1N\"1-X'TA(
M M*VNZTDIH^;X^N9$BQQPX<51,=RX[P+L
M "TMM=[84R5'-\WBJMX<>+=XN" 78                           +1U=
MPW%EOYO'CCYWG,=VU4PPP\3H@78                           +>MJ>L
MZ62IX>/FT1>''#'%43?@O1 EADYZ&.7##G&H[#?AQ)B!6
M            #@+]]3]8OP)Z+\IU//\ YKK<T%JK8 D      !VOX"'N3G;U
MQ;_05!1>)\]>M<^&\UNIUZ4JX                        #0/@O\ ^)_Z
M97+^"6/&_8^["OX/[?WI;^*Y8
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M]O[TM_%<L
M                                       .6]/OVU:T_G&W>@J2PXG^
MUC\T_,K^'_NY//'SMLIN*Y8OH%9(^A"MN\"1"!4W>2)$ D:!*TA*M-Y(F:$)
M&[PE.P"0(2-W 2-W!"M"1(G(!(W>!(F\#Z0D  6]3614KX(Y<>*=Z1LP3'IE
MV;?) N                             +>CK(JZ%)X<>!55.F3!<4 N
M                          6[JR)M8VA7'GG,YQ-G2\.*IO\ H 7
M                       (JFHCI('U$N/-L3%W#M7:N %<<C98V2M\R]J.
M3'?@J8@5                            X"_?4_6+\">B_*=3S_YKK<T%
MJK8 D      !VOX"'N3G;UQ;_05!1>)\]>M<^&\UNIUZ4JX
M           #0/@O_P")_P"F5R_@ECQOV/NPK^#^W]Z6_BN6
M
M                  '+>GW[:M:?SC;O05)8<3_:Q^:?F5_#_P!W)YX^=ME-
MQ7+%] K)'T(5MW@2(0*F[R1(@$C0)6D)5IO)$S0A(W>$IV 2!"1NX"1NX(5H
M2)$Y )&[P)$W@?2$@ #$WAKG5%M5K55$J&JN"8X)B@&6
M             Q67F.9;6M>U6NXW;%3!0,J
M  #%2,=W00OX5X$IU178;,>)W*!E0                           6%Y:
MYULJ&M15<J)@B;5\T@%S1HJ4D"+L5(V8I_X4 F
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MMI\]3X1>HCX38?%;6H?_ .*'?0_WWOJ=>_YO7O7O#Y'%@=O_ *^S_P#%Q_\
'L[3_ ,G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2227887d8-fc_problem4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d8-fc_problem4c.jpg
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M% H% H% H% H% H% H% H% H% H% J HH"BT%2DH% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% J$25*2@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"H"B@*+05*2@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"H1)4I*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*@** HM!4I*!0*#TELB-VUVI[O\ '[B[JV-&
MW;E7<\[B=+TIR&L-J;+B3K0EP'3H(MH\>=>5MG9??T5MTQC+U]?131%YK$RT
ML1W*]WK<>4B83.]H6\)C9SJ6'<K"R\AUZ.7#H#F@-,W"2;GU_B/*K6T[ZQF+
MY^Y2F_3>>F:8RV=M]FL#MWWIX/;#.,IS.UUF4^RU()N[&7C'Y+(<T:?60H &
MUKE-^1J+]Q:W;3>.$_J5T13N(K/&/T1.X>YG:["Y_*X9OL]AWD8Z9(B)=5-E
MI*PPZIL*('*^F]7IHV6K$^\GB7[C76TQ[N.$_;P2LS;?:ONUVKW5O;9&VU[+
MW;LI+,C(P&I3DR%)C/:K6+EM)(;<(TH%BD ZKW%(OLU;(K:>J+)FFO=KFU8Z
M9JIO9OM=A-U0L[OS?LM[']MMJ(2O)NQQ]?E2%VZ<9DG@"24ZO'UD@6U:AOW&
M^:S%*>U9AVVBMHF]_9A-O=Y>T#,SV+']FL6O;224?]9EO')+;_C=>RBE7CS5
MY:O&L_AMN..R<_X:_$ZLXC7&&IW4[;;.7LS&]X.U*I"=DY*0J#D\-+47)&+F
M\PWJ)42@\O642/5.I6OA;1NOUSKV>U'CY5-^FO1&S7R_!<L2WVLV)V V1OK<
M?;Z+NS,YV7/AR779CL)?UB7*"%%24.@V0VE%M(K"WO-F^U8MTQ&/R;5FFO16
MTUBTS^IL=[L5WRS@[>-=OE['SV19?5ALUCL@Y.T2([*GB'&UH924Z$*-B#>U
MO5OJ#;&[1'7U=41SC"==M.^>GIZ9\RB]@=DX?-=\(6R]W0FLECVE9&/,BK)+
M2W(D=ZQ!00;!:+CC6_=;9C3U5X<F':ZH]]-;<<9<LSK+4;-Y*.P@(89E/MM(
M')*$.*  ^ "NRDYK#CV1B\QYW0?=VVY@]V]X]M[>W'"1D,-,]N]IANZ@A?2@
M2'47TD'@M"5<_"N?N[S35,QSX?BW[2L6VQ$\OT7C/=TNR.$SF3POZD83_P W
M2WX?7^>'T:_9W%-ZM/LRK7TWM<USTT;;1$^\GCYOU=-^XUUM,>[CA]O(HG<#
MN%VXW1@T8W:?;6/M')ID(>5E&<BY,4IE*5A3736PV %%23JU>%=&K3LK;-K]
M4>AS[=]+UQ%(K]O0[7$[3; SWN]XMR#AFFNY62P$_/0LB@K#KWS+)9ZZ+%6D
MJ6AU* -->?.^]=\YG]L3CUO1]Q2VF(B/W37+R0A"W%I;;25+40E*4BY)/
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M*!0*!0*!0*A$E2DH% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M8AEU]]Z870TM++Z6"$]-M9N2L'B.5=F[N:ZJQ:8YN35VT[+37/)UG]QON/\
MI!A/]>7^+UQ_4Z>277].M_)R?NEV-WYVB,9[<[##^+EK+4;*0'%/15.@:NF2
MM#:DJL"0%H%[&U[&NS1W5-OL\W'N[:^KC/)L93L9N/%=IX?=Y[(05X*:&BW"
M07O:QUGBR+@MA' B_P OE45[JL[?=XXK6[6:Z^O*([9]H]Z]V,FYC]J0TJCQ
MRGV[)25%J'&"^746 22;&R4)4H^57W=Q35&;,]/;WVSP=FR'N/=PXT%R1 SN
M*FS$)U)B7?9UD?4I6IO3<^&JP^"N&/F5,\8EVS\NMCA+SCGL#F-L9>7@<_#<
M@9>"OI2HKPLM"K7'H(((((X$<17J4O%HS')YEZ32<3S1M747OM3VIW#W>W$]
MMW;SL>,]&BKFR94PK2PVVA24 $H2M1*E+  "?I US;]]=-<RZ=&B=LXAC[I]
MKMP=I-RIVSN%QF0^[';F1Y<0K4PZTX5)NDK2A5TJ2I)N/"IT;Z[:Y@WZ)U6Q
M*:[/=C=R=Y_GK\W\A!@_,GLOM/MZGDZ_;.MHT=)MSET57O;F*S[CN:Z<9CFO
MV_;3NSB<84'<.!RFULYD-NYI@Q\KC'UQI31\%MFUP?%)YI/B.-=-+Q:(F.4N
M>])I::SSA>=\]E-P["VYM3<V3GPI$/=R&G(+48NEUH/--O#JZVT@6#@'JDUS
MZNYKLM:(CV75L[2:1$YYNJ_N-]Q_T@PG^O+_ !>N/ZG3R2Z?IUOY'[C?<?\
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MLT]S3;$]/@X]O:WUS$3XNL_N-]Q_T@PG^O+_ !>N/ZG3R2[/IUOY'[C?<?\
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M?R_S*!]W##S]N^\S&V]E'4/Y+$/YC'2WFE*6VMZ)'D,K4A2PE122CU2I(-O
M5IWEHMV^8Y3AGVD3&^8GG&7HGO#MW"^\%M'<^'P383O[M_D'V8S*C=Q:T)OT
MP;?(E(3ZGDXFU[)->;V]YT6B9]FT?;U/2WZXW5F(YU<IVFA;?N3[O;<24K3/
M6E25"Q!$V(""#77L_P"W7[>#FUQCM9^_\7DFO:>&]E>X9_\ ; _\G_\ GZ\/
MYI_Q^_\ )[/RW_E]WYN?->Z[[P;N67)881C_ *^5LRUY1I.C4NX6.BXM8T\^
M OY5T?&Z,?HK/:[YM,Q/^70??&W+B8^Q]I=O9F0:RN^(+T>9DY""%.H0Q$6P
MXISQ27W' L)//3<CE7/\OI/7:^,5:_,+QT17QRNRNW>XNY_NN[*VQM>9&@Y0
MQL?*Z\QQUEKILI7J&IEMU5SJ%O5KG][77W%K6Y<6_N[7T1%9Q.(<@_<P[T?I
M)A/O[(?B==OU#3Y)]4?[<?P6[^7^9?GN2;>@Y7N!F]PSD!Z7AH ]B*[DH?F.
M:%.#_.T)6GC_ !J?,KS%(B/&4?+JQ-IM/.''>[N_<]OCN'FLUD9CRD,S7VL8
MP5J"(T9EPH:0V ;)LD"Y'-5SSKN[?56FN(CR.3N-MK;)X\I3>XO>$WQNKMK&
M[99UJ'.Q[ ;"\O(0Z[DEF.X5M'J%S2"E-D:M&HI'$\3?.G:4KLZX_1:_=VM3
MHEZ>[9;0S&_?<\Q^TL#(9BY?)-RT1I$I;C3*2WFWG3J4TAQ0]5!'!)KRM^R*
M=U-IY1_IZFBLV[>(CGQ_%RG]S#O1^DF$^_LA^)UU_4-/DGU1_MR_!;OY?YE6
MO=C@2L5[QN.Q<YQ+LR"K*Q9#J%*4E3C$5]M125 $@E/"XK7O9B=&8\S/LXF-
MTQ//BNG?KM#WFW/WISV>V;AISV)EJ@B!.8DMQVKMP([2R%+=1ILM*@2;5AVN
M_575$6F,\?Q;=QIW6V3-<X]/F7CWF'96"]W3;FWM[343=[NN8]M3I7K<7+BM
M$R'0>:]*24*7XE0)XFL.SQ;?,U]GBW[N>G1BW/AZW#/=-FS'N^6WVWI#KC99
MGW2M:E#A">\":[^_B(TS]SB[&]IV<9\&M[U$V8SWYW8VU(=;;'S=9"5J2!?&
M13R!JW8Q'N:_?^,L^\O:-LXGR?@[7[N8:[>^[IO#N;"82YN!\3I#3R@%7$%K
MIQT*O]2ETK6?._P5P=W_ .3?6GAP=_:?LT3?QXSZGCZ=NC<>2S:]R3LK*>S[
MCA?5DB\L2 X3>Z5@@IMX:;6\*]J*5B.F(X/&G9:9ZLSE[(W'/<[P>Y]^<VXT
MF5N7"(+XFE(*S(Q\DL*=N.?48)ZGI)/A7B4CW/==,<I_-[5I][VV9YX_!(;"
MVUGMX>YC#VWMAKK9V>W*3#:ZJ6+J;SKKBO76I*1ZJ5<S5=MZT[K-N7Z)T5FW
M;8CGQ_%2^S'N]=\=I=P<+N3-2$8;#07NMD__ *@EY3T=/RF2AE2PKJ#AZQL.
M?,"MNX[O3>DQ'&?0ST=MNK>)F>'I<Y][3=VW=W]VG'MMO-2H^+@,8R7,8*5-
M/2F77G%E*T\%:0XEO5Q^3Y5U]AKM35Q\9<??7BVSAX0XKCO[0B?9F_YXKNMR
MEQZ_:CTOZG;@RL:?O<=M\HN^+W-MZ>M35P"I3+J&'$H)!XJ:D*/^C7R-:S%.
MN/"8?53:.KI\L/,?NVX:1VOVQW<W]EVRSD-N(?P\9;B;#VJ EQQUNQYE3O03
M:O5[RWO;4K'CQ];S>TI[JM[3X?D^??7=<?PG:UYY96\Y%R2W%J-U*4IO'DDG
MS)J?EO._W?FI\Q_X_?\ DR^Z?BX>PNWV]>]N;; ;9CNQ,?J.DK8B#K.I2?'K
M/=)M/^<BH[ZTWO77"W8UBE)V3]L)C?#SGO ^Z[%WHI"7]X;54N1.+2;*+D,:
M)8MX!Q@ID$#Q %4U?_Q^XZ?"?M"^S_SZ.KQC\E6]QK;,'(;JW/NF2A+DO"18
MT6'J%RA614[K6GR.E@HOY*-;?,[S%8KY?R8?+JQ,VGR."=R=^[@WSOC*;DR<
MUY3IEN^P-]103%82LAIMH7]4)3;ES/$\37H:=5:4B(AQ;]MK7F<^*R[N]X/?
M&]^WL+MWN%J',A0^DI66=0XO(N.1U$MK4X7-.K2=!.BZA>YN366OM*4OUQ^B
M^SN[7ITR]+;"VUGMX>YC#VWMAKK9V>W*3#:ZJ6+J;SKKBO76I*1ZJ5<S7E[;
MUIW6;<OT>GHK-NVQ'/C^*E]F/=Z[X[2[@X7<F:D(PV&@O=;)_P#U!+RGHZ?E
M,E#*EA74'#UC8<^8%;=QW>F])B.,^AGH[;=6\3,\/2^=_/;2[P>]MM?"XLLY
M#$0FV8F5>;TJ8E.XSVF<\G4+!8T ,DW/R;#PJ=75J[:9GA/^\0KLZ=G<UCR?
MEF47[YW<'<$K?#6P6);L;;F-B,R'HC:BE$B3)!65N:;:@E!2E(5RXGQJ_P N
MU5Z.OQ4^8;;=73'+"+]SS?\ N#%]S8>Q_;'7MNYYF4E4!Q94RU(C1UR4NMI/
M!*B&BA5N8/'D*O\ ,-59U]7C"G8[IB_3/*5VVYMB!M/WVW<=BV@QCY"96099
M2D)0@S<8MYP) X!(<4O2!R'"N>]YOVF9^W%TTI%>ZG'C&43WZ[0]YMS]Z<]G
MMFX:<]B9:H(@3F)+<=J[<".TLA2W4:;+2H$FU7[7?JKJB+3&>/XL^XT[K;)F
MN<>GS+Q[S+LK!^[GMS;N]YB)V]W7,>VITKUN.2XK1,AT'FO2DE"E^)4">*JP
M[/\ =OF:^SQ;]W.-&+<^"4>[;9WNM[K>RMJ;>D1(V1,;'RNK/6XVSH92O4+M
M-NJOZW#U:I&Z-7<6M/G6G5.SMXK'DA7^QONN=P.V?<G%[QSV2P\C&06Y2'6H
M+\IQ\F1'<:3I2[%:3P*A>ZN5:=SWM-NN:Q$Y^WG9=MVE]=^J9APCWK/V^;M_
M\N_],BUZ/8_TU^_\9>?WO]T_=^#T QGU^[-[NVU7&6D_G7GI\6?+C*^4LOK1
M)D)4D_Q8S:(RB.1(->;-?B=\^2(^W^>+T^KX?3'E^V5,]\W:42:O;/=S! .X
MK.QFX<N2@62M1;Z\1T^EQHJ3\"!6_P NV3&=<\X^TL/F&O.+PG?=.APMG]G]
M^=U4,H?S,9,T(U@FT?$PQ*#=Q8@+6LZ@.=DUGWTS?;6GA_MIV4135-_MP>8(
MZ^XO=/=CLR$J?N#=KNN85,J6N0E*"+E%CZJ4W  38 <J]6?=ZJXG$0\N)V;;
MYCC+KW<_<OO%9KMBUMWN'M);6V\0&')>?EQ71,+C*PAMUUY3I3J(5TR0BZM1
MO<FN/33179FEN,^#MW6WSKQ:O#RNL^[!A9NY/=LW?MW&N(9R.7?S&/B//*4A
MM#TK'LM(4M2$J4$A2@24I)]%<?>VBO<1,^&/Q=/:5FVB8CG.7.?W,.]'Z283
M[^R'XG73]0T^2?5'^W/\%N_E_F7GO>>W<IM'=.5VQFGVY.4Q,A424^PM;C2E
MM\"4*<2A1'E=(KTM=XO6+1REYVVEJVF+<9:VVL*_N3<>(V[&.F3EYL;'LJ-@
M N4ZEI)X\.:JM>W369\D*ZZ]5HCRR]$^^;D8^/W%M+MYB@&<'MO#H7'C)%DH
M7(660D\!>S<=NWP_#7F?+JYK:\\YEZ7S"V)K6.40Z!W!GRNT7NF;5A[2=5 F
M;@3 8F3H]VWM>3C.3I"PL<0I6@MZN83P'A7-JCWW<S-O#/\ C@Z=UO<Z(B'E
M7MSW.W3VQW,UN;;\E2G@5"9#>4LQI:%CBAY((U"_K7Y@BX-Z]?=HKMKTR\G3
MOMKMF&MW#W[ENY>ZI6[\Y&B1<G,2VAYN VIIDAI(0DV6MQ1.D 7*O"K:=4:Z
M],<E=VV=ENJ7KMC/K]V;W=MJN,M)_.O/3XL^7&5\I9?6B3(2I)_BQFT1E$<B
M0:\6:_$[Y\D1]O\ /%[/5\/ICR_;*F>^;M*)-7MGNY@@'<5G8S<.7)0+)6HM
M]>(Z?2XT5)^! K?Y=LF,ZYYQ]I8?,-><7A</=JQ61SONQ[UPF(1U,MDG,W#@
M(UAO5(D8YIML:U$!-U*'$GA6'>6BO<5F>48_%MVL3.B8CGQ<][>^[3W_ ,1N
M_#9=]Y."8AS&G9,SYQ0ZM+#:@IRR&%KUZDW3H/ \E6'&NG;WFB:S'/[F.KM=
MT6B9G_+7]]+=FW=P;[P^*PDEJ9+P<-QC*2&"%I0\\[J#!6.:D 74 ?5*K<[B
MK?+M=JTF9\6?S"\3:(CP>9Z]5Y3^A/:3=!VA[O/;C+*<#49S)L0):E?)#$_*
M/1EE7H3U-7Q5\UOIU[[QYOR?3:+=.JL^A1VNUY1[Z*WO9U_- ;.[@2.%UM:-
M=[6M[:?\GIKH]]__ !//[/V^YS^Y_P#Y.?-G\EL[R[I.\/=P[B9A+O6C)S1A
M0UCY)CP<W&C-E/H4&]7QUCVU.C?6/-^33NK=6FT^?\W,?=.;9WSL;N1VDR:@
MJ)D8S<R"ESBVT^\A3*W?,%"T1UBWBFNKO_V7ILAS=C^^EJ3R_P!O*;K2V75L
MNC2XVHH6GR4DV(X5[$/'F,3A\5*"@4"@4"@4"@4"H"B@*+05*2@4"@]-;-]W
MG:_<?LBG=^P9DF3W*CW3*QSTAH,"2PZ=;(&A&@K:LMM2ED<@3S(\G9W=M>[I
MO[+U]?:TOJZJ^U^:\^[7MWWC<+O6,QNTY2)L"*T^G(1,P]U6S=I091&0ZI:D
MD.Z%$MV3I"KGC8X=Y?1:G[<=7F;=K3?6W[O9\Z%>[E[6V7[XV8S29+;.W)X3
MA,Q,:LEI#ZHS*7%KX@61):3U5>A2N-7C3:_:Q'CSC[>A6=M:]S/J:OO'>[KO
M?)[XG[[V+CE9W"9XMRGV8BD+?8D*0$K]0J!6A9&L*1>U[&UKF>S[ND4BMIQ,
M*]WVE[7ZJ\<KG[MO:G(]E,9N+NEW/4W@P8'0;BNK0IQF&%I><4[I) 6XI#:6
MVP=5^!%R!6/>;XW3%*<>+;M-$Z8FU^"M>Z?N%6[>^V_=T*;Z/SQ#FSPS_$3(
MR#+@3\0-JT[ZG1IK7R?Z9]G?KV7MY7/>Y78'O#F>XV[\OC-IRI.-R&;R4N'(
M2M@)<8?EN.-K%W ;*20>-=6GNM4:ZQ-O"'+M[3;-YF(\9\B-[9["W?L'OAL&
M#O#%.XF7+R++T=IXH45MA925#0I7B+5;=MKLTVFLYX&C3?7NKU1AUCO%_OA[
M'^S83\)57'V__5M][KW?]FOH_P!MKWLNTG<;?O<;%Y?:& ?RN-9PL>([(94T
ME*7T2Y;A0>HM)N$N)/QU'8[]>O7,6G''_2O>]O?9>)K&>"Q]I-LSO=D[1;LW
M?W 4S"SV04E<;&!U#Q+K#2TQ6-3:BE3CCBUDA!(".)/ VRWWCN=L5IR;Z*?#
MZIFSPFM:G%J6LE2U$J4H\R3Q)KZ!\_,Y?-2A[+[I_P"YKLOX,5_,<KPM'_:M
M][W=W_5CT0\P=K\S"V]W'VGG,DL-8['Y>%(ENGDAEM]!6L_R4W->MOK-M=HC
MR/*[>T5V1,^5ZG][?L_OO?.Z,-O/9N,5F\8G&-XY]J&4K>;6W(??2O1<%2%A
M_@47M;C:XKR>P[BE*S6TXXO4[WM[WM%J\>"8[?;9R_9KW7M[HWXT,;.R2<G)
M9AK6E3B53H34*.VK25#6M:!P\ >/C6>V\;NXKT^;\<M--)TZ9ZO/*J^YC_@_
MN=]AB_T$NMOF/MT9_+_8MZ5^]U)[&[Y[/XG&9<!^1LO-K<AIOZR'&[R6%GT#
MVA:1_)]%<W?1--LS'_*&_96ZM4>9\=B=S_G=W\[O9E#@=C!4:'%6GY)8@N.1
MFRGT*2WJ^.I[FG1II!HOU;;_ '.5>Y3W Q> W+F=E99]$8[B2P[BW'5:4JF1
MM:2R"3;4XESU?,IMS(%=GS'5-JQ:/!Q_+]L1,UGQ4[N#[K/=';NZ)4/;>$=S
MNWWWU'%SH90H=%:KH2\DJ!;4D'2HJ]7A<&U;:N^UVK^Z<2QV]ELBT],9AW?;
M&":]V+L!N"7NY]E&\,\'RW#;4EP^UO,]&-&2H<%]/BXXH7 NJUP 3Y][?$[H
MZ>4/0UU^&TSU<T#[I3[\7LOW'DQG5LR65R7&7FU%"T+1C[I4E0L001<$5IW\
M9VU^WBS[#^N?3^2F>[M[PN9C[E.RNYV6?SFU=QCV),K+OJDF,^]="=;CY42R
MY?IK"E63<*X *OOW?:1T]5(Q,>1AVG=3U=-YS$JU[QO9>'VKWQ%G06G1L#.N
M]6,&E:EQE)4"_&"UZN*0=315>Z3XZ36O9]Q.VF)]J&?=]O&N\3_QE=NY?NRO
MX?$X'>G8!^?FX4ALNR%M24JF:'0E;+S"FPR2D@D*2D:APY\=//I[S,S7;B'1
MN[28B+:OQ=E]WQ/=3![*W+/[[2GA@FD)=A)S;B9$IN*TVZ9BGRK6LMJ&BR7%
M$\%<./'B[OW=KQ&KGYO\.OMO>5K/O'\\I!:4^ZI@:62M1;2?!)/ ?0KZ6'SE
ML9X/6?N)?V_O+^IP_P"E=KQ_F?*KU_EO_+[OS<\S?9CWBG\UD7XV%S"HSLI]
M;*DRTA)0IQ121]>Y6KHKW&C$<897T]Q-IQG&?+^KG>_=B]Q-FN07NX&.EPGL
M@EU$!R:ZEY3B8Y25A)"UD!)=3_K5U:MNN^>B7'NU[*XZWJ?W:'L?W;[&[E[/
M9V0I!QZE-,.)LI;<68HR&'$@_*+4A"U6\M(KR.\B=6Z-D>+UNTF-NJ:3X*C[
MZ&Z(K&1VQVNPQ#>+V[#3*D1T$D)<<2&8[:K^+;*+CT.5M\NIPF\\Y8_,+\J1
MZ5@]T?#8W8>P-W=ZMR MPPTY'C+ ^NF%!^N/=,**0HNNZ6TC5Q4BW"L^_M-[
MUUPT[&L4US>?M$,47W@?=>A;G.\XNQLVUNDR7)IR@9C]8R'BHN+).1M=6I5^
M%N-3/:=Q->GJC'V\R([S1%NKIG/HC_;\][O:D/++V5W?P7UW'95,:%+>2+!2
M'1[3#=/\I!6DD^214=ALF.K7/V\JW>:\S6\>5;_?![;[W[@_F9^9N&>R_P W
M?.?MO04VGI>T>Q].^M2?E=-?+RK+Y?NIKZNJ<9Q^:W?:;[.GIC.,_DC?=N[5
MYKLC"W/W*[I=+ QQ!##<=QYMU:(P6'G%N=)2DA2E);0V@$K)N+ V!MWF^-TQ
M2G$[31.F)M?@YY[K^?<W5[Q^;W,\G0YF&,M/+9^H]I?0YI^+5:NGO:=&B*^3
M#F[._7OM;RY_%\=W.TW?C,]S-T97;V(RK^$ESW78#K$I*&E,J/JE*2\FP^*G
M;[],:XB9C.%NXU;YV3-<X]+D6^NV_=;:>-CY??V+G1,:I\1(TB:\EY/7=0IS
M0FSBR"4M*/Q5VZMVJTXI,.'=JVUC-\^M0:Z7*]IS_P#<.1]A8_\ X@17@U_[
MGV_B]V__ %?NC\6L"4^X0"#8CB".=_SGJW_];]OXJ?\ ])]OY.ZX3<F&D]M\
M=WQDI2[F8>U'52)"C8+ ;;D/M*\SUV-(MXWKS[4F-DZ_#J>C6\32+^9YYVQ(
M>E^Y9O.5(45OOY%UUU9YJ6N;$42?A)KTKQCNZ^C\G#2<]M,SY_Q;&W?]QO.?
M9G?_ %5FHO\ ]R/MX(U_]6?1/XN][$SV%RO;';?>+)-]7)8?;,E$B3<:M#2&
ME3!<CF7(7 ^''SKSMM9C9.N/&?\ T_%WZ[1:D7GR?^K@&QYTC*>Z%W)R<M6N
M7-RDV2^L^+CRH:U'XR:]'9&.ZI'FAPZ[=7;VGRY2GNBO1=R]H=_=N8\AMC-R
MW9;B.HKDUDX#<1#FD<2E"VCJ(\QZ*KW\37;6_A_J3L,3KM7S_DY1L+W;>[S'
M<;"L93;ST#'X[)1I$[*.*:5%2Q'>2M:T+2NSA(3ZJ4FY]%=FWO-4ZYQ/.')J
M[/9&R,QPB5A]]W,09W<G$8J*ZER5B\4A,U*3?IN2'5N)0KR.C2OX%"LOEM9B
MDSY9:?,;1-HCR+-[X.1G8C']H,KC'UQ<C"8FR8DEHZ7&WFD8Y:%I/@00"*R^
M7Q$S>)^W-IW]IKT3'/C^3OO9K=VW>[>&Q/<YME#6[X4)[!99#9L6EN.,/.H(
MYE"E-(=:N>"5$<[UYW<:[:IFGAS>AIV5VUB_B\S^[;_O.[F_\[_"Q7J]Y_UX
M^YYO:_\ 8M]_XM3NYVF[\9GN9NC*[>Q&5?PDN>Z[ =8E)0TIE1]4I27DV'Q5
M/;[],:XB9C.#N-6^=DS7./2Y%OKMOW6VGC8^7W]BYT3&J?$2-(FO)>3UW4*<
MT)LXL@E+2C\5=NK=JM.*3#AW:MM8S?/K4&NERO>'<[9FY]]>ZYV[PVT\:YE,
MHB'@)*HS)0%!E&+4E2O74D6!4GQKY[3LK3N+3:<1F?Q?0;-=K]O6*\\0IONU
M^[]OW9^_8W<'?4%&!Q&%CRG&!)?9+KCCS+D<DI;6K0A*%K45.6\+<.-;]YW=
M+TZ*SF98]IVMZ7ZK<,*[B][0>X'OC8[<6*7U<0K(B)CW1>SC$.&I@.)OQLX4
ME8]"JTMKG7VLQ//'YJ5V1?NHF.7Z+)[R';/O-N?NE-RVR\9DI6!<BQ$-/1)"
M6FBM#0"P$EU/$'GPK+L]VJNO%IC+7NM>ZU\TSC'E<)W=VJ[T8# R,WO+$9%C
M 05-KD2)<A+K3:G5AE!T]51N5.!(L/&O0U[]5K8K,9>?MT[HKFV<>EUI?NWX
M3=/9W"=P.SDF9D=VJ0P_D83\EK5U$-E,IEG2EK0XV[Q2%*N4CAQ(OQ_&37;-
M-G)VSVM;:XMKYNE>Z_A?>!Q>;F)[A.9!K93453;43-.EYXRM2>GT X5.)2E(
M5JXA''Q/+E[VVB8_9CJ\S?M*[HF>OD\C=WYF)R/=+=\[!*;<Q3^6EKC.,VZ2
MP73J6BW I4JY!'.O9[>)C76)YX>1W,Q.VV/*]/0/]PY?V%__ /B!=>3;_N?;
M^+U*?]7[I_%Y-V'_ (XVS^5H'X2W7L[?8GT2\C3_ &5],/5OO@;_ -[[*WSM
M<[4W!/Q#9QZGW(\20XW'<<3(4 760>FYP%O72:\?Y?JI>ENJ(GB];OMMJ6KT
MSA.9;%X#WM>SJ-R8]AJ-W0P3994A"M*A*:&M3"@3_L9'RFBKY"CSX+OG6UNT
MVXGV9:VBO=:LQS_-S/W*LI%P_<[-X+)J]DR.0QKC$9E[U%JD17T+6U8\=82%
M*M_FFNOYC7.N)CEER?+YZ;S6>:N=PO=L[NJ[BYEG$[?=R>/R>1D2(&384VF,
MIF2ZIQ)<4I8#1 5907;CRN+&M-7>:O=QF<8AGN[/9.R<1PF75?>X>8VUV=[?
M]O)3S;N;C.1'%AM7_P /%P%Q7%Z>>E2WAI)\JY.P_=MM?P_W+K[_ (:ZU\_Y
M)#;\5GWA_=@B;,PLIE.\]K-Q8Z8;JDHL]C06F-7B$O1[I2OEKO?D:K>?A^XZ
MIY3^:U(C?V_3'./R<C[6^ZQW!SN](D??6">Q&TX3H<RSLAQ*"^VV;EEDM+*E
M%SY.M!LD7-[V![-_?4K3]LYEQZ>RO-OWQB%"[X[9V-L[N'D-M;!DR96*QR4L
MS')3J'],X$EUMM2$(NE'JI.JYU!7&NGM;WO2+7YN?NJ4I?%7H3W4?V(]R_AE
M_P#IU>9W_P#;3[>+TNP_JGT_D\:5[KPGLOWKOV(]M/AB?^G5X78?VW^WB]WO
M_P"J/3^2R[TP@]Z/L5@,KM&4T_O+#%IR3#><2A1F)9Z4J.M2E'05FSC:E_*
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M'8C<N8=R.-Q("<='=2V$L@(#=DZ$I/R4@<:4TTI,S6,9-F^]XQ:6?<O='?\
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M_P!J6P_L+7X;7TORO^F_V\'@?,O[M?I_.'L>OFGOE H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M2FW"LH[3;-^CI_='%K/<ZXKUYX2DIO</9>.VO$WI.R[4?:\X-F+D7$N)0L/
ME%DE.H7MXIK..WV3>:1'[H\%YVTBO5,\/*EL%GL1N;$QL[@9:)V)F!2HTIN^
MA80HH-M0!X*21RK.]+4MTVC$KUM%HS')FRF2@X;&3<QDWA'QN/8=ES'R%*#;
M#""XXHA()-DI)X"]16LVF(CG):T5C,\H5C$=UNW^>V]E-UXC--R=OX:_SG-#
M3Z4LZ4A9NE;84?5-_52:Z+]KMK:*S'&>3*N_7:LVB>$*Y^\GV2_2UG[VF?:*
MV^G]Q_'\&/QNC^4)' =].U&Z,Q$P.!W(U,R\Y1;BQDL2D%:@DJ(!6TE(X \S
M5+]ENI6;6KB(]"].ZU7G%;1,I7&]T=AY?=<C8^.S*']U1%O-R,<&GTJ2N-?J
MC6IL(.FW@JL[=MLK3KF/V^5I&^DVZ(GB^(_=?M[*W<K8C.<:.[$.KCJQJFWD
M*ZS22M2 M2 @FP/)7'PJ9[7;%.O'[?*CW^OKZ,_N\B>W#N'#;4PTK<&X)0A8
M>$$JE2E)6L("UI;3ZK:5*-U* X"L=>NU[16L9F6E[Q6,SR?.V]RX3=^%B[BV
MY+$[#3.I[-*2E: OHN*:7ZKB4J%EH4.(ILUVUVZ;1B8*7K>.JLYA7=X=X>VF
MPI:8&ZMQ1X4\@$Q$)=E/I!X@K;C(=4@'PU 7K?5VFW;&:US'V\K';W.K5[5L
M-;:G?#M7O:>C%;=W(P_DW>#41]MZ&ZXK^*V)+;>M7H1>IV]ENUQFU>'K_!&K
MN]6R<5MQ=!KC=2)W)N7";0PLK<6XY8@X:'T_:92DK6$=9Q+2/5;2I1NM:1P%
M::]=MENFL9F5+WK2.JTXA!;.[K]OM_SG\;M#.-Y.=&:]H?80V^TI+6H(U?76
MT7%U </.MMO:[=49O&(9Z^XU[)Q6<LF\NZ&P^W[\6-O#,MXR1-0MR*VMMYTK
M0V0%'ZTA=A<^-1I[;9MS-(S@V;Z:_:G&4MM?=>W]Z8=K/;8FIR&(>4MMN2A#
MC8*FE:5"SB4JX$>59[-5M=NFT8E>FRMXS6<PT-Y=Q=E]OFX;N\<LWBT3U+3#
MZB'7"X6@DKL&D+/JZDW)\ZOI[?9MST1G"NS=37[4X2^"SN)W-B(F>P4I,W$3
MD=2+*0%!*TW*;V4 18@BQ%97I:EIK;A,-*VBT9CDRY3*XS"0'LIF)C,#'1TZ
MWY<EQ+32$^:E+( J*UFTXB,R6M%8S/)S%/O,]D%2?91NM <N$A9AS@U?[(8^
MFWIO:N_Z=W&,]/\ F/\ ;B^/T9QU?BZCC\C RT)C)8N4U-Q\E(<CRHZTNM.(
M/BE:201\%<%JS6<3PEW1,3&8<U<]X_LHTXIIS=C(6@E*A[-,X$&Q_P#@5W?3
M]_\ '\')/>Z8_P"4)#"=]>T>XI[6,Q6ZX:YSZ@VPT\'8NM:N24F0AL%1/  &
MY/"J7[+=2,S6<+5[K5:<1:'0ZXG4YAFO>([,X"<[C<ANIA4ME6AU,5F3-0E0
M-B.I&:<1<>/K5WT[#?>,Q7\(_%Q7[W32<3;\_P %FV=W'V/W 9<>VAFX^4Z(
M!>91J;?0D\BMEU*'$@^93:L-W;[-7MQAOJW4V1FLY?.\^Y.R.WOL/YY99&+^
M<>K[%K:>=ZGL^CJ6Z2%VT]1//SII[?9MST1G!MWTUXZIQE5D>\AV3<6$)W:P
M"> *H\M(^,J9 %='T_N/X_@Q^-T_RAT)C/X67A?SCASV96"Z*Y0GQUAYDLM@
ME2DJ;U7MI-[5Q32T6Z9CBZHM$QF)X(C9G<;9?<%N8[L[*HRB(!;3,*&WFNF7
M@HHOU4(O?0KE6N[M]FK'7&,L]>ZFSV9R^=Y]R=D=O?8?SRRR,7\X]7V+6T\[
MU/9]'4MTD+MIZB>?G33V^S;GHC.#;OIKQU3C*SL/-266Y#*M;+R4N-KY72H7
M!X^8-83&&RE9_O%VTVON [6SVX&86>26DJAK;?44F0 IO4M#:D"X4#Q5R/&N
MJG:;;UZJUS#GOW&NMNF9XKS7(Z$3N'<VW]IXUS+[ER4?%XUO@J1)6$)*O!*0
M>*E'P2D$FM->NVR<5C,J7O6D9M.(<Z9]YOL>_(3&1NM(6HZ0MR%/;;OZ5KCA
M(^$FU=L_+NXB,]/^8_VXX[_1,XZOQ=2Q^1@9:$QDL7*:FX^2D.1Y4=:76G$'
MQ2M)((^"N"U9K.)X2[HF)C,.;R/>+[+Q7W8LC=;*'V5J;=1[-+-EH-B.#-N!
M%=L?+]\QGI_!R3WFF)Q-H8_WD^R7Z6L_>TS[14_3^X_C^"/C='\H=!S^XL'M
M7%O9K<4]G&XMBW4DR%!";GDD>*E'P2FY-<>O7:\XK&9=5[UI&;3B'.F/>9[(
M2)(BHW6A+BCI"W(<YIN][<5KCA(^$FU=L_+NXB,]/^8_VXX[_1,XZOQ=2AS(
M>0BM3H$AN5"D)#C$EA:76G$*Y*2M)((/F#7GS$Q.)=T3$\89ZA+7GSHF+@RL
MGD'4QX$)IR3*?7\EMEE)6M1MX!()JU:S:<1SE$S$1F56V=W4V!O^7)@[0S;>
M3EQ&P_(90V\TI+95IU?76T7%S;A6^WMMFJ,WC#'7OU[/9G*;W)N7";0PLK<6
MXY8@X:'T_:92DK6$=9Q+2/5;2I1NM:1P%9:]=MENFL9F6E[UI'5:<0P[4WAM
MK?&)&<VKD&\EBRXM@R&PM%G6[:DE+B4J!%P>(Y&]3MU7UVZ;1B4:]E;QFLYA
MHY'N1LG$[KB;(R.60QNF?TS$QQ;>4I?6)"++2@H%])YJJ]>WV6I-XC]L*SNI
M%HI,\9:V\.[';W8,]C&;NS;>,G261)896T^X5,E2D:KM-K'-)'.K:NUV[8S2
M,PC9W&O7.+3A!Q?>)[+3'T1VMW14N+( +S<AA'$VXK=:2D?&:UGL-\?\991W
MFF?^4.E1Y$>6PW*B.H?C/)#C+S2@MM:%"X4E2;@@CQ%<,Q,<)=C+4#F\[OYV
MBQF7DX&?N=EC+0Y+D&5'4Q*]20TX6EH*@UIX*!%[V]-=U>QWS7JBO#GX.6>[
MU1/3-HRO.:S.,V[BI><S4E,3%0&U/RY*PHI0VGF;)!)^ "]<E*3>8K'.71:T
M5C,\H57:?>+MMOC*_,FU<\WD<ITEO^SH9D-GIMD!2KNM('"X\:Z-O:;=4=5J
MXACK[G7LG%9S*?W/NW;6S,:K+[IRC&+QX.D.R%6*U'ZE"1=2U?YJ036.O5?9
M.*QF6E]E:1FTXA0(GO+]D)DE,5K=;:'%JTI4]$FL-\?$N.,)2!Z5$5V3\N[B
M(ST_YC_;DKW^B9QU?BZG%E1IT9J9">;DQ)"$NL2&5!QMQM8NE25))!!'$$5Y
M\Q,3B7=$Y5/;/=?M[O'-2-N[;SC4[-14N+?AAMYI82RH(6074("M)/'2373L
M[7;KKU6C$,:;]=[=-9S,)3=N\]L[$Q:<UNS()QN,6\F,F0M#C@+RTJ4E-FDK
M/$)5X5GJTWVSBL9E?9LKKC-IQ"3Q>2@YG&0LQC'A(QN08:EPWP%)#C#Z XVH
M!0!%TJ!XB]9VK-9F)YPM6T6C,<I4'<7?[M#M7(NXG,;H83D&%:'F8S4B;H5X
MI4J,TXD$>()N/AKLU]COO&8KP]7XN79WFG7.+6X^O\$ULWNCL#N"74;0SL?)
M/LIUNQ@'&)"47MJZ+Z6W--S;5IM66[MMFKVXPUU;]>WV9RMKCC;3:G75!#2
M5+6H@)2D"Y))Y 5SMW+<E[R'93%3G,?*W8RN0THH<5%CRY;((OR=89<;4.'-
M*C7?7Y?W%HS%?P<-N^T5G$V7K;V[=M[LQ'S[MK),Y7%\;O1"72E21<H4@#6E
M=OJ"G5Z*Y-FJ^NW3:,2ZJ;*WC-9S"$VGW;[=[YRCN%VMG6I^58;4^Y%Z;[+@
M;0H)40'FT7L5"X'&M=O:[=<9M&(4U]QKO.*SF4WNC=FW=EXAS/;HGMXW$M+0
MVJ0X%*]=PV2D)0%*)/D!Z:RUZK;+=-8S*]]E:1FTXA3GO> [0QH$3)O[E0W
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MMW%XOC''GZ4O[Q&U^P&$VS#?[;RX/YT>V):7&Q4\STJCZ5]0O)+KH1I(3I/
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ML3$E(-ELF1 2MQ:3X*Z;:PD\P3<<16>C1&WO+1/*)M/^5]NZ=7:UF.<Q6/\
M"$]WWW=]D9;8\'>6]X!S.6S87(8CON.)88CE12BR4*3J6L#65*OS%O,Z]_W^
MRNR:4G$0S[+LJ32+WC,V;NZ_=0Z6],;NCM5E6MK,Q5)D.,/%]\LRFE I6QQ)
M*5#Y2%+MY<#84U?-/_'-=L=2^SY='O(OKGIP],IU!("R"NPU$"P)\;"YM]&O
M">P^J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#QQ[V_[4MA_86OPVOI?E?]-_MX/
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MI?C.)=02DJL0%)' UX]_F6Z]9K,\)\SUJ]AIK,3$<8\\N2>_'_\ 8'_YO_\
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M.\/ZE_\ -"O8^;?U4]/Y/+^6?V7^WC+\]VS;>+W?G.ZVV<TUU<9DVA'?2/E
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M?A$/$O68[?7LCG69_&?]-G9C$K=&Q.]W=#(I(EY%H1T'F-4R6F6^D'AP3I:
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M-FR;7FWC,Y=-*16L5\(C#AF[/<[[>YV>YD,#/F;>+RU+<ALA$B(F_@VA82I
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M"@QPX!IZ:4\^H;WKL[OO+=Q,9C&')VW:UT1,5F9RQ]W^R>$[Q?,WSQDI6/\
MF7VKH^R!LZ_:^CJU=1*N71%K>=3VG>6[?.(B<_DCN>TKOQU3,81N_/=[V_W#
MS^&S6=R\T1L+'CPV,:T&@RMF.O6K45))NY>RCY6\JTT=_;568K$<?%&[LZ[;
M1:TS^WP=@ "0$I%DC@ .0%>8[G)-S=@<!N#N5%[HQ\K,Q>?C.Q9"FXP:++CT
M.R4J4%I)]9"4H4+\17I:^^M35.K$3'^W#?LZVVQLS,2L?<CM)LONI"9B[IBK
M]IC7]DR450:F,A1N4I64J!2?XJTJ'C:]8=OW6S1.:S]S7?VU-T8M#B;?N2[5
M$D*>W3D%P]5RTAAE#FB_+J'4+^G1\5>I]9OCV8>;])U_RG_#N7;[M7LKMC!<
MB;4QX9>? $N>\KJRW])N-;A\!?@E("?17E;^YV;IS:7IZ>WIJC%8<<G^YELR
M?.DSG-Q91"Y+KCRDI3'L"XHJ(%T>FO2K\WV1&.F'GV^5Z[3,YGCZ&O\ N3[)
M_23*_P"K'^UU;ZSL_C"OTG7Y9_Q_IV3??:;:/<;;</;FY&7%IQZ4C'Y!E26Y
M;"@@()0HI4+*"1J24E)X<+@6\S1W5]-YM7Q>EN[>FVO39Q1OW)=JB2%/;IR"
MX>JY:0PRAS1?EU#J%_3H^*O4^LWQ[,/,^DZ_Y3_AZ"V1L;;G;S;[.VMKQC&Q
MS2BZLK47'77E@!3KBSS4JP]'@   *\?=NMMMU6YO6U:JZZ]-8X+ ZE:VEH;7
MTW%)(0X %:5$<#8\#:L8:N5=K.PNW>UF<R>XH62F97+9-KH+?F]*Z$K<ZKA&
MA()*U!-SZ*]#N>^MOK%9B(B'#V_9UTVFT3,S/E=*S.)A9[$3\)DD=3'Y*.[#
ME(',M/H+:P+WXV-<-+36T6CG#LM6+1,3REQ?#>[!M_"[.W-LEC<.1=P^Y_8U
M2@XEC4TY ?2^A;=D6NK3I5?F/@%>I?YE:UZWZ8S7/^7G5^7TK2U,SBWY.I;"
MV=#V!M'&;0Q\AV5#QB'$-2'](<4'75NG5I '-=J\_?MG;>;SXN[5KC72*QX.
M=->[5LV)W+;[DXV;*A2FYPR2<4T&O9 ]S6!=.H)4JZK \+\.%=L_,;SJ]W,1
M/#&7)'8TC;[R,Y_PVN[/N^[?[N9R%G<OE9D!^%$$)#44-%"D!Q;FH]1)-[K-
M5[7O[:*S6(B<RGN>RKOF)M,\%(A>Y9V^9D)<FYS+2F$\2RE4=G4?2H-*-O@^
MC75;YQMF.$0Y8^4ZHGC,N_;7VM@-F86/M[;4)$#$Q0>FRW<DJ5Q4M:C<J4H\
MU*-Z\C;MMLMU6G,O5UZZTKTUC$)BLFCF&S.R>$V5W%W#W'A9*5)R6XO;/:(;
MP;##?M\M$M6@I2%>JI&D7/*N_=WEMFJNN8C%<?XC#BU=I77LG9$SFV?\SE%;
M-]W/:>RNX3O</'3Y;LQ3LQZ- <#0CL&;K20DA(59*5J2FYK3=\POLU>[F(\/
M\*ZNRIKV3LC.>/\ E+;?[*83;W<_*]T8^1E.Y3+!\.PG W[.CVDI*M)"0KAI
MX7-9[.\M?3&K$8AI3M:UVSLS.9;W<WLYLKNO%9;W)'<:R,5)1#RL-0:E-)4;
ME%RE25HOQTK2;<;6)-4[;N]FB?V\O(GN.VINC%G'8?N3;2;EI<G;FR$B$%75
M':999<(\NH=8'^I7IS\YOCA6'GQ\IUYXS+T-M+:&WMC8./MW;$)$'%Q[D-IN
MI:W%?*<<6;J6M5N*E'T<@*\7;MMMMU6G,O6UZZZZ]-8Q"F]L>RF$[7YG.YK%
MY&5->SQ!?;DAL);TN+<]70D'FOQKJ[GO+;JQ68B.EAH[6NJUK1,_N8N[?8C:
MW=Y_'3LM)D8[)XY"V4S(8;*W&%G4&U]1*@0E1*D^5SYU/:][?M\Q'&)5[GLZ
M;\=7"87O!;<@X3:N-VD?^NXW'8]C%6DI2OK,1V4L?7$VTG4E/K"UJY+[)M>;
M\IF<NFE(K6*^$1AP?<_N:[!R\]R;@,G-P+3I*E0DA$N.DD\F^II6D>@K57K:
M_F^RL8M$6>9L^5ZK3F,PL_;3W9M@]N<FSGBM_.9^.=465.T!IA?@MIE L%CP
M4HJ(YBQK#N?F.S='3[,>9MV_8:]4YCC/G=7SV!P^Y\1*P6?AMS\3-1TY,5T'
M2I/,<0000>*5)((/$&]>=2]J6BU9Q,.^](M&)XP\Z9+W*=F2)RWL9N+(PH*C
M=,5QMF0I'F Y9'#RNDGS)KVZ_.-D1QK$R\BWRG7,\)F'8^V?:79_:G&NP=LL
M+5*E:3.R4I0<E/E%](4H!("1<V2E('Q\:\SN>ZOOG-O4]#1VU-,8JM6=Q+6>
MP>3P4AQ33&3B/PG76[:THDMJ;*DWN+@*X7KGI;IM%O)+>U>J)A2.T?9[#]H(
M.3@X?(2<@C)NMO.JEAL%):24@)Z:4\[^-=?==W;N)B9C&'-VW;5T1,5F>+H]
M<+K<IB=BL%$[N*[OHR<M674XZ]\WD->S7>B*B$7TZN"5:N?.O0GO;3H]UB,?
MKEPQV=??>]S.?TPZ-G<2UGL'D\%(<4TQDXC\)UUNVM*)+:FRI-[BX"N%ZXJ6
MZ;1;R2[+5ZHF'G']R?9/Z297_5C_ &NO;^L[/XP\?Z3K\L_X_P!)3;?NA;0V
MUN+$;CC9_)/2</-C9!EEQ+&A:XCJ74I59 -B4V-JSV?-;WK-9K'&,+Z_EFNE
MHM$SPG*_=U.QNR^[*6).:2]"S<5/3CY6$4I>Z=[]-P+2I*T FX!%QX$7-<G:
M][LT<N,>1U]QVE-_M<_*Y9C/<HV='F(>RNX\A-A)-U1F6V8RE>0*_KEAYV%_
M2*[[?.-DQPK$.&ORG7$\9F7H_"83%;;Q,/!8.*B%B8#89B16[E*$)\+J)))Y
MDDDD\3QKQ+WF]IM;C,O8K6*QB.4)"J+% H% H% H% H% H% H% H% H% H%
MH% H% H% H%!6>XW[/=V_D;(_@KE;]O_ &5],?BRV^Q/HE_*ROT!^?O8ON/_
M -G[U^S8[^;)KYKYSSI]_P"3Z;Y/[%O2]:5\Z]\H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M:9B%7VMELC-WCNB#)DK=APUM"*THW2@*U7T_#:M+Q$5AG29FTKM6+4H% H%
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MN-)U)*E<U D<;_PU2NRV5[:XPJ6?R\S.=KL/.?</MYFM-+>OZQ6T74!=^=R
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MSRDA[(3-*6F4@W)22/6O;RY>%3%:QQF<HFUIX1"\Q&GF(K#,AXR'VVTH=?4
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M6R0B8QW,;<R3YEM>R$%]AU?RDE!YBW#XAQYBIF8O'/$D9I/+,)/"R-WYK/\
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M&OY;&K,B&P71K"2G661<Z0JWQ5>:S$XE6+1,9?6!S#6?Q,?+,,N,-2->EIX
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M*!0*!0*!0*"L]QOV>[M_(V1_!7*W[?\ LKZ8_%EM]B?1+^5E?H#\_>Q?<?\
M[/WK]FQW\V37S7SGG3[_ ,GTWR?V+>EZTKYU[Y0*!04/%?M5SOY/8_Z*MY]B
M&,>W)E?VJX+\GO\ _2TCV))]N#??^(]E_E!7\+5-?*39S@_^VW_Y1_TM/_C^
M\_Y_<P=N9#.-G;@VY,4EG)MY!R0AM=DK<:< "2F_,63?AYU.V,Q$HU\,PG5[
MJC3<Y-VY":,@1HBWI4UM8+;:^(Z9X<^(\?X#5.C$97Z\SA']J/\ !4+[(_\
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M$D^#SZ-;OQINI)^$5>\=-<*TGJMET:N=NH&[GF6-^;0=?<2TTGVK4M9"4BZ
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MX4S.,&(SDFXC'9&1$E36 [(@+ZL19*@6UFW$6(OR'.D3,$Q$OSYHQWSI\]=
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M_M/S0WU+ZM/4>Z=_Y&O3;T6K7WMO*S]W7R+.TTTPVAEE"6V6P$MMH 2E*1P
M '  5FT:.=?RD;$2I&&81*R320IF.[<I790U)X%)N4WMQYU-<9XJVSC@YLUF
M]@-J1/.W'$[I2-7S:F*Y<21Y)^1;5XVOZ+UT=-_+P8=5?)Q6_MYA9V#VVVQD
MD].;)=<E.M>*"[:R3Z; 7K+9:)G@UUUQ'%DE=O-F3)*I;^);ZRCJ5TUNM()Y
M_(;6E/TJ1LM'B3KK/@G48V U .+:CH;QY;+)CMC0CIJ%B+)MS!K/,YROB,8?
MN/Q\/%PVH$!H,PV00TT"2$@DJ/%1)YFDSGC)$88X&)QV,=EO06 R[.=5(E*!
M4=;JB25&Y-N?A4S,R1$0B,EL+:.6E*FSL6VN2LZG%MK<9U*/,J#2D@D^9JT;
M+1XJ3KK/@FL?CH.*BHA8Z.B-%;^2TV+"YYD^9/F:I,S/->(B.2/A[3V]C\JY
MFX4%+.2<UZWD*6 >IQ5ZFK0+_P FK3>9C"L4B)RW,7B,=A8@@8Q@1X@45!H%
M2AJ5S/K$GC43:9YK1$1R0SW;O9;\HS7,0UUBK40E3B&[_8TJ"/BTU?WEO*I[
MNOD3,W#8K(P/FN;$:=QX 2F.4A*$A/!.G3;3;PTU2+3$Y7F(F,(K'[#VCC%K
M7#Q;:5N)4A2G%./$)6-) +BE6N#;A5IV6GQ4C76/!MKVO@7,0C N0PK$MJUH
MC%:](.HJX'5?F3XU'7.<K=,8PVYN(QV1D1)4U@.R("^K$62H%M9MQ%B+\ASJ
M(F83,1*H;\W&A4>7L^#"?E9O(-I990&[M:7;77JO]2/1P/HXUKKK_P O!ELM
MX>*U8#$M8+#0L2T04Q6@A2AR4L^LM7^DHDUE:<SEI6,1A)559%YG;N%W TAK
M,0T2DMWZ:E72M-^>E:"%"_H-6K:8Y*S6)YL.%VEMW;RUNXB B.\L:5.DK<<T
M^04XI1 ] -3:\VYHBD1R;J,3CF\HYFD, 9-UKV=R1=5RT"#IM>W-(\*C,XPM
MB,Y)N(QV1D1)4U@.R("^K$62H%M9MQ%B+\ASI$S!,1*I;PR34;)MPMS89,[:
M3K6IN:VTIUQF1R(58^J+?Q0#Q]!K6D<.$\65YX\8X*XW%PVXLGAL=LO%KCX>
M'+1/R614TIM!#7R4A:[J4;$V!\_*]7S-8F;3Q4Q%IB*PZ@[B,<]DV<PXP%9*
M.@M,R+JNE"KW%KV\3X5SYG&'1B,Y?D;$8Z'.EY*,P&YT[3[4\"HE>@63<$D"
MWHI-IF,$1$3E^O8G'2,C&R[S 7D8:5HC/DJNA+@*5  &W$$\Q3,XP8C.6OF=
MMX/<*$(S$)$KIWZ:SJ0M(/,!:"E0'HO4UM->2)K$\V/"[5V_MXK7AX"(SC@L
MMVZG'"/+6X5*MZ+TM>;<RM8CDRYG;N%W TAK,0T2DMWZ:E72M-^>E:"%"_H-
M16TQR)K$\V'"[2V[MY:W<1 1'>6-*G25N.:?(*<4H@>@&IM>;<T12(Y-SYHQ
MWSI\]= ?.G2]G]HNJ_2O?3:]N?HJ.J<86Q&<L\R'$R$9R'.91(BNBSC3B0I)
M'P&HB<$QE7X?;W9L"4F9&Q38?0=2"XMUU(5>X(2XM2>'APJ\[+3XJ1KK'@L$
MN'%GQG(DUE$B*Z-+C3B0I)'I!JD3A>8RK\;M[LV)UNABD#KH+;A4MU9TJYA.
MM9TW_P VU7G9;RJ>[KY%ABQF(<9F'&1TXT="6F6Q<A*&P$I'&YX 529RO$89
MJA)0*!0*!0*!0*!0*!05GN-^SW=OY&R/X*Y6_;_V5],?BRV^Q/HE_*ROT!^?
MO8ON/_V?O7[-COYLFOFOG/.GW_D^F^3^Q;TO6E?.O?*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0>./>W_:EL/["U^&U]+\K_IO]O!X
M'S+^[7Z?SA['KYI[Y0*!0*#X6XVT-3BPA/*ZB +_ !U(_4J2M(4@A23R(-P:
M@?5 H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H/
MPD)!4H@) N2>  %!\MNM.@EI:5@<"4D'^"I'W4!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!05GN-^SW=OY&R/X*Y6_;_V5],?BRV^Q/HE_*ROT!^?
MO8ON/_V?O7[-COYLFOFOG/.GW_D^F^3^Q;TO6E?.O?*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0>./>W_:EL/["U^&U]+\K_IO]O!X
M'S+^[7Z?SA['KYI[Y0*!01&Y\VC;N"F9A:0M4='UIL\E.K(0@&WAJ(OZ*O2O
M5.%;6Q&50P.Q&=PPV<_O1Y[)9"<@/HCJ<6TRRVX-24I#920;'B!8#E:M;;.G
MA5E77GC9D&T\KM'.0I>S@Z_AI3FC)XMQT%M".%W$EPCB!RXZK\.(-JCKBT?N
MYG1-9X+CG<JU@\/-RSUBF*TI82?JE\D)^-1 K*L9G#6TXC+EFT4SMJYO!Y'(
MN*+&[&%^UJ7R$E;A6V3Y7"D?ZQKIOBT3$>#GIFLQYW3-U_X6SGY/E_T*ZYZ>
MU#HO[,J)LSMWM7,[8Q^3GQ5N2Y"%J=6'G$@D.*2. ('(5M?9:+88TUUF,M?<
M^"8[>R<5F=L27F.O*3'?QRG%+;=0H$G@>)'"QO?F+5-;=>8E%J]&)AUNN5TH
MO*[@Q6$=BM9-\,&85I94H'1]; 4HJ5R2 #XU:*S/)6;1'-#PNX^TY\]O'LRU
MH<>5H8==:6VTXJ]AI4H#GZ;5>=5HC*L;*S+Y7W,V>B8(BIJM)5TQ*#:_9]0-
MCZ]K6]/+TT]U9'O:K%DLKCL/"7D,E(1'AHM=U5R"3R  N23Y 52(F9Q#29B.
M:LM]T-I+=;;<?>8;=-FWWF'$-'POJMR]-:>ZLS][5:9>0A0(:\A,?0S";3K6
M^H^II/(W\;^%N=91$S.&DS$*S&[E[3DOML^TN,H>5H9D/LN-LK/H618?':M)
MU69QLJE\MN?"X.0Q&RDGH+DMNNM**5%)0PG4KB 1RY#Q\*K%)GDO-HCFP8?>
M> S<&7D8D@MPX1 DNR$EI*;BX-U<#]&IM28G"(O$QE&H[G[04\E!DNH86K0B
M6MAQ+!(\E$?PBK>ZLK[VJP97.8W#8TY><];'C1]>;!<!#A 21IO<&]9Q69G"
M\VB(R@Y'<C:D:2MA<EQ33:^DY+;9<7'2OR*P+'XJO&JROO*G<%]F3L/)R([B
M76'66EMN((4E25.H(((Y@TU^U"-GLH^#W%VKBL7CH4B4MQUF+'1(4RTMQ#:@
MVD64H"U_@O5IUVF41LK$+E'R4"7 3E(\A"\<I!=$F]D:$W)))M:UN-^58S$Q
M.&N8QE5WNZ.T6E*TOOO,(5I5);8<+0-[?*('E6ONK,_>U6B!DH&4A-Y& ^E^
M$Z"I#R>5AP-[V(((X@\JRF)B<-(F)XJVYW,V@U)5']K6MM"M#DM#3BHZ5'P*
MP/ICA6GNK,_>U3N(SV+SJ9*\6]UVXCRH[JP"$]1//23P4/(CA5+5F.:\6B>2
M$F]R-J0I+L;VER06#:0[&:6ZTWQMZRTBWT+U>-5I4G96%A@93'92$C)0)*'X
M*P5!Y)LD <[WL01X@\JI,3$X:1,3&5;=[G;2;<6D2'G8[:M#DMIAQ; /\H#C
M\0K3W5F?O:K3$F19\9J9"=2_%>2%M.H-TJ2:RF,-(G+/4):65RD3#0'LG/4I
M,2. 75(25D!2@F]DW/,U:(S.$3.(R_'<OCV<2<XX[;&A@2NL 3=I2=0( X\0
M>5.F<X,QC+\Q>8Q^9QK>6@.ZX+H44N*!3P;44JN#8BQ!I-9B<(B8F,J#O7.X
MW-X[;66@.DP/GAH=9Q):%F[ZCZ]N \ZWUUF)F/,QO:)B)\Z='<W9_M28QF+"
M%*T)E%I88*KV^61ROX\JS]U9?WM5GFY"%CH;F0FOH8A-I"EOK-D@'EQ\;WX6
MYUG$3/!I,Q"L1^YNT7WT,F4XRVZ=+4AYEQME1_E$</CK7W5F?O:K)D<IC\3"
M7D<C(2Q"; *G5<1QY6 N23X 5G$3,XAI,Q'%7H?<C:LN0S&+[L8R#ICNR65M
M-+)-N"R+#X3:KSJM#.-E5AR>5Q^&AKGY20F-$18*<7?F>0 %R2?("]4B)GDT
MF8CF@('<7:T^4U#3(<CNR#:,J2TME#ES8:5*%N/IM5YU6A2-E96NLFB/S&9Q
M^"B>W9)PMQBM+6H)*_66;#@F]6K69Y*S:(YH)WN3M-J0652G"R%](S4LN*C!
M?EU +?&.%7]U93WE4WE,]B\1B_GF8]_].L@AYL%P$.D!)&F]P;U2*S,X7FT1
M&4?CM[[>RN9<P4"0IZ:WK]9+:BT>G\JRP+<//EY5:=<Q&41>)G#5G]Q]JP)+
ML4R5R%L<)"XS2W6V[&WK* M]"]3&JTJSLK"=QV8QN6@#)XZ0F1"()ZB+\-/$
M@@V((\C5)K,3B6D3$QE .=RMJ)89>9D.R2\E3@:896MQ*$**"I8MZHN/&K^Z
MLS]Y5/8?-8S/0Q/Q,A,B,3I)3<*2H<TJ2;$'X:I:LQS7BT3R0^3[@;9Q<QR
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MHUS,95G9$<$KA<]B=PQ/;<1)3(8!TKL"E25<[*2H BJVK->:U;1/))559RW
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M/[%O2]:5\Z]\H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M[D81B<S)@0,8I23,?@]53[J4&X"0O@+D7\/\E6BU*\85FMK<)7F)&:A16(;
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M?SFZC7L'L/L?3NKK=37JO;3IM_I5/5'3@Z?W9?NZ=O3<Y-P,F(XTA&+GMS)
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MR/X*Y6_;_P!E?3'XLMOL3Z)?RLK] ?G[V+[C_P#9^]?LV._FR:^:^<\Z??\
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MZTS;"MK8KE8(3ZI4*-)6 %O-(<4!R!6D$V^C6<\UXY-BH24"@UYKZHL*3)0
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MZ _/WL7W'_[/WK]FQW\V37S7SGG3[_R?3?)_8MZ7K2OG7OE H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H/''O;_M2V']A:_#:^E^5_TW
M^W@\#YE_=K]/YP]CU\T]\H% H*?W*@>U[5FO^U2&/9&U.=)AS0V[>PTNBQU)
M]%:ZIQ9ELC]JLY3&?-_:%YWVR5*]LBXY_1*=ZJ&=2V#H:%AI0+\!6L3G8I,8
MHWFMFYJ=@&LI)W%/9S/LJ78S,=WHQ&K(U(;T)%^ L"K55>N(G&.">B9C.6Q
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M]+\K_IO]O!X'S+^[7Z?SA['KYI[Y0*!05W?;;CNT,PAI)6OV=1TI%S9-B?H
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M_:K@OR>__P!+5(]B5Y]N#NI_96&_*\;^8[33SGT&WE'I8NY$EK'Y/:F4E71
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MX%0<!";'B3PMX5I^_/'DS_9CAS:>,Q$C/=HQ%QX+DZ%)<?2TGY16VXI12/\
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M$Y"ANNA]V.TM\6LZI"2L6Y<2+TS*,,Q 4""+@\"#RM4)?B4)0D)0D)2.20+
M4'U08WF&)*.G(:0ZW>^AQ(4FX]!O4Y'ZVTVRA+3*$MMIX)0@!*1\ %!\/Q(L
MH 26&W@GY/40E=O@N#3*,,B$)0D(0D)0D62E(L /0!4)?B6FDI*$H2E*KE20
M  ;\[U(_4H2A(2A(2D<D@6 J!A;A0F72^U&:;>-[N)0E*N//B!>IS*,0RK;;
M=&EQ 6GG90!%_CHE]U 4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%
M9[C?L]W;^1LC^"N5OV_]E?3'XLMOL3Z)?RLK] ?G[V+[C_\ 9^]?LV._FR:^
M:^<\Z??^3Z;Y/[%O2]:5\Z]\H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H%!XX][?]J6P_L+7X;7TORO^F_V\'@?,O[M?I_.'L>OFGOE
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H*SW&_9[NW\C
M9'\%<K?M_P"ROIC\66WV)]$OY65^@/S][%]Q_P#L_>OV;'?S9-?-?.>=/O\
MR?3?)_8MZ7K2OG7OE H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H/''O;_M2V']A:_#:^E^5_TW^W@\#YE_=K]/YP]CU\T]\H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H%!6>XW[/=V_D;(_@KE;]
MO_97TQ^++;[$^B7\K*_0'Y^]B^X__9^]?LV._FR:^:^<\Z??^3Z;Y/[%O2]:
M5\Z]\H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!XX][
M?]J6P_L+7X;7TORO^F_V\'@?,O[M?I_.'L>OFGOE H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H*SW&_9[NW\C9'\%<K?M_[*^F/Q9;?8
MGT2_E97Z _/WL/W(21C]Z6_Y['?S9%>#\TI%IKGSO=^6[)K6<>5ZRU'SKQ?<
MU>O\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI[FI\18U'SI
M[FI\19X[][4D]T=B7_YEK\-KW?E](KJO$?;@\CO=DVV4F?+^</8FH^=>%[FK
MU_B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<U/B+&H^=/<
MU/B+*UW&4?U?;L_(V1_!7*UTZ:Q>OIA2^^TUGT/Y7U]F^.>P_<A_L_>GV;'?
MS9%>+\QYU^][/8>S/I>L:\AZ90*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*#QW[VG[4=B?86OPVO9['^NWV\'F=W_93T_P"GL2O&>F4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@K7<7]GV[/R-
MD?P5RM=7MQZ85MRE_+"OK'RKV'[D/]G[T^S8[^;(KQ?F/.OWO9[#V9]+UC7D
M/3*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0>._>T_:
MCL3["U^&U[/8_P!=OMX/,[O^RGI_T]B5XSTR@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4%:[B_L^W9^1LC^"N5KJ]N/3"MN4OY85]8^
M5>P_<A_L_>GV;'?S9%>+\QYU^][/8>S/I>L:\AZ90*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#QW[VG[4=B?86OPVO9['^NWV\'F=W_
M &4]/^GL2O&>F4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@K7<7]GV[/R-D?P5RM=7MQZ85MRE_+"OK'RKV'[D/]G[T^S8[^;(KQ?F/
M.OWO9[#V9]+UC7D/3*!0*#R[NKN5OF#[T&/V1$S+S6U796/;<Q@2WTRA^,VM
M8N4:N*B3\JO5III/;S;''BX;;+1NBN>"J^\5W:[E[4[I3<#M;/R(.,:B1GD1
M64-*2"6>HXKUT*/@2>-;=IHUWUYM#+N=UZWQ6?!W?M=W+5F>R47?V<>]JFXR
M!*7EU\$*6[C>H%%5A8*6E"5\!]57G[M.-O3'C/XNS5LZM<6GR/+W;;O?W<S7
M<?:F-S&XY#N*RV3BMO1BVREMQAV1TUI%FP=/!2>=>KN[;577:8CC$/.U;]EK
MQ$SPE=/>4[J]R-H=RQ@]IYV1C\=\W1Y'LK*&E#J*+A6KUT*/)-8]GHUWUYM'
MBU[G;>M\5GP=J[+]R'-R=FX^\=PR3)GXIF8G-2"$A2E02M94;6%RUH4?AK@[
MC3T[>F/'DZ].SJI%I>7=B]]>[><[B;7BY#<4@X?+YR%'>B:&0TIAZ6VEQH6;
M!TZ5Z:];9VVJM)Q'&(>=3N-DWCCPF76/>=[E;YV3O/;..VMF7L;"FQ>I*9:2
MVH+7[047.M"CRX5Q]GII>DS:,NON-EJVK$3S>ELN\Y'Q,^0RK0\U'>6VL<PI
M*"0?B->97F[7GCW3>X>\]^_G?^=^7=ROS?\ -OL?62VGI]?VOJ6T)3\KIIY^
M5>EWVJFOIZ8QS_)P=IMM?/5+FNW/>/WCMON[-B;NR[L_90R4N!)C.(; CL]=
M2&W4%* KZU8$B_%-QSKIOVE;:HFL?NPRKW-HV3%IX9=[]Y'=^>VCVQ^?MIY%
M4&>N;%;;F,:%W9="R;:@H$&PKS^TUQ?9BT.SN+S6DS'-OX'N0C;W8O$]Q=WR
M%S'T8IB3*7ZJ79,EVR4(38 :EK('*PY\JK;3U;II7RK1LQKBUO(X-MW/^\QW
MWDR\WM?+-[;VVTZIIA0<,.(E0%^FE;;3CSJ@+:E6(!_B\J]"].WT<+1F7%6^
M[;QKPAFC=V^]78S=</!]W5'-[;FFZ91*'5%K4$K=CR$)2I11?UFG1>W@FX-1
M.C5NKG7PE/OMFJV-G&)==]X'O)*[;[,QL_:Q:D9;<2BG&35 .LML);#BGTCD
MLV6C0#PXW-[6/'VO;QLO,6Y0Z>XW>[KF.;DB]L^]@G:_Y_HWBEUKV4908MN5
MJD%DHZO!GV?V<G2;Z OCR OPKLZ^VZNGI<_3W&,YC[?<Z_[N?=K+]TML3?SC
M9"=P8=QMN3*;0&FI+,@*+3H2. 5ZBPH)&GA<<[#B[O1&JW#E+I[?;.RN9YJ%
M[L7<K?.]MY[FQVZ<R]DH4*+U(K+J6TA"_: BXT(2>7"NCO--*4B:QAEV^RUK
M6B9Y)[WK=^;NV)A=N2=I95W%OS)4AN2ME*%%:$-I*0=:5<B:S['56\SU1E;N
MMEJ5B:^5G[O;YW9M_L!M_=>&RCD3<,MK$*DST)05K,F/K=)"DE/K'CRJ.WUU
MMNFLQPXK;KS77F.?!S':T;WL=Y;5A[NP&Z4R,=/0MR*RMZ.T^H-N*:(LMD)!
MND\UUUWGMJ6Z9JYJ1OM7,6C[?<N_N\]\MW[LW-DNWG<4)<W#$2\Y'F=)N,]U
M(JPAZ.ZVTE*-2>8*4CY)O>N?N^VK2L7IR:]OOM:9K;G#G3N]N_.\N[^[-C;*
MW2J/[!DLH(D=\LMM-Q8<M3:4!716?524@7KJ]WIIJK:T>$.>-FV^R:UGEEES
M_<?WDNR.8QLC?DUO+X6:M6EEP1WF) :MU$)>;;2ZVL!0(O8>-E6-173HW1/3
MPE-MF[5,3;C#H/O)=TMRX/9FR]R[$RKV+9W!>25MI;4I;#L=MYL*U)6. 7X5
MS=GIK:]JVC.'1W.V:TB:SS5G%[;][O,8:'G(&[&'(D^,U-C(+["7%-OMAQ (
M,< *((YFM9OVT3B:LXIW$Q[4?;[EB[!=[=\Y_>V2[:=R@E[.Q1(Z,M+33#J)
M$-02ZPXEA*6R+!12I(\/&XMGW7;4K2+TY+]ONM:TTMSA2]Z[Z[TYGOQE^V^Q
MMRKA=20M&.C.=)#"$LP_:5@K+2SR2KXZWUZM4:8O:/MECLV;)VS2L_;"P?F-
M[X?Z7Q?OAK\6K+WG:_Q^WK:='<?RC[?<OG<GN/NSL]V<Q$W+J:R'<"4&<:N2
MOZXR):FUK<?(2E 4$A!L+#UB/"XKGTZ:[MLQ'"K;;MG7KS/&?S<LQNV?>QW+
MMIC?L+>*"B?&3DH>+1*Z<AUIQ =;"&6H_LX*DD605CR-CPKKF_;5MTS5S1'<
M6CJB8^WW.F>[9WDSW<S&9+%;M;2K/XC0XG((;#*94=TJ3<H2 D+;4FRM  L1
MPO>_+WG;UUS$UY2Z.VW3>./.'-LGW*[R=Y^Y&8V9VMRK6W\-AU/%+BEA@K9C
M.ADONNAMQWUU*%D-IL >(/.NJNG5IUQ:\9F6$[=FR\UIPPTI7<+OQV&WEB\9
MW"R0W/@,B ZM*"9276$D)=+#JVVWDN-@_)4-/+@0;U:-6G?29I'3,(]YMU6B
M+<8E?O>L[A[NV/ VI(V;F',;\XN3/:'& VL.H;2P4<5I4+#6;6\ZYNQU5O,]
M49;=WLM2(Z95/O1W'[H=O\GL7<^.S<A6W,SC84J7!*6BT[+C!M4E!.BX#J5H
M//Q5:MNVTZ]D6B8XQ*G<;;ZYB8G@]5-9O&.X1&XTR$C#+B#("4?DB*IOJZS:
M_#1QKR>F<X\7?EYL]W?N!W%[H]P]Q9C*Y=_\S<<EUYK%!+890Y-=4(S-PG59
M#:5GY5[I%Z]/N]5-5(B(XN'M]MMEIG/!S?8N\?>,[G9S*XC:F[E)>QP4^ZF4
M664AHN=,:2&%7-ZZMFO1KK$VKS84ONO:8K/+[>1T2/L?WOTOM*>W=%+(6DN#
MVAKBD'C_ /HWE7-.SMOX_;UMXIOSQM'V^YZGKR7>YMWS[E2>UFPGMPX]A$C+
M29#>/QR7;EI+[R5KUK ()"4-J-O$V%=7;:?>WQ/)AOV>[KEP3![>]ZW>NW&=
M^8[>3:&9[1F0\=[5T'G46ND(::C]!.JU@E2T^FU>A:W;4MTS5QUC?:.J)C[?
M<Z-[M?>7<?<1C)[=WDWU,_B4AYK(I:2R)#&KIK#B$A*0XVNP)2 "#R!%SR]Y
MV]=>)KREOVVVUXF+<X5#N?WR[@;JW\OM9V72428[RXDO)-);6\Z^U</:%N H
M::;((+G,D<"!:^^GMJ5IU[&6W?>U^BB(W#B_>P[88X[PD[E3F\=$0'L@PT][
M>EEKAJZK4AE%TCZI35]/.X'&KTGMMD].,*V]_2,YB7?.RO=>)W;VG\\=%$/-
M0G/9LM!0HJ2AW3J2M%^/3<'%-^1!%S:]>=W&B=5L>#LT[8V5RYA[K?=;?W<;
M*[CC;SR_SDS CQG(B?9HL?0IQ:PHWCM-DW '.]=?>Z*:XCIC#F[3;:^>J7I>
MO+>@\N[5[E;YG>]!D-D2\R\[M5J5D&V\84M],(8C.+0+A&K@H _*KU;Z:1V\
M6QQX.&NRT[IKG@KW='?O>"3W]R7;C8NXW(#3RXC6.BKZ26$*7CF9"[J4VLBZ
MBH_":UTZM4:8O:/MECLV;)V]%9^V'QN/->]CVFB?G-G\BUE]OLN-B:=,:6PD
M*-DAP);;>0DDZ2I%A>USRI2O;;9Z8C$IM;?KXS,3#TIVM[AX_N?LV%NJ W[.
MXZ5,3X=]1CRFK:V]5A<6(4D_Q5"O,W:IUVZ9=VO9%ZYAM]PX6[,CLW*0]C2T
MP=UNH;&.E+4$)0H.H*[E25@70%#Y-5U36+1U<EKQ,UG'-Y [D[B]Y?M4UCGM
MT[O]3**=1%]D4R\;L!!5JNPFWRQ:O9TT[?;GIKR>7MMNUQF;?;U.E[ V[[S\
MC,;<SN>W0Q*VF\[%F3H_6;ZCD)PI<4G2(X-R@\M5<NV_;XF(CBZM==V8FTQC
M[>9@VKW*WS.]Z#(;(EYEYW:K4K(-MXPI;Z80Q&<6@7"-7!0!^54WTTCMXMCC
MP179:=TUSP=,]XO<^>VAVMR&<VW.7C\JU(B(;E-A)4$N/)2H66%#B#Y5R]I2
MM]D1/)MW%YK29CFJ.(WYNZ1[JCF^GLJZO=HBS'!E"E'5UM9-UE)MIT\$)"?D
MUM;56.XZ<</T9TV6G3U>.)<O]W_OCW!S'<[$X+>><>R&'S3,AAEN0AM*0\$J
M6VM)0A)N5M%L?RJZ^Z[:D:YFL<8<W;[[VO$6GFNGO3=V=X;/SN!VULG).XV8
M8C^2R2V VM2VE*TM@A:56" RZH^=_16'9:*WB9M&6O=;;5F(JM?N]]QLKE^T
MF6WGO[*KF?-<V8J1.>" I$6-'9<L A*0;75;A<WK'NM41MBM8YMNWV3;7U6E
MRF'W&[^]_-QSFNVTC\W-L05@!S4EAMI*C9'7D!"W%N* N4-BP_B^)[)TZ=%?
MW\9<L;=NV?V<(,MO?WBNP65A2M]RT;FVO+=Z:EJ<$AAU0%U(0^6T/-.:>*=:
M=)_BJL:5UZ-\?MX2FVS;JG-N,.P=Y>Y,Q'8Y/<#8>27#7.,%V'+;""XA#[J4
MK0H*"@%#BA0\"#7%V^F/?=%H=.[9,:^JKD&RHWO6;]VS!W9@=WM?-60ZOL_M
M#K+;OUAY;"M21'5;UFS;CRKMV3VVNW3->+EU^_O7JBT?;[DMV\[S=V=J]UH?
M:[NRM,\S76H27>FP'F79"08[B'(Z4AQ"R4A6KB+^8M5-O;Z[:^O6OKW;*WZ+
MO6E>.]$H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H%!X[][3]J.Q/L+7X;7L]C_7;[>#S.[_LIZ?]/8E>,],H% H(7=VZ
M,9LO;63W3F%E./Q;"GW0/E+5P2AM/^<M92A/I-7UTF]HK'BK:T5C,O*."W+[
MR/?R7,S.S\FUM?:\9U3+)#IBQPL 'I]1MIUYU821J.G2#_%Y5Z]J:-'"T=4O
M.K?=MXU_;#>V;W>[M]LNXL'MUW@*LC!R+C3;<Q82X\VB2=#;[3S8'5:U<%A5
MR+'D1:J[-&K9KF^OAA:FW92_3?CEZLS.6@X'$3\WDG.EC\='=ERG.'!IE!6J
MUR.-APKR:UFTXAZ$SB,R\-;-]Y3N(CN!C,SN;+.KV5.R3C4N"MM C-1WC900
MI*0K_JZ74+ U7X"][U[VSLZ=$Q$?NP\BG=7ZXF?9F7N?+O.1\3/D,JT/-1WE
MMK',*2@D'XC7@UYO7>(NVFYO>5[K?.GYJ[N_LCV?VOVM3+/_ &KJ:--F%7_V
M2KU[NZFC5CJKS>1JONV9Q/+[>1+[C[B>\EV0RF,D;ZR#&8PTY:BEI0CO,O=+
M3U&PZAM#K:@%"WAXV/&LZ:M&Z)Z8Q+2VS=JF)MQA[%P^4CYO$8_-1 H1,C&9
MF,!8LKIR&PXFX\[*KQK1B9AZ<3E2>^>>R^V.U.X\[@92H66AM,*C2FPDJ05R
M6D&P4".*5$<JW[:L6V1$\F6ZTUI,P\[^[IWLW]GNY4+;V\\T[DL9F8DE$-$A
M+:$I?:!=2M)0E/$AE:/C\Z]+N^VI77FL8PX>VWWM?%IYPL7O1=WMY[3W7A]K
M[(RCF.=9@.9#)JCI;6I?54="5ZTJMTT,J7P\%<?"LNRT4M6;6CQ7[K=:LQ%9
M=)]VK=FXMY]M$9G<\]>2RAGR63)="4JZ;>C2GU D<+^5<O>4K39BL8AT=O>;
M4B9YNP5QNEY\]Z/NKG=C8[![?V=.7#W/EGR^MUA*5NIB-#0$A*@H?77% #A]
M0:]'LM$7F9MRAQ=UMFD1%><LGNN=U<QO_!9C#[KFJF[FQ$@.]=T)0XY#D"R;
MI2$@E"T*!-O%-.]T1KF)KRE/:[9O6<\X6?OSWC;[1[<8>A,MR]S95:VL7&>)
MZ:4M@%QYP)()2C4D6!%R1Z:R[7M_>V\T+[]WNZY\7%H.V_>ZW5AAO-G<AAF4
M@2HF(5(3%?<:6-2-#*&NBD$<DN+2?.NV;]M6>G#FBO<3&<Q'V]"[=@^]>[-_
M*SFQ=W-=+>F*CNKCSND&"M3:NDM#Z  E#J%E/)(N+\.''#NNWKKQ:O*6O;[I
MOF+<X<[WT/>H[>;=?W1N'=[?S9'6VTY[,XRZYJ>6$)LDQT^)\ZZ=7P^RW3%>
M+#9[^E<S:/M]S+LJ-[UF_=LP=V8'=[7S5D.K[/[0ZRV[]8>6PK4D1U6]9LVX
M\J;)[;7;IFO$U^_O7JBT?;[EC[C=QNX&W^_NR]FQ<VZQAIKF":R<)M+9;=5)
ME!M^Y*-7KCAP(K+3II;3:V./%INVVKMK6)X3C\6&;W-W[L3WDF]I;ES;LK9.
M2FI3$BNAM+2(V321'(64!5F7%!))/U!X^-3&FE]'5$?NC\B=MJ[NF9X2[[W4
MW<-B]O=P;H2L(E0HBQ")M_VM^S3' \_KBTD^BO.T:^N\5=FR_169<V]UO/;]
MW?M?*[JWKF7LFQ(E)B8IIY*$Z$QDW=<&A";ZU+">?U!KJ[VM*6BM8PY^UM>U
M<VE2/>:[T;OVYO&#L_863=@OX^&J7F%1D(6M2WD]5*%:TJL&V4=3@.2^/HW[
M/MZVK-K0R[K?:MHK5U_W?^X3_<;MO!RF2?Z^>@+7C\LX0 I3S-BEP@6^6VI"
MCP^5>N/NM7N]DQ')TZ-G72)\50[D[4]Y/);UR<W8&XV(&TG>A\WQ''FT*1IC
MMI=N%,+(NZ%GY7C6VF^B*1%HXL]E=TV_;,8^WF<1[;;N]Y'NI)R$7:V[SU<:
MAMV3[6IED:72I*=)#"K\4FN[=KT:L=5>;CU7W;,XGE]O([;N>?W9[?\ N\[@
MRFZ<V%[]AR&%L92,IMTH8?G1F@D'II3\E2Q\GQKAI&O9OB*Q^W]'9LM>FJ9F
M?W?JYCL4>]1W#VZQNC;V[V_FR0MQIOVEQEIS4RLH5=(CJ\1YUU;?A]=NF:\7
M/K]_>N8M'V^YU?M;M?WB<5NYB9W&W"QD=KI9>2]%;=;6HNJ19LV2P@\#_G5R
M;[Z)K^R,2Z=5=L3^^<P[Q7GNMYI[C;>]YIG.;ASNV]SL1-HL*?EPHW5;#C<1
MI)7ITEA1N #PU5Z>J_;XB+1Q<6RN[JF:S&/MYG+^VVXO>7[JM9%[:V[_ %,6
MII$KVM3+)N^%E.FS"K_(-ZZ]U.WU8ZJ\W+JMNV1F+?;U.@=X-U=W.V?:#:!R
M6?4UOAW(26,QD(W3=#K94^XTFZFP.#?3'!(Y5S]O35LVVQ'[<-]U]FO7&9XY
M>@>W>1FY?M_M3+9)XR,C/PV.E2Y"K!3CS\5M:UFP NI1)X5YVV(B]HCRR[-<
MS-8F?(X%L'N5OG*^\KG=F9#,O/[8BRLJVQC5);#:$1BKI@$("O5MYUZ&W32-
M$6B./!RTV6G=-9G@KW='?O>"3W]R7;C8NXW(#3RXC6.BKZ26$*7CF9"[J4VL
MBZBH_":UTZM4:8O:/MECLV;)V]%9^V$Q^8WOA_I?%^^&OQ:L_>=K_'[>MIT=
MQ_*/M]ST3L2)N>!M'$P]YR4S-T-,Z<G*00I*W=:C<$)0#PM]2*\W;-9M/3R=
MM,XC/-6N\6'[I9C#8]GM7E&\7E6Y)7.==6EL+C]-0"05-N?56/*M>WMKB9ZX
MS"FV+S'[)Q+RQN/=WO([7WSC.WF3W>?S@RJXC47I*96QJG.]%K4LL"WK<^'"
MO6IKT6I-XKPAYM[[JVBLSQG[>1WSM/MGW@L3NKVON7GV,EMOV9U'LS;J'%>T
M$IT*LEEL\ %>->?OOIFO[(Q+NU5VQ/[YS"H^ZEW)WQOO+;EC[MS+V49A1XRX
MJ'DMI"%.+<"B-"4\P!6W?::4B.F,,>TVVOGJE*>]?W WCL.'M9S:.6=Q2YSL
MU,LLI;5U TE@HOK2KEJ/*J=CJK>9ZHROW>RU(CIEL=_-^;NVKV8VGN/;^5=@
M9N?*QS<R8VE!6XA_'ONK!"DD>LM*5<!X5':ZJWVS$QPX_BGNMEJ4B8\J&]U?
MNON[>>6W#MW>F2=R4UJ-'R..6\E"5(9"M#H]1*;A75:(K3O=%:1$UC"G:[;6
MS%E$[]=\^X>,[FYO"[,SCT#"81#,=QMA#13U0E/56HK0HW#CG3^*M^U[:DZX
MFT<98]QOO%YBL\(=_P 5W/1M?L3A^XN[GESYAQL=UP72AV7,? 2A L  5*/$
M@<!<VX5Y]M/5NFE?*[8V8UQ:WD<,VUEO>=[Y+?W%M[--[<VZEU;<9068,.Z3
M<H;+33KSNGD5*U"_"_A7?>O;Z>$QF7'6V[;QB<0V<9WB[P]E-XP]L]Y"<KM^
M801-.AQQ+*E:2^P^VD%P(/%3;@U?R;BHMV^K=7JU\)3&[9JMC9QB?%?/>G[A
M;JV7@-L3]EYA>/\ G&0^'7XW3<2ZT&D*18J2H$<;@BN?LM5;VF+0W[K9:E8F
ML^*FXO;?O=YC#0\Y W8PY$GQFIL9!?82XIM]L.(!!C@!1!',UM-^VB<35E%.
MXF/:C[?<L78+O;OG/[VR7;3N4$O9V*)'1EI::8=1(AJ"76'$L)2V18**5)'A
MXW%L^Z[:E:1>G)?M]UK6FEN</2]>6[GACO1WF[J[>[H[GPF W')B8G'OH#$9
MM#)2VV6FR?E-DVNKSKWNW[?7;7$S'&7D;]^RMYB)X0])O]S5([!'N6EW_KYP
M:7PY86&26@,6L;BPD&U>9&G_ ,W1Y_\ #T/>?^/J\SSSV$[O]T=S=VMMX'<N
MX9,W#STS%O1'4,I2XEN%(<03I0#P6@$<?"O2[KM]==<S6./ZN#1NV6O$6GA*
M\;J[E;Y@^]!C]D1,R\UM5V5CVW,8$M],H?C-K6+E&KBHD_*KGIII/;S;''BZ
M+;+1NBN>"?[_ '?;-[+RT+M_V_81)WKD0V7'R@/F/[0K2RVVT;I4\L\?7! 3
M;@=7#/M>VB\==_9A;?OFLQ6OM2Y]F=N^]OL_"JWK)W,9@B)5*FXMF0F6\RVC
MUEE;"V>BI('$AI2N%=-;]M>>G#&:]Q6,YS]O0[%V;[ORNZ';S)Y:8PF'N3#H
M<9G%D$,K7TE+;>;"KVU6-TW-B#X6KB[C1&J\1X2ZM&WWE<O/';3<WO*]UOG3
M\U=W?V1[/[7[6IEG_M74T:;,*O\ [)5Z]+=31JQU5YO/U7W;,XGE]O(E]Q]Q
M/>2[(93&2-]9!C,8:<M12TH1WF7NEIZC8=0VAUM0"A;P\;'C6=-6C=$],8EI
M;9NU3$VXP]$]Q>\&'V+VXC[]#)DKRK+"L) 6="GGI;75;"_)*4W4OX+<R*\W
M3HF]^GR<W=MVQ2O4X!MAGWJN[T)6[L=N-&"P\@J5 2XZ8#+J4JM9EMAEQ93?
M@%N<_P",:]&_PVJ>F8S+BK[_ &1U1.(2>Q^]_<OMUOR/VY[V /QY2VF6<HZ&
MPZP'SI:>ZK0"765'@I2O63QN?5*:KL[;7LIUZUJ;[TOT;/6E?>M[D[XV)EMM
M1]I9E[%LS8\E<I#*6U!:FUMA).M*N0)JG8Z:7B>J,I[O;:F.F6I^8WOA_I?%
M^^&OQ:I]YVO\?MZSH[C^4?;[G1MJ1>[FU.V6\YG<;,(G;CCQ9LO$2V%H<Z*&
M8:E)Y-H%PXG5Q!KFV3JMLKT1P=&N+Q6>J<RY)[N7O";CRV[CM#N#E59!O,Z4
M8B8^EM!:F)O9HE"4\'1P%_J@ /E5V=WVE8KU4CDY.V[F;6Z;2NGO2]P-X['F
M;(;VIEG<8C)NSTS@TEM75#*H@1?6E7+J*Y>=8=EJK>+=49Q^K;N=EJS7$\_T
M1'O(;][D=L=];?S.$S#Z-HY%"'',9I;+*GX3J>NT24%02XVI'U7BJU7[35KV
M4F)CBIW.R^NT3$\'I-K-XQW"(W&F0D89<09 2C\D15-]76;7X:.->9TSG'B[
M\O,'8[N-W*[D[MWAN"?F7T;2Q,65)C8T(;#3;\LK]E:!T:B&T)6?E7ND7KU>
MYTZ]=:Q$<9<';[;[+3.>"<]TWN'O/?OYW_G?EW<K\W_-OL?62VGI]?VOJ6T)
M3\KIIY^54[[537T],8Y_D=IMM?/5+D^Q=X^\9W.SF5Q&U-W*2]C@I]U,HLLI
M#1<Z8TD,*N;UU[->C76)M7FQI?=>TQ6>7V\B;W7O/WG^RKF/S&[LJQE,++?#
M6E:8\F.XXD%?26I+;;J"I(41I(O;T5G37V^[,5C$K7ONU8FTQ,/1.?[PX+ =
MJ8O=*0RI4:?$COP<=JLXY*EH!0QJ('R3?4JWR4D@&O-KV\VV=#NMMB*=?@\^
M;9F>]%WM2[NC"9UO;NWU.+1#)68$0Z5>LEH,M.NN!)]76O5QN-7 V]&\=OI_
M;,9EQ5MOV?NB<0VL!WH[L]G]Z1-G=ZC[?A991;(.=-;C3+BM(D-/M =5"3\M
M*_6'HY&+=OKVTZM?--=U]=NG9RGQ7/WK>X6[]C0=J/[.R[F,.0<FB2M@-K#J
M6TL%'RTJY:CR\ZP['56\SU1EKW>RU(CIE>^PO=)ONCLAF;+6G\Y<7IAYML )
MU.A/J/ #@$N@:N'#5J Y5AW6GW5\>$\FNC;[RN?%1>SG<#>.XN^G</:^:RSL
MS XAW)IQT%:6PAD,9)++>DI2#ZJ#IXFM^XU5KIK:(XSC\&6G9:VRT3/"'%.Y
M?>_NWANXNZ\7B-RR6,7C,G*:8CI0R4-,-OEM">+9-A<)XFN[3VVJVNLS'&8<
MF[?LK>8B>$/4?<'N8K%=C9/</%.I8G9'%QG<:M)"BW)R24(04@W!4T7"JQ_B
M\:\K5ISNZ)\OX/1V;,:YM'D<(]W;NSW,W5W2A8'=6>D3L8[#D/KB/(:2DD,]
M1M7J(2>1!'&O0[O1KKKS6''VVZ]KXM/@;UWUWIS/?C+]M]C;E7"ZDA:,=&<Z
M2&$)9A^TK!66EGDE7QTUZM4:8O:/ME&S9LG;-*S]L+!^8WOA_I?%^^&OQ:LO
M>=K_ !^WK:='<?RC[?<M_>+<7<+M_P!BL5/=RZF-\,NPHV3R3&AS6XL+ZEBI
M&D@D?Q16/;TILW3&/VM=UK4U9SQX,?NQ]YYG</$2]M[IE^T;OQ5WTR%A*5RH
M2U6UD( &II1"%<.13S-ZGO.WC7.:\I5[7?[R,3SAIO\ <#>*?>PB[#3EG1M%
M;14O%:6^D3\SKD<].K_: *^54QJK\-U8X_J3LM[Z*YX(;N)A?>?Q$K=>Z,;N
MEF/M" YD<G$CI=:+K>-84X\A 28Y]9+0 L5<_&M-5NWGIK,<>'K4V1OC,Q,8
M^WF47MQE_>=[I8V9E=K[O'LL)\17_:ELLJZA0%\ &%7%C6^ZO;ZIQ:K'5;?L
MC,6^WJ>O=B1-SP-HXF'O.2F9NAIG3DY2"%)6[K4;@A* >%OJ17C;9K-IZ>3T
MZ9Q&>:Q5FN4"@4"@4"@4"@4"@4"@4"@K7<7]GV[/R-D?P5RM=7MQZ85MRE_+
M"OK'RKV'[D/]G[T^S8[^;(KQ?F/.OWO9[#V9]+UC7D/3*!0*#QEO7_?*Q?\
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MM-]LQ,_N4U[-M->8C]JT]A=G9#NYOH]Y]X[ABY*?C'VW%8J,"B2W):1HC]9
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ME6M\E/II;7;9V^+1^Z/R*WBF_A/"WV_%.^]Z4+[H[0:F$_-WL#)<"KZ %37
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M=Q;%IQCP7OWS(2,1@^WN'QZ"WB(:9T=INY(2([<1MD&_.R=5<_R^<S:9Y_\
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M;S/:3']N.]VTDGV.;$BG)-<>FF7TM+B%VM];DMA7C\K5R]6O0B\;9OKM]O\
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MVFR(V]5IQS=G<4FVN8A:^PF(RF"[1[9Q.:AO0,G&:D"1$DH4TZV52GE *2H
MBX(-8]S:+;)F.333$Q2(ETBN9L\I]IMD[OQ7O*;OW'DL'.B8"7)S:XN2>8<1
M&<3(FZVRAP@).M/%-CQ%>OOVUG16(GCP_!YVG7:-MIF.''\7JRO(>B\X^]SM
M+<^[,'MEG;.(EY=Z-+DKD(A,K?4VE3: "H(!L"17I]ALK2T]4X<7=TM>L1$>
M+JV.V=!W)VFQ.S-TQ%"/(PD*'.C.)TNM.MQFQ>Q%TN-K3<>2A7'.R:[)M7RN
MGIB:XEY\[(X#N=V9[FY#:>0P>1R&QLD_[*]E(T9UV(%C_L\Q*@" ""$N\?5!
MX\45Z/<WU[M<6B8ZH^V'%HI?7>:X_:A-YX7NMM;WA<OW%VELZ=F$1Y*UP7##
MD.Q'DOPO9E'4UI)L%JM97,5IKMKMHBEK8_\ 52]+QNZXC/\ Z+=^N_WF?_Q6
M_P#X.R/VVL?AM'\_P;>^V_P6'NIV[W=WO[3;?S$K'IQ?</'!R6<.X%1T$/>H
MZQ9XDH4H(;4DK5;A8\[C/1NKIV3&<U6W:IVTCPE1L+W=]Y7;&!C;5=[=R\A.
MQ[(B1LH[C9[JRAH!"%++/UMPI%AJ!%^9N;D[VT:+3U=7^88QNW5C$US*T^[/
MVBW?MW,9SN%OQ@P\IFV'(K6/>">LM$EY,A]UY">"+J;2$HY\[@<+Y=YOK:(I
M7E"_;:;5F;6YRHC.R>\GN[[[R>2V#@WMS;5R-T(;88=F)<C:]3:7FX_UQ#K5
M[!=K<_ D5T3LU=Q2(M.)AET;--IFL9B6MNV#WZ]XG+XC%Y;:3FVL+!65)>DQ
M7X<=OK:0MY:Y5EN$ >JAL?%XU.N=/;Q,Q;,HO&W?,1,=,+M[T7;O<>0VSL+
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ML\S:_4%K7JNCM[;<XQP6V[HUQF7-OWS^UW_A&?\ O:%^.5U?3MGEC_/^G/\
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M1)"5EQM*2VTA:] 4X5*20+^0-$Q&5DHA3YG<7&1,G+Q2,;DIDF$O0^8C"'4
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M:/B44H!^.H7SA<=@YSY]VS$?=5>9&'LLL'Y74: %SZ5)LKXZE68XJEAMPX;
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M^R8Z)B(;%_\ FXX<;3])-<.N<]O:?2[;QC?7T?[8>]/^];LC^M[?_#ZGM_\
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M.MN ) "C87TI38?#Y46GCQ6[<^YL?MO%OS'WD>TZ#[)'N"MQPCU0$WN1?F?
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MLA01_P!H=<M;6KY-JUV;K[/:G+.FNM/9A;*Q:E H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M8USH&OV1W4L:.H+*]4$ W'F#0RCLQLK;F<EB=/B?]=MI+[2ULK4 +>MH(O\
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M=$XE+M9&%E,6Y.QTA$B*XVO0ZV;BX!N/01Y&B'.L0ZX>SLMPK47-$CU[F_\
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M$H%0>;.H>KSOX@CQ'.B$#)[B[/C1H\I>1"FY04IE*&W2LI2HH)*=-TBZ2/6
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M!ZV/VVS[2]_%]K>L4#AXCU2/@-#E"#8G9%?<'/9%G#+S4B"41HP#K;?LR+$
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M?:S\[9HVUB-"5M)8;:+AT)TLJ2220#Q-J(B>*QP&5QH,:.Y;J---MKMQ%TI
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M6R5)NI:E"Q('@:$HG$[2EM-;KBY!:4,9Z3(<86THJ4EI_6 2"!Q&KE0RTL+
M[A8+'M8&*QC78\?4B/D'%N"R%**KJ;2 21>B9PS[7VMD-O3\_(S$AN;C\FA#
MKTE7JK6M(672I%K $N*Y'E0F<M#"8O=>*B%C9F2QV1VV\M:H;DOJ*6P%*.H
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M] ^*B>"UX+#QL!B8N)B$EF,G3K5\I2E$J4H_"231692- H% H% H% H% H%
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M0?BDI4DI4 4D6(/$$&@QQXS$1AN+%;2S':2$-M( 2E*1R  H,M H% H% H%
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M1*6H@H%!@F/F+#D24C4IEM;@2>1*$DV^E05+\]97ZO\ \\?96_:ON;4KI_\
M:O9^?/EQHMCCA;8;YE0X\E0TJ>;0X4CD"M(-OIT59Z!0*!0*!05Y_<3S6\HV
MV RDL/PC,+]SK"@M:=-N5O5HG'!8:(5N5N5^/O2#M=+"%1Y<14I4@DZTJ!=X
M <K?6Z)QP62B"@4"@4"@4"@4"@4"@\=^]I^U'8GV%K\-KV>Q_KM]O!YG=_V4
M]/\ I[$KQGIE H%!'9Z9D8&*D2\3$]NR#>CHQ>(UZEI2KEY))-"&['6XY':<
M>1TWEH2IQO\ BJ(N1\1H,E! [OW&-KX5S)AGVAXK2RPT38%Q=[7(\  31,1E
M!3=U;MPF.CS,[C8C3LJ;'B,M,K4;(>2XI95ZRN(TBU$XA>Z*E H% H% H% H
M%!#[GW#'VQB'<K):6^E"DH0TW8%2U\!<GD/,T3$93%$% H% H%!AER6X<5^6
M[?I1VUNKMSTH25'Z0H*GM3<>Z=QN,Y%W'1HVW'RYTW>H52+(U)'"]OE"WR:)
MF(A<J(*!01^;R[&"Q4G+2D+<8BI"E(;L5&Y"0!<@<S0AL8^4)\"+."- DLMO
M!%[Z>HD*M?A>UZ#8H% H% H%!"8#<C&XL0[F(C*FF$K=0VETC4H->) Y7\KT
M3,8?.S\\]N7!,9=]E+#CJG$EM!)2.FLIYGX*$QA.T04"@A\%N&/GUY$1FEMH
MQ\E4-2G"+K6V!J( O87/#C1,PF*(*!0*!0*!0*!0*!0*"'W/N&/MC$.Y62TM
M]*%)0AINP*EKX"Y/(>9HF(RF*(*!0*!0*!0*!0*!0*!0*#!,<?9B2'HS?6DM
MMK6RS_'6E)*4_&>%!KX65/FXN/*RD7V*>X"7HW/00H@#CY@ T);] H% H% H
M% H% H% H(>+N&/+W%/V\TTL/8YIMU]Y5@DET!02D"Y/!0XFB<)BB$/*W#'C
M;B@[<Z2U2IK3C_5X!"$-A1^$DE-$X:S^XGFMY1ML!E)8?A&87[G6%!:TZ;<K
M>K0QP6&B"@4$/E]PQ\3DL3BW&EN2,NZMIE2;!" V$E2E$\?JA86HF(3%$(G.
M3\M!]A^:H/MO7D(:E<_K3*OE.</*A"6H% H% H% H% H% H% H% H% H% H*
MUW%_9]NS\C9'\%<K75[<>F%;<I?RPKZQ\J]A^Y#_ &?O3[-COYLBO%^8\Z_>
M]GL/9GTO6->0],H% H.<3E[CRV_<EM^!DWH.+2PP[(<;/KMMA";AJ_!*EJ5S
M%%O!ED*R^Q\]BFUY23E-OY9X1'$SU]9YEY1 2H+L.''Z1]%#F_<WEY^<W4]M
MB)E?F7%X]I+D^6A:6WW7%@$(;4;$6"O#T^BA')KNY&5L[,8T-9US-X+(O>S2
M&I;R9#["UV"5A8-[>?"W#TT.;8W+*W"_OV'@<1D%PF)F."GE\5I; ==*G$HO
M;60@)!/G0CDULDQG=DY;#26LW+R>.R$I$.7&G+ZI'4/-)/+A?E;EXWJ#FW]U
M9O(2]QQ=HXV>G%-%GVG(Y E*7 V38(;*B+'_ (_0:DB$9E)<O9"HN6@[B>S6
M,+R&LA F/HDNZ%\UMJYBUN0^GQHGF_-\8EV1O#;;C>3E(3DG70STU@"-TT,C
M4SPX%7-501R;>[G]P0LSMC"8;(NH>DM.QG7W25:R$)07G$BP4I()6/\ .HB&
M^K"[NP."F,8C)O9K+RG4!AZ8H#H-V]90ZJU GX_+APJ3,(K-X.7AL8_/.]9B
M<Q';4Z&GY*4L..(3?0EDD?*(( X_!4$3YG[FWYFY.V3>:D2G8\A$=3DAM@A+
M;ZDJZ9"Q;D2-5A4D<)?$AO(8'M8O(1<G*7)>BP'F%+7QCAQ3(*&B+$)LJUJ@
M\6YO7+9B!A=MR,6^I,Z1)C)4"HA+I4W?2Y;B4J/,5)#6W%@MS8'$O;B8W/-?
MR40!Y]EPCV18U *"6OD@"_D:$2D-P[IR?S'M]K$Z6,UN4,AEQ7%+(<0A2U"]
M^16!RH1#2SNW]R[=PDO+8W<DV7):969;,M>MM2"DA2FKF[:DWU)L?"A$Q*W;
M3D/R]M8J3)<4[(=BM+==6=2E**1<DFB)YL6\83D[;L]#<IZ(6F77BIA025A#
M:B6U7!]57C0A2,'CG8_:Z?.5-??;E0']$1Q0++.A3@^MBW"_C4+3S;&V]L9_
M,;:@2GMPR\?]80F!&A'I-(:2+(+EB"LJMJ/&B)GBWMM;OG(V3D<OF3[1-P[K
MT5:N ZJVPC1<@>)6$DV]-23'%I8N!D,[CVLSE]X/PLC+2'V8L.0AJ.RA8U(2
MINXU&W,</*@G=B;AFY=C(8W*.(?R>(?]G=DM6T/()4$.<.''2KE1$PL\V,J7
M$>BH?<C+>04"0R;.()'RDGP(HASGMGB7DS<O,.1DJ1$R$AA<8K'2>-K=1P6X
MKXWO4+63G;K(3LCCLHY/D.27&LG(9;4ZHJ*6TH;(2+^ N:DLQ8G)3W>Y6?QK
MLEQ>/8BLK9C*42VA2D,$E*>0)U&AX(7;S&Y-U2<U&?SDJ%BX4]]"%QU$2%*)
ML$!P_)0@)X)'\:H3/!^89O=>0R^4V<[G'DP,8L..9)/&:I#@'3;#A)M?Y15S
MX>5"<<TGMQW+X7><K:LS)/93'N1/;(SLI16\@Z@FQ4;D^/TN5$3R8("\SO[(
MY&2UEI.*V[ ?,6*B KINO+1Q4I3@X\B#;CS^C)R9\;-S6U]U1=LY6>YD\5DV
MU+Q\N1Q?;<0"2A2N:KVM\8Y<:'.$:VUN?<NZ-PX:-FG\=C(3Z%EUHJ+B200A
MM!"DZ4FRB;'PJ$\(AT;&17H./C1)$E<N0RVE#LISY;B@.*C<GF?34J.?=Q\6
MZ]G-NO#(26TS)[,=#2% (85J2.HV+<%\;WJ%JI'<3V1PN1V=C6,A(<0[++,I
MUQ?KOI!1_M+6OSJ2&CN++NR]Y+V_DLV[M_#L1T.LNL+$=<AQ=B;O'@D#B/+A
M0CDF]O8[<&,RJDIRIS.UGVM34B2Z'9#;H/(*'R@?'_DXD2K2<BK<.Y,O!S6Y
M)."3"D*CP(,9X0]:$DI"RL\%$V!MZ>'"BW*%OVM#W'CUS(F8F#(XY*DJQDY2
M@7U(4+D+MS\+&_GX6HK+1[;9"=DL%(?R$AR2\F:\VEQU14H(2$6%SX"]"S#@
M<I.=WYN6%)E.+@1&VE,L+42VW=*22D>%$SR0^*ES-[KE9:?N)W"XL.J:Q\"$
M^F,[I3]6XKF;W\?I"U0GDE=JYJ=$W'*VED<@,LTED2L=D+I+BD< I"RDFY%_
MI>D5*)A>J*E!0MHNH8W7OEYPV;;>CK6?)*4O$T6GE"-Q#\[>J'\UD]QO8:$M
MQ:,?CX,A,=:4)-M3AYGCY_2J$\DOM'.3VL]/VEDIR<I[.V),#(C25+9-KI64
MDW4-0^GZ*E$PQ#"[DRSLN?N?-R<$QU5)A0H,A#*4M >JI:TDA1X\;^7P6&8?
M&R,K.1N++;:>ROSU BM(?B3E+#B['3=)6";_ "[&YYBA+7Q(S7<"1.ROSQ*Q
M6#COJC8^/ 7TEKT '6M0YW!'_):AR:VWHF4@]SWXN6E&:\WCR&9:DA*G&;HT
ME0'U0^23Z*A,\DWM?)3Y64WBU(DN.MPY11%0M1(:3]<X)\N0J42@]H8[<N[\
M"S-R.X9D2.VIQJ.(BRAYPA9)6ZX3=7$Z0GR%0F>"6VAG<E$1N3'9^49HVXK4
M)B@ XMG2XKCYFS=^)OQYU*)AJ8+&;BWE"_..?GI>-3*4M4"% 7TVFVTJ*1K'
M#7Q'CX>/&A/!L['F[@<W)N#&YZ893L$1VT6X-\ 0%I1R25@!2K>-02OBTE2%
M)!*2H$!0YB_B*E5R_:F#D(WUG6SEIBCCUQEN+*QJD@IOI>X<0.50O,\&[ 7F
M=_9'(R6LM)Q6W8#YBQ40%=-UY:.*E*<''D0;<>?T91R9\;-S6U]U1=LY6>YD
M\5DVU+Q\N1Q?;<0"2A2N:KVM\8Y<:'.%^HJIV.R$YSN-F,<Y(<5 9A-.-1BH
MEM*U=.Y">0)N:)\$!MYC<FZI.:C/YR5"Q<*>^A"XZB)"E$V" X?DH0$\$C^-
M4+3P?F&;W7D,OE-G.YQY,#&+#CF23QFJ0X!TVPX2;7^45<^'E0G'-)[<=R^%
MWG*VK,R3V4Q[D3VR,[*45O(.H)L5&Y/C]+E1$\FAC4;DW+N'<6+&9D0<1!F*
MNMA1#_K%00VVL_(2 DDVJ3DQX]O=9W)D=CISCRH#*$2E9-SUYB62E)T(63P*
MBL GPM<>5$\.:0Q1S&V]\1]N/Y61E<9D(JWVS,47'6UHU'Y1N?J/@X\N%$<X
M2&W<A.D;UW1"?D..1(OLWL["E$H;UHN=(\+U")Y,66R4]KN5@,:U)<1CWXKR
MWHR5$-K4E#Y!4GD2-(J4^"-?7N+,[\SFWX>5>@8MIN,ZXMLDK;3T6[H9N;(*
MU+N3Z*'@R1?GO:F\L9AG<M(RN(RZ'+":KJ.MN-))N%&YYV\N?+A>H.<,^0FY
MC=.ZI>VL7D',9B<6VE4^5&L'W'5@$(2OFFU[?$?14G*&O-7FM@Y/'/NY61E=
MN9!],20F<KJO,N+XA25_ ";>@^BAS;?_ -MG_P H_P"EJ#P:D!>9W]D<C):R
MTG%;=@/F+%1 5TW7EHXJ4IP<>1!MQY_1DY,^-FYK:^ZHNV<K/<R>*R;:EX^7
M(XOMN(!)0I7-5[6^,<N-#G##%5F=]Y?)K9RTC%;?QCQB,(@KZ3SSB/E+4L>'
MC\8]-#D^("]R8G?V-V_D,H[.QBH[SL=:S93B"A=@[;@I25)YG_D X82N)R4Q
M?<#<<%^2M6/BL1ELL*42VV5--J40.0O<WH>"*PK6;W^96;?S$O%88/+9QT3'
MKZ"]*/JG% &_/Q\;\A:A/!.8)O>&+1EH&0!R;49.K"SG5MI6^2DD-N>M?@;#
M4KT\>5$3A$-[=S3\/V[=.ZI>,R;NI1CQI*(\=JY-A9)LJP'@:)R^MGYK(93;
MV?B9&6F>YC5/QVIR;'JM!M6E5QSY7!\J$P@__M'?\/\ Q*H3_P DWGLC/P"M
MJ9QN2XG#D-0\G'U'I:76QI64\K@:C?T"I1"2[@92=%@P<1B'E,9?,2FXT=Q!
M*5H0% K4".5KI!]!HB%L9;Z++;.I2^FE*-:SJ4K2+7)/,GQHA3MW9;+/YK&;
M0P4CV*7D$*D2YMKK;CHU?(])TJ^EQHM'E8GMO[JV_)AS<%E9F::+J49"!D'D
MK!9/REH4X4A-K>''X>5#,2QY";F-T[JE[:Q>0<QF)Q;:53Y4:P?<=6 0A*^:
M;7M\1]%#E#7FKS6P<GCGW<K(RNW,@^F)(3.5U7F7%\0I*_@!-O0?10YMN9^U
MG'?DA7]*]0\&I%7F=]YG*%K+2,5M_&/&(PB OI.O.)/K+4L>'C\8]-#DT(<#
M*X[NEC(N4F*R 1"<$.6X '%,:72 LCFH**A?QX5"?!U2I4*!0*!0*!0*!0*!
M0*#QW[VG[4=B?86OPVO9['^NWV\'F=W_ &4]/^GL2O&>F4"@4%8[A39>/V?D
M9D%Y<>4WT.F\THI6G4^VDV(\P2*)CFA-XY;-PX6U58F0I$Z8\TV0HG0ZMQ"0
M X!\H:CQHF(:VY,-N7;.*=W)%W--E38A0N0P^08S@6M*3I:OI3SO;C4$3$M7
MN@AZ;MK';B$IYI+PC?\ T]*O^KA;B%N=2UKZQ?3?RHFO-M[ZQCN*V_B(KTZ1
MD%G-1U]>6H+<L6W!IN . M4HA8]S1=SY&="Q^)D''8904O)9)M2.L+7LA )N
M.7,#Q]%$1A4,\[+V8_!GXS=,C)J5(;9E8R;)3)4IM5]2@+W X6^3POSJ%HXI
MG>T_/,[EV]CL'+,9R<)#:P;J:X@)UJ1R44 E2;^(HB$7N%C<NRI&-G8W.2LF
MN>_[(Y%R"RXR77!ZI";^J+^5$QB7WNG';DVGCD[F9W'+F2V'6_:HSY_ZJL.*
M (2T/52+_2\J(CBDM]Y7-1I>V48-\QY&0?4UH));)<#83U .8257J2$5NB+N
M394>)GXN?EY)Y4A#,J)+5JCKZ@)]5 -DBZ;6'GP-0F,2S;EQ&Z,'AG=S_G)+
M<RD;0[(B@VAG6L)*4-#A8:O$<:E$3"PYE[<^7P^)_-W3%<R(:<GS+IO'9<2E
M1*$J()/K>''A1$85;<\27M: K+8[>,M[)1U))A3)*7DO:E@$):)\ ;VL>50M
M'%D[FH=R.T(6<,EUI+B(ZEP4*^L*4\->I0YDIO84*\TIN*=E=K8S'8'%SG9N
M;S$DL19LTAQ;8)2%*Y6.G4 +CA>I1'%BR6UMRX?'.Y?&;FGRLG$07W&)2^I&
M="!J4E+9N$W -N?^6AF&ON7=TZ7L/%[CQ:U1I;\EI+J&E$>NCJ)6C@;Z2I/T
M*$1Q;?YI;K9@9"6[N27)RDB*I3<9M2FVFY0*7 &[*( X%'!(X&AF$KM?<S<[
M9K6=FKNN(PL3E'GKC ZB?2H#5\=$3'%\=OW,I,P9R^6?<=D9)YR0TVXHJ2TR
M39"4 \AP)'H-"6[O* Y/V]-2W,>AEAIU]2HZ@DN)0TN[:[@W0J_$4(57M_"R
ML;9J,OCI3\R8\P^W#QCSB1%0XE]24J2#:WR;GCYU"9YLOYMY4P$3-P[PF8[+
MNH#CC:)*&(S2SQTZ 0#;D;&U299-K;PF?F1D<UEG!+D8EUYA+PM]>*$H+=R.
M'$K";T)CB^,3MW<>X,6UG,EN2=$GSD"1&8AKZ<9I#@U-A38MJX6OR_RT)F&G
MN>+N27L"0]N-UR+D,>2EQ#*T=*8V5MA"W B_T.''C:H(YMQS(R=E;#8GMRWI
M\V:B.F$F4H+#3CS0(2D #U4A)(34G.6?\S-T*A"8K=,X9\IZG3ZEH0=M?1TQ
MPTWX7^EX4,PTU[MR.5[;Y+*:U1,W!4(TE;1T*#J'&[J%N5TJX^F]#'%LX#$[
MG6U%W9D<U(D+<C&3\RHU!A04T2TCY=K_ "2?5O?Q\:$S"%VZXO=L14V9O&5"
MS[JEZ,>P^([31"B$CHFQ6+6Y&H3/!T#;*,^UBD,[D4VYDFE*1UFC?J-CY*E6
M &KSJ59;F4A.9&"[#:E/0ENZ;2HRM+J-*@KU2;\[6/HHASWM9CG$[;?R9FOJ
M:6F0R(!4/9TFZ3U FWRN%K^FH6LTM@[?S6;VTRI6:DXS&-+<3$8@'I.*5K)6
MMQ?,\38)]%$S/%9=B9/,*?SN!RT@SY&%>2AF2JP6XAS7I!)\?4OQ/CSJ42U6
ML#N+(M.Y'=FX96%?<6KHPH,A##+3:3874DD*_A\^-#+XV;/R62=W#MF1F%SF
MH>E,++LK27M#NH7"QJN18>)L;U!+5[9XEY,W+S#D9*D1,A(87&*QTGC:W4<%
MN*^-[T+.FU*KG6/^>=_3\C-1EY.*V_"?5$AM0%])UQ;=B5K6/,$&WI]'&%N3
M\Q+NY,;OZ/M_*9-R= 3#<=CK5ZI<;).DN <"I)!%ZDX8?DC)SMU;DR6,3F58
M/!8A?LZS'=2S)??!(599X@ I/TO/@.3[@Y29MG<^/PKN95F\+E@I##K[B7I#
M#Z;6"E@\020./GZ.(YPQOKW%F=^9S;\/*O0,6TW&=<6V25MIZ+=T,W-D%:EW
M)]%#P9(OSWM3>6,PSN6D97$9=#EA-5U'6W&DDW"C<\[>7/EPO4'.'WF\O/SF
MZGML1,K\RXO'M)<GRT+2V^ZXL A#:C8BP5X>GT5)')KNY&5L[,8T-9US-X+(
MO>S2&I;R9#["UV"5A8-[>?"W#TT.;[W [N*?OP;>Q62<@Q)./2I]:23TDA94
MI:$@BRSI"-7IJ".21EX?>./P\/"XC).3)+\A7MV9DJ!=8CD@>JEQ9)-O(GD>
M5ZDS"!W/$E[6@*RV.WC+>R4=2284R2EY+VI8!"6B? &]K'E4)CBR=S4.Y':$
M+.&2ZTEQ$=2X*%?6%*>&O4H<R4WL*%>:7W+D9^S-OL0H<UV=EI\@1XLR<I*E
M(+G$J42 +)\+^=2B.*.F8G(8['N9.%O1^1FXZ%/*9>D-N1'5)&HH2T387M8<
MZ'W+CM;-C<6!AY?2$./I(>0.0<;44+MZ+BX]%$3&&[E')[6/DKQ;27\B&S[,
MTLA*2X> N20+#F>-$*/^;>5,!$S<.\)F.R[J XXVB2AB,TL\=.@$ VY&QM1;
M+]VYN'*Y/M_FYDJ3U,ACD36&IK9 4HLL!Q"P4^(U<#Z*$QQ8-OX3<FZ<%$RN
M0W)-A..-:8K4110 E%T!;IN"M2B-1XT)G":[>YC*9/&3(V8<Z\[&2W(:Y'"Z
MPV!8FUKD7(O1$K5)D-Q(STMXV980IUPCGI0"H_2%$.:X=<_>,=><RVY7L.P^
MM8@X^#)3'Z;:%%-W/%1N/$>GQJ%YX)G9N=GG,9+:F4F)R3T!*7X>03IN['5I
M^5I)%TZD_3J43""VC$W+N_'R'9N?EPX$62XRU[*LID.+X*)4X3?2D$ )%0F>
M"7VE*S*,OGMGY:>Y-$%"%1IQ.E\(?2#Q5<F]E)(-^!J43Y6UV^RF0DQ<CALP
M\I_+8>4MAYUPE2UMJ)*%$GB>(4!Z+41+0Q>5R>7.[]P(ENIQ<=MZ+BF@HAL*
M8;)4ZD<KW"2#Z31,M=_,95/:,9<3'1E-#9]K"SU;F8$'UN?R>%#'%N8J#G(#
M WIGLX^\RF*N9(Q"-28Z4EHJ2@ KM=(M]3Q/CYCS-?!XG<.\,>G<&3STW'"6
M5*APL>OHMMM!1"=5OE7MX^'C0G@DMGYC+(RV3VCGWA*R&-"78\T"RGHZ[6*O
M2-2?H\>5"85W9D+<N\,*F5D-P3(D5AQ;3/LJRA]U0.HK<<)N0-6D#T5"9X)_
M8^0S",GF]M9>6J>K$K;]GF+_ -HIMT$@*YD\ #Q)^&I1*"VC$W+N_'R')N>E
MPX$60ZRT8RRF0XO@HE3AXZ4A0  J$SB'UMYO=>>DY3;<O./,0L+(4TY/8]68
M^5**4)ZA)( ""H^/&U"<);:,G+X_=.7VID)[N3C166Y,63(.IX!>FZ2HW)^7
MY^%2B>2,QTZ9OB3-R,K<#F$PK+RF($2&^F.\L(M]<6H\>-Q_R6XD\DEMK,SL
M=N=W:4_)#+Q76/:L;/*DJ=L+ZFW"DFYX*X^CT\")C@CL:C<FY=P[CQ8S,B#B
M(,Q5UL$]?UBH(;;63ZB0$DFU#DWL$]FL!O16U9V2>RF.E1#,BNRCK>00HBQ4
M;D_)4/H<J$\D5M_ R$=Q,O'.7FJ5 3$><>4X.I)&AM?3>-N*?J;>50F9X.J5
M*CEF<P<A_N3 C)RTQI4R.\^A]"P'&$_7#TVC;@CARJ%XG@S;EC961W)QD/$R
MO993F+#;DU20M3;0<>*U)!X:B!8>DU)')]Y-C.;)R^&E-9N7D\=D)2(<N-.7
MU;=0CBB_+A?E:UO(U".:P[DB;HR>2B0,;)5C,"$%R?D65(#Y4+V0FYU#@!Q]
M/HJ41A4\N_+V=D<7(QNYW\JA^2B/,QLV0F2O0H\5 7ND<+7MP-N-0M'%GWUB
M'GMY;=4G)2FAD'G4MA"P!%Z:&DDL\.!5S5Z:$<G2(C"HT5B,IU;ZF6T-J?=-
MW%E"0-2CXDVN:E15-_9"= ^8?8I#D?KY-AE[IJ*=;:KW2JW,&H3",W?F'U;K
MB;>EY=S 854;VA4QE726ZZ5$!/5/R0 /^/F*)B."2P>,SV.S#+D',KS>U9#:
MNJN6\'WFW/J2A8^5QMY"U_14DKE14H% H% H% H% H% H% H% H%!6NXO[/M
MV?D;(_@KE:ZO;CTPK;E+^6%?6/E7L/W(?[/WI]FQW\V17B_,>=?O>SV'LSZ7
MK&O(>F4"@4',W=PP\!W.RJ\B2W!DQH[2Y%B4MKT(*"NP-@>(O1;'!DS^3B;S
MW!@\+@7!,CP9*9^1EM@J:;0WR3JY$D7'PD>FH(X-'+P,)B-]39.[8:7<)ET(
M7#FN)4IMMY"0%)44\KV/TJ)CDS+5LAW.X[%;6PD;*R7' N5(:*PU':21ZY6+
M@D<_I<S0XI:9^UG'?DA7]*]4H\#N3_\ 8W^5X_\ EJ"J)W= QF.WLQF]QPQ)
MVY/CB,X\I*EH9D)Y%03QY ?$3Y5*8Y,64<V 'X<#;.%BYO*2W D,,E80ANW%
M2EB]K?2%[VJ#BD]_28^+W!L^?+/1@17Y >=LI24 AJW($^%2B'UG9<>=O794
MR(X'8SZ)+C3@N I"FP0>-C4$<I;'=&7/BX.,F.XZQ >E(;R<AB_41'(-^7($
M_P"0>-255[(Q^VD'#R&L"PUE,S(86B(A!7*>ZBD$!Q05<(TWU'@.50GBWH/U
M_LTL,W64Q'[@"Y&A]6KZ%JE'BU\KF,;E.TCL>"^'GH$7',2T *!;<2XRD@W
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M$M-("&TBR4) 2D#R %!\LL,QTE##:6D$E12A(2+GF;"@)890ZM]+:4O.6"W
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M@4"@4"@4"@4"@4"@4"@4"@4"@\=^]I^U'8GV%K\-KV>Q_KM]O!YG=_V4]/\
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ME]/JQFE#K%_C8)1I NI1X#P]-$]+)&W\M.4B8W-867B4SUAN%(?L4J638!7
M:3Q \;7XT,-W/[U@[>RC.+E1WG79#!?9Z UJ6O44);2GF5*(HB(RCD]QV8<L
M1=QXF5ANJA;D9QWZX'- OI]4 ZCR X\:)Z7Z.X2H\V*SF,',Q<":X&HTU\"V
MI?+6GZGT\2:&$[D=Q,X[.8K"+84MW*=3IN@@)1TA<W',WHC#XW7N5C:N,3DY
M#"Y"%.I9Z;9"3=84;W/\FA$98MR[O@[7DX]F>TXIN?UK.-\2DL!)MIYDJ*@!
M0B,HA?<54)Y@YS!3,7C9*PAJ:]8@%7$:TV&GAQ(N31.$EN:9B(^6VZUD(1ER
MI$HI@/!12&7+H]<@$7YBB(5/.YO(L]QX#J,3)>5$COM,1DJ3J?2>H"ZB_ "W
MGY5"T1P76%N9J5N*5MMZ,N-,CLHDMK604NMJ";Z?2-5C\?E4JX?>:W&SB)^+
MQ@85)F95TM--H4$Z$IMJ6J_@+T(A-404%7S&\VH&4.#Q>/?R^70@./,1[)2T
MD@$:UGE<$>%$Q#'A][IFYA.!RV,D8C*.I*X[;Y"T.)2"390MX ^%J&'[EM]0
M\3F7<&J%(DSTM(<C-1QK6\MSZA*1RL+J)/@*&&/%[Z]HR[.#S.*D8>?*!,0/
MD+;<L+V"@!QX4,-S<.[XV$EL8J/%>R6:DC6U!CCU@CCZRE'D.!H1"C[DW"O,
M;BVG$F8Y_&9&+DFENQI N"AQUH)4A8X*%TD5"T0ZW4J*[N?>$':K\!J<RXXB
M<'RE;=B4EA*3:WB5%0 HF(RQ8G>'M<"?DLSC)&$C0 E2U2P1K2J]M(*4DGD+
M6\10PCAW"EKCG*-;;GKP7%7MPT:RV/JPW_%].JU$X69K/8E[#?/Z)*?FKIEX
MOF_!*>8(YW!X6YWHKA6!W$DN1E96/MR<[@4W)G72%=,7NL-\;I%N>JU%L)3*
M[VQ6-PN/SZ-4C&Y!]MA#B?5T!P+)4H'CZN@@CG1&&C"WZ[*CY&:[@YD6!"C+
MF,R'QH2^VDBP3J %U W%B:)PLV(R*,OBXF3;06T2VDO);4;E(6+V)%%4#"W5
MC]Q;7S63=AK]AAIE,28RU#4ZAID+6 4VMJ"K43C$JWNW*M'MLPC#XUUG%SF4
M64E5TQ4(?;LE9)N==RD5"T<UUVI/DS\+'<DP78"FDH:0AX@E:$MH(<%O W^E
M4JRWLIE(6&Q[^3R#G3B1TZG%6N>)L !XDDV%$*DON!DQ$^<T;7G'$:>I[25)
M"NESUZ ";6XWO:BV$R]N[')VLK=D5"Y$%* L-<$.7Z@;*3S (/.B,<4,[W%=
M6P9^-P$V;B&Q=V>D:$</EE ()4$\B>'*B<+)C]Q8O(X1.X&GM&-Z:G7%N<"V
M&[ZPH"_$6_XJ*X5QKN(Y(;5D6,!.<V^DG5DD@'U$FQ6&^92+<3>BV&MV@4E>
MWL@M)NE62>(/H+3-"SH"E)2DJ40$@7)/  "BJEIW_(GEUS;N EY6"RHH,Q)2
MRVI2>>BX)5_#Z*+83&V=TP]SL2%L,NQ9<1?2EQ'Q9QM9OY>' _0HB8PBG-^K
ME2Y$?;F&DYEF(HHD2FE);9UCF$%0.JB</F;O%K+;4R,S%PY#DIM+L69#(#;\
M51;5=:P?!-O#^&ACBC=F92^P)#.1QCIQD*#(6MU2@$2FSU5+2@CB.'JT)YI.
M/NS%X;";>?8@+CX;)K3':.L$1M1X:[W)'RC\5#"RYG*Q\)BI65E7+,5LK*1S
M4>24CTJ) HK"(F[TA8["8_+3(SPDY,)]BQK8"Y"U+ ( '#P(O\-N=$X1DCN#
M+QBFG<]MV9CL<ZH(]L*DNA)/+4 !;X+W^&B<-#NOD9"<5#BL17'(CK[+QFH(
MZ1(U6;\R3\H4*K2]NF/CL"<[G8SN,2%%'LCME/%5R$I2!P)5:X]%$80RNX$J
M*TB=E=NSH6&<(_Z\=*]"5$64ML %(XT3A<V'V9++<F.L.,/)#C3B3=*DJ%P0
M?2**LE H% H*UW%_9]NS\C9'\%<K75[<>F%;<I?RPKZQ\J]A^Y#_ &?O3[-C
MOYLBO%^8\Z_>]GL/9GTO6->0],H% H*+_P#;9_\ */\ I:A;P(?[6<AZ<2G^
MD:J3P8=^*3^=NR4W&H2W"1XV*V+?P4(Y2R*;0ONTA2DW4WBM2#Y**RF_T":@
M\#=;3;F_MH!:0KC(5Q\T)"D_0/&A')]=R0+[;/C\[1^/T:%6*,$J[N3/:_E(
MQJ?8=7PHU:?HN?3J3P9N[08_-!PNVZPD,^S$\^I<WT^G3JH5YM7)MK>[@;.3
M,3J>]D>6Z%?\ZAE:K_$H7H>"<WKB(.:APXCV11C,DF0EW%O*4 I4A/ )2DD%
M5[CY/$<*(B5:R62WUMJ(7MSPX6?P;2D%Y] 2EQ-U ))24I%[G_FSQ\:A/"71
MHDAJ7%8E,?[!]M#K5Q8Z%I"AP\.!J55+[I?V5A_RO&_F.T6J^>YK:'4;>:<2
M%-KRK"5I/(@@@BH*IC?Z4JV=EPH CH7L>/$*!'TZE$<T#-S$/&;2VFPK&-Y7
M+3&(:,7&="2E+R6F_7U*!M8D<J)QQ:^Z!OUW;F2?S+^-A8\,*ZL>.AQUU0/
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MVICH^V7]L8^\>*\TMHND:UZG!8K5RN31&>*0P^.&(Q4/%I<+J8C2&0Z1I*M
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M4KA,+CB/IN%!>KCJOPMJ\J&>#0R^S/:\J<]A,D[ALPM(0^\TA+K;J1P&MM1
M)X#Q^*A$F(V88N7^?\WDG,SF$)*&'G$)9;:2;CU&TD@'CY_%0F5JHA5=Q[.>
MS.6C9O'95W%9*.R8Q=;1U IHJ4JUM2;?*-$Q+=C;<#&YWMS*DE;ST-,)3&@
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M@OXZ>V'8DA)0Z@^7,$'P(/$'SHA4$[$S;,4XJ-NJ4W@SZ@BEE"G@URT!_4%
M6X<!;T46RF5;1QS>UWMK0"8T1YLH+Q&M94H@E:N5R;41GBAD;!RD.(,7BMRR
M8>'4D)=B=)+BKD>OTW"H*0%&YL*)RL6/VSB<;@CMYAHJQRVUM/!1]=SJBRU*
M(MQ-_#EX41E6XO;[)1&?FMK<TM.WR5 P$MI2YTU&Y0'M1(!\;)^*B<I7#[*Q
MN+PN1P+BC)QV1?=?4V1HT)<2A(0#<GU= LJB)E&M;&S\:)\UQ=V2&\.!TTQS
M';4Z&^6D/:@H</(43E,G:&+3M=>U&-;<%;91U;@N:RK7K)X G5Q^ERHC/%][
M8P<_ 0E0IN47DT I$8N-AOI-H3I"!ZRK\J$RW<UB(>>QDC$S@3&D) 44FRDE
M)"DJ!\P0#1$2K4?96=3%1BY>Z9+N%0D->RM,-LNEH"P07[J5:W"BV6UBMDL8
MC#9G!QI:C"RI?Z0*.+ ?;Z=OE'586\N5$936"Q2<)B(F)2Z7DQ$=,.D:2KB3
M>US;G1$M3;NW4;>^<=$@O_.$MR8;IT:"Y]3S-[>=$S*)P6QG\"J9&CYAUS"R
M6WFV\<ML6;4]8:M>KB0!Y"A,IO;6$3MS"1<,AXR$QNI9XIT%74<4YRN>6JW.
MB)G*6H*IBMFR,-GY&4@Y=U.,E/.2)&*4V"A3CH(OKU>!-QZOA1.6G^8,V#,E
M/;<S[^)@S'"Z_#2TEY(4>>A2E#3Z.%Z)RD-N[,B[<R<O(QI3CYEM(;<2]ZRR
MM)U*<4N_$J/$\*(F<MS;NW4;>^<=$@O_ #A+<F&Z=&@N?4\S>WG0F3&;=1C<
M[ELXF07%97I:F2FP;Z2;<%7-[_!0R?FZC\ZOSG]H.OV3V/V;3PMJU:M5_I6H
M9X(R9LE]O*/Y?;67=PDF8=4QI+2)##B^>KIK( ))OXT,MK;^T&<--?R\V8[E
M,Y)&AV<^ +(X>JA(OI' >/TJ$RV</MU&(R^9RJ9!=5F'&G%-%.D-]+7P!N;W
MUT)E-T0A,WMU&:R&'GJD%DXE\R$H"=0<)*38FXM\FB8D_-U'YU?G/[0=?LGL
M?LVGA;5JU:K_ $K4,\#)[=1DL[B<XJ06U8KJZ60FX<ZJ;<57%K?!0R;BVZC<
M/S=KD%CYOEMS!9.O66_J>8M?SH1)*VZB3N>%N4R"E<)A<<1]-PH+U<=5^%M7
ME0SP,WMU&:R&'GJD%DXE\R$H"=0<)*38FXM\FA$FZ=NHW/CVH#D@Q@V^W(UI
M3K)+8(M8D<[T(G##NG:C&Y4Q74R7(.3@++D*:SQ4@FQ-Q<7' 'F*$3A!S^W,
MO-15MY[<#\^6+"*Z6DMM,C4"HAI*K%2@+:K\J)ZEBS&W49?+X;*JD%I6'<=<
M2T$Z@YU=' FXM;11$2^]T8!&YL,]B%OF,EY2%=4)UD=-05RN.=J$3AARVV49
M67A):I):.%=#R4A 5U+:>!-Q;Y-#+5W+M!W.9&'F,?DW<5E(B%,I?;1U 6U7
MX6U)MS/CXT(EBWS,Q4?:61@Y24V[(,8(2V5)2ZM^P+:@CB?E *^"A'-L[#PJ
ML%MF'&>24S'P94O5\KJO<;'TI3I2?@H3/%KPHTQ/<')2427WL>82 ZPK4([+
MZBT$)1<Z2HI0I9('"]#P6RB%/D[)FLYB7F-MYMS#O9 ZYC181*;6OGJ"5D <
M23X\Z)R^&]@)1E\?GGLK(DY>(X7),A\!0>20!H2D$!M(&JUK\Z)RF&=NH9W5
M(W.)!*WX@AF-IX !2%:M5_\ -Y6HC/ S>W49K(8>>J063B7S(2@)U!PDI-B;
MBWR:$2UMP;11F)L?,0)KF*SD9.AN:RD+"D<?56@D:AQ\Z$2BSV^D2LE S.7S
M;T_*0I+4@.J:2VV6V5!8;2VE5D7(XFB<KQ15"9C;J,OE\-E52"TK#N.N):"=
M0<ZNC@3<6MHHF)2&3QL/+P7\;D&P[$D)TN(Y>D$'P(/$&B%1&Q,ZW#.(C[KD
MHPENF(Q8;4\&N6@/:@H"W#@+>BBV5AB;8PT3!';C;&K%J04.(6;J65<2I2A;
MUK\;CEX41E7D["S#<0XAC=,I& (Z?L99;4\&>6@/WN!;AP3;T43E)9'9,"7A
M<9@X;IAQ,9);E-D)ZBEEL+N%7(XJ*R2:(RL,R(Q/B/PI2-<:0VIIU'*Z%BQ%
M_@-$*5%[?9*(S\UM;FEIV^2H& EM*7.FHW* ]J) /C9/Q46RE,5LR-B<!E\!
M'D'V?*+DJ2O1;HIDM!H) U'5I \^-$99%[1C.[0&T7I"E,!I+7M*4A*KH6'$
MJTW/)0'"]#/'+:VUAI^#@F%.RB\I90Z+CB.F4-A(2$#UE7 MYT)E];DV]#W/
MBUXR:I2$E0<:=1\I#B;V4+\#S(H1.$*C9F9E-)@Y[<LC(8D !41MAN*7$CZE
MQU)4M0/CYT3E]QMC(C[1D[2]O4MA]14B26P%(25I7;3JL>(/B.=$9XY6:!%$
M&#%@A6L1FFV0LBVKII";V]-J(0VW]I1,+M]S;K[GMT1XN=4K3HU)=YBP)_AH
MF91#.P<G&85BHFY936W5$@P.D@NAM7-"7[W2#?P31.4UM/;#.U($C'QWR^T]
M)7)25)TZ M*$A',WL$<Z(F<IB9$8GQ'X4I.N-);4TZCE="P4D7'H-$*=!V/G
M,8Q\VX_=,AC"@G1&$=HO)0HW(2\3=//F$T6RD=M;-B[7GSY4"2M<6<EH*CNC
M4I*V@?6+E_6)*E$^KXT1,Y:7YC3L?)D.;6SKN&ARE%QV%T$26DK5S+861HHG
M*3PNT<=A\9,Q_4<DNY+6<C,=/UYY3@())\.9M1$RCL/LB7B\5D<(YFG96,F1
MG8L9A;0'LX>"@5 ZS?Y7+A0F5AP6*3A,1$Q*72\F(CIATC25<2;VN;<Z(E"X
M#8T# 9V?FV'BXJ9K#+!2 EA+B]:DI-S?CRY43,L^Y=IHSTB'D8LQS&YF 3[-
M-:2'+)5S"D$BX^.A$HN?L"9G(KC6XL^_D'@/^JE++<=EI?\ 'Z39LI5N'$^-
M$Y2N9VFWF]MQ\!)E+0Y&2STYB$V5U&$Z0HIOXB_"]$1+X7M%.1V\<%N*<YE'
M-9<1.*0TZA7U)3Q5Q3?QO0RBWMB9N='3C<INJ3*PP("XJ6$-NK0FUDJ>U*)Y
M?5 T3E<H4*-CHC,&&V&HL= ;:;'@E-%6>@4"@4%:[B_L^W9^1LC^"N5KJ]N/
M3"MN4OY85]8^5>P_<A_L_>GV;'?S9%>+\QYU^][/8>S/I>L:\AZ90*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0:T^!#RD1R#D&4
MR(CMNHTOY*M*@H7MY$ T&=MM#3:&FTZ6T )0D<@E(L!0?5 H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H-3(XR!EXQAY)A,F*2%%I?+4G
MD>%!MT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@\=^]I^U'8GV%K\-KV>Q_KM]O!YG=_V4]/\ I[$KQGIE H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H%!$S=L8'(Y)K+3H+<C(,@);=<*B $DD>K?
M2;$^(H92U H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H*UW%_9]NS\C9'\%<K75[<>F%;<I?RPKZQ\J]A^Y#_9^
M]/LV._FR*\7YCSK][V>P]F?2]8UY#TR@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4'COWM/VH[$^PM?AM>SV/]=OMX/,[O\ LIZ?]/8E
M>,],H% H%!A]LB![V8OM^T?\UK3K_P!6]Z#3S^4^9L/-R20E;D9E;K;:SI"E
M(%P*$(*5N*<OM^O<##R&\K[&B05-A*DH<78\$JU#Q\:)QQ3&%RB7L'B)61DM
MB7,B1W5J64-E;CC:5*(' <2>0%"4O1#"N7$:=2PX^VAY7R6U+2%&_D";T&4D
M)!4HV2.))X  4&/VJ-U$-=9OJN#4VC4-2AY@7XT&6@A\>WFTYK)KG3&7L2OI
M_-T5NW59L/7UV0D\3RNI5!)+E16F^LX^VAF^GJ*6D)OY7)M0?2GV$M==3B$L
M6U=4J 18^-^5!^M.M/H#C*TN-GDM!"DGXQ0?*Y,9MM3KCR$M).E2U* 2#Y$D
MT'Z'V"S[0'$%BVKJZAHT^=^5J#]9?9D(#K#B76SP"T*"DW'I%!^I<0LJ2E04
M4\% $$@^F@=1O7T]8ZEKZ+C5;X*#Y4^PA*U+<0E+?^T45 !/P^5!^LOLR$!U
MAQ+K9X!:%!2;CTB@.NM,(+CRTMMCFM9"4CXS0&GF7T!QAQ+K9Y+00I)^,4'W
M0?+CC;2%..K"&T\5+40E('I)H/EE]B0CJ1W4.MWMK;4%)N/2+T!Y]B.CJ2'4
M--WMK<4$IN?2;4'TVXVZA+C2@MM0NE:2"DCT$4%6P.9R4W=^X\7)?UP8'L_L
MC6E T=1-U>L ";GS)HF8X/SM]F<EG,+(EY1_KR$2WF4KTH19M 3860$CQH3"
MS"9$+QC"0V9 X%G6G7?^3>]$,U H%!A;F1'72RU(;6\F^IM*TJ4+<[@&]!D6
MXVW;6H)U&PU$"Y]%Z#]4I*$E2U!*1S4384 $* 4DW2>((X@@T&)N7$==++3[
M:WD_*;2M)4+>8!O05K/9G)0MW[<Q<9_1!G^T>UM:4'7TTW3ZQ!(L?(BB8C@L
MS<J*ZXIEI]M;J/EMI4"H?" ;BB&6@<N)Y4&!N="><++,EIQX7NVA:5*X<^ -
M^%!G) !)-@.))Y6H,+$N+*O[,^V]I^5TUI7;X;$T&:@K.>QN\Y<X.X'-M8^#
MTTI+#C#;IZ@)NK4I"CQX>-$QA3<7,[BY3/9/ M[A:;>QENH\J*P4KN;< &KU
M"W!T#;T3<$.,ZC<.01D9*G-33K;:6@ENP&FR4IOQN:E64Q1##[7$ZWLW7;]H
M_P"9UIU_ZM[T&:@PMRXCSBF67VW'4?*;0M*E"WF ;T%9[@YG)8/"QY>+?Z$A
M<MEE2]*%W;6%7%EA0\*)B'[GLSDH6[]N8N,_H@S_ &CVMK2@Z^FFZ?6()%CY
M$4(C@L[TB/&3KD.H9038*<4$B_PFU$/IMQMU"7&EA;:N*5I(4DCT$4'U0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!05KN+^S[=GY&R/X*Y6NKVX],*VY2_EA7UCY5[#]R'^S]Z?
M9L=_-D5XOS'G7[WL]A[,^EZQKR'IE H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MC%8I?LV.Q^EY;2W$DI<6KH@\01XVY@>%0G'#@1,UM?%;OQ"]DRE&%DG1$R<
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M0!L[#@"WUB_T5&I1/-$=M@+[D-N)RT@$_!:H38VP!^?^[SX_]5X_Z%">1_\
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MOR!M1,1B5YW;,BHVAEI*G4]!Z"\EIRXTJ+S12BQ\=14+5*L<U'D?L2'V-O\
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MCB06R4D WN J_HJ#/E;FWMR3'H^X\1O!3<IO#)*)<MA!*765I4%A24 <;#P
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MD!94R&X6'5 "PU$7!X<+VO1,2V,#M7#;=ZJ\>THRG_\ ;RWE%U]?&_%1\+^
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M3[-COYLBO%^8\Z_>]GL/9GTO6->0],H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H/Q:$.)*%I"DGFE0N/IT'Z    + <A0?BDI6DI6
MD*2>:2+B@_0   !8#@ .5J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0>._>T_:CL3["U^&U[/8_UV^W@\SN_[*>G_3V)7C/3*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!05KN+^S[=GY&R/
MX*Y6NKVX],*VY2_EA7UCY5[#]R'^S]Z?9L=_-D5XOS'G7[WL]A[,^EZQKR'I
ME H%!%9;<N!P2D(RT]J,XL70VHE2RGE?2D$V]-J&&;%YK%9MDR,5+;E-)("R
MV>*2>04DV(^,4,,D/)P,@Y):A/I><AN%B2E/-MU)(*3Z>%!^#*XXY(X@2$')
M);ZRHW'6&_XWP<:#!E]Q83!!'SM.:BJ<XH0HDK4.5PE(*K>FU##)BLUBLVP9
M&*EMRFDFRRV>*2?!238CXQ0PH^QMU8[&[>>?W#DPAQ<Y]+1?6IQPI2$<$CUE
M6%Z+3"]XS+8W,Q_:\7);E1[Z2MLWLKR(Y@^@T5;E!#Y7=6WL(Z&,ID&H[Y /
M1)*G #R)2D$B]$X9\3G</G&U.XF8W*2C@L(/K)ORNDV(OZ11&&ME-W;;PK_L
MN2R+3$D"ZF?66M-^(U! 41?TT3B4A R,#*QDS,=(;E1E&P<:4%"XY@VY$>1H
MAM4%:VLJ!CL)+D)S)RD-EYYY^<Z5?6PE(*D\2HV2!>B99Y6]=JPNC[3E&4>T
M(2XT 5*)0L72HA() (Y7H8EFG[KVYC&6)$W),MM24AR.0KJ%:#]4D(U$CT\J
M&&Y&RV-EP#E(LIM['I2I:I"%:D!*!=5[<K6XBB$;*WKM6&AAR1E&4IDI#C-B
MI1*#P"B$@D ^9HG$LT[=>W,=&8F3,DPB/*&J.L*U]1/FD(N2!YT,-V#E,=DX
M8GX^2W(AF_UULW T\2#X@CR-$/W'Y&#E8J9N.?3(BK)"74?))2;'GY&@^8F5
MQT^1*B0Y"'I,%01+;3>[:E7 !_U301TC>>UXL9$M_*,I8<4I#9!*E*4@V59(
M!5P/,VHG$I'&Y;&YB/[7BY+<J/?25MF]CSL1S!]!HAI97=>W<(Z(^3R+3$@\
M>E<K6 ?$I0%$?'1.&]C\GC\M'$O&R6Y4<FW4:4% $>!\CZ#1".R.\ML8F28<
M_)M-2D\%M#4M23Y*T Z>?C1.)24?(P)<+YQBR&WH)25]=M04C2GGQ'E;C1#]
M@3X>4B-SL>\F1$=OTW4?)5I44FU_(@B@^(65QV1>E1X4A#ST)PLRD)O=MP$C
M2?3=)H(Q_>^U(\=F4[E60R_?HD:E%022DG2D$VN+7M1.)2T#(P<I&3,QTA$F
M*O@EUI04+CF#;D1Y&B$5(WKM6*PB2_E&4M.*4A!!*E$H-E>JD$V!\;43B4GC
MLGC\M&3,QLEN5&5P#C:M0!\CX@^@T0C9&\]K16TNOY1E"%N+93\HG6W;4+ $
M\+\3RHG$MS(Y[#8F,W+R,UJ/'=%VE+5Q6"+^JD7*N?@*(P^<3N+"9T+.)G-2
MBWQ6A!LM(O:Y2JR@/3:A@RVX<+@DH5EIK<7J?[-*R2M0' D)2"2/BH8?6)SV
M&SB%N8F8W*#=NH$'UDWY:DFQ%[>(H8:^5W9MS"/"-E,BTQ((!Z/%:P#Q!*4!
M1%_31.&]CLGC\M'$O&26Y4<G3U&E!0"AX'R/H-$*]MV?AL#MM,B1G?G&!UE)
M^<GM7%:OJ.)4>%J)E; 00"#<'B".5J(:4+,8O(17)T.4V[#94I#KX-FTE !5
M=1L. /.AA&,[XVE(E"&UEF"^3I2"2E!/*P60$F_H-$XE8*(*"OR=\;3B2C#?
MRS"9"3I4 2I(5Y%204BWI-$XE)2,SBHJH:9$MM'S@H(A*O=+JE6L$J%P;ZA:
MB,-J1(9BL.R9*PU'92IQUQ1LE*$BY)^ 4%"W-OV"SD<"UB\HV(+TE*\FI(__
M $>Z2FY(N$GCRYT6B%T5E\8C')RSDMM&-6@.)DK4$H*5<B";<_"BK0QV\=L9
M:2(>/R;+LI7!#1NA2CY)U@7^*B<2AMZRI+&?VBVP\XTV].*7D(44I6F[?!0!
MXCCXT3"SY#,XO%N,-3Y2&'I2M$=I5RMQ7 62D7)YT5PC'VHRMY17SE5MRA"*
M4X;UM*T:U_7CQM?PY>%$^#:E;HV_"$I4K(,M>QK#4D*/%+B@2$VM<D@'@*&&
M7$[@PN=2M6)FMRNG_M$H)"TW\2E0! ^*B,/K*YW#X-M+N6F-Q4K^0%GUE6YZ
M4BY-O0*&'SB<_ALZA2\3-;E=/Y:4&RTWY72;$?0H8?&6W+@<$I",M/:C.+%T
M-J)4LIY7TI!-O3:AAFQ>:Q6;9,C%2VY322 LMGBDGD%)-B/C%##?H%!'Y7.8
MC"-)>RTQN*A=PCJ'UE6YZ4BY-O0*&'SB=P87.I6K$S6Y73_VB4$A:;^)2H @
M?%0PQ9;=&W\&XEG*Y!J.\H7#1)4NQY$I2"0/3:B<-S'93'9>.)>,DMRHY-M;
M2@JQ\B.8/H-$*AM27*>RV]$//N.(8E%+"5K4H-CZ[P2"> X>%%I;?;*3(E[0
MB/RGEOO*<>"G'5%:C9Q0%RHDT1;FMJUH:0IQQ00V@%2UJ-DA(XDDGD!1"OM[
M[V@[(]E1EV.K?2"24HO_ "R GZ=$XE+Y#*8_%,)DY&0B.PM:6TN+Y%:KV'#S
MM1#-*E1X4=V7*<#49E)6ZXKDE*>))H-1S.XAK'M99R6VG'/%(:D&^A16;"W#
MQ-#"-E;ZVK&<DQU91CVF-<+02JVL<+ @6/'AP-$XE3.W*8&;E-YC)9F1)W+U
M'7U02Z>D&Q= )1IY>M<6-N50M9=IV]]J8V0J++RK*'T$A:$ZG"DCF#H"K'T5
M*N)2T#(0<I&3,QTAN3&7P2ZTH*3<<QPY$>5$(S([QVQB9)AY#)LM2D\%M"ZU
M)/DK0#;XZ)Q*6B2XL^.B7">1(C.B[;K:@I)'H(HA"O;XVE'E&&[EF ^#I4 2
MI /*Q6 4BWI-$XE/-N-O-I=:6EQI8"D+20I*DGB"".!%$/B42(KQ!L0VH@CX
M#0<^VTZK(=LBO)95V%K4X',FI2EN-@/\#>X/AIYU"T\UWC2(D'#QY#\Q*H;,
M=LJG.JTI6@( "U%1^JYU*J/C;WVI,ZPCY5E180IQP$J0="!=1 4!JL!?U;T3
MB4M\X01!3DU2&TX]3:7Q)6H);Z:P"%7-N!!HA"M;]V>\^(R,NQU%'2"K4E%_
MY:DA/TZ)Q*9G9*!C(XESWT,1BI* ZH^J5+^2.'G1"+D;UVK%FG'OY5A$I*M"
MTDDI2H<"%+ T@CQN:)Q*;+K0:+Y6D,A.LN$C3IM>]^5K>-$*MD=Z;:F0,E#Q
M^6:7/$5_I!"BDE8;41H40 3Y:31.)?G;Z<H[&@3\C))TID+?DR%WLE$AP74I
M1Y #QH3S;L;?.TI<E,-C+,*?4K0D$J0DJ)L %* 2;^'&AB5@H@H/EQQMEM3K
MJTMM(!4M:B$I2D<223P H*Z=_P"S@]T/G=C7?3?UBB_\O3I^.]$XE,R\ICX,
M%63E24-X](2HR;W;TK(2DW%[@DBB$9+WKM6#*]BE91EN3P"D7*@DGP44@A)^
M$T3B4VVZT\VEYI:7&5@*0XDA22D\001P(HA"HWIM5R<,<WE6%2RK0$A1TE7*
MP7;23_I43B4%VGERIFUUO3'W)#OM;J>HZM3BK!*.%U$FB;<UZHJ4"@4"@4'C
MOWM/VH[$^PM?AM>SV/\ 7;[>#S.[_LIZ?]/8E>,],H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H%!6NXO[/MV?D;(_@KE:ZO;CTPK;E+^
M6%?6/E7L/W(?[/WI]FQW\V17B_,>=?O>SV'LSZ7K&O(>F4"@4'-<K&S&W-W9
M'<1P9SV.GI;Z;K8UOQPVD @)TJ('#RXBW'G4+<X;VS\AL_)Y^9/PZ'L?FWF=
M,O'.I#22E)%U!";@FX%^-_1Q-23E]=O_ .U=X?E=_P#GKH2PL_M=D?DP?PHJ
M#P?&RX<;-[AW'G\DVB1,9FJB10YZ_1::N!I!X#A87]!]-"5FB[5QT'<#NX()
M5&<?9Z+\1D)2PX;WUJ3;Y7+E_P =2C*H]K,'BWL;.RDF*V_,<F.LAQU(7I;0
M$D)3JO:Y))M1-I;>U(K&,[@;IQT%(9@].,\&$ ! 6M"5FP'  %:K4)Y.@45<
MU9R6T<+FLH($.=N/-27E+E.-,)E%I1YMA5D@)!_B@^7A4+<6#;#A5W)?=1BU
MX5$G'E:H2]*2JRTC64IL$WMR_P".B9Y/AH979>7R[^1V\K,09\ER2G*,)#KJ
M6G"?54-*K#CR.GCYT.:P[#D;3DKR4G;*G67)#B7)F/> 1TE<;:4#@!Q/R2?X
M*E6<KG1#EVTOV:[E_P#,OZ"B\\TQL/;6%<V=$,B&T^[/:4N2ZX@*6K42D"ZK
MV"4\!:B)GBCNU&$QC^VUSI49N3)?><:*WD)<TM(M9"=0-A<DGX:%IXL>UVD1
M<5OV P-$2-)FH8:'R4I"'$@#XDBB9\$EVYV[AU[0BR)$-J1(G)<5)<=0%J4
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MLS#2LTG&:(L)F.V'6XXL>)2JP]:RBGXZ'@S3G9\S<V%S.&VU/QLEE\(R#JV
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MA9>;7"=$.$F.V'41TME222E1 !5IN/CJ$^#9>7/D[NPN8PVVYV+4'>AE''&
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M?ZH]_--$1S4#.DCL_BR.!!8L?]-50M'-?6-J[?Q>/*(V.CAUJ.IHOEI!=6
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M8PC#C9ZJG)*)+CQ2-26T=, )"E !15X4(Q#'F-LYR?VZ@X!N.D9:.&4N,EQ
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M.)^+GQY4(Q+/O3<V4C1-NSMNN<<H\CIM* TNI>0DH2JX) NH7M0B&IEL?OO
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MD>FAP;O;O-9?-1<L[F5WDL3G&@T  EH  E";>"22./&B)A9\I%ES8+L:#,5
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MI#ZDNJZ^KG<#AIY415([AFYW:/S!.DY-<W'(D&-F'%MH0%H>42A9"1PT))'
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M[>F!E;8EP,7+1.ES$)2$,>OH;U)*E+_BBW#CQO0B.+!O!1C[3VCD%I48L)^
M](4D7TH#0XV^E4$<VYO_ '5@9FU9<''3FITR8A/29C+#J@E"DN+4L)OI"4I)
M.JI(CBC]T?X"V9]GQ?X,JH3'-L;OEF=O.%M[+Y%W%;=5&ZVIMSH!]TE0TJ</
M"W"UC_":E$<E9WK"V3BHT:/MT(D9'VAMV9+0ZN3TV1<>NO4I(*E$<*A:,KEW
M(>:BS-JRY"@W&8RC3CSJODI2E25$D_ ":E6K5W%D(F/WC@-Y]0/;?>CK@N3&
MOKB$$ERRKB_"Z_#R-".6&UOW=&'?VX_B\;+:GY')A+$6/%6'E'6H7)"";<!P
M]-"(XM'<$!S&1^WV/=_VT:=#:=_EI+85;XZ$>+I#S+4AER.\D+9=24.(/)25
M"Q!^$45<7BLS),F+VP?U*9AY1QU]?@8#8ZJ0?Y6I2OH5#3SNU@   "P'(5+-
M2^ZO^"YGV1C^E31:O-I[O_MC8O\ 6Q_T5"/%F[K_ .'(O]?C_P "Z%4EW&_P
M5EOL;?\ 2HHBO-7-T_V!L;^MX_\ HA4)CQ2_=7_!<S[(Q_2IJ2O-([I_P1DO
MZ@O^CHB.:F;C0X>U>">0@K1']C==T\;(""+_ $2!4+1S3N[MW[>E[5FLP)S4
MR5/CJ:CQF%!;UW$\U(%RG2.)U6J41'%6\]^Q[%_"Q_/54)CFZ7N'^P,K_4Y'
M]$JI4AS65C).3[08WV5LO+AK]J6TF]U-H<=2K@.=@J_Q5"_BVF<9V==Q(RQ0
MRAO1K7'5+?\ :$JMQ1T^KJ*K\. X_!0XK5L!$ ;?3(QN*7B(DIU3R8SCJWRJ
MX2GJ:G.-E!/#X+^-2K+-OK&R<MM/)P8B2N0MM+C:!Q*BRXEW2!YG384(YM+;
M^]MNKVY%DRL@S'>BQT(E1W%A+J7&TA*@$&RC<CU;#C0F%6W3)R.[-F1-PR<<
M4QHD[KJBH4N[D$ I+AM8B_H\/6O:H6CA+-(QO9YG$JRZ&V74!&I$=,M_KJ7;
M@CI]74%?".'P4.+)F68C?:66Y!QJL3'?Z+R(;CBWE +E-V45+X^L %"A'-L;
MJ_\ L!_K\/\ Z.I1'BV]RR]JY'<'YO;M@(80&0Y!RKSG2"]5KI2M.G38W^4J
MUQZ:$90>*8C8'>N,Q6T,J[/QDE+BLE#ZJ7V6D)'/4GU0?ICSXVJ$^'%U>I44
MB?VJVSD9TG(2%R@_+=<?="7$A.MU14;#0>%S1;JE;X$-K'08V/CW+$1IMAHJ
M-U:&DA(N>'&PHJIN\_\ &&ROZQ*_@9HM'*2'^UG(_DA/]*S0\#M__:N\/RN_
M_/70DP?[3=T?U>)_0M4)Y$S]K.._)"OZ5ZAX&S/\8;U_K$7^!ZA/*&MVQR,%
MIO+8EV0A&37E)3J(JC9PH"$ D)/\DT+(O;G[,-Q_9)O]&FH3/->ME_X3PW]4
M9_FBI5GFH>$Q<C,[ W7CHB2N2YDWUM('-2F>@Z$CTG385"T\UBP7<#;2-O15
MSIJ8\R(PAJ3$6+/=5I(2H)0!<W(X6J43#!VMDKFQ\],6V6ER,H\ZII0LI)<
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MT46@F?M9QWY(5_2O4/ WG_C#97]8E?P,T(Y2=TO[*P_Y7C?S':%3.?M-VO\
MU>7_ $+M".1W _M79_Y78_GHH0=V_P#![G]89_A-"O-B[@2&\?G]HY65=&/B
MR7TR'[72CJ!JU_B23\5"$?W1W)ALAMWYOQLQJ=(6ZV\OV58>2VT@V*EJ1<)]
M924B_G4)K#?W?_;&Q?ZV/^BJ41XI+N=_@;*_]W_"6J(KS5S?F/:<QVU<O.CJ
MDX:"$-Y-M!6"&7T->MZA!%M)XCQM1:&/+8[M'CL6K(L,,SG%)_ZM$8F/EUQ9
MY)L'24^DD<*@XN@[;89C8."U'A*QS/2"T0EK4XIKJ$KTE2N)/'QJ5)2E H%
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MR(/$4,MAS%8MV&G'.P8Z\>BVB(II!93;E9!&D6^"@VG&VWFUM.H#C3@*5H4
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M,Q3:FL9#9B(4;K#*$HU'TV''XZ#*W"A-2G9K4=I$U\!+\E*$AU82  %+ N;
M<+T!V%"?D,RWH[3DJ/?V=]:$J<;U<#H41=-_&U!AR&'Q.6"!DX3$OI_[,OMI
M<*;\[%0-KT,LJ($%J29K<5I$PH#)D);2'2V+61J OIX#A0:L[;V"R;PDY#&Q
MI,@"W5=:2I9 Y DBY^.AEG&*Q87'<$*.'(8(B*#2+L@\PV;>K_HT&1J%"8D/
M2V8[3<J1;VA]"$I<<T\!K4!=5O"]!GH(R;MS 9)_VJ?C(TF3P!==:0I1 Y7)
M''XZ&6P,7C$NL/B$P'XJ2B*Z&D:VDFX(0;72./A0?.0Q&+RR$HR<-F6E!N@/
M(2O2?1<<*#)!Q\#&,B-CXS45@&_390E";^=D@<:#$,+B!D!E1!8&2%_^MAM(
M=N18G5:][&UZ&6>+"A04+;A1VHR'%EUQ+*$MA3BK J(2!<FW.@_%P(#LMN>Y
M%97/93H:E*;27D)-^"5D:@.)Y'QH/J7#B3V%1IT=N3&58J9>0EQ!(-Q=*@1P
M-!^284.;'5#F1VWXJ@ IAU"5H('+U2".%!"9:>C:./8:P^#>ELK4I*(V/;]5
M"SQ!4$@V"B>=$QQ8-B8.5B,4])R2 C+Y1]<R:D?4EPW2CAY#C\)-"96FB&*3
M%C36%QIC*)$=?!;3J0M!^$*!%!IX_ 83%.%W&X^/%=4+%QIM*5D>6H"]J&6S
M(@09CC+LN,T^[&5U(ZW6TK4VL$'4@J!*3<#B*#8H,$B%"EK9<EQVGUQUAV.I
MU"5EMP<0I!4#I(MS% 5"A*EIGJCM&<A'21**$EX-W)TA=K@7)X7H#T*%)>8D
M2([3TB,2J,ZXA*UME5KE"B"4WL.5 E0H4Y"&YL=J2AM8=;2\A+@2XFX"@% V
M(OSH#D*$[*:FNQVES6 4L25(274!0((2LBXN#QM0)$*%+6RY+CM/KCK#L=3J
M$K+;@XA2"H'21;F*!+A0L@R8\^.U*CDA1:?0EQ%QR.E0(X4'[*B19S"HTUA$
MB.O@MIU(6@_"%7%!I,;<V_&CO1&<7%1%D6Z[/104.:3=.H$<;$7%Z&6V] @R
M%L.2(S3KD4ZHRW&TJ4TKAQ02/5/ <J#ZE1(LYA<6:PW)C.6ULO(2XVK20H72
MH$&Q%Z#[Z+):Z!;3T-.CI6&C3:UK<K6\*"-C[8VY$D"7%Q41J2DW2XAE *3Y
MIL.'Q4,I6@4"@4"@4'COWM/VH[$^PM?AM>SV/]=OMX/,[O\ LIZ?]/8E>,],
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M6SF(RMZ;PDD RT/M-H4>:6UA1-OA*1?X*(GD_-UI2SO[:,B-PFNE]I_3S+
MM>PY64NA')^8M3B.XN[EM"[J8D8H'FH,-VH>""[>*W@C E_!QL<\Q(?<6\]*
M6Z'U."P.K3P^"H3;"=PF)W"C>SN<RQ@1UOQ2S*C0W5*6H"VE90L7^I'&I1/)
MIP<1O3:WM VF[#S6!=>6\W&<4 ZE2OE *U)%Q8#Y?Q"APE.[*SD#*N9-A.*&
M'S3#H5DXX NMQ=_7*@$DW(//_+1$PMM$% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H/'?O:?M1V)]A:_#:
M]GL?Z[?;P>9W?]E/3_I[$KQGIE H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'COWM/VH[$^PM?AM>SV/\
M7;[>#S.[_LIZ?]/8E>,],H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M/["U^&U]+\K_ *;_ &\'@?,O[M?I_.'L>OFGOE H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M4E25"X((X$$5R3&'4Y_M?O7L#>."W!N/!S'G<7ME@R\LXY'<;4AI+;CI*4J
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M_KMZ?R:_-,>\IE<^[^VO=IC=O\W)QBL%'SS45TX8X>2TJ4J;INTD-L.'4DJ
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MI2D@B]RH5XVRG>UK,VF<>/&/]O8U;.TM:(K$9_\ I_1S+WO<5-SO=G:6#QR
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M>]K$S,VQ'G>E6>TM.(Z<SYGH=IIMAI#+*0AIM(0VA/ !*18 ? *\:9R]5]U
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M/6KW4TCNXF_L^+IOYX>Y=]SXK^Y\A^*UP^Z[_P __P":/]NOWW9>;_\ +/\
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M1I[>)S$5=K:=:?:0^PM+K+J0MMQ!"DJ2H7!!' @CD:\N8P[GC7W9O]XC??\
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M!?LZG,9$CR&WG9+Y3];;#:%:^*B-?+2.=J\/5V>V]XKTS'E>SM[K72G5F/\
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MRS7GQ_%'<16>\B+<OT=Q_,+W5OXFV?[R:_&*\GW_ 'G_ .+U?H]3W';>2O\
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MML9Q$-' -^[[WPVLSN?=<+#8G=#R5IS#;4E.-E,R$J-UJ*5MEP*'K)6L*!'
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MU-'_ $;?>\W=_P!VOH_VXAOQK*;-W+O7MECPH8R9FFEI9Y*6B*MXQ0!_G)D
M_$*]71,;*4V3SB/_ %_!Y>_JI>^J/&?_ $_%V??F ;VMW_[,;;:"0G%8O 0R
M4\E+9GR4J5_I*!57F:+]?;;;>6;?A#T=M(IW.NL>$1^;V=7S#Z$H% H% H%
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M8M_Z.K9VU-EXM/.JT[GVWB=WX#(;:SC/7Q6394Q(0."@#Q"DFQLI*@%)/@H
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M;#W1OYGN-E/;#G&GHDA3#;K:8CBX(0&]:"V5$$-I"AKXBK:^^V4U^[C&./\
ME6_9Z[[.N>?^DGN;M!M7=F_,)W$R;LQ.>P*8Z(3;#J$1B(C[DA&M!;4H^LX;
MV4.%4U]W>FN=<8Q9>_;4OLB\\X7^N-TE H% H% H% H% H% H%!6>XW[/=V_
MD;(_@KE;]O\ V5],?BRV^Q/HE_*ROT!^?O8ON/\ ]G[U^S8[^;)KYKYSSI]_
MY/IOD_L6]+UI7SKWR@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4'CCWM_P!J6P_L+7X;7TORO^F_V\'@?,O[M?I_.'L>OFGOE H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MKBUNJ<N@5QNHH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MVB.;=A3H62CIEX^0W)C+^2ZRH+3<<Q<7XCRJLQ,<TQ,2CI&Z]MQ&R[(RD=M
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M[N?"936R\OF,MB3\_1'(N3BN*8=6ILMH>T\G$<+$'D=/"_*J7K$3P6I,S'%
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MV+%1V\=EH8;3*<:F(<?"$AQ20I=@56N1PJ-D_O3KC]J(_P#M%_\ #_Q*K?\
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MI%<[<H% H%!6>XW[/=V_D;(_@KE;]O\ V5],?BRV^Q/HE_*ROT!^?O8ON/\
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M[FCZAOIV(^'_ -AM'37QRB>JWF9<CA=P;?W+)W-MF*C(Q<BA*<EC"X&5ZT
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M6W18?4D\+J3XGA?E4XK:)F(Q@S:LQ$SG+;S69S^8W,O:6VI*,>F&TE[)Y)2
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M:&>:VUVN3EW4=13*W@TU>VMU;Q2D7\KGCZ*O>O5?"E+=-,M^-B^XTV"C++W
MW%R+J0\WBQ&;,=(4+AM2S<WL>)L;>GG59FD3C"T1>8SE.[-W&K<V&$U]H,3F
M'%1IK*;V2\W:]KW-B"#]*J7KTRO2W5"7R4]C%X^5DI-^A$:6\Y;F0A)-AZ3;
MA5(C,X6F<1E1L4C?>[((SJ<VC"1I%UP(+49#PZ8-@7%+(/&WI\^'*MYZ:SC&
M6,=5HSG#;V_G,]FV,MMJ=(1CMU8Q24&>TTEYM2%&X<#:K)-P+?&#Z*K:L1B?
M!-;3.8\4)VKB9DN9!X96V-CSWTRX/L[?_6'5-@=3JWU(XZ3I'#AZ:ONF/(KJ
MB?*ZG7,Z'.-CY!C$X[=^3DWZ$3)2GE@<R$ &P])Y"NC9&9B&%)Q$RRXEK?FZ
M8*<]\]HPS4F[D" U'0\D-W]4N*7Q-_C\_12>FLXQDCJM&<X2FU=SY#(1<K"R
MS 5GL&M34EN..#]@K0I /BK21_[;52](C&.4K5M,YSSA'PL=W#ST8Y&;FOF)
MQPJZ&,:BH<Z:0;#6I1"N-O3Y^BK3-(X8RB(M/'.&SLS<^1E1,VQN)QMV5@75
MMR)C*0E+C: HE5DV%_4/(#A;A47I'#'BFEIXY\$?AW-\;RC*S\;,(PF/<6OY
MNA)CH?U)0HINXI5CQ(MX_!5K=->&,JQU6XYPU^W*L@K=FZCE4(1D=3(DAJ_3
M*P5@E-^-C:XJ=N.F,(UYZIRVL)N;-R]A9O-2)6O)PURDQW^FV-(:0DI]4)"3
M8GQ%1:D=40FMIZ9E\8IKN#N?#1LRWG&\65LI,:,B.ASK*2+%QU9 TZU#59*2
M #RI/16<8(ZK1G+=V_O=]W9L_/9IL>V8IQV-(#?JAQUL)TV'(:BM*3Z:K;7^
M[$>*:W_;F6MCHG<7,8]K/_/;,-^0@/Q<3[,A3'34+I2M9]87!])'\$S-(G&$
M1%YC.6_V\SV8S\7*OYE0$AB<ME# 2E(92$@]/U0"=)-KJN:C96(QA;7:9SE;
M9;;[T5]J*][-)<;6EF1I#G3<4DA*]*N"M)XV/.LH:2YIV\AY=K.;AD/9>\2)
MD9"<DR8[:1*<'4'5U7NWZWK:4\/"NC9,8C@PUQ.9XMS%S=W;Z]HR>,R@P6!;
M=4U"2AA#[SVCZM>LBW/P/H]-1,5IPF,RF)M;C$XA([:S^:8STG:&YUH?R#37
MM,*>TD(#[-[<4@ !7P>1^$UM6,=4+5M.<2NE8M2@4"@4"@4"@K/<;]GN[?R-
MD?P5RM^W_LKZ8_%EM]B?1+^5E?H#\_>Q?<?_ +/WK]FQW\V37S7SGG3[_P G
MTWR?V+>EZTKYU[Y0*!0<SDY+'XKNQ(E9*2W%CG')1U75!"=1TV%SX\*Z8B9U
M\'/,Q%^*W?GKM+_QJ'_]^3_QUE[NWD:]=?*VW?FS<^&D,,/HDX^:VXP7FB%I
MX@I)!'BD_3JO&LIX6ARK!.3MP3,#LB<@Z=O2'W<H#<A28BM+(^#CH^.NJV(S
M;RN>N9Q7R)WN?!C_ #GM_+Y-MQS!,N+CY!394"VETITJNCB/'EY6K/5/"8CF
MMMCC$SR:V<Q';+$XHY#J*G!P ,1F)SBUO%1M8 +/#S)JU;7F<(M%(AFW7'9B
MX39C$>,N&RG(Q2B*ZHJ<;"@5:5$^(OQJ*3QE-^4.ENMMO-K9=2%M.)*%H/$%
M*A8@_"*YW0XF&YFK]5)*[#+:BNW_ .KK=?\ _N5U\/;\SDX^QYW;6VT-(2TV
MD);0 E"1P  %@!7(ZU*[IQ)+^VFI<9OJG&S&9KJ +W;;"TGAY#7<^BM=4\66
MV."4E;WVZSA%YMJ>RZT&RMID.)ZJG--PWHO<*OP(MPJL:YSA,WC&51W)N;+Y
M%C;$:4ZO;D'-ZESI"'/70@$!*0X0G3J20HW'#4+\ :UK6(SXX9VM,X\,HK>^
M$V5A\&\8LI>2S[VD15.R52'4@*!6LI00 -(/$BK:[6F?,K>M8CSI?=*@K;VQ
M%)-TF7CR"/$%H56G.RUN55KW_P#X-S']7/\ .%9:_:AIL]F50W$T^SLO9><;
M;+K&'^;Y,E"1J(:#2"56\K@#XZUK[4QY6=O9B?(MV7WQ@,=A'<Q'FL2SH)BL
M(<!6ZX1ZJ;"ZAQ^5PX5E77,SAI-XB,J1N]IJ9F=L;BW/$<BXB9&]GFH0XO\
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M:JU]FRUO:ADA?M;R/Y(3_2LU$_UQZ4Q[?W+Y6#8H% H% H% H% H% H% H%
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MJ,B&VTE,1" RA@ : VD:0FW*UN%J9,(J/L_:\24)L?$QFY*3J2L-CU5>:0>
M/P"K3>WE5Z*^1*R8L::PN+,90_&<%G&G4A:%#T@W%5B<+3&49 VEMK&21,@8
MN.S*3\AT(!4G^23>WQ5:;VGQ5BD1X-^3CH,UZ/(EQVWGHBNI&<6D*4VOAQ23
MR/ 56)F%IB);50EBDQF);#D64VEV.ZDH=:6+I4D\P1Y5,3A$QEB^;H'L(QAC
M-*QP0&A%4@*:T#DG21:U,SG)B,81T/9^U\?)3+AXJ.U)0=2' @$I/FF]['X*
MM-[3XJQ2(\$W5%VM-@0LE'5$R$=N3&7\IIU(6DD<C8^(J8F8Y(F,H^/M+;46
M,_#8Q49,:3I]H1TP=80H*2%$W) (N!5NNWE5Z(\C>DXS'RU1E2HS;RH:TNQ2
MM(/36FUE)OR(M58F86F(9)<.+/C.1)K*'XKH <9<&I*@#<7!](I$X)C+"_B<
M9):C,2(C3C,-25Q4*2"&E-BR2D>! Y5/5)B&2=CX.3CJB9&.W*C*XEIU(6FX
MY&Q\1YU$3,<B8B7/]\;4C0X>(:VWB;6R+3LGV1E2U!"0?664@G2/3PK?7?.<
MRQO3EB%^R&,Q^6CF)DHS<J.3?INI"@"/$7Y'TBL(F8Y-IB)YM)C:FVXT54-G
M%QTQEJ2XMOI@ZEHXI))XFWAY5;KGRHZ(\B2DQ8TUA<68RA^,X+.-.I"T*'I!
MN*K$X3,91D#:6VL9)$R!BX[,I/R'0@%2?Y)-[?%5IO:?%6*1'@WI^-Q^4:0Q
MD8S<IEM8=0AU(4 XD$!0!\0":K$S'):8B>;;J$E!IN8O'.Y!K*N16UY)A);9
ME%(+J$'4" KF!ZROHU;,XPC$9RVG&T.H4TXD*;6"E:3Q!!%B#4)884*)CHR(
M<!E$>(W?ILM@)0G42HV \R2:3.41&'S&QT&$](D1([;+TM74DN(2$J<7QXJ(
MYGB:3,R1$0T<CM3;F6?,K(XQA^2?E.J0 L_"18GXZM%YCE*LTB4C$AQ(#"(L
M%AN/&;^0TTD(0/@ L*K,Y6B,/B!CH.+CB+CH[<6,"5!II(2FZN9L*3,SS(B(
MY,63PF(S2$MY6$U+2CY!=0%*3?R/,?%4Q:8Y(FL3S?F+P>(PJ%-XJ$U$2OY9
M:2 I7PJYFWII-IGF16(Y)"JK-5>.@N3FLDY';5/926VI)2"XE"KW /@#<U.9
MQA&(SEJY/;F!S*TNY3'L2GDC2EU:!KL/#4+&WHO4Q:8Y(FL3S;&.Q6-Q#'LV
M,BM1&+W*&DA-SYDCB3Z329F>:8B(Y-RJI0L_:6VLI(,N?BX[TE7%;I0 I1\U
M%-K_ !U>+VCQ4FD3X)!K'0(\,XYB,TU!*2V8R$!+>E0L1I'#CXU7,YRMB.2)
MSK.4Q& Z>T(C/6BD%$$H&A31)UI2D%/'CJJ]<3/[E;9B."FR,QBWF)#>!V9*
M8W/*:4R"J"AI++CJ2@J4YX <>-A?QM6L5GQG@RS'A'%;]N[99@;2A[<RS3<I
M"$7DM+&MLK4X7B./,)4>'P5E:^;9AK6N*XE8$M-):#"4 ,A.@('() M;Z%47
M:;>&Q+6/5B6X;2,8NX5$" &B%&Y]7EQ-3U3G*O3&,/J1B,7+@MXR3$:=Q[00
MEN,M(+:0V+) 3RX#E2+3$Y3B,8?4O&8^>TTQ-C-R&6%I=90XD*"%H!"5"_(@
M&HB9@F(EDEPXD]A<6:PB1&<X+:=2%H/P@W%(G!,9:&,VQM_#O&1C,<Q&D$6Z
MJ$^N >8"C<B_HJTWF>:(K$<G[E-MX'-.)>RF/9E/(&E+JT^OI\M0L;>BD6F.
M1-8GF^D[>P2&HS*,='0U#7UHJ4MI ;<X>NFPX*X#C4=4G3#9^;H/MWSG[.W\
MX]/H^TZ1U.G>^G5SM>HS.,)Q&<DK'09RX[LR.V^Y%<#T93B0HMN)((4F_(BU
M(F8)B)8LIA,3FVT-9:&U+0V26^JD$I)M?2>8O;C:IBTQR1-8GFW&6FV&FV&4
MA#+20AM"> 2E(L /@%0LQRX<2>PN+-81(C.<%M.I"T'X0;BD3A$QEH8S;&W\
M.\9&,QS$:01;JH3ZX!Y@*-R+^BK3>9YHBL1R;61Q6-R['LV3BM2V+W"'4A5C
MY@GB#Z141,QR3,1/-@Q>W<'A5+7BH#,5Q8LMQM UD>6HW-O12;3/-$5B.395
MCH*YR,FJ.V<@VWT422D=0-W)TA7.UR:C,XPG$9R1\=!B2),J+';:DS"E4IU"
M0%.%-[%1\;7-)F9(B&U4)1V4P.&S73.5@LRRU?IJ=2"I-^8!YV-N56BTQR5F
ML3S9)V)QF3BB%D(C4F*FVEMU(4$V%@1?D?2*1,QR3,1+#B]O8/"E2L5 9BK6
M++6V@!9'D5'C;T4FTSS1%8CDDZJL^'6FGVU,OH2ZRL%*VU@*2H'F"#P-2(B%
MM+;..E";"Q4=F4DZD.I0+I/FF]]/Q5:;VGQ4BD1X)*9"AY".J+.8;DQE_*:=
M2%I/Q&]5B<+3&4?C=K;=Q#_M.-QK$>3:P>2BZP#SL3<B_HJTWF><HBL1R;S^
M.@R94><_';<F1=7LSZD@K;U<#I/A>JYE.($XZ"B<O)ICMC(.-]%<D)'4+=P=
M)5SM<"F9Q@Q&<MJH24"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@\<>]O^U+8?
MV%K\-KZ7Y7_3?[>#P/F7]VOT_G#V/7S3WR@4"@Q/QV)3*X\EI+T=P:7&G$A2
M%)/@0>!J<B+@;3VWBY EP,7'8DCY+J4 J3_))O;XJM-YGG*D4B/!L-X'#-0'
M<6W!93CGU:WHH0 VI1L;E/+P%1U3G*>F,8;S33;#2&&4A#+20AM"18)2D6
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M3B,Y99$>/+97&E-(?CN#2XTXD+0H>1!N#2)P814+:.V<=)3,A8J.S*0;H="
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M)?M H% H% H% H% H-1>3QK2U-N3&$.)-E(4Z@$$>!!-3B49A\_.^*^[H_\
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M;U2M)GBO:\1P?N!WEA]P2'8,</1,DR-3D&8WT7PGS";D'XC2U)@K>);>$W#
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M=*0A-]1.JUK6-[UG-9B<-(F)C*KGN?@=*I#</(NXM"M*LHB*3%'&URHJ!_\
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MXKKDH2-)2?E#SK2\3-^#.LQT<4K&RN]IN/0SC-MQ<9B^CH9.0D:DAG2 -3:
M% 6\"*K,5B>,K9M,<(1&SL.WG^ULG$NR!&2^\YI?5\E*FW$+3?B.%T\:O>V+
MY4I&:89Y&1WS@L8N!N7!,9K!-,]-]^*NRBR@6)4GB; "_P#LT_#48K,YB<2G
M-HCC&82.4QD3>&U,/*VR^C'^S.HDXMMX:6PXT5(Z2AQXA0MPORJL3-;3E:8Z
MJQA&97<.X(,4,=PMM-3<.EQ!5,BJ"VTJ!LE13=7&YMQ*:M%8GV9XJS:8]J'2
MX[S4B.U(CJU,.H2XTKS0H @_0KGEO#+4)4_?&1PL%[$^V8U>6S1?*L1";4I)
MZJ2DE1(X6!T\P?X:VUQ,YXXAE>8C"M[WG;UG;5GJRN(AXW%@-J>ZC_7D?[5&
MG1H]4'5;G5]<5BW"5+S:8XPS[S_P7M'^MX[\'72GM3]Y?V82.=_:?M7^KR_Z
M%VJU]B5K>W#%V[2F1G-VY&0-61.06PI1^4AI"E:4B_$#A;XA3;RB$:^<OG?*
M$1=X[.G10$3WI9CNK3P4M@J;2H'S "U?1IK]F2_M0QKF(VCOO...^K!RF/.2
M;3X%Z*DE0^$V6?CJ<=58,]-I06V8SFV\KM;.RE:1N&/(;GNG@"IY9>;)^$*1
M]"KVGJB8\BE?VS$^5,[90J?MS=NZG1Z^:]K4S<<1'8;6E ^(E0^*J7X3$>1:
MO&)GRHN?^Q2+_H?A1J\?V*S_ %NBOPXS6U'8*&TB*B IL-V&G2&2+6KGS^YO
MC]KELMQ?ZH< TI13&?G]*41_S/7D*X_ 4IKIC^R7//L0Z]-@P5XE_'O-H3CN
M@II36D:$M!-K >@<JY8F<Y=4Q&%7[4?X*A?9'_Z55:;O:9ZO97:L6KD&T7WX
M_:;..QB0Z%20%#F IMM*B/@!-==_[(<M/8E>]A1H\;9^(3&2 ER.EUPCQ<<]
M99/IN:PV3^Z6VN/VPK6!0F'OS>,"$ C'JCH?6A/R ^IM*CP'+BM=:6XUB5*\
M+2WNTD9EK9S+R$ .2'GENJMQ4I*] O\  $BHW3^Y.J/VKW6#90X7[6\C^2$_
MTK-;S_7'I8Q[?W,>%CLN=U=RR%H"GF8T8-*(N4ZV6@2/(D"U+3^R"OMR^MSH
M0GN+M%Y( =6F2A2QS*4H-@?1ZQ^C2GL26]N$,V[GE]R<_*Q4*/-F16VF6TRG
M.GTFE(3Q;^'Q^'TU?AT1E3CUSAMYS&[WS<_#RI<"#"?QTI#S+[<FZRFX*D '
MF#8<*BLUB)3:+3,.F5S.ASYU(E=W&D2QJ1$QO4A)5R"RKBH ^/K*XUT<M?WL
M/^;\[NQHZ\)CI2TCVEJ>TAI?#5I<2O4GX#I!^*HTSQ-T<&EN]63>[DX9F!&9
MF/1H2I$2-*7H:+A4[J5?^, D$?!5J8Z)1?/7#)NJ%OG<>(<QT[%8^.WK0XW)
M$GUFUI4+$:N%R+I^.HI-:SG):+3')M;[A3H^!P^Y;!>8P"V'WR#<+2K2'1?Q
M!4!\5ZC7,9F/"4WB<1/D?.4D,[OWE@<9&/4Q6/93F91\%*< +(/A?BD_ HU,
M1TUF?N)_=:(1V1<S3G=.8O&0V)TN%!;$5J6YTTH;4$%2T'S!6H?&:F,='%$Y
MZ^#+NG';[W Q#3(QT"'(AR$2(LI$GUTK2#ZHU>? _%2DUCQ+1:4GE?VJX+\G
MO_\ 2U6/8E:?;AB[=I3(SF[<C(&K(G(+84H_*0TA2M*1?B!PM\0IMY1"-?.7
MSOE"(N\=G3HH")[TLQW5IX*6P5-I4#Y@!:OHTU^S)?VH9<+%C.]TMS2G$A4F
M.Q%#%^8#C#861] #XZ6G]D)K'[Y?._4H8W+LZ:P F>J>F/J'!2F%K0%@V\!J
M^G37[,FSG#\8CLO]WI;CJ I4?%I=9) .E>IM%Q\2B*9_\?WF/W_<;CBQY'<[
M:P>;"QT7U&XOQ90XXCZ"A>E9_9*+1^^&3N$E/SOLU=O7&692%>("G&[CX[4U
M\I]"=G./2B,BYFG.Z<Q>,AL3I<*"V(K4MSII0VH(*EH/F"M0^,U:,='%6<]?
M!EW3CM][@8AID8Z!#D0Y")$64B3ZZ5I!]4:O/@?BI2:QXEHM+?S<=F1W5V\'
MDA:6X3KJ0>(UHZI2?B/$>FJUG]DK6]N'UW40CYNPCUOKJ,M'2A?B I#A('PE
M(IIYSZ#;RCTOK>G^,=D_UB5_ S2GLV+^U"^5@V*!0*!0*#QQ[V_[4MA_86OP
MVOI?E?\ 3?[>#P/F7]VOT_G#V/7S3WR@4"@KN]I>"A[>D.;B95)QQ*4^S(*D
MJ=<O="04E/B+\_"M-<3,\%+S$1Q02\IOB=C%M1=N1,7C"PI ]OD:]+(1;BVV
M$J'#P(J^*Q/-3-ICDJ76?:[+(#1(2Y)+;I'\0R";? 2!6O\ \C+_ .-U^)!@
MHQ36.90DX_H!E* +)4T4VY>D5RS,YRZHB,8<]W]&PD3MT(VWEMKQ3<EOI%EX
MR$ J45* 65+\3YUOKF9OQ8;,=/!)]V?\.1?RA'_@75=/-;;R?G<5I6,?PV\X
MZ;N8B2EN7IYJBOG2K^'2/Y5-7'-?*;.&)?,A2-T=Q(C#9ZF,VXP)2U#BA4I^
MQ1Z. TJ'\DT]FGI/:OZ";FH\?=D]K:N 5EMR!M",G,+W1:;38625+NGD!RM\
M=J17]O&<03;]W".*&RCNXW][;2>W#%B1'%/.AAJ*M3C@2-.KJ*/"W'U=/IJ\
M8Z9PI.>J,IS*_M5P7Y/?_P"EJD>Q*\^W!-_:WCOR0K^E>I']<^DGV_N8NV24
MR).Y<E(%\D]DG&WE'Y00GU@D>0N3P]%3M\(1J\9?.[T)B;^VC,A@)G27'6))
M3S4P-"1J\^"UTIQI)?VH?>V([*^X^[)*D@O-)CH;41Q <0"JWPZ12_L05]N7
MWFT(3W2VPXD +7&E)6H<R$M.D _!>HK[$IM[<+[6#9S['H3+[MY=4H:UP8+0
M@A7U*5I:*E)^-:A\=;S_ %PQCVY?O=UMI&W(^039$^)+:5$>'!:5&]P#\5[>
MBFGF;N3'NU2U;WV4IP:5E3A4GR)T7%33V;(O[4.B5SMU#[A?VKL[\KL?ST5O
MKY3Z&.SG'I8^X<=F5G=G1Y" XPY/(<;4+I4G4U<$>(--<\)-G.&]W2:;7L;(
MJ4D$M&.IL_Q5==M-Q\2B*C5[2=OLJWO)4Z1D=D1&&6Y14WUFX\A6EEUY*&R
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M-M)*T.J1Y76CS\:I6D1?"]K3-,M.)B-LST1W]A[C7%SR%I4!)D+NZ+^L%M+
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M )( \/#AYFNG7'[<QS<]Y_=B>22VQB(L;,MSMI9Q,K;BVU";C5OE]25F^E2
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M#:4I6+6M:XY<*M.9B.E6,1,]3<@RTR^X^%GQL8O&X1<=Z/ *F0P'-*'%%>D
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M2D6-N0]'HK:.J(GJY,9Q,QT\U@WAD6MO[\PF?R#;OS6B(ZPIYM&L!Q6L6_\
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M?)_8MZ7K2OG7OE H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M:5\Z]\H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!XX]
M[?\ :EL/["U^&U]+\K_IO]O!X'S+^[7Z?SA['KYI[Y0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"L]QOV>[M_(V1_!7*W[?^ROIC\66
MWV)]$OY65^@/S][%]Q_^S]Z_9L=_-DU\U\YYT^_\GTWR?V+>EZTKYU[Y0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#QQ[V_[4MA_86O
MPVOI?E?]-_MX/ ^9?W:_3^</8]?-/?*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!05GN-^SW=OY&R/X*Y6_;_P!E?3'XLMOL3Z)?RLK]
M ?G[V+[C_P#9^]?LV._FR:^:^<\Z??\ D^F^3^Q;TO6E?.O?*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0>./>W_:EL/["U^&U]+\K_
M *;_ &\'@?,O[M?I_.'L>OFGOE H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MD^0J,)RUD9K#NRS ;R$9<X$@Q4O-EX$<QH"K_2J>F3J@=S6'8E""_D(S4U1
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MHS28QR3O<IA3N*VS&9EK6M<^.VW.2H:U%2" Z%)X7/RKBJ:N<K[.4-?N#M/
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M H*)N?$9.9OG;61C1ENP8E_:7TCU4>L3QK>DQ%9AC:)ZH7:2E2XSR$BZE(4
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MR%2W4_);2L-6*OAL:4F(K)>)F8:>5QV=VYNJ1NK"0U93'Y)M+>2@MD)>2ML
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MN--C?Z-3-<1$HBV9F$S5%R@4"@4"@4"@C\CF<?BWH4:8[ID9!X1XC8!45K)
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M'Y^]B^X__9^]?LV._FR:^:^<\Z??^3Z;Y/[%O2]:5\Z]\H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M"E)/"XX&W^6K6M'_ "CBK6)_XSP8ME0I,3N%GD29AR,IN*V)DP@)!?<+:BD
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MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!XX][?]J6P
M_L+7X;7TORO^F_V\'@?,O[M?I_.'L>OFGOE H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H*SW&_9[NW\C9'\%<K?M_P"ROIC\66WV)]$O
MY65^@/S][%]Q_P#L_>OV;'?S9-?-?.>=/O\ R?3?)_8MZ7K2OG7OE H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H/''O;_M2V']A:_#:^
ME^5_TW^W@\#YE_=K]/YP]CU\T]\H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MKH\_J/WR>TWW+F?O5C\8I])W>;U_H?5='G]1^^3VF^Y<S]ZL?C%/I.[S>O\
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3!0*!0*!0*!0*!0*!0*!0*#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2227887d1-pht_tumor4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-pht_tumor4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#C6AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXP+6,P,# @-SDN9&%B86-B8BP@,C R,2\P-"\Q-"TP,#HS.3HT
M-" @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#TB>&UP+F1I9#HU-C8S.65F,2UE-#$S+31B,V$M.#<W9BUB
M,F9E.&0S,C$S93(B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z,D4S.#$S
M13(X.$1!,3%%1$%$-D(Y-$%"1C-#,S1".$$B('AM<$U-.DEN<W1A;F-E240]
M(GAM<"YI:60Z,D4S.#$S13$X.$1!,3%%1$%$-D(Y-$%"1C-#,S1".$$B('AM
M<#I#<F5A=&]R5&]O;#TB061O8F4@4&AO=&]S:&]P(#(R+C4@*$UA8VEN=&]S
M:"DB/B \>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS=&%N8V5)1#TB>&UP
M+FEI9#HP8S(P-V$P."UA83-F+30U,#8M.&%E.2TQ.3@U93@R961C93 B('-T
M4F5F.F1O8W5M96YT240](F%D;V)E.F1O8VED.G!H;W1O<VAO<#IC83(Q8V-F
M,2TR-C0S+3-D-#$M839B."UF969F-S(V-#8W-64B+SX@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0]
M(G(B/S[_[@ .061O8F4 9,     !_]L A  $ P,# P,$ P,$!@0#! 8'!00$
M!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,$1$1$1$4%!04%!04%!04
M 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!3_P  1" +^!VP# 1$  A$! Q$!_\0 Z@ !
M  (" P$!              4&! <" P@!"0$!  (# 0$!              0%
M @,& 0<($  !! $"! ($!PH+! 4( !<!  (#! 41!B$Q$@=!$U%A(A1Q@3)2
MTQ96D4*2(Y05E1<(&*&QP=%BTC-TA3=(<H*S)+)#<S2THE/#A"4U=39V\.'Q
M1,*#DU1E)E<XXF.C9"?4156U1A$  @$" P0$"P0(!0,$ @$%  $"$0,A$@0Q
M05$%87&1$_"!H;'1(C)3%!4&P4)2DN%R@M(SDS06\6(C@T2RPD6B<S4'0R3B
MLS;#\E3_V@ , P$  A$#$0 _ /?R ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" KVZMY;
M>V72CO[AMBM#*_RX6AIDE>[G[+&:DZ>)\%(L:>Y>=(*I7:_F.GT4%.]+*GAX
M+:2.(RM+-XRIE\<\R4;D39ZSW-+"8W\0>EPU"U3@X2<7M1*L7X7[<;D'6,E5
M=3)!8&\( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" PLCD:&)IS9#)68ZE* =4T\S@QC6CTD^E9
MP@Y.B56:;MZ%J#G-J,5M;-?M[]=LW6_=/SG(!U= L&O*(===->KIY>O16/RO
M44KE\J.97U7RUSR]YX\LJ>;]!L6K;JWJT-RE,RQ5L,;+!-$0YCV.&H((U!!"
MK91<71X-'46[D;D5*+3354UL9D+$V! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! 8.3RN.PM*7(Y6U'3H0#66>=P8P>CX=5G"$
MIND55FB]?MV8.=R2C%;V:_9W\[9OM>Z_G*5HZND3NK3"+GIKKTZZ>O167RO4
M4KE\IS*^K.6N67/X\LJ>8V+3N5<C5AO49F6:=A@EAGC(<Q['\001P.H59*+B
MZ/!G4V[D;D5*+3B\4T9*Q-@0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! 4G];O;7[25/PG?S*=\#?_  ,H_GN@]]#M/OZW>VOVDI_A._JI
M\#?_  ,?/M![Z':/UN]M?M+3_"=_53X"_P#@8^?:#WT.T^?K=[:_:6G]UW\R
M? 7_ ,#'S[0>^AVC];O;7[2U/PG?U4^ O_@9[\^T'OH=H_6[VU^TM3\)W]5/
M@+_X&/GV@]]#M'ZW>VOVDJ?A._F3X&_^!GGS[0>^AVC];O;7[2U/PG?U4^ O
M_@9[\^T'OH=H_6[VU^TM3\)W]5/@+_X&/GV@]]#M'ZW.VOVDJ?A._F3X&_\
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M)\#?_ SSY]H/?0[3Y^MSMM]I:?W7?S)\#?\ P,?/M![Z':/UN]MOM+3^Z_\
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MD_H+/ZD?,BVJ&7)#Y3<^ PD\=7+7XJEB1GF1QR'1SF:Z:C0'Q6ZW8N358JI
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M\#/?GV@]]#M/GZW>VOVDJ?A._F3X&_\ @9Y\]T'OH=I]_6[VU^TM/\)W\R?
MW_P,?/M![Z':?/UN=MOM+3^Z[^9/@;_X&/GV@]]#M'ZW>VOVEI_==_,GP%_\
M#'S[0>^AVC];O;7[2U/PG?U4^ O_ (&>_/M![Z':/UN]M?M+4_"=_53X"_\
M@8^?:#WT.T?K=[:_:2I^$[^9/@;_ .!GGS[0>^AVC];O;7[2U/PG?U4^ O\
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M3^Z[^9/@;_X&/GV@]]#M.ROW4[>VY1!7W#4DE<"0P%VI#?B7CT-];8,]7/-
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MSY]H/?0[1^MWMK]I:?X3OYE[\#?_  ,?/M![Z':/UN]M?M)3_"=_57GP-_\
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M(=9)'.>\^ESCJ5=I45#A)2<FV]K.M>F 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $![2[,?Y8[=_["3_CR+@>8_P!1/K/T
M7].__'6?U?M9K/\ :AY[8_\ 7?\ T*M^1_?\7VG&?7OLV?VO^T\\KISY.$ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!S8]\<C96'I>PAS#Z"#J%X
MU5&:DTZK<;8Q61BRM"*ZS0%XTE9\V0?*"I;D'"5#N=/?5ZVIKQ]9NCMQO2">
MK#MW*2B.[  RC*\Z":,<F:G[]O+UA4.LTS3SQV;^@^@\DYI&458N.DE[/2N'
M6O*;+54=<$ 0&L^Y&]((:LNW<7*'W)O8ORL.HAC/-FH^_=R]05KHM,V\\MFX
MY#G?-(QB[%M^L_:Z%PZWY#3&5R,>*H2W'Z:L&D3/G2'Y(_G5];@YRH?/]1>5
MFVY/Q=9J=[W2.=(\ZO>2YQ]))U*NJ'#.3;;>\X+TP" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MCEJ/ #T*TL6<N+VG*:_7=[ZD?9\Y6E+*4( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (#TA^R_P#^[MR?WBK_ ,.1
M<ISOVX]3/L'T)_ N_K+S&S^Z?^76YO[A-_T54:+^/#K1V7._Z"]^I+S'B!?0
MC\VA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MV5L^TAE(*P( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MMJTH+I.2U6KE?E79%;%Z?#H(=2"L" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M(R^?=E=*_P"]#C[+1Z&MY ? I<8*."*:]>G==9.K\-B,1;".$ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MW_XZS^K]K-9_M0<]L?\ KO\ Z%6_(]L_%]IQGU[[-GKG_P!IYY74'R<( @"
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MER[-2=4MG:6OU'RS3:?1V9VH*,I4J\?PE6[?9+MSCAD/K_C)LCU>7[AY ?[
M'5UZ],D?/4<U-UD-1*G=.G$HN2:CEUI3^+@YO#+3_%&X<]A.Q^WMM8O=-[;<
MAQV7\OW5L;IW2CS8S(.IIG&F@'I5%:N:RY<E;4\8^' [_5Z?DNFTT-1.SZER
ME-M<57'UN!H'=<^W[6X+MG:E9U7 /<SW*O*#U, 8T.UZG.^^UYN73:=7%;2N
M.LMY\KYE.Q/42EIUEMX95PP77OX\39?:79.T[6W,KO+?E9LN'CGCJ4Q(^1C6
MNZ@U[_8<TG5[VL&OK51S#4W5<5NT\:5.S^G.5Z66GGJ=7%9*J*K_ (\73Q%7
M[O;-@V9O&:ECXC#AKD3;6/8"2&-<.F1@))UZ7-/Q%3.7:EWK57[2P92?4O+(
MZ+5N,%2$EFCT<5XJ=C,?M]DNWF.?D#O_ !LN1C>V+\WB /U86E_F:]+X^8+>
M>JSUD+\J=TZ<33R2_P OM.?QD,ZPRT\==ZZ#<><PG8_ ;7QF[+NVY#B\N8Q5
M;&Z=TH\V,R#J:9]!P'I5#:N:RY<=M3QCX<#Z%JM/R73Z:&HG9]2Y2FVN*K^+
M@:#W=9VY;W!<GVG6?3P#_+]TKR]0<TA@#M>ISC\K7F5TNFC<C;2N.LCY=S2Y
MIKFHD],LMMTHO!OI-A[AV=MJCV3PFZZU!L>?M/@%BX'R%S@]SPX%I<6\0!]Z
MJJSJ+DM9*VWZN)UVNY9IK?);=^,$KCRU>/2:ZVIMN_NW/4MOXX-;8MN(=*\$
MMBC:-7R.T\&@'^)6VHOQLP<WN..Y9H)ZV_&S#;+?P6]^+]!N3+T>QG;F=NW\
MQC[&?S48;[],.J1T9>/OM)(V-X<0QNI 5#;EK-2L\6H1W>'VGT/4VN2<L:LW
M(.[/#-OIUXI+J6)#[V[;;4O[2?W![;3.=BHP77<<]SG^6P'1Y9UZN:YFOM,<
M3PXCU[]+K;L;O<WMNYE?S;D6EN:1ZS0OU5MCT;Z5V-;T]VPU?MBI!?W'AJ-J
M,2U+5ZM!8C)X.CDE:UPU!U&H5Q?DXVY-;4GYCBN7VU<U-J$E6,IQ3\<D;K[P
M]F\7BL.-Q;+I^[-H _G.BQ[Y.J#77S6]9<=6??#T<?!<_P NYC*4\EQUKL9]
M&^I?IJW;L]]I8Y<GM1XKCXO-U%:V1M';F5[2[HW'?HMGS6/-@4K9?('1^7"Q
MS?9:[IX$Z\0I>JU%R.JA!/U72J\93<IY?I[O*;]Z<4YPS4?#U4_.:A\%>GS\
M( @" ( @" ( @" ( @" ( @" (#?7[-__=-Y_P!WJ_\ 1L+F^=;;?6_L/J'T
M+LU'5#_O-"M^2/@72'S!F^/V9RT7]S&0$L%:OU >CJD7-\[]F'6SZ;]">W>K
M^&/VEPV"WM=D(,GNC8FVR<_A/,Z:4KW-L%[FGI,?F22-;YFCFAWQ*!J_B8M0
MNS]66_<='RCY;=C._I+/^I:KZNR7BQ:6;%+L/.FZ]Q7MU[@O;@R+!%9MOU,+
M=>F)K!T,C&O'V0--=.:ZG3V8VK:@MB/DO,M;/6:B5Z:HY/9PW)>+SF\NP.V+
M]/:F;W33C9^>,FV2KBC*2UG3 #HXD \'2'_R5SW-K\978P?LQV^'4?2?H_07
M+>DN7XKU[E5&NS#_ /EYB?[>]M=RX?;NX]K;OEJVL7F@Y\3X)'O>V:=I;*2'
M-;IJ0QPT\0HVKUEN<X3MU3C]FPM.3\EU-FQ>L:EQE"YLHW6KPEN712F^IY=R
M>/M8J_;Q=UI9;IS25YP>'MQ.+3_%P77VYJ<5);&?%M38E9N2MRVQ;3\1Z5&X
M\9M;LIM?)9;"Q9VJ6UXO<IRQK0]WF$2>VR0:C3AP7)NS*[JYQC+*\<3[%'66
MM+R:S.Y;5V-(^JZ=N*>PU7O7N5MC<V"EQ&+VA7PMQ\C)!>B,1>T1DDM]B)A]
MH'3FKG2Z*[:FI2FY+AX,XCFO/=+JM.[=NPK<JKUL/L2VG;^SY_F35_NEK_H!
M><W_ *?QHR^B_P#Y#]F1=-V=V-HXC<^7QES8M6_;J6GQ377/AZIG-('608"=
M3\)5?I]!=G;C)7&DULQ])TG,?J'1V-3<MSTT92B\7ZN/3[/I-)[IRU3.Y^_F
M*%)F-J6WM?#1B+2V(!@86CI:T:<-> "Z#3VW;@HMU:WGSCF6IAJ-1.[".2,J
M4CAAA3<;CW/_ /HW[?\ ^TK_ /%E5#I_Z^7C^P^A\R__ +>M?L_:5/L%D*=#
MN+69:<UCKE:>M7<> \U_2]H&OI#"WXU.YM!RL.FYHY_Z.O0MZ]*7WHR2Z\']
MA$]W,%E<+OO,RY.*3R;]A]JE:>TEDL4O$=+@--6_)(\-%NY?=C.S%1W+$@_4
MFCNV-;<E<K2;K%O>GPZMA W=H[EQF&K;AR&+GKX:Z=(+;VZ-XZ@=0UZF]6G#
MJ ZAR4F.HMRFX*2<EN*N[RS4VK*O3@XPEL?IWKLQ6PO_ .SE_F%)_P##K'_$
MB5;SG^ NM?:=/]#_ -?+_P!N7GB;1W!)B.Z. W)L;:=AV-RN$MO+ZATABM/C
MD<YW4!Q,;Y"[4^#]''UT]K-I9PNW%5279^FAVVK=KFUB]I=/+).U)X;%)UQ\
M3E7'CCU^6K-:Q3LS4K<;H;5=[HIX7C1[)&'I<UWHT(78QDI*JV,^*7+<H2<)
M*C6#Z&L'V&\.U_\ DGOO_P!:_P#",7/Z[^LM>+SGT3D/_P +JOV_^A&F-O\
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M $ 0! $ 0! $ 0'WQ'PC^,(>&]OVD_[3:?\ =;'_ *)<YR7[_6OM/I_US_\
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M.M9&HVQV VS^>][#+3,ZJ>#C]Y^&Q)[$7W/:=\2I.;7\EG*MLO,=Y]&Z'O\
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MJB?:2]1RV&BY?JE;?J34I17!..SR8=!Y+7;'PD( @" ( @" ( @" ( @" (
M@" ("Z[$[BY'8464CH4X;@RS(XYC.7M+!%UC5O1Z?,5=J]%'4.-73+X?8=/R
M7GD^7*YEBI=Y2M:X4K^\4OD .8'(JP.9+EL+N)D.W\N1EQ]."X[(QLBD$Y>
MP1EVA;T<]>I0-7HUJ$JNE#I.3<[ERUS<8J>=)=E3%V3O?*[%S;LWBV1R.FC?
M%8J2EWE2,>>H=72=06G0M*RU6EC?AE9JY3S:YR^_WL$G58QQHUZ:TH1NXLPS
M/YJYFA2BQ[KKS-+6KESHFRN'MN'5Q'4?:T]*W6;;MP4:UH0]?JHZF_*ZH*&;
M&BX[_3UEFS'='+Y/:&/V;4JQ8O&8_P KIDJ22B640CDYQ/B7=3M.94.WH(QN
MNXWF;+O5?45VYI(:>$>[C"FQNKHOTU(?;&]<YM;-U<[5LR69*I?_ ,O9EE=%
M(U[2TM>.KD0=1ZUOOZ6%V#C2E2OT'.+^EO1NYG++7!MT>%*/'LZ3IW=N-V[<
M]:W!+4BI6;8;[Q#7<\L,C6AO6.LZZN XA9::SW5M0K5(T\TURUFH=[+D<MJ3
M>W97QK:OM)?+]Q\EE]CX[8LU*".ACC$Z*TPO,S_*ZM.H'AQZEHMZ*,+SNUQ>
MXL-3SV=[0PTC@DHTQWX%)5D<L639.[[FQ\]'GZ->.U8CBDA$4Q<&=,H ))9Q
MX:*'JM,K\,C="[Y1S27+[_>I*6#6/21^X,S-N'-W\[8C9!8OS.L211D]+7/\
M&D^A;;-I6X*"W$37:MZJ_*\U1R=2+6\KR[Y+N-DLAL.EL&2G!'CJ3F.CMAS_
M #W>6YQXCY(^456V]%&-]W:NKW'5:GGL[N@CI,J48T];?AT%.BDEAD9-"]S)
M8B'QR1DA['-]H$$<01IKJ%/:3P9SD).+33Q6.';XGU&VL5^T+NBK193S6-IY
ME\( CM3@QR$@: N#=6D^L *DN<GMN58MQ.[T_P!::F-M1NPC<:WO#MW=E"H[
MZ[D[DW]-%^=GLAH5SU5\=6U$+'D:=9U)+G:'34\O#13M)HK>G7J[>)0<XYYJ
M.8R7>445LBMBZ>E[NC@C&V+O2[L/-OS="M%;G=7?6,<Y<&!LCFNUU9QU]G19
MZO3*_#*W3&IJY/S27+K[NQCF>5QQZUZ*'7C=XY;%[O?O+'$09&6U+:E@!/EN
M%AY<^)PUU+#KIZ?'FO;FFC.UW<ME*=F\\TW,[MG6/4PPDY2DU^L_9Z5NX[SL
MWQO#Z[909R?%U\;D'-Z+3ZKGD3@<&N=UZCJ:.&HY^/)8Z73NQ'+F;7F,^<<S
MCK[BN]VH2WT^]^E;./896WNXF1VYM+,;0K4H)JF9$GG6)'/\UGFQB+V0.'#1
M8WM&KEV-QOV?\39HN=STVCN:5035VN/6LI5:-DT;E:XP-<ZM+'.T.UT)B=UZ
M'Q\-."F3CFBUQ*2Q=[NY&:^ZT^S$LV_]_7^X.2K9/(5(:<U:#W9K("YS7-+B
M[4EWPZ<%$TFD6GBXIUJ77.N<RYC<C.45%Q5,&2N![O;BP.T+&S_(@O4)HIJ\
M,UAS_,ABG86EK>DZ$-)U&O+ER6B]RZ%RZKE6F3]%]37]-HWIVE---)M[$Z]J
M7Z#7G+AS'#@?4K4X^N)LO9_>O=6T\:S"S10YC$1-Z(8+G4)(F<-&->#Q:!R:
MX'3PX!5.IY9;O2S+U7T'9<L^J=3H[2M22N02P4MJX)/AP5.K!'?NCOKNO/XY
M^(Q\%?"8Z5ICF%/J,KV.^\ZSITC3GT@%86.56[<LTFY/I-VO^KM3J+;MP2M1
M>W+M[=WBQ-6_!R\%<G#'Q>GA>=B]S<YL6&W0JP0W\/<U=9QUP$L+M.EQ:1Q&
MH^4#J"JW5:&%]IMT:WHZGE'/[W+XR@DIPEMC+CT?;M+%!WYSN.EBCP^$Q>.P
MD8>)<3!%TQS&34=3G-Z2-/#I'PZJ*^50DO6E)RXEO#ZONV6E;M0A;7W$MOC]
M"_1K;,7ZN3R-C(5*$6+BG/F>YUW.=$Q[N)Z.OB ?!O(>"M;4'&*3>;I./U=Z
MW>N.<(*VG]U/9U?8MBW$:MY7EDV5N^WL?.Q;@HUHK5B.*2 13%S6$2CB26\5
M#U6F5^&1NA><HYI+E][OHQ4G1JG61^X,Q-N+-W\[8B9#/D)WV)(H]2QKG\PT
MGT+;9MJU!0X$/7:IZJ_.\U1S=:$6MY7ETV[W%R.W=IYK:-:I#-4S0E\^S*YX
MDC\Z(0GIT.G(>*KKVCC<NQN-XQ^QU.FT//)Z;27=,HIJ[FQ>[-'*5K$7WXC*
MT<K$QLDU*>.S'$\D-<8G!P!+>/$C13+L,\7'BJ%-I+W<7H7%CE:E3JQ)K?6]
M+N_,VS.9"K%3G; ROY4!>6EK'.<#J_T]14?2:9:>&5.N)8\XYI+F-]791R8)
M>?TDG4[GY3';%DV)C*<-2I,'>=D8WR"R]TCP]SN>@+M.GAX+1+01E>[V3KT;
MBPM_4,[6A^$MQ45^*KKB\?05S&;CS6+R-/)P7K#IJ<S+$0?-(YCG1.#@' NY
M'30J7<L0E%QHL2HT_,=1:N1GGD\KKM=,']NPE-^;WL;^RD.9NX^"C;BA\B0U
MW./FM:>II=UG74:Z</!:=)I?AXN*=42^<\V^8W%=E!0:5,,:\/#T&1L?N;N?
M83WQXN5EC&RNZYL;9!="Y_(O:0=6'0<2T\?'58ZK0V[^U4?$V\IY_J>7ND'F
M@]L7LZ^CQ=C+AD?VB=RS5):^&Q5+$V)OE6F RO!/BUK@&Z_[0*A0Y/;3K*3D
MB]O?6NHE!QMVXVY/?M_1VU-1V[=J_8ENW976+=A[I)II"72/>X\7.)X\U=QB
MHJBP2.#O79W9.<WFD\:[V6O8_<O<VPI'-Q,C)L;,[KGQUD%T)?\ /;IHYCB!
MS:>*A:K16[_M;>)?<IY]J>7ND,8/;%[.OBG3AAT%OR7[1.YIZDM7#8NEB)YM
M?,MQ RO!T^4T.T;KZW!R@PY/;3K)N1>W_K742@XVH1MM[]OZ/.:CLSSVIY;-
MJ5\UJ=SI)I9'%SGO?[1<XGB22=>*NXI)46PX.[.4Y.4G63QKQ)O:.]-P;(R#
MLC@)Q&^1H;8@D'7!,P'4"1FHUT\"-"/2H^HTT+\:3_P++EO-;^@GGLO=BMSZ
MUT=%&N-*FQ[/[1^XG0O=2PF/J9"4=+KGMO.OIZ21K\955'DT*XR;1UT_K>_1
MY;48R>\U'DLC>S%Z?)Y.=]F_:<7V+$A]I[C]P::::#30#@%=PA&$<L5@CA+]
M^=^;N7&W*6U\?#APP1F[6W#9VKN"CN&K"RQ9H.=)'#+J&.ZFENAZ>('M:K7J
M+*NVW![S?R[6RTFHA>2S.&-.WTU.>[=RV=W;@N;AN0QUK-OHZX(2XL'EL#.!
M=Q\-5YI["LVU!8T-G,]>];J)7I+*Y;NK @E**@N^T>X^2V=@\Q@:5*"Q!FFN
M;/-*7AS Z(Q'I#?4=>*K=3HHWIQFW3*=5ROGT]#8G9C!25S?XJ?I*2.&@U^3
MP"L3EF3VU-W9[9F4&4P-GR9RWRYHGCKAE9KKTR-) (U\>8\"HVHTT+\<LT6W
M+>9W]!=SV71[UM3Z'X>,V;)^TAN$QNDKX+'Q9%[2#:UD=X>CGP]'4JA<FA7&
M3H=E+ZWOT;C:BI-;<7X=IJ?.9W*[DRD^8SEEUK(6-.J0Z !O(-:W@&M:.30K
MJU:C:BHP5$</J]9=U5UW;SS2?FZ.A<"<V1W&W)L&61^%?%)3LEKK5*PT.BD<
MW@#[.CVN X:@J-JM%;U'M;5O++E7/-1RY_Z='%[8O8_M3\*%VM?M$[A=!*,5
MA,?CKLPZ77&ATC@2==0TZ G_ &M5 CR>%?6DVCH[GUM?<7W=J,)/?M-0V;,U
MR>:W:E=+:G<Z6>60DODD>XDN/W5=QBHI);$<#<NNXW*3JWB^EU+9G^XF0S^S
ML3LR>G!%1PYB,-F,O\U_DQNC'4#PX]?@H5G1JW>E<KC(OM?SN6JT=O3.*2M4
MQWND<OVD7M3>&=V3DOSI@IVQ3N9Y<T<C!)'+'J#TO:=.&HUX:%;M1IH7XY9$
M'EW-+_+[F>T\=^%4^A^"9LM_[1N=+730[?QL62+2/?#YCCRTUTX$_A*I^30V
M.;H=D_K:\TVK,%*FW'P\IJ?-YK);CRMG,Y><V,C;=US2. :!IH&AH'!K1\D#
MP5U:M1M148K!'"ZO5W-5==VXZREM^RG!;B,6\KP@" ( @" ( @" ( @/2'[+
M_P#[NW)_V];_ *#UR?._;CU'V'Z$_@7?UEYC9W=/_+K<W]PF_P"BJG1?QX=:
M.QYW_07OU)>8\0KZ$?FT( @" ( @" ( @" ( @" ( @" ( @" ^ZG^(_<7A[
M7 N6_>XF1W_^;'9"G#3.,C?%%Y!>[K$G1J7=?HZ5 TFCCIZT=<QTG.N=SYED
M<HJ/=IKKK3T#M_W#R';VW=MX^G!<?>C;$]M@O:&ACB[AT<3KKHFLT:U"2;I0
M]Y+SJ7+92E&*EG26.&PZ=K[^S.TAFVXP- SD+X9@[7\4Y_5TRL'SFAY U7M_
M1QNY:_=\O08Z#G=W1][D_P#RK\M=DEU5,K9_<C([,PN6PE*E#9@S#2)I9B]K
MV@QF+V0TZ<CKQ6&IT2OSC)NF4W<KY]+069VHP4E<XX;J%*9JPL?SZ""-?'3E
M_$K$YBKVETWSW(RF^K.,N6JL5"?$M<VLZL7DDN<UW5J_D6EO!5^ET4;"DDZJ
M1TO-^?3YA*W-QR.WLICP\U#AN+N)F-S;IQFZLA%'[UBQ7]VJL+O)_P"7?YFO
MI'6[4E+.CC:M2MI^U7RF.NYU=U>JAJ)K&WEHJX>JZ^4Q=][VN[^S,>;OU8JE
MAD#:XC@ZBTM8YSM27_[2V:32K3PRIUQ(_..:RYC>5V45%I4P\9B[4W9G-EY-
MN7P4PBL]!9-$]O7%+$=#T2-X:@G30CB/2L]1IX7XY9HT\MYE?T%SO+3HZ8K<
MUTKLH_*;+F_:.W$Z.22K@L=!D) 0;8,CCZ >DD$Z>LJH7)H;Y.AV,_K>]1N-
MJ"EQQ-297+7\YD;&6RTQM9&T[KL3NT!<[0 ?)T  TT  T 5Y;MQMQ48X)'!:
MG53U%QW+CS2EM?\ AAT<$BS[-[C9+9>(S&'I4X+,.9:6S23%X=&.AT?L]/J=
MXJ%J=%&_.,FZ92^Y3SV>@LSMQBI=YQKAA0@-MY[([5S-/-XF0QW*C@\'CTO9
MR>QX\6N'LN4J_:C=@XRV,J-!K+FDO1NVWBO*MZZMS[43&_\ ?U_N#D:V2R%2
M&G+6@]W:R N<US>HOU)=X\5HTFD6GBTG6K+#G7.I<RN1G**BXJF&.^IE]O\
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M^?3NZ".CR*D=^-<,=A2E9'*ET;W$R#>WY[>^Y0?FYS^OWSJ?YX)F\[E\GG_
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M22BI)Q<4]Z3]&[L->*U./" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M]FSUR_[3SRNH/DP0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M']LXO_SW^S]I<.T_^7&V?[E'_*H6N_CSZRZY'_06?U(^8N:AET$ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $!IS_4?_ (&KK_@_M'%_^>_V?M+AVG_RXVS_ '*/
M^50==_'GUEUR/^@L_J1\Q<U#+H( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (#3G
M^H__  -77_!_:.+_ //?[/VEP[3_ .7&V?[E'_*H.N_CSZRZY'_06?U(^8N:
MAET$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $!#;ASU;;]-L\H,EB9WEUH1P+WZ:\3X >*WV;3N.FX@ZS5QT\*O%
MO8CE@,TW.41:$?E2-<621ZZCJ&AU!T'#BO+UKNY4/=)J>_AFI0EUI)H0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MU!^XH[5,"QBTU5;SM7AD$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M,WV1W&]X8A##'"WY,;6L;\#0 /XESC=<3Z3&.5)<#M7AD$ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&G
M/]1_^!JZ_P"#^V<7_P">_P!G[2X=I_\ +C;7]RC_ )5"UW\>?677(_Z"S^I'
MS%S4(N@@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MJMYEMWGS3GO)WRV^H5S0DJQ?1P?2M_:7=6AS@0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M4WHO';3(23U;-1YU;&6R,U\ >!4'6PHTSHN27G*#B]Q?E7'2! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M'4W(NG. " ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MY%OR#8V;/52=>$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M5I!]!"DZFQW4J;F5_+]:M5!NE&MJ\WD+ HI9A $ 0! $ 0! $ 0! $ 0! $
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MU.D53B3=C?\ MB$'R[3K#AR;"QS]3ZCH%&CHKKW4+*?.--'9+-U%2SF=L;A
MFM1FCM^J?,\N3@^9XY:C^13K5I6L(^M-^0I=5JI:G&2R6HXX[9$]L/$RZ3[B
MN,+)[GL58W#0LK@\#IX=6GW%&UEQ86ULCMZRQY3IWC?DJ.>SHB7=5IT00! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&G/]1_^!JZ_X/[9Q?\ Y[_9
M^TN/:?\ RXVS_<H_Y5"UW\>?677(_P"@L_J1\Q<E"+H( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @.+G!C2XG1HU)/H XE>G
MC="'V_N&GN&O++6!9) \LEB=S U/2[X' +??L2M.CWD#1ZV&IBW'<\2:4<L
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M.2\/0@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @-.?ZC_ / U=?\
M!_:.+_\ /?[/VEQ[3_Y<;9_N4?\ *H6N_CSZRZY'_06?U(^8N2A%T$ 0! $
M0! $ 0! $ 0! $!$9W-LPE>"=U>2R^Q.RM###T];GR:Z =1 \%5<QYA'1PC)
MQ<W.2BDN+V$K3V'>;5:45<>@CQNYM>6)N6Q=S&P2O;$RS.UKH0]QT:'.8YW3
MJH'SM0DE>M3M*3IF:66O31X&_P""JGDE&36Y;2SKI"N.F::.O%)/*>F*)KGO
M//1K!J3]Q:[ER-N+D]D55^(RC%R:2WD=>SM.GA6YUH=/3>V)\?2-'.;.YK6G
M1VGSO%5VIYE;M:5:E)R@\K7'UFDMO62+>GE*[W>QX^0EU:D4( @" ( @" (
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M#$UF@#0.;>'HT7(W8RC)J6T^Q::[;NVHRM^RU@2*UDH( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M;[CJ^A'H*E4AH5(:< TBA8&-'J'#7XUS$I.3JSZE;MJW%16Q&2L3:$ 0! $
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M3>9^/=XD6)1"U" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MPMGJRME@>-6O80YI!]87-2BXNC/I,)QFJQ=4=RQ-AU.G@8\1OD:)#R:7 $_
M"=5[1F#DDZ-G:O#,( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @-.?ZC_
M / U=?\ !_;.+_\ /?[/VEQ[3_Y<;:_N4?\ *H6N_CSZRZY'_06?U(^8N2A%
MT$ 0! $ 0! $ 0! $ 0! $!#YK$/RPHALHB]RN0W':MZNH0DGIYC3755/,=
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M,F.:%Q=:J/;KULDX:_!ZDJ>=W3;XB/M8+\X9B;,N:V:E9#>N,M'XD::$1LX
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MO,+*8O$/MNL7VMF?8?\ BBXZB.5O/3U@^*Q;-UN<J416)\O'1LQU)>BO7L2
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MU&2K5;4]G44*Y="S=SVKF2<=B:]K];PP-Y8WO#MW)8%EF:#7*,_%STI&@ O
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MS?/_ ,L7?]JO_P"(B7/_ %!_0SZX?]<27I/XJ\?F98UT!$" ( @" ( @" (
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M72$=?#7@XM;[73ZQJK!:*3BI1:=2B?-X1N.$XRC3Q^3;0E+%+ ;JJLG'EVF
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M Z  ]PT!X:<5<]U![3D7J;T:**PV[MZ+)":=V9U'(8YENA/&)9(7DQO:YS=
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M2X]I_P#+C;/]RC_E4+7?QY]9=<C_ *"S^I'S%R4(N@@" ( @" ( @" ( @"
M( @*YOG_ .6+O^U7_P#$1+G_ *@_H9]</^N)+TG\5>/S,L:Z B! $ 0! $ 0
M! $ 0%;DWO@8;\N.LR2030NZ)'RQN# 1Z2-?N\E,6DN.*DL:E2^:6(W'"3::
MXH[\A@<-GV-N,T;8<-8LA5< _3_:&H</AU6$+T[6&[@S;>TEG4+,MNZ4=OZ2
MEY3;^4PLIN/:^2./BW*T 8YF@>,L8Y_"-0K&W>C-47Y9;/$R@OZ2Y8>9U?\
MGA@_VD9>.WSD*+&G)-;DL<= +M?A*T?TV>/\"USTD9/U?5EP?I-MGFMRVJS_
M -2'XH[?&BRY#.8R_MC(Y*G.V:J*\H<X'0@EI&C@="#J5#A9G&ZHM4=2WNZN
MU<TT[D7596:V[8ML/LY1\&OG1X]P81S\QYU:/AX*ZYBU2-?Q''_3ZDY3:VJ'
ME.4W=!N6P#\1>:^GG':1F1AT9(6G1W'4%I.G(K'Y=W=S,L8C^XE?L.U/U+FS
MH?HZC7N4R]R_8=!D+3YH*K.BL2\^RQWAJ3IQ4^%N,5@MIR^HU,[LJ3E516&)
ML_MOOC#8[&0[>R4\=7W>,OK3O=[+VZDN:[7Y+F_<(Y*HUNFE*3G'&NT[/D7-
M;-JU&Q-J.5>JZ[>A\&O\#25Z>"[?M&6RWR)YIG.U.N@,CBUP^$$*[C14QW'!
M7*SE)R6V4GY73R4(;(2Q,:;3*SFB%I:^:4"%D8'!IZB27%W@&A8S>/0;;=I)
M8;2)J;IK2O.+IRAV0T\V2%W6X-;Z7$MX:\^/%:W<4<9;/M)'P<VJQ3QZJ?XU
M)^":^8X[$]ZL()06Q^[/(E;TCCJ> !\"ML9O:B/*"C2NTK%ZY0I129*YB))I
M(R ;&DDS^@\WAK=21\YP!"C1<Y5<U1U+1P@VH6G54WT1*P77Q05IJ+ZC(Y>B
M=C'2"2Z^OIK(QK!H[D=0"W4+9&5'5O C2LIIUCCQ_23F-WI?=8LTMK68V8RV
MWIM5C,!&' Z.+H_E,<.1X+.YEN.+IBMXMRN:>,HIN$9?=W>#,FMGK6+N0W9G
MP2B-XZ3(SJBZO Z>+>'!9RC7U7Y")"[*W)2C1M<5X;"_4^_&;K2M9;KU[M<'
M1TL>D1/P#7@JV?+;;]EG26OJC41=)Q3ZL#:VU.XVW=UAL%68P9!P'55F&C@[
M3B&GD[XE47M)<M8O8=CH.<Z?5^K%TEP9;RYHTU('HU]*B%W4Y+P]" ( @" (
M @" ( @" ( @" ( @.+FAP((''AQ&J]/&>7-Y&Q7W%E*%B-T=N*3K.HZ>N-Q
M)8X:<#P756J2MQ:/C^O<H:JY"2HT^U;BGWKS8J<HMCJAUUX\"?4"M\4D5TVY
MX<"CY.TZ_F*51E;7'2O;/DKA+F,959P#&DGVI'\@-. U*T+#!M-]!:VXQ<7<
MHUA2*VMO?XD3,%]]JZ^X(F^XPAT%*%XU8'.'2']'B6CD"MR=2O<<NW:=1NR0
MVX*N/)-)SM'Q,(,MJ;[_ *R-!IK\0653%JL69^>HV+3*[\9)%[W%[#_,/ Q$
M:@CIYEO)>LUVI)>T4^*<NLO@_.K X2L$PZ3T$ Z..COF\5A4F..%<IR?GLA;
M?;Q&S'/96M@L_.G2!T-UT)!]+N/)>U,XVU!YKG8=(ERN+I/JXE\;:\(ZYLE8
M8&.D.NC@]QXD^C1>5,:1E*LNQ?88EK=E&_6\NC-+8EKCI)C88VR2CG\K35'@
M;5II1?K85\-QPREN0F>RWJ;YT+9/+UTT<[F/NK5)F=J&Q=)K>:K89>FO6[$L
M[G.)@B)+HXW/X\!JM+9>*:<%%)+IWLL<#)XJL=BQ,\.+&]<7A[7#[J$%M5=#
MJN49LG *T-M]25AU:!I[?3Z7?QK*+,[=Q0=7%2ZS9VR\9#4:VQDW1&W-&-".
MKIY<VLY J1$HM3.N$=A=<5C,7!.Z:OK/8)+VS2\2S7P8.06RA$<V\#(M3WHI
MM6-UCY/ZO'X0>:R-5:;\2FY^E<I78CAI7Q-LQ/="V1Q+(Y"_J<-3S_HM\%@\
M";;E&2Q,2U:_.6(L8ZS8,>4>W0.>TF&*5IU#CX:^@+VHBLLTTL#%JX*R:L3L
M_;@9#J"RU'^+>\_T6^&OI7E#.=U5>1>(L\->"]'/'1#)2^%L;.L]4;0P\"[U
M>E>D5MIXG1;BN575L'C(VNCL>U>M].@>!P(!'!H:/2ALBTZM^(S*UREFR^AC
M )*.,=J^28$122LX!SM!KH/O $/)1<5C@<,HUC?=ZU[S['GM>^*S W\0WRSH
M6Z#Y/ \CS^%&8Q3VH^8)N2A8ZQE',8^JPB*.-[G.8''0 ^#VD>T-1J%ZA<R_
M=\/#89M*&?(6VO,A<S74DGD/$_ $,*;C&RV8_P#:$M%KG5Z,36-AD8-#)J-7
M:GTZKPSRX)H[J-J"B8W/UFDD)#&D^!X%RR1IEMV$C#YGE6(W.\MG6 93R/CI
M]Q;-YH5,CKL+'B*=V:6"*J.FO)H]KSJV$MUXO<3IJM-R<56NTL=+9NN24?9>
M/1UL]&[4QU:ABV>3,RQ++HZ::+0M) Y ^I<G?FY2X'U[068V[:HTV]K1/J.6
M(0! $ 0! $ 0! $ 0! $ 0! $!%9G;^.SD0;;86SL_L;,?LRQGTAP_BY+?:O
M2MO#L(6IT=N^O66.Y[T:[OX_*;5OMD?.ZN9#I!E(!I'*?!L\?$$__2%;0G&]
M'!5_RO[&<M=LW-)<JWEKLFMCZ)+863%;]K![:6XNFE:/".TWC6E'@0>/2?AX
M*'<T;:S6_67#>BUL<WBGDO\ J/<_NOT&9G=I8W<#/?Z$@JY)PUCNP<62#T2
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M',KP]3H7AX'-IY#ARX\UX;8UBZ/:=>&CRV(;+0F:^6!LGF&:6RQ\HT #F->
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M\W6JB[=QTN1V]/2;#!!Y$'3T*N.E1]7AZ$ 0! $ 0! $ 0! $ 0! $ 0! $
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M3ITX@Z-TY@<RO(V+='14,KG,=5GCFFY4V>"+D.[>Y;UX/CM-@B80&PL8TL(
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MEBG<=*[%Q,S!YFOG:+;M=I8TG0M<02/'74>E:[EMP=&;K%^-Z.9$JM1)" (
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M@]ILK':![ PC[Y9(T7FUAO\ ,9(N5_\ F<G6Z)#>G<Z.9WM=0;HSQUT!.I'
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M9)0>0< 2UH_A4#5ZG3N#A"*KQI3])?<KY=K5=5V]-J/X6ZM]>Y&SE1G9A $
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M[C!^/\R3K>->75KQX^M0LCE[:KT;CH(W(PKW<DJ;Z^MXWN93,_7&,9+9VE!
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M.93+H;3!U.KS:!^GI&AT*H+^EG:V[#Z'H>:6=7[-4^#+*HA;A $ 0! $ 0!
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M:SS&Z<F1@=0)])435?"P@XQ7K='I+?EOS*[=4YR:M[\R2KU+:;15$=J$ 0!
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MAZ_-TXO!Y?$MZO-JC(MRPEC0V9B-QLVN1<H7&2OEXNQ^A>7@>H<B%'N:?O\
MU6O&2M-S!<O]>$ZYON<?$;,VUW=VID^FO>LG&7CP?!;;T-U]3AJ"J2_RZ];V
M*J.[Y?\ 4^CU*I*62?!FQJ.6QEN,25KU>:,\1Y<C7:_<5<XR6U,Z:%^W/&,D
M_&2 G@/*1A^!P_G6%&;LRXG,/8[D0?@(*\/:IG)#T( @" ( @" ( @" ZI9H
MJ\3IIY&Q0L'4^1Y#6M \23H L')157L,XQ<G1*K,#&9[!9QL@Q&2JY 1DME%
M::.;IT\#T$Z+7:OV[GL23ZF2-1H[]BG>PE"OXDT5#=7;QEMLES!L:V4ZNDHN
MT#'GQ,9^])^XKK3ZQQPELXG&<PY,KB<K6W\.Y]7 HN(SV?VG<=#5+^B,Z6<7
M9U&@'/IUXCXE97+5N\JO\R.:TVJU&CG2-<-L)?8;5I[TH9' 39VBQTHJ\;E0
M:":/3Y0T\3XCTJEGII0FH/?L9VMKF=N[8=Z&.7VEO7$CMW;IP\^Q;&7JY%\$
M%M@96DAX3ND)_LP-06NUX'T+?I]/..H47&K6U;B#S+F-B6@E=C-Q4E@U[5>"
MZ?,>;LOGV0RMK6?>;5J?2-LC-'D.>.#G:\_A72QE!IT5#YC=SIQS-R<NGSG0
MS(/CGB;0F;-==&V5AD)8R5P.A;H3]\ 0LK;C*WBZHCW^]MZCU(M223_R]76=
M=N+'96.62E=_-[&/_'=8Z6E_CTR<G-6M-6U1[S?.#U4FXNN7;_BO,9,&9QE2
MA%4R%Z*)C#Y-:P7.<R4-]+M.:QRYG54-JFK<5"5<%MHS7FZ-X8NI+/\ FOS<
MB^NX-GDKQ%S 7Z\#(1IKQ6ZUJ+=N>5RK.E<JVY>)%N<KO:B&=1I:4L9OCP7I
M9)V<QCLQA\(<>R5M*-_1+[P V3K;U$@@$Z:/Z-.*XGZYN2>EBX/U92=:<:++
MY,Q]X_\ J*&FCS2^J)7(65W?4Y?ZE/\ T5Z^DFG1T_<_#JTY<%\!4IYS]))S
MSE-ER3<&R?(NFCK8^,^VZ3V>IX<[IZ>&AU"^_P#TM*Y\O6?9F=.JB_[JGY:_
M^RX6?GTW:]MV[>?]?UO+ERU()VY]X[OS46)PF*DL4K# \V22UL3?!XUT'P:K
MH,K<CA%<A&WM]9'?-MNUM[)XK#1X-DS99#-+=E=YDDK=?QSFO' .6_)3:5SU
M&?9C]OZ/M+=GL5B;'_LO'4@;;V>8WRNH1Z:: /Z=3HM:N/-0WRTZ[O,G3QE(
MPFRK9RA97P+J=N$ET]GRCH7-X@<= 6DK.=J,XR@\,R:JMN/218W[JE&:=<DE
M)*6*]6CQ72]QBS8&KD\E-CLW>)FMZM+>@L92,?@1Z=53\NO.2G8R24;-(IR>
M,CH>:6HQ=K4JY;<]36<HP5%!\&O"A:O==HBD<33R+K,T;!&^UTM8'D-+.D=6
MN@.JLKEOO8N,U6+W>7<55NZK,E.W)J<?O4WO#?7;TD%4Q3=MW),A0UC;Y A?
M6#=72,CXAO'F5LR\#6KN94DS86.-:S5QY$#65G5O>)V-:(^N9X+G%XY]7PJ9
M;N896RDU.GROO$EZM?/MXFL[^^HJ5V1^X;4L;)>KW6E68YT+8VGI&I' '^%:
M+MWULK6!9Z31-P4XNLWMQI^DDL+N&KEIC'B<@T1] D>\2'J:T^R.ICP..O#0
M+1*<<"PA8GBGM\-YW9NYB#BK65R$+7Y&A+[O/JS3S8PWJ:[3CKPYJOTG,+>I
MN3A&,HNVJU=,<:8<']A/U/*+VDLPG<G"2NO",7BL*^MN\94(<CLB><5!8&+L
MS!L\;)F^27@_^;=R//DI[FEAO(D=/<:S4K'?X?:3UJ[@[K9JT\4[,I<8V)K9
M"&N?&SV0=6\1P'!;,T:)-$5VKF>;@]O1@C)P-C<&)GDQ4=.Q8Q;03"Z9S7$]
M0^0TDAW!:(ZNUG<%..;A5&V>@O.W&Y*$LO&C\E46J/)0>3"]KV5XHF_\S%8]
MBP'^.H/$\>73P5FJ.%6_0<Y)25Y1C&NVN'K4^SR'='D)+<K8*G!L@#1+R#M>
M73KR^$K5WB3HMO$VRTTG'//"*^[YFRI[@R.X8\U&7Q226+$+875I1[#BQ_2&
M]?CIIS13K7@9JTEE;;S8/I\?$D;&5L8>U$S'4G27K72)-"96PD#1S(W'CS6F
M4I1:5,"PMV[5R,IIIR2IT+T])9WFK1A<_)S%CI='QQCVI2=-= /'^)3FTE18
M(YV*FYJ3QEX>(PH\E7O12UJ1=#-Y E+IRWRGMD\6N;\H].NC?X5K7=1HJXLW
MN&IO*4J*D<7QPX>+_$Q\%'=JY:S7ZW%^-L"1K^K@Z.0:CQX@K;9N_=D_\#5J
M]*U)781VJN&Z2XJOWL/M-L1R,>6O=J890#J.8!_F6N2<73@64)*5'ND6-FQ]
MPS4H[U*J+U*8=4;X7-<\#T%NO@O(ZZTGEDZ,LGR;4R@IPCGB]E-IUU?KEA9.
MBI^<*AY>6&OZ3IZB"%E/X:ZL<K-=KX_3ND.\CV_I-I[ RF[LBR;ZP0D56#2&
M:1GER%VO(C3BN=UUJS!KNV=WR;4:RZGWZPW.E&7E59TH0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $!2MY[W9@=<?CNF7*$:O<[BR%I' D>+CS 7!?47U.M"^YLTE
M=W\(^F71XWP.DY5REZGUYX0\_P"@U#E,_E\F9!>O33LEX/C<\AA'/3I&@T^)
M?*+W,=5?;=RY*5>ET[-GD.]L:*S:2R02IT?:1,,>KNEH)U.@ XDDK0VV9W,&
M2S<=<B9YDE=[6>)(\/7Z%%O1E#VE3K(O>1;VF92J^?(&<F\R?4JZY,USE1%B
MAIQM9HQ@ '/AJ?X5 E<=2OE==3JEB$9ZF>R1Z%FG55-L95.R*2S*1%'[3G<!
MH.*][QF$HP6+,O\ ,MLM+PYKG<^G4ZGXR%<V^2ZFY#-%(T?%PK3$Q(W.A>6N
M:1H='#3D0J=.4&TT\.AX&^24D91O -T'M'3DLN\C2J-'<XF"[5Q+CQ)XGX5I
MS5)2P)"B]H:T*2O9(EY8G1EW->8P.8U^X5A,V:5-5.W%[VCVEB<@^^#-4@C=
M-3C',SDZ",'CIUD_$OI7T?\ 47PL9:>YC&CE#KWQZGM[>)'U?*7K+T,F#;I+
MJX^(U7=[A[_RUIV0=F)Z?42Z.K4/EP1@G4-#=#KIZ7:DJRO\_P!5*YF4VNA8
M+L_Q.RM<DT%J&3NU+IEBWZ/$;>[4]Q[6Y_.P6>Z/SY68)(9V@,%B$'0DM' /
M:3[6G#CKZ5V_(N</5K)<]M;^/Z3@_J'DD='2[9KW<L*?A?H9M)=6<:$ 0! $
M 0! $ 0! $ 0! $!IS_4?_@:NO\ @_MG%_\ GO\ 9^TN/:?_ "XVU_<H_P"5
M0M=_'GUEUR/^@L_J1\Q<E"+H( @" ( @" ( @" ( @" ("N;Z_\ EBY_M5__
M !$:H/J#^AGUP_ZXDO2?Q5X_,RQJ_(A ;MW5C=G8A^7R74YH<(X88_ERR.Y-
M;KP\.*KM=K8:2WGGXEQ+3EW+[FMO*W#QO@N)KO%=]X+-Z*'+8=U&C,\,%IDO
MG%A<= 7-Z!P^-<KI_JN$[F6<,JXIU^PZS4?2,HP;MW,TENI3[3<#7->T/:06
MD @CB"#R(7<IU.!:I@<UD8A $ 0! $ 0'5/!!988[$398SS8]H</N'5>IM;#
M"4%)4:J:C[M[=P%/'16:(BIY*5_08&<#,S0G70'@6GQ5YRZ]<E*CJUYCA/J7
M16(6LT:0F]W'_ TA%D+6/#J>4;YD8.L4FFIT'(_"/X5T$DGBCYS;N2MK)/%=
M/G('.3/BD@][CK6XY XM8!T2Q\>!;H?:'IT6N:5";9QV.C\A 79[,EAV(O4"
MVD6-LQQ22%YL2#B.L'0L9'IU:??'@5I>!.@J+-%^MU;/2WCNPH3_ )<UF.I!
M#-[N"Z!]NPQYCZG.CX>HN=P:T(1UA7 S[,MB66,N>\"'@V5P_&: >TQX&GM-
M\#]\%Z:V0IO8B>9M]S9XXX7NAAQ]&-K;#[$CM/,=X#4??.^)>&^*>Q^':1]Q
M^1R-U^,\RMAJ%?0M95ZIKIZAJXRR\M3R)\%Z;$X*-4J^;])C6;>*PD<52M7L
M,<XMDDK5V.GGLNUX:\#PUYZ(>QC.XZMKK>%#,O92:#$V+=JFVBRF!,VE$PRV
M7RRD "1^NGF.U]EC==/%*'D+>::@FL<*[NO'<863@S=]D%?%U:\>2F80ZU,0
MTLZ2-6/TY.;R.GBO#*VX1?K/#H\Y&1C<]3WBIE,9#).7^9#>;-K&=.'23IKK
MZPO70WR5ET<9/I5#-K37(H7-NS>Y1O=QDCUT.HT+3IST]*\-#46\,3NHY7)A
MS&3=-VH/;;>E+(]2#IH=.?#U(>2A%[,'P)7WI]D-BKAQ9)JXRDM.NA^2 .:&
MC+0C;+:,E]K&,%;+<7XZ>>0.IS%AXL?H-6.)UZ=>2&Z-<O%>4ZLE5SKS&['4
MG.:W26Q2KN:Q\P;\KVM?:(XZ!8F5O*\&_P!'AY"4MT:\A;D"]CJ$XBAED^3=
MB<_Y/7&>)Y'VF\>"QJAEGNW$A@\!9DPSL3D;<41C?)+!-)&V4QQ./LO+P=./
MRAIPXKQ6G)X;3/O:8&)EYJVW,A1P\M@V9YF_\M)&PROF?$SK(YG3@-?0O;\I
M1FL[QW&<+,KEN62.$=N/F)+ 9NK:M.BML;'-*_J\W30%I')6"U:G&CVE//31
M4FVECO\ .F;>VQN*YLD.R4-B&;&3_P!K3D<0YVGBP#CK\2J[]A:AY:/-Q+_0
M:V7+8]XI)VW]UOS&V=M=SMH;GC:VKD(X+FGM5+#O+D!^!VFJH;^BNV7ZR.]Y
M?SW2:V-;<U7@]I<&2,D:'1N#V^!:01]T*$7J:>PYH>A $ 0! $ 0! $ 0! 1
M&X<#C]R8FQA\FSJK66%A(^6W4:=33X'T%9PFXNJ-%^Q"]!PDL&>*NXO[,6Z=
MKPR#:5<Y;!-,D@:TDSQM/$!Q<=7:>E6\-5&2QP9R.HY9>A-R7K(\Y9>G8KB:
MC>A?%EY)&M='("T-+1PUU6[:1(IQ>."1\Q]>Q9L11UV/FEB;Y0;&TN)&G$@#
MBO48S>'69>0K9B.I) ZC;;-"6<X9 2-?6$;Z1"%)5IMZ"/?A=QVJ4KJ&*MS-
M:.MT?DO$A</1H%C5$JW!N:5&9V,V3NFEAHY9L!<-F0E[B^)VO'B!\2\<X\3*
M];FYO!T17[GYSE<:=;'SW+^I:(6,<XM/I< -0/A3,C*U9;?!'9'@MV11$25+
M5*)K>J<QPG5Q_HAP*\4CV<4G7+7K,!F.A-@E[[LMO[YCV]3ON=*]J'.35$D9
M72:HZ6UIRX^,X+1]Q#0^DX.DR+B7&1L,1Y= YE,1ZAVB:PS3H?U#Q0\HF=D@
M]XAEC8/*ED;TF1OCZB@3HTR+Q,.6HS>4'M:]GLN?(>II;X:+.I(O2MRQH6.*
MI8EK2,MW&S32/ZWO=Q=T\"!_ MB9"E.*>$:(S:%C,QVK5R-WF5HHOQD+#[+2
MWVN&OJXK-,USC;<%&F-=O62%'=&0>8W1,:8++NH2#7K!Y:GP  6Q,CW-+%5K
MM1::4LTK/?[$CX9FZCWAC^1Y-=H/!9)E=-4=$0>?I9DVXYKUL33PDF"Y9E>0
MV/@0 .3>//0+:I$RQ<AE:2P>U)(E)[%29D<YL=$H:#-"/'P)]8*Q(BBUA0C7
MXGS[7OF(L25++(P^-C?8 ##JX >OQ"R4B3&_E66<5)?H-C;<R\XF9=L]4+K,
M'3-#(.8TX/;IX:CB/0413WK:I18T+?BK8-KJD:.F,%[G<@=%DB))4Q*SALMG
M[=FU3BG;/7?8GZG3-_&5HW$DM)YZ '0+PDW8P23I1T[3E:HX3!XTFS)U!I+:
MMQ_"1DS^+(VD<^/@4/(RG.6!F.B96BECC+'M+W67'3I<SJ9Q'^R?$(:ZMD!1
MEIVYI)Z1'7U%DTHX=98WDX>#AKS\0B-]RL:5)ZAH'ON#V2(G&5OI<!_*C1K3
MH8$&1LOTG8UAG: "P\GM'_VP]*VQHGT&,JR7!EFBFC AL=30\Z'GQ'J*FIQD
MJ;&5<K=VT\]*KH,Z7-ZQ=#961L TZF<]%A\*ZDY<QA2FSQ$9'*_(VX\7@JLE
MO(V2&MZ072.ZO'0<AZ25N:C;CFF\$:HRG?N*%J+<I=N/AC4])=L.U\>U*S,A
MEPV3+O'7Y8XMC<[GJ?%RXW7Z]WY47LGU7DO)8Z.%9>TS:*J#IP@" ( @" (
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MGI8Y7]W3]Y'#K1\_T>O[B[66%?5FOM\3-=YS,B'WAFG4SS'"O'U:ZD<"[IY
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M2B3I_P#-&)_5K\2ZCZ=S+5PIQ^QE7SQ1^77<W!=M50]4+[*?%0@" ( @" (
M@" ( @" ( @-.?ZC_P# U<_\']LXO_SW^S]I<>T_^7&VO[E'_*H>N_CSZRZY
M'_06?U(^8N2A%T$ 0! $ 0! $ 0! $ 0! $!6-^S1P[8MB0@%[H P?.(F8[0
M?$%RWU-J(6M#+,\6XTZ6I*7F3)VB@Y750C_K^QMC\95TJ^)!U>!Z=%PMO_[$
MK>]:U2WU^L7'R1N.$L?(4WN7D6;UPT=&C7='9J3ML0/D< UW2""TCXU$YO\
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MR "(I-"8G:#4N'$'T+W VQE;7\2O4C%\G-T[<;C9][87=-F#31L;#J>'ITX
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MHFAYQ&]!YJ1FMQ><+DSF<=#D! ^LR;4MCD^5IZ?C5?..5M%Y9N.Y%2I2I)@
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MDDKFM?*UH9'T<@T:]+6Z Z>)7AJE<SX4H==^W''-DZ$FODU(XYA-%\OS01P
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M-RW[ EMF8,MW'R/;.]A\J(O#M'.U^)=A&BBDMA\3NN<[LG-IRKBUL;WE=M9
MEC+,+ *TD;@)V//F1DC1A &A(?S7M3Q0QZ2#W''/.6UHY2^Y98V,]3R]C.GV
MB0#QT])\5KD2;#2QW(U]GHJV.K-JQR3!K.C\8WI;JYGCIIZU'F6UAN3K@:JR
M+NJY(=7'CS=\I1'M.@AL1AE8,VHQI7 :DK!F^)$VG\#Z3S4>3)MM'L#]DW8
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M]X?Q?H1P:!Z3XK6R:U2B*1G+7G.DAC'L-<6N<X#Y7/\ @Y*-)EK9C3$U1?\
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M]P6<[BX;-N'HF<T$D<CPYKB]195N32/M?+=9+46E*2HR8R.*QF6@=6R=2*W
MX:&.5@>-/C"T0N2@ZQ=&3;^FM7XN-R*DGN:J0N(V!M+!9 Y/$XV.M;(+0]A)
M&AYC0J1=UMZ['+.545VEY+H]+<SVK:A+H+.H9=! $ 0! $ 0! $ 0! $ 0!
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M]*-H:R*] TZ <- ^+0Z >E0Y<LL7'C@^AE]:Y[K+,5E6:/!K[41.X^^G<'<
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MXZK6JADD<TK)W1.)<UW3"76P X$>);IH%Y4L\\GA14P_]-=CW=/$F=GT[$M
M PO9%5>Z/S)./F>@\>:](^HEZ_6=SJ4$=F>6A-UL#R'-:[K:QWB/B7J1AG=*
M,[G79J,+;9:)+$9\HEPU+&/&O#X=%)CC@S0DUZT>.*)3;.6HR9[%OR;0VB;4
M)F&NNL8>.I8W;;4'EVT+727E.[%2V5]%3WE&YCV-<P@QD M(Y:'E_ N$9]<1
MV+P]" ( @" ( @" ( @" ("J;@WI'M^UY4M*2>NW3S9(W N;KX])]"EV=/WB
MVT*;6<R6GE1Q;702N&W#B,] )\99;, /;9J!(T^AS3R6N[9G;=)(F:766M1&
MMN5?.2P.JT$TQYV]4;FZZ.<TC4$#0D<-%Z8M'F/<-FX^Y/':DD,\,CVZS.+W
M#I<06N!U7765'*J'QK7W)YVI-U3>T@32;8MMMR0"%L7(@Z&4^CI\&_"MQ"2K
MBU1><C\Q3R[Y&S57\6ZGH=PZA\WX$,<OXD0.:KY*.OU,ZG=4;881XAQXO<[7
MT<@L)&VTXU--[OQ%QUB2>::.6;4 QNZF$-U])&G#11)HZ'2W8I4Q2*%D:4S2
M9[)#)'NT8P<>HGER49HM[<UL1%2QOC/2\:%8-$E-,PY@#ZU@S?%D79CX'U*/
M)$RW(WM^S;W%NU;LVR,[EXX<)##YV"BL%K'-F,GMQ1R.T/3H>H,]/)?+OK#D
M\)1^)M6ZS;I.G"FUKR5X'T;Z9YAB[-R7JT]6O&O$]64K#GLDE=)Q8=-#SU"^
M/WK:32IM.\G;Q)K\ZL,<362%V@&H)5;\.ZNJ(CM&19OL8QI8_CXZK5"RV]AB
MK;,./)5W//O#PT>&JM=):MPNIW8N4=Z1DX.F!"WKT5FTZ%A=Y/*-H'$ZJ7&Q
MEJX+:_(2K<<*LT)^TSW"W1L*OB-I8&X*EO.T[$V2ML#3/'5<1"(XP02POU=K
M)Z.2^C_1W+;=[-JI)X/+%>=G'\_YE))6H8)[3R36A#0UK1H !ZU]9BCYY<D6
M+%1Q!QFGZO)A'4_IX.T4VU$J=3)[$7*E>K.+(8G] /!D<;7.]GX5+132@UBR
MWXYTVGFL(:Z%OLPN]IS?,/RS_2]2W1*Z:6P[,$&NR+W,KFQ3AUEJ21GVSYCO
MQG$G0Z.]K7P 4I;#&]1Q6-&]OBV%PP&5CS-1CIXV>897LM1MY:,<6MF9XC4C
MCZUFU0K=1:=N5%P7FQ1QGM/$[:SVMBBE#?.D;\LANI U/@0%X>*.%3OH:9*(
M20D1$ OL53\Y_ G7Q7NT2]5_:0L[R+1>Z%TL,;O*E<6]/(?SK98]5YMQODTU
M1F\NR7:^/?\ 2L7LKDY:="C((31JD-L/ZAJ'%Q&K6D<M%%UNM=BBBJM[WL+'
ME/*EK*SE++%895M[3=\/9+M5C) +\3[3SI[&1NO>#_NES054OF>IDL'3J1U4
M>1:*#]95_6DWY&R]X7:^VL#$P8+%5*3 /8?7B8UVA_I@:JNN7[EQ^M)LN;.F
MM652W%170B;6DDA $ 0! $ 0! $ 0! $ 0&)D;$=2I):?UZ1#J/EC5RRBJNA
MINS4(N3W'GG==^C+>FOT(9/+GE<VP3HY\<@Y]0'WI\%U>EMR2RM[NT^4<TU%
MO.YP3HW1_P"5]/0:XS[6V*_G1U&3-A)>2!P]));H?C5G+3VK\';N)2B]TL?#
MQ'(RU5ZQ<5ZPW;E%^W!M-=GEJF1.$JS9B<W(H(8((FOK2S#5H]MOR6M:#Q'-
M1KMF$8QA"D5'8EN)N@OW)3E=GZTI^U)[V_#$G6TK5'H?&WS(J-9X>VO\J5[^
M+^EOIU&H6V$6ETL\NU<ZQ6$4]G252O/F*LF2QM2M(_)1/\RM=LL:^(N):X,.
MO'V@0?\ ZH6AW6W1K&AOAI5"#DI85P2V[$^WK+%GJ5[)0F6M:(L68@ZQC"[J
M:^1NCNN(<W!KAKH..G@J_FNB>JTDK/'V7TK''S'3?2G.H\JYO:UN+BG_ *D=
MKR2663BM_&FWAM(>IFFUHG5IXS'.  8B"7$D:\-->H'P+>:_.6KY9=MWG"::
MDGL/VW8O6-;:CJ+%R-RU)54T\*?9TUV;R!RV<BPDLEC.8U\F*NM'6[3HFB,1
M=TG0\CH\G1WJ\5];^E^7ST-ESO/([N$4\&Z4=4O(?GG_ .R.>Z?F=^WI--6]
M'2MRN3AC%2DLN7,L,%MW8X=%8[AP1,P]C(4,B!0_%3UI&M=YK'N\"SQ#ASTY
M+M[L7[6SB?(]%<C5VWZW#=X?:5^EEI#%CLMD[76/*'XN-OM/+?$GT>E>+82Z
M96Z$!EF2YC!7<[C7RUC6G>Z6M".#HWG0O:&\=6^*US>%4;;,:7$I8UX^8O\
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MMU[9L?@J[K3?_LJR/>9=?3U2]7'XE"NZ^_<P<G3L++3\JTMAUA!5XO%]K+J
M&@ #0#D.0 "A%H<EX>A $ 0! $ 0! $ 0$/N+"0Y_&OHR^R\^U%(=?9>/%5'
M-N6PU^GE9DZ5Q3X-;&3-'JI::ZKD3SKG:]W;>6EQ\^C96$^T#J'#D"%\/UW*
M9:6Z[5S%K@?4]+JHZJTIQ6#,>*Y-9< 7=3E52M1@C=D) @Q1];I.(\%"K5TH
M89*F6S)P"#H&FOCZ=5H>GE4U=WB?:E]@>2XC7P7ERPTCQVZG9;OM< 0>*QA9
MW!6Z(PC<T(/@MZLC*=YS,$4>C07/T^2KG1ZR]8MNVE@S&5JKJRMSVY7V>IS2
M7..I'@BMIQVDV%$CJR-CRO)\V'KE?_9Q\M0.9*W6;#@JO82+4.]K1T2))F[M
MN[9V[?W%<P,]RSB?+?/"^0& M>[370#7FOHWTSR_0ZMM2AFG'&KV'$?5&HU.
M@@KD9UA+##:>@-D7,-F-NT-P8BFRI#E(6S!C&@$:\=#IZ"OHJLQM^K%)=1PZ
MORNQ4FVZEC<YL;2]YZ6-XEQ.@ 'K60/&W[7?=+9UV/%[4QN9ALY6K.9KD4#@
M]K6$::$C@3JK'20:=6<_S5N<4HXGEJE(VPX,;T@C5S6#T*P1S=S S+]JS#-[
MG#%T^?"#[RYWLZ:_)#?3ZUFS5"*:JWXB%LR^ZL/O$_F/:?8C'RR7<W:?-"\2
M)4578CZVA8LW/+J2-9"^,S6IF#_K!\G5;$.\BHXK&M%U>'E):A#D/<WR8J=T
M5NL]CH[8U&K_ !TY\UMC@R-*4,RSJJ>XW)MW=F+E;%!E'1PYAS!U@^R'N ]I
MP\!ZPMR9SE[3R57'V3IR=*";+1''-$CYYHY6QL]H,=U>T>'(>*"$VHX\"Y4H
MIJ[G5028W.XM'$=)!U"S(+E55-?9.CBY)X,>]TWO-*PZ22)@]M[R?8;IX:!8
MEG"4DF^*,ZU+:]RM4&.=7CB:/,F+M=>/&,GYQ]2&J"54S!Q$<%&ZZ68AE!K&
M-\MGLESR>+SZELC@CV?KM+&M23R 9;EEAAX,L0!]:3YSF<1\9Y+>UL-=ENK\
M-A!P"3H9)')J/#0<BIK69&%FMN3QV\3;NP^_>X-HB.EG'NR>%CT:&/!=+&T>
M#''CP5'J.6PNXQP9V6DYQ<LJD_6B>D<!W2V9N'%5LM7O>[06G^5&RTTQ/ZP-
M=-#P^-<[>T=VW)Q:V'7:?F%F]!3B\'QP+95NU;C.NK,R9OI8X._B4-IK:6"D
MGL,E>'H0! $ 0! $ 0! $!5-W;8DS$1M47=-]@TZ3P$C1X:^!4NQ>R8/84_,
M-$[RS0]KSFGKM+)86WYS&34;\1X31$L=P]('-74&I*BI)<#@[UJY9EFHX26]
M%BQ/=S+8U@CSE=E^$</>(CY4N@](TZ2?N*//0PD_5K%^0LM/]1W;2I=2FN*P
M?9L+75[N;+N,'G6GU'GFV9G 'X6ZZJ++EUY;%4N;7U-H9[9Y>LU%O._B<AN*
MYE<?()*D\C7QR>#ST@.(5SIH2C;49;3AN:WK-W4RN6W6+?:5VU=\@/;"[S+G
M3U1AW $?T0>94FA6YJ=+(6:"+S!)/%YLKVF1A(=(07#7AKQ&IYH85?$B<CCY
MIHW.ATL1MU(8'CV7>/CIKKX+%HVPFEM-:YZID(I'2W[44,+?9C9+('Z]7@YH
MUUT4:2+BS*.Q)ME&S45:)S'=!F=\IKV<&_[H4>1:VFW4KL].68AC"'1CJ+G>
M/7KR*UT)D94(:5G%S?FG0K4T3(LP)V$Z\/A 6J2),94,!KYJ%RM?K])GJ316
M8>L:M\R!X>WJ'B-1Q4:<:JA/MSHZGL#97[0VU^YFZ:.W9\1+MK.99ATG?8B=
MCY;X;U.BC)Z',$FA\OJ\?97RGF7TI."E<M-2Q]FF-/#J/H_+OJ&+2A<[?2;A
MCIY3'OE C$P!,3]..CQS!]!'B%P6IY=.M))JAUL=1:FJIG0(\@]K@^-_7_U8
M'$:K5\*T\%UFW/#B=]?#9&3IL3Z15V'6220]$;1Z2X\ %+MZ*Y-M*+-%W4VH
MK::G[T]_L/VPR5O:&W:0RV]1 8K5GJ#*N/=-"71N#RU_F3-+FNZ .D::$^"[
MKEGTXK^2]/U(K[OXNLY'7\YR)PAM\QXKLV\AE+DF1RMJ:]D+!ZI[5A[I97GT
MESR3XG@OI=NW&*2BJ(XB[=;=7BS*KPZ<^?I4J,2OG.A;=MTG6(YRTM;[3&N<
MYO4.DGB-/25/M1*353I0M>(Q#^MV0B!%&/A"P#G(T^'I6]1*Z[=W;R;L5;V-
MQ$HAB\RS,WJF>?O7O]('@ M\(D:,X2N*KP.&!M18W!V'=1B$)=$[T%KOE=6O
M'GQ "D4Q,=0I7;JWN7AX=I(;5@MR6I;\TKJTLD3F5_)T_$PZ]?4 [@=0/'TZ
MK-O<:]7*$4HQ5:;:[WL\FXDY;!-1EZ1AU:733=8XOX\&@>  /!8$1+&B,F@^
M6I*ZPT^8V4#\5R;T$<=3ZT1C-)JAG4,;D-QW)FXNM-:F8"\TX6^9-T,;[4C6
M :N ',K=;E'[SRHU7(3P4(YY4>"VTW].S_ V=V\P7>.Z+.,VFVWC,=:+1=R$
MX]RCT8.D-$CF=>@!^2P:K+5W-'"DITDUL6TE<KL<RN-QMIVXO:WAV85[,>E&
MS:'[,,5O2QNS<MFY:=QD96;H-?5+.Z1Y57+GCCA;@DO#<CIK?TQ&6-ZY*3\-
M[J_*;KVQMK&[1PM; 8CS31J@B-UB1TTIZCJ=7.U_@7/WKTKLW*6UG6Z>Q"S!
M0C6BXXDVM)(" ( @" ( @" (#JFFCKQ/GE.D;!U..FO <?!>I5=#"4E%59B8
MW,XK+Q>=C+<=IG_[-P)'AQ'-9SMR@Z25#38U-J\JVY*2Z"06LD@G1 5W-;JQ
MV+C=&?QTQU8U@^23IR]:DV[$I%9J==;M*FUFE]S0-R#S*&,I@N,ACCT#B3Z-
M%T6EN9/\Q\\YE:5['"&-<"J/BBJSMAOLEA>]WXB77I(+N'M #30^M6+E59HM
M8;3FW!0FHW%)5?JOT_I.-6''U_,JQ,Z)!(9)]6AO7(>&N@X?<6,LTFI/>9VN
MZC6"K5;:[V1]_'3VI3!3O113ZZMK&4-<XCC[+3IKHDZPQW&,;2NMQ369;J_8
M8EBOGJS>F>#WF)FCFMX.<U[>3FG^!>.XN%0M/-*C='Q,:[0_/^%%BJ#7OUI"
M]AC)$D;F@<CS&AY:+5*YZ[3Q3\AOMZ:ME22RRBWLWTPP^PBIL(=T4XC?8:VY
M*P=)%;C!8V<CF7 : ./CZ5K<(R]9I56_>O'MH;XW';EE@WZ^+CBHRXX+#-Y]
MY+34<1N'!QXS<$)F;T.JOE;[+VO+0"&N&O'3CQ"C:CEMK43A>NK-*WLQP\?'
M'$EZ3G-_26[EBS+)"YA)46[93S&L]X[1E;BV[4BD-NK&(),9<>[H>>E_2&R$
M?-TT(]*SYE?MZ:R[MQO+%>/H769<AL7]=K8V+-)3F\-RQVOH7'@^LI>5JS59
M*;J8:X.<:ERJ"#I+%[+W,/#U'UK18U$;]N-V'LR546^HTD]+?N6+OMVVTZ/"
MOH,;;%O*XC=;,.Q[I\;(?^<ZVM#7%X)Z6>DC^%87K\;,7.;I&.+9LMZ:6IE&
MW:CGN3>6,5M?V&VF0U:F+QF,,;8)Y[$UQ[&$>Q/(\:-X  Z,TU6C0<PL:ZW.
M=EU46ELH8<WY3JN5:BU:U,<LG6>VM=VWH-;ML9&#.7]NNMNAJR6S"#.UPAB9
M(_42.?TGV0%MN::S<G&=R*E.'LUW&JUJ]1:A.-B<H0N>WE?M=?!C/=I<G"R+
M\S35[$MUY=9:T.@Z7$:>8P/U#@1\GVE*=JJ?E(,>8)22DF\/5\6Y\"1WGM6M
M4VV,95BGJ,QL$,T-N!P>Z60<)&/:#Q.FJUQA)JG ESU-J,U*B;EN9+]J]TX.
M]B9,7%.ZON2B#8?,Z$R33X\-&@86:GK:=01S6^S.+E1E;KM+<A#-&BJ\2W7,
MK%:,5B(R/F@(\JP82)(G#D'.&O3\&JGVXM;-CW'.:F["2HW24?O+9Y"\0WX;
M=.AFHP.BZWRK+.7XQOLN'P+1':XEC<?JQN/:U1FBMRXKW+>F5L-87ELC(&S'
M[V)K>MSAZPW0?"HTHI3J6-N<I6G"N]^?S["^8G<^WLGC8JV*G;1CI Q2/D!C
M =TZG5WCZ25Z]1:[Q6\\>\?W:XO[.I=AX]#J>ZE=5J?<K#.HUBNNCKXZ=+9Q
MSF>Q&.HUFVLVR, AW3"72ND'@-&CQ4EW8)UK@5<=+=E%Q4<7L>_KHS%RF4Q&
M2RE.C1R\V-MRP>:V.&,'KB Y.ZCQ/B MVHOP:3CY/0:]#H;L934DJ+\5-O75
MX_H,G);<PN2QT%/,S6[+&2-GBM.'N\O7'R#3&-='<EIE/-%)U)%FSW-UN#C6
ME*+&E?(?-VYFW1VQ;N4>KS(?+KU(7N+](]0"-7<22T<3S24VMFU&-NU&3I)X
M2[5TE.ERK8<$),G$Z._9B#Z=.0=<D;A[>C7\'%C?Z2B2LVYW(W6O7C6G17;T
M>0L(7+T(2L)_Z<FJ_P";+BF]Z\3Q.C%/FJ;?=F[L8=;LM:(HI#SD<_Y9]('-
M;:UI4QRJ$I9<<?#QU._!0AV7AS%QKK3P#8E)YR3.Y.X__2 MD8XI[D>2DU"2
MQ<I>;@==EUNQF+=G)=0=&72SG@6Z%NHT]36\O_JK)MPK+::X6U?<;2]5NG 5
M<FW(7Z\%7H;2<]K&2R-+1U.<&ASM>  UXZKRSZSJS;J_4C2+JWO=$ET[#]!>
MWVW=M[7P%;%X%]>5XC8ZY8A>U[II2T=3WD'F2N9U5VY<G62:6[H/IO*M+8T]
ME1M--T69K[SXLM4\$-J)U>Q&V6%XT?'(.II!\"#P41-IU1;3BIJDE5%//:;8
M!N>^_F:(3:]72'/#.K777IZM%8_--3ERYW0Y[^VN79\_=1KX;C-W'L';6YJ+
M:=VHV-T0TKSQ#HDCTY:$?RK5I];=L2S19)YAR72ZVWDN1V;&L&NHU9D^TF9Q
M<#ZT&,I[AHC^RDU%>XUOAS&CC]Q7\.:6[CJY.V^V)PU[Z9OV(9%"%^&Y^S/T
M-]A?>V,&\:6-FH;GK&"M [3'^9()9A'\TD<P%3\QE8E-2M/%[>!UG((:VW:<
M-3&BC[.-73I+^JHZ@( @" ( @" ( @" ( O <&/9(T21N#F.&K7 @@CT@A8J
M2:JC)IIT9S69B$ 0! =,\+9X98'Z%LC2UP/+1PT6NY!3BXO>C.$G%IK<:!SM
M%T4DL;A[4;BQVG'BTZ<=%\?UUAQ;3W'T?37:I/B4>Y$6/U7-4HZ%]!U1RKR+
M1.(:)F@X%Y/HY*MOK U4)^M* JJ<:D><3*?,TL(6E0Q-&412 K&43QHR Y:J
M&#1WQO6,XU1IDCO;(M#1I<3A,_J+?4LHHS@J'7JME#90[(YS&.DC4?PKS*:Y
M0J<)93(=3P Y!91C0RC"AUAY');%*F!LH?7.E>-.0] X:I4\2BF?(\BZJ>EP
M/#GHI^FU-RULV'DK*D=%_.SV8G5Z[2 X$.=XZ'F!Z-5/NZ^Y<CE;P/;6EC%U
M96K]%UV(TIHG%MC1C0.?42.DCU@K'2MJ:R>U7P19V[KMO.GL)E_8K=#)_(KY
MBHZD>4\C)&R@>MC=03_O+ZT_I*ZY>U&GC]'VD)?5NE<:NW+-PPIV_H-N[-VC
MC]FX9N*HN=-(YQEM6W@"2:9V@+B!P T&@;X!=UR_00T=K)#'B^)P?,^97-=>
M[R>&Y+<EX;RQ*R*D( @" ( @" ( @" (#3G^H_\ P-77_!_;.+_\]_L_:7#M
M/_EQMG^Y1_RJ#KOX\^LNN1_T%G]2/F+FH9=! $ 0! $ 0! $ 0! 8]VG!D*D
MM.RT.@F:6/;ZBHFJTT-3:E:FJQDJ,W6KLK4U..U'GW?>W+>S[T)C?YM*P28+
M'(CIYM</3Q7Q+FOT_+03HWFA+V7Z>D^F\MYE'66WA22VH@8\C+/IUNU^!<S+
M3QCL+&422@G>TMU!#OO?A4"<$S1*!.NM3-K@N<-?'X%7Y$Y$7NU4^5[#Y#HT
M\O%)12#CQ.4\[HC[1UUY%8QC4*)B/MZG37B?%;E S43DV/S =2N@Y9RGXJ#E
M6E#V4\A#Y&VZ%[ZP.NF@U\>*B1TV63KN),%F(T3.KO:)P'0R'@1X$KZ%]+\Y
MM:>?=7O8;V_A?H.-^J.17=5#O;'\2*QC^)>DS&P21?\ ,0$Q\01PU8=/2"OO
M%N%O4VUFRW8;M_8SX)FO:.XY0<K-Q;?0T;!P/=?W"O%2S=#\3$T,;9J<M!\Y
MA/\ $DN7QI2VZ=#+FS]227\>-?\ -'T%WH=P=HWV@Q9.*-Y&OES'RW#\(!19
MZ.['[I=V><Z2YLN+QX&H.X3\9:W/:NT9V35G^6\OC<"QS^D!P&G \E=://&V
MDT<)SMVIZESBTUALXE5LVVUVN]H2RL9UQ5VZZ$#QUX<E-RO:4TKB3I7J17K+
MW3O98NRR#K!DB'FO:UNHUY,T'AP"]5#1*4VS%L19%[1H9I8>+PUCG$ZZ<>7'
M@C,8O A96YZQ,'VH!'1CX]=H,8'@^!+M"TCTH;:12Z3NRD>,CKUG7GESQI(R
M*#\9"'-XCVCH2 C,8-UP(FV,@Y\454B5DDDDTDX^#Y+AX$@\BO#;&FUG/;N>
MQ.%IR4K4GEV1.X6O=XP]Q+S[)'2> :.!'->IF5RW*;KN(2WN>AN3/1P429*L
M4,D,5B8&-[GZ\3T<2UI/ $\T:)#TSLPQ?AZ2L96:^=P5XZSY*$#A[=8<8W"'
MY1:1_!JO52A,M1AW3<EF?'@WY_$9^-S#,=?NT&0^6'QQV676@R/$G'1LK->I
MP/(:<=5Y3"IJG:S04J[Z4Z.-?28T6X[-::[>Q]-EK#6I!)/#-HT,DB)8YP'@
M#S/->T,W832C)TDO+P]!VV+$F0A&4P=@AYE>+<-AGLN&FOF-\2!S:!S7E%O,
M%'(\LUNPIYO3M:+EMK(;P@B@_.=-MK$2,:X/EE#+3&$\"T'CIIQZ2O2#>C9=
M<KQ\A;[%/&Y2!DUEC;-<$^1.X>W"[T'^8IM(:E*!K<8^;:NX;#0P2-$XMQG7
M@8Y&N(+=?#4+$LI3[V"ZJ$W#NT7&>]1TV067/>"V=^K@(^;NAH' ^&I7M2.]
M/EPK@5N4S6A?N2.;;L7/+B<9G'R>@N]KX@.0"\)4:)I;$N&TRL)7C9;,U0,;
MAJ;2>O35XD8= W7UCAHAC=DVL?:?VG/,9*WCL3:ORPOENW0Y_#DP$_BV>K7G
M\""S;4YJ-:)>#93-N7!C\58E\WIE@+PXN]IVLH]K0_>@>E>RVECJ8YY[%CPZ
M,%Y%VG':IOSY*2W6=[G%TOBJ,Z>MAZSJ7R ?*'BO&S9J8VXQ2?K;&_1XMY*6
M+8G@]^E'4&N=)*XZM A83HUH^#Q6LC)4P.[%6):5IUIHZJ\S0&QM!ZG-<-#\
M'@LX;3&ZJQIY?#RF8V*?*6)W4F.DB;TB=K&$N#M-2\M:"X@#F5*L^LZ5HB-?
MS02=,S?#S[-ALOMAG^Y5.6UB^WU0V;-UK&368ZX>V%C#H"7/(C;\KF[BMFMT
M^F23O/9NJ9\HUFNDW'31]K:VMGEH;3@[(]TMQ2-N;MWK-4D<-3'!--/*WU>R
MZ*/AZ@J9\STUO"W:3ZZ?I9U<>2:R\ZWK\EU-_91>0W;L_;LNU<#6PLV3M9>2
MOKK>O.ZYG=1Y:^ ]'%<_J+O>S<J*-=R.LTMAV;:AF<Z;Y;2P+02@@" ( @"
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M"A4^2'6)'2O=Z-2XE1YZ&V\9RS,FV^97$J0AE726+&]_^Y[',EO5,=+3U'6
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M3<RN6Y=S!T5,>G]!]*^EN6VNY>IFE*5:1KC2F_K-4>5:Q)%JI*YCQQ+226O
MYAP)T(*^?VM0VSMWDOK+)51/VXQ9KQ6F-Z6S,;(&^(#AKHO=1"F*.?AZDG%[
MG0B6$QOT/Q**U5$DDJL_0X$*#<A4UO F8;;=-=56SM,P:3,@6>K@#SYE:7!H
MTR2,F&7UK0T:&C-CF6B4#"AD-D]:U&#1W1ETG+@/3XE8RHMIKDDCF^)S1J5C
M&:>!@I)G5U+,VT/@)>[I'AS7NS$/!&1[N>GJ6CO<33WF)C.'2\ \EO1O6*,@
M%NBT2C*II9&91S6]#AS.H/P!3;1)M(P!+T  <_%2:$M1.Z"TZ*1DS-/,C<V1
MFH!'4P]0X'UA;+5R5J:G#"46FNM8HPG;4DT]C-^5)C8JP6"-'31MD(]'4T'1
M?J?377<M1F_O13[4?*KL<LW'@Z'>I)J" ( @" ( @" ( @" (#3G^H[_  -7
M/_!_:.+_ //?[/\ W%P[3_Y<;9_N4?\ *H6N_CSZRZY'_06?U(^8N:AET$ 0
M! $ 0! $ 0! $ 0'E7>D>8N[KRT>;=8=;$Y;5@]LLZ/^K$8'#0CT+XMSB>H>
MJDIJKK_A0^V\K=F&DM]U3+3%X>.IB^Y7L-8CBR,+H9&M:Y\;QH1U#4$KG]78
MG&L)*C-:NV[C;@ZHSYLG"Y@#' N'+14\-,ZXHQ<*'=^=G2,Z=./B=5K^%HS4
MXF14R+8]07::K5<L,PR5.=K(M>!H[4^E8V[#&2B,%]SUJ4K)ZHG-N:L@=#.D
MD<.HJ1:A*TO5DTF>2@MY%6S;?,UQ!>^0Z@^M2815#="2H?,J+]*@VR]A:Y\C
M8FN(.C"[CJ5,LZ7*L],"1IG&]<RO<J]9;>V7YRRV;;A<@\9##FN]\H>QOXIP
MXM(<T CJ/!=]]*<TU/?=TF^[2>' Y/ZKY5HKFG=QP2N52Z^),[VV.,03:JPO
MDH.UU#3KTK[/I-7GPDU4_/7-N4JSZT4W$UU)3Q#_ &6N<R0_>R:@:_"-?X5=
MQG-'%3T^GET/I,.0UZT9J3%T49=UQ2N(>S4<^(\"O95;S&A*$(]VZI5JGM(Z
M_!;)%J/22"-I=#*P]0T'@TA8J2V'DK<ZIK9Q,5MS(TL9!.ZN)A*Y[FV)'^VV
M('B6CAH>/ %:7!K$L4TXJIRMMJXEKF1LL31V7-)\D^WJ1KJ2>>NJ]Z32EC0C
MKM&*[7=[KBIKMMI8XPV)^CI)Y%Q:3Q^->,VP;K@R(ASE!TK<9DJK:T8Z8H70
MA[712Z](:YKR>!\$,W:=*HS;%>6K8M7:!;:J2MTF$9XLDCYZMY@^I#6FG1/:
M:_NY+S;\]1U'HG<X3UK,8Z&R$<]3Z1X@KRF!9QM^JI5ZT1V0@J6+GN=*84<C
M=9UOE8/9=-&-.@^+1\"R7D-]N4E'-)54=Q.;0%R8,@RK7>^T(Y?/CFCU+HVG
M@]AY.X'B?%>/:1]9D3K"E)4W[.CH(Z;$8MC[U6Q;?[_+JZJ_J()UU+7#7P&O
M ?$E3.-V>#25$5IN'S%22O<:V9[7RBO'-&U[HBS4#3B/1J3JLZIED[]N:<<%
MA5\:]?7LZ"V9W&6,)=&9QIF]WJ](?2$8,4@<-1(!R(^=_ L%C@5MFY&Y#)*E
M7][[']A:\1NJ+<M?SJ%)U>Y)+TS5YRY^I=H 8B  6:GB7::!>LAW]-W4J-U5
M-WV].XGZSI\5:DC=(ZQ&X%EJ$M#>H>EH](\"O")FKN*OW#R;&5\9!0>'S2R&
M&69[2WIA&KBUVOCX!>DW1VTW)RW+RD'9M1X^VV-\19%T-UDE^1*R0=)8QY^^
M!6)MC%R6#\.)D4Z\+_Q#CYF/L%O1,S@6/8=>D^@KPQE)[=_I+E%%1Q]$L>(:
MV+A&NFH&I/'X22LB W*3XLB\I7GEQV0FKB.:>Q$YU.,O'2\.;JT-^'P*&^VU
MGBG@JXFGJD$MBODJ4[R&B5IM/Y!O4WB#\!7K9TDY97"<5U>)O'_$E\3%/',Z
M.+JK&M$V*+KD]B34<7 >D\EJC%O:R+J;D<&M^+P\Y(6'EYCQ<49=-*UKI1IP
M:UW(?&O(Q;V&ER6ULZGV:OM4&7&LE8>B,-/4/@.G+BO8IUQ-DZ4P_P "4V_G
M\QM:_!D\9<?3R,0+8,A 000_@X'4$$'D0X+>H1>$E5,P4YIYX-PDMC\/M/3?
M:W]HZDZ%N+WM7BJ/!T.8I1!D+B?OIHF =)/SFC15NJY4WZUIUZ'M.CT'/5'U
M-0E'_,MGCX'H/&;@P>9@99Q61KW('@%KH)6/X'U ZKGIVIP=))HZ^W=A<58M
M-$HM9M.#I&-^4X#X3HB/#ZUS7?).H0].2 ( @" ( @" ( @" ZY(HY&EDC0Y
MKOE ^*,$<_ XV69TTL77U'JZ#IT@^K0:_P *KOENFS9LBJ25J;M*9F8-_9V$
MN:GW6-I=\O34'X0=>!6K5<KL7UC%)\4;K.NO6GA)T-8[VQFU,'5MMH7(Y,W5
M9U/Q[GASQKZ@/!<OS/Z?MV+$KL6WE.BY5S9ZG4QLRPS&K8,]0QDC+&X[D4%"
M;0&0Z#I<[Y(7(<LT4];>[N$:G7<XU-C16<\GEQIUFQ)-DOM5X;E%DCJ]E@?!
M/TZ,>'#4:$'Q'I5QJ_IB[!5IV'.Z?GMN6\@I-F9&*33RG :Z>T.GC\:YV7++
MSPCBR[CS"W2K9:]L]N;YLMEL5RR,\W/&@;PU!T/,? KS2?3.HO1];U>DIM9S
MJW'"./46W.]PMB]L(JN.W#DHZMRQRBC'7)H> <X#D/A7U/0:'N+*MPQRGS_6
M:^#N.4W1LQMT=Q.T%O#1/W'DL??QT[?,CB=TS$@CP;H>*G1MSK@B)/466JMJ
MAYE[M=[>Q\F R&S=L;7AM^_#I=:C8&-C>.1].OQZ*5"W.M6RNNW[.1Y4>1&3
MEL$E2"2:M1+^KR9"0PGTZ<E,H5;;XU.,,7E2>2\:1R<".?-#%NJJ=<<MJM=#
MHSTF,:./3PZED9-1<<2YXG.P/;!);:ZJ6G25@9YA?Q\"MJ967+#5:8DN;,-I
MTPR$C(6/DZ:<A/R [[TGUK-8D?*U[*ZSG2K3SWOS9=J"2LP:Q%_%S0WQU\%F
MD83FE',GCX>0^9^N_#0MBKM$U>T2&.)']H./20MT8BPU==7N+;MZA!?JTY[$
M;9K,+ 7]0!Z'$<= O:%?>FXMI;"Z5L%1L-:R>DUYUZV=(Z-"/@YK-(KW=:WD
M/GMN2;7CR&4I5792XV/S8=1Q <X#V].89KKPXZ!>T)5B:O24)RR1KCX<7NZ2
MI WYW0.OS,E,/R'L :TN>-7O.G@-=!ZEY@2GEQRJE>U='I:\1\IR>6^2<M#F
M.#@PNY^US(0354D86;KSV*D$L;V-,O76<--2&/YN^'3@/0B1OLR2>.['L.FI
M7:(C28YT4WLC1OR>CEH?B15KU$B3JJO[WA4LLKG/FAT'M1-;"T :>&@U]:NG
M*L:O:CGIISO))8;.S?Z":Q>:FVW=IWZ+FBYCYFRPN=J6"1G$Z^E0I6N\34OO
M(N(7NX:R?<9G;V[F;RWS-Y5ZZ]\,WR*57J#>/(:-X\?0M%C2V[.Q;-[).IUM
MW4>U+;N1W[6[#=R]U-BGKX@T:,G$6KSA WI^<&'VB/B6J]KK,-LLSZ"5IN6Z
MB?LQRKB_1_@;JVS^R9CZS6R;EST]B4Z%T%)OEQ_!U.XG[BJ+G-F_8BD7]GDJ
M7MS;+W5_9R[852Q_N5B1[-.+[#CKIZ0- H;YC?>\G+E6G6[RFRL1AL;@,?%B
M\37;6HP#2.%@X:^)].I4&<W)U>TL80C!4BJ(D5@; @" ( @" ( @" ("E[VW
M<,37DQ^,TGR\H+>GFV)I&A+O7HINFL9W66$2@YGS#N8N%O&;\G6:)]RR-_(1
MT*\?OERT\@1M&OM'B=3R 71J<5&KP2/F,K-VY<4$L\I/9X;#KW3M'-;<E;'>
MK^7Y@#FZ'S(G@<VM/(D>M+.HC=7JL]UW++VEE2:I7AL\3*?ELC;J8]XHP"2P
M7-_%M:?9UYG1;9U2P(5A1E*DG1$-!!:+9(K,;HW6(FO,!?YOER%P:[H /(\R
M%B2)-;MQGY:[9KXX10.D>UDC>F)C?;DB9HS0$^EW#BO68P57CX>'V&#8@\ZC
M._(-<Z'S!+5BB $D#= .GV>#M"./H7C6!FI4DJ?XE,W'2DGB@M"!N3Q8^5,S
MV96/^=KS&GB#]Q:)(L;$Z-KV65C,;3EM2QY'%3,BF]E_ER]0Z_2"6^D+4X$Z
MUJDEEDBIY7 3NRD<_E/$L8\J:%Q&NFG4'-<M;186KZR-$5)BWR2B(OZX2/,B
M>SV7:^@Z+RA(5RBJ9F&K66,-*\POL,8Y[ YNO4R3V>!//1>M&N])-UCL(W(8
MVM+_ &L98]CCJ8^?3ZUI<4;[=Z4=C(&UC88M27!OH#CP*T2MHGV]1)F ZGH>
M(&G@M.0E*ZF?!5&NFGP%,A[WIF8\LI7JEQ\0F;6FBG=">3Q$\/+3KPT.FA6-
MRUG@XUI5-=HMW\LU*E4FF>XJ'='95["MS;,W5BIEGF2,EE:R:,@<6.C)Z^H'
MPT7YRN_3NNMWNZ[J3=:8)T?3793P9]PM\XT<[7>]Y%+I>*\6T\A[NRM;/[JS
M.<IL<RKD+<L\+7C1W0XZ-)'@2!JOT-RO2RTVDM6I>U"*3\1\0YEJ8ZC4SN1]
MF3;1.;.FBQ0]XF;(\V 8WP,:XAT1Y^K4<P5T%B+H<MK$YX*F'AX<38GND;HJ
M[&ELAKR?B2'>UY+QX^KT:J04F?%G=2RE#'/]PO6>JK)+T=&A+XI/!X \/3IP
M6:,96Y2Q2W&1N:>K2QK[(;&9)7=<CHW-_&^6-&N!]?B2O5B8V(.4J>"^TB0[
MIA%F-KGV('1/?HW4Z/''_P"JO#=3&CV,S\?[M?%JL^7RYWF1DNA]IH(XO'Q$
M%>HURK&CH5!].Q1E91F]M],F$R:::M#?Q;_C"\HRQ[R,JRXX^GPX$G7K/8(I
MWO\ *_%@Z^EG5H0X'GSY*;"#:*R4U"7C\YN?+_LU]R*=&OE]NR5<S4GB;/''
M$XUK+6O:' =,G G0\FN4*WS2RWEEZOAT%_/D>IA%2@U/H6'D?I(7%]GN\F2L
MMKR;7EB!.CK-WRX6 #Q+G'4A3):_3P7MUZB/#ENJG*CM>-T-D8_]EW><\379
M'-4JC].,<8FDZ?5J':%5TN<VELBWV%S#D5Y[9)>)^DEZW[)TKG WMRL+?$1U
M>H_=>\+2^=\(^4D+D"WR\AL38/8O [#R\6>KY&U:R4#'Q,TZ8(7,D&A#XXP>
MKU G@J[5<RG?CE:219Z3E5O3SSINO9Y$;8527 0! $ 0! $ 0! 8MC'T;8(M
M5HI@>?F,:_\ C!649R6QT-4[4)^TDR&L[$VA;/5/B*Y=\YK2T_\ DE28ZR]'
M9)E=<Y1H[F,K<>PP7]K]EO=U#'EGJ9(]H^YJMOQ]_P#$17]/Z)_<IXV<#VPV
M:P%PI:D<C(][P/7H2GQ][B>?(-$ON=M64#=^WL128^#&6I(NC4F*I%T#3T.<
M2."L]+?G)^LD^LYGFF@LPBXVY./1%4\IK)M221TC(?.G:(W.?7_M2]HYZ-&I
MU'J5Y*2PKACMX'!PM.LLM9*CK';7Q<2'FKT+L'E-DDK2P@B:.5@\P,] <="I
M,Y456LQ LVXW&H1D[;WI[:=9#-Q./RED575VC&XR3WN.$'61TI/LCJTU(UXE
M0=1<7=)/%^@ZWEUVXG*U2BCL>W!F)+!9;+:-.2)ED2QPRO('F,C>2[\(M]D%
M:(W*M*."?I,[FF48RG.DI1KL6QTP^PP?<\Q=S)NT,@Z"]5TE%B61SV-T?Y0C
M:.(TZ0YCQIH?'P5'H;&N^)O._<S6Z^IC7QI;J+RX'0<TU7+8<NTRT]IK44_U
M6\-VS-L>/DQX'W<.&@,DN5BOODS(L16HY9VAD)? >$?4WB-6ZZ+H)6XIM-X[
MNLXVUJ)255&J==G#CCM(C.?GO!X/(9S;T_N>6Z77)VC1\<[ >I\<C':@\/$<
M5&G;>*WI5+#3ZF.:+QRREEKP;P\^!3L%ELGOJ*U#58V*SHUT['#2!K':$DZ#
MF=>2PMO,L,"QU'^DZR=6_L)/*;)R>)QEEV*N,LV'M#Y*3?9<)6_,+O3Z%M<5
M1T(D+[E-9U1>'F._'YK,TL+!4S%>2K;E;U>18@$]<Z#VAIZ2LE%N*JJ5(DY0
MC=EE:E1]J_QWDKLZ[A<G9EQ]9T='(R\64&2!T<P\2QOWA_HK#!*AM<7)YL>#
MK@G^DQ8ML18?<7YTHCR97E\=RNT'I<?"5H\">17CM)Q4U@SQ:N2NNQ+&&U=7
M#T8]!:J61=C,R<4RI"[ ]3+7N;G!T_6X>W+$">IKASTY+9=DI4E1)T--E25;
M=:I/'PXDIF=W8G%S/M4K+99^DN-5HZ'&0'Y0&G D<2L9RMQ6>;I3;X,PRZB3
M[JU&M7ZJIC7BJ8].!@VNXN=NMJ9"#&0QASXVW622N>Z:)AY1,;[+7$>)*U2U
M4+=IS;2A2K>W EPT=R_?C"CE=E2.7967!I[.G?0G-T;6Q.]\56AAF,#Y=9L>
M22P.^=%*W3B-5'T&MMZVSGMU<4Z;*8HE\VY7=Y7JNZNI0NTV53VE<Q>R<;@\
M?=%T,:(8)GRQR](=)TM(+FMYD#P*M^[BJ*IS,;]V;;<:/=5^1+<::P62MPW(
MIZPC=C XR0C7H;%#IH\'A[6HYJM4*]1U4YJ"V4EOZ67W"TL?;EDKF1LV)O\
MEV:QUT#F'CS]1X%;[5ND6UB5NKNUG%3]156._P#0]Q=:&#IX\O%+&,K!VKC;
M:SJ<Y^G,N=J5LM235<*D766Y0G1N62FT@IZU:*[,\2.M90#I9;E'F1Q.=R+&
MG74@KV:];'=V(PL.EOU%2K2HL9.N"HMM7LV8FM=S5=Z[EDB-V%S,5#(P?B9
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M:PGJXAO #B5M47M1!NSC5J5&FC[>RN5@GN2P9*;\VQ60VK"'N+ &/U(+2=/
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MX''VNODS3EP\/6I5J*6)YWK4L#9O:S?&"VSE;^.W!7DDQV4 JV(@T.8*[CR
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MS"=0UYTU.GPKF;UK2QGFT]ONT]N_RNK.XMZOF-V%-;?EJ)+8WAY%@;!6LR"
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MN))>VO(Z-KB3S.C1JOMG);TKND@Y;=G8?'?J&Q"SKKD88)T?YE4NRNSG0@"
M( @" ( @" ( @" (#3G^H_7_ /$:NO\ @_M'%_\ GO\ 9_[BX]I_\N-L_P!R
MC_E4+7?QY]9=<C_H+/ZD?,7)0BZ" ( @" ( @" ( @" ( @" (#"R6-H9>G)
M0R5=EFG,-)(I!J#IR]8/K6B]9A>@X354R18OW+,U.#RR6\J/:O#XREM>OD*M
M9D=VV9A9G&I>]L5B1C 22>  "Y_Z>TUNWI8SC&DI9JOJDTB^^H=3=N:IPE*L
M8THNN*;+VNG.9" ( @" ASMG"ON/OSU6SVY#U&27V]#Z@5N[Z:5$\"%\%9<\
M[C5])*L:QC0U@#6@>RT#0:>H!:28DD<T/32W<JJ#E+$E:VZ>U(SRWL.A;$UW
M$AVO @:*_P!#*D5585/G_/;59R<95DU3J-7N9!$]T%F$.D<-897'H:XZ<CII
MIJKJ3KBF<,HJ+<9*O![/"IA93(RTZ[ 8@;4F@8P:$- \3IKP"\2Q$YM16;!E
M9FW+EZXLFP?>:[7,8T,#8'#K&N@<-./#V01Q6#BU5K82;7^I%)X,A;K:F6K
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M65SJ$S/9:R8]49(]#O#XPK*VI3PH54H0MM4=/-U&7%%%0,;XX60M-B"R^>,
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MTT/-?549KQGIJG<JY"K#=I2MGJ3M#X96G5KFGD0502BTZ/:=-&2DJHR5X>A
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MBWQ+%BLS7LB25\!TA8!-=)$;.MYT]ANNIYKPB7+37H+&'1V0!'(/*!;%%,?
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M?;U3:FW\?MV@7/JX^(0QND)<]VG$DD^DE<7=N.Y)R>\[RS:5N"BMB)M:S:$
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M(R,,QIGT]&HUB/\ L.^)8ZC3Z;5+&F;BFJ_I-^EOZS1O!/+P:=/%P-Z;<_;
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M4L45B)\,S0^)X+7L=Q#@>!!"U7+<;D7&2JGN,XR<6FL&CS1W0VYDM@[C@S6
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M? D<G-Y$+K-!JK=V*;]I'#\RY==LR<$JQ>QU*1C<G?HW&14P\@'KB="XN+7
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MI9RX\=3P\3JM,XM.CPH6EA1:S5S5.N2&SE&,JV)3<HO?UL@>QA:]VOR7:>T
MH=^SWL'&M*K;PZ2RT^H=BXII5H]G'H+]V^N7<-7;B,3??MXTYI)7QNKB:NT2
MG5P',_R+3IM.]/;4*N=-[-VKU3UMV5RBMUQ45BDN'Z3OWG;=E<H/S9>$]* :
M/]VA\J&>4Z%QD+^(X_)T6OF&@CS&,5<;6393I,>5:^7([D[FGRUN+UJKPXD0
MS$FZ;,]1YAA8X>\P2EKN@N\ [T<#HKFW#N\L']U*/8J(YZ[<[V,KL7[3<NC%
MXD8-M7H<Q%(\B&F[VG6NDR-<P>/'@/0MDK#3XHBK7Q<*-97P^WI)/<^3L4L7
M+YMB*M/,.FH)-=2P?-Z0>.BCNVX.K)MN[&^J1V(I.(KXR]EJ8?YCI].DS$.<
MP2D^P6Z\!Z]0M,EO1;6VDJ/ V5D13P]75[C)*UI)8[Y).G\Z]L/UJHA\PM.4
M<C2Q:5=YKC/967,7J]F6=LDE1O1T0.>V&,#EJP. <?A65RMUUDVV2+%+,:12
MIU8_H1]B@\NG+,VU)++.]KR+1!:[B X@#CJ ?C4*6@M*\K^7_46\F0YA?=AZ
M?/2U+;%>&!9]LL?CLN9J<D9K&&01F9I]X+R!J.#BWI/W58VLV?=0@7XVU;WU
MJ6^O<CR=*22NP,<P$6JG/VO!PUY@JWA-THT<S=LJ#S1?2TO/Z2FVMF6K.1A]
MQ9_RDVKWR'_J^D?)=\ Y*-.RUT%C:NUKO)Z785O$X3$;D>#-CL@R8Q.<"WJ=
M7>6R1]7S@/:'J4FVX*<H)^M&A%G&[*W"ZUZLT^C9NZ>/42G:C;F"W9O*/:FX
M3Y%/(5IX8+)<&2,E/M1.C<>'5KPTY.Y+3S"Y*U;SPVI^0F\HM6[][NYNBDL.
M->CPQ/F^=A[N[-YZ.+(]<N*?)UXO-0:L8_IXM((XQRM\03]T+S2ZN&JA5;=Z
M).KT-S17$I>S]V2^S@S?/:[]I.K8@AQ.^Y.DM 9%G6CV3X 66 :M/I>.'I5'
MK.4/VK7Y?0=-H.>*F6_^;][@ST94MU;]=ENG,RQ4E'5'-$X/8X'Q!:N;<6G1
M[3KHR4E5;#)6)Z$ 0! $ 0'6][(F.DD(:Q@+GN)T :T:DD^I82:BJO89I.3H
MCC#-#9B9/!(V2&1H?'(TAS2T\B".&A6-J["[%3@U*+V-;#V47%M-4:.Y;361
M^3Q5++UO=KT?4UI#XI&$LEB>WD^-XT+7#T@J+J=-;U$<LU7>N*?%/:GU$BQ?
MG9EF@_0^AK>BM6<ON3:6GYUJRYW!-_\ [G38/?8F#73SH1H'Z?/9IZPJ>5_4
MZ/\ B)WK?XH^VOUH['^LJ=);PL:?5^Q)6KGX9>P_U9;NI]IU6^[&RH,/9RU;
M(-M/@:-*+/8LN>_@U@8\ \^9Y!9SY[I%:<U*O^78_*;+7T_K)7E;<<J?WONT
MXU7@SS;O#<>0W;N*QGKI+!*!%6K!W4V"!O*,'AKQ.KCIQ*^<:_72U=QSEAP7
M!'U_ENBMZ/3JS'=BW^)\?1T'S&4'AGGQ'H/,$<U1W+F)E?NJM&2M&4,N-=:=
MKT@AI/($\E[:O]U<C-K,DR%=C6%(DK;EK3](/'IX]31KI\.BZ+F?U$YRC+2K
M*Z49!M6Y1,:,1O+G-'J&O/0>*XJ<IR=9.K9(=4=3P(Y.IHX#FLX/B9K%'.>P
MQ\);SU&BW5,8P:9&]3V#1IT"S3)5$R/L&$_]<P2^,;B6NU^,:+;"M=CH;HSI
MM+/L_NEG=ETW8FM#!<H^<9Q%.7![>H#J:Q[#H =->(.A74\NYU>TD,D4G&M<
M:E+S+D>FU\^\E)QE2F'DJO\  W_1WWB,G3@LXR&U>GFC9(:M:![W,<]H/2Z1
MP;&-"=#J]?0;7-;5V"E!2DWN2?GP7E/EU[E=VU-QFXQ46U5M>;;Y#L?2SN>!
M&5?^:<6=0ZC4DZK4K?1)89IT CFV+C_36;M7]1A<?=P_"GZSZY;ET1_,:E<L
MV/8_U)<6O575'?\ M?E)ZK5K4J\=6I$R"M$.F*&,=+&@>  5E;MQMQ48JB6X
M@SG*<LTG5LR%L-9T6*T-EGESL#V\QKX'T@^"TW+4;BI)51MA<E!U3H8<V#Q<
M\7D/K-+1Q#AJ'@GU\U&>@L..7*OM-RU=U.M2LY/8L;0Z>C(7EHU$+P"X_ 1I
MJN:YCR#/:EW;\1<:;FN*4UXRM3;8N35[#&5GRD-/LM:205Q.F^GKT9-Y7@7D
MN805,4C6NX;&/Q-M^-L1/FR,6GFUV#I,1(! <X\CH>2CZK3QMO+)49T>BL7;
M\%<32B]CXF!2NX^W*RLYCZT\ATC;)HX.<3P:'#Q^%0HV(2V$F]I[MM.5<R7#
MT$PS;V4D.M&K-,\<"QD;CK]P+*7+;LUZD6_$R!'6VX^U)+QG%M*^7.ADB=%(
MTEKF/X.!' @CF"%'M<FU$I8QIUF<];:2JG4D,=M%UI[?-<6M)TT8-7$^&A72
M:?Z?<WZ\J=167>9T]E&VMO=O</CV06;,<DEEH#C#(_JC!!U!+0!J1XZ\%WW+
M^1V-,JJO4W@<CJN;7;E8II+BEB7==&4(0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M[$H2AC%KQ,YSDG+;>HC<C<JI)KK1ZAGVCCLOMANUMU-&<J>4V&:2TT=4G0-
M\D<GCYPXKD5J)0N9X>J^@[^6EC<M=W<]==/GZSS]N;]DIT%IUS8V;=%7.I&.
MOCJZ=>0;(W34?[0^-=!9YY54N1QXHY>]].N,JVIX<)%5JU.]'92;WF&*48AI
M_&Q1ZVL>\>DL'&,GTM4Z4M)K%3[W8_TD2%O6:%U7L]L>S:O%@;8V9^TQMC+B
M*INR X.ZXAOO()FIN=R^4.+/C5/J.3W(8P]9>4O--SNU.BN+(^/W>TW;2NT\
MC69<H3QV:DHUBFA<'L<#Z"TZ*BE%Q='@SH(R4E58HREB9! $ 0'P@$$$:@\P
MO#TJ?U>R6!FEM;3G8*DKC)-@K1(JESCJXUW@%T!/S=',U^]"I_@IZ=N6G:H\
M7!^S7_*_N^5%M\7"^DKZ]9??7M?M+[WD?29E/=5&2RW'Y..3$95W!M6[HT//
M+\5*"8Y!KRZ7=7I 4BUKH-Y9IVY\)?8]C\3\1'N:.:6:%)QXQ^U;5XT6%6)
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M.TYO/!Q]KS(Y8='L,K='EGB?'@MECUNLTZRWD;2V,LEQM.#%VO?M+%:1S8W
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MRWU>5)HXZ?T=53WM'>M8RCAQW%S8UMF]A&6/#8^PO"ADP( @" ( @" ( @"
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M6?7X>@VGB\3C,-29C\35BI4HAI'#"T,:/B"I9SE-UDZLZRS9A:BH02BEN1G
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MX\U[4\H8F,PF'PK'QXBA!1CD/5(VM&V(./K#0%E*<I;74QC",=BH2*P,P@"
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MG4!S>#O3X\E,YGJ+%Z$7!UE]G21M#9O6I-2]G[3TVN>+D( @" ( @" ( @"
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M ( @" ( @" ( @" ( @" ( @" ( @-.?ZC_\#5U_P?VSB_\ SW^S]I<.T_\
MEQMG^Y1_RJ#KOX\^LNN1_P!!9_4CYBYJ&700! $ 0! $ 0! $ 0! $ 0! $
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M(WM]8((6N<(S5)*J)-C47+$U<MR<91V-8,P-O;2VUM*&6OMO%U\;%.X/G$#
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MSJ/*=KQUB=JS7Q:0I/-;*C-7([)[>O\ 21>47G*#M2VP>'&G#Q;#T.J(Z (
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MI-7.^Y6Y98+8J+R])WFF^F]-;MJ-R.>6]U?DZ"ESW,EGLD^]EK+I[D^AEG<
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MS7NS<\$>1W)(<#B9=',@<-;4C"-?D^ (^<H6IYK;MND/6?'<3])R.[>C6?\
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M0[.W//%2I2I*+4; @" ( @" ( @" ("O[LRUS%XF;\V0.L929I94C:TD![N
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MT+N-)KE56;L>[GN6Y_JOP\9\LUW+G1W[4^^M[VO:5?QQW=>PNRNB@" ( @"
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M^YP=N6+ALXTZ>E;#T&8V$]3F@NTZ2=!R]"HB^H=B'H0! $ 0! $ 0! $ 0!
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M/ML>]9;-;OL1ZMIQBE5<?"2<]3R/@:W1>\[O42@M^)E]/Z?;<:Z#U^N3.P"
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M>_$L9:>&KBYV%2:]JVO^J'1QCM6ZJ+AS5R4@7H" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" TY_J/\ \#5U_P ']LXO_P ]_L_:7'M/_EQM
MK^Y1_P JA:[^//K+KD?]!9_4CYBY*$700! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0&)9I4[9B=:@9.Z!WF0E[0[HD'BW4<"O4VMABX
MI[3+7AD$!XJW_'F>X'<R] QCCD+5QF)PE9_*&O&=))B/#0<25U-C+:LK@E5]
M? X[4J=V^^+>6/0M[/5FQMDX;86WJVW\.P!C '6;&@\R><_+D>?'4\O0N=OW
MY79N4CJ--IXV(*$?\2TK020@" ( @*QCMB[6Q&XKNZL;096S62:&VYX]6A_]
M+I'#4^)T6Z5^<H*#>"-$;$(S<TL66=:3>$ 0! $ 0! $ 0! $ 0! $ 0! $
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M4M^\^0\_Y4N7ZIVXMN#6:+Z']JV%V5F<Z$ 0'S0:Z^* ^H @" ( @" ( @"
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MD( @" ( @" (#1G[2N:SV,PF#I8VU-1Q.1M2196W7<8G'RV!T,1>T@@/)<=
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MCSZRZY'_ $%G]2/F+FH9=! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! 4O!?YC[N_NF*_Z$ZL[W]+:ZY_]I1Z;^OO?JV_^\NBK
M"\" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M#'KUJ]2/R:L3((AJ1'&T-;JXZDZ-&FI63;>T\22V&0L3T( @" ( @ &B ( @
M" ( @" ( @" ( @" ( @.!>P.#.H!QY#7BO*HRH]IS7IB$!1.UW_ '+<O_T1
MY7_BA5F@V7/_ ')'3<_]NS_[%KS%[5F<R$ 0! $ 0! $ 0! $!@9;%4,YC;>
M'RD(L8Z]$^"S"[@'1O&A&H_C\%JN04XN+V,DZ?47+%R-VV\LH.J?2:UVKV!V
MEM?/5\\+EW)/HO\ -QU6Z^,Q02#7I?[#&ESFZ^R7'ASYJHT_*+-FYG6T[#F'
MUAJ]78=G+&&=4DXUJUPQ>%=]#;*O#A@@" ( @" ( @" (#3^5_9TV5E,Y/EO
M>KM6C;E-BYB8'L%:1[R7/ )87M:XG4M:[X-%17.369W,^)WNG^M=;:L*WEA*
M4513:>9<-]&UQ:-LUJT%.O%4JQB&M QL4,3!HUC(P&M: /  *ZC%122V(X><
MY3DY2=6W5OK.]9FH( @" ( @" ( @" ( @" ( @" ( @" ( @" \N]_MIS8;
M<D6XZSO.JYQQ)B ]J.Q QH<3IS:YH!U].OJ7SSGNB5J[WM<)^<^S_1_,5?TS
ML2P=K?Q3?G-:C).FC\O0M=R(/@5QKL).IU_<4=2Z9_/4LX=O-QSY [&XNO1L
M%[>C2Q"YQ);QXCB/:4SF6HC<C;R[80C%]:J<_H]).QWV>GKW)26_!\3LOYO/
M6&0/N9>W;;#*V:)L\SY R5GR7 .)&HT54^8ZBXUGG)Y755DWYS&UI+$6\MN,
M:JCHDJK@6&W;VINJ0YC)6;&#S$@!R#8J_O=6:1H ,C US7,+M.(_^NK6_>T>
MLEWER3M7'[5(YHM\5BJ5WE7;MZK1KNK<8W8+V:RRR2X/!UH=-7.X+!YW'9+;
M=>=U>@"RQ-:?TRV_,!:]W2-1'[+B&Z?&M"UMC2ZFW/3Q=(;6WC*NW]7#89W-
M)?U%B<+[59[%'9&FS'[V.T[K^7Q<;9[%;=>;E;(UYJXXB1LK'D'I$LSI"PM:
M=-2T:D<E,GJ;-)2C?NO#".->BLLU,-]%CT&FSIKKI&5BTN,L*>*-*U97K&9J
M.VKC\1[1NU\A8N3 M]CRY8FL&CCS.H*@SOPEHU:7M*;?B:CZ"UAI9_%3N?=<
M(Q76FV<=^YRAN'<=[)XXN-6RYCHW2-Z':-C:TZCPXA9<QO1OZN=V/LR?V(SY
M1I)Z;3QMSVQ])1KW3$/QKOQ;M7=8\-.8(^!8VDWL.CM8[-IN_8'8_$97"8[<
M.:LV&NO0MLLIL C+&OXMZG$NU)&AY!=CH_IUWH*=RXXJ6Z*Q[77S'SGG'U7=
MLWIV;48^JZ9MO7@;GQ^VL5C*0H5VR/K=)862RO?JT\-""="/B77Z?E]NS#)6
M4E_FDV?/KVONW9YW1/H2-59#MUF-A[J&[=AQ>;CI-?>,8220UWRV>)+?%I\%
MP?-M#?Y==5_3IRA%U5%FR\4UM<6L*_:DSMK'.K/,=+\/JW26Z7F?7Q-M87*_
MGBBRT:TM60@=<,[2US7>(]:[#DW-ES"UGR2MRC@U).E?\K^\O!T.$U6F[B;C
MF4EQ1**^(80! $ 0! $!K+&_Y]Y__P"AK&_^,LJ2_P"$NM_80H?U$OU8^>1L
MU1B:$ 0! $ 0! 4_/_\ S_L__LLK_P &)5&I_J[/5/S(O]'_ $&HZ[7_ %2+
M@K<H @" ( @" ( @" ( @" ( @" ( @" XOZNAW1Q?H>D'EJM5QR47E]JF'7
MN/5MQ*(WM;M^]<DR>XVORUZ4ESFRN(A:7?-:W1<+RWZ3C!9]5-SN2=99?5C5
MNKQ]I]JZCIG]0:BW!6[%+<5PVFMM_P"TZ6P-Z[<W#M:#W2*>4F2!FO0)(BWJ
M YZ![':%5?-=/\KOQG:;R^U%/&C3Q5=K6S;TXG8<GYC/F6CO6=0\S2V]#]#/
M0H.H!]*^HQ=54^4E;W>YABQ%.0ZQW,I4CD9SZ@QQFT^[&J[7XJ$?Q3CY,?L+
M#0X.<OPPEY</M+*K,K@@" T/MK;PW=W6S65W#"+$&/+C'#*.IG4U_EQMT/@U
MO'1?*N6VUS+73[[%)RE)<:.BCU>@^G:_6?!<KMV[+HY[UU5;\9M7,;)VSFJX
M@M8Z%CF_V4T+!%(P^!:YFG)=AK/IW17X-*"MO\4$HOLV/QIG$:;FNIL2K&;?
M0W5/M)'"X]^+QT5!\OG-@U9'(>?0#PU]86_D?+[NATJL7)*>5RHTJ>JW5$/5
M7U>N.:5*^<DE?$0@)]IX:7*?GJ!DE+)N<'36*<CH/. .NDK6GI?KXES=?6JF
M_P KL7;BN4<9UK6+<6^NFWI+"&ONQM]VZ2CN4E6G5O7B="?5L5X0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! :<_U'_P"!JZ_X/[9Q?_GO
M]G[2X=I_\N-L_P!RC_E4'7?QY]9=<C_H+/ZD?,7-0RZ" ( @" ( @" ( @"
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M! $ 0! $ 0%/S_\ \_[/_P"RRO\ P8E4:G^KL]4_,B_T?]!J.NU_U2+@K<H
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M]#WLC=TR2M +01P.G'4Z*++413H6,-#.4:X$PQ[7L:]A!:X:M(Y$'B"I*=2
MU1T9S7IB$ 0! 5W>^UH-Z[4R6V+$SJS,A&&-L, <8WL<)&.T)&H#FC4>(474
MV%>MN#WEMRKF$M#JH7TLV1[.*V/R&G=A]@]PXG=./S6ZLC4EHX686:,-'S"^
M:=FHC<\O:T-:-==.)/P+G-#R-V+N>3\.P[[F_P!7Z>]I9VM/"2E=5).5,%OI
M3:ST(NM/E80! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!H?N?A
M&[Y[CX?!TX^IM.-K<C.T'1K'O#R''U-"^6\TO1U/,^ZMTJ\L/&JN3_93\E#Z
M;R'5? <NN79/VGZJ\5/.;PJU:].%E>M&V**)H8QK1H UHT ^(+Z9;M1MI**H
MD?-[ER4VY2=6R.W/A?S_ (2UBP\1R2MUB>>(#VG4:@>'@5[=AFBX\27H=5\/
M>C<I5(\B;\V!G-FWF-NP^7'9#I*TT3NN)P!T+>K0>T->7HT*^?:[E\[6U'W;
ME'.+&NAZKJX[4]I4*]B6.0,)Z7DZ$D\U07+:+Z<$U4F(Y?=W,>]X<'>(YZ^M
M0'',07',L#*DOM<  =2M*M4-,;5#BRT'N:W7F=/NKUPHCUVZ&66-\HNUT(X\
M?#172Y?:^%[W-ZW CYG6A$6+['- :-0.))]2K(6F3X6684CW6P2TA@;J #QU
M].I4B*RDA+(;6_9_P'O>Z6Y"Y&9&487S5PW@&R?):]WJ]HAH^-=[R'1.*=U[
M]GI.'^L=9DTV2+IF='U</2>IEUI\7" ( @" ( @" ( @" UEC?\ /O/_ /T-
M8W_Q=E27_"76_L(,?ZF7ZL?/(V:HQ." ( @" ( @*=G]/U@;.]/E97_@Q*HU
M/]79ZI^9%_H_Z#4==K_JD7%6Y0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0&G/]2'^!JY_P"#^V<7_P">_P!G[2X]I_\ +C;/]RC_ )5#UW\>?677
M(_Z"S^I'S%R4(N@@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MM=VAK;KM27<M+(W"4R!- W5CYY7 D,#AR;XN(X^"Z+E'+5J5WEU42\IQ7/\
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MC4\J @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @-.?ZC_\  U=?\']LXO\ \]_L
M_:7'M/\ Y<;9_N4?\JA:[^//K+KD?]!9_4CYBY*$700! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!6]\;:;N_:^0P'F>1-98#6FT
M_LYXG"2)QT\ YHU4S1ZCN+T;E*T\VQE;S+1?%Z>5JM&]CX-.J\M"L8WNC5Q=
M5F-WS3N8G<E6,1VF-J3V()Y&C3S*\D+9&N:_F..O@I]SEKF\UAJ4'LQ2:ZTZ
M;"LL\YC;CDU,90N16/JR:D^,6JUKUF)O+,Y7=':O<UJ7!V<:R5H9C:\_MVYZ
M_F,+9'1-'4PGC[)U.BV:.U"QK+:4U*FVFQ/'"N\T<POW=5RV\W;<*IY4_:DL
M,<OW>HE.ZT4\_;^2.&-\LGGXX^6QI>_06HB3HT$\ M'*VEJ:O#"7_2R1SV$I
M:*D4V\UO9^O$[K44Q[O8V<1O\AN M,,H:XL#S:B(:7:::^I8Q:^"DM^=>9FZ
MY"3YE"5,.ZGC^U$P=A0SQ;3W3'+%)&]^5S#F->QS7.:][M" =-=?!;==).];
MI^&!'Y3"4=-=337^I=_ZG0ALA6LG]G>*H()#<_-%5GNX8XR]75'PZ--=?B4F
M$E\SK7#._M(5ZW-\CR4>;NDJ;]BW&7OK$2UMPX'=EMV0;@H:$F-R,^(?*RU5
M,CV2,E<(07NBX=+^D'3@=%KT5VMJ=I9<SEF6:E'NICA7@;N9:=QOVK\L_=J+
MC+)FS1K1I^KZS6&-.PR-LU-IYG<M6[BKN=R]C$LDFAOWI+;J,3IF^6Z,&P&A
MSW-/)H/+BL-3.];M.,E"*EN2CFPQKAN-NDMZ6]J%*#NS=NKS2<\JKA3UL&VN
M%>TENV[)8QNP2L?&7;CR3F=;',ZFES/:;U :CUC@H_,&GW?_ +<29RE-=]5-
M?ZT]J:X;./7L*L-O9//[)W[BJ$;FY"7<-ZS4BF!B;,8+$4S6ZN U9)T=(/)3
M^_A:U%F4MG=Q3Z*IKM14?"7+^DU$()YN]DU7"M)*2ZTZ4+/0[HX2\ZG0BHY'
M\_6)(X9\1[E,R:N\G1[I'/:V,,9S+@_ER4"?+;D:R;CD7WLRH^K?5]1:VN=6
MIY8J,\[:3CDE6/&K?JT7&O47Q51?! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 4_N;NRULG9
M&5W'1@]XNUF-96:YI=&V2:1L;7R $>PPNZG*%J[SLVG)+$O^1<NCK];;L3=(
MR>/&B5:+I>Q&ANW?=W?XWCB*.?R?YYQN<L-JS5G111NA=+KTOA,36D!IYM.O
ML_=7)\NYQ=N7\LL4V?3.=?3F@^#N3LP[J5J.9.K=:;I5?EXGJE=R?% @" (
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M_GO]G[2X]I_\N-L_W*/^50M=_'GUEUR/^@L_J1\Q<E"+H( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @,/(X^CEJ-G&Y*NRS0MQNALUY1U,?&\:$$>L+7
M."DFFL&2+%Z=F:N0;C*+JFMS*5M;LSL'9V69F\12E=D86N96DM3R6! '\"8A
M(3TDCAKST4"QR^S9GFBL3H>8?4^OUMIVKDEE>W+%1S==-IL%69RP0! $ 0$=
ME\@['51*QH?,]PCC:[734ZDD^.@ 6B[/(JDO36>]E1[# P^9M6;/NEP-<YP<
M^.1@T^3S!&OH6BQ?<W1DK4Z6,(YHG9D=W[6P^1AQ.5S-.ED[&GD5)YXXY7=7
M+1KB#Q\%NGJ+<'EE))F%GENJO6W<MVY2A':U%M$XI!6A $!T6:[+5::K*2(I
MV.C>6G0]+P0=#QXZ%:Y1S1:>\VVYN$E);4ZGEIG[-^]1>_,+K=+ZL&3H.5#S
M[P:WJ@Z?[33A\O37U+B_D-SO\U<*^'^!]H?UOHLG?99=[3V*>KF_6KL\53U-
M6@95KQ5H_P"SA8V-FO$Z,  U/IT"[6,<J26X^+3FYR<GM;.Y9FL( @" ( @"
M (#!RF)QF;I28[+4X;U"73S*]AC9(R0=02' C4+5.W&:I)51)T^HNV)J=N3A
M);TZ,ZL-@,+MVI[C@J$&.J=1<8JT;8P7'F3H!J?65Y;M0MJD4D9ZK67M3//>
MFYOBW4DUN(80! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M!IW?W=6OL'<T.(KT6WG:BS9 ?T.C;8 U8.!XNTZAP7&:WF/P=]PA%2H\WYMJ
M^T^@<H^GY<QTSN2EE^ZL-N7?XMA9]G]U=N;O>*\'F4KQ.@KS]/$^H@Z:K?IO
MJ737;BMSK;E)T5?9?#'IZ:%+S/Z>U&B69TE'BB]KK#F0@" ( @" ( @" ( @
M-98W_/O/_P#T-8W_ ,994E_PEUO["%#^HE^K'SR-FJ,30@" ( @" ("ISX#(
M2=Q*NY0(_P UPXF6@_5Q\WSGSB0:-TXMZ?'55<M/-ZM7?NJ&7QUJ7D-9;7+Y
M6,<[N*713+3:1&T^WDFV[6Y;!E$S+W75P49<2*V/=U2B+C\D&:1WIY J+I>6
M]R[CXU4>B.+IVLG\QYTM5&S&E,M)7/\ -/!9ORI&)#L?/LV)L[;SA!^<<)?H
MVK^DI\ORZTCG2=#NG5QT/#@%@]#<^'M0WPFI/J39OES6P]=J+V.6["<8X8UD
ME2N.!L'*5Y+>-NU8=/-G@EBCZCHWJ>P@:GCIS5U>@Y6Y16UIKR'*Z>:A<C)[
M$T_*4BMV^M6>WVW]OW+#<?N7!1P34<A7_'-KW8 ='#4-ZF$$M<.&H*K/@'+3
MP@WEG#%/@SI)\YC#F%V]%9[5UM2B\,T7VT>]'9+/W=LU3C&T<12N/'ENSS+$
MLL; >!D95=&'%WH:Y^GI7CEKI++EBG^*OF5#",.4QEWF:Y*/N\J3ZG.NSII4
MO%6.:&K##8F]XL1QM9-8+0PR/: "XM;P'4>.BMX)J*3=73;Q.;N24I-Q655P
M7#H,A;#4$ 0! $ 0! $!KK<9_P#YN;)U/'W/*\/_ +FQ65K^FN=<3FM7_P#*
M:?\ 4N_]IV=V U^*P$<@#F/W!BPYKN((,W(CQ7FA]J7ZDO,>\_\ X5K_ -ZU
M_P!1R[CAOYSV,[AU?6*N [AKQ@FX)H_9N?J/SHRYO_$TW_O+_IF5PMS%+NAN
M6$YZM@K.3CISXV6Y4;8%FI##T.CA>^6/3RW@]3!Z>I2:P>G@\KEEK6CI1UZM
MY54O0YC>7>QM.:@XYHUS14:43S+8]J\>\LFS<9IN;-9M^Y*N<R$L-:GD(J-9
ME>-CX>I\;GEDLH+^EY'P:*+J+G^G&.1Q6+577[$6W+K%+]RZ[L;LFHQEECEI
M2K5?6EC1]E#*[EYZ_M_;C+./?%6ELW*M)]^PP20TX[$H:ZP]KB 0SPU.FNBP
MT=J-RY1XT3=.--QLYUJYZ;3YH-1K*,<SV04G1R>S85#<,-FCN;8M6?<PSA?E
MA(V.=M<6VZUY 7M= &#RSKIHYOHXJ;::E;N-0R^KTTVKCO*?51E;U.FB[W>_
MZE:/+F]F6*<:>KXN&),8.]1PO<O=L&>FCJY'*"G8Q-BRX,;-1BAZ'1Q.<1J8
MWAW4T>G5:+L7/3P<<5&M>AUW]9-TMV%GF%^-UY93RN#?WHJ-*1_5:=5TU.7<
M?+X?,]M-V286U#<968Z"U)7<'M;.QS"X$C@2 1JFCMRAJ(9E2HYSJ+5[EVH[
MN2EE33IQP\IT[VNT[F*V1-4L1SQ?G[%,,D;P]O5H3IJ"1KHLM+%J5RJ^Y(U<
MUN1E;TS33_UK1U;QRL/;G>'UQF&F%SM)]/(@#A^<*+'2U7</&1G5%]Q>Z>#U
M%KNU[475=3V^D\YC?CRW5?$R]B[%QE^O!-P?C58]AT$Y;8?:N3*NC8[<F4G9
M=R]JPSS(X;&2F;URRM\6PM<!Q^:O?5OZC+]V."ZHK[3!=[H.7=Y1=Y-J4V]B
ME.2JWT17F,/=\-JE/LZ&SND9WS\]CI613LKML:]?&2!U<,T9Q]IK@>!YK;IV
MI*XU#+ZDN-/'4B\QA*W+3J5[O:WK;QRYNN.5+#BFG@]I89+=:EWFD=<GCKLG
MVXQD+IGM8'N%YVK1U$:Z:J+1O28?C_[2USQAS9N32K9C2N_UY>DKN &;J;MW
MCC?K)5P>3FR;[HKW*C9Y9Z<K&"&6.1\T>K&M'1TC7I(4JZX.U;>1R66F#V/>
MMA5:17X:O40[Z-J3GFI*-7*+2I)-R6&["M'O.^U@;4VRM_V<-G(MP7LPU_G"
MA"V")MFO"(YF,:R20%[V =7K6$;J5ZTI1R*/'A7 W7-))Z/5.W<5Z5RM<JHL
MRC1K:\6MO22.5W3LR;M/9?3O5!CI<2ZO6K!S"X2>1T-B$7R@YKOO>G@M=NQ=
M6I54ZYOMVU)6IUNC?*Y.$HY';:2P_#3+3["X;&X[+V]QU_\ 9M3CS_ZEBAZG
M^+/]9^<N.5?T=G]2'_2B/[I_Y=;FU_\ P"?_ *)6S1?QX=:-'._Z"]^I+S&5
M5@RUK9N-BP=R.ADG4ZOE6IH?>(V@,87?B^INNH]:UMQ5UYE55?0;XPNRTL5:
MDH2RQQ:S+=NJO.4W?V+W5%L>T=PWHLU7KWJ5R\RI5-;7'02M=,PL#W]0^_/J
M"G:6=OOED67!I5=?6W<"BYK8U*T4N^DKB4H2EECE]1-9L*RKQZMQ>(]U[3F;
MC1%E*<K<A(R/&LCD8\OD</9#&MU(.GW%7NQ<5<'AM.A6MTS4*3B\_LXK'J-<
M8;\\U=[;QQHW%5P63L7Q=9%<ILF?9I/B:V%\<KYH]6,Z2SI&O2?A5I<R.S;>
M1R5*8/8ZX[O\3E=-WT=9J(*[&W-SS4E"KE#*E%IN2JELPK1]9D3XV*#:?<;+
MQ[A@STF0JS,N^YPMKUX;56JYCM R20%[FEO7Q\%Y&=;MF.5QHU2O!OPH>W;*
MCH]9<5U77.,LV5))2C"FYO&E*X\#OLD>=VA]>FGZ,*P7_P"?P^\29O\ H>O_
M /Q,VPJ@Z\UEVGAED[8!E B.[.[)>7(.!\YUB9K7$^K0<5::^BU&.SU?,CE/
MI]-\N]7:W<[<\BO=OWY6'9U>I'N_'8=N-;)!D\9;Q\?G5IV.=YK9B^RPN)/M
M=1;[6JDZO([K>1RKL>;;PI@5G*.^CI%%7X6\E5*+MJL6JYLWKKKK3';O.S,X
M>#!;!VHYM[\];3QN9KY&_9BB+(CCWRR/:0P.=^*B=(SAK\D>I8V[CN7IX99N
M+2Z_2S;J-/&QHK%)=Y9A<C.37X&VUA7V8MK#91<#9K=T;7GM4*T64J3V\@7.
MQL<4K)GRZ,ZG%G23][XJK[BXDW1X;3JUK=/*4$IQ;G[.*=<*X>(IO;7*8G#5
M]P8C+VH*6XJN6NV,J+#VQ22">4R13^V1U,,9;H?4INLA*;C**;BXJGH[2CY+
M>M6E=MS:C<C<FYUHGBZJ74XTH562G>RW;[N+>P$;W83)Y&6WBH8FZ">O$8S9
M=$T?>R=#]-!Q4Q2C"_:4]J5'T/=V%-.W<O:'5RLKU)SS0I]Z*RYZ?K4?G+)O
MK=NSKW:O(_FW(59:US'F&A4B<U\G4&#H9Y3=7-+-./#V=./)1=+I[L=2JIU3
MQ+3FW,-+/EDW"<:2A2*75LHN&_#"F-*'*RUC]X]KFO#7:4+[V@Z'1S:46A&O
MB$7\*]UQ\[,II/6:.OX+G_3$DLL .[VW#R<[$9 '_P"^1$ K5;_II_K1^TEZ
MC_Y.S_[=SSQ,+9>;QFW\+OC,Y2<0X^CN')R3R<R.GRM&@?.).@'B5GJ;<KD[
M<8K%PB1N6ZJW8LZB[-TC&]<KY/+T;V<MBOKY;)R[TW%?JNW#EF^3B,5Y\;W4
M,>?:9$UNI_&R#VY2/@7FI]6/=P3RQVO\3_1N-G*UWMQZF])=Y<]B-5ZD-T?U
MGMDR$P_YZJ;XWCCV[BJX+)6KS;T<-VFVP^S2?$UL+XY'S1=36 .9TC7I*D7,
MCLVWD<DE3!TH^QE9I^^CK=1!78VI.2E24*N4:))IN4<%LHJT9(4L)MZ7%;TO
M[@W/7RN'RSHX<U-4B;5@K3P,;&7 LDD >08^H^D<5JG=FI6U"#BX[*XU3\&2
M[.EL.WJ)7;RN0N83RI14915-S='3+7I0@S6?VKD<%3?N&GNW Y6U%0@B\N-F
M2C;(#TRM? 2R5K /;<6C@CMPNQDU%VY15?\ +Y=@6IOZ2=N+NQOVYR45@LZK
MO]7"26_!88FUU4G7A $ 0! $ 0&G/]1_^!JZ_P"#^T<7_P">_P!G[2X=I_\
M+C;/]RC_ )5!UW\>?677(_Z"S^I'S%S4,N@@" ( @" ( @" ( @" ( @" (
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MJ6F\CP^SHVOQ$&7.=$FEWB];LQV5>Q5Z:%N!! (.H/(JO+<^KP]" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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ME?L0[J5NF]TDFZ;]_3O/3"[0^/A $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MM+CVG_RXVS_<H_Y5"UW\>?677(_Z"S^I'S%R4(N@@" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ("I=Q<U'@=GY#(2TX,@W\5![M;
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MZ_X/[9Q?_GO]G[2X=I_\N-L_W*/^50==_'GUEUR/^@L_J1\Q<U#+H( @" (
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M\Q'Y-I+5O179QBE)N[&O0G*B\1TO8<KMCM7M2W(^/!9J"$9-K'F/SV5:(E9
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M_J1\Q<E"+H( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MI3%NM*UV[GLZ#H==H+>ETMJ3J[EU9NA1_27)=,<\$ 0! $ 0! $ 0! $ 0!
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MF,=N5U335?&N)QP^R:6(R62R_OUR[D,M7BK79[<C7DB$. <T-8T-)#N0]D>
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M%PV(*\;2T1.;:#0XN&A.HZ>'$+3&\XP<-TJ>0EW-'"=^%]MYH*27#UJ5KV%
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MZ?1V[<U22JVN%6W3Q5IXBWJ&7(0! $ 0! $!IS_4?_@:NO\ @_MG%_\ GO\
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ME AFOH'5Q74:&.H5E?$.,KF_*FEU*NWKW\#BKN3,\E<O3M,I6!I" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MP^!(4J[*W<:E<4E.BP2]KAU5ZF5>DM:C31G;T\K<K6:5')NMMU>9-)4EE?\
MFB]S:VF?V<CE&T);$DGO#+>2R%F&UT]'GQR6'!LH:.0?IU#P6OF#7>TV44?,
M2OIZ,EI6V\V:=QUV9DY/UO'M)+?F!S65&$R6WVP2Y/!WVWXZMI[HHIFB-\;F
M=;6NZ3[?#@M>ENPCFC.M)*F!*YGI;UWNYVJ.5J>:DL$\&FJ[MIBYC;>XILGC
M=Y8IM)FYH:GN65Q<[WFE8@>1)T-F#.IKHWZEC_+X^(65N]!1=N5<M:I[T^KI
MWXFF_H[[N0U-M1[U1RRBV\LEMIFI7U7L>7HH2NWF;KEN2V]P5,=CJGEAM:C2
M<^Q-YFNI>^9S(QIIPZ&M^-:;O=I4@VWQ>'D)FD^*<G*\H05,(QK)UXN34>RG
MC.O8FWKVV\7<IY!T3II\C<N,,+BYOE69G/8"2&\=#Q66INJY)-<$NQ&'*])/
M36Y1G2KG.6'"4JHP]M;4R>(VIF<+;="ZWD+&2G@,;G&,-NO>8^HEHT^5QX+.
M]?C.Y&2V)1\AHT6AN6=-<MR:K.5QK]INGZ3"O[)R]KM+'L>-\ S#:-:HZ0O<
M(/,@=&7^UT%VFC.'LK9#4Q6I[W&E6R/=Y9=ERM:5-9\D8]&%-]*^0V"P%K&@
M\P #\05<SI%L.:\/0@" ( @" TY_J/\ \#5S_P ']HXO_P ]_L_]Q<>T_P#E
MQMG^Y1_RJ'KOX\^LNN1_T%G]2/F+DH1=! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0$#-
MMJ&2=\C)W1P//4Z$-!TU/$ ^&JA2TT6ZEI'7R4:-5?$FHHV0QLBC&C& -:/0
M - I:5%0KI2<G5G8LC ( @" ( @" ( @" ( @" ( @" ( @" ( @" K^\\-D
M-P[6RF%Q5OW*_=@,4-DES0"2"02W4AK@"PZ>!4+669W;,H0=&_#R["TY9J;>
MFU4+MR.:,75KPX;3Q.?/IF7&6&!OEO?&6>!T)8X<.8.G!?+UWFEU$;BPG!I^
M-8H^]Z[1V=?IY0GC"[!Q?5)%%SN$D][DFKGVR-9(SPZM. <#ZQP/K7Z:T.KM
MZ_3QU%KV9[N#WKQ>:C/PKS'07>4ZN>BU"]:V\'NE'[LD^E;\<:HB&X^5QT=J
M%*5MD5W50E*= 1Z'3BMT8$.Y<J2T$$LKVP0-UFD.C>&FG#B[7F-.:\U6JM:2
MS*]=>6$%5^CI;V(]T6@OZZ_"Q96:Y<=(^E\$O:? N<4XQ\4,46KO*:&#7F=!
MI]U?D_F.JEK]3<OSVW)-]7#L1^[.3<IAH-%:TL756HJ->--K\;Q-I=A-M2YC
M==G=5F1L4>+!\NL"'/EEL,+0[@>#6C7XU??3VEA.[FS?P]V_&J["E^K]<K.E
MCIXJKN;^"B_._,>FE]&/CH0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M&V]K,TDM@JTJE%CH:5>*O$Y[I',A8&-+WNU<XAH U)XDHVWM"26PRUX>A $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $!"MVMM]N>?N88^+\_R-$9OD:R](;T:-
MU.@]GAP6[OIY,E?5X$):*QWW?9%WGXMY+]322W7VAQ(\>/+4+43*G->'H0!
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MWO-6<8_BE&G:DVT2^Y=\'"7<#4Q^.ES+L\)_=!5>T.<Z&$2LTZM&]+]?:<2
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M.%:(\!\B+I\/$KS6R6=06R"R^GRF7);4NZ=Z:I._+.^A/V%NV1H7I0"_" (
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M&WK+L8JD5.5%P52PJ>500! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MCE4G0P>EM-YG%5?AB6X -  &@'(*.2#ZO#T( @" ( @" ( @" ( @" ( @"
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MJ'J+T[K5'-MTZR34@AA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!IS_4?_@:NO\ @_MG%_\ GO\ 9^TN
M/:?_ "XVS_<H_P"50M=_'GUEUR/^@L_J1\Q<E"+H( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MB='XU5%C5B5 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M?,AKFGJE^QYD0$8GPFR^S.]K=2:Q@=MPM.:;#$Z62O'<I>0RRZ, N+8G<7:
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MZ<D/ @/@ :- - .0"'I]0\" XM :- - .0 T"'K=0YK7 =0U XCQX^E <D/
M@.+0UHT T'H]9XH>L%K7  C73B/'CX% <D/ @.'2 2X =9'$Z<=/1JA[4YH>
M! $ 0! 4S)XWN/?OR5Z><QV,P;WES;,-*27),CUT$;?.F=#U:?\ 6%A_V5*A
M*TE5IM]>!*4K*2]5M]>'FKX;3[/VSVC;P-[;^2J/OPY3H=D[MJ5\EZQ+%QCD
M?/J']3#\C0AK>0 '!>+434E).E-G RCK+L)J<71K939V>?B:I[RX38/;?MS!
MM_!;>HR9BT!C\.^>-LDT+IY U]ATC@7EP<_@2>)]0T5CHY7+][-*3IM?H)VD
MNWKMQR<FDL?!&%)^S?LG!7=O8F[)8L19,2TY[AD;'T7(Z_G,<T=/M=;F2>R?
M5Z%C\?>FI.O3XOT&V/,;CC)JBRT["VY#L_L+8FP]P9&''LMY2IC+TS<E9;U2
MM>('EI8WY+2#\D@:^M1X:F[=N13>UHB_&7;UQ1K1-K NO:ETKNVNTG6-3/\
MFJF'DZEQ=Y+-22?$^*T:FG>RIQ9'UR7?SIQ.&>[;83,YENY:,]K!;F Z7Y3%
M2^0^8-Y-G80YDH ^>U(7Y1CE>*X,V6=?<MP[MTG#A)5[-Z\19W8O'R6Z^1L5
M89LI788X;SXF>>UI!U#7].K0=3J M.9TIN(7>247%-T>XSU@:P@" ( @" (
M@" (#X0"-#Q!0]   T' ! - 3KH-1XKP5/J]/ @.+6M&N@ UXG3TKQ(];.2]
M/ @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M-R&:C]I4?46-:".$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&F_]1W^!JZ_X
M/[9Q?_GO]G[2Y=I_\N-L_P!RC_E4+7?QY]9=<C_H+/ZD?,7)0BZ" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" TY_J/_P #5U_P?VSB_P#SW^S]I<.T_P#EQMG^
MY1_RJ#KOX\^LNN1_T%G]2/F+FH9=! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M\/JYW%^V\/Z'A^F3O;'NW^9^@?"Z[WZ_E+]X?5SN+]MX?T/#],G>V/=O\S]
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M\??JYW%^V\7Z'A^F3O;'NW^9^@?"Z[WZ_EK]X^?5SN+]MX?T/#],G>V/=O\
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(NFW_ #>(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2227887d1-lc_human4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-lc_human4c.jpg
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MW4;7L:9(S1PI(UIZ? LKX[4G2T:2QIDK>-:SK"^+6V" @(" @(" @(" @("
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M'QFD'O7/S8IQVFLNAARQDK%H94M+<(" @(" @(" @(" @(" @(" @(" @("
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MS'>X7:.'L;Z%VN&[AL+=L['>ELFC6.SN*X]LV2W";3\;L5PXZ\JQ\2+O./\
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M)R!SJ@D$'K[+:;N<D]%^?@1N]I&..NO+PMB>)MZXSD;AF:7CZTML#F;:RN;
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MXF3P2 $. ?'('-=0@'J%%;36=8X2FU8F-)4$>T-I18)^UXL#CF;9?77A6VD
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M:!K#&X%M!04%.BUQ:8G6)XMDUB8TF."Q8WC#CC$65[C<;M/$P6&1 9D+=ME
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M[,;LV)C'V6P,+:RLL3H<R-C'0,LX6N+JG7* ^2CCJ/4GK5:MW,UP16T^E/\
MU;=I$6SS:L>C#83E3RZ\>\L7K<QF([C&[A#6QORN.>V.6:.,4:V9DC7L?0=
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MYC9[J5TI8'#MT!P97OITZ+E;G+&3)-HY.KML4X\<5GFD55ED0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$&.9CC_ &'N&[-_G]K8C*WSA0W5]C[:YE('
M3J^6-Q[O2MM<MZQI$S'PM5L5+3K,1/P+KB<+A\#9MQV"Q]MC,>PU9:64,=M"
MTF@J&1M:T=GH6%K3:=9G5G6L5C2(T5RQ9" @(+#FMC[*W)>QY+<6V\7E\C"Q
ML,-YD+&WNIV1L<Y[6-?*QS@T.<YP /:2ME<EZQI$S#7;'2TZS$2OD<<<,;(8
M6-CBC:&1QL :UK6B@  Z  +6V.R @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M7ZQ]0^3/M+F^BH/E4]JV_P!C]*?,?E'<OQL_=5^L?4/DS[2YOHJ#Y5/:MO\
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MOH^\@=?1]Y!V;7T44CE 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M7!KC):)UB>*J5E@X<UKFEK@"TBA!Z@@J)C7A(LXVGMH3^\#%V_BUU?$&FO\
MT?B_>7(_)MEU]7JJ:^]^[DL>TY=-.J5W+&.88RT&,C26$>SI[*4]"Z\UB8T\
M#1JMEMMG 6ER+RVQT$=RTZFR-8/9/I:.P?<7,Q=IVF*_K*8JQ;QZ?)XFZVXR
M6C2;3HKG65H^[9?NA8;R-AC9.1[88>T ^CJKLX,<Y(R36.N(TU\.GB:NN=--
M>!:65I8QNBLX601O>9'-8* O=VD^LIAP8\,3%*Q6)G7AXY\):\VYSJ]UO8B
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M,)JR,'V * @@_ O1[;;Q...#Y?W?N62F>8F>7@6VWW?%?D/OGNDO  V-KOB
M#[JM>RZ<E&G=JY/G3Z3)MJR/O\W:N!$CZG\I6K6M#3V!4MS'367=[;;UF:LI
MJB:6T_Z(J?6O/>%]#GRO0N [_O*=&.KH^4,:7.H ._I1(A,S$<94T.5L9W%D
M4['/':T%I/WEE-+1X&FN;':=(E5^(T]A'WEAQ;W!D /4@#TFB(U>,U_;0-+Y
M96-:.M7.:%G%9GDPODK7G,,9R>^[6V!;9P.N"TT+P0V/[A[U;Q[6;1QG1Q]Q
MW2M.$1U+]A<A+DK&.Z?"83(*Z'=JK9:]$Z<W1VV6<M(MIHN5!Z0M2T4'I"!0
M>D(%!Z0@4'I"!0>D(%!Z0@4'I"!0>D(%!Z0@4'I"#D?"I'* @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M<*=E#U1,PW31B(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(""ER61LL/CKS+Y.86^-L()+J\N'5+8X(&&21YH":-:
M">B#!MG\Z<4;^S3-O;0W+#E,R^-\S;2.&X8XQQ"KC66)C>GPHG1(:($'A!?6
M5TYS+6YBF>SX[8WM>1\(!-$'N@(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @("#@]B#K0?JHH"@_51 H/U40*#]5$"@_51
M H/U44C%\/7ZS;B_U7^#7GMA_69?=X5C+_*JR5M-9KZ%Z".31/-WH/U41!0?
MJH@4'ZJ(%!^JB!0?JH@4'ZJ(%!^JB!0?JH@4'ZJ(.KZ =.W[B:)A8=Q9SYEA
M;/[NZ8.-*M[ONK?APQ>='.WFZ]1&NFJCQ>]<?=T;<:[;5T#I?B_X06S)M9JT
M8.ZX\G/T60QW44[ ^)_B-KT+3TH?6JW3HZL7K/+BJZ#]5%BR=7AI;0]G>AIJ
MC7E"%H;87C1\9SF$_"#^PNQVZVNL/(_J"D:5OY5\X\O_ !\%';DU=;N>S[A<
M7#^ZM&^KIEGW>!T>R9>O!$>+7Y66.ZU'=3^ZN?#N::RHLG>_-UA-='_L6UZ^
MFH"SQUUG1JW&3U6.;(]VKN;.9G<'MR.,!U&6'\%K:>S]]=3/@K3'$O*=OW^;
M/N/(O/(^Y7X/%,@M'Z+R[.EKC^"T@@E5]E@]9;671[YOO9L.D3Z5O[6OVY+B
M)Y:[Q1/(]I\5Q=4ZCWKU=--'R??3ZRW/65KL,H,8]C?=?>?>6Z8_4[L*BUE;
M;Q.*>,:ZL@P^8NL'<F6QF='(X>TWM:*FM!7UJKFK&2'6VFXOM^->"9-H<G6%
M[9,BS<GNU^PF-SG^RUP'805P\VRM'&'T'M_?<=Z1&2=+,LEW?MR*(S29&#0T
M5)\045.-ODUY.W;N&#37JA%>[N5A?/DQF)]BT>1JN21U8.CJ?"NKM]G,<;/'
M]Q[Y%M<=.7C6K%LN,C('8FVEE>*%TC'4()]=5;R32G-S-M%\L_[<2RV&VWG"
M!47FGT-E8?[JISZF?X?B=VN/>UY]7^J'O7<K_8F;>.KW.EC']Q8].&/X?B9Z
M[F>$]7QPJ+;:^7O'>)+;M9Z'SR>*1]P&BUVSTIR_9P;J;#+DXS'QSJR&PV?:
M0%D]\3<3LZM;0-C'P-'15+[B;<G6P=MK'&_&63,;H:&L% *"@]"JZ^-UIB(C
M2'K0?JHH"@_51 H/U40*#]5$"@_51 H/U40*#]5$"@_51 H/U40*#]5$"@_5
M1!V;3N4CE 0$! 0$! 0$! 0$!!K?E?.+M>PSV9P=ALW<>8^9;ZYQD][C[>&:
MW?+:R.C<YI$M:.TZFZJ&A'1$Z,VW[SY@=C8K:TIPV3S&Z-XQ1S83:UA$'Y M
M?&R1WBMK1FC6&FE27=@H'$#16; YUV7OS:&;W;_G&#9M<S-W/C<G'X=WCW6S
M7/?XC&ZB11CM-.I(+:!P(0T8ALWS6[3W5N3#86]V[FMO8O=$LD&U,]E(&QV6
M0EC?X>EKFN-"7%K!I+AJ(!(0T3ZB! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0=)H8;B-T-Q&V6%U-4<C0Y
MIH:BH/3M0'PPR1&"2-KX"-)B<T%A;Z*'I1!V:UK&M8QH:QH :T"@ '8 $'*#
M03B_^W5G_P"4\_\ P,Z,O W[1B(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @("#!>9VVLO%.[[6^R<>&LKS&7%G<Y2
M>.6:*WBNV^ Y[V0M<\BC^ND(0AGB[.[EV?RKM/C=^Z,9OC;.;VZZ_M[NPQUK
M928UMK&1%I?;5<Z*1K6M!G)<:]Q[26R.;&1=A<BW$5^=C:SBPH6@^\&-WA]7
M^S\:GQNGI1#2'YI__F$?^LN?]KV]\HC+@\/(0+@;\WR+O_Q8L8O'[#^4]Y.K
MLZ=OH0EOHC$0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$'![$'7V?U54![/ZJH'L_JJ@>S^JJ![/ZJH'L_JJ@QC$?_4^
MX_\ 5?W"X&P_K,ON\*QE_E59(VFLU]"[\<FB>;O[/ZJH@]G]54#V?U50/9_5
M5 ]G]54#V?U50/9_55 ]G]54#V?U50=) TZ>P$&H[4F4Z/":"VN(W6]PULC'
M?&:X5!4UFU9UAA>M;QI;BQ++;,CD=)-C'M8#U]UDJZ(].QO>*J_3=S/"SB;C
MM43.N/AY/ QILN3P$GA%TF.D<:ACNL#Z>BJL1%+QR<KJS;:=-9I/[&266^7!
MS8\O;FW8X ,N6&L9]9ZUZJM;:S/S'4Q=UCEEC3RPRFWO;>^#9;:5LD+NPM-1
M54II->;MX\E;QK6=6%\H!@PUL[50MF;I;]QRZ/;9UL\W^H=/4Q[ZV[#RC,9A
MLC?3M_(03,U.]#2VI6_N%>K)$1S4^R[CU6"]YY1+*\IN>WBPDF6QTC;BH:6-
M!Z=3WKGUV]HOI,._GW](P^LQSJC'<W(5YEK3YKB;X;S0ST/QJ$&GWEVL&PB.
M,O$[_OM\M?5PO?$=]$)+UEXYC+R9Y\/\8L&GH/4%6[ACM%8\,.G^F\]=;=7S
MI6'FFZ<W-6UN:NCCA#P/15Q5CMD<'._5<S&2NONYHKDM9)7/F ]D@>'[)-33
M[ZZ\R\9&.8OJMXNW6CV,?(QUS4D-):TM]5.O5:9T6NF59<96T9(Q\[])(%=)
MJ">_L45F(+=4O:'.17$4ONS/':T$-U$MI0=M:+?6T1QE%<?7.C'IX+VZN#=.
MRK(X"*>#4GU]17N53KX\%[)BZ8T5;+BWM8'OO[D4C8"UC?:,K"0!0M[%MC/K
M;285;;/KUTX>1G^UMZ/V68[L/$^-NP-<!<&D>L?<6G<;2N2-73[9O[;*=.<2
MN.6Y3NLC<2/L;J1EJ3[(B'1H]%:+1AV==.,-^\[UEM;T9FL+]L_=V#M?\ZS%
M])<7,GX,FK0SJJ^ZVLS\V'2[9W'%3CDMU3/[$IX?=N R]([*ZCD?V!@=0_K+
MCY,-J\X>SV_<,.;A65_:ZK>O9Z5HB-'0TUAYGH>@H#Z%EI$L=>GP/3[JQF4\
M9&D:C7]8J35W]G]55 5%>Q2EYDNKV&BC6$:^1W%"I3,  !)/4(.?9_550@]G
M]54#V?U50/9_55!V;3N4CE 0$! 0$! 0$! 0$'29XBBDD+FM#&EQ<\Z6"@K5
MQ[AZ4&D3N-^3^$^+<]R3LSEBUOV6-^_+7>-QT$-QC+R2::*WF,D\CWETE*5:
M6]VD=>J,E[L]T.WMYJ.%MVY" VOSUL@9"VMFEQB9=7%MDWRM%:CI5U/2-->O
M1#P,"W(ZY%WYKCAQ_F'B6 NJ&0'QOG(B3LJ*4\>M?[E4%_Y:]W'!GET&(H<M
M[SAC9$Z_WWW2/Q1[/6GC:>SKZ$'GOW)^=:/?6YX]JLS!VNW+7[<(8;6R=%[@
M+F06^@OC+BWP]-">J'!%F\.;?-?L"^@QN\L]D<-?7,7O%O!=6UD'/BU%FH4A
M/2K2$3I#Z=(P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$&@G%_\ ;JS_ /*>?_@9T9>!OVC$0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'C
M=VEI?VL]C?P1W5E<L=#<VT[&R1212#2YCV.!#FN!H01U08UM'C/C_8<UU<[.
MVY8X:YO1IN9[2%K)7LK707]7!E170#I]2#*T!!HEY%OTD\@_Z,W\[<C*6]J,
M5@W=O7;.Q,;%E]UWWS?CIIVVD4WA33UF>Q\@;I@9(X5;&XUI3HK&#;Y,]NFD
M:SIK[M6N^2M(ULP2^\R?$5M97-Q:9QU[=PQ/D@LV6=[&Z:1K26QA\D :TN(T
MU<0!WKH5[/N9F(FND>_'G:)W>/3FU>R/F#Y6OLP[+Q9U]FW6716%NR,6C&5J
M&>&YIU =E7U=ZUZNG:MM6O3TZ^7PN9.YR3.NK8S9_F9X]O\ ;EA<[ORC<5N0
ML+<A9QVMY+&)&$MUL=%%(-+P X#42*T[EYK<=FSUR3&..JO@XQYW1INZ37TI
MTE(.S^3]C;]N;FSVGE?G"XLV-EN&>[W,&ECCI!K/%&#U]"YNXV6;!$3DC37R
MQ^YOIFI?YLH=\REKN>7<NT[F_P 9N/-<10173MQ8W9[GMO77G3PG3MB<Q[H0
M/VS0/:Z@TK3;X1S]9\3:\$<M.X_Y S.2MK#W&;'X3+LN;3,[?\6Z8U\7O,DI
M?(R0]F@ -H0:EQ*)7_A_>=WY@M]VXS&:O<+M[8^/LI<?L]L\UM=Y=\L;:Y"]
M<TM\6$G21&'.%'-U=''Q N6WMLR>8/DKDF[WIG,O;[<V=EW[<P&!QE[)8P1N
MM2YDMR\1&KGO<P/:3]VH  (8E=S\A3<7<L[*M-R9"]S7$.:BOMO9OWB1M]+C
M8M<KH+F1A:Z4,@;(2'?A4'8UH!*0[7>62Y;YHV&-M7TUOMO![6^MN5@BEECM
MIKW,,:RUMKEK'#5X9T2AKJ_A>M$,.BN-X\><R[ VSD]]9[);JS.1F;NZXR\L
MK-K7=O<,\6.#'Q2@,$H#VQL9'\60TZ= B6Q?*F],ML/:;\[A<9;Y.^-Q#; 7
MU[!C+&W9,2'7%S<3D!L;*=0VKB2 /2#%K#R1S_G]]<,\CVMNZWQ6XMGWV%B=
MF]L9)]S97,61N30V]PP1OZ")S']2#]Y&6B6=Q<W[]N=P[SL>--I6F;P?'P#=
MPWN0O7VDMQ<MC=++!9L9&\%T;6.!+_PN[LU$:*!GF-W/NS<.VMN<8[3MLI=;
MGVRS<\,^3OC:1VCA=3VTT4H9$_4&.@+ YA]ISAV-J4-%H'FUENMI;4N;?"X^
MPWCN:\R%E+'F,FRPPUDW%. EGENY&CV7ZFAC*5)J*DANH:)+X2YDBY8M,[;7
M-M:VN?VS=MLLE\V7;,CCIVRAQBN+:X8 '1R:'T'=3M0F$JH@0$! 0$! 0$!
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M;@QZ)'FY:;J&Z;XT8#  T?&J!&?!&.L3K[OW<-$X,\Y+3&GN_?QU2XJ:X("
M@(" @(" @(" @(" @(" @(" @UBWQN[(9W=&7Q6>YTPG'N(QUW/:6^"PCH7Y
M,QQ2%C7W=U<.8^.4M%71Q-TMK3J15$JG8C]ZLOGGB_FC'\G06>B7)[<SHCEE
M]W<X-<]E];.?+&_M#-;2RO:@V41 @(" @T2\BWZ2>0?]&;^=N1E+>U&(@("
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MXGD;:&ZL_>R8W(V-KN'&YO)3Y.VRMI>SM@D+XYW%K)@7ZF/C#:=>B(9+P_\
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M$! 0$! 0$! 0:U^86'";9R^"M-I\<;-S6\]U#+Y&YOMQXNWF9(S#VS;J8%S
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M!?V>DT;I"WXSBWEGCSYTP/%&Y,+#LG)74]]9VN>LKBXO,2^[)?*RU=!*QDK
M\E[&S-Z=AKU+@[P>7QN*PNP,/B<QX\NU-RMW5FLE>QGQ\E<O\1T[J,)#7.+Q
MIJ31H J>U#5F.]N/KS=6^N/]VV]Y%;V^S;J_NKFWD:YSYVWML(&AA'0%I%35
M!@9X/WK;0<I[:L<_CG;)Y$DRN4@AFMI1?6F6S C:YSGM<6NA:&$4[3T/3L0U
M9?N?B.#=G%>&X^O<D^QRN"M\<_%YRU;J=;9/%1M;%<,8\C4*M-6DBK214'J@
MQN^XOY7Y!GQ&,Y9W%A9-GX>\@R,N/V_9W$,^5FLW!T0NWW,KVL9J&I[(FT)]
M'0M#,=D\?7FU=]<@;MN+R*XM]Y75A=6UO&US7P-LK8P.#R>A+B:BB#/T0("
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MKJD 1M^[VJ2,NLZ,>OMR6<#RZ2Z9!+( 1 '4+0!0#V:FJA<IAM:.3T&39+;
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MYI>9RSK&GCU>'_46^[5GPUC9TBEHMQ]#IX:3^]+R[+P@@(" @(" @(" @("
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M!<['X:UCM8I'_'D+![<CJ=-3W$O-.\HA?T! 0$! 0$! 0$! 0$! 0$! 0$!
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MSI[O?5F7WYBLEB(W8QYE-VWJ ?BCI75T"X7ZE[[B]EZ:<[1YFK;]KR8LNE_
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MTP("#Z;8S_=UG_D(_P!P%]!KRA^.L_\ ,M[\_*JEDTB @(" @(" @(" @("
M@(" @(" @("#03B_^W5G_P"4\_\ P,Z,O W[1B(" @(" @(" @(" @(" @("
M @(" @("#'<KL/9>=O7Y+,X&ROK^0-;)<W$#))'!@#6@N(KT HJU]KBO.MJQ
M,NKM^[[S;TBF++>E8\$3,0XQ>P-DX2^BR>(P%C99&#5X-U! QDC-;2QU' 5%
M6N(2FUQ4GJK6(E.X[QO<])QY,M[5GG$VF8\?RLC5ER1 0$! 0$! 0$! 0$!
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M/0O%YJS2\U?6\-XR4BT+B)!0?LK7#?,N=?ZJJ0U@=>GZZQU@&N#ED.R @("
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MR-@MIF!S@WH":=R)GD^C*,1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MF64B@_%(1#,4! 0$! 0?/?S_ 'Z2=L_R&/SN=&4/H0C$0$! 0$! 0$! 0$!
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MQ\K&N!]8)0:.^14@\D<@D&H-JVA_UMR,I;VHQ$! 0$! 0$! 0$! 0$! 0$!
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MKTRH+![&'4'T,+@[0#T(*Z&''7357S5THG+9''>]-V6L=]C+6*VQCQ5ES.0
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M)I@K%*_M]WNU=:FVU]*\]4L Y5P.U,IN"^P5WR+8X7#X^41V6VSBI)&8\AC
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MX^+BW!QGENVS+<MR6]\QDMV90T\62\G?%$X]O8USI?\ \U=.-M'.TZOHV/\
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M=/@4-U(F)UA7[%LX8HKB4>)(?$=;Q1DCV6LZ@N/KJHACGOU2[;UD@L[&W@G
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M<M\QY^7Q,#@X'0DT:UMM(YGW722#T]RQGM^UI\^^GN]Y;KW'>Y>.*D3'E_\
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M-[Y"QFH!SBPD'IU!,MN$8B @("#03B_^W5G_ .4\_P#P,Z,O W[1B(" @("
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M-V.PF\]D[CR+LS8[,S3\1BLL7OE9(R/6R2..1Y),;=#7QC\%KZ=E$1+99$"
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M /*>?_@9T9>!OVC$0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MK&KV?YY%XBFVQS>=/@CW? UKY"QV])=TYG*[KQ;[7)R3F3(.@B<;5DC@.C9
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M._L);:(Q$! 0$&@G%_\ ;JS_ /*>?_@9T9>!OVC$0$! 0$! 0$! 0$! 0$!
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MND:1#[/M:5IBK%8TX1\B*N3<'SCNUN;VSC;7$NV??.$=M(]Y9=F%CFO%27D
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M_P#+X?\ /_V[M#UXU^F! 0?3;&?[NL_\A'^X"^@UY0_'6?\ F6]^?E52R:1
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M:!#1KES/S/GN;,]89_/V%IC[G'VGN,45CXNAS/%?+J=XKWFM7GO1,0^NB,!
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MOTZ]7P>%N[QSR!Q_L;AW;5S?Y'W*T]WG$%K.&NO9Y67,K9G,AB+CI=*'D'L
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M'6G)T-KL<.VB8Q5Z=>?&9^699*MBZ(" @(" @(" @(" @(" @(" @(" @("
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MQ.D<51#975A Z6V<7XR>CI+61QU"G2K#W*&J+1R#$QOARVCPQYZ%E=/=6O\
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M;6TY&VTRU@C@8[" N;$QK 3[W/U(: C*'T.1B(" @(" @(" @(" @(" @("
M@(" @(" @(" @B_S$_H<W)_J/Y_;KG=Q_I[?!\L/9_HO_E\/^?\ [=VAZ\:_
M3 @(/IMC/]W6?^0C_<!?0:\H?CK/_,M[\_*JEDTB @(" @(" @(" @(" @((
MSY_O=IV/%&==O3%W.:PL_NUNW%V+C'=3W<US&VV$3Q\1PE+'!W=3L=\4DPA#
M8&U+[)<OX7<V4XNW9@(/']ZD??9B*?#07\=H81?26S;=KW3O#0TN\0#4:Z42
MV[1B(" @(-!.+_[=6?\ Y3S_ / SHR\#?M&(@(" @(" @(" @(" @(" @("
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MP=8S6P,,XE=XDCXW#H!V4:5NP8;4MK+K=F[3GVN?KR1&FDQS]YL>KSV@@("
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M>O&OTP("#Z;8S_=UG_D(_P!P%]!KRA^.L_\ ,M[\_*JEDTB @(" @(" @("
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M='#,93=7<EL=)?6C&&@.GH0*>T)3^B! 0$!!HEY%OTD\@_Z,W\[<C*6]J,1
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M:\H?CK/_ #+>_/RJI9-(@(" @(" @(" @(" @(" @(" @(" @T$XO_MU9_\
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M:"<7_P!NK/\ \IY_^!G1EX&_:,1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M;%PB>"IN,%<NFL+ULS;1VMMRQP,LYNQ91B-LKP!V>@!:<MM9UAMQTTC262-
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M" @("#Y[^?[]).V?Y#'YW.C*'T(1B(" @(" @(" @(" @(" @(" @(" @("
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MX?\ /_V[M#UXU^F! 0?3;&?[NL_\A'^X"^@UY0_'6?\ F6]^?E52R:1 0$!
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MCP3\7/Q3P9&K+DB @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MT/8X.8X5:YIJ"/40B9B8G27*($! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M\31X6GVM?B=]5<W7J-8]3KIX=7AL?7_>T^!EJIMH@(" @(" @(" @(" @("
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M1F]QYTN#K;2)+V_=JK3PK42]GI\.1U/NKHQEM/\ <M]'ZSS$[+''_P!['_\
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M//[JV&<LSAB8IX(MI,_'"W;M\D>P+V>V^IUO%B[9C'>\B\N;ZXDDD)%*?E:
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MMXI99XXF,FG+3/(UH#GE@TMU$=30=!5!Z(" @(" @(" @(" @(" @(" @("
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M! 0$! 0$! 0$! 0$! 0$&N>^^2N6-\<F9+B/@R:QQ,NVX(Y]S[KR3!-'#-,
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M\-TL)A[/;^(L<)C_ !#98^WBM('3R.FF,<$;8VE\CR7/=I:*N<:HQ5Z @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#
M")N-K&;EFWY9-]*,C;X,[=;C@UO@F(W+[GQ2[XVJK]-.Q!B6>\N>U]RW7(5S
ME,C=E^_IL9>%T(9')CKK#,>V"6W?0DFKSJU=U1WHG5Y8GR^1W&3R6<Y(W9D-
M[YF]PUQMJUN;B*"Q;:8V\C?%,(XX 097M>X&5W4UZU*&JV;:\L[\+E=F9'*;
M[RN:M=AS.=MW&W$%M%;0V[FAOA'PQJ<>@J]SCT    0U9'B>"<=B./-P\?V>
MX<G:LS^2N<P,Q8R>YWMK<7$D<@$;HSU:#& 0?C-)"&KSV#P?+M;?-QR/N?<\
MVZ=VR6)Q4%T;"SQ<;+9T@D<9([1C?%E)%/$>:TZ>B@U2ZB! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M#*]*DDEQ<21,I&1 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M87+KT0L%X]C87W :/%,3"7-874J6@N<0/640]4! 0$! 0$! 0$! 0$! 0$!
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MFP]D8+CG:>,V;MN-\>(Q<99$92'2R/>XR222.  +GO<7&@ ]  1#(T! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 01MS?9<J7.RW77$60CL]SXZXBOGVCXF2
M.OH+<E[K9CG^RTN(!H1[=-%0"43#4+.[9N/,ME+OE/9L>/L>2MN6MJW<_'5[
M;R,GO;W'RT>YQ?(!)&]C6QAKF@C2(WD&CB3R2!E^0-K^9[ZE;5P^4R>Q^9L+
M=W&0B@;933P8^\L&#Q6S._)@-=I)B?6K2TM>T%P#AR;%<5\:LXXP=Q;7N4FW
M#N?*74N1SNX;M@9/=7<[6,<0*N+(PV)C6LU&E$0SQ$" @(" @(" @(" @("
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MGI0:8;PYUY8W#)N3<FQMUV&WL=A<^[;&VMEC'QY#+9R[B+ 2X21R/9K#JMT
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M->^E=5/NH.Z @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
3@(" @(" @(" @(" @(" @(/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2227887d4-lc_contrl4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_contrl4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#@6AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXP+6,P,# @-SDN9&%B86-B8BP@,C R,2\P-"\Q-"TP,#HS.3HT
M-" @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#TB>&UP+F1I9#HT,S<V8S4P-RTW-C<R+31F-C4M.&1F."TV
M9#<Q-#(R,3DR.6(B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z,S)",T-%
M1C8X.$1!,3%%1$%$-D(Y-$%"1C-#,S1".$$B('AM<$U-.DEN<W1A;F-E240]
M(GAM<"YI:60Z,S)",T-%1C4X.$1!,3%%1$%$-D(Y-$%"1C-#,S1".$$B('AM
M<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@,C4N-" H36%C:6YT
M;W-H*2(^(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X
M;7 N:6ED.C(Q-CAA9F5A+6$X,F$M-#5D.2UB8SEB+3,T,V0W-&$X-F4V,"(@
M<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#HR,38X869E82UA.#)A+30U9#DM
M8F,Y8BTS-#-D-S1A.#9E-C B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F
M.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O
M8F4 9,     !_]L A  $ P,# P,$ P,$!@0#! 8'!00$!0<(!@8'!@8("@@)
M"0D)" H*# P,# P*# P-#0P,$1$1$1$4%!04%!04%!04 00%!0@'" \*"@\4
M#@X.%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!3_P  1" ,*!SL# 1$  A$! Q$!_\0 [0 !  (# 0$! 0
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M$A
M                                                   KSSGYG[/#
MF^L7L:ELU^YKF5H5[U>2&^M:5TMFS/6; R%M2PKW*L/9H[MZM-/=+$.'N^=7
M=N&A2]N'AC+8K%-<ULUVQ;GC8WJ[NV7'1M55]"*] N"R7&_(FW>4]HTMY;8?
M(N.N=3'PSM1D\$\2]+XI6HKD1S5]Q514T5%5%#%U@
M
M
M               %2_/-OBS6VM@>+L,KI<ONNVR>U6BU61]6J]J11]*=_BSJ
MQ6_5C4,H17REL5_E<W]Q5O\ P4:K2AJ5ZF==#KI/=J,2.^OU/:(95Z47W%]P
M&E_0&E<JY&G7R%&5L]*W$R>M.SM:^*5J.8Y/J*BHH8O<
M
M                                H5YN\Q9V]YF^/<_2H/RMS%4,->KX
MN%5;+:EK9BW*V!BM9(J.D5O0FC'=_<O<&4,OEKS2\C;EV!G-NV.)+VW*&6JR
M4KF5R2VK,,4,Z=+E1'TJ[4=IKTN5_8NB^@&";_)[C=LXOA:A#MS-1YJ2>U/:
MS$L37QI!?E1G5 K)&M>GAL;&FKD];WR>JJ!)3V$
M
M
M             ?SSM;8=YMO,GNB+[X2TMH8."2O!D*[&R]-2B]*\*1J[U?W^
M9SYDU^Q5WN!EH=-O[R*XK;NR\YG]N;DO9+-8NG+=K4)X(FLG]G3Q'LU9V]2L
M1W3I]EH#%+?DPY#_ #SXDAP%N7KR^T)4QDJ*NKEIO17U'?61O5$G];"2L6$
M
M                                              %"/-_N"':7F8X_
MW58A=8KX+'X?)RUXU1KY&4LQ;G<QJKV(KD9HFH90Z'<GGMV]GMOY7!XO9-V;
M(9*I/3@CLSQ/A5UB-8]7M8QRN:B.U5J)ZW=V=X,':^2/CK=6RMC9G,;GJ2X[
M\X[4$^/Q]EKHYTKUHW-\9T;M%;XBO]5%356M1>Y4"2M"$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:*#V]E>&>0^E+Q/_  F]]R._;':*#V]E>&>1X2^;'B&%_AOLW^I.WLIN]/\
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MP
M                                                         ?CG
M-:U7.5$:B:JJ]B(B ?,4L4T;987MDB>FK7L5'-5/J*@'V!\-EB>]\;'M=)&J
M)(U%15:JIJFJ>C5.T LL22-A5[4E<BN;&JIU*UNFJHG?HFH'V
M
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M,Z^Y-54Q^'5O3+;^7;YG-M_W=\?L')L[U>GO^.6C[Z?S>]]3_+H2@=B\8
M
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M$V^-):/WRLQ5632Y9R:>+(UBN1KL>WJZ>K734+@N4&(
M
M                        869FR=;$9"QA:K+V9AK328ZE+)X,<]IL:K%&
M^147H:]Z(U7>CO @.UPYS[OB1,AOGER;;:N7J;A-FPR5*\*+V]*6O%AE?I_^
M4:[ZX7%B8CBKEG"69;7&W.TVXK=946SA]S:9:L_T=,DJ3321(JHOO&([ZO8!
M/FU;&Y;6WZ,^\*=:AN5S%3(U:,JSU6R->YO5$]VBJUZ(CT1W:FNB]J!&X
M &CWI^AVX?Q9=^+O A[R9?,!@/MG(_')0LI]"            X#F[YI]U_:+
MO^TTXKOD2ZS:GJMSB:#RR_-!B/Z_=^,R&%CR(:NP_5*>.?&EXV'>@      (
MZYZ^9[>'V@[_ +;3LMF>LT<;AO>1+G/*K\RV&^V+WQJ0V=M>M5<4>)AEO(A-
M!TC9 (O\Q/S.;D_N'X_7.NVCZO5WO'#V?N7_ #>S]?\ RZSR[?,YMO\ N[X_
M8&SO5Z>_XY/?3^;WOJ?Y="4#L7C
M
M                    #!RN;PV"@2UF\C5QM55T2>Y-'7C54[=.J1S4 \<1
MN7;FX$>N!S%+*)&FLBT;,5GI373M\)SM -H!J=TX9VXML9K;[)DKORU"U0;.
MK>M(UM0NB1RMU373JUTU CR+AW*0<)XWBK'[LNX;,XNM'#5W+B7259$FB>KD
M5T;)$5T3M>E\:O[4].N@7%I<#P/G<ON#*[MYBW-'N?-Y#!S[6KP8^JF/JU\=
M:1Z3.1$5>J5_6[MZ41NJ]_9TC%J]B>7/<V#W)M&WO'>+,_M?CM++=FXR*FE:
M5%M=B/LR=2]2QM1J-1-?>IVHFJ.&+!W#Y7<YD\CN+ 8O>/L'$N[\RS<.?V][
M*C[GM*/;++'!/U(C62/8U473U>EO8[I7J&*R4,4<$4<$+49#$U&1L3N:UJ:(
MB?60(I_YVOTPX7_&=_XQC RA<,,0                            #QL6
MJM1J/M3QP,<NC72O:Q%7W$5RH!YPY/&V)&PU[D$LSM>F..5CG+HFJZ(BZ]P&
M4                                ,#$YO$9Z":SA;L-^O7GEISRUWI(
MUEBN[HEC<J=SF.31R>@!1S>(R=S(8['W8;-[$R,@R=>)Z.DKRR,21K)$3M:J
MM5'(B^@#/ \*URI=8^2G8CL,CD?#(Z%[9$;+$[I>Q5:JZ.:J:.3O10/<   \
M*ERI?A]HHV([-?KDC\6%[9&=<+UCD;U-54U:]KFN3T*BHO:![@8&6S>(P,$-
MG-78:%>Q/%3@EL/2-K[%AW1%&U5[W/<NC4](&>
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M^9S;?]W?'[ V=ZO3W_')[Z?S>]]3_+H2@=B\8
M
M                             UNX*F8O8>U3P&1;B<M,UK*^2? VUX&K
MDZWMB>J-<Y&]71U>KU::HJ=BA$5;A[@9S\EG-U6Z^\LUBVJN>SFY<FF1E@1B
M*J^.QTB00-;HOJI$Q$_F!<6OP7'/E?Y)EEDX]3'09O&(CDO[4N28W(5=5T21
M/9GQKHJ]B.<QS5!NI?V?A<_@,7)B]P9Y^XWPS.]@R5F!D%OV/I9T,LK%HR65
MKNO65K&=2::MUU52.@      !3SSM?IAPO\ C._\8Q@90N&&(
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M?FJ[^MK8;F'SO.>^'N_EME=3U&M_[-?'6G'R=7#>CAE-)VSYZ
M
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MY[8_Y_>^=]E_[)_VW^)_IK0'H7QH
M
M                  "%=V[HY2N\CW>.^)*F"Q;<;CX,WF\OG8IU2:7(2R1L
M;!'65.I5\)5?(Y%[45-45/6*RMG;?Y]H;JCR6Z[NSGX6V]'9QV(I6X<C82.%
M8XOWV3L<K=&)Z^NC4T0"8 @      "GGG:_3#A?\9W_C&,#*%PPQ
M                      $<\'?-^GX\W-_ZAR 64C! ".=@?.!RQ^/,;_Z>
MQH5(P0                                         !2[>?^_IM7[6@
M^(60RWET0Q .=W!O_8VU'3,W+N3&8F6!L3YH;MR&"5K9U<D2JQ[D=H]6/Z>S
MMZ5T[E ])-[;.BVW^>,F?Q[=J*WK3-^U0^Q*WJZ.R;JZ%7J]71%UU[.\#[VS
MO#:F\Z;\AM/-4LW2B?X<LU"Q'8:Q_P#0OZ%7I73MT=Z -V
M   1#RASYC>(]SU,7NG;67EVM;I1VEW50@6Q3AL/FEC=!*BHQ$5C6->JM>YV
MCT]3TJ7!UVR>5..^1H/&V7N*GE7]/6^K')X=MC>SM?7E1DK4[>]S CL
M T>]/T.W#^++OQ=X$/>3+Y@,!]LY'XY*%E/H0                 .5Y-^;
M;>/XCR?Q24PN>3/$TL]ZO<_0J\4HL\HGS;93\>6/BE0X,MY/?=-[N^KU?ISX
MJ4^FT], 1USU\SV\/M!W_;:=ELSUFCC<-[R)<YY5?F6PWVQ>^-2&SMKUJKBC
MQ,,MY$)H.D;(    *O\ D^_SS_Q9_AAY[8_Y_>^=]E_[)_VW^)_IK0'H7QH
M
M                                                 "NV_-N[BWWY
M@&8;';HFV*_";;CLT;^-BC^^.4CN69&S,61ZHCX('1M7PU1>ESNK[+4*[+:O
M$^]MO[@I9C)\IYW/4*KG.FQ%V.NVO.CF.:B/5C4=HBJCNSTH!*X0      !3
MSSM?IAPO^,[_ ,8Q@90N&&(                              CG@[YOT
M_'FYO_4.0"RD8( 1SL#YP.6/QYC?_3V-"I&"
M                  *7;S_W]-J_:T'Q"R&6\NB&(!"-/#XK(^:/<%K(4H;<
M]/:.-]E?/&V18EEN6&O5G4BZ*J)IJG;IV>E0N\BVI1V_^9V:QUW/)M!V-Y<R
M_P":F1?4;<Q=6]!+(D$%B%ZMC9 YKY$35S4:[1=?=*DOB#<-ZSR;NO Y^G@,
MANG[V4+^0WAM-\JU;47BRPP07(WN>D=EJ(Y[41RZL[>X(G4(
M    (/Y;W1S79WM4XXXDK8.NEO%,R-_.9F>-TL*2SS0*D=57.<YK4C1SG>!*
MWUM.STE1-)Y.L+(_(7-S[Y?9Y=OUI;^*JX9M+#QI:B:JM?'71K7/;UMZ7/;X
M2=Z]B]J%Q68XII[RQ_'6W:'(+_$WC5J-ARLBRMG<Y\;G-:KI&JJ/<K$;U.U7
M5VH8NQ    &CWI^AVX?Q9=^+O A[R9?,!@/MG(_')0LI]"
M   !H-]8V[F=D;EQ&-B\?(Y#%7JE2'J:SKFGKOC8WJ>J-35RHFKE1#"N,:9A
MJYNB:[-=-.F::HCD5>V5M#S1\?XJ;#;7Q$=7'SV'7)(Y)L3,JS/8R-5ZI)E7
MWL;>PTZ*;M,81\SQV5RVT\O3JVZ<(QQTT<[\WCR5YF=@UJUS=KH,?7N/=%6?
MX6-GZGM3J5-(%D5.SW257+M.DS.=VEEXB;F$1/Z,^);FC*^>E6FD7622)CWK
MW>LYJ*IOP]S1.,1+D^6\#E=S\;;DP&#K^U9:_3=#4K];(NN17-73JD<UJ=WV
M3D-[(W:;=^FJJ<(B6-VF9IF(5HV?MOS?;$P,&V]MXB&MB*SI'Q1/FPTSD=,]
M7N]9\ZJNJJOI/3W[NS;U>O75N_7YFE33>IC"(\37;XY;\T7&_L'YZ2U\9]\_
M&]A_><98\3V?H\3_ ,.LFFGB,]]IKKV')ELCL_,8]7C.&GROG8UW;M&GYEW#
MP[LP   J_P"3[_//_%G^&'GMC_G][YWV7_LG_;?XG^FM >A?&@
M
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M2N<OU)43T!E,+9AB 1SL#YP.6/QYC?\ T]C0J1@@
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MHNFO;V@B$PA
M                      "N^\\[N_"\^6EXDVRFYL_-M^JF]*MNS#1IQPMG
ME6@^.Q(O4D_;(CV=+D<SIT35%5"NQVKN[G;([@I4MU\<4,+M^5SDO9.'-P6Y
M(6HQRM5(6L17:N1&]GNZ@2N$       4\\[7Z8<+_C._\8Q@90N&&(
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MA=3;^0FRV!Q>4L-:VQ>IU[,K8T5&(^:)KW(U%55TU7LU4,6Q
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MD;8Q/YT[>VIMN=J]374L3;\6U*Q4[%;+:F>B+Z4C0"Y(8@
M                                                       ,/*Y;
M&8.C)D\S<AH8Z%6-FMV7MBA8LKVQMZGN5$1%<Y$U4")-]<><HY3D.#D#C+<^
M)P+7XN/&6VVJDEM;D39'S-\7UE8K6*_6)S4:]-53J5JZ!6PVK@/,#4W!2L;O
MW?@LCMR-SEOTJ6-?7L2,5CD:C)%<J-5'=*_6 D?%9S#9Q+:X:_7R#:%AU*ZZ
MK(V9L5EC&2.B<K%5$>UKVJJ>C4(V       *>>=K],.%_P 9W_C&,#*%PPQ
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MYFOE?)(J(B)T-<U&JOK+ZJ:ZF,Q,3A+/%_6<C
M                   !4KS_ 'S;;9_'B?%)PRA9G9?Z';>_%E+XNP,6\  <
MM6Y'V3:R>2Q4>:JMFQ4->S;GDE9'6\*VD[HU9,Y48_LK3*[H<O3T+U: 9.WM
MZ[:W18O5<->9-9Q]J>E/"[U'N?5\-9'QM=HKXT\5G[XWU5U3M Z
M       !@YN'*6,-D:^$L,J9J6K-'CK<C4>R&TZ-R12.:K7(J-?HJHK5^LH%
M?MY8/S,XG$86\O+>WL!#3H-KY^_DJU.&O8R2V;#_ !6OFHJUK5A=#'TIT]K%
M7I[=5*V?#-7G"[GV9K=?*6 WQLEL,C):V#CIN59WM18G>+6J1=B=^GB=H)3X
M$    !H]Z?H=N'\67?B[P(>\F7S 8#[9R/QR4+*?0@
M %;?.%^C>VOMZ;^PH:>9T0\E[R?AT<<^)G4_-KQQ7J5Z[\7FU?%&R-RI7J::
MM:B+I_;98S-/=<M/O#EXB(U:N2/VGO\ 2[XV_!><^YZG\;+VFGNLOB++]&OD
MC]I+6Q=ZXKD#;=;=&&AL08^T^6...XUC)D6%ZQNU2-\C>].SUCGHKBJ,8=WE
M,U3F+<7*<<)X5:?._P#YB?XV_P "/9>[O]Y]7]9Q9O>[ZW)Y!V
M 5IV!_O0[O\ ZQ;_ .U7.@R_KM??^9]?VQ_QG+\=/ZRRQW[Y
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M=88_Q$E\1R^(Y7+UO777MU [4
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MY&2QLEB<CXWHCF/3M16N35%3ZX13[SM?IAPO^,[_ ,8Q@90N&&(
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M\WKE5<[\MNBG5B(;\UV8
M "I7G^^;;;/X\3XI.&4+,[+_ $.V]^+*7Q=@8MX  @K#>6#:&*WQ?WO*F/NS
M9)V02QBY\/3=19#;;&VLV"'3HB= C'];T:KI^MW6%Q;/A_R^;?XBRMW,T;$&
M0OY&K%'9G?0KP31V^M[K$E>2/MA@EZF)[,SU&]"=X)E,00
M Q[UZIC*-G)7Y6UZ-.*2Q:G?[V.*)JO>Y?J(B*H%,>5MZ<#\F<V[:FWSNN'*
M\5UL'/%!5J3V&5X\ZME55;/@(V2-DD+FZ/:J>M&B*J)J&39\05.*<?YC8*W
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MQRIJB*K571=#EMW:*_)G%UN;R&8RDQ%ZBJB9T:T8-L<K1
M
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M?*K$:S1/5!*P00   *E>?[YMML_CQ/BDX90LSLO]#MO?BRE\78&+>
M              \+E.KD*EBA>A98I6HWP6:\B(YDD4K5:]CD7O1R*J*@%3.:
MUXOXTW'!M3:G"6(W5EH\-/N7+JD$5>.IBX)'Q+*ND,G5HZ-W5W:=G>K@RA[<
M$[ACN<H8O'-X>PFP%O8:7,5<Q7?$^S9HRM8D:U7L;&CVN5S>OHZ]$[] 2MH&
M(    -'O3]#MP_BR[\7>!#WDR^8# ?;.1^.2A93Z$
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MN16M5K4]1WOE3710.D
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MR$359%;=&Q9F-7O1KU3J1.WT*!E 4\\[7Z8<+_C._P#&,8&4+AAB
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ME&?&;>Q&-M(B6J=*M7F1JZM\2*)K':+Z4U0,6S
MA'EK;VR<)OW"<K;LWA#MFBN+N;7SF-M.;T9;%V&RR-@C1=7=3)I4D?TL=JW3
MWNG:5'OEXV.N4WEC=T-Y2H;YV[L3'2XC:N-HQI#:JU+C?#;[4Q6L>W2-O2WJ
MZU543UD1F@65L Q    !H]Z?H=N'\67?B[P(>\F7S 8#[9R/QR4+*?0@
M                 !P'-WS3[K^T7?\ ::<5WR)=9M3U6YQ.1\M^<PM+B;$U
M[N2JUK#9[BNBFGCC>B+9>J:M<Y%[3CL3&HT=BW:*<K3$S$;L[_=15YT<CC\I
M^9'WLMPW?"^^OB^S2-FZ.KV/3JZ%7371=-3VGN_=HIZS&8CR=_\ 2;F;O6YP
M^E'*M7^=>U_PW0^ZH?W9YKJ+G1GD=GK1PGYU[7_#=#[JA_=CJ+G1GD-:.%L:
MMNK>@9:I3QV:TFO1-"]LD;NE5:NCFJJ+HJ:'%53,3A*Q.+V(H
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M$
M            K9RSA=HYKF*.ES1N";$;!FPD;]IPOR4F*QDF0AG?[;XTK9(V
MI.UKHNGJ<G4QVB:JWL*V.P-B>6/$[PQ>0V-NBC>W7 ]ZXVI#N9<A)(]8GM<B
M5_:I.O1BN73I7W?0#=6""       *>>=K],.%_QG?^,8P,H7##$
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M*;%.FK3\_+/@=?:CK*YJE;H\>[          </S/\SW(/^K69^(3 AU6%_\
M)\?]K0_V-H&<
M       ##RV3IX3%WLSD7K'C\=7EN6Y$:KU;#78LCU1K=571K5[$ H_OWFGR
M][WYOV_O#=$TNY-BU<%+C%QTM*SX=3)^U+*VS+!*UJ2L?%(YFC4<J.:BJG8@
M98.BXDSG#NYO,M1R'#;&X#$U<#:BR%.*M-4BRD[G=B1PHU6,;$U&O>Z3H5SD
M31KNU0+E!B    #1[T_0[</XLN_%W@0]Y,OF P'VSD?CDH64^A
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MW'W&^Y,7NW*\D\AYFMF=\Y2G%B868V!];'4,;#(LWL\#97/D=UR+XCG/7O\
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M7W08I<"
M                  %6>5<WQ;MGG]^0Y7Q:;DQ=[;M6#'0SXV3*0XR6*Q,Y
MW5"Z)T:I.BZM>SK>UR*BHUJHJE=)L#??ECRV\,7C]C;7HT=USO>F-MP[97'R
M1O2)[G*ECV6/HU8CDUZD]ST@W5@@@      "GGG:_3#A?\9W_C&,#*%PPQ
M                    -9>W'M[&3K5R67I4[2(CEAL68HI.E>Y>E[D710/7
M'9K#Y?Q/O3D*U_P>GQO99HY^CKUZ>KH<NFNBZ:^X!P\2HG/-M5[$3:%;5?\
M&=@*A35?,%SKIVV./]J_]U)#$[^9K[3*GU_#3_HFC^)<[D/$?S'.\-NW\OM3
MX%L41$31.Q$[D-Y[8  4UY!W^_ <%U]DXMSG9O=6?W-$]D6JR-HQ;BO^)V)V
MZRN5L:)]DG5[AZ+8>5U[O65>31X_R:6IFJ\(PC?6.X;V#'QOQ]BMN.:GWQZ/
M:\J]/LKMA$=)V^E&=D;5_H6H=9G\UVB]->]HCB<UJC4IP=X:#E         '
M#\S_ #/<@_ZM9GXA,"'587_R?'_:T/\ 8V@9P
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MD*M31ZS(O3JY.WI"8-EY,OF P'VSD?CDH)3Z$
M "K'G*_S*_QI_@9I9K>>,]Y?[OZWZJTYNO9HC\SWS&[J_P 7_P I5CN-C^MT
M=_[LM?,?AR>6'YC=J_XP_E*R-L>MU][[L&7_  X2X=.V
M
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MNA&\ X?F?YGN0?\ 5K,_$)@0ZK"_^3X_[6A_L;0,X
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ML'O3]#MP_BR[\7>$0]Y,OF P'VSD?CDH64^A
M JQYRO\ ,K_&G^!FEFMYXSWE_N_K?JK3FZ]FB/S/?,;NK_%_\I5CN-C^MT=_
M[LM?,?AR>6'YC=J_XP_E*R-L>MU][[L&7_#A+AT[8
M
M                                 867R^+P&-LYG-7(J&*IL\6U<L/2
M.*)B=G4YR]B)V@0-O/DS;V=R[;NT_,-B=J8M(61KBXZN)R+5E:KE=+XMK5_K
M(J)T]R:!6NV7!L[<_(NWLMN7G&OR)G,3)-+MS 0LQ]&%+CX'L=+X-1=)'L9U
M*WL16]^H%EP@      "GGG:_3#A?\9W_ (QC RA<,,0
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M)&" '#\S_,]R#_JUF?B$P(=5A?\ R?'_ &M#_8V@9P
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MT$O@P5^F+P(W]/37CC1>URKJJ:G5[8RMNQ<IBW&$3'=X>ZYLO7-43BG$Z)M
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M]R:Z 2QQ5;MV.2N88)YY)8:V:H,KQO>YS8VNQL+E1B*NC455U[ B6P@
M
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MN]22=B+W,8U/ B3T(CO<:>AVOF:;5$9:WHC3S?/+4R]$U3KRM.>4;P
M !'/,W_D.W/];MJ_RW4"PD8( 5"\V/F)S6QLEF.)JF%JV\=N#;\D4V1EDD;-
M$F39/6<K6M]5>E$ZDU#*(=EY7_,#F.:'YO%9/#UL7'MZM2\&2M))(Z7QO$8O
M4C^[3PT[@DPL6$
M          5#\P^4XIQGF&VG/S'*[(;3;MN1(L0D=F6*I<DN2]%N9D;=)(Y6
MM?'TQJY_5&U7-Z= RAQFV^4_+GM+GZMNW8N2_-78]?$6*N96.GD/9LE;F?\
MO;8:T<4CV-9ZKW*]D::M31->U0NUMK<F%W?@J.YMNV?;,)DXDGI6O#DA\2-5
M5$7HE:QZ=WV34#%M0   !H]Z?H=N'\67?B[P(>\F7S 8#[9R/QR4+*?0@
M                     58\Y7^97^-/\#-+-;SQGO+_ '?UOU5IS=>S
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MNS:F:XOW_B^1N-<1-:VUFIH\;O[:F)AZD?&J*D.3@KQHB>+"O9)T-U>WZ[G
M:C%[KSO&_)G)D]OC_=>=H;@R=.YC;^#QT=FLZ*&A#"[5\L\/;U(J=B*!-&S-
MUOWCB'9:3 Y;;CFS/@^]^?KLJ7%Z$:OB(R.25.A>K1%ZO0H1T(
M
M #5[DW'AMHX.[N3<-GV/"XZ/QKMI6/D2./5&JY6QM<Y=-?0B@1)F,3DMYY^'
MESR_;QPLV;DI,Q.8IW=;N(OUH9'2PI.M55EAEC<YR:HG5TKIV:+J5E;>X]Y3
MW'N_#;OYFR^&EBVR^6Q@=N[9BLMHI>FC6'VF>2Y^^/<QCG=#>Y'+JB^A0F4(
M       IYYVOTPX7_&=_XQC RA<,,0                  1SR__P"%V;_K
M=@OC(5(P1'.P/G Y8_'F-_\ 3V-"N<\U&\\7L[AK-/OKU6\LZ''XVLBZ.EL/
MD;(J>G1&LC>Y5^I]4$.4\M&S[.XI[G-NY7^V9+-OE=AI9$T7HE54FL(U4]77
MMB8GV+4<G<J&K9MSC-56EYG9FSZZ+U=Z]NU8S$<_?WNXLH;3TH!'/./S?K^/
M-L_^H<>%A7_?.1O>93F*IL+ SN;L';CWONWH5U8](U1MBPB]RJY?WF#O[^KN
M<I[/+41L_+3=J\NO1'BCYY=;7/6UZL:(6\QN.HX?'U<5C(&5<=2B97JUHTT9
M'%$U&M:B>XB(>.KKFNJ:IW9EV$1A&#*,5        (YYF_\ (=N?ZW;5_ENH
M%A(P1'O)W+^V>-*2MN/2[N"5O53P\+D\1VO<^1>WPV?57M7[%%[31S6<HL1N
M[L\#U6P?=O,[4K^C&K;C37.CBCAGY3@J1O#@3FOS(9IO(T[\7B()JT=:JS*/
MGJ=<+))'M\&.&"=RQHCTT=)HKN_M)DKMRY1-5<:9W.)E[R9'*Y+,]5EZHJBF
MF(G=F9UM_6G##'N1H[B9?*UY>]Z<(W]RVMUWL7<CS,-2*JF+EL2N:ZLZ5SNO
MQZ\&B+UIIIJ;[RDRLH$
M               :7+[/VEN"RR[GL!CLK<C8D++%ZG!9E;$U5<C$=*QRHU%<
MY=/JJ!K_ -67&WR.P?Y,J?! =%1HT<94BH8VM%3HUV]$%6O&V**-ON-8Q$1$
M^L@&0    -'O3]#MP_BR[\7>!#WDR^8# ?;.1^.2A93Z$
M         "K'G*_S*_QI_@9I9K>>,]Y?[OZWZJTYNO9@      -1NO\ 1?-_
M:%K^PO.:Q^)3QPQJT2@#R6?H'N#\;K\6A/0^\'XU/Z/SRU,IY,\:RQYAN@
M
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M>>+-V\/;1M;.W%FZV:QS+*V<.ZLR2-U=L^JS1*DG9TJ]/$;I]DYQL.YE+P0
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MW+YB
M 8.;QC<UALCAGSR5F9&K-4=9@7IFC2>-T:O8O;HYO5JU?= ISR#PUPYQ9+2K
M[\YEW7BK.0:Z2I!X\MJ5[&+HKE95K2N:W7L1SD1%7N[@RQ;G@!G"<')E1NPN
M3-Q[PSKZEK3'9-EEE-L2,3J>_P!HKP>LGV/2J@E;L,0    :/>GZ';A_%EWX
MN\"'O)E\P& ^V<C\<E"RGT(                        %6/.5_F5_C3_
MS2S6\\9[R_W?UOU6_P#I?[)_ 65_8K_"F7::>!L_$=GHU>#G/I?[)_ 65_8K
M_"CM-/ ?$=GHU>#G3-L7>%'?NU:&[,=!+6I9#QO"@L=/BM\"=\"]70KD[5C5
M4[>XV**M:,7H,IF:<Q:BY3&$3\TX.B,VT   &HW7^B^;^T+7]A><UC\2GCAC
M5HE 'DL_0/<'XW7XM">A]X/QJ?T?GEJ93R9XUECS#=
M
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MTY=K_>+)NZ/%M.M^T>VV*>NG56K]/1X'_2UZO1IVF6#^E88
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MVN
M %>>5N*<ONWFK&YB;!5\SM#<&T[^T;EZ?I<N'MN6S:CNHUS7+U.ZDA8YJ=BN
M7M1>G4KBN#,3R,_E/;<F2X]GV77VMMZ7!;NS3X_"@S<T2,97E:J1L9*_K8DG
M6QS^]WK::(%E;L,0    :/>GZ';A_%EWXN\"'O)E\P& ^V<C\<E"RGT(
M                    &OR>"PF:\+[\XVKD? ZO!]K@CGZ.O3JZ?$:[37I3
M73W"3$3I<5=JBORJ8GCC%@?F+LGY-8K[AK_N#'4IX'%V2ST*?-A&?F!VIM;&
M<1;BNX[!X^G=B]B\*Q7J0Q2MZKU=J]+V,14U151?J'#>IB*)W'4;8R]JG*5S
M33$3N;T=*&W\N'S,;9_N[^4+)E8\B'/L7U.CZWWI2H<[N@   U&Z_P!%\W]H
M6O["\YK'XE/'#&K1* /)9^@>X/QNOQ:$]#[P?C4_H_/+4RGDSQK+'F&Z
M
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M$4<$+49#$U&1L3N:UJ:(B?60(I_YVOTPX7_&=_XQC RA<,,0
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MT/>KWAG:=_5H_!M^3'#_ &IX][@CCE*9V+Q0
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MS#=
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M?=^>J=^>^L4=Z^4
M                P<W?GQ6&R.4K4Y,A9I59K,-"!%6:P^&-SVQ,1$<O4]4Z
M6Z(O:O<!4GD?-4]R;GVUR!N?R^[EW7FK."A;[#)';DJX_P *_=1()X&TU:Z9
M4_?%25-.A[/5]*F25.)^8MS;JSU;:5OB'-[&PD=>5\60NUYJ]&+PDU;$B.J0
ML17:]B(X)@G (    #1[T_0[</XLN_%W@0]Y,OF P'VSD?CDH64^A
M                    (K\Q_P S&YO[A_E"L<%_R)=+MKU.OZOWH/+A\S&V
M?[N_E"R+'D0;%]3H^M]Z4J'.[H   -1NO]%\W]H6O["\YK'XE/'#&K1*N7DY
MS.'QNQL]%D<A6IRORRN8RQ-'$Y6^S1)JB/<BJFIZ3;UNJJ[3A$S]'YY:>5F(
MIGC6-_.O:_X;H?=4/[L\WU%SHSR-S6CA9%/.87(S>SX_)5;<Z(KEB@GCE?TI
MWKHURKIVF-5NNF,9B86)B6><:@
M
M         05S-4K[6W52Y$V_R%B-B[QL4TQ=JGN!T;\?E:4,CI8VOC5S9&NB
M>]W[[&BKHO3V!8<WL#+4=]\A8'+\A<I[:W-FL0^9^U=I[9<D=5+LL+F/LO\
M$<LLLC8NKH:J:-[50"S(0      !3SSM?IAPO^,[_P 8Q@90N&&(
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MHHCO\.-K6,9&QL<;49&Q$:UK4T1$3L1$1#T3X[,S,XR^@@
M                                               $'<W[8W]6RL/)
M.R.3*^RUQ]%E*UB<VYK<':2&6:9))72J]C9%23H5W@N=THFCDT"PYG@#S+[@
MY-W99V!N/!U9<E1BEEDW-@I9)<7(D.B=K)$<K>O[%WB*CE^Q0$PLN$    !H
M]Z?H=N'\67?B[P(>\F7S 8#[9R/QR4+*?0@
M $5^8_YF-S?W#_*%8X+_ )$NEVUZG7]7[T'EP^9C;/\ =W\H618\B#8OJ='U
MOO2E0YW=   !C9&E'DL?;QTKE9%<ADKO>W3J1LK%8JIKJFJ(IE15JU1/ DQC
M"N7T+-A_*#+_ +-;X$]+\07NC3X>=I]DIX9/H6;#^4&7_9K? CX@O=&GP\YV
M2GAEQ? NV*FR_,GN/:M":2Q3Q5&Y7AFGZ?%<U'UUU=THB:]OH0W=IWIO9&FN
M=,S'SN.S3JW9A<H\6[$
M
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M^3+Y@,!]LY'XY*9.&4^A
M                       %5>;,5QMD_,;MBOR[7C_-&QMQ$I7\CDEH8R*]
M7M6Y'-D:U&HKGM5B:OE8U4[/6TT"PGS9^6XQKQ1;:V'D,$R*-JOAQ6%GJ=C6
M^^<D5=W[*Z?7".N     #1[T_0[</XLN_%W@0]Y,OF P'VSD?CDH64^A
M                       (K\Q_S,;F_N'^4*QP7_(ETNVO4Z_J_>@\N'S,
M;9_N[^4+(L>1!L7U.CZWWI2H<[N@      %4>-O][K>WVO=_[58]9F_Y;;XX
M^=H6_P :5KCR;?
M                                                          @/
M>LG(NR^9[&\]C[!L[NQ>8PE;'9A[+=6HC)JLTKXE@DE>KD5$?I(Q8^E?55':
MZA72[5Y+Y0S>X*6+SO$U_;^)LN<VSF)LI3LQUVM8YR.6.).IVJHC>SW0)7"
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MB)JH1D
M          5:\RD_#46^L>WD3C/.[SS2XF%8,IB)+;*\=7VFSTP.2"U"WK:_
MK>NK==')VA8:GR\Y+@>UR<E'C_C+.;6W77I3R29')36Y(H:[T1%:]DUN9$\3
MN:JL^LH65NPQ    !H]Z?H=N'\67?B[P(>\F7S 8#[9R/QR4+*?0@
M                   $5^8_YF-S?W#_ "A6."_Y$NEVUZG7]7[T'EP^9C;/
M]W?RA9%CR(-B^IT?6^]*5#G=T       JCQM_O=;V^U[O_:K'K,W_+;?''SM
M"W^-*UQY-O@
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M"]79-9HNB=+6D;*U'HVDU5:JM[=')]<[5X/%9<(
M                                             $/\J[H\P>$W#6J\
M3[(QVY=NOI1RVKUZW#6E9=665KXD;)<KJK4C;&[7H^R7M]PKD./<#S]NOF+&
M\B<I8#'[0QF#Q5K&,JX^S%8DO);=U(Q_@V+'JL=I)ZZHB*U-$5554"QX0
M &CWI^AVX?Q9=^+O A[R9?,!@/MG(_')0LI]"
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M "P/8_.W^$*_]+@_@AK;*X)^WSF%_P"6!['YV_PA7_I<'\$-;97!/V^<PO\
MRP3#PU%S!%C,FG,$[)\DL[/O:L:4T1(.CUM?8VM3WW]%VG39^<M-4=1HPW=/
MSMFUKX?228=8Y@
M                                           .3Y.WC+Q]L'/[TAJ-
MORX6JZTVF]ZQ-D5KD3I5Z-=IW^X!I-S<1[,Y(MU=S;@3),ORU(8^BCE+M*)&
M(BO1/#KRL:JZO7UM-5"O+:/ ?&6RMQQ[NQ&.L3[D@8Z*MD<C>MWY(62-5C_#
M]HE>C5<U>G7373L3O4&*3 @      "GGG:_3#A?\9W_C&,#*%PPQ
M  #6Y+<. PTT%?+Y6GC[%I=*T5NQ% ^5?<8V1R*[^8!ZY3,8G!U'7LS>KX^D
MSWUBW*R"-/\ XGJB$F8C2X[ERBW&-4Q$=U 7+OFIV#MO:N:@VS/)F<Y)6EK4
MI8HE;399E:K&*]\JL5Z-5>K2-':HG><<7:9G"&C8VC9O7>KMSK3OSO1\NXA7
MA/';W\QFWL9M_)9]M'9^RJU/%V*<72CFL@B\.!6P-5.M[XX_ZK+V)ZVFNBH<
M5RW575IW'6Y_9U_-7\)JPM?+>WY[L\+YW]3\E&S,]D\!>QV5S>XJ*S,O25+5
MM8/;H]>J*25)6-1RO3I>L4;FM7L]"H;=%,8Q$SA#TD1JTX1O.DX'X@N\GY"A
MOK>,<C=@89C*NV,1)/)8CD@K._>H8W2N>Y:L7<J]7KKV=J=1ZS-YNUE;$6;&
M[-4;L\?SSX(:-%NJNO6J6ZP.TMJ[59/'M?!8_",M.1]EN-J04TE<FNBO2%C.
MI4U7O/)-YN   #197>NS<%;6AF]Q8S&WFM1ZU;EVO7E1KNY>B1[5T7T=@&HW
M#OS:LNR-UYS"YZ*_!@\5<NW9\!:JVKE=D=>61'1]7BQMETC<L7BM5JN3M14U
M I2GFMQ_W[<J[MY _-SV5O0U/S=]M]M\1W4JK[#X?A>'TZ)IU=6OH#+!:R;S
M%\6XG&U?$R]C(74@B66"*!TMCJ5B:I(]&QP]>OONEVFOU#KKFT+-&YCC/<>P
MR7N=M/-4Q7%$4TU1C$U51&Y/<W:O H'SURGN'<_)NXK>'S>6J[:M3U+-+%RV
MY8XXO#A@D8O@QRNC:YLC4D3I[G=O>;5F[%VB*XT2\_G\C7D[]5BN8FJB<)PT
M=['!+'EPSGF W=MK,5]GYFS<B2\C;^0R%J.=\*+"SH:U]MSWM1=7+^]--3-Q
MF)F(M:-_0]'[NU;(HIKKS\:U43&I'TN[CY.YP>5+?\T>7'GG=."Q[_;5WCF'
M6_%FJI?:C*L38WIU(^_) WM5VG3&T93+W;<S5<JUL3WAVOD,W31;REGJJ:)G
M=PIIQQPX,>#?ES'!/EBYCVIRSMG<&\=I,@VU1GE?D)9;N-M,:UU>5C56*.Q(
MYWKN;W-4[":8F,)>/IN543C3,Q/<?T*1$1-$[$0R<0
M                                                  &AWQGY-I[*
MW)NF&-)I<'B[V3CA=[U[J==\R-7N[%5F@%.LQR%R_A>"]OV9MW2Y'D+F#,1)
MAIH%\.7'4)4:QT5=S%T8Y7K$U?#8WH\143UD10R=UQM5WQPWSYC>)LQO.[O+
M;NZ<')DXW9-TCY:MNMXBJYB222JUKO!>GJNT7J[4U;J$6I"     T>]/T.W#
M^++OQ=X$/>3+Y@,!]LY'XY*%E/H0
M      .5Y-^;;>/XCR?Q24PN>3/$TL]ZO<_0J\4HL\HGS;93\>6/BE0X,MY/
M?=-[N^KU?ISXJ4^FT],
M                                                           (
MK\R?S%;Z_%C_ /ML"PYG&>7+QL;3F_6UR1'XD$3_  X]Q=+&]3$71J>S]B)Z
M 8NCVKP;^:VX*6?_ %D;ZS7L3G/^]>9SGMF/FZF.9I-#X#>I$ZNI/6[T108I
M7"       *>>=K],.%_QG?\ C&,#*%PPQ      *J(FJ]B)WJ!H,GOG96%1R
MY?<>,H].NK;%R")W9VZ(CGHJK]0Y*+==?DQ,\4.&;UN--4<J%N9?-ELS8>VE
ML['LU-T;FGF2O7KM=(M2'5KG++*]J-ZFITZ(UCM55>]$,[F7N6XB:Z9IQX8P
M96[E->C>1#L7SW[DM5[M3=FV*5W+(B/Q\N.EDI1.3JT<V1LOM"JJ:HK>E4U1
M%U]TYLGEHS%V*)JU<=_B6[,TQC$8JK<H;LSF^-^YS<VX'N=?O6GR,A<Y7M@K
MJNL,+-571L;.EJ)^SVZFO>HU*YIQQPG2Y8QPW=Q)^Q]L[ZY!V[B[<&8I67Q1
MK3KPY3*U(++8X)'1L8R.U*U_0C6M:WI30W\K5LO5PS'XG'5HWM$M&_[MWLWC
M?ILUUTZ-:-:8QCBW(:3G'8.\./ZNWJNZ7U>G)>U6*K*<L<_4D7A-57OB31=%
M>J)ZR^G0X\Y&4QCLT81OZ?GQ8Y+(4Y3&-75F>7PLCRS[<WEO'>>2VSLW<\NV
M;5C'.LV98I[-=)XX)HFJQ?9NUVB2N5$>J(3(W[=FYK7*=:,-&$3XVY>IFJG"
M)P<?OG85["[VR&&@S6&S+);4BULI3R]!]:5LCU5'/D=.B1.[?727IZ5U]':N
MC5IW'+"QW+^ZK7&OEWXXVCLG?B.W)0G;]\[FV,F_I6*>*Q*YGCU)$1T;7NZ6
MZKZW3KH<47*9JU<=ULU92]3:B]53,453A%6],]SA13PWS=RG5Y*P5G);DW!N
M:C"^>2;!6,K=EBM(VM*J,<Q[I471='=K%[C"_=FW1-41CAO-C9V3IS>9HLU5
M1;BN<-;@\,>-H^4.5>0K?(6X[E;<&9P\%F]+/'BH\C::RJDJ]?@HB.8B(S7I
M]XWZR&5JO7HBK##&'%G<O&7OUVHJUXHJFG6X<)PQW]/&D/8/F.WUM3@_<="C
ME+TN\OOLVW1W#=E9D5BKO2G$^#P[C)DTT1ZI]5W<B]IPU9F*;T6L-,8^/F=A
M1LBJO9]6=UHPIKU-7#N1../?:7 ^;CS V<YC*]O=OCU9K<$<\"8W%L\2-\C4
M<WJ;4U35%TU3M-FJK")ETU%$551'#+0^9?=ES>_)2[DO8QV(GM8^LB4GN<]6
MLC61C5ZG,C5=437WIKY:]-VC6F,'<;9V=1D,U58HKZR*8CZ7'&/#/C;CR^;&
MY$WUM7DO';%R"UH&X^!N3QS;$E=]]TL%U(*Z(U.E_6J/;I(YK/6[3&_;N5UT
M33.$1.[W=#9V5GLGE\OF*;]O7N7*=6W.$3JSA5$SNZ--.C=W&G^BOS_\B;/W
M13^'-QYO%_0S:'"''.*Q./FO;8K2YAU>%]_VWJN)[2K&K(G3,Z1B:.U[&IH:
M5.2LQ..K'?W7HJ_>?:55$6XO54TTQ$1JX4[D;FFG"?"YW=GE*X;WEN"[N7*T
M+<5^\K'2QT[*UZ[?#C;$U&1L;HU$:Q.Q#<BF(C"'GJ[M5=4U53,S.F9W9=KQ
M=P_LSA^A?QNS(K$57)3,L6DM3+.Y9(V]":*J)HFA6&+O0@
M                                                        !BY+
M'4LQCKF)R4*6,=?@DJVX'>]DAG8K'M7ZBM54 @+8?E(VOLO>.,W-<W'D]P8W
M;CWR[5P>0<BU\?)(]9.I%151W2]?$3H8Q.OUEU4+BZCC[@MFU.0\[RAN/<5O
M<^Z<IX]?&NM(Y(L?CYIED;!%UOD<JM;TL1VK41-41O:H,4OA     :/>GZ';
MA_%EWXN\"'O)E\P& ^V<C\<E"RGT(
M       '*\F_-MO'\1Y/XI*87/)GB:6>]7N?H5>*46>43YMLI^/+'Q2H<&6\
MGONF]W?5ZOTY\5*?3:>F
M
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MOCX7MWLJ.;XOL_7X?5JJ^]\1^GUPCJ@
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MN!41WJM>]-.WL[0CL
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MU]2*V6377N"Q+^E6%_\ )\?]K0_V-H8,X
M                          <IR9L>KR3L+/;(MS+6CS%988[*-Z_"F8Y)
M(9%;JG4C9&-<K=4UTT AG8'"G*4N]]E[BY5R&&DQ?&V.?C-MU\+[0Z6V]8O
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M!JM@LLD?Z\BM:FC6KZ0L)0QD,E;'4Z\R:2PP1QR)KKHYC$1>U/JH$90
M    !BY.&2SCKE>%-99H)(XTUTU<]BHG:OU5 B7RP\?[HXSXKK[7W?594S,=
MVW8=#'+'.WPYG(K5ZXG.;VZ>Z%E,@0
M
M         ^%AA69+"QM6=&]"2]*=:-5==->_0#[ A?G3@RWS#FMD9:MFH\2W
M:-JQ:DBDKNL+82Q)5?THJ2,Z=/9M/3[[Z@6)30$       0ON/@RWG>?-O<T
M,S4<%7"56U7X=:[G22JUEAG4DOB(B?U?^@7N"XIH"       (7V3P9;VESEN
MWE^3-1VJVYJL]5F);7=&^!9YJTO4LJR*CM/9]/>)WA<4T!       $+\ <&6
M^%?SI]JS4>8_.*U#:9X==U?P4A\7U5ZI']6OB?4[@LRF@(     !H=[[>?N[
M9>X]J1SI5DSN+NXMEIS?$;$Z[7? CU:BIU(WKUTU34#D^"N+;'#NP8=EV<FS
M+2Q6K%KVR.%:[52PY%Z>A7O[M/="RDH(     !'G-O&L_+?'>0V/7R+,5+>E
MK2I=DB6=K?9IF2JG0CF*NO3IWA8;?C'9TO'VP<!LN:VV_+A:K:KKC&+$V16N
M5>I&*YVG?[H1U@      (7\Q7!EOG/"X7$U,U'A78FU):=++7=921)(^CI1&
MR1Z:=X6)3#1KK4I5JBNZU@B9$KM-->AJ-UT_F!'N
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M6QA<K#XU:1S>AZ:.5CV/;Z',>US')[J*$;P
M
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MS_?2A(LSH*\EF21WA/:]S7=72U/5;U>KW*,%I0@
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MA=':JD;U[OL5]P&^_H+MV"U6V_BJU[7VZ&G7CLZ]_BLB:C_<]**&+9
M  ?$TO@PR3=#I/#:Y_AQIU/=TIKHU/2J^@#^</AVOU.+RFW+U?U?MW?[8SB%
M7/2MU>/HD7M"2I-UZ+XGA:=/3Z_U S3IC,A7QWFHY4OYR9E&M?V;7MT4MN2-
M?9HZM/Q4];3WKF2*Y$]Q?<#'>=9Y+Z]R#@3#/M(J13W,A+41=?ZC[2YO9]3K
M:\$K A
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M]R!RCRW8Q=S$X'=ENE7P$.2A6M8F@Q\3V/F6)_K(URJSI7_K)Z DK"!
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M-A;C7)[JNVJSHZ$%.E9EF1[+"^H_Q&2:,T[%<G9KJFH7J#$
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MZ'*K=57L[0F+KL7B\=A,=5Q&(JQ4<71B;!4J0-2.***--&M:U.Q$1 ,L
M
M
M
M
M
M
M                                :K/[GVWM2FS([IS-'"8^65*\=O)V
M8:<+IG-<](VOF<QJN5K'*C===$7W ,#!<A;!W3;7'[9W5A\U?:U9'5<;D*MN
M9&)WN5D,CG:)[N@'2
M
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MZ_C3DS;7*VW/SFVPMAE5D\E.U4O1>!:KV8=%='(S5R:HCD75KE3ZNNH1V(
M
M
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M:71-&M17:N5$T7MT+@N*&(
M
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MRLW(%BY?QD-]T.U<KE:_LE^W08FGB21JJNZ5716JYSEU5R=3D1 DIY"
M
M
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MDBEL=B-14=TZHYVFC5];3M&*U80
M
M              8]^M)<HVJ<5A]66Q#)$RU%_5(G/:K4>W7[)JKJ@$5\6<$U
M>/=S9C?>;W'>W?OK-0MJ6<UD6MC5E9BL7PV,:KM-?#C155R]C41$1-=2XI<"
M
M
M                                   &+=QN.R3(X\C4AN1Q/26)EB-D
MK6R-U1'-1Z+HJ:]X&4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M            !4OS!\V\@Y#DBAP'PQ)[+N>TL;,KEF*U)623Q+-X4;W-<D;8
MX?WZ65OK>ANG2O491#C]X<4>:7B/".Y!P_)N0W/9HK'-E,4EB[;['.:SJ;!:
M65EAK>SJZF-<C>Y.P&XM7Q!O#<.^>/\ $[AW7A+&W]QS,='D<?:@EJ_OL3E;
MXL;)D1WAR)H]NONZ:KIJ&+N0
M                                       J'YX]_;VV-^8?YGY^]@_;
M_OO[;[!.^#QO ]A\/KZ%37IZW:?74,H8F:X1\W. IRY? \KRYNW38Z9F.=:L
MMDF5J*O0QD[9(G.7T)(J)J#&$C^5CG?)<P[<R.-W4UC-Z[=?&R_+&Q(6V:\W
M4D<WAHB(UZ.8YLC6IIKHJ(G5HA)A8 (
M
M  I#SSN7E/)>9;'\9[+WID-N4\O7HQ0-@L31UHI98WN<]61JG?T]N@90ZGZ/
M/F<_][[/_?7OW0,863V'AL[M[9^(PNYLJ[-Y^E72*_EGJ]SK$J*JJ]5?J[N7
MTABZ(
M                                    "BNPG_>OSW[A@S;D;;MV,DVB
MKT1O]7J>- B:Z=\'8GN_S0RWEU=R[DPNT,%>W+N.VVCA,;'XUVV]KGI''JC=
M>EB.<JZJB(C455]"!B\]K[MVUO7$1Y[:F4KY?$2N5C;=5_6SK;IU-=Z6N35-
M6N1%0#<@
M                      !2#_\ Z&__ +./\=__ -/#*%WU5$155=$3O4,5
M&/)BYE_FWDO+8QB_>22&RL3F.5T;6V,BCX$U7OU8UVB_4#*5YPQ
M
M                      ?S\\Q."S>YO-OBL!MO*OP>=OU\?#1R\3Y(I*\J
MQ/5'M?"K7HNB?8J&4:$@?1C\R/\ [Y9/\HY?X<&*V.W:%[%[?Q6,R=MU_)4J
M=>M<O/<Y[IYX8FLDE5SU5RJ]R*[5RZ]O:&+9
M
M        5X\P7EKGY/RU'?NQLJW;_(^,2-L=I[I(H;"5W=4+G20HKXI8U]Y*
MUKNS1JIV(J%B469O@WS=\IUJ^U.2=X4(]IQ2,?.Y'0+U)&J:.6.G7B=.Y-.I
MJ3/1->W5%"XPMEQWL/"<9[-Q6RMOM=][\9%T>-)IXLTSW*^6:14^R>]RN7T)
MW)V(@8NH
M                       "MOFQX*WMS5^:/YGR48_O']\O;?;YGP:^V>R>
M'T=$<FO]1=KW>@+$N(N<2>=?<-67"YKD/'P8JZU8KCX["Q/\)WOD1U:DR3M3
MLT1R:]RKH%W$[<$\(X7A#:TV&HV5R69R,C;&8RSF>$LTC$5L;&,U=TQQHJ]*
M*Y5U5R^G0),I3"
M                                             *D<X>7[F'=O,T7)
M_'%_'8^2G7JMHV;4[F3QSUV.:YW0L$K=.WLU#*)8?ZO?/5\OL9_WD/\ $ ;B
MS'&M'>>,V/AZ/(5Z/);RACD3*W8518Y)%E>K516LC3L8K4]X@8NK
M
M
M
M
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M^&9J/8Y$<B*FK51>U ,D
M
M
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ML@O=^\P8R6/%M<O=ZUB99>GW8?J=A(3EQE\VVSOQ'C/BD01U0
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M[40YK.=M7:M6F=UUNT?=G/Y"SUUZB(IQB/*IG3Q2[XW7F
M
M
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M5U1S7MC145/0J%C+VHG&*8QXH<=S;&>N4S17?N54SN3$UU3$\<8NB.=U0
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M?DAA/R;4^#'9K70IY(/;FT?XB[^\KYS]6O'/R0PGY-J?!CLUKH4\D'MS:/\
M$7?WE?.@C9>/H8KS29K'XNK#2H003)#5K1MAA8BU87*C6,1&IVJJ]B'36:8I
MSLQ$81^1],VI>N7O=BW7<JFJJ9C&9G&9^G5ORL^>A?&@
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M?A^-K;\/\T/S_P"KP4_\I\3PNCWW]6Z^SH[OJ@P2F$
M   ?$BZ-)(K3B]]<D,S[&NDF7VO<'L,T;X>I/96OT<QK7(J-1NJIU-37ZIVM
M5JWA]5N313AWEF&^]3ZQU<--^@
M                       --NN3<\6WK[]F05+&Z.A&XV/)/?'3\5SVMZIE
MCU?TL:JN5&]JZ:(!!=_@3DO<K7YCDSFC+5^CJFFI;>TQ&.KL1-=$7K1'(W^C
MDCUT[_="XL';''&_,:LV0X8YV_.ME)VDV$S\L><HN75R)'+/!,]\"*K53][8
MBZHH%CL/)E)L10ESD,5;-25H79*O6>LD$=IT:+*R-[D17,:_5&JJ=J!&:
M (>\U'S ;V^UJ_QR +#J>&/F>X^_U:PWQ"$)+N                    KO
MYO\ ]"<%^-4^+RFIF?)AY7WC_!I_2^:7?\ _-!M;^L3?&93EL^1#M-D>J4<4
M^.4DG,[8
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M6.-9ZF;NQPO:Q&JU'*BN1%[?2IM9BF*9C#@ASW(PPPX$FIV)H:S@
M                                                  &HW1#N2? W
M8]H6JM/<G2UV/GR$;YJB2->URME9&J.Z7M16*K5U375 *\<M;VRVXMA9/C7E
M;&?J^W!D75DH;@G=)=VC?EK6(YTBDNP(CX&3>'TN9,C7,:O>[N4K;<)\3[FP
MN]DY R>+VIMO$KB),=4H[+6PZ&_[3+%,D\[I%Z%:Q(_WOIU5>KM[D!*Q 0
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M 'L,]_6)?BD)T%KUZKY;SZ_GO^*VN./OU++'?OD
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M1%[%5.PZNJBJG3#KJ[-=&F&],'"
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M_ /S0;6_K$WQF4Y;/D0[39'JE'%/CE))S.V
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MW-_</\H5C@O^1+I=M>IU_5^]!Y</F8VS_=W\H618\B#8OJ='UOO2E0YW=
M!6G;7^]AGOZQ+\4A.@M>O5?+>?7\]_Q6UQQ]^I98[]\@
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M&G]+YI=_P#\T&UOZQ-\9E.6SY$.TV1ZI1Q3XY22<SM@
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ML2_%(3H+7KU7RWGU_/?\5M<<??J66._?(
M '"\@\G4=C6,5A*F,M[BWEGW2,PFW,;T>T3) G5)+))(YK(H6(OK2/7]G1=
MY_'<QYW';CP^W.3]DV-F.W%8]AP63;?K9:A-==JK*TDL",6*61$]1KFJCE[$
M4+@Y_=7._)>S9<6S.\0V:\6<RL&!PTOW_P 9)[1?N*_P(](^M6=?0OK2:-3T
MJ@,&?N'FO?.T-M,S>ZN,K&,R-S+4<)B,4N9H6'6YL@DNCDE@ZV1HUS&M_?--
M>K77L4&#XRW-G(NT\=/N#?'$.2Q6UZ2))D<C3R^+R<D$6J(Z18(9$<K6IJJK
MKV P=B[E'&OW]MC9-&JMNONC$3YVEEV2=,:00]*M3PU9JO6CD5%U33W .]"
M                             #3;M@N6=M9:O0177):<[(&M]\Y[HW(B
M)]5>Y#*G#&,7+:F(KC'1BKJQT<B1JQ-6JU'QKHNB)IV?6[%.Y=\U6;S#</4E
MLHKY)ED\.*-Z=+.IS=>_1-6HB:]B]_81R44ZTN&DW;GI7JY;*(S77PTCCZ>Q
M=?2U5_GAL]72[#;VX9,U ^-\:,NQ*WQ.A=&JQW9UIU:]WI0->NC52AQ9-+^=
MS4@U\*:I.DZ*BIV1O9TJJ+IW+W?7-7,Q]%U^;CZ'?3B=>Z<
M                                            AGD3S"X_BO=KL-O+
M:^8BVH^*&2MN^G ZS1621/7CDU1G2K%[^ASW=J>J%P=ULOD[C_D.O[1LO<-/
M+Z)U/@ADZ;+&^[)!(C96?_&Q CK      A[S4?,!O;[6K_'( L.IX8^9[C[_
M %:PWQ"$)+N                    KOYO_ -"<%^-4^+RFIF?)AY7WC_!I
M_2^:7?\  /S0;6_K$WQF4Y;/D0[39'JE'%/CE))S.V
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M[E;VIJ(=7D<92POF0XTP^-9X>.Q^TLE4IQZJ[I@@6.-B:KVKHUJ=H$^!
M                          !^*B*G:!6W.UVU\WEZOA]*1W;.D.FB(Q\S
MGL[/0BM<U4^H=M:G&F'H+4XT1/<ARNZ\7-D\8K:[>J:!R2QM3M5^B*CFHGNZ
M+V'++8MU82C%6JBJBIHJ=BHO>1N.VV/C[4*39%T:I'+TQ1H[U=6ZZN>FJ=J)
MHF@:]V=Y8_B;"0Q8M^X9&JMN^Z2.)SNYM>*16MZ?J/5O6J^GL]PZV_7C5AP.
MAS=<S5J[T)&-=H@
M           $#\E7^=]T[[N<?\:Y' ;?V]!3AGO9>\Z*UDW-G325&U'+,O0G
M4B(KX&M5?LPJ*[_E!VK3H9BO@]ZV,GSS!73+TFU[57&NCEZO5D]DC59(HI'+
MT^*LG8NFB^A2XK;;6BS<&V,+!N5[)=QQT*K,Q+&O4QUUL+4G<U>S5%DZM Q;
M8    0]YJ/F WM]K5_CD 6'4\,?,]Q]_JUAOB$(27<
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MJZ9'N;JFJ]IE8JJFK=ES;$S-ZO,S37755&K.F9G@6]-][H
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M%'B;4R<P!6G;7^]AGOZQ+\4A.@M>O5?+>?7\]_Q6UQQ]^I98[]\@
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ML:W;MQ[IW+N!;<;8EAW%E9<G%%TNZNJ)LB)TN7N54] 1VX
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M@4CQ6>K9C(X_*U>I8TIXVXE:!S^N1??HB]:HGOGQZ)HJJE$\!
M       T^Z[^&Q>V\I>W%?=B\)'7D2]D8Y9*SX(GIT*]LL2H]CDU]5S5U1>U
M *,7^/<;M[?<N8ROF0LXV#*XBI9H9SVN^N<M5;*-FA;+H]J+75FCV+XZ]NGJ
M(&29_+MMGCVMOC,;EQ7*MKDW>TF,]ADGN22/DKXWQXGJB^*^5R_OC6:>OHGH
M3M4)*S 0    $/>:CY@-[?:U?XY %AU/#'S/<??ZM8;XA"$EW
M               I=Y8_GCR7VC>_L\1UV7\M\_V%ZW/%5XX71.Q?0
M                                                  #'O1VY:5F+
M'S-KWWQ/;5GD9XK(Y5:O0YS-6]2(NBJW5-?=0"GE./SIQ<GY;)1X_&/NR8V*
M!_C/L?FZL;9&JBUT=*C?:%T];TZ:AEN)/XJVCS[8Y-L\@<NW\?5H1XAV(J8/
M$32NKOD?.R9)EB57,14Z7(KU=UKV)[U B? @    -'O3]#MP_BR[\7>!#WDR
M^8# ?;.1^.2A93Z$                       %;?.%^C>VOMZ;^PH:>9T0
M\E[R?AT<<^)/NV/T;PWVC6_L+3:IT0]/8_#IXH\3:F3F *T[:_WL,]_6)?BD
M)T%KUZKY;SZ_GO\ BMKCC[]2RQW[Y
M                           %71-0/E9&-35SD1$[U7N \8KU.PY6P3QR
MN;[Y&/:Y4^OHI,87"7NBHO<5'Z     'XJ(O>FH'XL4:JBJQ%5.Y53M ^&NK
MS*J-Z'N8JM=IHNCF]Z?45 /31$75$[0/T              #\5R)W@>$MZG
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ME80(    "'O-1\P&]OM:O\<@"PZGACYGN/O]6L-\0A"2[@
M           4N\L?SQY+[1O?V>(Z[+^6^?["];GBJ\<+HG8OH
M                                              !Q?+C-M2<;;DCW
MC>M8W;#J;DR=_'_^+AAZFZNB]23UM=/L% ISNC,>47=D^,L7N0MWUG8O&4<-
M E1CXVO@QT+8(Y).K'OUD<C=7N31%7N1 RW4F>62IP%7W[D7\5[NW'G]PKB)
MDLT\YK[,RG[36ZY&_P!J5_71_AM3UNY5[/<)*UP0    &CWI^AVX?Q9=^+O
MA[R9?,!@/MG(_')0LI]"                       "MOG"_1O;7V]-_84-
M/,Z(>2]Y/PZ..?$GW;'Z-X;[1K?V%IM4Z(>GL?AT\4>)M3)S %:=M?[V&>_K
M$OQ2$Z"UZ]5\MY]?SW_%;7''WZEECOWR
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M)36I\YB/O_DKT=UK6VJ>%N,=%6BF1MBTJ-=)TI$CYG+HS3O8H%EBL0
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M\<+HG8OH
M     !SN_'9YFS\N[:^(K9[<"5U^]^'O*QM:S+JFC)%D?&W33^B>@$$[H_7U
M3GQC=K<+[6R,$V,HSY-\[L?&L.4EA:ZW WJN1ZLBDU:UR:HJ?9+WA73\-3\R
MR[GMMY$XSP6S,*E"18,IB)*C[$EKQH>F!R06IG=#F=;UU;IJU.T$IQ"
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M5[.QJG+:S]JY5%,8XRTL][H;0R=BJ]=BG5HTX58[^"3CL'C0
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MFHJ$64H%0  ?BJB)JO<!YQ6:\Z*L$K9$1SF*K%ZD1S%Z7)JGI14T4#U
M !^.<UJ:N71/= X>?+.S%V5['+[# ND#.[J7^C7Z_H]PX<<9<V&#]*@  U^<
MK.MXFU79VO<S5B>ZYBHY$_90QKC&,'-9KU*XE&<$+W96BFG1.RQ#T,DU:J/;
M)KIII]EW:FA$?2AW]=<=55AP2E:&O'7D@F9ZT]9W5!(_M5JKKV>CLT730[#!
MYO%V>/O1W84D;V/1>E[%[T<B'+$N*8P994 /&Q4K6VHRU"R9B.:]&2(CF]3'
M(YJZ+V:HJ(J+[H'VD;$[DT _>AJ^@ C&)KHG?W@.AGN ?CHHWM5CVHYJIHK5
M[45% Q,?AL3B85K8JC!1KJY7K%5C;"Q7N[W=+$1-5]T#,\-G:NG?W@>4LM6%
M6),]K%>[I9U+IU.T5=$U[UT3N ^8ZM)MEUR.%B7)&-B?.C421T;%5S6J[354
M17*J)]50,D       #E,_EUENMP\#M&IVVE3TIIU(S^;]E^P<54[N#DIC",6
M$B:=B=P4  %*(ES%)]2>6I*WIBC>[HZM41\7:C>W]@ZZNG#<>ER]V*Z8F-*0
M,%1C=@JD5G2:.2"-KFKVM5$;HB]J(NJH;E%/T8=#?JQN53W9=UA;Z21-IR.T
MEA:B,_Z3$31%^NG<IS1+5JAN.\S8@  !J-T[FP^S-O9#=&?F=7PV+B6Q<F8Q
MTKFQHJ)JC&(KE[_0@%),QR]Y<]U<[Y/>6^GR;EVE:P]6KA5M4K+X*%F!RI+&
M^L]B*[K]^Q[6N1%<[5/2AD[KRXY+C+.\\[US'$KEQ.TW82"%V \&:!EFREB-
M7W8V*BQQQL3][:Q7-=J]RHQ$U!*W 8@    A[S4?,!O;[6K_ !R +#J>&/F>
MX^_U:PWQ"$)+N                         !2[RQ_/'DOM&]_9XCKLOY;
MY_L+UN>*KQPNB=B^@
M              'Q++%#&Z69[8XF)JY[U1K43ZJJ!57D_".Y:YVDV'NS>UG;
M6P*>%@O86IC+<5=,G9?+TSJCW]4;I&*JM5JM>J-1JHB:KJ5F<'8S(;#YMS_&
MFUMWVMX<;5,''D+*W;#;:XW)OLI''721GJH]8T<]S6-:BHJ:IJT$K0A
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M=[->[%=R]5-=4X[L]RY"V)Z5\/
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M<8WW_P#-Y\D]J_=TW[8#[_\ F\^2>U/NZ;]LAN'W_P#-Y\D]J_=TW[90^_\
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MGCR7VC>_L\1UV7\M\_V%ZW/%5XX71.Q?0
M                              #2[NVMB=[;:R6U,ZU[\1E85KVVPO6.
M18U5%]5R=R]@%*^6.._*+P_FHMO;@Q^Y,CF7UVVYJN)L-G6"%[E:QTKII(6M
MZM.Q$55_934RW7:>5F7@J?D/+)Q3MS<V,S-?#RLR=S/K%[,R"2S65L2)'--I
M(]S4<WJT]5CM-02MT&(    -'O3]#MP_BR[\7>!#WDR^8# ?;.1^.2A93Z$
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MK58KH;#$D8JM=HJ:M<G8ISQ.,8NYMW(KIBJG1,8\K,*Y
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MM\=_]G^37'GJ_7H^6\^RY7_BE??_ ,Q: ]"^-
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M9KWH!'/FH^8#>WVM7^.0!8=3PQ\SW'W^K6&^(0A)=P
M       (0G\JO&-B:2>2;*=<KG/=I9CTU<NJZ?O)K=GI>=G8&6F<?I<OY'G]
M$_B__P"ME?NF/X$=GI3X?RW]KE_(?1/XO_\ K97[IC^!'9Z3X?RW]KE_(?1/
MXO\ _K97[IC^!'9Z3X?RW]KE_(A'S"\3[7XO_-S\VWVG_?7VWVKVN5LNGLWL
M_1T]+&:?U5VIK7K<488/.[8V?:RNIJ8_2QT]S#G6WXR^;;9WXCQGQ2(W[?DQ
MQ/<9'U>W^A3XH=49MT
M         8]Z]1QE26_DK,5.C7;USVK$C8HHV^ZY[U1$3ZZ@5!Y*K<=<M\]/
MPO)&^J\''5/#06-L5Z.5K14;%U9>FPV27J>QLJ*J^KV2.;TZ+H@9-MP%BMO[
M/YVW'LOBC=+L]QA%@F7LE5DMQVX:^7=:1B,K.9HC^F/M>]B*B=?2]>I&A)6P
M"     T>]/T.W#^++OQ=X$/>3+Y@,!]LY'XY*%E/H0
M       %6.;?]Y+CG_$G\KSFE=_$CO>-XS:G\QL_4^_*TYNO9@         !
M5_-?[V^._P#L_P FN//5^O1\MY]ERO\ Q2OO_P"8M >A?&@
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MPRY)L\4,;+4;FR+$E5BJCE:C=.OTA862X8^9[C[_ %:PWQ"$,9=P
M                      JQYRO\RO\ &G^!FEFMYXSWE_N_K?JI]XR^;;9W
MXCQGQ2(VK?DQQ/39'U>W^A3XH=49MT
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MPPT[=27'R.<DK9WP.1&*G3IJJJ@3!SGDR^8# ?;.1^.2@E/H0
M              %6.;?]Y+CG_$G\KSFE=_$CO>-XS:G\QL_4^_*TYNO9@
M      !5_-?[V^._^S_)KCSU?KT?+>?9<K_Q2OO_ .8M >A?&@
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M]#V@:OD/R\YJ3:,[L!=3)Y>I7W"VKCF0LA=8=N'*,O(G7)*C6^"B=/;[[O[
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MT*8N]ZV]71JG5IKI]0(^M4 ^(Y8Y458W(]&JK55JZIU-714[/2B]@'V
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M6_53[QE\VVSOQ'C/BD1M6_)CB>FR/J]O]"GQ0ZHS;H
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MU/YC9^I]^5IS=>S          "K^:_WM\=_]G^37'GJ_7H^6\^RY7_BE??\
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M9"C@ZMF5UF&M05$9+<=.CT2:VZ)9)&L71JZ?6 M6QO0FFNONE8OH
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MK$CQ\\6!R\E9B:1193)T'/N(U/L5<C(9')[KNK[()*8RH
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M;/\ 8X3;R_DO4>[_ *M]:?F3F;+T8
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M[_\ F+0'H7QH
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MS ;V^UJ_QR +#J>&/F>X^_U:PWQ"$)+N
M    !$/F:^:#+_U^E\9C->_Y$NBVYZI5QQXVJ\I_S7S?C6S_ &.$F7\EP^[_
M *M]:?F3F;+T8
M  !4KF#;F'Y)Y_\ S%Y3W=-M_85?"07<!C(+<5.&]<=+I*CWS(Z/Q6KKZJMZ
MU8C5;H@90Q^'+>TN)^:L[L?:W($.1XE;A8[L_P!]<E6?7J9B2PC6002=3(W/
M\-'.=X;>Y='^LU 2MQ5M5KM:&[2F99IV6-FKV(7))%)%(B.:]CFJJ.:Y%U14
M[PQ>H    T>]/T.W#^++OQ=X$/>3+Y@,!]LY'XY*%E/H0
M          %6.;?]Y+CG_$G\KSFE=_$CO>-XS:G\QL_4^_*TYNO9@
M  !5_-?[V^._^S_)KCSU?KT?+>?9<K_Q2OO_ .8M >A?&@
M
M                                             #%R63QN&H3Y3,7(
M,?C*K?$LW;<K(((F)V=3Y)%:UJ?550.1_7/P]_[@[:_+-#X8&#;[?W[L7=EF
M6EM;<^)SER!GC35\9?K7)61:HWK<V&1ZHW54350.A     "'O-1\P&]OM:O\
M<@"PZGACYGN/O]6L-\0A"2[@                                1#YF
MOF@R_P#7Z7QF,U[_ )$NBVYZI5QQXVJ\I_S7S?C6S_8X29?R7#[O^K?6GYDY
MFR]&                                                  13O[RY
M<4<F;A?NC=^*FMYF2*.NZ:.Y8@;X<*:-3HB>UO9K[@7%S'T,N /P!9_*-SX4
M&*;<%A<?MO"8W;V)C6+%8BK!0HQ.<Y[F5ZL;8HVJYRJJJC6HFJ]JA&P    &
MCWI^AVX?Q9=^+O A[R9?,!@/MG(_')0LI]"
M JQS;_O)<<_XD_E><TKOXD=[QO&;4_F-GZGWY6G-U[,          *OYK_>W
MQW_V?Y-<>>K]>CY;S[+E?^*5]_\ S%H#T+XT
M
M                                    :W<&W\/NK"W=O9^JV[ALA&L-
MRH]SFMDC547158K7)W>A0*=\NU?*[Q1N*7;"\56-P9&C4COY:2A/:;!3AG<C
M8_%>Z==%=JWO33UF]NJZ!ENNW\M66XZO;VS]#97%E[8F2H8Z-<K<R$LZR*VQ
M*QT4"PS*O3UHU9$=V=C0DK/A     0]YJ/F WM]K5_CD 6'4\,?,]Q]_JUAO
MB$(27<                                "(?,U\T&7_ *_2^,QFO?\
M(ET6W/5*N./&U7E/^:^;\:V?['"3+^2X?=_U;ZT_,G,V7HP
M                                   &BWE3W/D-KY2ELO(Q8G=,T*MQ
M>1L,;+%!/JFCG,<R5%337O8H%=\AM7S>XEC9<KS-MNC&]=&/LTJ4+7*GH17X
MY-0NX[+AMG,,.Z[+.1>3L#O+%/QTSJN(Q#*;+++#9X$2PO@5H'+&QJN8[UM-
M7M[.X$IS"     T>]/T.W#^++OQ=X$/>3+Y@,!]LY'XY*%E/H0
M               %6.;?]Y+CG_$G\KSFE=_$CO>-XS:G\QL_4^_*TYNO9@
M       !5#>N:Q>W?-'7S6:L)4Q=1*[K%AR.<C$=C^E%5&HJ]ZHG8AYN_731
MG=:K<B.9]OV7E;N9]V)M6HUJZM;"/\1-/Z^>)/E/!_W-GX([7M]CI>-\\^$=
MK>@GEI_:/U\\2?*>#_N;/P0[?8Z7C/A':WH)Y:?VG1[5W[M'>_M?YK9-F2]A
M\/VOPV2,\/QNOHU\1C==>AW=[AL6LQ;NXZDXX.IVALC-Y#5[11-&OCANQNX8
M8Z)GAAT9SNI
M
M         K5O?9>#S_,>\\+'O+%T9-\;8;B<UMZZO1D6W&Q*RA8K))HDK$['
M.:QVJ*WM3M]4K:\,<;\PXWD&]O[EN_CI+=? P[4QU?%N<YMB"O8;.EF55:WU
MM4=HKO67K7L:B(@)6 "     A[S4?,!O;[6K_'( L.IX8^9[C[_5K#?$(0DN
MX                                $0^9KYH,O\ U^E\9C->_P"1+HMN
M>J5<<>-JO*?\U\WXUL_V.$F7\EP^[_JWUI^9.9LO1@
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MIK0'H7QH
M
M     "JOF2O<39W<[MDV^-\GOCE'V6*6*3",=4FAADU\/QKD2.<K4]"/AD8U
M%] 6'0>638'-NS%R$G(V4E;M2Q#TX7;-Z\F4NTW^(U6JZ9K.EJ)&BMZ8WZ*J
MZ]" E8H(    "'O-1\P&]OM:O\<@"PZGACYGN/O]6L-\0A"2[@
M                      1#YFOF@R_]?I?&8S7O^1+HMN>J5<<>-JO*?\U\
MWXUL_P!CA)E_)</N_P"K?6GYDYFR]&
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M/]-: ]"^-
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MO[@);"     A[S4?,!O;[6K_ !R +#J>&/F>X^_U:PWQ"$)+N
M                     !$/F:^:#+_U^E\9C->_Y$NBVYZI5QQXT,<(\][/
MXVV;)MW.TLE8NNNS6DDI1021=$K(VHFLD\:Z^HOV)KVKT44X2Z#9>U[65LZE
M<53...YASPDCZ7?&WX+SGW/4_C9S=II[KMOB++]&ODC]IV?''-^U.4,I;Q&
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M_P"+/\,//;'_ #^]\[[+_P!D_P"V_P 3_36@/0OC0
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M?UNKN[ DK%!     0]YJ/F WM]K5_CD 6'4\,?,]Q]_JUAOB$(27<
M                         #3[FVO@MXX>; ;DJ>VXF=S'RU_$EAU=$Y'M
M7JA<QR:*B+V.,:J8JC"7!?L47J-2N,8GY;S@_HX<,?)G^_LA_&3BZBC@=9[%
MR?0^U5SL>_Y=>&X:-F:+;?3)'%(]CO;KZZ.:U51>VP)L4<#&O8V4BF9U/#5S
MH5\H'Z;9W\5+\8B-;+>5+SWNY^-5^C\\+C'8/>@
M                         Q[U&CDZDM#)5HKE&PWHGJV(VRQ2-]QS'HJ*
MGUT KWRK-NK9N[4R$'#6)WWQK%3K013T:=>3+U/!9T+&V/HE<Z)B:=#&Q:(B
M>^1 KIN%^1^$=\Y"U#Q]B*V!WA6K.=DL2_&1XW)15DDC:]'NB9TN8DBL14;(
MO;IJG<"4S!     :/>GZ';A_%EWXN\"'O)E\P& ^V<C\<E"RGT(
M                "J'/EZIC/,)L/)7Y6UZ-.+$6+4[_ 'L<465G>]R_41$5
M31O3A<CY;[Q.UZXHS]JJ=R(U?ORG#]=W$_RKH_TSOW)L];1PO1^U,KZ2&TP'
M)FP]TY%N)V_GJN0R+F.D;6A5RO5C.UR]J)W&5-RF9PB7-9SUB[5JT51,NK,V
MZ           "K_D^_SS_P 6?X8>>V/^?WOG?9?^R?\ ;?XG^FM >A?&@
M
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M,SA/O_E;].U)'-/0P]Q'0587NBDF1&/DT\)KI':="IJO0H%E4[BL7Z
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M6W/ZQ+_V%).AA<\F>)43R@?IMG?Q4OQB(T,MY4O"^[GXU7Z/SPN,=@]Z
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M&M.RM$Y[I%:CJT3UU<]55>UR]YPVZ8INX0Z;(V:;.TJJ*=$1/BA;$WGM@
M        5?\ )]_GG_BS_##SVQ_S^]\[[+_V3_MO\3_36@/0OC0
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ME>.U4F98JS-1\,\3D?&]CNU'-<U5147W4,VQ35%48QNP]0R
M                            J;SQL7;>4Y67=4_.<'&^XX<?#4BH1M\*
M['75%55\:.]6?T2*O5T].@90Z?@.G[/O"\_]?/ZT=<9*GYOZ_P!0_MB#^V__
M !ECWG]3]XG]4[_0I)6+"     T>]/T.W#^++OQ=X$/>3+Y@,!]LY'XY*%E/
MH0                           !6+;/\ O;[@_K$OQ2$TJ?QI>/L?S6OB
M^:%G3=>P           !5_R??YY_XL_PP\]L?\_O?.^R_P#9/^V_Q/\ 36@/
M0OC0
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MS/)>(Y&M<F;AOP-Q4^7N/?XM6MUMF6%T<KWR-5SF-5.O1-&^JG?J)6&"
M A[S4?,!O;[6K_'( L.IX8^9[C[_ %:PWQ"$)+N
M              >-J%;-6>NB]*S1OC1W?IU-5-?YX8U1C$PJG]#G)?*V#[B?
M\,:/99X7B_ANKTD<GY3Z'.2^5L'W$_X8=EGA/ANKTD<GY3Z'.2^5L'W$_P"&
M'99X3X;J])')^4^ASDOE;!]Q/^&'99X3X;J])')^4^ASDOE;!]Q/^&'99X3X
M;J])')^5&W+O"UKB>MBK%C,1Y1,H^:-K8X'0='@(Q=5U>_77K.&Y:U-]U&T=
MF3DXIF:M;6QWEQ^(?FOVC^*JO]C0["WY,/>[.]6M_HP[0Y'8
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MTUH#T+XT
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M^LK>SM!.A;$,0    0]YJ/F WM]K5_CD 6'4\,?,]Q]_JUAOB$(27<
M                                    K%YQO_+=I?U^[_V(32S6B'C_
M 'D\FWQS\R:>(?FOVC^*JO\ 8T-FWY,/0;.]6M_HP[0Y'8
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MV_Q/]-: ]"^-
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M":6:T0\?[R>3;XY^9-/$/S7[1_%57^QH;-OR8>@V=ZM;_1AVAR.P
M                               !R?)NRH^1=@;@V5).E9<S4?7ALN;U
MMBG14?$]S4TU1KVM54]P"O/'_"/,^<Y V3F^8GXR';G&51E3 5\>])7W)8&H
MV&9R:KHNK8WO>[I_J;41B:JX,L77<0; Y1R/*F=YHY<K5<5E)\>F#P6$I/1Z
M1U$E:]9']+Y-->CU4=(YRJ]VJ-T:@180(    #1[T_0[</XLN_%W@0]Y,OF
MP'VSD?CDH64^A                            %8ML_[V^X/ZQ+\4A-*G
M\:7C['\UKXOFA9TW7L            5?\GW^>?\ BS_##SVQ_P _O?.^R_\
M9/\ MO\ $_TUH#T+XT
M                        ')<FX._N?8.Y=N8IK79+*XRU3J)([H8LLT3F
M-ZG+W)JH%>+'EUWOB+&?_-R6I-B\AMVM2I8ZVK'QP7?;J]RY58DC7M;'(L<K
MXWJQ6L<_N[",F-A?+GOF2&Q2S3*]6HN,SM>AX=E)O9K-V^V]1Z>EK.QCVHJJ
MC6]W<FH,7QF?+5O2]'MRW/)#DK]BK-'N>)+3:CJ^2OW'79[L,CH9^K3K2/\
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M -^ W#_;6_T'_OP&X?[:W^@_]^ W#_;6_P!!_P"_ ;A_MK?Z#_WX#<8N2O\
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MT-?)%&BR2O[%ZHG:IT]VG:!9 (
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M>R<Z5<;EZ5RTJ*Y(:]F*63I3O7I8Y5T0#9@
M
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M$4#G>,M@8WB[8^+V)B+4]S'8KVCP;-OH\9WM5F6R[J\-K6]CI51-$[@.M
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M]G5H%WEOPQ
M
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M=RSY+!-W#BLO5IQ4GQO25T<E=S(>EJL162]+E;U+THOV6B$6""
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MKIHBZJFO<!Z8O,XC.5W6\+D*V2J->L;IZ<T=B-'M[VJZ-7)JGI0#-
M
M                                                  "NG-^)SVUN
M9..^;,?A,CN' X*"[BL]2PT*VKD,=F&9D4J0M5%<W6P]5]"=*:JFJ!8;+RQ[
M7W#CZ6^=\;EQ4V#M[[W%<S53%7&+%;AIRO<^/QF+ZS55TC]&N]';Z02GD(
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MLDCVQ,?VN:SQY&J]/Z%-??!%F@@
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MO-FFS-DUF8W;&X=I-N7,7#(]T3;->>1K)%:Y5T?I"O\ 3JOI";RT@0
M
M
M
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M:]-CFN<[UD:JR/5O]"FFKN_7L":P@
M
M                                                #B-\\O\ &_&U
MNI1WOGHL/:O1NFJQRQ3R*^-CNE518HWHFB^Z!Z;+Y:XVY#FDJ[,W+2RUR%GB
MR5(GJRRD>NBO\&5&/Z47O7IT3L]U .S
M
M
M
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MQM>YJ]2IKKZ2X+MAB
M                                             #PNV/8Z=BWT]?@1
M/EZ-=->AJNTUT7370"KFV/-KR#N[#2[DP/"N1R>W:[Y(K%['Y3VI6OB:CGM;
M&E%KG*B.3L0+@G3BOE';/+VTH-V[8<]L#GNKW:<Z(D]6U&B*Z*1&JJ:Z.:YJ
MHNBM5%^H$=E'/!,Y[(I62.B7IE:QR.5KO<=IW*!Z ?CG-8USWN1K&HJN<JZ(
MB)WJJ@?D<D<K&RQ/1\;TU8]JHYJHOI14[P/H
M
M
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MX,:YFY[<$74GA2V'+HWJ:[15ZW=R.7J5 8K6A
M
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MF.7KZO6<Y%:Y='*C4T$K8!B
M
M
M           P<CA</EU@7+8^M?6LY9*RVH8Y_#>J:*YG6U>E?JH!G
M
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MD#5:J1>([1$;JUO<WMZ4UUT0+BD4(
M
M
M
M
F                                               '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm2227887d4-lc_reprogra4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_reprogra4c.jpg
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M%!04%!04%!3_P  1" 1I!A$# 1$  A$! Q$!_\0 W@ !  (# 0$! 0
M      4&! <( P(!"0$!  ,! 0$! 0            $" P0%!@<($  ! P,"
M P4#!0<-"PD$ 14! @,$ !$%$@8A$P<Q02(4"%$R%6$C%E88<4+2U)475X&1
MT5*3L].4M%5UI3>A8K(S)#75-G:6.+'!DE1T);58"7)#-$?A@F/$A<4FIO#Q
M4W.#HH;"1&2DY6<9$0$  @(! @0% P0 ! 4$ @,  0(1 R$Q$D%2!!11H=$3
M!6&1(G&!,@;PL<%"X7(C,Q7Q8E,T=)*"LA;_V@ , P$  A$#$0 _ ._J!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*"C=6>I^(Z0[/=WEFX<F=!:D,Q2Q#Y?-*GR0#\XI L+<>-!H/[?W3;ZL
MYS]:)_#T6P?;^Z;?5G.?K1/X>AAUK14H% H% H% H% H%!H/JSZKMF](=X.[
M-S>%R<Z<U'9E&1#$?E%+X) ^<=0;BW'A1.&S>F/43#=5-EX_>V":=8@3R\CR
MTG2'VEQW5-*2L(*A>Z=0L>PBB&FM]>M'I]L3=^8V?+PN5GR\-(5$D2H@C<E3
MK8&L)UNI5X572;CM%$X;0W'U?PFVND#/627!E/8)^!C<FF UR_-AK++80VDZ
MEA&I)?3J\7<;4&7TFZGXCJ]L]K>6$AR8,%V0]%#$SE\T*8(!/S:EBQOPXT0O
M- H% H% H% H% H% H%!IG&^H_:V3ZSKZ)-8K((SZ)$F*<@H,^3U1(KDI1X.
M%=BEL@>#MHG#<U$% H% H% H% H% H% H% H*=$ZI;&R&^E].,9EFY^[&([T
MN;$B_.HC-L*2A27G$^!*]2P.7<J'>!07&@4"@YXZI^L/IITXRTG;D%F3N;/P
ME*:F-0"AN*P\GM;7(6;%0/!0;2O2;@V(M1.$#L;US]-MR9-K%[GQLO:Q?(0W
M/?6B7"2HFP#KB A: ?VW+TCO('&AAOSJ#OO&=/-D93?>09=G8O%M-ON-1"A3
MCB'7$-)T%:DI/%8/;V40YS^W]TV^K.<_6B?P]%L+_P!,?5ITIZFYAC;L9R7@
ML_+6&H43+-MMHDNJ[$-.M..(*CV)2LI*CP2#1&&V]W[NV]L3;L[=.Z)J(&%Q
MZ.9(?7<DDFR4(2.*EJ)"4I'$FB'-2?7UTP.2#"MOYQ.,)MYS1%+@-[7+0?[+
M<??O\E%L.F=K;HP6],!!W1MJ8B?A,DWS8DINX"@"4J!!L4J2H%*DD7!!!HJ;
MJW!&VGMC-[IFM+?AX.!*R<AEFW-6U#94\I*-1 U$(L+F@YA^W]TV^K.<_6B?
MP]%L'V_NFWU9SGZT3^'H8=)[#WA!W_L_$;RQK#L:#F8XE,1Y&GFH22196@J%
M^'<:*K%0*!0*!0:9QOJ/VMD^LZ^B36*R",^B1)BG(*#/D]42*Y*4>#A78I;(
M'@[:)P;O]1^UMF]5\3TDG8K(/YK+R,?%8G,!GRJ%91U+395J<"[)*KJLG[E#
M#<U$-2];>O\ MOH9\"^D.,G9'X]YORWD.2='DN1KU\UQ';STVM[#1,0V?BL@
MUEL7"RK*5(9G1VI3:%VU)2\@+ -KBX!HAET"@4"@4"@4"@4"@4"@4"@TSDO4
M?M;&=9T=$G<5D%Y]<B-%&02&?)ZI<5N4D\7 NP2X ?!VT3AN:B%2ZF[_ ,;T
MNV/E-]Y>*_,QV*\OSHT31SE>:DM1DZ>8I*>"G03<]E!A])NI^(ZO;/:WEA(<
MF#!=D/10Q,Y?-"F" 3\VI8L;\.-!>:!04Y[JEL9O?4+IJUEFY6\Y@>6K&QOG
ME1T,,J>49"D^%LZ4\$J.LW'AMQH+C0*!0*!0:9QOJ/VMD^LZ^B36*R",^B1)
MBG(*#/D]42*Y*4>#A78I;('@[:)PW-1!0*!0*!0*#576OKOMWH=%P\K<&-FY
M%&:<?:83 Y1*#&2A2BKFK1V\P6M1,0V)@,PQN' XO/QFUM1LK$CSF6G+:THD
MM)=2E5B1<!7&QHA(T'XI24)4M:@E"02I1-@ .TDT%0VAU0V1O[,Y[";0RB,L
M_MORPRDF-XXH7,+P0AMWW7".0K4473V<;WL%PH% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H*#UHW[^;7IMG=U,K2G)LL^7Q04 J
M\Z2>6R=*N"@@GF*3^U2:Z/3ZON;(KX.?U&W[>N;.9/3UZE>H&X>I4#;'43,C
M(XG--.1815%B1>5--ELJU1V6R=>DM &XNH5ZOJ_1TKKFU(YAY7I/67MLBMYX
MEVS7A/=*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0865P^(SL0P,W C9*"5!9BS&6Y#14GL.AP*%QW<*#B7UW[6VQMW
M$[)7M_"P,2N1(R ?5 BLQ2X$(CZ0HM)3>US:]%H=%](NG?3^;TGV)-F[4P\F
M9)V[B'I$A['Q7'7'7(+*E+6I39*E*)N2>VB&OO3CZC-[]7]^[BVMN6!BHN/Q
M$-V3&<QS,AIY2VY*&0%EZ0\DC2H]B1QH3!ZCO49O?I!OW;NUMM0,5*Q^7AM2
M9+F19D.O)6Y)6R0@LR&4@:4CM2>-"(9OJ=]0>[>B67VI$V["QLJ%FD27,@O(
MLR'G$)CN,I^:Y+[('!Q7O ]U"(:[WMZI/4!BL>QU"Q/3^-B^EDEQ QTO*M.O
M2)#+_P#BG'5-R&R@. 700V$\1XEW%R<)*1ZINK_43##(]$.GJY,;&QT.;CR,
M]!DMM2]&MR/&2AUG7I%C?BM0/^+3P)&&P_3)ZB976^%EL?G\<QCMT84-.O&$
M5B+(COE20M"'%+4@I4FRDE:NT$'C8$3"H=7/5GGL7OI[I?T;VZC<NZ8SQAR9
M;R'9+9EH!YK+$>.I"E%JQ"UJ6$I*5<"!>B8A7L+ZN^INQ-U0]N]?]G(P\";I
M4)\2._&?::6;<[0XXZA]M)X*Y9!''WE#21AN+U)]9LYTCZ=8C>FRVL=DGLGE
M(T)"IR79$9461$DR XWY=YDDDM(TJU$6)X41$-0;9]3G7OJ#FMMN[*V,PO:4
MI['XS+Y9V#-<B>??2VF8OG-NZ6F6G%*T E1"0"HDFU$X=F45?SJ]4N!3NGU4
MXC;"U:$9HX/&J7V:1,=2R3^IJHM'1L;T1[Z;P6QM_P"VL\HLC:3R\XXTLV6A
MA3*DR$CY&U1KGY5T)<D9?'3=P[5SW5+)@F7D]RHBI<XD*>E,RILK]8EG]>B7
M?VXMUO;(]'>"W1'QF/S#T';6V-.-S+!EP'>=Y%D\UH+05:0O4GQ<% &BOBE_
M3SU,C;AZ*O;^W!CL3MG'P'I[LYG"QE0X#4>'XUN<K6X=6D$JL>-"6G$>J?KO
MU/R^23T.V(S)V]C5>-^8TN1)TD'1S5A]EE"EV*@TG4KV%5KT3ALCT\^IJ3U5
MS60V+O7$-X'?N.0XYR6 XVP^(ZPAYOE/E3C3K9/%"E*N+GAI-$3#6>9]8_4C
M&=1MZ;"A;9Q^7E8^?D,-M*-!CRU2WIL;(".R9 $A?,')2XI26FTE2]-M(O1.
M&UNGG6O?6,Z7;GZA=>\.WMT8&48T2&S%?AS)1T((2&9#B@2M;J6VU)(2;$G@
M+T1AJ&)ZIO4COXS,]TRZ>1W]J07%)/\ DDO(+.D!1;6\AUD.+ [4LH"A?Y11
M.&X_3QZF,=UH,K;V9@IPF^L>WSG82%%4>4RDA*W&-?B24*("VU7(!!"E>+21
M,*CU5]4N[6>H3O2CHAMUK<>YXCBH\Z8^EQ]OS#0)>:::;6U8-6LXZXO2"%"U
MAJ(P^.GGJBWUCNHD3I?U[VRSMW,Y,LM8W(14K:1S9"M+/-2MUY*D.*\ =:79
M*A8CWBDG"5]3?J+WAT3W+MS%;>@8R7C\K&7)G+R#,AUY/+>"#RRS(9 \/[8'
MC1$0HN]?4[ZB8.*1U$PO3V/B>ERU-KAR\JR[(?=8>4$MN/EN0V4)<N-!#83X
MAXE7!HG#:\#KQN+>OIZR75O8.+BHW3AT.*R&'GI=DQ@N"4KE!!:<861R5<U'
M'^]-S1&$GZ:>MDWK9LN;ELVS$B;EQ<Q47(18"7&V.4M(<8<2EUQU0"AJ3Q7[
MR30F%*Q/J,WSO#U'2>DNSL?BG=F8V4XSDLH^S)=F)8@( EK2M$E#8N\"RT>6
M1<I)O0PB<!U@G3?5N]TV5M3;3,5,W(,_2%G'J3G"&,:\^%&5SB-2BC0L\OB@
MD43CAZ];?57NCI'U>&STXG'S]ILQ&)4B[;_Q%:WFEJT(=#X;3=82+EE5AW&A
M$+%T/ZN=;-U9O//]6]L1]J;-QN-.51.?A2X"T!2[H2%R'%)4@-H=4LVU)TCV
MT1+7$_U<]6NH6Y)N'Z#;)1D<7!NI4N6P]+DK:U$)=6&W&FV NWA0LJ)]M^ )
MPMO1GU8Y3<>]!TQZN8%&V=Y.N^5AO-(=CLJE$73'>8D*4MM:^'+5K(62!87%
MR)A]^HCU-[KZ+]3\%M;'X['2]L3,?$R64=D,ONS@AV9(9>#"D266P>6R-&M!
M\7:;4(A2][>IWU);:BQM\/\ 3R)@^GLQU A#(LO//*;=N4!]Q#[:FU+ \)+*
M!\A[R<-O9[U"27_37)ZY;1@,-Y1M$9/PS(A;[#4A61:@OH7RELJ6!K4I"@I-
M_"2.U-$8:IPOJDZ^=0=GM3>G&P8V2R^.0\K=&50R\8#;B7%J;9B,KDA2EA@-
MJ6.8M14K@@<*)P^-E^M#?>],(-N8#8Z,SU:?=TPF8?,3BU1@DJ4^XE3A<04$
M *27 DWOK3[M#"7Z6>J7J.OJM'Z2]9=NQ<7E9CPAMO1$.1WH\IUL.,AQ"G7D
M.(<!2$J01[P/$4,+OZA/4LKI/D\?LG9^)1N#J%E$H6U$<YBV(Z7UZ&0MMDA;
MKCJA9#2%)-N-^*02(AK=KU1];^F>9Q+?7G9#,';.75\W-A-+9DH2-(4I/S[S
M:R@'46E:%\>WLHG#:OJ1ZY9WI/L7;^\-CM8[)IS<QME#F0;>>85%>C./H<;Y
M+S)N=*;$GL[J(B&J)GJ<]0FZ-GL[RZ>=/F?HS AH<SF<D,.O(=EL-#SBHK0D
M)5R&W L"W-4$INI0-P"<+_TF]2&X^K'2W>&:P^!9/4K:L;6WBF$//Q);S[;B
MHQ;;"P[9:FEI4WS">'O<>!&''/2S>W5G;W5_/;EV3MAO+[^F?$?BF$7$DOH9
M\Q)2Y(LRR\AQ/+< 3XEFW8;FBSMKU$=8.I?2W#;6F['P$;+SLN7QE&9,27+#
M):;:4G2(SS13<K4/&3V45AN7:F2G9K:V#S&393'R60Q\27,80E2$MOOLH<<2
M$K*E !2B+*)([Z(4?U#[SF[!Z-;KW)C'2QE6XJ(D!Y!TN-OSWD14N(/[9OF\
MP?\ LT3#GCT.=)]J9;;.6ZC[AQL?*YA607C<8)C:7T1FH[3;BW$)6" XXIW2
M56N G@1J5<F6X^MOIAV;U@1CY,4L;8SL1_5)RT.&A;DB*I*M33B$J:"E:M)0
MM1.GCP-Z(B4?UMVK]!_2?G=HC(OY5O#8V+#:G2PD/+;;FLA 4$ "R4V0GY +
MW-".JG>BO9FS\]T>?G9W;^-R<T9F6V),V&Q)=T):8(3K<0HV%SPO1,M>^MCI
M+M;8_P!'.H&RH#6!?FREPLA'QZ1&9+Z$<]AYM#>D(6-"]10!?@>WM$-B=:(&
M\.M_I0VMN'#LKF9YM./SF7AL \R4&(ST>3RT)[?G'.<$>Q/"YM0CJU&_UNZ+
MGTPIZ:-891WQY%,(PS"2D#(A:2J;Y@<.*AS.W63X2+4,<NFO21LG<>Q>C<&!
MNAE<3(9"7(R;4%W_ !D>/("$MH6/O2H(YFGM&KC8W%$2W?*BQIL9Z%-91)AR
M4*9D1WDAQIQIP%*D+2H$*2H&Q![:(<T^KK9&R\)T,SF1PVW,7CL@W(@!N7#A
M1X[R0N6VE0"VT)4+@V/&B887HXV5LW.]%8L_-[=QF2G'(S4&5,A1Y#I2E:;#
M6XA1L.[C0EU!!@P<9$:@8V,U#@QTZ&(L=M+33:?8E"  !]P40J/5?J=@>D>S
M)F\L^E;S+*D1X<)H@.R93M]#2"> N I2B>Q*2>/90<J->IOU19O!R>HFW]@0
M/S?Q0XX7E19+R>0R5!Q97YEM;@18ZW&VPD:>-K&BV(;]Z/\ J'VQU-Z=Y3?&
M10,&]MI"U;FB+7S41TMMET/-J !4VXE*M/AU:@4\;7)&&D(WJBZ_]3LKD9/1
M384>5M?%KLMR8TN0^L7ND.."0PV%J2-7):U*%_>5VT3AMST\>HMGK(G([>S^
M-&#W]A4ER?CT:PRZRE8;4XVERZT%"R$.-K)*;CB;D)(F'/>T_P#C^D?TGEO_
M  >31/@==/\ C6V3_2>U_P"6-T(Z.^Z*N7_6#U6F=,?H9Y3;.W]Q_%/B>OZ1
MP%3^1Y;R=N1I=:T:^;X^V^E/LHF$WUZZX;IZ2=+]H;LVQC\8[.S+D6/(BS&7
ME16FW8:GR&D,OM%-BD!-U'A0B&L\YZH^ON4VFC?^Q=A1V]B0&&U9/.SF774/
MOMV1(6RVF0VI,=+I4FXUD!/B6+* )PS,1ZM>J'4O QL;TEV!\1WXPT7=Q/.W
M<QD5.HI;+5W6B2Z 2 XX--K#F<30PM'IR]36XNIFZ\ETZZ@X>/B]UP6GG67H
MB7&$+5$6&WF'675N*2ZDF]PJW BPMQ(F%<W-ZN=[[8ZR;CZ>)VU$S<""^YC\
M#!Q[4A.3ES5A 80MPO.(L5*.K2Q>PX"B<(65ZM>M73?>L+&=:=F0\;A)Z4OJ
MC0FW&Y;<52BCF,.&2\VX4D'4A7$VM=%Z&'WO'U3>H/$P8_4.!L"+B^ELQQ Q
MK^4:==??8>N6ENK;D-E',3XD*#>CLL5BUQAO!WKBYE_3O,ZU;8A,M9!J [)1
MC9NIYEN7'>+#K:^6II2DA25:2"DD6/"B,/STR=7=R=:-A9'=.Z8L&)D(F7>Q
MC;>,;>:9++4:,\%*#SSRM6IY5SJM:W"A*E83U&;WR7J?=Z*OP,4G:J)DZ,)B
M&9 R&B) =E(.LR"W<K; /S79\O&ACA&];/55NKI+UA9V:C%0)VT6V8<F:KDO
MJR:T/@EQ+2Q(0T%&UD:FS;OO1,0J>]?4_P"I78SL+<^YNGL+![+R#H;A1IC3
MZG5)4DK#;KZ7P4/%()&IE'8?!P-##IS$]7MJS^DS'6&:M<#;2X!R$E"[+=:4
M@EM;([ M?-!:1:VI5O;1#F%CU6>H+J-,GS>D/3YF1MO'KTK4Y&D9![@+A+CJ
M'66]:AXN6VG4/:>VB<-H^GWU1,]5LL_L?>&+1M_?\8.J1';UICRO+_XU"$/$
MN-NMV)4THJ\()OP(!$PYRZQ;H1LOUISMT+A/Y+X9+Q3S>/B#4_(=.'BI;:0.
M/%:E!/8?N'LHF.B_;L]4?J/Z<Y*#F-_=/H.+VKDED18;B'DNJ0/'H\RE]P)>
M">Y;7M\'L&&].K_4V-'].\WJCA,9!S$27#Q4^)C,Y',J&MN?+BI"7V4K1=2
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M/_M46ROO0OTMX#H_EW]VY++.[EWF^A;2)[K7(9CI>-W"V@K<47%^ZIQ2[VN
M!<W(F7[B?31\+Z_N=<_I1S=<F7*^ ^0TV\Y#<B:?,^9/N\S7?D\;6X=M#*<]
M0/0G\^N'P^)^/_ /A,ER5SO)^>YG,;T:=//8TV[;W-")2V8Z*[:W1TBQ'2/=
M+BYT#$8Z#!8R;*1'?1)QT=+")3227 A1L3I)4+**3<4,N>OL2;[:AKVG'ZL2
MD;!6LNJQ7)DADJ4O4;Q!+Y)/?JOQ/=1.70& Z';:VETAS/27;+RXD?-8^="F
M9A] ??<DY&.J.N2XA);"BD$60"D:4A-^^B,H[T_="?S%8?,8GX_\?^+26Y7.
M\GY'E\MO1IT\]_5?MO<4)E![7]-'T;ZZS^M7TH\UYZ3/E? _(<O1\00M&GS'
MF57T:^WE<?DH9.N7IH_//O#";L^E'P3X-&;B^3\AYSF\N0M_5K\RSIOKTVTF
MA$I7U"= ?S\0\#$^D/P#X([)=U^2\]S?,I;3:WF&-.GE_+>]")9V_.@.UNHW
M3;![ W%(<\UMZ+'CXO.QT);?:>CL)8*PA16-#@0-;95[.-P%4,M*?8[ZHN8L
M;->ZQS5;#2.6G&<J46N4%<&_+&7RPBP!TZM(/=WT3ET/TOZ0[4Z5;)^A&$0N
M3#D%QS*2I-B],??0$.+7I  !2 A*1V) [3<DAS[MCT59W9F^HV<VUU!>A[:C
MSH\U<-+#J)+S420E]$=[E/H0L>&VL]_'1W43ELJ7Z</->H1/7CZ3:-+K+OT?
M\C?_ !..3 MYGS([=/,_Q/R?+1&6Z<KF<1@HGG\WD(V,@A009,UYN.UK5V)U
MN%(N;<!>B'\V.N6*VWU8]3GP3IQ)1/;W!(@Q)TZ(I+L8R]"427FE(.E2&VTA
M:U#M4E9HO'1_2G%8R'A<7"P^.;#./QT=J)$9'8AEA ;0G]1*0**,N@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&+DL; S$"3B\I'1+QTQM
M3,J*\-3;K2Q92%)/ @C@14Q,Q.81,1,8E&;:V7M+9K<AK:F%AX9N6I*I28+*
M& XIL$)*M(%[7-JO?9:_^4Y4IKK3_&,)VLVBKXGIQL+ YE6X<+MS'X_.++A7
MD(T=#3Y+U^9=20#XK\:UMNO:,3,X95TTK.8B,K1634H% H% H% H% H% H%
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M:>QW>7YQ]3WVGS?*?H?:LZ!_6W^KLG^*T]CN\OSCZGOM/F^4_0^U9T#^MO\
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MR4S21#*@K0(Z%JU)5KO[M^T=XJDWS.(\%ZUS"+,W;D)N)C=PRV'H^24<>P]
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MSI5&<0!YH7L  $@<"3QT]M;1;M4E[_!3CE//X]A3\E92VN(R E+K2@3S'%!
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M%E!6D&_#@17-L]-]RW$KUVJ[T\;P&VXDK"";(QQCJ7-C1)*DK1I6>  4G4H
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M8Z(^M#3B07+W*OOE<?  25K](LCX6YU*Z?9%AM_=6V,^LYS<+;CCARCLM;Z
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MZ? MQ*K^(:;MGVU:M;>*DR@\A/D.,EE81(QK3P7#6XDOZ4)-SJ2H7%NSP_\
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M(82E"U+/,([5$&PXFAU5+T:=+)VT\5N3?6:PKV"F[EE<O$8J6E:7XV*94IQ
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MI3MKE-TFXL+V/"L^8E6$%G,.S'ELPV\=*B0GB I3:RZVAAL$:RH!5^R]ZO\
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MF"MMV^G@NR=-AQJDZ*WG,K?<M'1)P,++Q^WU8O',(?PRHUUHNII[7=9"6]/
M7/=:PJD]E;8QRB\S:.4:-S.L2EX<,C'SF&&V X#SUE]RP0%I.E1(-_:?#73?
M7$XG*D5F(G#RW7 S^B*WDIJ77E/1GF/+-I4\E39LMP(4GBFRB/NUA-HBV(:Q
M7-<RRDQ6T.OPH*OBDH(?BK<EJ4VXTMRX N"3HU>P7%^%6FV9Q*O;&$;MG(*F
MPQ)EXQ+[V,\SC$/LN+6+Q7W&&@%*'[1*5ZEB_&]1%YCHBU86).*9CO0,HUD
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M:YQ;<B25K0K4Z\@'0D'LOI([N)JD5A#$Q&!SN5QVF>7T8]!_[N<%FGFAXO$
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MQIUD: ;VTZ5 JN/>_P"2_/;&6>R\3$QXMZ55S% H% H% H% H% H% H% H%
MH% H% H% H% H.>>K.^.O>V'MW;LQ#.%P'3_ &@TP]!3ET^9?S>L#F:5LN_-
M>+P(0=*B2/;P);HV_N9O+;*Q>\9S"L>U.Q<?+R8SGO1TO1TR%H5\J+D'[E$.
M>^@_6OJ-U3S&)=R6Z-GMQ)/F'Y^TV$R$YY$=LN(1INLME7A0X;7L@\0#1,PW
MKDNJG3##3W\7F-ZX''Y.*KER84O*0V'VECCI6VXZE23\A%$)/;V\-I;N0^YM
M3/X[.MQ2E,I>+F,34M*<N4A986O256-K]MJ":H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H*]OB5Y/:V0DE*E<M+9TH.E
M1NZ@<#^K6FNO=:(3#1<(I>S*]LY9+LA3SHD-N)<4GD^#4!]SVVKNG7$0LLB9
MQ>W ]B7H+8TM:%25:2X"4\"+GB#PX&N>)XD5I./8QTY]AA^.IJ.E EB&%HFE
M+BKJ:"TV#8]T\#QM:MXG^(],^Y$94YE<Z\]!P+#3BE,NMI6YX4VYC91J.I78
M+\?EK&FWMA,4R\\?BXS^!@RL2S)>Y;RI\)N5=MY:AJ"#P-@D@ V/_/4VV=W7
MHF:XZ=4OD<A,R>)3@Y$9",NXEM;P224A''BA9[5I !L>%98K'^*:VM_W*#M;
M%9;'R<RUG,XU,<>5S,7/:*G'4-(UI<0XEUL^Z0BP23;C;@ *:ZWSF>BVSLQQ
MU6^).F0VE1RQSYC##4M<H#YN0"0I?A(';\HO6UJ1><L$'-S^4#.6GSBN*W&4
MY @M1G@RI1#B?=2HV/A_:BYXUIM[*5B?%-:9Y9D929K#>2@8U]A2XB);3LEJ
MSEH^H*#@2HG42-0L.-33;797E-ZI1U"L[C9T%N2XW*BV2^>-E.+2E8TW%_OJ
MBN*J,"4S'P,2.]D/,O2T2VVX<5YTO-F]DI<" 1:VG]0FG=F4LQ)F'=;$>)B>
M2TZVH*>0?FPV$'YS2"$E1) \0/"@P,?BSB=WMDP75NRTKBRI5T@-H)L'$I2
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MS7O$QF$K",^5D&HF3Q,D,%N2&W62$-DV2 V2H\" ;@WXUK]RU)4IRRVFWH^
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M*EMY"1Y:&FX4W9*02JQXI5;NM;Y:Z]4S$+QC"L0X4R)'893(8D*3(+*G2YK
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M71JUQ/5E-YB41NS;VX]QQX62P^3:"9,=UIUI\!M.AY04M: @#Q@)(NH&O/\
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M7@UQG59=,!3<E)4I3#+>J]DI0+)2 0;?_4UA6]>[$M+T_CE[0$J8+<7$0S(
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M62EW0.]1'98TS6/\I9]LVE7\5Y/<2#N!B&K)1$@LB<704NDJ*EE!797 $^Z
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M<<L!#)2"H"WO<#;C79::_;_5R;/\I;XKE9E H% H% H% H% H% H% H% H%
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M)[[5Q^H]1>)PZ]'IXM&65F,AEF\=(Q6W'/B,Z8I;2'Y#1Y;+BR4CE>(G4GM
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M$% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH*WO]F5(VAE&(807W$(39Q10G074:_$.(\-[5>DXG*8C,N?]QLXJ9A8CV9BN
M'(;<7'R#*4+.O4XLH+;;BKJ *;7JN_5GET1?MX9<)^)NLNN-0UQX&2),EXI2
M>86E6.HI4% E22;A7?6VO,5RI9ZR8D_&1%1'V&V,:N\&(ZX.:\[J(6@W38A/
MA)/&N[7BU>>K&6/BFXTA;DK*/):R\5LL-QT*!8<2E) 4Z0!VWTFW8+4B+1!
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M(>"4D$J!"KDV5W5G:DS5:58S./Q&+B^3QJF'7&WD.R,2% MAD\$\K4$A('
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MQS&Y<[$7HF1<.^X6WG(Y2I*RM*U-JTMG4I((]M$PU-TRP?32/O\ P,C$]?\
M+[GR:)05'P,F6\XU,7I/S:TJ400>WC1+L"BK36>],?3?<.Z,KO&9(S+&>S+A
M=G/P\F]&"NP!("+62D !*>X"B<KA Z6[7Q^;QN?29<B;C,"WM5E$J0M]ES'-
M$D<Y"KAQQ5_$XKB:(0&Q_3UTVZ?;D3NC 1IBIT9#S.)8F2W94;'-2B2\F(VL
M_-A=U7))/$\>)HG+:E$-!="O[7>NW].0/WAZB9;]H@H% H% H% H% H% H%
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M75()//OH<1)6D!&CQ%:2GC;3?OJ^J\9E5[R93,!46;%?=F8Z<V\I$1E:5);
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MEY<90+BDO+*@I*](;96G3]\#JXG3?VUO,XA&&R&7([V*U3HYC16D*;>0O42
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MC#MH#626E)+ED'66P+J3?O%1>.4>+YQV78W-ADO.05!X$EEMP!"CXBD+%C<
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M?+"!@'F\*RX_.>6V)+#J;+;4I*D<VR/O56'9[:RB)ZROB$8K 2X_D6LHTAR
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M9/%PWHK>2?2AU:O,$OK3SAJ(L% :==5V:<3-LL9V9KAT!6#(H% H% H% H%
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MH20K58]MQP\/"I_R'BWD\68#+33;B,FTAU*W73X=((-@$\""+V[ZC[>.1(C
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M#D^J77"?C9+4R#(S4!;$J.XEUIQ/(>XI6@D$?<-$RZ%H@H% H% H% H% H%
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M$%HPTF.\5M:G$)6X%*=)(/ 7)"36MXB(X6[L+C%QF,CXYR' BML1C$$1A:/
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M-25V-S[U>;;,RWB^(PF\5BMN85Y>Y4.<G)Y9AL2'992IQ0 +CEC9)O=(U?\
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M"F'77DQTH=!*];9X!201J4![*UBTG"EYN"\UN*/N:7G4+R<0!<$P7$F$$+(
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M>2EJTJ^;>YJM&D]OBH.UZ*E H% H-!="O[7>NW].0/WAZB9;]H@H% H% H%
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M5(:84I-[7 6H$BX[:SMLK7K,0Z]'HM^Z,Z]=KQ'EK,_\F']-]E_6/%_QV/\
MAU7[^OS1^\.C_P"*]9_^'9__ $M]#Z;[+^L>+_CL?\.GW]?FC]X/_BO6?_AV
M?_TM]$TP^Q*8;DQG$/1GD)<9>;4%H6A8NE25"X((-P16L3$QF'G7I:EIK:,3
M'$Q/@]*E4H% H% H% H% H% H% H% H% H*SU!E*A;.RLI%RIIM"@ 0DGYU
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MJMXKK 5_SUKMY@>KJ7WY#9FE+BE++4&,+\X(5;F)*D]BKZ?>]E5F,5)G+'W
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M%+"0I24A"E@*'<5 $*JDSRC#SA9-TOR<;\43\0R+2^4X$E3#?(/+4 $@ 62
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MI/$=Q-AV\ *WM,1&6?;,RJN#P>'W)DL?.0N;!5A7^8XV\LHB27%>,ITKTZK
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MKF]A5]U,0I-LPWU7&S*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#7_ %AZ;O\
M4W:K&+QV3.%W%B,A%SFWLL$<P1LE!*BTM2.\66H?)>]C:U$M=;;Z0]:MP[TP
M&X^MN\,9E</M.4K(X;#X1@MI=FA&AMY]98CD%%]5O'[!8$T,NA:(1>:W'@-N
M(B.9[)1\:B?);@03*<2USI3U^6TC41J6JQLD4$I05["[[V5N3*3<)M_<..RF
M8QU_/08<IE]]G2K0K6A"B1I5X5>P\#QH+#0:"Z%?VN]=OZ<@?O#U$RW[1!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0:OZX_YFVM_M1B?WQ=>=Z[_ !K_ .:K[/\
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M_+6FRLSAIJM'*OYAW<+.2Q&9?S"#BE?-Y5N+$0XCS-O#=3BO#I*Q8I!4>-^
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M^*P/Q^AA7]V^K'IUU,CXS&X'&9J._A\G"SDE4YB(VA4:$[9:4%J6Z2LZQI!
M'RBO.]=_C7_SU?7_ .KV[=N_/_X-O_\ KE8/M\]'OYDW+_%8'X_7HOD,'V^>
MCW\R;E_BL#\?H8;9Z.===I=;HV6E;4A9&&WAEL-2AE&F&E*5)"U)T<A]^X&@
MWO:A,-G404"@4"@4"@4"@4"@4"@4"@4"@@=YQXDO;,^-.1S(KJ4(6@=]W$@>
MWOM5Z3BPT+/A2(L5^:T^XZRM]"Y3*A90880I)38"W$FN_1/(^S"Y,/&S5MN2
M(.4>0\M;RRV&6RH>&R=-@$GA5^Z+3*)8N/5,BOK5B);JHF-=)T)39U\<0I%R
M!<A5_#V5-XX0^,WNAR5.6SFHQ:P49Q;9E-:[I%D!(44)U E:KV21V"HG5$5R
MF)>\EAR%C(V+PI\QD@XR_DH8:*FI:GRDJ'$6"1J)56/#2)>&5@8YW<2672MV
M,MXE^*UJ&F2E" %(X#B$V![K?+5JVQ!A[SUXW"3&7H25S4K;5YG&H3J+R[D)
M<6I79I4@#A41$3*)X(<G-PX+66GQBYC7WFC'Q[]WGHK+-RZH+-RK6 2B]SQ^
M2IV3$0BE<RB<CN/%[JPL3/X35*AJEZ9$!\:>6IQ5U)<[;(2E!)[;5AKG,M;U
MPF7(^<ST@1V.4Q"C--MO-DBS)<2HJ4VL7N=!%ODKNB8K#GB'A@L;&..>AYG%
MJ=\U+0J'(0HK2^M0)"R4D@) &HGL[JI,_P DLIL*A8/)P9_S:FY?)A/I6E*E
MJ.I6I0;N.U([15-DS-HP0QILS<3^>@P\<\4-Q(2"@G@F0IP6)MI )"DU>,>*
MS[@IDP68T3 /MC+-/_Y7%D6)4%@!:4*6.P&]K&HSB)RALC,R\?"P'Q*3S&W8
MJFQ9*%NJ25K+5BAL+N/$.[VUYLVQ9>(4'++Q^4@RVI1D0W\,_P E2V$D:E*4
M+E*4VO[*]"MLQ"LLZ8N/C^6,E&\OCFBV,:^R%**5.BPN!?L)':*K,H5;(IDX
MI]4%]2)D^:A+3[2@3S75%1:45'38:4_>UT5F(A*ZXIK."#&2IYB$ZTE#CL%I
M#>E6M))3JLJW'O!]M<N?Y"O[-<RS(EY:<^](;>=6T["<-V6D@DDH!X]J4A-7
MV5S(\7 QN&'*=<=<RK,*8MU^/Q:5JT)TI3I([+"K]N$,E4R*K)Q<AY),5R3Y
M4STR&END+T)4A+>G4 4"Q)/$&HQE+!RDB0F;&8FK;A3N>Z]%=N75NQ$"YTJT
MD<+ZB"?N5>L151C^5R68DQH&3Q*F,<%F.EO6WS3':(NZ"25#WA\A]E6M/ N^
M,\I$R(A18#D="GU)*U+!2LHL@*\2C>XXV%<MJRM",SF9G8F=AG7%-P&I3CC;
MO-25K2P2-( 3< D\;TI3NB5WM-5&^+OXB$@:9 <R$J;X5<M0*024K^]\(^2]
M5C7-3NR^<ED8F*<5D(H"'W=4> 7=6B5+>XDH ' $Z?$2$UKU5>,3$PLU+G,Y
MV $3TIBO/,EQ?B.@I*D:5  7*Q8>T5'3H/V7A! QT?R2F<662I(8?<UIY"%E
M.G5>]SVW_NU,3-H$]C9RGX;L6'$=Q[T$\M3+A0X5Z4DV2XDJ!^[6%M>)(0B<
M/BDXO(.Y"(3YM8=G%)6@J!5P)U*2$@?)6T6Q">W+XQ$>#"R&03CE)\L\A"6T
MH45<L!-_$%<#IO\ K4B,\HZ([&NX/#*5)7/\U) *;M@J'SI'B(%NRX/W*GMR
M92:V,PQE%)CE]K%-M J0GE *6UQX7)58WK15)IFP<QC5 %+LPI#[;3R$KLI7
M!)!(M8&_9^K7--IK)"MX#$XF;'D1IC*EY5M2VGW[%*0Z[X2ENYO8 =O96U[?
M%.&Z^FS,B-LO&QY2"V\T9*"@G4;"2Z$F_'M%C7%NG-I%KK(*!0*!0:*WY($+
M>,V5*=7IC\ORS;!&L!Y("E$6KLU4[HY3$X5N0F-E=P2(>0*$08;5XUC91UA(
M!4KO)"N(KH[>V.#+/A0<9)QRY8?1Y&(XM*0Z.6$*58 C^][.WC7-;,RGNA\,
MLX][&3Y""\VP\D%,QPE04Y8I\-K6X]M)B<+1.40_N3 ;13CHN2#T=63>6@./
M$D"Q3X@4)2-"E*3[;5CNOVM-5,KCG,=,(@S(Z6DY,W9+G#4&G.T(4;* !";@
M*^[4TCNYA3,H![$8W=&-1M_<$5UB)/NU+A*44O*!7:Z%)XBP]WOJ=VN)A>NR
M:])>D7!X3:(A8Y@K^%Z Q'9<U. +U7"U$GB;J)O45MB,(GE+-Q@LL-%UJ*XE
MU3RUGB7$<2=(41XE6[JF9G'#/$Q*++:9Z,I!Q+_+>*@K4\@-,@I([ CY+FII
MSU3+/VPTR_/G34+=>+9Y"%*2"U9I* 2W;O)[JUV3$0K")&&A9H3,O->+S;\E
M\!"KI4J,%^)OM\)"@0+^RII>?!+Q=2@!+;C1;FPM"'&(^M.EC7="U%1^]X:O
MUZM'52>HEIEUWXN)"I[<*_.4@_/MG[P 'APU%6K]K5[2F(>+,6+&R/P_/PEN
MHEK+Q?"R$*6E0*2E/#B >/BJ<SA5+)FMX61D&S!+L<D(8=U!;CB7$:N\'A>J
M1$Y$#&*&73->4AKR_+DAKEA+H2X0M*>T ]MB+5>8M/BB)B%M&23E#,DB"B0^
MAQ328J7?"OO"E@7%[C[M<]HFJU90F7RF0E.R9L]IQG#H3R%06@;.<ZQXGNT]
MNK[E:53+UQ$V1C\3-&3C>7VTWI1C8"P7I"VM"UO<PDCQ*)&GAW=G&L;]W=G+
M2LQCE[L2<)#>QD+'8]23E;RDQW!=TI#8*K$^XI 4+C_Z*GOGQ1-<]$?DWX</
M(N1,="?D.HBLH4'5:DI"2% K';P)_N5U5KBO,J8ECMF"OF1),(Q76U^8TL>)
M'-*!J*B%7!UG@ >ZJ5US_EE#'Q$N5"F<YII&4=6L.R'&KE6GCJ/ATVN+#W:L
MC#WQ603%FS,DYCE*>D**/+H.LE#S@/C4H7 '>!29RM$_%[##3)6LQEM090=L
M)01I3&;02L)"NT!6K[AK*;81&<LW([X@[?92AQ'-82TZZVZV=" MM(\!OQLI
M7&X/"]K5C>)GEI'7E&8YV;N7&KS&2B/(FSXEDQXS8+@;>=LA2'"H V38^Y5M
M4SXK6F(?N5P"(^-?3,<4^XV0EJ3'4E!#:5(:&NU[E5^_]>M[7B.C*&6J;C&L
M9B,@IMQPND1PERR4J:4A38+@[P.T?+58F96G&$#E,0['W3#SLJ3)D85"W4.8
M\V( <("24CA8W!O;NK/MME:)KAF19#,?,+8Q602 IP1$QWD (;C)(U)O>ZBH
M=@]I-:3$J9A];K:QB%*BJD_"(;*"Q(<D/-LM.VNI)92H@W*U*%K\:O79$=4]
MDST93CHQN @2V6'53\:XVRE";:B />=2G5X3:X-_NU3/?9&)CAX.[C&60S,G
M0#)U H$MIO43&!+A;L3[WA'?4WCL0R%PH\F"]D(VJ)D5K#Z%E12GFDJ)(1J[
MD#MO6>+0A6<DTY-Q\O*-.%;;TI2)#3BQK :2 L(-B#J4I)!L.%=FJ8SRBT9A
M;^F+/G-X81UM>AF A=FBKF$K6R0M1)[#J)22/UJS]1,=LHB)ATE7E+% H%!1
M^K;G)V/-?"%K<9=C.-\E(4X%)>1Q3?@"!?CW5IKB)MR9PYMSF2RV23&7C1(Q
M.)YXF3Y4M+KSSRD)*0@+U 6]X)2/>(^2NN=>.8Y:UG$/=_%8W'NA]W(H;AY%
MA"W(Z6U>95[JPI5PK22L$Z0.)'][6?9:\]T<8X3&V(XQEEXS!08.:E!@SU,S
MFVGTREJ4E:W-%VT-)\+:1[1;MO5YM,<VY1-L^#V7E<UC(RDM.\J2PSK2T_=Y
M#9N"=(;38!-^]*3VUO7$\LXCE"8EO;>Y<I-8(?\ B#+)6X\M5HB6[CF%I1N=
M6H=B1V7)X\*Y9_\ <C^K;'#*P$AB+#6IUQQS_*DL-QG%CE!))(7RUIN> ]ZU
M=5\YX98?F7D8UDO/Y25YK%D!;+BG.87'%JL&P!?0D$Z0-5ODJ>(YF2T3;A@Y
MQN5D/A(F%F)CVGU1YR;*#FFQ#:6](T (38*/"WWMJRVYSP1_%/Q8F4DX[)PX
MTA$C<4AD",R\EQQM+>DI0V]HX)*57O:]N/;5-M9PT[WD<EE,9@&G&V3'W VI
M$>3%CDHCODD:DI4JP'$A:^T6J([:UZ0G$R_6UOX>8J'E)R2WDW"X,*5 -L)=
M3I"&2RW8)4H)4%&QU$FJZ=4S.9E%KPC'=QP,'&7D,[*5B&<=I94812%(97J4
M$Z=1*UJ4+<#J[ZUVUK6"G,H'#YS:Z=QHW1$R63ST_*J#Z9;J4R7,?%*U*#(0
M7%<E-C8\!JK@KMC/#>VOA:W,HN,_,@(F-OQYIY[3\I;B5O)O]XH6XD '0/97
MI]U8B)F'+%)SQ+Q9S<.0I_9RIB9&7GI+RH:&VPAYP%(LL@*4.RZBNYK.=L-9
MU3$)/)XM>S\8O<;Z6(+L=E4J4ZQK60Z"0E 2$BX!-R+VK&^]6M$0UN%"\ G<
MZ<?)6K(1P^F<M9CH=?4K4D%*5&P![4@FK4M,^*+U>4?,;I=BP<Q*R*DIDMI2
MY")4"HK4I"E-I)2#V"U[5WZJ5K'2&,I%N ^)DZ2_F9D*#BXSP7&BNMNREI4@
MIUD%/ ?K\>WA7'O[KSVQ+II,5YF&L\CM_=HW(QE<1FY"X4SY];<M]Y;B8JC_
M (M;;7A*N']WC7%'I[UGF9=/WJ3'2&WL##;F8QIEW*6SD9XNL--N\SDMK-BE
M;5[I)[.([Z[ONQ$8<4US+]C;/:F9.;DEMR7,E( !7*;28X0E6E*4:-"B4VX6
MX5S=\9;8X4S?FX9NW/,;/VB'G=Q%#3DP,I=*UE9U*%^(!2D\0DW]OLK/;NST
MZM=6N.LKACX$1S;FVLCD\=(5E%PFT36P]R&-2FTB[ZD7((5V^'@?::UB)O7J
MPM,5MT1'PM_<&6AMY"&YCWL<_: T,@]DHCC:@=3EU(:(&D7!X>RU8VFV>%K3
M$,C>6[4[-6[,AB8\N6I+;+,2('E%)X$J4H>(\.U1M;LKIS;LYAE6T9Y9VS=I
MR-JX9#6/D%X9%C4MQ#.IW6O4L+6LD :>8JS8.FLM=OC#3JP,C@<O#A2,OL[+
M-Y_,I>0TP7W4N-Q])&H)"!<VOV*4=-^'95:[8[L1*TT[8?:YLC$87)9')XYR
M3(CM,O2IT5GS#SCJ'$)=*$N*2@J25**3<$ $\:[=MNRN6%*9E'[:WI$SLMW-
M3'F9,=-V8\0-%$MQ" +((?4$EU(!*@E>GV5E3;%Z]6E],^"6R(QLP91N2R^E
M<8(7$:CH06V2J]@DMIL5$^V_"K3?LCJQK7MGE1-O9;*[<5D&]VX*9DV<O-:3
MC\XIHRK*T)!+J%+25#@  .%AV5Y=-EZWX>G?$PV=-S$/"AG)QW>>_=I4AZ2X
M4%IM0-PAHJ3I(MX0;V'"O3OW7C$</-C^-LJGF7,1AHZTL*F2XN60[$BQYSDA
M]3B)""AUPJUK)!U:>P=O"HI7MZKS,L_%XV?,P4S!H?Y4=N,AX)E%8:*E6!*5
M'4I( ]B.SMK28K$Y4F9E#S<6U(<95A\FT)2F6FG%LI+80IHZ2E*EVLI1X7L.
M!XFKWM:T8_Q6I^K9G2#<V6R^^A#>D(>@QX\AI;;&AQ#3[.E.A3B!8JTV)X_)
MW5S[(B*]<HOG+HBN1F4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4''2-]=&=H>H
MKJOF.L$R/\3YF*A;=$W'R<B&HR(0+_+Y+#R47NV.(![;=JJ+/',=1.C.[^N_
M2+)=(),;XRUD)D3-O0<?(QJEQ)# 0A#G.89#@L7 .TBY[+T'9=%2@4"@4&@N
MA7]KO7;^G('[P]1,M^T04"@4"@4"@4"@4"@4"@4"@4"@4''GI0PN'R_4GKI\
M6Q\:?R<XQR?-,MOZ-<O*:M.M)M>PO;V46EU/]"]G?5[&?Q*/^!15K?K+MO;N
M/Q.VG,?B(45QW<N*9=6Q&::4IM3BM2%%*1=)MQ%>=Z[_ !K_ .>K[+_58SNW
M_P#\?;_RALCZ%[.^KV,_B4?\"O1?&GT+V=]7L9_$H_X%!ROZ#TI2GJ6E( 2,
ME#  X  >:HM+L2BI0*!0*!0*!0*!0*!0*!0*!0*" WJ0-LSM3QC@\H<X=J;O
M(']WLK37_E TCD"B24#(9+R1YVEU"/?5&0LE-DI':3:Y]E=L9A&4OE\MA\OB
MD!E:9V*6"TMI *E*Y82+)%PKA;NK*NO$Y0B&/,/!!RX,.')C,&&VE);=0^X@
MJ5[H4I)T@ZBOA?OK;,BGY,M9#+R)$2--\XXV@1H[B1RUJ;>*2IM;@6D+(3[N
M@^'C73$]U<2AY)WAE8+>MF7)GRGLI'AQY 0A')0\I6HO)2.+:4]GW*Y+Z^V>
M&U8C"WJ:?E8Z<ZT\Q+;CG0RTT4IDJ6@@A2ED!0).FXMV5E;.4Y>&X,S(8E-Q
M(ZHXE1H3KV2C,MB3J6I"2T' .*-*U*-K\0;UMV<91-F;A5[IGP\.L/-G&H2R
M[+<Y?*?4G1Q 38I" #;L!JMZUPB)0F=A8[:F8;><AQW&LDMQ49D)0VA,CEV7
M=/9=:56*A:__ "M6NN,K6M,LJ9.D.PQDH#K&+0A3:99^;6'DAL**4(L LZ#;
MY*;(RH1GLK(V_/Q*9"V(<-YE&/\ +--H=,=1!2C2FQ2@DCQ'^[6MHB.41&61
M+GPFX&/QTEWF.WY4N0E*%EF0ZD:2I/=WTK$S;*)XE]XM&1Q90B7/86TUICXM
MQP>)Y2P""+<>Y0JEJ1-LF7[@\:MV+.R&,:0_F4.J=CHEE0Y:M5U(5H([@;=U
M-MLS&>B]4EBLON].7E2<C*@.[4+23+C(OYJ)(0D!25*N0M*C=2>%Q_<KE^WU
MS_9IE [YWMA\1!3FXGC4Z?FGF@DM+"57(456 )L0=79:M:V[8Q9$5REX^YF%
M1\C.R4M'*<;:E18RT /-(<0%MA3:NQ?%-T\;5I6O=/"EHPP59QEYK#9G*QG^
M8ZF2VHH1>ZFAJ;*D</>XVJT1,6PIE@./ K.Y("E(FMDH5&0AQ*Y L GAJ5P3
MWVM>U7FO/)E(1(L_+NM2%S(ZXQ>YDA25:'DK9\:$K [='%"P!\M5M)E@*@Y/
M;>2.24^50DMJ<EM(TZ5JXV2$ 6U'5W\;"M.Z+5SXHRDLK$1\/:R4E]F! ?CD
M25K+B74,O!*@$HU:2Z ;>(<:I69A:#%1\-!QSN3A(>R"HY0PQ'=MI67RBQ2%
M7XZ5$\.Z]9VF9,/?+1)V1>48\M>+GQ+)G2U!39Y%RH(0I)L4@]]JM6<&$+C9
MC>(RK)E-N9'R"4NO2R[JT:S\VM(L =8(5V]]:S,3"83F+RKCRW<3D(RFT-,N
MS#-R#@<2E!<LBY"4BQX<*PB/@F9>^(CRT*.0RA.1A26%MN22A*0A',[$<.*%
M=U1*L1A\3FDO2L;*1APM")+;"&WAJ##31N'0@6">_P 59USE.82,./MUS)9N
M5"?6G)+'_>//60&[)5<MW/AOPN![*B>_)PI<&;&1$A1\MIR_/DNB*TEQ2G.6
MHZ;ZG"+V4D\+5VS_ !KE$+@WC).$9>BX1]U<B7=];\@A:T:1Q  3IN;6-81>
M+=4H=>+R4[$S69SKTR5F6S'6WY<J*4'M4L'0A!-^%U#4!PO:J;)IAI24/MD[
MF*$RI^&C0E&0MJ7"-B6F$"W-62XH^-(XD&Q ]MZG5;^$?!79$=S*=&";R<:$
MWC->.5_E#D]*@V$I:!\/L(/NJKHK/P4PP')B\=(;GR(ZW<7=U,5+SJTJ4Z_8
M%NZ1;3P[T_JUIQA">S4K=.%VTVK;>&1,?2VAM,1EP)DH4ZHK*N8X0-*!8]ES
M7%M_1->K):R.):G)RNM<G-NLEE2$K*62IH)*@!JX$W%)B;1RO+=&S'UR=M0'
MW$!M:PX2@'4!\ZL=M<EHQ*B=JH4"@4"@U'NC$LY;<N12VK0X@<N0Y<I5938*
M4@]P)/=6]=DUAI%<H6'BH&,PX98CM2\DV@ME9 /,4@E7$CM O43MM,_HF:PP
MMOM!WS2LQ"922I"N2A 0CE-G4@ )X&Q'#V5:;J]C&AML2HLD.K=7";<6AJ,E
M(T(3H)N/D!]E3-^(3C")D83"Y1V"[NJ)&RF6Q[BU8)+X#B4 E-^XV]U-D_(*
MKNUS:,M=5\0F=R36G,A$3(06M-B M15=Q9UVN+UOIB(IPPG,RD]N0$S8K4B0
M"SDF72EEWM<1I-BE-^-JRO:4<H??T/<<]EN*F2K&PX[BBZY&=4%]J5H*.78G
MW2"">_L4+BLKTG&8=.K'BK.W943)1)DF0XY&FQ7TM+CO*5S7%A8*7&U$ N)L
M%$**18]H%-<STEILK'@MTF'CIC\>6VB0^I86TLD@K:NU[H'R\/DXUO$.66'Y
MJ5 4Q Q&I?DT^83&7X7'-*0E ("KE(5J3]VIS69Q,HBL]7LI<V5+;@Y8)CS,
MJXV5LH3K38)3J2NYN/%>UZG^,=)&&F>,;DLS(4X#"+BFE04E+JE**+ !-^ [
MR.^KUG*,/K!Y+)-LM2\?$8=1+>+4AZUE!/&P4#Q  ' UGLRO&&?Y1[+2VI62
MR+*=*%AII!UK"K>+0>ZP!!M\E4C8K,(]4-YJ.G)1@M]4M:DN W^;B:@0%W4G
M2H)OI4+]U7MLXX(B,ON-$2_(6UCTF3*C.A<8RU\PN,N'YQ'&W9][J/95]>R<
M<J6KRRG<2WAY#*\ &GFGI)1)/- 6DG^YP[+"JS;,\M<1$,#)8^;B<TSR,BXR
MU(39WS9(8!"KJ23V<?O>';5Z,YC+/Q'*6ZM3\M4F"MI]1,EL\P/-N:5'401I
M -AXJF_^6(.V7E%=9YZLV^%Q,<VEQQ+VM7+"GEM!7A22 ?FDCAW'C6$US.%X
MLQW,CD<<EUR"EO(+05\]Y;?B6EVP0A) LK2/"H=];=F:\RI69GJK&SE[KD9S
M/S)-H,B)+2UCD/)2V%L&QYA XJNG3Q^[6%.ZLX\&TQ7"RNM+P3ZUIY)<7I4_
MY0$.!E*@E) X G4>![J[/!EPD6%0Y<[$/,.N.J:;DLI#IO\ /$)4 X4DVU"]
M<N;1GA,5RAI^=3EL:XY%:++*UK1)AR@0^7F'-*4I[BGP*-OE%5I$S/*\QCHB
M]ZYB1M+8TG)0\.9;GA:AL.V!0ZX5%5U(N?&;<!6.V\QLFL=&E(B8S*=P#<[+
M;<C9++_Y%DID-N!+@J(2A+ZD)0M20/9>PK:LL[UST2&*,$LMX_ $O0,@T^^G
M((5K 'NV2OL!N-7A[Q2)B43"&*LLMUL*A/O/XX%J-,<X!(4L)"U#L/=Q'W:[
M(BL54B)RCGX;;G)R<="HC4]"M13J#[KK9^;1I[A<']0U:)C"LUY8^7?4YE49
M%< &+&<:7(0T%)2A2$76"GL-BK5>II,3$K3&'GO7:>#Z@0<=MQ&32S'1(;D3
M&%)YP>C-D*+>HGPFQ\/RWKS[TF9:UOA*S'X#Z)<AEAYR#**D^ E4I)8=2I%T
MW5Q%[>$UT4B*1QU4MF9RS(41^:_&<VPZPG)-E+<U22"I,<DJ6$I%])U:?UJM
M-HM_DH\L\VN++:Q23YXHYT?2MPNOI,A"2%$$ AM%SP^45:OZCZQK>-3Y;$RX
MJ7B]',F6]=?+"BI*$Z2H\#=!N!5;1CF$QU3G2R1CDY_'1PAA<Q+SOE^2"G0P
MXA2KDGM)(-97S-9E-I="5Q*% H%!3.J4A^)LV7)C7\PVZPIJRM"=?-3IUG]I
M?WAWCA5Z5[IPM7&>7/D+ 97"8S(/[HR[&5SDUQAMIPH+D:.%-NK.G2A2P5!7
M:OP\ !;OTI;96V,<-Y[<<,5O&LY1AQU[*,(Q^.Y*"$!QM2B ;("5=E]9X_L<
M/0[YGB&.,,27C<GE\9!3%S\S%[;8<492D.J:+B6CX6DJ;TCWQQ\))3P-<UZ3
M,X\5XV,F$68)3D1YM:W$H#;*74E"WE$K.H$DA-AQ*NRMK6BD1$J=963%Q\-B
MGX;+S"4^:,A1FMJ9;0QK94ZX0I!UW4H6-A?B:X\YG,-?!^/P=OY3&/+AQ4C.
M-.-^;4T%O.H!"DH)YER04\; \37369EG-9A HGM:51HJ'I);<5'3'?2PELI'
MWZD.C22%<4CNK3[/W.O@KW8>R$Y>0AO-.,K>R;,GR4,NLJ4E+7;=U/8;CL5:
MHW;*Z^(6F)E)09$2 ZIAD+7&E-NNMOL-H:=&C@L W2K4%>% '"_R<:RV;+;(
MZ)I$859[%?%,SCLI,'PF2S*5#;?24.!QLZ@M3K>DHU*)"QJ'W1>QJDTF:X6F
MT0]-S9MIC,1IDYX3$-/);C&&DIE+O8 6T^+2JQ5Q[.RMIO\ ;XMQ+.M)O/"D
MS]_36]ZKQT#;Z=U03&4504-AQQ*R%**GB0I(7<*-E#W2+UYM]_W+8AVQK[(S
M*U;AR>V]OYW:^W8L5W;>4R*3*E/8=IF)&?&DZ67VVF_G[7/?PJE=4YX)OF$W
ME\;M:?$;R4Y^1.$=2W(:'.8M1D^]X$ZPD7M:Q5IN:]":S-?Z.:+=L\HW:S,7
M),'+#!.Q<C+EK=2E[YJ:J.E(!42WQNL@V23>JUK$IOLG"YC-X[*M'$3%.0'Y
M)#*8$E*UA<='<>!L3Q]\_P!RHMISS#"MY942;M6'@UXJ!&9FXS%MN*EQGPA:
MT+^36.-SV*%:ZZ3!:TVZ*''3B77(S<[R^.9D)<=B1G_\I?>0F^OEFRR@#A;W
M;]PKIMMK$=2*S;HD,AA)&)B(=YYPV(?;6J4M2.>LP@A1#(Y9L5*LE/'NO?A7
M%W3W=T-L<8EA;+S3V5F1H,195 GH6ATR0"\@,)4H)24I(;X(%TVX\?;75-^Z
M&'9B7M(@SX3^5<V3C40-PS$LL19;*$1XZV>"WE("DA((('O?+;OKS;5G+LB]
M.(RK&U.IV9B3QM3<;J%9F6\I*<A$*E+Y;2B/&4$Z1IXD"WM(]VL+7KG'BVM7
MAMB(UM?9:&<WB%B0G..E[(9-]2M2W5K)6;'@$ZBKN^[[:WIIF.;.;OMQ$-5[
M3S4K/;[S,1]IU_ R9,R9C0/ W(2IU;B6^:E0\*38H*>!'#B!5-=K5M^CHV4B
M:_JLSFX(SV\$JD+,##XM*VTWYKHYZ"FX;:!TZ0-:>/;[*Z]<VMTAC>(A/AEW
M<F.GJ@9%B5%=<2(SLIH![0DCP@I LFX-JZ:WFL\PY\?!X1MQY.,B#C.8T[BM
M1CR64-/*?<2%<2-"00;>$?<JD4B^647F)>V:V>\9P=VQ-5M/&Y!P/9CRQ4I^
M2ZAO0BR#J0T0 "K2E.H^]7FSHBE\P[.[,<O5S9;;^*1MO)O2E8]IMX-RF77&
MW2ITZ@]S6E!14FP-E I^[W]LS%XQ+"MIB5,,&%D=O91K&X]R9N:*P6<22XL+
M ;"@"W<H"EE7<H\?[E4OZ6:US5O3;_+E9NF4#=&"V@G&;AQZXDZ6259!3J7%
M-DE5BXXM>L@6\*;D\366ND9_E*-V)Z,G=$&0K%.PT.,RU:M4Z6ZX  X?<Y8N
M5!01;NM71,1%^BL6MC,H7';:F^4YD7':\9,UMKDI.I3>@C0Z><H+/&Y('"NB
MV^L<,NJ-\S.9RWT=?Q@R.'C)<+<U#GE5.*:3<H3RU(7X3[VI/Z_&O.M]R;9Q
MPZJ]N$S!R$A+&2@D2IT-(7'>AR%-E$<.:;$E(3<)L0$BY[ZWBL6M%O@SM$0C
MQCH#T8,IC/0HZ=#+K\=+J_,!7AMJ"Q;LOQKLV7F]<,HEM+I!CL?@\LSC<=%=
M@L)0\@0QQ8;TC45$JNK4HD\-1KSIIVPM:TS#>59,B@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@T%$R^,W_ ->=P;1B[!P>0VMMEE"-T[HG0X[LQS)OM!3+:%.)
MNH)"2A5PH^&]P+7)8TS,PNGO7?#;6RW3O!8_9FY%HC[.W5 AQFIC>2;82IQ#
MQ0GPZG"4( "38@W5Q"0Z&H@H% H%!H+H5_:[UV_IR!^\/43+?M$% H% H% H
M% H% H% H% H% H%!R5Z/_[2>O'].1_Y7E:+2ZUHJU?UQ_S-M;_:C$_OBZ\[
MUW^-?_-5]G_JG_O;_P#^/M_Y0VA7HOC"@X\]"/\ \S/Z3B?_ &51:78=%2@4
M"@4"@4"@4"@4"@4"@4"@4%?WPA3FU,FA#9=<Y:2AM/$E06DI_NUKJ_R@:"@M
MROB>05GVE.F#"CZWE-IY:'G.*0A8M<"UU5Z&56#C,-(BY##JR9D)4ZIUU>FZ
MFK.*/A(2FVE2>)L1X:MGB1(9-F;+Q^0W"Z#CBTXAN%%=NTX&D>#YTK('B7;B
M .%9TMF4H?*YE>5E0HBFDOM0G'&UY8K*6H\EWEJ"$E-Q;BD()!N>SL-=&,<H
MM".C27X$<2L@)$J$U-1*8GQVKI>>YE^6!87%@JHM,8*V7.5%FIW*C+X)]B8]
M-C/(E17UAH1V4(\+B4E04KYQ*4\> O7/$Y3E7\--F19,V;*:;3*A-H$B7"LI
M4D<PI"1VBY*3I/=;C5YYC!*T0F)2&\KEVU+8<G/LOJ9.L.("F6P$E2AIU!2E
M>[PKCM$Y6AY9>!.R[N&9=*XRERT.-R0RE];32$E2]6M)2.;P3Q'A[:UKQ&$O
M7/>6R.8@0DPW Q!UON.- +::L"E&M %CJ OI'&QX59#]PB83L!S,Y=)BE+I4
M!(3Y3F:? VLBR>'&XO6>WB2J'R.'V\U.80N0ZPYDE%TD'FI"-8=42H"PX#M]
ME=.NW\43U3F*AXY#SV)<>:E:>7,QK1-W4,@7U \>!4H]WMK.T\JH*+E<CBI\
MW-YUDL$7;=C1DDH4I;VDJX7X&]Q4S3[D=JT)*+/SK$B9.<CQDX:<-40J2$K<
M4H H"^([/OJRM'=QY4Y2^2@[3EQ$[=W3%BB.\ILM1U#0V\ZDA8T6/  V[ZY=
ML][6LH?<4!63SO/C1&ID1+:R^RH$+<=TZ""L&P(^6N_TUNVN&=V9D9"8VWU1
M\TDM29"U,M<EO6EKA\W^PKY:BM\W9JC%EGEJGK8?<S3[/);=2$CYQBR4Z$!-
MN(5J/"NB_*4A&4W%P[C4I#T.+#EZ'UK <>E+<25$A20!Q/L[A679E#*FS8KS
MTD8-M,5MYQMT/2DDK>>2GYP,I(\5DFQ !J:TPCQ?6$BOYI$Z3N#F*PS3Y,5@
MMJ;!1J-RL$<46%NW@:6MVKPPLI.;SSYQS,%V)B8:6)8D-I+24N]@(44V*>/"
MW;6M:QA+/Q,:##CAZ:Z&X<$A+JRHO25R2;D%/WP.HGAV5R[(Y$VMF<]*$;*%
MN-!EHL'F+)*^9?EMI-CQ">/Z]3$<#X?Q\/)X^=!E1%P&4H1#:FJ<#CBFPK5J
M"3P*=1_5O6?=@2<;&LMX5$!+BY\4MHCM@:+)2WW:D 7/AOQ-4G8A'16)3DY^
M=-MBX<-P14NK*AS66^P'62.-^%JT[L1D[47F]ERE9&3-@)4^R^5R$'F $OK[
M$D"QT7L;_(:TKMB4=KZV[!1#R4I4K*M<^& IQAHM%"4=E@ 24@'WC\M6WVS5
M,/9V1FL-*@P<0T]DL8VIHF4E:5ZA(4K45* ).C@HVK/52.WE,L"/NN.U/EM9
M!:59%3+I<;82MM;JTNA*6VR;:K =Q)-1-:RMTACS.9$+CC ?2_)M*BP23I%Q
MXDE!.I5N^M8B)CMA3.63&C8W<L;RTM3*)<8J8RB[EI;%[W"220?$-)[JK/\
MZ8D<A/@-/+PLZ,T]B8T;FPG@K6XLH2"2DIX)LD>VYI55D-N[8^%PD27T-(G*
MU1&I#BDEQRWA;\1OV6N*K-<2F'SC<6_'YGEELI5%4ZHP$6<LXX"0%J3W=_92
M+$RVKT[DOR]G8Y^2XEU]1D!3C8LDZ9#B18<.P"U<F[_*2%HK))0*!0*#4.[9
MN1@;DE-LLH5&F.I27E?>:4CCVCVUOUK#2B"FNX<38.0QQ<=2RM33Z6K@ *[5
MD*%["K4X@NB')2X;,2;C9*GXTAXD,GM2I=[DD]UNP5O75$J9E\XY]V&2AQ#I
M6YS_ #"D'46TA'O$#O/=2VN$Q+TP\6"]CIDA]AUUZ*2XTHC2NR@"5#C<GAWU
MS?<G.%WIM^1'SDB4N;'\S&0426>?8*"[CP\+5-K=G$$1R^X$21&R?-<<MBV%
MI7$"3=_4%6.M()]E4I.5K0G?I/C\MCW9<13B0AU*W A(4OPCL4+$@'LO4Q2V
M584^%BX63R[V\7/^[RXPB)'84M*M0:<4ZLZ3?BHZ$\/8/EJ)UVB<M)MPS\M$
MYB8:6 794]7-2TA6D--I/'4;]OC[:UT[8RI:D]KQP3FW8&5C0A(,7=*_\D:4
M6>8^^RTXM]Q"=8*>7<E15_SU7;%8ME:L_P <,W(1G&,K)?Q*PA;I#CTU9"KJ
M"AX4I/$7OQL.%JVK:N%)8N+Q4,+?GY)9CR''ER8K"!Q(X@DZAQX&]JB+<XA7
MP8LAW-+0]#VFZS(GM<R0UK3H04VLC6HCN/!5O;4;9F%:OB SF(+;2\^I#DI;
M5LBXR$E$=P@BR;(!-T]ZKU;^,0TE[8H3TH91%GI,AV+>.V DK<8%VU%S5PL%
M)_6J\]LQPS9#C6XX/,FPHK;4Q<=*ES$VT*<;\/@2+]J0;#364+,+*,N)A^8B
M % 69KQU N<Q)LI: #W_ /+712:QU5F7ER,A,QTY;TEUZ9I:>C.2$H0T1?PZ
M0NWB -R#[*SO6;?XIUSRP,*-V1MMS(N2D+R;JY:6U$-:+-NI4+$A(%KA/N\!
M6=(FD\]6UTP,D8K#N(RD9_E3"&U*6@\E+I;!TIL =('"XO>IM&)[G/#]P+K6
M/96EUI\E;CHD)2A6A2FTZDK1V:18$7[ZTOA=^RVHV1A2#*9$=0;#PE,D<TIN
MDZ5COM>QX56N4(UAG$RX<=4.87IZ62AB(24K<6AP.6)*>&G]8U:9F$Q$,Q[E
MQ'6<=BW519<@JD2W=02T'@-/+7J%N%OU:5_DM/#PRD=XXLPWDZ,AJ$H>2\6M
MLK/CN;D_+;LI6,2KEZZL>]B%0',@Y-B+N9$PV4$$J-TA!L?"18'3WTG5$VR3
M;A'(,E$Z$X_(&1Q<9QN.C0%A5W%!:4D?<(XBHM6(33,K>J=#.,0SAY#4>.'-
M"$I(0V$(OS6TW%@;$UEKU81E7V&Y+V(*YZ/A^,;6F5%>=<45*?4H)XD7)1=?
M=P_4O6O;R91VX<C@,9+PZI6767Y=VH<5JUUE )595B$CP6NLB]N%4[^<+Q#$
MDN(1(?6R%<R)%;#+ '.+ZG6VP;IN4^[73%8B&<RRV&#DDKC.-(\]'82J*E!"
M%JBK:2M85H\.I -K7OP[*<(3T+<V-@K0\\RZMJ0Z&UKD6*6VUI"DJ2 G6;@
MA-K^T5A;5.>[P3%IZ(#=>1B;.E*R[+2L2D.F.RJ,R\\Y*YH*CH2A*S8#4HV
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MEN.Q"*"$MO+X$()O>ZKD7-J;+\]%:QPA,G >>)C/0G4Y/7\S(9F(:E-NHT\
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MJ=7W,3-N/A.'Z[_K'X+UT^C^Y6NGMO/=7[M.^T^'_P#C7X=?CA:<-TAV+OK
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M9)-8>9D4"?D'DQ6G)"EOI0!=+2#9K41P-@+?<JT;86F&+ V_.A,O1I;""\0
MS'(!9>;965#QBUBOA6GW8EGAC.2%-1I+^=R:I49:D,.,QKW9YK@;0LD#[VY[
M#6-HRF$@QCWI+3"L \L-/Z8THD$..H92M&HE78+_ *M1W86EX18&4QP5S'P[
M@60OG1&G0MQ3A U$J/9:PM5J3F4(N)CL5$$AS'B3S)!_QH58!PD )2I0\)'
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M](H% H,1W)XUB6W >F,-SG;<J*MU"7E7[-*";G]:KQ2TQG'",PRZHDH% H%
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MB9;>6@9";CV(VEY]+3KXC-ZB^AM%EA2S:P*C>M9F)A5.L94MY2+CY#;<9]Q
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MK25'4 !I22#<A)'95M5ZUCE6=7\LH*3-W_F\ZG'F*C$[>Q+KLA;; "YKW)(
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MDA@Y:,VS,S#96ZELA,M*6V@E9"KE?B'#]2L^[*RR=,\<]#WI&5/F+$WD24B
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M:+ ZB /;65]LSFLKWIB,NC:P8% H% H% H% H% H% H% H% H% H% H% H%
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M7D%!(!E]HO0X4+HE@_5/T3VK,VKB^ET/*1YF0=R:I$G,8YM:5NL,L% ")=K
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M,,W'<9>0H.A]MQ=[+:THL?E"C5(V3W9:]]>W#WA=(]Y0HJX[6;C N%04H<P
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M38K\6C5?W>%J(5'8GITV!T]W*QN?#OY28_CFY#&!@9*:J5"Q34PDO)A-E(*
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MT?XKL\7;VUU^H]/]J(YSER>G]1]V9XQAM*N1UE H% H% H% H% H% H% H%
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M::O_ +N?^/W;R]&/^J>\?]HG_P!X:K@_(_Y5_H[_ ,?_ (V_JZ7KRWJ% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H.4L26W_7!FAF;%V/C
M$_!$J-P%?#HY\%P..A3Y/RZJ]>W_ .I&/CS^[R*__MSGX<?LZ WR]TW9;Q:N
MHQQ(CJE:<4K.!@LB7H4? 9 *0K2#QKSM7W.>S/\ 9Z.W[?'?C^[1GK0WRUB]
MF8C8<60EE[<TA+TU8)*48^&I*KJ"+JLITH(L#<(57?\ CM6;S;X.#\ALQ2*_
M%J9?4'I=L+K3L;=?3',IF[:1CXN"W.DQI,0AII"8BGW/,,M:KM\MWPD^-OB>
M-=GVMFS5:MXYSF'']W73;6U)XQB5YZ\/[J8]4VQ7]CQXDO=*<&V<;'R!4(BU
ME[):@X4+;-M&JUE#C6'I8K[>W=TS]'1ZJ;>XKV]<?56-SYGJ=UQW[CNBO5N3
MB=D&%+1,\I&CO\R6\&UA'(<4Y(0M1;<7HNZA!O\ ?*&FM:5UZ:3LUYLRO;9N
MO&O9BKH?J7U[V)T0G8O:V<QV4D*=@H>B?#FH[K:&&U*92E1>D,G4.7[#7FZ?
M2WW1-HF.KT=WJJ:9BLQ+2G5^9B.L/4?I(_";=8P^[<7-991+2E+S:)7-:!6&
MU. *!-_"HUW>GB=.N^>M9</J)C;LICI:%!VSGY._]M=*NA4I*C)QVYY2<Y&7
M[Z8D1:74W]H#<B2G_P#5UT7I]NU]O_V\?\?LYZ6^Y6FK_P"[G_C]V\O1C_JG
MO'_:)_\ >&JX/R/^5?Z._P#'_P"-OZNEZ\MZA0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*#D?8/43%^FK([]V1U*@Y-DY+<4W/[9R,>([):RC$YMM*&VEH&GFV93J"B
M %*()X46ZMOL[DW5O3H'GMP;LV^=N9O(X/*K3B-:W'4M&,Z&E*2I"5(4M-E<
MLW(N+\> (:VVK%DI]#C\53*Q*^C>53R2DAS47I%AIM>]#Q:PSG2IS9.PNEO4
M[)',;TZ?>2Q#^\]F9&9)>9BJE1VBV_%9;4@!#2UZ RL$>ZD^%1L2V%/ZH;1V
M+ZF,[O#//R?HYF=J8YK&SHD21+2ZIQ;;R>#*%$ H%^(HAT3L7?VW.H^$5N#:
MSKSV,2^N*5R8[L1?-;"5*&AY*%6LH<;6HA9J#0GJDBY.-B-B;SAX^1DL;LS=
MN,SN:8AH+LA,&,I2EN)0.T V!]E[]ER"85##;RPW7#U*;'WET_1,F[7V=BLC
M\8RKL5V/'0_-8>8;9"G0GQW=!M;CQM< D!8\Y'D'UG[:DAI9C)V2XA3P2= 5
MYR:;%79?C0\%?SW4+;G3'U3;GSV[3*8Q<[;,&'&?C1)$L*?YJ'--F$+(\*30
M\'OTOPG43=L[J[U.VFMW9\W>T_&M;2?S40G_ "7%G2Y(=BN W#K2BA!MP)5:
M@JW5/8.]]Q;GQ>UM\SF=Q;G?V5N3_O*'&\M&7);=\Q#3H2D!)"D-CY;42H>P
MX.X\[/Z;]2]R1W5;@W1O^-YITMJ!\GB8C,5I2KBX&KF]M!_06BKGCKS'R>T>
MJ/37K4G'2\KM?:YR$#<+4!M3[T5C(,*91)Y:>)0GF+*S_>I'?1,)?:OJ)B;W
MSV9F[9PDF1TJP&'<R.2W?);>BWF,A3BH\=E:+O> ?WI!!_O=0PYUB]+>O'4+
MI=NC>#<+;S4;>F0<WDH3%Y!.Y&GH"W%1VHNAOD)!0E:64K^]<[4W\)*V3K=?
M.H71G(SI64PYR>V\D,M-Q#JX$R//BAQ+R4NA)T!3K9L"/$@CVT$WT5P64V!O
M?J'TQRA4GJU-A.O[6ZAY OS/B,$MD1N8'U.)!85I6MM'O:5)-^7<B69U$VMU
M%(Z98GJEF8NZI,O?,1)?Q\,1&FX#D5QM:%I0D#M*O$?;1#F^=M;=<GISU#<W
M%'>=E;!8QNQL02VHJ6RC..272D6XZ-"4W'WI%%G]-Z*% H% H% H% H% H%
MH% H% H%!IOK;T,<ZG3<-NC;N:7MW?&WS;'Y$)4I"T!?,0E100I!0NZD+3?M
M((-Q;M]-ZG[<368S67%ZGTWW)BT3BT*2CT[=3]\;BPV1ZV;Z9SV$P;@?CXN
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M;9B8C&(:^FT3JB8F>LMJUR.LH% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M2_J)C-D=?\1'<Q^7+>F?%::2\TT\LH#[:XBBTXV@_P",1IU@#V\%##8?J/\
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MA:ZE%7$AP@E_03TR]7H/5?IQ#4ODL;EP"&L=FH+*4M(24)TLO-MIL$MNH3<
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M\X $:P@MI/S=BBZD\3XN-#*&]$./A;VZ;=0-A;G:5/VL]*BEV"776@1+:6'
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MI2E)*5I(U'M[A$J']B+;>2PLB/N[>>:W!N-2&F8&9D*\$-IM:5*2TPXX[?6
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M>7EM-OM:QI5H=2%)N#V&Q[*(9% H% H% H% H% H% H% H% H% H% H% H%
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M0W_M_';5C83"965N+$[;8Q#>Z-HYMG'/^>0I:_*S6)I;0Y$"EJ^<3Q*>"NX
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MO=+)/4]62FXC*+WGNA[F1TQ-Q9><\R6QS^<H!25IMR4:E$*/WWBHEUW14H%
MH% H% H% H% H% H% H% H% H% H% H*%U;ZB3^E^VF]V,;?>S^)BR$_'?+O
MLL.1(&E6N0E+I',4%:0&T]M^)3VT2TSZ>?43O3J5#>Q"\#)W+DL9'R$O*YM3
ML''(#I<6O'Q6VD\M)YB &E.6&E7%5Q=5"85;'^KS=LSJ<[M]C;$R3/?@-8J-
MLCFP6T-[C1(5SW#/("BT&APN;$_>CWJ)P[*;4I;:%K06UJ *FR02DD<02"1P
M^2BKZH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H-$=;O31MWJED$[QQ*F<=O^,&]+\QLR<;.0R E+,Q@W\.D:0X
MW921W*L+$Q+5G1KH]YGK?EI>]^EK>V(&(Q49<%++;SV&.8C2&E>9A23X5%8\
M81K4I/8KB#1,NRJ*E H% H% H% H% H% H% H% H% H% H% H%!6-[=/=G]1
M8N/@;RQB,K!QLQ&0C1G2H-E]M"D#6$D:T66;H5=)[P:#7?3?TR=/MAPF53(K
M.6W$VSDH3N8;97 +L/*K65-+90\M*BAM9:2LDG3V6X $Y1;?I#Z3IW$_-=QD
M=>UEXAC%,8)+3B'FI3#_ #C-\ZE[FJ=6/ KPW([5$<*&6_6VT--H::2$-H 2
MA X )2+ #[E$/J@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@U\OKET
MF1E<#A?I5#7D-SJ6C!);YCC<DMR%Q#9U""VD%YI;2"M:=:DD)O1.&P:(*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*#X#S1=+ <27D@*4W<:@D\ 2.VU +S27$LJ<2
M'E@E#9("E!/:0.TVH"WFFBA+CB4*<.EL*(!4KML+]IH#CS3("GG$MI40E)60
MD%2N  OWF@^Z!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M#FKJ+@]R]9^MTSI6_N:?MSI_MS#1\GD6,.X&)4Z3-<*0E:R"-(3V!:5I&GW;
MJN"5=SG3R=Z9-Q;&W'LC=^;R.V=P;BA;<SVW<R^B4RZWD0X><CEH90E;8;5I
M.C5JMXK:@2>KK>BI0*#&R"IR($I>,;;=R267##:?44-*?"3RTK4D$A)5:Y'=
M0<K8O>/6W:75G9&U-P[TC;NW!N*0\-X;,APF$L8>"="T2$/LI2L)2VO6DN:;
MVXA5[T68>\.I76'<F8ZM[IV1NI.!VWTH?3$BX,P6)",@[$4L3"\ZZG4/\2O2
M$WX$#P^\0G]P]5M]=2MR]+=B;"S/T-D[QV^-U9W*-Q6YSC+*V5E#+27A:W,9
M<257%[IX]RB%8<]0_4=KHW(QZY3)ZK-;O^@3>;2PV6U.#YPR^2$%O5I!;L$6
MO95J)PV+TNWIOC;?5C=W2#J-N-.YX^(Q#.X\9N-Z,S <3%NTB0AU#-TV"GAI
MN20$GC8@)(7O\_O13Z_8/^/,_A4,-A1Y#$N.U*C.)=C/H2ZRZ@W2M"QJ2H$=
MH(-Z(>E H% H%!K+>\[KXQG5M]/<5MF7MSE-E#V9D3&I?.(\8*61IT@]E$J[
M\4]6G\P['_CF1_8H<'Q3U:?S#L?^.9']BAP?%/5I_,.Q_P".9']BAP?%/5I_
M,.Q_XYD?V*'!\4]6G\P['_CF1_8H<'Q3U:?S#L?^.9']BAP?%/5I_,.Q_P".
M9']BAP?%/5I_,.Q_XYD?V*'!\4]6G\P['_CF1_8H<'Q3U:?S#L?^.9']BAP?
M%/5I_,.Q_P".9']BAP?%/5I_,.Q_XYD?V*'!\4]6G\P['_CF1_8H<'Q3U:?S
M#L?^.9']BAP?%/5I_,.Q_P".9']BAP?%/5I_,.Q_XYD?V*'!\4]6G\P['_CF
M1_8H<'Q3U:?S#L?^.9']BAPL6R)W7Q_.H;ZA8K;,3;G*<*WL-(F.R^<!X $O
M#3I)[:#9M$% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MI4CHX_N]&$>:WXYOD[_9VQ?3*3$XHY 2?_>\>;I/BTC3;5PH9;.Z5X7<6_\
MK+O'J]N/:V1VQMK(8-G;..Q.=9,6;)0LLN2%N,DZDI!9T@]B@H6XWL0JGJFZ
M+=*]F=&,SG]K[5A8O,QY$%#,R.E0<2EV4VA8%U'M22*)B73NR_\ 4[;W]&0O
MY.BBJ<H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H/%F7$D.O,,/MNO1E!$AM"TJ4VI
M0U + -TD@WXT'M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!053J%MO<^Z<"G
M&;3W(C:V4$AMXY-S&QLPDM(2H*;Y$HA U$@Z^T6^6@YHVMN:?*W;$A_GZ8R,
M6-E<? 7_ />/CXL2:_+>>2B.S+3W.F*ZV'T> 'W5'A19V%14H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MG?'Y?=_@Z&3[,6W?KSOC\ON_P=#)]F+;OUYWQ^7W?X.AD^S%MWZ\[X_+[O\
M!T,GV8MN_7G?'Y?=_@Z&3[,6W?KSOC\ON_P=#)]F+;OUYWQ^7W?X.AD^S%MW
MZ\[X_+[O\'0R?9BV[]>=\?E]W^#H9/LQ;=^O.^/R^[_!T,GV8MN_7G?'Y?=_
M@Z&3[,6W?KSOC\ON_P '0R?9BV[]>=\?E]W^#H9/LQ;=^O.^/R^[_!T,GV8M
MN_7G?'Y?=_@Z&3[,6W?KSOC\ON_P=#)]F+;OUYWQ^7W?X.AD^S%MWZ\[X_+[
MO\'0R?9BV[]>=\?E]W^#H96G8/1W%=/<P_FH.Y-QYAY^,N&J-G,HN?&2E;C;
MFM+:DI 6"V %>PD=]#+8U$% H% H% H% H% H% H% H% H% H% H% H%!B9+
M%XS,1%P,O"8R$%SWXTMI#[2K>U#@(/ZU!I_H=A]S8;>'5")E<*G#[:;S"$[4
M2UCV,>PY!N]<M*8:;YJ;!'B45=U$RW71!0*!0*!0*!0*#07K-_L S_\ VG'?
MRQJB8;AV7_J=M[^C(7\G11"<H% H% H% H% H% H% H% H% H% H% H% H%!
MK_>76?8>Q,TS@,],=&1<2E;R6&5/)8;<]U3I'9<<;)NJW&W97%N];JU6[;3R
M^I_&?ZQZ[\AIG=IK';'3,X[ICX?^.(_5?(\AB7':E1G$NQGT)=9=0;I6A8U)
M4#W@@WKLB8F,P^9O2U+36T8F)Q+TJ5"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%=W[NCZ$[)W!N_R
MQF'!X^3D$Q K1S51VU+""JQT@D<38VH-3]/NN>Y=W=23MJ;C\4-JRG9^,QTO
M'ONORSD,)'8=F/$GYM<1:W5-,N)"3=/&]$X;ZH@H% H% H% H% H%!1,IUIZ
M2X7(RL3EMZ8B%DX3BF)<1^8TAUIU!LI"TDW!![11.&)^?WHI]?L'_'F?PJ&#
M\_O13Z_8/^/,_A4,'Y_>BGU^P?\ 'F?PJ&#\_O13Z_8/^/,_A4,'Y_>BGU^P
M?\>9_"H8/S^]%/K]@_X\S^%0P?G]Z*?7[!_QYG\*A@_/[T4^OV#_ (\S^%0P
M?G]Z*?7[!_QYG\*A@_/[T4^OV#_CS/X5#!^?WHI]?L'_ !YG\*A@_/[T4^OV
M#_CS/X5#!^?WHI]?L'_'F?PJ&#\_O13Z_8/^/,_A4,'Y_>BGU^P?\>9_"H8/
MS^]%/K]@_P"/,_A4,'Y_>BGU^P?\>9_"H83&VNJ73G>.1.)VKNC&YC)I;4^8
MD*2V\Z&D$!2]*238%0XT0MU H% H% H% H% H% H% H/AUIMYI;+J0MIQ)0M
M)["E0L10<_8_T];V:9Q&S<MU".0Z28&9&F0, <8PW.<:@O<]B,]+2JY0A03=
M0%U =B:)RZ$H@H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H%!R]U0S74S<O721T]VOO5>RY&
M+PC>7VEC$M!3>>G ..N(=6HI24#EJ0I*M0"4%6D^*B51S43J1TQS.PMY9W?N
M5E]6=W9J*UENGKKX>QKD6:\4OL,,M+=;0AD%* L**0;%-C:B79]%2@4"@4"@
M4"@4&@O6;_8!G_\ M.._EC5$PW#LO_4[;W]&0OY.BB$Y0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*#2G4OT[X[J%NP;I1FG,8Y(2VC),!@/\SDH"$J;45H
MT'2E*>(4._Y#Y/J?QT;K]^<?%^B?@_\ =-GXWTOMYUQ?&>V>[&,\\\3GGGP;
MBQT"/BL?$QD0$183+<9@*.I0;90$)N>\V%>I6L5B(CP? []UMVRVRW6TS,_U
MGEDU9B4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@T_U\WD-IXW%-.;VQ>SHV4,IB0G,XIW,-36PA 4V
M$-D!(2%'5JX*"J)AKWH+N/;DK>D'$87?>V,VF-CY+$7#X/;;N'?1'*P^L-O*
M.E*.9\XM(]]7$\:$NHJ(*!0*!0*!0*!0*!05R9T^V%D)3TZ?M;$2ILA9<D27
M\?%==<6HW*EK4V2HGO)-!X?FRZ;?4[!_DR)_!4#\V73;ZG8/\F1/X*@?FRZ;
M?4[!_DR)_!4#\V73;ZG8/\F1/X*@?FRZ;?4[!_DR)_!4#\V73;ZG8/\ )D3^
M"H'YLNFWU.P?Y,B?P5 _-ETV^IV#_)D3^"H'YLNFWU.P?Y,B?P5 _-ETV^IV
M#_)D3^"H'YLNFWU.P?Y,B?P5 _-ETV^IV#_)D3^"H'YLNFWU.P?Y,B?P5 _-
METV^IV#_ "9$_@J!^;+IM]3L'^3(G\%0/S9=-OJ=@_R9$_@J!^;+IM]3L'^3
M(G\%09^)V9L_ RC.P6W\;C)I06S)A0V(SNA1!*=;:$FQL.%Z";H% H% H% H
M% H% H% H%!J_KENC<6S\#MS.8#SGE6-R8KZ1?#XRIKIPFM:I@+:$.*TE XE
M(O[#1,-&X?J7OW*_!.IN.WM+GS-P[M<P$#IVG'%$!<!N5REMI4I <2M$4IDE
MY=M)X*XA5$NPJ*N;,?A) ZYQ6]F[BR^:R>*GS<CU(S<N8\K%1X$IM7E<0&-?
M(YB%%)0E" 6P-2O8DE0\-EM[].,C+S>[Q.D[HW/B-W9;:\V-N)S*X\R<:P].
M#*X*4J80$MZ0A:'%BXMVFR25=RF[=V=/MF9%6VLWE'W=Q=+L)NS)/R9LJ6\S
MFLGE&(4B4TX\I?*4MJ0X;-J'^+OW T&W]L9K=73G*=8]J[&QT[>,7:+VW']L
MX&7,?D/%>9C(5,;3)D<Q5DB\C2"0+]US1"*D>IWJQ@<]MS%[VZ4*V]"W%DH^
M+CS)$Y1\;[J$**4AGB4A6JUQ0PZGH@H% H% H% H% H% H% H% H% H%!";L
MW=MS8^%<W#NJ>C&X9EQEEV6XE:DI7(<2TBX0%&VI0N;6 XG@#0:^V;ZCNF>[
M\5E<DG)(AO86/-R&3B75*4S @2%1^>5,)4D\RP6VA)*RD@@6HG!M'U'],=WY
MO)8*%E6D2XC\A$$H47Q,B1(J9;LI/*2=#822GYRQ*DE(XBU##RVOZENEN[-W
M/;3QF6:6ZXK'-822DJ6,B]D6G'5(;;2G6V6.7I=YH3I4H V) H8;AH@H% H%
M H% H% H% H% H% H% H% H% H% H% H% H-"]6NI^>A=1,7L+I;LF)N[JA$
MA+R9R.0T-Q\5#D$LD\U2FU#6#XP'4"Q2/$56!*NXCJ;U)P/4#:C?J"Z=8G'O
MYB2<-MG>&)4A\1)<VP#!UO25(YU@"0XCA?@H!5@Z<HASEUZZN;@Z>[ZB-1\P
MSB,%C-K9;/-Q'T)*<MEE$P8D0*58W;<=0_I2>P&X[+$PA/33N#?3&]CM3=&[
MI6[$Y?:D7=F49G.*?=P^2ER$!$,*4I10%L.APM^'3;@D=XEU11!0*!0*!0:"
M]9O]@&?_ .TX[^6-43#<.R_]3MO?T9"_DZ*(3E H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H%!7=_3MPXO9&XLCM./YO<\3'2G\1&
MT<PKEMLJ4T C[XZ@+)^^[*#G[H-U%WEN;?"<*WG<ON3!QUY56:DYG'>1#3(1
M%,%S5RD!#JG2^WR$$@(N>X&B9=1T04"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4%7WQU"VGT[Q;F4W3D6H@$>5)BQ%.-HD2A!:+SJ(Z'%("UA(X)!XFP[Z#+
MVIO';6]L<<IMC),9&(VI+4A4=Q#O)>4VATM.%!4 M*7$ZDWX'A03M H% H%
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MF[\3-^RL7K?&8GCF.DQ/]UHV?M;';*VUC]KXDN*@X]"D-K>(4XM3BU.+4H@
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M/">[_KRZZ:2M#2$.+YCB4@+<M;40.)MW7KZ:'X5:8F9F.'W4JE H% H% H%
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M_']Y/B(!O1:7;M%2@4"@4',WJV_SQT=_VNB_OC5$PZ9H@H% H% H% H% H%
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M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&K-]_VS])/_ -X__#VZ);3H@H%
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M.8RV+@<>!HEWO14H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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ML]TY0P_E\ YDE+BORS!4H9''/0D.-KY;B-32G>8 OA<"B84'H_TT<VGO_ G
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M'LO)4Z"U[X%N!*/O@FY'&_8:Z;^EVTI%[5F*SXJ1>LSB)Y66N9<H% H% H%
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MN,6S,SSSQUYXG_HZ(:;#32&@HJ"$A.I1NHZ1:Y/MKW(?E-IS,R^ZE4H% H%
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M)XI (%O3M^3]1;5]N;<=/UQ_5C&FD6SALFO,;% H% H% H% H% H% H% H%
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M*BJB>C</1OH9UHZ+=5GXV#R:,ET==7IDIF24MJ>9=;U!Q$9/,T/LN&Q59(6
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M=_2<C^3BA#=^S/\ ANV]_L/#_P#"$40YT_\ 3R_^8_\ ]I/_ +H43*#Z%_\
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M>Q7R[:B+]JJ=L_ [H^+#W=M'I=OQ+"=Y8W$9I4:XC.S RXZV";D(<OJ2"1Q
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MO]LZ#P</RN FG;/P3W1\4P<!TU5G6MT*Q>#.YF E+.9,>(9R$H;Y20F1IY@
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MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M("RZTE!6 "5I_;"@IW0WKAB>L.V)F>=7!Q>1C2)!=PB9:'I4: TH!MZ0"4J
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M0*!0*!0*!0*!0*!0:!]2V-+N1Z<9[-8:3G^GN$S3K^ZL;%87-2$.LZ([SL9
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MY5T2(]W4!1Y3H "T<?"L#Q#C1#,H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!
MK3J;URV-TOQ^4>R<H9#,XA$1Z7@(3C7Q#DSG0TVX&W%(!%R"KCP%O:+DX7/
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M$XQZ0[,7$C I:#\@W6I*22$@VX)39([ !1";H% H% H% H% H% H% H% H%
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M]61DM0X[TW'16&N:\H)2"I4SY;FP)M0PZ,H@H% H% H% H% H% H% H% H%
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M$-7"/ "4ZN*N/;1.7UN+TX;&W)/7/DY+.1#.A0\;N)B%D5,-9J/CVTM,_$/
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M!H-FS^AO5/.;>V2QB>J61V,YA-LXK#9/$065RFG)\-HAY\N(F, J5J"/=/!
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M(<=F)&0&XS"$M,MCL2A "4@?< HAZT"@YF]97^9^G'^UT+][<HF'3-$% H%
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MIS@D;9V9C_AF$;=<?1%YS\BSCQNLZY#CB^-OVU$+'0*!0*!0*#F:!_QP9/\
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M<A]H9(!06M#CB5:21;]2A+JVB"@4"@YT],?^N/7+_;C(_P H?HF71=$% H%
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MN"Z6_,PU.7467!Q3J)HB6Q:(*!0*!0*#F:!_QP9/_9%/^&Q1/@Z9H@H% H%
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MZ7TH)*G!J]X'31+I.B"@4',WK*_S/TX_VNA?O;E$PZ9H@H% H% H% H% H%
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M&XEI] =MK3=:'$E*M*>U/=PK.^N+]7G>M_'ZO5Q$7SQTF$YM+:F%V3@8NW,
MR6<;$"M 6K6XM:U%2EK4>U2B;G^YPJU:Q6,0Z?3^GIHI%*=(3=6=!0*!0*!0
M*#7/7W^Q3?W]!SOWE5$P@MZ>H#9/2L8/!9IJ9-R<F%'D/,P&VU\AA:=*5++C
MC8NHI-DCC;B;<+^MZ/\ %[?4UFU<1'ZN?9OK2<2VIA,SCMQ8B#G<0\)&,R+*
M),1X IU-.I"DD@V(/'B#Q%>;LUVUVFMNL-HF)C,,^LTE H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H-&];=M[%W5OC86!SL/,S-U9)4QC&KP<M4+RF/3RE2Y,AQ)%
MFT?-BW:KL%$PCNG>S>G^Q.MLW;D6%N%G=#&)6]A<KF9RYT"?CW5,&5Y<K42E
M;;A0E23QX7[*#H.B"@4"@YT],?\ KCUR_P!N,C_*'Z)ET71!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0:KV;_;KU2_HS:O^!DJ);4H@H% H% H% H% H%
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MCXY0^AE;DEEM#TY*T/I?=.@HCIU)4>)/NT3"@[@W4TZUU7RO4!,;"Y[=?3S
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M"=)!H2Z(EPXF0CKB3X[<J([;F,/H2XVJQ!%TJ!!L1>B&$WMG;;421CVL/!1
MEZ?-14QF0R[H-T\Q 3I58]EQ0>\G#8>9&8AS,?&D0XI0J+'=9;<;:4T+(*$J
M!"2D>[;LH,V@YT],?^N/7+_;C(_RA^B9=%T04"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4'//J5Q?4O(R<(=HLY"5@DMN"0QB0ZMP2RK@IU#/B*=%@DG@./9?CX
M?Y.FZ9KV9Q^GQ?JO^C>H_&ZJ[?<S2NS,8F^,=OZ3;C.>O]FW>G#.XX^QL$SN
MU2U[A1%2)I>5K=O<Z XKO6$:0HGC>]Z]3TT7C77OZX?"?F[>GMZ[;/IL?:[O
MXXZ?KC],YQ^B:CX3"PY[^5B8Z*QE)0M)FM,-H?=!-_&XE(4KCQXFM8I6)S$1
MEYU_5;KZXUVO::5Z5F9Q'](Z0UIZ@=A[HW]M.'!VL0]*ARQ)>QZG$LA]&A2!
M92RE.I)/ *('$\;UY_Y#T]]U(BGA/1]A_IWY?TWX[U5K^HXBU<1;&>WF)\.<
M3^C-Z$;*W%L/8HP^YE!.0>EO3$Q$N!T1FW$-I#6I)4F^I"EG0;>*K^@T7U:L
M6ZY_9S_[;^4]/^0]=]W1_C%8KG&.Z8F>?CXQ'//#9M>@^.*!0*!0*!0*!0*!
M0*#CWJ!@-G-]2LWC=S[MW'TYV[FI$U,MJ9!;^"9+XJAE$XQ,H0M+*9*6$<Q+
MUM)!MP5:BSKN&Q%C1(\:$E*(3+:&XZ$<4!I"0$!/R #A15[T"@YF]97^9^G'
M^UT+][<HF'3-$%!X3(<7(1)$"<RB1"E-K8DQW %(<:=24K0H'M"@2"*"@?F"
MZ*?4'!_Q%G\&B<J1U'Z-[9PV/<E;%Z4;6RC3424],=E-);DM.-(U-\B.B.X'
MR>/A*T<;#OJMIF(G##U%[5U6M7FT1./ZX<]](MJRMW9#-8W'[ VYN-?EE.*5
MDXC..9B.J6$ I?CQ5V405:6BCCIN+6-^31>UIY?+_A/7^HW[;5V3W5Q\.DY9
M>[=LN=)=N;;VSN;IQM$YSRX2YG S\37-$9*4+6X7660E:E*U*'B^[5]VV:8P
M[/S/Y+9Z7MC7_P!V>K<?27IQM7?6/B9W</23:>.VU,AJ<BSHZ N6[);<2T=4
M5<<);;79Q:3SE<-/MX;:[=U8EZWHO43OT5V3&)F&S?S!=%/J#@_XBS^#6CMR
MN^%PF(VYBX^$P,)G'8B("F+"C(#3+:5**R$I3P%R2:(9] H%!C9'X@<?+&)+
M(RO)<\B9048XD:3R^:$$**-5M6DWMV4'*/4#TZ]:>I&Y&=TYZ7LMG))0VU)3
M"1F&FI*&O=#H4XM7N^&Z%)-J];TOY3=Z>G97&/U\&-]%+SF5FQW3'U$XK?+N
M_H4W8K>2=PS&W4P1'RWD6X49WFHT(#FL+!\/^,M;NKRIM,SF>K?C&$UA]I>H
M7;JGU[?@],,4J4=4E4#&96*75#O7RG4ZCQ[ZTV;MFS_*TVQ\9RK%:QTAO1GF
M\IOGZ>?I'-T7T:[<=-^-K]E9)?= H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H.:=^9G*RNKFZ\-B]_P"(Z3'&8[&2EY!^#!5,SCCC
M;I0Z^_,+?,9BV+24)4JUSV42VWT9W?E]^],-M[LSK*&<MD8ZC)Y0TMNJ9=6R
M'D)/NI>" ZD=P5:B)<S=0\4G-=0,8G=_IHCR=W[G?E#%.M;O9BB>O'M&0\MU
M,4(:U<M.M1?XJ[.)X46=2],W,R=H0H^:V>UL1^'JBQ]N1YD?(-,QFK!LI=C)
M2BRA][:X[Z*K?0*"'R^U-K;@DQ9N>P>/RDR"=4&1.B,R76%'C=I3J%%!_P#9
MH/O*[8VUG94*=F\-!R<W'+YF/DS8K,AV.LD'4RMQ*B@\!Q210,QMC;6X7(CV
M?PT'*O0%EV Y.BLR5,.&UU-%U*BA7 <4VH)6@YF@?\<&3_V13_AL43X.F:(*
M!0*"%W= P>3VOEX&Y7 U@'HCHR+RE<L-L!)*EZNXI U _)5;1$QST<_J:4OJ
MM%_\<<_T:2]/>V^D6/SV6G[(W#(SN=;8+)1+:5&4U$4M)4MM"D(UA2@D%?=V
M6&KCS::TB>)R^>_#Z/25O:=5YO;'CQP]/5'+ZA1<=@CM)R>SA2M\Y1W&%Q*P
M\ CDAU3/C"+:[?>W[>.FGJ)MQA/YZWJ(K7[>>WG./ET; Z(O[OD=.,4[O;GG
M,JYNA<RXE*C:SRE.ZO%J*>]7$IM?C6VK/;R]/\7.V?3U^[GN_7KCPRV'6KU2
M@4"@4"@UIUYWON#I]TWR&XMLLA>42ZS'3)4@.(BI?7I+RD*N#8V2G5PU*%[C
MA7I_C/3TW[XI?I_S_1CNO-:YAH/;?57>_4GH-U=8WBL3E8K#O&-E4LMQROS#
M+VII264H02G0"-*;\>/=7=^9]%J]/-9U\=V>&?IMEKYRE.N70;?W4+.X/<NU
MBS.A+Q42&['??2PJ,IH$DC78%"M>KP\;WX5T_BOR>G1JFE^)SG^K/?IM:V8=
M(["V]*VGLK [:G2?-S,5!8B/R 24J6T@ A-P#I!X)O\ >@5\]ZG;&W;:\1B+
M3EUTKVUB%BKF7*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0:JZW[CVY%Q>.V3EMI
M2-]9C=*GTXG;44(2M?DD!;L@OK($<-:T6=!U)*AI[R"84[T\3W,!N#<NR=S8
MO.X;>.87](VF-Q2&,@MZ"TAF".7,8L'2T$-I5K3J[R3QH2Z&H@H% H.=/3'_
M *X]<O\ ;C(_RA^B9=%T04$=D,_@L2ZEG*Y.)!>6G6AN4^VRI2;VN M0)%Q0
M1&3ZC["P\)S(9#<F/1%:L%%N0V\NZC860T5*/;W"JVM%8S+#?OIIKW7GMAJ[
M'9+?65A,Y"#UUVXN*^"6U+V\PRH@$I-T.9-*AQ'>*5M$QF%M.ZFVO=2<Q+5&
M<Z]=4\+NJ5M=O=D/(1X\L1/CC.)CH:4DJ"5.(C\]>H"YT_Y0-7M%<MO48MCP
M?.;_ ,Y]OU$ZNS,1..O+<.KJ+^G/;7Y"B?Z5KL?4MDXS=NW8V-AQ\INO%3LF
MTPTW-FMOQXZ'WTH <=2T'5\L+4"H(U*T]ES1"2A;EVYDI"8F.S$*7*6"4,1Y
M+3KA"1<V2A1)L*"4H% H%!P[LCJ/ZCMP=4IF!ASEM9IY<A$S&95A:\7 T)60
M7&T %M"" D*0;JX<5$\?M/7>C]+3TG=3'2.V?&?J\[5LO.S$ME[^W5ZDNG&W
M7]R;DW-L=J,W=N,PF'DB[)D%"E(9; /%2M)[> [20!>OD_3^FV;[=M(S+OM>
MM8S+VV3N'U*[_P!NQ=R[<W/L=^#(&EQ/D\D'&7P 5M. D64B]C^N+@@U&_1?
M3;MO&)36];1F&O9_J"ZX;=ZH,;1S;D*8]!G,XZ=BH,+0S++BT@J:4X"^"L*N
MT=5K$$I-?4^G_%:+^D[Y_P IC.<]/^G]7!??:-F(Z.TZ^/>@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@P,WD7\1B)N3C0'\I(B,K>:QT,),B0I N&VPM24ZE=@
MN10<T[L@,9'>.1SF^.G.]][0FWDR,?CYCT4[>AHT)(#,/S+:%:;V6IX*N:)=
M012DQF2AKDH*$E+-@- L+)L.'#LX40]:!0<S>LK_ #/TX_VNA?O;E$PZ9H@H
M% H%!4NH&^L%TRVV]N3+,K6TIY++,:,E/-?DN@D"Y('8DJ4HGL'>>%9WO%(S
M+A]9ZNGI=<WM\?#QE ;+W?L/KO@'GY6%;DIQKX1(QV599D%EQ0U(6@G4+* (
MOP/ @CVUI:NR.CF]+ZG1^0UYFN>V>EHB6R&&&(K+<:,TAF.RD-M,MI"$(0D6
M"4I%@ !V 5L]:(B(Q'1Z424"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@\)TV)C84G(SWDQX,-I<B2^LV0VTTDK6I
M1]@ )-!J7.[B].'4E;<W.R-O[H7BI,2"S)<;;G%#V14@,-(6E*M:5K<2%!)*
M4JX+L0;$MNQX\>)':BQ6D,16$):88:2$-H;0-*4I2FP  %@!1#A//[R7D]T8
MS<&0]2F-&9VR_,5A5G; O$5-;5&>39+ 0Y=LZ/G JW:+'C19U5T1STO<>Q&<
MG-WFSOU]4E]L[@CP4XQM00H6:Y"4-@%'9JT\:(EL:B"@4"@4"@YF@?\ '!D_
M]D4_X;%$^#IFB"@4"@A=W[;C[OVQE=LRGE1V<G'7'+[8"E-E0\*@#VV(!MWU
M6U>Z,.?U.B-VNVN>.Z&INB_0"3TRW#,W'E,NWD)2XZX<1F,VI" VXM*E+65\
M=7@ "1P''B:PU:>R<O$_&?B)]+LF]K9G&(PWG72^C*!0*!0*!0*#7^[L#U7R
MN1E(VYN# Q-M/MI;3CLIAWI[IN@!P+6F6TE25&_#1V<.-3$S$Y@X4?+])>KN
M6VAE=CHW-M;&;?R\=Z+*8QFW78ED2$Z%J0$3M(41WZ:M?9:\YM,S/ZD1$=%@
MC;:]0$6.S%:WIMOELH2VB^!E$Z4  7_[P^2J)6G9V.ZE0I,E6^<[BLO$4A(B
M-XS'.P%H<OQ*U.27PH$=P HA;Z!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#1_6
MO 9%W?&QMRX+?<+9FY1YS!XAJ;!&17->R1:)0VV5 "W+%U%-A<<11,,'I]A=
MQO\ 660_O/J5CMU[IVGBWX+^!BXU.-DQFLJ8T@.G2JRTD(;X@&VH D'A0;^H
M@H% H.=/3'_KCUR_VXR/\H?HF71=$%!3=X=*.G._YS&2WEMV)F9T9KR[#\I*
MBI#6HKTBRAPNHF@UOOKTM[$R>$$?I]C(.V,XAY#ADH0OEO- *26W+%1 \6H$
M \1\O#';K[X>3^4]#/J]45B<3$Y:OV/LGI]C,$F/OWI'NK<^?4ZMQ<US KT-
M-J"0EIL^822D:=5U#M4::M?9&%OQGH9])J[)G,S.?^/V5C,[AZ;0.H\&+#Z=
MB%M2 @XZ7@906Q+6J06RIQQK4K0ZSXDH0%VX\>[3RWV1%^CY_P!5Z_57UO.N
MLS$Q'=_U^'"U;UV9T[R.W)438/17<&%W6M3)@9)_!N(0V4NH4OQAYS22@* 5
MH/ZG:.O;$S68A]-^0U[=FBU=4_RE*=$/3M'R(RD_JUM-EZ+I:;Q,;)(^?"KJ
M4XH!*@I*;%(LKM/W*Q]/2U<Y>/\ @_3>HT1:-G%?"/\ FWOMGHMTKV9F&<_M
M?:L+%YF.E:&9D=*@XE+J2A8%U'M22*ZWT^5\H@H(W<&$C[CPLW!RWY,:-.;+
M3C\%Y<62@$@W;=;(4@\.T4&L/LX[3^LV[O\ >&=^'1.7.VW=W=',SNYW!9#+
M[RP^WR71%W%*W3+#)#04K4^V=/*2H)X'6KB1>W;7O^I_"WTZ?N3:)F.L?^+E
MIZF+6QA)]4,'Z?I&R<I(P'59W(9K'-.9"%#R&<5F/,+C-.*\NTT\[P6[?2E2
M3VV[:X_QWKO:[)MC,3&&F[5]R,,CIW@?3U"V?C#F.K3\/+3&TS9T7'Y]6)::
M>D(22VIAERVM "4*4HDDI]E@*_D/6>ZV]^,1$83JU_;C#46=EXU_JVAK;<_*
MY?!M3VH&,EMYJ?(FR8RUAO4U*2]<%S62C2+"X%CQO]#Z;\9JOZ3NFT\QGKQ^
MWZ.2^^T;,8=E_9QVG]9MW?[PSOPZ^->AEM7$8UG#8J#B([KS[&/CM1&GI3BG
MY"T,(#84ZXKQ+60+J4>)/&B&90*!0*!0*!0*!0*!0*!0*!0*!0*!08.:G2<9
MA\ADH<)W)RX<9Z1'QT<@/27&6U+2RV5<-2R-*;]YH.=NHW4CJ9O;8>X]H1>C
MFXHLG-X^1 :DNN1E(;4^@H"E!*KD"_=1+HS%-.,XN$RZDH=;CM(6D]H4E !%
M$,N@4',WK*_S/TX_VNA?O;E$PZ9H@H% H%!6M];&P74/;[NW-P)<,-:TO-/,
M*"'F7F[A+B"0H7 )'%)%C5+TBT8ER>K]+3U.OLOT8?3GIIMWICAW<3@.<Z9+
M@?F2Y2DK>=< TB^E*4A*1[J0/[O&HIKBD8AGZ+T.OTM.VGCUF5QK1WE H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M%!BY*(Y/QTN"T^J*[)9<91*;2E2VE.(*0M*5A224WN H$>V@XWW5Z6^I,W+;
MDEL-8'<8DY7$/P9V0A,8N;(CL-QP^I#N.6V(R!I4V\D-:G "M UJHMEU+TRP
M<_;>R,7A,G!;QLV)Y@.0F9\G+--A<EU:=$J7\\M)2H$!SBD'3][15P3N7??2
MO(Y^?^:>"_TUR'/6'L_.S<F+&<>2H@ES&QF<@%(]H38'[M%W:?I^RLK,=-84
MN;NF)O&4E]]IS-8^(8+"BA0'+T%I@J*!P*RV"KOHK+:%$% H%!X2)L.(II$J
M0TPM]7+82ZM*"XO]JD*(N?D%![T',T#_ (X,G_LBG_#8HGP=,T04"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@U'U6P&\8N\=H
M]3MFX)G=4K;+.1A3-ON2&X<A3.32T.?%==!0EQLM64#Q4E5A1*/V3B]_;RZI
MM=4-X;21LB'B,._A84!R6S.R$YR6^VZIQU<<!*6F@W9"%<=2M790;LH@H% H
M.=/3'_KCUR_VXR/\H?HF71=$% H% H-';CW5T C=4V8V<@,N;W9?9;<RO(4J
M.U+38-!U04$E:?"-90K3PNH:>'-:VOOYZOG-WJ/01ZK%X_\ 4SUQQG]6\:Z7
MT90*!0*!0*#56"].O2S;VZGMVP<6IR4X75-0)"P] 94^"E1;94GV%0 45!-^
M '"WJ[ORF_;J^W:>/G+"NFM;9A>?H7L[ZO8S^)1_P*\IN?0O9WU>QG\2C_@4
M'VQM#:<6:QDHN!QS.1B@IC2VXC"'F@KB0A80%)![[&M(VWBO;$SCX9X1VQG*
M9K-)0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"#WD]N6/M/-2-G,M2=U,PWW,-&?
MMRG9:$%32%74D64H:>*A]T=M!J+ =9^K\SXD,CT<RJU1IKD>.(\J&QH92ALA
M*R^\.8L$JNXV @\+"X-$X;V96IQIMQ:"VM20I39()22+D$CAPHAC9?)Q<)BI
MV9G$I@XZ.[,DJ2+J#4=!<60.'&R30:IZ>=<7=S29#&\L1'VPTO;D??&/E)F^
M:9^ 2E.)#DE2FF@TXV$:ECQ"Q[>%$X::]5?5+ISNO%[#:VWNC&Y5R!N>),FH
MB26WBS'0A84XO239(OQ-$PZ!_/[T4^OV#_CS/X5$8/S^]%/K]@_X\S^%0P?G
M]Z*?7[!_QYG\*A@_/[T4^OV#_CS/X5#!^?WHI]?L'_'F?PJ&#\_O13Z_8/\
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MMO8"&\W(B8J''D-.O2&G6H[2%H>E"SSB5)2"%. >-0XJ[Z"2H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MVT)/SPENM*<=D+?2DZ &1RFA< J)X'M);CH@H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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>% H% H% H% H% H% H% H% H% H% H% H% H/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm2227887d1-pht_macrop4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-pht_macrop4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#C6AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXP+6,P,# @-SDN9&%B86-B8BP@,C R,2\P-"\Q-"TP,#HS.3HT
M-" @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#TB>&UP+F1I9#HY.#9D8C@U-BUE93,Q+30P-&$M83<V9"TU
M-6-D86$Y9&)D8C$B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z,D)!-S8P
M.$4X.$1!,3%%1$%$-D(Y-$%"1C-#,S1".$$B('AM<$U-.DEN<W1A;F-E240]
M(GAM<"YI:60Z,D)!-S8P.$0X.$1!,3%%1$%$-D(Y-$%"1C-#,S1".$$B('AM
M<#I#<F5A=&]R5&]O;#TB061O8F4@4&AO=&]S:&]P(#(R+C(@*$UA8VEN=&]S
M:"DB/B \>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS=&%N8V5)1#TB>&UP
M+FEI9#IC9C-E,#9F,"TW.3EC+31A,#,M.#-A-BTR9#DP9#EF-3@Y8S4B('-T
M4F5F.F1O8W5M96YT240](F%D;V)E.F1O8VED.G!H;W1O<VAO<#HQ,60V,C@U
M9"TR8F-D+34R-&(M8C!C,BTP8F(U,#AA-3EC,C4B+SX@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0]
M(G(B/S[_[@ .061O8F4 9,     !_]L A  $ P,# P,$ P,$!@0#! 8'!00$
M!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,$1$1$1$4%!04%!04%!04
M 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!3_P  1" 0.!VP# 1$  A$! Q$!_\0 \  !
M   ' 0$               (#! 4&!P@!"0$!  (# 0$!              $"
M P0%!@<($  ! P," P0%!0<." L& @L!  (#$00%$@8A,0=!42(387$R% B!
MD4(C%:&Q4F(S%A?!T7*"DI.STR1T574W&+)#4W,TE+16\.&BTF.D)34F-CC"
M@Z-$5&3QPX3$92>5*$5&U,4)$0 " 0(#! 4(!P4( 0,"  \  0(1 R$$!3%!
M41)A<2(3!O"!D:&QP=$RX4)2<C,4%6*"(S06\9*BLL+24S4D0W,'XB5CDT14
M-L-T12:C%_*#9$;_V@ , P$  A$#$0 _ ._D 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! 0ES&\S1"*D/G-5N4KS(EF<CD %/*1S$/GO]
M ^1.5$<S//.?WIRHCF8\U_>G*AS,]\]_>/F2B',R-LYK0@)REN<]\]AYU"CE
M)YD3&O:[D:J&BR9$H)" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MG>6XS^TD_27%5,P0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0$#I&L'$J:5(;H2'3%W+@.Y72,3E4EJ2 @(7/CC;5Y#!WDT0-I;<"FD
MR5NS\F#*?1P'SE646S"[T5TDA^2F(^KB:/75WZRMR<2CO/<B4;V\<.$H'J "
MGD11W9\2'WFYY^=)\BGE17GEQ'O%S7\M(G*ASRXD7OEV/\:3^RH4Y$3WLN),
M;D)V^V&.^<?KJK@MQ=7I+:5#,C"[\HTQ^GF/N*O*S(KR>TJ6/9+QC>"%5IF5
M-/8R)"0@)C92SU=RAHE2H3VO:[D>/<J4,B=2-06" ( @" ( @" UOD_[;,%_
M4US_  CE?ZIB^OYC9"H90@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" X
MSVO=[7LNK^7N=Y"V.!;=Y1LGOD?G0>89':*L+7U->7!>TS,;CRJ5NO-2.QT/
MBN2GEHZI<_,<O=\USYE55J]V)NAVYOAQTG4W Z:&O\@;R_>5P^ZSW[7I^D]O
M^9T)[K7]Q?[2T?$/-8S]-\'/C2PXV6^MWV9C%&&!UM*6:!PH--.Q9M(368DG
MMY77THT_%S@\A;<*<O,N6G#EEL\Q>>G.V<;N_H=B-OY5M;6[@G </;BD%S*6
M2,/86.XC[JP9R[*UFY36U->Q&]H^3MYO2(6KF*DI>;M2H_,<T[HQ>X-IWEYL
MG+2.$5G=&Z$0X1/>YA8RYCKV/CI7YCQ"]5EYPNI78[U3Z'TGRS4;%_*2EE9_
M+&7-T/\ :76MOKV'0EWM.ZW?\/N&QV.:9,I:V=M?640]I\EO6K!7M<PN#?2O
M,K,*SG)2EL;:?G/ID\C+-Z+"$%62C&2ZUY,P_HIU;Q&UL;-M#=;G6=FV:1]E
M?/:XMC=(ZLD$H:"YE'5(=2G$@T[=[4LA.[+O;>+:QH</PUKUO+6WE\QV:-T?
M#H?#CZ2V]1+3H3CL!<Q;,?[UN:;2+1]M/<S115>"XR.D=H TZA3B5ER<\Y*:
M<\(;ZI<#6UBUHUNPU8[5U_+1R>]=-#,.E<,L703<SI(W,9*W*/A+@6M>PVX
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MHK9%)+S%:H,@0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$!*DE#> XN^\K)5*2E0IR2X]Y[U<QGB @EEBA9JD> #R[SZ@BQV$.2BJME!+
MD)'\(!Y0[SQ/S<@LBAQ-:5YO9@6/-Y/[*L)<A+6=["&1QDGQRN-&BO=VJS:B
MBL8N;+2=P9;&OA=N/'QQ64Y#1<V[M0C<14![:FG#G_P"IS-;49.[4OE=690
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M:+QD3U4R! $ 0! $!K?)_P!MF"_J:Y_A'*_U3%]?S&R%0RA $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0$J632*#VC]Q62J4DZ%,KF,?\  GN0
M@MES>NE)9$:0=I[3ZO0LD8TQ9K3N-X+84M/F60P'H%4)H6C=W#:F>([,=??[
M,]7M?B1^\O:9;?S(XMV^XDQMJ2#I]'=]Y>QO'6M'071<!FY[_AP&.I4CGIG9
M1>>SS["Z_<3F_E1LC9<9ADS%I6K8,A)I'<'<_NA<5/:<Z6-#D#+$-WIFZBH&
M3NS0GA^7<O=1_"CU+V&W;6)MSIRRFY\"YO'^4\^\&WF7%S+[$NHW,PGW>PZ+
MIV47"J<.@TJ*B@TE*BAY0J4R*'E#VJ:D4/" I((2T]G- 0EO?R4IE6B;!=&W
M^K?Q@/8.8]2K*)DA/EPW%T:YKVA\9!:X5!':%A-L]4@GPRD^%W/L5&B\9$]5
M,@0! $ 0&M\G_;9@OZFN?X1RO]4Q?7\QLA4,H0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! 4-Y?6N.M9KV^G9;V=NPR3W$I#(V1M%2YSCP
M "F,6W18ME+ER-N+E)I)*K;P1I?.?$UM+'W3H,38766A:2WWLN;;1.(^DP2
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MJ5:=:[#%I&MV]1YN2+CR4VTWU-B+0/0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M%)5ZT7)4,X0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M2;^ZFY>OLF0_"L:R[IX4JRQ-/7YRP:Y]3S^XWO VV]^[_J.DUY@^H! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 4LKM1]7)94
MC#)U):$%'?W&D&",^(^T1V#N^56C&N)ANSHJ%N:.P<EF-0F-;4>A0V62(P %
M6I>A$ C9*19]W#_PEG_ZLOO]G>KV?Q(_>7M,D-IQ)MIU)HJGC04/IX+VM[8=
M"R=(]&P#G[DLY?9Y_AFKS.=^7S^XSYOY$;$VT W=&YH3S-Q%(!Z"VE?OKC<3
MG-;#C+<!T[PSY-1_VE>4_?WKWUO\./4O89H;3:'22]\[>6!@[#<N^6EO,5R<
M[&EN3Z#:F_X;ZSJ72O,G+H>Z">53ZD%#PMIP-0?2I3%"&BFI!0'*XP77N'OM
MO]H5T^Z>:SSJ_L*ZJ_(J=Y&M*JILO*7N3O.27)QHZ>DK"P+(:E"$A""$M0@A
M([%:M2I YO:.:D@J;*X\L^[O/ GPU[^[Y522WF6W*F!7JAL$;'Z#5&JDIT*M
M8C,$ 0! :WR?]MF"_J:Y_A'*_P!4Q?7\QLA4,H0&C_B;N+B/96/@A/U$^2C$
M].W1%*YH/[85]:[FC)=\WO4</2CPOC.<UDXJ.QS5?0S$?ACQ.)N,GG,M<,8_
M,6+8(K0/%71QSZS(YH/(N+0TD=@6YK4Y)02V.OG.1X*L6W*Y-XSCRKJVU^!O
M+=^T=J[M@L[;=%NRXAMKADEMK?Y3C(13RPX$.+7\G-[5YZQ?N6FW!TJCZ!GL
MCE\U&*O)-)IKK)U])@]C;8O;VWM8;'%XJWDN?(@8V%GU;:@ - XN( 414[UQ
M)NKDS)<E:R=B4HQ48P3=%T(Y"V':2;QZDXV3+/:1<WKLGE))7-#"(W&XD:2[
MA1U RB]IFVK.7DEN5%[#XII<'G-1BY4IS<\O3S/;Z"'?5D_9G4G(RXE[0VTO
MFY3%NB<"S1(\7$0!::4!)93T*<K+OLND]ZH_9])&IVOR>HR<-TE./#[2V<-A
MT=U/R]MN'HCE,W9$&UR%E:W$7>/,FA-#Z0O,9&#MYJ,7N;]C/I^MWXW]*G<6
MR48OTRBSF;8F^,AT_P S+G,=;PW4TL#[4QW)>UE)'-=6C".-6!>LS65CF(<K
M;6-=Q\GTG5)Z?==R"4JJF-?=OP)N^M^YCJ+E;;)92VA@FMXO=K>"S:\T#W:N
M;BYSG%W(?,%3*Y2&6BTFW7:9=3U6[J5Q2E%)I45*\?34S;=UMNC8/2';.W7F
M6Q?F[FZN<LUA+)&:P)(K9Y!J-335[:@DM([USLO*WF,U.>WEI0])J%O,:?IE
MJUC'G<G/_3'X]5#7N+PFSK_&EUWN)V)SH+M%O<6,DMF:'P_RB O<TGAXC'P7
M5N7+J>$.:/0\?0>5R^6RERWVKW)<X2BW'^\O@=@]+; 8W8V'@;E?MOZK6_(B
M<W,;GR&KFQ/=Q\MA\#0:'AR7B,W/GNR;CR]%*'VS1[/=Y2$>?O,/FK7S)\%L
M\QFRU3KA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0'.?Q.;:N9[;%;J@:XVMJ),??.''R
MVS.#H7GN!.II/>1WKT>BWDG*V]KQ7O/G/C+)3E"%^.R/9EZ</?7S&<=+^JFW
M-S;?LK7(7\%EG[.!D-[9W#VPESXVZ3+&7$!S'4U</9Y%<[.9*Y;FVDW%XK#<
M=[1M<R^9L14IJ-R*I)-TQ6]>6!*W3UWV5MC+6^+$K\JUQ=[_ './+9H[4"FD
M$UHYQ/T6&H]?.;.FWKD'*G+3B1G?$V4RUU6Z\_%QQ4?+K,%^)NX;=8O:-W$'
M!EQ[W+&'L+) 'QPN%6N (Y]HJNEHB[4T^CWGG/&TE*W8:WN7^DO.U-D=#;O;
M&%NLNW&'+3V-L^],N0=&_P ]\33)J;YS=)U$\*"BULQFLTKDE%RHFZ8;J]1N
MY#3=(GEK<KG)S.$>;MT=6E7ZRWFP]C8'IY@9+YFQ'6H?<>6Z^;:77O?!FL1E
MU9'T'%U%SLQ=O7*=[7HJJ>X]-IN5R5CF_+<N-.:DN;C3>^DYXZ'97&87J5E;
MS+WT%A:&WO8Q-=2MAC\QURPANIY J0TE>FU.$IY:*2;=5LQW'S;PW>MV=0N2
MN245RRQDTE\T3IJWWMLRYGBM;/<&.N+J5P9#!#>0OD>]W)K6AY))7E)9>[%5
M<73J9]2AJ64N248W8-O<I1;]%3G'K+)''UKQD\KQ%%']E22/D\+6L9-5SB3R
M  K5>HT_^3?[Q\S\0T_5[;>"['M.C3U!V(VI.YL4*<_Y;!_SUYE96]]B7]U_
M ^DO5LDMMZW_ 'X_$O-M=6U[;17=I*R>VG8)(9HW!['L<*AS7-J*4/!:[33H
M]IT8SC)*475/8:W^(7^R_(_SBT_VAJZVD_S"ZF>6\6?]=/KC_F1J3I?T4P._
M]KC/Y'(WEM=&YGM_+M_*T4B( /C8XU->]=?.ZE<L7>1)-46VOQ/'Z)X;L9[+
M][.4DZM84^!M[9?1#9FS,C'F81/D<I!5UO<7KV.;"XBA,;&-8T&G)Q!]%%Q<
MSJ5Z_'E=$N@]IIWAO*9*?>1K*6YRQIU42])J7XHQ_P"*\( /_P"G._VAR[6B
M?ARZ_<>+\;?S%O[OO9OVRW[L>.SMVOW+BVEL3 0;RW!J&BO#6O-O*WJOL2]#
M/HL-4R:BJWH;/MQ^)B/6??%CC^G$TV'O8YW[A/N%C<VT@D88I*^<]KF&A C#
MA7O*W-.RKG?I)4Y<6F<OQ#J,;61;A)/O>S%IX8[<>K>:(Z=;\W1L*TO/L#;@
MOVY)S'R7DD%R\%L+2UK&NA%"T$N/->ASF6M9B2YITINJM_6?.]%U/,9&W+NK
M7-SOYFI;-WO+3F]W9UV]X=^W&+.)RK9X;OW=L4L4<K[8!K]/F@$Z@*. [UEM
M6(=R[2ES*C\U34S>H7_SBS3AR2JG3'&G6M^\[9QF1MLOC;7*63_,M+V&.YA?
MWQS-#FD?(5X:<7"3B]J9]TLW8W;<9QQ4DFNIG,7PV_VB97^87'^U1KU>L?@Q
MZU_E/E7A'^>G]U_YD=%;_P#_ "-N;^JK[_9WKS.6_&A]Y>T^D:I_)W?N2_RL
MYRZ ;'VKO*#.G<N-;D#9.M!:ZI)(](E$I?3RWLK72%Z;5LS<LN/(Z5K7U'S7
MPKIN6SD;KO1Y^7EIB^FNQK@;PLNCG3;&7UMD;#!LAO[.5L]M,)KAQ9*PAS3I
M=(6FAIS7 GJ%^47%RP?0O@>^M:!D+<U.-M*4758RW><T;UFLLCLKJO:;TMX?
M,M;N6VR-JXU#'S6;61S1:NPEK03Z'+O:?*-_+.TWBDT>"\0VIY+4HYE*JDXR
M\\:)Q]_G.@L#U&V;N+&LREEF+:.$@&:&XFC@GA/:V5CW M(/R=R\Y<REVW+E
M<6?1\MJV5OPYX7(TZ6DUU\#GSKKOJRWSE\5MS:A^TH+*1P$T-7"YO;BD;8XO
MP@T<-0^DY>DTS+.Q"5RYV:KU'SCQ-J4,[<A9L=M)[L:R>Y<?-Q,PZP8)VV>B
M.WL"]P=/8W%C#*6\:RB&773T:B:+2TZYWF;E+C\4=CQ#EGE](MVGMBX)]='4
MP?!=%H=R],?SSQ=S</W$^.>6+'EL?D2"VF?&6-HW47.8W@:\UT+NIRMW^[DE
MRU6..]'G\IX;CF=._,0<N]H\,*8-JG6UZR\_#6-HW.5O&W=HT[PMVF?'WDSG
M$&T> QXBC/!DC"?$1Q+7=U5@UI75%4?8?MZ3H>#?RTIRYDN]6*?[.^BW4]C)
M/Q3_ /F7! <OL^3^&*MH?R2Z_<8O&WX]K[OO*[KSA;G#7FU>HF)/DW#&6]M-
M.T5T7%N!-;2'OJ YIK^"%BTNZIQG9ELQ?IP9M>*,M*U.QFX8-43?2NU'WDKH
MYMZ:79N^=]WX+[O(65_9VTKO:+1&^6=X_9/('[56U&ZN]M6H[$XM^FAC\/95
MRRN8S4]LXS2ZJ-R]?L*KX4_RFZ/\W8__ )RC7/J>?W%O!'S7OW/]1TJO,'U
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M:7Z7<1K<TD @<./:O*ZK=A.]V<:8-GU+PIE;UC*?Q4US.J3X47M9N5<@]@$
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M5#*$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MQ\8E-L'B,OJX-IJ(=2E>Y9K%KO9J%:5-'/YK\K8G>IS<BK397SXFEW?%7:-
M!VQ*"17C>,_BEW?T23^NO1])X7^MX?\ "_[W_P!)?-J?$;MK/9.+&9>QFPOO
M#VQ07<DK)[;S7FC0]P#2RIX D4]2UK^D7+<>9/FINH=+(^+<MF+G).+MM[VZ
MKW? R[J=U';TWQ]A?OQSLBV]N'6_EME$!:6L+]52UU>5*+3R>4_,2<4Z47"I
MV-9U=:=;C-QY^9TVT]S-:GXK+(&AVQ*".8]]9_%+J_H<OMKR\YY3^MX?\+_O
M?_29ITSZR0=2,M?8R'$NQPLK<7+I73MFJ"_3IH(V_?7/SN0>6BGS5J^'TGH-
M&U]:C.45;<.55VU]R+IO[JQMCI\&6U^YUYEY6!\>,M:&4,/TY'$T8WTNXGL!
M6/*Y&YF,5A'CN-O5-<R^GX3QF_JK;Y_+S&K6?%3+[S]9MEONA) TWGUG/L)A
MH3Z%UWH;IA/'J^D\>O'':_![/WL?\IN+8O4';_4#'R7F$E>V:W+67EA.T,G@
M>X< 0"00:>%S21\H*X>9RMRQ*DO2>XTW5+&>@Y6VZK:GM7EZ#5M[\3MM87EW
M9R;:D<ZTN);<R"[:T.\EY97\D:5I6BZ\-&<HI\ZQ5=GTGDKWC.-J<H=TW1M?
M-_\ 22'_ !6V36D_FO+P!(_EK.S_ -TK?HDOMKR\YB7C>#_]%_WO_I-A[YZH
MMV1MG#;D?C'7S,L^)HMVS",Q^="Z;VBUVKE3DN;E<D[]R4%*G+T<'0]-JFM+
M)9:%YPYN>F%>*KMH:]/Q660X?FQ*#Z;QO\4NC^AR^VO1])YG^N+?_"_[W_TF
M;=/^M>W-^WOV1Y$N*S!:Y]O;7!8^.9K!J=Y4C>!<T'46D#ARKQ6AF].N6(U;
M31Z#2O$67ST^1)PGP>_J9BF9^)BSPV9R&'=M]\[["ZFM#+[XUI>Z"0QZM/E&
ME=-::EMVM'E.$9<ZQ2>SZ3D9GQA"S=E;[IOE<D\:;'3@4I^*FT;35M>45Y?R
MQG\4LOZ'+[:]'TFJO'%O_B?][_Z39/37J/!U#P=[G/<OLR"SN#;/9+,V84;&
MR0N+]+0  [M7)SF3>7FHUK55/6:1J\<_9E<Y>11=,7T)]!A&Z/B7V]B[E]IM
MS'29@1DL=>OD%M;.(/'R_"]SA^U%5T+&CW+BK-\O12K//Y[QC9LRY;,'<Z:T
M7FVU]11X#XGL3=W+;?<>&EQ\)-'7=K*+IK*]KV%K':>\MKZE>[HLTJPES=%*
M&#)^-+4Y4O0<.E.J]B-Z6.2L\G80Y''3LN+&X9YMO/$0YCV$5!!7 E%Q=)8-
M'T"U=C<BIP=8O%,T-)\4]K$Y[7[7D&ESF_Z8SFPD?Y+T+T*T67VUZ/I/GLO&
MT$Z=T_[WT$[&_%'@[FZ8S)8&YL[,GZRXAF9<F.O:6:(R1^Q*K/1+B79DF^'E
M4RV/&EF4J7+<HKBGS>Y&YYMS8.#;[MSOOXA@VVXN_?\ G&8B*AP XDGD&CC7
M@N&K<G/D2[5:4/</-6E:[YR7)2M>@T=E/BD@9<NCPVW7SV;3PGNK@0R/;7GY
M;&2::CE5R]!;T1M=J:3X'S[,>-X1E2W:;7%RIZJ/VF4[$Z_[<WADK?#7UI-B
M<K>.$5H"[WBWED-:-#V %I/I:!Z5I9K2[EF+DFFEMXH[6F>*+&;N*U*+A.6S
M>GY=1N1<@]@$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! 4TQ^LIW!7B8I;24K%2VWS]5Q3\$?=/$K)#8:MUUD2FMH."L4(PJ-ED
MB8 A8F-'!59=$UC5!9$P J"Q:-X#_P '[B[OLR]_V>19[/XD?O+VEX[3A3;?
M%\8/%H ]8[E[:^;%DZ5Z'QANY+YQK5V-IQ]$S5YG/OL>?W&S?^55-\!I7(J:
M%#U5J30B#:]J5)H: ^*\4V=@R#2F5!K_ /HTJX6L?A+K]S/J7_QU_.7?_;_U
M1.;L/( 6AHYCM7SW,H^O9E'7>Q8O>>B%LS\*QNCP[F3RD_>7TG2?Y2'5[V?G
M;Q.J:G=ZU_E1C76YSKKH3:W#14,=CW/(Y- ?Y9)]%313J>-A]9U_ C2U2*XQ
MG[/H.5;.8,(I0 #M/->!N1J??[L:G8GPZN+^F\#B" ;Z\-3PJ ^E?N+W.C*F
M676?GOQPO_N37[$/8;8=R7=/ DIW8H(('-X*Q6A*<$14E.;\RL4)9"%3V!VF
M>+TG3\A"/%".$D7)4-HF1&D@]/!0R8[2J6,S! :VR?\ ;9@OZFN?X1RO]4Q?
M7\QLE4,H0& ]:?[+]R_S9O\ "L6_I_\ ,0ZS@^(/^ON_=]YJ'H/NC8^#V[D[
M?=-]8VEW+?:X&7>D/,7DQ"HJ#PJ#\J[&J6+T[D7;4FJ>]GC?"N=RMG+R5Z48
MOFPK391&(=;\QLS<&Y+5^R61SR^1Y-]=6;"R*>=Y'DM:&@:WMXC4!QJ!V<-S
M3+5VW;EWE5PKP]QR/$N8RN8S$?RZ4G3M.*P;W=?EP-@?$1'<P[$VE%>?Z9'<
M1LN"34^:VT<'5/?5<[26G?N-;*/VGH?%JE')65+:FJUX\N)3[,ZS].,#M7$X
M;+8RZER5C;-AN)66<,C'2-YD/>\%WK4YC3;\[LI1:2;XOX&/(>(\C8RT+<X-
MR@J/LQV^DV1L7J;LK>%UD8MNV-Q:26%N)[ETMO%;@QU(H"QSB:4]2Y>9R5VR
MESM--X49Z?2]9RN<<E9BXN*JZI+V-FANF.#CZL=2+[*[E)N+4>9D[Z#4:2U>
M(X(:@UT-!;P[FT7HLY=>5RZC#!X+U5J?/M&RZU7/RN7L5\TEQQPCU+#T=1U7
M<;=P%SC3B+C&6TF,+?+]T\I@B#2*4#0*#Y%Y%7)IUJZGUN>6LRAR."<:4I3
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MB]#F>]_+1[NO-ALX'SO3/RWZE<_,\O)V_FV5J;G=%\-E#4X#3V^)O+YUQO\
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M8V1GD!I&JO8T+R>7R\[USD6WB?6M0U"SDLOWLMF%%QZ%Y;#"6YSH3U)M_?\
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M%=RD/\JVO+.)]S;3UX-,;XP:EPY--'=X7MX9RS=55)+H>#$4U@=!?#[L7=>
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M&\>/:TU'H6*QFKEAU@S<S^F6,['ENQK38]Z\YK9GPQ[-;<>:_)Y-]O6OD^9
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MY%\UM-R^T_*AL9:!Z ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" \<X-YFBFA#9+,[!RXJ:%>9
M$!G-.  *E1*\Y"97GG]Q6HB.9D)>X]J4(J0H0$![P4@\4 ]U$=J B\U_X2AI
M%N9D?G$>E10GF(Q.P^A1REN9$;7-=R-54LF1(2$ 0! $ 0! $ 0! $ 0! $
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M! $ 0! $ 0! $ 0! $!*?,&\!Q*LHE'(E.E>?0/0I2*N3(":JQ4\0! $ 0!
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MC)JN)%SY<?4A)[Q4@\4$A $ 0! 1-<6\0:(*DUDP^GP/>J.)=2)X-54R! $
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MK@,^@'*'0S^V?+G\3*?[4%Z[4OY2/[OL/DGAO_MKO5/VHG]:MV9W>.]&].,
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M\^LPHTC2B]9Z/0]#>G.;<^;FP7"G&GVC;"Y9ZD( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MY6ZW)*M*XN+73P\D=-KS!]." ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M;-,<%X6ZV21FI$4K1Q(!-0X<1Z>*T\EGY9=\8O<=;6M"MZA%.O+<6%>/0_+
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MMXGD.=XW %[W$"KJ<.7:N9J&?5^D8JD4>CT#0/R+=VXU*Y)4ZN.TW(N0>P"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MH5(((J.2H94SU02$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M]4Q?7\QLE4,H0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M X\G<@?7W%8G![4;,;M<&5JJ9P@" C9)Y?J[0JM$IT*H$$5')4,IZA(0! $
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M.LJK9>**A4,@0! :VR?]MF#_ *FN?X1RO]4Q?7\QLE4,H0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MM%HLJ%0RA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M4.;_ .Y,C_-)OX-R\K;^9=?O/JU_\.74_8<7=+\GU!Q=Y?2=/;4W=Y)#&V_
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M=#UR.H1:<>6<4FUNZU[^'$VDN:>F" ( @" ( @" ( @" ( @" ( @" ( @"
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M!4WIO_"R'?N7?#TN9_*XKS*<?["AZ3;-Z59[:C[W>=Q;19=MW-&ULV0=:/\
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M0Q'B ("WWUV"3;QFG9,X?X(5XQWLUKD]R*(+*:YZ!5"2F;D<>^X]S9=PFZ'
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MDN#94VF0N',\RWQ\Y@K]9.?R8'94_P##@H)Y'2I9LQ+:S7<CK[)>X^Z5?)'
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M9%\$QD\XBT?J=32TMX]G%8\MJ$+5AVW%MFSJ>@7LUG8YB,HI1Y<'7<Z\#/\
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M^55DBT65"H90@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M" ( @" ( @" ( @" ( @" ( HH E %(" ( @" ( @" ( HH I 0! $ 0! $
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M(E0B4$A $ 0! $ 0! $!K?)_VV8+^IKG^$<K_5,7U_,;(5#*$ 0! $ 0! $
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M_H%U_F9/\!R P?HO_9YCOV5Q_#/5I;3';^4V$JF0( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @-<];/_(<W\[L_X9JO;VF*YL-A0_DH_P!BW[RHS*3$ 0! $ 0! $ 0! $
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M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @*7)?Z!=?YF3_
M<@,'Z*_V?8[]G<?PSE:6TQV_E-A*ID" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (#7'6O\
M\AS?SNT_AFK)#:8KFSSFPX?R4?[%OWEC9E)B ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" E3'PCTU5XE)%,K&,("AR3Z,CA'.0
MU/J9_P :M#:8+SP2**BS&L3 **I<BHH)(@%")(@%!8B:A*+7N;$'-8.ZQ[#]
M?(RL)_''$++9N=W--FGGLM^8L2@MK1SSF\'>6YEM<AJMKC2:,D86N(K2HKS!
M*]+&XI+LNI\KO9>Y9E2>#X4\QA^->+"[NL?-<.\V/RY(??0YD3#JTU)=V&O
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MEHCQUO;3.#3Y=I"/-T>(N)[*5X"OH*4,TI]G$ZBZ 9B^RV"OHIF!MM:O8RW
M!Y4X@D]JXNHQ2DGO/9>&Y2=J4:U2>!MXBBY1ZL\5DR"60I*D)"$$)'W5<H0E
M 3;!VB>2/_*#6/6WG]Q4DL#):>+7$N"H; 0$^ \2%$B\&3UC,@0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 4UY$Z>UG@937)&YC:
M\JN:0$!C?3[;M_M3:MIA,DZ*2[MWRESH"XQD/>YPH7!IY'CP4R=64@J(RU07
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" (##NHNVK_=FVI,/C)(HKMT\$P?<.<&4B>'GV0X
MUH.'!6BZ%9*JH9;&TLC:T\P %4L3$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MSN/J/ J7BB$Z-,N[N=%B-PA0$<9TN![%#V$IE6L9F" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" I).+SZUDW&%[2!20>CFI(+&Y^N623\)Y/W5F6"-)XNI,:.]021!14D] 5
M6RR0?+'#'YD\C(V_A2/#!]U2DWL39#DHJK:12#/X,.T?:=OJ[O,"OW4^#]!@
M_-V*TYX^DK;>[LKH?R:XCE_S;P?O%4E%K:C9C<A+Y9)DU\L,#3+<O;%"P5D?
M)P  [358Z-[#*VHXRP1RKU W ,GFLC=6DCXHY)7^2&T\R6*/BT!QX>(#DO56
M+?);2])\CSV85_,SFME:+J,<G%U*&RS2/C;+ V2ZB<ZD1::.#P[GYC!1H"S&
MC5(A-O:Y>]=)/&3CX!YHC< V.:4<?173]*J$IM+#:R5DX+ITD,GEVSX#4BL;
M*MJ*U I4*"(M4+7BL5#EKQEQ90AUO%(89YI&&%DLD)\P$ \7!IIQ'#@ALR=$
ME7<9Q#;V&(M;J^DNB'ANJ\O'\3H!]EK1P'< %#VF!8K P3=[3G7V\\#VLMK;
M2^WMRW69+=W-X(Y/)/$ J6;5B7*VEZ>!;KO;U_&]F0E$;;OW=L=K&^0CRQ7F
M& 4J!2CB:K%*36!M0N5PQI6KP+!>YF\BS-KC[F(&2X<V-]U2CP7#2">\=[@J
M<DI'2A&VK;:W;B_,BEPS)'Q2"28AS/>&M,L<4I' '3VA6A!HYUZ\KF'M->[T
M=[K#YD+]%S*PP.M*4J]YUND'+B[F318[LN)U=/;QKZ3 8<)D'0/O'M'D1BKN
M(U?)WK#&[%RHO8=5RBW2N)32-=$VNHM:?;)[!ZEFE5(R1BBS.BN[^?R8&27,
MYH6Q1-<^33R!#6U[%IT=QT6/0L3>MI152ZV&V[N+WB[S.-F$=E$9XK%[7,?<
M/'&G#CH%"7%;EG)R497+D72"K3[7T<2ZFMTECZOI*>7;MW>Y")V*8'VV3AEO
M<=5P;Y@@&J6&,B@+V$:0SM6.YE^\N5MO":<H^^/6N'I*RS$8+M/%.,7T5V5X
M5X]*XHHFS_4-%:@BO'\;DL"E5%I1HW4ROIS>^Y;D94NT/;I+10U-1PH>'H5X
M/M'.S\.:RS=DWN,S/)M6&,PR-/NK:LIY[P)*@U (YBA703/&XTK+@R.:]!SC
M[?(PLEC\TVUU*WZN1SH:&.9M. <T5#E8QI=BJV[?H*C<$9L\G/-;DZ)6PO?,
MWQ U!:0:<JT!0BUVH)/=ZB@REQ(RQC:(G>3([BYII2@KQ'/U**&6W%5VXF;[
M*WSNS;V(EQ&)RK[2RN)//#6M;J#W<'$.(J*@<0JNQ"X^:23:(_/7\O%PLR<4
M\<.)O+H]OJ_O\C/@]R99UU<W \S&LD\9\/!X\RE":?17/U#+124H*E-IZ#P[
MJ<YS=J]-MOY:_$W0YJX9[AD!5DRK*+(Y''8F SY2[AL81_C+B41#Y*FI5X0E
M)TBF^HQW+D+:K)J/6RTXC>&U]P73[/"Y2&^N8P7OCB)K0<Z5 J!Z%FN9:Y;5
M91:1J6<[8ONEN:DR]K7-LEO&II';173*-%UC=YD;9.\??"PTHS<3JJD2$A 5
MH/"JQ&<]0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0%&>9]*RF A0$,AT1R2=S*H0W1,LS1P"
MSLT$35!D(@JR"/0HH618LWM"QS]QY]W<SM<!X8V4,8]32MFWF)6U1)'-S6FP
MS$JRD_<8]/TH@=XK;)%A[!) T_>(6TM0>^/H.1/P[%_+/THL63V1N;;[#>6;
MV7D,8+R;8N;( .)\/:MB&:M7,&J5.;?TG,Y9<T'SI<-I9<COK)7FW[G#73G2
M^8W3!,:^8QQ["?I+,LK&,U)8&C<UFY<L2M2QZ=Z-.YVWR%[;W3[)HDN(@UL'
MF.<(S1S0XDM' M%2!VE;AR++BFN;9OIU%VSEQ%$X0Z_+%Q5_G$@>,-J X'AQ
M Y(8H*N/ I\"VX?C&R/<)IGRSL&L:=/EGAI![SS)0M=HI>8E/OX+:+(>]W!-
MW91AUX^-CBR%SCV-'%W,#PH2HMTZ20S<,5I88O(PO?<QW,U&R2>!\C&5:\1L
M?6C7"ND(75OM-/<B[WTL;L2^2T8;FRG:]TC""'5H2 X.]EP(' I4QQ@ZTV&I
M=H92>>XNH'RN&3E=)/);NE>Z&*62NAFD\ !3Q442.YFK<8I/=%4K3;TF9#<;
MX\5=R9*TB=FK4AGD1N?(YSRT>*AHUK>9T@G@HH:,X\TDHM\K]1ADLD4,3LY?
MS.NKK(2&. .8UI@MQQ+0UG8:=G'O4U-M)S?+%42VXU+9E-XPV>'@]SG=B_*<
MX-B87-D>"*#@>);3EVK%.YR])N6<A*5RLL?8:QO,[=W]U'/+(Y[8SKC\QQDK
M7M=7C7O6JWS[3T4+481HB='>/F=YCW./#A5Q'9P#1W!9K:6Q;BDDHXBPL+G<
M&8L\39&DUU*+;S2*AH(!<XCMTCBLD8.Y-);]_12ICG=5N$I26"W><R:]=B=N
MW0L\1*_\Q<A%+A;J_A\%U#EK1W&=\@\6ISZ$<=/EGAR6Q<<;4U&#I;=8/;53
MXMX8^JB97+VKEZ*G*7\:L9?LN#W)8]FGGKO,==N_=&WH;2Y%UYF:C:ZUDDN&
MB<N@95H:X/YDCM5[N:O9>Q!-ISKCYCIW,G:FG&G9;K])7?I3MLA#:#-;6M+B
M:SN/?;::RGDL',N>'U@# [CP%>]:ZU%24>>W5IUVTQ7F]YSIZ;--\ERBDN7&
M-?7S&+9G(V^6NYKNTQD&,CDD=*8('/E\<A+C5\AK3C[+0!Z%IW;BN/F4>7RV
MU-RW;E;5)2<WTJBPZ/?M9>NGEBZ[SS0'4>P-+7<^.K_B5(KM&OFYTLLW=@9#
M=9B\\UI\QCR;BHJUP/)P([BN@E0\;?5+:)45))9H+EPX&20R./-[74J.TU'#
MYU)#V5\Q<G9*&#RVR2.@DD.DL;&9!+PJ0/0!WA##W;:=#VZRN)\I\<C'.BE:
M3&SR*%P%3I801QH.""-J5:HAMIC,V&*R8]KY0T"&0@T)_"/('O"D./*W7$W9
MT<EVEM:ZGRF[;SW?+.\%B9F.,$+2/$0]E6\?2M#.*[./+%56\[>BW<K9FYW7
M26R-5L-QY;JMT_Q=L;J3-V]S45;';.$LCQZ&A<FWE;DW1*A[*]JF6@J\R?4:
MQW'UWR5_!)%MBT;C+0@@Y*\HZ4#O:SD/E77LZ9%8S=>A'FK^OSFOX4>5<9&,
M;6V1N?J9>_:EU-,,03]=GK\&5\G'BVUC=0$_C>R/2MZ]F[>5CRQ7:^RMW6SG
MY33[V>ESMM1^W)8_NKWF_-K;(V]LRV=#AH#[S, ;F_N#KN9:?C=GH "\YF,U
M<ONLWLV+@>VRV2M9==A8O:WM9D16J;9#VJ4596V;M5M%Z.'S%4EM,]OY43U!
MD" K(SX&GT+&9EL(E!(0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! >.]DH&42RFN$))-V=-M,?0?
MN\%,=ICN?*RUL'#U+(:J)H"DD]"HV62(Q0#L'K3:23 SYU!>A$%#))C!Q[E!
M9&B>HESB+G)NDQ4#[*XB<Z.]+F@1ND#N#J ]OJ7H<G&<8=IU3/FNMW+,[U;:
M<9+YOB:YNK"7WUK&-#3<T(DB=6(TXEQ:.514$A;R>!YUQ=:<?06^]LL*(68N
M_FEG<0'1O)#>,;M8 X'ER!)3$NI4=41:;"QMVVK+AS(+:C'/D%7ZYG%[JD<S
M3@I*-N3KQ1@L$L#]PWU[+*'6=SYGG^+34,:'-)^X"AOR_#26U%7CY;W(6LUE
M)9Z1CI8H;2Z:1Q936:-/A:YM=.JO%&4<8Q:==JV>HH(<S)%-/C;FX?+?1A[K
MH- ;!HE?0,>.0+>!8X\'*E-YM.*Y5))4]_P&8W5B,'!Y=XP09&($R26K&.:2
M#[%#XJ]_%)2H19R]RZZUJNDUYN+J+#DK2>R@LVD3O$TC2]X<7 >TVG$4IRJL
M3N/<=FQDN[DG4PV_W7F;I\?DW+H615C9&*-I4"I!IV]JQN3.A;M1BL-Y8II+
MN[E;).\R:Q5Y?XC0<N#N?R+$TV;<9**H5(PV5]SM\E[N8[&\F=;8^=XT13NB
M'UGEU]H-^DX5&H@<^"I:E&Y==J,JS5*K#"NRO7N,_+MJ]GJ)MM;7/EAT0\37
M /UDM(<14"GI"Z,<M.2K&E:XB65;=4TS,>G]K<8_*7^9="XC#V$LEOP)US2\
M>&GGP:?D6YE+,X3;E'Y53KJZX>CUG+S:?(HO"OE[S%\I>8VXDN)H8WVV%SK&
MW4UOQ(M\FT4>&@<VAW &FJC@5S[G+<Q:[%Y5?1->7G3X'4RL91254W'L_N[O
MBN@QV]\R[+.QD+&LJ>RGI[UK9B7>27!8&U.\JX;"5# 'G2VI/'LX+ H(Q.XV
M5QMG1!OSAQ]*SI8&&3-D[ PS[/%39<QE]T]KY(8QP)IP8/OE6A&LNHY6>DE%
M1XF=X-_UC[J%S8[<1QV]O<N>-$KB[6#JY O=5O'C4+=9YN]'=OQJN!<SCHX;
MI]XR,.JUT<3GN]B2I<6.'80>54,//54?EN( 727#96/$I@ ,DG^+#Y*:G!W;
MH;7EWH5K@45W"7VC8HIBZ $>47 ^9Y<9(TU[#QYH;"P9<L)*+=[!J=$S3JCT
M&KB>1X=ZE&"[B;%QVP,WFH&RV^VLO)')XA+3R8WU[?&X"GR+#+,VX[9(V[&G
M9BXJJW*GH+[8_#WNR_>UTL%KB83S?=/;+-^YB!X_*L$M2MK95^8ZMG0+\MRA
MUNK-F[:Z$[1P9BN<V]^X+Z'V!<^"T#N?"$<'>MRY]W4;D\(TBO6=_+:'8MXS
M[;Z=GH-G-8R)C8XVAD;11K&@!K0.0 ' !<[:=TA<I*,@*$$)[:(056/=6%P[
MG'[M"HEM,MO852J90@*J$U8J2,L=A,52P0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 0R>PY"'L*
M-93"$!(OO]#E^3[X5H[3'=^1EN:.*N:R(E((FJJ+%HW/;7%SB9&VP)?'XW,!
M(<6_BT[0LUEI3Q-//0E*T^4UKC-XYW S/8V0Y"P::FUN2?, [=+^8HNM/+0N
M;<'Q1XVQJ=_+/!\\>$MOI-A8#?FW<TT1BZ%I?4XVMT1&_P#:N]EWR%<R[E;E
MOI7%'JLGK&6S&"ERR^S+#^TRYG(/9Q',$<5I,[B- ]1L<['[JO(HQ]1<:;AI
M)X@3-JX>H.7I,E/FMKHP/E^NV.ZS<DMCQ])B[&VUL)9W-T-('G3NYGT#]8+:
M:;./&B+/<OCO'DNLXC"SZ3YG&0T-06Z6Z>[FI2,7,MQ07=W;R2-?+: MB+GR
ML+N+I'"A(%*./I*DM1\2Q.DPN8N=+HXWM82R*22,,+_,]IC'0\:U'$."&9.4
M5M)]Y%>X^0SO8V"P@C:+:T;32U]>,L@!K2A[5%0DFJ+%O:_<C3._-ZV4V4FB
MPX#3J<R:5H:6R\N8[=)Y+!*=7@=_*95\G;,5@-YF)?.G>^25]:A_'AVGY^"H
MW4[=FTMB(+_;TT##*\GS'#M)J&\J!51F:2+7:XF:YF?"UT=7 -U/<(V1U< '
M/>XAK6U[25DY:)MTV&)RH9OM7I@W-[G9M_)7K&R8Z5K\O:LJ)A;M=5P:3IJU
MQHW4W\*JX>K:C#*Y-WHNLJ=CK>SVU\QKVLVW=5(NDJ]K<NGKZ.)F^\L-EMT7
M&7PT,$,V!A$=QM2ZM=(983V48C]V#133'*&D<.&L#M*XVE:?^7A:O-N-V2_B
M5?SN;YE)OC'C\#%/6LOS.*;JGRRJGLJ\5N^*Z=NO&8BVMX[#,7UE=,LKR7W#
M<UH6/$T-S4OCEB;IXL<WQBG:'!>VC?7/*36$OFIOZ>O>6AG9*[."E!M*L']5
MK8T\=N[B^%".^RUSM''RX2UNXOMDW+W/O(/$YEI$?JVEW+6\=G<>*Z4[T[$.
M2M95]"W>=KV\$9H25WM/M*FQ\?H>)AUS<Y+*->Z24/=JU1QM ;0.YNHWM[*K
M1NW;EU8OJ1MJ26^A;YHA#$VV%'/J2\CC0GL]:U7&F!CBVW4D"3RZ<* "GS+&
MU0V$F7?"4RET+.:.L# 7O=732G#B?E4M2<73<JB;:BS:D-[/A]M0L;'&W(F0
M0P1F@U,-*UIW-!*RY9U56>?G_'N4=:+;0BO[;'6.WA"'/MX2\3:W$Z#%J9)X
M1R<XN% ?H\EN5=34M2G.[@JO9ZJ?VE_L,S)D<9%/=V\@O+IX(\-(W$$L8YQ^
MBXM\1;^#5&C3N6%;G1.JCA[_ $%+YIMHP^-]/=9':- .HZ@&NX=H(X!06VUZ
M2^9!\5Y9QS$%FD-,\3.!)Y$$=G84-:-4VF77I_?6&W]SXO,7['26=I<L>YDD
M?GQB)W!U1](@<13M6*]!SMM+:T;>7OJS>C*5&DU7#W'1F1Z_MO+HV.S-NW.8
MFY!SPXU_]W"'D?MB%R%IZ6-R21ZZYK_-*EFVY^709GL3<F\-Q07,FZ=LNVZ(
MBT6;GRDF8TX_5N\3:>GFM6_:MP=(2YCK9+,7[R;NV^[X8[3,7+7-]DHC@H*D
M+AW<U<JR60A4A=PXHV05%A[$_P#G/_9"B1DM;RK53,$(*F'\F/6J2,L=A-52
MX0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 4 \J%(/4 0! $ 0! % "D! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! 02_DW>I$0]A2+*80@)%]_H4OK"M':8KORLMX
M%%<UT1#FI!$U5J7(QP4$F.9O9&)S#GS"/W:ZD-2^.E">\CO6U:S4H8;5TG*S
M>E6;^-.5]!J[<^RK[!G6\B6U=6DM.+?6%U[&9C-88,\1J&DSL8O&)9[#-;HQ
M,3F8[)O;&>30YSJ>JI*RRM0GBXHU+.<S%A4A-^DMU[E<KE9)9<C=>]9+PMUN
M(+S&.RGH]"R0@H*D50U+V8N7Y-SES/UEFO[Z1TKVR@F)K=,C75TD=A]!]*R+
M Q)\Q*]^M9V6['O,>1NVB-D U"'4TT!>Z@X5'+M/!5+<NVA*N6L#609%UE[W
M7ZSSSH! / @ ]OK4EDL-Y;;N\&,O+6)N2@MF/U.-I8VVLO#3Q+G4X#LXN"%E
MBN/N\Q@?4[,0V.#DR6*NG22W)= X&L<T4AX.#F&M.2U[S:6!V--L.<Z-;#0=
ME;W-Y=<G/E=XG4X#TU)X#TE84EM9ZB4&L$;.V[CG08:ZAMW-%XUCIX[EK2=.
MFGA%>=!4BO:K1M\TJK<8[DG;55CT$YLC9Y?LJ^M-4$T#Y;"]\P$R4'X0X&O8
M!Q!6TK:I@<E2G+M*6-4G'@0S8.PMK6UP61@;'8;@\RVER+SI]WN*-="\NY4#
MZ-<#]&O):%^;4&X_4JVN.'EYS7MW9WK\YPEC:>$:[5];^WCAPI?=N9*+"V.4
MW!FF21;RVS8S86\<ZACG:WC;R%U/R@T")W'Q"CN17AM2M7,S.W:C)2L7Y1G'
MBJ?,NK&N.S9N.]*,8)1MK";K2NS!I_#R9I;'YO-8FX-QB[ZYM'@:JQRO8"3Q
MJ6^R:DGF%[N45+:JHO=LVKDJR@I<*K'T[2_S]1>H%Y;>ZW6X;CR2 UX9IC):
M>!&N)K7<O2L<;%N+JDJFDLC8@ZJ-?WI->AMHQQS&M+&.J86$N)/$GO/_ !K;
MHE1;C:6-&7NQV[>Y"TFO8&F.*V<UCG1ZGDF0$@AC16E!S6&_?C:DDT^9HQW+
MZA)1EM>/467(X\65RZV\S5)P+B/3QIW"GI*)J2JJX\39A+F)L%E;>099YV%Q
M<0+?B9#QXD]GW5*^:C6!L*572GG,\V-M0Y.5]UY)AQT(UR5'MTXBOR]BV'RO
M""HO6SG9[.*S&BVLO>Y_(%F)A ?>"YT$(8* N+:_/0<^T!1;59&A8;X]9:[A
M[[QN/?<%HQ<$3776L$LU%M1RY@.'9VK/L;6\I#L.27SMT5/69)8/DNK2TCE8
M!XO>&EA=H=X=(%3W JK.;."BVUU$V,MDNS=1.U1!@AX<CQYCY>U0'@J,G%\K
M)VZX]#6D21RCQ#S!RJ>VG<5)1)-&^ND.V^GW4.Z=:Y'!W5O?XZ&.2X$=VYV/
MNG$T<XLX.82>;1X5S,W=N6EV6J/HQ._I>3RN9ERRBTX[<>RSIK'8S'X>V;9X
MBTAL;5HHVW@8(V_+I'$KARDY8R;?6>XMVXVURQ2BN@JB235020%6*DH\U!4A
M(5D5)2DJ0HT"IL?9G_9#[P42+VMY5*IF"$%3#^3'K5)&6.PFJI<( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @,<R#-\!VK%S8QS*>
MQ<1W#3\['N^\N9>_.?\ INW^\I>U,PR5S<UZS#\KO'J/@'&3*86U?:M]J>W$
MCXZ?L@]Q;^V"X69U'4,OC.W%QXQ3I_FP\]#5E>O0VQ126O6N-@!R>+#(^3I8
M9FG[CP/\)8;7B:KI*V_,_=3WF-9])5DO69AA^HFULP1''>>ZW#N4-X/*/R$G
M2?D*[F7UC*WZ)2Y7P>'KV>ALVX9F$GM])ER[1LA $ 0! $ 0! $!8MP[IV]M
M.P^TMR9*WQEF/\9=2MCJ1V,'-Q]#:J\;<IND55F&[?A:C6;44:0W)\7&RL=(
MZ';>*O<\]M6^>X"QMCW%KI Z0ZO3&NE;TZ<OF:1YV_XBR\'2%9^I&#P?$]U:
MW;??9.R]I6<M_(*-BA9<Y"1C?PG$.B8T#M+^"V7D+,%64GZ4<^&O9F_+ELVT
MWZ?89RRY^**WP-UGLUDMNX=MJSSG6#[9T\^@"IXPN+ X#DW6?6M&[<RD,:2?
M4=:5S/1M2N3Y515I[MYK^]^)7J;MZY='.S&YB.,@ROFM9;6@K2H,4Q#>)I5R
MV+66M74G1QK^U7W'E\OXIOS<H\L7RO;1KWF18'XQ;=Y9'NC:TD()HZYQEPV?
MAW^5,(C_ ,LJ9Z8Z5C+TH[%GQ/;?SQ:ZG[C=.S.KFP-^Z8MOYB*3(D5^S;FM
MM> UH?JY*%WK9J"YMW+W+?S(]%EM0L9CY))OAO-@+ = \-!Q* PW,]2=L8<N
MB]Y-]<MX&*T^MX^E_!H^=<'-:WEK.'-S/A''U[/77H-6>9A#I,-O>L^0<XC'
M8R*%G8ZX>Z1W[EFG[Z\_>\3S?X<$NO'X>TU)9V6Y&,7W6'=$5W:6S[N*"6_N
MH;2&.*W#J27$@C;7431H+N)/8J6-6SV9E2'+'RZ:FN\])34*I.3PP*SJ)=_%
M!MN!]WL*SPNZ(&L),,CW17FKMI YL#74[-,Y<>Y>URN5N8.[?=>"A&GII7V'
M24;^^2I]W'V^XY]L/C1ZYX3*7.#W=LK'S7]CXKVTD@N\5=Q-)IX_-DD:*]A\
MM>JAID;J[#;]!DE=Y-IMC9OQR]-\S(VTW?C+[:UR\T=<$#(V0)-.,D#6R ?^
MY^5:US3;B^5I^KR])=3.CMO[CP.Z\9%F=MY.VRF+FKHO+*9L\9=S(U,) (KQ
M!XCN7,G"4'22HS(FF7Q5 0! $ 0! $ 0%GS>?PNWK-U]F[^&QM!P#YGANH]S
M1S+O0U9;5BY=?+!<S,-V_;M*LY4\MW$U1G/B)Q4+C#MS&37[AX1<W3A:Q5[P
MVCGGY0%Z"QH4VJW)4ZL3SU_78QPA&O7\/I1C$/5WJANB[%AMZTA9=O'ACL[8
MS.: :5<Z9SFM'I< %T'I64LQYKCPZ73V4.9^K9R_+EMX-_92]_,C/,5MGK%?
MP^?FMVQXN0L^KM[>WAN"UW9KHV-O[DE<F[F<C!TA:YO.T=:SEM0GC<N\G11-
M^JB]9HF]ZU]7+?+0XG%91UY<R2F&"%MG#+)*[B  P,)XTK0+T=S2\IRU<4EQ
MJU[SCY'4<S/%R>/U:+#_  UJ7#$_%)ONQD\K-8VPR+(W$2@-EM)Z@\02'/:"
M/\VM.YH=B7RMKU^7I.W'4;BVI,VOM/XDMAY]\=KE_-V]?.HT>^4?:EQ/(7#.
M ]<C6A<7,:+?MJL:371M]!OVM0MRP?9-O6US!=P,N;>5LT$H#HI6.#F.:X<"
MUPX$'O"X;33HU1G23KB51( J>2 TSO?XE>FVSWR6=I=OW#EHZM-IB],D3'CL
M?<.I&.5#I+G#N7:RVC7[JJ^PNGX&I<S<([,32>=^+O?%^^1N!Q./P]L?R;I_
M,O;AH[/$3&RO_NUWK6@V8_,W+U+R\YH2STWLP,$W9\0W6/$Q2OS6<N[.>./S
MFVD-K;V<FAS-3:CRFN <VA!/8L_Z?E(0<U!-+I;]Y2-Z[.7+S'4VQ]@Y_+8#
M$9_,]1-Q7C\E:P7S8;>:*SB N&-D#2-$CC0.H?$O+W\["+<8VH*F&./P.C"R
MWBYLVY:6@M;6.W$LD^@4\R9VN1W[)QYKDR=6W1(W$J(K% " ( @" ( @" (
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MYR\DOKZ0GZR4U#!^"Q@X-;W!H 7MK5F%J/+!41XN[>G=?-)X^7E@39<1E+?
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M7M3R3*?+74EI8E\7"22@8X\@TN )"E(B%)2H?0:P8R.QMV1-#8VQ,#6M %
M*  < %\JGC)UXL^C6Z<BIP-0_$I_Y6Q?\\?_  #UZ30/Q9?=]YYSQ!^'#[WN
M,>^$QW_9>[&=HO[<_/ ?UE;Q!\\.I^TW=(_".C5Y<[1\V=H[ROKCKALV":*,
M65WG[6%D8'C9YDOA.KF37FOHNI7.3+O?S)KU'EM.R%NW11;K%KSGT!WCN_ [
M&P%YN3<=VVTQ-BS5*\^)[G'@R.-O-SWGPM:.U?/[-F=V?+':>HDTL6?.#JYU
M5R_5O=3L[?Q^Z8VV:;?#XT$'W>WU5\3A[4CSXGN[^ X!?1<ADXY>"BMKVG'O
MW')F.;8VWFMW9NRV[MZT??9:^?Y<$#.5!Q<Y[N36- U.<> "Z%Z_"S!SDZ)&
MHK;G*B1N;)=-<ITDS$6,S,0EN)*3,R,()BNHZ>(1.=0^ FA:>/;VA:66SL,S
M'G@_-P.1J5B>,)*F&'Q\MA+P6;S&U=T0[HP5PV*[@!\NHU,?&\@NCE;P\) H
MX<^T&JR9BS"]!PEBF:F5O3M4>*DGQP?T=9VAT\Z@XGJ#A6Y"Q_D]_!ICR6.>
MX&6"8CL/TF'FQXY^@@A?.\[DYY:?*]FY\3W>5S4;\:K;P./OBGVDS+]0,O<B
MZ,3)H[=MRTMU$L%HQH+/6.!7L=*CSY.*?3_F9YV]G7;S<XM;&J8\8QVG973F
M%D/3S:<4?!D6'QK&5-3I;:Q@5*\3FTE>FE]I^T]-EFW:A7[*]AYN+J#LO:MY
M!C]QYB"PN;FGE1RZ^#7&C2\M!#&D_2>0%>SDK]Z/-"+:7EAQ,=W.6;<^24NU
MY_73892Q[7M#VD%CA4.'(@K4-LF( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @)3Y&1,,CR&L:"7.<:  <R2A%2B&6Q9@ANQ>P>[7+FQVTXE9Y<KWF@:Q
MW:21PIS5G"56J.J,??0HGS*CV8DWWZT-T; 7$9OVL$KK;6WS1&30.+/:TD]J
MKRNE:8<2W>1YN6JYJ5IOZR2,QB#9NOQ?V_V>TEC[GSH_):X'207UT@@\**W)
M*M*.I7O[?+S<RY>-<"=[_9"ZBLW7,0NIF&2*#6T2/8WFYK>9 5:.E=Q9W(J2
MC55>[>2FY7&.CN9FWT)ALW.9=R"5FF%[.+A(:^$^M3R2P5'B5[ZW1OF5([<=
MG7P)OVC84MS[U#2[_P!%\;?KO#J^KX^+A^"G*^&PGO(88KM;,=O5Q*U09 @"
M ( @" I91XUD6PPRVDM20$!:YFZ;F9@X#@X>HA9([#4FJ2:'>DB$1=R,LB(<
MU!8F!599$;%!9$T(R3R2&.=AAE:',D%"T\B$JUBBSBI8,YHW]:BYS-XP-;!:
M6TVG6T:6AY'A:.\@+TN6?83>T^4ZK^-)15$F8H^"62+R+8 .'$3Q#74=K23R
M6V<-=!8;[&1N8^&[:))KP>1HEI]2QY'$'EK=V@(;$;CK5;B+)V]OCV1N\MS<
M>TBW>(3[#-):)"*]W!W>A$).3Z2GM66\GN=Q:2,8R#2(O+;J):T$-<UQKQ:/
M#I<*40LZQ37$DP7V79=S0"[BEAF>?(+;=K)HVD4+/%4$#F":U0EPA1.E&5\V
M.?.!:7#&2%C&^:"P-%0/$YH'  ]M%62JA;NN#JG0TUNGIW@,S=WTFWG^ZY>T
M>6W=H\Z'FAH)&,_QC#SU-Y+5E8WH]1E]3N125WY6L'PZ'TFOI-F9>P>'W<0D
MAJ?KH7!X/K',?*L:MNIVHYB$]C*&\LS YL#@:-]D!IX+*D1+ EB!_EC0TZ(S
M4GM)^16IAAN,B=5U$VUL<C<Z6P6CY-3O#0'2=7)53P#E%;S.=O[9R\+_ "KV
M-S6W;:R0BGE. /&IYFGR*&N9UIBC5N7;.UM-HS2]P/DVL%TYSX@UU=3'&, Q
MT(H!RY=BSP5,3D7LYS.B)UOOD6UU'8WS63N(\'F-)E ^BXNCH6CU\:+*<UY%
MRCS(R6\@QES8N?<Q:9YF%T;)B9I!(X<#%*/:%:<Z44&ES-2P?H^!A-N^.XR7
MNC0]EPP-\Q[CPH#0CP<JGDTH=&2<85>PR3-W,MKAY;)KY+5\S>$[*-+&LH7.
M-:BKAP'X)XH:EE5N)[>@QO'6QNM8\G5+<!@?.XE_!GLC43P#:#E[7:AMW)4P
M>Q;C();2:R=YOO3G3QT$M?8<'\74K75Q[2AI\ZEM17R6AA$4XE9(Z5H?%/#]
M7Q[6$@\"/2I,=<3,-GX#J/Y WIL-TTS[9QCF;8S1ONV.'$1S6Y(+FGNH0>:U
MKURRWR7,.M/VG6RN5S27?9=8U^K2O[RWG76T<CF,OMK&Y'/V7V9FKB$.OK(B
MFB7D>!X@'GQ7F[T8QFU%U7$^CY2Y.=J,IKEDUBB^.YJAF9 Y000'DI1!+>A5
MD![%**LENYJQ5DN5NH!C>;J ?*5*PQ*M5P+I2G+D."QFR>(21-&IX])1A;2L
M6(SA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M.>BXYB::^LWYJNC/I>3N1G9BTZX)>>F*.9?B5'_C?*^F"V_@&KVVC?RL?/\
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MGA'Y;J-]+"333V4'9VH;4+$:5I4M-M<P6.1=FG7$;,B0ZLNMT=8I!H,0,=2
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MY4H]EK_U.ORZ3>T]R683MQ5R4I?Q(O\ ]#HC_BQ6SEY&=&+SY]"" ( @" (
M@)$[>(/:5>)CFB0K% @*2^BX,N/\GP=ZC^L5:+W&*ZMCX%,IJ8B,&J$D;"H)
M1'S44+$QI0LB,<E!8C!0DF-[$)(E!(:[57AP'#CVJ"1*P31^621Z1S'I45IB
M&JJAR+OS9E[MS/WXE8Z3'&X^JN2#I!G)>S4>7$U"]1E[ZG%4VGRO4M/G8N2=
M.SS;?68%<6<DVN*9I\QCO""./-;1RL4Z%SQ_3S>>5BDOK3!W4UE$'QRR.C\L
M.=&-1=1U">"PN_;BZ2DD=&UD<S<A6,)-+?3W;2TW$FBR9Y 8V6C6"0:26CG2
MO/CW+,G4Y_(T^U5=#P)-G?S$.CJ&/<=,D?)DC3[6D]CASHI(E%/86>\M(F23
M06[VN;,*L,CB [3V./>.51V<T-B$J;2T6^$N99XXX8&ETE&N#"*:O03R^7YU
M5X+$W(W%)J)?'[+W%CXA)EK2>TM9FZ[<&.K'<?"XR-%*5[ 5CC<C+>C9OY>4
M%@GU[BWC'73[D6L$>B\D(C,.D'7QH-([SR 6;"E?2:23;Y<<=E#-LMTRWEMO
M#-EO+:::RN(F73W0QO&C5PTN'80M>WF(3=$\3<OY"]:I)Q;5*X(V+\.NQXKS
M<#]P9?'3:,7&U^,N) 6Q"XJ15P/%Q:TU'<M34+[C;Y(M8^D[OAZVZR;BTEBJ
M\3JB>&&>-\,PU1/:62,["UPH?N+SNP]FU5-/8SC7*]%<HWJ/<[(@O8;.&\BF
MO\+=7#7%MPQAKY3=)%'MKXO4O3QSL>YYZ5Q29\_GI4EF7:JE6K3>]%+^A[K5
MLS(LRN!M)F7T=0V\Q=PQ[G,[BVH+FGM:YJK^<L35);.DEZ=G+,^:$77]EF16
MGQ#=4]FS,L]]X)EVT=LT,F.N2/Q2 8R?VJP2R5FYC!T]9LPUK,V'2]&OFH_@
M;HV#UOV/O][+"TN3C<X[A]D7I#)7._Z)P.E_[4KFWLK<M;55<3T&4U.SF.RG
M27V6;**UD=,@?S"L59 Y0R" \D((7<E)#)2%2!QYJY1GMK&))O-^C"*#]F>?
MS!59:"QKP*U09@@)D(U/X\AQ59,M':52H90@" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M9XVR1/%'QO <UP/80>!0JTI*C5485E^D>S<KJ=';.L)7UU>Z.TL/_NWA[?F
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M  [@M0L34 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M4CF0\YB<HYD1"1AY$**,FJ/00>2@D]0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! 8%O'=4L1;@,()9+J],]G>YFR,4S,+(8=3)[IKCX0*ZO%IX
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M2JN'O(RN0NYZ7/)OE;VO_2=4;(Z<;7V!:.M\!:Z9I0!<WLQ\RXEIR#G< !Z
MN!>S$[K[3PX'M,IDK66C2"ZV9DM<WP!1 >5" :@IH14EU]"<J(J0D]RN5/$
M4$'E?N*2#374GX==D=1\@W,2/DPN7)'OL]BUICN6C\-CN&K\=O'OJNCE=1NV
M(\JHUT[C4OY.%QUV,VK86C,;C[/'1O<^.RACMVR/XN<(VAH)])IQ7/;JV^)L
MK!)<"H)0@@<:(0R4?0A4\*L5/;6/6\W!]D<(O5VGY5$GN+6U5U]!5J#*$!'&
MS4_T<RH>!,54JUC,P0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! 0.D:WF5*15M(@=-3D/G5E$JY$HR//"OS*U$5YF0(
M5"$A $ 0! 1A[QVFBBE2:M$P7'>*^I1REE,C;*QW 'CW%0TRRDB8JE@@" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" (#!]X[DNH)(=M87SK?+Y:.ZCM,Y' VYL
M;&:WC#ZW3JT94'AP*V[%E.LY4:C3LUHW7@<G.YN46K5NJE-2I-*L8-*O:X&
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M=#*O =2[7.Y^WP!Q%]CKRXBDG:;UC8QIB''AJU&O8:*'"BJ2IU=#/E0R! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MH @" ( @" (#6^3_ +;,%_4US_".5_JF+Z_F-D*AE" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MV94J$:@L$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MWMH>]>?U3)]U/GC\LCZ!X7UG\S:[BY\\%@_M+XKZ>)K[H6/_ -\N2_893_:
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MX?<2 <#=7SR?+!/.C=1/R+TNK3C;LJVM]/4?.O"MB=_.SS#6"YJ_>D]G3O\
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M?[R^^OZ-Q/[BX_CT_0K'&7J^ _6;W"/H?Q//[R^^OZ-Q/[BX_CT_0K'&7J^
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M<%BNZ#;<7R2?-NK3X%[>LW.9<R5.BOQ_M.G&.:YH<TU!X@KQQZLC0! $ 0!
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M_P!,Y'_J_P#%I^O7/LKUC]&A]IGG]V3:O],9+_X'\4GZ]<^S'UC]&A]IGO\
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M_(.*4(;2(FQW$IU?D6]Y%2?D[/E4,E)OH*B.&.+V1Q/-QXD_*C;9=12(T+!
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M2IT8X5]9"MRYL**Y2/-/EPDJOL[=NW?A6N.PO%A86.-MF6>/MX[>U87N;!$
MQC3(XO?P'#VC4K%*3DZO:;=NU"W'E@DDMWM*]09 @" ( @" ( @" ( @" (
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MEU.I7*#*$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M! $!Z A!$QA?R'RI6A9*I.CA#.)XE4J74:$U5+A $ 0! $ 0! $ 0! $ 0!
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MX*2*8^TJH86PPMBB%&, :VI)X 4YFI45+I4)Z$A $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0$IT+#Q H?0I3*N*)9B<WF*^I7J8W&A*4
MD! $ 0! $ 0! $ 0! $ 0! $ 0$QD9=R'RE&R4JDUL+1Q/$JC9=1)JJ7" (
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MIPJ7M8S;" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @('L#VEIK0BG#AS0@]:-+0WN[T)(
MD 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!"6-
M=P(4U(:J2G6X[#\ZMS%' @,4@[*^I6JBO*R @H5/$ 0D( @" ( @/3P0@<T!
M&(WGC114M1D;;?\ "/S*.8MR$QL3&\A\ZJV6441J"P0! $ 0! $ 0! $ 0!
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M'%=GM<$;YLIGS6\;YH_(NG1L?-;DASHR\>R:=QJN \&>]A*J3:HZ;.!6H6"
M( @" ( @),YY#Y5>)CF4ZL4*#(NK)%'W5D/R\ KP-:\]B*9@KQ5ZF)(C')0R
MR)@HJER-K4)2)H%?4J-ETC7?6+IV[J!MH16&EFX,6]UUC'O.D.+A22$NY!L@
M#0">3@.RJY>H93O[=%\RV>7EB>U\*ZXM+S59_A7%2?1PET\OLJ<?ZKJQN9;*
M^ADMKVWD,4\$C3')'(TT+7--*$%?.[UAQ=&?HFD+D5.#4HM8-8IKB5K+[P@5
MY\!0??6D[1@=HDW%X'-/'T$%7A;,D+1L_H/TUN]TY^VW?E+9S-KXN436ID!
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M:+8F@ GTFG%>7NS<Y.3VMGU/+6(V+4;<=D4DB[+&; 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $!"YP:"2:-'- >@@BHY(#U $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $!"Z-CN84U(:(/(9V<%/,5Y4/(;WE.8<
MA#Y'I^XIYB.0]\@=_P!Q.8<I[[NWO*CF)Y!Y$8[_ )TJ.5$?EM[E%2>5$2@L
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 63<>"
M@W%@LA@;B::"*_A="^>!VB9@=VM/Z_J5[4W;DI+<S6S5A7[4K;;2DJ51I6]V
MSMW:>_-E;<DDW!>75CCKH6]S X&W>PMG<:T\0(U.\+.7@')=R-Z=VU<G2"JU
M@]N[R])XFYD[&6S=BU6[)Q@Z.N'UGUUV[-BY487B(=I_86S&Q0;G$0W%,;<G
MRM?FUM^+M(I3V*:*.J)%N3=URN?)\B]&/D_,<.Q#*]W9HKU.]E39M['DJ8_,
M2LQ%M/['W>'V^YPS\X(_//@+-=9^>H:3].A?XJEBM;[WFA3D^1T]7EZ2F965
M[N]A>_%C792O:]?'?\IEV-W'@-I;[WEN*UQNX;N]LL=;^;%<D&)[?J(Z.X:A
MS:6N?6@#J+3G:N7;-N#<4G)[/.=FUG+&5SE^[&%V3C!5K^ZL=_"C>ZIO3;6=
M9N3;^/SC;>6R;D(6S"VN1IE9J['#Y.![0N#=AR3<:UH>\RM_O[4;B3CS*M'M
M+XJ&R$ 0! $ 0%+-[961;##+:2U)!:KLZKF4#LH/F'_&LD=AJ7'61X.2L5(V
MA4;+HEW%U:VEN^ZO98X+:($RS3N$;& ?2<YQ%/E*K*2BJMT729[=J5R2C&+E
M)[EM,-N>L_2VRE,$VY;8N!()A;+.WAS\<;'M^ZN?/4<O'Z_HJ_8F>JL^$=6N
M1K&Q*G31>J33,AV]OG9VZ7:,!FK6^EI4V\4H\\ ?B.H\?,L]K,V[GRM/RX'-
MSFC9S)XW[4H+C3#^]BC)@LYR#"=[=*-F[_TW&8M#%E0T-9E+-WDW08.37&A#
M@.Y[7 =BT,QDK5_YECQ/5:3XBSNFX6I)P^Q+&/Q7F:-67'PJ#SJ6.ZWLMN>F
MXLFO>WU.9-&#^Y7$GH:;PEAU?2>[M_\ R)AV["YNB>'KB_:9)MGX:=F8B=MW
MGKJYW!,PU;#<:;:T)!J"8H_$[B/I/+?0MRSI%J#K+M''S_CO.WX\MF,;*>]5
M<O2]GF53<]O;06<,=M:QMA@B 9%$QK0QK6B@ #:  #L"[25-A\\E*4Y.4FVV
M]Y5Z12I5JE*%HS.XL#MNU%[GLC:XZWY-DN96PM+NYNHBI]2PW+D8*LG3SF[E
M<G?S4N2S"4W^RJF'?IVZ2>;Y0W-;ZN6KRIPS]UY5/NK4_/V*TYO4_@>A_I'5
MJ5[A^F-?1S&987<&#W':&\P>1MLC;5H9;65DK17DTZ2:'T%;<+D9KLM-'GLU
MD[^6GRWH2@_VE0N^EIY+*:9"YJE,AH@IW*Q4\([T(H0N:I(:);F]Z%26:4XH
MB"2X4-$*$MS5<HR615"I"TZ)(G]Q'W>"/%$+!HNIYJIM$41\;?6J[BRVE6L9
MF" UMD_[;,'_ %-<_P (Y7^J8OK^8V2J&4( @" (#PBJ@'JD! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M_5,7U_,;(5#*$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0'E0@/4 0'E0@/4
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MXR<=7(<2?$K5Z7Y;C$XMI=E?-[WVMFWRJ2KJUF?;Y%HQ=I.^:6,QPRO;HN@
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M*Q=[V?\  M_@_:W\JP^;97!;,%\Q2X/#YIF6V&7;,PD;&XV[\R1EPTOCKYI
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M#=9KVMUD^OCV+-JDG:RRBL*NGFI4T?"T(YC4)7)XRHY^>J5?6=<:1S7CZ'V
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M-N+6ZC9-;SL-6OCD&IK@>X@KS<HN+:>#1](MW(W(J475254^@KE!<( @" (
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M7=Y3]2]SXO8VSI!>X[S6&.2,TBN+R5M=9/X$+">/[+N5-/L++6Y7;F#]WT_
MSZ_GWJ68AE<N^:-=VQRIOZ(_[N!T'LK:>/V3MNSV_CQ5EL-4]P?:FG?QDE=Z
M2>7<*!><S%^5ZXYO>?1=/R,,G8C:CNV]+WORZC)UKG1" ( @" ( @" ( @"
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M!XT\MAFJU3KA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MWT\O.2=Q-JK[>/S+HZ,=OHJMPXG%OS.^Y)-EY6\?<82W9/=PS.;%?,#8P((
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M4Z'4X@^R>!["?;Y'.K,1_:1\!\2^'Y:7>3B^:S/Y7PXQETKUKSFTUTCR 0!
M$ 0',_Q80S%VTKFE;</OHB.P2/\ )<*_(UR\SKBP@^OW'U[_ ..Y1_\ (CO[
M#\W:^)H>P(X$=O'U]_RT7AKJ/IUTR"V?&!4\.VBYDTSF33)5T]CN([>7R\PK
MVTT6MIF/7VFIH/16O(KJ6CJVCKCH)!+!TJP9DX"9UU*P'L;)<RN;\E%]+TM-
M9>/G]K/SYXUG&6K7:;N5>=11LA_M+JGAV27]BN8V3+1M9)9.SA&/OE59>"Q;
M*I092?;M%2_Y%21>")ZJ9 @-;9/^VS!?U-<_PCE?ZIB^OYC9*H90@" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MM8;RTE9/;3L;+#/$X.8YCP'-<TC@00N>TTZ/!G=MSC.*E%IIJJ:*U"X0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M^X*U"Z^3RTKLU&**YW.6LAEY7[N$8+TO=%=+9W1AL5:8+$V&%L6:+.PMXK:
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M::>QHK4+! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M>?%M<US-:E=_C=F,?E@MD?B^GW&:/-%T#R[))4HHSR)GF3C_ "47$^D]@1O
M159="*Q09B-C=4E.SF5#9*565:QF8( @-;9/^VS!?U-<_P (Y7^J8OK^8V2J
M&4(# >M/]E^Y?YLW^%8M_3_YB'6<'Q!_U]W[OO-+]#^I>T-C8#(V&XKM]M<W
M-Z;B)K(9)@8Q"QE:QM<!Q:5V]3R=Z_<3@JJE-O7Q/"^&=8RN1R\H7I<K<J[&
M]RX=)?>J_5W8F[=BY/!X2_?<9*Y-N8(G6\T0/ESLD=5SV@"C02L&1T^_:O*4
ME1*M<5P9T==U_)9K)3M6IMR?+A1K9)/>J;BIZ.9MVV^B6=SX&I]A/D)XV4J#
M(V*/0#Z*JFHV^\S<8\4EZV9O#V9>7TB=W[+FUZ%[S">B>Q;;J'G,IN+=SG9"
MVLY&OGBE-?>KVYJ\NE(XEK0*Z?3W"AWM2S+RT(PMX-\-U#A^&]-CJ-V=^_VU
M'<]\G7:;]SW2S8NX,:_&SX6UMCI+8+JSA9;SPFE YCV '@>-#4'M7G;6=O6Y
M54F^AL^B9K1<GF+;A*W%<'%4:\Z_L-#]%LCDME=4[O9-U)JMKN:XLKN-M?+=
M<V8>Z.9H["YK2/4[T+T.I0C>RRNI8JGK/GOAR]/):C+*MX-RCT5C6CINV$GJ
M"+!WQ!Q-R0B.,=?8P70N=/D^5Y4.K7K\.FG.O#O5LK59'LUK26SK9BU;D>MK
MO*<O-;KS;*4CMKZS9W4*UZ*MVEE7O;A8YVP2&R?C?=Q>>]:3Y7E^1XR=5/Q>
M_@N3E)9OO8TYMN^M/7T'K=5MZ5^5G7NTZ8<O+S5W4Y<=OFXF+_"R;[_Q(UU?
ML[^2$_@^]$2:J>G3I^XMO6^6L>./N.1X)YZ7?L]GTXU-'VF$N\R_<$MI5SL7
M#<9&:+Z3K>.<,D+?V(?J/H!7?=U6^2OUGR^>AX"&5G?=UQ^I%RIT)T?HK[4=
M,[+ZG1Q]%W[ENY!)DL# ^PF:XCQW,0#+>O;]9JC/RE>4S&2?YKNULDSZMI^M
M+]*=^3[5I./[RPCZ<#F2^Q-^S;]IN>^>7G,W5W%%JXND=;ACI9:^E\FGY"O6
M0N1[QP7U4O+U'R>]EY]RLQ)_B2EYZ4;?I9T1U)W)=X#HGM^UQ\IBNLS:6-BZ
M9A(<VW-L'S4(XBK6Z/45YG)V%=S<VU51;?KP/IVL9Z>6TFVH/M3C&/FY:LI^
MA?2K;T^V[3=NX+&/(Y"_+W64-RT2P00,?H:1&X:2]VDNJ1RH.'&MM3SUQ77"
M$FDJ;,-QC\-:'9>7C?O1YY2JU7%)5X;*[R_]6.DNVLKMG(Y;"XZ#'9_'0ONX
MI;6-L+)V0@O?%*Q@#7!S0:'F'+6R.?N0N)2DW%NGI.CKFA9>]EY3MP4)Q7-@
MMM,6FEMK[2Q_#3N>YOL-EMLW,CI(L68[C'ZJG1!<AP=&"?HM>RH'XQ[%L:Q8
M49J:^MM\QSO!V>E=M3LR=>3%="=</-[SG['8+(YLYB7%QF67#PR9&XC97S?=
MXIFL>^,CMCU!_?S/,+T<[L8<JE]9I>E>\^;V<I<ORN.WB[:YNFB='3JK4Z<Z
M6=21OC9=_89*;5N?%6CVWE3I-Q"8R&7#1^-2DE.3NZH7E,[D^XNIQ^63P].P
M^L:+K*SV5E&;_B0B^;I5/F^/!]9@7PK?]\[@_F5K_"/72USY8=9YOP1^+=ZE
M[3&IK_;^,ZZY6]W2V)^ ARE[[ZV>(W$9#HWMCK& [5XRVG#@MKDG/)Q4/FHO
M:<V=ZQ:UB4K].[4Y\U57<Z<=YM;]('PY"O\ (\;WG_LA_P#_ (ZY7Y3/\7_>
M^D];^K:%PA_^*?\ L*+KM"S)=,,+?[8A_P#"\,\%R8K>,Q1QVCX7")YC &E@
M<X<V\*A3ICY<Q*-SYG58O?7B8_$T.]TZ$K"_A)IT6'9HZ8;ET&)=--_])<5M
MN#!;KP4<=]XO>\C):LOH[DEQ)<YP#Y&T%/#IH.Q;>=RF:E<YX2=-RK2GF.-H
MVJZ9;RZM7[23WR<5/F_U>8VUT\VMTKCREYNW83X;F2X8V$MAD\R.U!KJ$<;O
M'$7]H/=PH%QLU>S'*K=VN![+2\CI\;DK^5HZ\'\OFVJO]F!M%<X]*$ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! <P?%/3[:VXX@
M4%K=$D]E'L7J=%^2?F/E7CCY[75+VHF_#CGY\/G,ML3)--N^Y:+VT@?PTSQ
M"44[W1Z'>IM536+2G&-V..YOV&;PAF96;L\K<PKVDNG?ZO4B7\1F=N,[N/%[
M'QP,[[-AO+B%M#JN)F5:T]E61ASOVRMI%M6X2NRPK@O+I*^+LQ._?AE;>+BJ
MM=+^"Q\Y%\*^C[6W*6@4-O:&H'>^1-;V0*^!J\][JC[68C;[3L-Z=;\YMS(R
MR6]M=9+*/?+;:6R Q.>]M"X.'$CCP6W^8E9R<9QHVHQVG'MZ?;SNK7;,VTG.
MYLZV;5/PN;,-1]L9/CZ;?^)7+_6KOV8^OXGK?Z)ROVY_X?\ :9#NCHG@-U8O
M;V)N\A>06^V[8VEHZ+RBY["V-M7:F$5^K'LA:MG4KEJ4VDGSNKKY_B=;.^';
M.:M6K<I22M1Y52G!='0<Z[YV!C-J]0;79]I<2S6,YL@^>8,\X>]R:'4T@-X#
MB."]+E<W*[8=QX-5V="/F>IZ1;RV>C8C*34N7;M[1OW:'0/;NSMQ6>Y+')7E
MQ=V1D,<,PAT'S8W1FNB,&H#NPKSF8U2Y>MN#229]%T_PO8R>8C>C.3<:TK3>
MFN'2:PQVEOQ.2D@"F4N>)H/_ )5W:NM+^0\R]IY.U_\ I!^_+_*SJOSH?PV?
MN@O)49]:JCD[IZ&#XA[AP K]HYAU13\";M7K\U_(+[L?:CY#I.&N2^_=_P!1
M?NO>^<QDL_%TWVZ^0,/E,OX[<Z9;JYNZ>5;ZAQT %I<*\=7'DM72\K",'>FE
MT5Z-YU/$^I7;EY9.R^B72Y;(^7GV%TPGPQ81N-8-P92Z=E7-!>+'RX[>*0\V
MM#V.+@.79ZEBN:U<YNS%4\NDV,MX+L*'\6<G-K=L7I6)KW*66Z?A_P!YV\UC
M=&ZQ-U]?'0&.*]MFN#9(I8ZN#96#DX<J@C@:+I0E:U"TTU22]1YV];S&@9I<
MLG*$L5PDMZ:XKCN-G_$1?6>7Z983*69$EG>Y"UG@?SK'-;3.:?F*Y>D0<,Q*
M+VI/VH]-XNNQNZ?;G'9*46O/&1BO3_H+M[>.S\;N:[R5Y;75^V1[HH/)\MAC
ME=&*:F$GV>TK;S6JW+-UP48M+CU'+TGPO8S>5A>E.2<J[*<6NO=Q,=W-MC=O
M0;/6F5P63=-C+MQ$,S6F.*;RZ$V]U"#0U;Q!^5I:0MBS>M9^#C)4:V_0<W.9
M/-:%?C<MSK"6_C3ZLEY>8VEU6W]<W?1^PW%MV22T&X7V]O-*PD20QRL>Z5FI
MO$$&/R]0[UR,AE5^9<)JO*FSUVNZI)Z9&]:JN]:6&Y4;>/FH:]Z7=*NG^]-O
MMN<EGY&9^1SVR8VVDAA?;T>0VK)&O<_4*'5RX]X73SN?OV9TC#L\6GB>;T70
MLEGK/-.Z^\;^5-56WBFS8'3_ *(9'8V]W9J/-O?@HHCY<<.J&:XE?4>7<,%6
M.C8#J!'-U. IQYF:U)7[/*X]JN_=U'H]+\-RR6;[Q7&X);L&W^TME%MZS>:X
MI[@( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (#
M6&ZMLVN$L[V[M;!MSLI\5W<9_:5E9-GGR=Y<EM'AQ<""T@&@[OFW[-QS:3=)
M8)2;^5'G\YE5:3G%5M8N=M1JYR>QUVX>[T6>]M[SWV".X/GY.Z-\[:V9;CXA
M%M:+W1A$%WXZ!P!#?'W?(L\:4;6"7+S+F^?'<:4U+F2>,I<_=RY%2PN5.DMR
M=,,>'F*86\ADR)AMWVAM7UW<38P_^+Z61U"T!=QU>*@9^&#S5TUAC6ORXO\
MA]K?Y;C"T^U1-<OXG87_ )'9^ICOQP7VJ[<"MVYN"\V\<?-!9W4FV<P['V>,
MVM;6L<<^!9(PZGW9:[4&.(U5=ZUCNVHSJJKFCS-RJ^WU8&QE<U*PXM*3MW'!
M1MJ*K:KOEO2?S59MBVNK>\MV7-I,R:"059+$X/:X=X<TD%<IU6#/4QG&2JG5
M/@5:%@@-9[^S.<VSFK;<5ID?>\1C[*5USLVV8QU]?/<[0)(ZU=HCU!SR&^$-
M[:KH9>W"[!P:HV_F>Q=?6>>U+,7<O=C=C.L8QQM*G-/I70JIM]#XF983.6>=
MLH[NU<!*6QFYMBYKIK>1[0]T4K6DZ'LKXFK2N0<)-/T[F=C+YB-^"DO.L*Q=
M*T=-ZX%Z5#9" ( @" ( @" ( @" ( @" ( @" ( @" ( @" A+V-]H@)0BI"
M9F#MJK<K*\R(?/\ 0IY2.<@\YY[@G*1S,A\V3O5J(CF8\U_>5%$.9CS'=Y4T
M',SWS7]Z40YF/.D]"KRD\S(VSGM%4Y2>8B$[#SJ%'*3S(C#VNY%10LF1*"0@
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ER-U,/>.(4IT*R544JR&(\D8R6,QOY'_ (5385:35"VT>UYC
M?[0X']?Y5<P4:="8TT0DF#M*JT6)S5!=$P%06.?/B*Z<760;%O[!Q&:XL8?(
MS4$8J]UNPDLF ',QU(>!QTT/)I7F]7R3FN\CMWGUOP/KL+5<E>=%)UMO=S;X
M^?=TX;SG>UO!I#@01P((-0O#7+9]@N6RO]^%%K=T:O=%)<WG DGLXE9X6S/"
MT;R^'#IS=W.2;U%S$)CL86/BP3)!1TDD@+9)P#]$-\##VU)[!7V>D9-Q_B27
M5\3YEXWUN"M_DK3[3:=SH2V1ZZXOA@MYU&.'+DO45/C9ZA(0'GW4!"YU> 4I
M%6RAR%[%86DES)Q#!X6_A$\-/RE5D^55,UFV[DU%;S!)9IKJ9T]P\OE?P([*
M=P[@N;*3DZGIHQC"-$J) 1U%52I#D2WQ!21S$['Y"3&3ZN+K60_RB+F"/P@.
MRBSVKCB^@P9FPKL<:56\S*K'-#@06@ M([0>1^9=.M<3RCX$MSN'*IY >D]B
MN8FRKBB\F/2>+C[1[R53:9HJBH1H6*F)I%2>95&S)%$U5+A $!K;)_VV8+^I
MKG^$<K_5,7U_,;)5#*$!@/6G^R_<O\V;_"L6_I_\Q#K.#X@_Z^[]WWFG.A?3
MG9^],!D[[<>/-[<VU[[O#()IH=,?DQOI2)[0>+B:GBNSJF;NV;D5!T3C78N)
MXCPOI&4SF7E*['F:E18R6Y/<R^]6NE&P=J[#RF<P>*]WR<!M_)F]XN)*>9<,
M8?#(]S35KJ<0M?(9Z]=O1C*6#KN7!]!T->T')93)3NVX4DN7ZTGMDN+8Z/X5
MVY.A^?P4)#9KZ?(00$GE(Z*/14]VH"JG4;G=YN,N"3];+^'\N\QI%RVMLG-+
MT*AB70G?5ALK,97;NZ7C'PWTC0+B>C!!>V]8WQR_@Z@::CR(X\UMZIEI7H1G
M;QHMW![SC^&-2ADKL[%]\G,]KPHX[GY;4="Y_?NT]MXM^5RF4MQ &ET;(I&2
MS3&G!L;&FKB>RG_&O-V\K<G+E474^D9K4LOE[;N3FJ+I6/4<\=';3([VZNW>
M\I(C':6LUSD;MS>+&378<R*'5R+J//[E>EU"2L996][21\T\/VYYW5)9EJBB
MY2Z%S5HO7ZF4?4_%19WKK-@YWNBAR5SCK222,!SF":&-I(!X$CTK+D[G=Y-2
M6Y2?H;,&M9>.8UGNY8*4H+#;BHELZJ]+6]-;ZP=;2R9#!WP.F>1HCD$T1J^)
MSF"@U-H6&G?PX+)D,\\RFGA)>PU->T-:=*#3<K<N/%;5LW[O/P.G.F=MM2+9
MF,FV9![MAKN,7&@DOE,SA23SG<2Z0.;I=7NH.%%Y3.2N][)7'629]7T>.6_*
MPEEU2$E7IKOKQ:>#ZN!SWT!M(+_J%FK*Z9YEK<8^^AN(C[+F2SL:X'T$%>CU
M235B--TD?-_"T%//7(RQ3A)>EK PC-X_/;:R>6Z<1/?)')D88Q;4_+R1ES;5
MX[M;96&G;\BW[4H78QO?LOZ3@9FS?RUR>23PE-8<:?*_.GL-B]>=OP;5VKL+
M;]J 68^"\CD>/I2Z8#+)ZW/+G+FZ7>[V=V;WM>^GH1Z;Q3E(Y7+Y:U'ZJE_I
MYGYWB99U0V[<YKHCMS(6+#)-A+6PO96,%7>[FU#):#MTZ@X^@%:>2O*WFY)_
M6;7GJ=G6\G._I-J4=MN,9/JY:/X]14=!^I6#EVO:;1REY#9Y?&:X[43N$;+F
MW<XO88W.H"YM=+F^BJIJF3FKCN)54C+X7UBS++QL3DHSA58NE55[.K93H,@Z
ML]2\#M[;&1QMG?Q76X,C!);6EI;O$CV>>TL,K]).AK!4BO,TIZ-;(Y*Y<N)M
M4BGC4Z.NZQ8R^7G!24KDXM)1Q:JMOFVF)_#+MJYM,1F=S7#"RVR+H[6QU?XR
M.VU&1X[P7NTU[P5NZU>4IJ"W'%\%Y.4+4[TE13P7FK_9Z3%/AM:U_4++@@%I
MQUQ4'CP-S%P6[K#_ ($?O+V,XO@]5S]S[DO\T2GZD;5R?2+>,.Z-K#R\'D3*
M+9CA6*-\S2V:UD' &-P)<RO9RXMJIR=Z.;M.W<QDO*I.M9*[I.:5^QA"=>K'
MYHOHX?%%X^%D 9S<;1R%I:CYI)%BUSY8=;-CP/\ B7>I&-'&8/,=><IC=R!A
MP<^3OQ=^9*8&>".1[?K YI;X@.WT+9<YPR47#:E'IWG.=BS>UJ4+R3@YSK5T
MW=:WFX3TKZ"D4+++_P#BLH__ %A<3\]F^G^ZO@>S_0]'>Z/_ .,?^XR3/[MV
M9T[VG8.N'"3!4BL<?;6Q%RZ6"@;5FIQUL8SQ./R<R%J6K-W,7'3;M;.QFL]E
M=/R\6_DPC%+&OEQ][,5GZ>]#=[6C\KC#:6S9P7NNL9="U+":DUA<=#3WAT86
MXLWG+#I*KZUY>TX\])TC.PYX\JKOB^6GFW>@T]T\:[;?6BSQFV+\Y+'&\?8^
M^1T#+FS\LN>7:?"X-I6HX5;447;S?\7*.4U1TK3@Z^\\1I'_ (VK1MV)\\>9
MK#ZT?8Z<>BIV4O&'VH( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M"]-31TK/YS3\ZLK>;:E)*C=:5I1I\,=WHJ=8KR9]<" ( @" ( @" ( @" (
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M4IPH!R7</FS;;J\6R>'55J%:E%?W]GBK.>_R$T=K96S#+//,X1QL8WB2YQX
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M[%*[*F\N5O'J/G/_ /=#T=KOE61O<:D%O*I09".-NI_'D.)4/ E*K*M8S,$
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M1K*=*<S]W V6N>>B" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @-#=>NG.[M\9#$3[:LF745I;W$4Y?/' 0Z1S2T /(K6A7=TS.6
M[$9*;I7HJ>$\3:1F<].V[*34:UQ2X<693U$V'>[MZ;18&WB8<_CXK:>Q87-
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M1"\^?1 @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M<RHJVN?Y>7^'3_5ZC<TUW'F7W-.?F_CUV/[G17F\_P"R=##DN >^/4 0! $
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M9*2^RF-QH:;^]@M/,J&>?*R(.([M9')3&$I;$WU&*Y=A;^:2CUNA3_G/MO\
MIJQ_UF'_ )ZR=S<^R_08OSEC[<?[R^)-LLMBLA(^.POK>[DC <]L$S)2T'D:
M-K2JI*$H[4T9+=^W<PC)2ZFF>9#,8G$1B;*WUO8Q.%&R74K( 2/3(153&$IX
M139%W,6K2K.2BNEI>TEXW<6!S!+,3D[2]<T5+;6XCF>!ZF$D*9VIP^:+765L
MYJS>^2<9=33+NL9LA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M?:?*E'L-?7^][3?TZ4UF*VX]Y)R_BQ>RT_V/\2PK@N4Z-7GSZ$$ 0! $ 0!
M$ 0! $ 0! $!XYP:*E2D0W0IG2%Y[AW*Z1B<JDM20$ 0!S@UNMY%.TUH H!1
M39*)G" >:>\\!^N5D4.)KRO+<44EQ<3<))/#_DQP'W%=12,,IREM9+H K&,]
M0D(0>T*$T%"@H>4*"A[0H*"A04/*% >T*"AX@/#2G'B$!''++!^3E('=S'S%
M0TGM+*3CL9619'C2>/C^%'Q'RA8W"FPSQO<2MC?'*W6PAX[P51F=-/81(2$
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MGTFU%Q@HMN5$L7M?27!09 @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MLP2U'*]TKCG'DDZ)\7P^)J_=]ACMO;GGM]L11;@GCBMF?HV:V..TM8G.UNO
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M9+E[ZWS2[E*79E_S]+?HQ?VN5]K$Z67FT?1PI 0! $ 0! $ 0! $ 0! 2Y)
MP>D\@K)5*MT*<N>X\3572H8FZD* (#WFA!03Y&-E60#SG]_T!\O:K*-=IAE>
M2P6)0R/DG=64DGL'8/4%E22-9MRVGBDJ$![0H6/0$ H$!#))'"-<DC8QWN<
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MSKS,ORGXE)?9V57VL'B9QDNGG7S?4MO:;LE#;*!X+7W-Q;"!CC5I?Y5K74X
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M!+7M!/, MX+R>8M=U<E#@SZUI^;6:R\+J5.9&3+ ;P0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M>DI*+5$[G,W_ .O_ ,7[%4]NY8I+F[*VDL2&DDHM'VD4'AN=M\!^>!X@W36
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M4(" I[N[;;MX4,Y' ?JE2E4QSGR]9:G$N>7R$EQYN/:LR5#3;J%)!$!1"3T
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M1R,5%W(*E-J/HWA[7KDKBR]]\W-\K>WJE[O0=(+SI]&" ( @" ( @" ( @"
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M' \GAR,+8WV,3I0UVF:UD\3M![6'MIW(6[-*,N5AD[>">7R]3'1\ TF@KV.
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M,UMK%^NI] XI1)$R0<G@'YQ5?/3]#)U1,0D( @" ( @" ( @" ( @" ( @"
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MX=Q6 W(RYE4F(7" G0/'Y/Y0J-%XLJ%4R! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M\+<N.Y-R>UGW;*9:&7M1M0V11>EC-H( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ("3.[DSOYJT48Y,IU<H$!3WL_
MD149[<W >CO*F,:LQW)<JZRU-&D =@6<TD1 *&RR1,:U06(N 0 !0V62-?\
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M7T(8Y8+RKU'M_;L?"V.ZD:R6V<UHG)]ME:!KW=M?PNQ21%NN!B6X;N\DT6@
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MF-S]/,-8"27'MX+H9'+RN74ULBZMGG=?U"WE<M*+:YYIJ*WNN!QTU@C8&CD
M!\R]L\3XE2@0&\OAVWEC,3<Y+:N4G9:29.6.XQTDA CDF#=$D1<>&LC26@\U
MY_5LO*24XXTP?N/H/A+4+=N4[$VDY.L>E[UU^TZ>7F3Z<$ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!+F-&&G,\
M%**R>!2K(8@@*:^F\FW.GVI*-;^O\RF*JS'<E2/66P<N')9S3(@/F4,E$8%%
M!8C^\JMDHM6Y;]^,P=W=1<)-! -:4KZ5FL0YII,TL]>[JQ*2.?;R21\ID#1)
M',ZEP 6G@[Z7'F05Z9*BH?*KDFY-[GM,?N+R>W>;2^Q_O,K7!EO-'5KG@GA1
MW<.:FI10W,MMW+:02R0V(<^XF(=J=X@TCL9PIS[5!D2PQV'HP%_:PC)"1EP3
M%+6"0>-SYAP#9#X:\^+@J*.)FE=YDJX8EB-^_"6(O?*%I<2CRI(I:.$4$?MM
M8T\'$U#:D=OK5B>3F=-O3[V6_(V$3LC;WUZ2ZTCD$[H:B.-T\K::7@<_#0"O
M)#-&XU%QXX5,FM<Y:0:64C-HUGF01$'S(P\\G-!I0T\*DT^[?34L&9W87Y2/
M$6=HZ^B\3[R[TTMXI#P:PN(X]]!R3=4W+>6K!S;2HTDM_64%]+?Y4MQEB&P6
ML4C6R&YJ8)W/%7LC>[D .Y06ARQ[3JVZ[-W25619MG'0M@GF;)+:::RM!=$V
M0<.!YNTC@"ABAWDL5O+?+DK*P,%SB'LDT/\ -C=$X\7]Q;S(/:U#,K<I5JNL
MJK 76Y9AF,Q:EF/@G%IAL8YQ='+,:>?<2@4U!O!C&\@I(N*-F'+#YFJRK_E]
M_H/,I-;,O9L7!2!EZ7C&7,?^+NHCX0">QQ!%.Q"()M5>-*5702KK;>7F;[QF
M\NZ2 ANO'VXT-;(PZ@6NK74. =3FHV*A=9B"7+"*7[3*/';=NKOS,6Z\=%BW
MN;,RX)I);L9XWOXD<2ZG#T\4+2OI4E3%+$R.RV_-E+Q^,R5W[M>VS-<%Q;T;
M-(UW 2L;721IH3Z4-?O5'%+:]AD67E?;6ECCK8@W,YT6\LHHX,M64+S3D2*U
MIWJ36@DZO<4-XYS<9<7EI:,RF6LV_66S'N8VC3XFGR^)<!6A[TJ7@DVDW1,M
M%AN-N0)M;%[,7>N<X6<PC!+BRE8W^8:EO&CJ44&:=CD[3Q6_XE3<Y'<PNW/D
MA=#*;?R[B"!KO"(JZWQZ^):X$@A01%02VU*W;^X+;#20X3/CR0"78V9U3'I=
MQ+2>0Y\#V<D3%RWS+F*J]N;:WOI+FYM/,CK61\3M3XR[F0.1!'*AYJU364*[
M&5$L]L;9D[W"XLGBL%XSB6-/+CV$'F"ACWT+3C-P97:.YH+_ !UWY<OEMEMW
MZN#XB:.:6?C=OSK7NP4L)'3RMR5I\]MM->TZ:V'U:P^]7.LW1&ROV-%62.%'
MO[=/H7(OY1VUS+%'M=/UF&9ER27+(V$12@*T3OD-$((2%9,JT>*2"JL)*QFW
M/^+XC]@?UBL4D9[3PH5B@S! 5$!J""JR+Q)RH9 @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ("FO;N*SMW3R^RT<&CF2>0"F,>9T*3FHJK,,N;
MF:[F=/,ZKCR'8T=@"WHI)41Q9S<W5DI24%#44XD\@.:$&,;AW_M/;+C#D[]K
MKUO_ ,C;-,T]?QFM]G]L5LVLM<N?*O.]ASLWJ>6R^$Y5?V5B_08)>]>[5CB,
M;@996?1?=3MC)_:LU$?.NA'3'ODO,O>>?N^)X+Y+;?6Z%/%U]FU_RG;T>CM,
M-TZOR:V45OTM;I>HQ1\4/?:7FE\49/A^LVSLF[RKXSX>9W &[;JB^26.H'R@
M+5GI]V.*I+JVG5L>(,K<PE6V_P!K9Z3/H9X;B&.YMGMFMY1JBGB<)&.'>'-J
M"N?1IT9Z&+4DI+%/8UB35!)Z>(H4(,BPN3?<-]TN#6=@JUWX;!W^D+5N0Y<4
M=3+WN94>U%^6$W0@-0=3NM>+VC'+B-ON9D=SN:/"#KMK4'Z4KA[3NZ,&O?3M
MZN3T^5Y\TL(^M]1Y'6?$5O*)V[?;N>J/7T_LG+63R>2S>0GRN6NGWU_<NU37
M$IU.<.P <@.QK6^$#DO60MQA%**HD?)[]ZY?F[EQN3?'R]"V4V511K*:P0 M
M:\:7BH*BM!\VTWATMZYW&'\C;N]97SXSA%9Y;B^>&G ,GI76T?A^T.VO9P,[
MIJE6=O![U\/@?0-$\2NW2SF6W'8I;:=$OCY+I2TO+6_MFW5C/'<6\@U1S1.:
M^-P[]3:A>9::='@?383C.-8M-=!6(6" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ("GG=4AJO$Q39)5BH0%KOY!)<",<
MHQ3]N[BLL$:MU]JG D4[E9LQ(F-"@L1<P@/0**A<M.Z,7)EL%>648^M>W5$.
M=2%L9>YR7$WL-#4,N[UB4%M.?[W'W%9(GL#965:YM:&M*<O2O3*::P/E5RQ-
M2Q6PQ*W?D+7*QV5W?L]SGU,\DN:7-+@:%O/MX(32L=A=I[6(V;971RV%S0-;
M(T^(Z34$<*<5"J4>"6#^)*N+J.XLWB&.5S]+2\/(TAK>!+&\J]YHA"IL,:RM
MQ;#1'?0,O89@#;LF8/,C#3XB7#EI["$,\(O:G3B6?=F3PL>/876AENI7>4V1
MH=)+K)T@TJ*T)Y]B&QEK<Y3P:2I7'83\/B'X"\CCR5@UMI+;AQNYCYDCIXP&
MFHXT-*5;V(1>GSK![&5HPV-F:+O(73K4M?5UI"X,80'>$4XGC^*"H,:N-8))
M]9)W3C2ZU]\Q,4++V(Z[<@E\4@(H6T<0!*!Q!/.G%!8DE*DMF_\ M-:Q0Y',
M2?9;[HG'V'UN6GEA=&TR//Y-HYU'9QYJW2=N7+:7,EC+Y4G7TF1[?VSM^Y,N
M5MW%L$8 ]Y>7#RP>!TL/TG=G:HJV:-_,379EM,CO\A:XZP#K<BVN&02182TD
M/B:*<9W]YKQ]:&K"'-+BJXOW%AP5K/-B'5A=+=RRB[ADF:1[M)$P:'-:14M>
MZNKT%09[TUS8;$MWEN/=PRY*2VBCRWU,+96SW+]>NLE=38PV-H):.8J?04%A
M14NS5[O[2UXW<.X,3>.#[B'*8]TGUKG1 />V;FQFGBTAI\0^BK84-B=NU<CO
MBZ>9=9EU]8X[(Q6\\$\UJZ$N;CLA;N+;BV+N)B<6GQ1GN4(T+=R5MN+5:[4R
M1:Y#,V4S?M:5V4DMX7^;>\Y'-)(:6#EIIP-.-1Q4&22C*KBO*A"S&VU[FI,S
MA\C)8WTS?,GM7.>R"0EM \L')P XINH6=UJ')**:6_?Z2FR6*R<KH<BV%DYM
M96NO78]S7R/A^GX>!' 5/"J&2W<AL>%5A7U%TM;RXFM[2>*^>!8R.DL9YG5D
M-O-QT.C^?GV*JKO->>#>!.MH,2 Q[XFW%R'@R/G'F12,#=(:6UH*--*M5JF-
MREN>!Y'D[*"YDM(W%]M$9&VC7/#GB,_XF0'F&GV'<P$(<*JOI^@]AM+^2UKC
M+A\+ \.>^W!X<:D$$%IX<*$(JARCMHF6S(X^.^D]Y?YC;J$^&0.#I'@]AU\.
M![DHJX[#+;N-+EP]Q5X"YEPUU#D[K4R8.&F)C]+G$=M1R!40X%+S5>#3J=J[
M7OGY+;N/OY&ELLT+7&IJ>/I[5YB\E&;2XGU/*3<[,9/;0NQ6,V2$@%""$\"K
M+85$;_+N(I.\T/J/#[ZB2J3%T:9=B*+&;9X@(XCID'<>"AHF+Q*M8S,$ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M )K6.1GDEH;2OEN Y./ZA[5T5*AYN5I-4+0YI:2UW @T(]*S)U.>T>*Q 0!
M76S@\I@<[\M(*N/<.P#[Y6"<JF_:CRK':S(=NY3/[>N1=[?OY[&4'4YD;OJG
M^A\9JQP/I'RK5O6X7%VDG[3IY2[?L/FM2<7P^KYX[#H78'5=F?DAP^XXV6&;
M?1L$[/\ 1KE_<VIJU_XO;V=R\[FLB[?:CC$^C:9K2OM6[JY9[GNE\'Y=!M5<
MP].$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $!2/XO*RHPO:0(0"=()/8*GY$(+$]]1)/0FI+J#F?4LZX&@WO)5M>6\U=
M)<'#F'L+'?=4N+*QN1>PK0JF4]'>J;2Q$ A8C;WH2C7/53%XUN-AOXRVVO\
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M(J56/=]7)&>;#P]1XJDC/:V,JU4RA 54+M3!Z."HS+'83%4L$ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M?X?7OZC>+@N&>W("A!"0I15DVS=IN'L_"97YO_Q436!>T^T^HKU0V @*BW/
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MKYA(H2&GE3M"[5NXI*IX3,Y%VJ\KP-BXK+8YF4EQL+KXW3+;WB6*:$M@$+N
MJ2:&IX<%E9R';DH*3I1LL6;R\D.>M\3)'+66-DMN]K&S1$:"2*.%6DD4\)XH
M9[<*VW+#IV^XL%Y(R;/LN;=SF6HE;:31M;1KS2IX#@!P/$*#9CA;Y7P^@J-R
M/#G":%CI ( QGECB_P 8%/33FABLK<RH(<:3&EN]P:V,#VVM%*\>RI%49%"3
M!?Y-K877%VQC;B22CHXV@#RVDL)J.3J<^]*EW;BW@L5Y,HKF^R7O4=M<W3Y6
MM<U[8X@UA>PMY2D $4/%4,O+&CHMIDV"L8[^X)N*W,A%(K9I<UQ<3V$#B?6L
MR>\TY*KY5M9U?TMPNX</AQ'E9/)L2VMK9.B8V5M>USV\25Y[.7(3E6.WB?0=
M'R]^U;I<>&Y4Q,^>M$[C)9XH5("E2*$5OPN8O3J'SJ7BA#YD7)8S:" G0<SZ
ME61:!4*AE" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @/"0!4\D!1RY.RBX&4./<SQ?>0%')GF\?)@<?2\T^X*H"DES=T!X
MG1PCTT_]HH"VS;B8TTDR0KW,=_S @**3<MD34W4S_P 8!Y^^@)#MR6'8R9WI
MI3[Y2H(?SCL?\G-]S]=* ]_..Q_R<H^0?KHP36;DL.'ULT9]+7?J% 5D6Y8#
M[&0+3W2.</\ "" N,.=N'4,=Q',/VI^]0H"L9G)!^6@J.]A+?O\ ZZ JX\S9
M/IJ+HR?PQ^J*H"NCECE;JB>'-[P:H"8@" ( @" ( @" ( @,:W,RDMO)WM>/
MN@K9L[SFYM8I]98UG-$MN?LCD<!EL>SVKFSN(F^LQFGWUDM2Y9QEP:-?,V^\
MLSCQBUZCD",DM&H4?05'<5[(^+Q(D)" VCL7J_N7!8@[0]\@;'</9;XG,Y D
MQXQLA(>YX()>QHXQ@FC3S.G@N-FM/A.7>4V*K2W]'0>QTK7KUBW^7<E1T49R
M^I5[^*ILW5Z#H[;^%P&P-MS/-X?=6Z\CELS>/#I+B9XK)<2O)XEU/U O-7)S
MOS6&.Q(^F9:Q9R5E]K#&4I-[6]LFRLN;;;V_=LAES$+_  .6@;+&)6/C<YCA
MJ8]K74>UPYM/,%44IV9U6$HF6<+&=L4DN>W-5V/9M6VC.--Z[?AVGNO*;<@N
MQ>PV$@9'<,IJ+7L:\,?3AYC->EU.T+V^6O.];4VJ-^53XCJ6565S,[*ES*+P
MZN#ZC'UM'+-V= [)[;7/Y.E&R2P6@/?Y;72.^8/"X>IRQC'K?N/=^%[?9N3Z
M5'T8E^ZV738-C.M^V]O;:-O_ +O5*?O+6TY5O5X)OW'0\17.7*4^U**]YSR)
MI6MTA[M(-::BO1T1\XYF'RS/:&.>YS1[())"*)'.R6K% @" ( @" C9*^.I8
MYS:\])HJM%U)HB\Z< CS'4//B4Y:$N4C;7PX7WNN_KJT=RR&.E:/V<,K'?/2
MJX^K0K:3X,]AX2N<N<<?M1?J:]QUBO)GUL( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @),_8KQ,<RG5B@0%LOC6[/HC:/GXK
M)'8:EWYO,0*Q![0<U601& C19'J@DG %W <SW\E#9>AH#>>;R.9NY(L@^.=U
MH]\<30P,;I#N(J./9VKTF6M1@L-]&?,-5S=R]<I-UY6TC#KBVCNIXX;-TD;^
M!FB/&-K.W5V<N2V:T.(DF^S_ &$K)2W6.93%0,#0?H\"ZGX1YGAVH36C*8WL
MT\$4LT7U$A=+,YX'@9#R#B.TGDI*[S%<[%D\U!;F/'DVK7&1[F4)H35QH34\
M.  "&U::BZUQ+&ZWO<SC(,/9MGM[N&(/BF<#')&Y[ZDDFFES0*54&=.,)<SH
MZO9Y=)>,KC(;VSN+@RMOGQ&$N\(>U[H1X:N-2X\ZJ3#;N<LJ;*OT(L.&N+O+
MR0P95Q8]SWP/T@ PAHU11RN%*GZ+7 54&U<BH_+C@FO>2-\W5_;P.BDG;/$W
MZMSG4<(010-!YUYFJQS9N:=;3=:4-19>Y9= 0P,#&0 QL>2=;Z?2=Z5IR9ZJ
ME:(Q+(>87@N;5C2*O)XU_46%K!F:VN4ML[]9I7B.!KSJM38;%M4*>@';ZU>I
MG/*]H[4:) -?F4(4)L-M=W#3);V\TS&G2YT4;G@'G2K00"K1A*?RIOJ3?N*R
ME&+I)I=;2/8+*\N[GW6VMY)+D&AB##J!]([/E5XVYSERJ+;X;UUU^@OL6)"Y
MDD4IBD&B9A+7@T-"#Q"K*+C5/!I["CHE7<;PZ/65G<V$DUQ?MLKB.4V_LUF>
MRFH"+TKH97&)XW5[DE-<JK5>LWAYH;8Q1Q2,ALP*:I9 9*#B7.%:U*W3RU,:
M_P!A9LB]WG-O_*<Z")C8;*=XTO\ -<22\CF&D>RC,T%C2N_%&!XJ>(Y$P7-V
M\.Q<A:7/'U<LDSZMD%*FKG.#*'O3=4ZMV+Y4TOFQ]&[WF3V%S99BRMI(M<4-
MQ*Y@J?';SQ$AS7=[33AWA1LP-*["5N5-ZIU49(FN8_-\J%CC=W($(?+^39XB
MPF@XUYH%#"NXF6[&74-;,"XM'N EU'V&1?5T#3V&E:_*@>#Q+9="&WN@YU&2
M ALCP27GL&KY%%,3*G@;F^'O'G)[K>UL/GVMBWSII#Q#=9\-?65J9ZYRPPWG
M6T:QSYBM*I;>@ZR/.H7G#WY 5*()9YJQ4@/H4T*5##IGA([Q]W@HW$KYD7-4
M-D(23(?ROR*K+1VE4J&4( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MJO"?-I^,?+8YOK<%SLUFU:G!?:>/4>ATW2GFK5Z?_'#L_>V^Q&$-)>QKQR<
M1ZBNA@CSRJU4R[I=E?L/J%MZ]<X,B=="SE<>6BZ88C7Y7+3SMOGL2714[6B7
MNXSUJ3V<W+_>5/?4[B7AC[J$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M*E=Z+J?;6,VSQ 3(/R@]2J]A:.TJE0RA $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MY;Z&$_J(]@A\Q<%0V0@)]N.)*I(O GJID" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" (#PD 5*DALEF9@Y&J4*N2('3NY4 5^
M4KS$!E?VU4T1',SS44(J0H0$)" ]!X>A >ZG#M2@J1"5X'H2B)YF1MG/:*^I
M5Y2W.1ME8[MH?2JT9;F1,4%@@" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @(2X-!)X-"
MQ>^N3=SEXKY8\,8[AW^LH##,YD#=3FVC=_)H'=GTG]I]0Y!026#(Y&PQ%G+D
M,E,+>SBYR.XDGL:T#BYQ[ %EMVYW)<L55FKF<S:RUMW;LE&*VM^6)IS=._\
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M9$6P96=IXL>RA#=0%:\E-#.X1;JGL?06[<67O['&QWUQBH[R&  W-W Y\5Q
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MDH3;( OD?W 1_/Q42>"+VUBV5BJ9@@*F!ND$]Y5)&2)-52X0! $ 0! $ 0!
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MVH[KB:\^V/O.L5Y,^LA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M]Q1)U9EMX+K*A5,@0%7%P8%C9F6PC4$A $ 0! $ 0! $ 0! $ 0! $ 0! $
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MXU9':6UQ>R^3:0OFE_!8*T])[ /25$G0F':=$C(+39=[)1]Y<,MA^#']:_\
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M.ZQ9KRW%U/W'TCP=G'_$RSV4YH^;"2.AXR&RQN/(/9J_=!>:1]',Q4@( @"
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M7N:? ./.M%!M1E&;IN>UORW[C,,+N"XCNFPW40OP!HDE@A(E:[\(4-'L',U
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M ( @" ( @" ( @" ( @-;[__ .^;7^;#^$<H)+/B,]!8W#,;?/#()R!;S.-
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MCBEN7^=<.8P,=*^@;K?I'B=0 5<L#;>#>PW8PC%MI)-[2N0L$ 0! $ 0! $
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MC-3Z*&$JE6L9G" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M054;-(])5&S-%4)BJ6" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MM*I;LSNND55F?,YVSEH*=R7+%[_)%A_3;TM_WFM_W$W\6MK]/S'V'ZOB<O\
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M8N6_FBT=#*ZCELSA:FI/AO\ 07:_O+3&VD^1O91#:6L;YIY:5#(V-U.<:5X
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MKHKL\Q\ITG.7M/N0OT?)+!\)4VKK7ET[\ZZ92PSG2./,8R5MS87ES93V\H-
M6N?P'H(Y$=B\YID)1S/*\&CZ-XEOPNZ;WD'6,G%^8I^D6UL5O+HS%@<R'G'W
M%Y</D;$_RY/J[C6VCAZ0KY^]*SFN:.U)&'0<G:S>E*U.O*V_5*I@76WIGM?8
M&,Q%U@&SLDO;B2&X,\QE&AC-8H'<C5=+3<[=ORDITP5<$><\2Z-ELC:A*U5<
MSH]^'49AL+H9L/<>S,'G<C'=NR%_:QW%P67+F,+W<_#I-!Z%H9G4[\+LHJE$
MV=S3/#.2OY6W<DGS2C5XF+_%"T-W3A6CV1C7#YIWK<T7\.77[D<7QMA?M_=]
MYFOQ'#_]W.&_GUM_L\JT='_'EU/W'=\7_P#7P^_'_+(QKISTTZ5Y[9F*RVX[
MQL>9NFRON&'(>10MFD8T:-0T^$-[%LYO.YF%Z48+!;,.@Y^CZ-IU[*6[EV7;
M:=>W3>U[*&#W^)QNWNKV-QG3R[??1Q7MI[K-&_SW-D+AYT1D;[;0*ZCW5!Y+
M?A.5S*RE=5,'N.#=RUNQJD(91\R4HTH]F.*JMN^O1M-H_$?OF^Q-K9[.Q<CH
M79*)]UDI(R6O-L'>6R($<0'N#M7H;3D2N3I&64V[C^J\#UGB[4YV81R\*IS5
M6UPV)>=[?1O(MD?#MMPX2VN]X">[RUS&V5UK%(ZWAMP\5#!H(<YS:^)Q-*\E
M&9U>YSM6\$NA.I.F^$LNK2>8K*<E5XM4Z.+ITF$=5>E\O2^YQ^[-I7L\6/-P
M&1O+JW%G<T<YA$G N8X \'>HU!70R.=693MW%5T\O.<'6]%_3)1S&7DU'F77
M%]>^.&_TXFR=P;J=O3X?<EN"4-;>368BNVLK1MS!.QDE >0);J [BN5:L=SG
M5#<G[CU&;SOYS197=[CCUJ2KYF8'T5Z6;2WYM^^RF?9<ON[:]=;1F"9T3?+;
M%&\<!S-7'BNIJ6>NV+BC&E&JXKI9YSPWHF5SV7E<NIU4J+'H3]Y+ZI]&&[!L
MV[OVC?7!LK.5GO,4CQ[Q:E[@UDL<K0TZ0\M!KQ%>9XJN2U'OWW=U)U3(UKP[
M^0A^8R\G2+54WBJX)IKI-D[8WG/O?HQFK^^<'9:RQ]]9Y!PH-<L<!+9*#EJ8
MYKC^-5<J]EE8S<8[G)->D]3DM1>=TJY.7SQA-/\ N[?+?4Q3X5/8W7^RL/\
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M0OGI^B @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ("EECT'6/9^\KIF*4:$M6*A >2,9(TLDH6$4(*$-)JC+?
M)&^ T?Q8?9>?O'T^E7K4P.+CM/04!IJ;"9IWQ%6V>;CKHX,1-!R(C=[L#[BY
ME#)33S\/-=E78?D7"JYJ[-_S)GC)Y6\]<C=4'R?:IA^&UMV=!1;4Z4RXSK/>
MWLUJX;7QCWY/&3N:?)?)<_D8FGD71ESC3\45[%:_G^;*J/UI8/RZ3%D=#=K5
M)3:_A1;E%],J47F]Q!LRTW'MC??47<DF%OGQF"\DQ@]W>1=2FZ:Z)L= -=33
MEV54YF5NY9M0YEM5<=F&-2FG6\QELYF;SMR:I-Q[+[7:5*<?,678G1W>>;L;
MK/WV>O-J9*ZG>R:$PR,N)@WQOD>6RQ'2Y[G:6D>E9\SJ%J$E!15Q)<53S8,T
MM.\/9N]"5V5V5B4GC@ZOKHX[RH=L;>/3/J)@]PVDEYNNUG/_ &G?PV\CY/+D
M^JD9*-4I)TNU-)/9Z%3\U:S&7E'"%-BJOH+K2LUIN>MW4Y7U)]I\KK38ZXO=
MQ? N$^V=^]'MU7^<V7C79[:.3=JEL8PY[F,+B\-<UGC#HR:,>UKAIYA8U=LY
MRVHW)<DX[^/]ILRR><TC,2NY>/>69[8K&GHQPW.CPVERL]V]:-]Y['NP>'=M
M' 6LFJ^FOHG/C>TT#@_SF1N?0>PR-K>)J7=V*=C*V8/FESR>RC-NSG]5SMZ/
M=V^XMQ>/,MOI2KU+?OWJ=>[7OLE\0@R=]A9;O;3K4,?=SV_F69>RT+0"YP+"
M0[AZU6-Y1R7*I4E797':9;F3G/6N>=NMNFUQK&O)Z"B=M_/=+>K)S&V\1<WN
MS<\T^_164#IA;QRO^L: T>'RI*2,I] Z5D[V&9RW+.24X;*LU_RE[3=1[RS"
M4K-WYJ1K2K]5'BNC N75#8>[(-UVG4_IZT7&:M@P7U@T OD\MI8'-:2W6US#
MHD96M.7%8LEF;;M.Q=PB]_ V=:TS,QS,<YE<;D=J^''#!KT%HRW4?JYN_'2[
M<PVR+G&9"[C]WN[US9FAK9/"_09F,;'7CXG.-.SCQ6:&3RUF2G*XI)8T\MIH
MWM8U+-P=FWEY0E)4;:>_;M2Y>NK+I<=-+S:?1+-[=M(GY#<>0$=Q=1V;72:I
M#+&!'&!Q<V-K:5IWE8UG5<S<9O",:TKU,W9:-/*Z3<LQ3G<E1NG&JP70OBS)
M.DVSL7!T_P *S<&WK9F:8V87+;ZSC]Y#A/)IU:V:JZ:+5SM^3O2Y9.F&QO@C
MH:%D(1R5M7;4>=<U:Q5?F?%5V%?U=QMU?]-<QB\/9R7-R]D#+>RM6%SJ,N&.
MHUC0> #:T;W*F0DHWXN3HL<?,S:UZS.YD+ENW%MM*B7WEN*CI):7V,Z<;?L,
MA!):WL$#VSVTS3'(P^<\@.:>(-"%3/2C._-K%-F71+<[62MQFG%I.J\[-=6&
M*SN-Z];@W1-B+V3#,M;F2*Y;"\QS%EM%X(W4HYSG-+6@=JZ4[D)9.%M256U5
M5V8GF[.7O6]8NWG"7)RNCIM[*W\3%]G=*]\[SOLONS*Y&\VCE;JZD<"89&3S
M>=61]/K(G-C;X6CF#\BW+^?LV5&$8JXDEO7P9Q\AH>;SD[E^Y.5B4F]S3=<7
MOBZ$>YNFN]]@[@P6[<7>7N\;R&=KIWL@DDG8RWI5C_'*XMD87MY^A5M9RUF+
M<[<DK:IABJ8^9%LWH^;R-^WF(2E?:>/9;EANVR>*P+WG]I[WV#O.XZB=/;%V
M2Q&8:9K[%ECC,PSD221OA%':=7C:YO%IJ"*<\%K,6<Q95J\Z.."?T^53>S>1
MS>0S3S>4CSPGC*&_':J;>IK8\.NR;ENM\]5H8\%B>G[,$QTS)KK(3Q&+ZQO:
M^=\45&U)+@ YQ6>S&SE7S2N\]%@D_=4T<W/-ZHNZAENZ3=6VO>XQ]Y<^K>U=
MQV[MAP8?'7.:=M^T9'<26<+WQF2V="0#0.+0XL-*K'I^8A2[S-1YGO9M:_DL
MQ%Y;NH.[W2HZ)]'#J+U^E_J>][6.Z:W+6/>T.)-P: FA/Y(4H%@_(9?_ )5Z
MOB;ZU[/MT>5DD_O? W,ZE>=>17%VGL27621YCB]H>T3R _55MA7%NB*F**.%
MNB/MXDGF3WE5,RBE@B8A(0$R-FOU=JANA*52J HL9F" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ("3,> 'RE7B8Y,IU8H$(+/=2^?(7#V1
M]6WU#M^4K+%41IW)<S( /G5F51, '-06(@HJ21 44=9)%2B@L1M:A*(P%5EB
M(-/H4$T(VMHI+$=%!( (4 ] JA(<RK#W.!!IW%2R3GWIS\/.8V;OV+<.0REO
M<X7&NF?CVP!XN)C(QT;?-:Y@#*!Y)TN=Q"\_EM-E:O<[:HCZYKOC:SG]/=B%
MN2G<2YJTY8T:>&-7LWI%RZJ=$\YO;=/V_A,E:VUO>10V^0BNM8?%Y0T^9'H:
M=8(IX33B.?=LW\HYW.9'YRUGP]<SM]7(244TE)/HX4V]6!NFQLVV5A:V+7.>
MRUAC@:X]HC8& FG::572A#EBEP1[",>6*7# J*+*!I2@/*%000T[E(/*%200
M.:>SFH((%*9!"0K%2 BB$$)0J0$*4R&CPA6*E38RTK >1\4?ZH5)\3-:>XK5
M0SGHYH# LB=76K ^G"W-?WQRBE(^<LG67F-E+&90@,?W?N&WVKMG*;@N*%EA
M;OF;&3P=+2D;.'X3RUORK-8M.[<C!;V:6>S4<M8G=?U57RZ]AR3TLWSA-G;F
MO=T[F@NK[(SQO; ZV:QY;+<OUSR.UN9Q/+YU['/92=VVH6VDD\?@?&]#U:SE
M,Q*_?4I2:=*);WB]WE4@Z@[\Q.?WQ:;XVG!<V5[$()IF708TF[M'>!P$;G<'
M,#6NJ>Q3E,I.W9=JXTTZI4Z2NK:M:OYN.9L)Q>%>:GS1V;&^@W]U3S%IN+HC
MD<Y8NK:Y"UM+F/O DN(C0^D<05YS(VW#-J+VIM>IGT?6\Q&_I,[L=DHQ?IE$
MPKI5LK';[Z-9#!WE&3.R=S+97E*N@N6QQ:'MIV<=+A^"2M_/9B5C-J4?LK#C
MM.#H6G0SVE2MRP?.VGP=%B:GO<QG-O;=S73#-0.'EWT,\49=PMIX7ZI-/X3)
M6T<WL^EVKKPMPNW(WXO=CTGD+V:O9;+W,C=6R6'[+KNXIK9B=(?#K_9C9_SJ
M[_A7+S6K?S#ZCZ9X3_ZZ'7+VF,?%/_W'M[^>3?P2V]#_ !9=1R/&_P#+V_O>
MXV3TC_LSVM_5T7WER<[^-+K/5:'_ "-K[J-&?%'_ .:\/_5KOX=Z]!HGX<NO
MW(^?^-_YBW]WWF:?$=_9SA_Y];?[-*M#1_YB74_<=SQA_P!?#[T?\LC"]A]
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M;FHVK=VSWJ5'1.ON.3X=S=_*Y_\ *3=8]I4VJJQJO1Z-N)U>O)'UH( @" (
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M@N))MNKWGT6U;C;@H1V)&W8H8X(600M#(HVAC&#D&@4 4&0G( @" ( @" (
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M_".4/80GVC9JQFP$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! 2GL9*PL>T.C<*%I%00>\(# \_L@M#[G"MUP
MNJ9+$]@[HZ\Q^*?G1.A$HIIIJJ>W@:ZN\9)$Z0P-(<PD/A<")&D=E"NE:S5<
M);>)Y'.Z.X5E9Q7#?])0??[>_P"4+=/,GBD! $ 0! $ 0! %% %- $ 0! $
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M2ZBEL(T+! $!-9$7>@*&Z$J-2H:T-%!R6,RGJ$A $ 0! $ 0! $ 0! $ 0!
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MZH;!KW(_VRX3^IKC_#<FXC>;.8=3 >]8S.B)02$ 45 4@( @" ( 31 $ 0!
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M1]5R=[O;$)_:BGZ47I8S;" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M)[&<V=J<,)1:(:A6,00!" A(0@(2#P0  NY-)]+150W3:7C%RV*I.9:W#_\
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MSY"WT5CZ&T;%7//0A $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M<>]4;J94J$:@D( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MP?G<N5JCI8:XM+WGJ/"\>;/P?",G[CL->//L@0&COB8M2_:>(NP*BVR0:_\
M]]#(!]T!=O1I4N27%>QGAO&%NN6@^$UZTSF/7(0&@NH.3:G2/4O4T/EB;9"Y
MY=Q<2\^DU^^IH5;.K_AP>7=.B''@S(W8;ZB6G[Y*\CJWX_F1]>\).N1ZI2-P
M+D'L @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ("!S [GS[U*95JI*,)'+BKJ11Q)1!"DJ>( @"
M ( @" ( @" ( @" ( @" FB%SN? >E14LHDYL36^D^E4;J74:$:@L$ 0! $
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M+(B"5))K5!=$0YJA8G-"DL3&JI8F-"DDC"BI8(21JK)1, X452YZ@" ( @"
M( @" ( 15 0/YJR*LEGFK%2$HR#PJ2"4Y&5('(B"4X?,A1D)5B"2>U24('CP
MGU%3O*O87"'\C'^P'WEC>TVE\JZC \A_;-A/ZEN?\-R;@OF\QL>#F?\ AVJ)
M&2!/6,R! 0EK7"CA4>GB@(D 0$+6M%2!0GF@(D 0! $ 0! 0Z6ZM5/%W]J B
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M[ %6I-$1(2$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0%')[963<8'M(5(*3(4\N(]TGWP5:&TPW5@BD5S"1!0
MW4E$8[E!8FM% H+(F,YJ"Z)@Y%06(V\D))H0L1 4"A$GH"$DQK55LLD1JI8(
M @" ( @" ( @" (#P\U)!)*N4/$((3W(F00.%%)4E]B$$IZ%60%63*LE$44E
M"7+PCKZ"I95["Y1_D8QW-'WECWFVOE1@.0_MFP?]27/^&Y'L"^;S&QK?F561
M>!4*AD" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M8A2.-H:T=P H%\\/T2DDJ(G(2$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M>./LH0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MM]#8T7.QRFC*[)5Y>;#CBZ$_$=:NF.\,7'!O:""RO]%)[6_MO>8-5.)BD#'
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M\A[UT=7<>Y2?S57L//\ @^,Y9R<X5Y*.M>OL^HZO7DSZT$ 0! $ 0! $ 0!
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M[S\S5]G%UU[I7V=7N8\S3\NFJV=3Y?S-NFW"OI.=X7Y_TV]79VJ?W<?<8KT
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MJ^?TZM775^^")M^&Q1S:8@XEAI(YH%7:N2]MG86))=]LJZ8T/B&B7L];E/\
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MJG1<#VD/"NGQM\K@Y/BVZ^JB]1I.]ARW0;J9#[G=23XF41S&M&^]8Z1^E[)
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M:'G5*U)N,L55[5]:+\NDZ S/2[8._+R/=>4M);BZOH('-D;<2Q@Q!H='X6N
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M>&LB[\;UF78CCRI\RKNQK7KVU-XKBGMP@" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" A<T/%' $>E &M#!0  >A201*"2ENK*TNF@7
M,$<P'(2L;)3U:@43925N,MJ3)L,4<+!'$P,8WDT "GR!&622(W-:X4<*A$&&
MM:T4: !Z$)#FM<*.%0I1!#Y41 !8"![*BK%$1@ "@% @/2*H22Q%& 0&"AY\
M.:59%$/*B_R;?F"58H1-:UOL@#U!"0YK7BC@"/2$V$$'E1?@#Y@IJQ0B:QC:
MT %>=% (?*B_ 'S!35BA[Y47X#?N)5BB)B@D( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @*>>.GC'RJ\68Y(DJQ0("W
MRQ>[R:?HGC'^J/D5DZXFNU1G@Y*2"8TUXJ"Q&."J6)H*DL1CFJDD;7?,I+$P
M%02>H2>@D(2>@U4 B!["H:+$8/>H)%0JD@BO:I!C4VQ-D73WS76V<5-/)4S3
M26-L][B>9+C'4D]ZS+,WDJ*<O[S*\D>!#;X*]QN+=@L7[K#C"UT43V1^2^*)
MPI[$8#'. X \.\K#*4I.K=2:84+_ !1,MH8[>(4CB:V.,=S6B@^XE 6^[P&
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MEAR?\\^N7O-C5O\ HX_=M_Z2W=,]DX_?O12?"7FF.Y^T+N7'W=-1@N64TO\
MV)XM>.T'O63.YB5C-*2V455Q1@T73H9[27;EMYG1\'AC\>*-.7^:SV%P&4Z9
MYN L9;9".X9$\D&VGA)\P-_"CE:X.;3A](<RNW"U;N7%?CO1XB_F[]BS/)75
MLE7J>.SH?]FTZ0Z)WEC8='K*\R4D<6.@]^ENGR^PV%MQ*7EU:\*=B\SJ2D\T
MTMO9V=2/J'AR<(:7&4VE%<[?5S/:6JYZ'=,]ZVC<[M"]DL+6[^LC?CWMDM:G
MB1Y4@):03Q8"W2>P+)'4LS9?+<56N-:^7I-6[X:T_.Q[RQ)Q4L:Q?9]'E0T[
MG,9GNA^];9F+RC9YPR*Z:Z"L;9K=SRTQ7$-3[6D\R>'$+MVYPSMIMQXKS]!X
MG,VKVB9J*A/F>#X55?EDO[>*.S?-'D>=H=7R]?E_2Y5IZUXG?0^VUPJ5"$A
M$ 0! 4=U<V]E;RW-S(V&"%IDEED(8QK&C4XN)H *!"LI**<FZ)&JY_B/Z;07
MGNC)KR>-KBT7<5L3"X TU-JX/(](9Q766DYAJM%U5/)S\69",^6LGTTP^/J-
MF8G+XW-X^#*8BX9=X^Z:'P3Q'PN';P/'GP->(7+G"4&XR5&CU%F]"]!3@U*,
MMC+HJF8UQ=]9-EX_=/YH7K[JWS#;EEF[S+=PA$DI:UA,G+0=;2'=RWXY"[*U
MWJIRTKM//W=?RMO,?EYMJ=4MF&/N-CK0/0&O-X]7]F[(RHPN;DG]^\ELY;;0
M.F#6O+@T$CDXZ2:+>R^1NWH\T:4K3%G!S^NY7)W.[N-UI7!#=?5W:>R[NUL,
M][W#<WEJR]B8RW<^D4A<P!U.3@6D$)8R5V\FXTP=!G==RV4E&-WF3DE+9QKZ
M\"R?WD.F9X>=??ZI)^NMG](S'!>DYW]6Z?\ :EZ#+K/J%MG)[;NMU8:Y=E,7
M8L+[EEFQS[EF@5<TPG2\$ ZJ4Y<>*T996Y":A)<K?'8=RWJ=B[9=ZV^>,=M-
MOH*+9G539V_+R?'X&YE=>6\;9W0W$3H7/BKI+HZUU $\:<JJ^8R5VPDY+![S
M!I^LY;.R<;;Q6-&J,NV[]XX+8V-&6S\SHK9\C((F1-,DDDCJG2QC>)X-)/J6
M*Q8G>ERQ56;>>S]K)V^\NNBK3K?02MF[ZPV^;*?)8*.Y=802>0)[F%T#)'T\
M6C5[6GDY6S&7E9ERRI4ID-0M9V#G;3Y5O:IZ.)D\LK8HGRN]A@U'Y!5:QT6Z
M&#;-ZK;3WWDKC&[??<ON;:'WB7WB%T31'K;'P)YFKAP6[F,E<L14I4HWQ.)I
M^MY;/3<+3;:5=A<]Z;WP>Q,?#E,Z)_<IIA;!]M"9M+W-<YNH#D#II7O6++Y:
M=^7+&E>DV]0U"UDK:G=KRMTP52?M'=^$WMAQG,#(Z2R,CX?K6&)[9(^8<T\1
MS!]7%1?L3LSY9;2^1SUK.6N\M.JK0J-R[BQFU,+=9_+/<S'V@!D+&ZG^)P:T
M-:.)))H J6K4KLU&*Q9DS6:MY:T[MQTC$M&R>H6WM_QWDVW_ 'AT5@Z..:2X
MA="W5*"0&EW,@"IIWCO6;,Y6=AI2IB:FGZI9SRD[5:1I6O29FM4ZH0! $ 0!
M $ 0! $ 0&JLMUZZ?X3)7F(R$MX+W'SOMK@,M'.8)(B0ZCAP(]*Z<--OS@I)
M*C53R^8\39*S<E;DW6+H\-Z-E6MU;W=K#=VKQ);SQLFA>WDYD@#FGY1Q7,:H
MZ'IHS4HJ2V-8&";KZR;+V;F7X',RW'VA%'')(VW@=,QHD%0"X< :<:>E="QD
M+MZ/-&E.EG!SVOY3)W.[N-\RQP1E>W-PX_=.$M=P8LN-A>M+X3*PQN(8XM-6
MGEQ"T[EN5N;B]J.ME<S#,VHW8?++87M8S:" (#'=V;MQ.RL/)G,V9&V$4D<+
MC"PR/U2NTMX#LJLUFS*]+ECM-+.YVWE+7>7*\M:%I=U)P3]A7/4*S9<3X:".
M1XB\ORYGN9(8J!I/"KQ2I]:RK*3[U6G@VS4_5K+R;S4:N"3]M/:2NF?46SZC
M8FZR5M926$UG.;:X@D=YHU$!S2R0  U!X\."MF\I++R46ZU172-5AJ%ISC%Q
M:=&MI;MV=;]B;/RDF&R,UQ<W]O073+.(2MB<X5TO<7-&JG&@)([5DL:=>O1Y
MDDETLUL]XARF4N]W-MRW\JK3K+;F>N^!Q>X,/A(\9=7%OEH;.X==5$3H69&A
MA^J=XGFA!>*CNXK)#3;DK<I52Y6U3JZ37O\ B2S;O6[?*VKBBZ_>V8;7TFX%
MRCU80! $!@MUU0VK9;SCV),;@;@DDBB:UL+C%JFC$K/K.7LGBMN.4N.UWN'+
M]-#C2UC+QS7Y:K[RJ6SBJ^QF=+4.R$ 0! $!K#/==-B;;S-Y@LI+>,O[%_E3
M^7;.D9K+0[@X<#P<%TK6FWKD%*-*,\UF_$>3RUR5N;?-'H**'XC.F<DK8S=7
MD0<0#)):2Z6^DAH<:?(LCTG,);%Z4:T?%FGM_,U^Z_=4V/CLQC,OC8\OC+EE
MYC9V&6*X@=K:YHK6E.ZBY4HN,J-49ZFU>A<@IP?-%[&C"ML]:MB[LR\.!Q=Q
M,R_N [W>.Y@="UY8*EC7&HU4!-%OWM/O6H\TE@CA9/Q!E,U=5N#?,]E</)F>
M7]Y%865S?SU]WM8I)Y=(U.T1M+G4':>'!<^*<FDM[/07)J$7)[$J^@Q79/4_
M;'4&:\AVZ;A[K)D3Y_>870@"8N#>?/V2MO,9.Y8HYI8])R=.U?+YYR5IM\M*
MX<:F39;*66%QEYELA)Y5G91/N+B6E2(XVZC3U\EK0BYR45M9TKUZ-F$IS=(Q
M568-MKK9L;=>9M<#C9+D9"\UB 7%NZ%A<QA>07./M$-- M^_IUZU!RDE1'#R
MGB')YF\K4&^:6RJ\YLM<X]$$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MVJYF?O\ ?76]RP74>GT#(K*9.$:4E)<TNM_!47F-A+0.^$ 0! $ 0! $ 0!
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M+-V7-<MU_A=I]'3Y=9U7L[J'#O\ Z<9::X<R/<-A8SPY:W;0#7Y+],S!7V)
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MP/$>8?\ #5OY3*4>$J>M^7J,2_\ N^KU6,%+_#'X^UG8"\<?9 @" ( @" (
M@" ( @" Y/VF*_$K=- JTY/*@@]H,$P/W%ZZ_P#]>ONQ]J/D.2__ $@?W[G^
M61B&[K?)=-MQ;NVC9O\ *QF38V*KJDNL7/\ >(@TCM K&?1J6WEW',V[<Y8N
M/MV?2<C45<TZ_?L0^6Y1?NUJE[O29?OG:YVIT/VQ:2LT7U]DV9&_' .$UQ;2
MD-/[!FEOR+3RM_O<Y-K8HM+JJ=?5LB\II%J#^:4^:76XOV(O>;]Z_NO8DV^K
MR@8/>]/^1]]=6OHU::K6MT_4)5XOV'3S"E_3\:;,*]7/\:&<_#S]D#IU;-QV
MGW]L]Q]JAM-?O'F'3J[:>7HTU[%HZKS?F'79A0[WA3NOR$>3YJRYNNOPH:LR
MIM3\2-G^;>@Q_:5M[SY'L^=Y(][I^UUZ_35=6VG^0?/]G"O7A]!Y2_R_KT>Y
M^U&OH7-ZMHMC8?WE+@[C($/VG)[OY_L^=[M_)JUX4KIT>FBEU_(=C;R^JN)$
M.3]??>_:PZZ=GW>HVA\11@_1M-YFCSO>[3W?535J\SCHKQKIK6G8N5I->_PX
M,]5XMI^GOC54^@L&UO\ TR7_ /,<E_#2K:O?]@NN/L1S<C_T$ONS_P TBN^%
M[_R/E/ZVE_@(%36_Q8_=7M9?P3_)S_\ <_TQ,,Z!$CJON?CS@OJ^G^6L6WJB
M_P#&AUKV')\+_P#9W^J7^>)%U:_M[VS^RQ/^U.4Y#^2G^]["->_[JSUV_P#,
M4/Q"NO&=3\4]_E"-MG:FR-R/Y,"+B349*\-&KV_Q5;2N7\M+K=:;=QB\5<_Z
MC;V;(TYOE^9[??T&997#_$/F\7=XO(38.?'7L+X9V^$M,<C:$M.B@X<0M&W/
M(PFI+FJF=Z]8UN];E"3MN,DUZ?,6"XV9NS9'0[=F,S#H=$]W;W, MI/.;[N]
M\#923I%-6FI6TLQ:OYNW)5V-.OG.;/3LUD=(O6YT=9)X/=6-3,_AN^RV[#F]
MT\LY3WV7[3+:>;7AY5:<=/E^Q\M.U<_5VW?QV4P.WX1[O\GV:<W,^;W>:FPP
M/-FW/Q-V8MM'E^^6GF>7IIYONPU5T]M?:[:\UT;5?T]UX/VGG<SR_P!01I3Y
MH_Y4=2KRQ]5.=?BM_P"[]LGD?-O*?O<:]%HGS3ZE[SYQXW_#L]<O])FF_((H
MNA=[#'$QD4>(MRQC6@-:X"-P( Y4/%:66QSBK]IG>U.*6D26[NX^XM7PU0Q,
MV%=3!@$K\E<"1X :YVAD>D$\S2O!9=9?\=?=1I>#8I9)_??L1A/0<:.K^YV-
M #6PY - %  +^+@%OZE_*PZX_P"5G \,_P#:WET3_P Z,6WK@_SHZWY+;PG]
MU=DLBRW%P6^9H!MV&NFHKR_"6WEKG=9-2I6B^)R=3ROYK5Y6:\O-.GJ6[Z2R
M]0NG=UTYSMICLI.Z]Q=TQLT=_$P1N?&UU)V,:\N >T<14T.H+-E,Y^8@W'"2
MW;<>)IZOH\M/NQC-N4);]G7M>WXHZMV+M_;& V=;Q;2/F8BZA-VVZ<=<L[IF
M5\R1WA\1%.'9RH*+Q^9NW+EUNYM6%#[#IN5R^7RR5CY&JUXU6TT-\-5M#=[G
MSUK<1ME@FQCHY(WC4US'SL:X$'F#R(7HM:=+<6N/N/G/@N'-?NJ2P</>BV[S
MP67Z+[TGN,,#)M[+6]Q#:M>3Y<EM.TB2VD(J=41(<P_L3WK+EKD,Y:2E\T6G
MZ-Z-?4K%W1LTY6\;=Q-8[&G]5]6%/-TF4?"N V_W,P<2(+,5[Z.F"UM<^6'G
M]QT? SK*]^[_ *C!.J6\+/</4RXR=U'[W@L3<1V,4 =I$T%H^LC0XUIYC]?'
MN6_DLN[>726$I)OX'"US489C4>:2YH0=*<4GCY<"\]1.M^*W_MJ3 R8$V4K9
MHKFTNC=,D$4D9[&B-M0YI<W@>U:^4TV5BYS<U<*/#RWF_J_B2WG\N[3M.+JG
M%UV>KA[38WPV;H&0VS>;6N)/Y5AIO-MP>VUNB7B@[FOUCU47-UBSRW%-?66/
M7O/2^#LZKF6=EO&VZ_NR^FOI-[+A'O @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" (#C+.[BBVEURRNY)X'7$./RD\DD$9:U[PZ+RZ!SN XOKQ7
ML[5EW<DH)TJD?%<SG(Y3697FFU&3K3JI[S)=]?$-9;HVQ?;>QV'DMI,G&8);
MFYE8]K(GTU:6,%2XC@.Y:N6TF5JXIN2='N.KJ?BR&8R\K5NVTYJC;:P7O+[T
MVVKE-O\ 1W>%_EX76TV8L[FXM[:4%KQ;QVKVL>YI%6EY+B 1RH5KYV_&[FH*
M+KRM)]?,=#1\A<RVE7I7%RN<9/'@HO;PW^8UATRWWN_9461;M3#C*MO_ "77
MA,$]QY9BUAGY$C34//M+KY[+6;S7>2Y:;-QY#1-3S634^XM]YS4K@W3;P,FW
M3U>ZE9W;N3PV6VTRSQM[ 8KFY%G>1EC'\W:GG2*4YN6G9R&6A<BXW*M/95'8
MSNOZA>L3A<LJ,9*C?++VUIZ3-_A:_P#+VX/Y_'_ M6GK?XD?N_$[7@C^6N?>
M]QIG86ZMP;/W/D,GMS&#*W\L<]N^W='-,6Q.F:\OTP>(4+ *E=O-6+=VVE-\
MJP>[@>*TO/7\GF9SM0YY.JV-[Z[NHV7^G7JNXAIV:RA(!=[G?BM3R^5<IZ;E
M:?B/U'J_ZEU*M/R_^&9</BA.K%;6)X$S7)]1\F,K'HF$I]2]ID\;8VK77+V(
MUSFMLY386.V=U+VPZ1EM=6MM/+(ZKQ!?NC\;7CA]5.">'K%>(72MWXYAW+%S
M:FZ=/4>=S&3N9"WE\[8K1QBWT2IC5<)?'H+MUPW;8;XV_L_<..HUDL=]'=6Y
M(=)!<L\D21N]1K0]HH0L.F9>5B=R$MU/1B;GB;/0SEG+W8;^=/BGV:HR;K?=
MSQ=*]CV,;B+:Y;:/F(Y$PV0+0?GJM;38IYFXWNK[3I^);DHZ;EXK8^6O]TV/
MT/Q5CC>FN$DM&!KK]CKR[D XOGD<>+OV( :/0%R]1N2E?ES;L%T'J/#F7A:R
M%OE^LJM\7Y8>8O'4W$6.8V'G[7(-:Z".RFN8WD"K)K=ADC>">1#FA8<G-PO0
M<=M5ZS=UBS"[D[L9;.5OSI5-0?"S?7+QN2P/"T:;2Z:*<&RO\QC@!WEK6_,N
MUK<%V'OQ/%>"+LGWT-RY7Z:^7F*[XJ/^Z=M?SJY_@@J:)\\NI&7QO^!;^\S:
MG2S^SC:_]6VW^ %R,[^//[S]IZ_1OY*S]R/L)F_-G6.^=N7F!O=+)'@2V5P1
MQ@N6 Z)/NT(_!)"IE\Q*Q<4HF34M/AG<O*U/?L?![GY;JG'IFWLVW/2/2\G[
M4&K&CVC>>QI#_P#)5^L_!^FO:TLU_,?LGQ5SSB7Z=^WLZ?AO]9V#L'9UCL;;
M-I@+0-?)&/-OKD"AGNG@&20_-1H[&@!>+S.8=^XY/S=7 ^U:9IT,EEXVH[=L
MGQEO?EL5$<Q;HS\&U>N>1W'<1.N(<=DC,^%A#7/'D!M 7<!Q=7BO56;7>Y-0
M6UK#TGRC/9N.4UF5Z2JHRV+;L,GWI\1-EN/;61P.,P[[>7(0NMI;BYEC>QD4
MHH\AC*%SCV=@YK4RVD2A<4I2JEC@=?4O%D,QEYV[=MUDJ5?![2[]*MJY/ =*
M-XY7)P.MCF;*Y?:V\K2V7W>"UD#9"T\1J+B6@]E"L.=S$;N9MI.O*UCYS>T3
M(W,OIEZ5Q-=Y&37&G*Z&L>E^^]U[*CR/YKX5N7]]$)N=4%Q/Y?E!U/R'+5J/
MM+K9W*VKS7>2Y:5WI'DM#U/,Y-3[BWWG,U7"3]AM' ]:>IF3SV-QE]M-MO97
MMW!;W%R+2^:8XI9 QSQK.D4#JU<N1>T[+QMN2FVTFZ56X]=E?$.H7;T82L44
MI)5Y9[&Z5.B5YX^B&K]UN$O6'I_;2?D([;+W# >7FF%C0?6 NG85,K=?3%>L
M\SGL=2RR>Q*X_P#"1]8.'YB$<QNS%$?_ !$T_P#]3_VY>XIX@_\ R;_]HM^\
ME;1/YI=1MR;+D\&-S7_B7!CDT.F.B\B%>YX#PT<@E_\ BV(7-\>R_<9<D_RV
M=NV'\MS^)#S_ #KT[%P/,A_XOZLV.,]O"['@^TKS\%V4O&EMNP^F.+5)4=J1
M_A9=R^M<=/W5M^!%W_R]0C#ZF77,_OR^6O4NTF0]#8V2[#GBF:)(GY3*->UP
M!#@;I]0:\ZIJ5>^KT1]@\.JN4?WI>TJ+C^WRR'9^:LO#_P#3PD?Y-_?_ -)6
M7_<K_P!C_65._P _;>;VMLEG&'(7IRF4;S;[CB2)M+_1),8FK'E>Q"=S@J+K
M?P1L:G_&NVLONE+FE]V%'CT.5$4O6#_^QB.#OSMQ9'KK(LF0_P#4_P#;E[C4
M\0?_ )-_^T6_>2MG_P#A/J+N/9KSHQN;)W+A ?9#I7:+R)O942 /#1V$E1?_
M (MB%Q;8]F7N,N1_\;.W,N_EN?Q(>?YEZ=B6X9 _G?U;L<6TZL-LF#[2O1]%
MV4O06V['>F.,&13'^%EF_K7'1?=6WUB[_P"5J,8+Y,NN:7WY?+ZL4SWH/QV/
M*3VY7*<_YVY-2_&\T?83X=_E7]^7M-I+F'I#4EG='J-U,M,KCOK-H;)]XCCO
MAQCN\O<-\MXC/TF0L^E^%W@U75:_+V&G\]RF'"/Q?L/+PE^?ST;D?PLOS)/[
M4WMIT)>OH95]=0&;!EN1^5M<ACIX:<];;N,#[ZIIJ_C4XI^PR^(FUDW);5*#
M7]Y&T%S$>C"D! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 2
M)8^;A\JNGN,<H[R0K% @)$]OYOCCX3-%&N/(CN*E.A6<>;%;2D#N)!!!'M-/
M,?\ #O5C 36E"U2,&BHRQ&UW_P""DFI'506(@5 (JA22<I_$ITMFL;^7J1@X
M"[&WA:-P0L'Y&>@8VXH/HO%&R'L=Q[33U>CYY22LS?:7R]*X>8Y^9LT;FMCV
M]#,,Z/=9\GTWO(\7DS)?;(N'_P HM.+Y+0O/&:W[:#FYG(]G'GOZAI\<RJK"
M:V/CT,PV;SM/]E^53M?'W]ID[*WR&.N&76/NHVSVMQ$0YCXGBK7-(YBB\)*#
M@W&2HTSLJ7,JIUJ5J$"J M6=SN+VSB+S.YJY;:8RRC,MS.[D .  ',N<[PAO
M,G@.*FU:E=FH156R924$VSASJKU:S?4[(UG+[+:UH\G&XG50"G#SIZ<'R$<N
MQG(=I/T#(Y&&6C18R>U^6XXEVX[KJ]G W)\-/2R;'QCJ/GX#%=7419@+:04>
MRWE'CN7!W$&0>%H/T*GZ2X>L9Y2_@P?WO@;65M/YWYOB=)%R\V;Y"3\R @U*
M"#PFBD@@+M*$5)9-414@J]\GE1\QS/8!Z?2K-T*TJZ(JXXV0Q^7'RYDGF3Z5
M6IE2HJ(B0L>_?0@J8HPP>DJC9FBJ$Q5+! :WR?\ ;9@OZFN?X1RO]4Q?7\QL
MA4,H0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $!K'J?TCQG49L%W[R<=G+1AB@NVM\R.2%QU!DK26DM#
MC4$'A4KHY+/SR]4L8O:CS6M:#;U%)UY)QP4NC;1^<P>WZ![SR3+;&;KWK+=[
M?M2W190^=+5K>  $S]#33D2UU.Q;[U2U#M6[=)/J^!Q%X9S5VD+^8<K:W8O#
MSOUXT+UM3HUN'8FYY<KM?<K6X29X\_%W<!?YMM75H>YKP-;>.F0-![^!(6#,
M:A"_;I.':6QIFYI_AZYD<P[EF[V&\8M5JNEUVK<Z? W8N,>T" YVW)\-L^6S
M>2R>+SL5C8WL[[B&T=;.D,7G'4YH<)!4!Q-."]#9UGD@E*-6EMK]!\ZSG@[O
MK\KD+BC&4N;EIQ\_H-YX+$6FW\-886R&FTQ\$=O%44)$8 J?25P;DW.3D]K9
M[[+V(V+<;<=D4D:RZI]'+[J'N"RS=KEX[!EI:,M3"^%TVHLE?)J!#VTKKI2B
MZF2U!9>#BXUJZGEM:\//4+T;JGR\L4J-5V-OBN)M^-FB-K#]%H'S+D'L"R;F
MLLWD<+>6&W[YN,REPSR8KZ1AD$37<'.:T.:==/9->!62S*,9)R54MQJYNU<N
M6I1MRY)-?-2M/6:]Z6=%(-@Y2?-Y*]9E,II\JRD;&8F01NKYCJ%SR7NY:J\!
M7O72SNHN_%12Y5[3S>B^'(Y"X[LY<\]SI2G'T^6TR3J9T[LNHF#&/DD;:Y2T
M?YV-OM.ORGF@>TM!:2U[10COH>Q:V3S<LO.JQ3VHZ>L:3#4+/)+"2>#X?V_2
M4_2_9&?V%BIL'D<Q%E,4U_FX]K870R0:B3(RI>X%A-"!V&OR3G,Q"_/FC'E>
M_$IHVG7LC:=J=Q3C]7"E..]X?29]<1>=#)$#1SVN:">RHHM)8'<DJJAS5_=8
MRU*'<UOV_P#RC_XQ>G_7%]A_WOH/EW]#2_YE_=?^XONROA[R.U-UXK<;\]#=
M1X^5TKX&6[XW/#HW,H'&0@>UW+5S.K*]:<%&E=]?H.GIGA.63S$;W>*7*ZTY
M:<>EF;=5NF3>HMCCXH+MN/R./F<^*Z=&9089 !(P@.:>-&NY\PM'(YQY:3=*
MIK8=[6]&6HPBN;DE%X.GI6U>2*'I1TC'3FZR5_=Y!F2OKUD<$4C(C"V*%KB7
M-XN=Q<[23^Q63/9_\PDDN5+VFOH>@+3I2DY<\I)+92GMVX>@VNN6>J" ( @"
M ( @" ( @" (#3>%Z-W^)ZGR]09,O%+!+=WEW[@V!P>!>,D:&ZR_Z.OGI[%V
M+FH*67[GEW)5KPH>.R_AUVM0>;YZUE*5*?:KO\Y<^H'2.SWYN3 9Z6X; S&N
M;'DX2PN-U;,D$C8P:BG'4*D<G+#E<]*Q"45];8;FJ:%;SM^W=;IR82P^95V>
MWTE=U4Z>W'47"66*ML@S'&UNQ=NEDC,P+1&]FD .;3VN=53)9M9>;DU6JH9-
M<TEZC9C;4N3EE797<^E<2OVQLBVQ.P[79&8,>3MH[>6UNG:#&R6.1[W'PU)'
M!W?6JQ7LPYW7<6#;J;F3T^-K*1R\Z2233Z:MFIKOX<<[C[V>39VZGV5A< M=
M'-YL4PC)X,=);N:) !VN:NS'5X2BN\A5KT>@\=<\)7+<V\O=Y8O=BGZ5M,UZ
M9=%\7L"9^7N;HY3/O:8V7)9Y44$;_:$3*N.IWTGDU/93BM#.ZA/,+EV1X?$[
MFC>'K>GOG<N>;PK2E.KX^S$D=4>B=GOV]&;QMV,=GM#8KASV&6WN&,]C6 0Y
MKFC@'@\E;):C*PN5JL?7YBFM>';>?EWD9<D_4^OXF)'X<LYD,?)]N[KDN\O%
MY;+#4)9[:&,'QU$KR7:AP &D#TK;_5H1EV;:2]'EZSC/PC<NVWWMYRFJ<NUI
M>GZ*&PL3TVN\9TMN>GK\C')<SV]S;MOA&X1M]Y>Y]?+UU\.K\)<Z><YLQWU-
MZ=/I/29?296M/>4YZNDES?>;]E2IZ5=/[GIW@KO#W5_'D'7%XZ\$S(C%P=''
M'I(<YU::.:KGLTLQ-22I14]I?1-*>G696W+GK+FK2FY+B^!8^G?2&^V3N_)[
MGN,K%>QY&.XC%NR%T;F>?.V85<7&M--.2V,WGU?MQ@HTY:>RAHZ5H,LGF9WW
M-2YTULI2KKQ/=X]([[<_4'%;UBRD=M!CC9EUFZ%SW.]UF,I >' #56G)18SZ
MM696N7;7'K1.?T%YG.PS//3DY<*?9=3(>HO3;"]1L;':Y![K3(V9<ZPR$0!D
MC+QXFN:>#V.H*M/=PHM;*9N>7E58I[4=+5M(LZA;Y9X-;'P\J&L8>@W40V@P
M4N^WLVX1H-M'[SI\OD6B(R!M*?1U476>J6*\RM+F\WP/*+PSG>7NGF7W?#M;
M.JOJK0V]AMFV6+V?!LR\EERN-9;.LI'W9!>^!X<"PZ:4:T'2P#V6]O!<6Y?E
M*[WB[+K7 ]GE\A"UEEEY-SCR\N/#A\.!IJ3X;L]CLI)-M;=;K''35:7.;,RY
M;"3[#C"]K9*#E735=O\ 6(RC2<*OS? \2_"%VU<;L7G"+ZZ^K;ZB\8'X?7[>
MWEB=Q8_->988Z2.>2WGB+IYI0TB1Q>' #4XN(X< L%S5>\M2A*.+V8[#>RWA
M99?-POQN54=S6+PQQJ;X7#/=&KNKG2^[ZEV^+@M<E'COLYTY>Z6)TVOSVL H
M YE*:5T<CG/RS;I6M#S.N:*]14$I\O(V]E:UI\#(=P[2GSFP9]G,NV0W$ME%
M9^]EA<P&(-!=H!!H=/*JU[5[DNJY38ZG1S.1=[)O+UHW%1K3A3=YBBZ7;$NN
MGNVY,#=7K+]\EW+=":./RV_6-8VFDN=RT]ZR9W-?F+G,E3"A@T72_P!/L.US
M<W:K6E-RZ^!C^P.DE]LO>N4W9<92.[@R4=TP6\<)C<SWBX;.*N+R#333V5L9
MK/J]9C;Y:<M/4CGZ9H+RF<GF.=2YU+"G%I^XD2]&+^3JD.H8R\0M??67ON!@
M=JHR(1Z=>NE>%?95OU!?E^YY=U*UZ3&_#\GJ'YOG6VO+3HXU,JZE=/[;J%M[
M[)DF%I?PR-N+"]+-?E2C@X$ @EKFDAPKW+4R>:EE[G,L5O7$Z^KZ9'/V.[;Y
M6G5/@REZ:;'SFQMOW.W<EEX\G9!SGX[1$Z(P"8$O9XG.JW4=3>7$GO"MG,S"
M_<YXQY7O,6CZ;=R5AV9W.>.["E*[=_''TEAZ5=';[IQF[S*7.7BR#;NV]V$4
M<+H2/K&R5)+W5'"E*+:SVH?F(**C2C.=H?A]Z==E-S4N94V4X=)FN_-F8W?6
MW[G!9'P.=22SN0*O@N6@ADC1V\Z.':*A<_+9B5BXI+SG<U+3K>=LNU/K3X/C
MY;C".GG2+-[ L]PBUS=O/?Y>U9!9SBW>QMO-&)*/(\PEP!?7@1R6_F]068<:
MQPB_+<<'2- N:?&YRW$Y7(I)TV-5QV])YTPZ(1;$REWE<M?0YB:6W%M;M-OH
M;&2[4]Q#W/J74:."9W4GF(J*7+1U)T7PY'(SE.<E<;5%V=G'>;4=AL/(TM=8
M6SFN!:088Z$'F.2Y7>3XL]5W%K[*]"-2[#Z*Y/86\G;@L,[%+BI!/;RV!A>U
M[K60ZF-+S(1J80SCIXT/*JZ^:U%7[7)*+JJ8U^@\CI?AV>1S7>PN)Q=5RTW>
MGJW&ZUQCV@0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!R+;P6
MUY\1\]I=1QS029>X:^"5K7L-+=QXM-0>/?VKUSE3(56#HO:?(86XRUYII.+F
M^K8SJ*#;>WK>1L]MB;*"9O$21VT3'@^@AH(7E7=FUC)OSGU6.5LQ=5"*?4O@
M4/4$ANQMR.- W[,O*N/^8>LF6_%A]Y>TUM4=,I=^Y+_*S2_PIN:;?=(!!H^P
MX _B3KNZYMAY_<>'\#KLWNN/^HVMU>-.F6Z3R_D,G'YEQLC^/#K/8:Y_(W?N
MLUU\+;@[;VX"#4>_Q\C_ -"U=37/Q(]7O9Y?P0O_ !I_>]QJ'IIORPZ>;MR6
M:O[>2[BN(9[41VSV!X<^</!.L@$>!=C.Y668M1BFE1[^H\?H^J0T[-3N33DF
MFL*<?H-NN^*C;+6FF"OOWR#_ )ZXOZ+=^U$]DO&N6_XY^HM_Q/W#)L+M2<#2
M)I;F2A(KXHHS3[JRZ(J3FNKWFMXUES6;+XM^Q&S-FX;';EZ2X3"9.+S["]Q%
MO%.P=QC:06GL(/B:>PKE9FY*&8E);5(]7I]B&8TVW;FNS*W%/T')&_-I9'8N
M>O=NY(ES8ZRV=R[@RXMW ADH'*M!I=3V2"O997,1OP4UU,^,ZIIT\CF':>Q8
MKI3V/K.GMU;(_/SI)A\;:Z1E+>QLKS'22'2TSQV[1H/<'M);7LYKR=G,]QF9
M/:JM/TGUG.:;^>TVW!?,HQE'KY?>C4G3WJ[E.F#9=G[LQ<[[&UE<Z.$$17EJ
M]YJ]NB0ALC"ZKAQ^4@BG8S>GQS/\2W+%^L\=I6OW-,3R^8@^6+\\>A<57%>F
MK*KJ+UQGWSCG;0VCC;B&WR1$-P^2DMW<-J#Y,441=IU'@36I'#@HRFEJQ+O+
MK6'EB9-5\32ST.XR\&E/!MXR?0HJNTVST4Z?W>QML..5:&9S*RBYO8@0?)8U
MI$<=1P):"2ZGTC3L7'U'-J_<[/RQP1Z_PYI4LCEJ3^>;J^C@OCTF&_%4YHQ&
MVZFG\JN>?^9:M_1'VY=2.%XW7\&U]Y^XVKTLH>G.UJ&H^S;;B/V 7(SOX\_O
M,]?HO\C9^Y'V&8+4.N<E2.']YMK=0U?;+12O'_15ZU?]?YG[3Y'+_P#2"O[2
M]B.M5Y(^N'(TT5M=?$@^UNV,FMY<JYKXI0US7?R:M'--12J]>FUD,'BE[SY!
M*$9:^TU5.6]=!T_#MK;D$@E@P]E#.WBV1EM"US3Z"&U"\H[LWMDWYSZM'*68
MXQA%/[J*??1#=E[C)X#[,O*N_P#</5\M^-#[R]I@U'^5N_<E_E9RIT?ZI8OI
MO'EQD+*>].2]V,?N[F-T" 2 UUD<]?"B]=J&1EF''E:5*GR/P]K=O3E/O(RE
MSTV=%3;&,^)3;F4R=CC8L->LEOKB*UC>7PEC3,]K 3XJT!/&BXT](N0BVY+!
M-^@]G8\89>[<C;5N:<FDMF]T-ZKAGN36/4G3B=R[%W@[PP8_)/QUY(/HP96,
MP!SO0'AJZ&4?-;N6^*K_ '3S>K1[N_E[^Z,W%O@IJAYUC(;^8E33_P 68NGI
M/UBOI_\ ZG_MR]QB\0__ )-_[]OWD75RVN,=8XSJ!CH_,R.T+GWR5@\+I,?.
M/*NXB37@6'5QY449%J3E:>RXJ>?<9]:C*W"&9@JRLNO7%X215=)L3<VFVW9[
M)L+<YNFXDS61U<V^\FL,=>=&1:!18\]-.YRK9!<IET2S*-CO9_/>?.^BNQ>9
M>\H.@S@=C2D$$?:V3X@U_P#FG+)J3_C>:/L,'AW^5?WY>TFW!'Z?;(=OYJR\
M/_T\*8_R;^__ *2LO^X7_L?ZRJVG3/;XW5NP^*VL71[;Q;J&NBS^NNR.RCIG
MZ:_B+'??)9A;WOM/S_+ZO:9\DN_S=Z_NC2U']W&?^)_X2CZPD ;%J0/_ !9B
MZ5-/\JLFG_\ J?\ MR]QJ>(5_+?_ +1;]Y[U<MKG'6&-Z@8Z/S,GL^Z]]<QO
M!TEA*/*NXJ]Q8=7HTJF1DI-VF\)JGGW&QK=MPA#,P596'S?NO":]'H*OI1B+
MJUVX[<&59ISFZ;B3-9#5S:;@UBB';1D6D4[.*KG9IW.6/RP2BO+K,NBV91L=
M[/Y[S<Y>?8NI+UEIZ'7-O;["N;B:5K(8<IE7RRN(#6M;<O<XGL  XK+J.-ZB
MQP7L-?P^TLHV\$I3]ICV6ZAX[J3>SX&PW%:;;V%"XQ9/+S7<5MD<B/I16C)'
M!T<1'!\KA5U>':#L0RL\NE)P<IO8J-I?2<R]JUK/3=J-V-FTL')RC&4^B*;J
METTQ]*-D;=S_ $\LK>QVWMG+XD,CI#88^TNH)'FE31K6O+G$\2>T\2N==M7F
MW.<9=+:9Z+*9O)1C&S9N0Z(QE%OVU\JEBZN_]JG:FSXO%<9S-6SY&C_Z/'GW
MF=Y] #6K/D>QSW']6+]+V&EK?\3NK"VW+D:K]F.,C9ZYQZ,( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" I98]!UCV?O*R9BDB6KE0@)4
ML#)@.)$PY2CF/^+T(5E%/K*1PDB.B4 $\CV'U*R=3"ZK:1M<A)&"H:+'K744
M$DP.^92215"@DDS007$+[2X8V>UG:Z.:*1H<Q['"A#FG@00:$'FH54TTZ,MU
MXHY'ZP= ;_:SY]Q[)@EO]L.+I;G&L!EN; <SIYNDA'81XFCG4<5[+3]5C>I"
MYA/U2^DY=ZR[:YE\OL\N)=/A=ZC3VN3?TYR$Q?C;P276$<YQ/DW+/'+"#V->
MVL@'8YI_"6+6\FI1[Y;5MZAE+O++EW/V_2=7ZBO)G4/:ZN" XU^)/J)-N+=3
MME6,O_8.WY R=C#47&2(\9('$^4'>6T=^KT+VND9-6[?>/YI^J/T[3D9F[S3
MINC[=[]Q?NC?P^7%[-:[JZA6IM[)A;-CMO3"DDQ'%LETWZ+ >(B/B<?:H.#M
M34=64:V[.+WRX=729;.7<Z.6SAQ.IZ\*4 'T0.0'8%Y4Z51J*@BIX3WH00U5
MB"'71014@<>TT 0@A:V2?V3Y<1_QM.)]7K5FZ$).70BKC8V-@CC% .Q5,J5#
MU"0@*F*/2*NYG[BHV9(QH354N$ 0&M\G_;9@OZFN?X1RO]4Q?7\QLA4,H0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M-W!+;W$39896F.6*1H>US7BA!!J#6JC8\"914DU)53)S&,C8UC&AK&@!K0*
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M'TJ#&[M:X&H6HFF9FB#+9"\MW06.,B$F3O-7D/?7RHFLIKD>>W344;WJ:JM
MBRX7IOLS!9:7<-OB;>?<]T\SW.7F;YDSIY#J?(P.J(RXGZ&E;<LW>E;5MR?*
MMVSTF)6H*7,EB9<75[:K6+5/*A* \JI(/"X! 2W.KZE!4@UZG:(QKF_!'9ZS
MV*417&B)K+8$ATIU$<HOH#_C45X%E'B5"&0(#T"J GQ1:?$[VOO*C=3*E0G*
MI8( @" UOD_[;,%_4US_  CE?ZIB^OYC9"H90@" ( @" ( @" ( @" ( @"
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MN.W^F6W=M9:/-V$MY)?0L?&T7-P96Z910\"*^KBCDVJ%U!(SE5+A $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M&.+6RM.F2GHU--%SLQ:[JY*'!GH=.S7YK+0NTIS+U[_69,L!T @" ( @" (
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M;;SI&/\ ::;A[Y@"#R(#E&>N*=^4ELJ7T/+RL9&W"6VE?2V_>9VM([80! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0&E.DW]JW5+^>P_X<J[>=_EK/4_<>)T3_L,
MW]Y>V1[L3^WGJ%_-K7[T:KF?Y.UUOVLMIO\ V^9ZH^R)1;_QE_TOW:SJOMN
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M&H+! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M_>_#XDK0_P#[2P_\' O79=?^ _NR]I\AU+_OH_\ N6O])U@O(GUXX_W/+?\
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M=?U<<$)<0WM]7:F4MRN9+ECM:DEZ63J]ZW9UOO)_+&4&]^R,3;7Z?>E/=/\
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M7:GAT;^.!)R/Q#97*;KQ^)V#AOM.PF=Y1M[H.CN+J1Q'&/23Y36 5U.!X5)
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M0DC$3G=E!Z57F+<I&V #B351S%N4F!H;P 4;2U*$2@D( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M[7<\O)^S2GJ+VL9M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $!+/E=M%;$K@0GW?M_53$KV3S^3_\*J<1V3W^
M3^C[JC$=D?44]'RIB.R1CR^RB8EE0C52P0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
& $ 0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm2227887d1-tbl_exvivo4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-tbl_exvivo4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#,6AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXP+6,P,# @-SDN9&%B86-B8BP@,C R,2\P-"\Q-"TP,#HS.3HT
M-" @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A=&]R5&]O
M;#TB061O8F4@26QL=7-T<F%T;W(@,C4N-" H36%C:6YT;W-H*2(@>&UP34TZ
M26YS=&%N8V5)1#TB>&UP+FEI9#HR13,X,3-%-3@X1$$Q,45$040V0CDT04)&
M,T,S-$(X02(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HR13,X,3-%-C@X
M1$$Q,45$040V0CDT04)&,T,S-$(X02(^(#QX;7!-33I$97)I=F5D1G)O;2!S
M=%)E9CII;G-T86YC94E$/2)X;7 N:6ED.C)%,S@Q,T4S.#A$03$Q141!1#9"
M.31!0D8S0S,T0CA!(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.C)%,S@Q
M,T4T.#A$03$Q141!1#9".31!0D8S0S,T0CA!(B\^(#PO<F1F.D1E<V-R:7!T
M:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R
M(C\^_^X #D%D;V)E &3      ?_; (0 ! ,# P,#! ,#! 8$ P0&!P4$! 4'
M" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1$1$1%!04%!04%!04% $$
M!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04_\  $0@#&P=L P$1  (1 0,1 ?_$ .   0 "
M P$! 0$            %!@,$!P@" 0D! 0 " P$!               $!0$"
M P8'$  !! $" P,%!P\'!PD%! L!  (#! 41!B$2!S%!$U%A(A0(<8&1H3)2
M%['!T4)B<M(C,U.4U!55E8*2LM,D5!:BPD.SM'4WX6-S-'0U-A@X\$0EA7:#
MDZ/#A*2U5O'C1:4F5T81 0 " 0(# P8,!0(& @(" P ! @,1!"$Q!4%1$F%Q
MH=&2$X&1L<$B,E+2%!4&%O!"8E.3X3-R@J*R(S3QPN)#)#5S-H/_V@ , P$
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M3M#)-8GEAU +AVCRJ-GP6PW\%N:SZ?O\>]PQFQZ^&=>?/AP32X+ 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$'D"_%AYNN-V+<!A&&?F)Q=-IPC@\/F=KSN
M<0 /?7MZS>-G'@^MX8TT?!<M<-NMVC-IX/>V\7BX1IQYNU_L7V?_ ,[M[]-@
M_K50>]WW]?Q3ZGT7\+T#OP^W7[RU;4QVRJ%2_9Z?1XZ7Q=&3FC.U\3YHFN,;
M))(S+RZ<_D) .NA4//?-:8C-K\,+KI^#98Z7MLXI.O/PVX3,<HF8UTY^E3-N
M=<F9/=[=G[@P3L#<=(^KXLEKQPVTTZ-C<WP8] X\&N!/'3N.JGYNE^'%[REO
M%'/EV?&\_LOU9&7=_ALV+W5M?#];7Z7=]6.??YF7>'6Z#;VZF[2PF&=GLB"R
M&7PK/@:69#H(6CPI.8C4<W$:'AW%:[?IDY,?O+6\,>;L[^;?J?ZJKMMU^&Q8
M_?6X1PMI]*?Y?JSK_$.IU7V)*T,EN)L%IS&NG@8_Q6LD(U<T/Y6\P!X:\HU\
MBJ+::\.3VN.;36)M&DZ<8UUTGS\-?B?ENK!=JSTK3!)6LQOAFC/8YDC2UP/N
M@I6TUF)CG#&3'7)6:VXQ:-)\TO*G36S/TZZOOV_=<6P33RX>9SCH'"1X,#].
MSTG",^XY>QWM8W&U\<=WB];XET.]NF=7G#;E,SCGX?JS\,Z?&[7UPW!^P>GN
M09&_DM90MQT.AXZ3:F7_ /#:\*@Z9A]YGCNKQ_CX7T7]5[S\/T^^G/)]"/AY
M_P#3JI_0;;\6*V)F]T7:XF.3;*UD9);SU*C'@M#N[G>7@Z>0*=U7--\U:1/U
M?EE0?I'9QAV.7<6C7WFOPUK$_+.K-T6W)MG+W\RW:VT8\'=@JMD<X7I+ G](
M\L9+XQR#7[;BM>I8<E*U\=_%&O=IHZ?I??;;-DR?A]O&*T5^W,^+R<8X>=/]
M/.LD6^<_:V[;PYP]Z")\L;7V/'+W1.#7L(,4>CAKKW]A4;>=.G!2+Q;Q1YO]
M5IT7]31O\]L-L?N[1&OUM==.<?5A,=3>I-;IQCJ5M]+]HV[TSHH:GC>K_BXV
M\SW\W))\DE@TT^V7#9;.=S:8UTB$_KO7*],QUM-?':\Z1&NG".<ZZ3Y/C9&]
M1\?0V+3WON>N<3%=C$D%!K_6)7^)J8FL/)'S.>P!_8 !VG0:K'X.ULTXJ3XM
M.WEYVT=;QX]C7=YX]W%HUBNOBGCRTX1SCCY',9O::D,[I*NV'/QK'<IDDM$/
M()X$\L):TGR:GW5;1T7AQOQ\W^KQUOUW/BUK@^C_ ,7_ ..D.K[$ZA8'?]!]
MK$N=%:KD"W0FT$T1=V'@2"T]SA\1X*GW6TOM[:6Y=DO;])ZS@ZCCFV/A,<ZS
MSC_3RK8H2\<?]H?=%G";3K8:E(8I\Y*^*9S3HXU86@R-'?Z1<P'S:CO5WTC!
M%\LVG^7Y7@OUGO[8-K7%6=)RSI/_  QS^6/@:/1OI/MEVUZ>X]PT(LED\DWQ
MXH[3?$AB@YCR 1N]$EP',2X'MT'GZ]1W^3WDTI.D5[D;],_IW;?A:Y\U(O>_
M'Z7&(CLX<N/,ZA] J><MU+FRV5<1(YQ;D(7E[*Y9IZ+V-8UVCAIH6@ 'S=^-
MGU6:1,9-;=W>=:_1]-Q>MMK%<<_S1QT\\1&O%T_'/?M+:-=VZ<DR8XFJ&WLD
M06M<V(:!Q!U)<1H/*X^<JIO'OLL^"/K3PA[+!,[/:1^(O$^[K]*WF_CX9<CM
M^TDZ6U,<%M>:[C:_I23RS%DG)\YS8XI SL/:XJZKT;2/IWTF?X[WA<GZXUM/
MN<$VK';,Z3I\$3I\<ND=/NI.#ZA4Y9,<U]7(U>7UNA,07L#M='-<.#FG337X
M0."JMWLK[>>/&)Y2]=T;KF#J5)FGT;5YUG^.,.%[T_\ 4;6_WMA?]747HMM_
MZ$_\-_\ [/FO5/\ _8J__P"3#\E$S[3W_7]M_P#0V_Z42X=$^K?X/G6'Z]^O
MA\UO_J[KM'_PG@O]W5/]0Q>=W'^[;SS\KZ5TW_U<7_!3_MAN97$XW.4)L7EZ
MS+>/GY?&KR<6.Y'![==-.QS05ICR6I;Q5G24C<;?'N,<X\D>*L\XGXW%NM>P
M]G[>V--D<+AZ]*\VS P3Q AP:]QU'$GM5]TW=9<F;2UIF-)?//U3TC9[;8S?
M%CBMO%7C#!T-V+M'<>RY,AG,1!>NB]-$)I02[D:R,@<".S4K;JFZRX\VE;3$
M:.7Z3Z3M-SLYOEQQ:WCF-9\T)OK;AL7@>E3\9AZK*="*Y Z."+4-!>]SG::Z
M]I*C],R6R;GQ6G6=)67ZJVV+;]+G'BK%:Q:O"/.I>Q.KU;9^Q,=@L7BI\UG(
MW6)K,,?,R*&-\[RTN<&/))''0-T\ZG[KI\YLTVM:*UX?(\[TC]25V6QIAQXY
MRY(\4S$<HCQ3SX3_ !VNB]-NM.-WYD'86S1=B\QR.D@C\3QHIFL&K@UW*PAP
M''E([.]5>\Z;;!7Q1/BAZSH?ZHQ]1R>ZM7W=]-8XZQ/R<?(F.HG5'!]/(867
M(WW<M::7UL?"X-<6 D<[W'7D9J- ="2>P<#IPV>QON)X<(CM6'6NOX.FUB+1
MXKVY5CY9GLA0,?[2 9:@;N/;4V/QUGC';BE,A##IZ08^./G''B6N]XJROT;A
M/@OK,/+X?UOI:/?X9I6W;$Z^B8C7X)=7SV[*F)VA:WA0:W)4H:PN5VLD\-LT
M;M"-'\KM-0?FJFQ8)OEC'/"=='M]YU&F':6W-/IUBOBCCIK'GX_(Y-+[3%+]
MC-MQX(C,/L/B]1-KFC9 QC'"5TG@M.KG.+0P-^U))[E=1T6?'IXN&G/3_5X:
MWZZI[GQ1B^GK,>'Q<--(XZ^'MUTTT[.:Y2=7L=C]@T-[9N@^G-DBYM'%,D$D
MLKFN+=0XM9HT@<W,1P&G:2 8,=/M;/.*LZ^'G+T%OU)CQ["NZRUFLW^K3769
M^3AVZ]RBN]I'*,8V[)M!S<6\Z-F-EX![N$A@Y2=0K#\FKR]YQ\W^KS4_KC+$
M>.=O]#O\4_+X='7MD;UQ6_,(W-8H/C:UY@LUY=/$BF: XM.A((T<"".T? J3
M<[:V"_AL]YTKJF+J&'WN/6..DQ/.)<RJ>TCBW29"/)822JZHTBHR&QZP^Q-X
M@8& &&,,&FKBXD]G82K:W1K</#;77R::>EX['^N,4S>+XIKX>6EM?%.NFGU8
MT[]6+&>TC7_:C:6Y=ORXJJ]P!G9*99(@[L+XW1QDCCJ2WCY 5M?HT^'6EO%+
M3!^MZ^]\.?%..._768\\:1_'8N?4CJ?)L&IB\E6Q+<SC,GS!EN.UX+6N#0]F
MFD4H<'M)+2#W*!L]C^(FU9MX9KY/]7H.M]>GIU*7KC]Y2_;XM/+'\LZZQR6W
M;.>K[GV_CL_5;R19"!DWA<W/X;R-'L+M!J6.!;KIW*%GQ3BO-)[)7NPW==WM
MZ9J\KQKYN^/@G@H6UNLAW;OB;:6,PFM*%]CFRWK7,/ KDM$OA"'L>[E '/\
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M5F9GQQK]+C_P]G+X'[TKP&\,;U2_;,VV[>%PF2-P6(W1/;!!%*Q\S(^8M:-
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M//I0@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MM.XW'^Y;E'/37G,SWS\GGX=E5$^@H#>>T\?O7;UK 9 EC9@'P6&C5T,[.+)
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MXD?SA\(36#27Z'-=\D@^XFIH_5E@0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M6:YTGIN ' ,*[Y=CEQT\=HX../>8LE_!6>+I*@I@@(" @(" @(" @(" @("
M@()#&?Z7^3]=2<':B[CL2"E(@@(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @T\I_U-_NA;5YN>3DKR[H@@(" @((C=&X*6U-NY3<F1.E/%UI+4HUT+
MO#:2& \>+CHT><K:E9M:(CM8M,1&LOYD9)^;W-8S.[;;'V'/L^L92T!Z+)KS
MWN;KY YP("]/&E=*O/6UOK9[O]FS>_\ C+IACX;,OB97 G]E7-3JXLA:# \]
M_&(M;KWN:50[O'X,D]T\5UM\GCI#I&X=T;>VE2CR.Y<E!BZ$LHKQV+3Q&QTS
MFN>& GO+6./O*-6EK3I$:NUK17G.C[P.X\%NB@,IMW(0Y+'%[HA9K/$D?.S3
MF;J.\:I:LUG28T9B8F-81.=ZE[!VQD'8G<&XJ..R3&M>^K8F:R0->-6D@^4+
M>N*]HUB-6MLE:\YB%']H;J8[8FS+=;!9F''[SLB%U* \CK)K22^'))&QX/8
M[TM."[[7#X[<8X.6XR>"DZ3Q<X]E3?\ @ZV,S-+=&?B&YLYF(S6CNSEUJU+-
M%'&W3G)<XN=Z(4G>XIUCPQPB'#:9(\,ZSQF7J2Q8KU()+5N5D%6%IDFFE<&1
ML8T:ESG.T  ':2JJ(U3W/INO/2"O<-&3=M(S@\I<SQ)(=1_SK&&/_*4C\-DT
MU\,N7OJ=\+WC<IC<S2BR6(N0W\?..:&W5D;-"\:Z>B]A(/%<)B8G276)UY/(
M_MI_]][2_P"RV_\ 61JWZ?RLK-]_+\/S/2W2S_ACLK_<.+_V.)5F;_<MYY3\
M7U*^:&7=/4;8VRG-CW1GJF-L/;SMK2/YIRWRB)@<_3S\JQ3%>_U8U9M>M><Z
M,6U^I_3_ 'I/ZKMG<-._=T)%1KS'8( U);%*&/( '$AO!9OAO3G!7)6W*5M7
M)NJ&ZNJ73[95D4MS[@JT+Q <:A+I9VM< 071Q->YH(/#4<5UIAO?E#2V2M><
ML@ZF]/C@F;F&Y*'[!?*VN+WCM\,3/!<(W=[7D-)Y7 %/<WUTTG4\==-=>"9P
M>?PNYL<S+8"]#D<9(YS([5=P?&7,/*X CR%:6K-9TEM$Q,:PT]R[UVGLV!EC
M=&9JXIDOY)MF4-DDT[>1G%SM._E"S3':_*-6+6BO.=$-MWK!TRW7<9CL%N:G
M8ORD-AJO<ZO+(XG0-C;.V,O)\C=2M[8,E8UF&M<M+<IA=UQ=%5P_4O8.X<HS
M"83<5&_EI.?DIP3-?*?"!<_1H\@!)76V*]8UF.#2+UF=(F$QG,_A=LXY^6S]
MZ''8R-S626K#@R,.>>5H)/E*TK6;3I#:9B(UE@V[NS;6[JTUS;.4KY6K _PI
MI:KQ(UDF@=RDCOT.JS>EJ\XT8K:+<IU1VZ.I6PMERBON?<%/'6RWG%5\G/8Y
M2-0?"C#GZ'N/+Q6U,5[\H8M>M><Z-3;G5WIKNVVS'X#<M.U?ET$55SG032$G
M31C)@QSCP[&@E9O@O6-9ABN2MN4PNJXN@@(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(""J=2]WQ;$V-F]T/<!-1K.]3:[0AUJ7\7 W0]NLCFZ^9=
M<5/'>*M,E_#69?S7.*R][%7=T/C?+CX;<56W<=J?[3;;+*W4]Y(B<2?<\J]+
MXHB?"\_X;3$V\K^@?L_[V&^.F.)MSR>)E,8W]EY'7Y7BU0 QQ\[XRQY/E)7G
MMSC\&2>Y>8,GCI$N<^V;_P"#-N_[T=_L[U)V'UY\SAO?J1YU\]F;_@CM?_\
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M/8F[N8G'$QWNI>S-_P $=K__ *?_ /M&RHN\_P!V?@^1WVO^W'\=KS5[(_\
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M?9F%Z.26.2O2A#G,?*#X@<X^@SAR@N=W+KFVE<=/%KQ<L6YF]M(C@]'JN31
M0$! 0$! 02>%_+R?>?77.[OBYII<D@0$&CDOD,]T_64;/RA*P<Y1JBI8@("
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M4B" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#3RG_ %-_NA;5YN>3
MDKR[H@@(" @TLQ2FR>)O8ZM:=2L7*\M>*Y&T.?"Z5A8)&@D ENNH6:SI.I+C
MG3#V:L!TUW7%NR/,6,I;K0RQ58IH61-CDG;R&35KCJ>0O;I]TIF;=VR5\.FB
M+BVU<<ZP[@H24YSU=Z08CJYC<=2R-R3'6<9.^:O<A8V1W)*SEDC+7$#1Q:PZ
M_<J1@SSBF9CM<<N*,D:2TMK=#\)A.GF1Z:9F_-G=O7YGSQF5C8):[G\I_%%I
M=H6O;XC3\XG74<%M?<3-XO'"2N&(IX><.5CV*\5Z^)#N^Q^R^;4UO46>L<FO
M9XWC<NNG?X7O*7^83I]7BB_@JZ\^"=W%[(>S,K8JNQ&5LX>G5K1UO5V1,G=(
M]CG.=+)(YS2Y[R[CP\PT&@7.F^O'.-72VTI/D=OW=M?%;UVWD=KYIKG8W)1>
M%-X;N5[2UP>Q[3Q])KFM<->&HXJ#2\TM$QV)5JQ:-)>>L1['-/%9VIEAO&9]
M:G8CLQ0-H-9+K$\/:#*9W#7AV^&K"V_F8T\*%79Q6VNKN>_^F^U>I>(;B-T5
M72LB<7U+<+O#LUWNT!=$_0@:@<0X%I[QV*#BRVQSK5,OCK>-)<!F]BJBZUSP
M;SE92UX0OQ[7R\OD\06&C7S\BL/S"=/J^E!G8QKSX.V=,ND&T.E=*2+ Q/GR
MEIK6W<M:+7690./*-  QFO'D:/=U(U4'-GMEGBF8\5<<:0ANK_0W'=7;F+N7
MLO/C'8N*6)C88F2AXF<UQ)YG#33E6^#<3BUTCFURX(R::]CH>V\)%MS;>(VW
M'*;$.)HUL>R9X#3(VK"V$.(&H!<&ZD*/>WBM,][K6OAB([G#M[^R1LS<F0ER
M>W,C-MN:PXOFJQPMM4PYW$F.,OB<SCW!_+Y %.Q[ZU8TF-47)M*VG6.#7V=[
M(&T<'D8[^Y\O-N)D)#XZ0@%*LYP.H\5HDE<X>8/&O?PX+.3?6M&D1HQCV=:\
M9XN\9W*U=J[<R&9-5\E'#5);3ZE5K _P*L9>YL;7%K=0UOHMU'D4"M?%:([T
MRTZ1J\>G">SQUBW86[?OY/9F7R!?/)7MQ5HZ$DGRG",>*X,>[B>5K^7R-5QX
MLV*O&(M"M\.'-;APEJ]<MF],.F^Q\9M;:%R/)[EN9)ES(WI)XK%P05J\L?(X
M1 ".,OF!#>&NG'FTU&VVR9,EYM;EHUW&.F.D1'/5Z!]F"E8I]&L(ZPWD]9EN
M6(@>WPW67AI/N\NH\RK]Y.N64S;1ICAH=2?9BV7OW)3YVA9EV_F[3C);EK,;
M-6FD=Q<]\+BSTR>TM>W7M()XK.+>7I&G.&,NVK>=>4JGM[V,]NT;\=G<>Y+&
M8IQN#C3KUFT _3[5[_%G=H>_EY3YPNU]_:8X1HY4V58YSJ](XS&8_"X^MB<3
M6CIXVG&V&M6A;RQLC;P  "K9F9G64^(T<,ZE>ROMO?6X+6Y<3EY=OY"^\S9"
M(5VVZ\DSCJZ1K/$B+7//%WI$$\=.U3L.]M2-)C5#R[6MYUCA+3QGLA[-I;;R
M6+MY2Q<SV0;'&S,NA8T5F1S1RGP8.9P#GAG(YSGD\I.FG'7:=]:;1.G!B-I2
M(T=&Z1])Z727$7\11R4N29?LBTZ6:-L1:1&V/E :3K\E1L^><LZS"1BQ1CC2
M% WU[)>S=T9.?+;?R,VV[%EQDGK1PMM4^=W$F.,OC<S4\2 _E\@"D8][:L:3
M&KADVE;3K'"4'@?8QV_3NQS[BW-9RM)AYG5*M5M'GT[G/,LYT\O+H?.%O;J%
MICA&CG795CG.KTIC<;0P^/K8K%UV5,=3C;!5K1#E9'&P:-: JV9F9UE81&C;
M6 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 016Y<%#N? 9';MFS/4
MJY2!]2Q8IN8R=L4HY7ACI&2-!<TEO%I[5M2WAF)[F+1K&B@=-N@.R>EV;GS^
M"L7[F0FKNJ!V1D@E;&Q[FN<6>%!$0X\H&NO8I&;<WR1I.CABV]<<ZPZHHJ0Y
MYU/Z-[3ZLMQO^(Y;E6;%F7U>?'OBBD<V?EYFO,L4H+=6 CAP4C#GMBUT[7'+
MAKDYH*[[.6SLCLC&; MY;,R83$7);U&0SUO6&.G!#H^;U;E\/5SG <FNI/%=
M(W5HO-M(UEI.WK-(KK.D+]L;9N,Z?[6H;1PTL\^-QWC>!+;<Q\Y]8F?.[F,;
M(VG1TA T:."CY,DWM-I=L=(I72%'Z=>SULOIEN'_ !+@;^4L7_ DJ^'>FKR0
M\DI:2=(J\3M?1X>DN^7=6R5TG1QQ;>N.=8U73>^P-J]0\3^Q]U46VZ["7UY0
M3'/!(1ISQ2-XM/E'8>\%<,>6V.=:NUZ5O&DN'2>QELYUWQ(MQ9)F.YM?5RR!
MTW+Y!+R@:^?PU._'VTY0B?@J=\NU["Z;[2Z;8QV,VM2\ 3$.MVY7>)9G<W70
MR2'MTU.C1HT=P4+)EMDG6R73'6D:0Y3[0?4C8F'O0;#ZA[6L9G%7*S,A6O59
M6,DB>Y\D6L>O(6O:6'L?H0>/ Z*7M<5YCQ4G24?<9:5^C:-5/V5T]]EKU&KO
M>7<3Y:@'CG"Y[(5&20O83^+EK0M;(YP(^1S/#ON@>/;)EW&OAT^*'+'BP_6U
M^-SCHT7[L]HVOF<<W^R2Y+)99S@SD:RN]LT@):/DZE[6@=Q(4G<?1P:3W1"/
M@^EFUCRO:N]MB;8ZA89V"W32%JIKXD,C2630RZ:"2)XXM<-?</800J3'DM2=
M:K6](O&DN%/]C':)N&2/<F1;0YM1 8X'2AGD\7E U\_A^\I_YA;3E")^"IWR
M[?L+IWM7IOASAMK5#!%(X26K,KO$L6) - Z5^@UT'8  T=P"@Y,MLDZV2Z4K
M2-(4O=OLY[(WEO6??>4OY6++V):TSX:TU=M8.J11Q,T:^N]VA$3>;T^W7L7:
MFZO2GAB(T<;;>MK^+CJZIDZ$.5QUS%V'.;7NP2UI71D!X9,PL<6D@C70\-0H
ML3I.J2YKTTZ!;.Z5YVQN';U[)V;MFH^A)'?EKR1"*26.4D"*"(\VL3?MM-->
M"DYMS;+&DZ(V+;UQSK&J;ZC])=F]4:<4&Y:SVW:P+:>3JN$5N$..I:'$.:YI
M^:]KAWCCQ6F+/;'/!TR8JY(TER&G[&6SXK@EO;AR-FB#KZO&R&%Y&O &31_=
MVZ-'O*7._MIRA&C94[Y>@-M;9P>S\-6P&W*;*.*J@B*%FIU+CJYSG.)+G$\2
MYQU5?>\WG6>:;6L5C2'/,=[/6R\9U"?U*KW\H[.OOV<H:[YJYJ>/;<]SV\HK
MA_(#(>4>)KYRI,[JTT\'#31'KMZQ?Q\=70MS;7P6\<-8V_N.DR]BK0'B0OU!
M#AQ:YCFD.:X'L<TZJ/2\TG6.;O:L6C27 +GL9;/EN&6CN'(UJ).OJ\C(9G@:
M\0)-&=W9JT^^I\;^VG*$.=E3OEV#IUTHV;TOI2UMLUGFU9T%O(VG"6W,&\0'
M/#6@-'S6-:/-JH>7-;)/%)QXJTC2%W7%U$! 0$! 0$!!)X7\O)]Y]=<[N^+F
MFER2! 0:.2^0SW3]91L_*$K!SE&J*EB @(" @("#F^^.A73KJ)F_\0[HI3V,
MGX+*WB16986^'$26CE80/MBIV#?9<-?#6>"%FV6+-;Q7C6?.LNX-C;=W-L]^
MQ<M ^3;KXJ]=T#)',?X=-\<D0YVGFX&-ONJ/CSVI?QQS];ODPUR4\%N31Z?]
M,-H],JMVGM*M+6@R$C);(FF?.2^,%K="\G3@5ON-S?-,3?L:X-O3#$Q2--6E
MO_HUL3J9>J9'=M2:Q:I1&O7=#8D@ C<XO((80#Q*WP;S)AB8I/-IGVF/-,3>
M-=%QPV)I8'#X_!8UI9CL96AI5&.<7N;#6C;&P%QXDAK1Q*BWO-[3:><I-*16
ML5CE#=6K80<XWST,Z<]1<RW/[GQ\LV4; RL9H+$L ='&7%O,&$ D<Q&O;IH.
MY3L&^RX:^&L\$+/LL6:WBO'%;MI[5PNRL!3VSMZ UL11#Q7B<XO=^,>Z1Q+G
M:DDN<3J5&RY;9+3:W.4G%BKCK%:\(A\[OVGA=\;=N;6W#$^;#W_"]9BC>Z)Q
M\"5DS-'-T(])C4Q9;8K1:O.&,N*N6LUMRE&[!Z;;4Z9X^UC-IUY*]2Y,+,[9
M9GSDR!H9J"\G3@%TS[F^:8F_8TP;>F&-*1I"3W9M3";VP%O;.XJ_K.(NA@GB
M#BQVL;VR-+7-T((<T'4+GBRVQ6BU><.F7%7)6:VC6)0?3[I/LGICZ^=HTGUI
M,EX?K<DTKYWN$/-R %Y.@'.> 77<;K)GT\<\G'!M<>'7P1IJNRBI3DN\O9NZ
M4[UO292WC),;DYW&2S9Q<OJWBO<=2YT9#X]2>)<& G7B58X>HYL<:1.L>57Y
MNGX<LZS''R-G8OL]],.G]Z/+8G&ON9B!W-7R&1D]9EB/<8VZ-C:1W.#.;SK&
M??YLL:3.D>1M@V.'%.M8XNHJO3A!S/>G03IOO_/2[DW+1GGRLT<<3Y(K,L+2
MR)O*WT6$#L4_#OLN*OAK/!!S;+%FMXKQK/G5\>RAT8!U_9=H^;UZQ^$NWYKN
M.^/B<?RO;_9],K_L[I?L#8!D?M' U\=/*.62T.>>R6G[7QIW22<O#Y/-HH>;
M<Y<OU[:IF';8\7U*Q"VJ,D.2;S]FWI7O;(R9>YCIL;DYR769\7+ZN)7$ZESH
MW-?'S'O<& GO5CAZCFQ1I$ZQY5?FZ?ARSK,<?(VMA^SYTRZ>Y!F7Q&.DN9B(
MZU[^1D]8EA/EC:&M8T_=!G-YUKGW^;-&DSP\C;!L<.&=:QQ6[>^QMN]0\&=O
M;G@?8Q9E98,<4CH7>)%KRGF80>]1L.>V&WBKS2,V&N6OAMR?&Q=A;;Z<X5^
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MY=T00$! 0$! 0$! 0$! 0$! 0$! 0$'Q)''-&^&9C9(I&EDD;P'-<UPT((/
M@A!YRW/['>SLK?EN[=S-K!0S.+S2=$V[!&7$G2/5T;PT>1SG>ZK*F_M$:3&J
M%?9TF=8X-;;_ +&FUZ-R*QN'<-K+UHR'.JP0-HMD([G.\29W*>_E(/G6;;^T
MQPC1BNSK'.=7I&E2J8VG7Q]"!E:C5C9!6KQ -CCBC :UK0.P #0*MF9F=93H
MC1L+ (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MMO(3.L&%VA',QFC6!W'Y1;J.XA2<W4,V6OAF>'D1L.PPXK>*L<74U7IX@("
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M^L_<'6_M6_QU^X?2GUO_ +U;_AE?]63\#L^Z/:GUG[@ZW]JW^.OW#Z4^M_\
M>K?\,K_JR?@=GW1[4^L_<'6_M6_QU^X?2GUO_O5O^&5_U9/P.S[H]J?6?N#K
M?VK?XZ_</I3ZW_WJW_#*_P"K)^!V?='M3ZS]P=;^U;_'7[A]*?6_^]6_X97_
M %9/P.S[H]J?6?N#K?VK?XZ_</I3ZW_WJW_#*_ZLGX'9]T>U/K/W!UO[5O\
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M]P=;^U;_ !U^X?2GUO\ [U;_ (97_5D_ [/NCVI]9^X.M_:M_CK]P^E/K?\
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MO[5O\=?N'TI];_[U;_AE?]63\#L^Z/:GUG[@ZW]JW^.OW#Z4^M_]ZM_PRO\
MJR?@=GW1[4^L_<'6_M6_QU^X?2GUO_O5O^&5_P!63\#L^Z/:GUG[@ZW]JW^.
MOW#Z4^M_]ZM_PRO^K)^!V?='M3ZS]P=;^U;_ !U^X?2GUO\ [U;_ (97_5D_
M [/NCVI]9^X.M_:M_CK]P^E/K?\ WJW_  RO^K)^!V?='M3ZS]P=;^U;_'7[
MA]*?6_\ O5O^&5_U9/P.S[H]J?6?N#K?VK?XZ_</I3ZW_P!ZM_PRO^K)^!V?
M='M3ZS]P=;^U;_'7[A]*?6_^]6_X97_5D_ [/NCVI]9^X.M_:M_CK]P^E/K?
M_>K?\,K_ *LGX'9]T>U/K/W!UO[5O\=?N'TI];_[U;_AE?\ 5D_ [/NCVI]9
M^X.M_:M_CK]P^E/K?_>K?\,K_JR?@=GW1[4^L_<'6_M6_P =?N'TI];_ .]6
M_P"&5_U9/P.S[H]J?6?N#K?VK?XZ_</I3ZW_ -ZM_P ,K_JR?@=GW1[4^L_<
M'6_M6_QU^X?2GUO_ +U;_AE?]63\#L^Z/:GUG[@ZW]JW^.OW#Z4^M_\ >K?\
M,K_JR?@=GW1[4^L_<'6_M6_QU^X?2GUO_O5O^&5_U9/P.S[H]J?6?N#K?VK?
MXZ_</I3ZW_WJW_#*_P"K)^!V?='M3ZS]P=;^U;_'7[A]*?6_^]6_X97_ %9/
MP.S[H]J?6?N#K?VK?XZ_</I3ZW_WJW_#*_ZLGX'9]T>U/K/W!UO[5O\ '7[A
M]*?6_P#O5O\ AE?]63\#L^Z/:GUG[@ZW]JW^.OW#Z4^M_P#>K?\ #*_ZLGX'
M9]T>U/K/W!UO[5O\=?N'TI];_P"]6_X97_5D_ [/NCVI]9^X.M_:M_CK]Q\2
M]3NMDS#')9MN8>T?LVN.SW*Z?@MG'9'M3ZS\^ZW;AK;_ !U^XU_I!ZP_GK?\
M.A_J%G\)M/)[4^L_..M_U_XH^X?2#UA_/6_X=#_4)^$VGD]J?6?G'6_Z_P#%
M'W#Z0>L/YZW_  Z'^H3\)M/)[4^L_..M_P!?^*/N'T@]8?SUO^'0_P!0GX3:
M>3VI]9^<=;_K_P 4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]?^*/N'T@]8?S
MUO\ AT/]0GX3:>3VI]9^<=;_ *_\4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?
M]?\ BC[A](/6'\];_AT/]0GX3:>3VI]9^<=;_K_Q1]P^D'K#^>M_PZ'^H3\)
MM/)[4^L_..M_U_XH^X?2#UA_/6_X=#_4)^$VGD]J?6?G'6_Z_P#%'W#Z0>L/
MYZW_  Z'^H3\)M/)[4^L_..M_P!?^*/N'T@]8?SUO^'0_P!0GX3:>3VI]9^<
M=;_K_P 4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]?^*/N'T@]8?SUO\ AT/]
M0GX3:>3VI]9^<=;_ *_\4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]?\ BC[A
M](/6'\];_AT/]0GX3:>3VI]9^<=;_K_Q1]P^D'K#^>M_PZ'^H3\)M/)[4^L_
M..M_U_XH^X?2#UA_/6_X=#_4)^$VGD]J?6?G'6_Z_P#%'W#Z0>L/YZW_  Z'
M^H3\)M/)[4^L_..M_P!?^*/N'T@]8?SUO^'0_P!0GX3:>3VI]9^<=;_K_P 4
M?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]?^*/N'T@]8?SUO\ AT/]0GX3:>3V
MI]9^<=;_ *_\4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]?\ BC[A](/6'\];
M_AT/]0GX3:>3VI]9^<=;_K_Q1]P^D'K#^>M_PZ'^H3\)M/)[4^L_..M_U_XH
M^X?2#UA_/6_X=#_4)^$VGD]J?6?G'6_Z_P#%'W#Z0>L/YZW_  Z'^H3\)M/)
M[4^L_..M_P!?^*/N'T@]8?SUO^'0_P!0GX3:>3VI]9^<=;_K_P 4?</I!ZP_
MGK?\.A_J$_";3R>U/K/SCK?]?^*/N'T@]8?SUO\ AT/]0GX3:>3VI]9^<=;_
M *_\4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]?\ BC[A](/6'\];_AT/]0GX
M3:>3VI]9^<=;_K_Q1]P^D'K#^>M_PZ'^H3\)M/)[4^L_..M_U_XH^X?2#UA_
M/6_X=#_4)^$VGD]J?6?G'6_Z_P#%'W#Z0>L/YZW_  Z'^H3\)M/)[4^L_..M
M_P!?^*/N'T@]8?SUO^'0_P!0GX3:>3VI]9^<=;_K_P 4?</I!ZP_GK?\.A_J
M$_";3R>U/K/SCK?]?^*/N'T@]8?SUO\ AT/]0GX3:>3VI]9^<=;_ *_\4?</
MI!ZP_GK?\.A_J$_";3R>U/K/SCK?]?\ BC[A](/6'\];_AT/]0GX3:>3VI]9
M^<=;_K_Q1]P^D'K#^>M_PZ'^H3\)M/)[4^L_..M_U_XH^X?2#UA_/6_X=#_4
M)^$VGD]J?6?G'6_Z_P#%'W#Z0>L/YZW_  Z'^H3\)M/)[4^L_..M_P!?^*/N
M'T@]8?SUO^'0_P!0GX3:>3VI]9^<=;_K_P 4?</I!ZP_GK?\.A_J$_";3R>U
M/K/SCK?]?^*/N'T@]8?SUO\ AT/]0GX3:>3VI]9^<=;_ *_\4?</I!ZP_GK?
M\.A_J$_";3R>U/K/SCK?]?\ BC[A](/6'\];_AT/]0GX3:>3VI]9^<=;_K_Q
M1]P^D'K#^>M_PZ'^H3\)M/)[4^L_..M_U_XH^X?2#UA_/6_X=#_4)^$VGD]J
M?6?G'6_Z_P#%'W#Z0>L/YZW_  Z'^H3\)M/)[4^L_..M_P!?^*/N'T@]8?SU
MO^'0_P!0GX3:>3VI]9^<=;_K_P 4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]
M?^*/N'T@]8?SUO\ AT/]0GX3:>3VI]9^<=;_ *_\4?</I!ZP_GK?\.A_J$_"
M;3R>U/K/SCK?]?\ BC[A](/6'\];_AT/]0GX3:>3VI]9^<=;_K_Q1]P^D'K#
M^>M_PZ'^H3\)M/)[4^L_..M_U_XH^X?2#UA_/6_X=#_4)^$VGD]J?6?G'6_Z
M_P#%'W#Z0>L/YZW_  Z'^H3\)M/)[4^L_..M_P!?^*/N'T@]8?SUO^'0_P!0
MGX3:>3VI]9^<=;_K_P 4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]?^*/N'T@
M]8?SUO\ AT/]0GX3:>3VI]9^<=;_ *_\4?</I!ZP_GK?\.A_J$_";3R>U/K/
MSCK?]?\ BC[A](/6'\];_AT/]0GX3:>3VI]9^<=;_K_Q1]P^D'K#^>M_PZ'^
MH3\)M/)[4^L_..M_U_XH^X?2#UA_/6_X=#_4)^$VGD]J?6?G'6_Z_P#%'W#Z
M0>L/YZW_  Z'^H3\)M/)[4^L_..M_P!?^*/N'T@]8?SUO^'0_P!0GX3:>3VI
M]9^<=;_K_P 4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]?^*/N'T@]8?SUO\
MAT/]0GX3:>3VI]9^<=;_ *_\4?</I!ZP_GK?\.A_J$_";3R>U/K/SCK?]?\
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M#K?VK?XZ_<?$G4WK7, )+-MP'9_\-KCZE=:6Z?LIYQ'M3ZW2GZAZ[K]&UO\
M%7[C'](O6;\];_AL'ZNN?Y;L.Z/:G[SM^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_
M ,5?N'TB]9OSUO\ AL'ZNGY;L.Z/:G[Q^X/U!WW_ ,5?N'TB]9OSUO\ AL'Z
MNGY;L.Z/:G[Q^X/U!WW_ ,5?N/N/J9UK@U\.Q;;S=O\ \-@/9[M=;UZ?LHY1
M'M3ZW+)^H.N_S3?_ !5^XR?2GUO_ +U;_AE?]673\#L^Z/:GUN7[@ZW]JW^.
MOW#Z4^M_]ZM_PRO^K)^!V?='M3ZS]P=;^U;_ !U^X?2GUO\ [U;_ (97_5D_
M [/NCVI]9^X.M_:M_CK]P^E/K?\ WJW_  RO^K)^!V?='M3ZS]P=;^U;_'7[
MA]*?6_\ O5O^&5_U9/P.S[H]J?6?N#K?VK?XZ_</I3ZW_P!ZM_PRO^K)^!V?
M='M3ZS]P=;^U;_'7[A]*?6_^]6_X97_5D_ [/NCVI]9^X.M_:M_CK]P^E/K?
M_>K?\,K_ *LGX'9]T>U/K/W!UO[5O\=?N'TI];_[U;_AE?\ 5D_ [/NCVI]9
M^X.M_:M_CK]Q8_I$ZM_X#_:GK-G]M_M?U;G]0@Y_5?5N?3P_ TTY_MN77NU4
M7\'M??>'2/#X=?K3SU\ZV_.NK?@?>:V]Y[S3ZE?J^'7EX>_MT>E5Y1]?$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 08['Y%_N+,,6Y(M;N(@(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @V:7Y4_
M>GZH6);5YM]:.H@(/B3Y*Q+:O-A6CH(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(,L7?[RVAI9D6S00$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 08['Y%_N+,,6Y(M;N(@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @V:7Y4_>GZH6);5YM]:.H@(/B3Y*Q+:O-A6CH(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(,L7?[RVAI9D
M6S00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 08['Y%_N+,,6Y(M;N
M(@(" @(" @(" @(" @("#XDFAA&LLC8QY7$-^JLQ&K69B.;4DS.,C^59:?O=
M7?T05O%+=SG.:D=K7=N/&M["]WN-^SHL^ZLTG<48SN?'@\(YCYPUOX2S[J6O
MXFOE?HW-CSVME'NM;]9R>ZEG\37RLK-PXMW;(YGWS'?6!6/=V;1N*=[9CRF/
MEX,LQZ^0NY3\>BUFDQV-XR5GM;0(< YI!![".(6KH_5AD0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!@ENU(=?
M%GC81W%PU^!;169:3>L<Y:K\[BV</'YCY&M<?K:+;W=G.<]([6$[EQP[!(?<
M:/KE;>ZEI^)H^/\ $]#\W-_-;^$GNI8_$U\K[&Y<<>T2#W6CZQ3W4L_B:,S,
M[BW\/'Y3Y'-</K:+7W=F\9Z3VMJ*Y4GT\*>-Y/<' GX%K-9ATB]9Y2SK5N("
M @(" @(" @(" @(" @("#9I?E3]Z?JA8EM7FWUHZB @^)/DK$MJ\V%:.@@("
M @(" @(" @(" @(" @(" @(" @PRVJT'Y:9D9\CG 'XUSMDK7G,0Z5QVMRB9
M:C\[BH^VP''R-:X_4&BX3N\4=KO&TRSV,#MRXT'AXCO.&_9(7.=]C\KK&QR>
M1\?XHQ_YN;^:W\):_C\?=/\ 'PMOR_)WQ_'P/L;FQQTU$C?=:/K$K,;['Y6L
M[#)Y&5F?Q3_],6GR.:X?672-YBGM:3L\L=C;BOTIN$5B-Q\G,-?@[5VKFI;E
M,.%L-Z\XEL+LXB @(" @(" @(" @(" @(" @(" @("#+%W^\MH:69%LT$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$&.Q^1?[BS#%N2+6[B(" @("
M @(" @(" @UK5^G3']HE:UW<SM=\ XK:*S/)SMDK7G*&L[H'%M2'7R/E_!'V
M5VC#WHMMUW0B9\SDK&O-.YK3]K'Z ^+BNL4K"-;->>UHDEQ)<22>TGB5NY"
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M9I?E3]Z?JA8EM7FWUHZB @^)/DK$MJ\V%:.@@(" @(" @(" @(" @(" @("
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M3P/WI[U%M286./-%_.DER2! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 08+=RO2B\6P_E;W#M)/D 6T5F>32UXK&LJID<W9NDQQZPUNS
MD!XN'W1^LI5<<0KLF>;<N$(M=$=JW<C3Q[.>W*V/7Y+>UQ]P#B5O6DVY..3+
M7'&MI5:_O&=^K,?$(F]TLFCG^\.P?&I==O':J<O4)GA2-%<MWI[!,UVP7@<>
M:1WHCX> 4JM8CA$*S)EF>-I^-"6=QXJOJ!*9GC[6(<WQ\!\:DUV]Y[-%-FZK
MM\?\WBGR<?\ 1'.W7-/((:%(R2.X,:27.)\S6CZZ[_A8B-;2K9ZW:]O#BQS,
M^GXH2=3#]3LLWFH;?N",_)D%21C./D=*-"N5K;:G.T?'ZDG'7J^?ZF&8_P"6
M8_[DE'TSZSV02W%2M X^G-3B/'S.D:N?XO9QV_\ <[1TGKMOY)^/''SOOZ*N
MM/[K?^ET?ZY/QNS[_1;U,_D_7?LS[6/[S!/T^ZQTB?%P\[PW341FM/KPU_T;
MG:^\LQNMG/\ -\K$]-ZY3G29]B?DE$7/\=88G]KX.S QO%SYZLT0T[-0[0-T
M\ZZUK@O]6T?'"+?<=2P3_P"7#.D?TV^7DUX-WP.X6:[F?=,(>/@/*MK;2>R6
MN+KM)^O68\W'U)>KF,;;T$-AO.>QC_0=\#M-?>4:V*]><+?#OL&7ZMHU[N4^
ME*5KEJH_GJS.B=W\I(!]T=A7":Q/-94R6IQK.BQ4-XSLT9D(A*WOECT:_P!\
M=A^)1K;>.Q98NH3'"\:K32R-/(,YZDK9-/E-['#W0>(42U)KS6V/+7)&M9;2
MT=DICLY9I$1R$S5NSD/RFC[D_67.V.)2,>>:\)XPM=6Y7NQ"6N\.;WCO!\A'
M<HLUF.:QK>+1K#.M6X@(" @(" @(" @V:7Y4_>GZH6);5YM]:.H@(/B3Y*Q+
M:O-A6CH(" @(" @(" @(" @(" @QSV(:T1FG>&1M[2?J!:7O%(UEO2DWG2.:
MJY+<$]K6*KK#!V<WV[A[O=[RI<^\M?A7A"\P;*M.-N,H55ZP8+5RK2C\6U*V
M)G<7=I]P=I]Y<[Y*TC6TZ.N/%;).E8U5B_O)QUCQT6@[/&E[?>:/KJLR[_LI
M"YP],[;S\$*W;R%RZ[FMSND[]"?1'N < JV^6U_K2ML>&F/ZL:(N;)TH-0Z4
M.</M6>D?B46V6L=J;7!>W8T9=P,'"&$GSO.GQ#5<9W/="179SVRVJE7>&5'-
MC<19F8?MX:TKV^^[0A=L>/<Y?J4F?-67')DVF'Z^2L>>T0EH=@=4+?R,5,W7
M\XZ"'L^_<U2Z]+W]^5)]$?*@VZQTRG/)'_5/R1+-]&'53]VN_2JG]:NGY+U#
M['_57UN?Y]TO[?\ TW^ZQR].^J-8:OQ<KAH3Z$M:;L\S7N6END]0K_)/QUGY
MV]>M=,ORO'Q6CYD;9Q&^\:"Z[A;;6#@9'59"S7[Y@T[O*HM]ON\?UL=O9E+Q
M[G8Y?J9*^U'SHYF>>QQ98KZ.' \IT(]XJ-&XF.<)<[2)Y2W(<O1FX<_AN\D@
MT^/L7:N>LH]MO>O9JDJ]J6!PFJRN8[N?&[37WPI-;S'&LHM\<6X6A8:&[[D.
MC+S!8C^>/1D'UBK#'OK1];BJLW3:6XTX3Z%IQ^6H9)NM6760#5T3O1>/>^PK
M3%GIDY2I<VVOB^M#=7=&2&/S%K'D-:?$@[XG=GO'N4K#N;8_+'<BYMM3)Y)[
MUNHY"MD(^>!WI#Y<9X.;[H5YBS5R1K"ARX;8YTEM+NX" @(" @(" @(" @("
M @(,L7?[RVAI9D6S00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 08[
M'Y%_N+,,6Y(M;N(@(" @(" @QV+$-6)TT[@R-O:3]0+,1JUM:*QK*GY3,39!
MQC;K'5'9'WGSN4NE(JK,N:;^9&KHX(7+[CJ8WFAC_'VQP\-I]%I^Z/UEWQX9
MMYD'/NZX^$<94G(Y:WD'&6Y+^+;Q#/DQM'F'UU/ICBO)0YMQ:_&T\/0JM_=-
M2OK'4;ZQ*/MNR,>_W^\IV/;6GGP>:W/6<6/A3Z<^A,X#IMU)WT&3MKG'XJ30
MBS;)K1%I[VL ,CQY^4CSKGDW>VP</K3Y./\ HZ;;I'5>H\9_\=)[_HQ\7UI^
M'AY75-O>S=MFB&R[BO3Y6?3TH8O[+7U_DESS[O./<53FZSDM]2(KZ9>NV7Z(
MVN/CFM.2?9KZ./\ U.FX?9.T<  ,/A:E5XX^*V)KI>'ED<"\_P Y5.3<Y<GU
MK3+V6VZ;M=M_M8ZU\T1K\?-/*.L! 0$!!HY+"X?,QF++8^O>C(Y>6S$R4:'R
M<X.BZ4R6I.M9F'#-M\6:-,E8M'EB)^5SS/= M@9@/DI5YL1:=V/IR$Q\WGCD
MYVZ>9O*K+%U7/3G/BCRO*[O](]/SZS6LXYG[,_-.L?%#E.?Z#;ZVV7V]M66Y
M>JTD\D)\&QIYXGDM=_)<?<5QBZIAR\,D>&7C=S^D]]M)\6VOXX[N4_%/"?XX
M*3'N&[CYW4<]3DKV8SRR!S'12-/W4;]"%-G;UM&M)UA3X^K9,5O!N*36?-I/
MPQ/\>1/5K5>W'XM:1LC/*T]GNCN4.U9K.DO0XLU,M?%2=86'%[FNT.6*8FQ5
M'#E<?2:/N7?6*BWPQ;SK3!O+TX3QA=:&1J9*+QJLG,!\IAX.:?(0H-J36>*]
MQ9:Y(UK+;!+2"#H1Q!';JM'99<1G^;EK7W:.[&3GL]QWV5'OC[83L6?LLL*C
MIP@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""/R>6AQS-#Z
M=AP]"/ZY\@72E)LX9<L4CRJ?:MSW)3-8?S//9Y /(!W*7$1')66O-IUEKO>R
M)CI)'!D;1JYSCH /.2MHC5I,Q$:RJF6W=IS08L>8V'#^B#]4J73!VV4^??\
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M>=;1&K6UHK&LJ7DLE-D9N=_HQ-_)Q]P'V5+K7PJK)DF\M%SFM:7.(#0-23P
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MD\?*2O?['HVWVO&(\5OM3\W<^9]1Z[NMYPF?#3[->7P]_P#'!<E=O/B @("
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M&EF1;-! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!CL?D7^XLPQ;D
MBUNXB @(" @JNX,GX\AI0._$QG\81]L\=WN!2L=-.*NW&76?#"#79$4?<N=-
MM[J%1W]E8?QCQ]NX=WN!3\.+3C/-0[S<^*?!7DY[G,T^%PQV/U?=D(:2STBT
MNX!K0.UQ5KAPZ_2MR>,ZCU":3[K%QO/H_P!7<>D71J';K(=S;IC;/N&1HDK4
MW@.94YN.IU[9?/\ :]W'BJ/J'49R_0I]7Y?]'MOTY^FHVD1GSQXLL\H^Q_\
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MU[&N[ [[*@9<?BCRO2[3<>[MI/*70 =>([%7/1)W;N1\&;U*4_BI3K&3W/\
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MIX<1TM3ZM9IVM'>[["M\&+QVX\H>)ZGO/<8](^M;EZW:^@_3D8#%#=F7A_\
MC>3CUJ,>/2@JOXCM['2=I^YT'E5-U3>>\MX*_5KZ9>P_2?1?PN'W^2/_ "9(
M]FOKGG/Q.RJC>\$! 0$! 0$! 0$! 0$! 0$! 0$ @$:'B#VA!Y0ZP[$?L#<<
M6X<)'R8#)2$LC'R(9SZ3X?O7#5S/-J/M5[#I^Y_$8YI?ZT?)WOB_ZCZ9/3-S
M&YPQ_P".\\NZ>VOFGG'=\"/JV8KE>.S"=8Y!J/-Y0?<6+5FLZ2G8<M<M(O7E
M*_[4RIMUC1F=K/7'H$]KH^P?!V*NSTTG5Z38Y_'7PSSCY%B!+2'-.A'$$>51
M5FO6+NB_39,?R@]&4?=#[/:H5ZZ2M\5_%75N+1U$! 0$!!LTORI^]/U0L2VK
MS;ZT=1 0?$GR5B6U>;"M'00$! 0$! 0$! 08+EEE.M)9?V,&H'E/</?*Y9<D
M4K-I=<6.;VBL*#+*^>5\TAUD>2YQ\Y7F;6FTZR]16L5C2$)N/*?LVB6Q.TM3
MZLB\H'VSO>4'=9O=UX<Y66RV_O;\>4.;VK+*L#YW]W8/*X]@7F[V\,:O6XZ3
M>VD+-T?V2=RY5^Y\PSQ,91D_$QO'HS61H0-/FQ\"?/H/*K?H/3OQ&3WV2/HU
MGXY]4*;]2]5_"XO<8ITO>./DKZY>BU]*?)A 0$! 0$! 0$! 0:C\KC(LA%B)
M+L#,K/&9H:+I6"P^)NNKVQD\Q:-#Q 0;: @(" @(" @XUUKV(+58[QQ46ERL
M ,HQG:^%O!LN@[V=CON>/VJ\3^HNF>*OXBD<8^MYN_X.WR>9]!_2W5_!;\-D
MGZ-OJ>2?L_#V>7SN5XR[ZY7](_CH_1D'E\A]]>1Q9/%'E>VSXO!;R+[M'*<P
M=BYG<6ZOKD^3M<WZ_P *O=CF_DGX'F>I;?\ _9'PK6K91KI@K_KM,->=9X=&
M/\I'<??7H-IE\=./.'G=WA]W?ARE**:A" @(" @(" @("#+%W^\MH:69%LT$
M! 0$! 0$! 0$!!P#VA?:0J])^3;6W(8LCO>S&)7LFU=6I0OUY7RAI!<]W:R/
M4</2=PY0ZQVFS][QGA57;O=^ZX1]9YXQ&\/:^ZA0/W#@)\S8QL@<Z*>K!!3J
MN:TG40ZLC:_3L]'F/=Q*LK8]MCX3HK:Y-SDXQJW]L^U%UDZ9[@;@NJ=.;*5(
MBT6Z60KMIY**(]CXI&M9S]FH\0.#OG#M6M]EBR5UIP^1M3>Y<=M+\?E>XML[
MCP^[\!C]S8"P+6(R<+;%68<"6NX$.':'-(+7-/$.!"H;TFEIK/.%]2\7K$QR
ME*K1N(" @(" @(-;)2R08ZW/$>66*&1[': Z.:PD'0\.U9CFQ/)Y+]E;K9U.
MZD=0LE@]Z9S]IXNOAI[L,'JE.ORV([56-K^:O#&XZ-D>-"=.*N-]ML>.D36-
M)U]:GV6YR9+S%IUC3U/7JIER(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#'8_(O]Q9ABW)%K=Q$! 01.X+GJU(Q
M,.DECT!][]M]A=<==91MQ?PUT[U/4M6*3N_(F:RW'QG\5!Z4FG89'#A\ 4_;
MTTC51;_-K;P1V.<92.[N#-4ML8IOB6K$K(VLUT!ED.@U/<&@ZDJXP^''2<EN
M3PG4)R;K/3:XN,S/I]41QE[!VEMJCM';]+ 4 /"JL DETT=+*[B^1WG<[C\2
M\7GS6RWF\]K[9L-E39X*X:<JQ\<]L_"FEP3Q 0$! 0$! 0$! 0$! 0$! 0$!
M 0?A <""-0>!![-$'D/JAM4].M\^L4F<N"R?-9J-'8UCG?C8?Y#CJ/,6KVFR
MS?B<&D_6K_$2^(=;V?Y5U",E(_\ 'DXQ_P#:OP<X^!],>V1C9&'F8X!S2.P@
M\0N$QHN:VB8UCDZ-MS(_M#',YSK8@_%R^4Z?)/OA5N:GAL]-M,WO*<><)NO.
M^M/'/'\N-P</>[O?4>8UC1.K;PSJO\,K)XF31G5DC0YON$:J#,:+F)UC5]K#
M80$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!4=Q7/'N"NT_BZXT/WY[?@[%
M+Q5TC56[B^MM.Y"2RLAB?-*>6.-I<]Q[@!J5VB-4.TQ$:RY?E,@;EJ>_.>5A
MU=Q[&L:. ]X!6U*:1$0\GGS>*TWGE\S3Z7[5=U%WSZQ=878+&<MFVT]CF-/X
MJ'^6X:GS!RD[W-^&P:1]:W\3*@Z'LYZKU"<EX_\ 'CXS_P#6OPSQGX7KP -
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MD-[Y!G,("ZK0>[OGD&LSQ[C2&C[XJ/UC/X:QBCSS\SK^B]A.2]]WD_X:^?\
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M3RZKS'4-Q[[-,QRCA#Z;^F^F_@MG6LQ]._TK>>>SX(X.@*N>F$! 0$! 0$!
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MYH*G;J=-O/FCYD';1KN(\\_.]:>U<UKN@F["X EIQQ:2.P_M.J-1[Q5/L?\
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M2PZW5Q69R5""T]O(Z6.K'9B:\M[BX-UT4C<V\6WF>^(<-O7P[B([IE_0[<V
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MX>ZTZJ-,:K.)TG5T)K@]H>WBUP!!\Q4!=/U89$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$%2W+-XE]L0[(F $>=W'ZFBEXHX*W<SK;1 V9A6KRV'?)B8YY_D
MC5=XC6=$*]O#69[G)+UDPP6+<AU<UKI#YSH3\95Q2NLQ#QF?+X*6O/9$RO'L
MS84/?G=S3#FD_%T('D<?2_'2\?/^+4;K63ZM(\_S1\[O^A=MK&7<3SF?#_\
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ML5)XN.K/[^0-_F^C]90KQQE;XIUI#<6CJ(" @(" @(" @(" @(" @(" @("
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M5W.&/<WL,D;7"-Y^_:5,IO<U*>"MIB%)GZ'L<^;WV3%$W[^/'SQRGX86D
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MW[:;RXXGYTCC\0'UE%R\UEMH^@EUQ2A 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M=:S,3,SK7Z.L3I$1K.C/7SG4W<V1RFSXOV?@[F',4>6S41DG>^.R"Z.2K"X
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MTK= O;V671L?''*SB?RHY7:'O.BTF:1FBU?JZQ/F\GP.M*9IVDTR<;Q6U?\
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M*G[T_5"Q+:O-OK1U$!!\2?)6);5YL*T=! 0$! 0$! 0$%'S4?AY2P/*X._G
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M2'1FM#&M8.QH 'O+U<1I&CR,SK.K]66! 0$! 0$! 098N_WEM#2S(MF@@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M6[H5>+P((H?S;&L_FC10)G65U6-(T9%AL(" @(" @(" @(" @(" @(" @("
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M/(V-NI.@&KB!VE8F8CFVK69X1#-')'*QLL3P^-PU:]I#FD>4$++5](" @("
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M>'<V0-^!2]WC]]M9[Z\?B_T>>Z1GC8=7C7ZN3Z/M\O\ JT>OEXM]O$! 0$!
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MK.#C&2.WA/S+/]$]0UI?:WYTGQ5\W;'P3Q^%WU><?3! 0$! 0$! 0$! 0$!
M0$! 0$! 0$!!4>IFZV[.V=D<LQX;>>SU;'@GB;,P+6D?>C5_O*9L\'OLL5[.
MWS*7K74(V6TOE_FTTK_Q3R];REM2FYL,M^74R3GE8X\3R@\3[Y^HO7;J_&*Q
MV/D71<$Q2<MN=OX],K?B:1OY""MIJQSM9/O&\7?$J[);PUF7JMOC]Y>(=.[%
M5O4K%M>MJZ:VX=FD;#YSQ/UE'S3V)VUKSE9%&3Q 0$! 0$! 0$! 0$! 0$!
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M]'#B".X@\"/*O$Y,<X[36></N>VW%-QBKDI.M;1K#?7-($! 0$! 0$! 0$!
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M[K[Y<>J;6,E?>TYQS\W^C?\ 275;;;+.RS<(F?H^2W=YK<X\OG>F%Y5];$!
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M:[?)I/AGE+QG5MG.2GO*_6K\G^CT7T9ZAMWKM\4LA*#N+%M;';#B.::(<&3
M>?L?]U[H7G.H[3W&36/JVY>I]&_3768W^WTO/_DIPMY>ZWP]OE=,54]:(" @
M(" @(" @(" @(" @(" @("#S/UWW\_<&5CV+@I/$HU) <A(P\);0[&:_-C[_
M +K[U>JZ7M8QU][?G/+S?ZODGZLZK;<Y8V6&=8B?I>6W=YJ\Y\OF53'TH\?4
MCK1\>4:O=\YQ[2NV2\WMJTVNWK@QQ2.Q;]HXSQ[!R,H_%0'2+7OD([?>"A9[
MZ1HOMAA\5O'/*%V4!>K;MVEZO5-EX_&3\1YF#L^'M47+;6=%EMZ:5U[TRN*4
M(" @("#9I?E3]Z?JA8EM7FWUHZB @^)/DK$MJ\V%:.@@(" @(" @(" @C<W1
M]=HNY!K-%Z<?GT[1[X4/=8O'3RPF;3+[N_DE25YYZ-4]WXPD-RD0[-&6 /)]
MJ[ZWP*IWV'^>/A7G3<__ .N?@4>_4;<KNB['CTHSY'!4>2GBC1Z3%D\%M5^Z
M)[X]4F.RLL_E9(]SL6]Y^3(3J^'^4?2;Y]1WA>C_ $[U+P3^'OV_5\_=\/8\
MM^J>E>./Q6..7U_-V6^#E/D\SNZ^@/F8@H[]U;Q\5S8MM.,8<0USG2M) / Z
M>'WKK&.)[81[99B>4_$^';PW<YD#H=L2ETD9?*UXF9R.#B.7C'Y-"E:1/:VO
MD\/9,LD.[=U&O.^?;<K)V:>#&ULK@\D'M/)PXZ)-(B8C4KDUB9TG@UV;RWH9
M(VR;5D;&YS6N</&) <="=/#[EO.*(CG#E7/,SIX9^*7U?WANZ"[8AI[7EL00
MR.C9.6S-YPT\"-(SJ#YEBF*+1KK$-LF::3IX9GS0^#O7=XI.F&U9S;$XB\#E
MFT+"PNY]?#[->"1BB;::PS.:8IXO#/FT?M+>>[IY2R[M6>&+D+@\,F=JX=@T
M,8[5G)BBL:ZQ+7%GF\Z>&8\\2U9-^;W;(]L>SYW1M)#7<LXU / Z>$ND;>)C
M7Q1\<.5MU,3IX+?%+8O[WW=7CJFKM2Q8DFA9+,WDG C>_75FHC/$+3'ABTS'
MBB'7+GFD1/AF=>Z)8:V^]Y2-LNGVA9BDB@,L($<YYWAS0&:^%VD$GWEF^&(F
M(\4<?*QCW$VK,^&8T\DL-?J#OB2S#%-LRS'"][6R2<E@\K7$ G\EW!=+[:M8
MU\4?'#C3>3:T1X+1_P L^I^W^H.]:]I\539MJ>!OR9?#L#7X(BL8MO%ZZ^*(
M^&&V;=3CMIX+3YHF69^_=X-P[+PVC:-YTSHC3$=C4,:&D//XO70ZGN6D8(\?
MA\4>?7@Z3N)]WX_#/FTG7XN;#C.H6];=V&O<V;;JUY'<KYS%8T:/*=8@%OEV
M\4C6+1/FF'/!NIR6T\%J^>)AI/ZF;^:]P;L6XYH) /A6N('_ -BNL;2LQKXZ
M_'#E;?3%M/=W]F?4D<WO[=^.%8X_:%NZZ9G-/R0V#X;N5ITU;$>\D>\N.';Q
MDF=;1&G?,)&?<SBB)\-K:]T3/R-_9>\MS[BO35<WMJQA8(V<[)YHYF-<[R:R
M1L"USX(QZ:6BWFF)9V^XG+K]&:^>)CY5Y45+$',.L6^AM[$G XZ73,Y)A#W-
M/I0UCP<[S%_%K??/<%Y7]0=2]QC]U2?IW]$?ZO9?IGI/XG+[Z\?0I/QV_P!.
M<_ XCAZ7JT/C2#2:4=GD;W!>"P8_#&L\Y?2-SE\4Z1RA;=LXSU^\)I!K6K:/
M?Y"[[4?75MM,/COK/*%'OL_NZ:1SLOZ] \LL^V*7*Q]YXXO]"+W!VGX>"N-A
MBTB;RIM_EUF*0L*M52(" @(" @(" @(,L7?[RVAI9D6S00$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%,ZD]-<#U.PD>(S+I:\]63UC'
MY"L0)H)M"-1J""T_;-/;YB 0'.)^A/4;)0/PV;ZKY&WMN1HBGKMKN9/-#IH6
M/>;#N!' \W-KWA98==V?M#!;%P%7;>WH#!CJH)U>>:661W%\DCN',]Q[>[N
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MSFGL(\Q5K6T6C6'ELN.<=IK*KU[N3V%N*KN;!GE;&_4Q\>0M=\N)X':UP_\
M;4!6&E=QCG'?^/*\E?WO2]U7<X?J]W9Y:SY)[/\ 2'KO9V[L5O7!U\WBG^A(
M.6Q7<=9()A\J-_G'<>\<5XS<8+8;S6S[7T[J&+?8(S8YX3V=L3VQ/\>5/*.L
MA 0$! 0$! 0$! 0$! 0$! 0$')NM'5&/:&-=@<-,#N:\S0N:035@<.,A\CR/
MD#^5W<;CIVQ]];Q6^K'I_CM>*_4W7HV.+W>.?_+?_ICO\_=\?8X#M[$NK,-^
MV";<XU =Q<UKN.IU[SWKT&XRZ_1CE#P/2ME../>W^O;T?ZSVK-1I39"U'5A'
MIO/%W<UO>3[B@VM%8UEZ/%CG):*PZ94JPTJT=6 :1QC0>4GO)\Y*J[6FTZR]
M3CI%*Q6.Q*8NB;]ML1_)-]*4^1H[O?[%RO;2$G%3QVT7D - :T: < !Y%"6P
MC(@(" @(-FE^5/WI^J%B6U>;?6CJ("#XD^2L2VKS85HZ" @(" @(" @(" @I
MF=Q_J5LO8-*\VKF:=@/>%Y[=X?=WUCE+T6TS>\II/.$/+%'/$^&5O-'("U[3
MW@\"H-HB8TE/K::SK'.'-LMC9,7<?7=J8SZ4+_G,/9[X[UYO/BG';1Z_;YXR
MT\7;VJUE:<C'MR-0EEB(A[BPZ.!;Q#@1WA5N:DQ/BKSA;;?)$QX+<I_C1Z"Z
M7]0H=X8T4K[VLW#3:!89P'C,' 2L'],=Q\Q"^C=%ZK&[IX;?[E>?E\OK?+.O
M]&G99/'2/_%;EY/)/S.@+T;RP@(" @(" @(" @(" @(" @(""N[TW?C]F8:3
M)7"'V'ZLI5 ='32Z<!YFCM<[N'GT59U'?TV>*;VY]D=\_P <UMTOIN3?9HQU
MY?S3W1Z^YYA,]_<N6L9[,2&::9Y>XGL+NYK1W-:. "^5S>^XR3DR3K,_Q\3[
M+%,>UQ1AQQI$1_'PRF8();,S*\+>:60AK6CRE2ZUFTZ0@7O%8F9Y0Z5B\?'C
M*;*L?%P]*1_SGGM*]+AQ1CKI#R&XS3EO-I2E*I)=LQUX_MCZ3O(T=I4O%CG)
M:*PA9<D8ZS:5]BB9!$R&,:1L :T>8+TU:Q6-(>7M:;3K+[6S40$! 0$! 0$!
M 098N_WEM#2S(MF@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M]WV%PRV[$W;X_P":5E49/$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M*AWO3+8OI4XU],/>]!_56/=Z8L^E,OHMZI\GQ=T=E5&]X(" @(" @(" @("
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M<+UAOXIIUA:?MG#[;W K/9[?6?';EV*O>;G2/!7GVK0KI2" @(" @(" @("
M@(,L7?[RVAI9D6S00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MQEF.W2F'-'/"X/80?.%YVU)K.DQI+Z1BRTRUB])BU9Y3#:6KJ(" @(" @("
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MK&AK0 UHT '  !7T1H\_,ZOU98$! 0$! 0$! 0$! 098N_WEM#2S(MF@@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M5D$+?E22N#&CW2X@+,1,\FMK16-9G2% W#UMZ?;?YHQD?VI:;K^(QP\?B/\
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MTFN*4GL/@C+RVKK=(NUD1[7><^9<+Y-.$)F'!KQLM     T [ HRP$! 0$!
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M'_4PS^T3U FX5,-1B:1IJ8+,CM?*#XH'Q+:.D8(YVGXX<K_K'J-I^AAK$?\
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M8)MQGDM44,4$;8H6AD;> :%%F=5A$1$:0^UAL(" @(" @(" @(" @(" @("
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M]0(>%O#496@::B"S&[7RD^*1\2Y3TC!/*T_'"33]8]1K/T\-9C_AO'SRS?\
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MX._WUQMEF>273;UCGQ3#6M8T-8 UHX  : +DDOU89$! 0$! 0$! 0$! 0$!
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MP.-AXF(RN\LAU^+@/B6DY+2[5P4CL2#(XXF\D;0Q@[&M  ^ +GJ[Q&CZ6&1
M0$! 0$! 0$! 0$! 0$&S2_*G[T_5"Q+:O-OK1U$!!\2?)6);5YL*T=! 0$!
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M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @QV/R+_<688MR1:W<1 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$!!LTORI^]/U0L2VKS;ZT=1 0?$GR5B6U>;"M'00$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 098N_
MWEM#2S(MF@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @QV/R+_<68
M8MR1:W<1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!!LTORI^]/U0L2VKS;ZT=1 0?$GR5B6U>;"M'00$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 098N_WEM#2S(MF@@(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@QV/R+_<688MR1:W<1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!LTORI^]/U0L2VKS;ZT=1 0?$GR5B6
MU>;"M'00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 098N_WEM#2S(MF@@(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @QV/R+_<688MR1:W<1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!LTORI^]/U0L2VKS;ZT=
M1 0?$GR5B6U>;"M'00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 098N_WEM#2S(MF@@(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @QV/R+_<688MR1:W<1 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!LTORI^]/U
M0L2VKS;ZT=1 0?$GR5B6U>;"M'00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 098N_WEM#2S(MF@@(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @QV/R+_<688MR1:W<1 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M!LTORI^]/U0L2VKS;ZT=1 0?$GR5B6U>;"M'00$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 098N_WEM#2S(MF@
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @QV/R+_<688MR1:W<1 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$!!LTORI^]/U0L2VKS;ZT=1 0?$GR5B6U>;"M'00$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 098N_
MWEM#2S(MF@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @QV/R+_<68
M8MR1:W<1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!!LTORI^]/U0L2VKS;ZT=1 0?$GR5B6U>;"M'00$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 098N_WEM#2S(MF@@(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M+%W^\MH:69%LT$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$&.Q^1?
M[BS#%N2+6[B(" @(" @(" @("#2NY:E1U$K^:7\TSB[W_)[ZWK29<;Y:UYJ_
M;W'<FU;7 @C\H])_PGZP4BN*(YH=]S:>7!$2222N+Y7E[SVN<23\)76(T1IF
M9YOE&'XYS6@N<0UH[2> 66-6E+F<5!J)+D6H[0UP<?@;JMXQVGL<+;C'7G:&
MH_=.%9V3E_WK'_7 6\8+N,[W%':Q.W?B!V>*[W&?9(6?<6:SO\7E?K=VX<Z:
MND;KY6=GP$I[BQ&_Q>5GCW+A9. M!I\CFO'QD:+6<-^YTC>8I[6[#D*-C006
M8I">YKVD_!KJM)I,<X=ZY:6Y3#96CJ(,]:[;J'6O*YG?R@ZM/N@\%B:Q/-O6
M]J\I3E/<_8R['_\ :Q_7;]A<+8NY+IN?M)ZO:KVF>)7D$C.\CM'NCM"XS$QS
M3*VBW)E6K80$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$!!^.<UH+G$!HXDG@ LL(>YN*I7U97'K$@[QP8/?[_>76N*9YHU]Q6.7%
M VLSD+>H=+X<9^TC]$?9*[QCB$.V:UF@MW$08Y9X(!K/*R,>5[@T?&MHB9Y-
M;6BO.=&A+N##1?*ML/WFK_Z(*WC%:>Q'MNL4?S-=VZ\,T\)'N\X8[Z^BW]Q9
MRG?8N]C_ ,7XG73273R\@^RL_A[-?Q^+RLC=UX9QXR/;YRQWUM5CW%FT;[%W
MMF+<&&E^1;8/O]6?T@%I.*T=CK7=8I_F;T4\$XU@E9(/*QP</B6DQ,<TBMHM
MRG5D6K80;]7,Y"IH&R^)&/M)/2'P]H^%:3CB7:N:U4]3W%4L:,L#U>0]YXL^
M'N]]<+8ICDF4W%9Y\$PUS7 .:06GB".(*Y)+]6&1 0$! 0$! 0$! 0$&S2_*
MG[T_5"Q+:O-OK1U$!!\2?)6);5YL*T=! 0$! 0$! 0$! 0$! 0$! 0.Q!$7M
MQ4:FK(CZQ,/M6'T0?.[["[5Q3*+DW-:\N,J[<W!D;>H$G@1G[2+T?A/:I-<5
M80+[F]O(BR23J3J3VDKJC/Q!\2310CFFD;&WRO(:/C68B9:S:(YM&7/X:'Y=
MR,Z?,)?_ $05TC%>>Q'MNL4?S0U7[LPK3PE>_P [6.^N M_<7<IWV+O]#&=X
MX@'0"8^<,'UW+/X>S7\PQ>5]MW;AB=#(]OG+#];58]Q=M^/Q=[8CW'A9?DVV
M@_=AS/Z0"UG#>.QTKN\4_P S?AM5;'&O-'+]XX.^H5SFLQS2*WK;E,2RK5N(
M-ZIE\A2T$,Q,8_T;_2;I[A[/>7.V.LNU,UZ\I6&CNBM-HRXSP'G[<>DS[(4>
MV&8Y)^/=Q/UN"=CD9*P21N#V.XAS3J#[X4>8T3(F)Y/I&1 0$! 0$! 0$! 0
M$! 0$! 098N_WEM#2S(MF@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @QV/R+_<688MR1:W<1 0$! 0$! 0$&&U;KTX_%L/#&]P[R?(!WK:*S/)I:
M\5C657R&X+-G6.MK!!V:CY9'G/=[RDUQQ'- R;B;<N"'[>)[5U17Q++%"PR3
M/;'&WM>XAH'OE9B-6LS$1K*!N[NQ]?5E5KK,@[QZ#/A/'XE(K@M//@K\F_I7
MEQ0%O=65L:B)[:[#W1CCI[IU/P*17!6%=??9+<N"(GLSSGGLS.D/SI'%WU5W
MBL1R0[7FW&TM"7*8Z$D26H@X=K>8$_ %UC':>42A7W>&DZ3>OQM5VX\.TZ>L
M:GS,>1]1=(V]^Y$MU7;1.GB]$^IC_P 3XC\X_P#F%9_#7[FGYQMOM3\4OINY
M<.>V8M]UC_K K'X:_<S'5]M]KT3ZFQ'FL5+H6VXQK\X\G]+1:3AO'8DUW^WM
MRO'R?*W621R#FC>U[?*T@CXERF-$RMHMRG5NULGD*FGJ]F1@'VO,2W^:=0M)
MI6><)%,]Z<IE-5-Y78]&W(F3M[W-]!_UQ\2X6V\=B=CZA:/K1JL-'<.+OZ-9
M+X4I_P!'+Z)]X]A^%1K8K56>+=X[\ITGRI5<4MDAGFKR"6!YC>.]IT28B6:V
MF)UA8L?N-C](KXY'=@F;\D^Z.Y1[8NY.Q[C7A9/M<US0YI#FGB".((7!,?JP
MR(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @CLCF:M#
M5FOBV/S33V??'N72M)EPR9JT\ZK7<G;ON_'/TC[HF\&CWN_WU*K2(5U\MK\V
MFMG-JW,C2H-YK<S8^\-)U<?<:.)6]:3;DXY,M*?6G17;F\VC5M"OS>22;@/Y
MH^RI-=OWRK<G48_ECXT':W!EK6O/9<QOS8OQ8_R>*D5Q5CL0+[K+;M^)%RS-
M;K)/(!KVN>=/C*ZQ'<AVO$<9EHR9K%1:EUN,Z?-//_1U76,-Y[$*V_V]>=X^
M7Y&N[<N''9,7>XQ_UP%O^&OW(T]7VWVO1/J?/^)\1^<?_,*S^&OW,?G&V^U/
MQ2R-W'AW'3UC0^=CP/J+$[>_<WKU7;3.GB]$^IM193'3$".U$7'L;S@'X"N<
MX[1V2ETW>&\Z1>OQMMCR"'QNT(XAS3]<+FEQ/;"3K;@R]70,LN>T?:R_C!_E
M<?C7*V*L]B53=Y:]OQIRGO-IT;?K\OEDAXC^:?LJ/;;]TI^/J,?S1\2Q4\C2
MOMYJDS9/*T<'#W6GB%&M2:\UGCRTO]6=6TM'5N4LG;H._$OUC[XG<6'WN[WE
MK:D2ZTRVIR6G'9FK?T9^2L=\3CV_>GO46U)JL,>:+^=(KF[B @(" @(" @("
M @V:7Y4_>GZH6);5YM]:.H@(/B3Y*Q+:O-A6CH(" @(" @(" @(" @(" @(-
M#(Y>ICFZ2NYYM/1A;\H^[Y NE,<V<<F:M.?-4<AFKN0):]WAP=T+. ]\]ZF4
MQQ559,]K^9'+HX,%J[4I,\2W,V)O=S'B?<':?>6U:S;DYWR5I&MIT5V[O2!F
MK*$)E=W22>BWX!Q/Q*57;3VJS)U&L?5C5 VMR9BT3K8,+#]I#Z&GOCTOC4BN
M&L=BOOO,MNW3S(J65SB9)GEQ[WO.OQE=HCN0[6UXS+1ERV,A)$EN($=H#P3\
M U76,5Y[)0K[W!3A-Z_&U7;FPK3IZP7:>1C_ +"Z1MLG<B3U?:Q_-Z)]3X_Q
M3A_SC_YA6?PN3N:_G.U^U/Q2^F[GPQ[9RWW6/^L"L?ALG<S'6-K]KT3ZFS'F
ML5+IR6X^/9S.Y/Z6BTG#>.R4JN_V]N5Z_'HW8Y&/'/$\.'<YIU^HN4PFUM$\
M8E)5<[EJFGA6GEH^T>>=OP.UT]Y<;8JSV)=-UEIRE.T]ZO&C;]<$=\D)T/\
M-=]E<+;;NE/Q]2^U'Q+'1RV/R(_LL[7/[3&?1>/>/%1;8[5YK3'GID^K+=7-
MW;5/(6Z#^>M(6@_*8>+3[H6MJ1;FZ4R6I/!;,9N"M>TBFT@LGL!/H./F/UBH
M=\4U6F+<UOPGA*87%*$! 0$! 0$! 0$! 0$! 0$&6+O]Y;0TLR+9H(" @("
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M0MJ_I'IL<Z3/_-;YIAM_0;TM_</_ .MW?Z]:?FFY^UZ(]3I^T^E_VO\ KO\
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M*):LQS6=+Q:-89UJW$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M?7])=,C_ /7K_P U_O,OT&]+?W#_ /K=W^O6/S3<_:]$>IM^T^E_VO\ KO\
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MNBKYG65A$:0\^]8_91Q'5/=IW=C\]_AV[9A9'DHFT1<98FC]%LW_ %B#E=R
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M_P#E7#)76-4O;Y-)TGDMBBK(0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M$HN20(" @(" @V:7Y4_>GZH6);5YM]:.H@(/B3Y*Q+:O-A6CH(" @(" @("
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M#%7ACKP,;%!$T1Q1L :UK&C0  =@ 7C9G7C+[;6L5C2.4/M89$! 0$! 0$!
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MWB]8M':E\+=]2NL+CI#+^+D]P]A]XKEDKK"5AOX;+LH2V$! 0$! 0$! 0$!
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MJ%*WADS+.W&Q'\7#H^;3O>1P'O!3]O32/$HNH9M9\$=G-SC=&4-.J*L)TL6
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M'4KTOGF:<GT;],;?/AV%*YM8GCI$\XC7A"_JM>H$! 0><_;$_P# ^"_WL/\
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M'8^EM+9-#9M*#I[:]<VN7/DK2F5\Q#WG60'Q-',/-J7,(&A/8%AE<D! 0$!
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M!Q].NXM_DNXCZZA9HTLM]K?6FG<FEP2Q 0$! 0$! 0$&6+O]Y;0TLR+9H("
M@(" @(" @(" @(" @("#SQ[7U>Q8V3@VUXGRN&5!+8VEQ ]7EX\-5F&"G[56
MVZ]2O7=M;.%T4;(W$0PZ$M:!P_&>9-&5ZZ:]:<3U+RMO$X_#9'&RU*_K3I;[
M&,C<WG:SE:6O=Q]+5!1?9!KV*^R<XVQ$^)QRI(;(TM)'J\7'CHDL(WVC:6<V
M9NS$=4-JQ/-J[2MX+(&(..DDL$C89'<H.K@U[G#SQ-2!UCHGLW_ _3;"XF6/
MP\C8C]?R0(T=ZS; >YKO.QO+'_)6&7*LJ<WT%ZK9[>DF+LY3IUN]QGOSTF^)
M)5LN>97%X.@!:]TA:'$!S7<#J"%EAM[J]H.YO.M#MGHC1OW-TW98P<B^LT15
M8VN#B2)>=O'31QD;R!NIUU30;'M(T,XWHKB:>6G.4ST5VB,C:AC#1+.()?$>
MUD;6@-+NS1H2!V[; +=MX9KAHX4:P(/:#X+5AE*H//'7BO8EZM](9(HGOCCR
ML1D>UI<&CUZH=21V+,,/0ZPR(//'LP5[$&2ZBF>)\0?E8RPO:6\PY[/$:]JS
M+"A=)=_Y#IAFMWY#/8>[-L?(9.2.SD:T1D-2W&^0L<]IT]![7<3YN&O8@L.\
M-QVO:4RV&V;LO'VXMD4+;;V=SUJ,PLU8TLY6=HU#'OY6D\SG'L#6DH)KVC*<
MIWGTC;5@<Z&#)R@^&TN#&BQC]-=.P:!('?,QBZV;Q%_"W 33R-::G8 TU\.Q
M&8W::\.QRPR\T]/M^WO9^CN]/.IN-N,P\-F6?!YVK"9:\L<AU+1Q Y7$<XT)
M<TN(< LL/S<N3R7M*[IP.&VWB[5;IOA[/K>4S5R/PFSG@UP9KJ->7F8QH).K
MB7  (+WU3WGU"Z=;UQ.YHX)\OTK?#X67H4X(G2UY_2:9"\,Y]-"U[>9X82"T
M\O HRH?5+JUL7JSMF;:NSMOW-P[OO>''CWFC^,J:2->YXD!+V\ X>CZ/;S>C
MJC#;ZT[9RNWO9TVSMJX#8RF.L4(K0BUD#7MAFYF@C75K2>4'S(+UU$M]2L/T
MZVWF^G3G26,;%4ES&,C@CFELU!"S4-#F/?Z)'I"/1W*2>Y&5<R?M*=+L_A),
M=E<#>R.4FC+';<L4V3DV2"/#U<2WM^VTYM./+KP31A.^S1LS/[.V#.W<-=]&
MUE;TEZ''2!S9((3''&WG:[BUSN0GE/'337BDLNS+ (" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(,=C\B_W%F&+<D6MW$0$&CF)_5\=.\'1Q;R-]U_
MH_76](UEQRVTI*CJ:J5*WG:Y[4%0'T8F%[OOGG[ 4[;UX3*BZC?6T5[G.+E&
M;<FZL5MRL3SV)HJY(^U,[AS._DMXJXQVC%BM>7A-[CG=[W'MZ]LQ'Q\_BCB]
MJ5*L%*K!2K,$=:M&R&%@[&LC:&M ]P!>&F9F=9?>*4BE8K'*.#,L-Q 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0>5^O.'&WNH5;/P,Y:^5B98>1V&:$^%*-/.WD
M)]U>NZ7D]Y@FD_R_Q#XW^K,'X3J--Q'*\:SYZ\+?].B-!! (X@\05A/=&VW:
M]:Q$!)U?%K"[^1V?%HJS-72TO3;2_BQ1Y."P8Z?U:]!-KH&O <?N7<#\14>T
M:PL,=M+1*^*"N! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 05K=,^LD%8=P,
MCA[IT'U"I.&.U W5N4*Z2 -3P [2I""Y;D;7K=RQ;<?1D>YP)[F]WP!6U*Z1
M$/)YLGBM-FST%P_^(.H-K/SMYH,5$^PS7NFG)BB&GF:7GWEOU3)[O!%(_F^9
M5_I/!^*ZC?<3RI$S'GMPK_TZO5"\B^R" @(" @(" @(" @(" @(" @(" @("
M @PVZL%VK/2LL$E:S&^&9A[',D:6N!]T%9B9B=8:7I%ZS6>4\'BNG2FVYNG*
M[;L$\U>:6N"?MG0.(:[WV\5[G):,N*MX?!]ECG:;W)MK=DS$?!R^..*U8^R:
M=ZO:'9&\%WWO81\"K[QK$P]7BOX+Q;N=1!UXCL54]8L6UI]'V*Q/:!(T>YP/
MU0H^:.U.VMN<+*HR>(" @(-FE^5/WI^J%B6U>;?6CJ("#XD^2L2VKS85HZ"
M@(" @(" @(*]NRQR5H:P/&5Y<[W&#[)4C!''5!WEM*Q"I*8JW--P6O6\O9D!
MU8QWA,]R/T?C/%6N*NE8>6W=_'EF?@5"KC';MW_B-NCC!)/%%,/)$#XDQ'G#
M ?@5G%_<[>U^W^(AXW+B_&]3QX.R)C7S?6M_TO9[&,B8V.-H;&P!K&C@  -
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MV(/U 0?F@UYM/2[->_1!^H" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @QV/R+_<688MR1:W<1 006Z)>6M##\]Y<?<8/^5=\4<4/=3PB%64E7N:
M9R?UG+6Y.X2%@]R/T1]16F.-*P\MN;>++:?*^>AN-&<ZG3961O/#C(9[+7'L
M#G:01^Z='D^\N_4[^[VT5^UIZU-^E\7XGJE\LQK%(M,?]L>C5ZK7D'V40$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$!!QOVD,0+FS:>6:/QN,N-YC_S5EI8[_*#%
M>='R>'--?M1\CP7ZVVWO-E&3^W:/BGA\NCC>%G]8Q=60G4AG(2>W5GH_65MF
MKI>7F.GY/>;>D^33XN"^[*G]&W5)X MD:/=U!^H%6[B.4O4].MPM5;5#7#H%
M27QZL,W>]C7'W2.*@S&DKFLZQ$LRU;B @(" @(" @(" @(" @(" @(" @("
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M%:7N$C0?<<=#\146\:UE98ITO$NAJN7H@(" @(" @("#+%W^\MH:69%LT$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M&L:"7.)T  [22@QP6JUII?6F9,UIT<Z-P> ?(="4'V][& %[@T$AHYCIJX\
M./>4'S)8@B?''+*QDDI(B8YP#G$=O*#V]J"O[DV9A-RY; 9?*23,N8"R;6.;
M%((V.E)8_1XT)</Q0.@TX:]R"R(,!NTQ/ZJ;$0M=G@<[?$XC7Y.NO9Q09G.:
MQI>\AK&@ESB=  .TDH,4UNK68V2Q/'#&[@UTCVM![^!)"#*US7M#V$.8X M<
M#J"#V$%!B9<J23.KQV(WV&:\T37M+QIVZM!UX(,R##+<J02-AGL1Q2OTY(WO
M:USM3H- 3J>*#,@(*?U5H#)=.MQUR.8,I/LZ>>J1.#Q\GAJ;L;>'/2?+\O!1
M]>Q1DZ?FB?L3/L_2^9Y8VG*7XY\9_P!'*0/<(!^KJO5[J/IOE'1+ZX)CNE?-
MHR^'EN3NEB>WX-'?659GCZ+U^PMID\\+ZJYZ%=<$_GQ<'E;S-/O./UE#R?66
MN"=:0D5S=Q 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!S^W)XMJ>3Y\CG?"2I
M]>2EO.MI5K=\OAXGD_.RL;[P!=]92L$?25F_MIB\\N2[LE+,='&/])* ?<:"
M?JZ*[VL?3> ZW?3!$=\O4_2NB,=TZVY7 Y0^E'9T&G_O6L^O#R\Z\IOK>+/>
M?+\G!]7Z#BC'T_#$?8B?:^E\ZX*$O! 04&WU(GGPV"SFV\%;R=3,3/BE81RR
MU_"?X9;((O% <2#IQTX<57]6SYME>M*XYR3,Z3I\'D[=>";^G\>WZIAMEG)[
MJ(KK$6TUUXQ,3Q[)CBM&-W#1RN6S&&JMD]8PDD,5N1P;X3GV(A*!&0XD\H.C
MM0-"K:^*:UK:?YO7HIL.[IER9,===<<Q$]W&L6X?'Q2RXI@@(,,UNI6<UEB>
M.)[_ )#9'M:7>X"1J@S(,,]JK5 =:GC@#N#3(]K 2/)J0@RM<US0YI!:1J".
M((*!S-+BP$<X );KQ .NAT\^A0?$=B"9TC(I62/B/+*UK@XM/D<!V(*]@-F8
M+;^?SV?QSYGY+.2,DR#))?$8QS>9P#&Z#EUY]?2U\V@061SFL:7O(:QH)<XG
M0 #M)*#%!:JV@759XYPW@XQO:\ GRZ$H,I>UKFM<X!SOD@GB=./!!B]<J>L>
MJ>/'ZU^8YV^)V<WR==>SB@R22QPL=+,]L<;>+GO(:T#SDH/F&Q!99XE>5DT>
MNG/&X.;J/.-4&1!@AN5+#W1U[$<LC/EMC>UQ'=Q )T09T!!Y^]IW'--;;V6:
M-'L?8JR.\H>&/:/>Y7+TG1+\;5\TOF'Z\P:X\63NFU?CC7YE!JR^/5AF_.1M
M?_. *EVC29A$PW\=*V[XB70MH2^)B>37\E*]@]PZ.^NJW/'TGIMA;7%YI66I
M)X5N"3YDC7? 0HMN2SI.EH= 4!=" @("#9I?E3]Z?JA8EM7FWUHZB @^)/DK
M$MJ\V%:.@@(" @(" @(""@9J3Q,K:=Y'\O\ , ;]96&./HPI,\ZWE6]RR^%A
M;1':X-8/Y3@#\2E88UO"LWEM,5G+,I*8<=:E;P<V)_*?.1H%<8HUO$>5XW>7
MFF&]H[*S\CIWLS8_PMMYK*%NCK5UE?FTXEM:(.''O&LQ4'K5]<E:]T?+_P#"
MU_0N'P[7)?3C:^GP1$>N7<5Y]]%$!!!W=SU*><&W17FFRDF/FR==K0T1RM@>
M&&)KB[7Q"3P'+IIWK>]+1AG)$:Z=G;RU1J[FD[JNWGA-H\6O\ND3$3Y>W7ER
M06(ZAR2X>CD=PXBQBK62RL6&J5--7NDGTY)-)?"/(-7<V@)]$\"J_I.7+O<5
MKVI[N:Z\)UY1\'P+/K\8.F9:4K?WL9)K6)KI]:TS'?V::SY.Q>5-11 0?+WL
MC8Z21P9&P%SG..@ '$DDH/F"Q7LL\2M*R:/73GC<'C4=VHU0?9( ))T XDE!
MB@MU;0<:L\<X;IS>&]K]->S7E)097/:QO,]P:WRDZ#CP"#XDGAA+!-(V,R.#
M(P]P;S./8!KVE!7MX;,P6\6XQN;DFC_9MMENH8)?"YIF]C3J""#I[OD(065!
M@?=IQS"L^Q$VP[0-A<]H>2>S1I.O%!G089+56&)L\T\<<#].65[VM8=1J-"3
MIQ09(Y(Y6-DB<'QN&K7M(+2/*"$&,7*CIS5%B,V1VPA[?$X#7Y.NO8@S(,,]
MRI6+6V;$<+G_ "!(]K"?<U(U09D!!S_K9CQD>FN:;_I*S8K3#Y/!F87?Y/,K
M+IM_#N*_$\S^I\'O>FY8[HBWLS$O-^U)?$Q#6:_DI'L^$\W^<O1[J-+OG71;
M^+;1'V9F/G^=U#9$NM:W!\R1K]/OQI_FJFW,<8E[CIMOHVCRK4"001VCB%#6
M[I<;_$C9)\YH=\(U59+T,3K#Z6&1 0$! 0$! 098N_WEM#2S(MF@@(" @("
M@(" @(" @(" @(.'>U1GLYM[I[C;N R=O%7),S!"^Q1GDK2NB=5M.+"Z)S26
MDM:=.S4!9@;GL^]4IM[X&7;FXGO;O;;P\&^R?433P-/(V9P=QYP?0E[^;0GY
M22)#VBLME<)TIRN1PMZQCLA'-4$=NG*^O,T/L,:X!\9:X:@Z'BD"W].;5F]T
M]VG=NS26;EG#8Z:Q8F<9)9)9*L;G/>YQ)<YQ.I)XDK F[65Q=&1D-V[7K32?
MDXYI61N=W< X@E!M@@C4<0>PH,;;%=\KH&2L=.P:OB#@7@<.)':.U!^RS0P,
M\2>1L4?9S/<&C4^<H/F2S7BC$TLS&0NTY9'. :=>(T).G%!\&]1%L4#9B%YS
M>=M4O;XQ9\X,UYM.';H@^[%FO4A=8M3,@@9Q?+*X,8!YRX@!!\U+U*_%X]&S
M%:AUT\2![9&ZCNU:2$&=!JQY/&S6WT(KD$EZ/7Q*S96.E;IVZL!U'P(.,>SG
MGLYG/\;_ +:R=O)>J9E\-7UR>2QX40Y_0C\1SN5OF'!9EAVNS;JTHC8N3QUX
M&_*EF>V-@]TN("PR5;=2]"+%*>.S [4"6%[9&$CMXM)"#,@U(,IC+-A]2M=@
MFM1Z^)!'*Q\C=.W5H)(09XIX9PXPR-D#3RN+'!VA'<=.]!CMWJ./C\:_9BJP
MDZ"2=[8VZ^35Q 09()X+4++%:5DT$@UCEC<'L</*"-04!]B".1D,DK&RR?(C
M<X!SO<!XE!A.3QK;@Q[KD OGLJF5GC'AK\C7F^)!M(-:YD<?CF-DR%N&HQYT
M8Z>1L0)'<"XC5!FBEBGC;-"]LD3QJR1A#FD'O!' H/PSPB45S(T3N',V(N'.
M1Y0.W3@@QU;U*\)#2LQ61$[DE,+VR<KQ]J[E)T/F0?%S*XS'%HR%V"H7_($\
MK(M?<YR-4&>&>&S$V>O(V:!XU9)&X/8X>4$:@H..;QZFYG'=;]H;!HVJ\.V[
MM<W,I( TRR2'UI@B=(XD-:TPM=HT ZGB=."R+)U*VSN/=$VW+&VMUNV[!1LN
MGNMBL2PMNQ.,9$?XE[0\:-/RM1Z2P.AH-./+8J6T:$5ZN^\W4.K-E8901VZL
M!UX>X@W$&#UZEX#[7K,7JT>OB3<[?#;IVZNUT':@5+M._%ZQ1L16H-2WQ8'M
MD9J.T:M)&J#.@(" @(" @(" @(" @(" @(" @("#'8_(O]Q9ABW)%K=Q$!!3
M]QNUR1'S6-'U_KJ7B^JK-S]=7\F[DQUQX[6PR$>Z&%2*?6A S3I2T^27'\T[
MEQ5L_P#-D?#P5WA^O#PN_G3;W\TNS^S?6;#L2U.#J^QDIG$Z::!D4+0//V$^
M^JCK%M<\1W1'SO4?HG'X=A,_:O:?1$?,["J1[M&Y[.X[;>+FS&5D,=*#E#RU
MI>XE[@UH '>25%W6ZIM\<Y+\H3-GM,FZRQBQQK:7/\KNS>E[+X[%[:GH#$[L
M8Z7!9F5CQ+497BY[#'PNU$DF@YF:Z#MU\UMLK;;/@C/&LQ'9WZ\O-W2\IU:>
MH;7>?A(\%?',Q6T_R>&-;1IRM.G&O&/+R9']-,;%D8+-3=M^'?[&F3]J2V&3
MSR1$>DPU7^AX.O$-#>'E4B-Y;PS$TCW?=I\_/5$MT6GO(O7->,\?S^+69CMC
MP3]'P^2(YOVSTTI7K<%C>N[+F1W(\%F)MQRQXQ\#M/3-6&$Z<SN'-\I(WDUB
M8QTB*]L?6U\\RQ;HE<EHMN<U\F7^6T3&/P]_@BNG/MYM2ME>HN'W1#T_?D:>
M2_$C*C/VF$3Q8R.0QO9-$S0.>7 ,:_4>4^;:]<%L4YM)KV:=FNG?W.>+/O\
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M)2MQ\WB&5O'G!#'\HT[6_#/Z;DVV[P>]B9TCCYXUT^#B\]UW\PV&[C;Q%/\
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M8P [F(\1C@ QS07,T+W\W'AH@^MYQ;5Z'YO#[YZ2YZ*;$SVVU,_MFO?;=9)
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M+9MC_J$G_3._HM47+S6.V^K\*:7%+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MBS9(G+FF;3QTFTS&GT8YZ1$1$,NP]B8;IM1L4:EZ2;]HV&OY[;F-)?IRL8P
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MEC;(UIYF\_(=.S5!SS8VPL1OO;U#>.^K4^Y<GE6>LB*Q/(VE6#G'\5%!$YK
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MO:.(X(RP].QT<?U8M8/8&U-<A@(I93N>M8DEJ,<Z/P9&@/D(.OB.C!XZ\2.
MU1A$[:OTMO\ M8;N9F9V4OVMCA!CW3.#&RRRMI2L:UQX:EL3]/.-.U!O>UEN
MO"P;'BVHVU'+G;MR&8TXW!TD4$',YTD@'R07<K1KVZ\.PI C^O/_ *=-I_\
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M"TM^NJS//T'K]C&N6/(Z"JUZ-<MO,Y<7&?GN<[_*T^LHF3ZRTV\?0A*+DD"
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MHP6]A$<A<P>\U!?  T!K1HT< !V (/U 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M6411@\K'\22-==/E-\JSH.P8G*4\WBZ69Q[_ !*&0@BM5I/+%,P/:?@*P-Q
M0$%.V)U)P/427,_X>;,ZGAK#:C[4S?#$TA:7$L:?2#1IIZ0!\R"XH""E]3]Y
M9K8VVV9K X*7<-YUF.N:$'B<XCD:\F3\4R0Z M ^3WH+7CK,MW'U+D\1@FL0
MQRR0'76-TC XM.H!X$Z=B#90$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$!!CL?D7^XLPQ;DBUNXB @C,_#XV,D([8B)!
M[W _$2NN.=+(^>NM%,4M5J'NZMX.4\8#T;#&NU^Z;Z)^H%88)UKH\]OZ:9->
M]1(<D[:N^L3N-O"*&>*:734ZQM/)*-!Y6:_"K6*>^P6I_'D>*S9?P74<>X[-
M8F?-RM_TO:;'LE8V2-P=&\!S'#B""-00O#/O$3J^D9$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!!YB]HG,.RV\<9MB!Q,>.A:90#V3W"''4>:-K#KYUZOI&/P8K
M9)[?F?(?UEGG/O,6VK_+''SV]41K\*!8QL;&L:-&M :T>8<%M,ZI$1$1I"_[
M2K>#BO%(]*P]S_Y(]$?45=GG6ST>PIX<>O>L5>(SV(H1VR/:WX3HHTSI"RK&
MLQ#H0   ' #@ H"Z$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!5-SP\ER.8
M#A*S0_?,/'XB%*Q3P5VYKI;5 RQMFB?"_P"1(TL=[CAH5WB=$*T:QHY19@+'
M3591Q:71O'N:@JWK/;#R%Z<ZSYDW[.V8.)W?E-LV'D-R$),0[C/3)/ >=CGG
MWECJ^/QXJY([/G1?T9GG!N\NVM/UHX>>OKB?0].KRCZ\(" @(" @(" @(" @
M(" @(" @(" @("#Y>]D3'22.#8V N>X\  !J248F='BR;).W5OG+;C=QBFGE
MFB)U&C'$LB&A\C/J+W,T]S@K3^/*^#X<OXWJ.3<=FLS'R5_Z4_#$Z>:.%GRY
M'!C?=<= H4SI&KTU:^*8CO=5BC;#$R)GR(VAC?<:- JB9U>NK&D:)[;$//<D
MG(]&)F@/W3S]@%<,L\$W;5^E,K6HJQ$! 0$&S2_*G[T_5"Q+:O-OK1U$!!\2
M?)6);5YL*T=! 0$! 0$! 0$%8W;!_P!6LC[J-WU1]=2L$\X5V\KRE6%*5SEF
M3K>IY"S6TT$<C@W[TG5OQ%6]+:UB7D<U/!>:^57]O93_  EU-Q.8<XLJ23L$
M[NP>#8!AE)\NFI<I^2GOMM:O;'S<7EL.7\%U?'D_EM,:^:WT9];V4O$ON8@(
M" @(" @(" @(" @(" @(" @(" @("#RMUURPW#U&KX*%W-7Q44=9^GYV7\;*
M=?,TM'O+UW3*>ZV\W^U_$/C?ZJS?B^I4P1RI$1/GGZ5O1HTP.P >8!<UHZKC
M:WJ="M6/RHXVAWWVFKOC51>VMIEZ_#3P4BO="?VY!XV4C=IJV)KI#[PT'QE1
MLLZ53]M76_F7A05P(" @(" @(" @RQ=_O+:&EF1;-! 0$! 0$! 0$! 0<OW_
M -;,)L;,#!"C+DLC&UK[C8WMB9")&AS1S$.)<6D.TTTT(XJWVG3+YZ>/72.Q
MXSK'ZIP=/S>Y\,WM'/CIIK\_:NVU-T8S>."JY_%%WJMD$&.0:21R,/*YC@->
M((]_M5?GP6PWFEN</1=.W^/>X*YL?*WQQ/;$II<%B(" @Q6;$%.O-;LR"*M
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MUVN/QY(CX72U5/4K7M.MRPSVG#B]PC:?,WB?C*B9YXZ+/9UX3*QJ,GB @("
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MX@UH&@ #    L,N#^Q]$P=.<O,!^,?FYF.=QXM94JD#_ "BLR/K=@ ]K78A
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MG>]%L,7BOXNR%[5>] M^W:O@4?&<-'SGF_DC@/LJ+EG65GMZZ5U[TNN*2("
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MYSI?M"[@,_8J6;EG)2WF/HODDB$4D$$0!,L<1YM8G?:Z::<4%2VCTIZK=/\
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MR"Q4;@<-C9*-JN]\@MNE>RZT%C1&6%NMAG;(#P/#LU##/TQSTO7:MU/;9IC
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M&H?L^DR)P_'/].4_='N][L5?DMXI7>''X*Z=J07-W$! 0$! 0$! 0$&6+O\
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MJSN\Y[/7[/9UVM?'?C;Y/)#XSUGK6;J^7W.#6,4?]7]5O)W1\//E'XS&08R
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M\+>6-@T:/KE5\SK.J\K6*QI#*L-A 0$! 0$! 0$! 098N_WEM#2S(MF@@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M#N4"]_%*ZQ8HQQHWES=A 0$! 0$! 0$! 0$&6+O]Y;0TLR+9H(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(,=C\B_W%F&+<D6MW$0$! 0$!!\O8R5
MCHY&AS'#1S3Q!!66)C53\OB'T'^+%JZHX\#VEI\A^L5+I?569L/@XQR1:Z(Z
MM9S;#+9=:QX$=GM?%V,>?-Y"I6/-IPE5[G91?Z5>:E6*[F.?6M1:.'HR1O'U
M05.B>V%%>G.MH5NWMV:M.V_@YG5K,9YV-:\L<UWE8\$$%3J;B)CPWC6'FMQT
MF:V]YMY\-H\NGQ3V.A;2]H'<&">S&;UJ.R-=FC3;8!'<:WRD'1LGQ'SJ!GZ3
M3)'BQ3IY.S_1>[#]89]O;W>\KXOZHX6^+E/H=WVQOO:F\(@_ Y**>;35U1Q\
M.RW3MUB?H[AY0-/.O.YMKDPS].-/D?2-CU7:[VNN&\6\G*8\\3Q6-1EH(" @
M(" @("#2RF8Q6$JNNY>[#1JM[9;#VQM]P<Q&I\P6],=KSI6-9<,V?'AKXLEH
MK'?,Z.+[P]HS&5.>ELRJ<A:.K1?LM='7!XC5D?![_?Y??5[M^CVMQR3X8[NU
M\_ZE^M,./Z&UK[RW?/"OQ<Y]'G<<OG=&];_[6W3=ED<?D"30%K3QY8XQHU@]
MY75;8L%?#CAXN^WW?4;^\W5IT[(]4<JI>G1K4(O!K1AC?MCVN<?*3WJ+>\VG
M65]@V^/#7PTC2$KC<5;RDOAUF>@#Z<IX,:/.?K+A>\5CBL,."V6=(7[%8>KB
M8N6$<TSORDQ^4[S>8>95]\DVEZ'!MZXHX<T@ 2=!Q)[ N22M.%PGJ_+;N-_'
M]L<9^U\Y\_U%&R9->$+##ATXSS3JX)@@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @T\CCH<C#X<GHR-XQR#M:?L+>MIK+EDQQ>-)4NU4GIS&&
M=O*\=A[B/*#Y%,B8F."JO2:SI+5G@ALQ.@G8)(GC1S7=BWB9B=8<K5BT:3R4
M?-;:GH%UBH#-3[2.U[/=\H\ZG8\T6X3S4.XV<TXUXPK%RC5OQ>%:C#V_:GL<
MT^4'N4REYK.L*;/M\>:OAO&L(B@=T;*O?M7:UZ6-X^6(]"7-''EDC.K7CWE*
MM;%GKX<D*&FWW?3K^\VMI\L>N.5G9-G>T9C+?)2WI5..M#1IOUFNDKD\!J^/
MB]GO<WO*EW'1[5XXY\4=W:]KTW]:8<GT-U7W=OM1QK\7./3YW9\7F,5FZK;N
M(NPWJKNR6N]LC?</*3H?,517QVI.EHTE[_#GQYJ^+':+1WQ.K=6CN(" @("
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M(MF@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M:-S>%=?I&VMV:>:6J[:%(_)GE'N\I^L%O^+MW0BST+#V6MZ/4^/\'P?WI_\
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M/BF  !H.Q<4H0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MLTORI^]/U0L2VKS;ZT=1 0?$GR5B6U>;"M'00$! 0$! 0$! 0$! 0$! 0$!
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M['Y%_N+,,6Y(M;N(@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @V:7Y4_>GZH6);5YM]:.H@(/B3Y*Q+:O
M-A6CH(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(,L7?[RVAI9D6S00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 08['Y%_N+,,6Y(M;N(@(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @V:7Y4_>GZH6);5YM]:.H@
M(/B3Y*Q+:O-A6CH(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(,L7?[RVAI9D6S00$! 0$! 0$!!SN[UOZ=8^Y
M8H6LC*VS5E?!,T5IW 21.+7#4,T/$*SKTS/:(F(X3Y8>4R_JOIV.\TM>=:S,
M3]&W./@8/I[Z9_O*;]%G_ 6WY5N.[TPY?N_IOVY]FWJ/I[Z9_O*;]%G_  $_
M*MQW>F#]W]-^W/LV]1]/?3/]Y3?HL_X"?E6X[O3!^[^F_;GV;>H^GOIG^\IO
MT6?\!/RK<=WI@_=_3?MS[-O4?3WTS_>4WZ+/^ GY5N.[TP?N_IOVY]FWJ/I[
MZ9_O*;]%G_ 3\JW'=Z8/W?TW[<^S;U'T]],_WE-^BS_@)^5;CN],'[OZ;]N?
M9MZCZ>^F?[RF_19_P$_*MQW>F#]W]-^W/LV]1]/?3/\ >4WZ+/\ @)^5;CN]
M,'[OZ;]N?9MZCZ>^F?[RF_19_P !/RK<=WI@_=_3?MS[-O4?3WTS_>4WZ+/^
M GY5N.[TP?N_IOVY]FWJ/I[Z9_O*;]%G_ 3\JW'=Z8/W?TW[<^S;U'T]],_W
ME-^BS_@)^5;CN],'[OZ;]N?9MZCZ>^F?[RF_19_P$_*MQW>F#]W]-^W/LV]1
M]/?3/]Y3?HL_X"?E6X[O3!^[^F_;GV;>H^GOIG^\IOT6?\!/RK<=WI@_=_3?
MMS[-O4?3WTS_ 'E-^BS_ ("?E6X[O3!^[^F_;GV;>H^GOIG^\IOT6?\  3\J
MW'=Z8/W?TW[<^S;U'T]],_WE-^BS_@)^5;CN],'[OZ;]N?9MZCZ>^F?[RF_1
M9_P$_*MQW>F#]W]-^W/LV]1]/?3/]Y3?HL_X"?E6X[O3!^[^F_;GV;>H^GOI
MG^\IOT6?\!/RK<=WI@_=_3?MS[-O4?3WTS_>4WZ+/^ GY5N.[TP?N_IOVY]F
MWJ/I[Z9_O*;]%G_ 3\JW'=Z8/W?TW[<^S;U'T]],_P!Y3?HL_P" GY5N.[TP
M?N_IOVY]FWJ/I[Z9_O*;]%G_  $_*MQW>F#]W]-^W/LV]1]/?3/]Y3?HL_X"
M?E6X[O3!^[^F_;GV;>H^GOIG^\IOT6?\!/RK<=WI@_=_3?MS[-O4?3WTS_>4
MWZ+/^ GY5N.[TP?N_IOVY]FWJ/I[Z9_O*;]%G_ 3\JW'=Z8/W?TW[<^S;U'T
M]],_WE-^BS_@)^5;CN],'[OZ;]N?9MZCZ>^F?[RF_19_P$_*MQW>F#]W]-^W
M/LV]1]/?3/\ >4WZ+/\ @)^5;CN],'[OZ;]N?9MZCZ>^F?[RF_19_P !/RK<
M=WI@_=_3?MS[-O4?3WTS_>4WZ+/^ GY5N.[TP?N_IOVY]FWJ/I[Z9_O*;]%G
M_ 3\JW'=Z8/W?TW[<^S;U'T]],_WE-^BS_@)^5;CN],'[OZ;]N?9MZCZ>^F?
M[RF_19_P$_*MQW>F#]W]-^W/LV]1]/?3/]Y3?HL_X"?E6X[O3!^[^F_;GV;>
MH^GOIG^\IOT6?\!/RK<=WI@_=_3?MS[-O4?3WTS_ 'E-^BS_ ("?E6X[O3!^
M[^F_;GV;>H^GOIG^\IOT6?\  3\JW'=Z8/W?TW[<^S;U'T]],_WE-^BS_@)^
M5;CN],'[OZ;]N?9MZCZ>^F?[RF_19_P$_*MQW>F#]W]-^W/LV]1]/?3/]Y3?
MHL_X"?E6X[O3!^[^F_;GV;>H^GOIG^\IOT6?\!/RK<=WI@_=_3?MS[-O4?3W
MTS_>4WZ+/^ GY5N.[TP?N_IOVY]FWJ/I[Z9_O*;]%G_ 3\JW'=Z8/W?TW[<^
MS;U'T]],_P!Y3?HL_P" GY5N.[TP?N_IOVY]FWJ/I[Z9_O*;]%G_  $_*MQW
M>F#]W]-^W/LV]1]/?3/]Y3?HL_X"?E6X[O3!^[^F_;GV;>H^GOIG^\IOT6?\
M!/RK<=WI@_=_3?MS[-O4?3WTS_>4WZ+/^ GY5N.[TP?N_IOVY]FWJ/I[Z9_O
M*;]%G_ 3\JW'=Z8/W?TW[<^S;U'T]],_WE-^BS_@)^5;CN],'[OZ;]N?9MZC
MZ>^F?[RF_19_P$_*MQW>F#]W]-^W/LV]1]/?3/\ >4WZ+/\ @)^5;CN],'[O
MZ;]N?9MZCZ>^F?[RF_19_P !/RK<=WI@_=_3?MS[-O4?3WTS_>4WZ+/^ GY5
MN.[TP?N_IOVY]FWJ/I[Z9_O*;]%G_ 3\JW'=Z8/W?TW[<^S;U'T]],_WE-^B
MS_@)^5;CN],'[OZ;]N?9MZCZ>^F?[RF_19_P$_*MQW>F#]W]-^W/LV]1]/?3
M/]Y3?HL_X"?E6X[O3!^[^F_;GV;>H^GOIG^\IOT6?\!/RK<=WI@_=_3?MS[-
MO4?3WTS_ 'E-^BS_ ("?E6X[O3!^[^F_;GV;>H^GOIG^\IOT6?\  3\JW'=Z
M8/W?TW[<^S;U/B7KSTT?&YK<E+J1P_LL_P" LQTK<=WI@G]7=-G^>?9MZFC]
M.'3G]XR_HT_X"V_*]Q]GTPT_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G
M3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[
MC[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^
MC3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'T
MX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?
M[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[
M/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3
M_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=
M.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D
M^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I
M@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@
M)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?
MWC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S
M;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_
M=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^
M5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC
M+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U
M'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G
M3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[
MC[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^
MC3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'T
MX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?
M[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[
M/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3
M_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=
M.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D
M^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I
M@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@
M)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?
MWC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S
M;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_
M=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^
M5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC
M+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U
M'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G
M3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[
MC[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^
MC3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'T
MX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?
M[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[
M/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3
M_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=
M.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D
M^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I
M@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@
M)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?
MWC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S
M;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_
M=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^
M5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC
M+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U
M'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G
M3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[
MC[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^
MC3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'T
MX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?
M[D^S;U'TX=.?WC+^C3_@)^5[C[/I@_=G3?[D^S;U'TX=.?WC+^C3_@)^5[C[
M/I@_=G3?[D^S;U,U;KITWBD+GY*70C3_ *K/Y1]PL3TO<=WIAF/U;TV/_P!D
M^S;U-OZ>^F?[RF_19_P%K^5;CN],-OW?TW[<^S;U'T]],_WE-^BS_@)^5;CN
M],'[OZ;]N?9MZCZ>^F?[RF_19_P$_*MQW>F#]W]-^W/LV]3Y?UZZ9N;H,E-K
M_P!EG_ 6)Z5N/L^F&U?U?TS7Z\^S;U,7T[]-?WE+^BS_ ("U_*=S]GTPZ_N_
MIG]R?9MZCZ=^FO[RE_19_P !/RG<_9],'[OZ9_<GV;>H^G?IK^\I?T6?\!/R
MG<_9],'[OZ9_<GV;>H^G?IK^\I?T6?\  3\IW/V?3!^[^F?W)]FWJ/IWZ:_O
M*7]%G_ 3\IW/V?3!^[^F?W)]FWJ/IWZ:_O*7]%G_  $_*=S]GTP?N_IG]R?9
MMZCZ=^FO[RE_19_P$_*=S]GTP?N_IG]R?9MZCZ=^FO[RE_19_P !/RG<_9],
M'[OZ9_<GV;>H^G?IK^\I?T6?\!/RG<_9],'[OZ9_<GV;>H^G?IK^\I?T6?\
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< 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm2227887d4-tbl_pipelin4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-tbl_pipelin4c.jpg
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M  ( .$))300E       0_.$?B<BWR7@O-&(T!UAWZ__N  Y!9&]B90!DP
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M(95YU6;\,I-C_BV/[[O9*+\['(^"%Q,5X
M                                  %CL7[ZK?OI[)Q9?FAIY'Q67PK;
M@
M
M                    #Z@XO_1JS? :7_<M/+7^*>MV*\T/D52]#OP'LGDJ
M*@A8   $M/W[3_CL]D)YF']4,P-=U                   4ET_B^H_$,J\
MZK-^&4FQ_P 6Q_?=[)1?G8Y'P0N)BO
M                                L=B_?5;]]/9.++\T-/(^*R^%;<
M
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ML<CX(7$Q7@
M           6.Q?OJM^^GLG%E^:&GD?%9?"MN
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M6L953HU$3U$1#8XR<:559'Q6<EG7:
M                             ?4'%_Z-6;X#2_[EIY:_Q3UNQ7FA\BJ7
MH=^ ]D\E14$+    EI^_:?\ '9[(3S,/ZH9@:[J                   I+
MI_%]1^(95YU6;\,I-C_BV/[[O9*+\['(^"%Q,5X
M                                        %CL7[ZK?OI[)Q9?FAIY'
MQ67PK;@
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M;K[O'%!OC4[J8M#*^@D=3M\3JT2*26!M'%331NY5D1NO([E7CIP7[AE7A_\
MU:EF,YN%]:&P%W1[.LN5LW+?9KLS+6N2K=1M8WJ75B)IUG+UO)S:\>;5$U\+
M3F-?<Y^KJ8Q@NWF7CK=+'L#[0M):=S[_ )CD5L6*T9#&R!T% UKI*5M/IU*H
MB\B/U37K%U155>9/VI9F\+,Y<5B>6&%,_P#5,STKIA6Z&Q6V.4373$[=>ZMM
MRCDAK:ZK6)5IH'*DB14\6K5>CGL9S+([5$3I4QS,G.S*X6F.1E7,RZSR+5M1
MO#A> YQFM]KF5\UHOT[I+9U4,;ITC6>25$E:LC4141Z)X*KQ,L_(O>E8C#&&
M.7F5K:9TM!'1:@
M             ?4'%_Z-6;X#2_[EIY:_Q3UNQ7FA\BJ7H=^ ]D\E14$+
MEI^_:?\ '9[(3S,/ZH9@:[J                   I+I_%]1^(95YU6;\,I
M-C_BV/[[O9*+\['(^"%Q,5X
M                        %CL7[ZK?OI[)Q9?FAIY'Q67PK;@
M
M
M          #Z@XO_ $:LWP&E_P!RT\M?XIZW8KS0^15+T._ >R>2HJ"%@
M2T_?M/\ CL]D)YF']4,P-=U                   4ET_B^H_$,J\ZK-^&4
MFQ_Q;']]WLE%^=CD?!"XF*\
M                        "QV+]]5OWT]DXLOS0T\CXK+X5MP
M                              %9:I+9#<:>6\P2U5K:_6JIZ>1()GL]
M1LCFO1J_=Y5,;8X<G.F,.EFGROLUYKWS^5X/U(IU<W3'=^:S&FB3Y7V:\U[Y
M_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-
M7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F
M8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^
MS7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y
M7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJY
MNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&
MFB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:
M\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\
M'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-T
MQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT
M2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7F
MO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_
M4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.
M[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3
MY7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[
MY_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD
M-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?
MF8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*
M^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/
MY7@_4AJYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJ
MYNF.[\S&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S
M&FB3Y7V:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V
M:\U[Y_*\'ZD-7-TQW?F8TT2?*^S7FO?/Y7@_4AJYNF.[\S&FB3Y7V:\U[Y_*
M\'ZD-7-TQW?F8TT2QO):K$ZJ>!V)VZLMU.UBI4,KZIE8Y[]>"M5D,.B:=S12
MRD6CXI86PZ%C+&(                                 'U!Q?^C5F^ T
MO^Y:>6O\4];L5YH?(JEZ'?@/9/)45!"P   ):?OVG_'9[(3S,/ZH9@:[J
M                I+I_%]1^(95YU6;\,I-C_BV/[[O9*+\['(^"%Q,5X
M                                                          %C
ML7[ZK?OI[)Q9?FAIY'Q67PK;@
M
M                                            #Z@XO_1JS? :7_<M
M/+7^*>MV*\T/D52]#OP'LGDJ*@A8   $M/W[3_CL]D)YF']4,P-=U
M            4ET_B^H_$,J\ZK-^&4FQ_P 6Q_?=[)1?G8Y'P0N)BO
M                                                        L=B_
M?5;]]/9.++\T-/(^*R^%;<
M
M                                          ?4'%_Z-6;X#2_[EIY:
M_P 4];L5YH?(JEZ'?@/9/)45!"P   ):?OVG_'9[(3S,/ZH9@:[J
M           I+I_%]1^(95YU6;\,I-C_ (MC^^[V2B_.QR/@A<3%>
M                                                      !8[%^^
MJW[Z>R<67YH:>1\5E\*VX
M
M                                         ^H.+_T:LWP&E_W+3RU_
MBGK=BO-#Y%4O0[\![)Y*BH(6   !+3]^T_X[/9">9A_5#,#7=0
M        %)=/XOJ/Q#*O.JS?AE)L?\6Q_?=[)1?G8Y'P0N)BO
M                                                   L=B_?5;]]
M/9.++\T-/(^*R^%;<
M
M                                     ?4'%_Z-6;X#2_[EIY:_Q3UN
MQ7FA\BJ7H=^ ]D\E14$+    EI^_:?\ '9[(3S,/ZH9@:[J
M      I+I_%]1^(95YU6;\,I-C_BV/[[O9*+\['(^"%Q,5X
M                                                %CL7[ZK?OI[)
MQ9?FAIY'Q67PK;@
M
M                                  #Z@XO_ $:LWP&E_P!RT\M?XIZW
M8KS0^15+T._ >R>2HJ"%@   2T_?M/\ CL]D)YF']4,P-=U
M      4ET_B^H_$,J\ZK-^&4FQ_Q;']]WLE%^=CD?!"XF*\
M                                                "QV+]]5OWT]D
MXLOS0T\CXK+X5MP
M
M                                  !]0<7_ *-6;X#2_P"Y:>6O\4];
ML5YH?(JEZ'?@/9/)45!"P   ):?OVG_'9[(3S,/ZH9@:[J
M     I+I_%]1^(95YU6;\,I-C_BV/[[O9*+\['(^"%Q,5X
M                                               %CL7[ZK?OI[)Q
M9?FAIY'Q67PK;@
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MC7FA\BJ7H=^ ]D\E14$+    EI^_:?\ '9[(3S,/ZH9@:[J
M      I+I_%]1^(95YU6;\,I-C_BV/[[O9*+\['(^"%Q,5X
M                                                %CL7[ZK?OI[)
MQ9?FAIY'Q67PK;@
M
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M9RYBNLPLO5  "DNG\7U'XAE7G59OPRDV/^+8_ON]DHOSL<CX(7$Q7@
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M[7RSS>-2K#\C^+:<NE7)2Z]?UW'UG-_J_N?=,XS_ /VZF#'=?HUL6L3:4@
M    (XHI9Y600L62:5R,CC:FKG.<NB(B>JJD#H*@[+<D-+0QYAFMMQW(+FB>
M(V:1K)I9)'?]VCGSP\SD541>K:_CT:]WGSQO/JUF8AMQP^F6IMPMOK]MKD+\
M?OS6.D5B3TM5"JNAG@<JHCV*J(J<6JBHJ:HJ&WE9L9E<847I-)PEB9<K
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M:JM:U'M?"KG-:B/>]Z*U.AJ+KTW9?$6S+X5C]*NV5%:\O.R+/_[*6%?#*?\
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MO3X9V8LGQQMRI[I<:.9J7:6C=UD$58^JIGNA:[1->1KF([[NO1T$1?7SXG#
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ME=<[73<OB[XZ=K9)&\K$8Q$2)W6,>QC=>+51>E)IF7RLR*6G&)1:M;TUHC#
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M(X-'1131.;&U$:Q='N1W+HB\.'3K?PF9:9FMIQP5Y](B(F'/QT6H
M    !8[%^^JW[Z>R<67YH:>1\5G3O9 ])5U^8ZCXY2'*X_PXZ_Q=;AOB[&J=
MS^.Y>9(G3\NW/XY*;>3X=>J%&9\4];?^[S'8]V:\,Q^Z:QW:=U#I32+^Z-Y8
M9)GHJ:?L.9K%]370Y^1^K/M,<W*W,SDRXB5#OKZ!=K/@MN_FQIEPWC7[?O8Y
MOAU]NAD%TR_9K>.AL[\SNM?AN34L')$SK)**%KG*G,L;WL? L:/;X+EY7:=)
M57+S<J9U8BT+)M6_/R,7W-P#(*7--OZS*<K?E^%7BZ4E)2U52K6K%#/+"LB*
MK56-6R1^%UC5\+3BG1K;DYM9I;5C5F(5YE)UHQG&,4OM69'E%NS^UV^CKJF@
MM=-;H:F@CIIGQ,65TTJ.E\!R>&BL1OW$1/PSP5*S29PZ4<1:8M&"VV6X9]F^
M[& OW;H9HJ%:A5M<E50-I(IT8Q)FM:_D9UK5>D>J*YR)S='A<<K12F7;=S]J
M(FUKQK0E]I+,LQHMVJJBIKI64%#:8Z1UH93S20-;UD$<KY6\BHBN617-5W^3
MIW">$RZSEXX<Z,^]HLRKM(5$U5@.VN7U^E/F,D4,LLK4;'*CY*6*>7@B)ZR5
M$5$Z&JOW2GA(_7:L<RS/^&)Z60Y1A]/OQ3[7YY21(^.ID;1Y,C.'+3Q(Z:9J
M].B-DBFC;]V1I73,W&O7N9VKO-65KO>24.<=J?';#,K7V3&9)J6!BKHQ:ZFI
MY:ASM%X:I,QD?W>1#.M)IP\STRQFV.;$:%7N'58?3[OK>[KNA6V6_P!JGIDI
M[#':J^HC@8D<;NJ:Z/5CVS(O,[1%1W.8Y46G*PBD3$].,)O,:_.HZ7(\-RSM
M38K?L-J_&X*BBJ67)_43TR^-Q4-8SBV>.-RKU:1]SN=)E-+5X>8M[<L,=:)S
M8F&NNT7F^1U6YN0V."[5<5AI604+;<R5\=.K.IBDD1T;7<KM9=7:N3N)ZB&S
MPF77=Q.'*JSKSK3#8F56>KWXVDP3(*#6?)*&NAM-UE35[V)4/933RO[OKFQ3
M+ZC7*IK4MN,RT3S<ZZT;RD2Q+M49#3)?[)MY:OW.U8M11HZ%."-FGC;R-7U>
M2%L>GXREW!4Y)O//*OB+<L0T=8/X]M?PN#_>M-Z_PRUJ?%#LO?K.-O<5OEJI
M<QPV/)JR>D=+3U,BQHL4:2*U6>&U>E>)Q>&R[VB=6V#H9MZUPQC%H[<W?]^8
M8RS",5L46-8MX/7T\+F\TC8W<[8VMB9&R-G-HY41%U5.GI0W\GA=2VM:<9:V
M9G8QA$80V/-DETQCLE6>KL]5)15]4JT;*J!59*QLM=,K^5R*BM56M5-4]4UM
M2+<3./MR+IF8RN1+[,E;-<+%G^37:Y3+?&000/O4_/6U,%/!32\CD:JN>]&<
MJ*C$]=RH@XR,)K$1R&1.,3,FV&5;5X)<+Q65>YU7DUMND#FW"@J[1<NJ65ST
M7KGJYDNJJWG8[5/"YN/0,ZF9>(_1AA[X*6K&/+B\V7;3V79[=#(,0?SW:*HN
M$=#5LU9*E)24C9*>1&NT<BMZR1[47N_='$<N;2+<W(97)6TPT]@&;[Q107FW
MX4ZOO+:QC7W.!*9;LK6NYF\W5R-E1.?F5'+R^%W3=S<O*Y)MA'V->E[\N'*V
MCM2BIV8=Q$<FCDJ[@BHJ::+XE2=PU<_YBO9]\KLOPY2\ _LI9K\,J/\ !2#-
M^8JFGA2N&-7:XV3LB72XVJH?25S9GQ,J(G*R1K*BY10R<KDXHJL>Y-4,;UBW
M$Q$^W(5F8RN3VY4O8BZ7"Z[,;EV^YU$E72TM)5K R=[I.3KZ&57HG,JZ(JMU
MT]7B.)K$9M9CVY4Y,S-)Q4VT_P#9?W#^%5_Q*D,L_P"8KV??+'*\.52VIK\:
M[(]'78P]])4W"H<MTK*9RLEY):V2%[E>U45-49'"NG['@8X1;B<+>W(G'#*Y
M&I+9EV[M=MW=;%;V5MSP9'R?*E2ZD6N9"B-9*]KIWLD6)K4:DG2G+KS:H;DY
M>5%XF>2RB+WFON;#IL6O-#M78YMT]P9L=PJLZN>RX_14JSU4C',<]B.?&C7)
MJUW/RKSM3F17:.-:;Q.9.I7&=*Z*S%8UIPADF]<UHJNSGB\UCJ:RMM'C],E'
M57-4=6/8R.J9K(K>&O#A]PKX>)C/G'G99N&[6K?7T"[6?!;=_-C3/AO&OV_>
MQS?#K[=#F,ZC2  &UNS;Z:<9_A_\WU)J<7X4]GWKLCXX;BW7[-^:9]N+=LKM
MEQM=-:;BM+U;*F2H2H:D%+% [5C('-]=&JIX?0:61Q=:4BLQ.+8S,B;6Q6KM
M-7^RVW",5VQAN+;KD%I?32U]0UR.>QM%2OI=9M->5\KG\_+KJFG'I0SX.LS>
M;X81*.(F(K%67;Y7O!,=L^"W;,+ _):R.FGCM5J=/XM2Z/CI5FEE<C7JJMY8
MVM;RJB\RZ]"%/#5O:;16<%N;-8PF8Q:UWLPK!)]M<;W4PJV)9/E66*"JM\:K
MU2MGBD=T:Z(Z-\2MU:B(Y%U-GA\R^\FEIQP4YM*ZL6A(Q.[[16S';308[@%9
MN#EU0U/EGKHI6K'+RM5W5HUD[>7551B-;T)JY2;US9M,S;5@K-(CDC6E4=H/
M;;$K%#B&08_;78V[('=5<K<]5Y('.;&]%5CE\!S.=S7HU4;PZ$XZQPN=:VM$
MSC@9V7$83'(V+D^ 8OMS';K?8]HG9O9W0,=67J.?KZQ)>96O184CD>Y5:B/\
M'D9QT330UJ9MLS&9OJRMM2*\U<6@LKL&$Y9N;;<=VUIJVT4MUGAHZFDN42QM
MIJB23E<^-KGODY$:O.K7Z*B]'#1$Z%+7KES-^7!K6K6;X5;?RBCV?VSOE'@C
MMN9\AIVQP_*]_?UDDS.O1%5S51J\[D:O,J,=&B="&G2<W,C6UL/<V)BM9PU<
M6H]^MM*+;/,VT-G<];%<H$K:".1RO?#J]S'Q*Y>+N56ZM5>/*J:ZKJIN<-G3
MF5QGGAK9V7JSR<S$,"RB#"\LM^3U%MBN[+?USVT$ZHV-\DD$D<;E56O]8]S9
M$X=+>&B\2[-IKUFN."NEM6<733,ZONXG9SSO),@?&M6^JFAAA@9R10P,\55L
M;$U5=$5R\7*J\>DY>[C+SZQ#>UYMES,N03LN<    "HH?W[3?^*SV2$3S)KS
MNVM_=E\HW4N-DJ\>JZ"FCML,\4Z5\DT;E=*]KDY>JAEU3P>.NAP^%XBN5$XX
M\KHYV7-\,&.9)046RFP-RP7([Q#<,BO"3MHZ.%RKHM4Y$7JFO1'=4Q&J]7JU
M$YM4Z50LI,YV=%HCDAC:-3+PE+QZ7%J;LI6>LS&GFK;)2S33/M]-)U+ZJ5MV
MG2.%7]+6N<J<ZIQ1NNG$F^MYB=7G_)%<-UR\WYK(_'=L=U]G<CR[&\6BQ:_8
MTRHD1E/*LFJ4D*5"\SD:QLC9&:M\)G,CD_NYZ^9E9L5F=:)8X5O29B,,&N-J
M[AM/:+/<*[*[)593F:OTM=D2-ZTSHO!1-',YDYE57*Y7L71$X)J;.?&9,Q%9
MPC2KRM2(Y8QEM#,\#Q#)=F;IG4>"R8'DEK5'P4B\\;GQM?&BJYKF1H]CVR+H
MY8T<CDZ=.G5R\VU<V*ZVM$KK4B:8X82;>[;XW;MHK9F]%A+-PLDN<CG5='+4
MMAZF%'R,7JFN:]J\BL:BM1BO57*O0FB,W.M.9-9MJQ!2D13'#&6N=X'[=2VN
M@=;,/N6$YUS:UUJF@='1K#Q14UE5BJJ>"YCXXD147C]S9X?7QG&T6JIS=7#F
MPEG%IPC!]KML++F.3XJ_-,IR-L<T% JOZF&&>/KFIP:]K4:SEYG*QSN9=$X%
M%LR^9F36)U8A;%(I7&8QE8MV, Q*X;<VS=O"K3-CS9IDI[Q8I>;DC<Y[H^=J
M.];H]J)X*(US7(NC5UUSR,VT7FEIQ][#-I&KK1&#15!755LKJ6Y4,G55M'+'
M44TNB.Y)8G(]CM'(J+HJ(O%#H3$3&$M6)PY6U<2L^X?:"SJDN%YJI*J.@ZF.
MY7I88H8J:FC>Z1K4;$V-BR.U=R-1-57BO!%4T\RU,BF$=R^D6S+8RN?:CS.U
M93GL%NM$C9X+!3K15%2U$Y753I%?(UKDXJC/!;^-S:&/!9<UIC/2RXBT3.&A
MHXWVJ    #LRCP&\;D=FS%<;L<]-3UR]54]96ODCBY(I9M4UCCD77CP\$XDY
ML9>?,RZ.K-LN(A.VIV]D[/EMR#*,_P @HV4M3%&QM+1O>Z)5AYGHJ=<R)SY7
M:\K&M;ZO3KP9^;OYB*P9=-W$S,L8[,<M%<K)N=/7.=36VLZM]2YNBOB@ECJU
M>J<%XM:J]PLXS&)I@QR)QQ0[5T^R6Z]1<\%I,&6U>)T;JFENKZE9:Z6-CV1+
M(YZ(BLD1TC7<NKV?@X$YTYN5A;6Q1EZE^3!J';^DVUL.8W:FW-CJ;A2VQ\M-
M04--&]T=14Q2.9K(L;FNT3E\%O0JNX\$X[F;.9:L:G2II%8M.LWUAV&8+N]9
MKO356V$N$HR-%M-WT>SK72<R(^-W5PHY6*U%5NCVKZIS\S,OE3'Z]9LUK6\3
M^G!KSL[[=8WD]DR7*+K:&Y->+1RQ6S'Y)DIXI)%C61%>J\-7JG(U7^"FB\%[
MFSQ>;:LQ6)PB>E3D4B8F9Y51GKMNOHM<(,IVPN6!9,WF;9JJBC6:GDE1NK5?
M,J4\;FJ[P7MT<NG%JZD96OK1JWBT,KZN'+7"4C9[;K$:;;R[[M9O:Y;_  4<
MCH;798N96O5CF1\SFM5.972/Y-%U:U$5='=R>(S;:\4K.'O1E9<:NM/*NEQP
MW!]U-N+_ )1C6)285E>,L=424;5>L%1!&Q953PFQM=S-:_148UR.1-=4,(S+
MY5XK-M:)932+UQB,)<T'4:+/<9N-1G==:<1SO+I;9B%NC>ZGGJUZZ.F;%%RL
MCB:Y4TU1$8U-=$3^X:]XU(FU:XRNK.MR6GD;:[33[C38OAEEM%)U^WU!!"RV
MY V:.H;5RMIFLC35GK=(T54<OK]55/6FGP>$VM,_%H7\1S1AS.:#J-(
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MQ6XR8J2Z?Q?4?B&5>=5F_#*38_XMC^^[V2B_.QR/@A<3%>
M                       ,WVNSBVX)D;KC>K+!?[-50.I:V@J&1R>"YS7)
M)'UK7-YVJWNIQ153AKJ49V7-ZX1.$K<N^K/*VW;]S^SGC60R9QCN+7;Z1HLD
MU'2/2*&DAGF:J.5K$J'LC3PE1-&N1NO@MX)IISDY]JZLS&#8C,RXG&(Y6B<Q
MRBNS3)[GE-Q:UE7<YEF=$Q55L;41&L8BKQ5&M:UJ?>-_+I%*Q6.AJWMK3BL9
M8P                    L=B_?5;]]/9.++\T-/(^*R^%;<
M    &7W_ '2W"RFW+:;_ )%65MM=ISTKGHR-_*J*G.C$;SZ*FOA:\2FN32LX
MQ"RV9:8PF6(%RL
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M_P!RT\M?XIZW8KS0^15+T._ >R>2HJ"%@   2T_?M/\ CL]D)YF']4,P-=U
M                  4ET_B^H_$,J\ZK-^&4FQ_Q;']]WLE%^=CD?!"XF*\
M
M"QV+]]5OWT]DXLOS0T\CXK+X5MP
M
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MK=BO-#Y%4O0[\![)Y*BH(6   !+3]^T_X[/9">9A_5#,#7=0
M      %)=/XOJ/Q#*O.JS?AE)L?\6Q_?=[)1?G8Y'P0N)BO
M                                                 L=B_?5;]]/9
M.++\T-/(^*R^%;<
M
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M\7U'XAE7G59OPRDV/^+8_ON]DHOSL<CX(7$Q7@
M                                       6.Q?OJM^^GLG%E^:&GD?%
M9?"MN
M
M                         /J#B_\ 1JS? :7_ '+3RU_BGK=BO-#Y%4O0
M[\![)Y*BH(6   !+3]^T_P".SV0GF8?U0S UW4                  !273
M^+ZC\0RKSJLWX92;'_%L?WW>R47YV.1\$+B8KP
M                                       +'8OWU6_?3V3BR_-#3R/B
MLOA6W
M
M                         'U!Q?\ HU9O@-+_ +EIY:_Q3UNQ7FA\BJ7H
M=^ ]D\E14$+    EI^_:?\=GLA/,P_JAF!KNH                  "DNG\
M7U'XAE7G59OPRDV/^+8_ON]DHOSL<CX(7$Q7@
M                                      6.Q?OJM^^GLG%E^:&GD?%9
M?"MN
M
M                        /J#B_P#1JS? :7_<M/+7^*>MV*\T/D52]#OP
M'LGDJ*@A8   $M/W[3_CL]D)YF']4,P-=U                   4ET_B^H
M_$,J\ZK-^&4FQ_Q;']]WLE%^=CD?!"XF*\
M                                   "QV+]]5OWT]DXLOS0T\CXK+X5
MMP
M
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MZF-=D;T&6/X17_&Y"WC_ !I[%7 ^#':WB:#?
M                                      X;[-OI#W'^$?\ 53G9^H>'
M1R/I_P =_;2Z<:<5V$Y@E"8G2@$Q 0F-"4U@$Q.D"8T(34)$U"$IK>A"4(T
MC3I($UO02AZA,(36=PD3F])A+)8ZG^DE/^*G^!Q,"_@
M !8\G_>D/_B?]E21>H_]6S[R?X"!$                  **[_Q;4_B?XP)
M=B_BJG_S_9N N(                   6'&_P#SGX[?\80OP2
M        #C;'O[<UU_A'\TM.W?Y2/;I<6GS<^W0[).([0
M                 -9]H7T*YI\W/]FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW
M(6\?XT]BK@?!CM?-U#T[SD/0D   ,EVZ](6)_/-N^-1E6=\%NJ6>7\=>N'UM
M/'/7                   UGVA?0KFGS<_V;3:X3Q:];5XKPK=3&NR-Z#+'
M\(K_ (W(6\?XT]BK@?!CM;Q-!O@
M                            <-]FWTA[C_"/^JG.S]0\.CD?3_CO[:73
MC3BNPG,$H3$Z4 F("$QH2FL F)T@3&A":A(FH0E-;T(2A&@$:=) FMZ"4/4)
MA":SN$B<WI,)9+?+/1-NT4+X%=5JG@3=Q$T7[I,"Y@
M!;KO/1P0,=60K-&K]&M33@NB\>*H!<&JBM:J<$T31 /0
M !3UKXHZ25\[.LA:W5[/50"&W202T44E-'U4"\W*Q>YHY47^^!5
M          !;;3/13]?XG"L/*Y$DUTXKQ^ZH%R                   #C;
M'O[<UU_A'\TM.W?Y2/;I<6GS<^W0[).([0
M      -9]H7T*YI\W/\ 9M-KA/%KUM7BO"MU,:[(WH,L?PBO^-R%O'^-/8JX
M'P8[7S=0].\Y#T)   #)=NO2%B?SS;OC495G?!;JEGE_'7KA];3QSUP
M             -9]H7T*YI\W/]FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?
MXT]BK@?!CM;Q-!O@$N*>&=JN@D;*UJJURL<CD1R=*+IW1@)@
M                                              !PWV;?2'N/\(_Z
MJ<[/U#PZ.1]/^._MI=.-.*["<P2A,3I0"8@(3&A*:P"8G2!,:$)J$B:A"4UO
M0A*$: 1ITD":WH)0]0F$)K.X2)S>DPEDLM2QZY%3O1J\J-35VG#H<3 OH
M                67)6/?2PHQJN5).A$U_8J2+Q'_JV_>3_  $"(
M           4=U176ZH:U%559P1.*@2[(US+7 UR*UR<^J+P7U[@+@
M             %CQUCV>-\[5;J]NFJ:>J$+X$@                  XVQ[
M^W-=?X1_-+3MW^4CVZ7%I\W/MT.R3B.T
M    #6?:%]"N:?-S_9M-KA/%KUM7BO"MU,:[(WH,L?PBO^-R%O'^-/8JX'P8
M[7S=0].\Y#T)   #)=NO2%B?SS;OC495G?!;JEGE_'7KA];3QSUP
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MOHY,.3FY_=@BN[UZ[J>7'EY^9V2<1V0
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M[E?HEOW9[O\ R>?9TN7GM/Y(_P#6QYRNS[=QZ);]V>[_ ,GGV=;EY[3^2/\
MULGSE=D]$M^[/=_Y'V=;GY[3^2/_ %L>;KLGHEOW9[O_ ">+V=[DG]=9_)'_
M *T3YN-E'HMOW9[O_) O9[N:?UTG\D?^M#S<;*/1K?NSW?\ DENV N3?ZYS^
M2O\ UHGS4;+&?H]H_P#EGN_\DI=A;DG]<9_)7_K1,<3798S](M^[/=^:!VQ-
MR;_7"=?X,_\ 62?,UV4>DW_<GN_\DMVQUS3^M\_D[_UDGS%=E$_2K_N3W?\
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M4LYV/:O%%[K7(O%'(O!44\MF9=J3,6?6.'XBF?2+TG&)7A.A"ML/0
M*>OG?34<T\>G.QNK=>*:@06RIDJZ&*HETZQ_-KR\$X.5/\0%6
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M=KYNH>G><AZ$@  !DNW7I"Q/YYMWQJ,JSO@MU2SR_CKUP^MIXYZX
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M       4UPADJ**:&)-9'MT:G1Q @M5/+2T$,$R:2,YN9$77I<J]S[X%8
M                %JLM#447C'C#4;UCD5FBHO!-?4^^!=0
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MYN?[-IM<)XM>MJ\5X5NIC79&]!EC^$5_QN0MX_QI[%7 ^#':WB:#?
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MDZ5 KP                   LN/SS3>-==(Z3E>B-YW*[3IZ-0+T
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M?!CM?-U#T[SD/0D   ,EVZ](6)_/-N^-1E6=\%NJ6>7\=>N'UM/'/7
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M7].B\=95_9.[G0G=5?,\;QDYGZ:\SZC]%^BQPM=YF<N9/_:WTG0ARGJGH
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MJ!<0                   XVQ[^W-=?X1_-+3MW^4CVZ7%I\W/MT.R3B.T
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MNEM25M%4ZN1T;:AO+(G!414<B=#M?5Z0*\
M+?;+':;,^MDM=(REDN-0^LK7,UUEJ).+I':JO%0+@   %37@O0!B*;6[=MK?
ME!,:H/&>?K=>I3DY]==>3UG3W.4#+D33@G0!(K:.GN%)/05;5?2U,;H9F(YS
M%<QZ:.3F8J*FJ+W% @MMMH+10T]LME.REH*5B1T]/$G*QC4[B)_A7N@50
M                   #AOLV^D/<?X1_U4YV?J'AT<CZ?\=_;2Z<:<5V$Y@E
M"8G2@$Q 0F-"4U@$Q.D"8T(34)$U"$IK>A"4(T C3I($UO02AZA,(36=PD3F
M])A+)8ZG^DE/^*G^!Q,"_@                  !8\G_>D/_B?]E21>H_\
M5L^\G^ @1                  "BN_\6U/XG^,"78OXJI_\_P!FX"X@
M              !8<;_\Y^.W_&$+\$@                  XVQ[^W-=?X1
M_-+3MW^4CVZ7%I\W/MT.R3B.T            !C&-8'9,5ON2Y#;'3K7Y54Q
M5ES29[7QI+"US6]6B-16IHY==54MOFS:(B?Z55,N*S,Q_4R<J6@
M       !K/M"^A7-/FY_LVFUPGBUZVKQ7A6ZF-=D;T&6/X17_&Y"WC_&GL5<
M#X,=KYNH>G><AZ$@  !DNW7I"Q/YYMWQJ,JSO@MU2SR_CKUP^MIXYZX
M             &L^T+Z%<T^;G^S:;7">+7K:O%>%;J8UV1O098_A%?\ &Y"W
MC_&GL5<#X,=K>)H-\
M                  #AOLV^D/<?X1_U4YV?J'AT<CZ?\=_;2Z<:<5V$Y@E"
M8G2@$Q 0F-"4U@$Q.D"8T(34)$U"$IK>A"4(T C3I($UO02AZA,(36=PD3F]
M)A+);Y;C+'=HJ!&-6*1$57+KS="KZOW"8%S                   "WW>X2
M6Z!DL36O5[^54=KIIHJ]P"O:O,UKO51% ]                  %/6SNI:2
M6H8B*Z-NJ(O0!#;JI]91Q5,B(U[^;5&]'!RIW?O 50
M 6VTW&6X=?UC&MZIR-3EUXZZ^K]X"Y                   !QMCW]N:Z_P
MC^:6G;O\I'MTN+3YN?;H=DG$=H                                &L
M^T+Z%<T^;G^S:;7">+7K:O%>%;J8UV1O098_A%?\;D+>/\:>Q5P/@QVOFZAZ
M=YR'H2   &2[=>D+$_GFW?&HRK.^"W5+/+^.O7#ZVGCGK@
M    :S[0OH5S3YN?[-IM<)XM>MJ\5X5NIC79&]!EC^$5_P ;D+>/\:>Q5P/@
MQVMXF@WP
M         .&^S;Z0]Q_A'_53G9^H>'1R/I_QW]M+IQIQ783F"4)B=* 3$!"8
MT)36 3$Z0)C0A-0D34(2FMZ$)0C0"-.D@36]!*'J$PA-9W"1.;TF$LEKGHJE
M][AK&LUIV-1'/U3@NB]S77NDP+N                   %JOM'4UE/''3,Y
MWM?S*FJ)PT5.ZJ 7-B*C&HO2B(B@1                  "EN,4D]#/#$G-
M(]NC6ZHFJ_A @M,$M-;X8)V\LK>;F;JB]+E5.*:IT*!6@
M   !:;)15-'XSXPSDZQR*SBBZHFOJ*H%V                   #C;'O[<U
MU_A'\TM.W?Y2/;I<6GS<^W0[).([0
M -9]H7T*YI\W/]FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT]BK@?!CM?-
MU#T[SD/0D   ,EVZ](6)_/-N^-1E6=\%NJ6>7\=>N'UM/'/7
M       UGVA?0KFGS<_V;3:X3Q:];5XKPK=3&NR-Z#+'\(K_ (W(6\?XT]BK
M@?!CM;Q-!O@
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M>H\:Z^1TG*Y$;S+KHG$"\@                  !QMCW]N:Z_PC^:6G;O\
M*1[=+BT^;GVZ'9)Q':                                !K/M"^A7-/
MFY_LVFUPGBUZVKQ7A6ZF-=D;T&6/X17_ !N0MX_QI[%7 ^#':^;J'IWG(>A(
M   9+MUZ0L3^>;=\:C*L[X+=4L\OXZ]</K:>.>N                  !K/
MM"^A7-/FY_LVFUPGBUZVKQ7A6ZF-=D;T&6/X17_&Y"WC_&GL5<#X,=K>)H-\
M
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MWW^GE<9P.I^JG-H>J^B_7=__ .K.G]?1.G\W0C'*Y.)R'L40
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M<G5M3GQZ\76IQW7
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M                   .-L>_MS77^$?S2T[=_E(]NEQ:?-S[=#LDXCM
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M1.75-8^N<_D71535FA;?B<R\83/(JIP^72<8CE9\:[8
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MC%$O==^W?W>A.'3Y;C.,G-G"/A?5OH_T>O"5UK<N9/V>Z&Z$1$Z.Z<YZ1Z
M          %+<HWS4$\<;5=(YNC6ITJH$NSPR06Z&*9JLD;S<S5Z4U>J@5P
M                  6>PTM13>-=?&L?.Y%;KW4X@7@
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MQ6]&O5_B<<G5+*KD3E1.?P4U75>.G0IGN[:NMT<S#7C6U>E>C!F
M     UGVA?0KFGS<_P!FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT]BK@?
M!CM?-U#T[SD/0D   ,EVZ](6)_/-N^-1E6=\%NJ6>7\=>N'UM/'/7
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M,5/R.9(^-$:C7*C]%\%.CCQU-;C,JN7?".3D;/"9DWIC.EMTTFX
M  #6?:%]"N:?-S_9M-KA/%KUM7BO"MU,:[(WH,L?PBO^-R%O'^-/8JX'P8[7
MS=0].\Y#T)   #)=NO2%B?SS;OC495G?!;JEGE_'7KA];3QSUP
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M@C>QO)S450WK*9SDZ.;1'(NGJ 9F
M     X;[-OI#W'^$?]5.=GZAX='(^G_'?VTNG&G%=A.8)0F)TH!,0$)C0E-8
M!,3I F-"$U"1-0A*:WH0E"- (TZ2!-;T$H>H3"$UG<)$YO282R6.I_I)3_BI
M_@<3 OX                   6/)_WI#_XG_94D7J/_ %;/O)_@($0
M             HKO_%M3^)_C EV+^*J?_/\ 9N N(
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MHL:_>T]0"LVU>VKW&W/N$"\](^MH*1LB="S4<4K)4_S570#:A
M                          <-]FWTA[C_  C_ *J<[/U#PZ.1]/\ CO[:
M73C3BNPG,$H3$Z4 F("$QH2FL F)T@3&A":A(FH0E-;T(2A&@$:=) FMZ"4/
M4)A":SN$B<WI,)9+?*RW+=HGR2.2O1$Y(TUY531?N:?WR8%S
M       "WW=E ^!B7"1T<7/X*MUUYM%]1% KVZ<K>7UNB:?> ]
M        %/6I ZDE2I<K8%;^Z.3I1/P(H$-N;3-HXFT;E?3)S<CG:ZKX2Z]*
M)W0*H                   +;:66]G7^(2.DU<G6\VO!>.G2B 7(
M            .-L>_MS77^$?S2T[=_E(]NEQ:?-S[=#LDXCM
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M<YU1<:UVO-45<NBR2+KJO'31/N(A R8
M       !PWV;?2'N/\(_ZJ<[/U#PZ.1]/^._MI=.-.*["<P2A,3I0"8@(3&A
M*:P"8G2!,:$)J$B:A"4UO0A*$: 1ITD":WH)0]0F$)K.X2)S>DPEDL=3_22G
M_%3_  .)@7\                   +'D_[TA_\ $_[*DB]1_P"K9]Y/\! B
M                  %%=_XMJ?Q/\8$NQ?Q53_Y_LW 7$
M    +#C?_G/QV_XPA?@D                  '&V/?VYKK_  C^:6G;O\I'
MMTN+3YN?;H=DG$=H                                &L^T+Z%<T^;G
M^S:;7">+7K:O%>%;J8UV1O098_A%?\;D+>/\:>Q5P/@QVOFZAZ=YR'H2   &
M2[=>D+$_GFW?&HRK.^"W5+/+^.O7#ZVGCGK@                  :S[0OH
M5S3YN?[-IM<)XM>MJ\5X5NIC79&]!EC^$5_QN0MX_P :>Q5P/@QVMXF@WP
M                                                           .
M&^S;Z0]Q_A'_ %4YV?J'AT<CZ?\ '?VTNG&G%=A.8)0F)TH!,0$)C0E-8!,3
MI F-"$U"1-0A*:WH0E"- (TZ2!-;T$H>H3"$UG<)$YO282R6^6MB9=HJ1:=K
MI7HBI.JIS)P7[GW/5)@7,                   +?=ZR.B@9)+ VH1S^5&N
M5$1%T5=>**!7M75K5TTU1%T ]                  %/6S-@I)9GL25K&ZK
M&O0OW.A0(;=.RIHXIXXDA8[FTC;T)HY4[B)Z@%4                   %M
MM-;%6=?U=.V#JW(B\JHO-KKQX(@%R                   #C;'O[<UU_A'
M\TM.W?Y2/;I<6GS<^W0[).([0                                -9]
MH7T*YI\W/]FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT]BK@?!CM?-U#T[
MSD/0D   ,EVZ](6)_/-N^-1E6=\%NJ6>7\=>N'UM/'/7
M   UGVA?0KFGS<_V;3:X3Q:];5XKPK=3&NR-Z#+'\(K_ (W(6\?XT]BK@?!C
MM;Q-!O@
M        <-]FWTA[C_"/^JG.S]0\.CD?3_CO[:73C3BNPG,$H3$Z4 F("$QH
M2FL F)T@3&A":A(FH0E-;T(2A&@$:=) FMZ"4/4)A":SN$B<WI,)9+/403NR
M""9L3UA1J:R(U>5.#N[T$P+V                   %GR*&:>EB;#&Z1R2:
MJC&JY=-%]0D7:--&-1>G1/\  0(@                 !271CY+?4,C:KGN
M;HC6IJJ_@0"798Y(K;!'*Q6/3GU:Y%14U>Y>A0*\                   +
M+C\$T/C771NCYGHK>=JMUZ>C4"]                   !QMCW]N:Z_PC^:
M6G;O\I'MTN+3YN?;H=DG$=H                                &L^T+
MZ%<T^;G^S:;7">+7K:O%>%;J8UV1O098_A%?\;D+>/\ &GL5<#X,=KYNH>G>
M<AZ$@  !DNW7I"Q/YYMWQJ,JSO@MU2SR_CKUP^MIXYZX
M  &L^T+Z%<T^;G^S:;7">+7K:O%>%;J8UV1O098_A%?\;D+>/\:>Q5P/@QVM
MXF@WP
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MV/;N1Z1F_OV^W_)Y]G*Y^>T_DC_UL>:C8]NY'I.;^_;[?\GGV<[EY[3^2/\
MUHGS,;'MW(])S?W[?;_D\7LZ7)/Z[3^1O_6R?,QL>W<CTK-_>M]O^26[L]7)
MO1FLZ_P1_P"M#S,;'MW(]*S?WK?;_DE.V!N3?ZYSK_!7_K1/F(V/;N1Z7F_O
M6^W_ "27[#W-O]<9U_@S_P!9,HSXV5=OIF;,83FV^W_))=L=<V_UOG7^#/\
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M$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT]BK@?!CM;Q-!O@
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M&VLLR[VM\5=5EY2N
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MHY>E[4<W17>$OA<5;RD<12LTKF5C#6Z$Y%[1>U+3CATMUFBW0
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MZ+PXHH%P:B(UJ)Q31-% ]                  %/6LBDI)63OZN%S='O]1
M(;='!%111TTG6P)S<KU[NKE5?[X%4                   %MM,%%!U_B<R
MS<SD6373@O'[B 7(                   .-L>_MS77^$?S2T[=_E(]NEQ:
M?-S[=#LDXCM                                 UGVA?0KFGS<_V;3:
MX3Q:];5XKPK=3&NR-Z#+'\(K_C<A;Q_C3V*N!\&.U\W4/3O.0]"0   R7;KT
MA8G\\V[XU&59WP6ZI9Y?QUZX?6T\<]<   &F.U3:[G>-EKS06BBGKZZ2HH59
M2TL3YY7(VJC551D:*JZ(FJ\#>X&T1FQ,^]I<;$SE3$+90=I6V4M#34TFW>=+
M)#%'&Y6V5FBJQJ(NFM2GJ&4\',S\5>]C'%Q$?#;N0[C[E7_-=O:&Q8%BUVAR
M#.Y)K0D-ZH'1);Z)7+!45%6B=;&QKFJO5\SN+=7?L=%G)R:TO,VF,*\O)//U
M&;G3>F%8G&W)RQS+'MMA=TVKO5ZV(OE/5W3;[+Z.6HM634=,^-8ZBII_%ZJ"
MHEB:J1N<C?W-SG>#HW]MX.>=F1FQ&;'):O0KRLN<N9RYY:VZ6RL'V&P7;Z_,
MR.P/N+KBR*2!J5=;)41<DJ:.\!W#7U#6S>*OF5PG!LY?#4I.,8M*W';3*I=V
MF[1-MTR[0U>0)G4M6D;O%4B6%7242N1O*C%G:K$CYM=%1VG=-Z,ZNZWF/Z\-
M7\VE.3;>:F'Z,=;\FT:RUW-W:HM]X;13K:&X4ZF=7I$_Q9)_E&5W5K+IR\_*
MNO+KKH:D6CRTQTZW^C:F)\Q$]&K_ *M793MME<VZ\^TU';YEVFRJ^TV:U]8R
M-WBT3(XY%K*1ST:K&];+&WE9JBM\#AHIMTSJ[O>8_KK&K^$M6^5;>:F'Z9G6
M_%G.=ONVV&]U-NJZR5MYPN[V+Y NDMK@6JJ*":*=LS)%C;Q2-R,8G!43I_9(
MU%U\K#-R=3'"T3CR]*_,QR\W7PQB8PZD.,55UW8WNM>X]OLM=:,'Q2UU-#35
MUV@=235]96\S7)%$_CU;&N]=ZK>/3H+Q&5DS29B;6GHZ"DSFYL7B,(K'2Z!.
M<Z   UGVA?0KFGS<_P!FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT]BK@?
M!CM;Q-!OM<;C[1TN<7*W919[S58MG5H8Z&@R&@:DC_%WZJL,T3E:V6/5RN1J
MJG=[BJ;63GZD368UJST-;-R->8M$X6CI8_0;%WJ[9):\CW7SFJSE;%*E39[7
MXC3VF@CJ6^MEEA@<]LCFKQ3H^[JG LGB8BLQEUU<??BKCAIFT3>VMAV,^W(P
MN+<3";OADU8Z@BNT;(G5C(TE='U<K)=48KFZZ\FG2:^3F;N\6T-C-R]Y2:Z5
M]M- EJM5#:VO65M%3Q4R2*G*KDA8C.;3CIKH5VG&9E96,(P4V38Y:LNQ^Y8S
M>XEFM5T@?2U3$71W)(FG,U>.CFKX35[BIJ32\TM%HYX8WI%HF)YI:DH]@K_5
M.L%IS3<"KR3!\:GBJ;;CSZ"&E=(ZEX4[:JI9(YT[8TX:.:FIN3Q58QFM<+3T
MXM2.&F<(M;&(Z%]RK:.[5F:3[@8!EDN'Y+<:>.DO;O$HKG2UL<#4;$Y\,SXT
M1[&HC4=KT(G#IUKIGQ%-2]=:(YNA9?(F;:U9U9Z>E:F]GYK,(RC'4RJL?E6:
M31S9-ETL+%JJAD;D7J61->U(XE;S,Y$<NC7.3HT1,_-?KB<.2O-##ROZ)C'E
MMSRHK)L;N/C=JI;'8MW*V@M-$Q(J6D@LU UC&)ZG'BJ]*JO%5XJ96XG+M.,T
MY>N6->&O6,(OR=4+_DNS]VJLO7/\&RZ;%,MJZ2*@O51XE#<:6NC@:C6/DIY7
ML1)$1J(CD=T(G#IUKIQ$174M76CHZ,%E\B9MK5MJSWKWMOMG3X"EVN5;=)L@
MR_(9F5-_R"J8R&2H?$U6QL9%'JV.-B*O*Q%7IZ=-$2O.SMYA$1A$<T+,K)U,
M9QQF>>6=FNO                                              !BN
MYOHVS'YCN?Q24OX?Q:]<?>Y_U'Y7-_V6_P",M!=GG+<5LF R4=YOEOMU8MPG
MD2GK*N"GDY',B1'<LCVKHNB\3L<;EWM?&(F7DOHG%9.7PT1:]:SC//,0VRNX
MFW_G79_Y0I?TAI;G,V9[G9\]P_[E/[H_%"NX> </_P"*[/\ RA2_I"=SF;,]
MR//</^Y7^Z/Q0.W#P#3^E5G_ )0I?TA.YS-F>Y'GN'_<K_='XH/K"P'SJL_\
MH4OZ0;G,V9[D>>X?]RO]T?B\7<+ ?.JS_P H4OZ0G<WV9[D>=X?]RO\ ='XH
M5W!P+SIM'\H4OZ0;F^S/<Q\[P_[E?[H_%XNX.!>=-H_E"F_2$[F^S/<>=X?]
MRO\ ='XI:[@8'YTVCR^F_2#<WV9[CSO#_N5_NC\4*Y_@?G1:/+Z;](3&3?9G
MN8SQO#_N5_NA#]/\$\Z+1Y?3?I"=U?9GN8QQN1^Y7^Z$*9]@GG1:?+Z;](-U
M?9GN1/&9&W7^Z!<^P73^D]I\OIOTA.ZOHGN1YS(VZ_W0@=GN"Z)__$]I\OIO
MTAENKZ)[D><R-NO]T//I[@WG/:?+Z;](-U?1/<CSF1MU_NA [/,&\YK3Y?3?
MI"=U?1/<><R-NO\ ="1)G6$+T9+:O+J;\LRW5]$L9XS(VZ_W0II<XPI>C)+6
MO\.I_P L;N^B6$\7D;=?[H4K\UPU>C(K9Y;3_EF>[MHE7/%9.W7OA2R9GAZK
MPR"VK_#(/RR=W;1+">*R=NO?"E?F&)+T7^W>60?EF<4MHE7/$Y6W7OA3OR[%
M%7A?;=Y7!^63%+:)5SQ.5M5[X4LF5XLJKI?+?Y7#^69Q2VA5/$96U'?"G?E.
M,+T7J@\JA_*,HK.A7O\ +VH[X4[\GQI?_6:'\%3#^43%9T*YS\O:COA3/R7'
M..EWHE_A,7Y1G%94SG4VH[U,_(L?772[4?E$7Y1E$2KG-IICO4TF06%4X72C
M7^$1?E&<1+7MF5TPHY;[8UUTN=+^?C_*,XAKVO72QW(LLI:2#J+5*RJK9N#7
MQ.21C$Z-55-45?40R:]YT-V[![&24#H,^S6%S[Q+^[6RWS)QAYO^^E1?^\7]
MBB^M^_T<#CN-QQI3M>_^A?1M2(S\V/U=$:'2S>"(AQ7MGH    L>3_O2'_Q/
M^RI(O4?^K9]Y/\! B                  %%=_XMJ?Q/\8$NQ?Q53_Y_LW
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MO%>%;J8UV1O098_A%?\ &Y"WC_&GL5<#X,=K>)H-\
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M]Z%Z     %NN]12TT#'54"3L5^C6KIP71>/$"X-5%:U431%1-$ ]
M          %/6R1Q4DLDS.LB:W5S/53\($-NEAGHHI:>/JH7<W+&FG#1RHO1
M]T"J                   "VVFII:CK_%H$@Y'(C]-/"7CZ@%R
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MR-8B-37GT\'AP$B?N]DM?BN"5]PM$JPWJ:2"DMSVHCG==/*U%T1R*FO)S*G
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M9E.!VNYW)ZR76-)*2O>NG,Z:FD=&KG:<-7(B.7[X&:@
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M+X$@                  XVQ[^W-=?X1_-+3MW^4CVZ7%I\W/MT.R3B.T
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MB?MN9=.(%"E.ZW6[=B^8U&Z.FLU/38Q:EB7PFTT#VPU3D5$3CRMZUSDZ555
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MP"Z                   !QMCW]N:Z_PC^:6G;O\I'MTN+3YN?;H=DG$=H
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M]!*'J$PA-9W"1.;TF$LELFH*A]YAK6HG4,:B.77CT+W/PDP+L
M        %LO=#/74\<=.B*YK^9=5TX:*@%Q8BM8U%Z41$4"(
M      4UPA?44<T$>G6/;HW7@FH$%KIY:2ABIYM$D9S<VBZIQ<J_XP*P
M               +79J"HHO&.O1$ZQR*W1=>":]\"Z
M !QMCW]N:Z_PC^:6G;O\I'MTN+3YN?;H=DG$=H
M          &L^T+Z%<T^;G^S:;7">+7K:O%>%;J8UV1O098_A%?\;D+>/\:>
MQ5P/@QVOFZAZ=YR'H2   &2[=>D+$_GFW?&HRK.^"W5+/+^.O7#ZVGCGK@
M                :S[0OH5S3YN?[-IM<)XM>MJ\5X5NIC79&]!EC^$5_P ;
MD+>/\:>Q5P/@QVMXF@WP
M                     .&^S;Z0]Q_A'_53G9^H>'1R/I_QW]M+IQIQ783F
M"4)B=* 3$!"8T)36 3$Z0)C0A-0D34(2FMZ$)0C0"-.D@36]!*'J$PA-9W"1
M.;TF$LEFJ)94R&GC1[DC5J:LU73H=W"8%\                   "S9'++%
M2Q+$]S%6315:JHNG*OJ$B[Q\6-5?43_ 0(@                 !1W1SF6^
MH<Q5:Y&<%1=%0"79'ODMD#Y'*YZ\^KG+JOKW=U0+@
M%DQZ667QOK'N?RO33F55TZ?5"%["0                  <;8]_;FNO\(_F
MEIV[_*1[=+BT^;GVZ'9)Q':                                !K/M"
M^A7-/FY_LVFUPGBUZVKQ7A6ZF-=D;T&6/X17_&Y"WC_&GL5<#X,=KYNH>G><
MAZ$@  !DNW7I"Q/YYMWQJ,JSO@MU2SR_CKUP^MIXYZX
M &L^T+Z%<T^;G^S:;7">+7K:O%>%;J8UV1O098_A%?\ &Y"WC_&GL5<#X,=K
M>)H-\
M      #AOLV^D/<?X1_U4YV?J'AT<CZ?\=_;2Z<:<5V$Y@E"8G2@$Q 0F-"4
MU@$Q.D"8T(34)$U"$IK>A"4(T C3I($UO02AZA,(36=PD3F])A+)02TE*ZZQ
M53JA&U#4T;!JFJ\%[FNO=)@7(                   +?=J6FJH6,JITIV-
M=JCE5$U71>'$"O:B(U$1=41$T4#T                  2*V*.:EEBF>D<;
MFZ.>NB(B?A @M\,-/1QPP2)-$WFY9$5%1=7*J]'#I J@
M   MUKI:6EZ_Q:H2?G<BOT5J\JIKPX 7$                   .-L>_MS7
M7^$?S2T[=_E(]NEQ:?-S[=#LDXCM
M UGVA?0KFGS<_P!FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT]BK@?!CM?
M-U#T[SD/0D   ,EVZ](6)_/-N^-1E6=\%NJ6>7\=>N'UM/'/7
M        UGVA?0KFGS<_V;3:X3Q:];5XKPK=3&NR-Z#+'\(K_C<A;Q_C3V*N
M!\&.UO$T&^
M           !PWV;?2'N/\(_ZJ<[/U#PZ.1]/^._MI=.-.*["<P2A,3I0"8@
M(3&A*:P"8G2!,:$)J$B:A"4UO0A*$: 1ITD":WH)0]0F$)K.X2)S>DPEDL=3
M_22G_%3_  .)@7\                   +'D_[TA_\ $_[*DB]1_P"K9]Y/
M\! B                  %%=_XMJ?Q/\8$NQ?Q53_Y_LW 7$
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MWP
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MW/\ 9M-KA/%KUM7BO"MU,:[(WH,L?PBO^-R%O'^-/8JX'P8[7S=0].\Y#T)
M  #)=NO2%B?SS;OC495G?!;JEGE_'7KA];3QSUP                  -9]
MH7T*YI\W/]FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT]BK@?!CM;Q-!O@
M
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M                  .-L>_MS77^$?S2T[=_E(]NEQ:?-S[=#LDXCM
M                           UGVA?0KFGS<_V;3:X3Q:];5XKPK=3&NR-
MZ#+'\(K_ (W(6\?XT]BK@?!CM?-U#T[SD/0D   ,EVZ](6)_/-N^-1E6=\%N
MJ6>7\=>N'UM/'/7                   UGVA?0KFGS<_V;3:X3Q:];5XKP
MK=3&NR-Z#+'\(K_C<A;Q_C3V*N!\&.UO$T&^
M                                    #%=S?1MF/S'<_BDI?P_BUZX^
M]S_J/RN;_LM_QEISLR^C>7YRJ/\ =Q'4X[Q'G/H'RD=<MR*:#N);N@R8H"4(
M'!B@4EC*6[H)8H'=!,$I;NE"4(5Z"6"!280@7I7[QDB4A_2AE#"5#/W3)3*@
MG]:9PIE;Y^DSJJE0R=!FIE12F2JRBE[I95KRH9?6EE6O91R]"ED->RUU,<<T
M+XI6H^-Z*U[')JBHJ:*BH6-2[!J>IO\ M?D,&4XM,YD#7:/C75S%8Y>,4J=U
MB]Q?\?$QS<JN97"RKA>*S.%S(O2>QVAM?N=8]R[(VXV]R0W*%$9<;<YVLD,B
M_P!S5J_L7?XSRO$</;)MA/,^L_3OJ.7QF7K5Y^F&>&JZ@            %NO
M%PFM\$<L+6N<Y_*J/153315[BH!<&+S-:Y>E410/0                 !3
MUT[Z:DFJ(T17QMU1'='][0""VU4E9115,J(CW\VJ-U1.#E3NJOJ 58
M             6RT7&:OZ_KFM;U3D1O(BITZ].JKZ@%S
M   #C;'O[<UU_A'\TM.W?Y2/;I<6GS<^W0[).([0
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MZ5&]S,N8WF&$Z.AO4Y[?
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M_P!FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT]BK@?!CM?-U#T[SD/0D
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M^*@GDC<K7M;JUR<%10(+-+)-;89)7*^1W-JYRZJNCU0"N
M    "S6"HGJ/&NOD=)RN1&\RZZ)Q O(                   <;8]_;FNO\
M(_FEIV[_ "D>W2XM/FY]NAV2<1V@
M:S[0OH5S3YN?[-IM<)XM>MJ\5X5NIC79&]!EC^$5_P ;D+>/\:>Q5P/@QVOF
MZAZ=YR'H2   &2[=>D+$_GFW?&HRK.^"W5+/+^.O7#ZVGCGK@
M       :S[0OH5S3YN?[-IM<)XM>MJ\5X5NIC79&]!EC^$5_QN0MX_QI[%7
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M+;_S[.^3N;Z)8^=X?]RO?"!=S=OO.2@_/L[Y.YOHE'G<C]RO?"%=S-O]5_\
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MQN0MX_QI[%7 ^#':WB:#?
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M0:CK/0              +'D_[TA_\3_LJ2+U'_JV?>3_  $"(
M       45W_BVI_$_P 8$NQ?Q53_ .?[-P%Q                   "PXW_
M .<_';_C"%^"0                  <;8]_;FNO\(_FEIV[_*1[=+BT^;GV
MZ'9)Q':        -=;P;M6K:>Q4U7/#X]?[M*M'8;7SMB2>IT3PI)'JB,B8K
MF\[UZ-4]4V>'R)S9]T<[6S\^,J/?/,P;:BRV-V4NW"W$S2SY%NI=/^'MM%1W
M"":EM=/,BHE)11I(JJY>96N<U./%$UU<Y^QGVG5U*5F*Q[N?WRHR:QK:U[1-
MI]_-U)?9ZOMFQ6GW"PS(*^"W7BP9+<JRICJY&P<U!4<CHZE.=4\!W*O%%71-
M%7UR$\76;:MHC&)K!PMHKK5GGB967:G/[+@FW&X6\-^;+'8LCRRZ7*RT[6Z3
M54=0]K86QH[3B]Z/;JO!$:JKT&>?E3?,KEQSQ6,6&3FQ2ELR>:;3@BPUMGSW
M)*#=7>7+K*RJI%;4XGA45RIEI+4B^$V2HU>G65/!KM5]:O3T-:QF8Y=9IEUG
MWSAS_D9>%[:^9:/=&/,RR!NRE\WHRRWY!C\3,_IZ6DZ^HR%(IJ:LINJ1$DH8
MYI)8T1K$8CU:QCON>O*9WM<JLQ/Z?=_JMC=3FS$Q^KW_ .C%MEXL>M6[>Z];
MACH:?:&E@IO&)(G)\EMN,<2/GZA?6=6Q.NY^7@B::>#REO$:TY5(M\?VX*N'
MU8S+ZOP?8Z&L5TLMZM--<\=J8*RRU#5=25-(K70/:CE:JL5O#UR*G YMJS$X
M3SNC68F,8YFGMW/3IL;\)R#XI3F[D>#F?_Y:>?XN7VK;C=BM>3[\[YX]>Z=M
M5:;E06"FJX'?LHY+<Q%T7N*G2U4XHO%#.]IKDY<QSQ,_>QI6+9V9$\V$?<T[
M=I<GP;-MO-C<GZVLH[!FMGN>)7IZ)_Q%FEJ5C;&Y=?71N=RHG<\)OK6MUW:Z
MMZ6S:]-9QCWM*VM2]<N>BT8=3<EDO]BL':<W$FOMSI+9%-9[2R*2MGCIFO<D
M4:JC5D<U%73U#2M6;</7",>66[6T5S[8SAR0M>_>9V3<R3&=H]OJ^GO]_NEX
MIJJXR6^1E3!1T5$JODDEEC56HJ*J.TUUT:[7CIKEPN7.7CF7C"(AAQ.9&9A2
MO+,RZ6.6Z8       !K/M"^A7-/FY_LVFUPGBUZVKQ7A6ZF-=D;T&6/X17_&
MY"WC_&GL5<#X,=KYNH>G><AZ$@  !DNW7I"Q/YYMWQJ,JSO@MU2SR_CKUP^M
MIXYZX                  &L^T+Z%<T^;G^S:;7">+7K:O%>%;J8UV1O098
M_A%?\;D+>/\ &GL5<#X,=K>)H-]@.X^37"EFM.$XY)U>3Y/*Z".I1.9:.B8F
ML]3HG[)K=>3[NJ_L21K+?'QO'J#%\*Q">:F;;*:KND[VRO23J:1G,CY')ZY7
M*DJKKTN$#<&19S08_@[LSE3K(Y*6*>BI_P!E--4M188T[OA*Y-=.A-5[A U-
MLSDDMDLV9YWGMRE:SQYM+(L[WOTJ(D=))'%'JOA*Z5J<K?4]1"9&?T>[$2UE
MMCON.72Q6R]2LI[5<ZYD:0OEE]8V5&O58E=^Q1W^#B!77_<9EMR"3%K'9*W(
M;W2PMJ:^&BZMC*>)Z:MYWRN:G,Y%14:A EP;MXD[%:O*ZM\]#!05+K?66^HB
MY:UE<W_R_5HJZO7N:+ITZJFBZ3@*:AW7C^4[9;\BQRYX[#>I$@M597LCZN29
MRZ-CD1CE=&]W<1R?WN(%ABS?(+OO1\AP4%Q98;+ M/54D?5MC\8J)%:RKG3G
M15A6)R.8BZJG!>74"QX=N-507S.[O1VBZY%)/='-CAHF*^GIZ&B1S8W*]ZHU
MKGHJJC&(JKI]X#8[]UL5CPRWYL]TZT-T7JK?0MCYZV:I1[HUA9&BZ*]'-<GK
MN7[O00(++N4RLOE'CN06*OQRYW-CY+7X\D;HJA(V\SFH^-RHDB)TL7_"J$C$
M),C9#G.Y.3UU14_(6-VVGM;(Z=^B]9,U'R+&UW@)(CV\J*H%SMV?8W@-AP^R
M)!=JY+Y1RUM"R1&UEPY9$Z]C)4CT5SY'2<C$:FB=W1$U R#$]QH<DOU9C%;9
MJZQ7REITKFTM>UJ=92J]K.=JL<O%%<B*G]]=%T@7S+LDI<1QJY9)6-62&WPK
M(D2+HKY'*C(V:]SF>YK=?N@:VQS;:ISNUP97N3<JVKN-U8E536JFJ)*6CHH)
M4YHV,8Q47FY5375?N+JNJK(RC L:RG$[I>;16U\MSP_6*6P5%9-UU9$JM_=8
MG*J:\J*O@_>^Z!JW=:^WW,I\AJ\9K9:7'<#C9SU$#W,;57-\T;9&ZM]<V*/G
M_"GJ. VQF^4,HMKKIE%._J_&+6DE)(BZ*V2M8UD2I]U'2-(& 8UM]@DF,6NO
MR+)ZEETEI(9[@[Y96)C)9&(]R:*_1.55T)%[V1N%56+E5+3W.KN^+4-Q2"Q5
M]=(L[WL1KNL1LBHBN;ZU4[G'[HD9=N7>EQ[ <ANK']7-%1R1P2(NBMFJ$ZF-
M4^ZCWM(&']GVLNBXM<K+>Y9);I:K@]CUE>LCDBGACE8G,Y57I5Q,C"ZC*KEN
M%OC8*:V54L>*VZIE;2=5(YD=0EO3KIIE1JZ.:^1J,:O0J(GW0-BX#524>X.X
M>+(YSJ*FJZ2YTS575&/N-.DDS4UZ$YN71$X=(&RB
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M*V"@LSIT1)WT--% ^1$75$>YC45R)W$53&^;>_Q3,LJ9=:?#$0OY6L
M  -9]H7T*YI\W/\ 9M-KA/%KUM7BO"MU,:[(WH,L?PBO^-R%O'^-/8JX'P8[
M7S=0].\Y#T)   #)=NO2%B?SS;OC495G?!;JEGE_'7KA];3QSUP
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MKNNYE[JZ@7C:^2/(,RS[-Z7PK;<*RFMM!*GK)66V'JG2-]5'>"J*!M0@
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M]_;FNO\ "/YI:=N_RD>W2XM/FY]NAV2<1V@
M       :S[0OH5S3YN?[-IM<)XM>MJ\5X5NIC79&]!EC^$5_QN0MX_QI[%7
M^#':^;J'IWG(>A(   9+MUZ0L3^>;=\:C*L[X+=4L\OXZ]</K:>.>N
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MCE3_ ! 50                   6VTW!U=U^L;8^J<B>#W==>G^X!<@
M               XVQ[^W-=?X1_-+3MW^4CVZ7%I\W/MT.R3B.T
M                       #6?:%]"N:?-S_ &;3:X3Q:];5XKPK=3&NR-Z#
M+'\(K_C<A;Q_C3V*N!\&.U\W4/3O.0]"0   R7;KTA8G\\V[XU&59WP6ZI9Y
M?QUZX?6T\<]<                  #6?:%]"N:?-S_9M-KA/%KUM7BO"MU,
M:[(WH,L?PBO^-R%O'^-/8JX'P8[6\30;X
M                                  '#?9M](>X_PC_JISL_4/#HY'T_
MX[^VETXTXKL)S!*$Q.E )B A,:$IK )B=($QH0FH2)J$)36]"$H1H!&G20)K
M>@E#U"80FL[A(G-Z3"62U3TE2^^P538U6G:U$<_AHG!Q,"\
M      !:;]2U%731,IV+(YK]51-$X:+ZI(NC$5&-1>E$1%($0
M       I;E%)-0SQ1-YI'-T:WU5 @M$,M/;X89F\DC>;F:O<U>J]P"M
M              "T6.DJ*7QGQB-6<[D5FJHNJ)KZ@%W
M  #C;'O[<UU_A'\TM.W?Y2/;I<6GS<^W0[).([0
M           -9]H7T*YI\W/]FTVN$\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT
M]BK@?!CM?-U#T[SD/0D   ,EVZ](6)_/-N^-1E6=\%NJ6>7\=>N'UM/'/7
M                 UGVA?0KFGS<_P!FTVN$\6O6U>*\*W4QKLC>@RQ_"*_X
MW(6\?XT]BK@?!CM;Q-!O@
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MPF)B54G28I36]!*'J$PA-9W"1.;TF$LEJGJZEE]@I6R*E.YJ*YG#1>#B8%X
M                  "TWZJJ*2FB?3O6-SGZ*J:+PT7U21=&*JL:J]*HBJ0(
M@                 !2W*62&AGEB=RR-;JUWJ*!!:)I:BWPS3.YY'<W,Y>[
MH]4[@%:                   %HL=7457C/C$BOY'(C-41-$77U +N
M              '&V/?VYKK_  C^:6G;O\I'MTN+3YN?;H=DG$=H
M                        &L^T+Z%<T^;G^S:;7">+7K:O%>%;J8UV1O09
M8_A%?\;D+>/\:>Q5P/@QVOFZAZ=YR'H2   &2[=>D+$_GFW?&HRK.^"W5+/+
M^.O7#ZVGCGK@                  :S[0OH5S3YN?[-IM<)XM>MJ\5X5NIC
M79&]!EC^$5_QN0MX_P :>Q5P/@QVMXF@WP
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M\6O6U>*\*W4QKLC>@RQ_"*_XW(6\?XT]BK@?!CM;Q-!O@
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M)_@($0                  HKO_ !;4_B?XP)=B_BJG_P _V;@+B
M            %AQO_P Y^.W_ !A"_!(                  .-L>_MS77^$
M?S2T[=_E(]NEQ:?-S[=#LDXCM                                 UG
MVA?0KFGS<_V;3:X3Q:];5XKPK=3&NR-Z#+'\(K_C<A;Q_C3V*N!\&.U\W4/3
MO.0]"0   R7;KTA8G\\V[XU&59WP6ZI9Y?QUZX?6T\<]<
M   #6?:%]"N:?-S_ &;3:X3Q:];5XKPK=3&NR-Z#+'\(K_C<A;Q_C3V*N!\&
M.UO$T&^
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M>;7EUXZ'CN3'D?:(QPC'G5C.X$IS>DPEDM\J6_Y6B617>/Z> B:\NFBDP+F
M                  %NNZ4"P,^4%<D?/X/+KKS:+Z@%P;IRMY?6Z)I]X#T
M                 4];U"TDOC*JD'+^Z*G3I^ "&W)3)11)1JJTWA<BNUU]
M<NO3]T"J                   "VVE+>G7^(*Y?"3K>;7IXZ::@7(
M             .-L>_MS77^$?S2T[=_E(]NEQ:?-S[=#LDXCM
M                      UGVA?0KFGS<_V;3:X3Q:];5XKPK=3&NR-Z#+'\
M(K_C<A;Q_C3V*N!\&.U\W4/3O.0]"0   R7;KTA8G\\V[XU&59WP6ZI9Y?QU
MZX?6T\<]<                  #6?:%]"N:?-S_ &;3:X3Q:];5XKPK=3&N
MR-Z#+'\(K_C<A;Q_C3V*N!\&.UO$T&^
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MXJ?X'$P+^                   %CR?]Z0_^)_V5)%ZC_U;/O)_@($0
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ME2II'Q-1S.3D<O5.<Y%_OI52*9^-8KJS$8QA_JMO-\G"9MK1CA+H@YKH@
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MLSV)*UC=5C7H7[G0H$-NG94T<4\<20L=S:1MZ$T<J=Q$]0"J
M       "VVFMBK.OZNG;!U;D1>547FUUX\$0"Y                   !QM
MCW]N:Z_PC^:6G;O\I'MTN+3YN?;H=DG$=H
M      &L^T+Z%<T^;G^S:;7">+7K:O%>%;J8UV1O098_A%?\;D+>/\:>Q5P/
M@QVOFZAZ=YR'H2   &2[=>D+$_GFW?&HRK.^"W5+/+^.O7#ZVGCGK@
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M*LRHUK426637E5ZIKX1M9&9$:UHIJ1$<O7H:N?ES.K6;ZTX\GXNSSANT
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M7D                   .-L>_MS77^$?S2T[=_E(]NEQ:?-S[=#LDXCM
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M(U53BU%T,KYU[QA:9E%,FE.6L8,K*5H
M                  '#?9M](>X_PC_JISL_4/#HY'T_X[^VETXTXKL)S!*$
MQ.E )B A,:$IK )B=($QH0FH2)J$)36]"$H1H!&G20)K>@E#U"80FL[A(G-Z
M3"62USUM2R]PT;7Z4[VHKF:)Q71>[IKW"8%W                   "U7VL
MJ:.GCDIG\CW/Y571%X:*O=10+FQ55C57I5$50(@                 !2W&
M62"AGFB7ED8W5KM$71?P@06F>6IM\,\[N:5W-S.T1.ARHG!-$Z$ K0
M             M-DK:FL\9\8?S]6Y$9P1-$77U$0"[
M !QMCW]N:Z_PC^:6G;O\I'MTN+3YN?;H=DG$=H
M          &L^T+Z%<T^;G^S:;7">+7K:O%>%;J8UV1O098_A%?\;D+>/\:>
MQ5P/@QVOFZAZ=YR'H2   &2[=>D+$_GFW?&HRK.^"W5+/+^.O7#ZVGCGK@
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M.GR*PUDM%#27.FJ'W)DDMOZF9DB5#(%TD=$K55'(W]ER] %S
M                          .&^S;Z0]Q_A'_53G9^H>'1R/I_QW]M+IQI
MQ783F"4)B=* 3$!"8T)36 3$Z0)C0A-0D34(2FMZ$)0C0"-.D@36]!*'J$PA
M-9W"1.;TF$LEOFMT\EWBKVN9U,:(BM55YNA4]33N^J3 N8
M     6Z\6^:X01Q0N:US7\RJ]51--%3N(H%P8G*UK5Z41$ ]
M      %/70/J:2:GC5$?(W1%=T?WM0(+;2R4=%%32JBO9S:JW54XN5>ZB>J!
M5@                  !;+1;IJ#K^N<UW6N16\BJO1KTZHGJ@7,
M           .-L>_MS77^$?S2T[=_E(]NEQ:?-S[=#LDXCM
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M.OW7/<V16].B(O<40+ID%L7%+?L[%$G)7T-SH;=([HX5T21U*='[)=0-W$
M                                    X;[-OI#W'^$?]5.=GZAX='(^
MG_'?VTNG&G%=A.8)0F)TH!,0$)C0E-8!,3I F-"$U"1-0A*:WH0E"- (TZ2!
M-;T$H>H3"$UG<)$YO282R62I<OTCITU73E3A^!Q,"_
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M0"Y                   !QMCW]N:Z_PC^:6G;O\I'MTN+3YN?;H=DG$=H
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M2A&@$:=) FMZ"4/4)A":SN$B<WI,)9+'4_TDI_Q4_P #B8%_
M       "QY/^](?_ !/^RI(O4?\ JV?>3_ 0(@                 !17?^
M+:G\3_&!+L7\54_^?[-P%Q                   "PXW_YS\=O^,(7X)
M               !QMCW]N:Z_P (_FEIV[_*1[=+BT^;GVZ'9)Q':
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HASMV=DF.2+8VQ)(QS%=/7/:CD5-6NJI%14U[BFCQWC3V-[@?!A__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm2227887d1-pht_key4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-pht_key4c.jpg
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M\5)RDB-B4X*BLM(U0W,D5!;_V@ , P$  A$#$0 _ /OY $ 0! $ 0! $ 0!
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M^W<=(R4GX-,T[EBY;591<5XIHVEG, 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MB]'Z^M?&DNG>;5Z-S)LW%8OQO)K6,EJO5TIX5CU[CWI?4#Y@$ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MSN*'TQE*J1-WG[KA*,(0MN?U2C&C9.5Z4\T$ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MANP)WQ=E.28$]?\ ZG9:_P#3L6A>?R2]3^!FDM#ZT'BO*(U&55B @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M*3_E=-H-?8K>9X_:_ Q>3*J>Q]GY5WLU!A+_ +ED3A)J-%GN/Y?#\.UTI/\
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M:/;T6C)FU%'T_P"DE/[!XRG2L]!_T\B\SF_SF8)]3BX$_2^H]Y *@227+/\
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M^2N!Q/)RS)7%**CL=/C^!W^5XR.'&VXR<MZK\/Q%IS&YN?4"_P"'.MHVVUG
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MH173;31;/(X$+%K'NVVXW)TK*KKJEZ:&MQV=._=R+5Q*5N%:1HJ:-^FIVKS
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M*[?WQJM-J7:8.&S,.YE1C:L;)4>NYOL-;G3)).+>G4<+^U,Z"!L<E*[7&&W
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MTV 4!W/_ '?\*LD8YRVG,DF?.=SS7R'@%D2-9R;+:(R"M% %$!4 50DNH$)
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M7IU.CD<_.]*$W;AO@T]W:Z=GJUZ$IX_A8./8>UPUK(^6"T:YK))*;R'.+M:
M#Q7;P\6.-9C:BVU'O.+F94LF]*[)).7<<_E'#['E4N.EO)Y83C93/$(=M'.)
M::.W Z?#X+5Y#C(9C@Y-K8ZJGL_ VN/Y.>&IJ*3WJCK[?Q-KD_'K;E.'FPUY
M+)#!,YCG214W@QN#A3<"/!9\_"CEV7:DVDZ=/ P8&;+$O*[%)M5Z^)QL[Z=8
MS/8G#8F>[N(8L+$V&WEB+ ]P:QC 75:16C =%SLOA+61:MVW*25I45*5Z)?<
M='$YN[CW;EQ1BW==76O>W]YR?_"&T_\ V'+?_&;_ ,U:/_\ -0_[USWF]_\
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ML[H&HF@CD_QF@E5H34^;/5_^[SEKK+77)^"1MN&7CWS7N*<YL;VS/)<YT)-
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M 7H @" ( @" (!T0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 8I7T%!U5DBDF8.JN8PH!1U
M TN=H!JI!QYI3-)N/R_L#V+(D:DI598A0N 0DN0DJ A)=1"2H0'"Y/R>UXY:
M":2CI9*MC;[1YK-:M.;-/)RU9CXL\EO^99/*W1,D@9$[01DG:NK"W&!Y/(RY
MW3G93)6]G:S2S-?W]ORM/7P\UED:"CWD=@N(9298V&.*5E8RX@N-14T Z44&
M5HY60NS;W6(I)V6.G,$@J=1(T@5I_"ADBC/;'&RG\GN&R3RQGX9IAT-? FE?
M8A2C2J;-K@KCZB2Y?=Q6XAJV*W8P2,#.E:'3>>O1 Y]YI27#K&66U[;S ?B$
MLKB-Q'0AC-!5"U-VIDV7.4M(^Q2&;:>W(QY.V1I-0=>A3IJ/IZFC:XVP_,(,
M1R*W^MO99&M+V["YK7F@.\.J0LT97H6WLI0[/'QO2FG#Z2MQB,=8S22XNQ,_
M:^:-CG,(H30$N%2?T))W)13GU\.AAS5?WM7.G8:TEY;W5LU\ NAD&';LE![3
M2? N J5A.<HTZFI$W+PR"WR-L6&1XV2S=QK6$^(<!0C7Q0O\I+[T9.VLK2SF
M9#]9<N+93;-#8P&C0_<AK]IS+G&7O=+XI6/CI21K''N>W4T'V(9=R*?2S01
MR2M$;M6LEU=0^=*T*J14M9930W!O;61KH2VLMN7&F[P+?8K(G<NAN8_)R2L,
M%.W(3\8&FJ&)QH23'MFBI)4BFH/12BF^A[#PSDHO(6V-T[\9NC7>:Y=^S35'
MJ^.S?,6U]29D:+2.Y0MHI(+$(*$(06T0%IZJ4BK.E:3F5A#OG;H0L;1LPE4V
M%4R ]$!=%(0=>A52R9M*IE" ( @(%ZC^JN ].[>..\#KS,7+7.M,?#3<0/VG
MDZ-;7Q^X+=Q<*>0]-$NTG3M/(8?4S)\],]Y?6L%JVR@D,$4.]Q%=?B<3KT\
M%MY&#"U*/5MN@:J2GC?KL6RMM^3V3([-I#/KK,./;'3=)&XDT\RTFGDIN\;I
M\CU\3(X'MEM<0W<$=S;R-E@E ?'(PAS7-(J"".H*XE&M'U1C9F5B @" ( @"
M ( @" 5'F@-+)7_Y?:/NA"^X[8JZ.&A=0=2*D*8QW.ACN7-D:]2/8?G^(R]Z
M,?M?:SO![??V@.(_9JUQU6S/'E%5ZFC9Y"W<EM>C\26-+::%:M3I4+D!&>0\
M_P"+\8G%ID[S^F$ NMH6F61H.H+@W1OVFJXV;S&+B2VW)?-W+5^WN.QA</E9
M<=UN/R][T7L[S:X[R[ <JBDDPUT)GPT[T#FF.5E>A+7 :>T:+/A<ECYB;M2K
M3JNC1AS>-OX;2NQI7H^J9PW^KG!HWNC??2!S"6N'T\O4:?NKF/\ <F"G1R?^
MU_@=)?MO.:KM7^Y?B27"<APW([4WF%NV74#3M?MJU['>3F. </M"[.)FV<J.
MZU+<O3JNIQ\O"O8LMMV.U^G1]#A77JAPBTOW8Z;)CO,?VY'LCD?$UX-"-[6D
M:>8T7,N<_A0N;'/5.G1T]]#IV^ S9V]ZAIUZJON)='(R6-LL3@^-X#F/::@M
M(J"#[5WDTU5=#@M-.CZG)=R?#MY SC!F=^</C[K8=CMNS:75WTV]!YK1>?96
M1^GK\]*TI]YO+ O/'_44^2M*U^X9GD^'P%SC[/)S.BGR<ABLVM8YX<]I8T@E
MH--7MZIE9]G&E"-QT=QTCIZOQ0Q<"]D1G*VJJVJRU]?X,NCY)B9<_+QEDKCE
MX8A/)#L=M$9#37=2G[0\5*SK3ONPG\Z5:4[/7[2'@W585]KY&Z5KV^KV'66\
M:(0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MAV/[IYW)QNX\7-;:-='36M*]W4CG,[CE=UPVP&;R./FQ\<L++*.R=W)[H['
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MQT8>&M\Z?<N9-F] ^D?2H4X5CQX!]S3_ %B1>=S/YK]AK7.I-5JF(( @" (
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M"CF=Z1T@:?: X+Q&;-2O-KH3(FBU2@0! $ 0! $ 0! $!3<.GB@%4 !J@*H
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M&B@OO31BN'%V+?/&-D_=,0J*$/;J:CR0QI:FD^Q>,C%D3;;?JXOA>PTW.;X
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MT?X'I9<I#*4)PR/)HOGBTJ^RJ_$]9X7B9L/Q^WM;FR@Q]T\F:>TM7/=$Q[_
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M:AC" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M(N\-$9)RLMF\1CXGVU_<LC<]CAL<:$@A9(6V]4:]_)MPBXR9X5<?3LN7.B<
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MLS0&'\0M!V.-14THN\E*,M$<^[9N6Y?(JQ9Q?SWC&";8W+IHLC<VN/;:26L
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MT+[C_3R+S.9_-?L->YU)LM4Q! $ 0! $ 0! $ 0% ZJ/0"JA,!IJ%(*H @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M?;VQCDRD8WR'^89([X:G05\@%CDCMV770B<EG<8^_=<1O> Q[HX)7]7%IKN
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M[2*OL/K'T-Y+D^1XBX=EG1SS0FC+@1M;*YNGS%H%5R<N*3/1\=<E..O8>M@
M:!:21UBQZDAEB@J6E2B&6..A*L5-FS!$(>?VB3^E49E@J(SJ"Y52#8B%&!8V
M98]"XJC+'Q!_>!_]6<T:4JVT/_9HQ_ O<<7_ $T?;\3#<^H@5M-MI0T_P+?D
MBR)%890,V@FE*=3Y+5G V8R/K[T<<7^G^*D_>,[OOF>O(9W\]E9$]6F4" (
M@" ( @*$@("A>WS0BJ&\>?Z4%31R?USK23\NECCO *QN>-S:CP(KXJT:5U,=
MQRV_*U4\]LO4++8W+&QY+$UL(.QY8S8YCB:!W75OM6_+&3C6)PX<C.W<VW#T
MVVGCN86S1/:^)XW,>TU!!\BN>TT=^,E)51E4%BU[V1L=)(X,8T5<YQH !XDE
M0VDJLE)MT1K6F4QE^YS+&]@NGM%7-@E9(0/:&DK#;R+5S2$E+U-,S7,>[;UG
M%Q]::+I\A86S^W<W4,,E*[))&L=0^-"0IG>MP=)22?BRL+-R:K&+:\$7V]U:
MW0+K6>.=K31QB>UX!]NTE6A<C/Z6GZB)VY0^I->LK/<V]JSN7,S(8ZTWR.#&
MU]Y(4SN1@JR:2\2(0E-TBFWX%S98G1B9KVNB(W"0$%NWSKTHI4DU6NA#BTZ4
MU-89;%.(:V^MRXF@ E822?M6%9-I_FC[T9GC75^67N9N+8-<Q,NK:2>6UCFC
M?<PAIFA:X%[ \5;N:#45'2JHKD7)Q355U7:B[MR45)IT?1]C,JN4" ( @" (
M @" (!T0! $ ) %3H!U* QP7%O<L[EM*R:.M-\;@]M1X5%52$XS58M->!><)
M0=))I^)D5R@0! $ 0! $ 0! 8G7-NV=MLZ9@N7C<R$N >X:ZAM:GH51W(J6V
MJKW=I=0DX[J.G?V&57*! $ ) %3H!U* QP7%O<L[EM*R:.M-\;@]M1X5%52$
MXS58M->!><)0=))I^)D5R@0! $!BGN;>U8)+F9D,9.T.D<& GK2I(\E2=R,%
M632]9>$)3=(IOU 75L;@V8FC-VUO<= '#N!A--Q;6M*^*>9'=MJMW6G:/+EM
MW4>WI7L,JN4--9# $!S;MNV=SO!P!'V:+(C7FM2P=5)5&4>"@L7%024>P/C<
MT]' C[TZ:AJJ/'^4\&O+6:6]AJ^-Y+ALU*[%K(3C0\AF<?.#<D>>WD!;(&7+
M2:'YAH=%MG&IK0ULOF(,?CVF?<==C :$]%4O&!Q6Y"XOH3#+*'PB,26KF_#\
M+J @^XH7<4CL29"2TQ<C9(A)/"R,;I-=2*5/N0JE5F''WC;J65L#J,D@WB^:
MX. >'?+IX>T(2T:V;%L; R9B#ZL1?S=U%_.?R@X U"$P;KH<UN%,^$9+@[HS
M2VQ)@,?PR;7:EI 0R[DI49'[IV3R>(N[+)PF#,0M=$UTK#&YY/RN:XTK6BE=
M3+!)23(O96%R_$Q!LGX\/PSQD[G5KJ?<$E1G3MSU,6>L9<S"R2WB[+[8,WOK
M\+GEIJ:>'1:KT.I#YHFC]+#88QEQM:^X<*2-(^+4556ZEDFB&7KF,<^XH.XZ
MH$:I0L0[(XZ>X[EU(0"==IT.GDJM$IT.!)$-FYGMW:U(HJ-&1,QACB* $J"2
MK8I-U-IUZ5"A@V&V4M-U0*J"K9MVEH^;X& EK3\3Q_ L\(F-LEF+X_-<O9%;
ML)D-#2FOO*V(P;,,Y)(]GX5;W]C:EMS*XQQ?!LK1NNE05LJ%$<+(2;-Z1MW;
M7T]Q%,77$,FYDCOF#7#IKUT4&!TH=@BWS%K+]2T4<S9=VU:@!VFX54+J43<=
M2-Y>QQ^'^CLX"W;'015(U+S\('MHIZLS0EN,#&MMYH9W:ASG,IX CV*!K0Z-
MG ^:-]Q;EO?=41OIK6AI5253HU4AT$<L8A%PW9>,<67!K_E&ZN/VE6JC;HCO
M6AGE,;&ZESJ$'H50P:'VQZ/\>M<-Q"SFA;2:[8)'GWKBY,JRH>HPH4MH]""U
MS?+'H0RTH5+"B(9CD-&./W>]6*LWXF;86M'@%1FQ%:%R@"HZ)4DVF"C0%1F5
M="I!K4*C6I8\(]<O1.]YG<MY3QAS!GV1B*[M)"&MN(XQ\):[P>!IKH0N[QO(
MJRMESH4G'<?,.2XMS#!7'TN5P=];3:[0ZWD(<&FA+2&D$>Y>IC?M355)>\Q4
MDB<\(]&.>\MNXA=6$V%Q1(,UY>L,;MAUK'&ZCG&G3P6AD9]FTM'N?<C-%/M/
MLGCN"L^-86RP>/!%G8QB*,N-7.IJ7.]I)J5XR[.5R;E+M+MU.HJE0@" ( @"
M (#7FAD>=*4]ZM4QN+9S;G%WLM=CVBO3XC_@612B8)6I/H<>YXSF9:=N=@I_
M[QP_]DK,KL#5EC77T9Q+KA7(W N;=1M;KJ9G@?\ )657[?:C3E@WZ:3//<K:
M3QWSK(2MO+D.$>Z%QD#G=* D5-"NA"2VU.!?MRW[:[GX'L? \)E,+B6Q9*<O
M=)\3+<FK80?V05Q\B:E+0]A@V9V[:4B6+6.@>5<Y,_*>>8C@KIY(<-VOJK]L
M1VE[@U[Z'S^%@#?(NJO$<MNS,^WB5:A3=*G;U?W:>L]OQ.W$P+F71.==L:]G
M1??KZC?O_27&07=AD.(W#L'?VDH>^6LERUS:']E[ZU\*;@"*K:O?MRU&<)XS
M\J47UUE\7]]*&K9_<=V4)PR5YL9+II'X+[JU.%RW#V.>]7\5B<FPRV5Q9?BL
M:XL)[<=P\:M((U:%S.2QK>1R]NW<58N&OL4F=/CLF>/Q%RY;=)*>GM<48.9\
M?L_3*]Q')^+OEMV&?L7=HZ0O9(RF\CXM:. <""?(BA6+E,.'%3MY&.W'6C5:
MU[3+Q>9/E87,?(2EI5.E*=A+><<7P5S=NY7RV[EFP..MQ'^5M#VM#WO#0X.C
M>TU)=2GCIK0+N\M@6)3_ %&3)NW"--FO?UT?IH<'B<^_&'Z?&BE<G+Z].[IJ
MO34Y7I,(V\<S<UQ,!QE\\IM8990Y\-N&N[F_:265;3]?C4Z/[<HL:ZY/_BJZ
M)OI'MKW:?B;W[BJ\FTHK_EHJM+K+LIWZ_@<[AG!>/\DR;N408\V''+>79BK/
MN2O?<.A=_/2ND>X@5&C6TZ:]/BU>+XC'RKOZA0V6HOY(U?S4_,ZM^Y?X[?*<
MMD8MK].Y[[K7SRHOEK^542][_P /6LA>QXZPNLA,*PVD,EQ(.GPQ-+S^@+W5
MZZK5N4WTBF_=J>%LVG=N1@NLFE[]"!^G$TMOQ*_Y?=Q2WF1RUQ/>S,MV&6:0
M1.,;8V-;4FA:[:/"ODO,<')QQ)Y,DY2N.4G15;IHDE[Z'I^;BI9<,:+48VU&
M*JZ)5U;?V5-6Y]3.38J&VR^=XNZRX_=RMBCF,X,[=U3\49&ZM&DT<UJPSY[)
MLQC<O6-MN3I7=K[NOO2,T."QKSE;LW]UR*K3;I[^GN;/3U[,\8>:V_J1R#*7
M>4QN!XX;Z]QL\D<CA.UD0BC<6ASB\-^)Q::,'M7CX<YD7ISMV;.^4&U]6E%]
M[[CV$^#Q[,(7+U[9&:3^G6K^Y=YUL+ZD8K)<:ON0WT3[%V+/;O[0_&]LAH&A
MIHVN\G:*@:_>M[%YRU=QI7IIP\OZEX]E/7\30RN#NVLF-F#4_,^E^';7U? X
MO_B?R"WLXN09'B\D/%9W-#+QDS72M8\T#RP@:&HI4-!\USO[_D1@KT[#5E_F
MKK3OI_AZSI?V''E-V87T[R_+32O=7_'U',]1N1YB3/<5_*8'38F6>&\Q^R;;
M'?R[X7L8YOAM): 7?O+3YO.O._8\M5@VI1UTN.L6E[/'O-SA,&RK%_S'2:3C
M+36"I)-^WP[B49CG>3L[K&X'%X8WO*[VV9=7-B9FLCMMS-SFND.A((/B/?JN
MUD\O=A*%FW;W7I14G&ND=.__  .+C<1:G&=ZY<VV8RVJ5-9:]W^)FPO.WY&T
MS<=_CSC\_@HGRW>/?('M<&,+@6O U!IY>(ZU63%Y=W875.&RY:3;C7P[&8\K
MB%:G:<)[[=UI*5/'M1P(_5+D%W@1R''\9,N.MMWYC.ZX:UC"UY%(Q3>X;2TN
M=MH-?*JY:_<&1.QYT+%8Q^I[O'L[7I2KH=1_M_'A?\F=ZDI?2MOAV]BUKI4Y
MGJ?RS(93AV)O,7#+;X?*EKKBY$FUP?MD!MG-;\P-"ZO3X5I<_P C<O8=N5M.
M,+G5U]?R/T[#<X#CK=G,N1N-2G;Z*GJ^9>G:>JX.[R5]BX+K+V7Y=D)-_>L]
MXDV;7N:WXAH:M =]J]OB7+ERTI7([)/K&M::_AJ>(R[=NW=<;<M\5TE2E=/1
M$2R_J#D;'EESQ3'85V1O&PL?:=N41[Y'M:\[RX48T NJZOA[5PLGF;EO+ECP
MM;Y4TUIKH]>Y>)W<;AK=S$CD3N;(UUTKIJM.]^!EX]SB?.7&5X]FL><5R"PA
M>^6WW]QCV4%2T_\ ":?&H-05?"Y:61*Y8NP\N[!=.OIU*9O$QQXV[UJ?F6YO
MKT].A _3[D^?PO#KDX7!.R5M9W$UQ?W;YF11L9L8XM:T_$]P:*F@TTZKS'#9
M^18PY>5:WJ,FY.J26BZ=K=#T_,X&/?S(^;=V.22BJ-MZOKV)5/0CSTW'$;7D
MV*Q%S?W%XXQ,Q\#7/+)&N<UW<>UIHP%OS4UT^SU?]XW8D;]NW*;EIM6M'XNG
M3Q/*?V?;ERL7+D8*.NYZ57@J]? U,3SK.MY):<:Y3@QC+K(,=):2Q3MF;1H<
M:.#=PUVD?-]BP8_+W_U,;&1:\MSZ4E7TZ=_L,^1Q%C]-*_CW?,4.M8T].O=[
M2VY]0,O=Y^^P_%,"<O%BG;,A.9V0?$"06LWZ:$$#K6AT47.9O3ORM8]KS%;^
MI[DO=7T?<6APUF%B-W(N^6[GTK:W[Z>B[S/QKU&M\W9Y[)7]J<=885WQ%[BZ
M1T9W_,V@H[X:;03KHLN!S<<B%V<X[(VO?37L[].ABSN$E8G:A"6^5WW5T[>[
M7J<@>I_(39?VB_LM)_9+=M^K[[>]LW;=^RG3[-OAN6A_?\C9Y_D/R>_=KZZ>
MB\3?_L&/O\CSUYW=33U5]'X'?S_J#C\5B<7D,="[)W6;+6XJT8=CI"Z@.XT-
M*%P:12M=%U,SF;=FU"<%O=WZ%W^G3UG+P^&N7KLX3>Q6OK?=Z=?4:5AS;DQO
MY\-F>-OL\L;:2YL>W)WH)'-:YS6/?&'!F[:16IUTHM>SRN3YCM7;+C/:Y1HZ
MI^#:K2M#8O<5C>6KMJ\I0W)2JJ->*3I6E3-BO42VO^$7O+I;<0RV/=CFM ^H
M[S2!&S<0/GW,UIXJ^/S<;F%+):HX5JJ]O8J^-48\CA96\V.,G53I1T[.UT\*
M,@7(>8<LRF6XI=G%.MXIGLN[&P9<5CO'%S"S=4-I32A</%>7S>3R[UW'EY=$
MWNC'=I/I3T\3U&%QF)9M7X^95I;92VZPZU]/ E]W?6C_ %.XW%?8K9FY\:9?
MJN^[\"L=R71=L#:ZA#AN]OL7?N7H/D[*G;_Y';K7=].DZJG1]NIP;=F:XR\X
M7/\ C4Z4V_5K"CKU79H9+SU!S5[E<ACN'X$Y>+$NV7UT^9L32X$@MC!ZZM-*
M$D^2O=YF]<NSAC6O,5OZG6GN]/84M\-9MVH3R;OENY]*I7W^GM)1Q;D#>38>
M+*BUELGO)9);3 @M<WR)#=S371P"[7'YOZNRKFUQ\'Z:KQ.+R&'^DO.WN4O%
M>FC\#B\LYO<X3,67',38LO<S?1&=GU$S;:%K*N ^)W4G8[2H7.Y'E96+T;%N
M*E.:KJ]JIK^#.CQW%1OV97[DG&$'31;G73\4;6!Y!F,I'D;3/X.;%W5HQU7U
M+[:<4U[<H 'W$^_JLV'FWKRG&]:=MQ_VOU,PYF%9LN$K-U7%+_<O6B+<.Y9@
M\!Z>W6>@QYLK2&Z?''8MF=,Z2=S6 4>\5%?'R JN+QG(V,;CY7E#;%2?RUK5
MZ=K.UR?'7\CD(V7/=)Q7S4I1:]B%_P"I_)<-B8\KF.+FVM[PM-A*+AKF.#QN
MVO !<P[=14:^27N?R;%I7+MC:I?3\WQ[5H+/ 8U^Z[=J_N<?J^7X=CU.WR'G
M\^#SN+PT6+=?/R=OWHQ%)MD[K]P8P BE"X %Q.@U\%T<WF)8]^W:4-_F1KH]
M:ZT7O[>PYV%P\<BQ.ZY[-DJ:K2FE7[NSM+>/<[R=[R9_%>18?\JR9C,\&R9L
M[7- W4);ITKJT^'@HPN7NSR7CW[?ESI5:U)S>(M0QED6+GF0K1Z4-;*<ZY9%
M-D9\5Q663#8O<;FZO'_2R/9&"YSV1O =MH*B@=I]RPY'+Y:<W;L-PM]7)[6Z
M=J3_ (F;'XC$:@KE]*=SHHK<E7L;7\"/>IV=AY-Z;8?.6\3H8[N_8>TXU+71
MQW,;A72M'-.JY//9<<KC;=U*BE/IZE-'5X'$EB\E<M-U<8=?6X,[WJ',[C_(
M.-<N@JTMN#C;XCH^WF^+:?< \CV^Y=3FI?ILBSDK_-LEXQ?HSE\+']3CWL9]
MV^/A)>B/15ZT\F::R& (#2OV_(_P&A^U73,-PUP>E%8Q&0$*"Y?K]B N'0)V
M%D'!CA1[:M\CT52VCT9XYZ@V6.&8<VW@[=6[IG#Y2X^("[&*W34\7RT8QN_*
M>89J"P;%1[.]M<'!KQH".A6W0Y<&8\;9LN8A=W0#8'-+8XF"@+01J3]B$R9D
MO/RR<.MY YX<';]KCT<**"L:U*63[!I;:VPVL=\L= *;M#7WG5!*IKLL[VPO
M9(XF]VQFJ7V[M6:Z5'DA*FFJ&Y;8\8QQFL6%MM,:R,&I8?L4ARJ8LJ67D'8O
M&!^OP/'S-(U!!4"#9 \G8Y..X@^@CA, <\R'=L?MD]AZT)0W\>6NK.9!/:5E
ML9]T;'DB0TVT>W0#W%8YH[MF:CZB*Y5HC$\;9*QN=6KC4D]!KXA8#=;3([+A
MNY1Y?N=U Z456QM=#A9"RGDD,08XM'B$(-&3C+)6BL>QP\@J2+Q19_9J"UB<
M][23337R]RA4+,U1AXVP/=)7<:[3XBO@%>ACK08KCDV1NH[7>3O.@&E /-%
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M #0 NUIIUZ>"X6%PZL7W?N3=V=*5?8=[-YAW["L6X*U"M:+M)DO0'GP@" (
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M-J*/ISTD_P!@\6/ &XI_K$B\SF_SG[#7F3A:AC" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" PRBCJ^:LC'(PJQ0(#4OHJM$H_9T/N4HQ37::S>@5D8R]O
M56),@ZJK)1<JEBVXC,EO(P?,6D#[E:(DJJA\^<ELI+')7#)H7.N'O+NGP!I.
MG7Q7;L--'@<RW*,VGWD<D9"QPDF_"!-"UH#@5F-6C[#0O!;PQ2&%U>Z-7GJ
M/ >2%HZLPV$EO)8M!T$1<'@&M"22A$M&1V>ZGLKMMJ 9[25Y[;Z[BW?T'L0V
M%%-&R[+V>Y]NZ:.*XE8T;7@#=X:^!Z>*$*#8QEFUMVR,Q"%LATV#2IZ_84(G
M(D;L<6S/<\@,'RNI^@H8-Q!LQE<IC[R\%Y <A@I'%FR*G=@-/F'FT^(0W(04
MHJFAQ;0X*,.OHK%T\<XVMFMR&.IY/;YBB&62FGU+,??XR^9);V\>]SG$,,Q
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MB'7 /^L2+S6;_.?L-6?4FZU3&$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M?0BA%0?'3R45+09L&W9=6\;-Q8YHVN<XU.GCYJ2>C.;WYK2YDM!)5DS>VZM
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MJ35:IB" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M>C[NYP+&O'1SIW#[9Y"O)YR_YG["LR=K3,80! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M1^I<PU;W9'%[@#Y FB\)DW5=NN:Z&1DG6 J$ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M;7#[B/8LABZ%X5627 J"2YJDDN!0DJ2@#>H522]"2[<@ -4)+E("$A $ 0!
M$!0FB@@U[J!MU$8BYS":$.::$$(07Q,+&-8YQ<0*%Q\4!<@*.T4H@MJI(+2=
M"4(,3G@#XNGBA%1;VU=9!MCZAB.0C&O4W0 -!T53*$!52"YC-Y]@5662J;
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MPA8("H4@N8PO/N5662J; %!0*AE*H @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M*DI5,[(PWKJ52ID2+U!8( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @+'1@FO0JU2KB87L+3[%9,H
MT6'1"H!J@" ("M3YH!IY("TL:?! 6F&(]6 _8IJ5HBPVMN?\F/N2K&U%/I(/
MW!^E*C:BOTEN-=@2HVHN%O".C&_<E6-J+@Q@Z !":%WV*NI8I\7FA!52 @"D
M%:("H:7&@ZJ"4C*(?,_8JU+[3(  *!5+E4 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 8W
MQAVHT*FI5HQNB<.FH4IE7$QG3JIJ4H*JP"BH"D!0 @" ( @" ( @%5(" K10
M"YK''H$J2D9&Q?O*K9=1,@ '0*I<J@" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M*%H.A"$4+'0M(TT*FI&U&/Z<^=5-2NTH6/'4%6J11EATZI4J*A $ 0! *H!4
M)4%P8X] 5%2:,O$3O*B5)VEPATU*BI;:7AC1X**EJ%R@D( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ("TT\A]R#0MHWR'W*:D40VM\DJ*(IL9Y)44
M0V,\DJ*(KM;Y#[DJ*(J WR'W*"="] $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&/\ $4D#\1 /
MQ$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$
M0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1
M/Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _
M$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$ _$0#\1 /Q$!D'102$ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
%0! ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm2227887d1-org_clinic4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-org_clinic4c.jpg
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MP"0I4F'3L2JMR;F4J+;O+A]P_8;)E76BMKYU2A/@01J.(/057'2A $ 0! $
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MY(O?:J%Y:8C;77]%[7TU+EX,YO%H)X0$0YDX5!G6+U-J(:VXQ??[;.=!LJ&
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MO;W -=P[16MLC'*J(J*J$F2UFC8CWL<UKLRJBHB[RYE,);",$ 0! $ 0! $
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M>E"/W<E=+BT;W9W.>J[ZM<I,\[YSYWCF;7>TV^J@-NH:DQPP2T\;O  !T+@
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MI4F6VK+[!4063+&U,;J4/-%'4/,L0C>0'&%VKFEI+1[TJ\MY(I$5T=,N?G.
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MBU:OJXT7A.KG#)^K6'8;R\C.V6FIA7W&/H^^N!:-1W7NF*]8<G6RR3;M$\N
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MJ*O%^[L^'HCG*US7.V6T5=I<],E/)27<V7-Q#"<4Y;0$-J61?25W#= 3,[<
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M%WY/FEC[JT_:/79.,_\ W:?+S#T?\[_V[B[\GS2?=6G[0[)QG_[M/EYAZ/\
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M=" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M"PCD7,;)(WQK1R*B[N0ZUDUA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MV>KWMC:]ZI[+E_#GKP[Z%IYC>;ED'J_6>\7>H=57&JN+W3S. !);4U30-
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M/F>Q[3VG-(/%1[:9LUZKVYE;ZD+3%;%]E@:0OI5K]&FKE5.(H)=*?* @" (
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M=*J7W>V98<49(F=C6.X%53>76#EWSLK8[C1W=^.YK-&R%]#6 .AF>P:-#3J
MX_:C:[73[11XUN+%**W;9K3R\M99W#,.Q]R/9(L,]*;+M/+_ +5KK0I[*,9N
MF(WJIL5W8UM93D'<P[F/8\:M>T\-00KV"=LS$>W,?/<1P^6QG6&3.G J:T,&
MV?\ B5'_ ,>+^N%[D]Q=XT6?]=GYF^DM?UCZNIDSBFHWS/=2PT$3XH23L:Z1
M\FX@=&IVC4]Q4^#-3J5734[?OQ*];QK*^RC$6FZJNY#-Y4/=4\J>8M%4G=1P
MTLL\+7'P1*:60ZCNZQL6J_2EU$J9ZIZ25W><KL(NVKF1KE3Y%Y$-CRXI+''R
M0R*>[5LMNHZRL,-QKJ=G73,CU@8U@8T$D'=H>XXE:[USUO&HU*JB9$X29@4<
M#<$E61RL:]R[3DRJB>RW-1?)54CE@I^3N/7NWWRERZXNGM]1'4M8:%[0_JW!
MQ82&:Z.'@GN%295NY&*U8TRIKYRJLV8+:S,F9</JQ47W5X/=TYC%NE^LN3<\
M;3>["7.M]5=;40][#'N>Q\+'.#3Q&I;V5LCB?%9N:_.C7>LB75Y!=8W'+#E:
MZ2++FJJ*U#HY]5]95<RKG25$SGTU#'314D1/@QLDIHY7 #NN>25ZPIB);HJ9
MUKZ33WOG>_$7L<N1B-1$U5:BKQJ;[D+--36S.ZBG>8YX;8V2*1IT<U[&3D$'
ML$$*-BR(KHT77R%QW,<K8[E4SHUO_,KO 9YOU_QJ;K'&:2[4>^0DESNLJ&!V
MI[.H)U5I=M3J'I\*^@X_!Y'=H0NKE61N7?<E>$EOK U53-S%JJ>65[X*:GIV
MT\;G$M8'QAS@T= U)U*A80U$@KK52_[Z2.6_V57(C4HFJIM,HD?/ZNV'R2G?
M(VZ/C#CTAC'5S6C[ : M4"(E_)3H_22L0>K^[UNJY^LIP=8B<2'''/\ RY9=
M^=HO[RWK,W]_'^7ZCS9?_KMQ_P!B>F(R?5^_[EFWYN9_5G6O%\\>_P A+[D^
M[<_E;_S*<MG_ (E1_P#'B_KA7DGN+O'SZS_KL_,WTEM>LK_KJW_FF'_,U*I\
M%_HK^;U(=MWY_OF?]:?Q/-WRXI+''R0R*>[5LMNHZRL,-QKJ=G73,CU@8U@8
MT$D'=H>XXE1KUSUO&HU*JB9$X2WP*.!N"2K(Y6->Y=IR951/9;FHODJJ1RP4
M_)W'KW;[Y2Y=<73V^HCJ6L-"]H?U;@XL)#-='#P3W"I,JW<C%:L:94U\Y56;
M,%M9F3,N'U8J+[J\'NZ<QN+!=<>S#UA*>]6AQ=;I0Z:/K&&/K9X*$MU#3H1H
MYN[H["TRQR0V*M=GYR;:7%M>X^DL2^S2N5*;3D93)7A\WG*WYGU=36<P<DEJ
M]>L97SPLW'7[U \QQZ=S:T*UL6HV!E-1Q_>&1\F(3*[.CE3S)D3BRD_O%74U
MGJZ6A]5,^9\=RZICI"7$1QOF:UNI[  T"K(VHV_=35ZD.MN97R=W6*Y:KM4X
M'*B<12BZ ^9A $ 0! $ 0! $ 0'MWF9BOZXX9<K1&T.K@SRF@[?E,'A, [6_
MBS7M.7 64_4RH[1IWC]&X[A_WMF^-/>I5OYDS<.;SE+^KGE_T==JS#*]Y9%7
MDU%"U_#;51-TD9H>R]@U_HJ]QBWVFI*FC(N\<!W)Q+8D=:O_ !>TW?3.G!E\
MRGI9<J?7 @*^YK\NW9U:89[;(*?)+6XS6V?79NUT)B+AQ;J0"UW8</=5E8W?
M4.RY6NSG,X_@W:$2*Q=F6-:L7U5]>A2'6'GK/80+%S,M570WFF 8ZKCB!$H&
M@W/C);H3\)FK3V-%-EPM)/:@<BM4HK7O6MO_ "K]CHY$TTR+N_Z50W_M!\N/
MPBK\V=_Z5'[)N-2<)9>,,-Z:_*[D*AQ+F;1\O,HJ*>RUE1=\$K9.LDAJ&%E1
M$7GBYH=P+V]G3@\=H]%U/8NN(T5R(V1.!?+B.&L,?CPVZ5L3UEMWK7+7::J[
M^?=U[Y;W.3.:JRX91.QV5S:W(G,AHZAFK'M@D9O<]FNA#B"UH[6JI,.MD?*N
MWF9G.[[R8F^WM&]2OMS*C6KOZ?+68V-\@,-I+5$,F@DNMZE;OJJ@SS1,;([B
M0P1/;J!VW:Z]/<7N;%IE=["[+=Y"/9]S[)D:=>BR/7.[:<F7S*A%V6^KY*<R
M;10VRJEFPW*)!"ZFF.XL>7MC/1H"8R]C@X#4M.AU4M7I>V[E<GMLTE.V%V!X
MC&R-RK!<+397+1:TXJMRYZ9%J>A%S9]/" ( @" ( @" \=<ZLP;EF:5#*5^Z
MUVD&AI".A[F.)ED'\Y_ =MH"[?#+?JH45<[LO(?!.]>)?=WBM;[D7LIO_B7A
MR>8KE6IR 0! $!;F"Y9B%PP&OY;YC5R6F&:?RFCN4;'2,!W-D <&AQ!#F]D:
M$'I!5'=6\K9TFC3:W#Z#@^)6<M@ZQNG+&BK5'>?:XEUY#>8'>N4G+6]M?%>Y
MKQ75,;XJF\^3314U-%MW[61-;(]SGN#0>D#MC0ZQ[J.ZN6>[LHFBN52QPFYP
MC"I<DJR/<E%?LKLHF>B(B+G6FO?*FL=_98<RI,C8TS04=<*HL;X+GQ"34@:Z
M<2T]E74L*R0JS2J4.&M;YMO?I<)E:CU7?2O(6+S)'*K)7W/,[9D<QO59$QT5
MH$$C=U0UK8_"+V>"-&ZNXZ=HJKLON8J1*SV4T[AUN.)A-WMW3)EZQR9&ZW(E
M$R*E4S92FU?'SDLNRY78*3DMD6)5%7LR"ON,=12T?5RG?$U]&2[>&E@_LG\"
M[7@JJ2!ZW;)$3V43/\W*=A:XA S!IK9SOYCWHJ)1<U8]-*?A72<N6N>6*U6>
MZX1FD4DN*7@[S+""Y\$VC07:#CIX#7#:"0YO0=5YO;1[WMEB]]O&;<!QF"&%
M]I=(JPR:=2Z=W0E*9E,IV'\EJ8^539U45%(#KY+!1O$[@>AN[8=#W2U:_N;Q
M<B1I7?)2X7@C/:6Y56ZD3+_#ZC58+F5@PCF)+>:&&=^+R&:E8)-'5+*64C:\
MC70N!:TD=I;[JVDGMT:M-O/N5*_"<4MK#$5D8B]2M6[J-6F7BX-TWMPM7):F
MNM1E$N2U%VHI9754>/0TSV3/D>2_JWS.#0&:G0ZAIT[.JC,DNU:D:,1JYMJI
M:SV^"MF=<NF61JKM=6B955:K1=S?INJ:_FSE^,YCF=DO-)*ZJM,=#2PW*.-L
MD;VN;42R2Q-,C8R2&OX.'!;K"WDAA<U<CJK3@2A [PXE:WM]%(U=J-&M1V=/
MQ.5R9430N<S!BO)*:H;<X,TJ::V@]8ZVRTLAJ0 =2P2!@]P':?=*U?<7B)LK
M&BKKT$Q,.P17=:VY5&Y]FF7>S5XE7=-!S:SJFSS)VU]N8^.UT<#:2DZT />&
MN<YTA&ITW%W :]&G94K#[58(Z.SJM2G[R8NS$+E'1UV&)LI73ERKYR?Y+>N5
M?,VAL]YR#(9[-=K?2]16T;87RR/(\(AIV.!\+7:X$ZZ\1JJR&.YM7.:QFTBK
MD4ZV^NL*Q:..6:98W,3*FGT+7<H4(NE/E)87*GF#2X5<*VCO4#JK&KS$*>XQ
M,&YS=-0'AI(!&CW!PZ2#W-#67]FL[45N1S<QUO=S&F6$CF2I6*3([<W::LN7
M3P4) W&.1$%9]*ORVIGM37=:VTB"7KB-=1&7]6':=@^"#W>RHG7WJIL["5U^
M2ERF'X"Q_6K.JLS[&7@]W:]>Z13F?GC<[O<4U'3FDLENB\EME,= X1@\7. X
M NT' =  "G6-IU#,JU<N<H.\.,IB,R*Q-F-B4;R^<VO-;++!DMMQ"GLE7Y5-
M:[?Y/7-ZN6/JY=D0VZR-;NXM/%NH6C#[>2)SU<E-I<G&3N\N)6]W' D+MI6-
M5'9%2GNZT35H/G+3*[!C^*9[;+O5^3UMZMPI[9'U<LG6RB"J9MUC:X-XR-XN
M('%>KV!\DL3FI5&KEX4-6!8A!;6MU'([9=*RC<BK5=EZ:$R9TSF/RMSZW8G+
M<K-D=.ZKQ6^1=17Q,&Y[#H6AX&H)!:XAP!UZ".A9O[1TM',6CVYC'=W&8[-7
MQ3IM0RIEW-' J9%-K-A_)7<ZMCSJ=E"3O;2"CD?.&GH;KLUU[NQ:$N;S-U:5
MWRP?A>">^ERJ-U4R[WNUXBO<F&/"^5;<5,[K"TL;1NJ].O<!&T/<[0#I?N(X
M="M8.LV$ZSWM-#D,0^WZ]WVU>KR;-<^9*\=34K<5Y9=ZRNP5?);',2IZO?D%
M!<)*FKI.KE&R)SZP@[RT,.HE9P:X]*JHH'I=OD5/95,_R\AV%UB$#\&AMFN_
MF,>JJE%R)6332GXDTG?R-S#'<-OURK<CK/(Z:HH^IA?U4LVZ02M=II$QY' =
MG@O&*6\DS&HQ*T4W]T\3MK&61T[ME'-2F15T[B*5I0RLAK:::0Z1QRL>\].C
M6N!*M7I5JIN'(6ST9*URYD<B\9/N=&4V3*\RCN^.U9JZ)E'#%UXCEA(D8]Y(
MTE:QW#4<=%78; ^*)6O2BU.F[T8C#>7C9(';2(Q$K14RHKM:(I**_)N77-6U
MVU^9W&7'LNM\0@EKFPNE@J&#B>#01H22X [2"3TA0FP7%HY>K3;8N@OI;_#<
M9B9]T]89F)2M,B^E*:<M%0BV063E/9K/6-M60U=^R![6BA$4!@IHW%PU+R]O
M'P=>AWV%,AENGO3::C6Z=92WMIA%O"_JY72RT]FB9$XJ<9N,%RS$+A@-?RWS
M&KDM,,T_E-'<HV.D8#N;( X-#B"'-[(T(/2"M%U;RMG2:--K<)^#XE9RV#K&
MZ<L:*M4=Y]KB77D-Y@=ZY2<M;VU\5[FO%=4QOBJ;SY--%34T6W?M9$ULCW.>
MX-!Z0.V-#K'NH[JY9[NRB:*Y5+'";G",*ER2K(]R45^RNRB9Z(B(N=::]\K?
M%V8)<;Q=(<SJJFCHZK<ZWW"F:YPBE,FNKV!KB00?@]Y6L_7M8WJT153.AR=C
MV?-/*ETY6M<J[#DKDRZ=_=3@+"QBX<K^5=159%;,DFR.\24\E/1T4-.^!GAE
MKO#<[AIJ&\2[MZ JLF;<W:(QS-A*YSJK&7"L'<Z9DRS/5JHB(F]YM6=2%\L>
M8#<.S22_7-CI:*XMD@N/5#PFB9[9.L:WL[7-'#M:JPO;3KH=AN=N8YK <:2S
MO5FE]V2J.IHJM:TW%XJDGJJ'D79+A)DL%VJ+U#O\HHL;BB?&WK#X09(][&Z1
M@_:G3M'=T*$UUZ]NPK4;K<7LD6!6\GW"2+)^)L:9JYZ9DR;B[RUS&GYT9C8\
MSNMFK['.)FPT#8JIHCDC$4Q>YQ8.L:W737I'!2,-MGPM<CTTE9WJQ2WOI(W0
MNVMEN7(J475E1#YGV66"]8%A-DME7U]SM$!CN,'5RLZIW51MTW/:UKN(/O24
MM+>1D\CG)D<N3A&,XE;W&'VT,;JOC1-I*+D]FFE*+YC'Y/YS:\)OM6;XQYM%
MTIS2U$T0+GQ$'5KMHXD=(.G%>\1M73L39SM4T]V,7BL)G=;[DB45=5/4;JDM
M_)W#[I%D,>13Y$:>436VTQ4[X-LC""PSRD<0T\>#03VCQ"C.?=S-V-C8UKR%
MK%!@UC,D_7++1:L8B9OS+N9]&\I&^;V0V?*,XK+Q8JGRNW2Q0,CFV21:NCB#
M7#;(UKN!':4S#H7Q0HUZ46JE'WFOH;R]62%VTW91*T5/2B%EYUE?)_F/<FT5
MPN$M#-31-\AR.*"780XN+H)(WL#M&GB-1IQX$<=:FV@N[9M42M<[?6=GBF(8
M/BCT8]ZM5$]F2BIOM6J>E*9<BF@O66X/A6#5^%8#62W:X7GP;I=7L=&WJWMV
MN:-0W75G@!K1H-3J=5)BMYIYDEE391N9"KN\2L;"Q?:6;ED=)[SM_/J3-D1$
M\^4TO*G++!C5LR^GO57Y--=+?Y/0,ZN63K)=DPVZQM<&\7#B[0+?B%O)*YBM
M2NRN7B*WNUB5O:1SI,[95[41N15K[VI%UIG-=RMSV#![O5"YTYJL?NT/DMS@
M8 7[>.U[02 =-S@1KT$K;?VBSL396CFYB'W=QEN'S.21*QR)1WJ7C6J;IOZC
M$>2=1(^OI<WGI*!Y,C:%])+)-&TGWFI8"=.@>"?L]*C)<7B9%CJNNI;OPS W
MU>VY5K<^S3*FYE2O$OG(!E;<7CN[HL/?4RV:..-K9ZP 2R2AOANT &@)Z. 5
MG;];L?S*;6X<GB:6B34M5<K$1,KLZKI7R1#2*0599G-;++!DMMQ"GLE7Y5-:
M[?Y/7-ZN6/JY=D0VZR-;NXM/%NH51A]O)$YZN2FTN3C.U[RXE;W<<"0NVE8U
M4=D5*>[K1-6@V]MR_!\YPVVXCS JIK5=;*!';+U'&Z5AB #0UP:''WK6M=J-
M#H#N6A]O-!*LD*;2.SH6%OB=CB-FRVO7+&^/W7\6[HSUWZFKKL=Y.6:BJIOU
MIJ[Y7F&3R*EI*9T+>NVD,+W.:1INZ?""W-FNWJB;"-334B2V."V[559W2NHM
M$:FG1EIZT-+AENY<W:W5-%EUTJ;+>.N#Z*OCC=-3F': 6/:&NXZZG7P?=4BY
M?<,<BQHCFTRH5F$P8;/$K+EZQ2;61VBE,RY%3/75ODTBR+ ^6V)WZT8K>ILB
MON00BG?,V%T%/ S8]F[1_#4![CP+CT=A5ZPSW,K72-V&L.C2]L,)M98[>59I
M)4I6F1,BI75DJNM<V@T6!998+)@.:V6YU?47.[P".WP=7*_K7=7(W3<QI:WB
MX>^(4F[MY'SQN:F1JY>$JL&Q*WM\/N89'4?(B[*47+[-,Z)3A.GE5S M^(RW
M*S9% ZJQ:^1]37,:-SHSM<S=M[+2UQ:X#CVNC1>K^T=-1S%HYN8U=W,:CLU?
M%.E89<^FFC-I14SF]AQKD30UK;O+EE16VR-PF9:!3R=:\:ZB-SNK!([!X-]T
M*,L]ZY-G81%UELVPP&-Z2K.KFY]CU+[-?+*0_F9G3L]R 5\,)I;521BEMM*=
M-6Q-))<[3AN<3V.@:#L*?8VOV[*+E5<YSN/XQVC<;34HQJ4:GK\_(;GFMEE@
MR6VXA3V2K\JFM=O\GKF]7+'U<NR(;=9&MW<6GBW4*/A]O)$YZN2FTN3C+'O+
MB5O=QP)"[:5C51V14I[NM$U:#YRTRNP8_BF>VR[U?D];>K<*>V1]7+)ULH@J
MF;=8VN#>,C>+B!Q7J]@?)+$YJ51JY>%#5@6(06UK=1R.V72LHW(JU79>FA,F
M=,Y6BM3CRS>07^Y=O_X%5_<N51BW]NN^AVO<W_(I^5Q([_;^3649#7U]PNT^
M,7*&KFBNMO$1DBG?'(YIDB<UA#=^FI[OVO9,2)]W%&B(W;14R+J+N\M\&N[A
M[WR+"]KE1[=#E1:53)IIH\Z5(SS4SVS9%#:L8Q.)\6+6)FRF?("UTSPT,#MK
MN( :.&[B23JIEA:/C5SY/?<4?>+&8;IK+>V3^3%FW5I1-VB)KRFVLF8X3E^%
M4.$<P)YK95VDAMIO4+'2M$8&C6O#0XC0> 06Z: '4%:);::&9984VD=G0G6F
M*6-]9-M+U5C='38>G FO1D6N336N; JL;Y,V>GGJ)<KJ[W4]4_R6CHZ9T.LN
MT[=[WM(TUT^V"V-GNWK1&(W=4T26&"6Z*YT[I5HM&M33OT]:'3R0RNP8?E=;
M<\BJ_(Z*6W2T\<G5RS:RNG@>&Z1->>(8[B1HMF)P/FB1K$JM?4I$[J8A!973
MI)W;+58J9E7+M-70BZE*T5J<>$!:."9?CUEY<9C8+E6=3=KK&YM!3]5*_K"Z
M$L]\QA:WC\(A4]W;R/N(WM3(W/PG<8/BEM!AMQ#(ZCY-K92BY:MIG1*9]9 L
M;O=1C=^MU]I>,U!.R?;\)K3X3/<<W5OV593Q)*Q6+I0Y7#[MUI<,F;^!:^;2
MGG3(2_G)>,2R+*67_%*SREE=3L^D&=3+"65$?@:GK&MUW,#?>Z\1T\5!PZ.6
M./8D2E%R%_WHNK2ZN4FMW;6TGM>RJ94WT3.GH+!S*]<F,_;:JB[Y3545104P
M@$5/25!]]H3N+J=XU!'8*K+:*[MZHUB+5=:<IUF*WF"XEL++.YJL2GLM=I_V
M*5WE=DY345FEJ,3R:LN=Z:]@BI)Z>2-CF%VCR7.@C T''WRM();ISZ2,1&[_
M #G)8C:X0R!76TSWR9*(J+3/E_ W1NFXY>\R[%28Y48%GU*^LQB<N-//&-[Z
M<O.\C0$.T#O":YG%KOX-%Y9/61)8EHXL<%QZW;;+9WC=J)<RYZ:=_/E14RHI
MDOQCD)1R^7R9;6U=#KN9;XH7]<[7B&EW4 CNZAONA>$GOER;"(NOR4WKA^ ,
M7K%G<YO1]61M?1OD=I\FQ*/F=:;]::+Z$Q:AJ:;P"'2/$<.@=*]K-Y+CTD#4
M^Z5*6"7[9S'+M/6I5,Q&S3%(YHV]5"Q4T:OQ*B5]9V9KD^+W?FQ49-L-WQ:2
M:D=+&&OB=-%%311R -D#'#BT].FJQ;02,M49[K\OI4QB6(6LN++<*G6PU;HS
MHC$1<BTTZS?/QCD-<W^74>65EKIGG5]OFB>Z2/MM:YT1/1T'5WNJ-U]ZS(K$
M<NOR4M^SL!F7;;.YB='5\S:^DP>8V?X]6X[;<!P>*1F,6UPDDJI@6OGD!<1H
M" ="Y[GN) U<>@:+99VDB2+++[RD/',:MGVS+.T1>J;G77PY<^55UD7Y:7FV
MX_G-GO%WF\GMU+*]U1-M?)M#HGM!VL#G'B1T!3+V-TD+FMRJO*4> 745M?1R
MRKLM;6JY5_"J:,IU<PKM07W-;U=[7+U]OJZ@R4\VUS-S-H&NUX:X='9"]6<;
MHX6M=G1#SCES'<WLDL:U:Y<BY4T)KRD94LI#MIJF:CJ8:NG=LJ*=[98GCI#V
M$.:?L$+#FHY%1=)LBD=&]'MSM5%3?0] YKS:PVX89<I\?GVYED%)2T=RB$,T
M;F1M#NL!>6!AVM>]@VO/2N9ML/E;*B/3V&JJIE3RU'U;%.\MG)9O6!?YTK6M
M5-ER+33EI3(BNTE 4,=)+6TT5?*8*%\K&U,[6E[HXBX![@T=) U.BZ5ZJC5I
ME4^5P-8Z1J/6C55*KJ2N5> OWE[=^3?+RY55RHLOGK'U<'D[F34-4T ;P_4%
ML'<7-W<=W<-1%8B4W4Y3ZE@]W@V&O<YD[G;24RL=ZF%7Y?9N7-NMT,V(9+/>
M;DZ=K)J::EEIVM@+'$OW/C8"0X-&G=5O;R7#G4D8C4IKYSBL3ML-CB1;69TC
MZY45JIDHN7*U--#-8>6OHJD:[_<;KP6:B?=IY0.@C[WLZC7I^V[JU_\ D?=?
M^[IN:N4E(N&]DZ/N:_%7WN"FQYJ[IH\.MN&W*IJ69C>I;+3,8UU++# ^H,CR
M="TAC'D:#N*1<OF:B=6W:*S"X+&57?=2+&B4V:(JUUYD4M^KN_)NKY?T/+]V
M7SMHJ&=U0VL%#5=:XNDEET(ZC3IE(^PJ1L=VDZS;"57=3E.^?=X,ZP;9]>[9
M:M:[#JYU=T*:2F[O1XG0Y/%36FXRW7%VR0&6L=$^"5T9VF8!CFM<".('!7D;
MI71*KDV7Y<GH. N8K*.[:D3UDAJVJJBHM/Q:$7B-US2=R_=>J7T>[?HT4S?*
MM@G#.OW'HZ_CKMTUT_CU6BPZ_87KL]<F;U%AWB7#UF;]G2E/:I6E?/N$%5B<
ML7I0Y%ROR'E?8<.RF_SVRJMLOE$K8*:>1XD:9F@;A#(T@MEUX+G70W,=PZ2-
MJ*B[J;F[N'TYE]A=UAL5M<2JQ645:-=G2J=%4TD=N..<CHK?52V[,*^>X,AD
M=2POI)0U\P:2QI)IF@ G0>^"E,FO5<E8TIO_ /M%3+98$C%5EP]746GLKGT?
M^FAJN5W,9^!7*H96P&MQZY-$5QI!H3PU D8'>"2 2"T^^'V%NOK/[AJ4R.3,
M0>[V.=G2*CTVHG^\FK=3UZ_,2JMQ[D'=IG76DRBJM%-*3));>ID<8]3J6L!B
M<1W.+NXH39KYB;*L1RZ_)2^FL< G596S+&B_A3U(K57T[A#\VN^"L=:Z+E[1
M3TPMCWRRWFH)%142.+"TZ:\ PMU&H'< [,ZUCF7:69:[6C4<_BUW8IU;;%JM
MZM:[:YW+DINY-VFXE">U69\M>:=KHH\_EEL.4T<?5"Y4["Z*0#B>+6/&UQU.
MQP\$]#E7);7%JY>J]IJZ#J'XIAF,1-2\58I6Y-I.6BI1=3LVA=)TV@<D, JV
M7^*[U.3W>F)DH*5L1;&R1H\%QU8QNH/07.X=(;J%F3[RX38V48BYSQ;I@F&O
MZY)%F>GNIGR\")7?7=0J_,<LN6:W^IO]ST9+-HR&!GO(H6>\8W7IT[)[)U*N
M+:W; Q&-.'Q3$I+^X69^2N1$U)H3RTD^PGF?8'XR<"YC4;ZW'F\**LB!=+ !
MJ0" 0[P3[QS.(Z-"%6W5B]).MA6CM*'5X3W@MUMOL[YNU'F1VI-W3DT*AW.Q
M#D.V4U?ZZU9H-=XI1"_KMOP=>HUU_H+S]Q>YNK2OENFU<+P%%V_N';.>FG>]
MVO%4TG-[-K#F-QM<>.LG%OM-+Y(V:H:&&3B-"T:DZ #[;0]Q2,.M7PM=MYW*
M5G>?%H+Z2-(:[,:*E5R5S9M/"5PK4XTM_"LVQ"ZX1)RXY@2RTE%'(9;9=(FN
M?U1<XO .T.(+7.=H=I;M)!T5'=6LK)NNARKI0^A83BUG-8_8WBJU/PN\]4UT
MHOFH;*R77E3RK\JOMBNTN49+)$^&WQ]4Z&*'=V7$AH&O ..I.G0.*TR,N;NC
M7MV&Z29;3X3@^U+#(L\JI1J:N*B;JY]2%+5]=4W.NJ;C6R&6LJY7SSR'I=)(
MXN<?LDKH&,1C4:F9#YO/,Z:1TCUJYRJJ^<QUZ-),</L_+RY44\N89'/9JYDN
MV""&EEJ&OBV@[BZ.-^AUU&B@7$EPUR=6Q')O\YT>&6V&R1JMU,Z-U<B(U5R4
MSY&KIJ6GF=WY-YI;;!;:K+YZ9EA@=3POBH:IQD#V1,U<'0</[(=';51;1W<#
MG*C$7:W4W=W=.UQ2[P:_9&U\[F]4BHE&.RUV?@^$J3'(\-@SN"&^3NJL+BJY
MF.J7-D89:=N\0O>U@#P''87 #73574RRK NRE'T3G.$L&V;;]$E7:@1SLJUR
MIEV573ER5,?.CC)RRY'#O].%[/(M.L _LF=9IUOA:=9NTU['<7JUZSJDZSWM
M/EO&G&/MONW_ &W]*J4SZDKG^*OJR&LLM3;Z.[T%7=:8UEL@GCDK*0'0RPM<
M"]FO#I"W2M<YBHU:+3(0[.2..9CI6[;$5*IK0M23&^0]WD-?19366>&0ZOMT
M\3G.C[.UI,9X?TG>ZJ5)[UF16([=\E.Z7#\!G57MG=&B_AU;U6UXU,/F#GV,
MR8M1<O,#CE..TCQ+45U0"U\[PXO&@<&GBX[G%S1QT  "VV=I)UJS2^\N@C8U
MC5JMJVRLT7JTSN73ITY<^55,2]978*ODMCF)4]7OR"@N$E35TG5RC9$Y]80=
MY:&'42LX-<>E;(H'I=OD5/95,_R\A#NL0@?@T-LUW\QCU54HN1*R::4_$FD[
M^1N88[AM^N5;D=9Y'35%'U,+^JEFW2"5KM-(F/(X#L\%XQ2WDF8U&)6BF_NG
MB=M8RR.G=LHYJ4R*NG<12M*&5D-;332'2..5CWGIT:UP)5J]*M5-PY"V>C)6
MN7,CD7C+'YK9K9KUS"H,GQJH%=2T4-*YKS'+"#-3RNDVD2M8[M<=%5V%L]D"
ML>E%6O&AUO>#%H9L0CN(%VT8C="IE:Y5IE1"29?4\J.9-=!E=7E$UBK.H9%7
M6V2E?-(>J!(#"T::\=-1N![2B6Z75LBQHS:2N1:^7J+K$G83BKVW#IUB5$HY
MM,N3+DW<N=-I#5Y[F>#W3EI;,3Q0RP&UW,/AHZALAF=3-CG#IWOVAFKWR;MH
M=KQZ!T#?:6TS;A9)/Q-S[N3(5^-8I8S8<RWMJIL/R-5%KLT=[5:4RJM<]<IK
M:3++!%R5K\1?5Z9#/<&U$='U<IUB#XG;NLV[.AIX;M5L=;R+>))3V:9_,18\
M2MTP1ULKOYJNKLT7I(N>E,VZ,,RRP6GEIF&/W"KZJ[W3;Y!3=7*_K-&@>_:T
MM;_2<$N;>1]Q&]$R-SF<*Q.W@PRXA>ZCY*[*47+[*)G1*<*E9JW.)+/Y2YMC
M]@IK]C&5.DALF10>3R5D+2YT1<Q\3M0T$Z%LG2&G0A5&(6TDBMDC]YAVW=O%
M;>W9+;W.2.9*5U5147-N+YC<8\WE#R_OU%?&Y#/D58R=C:9D5/)!#2,>X,?/
M*='%Y8PN<&MZ?@]!$>9;JX8K=C83T[A96;<(PR=LR3+,ZN2B9&HN17+3/1*[
M^HB5_N^)7OFA77>XR2U.)5E6Y\LM.U\<IB='M#FM>&N&CM#H0IL4<K+9&MR/
M1/645Y=6=QBKI9%5T#ERJE46FS3<7.2NS67DUCUXH\GBS2HJX+?-'64UN%+(
MVH<^)VYC7.#1V0-?!:H<DMW(Q6=6B5R5J7MK:8-:RMN$N5<C%1R-IEKHK1*\
M2;I7^?Y5^NF67#(61.AIZES&TT+]-S88F!C=VFHU(&IX])5G:0=3$C-)R.-8
MC]_=NF1*-6B(BZD3R4O]^;,BY-19S-$8\CDMYLL%4YNDCY#)U.]I)XC5IE]T
M'W%S/VM;OJD]VM?7S'U9<6I@Z7:I238V$7XJ[-=ZOM'F*AD9#6TTTAVQQRL>
M]W3HUK@2>"ZYZ5:J)J/B]L]&2L<N9'(O&3WG3D]CRW,677'ZKRR@;1PPF;JY
M(OOC'/)&V5K'<-P["KL-@?#%LO2BU.E[TXA!>W:20NVF[")6BIEJ[6B:S-AR
M_'F\D:C$'5FF1/K1,VCZJ7C'U['[NLV;.@?"U6M;>3[Q)*>S3/YB6W%+;L-;
M;:_FU]VB].N>E,VZ:WDYDEEQ3-(KM?JGR2WMIIXG3=7)+H]X&T;8FN=QT[2W
M8C"^6+98E5J0NZ]_!9WG63.V6[*I6BKER:D4R.6<\55SCMU5 [?!/7U4D3]"
M-6/CF<#H="-05XO45+1474GJ-^!R-DQIKFY4<]ZIO*CB:9M0<I,HRNZ.N]UF
MQ>^T55)3W!K8C+#5]6[02M(:0UQ \+^(]*K[9]U%$FRW;:J9-PZ7%;?";NZ?
MULBPR,6CM3MW-2I%N9^=X]<;+:L%PELGZL6<[S4R!S3/* X @.T<1X3G$N U
M<>C@IMC:R->Z67WG%#W@QBWE@9:6M>JCTZZ9M_6M=)E\MLJQ"7![WR[S*MDM
MM)<9Q4TM<&/D:#I&=O@AVW:Z%KAJ-#J>*\7L$J3-FC2JHF;RWS=@.(6;K*2R
MNG*Q'K5%X-^E%;7+DRD3KJNRX/F5ON6$7-UXI[=U4YJIF&)LDVIZR,#1IVEO
M@_9/%3&-?/"K94V:E)-+!AUZR2T?UJ,HM5TKEJF9,E"P,ADY.<R*P9+47Z;&
MKS.U@N-)) Z1KGM:&Z@M;M)T&FYKN/20%60I=VR;"-VVZ#J[Q<&Q5_7NE6%Z
MHFTE.:BKNHII<QS;$[7APY=\O.MGMLT@FNMWG:8WU#P02 "&'B6MU.T#:--%
M(MK65\O739]":BMQ3%K2&S^RLJJU5]MZY*^C*M$KDI3(AB8OEE@MO*;*L9K*
MOJ[W<IVR45+U<KNL:.IU.]K2P>]/OG!>[BWD==,>B>RB9>,CX;B5O#A,\#W4
MD>J[*47+D;II31I4TG*J^VO&L]M%[O4_DULI?*.OGV/DV];32QM\&-KG'5S@
M. 4F_B=+ YK4JJT]*%5W>NXK6_CEE798W:JN5<[7)HJN=379U<Z*\YC>[K;9
M>NH*RLEFIY=KF;HW.U!VO <->Z%LM(W,B:UV=$(^,W$=Q>R21K5KG51?]25\
MRLKL&08G@5MM%7Y1766WFFN<75RQ]5+U%*S35[6AW&-_%A/0HEE ^.65SDHC
MER<*EQCF(07-K:QQNJZ)E'9%2B[+$TIES+FJ2.LO_+_F7B-@MN27Q^.7['X?
M)P]T#YX9&ED;'$!O [NJ:?? @Z\"%#;%/:RN5C=MKB]EO,/Q>UB9/+U,D24S
M9-"+N9:)IJA\9E?+.P8'E&&8_6SS5-5 TQ7&IBE!KZEY<'!C6LTC9&UK=-^W
M7=W-26WN))F2O1,BYM2&$Q+#+:QGM8'JJN;[RHOMN6J9,F1$HF>F??4B?)S-
M;=@^6NK[PY[+764SZ2HD8'/ZLN>R1LA8WB="S3@"="5.Q&V=/%1N=%J<]W8Q
M2.PNE=*JHQS5:NYE146B;U/.=.>63EU:Z=E1AU_ENU945))I#$61P4Q:X\7.
M:W5P=M [G86;26X>M)&[*(F?6HQJSPZ%NU:RJ]SG>[H1N7<UTH;'FMEE@R6V
MXA3V2K\JFM=O\GKF]7+'U<NR(;=9&MW<6GBW4+5A]O)$YZN2FTN3C)7>7$K>
M[C@2%VTK&JCLBI3W=:)JT$BILLY?\Q<1M=ASZNELV065G54UT;&9&R1@!O2U
MKAX36MW-=IQ&H/845UO/;2J^)-IKM!<1XEA^*VC(KQRQRQYG:_/2F72BZ<Q%
M,M@Y6V6PR6K%:NHON03S1O?=I6&*&&)FI+& AOOM>/ ^[V%-MUN9)-J1$:U-
M&LH\29A5O;NBMW++*Y4]M?PIN9$3+N5WRO%:''%H\L^9ELL-LK<.S&D=78C<
M-Q(:-[X7O]]X.HU:2 [@=6GB%3WUDZ1R21K1Z'<8!C\5O$ZUNDVH7>>E<^34
MO"B\6QEQ;D(R3Z0&7UKJ$G>+>R%YFT)UV;C!J.UQ'V5J2>^]W82NOR4FNP[
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MO]JHJ)F3=)QF$G*3F%=&Y=4Y5/:)Y(F,K[8^D?+,3$W0!A T!TT&HWA5UO\
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MO<&O3V3J5WMM;M@8C&GYVQ3$I+^=9GZ<R:DT)Y:31*2580! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M$]WVSOL#@NWL[-MNVB957.I\&QS')<2EJOLQM]UOK7=_T0AJGG.! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MT:D%6$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M^[N@$ ]I7]OAD,654VEW>0^=XEWKO;NK6KU3-3<_G=GX*%=*T.0" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MVU%T5XAX%NOW&?JY![,^6?6]N[\_S:=M1=%>(>!;K]QGZN0>S/EGUO;N_/\
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MZN0]/KDC[*$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!4?.W_OV"?GR'^LQ76&>[)^4
MX7O5_4M?^U/46XJ4[H( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @*HYUQM,N$
M3'7>R_TK!VM'G4_U0KG#5R2)\"G$=Z6Y;9?_ 'S2UU3';A $ 0! $ 0! $ 0
M! $ 0! $ 0&'5U$L4@:PZ MUZ->R4!C^6U'PAW@L@>6U'PAW@@'EM1\(=X(!
MY;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?
M"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>"
M >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U
M'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW
M@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'E
MM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(
M=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!
MY;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?
M"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>"
M >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U
M'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW
M@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" >6U'PAW@@'E
MM1\(=X(!Y;4?"'>" >6U'PAW@@'EM1\(=X(!Y;4?"'>" Y,K)W/:TN&A(!X!
M ;)8 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0'PN:.D@>Z@/F]GPAWT WL^$.
M^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.
M^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.
M^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.
M^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.
M^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.
M^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.
M^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.^@&]GPAWT WL^$.
M^@&]GPAWT WL^$.^@.2 ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ("J>=TC8H\-E>=&
M,R"D<X]/!H<2KC#$KUGY%.([U.1$MU7]YI:RISMP@" ( @" ( @" ( @" (
M@" (#77#^V;_ #1_&5D&(@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @.<7]HS^</XT!N5@! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! :^X>_9[A608: ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @-XL ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ("H^?/_ ''%
M?SY3_P!5RNL*]Y_Y5.%[W?TX/^UOK+<5*=T$ 0! $ 0! $ 0! $ 0! $ 0!
M:ZX?VS?YH_C*R#$0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0'.+^T9_.'\: W*P @" ( @"
M( @" ( @" ( @" ( @" ( @-?</?L]PK(,- $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0&\6 $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M[!_9NX%VO! 9;;K:WW!]H96T[KK&SK9*$2L-0V,Z>$8]=P;Q''1 9: ( @"
M(#$I+K;*^>IIJ&M@JJFB?U59#!*R1\,FI&V1K22T^">#NT@,M $ 0! $ 0!
M$ 0! 8=VNUOL=NJ+M=9O)[?2-ZRHFVN?M;J!KM8'./3V @.R@KJ6YT--<J&3
MK:*LBCJ*:70MWQ2M#V.T< 1J"#H1J@,A $ 0! 8-YO-MQ^V5%XN\_DUMI0'3
MS;7R;0YP8/!8'./$CH" [J&MI;G0TURH9.MHJR*.HII="W?%*T/8[1P!&H(/
M$(#(0! $ 0! $ 0! 8ENNMLN\#JFTUL%?3,>8G34LK)V"1H!+2YA(U&HX(#+
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!SB_M&?SA_&@-RL
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M-'$C1>FQVTB[**J*>7/N&)5414W"Z.6/,BR<TL5@R:RAT)WN@KJ&0ATM-4L
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MKKHQC &@<>P%7*JJM5)J(B9$/./)O_S(<U_Z7^88K.X_MV$&'^L_S%S\U_\
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ML3!T<.&O#AKPXE :V_\ *FONV8W#,[=?I+3=)(X!;9(&:F*2%C8W"4%VCV/
MT+?XQP('*T<M;_69-193G]^;>JJU<;91P0B&GC?TAY #>(.CN#>D#4Z#1 ;J
M^X/+><ZQ_+VUC8H;*R1CZ4L+G2%X?IH[4 >^[2 ^UV$S5G,BV9V*QK(+?0NH
M31;"7O<XS>%OUT ^_=&G80'R+!Y8^9,^>&L:89:(43:(,.X.&T;B_733P>T@
M([>>6>7SYO6YI8LGBH*JI8(:<34;*ET,(8UI8WK=S1Q!XM Z3VR@-O'A&2WG
M';UCN=Y"V\P7-D3:66"EBI74[HG%^[2,-#_##':'X/=0&EBY;Y]46<8M=<Q;
M^K4,/D[&TE*(ZJ6%C=K(Y)"=0S33=HXZC@>V@)=C.',LV#0X7<)_*X13U%)4
M3QCJ][*ETA=H#NTX/T0$?P; \TP^KI;>_)HZO#:)TSHK=Y,ULSQ*UVUKGD$M
M#7NW\''B$!N\1PR;&;WE%VDJVU#,AK!61Q-86&(!TAVDDG7WZ C,G+#)<>NU
M=<>7.1-M%'<W];5VRJ@;/"U^I.L9(=H./ ;=0.R4!N\-Y>R6*[5>59#<WWS+
M*YG525KV"***+AX$3!T= &O#AP ''4#(M>$S6_F)?,X=6-?%=J:*F91AA#H^
MJ9"TN+]=#KU7:[* ^9/@\N09=C63,K6P1V%[WR4[HRXR[BTC1P<-.CM("9("
M 9CR_N=VR.AS+%KLVTY'10FF<9HNN@FA)=P<.P='.'0>QT::H#6LY8Y'6Y)9
M,KR+)?I&YVRHZZ2G;!U5*R+0:1PM:X:'4>$\CPN':0&_ON#RWG.L?R]M8V*&
MRLD8^E+"YTA>'Z:.U 'ONT@/O,O"9<^QZ.R0UC:%[*J.IZY[#*"(VO;MT#F_
M#0'9S P2ESNU0TCZEU#<:*45%OKXQN=%*!IT:MU!X:Z$= * B%QY6YIE=N?1
M9KE@K8X8W"@IJ: 0P^4;=K9IRT,+RW7@W3[/2"!9>/6QUDL%JLSY!,^W4=/1
MNE VAYIXFQEP''37;J@-!S P49K24#Z6N=;+U::@5=LKVMZS9(-#H6ZC@2UI
MU[!'V$!$LAY6YOF=L=2Y5EK))(BUU'34M,(J4/!&Z24-+2]VW4-X>#V$!\]8
MIC9,-M4;O>OO-.T^X:>H" YUW*[.JZB.+RYHZ3#20TQR4[75Q@:=1$Z3I<!I
MIJ7?8TX("6W[!:6OP&;!;/(VAI3!%3T\KVF3:(I&2$N (U+MIU/;.J WN/VP
MV2PVNS.D$SK=24]&9@-H>:>)L>[3CIKMU0$9Y?\ +]N'XI58O<:AES@K)IWS
MD1F-CHIXVQN807.Z0WCQ[* T%!RZS[%&RVW"LKBAQYSWR4]'<*9L[X-YU(:[
M1VO3KV!KV.E 3/'[#?+?9JRBO]\?>KE6ND>ZK?$V!D?61AFR-C#H&@C7[/0$
M!B\N,-EP7&FV&:K;6R":6<S,88V_?-.&A)Z-$!B9MR^DR*Y4.2V&YOLF66YI
MCIZ]C!(R2(Z_>Y&DC4>$[[!((* Q[7C/,V2Y4=3D67Q.M])*R62CH*1D9J-A
M!+)'Z-(:[LZ(#)R'',\DO,MVQ3*&T=-4L8V6U5T J*=CF-V[HCQ+==-2 .GL
MH#E@^!SXS6W2_7FY&[Y->7--;6;!#&UC.AD; >CH[PT 0&)B7+BMQG$+OC4=
MY?%67.JFJX;G2,,4D#I61L;M!=J=.KX\1KKV$!J;CR[YAY+2"PY1E\4^.ES3
M4BFI&Q5,[8W!S0X\ .(![/'MH#LYM/JJ7';)A&*R2T]YNE3#26Z&FD=&YM-2
MM\(N>#J&-&S<4!95!3R4E#2TLTIFE@ACBDF<22]S&AI<2=3J2-4!D( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" YQ?VC/YP_C0&Y6 $ 0! $ 0! $
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MB_A,1Q(RM-*U)NHYN/(_++&K-FOK09?F%II__P 7L=J)IQ)J9(Y+G+K!O#N
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M8 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MX=+& UKC$7]62 T?:=WI6]+B1&[*+D-*PL5VTJ)4FZT&X( @" ( @" ( @"
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M3I[A!!0&6@" ( @" (#14>6V>NRBX8A Z3Z9MD3*BJ:YA$?5R-8X;7=GA(U
M;U $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0'.+^T9_.'\: W*
MP @" ( @" ( @" ( @" ( @" ( @" ( @-?</?L]PK(,- $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0&\6 $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M3&G-\=%KN?!#OCE<=.P96L<>Q]A ,U9RADY:/J+'2V_KYXA%9O)HV"O-5X(
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MX?H2!MT[?1Q0$(?SCJJNFJKOC^)7"ZXU2%XDNP<V%KFQ^_<R,M<2T:?8[.B
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M#.DN>X!HX]GCP0'7:>8U346>[WJ_XS<K)36ML3XXYHW/EJ6SES6B)I;'JX$
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MN:"2&R.C##P'8<@)<@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M"8G.;VP"UO'^4$!<[WLC;ND<&-U W..@U)T'3VR4!H<]_P!#9-^::_\ RTB
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ML6SK"'$%^TO/OC_)UX(8)+%R]ABY<GE\*]QB,#H/+S$-WARF4GJ]VG2=--R
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MMIVU<YH;=O&ND0VN(&OP6-B;WT!=* ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" WBP @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @*K]83_;F?\ Q=-_6*N,(_N$WE.*[Y?XY?S-+/I973TT,SP Z2-KW =&
MK@#P50Y*+0[*-VTU%UH=JP>P@" ( @" ( @" ( @" ( @" UUP_MF_S1_&5D
M&(@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" $ @@C4'I" X0PQ4\3(8(VQ0QC:R-@#6M [  X (#F@" ( @" ( @.,L
M44\3X9F-DAD:621O <US7#0@@\""$!$G<J^7;IC4'':/>3NT#"&:_P P';IW
M--$!*Z>FIZ2".FI(F04T0VQ0Q-#&-:.PUK0  @.Q $!\<UKVECP'-<-'-/$$
M'L% 1*;E;R\GG=428[1B1QW$,86,U_F-(;_ @)/1T5';J:.CH*>.EI(AMB@A
M8V.-H[0:T ! =Z ( @" ( @" ( @,2Z6NWWJ@FM=UIVU5!4 ":!^NUP:X.&N
MA!Z0"@.VDI*>@I8*&CC$-)31LA@A;P:R.-H:UH[@ T0'<@-;;<>LMGJZ^OME
M%'35ESDZ^OG8#OFDU<[5Q)/9<X_90&P?%%+L,C&O+'![-P!VN' $:]!XH#D@
M" ( @" ( @" ( @" ( @" ( @.<7]HS^</XT!N5@! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! :^X>_9[A608: ( @" ( @" ^/+FL<YK=S@"0T: D]KB@*GM_
M/[&&M?39/15EBN\!VU%))$Z9H<.&C2T!WW3 @(Q35<O-OFO:,CL5'-#C6/-B
MZZX3L#-[H)'3!O9&KG. #===NKN" 9=46VP<[Q>\Z@=+C,U-&VUSRQ&>"-S8
M6MUV@.UVR"0D $@N#M$!K>;^<6?+Z.V4>+P2U-FME;&ZHNHB=#3"61I:R%@>
MUI)T#CT#HX:]* M'GA_M=??_ )3_ #L" V>-VYEXY7VBT2.V1U]@IJ5[M-=&
MST38R=/LH"L>6^>T/+2EJL$S^.6U5-#/))2U7522Q21R'4Z=6USB"[5S7 $$
M'L:<0+$L7-?$\GO\-@QXU-PED8^22L9 ^.FB:QA=X9EV.&I&T>!IJ@(1SL+K
M'F.%9E41226J@J&LJWQC7;U4S)0/=<W=M[>B LW$\WQ_-8ZN;'YI)X*-S(Y9
M)(G1#=(TN &\ G33CP0%#<U)+ER^S2_S6INVAS*WO8[3@&R3.#9B-/MM0X_T
MT!>O+W'!BF'6JS.;MJ8X1)6<-#Y1-]\DU[>CCM]P("3( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (#>+ " ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M N=BJVUM#O=%UK YNCV::@AX:0>/:0&S0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MV'("XD 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MFKOH-]NMC 1%6.J8YVR2M=HZ/:UK7-(Z>(Z$!.$ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! <XO[1G\X?QH#<K " ( @" ( @" ( @" ( @" ( @" ( @" U]P]^
MSW"L@PT 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! ;Q8 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M/;* WM'14=OIV4=!3Q4M)$-(X(&-BC:.G@UH " [T 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! <XO[1G\X?QH#<K " ( @" ( @" ( @" ( @" ( @" ( @" U]P
M]^SW"L@PT 0! ?'L;(QT;QJQX+7#M@\"L*B*E%,HJHM4*!K.3.3LNCZ:B=#+
M;2_[U6/D#=(R>&]GOM0.G0%?,I.[5RDFRVBMK[U=&ZF<^MQ=[;18D<^J/IE;
M33N+F+RL]MCL]JHK5$XO91PQP!YZ7;&@:GW>E?1K:!(8FQI^%$0^6W=PL\SI
M%R;:JO"9JD$4("DL- =ZP.8M<-6F@D!!X@@OHT!PY:2'!.961\O*AW5VRM+J
M^T;SPT:WK  > XQ'PCVXT!D\M <WYA9'S&F!?;J-QMEC+@0 T#0N;VB(]"1_
M[PH#IY%?ZFYB?X^'^^K$!*+_ ,T+;:,@J,;QRRU.09&-'UT-"P-:PM:!]\DT
M<26C:#X.@Z->P@*YR:]7V]<T,%J[WCDF/3MJXHH>LG9.^>+KV'CL:W;MW'@>
MV@)'ZQK&R6&PL>-6NN0:X=PQ." MN.T6V&T_0<%,R*U=2:44K&@,$+FEI;IW
M04!5?JW$G!:\$D@768#N#R>G/_2@.CU?R-<O&O$7('3W>L0R=W.+_7/*_P#.
MQ_S-$A@VW/O_ &VK_P#CTO\ ?-0$OQ.6.##+'/,\1PQVND?(]QT:UK:=A))/
M8 0$(IN;C[E))2X%B%;>[;2.ZD5<6VCI=PZ PEC@![NAT[" C?*JJK:OF_EM
M37VXVBLJ*0RU%M,@EZJ1TL).KVAH<3KNUT[* R, :V[<[\SN=<!+56\2P4CG
M<>K:V1L +=>@[&[?<)[: NJ:DI:E\,M1!'+)3OZRG?(QKG1OT+=S"0=IT)&H
M0%+<PO\ ?'"/^%#_ '\R M7,?](W_P#-M9_</0$-Y!D'EM0@'4B>I![GWTE
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MIMUN')[4F;\J<J\2(70J$^AA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MBZZ+.!WU#P?9]*3A;](]/V8_@-L^2J/QA/%%UT6<#OJ'@^SZ4G"WZ1Z?LQ_
M;9\E4?C">*+KHLX'?4/!]GTI.%OTCT_9C^ VSY*H_&$\47719P.^H>#[/I2<
M+?I'I^S'\!MGR51^,)XHNNBS@=]0\'V?2DX6_2/3]F/X#;/DJC\83Q1==%G
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M<A .H@\6S[D(!U$'BV?<A .H@\6S[D(!U$'BV?<A .H@\6S[D(!U$'BV?<A
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MO_P]!'_U%U=M@-I#^';7XLO%FXCBKKO'>S_CV$U-R<>?C)I3TU-21""DA9!
MWWL<30Q@]P- "O&,:Q*-1$3<.>?(YZU<JJNZ=J]G@( @,6NMMNN<1@N-)#5P
MGAU<\;96\>XX%:I(8Y$H]J.3=2INBGDB6K'*U=Q:$$OG);"[LUSZ*&2U5)U(
M?2N)CU[L;]PT[C=JY^Y[NVLONHK%W,W OJH=-:=Z+R'(Y4D3XL_"GKJ5+D_)
MO*\?#ZBC8+O;V<3+2@]<!_*A.KON2Y<?>8!<P96IMMW,_!R5.YL.\UK<T:Y>
MK=J=F^;EH5X06DM<-".!!Z05SIU86 $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0%G<B/\
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M_MZNT&@_DMT"^A6.&P6B>PF7I+G/F&(8M<7KJR+DT-3,GEK4DBLRH" ( @"
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M]! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! ;Q8 0$ YF\Q8<,H11T.V7(:MI-/&[BV%AU'6O'9X^];V3W
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M+(A]2Q2^BPFU;'$GM4HU/2Y?+*OG/3--34]'3Q4M+$V&FA:(XHHP&M:UHT
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M2^DP_O=<HM(V,:U,R45?6GH0U-QL^7<HBV\V*ODO&),<UM9;JDDF)CCH#H.
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MGV?NU?\ W-HC7+[4?LKO?A7@R>8K]<Z=2$ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MB=1*:<JIEX"%*C.A" E>#X3/F%35/DJ6T%GMT?77&OD&HC9Q.@&HXD-<>)T
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M1X+@,D<3&2/H6;WM: XZTT!XD=/%7V,L:EI;*B?A_P"+3F\!>Y;Z[15R;?\
MR<50N1.W" LSEE9K1!9[[G-ZI&U\5E9MHJ.0!T;I]N[5P.O;:!J.&I/2%U&#
MV\;8I+F1NTD>9-WRH<?CMU*Z:*TB=L+*OM.TT\JFPQ[FY<[Y>J6RY31T558+
MC(VE?3"$!L76G8QS=2[4-)XZ]A2+7'9)I4CG:UT;EI2F:O(1;SNY';PNEMW.
M;(Q-JM<],J\)"L]L#,2R^NME$7-IHGLGHG:G<V.1HD: >GP2=NO<5)B=JEK<
MN8W,F5-Y<O$=#A%XMY:-D=G5*.WTR<><D_->)MVM^,YO$T!]WHVQ5NT:#RB$
M G^-S?Z*M,;3K617*?\ J-HN^GEQ%/W><L,DUHO_ *;JM_*ODB^<K%<L=B$
M0! $ 0! $ 0! $ 0%G<B/];2?X&;^O&NJ[L_W:_E7U''=[?[)/SIZ%/2B^G'
MR U]P]^SW"L@PT 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0$7Q/EUAN#U5TKL
M7M@HJR]2">YSNFGJ))I&N>X$NGDD(XO<=&Z#BMTDSWHB.7,:F1-8JJB9R4+2
M;0@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" I[U@+T9KE;,?C=][IHG5<X'9DF.Q@/N-:3_ $E\\[TW%9&1)H2J^?RX
MSZAW.M=F-\RYW+LIO)E7T\1;>"6-N.XG:[7MVSLA;+4@]/7S??)-?<<[3["Z
M_#+;[>V8S32J[ZY5.%Q>[^YNWR:*T3>3(A(E9E2$!&^8/^B+_P#X&;^J55XK
M_:2?E4M\&_O8OSH5IRYYJXGCV*VZPW5]1%5TO7=;(V+?%]]GDD&A:2[H</M5
MS&$XW;6]NV)]45*Z,F5RJ=AC?=ZZN;I\T>RJ.IIRY&HGJUE@1<T<!F8)&7R
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M":WED18&JQM,V[PJ5>%P74,2MN'H]U<Z:LF3,A'%6%L$ 0! $ 0! $ 0! $
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M>=#VP1P([2MXYG0X6Q[<[7UXU*.6!D^,OC?F='3]*&LYKVNDO%);>8]D;_\
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MZ$H:< :C;")$U>E54E<Y(Y"TA' BX'0__'>K9W^'3\_K4I&?YUWY/^*';?\
M3F1RYI\E9X>2XV##<P!X<D' EY[?#23[M>[K_P#(6*3?^I%D=NIK]?">+/\
M_&8BL"_TILK=Q=7J^4Z^:7^@N7_^!9_EJ=><:_L[;\O_ !:>L _OKO\ .O\
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M4]*+Z<?(#7W#W[/<*R##0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MY_\ F*I=A/\ X>/\R^EYPMM_GI?R)_"PJJDHZNOJ&4E#!)55<I(C@@8Z21Q
MU.UK02> U7)LC<]VRU%55T)E.VDD9&U7/5&HFE<B&QJ,3RFC@DJJNQW""FB:
M7RS2TDS(V-'27.<P #W5)?8W#$5SHW(B:5:O(1&8C:O<C6RL55T(YM?26%?F
M^2<BL>9&?^]7 F8]&NYU4\=GL;6]Y=%<ILX1%32_ZSEK1=O')E7\+,GZ.4A?
M+U[H\WL#F'0FMA;KW'.VG^ JCPM:7<?YD.AQE$6REKT%)U>+M;,9Y[5%VN+S
M#;J=P=,]K72$&>W!NNC=2=7/5_//';8NKWY&IZX^53FK:WENL#2-F5RYM&:3
MD0ZZVU<J\POM74PY-54ESND[I8Q- 6P"65VNW5S&\-3V7CW5XDAP^[F<J2N:
MYZZ4R57RUGJ*XQ2R@:U86N9&E,CLM$\_J(U/A5=B^?V?'[FYLL=16TAAJ6 [
M)899VLW:'B#T@MU_]*K'8<^VO&1/TN;EUHJEPS%&7=A)-'DV6NJFI4;4S.=<
MKY,_K&..K8H*=C!VFF,._C<5O[Q.5;UVXC?01^ZS42P:NM7>DW/*/[[B>?4\
MGA0FA:=O\^"J!_B"FX%EMKE%S;/J>5_>/)=VCDS[?_)AA\HKE5U+Z_#I[5)=
ML?NHUK6Q:-\G)&WK2XEH ( ^V!U V\>!T8%,YRNMU8KXWYZ?AW?+S$CO' QJ
M,N4D2.2/W:_BW/+SDOM&&6G#&W/)<-D_6R]4F^&CIF2Q'R0/:6N+PQVKW :C
M1H!(X =E7,&'QVFW-;KU[VY$2J>SOTSJ4-SB<M]L07*?;QNHKEHOM:J53(GE
M4HBMJ:FMK:BLK7%]942OEJ'NX$R/<7.)'NE<#(]SW*YV=5JN^?3(HVQL1K?=
M1$1-XD/+EC),YL3)&AS#5-U:X:@\#V"K'"D1;N-%Z158VJI92JG1-W=(HASH
M9"&-ZDWRE:8]!MT,\>HTZ%.F:G:E*9.M;_$A70.7L95KEZIW\*DISW.8<(RF
MNH,4MM/!=WNCFNERGC$CW.DB8YL<8U&U@:1KW>^;7$\12SN'-@:B.SN<J:TS
M)J2A2X1A2W]JU]P]RLRHUJ+3,JY5UK4UG,<4.28-C_,!M)'27:MG=25O4C:)
M'#K07'MZ.A.FO'0Z:E1L61EQ:1W6RC7.6CJ:<_T\9,P3;M;Z6SVE<QJ;3:Z/
M=]3N(D.,9U=Y>6-[O+H*055H?%3TS!#I$Y@$3=9&[O"/A*PL\2D7#Y)*-JRB
M)DR:,Y57^$Q)B<4574D157+E_%FU$7Y>WNHROFC17*Z00"9\$S'1PQAD6D<#
MP#M)/%56%7"W.(->]$S+F3)[JEUC-JVSPQS(U6E4SKERN0@&2-:W(KNUH :*
MVI  X  2N7/W:4F?^9?2=/9+6WC_ "M]"$]YM0PQ6C"C%&UA?; 7%H U/5P]
M.BO\<:B1P43\'J0YGNZY5EN:K_ZGK<2*^7"_X3C-@GP"CC%DJ*-D]?<X8&U$
MCYW-!<97$'0=TCN=C165S+-9V\:VK4V%;5SD2N7=*FTA@O[F5+QR]8CE1K57
M92FYY;NDJJ\7^7)KY3W.JI:>FJ7]5'.*5G5QR/:[C(6ZGPG:\5R=Q<K<2H]R
M(BY*TR5W3MK:S2UA6-KG.3+3:6JIN;Q,^<]")L_IJ&CC:R2HIJ:.-K0&@ODD
M>T="NN\$5;Q&M3.C3G^[$NS8*]RYG.7@1#;Y5DT?*N2EQ3#J2G97101RW.Z3
M1B2:61XUTX]L>%VAKH-%-O;Q,,5(+=$VD1-IRIE52!A]BN+HZXN7.V554:Q%
MHB)Y9/2?*>LI^;&'WN:[4D$666*+RF"NIV;'31[7.#7#CKKL<TC73B"-%ADC
M<3MI%>U$EC2J.33Y4]!E\3L'O(DC<JPRKLJU5K1<G+7A,3E1%9SB685%\IS4
MVZ!L$M1&P#K',C;(\M:>&FNFG2%IP1L7VTZR)5J;*KKTF[O"Z;[NW2)=ER[2
M)JRT0R,2YIU=WR&DQNKM5"S%[A(*2.VQP@-B;)X+.)X.XZ;M6\>XMECC3I9F
MPN8WJGKL[-,U<W.:\1P!D-NZ=LC^M8FUM*N>F?>W"O,YM%-8<MNUJHAMI*><
M]0S4G:Q[0\-U/:#M%SN(P-@N7L;F1<AU6$W+KBTCD=[RIE]!'U7%H$ 0! $
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MR&DYH7N"_9M<ZRD<'TD3FTT+QT.$#0QQ!'2"X.(/:4+&;A)[M[FYLR>;(6&
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MB;WE_P C)_M_@:3E7QS80! $!55A_P!]\G_-D?\ 4HER5M_F)OR)Z(SMKO\
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MZ%Y82TD D$C@J^:-8WN8N7954X"T@E26-KT2B.1%RY\J5+1N_P#L'8?\<_\
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M4JJ2.2*1T4K2R5A+7L<"US7-.A!!Z"%R2HJ+13MD5%2J9CBL&0@" ( @" (
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M&MHY/>3T[VRL)'2-6DC4=D(#*0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M+(ZGEISE3'@UDQ^VV)J.\M&8U%=>+I<X:2GN%5)404$8@HXY#J(H@  UO<T
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M^X3.J*R<@RS/XN<0 !K]@+,LKI'*YRU5=)B&%D+$8Q*-3,AC+4;0@" ( @"
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M*+3;?TG>I,R>G=(.J(Z,( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M'HVGMZH#NN%]P>S<RL7O?+6J8(:Z<4=ZH:6*2*$1R21QZACVM'AM>[1K> +
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M1R1V:]E['-!N<@!<".+6,U''M+D>[2*D4GY_4=MWL<BS14Z">E2U%UQQ(0!
M$!XXS&I;69;?*IA!CDKZDL([+.M<&]OL+XK?OV[F1R:7.])]_P ,CV+2)JZ&
M-]!I%!+$( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M];U;NJ^'H=O3IT]"];*TJ>=I*TKE."\GH( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @-[B.*U^8W<6>WR10S=6^9TLQ(8&,T^"">)('0K"
MQLGW<O5L5$6E<I6XCB$=E#UKT54K3)NDP=R9K6N+79)9PX'0@SN!!']%7"X
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M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0% W0C%N<[IY/
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MC12%W<NG7-BFTM5;5O!FXE0E7*S++]E7,!U1>:ITK644_4T[? @B&Z,:,8.
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MK_KYCUBNW%;6]TU5K%L;6ZBHG^GG-+RKLT3<JJ[G>(]M#C=//65K7C4!\0+
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M9Z5U==:N&BHV<'3U$C8F GH&KB!J>P$!%(^;_+:680-R" /)V@N9*QFO\]S
MW3NZH"8TU33UD$=523,J*:4!T4T3@^-[3T%KFD@CW$!I[]FF+8Q/%37ZZ0T-
M1.PR11R$[BP'3=HT'AJ@,:U\P\'O-2VCMU^HYJIY#8X3((WO<3H T/V[CQZ
M@),@" B.49W%CV06'&J>B=<+I?)=@C9((^HA#@#*[5KM1[X^XTH#=7W(['C-
M*RMOU='0TTCQ%')*3X3R"[0  D\ 4!I:;FCR]JYFP0Y%1B1W1UC^J;VO?2!H
M_A0$M8]DC&R1N#XW@.:YIU!!X@@A 1>Y<R,&L]=-;;E>Z>GKJ=VR>%Q<7,=I
MKH=K2->* XT/,S [G606^@OE//6U+VQ00MWZO>\Z!HU:.)* E3WLC8Z21P9&
MP%SG..@ '$DDH"&U/-GES25)I9LAIC*#H3%OFCU_XD;7,_ZR E-ON5ONU*RN
MM=5%64<GO)Z=[9&'N:M)&J Q+%DMBR:GEJK#71UU/"_JI9(M=&OT#M#J!V"@
M,7(,WQ/%GMBOUV@HYWC<V!Q+YMI[/5L#G:=W1 <[!F>+93O%@NL%;)&-SX6.
M+96M[9C>&NT[NB U4G-;EW%(^*3(*82,<6N'AG0M.AXANB X>EKEQ^T--_\
MG/BH"2V:]VK(*%ESLU4RLH7N<QL\>NW<PZ$<0#P* ST!IK]EN-XP(C?[G!0&
M?7J62N\-P'20T:G0=O31 ;E $ 0&FMV6XW=KK462V7."KNE(UTE13PNWEC6.
M:UQ)'@\"X \>E =^07.>RV2ON]/2&NEH87U'DC7B-TC8QN< XAW':"1PX]"
MQ<0R>CS''J+(*%O5QU33O@+@YT4C'%KV$C3H([7$<4!O$ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $!O%@'F7F#9*WEWG,-[LXZJDGE\NMSP/ :\.UDA([
M0)Z/@N"^6XK;/L+M)(\B*NTWUIY:%/L6#73,2LEBERJB;+O4[RTH>A,:R"BR
MBRTEZH3]ZJ&:OCUU='*.#V.[K3_Z5]&L[IES$DC=/$NE#Y7?6;[29T3\[>--
M"FV4P@A $ 0'QS6O:6N <UPT<T\00>P5A4J91:%/W3%,IY<W:?(< C-;8:DA
M]=8^+RW37WK1Q<!KX);X3>C0A<7/8W&'R++:IM,7.SRXJ94.]M\1M<3B2&\7
M9D;[LG/Z:Y%W%-G;^>6)S,++M#56NL9PEADC,K0X=(#F<?NF!2XN\MLJ>VCF
M+O5\N AS=T[IJUC5LC==:>GE4X7+GCCPTIL=HJN\7&3P88FQF)A<1W=7GW Q
M>9N\D.:)KGNT:.?B/4'=2X]Z9S8VIGRUYN,Q\;PG(LIO<68\Q0&F#1UMLO0V
M/0[FE[..T#IVD[B??=&AUV>'3W4J7%WH]UG*GJSKI-M]BMO:0+;66GWGZ]Y?
M7F3\);*[ X8( @" ( @(=S*S%F'8Y+41/'TM6;H+<SL]81QDT[3 =?=T'95)
MC&():0*J>^[(WE\Q?X'ABWMPB+[C<KM[5Y^4\GN<Y[B]Y+GN)+G$ZDD]))7R
M-5J?<$2F1#XL&25X/E-'CTURH[O%+/8KQ2/HZZ& -=*-0=CV![FC<W4])[*M
ML.O6P*YLB*K)&JUU,^XJ;Q28K8/N6L=&J))&Y'-5<VZBTUD4.FO#H["JB["P
M @" ( @)E0Y3;:;EK<L2>V4W2KN#:N)P:.J$36PCB[777[V>PKJ.]8VQ=!EV
MG/VMRF3D*"7#Y'8DRY2FPUFSNU]KE(:J4OP@" ( @)ES-RFVY?D@NUJ;*VE%
M-'!I.T,?N87$\ 7</"[:NL8O67<_6,K2B)E*# L/DLK;JY*5VE7)YB&JE+\(
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @-ECM?!:L
M@M-SJ0XTU%64]3,&#5VR&5KW: D:G0*5:2I%,QZYFN:O I#O8736\D;<[FN1
M/.E#-S:]4F195<KS0A[:2KD:Z(2@-?HUC6\0">R.VMV(W#9[A\C<SE(^%6K[
M:U9$^FTU-&^:!5Y:$SI\JM=MY=5&,V]LOTW=:H2W.9S0V,4\9\%C7!Q)]ZWL
M#WSE=LO8X[)865VWN]I=%$T>6M3GWX?++B"3OIU<;:-335<ZKPKP(16WFB;7
MTSKD)'6X2L-6V$ R&$.&\-W%HU(Z-2JF+8VTVZ[-<M,]"[F1ZL=L4VJ+2N:N
MBIN<XR?];<BJ+M'&8:/1L%# [0&.GB&C00"0">+B =-2IN(WGW4ZO1*)F1-2
M(5^%6'V=ND:K5V=RZW+GY".JM+4( @" ( @)]D&26:NY:8WC]+4[[O03R25=
M/U<C=C29=#N+0TZ[A[UQ7075W$^PBB:OMM5:IEW?,<Q9V,T>)33.3V'HE%JF
M7W=&?00%<^=.$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 6=R(_UM)_@9OZ
M\:ZKNS_=K^5?4<=WM_LD_.GH4]*+Z<?(#7W#W[/<*R##0! $ 0%=5?.7&*6Z
M.H6Q5$U+&\QR5T8:8]0="6MUU<WN]X%<I)WEMFR;%%5.EY:#LHNZ=V^+;JU'
M*E=E<_,I8-//#50155.\24\S&R12-XAS'C5I'<(*ZACT>U'-RHN5#D'L<QRM
M<E%1:*=B]G@(#S]3T)YS<S[LR[RR/P_&B88:6)Q:R1P>8V\1IIUI:]Y=[[:
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M.:>((/8* IKDI+]"9!F6!N>3#;:UU10M/BM[HG'N:@1'[* N9 $ 0! $ 0!
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MY#B-\Z[F5ZYM":D\LY]RPK#66,"1MRKG<NM?+,1Q5A;! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MEQ[ ^U[Y/RK%<5?>/HF1B9D]:[OH/LN"X*RP95?:D=G7U)N>DA"HCHP@" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M)[I:JLKE=[5*[.9J.2E,R9J::$@Q"IN5JMSL[RNYULEIIW%EIMSZF4.KJL=
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M3,:),:NNH^X9"G5HB5JZBKK5J:JYE7/GH1BPX777N_U=EZZ.FI[:977.X/\
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M#(;3D=!4T-9:Y'4T(JHW1NDI^#V$;M-0W<6?8" L) 4ERW!QSG!FV-2_>V7
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M0QU+HOHNUPAN^!C0[>7N&XDOU;[YQ(T/ =" B?(.PWVPXW=J>[T$UOJI:S?
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M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&\6 $ 0! $
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MK[A[]GN%9!AH @" ( @" ( @(CF_,C',#BC;=9'S7&H;NIK=3 /G>W4@..I
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M ( @" ( @" ( @" ( @" ( @-XL ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ("L>;G_
M 'S#?SQ%_68N6QWWH/\ L3U'9=W/<N/^I?66<NI.-" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" (#7W#W[/<*R##0! $!\>]L;'/>=&-!<X]H#B5A51$JIE$55HA1-9SKOYN
MCIJ*FIVVIKR(Z:1I+W1@]+G@\'$=K@.ZOF\G>>?K*M1-C5N;Y]6B[H6_54>Y
MVW3.F:NXFHNNTW&*[VRCND +8:R%D[&.Z6B1H.A[HZ%]!MYDFB;(F9R(I\QN
MH'02NC=G:JIP&8I!&" H;EA2QYOS.RG,[JP5 M<PBML<OA",O>]D3FCHUCCB
MT]TZ]* OAS6O:6/ <UPT<T\00>P4!0N-T[,,Y^UV/VS2*TWJ%[Q3-&C&ZP&J
M  ' ;7,>&]IIT0'7EUQ?R^YU_KE?*22;'[G R*GJ8V[^KTIV0OVZ\-S2PDMZ
M=KD!=-FON/971-KK-607*D:YK]6$.,;P=6[F.&YCAIJ-P!0&V0$;S2\Y'9[=
M"<5LQO-WJIQ3QQEVR&$%KG&24ZCP1II[YHX]/; KV^9!SPQ.WR9+=H+/6VN'
M1]90TPDWPQDANNIVGL]+7/TZ3P0%DV3)8,@Q2GR>A9LCJ:5U0R)_A;)& [F$
MC37:YI;KV4!4V+\T^9.<VX4&,VFD?>82]UQNLP='1PL<?O36M+SJ\C7M_P W
MI* D&#\Q,H?E\V 9[10T][ZLRT=52\&2AC.L((U<#N8"X.;IT:$:H#9\S.8U
M7B,MOL6/T3;EE5W.E)3.U+6-+MC7.:W0NW.U#1N'023PX@0O*<CYLV#&+JS-
MK725MFNE'44;JNWD"2DEJHG1LZP Z%NYVA.G]+70$";<C_\ :ZQ?_-_YV= 6
M"@*2Y0_[F<R/\?-_G)T!B<_VTLM\Q&"W ')W5!ZL1:==U9?&(]VG'W^NS7^4
M@,OUEO\ 3-G_ ,>?[EZ MK]8\>^MJ+SF+XR KCG]9[A?<'IZRT U4%#4LK*B
M.'PPZG,3V]:-NNH;N!_FDE ;_ N9^)Y=14M)1U$=#=VQM8^TRZ1N:YH TBUX
M/;PX;3KIT@("<Q110L$4+&QQM]ZQ@#6C4Z\ $!R0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $!O%@! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 5
MCS<_[YAOYXB_K,7+8[[T'_8GJ.R[N>Y<?]2^LLY=2<:$ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M)'6;=>SIQXH"R4 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! ;Q8 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0%8\W/\ OF&_GB+^LQ<MCOO0?]B>
MH[+NY[EQ_P!2^LLY=2<:$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&ON'OV>X5D&&@" (
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M;AMBIK#:P3!!JZ25^G62ROXN>[3LG^ <$!NT 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! ;Q8 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0%8\W/
M^^8;^>(OZS%RV.^]!_V)ZCLN[GN7'_4OK+.74G&A $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $!K[A[]GN%9!AH @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" WBP @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ("L<WYLU6%7QUHJ+!Y3$8V34U7Y7U8EC<-"=O4.
MTT<"W3=V%RV(XXZSEZM8ZI2J+M4K^D['"N[K;Z#K$EV5K14V:T7YDT%:Y=S:
M_6J:S3?0_DGT16,K=/*>MZW80=O]DW;T=/%<Q?XY]RL:[&SL.VO>K7B0[##>
M[OVB2)UFUUC=GW:4W?>6I)_:)_\ ^;_^[OR=6GBO_P!U^O\ ]DIO!?\ [[]'
M_MEPV.OJ[I:*.XUM)Y!4U439G4F_K3&'\6@NVLX[=-?!X'@NTMI72Q->YNRK
MDK3/3T' W<+(IG,8[;1JTK2E>-?2;!2"*$ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M >7,\5+]P4 \N9XJ7[@H!Y<SQ4OW!0#RYGBI?N"@'ES/%2_<% /+F>*E^X*
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MW#W[/<*R##0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!O%@! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M*-5<QBIE@AP#FG4'B".@A8,A $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0&\6 $ 0! $ 0! $ 0&KK<DQVVES;C=Z*C<P.+Q45,41:&>^
MUWN&FG97M&.7,AY5[4SJ:X<Q>7Q.@RRS$GH'TC2_.+UU+^BO >.M9K3A-O17
MJSW,EMMN%-6.'2*>:.4C3C]HXKPK53.A[1R+F4SEY/00! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0$9RO"K7EM1:
M:BX#PK74B?337K8NET3OY+B&Z^YW55WV'1W3F*_\"UWTU>@N,/Q26S;(C/\
MU&TWEZ7FRDF5H4X0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MCV!W5@'1/<;?35$5)4U<,-74?V$$DC622:G3P6D@GCVEFBF#)6#(0! $ 0!
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M^/55#= ]O1NC>-6O;_*82%<QR->E6K4J)(W,6CDH:-;#4$ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M/IYV&.:)Q9(P](<.!!6%2AO8]KVHYJU13K0]A $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! ;NPXO<,B;.^BDAC%.6A_7.<W7?KIIM:[M+8R-79BHQ#%8K)6I(CE
MVJYJ:-]4-764TE%5ST<I!EIY'PO+=2TNC<6G34#AP7A4HM"RAE26-KTS.1%X
M<IT+!M" ( @" ( @" ( @" ( @" ( @" ( @.VF@?55$5-&0))GMC:7= +R
M-=->VB(>)'HQJN7,B5-Q?L5N&/10S5LL,C9G%C!"Y[B"!KQW,:MCXU;G*K#\
M6BO55&(Y-G73U*IHEK+@( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MGG=5RP,?)(#.]C(W.UE<\\6QM&FNG!;))'2+5RU/#&-8E&I0WZUGL( @" (
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MVFS[3<WH/-"M2J" ( @" ( @" ( @" ( @+$Y6__ *6_^7_[52K?2<'WL_\
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M^;H/[\JGQ/W6[Y;8=[R[Q[C5 7AK[A[]GN%9!AH @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" WBP"G_ %B^<#.4V$NDM[VG+;SOI+)$="8R&_?:D@](
MB#AIVWEHZ-5-M+?K7Y<R9R'=3]4S)G7,>;O55Y*OSV]R\S<SB=56*@J"^ABJ
M?#\ON(=N?))NUWLC/%VOOG\.PX*SOKG838;G]"$"RM]I=MWF/>*Y\NP@" (
M@" ( @" ( @" ( @.BMHJ2XTD]!7P1U5#51NAJ::9H?')&\;7-<UVH((.A!6
M4546J _-3UA^3,_*/+RV@8^3#[N7SV2H=J[J]#J^F>XZ^%%J-"??-(/3KIU%
MI<=:W+G3.<W=V_5.JF92GE.((0! $ 0! $ 0! $ 0! 65RPI98Z6X5C@.IG?
M%'&=>.Z(/+N'],*7;ID53Y]WJE:KXV)G:BJOGI3T*:V]8/?ZZ[5M9!'&89YG
MR1DR ':XZC@O#HG*JJ6-CCMK%;L8Y5JUJ(N13!]'N2>+B^5"\]2XF>([/6O
MH]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/
M6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>
M([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=
M2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^
M5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>
M+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'
MN2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O I+<-LMUQV.L96TQD-0Z,L
MZE\;M-@=KKN<WMK?$U6UJAS&-WL%ZK%C=39KG1VFFI%([=,&R"MN596111B*
MHGEF8'2-#@V1Y<-=->/%:71.554OK7'K2*%C%<M6M1,RZ$H8GH]R3Q<7RH6.
MI<2?$=GK7@4>CW)/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I</$=GK7@4>CW)/%Q
M?*A.I</$=GK7@4>CW)/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I</$=GK7@4>CW)
M/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I</$=GK7@4>
MCW)/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I</$=GK7
M@4>CW)/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I</$=
MGK7@4>CW)/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I</$=GK7@4>CW)/%Q?*A.I<
M/$=GK7@4>CW)/%Q?*A.I</$=GK7@4R*'!,AI:VFJ9(HS'#*R1P;(W4AC@3IK
MIVEE(75-,^/V;XW-1RU5%3,NHD^8V>Z9#3TL-%3&-T+W/>9GQM!!&G#:YRW2
MM5V9#G,$O(+)SE>^NTB9D=ZT0B'H]R3Q<7RH6CJ7'4^([/6O H]'N2>+B^5"
M=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B
M^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2
M>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]
M'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O
M H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([
M/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X
M>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"
M=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B
M^5"=2X>([/6O I.K3:Z^BQ3Z&FA_YSJ:B/5KFEFZ5SRWCK_*'84EK51E#C+R
MZBEONO:[V=IJYEKD1*Z-P@OH]R3Q<7RH4;J7'9^([/6O H]'N2>+B^5"=2X>
M([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=
M2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^
M5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>
M+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'
MN2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O H]'N2>+B^5"=2X>([/6O
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M#@O+HW-2JDNUQBVN9$CC5:KN&A6LN0@" ( @" ( @" ( @" ( @" ( @" (
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M>Y>72JY**3;+ X+63K&*Y5W53U(A&UJ+\( @" ( @" ( @" ( @" ( @" (
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MM&OND(#IQG(:+*K'1Y!;F2QT5:USHF3AK90&/<P[@USATM/0Y ;9 $ 0! $
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M'=UP<5T6'2[3-E?P^@HL0BHY')I/,ZM2J" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M8W.CVO=JT.'9TZ0@,C,LSL^#6AMYO(E?3OE;3QQ4[6OE?(\%V@#W,' -)/%
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MYVJXVJJ9UM7/$='Q=8QS6N=M: UNCM=W#1Q0R>A$,! $ 0! $ 0! $ 0! $
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M:"UO Z\5K61J*B*N53:V)SD5R)D0TRV&H( @" ( @" ( @" ( @" ( @" (
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M7#BXZ=EVG80$-ML&5<FLBO#*:QU-]PFZR^402T+3)- =3H'!H.A =L=N #M
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MK&W>0Y6X2DCM\A:D$<( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M .:06D:@CB""HQN/#'K>_P"_.(?FJV__ %.K5_8?T7;Z^A"EN_Z[?-Z3W0J
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MZR=F14SYRU\F%+S&M'-SE?ADOT'GU+6>4UG4OVNND4D41;UCG:G9(T>3O#2
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M69B(N6AFU<G5/<J9*J8'K;6>LRNTXIS;QJNEN/+VJHXZ:"E&@BH)93JUP8T
M,$F@C?KQ:]FTGWH'JP<C%=&J4=Z3Q?-5S4>B^R><\#QV#+LVQ[%ZJ<TU->+C
M2T,U0P N8RHE:PEH/#70\.ZK25^PQ7:D*R%B/>C5TGL/..;&5\F<^Q_E3@F*
MF?!Z"&FIVT\[:FJGKQ6:%W4S.)(V%Q: -WA[M>&@%'' V9BO<[VB\?*Z-[6-
M;[)2WK:X!C6"<QZ;]6(6T5+>Z(7&HMT?]G#.Z:2-SHQ]JQ^S7;T ZZ<- )]A
M*Y[/:T%??QM8]%324&K(K0@" ( @" ( @" ( @" ( @" ( @" ]7^K+NSSE%
MS-Y1N(?630&OM,+G!I=/4PE@.X\ UDT$).I^V]U4U[[$K)"YLEVXG,\LI).8
MN81<M^=/)C#::I8VV8?0TM#7N8-(VBZ 4$SGC3CI#&V3N:Z]*U0Q]9%([2[U
M93=+(C)6-3,GKR$NYDV"/E%BO.S.H=D4N:R4U-:QJ#+K5P-AF<".@]=43O _
MD:]HK3"[K71MZ)ME3JFO?K_T(ORMJ<=J?5+<V;%),RAME;4.OMAIIY*>661M
M9UPEW1:O^]Q.B>0T=#5MG1WW.?9KF7S&J"GV^;:W/.5[DO-NV-Y/Y)@N(\J*
M[&<:N4L4E9<):JIJ*6GJ72PD.<Z6$>$[J6M:WK ->.AXZR60+UJ.<]%5#1),
MB1JU&*B%M\QKGAOH;Y:WRYX!-GN/16ZGA@\DJIZ9M XTL#-']0'$[BPL\+WK
MFZ=)4.%K^M>B.V5KPDR56]6U=G:0I+FSS/&58=AF*4'+ZLP_';7<-]JJZR:>
M=CVPMV/@A=+$S<!UH<[5SB/!'!3H(=ESG*[:54(4TNTC6[*M2IZZR/*;!#S8
M?R]K/_O5D&58UU=HR.!Q96,<R:K!@8XZAKFZ]=&1IJYO'4[ *=C'=7MYT:N8
MM7/1'[.E4/SCSS#[W@>6W3%L@:1<J"9S73'7;/&[PF3-)Z6R-(</=X\5T\4B
M2-1R',S1JQZHIM^7<_->UQW>^<LF71K8614MWJK3$^9S(YG%\8?L:X@$Q'PA
MVNGBM<R1+1'T\YLA65$565/6W)R]<P,BY/Y\[G>VI?CL5)*VAJ;S ()GPB"4
MU'%[6N>&.#-CR#X7 '4<*:X:QLK>JS[A<6[GNC7K.,I?U;^0\><.DYAYA#))
M@EF>]S*"&.2>HN-13MW&-D4(+W1M.F[:"7GP&CWVD^\NMCV&^\O$0;.VVO;=
MF,;UB<@YJ<Q;J^\7+#;[8.7]B!9;(*RW55/##&XAAGG>Z,,:^3P1TZ-&C1V2
M<VC(XTHCD5R[IYNWR2+[JHU-PH!616A $ 0'K#U%?]699^;H/[\JGQ/W6[Y;
M8=[R[Q[C5 7AK[A[]GN%9!AH @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MZ:G1CGC3CVT!O4!55=S_ ,/H;A66TV^ZSRT4SZ>62""%S"Z-Q82-9P="1PU
M0&\Q+FWAV8UOT903RTET=KU=%71B*1^T:D-+7/:2.UNU0$Y0! $ 0! $ 0!
M$ 0$8YAY+5X?A]RR*AACGJJ/J>KBFW=6>NGCB.NT@\ _7I0&TQNYRWK'K1>)
MV-CFN-%35<D;-=K73Q-D(&NIT!=P0&S0! 06UYQ<:_FE>\$DIX6VVV43*N&I
M;OZ]SWMIG$.U=MT^_GH;V @.Z3F+1Q\PXN7GD,QJY8S+Y=JT1#2!T_1TZ:-V
MZ]M 31 $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0'@?G%OY8^M!-D36
MEM+'=:&_L)!\.*8QS3CAIP+^M9P726_\VWIN*AS\W\NXKNU/T28]DK&R1N#X
MW@.8]IU:6GB"".D%<T= <D 0$6YF?[<9A^9+E_E)5MA]]N^AX?[JGFCU#_\
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M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (#UAZBO\
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MT'J62NE:-I!.]@TU&O$A>63L>Y6M7*AZ? ]B(KDHBD16\T! $ 0! $ 0! $
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MHI3!+)%$7["9'$QG=Q;VMHZ32R7LFTE$HBZR[CLHT1:K53R&KLHP@" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ]8>HK_JS+/S=!_?
ME4^)^ZW?+;#O>7>/<:H"\-?</?L]PK(,- $ 0! $ 0! $!&.8=@KLHPVZV&V
M&,5U8R-L)E<6,U9*QYU(!TX-/80';@=DK<<Q"TV.X%AK:*'JYNJ)<S=N+N!(
M&O3VD!&.;V"WO-Z:RQ64P!U!4NFG\H>8QL<&CAHUVO0@)GD]B@R7'KE8:C01
MUT#XFN/$-DTU8_\ HN =]A 5_P F^6%QP0W*OOKH9+K5[((# XR!E.SPCX1:
MWWSM.'\D(#-S;!;W?\^Q3): P_1UGDC=6"1Y;)HR82':-IUX=U 9O-S#KMF^
M*LM%F="VLCJXJG2H<6-+&->T@$-=Q\/5 1:DMOK!45+!1P5=H$%/&R*($ D,
MC:&CCU?:"&2Q<.9ES+06YJ^FDO/6OVNHQI'U.@VZ\!X6N[L(8) @*XY98->L
M1O66U]U,!@O55'-1=2\O.QDE0X[@6MTX2M0'WFY@%QS6AMM387QPW^U5'64\
MLKC&.J?H7#< >(<UCA]E 9.=X!49[CMNCJ:AEORFWAE13U<6KHHZAS6]:S4:
M.V%S1HX<1H#W$!HX)/6"@A;;G06.<L'5_2DCI-[M/MR&O:-?_A?80$YL=NR2
M+&74.35\5QOTK)A-4PL$46LA=L:T!K.#00-=H0&BY18?=L)Q:2SWHQ&L?62U
M ZAYD;L>R-HXD-XZM* PY<%O;^<,&<@P?0D=,87#>>NWFG=%[W;ITGM]" V/
M-?$[KF>)/LMG,0K340S#KW%C-L>NO$!W'B@-G<L1I<@PIN)7C@Q])#!))%Q,
M<T+6[7L)^"YNO=0%=VBQ<\L.HOU>L\MKNUI@!90U527"2*,G@ "6'A\%V\#H
M'! 23E[RZN&/W.ORS*ZYMTR^Z MFFC_LH8W$$M9JUO$Z-'!H  V@:(#79YR[
MR27*J?/\"JXJ?(6-;'64TYVQS-:W8#J00=6:-<UVG  @ZH#2Y)R^YI\P+;-)
ME5?14DM, ZV66C+FT[I]P!DF>=_VN[;Q=_1XZ@6/%B$-?R^H\+OFA MM-0U3
MHCJ&RP1,;O82..U[ YNH[" @=FL/.O!J06*QOM5]LT)/D4M:9&R1QDZ[= ^,
MCW-S@.P4!-\,I.8,<U;69S7T<K9Q&*.WT#-(X-"XN)>6AQ)U'#<[W4!K+1AE
MXHN;=^S:8P_0UQH8Z6F#7DS=8UE*#N;MT ^\N[/:0'"KPJ\S\W:'-V&'Z%IJ
M)U-("\]=UACE9P;MTTU>.R@&6X3>;WS#Q;)Z(PBV6?\ [WUCRV3@\N\%H:=>
M![: E&9VBJOV*7BS4)8*RNI98(#(2UF][=!J0#H@*[O=!%A'(M]BRF+KYF0N
MI3#2R:!T\U0Z2(M>6_:ZAQU;V-$!@XCR^YFMQ>V3TN<RV\2T\3X;<8!41PPN
M;N8T2/?V&D< W0='80&UY?Y?ET6;W7EWF%1#<ZN@@%1!<J=@8=-(W!KPUK0=
M6R#B6Z@\..J ME $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! ;Q8!X/];SE?58?F
M--S0QQCJ>V7N9KZV6GU8:6[Q^&)-6Z;>N#>L!Z=[7GLA=!83(]FPNCT%%>PJ
MQ^VFGTGI[D+S9I>;6#4]TED:,EMX;27^F;HTMJ #ME#0!HR8#>W0: [F_:JJ
MNH%B?31H+6WF25E=.DM)1"0$!YJYP^J-9,^O53E6)W)M@O=<\RW"DEBZVBGF
M=TR#86NB>X\7D!P<>.@.I-I;W[HTV7)5"NGLFR+5%HI5GL+YM^U%J^3J/B*7
MVFWHJ1NS5Z7$/87S;]J+5\G4?$3M-O14=FKTN(>POFW[46KY.H^(G:;>BH[-
M7I<0]A?-OVHM7R=1\1.TV]%1V:O2XA["^;?M1:ODZCXB=IMZ*CLU>EQ#V%\V
M_:BU?)U'Q$[3;T5'9J]+B'L+YM^U%J^3J/B)VFWHJ.S5Z7$/87S;]J+5\G4?
M$3M-O14=FKTN(>POFW[46KY.H^(G:;>BH[-7I<1>?)7U9,:Y35WZQ5M:Z_99
ML,<-8^(004H>-']3'N>=Q!+3(YVNG0&ZG6!<WCI4IF0FV]HV++G4O55Y-" \
MV^MMSBCPW%G8'8ZC3)\BB+:MT9(?2VUW@O<2.ATW&-O\G<>'!6=A;[;MI<R>
MDK[V?8;1,ZGY_+I#G0@" ( @" ("^/4__P![K;_@J[^X*KL0_I+OH66'_P!3
MS%VXUGW(B@Y[7BSVO%:^S\Q:^[W&TG)S*ZKB-RGJ)(9)6133R,C$CR[0MAT&
MNA ;JH#XIEA15<BMHBTW";')"DJHB*CE5<I$<!PZ[X1ZXL5JO5S=>:RJ;7W$
M721NR2=M90S2;GM' .!):0WAPX<."W2R(^UJB4S&N.-67*U6M4J2SDPZ$>ME
MS3#B!.ZGK!'J1N+?+*4N _@6FX_MF&V&GW#SQYG<=?#F^2Q77=])LNE<*POX
M.,PJ'[R=0.EVJNXJ;"4U(4LW]1V^IZ<R@/I/4?QN&Z>!5SU,?D@>/"+7W&HF
MBV\/$#77M*J9ENUIY9"U?5+5*^64FV=XS@.3<@>5=/S RDXK;J>UVJ6FJA":
M@S2_1; 8PT GWNI4>)[VS/V$VLJ^DW/8Q\+4>M$HGH*;YW\X<(J,%QSE)RIF
MJ*K'[!+%42WJ=KXG2R4S7A@8) QQU?(Z1[BQHW ;>"G6UN_;623.N@AW-RW9
M1C-'J)WC'.SE3SYI[3A'.NP-@RF3;1T%]BU9"^IF\ .9+&6R0.>[;X!W1%W3
MH."COMI(*NC7)J-[+B.>C7IE*:YEXC<O5PYPT+L=KGS-HA3WJR5,N@E=32/?
M&8I@S@?"CDB?P&YO'0:Z*=#(EQ$M=Y2%,S[>5-G?/2'K$YY;<9Y3/R#&J,T-
M_P";$5'Y95@_?12"CCW![@=-1"6P@#X3BJNTB5TM%S,+2ZEV(ZIG<>"UT1S@
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! >^^:^ <
MULWQ#E=)ROKI:"2V6W=<98:]UO(=-!1&!Q+'-+MO5R'AKI]E<Y!+&QS]M*U7
M576='<12/1NPM"M_7(K:N"SX#B]V@J*R_P!KI7&Z7]T$C*2>H=#"R1L,SVMZ
MQSG,,CPWWO#7CJ!*P]$JYR9ET$;$%]EJ<9V^LS"ZHY.\F:=G!\M'31M)[;J"
MF 6+):2O\M)[O$K&U-U#9^M%EEUY38UAW*? *R:RVMM"]];44;C!/-#$1$QI
M?'H1O=UCY=#X9/'LZ^;*-)7.>_*IB]D6)K6MR&+ZH.>Y#F5TR/EQF-=-?K!/
M:GU<<%QD?4EC6S1T\L8=(2=CVS\6ZZ<.&G%9Q")K$1[4HM3S8S.>JM<M3.]4
MBVR6>JYS6BWND=+024M)2NCUZTN@-RC86[>.[4#33LKS?K5(U7RS'JR;LN>B
M:%Y3>>K">;T#,LJ><+[PW#V4;3_^-9G)WMW&4M%=J_JA%NZS[3H6N]ZKV>KI
M7<YC99]91=NM-TT?J[55ES#E%F?++$;V,:S6MK:JIHI@XQU+J:41F)[2TM>Y
MNV,Q2;.+!Q[(UV7:*R5KW)5*&+96OC<UJT6JE(<U,9YY<MJ2BQ_.KA75&.1U
MC*RT58JGUE#Y9 Q[6.AD<=T;PUS]&$,/9V]E3X'PR*JM3*5\[9HT1'+5*\9Z
M.&-6GUJ\3Y>9O+L9>;'7MH<PCU:W?3QM$E2S0#_VCFQOB '@ME/=59MK:N<W
M0J9"SV6W+6NU9SS[ZS_,IO,#F/445ME#L:QH.M=L:P_>GO8?O\S0.'A/&UI'
M2QK5964/5QU7.[*5M[-MOHF9I2:GE>$ 0! $ 0! $ 0! $ 0! $ 0'MFBNN
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M$_=;OEMAWO+O'N-4!>&ON'OV>X5D&&@" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" U&3XU:\MLM18KPQSJ*HT)=&=LC'
ML.YKV.T.A!':]W@@(!2<JLSME,+?:>8E;36R-HC@IWTK971QMZ&M>9QIH/@@
M("2X1RYM6%.JJYE1/<[[7_\ ?KK5NW2R<=Q ''0$\3J22>D]" F* ( @" (
M@" ( @" ( @" ( @" ( @" WBP#29?BEFSC&KCBM_AZZU7.(PS :![#TLD82
M#H]C@'-/;"V1R*QR.3.AX>Q'M5JYE/SSH:G-O54YO.CJ6.J:2,[)XQK'3W2T
MRNX/8>(:[AJWIV2#0ZC4'I%1EU%Y9%.?:KK:3+F]*'Z%8?F%@SO'J/)\:JFU
M=JK6;F.&@?&\>^CD;J=KV'@YJYN2-S';+LYT#'H]*IF-ZM9[" ( @" ( @"
M( @" ( @(#S=YK6'E'BDV078B:X3;H;/; X"2JJMNH;VPQO R/\ M1W2T&1!
M Z5U$-,TJ1MJI^8F695>\UR&ORC(:DU5VN,IEGD/0!IHUC!]JQC0&M;V %U<
M;$8U&IF0YB217N5RFE6PU! $ 0! $ 0%B\D.8MOY6<P*/+[G1S5U'3P5$#Z>
MF+6RDSQE@(WD#@>GBHMS"LK-E"7;3)$^JEN#GUR"M635&?6/EC639O-537'R
MRMKW]7Y94/=(^4-=+.QAW.)&R+AV-%"^UF5NPK_9)B74#7*Y&K7RW2#8SS[J
MHN>3.<684CJHEL\;J"@VMZN)]*^FBCCZP@:,!&I)U/$])4A]K_)ZMIH9=_S=
MMQJ).<MQM7.BX<V\3A,#ZJMFJ64-9HX/IZ@;7PR[#V6GI:>!T(XA>_MT6)(W
M'A;FDJO:6Q=^=GJQ9G<'95FG+6Y.RV71]1Y+(UU-)(P#0R.95TS9-=-"Y\!.
MG;Z%#;;7#$V6O2GEN$IUS ]=IS5KY;I6?.WGK<.;<MOM=%;F6+#+,-+79HB'
M:.#.K$DA:UK>#?!8QK=&-U UZ5+MK5(JJJU52-<W2RY$R(AF\T.=5FSSE7@V
M T-MJ:6OQ6"DAJJJ9T9AE-+1"E)8&DNXD;N(Z%YAME9(YZK[W*9FN&OB:Q,Z
M4]!45HKFVN[4%S? RJ915$-2ZFD]Y*(7AY8[@>#M-#P4UR514(;';+D74>DZ
M#G%ZKM#6PY=!RNKJ;,J:5M73T\,P^CF5+';FEH\J;& #Q'_*<.TJI;>X5-G;
M2G'Z/66B7%NB[6RM?+=*4YJ\R;MS7S*KRZ[1-INL:VGHJ*-Q>RGI8M=D8<0"
MXZN+G.T&KB3H.A3X(4B9LH0)YEE=M*3/FYSHM',; <&Q*@MM31UF*T\<%7/.
MZ-T4KHZ:*#6/:==-8R>(6BWMEC>YRKG)-Q<MD8C43,4NIY7! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $![LYT\J,_P":&%<K?U%;
M&X6NUN\O=)4MI0/*J>BZHC4C=_9/Z.A<];3LB<_:TKRG17,+Y$;LK2A$_6!N
M5%BG(;&>5F37NGO_ #&I9X7U)BF-3+3L@,I+GN<=S0UKVP-WZ%PUT'#ANM&J
M^97M2C33=.1L*,<M7&-ZS<CX>3?)N:,Z/CHJ=[3T\6V^F(6;+^J_RTB]6D;5
MW?42GFEAT7K485C6=<N:ZC?DMJA,-TM$TO5O8:D,<^%QX['Q/:[9OT:]I)!Z
M-=4$GVKU:],BGN:-+EB.:N4Q^4V P>J[9+]S*YI7&DAO=92.H;59::822R-:
M]LKHFG3PY)'LC]X'-8WPG'IVYGE^Y5&,3(8@B2W:KGJ:WU-KM6U4'-N^N?I<
M)F4-:9- =)GBXRZZ$$'PCV5ZQ!J)L)O^H\6#MI7KKYSSOEW.SFIG5');\HR>
MJK+=-IUU'&(J2GD#=- ^*F9$QPX:\1T\59QVT;%JU"M?<R/2BJ2? ?5[SG/<
M4H\UP*Y4515MGDAJ;?Y1Y+6TDL3R&.W<1HYH#@2YI[0/2M,MVQCE:Y#?%:/>
MU'-4O#GA=*_$_5OH<"YH7>"\\SZ^6!U.&R=?41L@JNMZU[SX3ML(ZDR$#<YV
MGA<28%LU'S[3$HTG7*JV#9>M7+RFC]4*IGI^7O-B6"5T<L%)%-"YCBUS)!2U
MA#FZ=!U:./<6S$$]MGEJ/.'^XX\CDDG4]*N2D/BR8" ( @" ( @" ( @" (
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MJRA:]&^VM5*V9S%7V$HA#EO- 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MHCGFB#A%(Y@>-'AKBT.':.G2E CE3,=:R>0@" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @/6'J*_P"K,L_-T']^53XG[K=\ML.]Y=X]QJ@+PU]P]^SW"L@P
MT 0! $ 0! $ 0%-77F1S'JL^O&&X;:K;6?1C1*/*M[9#$!$'.+C41-/A2#@
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MNFYO_2ADOBR4-9;;324%PKGW.MIXPR>OD:&/F<.EQ:"=.^4,&>@" ( @" (
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M&" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @/6'J*_ZLRS\W0?WY5/B?NMWRVP[WEWCW&J
M O#7W#W[/<*R##0! $ 0$1J^66'5MS==9Z$]=(_K)8FR.;"]Y.I)8#V3T@<%
M128%:/DZQ6Y<]*Y. Z*+O%>QQ=4U^1$HBT2J)ODM8QL;6L8T-8T!K6M&@ '
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MQ!N[5IUT.HZ./% 5/ZM])-%B%QK'MV155P?U(X\6QQ1@D:]C4D?80'SU=/\
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MKM-0=9:"*7P"#T@EI8"/YS3]E 3?#<%L&"T#Z*R1.WS$.JJN8A\\SFZZ;W
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M ^L#AM=UKHP7%P[#CV1VT!N$ 0! $ 0! $ 0! $ 0! $ 0! $!O%@! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!K[A[]GN%9!AH
M@" ( @" ( @" (#37S%+!DD]OJ;U1^536N7RB@=UDL?5RZM.ND;FAW%C>#M0
M@-R@" ( @" ( @--^JF/_K'^MOD?_P",'5=1Y9UDO]GIMTV;MG1V=NJ W* (
M @" ( @" T]XQ:PW^NM=RNU)Y16V:7RBVR]9(SJI=S'[M&.:'<8VG1P(X(#<
M( @" ( @" ( @" ( @" ( @([D>"8CECV2Y!:H:R=@VMGU?%-M^"9(G,<0.P
M"4!K[1RIY>V*L97VVQ0MJXSNCDF?-4[7#H+1.]X!'8(" F2 ( @" ( @" (
M@" ( @" ( @" (#>+ " ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" (#7W#W[/<*R##0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
% $!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm2227887d4-bc_adverse4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-bc_adverse4c.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !&
M  #_X0,O:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C M8S P," W.2YD86)A8V)B+" R,#(Q+S T+S$T
M+3 P.C,Y.C0T(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UP.D-R
M96%T;W)4;V]L/2)!9&]B92!0:&]T;W-H;W @,C(N-2 H36%C:6YT;W-H*2(@
M>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HR1C8S1#A#13@X1$$Q,45$040V
M0CDT04)&,T,S-$(X02(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HR1C8S
M1#A#1C@X1$$Q,45$040V0CDT04)&,T,S-$(X02(^(#QX;7!-33I$97)I=F5D
M1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED.C)%,S@Q,T4W.#A$03$Q
M141!1#9".31!0D8S0S,T0CA!(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED
M.C)%,S@Q,T4X.#A$03$Q141!1#9".31!0D8S0S,T0CA!(B\^(#PO<F1F.D1E
M<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@
M96YD/2)R(C\^_^X #D%D;V)E &3      ?_; (0 ! ,# P,#! ,#! 8$ P0&
M!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1$1$1%!04%!04
M%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@#3 =L P$1  (1 0,1 ?_$
M -X  0$  04! 0             $!@$#!0<( @D! 0$  P$! 0$
M   ! P0% @8'"!    4" P,$"@P*" 0#!0(/  $" P0%!A$2!R$Q$U%AL11!
M<2(R4G+35@@8D=&R,U-S-)05E187\(&AP4*2TB.356*S)%1U-C=7@F-TM$,E
M->&BU(4)PN+C1*1E9.1%)H/#A+5&9B<1 0 ! 00'!00) @4% 0$!   ! A%1
M Q,A,9$24@0487$R!15!@:$S\+'!T>$BDE,6!A="8J(C-'*"LB0U\<('_]H
M# ,!  (1 Q$ /P#W\
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M3CB6BS*V%B1;C/:9X -T            !M.N(90:U[$IWX$9[SY" ;H
M       #:<<0W@:CPS&24]GNE;@&Z             VG'4M$1KV$9D6PC/:9
MX%N ;H            #:<<0@TDH\#6>"=F.T!N@
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M(\19B8FPUN0              &/6UW\GQ&_=N@LLA!
M          $\WY&_\6OW)@,'T0_TDLW_  N/[D!V            #8EX]6>\
M171VRZ0'TU[RWXJ>@!N@           VG?>7/%5T /B+CU9GQ4]';/I 4
M         FFF90W3_HGC^&)=("@MP#4           $LW'@;?#;]V7.72 J
M            23SPBK/Q?=%SET@*P            $LO'*SR\9OI[9?AV 54
M"            )9IF32<?A&_=ESD J             2R>_C\G%+W*N<OS]H
M!4
M   ZWK?^MMH?X%6_Z^" [(     2OX\>/ACAG5FW^ ?( J     32^]:^-1N
MQY>8!2     EFX]5=PQQP+=CR\VT!4     V9'O#OB*Y>3F :L>\M>*GH ;H
M    "6'WKN./OJ^7EYP%0    "5G'C2-^&9/+X!<NSV %0    "5./75[\O#
M1RX;S_$ J     2JQZXWOR\-?+AO+\0"H    !*]CQX^'>YE8[_ /D 5
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ML")""P21<Q$+.G21%D6*04             8];/?R?$;]VZ"SK9""
M                     )YOR-_XI?N3$&#Z(?Z26;_A<?W)"CL
M   &Q)^3N^(KEY.8!]L^\M]HN@!N            VWO>7.T?0 ^(OR=K'P$\
MO)S[0&^           ":;CU5W#''(>[''\FT!06X!J           ":7[SLQ
MQSHW8^&7( I             2S<>K+WYNYW8^$7)M 5             )9?>
MM88^^HW8\O, J             33,>&G#'WQO=CX9<@"D            !+*
MQS1\-W$+'?R'R *@
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MQX;G)FWH_&(JG$@2TQ("TQ("TQ("U,^1&_&W=\>_#'O#W8[?8!50
M                  PEO3N@E?SFHTEV7+K_ %<X4)$J0IR)"9622=.*QWK:
MG<I9U%CB)3HB>TJTV,V%               8];7?R?$;]VZ"RR$$
M                    8A>5\4*TV$-U=,U:YC;G"*# ES\$H+::SC-.$G?L
MS&0#C-$#)6D5F++]*EQU%CR&G': ["           !L2ODSV.[AJZ 'TS[TW
MXJ>@%;H(          #:>]Z<\570"OB+\F9PW9$\G)S; 10           "6
M:1=4=Q/9E/?A^<C+\@"DMQ"HU$4          $DXBX.)X8$MO?AX9<I& K
M           1SL.JKQW=SOPY2Y2,@%@            "6;AE:Q^%1OPY><C
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M"YI]<N"6BD:FP*\N2J*J7,22<J2D%D2ZATU*22#V)21[ 'Z(
M                             ,>MKOY/B-^[=!99""
M              )YAF4209;R;7A^J8#!]$/])+-_PN/[D@'8
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M7^5O^P7MA_'/,?V:MAZERW'!]E+E_E;_ +!>V'\<\Q_9JV'J7+<<-/LK<O\
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M[T/78          QZV>_D^(W[MT19ULA%0
M !LR?D[WB*Z!!^+CWRB1\<__ %BA]3R_RZ>YSJ_%+X&9B    !0$ 4!
M% 0          4!         %#$10$                   % 0
M        !0$               !0$      % 0     'K+T"?\^79_A#/_=$
M.7YCX:>]N8#WT.*VD\G#%C'X0N3D/E 4
MP/5JPSU-T[K]D(E]1D5>/DC2S22B:>;6EQI2D]DLR"S8=@!U[:4CTH*C6K=I
M5TTVB6W;M'47V@J\204]ZK--)R$VPRLL62<,R4I1[4_D 8-0+>CW'Z3%5MZ@
MU&/4M-Z!42ORHQXJTN(C7.\R<(HZU)[DE$XA4CA[R4 Y*YM&=0[@<UEMAJ#&
MCTB]9T6O4&N+E)-EQ^&F,10I$<BXA)<-E1*7M21'N,!R!6%J;>=T5:][BMJ#
M:DB)9U0M6E4>),;EN3Y4Y..=QQI*4-L(-.#258GMQ <=HKHS?>D\;Z(3$ZU1
M[MMQ/VC)Z2TX]3[CC,J:)"%[U1G$+R)RG@@T\X#<TYT?OJAU/0M^LTQE#-DT
MBLP[AQ>:>./*FI,F,A$9Y\3_ $D[@&/L:&:G4VV+3G1(!+K=IW57ZO\ 0D6H
M-0WWJ?6''.&N-)-*VD.)(R,B46[$@'>>BEF2K,M:6W/I3E$JE8J,FJSZ<Y4?
MI8TOR3+,LWB;:22EDDE+2E.&;L@.MV]$;NJNG6L]I2D,4NJ7O7JA4*+*-Q*T
MNQG%-.,&\;>)I2LVS0I)[DGN 3VOI=>TN%=E2KMLOTRZI5I/VM3GY=>:J763
M6VHR:2VVRVVVR2R(VUK5F(!CBM%M4*"5LU6%1W*PX[9$"T*Y2(=79I3L:3$(
MS42GUMNH=CK)1DLD;<=H#G;ITHU/8I<"R[:A.JL1NT#HL2E0JLB,N/6%Y\2G
M2W$)>D14I5E0E.!'AM1M ;$W2_4"FVKI^JC6I(5>=#MIJAS*U2*\S3)<9QLD
M_P!F<;>;=8?C&LLY]GF ?=PZ7:SN5"Q;[G(1<=VTVWY- N:%2)[-$<XTATG"
M>8==:4V:#+!#R226.].S8 [GTQLQ%F::TRTOHQ,#A1W2>I"YBI[;2WUK<6R4
M@T(-:,RSVY"PQV .I=-K(U;M:[Z-$IU(5:.F]..458I$NL,UVG'&66+3=-2;
M*9#'==TK.O BV8 .$T$MQNKZMW JFSV*MIGIM*J#5E2(JN(RF7<BTR9+:5[E
M''1F:[C=G ;RM%-0$:=+HK5*8*O_ 'EE=6!2&2-5*3-XQ/&YCAFX?Z../8 3
MW[I)JU]#ZM63;EM4VN4K4*I.UR#<+\UN.['4\39JCK96@U*<;-O!A>8D[<0'
M8MGZ<7)3=9:K=]2AH:HTJT*50XLY+K:W2F1E*XR$D1YBP+#NMQ@.O*3HUJHB
MW;5T@G4.F1;;MBXD5U=^M2TJ?DQHTQ4Q.2*22<3)<-7#<4I67#E ;]TZ)7Y5
MK<U.I[%(C/2KGOJ'7::A;S)\>EL/1U*6M1][@E"_W:MN_9M <M?^B5X7?6=9
M6:>TQ"IUXTN@L4&2MQ/">E4CNW&W4(S*0DS(D9C+L\@#)-'+%N6!=M2O2[K=
MDT6LKID>C-RI=;15W)#+2\YIX;#+;:&T*+]VHS-6&PR(!+K7$DS=1K+9A-.2
MG2IE9,T,I-Q9%GA[<"Q/#8,.+&AR?-**J\&+(F=/LAP'T!7_ .53/X+GM#6W
M9N?)]-B\-6R3Z K_ /*IG\%SV@W)N.FQ>&K9)] 5_P#E4S^"Y[0;DW'38O#5
MLD^@*_\ RJ9_!<]H-V;CIL7AJV2T.@5XL".ERR,]V+#FW\@;LW'38O#.R6OV
M?K_\JF?P%^T&[-QTV+P3LD^S]?\ Y5,_@+]H3=FXZ;%X:MA]GZ__ "J9_ <]
MH-V;CIL7@JV2?9^O?RJ9_ 7[0;LW'38O#5L<=<5NW"Y:-V1VZ5+4_(H5188:
M)A9K<=6S@E""PQ4I1["26\;?*1,8M,SHBUTO+\#$IQK9IF(L]L/%J=+]3<B<
M++KNXO\ ]G2O)CZ[/HOC:[VY/:U^Z[4[S*KOU=*\F&=1?&TW*C[KM3O,JN_5
MTKR89U%\;3<J/NNU.\RJ[]72O)AG47QM-RH/3#4TBQ.S*X1<ITZ27_\ +$SJ
M+XVFY4U^Z[4[S*KOU=*\F+G47QM-RII]UVIWF57?JZ5Y,,ZB^-IN5-?NNU.\
MRJ[]72O)AG47QM-RII]UVIQ?_P"%UWZNE>3#.HOC:;E0>E^II;[,KA%_ATGR
M89U%\;3<J;\/2356H26XD2RJVY(=Q-!*A/-$>4L3[I9)26SE,2<>B/;&U=RI
MR_J^:X^856_A-_MCSU.'>]9=3X>T"UM8;<>=L.KDVVDUK,F4*,B26)X$E9F?
M:(C#J</BA,N7"%I?J:98E95=V_\ YNE>3'O.HOC:\[E1]UNIWF57?JZ5Y,,Z
MB^-IN5!:7ZFGNLNN'AL/"G2=_P###.HOC:;E37[KM3O,JN_5TKR8F=1?&TW*
MFGW7:G>95=^KI7DQ<ZB^-IN5'W7:G>95=^KI7DPSJ+XVFY4?==J=YE5WZNE>
M3#.HOC:;E3VSZ$=NW!;EEW1&N"DRZ3)>JR'6F9S"XRUHZJV69*7$I,RQ+#$<
M?GJZ:JHLF-3;PHF+6?:_Z55S46FVY6+35#5=]G51%9I42J)SPI>4\%QWNY/
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MI'5:A/@E2ZBI;SSY28YJS'QR?6X3BS/>M6T]VX)TQ,>R3VQ-S@6_1BT6:/\
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M[Y1(^/?_ *Q0^IY?Y=/<YU?B][Y&PQ !M
M      -P           &     !V@#<  ':     "        W ',   !V@#
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MJES%TF J     2I+^W+/_E)]T?-^<!4     E41]=;/_ ):^E'-^<!4
ME>QX\;QU>Y/F/I(!4                  ,-N34:VK7DG F/.2*CAF.##0;
MSI)/<:L,"1CV,QCQ57%.MIX_-X>#HJG2V:!JC:UP2T4Y#CT&HO;&(TYLV3=/
MD0K%23/^CCB)37$O.!SV%BS9$Z6<#(WFR\^RP23?<2VDSP2:S))&?)M ;P
M -AUYEDB4\M+:3,DI-9D1&9[BV]D!O@ #9)YDG"8-Q).F6*6\Q9C+E(@&\
M        ,>MKOY/B-^[=!99""                            -F3\F=^
M+5T"#\7'OE$CX]_^M4/J>7^73W.;7XI?(V&,            ,         ,
M          #M  !S@            ':  #F             ,
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M^X+G/\P"L    !(GY<OEX2.3E/GQ_( K     2J,^NME_P M?2CG_, J
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MR=[Q%= DC\77OE$CXY_^L4/J>7^73W.=7K][Y&PQ   &         ;@#<
M!@   !S !@         !S@  0!N      #>   !VP                 @
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M]7R\O. J     2LX\>1ORYDX;_ +EV>P J     2IQZZO?EX:.7#>?X@%0
M  "56/76]^7AKY<-Y?B 5     )7\>/'PQPSJQW^ ?( J
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MQ&UZK_-5:]2PD2FXC")RTNS$H04AU!94*<))9S278(SQ,B%FRW1J2+;%@
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M192PP/8:L0&6 -F3\G>\170(/Q<>^42/CW_ZU0^IY?Y=/<YM?B?/2-AC
M           ,                   #$      .<          -X
M'9     .V         8  !S@  8 8   ';             ,      !IO$&B
M4I1CE(DX[\"P "2@CS$DLQ]G#;[(+;+Z%1ZR] C_ #[=G^$,_P#<D.3YCX8[
MVY@/?(XK:3O]\S\87+R'R *
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M #E/1SGK;U9OJC0)<=5N'2Z5,A0Z4],?I27UFXEU;#DTS6XKO4N+3L4?8QQ
M9GK%_J79G^%5KW<(? _UU_\ .C_KI?0>1?\ (]WVN('X._0   :XB@( #0
M %E/W5#_ *"7_5C[7^CO_HT_]-7_ (OEOZG_ /G8C#D[D]H?M[^?@5Y  !O0
M_ED;XYKW9!&MEH\4=\/50Z+]'>+O2*U7TWO"A5>.Q6:A3-0K%JB6Z=8E2:RQ
MJQ4&WV\AO0L%=9;5@?#5F+#?ARAZZMZ5.G4&ES*I&ZE49,..],A%_P" ^XV2
MG&^?(HS2 Y<!LR?>'O$5T -6/>&O$3T -T    !)#[U[#X5?)R\Q$ K
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M?C$]\HD?'O\ ]:H?4\O\NGN<VO7+Y&PQ@        !O ,   P ,0   .P
M                !M    Y@#M@        !    <P  ;P          YP
MY@      Y@#$ W  !V@       #     "           !ZR] C_/MV_X0S_W
M1#D^8^&GO;F ]\CBMI-)PQ8QW\0L/8/F,!2
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ME@K(1JQ2G$!]6MZ-.GMH7'3[FI<NNNU&F.&]'1+J\N2P:C2:3SMN*,E%@9[
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MD+ZQCAUN%>F1)ZG.OO\ )(7UE&#K<*]<B3U.-??Y)"^LHP=;A7F1)ZG&OO\
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MUZW'.9T[^.=GXPN@^<OS]H!0
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M^7EYR+\.R J     2L9NL2?&3[DN8NDP%0    "5.;KJ^3AIY>4^;#\H"H
M  !*K-UUODX:^7E3S8?E 5     )7L>/&Y<Q^Y/F/I(!4
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M9)LF9N8Z;8B+=:P1Z        8];/?R?$;]VZ"SK9""
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M?!SF9)_$1#'R7DW*<I-N%1$2]8_/8V-%E=4S#*AVFB   )8 H
M     QVVN^D^(U[MP"61                          #HSTL+=K]TZ,56
MC6U3)-7J[TN IF#";-YY26I3:UF22[!$6T!Q'I6H==T*CVRVT:JO<$^C4>"P
M18.=9>?;[TN5)),P'?#$0X-$;@FOBJC14LJ6>]1H;RX_CP >0+"_R70O^E3T
MF.?5KE\#SGSJN^61#RTP!H*\M1'H  &@KRU$>@   #<*@"@@  #-M*/\XH_Z
M5[_[(S87B=CRGY_N=\C<?9   VGO>G/%5T KXB?)F</ 3R<G-L!%
M    )IV7JCV.&&0]^&'Y=@"@MP)#4%          !+-PX/=;L[>_#PRY0%0
M           "2=\E7C_1WX>$7+L 5@            ))N&5G'X5O?AR\X"L
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MMZD51F,J(S.A1I"(;G?,I>;2LFSYTD>4P'- -J1[P[XBN@ 8]Y:\5/0 W0
M  $D/'*[\:OEY><S 5@    )&<W'D]M/+X)<X"L    !*DE==678X:>7E/GP
M_( J     2J(^N-\G#7R\I<^'Y %0    "5XE$]&+'])6._P#YP%0
M         #:6LFTFI9D2"(S-1G@1$7*8#S#>_I"W!-J,B%8QLPZ.PXIM-5>:
M*0](4@\#6VA7<H1CWIJ(U&/G>9\SJBJRC;+]2\G_ *0PZ\.,3F9FVK_#&BQQ
M]K^D)=](FM?:WAUJB&9)E.M,ICRV4=E:"1@A>7?E,L<-QC'@>:51597IB6WY
ME_1N#-$U<O,TU1&J?;]SU+!F1:E$8J$)TGHDE"7H[R#Q2M"R)23+MD8^EB;=
M3\EJHFBJ8G7#IV[O25M*W;DG6E0J+6[SKM),BK#-NPU3&X9G^BZYB2<Q=E);
M2[8D3;%L:KWF8LT>UF>FVJ5I:KT-==M24XI$=U46=#E-J8EQ)*"VM/-J[I*N
MR0]3%D1/LEYB=,Q[6>8EN!0C(RQ+< P+4S4ND:7TBFUBLQ),MBIU.+1FD0R0
M:D/33,DJ5G4G86&W;B/$3;731[:I)T4S5PPSX>P =8ZC:T6EIG7+9MNL)?E5
MVZIB(<&%$R*<;0M9-\=W,M.#1*5ACV?Q&%$;]<4QK2NK<HFN=4.S@4
M   8[;/?R?$;]TX"SK9$"                           QNMV?;]Q56AU
MJLPRE3K<D+FT@U+<)#,EULVN+D29)4HDF9)4HMF.S: YR7\E?^+7T& \:V%_
MDNA?]*GI,<^KQ2^!YSYU7?+(Q&F"   -!7D :B/0   #05Y:X@]6M >6HCT
M!BDLVTH_SBC_ *5[_P"R,N%XG7\H^?[G;=U7+2;-MVJ737738H])C.3)KJ2S
MF3;*<QY2[)[-A%O&X^S=961Z0$2Z;FH=N5RU:I:LBZX;M3M.34396W4(S22<
M5AP5J-MS(9+R+VX .ZP&T][TYXJN@%?,?Y,SCX*>C\8(WP           332
M445TRQQRGNQ_,9& H+< U           !+-QX1&6/?(W8^$7(9 *@
M     $LW$HRC+''N=V/*7(9'^4!4             DEXY6M_OJ-V/+S&0"L
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MG031^OW85[5BTH,NYB<0^N6M*B2X\WWJW&\Q-K,L-ZD[>R [,(B26!;"(!J
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MLTC-LOC&_=%_1,!4             G?QSL?&%T'S'^;M@*
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M&1=]R@/L!).P*(YCNP+?V^<RZ0%8    #8D^\/8[LBNC\0#Z8]X:\4N@!N@
M   )(>.5[XU?3S&8"L    !)'QZQ)\9/N"YSZ" 5@    )$X=>7R\)')RGSX
M_D 5@    )%'_;F]FWAKY.5//C^0!6     E?^41<>^SJP_4/G+\X"H
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MQZJSXB>CMGT@B@           $L[#JCN.[*>_#\YET@*2W D-04
M $DXRX/=8=^WOP\,N4R 5@            ))WR5>[]'?AX1<IET@*P
M      $DP\$M&?PJ.3EYS(!6             DFG^Y3FP]\;WX>&7*9 *P
M          $TC',Q\870?.0"D
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MNM[\O#7RX;R 5     )GL>/'WX9U8[_!/DV>R I
M                      !CML]_)\1OW3@+.MD0(
M         GE_)7_BU]!@L/&UA?Y+H7_2IZ3'/JUR^ YWYU7?+(AY:8   J B
M@   !BD@@      #05Y9OI1_G!/_ $KW_P!D9<+Q.SY1\_W.^1N/LP  ;;WO
M+G:/H ?$;Y,UXA<O)S[0&^           ":;CU5W#'-D/=CC^3: H+< U
M        !--QX.S'',C=CX9<@"D            !+-QZLO#'-W.[''>7)M 5
M             )9?>M88^^HW8\O, J             32_>DX8^^-[L?#+P0
M%(            "=_OF</A"Y>0^0!0
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MIVN6M65+=N>C(<D/+0<MK%"G5F1[>R1F/5,SO0VN4Q*IQJ(F9\4>UZ3&^^\
M   23B+JKF.[ M^'+SD9?D 5@    -F3\G>\170 UC^\,^(GH ;H    "2&1
MDE[#X5?3S$0"L    !(S\HDGSIY/!+F+I,!6     D3\N7R\-')RGS8_E 5@
M    )5%_;FS_ .6YR<J.;$!4     D?QX\;QU>X/F,!6
M                           #'K:[^3XC?NW0660@@
M            #8E_)7_BU]!@/&EA;+*H>P_DJ>P?*H<^K7+X'G/G5=\LAV\_
ML&(T[):X\Q^P8%DM-O/[!@6-<>8_8,"R3'9V?8,0LDQYC]@Q2R6FWG]@P+):
MX\Q^P8%DM-O/[!@62U+$^7#M&(M@>)<OL&!9+3;S^P8J62UQYC]@Q"R6FWG]
M@Q2R3;S^P8%DM<3Y_8,"R6;:4F?VO0>WY*]O(_Z(RX4?F=GRGY_N=]#<?8@
M VG?>7/%5T KYB_)F?$3T?B!&^           "6<1=4=Q/9E/?A^<C+\@"DM
MQ"HU$4          $DW#@EFW$MO?AX9<I& K             23_ )*O'^CO
MP\(N4CZ %8            "2;AE:Q^%1OPY><C 5@            )9I8M)Q
MP[]O?AX1<I& J             32,<S'QA=!\Q@*0
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M49]=;+_EKZ4<_P"8!4     E>,R>C%RK5[D^<N@P%0
M                         ,>MGOY/B-^[=$6=;(14
M            3S?DDCXI?N3 8#HG'95I+9QJ909_1C&])8GL[0/,TQ<S_JD?
MX%O]5/M ;L7'5(_P+?ZJ?: W8N.J1O@6_P!5/M"&[3<=4C? M_JI]H4W8N@Z
MI&^!;_53[0ANTW'5(_P+?ZJ?:%-V+CJD;X%O]5/M"&[%T'5(WP+?ZJ?: W:;
MCJD;X%'ZI>T*;M-S8E18Y1WC)AO8A7Z!<GXND#=IN?;$6,;*#-EOO2_0+D_&
M!N1<W.J1O@4?JE[0&[3<=4C? M_JI]H2PW8N@ZI&^!;_ %4^T!NTW'5(WP+?
MZJ?:%-V+H.J1O@6_U4^T!NQ=#5###9XH;2E7*1$0$4Q#>!Z  !LO8\%SQ3Z/
MQ -(N/5F?%3T=L^DP&^           "::9E#=/\ HGC^&)=("@MP)#4%
M      !+-,R9Q[&9OW9<Y=("H            !+.^2K_ .'I+G+I 5
M       )9>.5GXY'3VR_#L *@            $LPS)I./AM^[+G+\.P8"H
M          !._CF8^,+H/G+\.P H
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MY>7G(@%8    "1G'CRO&3R^"7,728"L    !*DU==6>&SAIY>4^;#\H"H
M !*HSZZWOPX:^7#>GFP_* J     2O&KBQ\"V9U8[_ /F,!4
M                               #'K:[^3XC?NW0660@@
M                #$+RORU+.92U<M1* N<V[U8C:==-60NZ/]TVO##$MX#B
M]#S)>D5F*3W254J.HO\ B3B0#L,           &Q)QZN]AX"NC\8#Z9]Z;\5
M/0"MT$          !MO>\N=H^@!\1<>KLX^ GH_$ WP           33#4<1
MW CQRGNQ_,1G^0!06X$AJ"@          EF&9L[/"1R^&7(1@*@
M   $LWY,K#''N=V/*7(1] "H            !++QRM?&HY>7F(P%0
M     ":8:N&G OTV^7PRY",!2             GDYL6</A"Z#YC 4
M                                          /--2M?7^UM4;^N?3BC
M4&H4>\505,RZM-<:<87"BDSF)II!XD2C4>&.W !MTG0"Z;;@Z2PH\EBI2[8N
M.=<5VSLQM)4_46W3<6P@R(S)*UD1)/;@0#C:;HYJ])O6Q+ANTV:G/M>X)L^K
MUQVJN.(D091.H8*)!R):C):)224@NZ,]QX .6AZ,7LQH+J5IZIF*5R715:U.
MIB.-^Y6S49"7&36YA@DS(NZ+#F 93=NFMS5>K:,RH+3'5['FID5Q*G23D;3
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M_C 5@    )59>O-[LW#<Y,=Z/Q@*@    $C^''C8X8YU88X> >[';[ "L
M                                        &/6SW\GQ&_=N@LZV0@@
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M            ":3AF8^,+DY#Y0%(
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M!N    ))V/57-^.!;L>7F,ND!6     V9&/ =P\!71^(!JQ[RUXJ>@!N@
M )(F.5WXU>_'EYS,!6     E8S=8D^,GW)<Y]! *@    $J<W75GV.&GEY3Y
M\/R *@    $JB/KK>_#AKY<-Y<^'Y %0    "5_-QHV&[.K']0^<@%0
M                                      ,>MGOY/B-^[=!9ULA!
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M3XR,?U2YBZ3 5     )4_+7/BT=)\WYP%0    "56/76S_Y:^E/-^<!4
M E?QX\;QU>Y/F/\ , J
M  !CUM=_)\1OW;H++(00                           !LR?D[WB*Z!!^
M+CWO\CX]_P#K5#ZGE_ET]SFUZY[WR-AC        -P   ! ',    0
M    8      !S@',  ',      -,1![U] G_ "%=7^,I_P"U:'#\Q\4=S>P7
MK<<QL     "29B;.TL>Z1[HN8_P]D!6             EG%C&67B])<Q] "H
M            !++QRL_'(Z>T?X=D!4             EF$9M%\8W[HN8P%0
M           ">3WS'QA=!\Q@*
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MZ>YS:_%+Y&PQ@       &(        !V@    #G                [8
M   'N >]/0(_R#=7^,E_VK0X7F/BCN;V"];CF-@     23C+@ECAW[>_#PRY
M3(!6             DG8=57CN[G?XQ<IET@*P            $DW'*UC\*CI
MYS(!6             DFF1,IQP]\;WX>&7*9 *P            $\G#,SC\(
M6'L'SD H                                             =!^EC3)
M=8T\HE-AG)0[(NBB-]8A(4I]A)R,IO(P(\IHQS$HR 89#TGF6]KY0J)6KCKM
MXTJN6K7(TJ;6W..<=MY;+2FFW$(02<Y*,\#Y $VAD"Y+FU"IUM70E\XVA467
M1..XLS1,J<UPVHK^\\<D%"=^.U6/9 =7Z9QZ9,8L55IPJT>K[=YOJE5-)3#B
M';K<Y_K>+IF<?JQ-]R:,<>)CV0',73 DG-O5FJTZON^DJ[<ZEV/48B)O"33B
MD-G#5&=2?5T1$,YB>2KGQ+$!D-ZVS,INL6I3UO4J0QJ56;29DV?4(S$C([5%
M1WD5!3#Q8M)<4@B2DE'OPPV@)]&Z1#2=>FVO,?AQRLZ3&N6@(IU98;?J)-GE
M>?>J"E(ZZA69*R:[XC ;>E-IJMJ?Z/=QTZ+4(]>N.GU6-=DMQV4M3J$PC-I+
MY.&:4<-6'"29%A@18 /O1MJC6WJG0J;1J1(NRJOR:@S4;F=BUFD5J"A9K4IZ
MJ-R5*B/I,^X2:3Y#(@''MP:L=F13N&)5)&F;6I5>=OJ)$1*XZX!K_LJG$,_O
M512<,N(2.8!\5^!43T:U+*T8E7BZ:R+CHIV%'?3*1(0P;[!35Q4.8/I8-TCX
M>;GP =Q:56O%L;7V_;9MV-)A6D[1*14$,../O1U3UK=0ZXE;JED:U%AGY>R
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MB1\<_P#UBA]3R_RZ>YSJ_%+Y&PQ            &X    P      P   @
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M'<;75H_P*/U2 ;P  DG?)'.T73SD?0 K     ;$GWA[DR*Z/Q@/ICWAKQ$]
M#=     21.]>P^%7N[?:(!6     D8QZQ)Y<R?<)YBZ3 5@    )$_+E_%)Y
M/"/FQ_* K     2*+^W-G_RU\G*CFQ_* K     2O8]8B\N=7N#YC_, J
M                                        !CUM=_)\1OW;H++(00
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M8]7:\4NCMF WP    $L3:E[XY?3VS_#L *@    $K&/6)/C(]P7.?00"H
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M>YS:]<OGG&PQ@   &            ';  #F                    (
M ( /< ]Z>@3_ )"NK_&4_P#:M#A>8^*.YO8+UN.8V     !+,QX/_$W[LN<@
M%0            "2<>$59^+TESET@*P            $LO'*S\<CI[9?AV %
M0            "689DT1_P#,;]T7.0"H            !/)QS,?&%T'SD H
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M_1W@,X  $DW'JKF&)'@6['EYB,_R *P    &R_[P[XBO<@-6/>6O%3T -T
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MKH ?BX]\HD?'O_UBA]1R_P NGN<ZO7+Y&PQ   ;P    #<          '.
M&                     !@  !@/>GH$_Y"NK_&4_\ :M#A>8^*.YO8+UN.
M8V     !+,QX.S'OT;L?"+D(P%0            "6;CU9>_'N=V/*7(1G^0!
M4             EEXY6M_OJ.7EYB,!4             EEF?"3O[]&['PRY"
M,!4             GD;V?C"Z#Y %
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MW@%R;?9 5@    )$X=?7NQX2.3'OC_& K     2KR]>:W8\-SDQWH_& J
M  2/X=8BX[\ZL-W@'R@*P
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M>_#PR\(!4             FD9<S&.'OA8;N0P%(
M                              ,.1IW:R;EN"['(JGJI<\)BEUE+ZU+8
M=AQ26E".&K86Q9DKEQ 8O!]'O3>E6[1+:I,:9!BV[.?JE"EQICS<V'*E8\4V
MWB/-E42C0:3QV; 'W]P&FWV,G6"<"2=NSZF=;-M4IXWF:@:B7UAE[,3B%9BS
M8YCW\X!3M M.*72;@HT6--3%NAR-(J[OTA*.2[(A%@V\3Y.$X2\=JC)7='O
M;](T*TYI=)N"D/4]^K)NE#;-?FU:4_/F2V62_=(6^\LUY4'WA),L#V[P&U#T
M%T\C6Y6[7ELU"JTNX4,M5'Z4J,N:\;<8R-@FUNN&;?",B-!HP/86T!REK:6V
MQ9-=J5VTHZA,N&IQ&H=2F39;LQZ4W$Q-K,;IX9D]Z1EAR /-'I+TBLZIW#9]
M(N-N+ILF*Q4I,6HW-.C*BRML9)M-G$<=RK(CS8*WD-SE,3<JMLF='L8L6+8L
MMLTNG?5P@?[P6-\^6.IU4\$[&OEQ>>KA3_\ >"QOGRQ>KG@JV&7%\'JX4_\
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MR *@    $K^;CQO'5[@^<OS@*@
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M\-/QC?+X1<AD J             3R._9^,+H/G+\_: 4
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M9:S6#@DB,J[#VX%\(-?F/ESW2R8<Z8?KB/F'1    23B,XKA<Q=/:5T *P
M  &Q)QZN[AX)]':/H &,> WXI=':(!O@    )8F.5[XY?3VB_#L@*@    $K
M./6)/C(]R7,728"H    !*G'KKGQ:.D^;\X"H    !*LCZZT?9X:^DN;\X"H
M    !*]CQXW+G/W)\Q]) *@
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ME]&     -I['@N>*KH_& ^(N/5V?$3T=HN@@%            )IN/5'O%/\
M#<?0 H+< U           !+,Q-G;NS(]V7,?X>R J             2S2QC+
M+Q>DN8^@!4             EEXY6?CD=/:/\.R J             2S",VR^
M,;]T7,8"H            !/([YGXPNA7,8"@
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MCCASX"BL  23\#B.9L,,"WX<O.9%^4!6     V9.'5WL=V170 U8]X:\1/0
MW0    $L/<]\:OIYC,!4     D9,NL2C+?F3CN\ N<!6     D29=>7NQX:.
M3'>?/C^0!6     E49==;W8\-?)CO3SX@*@    $CQ_OXN/A*Y/ /G 5@
M                                        QZV>_D^(W[MT19ULA%0
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M570 ^8N'5F<-W#3N[7, WP           2S?DCN.[*>_#\YD7Y0%);@&H
M        ))IEP>ZPPSM[\/#+E,@%8            "2>9=561X8=SOP\(N4R
M+\H"L            !),/!+6.'OJ-_;YS(!6             DFG@TG'#OV]
M^'AERF0"L            !-)WL?&%R<A\H"D
M                           'D75S5V]J'JY<MJQ=3J18-"I--@3:<BKT
M]N8<I^2VI3B$*,L^PR(S+;OV$ [#T<UTD791;(A7O!<@71==*G5./.0UPH$A
M-,>R.&DEJS(4MHR>))EWFW< WI'I)VPU0[5KL:@5J<W>LRH0K:AQ&&W94I5.
M,R):4<5)97<#4V9GNVG@0#=K?I'VE0:I*@SZ-650J-U1N[*PQ&0]!HLBH)2;
M;$M9.=^G.DG.&E1)[)@*;P](*UK)KTVUZS3:DJNI:A.V]#C,I=56RJ#A-)3
M42\%J;5L=)9IREMW /H]2U4_4J[:/,?J<QF@T"!5EVY%@-/FVN4LTX,.M+-U
MYU1EEX9EE+E[(#G+'U3IMY7%6K372YM%NB@-1Y$^FSR94HH\TE*:6ER.XZ@S
MV&2DFHE)/9@ P#7<L=0[+(]J2IM85@?CPQAQO#[W&\W^3'>Q'(CP2]@:CXTR
M(\$O8$4R(\$O8!#(CP2]@48EJPV@]'[WQ21D<:#B6!8?^H,CI>7?.CWNUY3X
MY[GB[@-?!I]@A]<[N]+7@,_!I_5(#>DX#/P:?8(#>DX#'P:?8(#>EGNA[32=
M9K!-*$D95V'@9$7P@U^8^7/=+)1/YGZU/)6XTXAM9M.+2:4N$1&:5&6!*(CV
M'AO'R[H/#VI&DEK6A7K:LW3^HU*X/2/JM;9K+UR+?<7,C4[C<1YZ;D5PVV21
ML0DTEB*/<R<V5)*VJ[)@/L!+.S=5<\+ MV/+S;0%0    #8D>\.>(K=CR<VT
M!],>\M>*GH ;H    "6+WKN/PJ^7EYP%0    "5G'K$G''+F3R^ 7+L]@!4
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MM'T /B-\F:Q\!/+R<X#?           !--QZJ[EQQR'NQQ_)M 4%N!(:@H
M        )IF/ V8XYD;L?#+D 4@            )9WR9>&./<[L<=Y<FT!4
M            EEXY6L,??4<O+S *@            $TS'A%EQQSHW9O#+D 4
M@            )G^^9W^^%R\A\@"D
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MT *P    &Q)QZL[XI]':,!JQ[PUXB>C\0#>     2Q,<'L/A5]/:+\.R J
M   2L8]8D^,GW)<Q=)@*@    $J?ERS_ .4GW1\WYP%0    "56/7FS_ .6Y
MTHYOS@*@    $K^/&BX[\ZO<'S'^8!4
M              #'K9[^3XC?NW06=;(00
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M<>$G'X1OW9<Q@*@            $\C',S\870?,8"@
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M7QS/N#&Q@ZI?4>2^&KOAVL-E]&     -IWWESQ5= #XBX]69\1/1VSZ0%
M         )IN/4W?%/\ #>72 H+<0J-1%          !+-Q)C;X;?NRYR 5
M            ))YX15GXONBYRZ0%8            "67CE9Y>,WT]LOP[ "H
M            !+-QX:?C&_=%_2(!4             GD8YF?C"Z#YR 4
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M7<,<<A[L<?R$9@*2W -0           2S,>$G#''.C=CX9<A& J
M    23<W5E;\>YW8\I<A&8"L            !+,QP:W^^(W8\O,1@*@
M       $LPSX:<,>_;W8^&7(1@*@            $[_?,_&%R\B@%
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MB_2E,G3V'&)TU7&2@I"$+-.6.LC/AXIQ/#-S /1   EEF9);P/#%QLNQX7.
MJ     23\.J.X[L"WX<O/L 5@    -F3[P]CX"N@!JQ[RUXJ>@!N@    )(F
M&5[#X5>[#EY@%8    "1C#K$G#?F3CN\ N3;[("L    !(G+UY>['A)Y,>^/
M\8"L    !*O+UUK=CPW.3'>C\8"H    !(_AUB-CX:L-W@'R@*P
M                                  8];7?R?$;]VZ"RR$$
M                   3S?D;_P 6OW)@,'T1_P!)+-_PMCW(#L
M  &Q*^3/>(KHYP'TU[RWXA= @W10          &T][TYCX)] *^(N'5F<-V1
M/)R<VP$4            EG9>J/8X893WX8?EV *2W D-04          $D[+
MP-OAM[\/#+P@%8            "2=AU5>;##N=^&&\N78 K
M2S<,&?C6^3EYP%0            "6;APDX[N(WOP\,O" 5             )
MI&7,QCACQ"PW<A@*0
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M]=679X:>D^?\P"H    !*K'KK1?\M?27/^8!4     E=QX\?QU>Y/G+H,!4
M                                          #'K:[^3XC?NW0660@@
M                           #$;QO*FVJPEJ=!J<PY;;N0Z93Y50R$@MI
MN&PA9)W[,Q[0'%:'F2M([-5V%4J,HLQ93VIS .PP           ;$K'J[WBJ
MZ.V72 ^V?>6^T70 W            ;3OO+GB'T"#XBXG&:,_!+H[9](HH
M        !-,QZJ]XI_AO+I 4@            )9AGP/^)'NBY#(!4
M      EG?)5_\/NBYRZ0%0            "67CE9^.1T]LOP[ "H
M    !+,,R;3\8WR^$7(9 *@            $\COF?C/S*YR 4
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M99**HF;+(>\!QVT    EE8Y6L?A4=/:/\.R J     2SBQB.%S%T]H^@!4
M   V)./5W?%/H[1] #5C'J[7BET=H@&\     EB;$O?'+Z>T7X=D!4     E
M9QZQ*Y<R?<ES%TF J     2I^6K^+1TGS?G 5     )5$?76S_Y:^E/-^<!4
M     E>QX\;ES'[D^8^D@%0
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M 5     ))'RB+XZN3P#Y0%8
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M.K[?#;WX>&7+@ J             1S_DJ\<,.YWX>$7*9$ L
M 2S,,K./PJ-^'+S@*@            $LW#A)QP]\;WX>&7* J
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MD:93:>J:NXVG,8SSZ'4-J:93E[M*<VUPE8&>PL0'=0  EF=ZUO\ ?4;L>7F
M5     )9N/57,,<<"W8X[^; P%0    #9D>\.X> KEY.8!JS[PUXB>@!N@
M  )8>&5[?[ZO?CR\X"H    !*SCUB3CNS)PW^"7+L]@!4     E3CUU>_+PT
M>%AO/\0"H    !,KY8WACAPU\N&]/X@%(    "5['CQ\-V=6._P#Y %0
M                                       ,>MGOY/B-^[=!9ULA!
M                         &S)^3O>(KH$'XN/?*)'QSW]8H?4\O\ +I[G
M.K\4OD;#$ &X        !H/( -1Z      ( W ':      'Z3>A9_H33O\1J
M'_<&/G.=^;+HX/A>A1I,H       ":;\D>RXXY#W8X_DV@*"W -0
M   33,>#LQS9T;L?"+D 4@            )9N/55X;^YW8\I<F!@*@
M      $LOO6L,??4;L>7F 5             )IF/"++CWZ-V;PRY %(
M       "=_OF?C"Y>0^0!0              ."F7=:M.DKAU"NT^',;[]A^6
MPTXGMI6HC(2!R<:4Q-8;E1'$/QG2);+S2B6A23+$C2HL2,CY2%%0
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M.HM%B,P*;#L>,U%@QFT--MMIDX$24)(B(@'I\  2R\32UC\*CI[1_AV0%0
M  "2?\D<[1=/:/H 5@    -B3CU9WQ%8^QVC &,>KM>*71VB ;X    "6'CE
M>^.7T]H@%0    "5G'K$KQD^Y+F+I,!4     D21=></]+AHZ3YOS@*P
M$JR/KK9_\MSI3S?G 5     )7\>/&\=7N3YC_, J
M                       !CUL]_)\5OW;@++(00
M        !LR?D[WB*Z!!^+CWRB1\<_\ UBA]3R_RZ>YSJ_%+Y&PQ !O  #
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M88@.\0    $TW'J;OBG^&\ND!06X$AJ"@          EFG@P6/AM^[+G(!4
M            DG&915GXO27.72 K             2R\<K./PS?3VR_#L *@
M            $LW'A%X[?NRYR 5             )Y'?L?&%T'SE^?M *
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MEY@%(    "6;CU5S#'' MV.._FQ,!4     V9'O#OB'R\G-M :L^\-X[\I=
M#=     2Q.]=W^^KY>7G 5     )6,>/(QW8IPW^ 7XO8 5     )4_+'-^7
MAHY<-Y_B 5     )E?+&\,<.&OEY4_B 4@    )7\>/'PW9U<O@'R *@
M                                       8];/?R?$;]VZ"SK9""
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M\WNQX;G)CO1^,!4     D?PX\;'PU9<</ /E 5@
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M7L>-&Y<Y^Y/G+H,!4
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M^73W.;7XO>^1L,8           !VP           #  #F  'Z3>A9_H33O\
M$:A_W!CYSG?FRZ.#X7H4:3*        FF?)'?$/\-Y=("@MQ"HU$4
M   $LWWG;X:/=%SD J             2S?DR_P#A]T7.72 J
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MUU?+PT])\WYP%0    "96;KK?)PU]*>;\X"D    !*_CQHWC*]R?,?20"H
M                                         &/6UW\GQ&_=N@LLA!
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MV#Z#!YC#IHIB9BV(AH5TZ?8W_N(UF\RJG^JWY09NJPN*-KSNR?<1K-YE5/\
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ML,AP^;KIJQ)F)MANX<3$.]1JL@       ":86,5TOZ)_AN/H 4%N(5&HB@
M        EFE^X+DSM^Z+D(P%0            "6;FZLO#?W/27,?0 J
M        2R\<K./PR.GM'^'9 5             )9F/#3\8WNQ\(N0C 5
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M'A)Y,>^/\8"L    !*O+UYO=CPU\F.]'XP%0    "21AQXV._.K#=X!\H"L
M                                          &/6UW\GQ&_=N@LLA!
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M ]GV0#V?9 /9]D!\K[P^T*/4]._]/B?$M^X(="-3]'P_#'="H5D
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MC?APU\N&]//A^0!4     E>QX\?#'+F5CO\  /D_. J
M                          !CUL]_)\1OW;H+.MD((
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ME<'$L<<R-V/AER&0"H            !+,S=75ACCW.['E+D,C 5
M    )9F.5KXQ&['EYC(!4             EF$?#3ACWR-V/AER&0"H
M      !L2-[.'PA=!\@#?             :'L(2=0\KVI4=7F(Q3JEI33[\J
M,:;-72KN>K-*7+5$XZS92;W"4>=HOW>*5%WN&!'B+1X8G5-BUQ&]5[8MT/2-
M%DU&=2(,NKP?HRIOLH<ET[C)D<!Y224MOB)(DKRGLS?C%JB(F]YAS B@
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M^0^8?O5[7VOIO+<$;#[47'_-)/\ $_\ 8'\B\P_>KVGIO+<$;#[47'_-)/\
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MI/PH[I5<VTM',2XVE1/&A/<I-9'C@7*,N)'YIBRQCIFV+61#RH
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MZ\OPN$CW1\_Y@%0    "56/76_BU]*.?\P"H    !(]CUB+RYU>X/G+\X"L
M                                          &/6UW\GQ&_=N@LLA!
M                           $\OY*_P#%KZ#!8>-K"_R50O\ I4])CGU:
MY? <Y\ZKOED0\M,     :"O+41Z &@KRT7WAB++U/3O_ $Z)\0W[@AT8U/T?
M#\,=SQIJ11M-W[YU;NM6K%5MR_*3&9>.E,._1!1WHD<CC)29X*F-F9%E)&XU
M=D5D>C]#[@N.ZM)+0N&ZTJ3<50IS+TXW$Y%*<46!.&G9@:TD2\/Z0#L8
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MX;_ +\7L *@    $J<>N+WY>&CEPWG^(!4     E5CUUO?EX:^7#>7X@%0
M  "5['CQ\,<N96._P#Y %0
M     ,>MKOY/B-^[=!99""                            )Y?R:1\6OH
M,%AXVL+_ "70O^E3TF.?5KE\!SOSJN^61#RTSG%0$5H*\@#41Z    ?*^\4"
M>QZGIW_IT3XAOW!#HQJ?H^'X8[F)W+I7IQ>-5BUZZK6IU7K,/ F)LR,VZZDD
M'W)&HRVD1[LPK(S!MM#2$MMI)+22)*4I+ B(MQ$0#>         ;;WO+G:/H
M ?$7Y.UCX">7DYP&^           ":;CU5W#''(>[''\FT!2
M FFX\#9CFS(W8^&7( I             2SL>K+WX]SNQ\(N3: J
M    32^]:P^%1NQY>8!2             FEX\).&./$;W8^$7@@*0
M     $\C>SO]\+=VE<@"@            !CUSVG;5XTQ='NJDQJQ2E*)9Q)C
M27VLZ3+!6"B/!2>QV1YFSVK$S&IY&LRW-,YRJK&BZ1T:3:\:BU6M6O4:J\AV
MI5(J3*.,X<M7#P92M>.3>9)PQ"VRF9GV1&S[WO<G>B/9,S'O^YZNT^GT6IV+
M;E2MZ$FFT.538KU/@(+*F.PXRE2&R(MG<D>78,N)$Q5-LVL-,VQ:RP>'H
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M;3P 6:\'_P#]#LH__P VUGW<08<7P^]Q?-_DQW_8Q+$N<:;XXQ+\"%#$OP(
MQ+G]@095IL?_ .^M.W[GNQ_RS&7#UPZGEG_(I]_U/0PW7VX   "2<6*&L</?
M$%MPY><C 5@    ))Y$<1PE;L"WX<O.1E^0!6     V9/O#V/@*Z &L?WAKQ
M$] #=     2PB[E[#X5>[#EYB(!4     D9(NL2B+?F3CN\ N8!6     D3A
MUY>['A)Y,=Y\V("L    !(HBZ\WNS<-SDQWHYL0%8    "1\BZQ%QWYE8;O
M/F 5@                                           QZV>_D^(W[MT
M%G6R$$                            3R_DK_ ,6OH,!XVL+_ "70O^E3
MTF.?5KE\#SOSJN^61#RTP     % 0  !\K[Q0)['J>G?^G1/B&_<$.C&I^CX
M?ACN5"L@          -I[WISQ5= *^(GR9G#P$\G)S; 10           "6<
M7]D>(]V0]^'YR,OR *2W D-04          $DXBX.W#8MO?AX9<I& K
M        23\#BK(RV=SOP\(N4C(!6             DF$1I9Q^%1OPY><C 5
M@            )9N!M)QP[]O?AX9<I& J             3R<,6,?A"Z# 4
M             DCP="F^C1<\VH5J]+FJ%GU-<VH0ZU:=,FS_ *(D-=:4;AH)
M,<S)F2:4NN(;4DE*,]@E%F[$^RR-#UB;V]5$Z+)G3V/:ULRJ'-M^ERK9-"K>
M=BLKI9M)-#?531^[RI41&2<NXC(9*K=Z;=;Q%EFC4YL>5
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M 5     -B3CU=WQ3Z.V72 ,8]7:\4NCMF WP    $L3'*]\<OI[9_AV %0
M  "5G'K$GQD>Y+G/H(!4     E29]=<+_EHZ3Y_S *@    $J\>NM_%KZ4<_
MY@%0    "5['C1>7.KW)\Y?G 5
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M2<R5;\![BR:9G5NS$;;7BJF8LG7$V_"QW>A"&T$A"22A)8)218$1=H0;@
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MZZL^QPT])_T?S@*@    $JLW76^3AKY>5/-A^4!4     E?S<:-XY^Y/F/\
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MPE'$>(M^4^7\Q'T *"W$*C410          2S<39P(OTD<OA%R$8"H
M      !)-^3+PQQ[G=CRER$?0 K             2R\<K7QJ.GM& J
M       2S#5PTX?"-[L?"+D(P%0            ">1FS,X?"%T*YC_-VP%
M           #"-1-,[5U0I46BW6V^["AR4S8W57W(CJ7T)4DE$XTI*BV*,>;
M-+U%4Q$Q>ZY/T1-',YO\*L=84GAJ>^F)W%-K''*:^+FPQVX8CT\NYJ)18=NT
M:!0::3G4*<PW%B\9Q3SO#9224YEK,U*/ MIF8M55LVI$6.7$4
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M@*P    $D[+U1W'## M^&&_GV *P    &S*^3O8[LBN@!K']X9\1/0 W0
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MR*Y.3GV /IKWEOQ4] #=           !M/>].>*KH!7Q$PZLUANR)Y.3F!%
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MIY<-Y\^'Y %0    "56/7$;\.&OEPWESX?D 5     )7MCT8OZ2N7P#YP%0
M                                          ,>MGOY/B-^[=!9ULA!
M                            $\PS*(^9;#)M>!_\)@,'T0_TCL[_  R/
MT .P            ;,G'J[N&_(KH ?3/O+?:+H ;@           -M[WESM'
MT /F-CU=K'P$] #>           !--Q**Z98]Z>['\QD?Y0%!;@&H
M    )9F;@[,<V9&['PBY#(!4             EFD?5E88X]SNQY2Y#(_R@*@
M            $LSO6L,??4;L>7F,@%0            "67B3188]^C=CX1<A
MD J             3R-[/QA="N0!0
M              E*9$-E4I+[9QD8YW26G(G+OQ5C@6'9 ;Z5)6DE),C29;#
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M2_MRS_Y2>D^;\X"H    !*LCZZV?_+<Z4<WYP%0    "5['C1>7.KW)\Q_F
M5                                            QZV>_D^(W[MT19U
MLA%0                           !/,+&(^DNRVOW)@/+&FWI5Z-6K85O
M6Y6*I*:J=+B(AS$(@R%I2ZUW*R)24&1D1EO&W3RF)5$3$:)[6.<2&7>N;H/_
M #B9\PD?L#UT6+=&U,V'9FG6I-JZI4)RY+.?=DTIJ0Y"6X^RN.KC,DE2BRN%
MCA@HMHUL3#JPYLG6]Q5$LU&-Z        3RL>K/>(KH[1] #Z9QX+?BET?B
M;P           -E['@N>*?1^,!I%QZNSXJ>CM%T -\           $TW;$>\
M4_PW'T *"W$*C410          2S2Q8P_IM^[+F/H 5             ))Q&
M<59>+TES'T *P            $LO'*SC\,CI[1_AV0%0            "69C
MPDX_"-^Z+F/\.R J             3R.^9^,+H/F/\P"@
M                             !^>T:O:IL>CI?U'I=I1)FGCDJOE*N5R
MHDU*:2N:Z;JDQ3+%7#/86"MH#NZO:T7#I@BHTRIE'>@2+-@5>P&R1@Z]4FTH
MB.Q%J,_WAJ><:<26_*9@.1K=W:V%?=I:84JL4:#7ZI::ZQ6:C.AJ=0FI1WD-
MN<!I#B<4F9Y<,3P+NMI[ &+-^D/?URT.P*31VHM(NJY2K!UFJMP)-98;.A/G
M&5U6(PHG%D\LLW='@A/* Y.H:N:RS:+IC CP8ML7E=U7J-$JWTI$=4SEALK4
MW+994I*R2HDDXE!GV<O. X&H71?^G>KFJ=W5:M,UR):EJT^;*IR8IL)D$MMX
MF$-_O5DQE>(W'%D2LR>T R>PM4]792IY71$34:5*MIZOP*]'I$NF18-0::XA
M0U]849/H41YD.I,LV4^4!#IMK%JS4JII94+N?I$N@:EP9ILT^#&=CR(DF#'X
MR%F\I:R5Q#[E2<F"<?Q@.2TXU0U,EWS3:/J;4X-O2ZL]*91:,VCRX;IK;S&T
MF#4C<4Q)[@B6KE[!$8#%[8U2NB#0XUKV= I%'N6\;_K]%BU%49:8$=N"KC.O
MNLI7B[(<(L,,Q9CV@.4N'7/4JU[(U BSCI<N^K K%)IIU2.TI$"='JRVE(-3
M!K4;;A)4:7")1Y=Y ,\TTO34!W4Z[=-;^DTVI2*1!@5F#4*6PY$234\UI4PI
M"UN&>12"-*SVF Z-]/\ ^4V!_P#-/<L#H^7_ #/<P8_A>,!W6@"@( #NKT2_
M]?[4\2?_ -HZ-/G/E3]/:S8/B?IK4(9SH,F$AY<9;[3C29+1X.-FM)ISH/L*
M3CB1\H^==!Y2TQL2B:<>EC4;:H)R'HY6@W+ES)SRI4R5+?E%Q7WG5]\M6&W#
M9LW /70  DE]ZUFP]]1O[?.9?AV %8    "2?@41S'## M_;YS+I 5@    -
MB3CU9WQ3Z.V0#Z8]X:\4N@!N@    )(FY[#X9?)R]LP%8    "1C'K$KES)]
MR7.?00"L    !(D_[<LNSPD\GA'SX_D 5@    )5'_;6R[/#<Y.5'/B J
M  2OX\>+RYS]P?.7YP%0
M   ,>MGOY/B-^[=!9ULA!                            &S)^3O>(KH$
M'XN.^_R/CW_ZQ0^IY?Y=/<YM?B?(V&-^B'H+_P"C<S_'9O\ 5,#Y_P P^9'<
MZ&#X7IL<]F        3RL>JO>(KH[9 /MKWEOQ4] #=           !M.^\N
M>*KH ?$7'JK.'@)Z.V8"@           $LW9$=(]V4^3\YET@*2W%VA4:B*
M         "2=[P6/AM[\/#+E,@%8            "2?LBKQ_H\G*7*9=("L
M           !)+QRLX_"HPW<O.9?AV %8            "6:9<)..'?M[\/"
M+E,@%0            ">3WS/QGYCYR 4
M                 .OXVD=CQ;%JNF[$%PK3K2YBY\53SF=2I[INOX.&>8L5
M&9EE/8 Q&\M'ZK>VH%C29[=,9T[L)Q-0IZ,'G:L_+0UPT,KS%PR92:4*/::E
M&D@'U?\ H@SJ)JM2;KKV1=JP*#*I2VF)#\2H)FOR$NI<:<8-!I3DS$KNOQ8
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M4/J>7^73W.;7KGO?(V&-^B'H+_Z.3/\ 'IO]4P/GO,/F1W?>Z&%J>FQH,P
M     #8D_)W</ 5R\G, ^V?>6\?!+H ;@           -M[WESQ3Z 'Q&^3-
M8^ GEY.<!O@           FF8]5=PQQR'NQQ_)M 4%N :@           FF8
M\'N<<V=O##'PBY %(            "6;CU9>'?=SNQY2Y-H"H
M !++[UK#'WU'+R\P"H            !-,QX19<<<Z-V;PBY %(
M  ":1WS/QA<O(?( I
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M-325@A)O-MKS-J299B2:3[ #HC_Z@'RFP#_Q3W,<='R^?]R>YKX_A>,1WVB
M   [I]$O_7^U/BY__:.#2YSY4_3VL^#XGZA#YQO@   ))G>-8_"M\GA<Y& K
M     23B(HCF8]F!;\.7G(R_( K     ;,GY.]XBN@!JQ[PUXI= #=     2
M0^]>P^%7R<O,1 *P    $K)?VB5XR>3P"Y@%0    "1.'7E[L>$GDQWGS8_E
M 5@    )%$776]V/#<Y,=Z.;$!6     E>+]_%+LYE<G@'S *@
M                                 8];7?R?$;]VZ"RR$$
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MAX9<I& K             32=[/QA<G(?*1@*0
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M    &Q)QZN[AX)]';+I &,>KM>*71VS ;X    "6)CE>^.7T]L_P[ "H
M!*SCUF3XR/<ESGT$ J     2IQZZ[R\-'2?/^8!4     E5CUUOXM?2GG_,
MJ     2O8\>-XZO<GSET& J
M      !CML]_)\1OW3@+.MD0(                            V9/R=[Q
M%= @_%Q[Y1(^.>_K%#ZGE_ET]SFUZY[WR-AC?HAZ"_\ HW,_QZ;_ %3 ^?\
M,/F1W?>Z&%J=]W>UQ;8K1(;-Q\Z=,2V1)S+S*946"<-N)\A;QSV9U=Z)<*;3
M- K0A5&._"F,M/I=C2&U,N)/K+ID2DN$1D [Q      &Q)QZN]XBNCMET@-6
M?>4>*71^,!O            VGO>5^*?1^(!\1<>KL^(GH[9])@*
M   333,HCI_T#_#>72 H+<"0U!0          2S#,F>0LS?NRYR 5
M      )9QX1E_P##[HN<ND!4             EEXY6<?AD=/;+\.P J
M        23,>$6/PC?NBYR_#L *P            $\COF?C"Z#YR 4
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MQ[ ">1Z2=JP[9:K[]&JR)S=?:M.JV^32%U.)5'T*6E"T)<,ED9$60T+,CS$
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M31,>:@$MNGPR=DIPC1T*/:EO#OS+,HS,P'KH  2R\V5K#X5'+R\Q& J
M2SL>K+PWX%R\O,1] "H    !LR,> ]XBNC\8#5CWEKQ4] #=     2Q<<KOQ
MJ^7E[1?AV0%0    "5G-UB5XR?<ES%TF J     2I-775GALX:>7E/FP_* J
M     2JS==;Y.&OEY4\WYP%0    "5['C1O'/W)\Q_F 5
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ME_ET]SG5^*7R-AB?HAZ"_P#HY,_QZ;_5,#Y[S#YD=WWNAA:GIL:#,
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MS(RYR 88S<5ZUC3;T9V6;KJD"J7/4W856JS$@URWFW26DS6I9J)9DG8G/CE
M9=2+BNC2S436.T*96ZG7Z/;UJMW/0XU9?74'&)BFS-1$XO%6!J/$T@.O;N3=
M%(]'^RM4XVH]=DW/=U2I;M:0JH'U:2<IXU*;8:3APB8PRGP^QCFQ >\9'R5W
MQ%= 2/Q=>^42/CW_ .L4/J.7^73W.;7XI?(V&-^B'H+_ .C<S_'9O]4P/G_,
M/F1W.A@^%Z;'/9@       &Q*^3/<F17)R<^P!],^]-^*GH!6Z"
M  VG?>7/%/H ?$7Y,UANR%R<G-L 4            FG9>J/8X89#WX8?EV *
M"W D-04          $LW#@;=V=O?AX9<H"H            !)/R]57CAAW._
M##OBY=@"L            !+-PRLX_"M[\.7G 5             )9V7A)QP]
M\;Y/#+P@%0            ":3AF8Q^$+DY#Y?S *0
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ME1J3TB*X3IK96993,FS,L<"+<,E%=4U63+?Y#F\;$QZ8JJF8FWZG>(VWUH
M "29WK6_WQ&['EYC(!6     DFX]5<WXX%NQY>8R/\H"L    !LOX]7=\170
M U8]Y:\5/0 W0    $D3'*[O]]7OQY><S 5@    )&<2?D^,GE\$N<^@@%8
M   "5)'UU>_#AIY<-Y\^'Y %0    "51'UUODX:^7E+GP_( J     2O$KC1
MR+'OE<O@'SD J                                           !CMM
M=])\1KW;@$LB      '2=?\ 1<T<N2O5.Y:I2)2JQ6'U2Z@\S4)<<EO++:>1
MMU)%N[! ,B@:(Z>4YFSX\:G/9+#D/S+:-R4\XMAZ6>+IJ4I:C<Q/L+W .8HN
MG%HT"M717Z? _P#,KQ=;=N W5J=;?-ILVB(VUJ-))-)F1I26!X@,;MST?-*K
M3K<:OT*DO1I,!:WJ=&Z],7"BN+/%1LQE/&TC;V"3@ [0<:;?;6TZDEM.$:5H
M/:1I,L#(^V ZF:]&_29FW*K:#-'>1;E7EL3Y-.*;)-E#\9PW6S9(W#X:249F
M:488]G$!F$_3ZUJE>%$ON9$4NY;?C/PJ5*)U:2;9E%E<2:"5E5B79,@"R]/;
M5L"FSJ1;$-4>G5*;(J4QEQQ;Z5R99XNG^\4>Q6&[< Q6D>CQI/0JZQ<%(HSL
M5^+(5.B06YLLH#$E1YC<;B$[PDF9\B<.8!]5ST>=)+CN"IW'5Z!QI]8+&K-(
MD26HLIS+D)UV.VM+:ED7Z1IV'MW@-^L:%:;UVU+>L^I4Y]VE6ME.@NIER&I<
M4B2:2R/H6EPNY[G:KL$ ^+IT#TPO"I(K%7I;R*KU=N%)F0YDN&[*C,D1(;D*
MCN-FZ22+>O$R(!S4O2NR9TVTZ@_3CZQ9"U+MO*\ZDHYK039F99^[V%^GB %I
M;9B*_=-SIA**L7E#13Z^^3SG[^,VV;*4DG'!)DD\,4X ((VBFGL.G692F:<X
MF%8$@Y=KHZP\9QWS,S,S5FQ66)[EX@.0=T[H+5SUV_*7'0W>M=IJ:5(F25+=
MC+::+]TE;.;*:<2+-AM/=B \P.>C'>-?^C:#)LR@6K'9JS51J-?IU7GS(Z8[
M3_%<;IU.?(TQS>P(E;?R /:$K9&>YFU= @_*BFZ!ZGUV$U6J73HBZ?/XDB,M
MRHPVE*:=<4:3R+<)23P[!D.YA<YA4TTQ-6F(<W$KHB;)JCX*O5LU>_E<'ZU@
M^5&7K\&]BWL/BC;#VIZ)=F7%8FF4JBW*PU'J*ZO*E(;:?:E)X3K;1$>=I2DX
MXI/9CB.3S6+3B5VTS;%CH8$Q-.B;7H :K.        V)./ >\171^(!],^]-
M^*GH!6Z"           VGO>G/%5T KYC_)F?$3T?C!&^           "69B4
M5W?CE/=C^8R/\H*J!            $LWWG9CWZ-V/A%R&0"H
M!)-^2JPQQ[G=CRER&72 K             22\<K6_P!]1NQY>8R 5@
M      )9>/"3AC[XWNQ\,N0R 5             )Y..9G#X0N@^<!0
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M!-V;I91IPAU-Y4]1MK224O8F:#(O>S[)D,F''YH=3RVF8YBG1/M^IZ%&Z^U
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MED7NW@.@K$U"NVZ;,IM?N/TFH5KUN<RI<JBRH5/4]%,E&DB6:E-F1F19N]W
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MQL>KM<F1/1VBZ" ;X           )II8Q'B_HG^&X^@!06XA4:B*
M  "69CP=N[.W[M/,?0 J             23BQBK+Q>DN8^@!6
M  EEXY6<?AD=/:/\.R J             2S<>&GDSM^Z+F,!4
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MKH_$ ^F/>6O%3T -T    !)#,\KWQJ^3EYC,!6     D8QZQ*Y<R?<ESGT$
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M1MX/A?8>3_(]\NP1G=H       !L2O>'_BU='X@'TS[TWXJ>@%;H(
M   #:=]Y<\570 ^8WR=CDR)Z/Q@-\           $LU1=4=,]V4^3\YD7Y0%
M);B%1J(H          ))ID3)8X=^WOP\,N4R 5@            ))V!15X[N
MYWX<I<IET@*P            $DW8EK'X5')R\YD K             23#(FD
MXX=^WOP\(N4R 5@            )Y'?,_&%T*YR E0
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M5\O+S@2J     2LX\>1CWN9.&_P"_%[ "H    !*G'KB]^'#1RX;S_$ J
M  3*QZXWOPX:^7#>7X@%(    "5['C1\.]S*S;_ /DV>R J
M                              !CUM=_)\1OW;H++(00   !P%MVK;]H
M0'*5;4%%.ISDA^8<5DU&V3\IPW7322C/#%9FHTIV%V '/@
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MKB**7'0VEU.#9XD1DV1ECNV&0]4X]54V3];;Y3S*<;%BC=B+;=+N$97?
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M^'A%RD8"H            !-(QS,8_"%T'S& I
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MZ>V?X=@!4     E9QZQ)\9'N2YSZ" 5     )4G_ &Y9?\M'2?\ 2_, J
M  2J/^VME_07TIY_S *@    $KV/'C>.KW)\Y=!@*@
M                         8];/?R?$;]VZ(LZV0BH
M            GE_)7_BU]!@L/&UA?Y+H7_2IZ3'/JUR^ YWYU7?+(AY:;N[1
M_P#RP[_U;ON4C;P?"^P\G^1[Y9TZTV^A3+R"<;6DT+0LB-*DJ+ R,CV&1EO(
M9W:24VETVC0VZ=2(;,"GM$?!BQ6T,LHQ/'N6T$22VGCL(!R0      GE8]7>
M\171VRZ0'VS[PWXI= #=           !M/>].>*H!\Q<>K,^(GH[9])@-\
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M*I,%4V578[B%PN,AQ*%QVS+OS3F+%:3RXXD [=  $LO'*U\8C=CR\Q& J
M  2S<>JN<ID6['EYB,_R *@    &S(]X=P\!70 U8]Y:\5/0 W0    $D3'*
M[O\ ?5[\>7G(@%8    "1DU<>5CNQ3AO\ N;\Y@*P    $J3/KJ]^'#3RX;S
MYL/R@*@    $JC5UUO?APU\N&]/-A^4!4     E>-7&CX;LRL=_@'S& J
M                                        !CUL]_)\1OW;HBSK9"*@
M                           #8E_)7_BU]!@/&MA?Y*H7_2IZ3'/JUR^!
MYWYU7?+(B$:<.[='_P#+#O\ U;ON4C:P?"^P\G^1[Y=A#.[0       #8DX\
M![Q%='XP'VS[RWVBZ &X           #;>]Y<[1] #XC_)F<? 3T?B ;X
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M%8    "567KK>['AN<F.]'XP%0    "21EZQ%W8YE9<</ /< K
M                                 !CUL]_)\1OW;HBSK9"*@
M                    ">7\E?\ BU]!@L/'^G]*J;MDT)UJ#(<;5$0:5(:6
MI)D9JVD9%@8T:J9WIT/AN;P<2<6J8IG7/LEDWT-6/Y=*_@.>T/-DW-/(Q>&K
M9+N+2B/)BVTZU*9<8=.4ZK(ZDT*P-*=N!X;!M843$:7UOE5-5.#9,3$VSK=@
M#,ZX       ">3AU9['=D5OPY.?8 ^V?>F_%3T K=!           ;3OO+GB
MJZ 'Q%PZLSAX">3DYM@"@           $T[+U1['##(>_##\NP!06XA4:B*
M         "6=EX&WPV]^'AER@*@            $D[#JJ\?Z._#PBY=@"L
M          !)-RY6<<,.*WOPY><!6             EG9>$G'##B-[\/#+P@
M%0            ":1ABQCA[X6_#D,!2
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M#17%W*W3HQ7"ME,1RJDRDY2HZ3S$T;N&;+CMPQ <R  ))>.5K?[XC=CR\QD
MK     23L>JN<N!<O+S&72 K     ;+^/ =Y<BNC\0#5CWEKQ4] #=     2
MQ,<KN/PJ^GG,_P .P J     2LYN/(QW9DX?JESGT$ J     2IS==7R<-/+
MRGSX?D 5     )5$KKS98[.&OEY2Y\/R *@    $KV;CQ\/#5[@^<@%0
M                                       ,>MKOY/B-^[=!99""
M                        )YOR-_XI?N3$&#Z(?Z26;_A<?W)"CL
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M_P M?2GF_. J     2OX\:-XZO<GS'^8!4
M                 #'K:[^3XC?NW0660@@
M  #$+SNYBUV$-N4>K514IMTB.D0'9Y-DE.]PT;$[]F)[=H#BM$.ZTDLQ6!EF
MI<<\#+*98HS;>?E =B            V).)QW?%/H[1] #Z9]Y;\4N@!N@
M        V7L>"YXI]'XP&D7'J[/BIZ.T70 WP           332QB/%_1/\
M#<?0 H+<0J-1%          !+,(S9_XF_=ES& J             2SODJ_\
MA]T7,?0 J             2R]S/QK?3VC_-VP%0            "69CPR^,;
M]T7,8"H            !._CG9^,+H/F/\P"@
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MHT]<;W8\-SDQWHY\0%0    "1X_[1%Q\)7)X!\X"L
M                        &.VSW\GQ6_=N@LLB!
M         $\WY&_\4OW)@,'T0_TDLW_"X_N2 =@            V97R9['P%
M= #5GWIOQ4] *W00          &T[[RYXJN@!\QOD[.'@)Z &^
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MQX\?#=F5CO\  /DV>R J
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MQ\(O! 4@            )Y&]G?[X6['D/D 4
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M286*6L?A6^3PN<C 5@    ))V!Q'#/=@7)R\Y'T *P    &Q)QZN[XJNCM&
MU9]X:\4NC\0#>     20^]>P^%7R<O,1 *P    $C)'UB5XR?<ES%TF K
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M;\D=QW93W_\ M(^@!26XA4:B*          "6<G%G$]Q*;Y/#+E(P%0
M       "2<6,59'_ $?=%RD?0 K             23"Q2UC\*CDY><C 5@
M          ))OO2<</?&]^'AERD8"L            !-)(\S'QGYCYC 4@
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MD R2\M=;<M"NR;<C4>LW)4:9#15*ZFA1.M(IT%TC4AU\U+;VFDC6248JPVX
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MOXI'NCY_S *@    $JS/KK9?\MSI1S_F 5     )7\>/&Y<ZO<'SE^<!4
M                                        #'K:[^3XC?NW0660@@
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M&7QC?NB_I$ J             3R.^8^,+H/G+\.P H
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M%5@@   "5)GUU>_#AIY<-Y\V'Y0%0    "56/7$'MPX:^7#>7-A^4!4
ME>-1O1S+=F5FW^ ?, J
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MNJNX8XY3W8_F(S_( H+< U           !+,,^#LQ[]&['PBY",!4
M      EFYNK*WX]SNQY2Y",P%0            "69N:W^^(W8\O,1@*@
M        $LS'AD18]^C=CX1<A& J             3R,<S/QA<O(KD!% *
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M  23<,C6/PK?)X7. K     23\O5',<,,"PQPPW\^P!6     V9/R=['P%=
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MXJN@!\1<.K-8?!IW=KF 4            EG9>J/;N]/?AA^78 I+<0J-1%
M        !+.R\#;X;>_#PRY0%0            "2=AU5>.[N=^'A%R[ %8
M          "69ERM8X>^HWX<O. J             2SLO!3CA[XWOP\,O" 5
M             )I&&9C'?Q"PW<A\H"D
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M6GI/G_, J     2JS==;+L<-7+RESX?D 5     )7L>-%Y<ZO<GSE^<!4
M                                        #';:[Z3XC7NW )9$
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M\!OQ2Z.T0#?     2Q,<KWQR^GM%^'9 5     )6<>L2?&1[DN8NDP%0
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MFX]4=\0_PW'T *"W D-04          $DTC-G;NS(]T7,8"L
M!+.+&,O_ (>DN8^@!4             EEXY6?CD=/:/\.R J
M 2S<>&GXQOW1?T3 5             )W\<[/QA=!\Q_F 4
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M\BGW_4]#C=?;@   )9IX)9Q^%1R<O.9 *@    $D[ HCF.[ M^'+SF1 *P
M  &S)^3O>(KH :Q_>&?$3T -T    !)"[U[XU?)R\QF K     2L8=8E8;\R
M<=W@$ J     2),NO+W8\-')CO/GQ_( K     2*R]>;W8\-SDQWHY\?R *P
M    $C^'6(O+F5AN\ P%8
M    ,>MKOY/B-^[=!99""-EY?"9<<(LQH2:L.7 L< 'B;36UM/-1K$O#7_7:
M+)NJH.5.=&4P?6)'4(<5XF&V8T>.HC+#,7>EB1 ,DT\ONW[!T-U*J>E5Q5&X
M(]H.NS*="N.(XT5,2^1*1$(EFA;C:2(SVF1]K$!GE+OO656E3NHM8D6I!F56
M)!ET>+.=?@08+<@LSKDN2M:^(K*>*6T$GNNYQ <#IGZ1%7JUXW3;%R3J/<=)
MH%"=N-NXK>:D1V5)C'^^8-$A2\QD6U*TJP =7:Q7KJQJ/Z.JK[N*#1HMC7%4
M(#U.IL4Y!U.)&3,(F'''%&;;AK-)9DDDL,<2Y@[3U"U[K%!OM&FEMU6W[;<I
M%*C5&IURZE/&PZ])01LQ&&V#0>)I,E+69["[&.\)U>D]7:YIA:%;M>BQ?O!O
M"N':L:+)<6=,9G-*,G7LY8+6UE(EH+9B2MH""W$WFGTOZ:U?B:>[6V+0?0W.
MI"741Y#!R,V<VW34IM6;,DTYC+9CB [/](/4NYM+;3H]:M6+'G5*?78%).+,
MSDVXB8I2322T*+*9F1$1X;.0!PE.U3U&M#52EZ?:JLTB1 N:GS*G1JE0TOM]
M7>IR#>>C.H?6HUD2"/*YLQ/L%B ZMC>F!7CB1[\>D6X5J2*HF&=EMN/G<C=-
M<>X)2S7CPS<+WQ363O>R [&FZF:KU_76X-*;).CQJ/2:;3JM]+5)A]Y:&9)(
M-:,C;B<RG#<P3CE))$ [COBZX5C696[NJJRZM1H3LMSL$I;2.Y07C+P20#P_
MIC-AZ:7EI=JI)KD675M2G)T/4".U*;>=8?J[W'B*<0E2E()LS0D\2+ R,!VQ
MZ25BW+.U'H%]U&S)&I>FE.I[D.7:<5];;L:6M:E=:)E)EQ<4X%A@>[;@ Y7T
M>6-$KGHEY6E9L*JP(,]22N2P*^IQ*8*7DK0:6&E'BEI>.!FE9XF6W#8 P6E:
M&:2R/2DK]AO6G"7:,2UXDZ-23XG!1+<>R*<+%>.)IYP'--6?0=7?2-N>QKT8
M<E6)IQ2*>Q;ML$ZMN$2GT)(W74)61N&1%@G'FY ':&G^BEG6!5KPM^B5ER7:
M%P,HX]@/NI>CP4NI4AQ3>99NI0Z1F1D>'Y,0'2BM"])"]*A%@?92']CSM/Z0
M.D]WP>M]8-'%[_'-ALW@/7D*F0:#0FJ/2HY1J93XQ1H<9O$DMLM-Y4(3F,S+
M*1$6TP'YDTGT>+SK].8K<2K4)F+4<\EAJ3,<0ZE#RU&1+23)D1ECMVCKX?F&
M#11$3,VQ%SD8F/A4U3$UQ$KO5@OS^=V[\_=\@,GJ6#?+'U.#QTGJPWW_ #JW
M?G[OD ]2P;Y3J,'CI/5@OO\ G=N_/W?(!ZE@WR=3@\=)ZL-]_P ZMWY^[Y /
M4L&^3J,'CI/5@OO^=6[\_=\@'J6#?*]3@\<'JP7W_.[=^?N^0#U+!ODZC!XX
M/5@OO^=V[\_=\@'J6#?)U&#QP>K!??\ .[=^?N^0#U+!OG8=1@\=)ZL%^?SN
MW?G[OD ]2P;Y.HP>.#U8;[_G5N_/W?(!ZE@WRG48/'2>K!??\[MWY^[Y /4L
M&^3J<'CI/5@OO^=6[\_=\@'J6#?*]1@\=+W+Z.MKU&R](J';=3>C2)T0Y1N.
MP7#>CGQ)+CA95J2DSP)6WN=XY6-BTXE<U4ZG5P:HJHMB;8=N#"S        -
MI[WISQ5= *^(F!QFL-V1/)R<VP$4            EG&1Q'<<,,I[\,/RF1?E
M 4EN(5&HB@          DFF7 V[L[>_#PRY3(!6             DG8=57CN
M[G?ARERF1 *P            $DW#*UC\*C?AR\YD K             233P9
M3CAW[>_#PRY3(!6             GDX8LXX>^%OPY# 4
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M^(!4     E>QX\?#O<RL=_@'R *@
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M]N)8]@!RVE.C<JPZ[7[UN>Y9%VWY<B6&:C5WV6XK:8T;WMEIEO$B27*9X["
M7PM+7H>MU5U>^DTJ:J-%9HB:5PL#0<=SB<3BYMN/@Y?Q@.%U"T/GU^]6M2M/
M;JD65?I1DP*C+:91+B3HK>U")#"\"4:>PK'DY %VDNC#>G4^N777JY(NO4"Y
M5-_3-P2T)9,V6?>V66TF9(0GM[<"Y %BM*W5:XIUA^DRX*:']!?1'!VXD\;O
M%XN;GPPR_C =CR_DK_Q:^@P6'C6P_P#)5"_Z5/28T*_%+X#G/G5=\LC'AI@H
M"  =@4  0  4  0!1Z TQ_R73^V]_6J&YA>&'VWE?_'I]_ULO&5U
M&V][RYXI] #XBX]7;QWY$\O)S[0&^           ":;\E=PQQR'AACC^3: H
M+<"0U!0          33<>#LQQS(W8^&7( I             2S<>K+P[[N=V
M/*7)M 5             )9>YK?[ZC=CR\P"H            !-,S<).&./$1
MR^&7( I             3/\ ?,[_ 'PN7D/D 4@
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M5XR?<ES%TF K     2I^7+^*1[H^;\X"H    !*HCZZV?_+<Z4<WYP%0
M"5['C1>7.KW)\Q_F 5
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MI :Q\>KM>*71VS ;P    "6)CE>^.<Z>V?X=@!4     E8QZQ)\9/N2YSZ"
M5     )4G_;EE_RT])\_Y@%0    "56/76R_Y;G2GG_, J     2OF?'B^.K
MW!\Y=!@*@                                           8];/?R?$
M;]VZ"SK9""       Q/4TR+3F[\?Y-4/^V< >,J=&G6_I9Z-NKJH4BH6I9?'
M^T:8C:GW8T>8O*4C(G::4&D\3+\X#OVF^DA;]]:@V[9NE$/[7PY7$D7)74D[
M'C4N(E)959UM%BXH]F39MV;P'5#=2U)U)UKOK4+3^U*==MM4IEVPX9U2?U%E
M#2,%3%,X$>?BJ4HE'V"P(!CMKUJIT3T:]9=&;H0F'<E@,R$IADYQ>' G&3S>
M1?Z24*-1$HMY&0#%M9[2J^GFE5.O&UFB38^I5NTFG7A"21\)BJQFFWH\PB+8
MDW<II/\ I;.R [GUJDZ4/TC3FD:KTZJTFGNTIAZD:BTM2VTTZ43",6''&24M
M.?*E6!I-)]C#> U]&R\;AEZDURS;?O.?J-I/ IR)#%R51A;:XT\W"245+ZR(
MW>YQQ[6/8/$,F]+)A;E-L.36H[TK3*+<D9Z_&&4K6V=/27<+D)1M-E*^_P!G
M)B Q*CR+2K?I".5;1=,8[*9M*8S?$NBH)JEN25)5U-"LA):6\DL#[DL23O 9
M!Z$MKV[%T9I5QQJ?&^GI\F<<BJ$RCK)IXZD$@G<,Q(P0192/ !]>D84RT-3-
M+M8Y<%^;9MKR)<2X78C2GW8;4Y"4(D*0@C,T$>\^QAV@&1T/TBJ)?VI%$L[2
MN%]JZ.MMZ3<MR))UB+3&227#))K1W:UF>&39V/Q%=(TS22I:GWYKV];MRU2W
MKHIE=X=*33Y2HT-YQQE2R3*0C#-B99"41]SS@CG]&+FL>'H#>M%?L1^;<E!<
M>CZCV@TXJ14IKRCR.2,7SSJ)2"-9;>YRF2>P8#K-FZ[6LAV@S?1HU&KM1K-1
MGQ6?NMGM/SF>&\LB>0X3B"X7#(S+''M* ?H0^:C@NFXDB<-I69..)$>7:6(*
M\<6%_DNA?]*GI,<^K7+X#G?G5=\LB$:( U$>F@KRU$>@ %0$4   !H*\O0&F
M/^2Z?VWOZU0W,+4^X\K_ .-3[_K8IJIK,=@5FB6=0+>EW=?MQ)>>IM"A+0QA
M&CD?$>>=<[E*2_+^(974<UI1J4SJE:QW BDS*'.8DO0*E2:@C*\Q+C*(EI)6
M"26G RP46PP5V""     #:=]Y<\570 ^(N/5F?$3T=L^D!0           ":
M;CU1[Q3_  WET@*"W D-04          $TT\&/\ C;]V7.72 I
M   23_DJ\?Z/NBYRZ0%8            "67CE9^.1T]LOP[ "H
M  !+-QX2?C&_=ESD J             3R._8^,+H/G+\_: 4
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M.8!JSCP6\?!3T -T    !+$[UW'X5?+R\Y$ J     2L8\>3CNQ3R^ 0"H
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M^BK=USW79U=.N51^XJ-2:U*IUKW-,1DD5&F-&61U6PL^&.&;L[@'H$
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ME2I=.8FNP'I+2V6YT<D&ZRI18$XDG$J29D>W!1&7* ZGL70)BT[OB7E5Z_\
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MZ/Q@*@    $C^'6(O+G5AN\ ^4!6
M           #'K9[^3XC?NW06=;(00                           !/+
M^2O_ !:^@P6'C:PO\ET+_I4])CGU:Y? <[\ZKOED0\M,    % 0 &@KRU$>@
M4!  =_Z8_P"2Z?VW?ZU0W<+4^V\K_P"-3[_K<_4:53*S&.%5X3%0A*,E*8EM
M(>;-1;C-#A&6)=H974;L6)&@1FXD-AN-$:3D98922&D(+L)2DB(BYB 6
M  #:>]Z<\570"OB+AU9G#=D3R<G-L!%            )IN7JCN.'>'OPP_+L
M 4%N(5&HB@          DG9>#MP[]O?AX9<H"L            !).PZJO-N[
MG?AX1<NP!6             EFX96<=W%1OPY><!4             EFY>$G'
M##B-[\/#+P@%0            ":3ABSC\)V<.0^4!2
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MV@/60  EE8X-?&HZ>V0"H    !+.^2N=HNGMET@*@    &Q)QZN[XI]';+I
M&,>KM>*71VS ;X    "6)WKN&_BKZ>V?X=@!4     E9QZQ*Y<R?<ES_ )B
M5     )4F?75EV>&GI/^E^8!4     E49]=;+_EKZ4\_Y@%0    "5['C1N7
M.?N3YRZ# 5                                            QZV>_D
M^*W[MP%ED((                            GE_)7_BU]!@L/&MA?Y+H7
M_2IZ3'/KUR^ YSYU7?+(A&BU[8* H(       =L5 10!W_IC_DRG]MW^M4-W
M"U/MO*_^/3[_ *V8#*Z@       #:=]Y<\4^@!\1<>K,^*71VSZ0%
M     )IAX17C/P3_  WET@*"W -0           2S#P8+QV_=ESD J
M       2S?DR_P#A]T7.72 J             2R\<K/QR.GME^'8 5
M       )9F/#+'X1OW1<Y *@            $\COF?C"Z%<Y *
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M,>KM>*71VB ;X    "6)CE>^.7T]HOP[("H    !*SCUB5RYD^Y+F+I,!4
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MAZGVOED3'+TV]OULQ&1TP       &T[[RYXI] #YBX]6:Q\$NCM%T -\
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M!<FWV0%8    "1.7KSF['AHY,=Y_C 5@    )5Y>O-[L>&ODQWH_& J
M2/X=8C8^&KD\ ^4!6
M#'K9[^3XC?NW06=;(00                           !/-^1O_%K]R8#"
M-$/])+-_PN/[D@&?@           GE8=6>Q\!6_#DY]@#[9V,M^*70 W0
M        ;3OO+GBJZ 'Q%PZJSANR%R<G-L 4            EG9>J.XX89#W
MX8?EV *2W D-04          $D[+P.ZW9V]^'AEX0"L            !).^2
MKQW=SOP\(N78 K             23<,K/QJ.3EYP%8            "6=EX*
M<</?&]^'AEX0"H            !/(PQ8S?"%OPY# 4
M                                #J^U=$K1M'4NYM4J8J0JNW,G+)8=
M-"H[!K-*G392224DW5)(UXX@.&N#T<K1KM9K$LZK6(%O7)*1/N:UH4HFJ54)
M2,IFIQ!H-19S2GB)0LB7V0'(UW0RVJ[(OMUZ9+CIOVEPZ+4&V#;2B/'@-*::
M..1H,R/ ]N.SD 7-Z0T%FZ*==93)9SJ=;?V18:-2.$N(9DHW3++CQ=G+@ X.
MF>CU;E%A6#%I5;JT*7IZ<A%+GL/-)>D1IKI.OL2"-LR4AS#*>5*=F(#<C>C[
M:T5JE,MU"=DI-V/WPQBIONIT@U&;2NY]Y+,>S?S@.)OS1"#(M^]WJ/!DW!5;
MNJ\.O/0NO(IKL:5")"$.PI'"4E#C9)):2<(R,\2Q <?HAIY>MNWO=>HE[,RH
M?TK3X-/9:JU0:JU4=ZGF-;[KD9)-H2>))0VV6PBW8@.O_2 H2O2/NNT;9L&2
M<2H4N-5)\EVM0YU/9-O-&:(FS>92:U&9_HEL+:8VN6QHPJK9N8L2F:M3KGU%
M=6/YS0OXLGR(Z?7T72P9$GJ*ZL?SFA?Q9/D0Z^BZ3(D]175C^<T+^+)\B'7T
M729$GJ*ZL?SFA?Q9/D0Z^BZ3(EGVB7HJ:@Z9ZGT2\:Y4Z5)I<$I2768;DA3I
MF_'<;3@2VDEO/;M&OC\Y371-,1.EDHPIIE[0'*;    "69WK6_WU&['EY@%0
M    "6;CU5S?FP+=CR\V!@*@    &U(]X=P\!70 ,^\-8^"GH ;H    "6'W
MKV_WU>_'EYP%0    "5G'CR,=V9.&_P" 5     )4X]=7OR\-/+AO/\ $ J
M    2JQZZWOR\-?+AO+\0"H    !*]CQXV&[.K'?X!\@"H
M                             &/6UW\GQ&_=N@LLA!
M              &'7E?%!M%A+=9.6:YC;O!3#@RYV!(+;F.,TX2=^S-AB XW
M0\TJTBLQ1=ZJEQU)[&].8@'88           -B3\F=P\!7+R<P#Z9]Z;\5/0
M"MT$          !MO>\N=H^@!\1<>KMX[\B>7DY]H#?           !-,QZH
MZ>W'*>['\V!@*"W -0           33/>>YQQS(W8^$7( I
M2S<>K+WX]SNQY2Y-H"H            !-+[UK#X5&['EY@%(
M":9FX2<,<<Z-V/AEX("D            !/(/ V?C"Y>17( H
M                                                 =;UPS/6NSRQ
MV?0E;V=IZ" [(     2O^_1<=^=7N#YC_, J     2RL<&L?AF^GM'^'9 5
M    ))Q8Q'"YBQ]GM'T *P    &Q*QZN[AX)]':/H &,>KM>*71VB ;X
M"6)CE>^.7T]HOP[("H    !*QCUB3XR?<ES%TF J     2I+^W+/_E)Z3YOS
M@*@    $JL>NM_%KZ4<WYP%0    "5_'CQN7.?N#YCZ2 5
M                              QZVN_D^(W[MT%ED((
M               GF&91'S+89-KP/_A,!@^B'^D=F_X6Q[D!V
M #8E8]6>\171VCZ 'TU[RWXJ>@!N@           VG?>7/%5T /B+CU=GQ4]
M':+H 4            FFD9PW2_HGC^&!] "@MP#4           $LW:Q_P ;
M?NRYC 5             ))Y8Q5EXONBYCZ %8            "67CE9Y>,WT
M]H_P[(*J!            $LPC-M./PC?NB_HF J             2R<<\?XT
MO<G_ $3_  [("H
M              !UQ6_];+/_ ,"K?]? $'8XH    ED8\:-XY^Y/^D7YP%0
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MW_"V/<@.P            ;$K'JSWB*Z.V72 ^FO>6_$+H$&Z*
MVG?>7/$/H$'S%QZLSXI=';/I%&^           ":;B41['P3_#>72 H+<0J-
M1%          !+-/!C;X;?NRYR 5             )9^)15_\/NBYRZ0%0
M          "67CE9^.;Z>V7X=@!4             EF^]%C\(W[HN<@%0
M         "63CGC_ !I>Y/G+\.P J
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M=@^==(^L(OE &V6H%B&LB1=%)4M9D24E4(RE&9[B(N)O,!E(
M               ,>MGOY/BM^[<!99""
M)YOR-_XI?N3$'4NCE[V9!TNM.)-N.EQI3%.80\P[-CMN(42=J5)4LC(R[)&0
MHSW[P[!\ZZ1]81?* 'WB6!YU4?ZPB^4 /O$L#SJH_P!81?* 'WAV#YU4CZPB
M^4 /O#L'SKI'UA%\H ?>'8/G72/K"+Y0 ^\.P?.ND?6$7R@!]X=@^==(^L(O
ME #[P[!\ZZ1]81?* -E_4"PULN(1=5)SJ29$E-0C8XF6S<X ^T:@V$EM"#NJ
MCD:2(C_\PB\GQ@#[^\2P/.JC_6$7R@!]XE@>=5'^L(OE #[P[!\ZZ1]81?*
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M"->%0C=RG ]^#@"C[P[!\ZZ1]81?* 'WAV#YUTCZPB^4 /O#L'SKI'UA%\H
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M6CLT>A4>*N%6*?49:EPF$\2+$?2XZV61O::DEA@?<\H#*ON_L7S8I/S"-Y,
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M8#%9FD]NR+]I-PLT&CIHD.FS84F(<)DE+?E/1UMK))-Y3)*6UEB?+SF RG[
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M R-*4I222+N2 ?0                          QZVN_D^(W[MT%ED((
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M_=_8OFQ2?F$;R8#3[ 6)YL4CYA&\F U^[^Q?-BD_,(WDP#[ 6)YL4GYA&\F
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MP'(?0E&^B_H/Z.C?0N7A_1W!;ZKEQQR\+#)ACV,-X#E
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M@.QP   =-ZZ:@5RAT^-8E@$3VI=U-OIIA_H0(3"#.34'C+O4-I+*WCO69%S
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MW#7TX@/T)M^I_35"I=8)!ME48D>8:/!X[1.8?BQ <L
M                        ,>MGOY/B-^[=!9ULA!
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MHF:G':2_QF#,BR),SRY2[ #UL
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M]'?5==J6]H].:H<:TK>KB*TF^XSKGTJ^VT^I\B*/D(TOKQRK<-S# ![&
M >4;ZT<UZOJ?7[&JU4HLK3ZOU!#Z[L=:)-<CTA#B7?HY#3:$DHB-)$2E*PY3
MP/ !ZAI\%BEP(E-BI),6&RW'81R-M))"?8(@%H
M                    QZVN_D^(W[MT%ED((
M      .GM==-;DOF/;%?LF3&8O:R:JBM4=NH9NIR#).1QEQ1$HTYRPP,MWY0
M$.C.G%ZT2Y[PU/U)5!;O2\5QFUTZE*6[$A1(*#;;1Q%D1J,]ZCY@'=X
M     ZAU0I>N4>XZ3=.DU2I\V!&8=BU:T*R9L1I"W#Q1(0^VDUI4GLIS%^/$
MP#0C3&M:<4.M2;IF,3;QNNJR*[750B641J1)PP:9S$6*4$6T]F)X@.W@
M       =,6EIY<U(](&_M19K;";8N&FTV'35H=)3ZG8:4DX:VR+%)8D>&T!U
M/6_1]U@1!NG26WIM(+1^\:TNLRZK(4[]*0V)#R'7XS;9%E6:C01)5C[&)@/6
M5.A,4N!%IL8C*/"9;C,D>T\C220G'\1 +0         !TMI1IQ=%HWKJU7*R
M33$"\:TBH41Z.Z3CG!)E;>9:3+N5$9D9$8#KBN:2>D7?42/IGJ!6J14+ :JK
M51F7:DE)J\J)'>XK<;JZ$I0A1;"S?E,!ZK;;0TVAILL$((DI+D(BP(!N@
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MX;" >D@
M
M                                                    !CUL]_)\
M1OW;H+.MD((
M
M
M
M
M                         #'K9[^3XC?NW06=;(00
M
M
M
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M;#3]6COU>(T_0FVWJVA;Z$=30\DUH4^9F1()1%F+-@/-NBWV+[;$$34BPI]
M<N>%<E.D6VRZF.[5&Y3:HR77%DA*%+(\"4:C)."L-X]6:NTUZDC^JNGR*-7Z
MY$N.G3(=MH4JK*C2V7> O<2%FDU$DU*[E./9'BJJRFUZIBV;''VGK-8US:?P
MM1WJG&H]"D$2)1SY#2#BR588QW59LO%V[4D8]U18QT3O:F:T>M4BX*>S5Z%-
M8J5-D%BQ+B.)>9<+L8*09D?.+-L+$Q.IRPB@
M                                                       ,>MGO
MY/B-^[=!9ULA!
M              !B5\7_ &EIS0UW#>52;IE+2I+:5K)2W''58X(;;01J6K8>
MQ)#U1155-D0DS$0AT[U6L75.GO5&R:JFH-Q%DW+CJ2MB2RI18ISM.95D2B[T
MS+#\H]8F'51-DQ8D51+B=1-8+9L"JT.B3:C";J52FLMS&I3QM*CTY:'5N23P
MQV$2"2G'>:B&&)MFRZ)M]T/<Q9%OTUN4TLOR/J19L.ZF#8)<E;J'F(JS=0T:
M7%$A"E&1'GX>52N0S'J8LL[H2)MF8NERA7]92[C^R";AIYW66TZ/UIHYF['
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MDG?S!&G43H94
M
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M>?!BO4V-5VU92*HHAOF:F>*>/<[MF)"3X:?9HU7/7^*?;VNZA%
M
M          8];/?R?$;]VZ"SK9""
M                             #S'Z7^DEXZFV[0JC9;"JC.MZ0^X_1DK
M)"WFY:$IXC>8R2:V\G>F98D9]D;O*8U.'.GVL.+1-4:&,>AWHM?MB5FNWE>4
M%RB,SX:*;!I3ZD]8<-+I.J><0@S)!)PRH(SS;3_'DYW'IKLBG38F%1,,GUYA
MWFY=ZY5*JK285$MVIU:%'^BNLK0[)2BGDSQ4N=VITW%&@\.XV[#(<K=F8JB=
M-MD?JG\&W$V;L]ML^Z'=%@6[5;6LFE6]4)C,R=!BMQD2(\8HB"2VV26R-LE+
MVI(B(U8]T?(,F+,S;9K8</1$6O);-,C_ '<1=*46Y-]8%JXREN33@/$\F253
M.0JJ?2&3(;)L?I<3^C@+1-LT33HBFRW[;?>M>JNW3O6V?8[ST_IJ6?2"U7DK
MA$@CC4 V)!L94&X<1PG3;7E(C,S[_*?;$P_!/_5/U0N)XJ?;^7_^I8/Z0C5G
MIUKL67J"B<BT6Z+5$/RJ<F=G3(4ZWPDFNGEQ=IX[!*++:K;H^O2]UV[E-G%-
MNQ\7-/M&#IY;VIVCK%0JL?3*L.NG%DHGG,>BU!"F9C)'.3QU$?%0OLI++L"N
M:J:HF^)IV_=+Q395$TW3$[/OACMTV!7[/M32.I5%R3&H\"14:O>=3BTY%85$
MJU91QTR7H;B'"<2VM:FC7D/A[R(6;**[(G1%.['T[4B9JHF?;5-LM$VC15TJ
MRG*8[/N.AU_4N/4)1U*D%38J\8CB7'&(9(2E,92B(\QH2DU?E1HJHBZ*OI]R
MU3;37/MG=CX_<Y"\[5?6CTDZ+0:*K@/Q*1*IT&+&R-N2$PL75L()))4Y@7=&
MC;CSC#'RIF?9B?;2]3;G1$>W#^/YOP57I4;3G'8M\TZ9.H)E;SL*G5J;0%U>
M@.I4HDO09$/(3[#ZEHQ2HDIS)Q+$QL8D_GJLT[WLOTVL>%'Y*(G_  SLFRSZ
M2[KT**4G2NW.N6VBTWS96OZ"82M#+"3><-*D-NF:VTN8DX3:MJ<<.P+7[.Z"
MGV][LX>'ITYJM:=>GUJ+<%(B+J,<HO4WXS&"GVC2LUDLDF99B5C@>!XD,&+1
M,Z8<+S/E*\68JITV.7TFMBLT*)4Y]79.([5'&E-05&1K0AE*DYG,,2)2\=Q&
M/6'3-,:6QY=RU>#1.]KF73&L%!OFLWM=+4:L,JAG"I=!B-'2,_[JXJ@1+9-S
MB;5-MM$M;O(>!I(>Z(MGOJB-D;SKU39&CV4S.W0[[K=$N-6FU5M^!-;?NI=)
ME1(<Z.R4%!S%LJ0A:$)4KAEF46&"MF_$><:VJF;#"_+,6O-5KLT:M-Z.6E8]
ML3*3J%9M1B/W=(<IST-=/BQV5(J*9$E2$I<ZRM6"2):N(>T;$3$XF]'@LGXQ
MHT,6F*)IGQ6Q]>MVUH7341+HU;<ZB4?-=LGJR^%P\[)QF=B,2+%&.[+LQ&##
MG_9I[ZO_ ">JOF5=U/U,<UC?L1R]WF]3:'5K>.'$:5:6H]O'-.4Z:S4;T93D
M%M2FUH7AE;=)25%MV!3[9C15;M^]ZG5%NF&',UR\X,'1S4;4Z/4G:?;]9K;,
MNK/0G%SRIDN.MBGR9D=A*EH6X1=V>3?AB0RTS$51;HFJB8F[>MAYLF8JB-,1
M5%E]C'ZVZW6:)<]:71:A*HTW5JESU4]VGOG(?@)CH-2NK*3F4E22,\#+;N'B
MC1--OLJJGX2]XDS5-=G!3'U+KO52[@AZYWI9%,=@6!(M*/3E/JAN4Z/+J\9:
MU.+;9<0V:C;:/(I>3F&.JV,.;=4U4S'P^G:R469E-FN*9MDNRF.TZ_)%5N^I
M3*-:MP6K1X-"J+-!;N*.\AF-DDPR);+YL.&M6?!)%GQQQV$,E46S7$ZYFWW6
M-?#F8IHF-40YR%3K?TSNRSZQ?L"I5?3QBRVZ-0:C5:8Y+>BSB?-QQJ3&;0Z;
M+KS1I2G%/Z.3$>IJ_-5$ZYB(V1I]]NDB/R4S&J)FWOF='NUPHJL:WK;EZ&7/
M%M2H6Y9$*?56EP9L5R7)@IJ32DQ$OMHXRVT+</,VD_>RY,!:9F*XB>&SWZ'J
MJR<.J8XHGW:6/W&Q"I%X5BFT6CR*U4ZI=3=0G:?W!17')+KSCZ,]1I]9C&61
MA*2)QOB+,DD1I/#</&#_ (8NF?\ MUZ5Q/\ %-\;7M45
M
M
M
M                   8];7?R?%:]VX!+(0
M
M       &$:C:?4W4R@?9BL3Y\*CNO)<J#-.?*/UME.)''>5@HS:7^DE.![!Y
MLTQ-SU$Z)9=$BL0HK,.,@FXS"$M,MEN2E!$DB+M$0]3-LVR\Q%D:%(
M
M
M
M                                 ./I_P!&9G/H_+N3Q,N.[%>&_GS
M.0
M
C                                           ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tm2227887d4-lc_rapidly4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_rapidly4c.jpg
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M -H  0 !!0$! 0             ' 00%!@@# @D! 0 " P$! 0
M   ! @,%!@0'"!    4# 00#"@@)!@P% P +  $" P01!082(3$3!T%A%%%Q
MD=$B4I)3%0B!,D+2(Y-4%J&QX6)RHC.45?!#TR0T%\'Q@K)SH[-$=#5U-V.T
M)3889"8XPH.$1656)U?BPY41 0 ! P$%! <%!P,$ @,  P !$0(#!"$Q41(%
M06$3%'&!D2(R4@;PH<'18K%"DJ)3%1;A(S/Q<H('LL+20R0TXF/_V@ , P$
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M,*"^
M
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M;'[*VMNVPR44=MQ:G5$2E&HRU*/NF+73,[91$4<M>]9_[^M'_3$?^8<%M/\
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M>"M\N\4CXTW,7/4VXX^[(6GAD;CQDHR2BIZ4E39M%KKN::JVQ2&ZBJP
M
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M?PBMULQL3$U;*(2
M
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MS6K:I:E*,S-1F0F;IG>K$4W,\(2
M
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MN(3,E&0
M %C<+?"NT)^W7%A$F!*0IJ0PYM2M"OC)H6^I"*)B:,9CF'XOB:'V\;M;%L1*
M-)R4QTZ2<4@C(J[3K2HM6912&PB
M       10!(" $@
M
M
M
M /A:T-H-:S)*2^,H]P#[
M
M
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MHJ^: PUWS?%K#)C0[Q<FHDN;_9FEDNKGE$G91)])D0#,G-BD9D:SJ7YJO%U
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M3JZP IT8SV+/T5=75U@*HF,.*)*%&9GN\D^KNEU@A=
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M+<Y,+^:3*:-53Z"/50!M)'JVEN 5
M           !SSS[_P#?N&=]'_FD"T=HZ&%0  'R9GW*[ 0A#F)S[9QNXO6'
M%XC=RND4S1,EO*445IPOC(3IH:U%T[B(;C2=,NS1S7;(<7UGZIQ:*_P[(Y[^
MWA#3+5[R.61923O-LB3H1F9N(BZH[Y)[J#4:DU_2(>_)T6VE;;G.Z?ZZNYZ9
M<<<O=.UT-BV36C+K+&OMC>XT&14BUE1Q"T[%(670I)[#(<YDQW8[IMNC:^G:
M74X]3CC)CGFMEG2.I#&]$*@D                         1%[QG_;Q/\
MU"-_FN"8WC=.7/\ [#QO_I\?_,("6TB
M
M                         4U;:4$"HD! "0                 ! !4"
M.HD     %/Q@'? 5           0  ) 0 D  0,=.NMMMC1/W*6S"84K23DE
MQ#39JWTJLR*H)7##S,EE#["R=9<(E-NH,E)41[2,C+89&)0N0 !2I *@
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M;S.RB]WF1D64W%M$9VXR$)92AA!_$;;09DDJD1B9D;K=/^7R/T0@7H@
M%#422J8C<-;BYUA4^2<"!DEKDSB,TJC,38[KQ&DZ&6E*S.OP"4RV(E),B41U
M(]QD"&A\T\W9P2RQKF_:T74GY),$PXHD$D^&I6JII5YM-PF-HVZSS"N-H@3R
M:)E,N.R^3);223J"5I^"M! R(   ./>??,6Y9#DTS%(KRF<=L[IQW&$&:>T2
M4;5J<I\8DGY*4[ND6B"4.Z4F6G25.Y0J"R'0WNY<Q+F=U^X5V?7)@.M+>M#C
MJC4MA;):EM$H]N@TEJ(CW"LPF'3PJ
M        ^5'I*I[ND!;1IT.62CB2&Y&GXW"6ERGHB!=B1%_,6[<NX&16)C,+
M4Y.O#QE[,?0@W";^F215/6GY9D>XQ,"3RW"!4  8;)9DBWV"ZS8NV3&AR'FM
M.\G$-J4F@M9%;HB>+%FNFW'=,;XB7!32C<;)UQ6IQ9<1Q1[U*4>I1F?29F=3
M'TBRV+;8MA^8\M]V2^;KIK,S-?:^BIWA?MJ\\0G[W8ILKCY';:*."GLTE)G\
M1+RM3:J=RI)*HY/K5D<]MW;+[!]#9K[L.2R?AMG9ZW1I;ASSZ2J
M             *&= &MHSC"W)ZK4G(K8JZ(6;:X)3HYR$K3L-)MDO57JH(B:
MI9]#B'4)6@]2%;4J2=2$H:9S0N&(6W&RD9O 7<;+VEI!1VTZS)XR5I.A+1NV
M](F!G<7>M4G'+9(LK!Q[0[&:5!CJ*BD,F1:$TJ=*=\0,X            ( *
M@)
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M-")T8R+4E#VWZ5*^A1;>[L$H2 "               6-U_Y>_P#H"8%\(
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M[?E5OCW7E[=KC"0^TVM$VP7QTG%)-!*2:TJ4Y11[-1*01U[@R3$[E(E-O+'
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MDV932N%.AJ,E*8=(B.E2WI,CJD^DAS^?!.*ZDM7EQSCFDMQ'G802
M
M                            (+]ZJA<N(M2V>U&#/ZMT5_?M9+?@N^W:
MTG&N6W.W(L/MB(N;,Q,7GPT$S"UNDIN*M&QLR0T7R=AD2QGOI%VU@MK38D>W
M\J;#R^Y7W^T&E%TF.PY4R7,DM)5JD-L*)"D)54D$V7Q>GI&++?S1LV49,<4N
MV[:RUKW4X,%>'S[@N,TJX(N"VT2S;2;R4&RBJ27341=51GR?#;Z&*W?/I=#D
M=2'G9%1(              #EJ#_^63]"/8;G@*#M&7%\$^O]J,OQ6KGWK;A%
MF_=G&XBB>O"GW7CC(\IQ*74I;;J1>>HSH,>**W^I-TTLKWKGF/=K%:LDQ+&(
M^(QLFYD,PX;$9V:ZM$=@T)HA!I)1$JJDJ4==A=-1:*S?=-OK13ELBK3;I]Z6
MN?>(OY7;+?9[T[(AFIBTJ-;*FC<4DEK.I^49;#ZA?%2MU)[/P4RUI;Z6:S22
MCE'S[;RU2339;W'=D/$C<I3C:D.%0O\ Q4I5\(Q8_ANM]C)?&ZYG_=?L3\IK
M(N8%Q+5,N\E49AQ6\T$KBO'\*C(O\D7F.6R(4KS7S*4>;63)Q+ +S=^R-3C)
MHHZ(KY:V5JD*2U1PNE):MI##,=C+#F&!R;DW#E+(Y@ED),H4V[/394),HFEE
M9H,E'KH2_)\GR>X0S9+N6G<QV1S5[W1'(C*$Y3RZM[_8F8*K>I=N6S&3H8,V
M*46E/1J)1&KKJ)RQMKQ19/9P2B,2X         ")'"^8S7L#R?F5BK"5(1?=
M+4=)$9$2'9")!?J&:?A%K(YK(M[_ +?@F;N6_F[FUY?!7RBO> Y"PV;:%X^Y
M EFDJ:I/!62C[Y&\D_@%KKJSDMXQL]2D6TMMGA+9^1UOEVCDIE>0Q24FYW%,
MUUAQ/QJ16#2DR_RM8:C9;$1P3CVWS*/.3T7-)-ANGW6PZS9*Q(=X<^5=%H.2
M@U(J2"2IQ)DDRJ=2+:?3L%LD1RQ"MLSS3/:S,?%<ZP#D[GT6\1TPXTQ^&3"6
M)#4E*4F[PY!?1+5IV:4*KM&/+=6(]/W,F.WWI6F'V'/[[RU*SX_A%DN-DGI=
M2=[==;3/XFO:LU*=(T+0=*%0J$,N6(F=ZF.:/3-,>R#&.0%HLV2H2U*:OIJB
MH0\W(1V5UI:D&2VC4FAF:J;1BONYLML^E:V*62Q/+J1'F\RL;>YIL/=E=AL(
MQU,E/#BT;(FXIFD]AM&:3IT&K:8SQ3WJ;V*[LKN=N=X>9E<G<VLCN]RYJ1T7
M?&[A=L0Q=TBBVV.A:6Y+]"6;BEZ#2:350J%\DJ=(R8MDS/;V(OVQ$=C5\3S^
M5$YU3LO*P2WG[DXXTNT)/^L,=H-"#-9Z-R*5/8,F.WW:?;>KDFMT3P=M#SPN
M"0         8?(KY$QJR3KY.0X[$@-&\XB.C6Z9$=")*1$S1,1645VKF#GG,
MPUHP5%ML-M*I*FSWT2IY$G?2,V=4]6HOA$T3-(EC,/Y?0\HR[)X^>SY63R<?
MDQF(ZI3BT1U<5LW#,VDF9%0]A%6@B-U>]-T[:=R>FVT--I;01);01)2DMA$1
M;"(2H]0 !939L.VPW[A.>1'AQFUO/ONGH0AM!54HS/=0@&F8SS:P[,<B<QO'
M)#LZ0U'7*5*)I2(QH2I*?)6NAJJ:N@A-!<9ES*LF'385H?C3+I?YZ5.1;5;&
M3D25-HWK--2(DE3>8B@N<1Y@8[FEKE72W.N1RMRU-7*+-1P)$5:"JHG4JJ22
MH6\30:JSS]PYV0RM42YLV&1([''R)Z(:+<M[5I(N)JJ23/<HT_ '*-FS3F)8
M\)["S-1)G7.Z*-NW6RWMG(DOFG:9I21EY)&>TS,1$!AG,.Q9LW.3;TOPKA:U
MDU<K;<&^SRF%4J1K0=?).AT,C"@UASG_ (8V^M91;FNP-R.Q.9$B(:K:E[5I
M_:5KIKTZ1;E&U9AS!Q_"K?"G7%3LI=R<2S;(<%LY$B2XHJD322V'L,MM1%"K
MPPWF19,SES;7&CR[;?+>252[3<F>SRDH7N7I,S(TGW2"@VFZ_P#+W_T @7P@
M     &$R.19(MBN4O)N!]W8\=QVZ*EH)R.49M)J<-Q*B42B(D[J"MTQ$5E:V
MLSL<57N[\H\X->1P/=CN]YPIW4XUE4"&5O6\PBJ>,VQ'X:E)V526O;W!:DV[
M]B(V[MJ=?=KQSD]!L,W)^3LRX*M%W<0Q/MMPDNO+A28VHS:4R]J4RLM7E;:'
MT"9K$*]K;^<N:WO!<>A7*QDSVEZ43"^T-\0M'#6K852VU(@B*I;Q89CUPLEM
MG2*=HEQ6'WM)43J=;)1T+N5,0EE 0  "-.<F*8S?L.N5ROL<^U6B*_(@365:
M'FG"35*25TI49%J2=2/O@.2L;P*[Y+BN29%%EG7'D,.*CI:(U.H<J;E%5V&A
M):MPO5#H'W7[W;7L9N&.-M-M7* _VAUPB+B2&GMJ7%GO4:3+3U;!%Q"?Q5(
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MC'%>.J3_ ,@ZI\ \G6,$V9>>-UW[6Z^C>H^/I9PW?%B_^,[OR30G<-&[Q4
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M=&\X_07XNL [=&V>4K;^8OQ=8%%.W13IY1[:?(7T_!U@!3HQ[E*]!733JZP
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M69)29U/NI47<[I=8)7((  !\Z4ZJT\KN@/H
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M$ROQC2@OHEG^DC9\ UUV]Y$I"H
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MZ4$AHS(]I&K:JG<,AS.ORQ?DI'8T^JOYKO0E\:YXP
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M1D9["KL")$SB   'QJVTZZ .5<0,LGY^.7%'[)$^5*,CV^3&2I*?PD0Z_/\
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M!TGFT*(ZDKAI2E)TZ-1&,F36Y;XI7V+W:B^Z*).(J)H6P>)YGT
M
M         #!Y'\6-^DO\1#/AWO#J^Q@>X/3#6J@
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ML,TGU-5EPSCNVNG.666(S7#+9?#41S%([//27R9+/DK(_P!(_*+OCR2Q-R
M       <\\Q/>-39KF_9,+BLSG8RS:E7209J8XB#HI+*$&6HDG\K5I[^\3$(
M:I8/><RR+*1]XX$6XV\U?3=E2J-(2GNHJI254[BMXGE*NEL>R"U939XM]LKY
M2+=-1K;772HJ;#2M.\E)/R5$8JEFP                       :!S9O<RR
MX7,?B8;(SQJ0M,2;CD30;KL5XC)Q6E:3)9)*E4D0K<O:YC@<U>0N%XG?L'5@
M>5\H3O[?"NLQFV/-O-K66PT2B4XHC2D]FRA=P+ML4J63RSS4= <@'^4YX Q!
MY-SRN.*P'W6GI1\7CKFJHXZMXWD-J4XK61J52FZ@R75V<&.&*YQ95D=BS+%8
M-HN3T*),-/:F6J$ERLA":G4CZ-@B(2G 0   L+M+*!:YTZNV+'=>K_HT&K_
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M#:L&FRKAAUCG375/S),)EU]]?QE.*01F9TZ3"1LH@
M
M                       !@\C^+&_27^(AGP[WAU?8P/<'IAK50
M &FYMS*QC!#99O+CSD^2V;T:'&;-:UI(Z5U*HDBKL%)OB)IVO19BF[;"RY;\
MQO[PTW9]NW]@C6]UEIE*G.(XLG4J,S69$1%33T"T?#5&2SDFC?Q9@!
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M4\0@"@Q"W-%_B_Q 5"A1"_FR_P 7^( [#$+839?R_P 0%5>P1/5D =@B>K(
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M^'J\1 !0(A'L;+^5/$ %!B%N;+^5/$0 4&*6YLME/P4\0 4&(5*-ELW?!3Q
M*%!BEN;3LI^"GB 5*#$(Z$V7\J>(!5$.*VI*D-D1E\4_!X@%R
M                    #!Y'\6-^DO\ $0SX=[PZOL8$MP],-:J
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M,UH6D]QD8TLQ,32=[M[,EM]L76S6)9 UI3O41=\Q5D5(R452VD J
M              ,'D?Q8WZ2_Q$,^'>\.K[&![@],-:J         \)9*.+(2
M6TS:614WF9I/8*7;I]#+9\4>E#ON_62]66)D*+Q;I%O4_(94R4EI;1K)*5U-
M.K>15$V?!$,VIF)OV)I%WD!                     \W&FWDFVZA*VU%12
M5D2B/OD>\)6C8\6X,)A1.,Q66G"W+0VA*B^$B(P3,S*Z!0
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M%B.0,2%,' 1*1.;=;2E)I=0XWLH=3*A[=@F8A$2QW,3#L:R+(+%<;W?DVF=
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M35PR+;J$P,[C$"';,=M=OM\DID*+&::8ED94=;0DJ*JG9M+;L$#-@
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MV;9I.]TEMT716-RZ%4@D
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M@MJE&+7$)B%0                 8/(_BQOTE_B(9\.]X=7V,#W!Z8:U4
M       Z*=!_C($E3KOJ9]T !
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MHMY<2WW)S]E'ED22=ZFUI,TJ/JWC#J-!EPQ68K#/INHX<\TMG;WMV&O;(
M           %#W (4YO+Q;FSBE[Y9V+F#:+-?U2$1IZ''(LMYMR.JIL+8<<2
MI"M9),E%Y25%4MHI,5I/"5XFF_@TVWV?WS\-@QF8-[Q//H45I#+7;D2(4QTD
M^22EN)T)4HB+:9JVB\SMW*4V)AY8WSF'?;))?YF8TQB]_8DK81$ARTS676$I
M2:7DK36A&9F5#[@M,12$(UY])(\]PRI$>U'_ )I 1NE+H<5   <J<[9'M?FO
M$MA+HS&1$C+5O))N+XBS/O$K\ Z[IM,6ENOGOGU1#X]]3<V?JV/'&WX+:=\W
M(XS**S><BN-ZQV,B';I;JE,P*FE))W:R,JZ3<^.I-*$/BMW7<<YIBZ/=KO?<
M.K?^M+\]D9=/?$99B*VSLBOI8!NR79Q6A;;;"3KJ6:S=/X"(B*HMEZW@BVMM
M9ESNA_\ 5_4;\D1GNLLL[:3S3ZMD.K_=]FVK[GN62&P4>?;'_P"OK*IG(5(\
MI+Q].I1%2G10=#TG71JL7-2DPZ;7]#MZ5=;ALVVTK$_M0G[X/.%Q]Q/*/&GM
M:E*;=R-QDZF:C,E-12IO/XJEE^B7='9Z#3__ ++O4Y?69I^"U+GNV<GF^5V&
M)EW1HBR^^I1(NBE%1;#6]N.1GYM:J_.,^X0\>LU'BW;-T/3IL/AV[=\HOYC6
M \%YCK7'(V[7/<[9%T%1)M/*,G&Z=PE#T=3MNUW1\V.W;=%D_<^<XL4=*^H\
M.6=F.^ZL</>K%/XI;LEQ#J$N(/4A9$I)ETDK:0_)TQ,32=[]31-8?75^ 56;
M[RTQ^!)M\J\S(B'E2Y*NRK=+41M-))O4DCV4-1&/L'TWTG#.EMR9L<77SQCL
M<5U367^+-MEU(C@DA+:&D:6TDA);DI*A%\!#NK;8MBD12&@F9F=J$N=.?F@E
M8;9EGQET*Z/-G4R2JFEE-.E5?*\ XKK_ %.G^QCWS\7Y?F^@_3'1XNF-5EC9
M'P__ )>KL8!_ES"L6&V]V_0F7[S=[A&4YQTI4J(TTE3J$-ZOBK.GE&7>'MZ7
MH+M'@F^=E]\;>Z.'YL&NZC;U#619;MQX]MO?=Q_)DZ%0BIWAE;-\.M-/MJ8>
M22VG2-"T'N,C$QLI*)A]V>#>LQM$6/*8*Z-VI:X[#CA(42";5H(]1T/:1%46
MOLC57<LQ%_)]U6MQ9L.BK,3R3=Z=K%3KU L%S/'I[;D%3+A(>(T&339*/X]"
M/:G;6J1J<FNQ:?)X5T3%)IW0WN+37ZC%XUE+JQZY[O2DV!R]CR&FY!W$GF74
MDMM<=)$E25%4C29F>\ATEFDBZ(GFK$PX[+UFZV9B+*3'%K','%Y.-(B7NWF;
M]NCU3,)="4C65#,U%LTGNZC&VT_3,6:R;;?^6-L5W7=S1Y_J#/@S6Y,E/ W7
M4C;;PN]# Q;K;YC27H[Z#2HJFE1Z5%7;M)5!SV7!?CFE\4EW>'48\UL7671=
M$\)(\R%=;U!QIB4@I5T<-GB%4TH0DC4NA[C495TD/5I]%DR1-U)BVW;,O%J]
M?CQ6S$3'-V0Z#CL-QF6HS):6FD);;+N)05"(;2'#S-9JCO/N:O+7'Y<G \ES
M2+B^27. XJ.M]PF'FFI!+;0^A;A</4DR4:2-70$QS;"-FU!^%<J.:N*03A<D
MN>]LO-F4ZY)]F7.)%FL(4^HW#)"F''302E*,S)!)+N$+;=R.U+_*Y_W@6;O,
MMO-Z/C[]G:CZX-YL*GD.O2361:%LO&6E)(KMT] G91"GO&)(^7B-6W_U"-_F
MK$QO&Z<N"I@6-D7\/C_[,A$C:A         H9TW -+YAY4>.V8VHZZ72;5J-
M0RJE-/+<IU5H76-GT_2^/DK/PV[_ ,FGZIK/+XZ1\5VR/S:UREQ6B591.152
M]3=O)1;:&9DMW;W3V%\(V/5M76?"M]?Y-9T314CQKNWX?S2R22'-3#JRA$ &
M52H%!K]XPS&[X2E3X*.,?\^U]&[7NZD[_A'LQ:S+B^&YX<^APYOCMCTHKSCE
MBNP6:=>K3/4MJ*WKX3R:.)J9)JE::;2J-_H^J^+?%E]N_@YK6]&\*R;[+OA[
M/^B/FFTLMH925$MD2=N\^LS[IGM,;]SG>^B!%$Q\EISSMGN5L69FQ E$<>NY
M*'T$LTEU$JOA'']7QQ;EB8[8=ST7+=?@F)[)HE$CJ-,WP
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M[.G_ &=?@_*(Y[3P;^![.G?9U^#\HGQ+>)X-_ ]G3_LZ_ '/;Q/!OX'LZ?\
M9U^#\H>):>#?P/9T_P"SK\'Y1'/:>#?P/9T_[.OP?E#GM/!OX'LZ?]G7X!//
M;Q/!OX'LZ=]G7X/RB/$M/!OX'LZ?]G7X Y[4^#?P/9T_[.OP?E$^):CP;^![
M.G_9U^#\HCGM/!OX*>SIWV=?@_*)Y[3P;^"OLZ?]G7X \2WB>#?P/9T_[.OP
M?E#Q+3P;^![.G_9U^#\H>):>#?P/9T_[.OP".>U/@W\#V=/^SK\ <]IX-_ ]
MG3_LZ_!^43XEJ/!OX*>SIWV=?@_*'/:>#?P5]G3_ +.OP?E$<]IX-_ ]G3_L
MZ_ '/:GP;^ BW3B<0? 61$HC49EN+PA-]M$VX;ZQL;>/%#< D:+S/QFZY+CC
M3-B6CVU;9;%SA-N_LW78JC,D*/HU5WBL>[,3P6C;L:U_>AS!4R40N6UR*[TT
MDI3B2A\7=77I^)7K$^A%&.9Y=99]U+-C4I#+C]PO?MO))*%D28A$LGN&TG>H
MS/R:ET]0F-DV\+4S->:>/[$X"(5:/FO+Z/E<F)=X%QDV3);>2D1+M#^/PU[3
M;6DZ$M(;DUV4:_%Y37FY3(SV=Y9*R&!"=2^S:C:3&C+=1M0ITDGY5.X)[:E>
MQ*Y$1$1%N+8"JH)    1ES@QC'YN(9!D4VVL2+W#M,AF+-=03CC222I=$&==
M)U.M=XM$[42Q<"0]%]W),B.LT/-XXLTK+>1\$Z_@#M.QJ-^M-N;]UF(;;*-4
M:!%F-.$1$I,A3R%*61^<=3(3&\G<RS9G=.<O+]5Q_K'!Q94QM+GE$3[A'J61
M'\JG2([$K9QQ5JYP<SF[811VW,8*<LFRH7:4,E1S9\JI[P[$1O6%MM5N7[J;
MIJ90I;D!Z:M="U')*0H]=?.*@GM(W/4UJN^6\E&+DKCL^RUR^&YY1&^W'3I6
M9'O/80=DE6P&A$'WE&RB$317&P*5-2FA$M3:SH:J=/DEM$=B>U+5W?9;AO,+
M<2EU2?)09D1GMZ"$0+HI<4]SS?1\HNG_ !B *7%/<\WZ1=/^, *7&/<\CTB_
MET@!2HIG4GF_2+^72 %+B&?[9OTBZO&(&G95RXY7YPI2\NQNT7E]S22Y,N.R
MX\9(II(W3+70B/86H(A*++K[GON_SGRE6BWRL;DD1Z7K)<Y$51+4=241*6XF
MI5[@#=>5'*QOE8Y<F&<VO&1V>:3)0(%]EE+*$3=:DTKR3\LU%4Z$+5V(HRO,
M[+<6QJS19F06M%[B.R";:CZ6G=*^&I6KZ2I;A$#:[/<+?)M4&3%TQX[\=EUF
M/4BT-N(2:4T+9L(R+8 OREQ#/8\CTB_ET@!2XAG^V;](OY=) .4_>:NB)V9V
MJVLK)2(<(EKTG4M<AQ1_YI$,N*WFNB.,IMBMT0C5.)29MN1=;:9+DN&9/15'
MI):45)*DJ/82MI[]AC>]1Z1X]L7V3[U'SGZAIGUM\_+-/9'^K'HL5]4YPBM4
MG66RJDDE'I&=*=8YC^T:JZZ8Y:?L<WY>ZJ_F8R[9835PG.)7,=4;2VT;4-(/
M:1$?2?=,==H-'CT%DWWSMFD>C:\G4=+=.#9OB73G(K/DW_'_ +OW-\O:]G2A
M*%+,ZNQ%>2VJI[S3\4_@&OZKI?"R<]OPW?M[7??2?5O-Z?PKY_W,7WV]D_G_
M *I9*9%]<V?<,E%U>,:67;0A_P!X;&(V1X<5YA:7;G8E]H2A)D:UQ5Z4O)V;
M]FE9=X*[TQOCTN8),"1;C;;DMJ0AU.J.M1&1*3YNW<I.XRWC=](ZIBUN+W9C
MFL]VZ*[:QV^B=[J+\<QMXO S)-5*V$72>POPC>U8HBK<<0Y;7[+6Y,JW/L0Y
M3"$+CM2G#86XA1F=4G389TKMZ!RL=>T]^MG!;=$\D;:=LSP_[>U;/_M61-T;
M)8Z=DN6*C2L1DWI^= XG >A-OG):6II6Y"B,S4FI?).AC<\NGR[:1M]3Q4PY
M-L4;%RKYB6CEN]*5)L7;)DL]+DY+I)D(:+^;2A94I7:>W:,&3IL3\,L5VBC]
MV705CYZ<O+UI0Y<%6V0?\U.;-LJ_IEJ1^$:^_09;>ROH>6[37QV515GWO WJ
M9/>MV$.IA6AE1M^TC0EQ^0:3H:D$LC2A!_)V5/?L'OT_3[8BN3;/!ZL.EBE;
MFL6+GES#L\I#LJX^UHNHC=B34(/45=R7$)2I)]PQZ<F@Q71LBGH9KM+9/<ZA
MP_,[-F5BC7Z X33;U4.QW#(G&7D'1;:N\?3TEM'.Y<5V*[EEJ<EDV326?[3$
M5LXR-OYQ#"QL)D=FL>3VU=NN*TZ#\II]I9)>:6>Y2%=!]72,N+-=CNK;-)8L
MN&S+;RW16'-N48[D&,W=JQW31*MDM2CA7J,>E+S2"JIM:2^(X1&5=M.X.NZ?
MKYSUMNC;#BNI]-C3TNLG9,^N%2(B(DD6E)%0B+<1%T#;M&^5)-942HT+(R4V
MM.Q25IVI4DRW&1E4C%;K8F*2F+IMF)B=KI##<@*]8O:[G*=1VJ0P7',S(C-U
M!Z%G\)D.!U.*,>6ZV.R7TO2YO%Q6WS^]%6?[7%]<WZ1#S/4=KB^N;](@#M<8
M]SR/2( *7%/<\WZ1 *=LB[^,WZ1 *]LB^N;](@#MD7US?I$ =KC>N;](A =K
MC>N1Z1"0[7&]<CTB$!VR+ZYOTB$AVR+ZYOTB 1)EGNZ<ALVGR[MD&*6]V\3G
M%ORKC'6Y%D+></RG%+9<1J57I.NT11-6BK]T3#K.9/8!G^4XA*3L;.%=E/,)
M3TD3;FW;UK$[1+/+#&,BPBQR+3EV;/YK,5*6]&NDYMMA]N.:4I)I6A:M1D:3
M5JKMJ)F:HHL.8A\L7<@L;N8ON)NR3+V7PC=T;'B^-P]GQZ;P@26<J,52-Y!&
M6_RB$!VN-ZY'I$ =KC'LXR/2(!R3)CJS/G/=&F%$9OR)A-K,Z$11HZT(/;UI
M(=7J+)MZ;=;VW64_B?(-%=;G^I(OWQ;DK/HLC_1JB"4A/#61I<;^C6E6\EH\
ME1'UU(?F3-9-E\VW;ZOW-@RVY,=MULUB7INZQAJSLQ:.:4'E3B^59&3R%WZ0
MABW6.W+,JN2U<19N&GI0T1U7X.D?2OH_33DF^*\)IW/E7UOJ(Q\DTV;8KWM:
M]UCE@_F^62>;.:F4B!!DK>B+DJJ<RZF>M3IU^,EHSU=:N\8^E:[/R6^';O?+
MM)AFZ[GN=T=JBU_;HV;_ "BZ_$-"W"*>?&,Q\AQ/VK#-#ETLBC?10R-2V%>2
MZC9M/=JI^:-QTK43CR\O9=L<9]6]-\UHYOB/>Q>]ZNV/MP1YRH@N959Y,1BY
M-Q[I;3+7'EE5M;#A52M!I/45-I&0XGZG^B\&3-XN*>3GV]U6]^B?JS+FTOA9
MO?NQT]/+V)(@<N''G"]NW:.40MKD>$9D:R*M2-Q9D9%LVT(<UH/H['COB[+=
MS4[(W.ZU'6[[HI9%$E1SML..W&C+::CQTZ&FDJ(DI2C93O%0?0;;8MB(C9#G
M9F9VRU+F/G\?$+.KL;B'+S,)3<!HC(])EL4ZK\U'X3&EZOU*-'BV?'=N_-O^
MB=*NUV;;_P =OQ3^"-N4.&E=9WWSR)1.,H<4N$A]1&;\@S,U/*KO2DR.G=/O
M#G.A=-G+?YG+MBNRO;/'U.L^I>JVX;/*X=GS4_=CY?6DGF3[.E8P^3TIMJ5'
M6F5"6:B\EYDS,M?YOQB4?0.VU$VQ9-7!].B[Q8NC=&^>$=J);/DUIO<9N1$D
MMF;A>4V9D1DKJJ95+N#2S:Z_3:W#J+>;'=$QZ5+ED=K@+8BG-8:F2W41F%O.
M$EIMQU6E*G%;=*2KTB;+)NFC%K>I8-+;7)?$3.Z.V6XX4Z>'7KV'+<)4=:NS
MR7=R5.UJ3GPF8XC0=0R:/JV2S--(R7<L_P#UE@UN&-5I8R6;XV_G#8.9F#V_
M,[?VB*ZTS?XB3[*\9DDG"*IFTX?<.FP^@QW?5NEQJ[*V_P#)&[O[FOZ'UF=#
MDI=-<=V^.'ZH^VU'O*SF$_C,W[H9,9M0"<-J.X]4CB/UH;:C/Y!GX.\.:Z-U
M2[3W^!FV6U[?W9_)UO7^C6ZJSS6GVW4K-/WHX^G]K;N<MY,X=NL3#A<">IQZ
M:E)_':CZ=*#_ #34=3+J'U_H^*+KYOX;O6^&=<S39BBSYM_HA$BD(5\8B/H'
M47X;+_BMB?3%7(8L^3'\%TV^B:**-R.;<N*K@RX:TR8KR=Z'6CU$9=_I$S9;
M-O+39.RBUF:^V_GB9KQ=06:\Q;G:(%R4XA!RX[3YIU%LXB"49>&H^>7V<ETV
M\'TS'?SVQ=QA@\HP3ESFU49?8;5>EF@F^+.C,O.)0DS422<46I*2.ODDH4HR
M5E%=Y]T'W>KB[VFWV9RP2DF:NT62?(B*)6^I)UK26FFPB33J ;'RMY.1N55W
MFRK?G-]O=ADQ^!'L5\FE,9C.:R6IU*O)\HR2:?B[A:)1,-HYFKP:1C9(S=]1
M64I+5."I9KX]%:/V6W=JZ@@9S&9%@;QVV)LCQ':"C-E!-Q1ZN 23T5U;=Q=(
M@9?M<6O[=OTB_ET *G+BE_/(](OY= !VN*6]YOTB_ET !RXI;WF_2+H_Q *]
MLB^N;V?G$ IVN)ZYOTB 5[9%+^>;](@'A*N4"+'=DOOH2RRE3CBM1;$I(S,_
MP";;9NF+8WRI??%ELW3NA!:52>8V8FX^HV;?6JJG0F8C9[$E^<K\9CLKIMT.
MG[_VRX2+;^HZK;\/[+?]4ZQUV^(PW%CK;;9922&T),J)0GN> <;-TW36=\N\
MMMBV*1NA[=KB^N;](A"QVN-ZY'I$ =LB^N;](@#M<7UR/2(!8W6/;KO;I5LE
MO)./+:6PY195HLM-2ZRZ!:R[DNBZ-\2I?9%]LVSNES7>;1.QJ:JVW8B2I&QB
M67[!]'0M"MU3Z4F=2,=WIM79GMK;.U\ZU>COT]U+MW9*R9<*2^W$AD<J:\>E
MJ,Q1;BSZB+8769CU7W19;-UVR(>/';=DOBRV*S=N= \O; C%;"4::^T=SEN*
MDSC0HC2EQ9$1((^DD)+37NCA=;J?'R5C=V/HF@TOE\46SO[6W=LC>N1Z1#Q-
M@=KB^N;](@#MD3US?I$"3MD7UR-OYQ @[9$]<WZ1 D[7&W<9OTB!!VR+ZYOT
MB .UQO7(](@%.UQ?7-^D0"O:XOKF_2( [7%]<C;^<0"A2XA[GD>D73_C .UQ
MC/8\CTB_ET@!2XA[GF_2+^72 =KBGN?;](OY=(!VN+7]LCTBZO& =JBF=2>;
M](OY=(!VN*?\\WMI\HNG_& H4N*9U)YO;N\HNG_& J4J*9U)U'I%TT\8 4N(
M9['D>D7\ND *7%K^W;](NKQD"0I<4S_;(](NKQ@@[7%,]CS?I%U>,!3M<4]S
MJ-OYQ=-/& %*B'N>1M_.+I_Q@!2XAGL>1M_.+I_Q@*E+B&>QYOTB_ET@!2XI
MGL>;](NKQD =KC5_;(](NKQD =KB&>QY'I%U>,!0I44SV/(V_G%TT\8 4N(9
M['D'7\XNFGC "EQ3/8ZCTBZ:>,!4I<4SJ3R/2+^72 JF3'6HB0ZA2CW$1D?\
MMX#W ?*JDG9M,100YF/N[8=DT]V[VMY_'KG(/7(7!))QUJ,ZFHV5>21F>_2-
ME@ZAEQ12-L.:ZA].:75SS3'+,\&*L?NP8M#DMR<CNLR_M-J)283A)CL&9'6B
MTM&9J+JJ,F7JF6^*;GDTGTII,%W-/O3";XL./ CM1(C28\5A)-LL-D26TH25
M"(B*E"(:J9JZ^VV(BD;EV"0
M
M    $ )$?\U[[=K-C;#=D?*%<KM.BVQN>95)@I2J&[\!%L%-LW1&ZJ\4VRU:
MZ6[(KYDUNY:0<GG1HUDMB9MZO#*B3,D/NKT,I69'_E4J+_%,W;J(W1'>VKE-
M>KK><7<3>)/;)ULFRK8N?L_K"8JR2EPS[ID85K$3QA$Q29AOY; 0CS+N:ENP
MZ]L6&79[G.F26B=CJ@L$ZAPMNI*?+(S,J>50A6+M_<ORL')Y]6F&3?:\8O\
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M <)OS"]$@#A-^87HD <)OS"]$@#AM^87HD <)OS$^B <-KS$^B0!PF_,+T2
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M%4C(R'11=$Q$QVN3NMFV9B=DPO194
M    !J.8\PL3P.*W*R6>F(;]>SQT$;DAW3OTH3M,B[NX1"6)PWG+@6=3/9EB
MN!E=#(U(ARFU1W%I+?H)52.G<K47FV85K"1!2J02
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MP=V=NL:P9VXB3%F+2Q'NZ4$TMIU9T2EY*?)-*CV:B(J=(K,)JZ=$
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M[2\(YS-9R7W6SV2ZO!EC)CMOCMADAA9P
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MN1E&IY1$BB?)09-GW5"^&L<TSNHKEI2([:NLAB6!(
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MLDN;-6YT]B:F.>XU*D4813N[*BO5KXG44G=LC\WAZ!__ #]'YYV3=6?;-(<
MM%1M-=VDNFO0.@MI2.#W6Q6E52,ZD9[^DA*(K,UEV)[BIW#CYF@O^5:82E;Z
M=HJZ1?J#1=3I6.+==-K[W!V<95(:1N&KY=@]DS&%P+FUIE((RC36B(GFC/N'
MTE7Y)[!KM=T_%J[:7QM[)[8;;IW4\VBOYL<[.VWLG[<7-^88IEF",S[4\XH[
M)=6S95)1MBO)KJ+66W2M-*[1Q>*-5T;4QDC;;7U2[S5VZ+ZCT5^"[9?-L_\
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MKBV>VQ[;"3HCQT$A/=,^DS[IF8Y/+ENRWS==OEVN'#;BLBRW=#(#"S@D
M    1]S;MYRL8*61$:X3Z'*].A=4'^,;GI&3ES<OS0T'6\7-@B[Y9B7MRJGG
M,Q-EDSJN$ZXP9'OI76G_ #A7JN/ESS/S15DZ-EY]/$?+,PWL:>&[!(
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M/K%=77U !0FR^6Y]8KJZ^H *&V1%Y;FRG\XKHIU]0 4)LJ>6YLI_.*Z*=?4
MH4)!?+<V4_G%=%.OJ 5*$V7\XY]8KJZ^H 1%;0HCU.&9=U:C[GB 70#X4DE)
M,E)(R,J&1[1%$H:RGW>[%=9SUSQJ>[C\E\S6]&:;)Z&IP]YDVHRT5/S3IU#0
M:OHF'--8V2ZC0_4>HT]L6S[T?>QMG]VZ$3Z'<JOS]UBH.JH$=M,5I=.A:B4I
M1EU%0>?3_3^+'-;IJ]6J^J<^2*61%J:X%NAVR&S;H##<:#%03;##9:4(0GH(
MATMML6Q2-D0X^^^Z^:W3697XNH
M  P%RQ#%;Q+.==[) GSE))*WY,9IY9I3N+4M)G0@%JGE]@B%H6WC5K2M"B4E
M10V",E).I4/1O(Q-9&TB                       %#KT"!42
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M*L^W&?=-39:T%WR,1!1OEJNUMOEO9NMHDHF6^2DU,OM'5"RK3IZRH8E5D@
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M)97)>B[=A&AZJD?X!V&H_P![1\W;2)]CA]+_ +&OFWLK,>U.XXYW()
M                                          $/9M[Q6!8A/=L\=4B^
MWA@]+\>VI);;2BWI6ZHR21ETDFH4&'Q[WI,$NDIN%?8D['5/*TMR)B$NQ:GN
MUN-FK3W]-.L322J;V)#$MEN1'<2['=22VG6S):%H652,C+89&6XQ N@
M14!(                 %0%*D 5( J0!4@%0%*D J I4@"I *@   I4@%0
M!2I %2 *D 5(!4!2I *@*5(!4!2I *@ "E2 *D J I4@"I *@ "E2 5   !2
MI *@*5( J0!4@%0%*D J I4@%0     !2I %2 5 4J0!4@%0 !&W.2UW:[XF
MTQ8X#]QNT>='E16XZDI-M;*C42UDHZ*1LH:12LQ=$PO;28ECV.8_,E+39/\
M+28I]*2)Q3<MI*#5TT(TF=.^+(HW?%+Q>+Y:SG7NS.V&;Q5M]A?<2\K0FADO
M4@BV'7<)5;$ AK+^8GW)YG1V[G)F/XY(MNB1 CLK6B/(-9FE[8DM>HBTG0ZD
M*VSME>ZW9#(*Y^<O5D:%>T#0K89=A=H9'L[@M$55G8D>WLQ&8C28#*(\12>(
MVRV@FTEK\KXI$5#.M3!"^               !977_ES_ .A_A$P+T0
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MQP=K9=S6Q,=KW%5@
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MD7C"XN02<KQ6-!:F%<92TR7(LE1TX1O)J2JD>XO&)G<)O%0
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M,_.:.A?@&@ZCCY,]T<=KH.F9?$TUL\-GL;6-<V@)
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M9\.]X=7V,#W!Z8:U4        !3H/N%OZ@2$=4U2=2W5WE424HJ(0
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M%W!$SL3VIDNQE[/?(SVZ?\(B!>$I/G$(#6GSB -2?.( UI\X UI\X@#6GSB
M-:?.( U)\X@$)^\LK_[.MM#+^WE\4_\ P7!:W>B4J8HI/W8LFW_]WQ/]BD52
MRRG$(2:E&1$154?40#\_;M.7=K]>+JJAG.FR'B/]-PZ#H.G6TLFZ6TT6RVZ9
M9+E_:SO>:6^(DM2#>(S,]U*Z2_ 8TFBNY]9?EG]V+KOPA\/F?-ZZ9^>_\7Q[
MP'.ZZP,MFX[AL@XC\1:4R[HW3BMZ"TH:9/;I-*:&I6^NPARO0N@6=0U-_4-1
MMB;_ '+?^W=,_@^S=3ZK=I<=NEP^[2(Y[O2@:-S"SB+<?:T;);HW<C,E=J3,
M?XE2.M3JLR,Q]4G3XIBE(<7;J+]\3+M;W8?>"N',;CX;F2T+RJ"SVB)<$D3?
M;(R#)*B6@MG%14JZ?C)V]!C0ZS2^%MC<W6CU,Y/=NWPZ7):3^40US8*ZT^<0
M#Y49&5*D9'T'TET@AQOS2Y;W/"KW+EQX[CV+S'5O0IK1&M#'$,U&T\95-!I,
MZ),]BB'8=/UUEV.+;II-KXM]1_3^;#GNR8K9OLR379%9B6A-MON.(9::<>>=
M/2VTVDUN+,]R2))557N#9^9PSNOM]5T.5_M>LV?[5_KLNC[W4?(KEU.Q&!+O
MM^:[->KJE#;<11D:V(B#J25TV:UF=5%T;"'(]2UD9[_=W0^R_3/1KM!AF[)_
MR7[^Z.'YI<E3(T-HWY+R&F4_&<6="_*-1-T1&UV=EEU\TMBLM&O/,%2JQ[&U
M6NPI3A5J?YJ1KLNL[+=[HM+T?][+-.YH.?8I=;U@&43[Y-3;V56R2:9,MPD&
M:N&9I359EH)1D22[XR:/#?.6VZ>-4Z_6X,>"[%C[8F.Z/S<L<N/> E8[;V+/
MD,=RXP6$DF/+;/Z5*"W)41GY5!O=;T7Q9YL4TJYWI?U#.&V,6:)NB/WOMO;9
M?_>7M"(BTXW;WG9:TT0Y*+AMH53>>\SIU#PX.@Y)GWYY8]K:ZCZHP\L^%;=,
M\9BD)&]SJZW&4SE%]R!U9OY)-8[(\LZ)6J&A9*)!'N+Z2B>\/1K+\6/);BM[
M(:?38<^?#=J+MM9^[BZN7PW&U)6232HM*DG0R/HIW*4'G4<O<T\%G\N;^QFF
M)FMBU+?)UO1M[))4==!_F+Z/ .MT&JMU-DXLFV:>W_H^/=?Z3DZ9GC5Z;9;6
MO_;/Y3_IP6O-O+X7,#E_8K\S':1=84],>[)HGBLN+:7HT*W\-9D9E7O#ENJ:
M.=/=2=W9+>:OJEG4>G1EMBE\3$71VV_Z3_U0I_C'/N2]"NSIW=/>"%H^WH=5
M8IR^@Y?R9QR'/9;CW$H6IAQ)$C9K4:-M-]#+:,N73Y;;K<^GGERV<=U]OR7=
MW#MB7W+H.JG#IK++X]V;8K'">,(HQV_9'R8R]QB4VMR M1(GQ#J2'V4GL6CH
M):>@QUVEU6+J>#FM]V^W9,3OMNX3]MN]T6HT\76QVQ.Z?Q_-U7$FV+-<=3)C
M.HEV>Y-&1*+?0]Y&70I)^ QKO?PY.$VN:SX8NMFR^-DH@L<V5R[S)R%-,S@J
M43,D^A;"SJVZ7>K4_A'69K;=;IXNMW[_ %]L.$T]]V@U4VW_  [O5V2GE#K;
MB2<0HC095(ZU*A[AQU'>/A]IF2RY'>)*V'4FAQL]I*0JJ3(^JAB"8B8I.YQX
MRJ3R1YPFA1F5D2[I7W'+7+5L/N?1_@H-='^WD?+XKTKJ'Z)_^-W_ .,^R&Z^
M\7@2'FV>8UB*NQM%VX)U,T;":D$9=S8E1]X;.)?4*UVI%Y*\Q"SK%T-SG*Y#
M:M,>XU/:XFGT;U/SR+;UD*I2?K3YQ &M/G$ :D^<0!J3YQ &I/G$ :T^<0!K
M3YQ ()YU7V]6S-<2C6RXR8<:0:>.TPZIM#G]90FJB3OV;!,0)VUH+I(0-;SB
MY)M>'7V>:MK,)^AD=/*4C2G\)CT::SGRVV\9AKNI9_!TN2_Y;;OV.4<:>]D\
MLLZNI5)Z:4.S,*+8>J0M2ET^ AM_J'+2VVU\AZ!'A:'4Y>V[ELCTS_U0GGEQ
M.WX]!C-+H_,F'),BW:8M"+\-!R/1M/XVNONG=CQTCTW_ .CZ9T6NFZ+6V??U
M&:9]6+9'MET+@.=PKU9H;5Q=*)=$,MZVWO(UD:2-)EJW5(>74Z>[%=,=[ZWT
M_J%FHQQQHVR=>[5;V#?ERVD-D6JFHC4?>(AY;;9F=C8WY;;(K,L;AW+>'SB<
MGY7?7I4*S-N)AV5#!I1QDM5-UPS4DZEJ\DC+IJ-W@Q3CMV[Y<1U#51J,E;=T
M-V:]V?EV@OI9%Q=,BW')0G\39CU<S647C7NX\L6OC,S'?])*/_ 1"*I>5W]W
M;EQ*M,R);X:HUP<:6F++5(=7PWJ50HR-1D9$JE2H%2CDZ]66Z8]=)%DO<=42
MYQ5&AYA9;^XI)[E(5O2HME!>JJT99=D/M1HS:GI+RB0RPTDU.+6K824I+:9F
M&XVSO=L<FL*DX-A<>WW$B3=ICBIL]"3(^$X[2C52WZ4I))]8QRLD;6GSB -:
M?.( U)\X@&L9#@6&96LGLALL6<_323[B"2Z9%\DW$F2J=50'M8\-Q/&6'8]C
MM$2$V^@VWS:;3J<1TDM:C-2BZC,$H2YI>[\AU3V0\OD<.01FZ_94G1)J+::H
MRODG^9X*;A:JJ(I^7R;] 19\R0OV[:R-F%=7$F4C0G?'ED=#41?)7\9)[ZD-
MIH-9."^G[L_:KDOJ/HENOP\UG_+9MCOCY9_#@VW&;G!Y@X1<N3>4.I2F<R?W
M8G.G4F)C?ELH4KH+5\4^X9ETC:ZS!R71J,>V/WOS<W]-=7NVZ'4;+H^"O_Q_
M)'GNV9??L-O65\M;G 6\Q+:=)V*Y4D1+C&5PC4ON)46^F\TI'(_5VHP8M!-^
M2*\WNQ'&OY;WTOH6/)=J?#M[-OHI]J)P9BK01ZY3[CBMJU$ZMM)F7<2@R(J#
M\Z8];FP[,<\D=WXOJM^"R_XXJK?+A=G<<GVEV0Y.M[B"4EB0HW%M+;,E)6TL
M]NRE#29[AOM-UW/DQS@S3SVW;IX2QX-+CT^HLS6;.6=OHEI$$BFVIR,OY2%L
MF7?K3\!D/OWT7JO&Z;%DS6<<S;ZNQ\J^M\'E.MQEMW9.2^.^8^+\&Y>[+=#C
MWB^V)U6DGF6Y24GY[*^&K\"AL>IV>[;<W^KI=9%T.E=:?.(:!JS6GSB 19S[
MNMQM."IEVJ8["EG.CH-^.LVEZ32LS*I;:&)C>-LP*2_*PJPR93RWI3L%A;SS
MBM3BU&BIF9GO,Q$C9]:?.( U)\X@#6GSB 1=SHDPU66):GD(=>DO\4E&7EH2
MT6TTF6TC,SWD-]T;',Y+KN$?M<WU[+3%;;QGV1"TPOE7CTNR0;E>NTR9$I/%
M.,M]9-:#,])&1:3.I?G"VNZCDMRS99,1$*].Z9BNPVWWQ69V_DE.%$A6^,W#
M@M-QXC*=#3+1$E"4]1$-!-TS-9=);;%L4C<N=2?.(0L:T^<0!K3YQ &I/G$
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MD5" >@                  P>1_%C?I+_$0SX=[PZOL8'N#TPUJH
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M=U)FC8?60F-Z)F73L+A=D8-DS-DVT<,U?&-.DJ&=>F@E5=
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MI452'!S%&SF*/80(B]XNO]WJ?^HQO\U8M&]#=.7.W \;_P"GQ_\ ,(0EM(@
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M48_$>2V-8M=$7Q^1)O%U8/5'>F&6EM6XE$DJU4714Q:V*(ORS<DH2\X
M                IU%LJ$Q5,2PUCQ?'\;.1["M[4$YBB7*-DE?2&FID:JF>
MZIB(V;%[KINWLT)8P                                  5;_:M_I%^
M,A$[I6MWPW@>!O@!$&5YG9YV0O6NRX0O,KQ:%$W*EI9;-F,Y\;A\9Q*O*(5C
M:O38PEYODV\2&[GEO)R1+3%(C.22FI#R$)V_%)!:B+N&)0EK%+_9<DL4.[6
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M<N6Z.]U>:VE\MO'G86C\T+5BEWQM,7,;DJUV<I+2RD(439F\1*TIJ:5%MV]
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M['2:#4>-AMN[:;6\CPO>"0
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MZ2_Q$,^'>\.K[&!+<0],-:J         "0$
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M=^U.>!/7U=8(.SN;?ZRYT]".OJZP%#CNF>R2X7P(Z^KK .S.UIVESP(Z^KK
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M25*$AY)*3O(_E5%>I64R5XPWVLCWN:.V$Q''=/\ WISP)Z^H:MX42^\.TM&
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M+X0%Z LFX41F0]*9CMMR7]/&?0A).+T_%U*(JG3K 7H
M LIL!J;P^*:BT5,M)D6_>+VW3:Q9,47[UK]WXOGK\)>(7\66#RMI[ B^>O\
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MO\ >+<>5L/8$7SU_@#Q9/*V'L")YZ_P!XMQY6P]@1?/7^ /%D\K8>P(GGK_
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M>5H2IS0HS2FI_&$QO@IP3='4M3#2G223BD)UDC:DE&6VG542K"X
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M3B.@H\3RDH^$]"1R6GB;\G-+[AU&Z,&EC''=";QMW&@D
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M8;P1D>[:-T\#Z$@
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M=3CR'TZ6GE'NV&=.H>;J\W6XO=W=KU]#BR[-/-\79^+JXM53KNZ!R#MU0
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M'8B5AFV46/F_EN'XCA<DKDU G)NUVG-D:6F8[%*T-9%56VE*=P(BA5T2*I
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M3EVUD$FY.7%[F/'R^U,H6R["BQHR20ZHRTJ-;*C,J4W=(2)3$
M                   Q5ZO4#'[5,O5U=)B!!:4](</H2DJ[.L]Q%TF(F:)B
M*N<^5W.;-,XYL,VZ;*2SC4WM;K%KX31<-IMM2VBXFC69EI(ZUVC-;C]R9G>Q
MW7>]LW5=0C#"X)                                             !
M0]VP!I-GYF8S>\QN.#PE/G?+7Q#E)6UH9HT9)5I76A_&"V)F*D[)HW<
M         099<2M?-.^Y-<\SF293MLN3]NAV5N0IEF-'8IH4:$4.JZZJ](K;
M'NQ/%>Z:32&=D<A.7"&5+C,2H#J2JF6S->2XU3;J+6HR*G>$RK5DN3MVN%VQ
M SN$P[@N#-E6^/<5[52(\=S2VX9]-:TKU"8VQ$D[YA(@(1%E[.1Y5S%;PV-?
MI./66/;"N)N03)N1*<4[PS22ZE4D=P4BLS/<O-(B.]Z_W-7/9_\ U!R&A=/:
M2H+QL1,I18:X++;1J-PVTI1K5\8])4J?68*O<          >#+[$AOB,+2XV
M=2U(,C*I'0]I /'VE *24$Y3)33*I1C<3Q:?HUJ ]GWF8[2GI#B6VD%52UF2
M4D769@/F-+BS&B>AOMR&3W.,J):3^$C,@'G=/^7R/T1,"]$          C;G
M#G%WP*PP[G96V79$B43*RDI4I.GAJ54J&6VJ2$Q!++WJ_+C\M9F1/F2)"[.<
MM6G8DG78Y**G5J4(2X7=/0PVBNWY769)WG\)CT]6NY<>/''I<E]99XMMP8?3
M=/L2VN\IY>\LW[YL1-@P#7%0>\YTKR62(^Z2EZO\D?.+L$Z_ZCLQ;[=/$5_\
M-_MF8=ET6SR/T_;-*79=O\<LER7PIVS8K9;&X1E<[FKMER<,ZF3TFBUF=?-0
M1%\ ZSJ&;S&IFF[='J=3T_%&BT59WTYO;N_!U/':;88;9;(DMMI)*"+=0BH/
M?;;%L4<E-TW36=\O875                ?)[3H _/7G/#?Y-^\BSEL%LV[
M?(EL7]A)%1*D/+TRFRIT&HG",NX8Z+3SXN#EGA1I,T>'FYGZ 0I<:X1(\^(X
M3L62TA]ATMRVW2)23[QD8YZ8I-&[B:OFY6^)=(3T":@G(KZ32ZCJ/N=PRWD?
M=%9B)BDKV73;,3&^$:3N7V00UFFVN,W&-7Z,W5\!\B/S]AI53SBWC67Z.:[)
M=/@ZU;3WX8%ZT3+9>(\?)&T)MZ%(==C,J-?%;/;M70MA4VD0\LV^%?'-#9VY
M?-89G'-)^W[6M\VK2O&LQC9'::(CW#1.BN(V)*0U3414[ODJ^$<MUG'.EUEN
M>S==[WK[6XZ'?&NT%^FR;[:V^KLGU.@L<N\>_P!F@WJ.9$U,:2Y3N*,J*+X#
M(R'T'#EMRV6WV[KHK[7S#-BNQ7W67;[9I/J9D9F$  &+O-N1=K9*M[Q?MDF2
M%=Q9;4F7PC6]1T=NKT]^*[]Z/O['ITV:<.2+X[)1W@\I#4Z9C=S0E46<2VW&
M'2(T\1%4J29'T*2/F_TCK;M+J;M-DFDW;O\ OMW^UU76,//CC-;V=O=/Y(CY
MA8/>>4>1QLLQ1Q;=E4[JB/%579W%?&8=[J%%4BKOW;Q]^T^>W46<E^_[;6DP
MY(RVS;.]/W+OF#;N8%F3.C:6+DQ1NY0:^4TYW2[J%;TF-+J=/=ANIV=C6Y<4
MXY[D/^\SABDJ@YW 3I,M,&YK1L,E%Y3#IF7</R? -1J+*^\^?_4^BF8MSV;X
MV3_]9]4MMP+GOA4W&+8G)K['A9"A'9Y33VKRG&O)XAF1&5%D6K>,UF2+HANM
M#UC!?AMG)?%MVZDS2O97T3V--YB6&W/R7W+:^U(L5Z2<B!*C+2XV2S.JB2I-
M=J%#M]%EC5:>;9G;N_*6CUEDZ74QDL^&?>C\82YRFRMS*L1C.3C_ /6;89VZ
MZD?QN.QL)?=HM-%CD\N.<=TVSV.XQ9;<MD7V[KH;^,;(  ",.8N>6K%<BL=J
MG6%JZO7&G!E.&V2F#-Y+>S6A1[SKL,A--A6BXYV7'V;RWNY'M.7PXA'T_3.$
M1_@(QL.FV<VHM[G,_4^>,73LL_-'+[9<0WV642#-EUH3+*]/=K39^$QY^HSX
MW4.7OBWV;9?*NEXN:VR.,_BWWW=+$JSX1+O[R:2+Q(4MO9M-B/Y"*=]1K'CZ
MWEY\T61^[^V7Z:^G,$8--=DGMG[H^TNSL8M7L:Q0+>?[5MHE/=TW5U6O]8S$
MVV\MM&DRW\]TW<99H68P                       &-N]LAWNV2[3/;)V!
M.87'D-F1&1H=2:3W]1BUETVW1=&^&/)9%]LVSNF*/SKPN++Y2<[YV&7,S1&=
M><M:U*W+;</7%<KU^3X1YOK+0^=Z7=?9'O8_?CU?%]U88/IS53I]7%L]ONW>
MGL_"?6ZIR!*KKRZDH^-+QV4W-:+>K@*/2HB[U3J/EO1=7SZ"G[^FOMOC_MF7
MTVS#$:R;/W=19=9ZYA%U]>7"3;;TP=';;+9D$KJ)9'7O;!^E;YC-ABZ-UT5]
ML/C'T]=.'5Y,$[/BMIWVR[&BR$2X[,ILZLOH2ZV?=2M)*+\!CA)BDT=-,4FC
M3^9^4P</QHKO/M2+Q'.2TQV1PTD57"49*\M*RV4[@0AG,7N3-XQVV76/&*&Q
M+C-/-14T-+1.)J22H1%LK380@9P!"G-^Y+FWJ#8V#-79T:S072\^=$E\"2_"
M.KZ/CY<<Y)[?V0XOKN6;\D8H[(^^4L6&V)M%G@VQ.Z,RAM7Z5*J_"8YK/D\3
M)==QEUNGQ1BQVV1V0R9%086<                   !"?.&&J)?8%V:+:\U
M0U?^)'54OP&.KZ/?S8[K)[)_:XOKN/ERVWQVQ]\2]>>W,)[%>2L[((!I5/NS
M#%OB*61*03DY.E:C2>PZ)U[#Z1HL>"N?DX3^QTU^?_8YX[8_:_-$DI25$E3N
MD7=[OPCJ(ASLR]F'WXKS4B*XMF2TM*V76U&E:5I.J5),MI&709")B)BDIYIB
M:QO?I_R%SF7S"Y7V3(+DOB7<DN0KBZ7RY$97#-9TZ5$25*ZQR6HQQCR3;#J-
M/DF^R+I2@/.S@                          M)42--95'F,HD1UTU-.H)
MQ&S;M)52 62<;QU"D+;M,)"T&2D+3&:(R,MQD9)W@/N18+'*=7(E6N(](</4
MIUR.VM9GUF9&9@+B';X-O;-J!&:BM*\HVV6TM$9]VB2+: I&MMNAK<=B1&8[
MSNUU3+:6S6?69$5?A 7*VT.H-#A$I"BHI*BJ1D?=(P&HW'EOA]RN]JOJK<F)
M=;0[QHC\*L4SVU)+A-Z=:*[=)^,34;F(  $2(SYRPW7<<B75I)K1:9S4E]*=
MI\$ZMJ/O$9D.7^I--.7233LG]K;]+R19FV]J/TK;<03B#)3:RU),MI&1[A\,
MF*5CM=_7M?5*]=>@.V@V3E)&7*R6^WI']B98:MZ7>A3A'Q%T[NF@^L?1^GOL
MLNOG=]OMZW(=<R1-UML,+S&L\R_<]L8M<"[R+%+=LLA2+A"T\9!(4ZHTEK*E
M%$5#V#Z-$['+]K>,4Y40[#?SRN\WF?DF2):./&G7):3-AI70VA)4(^@Q%4M2
MY$7*#&O&<V"1*0W>UWR7(* M5'C:+8:R0>TR(^D3=NA$-KYKW'#+<Q8_O[9C
MN5C?G);[:M.N/"=,O)<>H9>2>TO@$15+1L8^Z[W/F.[RS)@[$FSNED+EL(NQ
M&\:CX7Q?(U5T;A;L0Z#%$@                            #EWG_GUMO&
M5V_EK.GJMF,Q'6I&2S$H6M2C,M:6TH21J,B2=?TC+N"<<5FO9'[2_9%.V?V-
M/L&;8-:.>B,IA/\ 9\,::[+$<0ROR2[(3"")!%J^,6_X1EQQ=RW5WS+'DF*V
MTW1#L]"R6A*D_%41&7>,861]@                    ->S&[W>Q8W/NUBM
MB[O=HK:51[:C5J>4:B(TEI(S.A&9[N@0EH&#\R>9.0Y'&M.18&_8[0ZAPWKB
MYQ=*#;35)>6DB\HRIO%Z0K64P"J0                    !'G-.?S)@6Z
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M[/\ ^H>1&==QR2K^(3")G8D]ELV66VC6IPT)2DUJ^,K25*GUF"'N
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MDI9]Y3GXQJ++O&SS?/&K]&ZNFFT<8X[H_-T"-JY$
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MRI$VP=&R[Q^2.PU,^7T?+&^E/:X;2QYK7<\[M_JC<GD<>[H
M        1WS>MYR<=:F)*JH,A*CIYCGT9_AH-WTC)3--OS0Y_KF.N"+OEF/O
MV([S#$9W-+D#-QVVHXE[MKA/6]JM3<?A+-Q*"+H-:%*2GK%M7/@ZOF[)VHT'
M^]HN6-\;/8_/A]A^(\['EMJ8?96IMYITC0M"TG0TJ2=#(RZ2&XMF+HK&YX9B
MF]\-I4ZXVVWY;CJTMM)(_*4M9T2DNLS.A!-T1%9+;9G=M?J+R)P67R[Y963'
M+BDF[OH5,N3:3V)D25&XM%2WZ2,DF9=)#D=1D\3)-SJ-/CY+(MG>DT8&<
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M\5F'0*4DE))+<6PA1+Z                       0 D
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MY;8GB."7F%%=N!MW-R,?TLY];G&:4>C0LSV$1*5J26\>S18O&S1;.YKNH9_
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MME:_#?;OA((\E6 $@                                     " $@
M
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M&-]CB<V:;IV]OY/JFMNC2Z6,=N^8I^:;4E1)#;N.5$@
M *&8@?GISPARN3WO&L9=;D&W#DRV,AC4*B3)Q6F4BA=!J)PJ=PQT>FGQL'++
M2:C_ &LO-#O^#-C7*#&N,1?%B2VVY$=PMRFW2):#+OD8YVE)HW<37:O0%#W
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MG)5HJ]<7TQHQ&53X$4M!4/I)2U*'-:B_W,>/U^N9?;/H;21@T$YKO_V3,_\
MC&[[G76.6PK398< R(G$-DITR]8ORE?A,;*RWEBBN;)XE\W3VRS NP@
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M=F[L\3H^$R_".Q__ ,;1]]/ON<)__EZ_NK]UJ>J? ..=VJ
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MN9T/)^K[].GO *\.;7]LGO\ #[_7W@ VYM=CR._H[_7W@%.'.KL>1Z'?Z^\
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M+8=8\N[9_:+NLJ_[NQ7I(MJS_$0KH[-]SZ]UO/MC''IE(@VCF
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M$DI"B4E5#)23V&1])#G&\>HD
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MROJX%RO;'EOP5NJ)*%&E9FK0=:*-)D)WS0WPEI"DK2E23)23VD9;C(P5>@
M             +*Z_P#+G_T/\(F!>B          0][PWLXL%3VQ)JF'+:*W
M4,R^F,CU&HBV'Y%=XR8]\UX2KDF8LF8WTFGI[$1\J;([&M;MS>1_7;H[I:*E
M#X:%:4D74:C,QSN2>:ZG:S_0_3KM/IK]3F^/+=,SW6Q^%=L.J[- 1;+;'@II
M]$@B4?=6K:H_A,;G%9R6Q"^HS3ER3=/:R0RO.
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MH(+2''JEL/A%4Z]]0T>GMYLD3+Z'&".G].LP6]EL6_FG<;MRX
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MGX=E/,V3S+DX;D<FU3H5KA]KNK]M9=1PW'BHPT2G3+RS^,94^*)F(H)F%0
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MBS);=LI1-?+3(SR?"K5<G5'VQ+91IA*(ZD_'\@SV]TB)0]%TUEX+HI+;Q#&
M    *M_M&_TB_&0B=TKV_%#>!X&]      !%V7VW*L?S)K/L5MQ7MIV$5NNU
MI)PFI!MMN&XAQE2MAF1G0R%8V5[UYFL1'!@[Y=<^YF6]6*,XE(QRTS5(3=+I
M<W$F:(Z%DI:6D$1&I1TH)IMA&[<F:,TB.PW';^(TE*$5WT25"_$)K7:KW/<
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M1=\5HEHW(^R3(V,R,LO23^\&7R%7:::MY-.5X".\23J7?$R)3$
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MD+15MM2NEM2?)+N&,VFR4NFV=[6]3TTW8[<EOPQ$;.Y-Y%0J#9.;5
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MI:$J4V>I-309&9$?0(&499;CM-L,I)MEI)(;214)*4E0B+O$ ]P
M        !@\@(U%'))&=#56A&?07<&?%O>'516(80FG:%Y"_0/Q#-$QQ>#EG
M@KPW?,7Z!^(3S1Q.6>!PG?,7Z)^(.:.)RSP4X3GF+] _$'-'%'+/!7A.^8OT
M3\0<T<4\L\#A.^8OT3\0<T<3EG@<-WS%^@?B"L<3EG@IPG?,7Z!AS1Q.6>"O
M#=\Q?H'X@YHXG+/ X3OF+]$_$'-'$Y9X'"=\Q?HGX@YHXG+/ X3OF+]$_$'-
M'$Y9X'"=\Q?HGX@YHXG+/ X3OF+]$_$'-'$Y9X*<-SS%^B?B#FCB<L\#AN>8
MOT3\0<T<3EG@KPG/,7Z)^(.:.)RSP.&[YB_0/Q!S1Q.6>!PG/,7Z)^(.:.)R
MSP.$YYB_1/Q!S1Q.6>!PG?,7Z)^(.:.)RSP.$[YB_1/Q!S1Q.6>"G"<\Q?H'
MXA/-'%'+/!7A.^8OT3\0CFCBGEG@IPG/,7Z)^(.:.)RSP.$YYB_0/Q!S1Q1R
MSP5X3GF+] _$'-'%/+/ X;OF+] _$'-'$Y9X'"=\Q?HGX@YHXG+/!3A.>8OT
M#\0<T<4<L\%>$[YB_1/Q!S1Q3RSP.$[YB_1/Q!S1Q.6>!PG?,7Z)^(.:.)RS
MP4X3WF+]$_$'-'$Y9X*\)SS%^@?B#FCB<L\#A.^8OT3\0<T<3EG@<-WS%^@?
MB#FCB<L\#A.^8OT3\0<T<3EG@<)WS%^B?B#FCB<L\#A.^8OT3\0<T<3EG@<-
MWS%^@?B#FCB<L\#A.^8OT3\0<T<3EG@<-WS%^@?B#FCB<L\%.$YYB_0/Q!S1
MQ1RSP.&YYB_1/Q!S1Q3RSP5X3OF+]$_$'-'$Y9X'"=\Q?HGX@YHXG+/ X3OF
M+]$_$'-'$Y9X*<-SS%^B?B#FCB<L\#A.>8OT#\0<T<3EG@<-SS%^B?B#FCB<
ML\%>$[YB_1/Q!S1Q.6>"G"<\Q?H'X@YHXHY9X'"<\Q?H'X@YHXG+/!7A.^8O
MT3\0<T<4\L\%.$YYB_1/Q!S1Q.6>#Z;;=XB?HU4U%M-)ET]X)NBD[5K;9K&Q
MNA;MH\+=J@                    (PY]*4GES.41FGZ:-M(S(_VA=P1$5N
MB.]:$;PLKG/<J,EPN^FMN]VB$T]%-:CU/0'5MK09'O/1J(N\9#+DBLQ,<:2K
MCV3M6MSMK%\G<J;//4X<.=;T,R";6IM9I4L_E5W]8S71'B7>C\&*/@M]+;K8
MP_RPYH6O%;=-D2<6R%@U-Q)3ANFP\6HB4@SI3:GP&,%OO1,<-J]VRDI>N[!J
MB.N<9:22G]FDRT'MZ=@K"RZ**JA?UAX]W27B$"I1%$1?UAW93I+H^  *(K[0
M[X2ZNKJ "AJ+_>'?"75U=0"G9#K_ &AWPEU=74 KV17VAWPEU=74(%"BG7^T
M.G\)=75U"1"^3MG&S:\LN),EO)BOMK4=5.-<(F]7P*29#3:N)YZR['HU\>%3
MMA'O,Y*UV6+H2:C[1T$9G\50R:&8B^:S38KUN)G#'_<V:VMJ?+&H;:.)(??@
M$TV>S:WI6L_\DB,S&'%%<VSB]&LNBW2;>#H3LRJ_VAWPEU=74-VXA7LBJ_VA
MWPEU=74!4[(JO]H=\)=75U E0HBJ_P!H=\)=75U 5"BJ*A=H=V4Z2ZNKJ!!V
M16PNT.[.LNBG5U *E$57^T.]'275U=0@.R*K_:'?"75U=0E)V15?[0[X2ZNK
MJ!!V15?[0[X2ZNKJ J%#45/ZP[LZRZNKJ J%%/9_6'=E.DNKJZ@ HAE_O#OA
M+JZNH!3LIE_O#O1TET4ZNH$J]D5]H=\)=75U"$*=D.O]H=\)=75U"4J]D5]H
M=\)=75U @[&?VAWPEU=74 KV16S^L.[.LO$ %$47^\.^$O$ YE]]2S7&1RYM
M%QC.NN0;=<R.<G894?94VA:J%L(E%O\ SALNG3$9=O!KM?$^'7O<'%N*FX=*
MY^0Z$1F>XMXA">L=]USG==[%;KK <CQ8,Z.W)CL.SW&G$-/)):"4@DT2=#*I
M= U4ZS#$THW%NFS3$4FD,G_\2>?/VR)__P!)SYHCSV'@MY7-\WV]A_\ $KGS
M]LB4_P"I+I_FAY[#P^X\KF^;[>QO/+;E;F_*N8\UG!LN+NY:+>^Q)5*(C8(E
M+09J(M)F1["Z:#G.L9;,G+-D;H=E].Q=9S6WSMV42A^ <X[98W=QMJV2M9:D
MFTM!(Z5*<\E*2ITF9D0M9;68AAR71;;,RW&!@F3MP8S:UMH4AEM*FS>55)DD
MBIL[@]WELG%I(ZKIHBG+]T+G[C9-ZYOZY8>5R\4_W;3?+/L@^XV3>M;^O6'E
M<G$_NVF^7[H:E/M4ZRY#*B7*G'D,,OLN$HUDIM.I!D1G3<8\N;'=9.UL-)J<
M>:)FQ]= P-@LK@P[,0U;XZ27+FOLL1TGL^D4LCZ.X1&9B]MLW32'GSY+<=DW
M3NAO!X-DM3^F;,CW5>5N'N\MDXM-_==-\OW0?<;)O6M_7+#RN7BG^[:;Y9]D
M'W&R8_YYLNOC*/;\(CRN3B?W;3?+]T-(:BOVVYW>V34DF<Q+6MVAF>HGDDM"
MZGMH9#SY;+K)I+8Z/-9ELK9LBK1L_P#_ '!8NBIE_M4CW:3_ ([FFZM_SXOM
MVPDBT-JD9;C\1I&MTI2GS,MZ6FFU:E_!J(>;316^KV]6OB,%)[4X]D5]H=\)
M>(;IQ1V17VEWPEX@#LA_:'O"7B 4.(H_]X>\)>( .(HZ_P!8>V]9>( .&H_]
MX=\)=?4 =D5]H=\)=?5U@*=D54_ZP[X2Z^KK!)V15?[0[X2Z^KK 5[(K[0[X
M2Z^KK!"AQ%&?]H=\)=?5U@!Q5&=.T.[>LNOJZP XBC_WAWIZ2Z:]76"0XJJT
M[0[X2Z^KK!"IQ%'7^L.[>LNOJZP XBC_ -X=\)=?5U@D.(H_]X=+X2Z^KK!%
M0XBC/^T.]/277U=8%5#B*V_UAS;7I+IKU=8 <11_[P[T])=->KK #BJK3M#O
MA+KZNL$J]D54_P"L.^$NOJZP14.(H_\ >'?"77U=8)4.(H_]X=+X2Z^KK!%0
MXJC.G:'?"77U=8 <11U_K#NWK+KZNL"4"\V(SL7/"6Z1Z)=N:5'=4=35P7%Z
MT_Y.HAU?1KH\*;>VKC>O63XEMW91&>6?\I__ %J/\(]/5/\ @GTO-T;9J/4N
M667)-F@PV4<23+*/'CMEO6ZXI))(O!46MF(T?_A/[&*ZV9UU(^?_ .R;2P+*
M?7-UW'].K>/S3_BW4Y__ &1_'<^Z?W?2T^&?9!]P<J]:W]>H/\4ZG_4C^*X_
MO&E^6?9"OW!RKUS?UZ@_Q3J?]2/XKC^\:7Y9]D'W!RKUK?UZ@_Q3JG]2/XKC
M^\:7Y9]D'W!RKUK?UZ@_Q3J?]2/XKC^\:7Y9]D'W"RGUK?UZ@_Q7J?\ 4C^*
MX_O&E^6?9"GW!RKUK?UZ@_Q7J?\ 4C^*X_O&E^6?9!]PLI]:W]>H/\5ZG_4C
M^*X_O&E^6?9"OW RKUS?UZ@_Q7J?]2/XKC^\:7Y9]D'W!RKUK?UZ@_Q7JG]2
M/XKC^\:7Y9]D*?<'*O6M_7J#_%>J?U(_BN/[QI?EGV0K]PLI]:W]>H/\5ZG_
M %(_BN/[QI?EGV0?<'*O6M_7J#_%.J?U(_BN/[QI?EGV0?<'*O7-_7J$?XKU
M/^I'\5Q_=]+\L^R#[@Y5ZUOZ]0?XKU3^I'\5Q_>-+\L^R%/N#E/K6_KU"?\
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M&Z);,+,P                         4
M
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M:&VT$=>&TGH37:=3J8]>+#;CAI]5J[\]VW=P;F,[Q
M              #5<TPRWYI;DPY2EQI<91NP9S1$;K#M*5*NPTF6Q2>D>G3Z
MB[!=S6_]7EU.FLSV<MW_ $0#G>&Y#A=J7<+\Q"N5L)Y#+;K+BDFMQPCTF;2D
MG3=MVCH)ZI@R6TOMES<=&SX[JX[Z)&Y5<O(S46V9G<G2DRW6$O6N&VC3'B(=
M27E>574Y0_C'L+H&KU74)RV\ED<MC;:/IL8;O$OGFOXIAH0U+<U5$H
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M\P,FF9?-P+.+7&M^11XR;A'>M[BG8KT=2B(R+711*(^DQ,QL2E 5
M                     !;NNM,-J>>43;39&I2EGI(B+>9F>X@&"L^;8ED-
MRD6>QWB+<;C$0;K[,=PG=+9'HJ9I(R,JG3>%)I4KM;*
M
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M&1EO(QC67                       &=  0 D
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M!60[!!Z8S7U:?$&T6YVR*J2AY++7"2A25(T%M,S(R/=3H"H]^P0?LK/U:?$
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M$,'6^]C\#A2I)$E^8ZM;[ZDEM))N.&HR3U"9FHW$0
M          #E7G S"L'/;'<GR5@EXO+*,;CCJ.(U_5]2%DHBJ1Z3-*S(7P4K
M=WIR36V.[\V-YPW+&<NYC8C'Y>N,S;QQ&D/R8":),^,E39&I.PU((E*,^@A;
M%$Q=,SNHIDFML1WNO!B6                     $=<P.46(<Q)T:Y9$4KM
M,)A3#'9G>&DT&HW#J1I54ZA$TVP;]CG?DCREQ?F&YDC>2-RDIM;S343@N&SY
M#AN$==23U?$(98NI9$]M5+MM\QV.P+;"8MD&+;HQGV>(TW':U;5:6D$A-3Z3
MH0QS-9JM$4BB]$)                    65QA(GP)4!2U-IE-.,J<1\=).
MI--2ZRKL$)0Q9/=KLMCN]OO#61W1]RWOMR4-.+3PUFTHE$E74=!>+J*3%4Z"
MJP                                                 UC/;O<+!A
ME\O-H:XUS@PWGXJ*:OI$H,R53ITEY5.H! V(N,0<FAW"?F\JX,7[%9<ZYW1^
M41(BR7#21\))&:4*;J>DM]1>?0A+_)J\W6_<N;)<[TXMZ<MMQ!R7#JMYIIQ:
M$.J_226WN[Q68VI2"(   1QSGQZ]Y/@\BTX]#.7=E2&'&$$^48T&VLE<349D
M1Z:4-)[ZB8V#6V,I]X1N.AMS![:\XA!$MPIR4ZE$5*F1.;*]P3L1M2Q9W[C(
MM<)^[QTQ+HXRVN;%;/6AM\TD:TDK;4D[2%4LF   "(.;EDS>=?\ $[_@]J1<
M)]C>>?<6[))EK0LDEPEMJ4DE$HB/RMY&)B@^8F5\^5RXZ)>$6YJ&MU"9#J9R
M5*0T:B):OC[R343L0F$52    @W)K;S1LW-2X9;A./LW*WS(#,*0<J6E*'C0
M25&M*#6DT*29:=F\3%!LN)Y%S>GWQB+E6)PK98UI<.1,8ED\XA6DS01(U'74
MK88302:(    $ 1H?./$<RRZX8QB\>=9+W.[2VF7.26U%2XB*K(R)PCJ:*>2
M+[*(VM_PB]\S;E<)+.;XW$LUO;9)4:1&DD\M;Q*(M!IU'0J;1$T3"0!4  !\
M+VH41%4Z'Y(#G?#&>>>#6^79[9B$25;7)C\N*4JX)4ZTE]5=!K)9:B*FPSVB
M^Q&U+&"77/+HQ-5G-DCV5]M:"A(C/=HXJ#29J4>TZ&1BLT2W,0   U'F/:IM
M[P>^6FW13G3ID534>*3W9S4I1E0R<Z#+?7J$Q(C3'[M[P5BL=OLQX9;Y?L]A
M$9$IR:A*UI:3H2:B)PRK0A/NHVI:Q29D4^QQI650&K9>UZRDP6%\9M%%&2:*
MJ=:IV[Q5+/@   B[G9?+K9\>MD>VSU69B[W.+;KA?$?&AQGZZG*GL*M*:A,$
MHE<N;N'8OGL6V95+<GVJ\P%V*2[+XS\Q9(;4;6\]:%ZCU$G8+(=/P77WX<5^
M2WPI#K2%O->8I22,R^ Q1*\   !#_-BR9U)R?%,CP>THN$RR*D./*>DI9:4E
MTB+A+;4I)*U%4R46TA,! RKGLY/BM3\(MS$%QUM$IY,Y)J0R:B):B+7M-*=I
M"=B$P"J0   $(YG:N9=NYI)S#"+"S<8OLY,&2<B6E#;QFHU;$&I)H4DZ;2WB
MT3%!G,;R/G+,OD.-DN(0;=9'%**9-9EI<<0G29IHG4=?*H(F@E(0    .?8$
M/G+A^595+QO%8TZS7N>J6RF5.29D9&:=:3UD9)<+RM)EL%MAM2)@][YF7.=*
M:SC'(MFA(:2J(]&DE(4X\:J&DRU'0J;:B)H-^$   ,9>&5R+3/899[0Z['>;
M0QK-OB&ILR)&LOBZCV5 05A3G/S"\=BXW'Q"%,B0S<[,[(GHXQ(<4:R2I25^
M4:=5-0ML-J7<)N687.U.O9M:6+-=2>4AN-&>XZ#8(DZ5UJ>TS,_ (D;6(
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ME1;!?8B4C8->N9%TF2V\YQZ)98C;:51'8T@I!N.5/4E1:E4H5!6:);Z(
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MI11N@@                     %#*H#R0PTW7A(2@U;S01%7P /8
M
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MAEW*;.D7C8-APS F+'D4:Y(YA7&_*:2ZGV7)E-O-.:T&530E53T[Q EL5
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MGFM<F+:')FE39+0HS(U)KMKN[XOME#IIMQMYM+K:B4A9$I"BW&1[2,8TO4
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M$HED>\OA%]W8A(W+S$&\;G37V\RFY/QVT(-B7(1(0UI49ZB))G0SW"LI2,(
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MMPJ5H9T,)@2.(
M
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MMI1*3LU;=I!S2E*PJ   Q%_L5MR:T2[#=V3>MLYLVI31*4V:DF9*^,DRINZ
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M(B,ZKKT(+8*UJEM @  !K>;8TWF&*W;&G738*XL&TE^E20XD]2%4Z2)22,R
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M (=7^>D!>@     "QA?VF=_I4_[-(F1?"      6-L_LZO\ 3._[0Q,B^$
M         (SYQH<]C6B2K;$8N;*I'<(E$I*3/O&8\6KBMC=](NB,_J:=W>^-
M,[0V ,URN0MS,[X^S_9FH;#+Q]'%->I)=\DC9Z+M<QUN8I;':P?,9>2M<]<8
M7B#41Z^E9I'!;N!K3&-.IWB:C;,E5I6@VT;G+=K.VGE[F&1YG&S/F:[;5%;H
MSL.!9;<E:V#2^1I6ITW:FHC)1^34Q%=B6)]WVSVIF3F<QJ"PW*BWN3$C/);2
M3C<<MI-)52I(V?%(+IDAM7,_"\CO-QQW+</4PK(\;?<<:A2S-#,AE\B2MLUE
M0DG0MAA$C2L+>R>_<^)=SOZ(C<RU68F)D:VK4\Q&-Y9&AE;I_&<VFHZ?X!,[
MAT&*                  P]\D/QTL<!9H-1JU&730B,9<=L3.UX]1?-L11A
M_:4XS_M"Z=RHS^':\?CW\5?:,[UZ_")\.T\>_BI[2G?:%^$/#M/'OXJ^T9_V
MA?A#P[3Q[^*GM*?]H7X0\.T\>_BK[1G_ &A?A#P[3Q[^)[1G_:%^$/#M/'OX
MJ>TI_P!H7X0\.T\>_BK[1G_:%^$/#M/'OXGM&?\ :%^$/#M/'OXGM&=Z]?A#
MP[3Q[^)[1G_:%^$/#M/'OXGM&?\ :%^$/#M/'OXJ>TI_VA?A#P[3Q[^*OM&?
M]H7X0\.T\>_B>T9WKU^$/#M1X]_%3VE.^T+\(>':GQ[^*OM*=]H7X0\.T\>_
MBI[2G_:%^$/#M/'OXJ^T9_VA?A#P[3Q[^)[1G_:%^$/#M/'OXJ>TI_VA?A#P
M[4>/?Q5]I3_M"_"'AVGCW\3VC/\ M"_"'AVI\>_BI[2G_:%^$/#M/'OXJ^T9
MWKU^$/#M/'OXJ>TI_P!H7X0\.T\>_B>TI_VA?A#P[3Q[^*OM&?\ :%^$/#M/
M'OXGM*?]H7X0\.T\>_BI[2G_ &A?A#P[3Q[^*OM&?]H7X0\.T\>_B>T9_P!H
M7X0\.T\>_BI[2G_:%^$/#M/'OXGM*?\ :%^$/#M/'OXJ^T9WKU^$/#M/'OXG
MM&=]H7X1'AVGCW\3VC/^T+\(GP[3Q[^)[1G_ &A?A#P[3Q[^*GM*?]H7X0\.
MT\>_BK[2G?:%^$/#M/'OXGM&?]H7X0\.T\>_B>T9_P!H7X0\.T\>_B>T9_VA
M?A#P[3Q[^*GM*?\ :%^$/#M/'OXGM*?]H7X0\.T\>_B>TI_VA?A#P[3Q[^*O
MM&?]H7X0\.T\>_BI[2G_ &A?A#P[3Q[^*OM&?]H7X0\.T\>_BI[2G_:%^$/#
MM/'OXGM*?]H7X0\.T\>_BK[1G_:%^$/#M1X]_%3VE/\ M"_"'AVI\>_B>TI_
MVA?A#P[3Q[^)[2G?:%^$/#M/'OXJHN,TW$$;ZS(U%4J]8K..*)MS7S,;6WCR
M-N                                     -6Y@S[M:\(O\ <+$DU7:-
M"D.Q"3M4E24'Y1=:=Y=X!!=GP#DA<L)CY'=,BUWEZ*4F=>'+@:9;<I2=2_HM
M1'J2K82=-1;:C8EODU=+Q>.6UCN%[6MV<XTM)2'-KCK*'5H;<57SDD0B=Z4A
M"   $51,[O;&7<QXDLTR;7B\2/+ML1""2NJXRG5D:B\HZFGI$T&DHF\\3Q#^
M]0\FA%&[-[4^[G9T<#L5.)HXE*ZM/36O746V"=,<NZ;_ &"V7M#9M(N49F43
M2MZ">02S+X*B@RX   (;D^\)CL6X3K6>/WQZ5;7UQ91,1"=2EQLS(R,TK/?2
MHORHJK$Y_P!BF2X\-&-W]"Y#K;*5K@FE"3<4224KR]Q5VB)M*IC%4@  PF57
MQK&<;NF0.HXJ+;%=E$UTJX2341?#03 A^!E//.V6>)G=WB0+[CDMI$V58[>@
MT3HT-U)+2MM1?'-*#K2IB=@S*.8*,CYA8$O&+HIW&+S#N3DR,G9K>CMD9)=2
M9:DK0HSV!03$*@  -2S^\Y)CV,R;MBUJ*]75@T** >KRFM7EJ(DT,S)/00F!
M#L'F]S:RG';E<['C]I[/%8?[6ZU--,R'I0JJELK42TJ32I:DBU(15NW)K(N8
MM_L\-S+;<PFRKM[;L&]$^3DF6XHR(E.H(_),TU4>P5FD$)9$)  !I><YNG"7
M+"Y*B$Y;KM<6K;+G*<X:(I/$>EQ6PZD9D8F@T:YS^9^<YMD%AQ.],XQ9,96P
MPXXM@GI$AYYOB$JBB.B-]*4*G=$[!LO*K*K_ 'UJ^V#*S9?R'&)W8)DZ,G2U
M((TZD.$DB+2HBV*+H$2)($   (GSK*,ZD9G!P#E^Y#AW)4%=TN%RN">(A#!.
M<)*$)H=3-6_>+1 U.!D7/#-%W5BTSK78Y6)+.#=$FV4A,Z<T1FHTFI*M"#21
M?RW32$)4Y;Y4YFV%6G))#1,RIC9E);1\5+S2S;6:2/Y)J09BLQ24MP$   (E
MY\SY43%K;%[8];;'<;K%AWZY,&9.,6]TS)9D9;B/81B8$<9SB'*O",=1D_+^
M]=FS".ZPJSG#GG)=ENJ6@C0I!*54E$9UW%^(6VH=*P7'WH<9V6WPI2VD*?:\
MU9I(U%\!BB5X  *'N 0)%YHYB?*)63)-F5E$R\+L\)Y;9(9;-R3PFUJ2FB:)
M+N]51:FT>C\SFORTN5BN659''R.P7BX,6R?$2P3+C+TLS)*V3)*3,DF6TOP!
MLG<)X%0  %E.E=CA/RB:6_V=M3O :*KB]"3/2DMFTZ4(!#\?WD<9F-$_&QZ_
M/-&9D2VH1+35.PRU)<,JD>PQ?E15FL:YUV?)[[$L4>PWJ*]-4I*)$R)PF$&E
M!JJM>HZ?%H*S%")2F(2  #1^:.7R\)Q"3>;<PE^ZK=9AV]MRI-'(DK)M!KI3
MR2,ZB8BHT@\OYK\NE1[ES*:B7O%'S04ZXVELT/VY2CWN((BUMETG3X1-(G<A
MF\9RN7>^;=[A1;D<O%BLD&=;FD&E;&I]>UQ&ROE"*;$I4$   (NYNY[F& 1(
M=SQ^Q-W:UKXA7*4X;AIC4TZ#5P]I).IU4)B()1ME/,[G%+Q:)>HUMMT"T29<
M5+%UM<Y,A3BEND1,T)2J)6?DKJ6P6BV$;4X85<<QN-K=?S:U1[/=2?4AJ/%>
MXZ#8(DZ5FK;M,Z]/0*REM0@  !IO-"Y7>T<OLBN5@J5VCQ%KCFWM6BE"4M)%
MTI359"8WB%&>7W(UW!TY([D)G>%0^TN7D[C264K1J,^%JKJU_(TU_&+UE&Q,
MW*>YWB[\NL=N5^-2[K(B$;[COQUI):B;6HNDU((E"D[TMW$   (DB<PKY'N?
M-%<O1+AXB3;EJB)02#))QE.J2I2=ID:DEM,6F$-/>F\\+3B2>:<O)H3\5$=N
MYR,=[.E+'8W")6A+A%\;2?=K7IJ)V;A/5GN"+M:H%U;3PVY\=J2A"MY$\V3A
M$?6511+(@ "AG0!#+GO$XZB5*AIQZ^N/07EQI/"B$Z2'6E&E23-+A[=@MRHJ
MN+;SZL=SN,2W-X[?F7)CS;"'G8.EM)NK))*4K7L25=H3:1*7Q5(  -<S7(T8
MEBEXR131/^S8KCZ6C^4LJ$DCZC,RJ$0E%,3*N=V.6N)F>2Q8&08U*:1*G6NV
M(-$Z''<(EDM%*$YI2=5%M_PBU(1-6:C9Y]X>9^()QVZJD8I=K/-ENL-F1-K>
M:41%K29:DK1TI$=@E\0   T[F+D&38SC+MXQ2T%>;BPX@W81ZC/L^W6LDHH9
MFGN$)@0ZGF[S:R;$KI>K+8[4B Q&>.3-C3?ZW#T(/4I3*U:DK32I$I.T6Y81
M5(?*._\ ,.^VJ*]F-L88MBH$9VW71M\G9$LU%0UNI(ZI,RHH]F\5FB82@(
M  %C</CP_P#B$_B4)%\(     !9*_P";H_X=7^>D!>@     "QA?VF=_I4_[
M-(F1?"      6-K_ +.O_2N_[0Q:1?"H          #%WJS0K];)5HN*=<66
MCAK(OC$?0HNX9'M(Q6ZV+HI+)BR3CNBZ-\(7GXQEN+N*BOP'KS;D?L+A"+6Y
MH+<3C>\E%W1I\FENC=M=CINJ8[XI=-)>$2WY9>5E'M%CD,&K9VRX)[.RV72=
M%;3IW"%+=/?=V,V;J.&R-]?0EW#,3CXC:CA(=[1-?7QYTP]BG7E;SZB+<D;C
M%CBRVCCM3J+LU_-*DO"[/-S*#G#RGBO5MC.0XZ261,\)TS-6I%*F?E'MJ,KR
MMG :59>6V-8_E4_+K3VF//N6M4N*3ZNQFMPR-3G!I349EW>\)J,SDV/0\ILT
MBR3WY$>))T<1R&Z;#Q:5$KR5IJ95,MHBHML3PS',*MZ[;CD(HK3JN))=4I3K
MKKOG..*,U*,NOX D;*                  ,'D?Q8W?7^(AGP[WAU>Z&![@
M],-:J         :3H1T.A]0)H4/O_ 8 "                      !("
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MJT15I. <QX6?'="B07816MQ#2S>6ES7Q#52FG=32%LUMYNQERX^2:-W$L
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MDR5&RCZ"X>DO-TT%4LB
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M:XT9/E$9&LB2DR(CIN,33@531 3#3"C)MQ(* 32"C$UL;)G26G33HI2@J+T
M                          %E</C0_P#B$_YJA,"]$      LE?\ -T?\
M.K_/2 O0     !8PO[3._P!*G_9I$R+X0     "QM?\ 9U_Z5W_:&)D7P@
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MH%GE 0        ^F_P!JW^D7XQ$[I7MWPW<>!O0
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MK9A,-1FU+WFAE!((SZZ$*I9                            %C</CP_\
MB$_B4)@7P@     %DK_FZ/\ AU?YZ0%Z      +&%_:9W^E3_LTB9%\(
M !86O^SK_P!,[_M#$R+\0
M  #!Y'\6-^DO\1#/AWO#J^Q@BW$/3#7 (        :-S-P^\YQ8FK%:;@S;X
MZWB>G*?2M9N)07D)+1T$K:=12ZVLO5BR195L>-V2-C=B@6*&7T,%E+)*\Y1%
M5:C_ $E&9C)=-6"9980H                     /DRJ2BZ3H1")BJ8FC6,
M2P2P80<\[$EY/M%:7))ONF[Y2:TTU(J?&,1$4BD,M]\WS66TBS"
M                         #Z;_:M_I%^,A$[I7MWPW<>!O0
M                          !JV?Q;U.PJ_0\>,T7IZ$\B'IV+UF@_)2?=
M/<76 YBQ_+>5V,WNWO-P'8S"<;DVV_VQ;#G:I%S<4A*FUU(S4:Z*\K=09)B4
M.@^2]MNUJY:V&'>D+9FI:6I##E2<:96XM;3:J^:@TD*3O3"0Q
M                                       (EY]1)4K%;>XMA^;CD2YQ
MI&2PXI*-YVVH,^(1$G>1'0U$)@0:YD&&W&UYCB&&1%R9M_NT%W$H,1E:394T
MEOZ;:1:-!ZB/^1BVU#L""W(:AQFIB^)+0TA,ATOE.$DM1_"8HE>
M                         #3>9T.^3L R&%CAK]LO0W$QB;.BS/9K2D_.
M4FI)ZQ,#FZT9?RKQ^[/>S[>XQ E8HNTSK1V=SM+]U<>+4TX1U,U*(JZ]PLC8
MZ*Y2VZ[VGEQCMOOA*1<V(B2=;<VK0E2C-M"J]*4&2164MY$
M                      +*X?&A_P#$)_S5"8%Z(     !9*_YNC_AU?YZ0
M%Z      +&%_:9W^E3_LTB9%\(     !86O^SK_TSO\ M#$R+\0
M                                #!Y%\6/7=J5^(AGP[WAU>Z&"VT(>
MF&N *&T"AM H;0*&T"AM H 4*'W 0;030H%2AM H;0*%#[@(*'W #:": %#:
M ;0*&T"AM H;0*&T"AM H;0*%#[@(*'W  $T*!4H;0*&T"AM H 4-H%"@5*&
MT"@!0 H4/N @H?< -H)H;0*&T"A0^X"#:": !M H4/N @H?< -H)H;0*&T"A
MM H;0*&T"AM HJV7TJ/TB_P")W2M;\4-X'@;T
M              :IS N$VV83?)]OD/1)T>(XN,_':X[J'"II-+>VNT3 ARP\
M\<;1;K=(R;$+G*REEE"9EQ;MC;AK>;*FM+AZ%;=^X6Y)15->(9/$S&Q,7^%%
MDPX\@W"3'G-DR^7#4:3U)J=*Z=@HEL8
M                     BOG9E%[Q.PVNZ6!V04DKBR3T:,SQ^/'(C-QM1Z5
M:"4DMBJ?C$Q UF+SYP. \N5$PN[QY2R^D>9M;;;AUWU4E1&8MRR53=#DIF16
M)2$J0E]M#I(<*BB)PJT,N@]NT4%X
M  --YFW*X6C [[<;5)=B7.-&U19$=KM#J734DDT;VUJ>PS^$()119N>>+HB0
M9=]P^Z.Y,VRV4V<W;&UJ4^E)$I:73TG0SV[B%^5%4U8ID<?++!#R")&D1(\X
ME*;CRV^$^DDK-'E)(SIN\ I19GP0
M  "QN'QX?_$)_$H2+X0     "R5_S='_  ZO\]("]      %C"_M,[_2I_V:
M1,B^$      L;7_9U_Z5W_:&)D7P@
M          &/N5O.>39$O1H,SW5WC)9?RL&7%XD;UC]WEGO?(N\7Y1D\;N>?
MRG>?=U7VC]7\H>-W'E(XJ?=U7V@O!^4/&G@>4CB?=U7V@O!^4/&G@>4CB?=U
M?VC]7\H>-W'E.]7[NJ^T?J_E#QNX\I'%3[NJ^T%X/RAXT\#RD<3[NK^T?J_E
M#QNX\IWGW=7Z_P#5_*'C'E(XJ_=U7VC]7\H>-W'E(XJ?=U?K_P!7\H>,>4CB
M?=U?K_U?RAXQY2.)]W5_:/U?RAXW<>4[U?NZK[1^K^4/&[CRD<3[NJ^T?J_E
M#QNX\I'%3[NK]?\ J_E#QCRD<3[NJ^T?J_E#QNX\I'$^[J_7_J_E#QCRG>K]
MW5?:/U?RAXW<>4CB?=U7VC]7\H>-W'E(XJ?=U?K_ -7\H>,>4CB?=U?K_P!7
M\H>,>4[S[NK]?^K^4/&/*1Q5^[JOM'ZOY0\;N/*1Q4^[JOM!>#\H>-/ \I'$
M^[J_7_J_E#QCRD<5?NZK[1^K^4/&[CRD<5/NZOU_ZOY0\8\I'%7[NJ^T?J_E
M#QNX\I'%3[NK^T?J_E#QNX\IWGW=7Z_]7\H>,>4CBK]W5?:/U?RAXW<>4CBI
M]W5_:/U?RAXW<>4[U?NZK[1^K^4/&[CRD<5/NZOU_P"#\H>,>4CB?=U?K_U?
MRAXQY2.*OW=5]H_5_*'C=QY2.*GW=7Z_]7\H>,>4CB?=U?VC]7\H>-W'E.]7
M[NJ^T?J_E#QNX\I'%3[NK]?^K^4/&/*1Q/NZK[07@_*'C3P/*1Q/NZOU_P"K
M^4/&/*=ZOW=5]H_5_*'C=QY2.*GW=7Z_]7\H>,>4CB?=U7V@O!^4/&G@>4CB
M?=U?K_U?RAXQY2.)]W5^O_5_*'C'E(XJ_=U7VC]7\H>-W'E(XJ?=U7VC]7\H
M>-W'E(XGW=7Z_P#5_*'C'E(XJ_=U7VC]7\H>-W'E(XJ?=U?VC]7\H>-W'E.\
M^[J_M'ZOY0\;N/*=Y]W5^O\ U?RAXQY2.)]W5?:/P?E#QIX'E(XJIQ]25I5Q
M_BG6E.X??$3EJF-+$36K.EW!@>Y4
M    !$_,3)LU=RNU<O< =CP;U/BN7*;=9:>*B/%;4;9:4&2BU&9>:8F!Z<M<
MGS%>07W \\<CR[[96V)3%SAIT(D1I&PE&@B311'L/802)4$
M                                      (/NN0<U,VRZ_V?EY/A66T8
MNZF(_(F-\5R5,TZC1125T26X6V#<^5F7W#,\6[=>6$L7R#*?MMS;:/R#D15$
MDU)+H)6PZ")&^B                                   $29]DV<S\QB
M<NN7TB-;[B<([G<[M+3Q>"QKX:4H111&9GW"/?T"8CM%YRRRC+IETO\ A><J
M8>R/'E,J[=%+0W)C24FI"M.RA[-NP@F!)X@
M           65P^-#_XE'XE"8%Z(     !9*_P";H_X=7^>D!>@     "QA?
MVF=_I4_[-(F1?"      6-K_ +.K_2N_YYB9%\(
M
M
M                !#^?8ES)>Y@P\TP)<!*V+6=L=]H&9GY3ZG#HE)=PRVB8
MH-7CX?[P,7*IN8M.V,KS<(K<%\S-7"-AD]2=*:;#KO,6K;1&U,^(%E:;%'^^
MBHRLAJYVDX148TZCTZ>GXM!24MA
M                 $#EB'.K'LHRBY8:Y:$VN_7%<^DPU*<H943T%39T"VP8
M_&</]X+$X\^/9WK&E%QFO7*03NI1]HDF1KI0BHG9L(3,VHVI^A]J[*QVS1VO
MAI[1H^)Q:%JIU5W"B5T                                  (:S+$>9
MR>8B\TP)=N2EZV-VQTK@:C.B73<.B2+ND6VHM%.T:Y"Q#W@8&37/+8[MC*[W
M9EF/+-6HVM$8J(T)IL.F\3[J$U8JG)2L$(LN5'5D6E7;U0]C&K6=-'3\2GPB
MB6>                                   !8W#X\/_B$_B4)@7P@
M %DK_FZ/^'5_GI 7H      L87]IG?Z5/^S2)D7P@     %A:_[.O_3._P"T
M,3(OQ                                                      (
M>YL\WY6"W*W8QCML]K99=$I4TPX:N&@EJT(+2CRE*4K<1&06QS30G9%6!Q7G
M;EC&9PL(YFX^W9Y]R-"(4AC4DB4Y4D:DJ4LC2HRTZDJV&+Q9%U:=BLS,>M/Y
M"BP                     ^5*2DC4>XA%1K^/9EBV6G*1CMS9N*H2DHEDS
M7Z-2ZZ255);Z&)[*G;1L1'4
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MQPE([V@B_&0"\      %G!9<994APJ*-Q:O\E2C,OQB9D7@@
M                                         '+_ +P:F(O,3%KCBSCK
M_,1DVN#;&VN*A2$.&IE2MOQC.I:>DNX+8_BG[R^*VQ5@H]QO.0<[L>F<XHZK
M!-8)KV1$::I'6XA9FTDUJ4JB5.&=55/;Y.P7QTBLV[U+YF:1+KT887!(
M                B7FIS'R["[G!A8[BKE^BRHZGGY#9/&3:B6:22?#2HMI%
M41$5V2F=FUSORDYA97A*K\YCF+KORK@ZVN42">/@*1Q#2D^&E6_4>_N#/$>[
M$=E6.Z?>F7:-IE/3K7"FRF>SR9,=IU^.=:MK6DE*2=:'L,Z#%,4FBT;89$0D
M                   !8W"8FWP9,]:%.(BM./&VCXZB;2:C(NLZ;!$S1,(;
MLGO)6:]W>WVAG&[JPY<'VXR'G4()"#=4224JA[BKM&2+:JW31.0QI!(
M
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MP2,PO\3(K!?)[5KELM,$P]'D2:Z%MF24U21EM(_ &Q,)V%0
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M07):36SI52JR*GE;3_PAL0G852
M                   .?.;7+O.&\]MW-' F$7&?#0VF1 6I.LE,$:2,DK,M
M25(5I41'J(6LGEF>\N]Z(C@P"<,YK<V<[LV19O9V\<LUF4V?#(]*E);<)PR0
MDU+4:EF6U1["%K9MMF94NK,1#J(8UP                    !\+2:DF1'1
M1D(F-B44\G>5ETY:.7]=QGL3BN[S3K7 2I&@FS<V*U=W4+5]R+>"LQ6Z92P1
M4$)5                      'GPF_-+P /0
M                                                 !\*22TFE1$:
M3*AI/:1D UK#<0B81:7++;7WGK><E^5&0^9'P$R%FLVT4(O)29^276%1M
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M6J:9<*,HBTI,S(ZJ-!%1.P@F1+HJ
M                       "* )
M
M                               $897F7,?%L@?5&P]60X<:&S9D6YS^
MNH5H^DU->54B56GDEWQ,1 ^[!SRY>WYXH+]P59KJ2M#EONR.R.$OI3J75!^D
M'+,%4CH6EQ)+09*0HB-*B.I&1])"!Z@
M            "+LIS7F/BV023:PY>08?1"HTNVN5F)/07$UM554B56FPA:(@
M>V/\\.7E_?*$Y<CL]T)6A5ONJ>R/)<\VJZHK7\\12452.E27$DM!DI*BJ1EM
M(R,0EZ                                  "/\ .\@YA8]-A2L6QQO(
MK&;:O:3"'2:FH<)1:>&7RB,J_),3 Q%HY]X6_*]F9,F5BMY(B)R'>&E,D2C[
MCA$::=:J">62J2X<V)/C-RX,AN3$>3J:>963C:D]TEIJ1BHO
M      !;R>.3#W9B(Y&A7")6[73R:]50$/(YNYGBY&GF5A$N'&:_:WBT4F1"
M+SE$1F9=WXXM0;SBW,G",RHC'[S'E2CVG$-7"D%T[6ET4=.HA%"K<!   "$^
M:UMS)W-<7:LF1W.S6*]FN!+<@$;K;$E%5M+4@J$25UTU,^@6BB%Q_=!S!_\
M[K7GZI/](%8$DXW:I]DL4*UW*YO7F=&0:'KI((DNO&:C5J453+81T^ 52S8
M  -%YA9K*P.-;KRNUNW#'U/FU>WXY&MV(RI):7226Q1$KXU1,14:Q?\ G4S/
ME,X_RMB?>K)):4N)=:J4"*TOY;[AZ2*A;=->^?0)Y>(EQGB\%OC4XNDN)3=J
MIM_"*CU   !'N:\QON)?[4Q>X*T8C<4&T[?D$:T19FHR2EXBW(4GIWB8BHPQ
M\VI63Y1&QKEK;CO,1B0V5[OZB-,&/'U5<)M1TUKI72>[N5#EI&T2V(
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M+.*OMFW^N_55X@\.X\Q9Q4]L6_UWZJ@Y+CS%G$]L6_UWZJ@\.X\Q9Q/;%O\
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M)VIGL+89;3[Y!R2F,]DSO7Q;=HHSJ@
M                              (+YIL,%DAEF',EW&<6EMM]BL4$S;DN
M:4T=4M2",R2:JT.ABT"WQ.T>[C='BQ>Q=EOMVN2'$K<DE(D2G"0DUK4;CJ2)
M)D15J5 VHV)0P#%'\(QF+C3UQ7<RB*<X$AU.E265K4I"*55L01Z=XB9JEM@@
M                                         $$<T&(Q9,XG->93N.XQ
M*2V<&PP#-J0XE*")Q2UH(U$2E5IL,7CT(>>)6;W<;TZ>*6 HEZNMR;<U.R"?
MD25DVDU*6;KJ2TF5*[#(1-2*)0P/%I&%XO!QI^XKNAP>(AN4ZG2?#4LS0@BJ
MK8@CT[Q692VL                                  1+S?;F([!*FYW]
MRL5TJ:F<$OZW)?49&1(45#H2:UH?P"T(EIN,M>[9$F,M>U&\DOTMQ$=#]T-^
M:\XX^>@B(EHT%M/S?A$S4BB5,"P&/@2[U&M\M2[+<IG:X%L).EJ$2DD2D-U4
MJI&>WX!64MX$                  MI!/JCNHCJ)$@TJ)I1[2)9EL,^\8#F
M>1#Y?NW!V/S:YIOWRXQUFF3:H[CL>"VNNU%&4J(RZ#(M(OZD-PC8+RIY@6AE
M7+)V/;)MAFL.-7JWL+XS:D&EQ2-2^&I>I/29G0)F8WB<11(  +23*C0F52)C
M[;#"::G75$A)5.A5,Z$53V +A*DK22DG5)[2,ND@'V   #X42C29$=#IL,!!
M]UPWFU;X<F;=N9\:-:T$HWW)41I+*6U&>Q>LJ&1[A:)&DX/AUTM<:5.P?FG;
MX\"X3FXL@VHI(9=G*\I#2$NT+4:3V$@3,]R(AU&TE:&T)<5K622)2MU5$6TQ
M1+V  &+O,:?+M,V+:I78KD^RXB),-.O@NK29(7I/?I,!"&4X?S&MUED'F'-&
M$U8WTFQ(*=#:)IPE?)HHMIGT4V](O6.")67++$;[946)K&^94-[&9TER1&MJ
M(^DYB&%EVA#7%HOHH=-P720Z0&.$@D
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M"\ %39W"\ 4*J5ZOP!0JKL[A> *%56Z<5&PMJBW? (G<M;\4-W(B(J#P-ZJ
M
M@3.<'N5XS_)">LYW%G);"J-8[L:4N-P)<1M1FT9JV(-TR\E7Y1:HQ_+@Y=ZY
MCV6?:\1?QIFR6EV!DSTB.EA#TG2E*"10BJHE%75\;36NP)W#HL5
M                                  0!G.#7.[YSES;MF.X)R6R)18;P
MI"7&X<F"WY3%5;&S=41:5?E%HF@M^6RY5\YDVZ[6G$G\9A6JSK@9&N1'3'2]
M,.F@F])%4R,C\K>:=XF=V]#H<42
M ")>9&/R9F>X5?I-H._8['<?M\^'H)U$9V7I2W*6A1&1I3\HZ;*"T"+[/:;F
MQ>,2P>)A[T3*\:O*GYV1JCI*([;2=<4:S=(O+):%)I7<9;!-1U4*
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M+4^PH;C&RU BMFT?'.A$39I)!IH+=\H=@-)4AI"7%ZUI21*7W5$6T_A&-+U
M  !!_.1B- RS%<KR:UNWO!;<W*9G166CD)CRW2+AON-'34G93:+0(YP*X(RM
MO L7QN!(5=,=O$BZW&ZFR;;,2"IYQ7#)9GMXB335/P"9'6PH
M                             #!Y'\6-^DO\1#/AWO#J^Q@ME"[P],-<
M @       !K^39ACN'Q$S<AFIB(=J4=NAN.NF6\DH1M.G2>X5NNB-DLUF.;M
MRRQ/F-B.:.+9L,[B3&R-:XCR%-/:2WJ)*MAD748M&W<BZR;=[;>GJ!B
M                                                       ?3?[5
MO](OQD(G=*UN^&[CP-\
M                   QUWND6R6J;>)YZ(<!ER2^HMY(:2:E$77L 0U;7N>V
M?Q&\FMEV@8I8IQ<>V6]QCM#YQU'5"W5&E5#45#H7@%MB-K.X1EN:V_+3Y?<R
M$QW[N_'7.L]ZA)T-2VFC,EH4C9I6G:>XN\$QLK"4LBH
M                        ,7?+Q$L%GGWN>JD2WL.27S+>:6DFHR+K,RH0
M"';:?/K.X;620+O;\5L\U)/VVV+CE)?[.O:VIU1I49FHJ>(6V(VL]@N79G$R
MISE]S&;CNWM4=4ZTW>%Y+4QAM1I61H.E%H,SJ5"V= 2E+ J
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MJ4ZMMEULFR(B)O1Y6S;TB9@3X*@
M        P>1_%C?I+_$0SX=[PZOL8(MQ#TPUP"        '.O,54$^>-G3E]
M/NVAJ-PR>_8<,TG6O1IXGQQBQTYYJV45\+9O6V;3,=M7-S&)^&.1$N:XZ9Z;
M<:.!K6[HI]'Y-5-JVD0G'/\ N3P129Q3S;W2>XS(96N!
M     MY,F-"87)F/MQH[>UQYY1-MI+=M4NA$$S1>(JLXU^L4]],6#=(DJ2HC
M-++$AIQPR+:=$H69[ C:3;,,H"@                     \W%MMMFMQ1(;
M01FI2MA$1;3,S[@+1#&-9+CDAU+#%Y@N/.&26VVY3*U*4>PB225U,S[A"*K3
M;,,N)8P        !5O\ :-_I%^,A$[I7M^*&\#P-Z
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M-U+9*,M6E)D?P"VU"?<;L-OQ>QP,>M2#1 MS26&25M5I+:9F?29F=3%4LP
M "%LUS?E%FR9N$Y'>EVFYVZ6:6I#I+BNL3(ZC)+K3M--"/I,]I"T1*&-Q?DE
MC\Z<BYR\UD99:DRTW)R 3K9QWY:"(DNOFVM>M1$7X!/,43T6X42J  /)QPFV
MU.*W)(S.G4 @K(LNY0<U"A:<J7CV26UQ2K;/JJ%*84KR5)-3A$E25=*=0MMA
M%89+E]R8L-GGP+\[DC^3HM:G'+0T:T=CC./GJ6XE+:ED:C,Z[]X3*4T"H
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M-X'@;T
M
M
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M?$5"7H5JT*<6XJJ5;E; FY-'18HD
M         8/(_BQOTE_B(9\.]X=7V,%T$/3#7 (        6-PM=MNS!1KI$
M8F1TJ)Q#<EM+R$K+<JBB,J]8BC)%TQN>\=AB(RF/&:1'805$,M()M!=XDD1$
M)5K5[@J
M       JW^T;_2+\9")W2O;OAO \#>@
M
M
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M
M
M
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J.36TV\]/1*T:?H==DX:_]UOYI39)O07#IP]FFFZE/Q#5>EU\;GL(2__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tm2227887d1-bc_single4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-bc_single4clr.jpg
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M8HR:2DQFJCHWW"3<YBKYWG-V6#=<JJQ>;717(FJ:!:-C!
M   UWQ7XRXQP=IK-59-25]7'>ZI:&D2W1PRN;*B([63GIH=&[>AK[ 6C8@0
M
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MO_TN7HA:-B!
M                     ''GH2_UAQH_F=!_U%S#4KA?O2T;9\_R;AO1816W
MG)K54)0V&EMU0L\MRJ%3><KV)3IS$;&IO.=K)IZFFJH2C&R^E+GV"WNVTW&S
MAK-BV.W>9(:>\TU1W2R%57:KT1'-?NHN\YJ/:_=151KN0%&^^('$+&>&F(UF
M:9-4*RT4C6[C8$22:HEE72.*%NJ(Y[UY-J(B;55&HJA&B*3TA^/%[M29IC_!
M::HP56<_$^2O:E?/3Z*J2Q1;C9'(Y.N3<@>GJ*O*%HV'8O2!QO*>#EZXMXY2
M/J4L-+4S7"QSR)!/'54L:2N@=(C9$1'(J*V1&JBHO)KJB"C52>E[F>34U'6\
M,^%U=DE-3P139')3OJ*F&FJ)4WUI8Y8:;17-9HKGN;RZ]9HFJEHVGQ:X^VOA
M5366V2V>HO?$/((V.MF)4#]^97O5&=?(UCE1O.:QL5L:J]47=;L70E%"KO2,
MXP8&R"^<6N$TUHPJ=[&376VUL=7+2-D=NHZ6-JO37:B;KW1:K_8@*-^2YQBT
M6&.X@K<8W8BVA\:>,FZJQ:7<YS>1NF]JJ;-W3>UV::A&@[?Z17&3/Z>2^<)>
M$<UQQ%'/2ENMVKH:1]2V)RM<Z.-SHVKH[K=(Y)-J*FNJ*B%HMW!CTA?.3DEV
MP#*L<J,0X@V6)9ZFU5#UD9+$QS6O<Q7,C<U4WV.W51=6NWFN<FN@F$3/?2#O
MU)GE5PNX38;-FN86V-LUWD6=E+0TB/:UR-=([8JIOM1V\]B(J[NJKJB"C'XW
MZ2&4VO.;3P]XTX++AEVO\B06:Y05+*RAFG>]&-8JMU:B*YS6;S)7Z.<FJ-1=
M04;%XP\9<7X,X]#>;^V6KKZ^1:>T6BET6IJYFHBN1NNQK&ZIOO7DU1-JJB*(
MAJ:K](/CU8+<N891P7FI<':WGJAT->U]?3T^B*LDD6ZKT1B;7<Y"Q/55H*-[
MX=Q Q;.L.I<[L-:U<=J87SOGGTB= D.O.MG15T8Z-6KO[=.BBJFBA&B(/2<X
MA9[<[AYD.&LV48O:I5AGO=;4MHF3N:FJI$V3<1%5.N:W?<_14U8W70+1KVR<
M2(>)WIC\.KNZT5=@NUML]=:;W9:]NDU)<*>FNTDD>]HW?;NRL5';K==>1 O0
M[@#+F;TSLERZAX97K';?BTE9B=?344ESRUM;'$RAE;<H5;"M,K%?)SBL8S5K
MT1-_U@L/S@?Q+S6Q\%>[+SP^?;L7Q'$9+M:KRMRA>R[+0T_.HQ(F0JZ#G6HK
MMYV_N^HH)81GI@Y?E%OH:OAIPPK<AEA@2HR5M.^HJX:-[GOW:=DL%,F\]8VM
M?O*U--=-U=%4+1LCB7Z0K,!EQ[%Z+&*N_P#%+(Z6*JI\2HI-5IUE;UR33HQ5
MT:YKT3=BVHQSG;B;0E%'O_I&<<^'M,W(.(_"!:+$MYB3UE#<(YWP-E=NL61T
M7/-:NJHW21&:N5$U35 4=!VO.<9NV$P<0H*UL6*3T'C5U;/UB14K8UD>LB;=
MU6(BH].@J*@1H.@])7BEQ"DK*_@UPKFOF)T,KXO'%RK(Z+NCFT17)&QZL;O?
M\K9)'<FJ(NP+1;,!](B;/[%DU-;\1JJ?BKBK%6MP2IJ&T\LST>D?XJHDC1$;
MO;';\:*U=-4T5%44:!]%C+\\H.*'$2.V8+)<XK_?J)N42MN$,/B%KZRM1[GH
MZ->Z=Q)95ZS=UYO_ )DT++HJS<6+7</2)R'A-'BM/3W2U6^.LERMLS%J*AKZ
M:DFYMT24Z.1$2=&Z\^ON.3H(1\>+7I#T> Y'2</\2L-3FG$FN:U[+'1.YME.
MR1N\QT\B,D5%5.O1B-]SM<YB*BJ**=)Z3'$7 J^A\^/#.?&<;N$K(6Y!;ZA*
MV"!TB:HDK8^<:JZ:N5O.(_1%T8Y4T!1M#C#QAI.%O#AO$6@M[,CH9I:5E+#%
M5)31RQ5NUDK9DBF14TT5.MV@B&L'>DGQ1R^E\<<(N%-9?<8B;I+>*V;F&3RL
M325M+'HQ9&L<BM1[555Z+&KL!1L3@9QTM/&FUW-S+;-8LEL4K:>]62I=SCHG
M2;R-<Q^ZQ5:JL>U4<QKFN:J*G(JB8;8"-8\9N-^-<&K5237*GFNV179ZPV2P
M4?[152-T155=';C$5S6J[=<NJZ-:Y0L0U97>D3QTQ6B3*LWX,ST>%)^,J9Z6
MM26LI8%V[\L:-<K=U.7G(XT]56@HV5D'%FMO'"ZBSWA)C\F;PW95B=215D=L
MFI(>9FYV61TC).OAD8V-T:;=7:HNG*'._H1Y5FMMQR3'K3@[[KBEPO\ ,ZZ9
M>VOA@;1/6DIFK&ZF=&Y\FXC6OU1Z>[]90LNWPRY%]*VQ4&3\9.#6-W1F_;;O
M45=#5M3EYJIFIHW:>OH[8&H63T-[W74>+9-PGOC_ /USA_>*BB<SH)35$LBI
MNZ[53GF3_P!BH$E*]+.OK+];<.X,V>58[GQ!O,%/5JQ=59;:-[))GN3U&O=&
M_P!=&.Y00I_H.T=/;JOBI;Z1NY2TEWIH(&:ZZ1Q.JVM35?41 LKWQ9X;<8^+
M^6U6)R7V'%^"D38.Z74>CKE<U=&U\K%1%7K4>KF=>K&\B[DF@10O0:H8+74<
M4K92Z]S4=VIJ>'>75VY"M4QNJ]%=$"RZ^#*J\2<R\WN"7W->XO&/B6F6J[AY
MWN?G=UR)N\YN2;O+R[B@:'MOI29_Q M4%9PBX755]EAB8Z]U515(RBIJIR;R
MTT,CF1<^YK5:KEZU4]ZJ:."T>L=],2GO]IGM5/A5QFXN15CK=%A%.Y7NDE8C
MEDE=.Z-%CCC5CDEWX]YB^JFKD%$FP>DSFEHSZS8-QFP%^'KDDK:>S7**?GX5
MFD>V-C7KHK7)O/:U[F2=9JF\W1=04;.XR<9\=X-66CK[K35%TO%WF=2V2R42
M(M153-1-[15UW6-5S$<Y$<NKD1&JJ@B&J;GQX](ZR6Y^4W;@HL.*PL6HJ8V7
M%LE;'3L;O/<]C$=(S=3:JNI]B<O(H*-T<*>)]AXM8329K8VOIJ>5TD-91SJG
M.4M3#^4C>J;%T14<UW1:J+LY$(U!-Z3>7YMD-RL7 7 ),RH;3)S57D%55,HJ
M%S]532-9-QNZ[35BNE1SDV[F@6BT<*/2"?FF5UO#;.<;J,+XCT4:SI:JA_/0
MU,+6[SG0R;K=J-7?W=J*WKFN=HN@HJ&0^EO5T639;@>/X/47G-;+=&VBQVZD
MJ'U+K@UJS\_4O9'3HZ)D*1,56HK]=]-K417 HN=DX\5-IX55W$?C%CD^$ST-
M7)0,M#]]]562M:BQ\Q%,R)R+(N\UJ.731JO5V[M!11Z;TAN/EZMWUOQ[@I/4
M86Y$E@YRMTKYX-%5'QQI&DBHY$U3<@>GKNV*HHV_P?XQ8OQEQV2]V!)*6NHG
MI3W>T5.B5-'.NNB.TV.:[158].71>1R*B"C4,/I=7*\Y#?L&Q/A[57G.K=<Y
MK;;+=3UN]#/!2R21RU<\SJ=C8&-5K>M7>3KMKF\JBC*V3TDLHQ[,[9@_'3"'
MX55WUS8[/=Z>ICK:!\CW(U&2/8KFHFJM:YS)';JN3>:U.N!14O3PFCIK!@51
M,ND4-YDDD7371K(FJNQ/60+#-7'TD.,%?12Y;A/!^NK^'L;'3P7*NF6"LJJ5
MJ;R3LIV-<YK5;UR;K9$TVZA*-P<'>+5@XS8='EEBBDI',F=1W&WSJCI*:JC:
MU[F;R(B/:K7M<UZ<J+T%U1!+5E1Z3&79G?;E9.!'#^;,J.TRK3U>0555'0T"
MRH[32-7[K5:Y$56JZ5JJFW=T!1]L)])7(7<0;=PPXO81-AF1WC9:JML_/TD[
MWZI&WW/(]S58U[)'IO[%1 47_C3QMQS@O9:2MN=/+=+[=9'062Q4JHV>JD9I
MO+O*CMUC=YJ.=NN75R(C5U!$-9L](SBQBC*>_P#%GA/56+ ZE[$FO-#4)534
M,<KMUKZF!$<]$U5$7?YM?4155&@HV9P,XO-XT81+F;K0EB;%6ST*TBU7=B:0
M,C?O\YS4.FO.<F[T.4$M<U/I,Y;FF07&P\!,"DS2DM,G-5N05-4RBM[G[=D3
MI%8U4=HNZYTK5<FU&Z;046+AAZ0LN49A)PRXB8S481Q&;&LU+;ZB3GJ:MC:U
M7N6"3=;MW6N<B=<U4:NCUT5 43>+W'9W#[(+3@6)X[49?Q%OD:U%%9J>1(8X
MZ=%<G.32;KE37<>J)NZ:-57.:G***+6>DOQ*X=UMO?QPX928[C=RF;3LOEMK
M(ZZ.%[TWD1[8UD:JZ(KE;SK7[J+HUVF@*.FX9HJB*.>!Z20RM1\<C5U:YKDU
M145.5%0(]@
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MC[1<7I+Q8KC99\9S?'G(V[62I<K]$WEC<]CG,C<FZ]-U['L16*J;5U!,-QA
M
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M6CK?'[G:+S8K9=[ ]DECKJ6&HMKX6[D:TTL:.CW6Z)NINJG6Z;.0,LB
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MT=LQ5415:ML5JKT%\:TB;.F$A5[NYSO0@C5RJJ_5"C35=NQ&1(@.E=_17_\
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MQ28W8Q;(YRM38BNW[5MT]7:H7H=:AD
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M*A81/1[QJ^8?P<Q7&\DHW4%[H()F5E&]S'NC<^JE>B*K'.:NK7(NQ02I'"?
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M@99T
M    <Y4G#O-(_2_K^(K[3(F%RVEM-'=M^+FUF2CBCW=S?W_=-5/<A>AT:$ .
M/<>Q?C#Z.?$O,[CC6$R9]A.8U25D=113LBK85;+-)&U^J/<CF<^YK]YFZ[8Y
M')M0-:4/C9A_I&\?,2=656+0XO9;1+%56K#NZXJJYU]3(Y(732R*L4;$BC?(
MYK7;KMJINNU14$-L<6.'F4<2/1O@Q*WV]*?,64%KF9:JE\;7-JZ+FEF@YS>W
M$=HCVM=O;JKT41=0C!8/4<9,JX)9K@.:X0ZQ7*WXM)8\;<U[46XS.M\]-NJC
MY%1KM6Q;==U5<NU- ,CP8X07"3T;5X4\1;?);*NX-N$-73N=')+#S]2^6&5J
ML<]JN:NY(W;RIM!*EX/</20X VQ>'T_#_P XN+6^1[<?N]MK6TLB4\DBOW7H
MK)WHU%<NC7QM5NU$<YJ(%6'AG@W&7-N*_GCXM(_%[=00=S6'#J6J5[7-W7M:
MZH2)ZMW6K(]_7]<Y_P#=:U$12)%)P[S2/TOZ_B*^TR)A<MI;31W;?BYM9DHX
MH]W<W]_W353W(.A=O25Q7(,VX*9/C&+43KC?:[N#N2CC<QCG\S<::9^BR.:U
M-&,<[:O0!"%;^'=]N?HRT_#2M@;19--B[;8M-4*US(JYM-NL:]S%<FB2(FKD
MUTY=H%2]%Z;C)C-#3\+\^PE;-CE@HZCN._\ .->LU0ZJ21L2HV1[7(K9)%WV
M;.M3U02Z1" '.6.\.\TH_2_RWB+4VF2/"[A:8J:CNROB6.29M'01JU&(]7IU
MT,B;6] +T.C0@!SEZ'/#O-.&^#7ZU9M:9+1<*N[+4T\$KXI%?#W-"S>18GO3
MW353:H64O+L S"X^EO@?$*CM;Y<-M-BGHKC=4?$D<50^*Z-1BM5Z/556>+D:
MJ==[(.A:_25Q7(,VX*9/C&+43KC?:[N#N2CC<QCG\S<::9^BR.:U-&,<[:O0
M!"V<+[5<+%PSPRQW:!::ZVRQ6NBKJ9RM<Z*HIZ.*.1BJU515:YJIL70(XLXB
M\*:NX^E/)PPMDVN'YK<*'+[U01JBM8RG94.J%DT7K5575.XFS\HW8NP-=#NG
M(<>M>3X[<L7ND2/M%UI)J"IB;HW2&>-8UW?45$7K5Z"AERUA-/Z0WHWP5>#4
M&%^<K 8JB6:P5U#5-HZB%L[U>YCF[LSFHJKON8L6B/<[=>Y UI9S#\.XV<4N
M+-LXH\3Z:3"<4QYJ>)<4IJM7S3O1=YO/<TY-6[_72+(UJN1J,W-W:$9'/^'>
M:7?TK\ X@6ZTR3X?:+2VFN-T:^)(X9D=<5W5:YZ/7\M'R-7W0.A\^,O"3B%;
MN)EOX\<%VP5>64\+:6_6"I>D;*^!C.:U17N8URK%HQS5>U4W&.9UR A@<PR_
MTFN+UBJ, LG#)<&@N[%H[S?KG<&RQMI)6[LJ1ZQ1*B.15:[<;*[=541-=J%7
MF]<&JC$_1FNW";#XWW>\+;98VN3<B?5UU1*DLK^O<B-17*NZCG;&HB:KH$KB
MCXAP8JLC]%^V\),WIWVF[NHY6/1RLEDI*QE9)402?BW*BZ+N*Y$=M:JMUV@K
MBIV'YAZ3W"RP4W#FY<+TS&:TQ-H;)D5%7LAIG4T>K(>>ZQ^\C41J)OK"[=1-
MY->N"OIP*X8\7\?](#)N(/$ND8]<@L4BU%SI7QNI&5M3444K:.).<<_2&.)8
MT54TZSW2[%4DNJPCFWTDN%F>WC+L+XN\.*.*]7[#I6+/8)W-;ST44W=#'Q[[
MFHJZ[S7HCD=[E6[4"P]UF>^D;Q)MLF+8]PV7 IJ^-U/<,IO5>V5E)&_5DCJ>
M!L4<CWZ?DW(CO8TZX#Y>BKPMRGA_C&;X)GEE?#;ZNXO6EJ9'1.AKZ2:%:9ZM
M2*1ZM16QHJHY471Z>N"5:Q.R<=O1EJ[MC&+X@O$CAE5U+ZVS/IJIE+74SY$3
M5KTW97)L:B.3FE:YR:M<BJK0NEF\/X?<4N*W%ZU\8>+EHCQ6R8NQ6XOBJ2MJ
M9UE754DE<WDW7.WU<J-<KFL3=1J!&)XEXIQCP'TAJOC)PYQ./++=>[;%05$#
M7HUT<C88X7(]$>UZ*G<\;D?NJW=7=Y0K.<5<"S[,>,_!S-J&P2^++/W-49"]
M)(=*%ZU#)9&.U>BNW-ON$7D"-Y\0L/H\_P (OV&UVB0WFCEI6R.35(YG-UBE
MT]6.1&O3V CF_P!%'@SQ"QG*+IF?%2AEI+G;K938_C<-1+%,K:1B=>K.:>]&
MHQL;&-^$X-3*Y^E1PBRSB1:<:R'!FQU>3X=625E-:9W-9'51SK"YR(LBM8KF
MN@8J->Y$5N\FNNB*2)18>*_I(Y30ML=CX1KCF0SMYFHR"\5[/%M(YR(G/-A6
M-KY$37>1J*[1=FC]H&+]%GA5G_";,N(ENR^CDJ*"[OI)J')-^-8JU]))4;SM
MU)'O:Z3NG>Z].@H)8"NQSC=PBX]Y?FF$84S+,:S1\;N=BD:SFT>]DC]?QC58
M]KM_7?;NNY=>4*N57P[S23TOZ#B*RTR+A<5I=327;?BYM)EHY8]W<W]_W3D3
MW(3H0>)O"OB7A7%EW'7@I2PW>KN,*4V4XM-(D*U3=&-<^-7.:U4<D;'*B.1S
M9&[R(_>5J!ALWN_I*<=[,[A]0</?-[8+BK8[_>;I7-J%=3([56,TCA?NN5O7
M)'&]7)LU:U5U*O'%/A!6T'HP5O"+A_2276OI:>WP44*+'%+4217*GJJB5=]S
M6(KE2254W@E<6QN#MENF.<*\/L-[IUI+O;K324U;2N5KG1S11(US55BJBZ+Z
MBA):HP#AWFEH]*_/^(%QM,D&'W>TNIK=='/B6.:976Y=U&M>KT_(R<K4]R%Z
M'1H0
M
M                   :(X \(,KX9YAQ/ON1OI'T67W**MM*4DKI7I%'/72+
MSJ.8S=72H9R*O1"RWN$      T?QUX,Y-F]ZQSB)PXN\-FXBXGOI1.JVJM-5
M0.=OI$]R(_=T57HFK%:Y'JCM.5"Q*DWVS^F3Q'M-5A5]BQC$[)<&+2W*\T+Y
MG5$E*]-V5K$2>H7KVZHJ(QFNNF\U 8-\<,N'MGX6X3:L(LCGRTEN8[G*J5$2
M2>>5ZR2RN1.3>>Y=$_NIHWH!%N
M                                                          IW
M$Y_$>/%)IN%;**;+HIHG0T]RV4\L.NDC=55NCM%U3KDY.4#6_ CA#FN/9)D7
M%;BW6T]?Q)R1K*5&4JHZ*CH8]W\6BM:UNKN;C31FJ-:Q.N55<%EOD(
M
M
M
M
M
M
M
M
M
M
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M73OIGR?_ .8P$JU3U$T<Z5#D>^*98T<B:;$:U>3^TDD)Y%
M
M
M                    ?*:EIJG=[HACFW==WG&H_37ETU1?4 PUGCCBO=YB
MB:C(F21(QC41K4UIXE71$Y-JZFIT)#/&5
M
M                         >)?R3_@K[0&$M7T?!\'\*FI9A,(H  6CDK/
MWEW^A@DADB*
M
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M.;_;N]Z3QQ=^_P"I^6DZHX-FS&H^<W^W=[TGCB[]_P!3\M)U1P;-F-1\YO\
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M.;_;N]Z3QQ=^_P"I^6DZHX-FS&H^<W^W=[TGCB[]_P!3\M)U1P;-F-1\YO\
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MMOLI%,)?K_T)OK]YN-[GNF[\T:9KT-VGRC]+
M           >)?R3_@K[0&$M7T?!\'\*FI9A$R#)[#BM&VOR"NCH:5[MR-TF
M\YSWK_=:UB.<Y?801!,T?2ZY#9+';VW2\5\-#;W;N[/.Y(VKO\B)KMU7U!0J
M^MJO%KOE$RXV>KBK:&3W$\#D>Q53E35.B!.M')6?O+O]#"2L,D10
M
M
M         ?"IK:*B:CJRHBIVKR+*]L:+V2H*#Z12Q3L22%[9(W<CV*CFK_:@
M'L        JHB:KL1.50/G!405,:34TK)HEU1)(W(]JZ<NU-4 ^@    Y7](
M'^M%_-M_51'W?T[_ &;O2_%_K[_)W7Z9];4Y]4_,@
M                                                       =&^C3
M]$7_ />8/U;CX?ZC_?L]$OV7Z _L;W]4>IO,^2?J
M               #Q+^2?\%?: PEJ^CX/@_A4U+,-39A3VJ\<:K!;,J2*2RT
MULEJ*"EJ].YY*ESUU56OZUR]:FQ?4-1H9G2QE9#;>*_%V6UU.E7A&(4N[)"U
MVE--5OV*JJU=-$5=W_!ZBET0FF63X0PV^W9SGUGQIZ.Q2FFI'4[(WK)!%4.2
M1)&QNU5.AHNW^ZA)6W2W+:.2L_>7?Z&&);ADB*
M
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M?T[_ &;O2_%_K[_)W7Z9];4Y]4_,@
M                                           =&^C3]$7_ />8/U;C
MX?ZC_?L]$OV7Z _L;W]4>IO,^2?J
M   #Q+^2?\%?: PEJ^CX/@_A4U+,-=<9*#A=<:*ACXB7%UME8KW4%13:K5[J
MZ(]&M;%,JM71-=6:%BJ74Z5=Q?,> >-V&HQ2Q7N1D-R1T-34.I:QU3*Z9O-Z
MN>M,B:HB[-FB>H7%(F&TL-PZP83:&VK'H5CI7+SLDLB[TLKU3W3W:)JNGK&9
MEJ(HL-HY*S]Y=_H825ADB*
M
M                                       #24F9X%FUZO.(\4[)16JY
MVF964KJQ^\Z2'W[)]R-6:HJ+HCMJ*;I,:&*Q.E6>%-2D/$K)<5P>X3W# 4HW
MNCYU[WQ03JU$;S:NY.O5S45--Y/8-2S&E/X(YIC&$8E><=RJMCMUZM-=4R5L
M4^J22HY$1%:BIJY5W=-"715;9HA<1[YC^1\$'W?&;(ECM,]W@YN!L,-.DKFO
M5'2[L.Q=Y>BNT1I29P;!XJVNX7C@I7T5L:Y]4E#1S<TSW3XX'PRO:FG_ "M5
M21I:G0TU3-LMYX<TT5XXJSQ6A*:&"?'EH8W21/A:W2%C$>CE1JIHUR&F.C2S
M'%>SU%@K>&]R;>JBEL=# M']864^]) ]R[S95A<NQ5:O(J] 1*S&A.H[-8;K
MG^+35W$V;);Y32K-;864;'(C41'N:^2-_6[VG1Y =.E8N%__ +R\2_ST?^HD
MZ%MTRP'"G^ON,J=#NFLV?_BJL>0C3*LTO_Q2K?Y@W_KHATI_M7/BU_\ 'BU_
MF[9^ 1IE9_=1N(-1'8,EX1YA=]5Q^E@9!53*BN;#(Z*-4>[35?[V]_@+Y4GH
M?O$'+<=R3BQP]IK%7Q5[Z2IWJA\"[S&I*J*U-[D5=G(2(I"S-9=#G-T<K^D#
M_6B_FV_JHC[OZ=_LW>E^+_7W^3NOTSZVISZI^9
M                                                     Z-]&GZ(
MO_[S!^K<?#_4?[]GHE^R_0']C>_JCU-YGR3]0
M            >)?R3_@K[0&$M7T?!\'\*FI9AH_B9=\/L7%^S7'+XFU]L\6O
MCDII8>Z&02;ZK')N.16NUU7DY%-QH8G2R,'$_@-)-''#;J3GGN:V/2UQHN\J
MZ)MW/5)25K#=+%:YC7,]PJ(K>AL7D,-O5HY*S]Y=_H8)(9(B@
M
M
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MB/N_IW^S=Z7XO]??Y.Z_3/K:G/JGYD
M                                            #HWT:?HB_P#[S!^K
M<?#_ %'^_9Z)?LOT!_8WOZH]3>9\D_4
M      'B7\D_X*^T!A+5]'P?!_"IJ68:NXF9:RRY10V=,&@R>MKJ=7TLSHXY
M9W)&J[S6M6-[M&]+::B,&9E3Z[/YK.ZF6X<'XJ-U3*V&E=+31Q[\SO<M:JP)
MUR] M$KYFS,(SC+<CNCZ"^8=5V"C9"LC:NHW]Q7-5$1B;S&IJNIF8:B9;!M'
M)6?O+O\ 0PS+4,D10
M
M                                                   #E?T@?ZT7
M\VW]5$?=_3O]F[TOQ?Z^_P G=?IGUM3GU3\R
M                                                  !T;Z-/T1?_
M -Y@_5N/A_J/]^ST2_9?H#^QO?U1ZF\SY)^H
M           /$OY)_P %?: P%!/#3VR"2>1L4>FF^]R-35573:IJ66L.(4&5
M8UGELXAV.U/OUMCHGT%;10*O/1HKE=O-1$5=%UY41>3::C11F=-5>R#),PXN
M^+L:M>)5MFH65L%76W*XHL:1M@=O=;JUO_#55+$429F6_F-W&-:JZJU$35>C
MH<W1ZM')6?O+O]#!)#)$4
M
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M3:JKL&63-"X12LGB9-$N]'(U'L<G1:Y-44RT]@
M                 !&K*-:QK&]T34Z-55_$/1BKKZJZ*NPL2,19(N8N]X@W
MWR\W)$G.2KO2.U@C=UR]'373V"SH2%@,J
M
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MS"W&6@    1+C^S_ .)OME@2R           0[E^19\-I81+;R)[!%?H
M     !#K/RU-\/\  43"           0JO\ ::;X91-(          !#E^D(
M/8=[11,(          !$7Z03\VOME$L@          $1GTE)^:;[91+(
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MEJ4VP
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MS0X7Z6I3;
M                                                          9K
M$/ZJLO[]3?K6A8TNYCQ7D@'B7\D_X*^T!A+5]'P?!_"IJ684+B#Q.^JUWI<;
MMF-5647J>'NSN.E15W&-=HUW6Q3.U14UV,V%B$F6OLJXT9ZRURU,7#ZXX]5;
MT,:7FH;*Y&,YUJ\VO.4;$_&:[B==RN]4L0S-TMOX#E-XRVT27"]8_4X[4QR\
MTVEJ]_?D:C47G$YR*%=%U]3^TS,-Q-5KM')6?O+O]#"2L,D10
M        *CA_T_F_\XB_[;1FI9A;C+0    (EQ_9_P#$WVRP)9
M (=R_(L^&TL(EMY$]@BOT          AUGY:F^'^ HF$           A5?[3
M3?#*)I           (<OTA![#O:*)A           (B_2"?FU]LHED
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M2TP2N+JACM]C7Z*F\B+HO*FIR=7+?I _UC_@3]3"=[-#A?I:E-L
M
M                                       !FL0_JJR_OU-^M:%C2[F/
M%>2 >)?R3_@K[0&$M7T?!\'\*FI9A^+:+6ZZ-O3J2);LR):=M;NISR1*NNYO
M<NFHJ/5RMEOO%(ZANE-'5T;W,>Z"9J/8KHW(]JZ+ZCD14"I2(C41J)HB;$3U
MB#]M')6?O+O]#!)#)$4                   "HX?\ 3^;_ ,XB_P"VT9J6
M86XRT    ")<?V?_ !-]LL"60          "'<OR+/AM+");>1/8(K]
M     (=9^6IOA_@*)A           (57^TTWPRB:0          "'+](0>P[
MVBB80          "(OT@GYM?;*)9           (C/I*3\TWVRB60    !7L
M\_HK(?Y=5?JG%C2DZ&4L_P!$4'[M#^K03I(32*    #\:YKO<JBZ<NBZ@?H
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MTWC9U'W L.K>9YK9MTTUUV>J:KA1*8U6DRKEGT@?ZQ_P)^IA.]FAPOTM2FV
M
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M2S"W&6@    1+C^S_P")OME@2R           0[E^19\-I81+;R)[!%?H
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MJ>/CEFNBL9?QS4\VCS5K3I>5AFBFFDYM/\.6OG_>\]*5Z&X#D[
M                   '+/I _P!8_P"!/U,)WLT.%^EJ4VP
M
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M    $2X_L_\ B;[98$L@          $.Y?D6?#:6$2V\B>P17Z
M0ZS\M3?#_ 43"           0JO]IIOAE$T@          $.7Z0@]AWM%$P@
M          $1?I!/S:^V42R           1&?24GYIOME$L@    "O9Y_160
M_P NJOU3BQI2=#*6?Z(H/W:']6@G20FD4
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M2?\ !7V@,):OH^#X/X5-2S"810  M')6?O+O]#!)#)$4
M5:NSVQV;(9\?R"1+2J4W=M#7U;DBI*F%B:S(R1VC=^)?=,7;NJBIZUHB/B6<
MR9I<:F6SVJH9B$$:I37ZI186UE1O-32GB=H]8D;O?C%3:NP3%!<2*J.'_3^;
M_P XB_[;1FI9A;C+0    (EQ_9_\3?;+ ED           AW+\BSX;2PB6WD
M3V"*_0         "'6?EJ;X?X"B80          "%5_M--\,HFD
M  AR_2$'L.]HHF$           B+]()^;7VRB60          "(SZ2D_--]L
MHED     5[//Z*R'^757ZIQ8TI.AE+/]$4'[M#^K03I(32*
M                          "-6)<51GB]T+7:KOK.CW)IT-$:J%@8>S/D
MCN]W[M?&E2LD7..9JV-5YB/3=1RJO)IT>4LZ$AG>?@^-9V2&5.?@^-9V2 .?
M@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2
M .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-
M9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?
M@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2
M .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-
M9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?
M@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2
M .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-
M9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?
M@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2
M .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-
M9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?
M@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2
M .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-9V2 .?@^-
M9V2 .?@^-9V2 >)9X.:?^-9[E?[R>H!A;7+$V@@1SVHJ-VHJHG14U+*7ST/Q
MC>R0*<]#\8WLD <]#\8WLD ^EG5'-K%:NJ+4NT5/@,))#)$4
M   A7>FN-7;:FFM-:EMN4C-VFKG0MJ4B?[Y8G*U'>PJ@:(XI6:IAM<5JXE<4
MJ&.GF<VHI8'X_&^I1T:[)(VP3.D3;UJN1-%VHO1.D>:&9;(P-;TVY7.AN6;T
M^3>*D2CJ;;#;8K=+2S[%:YZLD<JHK45$ZW=7H+L,RJ^&55'#_I_-_P"<1?\
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MRM16JUDC?=-1%55753%_1/FC[?;#R8-6:)CSS]OMCY<5O,.@
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M4.X:+O:+L&]05'WLK&L95L8U&L2H=HU$T1.L9T"20R9%
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M0>\D[$4%?SFX0OPS(&HR1%6WU*)JW1/R3BQ&*3H9^S_1%!^[0_JT).DA-(H
M     #XU4<\M--%2S=SU+V.;#.K4D1CU38[=541=%Z!)6-+!8YA]#8[#+9:Y
MS;NZNEGJKM45,,:)5U-4Y7RO?$U-Q$77=1O0:B(;NF)B(Z(T?;TXL6Q29GIG
M3ZO5$0FKBV,+:O$*V6@6QZZ^+.Y8>Y-==?R.[N?\"3-=*Q%-#(4M+2T-/'24
M4$=-2PMW(H(6-CC8U.@UK41$3V!,S.DB(C0^Q%
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M(T5B.BZ?+"\GJ'U0
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M_9N]+\7^OO\ )W7Z9];4Y]4_,@
M           W%Z-_]:7'^5R_]1 ?,_47^/;^N/5<_0_H/_L+_P#BN_KL=/'P
M#]R
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MO1+ F(B(FB;$3D0@          $*Y(BQ,U37KVEA)3&IHU-/4(K]
M  (%=%&^>F5[&N5'[%5$7H%$_DV)R$           A5?[33?#*)I
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M5$?=_3O]F[TOQ?Z^_P G=?IGUM3GU3\R
M                 #<7HW_UI<?Y7+_U$!\S]1?X]OZX]5S]#^@_^PO_ .*[
M^NQT\? /W(
M              \2_DG_  5]H#"6KZ/@^#^%34LPU)Q+KKI@G$"U<1(;7-=K
M-)0R6ZN93HJNA?O;S554141':[-?47UC48Q1F<)JB</6WN]9'DG&/(K;-1P=
MRN@LM!*U6R=S1,15W-Y$V*C?=:;7*I9\B1Y69X14UZO%[R?B%>;?):F7]\$5
MNHID<V1*>G1R;[MY$7KM6[?9)*V^5MFT<E9^\N_T,,2W#)$4
M   Q>1U5YH;'7U>/43;C>H8E?144CDC;+(G(U7*K43IE@:4CRR[W:9L'$G,;
MC@[Y%36U4UL=:(M>1=RXS=T;R>NDC>INGD9;.PK$,(LSYK]C#TN-=7LYNKO;
MZR2XSU":HO73/D>B[6I[G0Q,RJXD54</^G\W_G$7_;:,U+,+<9:    !$N/[
M/_B;[98$L@          $.Y?D6?#:6$2V\B>P17Z          0ZS\M3?#_
M43"           0JO]IIOAE$T@          $.7Z0@]AWM%$P@
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MO\G=?IGUM3GU3\R
M#<7HW_UI<?Y7+_U$!\S]1?X]OZX]5S]#^@_^PO\ ^*[^NQT\? /W(
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MXF:E%[,JJ.'_ $_F_P#.(O\ MM&:EF%N,M     B7']G_P 3?;+ ED
M     AW+\BSX;2PB6WD3V"*_0         "'6?EJ;X?X"B80          "%
M5_M--\,HFD           AR_2$'L.]HHF$           B+]()^;7VRB60
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MMOZJ(^[^G?[-WI?B_P!??Y.Z_3/K:G/JGYD
M                    &XO1O_K2X_RN7_J(#YGZB_Q[?UQZKGZ']!_]A?\
M\5W]=CIX^ ?N0
M                !XE_)/\ @K[0&$M7T?!\'\*FI9AJWB)C'$NKSBVY1@K*
M1G<%(ZF66=[&N?SKE5S'M<BZM3H&HF*,S$U18%](_GH^?;:^8WF\[HZ'7<UV
MZ=;ZA<#\S<S-[<;O^[T3>T]7HG-MZM')6?O+O]#!)#)$4
M    "HX?]/YO_.(O^VT9J686XRT    ")<?V?_$WVRP)9           (=R_
M(L^&TL(EMY$]@BOT          AUGY:F^'^ HF$           A5?[33?#*)
MI           (<OTA![#O:*)A           (B_2"?FU]LHED
MB,^DI/S3?;*)9     %>SS^BLA_EU5^J<6-*3H92S_1%!^[0_JT$Z2$TB@
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M)ZNYO>P,"DNL[9<[?>K=2W:TU,=;;*V)E125<#D?%+%(F\US7)L5%12"6
M             K&:8-:<XHZ:GN,M12U-#+W105M'*Z&:&;33>338NSU4+$T2
M8JPN*<([+C=\^L];7UM^R%K%B@KKE+SBQ,78NXWD1=-FI9N2+6P3+3E?T@?Z
MT7\VW]5$?=_3O]F[TOQ?Z^_R=U^F?6U.?5/S(
M                      -Q>C?_ %I<?Y7+_P!1 ?,_47^/;^N/5<_0_H/_
M +"__BN_KL=/'P#]R
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M2V\B>P17Z          0ZS\M3?#_  %$P@          $*K_ &FF^&432
M        0Y?I"#V'>T43"           1%^D$_-K[91+(          !$9])
M2?FF^V42R     *]GG]%9#_+JK]4XL:4G0REG^B*#]VA_5H)TD)I%
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MO]S%N[NK.:)Z?)+[/Z0[$YSD^<NWF_W>2V=W,5K&G-9/1/FEOT^.?K(
M                                                          !X
ME_)/^"OM :]RC,Z? \/BR"JI)*R!DD<+XXE1JISKE3>551=B&Z5EB9I"E9RO
M"_.I;?>H,XI;#D=%'I2W*DK(FRM:_KMUZ(]B]:NO(Y%Y2Q6$FDL!:\:PBIN]
M%79EQ7CRMM'*V2DH)ZID</.(O6ZM=43:[?4TU+5*1Y6^*6\VBLKZFU4==!-<
M:)K'55)'(UTL39$U:KFHNJ(IBC:?:.2L_>7?Z&$E89(B@
M    5'#_ *?S?^<1?]MHS4LPMQEH    $2X_L_\ B;[98$L@          $.
MY?D6?#:6$2V\B>P17Z          0ZS\M3?#_ 43"           0JO]IIOA
ME$T@          $.7Z0@]AWM%$P@          $1?I!/S:^V42R
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M'4$O=53&KJFYU^[NK45DVBR/1.@U-$8Q/>M37;JI65_(
M !&K+A24",=5/5J/54;NL?(JZ<NQB*6(&(LD\=3=[O4PJJPRR1*Q516JJ-@C
M:NJ.1%3:B\J%G0D+ 94
M
M          !XE_)/^"OM 5J*WT-UL;;?<J>.JHIV*R:"5J/8YJJO*BFNEEJG
M.L7X&X)#!)=\=;-7USG)1V^E=4/FE5NFJHU)41&IKU#45EF8B%:Q&NX!7^[4
MMO?BLMGK*B7<H9:MU1S+YFK[G?;*J([5--O1+BD4;[H<:L5MNU;?*&BCANUQ
M:QE;5-WM^1L:(C475539IT$,5;HRUHY*S]Y=_H825ADB*
M    !4</^G\W_G$7_;:,U+,+<9:    !$N/[/_B;[98$L@          $.Y?
MD6?#:6$2V\B>P17Z          0ZS\M3?#_ 43"           0JO]IIOAE$
MT@          $.7Z0@]AWM%$P@          $1?I!/S:^V42R
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M&V5'HUNF^B;VZJ;.0Z;V^+[LWE_!G=VS;%)Z%M.+J
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MD=9KE2W%L*HDRTD\<Z,5VNF]S;G::Z+IJ*%4\B@
M                                  /$OY)_P5]H#"6KZ/@^#^%34LPU
MW?K551<8[)>JFWR5UKJ;;-1T]2R-9&4E2Q5>JOV*C=6KL<IJ-#/2U':*FNR6
MR4_#JU6*IENT5^DKIKP^+2"E@2I63>W]-454V=#^TW+$8X.JF-5K&M5=51$1
M5]70XNSU:.2L_>7?Z&"2&2(H                   %1P_Z?S?^<1?]MHS4
MLPMQEH    $2X_L_^)OME@2R           0[E^19\-I81+;R)[!%?H
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MO9H<+]+4IM@
M    '0_HS_L61_G:3_3*<MXZ[MODY.H
M                          #Q+^2?\%?: PEJ^CX/@_A4U+,*'GV9Y72W
MZ@PG :."IR.M@?5U%36+I!34[5W4<NU-55=?5]A2Q"3/D5OZV\8,$J:&LX@P
MV^XXS55#*6IJZ'K9J=TSM&.T1&)IK_R+[**6D2E9C2W6BHY$<U=45-47UE,-
MOVT<E9^\N_T,$D,D10                   *CA_P!/YO\ SB+_ +;1FI9A
M;C+0    (EQ_9_\ $WVRP)9           (=R_(L^&TL(EMY$]@BOT
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MKJYC41KEUZ'(Y"T2K.D5RSZ0/]8_X$_4PG>S0X7Z6I3;
M                                      .A_1G_ &+(_P [2?Z93EO'
M7=M\G)U
M   >)?R3_@K[0&$M7T?!\'\*FI9A3LIPR]U68V7-,8K8Z6NI=VCNM/,FK)Z!
MTB.?NKMT>B;VG]GJ%B4F,4#B?C]ROM?;/&EX@M7#VD?!471LGY6:J;,O-L1=
M.155B;5Y?5+:3#93-W<;N>XT3=TY-.@8:>K1R5G[R[_0P20R1%
M      'QFJJ6G5&SS1Q*NU$>Y&JJ?VJ!Y97T,CTCCJ8GO=L:ULC555]9$4"0
M!4</^G\W_G$7_;:,U+,+<9:    !$N/[/_B;[98$L@          $.Y?D6?#
M:6$2V\B>P17Z          0ZS\M3?#_ 43"           0JO]IIOAE$T@
M        $.7Z0@]AWM%$P@          $1?I!/S:^V42R           1&?2
M4GYIOME$L@    "O9Y_160_RZJ_5.+&E)T,I9_HB@_=H?U:"=)":10
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M^.$='=YG5%[J[))7W65ZHNM55/1[T33H-V-_L-SH8MC%TR<G5RSZ0/\ 6/\
M@3]3"=[-#A?I:E-L
M          Z']&?]BR/\[2?Z93EO'7=M\G)U
M                                >)?R3_@K[0&$M7T?!\'\*FI9AKC/
M\/SO,<KI*&WW>IL>'Q4BNEK:.1J.6KWEZUS$D9(NJ:;>0U$T9F)F5+RG@)EG
MB:7Q=EUROM5SD.[;:A_-QN;SK=YZNEJ-W5B:O3UTV;1F2;6V\ Q"LPVSR6ZN
MO-3>I99>>[HJ][?8BM1-Q-Y[]B:>J29JW$46RT<E9^\N_P!##,K#)$4
M           :?XDT&'UG$.P+Q%A@CQ9+=4)05E7^*IGW)9F_BII]FZB1:O8U
MSD:JZ\JH;BM,$E5*[%>"=;FE*VP4]!5X]36VMGRJHHYG245'$QK'4TR3QN5K
M)5=O)HQ^JIKJFPM9HF#;/"FIKZSA[8JBXR2RS/A>D,U3KSTE*V5[::1^\B*J
MOA2-RJO+J8G2L/IA_P!/YO\ SB+_ +;1EE(6XRT    ")<?V?_$WVRP)9
M        (=R_(L^&TL(EMY$]@BOT          AUGY:F^'^ HF$
M  A5?[33?#*)I           (<OTA![#O:*)A           (B_2"?FU]LHE
MD           B,^DI/S3?;*)9     %>SS^BLA_EU5^J<6-*3H92S_1%!^[0
M_JT$Z2$TB@                           .5;5C5U3CK+ACXG)CM->7Y
M_K52/=2#GHT]147>:W9T3K7!RIBE<;\;NS^)MOH+<QRV_,NX8*I6M56))35"
M,U=IZB.15UZ"BV<"Z,6RN.V%W#)L"CI;% M14VB>*ICHF+H^6&-%8YK/^9$7
M5/8,VRU=&#45):N$UV91VVDQW**V_3/CBJK8NK4@>JHCU>]Z;NC=JI_QT-XL
M8,[Q6PBCM7$:ERJ_V^X5^#UE%%25,UL575-+-3L2-JN1$VMT8U5]E>BFBR)6
MZ,6=X3V7A_4YEXVQ"SWMK*"F>K+U<EW*9SY=8UB1KT1RKNNU14)=6BVTJUMB
MW"VYY#9<DS.P334N96.]2R6R-56-DD=/I,J-V:[Z[W6]#5-.CJ69Q9B'2?#;
M-HLZQFGNCXG4MTB_$7.CD:K71U#-B[%_NN]TTQ,4=(FK <1N%UYS;(;3?[=D
M3K2^SL7N.+F4F2.=SM72MU73>5$;T.@6)HDVU:KI,,SF+C>RVRY742W6.VMG
MDOBP(BO@1R*M.J<FU.B:K@S2:NH&(K6-:Y=YR(B*[U53HG)U<M^D#_6/^!/U
M,)WLT.%^EJ4VP
M      #H?T9_V+(_SM)_IE.6\==VWR<G4
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M4G0REG^B*#]VA_5H)TD)I%
M   Y9]('^L?\"?J83O9H<+]+4IM@
M                     '0_HS_L61_G:3_3*<MXZ[MODY.H
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MQEH    $2X_L_P#B;[98$L@          $.Y?D6?#:6$2V\B>P17Z
M   0ZS\M3?#_  %$P@          $*K_ &FF^&432           0Y?I"#V'
M>T43"           1%^D$_-K[91+(          !$9])2?FF^V42R     *]
MGG]%9#_+JK]4XL:4G0REG^B*#]VA_5H)TD)I%
M                  Y9]('^L?\  GZF$[V:'"_2U*;8
M                                     !T/Z,_[%D?YVD_TRG+>.N[;
MY.3J
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MS4LPMQEH    $2X_L_\ B;[98$L@          $.Y?D6?#:6$2V\B>P17Z
M        0ZS\M3?#_ 43"           0JO]IIOAE$T@          $.7Z0@
M]AWM%$P@          $1?I!/S:^V42R           1&?24GYIOME$L@
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M['MT<UR<XY%Y4]03;&2+H\LVZHMFO\S-M\\2;)\D7:YNBGW95^.3L
M                /+GL8FKW(U/770#"VI4=?;VYJHK5DAT5-J?L\1J="0SA
ME0
M                                                     'B7\D_X
M*^T!A+5]'P?!_"IJ683"*  %HY*S]Y=_H8)(9(B@               #4G&*
MEQ&:NM<UWIKQ<LBIH*BHMU!8IG0RQT\6ZLU1(Y'-;&U-6MWU75>1-3=J2^&
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M5U\M+;NE,ZKC2;<5NYO)KJ;RS1RXMF;+6*LRBHY$5%U1>14,.K]
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MPPAMJGF;4015#/<2L;(WV')JA)BDT+9K%7T(H
M   $:LHFUJ,:Z>:%&*J_B)%B5=?55O*6)&(LD*4]WN\"/?(D<D2))*Y7R+K!
M&[KG+M7ET]@LZ$A8#*@
M
M          /$OY)_P5]H#"6KZ/@^#^%34LPF$4  +1R5G[R[_0P20R1%
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M895C&1M1C&HUJ;$:B:(AEMZ          (4S6K<*=51%V.]HHFD
M Y=B@8=UGM;KJDZTD:R[BNWMU.7U3>::.?#MK6D59A$1$T1-$3D1##H
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M&N.7+Z^C[Y_!L=C&QL;&Q-&,1&M3UDV(8:AZ
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M\QYE@/#>T
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M-2S"W&6@    1+C^S_XF^V6!+(          !#N7Y%GPVEA$MO(GL$5^@
M      $.L_+4WP_P%$P@          $*K_::;X91-(          !#E^D(/8
M=[11,(          !$7Z03\VOME$L@          $1GTE)^:;[91+(     K
MV>?T5D/\NJOU3BQI2=#*6?Z(H/W:']6@G20FD4  :E](>'G\*H&*FNETA7_R
M]0>%SEV6R/2^I^FO\F[]$^NUS1XN3WIZCC/T2IXN3WHXQ59>'E"D>=8\_=TW
M:^G7_.AVW.]K?$>=Z[M*?_R[S],NS#WS\C
M      !ROZ0/]:+^;;^JB/N_IW^S=Z7XO]??Y.Z_3/K:G/JGYD
M':W#3^@,<_<(?])^5=H_Y.\_5+^FNPO^OW'_ !V^I:CU[W8
M
M                         !XE_)/^"OM 82U?1\'P?PJ:EF&J,_H'YQQ.
MLN"5]3-38]344ESJH8'JQ:B7>W6HJ^HU$V?VFHPAF<9H@YHVJXB\1*;A?05\
MU'C5EI4J;Y+3.7??-NHK(U7DV(K.7HJO101A%4G&:,IPB2NQ_)<NX?25\MRM
M5D?336V:=V])&RH:Y71JO]B;$]?U1*V^1MVT<E9^\N_T,,2W#)$4
M        :^R*Z3.XF6"QUUWEM%E;12W*FBC>V!MPKHI6L6"1[O=MCC7?6-.7
M75>1#4:$?.MK9+9Q8M-+:[Q/5MOT55X[L3YDFIZ2.CIV\U4QQZ:PJY[6QNVZ
M/5VO*@Z!L4RJHX?]/YO_ #B+_MM&:EF%N,M     B7']G_Q-]LL"60
M    "'<OR+/AM+");>1/8(K]          (=9^6IOA_@*)A           (5
M7^TTWPRB:0          "'+](0>P[VBB80          "(OT@GYM?;*)9
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M>[
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M1+;R)[!%?H         !#K/RU-\/\!1,(          !"J_VFF^&432
M      0Y?I"#V'>T43"           1%^D$_-K[91+(          !$9])2?
MFF^V42R     *]GG]%9#_+JK]4XL:4G0REG^B*#]VA_5H)TD)I%  %%XK4G=
MF.TT6\UFE;&[5ZZ)LBE3\)Z;M>*[F/U?LE]!V%?DW\S_  SZX:8DM:1O5FK7
MZ?WF;4Z9\C.$ONK=]6'CQ>GJ&<S7%6#$[1S>1VB?G8NMJ87;J.Z[W2+IIIRG
MG\G;_P#=9C&F'K.?W]>7OBD_NRW-F]YJ<>P^^WVC:CJNW4-150-=M17Q1JYN
MO]J'VV\F8MFC\ZW<1-T1+7V+TM?A^>XU8VWN[7FCRBR5]PN/C:MFKV,K*!]'
MNR0\\YW,H]*EZ+''HS8FB(>9,16^V(PMI3RZ9C[>AXML3-EE\SC.$^>L5K]U
M/Q8GB#;<M3,K[E]?#=DP6Q4=%S;;?DM=96N9 DL]3-%1TB+'4/17HUZ3OCU:
MS1%=R'*R;;<9TYO3A^6F&BE:U]3=^:ZML:,OHQ_-7'3HI1O&"6.H@BGB7>BE
M8U[%7HM<FJ?\#,Q2:2MLQ,5A]"-          !I9^.\.>,%XNMQLTE;8\NM$
MR4];<:1>Y*I7MZU'*B+UVF[IO<ITQASPE#P?*\PLV>WSA??+JN0LHZ-\]!=7
MMTG8YL:/:V1=5U71VBZJNU!,01,UH>CS;K'7X)>)KQ3T]1<IZ^J9>W5#&.<K
M=U-CU<GN=%=_Q%U2W0P'$6DPFDX)U-+@=6^LL;;S#O*]TCD;,KUWVMYQK=GL
M)H6*U2:4P7CBI ^V<#+@EC@93.[AHHY.8:C%2!\L*2Z;J)L5JKKZVIGI:G0U
MU'BG$')>%ENM5/;L<I\9=1T\]/<DD6.>-&(UZRND5=$D5=><5>CJ:P9I-'VX
MGT^4TU^X86>M2EJZR*%4YJM>YU!+7,<C6\X[HIINZ"">AFY,*XDW'B'C&3WJ
MGLMJJ:"16.;;Y5BEJ8&[7HK575^ZU5_L45BBTFJ7PVH:*JXT\2)JFGCFEBE:
MD3Y&->K4>J;VBJBZ:]$DZ"-,L1PDT@S7C#0P(D='#4U?-0,1&L;I45341$3D
MT1$0>0C3*LTO_P 4JW^8-_ZZ(=*?[5IXIVNVTWH]6EU/1PQ/C;;GL<R-K51S
MT3>5%1-=5U741I6=#Z9XL=?G'!Z"_*DMDJ(6R.CFVQ252LBTWD78NKEC3;ZH
M\I/0G\5*2VTW%GAPZE@AAJWU#DE6-K6O<QKDW=[1$543;IJ+=!=IAO8YNCE?
MT@?ZT7\VW]5$?=_3O]F[TOQ?Z^_R=U^F?6U.?5/S(          .UN&G] 8Y
M^X0_Z3\J[1_R=Y^J7]-=A?\ 7[C_ ([?4M1Z][L
M
M                  \2_DG_  5]H#"6KZ/@^#^%34LPTUQ+L]HR'BK8;/F-
M<L.,RV^5]-"DZ0L6J8_5R/V[-4W=O1Y#<:&)TI\/"'@I%-'+%/#SK'-<S_U!
MJ]<BZILWO5)65I#<#&M:QK6^Y1$1OL(8;>K1R5G[R[_0P20R1%
M     (-ZMS;Q9[A:7/6-M?334JR)M5J3QN9K_9J!IJALN<Y%0X9P^O>.26NT
MXM44<MZNSIHI*6KBM,>Y R!&KO/294:KM43=-X:65IW+SE_$^V7%;15VO'L+
M\81MKJYB0K75E6SN7_P[=55T*,WGI)R*31"ME&55'#_I_-_YQ%_VVC-2S"W&
M6@    1+C^S_ .)OME@2R           0[E^19\-I81+;R)[!%?H
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M          .UN&G] 8Y^X0_Z3\J[1_R=Y^J7]-=A?]?N/^.WU+4>O>[
M
M                                  /$OY)_P5]H#"6KZ/@^#^%34LPT
M[Q=DX.QY% O$"FK9;LM,WFI*;GDCYG>=HG6/:FNNIJ*LS10HJ[T9()631T=S
M22-R/8NM2NUJZI_]0N+.#=^&<6<.S>XNLV/R5#JJ&%952:%8V\VQ43E55]4S
M,-Q=5?+1R5G[R[_0PS+4,D10                   *CA_T_F_\XB_[;1FI
M9A;C+0    (EQ_9_\3?;+ ED           AW+\BSX;2PB6WD3V"*_0
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M?N/^.WU+4>O>[
M                                                    /$OY)_P5
M]H#"6KZ/@^#^%34LPU!Q'O5'BG%.P9'EE+)/BB4$U-33MBY^."J>[KG*WWRI
MN^OIR<AJ-#,Z6"S_ #W#LW2RX_@D#J[)77*FJ*>>"F6+F61NU>JN5$7:G+IL
MTY2PDS5T!3T=-3HUT<$4<VZB.=&QK5]?:B&*NB1:.2L_>7?Z&$DADB*
M              !4</\ I_-_YQ%_VVC-2S"W&6@    1+C^S_P")OME@2R
M         0[E^19\-I81+;R)[!%?H         !#K/RU-\/\!1,(
M  !"J_VFF^&432           0Y?I"#V'>T43"           1%^D$_-K[91
M+(          !$9])2?FF^V42R     *]GG]%9#_ "ZJ_5.+&E)T,I9_HB@_
M=H?U:"=)":10 !B[\S?HV)_]U%_RN/4=JQ7=1^K]DO+Y6:7?<KO<Z>H?,<-[
M+B'<Z>H.&<1]Z&!&UM.[3DD;[9Y7*64WUOI<][?^25O/M'I@
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M;!"^94=(K6)HBN5J-37V$0^?WV]G>WS?.FZ:ONN4Y:WEMS9NK:TLB+8KIP9
MXO*
M                                          /$OY)_P5]H#6F<6S*K
MK@?,8;4.I[[&^.:+<?S2R,C<JNC1RJB)O)ZJG2-+$Z%)ES[C!-3=Q5W#1*N/
M=1DK9'K(QZIL551=Y%U+2&:R^=IR[B5;9VMH.%,%NCE<ULTE,U(>M54157<:
MFN@I!6?(VE9[QDM9DMVMMRLO<=CI(X76ZY[Z.[H>]-7IN]#1?:,S#:R6CDK/
MWEW^AAF5ADB*                   !4</^G\W_ )Q%_P!MHS4LPMQEH
M $2X_L_^)OME@2R           0[E^19\-I81+;R)[!%?H         !#K/R
MU-\/\!1,(          !"J_VFF^&432           0Y?I"#V'>T43"
M      1%^D$_-K[91+(          !$9])2?FF^V42R     *]GG]%9#_+JK
M]4XL:4G0REG^B*#]VA_5H)TD)I%  $&ZHUU.U'+HF^GM*>!ST1-D5\OM=-W-
M)8=6,Z"[#T4V6]#R,TOS<83+"YI?>E9&E1$N\NN^WH>N>5N++<]N/2Q==-'G
M/JVOMN$9%<+4JI<J:W54M*YONDE9$Y6JGKHI[[>S2R7+=16^&NL8L%DP_B+A
M]'A]##16^^XY<:F]NIM&)534TE L%1.B?E)56:1.==JY==%4\Z["=Y;HB)C#
MR368P\F&NCPMW$3N]W?6MVCTQ,5F9]$Q'HKYV(S>R6>[R<4\GN]'%49+C$E*
MS&J^5$2HH8X[=35,:TTB[8N<FDD1ZL5-_P!R[5-AQMNFVVV8TY_VVQ3T4IAY
MW:ZV+IFV<?R:/?Q]/G\S?%(^22E@DF3=E?&QTC?4<K454Z9+M.!;,S$5?8RT
M                          !&K&5[VL2AECB<BKOK*Q9-4Z&FCFE&(LB3
M-N]X;4N;)4))%SKV)NM5>8CTT15739HG*6="0L!E0
M
M                                'B7\D_X*^T!A+5]'P?!_"IJ68:XX
MA7_,KAE-!P_P>KCME9/2OK[G=96H]8H$=NHUB*CMJZ>UM0U$,S/0U]C&6\3L
M?M5+FEUO:7S%W7-UKN5#4,3GV:2\RDL;]->7;IO?V&J,Q,NDFN1[4<WW+D14
M]A3DZO5HY*S]Y=_H8)(9(B@                   5'#_I_-_YQ%_VVC-2S
M"W&6@    1+C^S_XF^V6!+(          !#N7Y%GPVEA$MO(GL$5^@
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M,I55T*2M1Z-EYM55S.<1VZNU!;?-LUA+K(NBDZ%M,-@
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M.:C<_P!RK$Y=/5,S92&HOK+<9S=
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M5^H>9NT-6:77!X[R
M                   'B7\D_P""OM 82U?1\'P?PJ:EF&HN(E#:\GXIV'%<
MPJ'0XNM$^HI*7G5@BJJQTF[NN>U4778B(B+KZG*:C0S.EA>(F$X/PYDLMVPK
M>M.7I74[:2CBJ9IWU$,DFX_>9,^1=W37;R= MJ3$0Z!8KE8U7)HY417)ZBG-
MT>K1R5G[R[_0P20R1%
M
M              !5\\FYFT0.UTUJ6I^CD/&YBW-;3SO%YF[+;7SM>=W_ /,>
M#P'K^.=W_P#,. <=D+#6[]ZH&:^ZG8G^8Z;O<TNB73=[ZMT0VV>S>V>)98H(
MGS3/;'#&U7R2/5&M:UJ:JJJNQ$1"3-%B*L)C6;8AF3:I^)WRAO3:)_-5:T%1
M'4<T]>1'[BKIKIL-4FE>B6:Q6G3"%>N)O#['+W#C5^R6W6[(*CFD@MM34,CJ
M']T.W8M&*NJ[Z[&^J+8S32,96Z,L5G0M9              !A,QN5RLV*WB[
MV>-DURM])+5012HKF/6!JO5JHU47:B+T2QI253MO$MU5P?\ .1-'$E4RBEFD
MA;JD?=,4CH=Q$5==%>FB;2TQ2N%7QP?BA+D?#&X9O<8XH:ZUQ5CZN&/5(T?2
ML5[41%55ZY-.B)C$B<&6X497>LUPRFR2_00TU35RR\U' CFLYF-VZU>N<Y=J
MHJB8H6S6%NAN%!42N@IZJ&69GNXXY&N<GLHBZH2C3ZSU$%-&LU3*R&)ONI)'
M(QJ>RJZ(0?D%33U4:2TTK)HEY'QN1[>FBJ!K;@SF5ZRZU9!67^=DC[==IZ.!
MZ-2-&P1,8Y-?8U7:;NABV:MD4U925K%DHYXZB-%T5\3VR-1?4U:JF&WTDDCA
MC?+*Y&11HKGO<NB(UJ:JJKZP&G,)XT5F:\3JS&*&EB9B[()IJ&L5'+-,D"M9
MSB+KN[KG;VFB&YMI#$75EN4PVY9]('^L?\"?J83O9H<+]+4IM@
M                                    &R.!7_N3;/S55^H>9NT-6:77
M!X[R
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M+\28LSNS8,>LEPEQO<>]V2542TE(]S?<I"V1$?)O+LUT30LQ1*KR94
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M#_6/^!/U,)WLT.%^EJ4VP
M       #9' K_P!R;9^:JOU#S-VAJS2ZX/'>0
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MEI</M>4\.9,29;X*N"ZK0:V]8N<2CEI)6N8[FUU5JZ)[KH^R9BN*MQ&%
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MU-9L&<N+9R(B(B(FB)L1$,-N6O2!_K'_  )^IA.]FAPOTM2FV
M                                    ;(X%?^Y-L_-57ZAYF[0U9I=<
M'CO(
M       >)?R3_@K[0&$M7T?!\'\*FI9ACLSNM58L2OEYH=U*V@H:BII]]-YO
M.11JYNJ=%-4$$M>8IQDK(H+=!Q(MCK+XQB9+0WUFJVZH;(FK=YVU(W;=J*O2
M-3:S%WE;<AFBJ(F3P2-EAD1',D8J.:YJ\BHJ;%0PV^EHY*S]Y=_H8)(9(B@
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M'M34W^IE9-DMPB=!.RD1T=#3PO>V188&/57.1%8WKY%WETZ&W7,W56(;2,J
M        --^DI4/IL%M\C%T5;M"W7_\ #5*_@/HNP-WGW\Q_#/KM?!_6MUUO
M)63'Q(_IO<M>-JCWY]U\K'D?CG&WGE/&U1[\?*QY#C;SRK7PRN4TO$'&XWOU
M:ZX0(J>R]#U_:'+Q;RU\T_VR][V!O;YY_<Q,X9G;Q^9OZ"
M                  !RSZ0/]8_X$_4PG>S0X7Z6I3;
M                              -D<"O_ ')MGYJJ_4/,W:&K-+K@\=Y
M
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MTU)536NT6^=]1%%0S/IZ:!ZU;W?BF1.5K5617)UB-Z[7D)656(@
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M6K<UQVNCN$-HK'VVMGA5'Q)51,8][&N35';N^C7:<CM4Z!:81/1*5QF.F/\
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M-3LF8Z*!9><598W,33>8B<J^J2Z^)A;;)B6[CDZ@
M                                          /$OY)_P5]H#"6KZ/@^
M#^%34LPF$4  +1R5G[R[_0P20R1%                           UOD5N
MN$^61VRGXD5-GN%U1TMNL$,%'(](XHU5ZM1['/W>L<[>=ZZ(:CT(K62XBMSJ
MV\/LGXI5CZN\0ME9:IZ:DB6HB23K=UR1M15WV;&H[>V<A8GIH-VF%
M  &F+SA_$:CCRO$<:I**;'<QK:FM6^3U"QRT+;DB)5L?!NZR?WN;5B[-=OK;
MK",OEF,7^[4MEX96>V)!A-,VWNN=^FFCVTMOD:Y*:*%O7K(Y86=?INH2)Z1M
M RH         H-9QLX74%744%9D4,572R/@GB6*H56R1N5KFZI&J;%0UEE*J
M7G'$[!,OJ<-M6.7F.ON#<JLTZP,CF8O-LGT5VKV-38KDZ)8B82K>1AH
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M<?S*TU\E1D.829!1.A=''1/M])1(R57-5)-^!$<NB(YNZNSKO6),P+610
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MY,M-<:L6_(VJR-K7+O*U$17>JJ)RG*7:'HB@
M C5E150-8M+2.JW.5=Y&O9'NHGJ[ZIR^L6!B+(^26[W>2:)8)G21*^%51RL5
M((T1%5NJ+JB(NSU2SH2%@,J
M
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M4/$T'Q]1\LX5*'B:#X^H^6<*E$FDHXJ)CHXE<J/<KW*]RN<KE1$Y5]@BI
M                         -99;28/G69T^'U]FJKA>[;%SM5?*+?ITMC9
M&.EB9)4QN:[>DTZV/:FW4U%8A&'EL. <*\JM==7V*OJ8JK<A@S"MG?7PT=3,
M]8VQR<X]>9UV?C4;_>TUY2XR-RF%         &O+S@N44%\KLDX=WN&UU-U5
MLEVM%P@6HM\]0QJ-2=NXJ/BD5$1'[ONN5=J&J^5$>FP+,LAN%#6\2;]35MOM
ML[*RFL-I@=3T;ZF';')-(]5DD1J]<C%ZW7I"L= V694
M                             'QK(IYZ2HAI9UI:J2-[(*I&MD6*1S51
MK]UVQVZNW1=B@:HR6DS'$;:^[9#Q;?14;>M8K[+;E?(_E1D;$:KGN7WK4-Q2
M>A'KA<G%RYW22]Y9=YOJ@YCDM]ON%%24EPJ-Y$W99&4\:+"B=!JO55]3HB:$
M-MF%
M    !Y;&QKG/:U$>_17N1$17*B:)JO1V 82[YIB5@JF45ZO5'05<FFY!/,QC
MUUY-BKJ6DI6&6CK:.:E2NBGC?1JWG$J&N18]Q-NN\BZ:$HK'V;*L;R*2>*Q7
M6EN$M,NE0RFE;(YBZZ;41?50LPE67(H       !!J;S::2L@M]57015]4[<I
MZ9\C4ED=IKHUNNJEHE4N66*")\T[VQPQHKGR/5&M:U-JJJKR$5@;=F>%WVN\
M7VV\T-=<(7:I!%-')(UR:IL3777V"TE*PG7K([#CD#*F_7&GMT$CMR-]3(V-
M'.]1-5VB()E-I:JFKJ:*LHYF3TL[4?#-&Y',>UVU%14V*A%?8          P
M][RO&L:1BW^[4MMYS;&E3*V-7)R:HBKJ6(293+;=;9>*9M;:JN&MI'>YFIWM
MD9ZO*U5%%8NZYOAUEK$MMXO=%1USMG<T\S&OV^JU5%)2L,NRJH8Z)*N.6)EN
M;'SC9FN:D*1HFNJ*FS30*A67*,<R/GEL-TIKCS"Z3)32MD5BKLVHU=@F$B:L
ML10        !Y>]D3'22.1D;$5SGN5$:B)RJJJ!7J+/\)N5?XKH+_0U%Q5=U
M*:.=CGJ[731$UVJ6DI6&<K*VCMU-)65\\=-2Q)K)-*Y&,:GKJNPBL39LNQ')
M:AT=CNU%<JJG1=6T\K))&(O+R+K[):2E8?6\Y7C6.R0PWV[4MOEJ%T@94RMC
M<_V$51$$RRT<D<T;)8G(^*1$<Q[5U:YKDU145.@I%>@         #XU=92T%
M+-6ULS*>D@:LDT\BHUC&-VJJJO(B 1[1>K3?Z)MRLM9%7T#U5K*BG<CXU5JZ
M*B*GJ%F"K%5><X1!7>):V^T#:]Z\VM')/'O*O)NJU5%)2L,U5UU#;J1];6U$
M=-11-WGSR.1D;6^KJNPBHUER"R9%2K6V*X07&D:[<=-32-D:CN715:NQ2S"1
M+)$4         8N^9'8<:IXZO(+C!;::5_-QRU+TC:Y^BKNHJ]'1"Q"3-&,M
MO$; [Q70VVUY%05=PJ%W8*:&=CY'N1%71J(NW8@I)6&2O>2X_C<3)[]<Z:W1
M2+HQU3(V/>]C5=HB*DS1]K3<[1>*3QA9*F"LHYG*O/TSFO8YVB:ZJWHZ:"1%
MARW&*F[OL%/=Z22]1Z[] V9BS(J<J;NNHI)5F2*          &(K\IQNUUT%
MLN-UI::XU+VQP4LDK6RO>_W*(W775>@6DI5DJFIIZ."2JJY604T35?++(Y&L
M:U.555=B$5AK1E^(9'5K3V6[T5QK8-Y5C@E9)(U.1VB(NOLZ%I*5A(O63X]C
MB0K?KG36Y*A=V#NF5L>^OK;R[>41%29HR<,T51$R>![989&H^.1BHYKFKM14
M5.5"*]@                                            &IJ+)+5PW
MS;)Z#,)/%M!DE8RZV:]3-7N:;>@CBDIWRHBHQ\;F:HCMFZNOJ:[I6$1N(^=8
MSFV.5>!8;5QY#D=^1E-!3T/XZ*%BR-<^>:5$W&,C1->7773V41%,26WX8UAA
MCB5RO6-K6[[N5=U--5]DPKV
M                      1Z]:U*&J6VI&ZXI#)W&DVO-+/NKN;^[MW=[373
MH :-M&#\7*:^ORK(K=9<DR1'+W)5U]=/S5&Q>1E- R!&1_"1-[U^4Z5AELO'
M:SB7-<FLRFUVBDM.XY734%5/--OI[E$;)&U-%Z.TQ-%6\B@
M                                                <\\',3Q_B#39
MADV6T$-UNESN=1 DM4Q)E@CT542'>UW--_8K=%1$1$Y#I=-'.V*L;PSI[W>.
M$W$'"[2]\M1055136M%=UVY(B:Q(O0UW'?VN+.E(T),M^AM-]QW+;38ZJTT&
M.6EUNN5-/2K0NJJZ=B14])&W1.=5).BFJ)RHHH5;FP&QW:R6'_U^J?57ZXS/
MN%R<Y[GQQSSZ*L<:*JHUC$1&Z-V='HF)ETB%I,J     !'KZ5U;0U-&R9].Z
MHC?$D\2Z2,5Z*F\U4Y%3H"!SE=,!M."<8>'D-NJ*JLJ:^6HEK:NNF6:61[$T
M1=NQ.53K6L.5*2O'I&5]738#%;Z65T++M<*:BJGL71RPN57JU%]=6IKZVPS:
MU?H4WC9A&.85A%BR'%*&*U7BT5%,R*LIF(R65%;RRO3;(NK475^JEB4NBD+E
ME[GTV<XWFMXM4]SQCQ/-3.AIJ9:Y8*RH<CT<L2(JZ/:NYO(GL[!'D6=*IX/1
MY%<:*AX;-DFM\*5DE]O+F/6.:CM;GM=346\Q=622.3>5$Y&EGRLQY'1)R=0
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M2:26DH4>Q=?Q4;V\ZFO0TY1.&*1Y&_3FZ
M                 #XU='25\#J6NIXZFF?[N&9C9(W:>JUR*B@?&WVBU6EC
MHK50T]#&[:YE+"R%JKZZ,1 )@
M
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M=#8)EH
M
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M5!5:):(B(B(FB)L1$('+L7D CTU!0T2O6CI8J=95WI%AC;&KE]5=U$U+42"
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MP4T3(86;&1QM1C43UD31$ ^@$;Q=;^ZN[NY(>[M-.Z>;;SNGP]-?^):B20
M       $5;9;5JN[EHX%KN^>:9SO9Z:_\2U$ES4<BM<B*U4T5%VHJ*01J6V6
MZA<]]%1P4SY/RCH8V1J[V5:B:EJ)1!\*JAHJ]B15U-%4QM7>:R9C9&HOJHCD
M7:*C[,8V-K6,:C6-1&M:U-$1$V(B(@'Z
M
M
M
M
M
M
M
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MJ-U1K455VKT"Q%4F:)E)50UU)!6TZJZGJ8V31.5-%5DC4<U=%Y-BD5]@
M
M
M
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M2W*B@J98N3=DEC1SV_V.U0YRZ0S1%
M
M
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M
M
M
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M^J)FI$48?#\&H,-J;[4T53-4/OU:ZXU"3;ND<CDTW6;J)L]D3-2(HM)%
M
M
M
M
M
M
M
0                  /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>tm2227887d4-bc_mostpreva4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-bc_mostpreva4c.jpg
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M .0  0 !! ,!               !!08'" (#! D! 0$  P$! 0$
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M @(" @(" @(" @(" @(" @(" @(!0<:BJP[<B:M WBBR@ 0=QJJ)0$! 0$!
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MUP<*C<FX2J" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M1Y-\NKAUGJ34T R,=..PM ;JX:#TF..IZ$YF7+*@:9[8/(+55X+&RU.+*9Q
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M"Z.7,9:.:(E6N;/9+YL\H<$S4V>;89/"%X9=7>'FGN&VI=['KFS00N:''8'
M%M=Y%173-XB<-E:\VU7.Q_S?R?+_ )FXS SWCF:3S\PM+^U>1U8ED'#%(*[G
M!_"-BZJ1S;&B^S:^DW.>#4U_RKU3;:,ZTZDFL7BP%N"97.J.(, J2XLX@*;>
MXN'5B<.K1F.:,OGCH3L.\Y-?1.S>HY;?2=M.[B$>8,LF1D#A7C-NQI+=NP]:
M]CN\NC$5:K3FVQ4>8G8,UKH72.3U9C]366<\V1&XN,?';S6\SX&>SZLDR N
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MO!?VR6?Y*M_&Y<6GX[<8^J'9;P5];8;]WD/_  >ROY8E^X0KNU/#7UN.N^6
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MK@U+XQ';+HTZYG@^0N8S/,#GSS#8^YGFS&I<U<=3:0/=1C.,^2Q@'DL:T;/
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M< =/,_B/ QHV5)W!6D8F"TY?:CE/%=6W+C2EK?QOAO(<39,GBE!:]KVPM%'
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MTOC>3Z9 79U-L:/")<=?,XM)><>4GR_-O7&4G<7/ESV2#0X'B#6W<@:-O<:
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M^Y:NK4VUKZW+7?+ W[Q+]I&GCTC&^-ZX=/S+>K[7;;RHXRS+^[G'#RLU*/\
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MMV+GFN;Q;T-L3[,PT:'83[10!:,7CQ44V9*"E/373S8:\.(["':);_\ M./
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M=-Y"R8=A.3E=;QNV=UY(2(RDSAO-V1N1.JN2&"SK=77%K)DLY);R-MK1[I1
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MNYR&T;E^7_*G3FC\]U?G;%V[H[H0NZR,.?*]] [IH'+=J6YK9:ZQB&2%K9B
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M(9(T5)[RQK7"VF9V2R)AL+B<!CH<5A;.*QQUN.&&V@8&1M&_8!X5GS3+'"H
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M)<2233>2LHM,Q##$1*OJJ(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(""*#N()0$! 0$! 0$! 0$! H@40$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$"@0*! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! J$! J$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0*A 0$"J @(" @(" @5" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("!4("
M!5 0$! 0$! 0$! J@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MT#SW^!3^D/701Y[_  *?[$>N@>>OP*?[$>N@>>OP*?[$>N@@YY@D;$;.;K'
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M_@4_V(]= \]?@4_V(]=!/GK\"G](>N@]5C?LO6R%L;HS$[@<U^P@A!ZT$H"
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MAU/#0[$'96O<4#:J)0-O>])!&U0-J!M03M0.A4=&)KUV1K]\.455*>-%2B"
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M-WB0<,?\PM_<!$>A%$$[$!!" @E!US^\2>Y=XE1I3RYT%D>9><S%BS-38\V
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M LHE);0<LL#>::T-AL3D7F2_CA$ER7$NI)*.(MJ[;LK182+M21"@("H*"4!
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MO#F^@M<[)17$!!""4!!" @D;BJ.C$^_9#\8<DJJJ@(" @(" @(" @(" @("
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M9?Q63M<SC+3+6+B^RO867-N\@M)CE:'--#M&PJ(]:@(""4$()00@ZKOYK/\
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M1UKI[4)EM+_'&1HX(G/$@<XN%:;C4T*J*5RT=>:\YVWNM\7;/@PL<DLLLIV
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M @\&:^BKKW'JA6!VX]K19PD "K&U])21ZJ! H$"@0*! H$"@0*! 0$! H$!
MI5 0$! 0$! H$"@0*! H$$%K7;' $=\(*1-''Y^@;PCAZAQI04K4H*N  * ;
M$$T" @4" @(% @4"!0(% @(" @4"!0(%$! 0*("!0(% @("#SWD<9MIB6"O
M[;0=Q!Y,"UOFZ)U!Q;=O3O05.@0*! H$! 0$"@0*! H$"@0$! 0*! H$"B!0
M(% @4"!0(%*("!1!!:UPHX CN%!1KYC!F<>T-%#QU%-FY!6: "@&Q!* @4"
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MC'>R:#X15!3,< +^_ % 'MH!X"@JE!ZJ"4! 0$! 0$! 0$! 0$! 0$! 0$!
M0>#-?15U[CU0K"2[L?\ ,X/<#Q*2KTH" @(" @(" @(" @(" @(" @(" @("
M @I,WZ00? .\9059 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'3=_-9O<.\2#Q
MX+Z-B]'QE05)4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!1\A],X[^/XD%80$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!!QD][=X"@I>G_F3OA'^-!5D! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 04G+_.L;\./&$%60$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$!!!W%!2<'[*]^&/JH*N@(" @(" @(" @(" @(" @(" @(" @(""D9_
MWBW^&9XT@58;T$H" @(" @(" @(" @(" @(" @(" @(""#T(*98?2&0]VWQ%
M0514$! 0$! 0$! 0$! 0$! 0$! 0$! 0>#-?15U[CU0K"2[L?\SA]PWQ)*O2
MH" @(" @(" @(" @(" @(" @(" @(" @I,WZ00? .\9059 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$'3=_-9O<.\2#QX+Z-B]'QE!4D! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 04>_^F<=_'\2"L(" @(" @("!L4P"H(%0@(" @(%0=R @("
M@(" @XR>]N\!04O3WS)_PCO&@JR @(" @(" @(" @(" @(" @(" @(" @(*3
ME_G6-^''J(*L@(" @(" @(" @(" @(" @(" @(" @(""#N*"DX/V5[\,?505
M= 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%(SWO,'PS$@E54') 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 00=X04RP^D,A[MOB*"J(" @(" @(" @(" @(" @(" @
M(" @(/!FOHJZ]QZH5A)=V/\ F</N&^))5Z5 0$! 0$! 0$! 0$! 0$! 0$!
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M)_B[_$LZ;VO4W,#+T^QY?:* @("H*"]>6/T_+\ ?M@N?7W.GI]\LO!<3O2I
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M^,#U$%60$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!!W%!2<'[*]^&/JH*N@("
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M^YU=/OEEX;EQ.Y*D J" @(" @XR>]N\!04O3WS)WPCO&@JR @(" @(" @("
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MRLQ)N+JPMI9G'83(Z%I=]6JSO&+2TTG-5RC<M3:E 0$$.]B4&#N=_+[6>O\
M)X6RQ' =.6E9+UCI PF9S@WBI3;1E:+.LX%:UARTY=8[E[E+63#V=K#86,TL
M%\(VLN(YHXR62"6G%Q%W?V[MJ1:<HM/LJC(C2^9,X/FWY6PV8.ZH8>LIZ-%+
M3F19VN<O@6=H+Y3JKJSA,9$&W F8)6'AB+@.$C;5Q5C<3O9*T_KKD5J2_9C;
M*PL(KJ0TB%U911![MP )!%2I.1[NT%D9</RMO6V($+;N2"Q+6 <(AE)X@!T
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M*N@(" @(" @(" @(" @(" @(" @(" @(""D9[WF#X9GC2"56&\()0$! 0$!
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ME0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!29OT@@^ =XR@JR @(" @(" @("
M@(" @(" @(" @(" @(.F[^:S>X=XD'CP/T;%Z/C*"I(" @(" @(" @(" @("
M @(" @(" @(" @H]_P#3.._C^)!6$! 0$! 0$!!1-7?HYD_Q=_B6=-[7?<P,
MO3['E]HH" @("HO7EC]/R_ 'QA<VON=73[Y9>&Y<3N2I *@@(" @(.,GO;O
M4%+T]\R?\(_QH*L@(" @(" @(" @(" @(" @(" @(" @(""DY?YUC?AQZB"K
M(" @(" @(" @(" @(" @(" @(" @(" @@[B@I.#]E>_#'U4%70$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!!2,][S!\,Q()55!R0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$$'H04VP^D,A[MOB*"IH"!OV%!UO(#:TV;!Z!6,;58]U5=<H\-?"[U<
M,3!DCY8=<11OG<1MK0-<X^DK69[%F)F-JI:4YA:(U;-+C=)Y%EZZS8UTL,4$
ML36QDT '61L%-G0LYI.^>UKSC8Z<3@>7NF]1308^WLX-49 R73N*CKJ0/<7/
M<TNJX"I*QK,XQ'8SMMG,]J](3Y)H*#H4GO':W<JB4! 00XT:2=R#!_: MN8V
M;M+'3FC[&:ZQ-TQ\N5EMJ!Q<UP:R(DD>202:=Y95Q$BP=)R\^-&8J+#8/1T,
M5O'M<]UN#(]Q->)[NL'$5E,PC+'++/<U\OD;V+7^&9CK&.)KK5[8^KXY"3Q#
MV;J[*+"56+KGE7KO3^N9N87+/AN)[N1\]W:58QX?*27U:XT>UU=P642*)DM&
M<Z^;>2LH-:6[</@K5W$_B#8V C>1&'%SG$&@.Y,X&=]0Z%QF;T+)HL 0V?R5
ML%H2T4C?&/YM^SN':L,[1@G"8CM"<NK6;3."QXO\67/%I<-ZN9K ^OE,)>.&
MM:^5N6<XE%\\E>5><TK>9#5VL'M?J3)';"'"1T8>2YY<YM07./M?34M96<EB
M/!F@/-=U[CU0K"2[K#YG![@*2KTH" @(" @(" @(" @(" @(" @(" @(" @I
M,WZ00? .\91.U5D40$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'3=_-9O<.\2#QX
M+Z-B]'QE05)4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!1[_Z9QW\?Q(*P@("
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MX1_C055 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%)R_SK&_#CU$%60$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$!!#MQ04G!^RO?ACZJ"KH" @(" @(" @(" @("
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M" @(" @(" @\&:^BKKW'JA6$EW8_YG![@>))5Z5 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$%)F_2"#X!WC*)VJLBB @(" @(" @(" @(" @(" @(" @(" @Z;
MOYK-[AWB0>/!?1L7H^,H*D@(" @(" @(" @(" @(" @(" @(" @(""CW_P!,
MX[^/XD%80$! 0$! 0$%$U=^CF3_%W^)9TWM=]S P7I]CR^T4! 0$!47KRR^G
MY?@'>,+FU]SJZ??++PW+B=R5(!4$! 0$!!QD][=X"@I>GOF3_A'>-!5D! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 04G+_.L;\./44%65! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 00=Q04G!^RO?ACZJHJZ@(" @(" @(" @(" @(" @(" @(" @
M(""D9_WFW^&9XT@554<E 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00=X04W'_2%
M_P"[;XBH*FJ"""0!4[D%LZ[UEC=#:;NM0Y$.?%;\+60LV.DD>:-8"105ITK7
M:V&=:Y:UMYS<\M8SRW6CL=\GL&D\,5G:,N*-W4=).UU3W: +HY,1M:IMF=CM
M&M.U&/\ JMW_ -VVG^23$&U!UGVHOKK:[ [OFZT%/_=+*M:YVI;/8VHPK[N3
M%6;[[YZZ&(W (#2)2QI?4#8#4G<M5XV[&5=VU[U%$! 0$! 0$! 0$! 0$'@S
M7T5=>X]4*PDNZP^9P>X"BO2@(" @(" @(" @(" @(" @(" @(" @(""DS?I!
M!\ [QE!5D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0=-W\UF]P[Q(/'@OHV+T?
M&4%20$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!1[_Z9QW\?Q(*P@(" @(" @(*
M)J[]',G^+O\ $LZ;VN^Y@;H7I]CR^T4! 0$!!>O++Z?E^ /C"Y]?<ZNGWRR\
M-RXG<E2 5! 0$! 0<9/>W> H*7I[YD[X1WC059 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$%)R_P ZQOXP/4059 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$'<4
M%)P?LKWX8^J@JZ @(" @(" @(" @(" @(" @(" @(" @(*1G_>(/AF>-()59
M!* @(" @(" @(" @(" @(" @(" @(" @@]""FV'TAD/=M\14%35!!Q?7A--_
M0@POVF+*[ON6ADMF%S;6]M[BX:W;2(-D82>\"X+5$QSQ/8SC=*ZN38QGZO<&
M<5P?)S;CCZL#;+4\=:#?Q577K>.6C3W+^H/X#_ M+8X2#H ]2B@Y1U /AW),
MCFJ" @(" @(" @(" @("#P9KZ*NO<>J%827=8?,X/<-45Z4! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 04F;]((/@'>,H*L@(" @(" @(" @(" @(" @(" @("
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M @(" @(" @(" @(" @(" @(" @I&?]X@^&8D"JJCDH" @(" @(" @(" @("
M@(" @(" @("""@IF/^?W_NV^(H*H@("#KDW5I4;%-@QSK3G;H;0\YL;^ZDO,
MFTT=9631+(S97RR7-:/3KWE8B959+.U=H]T@;)B+]L5:.<#$X@>#B'C645RQ
MF<,EZ,YF:2U[$Z33]V'7,8XI;*8=7<L!Z2PDU'?:2%9IA(ME>,)!94;J[/06
MMD[%00$! 00XT%=Y[B#CQFNY!+75KWD!SN%!Q,A VBI[@0<PZHJ@X&2FRG>K
MZZ#D'=/1T$;D')!X,U]%77N/5"L)+OL/F<'N&^)17H0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$!!29OT@@^ =XRB*LBB @(" @(" @(" @(" @(" @(" @(" @
MZ;OYK-[AWB0>/!?1L7H^,H*D@(" @(" @(" @(" @(" @(" @(" @(""CW_T
MUCOX_B05A 0$! 0$! 06;S/U#;Z5T-J#/W=F;ZVL+.2=]JU_5F0,&UO%T+9H
MUFU\->I:*US+3T=JC2Q_^QI?Z\?Y*]OX*T]KR/BZ]D']ZK2G]AIOZ\?Y*R^"
MGO8_&4_"?WJM*?V&F_KQ_DI\%/XI3XRGX3^]5I3^PTW]>/\ )3X*?Q2?&4_#
M)_>JTI_8:;^O'^2GP4_BD^,I^&3^]5I3^PTW]>/\E/@I_%)\93\,_0RIR$YW
M83F#K&?"XW34F(G9:/G-R^Y,X+6N:"WA(&^JX>KZ>=.(VY=G3:]=29Q&&SL9
M+@3LIT47EO2<U00$! 0$!!QD][=X"@I>GOF3_A'>-!5D! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 04G+_.L;\./4059 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M$.W(*3@]][\,?505= 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%(S_ +S!\,Q(
M%602@(" @(" @(" @(" @(" @(" @(" @((*"F8_Y_?^[;XBH*HJ""'$@$C:
M4&-^=NL[W1F@[S)8UW!D+A[+.WDZ6/G#CQ#OAK2M=MN([VRN(VRQCR@Y!X#,
M8>WU3KEDN1N\BTSQ63Y)(V-:X['2%C@YY.^A-.\5U7CDV0T1/-MEEJYY,\KK
MBW%M)IBR;'PEHZMIB?0_X\9:ZO?K5:IF6<,"\T^69Y0WV/UWH2YFM[:*Y#76
M[GN>87NI1H>22YCA5I#MJNG>>>*SNDM2)K,QOAL[I7+C/:<Q69;0#(6L%R0-
MH!EC:XCT":)J5FML,:SF%:6+(0$!!#C0$H,2\ZN:]SR_L+.PPT3+C464)%LR
M0<38XV["\M'LMI  658C.T8TO7]I7&8236$^6K!#'\IN;!L=J7L@ XC6,15V
M#;3V5%<1,C+/)CF3<<Q=.27=]&R++V#Q!?=7[!_$"6O:.BHZ%C:,#'6M>:',
M;4VOKK0/+206KK![X+FZ8V-[C)"3QDND:X-:"*;EEB,)E2YN8/.#E1G["WY@
MW#<M@[UU&O+8O8U%>"2)C2'#?PN2*Q(SQK/6MMI/1]YJIS6RQ0P!]JRM!)+(
M/(;7ODA8Q&U6 L'F.T1S LYM38;*"PQA+G6D(9;QL<65%&=9&YQW4J3O64Q$
M)$ROKDMS8SNI\CD-):Q8UNHL>/)F#!$Z0,<6O:YK0!Q CH4M7"LXK$>#-?15
MU[CU0K"2[K#YG![@>)25>E 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%)F_2"#
MX!WC*(JR*(" @(" @(" @(" @(" @(" @(" @("#IN_FLWN'>)!X\%]&Q>CX
MRH*DJ" @(" @(" @(" @(" @(" @(" @(" @H]_]-8[^/XD%80$! 0$! 0$&
M,NT&P'DUK5QW^:Y_%_A71TWF1Q<_4^7/!\N*'=Q&@'=7USY:-AM[I5-J-O=*
M)M[TU/=*+M[S;W2AF>\]$H9GO;'=BT5YJW;3N.,FKZ+VKR?F/@AZG03/-+Z!
MMV;NE?.QNR]US5! 0$! 0$'&3WMW@*"EZ>^9/^$=XT%60$! 0$! 0$! 0$!
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M(" @(" @(" @(" @(" @(" @(" @(*3E_G6-^''C"@JRH(" @(" @(" @("
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M" @(" @(" @(" @(" @@[B@I.#]E>_#'U4%70$! 0$! 0$! 0$! 0$! 0$!
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M>.7T$'0OG(W/>G>Y) *@@(" @(.,GO;O 4%+T]\R?\([QH*L@(" @(" @("
M@(" @(" @(" @(" @(""DY?YUC?AQZB"K(" @(" @(" @(" @(" @(" @("
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M" @(" @(" @(" @(" @(" @(" @((.XH*3@_97OPQ]5!5T! 0$! 0$! 0$!
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M(" @(" @(" @(" @(" @(" @(" @("#IN_FLWN'>)!X\%]&Q>CXR@J2 @("
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M$! 0$! 0$! 0$! 0$! 0=-W\UF]P[Q(/'@OHV+T?&4%20$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$!!1[_Z9QW\?Q(*P@(" @(" @(,:=H+]C&M?R7/X@NGIO,C
MBY^H\N>#Y;?7'P+ZY\N(B$002@!!L=V+?VK77Y-E^W8O)^8^"'J?+_'+Z!@T
MHOG8W/>[74+^R(^<1CPN'KK+$IF#Y=9??$?V;?73$F8/EUE]\1_9CUTQ)F#Y
M=9??$?V;?73$F8/EUE]\1_9M]=,29@^767WQ']F/73$F8!?6CG!K9F.<30 .
M!))[FU)B3,.V0UC=X"L<JING_F+OA'^-455 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$%)RWSK&_C ]1!5D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00=Q04G!^
MRO?ACZJ"KH" @(" @(" @(" @(" @(" @(" @(" @I&>]Y@^&8D$JJJ.2@("
M @(" @X2>P=X#XE.Q8WK(.\KC[7M=KBC(0$! 0>W$_/X/"?$5E3Q-&MX)78=
MX76\AS11 0$! 0$$'H04S'_2&0]VWQ%!5$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$'@S7T5=>X]4*PDNZP^9P>X"DJ]* @(" @(" @(" @(" @(" @(" @(" @(
M*3-^D$'P#O&4%60$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!TW?S6;W#O$@\>"
M^C8O1\905) 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%'O_IG'?Q_$@K" @("
M@(" @QIV@OV,:U_)<_B"Z>F\R.+GZCRYX/EM]<? OKGRZ%$%435 0 @V.[%O
M[5KK\F2_;L7D_,?!#U/E_CE] G5HOGHW/=EK@\#C=LZ3XUZ=8C#R[6G**#N+
M+$,>:44'<3$'-)0=Q,0<TIH.XF(.:2@[BF(.:56TN!^<6,_&(_M@M>KCE;=&
M9FS/3QY#B?:E>>])3=/_ #)WPC_&@JR @(" @(" @(" @(" @(" @(" @("
M@(*3E_G6-^''J(*L@(" @(" @(" @(" @(" @(" @(" @(""';D%)P?LKWX8
M^J@JZ @(" @(" @(" @(" @(" @(" @(" @(*1GO>8/AF)!*JJCDH" @(" @
M(.$OL'> ^)3L6-ZQSTKC[7M=J$9" @("#VXGY_#X3XBLJ>)HUO!*[#O"ZWD.
M:*(" @(" @@H*9C_ *0O_=M\1051 .P$H,;:^YTZ8Y=96WQ.<M[N6XN8/E,;
MK6-CV]67NCVESV[:M*QB5PM3^]3H#[RR5?@8O\JMG+MPPR#M5<OZ[;+)T[T,
M7^54Y99![5/+[[RR=*=,40_Z57"9/[U.@"-ECDZ_ Q?Y56M)F<)-L,U6%]'D
M+*WOHP1%<QLEC!W\+VAPKWZ%8S&)PN=CU**(" @(" @(" @(" @(/!FOHJZ]
MQZH5A)=UA\S@]P/$I*O2@(" @(" @(" @(" @(" @(" @(" @(""DS?I!!\
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MBM+NT@GAB;L#&21-<&CP T5O$Q9C3;"M!8LQ 0$!!Q<2!LWH.J6YC@##,]K
M]P8TN/#5QV "O22@Y\;MW2-Z#SS9.PM7]5=7,,,M*ADDC6N([M"4'5Y\Q)(I
M?6]/A6>NK@>QLW$ X4+3[$C:"H.B;)65N[@FN(HY#L#'O:T^D2@[A-Q-XFD%
MN]I&X^B@[D'@S7T5=>X]4*PDN['_ #.#W \2DJ]* @(" @(" @(" @(" @("
M @(" @(" @(*3-^D$'P#O&415D40$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'3=
M_-9O<.\2#QX+Z-B]'QE05)4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!1[_P"F
M<=_'\2"L(" @(" @("#&G:"_8QK3\ES^(+IZ;S(XN?J/+G@^6WUQ\"^M?+BK
M%""4! 0;'=BVOZU;NF_S9-]NU>3\Q\$/4^7S[<OH!(XM!._UE\[$O>V-4_UG
M<G7%Q_/6'V1'S:;NKUZZ>KC967F3.GG?!^LSD[_;6'^K3*^[U?PR>Q^*#]9G
M)W^VL/\ 5I4]WJ_AD]C\4)_69R=_MK#_ %:5/=ZOX93V/Q0C]9G)W^VL/]6F
M3W>K^&5]C\4!YF\G0*G6T/\ 5I5)T]7'ADSIQ_JA6-(\QN55[JG$66,U;%=9
M"XNX8K2V%O*TR2O< UH)V"I6O5I?DVPNG-.?9+9/C+VN/UI:2%YD/3>#3_S)
M_P (_P :J*L@(" @(" @(" @(" @(" @(" @(" @(""DY?YUC?Q@>H@JR @(
M" @(" @(" @(" @(" @(" @(" @((.XH*3@_97OPQ]5!5T! 0$! 0$! 0$!
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M-!-!M.Q:U4#)Y;KK&>'Y)<L#VD=9)&&MW[]YV+*(258L/F<'N!XEC*O2@("
M@(" @(" @(" @(" @(" @(" @(""DS?I!!\ [QE!5D! 0$! 0$! 0$! 0$!
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MPQ]5!5T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 04C/^\P?#,2!551R4! 0$!
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M $'H0>#-?15U[CU0K"2[K#YG![@**]* @(" @(" @(" @(" @(" @(" @("
M@(*3+^D$'P#O&415D40$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'3=_-9O<.\2#
MQX+Z-B]'QE!4D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 04>_^F<=_'\2"L("
M@(" @("#&G:"_8QK7\ES^(+IZ;S(XN?J/+G@^6WUQ\"^M[7RZ$1*J" @(-CN
MQ=^U2Z_)LOV[%Y/S'P0]7Y?XI?0.3V+O OGH>Y+XX2^^O]T?&OM:[H?(VWN*
MR8(02@A!*A*^^2O[7-$?EJR^[M7+U7E3P=/2^9#ZJ.][?X%\D^I4_3_S%WPC
M_&J*J@(" @(" @(" @(" @(" @(" @(" @(""DY;YUC?Q@>H@JR @(" @("
M@(" @(" @(" @(" @(" @((.Y!2<'OO?AG>J@JZ @(" @(" @(" @(" @("
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M$! 0$! 0$! 0$! 0$!!!W%!2<'[*]^&/JH*N@(" @(" @(" @(" @(" @("
M@(" @(""D9[WF#X9B02JJ#D@(" @(" @X2>P=X#XE)W+&]9!WE<?:]IQ1D("
M @(/;B?I"#PGQ%94\31K>"5V'>/ NMY#FBB @(" @((.\(*9C_G^0]VWQ%05
M14#N085YM\YLQRXSUIB,?A8\G%<VHNW32/D86.,CH^&C 1N95%Q,[E@?WJ=4
M;OS3@[_\[-_(64QC?VL*SS.#.UAJ*1Q;'IBV>X;PV:4D>DQ9^[RQYIB<.?\
M>JU1_92#XV;^0L>3#++@.U=J-\HA;I>V,M?>VS2\7I!M5G6D6G$%K<L-GL1=
MOO\ &V=[(SJWW,,<SHQ4\)D8'4J=NRJU6V3A8G,9>Y11 0$! 0$! 0$! 0$!
M!X,U]%77N/5"L)+NQ_S.#W \2DJ]* @(" @(" @(" @(" @(" @(" @(" @(
M*3-^D$'P#O&4%60$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!TW?S6;W#O$@\>"
M^C8O1\905) 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%'O_IG'?Q_$@K" @("
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M(" @(" @(" @(" @\&:^BKKW'JA6$EW8_P"9P>X;XE)5Z4! 0$! 0$! 0$!
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M4059 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$'<4%)P?LKWX8^JJ*NH" @("
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M$! 0$! 0$! 0$! 0$'@S7T5=>X]4*PDNZP^9P>X:I*O2@(" @(" @(" @("
M@(" @(" @(" @(""DS?I!!\ [QE!5D! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MON[5R]5Y4\'3TOF0^JCO>W^#U%\D^I4[3WS)_P (_P :HJR @(" @(" @("
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M5;@Z>E\R'U5=[V_P+Y)]2IVGOF3_ (1WC5%60$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$!!2<O\ZQOPX]1!5D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00=R"DX/
M?>_#'U4%70$! 0$! 0#N06QKKZ!=\+'XUC9S=1X)8Q6B'D1N%5% 5!0%25]<
MN]]_X8_^,ME'H]+N5#7OT.WORM5MN;.I\#&BU;'DY]"4V+F>PJF#,E4P9D_A
MTI@S(F$Y8WK^Y>5^3WG<ZP?:A;*O2Z7<N#/>\P?#,6R'=*JJCDH" @(" @(.
M$GL'> ^)3L6-ZQSO*XWM=J$9" @("#VXGY_!X3XBLJ>)HUO!*[#O"ZWD+0R?
MS^X]V5R6WO9TO!#RK!M%00$ ;T2=TN4?LAX1XT[47RNR'B*9C_G^0]VWQ%!5
M%00-Z"T.9&D;G6ND[S3MC=-LKBY+"+A[7. #'!QV-(.U86KS;V5;8E@(=DW/
MAQ/YSVH)WD02U/\ PEOY]F&$QF<N7]T_4']J;?XB7^4IS&'$]E+4+3LU1;GI
M]XEZ/XRL7B)AC-9;.8>T?88JSL7/XWVL,<#GC9Q&-@;6E3OHL)G,RRCL>\;E
M%2@("#B_V)067K_EQA.8UMC[+.2W#+7'SFY$=LYK#(YS"RCB6NV;>X@USUSI
M3":.YTZ-P^!MA:V+;C&O+*EQ+W7="7$[RML3L8RV^+012FSI6IDU:Y.6MOJ;
MG'JG/9*-LUQ#-<S0QR-XFL<^4BHKW!L"V6V,8WJQVI<+918K"YZWA9#>P7/R
M=TC!PDL>'/ -.X0I5953F[GKBZY"6&0CD/'DQ8QRO%6UC>"YP]'A4C>=BY^1
M."Q=OROP\K+:(RW\3YKI[F ESG2/&TD=P!+3M(8GT#&-+=HC*8+'M$=A=/N&
M&)NP >^-: .@%93N3M;7+6R>#-?15U[CU0K"2[K#YG![@>)25>E 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$%)F_2"#X!WC*"K(" @(" @(" @(" @(" @(" @
M(" @(" @Z;OYK-[AWB0>/!?1L7H^,H*D@(" @(" @(" @(" @(" @(" @("
M@(""CW_TSCOX_B05A 0$! 0$! 08T[07[&-:_DN?Q!=/3>9'%S]1Y<\'RV/L
ME]<^7$8B"$!!(0;'=B[]JEU^39?MV+R?F/@AZOR_Q2^@<GL#X%\]#W)?'&7W
MU_NBOM:[H?(WWN"R8(0$$H"A*^^2O[7-$?EJQ^[M7+U7E3P=/2^9#ZJ.][?X
M%\D^I4[3_P R=\([QJBK(" @(" @(" @(" @(" @(" @(" @(" @I.6^=8W\
M8'J(*L@(" @(" @(" @(" @(" @(" @(" @(""#N*"DX/V5[\,?505= 0$!
M0$! .Y!;&N?H%WPL?C6-G-U'@EC$+1#R(W"JB@*@@(DKZY>;[_PQ_P#&6VFY
MZ72[E0U[]#,^%;XTLV]3X&-5J>2* @*F!,&!$7]R\^;7GP@\06VKT^EW+@SW
MO,'PS%G#M58;_P"'>02@(" @(" @X2^P=X#XE)W+&]8YWGPKC>UVH1D(" @(
M/;B?G\'A/B*RIXFC6\$KL.\+K>0M#)_/[CW97';>]G2\$/*HVB @()&]$G=*
M8_9#PCQIVHOD='\.A=D/$4VP^D,A[MOB*"IJ@@(*;G,QCL!B[G,96=MM86K#
M)-,X[FCN=T]P+&;+$9:U9?M49F2[D_-?3\3K%A(;)?=9)(X#I(B<P-\&U;(J
MDSMPIK.U/KZ45BP.->!L);'=.\4RRY$R\]SVG^8EY6RML58V]X_R6&"&9\H)
M[C'R/!^Q65-/-H2;8;7X.:XGP]C<78I<RP123"G#_..8TNV&E-I.Q:[1BTK6
M<Q"HMW+%4H" @((-**#5GG%_Y@-(?"XO_3%MC<QEM&\[".ZM;)J]R(D;CN;.
MK,5=>1>%]P&L.SRHYC4#OK;=C"O]JJ[A;IG$8\N;\IGO.-K0=O"QCJFG<J5C
M4EU\VL=/9]G[#VCF$.LSC^M!WCR2W;3OE2-Z]C(7(RXAFY5:=$3P[JH'QOV[
MG-E?4'P*6WD;F&]+'SMVF,A>68ZRVMY;GK9&>4&\ X-I\*SG<QC>VJ>"YCFM
M):X@@.&\'N[5K9J!DL?<16-Q*^_GD :28W</"=N[8%8)5C'_ #.'W#?$DCTJ
M @(" @(" @(" @(" @(" @(" @(" @(*3+^D$'P#O&415D40$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$'3=_-9O<.\2#QX+Z-B]'QE05)4$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$!!1[_P"F<=_'\2"L(" @(" @("#&G:"_8QK7\ES^(+IZ;S(X
MN?J/+G@^6Q]D? OK>U\N*HA$$!!(0;&]B[]JEU^39?MV+R?F/@AZOR_Q2^@L
MGL'>!?//<G<^-\OOK_=%?:UW0^1MO<%DP$$H(02H2OODK^US1'Y9LON[5R]5
MY4\'3TOF0^JKO>G>Y*^2?5*=I_YD[X5_C5154! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 04G+_ #K&?C ]10594$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!#MQ0
M4G!^RO?ACZJ"KH" @(" @(!W(+8US] O^%C\:QNYNH\$L8A:(>1&X544! 5!
M$G<OKEYOO_#'_P 9;:;GI=+N5#7OT,SX5OC4LV=3X&-5K>4* J" H"(O[EW\
MVO/A!X@MU7I]+N7!GO>8/AF+.';*JJCDH" @(" @(.$OL'> ^)3L6-ZQSO*X
MYWO:0C(0$! 0>W$_2$'A/B*RIXFC6\$KL.\+K>0M#)_/[CW97);>]G2\$/*L
M6T0$! 1)W2Y,]D$[47ST+LAXBF8_Y_?^[;XBJ*H@((=2AKN082[3EQ/#RU;'
M$2UDV0MXIJ=+.&1WC:%IS[=?3+.)FM9F-ZXN6VF\/@^7%HW%P1-FNK RSSM:
M.LDDE:22YV\[Z"I73UF8M-?4U:,1LE8W9BE9YKU+:N($L5]5[=FRO$/464UQ
MIUX)-LZEGG[1>G8<)!C.8.% L<_:7+8Y+B(<+Y.+:TNIO(IM[Q6G3MC4BOXF
MRT9TY]#-NBLN<[I+#9IXI)?V=O<2]SK)(FN?3^-5;=2O+:8:Z3L7 M;,0$!
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MODK^US1'Y:L?N[5R]5Y5N#IZ7S(?51WO;_ ODGU*GZ?^8N^$?XU154! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 04G+_.L9^,#U%!5E00$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$$.W%!2<'[*]^&/JJBKJ @(" @(" @MC7/T [X6/QK&SFZCP2Q
MB%H>1&X114$! 1)7UR[]E?\ AC_XRVT>ETNY4->_0[/A6^-+-G4^!C5:GE"
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M(" @(" @(" @(" @(" @(" @(" @(.F[^:S>X=XD'CP7T;%Z/C*"I(" @("
M@(" @(" @(" @(" @(" @(" @H]_],X[^/XD%80$! 0$! 0$&-.T%^QC6OY+
MG\073TWF1Q<_4>7/!\MOKCX%]:^70JQ$! 02$&QW8N_:I=?DV7[=B\GYCX(>
MK\O\4OH')[ ^!?/0]R=SXX2^^O\ ='QK[2NZ'R-M[@LV"4! 0%!?7)3]KFB/
MRU8_=VKEZKRK<'3TOF0^JKO>W^!?)/J5.T_\R=\([QJBK(" @(" @(" @("
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MLU4C"\L9E\7F+87F'O(+^T+BT7%K*R>+B;O'&PD;%KF&<2]HVBJBI5! 0$!
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M0]H_]G$WXY:_;KFU_"^=_<'Y.W&/K:?=)7F/R\02@40$!)&QW96 /YS$[_\
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MP>X'B4E7I0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!29OT@@^ =XR@JR @("
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MS6;W#O$@\>"^C8O1\94%25! 0$! 0$ [D%@<S/88SPS_ /1K.B2Q\MK 0$!
M0$&5N7_Z/M^&D\86FV]G"ZEA*BH(" @(" @H]_\ 3.._C^)!6$! 0$! 0$!!
MC3M!?L8UK^2Y_$%T]-YE>+GZCRYX/EM]<? OK>U\LA 500$$A!L;V+OVJ77Y
M-E^W8O)^8^"'J_+_ !2^@LGL'>!?//<G<^-\OOK_ '17VM=T/D;;W%9,!!"
M@E07WR5_:YHC\M6/W=JY>J\J>#IZ7S(?51WO;_ ODGU*GZ?^8N^$?XU154!
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MG=G\4:SHDL?+:P$! 0$!!E;E_P#H^WX:3U%IMO9QN74L)45! 0$! 0$%(O\
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M! 0$! 0$'3<>\R^X=XEA:-DLZ>*&"7D%[OX=*^;VOTR-SCM[JJI\KNH%3[9
MV]U0-O=5%;T@/_J.Q)VGB=]HY='3S_<AYOS+\O;^.UE\[1NV=Q>[+X%AK4_T
M]??#.\87@Z_CGB_0>@\BO!23N6B'? @(" -X\*L#G#[ZSW3?&$C?#&VZ>#/(
MW#^'0OI7YBIMA](9#W;?$4%400=Q08$[5)!T3CZ??S?M'+5_KALCPRL+!=IV
M\PF'L<2W!1RLLH60!YD<.+@%*D+KM'-9HW0M#FASCN.9-OC()L:RQ\W3.G!8
M\NXN, 4V[MRPK7EU.;T86\YKCTKZLNU7>VEK!;#3\3NIC9&'&5U3P- K]1)C
M,I$K'YI\Y+CF=98^RFQC;$64KY0YCR_BXP!3;X%=.F-6MNXO;.G,-S=+"NFL
M3W?D=O\ <FIJ^.9])7PPK % M;-* @(" @((<@HV<TO@]20"VSN.@OX14M;,
MQKRTGI:3M'H)G IV Y=Z.TS<?*L)A;:UN0*-N P.E%=X#WU<*TZ"F<BY'1N-
M1PC;L[U-J"TLGRLT'F+SSAD,#:RWCG<<DH9P%SNZ[AH"3WU<BX\=B;'$6D=A
MC+2*TLXQPLAA:&, />"@J*#P9KZ*NO<>J%827?8?,X/<-45Z$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 04F;]((/@'>,H*L@(" @(" @(,?<Z/T%NOA(_&OGO
MG_Y2SZ7]M_G:M75^4OVP0$! 0<43O9D[//TQF_Q:'[HY?<?M?QWX/SK]X^'3
MXRV!7W[\T$! 0$! 0$'3=_-9O<.\2#QX+Z-B]'QE!4D! 0$! 0$$.]B:;T&/
M.9M]A+1N,\\9:WQ8>9NI-R'GK*=7Q4X0=VQ95E&/O/.B/[6X_P!*7^0L^8F#
MSSHC^UF/]*7^0G,F#SUHC^UF/]*7^0G,8//6B/[6X_TI?Y"<Q@\\Z(_M9C_2
ME_D)S&#SUHC^UF/]*;^0G,897Y>W6-NL!UF*OHLC:]=(/E,'$&\0I4>4 =BU
MRR7=50$! 0$! 0$%'O\ Z:QW\?Q(*P@(" @(" @(,:=H+]B^M?R9/X@NGIO,
MCBY^H\N>#Y;?7'P+ZY\N(Q$!!""0@V.[%W[5+K\FR_;L7D_,?!#U?E_BE]!)
M/8'P+YZ'N3N?&^7WU_NCXU]I7=#Y&V]QZ%FP0@(.2"$%]<E/VN:(_+5C]W:N
M3JO*MP=/2^9#ZJN][?X/47R3ZE3M/_,G?"/\:HJR @(" @(""#N06!S:^@['
M\<'W*1=G2>.>'W.G0WL1+U'=(B" @("#+O*?Z'N_A_47F=7XH<6OO9 7"YA4
M$! 0$! 04G+_ #K&_C ]1!5D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00=R"D
MX/V5[\,?505= 0$! 0$! *#$/:0_9Q-^.6OVZYM?POG?W#^3MQCZVGR\Q^8)
M"((""$$]*2-CNRO_ /<W_P )_P!*N_IMS[_]K^7?BNGM+?H%'^.0_;+9U'A=
MW[C_ "D\8^MJ1T?P[B\Q^90(""$$H)]9#L;,=ECZ+S_XS']R"]#IGZ%^V?)M
MQ9NSWO,'PS%V0^PE551R4! 0$! 0$'5<>\R>X=XEC;=+.GBCBP,[V1\*^;C<
M_38$! 0$!!7-(?I'8>[=]HY;]#S(>;\R_+W_ ([68!T+WH?!2PUJCZ>O_AG>
M->#K^.>+] Z#R*<%(.Y:'>(" @#>/"K YP^^L]TWQA(WQQ8VW3P9Y'L1X/47
MTK\R4W'_ #^_]VWQ%$51 .Y!X;S%V628(<C:PW<+3Q-CGC;*T.[H#@16B&7D
M&DM+TVX2P_JL'\A2N<+*!I+2_3A+#^JP?R$C*)_-+2_^Q+#^J0?R%<CB[26F
M#L&$L/ZK /$Q)F>P5>&-L,8B8T-8W8QK10 =  "D9[1V*@@(" @(" @(" @(
M" @\&:^BKKW'JA6$EW6'S.#W 45Z4! 0$! 0$!!'$$#B!0*A X@@<002#5 J
M@CB""4! 0$! 0$!!29?T@@^ =XR@JR @(" @(" @Q]SH_06Z^$C\:^>^?_E+
M/I?VW^=JU=7Y2_;$()0$!!Q1.]F7L\_3.;_%8?NCE]Q^U_'?@_.?WCX=/C+8
M!??OS40$! 0$! 0=-W\UF]P[Q(/'@OHV+T?&4%20$! 0$! 00=Q0:W]JL'J=
M*$^WO^_39;]U951K;_#<%D'H?4"H>A]0('H?4"!Z'U @>AXD&X79N;7ELPC[
M^N?#]:M<JO\ U%J=NGY(620&;K@7#A(%*&B1&4F5$_65!]X/^R:L^4S!^LJ#
M[P?]DU.4S!^LJ#[P?]DU.4S!^LJ#[P?]DU.4S!^LJ#[P?]DU3D,P?K*@^\'_
M &34Y),PNW"91N8QD.1;&8FS<?D':1P/<WH\"P5Y[_Z:QW\?Q(*P@(" @("
M@(,:=H+]C&M?R7/X@NGIO,CBY^H\N>#Y;?7'P+ZY\N(Q$#H0$ (-C>Q=^U2[
M_)LOV[%Y/S'P0]7Y?XI?063V#O OGGN2^-\OOK_=%?:UW0^1MO<5DP$$()0%
M"5]<E/VN:(_+-E]W:N7JO*MP=/2^9#ZJGWM_@]1?)/J5.T_\R=\(_P :HJR
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MOT/,AYWS+\O?^.UF'I"]Z'P##.J/IZ_^&=XUX.OXYXOT'H/(IP4@[ESN\5!
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M2O[7-$?EFR^[M7+U7E3P=/2^95]5#[V_P>HODGU*G:?^9.^$?XU15D! 0$!
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MV>]Y@^&8NR'V$JL@E 0$! 0$!!U7'O,GN'>)8VW2SIXHXL#.WGPKYOL?IL"
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MUOPB\M)1PR1.=MV]T&FPA285>B@\&:^BKKW'JA6$EW6'S.#W \2DJ]* @("
M@(" @Q]S ^?6?P+OMEU].\;K_%5:*ZYWO+CM$! 0$#N(,I:3_1^T\!\97FZO
MBE]%TOE0M?7GTE;_  7_ !ET].\_K_%"U5TO-% 5! 0#T(,KZ:^@<?\ !CQE
M>7J^)]'TOE5<IOI^W_%W>,K%TPJR*(" @(" @(,?<Y_T%NOA(_&5\]\__*6?
M2_MO\[5JZORE^V" @("#CT(G>S+V>?IG-_BL/W1R^X_:_COP?G7[Q\.GQEL
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M_;KFU_"^=_</Y.W&/K:?KRWY@A5!!-4$()&]21L=V5Q^DWAM/^E7H=-N??\
M[7\N_%=':6_0./\ &X?MELZCPN[]Q_E)XQ];4GH_AW%YC\R@WH""$!!R]9#L
M;,=ECZ+S_P",Q_<@O0Z9^A_MGR;<6;L][S!\,Q=D/KY554<E 0$! 0$!!U7'
MO,GN'>)8VW2SIXHXL#.]D?"OFXW/TV! 0$! 05S2'Z1V'NW?:.6_0\R'G?,O
MR]_X[68!T+WGP$L-:H^GK_X9WC7@Z_CGB_0>@\BG!2.A<[O%00$ ;QX4@<X?
M?F>Z;XU8[&-MT\&>6[F_PZ%]*_,E-Q_TAD/=CQ%1%3HJ)0$! 0$! 0$! 0$!
M 0$! 0$&(>TC?3V/+.\; XM-W<6]M(?^;<27#T0*+*N\<^1.F,)%RPQ$[K*&
M2;)Q/ENY'L#R\ND<*$D'90):=I#%G+N-ND^T'E=.X\=5C[EUQ'U(W!C3UC6@
M=ZNQ93N8Q.UM<M;)X,U]%77N/5"L)+NQ_P S@]P/$I*O2@(" @(" @(,?Z]:
M]]]:%K20(G"HV_7+KZ?=,O'^8;X6D8Y?:.IX"NK,;-KS)I,1GO.KE]H[TBF8
M[V.).KE]H[TBF8[S$G5R>T=Z13,=YB3JY/:.](IF.\Q)U<FSR'>D4S'>8ED_
M2O$W!VC"/K3LZ?9%>=JS[3Z3I8_MPM;73JY* N_HMGV2Z-"8B)F9>;U\Q%HR
MM==7K>:)ZP3U@GK!/6&RJ1Q,LJZ:>#@K #:1&#3T2O+U(]J7TG2X]W7@YR&N
M?M_@'>,K%T0JZ*(" @(" @(,?<Z/T%NOA(_&OGOG_P"4L^E_;?YVK5U?E+]L
M$! 0$''H1.]F/L]NIF,T?P:'[HY?;_MCQWX/SK]X^'3XRS]QGO+[_$OS3,.(
MG817B'>3++EE/7,]L$R<LG7L]LWTTRG+)U[/;-]-,F).O9[9OIJ[#$IZYGMV
MJ3,+RRALS7$ .!)Z*J93#A=D_)Y@=W [Q)$H\N"^C8O1\960J2 @(" @(" =
MR#7#M6^\:3]W?_:VZRJ-:UF@@(" @(-P^S9^S9O?OKG_ (JUSO52.?NO]2Z+
MOL/#@9HHF744CINMB;*26NILXE8&&_U[<Q?ONU_JT:N$R?KVYB_?=K_5HTP)
M_7MS%^^[7^K1I@1^O;F+]]VO]6C3 ?KVYB_?=K_5HTP)_7MS%^^[7^K1JX&S
M_)_/Y+4_+W%YO+O9)D+EUT)7QM$;3U5S+&VC1L&QH6$JN._^F<=_'\2@K" @
M(" @(" @QIV@OV,:U_)<_B"Z>F\R.+GZCRYX/EM]<? OK7RXJQ0@()""4&QO
M8N_:I=?DV7[=B\GYCX(>K\O\4OH'(:-/@7ST/<G<^.$OOK_='QK[2NZ'R-M[
MBLV @A!* %"5]<E/VN:(_+5C]W:N7JO*MP=/2^9#ZK.][=X%\E#ZI3=/?,G_
M  C_ !JHJR @(" @(""';E)&$NTP -'8FG3E&_Z/,O7^6>9/#[8=_1>*>#5[
MH7T+U"B&2B&152BB90JK:+LU-#M+9.OWV/M5\[\R\<<'E=;XH9KK2@7DX<!)
M3@-=R#$>M]&<VLOJ*XOM)ZL9BL*]L8ALG-J6%K ''V!WD$[UC&_:SWPMP\NN
M?P-#KZ,?Q?\ ^6MFQK8QU+JOF?A,NS XW7+\_F7/$;[;&Q=9PGN<?5\)/=IN
M65)BTLIS5LARCLM<6>E1^?T[I\Y-.^6DCF.?'"YK>%A+ !4$$JWFO8UQG.99
M "U,Q!2<O\ZQOXP/4059 0$! 0$! 04_+7'R;'W5PYO$R*-[RS<2&BJSTHYK
MQ$=[5K3RZ=IGLAAQO,3%\.W$R&O_ #J^KGY?J?BCZ'Q\?,]+MI/TGZQ,9_LB
M3XU3].U/Q0?J>C^&3]8F,_V0_P"-3]/U/Q'ZGH_AD_6)C/\ 9$GQJ?I^I^*#
M]2T?PR?K$QG^R9/C4_3]3\4'ZGH_AD_6)C/]D/\ C4_3]3\1^IZ/X97!HS6%
MGE\]'9P6#K9QB>[K"_B]C3H7#UW27T]+,SG:]#Y?UNGJZO+$8V,GLV[>YL])
M?/SLC#Z3>[$A14$! 0$!!!W(*3@]][\,?55%74! 0$! 0$ [D&(>TA^SB;\<
MM?NBYM?POG?W#^3MQCZVGZ\M^8(50031 H@#NJ2K8[LKG;J8=^T_Z5>ATVY]
M]^U_+OQ71VEOT#C_ !N'[9;.H\+N_<?Y2>,?6U)Z/X=Q>8_,H$! 0$!#L;,]
MECZ*S_XS']R"[^F?H7[8\FW'[F;L][S!\,Q=T/L)55!R4! 0$! 0$'5<>\R>
MX=XEC;=+.GBCBP,[V1\*^;C<_38$! 0$!!7-(?I'8>[=]HY;]#S(>=\R_+W_
M ([68!T+WGP$L-:H^GK_ .&=XUX&OXYXOT'H/(IP4A:'>*@@( WCPJP.</OK
M/=-\82.QC;=/!GENX?PZ%]*_,I4['_2&0]VWQ*(J551* @(" @(" @(" @("
M @(" @PUVFV/=RSD+15L=]:N?W@2YOC*RKO25<Y'7#).5FG!&X'@MWL=WG"5
M^SZJEMZPPYIEWG+M,W]W;5=#!+<]8]NT M:&[?16<[F$;VUBULW@S7T5=>X]
M4*PDNZP^9P>X"DJ]* @(" @(""#M!"# O/;7&J=)YK%6VG\B;*">U=),UL4,
MG$X24!K(QQ'H+WOE?34U:SS1E^=?NWYKU/1WI[F_+F.Z)^N)8F/./F62'>?W
M@C=_,6O^27O?IW31CV?YS][X'_*?F7_+_P"VG_U3^N3F9_:!_P 1:_Y)/T[I
MOP?SG[S_ "GYE_R_^VG_ -3]<G,S^T#_ .KVO^23].Z;\'\Y^\_RGYE_R_\
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M0:X=JWWC2GN[_P"UMUE4:UK-! 0$! 0;A]FS]FS/Q^Y_XJUSO58/:I^E-/?
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M];4GH_AW%YC\R@0*H(02$$]*'8V8[+'T5G_QF/[D%Z'3/T+]L>3;C]S-V?\
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M_'.3X[5/A*']T/E;]Y/^.<GQVJ?"4/[HG*W[R?\ '.3X[5/@Z']T3E=]XO\
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M>TM=QRFA%#0R.*LHJ/"[T%,*D<(V=(45'&S;MW;TPAQ,[J8$U:=B8 MZ1O3
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MS'"CFQ,!!V$$- *#U((J$ N W[$$<;:5J@D$':-R"4'@S+728RZ8P%SRP@-
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M-CK>25KV]8YQ(('%W %A,,F3U 001M02@(" @(" @(" @(" @(" @(" @("
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MADXW38^XCN8V'A<^%P>T'8:5&Q![D! 0$!!PKM4'3+8VLSV2SPLEDA/%&Y[
MYS2.X3N5':V7B=PTH4'8@(" @(""FYG+6N$QMWE+ROR:SC?-+3?PM%:#PT3
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MO]78F?$9OET;BTN&D5+9.)CJ4#F&NQP6<1"2LKEW)KOE[D[K)VVB9+^:9O#
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MDL'BY\?/>.S4X@;)"*MC\H-J?306/K+GO@=*ZDOL#=:<GO;BT<T/NF!E'\3
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MGT%EA%PZ%YY8/6&I['3UGIZ>QGNNLZNY>&!C!'&YYW"NT"BDP,WK%1 0$$$
M^@@ZY+:&4M,C XM-6D@&A0=@%$$H" @("#B\EK21O08&SO.'F=89:]L;+1#K
MJSMYWQP7($G\XQCB X4/2%E$$L3\Q9M9<PY([VYT'-89:.C3>V[7\3X^EKP=
MA[Q6<1#&5YZ"UYS#TU98K34.@^IM&R1Q3W3(GQEW&\!TKJ'::&I*QM$,H;.Q
M>QW46 YH" @((.Y!9',;F)!R^LK"[N;":_&0N1;,9;BI8:<7$ZO1W$%FZ[YW
M832&9CQEYI^XOI9+>*Y$S6MV"9@>&GB!-16BRB"5L?WF-,4#1I*YH.CACIXE
M<(S+RZU;::VTU%G[*R?C[>:21@MI  X&-W"3L[M%C*KL4! 0$!!U16MO"2Z*
M-K"XU<6@-J>Z:;T':@(" @(""SN8^I\_I7 -R>G,5YXOS<,A^2 .)X'!Q+O)
M[A 'HH,-W_-WF9D[.>PO^7AN+.Y88IX9&R.:YKMA!!*SB(3#%FG,9JW3.JOS
MBM-"RW-LUSG0XZZB=*R,N-:L)-06G<5GL3#:'E=K+56KV7\FIL$<(^U=&( X
M.!E#P[B/E'HH%JE61U%$! 0$'%SB$&,+3F]C\C=:OM#A[EHTLV1TID I.(W%
MA#?"14*C'_\ >8TQ6OYI7/V,?3_%5PBJZ:[0>GL]J#&X:WTQ<6\U[.V%EPYL
M?"PNKM- $F!GQ8J(" @(.J:WAGH)F!X&T!PJ/JH.QH#0 -P02@(" @(.+R0-
MB#".L>:W,7"ZBO<7B='NR&.MI.&"\ ?20;#78:*Q&26*.8F5UIS%MXVY'0$M
MKDH2.IOX&/ZVF[A=6H<WPK9$0QPJW+_6?,+0^&M<%9:!XFAS1/>=4^.645IQ
M2$':X#I4M"PVKM)'RVL,LC>"1[&N>SVI(J1Z"UJ[D! 0$!!:/,C7$'+[3GG^
MXLI;]G7QVX@@'E5E#CQ'N <*L0+&UMSLPNE'XOY7I^XOCDK1EW&0UE8VO)HT
MAP.T$(+6':9TR 0-(W.WIX8SZBRPC*W+'7EAS P]SEK#&/QD4%P;=T,@:"YS
M6AW%Y-!TK&57T-R@(" @$5%.Z@ZF6T,<CI8V!LC_ &3@ "?"@[4! 0$! 06S
MKC/9C3NFKS+86P\YY*#AZFR:"2_B> =VW8#5!A6;G+S2N8GP3\OC+#*TLDC>
MV1S7-<*$$$T((6>(3:Q+:8?5..U@S5%EH246K973C#S1.EM@75V-XC78=K>X
ML]F$PV;Y7:ZUAJV\O+;4NG#@X+6)KK=Y#@'FI;3RCT +7,,F3UB" @(" @("
M @(" @(" @(" @(" @(" @(" @("""T.WBJ"T=>ZIT[H/3[LQF80ZTC<V.&V
MC8USW/<=@:TT'?*L1D8?;VAX)1UEMH&YFMW;8I1&RCF]!V-66)3,+WY9\SCK
M?+WEA^;$V#%O;B8SRL#0^KPWA! 'A4F!E9AJT%8JY(" @(+0YDY[4FFM,ORV
MEL><GDHIHP^T#2\NA=7C(#:FHV*P,>X/M)Z>DE%EJS'W>"O1Y+S-'6(.W&IV
M$;>\KA&5L+JK :AB$V%REM?QG^@D:X@]P@&H6.)566&H->Z@Y(" @':*(*-J
M3-V&F<)>9V_-+6RC,KZ;S0; *])W(->W\YN:UU>8;,.Q<6,TEEKZ"TMS)&'O
M>V5XZ7;:\/2-BRQ",I0<P+^'FH_0.6M&16-[:BXPEVP\1E=$TN>'= V-?3P*
M85DB.FVB@YH" @("#J=!#42%@+V5+'$5(\"#"VM^=VG-,ZBN=.66"DSF8M'
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MV;4Y93+)5K>6]XP36LS)X7;6R1N#FGP$54PKT* @("""UI-2*E!C#FKS+O\
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MTMAO;I^&O3L=!?M$0K2OLJTHF!DRQR5GDHVW%A<QW,#P"V2%S9&D'OM*F![
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M,<]^5%:G(-V_\P[^2F)7+(&D]2X75F(9F,!()<:][F1R!O "6&AV$!8R*ZI
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M.*CCA>T!HS4>2M[35^ \WR/>&6]Y<1LFC8:@#B<X @>@IRF6P-J83'&ZW+3
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MH.XLIW#/KX ]IC?1\;@6N:[RFD'H(W+$:^QXRST7VBK2RP$++2PS=D9+NSB
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M#73)]EN^O\I?9*'6/R87L\EP8FV#CP]8XNH2+IM:5WT6?,CR_P!U+*?VX/\
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MUZO:FQ&6N6%CS L,+<1<P;F*ZRSK@N@DBDZT"#A  )X6[:U6,JOINY02@("
M@(" @(" @(*7G\2_-87(8EMP^U-];RVXN(Q5\?6M+>(;1M%:H,28CLQ:+LW-
MES-[=YF<&KG3.ZMCC_C-:35939,,AXGEGH;!M8,9@[.%T=.%YA8]X(Z>)P)4
MRJYX;>* !L30QHW-: T?44':@(" @(" @(" @(" @(" @(" @(" @(" @("
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M7)7KLGC)+8Y3'W#S5[*%A+!MV B3I[BLC.[=C0.\L1* @(" @(" @(" @("
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M?:":'I(VJ9VBG<BM6935.C',S9X\GB+E^.FFK4R"%K2"XBM30T)2PR@-R@E
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00ZO
M0@LKF;HB'F!IF;".E^3W0<V:RN-OD3,-033;0]Y6)P,1QXWM,XQL>(MK^TN+
M6%@ABNSU3JL:*-)<Y@=N[RNR47]RFY;Y+1SLGG=37C<AJO,N!N[IA) C;M#*
MD"NT5.Q)E64VUX17>L1* @(" @(" @(" @(" @(" @(" @((=[$^ H,$ZUY;
MZ]QNL+W7'+*_BMKK*,:,A8S$4<\-:"0'-+37A#CWUE$QVHH,NA.>/,'J,9KG
M)6]IIULK'W<#>%KY&M<-A;$W;NV5-$V=BMAL38V^+L;?&VC>"VM8FQ0M[C6B
MGJ+$>] 0$! 0$! 0$! 0$! 0$! 0$! 0$!!;&O-*6>M=.WFGKYQCCN6?S<K?
M9,D;M:X> JQ.!A*WT_VD=,PPX'$W]K>8VV_FK>X/5O(C'L>(O:';/1668D7M
MRMY<ZAT_E\EK+7%XS(ZMRD;8 ^,DB*%M*MK1HVD-W#9129&71N'@6(E 0$!
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MH4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M/ND[[2^@(G9%CHKW*S/OG0/V.C8\!K >^0WB]%)D98&Y0$! 0$! 0$! 0$!
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M<?\ >S/]40/]Y=B?_P <7/\ WLS_ %1 _P!Y=B?_ ,<W'_>S/]40/]Y=B?\
M\<7'_>S/]40/]Y;BCL'+FX![^6C_ -4"#;KE#S%CYL<NL'S!AQ[L5%FHY96V
M#Y?E#HA#/)!0R!C ZO5U]B@O= 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 06GS(ULSEYH;4.MI;,Y"/ V<M\ZR;((72B(5X>,M=PU[O"4&G7^\MQ
M1_\ ^<W '=\[1^I:((_WE^(__'%S_P![1_ZH@?[R_$?_ (XN?^]H_P#5$#_>
M7XC_ /'%S_WM'_JB!_O+\1_^.+G_ +VC_P!40/\ >7XC_P#'%S_WM'_JB!_O
M+\1_^.+G_O:/_5$%4TW^\6Q>HM0XG ,Y?7%N[*WMO8MG.48\1FYE;$'%HM16
MG%6E4&[C'<;0[NH.2 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @ZY&-.TBI0?)#4]K:WG:QUY;W<$=Q <YF:Q2L:]AI)(1Y+@1L4
M6&1OS<T]_LFR_J\7\E,MN(3^;>GO]DV7]6B_DJ)@_-S3W^R;+^K1?R43!^;>
MGO\ 9-E_5HOY*+@_-S3W^R;+^K1?R4,(_-S3W^R;+^K1?R4,,=\ZL1BK#1@G
MLK"VMIOED ZR&&.-]"'[*M:"K#"S?[L<T_NV:#_%[O\ T^Y58LYH" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @("#$_:8:!R"YBD;/^Q+L_\%!I_P!A
M_2>E=1Z%U)<:@P>/RL\.6$<4M]:0W+V,^31NX6NE8X@5VT"#:+]67+;^QV#_
M .[+3_)*!^K+EM_8[!_]VVG^30/U8\MO['83_NVT_P D@?JQY;?V.P?_ ';:
M?Y-%/U8\MO['8/\ [MM/\D@?JQY;?V.P?_=MI_DD&DG/[#8C ]JC1MA@\?;8
MRQZW R?)K*&.WBXW7QJ[@C:T5--I5'U0: &@!$2@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(.,GL4'R3S__ )M]=_ES-_=)$6-[
M*BQ;4J(A54H@H"HQGSU_0<?CL'B>K#"S?/L=?^6S07XM=_\ \0N56+.2#'G-
M/FA;\L;6QOKNQDOXKZ9T+&1/;&6EC XDEP/=6,S[41WLHC9,]S&G][?"C?IJ
MZ/\ \3'_ "%MY6$3$G][?"UK^;=U_68_Y"<IEE+EES*M^96(N,O:6,EA';W'
MR9T4KVR$D-#J@M [JEJX2+97XL615!"DB5.T%8!4$! 0$! 0$! 08PYX:[SW
M+_2\&8P'4_*Y+ID!^4,,C.%[7$[*MV[.ZL+3MB&RM<Q/!<7+;4.0U3H;"Z@R
MA8;^_@ZR<Q-X&<76.;L!)IL"Z=6G+>8<]+9KE=JTM@@("#@XN#33>DI#!O/+
MFMJOE]E<'9X!UOU.1CE?<"XB,KJL>QHX2'-Z'*Z4<VK%9W+?9IS;M9IQ=Q+=
M6%M<3&LDL4<CR!0<3F@F@5O&+3#&LYK$O8-RQ9" @Q1VF?V \Q?R'=?:H-5N
MP-^S_5'Y8'^BQ(-M% 0$! 0$&@_:4_\ -GHWW> _TYRJOJ&-P1'"5_ QS^AH
M)])25:^9#M5XBPOKJQ=IZZ>ZVFD@+Q/&.(QN+*@</20LJUF8REIB)PZ?[V^$
M_LU=?UF/^0KRBIZ>[3V(U%G,?@XL!<V\F0G9;MF=/&YK#(:5(#157E299W8X
MNI58*YH"F05! 0$! 0$$;:]Y!* H" D J" @XBM3MV="($FH^JI G;7O(KIO
M+B*UMWW$TK888P722R.#&-:!4ESG; /"I.P>+$YW$9ILCL3DK;(MCH)'6DT<
MX:3MH3&XT66)W]AZ.U4QNVH)0$! 0$! 0$$&O0@X2.<" #T;5(&"F<V=6NYV
MS<OR;<8&.<1 ]4>O+3"U_L^*A()[BSZ>(O6TSV&O[$UB.UG9A)8"=ZQ@<T&$
MM=]H;'Z%U+<Z=N<-<7DEL&$S1S,C:>L%1O:=R4B;8P6Q7>M[^]OA?[-77]9C
M_D+/E ]K?"TV::NJ_C$?\A.0RSYALF,OCK3),88X[N)LS8W4):'BM*A8S&$5
M)11 0$! 0$! 00:TV;T$>4I!*4@2J" @P/S&YM:LTOS/QFDL8;;S3=FV$O6Q
M%TO\\_A=1P</$KH1SS,3WFI[,9]#.S'<3 3T@*)#DBB @(.N1Q:-AV]"DC ^
M'YMZNON<EUH28VWF2*62-A;$1/1D8<*OXJ;SW%GHQS4SZ#5]FV&>6DD';7:L
M.U9<U4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$'&3V*#Y)Y_P#\V^N_RYF_NDB+&]E58M@H
MHB"*(@@QGSU_0<?CL'B>LH8V;Y=CK_RV:#_%KO\ T^Y58,YH-=.UK] :=_')
MON2PKYM/6W1Y5YX,@\H,/A[GESIZ6XQ]M+,ZU!?))#&YQ/&[>2*E=.M&+2Y-
M.<POG\W\#_LNT_J\7\E:LMKIN),;I_&W-[':B&TMF.GF9:P[:-%20R,;30+&
M9(6YHOFIH_7EW/9:=O7SW%NT22Q31OA=PDTJ \"H%=M%GRSA)F,KFU!G<9IS
M$W.9R\XMK"T89)I:%Q '< VDGH"UY91&5 T9S&TYKZ.ZETW+/-#9EK9I989(
M6\3ZD %X%30="SF,1ECG;AX9N<&AK?4=WI>YR3K;*6(E====&]D+1 PO?_.$
M<.P#9W5COC++"R,AVI=#V5V;:SL[[(6[3\ZB:V-I]"1P)])9UI,PD[&0]%<R
MM,:_MG3X"\+IHP#/:2#@FCKLV@[QWPK:DPQBV5V2S-B:Z223@8T$EQ-&@#::
MUZ%KW,F)-4=H[0FG;EUE;.GRUS&2V;Y&WR&N&S8^0@'T%:QE9V..E^T=H745
MZRPG=/B+F9P;#\L ,;G'H+V%S6UW;5LY):^:&8N/B9Q [*;"M4[&<;6/+3G5
MH&[R.1Q?G-T-SB1*;YT\4D3&]0_JWT<10^5N 5KMC);9.%EWW:HT3;WKK>UL
M;Z\MFD#Y6QK&-([H:\AWU%E6O,EIPR?H;7NG]>6#\C@;DS,B(9<0O!9)$\[0
M'-/=2:S"1:)7%?WD%A:R7ES*V"VA:9)97D!C6-VDDGH6$RSB,L*9?M0Z&QUX
MZVL;>]R<330W,+6QQ^AUA:3X5E$92=BS.=7,[2O,+EW _!7)-U#>POGLI@63
M1C@>*TZ17I"QM3%HXLZ6V3P9FY)BO*G3 _!3]U>NOJ9_NS_'8Y='P0J.MN8N
ME] VPN-07O52S;;>U962:3AH#PM%:#OE<>73AC:S[5.B9[L07%A?VMN30W3V
MLD:!W>%CBY;8I,M<VPS#@L_C-28^'+86[;>6$PJR:,FFS>"#2A'<HI,86)<=
M0:DQ&E\9-ELW=BTL8!Y4K]M3MH !M)--P6N99Q&6')NU/HIEX;>.POY;4'A^
M5@,#2T]/ YW%]1;8I,L)G#&W: U=@=9WFD\MI^[;=6IAG:^E6O8[K(SPO:ZA
M!"RT:37J(RFI;.C+;C"T\T6%/O:'[0+'5\<\4IX8>X;E@S2@(,4=IG]@/,7\
MAW7VJ#5;L#?L_P!4?E@?Z+$@VT4! 11$$!!H/VE/_-GHSW> _P!.<JKZAC<$
M1TW5.HE[O"[;Z!6O4V5F65-\-1>1%K:7G.+,PWD,=Q#PWQZN5H>VHFV;' A=
M=/)SP:=3SL<6V'YOX'_9=I_5XOY*TY;$C"86$B6+'6L<C-K7L@C:X$=((;L3
M(MW6G,33.@(;274=Q);QWKGLMC%$^6IC#2X'@&S8X*;9D6EJ7M#Z"TXR-L4\
MV5NWL;)\FM6[6A[0X<;GT:#MW55Q*X=>D>T1HK5F2AQ3NOQ-[</$=L+P L>]
MVQHXV%S14[-JS]W,1EKYXSA[M:<^-%Z)NWXV>23(Y2/9-:V8XNK/<<]Q#:]Z
MJU1M;)C"G:5[1VB-3WT6-F;<8FZN'!EO\K X'/=L XHR0*]];ITIPU\T,QPN
MXHVN)K7I6IFLS7/,_2>@(V^?KPMNY070V<(+YG@=X;AWRHL0QWCNU-HFZNVP
M7EE?6,!-#<R-9(T>%L;B[ZBVQIS+"9PS+B<Q8YNQ@R>,N6W5C<-XXIHS5KAZ
MBUVC"Q.5L9_FQH[3.HH=+YF]E@RTXC<QHB>Z,"8T:7/ X0I$Y93"T;WM(Z,A
MST."Q\5UD3+*VW^60M:V$/<[AV<9!(JME:3,X86M$0RGF<]CM/8R3,9BZ;:X
MZW;Q33R'9MV  "M2>\M=IPSC:PS==JC14-X;>WL;^XMP:?*VAC6]RO"]W%]1
M9Q29C+&9PNN7GWRW@Q-MF7Y20VUR]T0C9#(^5DC14A[0*CT4FDYPN62,?>0Y
M&R@OK=Q=;W,;)HG$$59(T.&P[1L*DQ@B5DZ]YN:0Y?N^3Y>Z=)DGM#V6%N..
M6FS:[H;6O25C&U<+*P_:AT/D;MMK?6]YBXW;!<SM;(RM>GJRX@>$+9%)839F
MBRO[;(VT=Y93-FM9VA\4K#Q-<TC>"%A.QE$Y6;?<V-'8_59T;>7KX<VT@.8Z
M.00@&/K:F2E!Y.W>E=N2=F%F9SM.Z%Q5XZUL8;O*M8>%\]LUK(Z@T-#*6U\(
M2(S"SL7AH'FSI7F&V2+#7$D>0A9QS6,X+)0TDBH^M(]RMEJ36,M<6S*@<U>;
M&CL)8YK1V1NI8\Y):.8V$0R/96>/B9Y8!&T%<T^U$PZ*[)AAKD%S-TER_L\O
M'J6ZE@DNY6/@$4+YJ@-H:EH*[;Q[%:N;/M6LVYQ-_#E<?;Y*V)=;W<;9H201
M5D@XFFAVC85HFN)95G,9>U1DMO5VL\!HJQ.1U#>MM+8GAB!JY[W;-C6-J3OZ
M%CE<,22]JO1T=R88\9?RP5(%P!&UI'=X2[B"V1&6,SADW1W,736N[1]UIZ]Z
MY\5!/;/!9*PG;M::'T1L2:S"1:)>S5VM,'H?%C,:@GDAL3*V$/8QTIXW@D#A
M:#[4K7S-F%GYGGYH#$8BSRWRV2Y&0C=+:6<4;NO<QKBRKPX>1M'URSPPA1,%
MVG=#Y>]997D%WB1(0UD]R&R,XCW3&74]%912<)-F98+EES"R>&3K(9&A\<C=
MO$UPJ".C:%A+*%K:WYEZ7T!;LES]V6W,HK!9Q OEDVTJ&C<.^318YS.QE%<L
M=XSM1:'R%XVWO;6\QT#C07,S6R1^B(RYP6ZNG,M<WQ"P,;>VF2[3C[^QF;/:
M7%Q')#-&>)CFFUCV@A7I:XI=>JG-J<&V_05IC>IZJLC4#7T;).T?C8I6!\;K
M_'-<QP!:07-!!!WK/I/_ +?4QZJ?9^CZVU_YOX'_ &7:?U>+^2L<LG%^ P7"
M:8NTK^+Q_P E,R*#JW76G]!6,%YGGRP64CA#')! ^1K74J >K;Y.Q8Q,S;"X
M5'3.J,1J[%19G!W)GQ\X/#)0M<"TT(<TT(*RM68WL8E3-:\R]*:"%L-1WCH9
M;NO4111OF>6MI5U&;0/"L8EEA4K+56.O=.'5,9F;B.HDO..2-S)>HB:7%W5D
M5W"H5MLEC&U9GZ_>7#\1/F69-_R>)_4MA=%(V9[Z<5&L(!.SIW*X5;%GVI]%
M7%XVWN;&_M;<FANWM8]@[Y:QQ=]19129VI,Q#,F%SV.U!CX<KB+EMU83MXXY
M8S4$>CM!'2%C,8(G+AG-0XO36,FR^:NVVEA#M?+(=E-U -I)/0 L,LHAA_(=
MJC1-K<NAM+&_OH0:"Y8(XVGP-D+3]1;*UF4F<+ZT)S:TGK^3Y/A[MS,C&WBF
ML;AICE [W0:=/"5;5PQBT2NK4VH<;I7"76>R\CHL=: .GD8TO< YP;L#=IVE
M:K3B&RM<RL.?GQR]@P,>H3D9'VLTCXK>#JGBXD?%[*C"*@#NE96V,:;5KX_M
M2Z*O+QEO=V=[86[G<)NI&LD8*[ 2&$N^HMD4EA-X9MQ61M<M919&QF;<6=RT
M203,-6N8X;""L)C#*)RH^L=:8#1%@<GJ"\%K;G9$P5=)(\"O"QH!)6.641EB
MB#M4:+DO1;S6-_#:UH;MP8YE.[PM)=]19UK,L9G#&W,G/8O4O.'368PURV[L
M+GY"8Y6; ?YS:"#M!'<*RZ:N+3Q-:<UB/0W!8.&,=X+7,[2-S%NL^?&BM&7<
MF.FGDR.3B/#+:V8XN [_ "GN(;7O54K.6<PIVF.TAH?45W'8W'RC$7$SFLB^
M5M:8W.<: <;.(-_C%;>26N;0R_'+UC0]KJM(!#ANW5KT]U:Y91M6?KOF?I?E
M]!$_/73OE4[2Z"RA!?,\#IH-P[Y*QC:RPL'$]I_0^2O&6E];7F,B>>%MS<-;
M)&#T$]67$!;/=S,,.;:QUI"Y@O>TC<7=K(V:VGFD?%*PU:YKHF4(\*NA7&GZ
MOM77GV_7'U-NCL6N-XE4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'%^Y!\D\_\ ^;?7?Y;S
M?W21%C>RJL&P0$"FQ53>@*(QGSU_0<?CL'B>LH8V;Y]CK_RV:"_%KO\ _B%R
MJP9R0:Z=K;]']._CDWW(+")QJT];;'EV]2U-%]HZYTIIC&X!ND7WHL(NJ%T+
MUT0DVDUX?DSZ;_;%=>K&;2Y=.%?_ +V-Y_8>3_O!W^IK3RMF6P&%OSF<-8Y*
M2#J?ET$<[H">+@ZU@<6DEHK2M-RQO2*[$I;FC+5WF-I_(<E^85MKC3,?5Z?O
MI?*@8:,8YVV6$@  -=M<T=&Y9:-\3R3VL]:O-7FCL<^;?,"7FKF<)H31DCYK
M*<Q27,@J!)<3AI#74/L(F[3WZ]P)32YKYG="3?%/2V)Y?Z.Q^A].VF!LF@F)
MO%<34'%),XU<XD=VNSO*ZDYEA2-F9:N9+2]GK+M#9#3V1E?'875].ZYZLT>Z
M.&)TI:#T<7!2O0L>E\%N++J?%7@V=;RWT*S'>:QIZQ^2\/"&_)V$G9O+J<5>
M_5296)VM8<K82<D^<ELS#2R>9YG1/B9(:EUK<$!\;J4KPNV5\"W=/.<U8Z\8
MB+-G>8."S>J])W.&T]?1X^\OFM8^YEXZ=2?9 < )JX5"YKUVX;*V[5G\N>4&
MF=!8H_G&VPR&<E<YTU[.UKXPVODM8)@*;-^S>M\WSL:^7;E8_:,TIHZ+35OJ
M/!QVEOE(;ED+VV?5M$D4P/LFQ[^$@4*TQ:T7K'?+9G%9GN97Y.96[S7+C!Y#
M(2&2Z= Z-SR:EPAD=&":]-&KHZF(B9:M+?AK)I#1UEK?G'E\+DY'ML!?7\]S
M'$:.E;#.[R"=M 3O6.C.*>I=>,W];:VXY9:%FQ3\2<!9MM',,;2R%@>*@CB#
MJ5J.[5:;;FR-[7KD.Z737.++Z5@E<ZPECN8"PF@)MGA['$=T .'HKHTK\VC_
M #^QIU?-7;VI=67F/Q&,TM:2&-F3,D]Z6&A='$6\+*]PN-2.\N:D<VIB.QNF
M>6DRO'EAR@TKIO35F[(XV"^S5S$V:]N;J-LI#W@$L8' T:W<NC6M[6(::1L8
MS[1_+?36!Q-MJK!VK<?=27#;:XMH&AD,@>TD.X6C8X$="T1;%H=$[:RRSRCN
M8K'E!I^]E-(;:PDED]S&^1QIZ2Z.LMB\^KZG/T\9K#!V@,.[G;S-RVH=3N=<
M83&TD^2$DL=QN+((MNYM&N>[P=]33K%-.;=LLM6TS?E[FPV9Y8Z'S>)DQ-QA
M;6*W='U<;[>&.&6/9L<QX;4$=!VK1.;,Z[)8,[/.4OM-:[SF@KN9TEHWKG1L
MKY/76[VMX@#NXFKHK,ZFES=N6JT<EY>?GSD\CJWF5C.7-M,8[*)]M&\ ^29K
MH!Q>1M]BQVQ:>GTXO>;=D1ANU9Y:1WRSK@.5NA\#B8\7#AK:X:V,-FGN(632
MRGI<YSA4DJVOF<,*QC:UIY^:#PFBM58N; L-O9Y=KYW60][BDC>T.X.X'<0V
M="RZ:\^^BIK1G2F6XF&^A[#\7A^T:FIXYXL:>&."H+!F("#$_::_8#S%_(EU
M]H@U8[ WZ :H_+ _T6)!MFH" @#:@$40$&A':3_\V>C?=X#_ $YRJOJ$-P1'
M1>>\2>Y/B*UW\,\&5?%'%HOH_7<G+SF'F,['BW98NENX/DS9C;D<<Q\KB$<O
MVJZZ^7ZH:=6/[WTLL_WL;S;_ /0TG_>#O]36OE997URLYS7/,O,7>,DT^[$,
MM8/E'6NN3<!WEM9PT,$5/9=U6U,0D6VK([6XIC=+4_I[O[2%:8\RK=_^=E[<
MK.6&CL7I'&7LN-@O\ED+:*YNKN[B;*\OE:'<(XZT KL71JSBTM&GX88I[2FA
M<'IQV)U%@;5F/?=R20W,<#1$PNCX7L>UHW.J=I\"T4MBW%OF,TGT,D<F>6.F
MH-)V&H,M9193-9=GRNXN[Q@G(ZPDAK>,'HW]];]2.6<=SGT]L96+VE=":>P.
M/QFI<)9QXZ\DN?D\[;=HC8\<!<'4: .(%N]<])GWCHF,UEF31>I)3RHQFI\@
MXOEBQAN9W$DEQA::^GPK;U/L6EHT-M88%Y1::;S?UOFM8:N)O;&Q>U[+.0ES
M'R3N>6,(-?(8QOL?!T+*D<FGGMEEJ3S6C#/VI.5VB]3XB;%3XBVM7/;P0W5K
M#'%-$_ZUS2 -QZ#O6BV=\-M9B&'.S)G\A99O,Z%O9#)!:A\T#231DD4@C>&]
MXUJNCQZ47:)CEU)JMSGWC3F.=-EB1)U7RV.RM^L&]HD<6DCTUJT-GTMNMX&?
M<!R<Y?X&SMH8,);W-S;T=\MN6"2=SVD$.+CW^]L5FVUAAAGM(9V_SFK</H&P
MD+;:,1NFB!(;)<W!HSBIT-;NV=*PZ>.;6B9[)PSU)Y:_S9ITMRHT5IK#0XYF
M(MKN3A:+BZN8F2RRO/LB2X'83Z2RO?FSAA6N&NW:(T!@]'96PO\  QFTMLFU
MYEL6T$+)&;"Y@&X'N*Z$_P!RK+5VTELG<9YFE^6$6>(J;'$0RQL.XR"!H:#N
M^NH%AU,S%K1&_,KT\9BO!@?D9HR+F+F,SK_63?.?57#8H(KCRV27#QQ/+P=A
M#&E@:._WEOF.73C':USMMP9DYA<K-)ZDTS>VL.+M;/(QQ.?9W=O$R)\<C!Q-
MVL JTTH0=ZY=29QGN;J]W>Q[V7M47=S8Y72UY(Y_F][9K<N/$1')4%HKT!S:
MKMU(Y].+.>/9O-6/>9^&&HN?D^$,SK=M_<6\#YF>S:QT3>*G?IL6CI8VW;M>
M?9JV:QG+'0N)QC<5:X&S?;!I8730MED=395[W"I*EIRE=C7(8RVY?]HJWQ>#
MK!C'7,(9$TT#8KR%KGLZ-@+C0+/I?:K,2PU]D1/I9]YE:,TKD-/YS.WV'MKC
M,-LY'"\DC8Z5ICCHWRB*[!N7/,8K+?3Q0PQV:M(Z:U+89Q^?Q=MD'0RQB%UQ
M&)"T%M2!5=MO*K+GCS+-IK"W@M+6.UMF-BMX6AD4;!1K6M% !W@ N>=[.-ST
M;5%80Y@\F<YK[7UOG<OEH#I2UZID>+_G.M$36@R 4'""]]=O<33Q2<]K*TS,
M87PW2O+BVLABGXW%,M@SJS&YD ?0"FTD5^JDS,SEC&S8UTT7:PZ-[03<%@YJ
MX>>:> ,8_B887POD:*C8>%P%%MZ>TWI.>QCK1$8PREVGC_X<QC_YC;_<Y5R_
M_I#IT^W@HG9^Y9:9O-)6NKLQ:,R>1OW2MA%RP2101V\KX@&-=45):7$KMU=F
MQQ:4Y=?:-T!INQTG'J/&8^&PR%I.QCWVS&Q"6.5P;1P: #2H([BY8MB\.F(S
M287]R1S$V2Y88J[O'E[K:)T!<34EMN2T?4"V]1LV^MHT98%TKCW<Z^;MW=:@
M+Y<-:F25]N'4_F8R6PQ [: NW]ZJRTJ1%)M++6M[45ALO=<M]"7>/=BYM/V/
MR0MX!P0-8X#=Y+@*@CNU6F9FTY9QL:TZ*TY;Z2[0L>G+65\]K873F0224X^K
M=$'M#J;*@.X2>]N"Z.GO-J7]#5U%<7IZ6Y(Z%SMAO3M&EW-S+NP'/,9P6_RM
MV.GL[H6H=U9D,5'\/%PNI6GM2L^DG9])U4;(]2_/[V%Y_8>3_O!W^J*\K'*M
M:.[1]UJS4N.T\[23[%E]*(C=&\,@8#MKPFU96GN@LIT]B<S+NK=,8S5^!O,#
ME8PZVNF</$*<3'C:US:C>"%HM7,-M;8EK3RQU-=<FM:Y?0VKI#%AI2Y\,Y)X
M62LVQR-KL#96';WZ=];HM[S3F.V&JU>6T3V2\NF;#(<^>:,FH,LQS=+8UX)C
M^MZJ,ET4(K4>6=K^]5-*.6F9WKK3S6B(W?Q];9?5T4<&B,]#$QK(H\9=-8QH
MH T6[P !W%R:V[+;3?#6?LX: T_JJXRF8S\ O6XUT++:TD =!QR<1+GM.^G#
ML7?;9IPT6\V6=]:\H='ZIP=Q8QXNWLK\1DV=W:Q,BDC>W:W<-H)WA<EL[V^.
MYB'LRYR^QFI<[H6]>7Q,8ZX@:22(Y;:012!HZ.(.!_BKJF>:F7/:.74PR%S=
MY5ZFYDY#'-M<O!98&S:.MLI!)Q/E+ZN?Y(I7AH!5:-.(K?FEOG;7"ZL7HKEW
MIVPCQ4=AC6QQ-#'.N6POF?3>7N>*D]U6=2;;6%8Q&&N&ML;CM#<Z<//I&1D-
MG=SVLW56[QU33-+P2,'":<)'0MG3S,[)-:8BF6?^>9KRISY[L,9/HRL7+J[O
M6Z.G\7J8>[./+G3VHK"]U)G[<9&2WF^365I. Z".@XGO+#O<=G@7;J;H<5-\
ML@\[^76E9= 9;+VF,M['*8N)MS;W%O$R)U&/;Q-=P@5!;4+CM,Q.77I1$S#J
M[,>3GO= 26<SRX6%T^.+B-:,?Y?".\#5=NOB(B?0X]/Q6CTL6ZX=>\U>=PTE
M/,\8?'73K(1--.&& _S[AO <2"%HZ:N8M:71KVY>6&QUGRRT+:XQN*CP%D;-
MK1&>.!CWN[Y>14D])4F4C8U=UIHW':(YRXK%XESACYKFUN887[>J$L@):.\#
MN6?3S[<1Z4UX]G+8[G/JVXT9R]R&1LG\.1N0RRLWUVMDG\DO'?:WB<._1<]]
M\0V:;&W('EEA;S!,UMJ&V9DLEDI)# +IHE8R-CRWBH[>YQ!J5UW]G9#GB9G:
MK//;E?IV\TC>:CQ-A#C\MBFF?CMXVPB2,$!S7!@%>]W%RS::RWXS&%7Y ZNF
MSG+1LV1D=)<8226TGE>:N='&T2L=MKN8\-]!='4Q'B[X:=*<VFO<PUHC#.YT
M\V,MDM2%]QB+'K+A\'%0=6) R&$;#1I&T]VBFC&-+G_$V:MO:Y.YLA?\M-"W
M^,DQ4V LVV[FNC:Z.!D;V5%*M<T5!'0:K78JUKY9X*+3//HX&"5TT%C+/%%(
M^G&6< +:TZ0#1;="<Z?J^UCU'C]<?4W)'L5IC>R<E00$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0<9/8H/DGG_P#S;Z[_ "WF_NDB+&]E58-@@(" @*C&?/7]!Q^.P>)ZL,;-
M\^QU_P"6S07XM=_Z?<JL&<D&NO:U_1_3O?O9_N(6$1G5KZVV/+MZF2N3D<3N
M6VG>)C23:C>![=RZ=:,6ES:<[%]=1#[1GI!:&P#V <(%&C=3<D[4C9.&&^T1
MJ3!XK0\N(R$3+O(9-X996Y(XF.;M,M*U ;W>^M?+.I:*UWMM,5S,[F&.066L
M=%:]^0:JLG6EYE8(H[&ZN&\!A=,.)I\JGDR @57H3,7KRUWPY<3%LSN;EQN!
M-000>_XEQMV6J6!(':ENJG_K=]_HLJRZ7R[<6/4^*O"&U_$W>#7N4VK"99-2
MNTO-'<\QL';0'BN([>(/#:$CK)?)K3P+;TL?W=F[!KS_ &<>EFWFIK:3E]H8
MY2V:'9.5L=M9AVT"9S:<1W>Q&U:=2=NQE2N88=T+RARG-/'MUEKG/7;X\@2^
MV@A=5U&N(J[C!:!0&@:%T7B*XGM:HO-I]#Q\X.2.F.7^D3G<5=7<UV+F&#@G
M<QS.&3BJ3PM!Z%I][[41C?+/EQ2?X[6:.08!Y583;_R<WW>1;^JWS+#3C%IA
MA?DQ^WK._#93[NY32\J.$,M;Q^N6V[O8GP%<_P#I9=K4CE@:=HK(G_G+_P /
ML2MVA&-*>'VM?4;-2'H[54;XM48"YE!-L;9X;LV>3+5P](K'I=FK:WHALU]N
ME'%M-CYHI[..:)P=%(T.C<-Q:X5!'H)?Q-=-S"_:F(_5_:#N9"+[1ZT7G%J\
M73I^&W!5-$M?)V?;2*,5D=A[J@&__E5U==XY]7V.?I-T-<^4_+;+<P#E68O/
M^9IL>83+%20ND;+U@#O(>W8TMIM[JV6CEIQ83X_2R=_=GUB 2=<$?Q)_\JM/
M/$PVVC,[U=Y=\A<MHG5L6IKS.LR 8Q[)(VP/8]QDIM+G/=W%::F,Q&YC>O-M
M[<K&U,6VG:?AENC_ #;[RR<QQV"C[:-K?2*=''+6_I9=3MQP;:->V@VUH-M-
MRP[2&K?:KI^<&E .B"<?^]C6733_ 'X76\B8;-X8CS/C]O\ U:'[0*ZGCGBU
MT\,<'O6#,0$&*.TS^P'F+^0[K[5!JMV!OV?ZH_+ _P!%B0;:*"2@A 0*T0"@
MT([2G_FRT9[O ?Z<Y57U"&X(CHO/F\ON3XBM>IX9X,J^*.+4KD&&OYR9IKP"
M"V^W[?\ ENX5U5\OU0TZL_WOI;;]3"?^3;Z06EL2V.)E2Q@:>F@"9&N':V(.
M-TO0U_G[O[2)8Z?FU9SY=F;M ;=$:>[UA;$?%-71KQ[=FC3\,,/=K&GYM8(#
M[[E^T:N:OFUAT1X+,K<JB?U=:<[UC%XEU=3YLN71\$,9=JRIT9BZ_P"T&_<G
MKCCS8==/#/!4\(Q\O9Q8R*ID.$F :-O0Y;^NGEO,\'/TFVL>M@/E-RPR_,&S
MR4N)U#YG^121LF@ D/'UC26N/ ]O<*WW\/K85\7J9)_NSZQ/_P![G;_B3_Y5
M:>?9+;A=7*OD;D>7FJ'ZAO<U%D6R020.8R)\;BZ1S7<1<YQKN5B^*<D;F-JY
MOS,?<WO_ # X,_X^-^Z+'0[>,MFOLI#:^M&U[M%AO8[H:E\S:6O:+QEW<4;;
M.N<;(USM@X&B-IW]\+/HMLW9=1LK$^C#;.(CJQ7N"JQG#&-S6?M:D%VG*;:"
M:JQI.-6K9,?VY7[S+CDEY$O$0+B,5:.=P] :R.M5EKSC5]<IH>'U,#\K>4>:
MU[@)\IBM3>:HX;IT$MD&RFC@UK@X\$C1M![G0NBUL16,;-KGTY]JV5\GLU:Q
M.S\^":[#Y%Q_E5ISV-M8QB>Y>W*3DM?\MLQ>Y2[R\>0;=Q")K(XG1$4-:DES
MJ[U>?V.7TI-<VYF+M5?^9NW_ !VV^XA;.CVS?@=1_H;<N(! [JT0K4O7I_\
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MRDC2[F[F&Z>YY#.NB^4#&SV=UU =P<8A(=3BH:5IW%GT\\O\V74QS5^A?/\
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M9K+<MI\J@6B67:YJJ(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M*[SF!0?_  L2#;10$! 0$!!H/VD__-GHSW> _P!.<JKZAC<$1Q(.W8@<%!0
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M! 0$! 0$! 0$$.W+&5AU'BH/15G>E78RM#54<D! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 4!4$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 00ZM-BDCCMJ%C#)S64,14$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
$!!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>tm2227887d4-bc_frequen4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-bc_frequen4c.jpg
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M -0  0 " P # 0             '" $%!@($"0,! 0$  P$! 0$
M   ! @8' P4$"!   0," @(*"PL* P8#!@4%  $" P0%$082!R$Q05&25!46
M-@AQD;'14G(34[,4=&&!(C-SDY0U574WH<$R0K+"TE87&"/3M/!BPR0T1H)#
M1.&B8X-D)O$EE2<XH^/41641 0 ! @$'"08%!0$! 0$! 0 !$0(#,5%Q$C($
M!B%!L3-3%#0%%9%2<H*2$V&!H<&RT>$B8C460B/PXB3_V@ , P$  A$#$0 _
M +_
M
M
M
M
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M>\!GEVT<;C[:]X#'+MHXW'^7O"@<NVCC<?Y>\ Y=M'&X^VO> <NVCC<?;7O
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M&.7;1QN/\O> <NVCC<?;7O .7;1QN/\ +W@,\NVCC;,-_9[P&.7;1QMGY>\
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M]M>\ Y=M'&X_R]X!R[:.-Q]M>\ Y=M'&X^VO> <NVCC<?Y>\ Y=M'&X^VO>
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MM>\![%+<*.M5R4LS959@KM'<Q ]D
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MVWJNS2Q[>\*CU+$QD5TN<<;4:QKFHUJ;2(0="
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MN  '< 8 .P V  #N@ "      V]@!N@-D  (-3!TEG^03N&4C;)LD#_9 '=
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M![@#<  .X W-CM  &  !M -D   =@   )^DGO :VR_6]U\="R-^0
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M1N>W&7'X28IM8&<7(T_51<K\PW9Z[;J3%>VA;B%K3S9&X  ;@   Q  /<
M'<  .R   ,>T  ?F =P  V@ #8   "@.P W@ #:[X#W &UM@-M0-3!TEG^03
MN%D;8@ .P   -T     &P [H   15 ;H !W0    ]Q0     ;@    ?[( Q
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MYZR3MC6'RB[>A$NBW'';V#"[*KN4 $! 'N  &(   [(  GY0    PV0
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MS;Y.M;5T<TL6ZSRCL=%?=/29JB_#UQ>JGC*L;NP% '<        ;H   _,
M;@ !N@    H   W0"[0#> )O       )MIV?S@:VR_6]U\="R-^0
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M]V5GH'F4945JZI_U]=?8_P"$]+DA:[</)D;GY@"KN -D   ;( !M@-D!L@
M    8@%_*      !^0          ;G9 PH&JAZ2S_(?F+(VV) Q0![H#_;
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M;,@   #$    /= ;@   Q  .X      !V  #_P#$   )B ]\!N@ &R V@&R
M @SK4= K=[EQ9^RX]+6,OTZOV6LMW/5W%57.ST5;4^LR-6:HIXY7JU$3!-)R
M*IC=+)+='EG+5NE\O06:AIIMC"2&GC8[8VME$13&HVJXJN*KBJ@5PZV7U98D
M_P!]W<4]+98REW5/^&F6-[U*/9,;EAV)BIL$&FS;T0S%]V5GH7EC*BM75/\
MKZZ^Q_PGI<D+7;*8(>;(VEQ  $]T!^<  Q  %4!W  #9  -D!LX   #N@-P
M  =T     'N@     W   @U,'26?Y!.X92-MN)@0 '8 +L@  #8P
M  '^V(!=D!^3    >X         8@    !7KK8[%@R]L_P#JY/1F>'E8RZ;4
MAE?+-QU;VRKN%EH:NJ<^5'33T\<CUP7=<Y,5).582;0Y=R];)?+6RT45'-MI
M+!3LC?CV6HAC56RV5V57%=\0*N];5?\ G;"F]$_\J'I8QF%A,D(J9+R_N_\
M(4_HTW3&1OC%DP][(V.DE<C(HVJY\CEP:UK=E57W$$(JMK8UC7C6A?(=7NK_
M ,I/:%E\G4OA14]:>BX:3G)M1-_*>EL42:IPU7ZKK7JULJ4]*BSWNJ:U;E7J
MWX3UV]!N\UJF-TU6(=U@K=M,-[$QA39W4       0![X!-L  V0    W  #N
M@      8>^ _. [@#:4 !E/= P     &IH_KZX;'ZC3)&WW3%6-D  V0&SL
M &Y[H#N@       -X   ;@    =D  1-L![X !V  #8P 8@-D  Q4HK/ULMO
M+*[N-1W$/2V&,I*U4Y5RM6ZN[#5UECH*BJDA<LDTM-$][ETEV7.5,5/.99.^
MH+!8;4_REKM=)12+LZ=/ R)W;:B"HV&RNWMD%3^M3ASQM6_Y!O[33UMR,96A
ML6/(=LWO5HL%W/T$,)6'O_[8F(@OK'V//>9J2T6C*]LGN5G5SI*Z*E;I+Y1N
M"M5^*IM+M&=LT)1YEZLZS.5;3!9+#8:BEMM,J^2B6A@>OPEQ57.794LTE(K"
M/+_<,^U&?(*_,%.^//;9H700.B:QZSHO^&GDTV%V=PSC(DRMEJ>NFLRZ6RY2
MZSJ62EN,=0C:!LD#*=5A5N*JB,V]D\99)(7\I%-S9   &T ]T    -P!L -L
M!@        V0      -KL@  #=    !/TD3_ &VR#6V7ZWNOCH92-^0
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M<[)U5^QL8,VC.43YM_E,%9 >X  8@         #W0&X _* WE
M   W  #8 =P !C=0#50])9_D$[A9&VWB     &  ![H !AN@9[ & "KO
M  _]H#W@           VP     A_7_D'-.?[3:*3*U+'53T=0^6H;+,R!$:Y
MF"8*[;,[)HDNJU39<NV5,BV^Q7R)L%S@>]TD3'I*U$<J*GPF[!C6LD9';$4*
M(IUV:J*K630451:9VPWBVZ>A'+^A,QZ8:..TB^Z6)1I=363];^6[PZ/.U8_F
MQ!3.AHZ#UF.>-),45JM:S93!"W3 G P5PVMRQYHS'DFKLV4?K2J<C7M\HV'2
MC1=E-)VP6V:2BN]AU,Z^\KSR5.7(VVRHE;H22T]; URMWL5Q/6;H84FK?\S^
MM9]L5/\ ^H0&/(RBJ7]45LUCVNSUL6LJJ?57-\K5I'2SLJ%2-$721%9M&,RR
M2&A@!0   'O@.P@#9 ;H   Q  -H    $7? ;(  H   7:Q PGY C*!3W  #
M$![@   [X&IH_KZX>(TR1MC%0   ;@#: 8       *  ?[8@ &R  *  ;&T
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MQT+(WY                                .?J>D\7R"_G*-FA  ( [(
M    -@   =P!N    !V0&.P 4     "@         !410&QM    !N -CW@
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MTH   ]T   =D!M;*;8#_ /$!L  &Q[X#>0!L@.X V &Q@ V@'N@ "@/=
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MM7AR<!10.<-J\-_ 44#G#:]Q\G 44#G#:O#DX"B@)F&U>')P%%!CG#:MQ[^
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MOX"B@<X;5X;^ HH'.&U>')P%)08YPVKPY. I:!SAM?AOX"DH,\X;7X<G 4M
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M')P%% YPVKPY. HH,<X;5X;^ I*#/.&UX?IOX"EH,<X;7X<G 44&><-K\-_
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M#U>G\TS@H ]7I_-,X*=X!ZO3^:9P4 >KT_FF<% 'JU/YIG!3O 9]7I_-,X*
M8]7I_-,X*=X#/J]/YIG!0!ZO3^:9P4 QZO3^:9P4[P#U>G\TS@IW@,^KT_FF
M<% 'J]/YIG!0#'J]/YIG!3O /5Z?S3."G> SZO3^:9P4 >KT_FF<% 'J]/YI
MG!0#'J]/YIG!0!ZO3^:9P4 SZO3^:9P4 >KT_FF<% 'J]/YIG!0!ZO3^:9P4
M QZO3^:9P4[P&?5Z?S3."@#U>#S3."@#U>G\TS@H ]7I_-,X* 8]7I_-,X*
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M!ZO3^:9P4 QZO3^:9P4 >KT_FF<% ,^KT_FF<% 'J]/YIG!0#'J]/YIG!3O
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MM#YAG: U5#%'#?ZED34:Q&)@U-H#?@
M #FZWI32_)M[JF7,.D,0
M                                                '.U72:#L)W"C
MHB
M                               .;3I0O8_=+1'2$4
M
M              &CI>D-5XB ;P                                <W
M6]*:7Y-O=4RYD=(8J
M                                             #G:KI/3]A.X6!T1
M
M                             '-ITH7L?F,D=(8J
M
M            #1TW2*I\1"C>$                                YNM
MZ4TOR;>ZIES#I#$
M                                           !SM5TFI^PG<+ Z(@
M
M                           #FTZ4>]^Z9(Z0Q4
M
M          &CI>D-3XB%&\(                               !S=;TI
MI?DV]U3+F1TABH
M                                          .=JNDT'83N%@=$0
M
M                         !S:=*/>_=,D=(8J
M
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M0
M                             <[5=)H.PWN%@=$0
M
M            !SB=*%['[IDCHS%0
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M^5\I/Y'RF./D=-=##'<PVB7+"5#%0#FZWI32_)M[JF7,.D,0
M
M                '.572>G["=PL#HR
M
M.;3I0O8_=,D=(8J
M #77_P"HKG[)4>B<6$E\>T1-G8_6=W5-TMR-3Q9Y6<$WC)YUDP3>!4P3>"5,
M$W@5,$!4P0%3!-X+4P0%3!-X%3!-X%3! E3! M3!-X%3! E3!-X+4P3>!4P0
M%3!-X)4P3>!4P3>"U,$W@E3! 5,$"U,$W@5,$!4P0)4P3>!4P3>!5>;J*HB9
M,S7@F'_YK'Z!#7?,MN-#8-QV9_):U-P^3&1])DH   &CI>D-3XB%&\(
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M4P=L+MEI2!UY@
M                                          YVJZ30=A.X6!T1
M
M                         '-ITG7L?NF2.D,5
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M2FF^3;W5+S#I"
M                                          .=J^DU/V$[A8'1$
M
M                          <VG2A4]S]TR1TABH
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MT%*Q(J>GC3!C&-3!$0QE7M  .;K>E-+\FWNJ9<PZ0Q
M
M           <Y5=)H.PG<+ Z,@
M                                                      #F_P#N
M?WOS&2.D,5                                              !KK_
M /45S]DG]$XL).1\?$W?&=W5-TC(U+%RAD\P
M      W0+S=17H9FK[UC] AKOF6W&AL&X[,_DM:FX?)C(^DR4   #1TW2&I^
M30HWA                                .;K>E-+\FWNJ9<PZ0Q
M
M                        <[5=)J?L)W"P.B(
M
M        YM.E"]C]TR1TABH
M         -=?_J*Y^R5'HG%A)?'Q-WQG=TW2,C4L7*&3S
M                "\W45Z&9J^]8_0(:[YEMQH;!N&S/Y+6IN'R8R/I,E
M T=+TBJ?$0#>                                #FZWI12_)M[JF7,.
MD,0
M                               '.U72:#L)W"P.B(
M
M               YM.DZ]C]TR1TABH
M                -=?_ *BN?LD_HG%A)?'M-WQG=U3=+<C4L7*R9/,
M                         9 O+U%>AN:_O2/T"&N^9;<:&P;ALS^2UR'R
M8R/I!0   -'3=(JGQ$*-X0                               #FZWI32
M_)M[JF7,CI#%0
M                                         <Y5=)J?L)W"P.C(
M
M                         YM.DZ]C]TR1TABH
M                          -=?_J.Y^R3^B<6$E\?$W?&=W5-TMR-2Q<H
M9/,                               +S=17H9FK[UC] AKOF6W&AL&X;
M,_DM:FX?)C(^DR4   #1TO2*I\1"C>$
M   YNMZ44WR;>ZIES(Z0Q4
M                                                  '.572:G["=
MPJ.C(H
M                                  .;3I/[WYBHZ0B@
M                                  UU_P#J.Y^R3^B<6$E\?$VU\9W=
M4W2,C4L7*&3S                               "\W45Z&9J^](_0(:[
MYEMQH;!N&S/Y+6IN'R8R/I,E    T=+TBJ?$0#>
M           #FZWI32_)M[JF7,CI#%0
M                                                           <
M[5=)J?L-[A8'1$
M ?FY'*_87>5$)4$541,$5<5W2PCSQ7>"F(#%=X!BN\ Q7> 8[P#%=[\H#%=[
M\H#$ J@,5WOR@,5W@,@8Q7> 8KO ,0,X@ ,8@,5W@&*[P#%=X!BN\!G$#&*[
MP#%=U &('@N*KBNQHKN!#9TDV=M?]D)"OT*     YQ.DZ]C]TJ.C(H
M                                        -=?_ *BN?LD_HG%A)R/C
MXF[XSNZIND9&I8N4,GF                              ,@7EZBO0S-7
MWK'Z!#7?,MN-#8-PV9_):U-P^3&1])DH   &CIND53XB%&\(
M                   !S=;THI?DV]U3+F'2&(
M
M      #G:KI-!V$[A8'1$
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MN#10    <W_W1[WYC)'2&*@
M         UU_^HKG[)/Z)Q82<CX^)N^,[NFZ1D:EBY0R>8
M                 7FZBO0S-7WK'Z!#7?,MN-#8-QV9_):U-P^3&1])DH
M &CIND53XB%&\(                               !S=;TII?DV]U3+F
M1TABH
M                                 .=JNDU/V$[A8'1$
M                                   1AK[Z!K[;3]U36>(_"?-'1+<.
M$O'?+=^RM>[[QRYV" *                              &XHE.=.?5W^
M)O\ \I3_ +#CH/"VQ?IAS/C3;PM$]*<#=G.P    <VG2CWOW3)'2&*@
M                                         UU_^HKG[)/Z)Q82<CX^
M)N^,[NJ;I&1J6+E#)Y@                             !N@7FZBO0S-7
MWK'Z!#7?,MN-#8-QV9_):U-P^3&1])DH   &CI>D-5XB ;P
M                   <W6]*:7Y-O=4RYD=(8J
M
M      #G:KI-3]A.X4=$0
M       !&&OOH&OMM/W7&M<1^$^:.B6X<)>.^6[]E:UV_>.6\SL$ 4
M                        8WQ.1)RITZN_Q-_^4I_V''0>%MB_3#F?&FWA
M:)Z4X&[.=@    YO_NCWOW3)'2&*@
M               UU_\ J*Y^R3^B<6$G(^/B;OC.[JFZ1D:EBY0R>8
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M-O=4RYD=(8J
M                                       #G:KI-3]AO<$#H@
M                                         C#7WT#7VVG[JFM<1^%^
M:.B6X<)>.^6[]E:]WWCEG,[! 50                             !C?'
M,DY4Z=7CXF__ "E/^PXZ#PML7Z8<SXTV\+1/2G W9SL    '-_\ ='O?NF2.
MD,5                                              !KK_P#45S]D
MG]$XL).1\?$W?&=W5-TMR-2Q<H9/,
M+S=17H9FO[TC] AKOF6W&AL&X[,_DM:A\F,CZ3)0   -'2](:GQ$*-X0
M                 5.ZRMWOU_SC;,E444ZVN)(U_P ..18GU4[M'%ZM145J
M)AM[1Z6QR,;DJY?ZOFKFAR_%;KE;$K*Z:)GKU4^1Z/=*K4QT=%41J(NU@8ZT
MK17R:U5>JG7A1VW+]4Z*'UZ%D2HN*NHYW8+%)CM[&PJGI6L,8BDKO[AXLT?Z
MWM84.KO*%1=(UTKM4?\ +VZ),%7RKTP\HJ+MM9MJ6(%):RU7BWW&SUUZ:YM3
M>GQW")9%57N8^=4TG8[ZHN'N'N\Z<KZ&VCZJH?D(OV$/"7H]T@ <W6]*:7Y-
MO=4RYATAB
M                                      YVJZ34_8;W"P.B(
M                                        C#7WT#7VVG[JFM<1^$^:
M.B6X<)>.^6[]E:SEKL$ 4                              8$Y$YTZ=7
M?XJ__*4_[#CH/"VQ?IAS/C/;PM$]*<#=G.P    <W_W1[WYBHZ0B@
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M>W>L4-WT5?#1UK6L69K4Q58G,<]KE1-E6XHN&X>FI-*L(N28CL6Z6'O&#)D
M         \53#9 Y[.6<+-D:PU.8+W,D=/"F$4>*>4FE7]&-B+MN7 L145@U
M5V&YZW=:57GV\PR,LU'4^NJJJN@V9JXQ0L=NHU4V4/2>2*,8CG6]GJ8::"2I
MG<C((F.DE>NTUK4Q55]X\F2IC?7>L+K=1VRW)5ADQPV7,=3L=L8[SIOR'ID8
MY7J]9&&*FUEV"GA;H00T=-'&Q-IK6S8(B>\+4E;6T?55#[/%^PAYRS>Z!ZCK
MG;FN<QU5$CFK@Y%>F**6DC13SP5&9:62"1LC-!$TF*BICBN\6G(.H,0
M
M                       '.U72:G[#>X6!T1
M                         $8:^^@:^VT_=4UGB/PGS1T2W#A+QWRW?LK7
MN^\<N=@@"@                             !N*)3G3GU=_B;_P#*4_[#
MCH/"VQ?IAS/C3;PM$]*<#=G.P    <Y_W/[WYC)'1F*@
M                              UU_P#J*Y^R3^B<6$G(^/B;OC.[JFZ1
MD:EBY0R>8           ,@8                  %YNHKT,S7]ZQ^@0UWS+
M;C0V#<=F?R6M3<[!\F,CZ3)0   -'3=(:GQ$*-X0    !KKY624%GN-="F,U
M)333QMPQQ=%&YR;'90\L6:63/X,K<L0KSU9\F6.]V^MUA7J!MQS&^Y2MIIJC
M_$]7<S!ZR-1=CRCG/QTE3%,-@_7=;J6V_C%7GEOG\'Y5-NI-:O6/JZ.ZL]=R
M[E:GT%I7[,3G4^CBUV^BS/Q5-W1P,-WV;L3/R08_+-EF;EEX:_,NV3).9LCY
MKRI1PVFY+7I#)%1QMA9)Y%\3FNT&(B8X.5J[Z*3!NG[L6<UT28LTPYG-,+.M
M5$1-SW.R8UY5>04         :N_WZU9:M51>;U4MI:"F:KI)'+MJB;#6INJN
MXA45+EFS3UD<\^J-<ZCRE0/5[%1%6*&!%P1V.TLKT,\D(M?E;+-HRC9*6PV6
M%(:&E3!/"<[:5[EW54PF:LD;=8NHS0N1X[5EJEDJ4NM0E-<%@1RRL@1-/8T=
MK%4V2VY1"&0<UZU-7%IEM%ARBV5L\JS2U4\,GEG*J?!:N&Q@W<,YHQ<EK(S9
MFW-69Z.[YKMK;;=Z>-D=/2L:YC7,9)I(N#ME<5V#*(A)6<U+Y[SYFI]31YLL
M[+=14D,244K6/8LB:.&*Z6P>=T490F!S4>Q6.V6N3!<-Y3!6LYM63=HV*NWB
MJJJX]LRUI&I=1TU#F.G@I(TBA5B.5C<<,5516:#JS" *
M
M           !SE5TG@["=PL#HR
M             (PU]] U]MI^ZIK/$?A/FCHEN'"7COEN_96O=.7.P0!0
M                          WQ.1.=.?5W^)O_ ,I3_L..@\+;&)IAS/C3
M;PM$]*<#=G.P    <VG2=>Q^8J.D(H
M                -=?_ *BN?LD_HG%A)R/CVF[XSNZIND9&I8N5DR>8
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M-\,<ODWZ2,B;(NFY7N:FF_:1$[!G9&I%?_IGBS7_ !YEHVKI(F*>^>,CS*
M       "N/6'RIK(SE>Z"W6&BEK,L4U.DVA&GP?6W.5%TE3;P1$P,[:)+D,K
M6KK$Y+M;;-ENTMI:%'.D=C3-?(]SMUSUV5PW#+D8\K</O/6J1BZ-)\+#8_Y5
MI.1>596R.N#[/0/NJ:-S=!&M8F&'^-HII[&YLF$LFP4@K3KXU>9RS3K M-WL
M5LDK+=3T\,<DS$V&N;-I*G:,K925C+;')%;Z2.9%25D,;7HNVCFM1%)*O:(
M'-UO2FE^3;W5,N9'2&*@
M                                                YVJZ30=A.X4=
M$0                                              !&&OOH&OMM/W
M7&M<1^%^:.B6X<)>.^6[]E:]WWCEKL$ 4
M   -\3D3G3GU=_B;_P#*4_[#CH/"VQB:8<SXTV\+1/2G W9SL    '-ITH][
M]TR1TABH                                              -=?_J*
MY^R3^B<6$G(^/B;OC.[JFZ6Y&I8N4,GF
M  ,@7EZBO0S-7WK'Z!#7?,MN-#8-PV9_):U-P^3&1])DH   &CIND53XB%&\
M(     \78;2BH@C6#UC:/+]YERQDVU+F*\P/6*>5%=ZNV5NPZ-C8VN?(K?UE
M3!$+;9-\5YBZ=6:3E?KJ?UMYRSYFZZY<S/;*:VK04GK*T\<<L<T<GE&-1K_*
M.5<,'8[6)GJ1J:T9&$W3%^KSNC?K>IJ/6C)JXO=MFMK*AD:6BZ3*FA4RO3'!
M$VD8Y?@L<B_I)@N!A9$W1,YF=\ZLQ^*3D=AL*FYB8CS*
M    <W6]**7Y-O=4RYD=(8J
M                                                   #G:KI-3]A
M.X6!T1                                               $8:^^@:
M^VT_=4UKB/PGS1T2W#A+QWRW?LK7O=@Y:[!&0"@
M        #&^)R).5.G5X^)O_ ,I3_L..@\+;&)IAS/C3;PM$]*<#=G.P
M<W_W0O8_=,D=(8J
M #77_P"H[I[)/Z)Q827Q\3=\9W=4W2,C4L7*&3S
M         &0+R]17H9FK[UC] AKOF6W&AL&X[,_DM:FX?)C(^DR4   #1TO2
M*I\1"C>$     :R_2U,-HN4U&B^MQTD[Z?#;65L;E;A[^!Y8FS.AE;EA!?51
MH+.[+%VO2,9+F22X/@K9G8.F9"C&NC:BKBJ-<JN7W5[!^N_DMMIFY=+QMK,S
M,Y:LZM5QZQ.L/%=E8'?MP&.'-<"-*7Q_^WRP]3K.OITO.0FTBHN86URNAT/C
M4B66%$QPV<%>FQ[Y-WZZ(G9I-6>+U4Z86.^%L(OO]D\I9QD>9D@
M          '-UO2FE^3;W5,N8=(8@
M                                                         .=J
MNDT'83N%@=$0                                              !&
M&OOH&OMM/W5-9XC\)\T=$MPX2\=\MW[*U[OO'+G8( H
M             QOEG(G.G3J[_$W_ .4I_P!AQT#A;8OTPYGQIMX6B>E.!NSG
M8    .;3I.O8_=,D=(8J
M      #77_ZBN?LD_HG%A)R/CXF[XSNZINEN1J6+E#)Y@
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M\B@                   '-UO2BE^3;W5,N9'2&*@
M
M          YVJZ34_83N%@=$0
M           !&&OKH&OMM/W5-9XC\)\T=$MPX2\=\MW[*U]XY<[! %
M                        &-\3D2<J=.KO\3?_ )2G_8<=!X6V+],.9\:;
M>%HGI3@;LYV    #G$Z4+V/S%1T9%
M               !KK_]17/V2?T3BPDY'Q\3=[+NZINEN1J6+E#)Y@
M                        !>;J*]#,U?>L?H$-=\RVXT-@W#9G\EK4W#Y,
M9'TF2@   :.EZ0U/B(4;P@    #DLP:Q<EY=K*BUW;,%%07:*-'^J3RHR1JR
M-TF*K5W]PPG)+*V*S",]4.O"@NF7ZR?6-F.@I;LRMDCIHY?)TSEID:FBNBU$
MQ3''9/TWV4B)SP\;)K,QF2%_6#5?N9KMOS[3RH]$8ZUM>S*"Y9;H]6UZI;A)
M55.A=60QLJ6+$]\;&,TE38<Y5=^BN)E@V:^+$3DI+'$NU;)G\5@<<%1$VCSC
MG93+]"@                   '-UO2FE^3;W5,N9'2&*@
M
M              YVJZ30=AO<+ Z(@
M               ",-??0-?;:?NJ:UQ'X3YHZ);APEX[Y;OV5K7;]XY9S.P0
M%4                              8',DY4Z=7?XF_P#RE/\ L..@\+;%
M^F',^--O"T3TIP-V<[    !S:=*%['[IDCI#%0
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M#<+KS2AJPE)J8)@8,F0                    <W6]*:7Y-O=4RYD=(8J
M
M                          #G:KI-!V&]PL#HB
M                            (PU]] U]MI^ZXUGB/PGS1T2W#A+QWRW?
MLK6<N=@@"@             ,$&2@             #&^6<B<Z=.KO\3?_E*?
M]AQT#A;8OTPYGQIMX6B>E.!NSG8    .;3I.O8_=,D=(8J
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M,*J\B@                   '-UO2FE^3;W5,N9'2&*@
M
M             YVJZ30=A.X6!T1
M              $8:^^@:^VT_=<:SQ'X3YHZ);APEX[Y;OV5K[QRYV" *
M                           ,;XG(G.G3J[_$W_Y2G_8<=!X6V+],.9\:
M;>%HGI3@;LYV    #FTZ3KV/S&2.D,5
M                 !KK_P#45S]DG]$XL).1\?$W?&=W5-TC(U+%RAD\P
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M14Q13R>CR                   #FZWI32_)M[JF7,CI#%0
M
M                <[5=)H.PWN%@=$0
M                 !&&OOH&OMM/W5-:XC\)\T=$MPX2\?\ +=^RM>]V#ECL
M$!5                              &-\3D2<J=.KQ\3?_E*?]AQT'A;8
MQ-,.9\:;>%HGI3@;LYV    #FTZ3KV/S&2.D,5
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MJ;2(FX%9                   #FZWI32_)M[JF7,CI#%0
M
M               <[5=)H.PG<+ Z(@
M                ",-??0-?;:?NN-:XC\+\T=$MPX2\=\MW[*U[OO'+78(
MH (!0                          #&^6<B<Z=.KO\3?\ Y2G_ &''0.%M
MC$TPYGQIMX6B>E.!NSG8    .;3I/[WYBHZ0B@
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MZK_IJB.;Y-[7]Q5 _<   YNMZ4TOR;>ZIES#I#$
M
M       !SE5TF@["=PHZ,@
M        ",-??0-?;:?NN-:XC\)\T=$MPX2\=\MW[*U[OO'+'8(R!5
M                        #<43D3G3GU=_B;_\I3_L..@\+;%^F',^--O"
MT3TIP-V<[    !SG_<_O?NF2.C,5
M              !KK_\ 45S]DG]$XL).1\?$W?&=W5-TC(U+%RAD\P
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MWI32_)M[JF7,.D,0
M                                            '.U72:#L)W"CHB
M                                             (PU]] U]MI^ZXUK
MB/PGS1T2W#A+QWRW?LK7N^\<M=@@"@                             !
MAMJ)R).5.?5W^)O_ ,K3_L..@\+;%^F',^--O"T3TIP-V<[    !SG_='O?N
MF2.C,5                                              !KK_ /45
MS]DG]$XL).1\?$VU\9W=4W2,C4L7*&3S
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M7MBXA.)BH!S=;TII?DV]U3+F'2&(
M                                                        #G:K
MI-!V&]PL#HB                                               (P
MU]] U]MI^ZXUKB/POS1T2W#A+QWRW?LK7WCEO,[! %
M            &-\LY$YTZ=7CXF__ "E/^PXZ!PML8FF',^--O"T3TIP-V<[
M   !S?\ W1[W[IDCI#%0
M      :Z_P#U%<_9*CT3BPDOCXFVOC.[IND9&I8F4,GF
M               %YNHKT,S7]ZQ^@0UWS+;C0V#<-F?R6M3</DQD?29*   !
MHZ7I#5>(A1O"     /3N=:RVT%7<94QBHX9)WIOI$Q7JG:0PNNI$SF96Q68A
M6#4[J^H=;E?=]96L!77-M16/AIJ%SU2)[F)BJOP5%T&(K6L9C@>\6_;PXCGG
ME>4S%]\YK4^3:L=7<M%Z@_*]L6F5,-%*6-KL/'1$=^4\ZRSI" L]Y4@U%ZP\
ML9NR<^2"Q7:I]5K;8KU>UK%<U)(T<Y556.:_%NEBK7)V#TP9F_$^W//%6&+%
M+=:.:5J-+#8_VP/'+6&;]#(         'C(YK&.>YR,8U%5SE7!$1-E555 J
MCK?UE7;6?>FZM,@-EFH?+>3K)HE5$JGL7!6N_P#@M7;W]L](BC"9JFS5)JOM
MVK6PI38-FOM8C77.M3;<Y-J-J^"W<,;IJRB'J=8-%75+F#!,4:R)5W<$\JT6
MY2YR/51>U<EW!B.33;5KBU-M,<=LMR6NDZR$C6ZJ+JQ5P?(^%&)OJCT4EN59
M:;JLQO;J]FD5,&/K)-!R[2Z.V+LI"<'HY6.1BZ+U1=%5V41=PQ5H76.[N<KE
MO$J*Y<51$P39WDQV#*L#T(Z6HH\P4T-34NJI-%%25^PN&.T6O(.O,
M
M                      '.U72:#L-[A8'1$
M                        1AK[Z!K[;3]UQK7$?A?FCHEN'"7C_EN_96O=
M]XY:[! %                              &-\3D2<J=.KO\ $W_Y2G_8
M<=!X6V+],.9\:;>%HGI3@;LYV    #FTZ3KV/W2HZ0B@
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M$\YEFZX@ <W6]**7Y-O=4RYATAB
M               8TD QI( TD SI(!C20!I( TD SI(!C20!I( TD SI( TD
M QI( TD :2 9TD :2 -) &D@&-) &D@#20#.D@&-) &D@&=) &D@&-) ,+HJ
MJ8IVR1(\MW'<PVRC(    YRJZ34_8;W"P.C(
M                       C#7UT#7VVG[KC6>(_"?-'1+<.$O'?+=^RM?>.
M6\SL$!5                              #<43D3G3GU>/B;_ /*4_P"P
MXZ#PML8FF',^--O"T3TIP-V<[    !S?_="]C]TR1TABH
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M&CJJ^:.GH++0-:V5SI7HSRKT3::F.R]Z[.YB*S=-"D6Q5(347!??1"*\P
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M/[G]>]9GVA3_ $9@])P/Q/\ V>__ .OL_N?U[UF?:%/]&8/2<#\3_P!GO_\
MK[/[G]>]9GVA3_1F#TG _$_]GO\ _K[/[G]>]9GVA3_1F#TG _$_]GO_ /K[
M/[G]>]9GVA3_ $9@])P/Q/\ V>__ .OL_NS_ %[UF?:%/]&8/2<#\3_V>_\
M^OL_NQ_7O69]H0?1F#TG _$_]GO_ /K[/[G]>]9GVA!]&8/2<#\3_P!GO_\
MK[/[L_U[UF?:%/\ 1F#TG _$_P#9[_\ Z^S^[']>]9GVA3_1F#TG _$_]GO_
M /K[/[G]>]9GVA3_ $9@])P/Q/\ V>__ .OL_N?U[UF?:%/]&8/2<#\3_P!G
MO_\ K[/[G]>]9GVA3_1F#TG _$_]GO\ _K[/[G]>]9GVA3_1F#TG _$_]GO_
M /K[/[L_U[UF?:%/]&8/2<#\3_V>_P#^OL_NQ_7O69]H4_T9@])P/Q/_ &>_
M_P"OL_N?U[UF?:%/]&8/2<#\3_V>_P#^OL_N?U[UF?:%/]&8/2<#\3_V>_\
M^OL_N?U[UF?:%/\ 1F#TG _$_P#9[_\ Z^S^Y_7O69]H0?1F#TG _$_]GO\
M_K[/[G]>]9GVA!]&8/2<#\3_ -GO_P#K[/[G]>]9GVA3_1F#TG _$_\ 9[__
M *^S^Y_7O69]H4_T9@])P/Q/_9[_ /Z^S^Y_7O69]H0?1F#TG _$_P#9[_\
MZ^S^Y_7O69]H4_T9@])P/Q/_ &>__P"OL_N?U[UF?:%/]&8/2<#\3_V>_P#^
MOL_N?U[UF?:%/]&8/2<#\3_V>_\ ^OL_NE34;K$S;G:ZW>FS#4Q3T]'!#+ C
M(DB<CGN<UV*MV]H^/YEN=F!$3;SMVX7\[WCS"Z^,6G^,1D_&J;DTMW:/A-^9
M    '.572:#L)W"P.C(
M      C#7WT#7VVG[KC6>(_"?-'1+<.$O'?+=^RM?>.7.P0!0
M                  !C?+.1.=.G5W^)O_RE/^PXZ!PML8FF',^--O"T3TIP
M-V<[    !S:=)U['[IDCI#%0
M          :Z_P#U%<_9)_1.+"3D?'Q-WQG=U3=(R-2Q<H9/,
M              &0,    "\W45Z&9J^]8_0(:[YEMQH;!N.S/Y+6IN'R8R/I
M,E    T=+TAJ?$0HWA     'Y21I,V2)Z? >BM=N;"I@IC=$7<BQ,PJM64N<
M>K5F9UQMR2WC5G=)O\:)R_H.>N.B[<9,W]5_Z+TV_<]\.8O_ ,+N2F26%T4K
M=&5TN>>LC1S4U/9=5T,MVS!<V,1E2Z%R^KOE38C9%AC),BKM?HM7?/+5FZ=6
M/;_1E$QS_P#]I>>K/4-6<ILSQK2G?<\SND2JAH))%E2*7])KYWI^F]%VF-^
MWW3VFZ+(I:\O\KLJPC=ENR>$/5Y%                    .;K>E-+\FWNJ
M9<R.D,5                                              !A-M0*#
MYGZ3WKV^I]*XZ/N_56Z(Z'\R>8^*Q?CO_E+5'N^>R1  4"   % @
M"@0   H    @ "@03MU8?KO,/LL'I'&N>=[-NF74> ^LQM%O3*RYJKK8
M.=JNDT'8;W"P.B(
M  C#7WT#7VVG[JFM<1^$^:.B6X<)>.^6[]E:UV_>.6.P0%4
M                 -\3D2<J<^KQ\3?_ )2G_9<=!X6V,33#F?&FWA:)Z4X&
M[.=@    YM.DZ]C\QDCI#%0
M         :Z__45S]DG]$XL).1\?$W?&=W5-TC(U+%RAD\P
M                  O-U%>AF:OO6/T"&N^9;<:&P;CLS^2UJ;A\F,CZ3)0
M  -'3=(JGQ$ W@    YK/^9:K)V4+KF:CI/7ZFW1-DCH\51)%=(UF'P45?UL
M2*@#^Z;-'\EIO_&3_P"6>FJQJ]6Y]9.\7J@J+5=<AQ5=NJV+%44TKIW,>QVX
MJ+'VEW-LQNPXF*+%U)JC#)V;[OD+-[LRY:L3VT4FG&MKJF/G5*=_ZC9E8CVJ
MU=IR;.XN*'O$_P".K,O.Z*S6$S6?K,9EN5WM]M?E!L,5;4PT[IM.?X#97HQ7
M;,:;6)A%D2LW2LLFUV#R9L@                    YNMZ4TOR;>ZIES(Z0
MQ4                                              &$VU H/FCI/>
MO;ZGTKCH^[]5;HCH?S)YCXK%^._^4M4>[Y[)$    4"  *  @% @  !0(
M *  @ "@0  $[=6'Z\S#[+!Z1QKGGFS;IEU'@/K,;1;TRLN:JZV    #G:KI
M-!V$[A1T1                                               $8:^
M^@:^VT_=4UKB/POS1T2W#A+QWRW?LK7O=@Y:[!&0"@
M           #&^6<B3E3IU=_B;_\I3_L..@<+;%^F',^--O"T3TIP-V<[
M !S:=*%['[IDCI#%0
M   :Z_\ U%<_9)_1.+"3D?'M-WQG=U3=(R-2Q<K)D\P  "@0
M              "\W45Z&9J^]8_0(:[YEMQH;!N.S/Y+6IN'R8R/I,E    T
M=+TBJ?$0#>    #"HBI@J8IO*21^<BQ1,?(YJ:+$5SL$W&IB!$"]9C5*BJU:
MFLV%5%_Y&;<7#>,HB9R$T@_N8U3+_P"IK/H,O>+J2QUH?M1=8S5;<:ZEH*6I
MJUJ:R5E/ CJ*5J+)(Y&IBJIL;*B+)F2;XB.5+B*B)@NX8LGD
M        #FZWI32_)IW5,N9'2&*@
M              PFVH%!\S])[U[?4^E<='W?JK=$=#^9/,?%8OQW_P I:H]W
MSV2(% @  !0(  H " 4 ! *! *   0   H " 4""=NK#]=YA]E@](XUSSS9L
MTRZCP'UF-HMZ967-5=;    !SM5TF@[#>X4=$0
M                        !&&OOH&OMM/W7&M<1^%^:.B6X<)>.^6[]E:]
MWWCEKL$ 4                              8WQ.1.=.G5W^)O_RE/^PX
MZ#PML8FF',^--O"T3TIP-V<[    !S:=*/>_,9(Z0Q4
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M0*#YHZ3WKV^I]*XZ/N_56Z(Z'\R>8^*Q?CO_ )2U1[OGLD0*! *   0"@0
M  4 !  %   (  H "    3MU8?KO,/LL'I'&N>>;-FF74> ^LQM%O3*RYJKK
M8    .=JNDT'83N%'1$
M      1AK[Z!K[;3]UQK7$?A?FCHEN'"7COEN_96O=]XY;S.P0!0
M                     !C?$Y$YTZ=7CXF__*4_[#CH/"VQB:8<SXSV\+1/
M2G W9SL    '-_\ ='O?NF2.D,5
M             !KK_P#45S]DG]$XL).1\?$W>R[NJ;I&1J6+E#)Y@
M                       !>;J*]#,U?>L?H$-=\RVXT-@W#9G\EK4W#Y,9
M'TF2@   :.EZ0U7B(4;P@    #\JB58(9)<-)(VN?AOZ**N'Y"3*PK2O6_IT
M<YO-!_P55N/*+=Q<.+F<6L9EC^[^G78YGO\ _P!1;_\ XY9M36<Y-<\[]8K.
M=B1+.^UY2L\Z32RHCGQ1,5[7R.=,]&H^1R,1K6L,\.(LG6G+&1,2=>W5C)*W
MJ)BB8;&]V#QEG#R                    !S=;TII?DV]U3+F1TABH
M                                         ,)MJ!0?,_2>]>WU/I7'
M1]WZJW1'0_F3S'Q6+\=_\I:K=/=\]DB  H  ! *   0"@0"@ (!0(  H$  4
M !    )VZL/UWF'V6#TCC7//-FS3+J/ ?68VBWIE9<U5UL    '.U72:G[#>
MX6!T1                                               $8:^^@:^
MVT_=4UKB/PGS1T2W#A+QWRW?LK7WCEKL$ 4
M     8WQ.1.=.G5X^)O_ ,I3_L..@\+;%^F',^--O"T3TIP-V<[    !S:=)
MU['[I4=(10                                              :Z__
M %%<_9)_1.+"3D?'Q-WLN[JFZ1D:EBY0R>8
M      7FZBO0S-7WK'Z!#7?,MN-#8-QV9_):U-P^3&1])DH   &CI>D-3XB
M;P     /%<-W?P)E$<9XUH:M=7\_J-\?%)=E:C^3:2G;/4(U4Q17HB(UF.YI
MN0D2M.=Z&KK6WD[65=ZJT6:RS4L]+3^M++5Q4[6JU'HS!/)N?LXN/6[#F(JP
MB^)FCJJ'6!E&KS969"HZYB9AH&)))2:.@Q=C2>R-VTKV)LN:FRG;,8Y8KF97
M?XT_%UC/T4,8B@\B@                   '-UO2FE^3;W5,N9'2&*@
M                                          PFVH%!\S])[U[?4^E<
M='W?JK=$=#^9/,?%8OQW_P I:H]WSV0@0   H "        4"    "@0   H
M$    G;JP_7>8?98/2.-<\\V;=,NH\!]9C:+>F5ES576P    <[5=)H.PWN%
M@=$0                                              !&&OOH&OMM
M/W7&L\1^$^:.B6X<)>.^6[]E:]TY=S.P0!0
M    !C?$Y$G*G3J\?$W_ .4I_P!AQT'A;8OTPYGQIMX6B>E.!NSG8    .;_
M .Z/>_=,D=(8J                                              #
M77_ZCNGLD_HG%A)?'M-WQG=TW2,C4L7*R9/,
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M<Q<=M%P,<#K=7/$L\7JYNS46/V%T5VDPQP/.<JQG>90
M  #FZWI33?)M[JF7,.D,0
M       &$VU H/F?I/>O;ZGTKCH^[]5;HCH?S)YCXK%^._\ E+5;I[OGLA @
M  !0(   4"   %   (!0(   4   @% @ 3MU8?KO,/LL'I'&N>=[-NF74> ^
MLQM%O3*RYJKK8    .=JNDT'83N%@=$0
M                  !&&OOH&OMM/W7&M<1^%^:.B6X<)>.^6[]E:^\<MYG7
MX R                              &-\LY$G*G3J[_$W_P"4I_V''0.%
MMC$TPYGQIMX6B>E.!NSG8    .;3I.O8_=,D=(8J
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M%C<CVQ1J_!9%<Y$663:PV$W$);&I69RLKKM:-6,BU*8Z..VIXLWD4
M   #"K@!E%Q   ,8@939   .;K>E--\FWNJ9<R.D,5
M                            !A-M0*#YGZ3WKVZI]*XZ/N_56Z(Z'\R>
M8^*Q?CO_ )2U6Z>[YS)           !0 $      !0(!0(      3MU8?KS,
M/LL'I'&N>>;-NF74> ^LQM%O3*RYJKK8    .=JNDT'83N%@=$0
M                                     !&&OOH&OMM/W7&M<1^$^:.B
M6X<)>/\ EN_96OO'+78( H                              QOEG(DY4
MZ=7?XF__ "E/^PXZ!PML7Z8<SXTV\+1/2G W9SL    '-ITH][]TR1TABH
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M@ !S=;TII?DV]U3+F'2&(
M       #";:@4'S/TGO7M]3Z5QT?=^JMT1T/YD\Q\5B_'?\ REJCW?/9(@
M  !0(!0 $        H$      !0(  "=NK#]=YA]E@](XUSSS9MTRZCP'UF-
MHMZ967-5=;    !SM5TF@["=PHZ(@
M               ",-??0-?;:?NN-9XC\)\T=$MPX2\?\MW[*U[IRYV" *
M                            ,;XG(DY4Z=7?XF__ "E/^PXZ#PML7Z8<
MSXTV\+1/2G W9SL    '-ITH7L?NF2.D,5
M                    !KK_ /4=S]DG]$XL)+X^)MKXSNZIND9&I8N4,GF
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MHI?DV]U3*,@Z0Q
M 83;4"@^9^D]Z]OJ?2N.C[OU5NB.A_,GF/BL7X[_ .4M4>[Y[)$        !
M0(  H "  *!   "@0   H$  43MU8?KO,/LL'I'&M^>;-FF74> ^LQM%O3*R
MYJKK8    .=JNDT'83N%'1$
M          1AKZZ!K[;3]U36>(_"?-'1+<.$O'?+=^RM>Z<NYG8( H
M                        QOB<B<Z=.KO\3?\ Y2G_ &''0>%MB_3#F?&F
MWA:)Z4X&[.=@    YM.E"]C]TR1TABH
M                 -=?_J*Y^R3^B<6$G(^/:;OC.[JFZ6Y&I8N5DR>8
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M=L]-6,X]&.>MJ,PTSZ^!*:?11$C1=+X..WB28A'7F"@
M                             PFVH%!\S])[U[?4^E<='W?JK=$=#^9/
M,?%8OQW_ ,I:H]WSF2  *   0      %  0 !0 $   *  @    "=NK#]=YA
M]E@](XUSSS9LTRZCP'UF-HMZ967-5=;    !SM5TF@["=PL#HB
M                                     (PU]= U]MI^ZIK/$?A/FCHE
MN'"7COEN_96O>[!RYV" *                              ,;XG(G.G3
MJ[_$W_Y2G_8<=!X6V+],.9\:;>%HGI3@;LYV    #FTZ4>]^8J.D(H
M                                        -=?_ *BN?LD_HG%A)R/C
MXFVO9=W5-TC(U+$RAD\P                               O-U%>AF:O
MO6/T"&N^9;<:&P;CLS^2UJ;A\F,CZ3)0   -'2](:GQ$*-X0
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M.D]Z]OJ?2N.C[OU5NB.A_,GF/BL7X[_Y2U1[OGLD0   !0(!0(!0(  H
M@%   (!0(      3MU8?KO,/LL'I'&N>>;-NF74> ^LQM%O3*RYJKK8    .
M=JNDT'83N%'1$
M1AK[Z!K[;3]UQK7$?A/FCHEN'"7COEN_96O>[!RQV" J@
M              #&^.9.=.G5W^)O_P I3_L..@\+;%^F',^--O"T3TIP-V<[
M    !S:=*/>_,9(Z0Q4
M     &NO_P!17/V2?T3BPDY'Q\3=\9W=4W2W(U+%RAD\P
M              !D"\O45Z&9J^]8_0(:[YEMQH;!N.S/Y+6IN'R8R/I,E
M T=-TBJ?$0HWA    -#G#-UIR/8:G,=[\IR;2JQ)?(-\I)C*Y&)@W%,=E=\B
MQ#V;)?J._P!EH\P4&DEMKH4J873)H/\ ).V454V<-@ROC4F8GF863K1$QSL6
M+,MBS-3R5F7[C3W*CBD6%\U+(DC6R-V5:JINIB)B:0M6V(H (!0
M .-U@:M;#K'I*:COKI6PTKUDC\BJ-7%=C9QQ,HF@WN6K!1Y6L5#E^WJYU%;X
MDAA5^R[11579P[))D;4@XC.NJ?)6?,)KY;VK<&HK65T7P)D1=_<=[Z%B:#0Y
M<ZO6K?+M8RO2@6NJHG(^!U4N*,<FU\%N"+[Y9N8T2HUJ-:C6HB-381$V$1$,
M63( #FZWI12_)M[JF7,.D,0
M         &$VU H/F?I/>O;ZGTKCH^[]5;HCH?S)YCXK%^._^4M5NGN^>R$"
M  *!         %   (   4"     !0 $$[=6'Z\S#[+!Z1QKGGFS;IEU'@/K
M,;1;TRLN:JZV    #G:KI-3]AO<+ Z(@
M                  ",-??0-?;:?NN-9XC\)\T=$MPX2\=\MW[*U]XY<Z_
M&0                              QOB<B<Z=.KO\3?\ Y2G_ &''0>%M
MB_3#F?&FWA:)Z4X&[.=@    YM.E"]C]TR1TABH
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MKAL[:8GFS>0                    .;K>E-+\FWNJ9<R.D,5
M                                    !A-M0*#YGZ3WKV^I]*XZ/N_5
M6Z(Z'\R>8^*Q?CO_ )2U1[OGLD0  "@0        !0  "  *  @      * $
M[=6'Z\S#[+!Z1QK?GFS;IEU'@/K,;1;TRLN:JZV    #G:KI-3]A.X6!T1
M                                             $8:^^@:^VT_=<:U
MQ'X3YHZ);APEX[Y;OV5K7;3L'+>9V" *
M  &^)R)SISZO'Q-_^4I_V''0>%MC$TPYGQIMX6B>E.!NSG8    .;3I0O8_=
M,D=(8J                                              #77_ .H[
MI[)/Z)Q827Q\3=[+NZINEN1J6+E#)Y@
M !>;J*]#,U?>L?H$-=\RVXT-@W#9G\EK4W#Y,9'TF2@   :.EZ15/B(!O
M !C!-X#\YV>4B?%CHH]JMQ3<Q3 PF.98FDU<%J[R+;-4>7:V@EO/EZ*>K?6R
M5=8D=,UBR-1-!5TE3<WSTF^O)F8Q;1LX]:>K>2=*=F:K6LSET6M]:BV5VMO'
M 4DJZN&>"IB9/3R,F@D3&.2-R/8Y-]%3%%(K]                      .
M;K>E%+\FWNJ9<PZ0Q
M    83;4"@^9^D]Z]OJ?2N.C[OU5NB.A_,GF/BL7X[OY2U6Z>[Y[)$8*,D&"
MC)   "@0"@ (          4"     !1.W5A^N\P^RP>D<:WYWLVZ9=1X#ZS&
MT6],K+FJNM@    YRJZ34_83N%@=&0
M                !&&OKH&OMM/W7&L\1^$^:.B6X<)>.^6[]E:]XY<Z_ &0
M                              QOEG(DY4Z=7?XF_P#RE/\ L..@<+;%
M^F',^--O"T3TIP-V<[    !S:=*/>_=,D=(8J
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M5R-7!S5[6>',7SJ\_,QQ(U(UN;)*UB+@F"[:'C5Z/(H
M  !S=;TII?DV]U3+F1TABH
M        ,)MJ!0?-'2>]>WU/I7'1]WZJW1'0_F3S'Q6+\=_\I:H]WSV0@
M" 4   @     4   @        "@0 )VZL/UWF'V6#TCC7//-FW3+J/ ?68VB
MWIE9<U5UL    '.U72:G["=PL#HB
M               (PU]] U]MI^ZXUKB/POS1T2W#A+Q_RW?LK6NVG8.6\SL$
M 4                              8WQ.1)RITZO'Q-_^4I_V''0>%MC$
MTPYGQIMX6B>E.!NSG8    .;3I0O8_=,D=(8J
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M^OOH&OMM/W7&M<1^$^:.B6X<)>/^6[]E;%VSECL$!5
M            &-\3D2<J=.KO\3?_ )2G_8<=!X6V,33#F?&FWA:)Z4X&[.=@
M    YM.E"]C]TR1TABH
M     -=?_J*Y^R3^B<6$G(^/:;OC+W5-TC(U+%RLF3S
M              "\W45Z&9J^]8_0(:[YEMQH;!N.S/Y+6IN'R8R/I,E    T
M=+TAJO$0HWA     &%:B[*@1GK%U(Y.UC3+<*ULENON@C.4Z/11TC6[#4F8Y
M%21$3:78=ANBS_"M.<GEBDHO;U16J_R4F<)5HFX:#$HDQ5=[06;10](O8ZM,
MB8-7>J/*&KB&1UFA?/=)VZ%1=*I4?4.9X#=%$:QF/ZK4[.(NOF8IS&KSN\T4
M_,>;)D                    '-UO2FE^3;W5,N9'2&*@
M                                PFVH%!\T=)[U[?4^E<='W?JK=$=#
M^9/,?%8OQW_REJSW?." 4 !   "@0       "@0   H$ H$ H$ H  )VZL/U
MWF'V6#TCC6_.]FW3+J/ ?68VBWIE9<U5UL    '.U72:#L-[A8'1$
M                                        1?K[Z!K[;3]UQK7$?A/F
MCHEN'"7COEN_96PY;S.P0!0                             !C?',DY4
MZ=7CXF__ "E/^PXZ#PML7Z8<SXTV\+1/2G W9SL    '-ITH7L?NF2.D,5
M                                            !KK_ /45S]DG]$XL
M).1\?$W?&=W5-TC(U+%RAD\P                               O-U%>
MAF:OO2/T"&N^9;<:&P;CLS^2UJ;A\F,CZ3)0   -'2](:GQ$*-X0      QL
M 9V%                        .;K>E-+\FWNJ9<PZ0Q
M                                 83;4"@^:.D]Z]OJ?2N.C[OU5NB.
MA_,GF/BL7X[_ .4M5NGN^>R1   *   0"@ (         H$ H 8 R0"@0  $
M[=6'Z\S#[+!Z1QKGGFS;IEU'@/K,;1;TRLN:JZV    #G:KI-!V$[A8'1$
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MO(                    '-UO2FE^3;W5,N9'2&*@
M                            PFVH%!\S])[U[?4^E<='W?JK=$=#^9/,
M?%8OQW_REJCW?/9(@    !0  "   % @ "@0 !0(!0(!0(!0 $ "=NK#]=YA
M]E@](XUSSS9LTRZCP'UF-HMZ967-5=;    !SM5TF@[#>X6!T1
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MM:YL=->8&M8W%[M%'N2-5C?'I;"NCP5NZAC9;KQ^*WSJZ,ZQ!YLP
M           .;K>E-+\FWNJ9<R.D,5
M                !A-M0*#YHZ3WKV^I]*XZ/N_56Z(Z'\R>8^*Q?CO_ )2U
M1[OGLD0*,!62(  !0(  H$ H$  4 !  % @    H  !!.W5A^N\P^RP>D<:Y
MYYLV:9=1X#ZS&T6],K+FJNM@    YRJZ3T_83N%@=&0
M                             !&&OOH&OMM/W5-:XC\+\T=$MPX2\=\M
MW[*U[OO'+>9V" *                              ,;BB4G*G3J[_$W_
M .4I_P!AQT'A;8OTPYGQIMX6B>E.!NSG8    .;3I0O8_=,D=(8J
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MH #FZWI32_)M[JF7,CI#%0
M        83;4"@^9^D]Z]NJ?2N.C[OU5NB.A_,GF/BL7X[_Y2U1[OGLD0 %
M 0    4"  *!    !0(!0(    *!  %$[=6'Z[S#[+!Z1QK?GFS9IEU'@/K,
M;1;TRLN:JZV    #G:KI-!V$[A1T1
M                $8:^^@:^VT_=<:UQ'X7YHZ);APEX[Y;OV5KW3EKL$ 4
M                             -Q1.1.=.?5W^)O_ ,I3_L..@\+;&)IA
MS/C3;PM$]*<#=G.P    <VG2?WOS&2.D,5
M                    !KK_ /45S]DG]$XL)+X^)N^,[NJ;I&1J6+E#)Y@
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M3WKVZI]*XZ/N_56Z(Z'\R>8^*Q?CO_E+5'N^>R1      !0(     %  0
MH$         !.W5A^N\P^RP>D<:YYWLV:9=1X#ZS&T6],K+FJNM@    YRJZ
M30=A.X4=&0                                              !&&O
MKH&OMM/W5-9XC\)\T=$MPX2\=\MW[*U]XY=S.P0!0
M           WQ*<Z<^KQ\3?_ )2G_8<=!X6V,33#F?&FWA:)Z4X&[.=@
MYM.E"]C]TR1TABH
M -=?_J*Y^R3^B<6$G(^/B;OC.[JFZ1D:EBY0R>8
M          7FZBO0W-?WI'Z!#7?,]N-#8-PV9_):Y-H^3&1](*   !HZ7I%4
M^(A1O"     /4N="RY6^KM\JZ,=7!+3O<FXDK%8J]I3&Z*K$T5@U/ZPZ+4]6
MW?5KK"8^VI!6/GIJ[0<^-JR(B+IZ**N@]$:YCVHJ'M77MC/'(PFW5NG-*<9-
M<.K!E*E8[--!Y##2Q272=M> B*[\AYZK*J#,\YJAU[ZP<LY2R9%)-9+34>MU
MMR>Q6-5FDQ9),%V48UK,&J[#2<[8,\*)MNUYYGGBS6W4C+*U2(B)AA@F\>?.
M]'D4          "N/6VZ/V;VAW[*F=C&Y*6I?\+<K^Q,[JDNRD.\,63UZRMI
M*&DGK:V9M/1T['2SSR+HL8QB8JJK[@%/<]9FNVO[/]%E;*\;WY?I'JD$BHK4
M2/:DJ9/!Q3%&^\>L11A/*MKENPT66+'0V&WMPI*"%D+5P1%>K41%>[#=<NRI
MY3RRS;17(UJN<N#43%57>0#2OS796/5BS.547#88Y47#>,]21K6U]-<LQ4U3
M2.5\6BC<516[**NXHF*0.M,
M          &$VU H/F?I/>O;ZGTKCH^[]5;HCH?S)YCXK%^._P#E+5'N^>R1
M     "@ (    *  @% @      *! *   !.W5A^O,P^RP>D<:WYYLV:9=1X#
MZS&T6],K+FJNM@    YRJZ30=A.X6!T9
M                   $8:^N@:^VT_=4UGB/PGS1T2W#A+QWRW?LK7NG+G8(
M H                              QOB<B<Z=.KO\3?\ Y2G_ &''0>%M
MC$TPYGQIMX6B>E.!NSG8    .;3I0O8_=,D=(8J
M                         #77_P"HKG[)/Z)Q827Q\3=\9W=4W2W(U+%R
MAD\P                              W0+S=17H;FO[TC] AKOF6W&AL&
MX;,_DM<A\F,CZ04   #24O2&J^30HW9     &%QW ./SKJ[R3GB!B9KM\4TL
M2:$->CO(5$:+N-E:J+A[BXH2)F))BJ.V]675$DFFM56N9N1K7,P[:,Q_*>FM
M*4A)64\I9*R31K;\KTM-0Q2X>6>QZ/FF<FPBOD<Y7.7W,<-XDS,E(AU+?T4,
M%>10          *X];;H_9?:'?LJ>EC&Y*6I?\+<K^Q,[JF-V4AW$T\4$4DT
M[TCAC:Y\DCEP1K6IBJJ8LE2]:FL.]:W<P0ZO-7_E)K,DNC.^/X*53VK@KWNW
M(F[V[NGK;;2.5C5/NJ_5E9M6]C;14;$ENU0UKKE7N1-.63#91%W&IN(><RL0
M[G]'OD5E41R*BIBB[:*!^7JE*FQY&/#Q&]XM9'/U3&19GI6QM1K?)HN#41$V
MUWB\PZ8Q                                               83;4"
M@^9^D]Z]OJ?2N.C[OU5NB.A_,GF/BL7X[_Y2U1[OGLD0 % @     4"
M   4" 4" 4" 4    !.W5A^N\P^RP>D<:WYYLVZ9=1X#ZS&T6],K+FJNM@
M  YVJZ30=A.X6!T1
M   $8:^^@:^VT_=<:SQ'X3YHZ);APEX[Y;OV5KW?>.7.P0!0
M                 !C?$Y$G*G3J\?$W_P"4I_V''0>%MC$TPYGQGMX6B>E.
M!NSG8    .;3I.O8_=,D=(8J
M          #77_ZBN?LD_HG%A)R/CXF[XSNZINEN1J6+E#)Y@
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M;\[V;-,NH\!]9C:+>F5ES576P    <Y5=)H.PG<+ Z,@
M                              ",-??0-?;:?NN-:XC\+\T=$MPX2\=\
MMW[*UG+78( H                              ;XYDYTY]7?XF__ "E/
M^PXZ#PML7Z8<SXTV\+1/2G W9SL    '-ITH7L?NF2.D,5
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M^E+KUU4U]7!14N8HI*JID9#!&D4Z*Z21VBU,5C1-E5&K)6$C-VC%60
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MUL    '.U72:#L)W"CHB
M       (PU]] U]MI^ZIK7$?A/FCHEN'"7C_ );OV5KWNP<M=@@"@
M                  $ H  ,;XG(DY4Z=7?XF_\ RE/^PXZ#PML7Z8<SXTV\
M+1/2G W9SL    '-ITH7L?NF2.D,5     Q3?
M            Q0      &NO_ -1W3V2?T3BPDOCXFVOC.[INEN1J6+E#)Y@
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M6'Z[S#[+!Z1QKGG>S;IEU'@/K,;1;TRLN:JZV    #G:KI-!V&]PL#HB
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M!Z1QK?GFS;IEU'@/K,;1;TRLN:JZV    #G:KI-3]AO<$#H@
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M-DW3J;=#OS\[]0    -=?_J*Y^R3^B<6$G(^/B;:^,[NJ;I&1J6+E#)Y@
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M96*Q58CFNEE<U?T6X,1C$=LJJ^[@7"MFV?N9EQ*3;J+8(J:..TAY96;(
M                .;K>E%+\FWNJ9<R.D,5    !6?K/?7N7_9)_2(;3Y)LW
M:7)./.LP=%W3""N\;++E\Y0B!0(  H$ H$   *   0   H "         *'Z
MQ.9>9<+4'^%]I\>I_P!0\TCS7Q$Z(Z'?>$?^;9IO_E*2SY+;@    83;4"@^
M9^D]Z]OJ?2N.C[OU5NB.A_,GF/BL7X[_ .4M4>[Y[)$   H$
M !0 $ H$ H  !  %$[=6'Z[S#[+!Z1QK?G>S;IEU'@/K,;1;TRLN:JZV
M#G:KI-!V$[A8'1$
M  1AKZZ!K[;3]U36>(_"?-'1+<.$O'?+=^RM:[?O'+>9V" J@
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MGFS9IEU'@/K,;1;TRLN:JZV    #G:KI-!V$[A1T1
M                            $8:^N@:^VT_=4UGB/PGS1T2W#A+QWRW?
MLK7WCESL$ 4                              -\3D2<J<^KO\3?_ )2G
M_8<=!X6V+],.9\:;>%HGI3@;LYV    #F_\ NCWOW3)'2&*@    ^=?7+_&J
MH^ZJ+_B&R>7]4UW?NLNT0K_N)V#Z;Y_-
M    >,GQ7;[AC.1ZX>6-+ZL:D/P@R3]ST?HD-4WKK;M+8]TZFW0[X_*_4
M #77_P"HKG[)/Z)Q827Q\3;7QG=TW2,C4L7*&3S
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M3Y)LW:7)./.LP=%W3""N\;*Y?.4(@4 !   "@0     *  @%  0"@ (  H$
MH "!^L7F.9<+4'^%]I\>I_U#S1_-?$3HCH=^X1_YMFF_^4I+/DMN    !A-M
M0*#YHZ3WKV^I]*XZ/N_56Z(Z'\R>8^*Q?CO_ )2U1[OGLD0 %  0    4
M@ "@0 !0(!0 $     "@03MU8?KS,/LL'I'&N>=[-NF74> ^LQM%O3*RYJKK
M8    .=JNDT'83N%@=$0
M      !&&OOH&OMM/W7&M<1^$^:.B6X<)>.^6[]E:^\<MYG8( H
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MAB     K/UGOKW+_ +)/Z1#:?)-F[2Y)QYUF#HNZ804;*Y?.4"! *    (
MH$      !0  " 4   @    H?K$YCF7"U!_A?:?'J?\ 4/-(\U\1.B.AWWA'
M_FV:;_Y2DL^2V\    &$VU H/FCI/>O;ZGTKCH^[]5;HCH?S)YCXK%^._P#E
M+5;I[OGLA @  !0(  H$ H$  4 ! *!   "@0   H$  !.W5A^O,P^RP>D<:
MYYYLVZ9=1X#ZS&T6],K+FJNM@    YRJZ34_83N%@=&0
M                              !&&OOH&OMM/W7&M<1^$^:.B6X<)>.^
M6[]E:][L'+'8("J                              ,;XG(DY4Z=7?XF_
M_*4_[#CH/"VQB:8<SXTV\+1/2G W9SL    '-ITG7L?F*CI"*    #YU]<O\
M:JC[JHO^(;+Y?U37=^ZR[1"O^XA])\_F@
M    /&3XKM]PQG(]</+&E]6-2'X09)^YZ/T2&J;UUMVEL>Z=3;H=\?E?J
M !KK_P#45S]DG]$XL).1\?$W?&7NJ;I&1J6+E#)Y@
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MKO,/LL'I'&N>>;-NF74> ^LQM%O3*RYJKK8    .=JNDU/V$[A8'1$
M                                         1AK[Z!K[;3]UQK7$?A/
MFCHEN'"7COEN_96LY;S.P1D H                              QOEG(
MDY4Z=7?XF_\ RE/^PXZ!PML7Z8<SXTV\+1/2G W9SL    '-_P#='O?F*CI"
M*    #YU]<K\:JC[JHOWS9/+^J:[OW67:(5_W$/IOG\T
M               !XR?%+[_<,9R/7#RQI?5C4A^$&2?N>C]$AJF]=;=I;'NG
M4VZ'?'Y7Z@    :Z_P#U'<_9)_1.+"2^/B;O9=W5-TMR-2Q<H9/,
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MIES(Z0Q4    %9^L]]>Y?]DG](AM/DF2[2Y)QYUF#HNZ804;*Y?.4"! *!
M "@0"@ (           *     $ H?K#F.9<+4'^%]I^4J?\ 4/-'\U\1.B.A
MWWA'_FV:;_Y2DL^2V\    &$VU H/F?I/>O;ZGTKCH^[]5;HCH?S)YCXK%^.
M_P#E+5;I[OG,@ ! *   0   H$     "@ (       ,% #)!.W5A^N\P^RP>
MD<:YYYLV?FZCP'UF-HMZ967-5=;    !SM5TFI^PWN%@=$0
M                                 !&&OOH&OMM/W7&M<1^$^:.B6X<)
M>.^6[]E:][L'+78(R 4                              8WRSD3G3IU>
M/B;_ /*4_P"PXZ!PML7Z8<SXTV\+1/2G W9SL    '-ITH][]TR1TABH
M/G7UR_QJJ/NJB_?-E\OZIKN_=9=HA7_<0^D^?S0
M          'C)\4OO]PQG(]</+&E]6-2'X09)^YZ/T2&J;UUMVEL>Z=3;H=\
M?E?J    !KK_ /45S]DG]$XL)+X^)MKV7=U3=(R-2Q<H9/,
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MY)LW:7)./.LP=%W3""D_,;*Y?.4"!  % @    H    @% @ "@0    4 !
M  'ZPYEYEPM0?X7VGY2I_P!0\TCS7Q$Z(Z'?.$?^;9IO_E*2SY+;P    83;
M4"@^9^D]Z]OJ?2N.C[OU5NB.A_,GF/BL7X[_ .4M5NGN^>R1  4 !      H
M      (!0 $ H "  *!   3MU8?KO,/LL'I'&N>>;-FF74> ^LQM%O3*RYJK
MK8    .=JNDT'8;W"P.B(
M        C#7UT#7VVG[JFL\1^$^:.B6X<)>.^6[]E:UV_>.7<SL$ 4
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M!Z1QKGGFS;IEU'@/K,;1;TRLN:JZV    #G:KI-!V$[A8'1$
M                                   1AK[Z!K[;3]U36N(_"?-'1+<.
M$O'?+=^RM>[[QRUU^ ,@                             !C?$Y$YTZ=7
M?XF__*4_[#CH/"VQ?IAS/C3;PM$]*<#=G.P    <VG2?WOS%1TA%    !\Z^
MN5^-51]U47[YLGE_5-=W[K+M$*_[B'TWS^:
M       \9/BE]_N&,Y'KAY8TOJQJ0_"#)/W/1^B0U3>NMNTMCW3J;=#OC\K]
M0    -=?_J*Y^R3^B<6$G(^/B;OC.[JFZ1D:EBY0R>8
M              7FZBO0S-7WK'Z!#7?,MN-#8-QV9_):U-SL'R8R/I,E
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M>9A]E@](XUSSS9MTRZCP'UF-HMZ967-5=;    !SM5TF@["=PL#HB
M                                        (PU]] U]MI^ZXUKB/PGS
M1T2W#A+QWRW?LK7NG+>9V",@%                              &-\LY
M$G*G3J[_ !-_^4I_V''0.%MC$TPYGQIMX6B>E.!NSG8    .;3I1[WYBHZ0B
M@    ^=77*_&JH^ZJ+]\V7R_JFN[]UEVB$ ;B'TGS^:
M               \9/BE]_N&,Y'KAY8TOJQJ0_"')/W/1^B0U3>NMNTMCW3J
M;=#OC\K]0    -=?_J*Y^R3^B<6$G(^/B;OC+W5-TC(U+%RAD\P
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MVV-C%<YR;&R98$4Q/N>['2F-U>KGE:-6HNRFU^8\<E99OT,@
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M!K[;3]UQK7$?A/FCHEN'"7COEN_96LY:[!&0"@
M       #&^)R)SITZN_Q-_\ E*?]AQT'A;8Q-,.9\:;>%HGI3@;LYV    #F
MTZ3KV/S&2.D,5    !\Z^N5^-51]U47_ !#9/+^J:[OW67:(5_W$/IOGQD@
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ML/UWF'V6#TCC7//-FW3+J/ ?68VBWIE9<U1UL    '.572:#L)W"P.C(
M                                           C#7WT#7VVG[JFL\1^
M$^:.B6X<)>.^6[]E:][L'+N9U^ ,@                             !C
M?',DY4Z=7CXF_P#RE/\ L..@\+;&)IAS/C3;PM$]*<#=G.P    <W_W0O8_=
M,D=(8J    #YU]<K\:JC[JHO^(;+Y?U37=^ZR[1"OZ;2'TGS^:   "@0
M                      #QD^*7W^X8SD>N'EC2^K&I#\(<D_<]'Z)#4]ZZ
MV[2V/=.IMT.^/S/U     UU_^HKG[)/Z)Q82<CX^)MKXSNZIND9&I8N4,GF
M                             &Z!>;J*]#,U?>L?H$-=\RVXT-@W'9G\
MEK4W#Y,9'TF2@   :.EZ0U7B(4;P@    #TKI305EOK*2J54I:B"2*=6[:,>
MQ6N5/>4\L6FK-<C.S+"J&I+69E35?=KYE>[W)M7EVKG2HH+Y2Q2NA1S$5N$D
M;F)(FDW#:8N#DWMD_9-;K(F<L/&9I?1-O]PVJ'^8D^C57^4>6JRJ_:DU^:J*
M^KIZ&EO[9*JJD9!!'ZO4MTI)%T6IBL2(F*KNC52;J)(1<4Q,&3)0
M           #FZWI32_)M[JF7,CI#%0    5GZSWU]E_V2?TB&T^2;-VER3C
MSK,'1=TP@HV1R^<H5 @    H$   *!       4    0 !0(  H /UD)S+S+A
M:@_POM/CU/\ J'FD>:^(G1'0[YPC_P VS3?_ "E)9\EMX    ,)MJ!0?,_2>
M]>WU/I7'1]WZJW1'0_F3S'Q6+\=_\I:H]WSV0@0    4"    "@0     *
M 0 !0(!0 $ "=NK#]=YA]E@](XUSSS9LTRZCP'UF-HMZ967-5=;    !SM5T
MF@["=PL#HB                                               (PU
M]] U]MI^ZXUKB/POS1T2W#A+QWRW?LK7NG+>9V" *
M           ,;XG(DY4Z=7?XF_\ RE/^PXZ#PML8FF',^--O"T3TIP-V<[
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M),EVER3CSK,'1=TP@KO&RRY?.4"   0"@ (       !0(    *  @ "@
M'ZQ.8YEPM0?X7VGQZG_4/-(\U\1.B.AWWA'_ )MFF_\ E*2SY+;P    83;4
M"@^:.D]Z]OJ?2N.C[OU5NB.A_,GF/BL7X[_Y2U9[OG!   "@   "
M4"  *  @     4" !.W5A^N\P^RP>D<:YYYLV:9=1X#ZS&T6],K+FJNM@
M YVJZ30=AO<*.B(
M  C#7WT#7VVG[KC6N(_"_-'1+<.$O'?+=^RM>Z<M=@@"@
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M]U3+F'2&(    "L_6>^O<O\ LD_I$-I\DV;M+DG'G68.B[IA!7>-E<OG*$0
M      *! *!       4 !   "@0    4/UB<QS+A:@_POM/CU/\ J'FD>:^(
MG1'0[]PC_P VS3?_ "E)9\EMP    ,)MJ!0?,_2>]>WU/I7'1]WZJW1'0_F3
MS'Q6+\=_\I:H]WSV2(%   (!0 $ H     0"@0"@ (!0  "     )VZL/UWF
M'V6#TCC7/.]FS3+J/ ?68VBWIE9<U5UL    '.5?2>G["=PHZ,@
M                                     ",-??0-?;:?NN-:XC\)\T=$
MMPX2\=\MW[*U]XY:Z_ &0                              ;XG(DY4Y]
M7?XF_P#RE/\ L..@\+;&)IAS/C3;PM$]*<#=G.P    <W_W0O8_=,D=(8J
M  #YU]<K\:JC[JHOWS9?+^J:[OW67:(5_P!Q.P?2?/YH
M               #QD^*7W^X8SD>N'EC2^K&I#\(,D_<]'Z)#5-ZZV[2V/=.
MIMT.^/ROU     UU_P#J*Y^R3^B<6$G(^/B;O9=W5-TMR-2Q<H9/,
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MFEKEJ:R5E/"CJ1R-TY7(UN*X["8J8:DK-T)?3:P4P9,E
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M-9XC\)\T=$MPX2\=\MW[*U[OO'+G8( H
M  ;Y9R).5.?5W^)O_P I3_L..@<+;&)IAS/C3;PM$]*<#=G.P    <VG2=>Q
M^Z5'2$4    'SKZY7XU5'W51?OFR>7]4UW?NLNT0K_N)V#Z;Y_-
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M6>^OLO\ LD_I$-I\DV;M+DG'G68.B[IA!7>-E<OG*$0 % @% @  !0(
M% @    H$       #]8<QS+A:@_POM/CU/\ J'FD>:^(G1'0[[PC_P VS3?_
M "E)9\EMX    ,)MJ!0?,_2>]>WU/I7'1]WZJW1'0_F3S'Q6+\=_\I:H]WSV
M0@  $  4           0"@0 !0  "  *!  G;JP_7>8?98/2.-<\[V;=,NH\
M!]9C:+>F5ES576P    <[5=)H.PG<*.B(
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M<_9)_1.+"3D?'Q-WLN[JFZ6Y&I8N4,GF
M   %YNHKT,S5]ZQ^@0UWS+;C0V#<-F?R6M3</DQD?29*   !HZ7I#5>(A1O"
M                                <W6]**7Y-O=4RYATAB     K/UGO
MK[+_ +)/Z1#:?)-F[2Y)QYUF#HNZ805M]HV5R^<H$"   % @    H$
M  H$  4    0 !0_6)S',N%J#_"^T^/4_P"H>:1YKXB=$=#OO"/_ #;--_\
M*4EGR6W@    PFVH%!\T=)[U[?4^E<='W?JK=$=#^9/,?%8OQW?REJCW?/9(
M@ *   0"@0 !0(   4"           "@  G;JP_7>8?98/2.-;\\V;=,NH\!
M]9C:+>F5ES576P    <Y5=)H.PG<+ Z,@
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MDG]$XL).1\?$W?&=W5-TC(U+%RAD\P
M O-U%>AF:OO2/T"&N^9;<:&P;ALS^2UJ;A\F,CZ3)0   -'2](:KQ$*-X0
M                             #FZWI32_)M[JF7,CI#%0    5GZSWU[
ME_V2?TB&T^2;-VER3CSK,'1=TP@I/S&RRY?.4(C!1D@  !0 $   *!  % @
M   H$    % @ "A^L3F.9<+4'^%]I\>I_P!0\TCS7Q$Z(Z'?N$?^;9IO_E*2
MSY+;@    83;4"@^:.D]Z]OJ?2N.C[OU5NB.A_,GF/BL7X[_ .4M4>[Y[)$
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M     $8:^^@:^VT_=<:UQ'X3YHZ);APEX[Y;OV5K.6\SL$ 4
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MUC] AKOF6W&AL&X;,_DM:FX?)C(^DR4   #1TO2*I\1 -X
M             !B    .;K>E%+\FWNJ9<PZ0Q     5GZSWU]E_V2?TB&T^2
M9+M+DG'G68.B[IA!1LKE\Y6 C) *!              4 !          "A^L
M3F.9<+4'^%]I\>I_U#S2/-?$3HCH=^X1_P";9IO_ )2DL^2VX    &$VU H/
MF?I/>O;ZGTKCH^[]5;HCH?S)YCXK%^._^4M4>[Y[)$      % @%  0"@
M"  *! *  @ "@0  $[=6'Z\S#[+!Z1QKGGFS;IEU'@/K,;1;TRLN:JZV
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MLD_HG%A)?'M-M?&=W3=(R-2Q<K)D\P
M O-U%>AF:OO6/T"&N^9;<:&P;CLS^2UJ;A\F,CZ3)0   -'2](:KQ$*-X0
M                       !ASD:BN5<$3;5=A$ K?F7K/RT&:IK+EVU07&T
MQ5#*5E>^1S5>Y51KE1$W$7$SU6-5B:&=:FBIZES=%9HV2*U-I%>U%P_*8,GL
M  .;K>E-+\FWNJ9<R.D,5    !6?K/?7V7_9)_2(;3Y)LW:7)./.LP=%W3""
MC97+YR@0(       !0 $ H "  *! *  @        /UB\QS+A:@_POM/CU/^
MH>:/YKXB=$=#OW"/_-LTW_RE)9\EMP    ,)MJ!0?,_2>]>WU/I7'1MWZJW1
M'0_F3S'Q6+\=_P#*6J/T/GLD0      4"  *  @%  0"@   "     !0 $$[
M=6'Z[S#[+!Z1QKGGFS;IEU'@/K,;1;TRLN:JZV    #G*KI-!V$[A8'1D
M \7;;23D%<]?W2ZW^P_\13G7$_7VZ'5^#_#7_$BHTYO0
MP09*             ;_(O3;+OM\/=4^MY3XO#^*.E\?SKP.-\$KB'87!@
M  (PU]] U]MI^ZIK7$?A/FCHEN'"7COEN_96O=]XY;S.P1D H
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M=\RVXT-@W'9G\EK4W#Y,9'TF2@   :.EZ0U7B(4;P@
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M[=6'Z[S#[+!Z1QKGGFS9IEU'@/K,;1;TRLN:JZV    #G*KI-!V$[A1T9
M /%VVTDY!7/7]TNM_L/_ !%.=<3]?;H=7X/\-?\ $BHTYO0
M                  ;_ "+TWR[[?#W5/K>4>+P_BCI?'\Z\#C?!*XAV%P8
M    ",-??0-?;:?NN-:XC\)\T=$MPX2\=\MW[*U[OO'+78( H
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M,MN-#8-PV9_):U-P^3&1])DH   &CI>D-5XB%&\(
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M!0(   4  & ,@   @G;JP_7>8?98/2.-<\\V;/S=1X#ZS&T6],K+FJNM@
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M;J*]#,U?>L?H$-=\RVXT-@W'9G\EK4W#Y,9'TF2@   :.EZ0U/B(4;P@
M                    $7Z\,B9EU@9=HK/EVI;"K*I):V.1^@R6)&JB(N.W
M@IE$T$/VS4;KML=(E!9<P<GT6DKTIZ>H1D>F[;=AOJ692B,M9.7,YY=S/16W
M.%Q=<+U/&Q]-4OE\JK6.DT6II;F#C.)8RLYJ8R?K%RY)4U.<KN^XT-5#&M#$
M^;RJ1IAC@B;AA=+*$PF"F" <W6]**;Y-O=4RYATAB     K/UGOKW+_LD_I$
M-I\DR7:7)./.LP=%W3""N\;*Y?.4"!   "@0          H " 4" 4"  *
M@  'ZQ>8YEPM0?X7VGQZK_4/-'\U\1.B.AW[A'_FV:;_ .4I+/DMN    !A-
MM0*#YGZ3WKV^I]*XZ/N_56Z(Z'\R>8^*Q?CO_E+5'N^>R$" 4 !    !0(!0
M $   *   0 !0 $     3MU8?KO,/LL'I'&N>>;-NF74> ^LQM%O3*RYJKK8
M    .<JNDT'83N%'1D    \7;:$D5SU_=+K?[#_Q%.=<3]?;H=7X.\-?\2*C
M3F]                               !O\B]-\N^WP]U3ZWE'B\/XHZ7Q
M_.O XWP2N(=A<&      C#7WT#7VVG[KC6>(_"_-'1+<.$O'?+=^RM>Z<N=@
M@"@           $ H                &^)R)SISZN_Q-_^4I_V''0>%MC$
MTPYGQIMX6B>E.!NSG8    .;3I0O8_=,D=(8J    #YU]<O\:JC[JHOWS9?+
M^J:[OW67:(5_W$/I/G\T                               !XR?%+[_<
M).1ZX>6-+ZL:D/PAR3]ST?HD-2WKK;M+8]TZFW0[X_,_4    #77_P"HKG[)
M/Z)Q82<CX^)MKXSNZIND9&I8N4,GF                              &
M\!>;J*]#,U_>D?H$-=\RVXT-@W'9G\EKDVCY,9'T@H   &CIND-3XB%&\(
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M7]TNM_L/_$4YUQ/U]NAU?@_PU_Q(J-.;T
M    &_R+TWR[[?#W5/K>4^+P_BCI?'\Z\#C?!*XAV%P8     ",-??0-?;:?
MNN-:XC\+\T=$MPX2\=\MW[*U[W8.6NP0!0
M   !C?$Y$YTZ=7?XF_\ RE/^PXZ#PML7Z8<SXTV\+1/2G W9SL    '-ITG7
ML?NF2.D,5    !\Z^N5^-51]U47[YLOE_5-=W[K+M$*_[B'TGS^:
M                        \9/BNWW#&<CUP\L:7U8U(?A#DG[GH_1(:GO7
M6W:6Q[IU-NAWQ^9^H    &NO_P!17/V2?T3BPDY'Q\3;7QG=TW2,C4L7*&3S
M                               "\W45Z&9J^]8_0(:[YEMQH;!N&S/Y
M+6IN'R8R/I,E    T=-TAJ?$0HWA
M.;K>E-+\FWNJ9<R.D,5    !6?K/?7N7_9)_2(;3Y)DNTN2<>=9@Z+NF$$IM
M>\;++E\LD0 %  0 !0(     % @% @  !0(    *! * #]8G,JX6H/\ "^T^
M/4_ZAYI'FOB)T1T.^<(_\VS3?_*4EGR6W@    PFVH%!\S])[U[?4^E<='W?
MJK=$=#^9/,?%8OQW_P I:H]WSV2(     4   @    H  ! *!    !0(!0(!
M0()VZL/UYF'V6#TCC7/.]FW3+J/ ?68VBWIE9<U5UL    '.572:G["=PHZ,
M@   'B[;0DBN>O[I=;_8?^(ISKB?K[=#J_!_AK_B14:<WH
M                 -_D7IOEWV^'NJ?6\I\7A_%'2^/YUX'&^"5Q#L+@P
M  $8:^^@:^VT_=4UGB/PGS1T2W#A+QWRW?LK7O=@Y<[! %
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M+;C0V#<=F?R6M3</DQD?29*   !HZ7I#4^(A1O"
M           <W6]*:7Y-O=4RYDYW2&*@    K/UGOK[+_LD_I$-J\DR7:7).
M/.LP=%W3""N\;(Y?.4(@    !0  "   % @              % !^L3F5<+4
M'^%]I^4J?]0\TCS7Q$Z(Z'?.$?\ FV:;_P"4I+/DMO    !A-M0*#YGZ3WKV
M^I]*XZ/N_56Z(Z'\R>8^*Q?CO_E+5'N^>R1 H$  4"  *!  % @%  0 !0(
M         !.W5A^N\P^RP>D<:YYYLVZ9=1X#ZS&T6],K+FJNM@    YVJZ30
M=A.X6!T1    /%VVA)%<]?W2ZW^P_P#$4YUQ/U]NAU?@_P -?\2*C3F]
M                           !O\B]-\N^WP_G/K>4>+P_BCI?'\Z\#C?!
M*XAV%P8     ",-??0-?;:?NN-:XC\)\T=$MPX2\=\MW[*U]XY;S.P1D H
M                            QOB<B<Z=.KQ\3?\ Y2G_ &''0>%MB_3#
MF?&FWA:)Z4X&[.=@    YO\ [H][]TR1TABH    /G5UR_QJJ/NJB_?-E\OZ
MIKF_=9=HA &XG8/I/P<T                               !XR?%+[_<
M,9R/7#RQI?5C4A^$&2?N>C]$AJF]=;=I;'NG4VZ'?'Y7Z@    :Z_P#U%<_9
M)_1.+"3D?'Q-M?&=W5-TC(U+%RAD\P                            #(
M& +S=17H9FK[UC] AKOF6W&AL&X[,_DM:FX?)C(^DR4   #1TO2&I\1"C>$
M                               YNMZ4TOR;>ZIES(Z0Q4    %9^L]]
M>Y?]DG](AM/DFS=I<DX\ZS!T7=,(*[QLKE\Y0B   48 R0 !0 $   *!  %
M 0     *!    'ZQ>8YEPM0?X7VGQZG_ %#S1_-?$3HCH=^X1_YMFF_^4I+/
MDMN    !A-M0*#YGZ3WKV^I]*XZ/N_56Z(Z'\R>8^*Q?CO\ Y2U1[OGLA @%
M @%   (    *!  % @%  0"@0"@ (   !.W5A^N\P^RP>D<:YYYLV:9=1X#Z
MS&T6],K+FJNM@    YRJZ34_83N%@=&0   #Q=MH217/7]TNM_L/_$4YUQ/U
M]NAU?@[PU_Q(J-.;T                               &_R+TVR[[?#W
M5/K>4^+P_BCI?'\Z\#C?!*XAV%P8     ",-??0-?;:?NN-:XC\)\T=$MPX2
M\=\MW[*U[IRWF=@@"@                             !OB4G*G/J\?$W
M_P"4I_V''0>%MC$TPYGQIMX6B>E.!NSG8    .;3I1[W[IDCI#%0    ?.KK
ME_C54?=5%^^;+Y?U37=^ZR[1" -Q#Z3Y_-
M      >,GQ2^_P!PQG(]</+&E]6-2'X0Y)^YZ/T2&I[UUMVEL>Z=3;H=\?F?
MJ    !KK_P#45S]DG]$XL).1\?$W>R[NJ;I&1J6+E#)Y@
M               !>;J*]#,U_>L?H$-=\RVXT-@W'9G\EK4W#Y,9'TF2@
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MM_L/_$<<ZXGZ^W0ZOP=X:_XD5FG-Z
M#?Y%Z;9=]OA[JGUO*?%X?Q1TOC^=>!QO@E<0["X,     !&&OOH&OMM/W7&L
M\1^$^:.B6X<)>.^6[]E:^\<N=@C(!0                             !
M@3D2<J=.KO\ $W_Y2G_8<=!X6V,33#F?&FWA:)Z4X&[.=@    YM.E"]C]TR
M1TABH    /G7UROQJJ/NJB_XALOE_5-=W[K+M$*_[B=@^D^?S0
M                     'C)\4OO]PQG(]</+&E]6-2'X09)^YZ/T2&J;UUM
MVEL>Z=3;H=\?E?J    !KK_]1W/V2?T3BPDOCXF[XSNZIND9&I8N4,GF
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MJ!0?,_2>]>W5/I7'1]WZJW1'0_F3S'Q6+\=_\I:L]WS@@ "@ (   4   @
M!0(   4"  *   0"@0"B=NK#]=YA]E@](XUOSS9MTRZCP'UF-HMZ967-5=;
M   !SM5TF@[#>X6!T1    /%VVA)%<]?W2ZW^P_\13G7$_7VZ'5^#O#7_$BH
MTYO0                               ;_(O3;+OM\/=4^MY3XO#^*.E\
M?SKP.-\$KB'87!@     (PU]] U]MI^ZIK7$?A/FCHEN'"7COEN_96O=]XY:
MZ_ &0                              QOB<B<Z=.KO\ $W_Y2G_8<=!X
M6V+],.9\:;>%HGI3@;LYV    #FTZ4>]^Z9(Z0Q4    'SKZY7XU5'W51?OF
MR>7]4UW?NLNT0K_N)V#Z;Y_-                                >,GQ
M2^_W"3D>N'EC2^K&I#\(,D_<]'Z)#4]ZZV[2V/=.IMT.^/ROU     UU_P#J
M.Z>R3^B<6$E\?$W?&7NJ;I&1J6+E#)Y@
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M>    #";:@4'S1TGO7M]3Z5QT?=^JMT1T/YD\Q\5B_'?_*6J/=\]DB
M       "@ (  H  ! *!  % @  )VZL/UYF'V6#TCC7//-FW3+J/ ?68VBWI
ME9<U5UL    '.U72:G[#>X6!T1    /%VVA)%<M?W2ZW^P_\1QSKB?K[=#J_
M!WAK_B16:<WH                               -_D7IOEWV^'NJ?6\H
M\7A_%'2^/YUX'&^"5Q#L+@P     $8:^N@:^VT_=4UGB/PGS1T2W#A+QWRW?
MLK7O=@Y<[!&0"@                             #&^)R).5.G5X^)O\
M\I3_ +#CH/"VQ?IAS/C3;PM$]*<#=G.P    <VG2A>Q^Z9(Z0Q4    'SKZY
M7XU5'W51?OFR^7]4UW?NLNT0K_N(?2?/YH
M     #QD^*7W^X2<CUP\L:7U8U(?A!DG[GH_1(:GO76W:6Q[IU-NAWQ^5^H
M   &NO\ ]1W/V2?T3BPDOCXF[XSNZIND9&I8N4,GF
M            %YNHKT,S5]ZQ^@0UWS+;C0V#<=F?R6M3</DQD?29*   !HZ7
MI#5>(@&\                         $8=83\)K_XD7I6F5N5)<EU4>A-?
M[8[N*6Y+72]8[\);QX\'I$);E66BZJ_0"I]L>+LI"=#%0#FZWI32_)M[JF7,
MCI#%0    5GZSWU[E_V2?TB&T^2;-VER3CSK,'1=TP@KO&RRY?.4(@ *  @
M   H$  4   @    H$ H$   *!  ;J#F7F7"U!_A?:?'J?\ 4/-(\U\1.B.A
MWSA'_FV:;_Y2DL^2V\    &$VU H/F?I/>O;ZGTKCH^[]5;HCH?S)YCXK%^.
M_P#E+5'N^>R1   *!    !0  "  *      "  *   0"@!.W5A^N\P^RP>D<
M:WYWLVZ9=1X#ZS&T6],K+FJNM@    YRJZ3T_83N%@=&0   #Q=MH217/7]T
MNM_L/_$4YUQ/U]NAU?@[PU_Q(J-.;T
M &_R+TVR[[?#W5/K>4>+P_BCI?'\Z\#C?!*XAV%P8     ",-??0-?;:?NJ:
MUQ'X3YHZ);APEX_Y;OV5KW?>.6<SL$!5
M  &-\<R3E3IU=_B;_P#*4_[#CH/"VQB:8<SXTV\+1/2G W9SL    '-_]T>]
M^8J.D(H    /G7UROQJJ/NJB_?-E\OZIKN_=9=HA7_<0^D^?S0
M *!                   >,GQ2^_P!PQG(]</+#ZL:D/P@R3]ST?HD-4WKK
M;M+8]TZFW0[X_*_4    #77_ .HKG[)/Z)Q82<CX^)MKXSNZIND9&I8F4,GF
M                               %YNHKT,S5]ZQ^@0UWS+;C0V#<=F?R
M6M3</DQD?29*   !HZ7I#4^(@&\                         $:Z_*:>J
MU3YA93L61[8HWJUNRJM;*W'!"QE27"=4^NI7Y7NUO;)C64]2DDL6ZULF."_D
M,[DATG66KZ>FU85E)(Y$FKIHHX$5<%56N1RX;^PA+.59>EU6Z9\6K;UI5^!4
MU<V@F]Y-VBI+B$W&*@'-UO2FE^3;W5,N9'2&*@    K/UGOKW+_LD_I$-I\D
MV;M+DG'G68.B[IA!*;7O&RRY?+)$"@  $    %   (!0(      "@0"@ (
M 4/UB<QS+A:@_P +[3\I4_ZAYI'FOB)T1T.^\(_\VS3?_*4EGR6W@    PFV
MH%!\S])[U[?4^E<='W?JK=$=#^9/,?%8OQW_ ,I:H]WSV2(    H     0
M H      (     % @% "=NK#]>9A]E@](XUOSO9MTRZCP'UF-HMZ967-5=;
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M *BN?LE1Z)Q827Q\3=\9W=4W2,C4L3*&3S
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M*_&JH^ZJ+]\V3R_JFN[]UEVB%?\ <0^F^?S0
M       'C)\4OO\ <).1ZX>6-+ZL:D/PAR3]ST?HD-3WKK;M+8]TZFW0[X_*
M_4    #77_ZBN?LD_HG%A)R/CXF[XSNZIND9&I8N4,GF
M               %YNHKT,S5]ZQ^@0UWS+;C0V#<=F?R6M3</DQD?29*   !
MHZ7I%4^(@&\                          #&" 9P    '-UO2FE^3;W5,
MN9'2&*@    K/UGOKW+_ +)/Z1#:O),EVER3CSK,'1=TP@KO&R2Y?(1  4"
M4" 4"   % @            4     _6)S',N%J#_  OM/CU/^H>:1YKXB=$=
M#OW"/_-LTW_RE)9\EMP    ,)MJ!0?-'2>]>WU/I7'1]WZJW1'0_F3S'Q6+\
M=_\ *6J/=\]D($  4"       H$    % @% @% @       G;JP_7>8?98/2
M.-<\\V;=,NH\!]9C:+>F5ES576P    <[5=)X.PG< Z(    >+MM"2*YZ_NE
MUO\ 8?\ B*<ZXGZ^W0ZOP?X:_P")%1IS>@
M     W^1>F^7?;X>ZI];RCQ6'\4=+X_G7@<;X)7$.PN#      1AKZZ!K[;3
M]U36>(_"?-'1+<.$O'?+=^RM>[[QRYV" *    H$                   "
M@0   #&^)R)SIUZN_P 3F#Y2G_8<=!X6V+],.9\9[>%HGI3>;LYV    #FTZ
M3KV/S%1TA%    !\Z^N5^-51]U47[YLGE_5-=W[K+M$( W$/IOP3DA@(
M(!0          ! *     $ 5 H   >,GQ2^_W#&<CUP\L:7U8U(?A!DG[GH_
M1(:IO76W:6Q[IU-NAWQ^5^H    &NO\ ]17/V2?T3BPDY'Q\3;7QG=U3=(R-
M3Q,H9/(                         *@   !4"57FZBO0S-7WK'Z!#7?,M
MN-#8=QV9_):U-SL'R8R/I,E    T=-TBJ?$0HWA
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M1S5E<J*BX;**;[@;SA1AVQ-T9(Y_P?SMO_E>]W;SB3&'=2;[N:?>EK>;M_\
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MF5G/^7+G]#F_A'WK,\>T^Q?F_23F5G/^7;G]#F_A'WK,\>T^Q?F_23F5G/\
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M  #&" ,$ R       !C! ,X 8P7? ;..V!D !SU^V;M9OEE_,>EN24=">:@
M        !C! ,X 8P0#(            , ,8(!D          U69/J.M\1/V
MD+;E)>S:OJVD^29W!.5(>X10 !K,P?4M;\FO=0MN5)?I9?JFC^2;W!.57OD
M  (                                 %  !SV5OT[I[2[\YZ7I#H3S4
M  8P10,D                               P0HQ@!D !I,V?4LWC,[IG
M9E&UI/\ I8/DV?LH8#]@  #39I^HZKL-_:0RMGE&QH/^BIODF?LH2<H]@@
M                                     #GJKI;1>SO_ #F<;(Z$P
M                                     :#-WU4WY>/NJ9694EO8_BV>
M*G<,95Y                                     /RJ8$J:>6G<JHV5J
ML54VTQ3 #\Z"C904<5'&Y7,B311SMM=TLS4>R0
M                 !Z-;;(JVII*E[W-?2/TV-;A@J^Z6)H/>(
M                              ]:X4;*^CEHY'*QDJ:*N;MILX@?I30)
M34\5.U5<V)J,15VU1-@#]0  #UZVE974DM(]RM9,W1<Y-M$]P1R#RI*9M)31
M4S%5S8FHQ%7;5$ _8                                        /1M
MULCMOK"QO<_UB197:6&PJ[B8%F:CWB
M          /3N=OCN=(^DD>K&/5%TFX8IAV2Q-![,3$BC9&BXHQJ-1>PF!!Y
M@  'J7*A9<J.2CD<K&288N;ACL+CN@?O!$D,,<**JI&U&(J[S4P _0
M                                  /0DMD4ETANBO<DL+%C1FQHJB[O
MY2U'OD                                        >E=+;'=*9*:5ZL
M8CVR:3<,<6[FR6)H/<:FBU&[R8$&0
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MZ_U5CFL26SU>D6K69*A)L7(]&*W#13?VRS%$B4S)M&*L@
M     C76)KKRAJ\F2WUSWUEY<W22AIDTE;O>47]7$RBVJ3**X.MRCJIC*C*[
MXZ)7KIS-J%<Y&8[>CH%U4UDT9 UH94UD4TLU@G>VJIUPJ:&I3R<[/][1Q7%J
M[BF,PM7;$4   &*            !%.MW713:KI;?2I;77*LK=)ZL\IY%C(VX
M;.E@N*^X91 D#+E\ILR62@OM(US(*Z)LS6/3!S<=M%["[!C,#;      Q0
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M(J/?U2:QY-9N7ZF^26[DQ:>K?2)!Y3RVDC&M=I8X)MZ6T)B@[\@
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MZGM;LNM3EE9+1R6MJ= U,)O+>4\NCE7]5,,-$LQ1(2HABH
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MWJNGOX'K'(QEWG5#7'G<O^_1_L2$O+5GCS9
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MFIH60RMDA8JM57L1%7W<3SMF:LYA%75(NLRW#,%D5R^0]7BKE;N>4<Y&8]G
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M\60N)E8VK/GFS
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MQVTV-@\F2G.:KE0W?K$,K[;.VHI'5]/&V9FRU71-T78+[BH>L9&$Y5U3R9@
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MA41TRN5<=#XQ-G!-+:,KJ<[&*KW439VT=.VI7&I2)B3+CCB]&II;/9/%Z/W
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MJDE1<51%7#85"Q=5)A>FWQOBH*6*1-%[(8VN3>5&HBH>+-[(
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M(IC-RZJ;+M:K=>[=46JZTS*N@JF+'/!(B*US5_.FXI@JM]_ZK]ZH*U]5J]S
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MMZU;Y7JK+?9Z>HJYZV2J:^E5RL1CVM:B+IHBX[!;IJ1%$FF*@
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MJ5N;J=8/4UD712%'H[2TT3PBS-4B$S(8J
M                                                      "--=>0
MLPY_RQ#;LN7#U*KI)TJ5@5=!E3HI\%BN_5P7X2%@0RF>NLQEQK<OR6.6NDIV
MI$E<M&^I<Y-I'>6:J([LX'I_BQY6PU8ZC,UW7-3,[ZS$TE23UOU>=WE9ZB?;
M:LB;;48N&!)F.986@3839/-60
M                                                  $$:Y=7NLBY
MYHM^>\C7)RSVN%(X;<C_ "2QX8J]S-O2\HBX.;@9VS"(^KL[]93-%--EMUCG
MH4JT6"2LAHWTS\,<%PE551$7=]PRI:)(U&:E*G(2S9AS(D3\R3L6*"&-=-M-
M&[]-$>B[*NW3"ZZI";TQPV=LQ5D
M                                                    !#FO'5WG
M7.+;1=<FW)8*VRN=+'0Z?D=.55Q;*U^.".;AA@9VS0E%\VL#K+N9)E]UBF;-
MH^KK<(Z*3RB;&&FV7'1Q_P![ R_Q8\KJ=2NHR\V*^<]<\HUUV8JR45,KTE>V
M:396:1WA>X2Z8R0L+$HF"'FK(
M
M                         #& &0
M                                                         !C
M!A[H&0
M                                  W ,8 9
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                   !C^0#Q5=E
M-E ,Z2 8TDQPVB5&%<J8KMHFXA1Y8@-G'W ,@
M            85<$Q0#&.P0%<N.&&)0TL-E5[1C7\1G$M:C"NP7#;4 JKN;
MB1E%Q3$HR                                   !C%,<-T!L[BD!57<
M0H)CN@9
M
M
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M=MJGOFN8WF6+=M74_1MV[^28.'_\:SG'SYSE?Y9U=7*Y=E5]9>B=K2/GSO\
M'/?TOK>FVTY,./T;2V:P-9.6G(^EN]5$B;;9/\=JIO+I8GZL#S"ZW8N_5^+'
M\JW>^/\ .RFB/[)=R5UG9%ECH<[T361JJ,2Y4N.#4W72M5=C_P )]W \XGDB
M^/S:MO?#U(F["G\I6(M5TM]YHH[C;*ME913(CHYHG:28+W.P;+9B6WQ6V:PT
M_$PK\.:7127O(J:..Y[IZ/)G% H
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MLGR\3"NLFDOIX>+%\5AVYYO4
M
M
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ML   8H!XODCC:KY'(QC?TG.7!$]]0#)&2-1\;D>QVRUS5Q14]Q4 \@
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M^BN\[#:4E%;/%"#.*;>X Q   /QJJJFHJ>2KK)F04T+5?+-(Y&L:U-M55=A
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M_P#@3_P#5E*NNRYGO*6;(DDL-V@JU5<$B1VA+P'X._(2BNBQ(,8H!G%
MQP YS-N>\JY&I8:S,]Q90PU#_)PXM<]SG>XUB*N'NEB!ZV4-963,]RU,&5KD
ME=+1M:ZH:D<D>BCUP3]-J"8H.L(
M
M
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MI3ZI7UIF/Y&#]I27K"U!Y,@
M
M
M                              /SJ)6PPOF?L,C:KWKO(U,5+$5E)FD3
M.9\Z<[7>;-VL.[W29_E&S5DC&*NY!$Y48GO(;GN6%%ML.&^:[U-V)B8DY^1[
MNU@B;2;':/LQ%&CA4"   >ZHH-1?J=)*9LZ)BZ-R8^+NGCC1&J^GN&)JWTSK
M3]5;,;KKDBJLD\FE-9ZE6PMQVH'HBM3L(N)IGF.#J7Q.=VKAC>=?=YPYGELE
M/B;1\MM[F-8_0+,7L$_["EA)R*=:A/Q5L7C2>C4];LC&U>S \6;A];]HH+QJ
M]O<%?&CV10+/$JHBJV2+9:J+N%C**F]7ZMJ*76?9UA<K5JD=!/A^LQR*JH>M
MS"UN-:^9=;536Y@M5XEJ>9R5CF1L? QD7DVNQ9@]&HN'ODBBRX+)%WSK9[G+
M49%DFCNTD6A*M/&V5RQ8X[+7(J;:&<T2%SM3%RS9=LD15F=72OOCJB9KUGC2
M)_DT5-'X+41#PG*SA(1!^-7 VJIIJ9RJULS'1JJ;:(],,4 C7+&H/5WER5M7
M)0\J7)DBR)5UBZ2XJN.&@F#=CL&6M*45EZP$$%-K0NT--$R&%K($;'$U&-3_
M  V[2-1$/2UC*W>JO\.LM^PQ?G/*<K*'7D4                5/ZT5W=4Y
MIMEF1<&4%.LNCN*M1NKVC4?.<29Q(MS0W[AS"IA77\\RX&VP-IZ*&)$V4:F/
MO[)SW'NUKYETS!MI9$/;/![@    PJ(NPNTNQVRQR2QNBL-?D"Y.RWK(L]:Q
MV#8ZM(G)N*V?X"HO"-OW#%F+K;FG^:[O%^%?9.:J^28K[QT=R!Y 4>ZQOXI7
M+Y&#T:'M9D82M9JA_#3+/L3.ZIY3E9P[3 @HMU@IZ6;6?=W4SFN9&QD<JMPP
M21OZ6.&[OGM&1YSE2Y<-5%XUE:I\CT--41TL]O:Z:19\=EKU7##8,:Q$LJ*U
MYAL4V6KY6Y>J'MDGH9EIWO;LM5R+HXF=6-%C=4FH.]Y4S5:,Y55;3R4K8EE\
MBS'3PGCV-S#8Q/.9AE$+*F#(]T"'KAU<<BW*]37VIEJEJIY_69&^4^#IZ6EA
MV,3+62B78XF11,B9L,C:C6]AJ8(8J@'K3WZAI\L6_+ZO:ZXU=0DZ1_K-B:BI
MI]O8/2S*QNR/0ZIUEJH;=>[](U4I*M[*>!R[".6+%78;Y+B%D4,&0
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M2Y187Z[SQ.8UR;,-,YJZ+?\ Q8(XNMRL:.IZI6S=,R?(P=U1>0M0>3,
M
M
M
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MP=U3.](6H/)D
M
M
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M]C&5<0\68   48ZPWXJ7CQ(/1-/>QA<MQJK_  ZRW[#%^<\9RLH=>10
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MBTZN+%';J-$FN4R(^XUZHB/EE5,51-YJ;B'G,U5V^)BH
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M-8;#;*>WQNV7)!&C<??VR3*MNFULD%;NMHBK;LO;'_FS;/!/2QC=#W.J:O\
M]LWU?_K6>C%ZPL,>:@%7>L];,WWF_P!HI+7;ZVXVB*!\FA1P/EC9+BFR[13#
M'>/2RB2BFRR:[,N4BT&7Z>_VVB5RR+!34\C6:3MM<-$O),L8B7KYGO&MRMMB
MPYSEO3[-IHJI<8WL@TTVMER)LEBA+6Y2N&?[>^J7(<ERCG>U$K%M;'/<K4_1
MT]%%$D+Q:L)[W4Y&L\^8UJ'7I\2K5NK$5L^EINPTD7!=H\I9NP(
M
M
M                                                          \7
M[6W@!2WK.9(FR]G-F:*./1M=[1'*YC=B*JCP1VDN^]=E#9?+<>+K=6<L.7\2
M;C]K'^Y;'^-_2CNW5K:RG:_]=$P>GNH;'A7ZUL5RN7;Q@3AW3F>V>TORA$
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MJ[!Y3%&;J"   HSUA_Q4O'B0>B:>]F1A<MOJK_#K+?L,1XSE90Z\B@
M         #D-9&3H<]Y3K[ Y$2I>GE:*1WZ+*F-%5CE]P_'O>!]ZR;'[]QWJ
M=VQ8OC\U(:9U5ERZU-LNC'13PR+!51.V%9(U<,</=VSFN^;M-W)SP['NF\VU
MBZ)_QN=0US7-1[5Q:Y,45-XU^8F)?=MNBYY$9  #&SN;98BJ2YV_W-F@ZCA?
MO+,_<1-X^KNF!-=:?R?*WK>(FML+)]77($V6[%+F>YQ:%UO2(E.U4P='2)@K
M6JB[Z[)T3RK==6S7G++E?GV^1B8D8=L\EO2G%,=)?R=@^Y+6&57!,2BCG6.F
MB;K4N;7/1%2&#%%^30]K,C"Y:[5 J.U9Y95JXHM$S!??4\IRLH=L10 !2SK$
M9%N]BSG59B;3R26.ZX3,JV-5S62ILO:]4_1V=K$];9><Y74:F-=^=;]F>Q9,
MK/59[3HK#).V-RU&A&SX.+M+#8PWA=$,HE:L\F3"@4DZQ&=KG><^5N7JNI1E
MHL[FMIJ1JX-5SDQ5[TW7'M;#"9<[D#6[<-7,$[;'16^6JJ5QEK:F-73Z/@HY
M')\$3;5(EVO]UV>=OU:V\!_\0U(95=IJHZP&:L\YWH\MW2"B91U$<CWN@:Y'
MXL38PQ<IA,01*RB;1@R9               \7M8]CF2-1S'(J.:J8HJ+L*BH
M*T*5?+#K$ZK*K5-K'K:>&)6Y:O$CZZRS[+DT97*LD;EVM)'8[&\;#NV-K6O@
M[SAS;-$<PS-F:CD7W%/IQ=5\R8F.1YKL&2!0  >$TS8&:2["F-UU&417(D3J
M\:JZO6SK*HJ:6%79<M+V5U[GV41&1JBLC1?"<Y$V-X^7O.-%MLYWT=WPM:Z'
MU09&V)K8XVHR-J(UK6I@B(FTB&O99??B*/,"$>M$YK=74:N5&IZ]#LJN'ZKC
M*U)<%U27L=><Q:+D=_RT.."X_P#F%N(6K,%  $*=93*=QS#DN*X6R)T\UIE6
M:6%B:3EA=^D[!-GX.!E;*2KKJWUR7W5=#74MLHZ>NIZQR2/IJMSHU9(FQBFC
M@N.&X>DVU81,KM90O,V8LLVN^U,38*BX4[)Y(8U56-5Z8X)CLGE+T;L@QAO
M9 ACK./1NK9^DY&M6JCQQ7!-IQE;E24>]4E[77/,B,>B_P"# KD:N*?I*97I
M"U&';/-DR
M
M
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M30:C4P16+O&473"3"1\OV2ERW9*&Q43GOI*")L$+Y5TGJUNUI*B)LF*MD
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M\!:C]J7+]BH9DJ:&UTE-4-142:&GBC>B+MX.:U%(-BB8
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M$29U+$V-7HFTBX)N%J-V0
M
M
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M$WC!Z,@
M
M
M                                     >#HV/7X;&KV41>Z!XI3P(NQ
M&U.PU.\!^B(B)@B8>X!D
M
M
M
M
M
M
M
@                                      !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tm2227887d14_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d14_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BDR!2;U_O#\Z '44SS4SC>N?3-.!!Z&@!:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN >.N>O6O5Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]+_]#>O5J\I_: _U7P\_['/2_P#T-Z /5J*** "BBB@ HHHH **** "BBB@
MHHHH **** $/0U\O?M#?'CXO_!GXE:;?:5\+Y?&_PR-KMN9=$+S:@LY()8J%
M.P*!@#:5;=RX/ ^H3TI-H/- 'YM3:;XJ_;$_:J^&_C71?A3K'PYT#PO=Q7FI
MZ]K=K]EGO1'*D@0\#>?DV* 6(\QB2 ,5LW'A3XG_ +"7QN\8>(_!_@J]^(GP
MJ\67!O+BPTI6:YL)2S,!M56(VEW .TJRE02I''Z&*,"@J&H ^*_#?[4/QO\
MCC\1/#=EX$^$E]X.\)P70DUK5/%\+QB6#HZ)\JX(&2-F\EMN=J[L[?Q5_:8^
M+WP1^+>KQ:S\(K[Q5\-I40:9J/A=7N;A,?>:7Y2-S$X*,$VXX9NI]L_:!\3^
M*?!O@FSU+PC:R7FH)JMFD\4=G+=_Z*TRB8F.)'<@(2244L .*ZOP%KVI>*O
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M0>.[[3HPT'E6R37,^GSV5S/<_)YLC++\SJ0L:AF&5\O&3R%]XN@/[#\0<_\
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MD<TW2?AWX4T"SM+33/#.CZ?:V@E%O#:V$4:0^:,2[0J@+O'WL?>[YH ^;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XKXW?\D7\??]
MB_J'_I-)7:UPWQWE:#X'_$.1(7N'3P[J++%&5#.1;2?*-Q R>G) ]2* -CX>
M?\B!X9_[!EK_ .BEKH:\-\"?&#Q9!X(\/1I\#O'EPB:=;JLT=]X?"N!$OS#=
MJ@.#UY /J!6Y_P +D\7?]$)^('_@=X>_^6M 'JU%>4_\+D\7?]$)^('_ ('>
M'O\ Y:T?\+D\7?\ 1"?B!_X'>'O_ ):T >K45Y3_ ,+D\7?]$)^('_@=X>_^
M6M'_  N3Q=_T0GX@?^!WA[_Y:T >K45Y3_PN3Q=_T0GX@?\ @=X>_P#EK1_P
MN3Q=_P!$)^('_@=X>_\ EK0!WC>"?#K^*E\3MH&EMXE2#[,NLFSC^V"+_GF)
MMN_;_LYQ6U7E/_"Y/%W_ $0GX@?^!WA[_P"6M'_"Y/%W_1"?B!_X'>'O_EK0
M!V3^ M-E\9ZCXED>>2\O]+CTB:!F'D^2DDC@@8W;B96!.<8QP*\_TC]E[0--
META[C7]?U7^QA9PZ6+R6W_T*WMIUGC@79"I9"T:!F?<Y" ;AUJ]_PN3Q=_T0
MGX@?^!WA[_Y:T?\ "Y/%W_1"?B!_X'>'O_EK0!FC]E?PY%9I8V^NZ]:Z9+:0
MV.I6,<MN8]3@BGDFC28M"67#2NI,31DJ<$GK3%_9(\%)XT7Q,+C5OMJZZ==$
M/VB/R=Y._P"S[?+SY'G#SMF<^9SNQQ6K_P +D\7?]$)^('_@=X>_^6M'_"Y/
M%W_1"?B!_P"!WA[_ .6M &K\0_@QIOQ&U62^N]5U33C/H]WH5U%8-"$N+6XP
M6#>9$Y#*RAE*E>>NX<5SWC']EOPIXSUEM7NKJ]BU+SX9XYFAM+E(S';?9]HB
MN()(R&3!.Y2=P!4K5S_A<GB[_HA/Q _\#O#W_P M:/\ A<GB[_HA/Q _\#O#
MW_RUH TO'WP3TSXA>#=)\,7NIWEGIEAY?%G:V2M)L "L"UNPA88R&@$97)VD
M<8RKC]FOPS<VNL6[7VK!-4LM4L)B)H\K'?7 N)BI,?W@XPI.<#J&/-/_ .%R
M>+O^B$_$#_P.\/?_ "UH_P"%R>+O^B$_$#_P.\/?_+6@#+\9?L\SZOXRTG6]
M \2ZAX?E_M=]4O[N!X6G3_B7&S18%D@="" A8.#U8@@X K3_ +'W@B32;:QB
MGU",VLMK/;S3+;77EO!;M;@E)X7C?>CMNWJ>3E=N!C=_X7)XN_Z(3\0/_ [P
M]_\ +6C_ (7)XN_Z(3\0/_ [P]_\M: -W4_A%I&KZ'X8TNXN;I(?#\AEMFMD
M@@\QC;RP'<D<2H!MF8X15&0,#'!Y;6OV8?#VL: =(_M?5+>U?1K'0908K.X\
MRVM?-\LE9[=U#DRDEU (*J5VX.;G_"Y/%W_1"?B!_P"!WA[_ .6M'_"Y/%W_
M $0GX@?^!WA[_P"6M $ME^S[HUAK8OX]:UIX%U*RU9;&66%XQ=6UN+=7+F+S
M#OC5-P+G)7(QDYRO$'[+/ASQ/K&I7-_K>O2:;>SWUV=&2:!;6&:[MS!/(A$/
MFY(8L TA"MR!CBM#_A<GB[_HA/Q _P# [P]_\M:/^%R>+O\ HA/Q _\  [P]
M_P#+6@"VOP2$VH:/J%_XR\0ZIJ.G6UW8FZN5LE:YMKA8P\,@2V50 8D8,@5L
M@Y8@XK'T+]F#P]X>FT^*VUS76T:TGM+TZ-)+;FVFN[:!((KASY/F;@L<;%5=
M4+*#MZ@W?^%R>+O^B$_$#_P.\/?_ "UH_P"%R>+O^B$_$#_P.\/?_+6@"I>_
MLQ^'KGP_;:1%JVJ06\.AP^'R9(K.Z$MK'(7&])[=T+$MR=HZ# %=+JGPAT_4
M-#\&:;#JVJV3>%)H9K&\CDCEGDV0M 5E,L;AP\;N&. ><@@UB_\ "Y/%W_1"
M?B!_X'>'O_EK1_PN3Q=_T0GX@?\ @=X>_P#EK0!=^'OP+TKX=ZQ9WUOK&KZJ
MFFV4NFZ5::B\)BTVVDD5WBB\N)&;)2,;I6=@$ SUSE^(/V9?"WB#PYH>DRW-
MXAT6_N]0L[N6&TNG5[EY'F1HYX)(F4F4@93(VK@Y&3/_ ,+D\7?]$)^('_@=
MX>_^6M'_  N3Q=_T0GX@?^!WA[_Y:T 5YOV:]&EM-=TY/$.N6VB:U&GVW2;8
M6D5NUPD,<2W*;;<-&X$4;!481[D!V8R*TM"^ ^E:3XBM/$%YK6L:[KT5^^HR
MZA?M;JURYM#:!76*%$"+$> BJ<\DG)S5_P"%R>+O^B$_$#_P.\/?_+6C_A<G
MB[_HA/Q _P# [P]_\M: +7PY^ ^E_#77[?4[/7=;U)+/3I-)L+'4)(#!9VKS
M++Y:;(4=L%% 9V8XX)/6N:T7]F6Q%U\09]0O)K*7Q#KL.JZ?/I<P:335A<30
MF/S(RH;[09I60JR9E(^85M_\+D\7?]$)^('_ ('>'O\ Y:T?\+D\7?\ 1"?B
M!_X'>'O_ ):T 8VL_LH:'K5G>))XJ\36]_J<-[;ZMJ4$EH)]2CNC&95E!MRB
M?ZF,+Y2H0%QW->F>#O MAX)?6VL9;B8ZM??VA/\ :&5MLGE1Q87"C"[8E/.3
MDGGL.,_X7)XN_P"B$_$#_P #O#W_ ,M:/^%R>+O^B$_$#_P.\/?_ "UH H:3
M^RUX;\-V170]9US1]1CUJ36K74X98))[1WB:'R(Q)"T9@6-V149&(!ZYYJ"Z
M_9-\)W6DW6EG4]8&G7FF1:==V[-;R"X>*Y>YCN7+PM^]$TLCX&(VW89".*UO
M^%R>+O\ HA/Q _\  [P]_P#+6C_A<GB[_HA/Q _\#O#W_P M: .Q^'W@6T^'
M7AU-(LYS<1"5I3(;.UM<EO\ 8MHHH^W7;GU)KI:\I_X7)XN_Z(3\0/\ P.\/
M?_+6C_A<GB[_ *(3\0/_  .\/?\ RUH ]6KRG]H#_5?#S_L<]+_]#>C_ (7)
MXN_Z(3\0/_ [P]_\M:X#XL_$OQ'KVH?#BTOOA/XO\-V[>,]+S?ZG=Z,\*?O&
M'(M]0ED[D\(> >^ 0#Z5HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ-A27^<_+G. #ZGTK]K7X2ZWXVA\*67C&WGU>>\;3X&^RW"VD]RN0T$=T8Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGSYS*T8),K$EMQ.?O<F@"S_PRU\,/^A8_P#)^Z_^.T?\,M?##_H6/_)^Z_\
MCM>K44 >4_\ #+7PP_Z%C_R?NO\ X[1_PRU\,/\ H6/_ "?NO_CM>K44 >4_
M\,M?##_H6/\ R?NO_CM'_#+7PP_Z%C_R?NO_ ([7JU% 'E/_  RU\,/^A8_\
MG[K_ ..T?\,M?##_ *%C_P G[K_X[7JU% 'E/_#+7PP_Z%C_ ,G[K_X[1_PR
MU\,/^A8_\G[K_P".UZM10!Y3_P ,M?##_H6/_)^Z_P#CM'_#+7PP_P"A8_\
M)^Z_^.UZM10!Y3_PRU\,/^A8_P#)^Z_^.T?\,M?##_H6/_)^Z_\ CM>K44 >
M4_\ #+7PP_Z%C_R?NO\ X[1_PRU\,/\ H6/_ "?NO_CM>K44 >4_\,M?##_H
M6/\ R?NO_CM'_#+7PP_Z%C_R?NO_ ([7JU% 'E/_  RU\,/^A8_\G[K_ ..T
M?\,M?##_ *%C_P G[K_X[7JU% 'E/_#+7PP_Z%C_ ,G[K_X[1_PRU\,/^A8_
M\G[K_P".UZM10!Y3_P ,M?##_H6/_)^Z_P#CM'_#+7PP_P"A8_\ )^Z_^.UZ
MM10!Y3_PRU\,/^A8_P#)^Z_^.T?\,M?##_H6/_)^Z_\ CM>K44 >4_\ #+7P
MP_Z%C_R?NO\ X[1_PRU\,/\ H6/_ "?NO_CM>K44 >4_\,M?##_H6/\ R?NO
M_CM>=_%[]GOX?^%=5^&.K:7H'V74+7QMI<D,WVRX?:VYQG#2$'KW%?35>4_M
M ?ZKX>?]CGI?_H;T >K4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?L_:U<_%*#QCXSL/#EQLU'4]2CLK>:2\%K+/'8I"R-)"F73[+)E\*1N7'4X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&*]'H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\I_:
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MO_R)1_PFOB#_ )\/"_\ X44O_P B4 8GVOXX?] OX?\ _@ROO_D>C[7\</\
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M /\ !E??_(]>K5%<W,-G;R3W$J001J7>61@JJ!U))X H \N^U_'#_H%_#_\
M\&5]_P#(]'VOXX?] OX?_P#@ROO_ )'KTJWU>QN]1N;"&[AEO;9(Y)K='!>-
M7SL9AU ;:V#WP:6QU:RU.2[CM+N&YDLYC;W"Q.&,4@4,4;'0X93@^HH \T^U
M_'#_ *!?P_\ _!E??_(]'VOXX?\ 0+^'_P#X,K[_ .1Z]4DD6*-G=@B*"S,Q
MP .Y)I()X[F&.:&198I%#I(A!5E(R"".H- 'EGVOXX?] OX?_P#@ROO_ )'H
M^U_'#_H%_#__ ,&5]_\ (]>EC5K(ZJ=,%W#_ &B(1<FUWCS!%NV[]O7;D$9]
M:FN;J"RA,MQ-'!$" 7E8*H). ,GU) _&@#R[[7\</^@7\/\ _P &5]_\CT?:
M_CA_T"_A_P#^#*^_^1Z]&TK7]/UN;48K&Z2YDT^Y-I=*F<Q3!5<H??:ZG\:T
M* /*?M?QP_Z!?P__ /!E??\ R/1]K^.'_0+^'_\ X,K[_P"1Z]+N]6LK"\LK
M2YNX8+F]=H[:&1P&F95+,%'<A03QV!J874!NC;":,W 02&'<-X4D@-CKC((S
M[4 >7?:_CA_T"_A__P"#*^_^1Z/M?QP_Z!?P_P#_  97W_R/7JU9,?BS1Y&U
MD#4K=!HS[-1:1]BVI\M9?G8X &QE;.<8- 'G_P!K^.'_ $"_A_\ ^#*^_P#D
M>C[7\</^@7\/_P#P97W_ ,CUWWA;QAH/CC2_[2\.ZU8:[IV\Q_:]-N4N(MXZ
MKN0D9&1Q[BMB@#RG[7\</^@7\/\ _P &5]_\CT?:_CA_T"_A_P#^#*^_^1Z]
M+N-6LK34+2QGNX8KV\#FWMW<!Y0@!?:.IP""<=,U%<:_I]KK=GH\MTB:G>0R
MW$%L<[I(XR@D8>P,B?\ ?0H \Y^U_'#_ *!?P_\ _!E??_(]'VOXX?\ 0+^'
M_P#X,K[_ .1Z[NW\;^'+NSUB[@U_2YK71I)(=3GCO(V2QDC&Z1)V#8C91R0V
M"!UK1TS5+/6].M=0TZ[@O["ZB6:WNK619(IHV&5='4D,I!!!!P: /,_M?QP_
MZ!?P_P#_  97W_R/1]K^.'_0+^'_ /X,K[_Y'KU&YNH+.,/<31P(65 TC!06
M8X49/<D@ =R:AT[5K+5A<&RNX;L6\SVTQA<-Y<J\,C8Z,.XH \T^U_'#_H%_
M#_\ \&5]_P#(]'VOXX?] OX?_P#@ROO_ )'KU:F331V\+RRNL<4:EG=C@*!R
M23Z4 >6?:_CA_P! OX?_ /@ROO\ Y'H^U_'#_H%_#_\ \&5]_P#(]>@>%O%6
ME^-=#MM8T6Z^VZ;<@M#<"-T$B_WE# $J>H/0C!&0:UJ /*?M?QP_Z!?P_P#_
M  97W_R/1]K^.'_0+^'_ /X,K[_Y'KU:B@#RG[7\</\ H%_#_P#\&5]_\CT?
M:_CA_P! OX?_ /@ROO\ Y'KU:B@#RG[7\</^@7\/_P#P97W_ ,CUYY\7;CXL
M/J?PS&O6'@R'2?\ A-=+\]].OKN2<+N?[H>%5S]37TS7E/[0'^J^'G_8YZ7_
M .AO0!ZM1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
M5\;O^2+^/O\ L7]0_P#2:2NUKBOC=_R1?Q]_V+^H?^DTE &I\//^1 \,_P#8
M,M?_ $4M9/C3_D:+/_L ZI_Z,LZUOAY_R('AG_L&6O\ Z*6LGQI_R-%G_P!@
M'5/_ $99T ?(W[:OCBV\&_L]>*47Q3'X5UJ_MFBTR?SFCFGE4B1HHRGS;G16
M3/0;QDC-?!?B+XW>,U_8N\'Q:'X^U*ZO[;6IX]<DLKV47=E$^_[)#-)D/M;9
M*PP=O &> *_0C]HC]ESPG^TQ::+!XHO=7L3I#3-;2:5<1QG,NS=N#QN#_JUQ
MQD<^M?F)^U+)XM\)>+]6^&]A!K>E_#S0Y8[+3M,DA>."Y6%<?:6PH65Y'+RE
M\<E^.  +,V>B^*/C%\85_91^&.HP^.KS2[V?5[V%YYM86VU"]MRR+;2;F<.\
M*N+A68G PN> "/U ^#-_=ZIX6\$W6HZA9ZKJ4EK9_;+W3YEFMYK@*@E:-UX9
M2X;!%?E1^QWH'B+XS^(K;X8^-K+7]:^&=Q:R%$D67R-*FCS-'+%(01"6(>/C
M 83$<Y%?JK\&OAUH?PFT/PYX3\-V\EKHNG3!8(I9FE8;YC(Q+,23EG8^V<#
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M&+/@88$$@BNH\!^/=*^)'A^+6]%^UOILW,$]U:2VXG0@%9$$B@LA!&&'\P:
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MV@/]5\//^QSTO_T-Z]6KRG]H#_5?#S_L<]+_ /0WH ]6HHHH **** "BBB@
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M9]G\ ?M2?"F+P'X;1_&^FHZZ;;*RMO!!$2Y!&VM[_AJCX3?]#SIGYO\ _$T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\B\?\
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M'XB^,-5\,WO@W7?".JV%A#J)35Y;.59H9))(U*M;7$HR&B;(;':@#U*BBB@
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MGE2N-JL"0>0<U]=T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5\YZ[_R=5XX_[$[P[_Z6:U7T
M97SGKO\ R=5XX_[$[P[_ .EFM4 =-1110 4444 %%%% !1110 4444 %%%%
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M=7MH;@3Z?J=L]O<1$W,I :-P&7((/(Z$5]%44 ?FS_P49\-^/K+]K7X->/\
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MZ?LU>*]D_P!5;B!6(9I.JD.5(!Y&#CSKXT?\%!(?#WP0\>ZUX6\(^(=)\?\
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MXD/VO=MV>?OW8W<;MF/?'-:GQ!_;F\$^ O&FN^'HO#OC#Q6GAUX8]>U?PWI
MN['26EQL6=]ZMG!!(16Q]017AR?L-_%[_A6TGP+/B/PB/@VVN?VG_;(2X_MO
M[-]H\_[/Y6WRM^[^/=T_*NTNOV;?CE\*OB-\1KOX->)/"-CX?\>7L&H3WWB"
M.9[_ $>95VR-#&$>*8$9P'QU' QD@%%/VX4\ _M#?%O1_%>J7NN>'K1]%M_"
M?AS2-/B>_NIKJ#>R0KA'D)R&/F-A1Z9 -SQM^UYXE^''[6VK^&[_ $3Q/KWA
M:/P5;ZQ#X4T+2;>ZOH+DR?O9'=6  5 0<RE,_=R2,\S\1_\ @GIXH\=?%KXB
M?$A?$>F0>-9TTFZ\'ZX)IHY;:]M8T69[F)(]BI*4'W-^ > .A]>T#X >-YOV
MCM7^)^O7.@1IJO@2'P[/:V%S-(R7X?=(R[H5'DYS@YW>JT 7-6_;D^'MG\.O
M ?BK3+'Q#XFG\<>8-"\.Z+IPFU2Z,9*RCRBX5?+92&);''!->:?'#]MAM<^!
MEIXH^&-]J'AG7[/QEI_A[6M+UO38TOK$R2$2P30R!U4E>C*3WP<@UC^&?V)_
MB=\,_ OP/U;PMK'A:X^)/PX34[::TU&2X;2K^WN[B60JLHC$BLJR#G9USV',
M>L_L)?$'Q3X#\37FK:]X;?XA^+?&VG>*=56W:>+3+6"V9L00,8V=VVL>649/
M4C&2 ='^TY^WE8^$_!WQ5TKP#IWB>Y\0>%(&M9O%MEH\=SI&FWYQMBE=R?FS
M\IS&5!(R>]=*?VX_#_@KPYX7T_5M'\4^-O%(\*V7B'Q WA?2DN%TV"2%&:XN
M/G14!)+;4!..P&*\W\>?L9_&*/3_ (V>"_!&N>#?^$%^)-]+K#76MFZ6_LIY
M,&2$+&C(48J!O))49.TGBLCQ_P#\$^_&C^*K;Q!H%OX,\37%_P"%=/T'4K3Q
M)?7]O%9W5M D/VB VX!FC(7[D@&?3F@#W?QW^W7X"\':SX2TO3=%\5^.+WQ7
MHPUW1HO"FEB\>ZMRQ& ID5@P 9B"  %.3GBHO#7[=?A'QAXSDT/1O!OCK4K&
M'5?[$N-?L]'2>QMKO."DGERM*J@Y!?R]O!YQS6=X%_9,UGP/\=OA5XLMI]"B
M\.^$?!DWAZXM+,31.;F21G+P1,' BRQ^])N'H:\@\:_L&_$;Q/\ &C_A)M/'
M@?PO=C7QJ8\=>')[[3]5-IO#-!)9(/(DD/0N6^;))/.* /T"HI , #.?>EH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@?0]5UO4M&\=RZUK;:3;ZG\.=,NVT^V&P'=<><[-&%(.YR=O*BO>Z "BBB@
MHKQ;]HSQE\1/AWIEAK7A/6/#$&G3ZCI^EO8ZSH-Q=S"2YNDA,HFCO81M42 [
M/+R=I^89XP=<_:(\0_"CQ]J/AOQCIK>+K?3?#D>NW>I>$-$> 0*9YUDDDCFN
MY-L:1QI\H=G8[B 1PH!]#T5YM<_M >$[?2/$6IA[N:ST*YL;6YDC@SO:[6%H
M2F2,C%Q'DG&.?2N9O?VL_#=M=W-O!X<\3WS)K$OA^U>&TA1+^_C+B2&%I)E!
M*B-FW-M4C@$M\M 'M]%>)>,/VHM*T/PXMQIGAOQ+J6LR://K#Z:NE,)M.AC+
M)YEW&S*57S%9<(69@K%00,U7B_:FL=$\%>'M:\0>&]>EAGTC3=1U?5]+T\?V
M;8-=1HP^:20.Z@MR(Q(5&-U 'NM%>=V?QU\,WT\-M%]L^W2^(I/# LS"/.6[
M16=B1GB/RU\S=_=(..<4O[0?C[5_A?\ !CQ9XJT&&SN-9TRS\ZTBU!':W:0L
MJ@.$96*\]F% 'H=%?,7C#]JW6].^'GPMU31M,TY]?\1ZC;6VM6EVLC1V$0N8
M[6\VA7!#K/*J+N)'J#BO1'_:0T.V\66^BWWA_P 2Z7!>3W5K8ZO?6"Q6E[-;
MH[RI&"_FCY8G*L\:JVWACD9 /6:*\1T_]J_0M8T/1-0T[PCXOOY]=C>ZTK38
M-/B^U7MHB([W2J9@%B'F(,NRL20 IR*Y_0?VPK*X\5>)8=1\/ZP?#%G>Z;!;
MZQ:Z8Z)9QWD$+)]M\R0,K>;+MPB$J,;@.I /HZBN-^)5[XTM[33H?!B:-;S3
M7!^W:MKJO+;:?;JC,9#"DD32DD*H D4#)).!6=\!?B+J/Q3^&UIK^IV]I'<O
M<W-L+G3PXM;U(IGC6Y@#DL(Y H=02>#U(Y(!Z'17AGQS^)_Q#^&9U/7K"V\-
MP^%M/:TAM;'4$EFU#7KB5PK06[1RJ('R0JAHY2QR< <UF7'Q\\71^(+C7$M-
M%/P]M_%R>$'MC#-_:3.95MS=B;S/+"B=@OE>7DJ"=^>* /H:BO!+3XJ_$S2/
MB3H.@:_I_AFXF\0P:C<6_AW3?-%]IL4",T,MQ<F5XY$D8)&6$<85Y0 6P:M?
M!GXP^*/$_P 3_$/@GQ//X<U#4-*TV"^NI/#T,T*Z?.\C*UG)YLC^<RA<^:FT
M'!RBY% 'N-%>3^*/BOXDT7X\^#/!<7AI(?#.LB[6;7;N=2\TD5L9@EO&K9 !
M #/(!Z*#]X<?X4^/OB[5-;\+ZW?V>C?\('XJUV\T+3K:VAF&HVS1>>(IY93(
M8Y!(;9_D6-"FY?F;F@#Z(HKY^\<?'#QM=:OK%OX+TC3]/7P[X=3Q'JEKXIM9
M?M,X=I@EH@CE40N5MY"9&\P#*C8>36+?_M.^)]1L=;\::#8Z./A_X=ETV+4;
M6]AF;4+L7,4$TKPRK($C\I+F/"M&^\JW*\4 ?3=%>??''XA:C\.O ;WF@V]M
M>^)]0NK?2]%M+P,89KR>0)'O"D,44%G;!!VHW(KQGQ]^UIXA\._"3X<>+],T
M?3I;S4M6?3_$VGW*2,;-;:*9K]8=K@AT-O)MW;A@#(.<T ?4]%>'WGQZU.X_
M:=\.?#W2K:PN?#%WI4]S?:BRNTXNA&LL<<;!@H7RV1FRI/[Q<$5TW[1WQ)U'
MX1?!GQ#XLTI]/CO]/$'ERZK&TEK&)+B.-GD57C)"JY/#KTZT >E45X1X ^.(
MO;77M4N_B?X*^)EEI=GY\FF?#_0YOMR,6 4[1J%T6!/RA=B\G.X &KDW[5WA
MNQM=2CU'P_XCTO7K+4+333X>N[>!;R6:Y5G@"$3&'#*CG+2C&T@X. 0#VNBO
M!-6_:KM-)\8>&;:\\-ZSI/AR_P!'U/5=2OM4LC#+IWV1T5U="W09;)4,#NCV
ME@V:MM^UUX1M-'U2]U/1O$FC3V,%M=KIU[8)]JN[>>98(I8421@P,CJI4D.N
M1N49% 'N%%>(2?M8^'[34[JSOO"WBW3_ .S[JTL]6N+C3XO)TJ2YV>2)V64Y
MR9%!\O?MSDX&">G^/6N^,O"'P[UGQ+X0U30K&71=/NM0N+?6](FOENA'$75$
M,5U!Y1.T@L=_4<<<@'I%%>!:;\:O$'@C3M!U#X@Z[HFH0:EX?O/$3P:#X=N+
M5HX((89&4-)>S LOF'M\V1C;@Y)_VR?#%HMZUSX3\9VJ6-I!J=T\VE(H@T^8
MD1WK?O>(R0WR_P"M&TYCX- 'OM%>2/\ M-^$U\9?V&+75GLAJ:Z*_B%;9?[-
M2^; %N7W[\[F";@FP,=I8'BO6Z "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^:9/V--_[,_BSX1_\)AC^WM7N=5_MC^S/]1YMV+GR
M_)\[YL8V[MXSUP.E>L_'CXI?\*2^#WBOQU_9G]M?V%9->?8/M'D>?@@;?,VM
MMZ]=I^E>!K^W/X@\.S:O8^-_A3_PC6JQ^$;CQAI4-IXCBOXK^WA7<R.ZPJT#
M'(P2C=Z (?BG_P $\-.^*GB76=7OO&+VQU'Q%8:V8X],R4A@MA;RVI;SAN$H
M ); VXQM:I+W]A37+&?P[?\ A?XF6^A:QH?B36?$%M=7/AI;R/\ T_ ,)B:Y
M4?(H(W9YSG:N*^EO 7C6+QI\.= \6S0+ID.J:7!J;P-+O%NLD0D*E\#.T'K@
M=.@KQ/\ 9W_;8T'X[KX^EN-$F\*V_AA#?PRW5QYO]H:7^\VWJ#8NU3Y3?+\V
M./F.:0'<^$?AY\4-&TS2(-8^*=AJUS;:L+N]FM/"D5FMY9;,&TV"9_+);YO.
M!)[;>]>L5\T?#/\ :E\?_$*^\*:T?@OJ-M\-O%,_E:?K]KJB75Y!$<^7<W5H
ML8\J)\9SO.W(SG(KG_AG^VIXS^*FO^1I/PP\/PZ.NMS:.UU=^/;>*[Q%.8GE
M6T:V#L>"P4'GH#WI@?6]%<_X3\>Z!XYDUE-"U.+46T>_DTR_$:L/(N4 +QG(
M'(W#ID<]:Z"@#BOBU\./^%I>&;/2/[1_LS[/JMAJ?G>1YN[[-<QS[,;EQN\O
M;G/&<X.,5C>,/@M_PE?B3QIJW]L_9?\ A(_"O_",^3]EW_9_FG/GYWC?_K_N
M8'W?O<\4_BM\:=0\&>//#O@S0].T2XUO6;2>]BG\2:RVF6A2)T4Q1NL,K22D
MN#L"C"@DGL5E_:/\.^%M#T>3Q]'<>"?$-_%/)_84D,MY,!"^R5T\F,EXAPP?
M:/D8,0O. #A]9_93\074>J:5IGCJSL/#FL2:3<ZC!-HC37336*0(/*E%PJHD
M@MTR"C$<X;FMOQ%^S9=:C\/K[PW;ZQHNH17?B*]UV>T\1^'TU"PNDN)9)/L\
ML)D##89 5EC=&W(#C!*UU^O_ +1/PY\,R::M_P"*;4+J%K'?0S6\<EQ$MM(<
M1SRR1JRPQ,> \A53@\\&K&I_'GP'I/C)?"MQXB@776DC@\D12M"DTB[HX7G"
M&))'7!5&8,01@'(H \HT;]D_Q)X+T2WM_"WCZVL=0N-&FT+5)]0TB2[A-L\\
MLT?V6,W(:$PF:1$#O(-NT'.VN=\8?L)77BN V4OBO1+JV.D:=IL-_J_ALWM_
MIQM(4C)LG:Y"0)*4WL I;+, _((]9A_:E\!6&A:/>:]KEK875_91W\J:>ES?
M6]K"[%4DEF6 "*,E2 \JQ@X/I72>$/BBOBR7QVJ:>(%\+ZD^GAQ<;Q=A;:*?
M?]T;,^;MQ\W3.><  \Q\,_"JZOOVG_%WCF"UU"QTRRTU+>VBOK7RX+G5RABE
MNX5)!=1!'#'NR =Q /!->@^+_A]K7Q7^!<_A/Q'J%MI>OZKI\45_>6=N9(8I
M\JSE(R_(RI&-_P")KS/1?VS[;5OV7]1^++^%)+?5+-S!_P (O_: 9WG.UHD$
M_ECAXG23=LX4G@XKT1OVC_ VF)H4.N:S%I&IZG8VM\]KY<LR6:W 'E^?,B;(
M0Q.U6D*!L<4 <7J'[(MM=Z]XJU&/Q-)%'K&KZ?J=I:M9!DTY8+M+NXB3]X-W
MGS)N+<;21PV.>:T?]B>[LO'%AX@N_$VB3W%AJ5]?#4U\.$ZO?K<QSIY=U>-<
M$L(Q/A0BJOR#Y>F/9V^/W@%?%L_AK_A(8VU>&22!HUMYC$9D0N\"S!/+:8*"
M3$K%^#\M<;X,_:X\(^*O#.E^);N>WT#0;K3;K4+B74994GMA#<1P_P"K,(#)
MF527W#!(&&Y( )/^&?\ 7O#6E?#R;PAXKL;#Q)X2T1O#YO-4TEKFUO;9UB#%
MH4G1D<-"CJ1(0.0<@Y$"_LRWMQX/\9Z1J7C6;5=0\3W>F7MQJMQIZAUDM%MP
MQ**X#>8;?/&W;OQ\V,GK;;]H_P"'5WX>U36T\1JECIMQ%:7*36=Q%<+++S"B
MP-&)7,@.4VJ=_P##FMCPS\7O"GC7PCJOB70=4&J:5I;RQ7<D4$JO%+$@>2-H
MV4.'4,,KC()QC((H YO]H;X0>(?C1X;TW1-'\6VGAK3X[L3ZE:7VE/?P:G$!
M\L$JI<P-Y>[YF7<0^ ",9!UO!6B^//#U[HFG:SJNAZOI,%C<)=SZ9HYTU1*'
MC%LD41N)=JB/S 1R#A2".E<CX;_;!^'&K>!_#?B+4]6;0SK5E]O%E-:SRR6L
M6[:TDQ2/]W$&X\U]J'!PU=;\8_C%IWP?\#V?BJZCBO=*FU"RLWF$^Q(XKB9(
M_.#!6W!0^[:!\V, C.: .)\<_ ?QWXE^,\?CO3?'^AV\%E D&DZ3K7A:74%T
MSC$LD3+?1+YLF3F0IN"X4'&<NN?V<M5F\4SQ)XJM4\!S^)%\6/HATPF[^VAA
M)Y8N?."^09E$I7RMV<KNP:ZT?M%_#QO"W_"0#Q"#8?;3IODBSN/MGVK&[R/L
MOE^?YFWYMFS.WG&.:NZW\7]&@^#VM?$/098O$.E6&FW.H1K%(8A,858M&25)
MC;*%2&7*D'(R,4 ><?#/]GCQ[X(\0^(=1U7XDZ5K3^(#.=1U&W\,26VK.61Q
M ([IKV58TA++L01;<+T!8M72_#[X/^*-+\?VGB[QKXNL_$VJ:;H[:)8-I^E&
MQW0O(CR37!,TGF2L8T^[L0?-A?FXM>%OVF?AYXG\-:AK*^(8+.'3+.&^OUNH
MI8?)BE^XZ>8B^:C,"JO&&#$8&2<5!%^TCX9UC6_"EEH,@U2'6=3GTR[DN!)9
M3::\=I)<YE@EC#C*H,!@O#!@2.H!U/BKX>_\)-X^\$>)O[0^S?\ "-2WDGV7
MR=_VGSX##C=N&S;G/0YZ<=:\[\,_LYZMH7B71(Y_%5M=>"?#NKW>N:-HZ:84
MNH[B?S<+-<><5DCC,\I4+&A.5R3MYUO"G[37A3Q_\4],\'>&)AK$=WIEWJ3Z
MB!+"J+#)"B^6KQ@31OYK8E1BO[L@9[=K=?%'PK90ZI+/K,,:Z9J,6DW897W1
M7<IC$<6W&26\V/& 0=PYH \V\:_ ?QAXCO[O4=/\<Z=IFJ:[H:^'_$4YT)G2
MYA5I"LULGVD>1*HFE4;VE7Y@<<<Y^J?LL77G:EHFB^)[?3/A_K4NGS:MHTNF
MF:[<VB11A8+CS56-94MXE?=&Y^4[2-W'2#]J+P+I6@:=?^(=:M;"XNX9;IHM
M-2YU"."!)GB,TCI #''N0@O(J*"&&3C-=5X^^)47@NV\)W$%HNJP>(-:M-)C
MD2?8L:S[B)@=K;@ N<<9SU%(#*^*/P.TKXP>*/"]UXF>'4O#>ABXF_X1^>VW
M1W-U(H2.9WW?\LT,@"[3DR9R,8/"V'['VD:+XF5]+U2*P\&IK3:W%X72PS'$
M\EA+:7$:R>9PLGF+)]S@AASNR.\\*?'CPMKWA?4=7O-6TZR;2K1M0U%+>>2:
M*WM_,E19 [1(7!\E^B\%2.< FQ'\?/ 4OC&'PNOB&(ZS+*ENL9MYA$)V0.L!
MFV>4LQ4@B(L'Y^[3 \Z\"?LMWGPSA\-ZA8^*GUK7= BU1EN+NP&Z]DN((H;<
M-^]&!#'!"F,_/MZIFN\^)/PWUGXM_!.3PKJ6JVFB^(;VWM'N;^*T-Q;Q7,4D
M4K$1>8A9"\9&-X.#UK>\4_%/PIX)?5EUW6[?3#I6G?VO>^>& AM-Q3S2<<C<
MI'&3G''(K,\0?'?P)X767^T/$$2R1_9AY%O!+<32&=&>%8XXT9I&9$9MJ G:
M,D <T <IXR^%'Q-^(G@C7O#7B'X@^&TMM0MUCBET/PO=64B.LB/B1GU*7?$R
MJR.B["0YPX[\%I'[&-[HVD^*H;;5/!=N/$$MA+/H,/@J(:&RVXE4Q/;-.S.'
M\P,7#K('3=N(.VNXUW]K?P-H/B3PU;27JW&@:[I5WJ,&L6J33L&MY8XWB-O'
M$TF1O<L3C9Y;;@.<=/KW[17PX\-SZ7%?>*K1?[2MHKV"6W22>);>4[8YI9(U
M988V/ >0JI/?B@#R9/V+I6\*:/H$_BF"33TL-8TO4+=+"01+;7[(_EV:M.Q@
M6%HD"*YD&,@U+H'[',MEH]]9W6H>#M*DD_L](IO"G@N#3#(MM=1W#/.PE:21
MY/*52 ZHO4(37JUA^T+\/=3\4MX>M_$D3:B))X5=[>9+622$$S)'<L@AD9 K
M%E5R1M.1P:Y7Q3^V!\/-$\$:QXBT[4)M:&F_96>SCL[B&66.XE$<<R!X@7B)
M)(D4,IVX!)(I 7O%/[/?_"2VOQ%A_M_[-_PE^IZ=J.[['O\ LGV46XV?ZP;]
MWV?K\N-_0XY] ^(GA+_A/O /B3PS]K^P_P!L:=<:?]J\OS/)\V-DW[<C=C=G
M&1G'45M65Y%J%G!=0$M!/&LL992I*L,C((!'!Z$9KF_B!\4_"_PMM+"X\3ZJ
M--2_G-M:(())I+B;:6\N-(U9F8A20H!)QQ3 X/QY^SG_ ,)MI.B67_"0_8O[
M,\+7_AKS/L7F>9]IAAB\_'F#&WRL[.<[L;AC)9XJ_9O_ .$FL_%\'_"1?9O^
M$@\*6?AC=]AW^1Y!F/G_ .L&[=YWW.,;?O'/&A8_M*>$]1\0.D%]:'PM'X=?
MQ#)XB>X*1QJER8'B>-E!5E(.<D,"-I7-78?VD_AS/H%QJZ^(2MO!=1V3VTEA
M<I>^?(I:.-;4QB=BZ@LN$.X D9 - 'G.E?L=VVA?$B77+.7PC)ID^M_V[+/?
M^$+>ZUI)20[PQWTCD+&7&X'RRZ D*PX(^DZ\ONOVF?AK9^']/UI_$F^QOFG6
M(0V-S+.OD';.9(5C,D0C) <NJA<C.,U<UO\ :%^'?A[5+"POO%%LDU[#!<QR
M0QR301Q3'$,DLR*8X5?^%I&4-VS0!Z)165J/BG2M)UO2='O+U+?4=6\T6,#@
MYG,:[W"G&,A><$YP#CH:X"7]H[P;;7U])+K-B=$MK6*5;N%YI;B:5[F6V\M+
M=827S)$54HS%CD!< $@'JE%>)^-?VK?"?ACPF?$UA/!K6CKIVHWK(CS17GF6
MA17A$!A)#;I K^84*<94@G'K'A?Q#;>+/#FF:U9[_LM_;I<1B1&1@K '!5@"
M/Q H U**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S_:6^&>J?&7X#
M>-O!.BSVEKJNMZ>]I;S7[LD".2#ERBLP''937FH_8E\%^$_@AXN\.^!O#&B:
M%XT\0>&Y-&GU=VE8/*\.TYE8.ZQE^2%7L/EXKZ6HH ^15^%G[2][\"+SX93O
M\,]*MSX?CT*UU?3M3U%KA %2)G8-:A<F(2=/XBO09(RO#W[ &H?#GQUX8U#P
M[XZU/Q!X>;0;GPIXAL/$US&'&ER1%8TL_(MU&4<E@LA_X%US]GT4 ?*_PE^"
M'Q[\!+X%\&W/CKPO:?#CPE, M]I-M,=7U>TC!$5M/'*IAC&" S(Q/RC&#S7G
MOPD_8Z^(WPM\4->2> O@GXB;_A(;C5T\1ZF;M]8BBDN#(-C_ &3 =%/R_-@$
M=>]?=5% '-^#4\4I)KG_  DT.B0H=1E.F?V,TI+6>!Y9N/, Q-][=MRO3!KI
M*** /(/C9X"\2^,-3M/(\.>$_B'X2>U:"\\*>+-L")/NREU#/]FG.[:2I1E
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M7X_UK58+2W?Q#XHOKVVDL5E^S2PF&")9(FE1'=,QL Y1=^-P !%>H?\ "VO
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M(/V7$^']YX2MK/6X=,MYG@M7M;>QNO+NP[6&Q)"(W>% 'P/)S(0&(SCZ8HH
M^4=8\':[J_C+0O'5M\$9=.T?2M5\ZZ\.>?8?VCJ&;)H%NS")OL^Z%B%0&7<5
M+'@A0>7\.?LR>*+@^,K[4O!=I:Q:MX6UZ#2-*EFMI/[,GO+MY8;08<JK;2"6
M4^6"Q&[BOM:B@#Y2D^ /B6UU6#3=-\-P:?H6J>&- T'5);::WC6-8;F1[Q2H
M;+'RCLR <^9P3@XJ?%?X8>*-2\4^*[W1OAWK6E^/;F<_V#XX\$ZU'IUG+$%
MA.I1/=*9&C^ZX:&0.JC8.<#ZXHH ^1/^%5Z]I7Q2^(&J^(?AS\0?%7]KWUI<
MVFI^#?%T.EVLJI9012%H/[5M3N\R-_O1DXQSBM#XL_#[6/$?BO5-5E^%GB)M
M;GLH%\/^*/!6NPZ;J-J?*'^CZBYO4$C1R%OFQ-&5.,$CYOJNB@#Y53]G?QSX
MEU#Q#J^N74-KXW@TK0;G1O$T3H4.KVL$RSDHIW")S)L<%5#)(V/;9\+_  I\
M7R_L0ZCX(UK088?&MYH^IQMI N8946YFEG>-!+NV=77#%N.,XQ7TC10!\=^.
MO@IXHB@^(.@6GPY'B&?QAING6NDZ]%-9I#HK16Z1,LV^19(Q%(K3J85?<6.,
M-7M/P!^&=[X!D\=W.KZ=#!J6K>)+N]CO@8VENK=DB".64D@$H?E;!&.17K=%
M 'RMI'[.>HC6/#-[?^$;&26#XD:KXAOII3;NWV.5+H03,=Q+9+P87EAQD#:<
M<QX<^#'BSX>7EW=ZG\+W\<V-]IFJZ19Z7;7%BW]G&74KF>,L)I5189HI8MQ0
MEE\L K7VA10!\5#]E/QM_P *N\?Z//:07'B.\T'P]86>HK/"7O/LD0^TVZ/(
M&V!L-&#(NUMW(*YKUC]F?X>:GX8U_P 7Z[J&D^*M(.J)9P#_ (2JYTKSIS"K
M@L+?3HEBC"[]H=G9G '"A1GWVB@#XNLO@?XTDNO!OAU/ 3Z?JF@ZSK-W=^/O
MM-F(YTNX+Q8YX\2^>S,TT6]60%2@Z@ US?A?]F;Q?-X%U+1[KPOXHCUFP\$W
MVA(^KWVBIIT]S(B!8K9;6%99D9T$@DN'38<9RQ;'WK10!\(^._A/\3O&EQJ$
M-AX U71X9[K1;NTM;&/0[>VDAMOLY<WL[N]P9T,<BJD3*F GS$$UTEW^SUXQ
MNKWQ8;_PD^J:=?V7B:);6+5H+5[C[7J4,]NJR9;8SQHS LNT$ /MS7V512 ^
M=_V<=$\;^"IM?;6/"VJ2Z=JNI6R6UYJD&E6NK+&L!62:]^R2"*5$*QHK(#*<
MY*XYKZ(HHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY!X!C^;Y_P#@.:VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\/\ X?>#?%WP]OM2U>#P/<06FL+X8D\1W8N'FD,6G[FD\FS9(_+S,5+KC /
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M+6M(@U_2KK3KF2ZBM[A#&[V5W+:S ?[$L3*Z'W5@?>OCZQT_7-#\!SZKX?\
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MK@;ASC Z59E^%&FS>./#>O;TBLO#=I+;Z1H\%K%';VCR*$>12%W?ZL; H(4
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M8JJ%"I7YNM6?%OQ\\9^#_'-SX?UDZ+K.JZ%'=7HU#24N[.TG4Z5<W,<<EO\
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M(E0,9%R!C!SQXI\3S_L;?$G4[[Q%</XCMKC78EU?3+J5&B:.\F13 Y<O&J@
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M0$D_*JA5 '   '%;U_\ !;X?ZHNC+=^"/#URNBH(]-673(6%F@(8+$"OR*&
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M%8VZ :&(/EM#O:W'[OI$<R,G\)RQ'4T ==1110 4444 %%%% !1110 4444
M%%%% !1110!R?Q9U#4-*^&7BF\TFRU#4=3ATZ=K>UTI]EW(^PX$3;7P_H0K'
M/0$\5\D?#G2?B!XF\8VVC75SXZA\&76LV,LL\4^NVR^2;&]\]1=7;BX"&5+<
M,08UW%=JKN!/VCXE\1Z=X/\ #VI:YK%R++2M.MWNKJX96811(I9FPH). "<
M$UP$/[2WP^N-/DNH]4OVD6>*V2P_L2^%].\J,\1BM3#YTJNB.P=$*D*QS@'
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M33)U!C60_:-OG>4KF0>4&<JI"LXKZ"E_:5^'L2Z=(-7NYK:]2"1;J#2+V6"
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M&O0V6LMJ6B6=CJ:)*<M]E$$\SO:(P^0Q&TB+,,Y4G-1^$KGQZB:Q#J#^.?\
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M)OB=K.CVW@LZ'IFD>(+R6VTK6=8LYKE=MO:)-<YB2:+>QE<QJ RX\F4G=C%
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MO6R:)'H6A)H-G?:7>)<SZA?O>PVS-)%<//\ )M^T *)$E:0HV6!.:0'H.C?
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MC\>>*O&-NVF^%K;_ (1B&_TW3KU)(4#9N;>&5Y1=/=IL*^>-L7V=RX0X;+
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M8!#U)(?.-W( '3FO*/V=?COXZ^*.MZ>?$>@6MCHFM:,=8L9X8$MV@^= (O\
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M7FEZ+IFL:AJ^FV5KJ=_II2)8;F*=W)LXK^5R4, *N95#AN@(-=3\*?C;XO\
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MYREE)+'(.:Y#Q/>>)=<LYM#:?QY>^+M8T#Q.FLV,[WTNF7DRH1;BS1LP.!N
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M%V=$.G>1!]L+!?\ 0B<_:LF7]YOV;<#;0!]*WOPV\ :?XDD\4W?AGP];:Y<
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MA2$R0+&_RLTJJ%/!-,\6?$_X6^*_"-U'K^J66H^'I+U[">.>&5HGFAB-PZL
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M?KJ!N7B:5(_LA@\_+QJS*=F& X)KD-/_ &3+>R\,Z]I1\32R2ZKH]K8M="R
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M96VH-H]S<6XGE(DMH'N5B,._+K(L;ME=V[ SFN[\?_&?PG\,;E(/$%Y>PO\
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MF"6W!0Q(8$GMOA]\(+[2OV>6\$ZQJ)/B#5M,N5U;4V02%KVZ5S/*0" V'D.
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MKID2Z@+*WDAS*=NYF5COW<9QBH[3]O3XA2^$/$^O2Z%X<2*V\&3>+-+C^SW
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M9\3=2^%'C#Q-HP\-_$'5]+BM&AT[0?"FLV+6PEDQ)-(EPY:Y5$W-LAPQVGD
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MB78%ED79DR[8T7<& ('W:^(OC7\0_B#X@^,:_$[3O#>O:S:_!]+&RN-0TR2
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M_P#$6T/E0^)-/L],MK:]FT?Q!=M:6T7B1H[R2*([7B;S5,:1Y2U"._FAD(!
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M/XL:G?7NJZMKUFU]X?B\,W,6GW$*)+9)<I<%3NB8Y=D"L0<%20 "<USOB/\
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MP#VK6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME2&3<0RG*,N<\T >W45X*W[56F:EI?B>WT33;V^U?1-)GNY+UX(Q9K<QV@N
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MGM+C?Y,Z;)'PK>6XVMM<8Y4<4 >@T444 %%%% !1110 4444 %%%% !1110
M4444 %><W7P*\/W?A/Q-H#W6HBWU[5Y-<DN4E03VMVTJ2J\)V8&QXT90P;IS
MN'%;GQ4U'4=(^&OB>]TBSU'4-4ATZ=[:VTEE6[DDV':(BR. ^>GR-S_"W0_(
MOA/4OB&NKW5MK#>/4^'1U"PGO9K*+6WO%B:VNA(L$LR"]9//6W\SRE3&<A50
MDD ]\F_9ATZ;51KG_"9>)X_%CW$L]QXB1K/[3.DD"0-"4-MY*Q^7&@&R-6!&
M=V22=76_V>/#^M?"+P[\/6O]1ATK03:-9W+>1/,QM\>7YJ2Q/%*#CE6C(/7
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MB):?#>?Q#:@7FH2:A;:@(O[/N6N5::<"X6W,RVX#.0-[,$.,"@#USQO\&/#
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MWQ7?1:OX.^UZU_;\UQ-'#J2S0A5"R?+ ^QY 8U"Y"Y()!- 'T=1110 4444
M%%%% !1110 4444 %%%% !1110!SOQ$\:6WPY\":_P"*+RWN+NUT>REO9(+6
M-I)9 BEMJA03SCKC ZG@&O-O!W[5GA3Q-XAU#1KU+G0[R.ZMK6T^V6MR$G:>
MTBN(UD<PA8';S&18Y"&8H2 <X'IOCSPJGCGP1X@\.27!M$U?3Y[ W"IO,0DC
M9-VW(SC=G&1G%>4V7[-=X=!N[34/%$%Q?7>NZ7KDUQ;:68H]UG#;Q>6J&=B
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ML@,03M7.!>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<;U_VER*UKKXA^%;'P@OBRY\3:/;^%FC69=<EOXEL3&Q 5Q.6V;22 #G!R*
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MNB@#XI\2?"7QZGA+XDQ0R:K<>")?&$LE_P"%+;25.H:CIH$ >6TG=69V^7<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tm2227887d14_ex99-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d14_ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0R<$E<XZT ?IY+\7/ L&NV&B2>-/#T>LZA&DMGIS:K +BY1QE&CCW[G# C!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME8&L?&/P;H/BOPEX;O-<B76/%BR/HD,,4DR7JQH'=ED12@&T@@LP!SQFNSH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG '/% 'YX:G^T)X_\/?#SQMX6T_XF:Q?^"K3XEV7A>W^(\]RL]Y;:9*K-/\
MZ7C!9"JCS3TW<$<8V_VH+BZ^'U]\#Y/A?XWO_C-K>E>(]7ETZ?6]834YEN18
MHPMVG0?/MSN"GD[@N1V_0F+X5>"H/!3>#H_".A1^$F4HVA+IL(L2"<D&#;LZ
M\].O-5-#^"OP^\,VVC6^D^!_#NFPZ+.]UIB6NEP1BRF<8>6'"_([#@LN">YH
M _.O6%?XO^&?V0GLOB9XEU+6->\1:@VI>)9;@'4;*[:%?M$,0?<L'ED,BJ 0
MHPPSFH[CXV_$/PEX<U3X<7OQ-U^WT&W^+7_"(W7CB_O VIV>F&,/M:Z8?*Q(
M/[P].<8'%?HY8?!SP%I=[;7EEX)\.VEW;7TFIP3P:5 CQ7<@VR7"L$RLK  %
MQ\QQR:DO/A)X'U#3-;TZZ\&Z!<6&N7!N]4M9=,A:*_G./WLZE<2/P/F;)XZT
M ?F7\:_&.LCX5_M.> +;QUJOQ)\!>'9="ETO6]8OAJ$\,TUQ$9K<W0_UF".A
M)QCZUU/[0'CF_P#&7Q!^-F@^)OBYJWPZTGP?X,M'\/Z#9:A':6VK--:;I/.B
M<'[2&9A'M'(WC&,5^@EC\%OA]IG@R;PC:>!_#EOX5F<22Z)'I4 LY7!!#-#M
MVLV54Y(SD T_Q)\'? 7C'6;+5]>\%>'M:U6QB\FUO=0TN">:"/GY$=U)"\G@
M<<F@#\PO#OQ)^(.L6?PI^'6DZSJ^B:+:_#2TU+3XM)\50^'#<7;DJ9GGD!\]
M8\ >2#C@D]Z]>UB\^*_Q%\??LW> /$'Q1UCPU>>(O#6I/XAU+P3JL?\ IK0$
M,DD<R;H][*BYD4'&YP.IK[3\1_ 3X:>,-$TK1]<^'_AG5M*TE!%I]E=Z1!)%
M9H/X8E*8C7@<+@5LV?PW\):=>Z)>6GA?1K6[T2W:UTJ>'3XD>PA88:.!@N8D
M(X*K@&@#XH\ ^-O$7@#]L6TT3QUXT\1^*;'Q!K%W:>&+[0_%<5SI?EQQ%?LE
M]IH&4D3!+2XR7'7@U]]5QND?!CP!X?\ &=WXNTSP5X?T_P 4W99I]:M=,ACN
MY"WWB90NXENYSSWS794 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX!^,]C\4/AIJ'B[1=,U'3X8$G\N+5HD'F-&FX,K12/')&>,-&[ \\Y%?+O\
MPWSXDL_A[I?B*_B\.VT\FE>'M3OXY+*=(+:.^O'AG?S#<'Y51"5!'RD9)8'
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M<G?$=V W&2#QQ7D5C_R?1K7_ &3BP_\ 3G>4 '_"[/C!_P!&YZW_ .%5H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ?&7[0FMVHUK7/!:1-#<S7&@Z5H6I0WL 20QH?M,LS0-SM) !.#QC%2_$?\
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M7B+Q%X-\4:#9-IMKKWAVZBBN7M6QNAE$D;QNA*AN4R#R"*S?"7['_@3P;?\
M@^\LY-6N9_#CZE/NOKE)SJDU^@2ZFO"R9D=@/X2H[8QQ0!X?JO[9OQ4C^#?A
M#Q=_PBVEZ+9:GJ5];7WBV?1-2OM+AM8L?9KM;6(K<)%<9X=R0H7/.17J7B/]
MI+7])_8KU#XOVB^&M0\0VNEF\7^SYY+O2I9!*$)4ADDVD<E20RGY2<BIK;]B
MCP[H>C:38>&O''C;PJVC7=W/I-SIFHPA[""Y(,MFBO R-;@C*K(K,IZ-VKIH
MOV6/!\'[/5[\'8;K5HO#5[%(EQ>_:$:^E>27SI)3(R%=[.23\F.> * /FJT_
M;Q^(!\%_$K6+-/!_C.U\,>'DU2/7]$TO4;6PMKTS(ALKA)Y"SOL8O^[D& .>
MM=5I'[9OB;3/A/XP\8:EJ/ACQA<Z='906&G:-X?U71L7=S,(HQ-)>,P=,L,^
M6,C:?45ZKX__ &./!?C^_P#%-T^J:]H?_"4:+%HFLP:1<01Q7J1,IBN'5X7_
M 'Z!=H<8&TD$&K4/[*VG:AX.U[PKXL\>^-/'V@:M:):FS\07=IBT*,&26!K>
MVB9)%*J0Q)' XH Y#QK\:OC+\"/A]XIU_P"(.A^$->,4=I%H=QX;DN+6.6]N
M)EA%O/',TC!59U;S%89 QM!Z<1\8?VJ_C#^SO;ZOI7C'3?!6L>(+KP[-K>A7
MFBP7<=JLT,T22V]Q%),788E!6177..0*]5L_V,/"5UHWBJR\6>(_%?C^?Q%9
M0Z=/J'B+4E>XMK>%]\*P&*.-8RKX??M+%ADD]*S[S]AKPKXAL=;3Q5XR\:>,
MM2U'2QHT6K:WJ$$ES86GF)(8[?; L:EFC7<[(S-CK0!Y!X8_X* ^+O%OQ ^&
M/A^RT/0UAU72)I/$S/%,7L]22.[/D0_O<*H:S<D.&.&'/>N/TC_@I?X]U3X:
M^"KK_A'?#:^--1\0+:ZM:B&X^S0:8_V8QSQKYVX.WVR( LQ&0W%?2NA?L*_#
MKPWXNN_$>GW6MP7]UKESKTBBXA\OSI[:2W:,#RL^6%ED91G(9LDD<5B6'_!.
MCX7Z=,L\-]XB%R-+TW2?/-S;[C%93QS1/_J,;V,,:N<8*K@!3S0!R7@?]KWQ
MOXS^-VN>$Y-:\':/9:?XLGT&'39/"^KW-W<01R!0WVN.4VZ.P)&6  (R1BLW
MX9?\% /$'C-M&T75-#TK2O%-WXXMM%\DQ2B&\T>:YF@^U6X,A/F*\+(Q)*AL
M?+\P ]M\/?LGP>$/%^KZYH/Q/\?:/:ZMK4NNWFAVMU8_899Y'#2*5:T,FQL!
M2-^<=\\U3C_8A^'<;?#N;S=7:_\  NM3:WI=^9XO/D>6X:X>&8B+#0^8V0H"
ML,#YNI(!YAX&_:U^*CZ+X4\;^*-,\'W7@/7_ !:_A4VVDP75OJ5FQNI+>*8M
M)+)'(-T8+ !3SQ5_X3_M:^/O%/Q^A\$>+;/PSX7-Q?7EM_PC&H6=[8ZM%#'N
M,,\-S*3;WH<*"5B"D Y'2NX\&_L/^$?"6IZ1)/XK\8>(=$TC5I-<T_PYJU];
MG3K>\>1Y/-$<4$;,5:1BH=V S5SPS^QKX9\-^,]!UIO%?B_5]+\/:A-JFB^&
M]3U&.73].N) P9H_W0E8#>VU7D8#- &9^V'^T[KOP!A\-V?A#1K#Q!KU[]HU
M.^L[XOB+2K5-]U(NUE/F'*JF<C)/!KK?CC\:=4\&_L_/\3_!%O8ZY:6\-KJT
ML5TCN)M-9D:9H]CKAQ$Q8$Y'R\@U)XW_ &4?AS\4/B1=^,_&VC)XQO)=.BTR
MWT_6XHKBSL8T9F+0(4RKL6)9BQZ#&*Z#X>_!/0OAW\(H?AM;W%_J_AJ*UGL4
M759$DE%M(6_<[E10557*KD9"@ D]: / /''[:/B./Q3XDM/!.DZ+K.D+J.C>
M&="O+PRJD^K7R><[2R*^/(BB*$JJ[BS8W"MZT^+WQIM_&_B?X9ZD? B^-['1
M(O$NGZW!8WATV>S\TQ3126YG\Q90V,,)2I!SCBN@\.?L1?#KPQ\"U^%EK+K3
MZ3'J/]KPZN]XJZG!>APT=PDR(H#IA57Y<;5 (/.>F^&G[.&C_#S6]?U^[\1>
M(O&?BG6[-=.N=>\1W4<MREJN2L$8CCCC1 26P$R3R2: /F2X_;)^,>C?!/X:
M>.]9G\ 62>.=42S@:+0M3N$T^$1SEVDBCN6DE;=$F-G0$Y![?2'P9^,>K>*_
M!V@ZAK'E^*KC6-3FLDU'PKH%[8V=HB(6WW$=XYEC7*E=_0EE '>LK4?V.?#-
MS\,_A[X,L/%/BK0H? MW]MTC5M-N;47RR[9%R[/;O&>)6Z(.U=OX6^$=_P"'
M+32(;CXC^,]??3]0>^:?5+FT+W:M&4^SS>5;(&A!.\ !6W?Q$<4 >B4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD^)/A5KMIX@EM[_P9:0V=^([4"+6TAMI((6D7?\ NW3S9"K9;AV4YX(ZZ\^
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MNGD,#ND49(&<<ULZ+^T-XC^(T%Q=_#SP)#KEC86EK<7[:SK']G2B6>W2X%M
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M3KO2%NI82KEC-:3"1/*E(.,NL@!564 @Y /59)%BC:1V"(H+,S'  [DUYO\
M![XV6GQCU#Q<FGZ9/9:=HE_':6U[.^?[0B>%)5N$3 VHV_Y<D[EPW&<5L_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH *^3+O]NZ:U\>^+/#J>";:^709=71OL6LRR782QB=S//$;0)##(R!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI:-'IE_I4QN8;BT";P+H/!($G0_(\@P6VN0XV=QXE_:4\<^$1JGB"YL]"O\
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M/#'Q;/C_ ,6?$N^\=ZFFARZ%;P7&D6EBD,4EQ%.S?N%7<=T('/K0![51110
M4444 >$?M>?\BQ\-_P#LH_A?_P!.<->[UYW\<_A))\9?"%AI%OK\_AB_T_5[
M+6K/4[:VCN&AN+699HCY<GRL-RC@Y'M7&?\ "E_C)_T<3J?_ (26E?\ QN@
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M2]B,"_O,2.9)O+(^ZU 'N6O_  (TG6O%$GB&+5M4T_57U:RUCS(#"R+);0-
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M"-*'A34O#UYH<5S-J&KZ?9>9#+!I5DUT!#9,T<C!7"R9"IE  P#?+BO*[GX
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M_M-S(\BQKU*AFW./O-ZUREG^SI;Z1\3[KQKI/C;Q)I,MPL$+:/;0:8UDEM$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[XN\37_C/1/$$^C/J>EP6=S:7FFV4L,(6YMS(J/&\SERC C<'7<,<+7:Z?\
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M(YQJ^!?VA])\=^*+'2(/#VO:9#J)ODT_4]0BMUMKQ[27R[A4"3/(N#R"Z*&
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MC;,8XS3\&_LO&WO=7.OZ]J+Z+_;U_J>E^'[62'[';^:K112Y,/F[UC=OD+E
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M]HWBKQ/H::#JEXTP\F&.6.*>)9&6.XC24"14D4!U#\X85ZC7#_!OX2Z;\$?
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M96^LWDS^+5T_Q9%KHTW_ (5U]FM6V6!MP[7F#&;@E1F7S=_E8785ZUZYX?\
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M7J/VH;7P[+\3C<ZQJ7@T74/A_8FC?$BVV:?=1&1RSV%UOS#< @*Y5'.#$<#
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MQEP^\D@*R% HQN;N+K]H?P]IWB)K?5]"US1=.#WL%KXAU&UB2TN7M8WDN%C
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ML4%MK%L\DUQ@?NU57RS\KP.>15Y/BIX$75=:L5\7^'AJ6E(9-4MQJ4 FM%7
M+3KNR@&0,MC&10!\W:E\5/'?A%ETW5/']RVGW]EX?O[[Q+=V-C&^B17DDZ7+
MQ[81$(\Q1JIF5]F\EBP%>G?LC7D5_P"!/%%Q!KP\402>+-5:/60(Q]L7SN)/
MW85#GU0!3U  (KJ-2_:(^&MM#H;+XPT34[77-5&B6TUEJ$$\3710L8V8/@<
M CKEE&/F%,\0?M(_#'PSX;UW5V\:Z%?6F@A!?Q:=J5O-);EG$:JRA_E)8XYQ
MR#Z4 >F45PG_  O#P/:V"7NJ^)]%T*UFO9+&TFU'5[1$NW0CF)EE8'.0=I(<
M C*BM27XH>#8/%$/AJ7Q9H<?B.=MD6D-J,(NW;:&P(MV\G:0V,=#F@#IZ***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[9B6.0!D-B!?VN/#%S:_;;#P_P"(M2TT:78:FU[;P6P0?;<BT@"M.KM+(XV
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M(^)<.B>'8Y?&^@Z5:RV&I74'B8:E:0V^IRPW/EQ1F:6Q:*8JF"Z6\<9DSE&
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MH?$;Q[KEM>:YJ]ZSS6'B?P_80>%)M.M'MX)9K>SGD.YX3+YHDE=5;>-N>!D
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MWX;DEU&\O/$>N7^N7!M3!K,J62W-NUM(TD+DK;A;A\NP9YUD+*2#U.>DTO\
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MR/9R:MXH\1>()]/2RM].EOI+96L[:UN8[B.%?+@4,&>*,.[AG8*!N'6O::*
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M:_A']EOXC)XMT76M<OM)460T=)4;69[QC]CN_.D,2"UBCA1E+!(D4!<#)YX
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M5SVC_LTZ+I7CW0_$\FO:SJ3Z&2VG6=]]F<6[&#R"!,(1/Y>TD^5YGEACD+P
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M-H'RX]OE^-OPVD\-C6Y/'GA=M DE:W&H/J]N;9Y%&6C\S?M+ ')7.<&KM_\
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M7LEZL&FZ:UF\-HL:*Z":$Q1W=LRC(\QFFBE+KM*[EKG?C?XB\3ZM\7=3\?\
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M(V0*1W' Z[X1_&G7_$GQ>\):3?\ CXZAJ.J#6&UWP6UI:K_8KP,!!&"D0F3
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MLD3(QE6[$=C69X/\(Z;X%\.6FB:5'(EE;!B#-(TLDCLQ=W=V)+.S,S%CU)-
M&U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=.O=)F&GZ7#I46KRW_V2-9F\R>&>:V$L<,:-E+9Y) ,$!U/WOI&BB@ HHHH
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MR/BBZ\;K\5M3\AO%_P#PD*^)K!-'AM8KHZ$VB$0_:#*5'V7.#<EC(?-#! N
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M.,<T <)=ZAX\L?V9/#>HW,FN7GB>UN=.N+]K>RD349;1+V,R[K=-TA8VX.Y
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MTL4%N\T<S;%AMXL,7B7DD\=NF #V.BBB@ HHHH \(_:\_P"18^&__91_"_\
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M9NK;>F#6;X7_ &7O#O@KXJ:7XRT34]:MHK*UOHFTJXU:\N89);F5)7DQ).5
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M=3T72)/&.DVFLV5WHD=RMQIMN]]:0O!)(MPK,S+=*/.C,9RDBA02& ![#;?
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MKUK=W*Z-X%@N].M-6UU=%@MI+1?L%O=Z8B021"21?*C%R'.U<,I.X+CFM<?
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M_4KV#P7X?AO-38-?3II< >Z(<2 R';E_G ?G/S 'KS7RAX1_9;U^U\&W%V?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,\5GV'[-GP\T^&2%-$GFA,<<$4=SJEW.MK%'.DZ16X>4^1&)(T;9'M4[%!!
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MO01^SIX'%F\2VNK+=/=+>MJHUZ__ +1,JQF)3]L\[SL",E-N_;@D8YJYX>^
MG@/PI=6%QI.@+9S6-Q%=V[+=3G9+';O;H^"Y!/E2.ISG)8L<MS0!Y8_[7]]=
M^%M5UO2O AO8_#]@MYKT$VKK"ULQN)H/+@/E,)\-;R,6/EC;C&6.VO4O'_Q-
MU+PYX@\/^'/#V@1>(/$.L6]S>1V]W?\ V*WBMX GF,THCD.XM+&JJ$.2W)4
MFO,_B9^R!9>,;H6>BWMIH'AZZ@$%["OVTW+ W3W+G<ETD<P9Y7*K.DBQDDJ.
M=M>Q>-?AAX>^( T]M8M[H7&GE_LMWI^H7%C<1!UVR*)H'1]K  ,N<' R.!@
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MOQQXF\,G5K*T\,:=_9OA:[\1:A#?)*S7+VUY/;O##MFQ&'$&=Y,FPL!A\YH
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MO1?AGXNT[46U:R\*ZQ8R"T6]:[CMIHVQS:B0MD?\M,QY_O\ R]:\2\%_LO\
MC#X:7NBZG87.A^)[G1KQ7ALM3NIK:*YC.DVUDTC.(9#'*KP,5 5P4<C()XQO
M"OP!U+1/B=X*\+BZ:2PMK$:GXK6UM)DLO.@N99]/BAE90K!9+A@%Z[+9,A>E
M 'N\.E_!_5+#7= AM?!-W9Z;#%%JVF1QV;I:Q0[C&MQ&.$6/+%0X 7)QBFZ=
MX"^#_C#PGIU[IOASP7KOAO3&EFL9K&PM;FUMFW;Y#$44JIW#)V]2,GFOGB/]
MBGQA<>&VT.XU:R0:;826EAJ+:U=2F])NX;C:\/DJMLDGD_/AISN;(Z'=[O\
M!/X6Z]X%TGQ=+JDL%EK&O7GVE3%J,VJ&(B!(E=Y98X@[_("0(U& H.XY- &/
MX>_:/\'V.A7OB2?PAK/A'POJ%G<:]%X@NK.U6UU..-%W2DP3.R2,@3:+A8V8
M  <C U- T;X%-=:<FFZ7X!M]0\36AN+6U2WL4N=0@EPS;4 W2*Q&3C()'M7E
M]K^S#XRNAJ<2:=X3\$27NCZA8:G<^&-1NOLVOSSV[1I+-8>1'#;X=A*64R/D
M%02"2=*[_9[\<ZG!JEA<1>&X8/$-SHU]?:FM_/)=Z7)9+ K1VP-NHF!\C*.6
MBVF5\J>X!Z!X_P#$7PAO;;54U:P\->+[A=3L+34[""&TO;B.YDE6V@>XC8Y!
M0R8RW(4$#/2M_P 2>)O!?P^^$&O:E;:?97W@_0K.X2XTK1(8'B\N,$2VZQ96
M//52A(&<@XKQ*\_9A\8ZY\.M.\"7EOX5T^PTI;>VB\16%S.NK7<2ZA#<2.)!
M"IMF9(F)56DW2E3N4+D]Y+\$_$4W[+^N_"R2YTG[:=.N-(TV]A+PQ2VYR())
MPL8*2%2-^P,-P+ \X !#9^)/AWXXU;2/"/C;X81^%;BPLDN]%L/%UCIDMN(/
M,CA MF@FGC0AGB3R\JWS( IKJO%&A_!V_O[NU\167@B>^U6[BM[B'4H[0RW=
MS$%6)&#\O(@D55!RP#@#&17+^+OV9-*M_!TX\'6,*^+1/I]PE[KFI75R9A:W
M45QY!GE,LD<;&,_=! )!VG%8G@O]GCQ.WQ0N_&/BH:# ]U+J\ZP:;<2W+V;W
M<=BD1C>2%,L@M9,MA>JX')  .R\7_$[X1:/X7B\-WUUX:U/PRU[%H%WID$EI
M+9:?E'95N8RP2*-1$W!'&!QZ87B?X?? 22#P9J^HR>!].\+Q-<MIEE)]@CTO
M49)TC0NJL-DC@1( 5Y_2N<T']G7Q:\?PYTS5](\#P:;X+N+$"_M3+->ZC%;^
M9\Y+0*(@2ROY.7&\LWF#:-V'XQ_9:^(.HZ/?Z/I5YH":=?1ZY$52\>SDB%[>
M/-'NE6TDDDB",NZ!'B4LO+.,$ 'NQTSX4:IX_M+?[+X.N_&VCVZ&WAV6KZC9
M0*,H47_61HH/&,  \=:U/!TW@+Q&D5UX4?PYJBZ3-/%'-HQMYA92RG=,H,>?
M+9SRPX+'DYKYWC_94\=3W]U9IJ6DZ#I=[8W$-Y=65_-=B6673_LQDCM9H,P3
M!\%IH9T#JN#'EB!Z'^SS\%?$'PVUO4M4\0+9Q32:79Z5"MKK%QJ!=("YW$R0
MPK&@WX5 K$ G+G@  Y^U^)?PUN_%,?BZ\^#EW8+=:ZVEQ>.+K2M+D66_CF:W
M1MT=P]RI,D>Q9&C7^') Q6WI2?![XD^.?#OCW5Y]#G\2>)-'L6T;1O$9M#>1
M1HTDL<D,3%G$A,IR4)&47'2G_#3]EO1/#&G2W>OVB:KXD&K:AJ=M*VI74]G
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MTGW#:",';UH T=8^*/AWP]K0L8?A1K-]K=C;Q^)=3M-.L=.>?2#(KQ+-)_I
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MU#?)SQPG6M2RTSX4GXEW;V=MX//Q %ONN?)2U_M00E ,OC]YM*8&3QMP.E>
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M6]&?%4D>GO*+I "/]*//F*%!^]N 7VKRJ7]E#QEXA\+GPS?S^'O#UI9Q:_\
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MOY?.92Y'5B>:Z2R\'Z/I^MZQJT-DHU#5S";V5W9Q,8DV1_*257"G'R@9[YH
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MC,\-_'?P1XCT:SU/_A(-/TJVOM0N=-L?[3O8(3>RP3-"WD_.1(&9<KM))!'
MSBO%/#O[,WCW0KC3-:NKSPYK&L:9<:9=QV#2-;6UTUNMZC([16P5"JW:,LBQ
M?,\98HF>.:G_ &._'!M[R0/H3/J]IJ%A=Z7::U=6=G9I<7\]T"A6V+3IMG :
M/$1)C7##J #ZYLO%^@ZCKMUHEIK>G76LVB;[C3H;N-[B%<@9>,'<HR0,D=ZH
M6WQ/\&WEWJMK;^+=#GN=)!;488]2A9[( X)F4-F/GCYL5S/P?^%$WPWG\:7%
MP;*6[UK5S>PW4(9I##]F@B592P!W Q,<988(YSFOGV?]D?XD:[!>QZM>^'?W
MOA[4=$Q'?R?9W:XGAD5H[:.SCCMXOW390;VRW+-UH ^HQ\6? YT!]<'C+P^=
M%2X^R-J0U2#[.LW_ #R,F_:'_P!G.:/!GQ,T/QOX*T3Q1;7'V#3=9VBT&H.D
M3NS,55.&(+,1P 3FO(-<_9^\2:?\8+KQSH%MX>O[=+I'M]"U"XDMH70Z>MH[
MLR02!)%*C;A6!1F!*YK=T;X%:I;_ +,&F_#NYN-.M?$>GV2&TN[(N;6VO8I?
M.MW0E0VQ9%3^'. 1B@#TK6/B3X1\.E!JOBG1=,+W1LE^V:C#%NN  3"-S#+@
M,OR]>1QS6'9_'GP!=3>*$D\5Z38)X;OUTW4IKZ]B@CAG9%<*69@.=VWG&65A
MV->0Q_LX^,=!L;>ZM(_#7B36]4\/7VE:X-7N9H8$N[N<SS7,)$$AD0NY4QL$
M)6./YAC%84O[*'CC2;RRDL-4LM1BTG48[VU<ZS/83WF[3(;*0R.MM+Y3JT&Y
M2/,W+*X.P\D ^K)==TV#3X+^34+6.QG,8ANFF412&0@1A6S@[BR@8ZDC'6LK
M6_B3X1\-1R2:OXIT72DCE:W=KW4(80LBA2R$LPPP#ID=1N7U%>8S_!#6[/\
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M@?$W0O%'BJ]T/2[C[:UMIMKJOV^!TDM)H)WE6,QR*QW<P.3QC!&"><9'A_\
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M!\'M'\&^(ET)KK1VDMX;GP_&8H;J#>3'-)&8T"3,#EP-P+9.XYKU2@ HHHH
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MP\+7/AZUT1[;2YY;:X*Q7UPLL<MO%'%!)'-YGF1NB0Q@,C _+G.220#'T?\
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MU;]GKP'KVM7^IZEI$]\]\TTDUG/J5TUD9)8C#+*ML9/)21HV92ZH&^8\Y)-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB.=Q/S$<G''H!7JU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\-^'M/TW1KW6YM:\.VW@>?P9/97-J!).);DW#7(D#80AF.U IVX7YN*^HZ*
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M*_QR\4>$_C-8^$M+32+*S:WLKA&UB:"$:AYUP\<RQR2W,3 QHH($<<I+.N0
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M3$'/.0C\ \#USXD_&'Q#\/?@UX5UG6+NRT7Q5J^Q94^QQO DQ@>8Q9GNH$3
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MUP/3/C7\8O$?PZE\,MI=C;7<7B>!M,TY9(G<QZO(8S;!R&'[HH9BW0_NNO-
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MZ9HKX^UC]J/QN_BOQM:Z3J'AN&'0YKFUCTZ\B1I]Z7D-O"^T77G.I5Y'<F)
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MXML/$0TCQ3IVEZ=IEWHUY_;4EA%%]GMYM1:">.9$O)=B!55CYIC<#<&5<@@
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M2_&OB#Q[8)H=]9^'M0T75M/A0:U(T5ZY\K["VY[YSD[7X\F$)N926!).M?>
M/'K:Q!,WAWQ7<>!]]KYGANU\11PWY5; H/WOVQ1A)^67SOF)5OFVT ?4P
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M]9TR\LM5BAT9-:BL'L;R6*!;9V;^TI3);@K/\K3.0TC?N]I%>H_$KP9XKN=
M\ VD.D:WK.DV&F2V^IZ3X?UA-/N?M?D1K;R&0SPAD1ED! <X+*VUL9 !Z3XD
M^*GA'PC?WMAJVK0VEU:6\=W<1>4[F-)'V1[MJD;G?A5^\QZ UOZ'KFF^([+[
M=I=U%>6[.T9EB.<.I*LK=PRD$$'D$$&OE*]_9G\5ZXE_=:_;7NJZY=+X4^TW
ML6MR1K<26LP-\^!,O*J,YP"3DIR:ZC3_  )X]LO%VFRZ[I7B/7M!CO-3:V@T
MSQ L!LY7U O;7$_^E1F2+[/@!<N5 92GS8H ^CY[.&YMWADC!C="A X^4C!
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MAM;_ /D2@#W:BO"?^&U?AC_U.'_A#:W_ /(E'_#:OPQ_ZG#_ ,(;6_\ Y$H
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M_P"0Z/\ AMCX5_\ /QXL_P#"'UO_ .0Z /=J*\)_X;8^%?\ S\>+/_"'UO\
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M ,_'BS_PA];_ /D.C_AMCX5_\_'BS_PA];_^0Z /=J*\)_X;8^%?_/QXL_\
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M?ZP?WJ[;P_H-MX:TN+3[6:]GAC)(DU"^FO)B2<G,LSLYZ]">.@P* -*BBB@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tm2227887d4-tbl_selct4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-tbl_selct4c.jpg
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M -H  0 !!0$! 0             ' 00%!@@" PD! 0 # 0$! 0
M   ! @,$!08'$  ! P(# P0(#PP( P4&!04!  (#! 41!@<A,1)!41,(87$B
M,I/3%#>!L=%R,[,T=)2T%196%QB1H<%"4B-3<S55=3;A8H*2LD,D./#"@Z)4
M9"4FTF/#A(4G\:-$165&**345Q$!  (! P,!!08$!@ % P0#  $"$2$2 S%!
M!%%A<2(R$X&1L<%"!:%2(Q3PT6)R,R3A\;)#-(*B%<+B!A:24R7_V@ , P$
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M$A(&]16?CSV,:8-ZC2(3K)BK8T08@[1M5(F8ZIQ K3&%8G(H2(" @(" @("
M@)C(8J<YF81/L[F/(H6$0(" @(&" @(![" @( 0"@(""&^M-YE;R/_$47M[5
M(Z5RC_*UC_A])[0Q!FG;CVD'#6IO^]&V>MMOQ4H.FW;SVRH%$! 0$! 0$! 0
M$! 0$! 4BF/]"B?9T1GUZJHDY%,=23''=VE'32#KG/<[:=) D#>IZ:QU177W
M&(Q.WU%&4FPJ9A(2.51TC7NCO[C$;E,QI[B/Q@4 @(" @(D1 @(" @(" @("
M @(" @((PZPGF?S)ZV'V]JE+9.J%YD;1[YJ_;$0G9W>E!S'UI_YUT<_C4_\
M\!!*/XSNV5 (" @(" @;M^Y$3)CMP4Q/9;&F3$;L=JB81DY<.7F35.(,40("
M @(" @("!B!O3V'L4XN3!3;2=$SI*H.S%))@4(,<$M\,:=UJ:YF5.(8X<O,I
MZ1B.K.ORSE50L(" B1$" @("!VD!!0[B@YCZXO[*RK[[G_P!2.QM/_Y&RW_#
M*/VAB#8T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$'/?7/\R=3_$J+TWH+'0+S0Y7][R>W/4)2,B! 0$!)!1E
M.!6P@4 @(" @(" I!1&LX.PIQIE&10L(@0$! 0$! 0$%.5!RSUG/.GIYZV/X
MZU2.[X/8(_6-])!]$'(FEOGOU:]]1_\ *H2F]$" @(" @*3KHB_5'52HRA54
M&5\JV\WS/=V=A16YO>1QX'&24XC!HP6?'$\MYK7TS[&MHCCKNMTSAIK[%UKV
MR?+8S+9C3C\^<OMC)>X#;T7&8-_)WRTK\$XG7W,_^2,UT][==)=5?G]!66R]
M41M.;[3(8;E;G[,"/QFXDDA;XB](O7I+*9FE]MNJ0ZNY6V@#3<*VGHP[O34S
M1PX]KC<,5S9AK$3U?6"JI:N(3TDT=1 [8V6%[)&$\P<TD*^V>^BN8SIJ^59<
M[;;PTW"MIZ3B.#?*9HX<3V.D<W%4S&<96Q/H]0UE'4Q>4P5$4M,!Q&:.1CV8
M<O= D8>BE_AK,R4UM"(LB:LU69]1\Q6"NK*.&T6UW0T#&2Q@RD#O@XG%V/\
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M/Y+57*D@J>2"6HA9)M_JN<"L*SF=&MZS$,3GVZ5EGR5?+S:Y>BKJ.BFJ*6?
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M_#*/VAB#8T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M?I3_ *5UKGYR],@/^_$#G5?V^,>;/N1YD3'ARP]US';M/>LC47;-4@H;/=*
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MU2]=:F2K;EJQ,D#_ )MNN48OA8"1T&/+V%CQ[?KXM\N):UG;QVQ.N5G<\VZ
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MYO%'_2OG3_$N_D_Y>'W2TOJ^:I97R;6YILN:*D6RFJ;I/-3U\P=T!<'N!82
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MNN+^RLJ^_)_\ 4CL;3[^1LM_PRD]I8A+9$! 0$! 0$! 0$! 0$! 0$! 0$!
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MPXGR8.&/*0M^"OT>*UOU7Q_!GSV^I:L1^C/\4^5-)3UU/)25D3:BEE!;+#(
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MT(9S!KL1Z*O:V;;K:Q[45KMKMC3W,%9])],\OUIN5ERK;Z.O=M-1'%B['?\
MC$A6I?'LCV)O&>NK-7[+&7\TT;;?F*W0W*B8\2L@G!+!(SO7;"#B.19:[HGV
MK=*8[87_  4]#2AK&]'34[,&L:,>&-HW =A7O>.L]D4B)]SF_.^:;1KMF>PY
M'RE#/4T-HKW55[KY8'1-B,/<< +P.^*GQ.+/-'+:<1%=/O3R6VTFD?JT=)PQ
MQPQ,AB;PQ1M#&-&X ; %$WFV<QW9<?RQ'H^BA<0$! 0$! 0$! 0$! 0$$8=8
M3S/YD];#[>U!LG5!\R-I]\U?MBD3L[O2@YCZT_\ .VCG\:G_ /@()1_&=VU
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M//4,)>S XC#A(Y53CCZ=LPVM?=&V5Y!E/+=+?),RTUMABO\ -"*:6X-!$SH
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M"%#O1#ECK.>=/3SUL?QUJD=X0>PQ^M;Z2#Z(.1-+O/?JS[ZC_P"50E-Z B!
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M).*C2TXC5-YS\T891D@D8'M<'-(Q:YIQ!'.KZJYS+VJQ.# JS&5A3.J.@G;
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MCNQ/5A8T6K-. _\ W><GMK:O_P ;B]WYL;__ ">2?=^#XW9K?M3VW9_^UC_
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M*'<4',77%_965??D_P#@"#L?('\C9;_AE'[2U2-C0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0<]]=#S)5/\
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MY+=(Z(\CFB.#97K>6<C#8^M"Z('8VTQ@>@7*O@SIS^V:_FQ\J->/V1;\D_\
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M^832^4?,SRLML JPX.+!O+2[DP79C_KUF_S9EA:(GFGZ?I]GW.A%RM%>1!1
M0$! 0$! 0$ [BB7,/7%_965??D_^ *4.Q\@?R-EO^&4?M+$&QH" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(.>
M^NAYDJG^)47IO06.@7F@RQ^HD]N>H2D9$" @(" @(" @(" @(" @(" @(" @
M(" @(" @IRH.6.LYYU-//6Q_'6J1WA![!'ZQOI(/H@Y$TM\]^K7OJ/\ Y5 F
M] 0$! 0$! 0$!"6)K,M9>N%R@O-?:J6IO%+[FKI8FNFB&&&#7G:%-)V7FWK!
M;,UBD]M5;OEVPY@\F%]ME/<6TCQ/2BIB;((I1@0]F.XX@*M8UWQU6K.EHGI.
M'UNMFM-[MTMHO%##7VJ8!LM%4,$D+VM((#FG80"-BM>?BBR*?#6</K0V^AME
M)%;[;31TM!3M$5/2QM#8F,&P-#=V&"CDS?,RK68K&8A@F:;Z?1W/Y;CRQ;6W
MC'B\N%,P3<7/Q88JT:3IHO>,SJS5SM-LO-$^V7>BAKK?+@)*6=@?$X#=BT[%
M6V)MG&INF(VQT?6DH:*AI([?14T=/00MZ.*FC:&QM9NX0.97F=TS%E:Q%-*]
MFO\ U;:>B[?+OS6MGRSQ=(+AY,SI^/##'BPQW*E/@B(@F-_5M  : T#  8##
M9N4VG=KT(T]S6KKI[D.^UPN=ZRS;KA<FD%M744[))01M[XCG44B*SNKI*UIW
M1BW5L,,$5/ RGIXVQT\30R.)@#6M:!@  -P 4VF9TMK/=E%?1@8,@Y'IKL[,
M%/ERWQ7QQ)=<64[!4'BW]WABE?AS%=(:<GQ3$>B[H,JY:M<=9!;;124L-Q+G
M7!D,+6"=S]YDP'=8\J3.:[)Z)F9W;H^:'WM%CL^7Z1M!8J""VT+3Q-IJ:,1Q
M@GEP&Q)SMQVA&8FV>_=B+MISD"^UHN5ZRO;:^X-((JJBF9)*#CCWQ&*17&L)
MM.[2>K9*>G@I(&4]-&V&GC ;'$QH:UK1N  W *TS,]6<1CY=&M773?3^]7'Y
M6N^5[;773N<*RHIF/E[C=W1&.Q4IMKI6%[;K:RV6FIJ>D@CIJ2)D%/$.&.*,
M!K6@;@ -RMF8ZZJUQMG;H^BJ1T$2(" @(" @(*M_"B7,6F?^]&O[=T^+.4H=
MT((>ZT'F1S1^JC]L:@C/JO\ F;M7ONN]N4"84! 0$! 0$! 0$!!0G#M_\;4S
M@QJUV_Y!R3FJH95YFR]07BIC:(XY:VG9,]K1M !/(J[-LY]5YOF(CV,2-%](
ML/Y&LH[5''AZ2O,9T9SI&68L>1LF97;4,RYE^AM3*L<%4*.!D0E:1A@[AWC!
M3:V8VHFF+19?6BP62P4\E+8[=3V^FF>9)8::,1L<]VTN('*5$_+L]&EK?'O]
M7FUY<L%CFJY[/;:>AFKI.EK9*>,,=-)CCQ/(WG>D3BD1[5=)ON6F8,DY/S2Z
M-^9K#0W9T6R(UD#)2T<P)!5(K7,K3:TQJR5LM%JLM&RW6>CAH*&+9'34[!&P
M=H!:3:TQ$S.84K6L:1I*UOV5LMYHA;39DM%)=J9O>Q5D+9FCM!RI-*Q.>ZT3
M:T8?:S6"R9=I&V^P6VGME"W:*>DC;%']QO,KVM:W7HI6M8TA95.2\H5EYBS)
M5V*BGS!3G&&Z/@::IA'*U^_E2L[)Q3JO;XNO1][]E7+>:J=M)F:T4MVIF.XV
MPUL39FAPYN)4V[9W=TQ:>G9]K'E^PY;HQ09?ME/:Z%O>4])&V%@Y=S5>9M/N
M4TKK]SR<NV'Y8^<(ME/\O%G1?*/1CRCHQN;Q[\-JKQXKNQWP3$SU[,H-VU(Z
M?:FOY,;>;%9<QT3[9F"WP7.WN(>:6JC$L9<W:#@=F*3$6F)[PM69TCMW?:6U
M6R>WFT3TD4EK='T+J-S 8>BW</">1)C=K96G].,0^=KM%JLUNAM-HH8:&V0L
MX(:*G8&0L:<<6AHV ;5:9F=)Z8*XKK'O^U\+-EK+^7&U#<OVNFM;*IYFJ64D
M8B$DI&U[L!M)"1.FO1/)_4MN[]UI?,AY)S/41U>8\NV^Z5,7L4U73LE>WL D
M+.E8S-HTGLM:UM*SK#,TE#16^DCH:&FCI:*(<,<$30R-K<-@ "UFTVC$L\5B
M-.RULV7K#E]L[+';*:W-J9#-4BFC$?22NWN=AO*B+;:UHFT;KS=9W_(^3<U/
MC?F:PT-W?%[&ZL@;*0=VPE9Q2(M./5>W)-H9.V6JV66C9;[120T-#%LCIJ=@
MCC;V@%K.9GXIRQI$5Z1JLK]E3+&:(6T^9;-27:!IQ9%61-E:#Z(6<UBTY[M-
MTQI+[V>Q67+U(VWV&W4]LH&G%M/2QB*,$C G!JTM:9IB58K$?+UE87S(^2\S
MU$57F.P4-UJH?8IZN!DTC,#B,"X;%6(VZPM:T[,=ERW+&7&W2*^,M-*V\P1]
M!#7-A:)XXAL#&N V# ;DFVF8[]4:8BL](U^U[H\NV"@NM7?:"UTU/>:\ 5U?
M'&&SS!N/#TCQM.&*F,UZ=$VM-IBUGRO^4\KYJA93YELU)=X&;6QUL+9FMY?Q
MEG/'6;9^U?ZFGV/O9,OV++=(*#+]LIK70@XBFI(FQ1@GL-6M^2U_=#&*XU?.
M_P"5LM9I@;2YDM%)=J=FUL=9"V5H/. 5E''&<M)Y+1'LE6PY8RWE>F-#ERTT
MMIHR23#1Q-B82=NX+6>2>D])4^G7=$=F65,83D0$! 0$! 0$! 0$$-=:?S+7
MGWQ1>WM0=+91_E:Q_P /I/:&*1FCN*#AK4W_ 'HVWUMN^*E$NFW;SVU"%$!
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M,0;&@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M"#@[)N:-:;78*>CR4ZZMR\U\CH!10.E@Z1SL9,'!A&/$@SWSYZRGY=^^"O\
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MXM$GSYZRGY=_^"O\6@?/GK*?EW[X*_Q:(/GSUE/R[_\ !7^+0/GSUE/R[_\
M!7^+0/GSUE/R[_\ !7^+0/GSUE/R[_\ !7^+05^?/64_+OWP5_BT'GY^=9+'
MAZ6_8\WDK_%H*_/GK*?EW[X*_P 6@?/GK*?EW[X*_P 6@?/GK*?EW_X*_P 6
M@?/GK*?I+_\ !7^+0/GSUE/TE_\ @K_%H'SYZRGZ2_\ P5_BT#Y\]93])?\
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M<#$ <.^07U'B:>,GF07" @(" @(&"#Q+[&_#?PGTD%A:"YS)<3C@1Z2#)("
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M/_Y&RW_#*3VEB(;(@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @YZZZ/F1J?XE1?XG(-GZL7F.RG^HD]ND2"4O
M(" @(,3#^U7=MR)94;RB%4! 0$! 0#N08F[]]%VG>F@OJ+W+'VD%P@(" @("
M @\2^QO[106%G[R7UP09) 0$!!Q1UQO.[IO^K9\>8A#M2'V&/UK?20>T',N@
MGGVU?]\Q?\J)=-(@0$!!BKQ_E>B@O:'W)%VOPH+A 0$! 0$!!;U_N27UJ"RM
M'>R]L(,J@(" @(" @(,%5^[_ .T/309T(" @(" @(""RNGN-W;'IH/=O]R1]
MI!=(" @(.(\C_P"^&Z_K+G\6<@[<00_UH/,CFC]5'[8$&%ZG7F*L_ONO^,.0
M3T@(" @Q4O[6;VV^D@RJ @(" @(" @QUW]BB]=^!!][=[BB]'_$4%T@(" @(
M" @H=Z#%VKV27T$&50$! 0$! 0$&#N7NOT @SB @(" @(" @M+E[D?Z'IA!;
MV?V.3MA!DT! 0$! 0$%'=Z4&$H?VCZ+D2S@W(@0$!! '7*\PE^]\T'QEB"9,
MH_RM8_X?2>T,09H[B@XFSO\ [X[-V[;\4>@[9;RH*H" @M;A[ED[7X0@^=K]
MS#ME!?(" @(" @("#!T_[0'KW(,X@(" @(" @(,9=_\ *[909"+V-O:0>T!
M0$! 0$%O6^Y9?6_A06-FWS>AZ9099 0$! 0$! 08A_[6;Z'I(EET0(" @AOK
M3^8[-'ZN#V^-!C.J#YDK3[YJ_;$$[.[TH.:NLSYPM%/X]+Z<"#I5O>H*H" @
M^%7[GE]:?208^T=\\=I!ET! 0$! 0$%"@P<?[2_ZA1+.H@0$! 0$! 08Z[^P
ML]=^!!];;[D9VSZ:"\0$! 0$! 04*#%6OV:?_CE0EED! 0$''77P_9F3_?<W
M^!!U#I\<<C9<_AE'[2U!LB @(" @(" @(" @(" @(" @(" @* 4@@(" @("
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MW#W+)VOPA!\[5[E';*"^0$! 0$! 04*#"4Y_\P'KW(,X@(" @(" @(,7=_\
M*[909&+V-O:0>T! 0$! 0$%O6^Y9?6H+&S;Y?0],H,L@(" @(" @(,2_]JM]
M#TD2RR($! 00WUI_,=FC]7!\8C08OJA;-$K1V:FK]L03N[O2@YJZS/G"T4_C
MTOIP(.E&;D'I 0$'PK-E/)ZTH,?9^_D09= 0$! 0$!!0_@08./\ :7_4*)9U
M$" @(" @("#'7?V%GKOP(/K;?<C.V?307B @(" @(""A08NV>S3_ /'*@RJ
M@("#CKKX?LO)_ON;_ B74.GPPR-ES^&4?M+40V1 0$! 0$%OTG=8<KC@%$SD
MQA]N4;=H3H/2D$! 0>2[ [=R#QTNW8,>91D>A*UPQ'W.5.@\=,<<.'9R[=JG
M(^A<1R*!028D;,,4R*N=PC%2*=)NV;U HV3B.&S#MJ1[!Q050$! 0$! 0$!
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MN<QPQ!]$*)K,6F)16VZN87@.(Q4+*H" @(" @(" @(" @(" @(" @(" @("
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MT\30R-@W!K1@ %:;S,S,J5K%8Q"Y:, D)54@@(" @(" @(" @(" @(" @("
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M;22XXXM\J9&".SB@EJWW.WW6E966VLAK:.08LJ::1LT;ASAS"04%\-R @("
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M]]U_QER">D'B0N [G?R((#U*UHS#4W\Z::.4C;UG4M_U]>3QT5N:>65[<1Q
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MFG;B@AWJ_P";<P9>OMYT'SU4OJ<Q98_.V2OD+G.JK2XXQ$DD[6,<P;T2Z,C
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MY))6T\SL0>_DDP;L'Y*(;EH_K//G:X7#)><+8<OZAV396VM[L62QM<1TT)<
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MDNBM,#FFJQ Y'1ER"<<JY?MF5;!0Y>LU.REMMNA9!3PQMX6@,&TX=D[2@S*
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MI"W+,1?Z==<=97>3<U:GZ.:GV33+43,#\VV',3'_ "3>JAKC6"1C22'N<XG
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MCAZ!"#?D! 0>7/:W'$X8;4'-FF#QG/K$:F9G&VV6:"'+].X.)XI&R]*YV.&
MW;D'0PM-+A^-]W^A!7Y)IOZ_][^A ^2:7^O_ 'OZ$'E]IIN$\/%CV3_0@YVT
M:K(=/]<]1=/+O((9LQU/S@L;G[.GB<7-<T=EH&*)=+A[3RH@XV\Z#G#K*W&'
M-&8<AZ66\F:Y7&\4]?7Q,./1T5,3QEX')W7*@G^"STK(8V=U@QC6C;AL:,.;
ML(/?R32_UO[W]"!\DTO];^]_0@&TTN'X_P#>_H0<[:IB3*?6&TRS,^,FSU[)
M[(^8G'@J*ES2S'F'<G:B72K'-=WJ(>T! 06EPK8+?25%=4.#(:6)\TKW' !D
M;2YQ/H!!SUU6K=#=K7G;.;2YU)F3,==44SFG .CCE=@YNS<<4'0(M-+_ %ON
M_P!""!NN'114^@]]?'CB*JAVD[/=#$$VY1_E:Q_P^D]H8@S3MQ[2#B7/C&R]
M>"S1NW'Y.!^".0=EFUTY/%W6./Y7]"#GBSRPY;ZW5TMD@>QF8K##)3%W>O=3
M"1SQCV$'2D9)QQ[';VH/: @(""AW%!S3JDXYAZR&FV7Z4%TEJ;/<:QX& 9$_
M!HV\^(0=$_)5-CCW>WLCU$#Y*IOZW][^A!"/6RRU)5Z*WBXVUCI+AE^6&]T@
M[_"6B=Q X8;=Z"7<E7RBS%E6TWNAE$M+6TL4K7MW$\(#MW9!09X''<@J@((8
MZT>8CEO0_-T\,[H;C6TIHK<Z,X/-3.0UH;V4&TZ8Y/@RUD#+=A?'T1HZ*-CF
M,. !=B\_?*#;_DFE_K?WOZ$%?DFE_K?WOZ$$&];3+K*C1>ZW")KW/M531UQ&
M./<LJ8PX[N0'%!-.6+O2WZPV^[T4@DI:R".:)[3B"US0@RZ @("#G'K)/I<P
MYMTPT_C?QW"MOL=Q=$PX/%/3QR N[#01O03^+538;2_=^5_0@&U4P&/=?WOZ
M$$#=:NWBAR';+S&'.I[;>;?-.-YX#.T%W:&*">;/60W"W4E93D.@J((I8W#:
M"U[00H2OU*! 0$%,0@YFND=/F/KC6L,)(L&7'";@=N<^64C'9_61+HOY)I?Z
MW][^A$(^UTRN;QI!G*VTA<*F>VS%F/=;8\'X88<O"@IU>;LR^:.9/N+(Q%Q4
M(C?'CQ%KXGNC(Q]!!** @(" @U#4R]T^7LAYBO-0X-BHZ&>0DC':&G#9VT$=
M]5^P34FC=B-QC=%4U1FJN#$;&SO+F\_(@^O6?H8:?1'-#VX\71P;SC_GL06W
M5"\R5H]\UGMJ"=G=Z4'-/6<:'Z@:*L.YU]F!]'H$'1'R73.)<2[;V?Z$%'6F
MGY.+;LW_ -"#GBCCILD=:^IZ27HH,YVKC8QQV/GI2&C#L[42Z6;M:$0J@(*'
M<4'/G6MO,;<F6?*D0X[AF6ZTE-30@=TX,D8YQ'+L!03-9['3TMLHJ3%Q$,,<
M???DM'807_R32_UO[W]"!\DTO]?[O]"#G?K+L?E7,.F>>86E]#:[T*:N#MN#
M*T"-KNQ@4'2<,C'QM>QP<QPQ:X<H.XH/H@("#SQM(.!VH.9- J6#,&L.LF::
M6026N>[1TL+V;>(QL+3@?01+H_Y)I?ZW][^A$*?)-+_6_O?T(/+[52C ]UCR
M;?1YD'.>G?!E/K19^L$SNAI\P4$%QI(1B&23=QQN&.\X8HETVS:W9]U$/2 @
M\&5@QQ.[>@YHTU:W-G64U$S/3 FTT=+36KIAL:Z>(,#@#RX8%$NC/DFE_K_W
MOZ$0?)-+_6_O?T(/E46>F?"]@+AQM+<<><8<R" >J75-MU#G?*$X,59:;_52
MOC>.%W!4<):[M'!$ND X.W(A5 0$'ATC6M+B< -YYL.5!S3H5')FG5K5'.#H
MR+7+61VVDF8< ]U)@QYY=V"#HHVJFP_&_O?T(.0^O131T]JR>&8[:N;'$X[>
M#M(.J-/_ .1LM_PRC]H8@V- 0$! 06=QKH;9055RJ2?)Z.&2HF+1B0R)I>X@
M<NP),Z+5C=,1ZH/^UYH\]NRIN&!_\([U5R?W57M?_A/(]GWL/?.N'IW0T8FL
M%%67BL#PWR5S?).X.]W&\.&SF43Y=<-N/]AYYGXL1'WM>^V[;.3)56/_ )^'
MQ*R_O(]'5_\ U^?Y_P#[?_$^V[;?H76?#X?$I_>1Z'_]?_U__;_^X^V[;?H7
M6?#X?$I_>1Z'_P#7_P#7_#_]RL?79M,DT39<G5D41>ULDWET3N!A.UV B!.
MVX*T>7"MO_X_.-+_ ,/_ !;Q'UN-'&#;4W#X&X_A"T_NJN+_ /!^3VB/O;WI
MSJ]D_5,W$Y2DJ)/DTQBI\IA,/L@Q;AB=NY;<?)%W!Y7A<GCXW]T@ C!:N%\'
M!IQ'.,"#N(*KU&,<RUV6CGG8R"AHV!TU0\-;$P  ESW88=M4F\5C,]EHK,SI
MUESQ8(I-<M:J//M+ 8\B9*,U/;*YVSRZJ>7-<YC<-K&X;PNCQ:SQ5MRV^;DC
M$1[([GD<D6B.&OZ9W3/M]'3D>UV([W^A9Y4A]E*1 0$! 0$! 0>9&E[2T<JB
M1$^HFBS<UW>/->7;FZQYN@P+*QF/1O<P=R7!O= C##$?<2ND^PG6&$GR-UB*
MVF-NJLW6F.C<.!U1#TXJ>'=CCY.-IY>Z5IBLFN&XZ8:5T6G%OJ&,J#7W>O<)
M*^O?L+W#;@T8;&XDG:K7MF-O96L:YEK&9-&,Q4N:Y<YZ:7F"S76K!\NI*H/\
MFD).)[QCS@3M+2T[52F8C$]%YQ/O6@T;SYF^\T5PU3S!2UMOH'B6"V6P2-A=
M(TC#BXXX\ <-N Q5XVUG,=5/BFN)9[632^^:@T%CH[#/1TWR7.Z245CY(VEA
M#  SHHI/R>7!5I..3?*^GTYKZI3CB<R,,)&(&&Q1.LJ5C$(<SGHI=:K-)SQI
M_=X['F*4\55'-Q>3RO(P+NX:X@N'?;#BHI,UTCHO;%NO59U>EVKV<)8*7/F:
MZ**R1/;))3V;I622EF[$NAB ^^M8FL3F&?Q3&$B9QT]M&=,L'+%SXA P,=2U
M+3C+%+$,&/!(./\ 6YUC-<SEI'HC:UZ<Z\9:HA8[#FNTRV6+N*=]:V8U$<?(
M&@0OPP[#UIF)C7JIC'1NNF^G%PR9'7UEWO$EXOMV>):^HD<[HN,8]XTCL[U%
MYS7$)KI.K&Z4Z97[(M]S3<[M44DT%\J73TK:5\KWM:97OPDZ2)@!P<-Q*TB_
M]**=XE2:S/)-EYK-I[>M1+):[;9)Z6">BKV5DKJQ\C&&-D;VD-,<<AXL7<H6
M%8Q>+>C>+?!:OJ^^I60[OG'3HY1MD]-%<CY+^=J72-@_T[VN=W3(WNVX;.Y3
MEC=.GJ<,[(F)],/E<M/[S6:2.R%%/2B\&@BH^G<^04W21EF)XA&7</<G\16Y
M_CG,*\'P3&6:TVRM<,G9+M67+G)#+74,;F2R4SG.B),CG=R7M8=SN5JTY;1:
MV894K-8PUBMTUOLVL4&HC:BD%DAI&T[H"^7RKC:US<0P1\&&W\M1PSLK:)_4
MOR1NF)]'SU6TUH<]&VU-)<XK1FVA<?DJID=@9.$\99@.Z.!'$"W<LHTMF.JT
M],--ON2M89<LUT>=LXT4>6Z.FEEK/(.E\HGCBC<>![Y(H^^PYRKWF,=-44SG
M/M9;JM0RQY%JI9&%K):Q_ XX=UP@8X+6_P M8]&59S:9]4ZK!J*1SUUT?,C4
M_P 2H?\ $]!M'5B\QV4_U$OMST@E+J#EW4A\VBNM]KU5;&[YE9G8VV9FD;B6
MP5&UL<S]P [T8E$NF:2NI:^G@JZ.5LU-4L;+#*QP<US'@.:003B""B%R@(*$
M@88\J#%WZ^6O+]JJKW=ZAE+;J*)\U1/(X-:&-&)VD_<00#H+;[OJ#GO,^O&8
M*<T]'<W&U9/A>"UPM4!P$O"?TN <"@Z2:,!V4%4$,=8_(%QSGD9USR[&'9QR
MM,+U82<273TGYWHAPC'\X6!J#8-&M3+=J=DBW9@@<&W4,;!>:(]S)3UT30V9
MCF$\0[K'#%!(V(050$'A[VLPXCAB4',^OE]=J9G&R:"9<<)_*9HKCFBHC[IE
M/2TS^D;'(6X\+G%F&#N=!T=:*&"UVRDMM*T-IJ.&.GA8-P9$T,:/0 07J @A
M7K"Z=WC-MAH\TY0X1GW)T_RK8@['"9\.#W0;!^/P@(,]I!JO9M4<M4]Q@=Y+
MF"E I[Y9YAP5-+5Q@![7,.W#'<[E023T@P!P.U!Z+@-_(@L[C<J&VT<M?<9V
M4M%3-,D\\SFLC:UHVESB< @YCLCY>L;J_0YM@CD;IGD"J$EHJ'@M97W!KP[I
M&8C!S6EFSMH.IHP0-N\H/:#BCKC>=W3?]6SX\Q!VG![#'ZUOI(/H@YET$\^V
MK_OF+_E1+IH[D0T_4_)4&?\ (MZRK+PB2NIWMII';&LJ "8G$\@#L$$8]6W4
M6>NM=3I?FYPIM0<G TM=22=P^:F:["*:,..+FEKF[0@GQKVOW?<.Q!Z0$'RF
MJ(J=CI)G!D; 7/>XAK0T;222@Y@IZR77S7NDKZ+%VFVFLCIZ>K;W4%?=7L,1
MX3M!#!([=^2B748W!$+6XT$-QH*F@J&A\%3$^)[3N(>""@Y_ZLEUGRP<S:,7
MN4F[90N%0;?Q# RVN>3CB>,<,1BX[0,$'1(>''# CMH/2 @(" @UG/>:;?DG
M*EWS1<I60TEMIWSO=(X-!< 0T8D[W$@#LH(CZJN6:JDRA<\^76"2"\9YK9+O
M,R4XN%/(2Z#_ ++^=!T$@H[O2@Y?U#M=\T*U-J-9,M44MPR1F%C(<]4$ =(^
MG,;W%M6QC=^''B[M(.@,J9QRWG*T4U[RU<(KC053 ^-T#VN(QWAPQQ:X<K3M
M09[I6]GL=E!87:]6JRT<MQO%9#04$#2^6IJ9&Q1L Y27$!!R]'+<>M!J)25L
M$$E-HYE&K,L%7*PM^5:V$\(+ [$&,;?01+J^%C61-8T8-:,&@;@ B'T0$%'=
MZ>URH.7]4XKIHGJK#K9:Z>2JR??&Q6[.%+ USW1%K6MCJ< -P VDG>4'1MDO
MMIS!;:>\6:KCKK;5,$D-3 ]LC'-/9:3VD&2#P[=B@%P&&/+L0:OGO/>6L@6"
MJS+F6L924%(TG!Q''([\5D;=[G..P8!!#.@&4\PYLS+=]?LZTSJ*\YC;Y-8;
M=('1NIK2PAL1>QP.#I&-8X[4'1[!@T!!5!Q'D?\ WPW7U]S^+.0=N((?ZT'F
M1S1^JC]L"#"]3KS%6?WW7_&7()Y(Q01!UB-.;AGS(XJ,MM'STRY,R\9><#@Y
MU32$2B+BW@2%H:4&3T4U7MFJ&4*>YM/D]_I?]->[6\@34]5%W+PYN.(!(Q""
M3&GB&.[D050>>,;>QO0:=J/J-EW3+*]=F?,-0V.&GC)IZ;$&:HFP[F*)N.+G
M..S ((VZMN2+Y06^ZZD9SA$.<<ZU)KJB' @P4V $<7==AO$@GQ 08'.N6:+.
M.5;KEBXMXJ.YP.IY!Z[:T^@0$$)=6[.DME%PT/S6XP9JR@XT]O;+BUU9;PYW
M1R1AVUV &W#D0=$M<'#$??0>D!!X,C1CCCLWGD0<O:S7*/6_4*T:%6"7RBP4
M-1'<L\5D8)B9#"<64_&W%O$[;B.=!TY34S:6&."+!L436L8WF:T #[P07""C
MAB,.=! G63R1?)Z*RZK9-CZ7.>0Y_*Z:F:"34T<G<30X##'8[BPQY$$CZ9ZB
M6+4C*M%F6S3 BH8T55(3^>IJ@#NXI&[VN:>=!NC7!V.'(@J@\.D:PX.."#FS
MK YPK,]W:CT R!(*F]WYP?F>NBQDBMMNA<V1PE<P]R]Y:& 'G03[E?+=!E3+
MULRW;&\-!:Z:*DIP=_!$T-&.SEP09E 06UQI(*^AJ**J8)*:HC=%*P[0YKQ@
M1]]!S%I9?Y]!]0J[1O.DCH<KWJ:2NR1>YSPTSN-Q<^E?(<&M?MQ ['90=0QS
MQR@.806N (<"",#VB@^@(.Y!1SPTX$%!$6N^K=+IWEXT%I'E^>K[_H\OVB$A
M\[YY.X$CF#:&-+L24%QH'IC-IMD*"BN1#\Q75_RE>Y03B:J?%SFXG;W/%PH)
M70$!!1[>)I;SH(FUCT;BU#@H;U9ZWY&SU8W=+8[VS88WG#%DF )+"!AZ*".Z
M77?5#3;H[+K!D"XUKXR8VYDR[$ZMIIHV=R'NACZ1[2=YQYT'TJ^L=G7.4AM6
MD6FUXK:Z1N NMZB=;**%Q_*;4",NPQQ[DH-NT?T5N65;M<-0,]7,7O4:]8^5
MU+<?)Z:,[1% '#$ # ()K:.%H'I(*H" @BO7O3>LU%R)-2V9[8LS6B472Q3.
MQP;64^+FC9MV[D%MH5JW1:B9;%'<W"BSS93Y%F&S2G@J(JB+N>,,=W7"_D*"
M6VO#MW+M0>L4'ESPWD)[00<^]8O422HIJ?1[)3S6YZS8X44T5.>,T5%,,)9I
M>''A'">7G02IIGDBET]R-9<H4;B^.V4[8GRG>^3$E[C@!M)*#;QL !00#URO
M,)?O?-!\98@F3*/\K6/^'TGM#$&:.XH.)L[_ .^.R]NV_%'H.U\.(>B@YXZS
M%HNV6ZG*VM]B8^6IR/5!UWIXAQ/DM-0YK:D[!B>!@<=_*@G'+68;7F6Q4-_M
M$[:FVW"%D\$T9#FEKQCAB#O!V'LH,PUP<,0@J@(""SK[I06RBJ+A<)VTM#2Q
MNEJ)Y2&,8Q@Q+G$[@ $'/6@G3ZDZ@YMURJ(GLLMP>VTY5Z0;'T5)^;DE;OV.
M>PX%!TB@(+*[6^DNUOJ+;7Q":BJHW13Q.VAS'# @]M!R]I7FZ?0;-#M$\_RO
M@RW)(^3)^8Z@<--(R5W'Y.Z0X-#@7%$NJ(9HG,:6.#FD M<W:W#L'F1#Z<8W
M\G806M?=*"UTDU?<:AE+14X+IIYG!C&@<I+B$'+L=?4=9O5*@J;='(S1[)52
M*B2JD:6LN=QAQ+6L#L0YC2=Z)=5M9P@!NQHP  ["(>T!!A\UV*DS/EVXY?KA
MC27&%]/+NV!XV';S' H($ZNV<*S)MPKM"<\RBGO]C>38*B<\ KJ!W>='Q88E
MO,$'2+7M<,1CAVD'H'%!3';@@L;M>K98[?4W6[5+*2WTC#)45$S@QC&MY27$
M#M(.;M'8;CK#JE7ZZW6GEHK);(Y;/E2EF;AQP@XOGVC\;BV$%!U @(-1U-R=
M#GW(MZRI,0PW&G='%(=S)1@6'[H01GU9<\SW++E5I[F,]!G/)#_DRNI7]R]\
M$9X(Y6@G:TM:-J">&/#]W(@](" @U_..;+-DG+]?F6^U#:6WT$9DDD>0T.(!
M(:,2 23N""%>K-8;O=XK[J_FF 17S-]4Z6DB<PL=';VX"(=UM'$-N&*#HI!;
MUU-%64=123#BAGC?%(WG:\$'TT'-^@5Q.F&>,SZ#WYW0QPU<MWR=/*[W3;JH
M!SHV$X8ECFO.';0=+-D#B0,=G.@](" @\.D:TX'''U4'.76:O]3F=]AT3RL?
M*<PYLJ6ONC(G#CIK53X&623;W(=Q;.?!!/MBLU/8;/06>C&%/0014\7K8FAN
M/HX((NZT_F.S1^K@]OC08OJA>9*T>^:SVQ!.[N]*#FKK,^<+13^/2^G @Z5;
MWJ"J"#>L;IW=\R6NV9WRB"<Z9*E-SM\+!W52QF#GPXC:<0W8$&V:/ZLV+5'*
M-+>*61M->HAT-YLTCV^5T=4S8]DL8)<WG&*"0^D;AB@KQCF*"SN=WMMHH9KC
M=*J.CH8&.DFJ)W".-K6C$DN<0$',^1X;CK]JR-3*^G=!IUE*5T64C,US'5L_
M$0:D ["WN1@42ZC:SA*(>T!!H>L&GM)JAD2Z91J7='/4QF2AJ#B!%51@F)YP
MVX!V_!!HO5\U5=?;4_3S.#A1:CY3X;=<Z.4]&ZH; .C9/$''%S7-:"@G3C'+
MZ"#T#B,4'GI&X8C=]STT$.:\ZIC)67_F]EP^6:@YD/R;8+;#W<HJ*D%C9GM;
MM:QA()<@S.A^G#-,<A6VP3R"HO,@-7=ZO#!TM7.3)(2< 3@7<(Q""3$!!Y>T
MNPP.Y!!>OF1<R/DLVJ&0(!49TRC+Y5Y" >*NHV]U)!LWEV& "#>-+]5LK:F9
M>@N=GJ!'<&M#;E:92&5=).-CV21D\0P.."#?!(T_T[$ R-!P]'D00IK=J_!E
M*WC)^46_+6I-_/D-IM-+^=DA,^+?*)@T]Q&SG."#-:$Z7R:6Y)I[1<)A59@K
M)'UMYJP21)4S.+CAB =@P&U!*: @\R#%OWT',>?ZF;0W6JAU,D@DDR%G-L5E
MS'.P$LHJKBQCJ'@;F<+,"3SH.DJ"NI*VECJZ*9M123-$D4\3@]CFNV@AP)!Q
M078.*"J#QTC02.9!$&ONJ=)D+*3K7;L:O.N9'?).7;7""^>2HJ@6<98WN@Q@
MXG<6&&Q!E-"=-WZ8Z>V[+]8\2WF0OK;O,#Q<=74'B><2!VD$G'<@XZZ^'[+R
M?[[F_P "#J+3_P#D;+?\,H_:&(-C0$! 0$&"SB,<I7X?_P =5C_\AZK;I+;A
M^>OO?EG'3'HQL*^>Q#]4>O)SZJ1&$Y/)NPK9E&9/)OZJ9,R>3?U4R9D\F["B
M8SU,GDY3$$8CHZMZE\3F'-P;L<YU*<3S<+UZ'A]_8^4__D-L[/M=< ' +TGR
M"VJJB*EADJ9W<,4+722/.YK6#$GT%E>^VNY:(S.'"&>>L3DK4?.];E[.=^J\
MOZ:V:;HS14E+43RW1[" \2.@8\!F(W;-B<%*VB>2^L_ICM'_ (M>2\TB*TZ_
MJG_)-^0NLSH#55-IR3DRXS0OEX*6@I?DZK@CQ:-F+G1-:-@WE=.V>69F>KDS
M%(Q#H6%W$&D;B%DTZOLI! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 04<,6D
M<Z"/]1=+:3/;:.MBN$]KO]L+G6^X0.<.#B.):6@X;3R[U$=1H-3HEJ1F(16[
M.6>G5F7VN!=34[7->\-W!W<L!]$E:1,1*,Z)GRWEVW96M--9;5&(J&E8(XV[
MR<-[G'E)Y2J6MNDB,,N 1CBB54'/771\R-3_ !*A_P 3T&T=6+S'93_42^W2
M)!*74& S3E&SYQL-=ER_T[:NV5\9CFB<-@QVAPYB#M"#FJTWS4/JPUQLF9Z.
MKS5H^Z5WR5>:1CIZFVQDX-CF&&)8UH0= Y,U7T_U H8Z[*E^HZ]D@#N@;,QM
M0W'\J)Q#QZ(0;>9F-;QN(#=Y<3L&'90:%GO6C373ZC=4YDS#203;HZ.*5LU4
M]YV!K86%SR2>P@A"2@U#ZS-WAEO-'594T9IYA(RAJ08JVYAAXFN<T;0P[-A0
M=06BU45GMM-:K="VGH*2)L%/!&.%K(XP UH[6""_ (&W>@J@^9CQQV[#R=A!
MS+GO3?.VEF<:G5;1R!U;05CC-F;*$>)%2YQ[J2%FX/ ..Q!(6G/6%T[S]_Y>
M*]MES1 &LK;#=2*2KBE(VL EX>/ _DXH)8;,Q[6N8>)KMH<W:/NA!:W&\VNT
M4SZRZUD%#21@N?/4RLAC '*7/( 0<]YUZQL^:ZF?(^@M#+F7-$KW4LM\B9Q6
MV@<3P]*Z0['\)VC#'<@W?171NGTWME3<;O4?*V>[R\U-^O<A+GRRR;2UA.Y@
MY$$LL:6C G$H/2 @^9BQ(.SG005J+H)55>81J%I7=_FIGEN)J. ?Z*M)Q)Z=
M@Q&)QVGAQ08.DUCUQR9TE%G[32KO)IL&"ZV!S'0S- V.#7G';R[$'W?UE,YW
M.*2GR_I'F*2X</YL5'1,CXCNQ.(08L:::UZV5%._5RO9EK(_$V:7*UL<1//P
MG8R>0 $#;B<'(.B<M97LV4;/36&P4D=%:Z-@CIX(Q@ !RGE)[)09@#!!5!Q1
MUQO.[IO^K9\>8A#M2'V&/UK?20>T',N@GGVU?]\Q?\J)=-(AY>WB:0-YW%!"
M>L.B=;F2X4VH6G=:VP:I6T 07)HP95P@8&"<8$$' ;<.0(-=RQUFX\N3_-K6
M^T5.4;[ 6PFZ21.=;*EVXO9*T$-!W[4$Q4NJ>FM9$)J?-]F=&[<3<*4'[ADQ
M08;,VO.DF5:7RFY9KM\N.QD-%4,K)7.Y UD!>24$-7/-FJG6,J763(]MJ\GZ
M:/[BZWZXQF&IK(B>%\<#<"X M&_9OWH.@\BY#L.GV7*/+678!!04C3M.)?)(
M[$N>]QQ)<24&TC8,$%#N*#F[7O)V8<L9BMVN^0*>2IS!9FB"_4,.)-5;1B'=
MR,07- 02_IOJ-EK4S+=/F?+%4VIHI,63L!!DAG:.ZCD&.+7#LH-Q:[BY,$'I
M 0$'SEF9"USY#PL8,7..P #;B2=B#EK.]XJNL;J%!IGEM[CICE^H;59ON[.Z
M@K'PX.CIHGC8<).'B]%!TY;[;36RAI[=0QMIZ&EC9#3P,&#61QCA:T=@ (+U
M!0C$$<Z"VJZ&"NII:.KC9/33L,<L4@#F.8X8$$'>,$$ W_JT5-FND^8]',S5
M.3;I48]-01XS4#R<3[$_B#-NWN6H,8VW];>C;\F&^Y>J)1@P5[VO#R=W$6B+
M#$H/O1]6S-6<ZJ"NUKSK4YA@BP+[%28TU"2#C@3'P%P!YPB70-FL-KR_:Z:S
M6:EBHK;2,$=/3PM#&-:T8;@!M[*(9)HX1AO[*"J @H1B"!L)Y4%C<+10W6@G
MMMR@CJ:"I88IX)&A[',=L((*#G"KTAU1T<K:JY:&W!EPRQ*3,_)MR<YS(W;R
MVG>>(C''\H*$KZ'K,Y@L CBS[IC?[6]K<*BLIHA4P"3DP$?$<''8%*%*CK%9
M[S1 8M.=+KU52RDMI*ZY,;34WKG-<0[A!&U!YL&@^<\^W^GS?KS=H[EY*X2V
M[*U&7"WP.W@OV-XB#SXH.CH(6P1-AC ;&P ,:T8-#0,  !N0?5 0<1Y'_P!\
M-U_67/XLY!VX@A_K0>9'-'ZJ/VP(,+U.O,59_?=?\9<@GI!XD87@8'##;^%!
MS[J/HQF:R9EDU-T5J8[=FN08W2SR$MH[@!R%N! <1R@(&7NM/EVW-CM.J]JK
M<D7^/!E2ZNA>:)TG*63-!:&X\Y1*18M<=(YJ8U;,Y6CH&C%Q-9"'#9CM;Q8H
MAH68NM5D*-\EMR%%5YUS"]W0P4=H@?+$92-G%,!P8<^U!@LI:29XU-S31:BZ
MYAL5-;W]/8<G-VQ4S\<6NG V.>,&[.Z1+I6.(1M:Q@#6-V- V# ;$0^J @\O
M;Q##'!!#>LNB\N<WTF<<F5C;'J?9L7VB\-&#7@8$P3X \3'88;04&JY3ZRDN
M6JMF4]<[3-E;,<>#?E4QN-KJ!N:]LH& QPY42F^V9\R7>H/*;5F&W5D.&/'!
M5P2#;S\+SAZ*(6E^U.T_RQ3/JK[F6VT4;&&0MEJX0\L&\AG%B?0""#,RZUYQ
MU<>_*V@%MG?33NZ.NSM6Q.BH((7#:82]N+G8C#'!!*>D.CUGTKLLD,#S6YBN
M1$]]N\N)EJ:@[7$D[AB3@$$F(" @\2QB5AC=@6NV.!&((/8*#G+.FBN=LE9G
MGU"T*KHJ.KJG&6\96J"?(JIQ.+G,&!#7'L8(E<6GK14MG H=3\HWG*US:.[D
M-*^JIG8;,6/A#AAZ*(9.3K=:*N8?(;G65U1MPIX+?5EY(Y-L8VH-5N>J6LFK
MP%LTIRM598L=5Q1SYGOK.@=T1[DNAC()#@0=X02AI%HU9M+;7.8977',UTPE
MO5[J<7SU$IVGNB20W'<$$G 8 #?ARH*H"#R]O$TM&PG<4&F:CZ9Y:U.R[)E[
M,T EA)#Z:I9W,]/,W:V2)XVM<,.3>-B"#Z*/K$:*%EKIZ,ZC9&B<(Z3H7!MS
MA@ P:'<7#Q8=LE!F8^MI:J-SZ:_9$S-;;DT]U2.H7S=K!\8(.*"TK]9=:<^!
MEOTUT\K+,)W<)OF8.".&)AV<88-N(QQ P*#9M+- AEV[29]U"N1S5J/5$N=<
M)\3!2C##@IV'!K1V>$()P:"&@$XD<J"J @(""A;Q8<P06=Q9_I),=N(P^^@M
MK0W&*0#8 [$#DVH,JT8#;SXH*H" @(*.!+2!O*""]3]!JBZ7WZQ],Z\9<U'A
M:.DJ&8BGK@P;(YV#%IYL>'':@P%MZP6=\D/CMFKV0;I2F/&-]_M4)JJ!Y:._
MP8"X!QW(,\_K:Z2=$7127.6HW-IVVVJXR[FVQX8H-7N&L6L6J 90:09.JK);
M9RZ.7,M^CZ%C&[N*.,@G$=EJ#?\ 2+0VWZ>OJ,R7FL??]0;IB;OF"JQ,C^(X
M\$8.QK1NV ()=8WA:&\R#T@@#KE>82^^^J#XRQ$IDRC_ "M8_P"'TGM#$0S1
MW%!Q-G?_ 'QV7_Z9\4>@[8;L""UNE!1W6AJ+9<(6U%#5QNAJ8)!Q,?%(.%S2
M.8@H.5;5<<P]5G,4]EO4%17Z(ULQDMMRB:93;))CQ%DFS$,!+D'4-BS!9<Q6
MR"[6&N@N-LJ&A\-52R,EB<T_UF$C9RH,F'XC'! X@@M+A=K=:J.6X7.IBHZ&
M %TU34/;%$UK1B27N( ]%!RUFC-F8>LQ=CD/3ATU)IC!(!F+-!8605L8(#X(
M'$;<23N0=-Y<RW:\JV:AL%D@;2VNWQ-@IH&# !C!_P %!ET!!Y>TN  [:#4L
M^:;Y5U'L[K+FRB964P/%#*.XEA>-SHWMP<TCL%!"%+IWUB=+6FAR'F6ES7EN
M+'R6@ON(J&,Q)#>D:"2!NQ+T'V;J-UH:O_RJFT[I*:Y-/=W.>8^0/QW\&#N+
M9V5"7S=HKJYJ?5PR:S9I9#EIC^E=EFR\4<4H [R60!CL,<.4J4.@LOY7LN5K
M33V3+U'%;[73-#8J>!H:T###;AO/9*#-(" @\O;QMP011K#HK;-2Z:FN5-4O
MM&=;5W=DOM/BV6%X./"[#>TD\N*"/+)K?J)I@66'7'+-9-##BR/-UI@=/1S
M;>)[8QB"1V @D:S=9#12]4PJ:7.-OB;^-'5RBEE:<<,"R7A<#VP@P>8.M9I-
M;724EBK9LSW@-!BH++"^K<YQ) ;QL!:,<.=!H[LIZM]8>X0RZ@P29.TJ8X3#
M+F.%=7#>SIRWO6CE'$@Z8M%DM]BMM+:;3 REM]&QL5/ P8-:QHV!!DD!!Y>W
MB:0@@;5_2C,-/?J;5S2@MI<_T X+A1[1%<J7>YD@V@N&'<E!F-+^L)DW/+S9
M+H\Y;SM">BJK!="*:HZ1N_HQ(1QCFP03 V5KAB-H[!!0.D;O])!JN=M3,E:>
M6R6Z9MN]/;H8QBV&21O3R<@#(P2YQQY@@Y]BH,U]:+,%+<KW0SV/1*W2FHI;
M?5 Q5%UD!_-R. V\';*)=24=!3T--#1T<;(:2G8V.&%@P:UC0   -V&"(7:"
MC@2T@;T$,ZZ:05N=Z:AS;E&I%NU(RZ>ELE>"0'#'NHG#:"'#$;0@M=(->:#-
M$S\EYWC.7M2;8T15UMKOS J7,/ 9*<NP#PXC<$$VB4';@<.=!Z#P=W]*"CI
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M_P"<ZNJSSF6$\3:Z^O-3$QW/'#*YX;]U!-<5+%!&R&%HCB8 UC&#A:UK1@
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M40(" @(" @(,;>/86>N0?:V^Y&=L^F@O$! 0$! 0$%#R(,7:_9I_^.5!E4!
M0$''77P_9>3_ 'W-_@1+J+3_ /D;+?\ #*/VAB(;&@(" @(,/FH8Y8O0YZ&I
M]I<JVZ2UXOGCWOSL92]P%X3]+R]>3*#)Y,$P9/)DP9/)DP9/)DP9/)DP9=']
M5.,QG,^S833?>#EW^)UE\O\ OGZ/M=,#;@5Z$='R[TI! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'/771\R-3_$J+_$Y!L_5B\QV4_>\O
MMTB02EY 0$!!BH?VJ_MN1+*#>40J@(" @(" =Q08F[[X^T[TT%]1>Y8^T@N$
M! 0$! 0$'B7V-_:*"PL_>2^N"#)(" @(.*.N-YW=-OU;/CS$':<'L$?K&^D@
M^B#F703S[:P>^8O^5$NFD0(" @Q5X_RO107M![DB[7X4%P@(" @(" @MZ[W)
M+ZU!96C=*>78@RH0$! 0$! 0$&"J_P!H?VAZ:#.!!5 0$! 0$!!973W&[MCT
MT'NW^Y(^T@ND! 0$'$>1_P#?#=?7W/XLY!VX@A_K0>9'-'ZJ/VP(,+U._,79
M_?=?\8<@GI 0$!!B9?VLWMM])!ED! 0$! 0$!!CKQ[%%Z[\"#[V[W%%Z/^(H
M+I 0$! 0$!!0H,7:O9)O0095 0$! 0$! 08.X^Z_0")9Q$" @(" @(""TN/N
M1_H>F$%O9_8Y.V$&30$! 0$! 04=N/:082A_:'HN09Q 0$!! '7*\PE^]\T'
MQEB"9,H_RM8_X?2>T,09H[B@XFSQ_OCLO_TWXH]!VRWE050$!!:W#W+)_P <
MR#YVOW*.V4%\@(" @(" @H>3MH,)3_M >N<@S@W(" @(" @("#%W?_*[909*
M/V-O:"#T@(" @(" @MZWW-+ZW\*"QLV^;T/3*#+(" @(" @("#$O_:S?0])!
MED! 0$$-]:?S'9H_5P?&(T&+ZH/F2M/OFK]L03N[O2@YJZS/G"T4_CTOIP(.
ME6[D%4! 0?"L]SR>M*#'V?OI/009= 0$! 0$!!0_@08./]I#]842SJ($! 0$
M! 0$&-O'L+/7(/K;?<C.V?307J @(" @("#R[D08RV>S3_\ '*@RJ @("#CK
MKX?LO)_ON;_ B746G_\ (V6_X91^T,1#8T! 0$!!B,S[<MWD<GD53[4Y5MT:
M\7SQ[WY_LA/ -B\)^D95Z$\R&5>@*(R= 4,G0%#)T!0R=!V$,NANJ]'P?.0'
M<33^DY=WB=9?,_O<_)]KHX;@O0A\RJI! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$'/772\R-3_$J+_$Y!L_5B\QV4_>\GMTB02EY 0$ [
MD&)A_:C_ .TB65&\HA5 0$! 0$ [B@Q-WWQ]IWIH+ZB]S1]I!<(" @(" @(/
M$OL;^T4%A9^\E]<$&20$! 0<4=<?SNZ;?JV?'F(0[3@]@C]8WTD'T0<RZ">?
M;5_WS%_RHETTB! 0$&*O'^5Z*"]H?<D7:_"@N$! 0$! 0$%O7>Y)>T@LK1WL
MO;"#*H" @(" @("#!5?[0_M#TT&<;N050$! 0$! 065T]QN[8]-![M_N2/M(
M+I 0$!!Q'D?_ 'PW7U]T^*O0=N((>ZS_ )D<T?JH_; DD,-U.O,59_?=?\8<
M@GI 0$!!B9?VLWMM])!ED! 0$! 0$!!CKO[%%Z[\"#[V[W%%Z/\ B*"Z0$!
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M"#I5O>A!5 0$%O6>YY/6E!86?OG]I!ET! 0$! 0$%#RH,''^TO\ J%$LZB!
M0$! 0$!!C;Q["SUR#[6WW(SMGTT%X@(" @(" @\NY$&,MGLT_P#QRH,J@("
M@XZZ^'[,R?[[F_P(.HM/_P"1LM_PRC]H8@V- 0$! 08Z_#&R7(?^%F]K<JVZ
M-./YH<:MINX"\5][D\F0R>3!$9/)D,GDR)R>3=A2C)Y-V$3E-?5_BZ/Y<[</
MI%=GC=9?/?NW6OVIO;R]M=T/GPD8':I@:IG?.^7,@6*IO^9JZ*BHX(W.;TCV
MM?(YK<0Q@.UQ/,%CR7Q&G5KQTW2U71#5&35K*S\U.HQ1P&KG@I(VN+RZ"-P#
M'.Q P<0=J[>7BV5I/\T1+&+?'-?1*;&\.SLDKFZ)A[5@0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$'/771\R-3_ !*B_P 3D&T=6+S'93_42^W/
M2"4NH" @'<@Q,/[5?_:1+*C>40J@(" @(""AW%!BKOOC[3D%]1>YH^T@N$!
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MU/\ $J+_ !/0;1U8O,=E/]1+[<]()2Z@(" @Q4/[5?\ VD2R@WE$*H" @("
M@'<4&)N^^/M.07]%[FC[2#[H" @(" @(/$OL;^T4%A9^\E]<$&20$! 0<4=<
M;SNZ;_JV?'F(0[4A]AC]:/20>T',N@GGVU?]\Q?\J)=-(@0$!!BKQ_E^B@O:
M'W)%VOPH+A 0$! 0$%"0,,>78@MJY[?))>PW%!9V@@"4$[20@RG&U!Z!QVA
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M/\2HO\3D&T=6+S'93_42^W/2"4NH" @H7 ;T&*A(^57>C]]!E&G'$A!Z0$!
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MLHQP.'X0@^=KD8*8#';B>WAVD%_QCL_<0>D! 0$! 04*#"4_[0_M.09P;D!
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M<".4*RC,,<'C$<^"#T@("#"9DS78,I6BHOF8ZV*WVRF:72SSO:P;.0 G:3R
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M\<ZT8/2 @^3I2W'9L'9YD'.>I&O%_N.99M.-'+<V\YAAQCN-[)XJ&A?B<07
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MZP9=U3LHKK8#27>G[BZV:H=PU5+,-A:]I .&.XX*\2QF,)%:>)N*E55 0"<
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M!T.-P51#G6G\QV:/U<'QB-!B^J%LT2M'9J:OVQ!.[N]*#FKK,^<+13^/2^G
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MDX]ZP;MFU!!_5XR%/=FU&MV>872Y[S2'/ACE.+:.B#L(V1MV@$AH.*IN:8=
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MY*8,G0#\E,&3H!S)@R= .9,&6WY(CX!6'# $L](K?BAY_EST;CCM YUN\]5
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MRLYH90W?,L+*QKCQ!\<-/+*&D8;>Z:"HE:O5,+0 T!H     [ 6$O2CHJB1
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MR(;CR=O,AN/)PAN/)QS(;E/)F\R&YLN5(Q&*H<A+/PK;B<7E3I#9SO"V<2J
M@(" @(" @(" @(" @(" @(" @(" 5$CF?7>IIZ+5G(%95RL@I:>6DFGFE(;&
MR-E;Q.<XD@  !6\?2\^Y/+_Q_:E6YZQ:9VFD-7-F6BJ&L'<PT<HJI7%HV!K8
M>([><X!1,=E81;I]1WG4[5&74VMHY:/+EO!BL_3-X#( '-9AQ;R >)V':6E/
M@B?64<GQ8](?'762FIM4\J5.;(WNR1'3L,KN%[X^DZ63I X-!Q([C'9N6?%.
MLQ/V-+3\,8]6?U"U#TIH\GW"W6&6AK[C7TDD5'36V)DCVE[2.)Y8W!F'+Q'B
M5+1.V/>5UM]C+=6TCZL*7;M%34@@'<3(5U<_;W.7A_5[T5:VQ7#(&>;A>;.W
MAI<VT$U-*1NXY1P288?C#''T5R\,;JWXOM=EIUI?^5/VDF5OFID6SVN2/HZU
MT+:BN!V'IY@'N!];CP^@M^>T3;V.?CB<9[MZD'<'!9M'->?ZD9*UWM6<\PQ/
M&6JFF;#%6\)>R)_1F)VX':QQXB-^!V*OCQB;>U/+\58CT2'G#5K3FERK7R1W
MZBN$M52RQ045+*VHFD?)&6M:8V8EN).WC P46IF$TMB<L1U:+)=;7DB:>Z12
M01U\YGI(I06GHB.^ (! <NB\Z0QCYIE-+6AN.'*L8:-8S?IUDO/3Z63-MG@N
MCJ,.%,9PXE@?OPP(WJ1S?UJ-)M.\F:35-ZRQE^FMUT%?21"JA#N/@D+N(;2=
MZ"5^K+3PRZ(93=(P./02[3^O>@EHT-(1@8FH.:^KM4OLN8]3,A5H$55;<PU5
M92@GNI::MD=*UP'8!&U4;U= *%Q 0$%#CLVX?TH.?-5FSYNU^TVR72#CCLX?
M?[H6X.,<<3RUK2!NX@X%6AE;JZ7CHZ?@&,8Q5F3UY'3?HP@Y1S.R/*'6>D;*
MWHJ;-MM:*64C!KY8"2YH.[':L>2,NSQIU2QV#O6#TA0*(" @QN8+I3V2RW"\
M53Q'3T-/)42/.["-I=]_!(C5$SBK$]4&P.IM)C>ZRGZ*7,-TN%T:UXP<89JF
M0QGT6D$+LCH\6_5/PHJ4CV(*RBOD5+^B"#F+7Z/YGZP::Y^Z'AM$U1+9;G68
M8,A\K=&R,N/(#W6TK2DB:>)C@'1NXHSW37#:"T[B"-XP75"55((*$[/^"@@?
MK U$>9;_ *?:749=-<+O?:2NJHX]\-+2R />_P#)V/V$KGY)0ZGIZ"E9#''T
M8(8UK!VFC!8#Z^14OZ((.+>N'&R+5S3<1M#1T;-@]_-0=JP>P1^M;Z2#Z(.8
MM"(HY===7A(T.'E46_\ LHETJ:.EP]B"(<Z=;2VS45@RCGJ@ C=E*]P5DI([
M@13.9&\NPY $3"=[5<::[VZENE%():.LB9-!(T\37,> 000H7A>(L(""JA*
M>MG="[(%OR/1,,]ZSC=J.WT=*T$N=T4@J7'9R!L1VJ6<IXM5GI;?:Z.@X&N%
M+!'$-F [AH"E5&G61RZZ]:*YMI** R5;*43Q1Q[7$Q2-<<!V@@OM)KS#F#3/
M*MWIW\<,]N@'9#HF]&01R$%JSET5U;IS*$BD$! 0$ ;2!Z'X4'/VE[!FCK):
M@9AQ#Z.R4\5JB<P8-QD)+@[G/<J\,+.F/(J7]$%*C!YSRY3W_*=XLK(P'5M+
M+"T]ES=F_LHF'/O5AO+:K3AN6:CBBO&5:J:U7"DDV21NC(<"1R@\6]<]W=Q3
MHFG>J-@HA1,$H]ULS?!DK3F]761[?*IH324,).#I9YNY#6\YPQ*FD:J7G$-N
MT#R@_*VD.5;-<H>&XQT;9*L$8?G)7.>?O$+J>?*2O(Z;]$$0>14OZ((!HZ8#
M$1-Q"#E32UL>1=<-2]/JN3HQ=JH9AM#9#[(RL)FFX#N.!D&S>%M24PGQ;I$2
M(*$X$(()HV,SSUJJ9M(#+09'M+VUM0WNHA45?1R-CXALQVG[BYK]59=2-HZ8
MM!,0Q6:'KR.E!QZ)N*#BG(S0WKOW4 8#CN>S_P"6<@[=00_UH/,CFC]5'[8$
M&!ZGU/#+H79S(P./E=?M/OAP_ @G5])3 ;(P#R8(.2;E3,RAUGKU23@Q19OM
MS*BDE<"(WOI0Z1S0[=B,=RPY*Y=_C6U2F,#ZBYGIB"AWH*@(*%#NA[.4$6;=
M==-LHQ?G9K?-+=:IK=O!&&NPX^08\&Q=''#S_*L['\CIR<3&"3O*Z'FJ&CI<
M-D00<_\ 6XM-1!I[:<W6R'BFRC?**[3-&XP-$D3L>; R J)A:)U2C9+E3WBT
M4%UI'B6EK*>*:*1I!#@]H/(LW9'1?J 0$!),-*U;S539+TXS)F2J?P"DHI.A
M'XSI7X-:UHY2<4A69P\]7/*$V5]'LL6NZT_17+H#/4QNVEKY9'/ ^X0MG&EC
MR*E_1!!Y=14N&R,??0<T9V>S(76DRIF&H;T%GSA::BQ&K_RVU;9&3,:]VX<3
M8CABK52GP8\JWA$JJ4" @TK5G,E-E+3G,=]JIA R"D?%$[\9TT_YI@;RDXN5
M)E*RZM64SEW1S+L-="6W"X1?*=6'C!YEK '.+@=QP6 E[R.E_1!!0T=+@?S0
M0<\];^POETXHLR45.Z5V6;C3W&1L32YPB;+&9'8#;L#56>B])Q*_L=TAO=HH
M+Q3.XZ>NIXZB-PYI&!V![.U<=HQ+WJSFFC(*$QT$2*$@YE*$699HFY[ZTUNK
M*1PEH-/[9.^K=&1PMJZQKZ?A<>4\+^]71QQAY/E6S.'78HZ7 ?F@MG$>14OZ
M(*10T=-ALB&*#"YQRU2YBRI>;"Y@:+E1S4I(_P#>L+?PI*<N*=';B^EMU?D2
MY1NI;[E:IDH9J.79(8FO<&O .\=I<'+3N^C\/DB:X28.RN9Z&!3G"(B9:%JY
MF#Y(RC4VZB/27R]86ZV4K!QR/EG[G8UNW <ZUXZYG+C\ODVUQ#JC1K)0R7IA
MEC+-9&#6T%$QM23O,CR7NQP]=@O1A\U:<RWKR*E_1!2J>14OZ((*&CI0#^:"
M#D[/#&Y.ZT]/<JMXBH<YVJ.CA=)L8:FD9'$UC#SG#<L;QEV^-.)2O_P1Z*YW
MIRHI0(""CGM8"]YX8VCB>X[@T;2<4/:C?JW4TV:=4]4M0##_ .323T5HME1O
M9,:)DK)2WG ."Z:0\CFMFSJ04=+@,8FK1SH%ZY$$,6@M\,; T^4T&T>^6H)G
MRC_*UC_A])[0Q!FSN*#B3/+0_KPV5KAB#\F[#[T>@[1-'2[^C&.."2.9L_LA
MR?UI\F9CG?T5NS-;*BU$NPX#/!&X1M'9)>%:HG< M[D[QO70D0$! 05&_8@@
MJE@;FKK61Q1@3T^4K0UT_*V.6=V.!/(XARQLATSY'2_H@LP\BI?T000GUK\I
MU%_T6O,MGA<^[6-\5[H8XFE[W34+N(  ;2<"@WO3O-5NSKDJRYEM<PFI:ZFC
M)<T[GL' ]I'(0YI5):0VD["JI405Y BV-$*=:3-+LN:.7VEH7N-^OS&VJST\
M'=5$E14/ ;P,WG<5>&<I&TVRA2Y2R+E_+?1-!MU(R(@<CCBYWWW%64;;Y%2_
MH@@HZCI</8@@Y[ZWEE?%D&SYSH8<9LGWBFNCRTX81/QIG8]C\ZJRM6=4C6VO
MI;K04URHWB2EJXF31/&XM<W8L9>E6=%TA B1 00/UEA\Y:/*FE]&[BN>:KO3
ML="TX/\ )87=(]WW6*U7/S6=4Q6^ECC9&(FAK&AH Y -BV<3V:.EP]B"""^M
MC99YM)YKO:Z825-DKJ*XO WB&&=ID([002;DV\T^8<J66]TKQ)!744$[7 X[
M7QM)'H'8KP,XK($!!78@=A$N=LN@YRZUUXO--&9;3E6T"UR5((Z/RF1[GEF(
MWD!ZRD=*>14OZ((,#G>P07K)]]M3(FE]70SQ-&_%QC.'WT$(=5ZZLK](;7;3
MC'5V":HM573O!:^*2&5S^%S3M&QX7303,KH$2("E H$6=8B_4]@T@S++42!C
MJZG-NIVG>^:IQ#6M'*3@J6E+?]'LMML.FF6K951'IV4$+Y&O[YID8'8$<FTK
MF&L=:*F@CT.S0YC UPC@P\.Q$K#J@^9*T^^:OVQ$)W=WI0<U=9H!VH.B@(Q!
MOTN(]&!!T<VDIB,3$W%!XEHJ8M+>C&!!!V(.&M.&3Y:SWJ+D2X=Q/17B>NHF
M'8Y]-5RR2 @'> "T;%Q\T:Y>YX-XQM2GN&'WURO4Z3@0D04*&-6I:FWF"QY$
MOM5.[;)1RTT+0,2]\S#& !O))/(M*1F6'D6B*2FKJU96?EW1?*EOKX2RJ?3&
MIECD&#FNG<7X$<F]>A7H^9O.92UY'2_H@I4/(Z7]$U2.<>MG0RV2BR5J+0-#
M!E6]0R5KB"6-I:HADCG=@ (.BK76T]RM]-<*2034E7&R>"5IQ:Z.1H<T@\H(
M.]!=H" @^4LL<,3Y97M9$QI<][R&M#0,223L 4CFWJW4K<RYWU0U($3C:[]=
M^AMLS@0V6*G!8Y[3RC$8*$ND/(J7]$$0>14OZ((/+Z.F V1@=E!ROJK2LR!U
MB<MYVJ#T-DS73BR33$?FVU(#6Q\3MS<3SK;CG43 "",001R$;0?N+N7@0$%G
M<KA3VJW5ETK91#2444D\TCS@T-C:2=I43.!H?5/M;KQ0YHU(JH'QPYJN4LE"
M)6\/'31NP:\ [<#@O.O.5727D5+^B"J@\BI?T006MRM=-54%32B-H,T;X_[[
M2$',?58F;:[#FC)-3C'<[)>ZM\M._$2".<MX#@?Q3P\BQEV4E/JJO@0$!!78
M 23@T#%SCN &TG[B1"<H-T)#<W:U:D9WCB+[5&^*TTU01W$CZ?!C^$\N'"MH
M<=Y=->1TOZ(*S-Q]U[(HXK7E 1M#<:N;=ZQ$NI=/_P"1LM_PRC]H8B&QH" @
M("#Y3[8)1_5=Z2A,-,Z#9N7-AZ65.@["8,GD_83!DZ#L)@R=!V$P95Z#L)@R
MIT'83!EF\OQ\!FQW'!;4<O-.6>6CF$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'F
M38P[_00:?F33K)^=*F&KS-:VW&>G9T4+WR2Q\+,>+#\T]F.TXJ(TG).L,=1Z
M*:76ZH;4TV6Z<2MW=(^:9O\ =DD<T^B%;(WNEIH*:-L$,;8XF-:V.-C0UK6M
MW  ;  HSE$1A87[+MCS)2.MU]HHJZB< >BF;B 1R@C @]HJ.DY6:[:M*-/;&
M*EMKL5/":J)\$SB9)'F*5I:\!TCG%N(_)(4YRCNN:*TY3TTL%9);Z<6VP4H?
M5U+6NEE#6@8O?W;GGL[%6U^A6OHA.\7ZBUMU'R[;K!#)499R_*:NOJI6<#7]
MVTX#EP=P@ %:\5=MIO\ 8CDGX-OJZ;#0!N"H*G<B6,O%FM%^H9+?=Z*&MHG]
M]#,P/&.[$<Q[(VIC!$M/H-&=,[=5,KJ3+M.VH8X.!D=+,P$;<>"5[F[^PISA
M&,M]C#8FB-@P:-@:!@ !S*N<G1]DA(I'//71V:(U/\2HO\3T&T=6+S'93_42
M>W2)!*7D'+6MELN>EVIMHUTM$)ER_*QMMS?31 N?T3R6MF(W=R7-Q/8597K*
M>++>+??[727JTU#*JVU\3)X)8R""U[0X;?156[(H" @P.<<W6;(V7J[,]^J&
MT]OH(S([$@.>_P#%8S'>YQV8(B45=73+5[S!=;_KEG" P7G-;^CL5.\$.I[-
M'AT+2-F!> UQ5H83+HUF'",-W85E7I!S]UH=/KEF'+M!GK+3'.S5D>5]TI6,
M!XIH& /EB &\N#, JS&5Z6Q*VT[SU;-1,KT>9+:XATK0RMIG;)(*EH'&Q[1N
M(*Y;1AZ]+[FVJK11 0"@A#6*\5F=[W;-$,J2EUWODK'7J6/:VFHF'B>)",>$
MN#2M:0Y/(OB,.M<J6.DRSENU9>HFAM+:Z6&CB &&R"-K,3V3AB5TO-F681 @
MT?5'3^UZFY,NN4+G@QE;&X4U3M#H*D-(CD:1MQ:2D"!=+]2:_*E<S2'560T.
M;K7_ *>W72?!E-7TS!A&]KS@.(@;L%TTLE.XV@.WM< 6GD(.XK4';E(TS434
MG+>FMDDNU^J :@]S1VZ/!U342G8UK&8@E4FPU70/3V_W[,=PUPU!@,%[O# R
MP6Z3$/HJ(XX MV8.(P7-:<H=*LY?25![0<4=<?SNZ;?JV?'F(0[3@]@C]8WT
MD'T0<RZ">?75_P!\Q>FU$RZ:1#7\[96H,YY5NN6;C&UU+<Z>2G>7#'A+VD!P
M[+2<0@@/0'.=PRG=ZO0//4CHLP6+B=9:N8AK*VA)QC$;L!Q.:UPV#F42O#HL
M':1S>BBRJ)$%G<[E16>@J;I<IVTU!21NFJ)Y"&M8Q@Q)./:169<Z:=,N.NNL
M#M5[C"Z/3[*T<M+D^&;%IDK"0Q]2 -CAPF0#MI"DNIFCN1COP4H6UPHH+A0U
M%%4,#X*B-\;VG:"UXP*#FGJ]W"7)E]S1H7>IB;EEVKFK+*YY Z:V5+^*,MY\
M.(K.6U9=!#=Z:-! 0$! 0:IJ/G.DR#DR[YKK' ,M\),3=Q=,_N(VC'?BXHBT
MM0ZKV4:NRY'GS9>8NCO^<JAUWJ^/:[@J"7Q-./,UZO#GF4\*4*.[TH.4]6\J
MYCT@SY-K+D2C?79=NS6MSI9H0YSR&.+O*(VX;\'''#F5+0UI?"2<BY_ROJ%:
M8;MEFN941R-QDI<0*B%PV.;(S$D;>=8R[*VRVD@X[BJKL/F3,MDRG;);OF&N
MAM]OA;Q/DF<&EV'(T'#$E6A$SA"66+/>>LGG6CS9<J66BT=R_,9+52532R2Y
M5,9P$I;AM9RCL%:UAQ7OEUY QC(F,8,&-'"T<P&S!:,7T0$ [B@Y]ZPVF=^N
MQMFI>0&AN?<LDO8T'W3288OB(PVDX##%3$X2N]+-5\O:G6H34,GDU^I?S=UL
MU1^;JH)6[#BPG$MV;"NJLI2#V.57%",=@WE0(EU=UCILDPLR[EN,W?4&ZX0V
MNUT^$CXY'[!)(!C@UN_<J6L-PT$TKJM.,L35&89FUF=K]*:[,%<#CC,YQ<(V
MG\E@=PKFF<RJE]@ : -R@>D'$>1_]\-U]?<_BSD';B"'^M!YD<T?JH_; @PO
M4Z\Q5G]]U_QER">'C$8((#ZSNG=XS#EZW9YR?&'9SR;.:^BB&(,]-L=/#ARE
MS6X*LQF&E+[6&T]SW:M0<NP7VVOPF(Z.MI7;)89V;',>WDVKCM&)>SQVW1EM
M:JU4.]!4;D&"S=FRS9)L57F*_P!0*>WTC2YV) <]W(Q@.]QY K5C+.UML98S
MJR9+NUUKKIK3FV!T5WS">CLU++LDI[>T]SLV8<1Q/:776'C<E]TNG%=D(,)F
M[+M!FO+=RRW<V!]#<X74\S3NP<,0?0(!0<W:%YEK\C7FMT*SH3#=+/([YMU,
MIP964 +BUK'':2 LY=5)=!C'#;O"JT50$%=F'(,-^/W<41+G'.M8_7G4ZVZ6
MV7_49$R]5-KLX5;,>BE?$<64[7-[(.*O6&%I=7P0QT\<<,3>&.-H8QHY&M&
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MH703,<,1@X8@X=@@$(9PY=T;S3<-/\P5.A>?97QW>WE\V7JV; 1U5#O:T/.
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M?+A4N/""^"2!C2?RN)@Q"CZ*]O-CLV&U:):RZM&-^?*DY+RH7<4UHI075<S
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MH" @(" @H=R#P^-CQW;0X#G&*#7Z*AHA<.)M/%Q<3SCP-QY>8(8;#&T,!
M[&P(/: @(( ZY7F$OWOF@^,L03)E'^5K'_#Z3VAB#-'<4'$V=_\ ?'9>W;?B
MCT';+>5!5!\Y&<6! Q/9W((PSUU?],M0)Q7WBS^37IO=17:@>^EJFO\ RN*,
MC'T5.1'DG5RS]EV*49/U:O%)0,/'#15U/35@8>822ASB.VIW#S'U>M2LR1-;
MFG5VZRT3R34TU%24E,7@?BB2-K7-![";AON2NKKIED:K%VHK6ZY7_8772YRR
M5<^(W8&5Q#=O,%$R)7:WA  ;@!L ',H'T0$! 0$%"@PE-[O'KG(,X-R @("
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M>$!K03L 'WD[LHZ/LB1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M&5&Y 0$! 0$! 08.Y>Z_0")9Q$" @(" @(""TN/N23T/3""WLWL4G;"#)H"
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MW(SMGTT%X@(" @(" @H4&+MGLT__ !RH,J@(" @XZZ^'[,R?[[F_P(.HM/\
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M @("#%7C_*]%!>T'N2+M?A07" @(" @(""WKO<DO:065H[V7T$&50$! 0$!
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MC[B;1Y8U[7;<.%3$#ZJ00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MD[7J(/%K]S#ME!?(" @(" @(*'D[:#"4_P"T!ZYR#.#<@(" @(" @(,7=_\
M*[909&+V-O:0>T! 0$! 0$%O6^Y9>U^%!8V;?+Z'IE!ED! 0$! 0$!!B7?M9
MOH>D@RR @(""&^M/YCLT?JX/C$:#%]4'S)VGWS5^V()W=WI0<U=9GSA:*?QZ
M7TX$'2K>]""J @(+>L]SR>M*"PM'?2>@@RZ @(" @(""A08./]I?]0HEG40(
M" @(" @(,;>/86>N0?:V^Y&=L^F@O$! 0$! 0$'EW(@QEL]FG_XY4&50$! .
MY!QUU\/V9D_WW-_@0=0Z??R-EOLVRD]I8@V1 0$! 06]6>&DJ#S1O_PI BT5
M!P&U>MM65\H*;13RE, :CLI@!4=E,!Y1V4P*^4I@;7DN7C\K/,6?A7'Y$8PA
MMRY$"D$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0<]=='S
M(U/\2HO\3D&S]6+S'93_ %$OMTB02EY 0$ [D&)@_:C_ .TB65&\HA5 0$!
M0$ [D&)N^^+M.07U%[EB[2"X0$! 0$! 0>)?8W]HH+"S]Y+ZX(,D@(" @XHZ
MXWG=TW_5L^/,0AVG![#'ZUOI(/H@YET$\^VL'OF+_E1+II$" @(,5>?\KT4%
M[0^Y(NU^%!<(" @(" @(+>N]R2]I!96CO9>V$&50$! 0$! 0$&"J_P!H?VAZ
M:#.!!5 0$! 0$!!973W&[MCTT'NW^Y8^T@ND! 0$'$>1_P#?#=?7W/XLY!VX
M@A[K0>9'-'ZJ/VP)(PW4Z\Q5G]]U_P 8<@GI 0$!!B9?VLWMM])!ED! 0$!
M0$!!CKO[%%Z[\"#[V[W%%Z/^(H+I 0$! 0$!!0[T&*M7LDOH(,L@(" @(" @
M(,'<O=?H!$LXB! 0$! 0$!!:7'W))Z'IH+>S^QR=L(,F@(" @(" @H[<>T@P
ME#^T?1<B6<&Y$" @(( ZY7F$OWOF@^,L03)E'^5K'_#Z3VAB#-'<4'$V=_\
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M(" @(" @(" @(" @(" @("#GKKH^9&I_B5%_B<@V?JQ>8[*?ZB7VZ1"4O("
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M0$! 08J;]K-[;?2095 0$! 0$! 08Z[^Q1>N_ @^]N]Q1=H^F4%T@(" @("
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M050$! 0$! 08*K]W_P!H>F@S@2!5 0$! 0$!!973W&[MCTT'NW^Y(^T@ND!
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M>A!5 0$%O6>YY?6E$+"S]\_M!,F671(@(" @(""A08./]I#]9^%!G4! 0$!
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M6.LEHW>A'1QYDIZ&K'<]#<G"CD:>8B0C H)>I:BGJ8&5%/*R6"0!T<C'!S7
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MMV;BFOFG8JH0<9!13X/+1N Q!VJ(Y:KW\/ECLE73GK1Z?YWJ([5<S)E?,3R
M+;=<(<3CA@U[^$''DV+:+1+CMQS7K"=FO8[<1CS*6;T@(""A(&\X(+:NJJ6B
MII*RLFC@I(6E\LTK@UC&C:22=@00/FCK79,MU5+;,FVZMSE=(7&-S+5&Z2 /
M'(9F-<-RKE>*RUJ/K :HND%<S2.XB-QZ0--0.+A.W##HMZC<G9/HS^6^MAE"
MKK([9GJT7#)5?+((@;G&YM-TA. '3.:UOHJV59K,)[M]QH+I2PU]MJ8ZNBG
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MZ/N?+KBT<718\K&DMQP5+6PVXZ9E.%!04ELI(:"WPMIZ*G8(X8(QPM:UHP
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MVXF&X6Z::EFC)VXC@< <#R.!491/&U.ES=J/U=;I2TN<ZZ3-FD-5*VFCODC
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MM@;5/ PX6MD:0=O96=IT:<<:H8I6L;30M9M8V-H:>P!@O&OU?HDZ0^B @("
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M4ZKL#^R40A[K1W6OCT.S.Z%W"XLB8XAIQ#'2 .^\HE:O5&^288*?*-EAICC
MRDB#'<XPQQ7G7ZOJN'Y(9TK-L(" @JI1/26AF62CZP^G,U*?SLXDBGV8_FS(
M,=RZ^#H\C]PCXH]SL=USJ\,!A@,?Q2NIXKDKKPU$L]JR@9.2LG V8?B!!U=I
M_P#R-EO^&4?M#$&QH" @("#&9A.%@NQ_\'4>U.5N/YH]XX89.>$+[K"5>G*8
M#IRF Z<I@.G*8#ISSI@5Z<\Z8$]=6V3C.8.W!Z3EX'[M^G[4)]"\"!56! 0$
M! 0$! 0$! 0$! 0$! 0$'@M?B=H["A+B7/E#<+;J)F;)5$TMCS1<*>5@9NX9
M9>E^X"XJ_C1F(S^DY+8G=ZQC[W8%%9:>FR[!8'-'DT5&RB+>0L;&(R/N*G-\
M43[5>/X<>QQU9+7<*W.5FTJK&%U/:+W5SRCD,;^B#B!OV-A<?16W#,7Q:?TY
M5Y,UB8C]6'7.>;&<PY-O-BC Z6NI)HJ<;@)',/!N_K8+FO$S.?1M2=J!]%;S
MIY16R;*&>[;;:/,5MFD89KK30 R-+B<#+*W#%O\ 6=N73:=WQ0PBNV=J0#FK
M1MF;+9EJS6:VW"ZU3\65%MHJ:6*%S.Z#C(QN')O:3@LXB>R]IPT366@ILJZJ
M6//=UM[;CEJIA93W!DL39HP]@?'@YKP6]Z6EN/*$X9B)M'J<D3,1,=F_5%^T
M(IK0;X8; ^F#.)L,=+2NJ78#$-$7!QX^@HG*8G.H+OER_:0YBO.6;4+3;JNV
MW$= *>.FXG,IY6\7#&,#NWK+GS\,3ZK<7S:(TT[TCR_G72&6H9"V',M5-*ZE
MN+B[%DL0P8W9N:<<#]U=?DS:L_#Z*<>,S%NF9;OHAJ#6539-/LUDQ9KL;C3L
M;+WTL,/<[_QG-P]$;56<6UB%8B::2F]P+F\/.L970QF7J^C,.::W-C<U5U!7
MU;B6^3L ,;,, QKPYIX0-BGCC9$^U-IW=4;ZOZ0UN3,E37N?-URO#&3PQ&BJ
MW.,),CB XXR.&([2F;:Q[UN./AGW)/T3R%46"U4F8GW^MN$=RHH'-MU0XF"#
MB:'8,Q<=V.&Y:<DXG#GI\J8&#9V]ZS:OG/205#@Z6-KRT8 N:"1CS%!SQUR:
M.&GT5JI(XV,<;C1-+F-#7'%S^4(-PZL;1]1^4R?T$OMTB$K;K099K,TZ*YHH
M+?%QUU/ *V C;AY(X3'#MAI5;=%J]7)64;HR]99M5Q8>)TM/&)L.20-'$/NK
MQ^6,2^_X.2.2L2S*HW$1G41*J) %"(U:IJ+7OH<K5,4+@*JN<VDI\?TDIP6W
M!&;.#SN2*\4^UWGI#EAV4M-<LY?E8&34-#%',T?I.$<2]A\-.LMHNM"RX6RM
MH7@%E3!+"]N&]KV%OX4(?E_8:>>T7?,66*QO!56BXU$/1G>&&1Q'WEY7E5QJ
M^W_9^2)X\,\N-[:J@D04051,PIZ.!3V(2!U3;/)F#6N_YDZ'CM=AM[:&*;D%
M5(YC_2XE['CUVP^&_=.7?R^[1WBT M!(!*ZGC,5F2U1WFPW.TO;BRMI9J<C#
M](PM],J)3'5^:V2VSVF2\Y0K1P7#+U9+221\S6O/#O7F>33N^S_:>3?Q[>\-
MK7'&KV9ZJ*4*J 4D/G4U$5+3RU,[@V&%CI'N.P!K1CBIB,RK:V(SZ)PZD.7J
MEN2[YG.LB,4N8+C))3.<._IHPT _W@5[=(Q#\^\F^^\SZRZG8P!H! V*[F<5
M]<; :N:;X?HV?'F(0[3@]AC]:WTD'T0<RZ"#'775_'_O,7_*B73#FCA. &Y0
MAS)UKJ6HLU?D#4BGB+HLO7417!PWMIZDM8#]TE1:,PUXIQ*0Z:HAK(8ZJF?Q
MP3,:^-PW%KAB".WBN7#UJSF'V1(B1$""(NL=>W4&G$]BHR3>,RU-/:K?&S:]
MSY)&N?@.Q&URO7JPY[8AT7D++8REDJPY9'="UT-/2$G\8Q, )73#RYZHTZUM
MAEONB&8XH&%\U&R.L9&SOOS,K22.7<DD2^.GUZI\PY(R]>:5X?!54$!:X'?P
M,$9';Q:5RVA[''K5LJHL*4" @(""F.W#!$(ETVXLU=9?,-V8WCM^6+>V@;)O
M_/RNXL/0P*WI#S^:=7598"-P6KF1OKMDB;/>EV8;!2-#JZ6G,E(#RRQGB ^X
MHE:'..D>9VYHR71U$CO]?0XT-?$>^9/"!B#CNV$+SN2N)?3>/R1>L>QO78YE
M1O$:JHG4Q&*@Q.6"SCF&FROERX7NJ<&MIHG%@.&+I""&@8\JO2,RSYK;*RD;
MJI92JLM:0T%3<FEMTS!43WJL$G?A]20T-([ 8%Z41A\M><RG%K-FX*5'KA;S
M!!0M;@<0,,-NQ!R_I:?JWUSS[IM72%E!F&<YCL+G[&.?4DRU#&D[SQ2#9V%:
M)'1.(QP__!:90JI!!Y)P('/N42ESK2RQZF=:8NHVBHL.GE"8Y:EIXHQ<*G@>
M&^N:>(>@LY'430TM!P"J'"WF"#B3(X__ +X+KZ^Y_%7(.W4$/]:#S(YH_51^
MV!!A.IVW'0RSDX'_ %5?]WRER"=Y&C 8 ;^9!Q)=+><C]8K-5GJ>X@S?&+K0
MG#N3(T.?(,>=<O-7+UO"Y-<-[!WKBA[N%5*)$08HD3)U1IFRE=G357(6G=,X
M$FK;=KA'NPAI3TC<3R;6+JX:O)_<+Z1#NIC,!A@!AS##8NUX;UP##<% @#K=
M62JETSI<VVYN-PR?=*6\M(W]%'Q1R;OUF*B5JSB6XY7O=%F3+UMOUND$U#7T
MT4\,@.((<T8_?6$Z/0K.C+(N("(%$R0C_6K.<.0],LP9B<X"HAIS%1L)P+YY
M2&M:,>=3$95M;#:.K]E&;)>DV6;'6,X*]M-TU6.:29Q?Z170\Y*' WF1#R]@
MX3B$'$N3(#DG6'4+3NIXFFJJA>[67[&/AFQ<\,)WX&0+EYJ]WK>%?LE4;=O(
MN5Z@@("#XU55#14\U7.X-A@8Z21QV -8.(^DIB$6F(AC^J/15%VASGJ%.W&G
MO]UD;;GN;OIJ?N6D=@XKT*1B'SO-;-I=.\(QW!68!:W#<%(Y9ZY=IJJ6UY1S
M_2MQ;EJXGRYP&+O)ZGHV'T!M6=XS#HX+[;1+ 4E5%6TL%93D.@J&-EC<-Q:\
M8CTUY=HQ+[&)S6+/NJIZZB(4Y5. )PY-ZB2-6GV2VNS[UALFY?@'2V_*[:B[
M79XVB,NB<R-IPY2[A7;P5QJ\#S^7,X=WAK2,<!CSKM>*KP-YA]Q!1S6\). &
MSF0<J]=_(UPO^0+3FNVQOJ*G*E4^IDBC;B[R>HX!(X]AH9BJ7C,.GQN3Z=XG
MTEQ333QU5/'41'$2#B^ZO%M7$X?J7C\D<O'%X?14;"22\R2,AC?*\X-8"YQY
M@%-(F5.6T4XYM+JSJ*Y'J1%FC4ZMBPI[O)'16DO!#NCI0[I' <H=QC ]A>UQ
M5VUB'YAYW/\ 5Y;6]7:+6XL:<!CAS+5P/7"WF""A:T G ?<"#BG.T)R5UF;Q
M33-Z*UYRHH*FBD)[ZIIXV,>/[Q*YN:,P]3P.3;9NG*N-[W150F(R(J(E0D <
M1V ;7'L<JCNB=&O=7"WRYOUOSQG_ 'VRRP4UEM\AV-<]S'B;@Y#M;M7H<48A
M\WY5\V=AM:WA&P+=Q("ZY8_^PE](_P"]4/8__4L03)E'^5K'_#Z3VAB#-G<@
MXESOMZ\5D[=N^_2.0=JD'#'82$'*%*UN3>M'F.RS$Q4^;K;%74>.QCI8>-\F
M!_*V+*\.OAMA-H./(LLN["JA7(BPB!3A.#DYU&1!FH,1SAKQIOE"G:Z1UEF?
M>*UP'<QL[D-Q._$\*UI#CYK:NM(XN$#=LWK9Q/H6M/($$&=;'*MRS!I)6W&Q
MMQON6:B"_4#6-XG.?0DN+0,#CB"HF%JSB60R!FVASQE"TYGM[N*&N@87#\9L
MC1P.#L,<#B"N>8P]&LYALP.(Q5,I%((0BGK!9OERMIQ<::VDOS%?"+79J=@#
MGOJIR ,!V@K54O.$MZ2Y.&1-/,OY3=@Z2VTK62O_ "GO<9'$^BY=+SV[\#>8
M?<"(4+1@=@0<X]<"R5C,F6+/M  9<E7:"YU&S::61KJ=_P!PR JMFE)Q+9+3
M<J2\VVENM!():*LB;-"\;06N"X\8>W6=VJ]0%(*$B(0AUAG29G@RYI-:I +[
MFNX0#H\,2VEA>)'O(')^;6E(<OD6Q#L:DHXJ.FBI86AL,+6L8!S-& 74\I]R
MUN&X(.?.MM:IAIY29KIHW22Y:N-)7R!@)<(6RMXR.? *)A,2DK+EXI\Q6"V7
MRE?QP7"EAJ6NY?SK [ X<HQVK.75$Y90*$R(J(")><=N&&..S8I3" ;7$S.O
M6U9=*<&6BR59C2OEWQMJ)G2'A&&S'!ZM#"[J4L',%=DB[K#Y9FS-H]FJWTK>
M*K91OJ*=O.^$A^'W H6K+5='<QQ9JTURY>8]CY*413LV$MDA<6%IPY1PA<UH
MQ+TN.V8;RH6%*! 0.10EKN><P4^5<HWG,-2[ABH*667LEV!P'HJ8U5F<++JI
M9>J+'I#;YJV#H*NZSS7&1AWX3.Q:?[JZGF3*^ZTH T.S1L'L<'QB-$,9U0?,
MG:??-9[8@G=W>E!S5UF1CJ%HH.>_2^G @Z3:UIQ.&]!\ZB&.6-T,@QBE:6/;
MSAPP*#@#)T,V4\]YXT\N+1%/0W2>MM[.1U)4R/>TCGP'"%P<]9SE]#^W\T8V
MI"!V8X;]JY'LS.%,$%$%4-&MZ@7MM@R?=JW'"=U.^&G:-KG2RM+&!HY3B5IQ
MUS:'-S\D5I,NB.K-E*?*&C66[96,#*V>*2OJ0>^Z6K>93CCN.U>K&D/D;SFT
MI?#!R@*5#A;S#[B#F?K505N6KGD;4^ABXH+'<A371PV<-/5C@XL>8;56T-*3
MB4LTU1#64T-93.#Z>H8V6%XW%CP'-^Z"N>8>AG+ZJ Y$%%."%"]K6ESW!C&C
M$N=L '.2A.B&.KM#+G/5?4+5-V+K2^<6:RN<W!KH(7%SG-Y#W0WK>L.#DMF7
M4G"WF'W%=D%HY@@^<C=VX=M!RI;1)IKUE[_:*S&*R9[@;5VR4]XZN8&\31CN
M)(P "I:'1QVPGX<N.SE^[M6>'0*!5"'SEE9#$^:5P9'&USWN)P :P8D_<4X$
M&:%Q_6!K9G756'N[' QEDMDVPA[J<M#R.;<M8AQWG,NIN%O,/N*S-7A;S!!I
M>K&6AFO3V_6(-!?4TLG W#'%[6D@?="B5HZN2M%KXZ\9$HH9FF.LM;G4%3$[
M8YKX3AM^ZO/Y(Q+Z?Q;Q:F$A+)T1(B1 05!.. &/:1$ZPU72RGDS=UEC50CC
MMF4K:X22[VBIF<PM;LY1M7;PUQ#P?.Y-UG:'"W#<%TO,<==>\86S)_ON;_ @
MZCT__D;+?\,H_:&(-C0$! 0$&*S(<,O7<\U%4G[D+E?C^:/>.!F3=R.Z7WV#
M*O3]E,"OE'948%.G[*G =/V4P*^4=E,!Y1V4P.@^K#)TAS$.8T_WPY?._N\?
M+]HZ)7ST: K @(" @(" @(" @(" @(" @(" @U:NT\RG<LR4F;JV@$N8:(-;
M35ADE'"&X@8QAX8[>=KFDI6=L:$ZMFX!@0=Q]!1(UJGT]RE2YJDSK#0!N996
MN;)6]+,<0]H8?S9?T8. WAJF)VQ@F,ME<P.& .'W% U/,VE^1<XSMJ\Q6>&K
MJVC#REKI()B.0.DA>QQ&SE*F)F"=7VRSIUDW)P?\VK3#0/DV/E''+,X#D,DK
MGO(['$IRB8RS=PM-#=J66@ND$=913MX)J>=HDC<.RUV(5<:Y2T>GT(TIIJQM
M=%ER'RAAXFM?+42Q8_JI)71_]E6S)AN-58;=66NHLT\(-LJ8'TLM,S&)AAD:
M6.:. @@8'#N2%2VLE=%KEK*5ERE;([/8*?R.VQ.<YD'')+M?WW=2.<XX]M6M
M:91$865;IOE"X9DI\WU-O_\ 4=-P]'7Q33PN[G'#B;'(UKMAP[II2DS$8)C+
M;$2(,+FC*ECSE:G63,5+Y7;7/;*Z$220XOCQX3Q1/8[9CSJ)A,3A>6JU4EGH
M(+90,Z*AI8VPT\6+G<$;!@!Q.))V<Y5IUG*L1B%Z!@H2J@YZZZ/F1J?XE1?X
MG(-HZL7F.RG^HE]ND2"4IU%'#6T\M-4MZ2GG:Z.6-VT.8\%I'H@J$Q+\[LUY
M;J-%]3;EDVN!9E2]U$MPR]5.'#%&V9[CT.)V=SWHVKC\CCSK#W_VWRML[;,S
MC]SG7G3&'U,1$QF)"IA$3HH@JB,9'.:UI<XAK6C%Q)PP"BL9E:V*5S+Y:/Y/
MEUJU2@KW1.=D')T@EFJ"W&*JKFG9&#NV8GG7I\/'M?'_ +AY,7MB.C] H&AL
M0:-@&P ## +K>*]EN_F.]$N$>M?IW4Y&SQ#JO9Z=S\OWDF',G "1%*",)7'<
M [$KGY:;H>G^W^3]+ES/1'$$T-3$R>!XDBD:',<-H(.U>/-9A]]2U;QF)?10
MF!0")B<*'L*$5KF6&S)>'6NC$=*PSW:J(AH*9@XGOE><&X#ME='%Q3:7!YWE
M5X>.<=7<'5CTF^K#3:FBKA_ZDOK_ )5O;R""9YQBQA!.S@80WMKVJQB'Y_>\
MVF9E-C1@,%*BA;CRH.*NM%I+=,K9C^N/)U$^>WRXC-5# TD\+=O3X#'DXB3@
ML>6F8>AX?DSQWRC.U76@O5%'7VZ9LT$@!):<2TD8D'LA>1;CF)?;TY:<E=T3
MJO%5JJ$)QW"0 2=@&](C),9C.<0U^WV6[ZR9JI].<I%QMSY&_.*[Q NCIZ7B
MP=M&S$C'9BN[@X9C67S?[AY\3&ROVOT<RGEZV94L%%ERS1""V6V)L%/$-@#6
M[]_.<2O1Z/EV:0<4=<;SNZ;?JV?'F(.U(?88_6M])![0<RZ">?;5_P!\Q?\
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MT\SY:-1,KT>9+4\8SMX:NFQ'203M/"]CQO&!!WKGF,/1I?,-K!Q"JO,*HF!
M4K0P>:\UV?)E@K,Q7V=M/04;"]Q<0TN(!P:W'>3AL4XRSM>(:9U9<KWB]7&]
MZXYMIWT]YS?PQVNCD!:ZGML!+(QPG##C#6OW+>(P\V]LNE<%9F(/G,T/9P.
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M4F'52VB=*2MI:^%E103QU5-(,630O#V$'F(6<PTC"VN]^LU@I7UU\KZ>WTC
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M_P"&4?M#$&QH" @("#$9G.&6[R>:AJC_ /DN5^+YX]\#\]F5 X0OT+"N5?*
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MP#<.92J^B @(*.:'# ]O%!J.H&G&4=2+%)E_-]O;7T$FUA)<R2-XVA['L+7
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M(" @(" @(" @(" @(" @(.>NNCYD:G^)47^)R#9^K%YCLI_J)/;I$@E+R"F
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M&';AM0>@ !@-@050$$ =<KS"7[WS0?&6()DRC_*UC_A])[0Q!FCN*#B;._\
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M\98@F3*/\K6/^'TGM#$&:.XH.)L[_P"^.S?_ $WXH]!VRWE050$# ;^5!:7
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M 0<\]=+S(U/\2HO\3D&T=6+S'Y3][R^W2)!*7D! 0$&)A_:K^VY$LJ-Y1"J
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M 0$! 08Z[^Q1>N_ @^]N]Q1>C_B*"Z0$! 0$! 04.]!BK5[++Z"#+(" @("
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M@(" @(" @H4&#C_:7_4*)9U$" @(" @("#&WCV%GKD'VMON1G;/IH+Q 0$!
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M! 0$! 0$! 0$! 0$! 0$'/771\R-3_$J'_$]!L_5B\QV4_>\OMTB02EY 0$
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M !B2=G;4VM-IS/56M8K&(9%0L(" @(" @(" @(" @(" @(" @(" @(" @("
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MR63C<WA) Z)C\,.RB4T?:ET"^FU+X"K\2B#[4N@7TVI? 5?B4#[4N@7TVI?
M5?B4#[4N@7TVI? 5?B4%E<.LWH14\'19SIG<...$%5^&$(/O3=:'02&!D<F=
M:4/:,"#!5XC[D*#[?:ET"^FU+X"K\2@?:ET"^FU+X"K\2@?:ET"^FU+X"K\2
M@?:ET"^FU+X"K\2@?:ET"^FU+X"K\2@?:ET"^FU+X"K\2@?:ET"^FU+X"K\2
M@^-3UH-!9H7Q1YUI7.<, !!5XD^!06]!UFM"*8.Z3.E,WBVC&"J'_P %!>_:
MET"P_G:E\!5^)05^U+H%]-J7P%7XE ^U+H%]-J7P%7XE ^U+H%]-J7P%7XE
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MXE ^U+H%]-J7P%7XE ^U+H%]-J7P%7XE!C*OK+:%35 ECSE3.;@-H@JN3?\
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M8UK6C  #F "#[H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MP:"1R%;5I,S&[3$L+V^'-4^4_2>3Q=+@9>!O&1NXL!CAZ*3C.BT=-7U4)$!
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M3.$.+&=&/S>[<@DMHX1@@J@(" @(" @(""A4"SN%93T%-+653Q%! TOD>XX
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M@P!P!&!01WI_HCDK32[W6]Y7CG96WC'RTSS.E:>*0RGA!W=T4$D 8#! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MM]-2PRTU-'!(^-G&Z)@82.$;\%>TSE2L1B&6 P& 5%U5((" @(" @(" @("
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M6V):5INC1H5)UE;97P,JJ++5TJ*:3:R:*%SF.'+@0%M:LPRB<]7V^T53[?\
MTI=_@[_43LGND/)&=6YTM?RG';JBWMXS'T-4TQR8CEP("F:XA6)UPVL;1BJK
M" @(*.&(43(U;4*>>AR;>:JF>6SLI9'1OYC@N+R].&?\=W7XE(OS1$_XT:+H
M79K=!I7;VMIF&.NC=-4\8QXWR8@DXKTO-K%8VQVAY_#,S>9G^9KG5MLMOH1F
MD4T09T=SEB:_>X,:0X-QY@24K,_0KGNORQ/]Q:.T+NZM%%UCK8:=HC-=:O\
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!:U/$()71>R
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MX<F.X'M*W'-K5F*]$6B-V9ZI J7TWDTIJW,\GX7=(Z3 L#>7$\RSF4Q[$=9
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MEL-+YQCKJF^TUU!<Z&FK;5*R6@E8'1.C[PMPV8*]XFLZ]6-9B>C+*%Q 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MDM.PN#&C%[W_ (K&CG)65[XF(CK*U*YSZ0B6'7_,UO9'><V9.J+3E"L!-#=
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MB^^OVPW3JU0OBTNH&SL='(99CP/!!W@\N"[_ "(^3_;5R4MNM:<8S,IHC(+
M1N7*V>D! 0$! 0$!!Y> 1@41*.-<;E7V?3NZ5MLG?35<8BX98S@X8R-&_M%<
MW),[JQ'JVXXB8G/:&5L%;5R:>T%Q?*YU:;:R8S.VDR=&#B<>RNG]PGZ<WF/T
ML?!_J17=W:_H;F*\YKR:+K?ZDU=:*F:/I2 WN6G #!H&Y;<U(K$3'>(8<-YM
M-L]IEKN5*NLDZP.:Z*2IE=114<3HZ9TCC$T_F]H;C@%AXT9XK3/\T?@]#RM/
MI^[\TZX#[B8<ZJD$! 0>'' ]M!'^H&?--<OL=:L\W"G9'48?Z*2)\[G8;<2V
M-K\-V.U4B8FVG5;6(SV93)N;\I9CMK'Y1KX:R@A:&M;%BUS&M P!8\-(V=A;
M6B>LLHF'VS-GFQ92DMT5[J# ^Z3MI:,!I=QS/W-V#8LZ_%;;W:6TI-NT-E8\
MOX7 XM<,?NIT5?12D0$! 00!UAG1/S!D>FN[BW+<M>!7!V)B)XF<(>-V';6?
M!C^XG=Z?#[VMIFO%-H^WW-7ZP]%DFEI,MFW,I::KDJH@\4;&L<ZD._BZ/#N>
MVIXZQ/D1F=/S37$\-K=TU2V_*+<B\/04HL(HAABQICX#&,#L&]/+SBT]V'B8
M^'#3>K6^I?D.8/<]U&RNF;0.?C[!BW# 'DYEU\\Z5F>N(4TF]MO3*;USM! 0
M$!!87>YP6BBFN-6_HZ.FC=+._#'!K=I. &.Y4M:(ZK5B9G1:V',MGS+;X[G9
M:R.MHI1BV6/DQY"",?NK28F(S*D6B9F/1DNE<,>(^@=F[LJB8:L_4;+3<SP9
M/CKF3W^8.>:6+%W!&T'$N<!@-VY3Q_'$S6<X3;%?FT;>-H!4H50$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$!!Y>0&DG<$%C\JVP$M?70!PV.!E8-OHG8HSDP\NN]I:!A74YV[NF
M9S'LJ,83.B$-;ZNDJ\VZ=>35$<N%V'%T;P\CNHQR%6\.O_9F?8S\G_@E/D8P
M&'*%$]%^[ZC<I! 0$!0/G)%&^-S'-!:X8$'E!46K$PF&+LV7[18(YX;13,I8
MIY'2R,8,&E[MYP"O-IF,2K$>CU?KK#8;-6WFJ#I(*&"2ID;'@7EL32\\(V8G
M8L[WBK3CI-IB/589/S/19OL%'F*B9)'1UK..-DPX7@8D;0"5K-,?<IG$S[)P
MV./ -P&W!4@P]*00$!!0@8'8@Q%9ERSUUSI;O4TK'W*C'#!4X=VQIVX8\VU5
MK.WIW)C/5DW!O =FQ,8.K3K;G^U5V>:[(<<,HN=!3MJI9B&]"6.X< T@DX]T
MIXXWUFW\MMO\,G).R:Q_-&6YL+<2&\F]2/: @(" @(" @(" @(" @(" @H[<
MHD8ZZW.AM5$^X7.=M+1Q8&6:38UN)P&)[:B<9P1$SJQ[+/E^]U]'F,0QSU4+
M ^CK0,#T<FT8;-Q5ZYIGVDS%HCV,\W@(Q;@>R-JK$$O> *D5  W(" @(" @(
M" @(" @("#RX#A(001K4 -2-,OXA+_BA4>)_SV]S3FG_ *\^^/QAE.LHT'2^
MI &P5=)]^4*M/^?C_P!T->*N:7]E9G\$E92P.7+7S^20>U-73S1CDM'M</%.
M:LW@L6H@(" @(" @(""A:#O0?"HB@D8YDS&/B<,'!X!;Z.*KT2A+4W+6A5+A
M69DJ*>SUPQ,,MO=PS\> _%A#MO;5(F8^5?MB>B+LIW[4.',5/3:4376^Y0;,
M!6376-K6AAW\+GEIP"Z>#$S\;#G^&/@=A4YD-/$91A*6-XQS.PV_?5+8SHFN
M<:OHH6$! 0"H'/G6+N=!9\PY&N5SG;34--7=)/,[<QC2,20-JKX]L>3_ /3+
MIM&?&M[X8;6S6;3#,^G]99[!F6EKKD^2(LIXQ*">$[=KF ;%&/ZE)]+?DKQ6
MV_<V_*FONCUMR[;*&MS;2PU4%/&R6(MFQ:X- (.$?(NCEGXO>Y..,1A).5LZ
MY<SK1.N>5[E'<K<'%AJ(@YK0X;,.[:"J;)B,K;HF<-C&X*JRJD$! 42*$ [U
M7JEC+M06FNA,-VIX9Z0CNFU#6N9_VMB:=R)F.CG#4.TZ#V2MJ'T%XJ+3F/>V
M"QN?([B&. #&-+=_941,_IROI/S,AHG?-6Z^]B&[054^1"PBDKJ]K(Y\!CAB
M,>+$GL+JXXB:7WZ6TPY>29W5BORND&@[.;#<L(Z-N[V-RD$! 04.!.!Y-OX%
M ^4S&$<):#Q8CA.XJ)T3C*)M2,LZ,/IW5></)+<X'B-5"1'.#M_1ASB?06>.
M\+[I[]$%TMXS)07IM-H97WF^4W$WIHZV+_2MC)&(:Z7A*VX<S;XLX]K*\5Q.
MWJZ_L3[E+9J*2[,Z*YF,&JCW\,G*-BM>(SIT9\>[;&[JRBJU$! 04.Y!INH6
M<:S)MJBN%':IKQ(^3@\FIQBX#GWA4F=5XC*);AK)4W9O1W/3:JK(_P B:%L@
M^^2D5B)TC1$6[2L/KTI,H4SJL9 FL](-AE$3(6]K80K7OC2-?8K6DS*4-)]4
MX-3[;4W&GM\U#% \-;TH(#\<=H)WK2]-M(MZLZWS:824SO1R]M9PT>E((" @
MLKO$Z>V5<+,0^2)[6X;\2TA8\U<TE?CGXH0KU<J^""V7W*T^$=XM-PF%5"[8
M[A<X\+L.7'!=M[QR<?',=(K$,KQMYK1ZSF$JU&6+--?8<S/IVF\T\9AAJ.41
MNQ! ]!RYHM-*SCNO/Q1$>B)-49X<PZI9,RO1'CK:*1U=5.9M,<8!:.(\FU7\
M2)KS6Y.VV:_>KY49X8IZVA/,/>=C'$=H[5"7T0$! 0$! 0$%'$\F_F01/K[8
MKI>LG&>U1.J:BUS,K7TK-ID9$0YPPY=@7-;->2G)_++HXYC9>G\T8?&RUV6]
M:]/);5%TM."V."OC,9CE@F8<0 'C ]ZNOGXXMB\])G,?8Y>&^W-8ZPV6ON]@
MTMR;!->:QS+9;8HZ6.9S"YTA:WA:.%HWG!9<_+,VSWM+3AXL1B.D-!T$HKC7
MU>9\[U5*^AH\P59DH891PO,;=O$6G=CBNB(V<-:3UB9G[U+VW\TWCIB(3LT8
M!8PEZ4@@("B18W8?^7U)'+&[TEAY&O'/N:\.EX][D32C1BOSSE^HO-+FZY69
MCZVI;Y)2N#8AA*[: 5U[<</'_LK^#GW9Y>2?]=OQ;X.K'=__ /HMY'8,@5(:
M2S&5- ;EEG,5!?9L[W6XQ4,G2.HIWXQ2@M(P</15HE683HWO1VE5*J @(!."
M#RX[-F_D40(!UE-9G//-@TW94OI[1,#5W01$M<^-OXN/-M4>-%>2]L_IA/-:
M:<43ZS"2+3I7D&TT3*."P4;XXP&@S0LE><.=SAM4[LZ2C&$?:NZ3Y:IK'4YM
MRS3-L^8K,WRFFFH\(FD,P+@YK0!M"SM>W%BWMB/OEK6(Y-)]$C::Y@ES+DNS
M7F9V,U13Q],>>0-[H[>R%U\](B[DX;9C[6YK%L(" @((FZQW2#2ZYN9&^4L?
M!(8XVE[R&31NV  X[ESW_P"6D^DMJ8VV]R-Z+K-97I\LQ69^7[TZ=E+Y.9/)
M3P\?!PX[=N'H+H\J/J3,QW<_BQ].L9ZPU[277VP9!R;3Y>N=BN\]7%(^0R4]
M*XL(?AAM.',M.6^:TB.L5K'W(I6=]L][3/WITTWUCL^IE364UJMEPMYHVM<\
MUT)A#@[D:>51/'-:YE,WUPDQAQ:#V%G$K/2D$! 04/806=PN-%;X'5-=4,IJ
M=@XG22N#  .VJS;"8C*%<[=9/(]HAGI[+'+F&=F+'FGB>:5CMV#WN:!ACLV*
MML3CWX6CI.>S%V*S:S9[-NNMQJ*7*^5I2RJBMM![*]CB'#$@G>.==,5^GR9M
MKCLQO?ZE(V:>UT+2L='3QQN.+FCA)YR%DOA]D! 0$! 0$!!0JLB*NL(YK-,;
MT]SL&M;$7$[@.D8N;FMMFL^UT<,;MT>QJMEUSTGILA45HFS52LN,=N;!)3D2
M\0D$>!;L9AO77Y]?J3>/7+E\*=L5^QKNAVL6F65,EFV9@S)34%<:F63H)!*7
M<#CB#W+"M>6V^M9](9<48FWOED-,<RV/-6N^:+UEZM97VN>BBZ.HB#N%V!C!
MPX@.55\>N.&W^Z/P=?DVSL]WYND>949*HD0$ J)'PF.\#?AB%%_E.[G;22SV
MG,^>L^7/-$$=;?*:Y.IJ:&I8'\-,T$-+6NY, -JMQ1']O6U?FG.?OG'\%_(F
M?K36>D8Q]S(:@Z:5V4:YNHNF,/D]WI#C<;1$0VGJ8!M=W(PP<%6O+:D_%K7_
M !JG;')&._9J^HV>K1G^W:?WBV2?G1>H(ZRE=LEBF:07-<T[1@M.*F/+X_2=
MW_IEERVSXG+'>-O_ *X=04V BB'+P-])1;KDKTA<*$B @("#4=0[9E.Z9>JX
M<YN8RR-9Q332'AZ/ 'N@=X/:6-XC,>O9IQYG2.Z+LO9"T7M.6:C.)JS6V"J@
M?$VX5CS(UL(<6$1AS00<1L6W+/TZ[9TRSX_ZDZ=D4TE%HE67=M*[.MYCRZ]W
M##;YFR,H7=UL:'EF[:E*S;2_S%IUF:].[KO+]NM-LM5+1V5C&6UC *;H]K2W
M#8<1OQ5KYSKU9TB,:,TJM! 0$!!:UL$-3&^"=HDBD86OC<,06G8=G*JVK%HQ
M*:S,3F.KGK-V0;WI14U6>]-JL0T#"Z>Z6.I=A3O:#Q.X.]P."I'+/%BMIS5:
M>..29F(Q9@3K5FW6*HI\H9 @;:)*B$.NUQJ7!KF =_T7=#$8#85M/#OS_+&%
M(Y8I&OS3T3#IMI+E_(,#JQO%7WZI'%672H/%(YYPQ#3AL&*M-XBNRL8JSBLS
M.Z\YE)8W!4:*H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @^50QLD+XW=Z\%I[1&"I,IA"%=U7]
M*[E635]1!5&:ID,DA%5(&\3M^ Q44C9&.J;6W:O@>JAI*&EP@K !O)JI !]]
M7C-59^)>V/JV:86.YTEZML52:VCD;- \U+WL#V'$;,=NY6B_TYW0I>OU*[93
M1&T;\<569[+^U]@I! 0$ [D'PEJ:>)P;+,QA/(]P&ST56,)>/+:'_O$7]]GJ
MJR&KZD5=(_(>8FMJ(BXV^J  >TGV)W96'-&:NCQYQR1/M8709K7:7V$D?Y'_
M #%=O+UC_;'X.2/FM_NG\4EM'",%BNJ@(" H'R?(R-H,C@UHWN)P'WTZ)B,O
MGY=0_P#>8O[[?51"CJZBP]T1?WV^JID0;EI[).LAF1S'A[3:XMK3Q#_)Y0K>
M+$QPW]M_R5\NV>3C_P!O^:>F@8G!4RL]*00$! 0$! 0>),< !RG;VL%$]!'V
MIFI5-D"EI8HZ62Y7VZ/,-LMT1[J63LGD&U8[YF<5[=6D5^&;3TA'YZP-YL#)
MJ3/.6I[3>I6<5KIF'C94$[FXDX@XK:_3X?FRK,8G/Z</%3J/K19*)N:[UEV!
MV77@324<+R:F&%W=8G=M [*9BD[;SK/=''_4Z)LRGF.@S78Z2]VYY?25;..,
MG>.<'LA;<G'/'.)8\?)OC+-K)J(" @*)$6=8<?\ VEO_ &J?V]BSC_EI_NAT
M</ZO=++95>Z/2VVR1DM>VT1D.&\$4XP6G[A;&^8<WC1TSZM;ZN-?7W33QM5<
M:J2KJ#63M,LSB]V (V8E=/-7$5]ROZ[>], ..*YH754@@(" HD>'[6'!!&6=
M=8;'E"^T.6(X*BY7ZL>UK:6E'&8VN_&DVC#!5XIF]\1T3>-E<RN-0]4;9IY9
M:6MKHI:FX5^#*&WQ;9'R$#8<2.4I.9Y(I5-(S3=;HU/*>N];67RFR]G>P5&6
M*^OQ^3W3'BBD')B[$[3@M:1%X]K.\[83= \/C#L>^ ([1W*N,+9?9(! 0$'E
MW>D#>F1%.K>E%;J146:JH;V^RU=G=))'41-XG\4O#@0=F!'"LXIB^YKO^":H
M_N75MSE>*<T%TU%KJRC+@XP3@N87-V@X$\AW*\^SJIF<Z+B+J^9_IV,BBU-N
M3(F -8QN( :-@ &/(I[HC2V>R8-.LKWC*5@%JO-ZFOU6UY<:ZH)+R#N&WF5K
MWWXQ#*E<9;@JM! 0$! 0$! 0?.0N&QO-BJS(X\U O&M%TSA<:&>DN<N58)2*
M:.W@0\<?)B]I!PP67#&:YMU;V^;%?1ZR_5PY=D;4T^D=75UP(>:NM<:B7B'+
MB\G#T%T3;7&&&WI&4B6[6K.TE13T?U>5=+3N<&&3<UC2=IPY@K4KF=5;3C*?
M:=YD@B>X<+G,:XM.\$C'!5GJF)S#Z*$B @(/+SLPY2JSKH-6SO:<E5UO\MSK
M2TL]NH@7])6M#F,YRJYB+9CJO$SC'9%MAJ>KEF2Y-M%IM]KEK7'")CH0WI,-
MAX2=^*UKQS,YCK&K.UL8B6U7O(FCN6K?+=+W8K724<0Q>^2)HV<P[*QM;;"\
M5FULKW2B^9.OUDGJ<DVSY.LL4[F,:(Q"U[FD@N !.P\BZ+9B(RRB8S.$BMW!
M4750$! *#!9OJKI1Y=N51903=(H'.I !Q$R#=L.]<WDS:..=G5OP16;QNZ.-
M!4:J9@J9)]0;'>KQ XGAHJ=YIH, =AP80NF(K$>UC;,SIT;UEK-E1E,,-BT?
MF@E:,!.0'S;.=Y.)4Y]%<)-R1JEFS--]9:[MDZILU'(TN-9*1P#A!.&]6BL3
M&?12;8G"76]Z-JHN^B)$! 42/+N0C>H[CE;6F]ZR39SJ+19(:YV4&M80Z@8U
MKW?E 2 @K/BQ.=S?DS%8V]VMV01VB7RRITJK[O<CW]5<9#4$NY\'.("WW3VA
MSXCO*1:;6G.U(R.FI--*NGIVX-#68-8!NW JW7JCW)YLU9+<+725L\!IIIX^
M.2!V]A/XI[2B8Q**SF,L@-RJNJ@(" @^<@& Y!CM*B<)11J-K98<FS"RVICK
MQFF8\%/;J4<1#\?QR#LW++XK3MI"^W$9MT:;9-*,X:E5L>8]8*TF@]DH\O0N
M+6,&.(Z3APV@;UT5BE/]S*;3;II"?K1:;=9J"*WVRFCI:.$<,<,30UH'H*LV
MF>I%8CHOQAALW*(2*00$!!\YW-;$XN.#>4E1,P(<SMH_'F"ZMS?DF[/L&9G#
M&6K@.,51A^6T;.54C/%TZ=X7F8MC/6.C7/FCUF)I'T=3FJVLMN'")XV#I^#G
M]CW^BK8BRLZ:PW/(6GMCTX?)<KQ<C<<TW)W!-<ZL_G'XD'@8#N&(6TVF8V5Z
M,YK^JTI4BPX=F[%9+O:D$! 0$! 0$%#AO*##YAO%OR_;ZB[W29L%!2L,LKW<
M@;M^ZL[WBO5:E<RT+3S46@SI'>KE9K+-06N$\5/62QB,59C:<7;#R'E6O)39
MQ1:9S[%*ZWQ'=&%9K;GS,<=P;2:>LO5BHJB1CJ@N#V!T+B.+ G>%C69Q6]HZ
MZMIC%YI'N37IGG6VYZRQ37F@CZ DF.>G'^5*W>WT%T\E,:^KGI/;T;SRK-=5
M 0$!!97%L;J>5LQ+82QW&[F;AM6/)$;9ST7I.J&<D:@Z)Z?VN:Q6_--/T8GF
MD>'N>XB1[R7#$CD*WB^ZE/2*PRBFV9]LRV@:^Z1C9\Z:79Z[U%"RYM6LNFU^
MN=/:+3F&FJJ^K?T=/3L)XGNPXMF(4Q7*)G"0&D%JKG$X3U>E((""AY.V@\D8
M@?\ '*B',VJ^<;=D/6:UYBN]-4U%!'1.C+:6(R/XG88;#@.3G67C3MFT>K7G
M^*E8]K+#K<Z?!N M-ZQ._P#TC?&*V=%)8+./6>R/F'+5TL]):KNRJK:=\,3Y
M*5H:"X8#$AY*K>N8CWPOQVQ9*F@["-+K)Q M/1[ X8'>=X*[/(UO]CDX.D^]
M)XW+!N(" @(+&[55)0T4M;7/;'24['232/[UK&C$DJEYB(S*U8F9Q"/,A:GV
M+4*[7&ALE!+\GT(P;<)(PV.4XX'A/*MJ4GZ>^?5G:^WDV^Q>ZEYQJ\AVRGNE
M#8I+Q3E^%9T+1C%$.^=V2N;?BV)TB6L5S7/HRF1,Z6#/=DBO=A=_IWDLEC<
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M->EH[>L?@K:EJ8MUK/\ "4\1/8\<33B-XW[EGUZK=WU!Q&.Y3$BJD$!!Y=B
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M<:&]VVFNM"1)1U<8EA?AO:1VE-JS2<3U5I:+1HR#8P#Q!N!/WE7.5L/H@("
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MPC@;[.XM!#=_?<@64SA>(R@N\76GU-UFL-+87>567*72U5RK&>PNF=W+6-)
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MA;9!&'AW= G9ACMQ436:3IH;XY.NL,-;^K'ERGDXKY?[G>H&D.-/53 ,P'.
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MLYPMN.WU;;9TGU]6?+'TZ[XUKZ.A(I.-N)&!P&SLD+/*SV,3O4BJ @(*'<5
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M,D4\3<7\1YCR+**S%XM$]FN^/IS3U1]-U:\X5$+Z>?4JYR02-X'QO+G-<TC
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M8TPG++V;+%BR]&^*R6^GM\4AQDCIHVQ-)'+@T!3-K3&)5BL1.67 (&!WHE5
M0$!!;USY(Z29\0XI6L)8T<K@-@]%4OG&B8ZZN*<ZT^MN<\QOFS'E>MN.7::9
M_06B-W0P.CXCP\1803Z*CAK6)S;6?X-.:9QBFD-_LNHVK&7;?#:[-I+Y)0P@
M-CB8\M P&&._:>RM;3,ZLHB(AL^6=4M7+M?J2@O&GS[=;IW83UAD)$8Y\"2E
M*Q:-5;3,=$Z0][CRDG%0F'T1(@(" @(" @$8H/FZ/B=CCN48& S)D?+6;H'4
M^8;=!7-(+6NE8"]O9:[>"J37*8E#=?U>KCE6Y/S!I5>W6FY!A8*6JQEA<S\D
MN<';-G,K5M-(G.L3.5KXY+1,]FU:09[S'F9]XLF9A ;O8Y&PSS4I/ ]QQ!Y!
MS+?;%N.+QTF9C[F,YKR33V1/WI=62X@(""AVJ)%I<!&::5LXQ@+'=+@<.XPV
M_>6?),=97IG.$"9=T#T'SK2S7FST=14T[YI1)*VKF Z0./%L)YUI''BL3ZQG
M[U?J3,S'I.&;'53T<P_9E3\+F]5(T)U9'+_5QTQRM>Z/,%FH)X;E0/Z2F>ZI
ME>T.PPQ+2<"KUO-,^U682T 0!V%EA9570(" HD>7'#9Z)2! 6>8(KYKGERUW
M%O2T=%2OJ88SNZ08;5'B1\5[3UC1/DS->*N.DRG:,<# T# -V8=I3K*-(T:-
MK!:Z*ZZ>WR&LC$C8Z=\S"1M$D>#P0>P0N;GFU8B:^L?BWX=9Q[)?+16NJ+AI
MO8:FH/%+T#8N([\&#A'WEZ?D_/+@X/E^U(XV!<SH$! 0$&K9_MN8[MERHM^5
M:YENN\^#8ZN3<QI<.(C8=N&*SO6;3"]9B.J-[!U><OPU#+KG:MGS1=VGB=+6
M/<8P2=N#"<"%O%JQ&(A29OZZ-NON?-/=-J$4E34TU"R-I$%!2M#I'</XK6,"
MPMR3.<:KUIZZ+33?4^;42KK9:2RU-!8H6M\DJZL!CIGDX. ;B=RVVXINEEG7
M1)K,.$8;E595 0$!!\JCV)W*,#B/0*K;H.4<CZ0Y+U*S/F^JS1!)-44M>Z*$
MQ3.CP:1C@0TJGBUQP1/MEOYN/KX_TU;_ /92TB(Q\AJCVJF3U5JQF5Q1=5W2
MBWUD%?2T50*FFD;+&75,A <TXC9BD6PK,93/3QB*%D33BU@X1V@IDA]5"1 0
M$! 0$!!X?O#<-Z0B4<ZV6:LONGUXHJ&/I:N-C9HF#\;HG-<1]Y<O-'2T=I=/
M!,9F)]%=(LYVK,^3+9Y-*TUM#!'35M-B ^.6)O"X%N_>%Z/-$S;=/ZGG<7PU
MVS.M=&]5MRI:*GDJ*Q[88(FE[Y'D-:&MWG%<E[16,RZXK,H,TOJ#G'5C-&>J
M!O\ Y&V-MOHZC<V1S.#B(YQBTK7AC9Q3/>\Y^[1//>+WK7^2)A/P!!&._E*K
M$J/:D$! 06\Q+@0!R'>JVC,$.<_L_P!QK+Q>+CEO4"JM\5;5RU%5341 :R61
MQ=PNX3O&."I6+12([:M^6T6Y)M_CH\LZKV9&W!UW9J%7MNCV=$^L /3%GY)=
MCC@M8TC##K&)7M-U:[^ZZVVX7G/=;=8;=4QU3*:I!D871G'#:=BOQS%;[O3_
M "4Y:S>FWU_SRZ%BCZ-C&8]Z /N!56B'T4)$! 0$%M.]L;B]YX6M&+G$X# =
MM1H:H9S]KI36^XNRGD.F=?LVR'HVB$<4$+CL/&['>!M6<1:\XCHUG;36WW,=
ME712YYBN S=JY6F\74N$E/:@3Y-!R@%H !(QP(757''TZ^KGF9OKTCT3A3TT
M%'"VGI(VPP,'"R-@ :T#DP66LSF5\1$:,@@(" @(-6U%!.3+V!M)HYA@-OXI
M7-Y'R_:WX)Q>)1AHKI[DJZZ;V2ON^7Z.JKI8>*:6>!ID<<>4D8KOY:Q&W'\L
M.2LYO?\ W6_%(;-*--WM#OFO;MO)T#/46.&F5]:M/<G6.L%?9K)14-6T$,G@
MA:QX!WC$<BG,HQ#9P, !S*$B @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(/G(X!I!V!5SGJ(;K=
M7+C<<^PY,R1:9+G%1S-;?;GA^8A87<+FX@'%P5O'CZF9MTCI[UN2-FG=*=W=
M<?DFJ=:VM-SZ)YHVR'N#,&DLXCS8X+/DB<:''C,;NB(,FZIWFJS$,D:GVMM#
MF%QXJ";A'D\_"<<68]D##!;<58Y:YCYJ]5>;X)_TRFV+<3RGDYEGG,&'V!Q5
MA5 0$%';BJS&4H>U4S)J))=:3)VGE 16UD7255X>/S5.S'A(QP.#N595CZDX
MG3"^=L9CJMLH]7_*EMH:J7-@&8LP7)CF5]PJ^Z/=;Q'CWO;"Z+179].L:,:S
M.[?/5JM5ES/FA=:^Y90,M^T^+N.JLLA,L].S'B<YF.)Y-X5:<LZ5OK':6EJ4
MGXHZIURCF6DS?8J._P!%')#3U<8D;',WA>W'>".PK\E=DXEG$Y9\88E5650$
M! 40-:SGF&JRQEVLNM'0ON%7"S"&EC[Y[W'   =DJE[3F(CNO2L=9[(6L6EN
M;=4+C%FG6"<QVUKNDMV6XB6,8T[6=(!@,0-A"VK2O%[996O-^GPPSN=M#HHJ
MB'-6F$C<NYIHF8!E..BIJEK-S'L&SL+#?:L[HZ>C3$6KB>K*:5ZEWJ_5U1E#
M-]JEM^;+=$7SN<TB&9@('&P[-^(73-8M7=#&9FD[92VPK*&CTI! 0$! 0$!!
MXDQX=B#GK64YKLVI.6<VY?RW57^*WQ2]+%3-):'%S2,7 '#<L>"9KR7_ -41
M^:>:N^*?Z95;KUJ:#YJ;GCR[7?\ LK69T3,8EC[[K1J;>K36VHZ6W.+RN%\/
M2=T>'C&&.'"LN3CWUQZPOQ7V6BWM2+H':KG:--[71W:DDHJYG2F2GF:6O;Q/
M)&(*]+R9B;:.6-;3*4N1<;40$! 01;UA@[ZI,P!K7./# <&@DX=.SD&U8S:8
MY*6]+0WX=,^Y&U@ZR>0K7E&@L51277RVFH64LKFTCBWC9$&G \6[$+?R)WS+
M"E=C6='-<\H9"RO+:;Q27'RV2LFJ0ZGI'/;T<F&&)Q',K6G$5CV+<NO):4[Z
M?ZT96U%K:F@L5/6QS4S!(\UD!A:0=FS:579F,LYM$3A)+3B,<,%"RJ @("#Y
MRGA;B53.(F9$%YJS[G?,V?7Y#TX;'3LM;F27RYS@.:&[RQIP.W:%;AK%OCF?
MA.:=L;8ZRF2.&I%"V&20>5=$&OF _P PMP+L.WM46Q,R5TB$"NS-J-I/FNFH
M\ZW#Y;R;=J@M@N+FX24\DA/"TD[ANV8J?&G=\$QJGGK$5W5="P2LGB;+&062
M@.:1RX@$*9C$JYT]ZX&Y$JH""A. )04=M9MY0H&AYPSU;\JW_+UBK*1U1+?Y
MW4]/( "(R"P$[=V/$G%&^\Q[%K1->.;=F<S!>+#E>VNNEZDAI*%KFQ&:0 -#
MI" !NY2JQF9B/63$XGV1ED:..BK(65,+(W0RL;)&]H&#FO&(/W%I,3$ZJ1.5
M['"R(<,;0UN..#0!O[2K.92^BD$! 0$! 0$!!Y<T':JR,3?<LV3,U"ZVWVCB
MKJ)^UT,S ]N/.,=RK-8G65HM,(KEZJVDDM=Y=Y%5QG$'R>.I>V#$?U.9369C
MKJBTY23EC)&6\G4/R?ERACH:;'%[8FX%[ACM<=YWK2;S92*Q#8@,  H650$!
M 0$! 0$! 0$! 0$'E[ \8'=RCG!0:CF_3+)F>&-&9+9%5RL&#*CA#9F@X[&O
M&T;U28UT6W-&M75<TDM=6*J.WU%5@<1#65#YX<0<>\=L5XGU4]R7*"U45LI(
MJ&@A93T< X(8(VAK&-Y@ DS,D1$+T# 8<R)$! 0$%'#'8J]Q97.U6^[4<MNN
MD#*JAG'#+3RM#HW#F(*B:1*=V$2W+JMZ27.L\L=05%*=_0TE0Z&+^X,0IB)C
MNF9RWG*6F>3LCQ.BRW;8Z1[QPRS@8S/ Y'/.TJ^[LSVML8P,;PCD5/>L]#<%
M; J@(" @(" @(" @(" @HX8A!Y#,,=N]!Z#0$%"P'>@JT<(P40*J00$! 0$!
M 0$'A[^$X# E!4/Q&.!0?-QQ#MXW\BK;HF$&:'?SCJ#LV_*'*-N&+OPK7C_^
M-7_=;\D<N/KS_MK^:>5F"D$!!1QPVIC)E879Q%%4C#_*<,?07/S?%68]DM>*
M/CARGH]KOD[3_+4]BO%-<):QM;5.+J6F,L>!E=AW0(77%MW%Q^RE8_@Y\8Y+
MQ_JG\4ACK8Z< 8&BN_;\C/\ [2S:,KEOK)9&S5?:++UMH[DRNKWF.%T],8XP
M0">Z=B<!L5JTW1E69PF,'$8J,)50$!!0H/)(P!Y]BK/40+JEDG5"JS[1YPT]
M;1&>GI_)RZM=W.W#'!I!YEGQSMM;VRTY?CI$>C&!_6VW!UBVG=P-Y3ZU;,[=
M5G>+7UK+W;:JTW 61U'61NAG# UKBUPP.!#=BK:N?OA>+8E,>E67+EE7(]KL
M-W#&W"D81,(SQ-Q[!V+HYK;K9AS<5=L8;RL6P@(" @U/4;-_S&RM6YD\DDK3
M2-XFT\>(+B2 ,<.3:L.2^VT1ZM*5SE"5@OF?M97&1F;Z3+EHD.)MUN<#7< V
M%KWCA<,5O''.<RS^I$3B(8NR::9:RMKQ06>&%]?$^C=4S25[O*'OJ,-K^Z[(
MQ5_'G2_L6YH^"L^LNI886LC#&=R!B !N^XLLYE2(Q#[M&#0%9*J @("#YSC%
MF&X8[3Z"&4/W;.N0=,LQ-L=KHGU.9+[4L?44M$.D>#(X-+Y-O<@!5X(S\$=%
MN2L_//5*CJMS:1]1%$7EL;GB,=\X@$X#LE+Z912=TPC;)FMELS)>I<LWBWS6
M#,+'%L='6C@Z7 X#@)PQW*W''U*YCK'7V(Y(V7QV]4KQG%@)&'8&U!Z0$! 0
M$! 0$%-[NTB%A<ZZAH*>2IN$S(*5@PDDD(:T8[-I/;5+3'1:,HES'H5EV^UK
M\TY/NL^7+M6?G):RWR%L,G%MXBP$#LXI\=(Q,]TYK;6(8.W]7NYW<B+.N?+A
MF6T<0)I6O+(W!NWA)#G8A:1%8F)F-5+3;M*5,K/R=9*@Y)R]-30U%MC#GVR)
MWYR-AP[IP[..]1-IM$^D)CCV:SW;AQ#$=G<HB!Z4@@('84#XR1X@G' X8*O)
M\J8<T:.9\R?E&\9[ILR7NEMD\]]J'Q154G 7L#G#$ X[,5K2^?'X_7XO_5*W
M/3'D6^S\(2XW6[2;A .;[:/^L%2.JN'UI-9],*ZIAHJ/-%OGJIWB.&)DP+GN
M.P #G*F-43HWEL@> 6[0=Q241+VB1 0$!!#.OF7]2,SV^CM&1*V*EII^-ER:
M^80/>QP #6G G;MW+GM3=?7HWI>*U]J*\E:>=8?(%*^ERQ0V&'I7<4U4]K'U
M$COZTA;BY=<VTPY8KKEM?'UMF@EQL0:W>2QNS';RM6>[$3+3&4I:8UF<ZS+_
M $F>I:*:]]*_%]NX3"6## =S@,5K>(C&%-8M,-]6:P@(" @^-1 RH88Y&AT;
MA@YI&((/(56U<PF)P\4]'!21,IZ:-L4#.]8T  #FP"M,HQW7#0 ,!N3(J@("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(+*O#GT51T9_.<#@SMD;%CR?+,K4ZPA/JX-BBH\RTU
M3PB_1W6H\N:[V7#9PD\N&]=%9B>"F.FOWHY\_7M/LA.3]PQ.(&TE9PA >N(I
M)L[Z?041'RVVY!SBS:\4_$SBQPQ.">'KSY[1U3Y$Q'CVSU[?>GJ/BV;<'8 A
MJMC55<-QPVJ(2JI! 0?,N.&'*HP91UJ9J9;].J.!_D;KE>ZYW1T%M@.$TCCC
MRX$X []BSB9M;;7JTBNFZ>C8,GW6[7S+]+<KY;S;+E.WB?1DDEF.&'-M73RU
MBMM'/QS,QJCK.VJ.;LAYH=\XLOMJ-/JAS(H[E3XE\1=AQ.EW@MV[L!VUS\4Q
M,[;]<Z.CDKB,T]-4KV"2W5%MIZFTA@MT[!+ 8MC"UVW8!LY5I>)C26%)BT9A
MEF[<2H754@@(//$<1V41ECKI6TMLHIZ^X/;'14T;I9I'[FANTG;VEG:T1&97
MK6;6Q"-M/M5;CJ'F"MCMMCDILIT@<VFN\Q/#42-<!BS8!A@MZ5G9FW65.28W
M;:]NK8=1[OG.S645V3+;%=*Z)_'44\NPF%HQ/#AO)PV+GM;$Q/9K2L3$YZ]F
M+TPU M.H39*SR$6[,] ##<**7;-%MVC$X' [UT6K&W=2=&%9G.+=4EQ8[<3B
M>7MK.(7?12" @(" @("#R\8@=OD42-8S=G*PY'M,MZO]2V"F9BUHWR2.YFM&
MTD]A9S>(M$=Y6Q,UF?17)N:J?.=DAOU'!)34]1CP13@A^ W': 5T7I-9Q+.+
M1+3\RZT6K*F<1EG,%MJ*.@>&B"]O!\E?([\7O<!AS\2RX?ZDS7NUO68C/9)]
M%/#54L=13O;)%(.)CV$%I!Y01L5IB8ZLXF)UA<J$BD$! 0:MJ!F2@REE:NOU
MUI_*J"EX#+!@#Q![PT;P1O*IC=-8]9AI2N9GW/%IBR]=K'2WQE!3Q4E5"VJ!
M=$SN6/9Q;=G(%;EC9G/9G6VY[L3<HYCHS<;/#1U='Q.8)8F,<WB;O&("M:LQ
MJG.LPSE+:K?1DOI::.![A@3&P-V>@%$3.%<+QHX1@H2JI! 0$'PG:[@<&G>#
MO5+:Q,21I,(%TTJ:;+NK><K!=WMIZ^XO%7022]STT9#-C<=^&U3X\Q]#9WBR
M>>LSS1?MM3NSA[X;6[PIE$(,ZQMSH:RVV?*5(YM3?*^M@?!3,(=*UL;PXNP&
MT;E7CK-N:LQTAI-MG%9-5HIS!:Z..0GCCAC:2=^(: <5M><WF7-2,4B&3&Y9
MPU%(("#R_O5 @76DX:C:8DG!PKY>)QV#OH3][%3XMXKSS[I_!?FK,^//OC\8
M9#K'S12Z950$C7$U5* T$''"0<BIQ9_N:9Z;H;<<Q]/DGOLE)F5ZF%F7;5C(
MS'R.G![H8^QMY,5T<^O);'K+CX_EAG(I6R@EI! Y6G$+'HN^BD$! 0$! 0$!
M 43 H1BDQD,$P &'*5(J@(" @(" @(" @(" @(" @(*<(QQ050$! 0$! 04(
M!()Y$##;B@J@8*)@%((" @(" @(" @(" @(" @(&&W% 0$! 0$! 0$! 0:;J
M+EW->8[.*+*.87Y<N(<":UC.D);S8%9XE:)10W2#7SA'#J_4 <@\F'JJ\0B9
M5^I_7W=];\_P8>JIF,H;=I!I=?-/7W:HOU[;?*^ZRB:6I$1A=Q#'$N[H[=JT
MW8I%(Z1K][.8S>;SUQ$?<EI9M! 0$%"HD8^Z!SJ&H:&XDQ/.[?L6'/$S2?<U
MXI^.$/\ 5YR[$W)4WRQ;6MJO+JHX5,($A:9G88\0QW+LZ<7''^BOX.;/]2_^
MZ?Q2\,O6/#]G4W@F>HLVCW%8K/!(V:"BABE;WKV1M!':."F)P+\##9S*N!52
M" @H1B,$'DCA;LY,<%6-3HAK5K/&;Z6]6O(N1!%%?[KB^6NE[KH(!O(;B-NT
M*G#$\G+,=H:6Q2D6GK,X:;75FLFCTE%>LS9D;FW+D]0R&O;+$&24[9#ABT@[
M0M^*T6Y(I/>=&-JSLFT=8='V^HBN%#!6Q$]'4,;*S#F<-BBU<3A,3F%SP#G5
M82]*00$! 06]53Q5+.BG8V2)V(<QXQ!'-@568B4Q,PB_-.@F0[[,ZXT,4UDO
M6/2-KK;(8GE_(7-.(*1NC6)6S'>$95&1-7]/LX09Y,OSYBHX70#BPAJ>@ V-
MP!)<[#EP5N*^W,3W5O&^(C/RSE+FG6JU-GV2IH'VNILMZH6AU705;' M#B0"
M'%K<=W,KVK$0IG5)#22T$[\-JSA952" @(/E4$B/9O\ Z%6R80!HK04]USGG
M',5VC$N88ZXT\;Y "Z.$#9@#NWJ/'ILX(GKF9U:>5&.;'LA/7!^*#@.QLP2>
MOL91Z((ZQ%MH:)^6,Q4;1'F"GN43()F[)'->X<0P&_<K>+;_ +,17I/5K>(M
MX]]WZ8S">+>7NH:=TGLAC:7=LA7M&)EA7I"Y55A 0$! 0$! *@13K_Q-TUO+
M@2#^:P(.'^:Q<W-,S-??'XNC@CYO<S-AXOJOMYXCB;7&<>7'H5U?NG6_VN7]
MNC=6F>[5>K>Y\NGYDD>Y[O+)QQ.<7'OL-YQ75Y/2O^V'/P6F9MGM,L3E%C3U
MB<W8;,**(C#GPB7+XLYX;_[H_!Z/E_\ M^Z?Q3NQN+L<3L5<L'V5@0$%.7%1
M,CY2N<,1LW$_<5+_ "ICJYBTCTWR3G:\YZJ\TV2"Y3P7R=D$LW&"UA<\X#A<
MW>5K6L1X_'/?XO\ U2MSWFW/;TT_"$K?9_T=& ^:=&=G/+_[:K,J87%'H1I-
M;ZNGKZ/*]+#64KVS02M,F+'L.((Q<=RM$X1,92$R-L;0UO>C<.THDB,/:)$!
M 0$'-W64MUQO&9\E6NU5[[=7SSR"GJ6D@,D'#PG ';MYUEPUM//..T1HORVK
M7AC/>5_D_6"^96ND.1=68/([E'^;HKZ<135+!L:XN(P!([*Z-].6,QI/HRGB
MMQQGK'\4T5T\4]GJIX)!)$^G>]LC""""TX$$+EY]*SGT:\.MHPB?JSO,F2:H
M2.<]YN53@7$GE;SKT.:)^&?9"G),?5M"<ES @(" @(*!N!QQ*C JI! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! .Y!\7CN'8#:J=>HAC.>D^88\QOSKIM=?D>_3 "NHWC_35
M6!QV@'8X\Y"K2T\<XCY97O._WL*+GUIYI#;Y;)::>E[WY3\H87 ?E</'CR\R
MTBF=6=K8Z0V+(VD%PH+V[.>>KH;]FEX_,NX<(J8.Q)#,25I-XI$X[JS6;XRE
MUC#QAP64Y:3U?<*R%4! 0?,C9B=I["KW,((S7#3'K 99=> #1.H'^0])M9TW
M'R8\J>)&+\GKM_,\F9^G3'3=K]TITX&$##=BHGT3#4-48[8<@YA-UX32"AJ"
M>DP(#NC=PX8\N.Y9<V<1ZQ.C;@^?7IW]S$:%^4MTOL9F+B3".C+MIZ/$\(V]
MA=W/.<3WQ&7'6(B;8Z;IPDJ,XA8-7M2" @I@">TH@1CKNVNDTOOHH.+I1&#)
MP[^B#L7_ 'EARXS3/3=7\75X_6?=/X,KI9';&Y#L'R4&>2&C@.#!W/'T8#]W
M+Q8XKO\ (_Y)].SS^+IGOG5N;V@!^S9@N:8C#:.J!<GM@'6,S,;.6BA%N;Y:
M(N\\H_-;^RK^+']"_I-]/N/(Q-Z3WBJ?8F\)/+V5 ^B @(" @(" @\R'!O.H
MD<_:GT<.8=8LG6&\ /M$;9*IM/)MCEE:YN#7#<5'B4C?R3/6L1A;R+S3CIM_
M5,Q*>*6F@IHNC@B;%$,!P, :/0P5IG,ZJ8PU+4[+UHOV4+I3W:%CXHZ=\L<K
MV@F-[6G!P)YEQ^1,UK-ZZ3#K\:,WBL])8'J]W"LK],[6ZL>9'1&2)DCCB7,8
M\@+V/+^;/LAY_'$1,Q'3*5<=N"XVRJ @(*'<@BWK#C_[2WXD[A!M[<[ LXG^
MK2?]4.CAZS[I9/*[VC2ZW#$8_)$>S9_W?LJWG:Q;#GX-&I=61S6:;-.(:/+*
MC9B.QV5T\WZ?<K^NT^U,HF&. <''EPVKGA9]VDD#'>I%4! 0"@\.([WE*CVB
M/=1=*;'J!%#-.^2VWNE(-+=:0\,[,,3AB""0>95C-9S7NMNS&)1\-&=8XI!3
MTFITK;2-@B?$]TO!S<7$K:S\RON;?D71.SY4N1S!=*V:_9C..%PKCQ.9B,"&
M DX*U<5B=JDQ,]4IL8TMPY!N586F'L;DB,)54@@(/+S@TD;PHD19JOI?8=1G
M6HWN[U%IDMIE=3RT[Q&YQEX,3B2-W"LZQB\S'5KNG9A'4_5ER34QF.HSS<IX
MSOCDJ ]NS;N+R%K,ZQ/>%(G28_FT>AU:\H-  S[=0!L:T56 '8 XU.=4=L)E
MTTRE19+R^VS4%SGNU.UY>*NIDZ60D\F.)]-6LSJW-47$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 04+03B>1 P Y$%<!S(*<(050$! 04(Q42/#HVN.+AW.&!4
M=3HI!3Q4[>&)H:W'' =E7RC#Z@8# *$B @(" @(/+N11A+GS.-SH+5K_ &FK
MN55%24K:!P,T[Q&P$\/*5'B6B+<D)\FLSQTGVOMKWG'*MUTZK*6VW>DJJHOC
M(BAF8]^P[< "J1,_5I[W1PS$;L^C>\HY_P ETF5[53U&8*%D\=-&U['3LX@<
M-Q&*Z>36\X<''&VD9;O17.CN5,RLH9V5%+*,8IHG!['#L$+/$PTB<KU$B @(
M"#6\\LS0^PSMR<8A?MGDQG.$>\8X^@L[9S"T8Q*&;I/UD+505%PJ9;:8J9AD
M?PD%Q#=IP[M+7VURM2F;86&4[WUB,Y6&DS%:WV\4=:T/C#S@[##E'&M;T^&O
MMB)^]C2V9F/29C[DE:=4&I--75]3GV*A'2,8VGEHVM$CB"<0X@DD!7TVX1KE
M)K.]':64+O2D$! 0?.8$LV;-OX%$B#,YY*SQD[-DNH>FT<=>*D 7>Q2N$;9@
M#@7M)(&.!67%,\6:3\G7[6EYW_%/6&/^T'G!DQH)-,[K\I;BYKAT&/.'<.&'
MHK68S$*8QK#Z6C)F?]3,U4&;M2(([+:;2_IK58XGME+G$\0=(02-F Q6O'%>
M/XOU*\GQQMCHZ AV1- &&&S#M+,A[1(@(" @(" @H3@H$8:]T]95Z:WB&BIY
M*JIX8W-AA:7O=A(T[ -^Y<W)$Z3[6_%/7W(IMFOMTH\ITV7':=WQ\L%(VD,_
M" SB#.#BPX<<%T^5'U-WM<_C?TXK[&&TPUBO&GN6OD*IR%>JV3II)^FB9P-[
MLXX8.;BM^6V_;[(PI2FV;>]M6CMXNF;=8,Q9LJ+%6V2DK*-C8X:YA!Q86-PX
ML #N5>*(IQ6CVMN:VZ:^R'28:&[EBJ]*P(" @H6M.\=A!86^R6JU.J'6ZECI
MS52&:HZ-H;QR'>XX;RH[8]$SUROP ,$PA52" @(" @((,UFHZJHU$T_EA@?+
M%%5N,LC&EP:"6;RJ^/7^M:?],'//]*/>D7-^1\OYXM,EKOU*R5CFX13%H$D;
MAM#FG>#CV5E>D3KTE>LS&G9!4]?GG0CRBV7ELV8M.:ELD5+<&DF>D<YN#6N'
M='A !VJ_)S?5B:WZX37CVWBU.GHVSJORMJ,@5$\3L8Y:^=S#AMVEIY5Z'DTV
M[8SVAA]3?>;83NN-<0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!0M!WA1@4Z-F
MS9NW*0X&\RC KPC###8F P ]%2*H" @(*$# J,".]3M-Z?/MNA=%4/H+W;W=
M+;;A#L?&\;@2!NV[E2,TOOKU6G%J;9Z(Z%RZS^7(V4%/9[=F1K0&BN?,R)Q
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M/0  P P',@J@(" @(" @(*$ [T%'1L>,'#$'>%$QDB<*=%%^0%(&*(G$L&*
M(8@>(,&*#V@(" @("!@@(" @(" @("#Y24M/,]LDL37R,[QSAB1VE$1B<DZO
M? SF4BUKK9;[G3R4EPIXZBEE&$D4C0]I[8.PJMJQ:,2M6TUZ+:R9?LV7J1U#
M9J.*CI"XO,,+0UO$[><!@KS:9ZJ8950D0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MRY6LK[<3P-GC#@W$<G= %3:EJ=45M%NC/-& 5(A952" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M7!101S1':6O:P C[JZ+S$S,PYJ1,1B6Q]&U9K8>>B'%B!Z*:F'T:,!@B54!
M0$! 0$! 0$! 0$%",568'@L./(D1K*<O36D)$(>E, I! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!!1PQ""C6D8]E!Z0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
3! 0$! 0$! 0$! 0$! 0$!!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tm2227887d4-lc_pt4comp4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_pt4comp4c.jpg
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M .(  0 " @,! 0             &!P0% 0(#" D! 0 # 0$! 0$
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M>IVI<?DJ4W%T5JN0'M:\<'MX\'=Z8C$6CA:,Q^".%IK/&O'V93! 0$! 0$!
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MT.J']HY_(E/[) _-#JA_:.?R)3^R0/S0ZH?VCG\B4_LD#\T.J']HY_(E/[)
M_-#JA_:.?R)3^R0/S0ZH?VCG\B4_LD#\T.J']HY_(E/[) _-#JA_:.?R)3^R
M0/S0ZH?VCG\B4_LD#\S^I_\ :.?R)3^R0/S/ZG_VCG\B4_LD#\T.J']HY_(E
M/[) _-#JA_:.?R)3^R0/S/ZG_P!HY_(E/[) _,_J?_:.?R)3^R0/S0ZH?VCG
M\B4_LD#\T.J']HY_(E/[) _-#JA_:.?R)3^R0/S0ZH?VCG\B4_LD#\S^I_\
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M9/<V-NVW^O9L[8Q4LI\Q<\%Q41H3+;P[*ZDUHV05^H8BAC ;'''@Z+6AHX
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MQ)NS\-87CU2]X#,X+?$72;I1MAV].I3X1:NP/E]GQ^.A>!RFQ*=/2(/-IS
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M(;3I1\V&S/D7'_BT:@3)2" @(" @(" @:H" @(" @(" @(" @(" @(" @("
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M>DQ%HSP8^W(,S6PM2#/V([678S2U/$-&.?KV_245SC5.Y-9M/3&C<*S,0$!
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MFLQQ;164$! 0$! 0$! 0$! 04][TWS"[S_!H/QJ%!96V/Z.XC\!K?>@B6W1
M@(" @(""N\E\]F _1_(?C-=0E8BE @(" @(" @UUO+5:W( ?%+G^&X,(.A\Z
M#8H" @(" @(" @(" @(""B.@WS@=;/TI/WA!>Z @(" @(""%=7/FRW;\F6?K
M$$BP'_(L;^"5_O80ELT! 0$! 0$'A-9A@'VUX:="0TGB=/(@\<;D8LG![1""
M&\Q;Q\R)F&:B! 0$! 0$! 0$! 0$%$]>/G Z)?I2?O""]D! 0$! 0$! 0$!
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M+3S/9S#0N(U.H.KN/ JE=(Q'!,SGB]]B>[CFJN^J/5#J]O2QOS>.)8]F$B=
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M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!1'63YZ>B/RED_Q5J)7NB!
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MM[T&W0$! 0$! 0$!!JL]EF8/$6\K)$^=M9CI/ C&KW$=C0JVG$9:4KU6B/%
M=G]:,+N6]5Q5J#V'(VGF*.+GY]9#V#70=O=YUC3>BTX=V_V%]N,\86FNAYH@
M(*(Z#?.#UL_2D_>42O=$" @(" @((5U<^;+=OR99^L0;S%3MJ[<H3O!<V.G
M2UHU/W,(-I#*V>)DK06M> 0#P*#U0$! 0$!!A7<;6O@>,WTV@AK_ ":H.,7C
MH\94;6C.H!+G'334E1"9G+.4H$! 0$! 0$!!'K6Y!!9?%'#XL49Y7.UT=S#S
M>1$X;>G;AO5F6ZYYHI!J#^P=?@0F,,I$""B>O'S@=$OTI/WA!>R @(" @("
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MS7373RJM)7WXG.O)82U<H@HGKQ\X'1+]*3]X1*]D0(" @(" @(" @(" @("
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M1Y"MG"]4%$]>/G Z)?I2?O""]D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$!!K,5]VR/X4[ZUJF1LU (" @(" @(" @(" @(" @(" @(" @(" @("#1;I
MW'BMH;>R6YLW+X6*Q==]FR\<3RL&O*T=[G'1K1YU:M9M,1"MK16,R_/3?WO0
M=4]X9.:;%Y>QMK#EQ]BQV+>(9(V ^B99@.=[R/6XAH[@OHMKL*5CXHS+P-SO
M;VG2<0D'23WKMZ[7S5:EOK(2[@VI.]L=N:SHZ]6#R 9HYM 7AO:YC^[LT67<
M=A68S31IL=[:)Q?6)YOOZO8ALPQV:\C9()F"2*1IU#F.&H(\Q"\##W64@("
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M- ))\@59:5SR2O V&V,35D806\G*"WB-&\.&BE68Q+:*55$]>?G Z)?I3_\
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M'-#(UX\Q0>-BS0JOYYBULDH[=!JYH[D3E%:V0\/<$+XX!#CY&:$CE;H2>0
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MDTV0ONYKV1N2&>S*1V O=W#MT"3.1-% UF*^[9'\*?\ 6M5I&S500$! 0$!
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M]_,QOGY&N?>R@V?2?YL-F_(N._%HU F2D$!0" I! 0<:A0.5((" @(" @("
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MJ3UH[#(H_;Y6M?:,>O@F0]I:#P2F,*[W5$XG@E&!J17KQ(=S5XB99=#J#*"
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MDRF-&'M"];IC'ASGOC97DY6AY=]61Q<%T7ITQ6?YJQ*L_-:.43A8RS! 0$!
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M)4]HU9&\,(!],CE!U/?HD:C?UK5>Y"RS3F98KR#6.6)P?&1Y06D@IP&4@("
M@(" @(" @(-9BONV1_"G_6M5I&S500$! 0$! 0$! 0$! 0$!!Y2LCEC='(T.
MC<.5S3Q!!X=B#\[>I7N]Y>7?^YL?TIIRY[#8<Q37J\'*U]*>YS/]C9SO'BE@
M]+T>+6D KZ+9[N*[<3N/G][MIF]HV]6+L+W5.JFZ\E S-8V3:^'#P+E[(%@F
M:S7B(8 7.>\CU2=&CO*G=[_;K'PZRC;['<M.+:0_03:NV\5L_;N,VQA(?!Q>
M+@;6K1GB>5@T)<>]SCZ3CY5\]:TVF9E[]*Q6,0WJJL(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(""NNO?S,;Y^1KGWLH-GTG^;#9
MOR+COQ:-0)DI'!X<4'Q/U>]TS?&X>H62W#M&S4L8C.VGW9S:E\)]668ZR C3
MTF@^KR]R]OM^^K6G3;D\G?[.U[YC@^J.FFSAL#8V$VA[1[5)BJ[89;.A:'R:
MESBT'NU<=%Y.[N==YMXO2VZ=%8A,5DT5/U.Z:1]0=U[/DRE W=LXMUU^3Y;+
MZSVF6'EB+3$]CSJ[N!4;41&Y:T_R8CT]7[C<F9I6(_FS/HQ+6;[Z1U<?T_.$
MZ:X:-MR#)4<H^HZ<B:V*=ADKFNL6'/.O*#R\[] M-O=FFY29C,5S[XXK5B,6
M\9A)-^;.W-O>K@Y<5G&[;GQTS;T]2Q2BRD4DW)Z#7M=(QI,9UTTU&O%8VB:W
MS$\(F/XIK;X,3''']C6]"-F[TV3MK*8_>EJ*U>M9:Y=KB&)D?VJ9_-SGPW.'
MVSUM#ZO8MLU^G2L1\M8A6TS-[3XRME40(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @("#R?%%(0Y[ YS?5) .B"O>KV&H9_;\>(L9*+&W+4[!4\4C6
M9[02(P#V_"NWLMR=K<ZXC..+POO?;4[KMIV+7BG7.F><^# Z.;;RFU<=/B\I
M+%*YKR^OX#= UKO6U)]8DJW?]S3?OUU\&?V'[=O=CV_T=RT6Q.8Q"U6\  N!
M]"HGK)\]/1'Y2R?XJU$KW1"([[R&^,;A'6=@X>IFL]XK&BC?L^R0F%WK/+^/
M$=P5)F<QA:L1S5=8W![T^3AEQ[=D;=QC[,;H?;W91\[8/$!;XA8P:NY=>Q+[
M<;E9K,XSIZBMYK,3C@LGI?LEO3W8V'VD;'M4]",FS9 ($EF:1TDC@#V O<=
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M8Q1;$Z;VG(UA# >4AO*'!Q](Z\$F!/E UF*^[9'\*?\ 6M5I&S500$! 0$!
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M.2Y/Z1)=V  Z\ODXK#=O.>EZ/:;-)CZELS->31ORN9I5XG7#'7R-(^QO@@:
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MB\Q VMEJ4-ZLR1LS8;#&RQB1GJNY7 C4=RHE4/3!C(NLW4R*)H9&TU0UC0
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M1.X\NNFA\R"08[*PWVZ'1DX[8R>[RA!LD! 0$! 0$! 0$!!KLQX+Z$S9G<H
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MTU]2](8HX(V11M#8V-#6,'8 .Q=;QYE[(""B>O'S@=$OTI_^@B5[(@0$!0"
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MHX.(_P"BP#R.?J)I?*2/(NGN+1&-NO"/?+GV(F9G<GC/X+97(ZA 0$! 0$!
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M:.P<$'9 0$!!QKIVH-#>B?6@-1EB1\MN0\I(UT![M>Y0-')7L-)\2 AL6C9
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M]5NP?Y@W5^19_LD#_JMV#W8#=7Y%G_=08U?WMNFUQKW4\3N6RR-YBD=#B99
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M_DL_[J@/^JW8'\P;J_(L_P"ZI#_JMV#_ #!NK\BS_9('_5;L'^8-U?D6?]U
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ML7BX\:QVKC-;F//9LO\ 7D?Y3Y .X=RFE.GTJ[^_.Y/A$<(\&S6KE$! 0$!
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M1R7A .6.:QR>GR^0$ZZ*EIS.G!>.&KRQ]3&TBV&O!'6H-?SFO"P1@\YU.@:
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M^(W18M4JL5JCDZ;8Y+%#(P.K61%+ZC^1W:UW<0K8G&?VRJE:@$! 0$! 0$!
M0$! 05_U%V)2W=8VSFK^1EQ\6S\HS/AL;6O$IK,=Z#M>P:'74<569B(S*8C,
MXALML[WJ[JF:VEB<K5JR1>T0WKU-U>M(PD:<CW$ZZ@Z@+3IF..GDB9C/BERJ
M" @X)T04BR_LZMUHL;Z=?R'C3T8]IND]D)Q+;+9_' ]I!^Z%WH\NFB4^+'GP
M\_0FT=.<\N/EZ5W ZJ$.5(("#'LV(JL$MB<\L,+3)([R-8-2JVF(C,K1&9PJ
M3HO7Q>'?GX<3!FIJNYLI;W&V_DJ'LE4&Z6_:XY XAWJZM)[5IB<:Z*SI.%Q
M@CS*HY0$#71! ]^9#;F7JS=-K^1-7)[MJVL=7$#?%EC;)"X.>1V#1IU'-IJE
M8ZLXY1E,QB,M+MG=VT]A8O%; -B[<J[?96P<F?=5/L+;$;!&QDDK?1:\G0$=
MQ[U%/CX<^'GZ"T=.?+CY>E:H.J(<J00$!!\W>]'F9\0[;)@I4+GC&US?&%5E
MOEY1'ZG/IR^=</=6F,8?1_9MJ+]>9F.'"</ES)6'Y2Y)=E@KUGR  PTXFUX!
MRC35L;> U[UY\SE]52L4C&<L4U]1IV:\->]5:92S&[MN1V:$ P^$<ULU>/G=
MC8G2$![6ZEWE\ZVKN3GDX;]M7$SFW/F_0>PV1]61D30Z1S"&!^O*26]ATXZ+
MU[YF)CR?GU=)A0=#;>4RN3VUA*&R#M'-;=RK;^8S-2!L6,FK,$@<RO9#B^;Q
M.<>@\</H+3:Q%HMG$168F/'R]'F;DZ6KQFW"?#7.?2^AFC3M557*D$! 0$!!
M1/4W [?WKU;VEM'<D+6T6X^U=\0/,<MEX?RMKAVO!H+2XZ<3Y5-.-I]";<(]
M+<6_=VZ2&M,#BC5'([_26V9@8^'K@N>1P[>/!)M*(A"^C72GISNC:T6:R.)%
MC(T;]BJR^R:5C9_9)?M<P8'Z>D--=/(M)M,8GR4Z8S,>;Z262X@(/&2>"$M;
M+(UA=ZC7. U^#5![("#ISMYN74<^FO+WZ(.'R,B87R.#&#M<X\H'T2@,D9*P
M/C>'L/8YIU!^B$'H@UF*^[9'\*?]:U6D;-5! 0$! 0$! 0$!0*;ZESR]0-T8
M_HYC7N&,D:S+;XL,.GAXN-P,50D=C[3V\?[P$]A7;LQT5G<GT1Z?X.+>_J6C
M;CTSZ/#UK:KP0U(8JU>,1P1-$<,3!HUK&C1H '8 %Q\7;P92 @(" @(" @("
M @X+@%$Z#3Y/*2ME&,Q@$V4E /'BR!A^KDT_8'>L;WY5XNW9V8F.N^E/Q\H>
M^+QD>.C=Z1EM3'GLV'\9)'GM.OD\@[E;;V^GTL]_?G=GPB.$>#9+1S(+NKJM
ML':%HT,WEVMOQC62I7:^Q,P'L+Q$"6_175M=MN[GRP\ON_NG:]M.-R\1/AS]
MC-VGU"V?O0/;MW*1V;$8YY:KM8K#0>PF-X#M/.J;NQ?;GXHPV[3O]CNHSM6B
MR6K%W" @(" @(" @QYX(;,+X+$;9H9 6OC> YC@>W5IX$*)B)C$K1,Q.85[?
MZ']-\A.;)Q!J/<>9[*DTL$9)[?18[E7F7^U]M><S5[&U]Z[S;C$7E)=M['VO
MM%A9M[%PTWR#26< NF?_ (3W:N^AJNO9[;;V8^"N'!W'>;V_.=RTV20#1=#D
M<J00$! 0$! 0$! 0$'!\J"*[OV+M;?%.M3W1CVWF4YV6J;^9\4L,\9'*YDC'
M-+2=-.WCWJ(^&T7CC"W5.)KRGB\M[=/-G]1,,W ;QQ4>4QL;V2PMD&DD4C"-
M',>/2:?@*K,?%%N<$3B,<FNVKEKC=\[BV>'-;@L%2QHQT(;H]@E8_FU=VGU0
MMXMUTF\\>J7/CHO%(^7IC\U@K-L(""NNO?S,;Y^1KGWLH-GTG^;#9OR+COQ:
M-$IDB! 0$! 0$! 0$&#DX9):W-$]['Q$2<L?:[3N0>U29UBNR9S#&YXU+'=H
M09" @("# C9*W(R.]G8V!S1]O'KD^0H(_FZ+:UKGC'+%+JX<=?3[QYD&'5K&
M>1G.>2 D^)*3H !VJ!ML7-1K69*43W2QS ZSGT1P'8%(PGU\9/-$RI.Z,/<6
M&-[23KW'7SJ FPMVO"ZQ(&!K-2X:]@'[JD;'$^R7J!H3'Q'LU<?*&D]Q\R#&
MKXVG<;9BBA8^W7<606Y6-,C0[N#M.8:Z*<SC&=)5Z*S:+8UCGAC34K6/A?-/
M(Z.5Q\-@9QY@WO)[@H68UF6*9T<FKN?E:)B[3M'>$&=E)JUB)GL;!)X8:9IP
MW0^;5!5_5)VXH,'5N83+8[#XZO;C?GY\NP.KOI<W%IY@?HMTX]RZ.WBO5K&9
MQIAENS:*YB=(XLG:O4[96[Z%W(8?(M9C\;9;0ELV&^S0ND</0\(NT!:[3T0%
M%^WO3$3Q13>I>,Q.C6]5(NG%*OA-W=1"]D.#NL=BIHB]W^D2G@"R/U@".<JV
MQ.Y.8IA7>Z(Q-E@PSQ6H8[,#Q)!,T21O'8YKQJ"/A7-,8T=&<NZ#CM0"YK>+
MG!HUT&IT&I[M2B)F(XN?V^]$G=YDP&J@->&G<I'E%5A;>%^*O&,F6"(6FL;X
MQC!U#.?3737CVJ<SC&=$8UR]P.9X#G>L="X\>WM*A+0;UV3MK?-6IC=RQ>W5
MZ,[+-8QN,7+)$>&IX:@CM6NWNVVYF:SC,*7VXOI,-W*Z"O)'7?(QKG^A TN#
M>?D X,!XG0>19X6FSA\<;^7Q&->&N#V![0[E<WL(UUT/G403'B[D$=O_ &U4
M);/ QAV0C?S-'*UV@)XGNX*1,$%$=9/GIZ(_*63_ !5J)7NB! 0$! 0$! 0$
M'!U[E$B$QX3J&+PFDW;6?1$O,:HQ; 3%KKR<_B\#IPYM%-=.*;:\%9<F%HVH
MV[,.0J=1GYAOMF.NS2/G]F?+]O+XP1%X);Q#PW7SJ=G],?IY^4:^]&[KU9X\
MO3I[GT&.P:]J@<H" @I+<>:QNU=X;Y?N&0UH\[BH&XISF.<+#HH7PNCC(!U=
MS'3E6/S;5J1\W5[<Q^3:-+TMRB-?^98'3FE:QVQ<!3NL=%;AI1"2)XT<PEO,
M&D'L+0>Q=F].;^S\'-3AZY_'*6K%<0$!1(^>Y6X:E;(V:<C3ZDR9@&QC[L\C
MYS7DF'C%T8(B\ LXAVG9WJ=B(^"(^7&OE&O'S7W<9O-N/Z?.?)]!#70:]NG%
M&;LB1 05KUIHUI=B92[[.V2]&V&..8-YY&M=8C+@W34C7O45TW*?XH_-I'RV
MCREH,SFL;M#?.>R&Y)34HY;!P1XZ=['N9-+ 'A\3= ?3U</15+ZTW*QQF=/8
M5_[<^$:^V$SZ5TK6/Z?8"I=C=#9;7:YT,@(>QKR7-:0>PZ'L73N\<<<1'X,8
MUF9\9F?>FRR6$! 0$! 0$! 0$!!&=P8W=EZ6%^WLY#B(F-(GCEI-N<[M>!!=
M(SET"C5*!;JQV%KW\(>J5VS<;"RP(\S7#\?CP]Q ;',V%Y>)"/4/-H4CIZIQ
MI.(CT^A:<],>5L^Y*.ETN:FVP'Y=\DL8LSC&23Z^,^AXA$)<3Q/H^J3W*\YQ
M7/S8U]+.<1:W3\N=$[54B @KGK!%*=LT[K(GR5\;E*5ZX&-+BVO!)]L?H.)#
M==2HK,5W*3/#*W&EXCC-6!LS)4MR]2MQ[CP4AM8/V&G3]N8'-AEL,+G.:TN
MYN0'BKTB:TMGG;3V(O,3-<<HGWRM550(" H%7]1H-GOS>%FWLVY#C(F3B&\R
M9\-!DK@!R3.B(>'GZCBJ5QU6GGC'IUX+S\L>G\FTZ7RYB7;3G9)\DM?VRP,3
M)/KXKL<U^D!<7<3P]77M"WM,S%<_-C7]OQ4G'7;I^7.GL_?E/%0$!!CV:U>[
M7DJV8VRUY6\LD;AJUS3W$>10E0%^C.=L;X=6K/,%'=4=J2&-A!%6LZ%SRUH'
M$!H[E.W;IKLVMPCC[VEHS;<B.,UT]B7[5RN/W5U0R.X-OR&WAJV'KTIKS&N;
M$;!E=(& D#4M:=3Y%:D8K?/ZIC'JAE><]$>$3E;"J" @(" @(" @(" @U^1B
MO3T9XL=994O/:1!9?'XHC?W$LU'-\&JBV<:)C'-",CA-Z08C)G<.<.<Q;JDK
M)<=C*+*EN3F;H/"D\5VA'DY>*KN=/1BWDOMYZXQIZ4;V0[$0[JP]7IW9GFP'
ML4WYR0SRRS"*9K6"$/\ $)Y)>;4<K-.];Q,S-L_+R].>7EAE,1TQRMG7T8Y^
MM=:S2("#@]A5;1F$OFR6]69M2?I\\/.\I-Q\\>.#'&4QFX)O&!T]3DX\^JTV
MIZOI8_3&OEC*^[.)W9_FC3STA](Q@M8T.[= #] *L\64<'=$B @T6ZF-FVWE
M(WP6++'UI6/@I.#+3VEO$1$ZCFT[%ENQ$UF):[<SU1A5^R3B(-T8.ITZGL2X
M,U)OSGKSRRS>'(QK1")1(2&3!Q<-&:=ZZ8F9FV=8QIZ?+U<7/,1%8QI;/N76
M!Q^@LEW92"#J\>BHD5EO:C7AWUL6Q7K!DMC)3OLSL9Q<6U7!I>X?2&JMLZ7M
M']R?QA:\YV_^*OYJ^R>0JUMM;FV%/S_G=D-P.DHXX,<9IF3VXY62MT'%G(->
M;55VOBC:B/T\?+&6M[1%]R9X373S^&(?14#7,ACC>?3:T _0 '[:O:=9<U8Q
M$/956$! 0?,OO91\\FU#Y/:_VHUP=WR?3_8Y^?U/FWP/,O/?2Y<^!YD,O>A!
M_P 0IG3_ /6(/OC4CC"MY^&?0_2)G +WWYK+GF'8H'*D$! 0$! 05IU<VUL#
M-X2&_O;(##''/+J.:CD\&Q#*_CHSUB[737ET^!1$S$IY*LP>TMN[TQ>3MS]6
M<WF-H8<-.5B?XE>)L6A< YTFNHY6]S2M)G$9F%8UTB=5^;0H[<QVVL;5VF(A
MMYL#74'0'G:^-W'GYNTEQ/I:]ZK;.=2N,:)$H2("#YHV!LK&=9X]S;OWG-9L
M9";(3TL8UL\C&TH8=.01AI X$_L>=7F<(XIU[OFX<CF]CR5LK8DMVL/=GQ[+
M4IUD?#"[5G,3Q) )'%1:!.=WX;,Y[$.QN$S4N M22L,F0@C$LHA!])K0= "[
M7UNY5A*I>C>/GQ'4_?\ AY<A:R0HMJQ-M7I3+.[4N<22>':>X*]N"(>F\Z1Z
M@]:*.P<U-*-JXS&G)3T8)71"S/(3ISEI!X<.'P^51&D!L2E^8/6;+=/L38F=
MM6]CF9*K2GD=**\P(UY"XG37TOV%,\#FOI42UF*^[9'\*?\ 6M5I&S500$!
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MYITX:M*>?BF=)F)XPV*E @("#SY&CFX#CZQT51PR-D;>6-@8.TAHY?VE8>J
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MP2^Q>I%H>R$ZZ<D?, YVG$Z^17V*]=;VGE$3'KGBMNQT17'&9U]BY0=5"CE
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MX=Q'>IF,3A6LYC+*4)$!!7/7KYF-\_(UO[V4&TZ3_-AL[Y&QWXM&@F2 @("
M@(" @(" @(" @(" @(-9D\=':@D,;6MG.CO$TXG3NU01!KBTG3@3J#KYTX:G
MHXL;;^[O%S>1VU4HSLM5@PONR B%P?W-/F71N;$UVXOF-7G[/>QN]S?9BLQT
M1QY3Z%@4H)((&LFD,LOU4A[3YC\"YWH.D]R2"W#"YC? EU!E+M/2\@0>,1J1
M92<!\GM3V!S@=?# 'D0>0S;G@OCJODC\7PFO;Q!'E09$]=PG\36)E!X/M+'
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MBLO=MAC@V%>AB:&11YW+-8P=S?:7:#5;V_R]O_!"=[_/W/3_ .V%S+-00$!
M0$! 0$! 0$! 0$! 0$! 0$! 04S[SS.;I+>;R\P%W'N/#4#_ $IB;7_]&S_C
MC\+-:_Y>Y_@L]O>)#7='\E&[B3)1:T=I+O:(^[Z"5G'<;7_[(_"641G8W/\
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MS#*\T38[;9*KR]L4K'%P!/?H5?Y-R+1K-?9P*WS6T<.J,)X.P#S*J'* @("
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M+O1=KY%EUQU],Z1CCR]#6*STYCB^?Z,=OJ!>&Z>F'3Z+;NY7<I?D]J[FIT[
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MGAF96"7<-MQN5\R27-EKGE+HQP&CCQ\W9W+#N9MF*SC3P;;&/FC,92;=G3_
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M! 0$! 0$! 0% ZEPU4CGF;IKW( ((U'8@<S?*HR..9I0.9J 'M.GG4CL@("
M@(" @(" @(" @(" @(" @(" @(" @XU"#CF:H#F;Y?,IR..=NFNO#73Z*@<\
MS>S5,CGF'E0=>=O#CYE([H" @(" @(" @("#@]B"E>O<?._ ^8V/_P!!<G<<
MGM?;?U*:]G7)A[&3P"F#+UJ5S[76_P M']>%,<5;3I/H?8DT,<\1AD;XD4@Y
M7M/$%I'$$? O2F(F,2^1B9C@KW$='-IX7+09*K)?FI4I?:<3@K-@RXNA.007
MUJY'H.])W:X]JO6TQZ<8SY>"+?%GSX^?FL9C="=>](0[H" @(" @U&;W#A-N
MU#>SN0@QM4GE$MF1L;2[R N()/F")PCOZXNE_P#6O'_QJG$JYA),-FL1N&A'
ME,);COX^4N$=J!P<QSFG0@$<>!&B3&.*8U;50" @(" @(" @(-9BONV1_"G_
M %K5:1LU4$! 0$!!I<_N7 [5QS\MN/)5\7CF'1]FU*V)I=W-&I!+CW *U:S:
M<0K:T5C,J\=[R/1J6ED+E#==6[+CX7SFFP2Q32E@X1Q"5K ]SCZ+6M6\=MN9
MQAC/<[<1QAG](]L96C0O[TW7%R[WW?*W(9-AUUJUM-*M-NO8V&/34?OM5/<7
MB9BM>%=/WH[>DQ$VGC;7^"SERND0$! 0$! 0>;WLC:7/<&-':YQT ^B5"<.L
M4\,S.:&1KV]FK"'#]A3!,3#3WK]BQ9=B,.X>U_\ ZW;[65V'_P#3([ L+[DS
M.*_V.[9V:TK]3<X<H_F_@V&/Q]?&0"O6:=">:61W%[WGM<X]Y*MMTBD8AS[V
M];<MF?[&<M6 3H@\B]FA).@':>P#1$*YMV+/4N]+AL?*^+8E20QY;(Q^B<C*
MP^E6A/\ [H'[J_O[ O1K$=O$6GYYX1X>?I\'S>Y>?N5YVZ?Y%9Q>W\\_R5_N
M_P T^KQQ8-2K!2@BJU8FP58&".&&,!K6-:- T < O/FTVG,\9?1UI6E8K6,1
M#*4+" @(" @(" @(" @((QO+>^V-@X.;<.Z\C'CL7!Z//(>9\DA]6-C!JY[C
MW!JO2DWG%5;6BL9E\TY?WZ\#%<='@=GW;U!KM&V;5F.H]S1WB,-D(U\Y7I5^
MW7F.+@GOJ0L7I?[T_3SJ1?BP<HFV]N*<\M>ED2WPYW_O8IVGE)/[T\I/=JN;
M>[2^WKR;[7=5NOA<3J%((" @(" @(" @("#APU"@5_U"VQU W$VD-B[O;M1\
M#G>V&2A%D!,"/1 $KARZ'R*D1/5GEC@MF,8YJLW5C.O73# 7=]W-^T=UXW"-
M%J]A+6(BIB>NUP$@9+$\EKP.SSK3ZE:S'5PF8CVZ)KM3N:5XOH#!Y.'-8>AF
M:S"R#(5X;4;'=K63,#@#\&JON4Z+37P8;=^NL6\6T5&@@(*ZZ]_,QOGY&N?>
MR@V?2?YL-F_(N/\ Q:-!,D! 0$! 0$! 0$! 0$'E*Y[(G.C;SO ):WRH.E.2
M::NR2>/P92.,?D09" @(,2&O/':FFDF+XI-/#BTX-T09: @(" @("#PG,;&&
M>1@=X0+APU/9W(,3&BE/3\2O"&12DN>P^EQ\Z"#;^VS@][PNP^Z<8R[BF.'@
MQS  M?RZ>)&\:$$CO!6FWN6I.:SA2]*WC$QHT.)J;8P-.+IU@[ QLD%-[*M6
M%Q,T<;M?MC"[75^IYEK:NY:/J3&8SZG-'<[-=SZ$6^/&<<\>*D<5U$S& V^S
M8O3V#)YS<7M]G&NW'G6-B$$@?S-/I'BS5W //#]A=D[-;6Z[Z1C.(91N32.F
MFLYXRTFT>M?5VWNTTI?9]U8NG)9.3J8F#E>&0Q_4DAI:SF;JUQ';JM=WM=J*
MY^69A3;W]WKUUB%G8OK_ (G*;=KY>C@[]G,-NQ8_*X:NPNDIR3'0.+M!S-\G
MG7';M)BV)G3DZJ[\=.<>E,NI;+\^P\Q!BY;=:]9@#(9Z(_TJ,O(U=H=#H.QV
MG%9]I6+;T1./6Y_N7<6V.WMN5K:\Q^F&/L/IU@MK,9N.+Q;.[,A2@KY7*6W'
MVF;E:"2YOJ@G0:Z'7A\*C?WIM,Q/")TPZNWK\,6YVA-ES.AJMP[@I;:QXR-Y
MDLD)D9#RP,YW:O.@.BWV-FV[;%9PX.^[ZG:;7U+1,QF(T\VTC>V1C)&ZECP'
M-!&AT=H1J"L)C$NZLQ,9C@B=#:F9K;YR^YK6X9[>"R%=D%?;\C1X-=S>',W7
M7L[N_P JVG<KT1&-8YL^B>J<SI,<&VV_@A@*]B 7)[OM$[Y^>P[F+2\^JWS!
M6W]Z=R8F8B,./L.S_P!+6T1:;]5IGXOP;CAIII]'L*YWHX<@Z$>4<=4 AP <
M00#Q!\NB"NL5A^HVU<9EGORS=UY&]DO:*4<[1"*U21W%H_N]PTX+OI.S>T1;
M-8Q[7D]W/=;6U_0K&Y;JC$3/+FM3;4S9+_*'-,S&<MB.,B0,?VEKCW+AF,/4
MK:+<]8X^29J%E#=9/GIZ)?*.4_%6HE?*($! 0$! 0$! 0$! 0$! 0$%!]0LA
MF<CUHP^S';PO;5VW)@K&1E./F@K.DM1SB-I+YV/X:'U0HVHZOJ3,_+TX]?%I
MN?#6F/U3;W(MN;?.[]GP;\VQ@MS6-PX_$;=;F*>YYWPSW*5Z6?PS"Z6-K8WZ
MCTFCE]%4MF:3,_#B]:Q/C$XRM2L==8X]46S'ACA++S#LEM3IXSJ!1ZIY:]G:
M5.K>&+NV:=NI8GE#-8'P1Q->[G<[E: _4=JVWO@W,5CJ^+&/+./PU9[$1N8Z
MIQIGW,;=^_);'4W'XG>._+^P,%8VQ5RC*E.6*N?C"=X\1KG212DZ D:*.F(M
MNQGY+Q6OHQE&O1M6_FB9E:.R['L^UI,ILW<5SJ&R]8;%7N9&S$60Z$-?Z;(X
MO09ZSAH2>Y1;,1'+C.5:XF9U.B&Y<_NG:E^_N2V+N1@R^0J>,U@8SPJ\Y8QK
M6@=@ 5YB/ITF.=8EINUZ=V]>43^4+26<*"D$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0?.?7G>6_-M;_V56VCDGUL='7NY7,8X!ICMUZ3H^=LA<"=&QEQX'N4
M]MCZMNO6L17_ *IF(GVX3NU_I1TZ3,S[HRV'O#;WW%B]EUK>Q,L_&W&LKY>S
M<A#'/]@=-%&QOI CEE+^4D>11%<;U8GA%L3YY:4B+;<Z:S$X\L:M)7ZY3;5W
M%ONIN&_\9W67\=CMGX![F1R2V;=;F+ 0!RQ\W%[W\ K5K-ZQ6OSS>\>J)TSZ
M&<XB8F=*QMUM/IGBV>]KW4O8VS,/D\ON1\NY\WN7&,OMK,C%2I7LRAKZ<#2W
M7P].!>[B[M5]J*3O[>W&L?%GQG0O_E[E^&(T\M6/N?J%8SVY-PT&;BRF AVS
MD8\=2&"KFX/&\+G=/DM(WZ5^;T=/1X \5AMYFD;D3'Q=6,_+I.-?->TUBW1B
M9TC/CF==/5A)MV4,A)M&+?6XM\Y+#MQV.$U^/:]B%N/LO )#X?'A>2920UO'
MMX)O?!:<1.LZ1Y^"-F/J1$:>G\V[Z-8W=M'9=6WO3+V\ME\H[VT-ONC?)5@D
MXQ0ET;6:N:WUR1V_ M]RL5F*<Z\9\9YL*3U9M'">'H66LF@@(" @(" @(" @
M(" @(" @(" @(" @(."=% HS=^0WAG>M$>Q<9NZUMG!1[?\ C9WL4-:222Q[
M2(>+K#'\-#V#O4;,=<;DS/RVK$>NN6F[\,;>GS=7N1'=O4;?VS:'4':M7/.S
M-C;6+I9'';KDA@$\,]V<1N@F8QOA%P:2YOH]G:DYO6)X?U*U],<UJTB+QG6+
M5M/HF/WI3E(.HNP-HR=0V[SM;ECH5(K]_#96"K%!)5<&OF\.2O&QS7M:26<=
M.Y:;EHV[XGAU8GQXXT];';K.[&DZXS[LM@[>.>ZC[JGVELO)G X:AC*N1RV;
MCC9/>$^18)8((6RAT8T80YSG ZZZ)T3\>?TVZ?3//U+=416OC>.KT1P]KC<-
MKJCL3:.\9KN4CRM'&8>2[@MQRQQQWVW&-(='8A8/#?\ O@\-T[BL=RT33PMU
M5CTUF8U]+78VXMN1$\,3[<-5CJ74[%]/ZO4FOONWFK[,3%EY\)DZU5E&8.@$
MTD?/ QLC>&O(0>U;;\QM6F,9C./5EAL1.[$<IG\6WWMU.SYZ3NWOLREX!M8<
M9AN2L<KH*Q<&$1\O:^0EVG9IPU4;VW-+].=.JL>G,M.VB+S&?/W96CMNW/>V
M_B;UE_-8LU()IGZ::ODC:2=!YRM-ZL5O:(Y2Y]JV:1,^#;K)H(" @(" @("
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M5EEU)9C\3BL7&(<92@I1#L9!"V%OTF@(-@@(" @(" @(" @(" @(" 3H@("
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MO#6-2Y$R>O+=:0QS6O:3&1Q<TD'0.\R3$P92+$302THV0R<YC :[R@_10;%
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MK07*4M>:9TFC8Q,QS)'$D=C ==4'Y_6N3&.-2R]C7P'P@6$O:\1^B'L/:6N
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M1OHR#7@?A4UQ6VL<%Y^*N8GCP43C.IF#GVEFNE/4<Y=N<QU*U#8O.A)LW:\
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M"US7#4$'@00B>#YRWYM5V&R5F&*N8:3YG&I(QVK"V3TFM=^]([ N'<IB7O\
M;;\6JN'IQF+N5VW"S(D'(4S[/*0==6@>@X^<A=.W,S#R>YI%;SC@F2U<H@HK
MW=?^==7?TSO?6L07J@(" @(" @B/5#YN=V?)5W[PY"&WVO\ T;PWX#5^\L0;
M= 0$! 0$! 0$! 0$&'D/;? /L'+XVHUYOWOF0>E1MAE=C;3@^<#TW#LU09"
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MXZXS(4H+;7-<)&!SBS4CF[P->/ JT*6C$X4W[VGS.7/E+%_CD2E"[:_W"+_
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M(T.;J./?P6%;36<Q,^IW[FW%HZ;1F/-K\AMS$93(T,K=@\2YCN;V5W,6@!W
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M#%;GM2'V.#T8I-#K)KVZ>?S)UQB59[>9F(CBYQ5>GCZYR&,'-CKH\>=SCIR
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MM#!.M3P%TE\Z$L<?1&NAY=!Y M)F*N>L6W,1/!KK^X,_:K0_$#(#9+P7LD<
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M56TYF937A#,4)$!!$>J'S<[L^2KOWAR$-OM?^C>&_ :OWEB#;H" @(" @("
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M>R($! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$&LQ7W;(?A3_K0ID;-0"
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M@[?\>_V3_.)H'_'O]D_SB:#M#\;\[?']G\'ZKP^?F^AKP09Z@$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 05UU[^9C?/R-<^]E!L^D_P V&S?D7'?BT:)3)$"
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M!B[L-?:V7Q.9IO$^0T;4L-:.#^YQ)[.4\0IK,168E7<I,[M+TG2O%UJVX:&
MCK7K ?BF:,;"=">?7UR>W755B<1JO:LVOF(U7CTGQ=&IMEN1K1".3(/=+([E
MY7:,/* ?*.T@^==FS$15XG>7F;XGDL);N$04;[VGS-W/E+%_CD2"[8/N$7^
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M(" @(" @(*ZZ\_,OOKY&M_>B@V?2?YL-F_(N._%HU F2D$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$&MS<8DQLVNOH@.&GE!00[4CB/H*!QQ_P"W>I$9O;&PN0WI
MC=]SOLC-8N!]6O&R5S:SF2:G5S!VD:GS'O6L;LQ2::8EG-(FT6\$F67-H("#
MNQCY'!D;2YQ[@-2H&<W"9%WA_:N7Q/*?5^%2)+4QE:I&&MC:Y^FCY"-24&<@
MZZ-YN;3TO*@[(" @(" @(" @(""B.LGST]$?E+)_BK42O=$" @(" @(,6_\
MZE:_R4OUI4"&=%_FLVK^!-^N<I2GJ($! 08\-2O7=))$P-=,>9Y'>4&0@("
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MKVJ!FC'ML FBR21K7 &1V@#@>TA2-]4PE2K*R=I<Z1HX:GAKY4&U0$! 0$!
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M5ZH@0$! 0$!!$>J'S<[L^2KOWAR$-OM?^C>&_ :OWEB#;H" @(" @(" @("
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MBK42OE$" @(" @(,2_\ ZC9_R4OUI1*&]%_FLVK^!-^N<@GJ($! 0$! 0$!
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M^<CHA^DDOXLB5[H@0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$%#=;J>SK>:HMR.WK^Y-SQ49K3*M&T^I'!0A)+YI'C0-',=!PU*M7)+TZ9X
M+8&#W=BG8?%7,?F,M@VY2G//<DM0/BF+1-$&N)])FHXD*)RA>JA(@(" @("
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M8-$B)3>T3P3969" @(*(Z[?./T0_227\607N@(" @(" @(" @(" @(" @("
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MY6#5A(:UH]5H*K,IC1/% (" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MBAG;,,;\U@<W.)7,C:\\DL8C C>UI=R<[?2\O:IG/3A7F^NVG4*D)<J00$!
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M^[D)C9R&0N/$EB:4C0%Q;RMT &@ "M,Z1'*%8C69:7_UR_\ *?\ XDJK+"1
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MW;<(KR10/#Q"V*@"UC''B[3356IB)RBTS,8?4#;'O:1@,9CMEM8T -:);N@
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MO:'^^6OW40#,^]M_5O:'^^6OW4$9VAU1]Y7>[<N_!;=VJ1@\E/A;WC6K3/\
M2ZI'/R:..K/2&A027XX][7^K6T/]\M?NH.?CGWM?ZM[0_P!\M?NHD^.?>U_J
MWL__ 'RU^ZB#XY][7^K>S_\ ?+7[J#5[@WI[TFV,'D=Q93;>TQCL76ENVS';
MM/?X4#2]W* 1J= =!JB7&W]Z^]'NC!X[<>*VWM,XW*UH;E4R6[37^%.T/;S#
M4Z'0\0H&U^.?>U_JUM#_ 'RU^ZI0T=G:/7_>^^=AYC?.*V_0PNT\K\8R/Q=J
M9\SFNC+'#DDU!\VB#Z30$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$!!2G4R[C<)U(VQGMY-LG9E&M*ZE-"V1]>#+B0.#YFQ:GU/5U[U:-42Z
M;/S&*W1U>N[BV-[1+M^;&F/<5YS9(JL]QKFBOR"70%X8#KH$F-$Y7<J@@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(([NK(YW&XULFW<;\996::.O%$\\L4?BG0RRZ:'D8.)T5=9F(X>?@M$
M1KE$NF]D8[,[EVC/B:&/R=6PS)Y"WAFO;4LRWVESGN;(2YLOH^GJ5>-:=4<I
MZ?8BVEHCQC+7NZF92YO2[@*60P].A3NQTVMO17'SREH:9/ML9$+'<Q+6@E1M
M8M$3Z?<G<^&<>CWZK=:===>U0J[*00$!!P2!Q053G]_[N@N[BMX"E0EP&U'1
MQY%METHMV7$<\O@EIY6A@_? ZJL6CIZK<)G'Y-.G-NF..,_M[&7FLABMHXH[
MJVIB*K-P[SM4H_%<.1L]FTWECDL.:=2&-*O:L_5BGI]S.EHFG7/#'XMGM#<^
M<O9G,;6W-#59FL.()G3T#(*\T%H$M+6R$N!:1H=2E<6IU1XS"+:6QXQE.5"1
M 0$!!P1]-!7.[=S[ZQ4V6NX;&4XL!@JXM3V<DZ0.N ,+WLK>&0&\H'+J\=JI
MU8C,\,XQS]/\%^G.(CCCU/'*YC X/;-WJ]2Q4%7<63QU7QK,[2)GL<6^%%*Y
MO$M87=@^@K[L32W3YX5VL7C/+#8=/MTY3<C;4N1R6+O"+E:R+&Q6J\C'=I\1
MEO1Q'D.BM,:*ZIZJI$! 0$'&HUT[T%4;SZD7\/NW\VL;<QE#P:T4\\^3AMSZ
MR3/<&M'LNH8 !J2_RJM/BF?#.%K1%8CS;+<=C%[)Q.2Z@5,93L;KRD52K/=K
M@M%J3F;#"'/XDL:7:_ IMF;Q6/U3A&WK7,\HS+(VQN?<CMS7-H;M@IMRL-./
M)5[.-\1L,L,C_#<TME+G!S7=^O%6B,UF8_3./S5G,3'G^2>@ZJ$N4! 0$!!7
M?47<.[]K4K&;QDV*&)@8UK*]Z*S):ELR.Y6QL\)P!+B0!P5,SF(YS+2(B8]#
MBUX6#P4O4S<N)HP[YJ8A\=RS '>A'KX@KA[R7<G-H3YU?=F*SB/'"FS'7,=7
M[0Z=.]Y9C=4DS\AD<58C9$U_LN/AN5YXW/X^E[5IS-&OK-[^]7FN(4SP6../
M%46<H" @(!.@42*R/4N[%E]R07<4^GC<)CAD:IF/+:G)<6Z.9Q# 2.'TU2;8
MV[6YQ,1[5ZTF=RM>4Q/N:O;>2R+=\XG+;HPF*@S6ZL86T<MCFRBRR"'2<59W
M2D\W!W-S-X:KHZ?BM7G77WX_%CU9K%HX6G'YMMN/>&Z_SCR>#VE5HR#!T69#
M(R9 RZR^)S%L,0C(Y7$-UYG+GZIBEKSPB<?O;S7A6/FM&4OVIG8MS;<QN?AC
M\%F0@9/X1/,6.=P<W7S$+?<ITVF&-+9AO%180$! 0$! 0$! 4#2;AP6$W)C)
M<7N*C#D<2XMEEK6&B2,NA(D:2#Y' $*+3B)E,1F<*\V5U(RNZ<ZRN+^'AQCI
MIF1X]L-MMQT$;BQG),\B%SCH'$-U5ZQFN>.D3[2^DX\\+='G54.5((""EMWY
MW(VMPY3<6+P>+NMZ>@D6[XE-_GGB#K JN8X-C^U\-7 ZJM+1B+6^6;8_+/M:
MS3XHK''&?W0MK%Y"/*8RGDX01%<ACG8#Q($C0[3Z&JTO7IF8GDPI;JB)9ZJL
M("#JY[6 N/8!J569Q"84ALG=<&;WQD,I1^(*-C*V'5[CFU[;,G:K4BZ.$&PX
MB%[P.QK==%>D9K$^62^EL>"\55 I! 00'J%O7);3@JNQ^+]L,MFM#8L3$LK0
MQ691&>(T+G\=0T*=J.O<K7E/[EIC%9MX1E&9LGD=J6<[M_IOA<72P>UH?C')
MUYFRQF>:RTV7MA$1#6N+1S<SAVK.+?#-[?+U8_BMT:Q6.-HRL[;^7BSV$Q^9
MA9RQ7X([#6$ZEOB-U+2>_0\%M>O3.&-9S&6V5%A 0$! 0$! 0$! 0$%0;OSU
M#IUG8L;M:'%8B[N.2?*YJW:KV9?%E&C&O+*FKG.>=07'AP5:SFTQX8]Z\Q$5
MSSF5C;>NV+^&IV[5BK;L31A\EBAS"L\GOC\0DZ*]M)9QJW*A(@((7U%SK\1@
MV5*].&_;SEB/#UZUK7V9YM!P=XP;Q+.4.Y@.U5UFT5CC*V(Z9M/"&KZ<Y"Q1
MGR&P+>-HXV;;+8&5H\2'QTG5)VE[.1DA<YO+V'BKZ37JCQQ*+1,3$3SC/Y+(
M4($! 42*BZPY_'1S8;;%ZMB[$-R1U^09FO8N0Q.J:&%[(JVKR_GU]+L"BOQ3
M,>2TQB,^:PMMWK.1PM.[;LU;=B9A=)9QX<*SN)XL\0EP'EU[U>T8G"D3F,MV
MH2("##OV_8:DUKP9)S&W40P-YY7G731K>&I5;3X+1&5//W@V_0FWUD-MTV[X
MQ.5GVW@C(XR.A]I<UG*^4:: ZZO#?H*^)F-N(XWC^U,Q'Q>%8RF.T]S;AL[B
MRNTMU15!E\;%!;BM8_Q!7F@GU&@;+JX%A&B1B:YCE.)4F)B8SSX)XH! 0$!
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M @:\').$K=500$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MH9J]*>6:%D=@!DNL$CHR2T$Z:D+2U)K$9YQDG2UJ_P LX2Q50(" @(" @("
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M" @(" @X/8@I/!R0X/W@]Y3Y6:.G%EL-CYL<^=PC;,V!SF/Y7/T!+2.*=O\
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MKNE5,@AW^G9'7OT/M<J[-V?AI_AA&Y_G;G^+\H7$L$" @(" @(" @(" @("
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( 0$! 0$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tm2227887d1-lc_asses4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-lc_asses4c.jpg
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M- ;!T>$B,A;P8H*BLM)3<S5"8P?QXB-#PH,7)/_:  P# 0 "$0,1 #\ O\
M
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MDY-.=JIS:Z!-$M!
M
M
M
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M<JCI[A.Y&4\=P@J*%DCEX(B2SQLCU5>"(K]57L":)B"
M
M
M
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MOHG1MDI^9R]JM171?Y+$")6,"
M
M
M
M                     <H^JCZ?\V]TT_YG %X=7 HIC_>#Q2+8<%G1JK"R
MKN#'O\".?% K4^VC7?<"T),Z-<@M%=L'9+=3U<2UEBEN$%TAYVHZ%TM;/5,5
MZ:ZHBQRM5%7@$2I-U2Y79<QWOR6[X]4LK;5'YK1Q5D+N:*5])31Q2.8Y."M1
M[7-1R<%TU3@H6A9C^\#_ *GX=\9U'YN@1#>.B3Z"J3XSK_W;0B52M]?TL+K\
M>6K\E2A:.)T(WG^A[<'^S5Y_,)@I"E/093MJ\_RVE>JM9/C\D3G)VHCZJ%JJ
MGW0M*-]DK[!LGU 6]^;(M'3V>LK+1>)'(OXA98Y*59=$U56M>YKE5-?([ F7
M2#,-V<"PO$ZG+[E?**6W10.GHV05,4CZQ_+S1Q4Z-<O.YZZ(G+KXUX(JA1S^
MZ/<=N65[]6^_,B_U*QLK+K<I&HJ,:LT,D$;45=>*R3-T3MY47Q!>7CW*BCFZ
MN:R&5J/BDRV@8]J]BM=/ BH#D=0PH  .6>^]@KMENH>MN5F9W$<5P@RBQ<.5
MG)-+YQRHB?>,F;)%]AH7AE>G"PUN\?48S*+Q%WD%+65.67;BKFI*V;O(6(J]
MO^L21^3X6HH)=%L^L4^48+D^,TJZ5-YM-?;H5U1-)*NFDA;Q7@G%WA"CG#TE
M9U9ML-Y7+F$J6NCN=%4V*IJJK6)E)4/FAE:LRNTY$YZ?NW*[@WFU=HB*J%Y7
MIWNW8PW!]M;]<*N[4DU?6T%136>@CG9)+55-1$Z.-&,8Y7*Q%<BO<G!K>(5A
M4/H/Q6ON6YUTRM(U2U6.VR023>!:JN>UL<?J^0R5R^+1/&$RU&T_IF2?_I!J
M_P"E9 GD6 _O HI%PG$)T:JPLNLS'O\  CGTZJU/MHUWW B&X=$U_M-=LC2V
MFGJHW7"S5M;'<*;F1)(TFF=.QSFZZHUS7\'=FJ+XE")5!ZM<LL>8;VWFNQZJ
MCKK=1P4MO\\@<CX9)J>-.\Y')P5&O<K-4X*K>' +0L7UR?0]A/QG!^83!$-J
MZ%?H4J/CRM_(TX1*K'5)^E#D7NFS?T;1!:.)T6W-^C;,?B.Y_FDH4<_^BJV.
MO6X&96=BHC[CAMSI&JJJB(L]511IQ147[X+RCG9S$<*O6Z5/A6Z\U1:+;.^H
MM\DL<K*5\%RC72-DKWM>B(KVK'V>N5.()6;W1Z=>E[:&T4EXS"XW]L5=.VFI
M::EJZ>:ID545SGMC6%JJQB)Y3D[-4\*H$5E+W2]CVSULQJ\7C9RMN==:+E51
M0W%]U:]CF5-)&KD8SGAA1=&S>4K5<GJA$IW"
M
M
M
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MD>G[$)JN-AV'X_@6-T&*8O2-HK+;F=W!"G%RJJ\SGO<O%SWN57.<O:H59T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                PUMR_$[S7/ME
MHOUNN%RB1SI*.DJX)YVM8J-<JQQO5R(BKHO#@!F0/+-<[;3R.AJ*R"*9NG-'
M)*QKDU35-45=>P#Y_#5G_E"F_P!-'[(#V1R1RL;+$]'QO35CVJCFJB^%%3M
MQ]WR&P8_&R:_76CM<,BZ1R5U1%3-<J>!%E<U% ^MLN]IO=*E;9J^GN-$JZ)4
M4<S*B)53P<\:N0#V@8F\91C./.C;?[U0VITJ:Q)754-,KT_8]ZYNO9X /;07
M"@NE+'76RJAK:*5-8JFFD;-$Y/V+V*J+]T#T@
M
M
M
M
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M7Q4&2T;7.6DGHZA&*RK8QVFCVQO9,QW!VGDKP54!QNG@4
M
M
M
M
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M1'N1JJGX_P!4%'0 *@
M
M
M
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M(FJA>'2T*
M
M
M
M                "!MZ>JO MI)I[%3-=D6:1(B/M%(]&14[EXIYS4*CD8NG
MWC6N?XT:BZA,0IUDG4EU"[MW"6VX[4UM'3R:]W9L5IYFRHQW#C)"CZAW#M\O
M3U$[ M1KR=/O4-D\JU]7B-XJJAZ<SIKDY(I537PK5R,=KZ@*OU]7?J(QQ[:Z
MDQ&[4LZ(O++;I&22HB:?[+*YR=H*LY9.H'J2VBJXJ:_U5S?3-5$6U9;2SR<Z
M-X\J/J49.WAX&2H"BV.SG6)@NY%328]DD*XMEM2YD-/%,_O:"JF>J-:R&?1%
M:YR]C)6IX$1SE"LPL@$   !C,CH9[GCUWMM*B+55E%4T\*.71O>2Q.8W5? F
MJ@5)Z7NF_<W:G<J7*,NIZ.*U/ME31M=3539W][+)"YODHB<-&+Q"TRN!<*"C
MNM!56NXPMJ;?70R4U73R)JR2&9JL>QR>)S55%"J@^7]'.[N!92N0[+7-U?2Q
MR.DMKX*QMLNM,Q_#NWOD?%&]$:O*KFR)SIKJU.P+5?FP])6^FYN5PWK>JZ24
M-&U6MK*FKKHKE<7P,<J]U3I"^:-B+JNG,Y&MUUY7=@*KU6S%,?M&+T^&4-#&
MS&J:C2VLMZIS1K2\G=JQVOKN9JKS*O%RJJKQ4*J,9CT@[P[?Y?)D&Q]=)5V]
M7N=;I*:O9;KI2QR=L4CY7PL>U$7EYFR>4G:U M5E-I.CW/[QFT6;;X3-;3PU
M"5U5;Y:MMPKZ^I:Y'(D\L;I&)&JIY:]XYSD\G1->9!,KL9)CUJRRP7+&;Y E
M1:+K3R4E9#V*L<K5:JM7P.3M:[P+Q"J@]WZ3^H+;+)JFNV?N$M=0S<\5/<+;
M<8K76^;/75(ZELTL#55-$]8YS571W#P%JMYZ?>D3*++F5-N+NY)%Y[;Y_/Z"
MSMG2LGDN".YVSU4S5<SR'^6U&/<KG\7*B)HX3*Z85  '-OK"_2-B]S6K]4+P
MZ2!0
M
M
M
M           055]+.U=PSF^;CYJV6^5MUJW5B4=7)W%NIT7E1J*QBM614TX]
MX]6K^"$U3)8[/8;';HJ'&Z"DMUI:B+!3V^*."G1-."M;$B-[ AD0 'GK:&AN
M=+)0W*FBK**9.6:FJ(VRQ/;XG,>BHJ?90"$\AZ3=I;GD5KRO'Z%V+WNUUU/<
M&I:]&T4SJ:5LJ,?3.U8UJ\NGXGD^V$U3H$                    <V^L+]
M(V+W-:OU0O#I(%
M
M
M
M                   $9;^[I/VAVTN66TL#:B[N?'0VF*3_ #7G=3KRNDT^
M]8UKI%3[[EY>&NH3"C=!?.L*HL;MZJ2Z7^?&(E?7/J75C'42Q1.7G>EL=)HL
M":+JJ4_)RHJ]B:A;@9*HH-Z>M*_U5UMKZ:UXS9(::!*:MJ)8;7!5K"G>)&D4
M<KWR2/1[]>15:Q6M<[3EU(XGQQBOW5Z/]S[38\KJ4DQ&ZO8^OIJ:=\]LJJ.1
M_=23P]XUBLFA7RN+6.X(CO(=Q)XW24*                        !S;ZP
MOTC8O<UJ_5"\.D@4
M
M
M
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M]4+PZ2!0
M
M
M
M              ^$5#105,];!311UE4C$J:AC&MEE2+7D1[D35W+S+RZ]FJ@
M?<# OCPS;^T5MS6*VXS8XW.J;A4M9!04W.]W%\BM1C5<YSNU>*JOC C*HZM^
MGFFE=#)F;'/;VK%07*9GVGQTKFK]I0FCY_6^Z=O3+_LRZ_P0%&TX#OOM3NA>
M)[!@U_\ A6[4U,^NFI_,ZVFY::.2.)S^:I@B:NCI6)HCM>/9V@HD8(
M               <V^L+](V+W-:OU0O#I(%
M                  "K>[F-;E8KDN)I;-U;ZRDS7)H[0ZE1E.C**GK.\D3N
MO)U7NT1&MYO $IZP'%;UB%GGMM]RBNRVKEJ7U#+C<VQLFCC='&Q(6I&B)RHK
M%<GJN4(;4
M
M
M                               "AW7]E=V7(L7PEDTD=DCH77>:%JN;
M'-4S320-5_WKEC;$O+^#SKXPM#4,7Z&MU,AL=%>ZNYVBT>?PQU,5#4R5#ZF-
MDK4<B2I' YK7:+Q:CET^R"K,?4!W)])K']VK]H!5,?37TP9;LKG5PRF_7BW7
M"CK+3-;&0T*S]ZDLM333(Y>]C8G*B0N3M\*!$RM*$
M  .;?6%^D;%[FM7ZH7ATD"@
M    #P7J6[06NHEL5/%5W9J)YM3U#UBB>[F1%1SD[.&JE+YNBW[O&R=+;BNR
MQ&69MLY9B*SX%<-Z;CN-->]K77NRV^EJ(LOHWVQD%4Z1LM4D,W*R153R6JNF
MJF/9=FFM;8XN#A;;48=W6W6>JR7W1,_>K;2EO/'/*;\=N.XU3<FQ9-9K?0VO
MD<KIZ6J=-(CT]:G*J)P4G'=FF?O1$1THUN'=]N.N#)?=?S76TAMYE-"
M
M
M
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M98^*P
M
M
M                          % _P"\ O%U?F>*6![WI9(+8^NACUT8ZJGJ
M'Q2*J>%6LB9IKV:\.U0M#[8OT!WB[V&ANE]S:&TW*LA9/);Z>VK7-A25J.1J
MRK50:N371VC-->Q5!5E_\/+_ .(__8G_ -X JE38/I7^8[,*[+/E9\/>>6R6
MU^9_!WF7+WM1!/WG/YU/KIW'+R\OA[>'$B96+"                     '
M-OK"_2-B]S6K]4+PZ2!0
M#Q7*\6BS1,GO%?36^"1W)'+5S1P,<_15Y4616HJZ)V%[,=U\TMB9Z$3=$<;
M73)MM;W036N[WNRUMMJ41L]+/64LD3T:J.1'-5^B\413(LPY[+MJVVZ)CN2^
M<WV3%)F$#;N8UM0Z_;6T^(T-EECJ\PH:6ZQVU*>5'T\T,Z=W*D2KY+M%X+VG
MTS9M3P3?-W!/!6I99CX=FBP%EV]P?'*Y+G8<?H+=<&M=&VIIH&12(Q_!R<S4
MUT4^6359LD4NNF8Z4VXK;9K$-E,5]
M
M
M                                                   *==>E1@SK
M)CE#>HJZ/,_]9J+!74D,,M,L+5B;/!4J^:-S6N5S',<QCU:K>SBNI:&H;===
M]38<<H+#FN,ONM9;H(Z9MVHJEL3YV1-Y&NEAD8J<^B)S.:_15X\J HW'_$#P
M_P!#KG[XI_U@423LEU16'>S*JS%;78*RU5%';Y;FZHJ98I&.9%/# K$1G'55
MF1?M!$PGH(                     <V^L+](V+W-:OU0O#I(%
M                                ,3?L8Q[*::*CR.V4UTI87][%#5QM
ME8V316\R(Y%T7150^V+-?BFMDS;/<4NLB[CBJ&+SMO@4.]>,62+'+>RT55GK
MYZBB;3L2&26-[4:]S=-%5/ IN\>KS3I+[MJ:Q='#5B78K/6Q%."CP[PX=BN*
M9)M&[&K-26IU5F]M2I6DA;"LB1Q3\O-RHFNG,NGV32Y=1DRTV[INISLRRRVW
MBBBQ9\%@
M
M
M                              $/[U]/&,;XU5GJL@NE?;GV6.>*!M L
M*(]*ES'.5W>QO[.[330)B45?4!VV])KY]VD]H":GU =MO2:^?=I/: 52)LUT
MP8ELKD]7E-AO%QN%964$EL?#7+!W212S0S*Y.ZC8O,BPM3M\*A$RG$(
M                <V^L+](V+W-:OU0O#I(%
M                  $57[Z?\1^([E^[:;;%\'?YUK%N]K'1+"]0/]8MF_[<
M4'Y*4U++A-X0
M
M
M                                   J'UL;T9/A4-GP#$:V6UU-YIY*
MZ[7&F<L=2E*DG=1112-5%8CW-D616\=$1-=%=J6B%-[9M3NYE]*R^VW$KY=J
M.J1'Q7%M'42QS-7L<R1S='IZK54)>SY@MZ_0&^>\9O8@JL;T6[8[AX7NE=[I
MEN,7&RVZ:P5--%55U-)!$Z=];1O1B.<B)S*UCET]10B5ZPJ
M        YM]87Z1L7N:U?JA>'20*
M          (JOWT_XC\1W+]VTVV+X._SK6+=[6.B6%Z@?ZQ;-_VXH/R4IJ67
M";P@
M
M
M                          !3+KLVKO-ZI[1NA9:9U7!9Z9UNOK(F\TD-
M*DCIH9U1.*L:Z21'_@ZHO9JJ%H3+M-U![1Y5AME;'D5LL=SIZ."FJK'7U,5#
M+!-#$C71QMF<Q'L3E\ET>J<NFNBZHA%&_?.;MMZ8V/\ G.D]M"&0M&88ED%2
M^BL-_MUUK(V+,^GH:R"IE;$U4:KU;$]RHU%<U-?50#-
M     <V^L+](V+W-:OU0O#I(%
M       $57[Z?\1^([E^[:;;%\'?YUK%N]K'1+"]0/\ 6+9O^W%!^2E-2RX3
M>$
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M0
M                                   %)NO'<R_6V:R;96FJDH[9<*1U
MUO7<O5CJF-\KX(87JW36-%CD<YJ\'+RZ^M"T*[8]TP[[93:*6^V;#YI+76L;
M+2RU%514;Y(WHCFO2.IGB?RN145J\NBIV!-64^J#U$^AO_:=J_A8*I]Z1=B-
MUMK]R;I?\YL'P5::FQU%##4>>453S5,E722M9RTT\KDU;$]=5;IP[>P(F5T0
MJ                     YM]87Z1L7N:U?JA>'20*
M                        (JOWT_XC\1W+]VTVV+X._P ZUBW>UCHEA>H'
M^L6S?]N*#\E*:EEPF\(
M                          !X;M>[-8:5*Z^W&EME$KTC2IK9HZ:+G<BJ
MC>>1S4U71>&H&#^<W;;TQL?\YTGMH#YS=MO3&Q_SG2>V@5UWIZL:ZS7R3%]K
MO-*M*;1E7?GHE7')*Y$7DIFM7D5&ZZ*]W,CEX(FB:J&&VNZN<F9DE-8=THJ=
MUKJI&T[[K'#YI/22/71'S,148L:+Z[1K5:G'CIH2+1_.;MMZ8V/^<Z3VT@/G
M-VV],;'_ #G2>V@9BSY%C^112S8_=:.ZPPN1DTE!41536.5-41RQ.<B*J>,#
M)   %6.OGZ'K)_:6E_,*\)A-^S'T/;??V:LWYA"$2W@"D'2?^DCNO_O3^EVA
M:6_[L=4MYVJWCFPJMM--<,6BMK*J&*GBG^%*BNGA<L,+)$E6-K72\J*O<JJ-
MU[5T0(HP5VSWK>6@ERZFPRV4%FCC\Z;9&LBGJT@;Y6CXG5*SN?R^N8U&O\34
M7@$\"0=H-_KUO3MGD-UQ>TTL.YUAA[M;1,]5H):N9CW4ST<LC')%*K'(K7/1
M6JU4YE[0BBL6WEYW^I^HS.+AC./66JW1FHZEN06JJD<ENA@6HI%D="[SMBJJ
M/2)$_'.X*OVB5CM\]_,QV:^;'SVAMC5R7O/E@DT4\_FWFOF7?^:=U4-];W\N
MG-WFNC?5U(B&E63>CJJS+([7D&-X-#2;;7FN@@H?/:5\G)05$C6)43/9*V71
M&.[Q96M2/PIJ@32&Y[T]25WQ?,*?:C::QMRC<JI5K9V2(]]-2ND9WB,5D;F*
M]Z1_C'JKVLC;Q<J\40B(:C>-Q.LG;:VKF&8XU9KWC-*G>W6DH^19Z>%-%<Y5
MIY%<W3PO1LC6IQ<FG$)X%A-J-T<<W=P^FR[''.9&]RP5]#*J+-25;$17POTX
M+HCD<UR>N:J+Z@50+=^I+=+<?-+KA73KC5)<J2SJZ.NR2XKS0JB.5B2QZR11
ML:YS5[OG5[I$35&IQT+483+-X.K?9N&+(]P\>L]WQ-9(X:J>E1O(Q7KHC5DI
MY.>)7+Y*/DB<S71.U04A.MSW"SC,MJ;)GFQMJH;K=[RL,J4%Z=R114ZI(VH:
MY6ST_P",BE;W?!^G;IJ$*E]'=TWIHH*^FVZLEIN6(SW:C3):RXO5M3!&J(CU
M@1*F'54BYG)Y#^/W F5H]_NH&V[+T5#;Z.A6^9O>M4M%F8JHB-YN3O9>1%=R
MJ]>5C&IS/=JB::*J$1",693USI;_ )4NQJR.ID;YRN/*R-*E8M->7NTJ.]UT
M^\[WO->&FO )X$J;";^VC>JUUD,M&MFS*SJC;S9'N5W*BN5J2Q*Y&JK%5-'(
MJ<S'<'=K7.(F&A[J=267OW ?M!L58HL@S*G<Z*YW"H17T]/*S_.,:WGC:G=:
MHDDLKT8UWDZ*H*-2S7=7J-V\Q>[4F]>+T5=B5_H:JV-OMF5G/15-9 ^*/O4C
M>YO+S.1%1S&Z_>N5?)4EN70K]"E1\>5OY&G")69"
M
M               IIUXX3;+E;[#F<-VH:6_VV.6EEM%7504]564"O1_>4T<K
MVND="]R\S6(JJC_4XEH2'MEU;[.WS%;7'D%[CQW(*>EAAN%OK8I6QMEC8C7+
M%*UCHW,5456^5S:=J($4;I]9/8KTZMG[=_L 4;!B&[FVV>W*6SX=DE'>+G!
MZKEIJ9SE>V!CV1N>NK4X(Z1J?;"&Z                      <V^L+](V+
MW-:OU0O#I(%                                          $57[Z?\
M1^([E^[:;;%\'?YUK%N]K'1+"]0/]8MF_P"W%!^2E-2RX3>$
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M,>C7M]5 JA3H5^A2H^/*W\C3A,K,A
M
M    5DZK=@\YWHN&,56'R4#([/#61U?G\[X%5U0Z)6\O)')KZQ=0F)5V^HKO
M7_M%C]^S?P<+5/J*[U_[18_?LW\'!5-O2YTV[A[.[@7+)LMEMS[=5V>>VQ)0
MU$DTO?RU5+,FK7Q,3EY87<=?$$3*VX5                     <V^L+](V
M+W-:OU0O#I(%                                          $57[Z?
M\1^([E^[:;;%\'?YUK%N]K'1+"]0/]8MF_[<4'Y*4U++A-X0
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MR\1$,KT*_0I4?'E;^1IPB5F0@
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M",=2OI)+PVC;Y[5-MZ3M[Y:BJD:V.*-6HO%K&+X$<H31>@*@
M       <V^L+](V+W-:OU0O#I(%
M         $57[Z?\1^([E^[:;;%\'?YUK%N]K'1+"]0/]8MF_P"W%!^2E-2R
MX3>$
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MUJ*YO[%RZ 9BTV2S6&E6AL5NI;91*]9%IJ*&.FBYW(B*[DC:U-5T3CH![@
M
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M+GJJ^J%6;                    !S;ZPOTC8O<UJ_5"\.D@4
M                                03NKEE/A.[F-9%54[ZJ&FLM:QT$2
MHUR][.R--%=PX<QGW9HQ:#)=/#]ZUF;LW==K];9AMF+9FV[AGN<**MVM_<=R
M:]8!/%124SL8R2EO-;$^:-SE@ABD14T3UJJKF]OC-'BU%V2)F+9^MM]?NG%I
M,L8YSV736EU(G[G=GHYN--V#[^V/.LAH+!;[9-$ZX=ZL56LL<D2=S$^5?6=O
MK%0^>/6;62+)MF)9NK^6_4Z.[569K,EEM/PUY9B/I2Z;%QX
M
M
M
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M;[;:QW8OMF)^CONA9]VL
M
M
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M2Y&/9,UVB.<WR7=H.-TV"@  YM]87Z1L7N:U?JA>'20*
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MF[)EB(B[DMB+HNIWZ+3%VJ
M
M
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MW&W1K]X-RZ3,[E00VVJE6BI5I:=[I(T; Y$1=7\=5U"77,*
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MJ>3Q73EVV_;\-(C_ -GDCN_0P-%%]:_Z5M#D&U
M
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M!IU[W7VTQN\/QZ_Y7:[;?(EC22WU55'%.U9FH]FK'+JG,UR*GV0-Q
M
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MK;/:+%U!0T%DH*:VT+:>UO2EHX8Z>)'.7BO)&C4U7P\ O#IB%
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M[=;J&TT-/;+93QTEOI(VPTU-"U&1LC8FB(B(?>^^;YFZZ:S+41$1%(>DJD
M
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MFAD8OWS'L56N3U44#T
M                                             $?[P[18YO-B,F+W
MY74U1&]*BUW6)J.GI*EJ:(]J*J(YKD7E>Q5T<GB<C7(2H#EW1OOAC59+';;1
M%D=M:JK%7VRHA\IJ:JFL,[XY4=HG%$:Y->"*H6J\..=(F_&0U,<4F-I9Z5ZH
MCZVZ5,$$;$55356,>^9>S[V-?^% 57QV$V(LFQ^.345//\)9)<U9)>KLK.1'
MNC1>2*)O%6Q,YG::KJY555\"(5F4MA     ,7DM%47+'+Q;J1J/JJNBJ:>!B
MJC4626)S&IJO!-54"H/2OT\[I[7;FS9+F5KAH[0^UU-&V:.KIZAW?2R0N:G+
M$]R\48O'0+3*Y\L44\3X9F-DAD:K)(WHCFN:Y-%147@J*@54$W!Z2MU]O<U=
MENQDTM5;4E=/;DI*ME)<J#O-4=$JROC22/1W*BM<JN;P>WPJ6J^.#=)N[^X^
M;,RG>^26BMCY6S7.2LJXZJY5K(M$2*-(7R)&U4;R:N5O*WUK5X JOQ56JW5U
MKGLE731RVBIIWT4]&J?BG4TC%C=&K4^]5J\NGB"J@65=*>]VUF929!LK4SW"
MV\S_ (/K:*KBI+C!!+VPU#)7Q))IV*K.9KM.96M[$+59/:KI)W+RW.H\WWP5
MU/0MJ&UU;3553'67"XS,5%:QZQ.D:R)=-'\SN;E3E:U-=6BJ[^4XU:,RQRZ8
MK?H>_M%WIY*2KC1='<DB:<S55%T<U?*:[P.1%"J@5?TS=1^T&455;M/4U%?0
M3H^"&ZVFKAI)I*9RZM94P32,X\->"/8CDU1VN@6JW?I_Z3,TILWIMR=X52">
M@J?A*DM;ZAM965-P1W>-GJ9(W/:B-?\ C-.=7.=Z[1->83*[H5  '-OK"_2-
MB]S6K]4+PZ2!0                                       $5=/W]2K
MA\>77\X4VV]/:QYMOD8NF_#WY0YUBW_O;OC>,1NX4M/-<9VIV*M2](H]?51(
M7_=-WN#%2V^_GFG@_P"K$UUW#$-BI[;\AK1BE(J<D]'A-TJ)&^*JJF+.]/\
M2R*APV^<^WJ[K^Y=XN"'IWRU@V]!L<^?#Y>%5KIKH_A'JGM+D1>ZAK[Q4O5%
M1%1(Z6J5O;V^5RHNA?#%++8[D.4UN3UF?)?UKKI\,NG9]6"
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M
M                          !7WJAZA:C9:T6^UXY3Q5697QLCZ5]2BO@I
M*:)4:Z9[$5%>YRKRQMUTU157LY7$Q"E51U7]0-3*Z9^:3,5WWL5)0QL3[#6T
MZ(%J/E]:C?\ ]-JGWO1^T HL'T>[T[G[C;F76QYKD4UWM5/8JBMAII8J>-K:
MAE91QM?K%&Q=4;(].W3B$3"[(5                     <V^L+](V+W-:O
MU0O#I(%                                        15T_?U*N'QY=?
MSA3;;T]K'FV^1BZ;\/?E6K<95W(ZBY+*U>\I'W2ELVB<>6"E5L4Z_:5)7*=1
MI/\ ^?0[7+LS=X>+Z&NR_P#DS4[M$Q]0]8E!=Z1&>2Z>SSTT:)P3\951(J?M
M>8\EWC=2Z.['TO;?DZR)P73/%;DBZ>]9<J_T2T[[KOQ)<9&HLE-:[A6OY6<R
M-=*^.%51?O?\]IK]KPF[AYA=-72<E0
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M;I@>;V3,)MQZB[16>I2I=;GVY\+9D1%3E5ZUTG+V]O(H*M8W\_3,VF]S6?\
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M>G:S354374)HD@(
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M57<T7?P2AGH!HDDW&R>XZ)K3V3S=':KJGG%7"_33LX]R;QYC+H.%0
M
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MY9=OE)N1?>;X0NJ\ZQQ-E?WDK(W2>6]9'HCGR.:U5T1$1..I$RG0(
M
M                   %3>M_=KY,8O2[9T%'3U-=E$+Y[A/51-F;3T43^5JQ
M->BHDKY$7ED[6<BJGE*US2T*+XUD6?6%CY,.NMXMD;G+WC[3455,BOTT75:=
MS>.B_<"S8OG-WY],<N_G.Y^VA"QO1;F&YF0;I7>BS._WVZVN.P5,T-/=ZRLJ
M:=M0VMHVM>UM0]S4>C7/1%3CHJA$KUA4                    !S;ZPOTC
M8O<UJ_5"\.D@4                                  _$TJ00R3*USDC
M:YZM8G,Y4:FNB)X5 @B?JPPNEK:2VU6)9C!<;AWGF%))9'LFJ.X;SR=TQ94<
M_D:O,[E1=$[0FB6\,RRES;'Z?(J.WW"UP5#I&-H[O3+15C5B>K%5\3E541=-
M6^- AGP-,ON29_076HI+)@_PQ;(^3N+C\*TM)WO,QKG?BI&JYO*Y5;Q[=-3$
MR9<L74MLK'/M1#H-)H=!DQ1=EU/J[YX[?5774X>>)I-8X59JK-,ELFQV0VU]
M@2"UWF[UM#\,+71+R3U%0KY8$@1O.[R&/;S:Z>'U#LL=M^3>%D3;]V++9F:_
MJ\W2Y_)ATUFBNOC-7)M3$6;$\,5X]KBC@X:=YN725C,GR,R>^-E=2U-WG2W4
MU2S19(VTL*KWC->'!\_W6C?^6N2VSFBOA_Z-=HK:6S*%NI;%\MQ&[T]DO&=W
M3)J>IL%PK^\KXJ9'M[IZ1]TBM9KR.YN.BZ^(X_-;;6V9BLUAT^BU&:VR_';?
M=;;-LUB.*>"E);#_ '>M"JR[@7)R*B-;:J>->&B\RU;W^KPT;]TR6KE>(*@
M
M
M
M                     *.]?6!72:KQS<FDA=-:X*9;+<Y&IKW#DE?-3N=^
MQ>LLC=>Q%1$^^0+0M3M!?\*R#;VPSX'+2_ D-%3QMHZ16(M*](T1T4K&\6/:
MY%1W-Q5>/'M"K>0                       #FWUA?I&Q>YK5^J%X=) H
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M(_1.U=&JJE\>JPY)I;?;=/<F)8>32YL<5NLNMCNQ,/:9+&
M
M
M
M        I_UMV3<V_5&+4."VZ_7.U2TU='>*:R05E13NYGP<C:AE,US5U1'<
MJ/3QA:%/H-H-Z:63O:; \HAETTYX[1<&.T7U4A0)>GYLM^?0[+OYLN?M0%C>
MBW#]S,?W2N];F=@OMJM<E@J88:B[T=934[JAU;1N:QKJAC6J]6M>J(G'1%")
M7K"H                    #FWUA?I&Q>YK5^J%X=) H
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MS!
M
M
M                        A??/J*LNQE79:2[66JNSKU'42Q.I9(XTC2F=
M&U4=S]NO>> )B$2?X@>'^AUS]\4_ZP30_P 0/#_0ZY^^*?\ 6!1).R75%8=[
M,JK,5M=@K+544=OEN;JBIEBD8YD4\,"L1&<=569%^T$3">@@
M        !S;ZPOTC8O<UJ_5"\.D@4
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MK-ZX9C4X+Z\>2V/$Q=W;QMOW;ETL6\-EM]VU7CKW%TCK'!
M
M                                            >1ETMDM2M''6P/JT
M[:=LK%D3M^]1=?O5^X!ZP
M                                            0_O7T\8QOC56>JR"
MZ5]N?98YXH&T"PHCTJ7,<Y7=[&_L[M-- F)15]0';;TFOGW:3V@)JP&7] 5I
MCLU548/D]9)?(8U?2T=TCA=#/(U%5(UDB2-8^;@B.5KD3P^H*O'T)TF!K>;Y
M+'#64.Y]NH9**OIIID?25%OEJ8G.ECB6-'LDCDBC9(BO5/*14]=HT2O %0
M                  '-OK"_2-B]S6K]4+PZ2!0
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M+O?VFG_NV_2R-T_@U']J[Z%A#HG.@
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MW=K]X=MF7>^-:F26FI=:[M+&B,9/)'&R1DZ-3@WG8].9$X<Z.T1$T0(E,X0
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MU=*RH5%3[UJ!>'1S;+Z-L.^([9^:1!1M0
M                                      !$V\?4)A>R-3::7*Z&Z5DE
MY9/+2K:XJ>5K6TRL:[G[^H@T5>=---0F(1C]?G9[^1,E]ZT'\/!1A;YU_P"%
MLH*KY-8M=)[GRN2A^$5IX(.=47E=+W,LKM$715:WM\:=H31$/1.V\7G?>KO>
MCGM;;:^JNLS4Y6?ZS)&B(NFB>5(Y%1OJ>H$RZ/A0
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M45%HV66G5%5%7\50M9VIV]ASN]_::?\ NV^270;H]GJ/[5WEA+QT3G0
M
M  :)N%NG9]NIJ"&Z4=35.N#9'Q+3=WHU(E:B\W.YO;S&%J-7;AI6)X72[FW!
MFWG%\X[K;=BG'7EKS1W&E_6<Q+^2+C]R#VPQ.U,?-+H?R)J_ZEG[WU,-EO4'
MC.0XQ=K'36NNBJ+A2RTT4DB0\C72-5J*[215T/EFWC9?9-L1/##8;N^3=3IM
M3CRW7V3%ET3P5Y.\KL:)ZLS.)7B#'LGM-\J8WRT]OJHJF6./3G<V-R.5&ZJB
M:GUPWQ9?%T\DM?O'37:G39,5LTF^V8X>ZL3]9S$OY(N/W(/;#>]J8^:7E/Y$
MU?\ 4L_>^H^LYB7\D7'[D'M@[4Q\TGY$U?\ 4L_>^I*^*Y%2Y9C]%D-%%)!2
MUS7/CBFY>\:C7N9QY55.UOC-GBR1DLBZ.5Q&\-%=H\]V&Z8F;.;BXJLP?5@
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MI@VMG==LQVIO$;)*6Z.IJBIBM[9>=L<BO:DC(.65O=S-YD9RJDFB< +>!4
M                                                         (7W
MSZ=;+OG5V6KNUZJK2ZRQU$43:6..1)$J71N57<_9IW?@"8E$G^'YA_IC<_>]
M/^N$U?J/^[]PM'M67+[HZ-%\MK8*=KE3U%5':?<!587:S9[!]GK/-:,-HWQN
MJW-DN%QJG]]653XT5&+*]$:FC45>5K&M:FJJB:JNI%6^!
M      #FWUA?I&Q>YK5^J%X=) H
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M?VFG_NV_2W^Z/9ZC^U=]#?#HG/
M                                  UO*,!Q+-)*:7);?Y\^C1[:=>^G
MAY4D5%=_F9&:Z\J=ICY=/CRTVHK1M]!O?5Z&+HP7[.UQ\%L\73$M?^8K:O\
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MV]T]!D-ZY$M5!,KFR5"RR=TQ&<-%5S_):FNJJ!LX
M                                      !0_J)ZFMW]O=X\DQ#%KO!2
MV*W>8^:0245-,YOG%!3SOU?)&YRZOD<O%0M$(O\ KF[_ /\ +]-_-U'[4$T/
MKF[_ /\ +]-_-U'[4"A]<W?_ /E^F_FZC]J!1/'29U ;G[K;C7/'LUN<-;:J
M:R3U\,45)3T[DJ(ZNDB:[FB8U53EE>FG8$3"Y 5
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MC_R:?^[;Y)=#NC\&H_M7>6%U3H7/
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M[N'1:]RJM:^1(XXE>Z1C5>KUD7F=IX2*K6A
M                                  U6\;9;;9#<9KQ?\.L=UNU3R^<5
M]=;*2IJ9.[8D;>>26)SG<K6M:FJ\$1$ \/S,;/?]WV-?S-0>T@JB#-LXZ-<"
MN$MHNU@QBKNT#E944=LL-)7.B<BZ*U[XH%C:Y%[6J_F3Q!/"\F*;D]%F6U\=
MLIK#C5MKYG(R".ZX_2T<;U7@FDSZ?NDX^!TB*O@!PI_Q_;_ L5JWW+%<7M%D
MKY8E@DJ[904M',^%SFO5BOAC8Y6JYC7<NNFJ)X@AL8
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M$BA8KD17(SF<JN5$U5R^#0YW?'M-/_=M\DNAW1[/4?VKOH60.A<\
M
M
M
M               JMUK;PW7!L8MV#8U4OH[QD[99*^LA<K)H;="K6JUCDT5J
MS.=R\R?>M<GA"85MVDZ1=PMT[%!E3ZNDQ[':SRJ&>M222HJ(T7E[R.&-/6<%
MT5[VZ^!%3B%JLGN7T6;BX'8JS)+3<*3);9;XWU%;%3-DIZQD,:<SI&Q/YFO1
MK457(V3F\2*"J6^AW>6ZWR.NVGR*I?5NM=+Y]CM1*JND921N;'+3*Y>UK%>Q
MT2>!O,GK4:B$2N:%0                    '-OK"_2-B]S6K]4+PZ2!0
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M1[/4?VKOH;H=$YX
M
M
M                                     !S]_O +=5Q9]BEV?S>8U5G?
M2PZIY/>TM5(^31=.W2>/7CX@M"VNP><XQG.UN-5&.5,*OMUNI+?<+=$Y.\HZ
MFEA;"^)\>JN:FK/Q:N]<S14[0B6S9_G.,[=XM7Y/E=5'3VREC=I$]4[RHD5%
MY8(F+Z][UX(GVUX(JA#G_P!#MNJJ[>YU?3Q\M+;[56SU*MUY&ME6.%K=5U^^
M>FG'7@%Y=)PH                     YM]87Z1L7N:U?JA>'20*
M                           0CU7WRZ639VX-M;G1K<JJGM]9*S5'-II5
M<YZ:IV(_D2-?4=IX0*K;?[28+E.T^3YQ>LJ^#LAM"3K26U'PMC:L$221I,R1
M.\?W[O(9W:I_QEX$B0>B%R.R;*&/@1ZQT$*Q52IY42/F\IB+KV/T1533[S[M
M_67;.Q7[M:T[JNS%:\J8.HG/?@ZW1X3;9=*RX-2:Z.:O%E*B^3'JGAD5./[%
M/$XT6\M1LQL1QSQO3/DO='K<DZJ^/NV<%O=NY9[WEZ&6V!P+Y-X\N27"/EO%
M[8UT:.3RHJ+US&^-%D7RW>IR^(^N[]/L6;4\=WD8/SAO?WK4>HLG[F+QW<O@
MXH[_ #O!TK_1U=?[2WO\[4VCA)5<ZY<OER;=2U8-;G.GCQVD9&ZG9Q5;C<U;
M*YJ(G:JQ) GV0F%J([M-L=A^(8+;J*&J;0VR.*HD>YS>:H9IWST1O#RY%<_[
M9RF^M]7Z"^VVVV+MJ*\+J=R[ELU]EUUUTV[,TX&O7K=JXWJ>USRVZ&);75LK
MHT:]ZH]T:*G*NO8G$X_5?,>3/=CF;(CU=T7<<\-'7Z7Y<QX+;XB^9]9;-O%'
M!5EOGXN_\D4W^DD,_P#-^;^G;X98'Y0Q?U+O!"=3TQYH
M
M
M
M     !&&^NS5JWJPM^/54R45YI'^=62YJWF[BI1O*K7HG%8Y$\EZ)ZCNUJ!,
M2YQY/LMO;M9=96U%BNE.L:JR.\69LT]+(Q5T16U%,BZ([P-?RN\;44+5>:U;
M8;W[FW.**&PWV[U+E5OGUR94-@CYW:KSU-7RQMU7CQ?Q Z$]-^PM-LEC$Z5\
MT=;F5Y[N2\UD2:Q1MC1>2GA54158SF55<NG,Y=>Q$1"LRFL(
M         <V^L+](V+W-:OU0O#I(%
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M?,<,UYED3UYY$
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MV2>)E+4.:^1JTTKHE559PXJW4#=P
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MR>LR4K2G ^.AT./28_5XZTK7A6W/=WA(
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MK64-0UT/,J]KXEYHN9?&OC"T\3VY5#%/U]6J&>-LL3O-N:-Z(YJ_^AW+Q1>
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MX2+X&R-;JO!-5"*)\"
M                                    #3<TVGVWW$8J9GC5#=9E3E\\
MDC[JL1NFFC:F)63-3A]Z\"N&<= ^)W#O*K ,@JK+4+Y3:"Y-2NI57\%LC>[E
M8GJN[Q0M56[-.EC?# 975:V&2\4<#N>.Y6!RUJ(K%UYDC8C9VZ=O,Z) FKZ8
M5U3;X;=3);Y;Q)>**F=R26K(&.JE;R\.7O'JVH9HG!&I)HGB!1<OI\ZHJ'>^
M[U6+U&/RV;(J*A?<I7QS-J:*2&*6&%W*Y4C>URNF;HWD<FFOE!686#"
M                '-OK"_2-B]S6K]4+PZ2!0
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M?/\ ]G\/_1ZS?_X-S_\ U_Q?]5BSUIY,
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M]'!5N(
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MUVUU8NGZ/I=!\S7[&AV>M-L?3]"QAZV\E
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MBTF$[>8QB<^BU5HME+2U2MTY5J&1-[Y4TX:*_F5 JVL
M
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MC<_-^2F+'9SS,^"/M3D>E/-0
M                                            B^X;"81==U:;>"Y2
MU]5E%&^)]+3R3L6AC6"'N8T;%W?,B-_SB>7Z_B$U2@$ $48AT]8'@NX5PW)Q
MN6X4M[N;JM:RD[]BT+F5S^]DC2/NN9&(]&O:G/P5J> )J]^ [(X;MOE619AC
MTE:Z[9.^22Y-JIF20HZ69TZ]VUL;%;Y3E[57@"K<,KQJW9CC5UQ6[+(VV7BE
MEHJM8'(R5(IFJUW(Y4<B+HO#@$,/MIMMCVU.+QXCB[JE]JBFEJ6NK)&RR\\Z
MHKO*:QB:<.' "*<IZ,MH,HR>HRGO+M9ZNKG6KJ*6UU,,=*Z=S^=ST;-3S.9S
M.XZ,>B)X$0)JW[--D<-SO.L;W#O<E:V_XL^FDMC:>9D=.KJ.I\ZC[QCHW*[R
M^W1R< 520$  #!9EB=KSK%[IB-Z65MJN\*TU4ZG<D<J,547R7*UR(O#Q 8S;
M3;;'MJ<7CQ'%W5+[5%-+4M=62-EEYYU17>4UC$TX<. &X  (1W&Z5]LMT<LJ
M\RR6:Z,N]8R&.9M'4QQ0\M/&V)NC70O5.#4UXA-6J)T*[*(J+W]\7U//8?X.
M"J3-O.G_ &GVOJTN6*6!D=Y1JM2Z5<DE75-14T7D=,YR1ZIP7NT;J"J30@
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M4WC(XT7S>Z7>1DSX%<FCEA9''&QBK^%RJ].Q'<5!5-00
M
M  >"GL=EI+G5WJEMU+!>+AR>?7".&-E3/W;&QL[V5$1S^5C&M3F7@B(@'O
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M@
M
M
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M51R<?7*K8_MFEU^:=;O"ZZ8X*^*(_3PO8M'FLW9\O6W63]ZZV:3^O?,_P_\
MQ7M-L\>   #2]L?ZOU7QC6_E5.=W!\/=Y]_E=#O[XBWS+/(W0Z)SR"M^/XWM
M'N:3\H>9_-_ML?FSY7I?RA[+)YT>1O>T-)YM@M%)IHZJDGG<G_C'1I_P,0Z;
MY:Q[&AMGK3=/CI]#F?F7)MZZZ.K%L>*OTMZ.F<T
M
M
M
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MRG.1.&FJA$RO2%0 !S;ZPOTC8O<UJ_5"\.D@4
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M6UBNS'CBKB-ZS=?J\MU)IM3XIHV,V[4@
M
M
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M+K)GAXUH#VAXP
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MD&06?%;+6Y#?ZIM%9K?&LU95O:YS8XT5$U5&(YR]O@0",/K4; >FU-[WK/:
MFC(VSJ,V.N\L<-'G5K;)*JHQ*J5:--4X<5J&QHGJ:@HDV&:*HBCG@D;+!*U'
MQ2L5',<QR:HYJIP5%3L4(?L   UK(]P,.Q*ZV2QY%=X:"[Y'4-H[)1O1[I:F
M=[V1HUJ,:[1.:1K>9VB<>T#90       /A65E+;Z2HKZV5L%%2QOGJ)WKHQD
M435<]SE\"(B:J!J&#;O;;[E557181D$%WJZ&-LU5#&R:)[(WNY4=I,QFJ:\.
M&NGA[0-V U&Y[GX'9LQH=O[G>8Z?,+FUCZ&UNCF625LJN1BHYK%8FO([M=X
M-N          ,!FN:8[M]C5=EF55:45FH&HZ6317/>]R\K(XVIQ<][ET:B?J
M 47S;KSSRX7"6/ [/166S-<J0RU['5E:]J+P<_1[8F:I]XC7:?A*%J/)BG7C
MN;;:^/Y66NVWRTN<G?L@C?0U:-\/=R->Z/[3HEU\: HO-MSN-BVZ>+4V6XE4
MK/;YU6.:&1$;44U0U$5\,S$5>5[=4\*HJ*BHJM5%"K;
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M">-8T]<>2
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MF[[$UGS1;GPWX_5S&U$Q^+G[R73O'!@
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MXX8JZOC>^:.F:YL2*R5[$Y4>YZ]C?"Y30ZG'&/)-L<4--GQQ9?-L<C:3'?
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M9/5>8)50N5DT5'$Q9*AT;D75%=Y$>J=B/7L70(A]]HNE+:_%L,M[,LQ^FO\
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MKJ3*Y@5       4BZ_,&N$ZXQN)21++;Z:.2SW.1J*O<JY_?4SE_8N5TK=?
MNB>% M#];']:>+6/#K7B.Y5)5T]=9:>.AI;O11I40STU.U&1=ZSF:]DC6(UJ
MJB.1VG-PUT!,,YNAUS8;!CU;0;8P5E?DE4Q\-+<JJ#S:DI>;5O?<KW<[WHGE
M,;R(FOKE^]441ST%X177#.;SGLL3FVBS43K?!,O!KZVL<Q5:BZ\>2)KN9/!S
M-]0$N@H5                     <V^L+](V+W-:OU0O#I(%
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M>.*1'Z5GNO"]5JLFIR3DR369_2D=QD#*8H
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M@JM_B&(8[@F/T>+XK0LMUEH6\L,$>JJJKQ<][EU<][EXN<Y=54*LX
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MH]3VE;ZBGJ]K'2G[/TL?!Z[LV[U]=O9R5K^U]"S9[*\;
M
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M\<_S7=DQW6>KB-J)C\7/WDL'<N&
M
M
M                                                         4EZ
M]=N+Q726+<ZVP/J;=04RVB\K&BN\W9WSI:>5R(G!CG2R,<Y>"+RI]\%H6*V?
MW4VVR_![#\FKM04KJ>AIZ:2QK-%#4T;X(D:L+H7*CD1G*J-<B<KD35%5 A(7
MPU9_Y0IO]-'[((?6GN%!5O6.EJH9Y$3F5D4C7N1J<-=&JO#B!Z0
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M_P"#%TW?0FX](><
M
M
M                                               "F?71NS?;##:M
MK[#4NHJ>\TCZ^_2Q.Y99J1[WP1T^J<4C>K)%D_"T1.SF12T*H6+8K>#);7!>
MK)AESJK75-1]-5=RL;)6*FJ/9WBM5S51>#DX+X FK(_5LWU]!;G^T9[,%5B.
MC7:/<G MS[M>,QQNLL]LGL-1215-2UJ,=.^LHY&L31R\5;&Y?M!$KQ!4
M                !S;ZPOTC8O<UJ_5"\.D@4                      (
M4ZC-O<&NFV^;9?<<>H*K**2RU+J:[RP,?5QN@A<L:MD5.9.7P!,,YLOM[@V-
MXCC626#'J"VW^X6*A;77*E@9%43-G@AFD1[VHBKS/:URZ^% 2K[UMY+=5O\
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M.EW'N?)H+KYONB=JG%7DJYK?F^,>NMLBRV8V:\=.6B03JW*@
M
M
M
M                   "F77CMW)=:*Q[A6Z:)U7:H9*&Y4+I&I.ZC5_>1S1L
M545S8GN<DG*BJB/1>Q%"T)?VNZD]GLFQ&T.J<FMN/72"D@AK;5=*B.@[B:.-
M&N8QTZQL>Q%3R58J\-.Q> 11NWSS[/?]X.-?SS0>W!%&5L&X&!976/MV+93:
M+W<(HEJ)*2V7"FK)FPM<UBR.9#(]R-1SVHKM--53Q@;&
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M7/>OKGN7PN<O%?UCU;1Z3'I<48[(X(\?=EY5J]7DU.6<E\\,^+N0R1EL0
M
M
M
M                               %5>K[9+<3=NXXI48/;XJZ*U05L=:L
MM3#3<KIWPJS1)7MUU1B]@3$JT_4RW_\ Y IOYQH_;0M4^IEO_P#R!3?SC1^V
M@JGCI,Z?]S]J=QKGD.:VR&BM539)Z"&6*KIZARU$E722M;RQ/<J)RQ/77L")
ME<@*@                    .;?6%^D;%[FM7ZH7ATD"@
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M@
M
M
M                                    5SZG>H?)]CJ[&Z7'[707%EZA
MJY9W5Z3*K%IG1-:C>ZD9V]XNNH3$(#^O]N3Z,V/[E7[>$T/K_;D^C-C^Y5^W
M@HF/IKZG\MWJSJX8M?K/;K?1T=IFN;)J%)^]66*IIH4:O>R/3E5)G+V>! B8
M6E"                     '-OK"_2-B]S6K]4+PZ2!0
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MNIW)K2OEZ*-U@U%F;:V)KLSLSTQQKFGOCP(
M
M
M
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M\[DHFO93J[F73D1_E(G+IV^$UM^SM?=XF!?LU^[Q,B44
M
M
M
M                $ ]1G496[%5N/TE)C\5[2]Q5,KG2U+J;NO-G1M1$1L<F
MNO>!,0A#_$(O'H'3?SE)_!PFC"WSKZSZNH*JELF-VVU54[7,IZU\DM6^#F14
M1[6NY&.>WM3F3EU[6JG %&.Z&L?O-YW=K\L5KWVZTV^H6OK7\RHZIKG(R.-7
M>%[_ "W\? U02Z,!4                    !S;ZPOTC8O<UJ_5"\.D@4
M            >26Z6R"1T,];!%*WUT;Y6-<GAXHJZ@?2GK:.LYO-*B*?DTY^
MZ>U^FNNFO*JZ:Z 4 ZK+DESWOJ**XUBNM5O@H:5.Z5)%@A>QLLJ(U%]=S2.=
MHO'L)&'WUQ_9BQ?)_P":6[+<9*B&1UU8V=U2QK6\G=/<YR)R2.U?S,\&GK6^
M$+ ['[04F,[9V/.=N+39YMR;RQM55W;(UGGCBADYT?'3K3\8E3@FC$15XH]5
MT33[:><,W?\ DKL_JTK7OHRVY+>"(I/=YIX7NO\ 5;J0YW8\?O-BV\JLGOL<
M\]#<):2MEY4HF\ZH^61>\15^\Y6K]HW-FGT=V.[)'K*6TK^'E84Y,L71;]WA
MZ6_+DVZ>(6RLO&X%)C]91,6**B@L,E;#)WCW:*LCJIKTY43LY4.7WYK]/HM/
MZW%;?=-:4NF(X^B);W=&@R:W/ZJZZ+>"9K$5XN_"$+KD.67NVU=HN617">WU
ML3X*F%SX]'1R)HY%_%^%#R_3_->MPY+;XV9FV:\,33^)Z[J-R:'-CNL]5;;M
M12MO''16O#WF/KYKK=;9166YW>LJ[7;VL;24LLC>[8D3.[;P:Q.QO!#'U/S)
MJL]TS=L\,S/+R]]L-!I,&BB/4V6Q--G:Y9Z?I?JBIKA<:I;=9;;5W.IB9SS,
MHH7S)$U$U3O')Y+55$\E'+JO@(W=\O:S7XYS6;-MM:5NG9VIY=GGIR\C6:_?
MFET>38R3.U/#2(K3IYJO!B]3%FE_9CMAHIJF[O5W>L?"K$B;'P>^5SO6-;V+
MKX>';HAT.7Y+WOI\>U-UL6_W/(TUOS7NV^[EF?,3=B6SE8E95Q9A31OM<],K
M(U@G5)6SI-$]JM<S1S>#7(JHO8NGA&Y?E_)@SS=J++;K=F:1-+N&L<G15A;V
M^8L>3%$::ZZ+MKFIP4GZ:/#G^V6*V&XX=3VQM7%%=[W!;Z]'5<[^>GD8]7-1
M7/7E75.U.)WVGW9H[XOKAQ\%M?P6_4T&'?&KNBZN2>"*I#MFT&"6NJ2KBH9*
MAZ-5O=U=1-4Q>5X>25SFZ^)=#"NW=I+HIZG'Z%OU,2[?6MF*>LN\+>C/:9^)
M98X(GS3/2.&-JODD<NC6M:FJJJKV(B$Q%1#FP>4VB^RYQ#0R*LU1D-;>8HWI
MRN6DKU:D;M/46->;Q</&;/7XKK=BO5B._#8ZS'-NQ7JQ'@29E%#D=PMJ08M=
M8[/<TE:Y:N:G;5M6)$7F9R.5$U553B8&*ZR)^]%8\#"QS;$_>BL(JO,N\=GR
MS&,6=FE)+)DOG_)4I:H6I#\'P-F75NJ\W-KIVIH;&R,%UEUVQ/W:<O.S[/4W
M677;,_=IR\Z0L4L^>VZLFERS):>]43XN6"GAH64;F2\R+SJYJKJFFJ:&%EOQ
M3'W+=F>FK$R78YC[MM.^VTQF.
M
M
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MFW?:>5W7>>5RZ]G-Q-9?LUG9XF!=2O!Q/855
M
M
M
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M^BN:SRFKHU-? 4PZG-DRTMFE>3D[JF+49;\OW9I7P*>'3NA;CA%%N/6)55.
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M2SQSJQ':Z<W(Y=-=/"4NLNMXXF%;K+K>.*/>44
M
M
M
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MI<=M-+;752-29])$V/O&LU5NJM3CIJNAS5^6^_\ %,RT%^2Z_P#%-6:/D^8
M
M
M
M                    '+'J^_2)S+_=G]%4@7AU."@
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M<**5)J.KB9/3S-]:^.1J.:Y/LHIS-ULVS27/S$Q-)?<A
M
M
M
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MJJJIN,6*W%9%EL4BV*0T^7+=EOF^Z:S=-9?<^KY
M &*OF,X_DL44.06VGN4,#E?#'51ME:QSDT541WAT/I9DNL_#-'TLR76?AFC6
M+OM]M38[767BXXS;(J"AA?45$GFL?!D;5<NB:<5X<$\*F19J,UTQ$736>Z^U
MN;+=,1%T\*C5YKH;G=JVX4U)%0TU3/)+#10-1L4,;G*K8VHG@:G ZZRW9MB)
MFKIK(I$1QMEQ+<[<#$6I'8+M4>84[>9U#-_K-*V/5-?Q<B.1B:JG%G+]DQ\N
MFQ9/Q1POCET^._\ %"6J3JKKWV6LI[E9&1WU:=[:*MI'_B/.%;HUSX9-51J+
MY7![M>S0UL[KC:B8G@8$[NC:BD\#8=C]Z+'\E4L>:WB.DNMNE6.FJ:UZIW]-
M)JYBJ]W#5BZL75>SE/CK='=M[5D5B7RU>ENVZV1P2F*CSG"KAIYCD=LJ%5->
M6*L@<[LUXHC]4^V:N<&2..V? UTX;XX[9\#-PSPU#.\@D;+'V<S'(Y-?LH?*
M8H^<Q1HN<[I6C!\BQNP5O*K[U.J5DBKIYM2JBQLE7U%E5./X+7>H9>#2W9;+
MKHY&3AT\Y+;KHY&_&&Q7AO5WH;!:*V]W*3NZ&@A?43O\/+&FNB>-5[$3PJ7L
MLF^Z+8XY6LMFZ8B.5C\+RN@S;&;?DMO3DAK8]9(%=S.AF8JMDC5=$UY7(J:Z
M)JG'PE\V*<5\VSR+Y<<X[IMEGCXODQ5-D=GK+_78S3U+7WFVPPU-93^%D=1S
M<GV5T1%7Q(YOC/I..Z+8NY)?2<=T6Q=R2RI\WS /C5U=-04L];6RM@HZ:-TT
M\\BHUC(XT5SG.5>Q$1-5)B)F:0F(F9I#ZM<U[4>Q4<QR(K7(NJ*B]BHI"']
M^$%;25,U33T\[)9Z-Z154;'(KHI',;(C7(G8JM>UWV%)FV8[Z9B8?<A#X5%;
M24DE/%4SLADJY.XI6O<C5DEY'2<C=>U>5CET]0F+9GB3$3+[D(?Q51J*JKHB
M<55>S0#XT=92W"D@KJ&9E11U,;9J>>)4<Q\;TYFN:J<%144F8F)I*9B8FDON
M0@ ^$U;24\]-33SLCJ*QSHZ6)SD1\KF,=(Y&IVKHUJN7U"8MF8KS)B)E]R$
M
M
M
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MXO7T=5>:A*6*JEGA='&Y45=7(U-53@$46>"
M
M
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M0FF]\5GMX*LDG3QL^U$1,>>B)P1$N%QTT]\GU];?SSX5_67<\GU>=H?1]_\
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MWQ6>W@J?57V ]":;WQ6>W@J?57V ]":;WQ6>W@J?57V ]":;WQ6>W@J?57V
M]":;WQ6>W@J?57V ]":;WQ6>W@J?57V ]":;WQ6>W@J?57V ]":;WQ6>W@J?
M57V ]":;WQ6>W@J?57V ]":;WQ6>W@J?57V ]":;WQ6>W@J?57V ]":;WQ6>
MW@J?57V ]":;WQ6>W@J?57V ]":;WQ6>W@J?57V ]":;WQ6>W@J?57V ]":;
MWQ6>W@JI%M[:K?8NL&"QVF!*:U6S,+C14-,U7.;%3T]3/'&Q%<JJJ-:U$XKJ
M%N1T^"@
M
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M_(Z9!0
M
M                                                  *M[V]*N0;J
M;GLSZWY!1V^C;%1Q>9SQ2ODUI.U>9O#CX F)6D"
M     53V$Z3<AV?W"AS.Y9%17*EBI:BE6EIX98Y%=.U$1=7\-$T"9E:P(
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M94G[JKGEE2/F7R>9$DT50FJU@0
M
M
M
M
M
M
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M*E6IJK8)8W.:YR)QY'<KE\"+HH*)T"
M
M
M           %,>O[,:JDL^*8+2R.93W*6HNEQ:U=$>VDY(X&KIVIS22.T7PM
M:OV"T,KT[]-NVF2;&45QRRRQ5U_RJ&HJ)+F_5:FEC=(^.#S9VOD*UK6R<$XN
M54=JG $R@#I6OUQV]ZA:/&YIE2FN4U7CUTCXHU[V<_=+RKX4FB9IKQ1%5/"$
MRZ<!0                    !$?4EB&>9[M?5XCM^V)URN=3!'<$FG2F1:"
M/FE>U'KX7/9&U6^%JKKPU"81+TY=)EKQVT72X[R8U25^3352PT%)4R15U+%0
MMB8J2(V-SF<[Y'/1>;BB-3335=29E6?J>PW'-KMYJBW8&JV^DC@I+E'30R.5
M:*KDU=RQN55<WUK96\>'-PX:!,+A=4F=W7'^G+SKG=3WG*64%JFD9K&YCJR)
M9ZE-/!S1Q2QJGB<%80ST5[+83F]@R+,LTL\%[2*L2TVZGK&]Y#$L<+)IG\FN
MBN<DT:(JIY.G#M"9E$&:T;>GKJ3J/DXZ2&W8Y=::NHV<SG+\'U<<=0Z!7+Y3
MF]U,Z%>.J^'B$\;J@US7-1S516JFJ*G%%10H_H                   ?*J
MJJ:BIIJRLF93TE.QTU1/*Y&1QQQHKG.<Y=$1$1-550.7?4+NC>]]<NO%YL<<
MTF 8?"B4*:*QD=-+4Q4JU<B.TT?/-+&B)VHWE33R7*%X3Q_=[_Q/GGNFV_DZ
M@(EI77MF-57YY8L)CD<ELLUO2NEB1=&NK*Y[DU5$[>6.-G*J_A.^V(2U2]+F
MW<O3JRF=9HOES+8DNWPZG,M8ET=3><HU'HJ_BD<O==VB:*WP<W$(JA[H-S"K
MMNXMWPR25?@R^V]U4R%5542LH7-5KD3L36)\O-X]$\03+H:%0
M        .86]5UN6]G4Q-BZ5:I0?#,.*VO1>:.G@AJ$II9&(JZ+K)WDJKX=?
ML!>%H<ZZ=>GZ^XM)M[B4UCL.=0=W';*WSMC[BD['-5R5#>\[V7G:CD5KD737
M5NFB!6K=.G79&\['V2\62XY(R^T=RJ(JNGIHJ5U,RFE:Q62JCG2R*_O$2/[U
MNG)X=> F5&I^;?SJ>6ENTCWVR^WYU.K4>J.;::-SD2-KD7@OF\6FJ>'B%N1-
M?65L;@>'X+9LQPFRP66HHZV.V5T-&U61S4T\4CF/D3CJ]CXT3G7B[F\I5X!$
M2E+HES"KR;9IMJKY5EJ,9KYK9"YRJYWFCF,J(=57P-[UT;?$UJ($2L@$
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MA]@RAB(UMZMU)<>5O8WSN!DJIQ\7-H%&<
M
M
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M=?!S<W9X=0F'1.R_1M;_ (CA_-&A1SIZ,OI_L'N:X_F<H7EU "@
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MZ2<9^(T_.YP0N%L%]"F _$=#^1:$2D8(
M
M
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M@1$)AZ*L,J\5V9AN5PB6*JR>MFNT3'HJ.2D5D<$&J+X')$LK5\+7H$2L6$
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M0Z58A8(\5Q.PXQ$Y'QV6W4EN:]-=')20,AUX\>/+X0HS0
M
M
M                         /%=K1;+];*JS7JDBK[571N@JZ.H:DD4D;TT
M5KFKV@5HNO0=M'77%]7072]VRAD=S+;X)X)6,37BV-\\$CT33LYW/7[(35.6
MVVUN%[3V-;#A=O\ -*>5Z2UE3(Y9:JIE1-$?+([BNB=B)HUO@1-0AN0
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MAF%8QM]C]-B^(V]EMLU+JK(6:N<][N+I)'N57/>[PN<JK]I$"&?
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M55VR-C7,@NEUD9*^!'IH[N8XV1L8JIPYN57::IS:*H*II"
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         '/OJFWIW4PS>>\V#%\JK;79J>GH7PT=.YJ1M=+2QO>J:M7M<JJ%
MHA&%-O3U.5L$=51W_(JBEE3FBFB@?)&YOC:YL2HJ!-'KMG55U#XA<&1W&_S5
M2PJBRVV]4<+T>FJKH]5CCF1%_8R-4%%XNG[J#L>^%FG:L#;5F%L:U;K:.?G:
ML;EY4J('+HKHU7@J+Q8[@NNK7.*S"9@@
M
M
M
M
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MVU=(]WF-5(Q%<L7+*KGQR:)JQ%>]'=FJ+HCB)A:((
M
M
M
M
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M].Z7N7)&J:IW*.Y4[0B:K5A
M
M
M
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MC;G<;!=UALUVH>+:B:EJ.6&6)&N<B\ZM141'*GJJ%G9(*
M
M
M
M
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MCHJZ*A$RM.$
M
M
M
M                                       #6MQ*:^5F Y138Q+-!DDE
MJK4L\M*_NYTKD@>L'(Y.Q5DY4 YP9#MUU8;E55/;,KM&1W9*9_\ J\=S<Z.C
MC?ZQ7HZ5S(454^_UXIX0OP+G],6PS]E<7JY+Y)#49G?'LDN<D"\\4$,*+W5/
M&]417:*YSGN31%<NG%&HJE9E.H0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MNNG,I$PEH(
M                                                           !
M^)98H(GSS/2.&)JOD>Y=&M:U-555\2(3$5(BK#63,L4R2HDI;!>:2Y5,3.]E
MBI9FRN:S5&\RHU5X:JB'UOPWV16Z)A];\5]G#=$PSA\7R
M
M
M        #SU%?0TCD9554,#W)JULLC6*J>-$<J ?'X:L_P#*%-_IH_9 /AJS
M_P H4W^FC]D ^&K/_*%-_IH_9 ?N*Z6R>1L,%;!+*[UL;)6.<OAX(BZ@>L
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M)[%>G5L_;O\ 8 H?63V*].K9^W?[ %#ZR>Q7IU;/V[_8 H?63V*].K9^W?[
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M+U9/GDVO])Z+]L[V(]SS=63W7+U9/GDVO])Z+]L[V(]SS=63W7+U9/GDVO\
M2>B_;.]B/<\W5D]UR]63YY-K_2>B_;.]B/<\W5D]UR]63YY-K_2>B_;.]B/<
M\W5D]UR]63YY-K_2>B_;.]B/<\W5D]UR]63YY-K_ $GHOVSO8CW/-U9/=<O5
MD^>3:_TGHOVSO8CW/-U9/=<O5D^>3:_TGHOVSO8CW/-U9/=<O5D^>3:_TGHO
MVSO8CW/-U9/=<O5D^>3:_P!)Z+]L[V(]SS=63W7+U9/GDVO])Z+]L[V(]SS=
M63W7+U9/GDVO])Z+]L[V(]SS=63W7+U9/GDVO])Z+]L[V(]SS=63W7+U9/GD
MVO\ 2>B_;.]B/<\W5D]UR]63YY-K_2>B_;.]B/<\W5D]UR]63YY-K_2>B_;.
M]B/<\W5D]UR]63YY-K_2>B_;.]B/<\W5D]UR]63YY-K_ $GHOVSO8CW/-U9/
M=<O5D^>3:_TGHOVSO8CW/-U9/=<O5D^>3:_TGHOVSO8CW/-U9/=<O5D^>3:_
MTGHOVSO8CW/-U9/=<O5D^>3:_P!)Z+]L[V(]SS=63W7+U9/GDVO])Z+]L[V(
M]SS=63W7+U9/GDVO])Z+]L[V(]SS=63W7+U9/GDVO])Z+]L[V(]SS=63W7+U
M9/GDVO\ 2>B_;.]B/<\W5D]UR]63YY-K_2>B_;.]B/<\W5D]UR]63YY-K_2>
MB_;.]B/<\W5D]UR]63YY-K_2>B_;.]B/<\W5D]UR]63YY-K_ $GHOVSO8CW/
M-U9/=<O5D^>3:_TGHOVSO8CW/-U9/=<O5D^>3:_TGHOVSO8CW/-U9/=<O5D^
M>3:_TGHOVSO8CW/-U9/=<O5D^>3:_P!)Z+]L[V(]SS=63W7+U9/GDVO])Z+]
ML[V(]SS=63W7+U9/GDVO])Z+]L[V(]SS=63W7+U9/GDVO])Z+]L[V(]SS=63
MW7+U9/GDVO\ 2>B_;.]B/<\W5D]UR]63YY-K_2>B_;.]B/<\W5D]UR]63YY-
MK_2>B_;.]B/<\W5D]UR]67@OF[VVE39+E3P9+1OGFI9XXV(YVKG.C<B(GD^%
M5+V:3-%T?=GC6LTV6+H^[*$^E+^N-Z^+%_.(C;;U]G'2V6\?P1TK:'-M"
M
M
M                    %*.L[:C<7/\ .[!<L-QVKO-#36A*>HGI6M5K)?.9
MG\JZN3CHY%"T*V?5LWU]!;G^T9[,)J?5LWU]!;G^T9[,%3ZMF^OH+<_VC/9@
MJD_IVV,W;Q7>?$[_ )#B5?;[-15$[ZNLF:U(XVNI9F(JZ.7M<Y$")ET;"H
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MS=S$8P
M
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M<QK/:=YZ=\?T@4_?[3^XA/&];\3X'ZB^5/\  =[+Y;EUSJ7YW
M
M
M
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M"(B)V(@0_0  !S;Z%?IKJ/B.M_+4X7ETD"@
M %2NO[Z-L9^/$_-)PM"1ND']';#?]Y_TK5A$IO"$%;\?QO:/<TGY0\S^;_;8
M_-GRO2_E#V63SH\B8L;_ *NVCW%3?DFG?Z'X?'YEODAP.N^(R>?=Y94RZL_I
M2A^*J7\K,>D;C^'_ &I^AS&L]IWGIWQ_2!3]_M/[B$\;UOQ/@?J+Y4_P'>R^
M6Y=<ZE^=P
M
M
M                                             %6.NS$:^^;8VO(K
M? LZ8Y<>\KN1O,Z.DJXUC=)V:\J2)$COLZKV!,,1TC;@S;G[9WK9F\VY&TUE
MM<U#\*L=JR6CN2RQLC?'HBH]J.>FJ+HK43P\5)E!W3_OW-TYW3*,1S"SU-;0
M35*MJ*:E<QM12W&B<Z%Z<LBM:K7HG*[CJG*F@3,5>7#<TNN\?5K8,UIJ%:.>
MY7JDJ&T4;ED6&AMT+6JCG(B:JD$"J]=$377AIP!R.G(4
M'-OH5^FNH^(ZW\M3A>720*                           5*Z_OHVQGX\
M3\TG"T)&Z0?T=L-_WG_2M6$2F\(05OQ_&]H]S2?E#S/YO]MC\V?*]+^4/99/
M.CR)BQO^KMH]Q4WY)IW^A^'Q^9;Y(<#KOB,GGW>65,NK/Z4H?BJE_*S'I&X_
MA_VI^AS&L]IWGIWQ_2!3]_M/[B$\;UOQ/@?J+Y4_P'>R^6Y=<ZE^=P
M
M
M
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M0                          "I77]]&V,_'B?FDX6A(W2#^CMAO\ O/\
MI6K")3>$(*WX_C>T>YI/RAYG\W^VQ^;/E>E_*'LLGG1Y$Q8W_5VT>XJ;\DT[
M_0_#X_,M\D.!UWQ&3S[O+*F75G]*4/Q52_E9CTC<?P_[4_0YC6>T[ST[X_I
MI^_VG]Q">-ZWXGP/U%\J?X#O9?+<NN=2_.X
M
M
M
M           "&>IK:*_;S[>TN,XW5TM)=*&YPW5GGRO9%*V&GJ(5CYHVO5JK
MWVJ+RZ</MA,* 73"]^>GZZ+='4MVQIS%1/A>WO<^@E375&OF@5T+D737NY/M
MM"R9=N^O++;5W5#N19X;_2)HUUSH.6CKD3PN='_F9%\2-2+[(11;3;C?[:K=
M)T5+B]]C2\RIK\"UR>:5^J(KE1L;^$G*B:JL3GHGC"*),"
M  !S;Z%?IKJ/B.M_+4X7ETD"@                          %2NO[Z-L9
M^/$_-)PM"1ND']';#?\ >?\ 2M6$2F\(05OQ_&]H]S2?E#S/YO\ ;8_-GRO2
M_E#V63SH\B8L;_J[:/<5-^2:=_H?A\?F6^2' Z[XC)Y]WEE3+JS^E*'XJI?R
MLQZ1N/X?]J?H<QK/:=YZ=\?T@4_?[3^XA/&];\3X'ZB^5/\  =[+Y;EUSJ7Y
MW
M
M
M                                      ?F22.&-\LKTCBC17/>Y4:U
MK6IJJJJ\$1$ A/<'JIV3PB.HHJJ\MR*XHCHY+796MKM?O7-?+S-@3Q.:Z37U
M FB@N\6Z6%[BUSZC%MNK7B2K)SK7TKY?.Y4UX\T<*PTR<_:[6!SO$_MU+)"Z
M3]H=R)MT<8SR3'JJEQ&VR2SSW2L:E-&]DE-+&U84E5KI=7.3C&UR>,$NDP4
M               '-OH5^FNH^(ZW\M3A>720*
M    5*Z_OHVQGX\3\TG"T)&Z0?T=L-_WG_2M6$2F\(05OQ_&]H]S2?E#S/YO
M]MC\V?*]+^4/99/.CR)BQO\ J[:/<5-^2:=_H?A\?F6^2' Z[XC)Y]WEE3+J
MS^E*'XJI?RLQZ1N/X?\ :GZ',:SVG>>G?'](%/W^T_N(3QO6_$^!^HOE3_ =
M[+Y;EUSJ7YW
M
M
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M*\54S='OO3:O)ZO',UZ&%K-R:G2X_69(BG2VTWK1
M
M
M
M          *H]4W47N!LWF%FL6(Q6Y]%7VU*V=:Z"29_>]_+'Y*LECT31B>
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MD3=5:R&I:BKVZ)P.8^6HIKZ=RYT_S+-=!7NVK%'K3R8
M
M
M
M            !IN8;4;<Y_707+,L=I+S74T7F\$]4URN9%S*_E31R<-7*H&G
M[NILCM_@%@M&X]DC7;Z*YPT-MI&0/J(*2I6GJ9&2.9&[O.5&-E;Y".7RNSPH
M2Q^*[1=+F<4"7/$;!8;S1\.=]&]958J^"1B/YF._8O1%!PL]]6S8KT%MG[1_
MLP59/']C-I,5O%+?\>Q*AM]YHG.?25D+7))&YS58JIJY>UKE0%4@A
M          YM]"OTUU'Q'6_EJ<+RZ2!0
M    $$;O]/59NAEC,D@OT5M8RDBI/-WTSIEUB<]W-S)(SMY^S0W^@WK&FQ[$
MVUX:\;!SZ:<EU:J1[EX7+M[OS:L1FK&U\E!56E753(UB:_OWQS<&JYVFG/IV
MFMUNI]XRS?2E:,O#CV+-EU3,)<   *[[2_2$[][JCR;Y<_R'>N>L?,?^/[]J
MQ!ZR\G
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M7BBHJ=J*!^@
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MQ.D@4   "N^TOTA._>ZH\F^7/\AWKGK'S'_C^_:L0>LO)P
M
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MJ@?58Q>Z"]TL:\LDUMJH:R-KO$KH7.1%X 9<#7+YN#@6,U/F>293:+/5\/\
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M
M                                    #S5]PH+522W"Z54-%00-5\]5
M4R-AAC:G:KGO5&HGV5 @'/>LW9W#^]I;-5399=8]6I%:FIYJCT7[ZJEY6*W]
ME%W@312#=W>;YWKDLM-A5EL$DLJ.9/;J=7W29SEX-FJ4Y.]557_FD"U$K=+6
MP.ZM)N3CFX-XL4EFQFV22SR2W-?-IY6RT\L;4B@=^-757HNKFM;IX0B9=$ J
M                .;?0K]-=1\1UOY:G"\ND@4
M            YM]3/Z6#?=-B_)4X7CB=) H   %=]I?I"=^]U1Y-\N?Y#O7/
M6/F/_']^U8@]9>3@
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M/R\W*FOB0*LX   4@W)_3JQ'_=OY&0+<B[X50]U4?0!FWN:G_/( F&#Z,OH
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M>X
M                                      *P==5'-<=J\=H*9T3:BHRB
MCCC6>:*FB174-<U%?+,YD;&ZKQ<]R-3PJ$PB7;#H5K[[34M[S[):>FMDZ)(R
M@L+V5DLC%7CK5JBPM7A_R;94]4)JMQM]LCMAMA&U<1Q^GI[@B(C[K.BU-<Y=
M-%7OY>9S=?"UG*WU BJ00@                 .;?0K]-=1\1UOY:G"\ND@
M4                                  YM]3/Z6#?=-B_)4X7CB=) H
M %=]I?I"=^]U1Y-\N?Y#O7/6/F/_ !_?M6(/67DX
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M*O<
M                                       %6^N;#LDR7;FTW>Q4\M91
M8]6R55VIH4YG,IY(58E0K4XJV-4T=IV([5>"*J$PQW0]F>!TNVL^,+<J6ARY
MMQJ*FNHJJ9D4\['M9W<L37JBN8C&\JHWUKD55TYN),K:HJ*B*BZHO8H5
M              !S;Z%?IKJ/B.M_+4X7ETD"@
M          '-OJ9_2P;[IL7Y*G"\<3I(%    KOM+](3OWNJ/)OES_(=ZYZQ
M\Q_X_OVK$'K+R<
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MG*O 576MT#Z6WTE++IWD,,<;].*<S&HBZ?<"KT@
M
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MP(E=,*@ #FWT*_374?$=;^6IPO+I(%
M    .;?4S^E@WW38OR5.%XXG20*   !7?:7Z0G?O=4>3?+G^0[USUCYC_P ?
MW[5B#UEY.
M
M
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M/;PFA]?[;;T9OGW*3V\%$(="OTUU'Q'6_EJ<)ETD"@
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MG1&N5O'153P'5Z/56ZG#;EMB8B[G<KK-+=ILUV*Z8F;>9DC,88
M
M
M
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M^T[K_"PFI]4'IV]#?^T[K_"P55*Z%?IKJ/B.M_+4X6ETD"@
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MCZ)\LN/W]\=DZ8\D-M-ZT0
M
M
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M'YT^1W7RA[7)YL>5MVV/]1+-^]R?EGF^W!\#CZ)\LM%O[X[)TQY(;:;UH@
M
M
M
M                  1COKLY3;W8E18I579]FCH[C%=$JHH$J7.=%!/!R<KG
MLT1>_P!==? $Q*OG^'O9_3RI_FV/^$!-3_#WL_IY4_S;'_" 53=LUTV8!LO-
M-=+.M1=<EJ(UADO%P5BR1Q.5%<R%C&M;&UVB<R\7+^%IP")E,80
M       .;?0K]-=1\1UOY:G"\ND@4
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M=U\H>UR>;'E;=MC_ %$LW[W)^6>;[<'P./HGRRT6_OCLG3'DAMIO6B
M
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M-NDU9=V4\E8Z&2DJ*=O<Q.:UR\TK&IP5Z<-0FB4@@
M
M              1KO9O-8-E,3^4%VB6MN56]:>SVF-Z1R5,Z)JNKE1>6-B<7
MOY5TX)IJJ($Q"OW3KU.;D;M;P)CV1>94^.U%#5SQ6ZB@1B1R0\KF.[V17R.7
M35%\K1=== F8;1U5=3%QVKEI\(P5T/RRJX4J:^X2L29M!3OU2-&1NU:Z:317
M>6BHUNB\J\R*A$0IDG41O@VL2N3/+OWZ.Y^1:A5AU7_P*IW>GJ<N@6HNETM=
M3=5NN^;"LV2*/-J2%:FDKH6I#%7T\>B/U8GDMF9KS*C/)<W541.50K,+/!
M               YM]"OTUU'Q'6_EJ<+RZ2!0
M             YMW;]."/^UU)^[C"_(Z2!0  8K)_P"K5Y]PU7Y%Q]L/M+>F
M%;_PRJ5T>_UXOOQ4OYS$=?O_ -C;YWT2U6B_%/0N4<4VX    (DWX_BBT>Z9
M/W!PGS?[+'YT^1W7RA[7)YL>5MVV/]1+-^]R?EGF^W!\#CZ)\LM%O[X[)TQY
M(;:;UH@
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M.9\;F^4Y.P"M7]X'_4_#OC.H_-T"T+3X7_4['OBRB_-V!5G *0="/]<=S/\
MZ)^<506E9&JZ=MD:VIFK*K";=+55#W2S2N8_F=)(JN<Y?*[550BJHN=[;8);
M>K[&<%H;%308C5^8^<VAB.[A_>Q2.?JFNO%43PA/(MI]6S8KT%MG[1_LPBJ
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MIW*JZ)K++$UK$7QR*U FB:HI8IXF30O;)#(U'QR,5'-<UR:HJ*G!45 A^P
M
M                        #G5UZ7NIK=UK18U?K16JS1/CB1VJ)/5SRND=
MIX%<UD2?:0+0M'T[;#85MKBMCR.&A2ISBX6^*HN%YF<KY&NK(FR/AA37E9&W
M7D16MU=IJJA$RYX;G9%5[G[M7^]T:K4R7VZOAM;=>970=XE/2,1?WMK&A9T_
MLVRVWMLV\IMMZBQT=79&4C::K62!BR3S<B))4.?IS)*YWEH]%U:O9IH@5JYV
M[0T]1@'4]8K)33.[RUY-+8G2JJ<SXW3R4#]>7AY37*%N1U4"@
M     YM]"OTUU'Q'6_EJ<+RZ2!0
M   YMW;]."/^UU)^[C"_(Z2!0  8K)_ZM7GW#5?D7'VP^TMZ85O_  RJ5T>_
MUXOOQ4OYS$=?O_V-OG?1+5:+\4]"Y1Q3;@    B3?C^*+1[ID_<'"?-_LL?G
M3Y'=?*'M<GFQY6W;8_U$LW[W)^6>;[<'P./HGRRT6_OCLG3'DAMIO6B
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M'\_+PT1JHG@!*5 @
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M1\SF,3_*"TNIH4                '-OH5^FNH^(ZW\M3A>720*
M                            '-N[?IP1_P!KJ3]W&%^1TD"@  Q63_U:
MO/N&J_(N/MA]I;TPK?\ AE4KH]_KQ??BI?SF(Z_?_L;?.^B6JT7XIZ%RCBFW
M    !$F_'\46CW3)^X.$^;_98_.GR.Z^4/:Y/-CRMNVQ_J)9OWN3\L\WVX/@
M<?1/EEHM_?'9.F/)#;3>M$
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M)ZT)F$J!
M                                   U;<';S%=S\:J,4R^C\[MDZI)&
MYCN[G@G8BHR:%Z>M>W5=/ J:HY%:JHH5.JO[O>G==5=19X^.R*[F2.:VI)5-
M;KZWG;4,8Y?V?*G^3XRU5G=J-H,-V=Q];%B=.Y9)W))<;G4JU]95RM31%D>U
M&IHW7R&-1&MX\-555(0!U!=+&;;O[LID]CKK?;L?EH*2"KJJR219DFA61K^[
MACC=S:,Y/7.:B^,)B4T[)[$8GLC9IJ.RN?<+Y7\JW6]U#6LFFY/6L8Q%5(XF
MJJJC$5>/:YW (F4IA                 YM]"OTUU'Q'6_EJ<+RZ2!0
M                                YMW;]."/^UU)^[C"_(Z2!0  8K)_
MZM7GW#5?D7'VP^TMZ85O_#*I71[_ %XOOQ4OYS$=?O\ ]C;YWT2U6B_%/0N4
M<4VX    (DWX_BBT>Z9/W!PGS?[+'YT^1W7RA[7)YL>5MVV/]1+-^]R?EGF^
MW!\#CZ)\LM%O[X[)TQY(;:;UH@
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M<]LF@359C#L0L&!XW;\3QBE2CLUMC[JGB3BY55>9SWN^^>]RJY[O"JA5G
M
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M_+/-]N#X''T3Y9:+?WQV3ICR0VTWK1
M
M
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M\BX^V'VEO3#Y7_AE4KH]_KQ??BI?SF(Z_?\ [&WSOHEJM%^*>A<HXIMP
M1)OQ_%%H]TR?N#A/F_V6/SI\CNOE#VN3S8\K;ML?ZB6;][D_+/-]N#X''T3Y
M9:+?WQV3ICR0VTWK1
M
M
M                                    !0CKOV[OS<LM>Y%%225&/3T$
M=NN%1$Q7-IJFGED<U95;ZULC9&HU5\+537L"T*X9;O#N7G=BI,:R_(ZF\66A
MFCJ::GJ4B<YLT4;XFO61&)(Y4;(]/*<NNH31[\2WYW;P6QP8WB>3SVRR4SI'
MP4<<-,]K73/5[UUDB<[BY57M!1F_K4;_ /IM4^]Z/V@%$F=/?4)O'F&\>*XW
MDF53U]DKYYF5E&^&E8V1K*65Z(JLB:Y-'-1>"A$PZ(!4
M<V^A7Z:ZCXCK?RU.%Y=) H
M #FWT>_I&R^YKK^J%Y=#\G_JU>?<-5^1<?;#[2WIA\K_ ,,JE='O]>+[\5+^
M<Q'7[_\ 8V^=]$M5HOQ3T+E'%-N    ")-^/XHM'NF3]P<)\W^RQ^=/D=U\H
M>UR>;'E;=MC_ %$LW[W)^6>;[<'P./HGRRT6_OCLG3'DAMIO6B
M
M
M
M         #^.:US5:Y$5JIHJ+Q144"&-^-@+=N]BM)8;-+0XY<(+E'<9KDVB
M9(^5D<$\2QKW:QN\I94=JKOO0F)8;$,;VEZ==O[=BVYE[L-1<87U,S:VLIH6
MU4[)IGR)R0.[V9R,1>75-0<;*V7=GI?O]8V@MMVQOSIZHV-E52QT2.<Y=$1K
MJF&)JJJ^!%!PI5H\8QBCFCK;?9J"GJ&>5#404T+'MU335KFM14U1? $,N
M              <V^A7Z:ZCXCK?RU.%Y=) H
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M.R=,>2&VF]:(
M
M
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MX/@<?1/EEHM_?'9.F/)#;3>M$
M                                           5WW(ZO,*VWW!GP&NM
M577/HGTT=QNE/)$D$#ZEK9')RKJKEC8Y%=IX=4\ 318:.2.:-DL3TDBD1',>
MU4<US7)JBHJ<%14"'Z   ,9D&0V/%+157_)+A!:[-1MYZFMJGI'$Q%5&HFJ]
MJN54:UJ<57@G$#^8WD%KRNPV[);+(Z:T76!E70S/8Z-SX94YF.5KD1R:IQT5
M-?&!'&V&_-HW/S7*\*H+14T%5BDDL5153R1OCF6*H=3JK$;Q356Z\0FB6P@
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M)-ZM^;1LK5XS272T5-T=DTE3% ZFDCC2):1U.U5=S]NOG"::>()B$MA
M
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M<GFQY6W;8_U$LW[W)^6>;[<'P./HGRRT6_OCLG3'DAMIO6B
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MJRGY_6N<UKGM<U=.#V.5/!V\ 42*$
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M>;7U- -K:YKFHYJHK535%3BBHH']   .;?0K]-=1\1UOY:G"\ND@4
M                                !S;Z/?TC9?<UU_5"\ND@4 (_WP^B
M7+/<+OW338[M^)LZ7PU'LY0IT8__ (V_W5_YX;SYA_\ 7^U_\6%H?]7>^E:L
MY)M  !$F_'\46CW3)^X.$^;_ &6/SI\CNOE#VN3S8\K;ML?ZB6;][D_+/-]N
M#X''T3Y9:+?WQV3ICR0VTWK1
M                            %;-]J3?&?-HW[=NNZ6#S&%');IECA\XY
MY.?@CD\K3EU.GW9=I(Q?^79VJ\K7:B,NU]VM$9?!W59^'DGOAWLS:;>[OU/
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M/BT*6^RYJRE96T,+593*Z[SR44L;6M31$[Z..HY4X([3L0+<B\ 5
M
M             !_'-:]KF/:CF.14<U4U147M14 ^-/1TE(CDI*>.!'Z<R1,:
MS73LUY40#[@       07U?W_ . =A<C8QR-J+L^DMD*JNFO?U#'R)ZNL3) F
M%(=I>E[<'>3&)LLQJOM-%;8:R2@Y+G-4Q3/DACCD<]J0TTS59^,1NO-KJB\
MM58'8CI%W)VOW6L&<W^Z6.IM-J\\\XAH:BKDJ7><T4],WD;+21-71TK575Z<
M-?L!$RRG7)NU=L8L]IVWQZK?1U5_BDK+U/"Y8Y?,&.[J.%'-77EF>DG/XT9R
M]CE0$(6L?1YD-ZV7^=!EZ;'>YZ!]YH<=\WU26B:U96(L_><))(TYV)W>G%$5
M>*JA-4C]"^[EWK:VX;3WVK?54,%*MPQU9G*YT"0O:V>G:JZKR*CTD8WL;RN\
M81*[X5  '-OH5^FNH^(ZW\M3A>720*
M          YM]'OZ1LON:Z_JA>720* $?[X?1+EGN%W[IIL=V_$V=+X:CV<H
M4Z,?_P ;?[J_\\-Y\P_^O]K_ .+"T/\ J[WTK5G)-H  (DWX_BBT>Z9/W!PG
MS?[+'YT^1W7RA[7)YL>5MVV/]1+-^]R?EGF^W!\#CZ)\LM%O[X[)TQY(;:;U
MH@
M                  %$:6BH>I3JZN2W*)MQP'$H9H'0/570RTMOU@:U%1=%
M26JE65-.UFOV0MQ0LU]6S8KT%MG[1_LPBJMO5WLKCNW-DQO<;;*U16%]JKT@
MN/F2*FDDFDM+4>4JZ+')&K=?&]H3$I6W8S>EW'Z0+MFE*K4^%;7225,;>R.J
M960QU$?_ !)6O;]H(Y6P](/Z.V&_[S_I6K!*'?[PC^)\#]TW+\G3A,)4ZS$5
M=@+_ *)V5-NU]^1!$-CZ<,DL=WV<PFBH+A335]+:((:BCCFC?/&ZE3N7\S&N
M5R:.3PH"4$=)/T\[Q>Z:K^DY0F4[5?3#L17U<]=5X932U53(^:>1:BK1722.
M5SET2=$XJH15M6";5[?[9^?_ "%LD5G^%.Y\_P"ZDFD[WS;O.ZU[Y[].7O7]
MGC"&X@4@Z[OZX[9__2_SBE"T+OA4 \-Z_B>X>YIOR;@*3="&4XQCMIS9F07J
M@M+ZBHMZP-KZJ&E61&,J.96I*YNNFJ:Z!:5L;GO'M/9Z5]7<<WL<4+$5VC;C
M322.1O:C(XWN>]?4:U5"M%-,SO4O6#OQ8L=Q:&9^W&-IK4UTC71?ZFZ1CJRI
M5':*Q9N1D,35\K@U51/*1I;B7/SC:C;W<EMN9FUBANS+2DJ6YLCYHDA2H[OO
M$:D+V>N[IG;X@JU:DZ8=B*"K@KJ3#*:*JII&302)45:JV2-R.:NBSJG!4":I
M;"%2NO[Z-L9^/$_-)PM"S.%_U.Q[XLHOS=@59P"NG6W]!57\9T'[MP3"1=@O
MH4P'XCH?R+02KIF?Z>F*^YH/S"I">1;7-/ZG9#\65OYN\*JD]&N4T&$[%;@9
M==%1*&S7">LD;KRJ]8J&%6QM5?OGNT8WU5"TL5TF[2V3=J/,=T=T+5#?77:X
MNBHVU2.5OG*JM15RHG-JJ*LL;6KX-'("5D_JV;%>@ML_:/\ 9A%55<UM]%TP
M=4MCR*RP);< OC(724\>O<QT53I35D?'M[I[4J$37\$)XX;5U[7%UKN>U-W@
M1)74<]UJHVZ^2Y87VZ1$U3P+H"%L,/SS%\ZQ>ER_'KC#46:IA29\O.U%@7EU
M?',BKY#V=CD=V!54*LN=)O[UCV"NQ1WGV*X-%3OJ+K%Y5.Y+5+)5=XU5X*CZ
MF5L+')Z[3F3AQ"W(O"%0
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M>'^1,:]ZU_\ #PFA]?G>'^1,:]ZU_P##P4>'H5^FNH^(ZW\M3A,ND@4
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M&HKN&JK]DZ+%?-]EMT\L1+PW>6FMTVKRX;:[..^^V*\=+;IB*LT?5KP
M
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MJB.FE=Q735>5J:-;JNB)J$-T
M                                             %<.M2_91C.U]EO>
M)7"MMERI<BI725MODDAD9#YG6HO.Z-4\A7<J*CO)7@BA,*[X!US[DX]W5'FM
M%2Y7;VZ-=4Z)05Z-[/\ .1-6)VB?A1:KX7!-%H\!ZM]F,Z[JFENZXW=I-$\R
MOB-I6*[PHVH1SH5X]G-(U5\011.,,T-3"RHIY&S02M1\4L;D<QS7)JBM5-45
M%"'[      !$V[G4/@FR]?0VW+:>Y3U=QIW55*VWT\<K7,8]6*G-++$WFU3L
MU\*!-&^89EUGSS%;3F%@>Y]IO%.RJITDY4ECYT\J.1&.>U)(W:L>B.5$<B\5
M"',Z^O@R?JPEDQ!Z/CK<RA=1U%.B/:LC:YBR3M\"MYFNDYNS3CV!?D;OUY62
M:AW9M5ZY-*6[6:%&R:*FLU+-*Q[=?"J-6-?MA$+C[>YI:HNGZP9JV=C+=;L8
MAJ*B75'MCDM])R3,\&JLDB<S[*!"B_159)[KOQ:[A$U5BL=#7UT[D[$;)3NH
MTU^RZH0+2Z9U%+35;$CJH63QHO,C)6H]J.3AKHY%X\0H\WP+9_Y/IO\ 0Q^Q
M ? MG_D^F_T,?L0.=/0K]-=1\1UOY:G"\ND@4
M                !XELUH555;?3*J]J]S'^L!_/@6S_ ,GTW^AC]B ^!;/_
M "?3?Z&/V($7=1UJM<.QV<2PT5/'*RVO5KV1,:Y%YV=BH@3"O_\ =Y?^\?\
MW)_ZP"97?"H  B3?C^*+1[ID_<'"?-_LL?G3Y'=?*'M<GFQY6S;:T%#+@]GD
MEIHGR.CDYGNC:Y5_&O[55#>;AMCW''T3Y9:??N:^-=DB+IXXY>Y" >KRFIZ>
MXXHE/"R)'05O-W;4;KH^'MT1"F]HB)M[[T__ (WONNQY]J9GAL\ERQ6V?T<8
M?\26W\TB-UIO96^;'D>4;]_R.H_NY/XY;29#2@
M
M
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M]W)_'+:3(:4
M
M
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M_P"1U']W)_'+:3(:4
M
M
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M]GGZ;/)<L+MG]'&'_$EM_-(C<Z;V5OFQY'E>_?\ (ZC^[D_CEM)D-*
M
M
M
M           0WU+;/Q[O;<U5%0PH[++-SU^/2<$<Z9K?QE/JO@G:G+VHG/R*
MO8$PYHY/MCN'A=!'=,MQBXV6W33-IHJJNII((G3O:YZ,1SD1.96L<NGJ*%GW
MQ_:7<W*[7%>\:Q.Z76T3*]L-;1TLDT+G1N5CD1S45%T5%10,G\P6]?H#?/>,
MWL053;TW=,.Y46Y%DS#-+-)8<>L%0RX:5CF,J)ZB%%?"R.)%5R:2<KG.>B)H
MFB<0B9="PJ                .;?0K]-=1\1UOY:G"\ND@4
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M;/Z.,/\ B2V_FD1N=-[*WS8\CRO?O^1U']W)_'+:3(:4
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M948NJ\SF>3IIH%J+F!4
M                     !%FY_4%MUM#=Z.R9E/5Q5U=3>>4Z4M,Z=JQ=XZ/
MBJ*FBZL7@$T:_NMGFQN0[3X_FFY-#/=< O%=#):(EBF25*QT%3W;W,AD8Y-(
MVS)Q73B!I>)=5G3-@MC@QO$X[A;+)3.D?!1QT<[VM=,]7O7621SN+E5>T%&<
M^NWL5_M=S]X/]D"C/85U5[29]E%NQ#'JFO?>;H]\=(V:C=%&KF1NE75RKP\E
MB@HFT(                '-OH5^FNH^(ZW\M3A>720*
M                           $5]2?T%9U\6/_ '; F%=/[O+_ -X_^Y/_
M %@$RN^%4%=6?T6P_&M+^2F-_N/XC]F?H86L]GWSI,^BV;XUJOR4(WY\1^S'
MTFC]GWV:WX_BBT>Z9/W!Y+\W^RQ^=/D>C_*'M<GFQY6W;8_U$LW[W)^6>;[<
M'P./HGRRT6_OCLG3'DA7[K"_C+$_WBM_=PGSWMQV]]ZC_P :^SS]-GDN6%VS
M^CC#_B2V_FD1N=-[*WS8\CRO?O\ D=1_=R?QRVDR&E
M                                               %9^I*YW*BRJTQ
MT59/31NMZ.<V&5\:*O?R)JJ-5#G]YW3%\4GD>P?)&#'DTN2;K8N^_P L1/\
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MVK4<QW!R<6JXB82^$
M             *Y]0_3%7;XY/:\@I<DALK+=0)0.@EI'5*O5)I)>9'-ECT]?
MIIH$Q+[YMTUUV6[&XEM!'D45+4XS5053[LZE=(R=((:F+E2))45NOG&OKU[
M50O_ (>]X]/*;^;9/X0$U/\ #WO'IY3?S;)_" 5;IM-T8W/;3<2Q9Q/E\%QB
ML\LDKJ)E"^%TG>0R1:(]9W(FG/KV JMR%0               !S;Z%?IKJ/B
M.M_+4X7ETD"@                                          !%?4G]
M!6=?%C_W; F%=/[O+_WC_P"Y/_6 3*[X505U9_1;#\:TOY*8W^X_B/V9^AA:
MSV??.DSZ+9OC6J_)0C?GQ'[,?2:/V??9K?C^*+1[ID_<'DOS?[+'YT^1Z/\
M*'M<GFQY6W;8_P!1+-^]R?EGF^W!\#CZ)\LM%O[X[)TQY(5^ZPOXRQ/]XK?W
M<)\][<=O?>H_\:^SS]-GDN6%VS^CC#_B2V_FD1N=-[*WS8\CRO?O^1U']W)_
M'+:3(:4
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M++I"BHWRW,1[M=?*XA*0 @
M                 !5KJ?ZE,ZV5RVSV'%K?::RCN%N2NF?<X:F65)>_DBT:
ML-3"B-T8G:U?LA,0@[Z_.\/\B8U[UK_X>$T/K\[P_P B8U[UK_X>"A]?G>'^
M1,:]ZU_\/!1ONRW6%N9N-N?CN%7RU6*GM5WFEBJ9J*GK&5#6QT\DJ<CI*R1J
M+JQ.UB\ 3"[(5                '-OH5^FNH^(ZW\M3A>720*
M                                  $8]1-+4UNR.;4M'"^HJI;<]L4,
M35DD<[G;P:UJ*JJ$PYU;9YGOAM%\*?(6W5U#\,>;^?\ >VI:GG\T[WNM.^B=
MRZ=\_L[0LW_ZS/5A^#4_S%%_!P4AKF:[W]0F8V=+3F5-/46ALS)T8^T)3)WS
M$<C5YXXHU['+PU,K39\F*_:Q\?15\LF.V^*7<1A6]_4)AUG6TX;33T]H=,^=
M6,M"5*=\]&HY>>2*1>QJ<-1J<^3+?M9./HH8\=MD4MXC+NHG?ZX4U,S,7+'3
M,>JTRU5KCI$5ZIQT5(X]>'@-+K-WX-7$1EC:B.+AF/(VFCUV;23,XIV9GCX(
MGRK'[6;G;F5.WUAJ*=7/BEIU>CHZ-KF*JR.UT7D7P^J<'K=;K-%FNP:>)C'9
M39^[7CBO',3RR[G1:+1ZW#&?43$Y+Z[7WJ<4TXHF.2'EW!JJ[,YJ"7.&JLM&
MV1M%SM\T\F16J_1&\G-Q:AIM1O77Y*;=?1I]#LMS8\>AB^-)Q74VO]7%6G.V
MRS9SN%:[/;[9:4?\%45-#34.E(V1/-X8VLCT>K%YO)1..O$RK-];SMMB(K2(
MZGV-%JMT[ORYK\F2FW==,W??I]Z9K/!7@X7VGW7W#IG]W4U*0R::\DE+&QVB
M^'16(4O^8MX632ZZD]VV/J4L^7=WWQ6VVL=RZ?K6+IGNDIX9'\7/8USE]541
M3UNR:VQ,\SR6^*73'=?4NH
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M&/\ )U1KO7<1*TP0
M            T7-]F]M-R+A3W7-L?AN]PI(?-J>>66>-60\SG\J)%(Q/7.5>
M*!-6L?57V ]":;WQ6>W@J?57V ]":;WQ6>W@J?57V ]":;WQ6>W@JRN-=/>S
MF'WRCR3&\5@H+W0.<^CK&353W1N>QS%5$?*YJZM<J<4!5)@0
M    .;?0K]-=1\1UOY:G"\ND@4
M            !!75G]%L/QK2_DIC?[C^(_9GZ&%K/9]\Z3/HMF^-:K\E"-^?
M$?LQ])H_9]]&/]X'_4_#OC.H_-T- SX3%TK_ $ 83[FJ/SR<(E&76%_&6)_O
M%;^[A.>WMQV]][;_ ,:^SS]-GDN6%VS^CC#_ (DMOYI$;G3>RM\V/(\KW[_D
M=1_=R?QRB#>W^N4?N*']W(>7_-7QD>9'EEWWRK\'/GSY(6!H_P#HE/\ O;/W
M*'JF+\$=$/*\OXYZ7W/H^8
M                                !\:JE@KJ6>BJF=Y35,;X9H]53FCD
M:K7)JFB\47P :]AVW>$;?15<&%V.ELL5<YCZQ*5JM[UT2*C.95557EYET^R!
MLX'@O5EM61VJKL=\I(Z^T5\:PUE',G-')&[M14 UNW[2[<6K&+CA=OQVEI\5
MNTB3W&TL1_F\TJ<GE.:KNW\6SL_!0#/8WC5BQ"RTV.XS0Q6RR4?>>:T4"*D<
M??2.E?HBJO:][G?; QN8[=81N#%20YI9*:]14#GOHVU2*Y(W2HU'JW14[>5
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ME@HJ.)D$+$7BNC&(B:JO%5\(0R
M                       %(.M;$=R,ASW'ZG"[%?+K016A(ZB:STE74PMF
M\ZF7E>ZG8YJ.Y51=%XZ!:'LW6Q3<2MZ2MM[':K'>JC+*2X4C[C;:6DJY+C%&
MVEKVN6:)C%E:B.<Q%YD[53U <JK7S9;\^AV7?S9<_:@D^;+?GT.R[^;+G[4!
M*73C@>[]IWKQ&XY%C.24-E@J)UJZNX4%?#2L:M+,U%D?+&C$17*B)S+V@ETF
M"@                YM]"OTUU'Q'6_EJ<+RZ2!0
M                          $%=6?T6P_&M+^2F-_N/XC]F?H86L]GWSI,
M^BV;XUJOR4(WY\1^S'TFC]GWT8_W@?\ 4_#OC.H_-T- SX3%TK_0!A/N:H_/
M)PB49=87\98G^\5O[N$Y[>W';WWMO_&OL\_39Y+EA=L_HXP_XDMOYI$;G3>R
MM\V/(\KW[_D=1_=R?QRB#>W^N4?N*']W(>7_ #5\9'F1Y9=]\J_!SY\^2%@:
M/_HE/^]L_<H>J8OP1T0\KR_CGI?<^CY@
M
M
M                                               /Q++%!$^:9[8X
M8VJ^21ZHUK6M35555X(B(!6K-^M[:;%Z^6V6&&MRF>%5;)5T#614/,BZ*C9I
MG(Y_^4R-6KX'*$T:Q:/[P#"*B9K+YB5TH(5719:2:GK51.&BJU_F_JZZ+]T)
MHLM@6XN&[FV1N087=([E;^;NYT:CHYH)=-5CFB>B.8[[*<>U-4XA5M(
M           !S;Z%?IKJ/B.M_+4X7ETD"@
M                    (*ZL_HMA^-:7\E,;_<?Q'[,_0PM9[/OG29]%LWQK
M5?DH1OSXC]F/I-'[/OHQ_O _ZGX=\9U'YNAH&?"8NE?Z ,)]S5'YY.$2C+K"
M_C+$_P!XK?W<)SV]N.WOO;?^-?9Y^FSR7+"[9_1QA_Q);?S2(W.F]E;YL>1Y
M7OW_ ".H_NY/XY1!O;_7*/W%#^[D/+_FKXR/,CRR[[Y5^#GSY\D+ T?_ $2G
M_>V?N4/5,7X(Z(>5Y?QSTON?1\P
M
M
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M7Z:ZCXCK?RU.%Y=) H
M    ""NK/Z+8?C6E_)3&_P!Q_$?LS]#"UGL^^=)GT6S?&M5^2A&_/B/V8^DT
M?L^^C'^\#_J?AWQG4?FZ&@9\)BZ5_H PGW-4?GDX1*,NL+^,L3_>*W]W"<]O
M;CM[[VW_ (U]GGZ;/)<L+MG]'&'_ !);?S2(W.F]E;YL>1Y7OW_(ZC^[D_CE
M$&]O]<H_<4/[N0\O^:OC(\R/++OOE7X.?/GR0L#1_P#1*?\ >V?N4/5,7X(Z
M(>5Y?QSTON?1\P
M
M
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MY?QSTON?1\P
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M/"GAXOD5J)]T#%6+<# \HJ5H\9RBT7FK1%5:>W5]-5R(B)JJ\L,CEX(!L0
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M\\K&MX:^,%$K!   YM]"OTUU'Q'6_EJ<+RZ2!0
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ML_<H>J8OP1T0\KR_CGI?<^CY@
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MF18HFJO#LXA%4_A   YM]"OTUU'Q'6_EJ<+RZ2!0
M                            !3S^\#_J?AWQG4?FZ!:$Q=*_T 83[FJ/
MSR<(E&76%_&6)_O%;^[A.>WMQV]][;_QK[//TV>2Y87;/Z.,/^)+;^:1&YTW
MLK?-CR/*]^_Y'4?W<G\<H@WM_KE'[BA_=R'E_P U?&1YD>67??*OP<^?/DA8
M&C_Z)3_O;/W*'JF+\$=$/*\OXYZ7W/H^8
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M MP'P3UP?\YEWOM_M@. Z%?IKJ/B.M_+4X)=) H
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MSS0_..\K+;-7EMMBD1??$1W-J6:/JUX
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M=_=[_P 3YY[IMOY.H"TMJZ^?H>LG]I:7\PKPB'AZCOT0<9]S8]^;L"8XTW[
MN:[9/ E:J*GP)1)JG'BD2(H1*M75C<*:;J)VFML;T=4TDMOFG:BHO*E1=$1B
M+XE_%JH3#8NO7"JNZX5C^<44:O3'*N6FKW,[64UQ2-&R._8MEB8S[+P0L/M5
MGUMW,P&R9A;9F2NK:=B5\;51705K&HD\3T3L5K]?!Q314X*@5;DJHB*JKHB=
MJ@5KVZZCLEW(W\O6W^.VZ@K=N;=YP]+VQ)4JF0TD;8ED1Z2+%(V6IT[OR&^0
M[75= FB*^I1:[?3J%QG9&QUGF]%9V.96U:,69D-34Q^<U4JL1S$?W<$<:(U7
M-\OF;JFH3#<6='FXT;&QQ[[7MD;$1K&-IJM&HU."(B)=."("J%]Y]H<UZ<\A
MQ'=3Y6U&85GPBSGN-7!)!+'44B-DBAD=)45*O;+&V1O:FC6JF@(FJZ6X.06[
M+.GS+<GM#^\MEWP^YUU*[AKW<]ME>B.T[')KHY/ O (1+T#?0]>_[2U7YA0
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MQ'6_EJ<+RZ2!0
M !6KK&_JUC/NZ;\B=/N#VE_0UVN_#"2NG[Z'L6_>)OSF4UF]/BK^GZ(9&F]G
M"2S5LD YM]=7TUT_Q'1?EJ@+PZ+67^)[?[FA_)M"CW                 %
M1^K[^LF-^X9ORQSF]OQV]#W7_C?X;-Y\>19G!OZE8W\5T/YNPWN#V=O1#Q[>
MWQN;^Y?_ !2SY]FK
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M9;4[F8]T^Y3M)E4E!+=:B@NMOQR>GJ'R0I%<Z:1&,E<Z-KFHR:1ZZHU?)7U
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M52.$  #FWT*_374?$=;^6IPO+I(%
M                 %:NL;^K6,^[IOR)T^X/:7]#7:[\,)*Z?OH>Q;]XF_.9
M36;T^*OZ?HAD:;V<)+-6R0#FWUU?373_ !'1?EJ@+PZ+67^)[?[FA_)M"CW
M                %1^K[^LF-^X9ORQSF]OQV]#W7_C?X;-Y\>19G!OZE8W\
M5T/YNPWN#V=O1#Q[>WQN;^Y?_%+/GV:L
M
M
M                            K-UM;A77#ML:2P66=U+5Y75.HJJHC=RR
M)00Q\\[&JFBISJZ-COV*N3PA,*S;(=(V4;NV"++[A=XL<QBI>]E#*Z!U755*
M0N5CWLBYXFM9S(K$<Y^NJ+Y.FFI:92;?_P"[ZJHK?+-C&;,JKHQKEBI+A0K!
M#*[3@BS132*S[/=N"*HKZ9\HRW:??BBPJX)+2172O7'\AM#W:L[]7.BC?HBJ
MWFCET5KTUU;JB<'!,NG(4                '-OH5^FNH^(ZW\M3A>720*
M                                                *U=8W]6L9]W3
M?D3I]P>TOZ&NUWX825T_?0]BW[Q-^<RFLWI\5?T_1#(TWLX26:MD@'-OKJ^F
MNG^(Z+\M4!>'1:R_Q/;_ '-#^3:%'N                 *C]7W]9,;]PS?
MECG-[?CMZ'NO_&_PV;SX\BS.#?U*QOXKH?S=AO<'L[>B'CV]OC<W]R_^*6?/
MLU8
M
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M*2TVR"Y37.WVJ:IB;65-7RJM-#%&KD>_NFHDDKVMT\G3P\"9="PJ
M        .;?0K]-=1\1UOY:G"\ND@4
M                   5JZQOZM8S[NF_(G3[@]I?T-=KOPPDKI^^A[%OWB;\
MYE-9O3XJ_I^B&1IO9PDLU;) .;?75]-=/\1T7Y:H"\.BUE_B>W^YH?R;0H]P
M                !4?J^_K)C?N&;\L<YO;\=O0]U_XW^&S>?'D69P;^I6-_
M%=#^;L-[@]G;T0\>WM\;F_N7_P 4L^?9JP
M
M
M                            %2>J[I]W&W>S*RWO#8*26AH;8E'.M54M
M@<DOG$LG!%1=4T>G$+1* _J2;Z_[';/?[/8A-3ZDF^O^QVSW^SV(*GU)-]?]
MCMGO]GL052'L7TJ;MX#NOC67Y#34++-:YII*MT-8V61&OIY8DT:B<?*>@1,K
MWA4                <V^A7Z:ZCXCK?RU.%Y=) H
M                              K5UC?U:QGW=-^1.GW![2_H:[7?AA)7
M3]]#V+?O$WYS*:S>GQ5_3]$,C3>SA)9JV2 <V^NKZ:Z?XCHORU0%X=%K+_$]
MO]S0_DVA1[@                "H_5]_63&_<,WY8YS>WX[>A[K_P ;_#9O
M/CR+,X-_4K&_BNA_-V&]P>SMZ(>/;V^-S?W+_P"*6?/LU8
M
M
M                                         !Y;E<J"SV^JNUUJ8Z.V
MT43ZBKJIG(R.**-JN<YRKV(B(!1W<SKRNSKA/;MJ[13Q6N)RL;>KLQ\LTR)P
MYXJ=KF)&FO9WBO54[6M7@%J-*LO75O'05C9;M36B[42JG>T[Z9]._E1>/))#
M(G*J^-S7)Z@*+J;+[WXGO98)+I8>:CNU$K67:RU#FNJ*9[]>5R*FB/C=HO)(
MB)KIQ1%U0(F$FA                 YM]"OTUU'Q'6_EJ<+RZ2!0
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M=?\ C?X;-Y\>19G!OZE8W\5T/YNPWN#V=O1#Q[>WQN;^Y?\ Q2SY]FK
M
M
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MQ'6_EJ<+RZ2!0
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MQ-41RKQ//OE749<F>^+[INC9Y9F>6'H'S3I\6/!9-EL6SM<D1')*;STEYN
M
M
M                      "M'6[@]QRG::&^6N)T\^+5J7"KB;JKO,9(W13/
M1$[>158]WB:CE"807TT]6-IVQQF/;_.J&IEL%++++:KG0M;+)3MJ'K+)%+$Y
MS5<SO'/>CVJKO*TY5\!,PFK*NNC:>V6J:7%Z>X7R\K'_ *K3.@6D@256ZHDL
MDJZHU%X+R,=ZGC"**T]-=HR#=OJ+ILQN:+*ZCK9\FOM5&WDC9+S.DB:U-=$1
MT[F-:W7UNO@0+2Z;A0                <V^A7Z:ZCXCK?RU.%Y=) H
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MJ[*39;-8GAKQ)$.L<F
M
M                                          #6,YSK"\"M<%?G5R@M
MEHN-0VW1R5+7/BDFF8]R,<C6N\E6L=JKDY43M K%E_1IMCN0LF5;0Y3!;*.K
M59/-:58[I:E>J\4A?%(UT2=NK>9Z)V(C4X!:K6K+_=]7%U6QV19M R@:J*]E
M!1/?,]OA1'2R-:Q?5Y7?8!5;3;':K#=H\>3'L/HUABD<DE;6SJDE753(FG/-
M(B)JJ)V-:B-;X$0*MU                 .;?0K]-=1\1UOY:G"\ND@4
M                                                  !1_JS^E*'X
MJI?RLQW>X_A_VI^AI=9[3O+JVO\ BRB_>(OW"'#W_BGI;F.)ZRB7,W+/TUJ?
M^W%I_/*8+\CID%
M
M
M                            5EZU]N\HSC;VV7/&*:2X/QRKDJZ^WP)S
MRNII8N1TK&)Q<L:HFK6\>5RKX F&I]%VZFV=AV[GPZ\7>BL.41W&HJJEEPE9
M2)5-E:SDD9)(K6N5K6]VK>;F3E[-- F5JDS3#E35,AMBHO8OGM/[,*OM291C
M-?4,I*&]4%352JJ1P0U4,DCE1-5T:URJO! ,L                 <V^A7Z
M:ZCXCK?RU.%Y=) H
M         "C_ %9_2E#\54OY68[O<?P_[4_0TNL]IWEU;7_%E%^\1?N$.'O_
M !3TMS'$]91+F;EGZ:U/_;BT_GE,%^1TR"@
M
M
M                                                *^]86 9AN-MG
M:K'A5K?=[K3WVGK9J:)\4;FT[*.LC<_65[$T1TC$[=>(3"DOU5]__0FI]\4?
MMX6J?57W_P#0FI]\4?MX*I,Z>^GO>/#]X\5R3),5GH+)03S/K*Q\U*]L;7TL
MK$549*YRZN<B<$")ET0"H                YM]"OTUU'Q'6_EJ<+RZ2!0
M                                                    %'^K/Z4H
M?BJE_*S'=[C^'_:GZ&EUGM.\NK:_XLHOWB+]PAP]_P"*>EN8XGK*)<S<L_36
MI_[<6G\\I@OR.F04
M
M
M                            #4]QMQL6VLQ:IRW+:E8+? J1PPQHCJBI
MJ'(JLAA8JIS/=HOA1$1%551J*H%,[S_>!99)6O7'L0MU-;D54C;7SSU,RM\"
MJL2PM15\6B_9"U$L;)]96/;D7NFQ++K8W&\AK7-BMM0R;OJ&JF<NC8M7-:Z*
M1RKHQKN9'+PYD54:I$PM $                   YM]"OTUU'Q'6_EJ<+RZ
M2!0                                                     %'^K
M/Z4H?BJE_*S'=[C^'_:GZ&EUGM.\NK:_XLHOWB+]PAP]_P"*>EN8XGK*)<S<
ML_36I_[<6G\\I@OR.F04
M
M
M                                "AG]X'>ZF3(\-QQ)52CIZ*IN"PIP
M:LM1*D2.7QJB0JB>+5?&%H978/H\PC+=NK;F6?5%;47&_P 7G='24<R4T5-2
MO54B55Y%<][D3G557E35$TX:J)E73?O:F39+<F7&J&NDJ;=)#%=;)6/7DJ4I
MI7O:U)%8C4[QDD3V\S=-=$=HFNB$PZC[?WJ?),#Q?(JE>:IN]HH+A,[335]5
M31RN73P<7!1L0                  YM]"OTUU'Q'6_EJ<+RZ2!0
M                                              %'^K/Z4H?BJE_*
MS'=[C^'_ &I^AI=9[3O+JVO^+*+]XB_<(</?^*>EN8XGK*)<S<L_36I_[<6G
M\\I@OR.F04
M
M
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M(@0  .;?0K]-=1\1UOY:G"\ND@4
M                    !1_JS^E*'XJI?RLQW>X_A_VI^AI=9[3O+JVO^+*+
M]XB_<(</?^*>EN8XGK*)<S<L_36I_P"W%I_/*8+\CID%
M
M
M                                                         ISU
M?;';H[HYO8KO@EA^%;=1VI*2IF\[HJ7EF\XEDY>6IGB<ODN1=430+1*N_P!4
M'J)]#?\ M.U?PL)J?5!ZB?0W_M.U?PL%3ZH/43Z&_P#:=J_A8*I)V!Z:MZ\)
MW?Q?*<GQCS&Q6Z>:2LJ_/[=-R-?32QHO)#4O>NKG(GDM4(F704*@
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M:?V91+G!E-PH).LF"YQU4+K<F:6J9:QLC5@[IM73JK^\1>7E1$XKJ%^1T?\
MEIAWI#;/?M/[,*'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6
MF'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'
M>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D
M-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L
M]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^
MT_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_
MLP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP
M'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'R
MTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP
M[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[TAMGOVG]F ^6F'>D-L]^T_LP'RTP[T
MAMGOVG]F ^6F'>D-L]^T_LP/?;KQ:+NV1UIKZ:O;$J)*M+-',C%=KIS<BKIK
MIX0/:
M
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MY=5_Y U\\+[U?CZ@.Y/I-8_NU?M *GU =R?2:Q_=J_: 5/J [D^DUC^[5^T
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M)K']VK]H!4^H#N3Z36/[M7[0"I]0'<GTFL?W:OV@%3Z@.Y/I-8_NU?M *GU
M=R?2:Q_=J_: 5/J [D^DUC^[5^T J?4!W)])K']VK]H!4^H#N3Z36/[M7[0"
MI]0'<GTFL?W:OV@%6NYYT8YW@&'W?,KE?[14T-FIUJIX*=:GO7M1431O/"U-
M>/A4)JEG^[W_ (GSSW3;?R=0$2NB%0
M
M
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M.,\]S6W\I4!,KVA4                  $5]2?T%9U\6/\ W; F$!?W>_\
M$^>>Z;;^3J F5T0J
M
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M%0N@2AKJ3+\O=5TTL#76VG1JRQN8BKWZ]G,B!:5\PJ
M"/-^8Y)=E\\BB8KY'V2N1C&HKG*JPNX(B=H3"KO]W_0UM)=\Z6KII8$?36[E
M65CF:Z25&NG,B!,KRA4                  $7=1T4LVQV<10L=)*^VO1K&
M(KG*O.SL1 F$#?W?]'5TEGSI*NGD@5]3;N5)6.9KI'4:Z<R($RN4%0
M
M
M
M
M
M
M
M               #X0UM'4O?'3U$4TD?KV1O:]S?!Q1%70#[@
M      #XU%724C6NJYXX&N71JRO:Q%7U.94 ^C'LD8V2-R/C>B.8]JZM5J\4
M5%3M10/T!\*BMHZ/E\[J(H.?7D[U[6:Z::Z<RIKIJ!]P
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MZZ21N1[5TX+Q35 /H
M
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M:'+:V:KM->R9EE2L<Y\U'6TS5D= USM52-[&/3D7@UZ)RZ:KJ1,+[!4
M       ""=[.J/ ]IZ6KM=!4Q7_.F(Z.*S4K^>.GF35-:R1O"-&KVQZ]XOB1
M%YD)B%']D,@NV6=2>+Y+?9UJ;O=;TM763KPYI)4>Y=$3@C4[&M3@B<$"TNJP
M4<U-Z=QLXZAMX5VWQ2K>F-I<5M%CMK971TDSH7JR2MJ.1%YD7E=+JK5Y(^Q-
M==2\,'N!MENETIY'8L@MU^:CZ]'.H[K;'2,B=+3JU9*>>.1$1S='(O*]%:]J
M^HJ(.-T'VNW/M^?[5VK<BJ5E'%+1R3W=K=>[IYZ/F95(FO'E:Z-SFZ_>Z!5S
M[N%YW)ZNMVO@2DK%IK=,^:>W6^ID>E!;+=!JO.]D:.YI-%:US^75[W(G!NFA
M;B?.[T.Z?2#N92PTMT;*V6..M;YNZ3X.N5&YRL='-$[3BBM<U=4YF+HYJ]B@
MXW3'%LBH,NQJT91:U5;=>:."OIM?7(RHC21&N]5-=%]4*,N
M
M
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M5?M-1 B5,MRW+9NJVYU-!^+FI\MIZN)W%-)G544RKPT7UZZA;D=30H
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M(X$)[Z2ZN:LZ>\+FG=S/;'70HO%?(@N-3$Q..O8UJ($2FD(
M
M
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M@OJ*$2J1NRWY:]4]WH+<Y)7U^2TUJB='Q3O(I(:-?'V.8NH6Y'4T*
M       *%]?^1WA<EQ;$DJ7-L#*!UT6D;P:^K?-)!SO\:M8S1NO9J[QA:$88
MQU99WA^!Q;=6''\>IK!'22T2O\VK5J'^<-<DLSW^>Z+(]7*Y5Y=->Q-. 31'
MVT^ZN0[.Y0_+<9IJ*KN+Z66A6*Y1RRP=U,YCW+I#+"[FU8FGE?: LOUBU%QS
M'9_9_<:OACCJJZE;+7)3HYL,=1>J"FJU8QKG/5&ZP/Y>9RJB)VA$)EZ)[C2U
MNQ%OI8'HZ:VW"OIJIJ*BJV1\WG"(O_$E:H1*G65-^6O5A5TUN<DK:[,8Z2.6
M/BWDAK6PJ]%X\$:Q7*OVPMR.IH4              4X_O!++-48OA>0MC5T%
MOKJRADD37R75\,<C47P<?-5"T-IZ$UM"[.UB4/)\)I>:GX4TT[SG6*'NM?#R
M]WIR^KKZH1*L?6"RFH^H6ZRV/R+BL-NFG\W]>E=W#%141OWZM2-WV>(6A+W]
MX#::J2W;?WZ2-$6)UPHJQ[%56)+,RGEC:W7P?BY0B$Q=&MQI:[I^QRFIWHZ6
MVSW&EJFHJ+RRNKIJA$7Q>1,Q?MA$J60M^6O5KS6YR2T];G#IHI8N*+207)9%
MD3M_Y)BO"W(ZFA0             !2G^\%OETAHL(QR)[X[-625]=4M35&2U
M%*D$<>O@7NVS/_;A:$L]*N$853;&X]64EMI*NHOD,U1>*J:*.=\\[I9(WQO5
MS5U:Q&]VC.Q-/&JZD2IID<5/MKU6/@P#_5:6V9)2LHJ:F5>5K:A\??TJ(WCR
M:R20JS\'R0MR)B_O![1*VMP6_-9K#)%<*&637UKHW02L14]5'/T^P$0GKI(N
M-+<=@,22F>CGTC:REJ6:HJLECK)ET73LU:K7)ZBH$2H]A3?EKU9T5=;G)+%6
MYK->8WQ<6N@@N#Z]SD[>'(Q5^P%N1U-"@             #E_MU^E]3?VNN'
MYQ.%^1TTN]"VZ6JNMCM.6MIY:9VJJB:3,5G:G'PA1S%Z2:EEBZB,=I;I_J\S
MUN% Y'JB<M0ZDF:UB^JKTY$]50O*R'7]=((MN<8LKGM2IK+WYY'&OKU91TDT
M;U3U$6H;K]E B&O[$8G65G1CGL#8U?)>UO5QHF<4YUI:6*)J-^S)2JGV03QM
M"Z";C2TVZUZH)WHR>NL<R4R*J)SOAJ:=[FIXUY=7?8:H);+_ '@]T@EO6"65
MKVK4T=+<:R2-/7HRLDIXV*OJ*M.[3["@A8_I:M,]FV!PBCJ$5))*2:M1%_ K
MZN:K9_\ )E0(E+X0
M
M                                                      "IO51T
MNW?<FZ)N%M\D<F4K"RGNUHE>R%*UL+>6*6*5ZM:DK6HD:M>Y&N:C>**WRBT2
M@BX;2=7>Y\=KQ'*Z2Y36>V.1*9UXJ8(J2'1.3O'O1RNE5J<$=I(_373M">!>
M?9;:JV[.X'18?0S>=U2/=5W6OY>3SBMF1$>]&ZKHU$:UC$_!:FO'4*RD((
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M)N(R.#(V120V>T1R,G=3=^WEDFFDC5S%D5JN8UK7*B(JJJZ\$(F5N J
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MC4]1$1$"KT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                              #^.<UK5<Y41J)JJKP1$0#"?+3#O2&V
M>_:?V8'];F.(O<UC+_;7/<J(UJ5D"JJKV(B<X&8BFBGC;-!(V6)WK9&*CFKX
M."IP _8
M
M
M
M                                       /#>OXGN'N:;\FX#C#C]DK
M\FOUKQNUHUUSO%93V^B;([D8L]7*V&-'.7L3F<FJA]$\2=$V^[&.>V@MTCFI
MJC&U\2.=ZB<R(GW5"*M#AKMY>G'+VTROKL7O<:I.^B>]'T=7%KIJYK7.AGC7
METYDYN*<%14!QND^QV[EMWEP2ERFEC92W6)RTEZMS7<WF]9&B*Y&Z\>1Z*CX
MU7P+IVHH5E)(0
M
M
M
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MA8@(
M
M
M
M                       >&]?Q/</<TWY-P'(?9CZ8=OO[2V;\_A"\NPP4
M5XZU[A34>P]QIYW<LMPN%!34R?A2-F\X5/VD3E"85XZ Z&HDW2R*Y-;K24]@
MEIY7\>$E16TKV)XN*0O"969W]WQVAVX:RQYI:H<JR":))8K!YM!5*R)RKRNG
M?.BLC:JHNB<7>'ETXA$0@J3K-W?S5SK?M3MTQ%32)O=Q55ZECX<-$IV0,;P_
M":J($T5@AGOU3NY'4Y2Q8LGFR-)+U&YC8G-KWUVM0U6,1&M5)%=Y+4T0)=/]
M_< 3<K:?(\9BC[RY^;K6VE$]=Y]1_C8FI_E\JQ+ZCE"L*/=$V<+BV[Z8[52=
MW;\KI9*!S7+RM2LI]9Z=R^KY,D3?5>%I8GJQRZIW#WVN-JM?-5061T..6V&-
M>97SQ.7OD1$X<RU$CV>KH@(7[L>U%LMNRL.T#WHRD?9)+15U$::_ZQ5Q.2>=
MJ*O:LLCY$0*N;628+O'T]92ZO='<+'54CW1TF1V]9$HZB)SM$Y9V)R.:_1-8
MI./@<T+<;?\ '.MG=RW1-HLHAM>6VY5;WT=PI6PS.:Q45-'4W=LU143BZ)P*
M+E;%]1&(;VTM126RFEM&2VZ)LU=99U:_2%51G>02-1$DC1RHU5Y6N1535O%-
M2LPF((
M
M
M
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M&@J
M
M
M
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M($75SW=KY'N57O>NB:N>Y5"&>
M
M
M
M                                                      (/ZEMC
M+GOAC]FM]FN-+;;E9ZJ6H;+6->Z-\<T?(YFL;7.3BUJ]G@"8E!^$] <\-UAJ
MMP<G@J+5"]KY+=:(Y$?.B+KR.GEY%8U?#RL5?$J=H35=BAH:.V4--;;? RFH
M*.*.GI::)$;''#$U&,8U$[$:U$1$"KT
M
M
M
M
M
M
M
-              ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>tm2227887d1-lc_itcar4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-lc_itcar4c.jpg
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M5P ZC*.N.DN>[BVT95S90UUU?CS5$KGT\\F"8JD;)VQN>J)MZQ%"<%@!
M
M
M
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M;$WZND5&\XN&"8R,5DCL$Y7*@5E:X0
M
M
M
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M1..QW:I?.Y:BF,86*=ZQ@
M
M
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M%,K4W*IF-E7^F'[51_D)?]2'#=%?GH]&IDWO)7<>Q,
M
M
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MOZ*_/1Z-3,O>2NX]B8
M
M
M                Q=](1\CY#\)N7<Z<+0G' KZE*CSY6]QIPB6F0@
M              !BSB\]9-J\QT_ONK-?F/*^AYYTD^9I]"._4TIHAZILI^ M
M_"<9=KR8=?JKY2WW$_/JV@         \L>+[_$3G+_EG]E4@7AZ@67Y'M_@T
M/<VA1S@ $"UJ]56:O G?A-,/.^YJ[CINB_ZI8]-GWA'_ &UOGFM??$1I-4^\
MGN>%ZG_]&^2M?F?]:FOSIW@P      #J\R_LY=_ JGN3C6ZT^3O?EU_AE>CR
MH5+IA^U4?Y"7_4AY?T5^>CT:F9>\E=Q[$P
M
M
M                               !B[Z0CY'R'X3<NYTX6A..!7U*5'GR
MM[C3A$M,A                    $'U=SM-I_D&ZYCI$:ZY1M93V]'IO-[X
MJ')&URHO*C,5?AU<,#YW*N#3BUNLLU.6L55QM]CNR\\;I=;E>Z^>Z7>KEK;C
M4N5\]3.]9)'N7V57_0:N9F=MY3<N57*IJJG&963HSK/<],+HL-<Z>ORE4->E
M3:V.15CE5,6RPH]4:UV]L=M1'(NW:B8?6U=FB>TV^K-:592K"<9HGL>&%Z=,
M#)'D*Z_6IO=3)^)IT.EZRV/-JWO&=,#)'D*Z_6IO=1\33H.LMCS:M[QG3 R1
MY"NOUJ;W4?$TZ#K+8\VK>\9TP,D>0KK]:F]U'Q-.@ZRV/-JWO&=,#)'D*Z_6
MIO=1\33H.LMCS:M[QG3 R1Y"NOUJ;W4?$TZ#K+8\VK>\9TP,D>0KK]:F]U'Q
M-.@ZRV/-JWO&MK3?4*V:F9>=F.TTL])2MJ9*18JK<YS?B:QRKUCG)AU_LGVH
MKBJ,6]R.=IS5OATQ,1CALI>?1GO+'B^_Q$YR_P"6?V52!>'J!9?D>W^#0]S:
M%'.  5OKS<Z*V:4YA[\E2-:N%M)3-ZKYIGMW6HGU$5R^TBF!GZHILU8]EUW1
M&Q7=UI9X,8\&>%/:B(92T2U+M6F-_N%VNU)45D-91]ZL92[F\CN=8_%=]S4P
MP:<[DLS38JF9C'&'MO2G4=W6MBBW;JIIFFKA?:QT3'8B=*\NEQDKR'=/K4_N
MIM^=K>B=YYO^W.=Y6WZWLG2XR5Y#NGUJ?W4<[6]$[Q^W.=Y6WZWLG2XR5Y#N
MGUJ?W4<[6]$[Q^W.=Y6WZWLG2XR5Y#NGUJ?W4<[6]$[Q^W.=Y6WZWLG2XR5Y
M#NGUJ?W4<[6]$[Q^W.=Y6WZWLK[H*QEPH:6OB:K8ZJ*.=C78;R-E:CD1<.KM
M-Q3.,1+S&];FW751.W3,QN.06?)!-0<X4MMHZBQ4F[-<*J-T4_5;#%(W!<</
MNE1=B?NK[?%=(]=46+=67H^U77&$_P L3X=&[W<BU;QG%6.6KY)EV[PW-D:3
M-8BLEC78JL?L7!>HOL'G6J\_.2S$78C'#8F.U+*KIX48+(^=NR_H-5^;[<]
MZXY;S*][QL;B)/G;LOZ#5?F^W'7'+>97O>,XB3YV[+^@U7YOMQUQRWF5[WC.
M(D^=NR_H-5^;[<=<<MYE>]XSB)/G;LOZ#5?F^W'7'+>97O>,XB3YV[+^@U7Y
MOMQUQRWF5[WC.(E/XWI)&V1-B/1'(B^VF)W%-7"B)TL9^BP
M
M
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M&IO^S0_P&_ZD/=[7D1W(:V7U/J@
M
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M8X[ C!8@0            !B[Z0CY'R'X3<NYTX6A..!7U*5'GRM[C3A$M,A
M                    #@7"R66[.8^ZVZEKGQ8<VZI@CF5N"XI@KVKAM(F(
ME\J[5%?E1$]V'-CCCAC;%$QL<3$1K&,1&M:B<B(B<B$OI$8;3]!(     &:^
M,3]FLM>'3=Q,3,[4.0Z2^[H[L]Y(.$[U73>=:KN<);+^2RNCORL^E/@5+QT:
MMWJQLM>EEAJ7T<=VI%N5]GA<YDDM*^1\,5/O-PZQSHY%D3[I-U.3'')=/#"
M67#PZZW7#1K.M/4U51,_)-R>D.8;='B]JL5%1M0QBKASD2X.Q3:YN+>J$3#:
M/3;T*_2[GX@_M@K@=-O0K]+N?B#^V!@YF1=;.'S53-L.6,O6>*IS!<4GJ$=5
MVB*-'K$QTTCGR.:NU415V\JGQFS;G_C&XV-.LLY3$1%VN(C^>KQKA_4?)7HY
M:_$:?M!Q%OS8W(3SKG>6N??J\;M:"W6^U4Z4ELI(:*E15<D%-&R&-'.Y5W6(
MB8J?2FF*8PB,&%>OW+U7"N535.F9QG?<DL^(  P;Q%>N/,G^X^\*<X[6/S%7
MT=Z'Z9Z%_H]G^O\ _I6V]EK]G+/X%3=R:=;:\B.X_.>>^8N>G5WY=H?1A 'Y
M:QC%<K&HU7KO/5$1,78(F*^RN"%8IB-J-L?HL     H+/G[77/\ AL[FT\0Z
M0?/W>['X8;&UY,+XIO\ LT/\!O\ J0]JM>1'<AKY?4^J
M
M
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M06?/VNN?\-G<VGB'2#Y^[W8_##8VO)A?%-_V:'^ W_4A[5:\B.Y#7R^I]4
M
M
M                            !EC7C575*^:E4V@VB2I29@6F;57V\8M9
M)"R5B2(QLCD<D+&QN8]\B)OJKFM9@OVQ,(8O#)Q50/==(-65?=\-]4^.+NB.
M?AM;ONBVIU$Q;A[2!.,+(X<]7\_W3--^T9UAA1NH&7(4J8:W=8UU32M5B+SB
MQX1N<B2QO8]B=>QV*[455(F&D@@             !B[Z0CY'R'X3<NYTX6A.
M.!7U*5'GRM[C3A$M,A                             !QZ^MIK;0U-QK
M7\U1T<4E142+M1L435>Y?W$0B9P4KKBBF:IVH>>^JFK>8=4+JLM<[O>PTLKW
M6JV-1$2)CMB.>Y-KI%;AO+CA["(AK+ER:Y>5ZPUC<S=>SL4QM1_'9=IHUK/>
MM-;K!;ZB5:C)M5.BW&A<B*L?.8-=/$N&*/:B(JMY'(F'+@J3:NS3/:??5FM*
M\K5$3LT3.S'AAMR"?*.I65'/:VGON4KPR2)[)HE=!.R.1T;T5DK478]B]3E3
M%#91,3&,/2K-ZB[1%=$XQ*BKIP-:)7"O6MIGWFV0*Y7+04=9$M/M7'#&H@FD
MP_\ >$OOBN/3O2K(FE=LDM>2;2RWQSJCJNI<YTU5.Y.19)I%<Y43J-QW4ZB(
M$)D!%=3?5MG'S'<_>DH'G3P9>O\ L'@UQ]YRA>7J %     8*XA98IM8<ROB
M>CV(ZC8KFKBF]'0P,<FSJHY%1?;..UA.-^KZ.]#]-]#*9IU19B?Y]^NII^Q:
MY:4TECME+49EA9404D$4K%BJ%5KV1M:Y-D745#H+>>L13$<+L=MXWF^BFM:[
M]=5-F<)JJG;IT^D[#Y^M(_2>#^9J?<B_Q]CSN^Q>J.MN0G=I]H^?K2/TG@_F
M:GW(?'V/.[YU1UMR$[M/M.VRYJID#-MS;9\NWN*NN3F.E;3LCF:JLC3%RXO8
MU-GU3Z6\U:N3A3.,L'.]'\_D[?&WK4T4XX8XT]GN2F!E-    '&KZ^DME)+7
M5TJ0TT*;SWN_U)[*KU$,?,9BW8MS<N3A3"8B9G"&?,Q72.]7NLN<3%CBJ'XL
M8Y<7(UK4:F.'57#$\*UEFXS69KNQ&$53]3944X1@MVU:AY9GM\#ZJJ2DJ48C
M9:>1KW*US4P7!6M5%3V#U/*=),E7:IFNK@58;,3CX(855JK%S/U\RCY39V$G
M:F7U@R'*QN5>)'%5:#]?,H^4V=A)VHZP9#E8W*O$<55H/U\RCY39V$G:CK!D
M.5C<J\1Q56@_7S*/E-G82=J.L&0Y6-RKQ'%5:#]?,H^4V=A)VHZP9#E8W*O$
M<55H=M;+O;KS3NJK9.E1 QZQ.>U'(B/1$<J=<B=1R&SRN<LYJB:[57"B)P^G
M^)4JIF-MS3,5
M
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MRN0$M7A4             !B[Z0CY'R'X3<NYTX6A..!7U*5'GRM[C3A$M,A
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M#8?2BYPI3K2;]G*KPV3N41VG0_Y.K\R?PTL>_P"4GAVK'
M
M
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MOS)_#2B_Y2>':L<
M
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M*(^O0_Y.K\R?PTHO^4GAVK'
M
M                                           ='G/+5/G/*-]RE52+
M#3WN@J;>^=J;RQ]\Q.C1Z)BF*M5=[#V@,295U@U@X4+0_3K/>1EO.6[=/,MF
MN<<SZ2G5E1*Z5R1U;8)HY&.>Y7HUS4D;O*CL-C4+;;[9CXF]5=?[)6:=:::?
MR42WV-U!<JZ.HDN"LII^ME19>8IXH6N:NX]\F*;JKR+@H,&N='<@NTPTTR[D
M:2=*JIM5.[ON=F.XZIJ97U,^YBB+N))*Y&8ICNX!5. &"+ABG)R
M       ,7?2$?(^0_";EW.G"T)QP*^I2H\^5O<:<(EID(
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MNM1_J.7_ #;?XX9)X8/6K3^!5?X*'-:L]]]$O<^GGZ7/ITMO'6OSD
M    "M=6J^D6CHK:V5%K4EY]T2;5;'N.;BOL8JNP\]Z89BWQ=%K'[6..':PE
ME6(G'%&;!G63+>79:"@C1USFJW3;\B8QLBW(V\G555:J'.ZNU[.1R<V[<?\
MDJKF=G:B,*=^<'UJM\*K&5I96S319FHN>APBK(D1*JE5<7,<O53V6KU%/2M4
MZVMY^WPJ=BJ/*IT?4Q*Z)IEWQNGS
M
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M0
M
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MD(^1\A^$W+N=.%H3C@5]2E1Y\K>XTX1+3(0
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ME=-L^3:/\A%^ AZ[E?<T>C'>8,[;E&2@
M
M                                                   !Q:FV6VM=
MOUE'!4/P1-Z:)DBX(N*;7(O(H'U@IJ>E9S5+"R&/''<C:C&XKU<$1 /J
M            Q=](1\CY#\)N7<Z<+0G' KZE*CSY6]QIPB6F0@
M                     ,F<9'RGE+\A6_APF%F=N'#=)O*M]RKP+?X;_4OE
MG_?O[0J3[V?(AOM1_)T?U?BE:A]F[       8N^D(^1\A^$W+N=.%H3C@5]2
ME1Y\K>XTX1+3(0   $7U+]7.;_,ER]Z2&/F?=5^C/>;K4?ZCE_S;?XX9)X8/
M6K3^!5?X*'-:L]]]$O<^GGZ7/ITMO'6OSD               49J5^UU7_ A
M[FT\9Z3_ #]?<I_##/L^2NFV?)M'^0B_ 0]=RON:/1CO,&=MRC)0
M
M
M                              #%WTA'R/D/PFY=SIPM"<<"OJ4J//E;
MW&G"):9"                                R9QD?*>4OR%;^'"869VX
M<-TF\JWW*O M_AO]2^6?]^_M"I/O9\B&^U'\G1_5^*5J'V;L      !B[Z0C
MY'R'X3<NYTX6A..!7U*5'GRM[C3A$M,A    1?4OU<YO\R7+WI(8^9]U7Z,]
MYNM1_J.7_-M_CADGA@]:M/X%5_@H<UJSWWT2]SZ>?I<^G2V\=:_.0
M       !1FI7[75?\"'N;3QGI/\ /U]RG\,,^SY*Z;9\FT?Y"+\!#UW*^YH]
M&.\P9VW*,E
M
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M?ZCE_P VW^.&2>&#UJT_@57^"AS6K/??1+W/IY^ESZ=+;QUK\Y
M    .ES1F&#+5K=7RQNED<O-P1HBX.D5%5-YW(B;#4:UUE3D;$W)C&=J([?;
MT+T4<*<%"7.Y5EWKIKA7/YRIF7%R\B(B;$1$ZB(FQ#Q+-9JYF;LW+DXU5-C3
M$1&$)G:=4KC;Z"&BJ:-E8^%-QLZO6-RL38U%1&KBJ>R=;D^EEZS:BBNB*YIV
M,<<-C<?"JQ$SBYOSOU/DIG\\O:&7USKY*/O?4K\/VW9Y?U*GO=XI;6ZW,A;4
MN<U94E5RI@U7<FZGL&QU=THJS68IM3;BGA=GA=K'0K79X,8XK".[8P
M
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M=\BK(SKUZ_9O;%Y M@]%0J  /@^LI(YVTLE1&VI?]I"Y[4D7'V&JN*@?<
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M=[1!,M'IRRW5,]ILSX8.=QIY(6,GEF1BR;[T<YRL23<;CAMPWE+3#6H5
M              !4^H?#OHSGZ*HK<QY?IJ"N5KGRWJW*ENJ&KM59'OCP8]4]
MF9CPG%A343*V3=&+R^YZ/:PK6W>-W6T5!SZ5+8T=CN.K:'>IY.3KFNW$7JH%
MDUT^XV]4K!2QOSQ:8\UV!CD@?<FQ]XU37X;$6:)BPN7#;NNC1R_?!&#8FDVN
MNGVLE)(_*E:^.[4S.<K;+6M2&NA;BB;^XCG->S%43?C<Y.HN"[ C!900
M        !B[Z0CY'R'X3<NYTX6A..!7U*5'GRM[C3A$M,A
M                  9,XR/E/*7Y"M_#A,+,[<.&Z3>5;[E7@6_PW^I?+/\
MOW]H5)][/D0WVH_DZ/ZOQ2M0^S=@     <.[7:VV*V5EZO%2RCM5!"^IK*N5
M=V.*&)JN<YR^PB(!YG<3O$+0:VW"VVZQ6M]%EZP2U#J*MJ'?[35+4)&U7NC1
M,(V_B^M;O.7V<.1"\0E_"AQ+6'32CCTYS?1][6*X5[ZF+,+'];3S5+8X\*B-
M4_BNL3&1J];U45-J$3#T-:YKVM>QR.8Y$5KD7%%1>144*OZ   1?4OU<YO\
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MJ_:5XVK2JK(?[76S^&_N;CS3H_\ /VN[/X99EWR97Z>WM<
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ML-HROQC9SR]8:5M%9[;05M-14K,5:R)CJ1$3%RJJK[*JN*KRA,[3<05
M            #'>LO%SGBQYYNVF.FV5F5%\M]0M$E?*DM?/-)NHN,%+"UNW;
MLWG/_@A:(06ET$XHM=I65^J=_FLEDD<DB4UUE7%J.P7&*VTVZQCD]B3FEV Q
MA>V0.#+1_)W-55ZI9<VW9F"K-=53O1')][2QX,5/:E60(Q7VVS6AEL^)66^F
M;9MSFOBY(8TI>;7:K>:PW-WVL AB!^FMRR3QEVMVFMDJJ7*[*JFFKG4U-*EN
MI8:RE5:N-)&MYMK%8KG-;C@CEW4Y$"W8;L"H            &+OI"/D?(?A-
MR[G3A:$XX%?4I4>?*WN-.$2TR$                               !DS
MC(^4\I?D*W\.$PLSMPX;I-Y5ON5>!;_#?ZE\L_[]_:%2?>SY$-]J/Y.C^K\4
MK4/LW8     &<N-VZ7&W:'3P4+W,AN5THJ.O5NS&GPDGP5?862)@3#S/"X!<
M5GXJ->K#::&QVO-SH;9;:>*CHXGT%MF<R"!B1L:LDM,][L&HB8N<J^RH1@YO
M2^XB?3+^K+5\$!@].<L5E3<<MV:X5C^<JZJAIIZB3!&[TDL+7.7!J(B8JO40
M*.U B^I?JYS?YDN7O20Q\S[JOT9[S=:C_4<O^;;_ !PR3PP>M6G\"J_P4.:U
M9[[Z)>Y]//TN?3I;>.M?G(                  %!9#_:ZV?PW]S<>(='_G
M[7=G\,MC=\F5^GM[7
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M0CY'R'X3<NYTX6A..!7U*5'GRM[C3A$M,A
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M>\W6H_U'+_FV_P <,D\,'K5I_ JO\%#FM6>^^B7N?3S]+GTZ6WCK7YR
M             !060_VNMG\-_<W'B'1_Y^UW9_#+8W?)E?I[>UP
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MQUENL]3+<KK=)&2W2[5#6QOEYE')&QL;55&,9O.5$WE7%RXK[!$RM,(
M         8N^D(^1\A^$W+N=.%H3C@5]2E1Y\K>XTX1+3(0
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M4Y<4P4]SIN45;4Q+78/J?1
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MVD0#I-0=$<B:FWZRYDS3#4R7.PX?%[J>=T+$W94F3>:B+O=<@3BL8(
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M;@   "OK)HQDC+^HUTU3MT52W-EX9+'6R/G5\"MG5BNW8\,$_BVA.*P0@
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MCYX;)4V?O'O#XE[ZM<UJYWGN^>^-WG6MYS=W(L</M<?;")7Z$
M   ,7?2$?(^0_";EW.G"T)QP*^I2H\^5O<:<(EID(
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M_P VW^.&2>&#UJT_@57^"AS6K/??1+W/IY^ESZ=+;QUK\Y
M   !6^J-EO%7%%<Z>5T]LIF_CJ1J?Q:]67!/MDPY?O?J8GG_ $KR.8N4Q=IF
M:K=.W3H_F[?@[C*LU1&PJ<\Q9:6Z:_M=2?P)NYN.HZ,?/T=RK\,OC>\E>9[,
MP
M
M        #"7T>_RQGSP:V]TJ M+=H5   #BW*O@M=NJ[G4[RTU%#)4S(Q,7;
MD+%>[!%5,5P0#.'3JT4_1[YXE#\("<#IU:*?H]\\2A^$ P.G5HI^CWSQ*'X0
M# Z=6BGZ/?/$H?A ,%F:1ZZY)UJ^./U/CKH_B/O;OWO^%D&/?G/<WN;DDF/\
M2['DZ@,%FA              #%WTA'R/D/PFY=SIPM"<<"OJ4J//E;W&G"):
M9"                                  ,!<2'KHS-_N/]GTQK+WER\NU
MY\Y7_3^&&\K7\F4?Y"+\!#91M/3K?DQW'+)7        /+'B^_Q$YR_Y9_95
M(%X>F62_V.R]YLHO>[ H[P"+ZE^KG-_F2Y>])#'S/NJ_1GO-UJ/]1R_YMO\
M'#)/#!ZU:?P*K_!0YK5GOOHE[GT\_2Y].EMXZU^<@                 *B
M*BHJ8HNQ44"(/R-8K;47&\P1?C'0R.@IUPYJ%ZL=O.8GM]3[WJ>URLZARMBN
MY?IC9X,X1V*9PG&8\&CL/MQLSA"N]-?VNI/X$W<W'!]&/GZ.Y5^&63>\E>9[
M,P
M
M         #"7T>_RQGSP:V]TJ M+=H5   #X5M-35E'44=:U'T=1$^*H8Y51
MKHI&JUR*J*F"*B@4[3\,O#E5N<VDRE03N:F+DBK*IZHGM[M0H3B^<O#9PV0R
M.BFRM;HY6+@YCZVI:Y%]M%J 8OST<.&CT9MGCU1\)!B='#AH]&;9X]4?"08I
MOIYIQIGI]\9?-U;*:W?&/,?&7>L\E1O][\YS6]SDDF&'./PPPY0A.
M        ,7?2$?(^0_";EW.G"T)QP*^I2H\^5O<:<(EID(
M                    P!Q&R,DUFS.Z-R/:BT355JHJ;S*"G:Y-G5145%-9
M>\N7EVNYQSE?T?AAO*T2,EM-#)$Y'QOIXE:]JHK516)M14-E&T]-MSC1'<<T
ME]       '%N-QM]HH:BZ76JBHK;2,=-55=0]L4,4;4Q5SWN5$1$]E0/*'B2
MS9E_/&M>:<SY6K$N%BK'4;*6L:Q\;9%IJ"GIY%1)&M=@CXW(BX;>5-@7AZ3Z
M.:@9.S[DBU393NT-R6W4=+27"!F\R>GG9"UJMEBD1KV[6KNN5NZ[#K55 K*P
M0A%]2_5SF_S)<O>DACYGW5?HSWFZU'^HY?\ -M_CADGA@]:M/X%5_@H<UJSW
MWT2]SZ>?I<^G2V\=:_.0                  .+<_DVL_(2_@*8V:]S7Z,]
MY,;:EM-?VNI/X$W<W'D71CY^CN5?AEG7O)7F>S,
M
M                                               PE]'O\L9\\&MO
M=*@+2W:%0   X%[MSKO9;C:6R)$ZOI9Z5)53>1BS1N9O88ICACB!1/#MPUUV
MAEZO5VJ\Q17IMVI8Z5L45*ZF6-8Y-_>572R8X\@3,H)J=P4W34'/U_SI#G&G
MH(KU5.JFT;Z%\KHT<U$W5>D[<>3V G%$O\O>\>GE-_1LGP@&)_E[WCT\IOZ-
MD^$ Q7OPX</=9H/^LW?=^BO?Q_WCN<U3.IN:[Q[YQQWI)-[>Y_VL, B97L$
M             ,7?2$?(^0_";EW.G"T)QP*^I2H\^5O<:<(EID(
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M1Q__ *.7_-M_CA_>&#UJT_@57^"AS6K/??1+W+IY^ESZ=+;QUK\Y
M           XMS^3:S\A+^ IC9KW-?HSWDQMJ6TU_:ZD_@3=S<>1=&/GZ.Y5
M^&6=>\E>9[,P         !PJ*[6VXRU$%#4LGEI'\W4-8N*M=_Z?JIL,2QG+
M-^JJFW5%4T3A/:6FF8VW-,M4                                  !Q
MZZNI+;2R5M=*V"EB3&21W(G[B;55>HB'POYBW8HFNY/!ICLIB)F<(?2GJ(*N
M".III&RP2M1\<C%Q:YJ\BHI>W<IN4Q53.,3M23&#Z'T0
M
M PE]'O\ +&?/!K;W2H"TMVA4     #+O$AQ0W'3Z]QZ;Z:TC+EGR;FTK*A\:
MU+:5U2B+##%"W;).]'-=@J;J(J;'*N"$Q"H(=.>.7.6%WKK]=[0LR*]D4EZ;
M:\47#_X:CD;N?4=&T)V'QJ,U\8^@'-WK-O?E[RM&YJ5+[C*R]4:MQ1J<Y41O
M?/#BJX(YSV8K[(-AL?1W5JP:R9.@S59&K35#7K3W2V2.1\M)5-1%5BN1$WFJ
MBHYCT3KD7J+BB$2L (              8N^D(^1\A^$W+N=.%H3C@5]2E1Y\
MK>XTX1+3(0                                "K-?--ZW4?)/>EGW5O
MUKF2NH(G*C4FP8YDD.\NQ%<U<6X_=-1%P3:?&]1PHV&DUQD:LU9PI\JF<8[?
M:8*K[=7VNLEM]RI9:.NA=N2TT['1RM<G45KD14-9,8/,JZ*J)X-482^M%!/3
M7>D@J8GPS-GBWHY&JQR8N:J8HN"\BDQMIIB8KB)TO4,W#V<      !C'CKTH
MN]Y@M.J=EIWU<=HI5ME]BC17/AI&R/FAGP3[AKI)&R+ALWD7DQ5"T,(!9:N@
M.C=SUDSU26?F9F95HW-J,Q7*)-UL-*W;S;7JBHDLJIN1IM7E=ANM<$3+9_05
MT4_2+YX[#\'"N+JLS\&6D.5LM7G,ULGO"W&RT-5<J-)JN)\2STD+IH]]J0(J
MMWFIBF*&/F?=5^C/>;K4<_\ ^CE_S;?XX0_A@]:M/X%5_@H<UJSWWT2]RZ>?
MI<^G2V\=:_.0                  *ZU$SE-;M^P6Y'1U,K$[YJ514W8WI]
MK'CRJJ<KNI]7DX+I+KNJSCE[6,53'VJNU/8CQ]CN[63:MX[,JOMERK+170W"
MA?S=3"N+5Y45%V*BIU45-BGG&5S5S+78N6YPJI9=41,82G?SNW+R=!V;SM.N
M5[DZ=V6/Q$:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;
MEY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7N3IW9
M.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7N3IW9.(C2X-WU.O%SH9*
M*"&.B67K7S1.<K]Q>5$5>3'V3"SG2K,7[4T4TQ1CV8QQP6ILQ$XHK:+O762N
MCN%ODW)V;%1=K7M7E:Y.JBG-9/.7<K=BY;G"8W^U/:?6JF*HPE./G=N7DZ#L
MWG9=<KW)T[LOAQ$:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$
M:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7
MN3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)
MT'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$
M:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7
MN3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)
MT'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$
M:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7
MN3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)
MT'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$
M:3YW;EY.@[-XZY7N3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:3YW;EY.@[-XZY7
MN3IW9.(C2?.[<O)T'9O'7*]R=.[)Q$:49S-FZY9GDC[YPAI(ML=+&J[F]U7+
MCRK_ *CG=::YO9^8X7V:8VJ8VN[W7UHMQ2Y^2<Z3Y>G;15>]-9YG==&G7.B<
M[[IB?ZV_^DSM1:\KR5? KV;4^KVX\,>%6Y;X7=7@UR.:CDY%3%,4P7;[2GL<
M3C&+ ?TD                  !'<[YYROIUEVIS1FZX,M]IINMWW[9)97(J
MMBB8FU\CL%P:WV%7D15 RK4\8VI>=:^HIM%=,Y[M14ZJWORLAJ:YV")CC+'1
M*QD7*G6K,[ZNT+8/C%QB:L9'KZ6+6?31]MMM2[=2II(*NW28<JK$VL=*R543
M[GG6_50&#6.2<[9:U#RW1YKRG6MKK/6HNX].M?'(W8^*5B[6/:NQS5_U8*%4
MA S-Q"\4];H_G"CR?ERRT]\KUHN_[FL\DC.8WU<K&(D>.U&,61V/(U44)B%U
M:79\HM3,@V+.]"Q(FW6G1]13M=O)#4QJL<\6*X*NY(US47#:FT(2\#$DW&MJ
M359DNN7<N:?P7FHML]1&L=&M743<S3S<USCF1-<J)BK<5Y,5"V#E=+;7G_[.
MU/BMS]R!@YMEXZ'V^\P6;4[(=7EQKU:E15Q2R.EB1VS?6EGAC>K<=NQZKAR(
MJ\HP:ZMESM]YMU)=[54,K+97PQU-'50KO1RPS-1['M5.5%1<4"KE  ,19)X[
M;S?LWV.QW_+5!;[-<JV"CK*Z&>9SX&5#TCYS!R8*C5=O.]H+8-NA5_'.:QKG
MO<C6-15<Y5P1$3E55 QUE'C5N^;]4[9DFARY1MR_=KPVVTMQ6:7OCO26?FXY
M5;]KOJS!RIR8A;!L8*@                                  ,)?1[_+
M&?/!K;W2H"TMVA4     #$VA-NMU=Q@ZH5694YR_T%1=IK$RIP5S6.KDC;)'
MBOVS:=S6LP^X<OL!:=IMD*OA6T5)<:.HM]? RIH:J-\%333-1\<D4B*US'-7
M%%147!44#&/!/"VWZCZK6FQO<_*E+,R.F<CM^/"*KJ64R[W558T?MZH6EM4*
M@             ,7?2$?(^0_";EW.G"T)QP*^I2H\^5O<:<(EID(
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M4?ZCE_S;?XX9)X8/6K3^!5?X*'-:L]]]$O<^GGZ7/ITMO'6OSD
M
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MC5TY:U$1J)9$1$V(B)63 C:;@"H
M         !&<YZB9(T\HXZ_.M]I;-3S*K:=*E_XV54PQYN)J.>_#';NM7#J@
M5U/Q;\/-,_FY,YL<[#'&.@N4K=O[Z.E<@3@^?2^X=O3+^K+K\$!@E.F&MN1=
M7ZV^TN1YJFKI\OI2=]5L\#J>&5:WGMSFDDPD7#F';V^QO*F&(,%C!
M       #%WTA'R/D/PFY=SIPM"<<"OJ4J//E;W&G"):9"
M                    'GOJWZZ[_P"=6?ZV&KN>7+RO67SM?I/0@VCU0
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MO3XCJ7KCD?7M^VLZ*1DT;)HUWHY&H]B\F+7)BB[3/B<7'54S3.$[</V2J
M
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M'U9H:ZXY(K9*VEMTK:>J?+!+3*V1[=]$1)6M5=GL!";@
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M6[77?=7DA8[\1$O\)R+(J?O6^R:#6M_"(MQW9>P?_/=4<*NK.5QL4_9H[O\
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M\A%^ AW-.U#\F7_>5=V>^Y19\0
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M6R"JBF6H6HAC8BNFJ9F[NZY^*;J+CAMY0F8:G"
M      &&M.LQ6C2#C U#H,[5++91YGFK745QJ7)'3M=<:J.XP;[W8-:US'*S
M>5<$=@BA;L)QQWVI+KI-8\P42I/%;KQ$KI8UWV=[U=/*S?1S5PP5Z1I^[R^R
M1"]-+<\V?-^F&7\X1UT*TK[;"^YSND8UE/4P1-2I;*N*(Q8WH[>Q^KR!#-?!
M_=8;[K-K'>K*KERW<ZR2MIE1-UFY47"IDIL4ZB\VY^"?5"TMFA4
M    !B[Z0CY'R'X3<NYTX6A..!7U*5'GRM[C3A$M,A
M                 #SWU;]==_\ .K/];#5W/+EY7K+YVOTGH0;1ZH
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MZ(_I-CN3^*IO*V?)M'^0B_ 0[&G:A^9;_O*N[/?<HL^(
M
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MSY-H_P A%^ AV-.U#\RW_>5=V>^Y19\0
M
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MC=A]J6^66MF2GHKE2U-0[%6Q0SQR/5$3%<&M<J[$)QA:F[15.$51,]USR7U
M       (/K/ZGM0?[M7GWA,"&!>"3UZT?FRO_ :%Y>F04    !@/7KUN9G_+
MP^]HCC,_[^K^.P_4'1'])L=R?Q5-O6W,F76VZD:Z[T2.2&-%1:F+%%W$_?'6
MTW*,(V8?G*_D<QQE7_CJVY_XSXG*_67+GEBB\9B[8MQM&F'Q^!S')U_=GQ'Z
MRY<\L47C,7;#C:-,'P.8Y.O[L^)]Z2\VBOEYBAN%-4S8*[FX9HY';J<JX-55
MPVDQ73.U+Y7,M>MQC7153';B8<TNQP
M
M                    (/K/ZGM0?[M7GWA,"&=/H_/V/SCYSI_>ZA:6PPJ_
MCFM?AO-1V"HJ8IC@J<B@?U41>5,?_P
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M]]]#4_\ T#]-C\RGO5-J'5OSR
M
M               !!]9_4]J#_=J\^\)@0SI]'Y^Q^<?.=/[W4+2V&%0
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MWYY
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M?IL?F4]ZIM0ZM^>0
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MSR
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M[F=Y_>'Q]WYN[V#=_FN^MF.&[O;OM!+?' KZE*CSY6]QIPK+3(0
M                            ,"\27?\ \\-^[^QW-VD[SQQW>]^]8\-W
M'J;V]C^^Q-9?\N7F&O.%\97CVL.YA"J#XM&EEA^<WXN9^J_Q[\4[SMSXM[\[
MVW\>NPYGK<<>4O'"[&+.L_$\'_Q\/@]KA8;S[7*\:L6:)D]WK\Q6^"1VY'+5
MS5T#'/P5=U%D5$5<$Y"9FJ-O%:N[FZ(QJFN.[PH:CX4;Q=KSDV]3W>OJ;A/'
M<U9'+5S/G>UG>\2[J+(JJB8KR&9EYF8G%VG1Z[779JFJ9G[79V>Q"_#)=.
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M>K4_>_4"(6/P/Y8J;%HO\:5<:QR9BN=3<(-[%%6FC;'2LV+U%="]R+U47V,
MB6DPAB[Z0CY'R'X3<NYTX6A..!7U*5'GRM[C3A$M,A
M                    K'5O16PZJP05,T[K9F&C8L=+<XV)(BQ*JNYN5BJW
M>8BJJI@Y%:J^VJ+\;EJ*VFUCJNWG(B9G@U1V?&IBS\'EU6X-^/\ ,E.VUM=B
M]*&)[JA[?83G4:UBK[/78>PI\(RT]F7/VNC57"^W7&':V_XW6HLO9?M.5;+1
M9?L=.E-:Z"-(J>)-JX<JN<O5<Y55SG+RJN)F1$1&$.SLV:+-$441A$*)XP/V
M(L7G5/>TIC9GR8<STE]Q3Z7@DX/_ -B+[YU7WM$,MY,G1KW%7I>"&B3*=8
M  "#ZS^I[4'^[5Y]X3 A@7@D]>M'YLK_ ,!H7EZ9!0        S=JUH9J5J1
MG&IOT=RM,5KC8VFM=--/5(^.GCV]<C:9R(YSE<YV"KRX8[#19O(WKUSA8QAV
M-OQ/7.CO2S5NJ\G39FBY-<[-<Q33LU3_ %[41A"#=$O4;RI9/Y^K^"&'S3=T
MT[_B=)^XFKO,N_=H]MIO3&QYHRSDVWY?S;44M7<;:BTT%31R22L?2LPYI'++
M'$J.:G688<C4VXF_RU%=%N*:\,8>.Z^S>5S6<KO9:*J::]F8JB(^U_RVIG8G
M;[LREYE-"                .+<_DVL_(2_@*5JVI?:Q[RGNQWV#=!?6YEC
M\O-[VE..R'OZ?X[#]-=+OTF_W(_%2WX=F_+X
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MGJ*;=YYB1RLE16[[7-Y6(FU ,Y= '3;TFOGUZ3W +8G0!TV])KY]>D]P!B=
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MB+%YU3WM*8N9\F')])?<4^EX).#_ /8B^^=5][1#+>3)T:]Q5Z7@AHDRG6
M   @^L_J>U!_NU>?>$P(8%X)/7K1^;*_\!H7EZ9!0
M          XMS^3:S\A+^ I6K:E]K'O*>['?8-T%];F6/R\WO:4X[(>_I_CL
M/TUTN_2;_<C\5+?AV;\O@
M
M                         9*U)X)/G"SW?<Z_KU\7?'52M5WC\4]\<UO-
M1-WG._8][DY=Q MBBO\ EY?^8_\ 4G_B ,3_ "\O_,?^I/\ Q &*\.'CAX^8
M7]8__P"Q_K!^L'>/_P #WCS/>/?'_P"XGW]_G_WN&[U<=A$RN\(
M     8N^D(^1\A^$W+N=.%H3C@5]2E1Y\K>XTX1+3(0
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M>IX5/\:<,)[E4)"?=J@
M
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M>=4][2F+F?)AR?27W%/I>"3@_P#V(OOG5?>T0RWDR=&O<5>EX(:),IU@
M(/K/ZGM0?[M7GWA,"&!>"3UZT?FRO_ :%Y>F04
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MQLUT&U9;LUU1%6--,SY6B&T#JGY[
M
M                       #%^@<=NMO%SJO1Y@1L>8ZFHNDMD2H^W=!-7=\
M*D2N^Z6!T;DPV[B+ALQ"T[3: 5?B7FN:?SV[S.ZO.;^&[NX;<<=F& &+N">"
M+YQM5JG+Z(F3>?9'1+%_$*WONI6EW?9PBWL/81?;"TMJ!4             !
MB[Z0CY'R'X3<NYTX6A..!7U*5'GRM[C3A$M,A
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M.HB(<G=B(S$Q&UPO"_16K[E=S4]%=<S55-G&9G9F?L]F7H$=H_+8
M
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M?(?A-R[G3A:$XX%?4I4>?*WN-.$2TR$
M            9VXP/V(L7G5/>TIBYGR8<GTE]Q3Z7@DX/_V(OOG5?>T0RWDR
M=&O<5>EX(:),IU@    (/K/ZGM0?[M7GWA,"&!>"3UZT?FRO_ :%Y>F04
M                                    !@/.OKQNO]X5]](<9>^9GTO"
M_4&J_P!$M_D_]6_#LWY?
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M]--2LO::UVI%SKJ[,,=%+#70U]>R*)*^LDI&HYKI<5W5C5RX=0)7/T2=>?\
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ME36S25,NXV*!4;OR.<N"8KLQ!+180
M                                     !B[Z0CY'R'X3<NYTX6A..!7
MU*5'GRM[C3A$M,A                                         &<>,
M&JIDRC8:)9H^_%N7/)3[R<ZL202M5^[CCNHJHF)B9G:AR726J.)HC'9X7@DX
M/JFF7*-^HTF8M6VY<ZZGWDYQ(W01M1ZMQQW55%3$9;:DZ-51Q-<=GA>"&CC+
M=:    "#ZS^I[4'^[5Y]X3 A@7@D]>M'YLK_ ,!H7EZ9!0
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MRJC',:BK]8(A7_ KZE*CSY6]QIP2TR$
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M,X/!V<-O'P0G1]&R   "#ZS^I[4'^[5Y]X3 A@7@D]>M'YLK_P !H7EZ9!0
M                                      & \Z^O&Z_WA7WTAQE[YF?2
M\+]0:K_1+?Y/_5OP[-^7P
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M              Q=](1\CY#\)N7<Z<+0G' KZE*CSY6]QIPB6F0@
M                               'QJZ6"NI9Z*J9SE-4QOAFC7D='(U6
MN39[**%:J8JB8G:EY\ZDZ-YNT]O%13R4,]=85>JT%W@C=)$^)5ZU)%8BHR1$
MV.:[#;R8IM-77;FF7EF>U9=RU<QA,T]B?X[*#5-HNM%2Q5M90U%/1SN<R"HF
MB?''(YF"N1CG(B.5,4QPY#YX2UE5NJF,9B8B6T>$[U73>=:KN<)GY?R7H?1W
MY6?2GP+T,ETH   0?6?U/:@_W:O/O"8$,"\$GKUH_-E?^ T+R],@H
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M-M2\KZK9>=FC*,DTMJ94R4;G5,2P/YV)K'.ZU579@]-H0F
M                                  5MJEKMIOI D$.<+DY+I5,YVFM-
M'&M16/BWE;SBL14:QF**B.>YJ+@N&."A."II^/31N%^Y':\Q5#<,=^.DHT;]
M3\96L7_0#!\NGSH]Y$S+XK0?#P8+&T/X@;/KI6YF98K/4VRW9>2AYN>MDC6:
M=:[OCECBWFLW>8_E'8X]3#:)A<(0              Q=](1\CY#\)N7<Z<+0
MG' KZE*CSY6]QIPB6F0@
M !F'C(^3,I?EZW\"$P\SM0XWI-Y-ONU>!*N$[U73>=:KN<)?+^2S>CORL^E/
M@7H9+I0   @^L_J>U!_NU>?>$P(8%X)/7K1^;*_\!H7EZ9!0
M                           & \Z^O&Z_WA7WTAQE[YF?2\+]0:K_ $2W
M^3_U;\.S?E\
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MRO1$<_=:B)BJ-3:$.X
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M8@3# G!A<*"W:YVY]PJH:1D]#64\#IY&Q(^:1B;D;5<J8N=AL:FU0M+T["@
M                                      ,!YU]>-U_O"OOI#C+WS,^E
MX7Z@U7^B6_R?^K?AV;\O@                          %5$3%=B(
M
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M' KZE*CSY6]QIPB6F0@
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M8[<;$N0Z6:HYOSU44QA;N?:I^G;C^F=[!9AGN/
M
M   *;U!RKH;KU65.2<P7"FJ,VV&5\",I*AM->:-^".>C&R(JO8J88XL?'U>4
M)3BQ:=Y<LVGE'IG/#\9Y:IK>EJFBJT:JU$&[NN63<1J;SL<55N&W:@0R]>?H
M^['4WEU18LZU%OL3W[R4-30MJZB-N..ZV=L\*+["*L>SJ[P6Q:6TKTKRMI#E
M:+*V5HGK$KUGKJZ=4=4U52Y$19)%1$3D1&M:U$1$3ZJJ53<
M #%WTA'R/D/PFY=SIPM"<<"OJ4J//E;W&G"):9"
M                     &8>,CY,RE^7K?P(3#S.U#C>DWDV^[5X$JX3O5=-
MYUJNYPE\OY+-Z._*SZ4^!>ADNE   #QJU&R/==.,ZWC)UXB?'46VH?'#(]-D
MU,JXPS-7!$5LC,')]D+HN$M#:"\*5XUJRY6YIK+X[+-HBJ$IK9*^@6M[\<Q%
MYYS<9Z?!D:[K-Y-Y'.WDV*U0B96Q_EY?^8_]2?\ B 1B?Y>7_F/_ %)_X@#$
M_P O+_S'_J3_ ,0!B?Y>7_F/_4G_ (@#%E'53(GS9Z@7O(O?_P :?$\L<7?_
M #/>W.\Y"R;'FN<EW<-_#[=0EZ_V7Y'M_@T/<VA1S@
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MN[.U5L./Z8ZH^/R,S3'_ )+7VJ?^T?3&_$-VG8/S2
M
M      94UDX,Z;/N9KEGK*>9I;5F6XS=]S4M<SG:19T1$18Y(4;)$F*(N.[(
M$Q*LF9EXQN'SK+[239MRE3+MFJ$=>:5(DY7)4Q*E3"B(F#>>5K4^]"=A:FGW
M'+IKF/FJ/.M)4Y3N3L&NG<BUMO5W)_&Q-21N*_?18)]\$8-(V',>7\T6]EUR
MW=*6[VV3[6JH9HZB+'V-Z-51%3JHNT(=F              !B[Z0CY'R'X3<
MNYTX6A..!7U*5'GRM[C3A$M,A
M       #,/&1\F92_+UOX$)AYG:AQO2;R;?=J\"5<)WJNF\ZU7<X2^7\EF]'
M?E9]*? O0R72@  !7VIVBFG>KM-#%G*U\]6TK591W2F>M/6PM<N*HV1OVS?W
MLB.;U<,0G%5%BX&-%[1<65U=/>;W#&[>;05]5"VG<B88(_O6"!Z[?WZ)[0,6
MCK;;;?9Z"FM5II8J*VT<;8:6DIV-CBBC8F"-:UJ(B(@0Y0    \H^*CU_P"=
MO":?WG %X>IUE^1[?X-#W-H4<X                               C^9
M,CY3S>^GDS-:H;F^D1S:99]Y4C2145VZB*B)CNIC]0^-RQ1<\J,6TR.M<WDH
MF+%R:.%MX=G!T7S*Z5>BM%V+NV/C\%9\V&RZT:TY>MV^7M/,E94K7W'+EEI[
M=721K ^:!'(Y8G*CE:N*KLQ:BGTMY>W;G&F,)8.=UUG<Y1P+]RJNG''"=*3&
M0TX                        <>NHJ6Y451;ZZ-)J*JC?!40JJHCXI$5KF
MK@J+@J+@I6JF*HPG:?6U=JM5Q71.%5,XQ.B80KYE=*O16B[%W;&+\%9\V'0]
M:-:<O6?,KI5Z*T78N[8?!6?-@ZT:TY>M.XV-C8V-FQC$1K4555<$3!-J[3,<
MU,XSC+]!
M                                #Y5-5345/)5UDS*>EA:KYIYG)'&Q
MJ<JN<Y41$^J!1>?.+[1?)7.T])=7YGNC,42ELC6U$6\FQ,:ESFPX8\JL>Y?:
M"<&2,ZYJS/Q.762'3_2&AIZA7ISMYHH7OKD?CL6HKFK34Z(J=29B^TH6VFH>
M$S0G-^C%OS)4YQGH^_<Q=X+%0T<CIG4Z4/?.*2O5K6JYW/\ (Q7)LY0K,M'A
M              #%WTA'R/D/PFY=SIPM"<<"OJ4J//E;W&G"):9"
M                                  &8>,CY,RE^7K?P(3#S.U#C>DWD
MV^[5X$JX3O5=-YUJNYPE\OY+-Z._*SZ4^!>ADNE           !Y1\5'K_SM
MX33^\X O#U.LOR/;_!H>YM"CG
M
M                                                       &+=2^
M'#6[6;4Z_5-XOZVK3N.M7XF;7U4E4QM.UK6[U-11.W4VX_;K&J\N(6Q69D#@
MTT=R;S55>*27-EV9@JS7946E1W[VECPC5%]B7G C%?\ 14-%;:6*AMU-%244
M";L--3L;%$QO+@UC$1$3ZB!#[@               ,7?2$?(^0_";EW.G"T)
MQP*^I2H\^5O<:<(EID(
M 9AXR/DS*7Y>M_ A,/,[4.-Z3>3;[M7@2KA.]5TWG6J[G"7R_DLWH[\K/I3X
M%Z&2Z4           'E'Q4>O_.WA-/[S@"\/4ZR_(]O\&A[FT*.<
M
M
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M#)=*           #RCXJ/7_G;PFG]YP!>'J=9?D>W^#0]S:%'.
M
M
M                    ,;:D<2FL^C6I=]I,P99^-].7UJ_$L]53R42K3JU%
M1E/6Q,6-VW>_C&/=]0+8+-T_XP-&\\<U2UUR?E:\28-6DO2)#"KMB=;5-5T.
M&*[-]S%]H(P7O35-/601U5),RHI9FH^&>)R/C>QVU'-<U5147V4"'U
M          8N^D(^1\A^$W+N=.%H3C@5]2E1Y\K>XTX1+3(0
M                              S#QD?)F4OR];^!"8>9VH<;TF\FWW:O
M E7"=ZKIO.M5W.$OE_)9O1WY6?2GP+T,ETH           /*/BH]?^=O":?W
MG %X>IUE^1[?X-#W-H4<X
M
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MO6_@0F'F=J'&])O)M]VKP)5PG>JZ;SK5=SA+Y?R6;T=^5GTI\"]#)=*
M      #RCXJ/7_G;PFG]YP!>'J=9?D>W^#0]S:%'.
M
M
M           ,I:S<9]+I_F2Z9(RMEJ2YYAM<RTM367"1(:-LVZB_BXX5=)*F
MW#:Z,)B%6LM?&3Q![:^>HRQE6IQ16S*ZQT*QNQV<U&BU,[5PV;S9$]L)V%H:
M?\">G]BYJLSY<JG-%<W!5HX<:"@1>7!4C<LS\/9YUJ>RT(Q:7RWE/+&3[>EK
MRK9Z.S6],,:>A@9 URI]T[<1%<[]\[%0AW               &+OI"/D?(?A
M-R[G3A:$XX%?4I4>?*WN-.$2TR$
M        ?Q51J*YRX-3:JKR(@&(^)#5BQ:@W*@LF7HW34%AEJ-ZZ*[".HDE1
MC5YIF&.XW<V/5>NZB8;5U]ZY%4X0\YUYK&C,U111M48[.GN)7POZL6"S4S-.
M+NQU+65]:^>W5ZN18)9IVL8D+DP16.56=8NU'*N&Q<,;V+D1]F6;J#6-NB.(
MJV)F=B? UD9KN0           >4?%1Z_\[>$T_O. +P]3K+\CV_P:'N;0HYP
M
M
M                             !AO2S-=?<.,K-]G@M]K90U%UNK:F:KH
MXIJYB6MKX4=35+L)6.D=$USF[ZMPQ5&A;L-R!4                 ,7?2$
M?(^0_";EW.G"T)QP*^I2H\^5O<:<(EID(
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M7_G;PFG]YP!>'J=9?D>W^#0]S:%'.
M
M                                                           /
M-/B.U"MMEUVN5\R/9Y\L9_R[7[D^8*:M;+!6/CB1O.NHWTR(Q[FKN/\ QKFO
M;CO-7%5"\)!:./G4JE@;%>,O6>XRM3#GXDJ*5[E]ER)+(W'^"B!&#L?\P/./
MH=;/&*C[ ,%_<-'$#>-=?UH^-K/36GX@[PYGO6223G._N^=[>W^3=YA,,/9"
M)A?H0              Q=](1\CY#\)N7<Z<+0G' KZE*CSY6]QIPB6F0@
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M$T_O. +P]3K+\CV_P:'N;0HYP
M
M                                                      !6&8.(
MG1C*MZK<O7_-E/17FWR+#64CX*ISHY$1%P560N:O+U%"<'6]*C0#TVIO%ZSW
M &!TJ- /3:F\7K/< 8)AD3533_4SO_\ 46]Q7CXKYGO_ )J.:/FN^><YK'GF
M,QWN:?R>P$)B              !B[Z0CY'R'X3<NYTX6A..!7U*5'GRM[C3A
M$M,A                                              8"XD/71F;_
M ''^SZ8UE[RY>7:\^<K_ *?PPW1EC]FK-X#3=Q:;&G:AZ58]W3W([SM2S[@
M      'E'Q4>O_.WA-/[S@"\/4ZR_(]O\&A[FT*.<
M
M
M           4'G+A!THSUFBZ9NO4UW;=;O,M35-IZJ*.)'JB)UK5@<J)L]D)
MQ=%T%=%/TB^>.P_!P8H9J%P&9;;8ZRNTVO5P;?H&.EI[;=7PST]0K$QYILD<
M4+HW.^Y<[?3'8N";4)Q27@BJ<AU64[\[+UH=9,YP2TM+FVE6>>:.58.?[VFC
M9.]ZQH[?E:YOWS5ZFZ$2U.$              ,7?2$?(^0_";EW.G"T)QP*^
MI2H\^5O<:<(EID(
M# 7$AZZ,S?[C_9],:R]Y<O+M>?.5_P!/X8;HRQ^S5F\!INXM-C3M0]*L>[I[
MD=YVI9]P       #RCXJ/7_G;PFG]YP!>'J=9?D>W^#0]S:%'.
M
M
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M?[C_ &?3&LO>7+R[7GSE?]/X8;HRQ^S5F\!INXM-C3M0]*L>[I[D=YVI9]P
M      #RCXJ/7_G;PFG]YP!>'J=9?D>W^#0]S:%'.
M
M
M           ,JZB\%-KU!SO>\Z39QJ*"6]5*U3J-E"R5L:N1$W4>L[<>3V G
M%&/\O>S^GE3_ $;'\("<7*H/H^\K1U#77/.EPJ:1%3?BIJ2&FD5,=N#WOF1-
MG[Q08M09 T_RMIEEJGRIE"C[SM4#G2NWG+)+-._#?EE>[:Y[L$Q7D1$1$1$1
M$"J3@              8N^D(^1\A^$W+N=.%H3C@5]2E1Y\K>XTX1+3(0
M                                          & N)#UT9F_W'^SZ8UE
M[RY>7:\^<K_I_##=&6/V:LW@--W%IL:=J'I5CW=/<CO.U+/N        >4?%
M1Z_\[>$T_O. +P]3K+\CV_P:'N;0HYP
M
M                                                           #
M'FN?&/<<O9GJ<@Z36^&XWBCG6BK;O41OJ&+5M=NNAI8(U3?<UW6*]V**N*(U
M=C@M$-":)WS.69-+\OWK4"EGHLWU3*CXRIZJF[RF18ZJ6.-SH%8S<WHVL<G6
M\BXA$LM:]\3.H-^S_+I-HH^6)]/4_%TU?;V)-7UM:W%)(X'8*D<<:XHKFX.Q
M:KMY&A,0B-PO7&7H7!#G+-%5<*VP;[%K67*JBO=&U9';(Y]R65\**YR-1S',
M3'!K7<B V&T]&]5K-K'D>DS?:8UI9U>ZENEN<Y'OI:V)$5\:N3#>:J.:]CNJ
MUR8HBXHA$I^$              ,7?2$?(^0_";EW.G"T)QP*^I2H\^5O<:<(
MEID(                                             # 7$AZZ,S?[
MC_9],:R]Y<O+M>?.5_T_AANC+'[-6;P&F[BTV-.U#TJQ[NGN1WG:EGW
M   /*/BH]?\ G;PFG]YP!>'J=9?D>W^#0]S:%'.
M
M
M       BNIF8)\IZ=9KS+2KNUEIM%=64J_\ Y\-.]T7L_=HT#*7 1DBV55%F
M;4FX0)57EM8EHH*J9-]T*-B;/4.8J_=R<[&CG<N"8?=+B6EJW4S-*9(T]S-F
MS>1LMIMM34TV.&"U#8U2%NW[Z16M"K&_ 1DUMRS)FG4.X,YZ6W0QVZAGEZ]>
M^*U5EG>BKBN^C&-:JXXX2+[(6EN*^66W9CLMPL%WA2HM=SIY:.LA=@J.BG8K
M')MQVX+L"K%/ -6UE#F3/N6%EYRA9%35&'(B34\TL.\B=3>1VWZB!:6Y@J
M            Q=](1\CY#\)N7<Z<+0G' KZE*CSY6]QIPB6F0@
M                                   //SB&K*2NUBS+4T4\=33JZC8D
ML+VR,WXJ&"-[=YJJF+7-5KDZBI@:R]/VY>6:ZJBK.5S$XQL?AANC)U925V5+
M)4T,\=33.HJ=&S0O;(Q5;&UJHCFJJ;%3!38TSL0]*RU456J9B<8PAW99D@
M     'E'Q4>O_.WA-/[S@"\/4ZR_(]O\&A[FT*.<
M
M
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M_P [>$T_O. +P]3K+\CV_P &A[FT*.<
M
M
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MX6A..!7U*5'GRM[C3A$M,A
M       KG6S3F74O),UGH7MCO-'*VNM;I%W6.FC:YJQN7J(]KG-QZBX+U#Y7
M:.%3@U.M<E.:L<&/*C9AA*Z9(SC9;@MJNEBKJ:X(Y6-A=3R*KU39BQ6HJ/3V
M%8JHIK9IF.P\SN92];JX-5,Q/<7OHKPW27F*HOFIENFI;=+&C+;:GO?35+G*
MJ*LTB,5KF(B)NM:[:N*JJ(B)CDVK&.S4Z;5>H^'$UWXF([$;4]U;O1DT?\D3
M^.U/NA]^(H;[F')^;.[+H<\<.^E=DR5F2\VZUS1W"W6NNK*21:NH>C9J>G?(
MQ5:YZHN#FIL4K79IB)EBYO4N5MV:ZJ:9QIIJF-F>Q"E.%GULTW@-7^"ACV/*
M<[T?^;CN2W0;%Z4   '%N5RMUGH*BZ7:KAH;;2,66JJZE[8H8HV\KGO<J(B)
M[8'DOQ!YFL><-9,V9CRW6-K[)75,2TE8QKV-D2*GBB<J)(UKL-YBICAMY4V!
M>'J%IKGO*&?\K45TR?=H+K20Q105/,JK9896L1%9+$]&OC=LV(]J8IM38%$P
M                       1//NIF1=,;8RZYXO,-JIIE5M-&_>EJ)W-PQ2*
M&)'R/PQ3>5K<&X[< *LLO&9H3>+@VWR7>JMG..W(ZJX4<D=.JKAAB^/G-U%Q
MY7HU$PVX($X+YI:JEKJ:&MH9XZFCJ&-EIZB%[9(I(WIO-<QS55'-5%Q14"'V
M
M
M                       ,7?2$?(^0_";EW.G"T)QP*^I2H\^5O<:<(EID
M(                                                 174[U;9R\Q
MW/WI*4K\F>XPL_\ +7/0J[TL@\+/K9IO :O\%#!L>4X+H_\ -QW);H-B]*
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MDYJHB:JXX,5SHWM:FQ%5R]4*RVH%0
M
M                                                  !B[Z0CY'R'
MX3<NYTX6A..!7U*5'GRM[C3A$M,A
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M^E;?8HZ&R0RHK'R4D;^<EGP7[E[T8C/9W57D5 K+8H5
M
M
M     &+OI"/D?(?A-R[G3A:$XX%?4I4>?*WN-.$2TR$
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M:UK&M8QJ-8U$1K43!$1.1$0(?T
M
M                                                 Q=](1\CY#\)
MN7<Z<+0G' KZE*CSY6]QIPB6F0@
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M/E1[TI#(R_D_2Z#HW\M5Z<]ZE?YDNH
M
M
M            ,7?2$?(^0_";EW.G"T)QP*^I2H\^5O<:<(EID(
M                                       ?*HIJ>K@DIJN)D]-*F[+#
M*U'L<U>HYKD5%0(JIBJ,)V8=3:\FY0L=2M;9<OVVVUCMBU%'1P4\JHO[Z-C5
MZI6*8C:ACV\K9MSC3133/:B(=V69(           ,[<8'[$6+SJGO:4Q<SY,
M.3Z2^XI]+P2Y7"'ZMKKY\J/>E(3E_)^E].C?RU7ISWJ5_F2Z@
M
M
M                          ,'ZZ<86=9\WUF2-'WLHZ&BJ5M_QO%"RLK:
MZJ:[FW)3M>U[&L5^+&;K'.?]LBIC@%HA"Z+B?XDM+LQTT.HK:JJ@>C)I[)?J
M!E#)+3N7!712-ABD:NQ41R;S4=RM7# )P>@F1\XV;4#*=ISC8'J^U7:!)X4?
MAOQNQ5KXWHBJB/C>CF.P7E0*) !B[Z0CY'R'X3<NYTX6A..!7U*5'GRM[C3A
M$M,A
M        !G;C _8BQ>=4][2F+F?)AR?27W%/I>"7*X0_5M=?/E1[TI"<OY/T
MOIT;^6J].>]2O\R74
M
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MJZ[U50VEJ7.1ZQ210(UVQJ[%5J@F%^=)/0KTZMG9O[0(P.DGH5Z=6SLW]H#
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M@,#I)Z%>G5L[-_: P.DGH5Z=6SLW]H# Z2>A7IU;.S?V@,#I)Z%>G5L[-_:
MP.DGH5Z=6SLW]H# Z2>A7IU;.S?V@,#I)Z%>G5L[-_: P.DGH5Z=6SLW]H#
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M,EII+[8JME=:*YB2TE7$JK')&JX;S<<-FP(=@
M
M              "O->8WRZ+9^;&U7.2Q7!RHFWK60.<Y?W$3$)AAS@6<UNMD
MR.<B*^R5J-15PQ7G:=<$_<15"TM#\>%0V'1BWQN156HS!1Q-5.HJ4M7)BO[C
M%"L(E]'S3R-R]GBJ5/Q,M90Q,7]]'%,YW^A[0F7RUWX1=2=4-5K_ )YL%TL=
M-:;KWGWO#75%7'4M[VHH*9V^V*DE:F+HG*F#UV8?4!$LUZQ\/>=-$::TU6:Z
MZUUD=Y?/%2I:Y:B5S74R,<[?Y^G@P1=],,,0F)=KI/PN:@:Q97?FW+-RL]);
MF54M"L5RGJHI^=A:QSEPAI9F[N#TPZ[]P&*== ;6'RWEKQJO^ !&)T!M8?+>
M6O&J_P"  Q.@-K#Y;RUXU7_  8G0&UA\MY:\:K_@ ,3H#:P^6\M>-5_P &)T
M!M8?+>6O&J_X #$Z VL/EO+7C5?\ !B= ;6'RWEKQJO^  Q.@-K#Y;RUXU7_
M   &)T!M8?+>6O&J_P"  Q.@-K#Y;RUXU7_  8G0&UA\MY:\:K_@ ,3H#:P^
M6\M>-5_P &)T!M8?+>6O&J_X #$Z VL/EO+7C5?\ !B= ;6'RWEKQJO^  Q.
M@-K#Y;RUXU7_   &)T!M8?+>6O&J_P"  Q.@-K#Y;RUXU7_  8G0&UA\MY:\
M:K_@ ,3H#:P^6\M>-5_P &)T!M8?+>6O&J_X #$Z VL/EO+7C5?\ !B= ;6'
MRWEKQJO^  Q.@-K#Y;RUXU7_   &)T!M8?+>6O&J_P"  Q.@-K#Y;RUXU7_
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MRWEKQJO^  Q.@-K#Y;RUXU7_   &)T!M8?+>6O&J_P"  Q.@-K#Y;RUXU7_
M 8G0&UA\MY:\:K_@ ,3H#:P^6\M>-5_P &)T!M8?+>6O&J_X #$Z VL/EO+7
MC5?\ !B= ;6'RWEKQJO^  Q.@-K#Y;RUXU7_   &)T!M8?+>6O&J_P"  Q.@
M-K#Y;RUXU7_  8G0&UA\MY:\:K_@ ,3H#:P^6\M>-5_P &*EM7=(LR:+YDI<
MK9IJJ&KN%70QW..2V232PI#+--"C7+-#"[>WH78INX88;0EZ5\-GJ*R+YL9^
M&\*RM0(
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M<%VX!$M%A
M         <*[M<^TU[&-5SW4\R-:B8JJJQ<$1 /-WA3R+G>S:^92N5WRU=;?
M;H/C'GJNKH:B"%F_;*IC=Y\C$:F+E1J8KRJ%Y>EX4 (1G32+3_/\R5F8[0R6
MY(W<2O@>^GJ%1$P1'/C5-_!.3?1<#YU6Z:MMK<UJW+YF<:Z=G3M2_>2M)\A:
M?R/J,LVED%?(W<?7S.?45*M7E1'R*Y6HN&U&8(HIMTT[2<KJZQEMFW3LZ=N4
MT/HV(
M# ?'#D_-N8-6+-6V&P7&ZT<>7::%]10T<]3$V5M=6N5BNB8Y$<B.:N'MH%H:
MPX>J&NMFBN2Z"Y4TM'74]N8R>EJ(W12QNWW;',>B*B_50(E9@0
M
M                            K?4[0G375Q(YLX6K?NL#.:I[O22+35K(
M\55&[[=CVHJK@V1KD3%<$"<4/R?P@:)Y/NT-ZCME3>:RF<DE*V[U'?$$<C5Q
M1W-,9&QZI_\ F-<GM Q7P$
M
M
M
M                !2>I7%5I)IA>)LO76KJKM?:5=VLH;/"RH= _[R2262*-
M'^RQ'JY.JB!.#N]+.(+3/5^:6ARI<9([U"SGI+/<(^]JOFD7!7M3%S'HGW7-
MO=N]7#$&"T0@
M          5?JAQ!:8:1S,H<UW-S[U(U)&6>@C[YK$C=R.>U%:V-%ZG./;CU
M,0G!'=.N++2'4F\T^7K?55EGO58[FZ*DO,#*?GY%541C)(I)H]Y?N6N>BNY$
MQ78#!>+G-8USWN1K&HJN<JX(B)RJJA#/&9^-31/+=WDM,,]QOBPR<U+6VFFC
MEI$<BX.5))IH=]J??1HY%^YQ"<%JZ<:JY&U7M,EWR3<VUL5.YK*RF>UT-53O
M<F*-EB>B*F."[KDQ:[!<%7!0A,P
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M
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MRI>^W276MRK6J[9WQ$LKXJ=ZHFQ%65D3_K^R$SM/2\*
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MR\YIT_FE5]#-2LO='"['=CE@D933JWJ=>DL6/\!/;!+=H5
M
M                        4]Q4(JZ 9VP3'_9:?_160!,*!^CR_P#]'_Y)
M_P#R 3*NN.KUUT_F.B[M4!,/0G)S7,RC8&/:K7MMM&CFJF"HJ0,Q14"CNP
M                                                      *ZU[:Y
MVBN?D:BJOQ'7K@FW8D#E4)AYS</&E5PUFS;59)^-YK3EIM.ETOKX.N=*RE>D
M<+6L7K5?OS]:K]C4WEP54P4M*8ZV:3WGA6SCEC-60<P54D%=SSZ&KE1K:B*H
MI%CYV&;FT1DD<C9&[%:B.3>:J;,5$;*T^+O-D>?.'S3G.447,)>:ZGJY8$Q5
ML4TE#.LD:*O*C7HYJ+U< B%G\$GJ*I/.=?\ AM")9+NC7/XS6(QJN7YP*5<$
M3'8VZ1JJ_N(F(6[#T_"@
M              $7S!:;59,A7ZW6:AI[=01VVM5E+21,@B:KH'JJHQB(F*]4
M##_ #ZR<S>8U]]P!:7H0%6=^)'B;M.D='-EC+;F7#46JBQCBV/@MS)$ZV6H3
M':]47>CBZOVSL&X;Q,0I3A(T,O\ FG-;-;]08YG444SZ^S=^HJSW"X2JK^_'
M;VU6,<N^QWW;\%1<&KB3,HYQ\HOSP61<-GZM4NW_ '^O!#:%E]0UO_NC#_9C
M0AB+@4:YVM54K6JJ,L58KE1,<$Y^F3%?W51 M+TC"@
M
M                   "+ZD94_7G(.9,H-<V.:\VZII*>1_VK)Y(UYISL,=C
M7[JJ!YZ<-NK5/P\9\S'9M0J"LI**OC;172*./?J*6MH7N6-7QJJ;S<'R-7=]
ME%38%Y<'-5?4\4_$5$F7*.>*S7*:FI(E>W\;3VFC1K9JB;=5R-V;[\,>5S6X
MJO*-IZ?QQLBC9%$U&1L1&L8FQ$:U,$1/J!1^@
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M4DDE/"URIAO<Z]'(GWK'!,O20*
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M$D2:J>W'#%J.CB8CDV*Y')RM!+;05
M
M        (!GK1+2O4JJ97YURS37*XL:C._FNFI*IS&_:M=-2OBD<B=1'.5$"
M<78Y&TNT_P!-::6ER/8*:SMG1$J)HD=)42HWD22>9SY7(G41SU0(2X
M                                                     AN>M*-.
MM2XHH\\9>I;N^!%;#4O1\-3&U>5K)X71RM;U=U'X <+(VB&E.FU4ZOR9EBEM
MUQ<BM2N>Z6KJFM=RHR:J?+(U%ZJ-<F(3BGX0JS-'#AHEG*[27R_Y/I9;I,Y9
M)YZ:6IH>=>NU72-I)8FO<O55R*J]4)Q3G*V4<L9)M,=BRE:J:SVF-5<E-21I
M&USU1$5[UY7O5$3%SE5R^R$.Z
M                    !\JJF@K:::CJHTEI:ACH9HG?:NCD16N:OM*B@1+)
M^E&G.0*Z>Y9-R[26:NJ8N]YYZ5KD<^+>1^ZN+EV8M10.?G#(.3L_TE/09RL\
M%YHJ219Z>"I1RL9*K5;O(B*FW!50"'=&S0KT%MG8/[<)Q?:EX=M$:*IAK*7)
M-NBJJ=[9896L?O-DC5'-<G7<J*@,5DU5+35M--1UD+*BDJ&.BGIYFI)')&],
M'-<UR*BHJ+@J*$*D?PLZ R7/XV=DFE2JW^<YML]6VFQQQ_[,V=(</WO-X!.*
MV:*AHK;1P6^W4T5'04S&Q4U+3L;%#%&Q,&M8QB(UK43D1$"'W
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M      /+','$!KNN<+I9K1G"ZR.^,ZBDH:*GP>]R]\.CCCC8UBJJKL:U$VJ%
M\'<R9YXS[<WONI;G*"*-<5DJ+34\VGU><IMWZX-A(M->-O4C+EXAH=3&LS%8
M=](:V1((J2Y4Z(NZKF+$V-CU9MQ9(S%WW[>4(P>@MFO%LS#::*^6:I966FXP
MQU5'51KBR2&5J.:Y/W%Y JYP
M
M
M
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M:G"
M
M
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MM>QJJWDQVX%9AI\(
M
M
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M=WPD7>?3VJBJ$G<DSTV8K&B18X]<YR)U0F7J\%
M
M
M
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MBU$K-Z6HF5.3G)I7/D?AU$<[!.I@$):
M
M
M
M                 R[G+@BR5G'.%XS;/F2Y4;KW6SW&KHX8Z=S6RU4KI9$8
MYS=B*KEPQ10G%<NE>CN1]';//:,FTLC75CVR7"XU;TFK*ET:*C.<>C6I@U%7
M=:UK6IBJX8JN(Q3T(
M
M
M
M
M
;                                !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>tm2227887d1-pht_profnd4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-pht_profnd4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$$8VAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXP+6,P,# @-SDN9&%B86-B8BP@,C R,2\P-"\Q-"TP,#HS.3HT
M-" @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/2)U=6ED.C<Y03(T-#(Y+39!.34M-#9$-2U!1C!%+4%"-3A%
M1$%%-30S,2(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HR1#0R,D-$-S@X
M1$$Q,45$040V0CDT04)&,T,S-$(X02(@>&UP34TZ26YS=&%N8V5)1#TB>&UP
M+FEI9#HR1#0R,D-$-C@X1$$Q,45$040V0CDT04)&,T,S-$(X02(@>&UP.D-R
M96%T;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B R-2XT("A-86-I;G1O<V@I
M(CX@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI
M:60Z-3%C-S X8F4M,61E8RTT838V+3AC93,M83@V-F,V-# P,3@T(B!S=%)E
M9CID;V-U;65N=$E$/2)X;7 N9&ED.C4Q8S<P.&)E+3%D96,M-&$V-BTX8V4S
M+6$X-C9C-C0P,#$X-"(O/B \9&,Z8W)E871O<CX@/')D9CI397$^(#QR9&8Z
M;&D^5')I;6UE<BP@3'EN;CPO<F1F.FQI/B \+W)D9CI397$^(#PO9&,Z8W)E
M871O<CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CY0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CPO<F1F.FQI/B \
M+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D
M9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H
M;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"24T$
M)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  $
M P,# P,$ P,$!@0#! 8'!00$!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-
M#0P,$1$1$1$4%!04%!04%!04 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 6H
M!VX# 1$  A$! Q$!_\0 Y@ !  (" P$!              4&! <" P@!"0$!
M  (# 0$!              4& P0' @$($  ! P,# 04%! ()#@D( !<! @,$
M !$%(1(&,4%1(A,'87$R% B!D2,5H4*QP=%2,R06-QAB<I*RTI-4=)2T5756
M%^&"4[/3-86U./#Q0S34)94V=J)C<X-$I:3$Y$=GA,5(PF2&)Z/#5PD1  $#
M P($! ,&!@ %! $"!P$  @,1! 4A$C%!$P9187$B@3(4\)&AL<'1X4)2(S,5
M\6(T%@=RDE,D@K)#HL+2XD0E%__:  P# 0 "$0,1 #\ ]_41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HBUOR3UMX7Q;,RL'E'G$38:DI= 3<74D*%C[C4I!C99FU
M:H>ZRT%N[;(:*)/U'>G8%Q(=/LV5LG"W Y+3'<5F3\X7%'U)>G*[A,AW<.HV
M@?MUB_U,_@5E_P!]:?UC[U@9#ZI?3?'2(\=U4A9DK\M"D(! )[]=*Q.QLS>(
M*SQY>UD!(>-/-9<KZEO3R*4)*Y#A6=IV(OM/MUK-_J+C33BL SUG4@O&BR6_
MJ)]/WOX)UY1[1Y9!'WUKWV/EM6@O'%;..RMO>N+8W<%]_I#<"*B@.N[T]1L[
MZQMLI3&U]-'+.<A!U71;AN;^J^CZAN ;@A3[B5GH"G_AKP;64?RE:<V9MHG;
M7.%5EJ]=N$H85(6XZEM())*.P5EBL99" !Q4F;AC8C(XT %?N6 ?J-].[?P[
MM_ZRMX82X)I10([DLB?G7-KZA^ O)4IMUU03U(3?]NM*XL9(31REK;(03BK'
M K!=^ISTX:S+6#4N1\X\V76_P_"4C3K>HZ4EF@U4Q:0&Y<X-_E4TSZZ<,>0'
M$J> 4; *18Z5LPV[Y&UX+Y+"6/V\2J?FOJ\]*\'E7<3+>?\ /9L'%;/#<B]J
MQOC+2O!80L$_6AZ1@A*7GE$Z@)3<FW96*JQG0$GDI3)_5CZ98J*S+D_->2\+
MI(;&E^_6L3)0XT4?:9""Y>6L<"0HH?6AZ2%.[SG@>NTIU^ZLZD]JR(7UB>EF
M2<+,$R9#P!/EH;)-A]E>MCO!>7 CBIF5]4'IW"Q'YO*^9:;N 6U-V4"=-:]&
M,A83)0T4$/K,](C\4IU(_K;UCHLJ^*^L[TA20!*=4#VA/2O)7H!3.$^JOTNS
MP<^2DO%;9L4E%B1WCV5O0VCI>!"CY[QD)]RE#]1GIX+CYAVX[-E2 PMP> 44
M>X;0&A<%*8;UMX9G LPG7"&[%1*>_P#\U063_P#H&DJDK;(0W'^,U6-)]>N$
MQ7W&'%O;FS8V17B%[96;FE2.G-3$/U7XO-B)EM+<\M0*@-NMA4;-DHHI#&[Y
M@LK6;A4%5J-]17"9'F[F9;):6INSK6W<4FUQ[*W[:9DPJ"%BF(C%25\<^I'T
M\CJ"93SK)) 3O3:Y/3MKVR1KS0%1L62@DDZ8<-W@N;_U$\&:;0ZA,IYM2P@J
M;:W;;]I]E ]IDV5%5NR2M8*KDKZB_3Q&BGW@KN\LZ5/,Q$K^%% 2]PVL;MKC
M0K%3]3'IRN4J*'7]R1<K+?A^^]?/]1/6E%[.?M-M=X7?_2.].O\ "'?[#_AK
M[_IY_!8_^XK/^L(KZC_3L))#SRB.P(_;H<-< 5HOK>X[(NIO"Z6/J5].W5*2
MMQ]&W_ZF57^Z]>H\+</X!)^XK*+7?7TU_)8^4^J'TYQC:'/XU(WD )9:)5<^
MPD5K7&-E@^9;-EFK:[-(W:^'-9&/^I'@\YOS2U*83U2'&[$_94:QI<IJ0AJR
ME?4-P) W../)3WE%;=O9OF=M;Q6A=7\5NS<\T"X?TC?3K_"'?["I+_1W'@HC
M_N6R_J7T?49Z>J'@?=4;VMM_X:UI<9+'\P6W#FK>;Y7 KFKZAN H%UN/) ZD
MHK!'8R/- %M39&&)NYS@L.3]2_IY&4VD+?<+AL-B1I[]:V'XJ=O):L><LW_S
MC[UE_P!(?@ 1YBWG4ITZI[ZUV6$SG4VE9Y,I;L87EXH%CN_4KZ;LK;0J0Z2X
M=J;(OK]];;L1.WB%IC/6A%0\+O3]1/ '/X-UU0]B/^&L4N-EC;N<MB#+V\WR
M.JN ^H_TZ*UH$ES<@V4"CM^^LC<1,YNX<%ADSEK&[:YP!78?J(X " IYP$FR
M04V)/WUJ1V;GNVCBM[Z^/9NY+I:^H_@+[Y8:,A5@;K\O2X[*7-F^!P:_FEGD
M(;H$QFM#1=KGU#\&0XA%I*M^A*6R0/?6M$P/=MJ MB2<,%2%\1]17I\XXEI+
MSI<4K8$[.TFU;5Y8R6T1E?\ *%IV>5M[F<0,<-Y63R3U[X1QC'JR,]3RF4VW
M!"+FQJ$@NA*: *PS6QB%25%8SZG?3;*1&YC+LAMMP72EQNRK??5FBQ$\@JT*
MISYZTA=M<X57-SZF?3=M]+!=D760E*RV0BZO;6M=6$L ]P6W992WN_D<K<QZ
MI\7D,!]#JB@B^@OI5<EOV1NVNXJ8#:BJK;WU%^G;+[L<R7"ME90Y9/0BK#96
M,MTS>P:* N,U:P/+'N%5Q'U'>G*OADNGW(-JW_\ 27'@M/\ [ELZT+D_I'>G
M(T,ET'_ZV;??0X2XI6B^'N:RW ;N*^#ZC_3J]OF'?>$7_;H<)< 5HLI[ALQ_
M.%)XSUPX5E(3TYAY:6&20LJ &B>WK4!>5MI-CQJIBUO(K@58X$+#'U!<$-R'
M'K=A".M>7[F@&G%;\8:\D \%Q_I"\%O;>]?^LK>%J\BM%'_61;BVNH7!7U&>
MGB-%OO)4-"/+J19AIWMW :*)E[@M(Y"QSM0L6/\ 4UZ;R<A(QK3SRI,9*5.#
M9I9?3MJ/FMC$:..JF(;J.1NX%99^HKT]3;>^Z+FWP7U^^MB'&RRBK=5&W.;M
MH#1[J+J'U'^GA*AYSHMWHZ_IK-_I[CP6$=PV1_G"QV?J:]/7WRP#(1;]9;=@
M?TUB.,G'(K*W.V;N#PKQPSU'X]SIR2UA5.*5%"5.;T[195[6^ZHV1A8[:>*F
MHY&R-#F\"KA7A9$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1%7>3\TPW$EQ$99:DJF**6=HN+IZWK5N+EL JY9X83(:!5;(>N'#,<X
MEI];NY8N+([*^6UTR?Y5DFM7Q<5&P?J,]/I^9.#:=>3+#0>2I3=D$'LW=+U]
MNKEEN 7%?(+=TIH.*GE^K_$6FE/NO*0R@$K61H+5&MS,!=M'%2#\1,T5*@&_
MJ,X&M*EDOH0%%"24?%8]14T"2W< HAS0TT)75)^I#A$=>Q+4EP6ON2C2O3&N
M<*T7@N8.:X1OJ7]/7UEM:I##@ 44.(L;&I&WQ\LS26C@HJZREO;FCW +-:^H
M;T]?.UN2X3W%-C^S6A=--O\ .M)G<%HXT#A5<GOJ#X"QJZ\ZD=^S_AKW91FZ
M-&+++FK>,5<=%T_TC?3KLD/6[_+M4R,'<'DM0=RV1_F77 ^H_@60><;9+X0V
MK9YBD:$^S[ZA[B%\)(<%8;&>.[UC-5-S/6CB$*,)3JW/+4+ILGK4-%D(Y)-@
MXJ9FQ[XF[G<%%CZAN A00X\ZA9Z I_X:G)(',9OY*J7&8MH'[7N *[O]_O!;
MV#KI/L146VZ::^2\C,VYX%?%^OW!T_KO?V%>HYQ)\HJMR.]C?P*ZE_4)P9)2
M 7B3_45N%M!4K=#@>"XN_43P%E3:7G'4%U00BZ>I-8Q4M+J:!:\]S'"W<XKC
M-^H[T]A17):WG5MMZK"$7('?UKS;N,YHT%:%MF+6<T:\?>L1?U0>F*([$M4E
MT17S8.E%@#[:\.F:'%O,+>CNX7NVAPJL+%_5?Z8YK.-X''.2'ICKGE((;T)
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M@N0V]U>Z!8U,8&#$FS$HED)CI!*[]";@ 52.XLXZT/2C'N*M?:UE#=7E)_D
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MP=M@FRP.\U^4^Z[:6&X+I*_:J_8O;63M'V8Z=/P\ NO,0,5B8#Y<8;;192@
M-2I5R2/MK9[8N[N>=K6UVU'ZK%GS9-LI)'TKM)6HW7&TDJ";H)) '9<FPK]/
M6S=K&@\:+\C34DD<YORU/\$)\RQ"2D#45LENJUAHN<=;*%++UM]_"3W5#7<4
MF[VJPXN6W8"9!KR72E+*LHC(K!1M1Y02#X/>14)?X)LK=Q))6=F1BEF'4: W
M[<5$\IX;AY&*G3HRE196Q;WF(60DK2F_BUUJFRM8RL9&K5V#&R=*&,,/L T6
M?Q=E['\4A,QG27/E@H. W*EN)W56FR.9)J:!=XM+9OT]7"M17\%JW#CE*^0*
M>:<?9?6^&I4A0)(3<C6_LJ7,K'-&M5P+N5\43O[Q (.BV[RCF+7#8+$F+$3(
MER0&W7>A-D]2?LJ5MK]H;M 6KB<G%*[:Q:JXKE6U3I^5GXQ4YIQ:G%K""M*"
MHW(MK6A)&]YJU,W9W%P]AC( !'&JN> GJS,?\J9A.Q67$**%H"D)V7Z)-A8U
MJ/MY&NW45$R.#NH)3<-(+JUT4_'^4QS43#S'"4K.QCYBZUJ4-;$JK7DDED.O
M)1S+J\R#Q&_2GD>2[,-Q]O'LSFELM+3)<6M-D@"RNRLK@YHX:JQSV%S;MZA-
M2M;\J].)+;V_ -&0BRBZ%$J*5=W47KW!=M!_N:+;P^><YQCE-:<UKMV*]&<4
MS*1Y;R;A2-001V$$FI&K'&K>"OD<K9&U:N#+$J2HM1$%11JJR37TAS14<%E+
MF-'N65%D+Q\V,[(0KRFW4*<1V*"5"X/W5X+R1H5KN8V=C@RAT*]&\>R,.=C6
MGHCJ2FP*T=J">RU:4%GU'[G E<XQ>),!_O\ BI9UT6N3H/;4FRS>#1@HK)=-
M@8RL9H5$2Y)*U.J-RCX0GN'=7EV#N:$#4+D%_/-).=SOQ7V)EG'EI0MI0:2"
M=RS<DFM-N-N+9I<!^"E[7,/MF[02?4U7)S(/A:5J^#H4 : 58<+CX[EAZ@-5
M@@S4O7$C^'@N]QZ%)0#(V+"=0%6-B*R.Q,DLM*:+I,'<$(CXA8LF:I\EMLV:
M[2/VJM>.Q3;<UIJJ'E\X^9Y;&=%'JCMN)V.#<GLOV58"T'BJJ'D:A=H2A";7
MT&@I0+P225V(?4TDE*RD'KV:5#SXR":;JO%7+TUSV_*2/1=+;@D6V@J6LZ;=
M2:E&AD;>0"]EKR[F2I&3A,I$C"9(CK;8) NKKKTTK1BR4$LW28X%RWIL;/%%
MU7MHU0,=B6U-D.&WRZ[;$COK;C%'$G@M>1['1M',+,4IQ"T)VJ-QH>P5JBZ@
M;)2M"L)<7#4\%VJ0YMO<:]G;4EQ"P@BJ[$ON^3Y)MLMMZ:U'?Z^/J;]:^JES
ME9NCTA3;2G!8ZT)=;4RKX3H3VU(;=*%1;7%IW!169QD=W&*9\OS-MB =3H:T
M;BU86\%(VEV]LP?752$1"(\5M#:=J D#8!:U;4+ UM M2XD=+(7..JFWN+Y"
M% &:>8VLK'6^MJ@;7/6UQ<&%M=P_X*4EQ%TR'J$#:N&&D+;D*?;-EIVE![;B
M]:/<T E8&'G56+L\ADSO'3]5D<OS;O)?EHDQ(VPU;T*'7<*C.W^VH+4]1NZI
MUX^*SY_N"5SG0M IP)HH@&P".S[ZZ(5SD^*[V9#S2/+;(VW_ %A=7Z*J&7DM
MH)6F1KC7P4[:9NYMHBQA%%A9>*SDV0UDA\PRV2M*%]$GO'=6[';VEW%O:S;3
MX+PW,W3G5<ZODH3@V5>6_E8L@J=QT9P)ANK\1"?WOMJ#-M/._8PZ>:O\5[;P
M0[WZ&GQ5HDY-"WDPV#9Q2=Q/L-2]GC7,/NI55[,95[F48="L!4E+;Z(ZK@KT
M2;:7JR!U-.:IHC);N78XH-)*B#?N%?318VC<L:1 ASG6)+R27&#N;-AUK!(Q
MCR*C@MF*YDA#FMX.T*D8RFTO(+W\"D_I[+UXO>ITCT^*W,2^W9=-,_RKMD2(
MZ)#;\50*T&Y4BVTCN]]06/;=/J)^"G\M=VL5TR2V'"E?#_BN>7S4;+1S'B)5
M\VR-'"+)!]MZD8H9(W4:0MO,96TNHV[@XE0/Y89D9M&5 4XVL+24: $5N/MN
MH/[BI?U'3<3%P*DXT#SU!:24M#0J/;;NK3O+]D#=JE<9BY+LU.C5(MSX32U1
M?-27&4C<C6]NGVU17VDMZ\EOP73F7-MC(6MD/ 44=.D1C+#O0J2&TJ4+%1N>
ME77&6[[>+;)Q7-<W>LOIMT(]H'AZK@TA2WE )4LJ(2$VU!-2CY6QMW/<% M@
MD>=K6FJG7N(YUED2515>64[]#<VJN?\ <=DZ7I\2IQW;EZV+J%NGXJ"=7Y(!
M5WV-ZL]6- (5<:-R^70L&X"@1T]M90YI7W4+X@)0A+24V0D:#LUKSY(:DU7H
M?Z4&&&\SR!Y( =6RP@VZD)4L_MU2.XHFL+2.+J_@NI=G7#Y&/8>#*4^-5ZHJ
MGKH241*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB\_\
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MC28[L>4D%@I\?]:-:T'71+=X*LAFMYFF@THON"YG"P"3(QWXD%E-BEL'7:+
M55\A9BZ(W*F6^7^EO"P_)72BZ^0\F_E4XSD&6/+;V;47'B)/?77>V\0W'VH
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M-K1:2]28<"$_&$!/RTE24^<TW=*0/%<E([=*M%M(75)43@7!S"^4"H%5V1^
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M@0/)=6[8Q5G-"7/HXZ\5W<NQL+$YA2<:$>0^ H!&H%OW:LW:UW/<6^Z;YO\
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MP<@^Y'AJ?CJW.I4D@#J;J%]/=6I,_2HXM6[!&U\FUWRJ8PN2R4%YC(07_)C
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M"O'4M8XB]BUGD9:<OD'I+*=J):RIL'2UQVU^A,=$ZQL@T_RA<(O#]7>N,?\
M,?T7067&%A"C90U2I.M2,<C+EE"M:>&6SD!KKY+M>RY9;+;NT$Z!734^RHW_
M $\,;]P)5A'<EQ+"8W-!T6,AM((> \9'7V5/ 4%2J:7'@NZ/*?840V 4&Y-^
M\_\ FJ,O<9%<ZO4S8966S:0W@5TN.O*<4XZ=R_VA6Q;6S+5FUO!:$\[IWE[N
M)4#,Y*DOMQ,<CYB5YEGFTZE('6_=6"7(#=M;J5OLQCFLWR>UI&GFIMPN-I2I
M(N=+WTT'6I(U"BF@.-%C,9*+-*VX3H4^BX6FX-E#OK"R=LA+6G4+9FM)(:&0
M:.X+EAHV4C)D*4\I]UTE6P_ DJZ6J(FBCA]TAJY3MI/<R#9;BC0-5%Q/FLGD
M%JR#"XL>$H;$E0)<<%[DV[.ZO<)-T0Z5HHS@L-P]UFPQQN.Z0>]2T^0['\G:
MT5>:M*>GZJCUJ0$D;B %$-MG"I?II51W)&\Q(B!C$60^M5RZ3;:E/8*Q9!DK
MFTBXK8QKK=DFZ;5HY*E,P.7-YN%-DW==9(1=6J?+61NT&G2JPRUO!*"Y7Z6\
MQ;[9P9IPT5_GYF#BF$JFKVJ4-$=I/LJW27+(F^Y<ZM[*6X=2,57I7Z2RIW(9
MQXC:E3#'A/4&ZZJ/<#@YD;ASK^BZ!V>PL?,T\BW_ /F7JBJ<NCI1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+0'U$8>9F<YQ*,B3Y.
M/2J2N4V/U]J+@?HJ!S-R(8JE:]Q8MN6T=P6G^0>F8R+D%>-E?*M1%^8ZQ;1P
MCI>JC:94,][]0L%I@H8"'-  "^0,#F5-2\:S/^72T05MHLH+!!T]E25YDK>1
M\;V#D>2DHR'.+6G@J=D$3(KJ([;?XWF;7"?U$CJ:OT$^^(."U!%&Y^O%6? \
MA<@(^2\CS@HG:4]=QZU[9<D-]P% I>&]Z((/!5OD..DKFN29\$HB/*WA*K!)
M(U%ZQ2V]M,W=&^CEP;,P2,O'S[?:23^:Q6\NN*V!M4D @ ,C7[AW5 -:QM=
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M Q4N<ZW-V!#9( 5;]NN?9(RL=1M3Z+#VY96LLSVO'RFBB.4<9Q3?+!EH#[B
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MNP=B:_/?_<UW'D.E0@5;R\UWB;!6EZQKW<?548ISN-9:@_F3K^'4DI=CNG<
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M$2B)1$HB41*(E$2B)1$HB41*(E$7G;ZJW'&,3AY MY3:W2Z3J0+#I6G<.<*
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M*FK!I?(&L J5U+ YQD4 WNX+5$+B>1D9^)QYY)8E2EI W&]DJ-K]36[>L?;
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MZKID)A'"BK[I<"[J-RK4GVU,/-&Z*K%V\EQXE<)CC+20[((#8M<UJS-8Z/\
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ML7^:[(:MF**-Q>405!0Z]E=%AMVR$#FH6ZOG6S":5HN47"N<%B2\NT]YZ5I
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MO=-Z\2]( 4IQHJ<6074R&U**&P4J ^'7OJR$C=J51&,>6'VZ>*RVI"VE;VR
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M5:N3Q>/H8BC$K0MQ( 6$FXVCM-<KM;>\N+MTEPTCW'E1=?Q>9CM(&PVKQM:
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M6 ,T5OL^Y)(V%KQNT63&=<P$+_WA)\R*RA*$N*%BD 6%_LJ1C88(:N.C5 R
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M[=_MX+O8;*4E+P2I=R$GN!KZUG]2Q/=7AP4DS*:88+:TV6D6 'ZU0%SCY73
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M<6/#M![;FJT;0"T=+,T$4TYJRW^3;).+:(EKZTT4GS3$8>#Y4F))+LUQ.YQ
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M:NG3Y29L7!M-*3E\H?)C6!4FYU)*AII5BDCZ.KAH%#V?:%VX[R10^O[+8Z>
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MN3I>U7#%]L6S+5LA/NIXKF=_F[C*.Z0&AX*%CS\0M .<CH:DMJ-F'4[W-O>
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MBIW'W0G!*IF0L)+24M<NEM#;:5* (*C<@UN1[14CQ4<XDKFV4G]FU96D%>7
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MW =B3:]]+&MW(VHN(23IMJI/"7\EM. S^8@%6:/%@86"F/%;\ME/\&@&YO\
M;5.L;.24%HY+J.1R,-K#U' ;C]ZB%16E*4\4!+JB5*4!K<^VNCPQAC *+B\M
MR^1Y<3Q73D)+L*$J0VG>4BY'L'6O%Q*6LJOMO$)9 SQ7V/(CSXB)5[,+2"=;
M =M?:QRQ@NU"^30OAD+"/<%V,RV'0$1EA:1^](.E:\UI#-$6M 7@Q.::O!"F
M?S*.ML;P24BVRVIT]M5.##2125!VC[E?K?*V3(=1N-*4H"5&B"HNMR9 6E*
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MS'=DNI8825.*-DCJ35D=(V)@W>"N-C;L#-KG5(\UVR8)QDMC\R;"#O2-JM;
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M>5?M&A5Q[;QSFQ]1P^9=TG'M. %E"4*Z6MI;W5YQ^2=&VDGN'FON5P4<Q!A
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MP\M.@(O4=E\W>13#IUIIR79+3&VTL)<\#<1JN?)L7C(.0#6,<W,K)LCJ$_\
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M!<^$OCCW)IF9<?<D19""!$4!=![TFJIE^U.LP4('Q5APV9M(P[8TCX!7'/\
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M='(>N!Y+"]4.,Y*&S'RW'W0EE#B$2(I%PI"C8D$5KX2_$@+'\59,UVVR1O\
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M5R.9D,_)QLC'9:=0+!+:CH"F_4WK<B ;5HY*V8J6.(N@;\S*5/D=0OTU2+)
M[@*V5:E]HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1>%O7$J3ZG<A:W$I4^A9'_V).E= P-H&Q]3Q7)N[+]SINCR;0_FM43$9I,YA
MV$Z#!W /L#JM-N_V5*7=HZ21KAR*KME>,BA>PU]XU77+G9AK)B)'BE<(;"J0
MH@::;A:AGF8\-(T7P6MJ8B\/U\**3"FB[Y+8"Y9&C8("C6W/=10-W.*U+6RG
MN7;8VERR5_-10=B?*<6DC<=4WMI>U1TKH<A& -5)Q"]Q4NX@M^W\5AQ7,HMD
M#(.)<=22 4"PMK;[=:S6-B+=M M?)Y)UX\%QT6'*XE^=S$S1,?A.,H"%>2H
MKU)U]U0><K$YI'\]?PHK;VN&30RM(^0 _?53Z92\>&82$%]MINRY"CK<?OAW
MU%P8][R''FIY^6BBC<RO!89#BDA2A=:C>U7^!FQBX_))O>25(LN+^7W%)W-C
M:4GV#K7*^[;*4S"2/6H_5?I__P 9Y.%^-D830L<T?@M4XJ7F,%R&1D>1+6QC
MIVYO<I5TA=SM%O8-*F+%DD36NF%%1LW+'>QN9$^I#G5_$*Y-N,95Z#E<8I+S
M4=TE3R= I-BDB_V@U8;BUMLBUA!!+51<9D[K#.D#:T/Z</S4HYY/G%Y:$F2L
M *< L;:Z:5*PV<<5 P45=O+ZXO'F25Q<?L5S;2[O'EI-T>-%NQ0UO6:X?&&'
MJ<*+S9VT\\@Z(+G#73DI]_U,8S"7./N1+RH*4>?)O<;["X%<AM.W6SWSY6.]
MFXKL)RS[.U;UVZT'WIB),.7D(\60=B'%C<%:7UZ7K?R6(N887N8:M /Y+'C>
MY+2=X92A/BK3Z@P./,X9+/EA,P@!@MJ(7[#<:?>*IO9L5U-<U<3Q_=;'=<]O
M';T-->"TSCHF4;R#JI+Q=BH_@>R]^M_=7=(HIF/]QJ%R2YE@,8V"CN:ET+LZ
MH!5RC4'H:V1[J[^!6B3TW!S#\4X[A).4Y)Y<K(K^4?4=K:K6!MT!^RJ_>N&,
M@?.W@I^&;ZYS(I./BK9E>.+X_E-B'O,1M&TC0B]OW*K]OGFY&SJ>))5N@P)L
M;D2-/M(I^2^NY/(*C+9$A93:VV]1-ACK,3[W@;JJUY%SQ;&G@JI< "^I/7M)
MO770T%H!X+@!)))*+<2E1!&O4J)[*^!@;JONKM25F8UL.DR&U#RSX!;7VFJA
MG[T.9TV'5=,['M@R<S2#0:?DN60^7"51G4AS4*5NU";:C[:C>W<5)I*]6WOW
MN]DK/HX1ZD'A4+!2\)"_PC<(.VPZ5T,R :+A!C#&U)U4SP>#D\/D'\A@5ER1
M,%G8KRCY1(/8>RN'=XV#7$EYH%WOLIIGM0&\=5F9X<KSN7\O+LM1$-63&;:/
MF)63INW:&O':5_%9 [G>VB\]U=ORW( &AJOF8XK-P45,B<M&Q5O9U[M:W[ON
MWKW&VW/#P_X+EF2[8N+.+J$U'I_%0*T@>(=M=#P>4^LCH?F'%5(%8[SK#*=S
MIL3ITOUJQ&1K5E8USCHLR'*FH4J-!>4TTZ/Q .A%K=*ALC%:AH?(!6JE\9]0
MYYCC=2O%=7C94MER^X=I[1WU*6TT3HQLX*.O+9\,I:[BN* "%7K8<5K$D+*8
M=D.% 6X5(4H)Z #VZV[JYOGIH;:3^T!O4XW*W4KF->XEM1X?LNN7F,8ZX]BF
MGDF:WM); -[ BO&#?)),''BKWG;B%V.VM(K[?S6/8;;+&X'J+5TK0-U7*14G
M1<BA;)"5HV7^'[*UX+ACZ[5LW%K+#3>*572Z7_)<4R/$- H] :\OGVG;S2.
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M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+SY]4O_5&(_\
MKB_VJT;H:!4KNX?_ %/B/S"\QXB=,?$PY#:VEER[('4I/2L$,W1%!X*"Q>:;
M! :GA^J[)!<<?C)C,H<94J\ERY"D@C2_VUY;#UW5!U*V>A89+W C>=3XK"S^
M%@Y:.B%/9+D-E?F-E*MJ@HW!&X:ZWKRYKX'4*K]Q)/C'AK*[/WKZJC0L0YQS
MFD'!+F+1B93:W6HZUW"2=$I-^ZU9-W4C):-5.O'U]M[V[7#ASX_\%?9..:QR
M$&&$I0+>8E  &X]5$]M7SM29P:Z.0<S^05:R.-EBB#G&HT6)&EK>6ZTXD -$
M;%]JMP!/W5"YO&21S%[![?X*ORL :VGFIC%DM.J?9442$6L1W5$C(.?%]/)H
MT_HK=VI<B&<GG_ JZ15Y+EJA#?>"6F$^9OMU(TZ?;4%DF0V&V6$[BYP"[,9#
M.:JO9)MR&\[%D.;RP2GQ'3[*N.,!E#96BCG<5"Y"[C:US7'@J)R/&9')XR1'
MQ:_+D_&SK:X2>@^RK-E,TR.'8'>_1<:L7PBZ)/RZKA_*'(8W&8Z).AJ_-%CY
M=IU)"D*7MV^+N[ZY_!!]3<"KJEQ"E1-'+)U(]!#KZC@I:"_/B8A$-*0Y+:9"
M$/=A6$V!(KI#NWP8P-_(<E*6G=_1-'-T]?X+KQ9F1XS;,U]4F4CQ+=5IJ3>U
MNX=E:+^U8*5+_P /XJG9.]==3]7TI\%WK5YCF\FZCVFK/88Z*V8 Q1SG.=J3
M5<0D//):*MI5^L!>M^>4PQEU*T6Y96XFD#": KOR11AL;+R:)"FE1FU+96GJ
ME0'MO>N69C+2W;0P?*>*N<>&%M<-E:32NBY<?SDOD^"Q^0R<DSGD(NA:K72O
MH>E1T-G!  Y@]5TH[WM;4\EDS9OD'8R;.6!-^ENRKCCL4R<]0_)R]52,]G7V
M[^G%\W/T6O\ E6-SDS*P,SBAYLJ,;.)-D@@=AKYE8H+%P>SBH:PSP.X71J/1
M3>)9S;2W'<OY-W;*0VP2H#V&X&M;F%S3;EQ:[P4#E7V\CP8.?@IEF:J,M24H
M\)ZH)(M^BI6ZQ<=T*K+C,I-CG$$5\CHI"--$C2Q3V6.HJH7ED83L"Z)C<Q]:
M*O&T*<Q?)I.,0_"BJ!4X+B_8:KM_@7OC$A&BGX,K"9W6T9U _-5O-.ONS4R7
M7"77!=:K]J?_ #U>^WH(V6VPCP7-.Z(OI[L/;HXU5(F^I+V+R;T:3$\S'!00
M'AH0KM.O94'=R113T'BKEBI)+JU+G'W4*L$2?'R,826%!;;OB"A[=;5T.U>T
MQ-</!<@NV.;,[=QJ5G--LH*''&D+&E]R$J-O837+.YY]]R /!>+>\?"[0Z<U
MUY5J,^M!B14>8"E7G; FUKZ=]55IIS4I=7T;V[6E<I+;:XKC;BQY:T['$ZBY
M5V5NXV$2S#<-%$QO,;MS':J5P_(,WB((@Q)&R,E&Q@$!24::7]E77+XS'QL$
MI8.H**SV/<TT1+9'5;1:KE<JS>-Y8M&=DMJBJ/C6V@I38W(.M>,7EW%NIHT*
M;=BF9.WZK/G*L4"7E9+CLV(4HCK_ /5E.H.H/;UJP2,&4B<W=[:JMW=NRQ<U
MKFU=3BK#&GR&V V\\"X1XB  +^RHRU[59%)N)JHQN3NHS_;>0/@OL686"I*D
MEQ*S?<-"/LJ1R&%C<SV:$*S8[NF:+2;W>?V"PY.*Q4R:G*28"%S0D;5.:BW8
M2+ &N432NJ6D\"HFXST[W&OP5CQ? Y<]A<V!'::WC<I.W9<_94]ANZ;:U/1?
M^:WXL!?7D?5KQU4-)B28I4E] 24*V* -[&NFV>2BN#1AJH>[P\]LS?(.=%%R
M<7$F/AV0T%J&@))%ONK<?;A[P2M*.Z=&P@<UDJ;2TTEIH;0FP%N@%;56M]JU
MP2XEQ73\DU%>\UL:.:J!/4U@CB#'$UT*]]8O;0\EWM.38[Q6E[='(\+1Z ^^
MHF?&1W$NYQJ%,VN9DAA,7$+#S<S(QL8Z]CT),A((.X7 !ZD#V57+[ML1_P!V
M(\-5IXV.)]R&R<'&BQN&QY>9P_SLR8Z)!.W\.R=IMW$'I45=7<ES&&$5HNG_
M /;-INJ!HIA4=MI+C+SI>4+#>K173V5><1&!"T-;04U7,\I&(+MS8CHTJ[<*
MY;BL)BCBY+ ;;!4I(0GPDJZG05S?NWM6>XD$EN%=\=W+$V';+Q4#EI;>1FK7
M'3X%*\  M>_3K4/BYY<8YNX:MXJD92Z;=3UC"C$1#**]NW:THI4#J=Z=375V
MYN&5K=PXT6:RQ$T["\:4JOL24RT'7'P2;>%(!)('9I67*Q/E8.F5(X&YM+;<
M9N)]5)15QS'^90/+:7XE7ZW-4"\OY=P:\[MNBO,D]I80&6.@W^[[U%J6Y"3(
MR#3.]24%3Y;3J4#6QK>O;VRGM]FX!W@N81W-U<REP)/CX477CY[65BMS6-4N
MDV3^L".H([*I#HRPT"T+BTD;)MXDE;3Q&?Q3G$Y"Y\MN3\JE06A"P5$@:  =
MMZJ$]G,;C<VH"[?CI6-LQ'>$$^:HO#,]#S65Q^4;4&XQ=<063U;VW38^_2IR
M]:X6[F<Z*E]+Z;*P//\ C).W[M5LCGKV/5@BIU]*!N&TGQ*^X56L87]4*[]S
M6L=U;::<%KOC^2&*R;4@V+1M=1T(!U!JUWD!?'IQ7(\1=BPO!OX5U5EY%G&,
MK(9DX]5EL#50MV&]?,2QS#L>-"NLQ9N&Y=_:(T69Q[D*5EZ/F7/-CK'A#FNO
M=TKSF,=';T?#Q)4JW+!@H\JI9MII<N5\J/XJA94SWE&G[!O4HS<^UC<[C0_F
MJ!W:/J8VR,X,J?R5-Y3.GX]&+R+#9_+XC_\ 'R@W)3I8D=U>HB' @JLXQK)H
M^&K>'KHOG(HV,S&-C9")'2\\TXV^5)3M6M(5N5;O)&E>83(QVVNBRP73&[H?
MYW:?$J1PO(&<UBTRH&YJ.C\)Q*B 04Z6[ZPS [_=J5IW[+F!@ J&@:_;BL#,
M\1B<BEQLI)?4T]$)!\L *4E-B!65LP8*>*SV>4DZ#@\U&OY*0GX3$9[RF<K&
MWI;!"'-Y"D@(L3<>ZO+)"TZ+SB\F1=5:*%_GX K7'IY)$3E\K'IDD0D(?;C(
M4JR%*0L;/MM4A.#M!'%= RD'3A$L7SN'WZ56Q<=-=7ZI\$@EX%#^12Z\BX^)
MOX";=W6O-L.)*A>TVR/FD?)JX@?;[E^EJ3=(/>!4@NE+[1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB\->N,5Z1ZF\B<CJ *7$BQ_
M?!I %77&Y,1VVP<0N:YK"ON;S<"*$!:.XYF\HO*2,)EF0W.B"RU W!U-K=UQ
M6_ALJ^Y&UXU"@,YAVVC0X'CR5E>5LW+(W =@U-60T56:*Z+XS!C?F\?)? \V
M"-P[1:W2H3*VX>RJL> O#%.&DZ?JLG\T.48668CS<<'5QQ)2=%=4]]5S#$-G
M+2>!_17;N8%]KN:*UU_$*L\FY'*P?DK8AKE,KN%E!L0=+&YJT7U\Z(@,%50\
M7C8[D$R.V^"E,.]D%06W9"]K[XWN!)Z;C<#[!7V.+K,:Z05*UYIS;2/9 XAI
MTTYT^Q6<$DFZM5'J3J:DV,#10!1+GEQJ2N7[59#P6-6Y/!AD.*+R")CB%.!+
MY#9L1M(-JY'G.YVP770+0:$CAX+KG;N+E-I6-Q;OH=#3B%1LKA(DU'R.2;2^
MBP5V@E-^_L-7^+;>VP5(F$V*NCSY^H6PT<<XG&X A.+;3&^5;NG:;J\R^H-^
MVXKF.-FNK+,/BXLW4_!77(W,5_C!*  6M)^-?X*B%2 D ZD#0^ZNT,:X^Y<H
M *^87,,RFI <065-+*"L"Y4![JI.3LKF]-&&@KXKK_:F?LL*PMF:TN<..W=Y
M_A5<&N/,*S$C--/^6W(;2A3*$VW$?K*OVU%VD$V.E#2?Q4QG,E:Y6 [!H?\
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MT<K?R#%97!\=D9WR%.QV&O.V)'CM:^ONJ!;WC;D[0/<K./\ Q_<A]7.&W\5
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M6"%L+=HX+7GE?,\O>:DJ2XXPPO,Q!( 4QYEW+_" 0>M0>>N!%:.V_,:?FIS
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MV9"/:XT^%5FMKA\,@>PD$$<#2JM.?Y B=B?+*QN4+!(_8JOX'MJ+'R;FBI]
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M^$O)&=1C/34?NN;<:?$\HMN",PQX2W9("QV#0Z5#9Y\#H_[7[*PMARL,--M
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M\,<L%QFHV69E9J[X<U'(9DJ\Q,1""X25E)T%R;]U=,GN&6L-"N<6EH_(S'4
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M]V]&R2Y =X*T2,LN7/QGYU*6B!"<#GRZ$GQ[=/%;4VKCW_;C[ICGP"KJ<?\
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MDK:+C9#9LX!JKK:U>,SDW6;0&\2J@TT/#1=2E.(2$'Q+]G::E;"<R0A[E[:
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M?I5PF3B>;<=C8_+R&8[&18>=CE*5)6DKN0+BX^^MG:PT(X\U>L;W+>ME=9R
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M5G<"3U_8KUCLY;WVAI]ZULC8"W<&UK\*+/:*$)===LG?XKZ"Y&E6!K(FDEM
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M4HB.ZC<VKPJ%^HL:L>4<Z. D%<[P\8?>QM/ G]%-\=$#"YF-\T$B DD!2D^
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M^UL[;0M:?.OAZJ@PGY1D.L.-6?CI#A<0+M%"K@$'[#>K"\:57-W6SXQU8CN
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M'_VXAT@W^G197'IMZ\_]Q[^3M?-8P47;I7I<DV'07UJ=C:6^WCY\U7)#5Q<
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MZW%1D@$+JZD%340-VT-T!;SX:?JI!&;C_)JE1RX8Z;[B I.X]FE>G&-S1(6
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M;'; _P #6BR(V>Q#7%%1]Z$R=ANWWJ[2FXOI4+:XNXGOAMJ14>"DK&[LG8X
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MH^EW4U_@L@F?)0.)49B/-5&+[C2FG7UJ4I"C<VOI[JEK&I821J5L75 [:#4
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M2I*][6CZ&Z U-?MQ*ZF,>ZHWDC:G][W_ &BI.]S+&M]A4-C^VI7/K,V@\/\
M@5PEL)BK"D"S:A8GL!K:Q=X9&U>M#.8L6[P8QIS7+&AI*U;R/,5\-^X5K9F:
M=K/:TEOBM_MDV_4VO(WG@-5ESUMI8*"?&L$)%0>&M'3/ZE>"LG<TL$,)97W.
M&BB@TH + 4D:$*VGK5[;.QU6U7,!;3M ?M/W*35R?D*HR<<B</R^Q2ZE2 I9
MO[;BU5,]JV9N_J--U:_;56/_ +HNQ;]'G2E?L%&I;"38"X_J02/N%6]\C8P
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M'9K>O=Q@+N0[=VG_ *BIW_N.*.,%M:J3??3(=NE-@$@$?MFJY<V=YCC3>?\
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M[:ON\%6SMW_(Y43O"GT[?_4O(:HLF3RQF4F*OY6.RK=(M9)4M)M]U3DKQ)=
M>BJ%MOCL'$5U/X4*L(94K\7RCY:=%*M;K4K+=P0:$BI4$+.=T9DVG;XKN4XC
M:&TGNT[*KS<(T7?5Y4_51P#N:@<VG/><E&'+26CJXI8NI-N[WU,78GW#I\%,
MV,EL(W"8$D\%+1FE*8;\_P 3NP!Q0-@56UJ3B)VC=Q4:Z0M<=N@*ZY<*2Z6W
MHKKL9UJZ@H7VFW?I8BHR]BAG:6DBI\U,8^6YLW=4,=3QVK%?A.Y1,1>5>+CT
M57FI*3LNOM.EJU;+$QQ:\UMW^?GN:CEPX!26UNUNZK#M:JO4KK^:::=#.^RU
MW4$CJ0+?L5H7$L$)!?S7KIEPK14Q'-\P>8M8R+I 0?)<CN)M?;>ZKZ'NKG]Z
M/J;G^WP_BNNXZX-KC-[CP_\ Z5>LFS R\<1YD5MT@%*RXE*B+_O5$7'V5%9/
M&3P/W@5!\E1+G/SR, :=OCP^"AIL['<0A)*HZS!N$)*5*5M/32YJ#:PN>*ZK
M2M8),A)3BXJ-;Y]C9JVVHN]R6ZL)1'";D@FU]PN*Z98Y2)K*,%**9F[5FA'N
M(JI;D.4/&L>G(R65+22 MM.I3N[S6]_N0#5?(^U[A] =%FX?()EM,S%((2^D
M)V]ME=]8<E:NO8=X4+'%T;@Q.UK[3\5*O0%%U(8'\(=MJAK3-,L861/XA2.3
MP_0+ P?,5?Y/"\!&P2<A(48[K+/F/R-Q T%R;'2J!+WO=/O',C)VU/)O[+H4
M'9]HZS#G#W4&M7?O10.!PS63P1ST>0D0'$E;.^P-TZ7O]E1TUW/<70#&ESA2
MM%I6/;9M!U'NHRM=?W73 Y#)QC;R(#R2ET;5 :ZG2]73_3LN-KYVT]:A3;\M
M'+"8X7!SAX$%:ZSW.&\!)0B4HNO2' A\*N2DK/6K9?NMFQL8QP]I'/D%4<#;
M7VZ3>UU"#Q'-<9/)<2W'2EM?G2';(9;0"2I2N@]E2\F9MF1UJJQ_HKMLI!::
M \::+#XGQ;,8OD$B?,7Y,::DJ=C(65 J7<W.O?7);^X%P\D>*L63O6R!EJT5
M.T T6R)G#I;V'1F&7 6X^\K0/UKC3[JS]O9)D%_T7#4T_%:MQVVZUM>H=3JJ
M!GN*N\E7!;;<VAMX*<5<@% Z@#OMVU<NZ;D0[?,+5[>R+()#$1\ZMO\ )1&/
MBK?BPEMJ 'XME$D =I/6]0N'R44-P 7#W?JKCFL0Q]G2)ON!JF/+JTK:6E0;
M %@H6[[ZZ58\RQK)62L<-*U4'@([B1KHI =FG$4\5BS&TLNEN_X=@1K>W9:I
MNUR >P;W"JJN6LV6LY8SA2JZD))(2#<]@%9KYK&PN+173DHAK2\T:*DJ5DQG
M!$&RZG!MN$]PKDF*B8^])F!#:GCHK++AY^B"UI)T4!+EI>2Y&8>2U,VE*-YV
MV5[CU-=$E-G:1&2%P!]:K%B<%<75PUA80"16H/!4YG'\QPN?BY#)NF=#D+2A
M\MH39*!^^ '95.M,G<7#W%CJE=JSG;%M8V['R-IM]5M7S8H4V5% > NC4!5E
M=U91#>.:20>/@HM][81%NHK0?S+$FXM,F8SD XL2&19+959DW[T=+UIR2S!A
M XKYD[**\ V<5U.Q&(+BG$-H_%N24#;N)&H^R]:F,M+FYEU!'CHN27]K+8W(
M$FHU(5<Q.'<Q4IY275JCNJ*PVM14$E7=>NM6EF(=*K'>WS;AC0&ANW\5%\UY
M"]!4WC(K06]/'E)7^]W&W?6GE+@M;TQS4QVU;LW.D?R6P>-R%8/'1FXDCRW&
M&@%*2JYN!K5"?@GRR[7CVNUYJ_VV3M(V.<PBHKS4DB/D,U$=G.I4M+@.]1ZU
MEEGM\1<"*+C7Q_=>[&VGRMFYQX.'A^RKF41'QL4/R) 0@J"?&!:YTM5NL\ZR
M7_)H%2+OM9\+3M-7+JF8:5D,7*99;\QY]K:PV-2HD=GOK%F,Q$R'VG1;7;^$
M?U"Z4>BJ>)G/\4QK>/Y''?AR6[[$.MD;DC][85K8;/V[XJ$ZA>,SV[/)<%T0
MT*N6)\N:N/)%TQU;5W-[D&I?(W^R$NIQ&B@L3CI'70#O;L/-;P?E_EW&_F8*
M4W;:!;L.FE?G*WM!>Y.DFFYPK71=LN;B2"U.W6@6E)DJ1EY*YLI7XRSU.EK^
M[LK]&-Z&)MPU@TI]N*_/=W=R3RESSQ/W*#CS,@F7*C2FBM#"OPGFQ=*DGH![
M:T;;N-CFDOT66XMHFTV.!JIO'MO38A>6PIE96 @.7"B!U-O;5$R$)N93)'S5
MIQ';/7&Z7Y?B%ULY+%*SRL.A2G76TA:VAH0%'I4#6:-A(T<"HV]PHM)]6E\=
M>2L_)D\3C\?3*QZ=N100D-I4I:E*OJ.IJ6P7<-ZR=K)R2VO@!^BG9<387,/_
M -:C7_\ J)_55V'#DOMH5* ;0HW\GMMW7KI$F=:X$!:\/:;F/:7N!',:J1<?
M"&EK:6"0?+4$V)22#:]<VR$C9'ZJ9[ANC;P4;ST_!1,WRQ#7*F >4Q9?F$=O
M3K6/%7#8;IIY+F<;996DA1LF03#,B*"XLI"VTCJKMKLF0#IK4[>)"\QQ_P!S
M:Y84/GYF3&</%QZXTE)M(4]>P ZV%^V]<OQV(,ERT.XU5V;;OL[;K-I[5+3<
MDWCV%RI1+@TW[>NM7/+XQKH=!P5*/4NY:D^XK-CMR<K$5'Q[JFWGVRIE:+$A
M1Z=0:Y%(X0.WNY+=Q=N9;CHN6-&B9N TPG+-%G)-) <)&A/2^FFM=;QV7LG6
MH&X5(%=5GNH)L=<;@TM%=%]X]ELIE)^28F1_*8BK2F,NUBI)!UJH7MQ&VI:N
MO87KWD0D'#T7S'S7X?J(B:8NT18EHTI73<I1W"_V"M=F.=?0'PHI&ZOH[=[6
M2&A/!;AX_P L5E9"VL@6DM)1N"C8)!'6]4')X'Z$;F\?BMNTO[5Y+2177FJ7
MD8D?)<N0TVYY<:0\D^8CH$C10!]MJRQ2/CM"XC4 KCEY:!^::SD]S?R_@I/G
M;&,Q3,6-#3^.L6<VJW>$6U([ZENVL1<7M9'\*^'B%)]ULCM0R-HU</R*PV>&
M2GL:YD4)NWL+C8-[V J-FO\ IS](<5'CM=Q@=(.321\ M<YOC4#.38$B:5^5
M"6I2D()2I04.Q0U&H%3<;W,J%7<7DC9[O^96"*XU$(-B4VV)N=Q[.T]:QQRN
M8ZH7C'9%UK<&:AUK^=5/<71-RW+N.LXU19*<G%7(4JVK07=0T/:!4B+HEU?%
M=*QW<9O9=IKI3P7Z )^$>ZMU7A?:(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$7A3UP6EWU6Y"@:>6XA*OM:0?VZZ1@J" #Q_@N-=V
MN/UG_P"(_,JF8YR,U%5&)V^7=:T^Q2B:B,OC2Z8;?YBK%V[EXHK0MD/R#]2L
M%MYYPJWA24(4I"#<C<E).T_:*LEA:".(->!4*EY;(=:<NB<=I]1S*P\AE8F'
M85)EO>0P3M)N;$_966Y?$P@O 6K8PW4M6PUUXT-%P@Y2!DDH=@O(=;'C%NXB
ML\-S')\JU[BUE@);(""L]#;SQ_"3=)-KWMK6+ZAK92"=*+W;6,L_R!=KK#S2
M27$[;="-02:\P7L4V@.J]W.+N+<;GM]OBNA !/C.O94@!11Q/@LN+&0\DI*R
M'AV=@UTJ O;N6V>"15I5GQ>+AO8W ./4 _X+'D1GF7FE*.QQ)NVI![JVXKF.
M\CV\O!1]U:38^37CR*FLERS,Y2$F!)< CBV[:-56[#45C^WK6SEZK& 'QIYU
M6:\S5Q<LV.- HAAU;"KMIND:*3TO4S>6K+H4/$+3Q]^ZTDW4J#Q"^K=*EE90
M$ ]4C47[ZSVT#H6T)JL%[<-N)-[6AGHNE2@L@#2U9SXA:@%%WQGD,R$K6;)V
MD$^^HW)0&X@+*:J=P5VVUN0]V@H5\G>8I_=:^ZVP^P=GWUK8F-C(MO,++G'/
M=<%[CHX:+&-[C>D!0J9T(JW6JK_HLA]M]N&J6A[Y=83X'02%"_345"W-Y!+6
M%^JM-EA;@1BX::4U71YLR0PVN>Z7Y0%E.$WZ=*W[>UC@CVL:!Z*OW5R^>4O<
M22?%=A40BU[5O"@:M.FJS<9E)\%"F8[JA'6"'&KG;8GK:JWF+*UECWR,!=XT
M5@Q>;FL7Z..P\JZ>JS),82&AN-C:Z5=:J>&O3%*6MT'@NA7]K'D;??76E05#
M;"HD;M4DBW?:NG-?N"Y"\=-Q'&FBZW%;5  :&OI 7QHJNVR=EK5ZY+'S6!\X
MWYWRSB5AV]@-I*3?VU@,H&A6V(7$5"[6Y3:YJX!0KYEL;K*!&GLO6!MU#6E5
MG=9W! )!7+YD(E&,6G =MRLH(3;WUZ;=1EU 5C=92AFX@K(6XZM"$J5=*-4G
MMK[':LC<7CFO4U])-&V-YJ&KB!<W!L>^MHZ\"M!<I$5UU&XA26B/C%@1]G6M
M5MQ%+[0[52G^MN8HNLYGM^WQ6,U!#*@E#JUD=2HZUDB8 *$U6B9R=:45AQG)
M\IA%)7&=4MI/5A9NDG[:K&6[<MKYA.P!_C13N,S]U:NH7ES? E=61R;^?EB3
M((0XXH)'<G<;5$XS&SXN,[B2%J7]\^_N@3H":#XJ_P C!8+"<=\R86G7E(\"
MED *)&E@:YO<Y:[=?^QQ:->?FNUVV*B99@'W-TT6NY.,0^\E]I:FT@6\I%@D
MW[:Z98964_Y''@JUE>WX) .DT,/DOJL<VEA00D^<!IKJ31W<$M2&CFM<]L1=
M"AXTX\U&11).UUR[<A)MM2=01W$5977#66X,HH"N8OK&_:WB#R60ZU)(6^ZV
M3VE:C=7OZUEMLA;.#61'X44B_%7?3,K@:<>*PWEL^6$O*2 I0 W=+DU(3O$;
M*NX*/@B?)(&MXE3##$:&E#KRTW60&[Z6]U47)9-TOM;P75,/@F67]R75W+R]
M%FJ"5#47!OU&EJ@.@^HHXBJL[I64)<T.\%'*B(C*\])'E-$J"+6 ]E7.+)&=
MG1I0\*KGLV';:2FYK5H).VBYHG1UFSJ"@GH2 1]]:<N(N(&'8XZK=M<_9SO'
M4C#?55R/@L0W,7DOE?/6MU3B2Z;VN>P'2M^/#B2'4^Y09[@;'.=K!MKIZ+9^
M,Y+CVN/.8U37@4DV(T O7.)L%<0WS7BM*A=#_P!K!<VI(IJ"J(H NJ;:%QN(
M0/9>NS1R!L0+M*!<3?%NF+6:ZFB*;<2H>8DHOT]MO=7V&YCF/M*^W%G+!3J-
MI5?"T;C72MK;0\5J;EV1V/-D>6;[ +FVE1.0N>DWBIG%68NI=I&BE1$C@?P:
M3]E4I^2F)T<5U*' 6P&L;?N4-(;L^XC;MLHV]U]/T5?;5_5B:>= N2W\71N'
MLI0!QIZ5T2X0I)(O8@_<:V)F581XA:D#]LC7>!"F8[[;Z"6S>VBATKFMY9RV
M[ZGFNV8S)0W<=&?RZ%<G&FU-E!.Q*NIZ5&OO"[VN4TVP ]S5P?/DQE! T2DV
M'=I8?=6_CK5LD[-=*J"R]RZ&W?IK15K*0$Y*$J*ZI2 X HJ2=3[:Z,Z)DL98
M#PT7((Y9+>42$:GW"OYK.;Q"L?CVVE/[_) 0+BU^ZHJTOMU8.=%8\IA.A%UR
M[B5F0'WWEJ2M0VIMH.R]ZT,A;0P,&X5<>:D.W[^ZF>6AWM%/U7?D6XXC.2'D
MZQT*<W=H"1<V]M5V"Z="[VA7#(XZ.Z9M>=5)\/XQPWG?'A/R93(9>)4TVY9*
MV]EP2/;>H#N7-RW#H8X_;M+MWGP7C!=N?1E[G.KNI3RI55K#<19XZJ;CVY:Y
M$/SU_)A75#5_"+COZU*8S+S1-#:K+D\';S'=(*GQ4HV_';0ZVV;>3;>+=--Q
MK?N(Y+F5NX5+BL,,]O90.#/:&@_NL%4]XN;T#\,=!VD=]6ZWQ3614/%<_N.X
MYGRU!]H4BD,.V="4J)U"K:_?54GEGB<6!Q \%?X(;2Z:)=K2[D::^2W-]+4W
M)KYGRF&^FV.;C151SMMJ2Y<[OLJ%EW%Q)5EB(V <UZLK$O:41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$4=GL_AN+X>7G^03&\?AX#9=E2WC9"$C3LN22=$I2"
M5'0 FO36EQH.*\N<&BIX+R'SGZXY*93L3TZX^RJ(V2E&3S)6HN6-KIC,+1M'
M[TJ=)[TCI4U%C-/>?N41)D/Z1]ZUPY]9/K2M:E)D8UM)-PA,).T>P;E$_>:V
MO]?%YK7^OE\E;N)_7'RV)(0WS3 0LE ) 6]C2Y#DI':JSBG4+_K;(]]8),8T
M_*:+*S(.'S!>O/3_ -1>)^IN!1R'B4WYJ'N\N0RL>7(CO 7+;S9U2K[P>H)%
M0TL+HW4<I>*5L@JU6JL*RI1$HB41><?JO_ZNP [W71_]+5L[=%9'*B=X&ENW
MU7FR-DX"%1L=(< EOI46VCU4$DWM6'*2.@N*M-."RX!C+BR#7@'C^:D7 EEE
M5@"E(Z#05H0&2ZG]VNJE9VLMK5_L&UM*!08;+P6(Q ?*5*3^]3?IU]IKH\LH
M@CW// +C]G937UQLB9Q/#D!58\5B>B*DY()^8*E)\![!T/VU&8O*MNRYH.K*
M?BK'W+VU-B2Q[AM;)6GPHBY\6(4QWG4MNKU2E1M[*F'S-&A.JIH@>_W 5 4L
MWDHZH]BF^A&SJ#?L[M:K,MC*Y^YI5^AST @V/%=#4>/DL%Q2"5+MMN20@= #
MV5988RR,;C4JB3R"25SFC:"=!X+@PZQ, 6RJZ.TCV5K7-QTHS(-0%BD8Z(T<
M-5U-M*CYZ-,\HN,!EU!(%PDJ4C7]%<JS&5?D*!HV[?U4E9W0CB?45.BC(K,%
M7.I4S(M!#GRK:&'W  E2E*5NMV7M:O%O)*RC@3HK_P!M4N;9XE.\$G0^BG5[
M$R%!'B">FM^S]BNK6DC;N$%XXKG>1MQ#,YC?E_@H?)I;RV1@82>R#C5J4Z\Y
MU&Y(ND&_?:U4/,8<PRE\8T-5)XV38RK';' \?5;5;XKQ1GBS#D=N+$?B J0M
M*4A=DBX!M5&Q+[QMUTWMJU]&\?$KITLT;K;J/?4LJ?N6G?4W-+;P3F.1%<=^
M;2E1D;"6DA"@3K;0D5>,C#].0U;6'G-RWJ$Z:+K]-Y+N0PRTO.A2XBP#V*".
MH/Z*U9,_)"P1A<_[DL>E<]5ATT)6P\7*8>S$1J6LMP]]U+Z"_9<FOE_BG75B
M+AH]U"M)N1;=W,0>X@ Z_HLGUZY/A&>&IPL6:E<Z20&FVE;CL /7;[:YAB+!
M[;LES?%=N+XN@VAJ*!2/%(Z,SZ>8_&Q067&F$-K;4+$*2+'[ZEX;E^(R1DF%
M X-4M>6\.4L.C#0DU_95WD$"?Q+'+R\N.M]E'A+;*;JM?K:YKI#^Y;2]C(8-
M5RR'M"ZQ4G4>=%H#D&0<YKR9W\NB*((!0GJ=+"YOW56VU).Y7&>X98V_5D=0
M*Y^GW$,CB<\MS*Q/ TT%,N+ /B)[*R-(<VA45;7[,B"(Z@*X9SE^(XSDVXLU
MMQ3KZ"ZIVXVI"E'L)'4BH]D!WUY*#L, +>[=(1NX\:<RI+"<WD\@PSS$):D8
M]UTH0V0 2$G:=?::R59;7@F+0:4U]%'=S9I[Z6C!0UI]ZSX++<)Q+CA"E7W"
M_1/NJ5[@OAD(0YK> 6O;8..UMQ/(?=0'T5SF<PC3L*N&EFSCJ2WY@TM;2XKG
M]IBIGSB0N(#:?@KKB\M'>0[0*E<..0>/G'.O9-8"]4V6;J [Q4QE9[V20,BJ
MX>JD0^&V8=] J#+D17);S;"TN(05) -[A()L35BL<;D)-NZHX<PN%9B7J7+G
MC4< OD)8+J%MH"EW^$]WOJ4S;[J(]-CW >2T[%TC+ANP;C7@I&8XMM'FMV18
MC<>O6J]$R6<B,$[E>LO-?PPA[?8.="H.'Z9+YMGSEHT[Y%^($* 2FX6H:W.G
M;7S-1OQ<0$AJ#X^:G^R\O)(YV_5P5CR^(G8V.^P^WN6VD[EI3=*O;6[VH^*2
M5C@=M>2L7=V0GN;9S220 55IKRX\-V:TRIYMI/B2C56@[JZG=WL=LTUU7$L=
MBYKUWMX#FJ;QG.9#D>?DRUOO,1X]E-Q"LE)-[ D VJN6%K'>3%]:#P5[S=W+
MC8V-C-'<RMTP./Q\S@G<H])#3[((3V#S!V5"SYB3'7IB8S<"5KRQLR=F))#[
MP./GS528@N2W"\ITI"!8('0FU]:NMWD.@6EW-5C%8GZR)Q'$*+S?'WLHT@--
M)$IEP.(<586VGLO4+D\Q;D-(I58+>.:UE+' ^"R4*)9(207MI )U%[5;&2"2
M(/;X*&(H[R6Q^$34& QC)1&]:$@V_641K7Y][MAF=.9FZ$&J_4/9U]!'8M:1
M_*%-93TSQ&67Y,PE4-5EJ9/[\:@U!6N?'3HXZA8[ZQ,\Q>PT&J^8+A<G#98/
M%[S<>@'RTJM<6Z:U.W^=AO+<,B:-WQ56L;.6UG+GO);YJC^N;<?DC&,QF/0'
M934H?,/)2+MM]M>\!B[MC#)(-K5OW>1B>\-8=5#O-F"B,PR2E+: C<-+[0 *
MZ]B]MW'M?J N9=P3202-,9VUYA=Z\]F_E_D_G'/E"-I;N+6^ZI)F$L8W]3IM
MW>-% .SM\]FPRNHL3502I)MM%JWI(8Y='M!"@/58TR8,?'<DJ%TM@KTTU&M5
MC,X6-T9<P!H&NBSPQF1X T*R\?DLHN,),U" 'D)6PV/B2GO6>\U3<1<,-PV+
M@.%5>_\ ?26$/T[AO<5$G%P1F5YO:I,]:;%042+#MKH5O@X 2YPW54%?9>>[
M% -H\O+FIF+(""%#Q_ODGMJH]R8Z.&CHQ11%E>R6<H>W[O%9*LEL5=+1*?>-
M*SXK$LO(0YK]1Q5Y_P"[VD#^WJJT_CYK<YR?C7E,EY25.QUJWM+VGM!Z5+7?
M:\3V^TZJ#O<XVZ-'MH/O4R\KYZ&(TUM*FSMNA/P7%^SMKFUS9.M)2/ J#=>/
MH6MT'*G)<"PE"6V6T! Z VL !W5T? WSGP_W';J+S;0R2R#B*GBNKD[D?%8&
M9ED(1\VVV2ATI&XGLZ5#W-Z8KC>PZU7:+>QBN+?HN=\PHJUQ++S>08YUZ8T"
M4J* H: FW2QJ;A[@A<TB8T7,LW9Q6-P&1.Y?\5MCTMQ$/%0)>5S3Z?-\Y2HB
M5FX::[  :XOG3+>W/2MFU!/HNA8B+'AHG;3UHN/*9"<K/>?CKW-JMY=NA [Z
ME[;$OMF#J:&FJP]U6?U<37Q'A^*KT6*MG)R)8EI4T\A*2Q:VTMWN?TU@?(6G
M45"\X;N6*T@Z>[457#(*$EP!I7X: 0D@6)/6K]VYD6A_2(T=_%4[N+.LOY&%
MH^2NOK3]EU6LV4W/C%EV)%QW&H+..<^Z(/R\OO*J3)Y&NW-<0?5?4R5M*:V$
M[F[;-2-!V5+XK&P36KR\ T:>7JMN&]E;.R=Q+BP@ZGP4HJTY(=>&]2.NZY(K
MXS)-L6].,;:^"Z;!/;YD!SP"YNGIS5DA\KGQL>O'*2'$*04(/3:#[:JCL.U]
MT)?3\U<)'5A,0TJ"/O5(EH<BKNX IL_K#]D]U7Z;'07$):P /'-<1R>$ELG:
MZM/ JJSI.2SN<;@8.4VG'8TI>G/I(5=3GZEQ?L35%EB$%0[4\%+6D45K:GK-
M#B=17S 6U/3-13SWCZ02+S&PKLOUZUI,J2#YJ'P#C]=&!P)_0KWR.@J?7?%]
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41>'?7"&I
M?J;GWV -_FHW#OLTFKQB<A'#&&.7-NX\3)<2]1G%:L6%,R7'I)#:-J0 K2PZ
M]:LC-E=Y(*H$D,D8V$$%=S;B'4A;3B5H[TD$?HK;8X.U"TW-(T(HH_+XK'9I
MM,.8GS D[_+!U/9K[+U@N;=DPVE;UG>2VKM[#186$XQ#P"GUQ 0V[;:V;G;[
M!6M:60A)*V;W)27=-W)73$H*VDI6"FZMH/\ 7$6JHYFY,4SJ?T*^=L05A!(Y
ME6WD?&8V)Q[#K+A<\X +"SI=0N:YKA\FY]QJ3H0K[>VK7P.;04(U6OG$MI6M
M-[%"MJ3?L%?H..3= '#C0?DOSS-%LG<SD'$?C19CZFHJDKC*"G?U@3<;=#K;
MI4!:=:\!$PH/2BMEXZUQCVNM7;G$ZZUTXK%=DN37D[0D%-[:Z#[:VXX&VNK2
MH>[NI<C( 13BOBFW&G ESH>T=*E8;ALHT49=6CX#1R[$(#CR&@K:%7OWZ=U>
M;J3HQEPXKUCK47,[8W&@*Y/L!AX-[MP*=VO6]ZU[*[=."2*+:R]@VSD#6FH(
MJN@H"=5&I$5"AJIL!N>RO@K75*J0QL63F"S#B *?"K*)_5'2YJLW=Q%CWOE?
M\NTJU-8^_MV1,^8.U]%-S>'.8U]IB> 52" '@; 54(^\VSL_L _<KS;]GP1V
MW]TU=3Q63R3C.+C8]J,W)#WF$%Q*5#L[*KUOEKJ2YJ]A _\ 2IZWLVBW,0.G
M\%4'HZXRMBR"D_ H=PKL]E=-F;IQ7%<GC)+*2CM0>!70IP?#U5W"MQSQ6BB@
MT\4:=6I-R@MF]K&U_P!%8IH!,S:4<T \:K(7)<+8;6X=H%@!II45:8B.)Y=1
M;(O)]FP..U8KC04I"T_J=*F@P56NUU 05V[0=:RE8ZKI>DH805KU T [R:QE
MX"RLC+C0+N97L<2^4!2>XZD>ZM2[MC,S0T6[8W0MY0XBH5;Y0QE,UFH3>/6Y
M"C-(5YTE)LHZ]-#53.&F+Z55^;W';=.I:?P5R9GQVF4(<*EK VE13\5A7TXB
M=I!JLC>X[1S2"#P\%$3LA#QK7G3' TTI5A?VG05;GRM@8.H:+G#()+F4B)M>
M= LF&Y&<<:>W!3*M0H'2_45@NR3 3$:U6[C1&RZ G% #^(4ZA&\!T$E!'<;_
M '5R6;?:R[=VM?%?IBUOK:[Q_P OCR4?/\KS&T(T6DW4;=G<:Z#A>J1N=P*X
M-W0^W!:R,>X<5'!LJ!3<$W)'6K4?$*DEU%P#CC;R6=ET*&JNP5A<!(*$+WM!
M;6JE</CXN;Y%!D\@E.O8Z&DA,=:B6BL6VW'LKF_<^)CCA+X1_<JNE=IW]Q-+
MTY#6-H5MY2U@8RPO%. K(NII/PI [JK7;EK<O?6XT!]0K=D,C'&#0\%5&\GO
M(*TI"2;)-];>ZK%GH7V=#&-"N;O[FG>_:UNGXJRL\1>:@',H<2ELIW;#VCK<
M&J9#G)[M_2.M/)6+&X..,]63B=56LA+;"%,H(4XO10[DFND8/'N)WFHHM?N'
M*L9$88]:Z*,&';S,N$VH*46W4E* 2 2.A-NRK)EMK+<N<>"IV"<[ZMK0*U5@
MY9AWL5Y$>64J"P5@)ZCNJK]LR1W0?455O[NG>TL:TTU45C\@VF-Y:VU-E)T(
M\5Z^NPTTDCJ:"NBVXNYK>*%@=J=NM-5CC_WFZY&#BPG52[&U@>@J>NF10P@#
MY@JI8OGNKDN-2QU=/)=SL-R./+;!6V!IVJKW891KF!CSJOF5P4D;R^(5;X<U
MC-MNR2MD)N4D!23IMOTJ0FO(F#B%#PX^>1U&M/W+NCXF6E;R77AY2OX-(O\
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MB)1$HB41*(E$2B)1%X7^MOG<^;RS&>GT9Y2,/C(S>0F,I-@Y-DE01N%M?+;
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M7%Q+YBRP=Z5C3<1V&U5^3(7#AHY=%_TEEM! &GHL?#8[)P<:S&S#P<FKNGS
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M;AS JU>8X6LA9(?N4;G<9ESF\7/CREJQ]RB1%0HA-K$BX!L=35:P5N))0ZG
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M=1TO6T>WK)T1,0UIXG]UKOS-^7!SWD-)_I%/R75E'1(4VXE-VP-%#IJ:U,#
M^)KXGFB\92225S9"*L\>2Z)KK3Y!3XDA( ]_;5HL+-L#"".)JM?+7#996EAJ
M-H76WM*-JR0 .A.E;W3836BAWRR$4J:+N7$<\A;CI\I %T@CJ*CW9%@>&1^_
MT4ZW"RL@,TO]L<17FHYR AV4S*4I6YE)2E%_#XK5O_3M+M_-0XN'!A9R5RX?
MG',,ZZ"V'6_;V7[+U0NZ<8+IFAVE= [1NY"XL</8*:^"P^02U3"\\FR5.KN
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MOA!"CY=N[6H'N=T#V#:X$_P44VW=;ZRM+?"JP,JG,XO-0Y$.8X[ R#WDO-+
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MTT=15+D7-<8]%:R3\]#JG]@44*"B21[->M6OMPMMIC4+F&4GN[C^VUY/BN+
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M8,3!=VL8GXL'VXJJQ7EQ93ES3Q.JZUY*3D4J+B2D+4=Z;7*CV_96>PL+2)Q
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M#9"2S>YNIRX O]EZU<+C3,^N[:6J;CCFQC#OBJ/ZJ_\ %8T:(9.]S?L2I1T
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M!="XCSC#BD(4X4V;2E1^(_M54WX^?:'D&E5LX&V$<^YY\-/W5M4B/(B,/MN
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MQG#KM2>@T[:E[.QNKRT,L?GS6I)G(+.\$3_YJ*Z2_37@F9QZ\QCF50):D;F
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M/MY+2EO&1NVD%3'J!Z_\.]../<:Y+G(.3D0>4L_,8]N$U'6ZA'E-O6=#DAL
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MZK*O+D1YSOFQWG#=2$[0G:>[I7(;2\%Y=$ [CJNTSQPVD TH-%@-Y/()R+Z
MVA6--BROHKP@!7WFK_/BY)Z Z*DO[DA@J(QN4IC<)DN1OK$9H+0#8K)LE-^@
MK/<Y"VQ,(9(1NIP\>2KC+>ZRTY>WA7[O)=B..Q^,3G'E,(8FDDO.)&U*MOZU
MJI3+B/*DMB%#]@NJ1ULX )3PY\%U>I7-,GF.'KX_C(J'GI0"),C=;:V@I(V@
M=IJ,;VE/#/U..JU'=QVVT-+@=JH'%N)NX/8\B02IY(5)2KM5;7]FNJV5@86
MJA9S/LO6=,,H >*M\=]<5]*PKP+(W)!M;V_96;)6S);<U&H!4/BLB^UD%#H>
M*E.1ESD> <Q61?<>B**%AM"[:MJ"AT[B*XY%:Q,NJ5\5?;WN%Q@_M^XZ<%"P
M&TXR(($-"4,IT00+6*CU.FM=9CL8BYIW#0U5+;E;AK"'#EQHN1%R4J5O/[X]
M ?8*FFL8PDTXJ!?*YYW.*M".?3L5QF1CHL4/Y!+:O(4I02DW'[-<KS?9YEFZ
M\9HWF-5T[#=S!\/0DT=X^*TU/]0IN1Q4N$J!><X F2ZDD[03W6[;=]0<=KTG
M^W@%O6.#:R8RDAQ=0\^"F>$8[-QL8B3D"ZX']6$N7*DHMTUKI.&N&.9[G*N]
MSVSY9AL9P%%95H=02IQ!3NT!/LJQMFCDJUKA54V:SF@ +VEH*R'9^.A8_=)=
M"04V)/0*/?5#[@@F#=*T5OCZ+L:6M(+Z<.=5")S\"1DD8R.OS'UHW)4D':?8
M#TK[V]<B-A;(:<>*K3<-=;-VPZFG!=F6ST+"@LSRI#^RZ4!-[WZ:C36J[EFM
MEO'.:=%D.!O [W,('BI%"&GXC#UDE+[:7"D6TN.AK)V^YS;JCOEU4;<Q&%X&
M[=HOB,/'R49UF8@*B. ME([1W_95^RU_&R,QM%5<.W<8^1_7=HSDJQ$R+>#S
M/\E7E$1FMJ8*UWU"[6N=>E1.*RD;8W;]**2S>-==. A<';>(6Y9W 84;CQG%
MXKF);\S?>R;D7%A>U56U[REFR&RAVZ#EXK;D[2BALC(3N?0^/AX55/Q0)2MP
M=%'PD=NVK=W"\NV.;KQ6GVDS8U[B.-%!97GL+%YD89V*ZX]N2@.(L1N7K:JN
M#UB!PHNA2R 1$C4A2\EG\S2EB=$#D=>I2X H"K>QUNV(ZKG@N;R>4!\9 JOL
M#&8_!QI"8;8;9=U+(^&Y[JIXQPN9Z@:56[D[>**W)?I4<TCPH>0CGS6D+>U3
MN(\0^WLK>OMME(&,.E%X[<$3;+W_ -17!. 0U ,)MU27@E24/=2%'I[ZVX<O
M(QODMZ3M^"Y.YH7'&8B:U%\K(O>8ZC0*2+7[C6\W..=1I4=)V@QNYY=\%RQY
M*']MKE8LKV6J9S+!/;@JM]NSOBN]H%:_HK[P]N,N>IR0[Y2&QH+D UQ;."L6
MQK25VVV/5=0Z*N\Y$-6?<7%/F-%(*R.^NH=EME%E[]-2N-=W-:V\H#K1<^%X
MN+E\LEB2C?%8 =+:CIN!T(^ZH_OIS([2I'NH5L]G=9]P1OHT<E;?4#.+A1DX
MIIO1](*'!:R0GJ*I?8.%ZSS='@*BBMG=N3?:1B)G%W-:Q9R+8<5&2^E+Y%TM
M+(4M7?8$5<>YF"*0.::57-()+XPN<UU6CXKL+#4IMUMY>Q"AM41U\541SGN<
M*E1=HP.DW/X _FK3Z?QWVDKQ7'I26F&0?.(.ZQ[[>VF3,=O'O<-5^@L<YQMP
MUF@HHCEV)FP,PM,MWS5/^,+[P +UU+M2_9/8-<T4( 7'NX[5T%R7.-=WX4HN
MEN'%2I*T"]K%(N3J!6A=9B8-+*<U=K/MZV+FRC70'GQ4WB)GY=($E;:EM &]
MO=5'R5E%=1:N&[P72,;>26[]&G;XJ(Y:K&\ODQ9@B;UQ%J2TL^( @C[.M1F
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M_P M\U\C\S\S9AEG=L^8:V?P5[;E=:Q07?2<YU*[O-9)K7J-:*TVK4W] O\
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M1[ARLS_[!%&A8C25-H+N^RDFZ#[1J*FW[#5IX%4X2%KP6\0OF?Y!R[.LQ\)
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M+Z[$,(,?\R^XS'F[N7=4GVZFO%2;D9AYA45P?@VVJ2--*H4]Q)NW+J]K:P[
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MIL.VJ1'F+FX:'GX*,RO9K[69K&&HKK^'!96'+ <C9B(X76M'F >WNZ5<3?\
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M@?2"HXA0N2>]E^[I'6OZ+J4FYWN@E?56ZX-2,1;TZMHH68RE_OJ"?%=[^/\
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M]1/)_1WD^+P>#Q<"?'GP!-<<FA[>E?G.-V'EN(%K(J3M+1LS223Q4==73HG
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M<@J]DI.4F.(3&4AEG;<W&XW[*N%M8.MW^TZ+F][E_JQ_<'-8L1[(>=Y,ML%
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MRT_PI%MP.E8C&QQJLHE>&[>2['WT1HSCH%]B20.\@5]>]L;"1R7AC"]P"M7
MLK#XY#E3\A%2J3-6'PI*1= "0+:Z]E<7R6(ES4E?EJ5W"&ZBQ<&G !07JADY
MW,8[3F*W0S%!*4@B[F[OTJ6L>ROI6<:E5-_=[9IANC&VJC/2;A&;6)Z'Y"/-
MD!+@-R5)*>PG2H7.V3K)@>[A52ER#EV;+8[0/#R5OG+F\1DE>0?0A#0)\XD=
M +VUJ M[LRT+*J&@=D;&=L3W5'JH+.<U5R>/#CHW/M*7YJ=R"$@)[373\;"]
M\C:CDK1F\S_](L>:N/)=;2&4E*U!*EMZI*@#K]M3N<89(2*5HN,Q7$D3PYAH
M5E9#(2&FD*CI3YZTW*57_1:J998V6X@<1Q"Z+99WH-!FXD* S/)VXK:/.2X\
M]N"5-MI)";]>G=6A8VWTMS64<%5VVMWD7F0ZA2$:ZV$O)T"P%#<+&QKH[,W
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M%P!XE'K7-AFIH)Q#&.*O':S0++=(>/\ _2%KG.QILC((,*0E$)#@+JM;J";
M@?=7Z CAFC:P5TKJN9S7-N^65Q%:CV_@I!*0M(%[Z6UJ< !5>)HN,N%'R<4P
M\@D2(HU#:CV]A/NKGO< IP:IB/-7$;=M:A=<-O,8Z28T7*/+P!CI;3 6JZ6U
M Z@=U<W=$PZN'NJI2^SSYK5D0)X4*DT1TKE>2 M#A;2M;A%T:WT'MK,YA(T"
MUXL&^:,.&A5D]/L5$C<]P,IE \XS6BM8%B=;:U:L3(Z.)X=_,%9\?A7POC<X
MDT*]]#H*T%TI?:(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O!_US?SA<
M<_U,/\Z>JPXSY#ZJ"R/SCT6TO1OZC/1KBGI?QCCN?Y+\IF<="2S,C?(Y!W8X
M%*-M[4=:#U_54:U+BSE=(2!H?,+:@NHFQ@$Z_%7G^E9Z!_[6_P#W.R?_ ++6
MO]#-_3^(_=9_K(?'\"G]*ST#_P!K?_N=D_\ V6GT,W]/XC]T^LA\?P*?TK/0
M/_:W_P"YV3_]EI]#-_3^(_=/K(?'\"MQ,NMR&6WVCN:=2%H58BZ5"X-CKTK1
M6XN=$7BWUC23ZE9T@V(?3[_X-->VPAS35:-S Y^@*UFPF=F<A)BL8]\.1@%!
MTZH7?33VZ5&16X8ZCG!GKHN:97M^=SZL!)*@&9CB\]D<*^V69$,I)W]2% $_
MIKJ&$NP8]A.ZB@,GBWV3&%W%P_%1G)'L\9<#'X1TH7*7Y:W$#0"U]3W:4[BF
M+6L '%P4]VG:ME?(^M"UII^"L&3A9.+BGI32TOSFD;B%?K%/6M09IL,;6-&M
M%M7';,\LKI7/#JFOFN''Y[XA)D2DDNO)WE( \/9;6I&>R?=Q[B>*B[3(Q8^0
MMVGBI=/,.3.0'X$1WY*%\ "DA3@'6X/MJK1=H,+^J[0@JQ7G>(+!'&*[AKY+
M$EL.Q8XFNO)2A WK)\)%];WJR1Y&*G0.E-/N4#-V]=-;]0PU)]VG'759#&11
M(;!6D*:6!XP01M5VZ]E>#B#&-\;EGC[A$G]J=FAT/Q62_+C8^$J6NXC(%[I&
M[3V 53KTN=)23BND8UD;(08J4H**NQ.4X[D;2SCE H0L@%0LH]0=*MV)MHP*
MCBN>]RWLU=A&AY_>I]L1 RPMQ"2L)!"R!>X&MJB+BR?-=2>15@L[UEO8P%Q_
ME79,2R60X$ .*6-RK=18]355EM+B2?:P_:JB.[7NDMV.:#2H_(KHA_)LM+1=
M*'+E2[FVM_;[*LD=E>PL#>/WKSV_>68M0)2 YM>-/']E\E97#1TE,F4VVH#X
M;@$ ]MJPLFE@<X.--5<(H[>Z;N J%EMHCR&$*:(6VI(4AT:_:*U67<S&UKH2
MLK+*"4TV\."QI6.5(2K:Z0I0*>NAN*F[;*,;'MVJNWN"DEFWEY'Q*AX^/_+D
MIC622DW786!)-6RS/5BTT7/<E%]/<4)W4U4LUD(Z2JS2DW^(@)[/MJ$N<3<.
M%0X?BK39]Q6D)),9J[CH%W)>A-CYK0*4+[NTWJ/?;W3AL.JFH[FPA/U0T+OO
MU4=*E*>D>:BZ!8 =_P"BK59V+8X=K]50,GDS=7'595N@78B6\FRW+.-@:C]:
MO$=C&6F@(62VS<C7CJ#<!]Z[\Q(^7QZGDHWZH2 1J"L@7^R]52U8Z*Z]M:5_
M57_*F"6S)(II^B@LA-=B-H<0RIT+4$D)U(O5ZG>YH! JN3P1!Y()HLUI96VE
M9!22+V/45L,-0M9PH:+(AI:=>(=L2 -B5=Y[?LJ%RG6VCIJQX&"&2;^X1Y55
MXXIFH6"9>;D->87ED^:.NU79]E<<S]M=W?MW<%VC'P00>ZFB[.;97 /8Q$7'
M!M4AQ05^& "D#4WJ4[&L+V.Y+YB=H!'-4SO*]MGPAC*;JCP5.QE@R4_K F_?
MUJXYR0A]%A[5VNA\UTY+:7D(  58J5W^RI'!14:7$*%[KF!D:P*.?C)EH4E2
MB$D6(!M5E<W<J4R0L*-,I993&:OM2+ ]30Q MHOID)=OYKIPF)C8F4M^,G\6
M2J[I&I)[[57[S&0",D\5/V^2EGN&[ANY:!3F3LII%M%*4-O[=1^#B#7D :*Q
M=Q]-MNW36JN?#>00DXAS&*9VR4 A2NH5<:&JAW%VS--="8.]OA4^*G.TKUDL
M/1I0M5>RD92$O)4+[@HZ=MZEK%PM'M!\5-9NUWV[J:Z%4Z;CV<A",=^^Q=M$
MD@Z=E=!E#;B/C0+A\,KXI-.*FHN*:AX]MAE1W-)(3?M'76N5OMY(KP4)I56J
MX[??*SJ BO%8#P4^T4H_"-CTMI768Z[ %36C8_76BY-K>;@-0T/*,E)"EO*M
MXM>FE5Q^)>'&0N"N[>X8Q"(VL-?@I5$U(:)6VH+'8$];5&SXSJ'<7 _%3MOF
M1T#[' ^%%CIR3J7;+1^'V)Z*]G6I%N+9)#1I]RK\?<DT<IZC?;X<U]A(BN27
MW;$NND%2'#<6]E1>0LIH& @U"L.'R5M=2$$;3YT5>1EDO\CGX]A8O%"-NSL-
MM;U*XF0RQ['JO=Q0-@F$L>FO[*S0'WG;A?B0 ++[S6CE[>&!M1Q4MVW?W$[J
M/X#FLMX[&E*L38$V%5[';I)!K17#+NZ<)<6DZ%5V4X6VG9 23HI02.ZUZZ@!
MTXJD\EPT_P!^;VCB5G1)34[ IEQT%/F-%24]MP"*Y\Z_E^HK0T77HL3 ZSV
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M2^*P##S 2NPD:'S.T+&IM4RZR:YM"JO'D'QOW-X*=$F2VV$*6#8 %1&M8O\
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MGL<6OT(7V/)$G(C'-I*2&_-+I'AM>UA4==9)EL=I4MC\)-=T(T!YK*D076)
MD+<WH"=M^@3?V5K8W(LFD(;I5;^9Q4]K$T..]K13T6(IB._)29;P$8(4A#2S
M^&I1(/VFJ]W-!L.]O/\ BHZSNYQ"8VNVM%3\5"<BXS@?R#)2$QD1WFV_-;=2
M+66.G3OZ50(IGME;4Z*3P>4N&O+=U1I^JKWICQ@Y/%R)B\C(93\PM"4M*('1
M*KG[[5.N<9'BAH*+L4<T9:0*+>7I>S%@\NPF-8?^8>8EM>:5G<OQ$$7K[,T;
MB":A>&2%M!R7OM/0>ZL"V%]HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB\?_ %M>I,Z"SBO3+%OEEF>S^9YS8;%QD.%$=HD?J[VUK4/8C[9K&P@U>?0*
M(R$I%&#XJA_2[Z%\OY!G,-ZI&6C#<?Q,U+T-;K9>>G^2K:ZAM 4C:V1N;+A/
M7HE5C6Q>W36@LXD_@L%G;N<0_@ O?E5U3R\X?4E]/')?5J?'Y/Q[,M"=C(7R
MD; RD%MIRRUNJ4A\*(2M94$V4C;H+J%2=G=MB&TCCS4==VKI34'AR7COTYYI
MR3T5]1F,DXT]#DX^087(,6X"E3D8+"7V5I/ZPM=)[% &IN:-LT=/N4/%(Z)]
M?O7ZGL/LRF&I,=8<8>0EQIQ/12%BX(]X-5(BBM(*[*^(O$_K$A0]1^2E9O9]
M"VP.NC2:TKJ!\@TX*HYJUGEKL.BUW$DJFQD&:SM4XLEE+B=2 ="0>E:EOM@?
MKP52QU_],]K)A1Q/&BJN0Y5@(F2>QCCX#H=4VL6LD**M1?I85URPR\1B:/(*
M/O<3/+,^6,5:237XKLRG$XW*L9L2L-W!+$E%E6O[NRM+,S12[0W4U4OV[8W4
M4^\^UOKQ5<P/IW'PV00]+>,U+!"T6T3N20;_ 'TML0)&AYXE;F6[E?'.Z)NH
M8:>JV> B:QW ]WNK#U?I)*$+>8P9*W)KQ_98*6VFG0B=8-BX%_A4/=4A?Y1K
MHALY\55,;C1;7@Z_(^WS4=C,=PW\[^:QGE#*(24A"#JGO-JH\@8\U772]SFC
M;P6/ZB(R_P"3+D8E:6TLI4N1;^$4+'1)K89=S1L+6'0J/N<9;32,>\#VFJK_
M *:8K*-0)<V6G:B0M*D!PVOIJ1[*LV$NG1@B3FJ?W%8&]E'0I1@HN_*<KS'\
MI,=@,0ZE\/[DR$FQL!K;=[@:T;]MO]2'4TTY+8L[2>YL'1S.]S:\_*BV7Q?#
MS,G*5&'@4H;M3II?I6EW%DX(+=O2\#^B^=K8^XC<]KM!I3\4RD1>)F/AY1<4
MU=*D]US?2JOAFR7)JL4V/EL+MT[C5I!_$U4'+DKFK:VW2F]T( \2C[:ZS964
M=FTR'B0JODLK-D7]-HJ.2D8;"F6CN_A%BY'=?H*IV0OS=3;1P5^[<Q9LH3))
MQ.JIN%PO(&<E/?>?:>9><*DJ7>X%[;1:I:UG-D!N&A43?V<66>3&[W-5N@1'
MF%'S"-O<D^&ON0OX9FT:OF&Q%Q;.J_AZJ"Y],RD'#!S%I)<+J0Y87.WV?;58
MBNS;NW!76>Q9=LV/X+KPKF1=Q3#V88\J4L6M;3V5T;&Y!MW$">*X[F\.^QF(
M ]G(K['RY;R:HS3!NW8*6?AL:\7@=+6,!?<8YEL1,\JPN9%L-(=0DJ*B0>SI
MUZU6X\-N>02KG=]RL$+7,;6I2([#<4HM)2V^1X@  :T[W&20ZA2V)S<%R*'B
MNV8TVN.LKLDH23O.@!M6&PO987@'A759<QC(;F)Q:!NH:>M-%@QY#L=I-F]S
M2KE+G98GO%^^K7<V-O=RUW:JBV65O<9#M,?M\?C_ !69&F-O)*EE+:]Q !-[
MV%]*@,A8N8\1M<:%6[$96.[C,LC0T@_Q7UF6T^C>2 #H4_\ !6O_ *>XMGU%
M5MC-VERR@(HH3D&5@XQD,PVA(R;OA8B(-B;]OL J1CO[D':H:YQN.+=P 43@
M84^*VM_(/%QYTW\N]P@=P-6BTAD;[GE<\OIHGNI&V@"Q>78B?E(K:8:R-B@2
MW>P.O?7C(PO>T;5NX6\BMY"9!Q'%6SCB$MXUEK9L=;2$N([=WOJIY<2-C%5?
M.WW02/);XE7>!P%[(PW9V3E%+2AYK"&QJD =MZHL'>(L)1&T5JIS(]OMOFZN
M.BUDSE\;D7I,:$_Y@CN*;4H"R@0;:BNR8V_;>1AW!RY)D\/+8OUU:LMF*I#7
MX5W4A5MW;N(O6SUPQVQWJM!MM+,W>UNE=JFX<81FQ^_58J/76J7E;OZA] =&
MKK6"QXLX?</<[BH?*NQL.\_D%*\M)2%N&]@JU[C]%2UF8G6Q,NM-%3\FZ:"_
M'2_FU]=5$1.=Y[DL^)%QP>8P;2E&8MT>!20- *YS>8V-[R^-JNV0G_\ J>_P
M-5D<H8E2L4MG&7$A3M]#8%O46O7VQQ\T[]H"YEAYK..>LPTKIIR4["A)5BHT
M91L4(1O*?WX&OZ:L5M(ZQ?1ZZ9=64.2B]CC\%B/(?:6IA2U*2!WFQ'NO5\M6
M0W#1(T:KE>09<6CS"]Q(]=%Q;\"T..("@DWVG72L]S;NDB+:K5L+H6\[7D5
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M@HN_P++Z0/C-/%7>3ROBD9MJ;\TVIPV"4MF[FI^$@>^M2Z>^X?KS5J;&RUC
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MM3'OCW3/TTX>BK:Y7+69OEAYAV$'+J7M(7L!U'=6O!@97 .J*%2%UW5 QSF
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M[;7.*(+B2:_Q5EPUY'F(R\< -/AHM;<I08"2KRB^J(];PBZA?0G[C72>V[D
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M$2B+QG]?*TC%\2"Q="9#RU =P3K7H"J4JJ'QN+$E8^-,BH2,>\VAUG:-H(6
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MM@&_4IL*O5Y/MMS0C@N(2/<QY)T-5(M1TI;1'CH ;2/"@=@%<SQ%S&V[W/\
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MB+*!H("T;@/E>7TXE2>,1!;D.OH0A"%#<I=A\5ZC,F0QG]OB59.WI*2D2ZM
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M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+Q7ZR$?[R,]?\
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MPE6I_P"&OCXVO;M/!>V2O8_>W0A1,S(9:7R"#C9+#;F'-UNJ )!/]4#I7/\
M)8TPNJP:+K.$S0N6;92 5E\TR4G%8=F3A' EU#R;;!N24Z^'3LJ!EBZT9-"I
MB\BM0PBH"S\9.EN1&)4DH+CS86XAL'0D5$6=LQ\P:5RQE^RTN"X"NO)29>B2
MFAYMDJ!^%1VJ%NWK5]-M/:2?V&DU'+57@W^.R-N#<.#37@30_@JORR,M!Q\N
M$M7RB'P)002JX.@N;U[9<7!E#9_RHM&YM+*&V<ZU()IR-5(H%E 6*@H=!J>E
M7-HCIO')<V#72&C=2L)N<T]*D0+;7F+;DGJ;B]:T-XU[RP%;4UI)!0O%*JQQ
ME-38^UU!";#]'NJAS/EM+XN'FNL6D,%_: /\ H;)0HZT.PY1"F7!VD@[3V5=
M;>\9<LHY<VOK.6PN*M\="H##<1Q6+S#63860VT+H;.W:D@=;VOTJ(N\-&RLC
M2IVVS\\[F1R+$YKS&(94!C"RD/.(='S5CX0+VL:@O]E*QP#3HKO=XAMQ!3G1
M6.)D6)NUMAQ+B]H4K80JU_=5WCO;>-@&\!<:NK*2W<0\467M2D'=U[JV;:Y;
M,"0:@+2J2N!2$!;@0;6N56TL/;7V2:-G,+;CMY9*4:2/1:DR.8C9?F4-U*=J
M8SR46[R#UJA9:Y=(ZK0NO]NV(MX*/.IU6[YS"#%4[;;LLJ_05MX?(DG:]1N?
MQ Z1<P:\527<%B,YGP^ISS'XZ L(2JXW ]M2]R(C)OJJUC'7#(G1;2 X>"O_
M !M(8R3*WT[?)6A-E#3:#<J!J [EONI!TV>"F^V<2^.1TKQ2AHK)SV;Q0!F7
M#8;F9<J#:E11N=2BQN5!/4>^N*XFWN=[@ZM/XJ^Y:%EU#MI7_@M?1Y,3)22B
M&TXMUI6S:ZC8YN(UZ@5UKMYCH-TTFC6TU7#;G&2LGZ$=7%W *T,^FV5SF*DI
M4ZF,M22$I<!-]-!>ON=[VM[8].+W[O CFKOC^SKHR-?,:  <ED< Y+-XOAV.
M+YEM/G8YQ4?>/A*+W!O[C7)KRP$Y,S/YU89NY8[2X-L=*:>7"JPO6KG>.3@V
MHV"DI7F/,05H:&Y2&Q8J!/M%;?;]O-$XE_ %3D]S%/&*/ JM2XWU"^;>8B,P
M7'Y3QVG:4VW6N3U-=UM<YU:-VFJYA?=LD5D$@H2K]!A.SXI<?)8<4"/+!!(/
MMKU=9@L):6T]5BLNVQ,TNWUIX*D2?2F>Y-#WYGYS1<).\*W(23?2_6J4^1TD
MFX+I[8&0VX9IX*T9]J=B,0A$!A<Z0$!E6P>*P%@HBK=#?R" M J:+GV1PL3I
M6.#@T'BM2<?:Y"YEG8L)UZ(AY9,E.J4"YUO>J_!8S3S5*N.0R,-I84&NE!1;
MC;CMLM(;1;P  6KID;#&R@7"7/+C4KNRG!'40QG)L-(0[MLZ?C"3T_9JM-R&
M/FNC&'#J"H.O-65MM=P6O4(HW0_ K&CX]B'$3%9)+:KW;4=U[]>MZL#((FMU
M"B8[ZX<\AI.O@%P9,1R,XQ#6G\,%%D_JDU\B+'-HQ:TC9&/K(#\5W<2PB</&
M>4Y),B1(<+BB3?;?]7[ZH>6MW1DDKK^)NH#"'"@T_13TJ4RR@ #>Y^M:VE52
MRGWSM9XD!0V2[A9%)L;KXT4,KS%DJ0+;E%5C[3>NP/>+:WW.U  7.+B5LDKG
M_P!1)^]<I.5Q>$A>?D7 D.G:JX) OIKW5SN?N!\SZ,J N@]K-MI8C&ZFYU=/
MP4[@N1-P&4YC"[)#12E(LH66C<- 359RS1<,U.I5S%W;XMFT$#;IQ65R7E3F
M8?0XPCR0A(N-#XA>X'72JY8V0A-5S?,]QR74M(M /XKGZ08]47E^-=<W*7,R
M+<AQ:NFY9&@]@ %6&.3<2%/87*7+G!L@-*Z$A>_1T'NJ4715]HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41>(_5B5\QZF<H1:P8EA
MLGW,H/[=;D) 6E<-)X+6^6PD3-,?+S#_ !10&@-O#VZU,NNP87,'$A59F/D;
M=,E/!I45CN!8N#/$QI]Y^'M(^4=5O;U]MZB(;B9AH3HK#/96Y<)6#W<?B5&\
MVY+C^-N(@--;Y#K)*&46 0!8:]W6K",ALCHY5&ZP?U%X)(]*$$^&BD/35Q4C
MBK+CC7EN+<62H_K:]1>JX+U['N?RKHKC)"UU& >JLZ8[$=:UILBXNM1.E@14
MI)E)KJ&CQHH6'%V]I/NC^8C]5!<@R>:;7&1QYMMXK5^.I9M9!M8COK4@QDLC
M.HW@MFXSL+)^D?F"ELC/.,Q3L]:#)7&;)V-]5*3U K7=%L?5REQ()F>U5W"9
MG\_#SJ8[C#S5O/C.I*5I%A8B_6K]87\3FAI.JY-FL-.V1T@%1_!8'*96=9C;
M\&TEY738>O6MJ_=(64C4;AVVO4K<&GXA3. SDK(0%JS,3Y5]!"=G7=IUJHV=
MC="3<ZOWJ[WN7LG1EE01Z>2[CY9!2CH"=I]E]/T5>V$[:<UR^6F\[?EKIZ+H
MSN,C\DPZ\:XV0ZD>8T4]BT  ??>JC>X\MJ7FH)71\/F Y@C8VA _91>"P!XC
M@TF>M(UW/.7Z*5TO6YB[JWB;L&A4;GK&[D<)#JT\O#X+,GXV/G&4,R"KRB I
M-CU!Z7'=4^Z*.<:FH56@GEL7[@*.\U\G-QH, Q L-!:/(8 L+%0L.E:\\<<,
M3J::%;4,L^0N6[O<:CX!9>(XX_C\<PP9)D. !2E.'47Z6/LJKV^;9;1[7JR9
MG!RM=U(E-0CXEMO+W.WM8BXTTJIW&4#I=S1HL^,SS7-Z,PU&GBJ2_@CD\U+F
MY2.M$)AT)BM*NE V6\0MWD5;<>QE^P]1R^Y*;Z,-DMF[03K045YA26); 6RH
M61HH WL1V5!W4?0E+&FH5TLBRZMFR.]KB HWDG*,;QAAIV>5 OJ"$)2-QN:Q
MBW=6H6P)F!M.)3\UBY6&V]%3N:>2%!2M".VK?BL?(VCW.-%SCN#+12 Q,8*\
MS3@L4D.W0TH[D'QA(O;[JL<CVC2M%28XGG4-)4=E,ICL"PK(365.E8 1Y8N2
M;V OU'6HB^D=;MWMU5@PUJR\F,;^"QL)-GYF\^5&5$C_ /VLA1NI2#VFLEA.
M^Y;N<M?*6L=I(8V&JL4G++QF/W-Q5R5-=6VB HIOUU-5_,VDC7%W\I5S[9R$
M4D8B.CFJ8;/S4="EHV;T@[%:]>P]E0%NU\1W,5SG,=RTQ2#18&$G+QF47(?9
MW)CK\L7.I2;&X]U6^_LW9.R+":%<NLKYN$R6YHWMX&O(&AK\%;<SRK%Y"!Y3
M:E;U*&]M25$:?97-,5V1=VT^]XT]1^ZZ_D/_ "%CYX-K7>ZG]+OV5;.8=AI#
MV.6420;M+(T2>\CMJYR=JFX=61Q:/)4"?NV%C?[0WN\]%VPLGG9K#BLSD/G0
MXJZ $[ /LJNOPEO:S$-_)6?'Y?ZJ'>N_PJZF]NE>Y&[&$ E;<;F2&I4=DW4^
M%E.JM%'V"KC@[5S3OKI1<_[JNXB!$WCQ6*W%??07$@;>B0>VINXR<<4FP\55
MK3"SW$)E;P_-57+<;$G+1LRV=SL90"V/U38ZW';6*XL6S.$@6Q995]K&Z$CC
M^:GBM96E0025=5=-MNRI.-@8* *$ED=(2YQU75)@1<AL1):\PI.Y&ER#WBO,
M[(GC^X!3S66UFGC=_9)!/@IG'0?((4XD(2E.U [ !5:RM[$YFUBO. Q,L<ID
ME%*KA/S..CMADRT)><.QH%0!*C5:L"WJ OX*V9D2] B+C18DA2V0DO)42X0A
M*CK<_::O[;VV8V@(7)CC+V4[G-)]3_%2L-MQIH(6?L/9K52R,L3GU:NAX6VG
MBB#7\56>5Y]R#*9Q$5E:Y<L'RWA?8".MS]M9;"XJ=K>*PY6THW>\T:.*R,4J
M=!82Y-<2ZZD>,C06ZV%69]HZ2.DCE0X;]D$^^%FGGQ5:;SS7*N7.07XB51L8
MA>Q9&X;[CM.FM5>PC;%<4(JU=#S3GSV(<#M<L#D.&B9#.8\8H"+.:4%/K;T!
MVFX)J0N;!LDE&\U"X_,OAMR7UH !ZE;"<FNOQ_EG$ A2=JE'M^RMNVP[&&I4
M=>]RR2M+6"BG^%YN+@YMIRK12@A)(O8]U1/<V"==P?VC0CP]5YP><=!)24^T
M\RL;D62@9_)3</B'4.3Y@6F/%!VJ)4G]%<_^FDL(@9=:%=>9?1SL_MJ,XYPG
MDW&\2EGDT5M*DK_"<0L. WUU]HJ6M>Z1<1].'BH8X1DLG4D:*_>L[SH,!Y+
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M(E$2B)1$HB41*(E$7GKZH76V8N$>=4$-I+I42;=E>FK')P7DE>*R<OF6,Y5
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M3A\2@$(@L)!Z@-('[5-[O%-H08C%)5N3"8"NFX-IO;WVKX7$\5]H%S_+<?\
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M4V?7;[KU?,Y<16T1C9'\W _$+D,F4NBZN]U?5;&X5G\K*8?5E\DZ7BKP O*
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MA2V-_74:W'MJF6^5-O-LE&GBI 1=456C4X7U9AR5L9?)Y""1_P"D=D+UOJ+
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M#9OKK7/L4RZ#M\E:*R7]K')[/EJJR7\BKRF#)>\NP2MU#JAX@.Z]=1L>XF,
M:\ T5$R'_CUTK2^*1VX^&GZK);F3&6$M_-NK4+^+S%7M?VFHK.7T%P[>P<E/
M]GX2[L(^E< G4ZGU14N:M2"93P*3?^$5K[]:K%C>.8[1=!OL-;W'S 44UQ6=
M%;S*9.8F.(3M*$>8Z0W<]-+U\RF1N9&;6$U5+R7;=C:-ZHI7T69SB1B=Z8\#
M(;Y+Z3YK"'E$;#VV!J$Q\EUN]U5N85[;MFPE4N$VO&1]L5Y2'"D^(+5UZZW-
M6BUN2U^O%3]U@[::(L+!N\5&P9:,ZE<;+K+DU"E(>0'%BX!T.BJV99Y?J@7\
M-%6[;%QVU@^(-K)[J*U\,R X@MUU*5*4Z D[7%'H/MJ4[E=;R-:8#314+M;M
MO)3;VWQ(%?;P.BP\IE)SV0?R@D.I0\O>M 6JP]G7MJ>[=CBFM# XU<36JJG=
MUE>82^9<1/+V"@(X<_U68M_+,P1DD2'38!0;"U%7NZU"W>,EM9#TSHNM6&8M
M;VQ;)=-#74YZJDR^,<XYU(>E9G,NP8+)(AQFBJVWL4;*!O6_!;.GCI(=57+B
M=[I:VX_MTXK=7&N2,XG"1>/19*GLM$CAMM*UD!UP=-;Z7KF^=Q=W;R[JD,*C
M+:_BDD+'$;@H/E?*.7Q(C<C/!.-9"K-AEU3@4?;H*^8^1C=0[<5?\1':2.I*
M J#AO]YG.'I61PS^S#M.*0T\ZXM"E!)U\.MZM_\ W/%8CIZ:J@YW#0WEUO:]
MS=H_E66WQMK$352G%O\ YB@DN;GED!9ZFU]*UGWO5'4;S5E[8Q_4K&\;AXE6
M7C[2<ODFF<AD7F&$'?8.E 6>P$U&2Y:6!I?Q*GNX^W[:*V): #HL_F<1CC+3
M,M646VT\ORTI<<(UM?K>L-MW//>^PMI\?X*J]N8VRC<1+0^JU]-8GOP)\C&9
M1YYR6DE"0Z2B]N@(-6RVR+H87-(X\UJW^%9<9%IM^#2=!S69C,E+AX^''FS%
MIEM,H\U*G3>X%B=35:^HGBEWL'%=5_UD4T(9)[:+)D9"9*82&)SNY2KI#:U$
MD7MV&K]A8;B5XFG^4>*X;WS)C;%IA@/]X\* U4UD>*<QBX-65A3%/24MAWY9
M3KB3TN1<$ZBM:Y[WM(9G0-8#0G\/@J7C^VKNX:V3K.:2!4>'_P#$HJ+.R1CM
MKD/.MO;07KNJ(2JWV5'3927(?V8V\?#S79L=V]:XAGU5Q,:_\WEJL65GRDO1
M7)SBEI;WJ 6OH0>AO5=GL+BUE&ZNBO5MD;.]AZD(#AX^*H'%L"ZZ\UF59*2M
MQ3CCH:+B[)\:@!UOTKI&+CC,76?Q"_,O>N8EAN70Q^T$5T]2N7J=G<G$@1XS
M<N0A;R][;@=6-$Z&QO6+(9*WN6T8!4+2[0$\LCGN<2VG/54"'SCDL''/XZ-+
M6MF0H%T+<7OOWA5ZC+>X#="K_<68D-0:*6S_ *C9+,X>/BE%UCR=A4X'EE2B
MC]VMBXNFN&BT;.QDC?5QT"@<?R*9'F,R)\R2[#9<2I;9=<5X01T%ZT[4C?JI
M*[8YT1#>*E>5<N1E,@F7@WY,9D-A"B'%IW*^P]E;%XYO):M@R1H.]27 N+<W
M]03D!B,N\W^7(2MWSI+R=Q<W;0+$ZG;5:O+^.V(#_P"92]*KO=Y+Z@^GLZ/B
M<L^\EAJS@C.*4-S>XC17V5(6MW%*SV\%A+02ML<8]:,SB,1)R>1Q3YPSJ/,C
MO)=WJN18$B_2_;4/<VCW2 CA5?=U!1>?,KR?,9/)2IGSLAM$IY;Y8#RPA.Y1
M4!:]M*EX6[&@+ZP::K*X[S7*8',,Y%R3(E(:"DAM3RR!OM>US[*R$ZHYM5G9
MWU0S\[)KFP)SV/2MM+9:2X57M<W-[VZU[$;G"H6-D(K5RK2WN295:G694AY9
M)+GXB^JB3I8]M^RO;"RFUPU6Q',V)P).@7J/T<A#%\FXTTA2FICTB/\ ,)\U
M:RHA5^T^VHN>RFMSO?P=P^"LD-_9W,;A$1N:-?CP7Z$#H*W55ROM%\2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+PIS[&3%\ZS^0;;
MO&;R#RUKL;#:X;]GLJLW%PSJ%CN/!<DR>*N/K'7('L#@[_V_\%W9GEF/F\?:
M@@AQYP)#J.VR;5$X[#3ONG/:"6U*G9^Z(A9T::G3147RGIBU% "!:Q.M@GI]
M]=4Q63BLV]&1AK^ZYU;6\E_.2*"O_!77&\OR&.A1XGEH6AA&Q*CU)[_TU3\K
M@8+J[=(/YCXKNN/<^WA:TZT"MG'<^SF6G6#M1DVTW4E/4A5P%>ZJ3?V1Q]RU
MSA5H X>JG.J)F4'%1<?CO(\<J2[#E(\3BE%LW(5W&K-<9C&WFUI!&O,A0,-K
M+;.)JJ'EU3F92XLL>3D705[[:;CKTJ]6.*:^T+X7 @4\U$W>3$5PUCM-P)4#
M,A9=+\=]S('Y-LCS6FVKK<62+#0UYM9KAH+0=5(S63;@ E7##1<B[(1&A)4T
MZ\@J4GX1:X&H^VH#,$MB<Z;[:K.;6D!C:LJ!)Q7",\W"Y&")>2"OE'-A<2;&
MY!ZZU3;ILMRP&(T 59PN&^AE?),>-54/4:5E9GSZ>,)#FU:7F4I.P>!()_;J
M9QL3&[3(17^*A!D'39;:UWL!'#_TZK%PV3EY+CS$G(MAJ?(OO0.H"5&Q/O O
M4E/*"Z@X+5[ERK)FF)IK0TT\BK'QCF0XDJ;\W$<EPWP'D%JQ4A21MMM)[;7J
MO93&NG+2TTHI+LW*0V['1O.I5,=Y[ Y[RJ3)96O'P6F0E,9:@GS% WW$5;>W
MH)K%S2T5\58\MC8[EKG#@];):Y/#@\>_+$L)>+J?"-%#7H?T5"76.FO\AN!
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M7;F^R?Y^7Z*/?)&]NX<%#3,KCH2DIER6V5'IO5M!]FM6MK9'-=O%%%NECD<
MT\%@\]]4.&O8O'Q,(!(R?G-M.*2@I0D7VDE7;47@I+NVNZGY#^ZCNXK**XM]
MK>(U^Y1"(,.3($MQ)\Q0N23=/V"NR&R@D<7N&I7&G3.8S:%(L1E25Z32U&:/
M\"G;XC[237+L^PQO]@T6>U,;F.;(:?@N\9E_"M.22E9C$6>2V;FW?8=:J8A#
MW"O$+:PMTZVN :^TG5=[JD9?$.B.DI3):4&_,!'Q#2XJSL+&QU\5VR*X;+P*
MCO3J/FL>R]CX^77.+8L8+1)2T;]VIJ+N(H*@NT6X6.'RK;&#S6.Q&/>D9%?\
M?)LX#\9 [#?LJNW&*?=W(9#\K3HO-U=1PPATAX+%Y;R[%Y#!&/ 6''9'A*=-
MR1V]+VJV=J]LW-M?=64:"OBJ1W%W+;SV9BC-2=.2TYR2"<OCWH26BXI0'EH'
MZR@1I]M=8R+=\+A3@%SK$3.M[ACQXT6PO3I;WIWP-I_F40QF&U[D/).\I0NU
MMUNE?G3)/^IN3"':^J_0UJ\E@=16+DW)</D,+YW'IC3[\T@$LK!40>\"YJ3[
M1Q6VZ)G^4"JK_<DTCH2UG%VGWJDQ\)DXZ3+FL%$-T#RW =2>ZQKI&4S$3WAL
M5"6\]%3<+V\^,[I>:HDV#S#-\ND-<;QZI8@MB[:U!M!2KM"C46W/RVIZDA%%
M9KSMR&:,AO$^"YJ]./4'ELU)DXI..=QZA<.K_A KJ4D @UH9+NR*7:X$%><9
M@W6L3F &IYJ[+P4S!3T19?X;JF[H3U%M+ZU8WYR.^LPUOS4"AL=AY+6_,G+7
M\58N.L_QYJ4^RIR*UJM0%TBW?5'R,@;#M!]SC3[U>7.(DW4T 4D_SG#NYY@,
M8@2V@/+7D $!2;Z#0F]J@YNU[JR95QT=ZK#CLU%>/+6?R\59L[(P\/&.+<:0
MM3K92E";$^(6!.M5NWQUZ9M@!(\:%2QGB:Z@(JM>+D\<Q7%2O(/!,QE! L?Q
M%N#4!(/6]6R!]W!>-!^6HY*9N(X+JS=M^:A6L KE&8F0\AQ]*\?\DX'"984@
MN*O<:6.AKI>:R(N(6QMYC5<BP&"-M.Y\^M#HKQA/53ECF:5C.58M*8:!M3)8
M\0+FECK;OKFU_P!H2-CZL0/CS70\=W7903F.0T(TUH%;.6\)7D&CRN)('S#4
M;2.19M20-UR==?LK7[:S;[&X$4E>*T^[[*'+Q;HN(U6JF,C%RC32FWAXB"I*
M2"0;ZC2OT''D631;F<2%P,V;K:;;*-*Z^BF<C@<)DI$!^6$K^565M $6) -R
M17.\K/-%7=57^XGM+5L3[8BF[6A!T60S&BSY(8QBFOPR"Z$=-#<:"IWM^^:8
M7-=Q7G*8V6_EBFCI2FOYJ ]1\3DY#28R763C6E)?E(42'/+0;D"U8),8X-+P
MK)/?11O;'771<9>0Q;G&O,XTY:4EM*8YA_P@6;6%DB]5:<,=4R<E*,>8P-JE
M^*Q.8Q<5YO+67DNN*):>?4"M22!8$=16"TEAD=LC(&JRW+S&T^VNBQ\@ZX _
M(9;+BDF_EZ#X=+5V&"%UO;4!J:+@]S,R6\+G"@)&BUVU!Y/R@K@RBB/C2[9Y
M2SM(VJN+ G6U5*?ZRX:X'Y*^"O%M+C;1[)&?-3C7Q\BK9C.)Y?"2DXW#Y,IQ
MSS*W5N.-A9;<! 3M-QJ;WJN3XU^ZI"FKBSM[FX;**5T_!0;/IAF6LBZ$Y*T5
MVQ??22A:TJ)W#:.VO@: X>2L3G@.:T!3XX:,*%N<6='F.!(D,NJ!'AOJ"/?4
MICKHPU/JH?,8UMZ '?;BJSF8OJ%FV'^/R8[:X[!#J@W8)-S=/B)'MJ*D:)9S
M(LN+QC+1@ Y++]-$<4+4KCG*&$*R[KY;83(&ZP2 FR+Z7"@:DK,M<UP/&JGF
M $U71S_TVGX=&.:Q>2<E-3)*6&H[Y/@W GOZ "C[<,J5]GD:S54KD_$\OQ=#
M#DX(<\\[$%LW&X#[.S6H\,J[P"\1/:X56QG^%^J7&^-PN0P9OG,.MI2W%0HK
M4A+@\-TV&GVU V&:B^I,;10_Q6(6D=O[P*55(@9ODW$N5-YC+))R[@*I"5Z[
MVEFUM/8FK.Z?9,7?;@LP=4!X7OCZ0N9JYCA.0/&&8B8TI"$A5B570#?[JQ7$
MW4-5[<=S0?%>E:U5C2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$7C+Z_S_ .X^*)[?F7C_ /25]7T<5X/ O?N N37P"J]HK>-FT70J
MY41V =/OK( -I\0OE=:+;/I;Q'B^38C9CD!4\WYJT.1=UD%(&@4.OZ:UG6UQ
M.P](<U&9*_AM7!DAXT_%;.SCG'#(2UQLI&/938H!44!?2PW$]+5>NV;:2&(]
M;CI3\5RSN>^9.]C(R=*U_"B@93ZD(2#9)=7M0HZ#7M%6XN!T)"JS('#W4-%#
MN\1AO ,Q);T9PK#JE,JN5:[E>&XJFYES88G!G@:_<IJVRCB3U6[M*"@K165_
M$Y"+#;<?WJBZ!N01M)TT*C4=VHZ"1SMQ&X'A\%IW%G,UIG+3L<>/KP5CXOQ/
MCL^,]E9S0^?%T?.J606VSH2C6PT%5;N^\N(+W;&=*-7=NP+.WFQCMXU=OK^2
MJLW'8V!A9@^;$V$RI5WUJN/*W:]/95@Q.8>^%AN-6 ?%5G+=MV[#(;71XIST
M^'P5,<D\3G/P86.6&9*CO96SX2--03]E6H36LSF]+0JE1LR$4;S(VK16NY7#
M!1,]#S'S4+(.O-J2$B,KX >\VM7C(82"9V^<U#=?-;F'S]\T""V:-SC2NM /
M@=%G9R._.R;9G9!UN9VL;DD*%NMB+VKG7U$EA*_HZ-J:+]%6W;=KD8&&Z]SM
MHKPXT\_-1L]Z;BG(S4*$]-;4K<X[=/A%_=>I'_N.22T,3J5-:GR*KTW_ (]M
M;;)QW,.X,8YAIZ:^"@.7<LS.'D8Q<6'Y<62Z&WU2.I)(L!;II>JM;V39GTJ?
MO71,GE#:-+V@;?,*SL-NYA;"WRD1$I#@2FX.\]-0>E6B;"S6T8<QW_\ $N9V
M7>T&1E+',X&GRK-=,:2RZX@@EJXW@7-T=EZR8KN!]L=DE2OO<79463BZ]N T
MG@>'Y!4[CG*,1R:3/QDV-N$9>GF)*@0#;I4[<7CLCI&!\5SQN)CP;=UP22?!
M22FLO@\G\QPF.PF.^D"7'<24I*AT5>_=6M-:W%FT.=MH2IC&YR*Z+FQ$UIS7
MT8?.3DSI>2DF%/G=1'-T  6%B1>J7E+QQDJ6C[EVCM^P9+;:..[3FNC@G'\_
MAY<I66FNOMK 0VA;JE@]I4$DFU9[+I..[;3X*EY6*X9(6/?[?56F5#"%*<9O
ML/Q)[?LKH,.5$,'4.NBY%==JMGN@(S0..JE^,\;A9N9\J[N#:1O4X#XR>ZXM
M5-R7?$T6K0!ZA= =_P"/+:"V!?J3SKJHSU:]-GH?'9$V#DO+AM;?-CK2"I22
M=;*[*B(N]9[V/IN&OD/XJ,QO:MO9SME%3KSU_15[BG&L=B,4TS"<4XE?C4M2
M@?$1?NJY=OY*8QNJ!0>*W^[^W;:9\;FU#B.5/V6%S-K)8^.[E<(XX)ZRE"F[
M>8%"]NE5"64WDY+1^"Z@VV9B;!I:[7_F/*BW!PL8V'@XF3\L'(*8!D@E15NM
M?H3I4;&Z_CO>E3VU\UI07-M+!]00"[CI2JJ?(_4[BL22ZS-=*)Z5 +B$'S0"
M1KIV5T!A8^D<@U]%6KB8?Y1N'+122N00,GC"[CW0^'D'8=2$GL)O49D9H(6[
M:4JK-A89YP)6$$>:UC)G<QB9]IC8U,@N6W>6DI*4WZG6JU)'$UNX\U9YKB\:
MX AM/)6C*HD.P7$Q[HDJ V6[#[:C8=^[;RXJ:>:QBFA7<A;L>*REU"G'+ +*
M=3?MK(8VN-!H5]C#F"C]3Y+[*;:D,;76@Z!XDI.EU#I6!C6-=SJL[X8W-.X5
M\E6,KQ-4^1^<PWWH>52V VT%_AZ=ATZ5M0RM9H5 '#L WL.UWW!=\B-GY>$D
M1LC);B24 7>8-_"!U-ZR-:"_<%GDBN#'M<1\"NC@BH+N+"VG _/2M29#JOC*
M@JQZ^ZO=ZY[C1U/@O&!:QT+G.K6IXJ[F)(:B&:IE9C V*DI*OV*W<)8PWSC&
MYWN'FJUW1W))BF M;N!\&U47*FMD!+.J#JHD=HU L:Z=A,)]&';N.O-?G[NW
MNYF2+1#J-":CF%L7!8*3E\ U)+B6UNH\(MI5 [B[@;:7!BH>/@KCAII+FS:'
M4&B@U8W)-*6RR\EHH)0X3K>U3>)N#,P/=P6W-;S;"R,T5*#F43DG$8I3?YGC
MWDJ67B;*'77M-ZD>Y+B&> 1@+G^)P\]G=%\IKZ'CZID?4;-Y_/.8/DK$:)$A
M(\U.M]RCV@FN4_ZEELW>*KNN$ W![^"GN ^L''V\BWQ6(SYGG.[42$62WN)L
M:C+W#/EC,G@M;.7\?6_MMH-!P4MZS3L;Q/&'D*&]\MUQ(4T#JL$V) K'@3),
M2P<O%;^/ROT8UIKX+4&;YA$Y!A4,\==<_-E%M82U=*V]03>W=5MML;++-M(J
MLF;ST(LG.>:<.*[.&8W,<ASZL?SV2O(QV&?.B,O.$IO<#4"U[5;(L1# ?< "
M%SO%Y47SZP@Z>2LN9Q/\GLCYN ;28:D;7(16H-I/>GK6:YQ$EQ&#%3:MV'NV
M+$7;FS?,3III\5ASL#!SDQC)O)D#RTH\U#:B$V!N;@5(NPUG:0!T[O=ZA4V3
MN_)9+(?_ %1[.>A\>/'[E=UM0F_DG(;7DJCE*T)*0+^PW%1%Q>1O@+(SHK)=
MPMFG:^1E7@\2%W\UY;R3)X)>/P2FXDQRR5N*U\/;8:6J@G$11R]1VI*M-A9R
MW?\ CH-OP5&XZYR0AZ+R)E"D)3M2ZW=.\]+]:E(<C].[=$/<KC==OC+0]*[-
M&C^DT6;DLIB\>\E,M(#SB2&QLW%24Z6TK'+=W5TXN?1;=HVUQT8MF"K6B@IK
MP\57L)#F8V?D,E-4&L7)_$CH)(+?4ZBW0U9_]==MM=P(VGS7Y:[SO;:]O"R,
M$.;IJ*:U/X*H^HN;Q>6,2-CWA(6W=2UHOM%^@'MJ$MHBTJ0[;Q4UD2Z0Z."H
M+T5^.H!U!1?I?MK=.BO[=5+8+C,S/%WY=12EFP4L@$7(O;50J3M,;+<_+10F
M1S$%C3J5U\ L3)8J5AY:HDE)2L#<-PMN3WC4BM::W?"XM/);UI=QW,8>S@5'
MDE>AT_8K5))6ZI[CO*N0<2>5(P$QR(MS;YX1\+@3>P/NO6"XM(Y@-XK1?%SY
M7S+.<UG,S\ZZEV4TWY*"E.T!(-_V37BWMFPBC5\VZU7;_+?+.8+^39"/DDI#
M25%!"P@=!>]21&B\[!6J@F6'Y#@CQVRX^OX4(!*C[AK6!SFM&IHL@%5]EXZ9
MCW2S,:4RZD;E-J%E;?=7B-P?\IJO-5N/T=X)P/EF R$WD;WESV%E"$+<#90E
M2"0JW;4%DKN>&7;'P65C.;N"K>&Y=B.*Q,IAVXID/(D/ICR18[TA6U!)MW"K
M!9N&S<_YBM2XBZFC>"WUZ3^G;N1G\/YBO/K$Q,AJ0I*;!L[E#\,Z]PM4%+F9
M;F7I/&C3IHL-ECXK(E\=:O\ FJ?#@O?(Z"IQ;2^T1*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(O%/J+SB!A7N4,NQE2)")LM6UH DC
MS5$W!JHW=DZ6Y)&@T5>O\M;LK:N^9VG_ +EISCF91R=^2Y'8<CPXRMH+@LHJ
M4+V^RNB82\9:0/#J;JA4X=I$3>X^PZJR*;>B-[F2;*-E$Z^VH&_E,U\*G3VJ
M&OK67&G="313G$%XR6\\SFA:W\&J]K^ZL?<];=L;H'FIK^BMG;O<+9?9-Q%/
MCQ4FOT]GC.R.4<8SBHA7&\AB,I =:-B2;ZCMJ@3YD.HV8;O5=(8UIUCYJ'XU
MR#G/'&GT<U6775RU^5W%CL*;=A[JV9L?:W+?[( -%4,UEI+%XZ@T+J?@NGFN
M?B9B5#DQ$6=;1X[]2%'0?=75NS+9[+*1A<:!P'W!4?.Y6.YFADBUVMU^*^XR
M/)ER B,WYCGQ!'L&OZ*TKBY992;GNT74\;+OC4S+RF4X\\MUF,"^V@!VX)L%
M$=O9WUZ+;7--Z9?1I_X_HM#,W[K.%TC14C]P%!<BS#G*O(46+.QO$FW5'?XO
M;51M<>+>4LW>U<_O\W/DV".$&O$^B@B\[&5?:I"P-.X@Z&KR[MR"6V,D;]SJ
M<**H.@N+.05JQR^.-N-M)V)V@@% _J3TK#A["WD#S*=6DA:CF.8X;N8K]ZN"
M^"3!#;R (U 4ID"YM[*H5[DV-G+6\%T+_M5Y+98S36M/1:TB_3KGLK.D3SD$
MPHQ4HM;;A:A>X! M:WOK(_N40@!GQ72+.![[;IN^:E*K9#WIYG$>5#C;+--H
M"I"CX?"-0!UO7O$]Q013[Y'*CWO:#Y7U+C56#!8QCCN#F',, .!1'F$"ZA:^
MEKZ"G<.5;D)FF)U=5,6N/CQEJX3>'%4'YJ(W/7):9"FRHD=AL?8:DK._N+=H
M%5R^+(PP71D:RK:FGQ7#,YD?(R)ZF-S4/:YY%SJ-1U K;R=^+D-#>*FH;AN6
MGI+[6-(\_)6>)S+@&7Q$2)B5)<FO%M)0RCQH4JR25>ZJ=;F]M9'./RZ\UUA[
M88(F,9PH*>BO^(P,?%LDL.*<=6-'%'34=@JOW^0DN7"1[: '\E,]&D=0J)D^
M+<@=DRS$9#S^[S+K.P*N>@-72VSUO% QK:;B%'_3O<LO+<-PJ<.SE)*"C,14
MA1*%WNOM3UM47:9&>6[U/M_BLKH QM57XF9EP%%J.\6BX?A["2/VJZ#/BXKE
MA>14 54*_)M8\1UU=HIG-\9<;P;V5??#JEH\Q2%#115U%0V%R9EO/I=E&-T^
MY?,^]T-D7@Z@*MPN492'A7<*AHKCK!0AQ-@&Q:_3V5=LEC,<V=LSB&EM#2G@
MN909R<6CAQ.NOV\%!O\ '(.9"/SADO-MJ#C(4>I]M>KO)07( BY*;[79*&ND
M>3[^"[G.+X)]I$=<)H,MJ"TI"0+*'<>M:[96-'#56$6SW2$N.BXRXK#*MK=@
MBVC8_5M^[5KQ%\)ZQGBU<\[AQAM9!(WY7_FNF,A&[RF.JU7/LOU-;-W90.!+
M@JY#;ON)&L'-6N1'Q#<-"'RV219*5VU(&M4&ZL&$'8-5U>XPMK!;;G4]H\/)
M0BY[B&Q^&DD"PVFPM^FO.&QQ>=DG)4.T[AEBXBOX+*X;F<%QW,J?89\MV2;2
MUI2=WB[;ZBM?/8"25O\ :Y>"Z7C.XHY0*\5G9.&YRF9,F\<7\UCFU$.'I9Q.
MI!K8[?OK''0,9<FDJA,]975[(7QG^WX*K#S&5*0YHM!(4F^H([*ZD)^HT.CU
M!"Y?+&6N+3H0NZ&VJ0\T64V?W#8.MR#?]JJ/FL_);[HG,H*<:K9L0?J(V_\
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M5.*1L(&FG05[.JTV A57#<BG8)Q:X:P4.BSC2A=)(Z'WU(6U\^#Y5'7V,BO
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M&]:QPTT_-=0NP&6I<3K_  6MF8JOSIJ0X_M2XT6_Q%$[B-;"]=(S$S[!XGC
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MJZ8##2;+4"1O5K6WC(97M)8>1YJ-RK+>Q<'7U2*T&FY8'J#%E.\3FR&DK\L
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MV>2VD[00L$E2CT-K"JKD,TYCV-CYJS6>*:6.+O!. \1P[<^=/0[\TN%)?B-
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MW5"BO]JMF_>R/:"/:%7,.PWMW,\._N$U9\=U=.>BR4G\A;^>3*#?RPW><1M
M [^O[%1TN;LYAT7#3U5DD[ R4<9NHWC=7^DC]U5N68_G'J=D(DR.V3B&&K1I
MQ!0T3<WL1U/2JJ+2T;<.; [UU5BQ++MT0%R/=Z*\X#T^R+6-8AHE&5.2D%W?
MTT'?5I_W,5C'NG^5NB@LOVE]6\OM]'\^-"N$*'EN$Y-^8^P6URMK:RN^Q6WH
M JHZ>WQ6=8#N&^O#=^BB<;F<A@)-LC#L'E^O[IF_5Z7Q];#DF )##Y\I+#1
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M]O;6YC[G%S0A\8;3T5:S%QEQ=NC<]YKJ-=*54:[C.0O9:([QL;(SZMDU\6V
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MN!:AA821KP66Z4H"5K5X2;*%[&NA2$$<54X@ ^C@=%D-EMQA3;I#2&_&JYT
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M@JXT7B7&\3S&1R#4%N.IIYVZO,<N&]J1<ZW-9C#)3719(90^,N+FGT7ISA>
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MA7]2I#"Y-WA^-1CLVTM#)5X'"H+00>_4V-6RR=]&VDC:5\ES#*!V5E_L2%P
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MWB[&(?<B<KC;)DA(^5"B0VH=%$6(UO6WAHK:\W G4%43/Y2YA>UUN06TUYK
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MR;'.D9=Q\&0XV'(I2+!O;8 =M5VWQK+(4'!6V9SJ46$UZLY"/CVXST9#LU(
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M5!)#J$+);6O4';VWJZ3V\MJ 'Z5%?O7#Y#MG=L=4:ZU63A\7D<M\V(\?\-H
MD]3J= *C;F9D="2MVQQ\ER'](5T6W>*8[\OP[#3[80_:RC;4FJ/D;D2/W \%
MW/!6 @MV->/=M'Y*I<]QD)J0%,DID+NXXV?WW9]]6;$W4QCI337DJ_W?C1+'
M[>(U_ IQ/$927&4E$KRVVE)4A&NGLK!>OA +B-1]Y4/V[87;&4+M/BI6-B,U
MDLHY^9K/R3*K%*NBK=U99\C;Q0#I@AW\%T>&VD JXK"S_P C$Y%&,=K8EO;Y
MH1WWL*D+=TES9$%P!(_58S)&'TJM@%Q"&O.60AL"ZE*TL/;7/)QND,3>(/Y*
M7#FM *PY^38BX]S(HVR$-6"=NNI]U;,-LZ1W2X4_5>:M=J%69<*;S!+#Y:#$
M4 @[];ZW!M5GADALF%A^8*(R&.9>,VO%0LCCT#+8N88:S> U<@GM)J(OKJ.5
MM6<5!86WFMI3&?\ &%86I<+>IP/B_P )!4  1[*AW02D"@5R%["\T:>"RP00
M%#5)U!K'+'LH'<5E#2[4<%BY1M;D"0E'Q%M0 '?:MK&R!ERTNX5"\R^X4'%4
M?#<6QBV'<AGV '&KAAQVX*;C4C45>KS(/EE;' *G[U&N=&UA#U6IL%_SI"\0
M#)@M:)(23J#[*WA*ZS>.MH\_!<ENH[DS.=;?+]O!0\E]Q&YAQ 4NX"2 ;B^M
MJL6+@%](Z5YH&_#BJQ>W,LCG12ZNTHN<6)(2[YSS2FD%)"0M)25'[:N62NX_
MIQ&QP/!63M?%RMFZKP0*4U^"YN8T3Y*26TE]L%+#I^(7ZC2J7->&TVO;R*M&
M>MYYALBYKI?Q^2BN.,2(KWEM!*M^U1;L1V&U:4%R,A< [A4KF5UB;V(>YKB!
MZE8T>3LD@%5FE:$=EZZM/CHF0:"K@L^$NS;3"O J7VO24!J*T7G7+C8!?P]]
M<OR<G3!W>U7[,WUPZ)K;=N[=Q4)/AJQ#2_-26ELH\T)5I;:";'[14EC^Y"(P
MP>YJYD^*6"=K7#W:%9&*S&1?P0DYIPA'B<0V#=)0.G;6C=7,;YB6"A*ZA!FF
M1LZ4XIX*4X=R: A R6'2"P5*!0I)3XNAJ)O,<9Q[W5^*SXZT='(9&'VG6BD\
MSGYG(T%J9%;90@_A;3N)]M[5O8BWDL/E*L=W9LOF[7A:PP/',AA<])R;[SOE
M.2BKRPFWF(20:NC+'ZR%Y<=KBJE>WMQB7,B8T.;Y!;VE*B\JQ,=V"DL^62FR
MA;IH0!7$HKM^/N7AYJ-5TIF*FOK3<T@$K7>0Q$D.^4MZP22'5;;'8.XU><9E
MWPQ]2.@JN)W_ &Q/;.<^9VZFI6QO3YG&8KCB_DWUK;2I:W"\JY!MV=PKG6;-
MQ=W-7"OHND]OY"!]I5G\NBUUR#*N9[YME\^=$<W);;*K#NN#5KL[06T;7;>/
M-<HO\Y*^[=OU96E/3FM6\9R\'C[AP.32J-+2\H)>(_"(6=+JKI%CF66\% -5
M+7N/%_")8CK3[55_D,E826RE3:DDA23=*AW@UXQG<;GR[7#0GP5$DA=;OVR#
M51.,Q[LCD+&2B[&F8J2W*24$%85V>VI?*7&R0/&BZ)VY#U(R':A;';>A(BN>
M4D-7!\)(HRX=(0[BKL!;1V[V-H#KX*GH5YM]H[.M6BXN&Q#<XT7Y[(VKLCPY
M#H*TN!""3IKK:M"7+6[&U^;[E9\;B9;J/<QX;]ZE8[)90$J65DZW4:H\]^+J
M0D"BZKB\=])#[W[OBNU)"5)7:X2;D>ZH>Y/786!3# VM0K)R#FBWL+\M#0MF
M8M(!6WU2.G6M/"=K0&??([G7BH+,Y:>WC.P5/HM6Y:9RS( ,Q)S*&--B5ME2
ME*.A!5?2NHW%G('=2)P#1^BI<&?-XSZ><:NTKZJ>1>)CT+=0GYA*4A5M?%TZ
MU!0,^IG]QYJ?O S'VE6BI "R<=E)##?S:'0V\CJ4Z"U:V0Q$;[@0M!IH5YQF
M7D?:&:4@'4*#R3QRQ==F@*\Z_G]UOMJ[6]E;6D A!HWU7,)KN268RN/N*Q&F
M668J8V+"6DE(V+2D$ >WI6W$P=.C-%A<]SG[I-5D-M) 'F*)<  4KI<CMK8#
M]HU"PN=X<%]<FG&H5(W)\L ;S:]Q]E:%Y'#*VLG)2N+NIHI*1<7>*SDQ_P %
M4EYVS) <U!/6N>9N>*2,-B;J"I>3 3R2;MVIUYKHG,LK9;+B_-;7XF]3H4VU
MU]]8NWXYC,"X$-"C,A:W-JX-D?NK7F3^:@N48C,3L:PSC/ \\\E-[[;)ZW-6
MK-7PBITU/XK$!C.O+\ I1;LS%-,1$+O,*$MM[KEM2D)%Z^07%M?1!O\ .5'1
MW\UK<%[2>F*:<J>2F($Q3K2$2R!* _$MX1IW=]0]UC'VSMXU"O\ 9=P6]Z0P
M>WUT5"D9V;@^:R,=D9B405->;%)[$K(LDD^XUFQM_P!8F.30*/RV*DM/[]M5
MSB?73BL?(>H\5&8=:5N?B(0E"%LC==PDW%NWLK>CNXK6<AHJ%&2XV[R$ DE.
MTBOEX+.@8^'+R">1O,J:DK1Y:4K 20GN]]3S+>-[^H12JK%Q=RQQ_3AU0#Q'
MW?<L'G+:$'&R4250RV^$EU"MJ]B[:"W=6GEHF#:5+]LOE+GAIY#[UV9M7&&H
M[K$Q]O(27&U%EQ:BZXLJOM%QVUJR"W$6O&BD7/R/U7_+\:>7Q6+P?-<HP^ ,
M[)15RL0PG9';'A>0$&PT/9:J9)3<:+I,;FE@KQ6+DO5><MB3'9B^1)4H%EPF
MY2 ==P'LK7)-5]##6HX+ @XCD7J.M6;?>9VQU)CE*MR18>+PC6O07HFFBNW(
MLYQS$X%*F R[,B*0AEA-BI+B397[!K-UJ+5Z%5ZQ^C[D\;D_',S*CMK042$I
M6%=-VQ-P/=6!QJMIC=HHO2U>5[2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1>5OJU]=<KPX,^G/#Y*H>9R$<2<QDV5;7H\9TE*&FE)-T.+VDJ5U2FUOBN)>
MPM0_WNX*+O;@L]C>*\J\!]&/4KU1#DSBV'<DX]*RE[*R5ICQ?,_6 ==(WJ%_
M$$;B.VI>6XCB^8J*BMWR?*%LH?17ZPD7\[##V?-N_P#05J_[&+S6S]!)Y+7_
M #ST$]4_3>(K*<BPBOR=LC?E(3B)4=!) !66R5-BY !<2D7K9BNHY#0'5:\E
MM)'J1HO1GTA^N68SLM7I?RZ8J;(;84_QZ>^HK?*&!=R,M1N5[4>-LG4)2H7M
MM C+^V#1O;\5(V-P2=CO@O7M0JETHB41>??J;8#[?'DFP(<=U-KZBW4T%BZZ
M- IS$Y2*R>3(.*\[NXU<"4I1?4ZF39+39Z(-O96M) ;-^QNM?U56[D[FE?(&
M  [M!ZT6%.QYBNMOR@51GBDO%-M"D]->^NF6$QCL_9\U N5Y6P<R9EQ,#L=\
MU.7\%L!&4PV.@/F(XVLM-[E,(4%.*-N[K7YKNS<37E9B[YO/Q7ZEL([9EKLC
M )+? >"U5RYE&<P3ZPA;2G2%I5\*T J%=;L&=0@;CM/#5<RRL8B8\2,:"T>"
M^Y+D&4B<9D0("@9,:+M:? .XE"0G[??5XNL='%%N!^]4G#=SW,C^@X"E="VO
M)4;A/*LKDI(XYFHY>W-J(DK'_HP+[5 ]M<EN8V[MS5^B\1DY98VQO!V\^/ E
M;<B\:>R6$F&*\(SS:%-Q3;PA038:=U0<,W4N-I"L%]+]/">F*#DJWC>.Y#!0
M&L?+?1(>83M60-2!V "NX8V[ABC$9-"ORQW-VI<R/DNV_+0FG/2IT7)TI6=B
M"-VMK=E6EC@10<ER-NFI77&9F?FL*7%D>2(*_/<2-=^W2WZ:J?=,3Y;;V'G^
MZZ+V+'')?D/_ *?U"L?*?4 YA;.(="&GFTH? 2KQ*-SII[JYQVABK?KO?-RI
MQ72N_P!UQ;1-CMBX;S3V5\ ?Y5'N%M3 4X=R4HNX;W'2YIW!TQ<?VZ4U_-=0
M[*BGBQS&W!J2&G4U/RCQ5%S,S'\RBHXU@$H7DY:ALW(L&TMG<5$]E@*Q6\)>
M]I/BF:OHC#M8SCIP\E)XWT\X[AI4*/EX:7W$*;,EY5_'M/BZ$:5T=^,;+9N+
M?F%*+\YY/,W-C<AC]6'C_!;GY6O *P3$''M,[T)1\NE*00E(ZCOKE.%^OL[I
M[G>=-2KR8;:^B:"!MT)X*E,3_P KNX4?A@;;)'[57"UN;F>Y(D\E;)+/'VN.
MW0T#J'P4(],$V4XA+J4NN.&Z>J^\:>ZNFMG:Q@:#K1?F:2W-Q>NWU]SG<%GX
M.*R]/;1+0=Z$DE.J=01U'N-:.6M67$/N5E[,NYK/(D"K:C4:CF%)Y.(VQ**&
M4^ ZA/OKC-[9/CE.T%?K*PS#'MU=KYJ7Q/"<AE(AF)<#04+M#M-56ZR 8\,>
M/P2XS<;F&/2JB\9Z:\Q;B3I?(<T7KDJ8AJ)*&TI)L;^ZK#A^XK*UGV[/:>/M
M7%,]B)LG[6:56?ADM,10A3H*V]%*.G[-=(AO(+@U@&A6;'X"?%QCJ46O/4#T
MTR/*LHK+(FH\BR$-LD64E(ZV-_?6AD(F-][N"V;FZ,3R]WR^2V7@&(?'^-QL
M1':2IN,T$I61XB0-2:B(, SJMN(WNUUH3HIBWR43X=P'X*A1.:/\D$MAEI<1
MN*ZILBY"E;;_ +-=$Q\4<E2[D%R3NZ_G9M#7$5/*JC)O.H/%2J))+C3R$%3;
M6SJ2#8WMWU0LI$8KHNB.E?%0V/AR+9&RO)VGQ.J^<91F>?8*=D94IMMZZV6C
MM)L+=NM6>UOI^@6BFJN[\%'/(V6:I('XK2TJ)+9RC\5+8==:>4A:4WL5(400
M+>T559(W D*QG8&U<O2_$>:XKEF,@<&QT5>,RJ&4)4^MJP24 !122-;U1+NT
MN[)YG<3L\*KPRZA>1'&[5:[]7,+R3@^;B*C9AZ8B0G>TVD'PD=;I2.E6;"WS
MKMFYH]P62=C(O\A%%0IK?+.8MF7,8=DHC>&[:"$C3N J8>]VXAP%5C:Z-H#H
MSHY04:!+>EHQ\=E;DE1*4MVNJX[ZP/=I5;T$+IC[5LGBG(9O$&W,=RQ+S+2O
M_55@':G3H#V5IQM8XZ@+?OVW<(#&GV>9U5OXA(P2'%Y7#K^9RTK==<EQ>\IZ
M@:WKY'(^VDW- VKFUUD+J*Z#86U.OS5 ^]4#U:AYU_+,9F<AM#+@#2$M'H$]
M=U2LDIF=N=H**YQ3[F4<!N4!Q?D7(N(9)&=PL=2@BP<5Y:BDI[B?MJ*NH8;B
M-T;BMB"UF=[J>U7KF'KUD.3-8WR(1BF&L+? )VN*&EK5$6^"CM^.M5M6]R8G
MU %0>:ZHOJFU-#<9>/6EYU8 VN#KWZWJUXJX^@)<!R6IW0TYX,A)H*ZTT6^_
M3O+K:+>*4R/QAYA4.HTZ$]M<Z[CF?.\O/ E6>+MR*PL&EO\ * %.<LY6UBVG
M88:+CBDV).HUT%>^VNVO]BZKCMI\%S[/9+Z:%SBM7_G<0@(5+2U)*BI;>X)4
M!TTZ:59+[%]"XZ#:&GBOG_C][VL=.\5#C756+C6(=Y&J2XEPI0S<)5U*_;[J
MDLW<0XZ)D;=7$ Z>:^8J2:[O9"YI# X@:>:JPX]C8F3F.V*9$ES:\Y>Y)Z7%
MZQ8?N&2U!<0#57G-=BV^3B#VDAPUY!;<=0G#\4#<0_,!;>T%7BONT/OJF=:3
M(Y(R$4U=2B@663[%H@J7>IKP6JYB,5BX[LF4VRPRC5Q92!:_MKH,@(HQ:3YI
M(7@K6TOU4CQ9LJ.U$^8BH7_%G4*%BFP[/?4=):D&HXA7>PS_ $V /'X+/Q'J
M1!R3*F991%DK.T(5KN2K0:WJTX&UMFL)F^8E<W[N[ARLLE(!2.G$5KS\U$\H
MX^C^*G!!;&2>=3M#*RDJ"CJ>M2&:M+>%@D9H0J!@,Q)#*XSC?4<7"I_%7GT^
MRO)N*1E-S'E.S'EV<0^I3GA!L +'32HVWQUMDK<]5SJK8N^Z9C= 6S13@:CG
MSX%3O*.4Y)V?'6^EUY,D[&FXX-F[#K8=E4481L)+6"H\UW+!9B)E.J-3Y*4X
MSFG^/277T-J6W+*52-Q)-Q[Z@KRQ;)[- X<%<YK.WNF&5E!]P4F]ZH949M,2
M-AE*Q6VQD*5MU[=*Q6_;I>W<\\"N;WP-M)0*5Q/-9$B?\N^A*VWUA+>MMHM6
MWD<&QL/4835JU&WCB[:0L7EHEP\D'D+_  74W24C0>R]6+#Y,MC$;BO,LCQ\
MM%HCU97B)<<.K<2<ZTI(" KQ["==/=5@?*)&^2P!TE:.65Z5^DF(Y?@UYK/I
M>T=*(P;-D$#K[ZHV6R\MN_IQ\2K;B[.*5A(/WK=2\?POBN*^7PK+3$OPH.RP
M6I0Z[O;3!WEX'%SJ44#=N9#)1JHG.>&<BYOCX3T$-L0X;BG77U$A9%K62!:N
MD ]?80:56E<6DTC'3$#;'K]^BT_R3A4O%&,_ >>G/+4-Y<-UI"1H05'I?OK>
MO,6YP&VI*IF/ST$NYA :&U\N"OG#L9R=]V^6=5*DR'4J:0#N*4"W6W36I&T9
M]!:/,II1I_55&:YAO+^,PM)HX5^!"NN>PKS*5XW+-;FGDV4V>A2H:UQNZOC)
M,XM)U*_66'M8;FVC :*M: :CG15.' @8M^5&QP2TP@I):2/A40;_ 'VUKK';
M)E;#]ZX/_P"3VP"9HC K[?"O!RVQA>$X48(9:7O<<>C!Y85J!8$Z U1LIWA=
MPY)]MIM#J#CX*/L,#:?1,F<VKG-!U%5K(Q5.N2VH#ODJ6I3K+BANL+@ 6]U=
M1OYMF/#SQ<!^(51PF+_V.2Z3= TD_ ._BN7$\AR/#>J/#_F)*)4:9-:;#83L
M"2@C<?>0:YYC\F[IN;6M0NX9_MB.W?$^I]KC3[E^EB3=(/LKRM-?:(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7AWDTJ*WZI9HY%L
M.1F<@\H)4-P!#A-[?;56O83M<&G5U?Q7,>N'YDQOX5%/P_=1/-)D;*RDJQ[=
MT- AM:18J*CK<5/=KP-M6.;=?(\@FOII^*E.Z[.(Q QCW\J>HJJDRS#EA2I
M2M;25*;2KJEQ.GWU\RTD0E'1^73@N86S6LW[S0[33U5XX-C864BS8TQTJ"MJ
M?E[V &NOMO51O+U]I.R1@X55\[.M8;B*5LCN.WV_?^:@<IC8^&R,B*XZ5-@'
MRD%)T!N!KK5IO,S_ +&)I U 'X*N7=E;65R]KG5T=04/.M/%9/%\Z_B'GFF
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MJ=%Q;NH-%Y4#DJZZVE4?:>AT(]E7QT6XFO"BIK'$.JL/'8^+CMZ(K26T$[E
M=I.M8HH(X0=JVKFYDGH7FM%VPYS<A3@:-PVHA0_JA6OT8+IC@6C[EXEC<QH!
MX'567&\OS>*C(B1G0&$FR=Z?"+GOJFW':-EMWN)JW7E^RL>/SE[ QD3*;> K
M7]UT9)V9/=.0D/>:"/$;W2+_ +VEO?XZU9MV#3_E"W.X,?.6"X>ZNG"O"O@H
ME^!/=2^AMJZ%(_#L02HGLK;?W!;N@<6C2G@L6'P+YMDKZ;:JPM8G(8G'PT9!
MCR'%M @=GZ*H]O?17$A:.*ZNZ 0@.:* +K6^VTM"5J"5N:!%QK:MLQ/B)'(K
M))/4!RYZ6U[>@%9-HCC#5]Z76:=5#3F6V7]R+$*)"@#>RCK70L9>!\88>2XY
MW!CA;R[F\''\5C(4I"E:>&K!M#552 0N]E86E1Z&XT[+5RCNFU<V4/Y(X -I
MS7<WA\?D$ID2F Z\RY=I1ZI4 ""#5:LI")@  =.:NG;-H9=Q!-=1Q]%W*&2W
MMH=?6XVA858K418=-#739G6A@UC9N(_I"VH<=D+>Y#B\EH/]1_)7;CW,,;A_
M,CY>9Y:GS=@NDD*/<.M<6SF/=+(-@ %?3FNKPW#Y(J>2H.<6SE\C,<?;LT\O
M1O4$]GZ:[O:64<5FUE=PISU7 ;Z622[):/<33]%V0/*L,>APL(C-DAL=B0>V
MVE<CRQ;#,X1\RI=^+OV0]2=Q8T#D?S6(SDHS4YS'OL[BMLN(\.X+0DBX/Z*E
M[*>61H%7'[U*]LNBAA=(1S(J>/)5>?ZB?DKTA>#0[&R3=_*;"%  6L+V%K59
M;J]A=;F&1NOHLMC;RSY#KQFC">1\J:J^\*]2<]F^,)EY!]+L@[TRCMMM%R!^
MBJ);8""6?=&3N/*JZ'D;D6\1>[4 **@O2,2'Q ><:CRG%+<CE9*25:FP[+^R
MNKP8* 1C<T;O&@JN+29ZX?-O:2&^')?7G')(2Z\D!"/AM[>\U)VMFV#5:=_D
MWW9 ( HK1Z:<\@0VI^$>:<"XSA<#UB4J\SLZ=EJX?WGAYKJ[WC4:+KO;%T(K
M&@&M"ON;Y$]D,FM;@!CCPMV!N$VU/MJ-QT+X* <>8Y*C7V>F9>.#P-M?.O!0
M$N8V28X%T=JSW5TO'8GZZV+W&AJ?P6MDLZ^2'I1DC7BJ:9",SR)<1+JF8^+2
MV RC0*45;KG[*]XFQ?)U('N.@\5@,O2L!N:"YV@//CXJUDC5O<!X;[N\]PJ$
MR6&?:R#;JJFT5!*XLK5'E(VD'?M0=W<2*Z');@V?N/ $_@IK#W+XKANP?,0/
MA4+OGX#&950<F(/A!24(6IL*W=IVD7KGT<DCR6 FB[7)!$Y@=(T?<H+(X3'*
MA/8B&TA#=MH*D@[3?L-="@B$D.TM -/!<BO+ED-WOB<X@'A71=;F0Q_&XT)B
M:XF*@)#*'$^'<0 -3[:]?V;:@D -?%8A=7=V3TB=-="1Q^*Y1LGB)^61#B/H
M?R$E!7YGQJVH&NO=:L,U[;Q#0 U\EEML=?7+JN+A3F25V/G&>G\.7DOB&1EH
M4I)LE(WFQVV[DDDU1KJ4.-0NNV4+HV .-:*C^I<+C8;8R.*<;5D9CQ4^A"]U
MT%"B5V[-;5'DA;39QOVKM].L5@3AYN3S#>U;3A+<A:E!(0D#H01VUL6[&]5I
M/#1:V1EWQE@XKNY?S2#CL06,%.:><EJ"'TM#<0@IL2??H+U8\OTIV@1BAUX:
M*L8*RN(9B9'%P\Z^:]7?0*H*X+R!2?A.0N.S0M(JJD4T5Y/%>NZ\KXE$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB_,/ZF?Y\^8_XPQ_FC-6NS_PM59N_P#*
MY>I?Z</I/_H;D7^30?\ VVHG_6R^(_']E*?["/P/X?NG].'TG_T-R+_)H/\
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M&8#&.R,+"0T&HR[&.PH(4+'0G;6TZZ$L+".-%3^[',@BU&ZOG3FL1:U*6
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M6TK2!9MTH!MIUT%>N[<9_;!MO+SYK!VWDIQN$W(GE11N?GQLIGUR\4V5LZ;
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M6M69[Z'1:))A#GC512,BT\I6\D+/7=T5?NM>LT]A/;4D)&WXU5/L,['?ES'
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MT_56]7*WEXAG#KCI+#( WE5RJW;J*YO])/=W/5C-"XUH."M%OW;)%;"#IAU
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M:2R7?);.B6T7*O[%-S5WG?;0C;(!3TJJU;?5SDEA</B0%.^G?JUPB%DW<=E
MMN2YM3#E*:4O>2>F@)%<K[LN;F]H+4F@/C3DNK=NX:.WMNM(T;M?-57U>S6;
M?YNU/P+,AK'J2A"/)4H!TI-R2A/[8K0Q3)( &SGW'XJ?NGMG@=T_::<M%+JD
MMQT(?E+\A2T@*6YU"R ;$UV.YMHY;<!QV@CBN S12ND<UU7.!66V5N("BL/
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M>=4$QM@!?6FX%];BUZYADX;RZ8',&HYT*E\/G637#XI--?(+5GJ[R7CO(WQ
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M3="=35:[;N&R$@\?XK:S\!.K= /V73Z=<:5@L,%RP#,FJ3(<&H4A*P-J#?M
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MB7?QVM0DIUM?2]7QW;1R,7U+#P\Z>?@JE==PQVK^@_4GX^7BH":A$Z69)O\
MB&ZK6 (]UJU8;%\,9).HX*M7^";</%PWXCT^"K:,9!Q&4?<A!U3DE)0Z'5%Q
M.Z][I"NE;,%U=%FI-/BJM?WC TQ,:!MT-1^2GN*_E.2SK6*FH<4M)NM*DCRB
M+="2-:@+YTD;"X*0[=QL#Y6OE=[@:TJ%9^:(:X[FL&8.)4]CGW W*\D60TD&
MP/;4/C;USXW"M'\EW"7:0 !HKAR//L<?A-.^7O=<T0G2]ZBK6UGEG=O-0H/N
M#,Q8^(&FNBTWR7*/33)S<E1V,I*QN-D@)[.ZNL8;*R6L(M0&T.E2-5QFZN9\
MK<%VM#]W_%0^*SL7.1F9D!MYI()U>">J>NW;V5=<)9O=N<XBA/(K'>V9QTK2
M*AW'56H8K/Y'%#(E5\4V"0QJ?&FX*A[Q5.REU%C[TQP&CC2O#G]RLEX+G)8Y
MLG]%7<^6FG%<,+QV9FRZ(FP!H745&US]QJ#OLF72M;*>*KF'PDN1)+2 &^*A
M)#$B).6'7U-K9)0IM!&PG[1>NFL[;M)H6O:7:TYC]E'31.MGNC(&YIXA<\4P
MU&RCTII*A*EBREI4JXMW"]8;W 0VL)<-:>.OZ*X]NYB7J"$\#P4OE(.2,42$
M,.JC+-EN $FM;#W-E$2[=[AZ44SW+]2Z/:P5!XTK51)A.MC\>Z7#JE73_P K
M5+V>=^JN714!;Z?Q7,)HY;=X#FEI4MCY+B4-O*L2@WU&A*3V^RJ_G+8.E+&Z
M>B[9@KYLMH'/"N;/*^/9E"F,^IN((H!#BE>"_0_97/\ (8B[QHZ\=3NTU)/%
M2MKEK:[>8&D5&JH[3^(S/.LA X<%28[<=!=+9)9\V_B()]E;6.N3#;F2?0_;
MQ6X;<U]IT]5RY!$FQ8DB,-L>;L4EKS1<;C5TPLOU#>I!Q^W@JIFC$QA$A5/Q
M6'2QDOS.8\I_)%HM[B+-@+%C8'7]-3F7Q#IK<R./N&O%<LGOG"/IQZ,_<+AR
M/DF2XNY%RD/'IDQVG$EU:U^&]^A3M-O?>JI%E9!;_3MH*CC]BI;MZT@GD!=7
M<T^5/R5J'KI@N801"=95C5HT?:<&]*RG0A.WLTJM8W .CN#77=KQKQ^"[5<7
M$38]SQ2BS^*<Z7CX*XT!8$!+BOETN(4 $DW-A[[U.7/9;KRI;^?\%71W3:PN
MVG\E:.0<GP7)N/2<4M'FSG62$%:!M2X1\0UTL:K<7:]SC9"]WR^I_9;T6;MK
M\F-FII5:V8QR(.#;@RY:$9!+>T/*<"=0+#KJ:L1RMU"  3^/[KFUW8MDN=NV
MFH4ECU/0L2RJ> J0A("_*L=RN_H.M2$DS[F.KR?O71;*T9;Q@-:/N6P>'\E:
MR*!Q^9!=:;V'^,.%(0H']70US#-8N4S]2+CHIUUS&W^V= 56?4#"8UF6TQ *
M76WP0^PDW((M:Q%=&[,M)"UTES[=O#EX^*Y/W-BXX9VR6^I=QIKX<E5\MP!'
M'9,7,KF%WYID6A*\00K35))-6G"WSKVY<?Y6EP^XK4RENVWMVM=HX@+!>6Y,
M:'RCZ4K2JSJ_BT'46[ZM=ZY[HG=,ZA4]@$9]P]%FX?C&,Q4Q>4C;R\^C\4DG
MQ%9!N1TKEEM=32SNC)H:GQ5WP]RX2L<_5H'"GDLN;G8>/C/2)&X,,@JZ6O87
MMK4__HGB,OW?BK+'W1$^X$0:?_;_ !40,_C,M&3E67$B.4 CQ#</>!5FQ3(H
MH-#KS5([BN);F\+=N@.FGWK$<XW@<Q.C/952FV'UH#JT.%H%"CVG2O&5M8Y8
M72CB&E8\)DY[>=L;3[2:%6SU)]..'8CCL:?PZ%Y.9C2&7&1#=N7&P05%=U =
M*X9@+K(7$Y:]M&Z5T<%VBX%HU@>*;O@LE[,?-(BM-QU-%2 LH4-4DBY!L>RN
MMNM&R1[B:;=%6)\V>LV%K:U'A_%5O+\1:Y#/CRLL^51XJ2&8[-VR%'2Y4#<Z
M55'QO$@V$CXJQP2,=&1( =/"JEL%Q%E^0K'8\B/&V;UN.K4JQ3_7$ZU=H<DV
MTM2Y_N</BN:7F%DO;ZD8#6?=^BI2/4?C.)_,((CK9ELO.)\EM(/FJ0=H65=E
MR*JUW*V;^XT4K\%?\9 Z!NR0</BK+Q[EF/S\=I;&\N$6>*DD!#G[T=]8XX)'
MLWC5?9+^$R]'@?N7K3Z9P1B,O_C _M4UK/:6G5;\;@1HM[UC61*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1%^=?U#>FWJ+FO67E>4PW$<UD<9(?95'FQ,;+
M?8< BLI)0XVVI*K$$:&K-:31MB:"X ^JKUU$\RD@'[EK+_=%ZL?["<B_^$3O
M^AK:^HB_J'WA:O0D_I/W%/\ =%ZL?["<B_\ A$[_ *&GU$7]0^\)T)/Z3]Q3
M_=%ZL?["<B_^$3O^AI]1%_4/O"="3^D_<5=_1STP]2L7ZJ\.R.2X;G(>/BY:
M([)ER,9,99:;0Z"I2UK:"4I ZDFL%Q-&8W .'#Q6>"%XD:2T\?!?I5565D2B
M)1%Y[^I\?Q;!D*L0IVP[]*\/BDD:0Q2./FMHI@9SM'I5>=(4827PAU?EE7?I
M4)9PN;)TG:@^/FNK7&3;T Z+W!IJN>.XP<=RB3G&I9<C.QTLK86=UB#NND=!
M5\M(&6P.T#U7.LE(Z^F;UO:TUH!JDV>X]+WI-F6M-HTN >I-5"ZRDCGT\#^"
MN [9AZ8<X_@%9L-C6>2I):<\@L ;@-3=70_HKQE<U'##5@%>:JF2QSXW@5.W
MDK[B8[\.(W#D2!(>:N-X^+;?0&N3W5TZ<F1HHM'IR<&\%E+W+46OA*DG:;V(
M/NK!$X-(>X5\:I*W;0$^JU5RKA+KRU)GH$R/)61\.Y0)Z7N.E= L\PSH[6 <
MO%<\[AM+@.!8YVP^!\]%6\5Z5*XM&E>8ZH,/.EZ.@ >!%NBM*Z+@L^R*'4^/
MBO;NUHKXM:7.ZAH.7[*VX_E<2-QEW"EI:W5-+CA5@1L6DB_OUKG.4@%QD'W%
M3[G577\9V4ZWMF0R:;10\"M28/ (XG-=9@-/2V9H"BI2A^&1>Z23V5*]=Q90
M*QP8P6_M8T%OP76U+AX+.3,CR)],>1D"E$-).\)2E(38'4"CY9)6!I).U>;>
MVML?<&1S&CJ$<N-/&BE>1<3@\MQJ$.+*%;0J++;/B'?M/M%(8IF^[D/->,I=
MVMS(&NH/@J_B>%8/CT@XV8M,V;/\31DH3J$IUUMW"KCB,G;N;MD^7T\URCO#
MM6[D=&+)QJYP'S!HU'[JD\]P4+"9%MN*0GYA)<6TBY2@W%MN@ZUXO#:EU8"2
M/,44?88V_L 8;NFYO"AKZKH]-8J)'.L9YB=Z6PI9"N@(T!_36>R9N%"I4FJ]
M(Y9,5MQM'A"W@;-CJ0.NAKW=0!G#BL3G-H21[5J#+\%Y)C\ZYD>*J_"=5YBT
M!:4*NHZIV]M0$L =6O$+/9Y(Q/;TWN '@MP0L1R#"1XF:?CAI82DG=M405=>
MFM5.WOV.G+8SJWBNN.S%M.SW\:<::KM>Y)DI;NR0YX1>R$:)UJ6=?S]3C0>J
MA\S8;[$RQ'6GHK1PEUDN/?-/)5,W':%'HF^G7V57^X<K<S1B(_+4<US/MZRN
MXF.?/[M7<ZZ<OP5E3R#$+?7&^90EU!LK=X1]YJKNP]ST^J1[3YA20G8^3BJE
MS'DT&6PK%0WT/,.>&3L.Y)'[WN-3^#M&-=63BI0XBZNANA +1Y@*0XDW.:P*
MXJ&$-14I(BI2 G0^P:4R@BFNFESR"2-%%30/#7,(Y+2W,?4Z7PC)+:P!3(R"
MUE4OHIO:1;9?L/;5]LK5D+00:@JHXBSDL[I[R*-)K7\%F<*@\@SF4D93D'DH
MR.74A86C: A!&B?NI-,VWB+BX[C^2LD\AGFJ/EHMCR/2+TZE!+>2QS1FJNI3
MX);4LGVBU<Y=EYQ.=I]OJLK8F/T'%:WYKQ3 8&!D\)BH25!#9+#5MR[DZ>(_
MNUU#'PS7,(>UM16G%5U^6MXIC%N]X%>!_-5O!+C\/XFW+EP-\I@%;JT[2LDF
M_6K'<X:1C!)3AQ"@AW.R24V\57;M 3HMC>F_.^%<AQ<AQUDKE-J&]AYK=8$?
MOK$5S?(27[IP(7N8!7@ZBNSK.-EN.JT.+@..JL.+QV-SV5DFXCPK_@M)LE7L
MM6E=3W=M'_=&_7B34T4L[Z2*)CXM#4<J+/XYCH>(Y!,8<DH-A9I*U64;]E5R
M^D=<L!8T !7+(7<D]DVC1P6%R['XQA__ -W+W37%;E1T'=<FI?'925K-K]&C
MS4=BL>UYK(-*+#X_QSE*LPA,AA+.%<9W+6L>/??I;K4O#W*RW:0>/Q47?VS(
M):0N);]RSN:HXOAHS*)$AIC*ND)9;*@''#[!UK5ML]>7,I-/;ZE1]K80R7 )
M !\:*!XWD78&68=18A:MI22--W?6G>Q.>TA_S<5U:]B9)!1XU _17OF67A1\
M8J*K:[)?&UL  V_<JLXRW<7FA- JKA+*8R$LU:%JXO%AHOA.YQ!&T]O7]%=?
MPE@VYCZ=:@E0'?\ ?.L )F"I "UOZJ9#E4QMM:Y;@P8&UZ,%DBXZ*([=>RI6
MY[8AL1U&-'W!4#%=XR9/^RX4=ZDK66&PC^<G_*0DI,EQ)6-+$A-KW-JBY)2U
MM2=%)7]Z+.(R$5IR5KQOI=E9,U$?(V:B6*BXTM*S<=!8CMK2?<-(57;W=&]C
MNBWWT- :K>WIQQG&!+6)D/.NH8'A2[U('9<6JH9:XDC&X'16[MOO^:Y9T"T!
MX\RMB.\0P<:0'RX66$>,QE$;??KK6A;YRX='1GYE2]PW7JO<:K%Y5 Q^;QML
M6$N2(RT*)C6N$I.J3:O=E<2OE_O:56>PS+V&L>OQ6O7XZVU;2D[A\1.FOMJW
M/MW-;N8KY99:.YB<V4T/WK-QG)LCA'C&B)2M#XNXDCIU%ZMXP\-]9&2X-"VM
M.!X!<2S&1-MF60V@W[MM>7-9&-Y-,Q'S'RS:/.?-R];4=M<UFQC7.H#H."[S
M]#)/!&]^AIJ%%2Y;\UY<F0K<^X;J4-*]QL;!I6BG&1-+0TZ!=-M02=#VUZDE
MWA9HP65HT4Y(HV%DZGLKX"7#:>"R,CW2A[M!11K^799G-XUQ"U/O)WHVI*A8
M&UB1TK9Z728HV>:.*<@:Z+"RPD8</YC%Q52I"P _'"PA!0GMM>UQ7N'IRM-3
MJ%&3P]!PFC ).JB^,R)W*I:>0NRGH,=APL&"VH*2H)M?=U[Z7#G11D!8;9[[
MSW@D'P'DM\2(N%Q_&7<ECVDB0MD@%=B22->M0F$+ILA'&\T#BJ)W3?3V\;R"
M26CY:Z%:+C^DT5&35R&00["5N=^2=\5E$W"K]!UKJ.8QS8F_VW$A1_9DTEPW
M_P"RP,).E-=%+R)\F+E(T-+*U0G46NA.]*5=_P!U4<L:UI\5V.1W2FHWY2IM
M*7 A:B;Z?AH59('MTJ9P[8VR!TBY_P!WY2YCMW1QM%3PUHHA;[;"KR-J$)^)
M:S8>^]=<O)G]#=& /PY+\?36\K7EKJ[OO5OXIS2%A8CK#L<.M+NI+R;%.I/7
M[ZYK)@+R\/6<]U#KQ"N6 SHM&="1M:\*^I7#BW/L5 R4Z3,<28$@J<)CH+J@
M;Z)LC<=16WGL)(^P#87N<X;:_JI7%Y86]Z3<-#&.J6D>NGBJ/F?53!YCF<J#
M'96U#6XVS'>6A2"7" #=)%QKWBJ5;XB:.-K'#4E=_P 1W+&&%Q=[>7'BI=Z+
M\EEHF>0K<Y&:6R&-U@H.Z$U=\%8!DFT\/X*E]T=USL8Z0-!:#IJ1S5HQ64<R
M#CK;C8"6TW2L==>S]-7"[L8X2'-.JK^![BN<K&\3, 8VNM?PH?(JM3&@]/DF
M+M"$J!M>R==#T]H-;L^2BM(F=9Q&X>JHC.WY\ID9A9L:YD;A6I#1K_$%0?-<
MJQC>-Y!IQA2BXV6QY:=UE*TO;[.M5O(PAP$KC[7</CP5FQ>0%E<_2-C#3SIX
M\#^2V#Z)\6PF!RG&GF-ZI$AZ,ZXXM95=:@%&PZ 7/96%MKLA)&IHK:^5C"T$
M\3HO? Z"JXLB^T1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(O)0BM)Y]RAT(L3,?OW7\Y1O[ZYUW%=.8ZGVX**Q40^ID+OMJH7D_\
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MVI6"07 H7&EK5O8>ULI-XD=J*<'!8NZ,_D>JQUJ!05KN!\J</BL*.\7W"VL
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M-% 6[:FK/&.N 7D+6NLG;V<^@&JNW'.-9"0Y\VTXAA<58VK5]]0-V^.U>YA
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M^'Z*@,N)@K6VX2L#12C8?;:K7CK:6ZF'3^*XWC[H65S0\*K+$IQ;:E0'0B0
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M_-QW+E;2S8I[3XE6)KS->0L<6N/'T4?-;-<-1N"J);]3\VIS%S(TEYEEP?-
MH90$K0;^R^O=6Y96;7EKF\"HV/$QAN]M1SIH/R"V@I,#)LG&9%I"TBR%,. !
M15TZ$]_=5CO<;%##O)U/FHJPR#KBY<PBFPD*PI],^1RH@?Q>8;Q,<-_@QEL>
M9M"1UOO%JYG<=Q-9*(B#Q\/XJZ16M:GR7F/,S\]"Y#)<E2P_.B.J;$@ZI(;(
M/06L#;I5E<1,QI'-9;2?Z:3>.(6\>)RW\S@(L[),I"WTV*>J%6[;'OK0CMBR
M2I5EG[D%Q"6_I_%5WFO+FN*R1"AQMTAQ 6D&WE) TMM !-6FZN6OAV4U]%Q&
M?M@7-T9''0GQ_2BV]Z-YO#\LXXW-D-LC,,*4B4TGP@?O2$J)[*Y%F(I624'
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MVI4E21T:W?M57[:TO;C;$_1KAJ:ZK9R5V2PR [J>*Q\GZJ):Q$N1+C-!L-N
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M'6=RP+J3T%C[.VO6H]%C>S2JPU2#'?VI39@"VT#I[K5"RY LDH JS/E9VR;
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M#W@U1\A@Y)+L3'37Q"RLN#P6L.*^F?+,;D\IGW8S2<5,+KS"$.A2O+*MPN@
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M8\YQCQJ O;[*R7&.BC8 #R\ET"2 WDYF'B?W5DWR^88B2RXR&'$JV))-O?4
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MI04W]EZ\@Q&)NSCS5L[G@BB+&M'OJ?T4KQ7D[N*+C#B/,3J2+6/NJ&NK,O\
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MY^"K&'Y,SFN4RHK;#@A2#=+Q20-S2 "#IIK[:\V64-E&YI:2:K8RF(CR$[)
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M[D@[B.@'NJ_6#A)%4\5P[N%C;>;IC7[!1;*'I"TQVP5*<5=*1VDBMR1X KR
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M( .[0:JKDF8$TLI=$3I^BO-M?VUP[I$ KES;!X&'@6_D&VFBP=S246LH5/\
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M^JK^9R$%A&"*451PN4#4QF6X%I0ERRP3;MZU?,] RW 8T@DA9^U'G+M?(T:
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M!"PG):GN03I7&65QG)ZM\A"/%YBDBVXBM^UPEK9V3?JW!X '%;%SFKF>[_\
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M1!G+^6QL!XE#J!M+MNA)O62RFGR+=[O:T\DR3;?'_P!J/5[>?ZJZPIQ6Z&7
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M24&RBMT ^]-:%TP.(JK/@Y^B7.7F>.RZU(;1(>WRFT)<4H>$DBR=+=-:E?\
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MDI*[$H"ATW@[=#79L/<FX?&WEM7YZ[RCM)!+,14[M-?$J?PG*YV+Q!QZ5 N
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M',+>*VAZ6*QB..MI@/!Q-@7R5='+:BQZ5<[-VVK"OK'*RM\@Q$_(/8%I\.2
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MBJV0B<VC27VT*CHQZU_@KU4\EO\ 8JP6T?\ =)/%Q6'*PL@MO:. 1A,@)0V
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MRDPA<*"M.85F.+ML7;NF9R%?N6@^=PIO(,>6880VKS-[2;VT[B=:Z^, UL(
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M!J5G+ 15:2]4_3]N<@\CP\=US+/N)2\V+D%)%NG9:U3L\0>P$<UJAFO%8/\
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M=UZW[EQFN7/ T<?N5&QV&NK>^HVI:/YN1^%5L+%L8U/&WGGV4-OK2H)6YVK
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M6%NG1+CAU%O;?K3+W-A:QALQ#:<%KXB"_=,)(FN(KJ?'[U*PN-R9&;1#S?\
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MG,:L3[9SQX!;EX7'PS>)8C8UAN-)C-AHE"!N '37MO5-SD#X)JEQ+75/HMN
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M\C;;<D6U!-:>4$$-(6MJ?'U4Y@I+JY+KA[Z-\*>%%)MNI<40D@@&QJ%FM#$
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MY*Y^D_JARCG/+%X[.NJ>Q9:4I;:$;4)5;2^@L#4#F,;%91=1A%?5=0MX99P
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M(ASBWFJL^)D]W1SA[2%*Y;!8_(N,R'@=S1"0I&MQ?2XJLVN3F96,^U7=ENP
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MKEG/3/TRD8;*Y/'RPZNSKJ))<!*'!<V -CUJ AR-YUF->/:2%T"TL(3;N?\
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M<YQ'M!*B>7YW+\I7C407$1X<"3Y\LZ[WD)TVZ=A!J>QM@&#:15<B=EHLLV0
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MX54Z5("#N7X;C6U4;N[,20W[8F"OM&M/-="[/$;;,N)I[BH6;!0XOQI.Q"O
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MIJNGCTS(N.Y%C)0U7BG\!S;9"[#LOVUI9+(;Q3FI#"8GZ?4\'!9&,Y*O)1Y
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MK/*Z-I]P*V5ZRP>1\+C1\OQK).M0'5>4ZA!(<!M<:CLTK0QMZW)C^ZW4*9?
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MY-B!LK+S(^&W:KV5MG!MF/LT3*9%EJ: U53@N\<Y='G9UF$V#,6HNH4/$%J
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M*(E$2B)1$HB41*(E$2B)1%3LQZL>F?'\E(P^<Y9B\?E8I"9,.3*;;=;4I(4
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M+%PVY#B1,F)^:.\[%-6*E)/OM:JKD#!;L)::E6FWEO3&YTHHU]#P5D]0_13
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M; S0<%YDDWD>*S\-B9.:E(BQ1N4L[0>P==3]U>"[11>1O6V,>]ZVSPGT??\
MSV+(R4UM,=HAQ!9-R7$GX=:@<AD>E&Z@X+9P5Y%D7M X%;3]?,VB'PAH.)2M
MSYICP$?$D+&ZU57!"6XN2ZO(JWY+%1MCX\UG\3]5^$9K%I@8\)AY#R"E<,)V
MD6%C8@6KW=8F82![M:%56YOFVT(]U*^:T+S_ (0Q!$G,8M2G&4.*7++ANH%9
MT(MV7JYV5P2T-(HJ7CL[]1<.CK4 \53^(8S&97+(C99:H\8C1Q0VW5?I<U/&
M$@5J%<''167GG!L5B(+63PBG'!YFR2 KS$A-C8Z=*\FLF@'!>XW #50?"N,R
M.32WV67EQX[* IYP7%PHFV@Z]#3I:<5KS2$&@&JFV_2]<CD#V)7(*8D="73(
M'Q*"N@MI7QAI[2.*"X>T<%CN\"R&+SJ(B?-<Q#;S)>E(*DCR2H;B2.T"]>)(
MF'3BLL=Y*P;Q[2KSR#/,1<>CCW'6OS%V1'6P VHN%M%MMU=>^C0&Z +&]\DA
MZCC4+&]&X,YV:[QC(1_)9:29(6[="R-$D"]MW2J[F7.A9O'%1G_;467N@]Y]
MM>'#B/X*^\ZY!R3TRXXIJ$XB;%G.N)#[B;%DN#P@#M%A4!9,BO9->/[*WWN'
M^A8&QCVZ*%^FSC>5Y1SG'<WRLX.?)S4QT)4-Q40$J^RUZL%Q=="5D8'\RQP6
M#7L+P%^E@Z"I]1:^T1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41>#_KF_
MG"XY_J8?YT]5AQGR'U4%D?G'HO-^$PCF<D?*LS84-XD;3D)+<-LW_P#JCQ2V
M/M54FYVU1S6U6T<9]+OJ[FXPFX:%CLC#5\,B)E8,AH^Y3;RA6HZ]B;H:CX%;
M(LY#PI]X6;_1%]<_]!Q_\OB?])7SZ^'Q_!>OHI?#\4_HB^N?^@X_^7Q/^DI]
M?#X_@GT4OA^*_1G',N1\?$CNBSK3+:%CK924@&JP>*L0X+)KXOJ\S9@,R\OF
MHJW//_CLI*@OJ+NJ-O<*Y+F'/CNW$<*K.P,GB,9XZK4?*.)IQ+;T\+'EE0*$
M7_?*MT^VIG'9!TU&KCG<';[+-KY0>?#U*IL++(RL);D>_D,/*C[K_$4BQT^R
MI^1H#_.BK]Y&^.W;705_19 DK^77'4 ME:2A257Z'[:^MT>"5JP9.:&,QC@5
M,<:XYE,@R_)@J#3;:?+18V.E1UY<,#J$54UAL7<7#'2Q':=0L*.A<7,M)G>)
M:' '+ZZ]!^U662CH#L\%&VNYE^T3ZD.%>?I^BVSF\:[G,,VQ%=\I*@@WO8:6
M_<JDV]W]/*=XKJNVY/%NR%F!&ZFC5K'D7'W\+*V+.]*@-2=;_;5QL[H3!<@S
M>%?:/K6H-%)\2?;Q'G39T52T+VI02-!:_P"[6.[C=*X,:59^SK!S2Y[V\:4_
M%6YKF4!U:&$L%,58VN*[-=*AO]7) "'GW<1K]ROKLPV)^PMT]%6^8'C*V4IA
M.!$E*KV0+_?4_@,A>VP(<2:^:I/<^0L[AFPNH[R"HJBGS%)1\))(5:U3$]R^
M75Q7*G <N"&M8+PBL5%S:1BYH)C/J&[:;&XO:L3Y#&"X<5+XF3;<-:>!/Z%;
MCP6'P?",*S#:.U@_K+\2B2+]M4Z2:>_E+8]#]R_0T,,-K "-%6\SSJ0AV1$B
M)"F"-H/0"_=4I:8KI?/Q7-LOW8YCW0L%0%15+7(>)5JZZKK[35A:P-;IP"YB
M]SII*GBXJWG%Y/C<-K)L_P $@;U+2;DCKV5AL',OY>D1K^ZZY96@QEMU0> K
M^J@\UR.;R!25R/"AKH@?LU-77;W^O)<.:Y]F<S)?O&[0#@N[BXR3LKY6,ZHH
M=6#XE&P[P*KE]%%LW'BI/ 7-T]P8T^T'Q6U,S!ER,(8S2BJ1M N.TCK54Q]]
M##,2\<%W*)N^(#FH:%!PW'V6E93Q35C<!:Y!]E;UQ*Z]D]AHU0<TEK#*!(/=
MZ*0GY=B7@7Y,9*BA0+=R+$"M&.S=!<-(/-2EY.UD!<!RT4<T_&?XL8\8&0\$
MV*#XE7)ZVJ:CAVW0=+[0:K#"SZVVH]=O#H"&XSCCL,,R4*.U93:]:>4DZ3V@
M&K20M>PP\+ >D*%4?EV<R"LR[%FMBS"MJ0-/#[*[3VUA(C:ME8=7!43)=PW%
MI=OA>T%K2JVC*37),EIQO;%LCY=5P"#K>L$G;C7RDUU5:R>99<L]HH5GQ,WD
M8:@XQ)7=.@W**@/OJGW^*$3Z. 4';Y2ZA/M>?B25QR<J5(<1)G+"G7A8"^NG
M;6G%$&B@7V_$TE))#J5PAR6V%A"4;7G#\:>JC[>VK396,4T1+]*!6S Y]S&?
M3N%2[0'U6T.)8YM$-K+*D%*7!JDFR=.^]<KS _O&*/W!=/Q=ET0"2IV3F<4V
MVO>^A8 N47O>HZ#'7'4#/EK\%*7F0CB;J5J+D^=BY.>X8+&UA0*%[OA4/=W5
M^@,+@##:C>_6GBN193NESI"(AIXJ/@3G<8VE&/0B,E&H2V+#]FJ-DK9IF(=K
MJJP<_=5T("S<CD,Q-92_,)"'#X5V(Z=@O7C'S0VLAV '19KG*7W3#G^T.YJ-
M#BTA;P27G6D'RVR=5$5MW%ZYS@6G;Z+0L)'/FW.))4,R]RJ5(CO3"W"A74I;
M2!=PCL!O6X^\H >-%<IL\88MGB%(R"S"2T73L\_PH!ZWJ9ES$MXWIQZ55 -M
M+MW$:+DAY+;@*TA;1ZFUR/=4SC>W7L;O)HY;6.FCBDK(*A6?B[.,DY>*MY*?
M)))"K6&X#MJ*S]Y=6MLYAUT*ZQC+:SFD9.P#4^"L?/%1S(B^5L+B$$!2;$@=
MU<_[5C-7/>#5Q5MOG[?E5)Q^=R#"7X/GD15A14-3:Q[*ZEG+6&.(2EHY!<IQ
MV=>R=XF=[!N/W+BY/ 6E3*=R1??<6O<6 O7-R-Y((6O=]Q@7C;BW;\IJ=*54
MCBG1"GLSTLAYDZD*%]%=E1LL8<[:#0K]'6>>M\CCVO) =0?DHW/NQIF9<D1T
M>5'-@0.HUN;5T"VROTUCT*^XU_%?F#N"]9<WA/(:%8#X;%PR26K6W*ZUO83&
M0WS-S_F'%5R7I[_96GFIGT^]/O/RKF:=4\W$<;59N]VU*N-;&JKWE+;VQV1\
MA^*ZUVMCS<PA[P/+T6XI&-C/POR]8NT!8>X#NKCT-Q(#NU70Y8&R-Z1 HO-7
M._32+)S3B8TE;<A2RLN/&Z-I))%OLKJ.-O1)"#S7+9[TXR],+:!K@3^?[*P8
M.'%Q6.CXR.H+$9 !5WGO^VK2R)\C&R<E.XG,QS5 .JYY%3N].\I\H ^7;K?M
MO6Q@;=[,B''@=WY+GO<SR^Y'AJH[J=:ZRX"JJRRH<-MY#JE:*N DCJ+57<CD
MG02-:T:*Y83%Q7<+R\Z\O)=\%IYN0M:D[4I24!?>+C]RH_.W$4ULT'Q!4KVQ
MC98;USB/: X5\=5L7BL/'9#'+3*;LII>XNJ-A;WFN%YXB.7=%_,5TSZ>*4^X
M+$]2,6REF)/8LE2/PK#H4GM_15P_\?WTS7F(ZM<XD^5 J%WKC&M8V9IT:/S*
MT]F\*SFHRX\K0@?AN#JDCN-=INX&7#*.7/+&^?:/WL6)CLM @LLX=23\VSM:
M+"4E2B!T58=E:#;^*!@C<:4T4F[#W5S69@J#JK2C&-N@2'[A5E%L"X-M-;&Q
MK0;DV22[8S52<';[HXB95C,O2(Y$N(K^,H.]I1Z7!TN*GKN/K1&)P^8451AF
M,,S7-_E*V#B).;YS$2W+<;28ILZI(("E>V]<0RUE%@IMS14O]WWFB[?B,C]?
M!7^G0^M%!Y9C\FE.1)%O-&B=HZE0TZ59K&R==PF?U_!8;G)P6;@WF5RX%A,U
MRG%2Y&<9..=96MEL_OQ?17W52\CEFV\W3KJIRS+KEG4.@56;Q/'^,SUM1FPU
M,?4+OJU-T+.N[VDU,7]K(8VR<C3\ES_N2Y)>UD9]U6_F5/R6&Y3+K+NK;R2E
M8]AZUM0Q4B *M^.<6VXW<:+T'])G'\?@,'G&L>DH0]*2M8/?L2*.%%*,-0O1
MM>5[2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?F']3/\^?,?\ &&/\T9JU
MV?\ A:JS=_Y7*D<<X?,Y0L-8_(XN-()VAG)3X^.-^P RE-I5?LVJ/WUL/D#>
M(/W56!C"[@0MF1_I.]:YC"),3$PWXSHW-O-9&&M"AWA272#6H;^(<_P*V192
MGE^*[?Z(OKG_ *#C_P"7Q/\ I*?7P^/X+[]%+X?BK;Z7?3%ZP\8]1N+\AS&(
M89Q6,R4:5,=3-C.*2TTX%*(2EPDV Z"L$][$Z,@'4A98;21KP2- 5[UJO*>2
MB)1%YG^KGCF.Y%!P3$]O<4E[RW1U1<#47KZ"!Q7EP)X%>87TY+ /XK%8J-YF
M#V^7)=/Q)U"=*^DA^E-%B:SIFO-=^>D_DZ\$MB0(L<Y*.T\[>Q#:EBY!/Z?9
M4+?6C2."L<N7,ENV-QT HM^Y)_&2L2IM^2A;3Z+(4E045&U] .O2N;V;98+F
MH]H_BL#VM,=5JG"*1D<U%ANLN-1Y+JT?B@H.Q%Q?7OMI7:7LC..DN :O8VOX
MKG[LBYM\R&G^0G7T"ZN83,7Q7D4;!/O@*ELEYHJ[@HBU^\VJ#P=T^_86C0@J
MS78%J-[M11:IR_ G.0\G?FM/I9@R %NH5\8( 3T[;VJUWMB8&#6I*@\5E69$
M/:P;:?JKEQ_T6XIDG1!DO+9#0W./A02I9 M87JM9"6=C6]-G)3K0&D NT"UK
MZB>F4SAL]QS'$R<,Z]Y;#H\2P"+^*MR..0,#G!;LSV 5)T5Z]&.-9*=@YZ1!
M*]C_ (G%I W!216K-DX(G@.( 6"*)TP+@:A:VY5P/DF)S[\*1CW4A]U;D<)0
M2DH4LVL1W"O,%[%."6&NJ-:]K=1P7H/T-XIA</Q93^989&9G.K2ZA_:5I0DE
M*4@*]@O5*SL]QU_;4-:MJ M+14<50E_3MF\[R[+K6O\ +,+Y[SL)U("KM*<4
M4)2GW&I5O<T,5H&GW.T7EC*2TI[=5&Y[T'=P\YR$G))?;2C<'+!))/1)%M.M
M3&+O3>Q[J4"P.DVR$!8</U/Y[%:9X1\[Y*6'1#$Q-MP2DVMNMV@5DAP=K/<U
M<*$DK5OKIT,1<#6E/S7;R*/&9QLG)9.8I>=+)#4LJL\I1L +Z&NAS8FUM(!M
M JN=8[-WL]V0TD-\**&X-B>39IAP(FNQ,:4J!<4-^XW-[7J$M\B^,%FZC5<\
MCB(;F42O;N<MA*]$>,+P/GC)J5G'/'N4H>(]O@ZU&W#]C"^NY665\45N* "@
M79Q5$7TR8D@978MU.Y[>0$+/9M3VFJE<1-O "6Z@KFL&9GEG,8=H"M:YWU!S
M'*VI&"4A+K\I1NM NLB][6!-6&* 10T(T5T;+],SJRE5UF#R7#EN(V7H_P R
MH)2CX=Q/8*WH+\QQEK30*)==8[($N=M<6J3S$SF>$@IAY(K;COILG<57*>WJ
M:TB62NW'4K%:XW'22"2-HW#7FJ@'%*)["3<FW;WFL_%6@BO%;0^G^#G7><"1
MB;,1VT?QQU0W)4W<Z:=M07<+HC;;7FIUHL\3B':*[_4QE\RS)A8<2?\ W1(;
M"U1D_K*!.JN\::5"=K1Q]-Q ]P/%>Y'%KJA:!DYR=)0F%,D.%ABQ:2I5T^RU
M7US UE>2UPUQ/M%2MS<7P/JYQ'!#D^$)F1);:3\DXHK4$]A UM4 W,V\4NPJ
M0M+F2A#O:H[!1,QE>3R\[S?'.&8^G\(OMV3N'8+^ZMBYO!./[;E0.YLA/:Z[
MB6FNGFLKU RGR;.%9A(2K)-O^:PRE.I2+C2L=DPF8ERKO;MVZ:@?]N*NF">R
M+L-B7D &I*@E8; U2;=ONJ6DAWDMK5= D:6MJS0J/]5N43SQQ+*IBDNA8+.U
M5E!0[=*KEOC&0SD[5#1W5VZ<,=[FK6W"N-<HSZ5YB/(/R*EVDJ4K5P :CVU=
M\?:M<ZAT:IC(P3-@)A%'<EG\FXGB$P'IS+?ERF/"?*%];Z@VJ?R%G9PP^R@*
MYUBLW<LN^E<'0\:\EKS&S<OCY*ABW76GE?%Y7Q%([#5(>QCOF%5T]\3)F4=J
M%?L-ZH3<;&:AY2*IY]"M7G+I5M)[0>M>I(VF/:W0K5AM_IZ]+16CF3<WE7&X
MSN,C^?YJB[8@)4A(!&E:=G:N:":Z*NV;+ITVZ5Q.I6KX'I_RS+PG\M"Q[C\"
M,5)=<2-$E'Q5]DOH6N#"=5=1HW116.QLZ;.2Q :*Y+9^ 6T*3VW[K5)10NF]
MK5'7<T<4?]S4%;QRWJJ]C^!N<;RF'<8GN,?+N27 /+4;?%?I>JU-V[*+G?RJ
MOMALZ=6"B\]J"2H. V*OUTV.E[D59&DL&TK>)J:KFRT7Y#;3-D.+6$C:!K?2
MQH9M#NU"\TT7K/$\0SF'X/#WN^6GR-[S(Z%*];'[ZIME=V\M[1WBJ9E<?>O;
M6%Y:J _(B\;C29T-I'F.*!\M)"4K6#8=*ZME\;"Z$/9X!<Z#KBYG D).TZ_!
M9L;(Y?$XU<OD#J6HLA?F%P*W)1OZ)/6N<.AC+P&\0I"\CNC01DT6J^5QXF3R
MX=XRRM3!L%2F$':5FU[:>RI5CB![C57;!WGTD?3G-?\ @K?B/3S.*:CQ,CD'
M5PUIW/QVUV)2OLN>VM0SM<[0:J%NLB)+G?'#[AS!6V/2[C?%,'+F8IV$A4EQ
M*5A<L)6=HTT)%NVJ[FOJV^YM=JN6%R3Y0X2L+7>:@?6',P.&L/X?!/"._D$E
M:$1B$ALGJ2!WU8,+?RO@VR:JR32EM-FBT)E^6<FS<%C$Y+)NR<>P?PF5FX%A
MVUNMM(FNW-;0GBO'6)%3Q6!(RF6<93#^968I39:+Z>&UA4NZYD=#L)T'!:$%
MK%'.9FM >:Z^JP-2L+)-@+%%A8UK!P#:$+:]%N#TY])87*L$KD\^<$1XZU;H
MI LH-]=QK(V FA/ K?BMBZ,D<0KOQC@O&<SD53<#(;CN0#L>0QXD*W7 !'V5
M5<[>&W_QBJ^,P3,@W9<:^JAO5S+1>-0XV/Q.4MGV'TK4TP-EDCM)J/Q=;H$R
M-T/BO#<##BM830A::SW+,_R5+;>;FN26VC="%J)2#[B35FM;2*V-8V[4DNI)
M&[7FH7;Q;/?D.2;G!H.H2"EQHZ72KK^Q6=[:\%4\OC1=1AH'#DM]<&F\<]0F
M,AB'6U(&S<I"R-UCH+'6]JI^7FEMJ/;HMWM#M:-I<7C4G]%5LUZ&M8R<H,Y$
M_+K!4RI23NOW:6Z5.8N^^JC!K0JRY>T^C=QT5[X;A<3CL5^0HVR9+2 9Q6-V
MXN$VN#?NJ\PNC;#5Q]5'P0"8@M/%?#Q;$\6G.Y!J((C$E2$*(T2>X?>:@H;R
MVFGV!P6:ZM982#LT56]4<P_C9./A\<NG.+)5(;:3N<5'2+B]O;4E?MCA JL,
MKMX]HHJW/]4#%Q!B2X#GYGY1:6E0*05$6N;CVU%P%KR2#0+$ 2-KA56?TVX[
M+Q_$FLM,@?+*<W.*DJ W*96;@_=48S+V_4,;SJMY^+G9%N'RKNY1BYT]R _B
M)WR,Z.X7//2;*""FX!/<=-*^3/;.2RFX<E31W-'87(C!H:^[[M%:O43)<<F>
MGTB/GW$NR RE+.X7*I.W0BW>:IEMB[B&[W,:0/XKL4V0CGM0>)T_)5+Z8<U\
MEEXD 30V9&5:"8Y4 %7"1<>V^AJ_26;'/J\:C@J8+R1HVM.B_31/PCW5G6HO
MM$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6K?5?T"X/ZOR(^0Y&N;%RT
M-CY6+-@O)04M;U.!*D.(<01N4?U;^VMN"Z?#H."U9K9DNIXKSGRCZ&.0Q@M[
MAW*(N03U3%R;*X:P.X.-%Y*C[TH%2;,FT_,/N4<_''^4K4F5]$?7GTWDG(L8
M/*1E-?#DL$ZJ19(UW;H2U+0/Z\)K=;<PR:5'Q_BM1UO+'K0_!9_'?JB];^(.
M?*2,R<JVR;+AYM@2%A0ZA3G@?^]RO+[*%_*GHO3;R5O.OJMQ\9^NMD[&N9<3
M4GIYDO$2 KWV8D!/_/5HOQG]+OO6XS(_U#[E["C/HE1V9+8(;>0EQ(5U 6 1
M>U^^H4BBEPNVOB^KQ1R/.3L1ZB<A6+J@B<^2GO\ Q#T/WU5;S'LN217:2J+;
M7%TW+/;_ /MC;^G\57N8963G"B0PTM$)(.X=1?2UZU;*Q99.+20XE1O><DTC
MFT!VBM?O"IW'L$<;BS#+GB<?=?4M0ZEPW%A[+U+N:Y[M]-."B&6LF38T#V!O
MCY:*U8' _G$Q$55MC8)6NU@0._[ZU,K(+5H>#Q5@LNUHY7M:]P=M_%;'Q6*A
M<?:5&2\$AV^P'3KUJA37+[AU0"KY8V,..C,8(UK^*J>>X2Z7'\G'=*DGQ@#4
MW%35IDPT"-P5'R?:QD>ZX8[7C]RB,;SG)XQ*XJPF0V@E()'3;I^U4A/BHYJ.
MX*#L.Z;FQ>8Y/< 2/NT47F<],S<KYA\Z)(*$6Z6[ZD;&P(]K!4JN9/,37DFY
MW '0*]8?.X*?@?EI:4MJ2@A:>TK [*C[W%Y"WF#J&FO)=H[<R$,UJUS10M !
M]5VP<AQ=O'MH6D7!4-1XK'OK3N8;I\WN=_+X+[>7%O'J_6JP&.'8O,F1,CO'
MQ&Z$ Z6M87K7.3DAVL=]ZK8[:M;YYF#M#RJM?SHXB927CE708RR-R@;$>SK>
MK3&[<P.\5SK*8PVEP8R:#6GHN :4X[Y+/XJR;)"0;FW;4W)BI60"8\/V46RW
M?(_9&-Y\E\DB7C0MTLK$AI"G&T6U)0+BW?40QS)-%M1VLT4[6.!:ZJL7'Y?-
M>9\<9F96+\NHK/D)L=6QH"14*Y\%C-5IU*ZS>Q7EU" S3AR5CX]P9Q2'WLP"
MAU:MJ$"QT[ZT[W*C<*:U\%K8SM0T>^8U<[\%+O<(QY:L'"A8Z*.EK5$1Y5^^
MG)3DW;,?3TI4*JY[,2F8CN#5N>CHNGS4#0CH+FK-81F*03,T-52LI>RQ1&W+
M2[0BH45Q[CKF0FMB2RM,=5M;$ WJ6R.<?(T@NJH?!85UQ)_>8=OFM@L\.1CG
M@_CG0E;9W-I7\(/MJ@G)ND)#@NIVG;S+9P,;@!X*R1?F?(;^;VB3^OL^&U1$
MS6/J6@JW-.T 4^*JTV;&G\Q3AI$7\.-'^85*41M)42 G]%3L$<C+7<SC50<T
M-M+-[^(7<_G<*ZN3B7VRW'2""M/PD^RU;D%E<!K)W'GX+)<7$ !!X!=/#V(;
M)E/-/I+;BMC:%$ ]=*^9R\DF+&T.@6'&WK) [I\*J0Y-E<AA87S4%A#J;V<6
MLA.R_;6A# V=X83HW5;&1O&V%L7CB:K4V1=R.=D+R#C2G +^)";) O[>M=*Q
MV5DL6].-U/Q7 [M]WD7NEVES1S T67C\ YD,;\ZRCS0DD+2DD$?97N+N"2.<
M[^/BIK"8"&\BWDU/@L2?BYL*.VI,%:6"2I;YZ"P[;ZUKW>0^HG]SP5N9OM]M
MM;!\8I0Z^BPFD)>>;#QW:Z;B3;K^Y6"2H.BI-H#+,QKC4%7;AS$%>1\F4RE9
M()1<7 -,S.Z&$;#Q7<<;C+2,@ #=Q5EY1BVTPE/,2/ED@>%@&R"![*J.&N6"
M6M-5-WDS(FZN 6L,C*2V@(W>%7Q.7T]UZM[Y'7#]QY+C.>R#YCL94CQ"C%MH
M<;4@J("AH4]0>SK69MU+2E2J>RC#[EF\:<:3*:;RJ 2%;0X#H4]EQWUHWC7%
MI(4]C9+7K-#VZGFMKY[%0I7'S\NE/DH3O![=!5,M+EPN*$%=?R.+AN;3:!YK
M0DCD*6,NG&HAOE*UA")!!2+G]RN@] M:'$\5RF;MV6.,RAP '+FI'YE]R8J.
MEAQ>WJ]U3]]8R!34JOFW<YI=7=17?$<(;Y!BOGY2KOM F,DCIW$UIV>89:78
M!X*^XC"S75GO?PIIZ*F26)$%]V(\@^8VK:H_MU^A;.[9<PA[#Q"H=S 8I2QW
M%I4IC2$1TN!5O+*BK77J:H/<$S1*]K_#1=$PEY!#9-<3JTDD<^*[W)B76U/K
M4M0! \74W[M:K=E,]TC8XV\EL3]T1/B=(&N\%CP</+FH6^PV0S<W<L3[ZU<M
MD7F012&GDJ)9XJYOB9&Z-)I5<9*7(\9+*5705$*-K&X-ZS6ABMI1)(-X\ M_
M+V$N.B$6X$.K73XJ+FSY&/B+<CH<=((/DMFQ4:PWK[>:7?&W:/-0=CU9'])K
M]@=YD!6]CA64=Q;>24FZG$!TL'10!U-S>JP,FPS[**\P]E/TD>_<WT59R;?D
M.(0BR=P.X#47'OKMW;,<;8G$<U YS&PV;F[.=5L[TUY5&SD!S'H85'<QQ2U=
M>GF"VBD^RN$]X6,K+DN^9M?U*Z_VP\?3M#-!157D+G),5S^7*B9![Y%+"'&H
MJM6RM1(/[%>K*&"6T I1:7<&2GMG'IBKE$9;*2,M,4]**?-&A %K=]3EGCGQ
MQ>QA(\5Q;)WTUU+NET(6-'2$2[%:=1M !T)N#UKHEA*19"(L-1752. <([K:
M7#73\ET9/>P_='XV\V"1IMM5ALJ-#7!OR\UESUGTKBI>#N_!=*D+\H/6 03M
M]MZG&W+3)LYT4*;1PA$O(FB^-/24%:FTJ2A.I7U20*TKEUO(_8_0K:MC<P,Z
MD==I4IC\G%46$OW6EP@KV]+7UJLY/%23M/3.@"OF,SK+=K6O!+G>'FKWR/.<
M7C\4?A,2TPW9C?E-&^U9</=7&8<5<27C8W<CJ::*^R7+!:EX!K1:L5.FH0AB
M?E''H^C;7GG06KO&.QL&,CJ!J[4^JXY?Y.?(OZ0^7]E*,8T@_C*"D'0I%QUZ
M:UCOLX0VD8H5*V':X,@ZIJ/ :+'XUCX7$^<O\GDM_,PIK)96V4A1:7=.J;]E
MA5,O<7+EF$!X:XJV7.09A=K0PEGE_%6?U&R6%RD>,_A' C*I( >18)2T1<A2
M>\WK2[>P-_#=U<?:WG3P(49F^X;::'^W\QIHJ4E"TM#9<I2+E203<"NT32M
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M05+<MM0!?K<UY[DOK5\H).FE5$8#MZ61_4?HTJ2Y!#E8Z2VU+24G6X[+U/\
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MAV.V$$#[M5%NS!$4U$6E2W0@N*<_5-U$6N:V,-CI+B5Q#QMHHJ/*R8R$1O\
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MEK/2GO/>5M8W;D) /:!I6:WBM[?2/@%8;I\]"]Y-%?X?IEATE#DZ4YMVC>0
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MP1G92T,+6M.X)W&VH-1,L6X[2L[[%E^T GBO1N4XZ>*<9_-,[):EL('XCP0
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M2FFBIAQ/<L:&U:]V+AS08U4L=%9XRX_^P=1]M%7"<VSRJ2C'QVF>)H44QP0
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M057NY<1.TAP^33\ESS$Y9EP7-<ZC@2W[C1<O40/H7&G1<>Y):*#YCK(OH+$
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MSMV]==- :[<5"\GAQT3G9,V,E")ZK)"Q?<KN)JP8BZAZ9CYC16N\L[F,@N%
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M_FT1^6<BI2G9+A=LZ+*1N-]M2<5R T!AT"KV1S5Y$!$_1W\WJI;#9IW&SFY
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M@LJ43T-]+]*UPYSF&(>U3M_C[6VC=*65<=5=L_R>?D<'^68Y:X<D)2E4H?$
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MYIU2HBT-2$Z+4@#4=@-JJ^+RS['YP:.4UD?IIJ"$C1:_G8)Z!DWX\P A*U$
M$F]SH:[U;Y^-]HTP:.H*_<N&VW;;Y+V1]P*MW.I]^BG&&\$CCDIO)O-L,;5A
MVYVD)/[M<BR!N9[[?J=0NOXBRL8;,L+16A4!A>68O"^4F"\EYM0V,L7U7;H
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M2&1A%37SXJQ\ED_R8SH=PB$^<A(1L()0@'76M6R+KB(B0JLY=_\ K[X7 UX
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MQ/+6?+CNIW%5K >ZH.0QV[_,*T"2XR=N/Y=P6/%]/I1:>9<= N;H)TO4C%W
MQG%9\1VN^ &IXJO\FX^O"*:*W$K!2 I*>P#MJP8YS\C*-C=%5.Y\&^W?U6#V
M_DJT@J\SS&E$*&H/LKL3]EG:^]O)4V"X? X.::$+LR7YC+>@)@*2$;R985V)
M [*YM)E27'8-JM]SD8\A &$T<MD^G<=I@ON..CS-Q2D=-"*YSG[J9[M*E6/L
M^(0EP<[2JD.9\E5BVT1XJDJ<6?$ KQ:??4?CL=U-7J?[C[@99, C-7$\%"3N
M?QY6),=3)3(4-KAUZ#]%;L6&<R3<#HJM-W=%-#1P.[P5,#K\B2'8S=U)4%)2
MD;C?L)JQ%C6MHXJ@FYEDFW1-H:\M5(9+.Y=UP,N2%(+0"#;3LZTQ\$$4K7D5
M%5)7F7O!)TR^E*>"R\)ZU\9QQ:P$X2%3FCL<?""IL&PN214?F<3]1.96:-KH
M%V3$7+&6C2XZD!5O)QI&1S4G.IRKLC'REE;4<)"0$= -=>RI2&5S6; *47,L
MY+"Z8N+=_G5$-.MH4XD*4EL;]Q[ -?96:,^X55-BMY9'58TKIX]ZMQ>/9%$*
M,#-1+6$*CINGRS>Q4=-*L_<&,M[NU:V/_)1JZ%@;JZLG[YS_ &Z<Z*=Y#F!E
MYID@!&ZQ6$]#W7[["J9#8OMB6.&JK/<&4%W+[#[5#/P9+VVR;-K![=;&NC]L
M7+8F/#CS6A:8RXD (;H5K],:3PWF#V4>:?E8L-*(=%U[ X>\]QJ$R43'.-#Q
M72+]SGQAI^8"GX*T1.48>?#<D,2MKH2HMM$'S2H#32H%\-%2+/!RF:K^#3]Z
MVGP/FT=GB\%.2CN,SR@ETV\6A-CKWBJY?X-T[ZMX+M&,D8R,-'@M?\E]5\%+
MY!.:1'>"FU!""A%RLI OT]M6W$6?0BV56T\!SZKCA,W'Y5!EJ>85&0F[2DKT
M596@-;,UU) TAAUJJ1W%*QC37P_573AW'8L]?DKNAE*1NU\=QTUJ#R^8F8P$
MFO\ P47VM$UKR[F?W4'S[(CA.<6RUCI;^*#*7OG&@5(2LD[@I6EN@K8Q62CN
M8AO^Y=-N &C<HN'^8Y5(F2W+O/)\]CS#JEDZI23[+U;H<U%9Q[&#B?S7#KG?
M=WU"?O\ #<I";&1*QZ42S920'"4$CQ 7-;=G*US@:<5TC*,V69]U-"J]D7YD
M6 [)@-)>F(%TH5^L=MJOD[";>C!KHN38Y[3=-,ITUJJMP'CF6:R<_(3V0A3R
M;^8K0[U*WFP^TU3K'J6<FZ0471LBZ#*Q].$UVBOQ6/RWEN0PN?\ RYA&UILH
M#H.I*5$;B /96[<YK=* PZ*)LNV*V[S(/>."ND;,MX]^#CNV8;1V5:7N-RC?
MV6IE3 R,%OS%?,"+MLW3DKM _56NJD]M-5TDO:#M7H/Z6(DYB+R-Z4XE;3LE
M!8 ZA.Q/6L)JLK:47HFOB^I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(OS#
M^IG^?/F/^,,?YHS5KL_\+56;O_*Y?IY545F7Y=^J>*<SOK[R7"-+V.Y+DCL-
M"[7VJD2O+!M<=-W?5L@=MA!\ JQ,VLQ'FOTCX5PCC?I]Q^-QOB\)$/'1TC<4
M@>:\[8!3KR^JUJMJH^X: "JQ)(Z1U7*QQQM8*!6&L2R)1$HB41>,_K__ .H>
M*?XR]_:5]7T<5X.KXO:^41?02D^&B*>QG+\SBX/Y9%=2B&5^846UN2"=;]M>
M)F]44<M<PM%2.)7JJ!ZX<$3@,:N5+"I:VVFW8P1XD*"0#>^FAKG,N#N.LYS#
M3CXK:%P"T->%C\[Y!ALBRS- 3%C,E(<D* 22E0Z'WUT3M RXP/,QW;FT'W^:
MJ^>Q$>0+!'[=KM?10,>?CW&T)B/)?Z(26SO]@O;I6YEG"<%X5I[:!MYV0$[0
M!37R"^N%01N2FY"K%/0_IJC-GDW;2NZC:'[>(IR4-G^,L\BBKBJDN,A:DK58
M@IT-^G_%J=LX'%KWDBC:*K9F:)CF6[JDS5#:<J:FJ^IB'#X-&"QJBE*&2VEY
M?B^(G6U7W$VL5U:ND&FTD?<%^>>Y+I^%O!$T5W#=KYD_LL?C6#@\/QB(TIS;
M,?=VJD*N XM9) ![:HUU*V6.G,*_]I=P/N;Q[0PM#MNI&AX\%,1\+"9R;V8&
MX2'4[3=1VBW72]8\1M%=RG.Y;.*20%H]W\5=I?(($[C<.!"6'"E5G[=BDZ'6
MM&QLWQSEQ(+:*N3$O+6'0U41A9C6&RIS#:+O+'EO:G5/[%;64Z$K=H^93%EB
M+C>2X:>BN<#U"@R'74RXZV$((#:^NZN?OQLC'*;B[>E<"= J+D\C&S^2GJ;0
M7(:'!Y8<18E0&MC5XP]D!& [B%RZ;%W=O?2%U"S2FGWK)QG&9TQ"G,8Q>.#K
M97;W:FM3)W@@?M:*+J6+N;>6'IO&H]%K+D?,LQ^9Y+BF/Q2WYS.]GP^)0/0G
M;VVJQV]PSH5>>*KV0>QMP-G 4(]5(\-GYAJ*J+RAOY.4"$QF7D%I2D]+C<=:
MU66MO(=U:_%?7YV\/L;3[E9E/2$2=B$I^5";A8^(*KX^Z8SVM5CML?=7<HEF
MI0!<2A&\O$#>192M+GNJ"G+MY)X*^PPMC;4Z56)DH\7)8Z1$>_%;6"VX@&W6
MU6[ 6(F.X\%S7OW/FSM*0^Y^GFM.<BX++P05E&VP<4EP;-QLL#KJ#[JE+ZS;
M$YP!!7.,1?W%Q #,"'&ODMZX7GV YEPU&"APBE,5MME]#J1MND"Y%M:J&*L)
MH+HR/(+:\%OY &6/8-"M<\0YC@O3OG.;R&2A.+:L6XR61?80>Z_;4EG[1]X0
M(_:/-8K F%HJ[<1X<E@Y7FG..4Y]&72EV/CGGT!E!38!DJTOW:5EM,.;:( B
MOFM2^-I>3@.=[@58O49N=D,=%P^.94[+?7YBRGH$MIZ$CO)J7=OBCIR69HMA
M(&M&H6K7N$9J/"=G2FPVEH*4ZE1\0">VPO?OK,S&R.M^MR6&3-VK+@P5]P^Y
M7_A?'\-B\4C/2!\Q*#7G)4K5M ";ZBJM<.<52[O)R7ER88FG<*T\-.:SX;O'
M.7QI#[+*%3'TJ0A%MKB56T58:6K%5\1HL$;\A8/'5%6N\!P*U[A./-1N88_&
M\H0J+C5O;7G%>%! Z6/<:V,@][;?>S4T78<(^.6CI%L+U%Q?IU@LCAY.(<:(
M45)D(:<\Q.VP(4;7K7[4NI7S;IP0T+8[JM6.M'-@/N(40,Y@LMGL?C0\7<<X
MDI6ELE*2HZ)2;@$UT#*7D<@VMK1<HP&&DA>7S!=W,_3D2O*>XZT$K^%QE2C;
MW@DU6!M&FJO9=L=H#10&'PO*>#<JQ<F&J.G(N$A@JNM&O4$:5ANH.JPMY%;1
MF;&:'7T4CZQS^:Y1R$]F'V92#=$9MA!24J/4;;W-:V.QT5FTT!-?!>6.$KSR
M]5 <<5Z@8#,1'\2TZT\H6;2^"6R#V:FPK+<V;)FZTHMF&Z;!60:N&FB]3>G"
M.59/#N3N42&5S5J.QIA%MENPZFN:92UAMI&AK316*PS$SF%TE/N6HO4;U8BQ
ME9# 04O-Y5MTL%\V"!M-C:NKVDD<MFUH;R'JJU>S?5[JUI5:[V<URN,,E]]Q
MW'7NZ%E \ .IU-_N%:3Y&MK15*"YL6W/1_G\UZ2C<4XYG/3%KCN-<8+TF,DI
M6D@J\TB]R1KUKG9NY8KOJ2@[*E7^*SZM&L(54XM$YMPZ8SQCD&39>PP8)BAI
M)N;'H2>ZKYV]]/>O+PT@^:QY&V-F1N.BE^5O2G<)+;Q"PK)J00P+CXOMJZW4
M#&QG<."B9Q#<T:#Q6?AH64PF+AY9V0VN4AI >'6ZR+']-<SCO(KB9UMM=0D_
M@I%V&-M")0X$>"S7Y>7E[.0(=_%(,?Y=*;I )%C[ZTA96HD+'@BFJF+>XGBM
MRYOFH?&>F^8C3I.<\YQ^9D?&\DJL$@'06[*W8,I9P.V@:MX<%!1FYF#G/(%5
M]GR\GC6GX,@D)0"I:.TV]M3+;6WN)!,.-%@&2F8PQ4YK3F"5G/47G28T)\0H
MD11<*5W-PRK7IWUXR=PRVC<2"131;]G9-NBT'YEZ)1PIE]/EI>(= %U$7%4N
M3N5S:;1IZ*;O,0QD6YW):HY3*Y+A>=?R;A(;>@EM+RW2+%+?ZQM5YQMPVZBW
MT*J3AL;H0/5;+X0B$RF0A6QIUY25J)ZJTZZU5NX;*2>1@8"="K+A+AD,4CGT
MK4*<Y3-X^QC_ "93J$K<6E"71U22>IM4%C/JH7D,::CR47D,FU[2"YH6&C)\
M:X_&$!+@EOR0I0*1N!%N_LJ\0XS*7=)ZM:!K0@@JJOR=E%M@=5SG\**E.!)<
M6M(VA:B0GV59I&D, ?6H6>WMFCW#@K_P6)CH..6XTEMN5*65+L;*5[;5R_N)
MLCW@M::54];%M*5%599\-J:R67+@#6XZBH;&9*:VF'@MI[!2HXA:WRCS:%O1
M&"5K22D"VNE=ZLKQES&-=2HF[N'O;H.'DH3'\IE81U]IJ/=;R"VXE>BO98>V
MMBY[3ANF;Y7@TX4*Y_/W9-#((FQFM:&H^ZBOF)BX;%1!E9KB%&8A)*5#< 3J
MH >^N1Y,3R2_3,^1O_\ *:<5T&RD#V!\G-:F]6_6J(QC7^,\=;DQ,HVZV$R$
MI2$A(5?2_4&L^)P$C9]TA! X>JS2W <-K!0+4Z^#<CS4E$Z=*2LR5!3[CI/F
M6/<!IV=]=5M,$]S:D@!4"Y[IAAD='&PN<TD?$*NYWBLW"/.#8IR.GQ"0+ANQ
MZ:D]:T;W%OMCXA3>*ST=\T!Q#7>"X<5R2L=G(4AY2@VEP[T()L0M)3J+Z]:U
MK)P9,USQHMW,-E-L\0':ZBV].]-)WJ,MHX5+4=V(-SLB1="5(6!9-P#K>LW=
M.<MH2T 5X<*>:J'9C7NWZU=4_HMG>B+V7X1R3$<&E.M2'8\Y"72T;I27%%?;
MK;6M6/&VLL+;J/1SJ[JGPX+;ERTL5^;:0:$C:1YBI7O4=!6NKFOM$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$7@_ZYOYPN.?ZF'^=/58<9\A]5!9'YQZ
M+3.&];/5;CV+BX7"\KG0L5"0&HL5I20AM -["Z3WUO.MHW&I:*K3;<2-% =%
M6^4<NY)S3)#,<JR3V5R:6DL"3((*PT@DI3H!H"HUE9&U@HT4"Q/>YYJXU5KA
M>O'K!CH<?'P>7SV(41I#$9E"D;4--)"$)'AZ  "L)M8B:EH687,@% Y=_P#2
M%]:O]M,C_9H_N:^?21?TA/JI?ZBOT^QCBWL;#==45..,-+6H]2I2 2:J;N*L
MXX+*KXOJ\A^JF3Q<G*9: W)3\XS+=4I .H\9&ONJI.GF;=$'5E0M2^OXF0EK
MW<BJ/PS"1LSE)WYBXF5BW6O*1$5H-Q^)5_:*U\YD1"*QMI_Q4)@W65R\[-3Z
M+HSG%,=@,M'BXN&EJ&Z$AIEM-O&2?$;5FQ^6FZ)=NIQYJL9>Q$.2C<1N:2T4
M'C7BI*?Q.9!0P\RCSVUV"A^]4NO<>5;=.VN*O%QBFR;7D:*TXSB&/C;'GT;Y
M!3=:2!MZ7JGS9%QE+!PK^J]C 0M<' "M%0^8?)KDJ$2/Y7DKVJ5VVMK5WL+N
M:-FUIH"J%W?9A@:6C4']%78S0=>"%@A.W=W$BM@L<34G4JD8RS%Q.&.X4JLN
M2RR65%" DIUN !6:>'8*U5MSN%BMH=S13_@HXI.Q:Q^K;3ON:]V$399FQN-
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M5CP/''\^XYY#FP-@Z'M(M^[49=WWTP%5)8?"29 $M-*+E*XSEH4Q,$@%Q=@
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M%5J%K#/N:*$JPX_NFYO7=,-.WU"LW#YJY;DF/MW1HBT[]^GBZZ?=4%W01&X
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M!'!4C"GJ7X,WG2JE^51(,*8Y$@?!L(5<W\?9478%]Q!NE!!%?P72>Y(626Q
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M5R;(-TGQ$*</[M5N[OX]^UW)<US]M?2O/3^7U5.Q&!Y?B\S&R6,CB7&;5>3
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MG7H!5<M[BXN9"(B %(V&(,%KM)TIHM<RHKSLG\,%*7E7;4K]6W?:NAX;*,L
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M3SJMDIYABUX$06QN>#00I'07 L;WKE%S:/\ JS*=?!=3B[DC,6V+CX+7:L+
MY?R6)@LE)V84-_-2&D$'<M)T25#LJ6DOI6Q?@I+%3F=W]XZ'6G%6_FG&L7AX
M;*X@#;1LTD=2JR3IIW@5"V%U))(0>"K_ '9BK.!G5C.UWD.*H#7RV%94]':\
MMM!+FUL7)4K0Z58S[BJ%9W+G3L,A)#5)IF1?*3(CH2EQT:';M5<ZF^E6E^,F
MN;<;5>,UDA';@1G4KKCAOSBZY8A(W&_:;U6+JUE@%'"A*Y[9EN_<_@W5=3CH
M==6M+?EIOH.^L#6FFIJL5P]KWDM% 5T(:<5-3(==_BB; QDIN5&UKW)KV[04
M''Q6Q"^ #WC[?;S60O;N41HC4@=PI&W>0U:3R"X[1HOB05I*D@D)ZJL; =]Z
MFK[%BVC#]U:K[TGTK0T4AC%.MR4R H^9'LIN_2ZK]_NJ'9;"Y&P"GBK9VU;&
MXN0YQ/\ ;U'Q5QBXJ7RE3>7R3NQF,=;:#:+$_L5!WM+*K!Q*Z+E,&V]>R5SC
M1BEYS^/R,Z Q'=\YEH[7&A>Q]M1\.ZTC+QQ(*GQ?QOVQ-/ KARK@R^02X9AS
ME8V"TE27PP!N7?H->E1]CE-NYTON)\5DOL6R20.')2F#XJWA2UMR$N2AI.P-
MR' I'OL *TIK]\I.P!OHIF*%H9M*Z.18"5FIK2=P3! (6![:E,;?-AB<7 %U
M-%"9+&,N(^G31?,=Q7$8A2WV+/NM))4DZG3WU\%S=S. ^6O"BB['MJVLF%XX
MJ"PT['<CY"\V["0VV@%*+?K$&QKI.=LKC'8V/^Z7N<=1IS"KF.NX[^]?$6@!
MO#\E<)S,'%8MZR AI*2#I?K7(H).K-M+C57ZZBCL[8D::+4^#>A2,TG\P41$
M<)  -A:]P+5=YV%L-&KA^)O&RW]935KJ_FISU:6K"\,,CCI,>8^\VTU(C_$
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M;G83R'@DGL4$DE)]BK&JH]CF&CA169KVN%0:J8KPO:41*(O&?U__ /4/%/\
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MH?3\\ZE^3OML4XZH6[>E:#K8_,J#F,)%-OEH=P6.QQ[%0Y2I<>.%2'"7/F%
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M3QU71.RNXX[V'H ?+IS_ &6M./P\MQW/9?&REF26G2^E?]=XKZ^_I5H9<B:
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M;M'!<QFN;:*<R>)5OD/1C!6XI:4H2-RB3:Q[!:J--.^66M.*T\A)'=QNZ6I
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MR*E8<639:>B;:C=[#>L$]MOC((J%O1-8^Z:">7ZK Y5F5Y-<?(912MZ"&4!
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M9!?8;(VV0FPM8=IO>KKC(7,A<''4!:A-#1;O^GER#Q\27\@ '<J4)8<"1=*
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M0$8C&-P(J-B393HN5$K/74UCD=5U5Q#(YF:[):=!\5)8["XZ;F84:6RDRG'
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M&Z+)B>'/U7SE2?SUB2EA:GXRD*2PMNY25&XZCNK$8;>2.I<-P6;(WUXR_#6
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M20-I_P""M]F6;-%T=^G[*"EPX-QUJ:U/XJ64N2S9:#9T#\)2QH;]+UHQN+9
MV)VBFG;FBJ\_^HJN2RLW(F9ELH:OY;91N#)2GX;7TN0:S7(I(5DC?N%3Q*I0
MT-:RS+>WIIR? Y/FW \9CX8;G,Y&/YBDHVD;0;@&VMZ]U6$-(*_49'PI]PKP
MO:^T1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?GG]:$%^+ZQ)DNI(:G8
MF(\RJVA"%.M$7]A0:LN.-8OBJ_?BDGP7LGT(R^-S7H]PN3C%I6S'Q,2"^$V\
M,F$TF.\D@=#O0K]FH.Z:6RNKXJ8MG QMIX+8=:RV$HB_-/ZJ\OB\QZW<@<Q2
MDN(B)BPI3R#<+DQV$(<^U!_#/M35IL6D0BJK=XX&4T7Z%\#C/0^#<9B24%N1
M'Q,!IYL]4K1&;2H'W$56I35Y]2K!&*,'HK#6-9%^>W*/03(.>K>1Y)-<:DXM
M_+/2)+/0EHNJ(!!%57)9L1 Q<ULLA)<">"O/+X6'@<=>3!8:8-T>4EI*0?B
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M-1/=61;>.#*BJZ/A<''CG%_&JM4'E'%.38E,V2VUY9)W1GD#S$J2=+I(N#5
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M)0&-SG++2,^ADR>/BY98NG>6QH%#6L5Y+NGW#@M^P@Z=J&'C0*W8U'YI&:R
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M'$*;7J% I.NVX-5OK/<X$<EO4HJUGN/PSAA$B%#"65%:2HC70FU6O%9)_4
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M3I?6VFI%:EC.8)Q(WE7\0N85-*!=BFBV$G>E2^T(-R#6K<2!SRX+-)'TR"'
M^A5XPO&N.OPT/3I_F+>2#M4;%)'6QW55+N[G:ZK/R73['$XV6V#ICN<1QW+5
MV+X#%/J&K/9V:S(QJ)2EADG52462W?7L %3TMT]T  &I&JW8,U91N$0/M;IQ
M'[K:O,Y."FQ8T;&E"7BZ @IT'VU6\:V9CR7<*+2[JGM9XF-A(W.<NU? HD?%
MF:)13)#(4A1^#>1W7KW_ +-SI=G)9XNT8H+=L[R:[1^(6G/(Y6)*FWWXCL+S
MMI* L.%F^MK@CIVU;BU@%>:H,KL>T'8'5!\0KQA93^.69<%2FP? 0K7W:BL
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ML\[X9F8>/A/XV0R)2WD_/-DG1.I5MK/B,H([C<[^4Z+GN0[>M[<22'4G@*K
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MO'<%QS%,S"H-O':%.+(\:B.P5RK'=Q2WE\Z)Y(%2NRX_&6^,@$A'+4JMR/\
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M)N$)M_7:_L5:8^XF8JW;#+HX#[<E9)^U/J9MT9H#Y?Q6T^/.Q(/%861R>/3
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MH'<@S/D!3,R,2@)M=*D$:Z&KMBKH!VYA45B,1(^)\<@(UT4F)+,10CMJ"GE
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MB3G83?S"4N(4P4^$ FP(N/95JL<9-NZ<()'D%SO,Y<NN6FGRU^W!5+B$ER/
M>Q;[!:^5>7Y6@!V+-QV=*N-IVT^X>2\[#11>8EZP8=#IQ_16%3B['RU'Q"P
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M0G!X #[C5><N/\)S\C/#D*\8Y^0-374O**19(2H]EM #706Y.".@<=?53MG
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M$_BK=DL6VTD#&@#THOO!XF;PRW(C.5=D.SUA6YXW"2>P7K'>6<087O%?A5>
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MK^*W)QYK()QP<R+WGETW90>J$GI^BN69 MK5O%=3LF/?;@OU47S=J(C'!>U
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MP_NUL09F>)H:*:+6G[9LI7E[@:N-?F*X_P!&/@?8]*_OA_=K.[/W#A318?\
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MN$@MWES.:[S]-W%#TGR1]W[M13GDBG)2[H&E?!]-G$Q;=/E$ W[/W:SB9H
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M2?\ ,85;>2_RCT_4K6Q_^,^OZ!>CI^0@8N*Y.R<IF%!9&YV3)<2RT@=ZEK(
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MP/E .HU_)8[IQ;$2./\ %17TN\JY#S'TICYKD^0=R>57.EM*E/D%90VH!(T
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MEH7:Q4EN4XA#S;P2+I2[X5:Z&Q("*"X!V>UR&2: C=[@O87%>3X?F?'<=RG
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M=5YH^G'_ ,4?,_\ MS_O!%2MY_T[?A^2C;7_ #N^/YK;OU7>L>3]-N,0N/\
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M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB_/OU7_ )RN5_ZSE?\
M.&H67YSZJUV_^)OHJ=6)9THB41*(E$2B)1%^D7&__EW$?XE&_P":34ZW@%4'
M_,?5:M^JS^8/EO\ V=_WG%J0L?\ ,WX_D5H7G^$_#\UYF^GGZ;^+>L'"Y_)L
MYELA!EQ<H]CD,PBSY9;:CQW@H^8VL[KO$=:E;N\="\- '!1EK:ME;4D\5M23
M]"_!U(M$Y/E6G/WSJ(SJ>G<E#?[-:8R;_ +;..9XE:IY%@?5'Z0.2PLE@<PG
M*\2R[GB!;+<64IC53,ADE?EN;3=*T+N1T.A%;C'1W;:$4(6HYLEJZH-05[BX
M3RO'\YXGB.78L%$++1D24-*-U-J.BVU$=2A04D^ZH"2,L<6GDIN-X>T.'-3U
M8UD6EOJNS#V(]#^0".LMO9!<2"%"]]CTA!<'_&0E23[ZWK%M9@M*]=2(J#^C
M3"1,=Z.MY1E ^;S.0E2)+GZQ\A7RZ$W[@&[@>TUDR+B9:> 7BP:!'7Q*] OL
M,RF'8TA"78[R%-NM+%TJ0L64DCM!!J.!HI BJH/'?37@7H_ALUE.#X9./?\
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MK*>@K+) P7#"!QK^ 6*.=Q@<*\*?FJEDQ?(2Q_\ 5W/[8U:XS0#T6IDK9\[
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MI2_ T(F<2M:'+] AMU82H]FQ7=5AIUK6@X@?DH*O2N=>!_5>\4J2M(6@A2%
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M<"7G04HH>_E:0&CBM^?3MQ^=QCT6XCB<D@MS/E7)BVU#:I GR'9:4J!Z$)>
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MVWT3?6L+LAJ T4:%E%CH2XU<5N+T/]-IWI1P-GB.0G-9"2U)D23)82I""'U
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M &4@_P!BK^ZK#])%_2%*_P#<61_^9R?[D_2C_92#_8J_NJ?21?TA/^XLC_\
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M#C\])-[B[<EQ;>G]96-]Y,[^99&VD3>2VJVVVRVAEE"6VFTA#;: $I2E(L
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M<N>WC)&&==5N=:Q4@L,$GN:<2XA ]C:4CV5OLOY6BE:^JT7V43C6E%9/3WT
M],/3.6,GQ[$EW-)!",I/<,J2@$6/EE5DMD@FY0D$].E8Y;J204)T66*VCCU
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M(_T_BG]$C'?[4O?Y&C_IJ?2#Q3_9'^G\4_HD8[_:E[_(T?\ 34^D'BG^R/\
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MG,1O4OD#$;(266$.M!#;;SB$B[#9T 4 *KET]PE.JYME97BZ> X\?'R"HO\
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MC'8_F>%D35*V-LMY",5+5W(\?C_XMZS&"0"I:?N6(3QDT#A]ZN0((N-0>AK
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M71D<1Q&&>*R) C0XSC,IQUPK7M2CYI*TH+I.GA;M_4FMO_71@4+M5K?7R$U
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M8HGW#M[^'VX+W+B\7CL)CHN)Q,5N%C(3:6(L5A(0VVV@6"4@57W.+C4\5.
M"@6N/7[U/R_I)P5OE.%AQITQ<]B$69GF>5L>0XHG\-2#<;!VUM6L(E?M/@M:
MYF,3*A3WI)S*=Z@^G>"YCDX[,6=E6G''F(V[RDEM]QH;=Y4>B.TUCGC$;RT<
MED@D+V!QYKRA])G_ (A.;?ZNRO\ WI$J8O\ _ WU'Y%15E_F=Z'\U,_7I_\
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MF$>OJ^+6=$2B)1$HB41*(E$7Z!>E/\VO%?\ 5D7_ )L5\7U3/*LQ_)WB^;Y
M;$8J!*G^+I_%65NZW_K:]L;N<!XE>'NVM)\ O%?T2X1&9]0>2<MR%Y$S&0@E
MMYSQ*$C(NG<Y?]\4MK3[E&IW).HP-'/]%#8]M7EQY+W75?4XE$7E7ZX^,Q97
M"\!RU+8&0QV1_+U."P48TQI;A!/;M6RFP_JC4OC'D/+?$*+R#*M#O-9O!^.Y
M[UO^F7BF%@<@<P66@/\ D.Y% 6M1:QKC\=MO\-Q"M6RWU/9TZ5YE>V&X<2*C
M]U]C:9H  :%>9O33TKSO,_5?-\%QW)7,3E,;\_YV90EPK>^3D)97<(=0KQD[
MM5FI6:<,C#B*@TT4;%"7R%H-*+UIZH\5G<(^E;-<6R>25F)V.AMMO9)84E3Q
M7D$. D+4LZ!6W51Z5#P/#[D. I7]E*S,++<@FO\ Q7FWT/QWK'ZD<<>]->"Y
M/^3O#X<E<_-YE"G&5*<DA*4M%QL[U7#>C2-H.N\VM4I<F*-V]PJ>04=;B21N
MQIH.:LW.OI9Y[Z5X*;S[B',W<C+Q39FY'Y9M[&3$,M>)QUM:'W=_EBZU7*38
M'W5ABOF2NV.;2OQ622S?&-S7</@M]_2WZLYCU1X/*3R5P2.18&0F))EA(29#
M#J-[+BPFPWZ+2JPUVWZFH^]@$3_;P*W[.8R,UXA0/U.>OF5]/E0^"<%UYIE6
MPZ_*2@/+BL.J*&TM(L07G% [;@[1K:ZA;)96HD]SOE"\7=R6>UO$J@X?Z/>=
M\SAHS_J9SA^/R*2D.B*M#F4>94H @.O./H&X=J47'<JMAV08PT8W3[EKML7O
M%7NU^]0Z^0^KWTG<PQV-Y+DWN4>G.1N&4K<6MI;3=@OR Z5*CO-[@KRPK8J_
M;U3[V17326C:X+QNDMG $U:O:!RL+,\7.;Q3X?Q\^ 9D*0C0+9>9\QM8]X(-
M0>TAU#XJ9J"VH7YR>E7+/5GD:,KZ9<*R$IW-<N<B>;D7I3H5%AP$R%/ .$J+
M25^:G>I.I"=NNZU6>>.)M'N&C5787R.JQIU<O0OHE]-OJ3Z9^HL3/9GD3+O'
M4LOO3F,9*D@29*D[$-OMN-MA:;J\S<;ZHUM4;<WD<D= -5(6]H^-]2=%ZMJ'
M4JE$7C"OSPOT*E$2B)1$HB41*(IKA_\ \VX'_6,/_GT5(XS_ *N+_P!;/_U!
M1^3_ .DE_P#0_P#_ $E>M:[LN%)1%Y"^N_\ ZIX3_C&0_M(]36+XN^"B,CP;
M\5E?4/PS^4'TW<-Y+';WSN+P<9(4H:GY.7%98> '7X_*6?8DUYM)-L[F_P!1
M*^W4>Z!I\*+</T[<S_EQZ1<=R3SGF9&"S^59 D[E>?!_""E']\ML(</]=6E=
MQ[)2/BMRUDWQ@K1?J)__ %C^J[C_  EH^=Q[AX0O(#JT51[3)-_Z]7E1E>T?
M;4A#_9MB[F[[?Q6C+_=N WDU57ZI?_$;QK_%\1_GCM9K+_ ?C^2Q7G^8?!>P
MO5'AC7J#Z?\ (.(. %W)1%IB*5T1+:L['4=1HEU""=>E0D$G3>'>"EYH]["U
M>;?HAYBZTCDWIIDE%N3#<_-H+"]%)U3'E)UZ;5!HV[U*J4R4?!X]%'8^3BPJ
MX?6;SC^3OIM'XK%=V9#E,D-.)!LKY&&4NO$$=ZRTCVA1K#CHMTF[^E9K^3:S
M;XJT>C?'V_1[T!:G3&0)[&.E<ERS9\)+RV#(V*UT*&D-M'^MK#</ZTU/.BR0
M-Z4-?*J\^?21PR/ZC\^Y'ZD<Q2G*2\2XW):$D!:7,GD%N.%\I.A+8;44@C12
M@1JD6DK^3IL#&Z5_(+0LH^H\O=K3\U[J4E*TE"P%(4"%)(N"#U!%5]3B\">M
M6*9] _J#PW+N)H^1Q,PL9CY1@;&DI4ZIF9&2$_J+2E1VCH'+#H*L5L[KP%KN
M/#]E W#>C,'-X<?W7KWUQ_F>YQ_J:;_S2JAK;_*WU4M<?XW>BTU]#/\ -[R/
M_7)_S5FMW)_./1:>.^0^JK/UZ?\ Y/\ _MG_ / *S8O^;X?JL>2_E^/Z+TQ_
M^2?_ /EW_P# :BO_ -SX_JI+_P#;^'Z+QG]&7I[B>6<VRO)\RPB6QQ9F.Y#C
MN@*0)TM:_*=(/7RTLN%.FBK'J!4YD92Q@:/YE#6$0<XD\E[XEQ(L^*]!G,HD
MPY*%,R([R0MMQM8VJ2I*K@@@V(-5T$@U"GB*Z%>$^)1AZ*?5RKBV(4MGCV1F
M)QR8]R4JB9=E#S#=SU#3JVP"=?!5@D/6MMQXC]%!L'1N-HX?NKK]=_\ U3PG
M_&,A_:1ZP8OB[X+-D>#?BMN?39P'"\1])N/R6(;7YKGX3>4R<PH27GA.2'D(
M4K4[$MJ0D)Z:7M<FM*\E+Y3X#1;=I&&QCQ*UU]:'(OY+^G>#X3A$(@0\],=5
M(8C)2TV8L$)<4V$)  "G76UFPZCVUM8YFYY<>2U[]VU@:.:V/]-WIOB.!>F6
M%E,1V_S_ #\1C)Y>=M!>6J4@.MM%77:TE00$C2]U=5&M6\F,DA\ MBUB#(QX
ME73U&X#A/4KB60XMFV4+3*:5\G)4D*<BR=I\MYL]0I*N[J+@Z$U@AE,;@X+/
M+$)&D%>6/HAY/DX>?Y5Z<SE+^60Q^:LQU$D,2(SR(K^T=!O\UO=_6"I?),!:
MUX]%%X]Y!+%4?J?P;O)OJ0@<;97Y;V83B,<VYUVJEK#(.I'0JK-9.VP$^%5A
MNV[IZ>-%[IXQQG"<.P,'C?'8B(>(Q[8:890!V=5*/ZRU'Q*4=2=:K[WE[JGB
MIQC P4'!>5OK;X%C&,;A?4K'1TQ\S\XG&9-]D;5/(6TMQAQ=OUF_)* KK90'
M8+2^-E-2P\.*B\A&*!XXK<6!Y3(YK]-J^2S%EV=,XO-3,=/5<F/&=8>6?ZY;
M:E5I.9LGVC^I;C7[X*^2U!]"'_5/-O\ &,?_ &DBMW*<6_%:>.X.^"V1ZG_3
M?']4?43&<VS/(E_E4#Y5ISCRXOF-.18[GF.-)>#R2CS25[CL/6M6&\Z3"T#7
MQ6S-:]1X<3\%LR?SWTZXLRF)D>28;$M1D):;BNS(T?8A LE"&RL$6";!('96
MJ(I'< 2MDR,;Q("\3?5[S3TVYMG>/3^#3X^3R\=F4QG)D5M82IL%DQ075(2E
MRWXUMI-ONJ=L(Y&-(<*#DH6^D8\@MU/->OE1LOR'T(,3'J4[GLKQ(M15WVJ5
M,DXW:@W'0E:AK4+4-FUX!WZJ7H71:<2W]%Y$^F+UHX=Z0.9[ <Y@OP)$^0V3
ME6V%..M%@%M3$AL?B)"#=0VI)N57%35[;.FH6E1%I<-BJ'+U7ELOZ1^O_$IW
M$(/(H&2;R#=VD-.($Z.ZG5#R&'@EQ*DGM*!I<=":B&ME@<'$$*5<Z.=NVJF/
M2?TIPWI#QZ1QS!9"=/A29*IJSD%M+*'5H0VH-AIML)20@&QOK6.><S.J0%[A
MA$0H"O+'K5_XPN'?ZQXW_G;=2]M_TKO1RB[C_J6^K5[CJ 4VE$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41>(_6K^=#D7_P!>:_S=NJU=
M_P"5RYEEO^K?Z_H%0JU%$I1$HB41*(E$2B+WMZ??_(7%O]48_P#S5NK5!_C;
MZ!=7L?\ IX__ $M_(*QUF6XO.GUJ?S/,?ZYB?\T_4GCO\OP4=?\ ^/XK3G.^
M&?GGTB<"Y9';W3.,+>+JNT0ITQQESI_]4#)]UZW8I-MTYO\ 4M.2.MNUW@O4
MGH%S/^77I-QO-.N>9D&8PQ^1/ZWS,'\%2E>U82ES_C5$W4>R4A2EM)OC!6K/
MK3Y>_!X9A^!8Y15D.43 M]A&JEQ812H(L/WSRVMO?M-;>.CJ\N/\JU;]]&AH
MYK3GU3\09X%QKTJXBS:^+Q<QI]2>BI*EL./K']<ZI:OMK>L9.HY[O$K3O&;&
ML;X!>WL!+3C^"XN>MMQY,7$QWU,L)+CJPW&2K:A(U4HVL .IJ!>*O(\U-M-&
M ^2\9<1].N=?4YZBYG.^IS^1PG'\64J^04VMEQI$A2PU%B(?3M0$A!+CFPFX
M\0*E7J<DF9;1@,H2?MJH9D3[AY+Z@!;;S'T3^ELO'+8P\[*XW)!!#$M;S<E'
MF=A<:4VG<.\(4CWUI-R4@.H!6V['QD:56L/I1Y'R7A7JYF?1_)RE/XO?D(SD
M4**V6LCC%JW.M7^$*#;@5;XO"3TK;OF-?$)!QT^XK6LGN9(6'S_!;S^I[U>F
M^E?"&6<"X&N5<@<<BXU\@*+#324E]\ Z%20M"4]RE ]EJC[*W$K]> 6]=SF-
MNG$K4GI!])L'F.!C<[]5<E/DY'.H$YB T]M<\E\!:')+RPM:EK2=VT$;;ZF]
MP-VXORQVV,#1:D%D'C<\\5!^M?H/,]"G,9ZF>DN3GLM1Y2&)#"EAR1&=<_@U
M(4E(\QE9'EK0X#U%]P4;>[:Z$]62 +'<6QAH]A6[N;<LF\X^EC,\GR<)S'92
M;AUB?#=0II2)++H:=LA8!"5*05(O^J16C'&&7(:-15;LCR^W)/@O*_H?Z:<G
M]<HBN%N9=6)X'QEU62E+0WYI7.GV0D!!4D*64-$!1T0D'3Q:RUS,V [J5<5%
MV\3IO;6C0O4GI?Z$\;^GF1RCG<O-.9.&C&G:\ZPEEV+$C[I$D':M065^6V4V
MV_#:U1,]TZXHVE-5*0V[8*NK71>?>-XCG'U?>H<_(\@R+N,X5B%!98:\;<1A
MY1#4>.DV2IY82=[JAV7.FU%23W,M&  5<5'L:^Z?4F@"W/G/HE],Y>)5&P.1
MR>.RZ$'R)S[K<IM2^PNM>6BX_K%(K1;DI =0"%NNQ["-":JB?3OZC\P]-O4I
M[T&Y^\M^$7UPL<75ESY26E.]H-+5KY#Z;;$VZJ20!=5]B[A;)'U6+!:RNC?T
MW*W_ %S?S>\<_P!<C_-7JP8SYSZ++D?D'JJ;Z.>@L[ULQ,3U!]6LG,<PP8;Q
M_&\3'<\JT.&/("O$%>6U='A2BQ6;K)U\6>XNA"=D8UYK#!;&8;GG3DN/KC]-
M,?TPQ'^\WTIR$Z$O".(?F1%/%3S"+A(?CO)VK&PD;TJW:$F]A:OMM>=4[) -
M4N+3IC>P\%Z$^GOU1=]5O3J)FLB4_P H(#BL=F=@"0N0RE*@Z$BU@ZA25FP
M"MP&@J-NX.E)0<.2D+6;J,J>*\9^H">6N_4_GHG!9"XG*IV5=@8^2VK8ILS6
M/EW%;[$H ;<7=8U2/$-14W%M^G&[A10TN[KG;QJO0&)^B+@(Q@'(\[EIV?>3
MNE38SC+#(>5JHH0XRZHBY_762?94<[)/KH!12#<>RFI-5I[A".1?3K]1L/@H
MR:I. R4V+ E7_#8E1,EM0P\M!-DK:4L$J["E0OM)ONR[;B#=34?HM./=!-MK
MH?U7LGU>Y9F^%>GN9SW&L>]DN0-MI9QL:.PN20^^H(#JD(!)2V"5F^FENVH2
MWC#W@$T"F)WEC"0-5Y9]&OILD>K<"3ZC>KF4R:G\B^ZF-%W^7+=\E1;6Z^X^
MA:@G<"E"$@?#UMI4M<7G2.R,#11<%IU1O>2K%ZK_ $=<,Q?$,OR/@\^;$R>)
MBO3OD9CJ)$9YJ,V7%M@[$+0HA)VJ*B+Z$=HQP9!Y< X:%9)K%H:2WDI_Z+>?
M9KE'$,WQG-27)AXT]&^1D/**W$Q9J7=K.XZE*%,*VWZ!5N@ K%D8@UP<.:R6
M$A<T@\E ?5;ZG\FR')\;Z(<$><;FY'R$9<QE%MUYZ<0EB)O!!2@I(6YV*"@#
MH% Y;&%H:97<OM58[V9Q<(VJ<XU]$GI]&PC;/*LGD9^>=0/F)4-U$9AIP@7#
M*%-KN!TNY>_6PZ5C?DGD^T"BR,Q[*>XFJ\\^NWI]R_T:;8]/G<N[E/3K*R1F
M<(IT6")45#C+B=ER$.)3(_$V>%8*%==$R5K*V;WTHX:%1]S$Z+VUJTZA>ZO3
M3(P\1Z+</RV0<#,"!Q?&RI3QZ(98Q[:UJ/N2":K\P)E<!_4?S4Y$0(FD^ _)
M>0<1#YK]8/J//>R61>Q/ <,H/)83XT1&'"4LM-HN$JD.A*BIQ72RNP)09IQ9
M:1B@JX_;[E$-#KI^IHT+<F8^B?TPDXA<7"S\I RZ4$,9!YYN0E3EM"\UY: 4
M]X045HMR4@.H%%N.Q\=-*U5-^G+U&Y?P'U%D^@'/WC(9:=>BXEUQ:EF/(907
M$H;6JQ+#S8W-@]"4V W$5GO(6R1]5BPVLKF/Z3E/?6KZA9[CN"P?#L+(7#C<
MA$IW*OM**''(\?RT!@$:[%EPE??8#H2*QXZ)KB7'DLE_*6@-'-9O$_HQ]+A@
M(CN<R$_,9*4PVZ[-C2$,1MSB ;L)2@G9K=)6I5_T5YDR,F[0 +ZRPCIKJM<S
MO1[U.]!?5K&Y7TFC97D7&GPA]]+396%Q@LI>B2U)"&E*V^)"B$]00 I-;0N(
MYXB)* _;4+7,$D,@+*D+W&#<7[_LJ 4VE$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B+RSS?_P";\W_CCW]N:E(_E"Z18_\ 3L_](4!7M;J41*(E
M$2B)1$HB]<XC_JF!_B[/]H*BG<5R^;YW>I6@/K4_F>8_US$_YI^I''?Y?@HF
M_P#\?Q4W],V,@9KZ<>.8C*QT2\;.9RL:7&=%T.,NY*6E:5#N(-8[UQ$Y(XZ?
MD%DM #" ?/\ ,KS-_P"_OI*]<?\ TLOAT[[IF'?7]@+\<CV>)/8E>LK[;N'S
M_51FMM+Y?HO1OU39.!FOIZR.7Q4A$O&SEXR3$DM&Z'&79+2D*2>X@U&6+2)P
M#QU4C>$&$D>2X_1Q_,K%_P!8S?[=-,A_E^"6/^+XJ0S_ -/G#Y?JD/6/DF;>
M=$9]N9(QV0\CY!)8:#3 WJ"=J&U!"P%7N1[:\LNW"/I@+TZV:9.H2K5EO7CT
M<PNX3>:XM2D&RDQ7Q-4#II:-YA[:PMM97<&E977,8_F"\/\ U-^HG"O4#U"@
M\DX"\MY$:"U'EY#R'(Q>D,NN*0L)="5':E21N4D'2W0"I^RA?&PA_BH2[E:]
M]6K]%\O_ -4S_P#%WO[0U66\0K$[@O&OT(?];<V_Q?'_ -O(J;RG!OQ4-CN+
MO@MF?6I_,\Q_KF)_S3]:N._R_!;-_P#X_BKG],W\QG#O\7?_ ,[>K!>?YG+-
M:?XFK,^H7^97FG^KE_VZ:\VG^5OJO5U_B=Z+6GT/?S3YG_Z(I/\ F,*MO)?Y
M1Z?J5K8__&?7] M%^M?'F>6?5O)XS))$7+9/!0Y*@;$,O0H27".FH23:M^V?
MLMMW@#^96C<-W7%/$C]%^@47'P8,%G&PX[;&/C-I98BH2$M(;; "4I2-  !I
M5<))-5/@ "BU'ZM_3WQ[U7Y+C>4Y_-3(K6*9:85CT^68BH[3JGG+W"5)4X%;
M5+W= .ZMV"[=$TM XK4GM1*X$G@K/D/6'T?XPTF%)Y=AHJ(B TF'&DLNJ:0@
M62@-1RHIL!HG;6(6\KM=I60SQMYA>1_JS]6/33U*8X_'X9+.3RN*>D"3/$=U
MA 8=2G\,*>2@J\2;Z)([CKK,V$$D==V@*B;V9DE-NI"]=>B3KCWI!P=;JBM?
MY)!3<];(82D#[ *A;G_*[U*E[?\ QM]%Y8^A3_YLY9_JZ/\ \^:E\G\K?51>
M.^8^B]QU *;2B+P']</\[&&_^AV-_GTVK%C?\1]?T"@<A_D'I^I6+B?2KU?^
MID9CU,Y!-3&9#+J<"F0DH:D.-$E$:*W<!MA)NDNF_B_?*WD>G3Q6U&#XKRV&
M2XJ\_!7/Z3/6:3@,FKT9YLM49/GN-8%<JZ%QI@60["6%=-RMQ0#T7=/ZP P7
M]ON'4;\?W6>RGVGIN^'[+VG4$IE>=/K4_F>8_P!<Q/\ FGZD\=_E^"CK_P#Q
M_%7/Z9OYC.'?XN__ )V]6"\_S.6:T_Q-7G3Z3/\ Q"<V_P!797_O2)4G?_X&
M^H_(J/LO\SO0_FIGZ]/_ ,G_ /VS_P#@%>,7_-\/U7O)?R_']%Z%Y!R1[A_H
MA)Y-%.V9C>.I>B*(N!(^42&B18Z;RFHQC-\VWQ*D'/VQ5\EY$^E3E/I9P_*Y
MSF7J+F6HO)E%$?$+E-O/K2AT*5(>!0VYXUDI3N)O;</UC4U?,D> U@T419OC
M:2YYU7J=7U+>A2TE"^81E(4"%),>600>H(\FHCZ.;^E2GU<7]2\F\5Y'Q;BO
MU60)WII,1(X9F\FQ!93'2MIGRLPE#;K.Q:4$(:?<NA-K#:FIA['.MB'\0/R4
M4Q[6W%6<"?S6Y_KF_F]XY_KD?YJ]6CC/G/HMS(_(/57;Z4N)8[C?H[ALA'92
M,GG_ #,CD)( WK*G%(:3?4V0VE( [[GMK!?2%TI'(+/9,#8P?%;L2A"!M0D)
M!)40!874;DZ=Y-S6@MU<J(O#?U8S9W-O6[BGIJT\IN"A,&(V@&X$O+R E;EN
ME]GE 7[O;4_8@,A<_P!?P4)>DOE#/MJO:F#PF*XWB(6!PD5$/$X]I,>)&:%D
MH0@?I)ZDG4G4ZU!.<7&IXJ9:T-%!P6L/6ST P?K0[AY4R>K$9'%%QM<UAA+S
MKT5RQ\DE2T6VJ&Y).ZUU:>(UMVUT8:Z5JM:XMA+3E1:R^KG*SN%^CW%^ QY[
MTE4]QF'-FNZ.RHV+83<N;=+K<+2U>T5M6#0^4OI]BM6])9&&_;1<OI^]3_0?
MTS]-L9C)/(XT3DDY F9]2F)"GE2G+D(4M#)!#22$) -AJ>I)*[AFDD)IIR2V
MFBC8!77FKASKUH^G?GO$\KQ3,<JAO1<BPMM"G(\HEI_:?*=0?(-E-JLI)K#%
M;3QN#@W@LTEQ"]I:2M4?0MR:6)O*N'.+4J"IIG+1FR?"VZE7D/$?UX4U?^MK
M<R;!1KO@M7'/U+?BHWUJ_P#&%P[_ %CQO_.VZ]6W_2N]'+S<?]2WU:M_?59_
M,'RW_L[_ +SBU'6/^9OQ_(K?O/\ "?A^:AOHX_F5B_ZQF_VZ:]Y#_+\%XL?\
M7Q7GG*<DR7H)]3N?Y9R?#.3H,^;D94<:)6N!E'5K0]&6L;2I .PB_8I%QU$F
MU@GMPUI\/P4>7F&<N(\?Q7J#BWU0>BO+@F.<\G$27AM5$S39A@!78IU6YC_^
M[42^RE9RKZ*39>1.YT]5F^FOH;Z<<#S\KG'"WY+LC*MOH"Q)0["^7DNATMM)
M:0E.Q*D)V:FUNM>9KF21NUW)>HK=C#N;S6UZTUM)1$HB41*(E$2B+PS]0?\
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MBVQ[T&L.1>!MC' +-8-)W//$K7OU2_\ B-XU_B^(_P \=K9LO\!^/Y+7O/\
M,/@O>%5Y3J\-<_;/H9]5F.Y<RDL\=Y"^B<_;1'D9(JCS0>PE#A6\$_UM3\7]
M^V+>8_3@H.3^S<!W(_8KM]04*]</JOQ_#@"]QSC;B(<M.I1Y&/O)F[NH!6X5
M,7_K:1?V+8NYG[!?9?[UP&\A]BO7?J)BW\UZ?<KPL,7E9'#9"''2!?\ $?BN
M-I &G:JH6%VU[3X$*6E%6$>17EGZ$<O#2OF> 6L)R#@A3F6S:ZV6_-:<([?"
MI:+_ -<*E\FT^TJ+QSA[@O9=0:F5X2^LJ7_*7U;XWQ#&6>R#$)B,I"!=0DY&
M0K8V=>NWRU?\:K!CAMB+C]J*"OSND#0O5OK@ GT=YND=!A9@'V,FHBV_RM]5
M*W'^-WHM-_0S_-[R/_7)_P U9K=R?SCT6GCOD/JJS]>G_P"3_P#[9_\ P"LV
M+_F^'ZK'DOY?C^B],?\ Y)__ .7?_P !J*__ '/C^JDO_P!OX?HO,?T(99A,
MCFN"<6D2G40)L=O]93;1?;=/7HDK;[.VI7*-^4^JC,<[Y@O9U0:F5X1Y*MKG
M'UJ0FL2//:QV8QX<6@_K81AMV03;]XME:?LJP,]EIKS!_%03_?=:>(_!7'Z[
M_P#JGA/^,9#^TCUAQ?%WP6;(\&_%>B_2+^:?@G_T.XC_ #%FHRX_RN]3^:D8
M/\;?0?DO.OUWXR0[B.$YE(/RL23D(;IMIYDMMAQ&ONCKJ3Q;M7#T4=D1HT^J
M]$>D.7AYWTNX?DX*PMAS$0VR1;PNQV4LNHT[4+0I)]U1EPTMD<#XJ1@<#&TC
MP5MG38N-A2<C-<#,*(TN1)>5\*&FDE:U'V "]80*F@64F@JO$'T8HD9GU;Y=
MRD-%,4XV1YI T0[/G,O(3U/8TO[JGLCI$UOG^BA+#60GR7SUSRS&"^K;C67E
MK2W#AR,&[)<7\*&0ZGS%=1T3<U]MF[K8CU2X=MN ?1>YZKZG%YB^M_-0XGIO
MAL$M8_,,EED/LM7U\B(P[YB_L4ZVG_C5*XUI,A/@%&9!P# /-6;TXP[^#^E!
MJ#)06W5\:RDW8KKMGHDRTG[4N@UBF=NN:_\ ,%EB;2WIY%:Y^A#_ *IYM_C&
M/_M)%;64XM^*UL=P=\%7?77G/.?5;UD'HAQ7(JQF"1)1C'6T+4VW(?V!V0[(
M*/$I#8W -ZCPWM<UEM8F11=5PJ5CN)'R2]-IH%?\#]#_ *=PFVU<@S>5RLI-
MO,#"F84=1[?!Y;JP/_LM:SLD\\  MAN/8.))6GOJR].?3STT5P["\(QZ($M]
MN?(R8+KK[[J"J.AA;BG5K-KI>VVL.M;MA,^3<7'P6G>Q,CVAH7LOBN<Q/&_2
MCCF<SLMN#B8>$QJY4MXV;;28S203:_:0*@WM+I"!QJ5,,<&Q@GA0*D3/3KT!
M^H:+*Y1CXS.0?2^N))SN,\Z#(,A"$*4%W2@.D)6FRG$*]AK8$TUN=I^XK"8H
M9]1]ZTOS[Z)7<3CI>9X#R-R4[";7(;QF3;2AY8:!79$AG:G?IX;M)%_UA6]%
MDJFCPM*3'T%6E7#Z-O5+DO,,9F^(<FF.Y)>"2P_C9TA1<?$=\K0IE;AU4$*2
M"@J)591'PI &'(0-80YNE5FL)G.!:>2H/K5_XPN'?ZQXW_G;=;%M_P!*[T<L
M%Q_U+?5J]QU *;2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(O$?K5_.AR+_Z\U_F[=5J[_RN7,LM_P!6_P!?T"H5:BB4HB41*(E$2B)1
M%[V]/O\ Y"XM_JC'_P":MU:H/\;?0+J]C_T\?_I;^05CK,MQ>=/K4_F>8_US
M$_YI^I/'?Y?@HZ__ ,?Q4UZ)\=B<N^F3#<7G:1<OBYT)Q5KE/G2)"0L>U)(4
M/:*QW+RRX+AR(7NW;N@ /,+5?T7<AF8+.\Q])\U=F=%=5.9C*/P28JQ$F)'>
M=&NG[TUN9%@<&R#[>"U;!Q!<PKZ KUC^L(G^'XYP$:G78%XL_=<S7/M2GV4_
MPVOF[]?X)_EN?)OZ?Q49]=__ %MPG_%\A_;QZ]8O@[X+SD>+?BO7/&I,:%PK
M#S)CJ(\2/BXSTA]U00VVVW'2I2E*-@  +DFH9XJ\^JEF&C1Z+S-R3ZP\]FL\
MYQ_T8X@O/K05!N7*9D2''PDV*T1(Q0M*.T*6N^NJ4U*LQ[6MK(ZGV\5&OOB3
M2,570SF/K<YD?+C8^/QF*X %ON,PHNT*'=(4^\/^*BX^ZOI;:,YU^]?-UT_E
M1:V^GB%E\=]4;N/Y!*$W/1)6<CY6:E16'IC3;Z'G I023O6%*N0#[*VKL@V]
M1PT6M:@B>AXZJP_74_(5S'BL90/RK>,><:5?0N.2"%BWN0BL6,'M=ZK)D?F'
MHO<$5AB-%8C10$QF6TMLI3T#:  D#[!4"35387=7Q?5K/ZA?YE>:?ZN7_;IK
M:M/\K?5:UU_B=Z+4OT,-H' >2.A(\Q68"5*[2E,5H@?9N-;N3^<>BU,=\A]5
MM/ZD7GF/0_F2V"0LPT(-M? Y(:0O_P"E)K3L_P#,U;5U_B<M;_0ZRRGTMS<A
M*1Y[F??;<7VE+<.(4C[-ZOOK:R9_N#T_4K6Q_P#C/K^R]-U%*37A3Z@T,Q/J
MKXO)@D)EN/X%Y]0.T^>F4$I)(&G@0BK!::VQKYJ#N=+@4\EL?ZYOYO>.?ZY'
M^:O5JXSYSZ+8R/R#U6]/2:/&B^EO"F(A"HZ<%C2A8TW;HC:BK_C$WK0G-9'>
MI6]"*1M] N[U.:9>]-N8-24A3"\)D@X%=-ORCE[U\A_R-]0OLWR.]"O,_P!!
MSTE4+G3"[_)H=QBVAKM\U:90<M[;)1>I7*<6_']%&X[@[X*N<;;0Y]<KR7$A
M21DLDH Z^).*?4#]A%ZR/_Z/X#\UB9_U7Q/Y+W+4 IQ>&_J- 'U1\-( !4<&
M2>\_/K'[53]G_P!.[X_DH2Z_SM^'YKV)S7FG'_3_ (W-Y5R:1\OBH205;1N=
M<<4;(::3<;EJ.@'VFP!-0D<;I';6\5+R2!C=Q7E@_57ZP\\G2(_I+P 2(#:_
M+\]UB3D7$#L+JV5,M-%76RK@=YZU+_0Q1C^X[]%%_62//L:L;D,?ZR.6<9S$
MCD;\?CG&6X4A^>Q_$XZW8S;*E.H 82\^"I(4-JE)!OKI7UAM6.%-3\5\<+ES
M370+N^@O_P#*!_V-_P#A],I_+\?T7W&_S?#]5 XW9+^N-?YDHE*<I)V%0N=S
M.,<\@=#H"E '_D:R'2ST\/U6,:W6OC^B]T57U.+RM]=#;!X+QEU03\RG+*2V
M3\7EJC.%=O9=*;_94OC/G/HHO(_(/56_D+[L?Z0&7&5%"SPK'-DC]X["80H?
M:E1%86#_ .U_^1_-97?]-_\ B%YA] _Z1,?!961Z+PF7\0[+2WDG7%8T*^9;
M;!2FTUQ*K!*[^$6UJ5NNA4=3C\?T49;=:AZ?#X+;?SOUX?Z-C_V6!_Z:M.EG
MX_\ ZEMUN_#\E4L7Z0?4AF/6+ >I?-..I,IC*XV3EIC$O%-7C0W&D+/ELR!<
MAE&W1-S69UQ (BQIY'Q6(03F0/<.8\%Z2]=_1+'>L_'XT7YH8[D6*4XYB)ZD
M[VQYP2'&G4C4H7L3J-4D ZZ@Q=K<F%WB"I&YMQ*/,+RZWP[ZM_15 C\?<R$[
M!Q39EO&+3F(.T$DA$5Q*UH2>W\%-2W4MIN-*^>BC.G<1<*T^]6W@_P!:6;@Y
M5O!^JV 0P@+#,G(P4.QY$<G]9Z*Z5;K7\6PI-NB3TK#+C@16,K+'?D&CPO9$
M:2Q,CLRXKB7HLA"76'D$*0MM8"DJ21U!!N*A"**8!JNVOB^I1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1%Y9YO_\ -^;_ ,<>_MS4I'\H72+'_IV?
M^D* KVMU*(E$2B)1$HB41>N<1_U3 _Q=G^T%13N*Y?-\[O4K0'UJ?S/,?ZYB
M?\T_4CCO\OP43?\ ^/XJS?2G_,'Q+_M'_O.56*^_S.^'Y!9;/_"/C^:D_7OT
MDB^KG!W\6TE".2X[=+P$I1"=L@)\32E=B'@-JNX[5?JUXM9S$^O(\5ZN8.JR
MG/DO#,;U1R<'T>Y1Z*\G0\E^-*8>PH=!"XSK$Q!E1%@ZI (4XF_0[QVBK 8
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MV@WV*L$[OZDD'I<;UT&S0=3FM.V+HIMG)>]JKJGDHB41*(E$2B)1%X9^H/\
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MD?R_RVT^9YWR>S9MZ[MVEJCJCJ5\U(4.RGDO#7IEZ,>N_&&Y?J#Q3&2\1RS
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MGA\I(X+/;-+8P#Q6D_IS]*?4'AGK/RKDO)L&[C\'/A9!F',6XRM+CC^0CO(
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M2V4I*>S2W32H>.5S';AQ4J^-KV[3P7D7%^GOU+_3OEIK?I\PGE/$Y+GF%II
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MZ:QGWR/^BHB?T4.9?Z:QGWR/^BHB?T4.9?Z:QGWR/^BHB?T4.9?Z:QGWR/\
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M4F]]@ZUEAN'Q5VGBL4L#)/FY*ZPH;&/AQX$5)3&BM(89225$-M)"4BYU.@K
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M7GASZW,I(6]-P_IT_)P48D.R5S5[MH[5J;BK0V;=A*O?4E_K0-"_7[>:C_\
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MJQ>.?6SAE9-&+Y]Q27QT%6UV6RZ9?EW.A<86TRX$CMV[SW"O3\::58ZJ^-R
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MA-:E38A8!2@6L/7;Z?<YZR<GP>3_ )1-0N/XMI#"\4ME97^(\5R76W HC>M
M0D73;PBMNUNQ"TBFI6M<VQE<#70+<,1KB?!L/&Q494+!82$V&XS"EMQFD(3[
M5D7[RHFY.IUK2.YYKQ*W!M8*< O&GUE9?TQS[V!R/%,EC<CRQMU]C*NXQUI]
M2HVU)1YZV=R2I*@0FZKBYJ<QS9&U#@0/-0U^Z-U"TBJ]7^C,N1.])N$RI2RY
M(7A8 6X=2HI80FY/:3;6H>X%)7>I4K :QM]%X@^FWT\P_J%ZR3VN0QD3,+A6
MY63>ANZM/.I?2TTA:>U.YS>1T.VQT-3UY,8XA3B5"6D0?)KP"_0M_$XN5C5X
M:3"8=Q#C?D+@+:0J.IJUMA;(V[;=EJK8<0:\U8=HI3DO#'H[C4<$^KV7Q+$;
MF<4J5F("&0J]H8C/2VD$]NWRF_NJ?N#OM=QXZ*#@&RYVCAJMN?7#_-/AO_HB
MC?YC-K3QO^4^GZA;>0_QCU_0K9?T]?S*\+_U<C^W56I=_P"5WJMFU_Q-]%A_
M4S_,9S'_ !=C_.V:]6?^9J\W?^)RIGT5_P SS_\ KF7_ ,TQ6?(_Y?@L-A_C
M^*U/_P#MS?\ :/\ ^J:W/_\ #^'ZK5__ ,KX_HK_ /6WS6;A>&X3A\!TLCD<
MAYV>4&RE18 ;/EJM^JMQU"O;L]]:V-C#GEQY+/D)"&AHYK8?TZ>E6$].O3_%
M3416SRC-Q&IV7R"D@O7D)#J6 HZI0V"$[1H5 JZFM:[G,CR.06Q:PB-@\2I[
MUC]+,'ZJ<.GXB=$;.;:8<<PF1VCSX\I*2I%E]=BE )<3>Q'ML1CMYS$\$<.:
MR3PB1M#QY+0/T.<UG2(_(O3^:ZMR+!2WE,6A6H:2XLMR$"_0%1;4!WE1[:D<
MG&-'CT6ACY#JU5#U%;?]<?JLC\%GNN?R=QDG\L#*"4[(L!I4B98CHIQ:'$A7
M]:.P5GA_L6VX<3]@L,O]ZXVG@/L5[CQ&'Q6 QT?$82&SC\7$0&X\2,@-M(2.
MP)3;[:@'.+C4\5-M:&B@7GCU"^F7*9?U7Q_J3Z>9.%QLM+8FS6U(<W*R##A4
M7$-M)"=KB0D. J&X[B;[C4E%>@1ECQ7]E'RVA,@>TT4#];W!C-X_A/4*&W>3
MB'ORW(K2/%\K*.YE2C;HAT%(UZN5DQLM'%GBO&0CJ [P6]?1?FP]0O3+CO)G
M' Y/>C)8R1UO\[&_!>)!U&Y22L>PBH^YCZ<A:MZWDWL!7E[ZAY4GU?\ J#XW
MZ3XUTJ@8M;4.24:['96V3-='0'RV$I^U!J6M!T8#(>?V"B[H]68,'+[%>IO5
M*+'@^CO-(,1L,Q(W&<HRPTGX4-MP'4I2/8 +5$P&LK3_ ,P_-2DPI&[T/Y+0
MWT*?_*?+/]8Q_P#F#4AD_F;Z+1QWRGU6)]<7-YT/'\>X%">+4;)>;DLJA)L7
M&V%!$="K=4[_ #%$'M2GNKUC(P27GDO.0D( :MI>C,3T@]+N%X[%P.0X)&;?
MCMNYO(&=$$A^4M(4L*47-P0A1*4(Z)'MN3IW!EE>20:<M%M0".-H (JJ[]2D
M+TJ]0O3O*SVL[AGN6X.,Y.P\EB=%5)5Y \QQ@!+FY8<0% (_?6(%ZRV9DCD
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M8QL8^U%]L6ESG/*]-^KO\T_._P#Z'<O_ )B]45;_ .5OJ/S4G/\ XW>A_):
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M7'D_"?0;U^FR6C*@YGD&.:;2]E,)+093+2RH("G62IM8N% !P*M[*,DF@',
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>tm2227887d1-bc_119ct4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-bc_119ct4c.jpg
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M4I*BTG,481(3\"+"@>&S0D-T-@?Q5/_:  P# 0 "$0,1 #\ O\
M
M
M
M
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MX
M
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M<G8VZIE9JB-3J>QKOK!,PT/"H
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M18L)N%177"DIW5E0DE'44\;(6O9'JKY6-;JKGIHW75?K*"Q)H0
M
M                         "AG/KN+55-^LNV-#,YENH8&W:ZL:NC9*J=7
M,@:[T>SC:YR=S[IZ706AX/)ML/8]Q*VXY[F=(VOQVRSMH[=;94U@J:_A;*]T
MR=3F1,<SO%Z'*_IZ&Z.$RT*BH:*"C;;X*:**@:SLFTK&-;"D>FG"C$3AX=.Y
MH%5,N:;E9GNUQM>5[/X\UUQN$[J6]V:@2."%7N:LC*IK7*R.-.]<R5=4155J
M]:N52T2Z?E*V/W:VBNUYJ\O\!I<>O-+&V6UQU7A%4VL@?K%)I&QT6B,=*QVD
MNO2G7H"9>SG7.9ANWV77?#+[C-Y]]+/4+3S/B\%6.1-$>R1BNF1>%['->W5$
M71>D(L39MWG=FW+PVUYM84>RVW1CGLAFX>UB?%(Z*2-Z-5R<37-5.A0A]N89
M1;<*Q:\9;>%5+;9J26MJ&LTXWI"U7(QG$J)Q/71K45>M4 K]B7.OA.:9/:,3
MLV+WMUSO-5%14RN2EX&NF<C>-_#,JHQB=\Y=.AJ*H38BWG&WWQW);?<]GZ2V
MUL-[L=XAEJ*Z7LO!'I3Q2(J,X7J_I[5--6A,0A/EKW?LFRN=7#*;]0U5PHZR
MTS6QD-#V?:I++4TTR.7M7L3A1(7)U]U F6D.TVY]HW>P^+,K)1U-#0RU$U*D
M%9V?:HZ!415^YN>FBZ]'2%'\;F[Q8#M';67#,[FD$U0BK0VV!O;5U3P]?91(
MJ="=U[E:Q.ZX"M]P_>#8]'4JRUX/65-'QZ)+4UT5-+P=/3V;(9DUZNCC^N%K
M$B;:\Y.U>?5\%EN?A&+7FI5&0-N:QK1R2.71&-J6+HBK_P!HUB=Q.D(L6("&
M=//SYX;)^C5+Y?7A:$W\@WF>O?Z2U7D% $2[#=KFNV[VER-N*5T%9>KS'&DE
M?#;$A<VD5R(K&2NED8G&YJ\7"G4FFO6@+'J;-<P5MWMJZYF-XS=:*U6U$\,N
MU?X.RF;*]-60L[.1[GR*G2J(G>ITJJ:MU$P\7F!WCVMVRO%GH<_P[XS5E?32
M3T<_@E%5=E$R3A<W6J5%35>G1H(AT>P&Y&";EXW<[M@..?%JVTE=X+4TG@]-
M2]I/V,;^TX:55:O>N1-5Z>@$OCWIYC\6V0NEKM606JX7&:ZT[ZJ%] D*M:V-
M_ J.[61BZZ^@"(?):>:O;&LVX?N7=GU-FMBULUMI+;4MCDN%540,8]R0Q1/=
MQ)I(FKE5&M^V5 6(CJOW@U@96K'18-636[5=*B:OBAGX>C1>R;#(W5>G5.U"
M;$^[/[]8'O325#L9FFI;S1,;)7V6N:V.JB8Y>'M&\+G-DCXNCB8[HZ.)&ZH@
M18E (0+NSS:;9[6W&;'V=OD>34ZJRIH+:K.QIY$^TGJ'KPM=Z+6(]S5]4B!-
MB+K=^\&QV6J1EVPBMI:+CT6:EKHJJ7@Z.GLWQ0)KU]':?7";%F]N=S\*W5LG
MO]A=R;6TT;DCJZ=S5BJ::54UX)HG=+5]!?4N^U54"KL  'D95D%-B>,7O*:V
M)\]'8Z"JN=1##IVKXJ.%TSFLXE1.)49HFJ@0'@G.AM]G>5V_%::SW.VR5_;*
MM?7+2LI864\+YWOE<V951J-C7IT";'+Y)S\X9;+]/;L?QBLO=E@>L?OLZI91
M]KPKHKXH712*K%ZV\;F*J=:($V+([<YW;MR<+M>;VNDJ:"WW5CY(J>N:QDS4
MBD=$Y5X'/16JK%5KM>ENBA5"NY'.IMCA%SFLEAIZC+;E3.6.HFH7LBH&/:NC
MFI4/XN-4]&-CF_T@FQR%B_> XE5U<<61X?7VRD>O"^HHZJ*O5B*NB*K'QTZJ
MFG2NBZ^@BA-BTN'YGC&?6&GR;$;C%=+-5:I'41:HK7M]4R1CD1S'MUZ6O1%0
M*H\YJ/,!FWN:G\L@"842Y0?VB<-_WG_RJK"TM3@HKCN;SF[8X#<YK'9XJC*[
MO3.5E2MO<R.ABD:NCF+4OUXG)_V;'M[FNO0$V.(LO[P/%:FK9%D&&UUNHW.5
M'5%'5Q5SVIKHB\#XZ?7HZ5T=]34)L6CPG.L5W$L$.2X=<H[G:)E5G:LU:^.5
MNBNCEC>B.8]-4U:Y$[B]2H%7ORRQ01/FF>V.&-JODD>J-:UK4U555>A$1 *O
M9SSS[:8W<I;9C%MK,I? Y625T#V4E"Y471>RD>CWOT_G=GPKW%5 FQR%#^\)
MM4DJ)<L"J*>'BT5]/<V5#N'T>%]-"FOI<7UPFQ8[:C>[ =Y+?+5XC6O2OI41
MU?9ZQJ0UU.CNA%<Q%<US57[>-SF]S77H"+'>7&XT%IH*FZ72ICH[=1QNGJJJ
M=R1Q111IQ.>]SM$1$1.E0A5K+N?';FS5TM%BUEK\C9"Y6^'*YE!2R:=V-9$?
M(J?Y430FQX%J_>#V&:5J7O!JRC@5>_?1U\58]&]'2C9(:9%7_.0)L66VRW9P
MC=RROO6&5ZU#8')'744[>RJZ61R:M;+&JKIKHO"YJJU=%T5=%"KMP(+W;YK-
MM-J*^6PR.FR#*(55M1;+;P*VG=_-J)GJC6+_ $6\;T[K4";$3T'[P;'Y*M&7
M/!JRFH>)$6:FKXJF7@TZ5[-\,*:Z]SM/KA-BR^VNZ^#[M69]YPNXI5,@5K*V
MCE:L5732/35&S1+TIKHNCDU:[1=%70*NU
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MBOS>KCX:_*ZK2F<J=*4%O5T3--4U3BE695]%$:H5E:D(
M
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M^GM\E4RV9'2.548ZCED2.7C3JXHE^Z-_I-]#4+2UJ"@!P^\_F>W!_1J\^03
MAD#0LK):N*GM_&M94KX/$R)51[UG3LU8FG7QH[A5.[KH'D7CM_[O^T28Q#[Y
MY;509A)"CIG0P126^*=R:JQ&+I(]K5[WB[1O%UZ)U!6UTW-?EJ[-[*X]MGB,
MSZ.6[Q-LT4[-&R):K= QM1TIIW\G'$QR]U'N[H(5BY8MB:7>W*;@E[J9:;%<
M?CAFN:4RHV>:2I<](86N<BHU'=F]7.TUT;HG2NJ$S*Q&]?)GM_1X)=<AVXBJ
MK9?[+325R4<E1)505<5.U7R1JDRN<V16M7@5KM->A4Z=4(B4%<G>YEPPK=>W
MXU).OQ<RUZ6ZLIG.7@;5N1?!96IU<?::1_Y+U]! F5UN:CS 9M[FI_+( K"B
M7*#^T3AO^\_^5586E<3G)W-N& ;7MM5DJ'TM[RJ=;<RIC7ADBHV,XZES'=:.
M5%;'JG4CU5-%1 K"FW+3L?#O9F-517:JDI,9LL+*JZOIU1)Y5D?PQ0QJY%1J
MOT<JNT71&KW50+3*S6[G)9MVW";G=-NH:JV9-:Z:2LIX'U,E5!5]@Q7NB<V9
M7*UST:J,<UR(CNM- BU7/E*W,N&!;M6FTK.J8[E4T=IN5*YR]FLTZ\%-*B=2
M.9*YJ:_S7.3NA,K[[^X5F^XFV]?AV"5]);KA<Y(XZ^:NDEB8^A;JZ2)KX8Y'
M(LCD8U>C16<2+UA6%6-I^1V_ORFI?N\C(\8HXD=316RK:Y:V=SE3A5Z(CV,:
MB<3M6M<NJ:=T)M=+S#<K.SV&;97?+,82:Q7NU,9-2LFK7S0U2\;6NB5E0Y[E
M<YJN5O9N1>+T4Z 1* N4.[55JW^Q9E.]R0W!*RBJXVNX4DBDHY7HCNO5$>QC
M]/1:$RM7SW7JZ6S:.W6^AD=%1W>\0TUQ5FJ<<4<$T[8U5.C17QM=I_1"L*G<
MN%OV'N.0W*'?"I=##V</O''-+/3T$DBJ_MNWEIU:]KD3LUCXGM8O?<7<0+2M
M-G7*CLMN'AU57;-+0T>11-1]NK[=<7UMOG=KKV4_W2=J-<FNCX]'(NB]\B<*
ME;7S\O'*QN%M!FL&7W3*+<E.Z":EN5HH(YZAE3!*W5K5DE2#A5LB,>B\"^I]
M,)F4O\QNXU5M?M+>\CMC^RODZ,MUHDT1>"JJUX4D37HUC8CY$Z^EH1#.#9;;
M.MWJW(I,6FK7P0U"35]XN+E[29M/%WTCDXM>*1[G-:BN[KM5"TKLY/R.[25^
M.3T.,)66C(F0KX'=)*J2H8Z=J=ZL\;]6JUR^J[-K5] *VJ4;1Y[?-EMTZ&[.
M<^F915BV[(Z)5[V2D[7LZF-Z)T*K-%<ST'M10LUR:YKFHYJHK535%3I144*/
M]                                                       !5CG
MY\SUD_26E\@KPF&=36N>YK&-5SW*B-:B:JJKU(B!==+:;DF6[[?72[;A.DM^
M77FC5,>H%5S/>UZZ/CFJ4;TND<J(CHOM&*J+WZ]X5M4\O%INN,7NMLMUA?17
MJTU,E-50JNCXJBG>K7(BIZ"IT*GU4"S3OE>WK9N]@;(KK,BYKCZ1TE\8O0Z=
MJHJ0U:??4:O'Z#T=T(BM"DPG((9M\]7GKI_@.B]NJ O"4_W>_P"1\\]TVWVN
MH")?=^\#^1^'?"=1Y.@(0AR2>?6C^#*_UC0F5T>:CS 9M[FI_+( K#,S;+SD
MX=\.6SRN(+-E HQ"#R-A=F/,]M]^C5F\@A#QRS;YJ//_ )M[II_(X O"XW(S
M;X:39-]7&B=K<+Q63RN1-%U8R&%$5=5UT2,*RFK=&-DNV6:12M1\;[%=&O8O
M2BM=1RHJ+]4(8W!Y&M_,553T>QV=S4[U9(ZTSPJYO7P3Z1/3ZBM<J*%(928S
M1P7#)+/;ZIO%355=303-]%DLS6N3^10NVH:UK&M8QJ-8U$1K431$1.I$0/&@
MCG(H*6LY?,EJ*B-'RV^:VU-*Y=.\E=7P0*Y/\R5[?KA,,_\ 8+SUX#\.4/MS
M0M+7@*  ""MV>:_;+:NX3V![I[_E%,O#4VVVHU60/_FSSO5&-=Z+6\;D[J($
MV*YY)S_9Q6<<>*XM;;2QW0V2NEFN$J)Z*<'@S=?JM5 FQ7S<W<'<C<BX4-_W
M$J)JB18G,M3WTK*2!*=7<2I"D<;&N;JO2[I7T5"5I?W>7_J/_N3_ ,P")>WS
MI[%Y)F,]OW+PZCDN=7;J1+?>;93-5]2M/'(^6*>)C457\*R/;(C>^TX51-$7
M01*C=ER'),2N/AV/W.LLMTB7@=/132TLR<*]+7+&K5Z^M%"R:\5YS-\L;[..
MLNE+D-)'T=C=J5CG</H=K3]C(J^FYZA%BU&S'.-AVY=TI<7R6A7%\HK'MAH4
M=+V]!53.Z&QLEX6*R1R^I8]NBKT(Y7*B!683;N/AE-N'@M_PNJE[".\T<E,R
MHTXNRF]5%(J=U&2-:[3NZ!#)//-N\QVSOLU@R^V36^LB>Y()U:Y:>H8U>B2G
MET1LC%]%O5U+HO0%W28CS#[SX0R*"Q9?7+11=#**N<VX4Z,_FM95-D1J?Y&@
M+$^8)S]9!2S0TNXV.T]PHM4;)<;.KJ:I:WNO6&5SXY%])KXT"+%U<,S3&MP,
M=I,IQ.N9<+-6(O9S-16N:]BZ.9(QR(YCVKT*UR?] 5>)N=N]@FT5JCNF:7'P
M=U3Q)0V^!O;5E2YFG$D4::=":IJYRM:G1JO2@%5\F_>"2J^2+#<,:D::]E5W
M>J557T.*GIVII_MU"UB#MQN8O>C=S'[C;KS(R'#%6%USH;71<%&U63,?%VLS
MTEE1.T1G"CIM%70)L>1RV>?7!?A-GK'@EK#<*"DNM!56NX1-GH*V&2FJH'IJ
MV2&9JL>U4]!6JJ!1CEN+AM7M]G5_PRMXG2V:LEIHY'IHLD&O%#+IT?Z2-S'_
M %P\C2W -XZ6JY<*7=2Y2)-56FS2K<D>O3)<+<UT#FKIU+-*Q%;_ ):!2QF)
M;:&\YQE=+;H56JOV15[(6O=TK)55TR)Q.T]%S]5"[8W%,<H,0QFT8M:TTM]F
MHX*&GZ-%5E/&C.)>OI=IQ+Z8>-ZX
M
M    9B\Z&.3V/?6ZW%[.&EO])17&F5$[U4; VDDZ?1XX'*OU0O"R'(AEE)=-
ML+GB:RI[YV&Y22K!Q:N\$KFMDC>B+W%D;*GUO3"LK5!"&^8??:'8RQ6:Y16^
M*[W6[5JP1VR29:=74D,:OGE:]&OT5KEC;ZE?5A,0^/9;F?PS>FZOQVUVVX6O
M(H:9];-35+&2T_8QN8QSFSQN7J5[4[]C>L$PZ;?W /UE;3Y'C,,?:73P=:VT
M]&KO#:/[M$U/OG"L7U'*"&<G+;G2[>;R8W=IY.RMM;/[TW3551O@U>J1*YWI
M1O5DJ_Y(6EU'.1FZY=O5<;?!)QV[&(8K/3Z+WO;1ZRU"Z?SDED=&O^0@(74Y
M5<!^(.S%BAJ(NSNU]:M\N.J:.XZU&K"U>ZBM@2)JI_.U"LN/YZO,I3_#E%[3
M4 A 7(-YX;W^C55Y?0!,K?\ ,O'5R[$9RVB729+<KW=&OW%DL;I>XO\ \-'?
M_F"(9S<NLE/'OC@CJI6I$MV@:WC35.T>JMC^OQJW3TPM+7 **D<_SZ5-NL7C
M?_;G7KBAZ4_T3:29).C37K6/NA:$3\@D=4NZ>0S,1? F8_*R9?M>U=6TJQZ^
MGHUX)?AS\^>&R?HU2^7UX(0)@>VN9;EUE?0X=;7W">V4<M?6*WH:R.%JN1FO
M=DD5."-G6YWI(JH2[CEIW>?M#N12UE?*K,5O'#;L@C[C(7.^YU&GHPN7B7N\
M'$B=8):KL>R1C9(W(^-Z(YCVKJU6KTHJ*G6BA10;]X'\L<.^#*CRA M"1N0'
MS;9-\.+Y) "4<_O _ECAWP94>4("'<?N_$3XGYBO=]\J;I_^H4$I]W]\RF??
M ==[2X(AF;L%YZ\!^'*'VYH6E<#G_;4?J\Q9S43P1+TJ2KT\7:+2R\&G<TT1
MX1"GNT&.;O9+?*ZCV;GKX+]%2++7K;+DRTRK2)(QJ\4CYX.)O&K.]XEZ>G0)
M3)^JCGJ_'\E__"R'_P"Z01X'%3<H_,?4S25%1B+IJB9SI)99+K:WO>]ZZN<Y
MRUBJJJJZJJA-K4&V)4MMM&VM:YM8D$25#7N1[DEX$XD5R*J*NO=10H^H#A]Y
M_,]N#^C5Y\@F!#*W:""*JW9P.FG3BAFR*T1R-ZM6OKH45/Y%"[8H**'_ +P=
MM1[_ &#.<B>"+1UZ1+T\7:)+#QZ]S316!:$%;.8COYD]/=W[+U-S@IJ9\"7A
M+7>&6A%?(C^QXVOJ:?CZ&OT7IT"927-M#SR5,,E/45>1S4\S71RQ297 ]CV/
M31S7-6XJBHJ+HJ*$>!Y6"\J_,#8,WQJ_5>(NAI+7=:&NGF9<[6KF1TU0R5SD
M1M6KM41NO1TA-JYW-1Y@,V]S4_ED 5A1+E!_:)PW_>?_ "JK"TIL_>%MJ.VV
M\<J)X(C;PC%37B[15HN+7N::(W3ZX1"N^S6*;Z9.MZ396HN4"TO@OOVEKNS+
M1Q=IVW@_:<=33]IIPR\.G%P]/5KTDRE)^TG//(QT<E;DCXWHK7L=E<"M5J]"
MHJ+<>E%"/ Y[&.5'F%M&26:[2X@Z.*@KJ:J?(RYVOB:V"9KU5-*O75$3N!-J
M]V^6\5JV5PM^35M/X?<JF5M':+8C^S[>I<U7=\[1RM8QK5<YVB]Q.M4"L*+,
MWQYH-\K_ "6/#KA61U,K5D2V8ZUMNB@B1417.J>)LC&ZJB<4L_6NFH6LA^V9
M<J^\=MQ&][C;B7JE<MHI754M//63W&X2*CD[U7JU6)JKNOM5^H"UR/*OY_\
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M,-#31UD;W-D<V=D+4>BO:KD<J.1>E%5%"CU0
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MK/&Y4U:M?6(Z&!%^HSMG^DK4"):0!4
M
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M&IZGODU=HQ.M$"9AI6G0B)KKZ84
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M.5B3L9Q(W5-=.K4$OLYXL2RK+<5Q2GQ6Q7"^U%/<)Y*B*V4D]:^-CH$1'/;
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MW%>H4E/@0
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MBYH+4_8#MIA&V-J6SX3:(;92R*CJF1O%)43O:FB.EFD5SWJG3IJ[1.XB!#K
M(KW.Y=MJ]V*E;EDUI=!?E:C%O-ND\%K'-:G"B2*B.9)HB(B+*QRHB:)T!-J)
MZ?D&VICJNTGOU_FI455;!VU&QVFO0CGI2]/1UZ(GU@6IZV\VKP/:RV/M>$VB
M*W,FT6KJ55TM54.;KHLLTBN>[35=&Z\+=>]1 AV0
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M+:<7CEN=?/IWC7K&Z&G9Q=2.=(]'(G=1KO04)EIX%
M   #CMR]RL>VIQM,KRAE2ZT)4Q4DCJ.-LTC'3Z\+G-<]G>ZIHNFJ^D!5+?3G
M0QC(,+N.([9P5SKA>874=9=ZN)M-'!23)PRI$WC<]TCFJK-5:U&ZZHJJ%HA5
M+:G +AN=G]CPR@8Y6W"H;X=,U/\ 044:\=1*J]2<+$737K=HG6H2V%I:6FH:
M6"BHXFP4E-&R&GA8FC&1QM1K6M3N(B)H@4?L
M
M                   %+.<+:#<[+\^M63X!9JRXT#[1%07!U!(QJI/!45#V
M\;.-KE[R5.G30+0A##>3W>S*;A%!<K.W&[6KD[>XW26-.!NO3PPQN=*YVG4G
M"B>BY.L)M:.[?X-9-M\/M6&8^Q6VVUQ=FDC].TFE<JOEE>J?;2/5SE[G3HG0
M%'2@
M
M                    "$MX.5[;G=^L??*Q)K)E3FHV2[V[@19^%$:WPB)Z
M*V31$T1R<+NI.+1- FU7ZO\ W?%[9(OO7G5+/%KWOA-OD@=PZ=W@GEZ=?_X[
M@3:]/'_W?,#9V2Y3F[Y:9-.UI;91)$]?1X9YI7HG^Q4%JUVWFVN';6V!N.89
M;THJ'B[6HE<JR5%1-HB+)-([I<[1/J)U(B(%76@
M . WGVS9N[MY<\&6X):IJU]/-!7K#X2D<E-.R7ICXX]4<C59T.3377ITT4F%
M4:;]WQ>75+FUF=TL=(BIPR0VZ2214TZ=6.J&(G3_ $E";5F=F=@<(V3HITL#
M9:Z_5S&QW"^5G"M1(Q%1W9QHU$2.+B3BX&]?1Q*[1 B92H$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%'6K+3S4W"Z='*S1)6MUU1B]02[L(
M
M
M
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M>TN"85T_=[_D?//=-M]KJ F5T0J
M
M
M
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M"C9/,Y7RR)!&C.-[G*JJYVFKE5>L*O2
M
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M4<@3X'R5^ZO-IR]U=)4;D0+?L6EE2))*[L:JGE7NM;6TR=I'(Y$56),J]6O
MNB@\"Y^VNX=@W2PZWYGCCG> UJ*V6GET[:GJ(UX9(9$153B:O\J:*G0H5=:
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MG]YJ/142&WP=,M5*U>AKY51'.UZ?4,Z=$"\.TY%?/74? =;[=3@EI(%
M  &;?.%^T;%[FM7_ %A>&D@4?C54M+7TL]#701U-%4QOAJ::9C9(I(I&JU['
ML<BHYKD545%314 KY?MY>6C8"[W2W66CI:?(:A6LN]MQ>BC5Z.IU>K&2JU8H
M&N:LCTX.-%;W43H";'!7;]X#C:?<L:PJX5]0]4;"VMJ8:35SET3HA;4JOU$Z
M^H)L5_=F>0[@<T>'99D]D7'[M7Y#CJNMKHY8U;#'44T<3E[9$<O$QK5XM-%[
MG0$^19_GY\SUD_26E\@KPK#J^32V4M!R_P"/55.W26Z5%QK*I?1E96RTR+_4
M@8@)1%^\'O52RFP7'8W*E',^X5]0S[5TD*011+U];4DE_E"86>V5LM'C^T>$
MVNA:C88[+0RNX41J.FJ86SROT3NOD>YR_5")=I745)<J*IMU?"VHH:R)]/4P
M/35DD4K58]KD]!4544(9_<D-O2T[]99:T=QI0V.XTR/Z]>QN=$S7J3KT] +2
MX+>7-::EYI[SEE\HW7:WV"^4Z.MJN2-)8K0D<;8M7(]$:Y8NGO>G5>CI"8\2
M=/XA%G^8=3_Q*/\ PX18X?>#G$L.ZNWEXP:3"YJ.2Y-A6GK9*YDR034\S)FO
M1J0-7[3AZ')T*H(A*?('=*JHV[R6TRN5U+0W=):=%77A\)IV<;4]!-8]?JJH
M)1;RX_M?9-[IR'RAX)\30@*@&?O[P"\SS9[BN/ND5:6AM#Z]D7<22NJI(G.^
MNE*W^0+0O7BM@I,5QFSXU0L;'26BCIZ&)K/4\-/&UFO4FNNFJKW0J]26**>)
M\,S&R0R-5DD;T1S7-<FBHJ+T*BH!G;RS0OPOFQNN(T+ECHVSWZR2,354=#0O
MDD:BJG1T.IFKJH6GQ/ZR>WTUTYZXZ2L8CX/C!;IE8O2BNIZ6"9J*B]:<3$U!
MY&B854>_>&1L23;J5&HDCDO37/[JM:M J)];B4+0G+,/V2ZW]!XO^7,"/*AW
M]WO^1\\]TVWVNH"9<YSQ8C68KGN,;N6+6GFKNS@GJ8^A8[G;'))3R*O\YT>B
M-^] A<?&MP++?MMZ'<N25M/9:BU)>*QR+Q) R.%99VJO=6)6O:[TVA52WE2M
M5=NWO]DF[]\C5T-K?47%J.57-96W-SXJ>)->ML4/:</H<+0M*_X5
M
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M/Q'V8M534Q=G=LF<M\J]4[Y(ZEK6TS=>O3L6L?IW%<H5E/ 0
M
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MB5\:^^&35"TU"]Z+JE!1.5KG(J_ZR97H[[VT)E;0*@
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M;;+?+94V"_PPU5KNL3Z2HHIU3AFCD;HYFFJ+KIZ'2G6@0IGD')7G^)9#+?\
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M0
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M;:;>"Q6C/*[%;5=VWFEAK8*NMHJ>:J1LK$7LY).%556+WCF\2HBH!&'-Q?\
M&]N-BZK#K%34EIFR.6*WVVUT,4=/&V!DC)JE[8HT:U&HQO JHG6]H(=1RFXA
M4X=L=C\-=&L-?=UFO,\3DT5&UKM8==>ZL+8U!*;0@
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MI4O.0H^.SK5-TGEAJ9.VJ:QR+TIVS]$8O0JM1R^I<B@E<$*@
M
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M16=[+]S8_M>#LNRTZ.A.\X@M*_85
M                                                   \W(;)1Y+8
M+KCEQU6WWBCJ+?5HWH=V-7$Z)^B^CPN4"B.(KOURB7J[VGXI2Y=@MQF29*BD
M9,ZGD<S5C)F30-E6GD>U$1\<S%ZDTUTXE+>-[^4<RF^VZUJJ<.VYVRK[)4W.
M-U)5W!/"*V:..35K^"9]/310:IJWCDUX>G14=HJ"Q-_+#L;/LMA]4V]R1RY?
M?I(ZB[=@O'%"R!')#3M=]MP<;W.=U<3E1-41%4B93D$
M                                     X_=3!*?<W;V_P"#5$W@R7>G
M[."I5.)L51"]L\#W(FBJULL;%<G=0"FNW^>[]\KM-48'DFW]3D6,LJ))K?+3
M]LD372KJ[L*R"*>-6.7O^!S.-%5==-= MXWU9MN]S <Q5K?@6$[>5>/6&YJR
M.Z5;^VDXXM458Y*V:*GBCC7H<YJ-XG)T:JFJ*++%I=B-IZ?9O;RCQ))FU5TD
MD?77FKC14CEK9T:UW!JB+P,:QD;57I5&ZZ)KH$2DL(
M                                             9?\YOG_ +_[FMWD
M<07A?K8+S*8#\!T/M+0K*1@@
M
M
M
M                                                          R_
MYS?/_?\ W-;O(X@O"_6P7F4P'X#H?:6A64C!
M
M       #E\ZW%PO;:T+>\TO$%JHNE(6R*KIYWI]I#"Q%?([TF-73K71 *?Y_
MS]5\DLE'MGCL4-.BJUMUO:K)(Y.K5M- ]K6+W45TKO3:%K$'7;FKW\N\ZS2Y
MC/2MUU;#104U*QOI)V<2*O\ G*H38^.@YF]^;:]LE/G%>]S$T1*E(*MO7KTM
MJ(Y$7ZZ L2MAW/EN/:IF19C:+?D-"FB/D@1UNK.OI7B9QQ+]3LD^J$6+:[6<
MQVU^[/94=DN?O?D3TZ;#<^&GK%5$U7LN^5DW4J_<WJNG2J($6):"
M
M
M                                               &7_.;Y_[_ .YK
M=Y'$%X7ZV"\RF _ =#[2T*RD8(
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M]O6U=.I4] #^P '\-FB?(^%DC72QZ=I&BHKF\72FJ=::]P#^P
M
M
M                        &7_.;Y_[_P"YK=Y'$%X7ZV"\RF _ =#[2T*R
MD8(
M                                      !F-RFY/DEPY@<0H[A>:ZJI
M)/?+M*>>IFEC=PVNK<FK7.5%T5$4+RTY"@  ^2YW6V62AFN=YK8+?;:=JOGK
M*N5D$,;4[KGO5&HGU5 H'S5\T-NS^ADVWV^D=+B_:L?>;RJ*Q*YT#N)D4+5T
M7L6O1'J]R(KW(FG>IJ\M$)$_=^?(_,?A.G\G4$K+[FYS1;:X'?<WKV=K%:*9
M98H->'M:B1R101:]SCE>QNO<UU"K-BQ6/>3FQS:X*ZYMJZNF8M7437":2"UT
M$3W<+(XHV-EX$5>AK6,55T55UZ5"_B?5BV:[H<JNYS\<N\\KK?0S1I>K$R59
MJ"LHYM']K CM&H]6NXHY$1KD7H=]LT'C:;.R&T-QY<K\*:M@2B]]/#4]1X'V
M7;]I]3@[X*,R,ES/=/FKW,;CMJGD;15TTGO/873.AM]%1PZO[2?AU:KFM;Q2
M2*U7.=T-3U+0OXGRWRR[Q\IN<4'#<V4E941I602V^:2>UUT+7*Q\<L<C8^-$
M7H<U[$<W5')IWK@>-I5MMG%OW(P:QYM;6]G3W>F25\&O$L4[%6.:+7N\$C7,
MU](**!\PV]&;[O[ES[<8955#<8AK_>2UVNCD6)+C5=IV"RS*BHCT?)_HT>O"
MUFBZ:\2A>(<GG>SV\7+7-9LMFN4=$^LE[.FNEBJIE2*H:WM.PFXHXM5<U'=[
MHYCD1W6"VU?CESW:?O#MM29!7\#<CH976Z^QQHC&K50M:Y)6M3J;*Q[7^@CN
M)J=05E6KG*W_ ,DARB;:G#[C+;+9;HHUR"KI'NBGJ*F=B2)!VC%14B8QS>)$
M5.)RJCNA F(0_E7+EO'M=AU+NI7NBHX8UAFJ6T-5*VZ6]:E4:Q\VC&(U>)S6
MKV<CE15Z0FU;SE!WPNNZ>+W#'LLJ?"LMQQ8]:U^B25=#-JD<C].N1CFJQ[M.
ME%:JZN50K,+)A
M
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M:Z] 38Z'$LOQO.K'!DF)U[+G9*ETC(*R-KV-<Z%ZL>FDC6NZ'(J=00]L
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M4-,V"K:Z6HJ'I'&Q%="B(KG.1.E= FQ*H0
M          9?\YOG_O\ [FMWD<07A?K8+S*8#\!T/M+0K*1@@
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M1LBL=TZ(BA-BD'-O0.H^8'+%1>..K6AJH')HO$V:@IU733^EQ(@6AH;>-P<
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MV2MJNTX'PM>O&K?N3D7B:U?2!8D8(
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M/>                91[;?M-V+]+D\N4+M7 H
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M65DL<BRR,BZ6<*IZE?5*%9E:0(
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MH*RDT(               ,H]MOVF[%^ER>7*%VK@4
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M==MO]N[#AE[N,=UK[- ZE6NA8Z)CHDD<L34:Y57O&*UGI\.H4=H
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M-E3<VQ&T96VW55I]]*=L[K=7QNBJ(7+T*UR.1JJFJ:M?IHYNCDZ%"CH0
M                                              %;><+>F^[68G:K
M+B-0M%DN323M2XLX724U'2(SM5C1=>%[UE8UKM.A.)4[Y$5"8A0NWVK>'.^.
M[6JBR7)=5<DE=2Q5]QU<BZNUD8DG3JO3TA9]WZLM^?F=EW_#+G^" E[E>P7=
MNS;Z8K<LGQK([?8X/?#PJKN5#704C..VU3&<;YF(Q-7JUK=5]4J=T(EHT%0
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M[&([77TP/>    &=//SYX;)^C5+Y?7A:%T-@O,I@/P'0^TM")2,$
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MT[43U*<76W129AI0%                !E'MM^TW8OTN3RY0NU<"@
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MW.15;Q+IT@=>
M    5.YZ-M;OE&(6;-[+3OJGXJZI;=((D5STH:M(U6;A1%U2)T2<6G4URN7H
M;T%H=MRU[M[:WC:?%['27B@M=YLE!!;KE:*F:*FG2HIV<#Y48]6\;9G(LO&W
M7U73WVJ!$IM]^K/^<*;_ &T?L@A^D-SMM1(V&GK()9G:\,<<K'.71-5T1%UZ
M@/J                         &=//SYX;)^C5+Y?7A:%T-@O,I@/P'0^T
MM")2,$                       #BJ3:; +?N!+N=0V:&GS">G?2S5D:<+
M'=JJ<4O9^I2943@61$1RM5474#W<KQ:R9KCMQQ7(Z9*RRW2%:>K@5=%5JJBH
MYJITM<UR(YKDZ4<B*!_N,XMCN&V:FQ[%K;!:K-2)PPTE,WA;KHB*YR]*N<NG
M?/<JN=UJJ@>N  XJOVFP"XY[;MRZFS0_'&VM>V&O:G#VBO9V;7RL3O7OC;T1
MO5.)OH]":!U-UM=OOEKK;-=J=E5:[A!)2UE-(FK)(9FJQ[53T%150#Q\(P+$
MMN;'%CN'6R*V6R+I>V--999--%DFD=JZ1Z_SG*OH=0'2  .*RC:; ,QR>QYC
M?[-#4Y%C\S9Z&MTX7.6/56,FT_TC&.5)&([U+DZ.M44.REBBGB?#,QLD,C59
M)&]$<US7)HJ*B]"HJ <K@6V>#[96Z:V859X;9!4R.EJI&:OGE<JJJ=I*]5>Y
M&ZZ,:JZ-3H1$ ZT !Q6>[38#N8^V2YE9X;A4VBHCJ:*H5.&5$C>CUB<Y/50R
M::/C=JU?JZ*!VJ(B(B(FB)U(!R&';78%@-;=;EBEDI[?<;U42U=PJV-XI7NF
M>KU8USM>")%7O8F:,3T-0.O                 ,H]MOVF[%^ER>7*%VK@4
M                           XK&MIL P_+;SFV-V:&WW^_1LBKY84X8]&
MN5[UC9U1K*[A=+P:(Y6HNFNJJ'IYO@N+[BX_+B^7T*7"RS213/@5SHW(^!Z/
M:K7L5KFKT<*JU47A54[H'JVBSVJP6VFL]DHH;?:J1B14M'2QMBAC8G<:UJ(B
M ?:  XJDVFP"W[@2[G4-FAI\PGIWTLU9&G"QW:JG%+V?J4F5$X%D1$<K55%U
M ]W*\6LF:X[<<5R.F2LLMTA6GJX%715:JHJ.:J=+7-<B.:Y.E'(B@?[C.+8[
MAMFIL>Q:VP6JS4B<,-)3-X6ZZ(BN<O2KG+IWSW*KG=:JH'K@ .*K]IL N.>V
M[<NILT/QQMK7MAKVIP]HKV=FU\K$[U[XV]$;U3B;Z/0F@=3=;7;[Y:ZVS7:G
M956NX024M932)JR2&9JL>U4]!454 \?","Q+;FQQ8[AULBMELBZ7MC366633
M19)I':ND>O\ .<J^AU =(  XK*-IL S')['F-_LT-3D6/S-GH:W3A<Y8]58R
M;3_2,8Y4D8CO4N3HZU10[*6**>)\,S&R0R-5DD;T1S7-<FBHJ+T*BH!RN!;9
MX/ME;IK9A5GAMD%3(Z6JD9J^>5RJJIVDKU5[D;KHQJKHU.A$0#K0
M                           ,O^<WS_W_ -S6[R.(+POUL%YE,!^ Z'VE
MH5E(P0
M                                      58YVMV;_@F*V;$L8JGT%?E
M+JGPZN@5631T5(D:.C8]-%:LKI417-Z>%JIW0F%(L8V8W5S*V-O.,XE<KC:9
M%5(JV.!6PR:*J+V;W\*/1%1456ZZ+T!:U[7T;-]?F+<_ZC/9@M2WRR;([L8A
MO?BV19-BE=;+)1^^'A5;.UJ1Q]M;JF)FJHY>M[VM^N$3+0\*@
M            !G3S\^>&R?HU2^7UX6A=#8+S*8#\!T/M+0B4C!
M                                                    &4>VW[3=
MB_2Y/+E"[5P*
M                                    ,O\ G-\_]_\ <UN\CB"\+];!
M>93 ?@.A]I:%92,$
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MH?:6A$I&"
M           ,H]MOVF[%^ER>7*%VK@4
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MJZ&.IHZJ%R/BE@F:CXWL<G0K7-5%10A](
M                    5BYQMIMP-U;;B5/@5H]]IK9/6R5S?":6E[-L[(48
MNM3+$CM58[U.H3"IWT0>8GYF_P#B=J_Q86M/H@\Q/S-_\3M7^+!:E/EPY<-Y
M\"WGQG+,LQGWOQ^W^'>&5GAUOGX.WM]3 SO(*F1ZZOD:WO6KU^@$3*_85
M                     #.GGY\\-D_1JE\OKPM"Z&P7F4P'X#H?:6A$I&"
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M'QTP[YPVSQVG]F!Z5!<K==(/";95PUM,CE8LU-(R9G$FBJG$Q535-0/J
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M1%54DFO9U$#VRQNX55JZ.:JHNBHJ ?N
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MN=GLMNM]:V-W&Q)Z2ECAD1KDZTXFKHH4=,
M                    *5[\7[FFPG=C(<@V^9>I\"F\#?0L@IVW6@:UE# R
M;2!6S+"G:MDXN]9TZN[NH6BQRN-\^N>VB7P+.,5H;HL*\$KJ1TULJD5.M7M>
MD[%<GH(QGUNL%B:,6YXMFKXC([ZEQQJH7H>ZLIEJ:?7^B^D65RIZ;HVA%B:\
M6W-V]S9K?BID]MNTKTU2GIJF-U0G^5"JI(W_ #FA#JP
M         SIY^?/#9/T:I?+Z\+0NAL%YE,!^ Z'VEH1*1@@
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M(ONW.T..X9DS(H[W;/#?"F02)-&GA%?45#-'IIKWDC0K*30@
M                 R_YS?/_ '_W-;O(X@O"_6P7F4P'X#H?:6A64C!
M
M                           !X61X7B&7P^#Y58;?>8M.%J5]+%4*U/Z*
MR-56KZ: 0OE/)=L=D2/DM]OK,<JG=/:VJJ?P<7<UBJDG8B>DQ&__ )0FU"N4
M?N_K[ YTV%9A2U;>E8Z:[024CFZ=2=M LR.7T^S:$VOKVAV]YJ-MMRL;MM_G
MN=1@#ZML=Q[&O;<;<E/PN15[-TCW1)KIT]FP'@7D"H
M      9T\_/GALGZ-4OE]>%H70V"\RF _ =#[2T(E(P0
M                                             !E'MM^TW8OTN3RY
M0NU<"@
M                             #+_ )S?/_?_ '-;O(X@O"_6P7F4P'X#
MH?:6A64C!
M                                         !5SG.W/SS;2V8A/@]YD
ML\MQGKF5KHHX9.T;"R!6(O:L?IHKEZ@F%1OI4;__ #VJ?%Z/\ %K#Z5&_P#\
M]JGQ>C_  L?ZWFJY@&.:],VJ-6JBIK343DZ/118%1?K@L3KL)SFY1=,IMN';
MI^#UU)=IF4=+?X8F4L\-3,J,C[=D2-B=&YRHU5:QG#KJNJ!$PO,%0
M               !G3S\^>&R?HU2^7UX6A=#8+S*8#\!T/M+0B4C!
M                                                       &4>VW
M[3=B_2Y/+E"[5P*
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M!
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M+0NAL%YE,!^ Z'VEH1*1@@
M                       #*/;;]INQ?I<GERA=JX%
M                                                  S#YS;C<;EO
M_>J&H1[XK;2VZCMS%U7[E)21U"HQ-.[+-)U=T+PF;$.0*V2VBCJ<VRFKBO,T
M;9*NAMD438H'N1%[-)9>T5_"O6[@;KW$[H1:Z'Z .VWSFOG\M)^ !:]&P<C.
MWN/7ZUW^FR*\RU-JJZ>NABD6EX'/II6RM:[2%%T56].BA%JT@0   $&;A<IN
MU&Y&05V4WA+G27VY/;+655%6:(]S&M8G>3LF:B<+431J)T=03:ZO<#>+:[:2
MTSTM_N]'!64%*G@N-4[V/KI&-9I%$RG:JN:UZ(C6N>B,]/1%!8SEY=<-O6=[
MT8RMGI7-I+5<Z:]7.>)KDAI:6BG;4+JY/4\2L2./I]4J!:6L04<E<MU-L+-7
MSVN\9K8;?<Z5W9U-%5W2C@GB>G3POCDE:YJ^DJ ?)^N?9[_W!QK_ (S0?A@6
M'ZY]GO\ W!QK_C-!^&!8SGYL[[9,DWOO=VQZY4MWM4M/0-BKJ">.JIWN921M
M<C9(G.:JHJ:+HO0H7AH5L%YE,!^ Z'VEH5E(P0
M
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M;Z*]*J$M;(88Z>&.GA;PPQ-;'&W55T:U-$35>GJ"C^P
M     &=//SYX;)^C5+Y?7A:%T-@O,I@/P'0^TM")2,$
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M15:JL54UT5%T/'5153-E46/:NK^[O8MNZHJC])B=Y])1Y@
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M)^C5+Y?7A:%T-@O,I@/P'0^TM")2,$
M                                91[;?M-V+]+D\N4+M7 H
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M-H3*8)T
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MI:$2D8(
M         RCVV_:;L7Z7)Y<H7:N!0
M               '#;P^;F]?W7RN$P./:C><G.I;)LUVC=\K,J55.3.V@
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M[8T3HTXFNIT?TZ]QJ]7U-2;5A=AN4"R[7W6GR_+ZZ._Y=2]]010L5MOHY?\
M6,XT1\LB?:/<C4;UHWBT<A$RLX$   !E_P YOG_O_N:W>1Q!>%^M@O,I@/P'
M0^TM"LI&"      ()YG?R%8?=<OM1L6"<>K<<TV\YBZRIWE9S;''P
M        !:GEH^0EP^%IO)J8T[&N>C)]LNU[#:C7]R<VA,I@G0
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MLGZ-4OE]>%H70V"\RF _ =#[2T(E(P0
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M#[2T*RD8(      @GF=_(5A]UR^U&Q8)QZMQS3;SF+K*G>5G-L<?
M        %J>6CY"7#X6F\FIC3L:YZ,GVR[7L-J-?W)S:$RF"=
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M_1JE\OKPM"Z&P7F4P'X#H?:6A$I&"
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M?:6A64C!      $$\SOY"L/NN7VHV+!./5N.:;><Q=94[RLYMCCX
M        M3RT?(2X?"TWDU,:=C7/1D^V7:]AM1K^Y.;0F4P3H
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MY?7A:%T-@O,I@/P'0^TM")2,$
M        '.;@?(B_^X9_6*8S%-4O,F67P?7;K+IWU/SC;O0       !T>W_R
MWL'NZ#UZ&3PO6[O*AB,8U*]R*MY< [(X*     !E'MM^TW8OTN3RY0NU<"@
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M9=77ZNJDOF<5$2PON/!V=/2QO]7'3,75=7=3I'+Q.3J1J*J*5F4]A
M     ,O^<WS_ -_]S6[R.(+POUL%YE,!^ Z'VEH5E(P0     !!/,[^0K#[K
ME]J-BP3CU;CFFWG,765.\K.;8X^                +4\M'R$N'PM-Y-3&G
M8UST9/MEVO8;4:_N3FT)E,$Z
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M"T+H;!>93 ?@.A]I:$2D8(
M     .<W ^1%_P#<,_K%,9BFJ7F3++X/KMUET[ZGYQMWH        Z/;_P"6
M]@]W0>O0R>%ZW=Y4,1C&I7N15O+@'9'!0     ,H]MOVF[%^ER>7*%VK@4
M                                            !PV\/FYO7]U\KA,#
MCVHWG)SJ6R;-=HW?*S*E53DSMH       !W&SWG&LO\ >O))C/8#KUWRLVIK
M>TO9UYR<^E:LZRXD    #Y;E/)2VZKJ8M$EAADD9KTIQ,8JI_P!0&:_TV]]?
MQRV>(,]D%[#Z;>^OXY;/$&>R!8?3;WU_'+9X@SV0+#Z;>^OXY;/$&>R!8]S"
MN<?>J^YECMDKZJW+0W*YT5'5(RB8URQ5%0R-^B\70NCEZ0BQHL%0
M   9?\YOG_O_ +FMWD<07A?K8+S*8#\!T/M+0K*1@@     "">9W\A6'W7+[
M4;%@G'JW'--O.8NLJ=Y6<VQQ\                6IY:/D)</A:;R:F-.QK
MGHR?;+M>PVHU_<G-H3*8)T
M                             /.N6/V&\+K=[71UZZ*W6KIXI^]5-%3[
MHU>@#Y;?AV(VES7VJP6VA>Q=6.I:."%6JO=16,30#VP       /,R#'K+E5H
MJ;!D-%'<+-6<"55'-JL<B1O;(U'(BIJG$U%T[O= B;F6M=LLO+EE]KL]'!;[
M;34E,RGHZ6-D$,;4K(.AK&(C43ZB!,*X?N_/ECF/P93^4*$RL9S??L[9E_NS
M_FM($0KG^[\^6.8_!E/Y0H3+JOWA'Y'P/W3<O:Z<$/OY8U5>4O.-5ZO?_3_A
MS 3XT \F7G_L'N:X^1RA,K:\[?F*J_A.@]>X*PBS]WDJZ;CIKT?_ "3H_P"(
M!,JYX7^TCCWZ<47_ #=@2TDW]\RF?? ==[2X*PI#R*JJ;UU&B]=CK-?]M3A:
M5E^<:JW%I,&L+]MY[U!=779$JW8\^K94+3^#3=$BTBH[@XN'U71KH%84P]^N
M:K\X;@_[:]>R"W@/?KFJ_.&X/^VO7L@>!P6;56X%7=89-QYKQ/?$IVMIWY"Z
MJ?5I2(]ZM1BU:J_L^-9--.]XN+NZA+5/8+S*8#\!T/M+0I*1@@
M                                 YS<#Y$7_P!PS^L4QF*:I>9,LO@^
MNW673OJ?G&W>@       #H]O_EO8/=T'KT,GA>MW>5#$8QJ5[D5;RX!V1P4
M    #*/;;]INQ?I<GERA=JX%
M           <-O#YN;U_=?*X3 X]J-YR<ZELFS7:-WRLRI54Y,[:
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MNU[#:C7]R<VA,I@G0
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M],)E?L*@ #.GGY\\-D_1JE\OKPM"Z&P7F4P'X#H?:6A$I&"
M                              #G-P/D1?\ W#/ZQ3&8IJEYDRR^#Z[=
M9=.^I^<;=Z        .CV_\ EO8/=T'KT,GA>MW>5#$8QJ5[D5;RX!V1P4
M   #*/;;]INQ?I<GERA=JX%
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M
M     #D=R=R<6VIQ:HRW+:AT5OB<V&""%J/J*BH>BJR&%BJU%>J-5>E41$15
M541 *G7+]X2J3O99\!UIFN7@FJ[GH][.YK''2JC5_P ]P6L?#_$(O'S#IO\
MB4G^'!8[S9KG&N6ZNY-DP*HQ*"V0W;PKBKHZU\[H_!:2:I31BPL1>)8N'U7=
M!,+8A4      !Q&[^#5>Y.V]^PBAJXZ&JO$444=5,USXV+'/'*JJC>E=49H!
M%/+;RVWO8Z]WRZW6^4MUCNM+%2QQTL4D;F.CDXU55?UHH3,K&A"FF[W(TW(K
M]4Y#M?=*.T,KWNFJ;'<4E9212O75RP2PLE<UBJNO9K&J-[BZ:(A:UY&W/(57
MTMZI[AN=?J.HM-,])'6JS+-)X3PKJC))YXX58Q?MN&-55.A%:O2"U=Z""&E@
MBIJ:-L-/"QL<,3$1K&,8FC6M1.A$1$T1 JK)O[R@VW=&\RYCAUPAL6556BW*
M"I8YU#5O1$1)%6-%=%)HG?.1KD=UZ(NJJ3$HCQ;D!S&6Z1?'7)K92V5KD6=+
M.M1553V)UM;X1! QBKU(Y>+3KX5Z@FU>3%\9LV&X];L7QZF2DLUKA;3TD"=.
MC6]:N7NN<JJYSNZJJH51#S!<M-AWMB@N]+5I9<UHH^P@N?9]K#40(JN2&H8B
MHJHBJO ]JZMU7H<FB!,2K9;>0+<F6X,CO&2V.EM2N^Z5-(ZKJJA&Z]:0R4\#
M573_ +5 FU=7:W;+&]I,0I<0QEKW4T3G3U57-PK/4U,FG'+(K41-51$:B(G0
MU$3N!5V8  !G3S\^>&R?HU2^7UX6A=#8+S*8#\!T/M+0B4C!
M                               !SFX'R(O_ +AG]8IC,4U2\R99?!]=
MNLNG?4_.-N]        '1[?_ "WL'NZ#UZ&3PO6[O*AB,8U*]R*MY< [(X*
M    !E'MM^TW8OTN3RY0NU<"@
M           .&WA\W-Z_NOE<)@<>U&\Y.=2V39KM&[Y694JJ<F=M
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M _ =#[2T*RD8(      @GF=_(5A]UR^U&Q8)QZMQS3;SF+K*G>5G-L<?
M            %J>6CY"7#X6F\FIC3L:YZ,GVR[7L-J-?W)S:$RF"=
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MC&-2O<BK>7 .R."@     91[;?M-V+]+D\N4+M7 H
M                           #AMX?-S>O[KY7"8''M1O.3G4MDV:[1N^5
MF5*JG)G;0       #N-GO.-9?[UY),9[ =>N^5FU-;VE[.O.3GTK5G67$@
M    &:G-[D.7V7F(N-?25]9:Y:*BM[+%64LTE/*VE6!LCEC?&K51/"%FZEZT
M"\+[;05%;6[6X?7W&ZRWNX5UII*RJNDZHZ2:6IB;,_541/4J_@37IT3IZ=0I
M+M0              ,O^<WS_ -_]S6[R.(+POUL%YE,!^ Z'VEH5E(P0
M !!/,[^0K#[KE]J-BP3CU;CFFWG,765.\K.;8X^                +4\M'
MR$N'PM-Y-3&G8UST9/MEVO8;4:_N3FT)E,$Z
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M,1C&I7N15O+@'9'!0     ,H]MOVF[%^ER>7*%VK@4
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M]I:%92,$      03S._D*P^ZY?:C8L$X]6XYIMYS%UE3O*SFV./@
M       "U/+1\A+A\+3>34QIV-<]&3[9=KV&U&O[DYM"93!.@
M                                                      "*MZ]B
M,=WQI;/2Y!<JVW,LLD\L#J#LD5ZU+6-<CNU8_J[--- F)0_] ';;YS7S^6D_
M !-I] ';;YS7S^6D_  M=;MER@X1M=G%KSNT7VZUEQM7A'8TU6M/V+O"J:6F
M=Q=G$UW0V5531>L(M6("                         SIY^?/#9/T:I?+Z
M\+0NAL%YE,!^ Z'VEH1*1@@
M      YS<#Y$7_W#/ZQ3&8IJEYDRR^#Z[=9=.^I^<;=Z        .CV_^6]@
M]W0>O0R>%ZW=Y4,1C&I7N15O+@'9'!0     ,H]MOVF[%^ER>7*%VK@4
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MVO8;4:_N3FT)E,$Z
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MY4,1C&I7N15O+@'9'!0     ,H]MOVF[%^ER>7*%VK@4
M                              !PV\/FYO7]U\KA,#CVHWG)SJ6R;-=H
MW?*S*E53DSMH       !W&SWG&LO]Z\DF,]@.O7?*S:FM[2]G7G)SZ5JSK+B
M0      #.GG'S7,K%O554%DR*YVVA2W43TI:.MJ*>)'.8[5>"-[4U7N] 6A
M/ZS=R?GC?/\ B=7^%"3]9NY/SQOG_$ZO\*!UVVF<;GW'/<5:[)+]5V]]ZM\5
M2BUU9+"K%J8^-K^_5JHK5Z47N :S!0           &7_ #F^?^_^YK=Y'$%X
M7ZV"\RF _ =#[2T*RD8(      @GF=_(5A]UR^U&Q8)QZMQS3;SF+K*G>5G-
ML<?                %J>6CY"7#X6F\FIC3L:YZ,GVR[7L-J-?W)S:$RF"=
M
M      %)_P!X-?:R.DP?&HGJV@J)*^X5,>O>OE@2&*%?\U)9?ZP6A)?*=L_A
M>/;7V++Y+;2U^5Y!!X?4W2>-D\D3)'.[.&%7([LVM9IQHWI5VO%W$0B93/FF
MWV&[A6J>SY=9Z:Y4TS%8V66-JSQ*J:(^&73BC<G<<U0AG-L=#5;<\U5#C5NJ
MGSPT%\N&.SRIT>$4[734JJ]$Z-%5K9/25$7N!>?$T_"@
M        9T\_/GALGZ-4OE]>%H70V"\RF _ =#[2T(E(P0
M                             <YN!\B+_P"X9_6*8S%-4O,F67P?7;K+
MIWU/SC;O0       !T>W_P M[![N@]>AD\+UN[RH8C&-2O<BK>7 .R."@
M  91[;?M-V+]+D\N4+M7 H
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M@G0
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M(QC4KW(JWEP#LC@H     &4>VW[3=B_2Y/+E"[5P*
M                            X;>'S<WK^Z^5PF!Q[4;SDYU+9-FNT;OE
M9E2JIR9VT        [C9[SC67^]>23&>P'7KOE9M36]I>SKSDY]*U9UEQ(
M    !4GF"YKLRVAW&GPVR66V5U#%24U4D]8E1VJNG:JJGW.5B:)IT= 6B$6_
M3^W)^;-C_DJ_PX+'XU//WNA)"YE+CUAAF5-&RNCK)$;Z?#X2W5?K@L03;HLM
MWPW3I(KA,^Y9/E5PB95U*-TX6N5&O?PL31L<,3=>A-&L;Z02V$"@
M   ,O^<WS_W_ -S6[R.(+POUL%YE,!^ Z'VEH5E(P0     !!/,[^0K#[KE]
MJ-BP3CU;CFFWG,765.\K.;8X^                +4\M'R$N'PM-Y-3&G8U
MST9/MEVO8;4:_N3FT)E,$Z
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M];N\J&(QC4KW(JWEP#LC@H     &4>VW[3=B_2Y/+E"[5P*
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MF\FIC3L:YZ,GVR[7L-J-?W)S:$RF"=
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MMW>5#$8QJ5[D5;RX!V1P4     #*/;;]INQ?I<GERA=JX%
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M:]AM1K^Y.;0F4P3H
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M8QJ5[D5;RX!V1P4     #*/;;]INQ?I<GERA=JX%
M                           <-O#YN;U_=?*X3 X]J-YR<ZELFS7:-WRL
MRI54Y,[:        =QL]YQK+_>O))C/8#KUWRLVIK>TO9UYR<^E:LZRXD
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MYBIZ:.";$A8OF6*9M;UNF(WFCO5 U4;)-13,FX'+T\+T:NK'?T7(BA#W
M!E_SF^?^_P#N:W>1Q!>%^M@O,I@/P'0^TM"LI&"      ()YG?R%8?=<OM1L
M6"<>K<<TV\YBZRIWE9S;''P               !:GEH^0EP^%IO)J8T[&N>C
M)]LNU[#:C7]R<VA,I@G0
M                        "N_-QA687C!DS/ [M<[?>\91\M;1VVJJ($J[
M>[1955D+T17PZ=HBZ>HX_2"89SY#>\TN[(&Y7<;I7QQ*Y:5+I/43-8YVG%P=
MNY=%71-= N^ZU91N906^"DL=ZOM-:HD5*:"BJJR.G:U7*J\#8W(U$U5>KNA#
M[F9AO)(]L<=_R9\CU1K&-K+@KE<O0B(B/Z54"7.5?9O/+[NS9LON]HKK?CMB
MG?<:NZ5\,L+9IXVN[..-TJ-61[I%17Z:Z-U5>XBB9:4!0
M         ,Z>?GSPV3]&J7R^O"T+H;!>93 ?@.A]I:$2D8(
M                              .<W ^1%_\ <,_K%,9BFJ7F3++X/KMU
MET[ZGYQMWH        Z/;_Y;V#W=!Z]#)X7K=WE0Q&,:E>Y%6\N =D<%
M  RCVV_:;L7Z7)Y<H7:N!0
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M8]$<B_710H_4   R_P"<WS_W_P!S6[R.(+POUL%YE,!^ Z'VEH5E(P0
M!!/,[^0K#[KE]J-BP3CU;CFFWG,765.\K.;8X^                +4\M'R
M$N'PM-Y-3&G8UST9/MEVO8;4:_N3FT)E,$Z
M                                         (RWDV;P3=NW4#L\JJJC
MM]@\(J8ZBFJ(Z5C&RM;VCI7RL>G"B1HNO1H$Q+E\0W?Y<]L,:MF"V?/**2V6
MI'4]*]\SJQ_W21TJJZ6"/@5-7KWW4!T/TD]BOGU;/Z[_ & +'YX_S([1Y;F=
MJP3%+R^\WR[+.D2TU-,VGB2FIY:ERR2S-C316Q.1.#BZ=.YT@L2P$
M                 !G3S\^>&R?HU2^7UX6A=#8+S*8#\!T/M+0B4C!
M                                      !SFX'R(O\ [AG]8IC,4U2\
MR99?!]=NLNG?4_.-N]        '1[?\ RWL'NZ#UZ&3PO6[O*AB,8U*]R*MY
M< [(X*     !E'MM^TW8OTN3RY0NU<"@
M                  .&WA\W-Z_NOE<)@<>U&\Y.=2V39KM&[Y694JJ<F=M
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M/P'0^TM"LI&"      ()YG?R%8?=<OM1L6"<>K<<TV\YBZRIWE9S;''P
M           !:GEH^0EP^%IO)J8T[&N>C)]LNU[#:C7]R<VA,I@G0
M                                                          !4
M'GXS6XVC$\:PJ@G6&GR&HJ:JYI&[1SX+>D79QNT7U#GS<>GHL0+0JI7<OFX=
MLVGCWCK8J6+%Y4@E93=JYU<M-52)%%.L;8U8D;E<WKDXM'(O"$VO=P7E4W*W
M'P2ES[$JNT5E#5K.V*VOJI8:Y)*>1\3F.22!(4559JFLVFBHH+78\F>#TKMZ
MI*J]7-]IRS#TK%^+<]-]TJ>.&6AG3M5D3@= Z75S.!57N=&NA$M&PJ
M                  &=//SYX;)^C5+Y?7A:%T-@O,I@/P'0^TM")2,$
M                                       '.;@?(B_^X9_6*8S%-4O,
MF67P?7;K+IWU/SC;O0       !T>W_RWL'NZ#UZ&3PO6[O*AB,8U*]R*MY<
M[(X*     !E'MM^TW8OTN3RY0NU<"@
M                .&WA\W-Z_NOE<)@<>U&\Y.=2V39KM&[Y694JJ<F=M
M     .XV>\XUE_O7DDQGL!UZ[Y6;4UO:7LZ\Y.?2M6=9<2
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MO[DYM"93!.@
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MUN[RH8C&-2O<BK>7 .R."@     91[;?M-V+]+D\N4+M7 H
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M&N>C)]LNU[#:C7]R<VA,I@G0
M                             !'F\4VU-5C#<6W;KZ.AL>0R>"TKJV7P
M?_O$;5D22.5>B-T>FO:.5&IU+ZK128<_R^[*6#9VUWM<=OOQAMF0U,5725W#
M&BI30L5D;%DB<YLFBN>O&WA3I]2G=$RA'=[D;K,BR>NR3;2\4-OIKG,^IJ;-
M=.UBA@FE<KI%@E@CE7@55U2-8^]ZD731$)B7?\N_*E1;/75^7Y)<HKUE_9/@
MHO!F.924;)4X9',5^CGO<WO>-6MT:JIITZA$RLD$
M    !G3S\^>&R?HU2^7UX6A=#8+S*8#\!T/M+0B4C!
M                         !SFX'R(O_N&?UBF,Q35+S)EE\'UVZRZ=]3\
MXV[T        ='M_\M[![N@]>AD\+UN[RH8C&-2O<BK>7 .R."@     91[;
M?M-V+]+D\N4+M7 H
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MC6?A06IUH:*GMM#36ZD:K*6DBCIX&*JN5(XFHQJ:KTKHB!#Z   #+_G-\_\
M?_<UN\CB"\+];!>93 ?@.A]I:%92,$      03S._D*P^ZY?:C8L$X]6XYIM
MYS%UE3O*SFV./@               "U/+1\A+A\+3>34QIV-<]&3[9=KV&U&
MO[DYM"93!.@
M                "GG/I@^37RQ8SE]IIY:RRX\M;'=V1(KUIVU?8.9.K4U[
MS[DK7N^U[W7K"T.CY-,]V[9M%;,4@NM'0Y715%6^[V^HEC@J)I9ZE[HYF->K
M5D:L2Q,XFZZ</"O5TD2L[%-%/&V:"1LL3O4R,5'-7N="IT!#^P
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MLPG (  &=//SYX;)^C5+Y?7A:%T-@O,I@/P'0^TM")2,$
M                            '.;@?(B_^X9_6*8S%-4O,F67P?7;K+IW
MU/SC;O0       !T>W_RWL'NZ#UZ&3PO6[O*AB,8U*]R*MY< [(X*     !E
M'MM^TW8OTN3RY0NU<"@
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M      $$\SOY"L/NN7VHV+!./5N.:;><Q=94[RLYMCCX
MM3RT?(2X?"TWDU,:=C7/1D^V7:]AM1K^Y.;0F4P3H
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M*]R*MY< [(X*     !E'MM^TW8OTN3RY0NU<"@
M                        .&WA\W-Z_NOE<)@<>U&\Y.=2V39KM&[Y694J
MJ<F=M        .XV>\XUE_O7DDQGL!UZ[Y6;4UO:7LZ\Y.?2M6=9<2
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MH3*8)T
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MRUQ71:J6!*9S72U%1!P<+7OU1.PUUU[H3$M']@O,I@/P'0^TM"LI&"
M                                     #G-P/D1?_<,_K%,9BFJ7F3+
M+X/KMUET[ZGYQMWH        Z/;_ .6]@]W0>O0R>%ZW=Y4,1C&I7N15O+@'
M9'!0     ,H]MOVF[%^ER>7*%VK@4
M               !PV\/FYO7]U\KA,#CVHWG)SJ6R;-=HW?*S*E53DSMH
M    !W&SWG&LO]Z\DF,]@.O7?*S:FM[2]G7G)SZ5JSK+B0      "GO.QO?=
M<7IZ/:W%:I]'7W6G\-OU; Y63,HWN5D5.QS5U;VJL>LG=X41.IRA:(5<VQY<
M-U-V+>MYQJVQ4]AXG,CNMQF2FIY'L71S8TT=(_1>A7-8K47H5=0FUU.7\FF]
MF)6ZHND='0W^FI6K),VRU#YID8B:JYL4\4#WZ?S6-5WH("UZ'*3OE==OLVH<
M&O%4^3!\BJ&TJT\JZMHZ^=49%/'KZE'/T9*G0FB\2]+03#2P*
M R_YS?/_ '_W-;O(X@O"_6P7F4P'X#H?:6A64C!      $$\SOY"L/NN7VHV
M+!./5N.:;><Q=94[RLYMCCX                M3RT?(2X?"TWDU,:=C7/1
MD^V7:]AM1K^Y.;0F4P3H
M                        !!'-3LL_=O 5J;)3I+FN/*^KL[6Z(^HC=IV]
M-JJIZMK4<S^FU$Z-5"8EG+F.V.?;?14DV:6"JLL5>Y[*-U4UK4D=$C5>C=%7
MJXD"SU<?V,W;RJSTM_Q[$J^X6:M:Y])60M:L<C6N5BJFKDZG-5 6O49RU;[2
M/;&W!KBCG*C45S8VMU7HZ5<]$1/34%J>.6CE7W$L.XELSG<*WMLEKL;GU-'1
MOGAFJ:FJX7,C[V![^!C%7C57JBKHB(BHNH1,KX!4          .5W-\VV8_
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M5  &=//SYX;)^C5+Y?7A:%T-@O,I@/P'0^TM")2,$
M                        '.;@?(B_^X9_6*8S%-4O,F67P?7;K+IWU/SC
M;O0       !T>W_RWL'NZ#UZ&3PO6[O*AB,8U*]R*MY< [(X*     !E'MM^
MTW8OTN3RY0NU<"@
M .&WA\W-Z_NOE<)@<>U&\Y.=2V39KM&[Y694JJ<F=M        .XV>\XUE_O
M7DDQGL!UZ[Y6;4UO:7LZ\Y.?2M6=9<2       9<\XZU:\P>3^$Z]BD-M\#U
MTT['WO@UT]+M.,+PTBV]2QI@F-)C79_%]+91^]O8Z*SP?L&<&FGI=?IA1T@&
M2^^*4";_ &5_$S@X/?K_ +GX/IP^'<3.UX=.C^T<?4%X:T!0           &
M7_.;Y_[_ .YK=Y'$%X7ZV"\RF _ =#[2T*RD8(      @GF=_(5A]UR^U&Q8
M)QZMQS3;SF+K*G>5G-L<?                %J>6CY"7#X6F\FIC3L:YZ,G
MVR[7L-J-?W)S:$RF"=
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MC5+Y?7A:%T-@O,I@/P'0^TM")2,$
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M$Z
M        *6?O \BN-/;,+Q6![F6RNEK;A6-151LDM(D,<*+Z/"DSUT]- M",
M]L.2K,-P<1M^7W*_TM@I;M$VJMM(Z!]7.^FD36.23A?&UG&FCFHBN[U4UT7H
M!:D#^'E_^,?_ ,$_^^ +7<;0<FOZJ=Q;-GWQU]]_>CPK_P"7^]?@O:^%4DU+
M_I?#)>'A[7B]0NNFGIA%JTX0                        &=//SYX;)^C5
M+Y?7A:%T-@O,I@/P'0^TM")2,$
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M>D[5/1!:GBU6FUV*WT]ILM%!;K72M[.FHJ2-L$$;$[C6,1$1/J($/L
M      #+_G-\_P#?_<UN\CB"\+];!>93 ?@.A]I:%92,$      03S._D*P^
MZY?:C8L$X]6XYIMYS%UE3O*SFV./@               "U/+1\A+A\+3>34Q
MIV-<]&3[9=KV&U&O[DYM"93!.@
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M8QJ5[D5;RX!V1P4     #*/;;]INQ?I<GERA=JX%
M                           <-O#YN;U_=?*X3 X]J-YR<ZELFS7:-WRL
MRI54Y,[:        =QL]YQK+_>O))C/8#KUWRLVIK>TO9UYR<^E:LZRXD
M    I#SF[^958\B9M;AEPFM$,%-%4WZOI'K#5225**YE.V1BHYC$C5KG<.BN
MXM.I.DM$*91T>0Y#.L\-/676I<JHZ1C):EZJG?*BJB.7NZA9]/Q,S#YO7/Q.
MH]@!U&V^(99!N)B,TUAN,<,=ZMKY)'TD[6M:VKC55559HB(@0UZ"@
M    ,O\ G-\_]_\ <UN\CB"\+];!>93 ?@.A]I:%92,$      03S._D*P^Z
MY?:C8L$X]6XYIMYS%UE3O*SFV./@               "U/+1\A+A\+3>34QI
MV-<]&3[9=KV&U&O[DYM"93!.@
M                              " ^9W8C(M\:'&Z7'[E16Y]EFJY9W5_
M:HCTJ6Q-:C>R8_J[-==0F)5S^@#N3\YK'_+5_@ FT^@#N3\YK'_+5_@ 6I"V
M.Y0<WVNW1L.=W>^VJLMUJ\+[:FI%J.V=X513TS>'M(FMZ'2HJZKU F5Q@J
M                      &=//SYX;)^C5+Y?7A:%T-@O,I@/P'0^TM")2,$
M                                           '.;@?(B_^X9_6*8S%
M-4O,F67P?7;K+IWU/SC;O0       !T>W_RWL'NZ#UZ&3PO6[O*AB,8U*]R*
MMY< [(X*     !E'MM^TW8OTN3RY0NU<"@
M                    .&WA\W-Z_NOE<)@<>U&\Y.=2V39KM&[Y694JJ<F=
MM        .XV>\XUE_O7DDQGL!UZ[Y6;4UO:7LZ\Y.?2M6=9<2       9L<
MZ^'5MBWIERFLBD=9,IIZ6HAG9HB=I101TDT+7*BIQ-;$Q_3_ #T"\-"<*J<7
MK,3LU5A7@_Q4EI8G6EM(B-A;3\/>M1$ZE3J<B]*.U1>G4*/>
M   R_P"<WS_W_P!S6[R.(+POUL%YE,!^ Z'VEH5E(P0     !!/,[^0K#[KE
M]J-BP3CU;CFFWG,765.\K.;8X^                +4\M'R$N'PM-Y-3&G8
MUST9/MEVO8;4:_N3FT)E,$Z
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M\+UN[RH8C&-2O<BK>7 .R."@     91[;?M-V+]+D\N4+M7 H
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MLI&"      ()YG?R%8?=<OM1L6"<>K<<TV\YBZRIWE9S;''P
M   !:GEH^0EP^%IO)J8T[&N>C)]LNU[#:C7]R<VA,I@G0
M                                                  !2G]X+D%9%
M083B\3W-H*J6NN-7'KWKY:9L,4*_YJ2R_P H6AZF);";;8_RN7;,:BSTMXRV
MZ8?77Q;O6QMJ'T\]1;7U$3:='HK8EAU1$<U.+B377JT%OA?'R68I8,WV6S/%
MLHHFW"PW&](RKI'N>Q'I'3TTK%XHW-<BM>QKD5J]: E#>V=GCVSYOZ'%\?JG
MU%OMU]J;3%(YR.>ZEFCDB5DBMX45S&NT=T>J;KIW GR-,@H
M           &=//SYX;)^C5+Y?7A:%T-@O,I@/P'0^TM")2,$
M                                '.;@?(B_^X9_6*8S%-4O,F67P?7;
MK+IWU/SC;O0       !T>W_RWL'NZ#UZ&3PO6[O*AB,8U*]R*MY< [(X*
M  !E'MM^TW8OTN3RY0NU<"@
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M8;4:_N3FT)E,$Z
M                    *Z<X.SUWW1P2ANN,P.K,EQ:6:I@H6=,E125+6I41
MQIW9$[*-[4ZW<*M3550)B5)\:YB-S,1P"[[6,EIJW%KC1UEK6EN,+WST<5<Q
M\4R0/8^-S53C<K6R<;6K]KW M8_C;?F%S_:C$;IB6%^!TK+M4NK)KI-"L]9%
M(Z)D2=CQ/[)-$9KW\;ND%B6N3/:S(<MW$_6W?XYW6.SNJ)X+A5<3EK[K4(^-
M5:Y_2_L^-\CWZ]#^%/1"):&!4                        ,Z>?GSPV3]&
MJ7R^O"T+H;!>93 ?@.A]I:$2D8(
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M5N6AN5SHJ.J1E$QKEBJ*AD;]%XNA='+TA%C18*@           R_YS?/_?\
MW-;O(X@O"_6P7F4P'X#H?:6A64C!      $$\SOY"L/NN7VHV+!./5N.:;><
MQ=94[RLYMCCX                M3RT?(2X?"TWDU,:=C7/1D^V7:]AM1K^
MY.;0F4P3H
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M0Q&,:E>Y%6\N =D<%      RCVV_:;L7Z7)Y<H7:N!0
M                             '#;P^;F]?W7RN$P./:C><G.I;)LUVC=
M\K,J55.3.V@       '<;/><:R_WKR28SV Z]=\K-J:WM+V=><G/I6K.LN)
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M+TH9F)MBU@)BR;)?T2@
M!47GTSJXV3#\>PFW3NABR6>HJ+FL;N%SZ:WI%PQ.T7U+Y)D=_F!:'^<E.R^0
M8C;UW2NMR9'1Y3;5AH[$R-7.[!TS)(:F67B1$<J,=PQHU>]?JKD7O03*5^8K
M8ZJWQQJWVBCOB6:JM,\E93MEA6>GGF='V;6R<+FN8B:KWZ([35>]4(B5-.53
M(<AVSY@(\'KU=#%<ZBJQ^_4*.XF)54O:=FY--45T<T?"COYKG>B%I:7A0
M                     ,Z>?GSPV3]&J7R^O"T+H;!>93 ?@.A]I:$2D8(
M                                          .<W ^1%_\ <,_K%,9B
MFJ7F3++X/KMUET[ZGYQMWH        Z/;_Y;V#W=!Z]#)X7K=WE0Q&,:E>Y%
M6\N =D<%      RCVV_:;L7Z7)Y<H7:N!0
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M"      ()YG?R%8?=<OM1L6"<>K<<TV\YBZRIWE9S;''P
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MB+^NW[(_DI\\'\5?FGT'AM'^,1?UV_9'\E/G@_BK\T^A^_7TIU'D>(
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M7R^O"T+H;!>93 ?@.A]I:$2D8(
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M        5-W6\X-\^^Q^TQG(L;UV\W8WH=QV>[/NMR<Z7'&%;
M      +N47]CI_O3/6H=SN^+&X^<[WCSNR_<\CQ
M                #S[Y8[1DMHK+#?J.*X6>X1.@K*.=O%')&[N+Z"IUHJ=*
M+TIT@4RS?D"66OEJMO,HCIZ"55<RVWF-[G1:KKHE1 CE<WT.*+5.ZKNL+6N<
MLG[O_.IJB-,DRNTT5)K]U=;V5-;)PZ_:I-'3)JJ>F"U;[:39K#-FK$^SXK ]
M]55*U]SNM2J/JZJ1B*C5>Y$1$:W5>!C41K=5[JJJD6I""
M          SIY^?/#9/T:I?+Z\+0NAL%YE,!^ Z'VEH1*1@@
M                               YS<#Y$7_W#/ZQ3&8IJEYDRR^#Z[=9
M=.^I^<;=Z        .CV_P#EO8/=T'KT,GA>MW>5#$8QJ5[D5;RX!V1P4
M  #*/;;]INQ?I<GERA=JX%
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M/P'0^TM"LI&"      ()YG?R%8?=<OM1L6"<>K<<TV\YBZRIWE9S;''P
M           !:GEH^0EP^%IO)J8T[&N>C)]LNU[#:C7]R<VA,I@G0
M%3=UO.#?/OL?M,9R+&]=O-V-Z'<=GNS[K<G.EQQA6P                "[
ME%_8Z?[TSUJ'<[OBQN/G.]X\[LOW/(\0
M         BS?K>FV[(X<V_3TOOC>:^;P2SVWC[-LDW"KG/D<B*J1QHFKM$U5
M=&]&NJ$Q"C]RYV]]:Z=\M+66VVQN<KFPTM!&]C4_FHM0LSM/JKJ%K'Q?3-W_
M /S_ $W_  ZC_! L2AR[<S6[^X6\>-XAE-W@JK%<?#O"X(Z*FA<[P>@J)V:/
MCC:Y-'QM7H4(F%\ J                        &=//SYX;)^C5+Y?7A:%
MT-@O,I@/P'0^TM")2,$
M  '.;@?(B_\ N&?UBF,Q35+S)EE\'UVZRZ=]3\XV[T        ='M_\ +>P>
M[H/7H9/"];N\J&(QC4KW(JWEP#LC@H     &4>VW[3=B_2Y/+E"[5P*
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M-N]FMMMJXY?B38HJ"KG9V=1<'N?45DC-456K-,YSD:JHBJQJHW7N!#O
M @'F.YDZ;9'WJM5HHZ>\Y5<56HFH)Y',;3T+45J2/X.G5[TT8G=X7>@$Q#J.
M7O=FX[S8')E]SMT-LJ67">@2FIGOD9PPLB>CM7].J]H"4K!    9?\YOG_O_
M +FMWD<07A?K8+S*8#\!T/M+0K*1@@     "">9W\A6'W7+[4;%@G'JW'--O
M.8NLJ=Y6<VQQ\                6IY:/D)</A:;R:F-.QKGHR?;+M>PVHU
M_<G-H3*8)T       !4W=;S@WS[['[3&<BQO7;S=C>AW'9[L^ZW)SI<<85L
M                NY1?V.G^],]:AW.[XL;CYSO>/.[+]SR/$
M                          *2?O"+=<7PX'=FHYUIA=<J614]2RHF2G>W
M7TWMC=I_DJ%H27L+R\[/+M5B]ZN6.4-_N]\MU-<J^ON#$JG=M51I(Z-B/U:Q
ML:N[/1J)ZGIU4(F4L?J8V>_]OL:_X-0?@0BU]UGVRVVQZXPWBP8=8[5=J;B\
M'KZ&V4E-4Q]HQ8W<$D437-XFN<U=%Z454 ZH
M 9T\_/GALGZ-4OE]>%H70V"\RF _ =#[2T(E(P0
M                      <YN!\B+_[AG]8IC,4U2\R99?!]=NLNG?4_.-N]
M        '1[?_+>P>[H/7H9/"];N\J&(QC4KW(JWEP#LC@H     &4>VW[3=
MB_2Y/+E"[5P*                                    '@YM<ZRRXA>[
MM;WI'745'-/3O5J/1)&,5454=JB]/HGLZ-1%=[33/BF6,Q6_KN-$O;RCP54T
MS,;L0JW^OS<W\YP^*P>P-OZJT?S>N7%^]^)>_'PT\!^OS<W\YP^*P>P'56C^
M;UR=[\2]^/AIX#]?FYOYSA\5@]@.JM'\WKD[WXE[\?#3P'Z_-S?SG#XK![ =
M5:/YO7)WOQ+WX^&G@<MBV<Y-AMXR*^V*K;#<<IJ4K;P^2*.1LDZ232ZM:YJH
MU.*=_0T\E6&W%41$QXOU>M=;3:==5554U1$US;/]L>'^K74_K\W-_.</BL'L
M#Q]5:/YO7+V>]^)>_'PT\!^OS<W\YP^*P>P'56C^;UR=[\2]^/AIX#]?FYOY
MSA\5@]@.JM'\WKD[WXE[\?#3P/PK=W<YRBEDL5YKHYK;5(G;1MIXHU7LE25O
M?-:BIHYJ*:]M%A>CQAU],1X8IM\<^./##<]BMJL0O<;T:[JKC]M=?[9_MI\4
MQ,3Y'BGSB^V0       #N-GO.-9?[UY),9[ =>N^5FU-;VE[.O.3GTK5G67$
M@    ?#>OR/</<TWM;@,H^6SSZX+\)L]8\+RUJ"@       !6+FBYF[UL[<J
M;"L6M<4N0W*W,N+;S5NXX*>*:6>!$9 B)QR(L*N17.X4Z-6N"8A0/+(LUN3J
M?.<R2KG?D[YYJ6ZURJKZQ:=6-D<SBZ58WB:UJHG#]JWU.B%V@'(KYE*CX<K?
M::<*2LR$   !E_SF^?\ O_N:W>1Q!>%^M@O,I@/P'0^TM"LI&"      ()YG
M?R%8?=<OM1L6"<>K<<TV\YBZRIWE9S;''P               !:GEH^0EP^%
MIO)J8T[&N>C)]LNU[#:C7]R<VA,I@G0       %3=UO.#?/OL?M,9R+&]=O-
MV-Z'<=GNS[K<G.EQQA6P                "[E%_8Z?[TSUJ'<[OBQN/G.]
MX\[LOW/(\0                                     K#SL9S18W@UKQ
MFZ6&"]V[)I:ACWRRO@FI)J)L3XIX'M1VCT61>M%33H5%:JHI,*A[7<SFZFTU
MI3'[!54M?8(WNDI[;=875$4+GNXGI$Z-\4C6N7I5J/X=5541%55"UB1/I\[P
M_F3&O%:__'A%B1=B.;K<G=#=:P8-?[78Z:TW7PSPB:AIZN.I;X-13U+>!TM7
M*U-71-1=6+T:_5!,+HA4                        ,Z>?GSPV3]&J7R^O
M"T+H;!>93 ?@.A]I:$2D8(
M     .<W ^1%_P#<,_K%,9BFJ7F3++X/KMUET[ZGYQMWH        Z/;_P"6
M]@]W0>O0R>%ZW=Y4,1C&I7N15O+@'9'!0     ,H]MOVF[%^ER>7*%VK@4
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M.;0F4P3H       "INZWG!OGWV/VF,Y%C>NWF[&]#N.SW9]UN3G2XXPK8
M             !=RB_L=/]Z9ZU#N=WQ8W'SG>\>=V7[GD>(
M                        <CG6V&![EQ44&<6:.\16YTCZ)LLDT?9NF1J/
M5.R>S75&IU@1%ENT/*!@:,3,+;9K/+(B.CIZJX5+:A[573B;"E0LCDZ.M&Z!
M/A>'CF)<CF65;*"Q,L<U=*Y&0TTU;6TDLCUZ$;&VIFC5ZKZ#=0>%+V*[ [08
M3?J3)\6Q>"W7VA[3P2LCFJ7N9VT3H7Z))*YJZL>YO2G=!:DD(
M    ('I>;;;"OW(BVRM]+=JN[S7-+-%<H8:5UN=4+)V2N;(M2CUC1WVR1=/6
MB*$V)X"');@;F83M=9VWO-KK';:25RQTT:HZ6>>1$U5L44:.>]4[JHFC>ZJ
M0U;>>+9"ON"4-0Z[VV!7(WWPJZ)JT_3W52"6:31.[]S";%A[9=+;>K?37:T5
M<-=:ZR-LU)64SVRPRQO35',>U5147T@A]8  !G3S\^>&R?HU2^7UX6A=#8+S
M*8#\!T/M+0B4C!                                           !SF
MX'R(O_N&?UBF,Q35+S)EE\'UVZRZ=]3\XV[T        ='M_\M[![N@]>AD\
M+UN[RH8C&-2O<BK>7 .R."@     91[;?M-V+]+D\N4+M7 H
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MEFN@         !RNYGF^R7X.J/:U/<T+GZ-V&$QW4+[(JWE&SH3YO
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M5L                 NY1?V.G^],]:AW.[XL;CYSO>/.[+]SR/$
M                             (7YFMY)MG-O75]H5BY7>95H+(CT1[8G
M\*NEJ%:J*CDB;U(O1QN;JBIJ$Q#/S"-H-W]]JZOR"ST<]V5\R^^607.H2.)U
M0J(JHLTSN*1Z)IJC$<K4TUT30+.AS3E&WKPJU3WNHM5/=K=2L66K?:*A*F2*
M-J:N<L3VQR.1$Z5X&.T3IZ@6IKY+M_+Q7W1FT&7UCJV%\$DF+UL[E?.QU.U7
MOI'.757,[-'/CU]3PJWJ5J-(F%WPJ              H3OCS<95F%;6[9[56
MRJMK9ZB2V5->B=I=:MZ/6)T5-'"KNS1RZIQ-5SW=S@"T0@/8VEJ*'?7"**K8
ML5539!20SQ+UMDCJ$:YJZ>@J!,M<@HRWYC<HNNZ^_P#<;)33J^FHKBS&+) Y
MR]E&Z*9*=[D[GW2=7O5WH*G<1 O":=]^47 \'VAJ\GQ!]7\8\=CAGKZFIF61
MM="KVQS*Z->]C<G%VC>#1.CAZ==0B)?3R"[@5E53Y'MI73++3T+&WFSQN77L
MHY'I%5-37J;QNB<B)T<3G+W02NL%0 !G3S\^>&R?HU2^7UX6A=#8+S*8#\!T
M/M+0B4C!                                           !SFX'R(O_
M +AG]8IC,4U2\R99?!]=NLNG?4_.-N]        '1[?_ "WL'NZ#UZ&3PO6[
MO*AB,8U*]R*MY< [(X*     !E'MM^TW8OTN3RY0NU<"@
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MIKCQ+$QS]-9*?37A10M"4>1RFJ*79>HBJH7PR>_=8O!(U6.T6&GZ=%1 B5E
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M:26ANO-G;JK$&HVR5&37"JM;(FJC4MO'42M1&HJ:(D">CT)Z(7\C40*
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M;10U,K(HW-IV/?(UFD3&)HCI'KU:](2U3V"\RF _ =#[2T*2D8(
M                                  .<W ^1%_\ <,_K%,9BFJ7F3++X
M/KMUET[ZGYQMWH        Z/;_Y;V#W=!Z]#)X7K=WE0Q&,:E>Y%6\N =D<%
M      RCVV_:;L7Z7)Y<H7:N!0                4CK?[94??7^N4X9><:
M=U]&W7$C<A^!XWD        +N47]CI_O3/6H=SN^+&X^<[WCSNR_<\CQ
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M$Z        J;NMYP;Y]]C]IC.18WKMYNQO0[CL]V?=;DYTN.,*V
M        7<HO['3_ 'IGK4.YW?%C<?.=[QYW9?N>1X@
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MX4=*]&(JZ3*NB*I$Z%5$6VPM1CUU55$?MJ\.YPK(&/;(
M               '.;@?(B_^X9_6*8S%-4O,F67P?7;K+IWU/SC;O0
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MGRX_00        [C9[SC67^]>23&>P'7KOE9M36]I>SKSDY]*U9UEQ(
M                   ,O^<WS_W_ -S6[R.(+POUL%YE,!^ Z'VEH5E(P0
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MJW>!K.E=I763]2S1CFS   !2.M_ME1]]?ZY3AEYQIW7T;=<2-R'X'C>0
M    NY1?V.G^],]:AW.[XL;CYSO>/.[+]SR/$       Y7<SS?9+\'5'M:GN
M:%S]&[#"8[J%]D5;RC9T)\W@       'V6O^W1_4?ZQ37=I.S+_(EO&P?;VB
M?=I>^?+C]!        #N-GO.-9?[UY),9[ =>N^5FU-;VE[.O.3GTK5G67$@
M                        R_YS?/\ W_W-;O(X@O"_6P7F4P'X#H?:6A64
MC!      $$\SOY"L/NN7VHV+!./5N.:;><Q=94[RLYMCCX
M  M3RT?(2X?"TWDU,:=C7/1D^V7:]AM1K^Y.;0F4P3H       "INZWG!OGW
MV/VF,Y%C>NWF[&]#N.SW9]UN3G2XXPK8                !=RB_L=/]Z9Z
MU#N=WQ8W'SG>\>=V7[GD>(                                     4
M\Y^\QK[;C&+X513+'2WRHJ:VY-8JHKX[>D21,=Z+5?,K]/18@6AZ?)ELA6X9
M9H=T[C='.J<KMG!!98V)V4=)++'-#*^15U=(K6:HB(B(C^ZO41,I7WZV.H=\
ML>H;157FHL]3:Y9*FADBC9- Z:1G G;1NT<Y$[G!(WK7KZ-!$J1\L=UONV',
M=!AU7)P^$UE;C-]IHW:Q/E@61C537H7@GB:K7::\.J=U0M+34*
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MW$U-[T:]F]NJ*Y\'[J8GTQ:YOI=S%S?UW<3;%%55/HFQZ![#U0
M       YS<#Y$7_W#/ZQ3&8IJEYDRR^#Z[=9=.^I^<;=Z        .CV_P#E
MO8/=T'KT,GA>MW>5#$8QJ5[D5;RX!V1P4     #*/;;]INQ?I<GERA=JX%
M         K+N)^U_MU\#M]=<S(W>KU;O UG2NTKK)^I9HQS9@   I'6_VRH^
M^O\ 7*<,O.-.Z^C;KB1N0_ \;R        %W*+^QT_WIGK4.YW?%C<?.=[QY
MW9?N>1X@      '*[F>;[)?@ZH]K4]S0N?HW883'=0OLBK>4;.A/F\
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MQA6P                "[E%_8Z?[TSUJ'<[OBQN/G.]X\[LOW/(\0
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M\J5FC'-F   "G&:_++(?A.M\H><7Q#6KW+JSI=_PO4[G[=&;#PST&2
M  +CX5\C<>^#*+R=AVC#]5NLBG-AP#%-<OON5YTO</?8T
M  .<W ^1%_\ <,_K%,9BFJ7F3++X/KMUET[ZGYQMWH        Z/;_Y;V#W=
M!Z]#)X7K=WE0Q&,:E>Y%6\N =D<%      RCVV_:;L7Z7)Y<H7:N!0
M    *R[B?M?[=? [?77,R-WJ]6[P-9TKM*ZR?J6:,<V8   *1UO]LJ/OK_7*
M<,O.-.Z^C;KB1N0_ \;R        %W*+^QT_WIGK4.YW?%C<?.=[QYW9?N>1
MX@      '*[F>;[)?@ZH]K4]S0N?HW883'=0OLBK>4;.A/F\        ^RU_
MVZ/ZC_6*:[M)V9?Y$MXV#[>T3[M+WSY<?H(        =QL]YQK+_ 'KR28SV
M Z]=\K-J:WM+V=><G/I6K.LN)                        !E_SF^?^_\
MN:W>1Q!>%^M@O,I@/P'0^TM"LI&"      ()YG?R%8?=<OM1L6"<>K<<TV\Y
MBZRIWE9S;''P               !:GEH^0EP^%IO)J8T[&N>C)]LNU[#:C7]
MR<VA,I@G0       %3=UO.#?/OL?M,9R+&]=O-V-Z'<=GNS[K<G.EQQA6P
M              "[E%_8Z?[TSUJ'<[OBQN/G.]X\[LOW/(\0
M                         ^:XVZ@NU!4VNZ4T=9;JR-T%52SM22*6*1.%
MS'M=JBHJ+TH!4;-^0?%[I7RUV"Y)/8*>55=[UUL'OA"Q57U,<O:QR-:G<X^T
M7TPM:YVQ_N^:E:B-^29NQ*1%UEAMU"JR.;KU-DFE1&KIW>S=]0%JV.VFUF&;
M36!,?PVA\&@>J25E7,[M:NJE1-.TFDT3B7T$1$:W[5$"KLP
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M#6=*[2NLGZEFC'-F   "D=;_ &RH^^O]<IPR\XT[KZ-NN)&Y#\#QO(
M  7<HO['3_>F>M0[G=\6-Q\YWO'G=E^YY'B       <KN9YOLE^#JCVM3W-"
MY^C=AA,=U"^R*MY1LZ$^;P       #[+7_;H_J/]8IKNTG9E_D2WC8/M[1/N
MTO?/EQ^@@       !W&SWG&LO]Z\DF,]@.O7?*S:FM[2]G7G)SZ5JSK+B0
M                      9?\YOG_O\ [FMWD<07A?K8+S*8#\!T/M+0K*1@
M@     "">9W\A6'W7+[4;%@G'JW'--O.8NLJ=Y6<VQQ\
M6IY:/D)</A:;R:F-.QKGHR?;+M>PVHU_<G-H3*8)T       !4W=;S@WS[['
M[3&<BQO7;S=C>AW'9[L^ZW)SI<<85L                 NY1?V.G^],]:A
MW.[XL;CYSO>/.[+]SR/$
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M93 ?@.A]I:%92,$      03S._D*P^ZY?:C8L$X]6XYIMYS%UE3O*SFV./@
M              "U/+1\A+A\+3>34QIV-<]&3[9=KV&U&O[DYM"93!.@
M   *F[K><&^??8_:8SD6-Z[>;L;T.X[/=GW6Y.=+CC"M@
M %W*+^QT_P!Z9ZU#N=WQ8W'SG>\>=V7[GD>(
M             <WE&?X9A53;*7+KW2V62\.ECMTE<_L(9'P(U7HLKM(VJG&W
MU;DU[@'O4M725U/'5T,\=32RIQ13PO;)&YJ]UKFJJ*@'[ <_-G.'09'1X?)?
M*+XU5ZR-I;,R=CZQRP1/F>JQ-57-1&,<NKD1.CT0.@
M       &=//SYX;)^C5+Y?7A:%T-@O,I@/P'0^TM")2,$       *R\Q/GGV
M4^&(?^849D=&YNO<]DM9Q36KC*_RI6:,<V8   *<9K\LLA^$ZWRAYQ?$-:O<
MNK.EW_"]3N?MT9L/#/09(        N/A7R-Q[X,HO)V':,/U6ZR*<V' ,4UR
M^^Y7G2]P]]C0                 YS<#Y$7_P!PS^L4QF*:I>9,LO@^NW67
M3OJ?G&W>@       #H]O_EO8/=T'KT,GA>MW>5#$8QJ5[D5;RX!V1P4
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MQI%Y=5>&:*JJ?1,P^Q<+TRG3-#N=(HB8IO;NBN(GQV54Q5%OZ^%_)Z;)
M    %W*+^QT_WIGK4.YW?%C<?.=[QYW9?N>1X@      '*[F>;[)?@ZH]K4]
MS0N?HW883'=0OLBK>4;.A/F\        ^RU_VZ/ZC_6*:[M)V9?Y$MXV#[>T
M3[M+WSY<?H(        =QL]YQK+_ 'KR28SV Z]=\K-J:WM+V=><G/I6K.LN
M)                        !E_SF^?^_\ N:W>1Q!>%^M@O,I@/P'0^TM"
MLI&"      ()YG?R%8?=<OM1L6"<>K<<TV\YBZRIWE9S;''P
M   !:GEH^0EP^%IO)J8T[&N>C)]LNU[#:C7]R<VA,I@G0       %3=UO.#?
M/OL?M,9R+&]=O-V-Z'<=GNS[K<G.EQQA6P                "[E%_8Z?[T
MSUJ'<[OBQN/G.]X\[LOW/(\0
M KQS<[5T.X6$T=]N.3TN,4N)+454E17Q/DII4JDCC1CG1*KVJKF-1O!&]7*N
MB-U"89UXM7YO0W-U+@5==&7)7<3?>*2JCF?P*B(]&P<+].K35-0NZ/*,BWY@
MMZ-S6ZY=':Y55B)>*BYMIW.7K3_O#N%5"$V\DVV-)>LVH]R8LGHDK,:6J2HQ
MAD<KJY6U=--2->]S^!K6?=>-'1]HG1PKPJO01+0L*@
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M!^ Z'VEH5E(P0     !!/,[^0K#[KE]J-BP3CU;CFFWG,765.\K.;8X^
M            +4\M'R$N'PM-Y-3&G8UST9/MEVO8;4:_N3FT)E,$Z
M J;NMYP;Y]]C]IC.18WKMYNQO0[CL]V?=;DYTN.,*V                 7
M<HO['3_>F>M0[G=\6-Q\YWO'G=E^YY'B
M         %*_W@F07."W85B\+G1VFNEKKA5M35&RS4B0QQ)_F)-(NG]) M"9
M^5&QXC:]E,;K<7C@=4W*G[>]UD:-6>2X<3DE9*Y.G6-W>-:O4U$")3+745%<
M:.>@N5/%56^I8Z*IIJAC9(I(W)HYKVN145%3K10AFIL_<[?BO-M#38%,C\6J
M;Y7VJE;"[BBDMD[I6-:CE5.)C41KV+KT\+5Z0OY&F84
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MA]I:%92,$      03S._D*P^ZY?:C8L$X]6XYIMYS%UE3O*SFV./@
M        "U/+1\A+A\+3>34QIV-<]&3[9=KV&U&O[DYM"93!.@       *F[
MK><&^??8_:8SD6-Z[>;L;T.X[/=GW6Y.=+CC"M@                %W*+^
MQT_WIGK4.YW?%C<?.=[QYW9?N>1X@
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M?:6A$I&"  !2S>;SFY#]^B]HC-]PW5Z/Z\KYYVG[2OMV,V'"&1:T
M=-3_ -G@^]L]:A\Q;5=J7^5[(??W_P ^_P#7]$R/\I?J:NWX        N/A7
MR-Q[X,HO)V':,/U6ZR*<V' ,4UR^^Y7G2]P]]C0                 YS<#
MY$7_ -PS^L4QF*:I>9,LO@^NW673OJ?G&W>@       #H]O_ );V#W=!Z]#)
MX7K=WE0Q&,:E>Y%6\N =D<%      RCVV_:;L7Z7)Y<H7:N!0     "B>??+
MO*/A:O\ *9#HFB<S1DT[SYIQC7K_ .Y7G2YT]IB@       #I:7^S0_>V_\
M4A\IXWVAI'W;S/E^BFR?8NA_^/<_\=+]C#-H        +N47]CI_O3/6H=SN
M^+&X^<[WCSNR_<\CQ       .5W,\WV2_!U1[6I[FA<_1NPPF.ZA?9%6\HV=
M"?-X       !]EK_ +=']1_K%-=VD[,O\B6\;!]O:)]VE[Y\N/T$
M.XV>\XUE_O7DDQGL!UZ[Y6;4UO:7LZ\Y.?2M6=9<2
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M.'AX==>CK ]FTXEBM@E=/8K%;[7,Y-'245)!3.5/36)C5 ]@
M              ,Z>?GSPV3]&J7R^O"T+H;!>93 ?@.A]I:$2D8(  %+-YO.
M;D/WZ+VB,WW#=7H_KROGG:?M*^W8S8<(9%K0       !TU/_ &>#[VSUJ'S%
MM5VI?Y7LA]_?_/O_ %_1,C_*7ZFKM^        +CX5\C<>^#*+R=AVC#]5NL
MBG-AP#%-<OON5YTO</?8T                 .<W ^1%_\ <,_K%,9BFJ7F
M3++X/KMUET[ZGYQMWH        Z/;_Y;V#W=!Z]#)X7K=WE0Q&,:E>Y%6\N
M=D<%      RCVV_:;L7Z7)Y<H7:N!0     "B>??+O*/A:O\ID.B:)S-&33O
M/FG&->O_ +E>=+G3VF*        .EI?[-#][;_U(?*>-]H:1]V\SY?HILGV+
MH?\ X]S_ ,=+]C#-H        +N47]CI_O3/6H=SN^+&X^<[WCSNR_<\CQ
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ME,$Z        J;NMYP;Y]]C]IC.18WKMYNQO0[CL]V?=;DYTN.,*V
M          7<HO['3_>F>M0[G=\6-Q\YWO'G=E^YY'B
M                   ,S>=OSZUGP90>L<%X:+87\CL>^#*+R=@49F__ /87
M_P#LK_SX+^1J<%                           ,Z>?GSPV3]&J7R^O"T+
MH;!>93 ?@.A]I:$2D8(  %+-YO.;D/WZ+VB,WW#=7H_KROGG:?M*^W8S8<(9
M%K0       !TU/\ V>#[VSUJ'S%M5VI?Y7LA]_?_ #[_ -?T3(_RE^IJ[?@
M      "X^%?(W'O@RB\G8=HP_5;K(IS8< Q37+[[E>=+W#WV-          #
MC;CNUME::ZHMESRRUTEPI)'0U---51LDCD8NCFN:JZHJ*>6+FN8MB)>G5IMQ
M3,Q-<1,?J^;]=6TGSTL_CD7V2?X+SW94ZPT?WZ?2?KJVD^>EG\<B^R/X+SW9
M.L-']^GTGZZMI/GI9_'(OLC^"\]V3K#1_?I]+U+!N-@>55RVS&\BM]UN"1NF
M6FI*ADLB1L5$5W"U571%5"M5U53%LP\MUI5S>3915$S^DNG/&]ISFX'R(O\
M[AG]8IC,4U2\R99?!]=NLNG?4_.-N]        '1[?\ RWL'NZ#UZ&3PO6[O
M*AB,8U*]R*MY< [(X*     !E'MM^TW8OTN3RY0NU<"@     %$\^^7>4?"U
M?Y3(=$T3F:,FG>?-.,:]?_<KSI<Z>TQ0       !TM+_ &:'[VW_ *D/E/&^
MT-(^[>9\OT4V3[%T/_Q[G_CI?L89M        !=RB_L=/]Z9ZU#N=WQ8W'SG
M>\>=V7[GD>(      !RNYGF^R7X.J/:U/<T+GZ-V&$QW4+[(JWE&SH3YO
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MSI<<85L                 NY1?V.G^],]:AW.[XL;CYSO>/.[+]SR/$
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M ,M[![N@]>AD\+UN[RH8C&-2O<BK>7 .R."@     91[;?M-V+]+D\N4+M7
MH     !1//OEWE'PM7^4R'1-$YFC)IWGS3C&O7_W*\Z7.GM,4        =+2
M_P!FA^]M_P"I#Y3QOM#2/NWF?+]%-D^Q=#_\>Y_XZ7[&&;0        7<HO[
M'3_>F>M0[G=\6-Q\YWO'G=E^YY'B       <KN9YOLE^#JCVM3W-"Y^C=AA,
M=U"^R*MY1LZ$^;P       #[+7_;H_J/]8IKNTG9E_D2WC8/M[1/NTO?/EQ^
M@@       !W&SWG&LO\ >O))C/8#KUWRLVIK>TO9UYR<^E:LZRXD
M                &7_.;Y_[_P"YK=Y'$%X7ZV"\RF _ =#[2T*RD8(
M @GF=_(5A]UR^U&Q8)QZMQS3;SF+K*G>5G-L<?                %J>6CY
M"7#X6F\FIC3L:YZ,GVR[7L-J-?W)S:$RF"=        5-W6\X-\^^Q^TQG(L
M;UV\W8WH=QV>[/NMR<Z7'&%;                 +N47]CI_O3/6H=SN^+&
MX^<[WCSNR_<\CQ                                    %-N9#E>W*W
M6W-J,NQ>6V,M4M'2TS6UE3)%+QP-5'=ZV%Z:=/1TA:)1)]!7>O\ &+'X[-_A
MPFT^@KO7^,6/QV;_  X+3Z"N]?XQ8_'9O\."U).P7*ANAMINUCV;9%-:G6:U
M^&^$MI*F269?":&>G9PM="Q%[^1NO?=01,KMA4
M  ,Z>?GSPV3]&J7R^O"T+H;!>93 ?@.A]I:$2D8(  %+-YO.;D/WZ+VB,WW#
M=7H_KROGG:?M*^W8S8<(9%K0       !TU/_ &>#[VSUJ'S%M5VI?Y7LA]_?
M_/O_ %_1,C_*7ZFKM^        +CX5\C<>^#*+R=AVC#]5NLBG-AP#%-<OON
M5YTO</?8T            "N.VW[56YWP?#_U49[][S%+7-$[0O=S@6./0;&
M .<W ^1%_P#<,_K%,9BFJ7F3++X/KMUET[ZGYQMWH        Z/;_P"6]@]W
M0>O0R>%ZW=Y4,1C&I7N15O+@'9'!0     ,H]MOVF[%^ER>7*%VK@4
MHGGWR[RCX6K_ "F0Z)HG,T9-.\^:<8UZ_P#N5YTN=/:8H        Z6E_LT/
MWMO_ %(?*>-]H:1]V\SY?HILGV+H?_CW/_'2_8PS:        "[E%_8Z?[TS
MUJ'<[OBQN/G.]X\[LOW/(\0      #E=S/-]DOP=4>UJ>YH7/T;L,)CNH7V1
M5O*-G0GS>        ?9:_P"W1_4?ZQ37=I.S+_(EO&P?;VB?=I>^?+C]!
M     #N-GO.-9?[UY),9[ =>N^5FU-;VE[.O.3GTK5G67$@
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M,:]?_<KSI<Z>TQ0       !TM+_9H?O;?^I#Y3QOM#2/NWF?+]%-D^Q=#_\
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M?                %J>6CY"7#X6F\FIC3L:YZ,GVR[7L-J-?W)S:$RF"=
M      5-W6\X-\^^Q^TQG(L;UV\W8WH=QV>[/NMR<Z7'&%;
M    +N47]CI_O3/6H=SN^+&X^<[WCSNR_<\CQ
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MM        '34_P#9X/O;/6H?,6U7:E_E>R'W]_\ /O\ U_1,C_*7ZFKM^
M     +CX5\C<>^#*+R=AVC#]5NLBG-AP#%-<OON5YTO</?8T      !YU_\
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MOW/(\0      #E=S/-]DOP=4>UJ>YH7/T;L,)CNH7V15O*-G0GS>
M?9:_[=']1_K%-=VD[,O\B6\;!]O:)]VE[Y\N/T$        .XV>\XUE_O7DD
MQGL!UZ[Y6;4UO:7LZ\Y.?2M6=9<2                %>>:'F*DV9MM'8L:
MCBJ,YO$3IZ=:A..&CI$<K.W>S5.-SG(YL;5Z-6JKM43A<3$*91;I\T.04%7F
MM%?,HJK)2.<ZLN=$R=MMB5O?.XNP8D#4;IWW1HG=ZPMX%B^5SFLOF9WZGVXW
M*ECJ;M6-<ECOK6,A?-+&U7+!4-8C6*YS47LWM1-53A75RHH1,+D!4   ,O\
MG-\_]_\ <UN\CB"\+];!>93 ?@.A]I:%92,$      03S._D*P^ZY?:C8L$X
M]6XYIMYS%UE3O*SFV./@               "U/+1\A+A\+3>34QIV-<]&3[9
M=KV&U&O[DYM"93!.@       *F[K><&^??8_:8SD6-Z[>;L;T.X[/=GW6Y.=
M+CC"M@                %W*+^QT_WIGK4.YW?%C<?.=[QYW9?N>1X@
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M&O7_ -RO.ESI[3%        '2TO]FA^]M_ZD/E/&^T-(^[>9\OT4V3[%T/\
M\>Y_XZ7[&&;0        7<HO['3_ 'IGK4.YW?%C<?.=[QYW9?N>1X@
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M-B[B\N="KIO*9IG^2?!,3'_31YTM_'3#OG#;/':?V9A6]'QTP[YPVSQVG]F
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M>G0W"@N<"55MJH:RE55:DU/(V6/B3K3B8JIJ@'T@
M       S9YXKO=:G>1;145L\EIH;=224="Z1RT\3YFN61S(]>%'.^V<B:KT>
M@%X5KAE?3S1SL1JOB<U[4D8V1BJU=4XF/1S7)Z*.147NA*6:7F?WVHJ:&CH\
MPFIZ2G8V*"GAI:&...-B:-:UK:=$1$1-$1 BQ^OTJ-__ )[5/B]'^ !8E?EJ
MW^W?S;>O&,8RG*)[C8J[P_PNCDAIF-?V-NJ9F:K'$UR:/8UW0O<")AH*%0
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MUH;=H6GW%W<TTU563'Z3YW&<>V=T_2=.O+V[N_W4U3%D_NI\T>>IR?QVQ/\
M.]-_7/=ZST;WO5/ P7=3%.B^:CZCX[8G^=Z;^N.L]&][U3P'=3%.B^:CZCX[
M8G^=Z;^N.L]&][U3P'=3%.B^:CZCX[8G^=Z;^N.L]&][U3P'=3%.B^:CZCX[
M8G^=Z;^N.L]&][U3P'=3%.B^:CZCX[8G^=Z;^N.L]&][U3P'=3%.B^:CZCX[
M8G^=Z;^N.L]&][U3P'=3%.B^:CZCX[8G^=Z;^N.L]&][U3P'=3%.B^:CZGNP
M[C8.R&)CKY3(YK&M5.)>M&HB]PX1M!AFDZ3B%[>W5/[J*I\$VQYH\\OL+8W$
M]&T'!]'T>_J_9>7=%E463-DVSY8B8]$O[_61@WY\IOY7?8,!U%IO1^NGA;?W
MCP_I/EJ^D_61@WY\IOY7?8'46F]'ZZ>$[QX?TGRU?2?K(P;\^4W\KOL#J+3>
MC]=/"=X\/Z3Y:OI/UD8-^?*;^5WV!U%IO1^NGA.\>'])\M7TGZR,&_/E-_*[
M[ ZBTWH_73PG>/#^D^6KZ3]9&#?GRF_E=]@=1:;T?KIX3O'A_2?+5])^LC!O
MSY3?RN^P.HM-Z/UT\)WCP_I/EJ^D_61@WY\IOY7?8'46F]'ZZ>$[QX?TGRU?
M2LKC',YL3;L:LUOK,SIHZNDH:6"HC["K=PR10M:Y-6PJBZ*G<4ZAH5W5=W%W
M35X)IIIB=V(<?T^\IO-)O*Z?#3575,;DS+UOI4; ?/:F\7K/P![;T;#Z5&P'
MSVIO%ZS\ "P^E1L!\]J;Q>L_  L/I4; ?/:F\7K/P +#Z5&P'SVIO%ZS\ "P
M^E1L!\]J;Q>L_  L/I4; ?/:F\7K/P +'Q7?FAV%JK37TL&:4SYYZ>:.)O85
M::O>Q6HFJP(B=*]T\EW,15$SYWKZ3=U5W5=,>.:9CU*@_';$_P [TW]<W?K/
M1O>]4\#@G=3%.B^:CZCX[8G^=Z;^N.L]&][U3P'=3%.B^:CZCX[8G^=Z;^N.
ML]&][U3P'=3%.B^:CZCX[8G^=Z;^N.L]&][U3P'=3%.B^:CZCX[8G^=Z;^N.
ML]&][U3P'=3%.B^:CZCX[8G^=Z;^N.L]&][U3P'=3%.B^:CZCX[8G^=Z;^N.
ML]&][U3P'=3%.B^:CZCX[8G^=Z;^N.L]&][U3P'=3%.B^:CZGZTN<XA'4PR/
MO%,C&/:YR\?4B*BJ>IIFGW%Y<5TTU6S--41X)\L;C)X5LUB-SIES>5W5E-%Y
M15,_NI\$15$S_P!3V_UD8-^?*;^5WV#YTZBTWH_73POM[O'A_2?+5])^LC!O
MSY3?RN^P.HM-Z/UT\)WCP_I/EJ^D_61@WY\IOY7?8'46F]'ZZ>$[QX?TGRU?
M2?K(P;\^4W\KOL#J+3>C]=/"=X\/Z3Y:OI/UD8-^?*;^5WV!U%IO1^NGA.\>
M'])\M7TGZR,&_/E-_*[[ ZBTWH_73PG>/#^D^6KZ3]9&#?GRF_E=]@=1:;T?
MKIX3O'A_2?+5])^LC!OSY3?RN^P.HM-Z/UT\)WCP_I/EJ^E[6'[K[=VO*;/<
M:_(*:*BI:N*:>7OW<+&.1571K55?K(>]H&#Z7=Z117519$51,^&GA8[$\=T*
M]T6\HHO+:JJ9B/!5P+(_2HV ^>U-XO6?@#IKD5A]*C8#Y[4WB]9^ !8?2HV
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MBNNBRF+?+'NS'G83',:T/2-"KN[NO]U4_MLBRKR51/EA8'Z5&P'SVIO%ZS\
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MM7OY5,*RC =I*;'LOMS[7>65]9,ZDD?&]R1RN16KK$Y[>GZH5E-H0
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MIT(C&O5SO01 LV"CC9%&R*)J,C8B-8Q.A$:U-$1/J!1_0
M      &/.S'GAV^_26S>7PA>6PP4                        "LW/5YE*
M?X<HO::@)A%?[O?\L9Y[FMOME0$RO:%0
M                 S-YV_/K6?!E!ZQP7A>_$-R-NX,3L,,V766.:.W4C)(W
MW*D:YKFP,145%DU144*O9_6;MM\\;'_Q.D_"A!^LW;;YXV/_ (G2?A0/KMN=
M81>:V*VVC);5<+C/Q=C24E=3SS/X&J]W"R-ZN71J*Y=$ZD ]\
M        ,H]^?VC<I^'&?]<87AJX%                   0AS??L[9E_NS
M_FM($P@']WO^6,\]S6WVRH"97M"H                           "B7[P
MC\L8'[FN7ME.%H3]R@_L[8;_ +S_ .:U81*;P@
M          %9N>KS*4_PY1>TU 3#E?W?GR/S'X3I_)U"97#"H
M                #.GGY\\-D_1JE\OKPM"Z&P7F4P'X#H?:6A$I&"
M                    0YS ; 67?&QTS'5*6O*[4CUM-UX>-G#)HKH9VIHK
MHW*B+JG2Q>E.ZUQ,2I55\F&_]'5OH*:UT=92.=HZLI[C3MIW(SU+N&9T4FG3
MT:QZA:U9OELY5$VFK_CIF=53W'-.S=%004G$^EH62MX7N1[VM5\KFJK%7AX6
MHJHFNNH5F5G0@                      QYV8\\.WWZ2V;R^$+RV&"@
M                     5FYZO,I3_#E%[34!,(K_=[_ )8SSW-;?;*@)E>T
M*@                                            !F;SM^?6L^#*#U
MC@O#@J7EVWNK::&LI<)N,M+4,;+#*UC.%T<B(YKD[[J5%!:_7Z-F^OS%N?\
M49[,%I]&S?7YBW/^HSV8+4M\LFR.[&(;WXMD638I76RR4?OAX56SM:D<?;6Z
MIB9JJ.7K>]K?KA$RT/"H                  (SO7+WLYD5_J<HO6*P5=^K
M)DJ:FM=-5-<^9--'*ULJ-[B=2!-J3 @                  $(<WW[.V9?[
ML_YK2!,(!_=[_EC//<UM]LJ F5[0J                            HE^
M\(_+&!^YKE[93A:$_<H/[.V&_P"\_P#FM6$2F\(
M           !6;GJ\RE/\.47M-0$PY7]WY\C\Q^$Z?R=0F5PPJ
M                  SIY^?/#9/T:I?+Z\+0NAL%YE,!^ Z'VEH1*1@@
M                                                ,JMI=I=U;;NK
M@UQN.#9!26^DR"TU%75U%IK8H8H8JV)[Y)'OB1K6M:BJYRKHB!=JJ%
M                   KSSFXYD.4[0P6S&;16WJXI>*29:.VTTM7.D3(IT<_
MLX6N=PHJIJNG="81MR,81FF(W7-),KQRZ6*.JIZ!M*^Z4511-E=&^=7(Q9V,
MXE;JFNG5J$RN>%0
MS-YV_/K6?!E!ZQP7AHMA?R.Q[X,HO)V!1[@
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MI61ULL]+%14BSN1\JQ0M1K>-R(U%71.GH"'L
M
M                                             ',WO;C;S)J];IDF
M)66\7-S6QNK;A;J6KG5C.AK5DFC<[1.XFH'1PPPTT,=/3QMAIX6MCBBC:C&,
M8Q-&M:U-$1$1-$1 /[
M
M
M                                                    '\R21Q,=
M+*]&1L35[W*C6HB=U57J \JFRK&*R9E-1WN@J*AZZ,ABJH7O<OI-:Y54#UP
M        #Y9+E;H9EIYJN&.H1418GR,:_5W2G>JNO3J!]0 #^)9HH(W33R-B
MB;ZJ1ZHUJ=SI5>@#\Z>LI*M'+25$<Z,TXEB>U^FO5KPJH'[@ /EFN5NIY>PG
MJX8IDTUC?(QKNGJZ%74#Z@ '^*YK5:CG(BO71J*NFJZ*NB?615 _T
M
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M->UDNBZ=*JOJ LO$%0                                  %(/WAO\
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MB.8]JZM5J]**BIUHH4?T
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M7.14[J1R0)]8):0Y;NHQW+'6;G1RHVKN..,?&]NB<%QN$3:9$33NLJ)--$]
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M>_NNJZ-SJ:9RHO5Q/C<[ZX1*0P@
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MDD=ZISJ+6FU55ZU7LNE>Z%926$
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MU<NG1W5"K.K>9%L?-9=IZ37M8,BH*V/LF)Q=I(M/4=#>I5XG?74+QXFHX4
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M!*T68\\>,YEBMYQ6Y8!-)1W>CFHY.TN$;VM65BM:_3P=.ECM'-TZ45-4"+'
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M>]U1%T=JU TQY6HWQ; X0V1JM<M),Y$7H[U]7,YJ_71=0K*7P@
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MUFJ)F\$EXJJVY*U==>%TRP,5=?YS(6N33N*$2GX(
M              J7S[8G77; ,?RJDA66''JZ2.N<U-5B@N+6,1Z]'0WM(HV=
M?6Y M"#>4SF$L.T-5=L<S/M8L7O4D=3'<(6.F\$JHVJQSGQL17.9(WA158BN
M16IT+KT$S"VN1\V^Q=BL\USI<D9>:M(U=2VR@AG=/,]$71FKXVMCU5.N1S=
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M*/?
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M+PRC[66#C["5D[._@?&]-'QM=WKDZO0"'A[>;0;=;4^^7Q!LWO1[[]A[X?\
M>JNJ[7P7M.R_M4TO#P]J_P!3IKKT]P#V<PPC$\_M#K#F-II[O:G.1Z05#5U8
M]$T1\;VJU[':*J<3'(H$-)R5["I5>$+:JYT7%Q>"K<*CLM/YNJ.1^G^?J$VI
MHQ/#L7P6SQ6#$;53VBT1*KDIJ9NG$]=$5[W+JY[UT35SU5R^B$/\RW"\5SNT
M/L67VFGO%K>O%V%2SBX'Z:<<;TT<QR)]LQR+Z8$+3\E.PTL[I8[;7P1N75((
MZ^96-])%>KG?RN";4I[?[4;?;74DM+@]C@M:U"-2JJD5\U5,C>I))Y7/D5$7
MI1O%PIW$0(=DYK7M<Q[4<QR*CFJFJ*B]:*@$)91RD[%Y37R7.;'5ME9,Y7S+
M:JB6DB>J_P#8M58F_P"8QH3:]_;SE[VFVPK$NF+6!B7IJ:,NE:]]95,U31>S
M=*KDC545458VM54Z%!:D\(9U\TN,5^T._P!:MT;/ K;;=JNFOU,YB:1I<:*1
MBU,2KU:O5K97:]?:*%H:#VBZT-]M-#>[7*D]MN5/%64<R=3X9V)(QWUVJ@5?
M:   4+YZ<GJ,FSO$MK[&CJNNH8^WEI(>ESZ^ZO9%!%I_/1C$5OWP+0N/MAA<
M&W>WV.X7 J.6T4<<-1(WH;)4NUDJ)$3T'RN>[ZX5=:           .'W#V@V
MZW6][?C]9O??WH[?WO\ ^]5=+V7A79]K_99HN+B[)GJM=-.CN@>YB&'XY@>.
M4>)8I1> 8]0=KX)1]K+/P=O*^>3OYWR/75\CG=\Y>O3J CVR<KVQ6.WRAR2S
MXDVGO%MJ8ZVAG6NN$K8JB%Z21O2.2I=&O"Y$5$5N@3:[3/MN,,W0L\%@SFV>
M^MIIJEE=#3]O44W#4QQR1-?Q4TD3ET;*]-%=IT]74$& [<89M?9Y[!@UL]ZK
M34U+ZZ:G[>HJ>*IDCCB<_BJ9)7)JV)B:([3HZNL#Y]P-J-OMT:2*DSBQPW3P
M=%2EJ55\-3#Q=?9S0N8]$UZ5;Q<*]U% C&W\F&PM#6,JY+/5US6+JE-55TZP
MJJ+JFJ1N8J_45VGHA-J<[3:+78;;36>R4<-OM5&Q(J6BIF-BAC8G<:QJ(B!#
MF-P-IMO-T*:.GSBQ07-\"*VFJUXX:N%%Z=&3PN9(C=>GAXN%5ZT BV+DIV&C
MG;*^VU\L:+JL#Z^9&*GH*K%:[3ZC@FU-6)X;BV"6>.P8A:J>T6F-5>E/3-X>
M)ZHB*][EU<]ZHB(KWJKNCK"'HW2U6R]V^HM-YHX;A:ZMBQ55%51MF@E8O6U[
M'HJ*GU4 @NZ<F6PMRJWU<5EJK>C^EU/1UT[8=5ZU1LCI-/J(NGI!-J2MOMI-
MN]KJ:2GPBQ06V2=.&IK-73U<K==>%\\ROD5NO2C.+A3N($.LN-OH[M;ZNU7"
M))Z"NADIJJ!WJ7PS-5CVKZ2M54 SPV&96;#<TL^!WV1T5)7OJ,?[>1.%LT52
MK9J&9$TT^ZN9"B*G5QKZ86GQ-& J 1OOWFT>W^T>59#VO95O@4E%;5^V\-K4
M["%6IW>%S^-?2:H3"MW(/MW+##D&Y]=$K65">\MG<Y-.)C7-FJGIKW.)L3$5
M.ZCD"979"H     '%[A;3;?[JPT%/GMH]]H;8Z22A;X354O9NG1J/76FEB5V
MJ,;ZK4#U<,PG&-O<?I\6Q"A][K%2NDD@I.UFJ.%TSUD>O'.^1ZZN<J]+@. H
M.5W8FV7VFR6AQ)D5XHZMEPIYO#K@]C:F*1)6N[)U2L:HCDUX%9P]S30)M=QG
M6WV(;EV1N.YM;O?2S-G95MINWGIM)HD<UKN.GDC?T(]W1Q:!#\, VRP?:ZVU
M5HP2U^]5NK)_"ZF'PBIJN*;@;'Q<53+*Y.]:B:(N@']9WMK@VYEM9:LWLL%V
MI855U.^3BCGA<[H58IHE;(S71->%R:]T"**7DMV%IZMM3):*VIC:[B\%FKZC
MLEZ==%X',?I_G!-J<+!CUCQ:TTUBQRWP6RSTC>&GHZ5B1Q,15U5=$ZU5>E57
MI5>E0AY.<;<X1N1;6VG-K+3W>DC55@69%;-"YW0JQ31JV2-5TZ>!R:@1 O)1
ML.LW:^]UP1G%Q=AX?-P::Z\.OJM/\[7TPFU,&#[=X5MO:W6?";-3VBBD5'3]
MBCG2S.:FB.EED5TDBHB]"O<N@0Z*JI::MIIJ.LA944E0QT4]/,U)(Y(WIHYK
MFN145%1=%10(,OO)YL-?*YU>VPS6N215=+%;:N:"!SE[J1.<]K-/0C1J>D$V
MNVVZV/VPVL5T^&V&*EN4C59+=)W/JJUS5ZVI+,KE8U>ZV/A:OH M2$$,X-PK
M5)R[\UMOREL;J?%ZNY,O--,QJHQ+?<7.BK8VZ(J:QI),Q&I]KP^B%O'#1UCV
M2,;)&Y'QO1',>U=6JU>E%14ZT4*OZ   ,\N;&OK]V.8.R[9XVOA$UM93V>-K
M>^8VNK7]M.]5_FL8Z-)/YO NH6A?G&[%0XOCUJQJV-X;?:*2"@I47K[*FC;&
MU5T[JHWI"KU                                   ?+<K;07BWU5INM
M-'66VMB?3U=+,U'QRQ2-5KFN1>M%10*@9UR#6.XU\M?@&2OLU-*Y7):;C"M7
M%'Q+KI'.U[7HU.XCVO7T7!:UQM+^[]S)\RMK,PMD-/Q:))#3U$SU9Z/"[LTU
M]+B^N"U8W93EAP79FH6]4\DM]R]S'1I>JQK8^Q8].%[::%JJD?$G0YRN<_35
M.+A54")E-P0 4UHN0OP/)*?(?U@<?85S*_P;WFTUX)DEX./P]=-=-->'ZP6M
M7*"K\*VG\,HZBDXN#MXGQ<>FNG&U6ZZ:IKIJ!2?^'E_^,?\ \$_^^ 6M/X>7
M_P",?_P3_P"^ +7>X+R,[8XU6QW'**^LRN:%4<RDG1M'0JJ+JBOBB5SW:='0
MLO"O=10BU9ZGIZ>DIXJ6EB9!2P,;%!!$U&1LC8G"UK6MT1$1$T1$"'Z
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MG0BHBJBD3*=@@
M                                       1'OAR_8OOC36M+O5S6NZ6
ME[_![E2,8^1T$J=_"]']"M5R-<GH*G1UJ$Q*2L?MM39K%;;165\ETJJ"FBII
M;E.B-FJ'0L1G:R(WHXG::NT[H0]("/-Y-K&;PXDW#JJ]U-EMKZF.IK'4C&2.
MJ&P:JR)_'T<*/X9/\IJ!,/7VVV^L>U^&VW"\?:Y:&WL7M*B33M:B>1>*6:33
M[9[EUT[B:(G0B!#K                        #@MWMI\>WCQ"3$[^]],C
M9HZJAN$"-=/33QZIQ,1W0O$U7,<B]Q?1T"7V[7X([;3"K=A27:>]4MKXXZ.K
MJV-9*V![U>V)>#H5&:JC?Z.B=P(=@   0CC_ "UV"V;OUN\M[O-7?L@J)IZJ
MEIJJ.-D%--*G9QJWAU5R0Q?<XT=U="]:($VIN"
M       "%MY>6_&MX+[:,IENE5C^1VAG9,N-O:QTDK&/[2'BXNIT3N)6.3IZ
M?J:$Q*9*:.:*GABJ)>WG8QK99^%&=H]$1%=PMZ$U7IT0(?J!%6^&RD&]UJM=
MCN.05=FM5NG?5R4U)''(E1.K."-S^/\ U;5?PZ?SU]()B7>8EB]GPK&K7BE@
MA["T6FG934L:KJY6MZW.7NN<Y5<Y>ZY54(>R
M1?O9L=C6]]CH;7?*B6WUMLG6HH+G3-:^:-LC>&6/1_0K'Z-54]%K5"8EV6%8
MY-B.)VC%Y[E-=W6BF91LN-2UK)I8H>]CXT;T:M8C6Z]W35>D(>\  +KHNG7W
M (1VOY:\?VZSNZ[CUEYJ\DRNY]L[PRN9''V4M6]7U$C4C^W?KPZ]QNJ=T)M3
M<$
M
M
M
M
M
M
M
M
M
M
M
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M^EHOMDR"F?6V&Y4MUHXWK"^HH9XZF)LK41RL5T3G(CD1S5T]- /0
M                                #SKQ?[#CT$=3?[I26JFE?V<4U=41
M4S'/T5>%KI7-15T15T _RSY%C^112S8_=:.ZPPN1DTE!41536.5-41RQ.<B*
MJ>B!Z0
M
M
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M-K<LVCV\N>-YC'!%<ZJ]3W")M-,D[.PDI:6%JJY$31>*)W0"4YA
M                               (#YKMILPW>PVRV3#8J>6NH;FE94)5
M3) U(O!Y8^A51=5U>G0$P^7E-V?S/9_'LBMN9Q4\55<JV&HI4I9DG:L<<7 N
MJHB:+J"5A@@
M
M
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M5#\FWNWWY@LS7'\+GN%'2UCWI;<9LL[J5C:=O3K4S-=%QZ)TO?,Y&(O4C>A
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MZJKWK-54M7'&Z1B=L]5>Z-Z,6/A<JZ.5JIHFNI$POX%0
M
M
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MTJ-5.CN*BZ*%Y:[!0
M
M
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M]N:%Y:\!0
M
M
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M1S>-J0-54U3IZ0FU8$(
M
M
M                        #\ZBG@JZ>6EJHVS4T['130R(CF/C>G"YKD7H
M5%1=%0"DVX7(/+576IN&VF0T]);ZASI([1>&RHD"N55X&5$+9'.8G4WBBXD3
MK<Y>D+6N'IN0?=Q]1P55[QZ&G1R(Z5E16R.5JIKJUO@;==.KOE:"U:#8+EDQ
MS9)\]ZEKG7W,:R'P>2Y/C2"&GA<J.='3Q\3U3B5$XGN<JN1$T1J:HI$RG4(
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MA?:5<#7,C?X5635*:([I31)4;]8$N_"
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M      >?2WVR5U7);Z*Y4M37Q<7:TL,\<DS>!='<3&N5R:+T+T >@!_CG-:U
M7.5$:B:JJ]"(B >5#E&,U$4T\%ZH)8:9J/J)&54+FQM<O"BO5':-1573I _'
MXZ8=\X;9X[3^S ?'3#OG#;/':?V8#XZ8=\X;9X[3^S _:3*,9AIX:N6]4$=+
M4J]*>=U5"V.18U1'\#E=H[A54UTZ@/Q^.F'?.&V>.T_LP/NH;U9[GI[VW"FK
M-==/!YHY>KK]0Y>H#[@
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MHJ+U*B@?Z
M
M
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MPK4-MU-6W!_:55!52:=BCIE55EIY>)O"Y7+PHK7-7@!,+U!4
M                 C3=K/+WA/O/[S-@=X=X3V_A#'/_ -#V7#PZ.;IZM=36
M,<Q.]T/]G\=G]W[K;?TLX6X;.X1<:?\ R?RV_P!G[;+)\_[OT_1&OZ]\W_U=
M#_L7_A#6.\NE^:GT?[MO[HZ%YZ_3' ?KWS?_ %=#_L7_ (0=Y=+\U/H_W.Z.
MA>>OTQP'Z]\W_P!70_[%_P"$'>72_-3Z/]SNCH7GK],<!^O?-_\ 5T/^Q?\
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M5.ONHP>->^CK*6X4E/7T4K9Z*JC9/3SL75CXI6HYCFKW45%U0*OW
M
M
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MXY>GZ@6A;S;'()\LVYQ/):M5=676T4-75.7NSRT['2^A]OJ%75@
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ML:!$I5"
M
M
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MZ@6A939&AJ+;L]@E'5MX*B.Q6Y9&=.K5?3L?PKKITIKHOIA$N]"
M                   $&\Q/_P"S?]^_^SFB;5_]KE_XND[%?][D?YH.-#=(
M       3QR\?V.__ 'VF];(;_LKQ;S=I]KF6VG'NMRKV)K-X<[   #/+<E78
MASQ4%TK7+%15=YLM0R=R)IV%7!3P/=T_:M=QM5?2]$+>1H:%0#Q+[F&)XO44
M-+DE[H;/47-9&V]E?4Q4O;NAX>-(UE<U'*WC;JB>B![$4L4\3)H7MDAD:CXY
M&*CFN:Y-45%3H5%0"K?/SYGK)^DM+Y!7A,)&Y5_,!A/N:H\LG!+J=W]P_P!5
M.W5YS[WM]]_>CP7_ .7]OX+VOA57#2_Z7LY>'A[7B]0NNFGIA"K'\0W_ /%Q
M_P"-_P#WO"UB?N7[?;]>MGO%V]X/>#WIJ8Z7L?#/#NT[2/CXN+L(.'3JTT4(
MF$PA"@F6?M_4_P )VG_D],%O(OV%0"@G[P/Y8X=\&5'E"!:%^PJ 5FYZO,I3
M_#E%[34!,.XY5_,!A/N:H\LG!+S.9C8&/>O'*:HM$L=)FMD21UJFF[V&HBET
M5]-*Y$5415:CF.Z>%WI.4$2K_BFXG.=MA0T^$/P6HR&"A1M/15%?;*JXI%"Q
M-&QMJZ":-CF(G4LCW:)T:Z)H$^!RV^VWVZM7@]1O%OI<6P9)4U-):L<QN!6=
MG2Q3*^9_$V-7,8O!&Y48CG.7I5Z\2: A<+E@I9J383!XITT>ZB?,B=/J)ZB6
M5B]/HM<@1*6P@
M
M
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M>)HY%%%!$R&%C8X8VHR.-B(UK6M31$1$Z$1$"C^P
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M=5"KU0
M
M
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M-VLBR=,:*B::]7JE,IH6'W6B1,7=O]WG8?$,4O\ 3IIF]L_M\5D6>-T)D6*
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M-54U5(V-UZ-==$"+4H!
M
M
M
M
M
M
M
M
E                                              #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>tm2227887d4-lc_ct1119a5494c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_ct1119a5494c.jpg
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M /   0 " @,! 0             '" 8) P0% @$! 0 !!0$!
M   ! @,$!08'"!   0,"! $%!@H/$@L&! $-  (#! $%$1(&!Q,A,2(R"$%"
M4A0W"5%A<6)R(Q6U=A>!D:&"DJ(STY2T=9465QFQLD-CD[,D=-15A<75-E9'
M&#C!T<+24W.#H\,T5/#A1(0E-?'BXZ5DY2;R94:&QB>'2*1%9Q$!  $" P,'
M" 8)! ,!  ,   $" Q$$!2$Q$O!!4:'1(@9A<8&1L<$R$^%"@J*R%%)B<L+2
M(S,T%?&20S7B4Q9S@Y,D_]H # ,!  (1 Q$ /P"_P
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M5J3W@'@[;;W[9;OOW%K;R^^[#EI2RY<*>)RX=6T2<]$?\VRU56-4*Z@$E@
M$>;D;P[=;1-0)>X=YK9F+FMUN OQ27+HXIFB:K_Y5EW+AF3U\/S0/3T'N#I+
M<W3S6J]%7"MSL#[CK#,S@O1\SC*\BZ9)"&E\_K, ,P   ,%UMNEM]MLRV[KO
M4L*R4?2M<=F4[A)>0UUE-LHI5Q>'HH0!A=@[6/9YU1,I;K5KN&F2Y5*$4GLR
M[:BM5_IDYAI'S0)I0XAQ-'&ZT4A5**16E>2M*@<H
M
M
M     1EVBO(1N1\';E]K+ H%YO#R[3O@[-^VH8&QG4FXF@-'2686K=56>PS'
MT<6/'NMPC05N(QRYDH?<;JI-*\E:T \O5V\&V.A;)#U'JK5$"!9KBS23:Y-'
MO&/'&<E%\2*ACB.2$52I.*VD+ITD^D!Y^A.T%L[N9-]S]%:MB7"Z5QRP7$O0
MI*^7O&9C;2U^CT.0#Q.T=H':O</2MLM.[FJ*Z5L46XHE1)WC\.V<65P7F^%1
MR>AQM704I>1%,W1 YNSOH/;#;O1,ZR;2ZGKJO33]U>F2+CX]#NG#FKC,-K9X
MT%#:*8(0VK+7I=+'OJ 34!'FYNZ&E-H=*/ZQUD\^U:VG&X[28K2GGGI#M%Y&
MD)IR8URJY7,B0-9G:$[26L]_ZJ:CV]RT[=6>0E;4!%5.TJ\YF0R]->I3)G72
MBN&BE<J>EUJ]*H6=\VUY/]9_=AG[50!=D        !7+MS_W;-4?MBU^^# $
M ^;/_P#==R/VO:/S\P"Z5ZW4VSTS<W+3J765BLMU:HE;D"Y7.'#DT0Y3,BJF
MGW$+I2M.;&G,!T=P=Z]K=K>&C7NIXEIE.)HM$+%R3+JGN+\6CH=>R<G7R ?N
M@=YMK]T4N?@'JB)>'VTYW8B,[,Q*.7!2HSZ6WJ)Q[O# P?M(;;;/[CV^P1=X
M-84TC$M[TARUNUN4"U5D..H;XB<\]MS/ERIZ@&4;#Z/T!H7;^-I_;'4'X2Z2
M:D2'(]U\;BW',\XY6KB>-$0VW7(KN4H!*P #QK]=$6.Q7*\J:4^BW1GY:F4=
M==(Z%N9$_0\@&IK1FW^X7:6WUK#UZ],MURNZI,^]39;#B51H<;K-1FG^JE&=
MMAI'>9D@2GVD^QCI?:?;F1N#HV]W"0S:7&$7:%=JLO9DRGD,(4RIAEO+@M::
M95YN?K 2GYOG<J]:FTAJ#0EYD.RV=*.PW+,\\O,MN'.H\FL>E:\S;:FJ51R]
M_EIT4TH!=@
M
M                                   (R[17D(W(^#MR^UE@4"\W?Y=I
M_P '9WVU# R#SD7E+TE]P5?;CH'J;$]DSX^-%VO<?=C5%S\4>AL6K3-OMBV6
MWF;9:?V&SG6^PXA*?:E9&T-^O4M2U* KCO/MU<M@]WIFG+5<7W'+,[$NECNR
M4\%ZB%Y'V7.[@MM?0S>&D"WO;MN[NH.S[MU?7DY7KG<8,U:4]Q<BV/NX?(S
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M#20Q1_AKZ&->@^ROJ^ L"W'G*OYN;?\ [>N/ZRR!)_8*_N[VO[I7']? LV
M  -</;<[2-FU:A>S^AY-)=KBR4NZFN[:L[#\B+CDBM5Y<R4+Z;B_#2G)WV8)
MZ[%.SMQVQVU?O.HF:QM2:Q<9G2(JDU;=CP64*\6:<IX=>(ZYS4RY\G.FN(6D
M
M
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M/8=!V0CZ!M7+TEY%I"Z@
M
M                       \NYW6W6:"[<+M,8MT%E.9Z5+=0PTA/KEN5RTY
M?1J!YNG-:Z0U<V\_I/4%MO[#*J(>=M,UB<A"J\U%<!:Z)KZ50,F
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M
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MTNII3VOH85[Y*:@;-8DIF;%CS8RJ*CRFT/,J\)#B,R?EXX@=L
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MY^^R_( EH
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M@&:@
M
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M*K=6*JD0WJUI1Q?HNHHGIHR\O634"=FTJ2VE*U9E4I2E5>C4#D
M
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M[GP*!>;E\MU_^"TOWPMX&ST
M
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MM]XW8C.,ZD7(>;8=DLTB2I,)NJ."\\SD:R+KTL,$]-"4K[X";P
M          4F[3FYW:;TIO!9;+MA!F*TT]'C*MS42WHG1[C*6NO&2\Y5MS)6
ME:9*ISHJA'2[[,!=%E3JF4*?31MZJ:9T4KFHE5>>F/= [
M
M                                                           $
M?;Z^1#<KX*WWWN? H'YN3RW:@^"TOWPMX&ST
M
M                                       =6F+5,JU9J5]+ ;X,>F7E
MW74=DLM4-7*>Q$<73%"9#B6\?4S&OO9O+VOCG#ULRUD\Q>_I435YG67K;1V-
M*_A!;\*>A*:_SB:LU9QIJXO:C\G?W<,[?(?AMHZM*5K?[?\ 937^<5SF;41-
M7$?E+V[AEW+1=[7=D*7:Y[,YENN#E8ZJ+I2OSI7:S5N[\,J+^5O69_F1,>>,
M'IN5KEQI7!7<+U45<RSYG8*U(
M             "/]]?(AN7\%;[[W/@4"\W)Y;]0?!67[XV\#9Z
M          "'>T'O4UL1H1&LUVI=XD29K5LAPN+P$5=>0X[F<=R.94Y6E=SG
MP YM@=WX^]^WS.MH]K79GO&G8$V#5=74(?C9>5#F1O.FJ5I[SDKT>=($N
M                  JCOIVQ(.RFXT70JM,NW=EEF/+N\_QGQ9:$2*UKDCM\
M-VBZI17/TUH\'TP+3L/(DLH>;QRN)2I-%4PKA7EIC0#G
M
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MT-C*6[/P^]SN:SU_,3C=G'U>Z'O.4KEPI3E[G*7ZN+F8L;-SL%:D
M                                        !'^^OD0W*^"M]][GP*!>
M;D\M^H/@K+]\;>!L]                    !C.J-'Z;UM:'+!JRV,7>S/+
M2MV'+11QM2FZ]!6')TJ84YJ@<NF],V'2-GCZ?TO;F+59HE*ICPXJ.$TG'K<E
M.^]=7E],#(0                    8-J7:[;[6EY@Z@U1IN#=;W:ZII!FS
M&$NNMI:7Q$)]<BB^E1*J@9R
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M@MJ-M=3P=(:SU&U;;W<:(<0PIIYU++3J\B%ON-HJEI*JTQZ=:>%U );I7$
M
M                  P#=SR<WS_ROVVR:'7O[&Y]G\5+I?#7_86OM?AJ>OHG
M^:-@^YT3]90;/(_T*/,TV>_N+G[4^UE!EL,
M                          1_OKY$-RO@K??>Y\"@7FYO+=?_ (+3/?"W
MA#9Z$@                   19O7LY8-[]&TT;J&2_";:DM7"#-B43Q69+2
M'&Z*R+QHI-4/*1E],#FV;VEL6RVBH^BM.N/R(Z)#LR5.DT3QGY+N7.NO#P2F
MF"4(HGP4@2:                    "N.[_ &2-!;Q:]BZZOL^? F);8CW*
M-"JWDEM1JTR8K6G,VK+T*J37FI0"Q#++4=I##*:(:;IE0FG-2G-2E .8
M
M              !@&[GDZOG_ )7[:9-!K_\ 8U_9_%2Z7PU_V%K[7X:GKZ)_
MFC8/N=$_64FTR/\ 0H\S39[^XN_M>]E!EL,
M                          1_OKY$-RO@K??>Y\"@7FY/+?J#X+2_?"W@
M;/0                    <+SK;"*NO*HVTFF*UKK1*:4IW:UJ!^-NMO-I=
M;5132Z9DKI7%-4U[M*@<X                    .LX_';<;9==0AQVM:-)
M4JB5*K3N)I6N-?D =D
M                                      P#=SR=7S_ROVVR:'7O[&Y]
MG\4.F\-?]A:^U^"IZ^B/YI6'[G1/UA!L\C_0H\S2Y[^XN_M>]E!EL,
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ME"%KJZM*4I4XKG56E.57R0.P
M                                           P/>+R>7?_ ,M]M-'/
MZ]_8W/L_CATWAK_L+?VOPU/<T17_ /,W3WW-B_K*399&/Y%'F:7/?W%?[4^U
MD!G,,                                                   1_OK
MY$-RO@K??>Y\"@7FY/+=J#X+2_?"W@;/0
M
M                                     Z,NYVZ#5*9TQB,I?52\ZAO-
M]%S@8!NU>[/(V_NS#%PC.O*\7R);?;6JM*26NY2IHM>IF<C7A^K^*'2>&?\
ML+?VOPR]C1E\LS6D[$VNY1$N)MT6BT*?1R5X*/75-EDH_D4>9IL[/_\ HK_:
MEE,2=!F)K6%*:DI3UE,K2YAZ5:IQ,MB.X
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M;>4FF=%*YJ)57GICZH0[
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M:X9,4JK0ZJU>B_3Q.,N6ZLO_ "IC#!FSE$J:JBM.CR<G*(KB9P.#'8[!6@
M                                              !'V^OD0W*^"M]]
M[GP*!^;E\MNH/@K+]\+>!L]
M
M                          '3XE4J31-<4J_P$SNQ4SC3."LF[FJ9%_U*
M];FG/_3K2XIAIM/?/4ZZ^YWW0^0>8ZYJ$WJ^#FCET/8?#>G4V+,7)WU(QO>/
MN;(]#H?,6DIT"NJ-2MU8;>]^"I<\24T3IERG']'\<.Q"K7Q*+R<G!1^<-5GJ
MYG-5U<^+:Z933^4HIQYDO;(:JDVZ]?@Q*7G@SZJ4PFO)PY"$Y_IT)_.G2:!J
M$Q5\N>?ET.6\5:?3<H_,4[XWK#X)4K-CA6O-3EJ=]A%.UYAMG:[!4
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MI.;%-<*\O+0#L
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MK>[75-(4V8REUQNC2^(A/-TD47TJ)54#.0
M                                                   ,=U#?K1I^
MVKNMU>HU%;QP[JW%>"A/.I7(8=[,TY6,:MS(L96K-5131O5=U'=96N-42KA
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MXT0XVQ5AYY#+#J^&A3[C:*I:2JJ:]>O)UNH!+M*X@
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M$WSY4T;Y?D@3MYLO^M'^ /XR O\ @
M      $?[Z^1#<KX*WWWN? H%YN3RWZ@^"LOWQMX&ST
M   $6;U[.6#?#1]-':ADR(3;4IJ?"FQ*)XK,EI#C=%9%XT4FJ'E)R^F!S;.;
M26'9;1,?1.G77Y,=+[TR5.D9>-(DNY:+77AX)32M$H11/@I DT
M          %<=X.R/H'>+7L77-\GSX$RC;,>Y1H7#R3&XU>A6JUIS-JR]"JT
M=S "Q#++4=I##*:(:;3E0FG-2E.:E .8
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MH
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MYN-M-I'6<A:79USMZ/'W$=54V/6L>37#'"GMK2^Z!)0
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M) [
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M0W+^"M]][GP*!>;D\MVH/@M+]\+>!L]
M
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M(CP(;:&(D=NE4H;::31"$)IW*)33 #TP
M          !'V^OD0W*^"M]][GP*!^;E\MNH/@K+]\+>!L]
M       ! 7:KU)NKI/:M^Z[1,OKOOCK+5R?AQ_&Y42WY'*NNM-50YCTD-HS9
M*Y$*4KDZR0[W9AU#N?JG:FWW;=>.\QJ5;\A+#LMGQ65)A4R\%YYFC;>1?*M%
M.ATT42OO@)O                    !27M-[D=I[3&\%DM&V$*<K3#C,9=M
M:A0$2XUPE.+K1Y$E=4.>PJC.C(CI^N NDRIU3*%/)HV]6E,Z*5S42JO/3'N@
M=@
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M)?I[5#DO^(RU5[N#$OAN?2 2BE25IHI-<:5YJ@?0
M                   C_?7R(;E?!6^^]SX% O-R>6^__!:7[X6\#9Z
M
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M9=&Y/>1F\BJ*6E."^FNG@>N M0P\F2RA]&.1=$J3FI5-<*\O+0#L
M                                                        ?*E4
M33-7FH!5S<7<BX:CGNVRU/U9T\S7ATHBN2LBOAKK7ER>L/-=5U.<Q-=-/P[.
M6YZWHF@V\M:X[T=_V>J4?5313B<O+5..-/5H<W335%%4SS8=;KZHIFC"K=+L
M19T^"IQR)*=8H\A3;J&EJ3F1X*JEVC-W*:>"F<%FY9HN5854Q.'/]"2]H]OK
M=J%3FH;HM#\:,[PVH%,:XKI@K,[R]7EZO?'3:#IL7)X[FZ.72XSQ+K-VU'R+
M<88_6]V&'7BL2VBJ6TI^8=_,Q1LI>81C/Q/O)6BJYJ]'T,!&%$8RIPF7.7
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M'1ECUM::53;[Y$:FM-*5G6W5Q-*K:77PFUYD5P\$#+@
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MJC3=ON]\MF'B,^7'0\ZU@NBT)YJYDH7TZ45U>YW0,Y
M                                              Z]<$THNE.1./\
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M,L#7[YORMBM6[VI+9?FJ0=7TM:HUKC3$U:>2MM]/CK*4.88.]%.*<,^1*O7
M;,0*!><=N>FJQ]$V1*VG-8,+E2E(3DXK-L=HEOI]U*7'4TX?L% 66[,.D;GH
MC8G16GKPVMFYLPW9<B.XGAK:7<I+T[AK36E,%(H]DP F<
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ML/.H99=7PT+><;15+25537K^RZ@$NTK2M,: ?H
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MW.!;_L,[O;D;L*UXK<*^N7JMJ]R/<[B-1V>#XUX]1W#Q=MKK5:1S^"!<L
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M4:5.6^IF$TM]:4<2"TFJ\J.ZM('L>;D\M^H/@K+]\;>!L]
M      !%N].SVF][M&TT=J1^1$9;E-SX4V)5'%8DM)<;0K!?14FJ'E)R^F!R
M[.[2Z?V7T7&T5IQU^1%0^Y-F3)54T=?D.Y<[E>'2B4\B$(R^"D"30
M             5RW>[)6WV\6NH>N[[,N$*71#+%VAPEM\&:S&KT*9EHJIM6'
M0JMOO?!ZP%AV66H[2&64T0TVFB4)IS433FI0#F
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M?Z%V+[V0_K0&![MV30>WVVVIM;6W0NGI<VQP7)K<:1;8U&G%M8=%>1NE>[W
M(Z[&V]'QO?AI7\#['I.EG]R__8(WBWC/C7CGU;PLG!Z'LE 6M
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MS;3\E65AIQ:4J<KAC@BF.-:^D!W
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MR4Z'$R@20      "/]]?(AN7\%;[[W/@4"\W+Y;=0?!67[X6\#9Z
M            "!^U'M5J_>/:]>E-'SFX=T1/CSUQ93BF69C+"%TK&6MO'DJM
M:'.7HYT)Q\*@=OLS;8:IVDVKAZ/UC.;EW=N5(E49CK4ZQ%:DJI5,=M:Z4JI.
M-%+YL,ZJ@3:                    "EG:5[+^Z>[.[5JUEI.^16+.EB-&H
M])D/-/VMR.NJU.,H;3TL:]-.2N?/X/6 N6PE3;"&W%U=6A*4J<KABJM*<JOD
M@=@
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MZBC_ ! <C$.)%Q\68;9S<JN$A*,WJX4H!V0
M            "/\ ?7R(;E_!6^^]SX% O-R>6[4'P6E^^%O V>@
M
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M>W?:K9 R4D
M $?;Z>1+<OX*WWWN? H'YN3RW:@^"TOWPMX&ST                    $!
M]JS4NZNE-JG[MM(R^Y??'&&[D_#C^-RHEOR.5=>;;JASOD-HJK)T$J4KDKTD
MAW>S)J/<_5&T]LNN[,9V/J5V1(1'=E,TB2I$%-:<%YYGAM40JO2I3H=)-$K[
MX";P                    4F[3>Y':>TSO!8[/MA!G*TRXS&<MK4. B9&N
M$MQ:N,W)75#GH9<F=&1'3]>!=%E;BF4*?I1#RJ)SHI7-1*J\]*5 [
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M?5D8M_&\6E/+\%IJ11M:_41B!*
M      C[?7R(;E?!6^^]SX% _-R>6[4'P6E^^%O V>@
M
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MU#6/41^>)$GD     (WW[\D^H/4B?;K &1[>_P P-*?<>W?:K9 R4D
M   %*NUGV7=R-[]R+7JO1\BUL6R'98]K<]T9#S+G&:E2WU8);9=IEHEY/+B!
MC,GL'5C[.19$%Q<;?:TIDR^/;IBUP)[[4I:X[2/&*-<)7!X:&W$9,J^N!<+;
M*/KF-H2PQ-R%M/:U8B-LWAV(YQFW'FNA1W/D1[8M%$J<PZ.?'*!G(
M                              !'^^OD0W+^"M]][GP*!>;D\M^H/@K+
M]\;>!L]                    !#?:%WI3L3H).LJVI5WE29S-KAPN)5AFK
MSK;SN9Q>1>5.5I7R< .?8'=YG?';UC6\>UJLS]9+T"9!4NKR$OQLF*D.9&\R
M*I4BO-R=7O0)=                    !4_?CMC1]E=QHFAOP97=V&V8\N]
MSZR*1UI;DUKT(S>15%+2BM%]-=/ ]<!:AAY,AE#S>.1Q-%)S4K2N%>6F- .P
M                                                   Z$BLAIE:H
MR:.O4HJK2%<F*N4HKF>'N[U=$1-4<4X1YD8KO>_-*8)TS;JI[OMK5/S9ISE5
M[4HJGAM;/VJ'449+2II[V8G'_P#.MX;&M]V7K\]IIFRV^MUBM\=<7%/1;KEK
MUZR<O?I[IBTZCGZIX(MXU?M4_P"C-G2-+HLTW9O3A..WAJ>RU=MZZ/-)?T]
M3&4I/'4EUNM:(^S*U^49-.;U+_T_?H84Y/28HJ_GSCS=VKL2[6E,$T] Z29P
MERN]\U[M$TQK4KFG'>IXD$;N;B5:<?TE9'ZYD]"Z2FZ]3])3W:\W3^A\(X?7
M=4_XJ/3Y?7',]"\.:'%>%^[&,?4CS;YV3[39_;BN+6K+TW@FG3M45=.;"OU9
M=?D>UX^R\$IT32^*/FUQOW<L3Q%K,XSEZ*L<-E<]/1&[9AY-Z?#NGGP   =9
M^0Q%86_)<2TPTG,XXY6B4)1ARYL>2@%<MVM<Z2NFM=OY,"[1Y<2RW/CW20RK
MB(91QH:\^=O'-U%?4\>J3@A.UAU7I[4K%9%@N4>XM)PXG 712T>S1UDU]F1@
ME'&ZN]ENT8EZR6*J)VI^5"TXYV8F/^EKCRK]93YX8"!](:'UEN_?G[I*D.^*
MN.9KA>9'30FO@([BE>L1U/6 6UT?HNPZ&M:;78V.&W7I//JIF>=<\)Q?=J!E
M0      (WWZ\D^H?_)_;K &1[>_S TI]Q[?]K-D#)20      !2#L_\ ;JL^
MHU1-+[R.,V6^8<)G4Z<&;;(7_P#B4?\ AUUQZ_U+_5TPH!=EMUIU"76E44TJ
MF9*J5Q35->[2H%0NT%VV--[?UF:5VS4QJ+6;2EL2[@I55VR NF./2I_S#O<R
M-UR)[Y71J@"4^ROJG4&MMC=+ZKU//>N5[N;MU>G3)-<5K<I=I:*88<B4(0E*
M$(12B$)IEYJ4 G                                        1]OIY$
MMR_@K??>Y\"@7FYO+=J#X+3/?"W@;/@                    8YJ72>G-9
MVAZPZHMD>[V:1EJ["F-I>955'*E6%<>E3N*Q Y-.:<L.DK4Q8=-6YBTV>+2M
M&(,-M+3*<U:J5@E')C6O+Z('O@                    P;4>V>WVK;Y;]1
MZHTW;[M>[96GB,^9'0\ZU@NBTIYJYDH7TZ45R)YZ=T#.0
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MWZ4TO"3;-/VQNC4*"W52TMI4JKBNDNJE*4M:U*6I=<RE*K6M0,H
M                              $?;Z^1#<KX*WWWN? H'YN3RW:@^"TO
MWPMX&ST                    &$;@[CZ3VMTVYJS6UPI;K.TXF/1S*MY;C
MSF-4-H0WBI2JT2JN'H44!RZ"W!TMN9IJ-JO1LZEPLDI2T(?R+:4E;?(I"T+I
M1254 S(                    $1:^[0>T^V>J(&DM::C;M]\N-$+;9JP\\
MAEEU?#0I]QM%4M)55->OS=;J 2YC2M,: ?H
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M/Z:UY?VF6KQ=42DRTQ**2S5<*8]$SI2NM<N?A47AZ?H 2N
M                         (^WT\B6Y?P5OOO<^!0/S<GENU!\%I?OA;P-
MGH                    (MWHV>TYO=HVFC=22)$5EN4W/A38E4<5F4TEQM
M"L%]%2:H>4C+Z[G YMG=I=/[+Z*CZ)TXZ_(BH?<FS)DJJ:.OR'<M%N5X=*)3
MU4(R^"D"3                     5RW?[)6WV\.NX>N[Y,GPI61AB[1(:T
M<&:S&KT,5+153:LO0JMOO?!ZP%AV66H[2&&4T0TW2B4)IS4IS4I0#F
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M(>1)2XW(GR'EIH\UT%\-:U-<E.7*$I,"
M           C[?7R(;E?!6^^]SX% _-R>6_4'P5E^^-O V>@
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MVKAZ.UC/;EW=N5(E49CK4ZQ%:DJI5,=M:Z4JI..9SFPSJJ!-H
M         *5]I7LO;I[M;M6O66D[Y%8LZ&(\:CTE]YI^U+C+JM3C*$)Z6-:Y
MTY*Y\_/EZP%S(Z%-LH0M=75)2E*G%<ZJTIRJ^2!V
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MGP*!>;D\MVH/@M+]\+>!L]
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M//-IKQ7<N/1XB\R\,>^ S0
M 1]OKY$-RO@K??>Y\"@?FY/+=J#X+2_?"W@;/0                    0'
MVJ]2;JZ3VJ?NNTK+[E^\=8;N3\-CQN5%M^1Q3KS;=4.=\AM%59.@E2E<E>DD
M.[V9-1[H:IVFMMUW9C/1]3.2)"8[TMFD65(@IK[2Z\SPVJ(57I4IT.DFB5]\
M!-X                    *3=IS<CM/:8W@L=GVP@SE:9<9C+MK4* B9%N$
MMQ:^,W)75MSFPRY,Z,B>GZ\"Z+*W5,H4\FC;RJ4SHI7-1*J\] .P
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M&IRG>KVS[.N7 :AXAOYNU\NC93._=MZH2S2GHUY3I'*OFE4UQJ1/=3CB^R0
MAG>/=MC1$-RQV5VCFK)B*8*KTD0FU\E'%X=_6GU-'SWLI$.[2;5S=PKDO46H
MJN?@XT]FD.N*75<U^O70A6/ZHO\ [)"WD:*S"9;C16TLQF4I;::12E$I0CF2
MFG)A2A [@ "$=[/Y_P"TWW8K]MP"1-Q          .C+MENG52N="8DJ3U5/
M-(<R_18X </X.:?_ 'JA_8S/^: _!S3_ .]4/[&9_P T#L1(,&&FM(49J,A7
M6HRA+=%>G6B:4 [@    Q_46H['I.U/W_4EQCVFS1,GC-PFNI98:HXM+:,ZU
M\E,5J2CU5 8E_:)V)_&/IW[YQ?K@#^T3L3^,C3GWSC?7 ']HG8G\8^G/OG&^
MN /[1.Q/XQ].??.+]< RW3VHK'JRU,7_ $U<8]VLTK/XM/A.I>8<X:U-KR+1
MR5P6E2/52!D                                        C_?7R(;E_
M!6^^]SX% O-R>6^__!:7[X6\#9Z
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M_M7C])C++B'T)\9GR)*.FWBFN*'4^B!,0
M            C_?7R(;E_!6^^]SX% O-R^6[4'P5E^^%O V>@
M         ASM";TIV(T$G6-;6J\2I4YFUPX/$X#-7G6WG<SB\J\J:):5W/!
MYM@=WV=\-O6=;QK4JS2*RGH,N"I=7D)?C9,5(<R-YT95(KS>M[T"70
M              5/WX[8L?97<:'H;\&EW=AMF/,O<^LBD9:6Y-:]",WD512T
MHK1>*UTQZOK@+4,/)D,H>1CD<31::*IEKA7EY: =@
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M1<6S6.V:;MD:S6>.F-;8J<C+2?FJQIC6JN[6M2D>R
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MRM/$9\MA#SK6"Z+0GFKF2A?3I17(GGIW0,Y
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MU=/:8D7P$(_6T?\ SK M_I;2UGTC9X]CLC/"B,)PQKRK6OOEK5WRJ@9(
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M6J(&DM::C;M]\N-$+;9JP\\AEAU?#0I]Q"*I:2JJ:]>O)UNH!+E,*TQH!^@
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M_P -!A?YJ/IU^R MMHG1-HT+9&K-:44K2F"I,E5,'GWO](NM.Z!EH
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M;0PRFB&FZ42A-.:B:<V ',
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MD
M                (^WT\B6Y?P5OOO<^!0/S<GEOU!\%9?OC;P-GH
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M&^+X P%P]IMN[/HFP-.Q7FI]SN32)$NZ-<J'$.5HXA+.'Z%ART\+G*)2DX@
M                            (LW]W#N6U&T]_P!P;3$8G7"R^)U9B2<_
M!5XU-9B*SU;P53!#JN:H%)_RD6Y7]$;%\N9]? _?RD>Y7]$;'\N9]? ?E(MR
MOZ)6/Z*9]? ?E(]R_P"B-B^7,^O@77V"W$N6Z^U%@W!NT1B!<;SX[5Z+&S\%
M'BLUZ(G)Q,55Q0TFO+4"4P
M!'^^OD0W+^"M]][GP*!>;D\M]_\ @M+]\+>!L]                    !
MW:CVJUAO'M<O2FCYS<.Z(GQYZXLEQ33,QEE"Z5C.+;QY*K6ASEZ.="<?"H'<
M[,VU^J=I=JX>CM8SVY=W;E2)5&6'%.L16I"L:1VU+I2JDXXN<V&950)M
M                !2OM*]E_=/=O=JUZSTG>XK%G2Q&C4>E/O-/VM<==5J<9
M0A/2QKTTY%9\_@]8"YC"5-L(0M=75H2E*G*X8JK2E,5?) [
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MR>6_4'P6F>^-O V>@
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MZ]FS0FH-L=F-,Z&U0AIN_6KQZDM$9SBMI\:GR)2:47AA7H.IY@)?
M                         #Q;Y?;+INVOW?4=QC6JU,4]NFSWT1HZ*5\)
MQQ5$\X'B:9W,V[UNZ[%T;JJU7R8Q3,['MTUB2ZVCN+4AMRJLM*]T#-0  "/]
M]?(AN7\%;[[W/@4"\W+Y;=0?!67[X6\#9Z                    " NU7J
M7=32FU+]UVD8?<OOCK#=R?AQ_&Y42WY'*NO-MU0YWZ&T55DZ"5*5R=9(=_LQ
MZDW/U3M-;;KNS'>CZE<D/HCO2V:194B"FM."\\SPVJ(57I8=#!2:)7WP$W
M                   I+VF]R.T[I?>"QV?:^%.5IAQB,NVM0H*)D:X2G%KX
MS<ERK;G-ADR9T9$=/UX%TF5.*90I]-&WE)3G1CFHE5>YCW>4#L
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M>3']CF]<!/\ V7]4SM9[#Z(OMQ4IV<J$N"ZZZOB+<K;)+L'B+76O24ND?/F
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MH3S=;,&R8   C[?7R(;E?!6^^]SX% _-R>6[4'P6E^^%O V>@
M
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M7MCH>%MKH/3^A8"Z/,6*&F*I_+DXKW7>=R_ICBEKP]&H&:@
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M.'&O,!YY]]V \A"$(;>JM2U+K1-$TYP*@^;D\M^H/@K+]\;>!L]
M           !#?:%WI3L1H).L:VI5WE2IS-KAP>)P&:O.MNNYG%Y%Y4Y6E=S
MGP [&P.\#&]^WK&MF;4NSO4E/0)<%2ZO(H]&R])IW(W1:*I6FO4]%'>@2X
M                  "IV^W;%8V2W(B:$KIER[QVF8\N\SZR/%E);DX]",WP
MZT55",%=-?/T/7 6J8>3)90^C'*XE*DYJ85PKRTQH!S@
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M8UIF76G>^ GT 0S8 !"-B_O,ZG^X[7ZW# FX
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M/J9@M+?6E'$@M)JO*CNK2![/FY/+?J#X+2_?"W@;/0
M  8YJ326G-96EZPZIMD>[V61DJ]"FMT>:55%<4JPKC@JF'(H#DT]IVQ:2M3-
MATS;F+39XM*TCP8;:6F4YJU4K!*.3&O/Z('O@                    P;4
MFV>WVK;W;]1ZHTW;[O>[96GB,^7'0ZZU@NBTIYJYDH7TZ45U>>G=J!G(
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M5I+*:^CS) R$     (^WT\B6Y?P5OOO<^!0/S<GEOO\ \%I?OA;P-GH
M               ,(W"W)TEM;IMS5>M;A2WV=IU$=+F1;RW'G,:H;0A&*E*K
ME57#T$U"7+H'<'2FYFG(^K-&W"EQLDI2D(?HA;2TN-UP4A:%THI*J>F$,R
M                  !$6O\ M";3[::GM^D=::B1;[[<:(<2Q5AYY##+J^&A
M;[C::I:2JJ*]>M/"Z@$NTKB                              _*UH1PF
M)@1M# ;1\I52M,:4_P"U"=VQ&.+P=3:C@Z;LTB[SOJ3-*Y6Z=9:^]2GU:F%G
M<U3EJ.*6;DLI5FKD40K39[==]S=9*7(<KB^YQ[B^BF*68W<R_G&SSFQ9KU"]
MQ3T\NAZY?OT:3D\/11Y9Y^GS[5H($!JUPF8$)BC$:.VEMAI->JFG<[IZ=1;P
MHBCHAX[>NU7*IN5?%.]ZY>60    1/O!K;2,325^T^]>8U;U(BNL-P6U\9^B
M\.HM#?5^? ZNR^M])O:.L6G*7F,B^QV>$N XK@NY\Z^@CB89_G"<$.;=C=V!
MH&.JV6VJ)>JWT^UQJ=)$=NO+1;V%>3UB.[ZA K_H70&IMW+_ "+I/D.>YU'J
M5N]X>Z:U+\!'AK^D0$K>Z<TS9]*VMBSV1BD: Q3D1SJ4KNJ6KOE<G.![X #B
M==;8;6\ZJB6VTU4I5>:B<,:U PSXW]LOZ30_HE_X@A$EHUUH]C?B^ZC=O$=%
MCE6M#$>=F]I4NB(W0YO6*^4$I:1NSMRZXAAK4D-;SM<C:<RL:K]#F SD
M                             *R;R[W[)=FZ8EN%IN%*W!>:JY'M-FBQ
M8;K;+G?29*&Z<%"\,._57N)R@5[?\Y%KKQS/'T5:6X%*X59<DR''OHZ9*?[L
M"PFQ7;'T#O#<6=+SXKFE]92.6+;Y3J7XTI7@1Y.#>+GZ6MI./>9@E9L(
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MEQ?)UUXU ][;K9/:[:EIRN@M-1K7)?3@].Q<D3%IYZ(K(D+<<RUPZG$R@22
M     "/M]/(EN7\%;[[W/@4#\W)Y;M0?!:7[X6\#9Z
M  "+=Z=GM.;WZ._ [4DB1$8;E-SX4R)5'$8E-)<;2O!SHJ35#RDY?3 YMG-I
MM/[+Z+CZ*TVZ_(BH?<FS)DJJ:.OR'<F=:N'2B4]5",O@I DP
M        %<=WNR7M]O%KJ%KJ^3+A"F4;98NT.$M'!FLQE=#%2TU4VK+T*K;[
MWP>L!8AEEJ.TAAE%$--THE":<U*4YJ4 Y@
M ?E*\F(D=!Z[6Z.Y5E^6RV[3G0XZE"OE<A8F[$+D6YEQ^[MF_P"OC_JR/\8^
M?"?D5=![NV;_ *^/^K(_QCY\'R*NAV&)K#S276'$N-KI6M%H5F3R>G0N15C3
MQ**J>&KA5FW/UD[J^^HMMM55VU1'*MQ$M_\ B'Z]&J^:GL6__F/,M6S\YJY-
M$;HEZUH&F1E;7S:M\QZNM,FW.C6]&V-,9Y-*WB5E<G/4KSKY\OH944KA0[C2
MM/C*T8<\N!UK4YSV8XOJ1\'F]6.V=NUF]:)S8HK@E7(JN'H&WC?+0SLEVB0
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M[<K:726M)*J+FW. GQ]:>1%9L9:H\E5*?ZUM0$F
M                  "/M]?(AN5\%;[[W/@4#\W)Y;M0?!:7[X6\#9Z
M               #KOOL165OR%I:9;IF6ZNN5"4TYZUK7DH!^M.MOMI=:51Q
MI=,4K36BDJ37NTK3DJ!S@                    Z3TV)'=:8??;:?DJRL-
MN+2A;BL,:T13&E55P [H                            'Y6E*UQ(Q,&
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M/N%IOL/4^\K\:1'@N(D1=+1%>,MNO-UID\<>Y$9$5YV49Z+\/+F2H+]@
M                                   !'V^OD0W*^"M]][GP*!^;E\M]
M_P#@M+]\+>!L]
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MVS_=DUS_  3[\P@( \V7_6C_  !_&0%_P
M                $?;Z>1+<OX*WWWN? H'YN3RWZ@^"LOWQMX&ST
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ME<W(C''RT]L/7JM8RF2MQ;NSA_N]T2X_=^W?Z57T*_\ $4_X',_H==/\2/\
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M ZNS'DOTW^UU?KRP,]                   #I<.JJTK56>O?)PPS>AR]S
MMS\4*HQCGW(8WBE,)UCMZNKB:J:N.=Y5:X944DP\%*IWIOM.C&S=V\T>]P/B
M*YAG<E..&%5>/IX$RMN9TI51-*)KU54K11I)JJZ'>13Y'9K6B:4JKF[A&-4\
MR9F(<Q4@ _$\Q,HAYUSNL2UL^,39+45A/.Z^M+:/HE"(45UQ2P.Y[V[=6EJO
M#N/CTFG+1B&AQWDP\/#)3Z(S:,A=KG=@YS,>)M.M;KG%/DBJ>O#!@=V[2Z58
MHL=DK7P'YKO)] BG^6;2WHU4QOY>MR^9\=TT586[?%'3Q8=7"P.=N[N1J#.R
MQ/\ %U.TI2D6WQ\JZ]SH+I1:OE+,ZYIM-BJ(F,7.WO$^H7[G<GAQYHB)_=8/
M=(USC2%,W>,_&G*IQ7:24K2ZOB=/.JBS:6YCAQB=CF<WEKEB]A>C;.WZ=CSS
M(:L D/9JR2+KN!;5-I_8\#-+D*\%"$X(^6M:34ZI>B;#L?">4F_G8JYK>WW+
MA.5152$5YU8X<_<Y3AM]+WN9VX=+LE:  !7_ +;/]V37/\$^_,(#6]LKVA=<
M;$)O?X$L6]Y5_P#%?'ZW)EQZE*0>-P^'1MYK#ZNH"5ORA^_'_1:=^P9/[K ?
ME$-^/^AT[]@R?W6 _*'[\?\ 1:=^P9/[K OAV=MP;]NEL]IS7VI&H[=XN]9U
M9*(3:F6$^*SY$5%$(6MRO5:3W_.!+8
M         C[?7R(;E?!6^^]SX% _-R>6_4'P5E^^-O V>@
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M_*N9*JFB*J53N4Y>JGN'&YW.U79VO:M&T2C3[7#OGGGE+.TO-N8Y59E4Y>;
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M]55YZ=PXW5,Q%56#V?P;IU=FU-ZY]?=YN7TIX-*]
M                                            1]OIY$MR_@K??>Y\
M"@?FY/+?J#X*R_?&W@;/0                    81N%N1I/:W3;FJ];7"E
MNL[3J8Z7*)6\MQYS'(VA",5*56B55P];4#FT#N#I3<S3D;5FC;A2XV64I:$/
MT0MI:7&ZX*0M"Z44E5/3 S$                    $0Z^[0FT^VFI[?I#6
MFHF[??+C1#E&5,/.H89=7PT+?6TBJ6DJJFO7K3PNH!+U*X@
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MD9E-&V&TT2AI*<$T33DI3"AHIGCVO1XIX8\CO@
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MCR_XS51#M]M/,X%TD5ITT\G<Y:4$TT'%,_5ZWH$H
M                                           1_OKY$-R_@K??>Y\"
M@7FY/+?J#X*R_?&W@;/0                    ==]]F*RM]]:6F&TYG'5U
MRH2FG/6M:\E /UIUI]M+C2J.-+IF2M-<R54KW:5IR5 YP
M     =)V;$CNLLOOMLO2%98[3CB4J<5AS(ICTJX=P#N@
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M[3/[S6;]4;^O@2-H][5#UDC.:P:9CZ@6IWQIF-]13[8O)2E>(YCT,O=(&3@
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M57..#K<KEHR]$4Q.Y[Y2R0
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MR:.9,?I:G":O5QW7O'@^B;>GQCSS,]:554I3#Y)K>9V?/#E"
M
M   1_OKY$-R_@K??>Y\"@7FY/+?J#X+2_?"W@;/0
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MTG:[':]651[IWJ='9EMRGTTJF.MQ%*Y&D5Y**1X=>F6Y5)K(
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M_,+,,AR$I
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MBL\S;*<M*5K3T,>Z<U>O5USQ3.+U*SEJ+,1%,88/>(70
M
M$?[Z^1#<KX*WWWN? H%YN3RWZ@^"LOWQMX&ST
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M.5PB?UXV=2;33.U
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M,<EF,Y5=EZ[IGA[*Y';1'>Z=O;,)*,)T8
M
M          "/]]?(AN7\%;[[W/@4!\W+Y;M0?!69[X6\(;/@D
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M'#;Y^6*T2$(2Y52:=*O*NN/I<AR4/8.&/2[)(
M
M               C_?7R(;E?!6^^]SX% O-R>6[4'P6E^^%O V>@
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M#A[]_P"9+W71]*HR-K@I9K2M:KK2O-W3&AM<=KE"0
M
M                  $?[Z^1#<KX*WWWN? H%YN3RWW_ ."TOWPMX&ST
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ML'*]WD]'D)P-KZ3E32M>YW:A.&#[)
M
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M,O;X;41'F9$6V2
M
M               (_P!]?(AN7\%;[[W/@4"\W)Y;M0?!:7[X6\"_>Z&XL3;J
MR>/U2F1=I*ZM6Z'563B+[Y2O00BE<:@5 U+KO5>KY+DB^7-YYE74B)5EC-]S
MH,]0#S;5?;S8I"95FGOP'TJS9H[JT<E2Y@+0;-;QN:U?_!S4F1&H6F\\>2CH
M-RT,TZ=<G>+Y,_\ ^B4S G,I&,:JU3 TQ9KA<I$ABDB'&>?9CN.H0MQQINJT
MII2M<>G6@%"94J5.E/3I;JGI4IQ;KSJNNI;OMBUE2EP@ )1VIWA=VXAS[?)A
M+NEOF.(D,LI=X-&7^_7U'/JG1^A"4AN]JN.BB:,Z76NO?5<FT;P^5'<&"75>
M[5<FN7@:62G'PIV;\Q@8#KO=J>]*K[1IV,E/HJDK7_D4& Z3W:EU>I?[%M%N
M;3X+G&7_ );8P'6KVHM?X]&VVBJ?]1)_=12.A*[26Y4FJE-K@1$]Q+,?']=<
M= \]>_\ NFJM:TN[5*4YD4B1J_Y!3,<*[QTT[T>7"XR[O<)-TGN\:?+>6_(=
MRY,RW%\19<HE17<BMU2M0 =JW*4F='JC_2&LU*+=O)S52V6E6[OYR(KW>AE+
MMI@.*S*BHQ];T#RZUJN8IC")ZH['L=>CY6[,353UU=KZ8AQF*8QFTMHKSY:%
MF]G;ER,&9ELI1:VX=[EZ$E[8;>Q]84FR;FAVEJC4X3+C2^$JLFM>?-3"O03^
M>H='X=R5%RJ:KD8^OW.&\7YK"(HHJPK\W;L9L]V>;"]7%N[7%JN7DRJ;JGYJ
M3T.BBS3_ ,<?[I[7DEW)7:X_KU?[:/X73<[-5N6FO#U'+17],90Y^95!L;>;
MR]&^U]ZKZ6BO^'K]?PYF?311/8\N1V9)*$_L;4B7J]VCD1:*?KZS.HU:F/J8
M>GZ&BJ\%7</[C'[$?Q/'D=F_5[7+#N,)W_656U_@<,K_ #<1SS'HAKJO EZ9
MV78G[/\ Y(\UKHBY:.F,VF]M-MNR&JOL/L+4ZS7%:D=\E&&&/TQ@YV+>>IF[
M:V8-IIE^O0,U%G-;<O<Y^C"/)$U[_1M]$85(COQW,KJ<O@+[Q1SUJ[^8GY4;
MX>I7LM79IBNOX*MMN>GIV;_6X3)H[E"W9X:+W%7\57PQ]+THT-4>E'WDY5_H
M+7?^S&G6OS%S:TOB#5/\-1,U?W57PQU8[JJ-W+%-=J[.U^G1V)$ZYM0^,A"Z
M(2WQE)HY3JXYFZX?(.EG5;-.ZCKGL>=6/!68KIQKKB-G1],,AB]FJW)16DW4
M#[SG=2S'0UA]&XX8]>N4<U'7/8V-CP+:Q_F79G[.'[TO?B]G/1C&%9$J9)K3
MGHXM+=/I*4,>K5[T[FTH\&Y"/BB9],]KW6=E=M8U:5]Q^*NE.53K\ES'Y%7,
MIBU:AF9Y_8SZ/"^ETS_2Q^U7_$[E=L= U8<C-V*&VI2%HH[P:*=31RG+E4JN
M-%?)+7YNYQ8XMC.D9;AFB*852UAI6XZ2O$BR345JAI>,1_#HNL]ZI->YA7G.
MTR=^+E$2\+U/(SI^:FBN-G-S8QU\_6QLSG/OMMIU]Q+#**N.NJRH0FF9:E$3
M."NFF:IPC>MSM%H>5H[35:S4<*\7):9$M/(K(G#HM?.4P^>K4X'.WZ:JMFY]
M!^&M*G(9?AK^*=L\N6W%)5*+K6O=PI3E_P"XP=E4.ECXG[1E2>6BL:^I_P!Y
M&%*(B>E]Y54[HPI3MZ7#5#O$IPU96N[3_P")-48HGBQ1_NEMXUKBU(4RM,6^
MPLZH4BO22KB4P6TOUB^:O(9^5S4VI\CGM=T>WG[>&.%4;IY3"J-\T]?+#+K#
MN\)R(XE65"UTI5M?L%TZ"CL\M>BJ,8G%X7G--N9.<*XPY>EU(%NGSI-(EOC.
MR9*J8I0TA2E4]7(9%VN(C'%BY?+5YFKAHC&5D=I-J']*O5U+J1"47E;=$1(R
M55<I&2[A56*Z<Z^YS?FG(:CJ/SIX8>S>'/#OY+^;=^+V=<Q]"95*Y55KRUY,
M4\V-.<TLSA#N\)CO0[H0
M
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MC>@     <#[#;R<JTT6GP54S$J:HQ?$6''B(R,-):3X+::)^90$4X.T0J
M
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MEW&;;VKHPY;''76:,NO/,42JK[+"LV9A>/0] #;CL5Y$-M/@K8O>Y@"0
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MI@&WP                               U __ -[O_P#57_\ B,#;\
M                            :@>VO_>:UUZMI]YH8&WX
M                   U@^<9\MVG_@M#]\+@!?[8KR(;:?!6Q>]S $@
M                                     CO<+9S;7=1EEG7^G(UX4QR,
M259X\IM//E1(CK;>2BM>\HL#%]$]E_8O;RZMWW3>D6*7=BN:-,GO2;@IE?.E
M329;CJ$+YL%H1FQ FP    1_OKY$-R_@K??>Y\"@7FY/+=J#X+2_?"W@;/0
M                             #4%V)_[S>A?5NWO/, V^@
M                    &H'_ /O=_P#ZJ_\ \1@;?@
M            #4%VV/[S>N_5M/O-# V^@
M   &L+SC?EOT_P#!:)[X7 "_NQ7D0VT^"MB][F )
M                             !BFN]-*UIHK4FCT2?$OPAM4VTJG5;XW
M I.CJ8XO#SHS9,^;+G3CZ($"=G?LC+V#UM/UBC6'X05G6IZT5A>YGB&7BR([
M_$S^-R,?^7RY<G? 6F                               *=;,=A[XG]S
M+%N.K7?NU2S5E?\ IM;3XGQ/&H;T3ZMX\[ER<7-U*]4"XH
M                !3W^Q!__ #M^.#\._P#]JOPM]QO<?_\ 6'C_ (MXSX[\
MYQ.'Z[(!<(                               IWO/V'OC@W-OFXGX=^X
MM+S6+A;?<GQSA^*Q&8GU;QUG-FX6?J4ZP%Q
M      "K/:([(JM_=:P-9*UA^#_B-J:M%(7N;X_FX,B1(XO$\:C\_'RY<G>\
MX$]Z$TTO1>B]-Z.7*\=KIZUPK32=1O@\>D&.ACB\/,O+GR9LN=6 &5@
M
M
M
M                                              8%KS=?;S:Z,W-U
M[J*+96Y"5KCL/J6N2]1O"BN%';HXZO"M4]1 &%:2[5FPNMKFBRV;6##-SD52
MTPU<&)$!#BW,*)2AR0VVW55:\F3/F"4Y!
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M[U3<V[3;M9M1ICJJ):K<H\F RJO-]6D--MT^?6!.Z5)6FE:5QI7FJ!]
M                                        '5D2H\2.[)?71MAE*G'%
MJYDH;ZU?4PH!J,MK-X[6_:00S<I;\6)?Y3JLU:<1<"RP6UN(:0GE0A7"1D\'
MC*S=\!)':H[(^F-F]&P-<Z%FSY4"/):M][B7-QIY7MS?M<E"VVVLO31E<3Z*
MTY<O*!9;L0[G7'<':!%NODA4J^:3E5M*WW%9W7(>1+L9:L? 2I3/^S L^
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M$NK2\/ ;<C5I^?4!97L<3G[AV;-"/2>5Q+$Z.GT:MQKG)81]*BE )Z
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M6WT^H2+1'?57U[,G(GYCR@-D8
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MR52FO-6.MU3#<K M<9VO46ZWQGWTT]-%%LU^> O^
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M(69<B6[2G&E2G,*NO.88\JZ\W@HRIYD@2"
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    !3KMP;S[F;/*T-7;J]^XE;O[JTN-?%8<NKM(GB7!
M_P";9=RY>*YU,.?E J/_ &V>TU_3G_[39_W" _ML]IO^G7_VFS_N$!_;9[3G
M].?_ +59_P!P@6T[6F]>YNV&A-N[SHB^UM=SOR%*NLCQ6')XV$9ARG1D,.(3
MTUJKT,H&6=BW=77N[.@;[>]P;O6[W.%>50X\CQ>-$RL4BL.43DBMMHKTEJY<
M +.@               ,3UY<9MFT/J2ZVUW@W&W6N;+B/X)5D>CQEK0JJ%]"
MO233DY@*!]F_M1;ZZ^WKTGI#5FK:S]/7-Z2B=#]S[:QG2W#>=13/'BMK3TT)
MZBP-E
M
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M6?76I(&D=PK,WINXW-:&(%WBO\6 N2]U$/(<I1;5%5P0A6=?*KI9:=("Z8
M
M
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MJ13ZI[6XM%,?!Z*0NTRW1ENC2,V5%,*9JJ6KZ)=<:_) [
M
M
M           1EVB?(1N1\';E]K+ UG]B?^\WH3U;M[S3 -OH%%O.5?S;V_\
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M,M77GHR%J<P]?6N?D SX
M
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MAPXULB,0H3*&(45"6H["*42AMMM.5*$^E2@'H
M
M
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MI2%Q
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:]VF'(!S@
M
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M]O\ ^F=X_4(O^8!;[3MH;TYIZUV!EQ3S%IB1[>RZY7%2D1FDMT4OT^AR@>X
M
M
M                                     *E[^[DS+I>9&B[2^MNSV]7"
MN56U9:R)7?H77P&_ \+'UI7"$(%0%"%G>SUN9,O2'M&7U]<B;%;X]KE.5XBE
M,(K[8RM7=R5KBWZSV)$IA88A(     $8]HKR$;D?!VY?:RP*']GC92'O=V>]
M=V1I"4:LMEW3.TQ*7T*)E>)(]I6O#J/IZ"_G5=[0"3>PYOC*BR']@M=+<C7>
MU+D?@W29BVZFK2U5DV]=%]+.W6BEMIKRX9D]ZF@%ANUS_=RU_P#M%K[;9)&
M>;Y\@2ONY</SC! QWM[7Z?=+-H;:"PKS7G6EY0JK5%89D,53'90O"E>@X])2
MOYP"U^F[%!TOIZUZ:MB<EMLT2/ AH]!F*VEM&/R$8 >Z!K5[!']Y+6WW!NGO
MM  V5                             85J+<K;W24U%NU=JVRV&Y.M)D-
M1+M<8T)]3-5+;HXA#[C:ZIJM"TT5ASIJ!V=-:YT5K1<I.C]26O4-(7#\<K:9
ML:=P>-FR<3@+<R9\JL,W@J RP
M
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M#M?!]-:%/1D?*0MN9,]/ZE]"%X  &M7L$_WDM;?<&Z>^T #94
M     KSVE>TJOL[JTQFTQ34=-2>/<T_Q#@^(>+X_^%D9N)XQZWJ@8_V=NUVK
M?S6T_1J='?@_XC:GKOX[[I>/YN#(CQ^'P_%(_/Q\V;/WO,!:8          U
MA><;\MVG_@M$]\+@!GWFR_ZT?X _C("_X
M
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M_K1_@#^,@+_@
M
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M[S9?]:/\ ?QD!?\
M
M
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MQK'3"G&6N,J)-@R*_LB+):HE2VE]RO16E6:G>JQ DL#6%YQORWV#X+1/?"X
M9]YLO^M'^ /XR O^
M
M
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MA.:F&..5($K :PO.->6W3_P5B>^%P S[S9?]:/\  '\9 7_
M
M
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M*I7+X'L@-@X&L+SC?EOT_P#!6)[XW #/O-E_UH_P!_&0%_P
M
M
M                                  4 \YI_5=_#_P#%H& ^;E\MNH/@
MK+]\+>!L] JIVU=I]P=V](::M.WUG]V)]MN3DJ4WXQ%A\-I3"V\V>6\U2O2
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M9@7_
M
M              #YY<.A_P!OEDH=1RKF.&.'RBG:G"MS(35-,*TR_)*>*83O
M?CF1'+S%?Q*>[#L!(                                * ><T_JN_A_
M^+0,!\W)Y;M0?!:7[X6\#9Z          :PO.-^6[3_P6B>^%P S[S9?]:/\
M ?QD!?\
M
M                 .+-3)6M%<W/7 IPX8VGQ;F#7/<W1=M=5&E7=MR0FN5:
M&&W'J)K[)M%4FHS&KVK,X3[^QO,KHF<OQC1&S[,>]W+#K_2E^?3&MMU;<E+Z
MD==%MK53UB7*4S?.8E[*ZE;S'P\NICYK2,SE?CCV=K*GN6N&)M(:ON\[L$
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M/_FY/(E?_A5,][K>2E;\@  % /.:?U7?P_\ Q:!@/FY/+?J#X*R_?&W@;/0
M        #6%YQORW:?\ @M$]\+@!GWFR_P"M'^ /XR O^  \J?<(-K@R+C<9
M+<&!":6]+EOK2TRRRVFJUK6M>"$H2FF-55KAAS@8S9]U]LM27-FR:>UK8+S>
M)55>+VZWW2'+DN5;15Q>1IIRJU9$H4JN%.:@&=@
M
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MW"#=(,>XVZ2W.M\UI#\28PM+K+S+B<Z%H6C%"D*37&BJ5PPY@/5
M
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M(0C!"4)33D32F%*<P'J@
M
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M*4GVI8$-=GC;RR;K[OZ>V_U"]*BV>[TG>-/P%H:DHI%A/RD9%.(=1UVDXXH
MF1_L,;XZ:W$M$6P2&G]/(GQ76M:VN2U'>MS7C7))5&>?COT?92E+^1A:^XE#
MJE ;*;%:O<6SVNSUF2KC6W1F(?NA<7:R)LCQ9"6^+(>PIG=7ESN*Y,R@/;
M
M
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M?I%YM-7O%6)\B&Y&525&<BKSI;A-*ZCJL.G0"RP
M
M
M                     "@'G-/ZKOX?_BT# ?-R>6_4'P5E^^-O V>@
M     &L+SC?ENT_\%HGOA< ,^\V7_6C_  !_&0%_P
M
M
M                            4 \YI_5=_#_\6@8#YN3RWZ@^"LOWQMX&
MST !CFJ]2QM'Z8O.J[DTZ[ L4&3=)C+%$5>4Q#96^XEO.M":KRIKA2JZ4 @W
M;+MH;9;KZXM>@=.6B^QKQ=JO^+/SX\-N,FD6,Y*7G4W,=5U6E<R*@65
M#6%YQORW:?\ @M$]\+@!GWFR_P"M'^ /XR O^
M
M
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MY<J@/<   -87G&_+=I_X+1/?"X 9]YLO^M'^ /XR O\ @
M
M
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M-<:*I7#T /5   -87G&_+?I_X*Q/?&X 9]YLO^M'^ /XR O^
M
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M
M
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M-4#/      UA><;\M]@^"T3WPN &?>;+_K1_@#^,@+_@
M
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M
M
M   !P)5GJE7=K7#Y0E-482\;4TYZW:?N<^-6E),>*^\TK#-2BVFU+3R5YRY;
MC&8ACYJN:+<ST1*KWQ][F?OHS]BL?6SL?\3E^CV]KP__ .PU#]+JH_A/C\W+
M_?1G[$8_S!_B;'1[>T_^PS_Z751_"CRX3I,Z?)FRET7*F.J?D.889EN+SJ]3
M#TC:V:(IIV.9S-^<Q5-RO?+KI35=:-IIR_\ :I%O?BQJ>YA5.Y^UI1=:U33!
M%/\ MZI735\O>B8BB)IF.\]2Q:@NNFKHS=[.]1F4U124+4E*T97$Y,<B_3H6
M+N7IOQA+/R.=KR5?';GO<O/'4S5>_.Y2*T12YLUI3N^*L_YA@V])R]7*>UT5
M'C#4)CXNJC^%WK+O3N%+O5M@OW%IQB5*88=12,RW52''4(5WG/3'N&+?TZS3
M$S'-Y^UGZ?XGS]R]33-6,3,<U///[*VAR3V<   *L]OJ"_*[/TE]JF*(%XMT
MEZGK%56Q^?=2!Z788D,/=G+3K;2L5QY=R:>3SX.5FO.4I] M%0+*    #6UV
M7O[[6MOVUJ?[=J!LE  5D[>W]W>Z?=*W?K] /;[$W]V30W\+>_,T"P $?;Z^
M1#<KX*WWWN? K/YMKR?ZS^[#/VJ@"[( #71V _+=N/\ <^1[XH O)N/H6S;F
MZ*O6A+_C[G7F/5A;E$XK9<I6CC3J,>_;6E*Z>H!0337]J/L>WB;8(&FW=4Z$
MD2%2$<&,].MKU:U0WQFG8_MD9U?(C([] KK 9XJ^]IOM4,_@?/T_7;3:J4I-
M=1W5UI^/*D1L]%K:0N3@IRBZ=XTVA')TUY:Y0,>\W(RA6K=P),9*_$40H*$\
M2J:K31QYZJ,WSJ.X!L3  59[779VUOOZK1]-'3K9!_!ZMSI,]UG9#-%>/4B<
M/A^+L2,?^77CFR\] ,7[*O97W%V)W"N>K-6W*S3;=+LTBUM-6I^4Z\EYV5&?
MHM7'BQTY,L=6/3[J0+G          %,>U5V5]Q=]MPK9JW25RLT.W1+-'M;K
M5U?E-/5?:E27ZJ3P(LA.3+(3AT^>B@,H[(W9WUQL#76"=8S;9._"&MKI$]R7
M9#U$T@4E\3B<=B/ACXPG#+FQPJ!:8
M
M                                  'RI*5IK2M,:5YZ =3W,A_].W]
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M%/!RJ[X"X0
M
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M-4U[F %+->]@2US=1KU)M;JM[1ZZN+=1;5M+>:CK<_Z9YI;;C:*8UZ%<_I*
M:%[ EIC7^FHMUM5R-7O)6AU5O;;7':>4C#_F9#CCCSB*T[Q'#YN58%R(42-;
MHK$*&RB/#CMH:88:3D;;;1T4)2BE*T2G#DI2@'I
=                                   __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>tm2227887d1-lc_carmno4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-lc_carmno4c.jpg
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M  (# 0$               $"! 4& P<0  $# P," @,'"PP.!@8!%0(! P0
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M7*R'%)>)OQY!1V8LY]B0X\()U<%8Y$B!KT15\?%.E!M- H% H% H% H% H%
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M@4"@B>X^6;@R[7"7=;CAT=^X3GG),M]7Y:*;SQ*9DJ"\B)J2JO1*)JZWYJ_
M'\R8W\(F?W^A57;C7+N,^(.0.5<:N=P8L%M:OJLVB&:/.(D>,3H:"J"XN@ZH
MGK+K4P2VSD/G;B6[X!E=IMN41I%QGV>X18C MOH3CS\5P !%5M$U4E1.M2B(
M9#R]^7OAS,.',5R3),58GWN>P\<R8;TH"<()3H(JH#HBF@BB=$JJ9E)OYJ_
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M@\P?-<;8-TX"O*;A7[)#G+(U--/$!A^JG7TE54T?@^:F^Q=GSUPSFL'<&[I
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M...-">Z,PZ*:DT::*6O3P\*)HW6V7&T95885WMY#.L-ZB-2XAN-D@/Q);:.
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M#9&AH+D80]<PT3:@EL(A0EVKX$U73L]NA8W9+78V'-(=NCQ[?%)XDW$+#8M
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M*+0J]-N.&KW'X\Q)C)5?7(VK+;@O"S#5R2LT8K:/]TR4E(^YNWJJJJK11LU
MH% H% H% H%!'//OT*9]]XYWW$J)AYT^5?Z?\)^,R/D;]%I>KE%%#_+K]-O+
M?QZ5^$7JF$W+25*I059Q[]/N-^W_ .6"JLK]"][H=UHV]Q!O%1W@NA)JFFJ+
MZ%2BJ-.$^'&>&;+=;.S?YE_2Z3BN!.S40.V1B@JB"A%ZQ::F>OK+Z*)F4G40
M4"@4"@4"@4"@4"@4"@4"@4$63N%(TWFZ!S0N03FY,&&L)+&.GLQ(K1L_#UU1
MM4/>K>WJ:;M?11-4IT04"@4"@4"@4"@4"@4"@4"@4$=<T\4,\R8>&(OWJ38V
MPFLS_:H@HYO5@3'MN I!N!=^[37H0BOHHF&\6BW_ #3:8%J]H=E>PQV8OM4@
MM[SO9! WN%Z2+34E]VB'=H% H% H% H% H% H% H% H% H%!3#D?E#S&9]S)
MD?''"CGL%NQ709.T(;1FHB FZ\],1?%PU%L 5-1ZZ+HJH6? X;Y]5%%7*8PJ
MJ:J*OV_5/>Z1UH;%Q;.$]NT0&[J:.70(S(S3314*0C:(XO1$3J6OA15K?*EP
MS.U<?WNX<>Q?;<R8:;6U1>VCV]Q7@0DV$J(OJ*2^-!5'^DGSU?S1_P!VL_WR
MBVP_I)\]7\T?]VL_WRAL62X*O/*%]PER;RY;_FW*DG/-A'[(Q_\ !!!M6RVB
MI)U)3ZT1*3:(*!0*!0*!0*!00]YJ/H S;XM'^6,43".?(-]#U[_XEE?((%"5
MIZ(*!0*"KW*/';=SO^5<>H BQFD;Y[QAPO5%F^PM[@BA+T'N+W6R_M7$K5\N
MS_T/,:?N9=OW^/V.BU$?U>@MO_>PS2>SH\/M29Y>N1'^1>-X4JZJ29/9C*T7
MYMSH[[7%1$[AHO5%<!1(NGPMR>BNCUV#Y668C=.V'-636$JU@+E H% H%!H7
M*O%5BY3L26^X*L.\PU5ZS7EE/L\1_HJ*BHJ*H*J)O#7KXIH2(J>=]D70QL^"
MW+;2=_1+2.*N5;[;KZO$7+J)#SJ&B!:KJ:_8+LQU0"$U1$5Q43HOU_@NAHJ+
MYV7S7ANWL?!GNB[Y>3S>]A,YY&\RV!V&Y95>+%BHV&WD&]QOVIQ[8^^##?JI
M+355(QUJMU^2V*TAYY<VHQVS=,6TCTZVRX)DOF)OTRQW+(++C3&'W(69,F1$
M*0DL8K[:."H"<DT0M%3HHK5[9OFE:4>V*_/=,3,6TGTZTU5[L\H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H%!"MT\O'SG<YMR_I#RN+[8^[
M(]F8G[66NZ:GL =O01UT%/<KPG%7IEK[M'6:\=WM=3\VK_\ .3E_\H__ '-1
M\GURC^B_WW>U7'-<6?XJY+N]AO<R1+B70&9=KO=P/>Y);T5%5QQ=-20E("U_
M6^^E:77X+NC;1QW.]'?$Q2LT^VK"Y)>(+=K?ALN#)FS0*/'C,JCAD3J;$T0=
M5]-:[!BNF^)IN:#1Z;)=EB:3$1*QF&^6>X-XK9TNN<Y-:;DL5HY5L@SNW&C.
MF.XF@':NFQ5VK[]=3;AV;Y?3,>BGABMUT3VLY^;5_P#G)R_^4?\ [FK?)]<O
M3^B_WW>U+&&XU^)^-PL=^<IEX]B[O_Q&Y.=Z6[WGC=^R'HFNW?M'^U1*]K;:
M11FX[."V+:U9VK/0H-4Y0@3;KQIF=KMR*5PG6*YQH@CKN5YZ&Z (FG77<J4$
M9>3>=$E^7S&F(SB&]!>N4>8*>(/%/??05]_MN@7ZM$RF:_W^SXM99N0Y!+"#
M9K<T3\V6XA*+;8^*Z"BDOO(B*J^BB$9\T<N6K&.#KMR!C<\)"72(D7')K*JB
M.29VK33C>Y$^UIN=\/ *)A!/&V7'B7"H<3W7AO/9S4^'+9O<N/97-CSUQW]P
MVU+1?50D%LM-=!%?&B6\^2[,Y\S"+GQGD+,B'DF$2B9]CFMDQ)"#+(G&Q-MS
M0T)MQ'!45^".U*(E&G$N&\@9=S#SI^(N?.X-['DKWM_:MK-S]K[L^Y=K7O.M
M[.WL/PUW;_>HEU>1,?S^RY[:,&\Q?(5WG\5Y(8MQ+U:NU"ANOMFFUJ:WLVM(
MBJ)$OKHB:%Z"4 N_8+%:,9LL#'[!&"'9K<R$:%&;U40:!-$355557TJJKJJ]
M5HJCSS)_05G7WL/_ +X43" !!, M?ESYJ:U;@A;X6*9,YX![#<&%5DST^M:4
MGC77TH-$I6+_ /Z+YHQ;5.[8.)K3OZ>L'S[?!3373ITCIT_6F']@CH01QE?[
MEC/D=SNZVEPF9WSD]#%T%T,6Y[D&(ZHJG5%0'2T5/"B>E:?A+!<7QOA_&K-
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M9:4D%=@$Z:[MH_"TVHB)0JV'R^81?>.>(<=PS)@:;O=L]M]J!AQ'FT]HGR)
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M0*!08AS%L9=R!G+';/"/*&&5C,7DH[2S08+5% 7E'>@Z$2::^E?=6@R] H%
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M8$BHJN*G;;0DT^$OUO4F(2'P-EM\SKB3&,LR1\9-[N;#SDQ\&P9$B"2ZVF@
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MS(JN@33BLR&T<#<!HA"NTDU$DU3TT0BOS4?0!FWQ:/\ +&*)A'/D&^AZ]_\
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M1:;9 )!*QJ33*"HM HJXB$JD>G5?6W46HU9C _.Q/L0\BIG",OFQ\Z-V(IQ
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M4"@T25S!@D/DN+Q*_.-,TF,>T,QD9-6?M9/(!.Z;4-6P4T3W/3JNE!O= H%
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M5--%\*S(I38WEDVS%;=S+U9<H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M H% H% \>B^%!$7$B_BUE.9<=N>HW"E_.=L;]'LDE!31/>$5:\/2JUH.6_\
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M6ZY&_,C.P[(Q9HZNPXCD4 !EJ0H(2MAH2;-!ZB):>%$OOR]<9/<5<86S'KB
M#D,LCN=^[>W:DZ5HI!J'JKV@$&M4Z+MU3I0E*=$,3?,7QW)DA)D-KC7-+;("
M= 24T+O8E-? =#<BZ$FO14H,M0*!0*!0*!0*"O/+/FDLO$7)(X-E=A>G6&5;
MV)BW*$8&\VL@W6R X[NT3'U/%'$7WEHFCEQ6P>4OF1Y;EC=GQ^X71Y.X_!;9
M2!-14]8B.*G:+QUW&@*A?KEH;4Q8O@^'83&*)B-B@V5AS3NI!CML$YIX*X0H
MA&OODJT0S] H% H% H% H% H(YY]^A3/OO'.^XE1,/.GRK_3_A/QF1\C?HM+
MU<HHH?Y=?IMY;^/2OPB]4PFY:2I5*"K./?I]QOV__+!565^A>]Y7!:<)D4-Y
M!56P5=J$2)T15]&JT51IPGDG+>2V6ZR>7<<CXY=6)Q-6YB-ZJ.1MJ+JHJZ]\
M$EVH>[UD]'I4F4G404"@4"@4"@4"@4"@4"@4"@4$5SLEYC:YN@8W#QN,YQ$[
M#5R9?U5>^#W:,M=_=1$5'1!M&^TNHKNU](DI4H@H% H% H% H% H% H% H%
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M\2)29S=PA8>8<=6+HS:\NC.-/6C)!:UDQC;,5)%(% R @14V[M-="\42A$I
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M4"@P[F)XN[D3.7NV:$>5,,K&8O)1VUF@R2*B@+RCO1-")/'P54\%6@S% H%
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M@4"@4"@4"@4"@4"@4"@4"@CGFKBMSF##@Q1J_P G'#;FLSDFQ0[N]&1<!6G
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M:4E56]YGHI;O6^HE9-EDV]-6SPX9QUK=-W:WZO1DE H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH%!63GSRI7#FC.6\PBY.S9VP@,0/9'(92"56#</=N1T/'N>&E$Q**7__ *GS
MD MZQLXAN.Z_!<@.MCI]5'C_ .JB:H?Y/\N%\X=O=D#.;JV.&7E_V;\9;6P4
MSV<T34D<C.&PNY$];1'.HHJBJJBC1-7IA@5GCX[@N,8_$G#<XEJM," Q<FQ0
M DMQ8S;0O"*$:(CB#N1-Q::^*T4;#0*!0*!0*!0*!01SS[]"F??>.=]Q*B8>
M=/E7^G_"?C,CY&_1:7JY110_RZ_3;RW\>E?A%ZIA-RTE2J4%6<>_3[C?M_\
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MGHDH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MEC0F6XS*FNI;&00!U5$35=$HACLORVQX+C<_+,D?*-9+8 N3'P;-XA$S%M-
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M H% H% H% H% H% H*1^=WA2\3YS'+V,17);+4<8N3,,"I.,C'1>U+T%-5!
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M*[O>=1J6$A4;V 0]1'3UE3K1,2G*YVV#>;;,M%S9&1;;@P[$F1S^"XP^"MN
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MR>8,#A\E1>)7[B0YI+9[[47M&K7VLGD;)W3:AJV*FB+Z/?5$H-ZH% H% H%
MH% H% H% H% H%!J'(_)F(\4X^&2YG+.);'9+<%E6FC?<.0Z)F@B((J_!;,E
M5?0GNT&S6ZX0[M;XEUMSJ/V^<RW)B/HBHALO"A@2(2(J:BJ+U2@[- H% H%
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M\XWV=='KCZ5JJY][% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MREJU*DH((@G$ -R*XFOV3]6B]5@_(-]#U[_XEE?((%%96GH@H% H% H% H%
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MD*YH/:D%IKL:=3;ZZZ+M0@'=];JO2J:GEV3%;Q1/%'J+;XE-]:IZ% H% H%
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M^X))E\3V5^Q8F%SD,I%E:HX<D6V5<=T5YY40D443U_1X)1$I:H@H% H% H%
MH%!#WFH^@#-OBT?Y8Q1,(Y\@WT/7O_B65\@@4)6GH@H% H% H% H% H% H%
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MXYFVV^G75Z8YZ%NZYM[E H% H% H% H% H% H% H% H% H% H% H% H% H%
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M]1RNZRWBLGBI[41DKO6-K2/4H% H% H% H% H% H% H% H% H% H% H% H%
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M<Y"CLQCFR%W//DR" KCB^DCTW$ONT0[M H% H% H% H% H% H% H% H% H*
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M##4N&^.J(XP^". 2:Z+HHJBURMULVS,3OAD.U50H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M5HG8LCPB[RV]AKA\T,!'S#VUY !M8:C['L;[:_X$1M_"W^G7W:(E)%$% H%
MH% H% H(>\U'T 9M\6C_ "QBB81SY!OH>O?_ !+*^00*$K3T04"@4"@4"@4"
M@4"@4"@4"@4"@4&%RK%;-F5G=LE\95V(XJ&!@NUUIP=4%QLM%T)-5_ZEU2L;
M4:>S/9P7QL96FU633WQ?9.WW]J)Q\NIDY[._E\QRRZZ+#1A!=[?ZWNJZ0_\
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M7WDH-DM\^'=8$6Z6]U'X$UEN3%?'5!-EX4,"35$7115%ZT'9H% H% H% H%
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MU/'5Z6S48YLNC?\ 9/6MXTX+S0.A\!P4,=?<)-4KZ_$UBKY',4FC[J4% H%
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M6Z?N7MMB&[UBK%!73G7@/(<GR5ODKC23'8RWLC&NUMEKL8GM-H@@2'X(:"B
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MGW$*V]NY]2Q^6.QH<W,.6&>;K?A\3$VG>*GX2OS,G5'%=;?1IPOMB.(VGV1
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MC04!M"7X(&2^\E!LEOGP[K BW2WNH_ FLMR8KXZH)LO"A@2:HBZ**HO6@[-
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M';%F.R(MM--B@   F@B(IHB(B)HB)0?= H% H% H% H% H% H% H% H% H%
MH%!'//.)7S.N),GQ/&V!DWNYL,MPV#<!D2()+3BZF:H*>J*^*T3"L=@Q/SYX
MO9(&.V*7&B6:UL!$@QM;"[VV6DV@.]QHC+1$\2)5HG8R/L'_ -4(_P!9QO\
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M_D]\_@3/\8H4/SZN%/\ )[Y_ F?XQ0H?GU<*?Y/?/X$S_&*%#\^KA3_)[Y_
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M>/Q/;G-_,?LWMOM[(,:^V=[M[-CCFOVDM?#T4*)-H@H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M)PWMZZ1W64-?5'X6M>./3XL<UMMB)]4/?+J<N2*7W3='KF967_-!\NW\S?\
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M;]=AJ_IV=G@UV19VM8\"@KOB7Z;LGXLOX$;K-U/Z+T_$S,/0NG7*LPH% H%
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M1!0*!0*!0*!0*!01SS[]"F??>.=]Q*B8>=/E7^G_  GXS(^1OT6EZN444/\
M+K]-O+?QZ5^$7JF$W+25*I059Q[]/N-^W_Y8*JROT+WN@KC1MH9-J8J*&&B$
M.J::IJB]4HJC+A'B6X\162ZVFY97+RMVY3CGC(F 32-(8H*H@F\\JD2IN,]R
M;E]'3529='S0?07E7^S_ ,)1:\<WDE@:[Z-W=[X:EP1]$V-_O3_RIVM2Q,'T
MX2)1[L3E/Y,7KXA*^XE1$[FA^2G\@L@^^Z_)6:V6F\LJ<L\D]JS-93;/-2Q_
MEOE/QJ3\I.N8UV[O?,N<[H_-+;JU+F2@^N$_TF;'_G?X'>KH>7[K>_Q=WR+=
M9_%XK]UO'<*2^<WZ1L9^]8?*W:P-3YH<QSK=/Y9\4$5BOG908^[?: _9_P#8
MM&VY;YY['J5BGY+6/[WQ/N(5M[=SZEC\L=C1)W$=SE\V6_EL,NG-6Z%"*&>+
M"*^S&JM$W\/N;4!5+N$"M*N\47=X:6>B4J(47\M/TC<D?OZ_*WZ[#5_3L[/!
MKLBSM:QX%!7?$OTW9/Q9?P(W6;J?T7I^)F8>A=.N59A0*!0*!0*!0*!0*".>
M:^+YW+>'!BL#))&+O!-9FE/B@3W<%D3'M. +K*D*J:'\/X0BOHHF&]6B"Y;+
M5!MKLIV:[#CM1SFR%W//$T" KCB^DCTW%[]$.Y0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*")/,SD-UQSAC(I-DD%$NDY8MK8EMJ
MHDTEPE-1W"11T5%[9EHJ=47K1,-#YVX[PSB;B6+G&!V>-9LDX_E6R5:KC$;%
MB4^)S&(CK<ET$0G1=!U>YW-V[TT(64:=;>:!YHD-IP4,"3P4235%HA]T"@BC
ME2_W:_72'PWA<HHN29 RLC(+LQIOM%@0NV\^BKX/OZJS'3QW:ETVZT2P7E$8
M;B\(VN,UJC3-PNK8:]5VA/>1/^JA*=*(*#6^08UUF8'D\2QS0MUY?M4UN!/>
M/M-L/E'- <)Q538@KUW_ %OCZ*"E#M]XNN_$>'8?@=@"Q<P),ML.WY0XRU%9
MCW:-(!94M;PJHT^#O;=V(#IJ>X4$.B(A9?NBI0:_FD/+KACTF%@]QBVC(9"@
MVU<YS)2FX[1&B.N"TBHAN(&O;0O5W::]*"&/+-9'\<R3ENR2KG)O,J'D#(2+
MK.)#DR75BH1N&J>E25=$]"=*)EM+7#_'F.2<VSWDKYOR-Z]RGKC,NU]B,FW
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MBI1,(YX:S;!L3EQ[5$Q/-9N8Y/,8;OV87JR.@[*ER3%M77WB<+M1P5=4!/5
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MYVZ,XK,B8PRZFFK;C@ 2:]4Z*J+0<?SU9_\ 6$;^[-_NJ#AD9)CL04.5=X3
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M6[MEF)VEB79);$-MA]R9&8)28C V?J.&))H0KZ*+1*)?S,N?_P#4$;^48?\
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M>7<6FXUW::^CTJ3+H^:#Z"\J_P!G_A*+7CF\DL#7?1N[O?#4N"/HFQO]Z?\
ME3M:EB8/IPD2CW8G*?R8O7Q"5]Q*B)W-#\E/Y!9!]]U^2LULM-Y94Y9Y)[5F
M:RFV>:EC_+?*?C4GY2=<QKMW>^9<YW1^:6W5J7,E!]<)_I,V/_._P.]70\OW
M6]_B[OD6ZS^+Q7[K>.X4E\YOTC8S]ZP^5NU@:GS0YCG6Z?RSXH(K%?.R@Q]V
M^T!^S_[%HVW+?//8]2L4_):Q_>^)]Q"MO;N?4L?ECL:).XFO,OFRW\L!F$YJ
MT0H10SQ44+V8U5HV_A=S:@*I=TA5I5WBBZ^&EGHE*B%%_+3](W)'[^ORM^NP
MU?T[.SP:[(L[6L>!05WQ+]-V3\67\"-UFZG]%Z?B9F'H73KE68I'YO\ Z;,!
M^*Q/PBY75<H^C=V^#'R;W'6P4*",N:_]!V[XW_[LJ]L6]$O1/#_R2L/WNA_<
M KA,OGGMEEQN9JO))0*!0*".>:^-+KRMAP8Q9\ED8M+;FLS5GQA,^X#(F*M&
M(.-*HKO0_A?"$:)AO5H@N6RU0;:[*=FNPX[4<YLA=SSQ- @*XXOI(]-Q>_1"
M!>:/I<P?ZL+Y<M<ASC]3C[OYG:<E_1Y>_P#E2G7JUQ01'S]^3UK^.K]R*M7S
M#R1VMYRCZEW9XI^Q_P#T#:_BD?[D-=QA^G;V0X;/]2[MGWLC7L\2@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4%(,;_3^N_P#G/X'&BW0G[S4?0!FWQ:/\L8HB
M%<X'_P#+WN?QD?\ F%BB>E(W%'Z"L_\ X:RS[M<J(Z7SY+&P#R^WL@%!)RZ7
M(C5/KB2)''5?U$1*$HK\H^.2\OX@YGQ>WJB7"[0V8D/<J(*ONQ98MHJKX(I:
M(M$RCGB.T^71FSWNW<[+=+-F=JE.HVPW[4/>9$1'LHVTT>UX'$-"1S;XIUZ+
MH3*T'D[M>!S(-^S'!\3NN-Q9':MY2;G.2<Q+5LB,D878VOV-=-Y;=-2T371=
M"LK#YI^1V0_>R;\G.B%9O(#]&V3??Q?DC%%I:KY;?TPN7?\ _8_P]&H3N.2?
MTZL1_P!F_<7*'0Z7*$N9P3YMXW*^0P7I&%7S0QF,@I: ]!2&\(KJB*XT2=S9
MXJ&GNT.AU/,KR]8/,*YB?&7$3$F_W!R?[8<CV=R./=5HF@;%'A$M!0S-TR1
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MEGDGM69K*;9YJ6/\M\I^-2?E)US&NW=[YESG='YI;=6I<R4'UPG^DS8_\[_
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M9NI_1>GXF9AZ%TZY5F*1^;_Z;,!^*Q/PBY75<H^C=V^#'R;W'6P4*",N:_\
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MS$]CQOQ7V>:)CMBCMUZ/,H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M\(N5U7*/HW=O@Q\F]QUL%"@C+FO_ $';OC?_ +LJ]L6]$O1/#_R2L/WNA_<
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M$R!;=R(A2'NAGT0=$TV%U]^).3^->1;5(B<9O;K3CPL1"C#%<A-, 8EV@ '
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MWZ[#5_3L[/!KLBSM:QX%!7?$OTW9/Q9?P(W6;J?T7I^)F8>A=.N59BD?F_\
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M5RBBA_EU^FWEOX]*_"+U3";EI*E4H*LX]^GW&_;_ /+!565^A?!QP&FS==)
M;!%(S7HB"*:JJ_4HJU+C[E#".48$VY8/<TN<.WR%ARC[3K"BXB(2+M> "421
M=1+31:#4/-!]!>5?[/\ PE%KQS>26#KOHW=WOAJ7!'T38W^]/_*G:U+$P?3A
M(E'NQ.4_DQ>OB$K[B5$3N:'Y*?R"R#[[K\E9K9:;RRIRSR3VK,UE-L\U+'^6
M^4_&I/RDZYC7;N]\RYSNC\TMNK4N9*#ZX3_29L?^=_@=ZNAY?NM[_%W?(MUG
M\7BOW6\=PI+YS?I&QG[UA\K=K U/FAS'.MT_EGQ016*^=E!C[M]H#]G_ -BT
M;;EOGGL>I6*?DM8_O?$^XA6WMW/J6/RQV,'(Y7P*)R%&XL?NPAF\MGVABW=I
MU44>V3J"KJ!VT-0$C05+73ZJ:V7;G047\M/TC<D?OZ_*WZ[#5_3L[/!KLBSM
M:QX%!7?$OTW9/Q9?P(W6;J?T7I^)F8>A=.N59BD?F_\ ILP'XK$_"+E=5RCZ
M-W;X,?)O<=;!0H(RYK_T';OC?_NRKVQ;T2]$\/\ R2L/WNA_< KA,OGGMEEQ
MN1-YO?H*OGQFW_*VZV'*_P!1'?[E,FYY[P/\4:^HO_6M?1<7EAI\GFEV:]7F
MXW_M#G[ O^JJW;I6MWPN?Y%?H\R/[]+\E8K@.<_5M[/%N,6Y/O('(V'\7V(,
MCS:X?-UI<D-PVG4:=?(WW4(A 0:$R5=H$2]/ 5K0O9L4&=$N<&-<H#HR(,QI
MN1%?#X+C3HH8$GO*BHM! /-'TN8/]6%\N6N0YQ^IQ]W\SM.2_H\O?_*E.O5K
MB@B/G[\GK7\=7[D5:OF'DCM;SE'U+NSQ3]C_ /H&U_%(_P!R&NXP_3M[(<-G
M^I=VS[VB<^_1C<_WZ+]W"M9SG]+=VQ[VWY'^KM[)]R$\4_)Z#^Q+_OE7R7/Y
MY?2X9FO%+J77_1DW]X=_[BU:SS1VHE(GEG_(2X_?=[Y-&KZKR'Z$_FGW0^>_
MY%^HM_)'ON3-71.94.G?E!>/C3_W4J^0Z[SSVR^\<F\G\-K\K6.B*#=N#_I7
MM_[S)^3%75\@^O;V7>+YY_E7TK^VWP6\KZ,^4%!7WS#Y5.?>LV#MXUELRT.W
M2(_>)6/M"RS<8:L/D4)F2,AMSN(: Z0"*;D!4W)XT3#,^7N-<8;&5Q_F?(L?
MQ5+@R6-V;*E<<E,L+&!'5;<==>+83B$NS>2![JJ2T)8GGR\P\:R#%8+-PQC%
M&\A^<G9^0Y!;6IZD]"2-VFD$E#3?WB4G"71-J)JFJ(0A(7#\EN7AC3S5_M&2
M@LAY/G3'HK<* NBIZB--&8[A^N77K0;[1#6;=C]RM5ZR6\17F'"OT^#*!MU#
M1&X\>-&BOHJCXFH-&3?HU5->FM!@L4X_NEBO-N?G3([UHQYBZ1;(#(.)(<;N
MTIJ1ND*2[4)H6D;]3H:JI>KT&B6VY%C&/9=;2LV46R-=[41BZ4.8V+S2FWU$
MMI(J:IZ*(57\M^".<A>6VT6F/=%M$N!DJWB+-1A)2(_;I(/-HK9&VBHI(FOK
M46EG.5?+/G&9,1;Z.61KUD-D;=^:X#MM;@-.=T@(Q[G>=1#7MH@[AV^A51%U
M3SR1=,;-[%SVY)M_ZYI*#2NMVM=D.S7:V2X^0VRZ6L7[>=TNL(7'HUPBO=MR
M)(D/0'%46R4=Z,:?;!0MNJ>%F:8\S!P:RZO#D]/3N35&N.=Y1RUBL7L'QQ=6
M+5>?9)<URV7CVKONP-6D8:D%IKVE774273U5Z%7O&6VZ:1+8QELK2NV6U<M2
M^:L;PB0]=LBLBV-)]ICSK]:6IMCNS,:3=(C!D"+(E-(I(:BXO<!$!5KT>S 6
MS(KI9^0<:BX!D,S/'9K%R]OL<W(D>8V,M-J#BD?>$5%273U>M3*(;'RWF7*;
M. 70YV+?BO"5R$$F_0<A%),5IR:P!D"L,M&FHJHJHN#HBU"6E69MG&L_QF-P
M_?TO5SO,NYR;O:;GDL^1;I)K",R?DH"S/LFHH2.*RJJ2)JM3*(;IRY%YLNG'
M%_C7F#CAVIR,/ML"U)<KC-=#N@I RA--(2HB+XMKK^M2H2CN%%Q>]9_AX\(6
M>)8,IMESFA<;L[B\R)%B-K9Y6YN4JL0]5)'0005U%W&!:+4B2.6,2YKG\8Y7
M#<RJVWKOVJ4V5GMV-2 ERMS2HK+)C<WE0R\!7M%^QJ!'#=NL=WS/%6.'\.3'
M,OLE] [K<Y>)S(46$P5LE$K<TA:B$B.(\RJ-D\"KN D]%3(D_E"W\[+QMF".
MWG&9;"V2Y(_&@V>Y,3'&EB.(8QS6YO(CJI]KU;+UM.E0(91,.9R'!GN(K.$O
M.(F00BNT4AG0 )GV%]3&5(-AQ&T55:750+ZWII4RB$\91R9R;C^,WJY7#C:9
M&?AP)4AFX6VY6VYQF76F",3<!UV(Z38DFI;6E71%Z>&L)1TQ?LVP.1!Y&NF3
M#/BY=<K(.1PF;/O-6#;"/]@&.3KJD+?@C;:D2^BIHBJ4KCYA>*H%NES5O@MR
M&&#>:BSH\RW$Z2"J@&LE@-NXDVZZ=%J$T01C/S+@U_A<J7+C'&;)B]\DV!N!
M+;N@B=C;EN(P<M%.W-!U20CCOKMHB!\+TI-"JQ[O,_$W9=*)G6.RI(-FXW&:
MO$$C<4!4MJ(+JKUT]RH116G'IWS9?[/R\[Q?;[?B=V:L(P6PO[CKD*1<)V@S
M]JQ10C-)C(DVNB(C?PNO11*Z%$*[6/S!/W/D8,6/+\)?L!I$>9F17)*O2?;)
M+S'LC*D^H+) 6P)>FGV0>E$T6)HAHS?,7&;M^'%V\CC%?SDI"& @N]U9!.]E
M ^!IU/U===*)HWFB&C2.9>*(EW=L$G,K0U>F))07H!RVD?"4#G:)I05=4-#3
M;I[M"C>:"'Y_-600\W_$L,#D/&XLE^+<$O%H!EVWQ)+<<Y6TI"$"?9FR1H]'
M-%^#T+0FB8*(58R?DV.F;'<8&:9RU@,1;P62R8-F!Z!!EVY]D&V6'EM+FK Z
M2D=(C/38GKIZ25HV'FY+#4AE=6G@%QM=--1--4Z+[RT0JYGF6R)F;SKQ;&L_
M_%"QOW2+E16FY18T7OP !L"A-%.;5 $@<(]PBJZ]$6E$K.VRX,W:VP[I'$AC
MSF&I+0N(B&@/ ABA(BJFNB]=%HA73DW+<13DN RF<Y);[>W)EQ\PC6M^YMPX
M2QH*=E 1AD@%2<05/8JZJJJOC1*Q5JFP[E:X5QMSZR;?+CM2(DE==7&700P/
MUD1?6%47JE$(%Y2O=MC<I8K;6>3IED@7J9-C9);XMUA,-0 AVMQUG07&R5E7
M'FPW=Q5W*2HGBE$I[MKD=ZW1'8<I)T1QELV)J&+J/MD"*+N\/5+>GK;AZ+1"
M-N1K]RG8<BQZ+C$['PLV2W1NS16[E;ILB3'<6!)F&Z;C,]@#15BD*"C8Z;DZ
MKIU)29#26,2.-P-MR>C8)*<8 FV2>04WJ $1D(J6NU%(E1/2M$.>@4"@J%G6
M1+GG(%RD7_ .1IEMMUKCM6.TVU%MIQ)O>D=R281IG47D[:-O%KIL5-A>@LL;
MQDS>7>,\8CY<DA^^%:8K5W&Y-[9)/=E!<%\"4M2]!;E55\5ZK157S+<FB-\@
MY7CWXWX+@L6QRV8L&UW6RQY4AYAR&P_WR>)QL=2-TPV)U';U3P52RUL1=8C"
MH8N(K8+W&TV@7JIU%$\$7T45<U!'Z\?7!S )N!N361CW)+PDF:@&1MK<I+\E
ME0#5$+8KJ(:*J:Z=%2B68Q/'[M;I][OV0/1CO-[=CDZS!1SV9IF&P++8B3OK
M$2KO,ET3X2#HNW<1"%/.IC&/2N'[IE4FV1G<D@G!C0[J;8K):8<F!N '--4%
M=Y:I[]$PWR]<:7W(+I:\NQW)@L<Q+)&M3K#L 9P. V9/B6I/-[5U<T\%J80A
M?R_6O .1;GF%DY%LS?\ 2Q"NLF1<7P<=AO.,ALCD+3D8VCT9<;)"'7IN1?KE
MTV&KT<X8BZ)XK;NE2V^NQN61\9Y-@W)5OR?CS&KME-B*QRK9)CR+\+Y1I#TM
MA\>VMYF*: HM+J@+IJM:Z'HR''V'<U,GE%^;G,80[>+T4YG&KO#B7QIQM($*
M.CQ/P)C9 I$R0;4=Z(*+MZ]0PN:W3/6>0K)8^2LKB8[9W;+<9<:1C-QEV=N3
M*9E0FT[XR#711!T]@HX?I]RI@=WC#+\\:N>9VW%(CG(..P+G&:@W:X9 "FTC
MEMB/.,@;C3V\4<,UU0NBKIZ*@8[E*[WO(\LQG&N3H[N$8E<;7?4DQHF1FW&N
M1(4!OMR%C^S(0@#AH@.;D)#+IXU,(=OC&XY\%[RZT\;3[?DV,07[>#$S);_<
MIQ1B<BB1A'46I>X-==1[P:+Z*2.CRPSD Y%B=WYJM-FN>'P6KN9A:+9<+PQ&
M,FV%0Y*&R]TT'43[0HFB]:0E\<46B_7+)\ING#4BW8CA,UFTDA3<:E-M2G$:
M?7N1FB<MZ*B(2;BT5"U1=:2.[RMC67-WC$;AR4K&?XG#>GG*@VG%)+R1S.(H
M@Z^V$BX;AW>"JV.B]=:B!TN);;D,O*LER'AFWV[$\-NELL9-.7K&YT:)/-"G
MN([#%IZWH2(#@J9IO0D,/#TS([/,,'-1GX67+$NS77! N<DK@%EMERCF!_-D
MM&U?19<S<WO4/ 4];3T5 Z/$MPF6O+<JE\+8O%O>%R+;8M0=F2+,".H<]4*)
M[1%=!U% AW^L"(FS15UJ9&XYMR=R8T_C-ACXQ-PBXWJ[I"=O4WYMO$!6$A3)
M"MM^SRE/ND3(JF]L?50NOAK UWC_ #M[B'(V>+<QOCEPQ.TXY!?LTF/9Y+CK
M1+)>B['BA!(T3:RFAN;455TH;VP<B<S<9Y%:8&+6R%;<[N-\N#,(<8NCCMN!
M=J&ZKKB/Q'B^Q$V.J=K5%5/"@U?AB]8MPY,:PO-K/C>$7"3:RENY0EU9;2Y%
M'DH M.(_'B^L*.JHIW#Z(M*&]O')G+/'5TQ8;18I%BY"E7>=#MR8[&O<=KN$
M\ZA 9N1TD$* 0(7P*#4/+LQ,PO(QP*_XE$M-^GVZYW9,ACW0IQRF&+DTH1B9
M)D$'M!, !)#75&]=.O10JG'/<F8Q+&95X=NULLKHJVU&G7PB" +KA(B"XH$!
M=4UTT+QHA'W"',$KDQV8U<[WC<J<TDLFK18S?6:#,*:47VAT777/L3J=MP%1
M/!P:)E+-WN]NL-MDWB[R!BVV&'=DR#15$ 3IJJ"BKZ?<HA@<4Y,P3.)3\+$[
MVQ=948%<?;81S4!$T!552$4Z$NBI0;!=+I;K+;I5VNTIN%;(39/RY;Y(#330
M)J1F2]$1$\5H-?QCD[CS-)[EKQ+)[=>KBRR4EV+!DMONBP!""FH@JKM0C%-?
M?2@S=]N$FTV>;<H<-;A+C,DXQ!%YJ,K[B)ZK:.OD#8*2]-3)$H(_XZY9N^>7
MJ?:I6'OV.-;77HDJ<_<[;+%)L=&R5D6HSQN%J+F[N"*AT^%1+<LVO-NQ_$KQ
M=[M.DVRWQXKG>N$%M'I<?N)VT<9!6W4)P5)%!%;)-?$53I1"$^)LWD/9Y(M&
M1Y+F4DI]PD0\1A9!:1@0ID)JW-RR<=<^;(RH^)MRM![@>J*>JOBI*:<[OUOQ
M?#+_ )#=O:DMEM@2),M;<HC,1H&U4E84B!$<1/@*I)U]-$(&XUR:=;.0FAR!
MG.@M.07 (6'?/EPBRX0MG:^\X,QMN:ZJFKC,EQM1$M$V]47HA*Q]UFP[;:YM
MQN+ZQK?$CNR)<E-=6V6@4S/U45?5%%7HE$*Z\99;B*\ESV5SG)+A;W),2/A\
M:Z/W-R'-63!7O(:/LB!*+BDH;U31414\*)6/EN,LQ'WI+Z1H[;9F])(D;%L!
M%5(U(N@H*==5\*(0)QW=;,]R5?[>YRI-O$*U28+-@@2;O!>:G>UPT-T5$&Q5
MY1=)41&U314THE8&B$/XCDO+URY)OV'7R?C9VS&6;7*GNPK9/9?DM789*H#1
M.7%T6R#V?X1">NOA1*8*(*!083+<C/%+&_>@LUROY,DV*6RR,!*G.=PT#4&S
M<:14'7<7K>%!4OCH;Y/R#$,@AXWGK.8S+XCN2Y=--QRS2;6X^[O V4DFTC:B
MHCM0$1GJJ$:BFI9:W.ABMXE>;D_ AW!^UP94Z&S<@ XW?88,P4U<Z".J:$6J
M=/315!'!V2,7_([+,_'[#KK)F17'W,=L]G9M]T$R84B!'.YW![:Z[]6^J)1,
MK,T0P&8X^]DUHC6UAX6#8NMFN:F:*J*%IND6X&'3TF,=03WUH,9D6/9/.O-N
MR.S/P&[K:5FQ8;4L7B8.%<&F=Q'L5"1T'61)-/5(=1Z*NX0S>*6!C$\6L>+1
MG2?C6.WQ+8R\::$80V09$E1-=%5 UH(#?QC'L:\WV-_B_;(UM^<L9N,ZX>RM
MBUWY3LAW>ZYM1-QEIU5:)Z'3Y0XRR[#<!OL>VY4$G&;M*N#<R =N;!UB/?Y$
MAUW20KQ*NTY&U%V)XZ^BL'6ZJ=/BXXCBV]C8:#21J<O!-W#LZJ[F]XKP]Q!?
M+!"NMAM4BT.$V@.%:;A<+2\S):W X)!#D-"AB:EJFFGU4TKWP9K<MD71_IZF
M/J,-V&^;+NC[8ZT=CBG+&/8[EN$6SC^XW>%.G7]+9>W;S:S)Z-<Y4@V'G5E3
M.^1*#@D:N^NJZ[NM9%6,DZQ8QSGC]CMD:%E5DN2L1&6CMUYM+C1LD#8IVTE0
M)B"6W3;N[*ZZ:]=:A*&9>0W%VU9S<<KY EVG-+9/O33-JMM^>CPVCB$?9!AA
MP@-0U1$'4$UJ4)GQS,N7G\>M#ZX Q,5R%&-9;E_9$WMS0KW"18RJBE\)>M0E
M"D^3;K[-S"_YSDDZP9M9;G<AM-J:RB4TEO1(H((1A:?9%$+<HJK;8[D72IA$
MRE[";CSW<<,QV4U%Q?MOVJ$XW.G7"YS);RN1P)'7Q2(UZY:[C3N%J6OK>FH2
MAVX,XG R?-H_+^-Q+CG-WO#BVN5'QN=<6)+0VF+L&&\L60JH*M.DH=S45$BT
M1*F"4J<6XQS<SQQB+'XW6>TQV;+;6X]NDX[(?E1VQB-H+3Y%<F/L@)ZI^HG5
M%Z)X5 CB[6NR6/D++/Z8,77++_>;I":L]^8Q&3(BSD&SQE1F)ZDU-P(RZA-@
M^2ZMF6B=428&\\*8]SK:.*L6MK5PL-H;CPD ;9>K'<EN+";R78_MN,=-R:_^
MR'IZ*@E'MVCXFQR#F'].K4*9E+UT@C;)42#<0@NA\T1>VD05)]4+1#W#W"7>
MA^BIA$I%XBR/E.R\<8_%:X_^=[4TPJ1)$:[LL3C95UQ1[D:X-1T D31-.^OU
M:A+$W6[9_P H9/=8#LE["X6)W*U3H5EGP8<R6,MJ.$E#<=8DN 0*:JHHA=1T
MUT\*FB&SX!S_ (P]BD,\\NSC&2-N26+A(6U3V(AJS+=9 P=&.3*BH@.J@XJ(
MO15UJ$H_Y)N>.\WY&XUAN(6#+/Q;D69R3D\Z<K#KL9F4LMVW(W["\0@X@NM'
MN/IO5=J^"J&Y)G&_,W%;>'PHEPNN.8+,@.S+>[BA7B&/L2P9CT9$1'/9BVFC
M?='5H?5)/JT$=<P7>W<KY!(L6"8Y:<N?L\>S37,K:OJ- $=Z<Y(.( ,-.@2.
MMQG6R+N:BCFNB^"C<F?AB^Q+[@S7L=C:QL+7.N%H<LK$I9[;#UOENL.(+RMM
M*2$0J::@GC1#6>;^8)7&;L-JV7O&XLYU(A.VB^&^DTV9LT8OM#0M.M_8FD[C
MAJJ>#943"0<"R9C+<9BWAJ[6R].DKC4F=8R(X!.MDJ*+:F1ET3374O&B'SEO
M(F%8(L8<NO+-I66A%&[Z'H: HBNBB))T4D3K09/'\BLN56MJ]8_,"=:WE,6I
M+:$@DK9*))H2(O14T\*#H95GV$X-[)^.%_@V/V_N>Q>WO@QWNQL[FS>J:[=X
MZ_52@[N.Y/CV76T;SB]SC7>U$9-#,AN"\TIM]"'<*JFJ>F@U3E;DJ;QE:4OC
M...W^VL,2)5T=CS840HC,9 5"[<EP#=WHI:(R)*FWKXI1+8L.O\ <\DLR7*[
MV8K#.[IM';G)<6>0H&FA*[#<=;]9%UTW:IZ:(1SS[EKMDM:6VQ7O(+=G#EMN
M,^P6_'("7!)C\< !M):+#EJ+2/&T*DBM_#^%X:$PV'A[)(-^L$MAB\WJ\W*V
MR19NIY)$2!/8D.QVGD:[218GJ;3$P7MZJA?"6@P'/5_<AQ+=C=J#)#RR[1+I
M*L:XQ*9AB+L$&0W2R>D,:MH<EI=H[E\>GNAW^#;^-QLMQLDEO( OUG=C_//X
MT2&9<CVB5&;/[ XT^^G97;N$55-%5>G6B'-S;D..6C&P@WC(;C8+M,&2_8EL
MYRFI4F3$8+[&JQ6S5017!4A+1-=%]%!P<#7ZR7C$VV(607.^Y Q'A/Y$%Y<E
M./QIDF.FYL?:@!4!2 ]$#5/&B69Y<EVZ)B$IV9E;N)RF0>E0)4:8Q!=D/L,.
M*+&KXDABJJBJ IKJB=:#H<)3X%QP^%,:S![*[O+A09EW&3-CS7(<B1'0B;VL
M"*M(I(>@GUZ+[E"6VYB>4M6-Z1B$FWQ;JQJ\1W6,],CDRV!$0H#$B,2$JZ:%
MOT3W%HA@N);UFV3X=:LJS*1:G%O]O@W2!'M$21$]G"9'%\FW5D2I/<5-XHA#
ML\%Z=>A+>Z(*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*".>??H
M4S[[QSON)43#SI\J_P!/^$_&9'R-^BTO5RBBA_EU^FWEOX]*_"+U3";EI*E4
MH*LX]^GW&_;_ /+!565^A?$A$A421%%4T5%ZHJ+15@<4P?$,%B2(&'V:+98<
MMY9,AF&VC0FZJ(.Y=/<1-$3P3T4&@>:#Z"\J_P!G_A*+7CF\DL'7?1N[O?#4
MN"/HFQO]Z?\ E3M:EB8/IPD2CW8G*?R8O7Q"5]Q*B)W-#\E/Y!9!]]U^2LUL
MM-Y94Y9Y)[5F:RFV>:EC_+?*?C4GY2=<QKMW>^9<YW1^:6W5J7,E!]<)_I,V
M/_._P.]70\OW6]_B[OD6ZS^+Q7[K>.X4E\YOTC8S]ZP^5NU@:GS0YCG6Z?RS
MXH(K%?.R@Q]V^T!^S_[%HVW+?//8]2L4_):Q_>^)]Q"MO;N?4L?ECL==W!\0
M?RMC.GK-%/+XS*Q6+RK:>T@R0D*BA?L3(=?':NGA5EV?H*+^6GZ1N2/W]?E;
M]=AJ_IV=G@UV19VM8\"@KOB7Z;LGXLOX$;K-U/Z+T_$S,/0NG7*LQ2/S?_39
M@/Q6)^$7*ZKE'T;NWP8^3>XZV"A01ES7_H.W?&__ '95[8MZ)>B>'_DE8?O=
M#^X!7"9?//;++C<B;S>_05?/C-O^5MUL.5_J([_<IDW//>!_BC7U%_ZUKZ+B
M\L-/D\TNS7J\W&_]H<_8%_U56[=*UN^%S_(K]'F1_?I?DK%<!SGZMO9XMQBW
M+&95AV+YQ:TLN76J/>+4CH2!BRP1P!>;U03'TH2(2IJGH54\%K0O9EHT:/#C
MLQ(C0,18X"TPPV*  -@B"(B*=$1$31$2@K]S1]+F#_5A?+EKD.<?J<?=_,[3
MDOZ/+W_RI3KU:XH(CY^_)ZU_'5^Y%6KYAY([6\Y1]2[L\4_8_P#Z!M?Q2/\
M<AKN,/T[>R'#9_J7=L^]HG/OT8W/]^B_=PK6<Y_2W=L>]M^1_J[>R?<A/%/R
M>@_L2_[Y5\ES^>7TN&9KQ2ZEU_T9-_>'?^XM6L\T=J)2)Y9_R$N/WW>^31J^
MJ\A^A/YI]T/GO^1?J+?R1[[DS5T3F5#IWY07CXT_]U*OD.N\\]LOO')O)_#:
M_*UCHB@W;@_Z5[?^\R?DQ5U?(/KV]EWB^>?Y5]*_MM\%O*^C/E!00QYE3M3&
M(6.=.N%WMUP@7QF99G,<ALS[F<QB)*/:VV\HB@HTCKADI)ZHZ+T6B8??E\RB
MY9-:KV=SN>17%^+(CBGXUP8-ME-@_'%\.TW",T)LP,30S\=>E"72\PE]?MDW
M$;;<<B+#<,N1STO65M0PENLOL R46*CKK;@,(_N<+>HZKV]/JB&R<"WZZY'Q
M\U<+E(2X,#.FQ[3>_9$MQ7.W,/D$>84<1% 5P4] IKIKZ:$I-HAP1YD26KJ1
M)#;ZQW"9?1HQ/MNA\("VJNA)Z47K0&9D20\_'8D-NR(RBDEH#$C;4TU%#%%U
M'5/#6@YZ"NGDD^@J)]\Y_P#WQHF5BZ(0CYG,$ME_XWO.11[<;V3VQEE69,7<
M+QQ$E-$\#R!]M: $)W::+M4=R:5X9K:VUZ6NU^*+L4W1&V%7N%+'.S;/'849
MBW7=YFTO&4'(G7);#K;;C([&W007&33=JV;8DH:>&FM8."V9GHES_+[K\U\U
MV[/WHIXS[4N<AW:;CV&W3&;S)FVN'-%F*[B.9"Y=81 X^V/>MEX8<!QSV?H]
MVW72/0?@#I63?=-L>GV2W.2^ZRVE9M]4^%WJ<_#^'X3Q;RU;+?:[E&NLC(+3
M)%N5*>;23'=;-DQ[* 2 HR$54$=BN>KT+;NU\]/DF;J2O@G@R1$W3-8Z96;O
MUK*]6:;:@=!AR4T3;;[C#4H6S7J)JR\A >U=%T)-*V#:H\XVX:+CR\SKK\^C
M=6[@_)FO,':X$4AE2]J&;;S (8"B#HC8J@=?"B:I+N$"'=8$JUW!I'X$UER-
M*8+5!-EX5 Q71471154Z40U;&N*..\/N:WG&;!'MMT5"$I+*N;E1Q$$M=QJB
MZHB)0;7,B,SXDB#(W^SR6S9=[;ALGL<%1+:XVHF*Z+T(214\476@TW&>(L%Q
M"]'D-ACW!F[/*I/O2+Q=IH/$K2,;G6I4MUMPD;1!$C%5%$3331*#=9#2R([K
M".&RKH$".M*@N!N33<*JBZ*GBG2@T+%>)XF)Y#)R2-E&03Y4YWVBY1I\MEV-
M+=&,,0"> (X*J@V (.A)\%*);I=[?$NUIGVJ>PLJ#.CO1945"5M76G@4#!"0
MA4=R*J:H2:>[1"NV <8/QL].7>N.,AM^.L3(4O&79^3!.C6LH3"*1.L!>'U<
MW/#J"=MS37T)1*Q=UM[5VM<VU/$0,SH[L5PPTW"+P*"JFNJ:HBT0JIAUH@WW
M+H>(W'+<IF8=9I5CDXQ&FXR<-B8[;C]H)J2^5I95MMLV6AW&X&Y%7JM*I6;N
M6'XQ=&'6I5G@F;C9-"Z<5DS!"14Z*0^C76B%5K38[+?;W!X@G9K.N?'L.)9&
MH+,C'S;&9*A32U@NN%'30!"+'4C)="0UZTJE/2\#<:L:G8X,W''NNQVP72XV
MG;N\= BR&V_[(4*H%@6CDN7A]EX39P^=:\QLL7'9LRYN2K0_%BQH]R DE;1F
MKW$UA/:-HBDNWJB(J5-1/7S=SU:T48U]QC(FTU5/;[=-M#R^&@JY&DRP_51G
M_P#9 K3*G2(_&O\ 26&:74N3"AL,N"%Z<4B3VY-8Z-D2+V_6)4%4].M31%=J
MS7X[<G_U7R?Y9M?]\J$J[3I-[<X\N_++N8WB'R!%MMT!EH9S"BR#,ITQC("-
MKJ"$T'@O73QJ:(JL,EXYUGDOLV)XW:&O=GWR7+<5-5Z[(UN$==$35.Y^JM0E
M4ZYV; 5X[O%@NN)&YS')B75X19QZY.2')7M+B(ZR_P"R*B@BN-HCF_1-PZK4
MFU;'^CK.I^B7SE*]$UJBJS:(=JM@JON;UBONHGH^V?JZ]:@0=(PSE'';5<.$
M6+1;[D_F,?*)%KO\J\N XL5U]$-V0VD OLJ)/;71#T-4+J-3437"X"XS"%'9
MGVJ3+>$&_:/:;K=)(FX*(J[N]*+<FJ>"]/>J"JO66/+QYD%WXHL^:8;:,:OL
MB\./-7$92RK2U* 7 9?))0"A&+OV+4/1Z:FI18"U>7[CN!;(,4HDYF9'C@R\
M_;[S=X(F:"*&J#'EMH@J2;D'31/<J"J,)>/YM@=PN?']KL!7>-F=PNAX]<YM
MY[CY-^Q"9>T'(%QQ2$6U74S77PJ:HHD7%^'\EM&,V>"G(V3VVX1($1EZ(R[:
MY4-E]ED1(6TDV]TE;%4T0=_@E0E%+K#F'7N^8QEN-77)LDR6\7$[%>BML(SN
M(C$%U2%6NR"*(-F2H+8HB)4Q*)A(_'F+<ZV'C_%;>QD=A;.)9H$<K/=K'*[T
M16HS8HP;T:YAO-O3MD?;3737;4)1*]+P!S,LS;YKO5L;S&#?D6,V-PE0H[3'
MS9#V%&:.0A".ININ\=5+KI4PB5AN"I$B7PW@LF4Z;\EVRPC=>=)3,R5D552(
MM555]^H3*0:(*!05;YMN[>/<L+.QV\YA%R>=;(,&=#Q"T0;DTH*<QV,+Y2S!
M%=-&GR 4U7:*Z>FB83[QS=%O>!XY>%E2IWM]NC24FSP9:EO"ZVAHX\$=2:$R
M1=21M5%%\*(5NY;SBZVO-LO*5EY8YDEC..F#88%G;F-7X78S1@3CA-$;_M#Y
M''78:=G;KXT66QAF^Y$CN26D8DDV!/,(NY -112%%].B]**N8B$!(S)! 452
M)5T1$3Q55H.*/*BS(X2XC[;\1Q-S;[1B;9#[J$*JBI0(LN).9&3"?;DQR54%
MYDQ<!5%=%T(55.BII001YS?H O\ \9MWRQJB83?9?]#V_P"+,_<QHA4CDS%K
MEA/F)2_8^^-M=RAEFY6::6J1V;T))%('UU1>Q)<(&'TU_P#PE"^M2NCT^2,F
MFX;MO#LGLW^V-\=CPNBERT.#9A#S?'VKS'9.',;<.)=;8]IWX5PCKM?CNZ?7
M 7@OUPJA)T6M%FQ3CNI[)ZXZWM$U;)7BEB;SBV,9$3)Y!98%V..A(P4^*S*5
MM#TW(*NB6FNB:Z4'+9[!8<>8<C6"UQ+5&=/N.LP8[48"/1$W$+0BBKHB)K0:
MORAQU_238BL2W,;6R\U(C27T@Q9SI,2V^T8ME)$E:73KO;5"UT]R@R&!8>]A
M=H<MDBX-W-XG=XRFX,6W*C0M@ @01  2T427>7K>M0=O*L+Q?-X+=MRNVM72
M"R?=;8>4D%#45#7U2'7H2IUH&*X7B^$07+;BEM:M<%X^ZXPRI**F@H&OK$6G
M043I0?>4XE9<SMP6F_#*."#J/H,*=,MIJ: 0:$Y">9,AT-=0(MJ^.FJ)0=;#
M<$QK +<5IQ9B3&MRHV(1Y,Z;/%L&0V #7MCSRM@(IH@!H/O4'9RG'/QIM16E
M;K/M &:$<FU.@Q((=I"K:D;;B;2W=4VT'1P/!HO']E:L%ONMRN=MC-LQX+=T
M>;?6-'C-HTVTTH-MZ @HG1=:#H<IXU;<EQ^,W<,:G94Y;YK<V%;K7</FF6#Z
M-NL=X9'M<)$00=,5'N]=W@M!I?E]P*7B]N]OR?%+E9<[2W0[?=[W=+N-W2XD
M"F;G9%N=+1H <];38W\/HGCH2VSF"S6JZXQ%E7:ZW&RMV>X1[E&GV:$5SEA(
M!#9!$C#&EJ8KW5U^Q+IXKHE$(ZX#M3>1R$RW*[K=[QF3-L6!.MU[LOS7%B@_
M)[J=DB@11=)>TFNTSTUZZ42W?E3",/>QOYV?<:QAVU3HMS2^6^VA+D@\V\B
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M[W'$!>V+2;1TZ:5,H6)J H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H(YY]^A3/OO'.^XE1,/.GRK_3_A/QF1\C?HM+U<HHH?Y=?IMY;^/2OPB]
M4PFY:2I5*"K./?I]QOV__+!565^A>]X%=:<;$U;(Q44<'X0JJ::IKZ4HJC/A
M+BR^<4V2ZVJ^Y;+RQ^X3BF,R)G<3L@HH.U$<==7<6FXUW::^CTJ3+H>:#Z"\
MJ_V?^$HM>.;R2P-=]&[N]\-2X(^B;&_WI_Y4[6I8F#Z<)$H]V)RG\F+U\0E?
M<2HB=S0_)3^060??=?DK-;+3>65.6>2>U9FLIMGFI8_RWRGXU)^4G7,:[=WO
MF7.=T?FEMU:ES)0?7"?Z3-C_ ,[_  .]70\OW6]_B[OD6ZS^+Q7[K>.X4E\Y
MOTC8S]ZP^5NU@:GS0YCG6Z?RSXH(K%?.R@Q]V^T!^S_[%HVW+?//8]2L4_):
MQ_>^)]Q"MO;N?4L?ECL:'-XHO\OFZW\K-YE,9L4.$L1S$T$ECN$K3C7PNX@;
M%)SNJBM*6].B^&VST2G1"B_EI^D;DC]_7Y6_78:OZ=G9X-=D6=K6/ H*[XE^
MF[)^++^!&ZS=3^B]/Q,S#T+IURK,4C\W_P!-F _%8GX1<KJN4?1N[?!CY-[C
MK8*%!&7-?^@[=\;_ /=E7MBWHEZ)X?\ DE8?O=#^X!7"9?//;++C<B;S>_05
M?/C-O^5MUL.5_J([_<IDW//>!_BC7U%_ZUKZ+B\L-/D\TNS7J\W&_P#:'/V!
M?]55NW2M;OA<_P BOT>9']^E^2L5P'.?JV]GBW&+<F'FOC:\\IX:&-6+)I&*
MS0FLS%GQD,NX#0F*LN(VXT2BN]#^%\(1K0O>&\VB"Y;+3 MKTIR<]#CLQW)K
MZZO/DR" KAK^N-4W%[]$(&YH^ES!_JPOERUR'./U./N_F=IR7]'E[_Y4IUZM
M<4$1\_?D]:_CJ_<BK5\P\D=K><H^I=V>*?L?_P! VOXI'^Y#7<8?IV]D.&S_
M %+NV?>T3GWZ,;G^_1?NX5K.<_I;NV/>V_(_U=O9/N0GBGY/0?V)?]\J^2Y_
M/+Z7#,UXI=2Z_P"C)O[P[_W%JUGFCM1*1/+/^0EQ^^[WR:-7U7D/T)_-/NA\
M]_R+]1;^2/?<F:NB<RH=._*"\?&G_NI5\AUWGGME]XY-Y/X;7Y6L=$4&[<'_
M $KV_P#>9/R8JZOD'U[>R[Q?//\ *OI7]MO@MY7T9\H*"+.3I\H+C;&[U@5W
MR3'+;,CW6V7;''VWY;$]D3;47X:N1W-B@XX!;%< P)1)$UTHEK_#,$\?FR+?
MB6#Y);K%.=!;I?<VEMM2&F(C/9C1HC&]]XVVA1 :$T;$1U];P11+?>0^2L1X
M_C@.5(\ZW(AS[@K++'M">RVML''3/54$44W&F@W+ZSC@I[JH0[^!YO:\_L/S
MY:XDRW(T^]"EVRYLI&FQ9,<MI-/-B1H):*A)H2]%2@V"8#[D20W%+9))LQ9/
MPT<4505_46@A_BR.[:)-O?\ FB=;(L'';/8[V!VZ4P3U[]H5I5V]G5]&E,R<
MDCN:$3WJ>W<2$N#CZQ7>#G\5MF*XW:K3'OS4V>_;9-O??.?<([S22'W=6I3A
M*)F)L$0Z(IJH[T&@D+D7&<ERW&G+/BF4/8?=R>:=&\QXZ2G!;;55)OMJXUT+
MW=U$(@\DGT%1/OG/_P"^-$RL71!0:IDN!6>^6T&+< 62\0G2F6:[P6P;>AS5
M';W4041#$D]5ULO5<#U5]ZEUL2\;\471LV3T2CS*KDUGV!Y/QIR&8X[F4.,W
M(E&RVX_'D-QW@<9GPQ!%<=8-P!1P!]=O50+KHJ^5WQ6S;.R6+DGYF.['?LGT
MVPK]Q=@^-66_/WO,K<U<\6CLS(ETC,LW EB,B\VT%T)9,=K[#JFJ=HNZV)(X
MJ>J6W$PX^&:W35I])@X)F<D\4=F[U[EA\DN.<\2XO+O^.SVLSPMMD3@LW1Y2
MN,3OJ@LJW)!426PI&*;3)'-%30RK,NF;(KOAN;YOQ6UMGBM]>_\ :Y\*Y#Y(
MD9E;<:Y!M=IM\:\0Y#]O=M9/O'[5%0#-APG#5!5 (BZ(HKIT*O/%GF^:2G%F
MR3?$71&WJ3#66SB@4"@4"@4"@4"@4"@4&C0^'>,[?? R6'CD9F^MO))"<).]
MQ'1-7$+J>G0E5=/"A5O-!!C/EOC-YNF8G?V'&>^"N6=<>L:1BAA)61[/JD7<
MBJBJ"OI]FT^OZ)1-4YT0@.X>6YF;F[^6(N(?-[JO-I9GL-CO L=Z2C^YPUG"
MAR4%-GM';375?5ZZ435/E$(\E</V:7E7XXN7_(0O J\C7;NKPLM,27@D.1VP
M3H+"FV'V-.F@I[E$I#HAHT_AKBBZW5^^7+#;1*O$IY9,B<]$:-YQ\BW*9$J:
MJ2KUUH5;S0=1VUVQ]PGGX3#KI?"<-H")?1U54UH.W0:!DW$MGRK(FLFFWR_1
M;A&52@A N;T9B*1LI'-6&QZ!O!/7T\55?=HEOK8=ML&]REL1!W$NI+HFFJKZ
M5HA%N;X+R3D6;V+*;'?K'!@XN^_)LL.;;)<EU3FP2A/I)<;GLH:?9#(.V :>
MKKNT74E*$=)"1VDED!RD 4?-H5!M7-/641)25$5?!%)?JT0BSDN-R-=,DQES
M',5CW&U8S=V[TDQVZMQ2D_\ P^7$)I&B9)05"E:[E5==OAUHE*$-R2]$CNS&
M$C2W&P.1&0T=1MPA12!#1$0MJ]-VG6B'/0*!05USDF;M<;D>8\:YG"R*2Q'C
M#><,?&<RX%MD$_%>8>9?:5MX"-S83K &@&0KT6B4G<4I<HV-Q[.N*2,4QJU1
MX\2Q1KG*9D71YL!)#<DML*X#2KZB]7B,B4MPCHFXA@\VYZP/#;D_$GV^YW6Y
M6R6["<^;822";)B"-PF. 1FWJ$>.8'(4%51W(FB]=":)4CR&9<=J5&-'([X"
MZRX/42 TW"J>\J+1#5.4(,VXX/<XL%@Y9*45R3$9!77'X;,MER4T+8HJN*;
MN!VT15/7;IUH--;M_P Y8ER-;68=R@6?*),YS'8S%MDMNC%&SPV7M(S@,]ON
MRFY!BVZK?>W*J+J>M$LKQ-&NWM>4767#"!;+A)B>PQV8,FU,D<>&VTZXW&F"
M#HBN@!N(4U4%TU%$50B+SN8SDLKCZ3E,7*'HF,01AQIV*#'0F9;[DQ-KY/=Q
M%%0W#ZO;7X/C0A9NR_Z'M_Q9G[F-$(J\QF,0;OB,._S-0CV*5I<7P1%=;M5R
M'V.68:]-S/<;E#[A,HOBE;+09)MOFV/WO?&V/;N[U+XV(XA9OE5JRBWEB[<3
M^D2=$EVWD>VW%32VE-L!L1VKBG:5#[KPO H;$5#:,=VFQ%K.^1;?;/%Y(F)L
MF-]+NCTZ58G:G3C#.I6=V2=)N4$+=>K/<'K1=8S+BO1_:& ;=0V35!50-MX"
M3<FJ:Z+X5J=3@C%=$1-8F*P](FK=JQ4E H% H% H% H% H% H% H%!T+U9;7
MD5KD66]1AF6N6B#(C&I()H)(2(JBJ+XHB^-!A<3XWP?!7I#^)65BU.RAV2"8
M4_7'<I]4(B3X2ZT'?RW'QRK'+A8%>",LT$ 9#L6//!LP,3$_9Y8.,FHJ**B&
M"IKUH-!XJX2:XPN<VXC>@NZ3$D$@%:+9 <;>EO\ ?=(7XC#;NQ5U06=W;%-$
M$404T)JD'*;&WDN/7"QNMPW4FLJV(72&-RA;T5" GHID".B)(A;=X^'BE$(S
MXJX+;XXOLN]2G,=GF^<J1&=MV-,VF=&>F&*J+4I)4@A8$-[8LB*="^%TT4FJ
M6+I &Z6Z5;BD/Q!E-DTLF&XK$AO>FFYMP>HDGH5*(:CAO%MHP>Y2[G:[O>I;
MD\W'ID>XW%V7'=D/;$)XFSZ*YHV*;_'2B6X7"WPKM E6NYQPEVZ<RY&F17A0
MVG6'A4' ,5Z*)"JHJ40UC'>*>-<1N0WG%\5MEHNH@30S(<5MEU <Z$.X41=%
M]-!MY")B0&*$!(J$*IJBHOBBI0=9FV6Z,XCT>&PRZFNCC;8 2:]%ZHB+0=AP
M.XV;>Y1WHH[A70DU335%]"T&A8SQ+9\5R)W)H5\OTJX250IP3[F])8E$#*QP
M5]LNA[ 7U-?!43W*);ZYW%;-&E1'=%V*2*HH6G35$5%5-??HA&.(89RA9,QN
MN27J_6&9"R!V.[>(D.US([J>QQO9FTCN.7!U UVBI;Q/7KII1*4*(0UAT+E"
M)RAD>5WG$(T*T92Q:(;Q-W=J0Y#&U#*0G-J,#W-_M":"FW32B4RT04"@Q.23
MKY;;0_-QVTC?+HRHJW:UDA")X-R(: ZX) AHG44/:*^"D/C05R9MF-K>+!+M
M/%G(35VLCR'$M#A,Q[4;C,QZ;&24\]-)DFHSS[AQUW^IN\*)6+;O$BWXT=_R
MQEFTN1(KDVZL,NE+:C-M"3AHCJ-MJ>P4ZJ@)JOA1#1<6YPPK),R9P^V6ZY1+
ME/8:D>W288L1%EO00N'L;CB&I>U!'/>8*.B:*F[5*)HE*B$/<N6R5)N4YP[5
M*NH3L7N5KL/LD-Z:K-X?,"#UF@-(ZGHVHO&H"FSJ2;:)=GD1EQ];#<#BO7&3
M9EEV^8Q(LLZ[0G'945I#=1I@!<(M-19>$5:7<XT1"I:H&Z\?0+K:L"Q:UWS=
M\]PK1;XURWGW#]J9BM@[N/ZY=Z+JOIHA7FU8SDN-^;ZT_C'E#V3?.5BNDZW=
M^.D?V&([(=V1!T<<WB&G0O5U]RB>A:FB$,V2-'QS.;K9);0E8KI*>M,I@DU:
M4)XE/@JJ>E"5R5&Z^X*:USN*V,6>ZR?+=,VSW_%;[[K?8Z;-=.;3VWQYK8BZ
M/X?AN]UMWM=FU9E?<6BW. S;?GK%<;E/PQN12>W.]EC:;A%H@)'%CJA-[E,=
MZ"FG7QBS778*V4XK+)F*UVTCWTW>LR:&S/-M_%P7Y(B:4V5GU]'%OW;$LL/M
M26&I+);F7@%QLO=$TU1?["UT43$Q6'-W6S;-)<E2J4"@4"@4"@4"@4"@4"@4
M"@4&K99QO@^=/1W\MLK%U=BCLCD^I^H.Y#Z()"GPDUH,U9;+:\=M<>RV6,,.
MUQ$48\8%)1!")25$4E5?%57QH(^Y<X;9Y62(#EW&T!'#MOD-KMT]YU!=%YM$
M?ELN.MH)"OJMF*%N5"U2B:MJP/$?Q)QUJQ%+;GO XX\],:@P[6CA.%JBJQ!:
M9:14%$'5 U73K1#5.9>'PY7@QX;;UF@/-MNLNW&YV-N\S1 R P2*\4B.3&BB
M6[3=NW>C3J3$MFX^PT,'L)6=&K0VZY(<DO%8+2W8H9F:"*$L9MUY-^T!%34]
M51$]RB'QGW'EIY%MR6F]S[G%MA-O,2HEMF.0VI+4A!0@?$.CB(@^JA>&J^[0
M9C';"&.6T;8W<)]S$3)SVJZR3F25W^A7#ZZ)Z$]%!U,IP7#<W;C-9A8H5[;A
M*91 GL ^C1.(B$H[T737:FOU*#LXUBF-8=;EM.*VJ+9[83A/K$A-"RTKIHB$
M>T41-504ZT&2D1(DL1&6PV^(KJ*.@)HB^]N1:#]CQ8T0%;BL@PVJ[E!H4 5)
M>FN@HG7I08;+\4BYE:%LLV?<+?%,]SIVN4<)UP%;-LFS,.I-DAKN'P543W*#
MBPO#8.#6@;);9]PFP6]@QTN<HYA,M-MBV#32G\$!04T%*#YSJU9/?,>D6C%9
MT"WS)J''ER+G%>FM>R/-&V:-@Q(CJCFI"HD1**:+ZJZ] ZW'5ARS&,<B8_E%
MQMUR&V1X\*VO6V(_"7V>,T+2=Y'I,C<:[474=J>]0=_,G\A9L+X8S: O5RD(
MK"Q798P1%MP"17.X8.(NU=/5TZT& X?AY?9<(LV+9;96K5(QVVV^U,/L30FC
M+]DC"R;F@MAV^H(J"JEX^/2B6_404"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4$<\^_0IGWWCG?<2HF'G3Y5_I_PGXS(^1OT6EZN444/\NOTV\M
M_'I7X1>J83<M)4JE!5G'OT^XW[?_ )8*JROT+WND8-&38=QP150;UV[B1.B:
MKX:T51GPEFW).<6.Z3N2L27$KC$G'&A1B!YGO,"*+OV/JI*B$JIW$]4_K:)E
MT/-!]!>5?[/_  E%KQS>26!KOHW=WOAJ7!'T38W^]/\ RIVM2Q,'TX2)1[L3
ME/Y,7KXA*^XE1$[FA^2G\@L@^^Z_)6:V6F\LJ<L\D]JS-93;/-2Q_EOE/QJ3
M\I.N8UV[O?,N<[H_-+;JU+F2@^N$_P!)FQ_YW^!WJZ'E^ZWO\7=\BW6?Q>*_
M=;QW"DOG-^D;&?O6'RMVL#4^:',<ZW3^6?%!%8KYV4&/NWV@/V?_ &+1MN6^
M>>QZE8I^2UC^]\3[B%;>W<^I8_+'8T2=G')K'-EOPB+AJO<:R(1/RLL^R*C;
MR-&?VQ%[8Z&@M=HDWKKO1=*L]$I40HOY:?I&Y(_?U^5OUV&K^G9V>#79%G:U
MCP*"N^)?INR?BR_@1NLW4_HO3\3,P]"Z=<JS%(_-_P#39@/Q6)^$7*ZKE'T;
MNWP8^3>XZV"A01ES7_H.W?&__=E7MBWHEZ)X?^25A^]T/[@%<)E\\]LLN-R)
MO-[]!5\^,V_Y6W6PY7^HCO\ <IDW//>!_BC7U%_ZUKZ+B\L-/D\TNS7J\W&_
M]H<_8%_U56[=*UN^%S_(K]'F1_?I?DK%<!SGZMO9XMQBW)AYKS#D#",-"]<;
MXRN57]9K$=VWHV\^K<5Q#4W>U'5'"T(1#U5Z;MR]$6M"]X;U:)$V9:H,NY1?
M8KB_':=F0MR'V'S!"-O<G1=A*HZT0@7FCZ7,'^K"^7+7(<X_4X^[^9VG)?T>
M7O\ Y4IUZM<4$1\_?D]:_CJ_<BK5\P\D=K><H^I=V>*?L?\ ] VOXI'^Y#7<
M8?IV]D.&S_4N[9][1.??HQN?[]%^[A6LYS^EN[8][;\C_5V]D^Y">*?D]!_8
ME_WRKY+G\\OI<,S7BEU+K_HR;^\._P#<6K6>:.U$I$\L_P"0EQ^^[WR:-7U7
MD/T)_-/NA\]_R+]1;^2/?<F:NB<RH=._*"\?&G_NI5\AUWGGME]XY-Y/X;7Y
M6L=$4&[<'_2O;_WF3\F*NKY!]>WLN\7SS_*OI7]MO@MY7T9\H*#1N4<VOF$V
MJTNXY96KW>+S<V;3&8E2D@16B=9>>[CSR@:".C.P>G4B%/'HI+O8-<\^N<26
MYGU@AV"8VX(PV8$[YP%QM1U(B+MM[51>FFE$(DYBMMRSB^QH5UP!;K;K!(-(
M<MG*85L&9'=-AYQF1',5)6C..T1-EUU!%14HF$E\26YVVXHXDFU.6F=+GS)T
MUI^Y-7EYV1*=5PWCDLH@*I*NB"B>JB(E$-[H% H%!73R2?05$^^<_P#[XT3*
MQ=$% H(K\P48XW'<[+K6P:95C!-3K)<8_JR(A$^VV^XBHB[FT:(U=;)% A3U
MD]*>.7RUZ886MK&*;HCXK=L(@\MG*.?Y?FD[&<DN#F0V%^ ]*DE*!LECF!
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MR""O;.0S&:8>(?A-IIT7K19:R( MQ&&P:1D!; 19%4(01!1$%%3HJ)X45<U
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M<J(^/@33HH0K[R]>J>A:T=]DV73;.^'K$N_5$E H% H% H% H% H% H% H%
MH,#FN51L)Q6YY5,C.S(UL:[QQ8^Q'7-20$$>X0CJJEZ22@U?\?\ D#^J>^?R
MECW_ )E1)^/_ "!_5/?/Y2Q[_P RH'X_\@?U3WS^4L>_\RH'X_\ (']4]\_E
M+'O_ #*@?C_R!_5/?/Y2Q[_S*@?C_P @?U3WS^4L>_\ ,J!^/_(']4]\_E+'
MO_,J!^/_ "!_5/?/Y2Q[_P RH'X_\@?U3WS^4L>_\RH'X_\ (']4]\_E+'O_
M #*@?C_R!_5/?/Y2Q[_S*@?C_P @?U3WS^4L>_\ ,J!^/_(']4]\_E+'O_,J
M!^/_ "!_5/?/Y2Q[_P RH.>Q\CW6=E<#$<APVY8S-N<29.@/S9-ME-.A;R8!
MX?\  94A15/:6_A(FOHH-_H@H% H*3X+?>/"Y#M<Z+@^)Q9<J\VE+1'A27SO
ML4;A*N<9PWA(E%9$=R&P\ZVC8HVV?K*NY%0LM5R18,8O6*SY648['R>/9F)%
MSBVN2R+^]^.R9(+:$A:&2:@BZ>FBJM_!&2XE)Y#L\2V8YA27B8]/!9F*LJ$J
M%$^9H,YH]5,UV;WY$-XRV[G4VB@[2&BTK?451KR)E.0VNX7"/9)B00L6/3<F
M=%66WTENQ2VMQW.XBJ+2H)[^WM-=4T,=%W$G(V69';X^/,8PU+.?=@E2G8=L
M9CR;@K4:+W$V)+T91I'3:!Y57>J$B!ZRZH&YXI=3OV+V2^..,O.7.!%FD]%W
MI'-9#(.*37<1#V+NU'<B+IX]:(5R@9+?<C\WUF^?,:DXY\W6"YPH/M3HN^VQ
MFI#NV4WM$=H'Z$6B>A:2B&I<C ;..I?&14I&/2H]X!$]+<4_LZ=.O5@G4_5K
M UT4Q\<;[)B[V;_LJV/+YKEX)W9(FWV[O_51H;')-GQ;(<E@MPWKABCTY9#D
MME 4([SP(DQ$ E17 1Q%-=J>*EXUHYYQ@T^>[%.VVZ?9,[_M\6\_M.;48+,F
MZ^+:=L1Y?L\&[<>OC#C3\35SN)8GD& XJ[NY:Y:=Z&:+Z4$55KI_[.MUHIX8
MG'^"=GY9VV_=W-+K[>*;<OXXV_FC9=]_>W.MBUA0*!0*!0*!0*!0*!0*!0*!
M0:3EN?S<>R*VXM9L8GY->;C"E7-&(#\&,C46$ZPRX1%.D1Q7UY#:(@JJT&/_
M !_Y _JGOG\I8]_YE1)^/_(']4]\_E+'O_,J!^/_ "!_5/?/Y2Q[_P RH'X_
M\@?U3WS^4L>_\RH'X_\ (']4]\_E+'O_ #*@?C_R!_5/?/Y2Q[_S*@?C_P @
M?U3WS^4L>_\ ,J!^/_(']4]\_E+'O_,J!^/_ "!_5/?/Y2Q[_P RH'X_\@?U
M3WS^4L>_\RH'X_\ (']4]\_E+'O_ #*@?C_R!_5/?/Y2Q[_S*@?C_P @?U3W
MS^4L>_\ ,J!^/_(']4]\_E+'O_,J!^/_ "!_5/?/Y2Q[_P RH'X_\@?U3WS^
M4L>_\RH,_@N9)FUJEW K7)LTJ!/DVN;;IAL..M281['$WQG'6R37P436B&ST
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@CGGWZ%,^^\<[[B5$
MP\Z?*O\ 3_A/QF1\C?HM+U<HHH?Y=?IMY;^/2OPB]4PFY:2I5*"K./?I]QOV
M_P#RP55E?H7Q(1(5$D115-%1>J*BT58'%,'Q#!8DB!A]FBV6'+>63(9AMHT)
MNJB#N73W$31$\$]%!H'F@^@O*O\ 9_X2BUXYO)+!UWT;N[WPU+@CZ)L;_>G_
M )4[6I8F#Z<)$H]V)RG\F+U\0E?<2HB=S0_)3^060??=?DK-;+3>65.6>2>U
M9FLIMGFI8_RWRGXU)^4G7,:[=WOF7.=T?FEMU:ES)0?7"?Z3-C_SO\#O5T/+
M]UO?XN[Y%NL_B\5^ZWCN%)?.;](V,_>L/E;M8&I\T.8YUNG\L^*"*Q7SLH,?
M=OM ?L_^Q:-MRWSSV/4K%/R6L?WOB?<0K;V[GU+'Y8['6=P;#W\K9SIZRQ#R
M^,RL9B\JTGM(-*)#HA>[M(AU\=JZ>%67;!047\M/TC<D?OZ_*WZ[#5_3L[/!
MKLBSM:QX%!7?$OTW9/Q9?P(W6;J?T7I^)F8>A=.N59BD?F_^FS ?BL3\(N5U
M7*/HW=O@Q\F]QUL%"@C+FO\ T';OC?\ [LJ]L6]$O1/#_P DK#][H?W *X3+
MYY[99<;D3>;WZ"KY\9M_RMNMARO]1'?[E,FYY[P/\4:^HO\ UK7T7%Y8:?)Y
MI=FO5YN-_P"T.?L"_P"JJW;I6MWPN?Y%?H\R/[]+\E8K@.<_5M[/%N,6Y8S*
ML.Q?.+6EERZU1[Q:D="0,66". +S>J"8^E"1"5-4]"JG@M:%[,M&C1X<=F)$
M:!B+' 6F&&Q0 !L$01$13HB(B:(B4%?N:/I<P?ZL+Y<M<ASC]3C[OYG:<E_1
MY>_^5*=>K7%!$?/WY/6OXZOW(JU?,/)':WG*/J7=GBG['_\ 0-K^*1_N0UW&
M'Z=O9#AL_P!2[MGWM$Y]^C&Y_OT7[N%:SG/Z6[MCWMOR/]7;V3[D)XI^3T']
MB7_?*ODN?SR^EPS->*74NO\ HR;^\._]Q:M9YH[42D3RS_D)<?ON]\FC5]5Y
M#]"?S3[H?/?\B_46_DCWW)FKHG,J'3OR@O'QI_[J5?(==YY[9?>.3>3^&U^5
MK'1%!NW!_P!*]O\ WF3\F*NKY!]>WLN\7SS_ "KZ5_;;X+>5]&?*"@@?S"2<
MKM3-N<<R>R0<%O\ <(MFF6_(+(U/M\;>VZ\4F5(>?0=FYE!$2:TWD.I(GK(3
M#N>76Z]^-EE@BW&RW>RV*Y-,6VY8M;6;9:'A?C \YVTCD39N"1*+FU51-$]9
M=>@EW.:;Q\SWO#)&0VZ1<>,P<N#N2-1K4EY!98L@W %]KMN&#2]Q\MX#\,01
M=*$,KP0]?W>/F1OC$EF,S,F-6!;A$"WSG+,#RI$.1';$!;-0]P4U'0O%:$I+
MHAK=JP/%;&+PVJ"49'RC$2C(D$H!!=[\=EM2<56V&S55&.WM:]8DVZ$2*'+:
M<*QFQW)R[VR$K,TT>%M2>?=:8&4XCSXQV7'";8%TQ$W!9 $)415UTH,_05T\
MDGT%1/OG/_[XT3*Q=$% H% H(HRFWP\!ODS(Y,9N5QME)BQFEM> 78T66]HT
M%P5LD45:=Z-RDT_6FNOK5XW1PS7HG>PLD1CGB_=N\WW_ 'MAQ2#Q#&NBN8/&
MQMJ]=HD(K*$ 97851W(JQD0]FNW7T>%6MBWHH]<<8HGX>&OJHU?,+&_QC!O&
M4XP1C@\AIY[*L:9?6(3(."7<FVIT2#L/INW$V)"AKU':>FM;HX=L;GCDL^5$
MW6^7ICQAIG"6<V*Z9Q/MLF7DS<RX//O8M'OETDS8QP C,J;)MG*>'OB0O.IO
M'7:O0NFE8VGSV7W3$2U^@UV'-DNMMNF9CKF4[9E8TR;$K[CRCN6Z0),,1W]K
MUGVB ?7VGMZKX[5T]Q?"LVZ*Q,-UDMXK9CKA"=KXWYMN=QQH<@F6>R1L<W/Q
M[G;-TQY981R8;(V)#8@0*)D)@)A\+5%31*PL>"ZV:M?;@RS,5I%&\W+.L\PB
MW2Y6<8XW<+=$8<?+(L>(GHP(V"ENDPGE1]H4TU,FR=1$K*FZZW?#)NRWV1\4
M5CKC[O\ 5KF&\N\BW'(\;@9IC$*QV+)%<;BS6I!O.H_[.;[+1 BJ@&:#X%[B
MIXUXX\_%=1Y8]1?-T1=$1$IQK+; H% H% H% H% H% H% H% H% H% H% H%
M H% H% H*D<EN7[\=IF,\AYUA0I:+8U=[1,RW&8B(Z4MUX"9B=^0]N[?8#N$
MVN[4DT!=%HLL3Q;>IN1\;XK?KD.RX7&UQ),D>PD1$<<:%2VLHI((Z_!1%\-*
M*H(Y2OEV8R/.H,^U7-W/B>MZ\4R(./M7%I&H;+<@>W,)DT3NR2<"4CAIL#X/
MN42L]#*442.4X0":K8+)!M54!=44WH*KXHBZZ40X[G;(%YM\FU71@9-OEMDS
M(8/70@)-%ZIHJ+[BHNJ+U3K08AK!<6:MKEH6"KUO?21[6U)??DK)6:';>*2;
MSAD^1#ZNYY25$TTTTH.Y8L:L^.!(&U-.(Y,<1Z7)DR'YLETQ!&Q[C\EQUPD$
M10113T%.B:4$,><WZ +_ /&;=\L:HF$WV7_0]O\ BS/W,:(=Z@JEYR,@N5OF
MX1;[/)E6JZ 4^?&O,24_&=:4!:8(&D9<!%-1<5%(D51%50?AE72<EP1DF^M*
M;-E&)J<DV15Q^4O,KM[;<;/?">=B9&_)?@W"0\](*3>+8VQ[:JF\3AJ3K#S!
M]27UFW-.G1*\VP6V^7]WW3N^VOMA?#?Q17K2E:;U9N'LMN>(9'<8MGPB^*]?
M<3G3WVXL5AXW$]OM_<=,1':XX,AD?UKA(GP:UUUEV>R+[8K=&RZGV3X2]:TE
M)MDR&P9+#6XXY=8=XMZ&K2R[?(:ELHX*(JAO:(AW(BIJFM8-^.ZR:71,3ZUH
MFK)51)0*!0*!0*!0*!0*!0*!0*!01SSS]$64_%@^[MT3"1J(=>=-CVV#)N,L
ME"+$:<D/FB*2HVT*F2Z)U71$H(W@<^X'<'[6RW'OC#-XDQ(=OFRK'<XT,WK@
MX#,?[.ZP+:(9&*(2EIUH)0H-9SR]S\?L<2?;E$9#UZL-O-3'>G8N=YAPGTT]
MU6GCT7T+UH,/>[QD<OD),)M%Q"V1W\?<NK<SV<)+C<EFX,,Z[35$5%;(AT7W
M=?11+3X]_P"1F,&NN3R<G:D2PO4K'HC7S<PV#2QLE6SI(70O6)6FR+8O3<7O
M4&VVF[Y?8,Y@8;D]QC7R#>[=-N%LN+,7V&2R[;'HX.M/ +K@."8R@(# 0VJ*
MHJ+JBT$@T04"@4"@4$<Y']-> ?>/*/NUGHE(U$% H,1DT'(;C9WHF+W=JQWD
MR!6;E(AI<6P$21316%=9W;AU'7>FGC05)P?+)1YCBF4NY#A\W+L@OZVJ\6>W
MX]$CY4VR;KC3CD@P=)]M=&T5]3Z *JJ$>G4LMUD;MW8QZ[O8^V+U^;A23M;)
MZ*)S!:)61754313VI157KB6\R)N<8FSC-KN<=\;3)C\GOW&P-V<%F"WW6G3>
M1EK62LE=FP"(5#5?K=:)68HA@L@P[',I-AR^PO:BC@XR.CKK*&P_M5UEU&C!
M'67% =[3NX"T34>E!\W7#,>O2H=P8?5\7CD-R6)DN,^!NMBTX(.L.@8-F("A
MMB2 6G456@S$&%#ML*-;K>P$:!#:"/%C-"@-M,M"@  BG1!$41$2@@G(OTOL
M-_X1G?*':)Z$^T0XI49F9&>AR!WQY#9-.@OI T423]5%JMUL71,3NE:VZ;9B
M8WPKFG'S,;&OG9^Y/M08=Q2VY3 00W(#4I(DA]MWJH[PVO%T7Q546N'OY1BF
M(S73/PW4NCLFDSXN[MYK?QSBMB/BMXK)[;:Q'@ER_LMXWD5@R.,*-VYQ!Q^Y
MBG018D$BQ#7T(C;R(&ON.5U.:(Q9++XW>2>R?+[)V=[EL$SFQ7XYW^>.V/-[
M8V]S=:V+5E H% H% H% H% H% H% H%!',_Z><>_X1OGX3M%$N[=^9>*+!<I
M-FO696B!=89]J5#D2VFW6C3KM(575%ZT11&K?-G(%XLE_P OQB#CTS%+9)NP
M6]]R1+5V5$M3[S8.HK8*'V46MXZ+IUJ:#=+-Y@>(;C;[>])S6RL7&6RR;T/V
MUK<#[HHI-Z*6NJ$NVH31FLZGNP<AXY09!L1I62.QI2 1"#@.6&[*V#B)T(5=
M1M40NFY!7Q1*(8"+:(^6\C9]9KX[,>M,$;"]$88FRX@M/%&E;]I1G6U3<AHI
M#KHOJJJ=$HEIN.XY!=XVXD==DW(W\N.QNY"\5UN*NR3.R2I)>NLC<VA.+O)&
ME%%Z:^"4&^X4RYC_ ")DV%6^X3)V-1+7:;I'8GRW[B[!ES'IK+C(OR3==V&W
M&:<%LW%V=5'02H))H@H% H% H% H%!'/$'^*YE_Q=??E-$I&H@H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H(YY]^A3/OO'.^XE1,/.GRK_ $_X
M3\9D?(WZ+2]7***'^77Z;>6_CTK\(O5,)N6DJ52@JSCWZ?<;]O\ \L%597Z%
M[W@5UIQL35LC%11P?A"JIIJFOI2BJ,N$N++]Q59KM;+]ELK+7KC.*8Q(EHX/
M9!00=J=QUU=Q*FXE1437T>E29='S0?07E7^S_P )1:\<WDE@:[Z-W=[X:EP1
M]$V-_O3_ ,J=K4L3!].$B4>[$Y3^3%Z^(2ON)41.YH?DI_(+(/ONOR5FMEIO
M+*G+/)/:LS64VSS4L?Y;Y3\:D_*3KF-=N[WS+G.Z/S2VZM2YDH/KA/\ 29L?
M^=_@=ZNAY?NM[_%W?(MUG\7BOW6\=PI+YS?I&QG[UA\K=K U/FAS'.MT_EGQ
M016*^=E!C[M]H#]G_P!BT;;EOGGL>I6*?DM8_O?$^XA6WMW/J6/RQV-$F\59
M#*YMM_*C>9S6;!#A%$<Q(1)8SA*T;?CW4#8I&CJHK2EO'Q\-MGHE*B%%_+3]
M(W)'[^ORM^NPU?T[.SP:[(L[6L>!05WQ+]-V3\67\"-UFZG]%Z?B9F'H73KE
M68I'YO\ Z;,!^*Q/PBY75<H^C=V^#'R;W'6P4*",N:_]!V[XW_[LJ]L6]$O1
M/#_R2L/WNA_< KA,OGGMEEQN1-YO?H*OGQFW_*VZV'*_U$=_N4R;GGO _P 4
M:^HO_6M?1<7EAI\GFEV:]7FXW_M#G[ O^JJW;I6MWPN?Y%?H\R/[]+\E8K@.
M<_5M[/%N,6Y,/-?&UZY3PX,:L632,5FMS69I3XR&7=;:$Q5DT;<:)1530_A?
M" :T+WAO5HA.VRU0;<_*<G/0X[4=R:_U=?)H$!7#_MC5-R^_1"!>:/I<P?ZL
M+Y<M<ASC]3C[OYG:<E_1Y>_^5*=>K7%!$?/WY/6OXZOW(JU?,/)':WG*/J7=
MGBG['_\ 0-K^*1_N0UW&'Z=O9#AL_P!2[MGWM$Y]^C&Y_OT7[N%:SG/Z6[MC
MWMOR/]7;V3[D)XI^3T']B7_?*ODN?SR^EPS->*74NO\ HR;^\._]Q:M9YH[4
M2D3RS_D)<?ON]\FC5]5Y#]"?S3[H?/?\B_46_DCWW)FKHG,J'3OR@O'QI_[J
M5?(==YY[9?>.3>3^&U^5K'1%!NW!_P!*]O\ WF3\F*NKY!]>WLN\7SS_ "KZ
M5_;;X+>5]&?*"@B7S!/W2)B]DF6N[62V(Q>HYS8^4SQMMHGQDC2=\1]314=W
M+H:-?VF_ZS2B8=WA7)9&0V.:TXF*-Q;>\+46/A-P"XPVQ,=RHYVQ 6R5>J#I
MU3K0EBK]SG)AWZX8?C6+G?LR8O7S%;K7[<U""2C=M&YNR#>< D9 &U(411)2
M).GO"C=>.LW_ !]L#MS?MIV>[0)LJTWBU..A)]FGP7.V\V+S7J.CKHHF/BB^
MBB&UN. TV;KI(#8(I&:]$013557ZE!JN)9Y"RQT6FX$JW'(A,7>VI+[.LJVR
ME)&GP1IQQ1UT3<#B"8[AU3KT#[MF:%<,J>Q)ZP7*!-CQ%N#LN0L%R,+!.JRU
MN6-+>,5>47%;0@35 /PTH,GD63X]B-M*\Y1<XUHM0F+13)C@LM(;G01W$J)J
MOHH(*\DGT%1/OG/_ .^-$RL71!0*!0*#1>9X-SN7%>60K.I_.#MO=1L&P-QQ
MP4T5QH1;$B4G 0@31/%:\\D3-LT8VJB9Q71&^BIOEUB7/$.5;7-O\*7CELFL
M/V]7[C$?BL2'WQ168W<,$%#(Q0AW*FNW1.JHE86&)B[:Y;E&'-ARS.6=DKG9
MO;;)=\/OMNR4R:L#\&0EQ>;U[C; MJ1.!M0EW B;AT%>J>"UGW1$Q-779;;;
MK)B[=15[BG#[3=,OF/6'/7OQJL4AY,2<6UD#$B/[*'<D20>'0T)'G8ZB)MDF
MU2%>J::W3Z:RRZ9MG:YO0<OPXLETX[OBZ-G0G5.1KA9=;'R1&;Q2[2!-BWY*
MWK(L$A]45 (7CV]D]?6[,G;KIHA%6?QTV3L;WYTV[+_AGKZ/3M:_Q?R#-RO-
M+Q9G,[@7N':W$2#%CP BG<(ZQFR-]MSN+ZK3QDVNS<B[=?!:ICOXIF*U>6GS
M\=\QQQ-$N7JV,7NSW"S2A$XUQC/0W@<%3!6Y#9-DA")"JHJ%U1"3ZJ5[S%8H
MSKK>*)CK0I;_ "^94LJRID/),R?:["AK;V8,$;;+:=[1--.C)"0XJF"+I]E!
MQ%'<*IZRK6+;IZ36K7QI+JQ6_=ZJ-KE7KDCCR$_*R)EK-<9B-&Z[>8(!!NL=
MIL5)3D1%7M/"*?"-@A+1->VM>U;K=^U[S=DQQM^*.OI]GW-<Q;FG.+G=<8#)
ML/C63'\G=%B/<O;U?,''FB<8$FA914)W1$%"T]_1>E>-FHXKJ4>6/4WS,5MI
M$^M.-9;8% H% H% H% H% H% H% H% H% H% H% H% H%!7#EZ\W2Q<FE*.Y
M8--M#ELAK&L6<7AF([$E-.OJLF*PX!=ON(2"3GB6U.J;:)35:\D?/ V<LF^Q
M2I VQ;B^EHD))@.$#*N*D=_3UVUT]4]/"B$4/^9&X/VW\8,<PAZ\8W:K+;<@
MR^>-SC1CMS-SC>V=IEIT-91M-(2D@D'K)M\:)HG:+)9FQ6)D<MT>0V#S1:*F
MH."A"NB]4Z+1#HY%?H>,V:5>IPFXS'0!%AE$5UUYXQ:::#<HCN<<,0'<2#JO
M543K0=*SY3\\0+H\U;)07>S/E"N-D4HRR0E(RU)%L3[R,KW&GFG 57430TW;
M5U1 _,3RT,L2YJW:9UK^:I96][V[V4A<?:%%<1HXDB0!(V2]LUW=#0A\170(
M.\ZF3X]%X?NF*R;G&:R2<<&3#M1N"DEUAN8&XP;UU44V%JOO43"PME_T/;_B
MS/W,:(=Z@T+E#B/&>6X4"W90_-:AV]QQYIN"XTUN<<04W$IM.+J*"J)M5/A+
MKK67IM5?@F9MIM5NMB=Z*<=Q>18N(YELL8N/Y?Q)D,R9#;)! WQA.*^K8HV(
MKMF6]_;UUW&>JZUL,F2+LT3=Y<ML?;]URD1L['%YA;SB=U_H]R3*'0E\83F9
M4MK3[(VLZ0TP41YYH-7#;[1.CZJ*@D2;O%*MR^RZV;[8\\>[I3=,;*[FV>6&
M0S+P6Z/VAW?B!7F4.,M$:N.LP@;:$@)"52 >ZCA-@>A(*IZ%2L;F44R17S4V
MIL396K7*!0*!0*!0*!0*!0*!0*!0*".>>?HBRGXL'W=NB82-1"+K]PI:KA:[
MFQ$R#*%F2H[X,-NY/>5C]UP"04,%DJ.S5>H[=-/11-4>N<9\M7O'\9PR\66V
M6VTVR99"GWB!?I/MB1K5)8<<-@6X+) Z0M+L47D42T5"Z5-4)=LO%]GL5TCW
M:->\DE/1E4@8N&0W6=%+<*C]D8D23;-.O1"%>O6H&<RS&(&8V"5CUR-UF/)5
MEP)$8D!]F1%>"0P\VI"0[VW6P<'<*CJG5%3I08O&\(=L]\DY->KY+R*_O11M
MS,N8U%CBQ#!Q75;;;B,LCJ9KN,BU5=H^")0<<OCN%(P^=B+%PDQFIMSDWH9P
M(T3[4F5=SO/JH8$"B#Q[10A7U4ZZKUH.6PX.5MOJY/?+Y-R*_A&.!#DSAC,M
MQ(KQ@XZ##,1ED$5TFFU<,MQ+L%-41-*#;:!0*!0*!01SD?TUX!]X\H^[6>B4
MC404"@4%6.+<MOMJR6V6:?=>.;U<GYI0Y-^:O[,K)Y,9Y\E0"VAO>>$20$'5
M-=$31*)3UG6=PL$7'"GL=V/D%X:LBO=Q&QC]Z-(D=U?5+<B)'V[4T5=:(:5@
MG-]URN]X_#O6&O8_8,S8D2L-NYSX\PYC<5KVA>_&:$2CJ3/V1-2-/K=:)HF*
MB&IY7GD+%)'LSD"5<"8A/W>YK$[*>R6V*J"X^:.N-J75?5!O<9():)JB(H=K
M*\M;Q6RN9 5LEW2U,,N2I3\ X8HRPT&_>7M4F/NW)\%&]RK[GA09FW2SGV^)
M.<BO07)3+;Y0I2 ,AA7!0E;=1LC%##7:6TB37P5:"NK^3X]DOF^QO\7[G&N7
MS;C-Q@W#V5P7>Q*:D.[VG-JKM,=>J+1/0LG1!00=>>0,4L>29QBUX8EN6J[$
MT+OL[;9@$IZ,D>1J2N(B(HBT2*J^.NNE<OFYA@Q9LF*^M+^S?2D]/8ZW#R[/
MEPXLUE*V=NZM8Z.UO=D83->.OF:[DOMI1W;5<#Z[PFPB5@G/'X2.-HXGZE;;
M%'S]-PW;Z<,]L;/?M:?-=_3ZKCLW5XH[)VT]DT9;"[R_?,>BR9R(-VCJ<*ZM
M^D)L4E:>33IIJ0[D]Y4K(TN6<F.)GS1LGMC9+&UF&,668M\L[;>R=L-@K*89
M0*!0*!0*!0*!0*!0*!0*".9_T\X]_P (WS\)VBB4C40B&=Y?[=+6]M,9IDL"
MV7Z7<)TVV17+7[.)W9YQ^0 *[;G'$!2=+35Q51/34U$J6RWLVFVP[7'(BCP6
M&HS1.*BFH,@@"I*B(FNB==$J!U[[C]ER>W':;_!:N%N,@<5A\=R(XT2$!BOB
M)"J:B0JBIZ*#BQW%L?Q.&Y!QVWM0(S[JR)"-ZJ;KQ(@J;AFI$9;1$=2)5T1$
M\$H.K.P;$[E8;=C$RUM'8;0C VR$BF QTBM*RUVU D)-H*HIU\*#FL&/8MB,
M!]G'X46V07'3>EFUH/<?3U"-YQ553--NU2,E7IIZ*#,=YGL^T=P?9]O<[NY-
MFS37=N\--.NM!\/RXD4!<DOMLMDN@FX8@*KX]%54H.1MQMT!=:-#;--0,50A
M5%]**GC0?@/-.J8MN"9-KM<0515$O'1=/!: T\T^V+S#@NM%\%P%0A7T=%3I
M0?0D):[21=JZ%HNNB^XM W#NV;DWZ:[=>NGNZ4'[0*".>(/\5S+_ (NOORFB
M4C404"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'X1" D9D@@**I$JZ(B)
MXJJT%3[]YXK1'N]Q;P_![CDV+V@MMPR%M]8[0#N44<0!CO(C9*GJ$ZX"E[B4
M6HL1QWR#CG)^)P<QQ=XG+;,11)IU-CS#[?1QET45=#!?'151?%%5%1:*MIH(
MYY]^A3/OO'.^XE1,/.GRK_3_ (3\9D?(WZ+2]7***'^77Z;>6_CTK\(O5,)N
M6DJ52@JSCWZ?<;]O_P L%597Z%[W2,&C)L.XX(JH-Z[=Q(G1-5\-:*HSX2S?
MDC.;)=9O)6(EB5QB3BC0HY ZUWV!%%4D!]5)40M4[B>H?UOA1,NAYH/H+RK_
M &?^$HM>.;R2P-=]&[N]\-2X(^B;&_WI_P"5.UJ6)@^G"1*/=B<I_)B]?$)7
MW$J(G<T/R4_D%D'WW7Y*S6RTWEE3EGDGM69K*;9YJ6/\M\I^-2?E)US&NW=[
MYESG='YI;=6I<R4'UPG^DS8_\[_ [U=#R_=;W^+N^1;K/XO%?NMX[A27SF_2
M-C/WK#Y6[6!J?-#F.=;I_+/B@BL5\[*#'W;[0'[/_L6C;<M\\]CU*Q3\EK']
M[XGW$*V]NY]2Q^6.QHL[.N2F.:[?@T7##>XXD0U?E9;HYL;>1IP_MB?8T]<1
M:[1>NNNY.E6>B4:(47\M/TC<D?OZ_*WZ[#5_3L[/!KLBSM:QX%!7?$OTW9/Q
M9?P(W6;J?T7I^)F8>A=.N59BD?F_^FS ?BL3\(N5U7*/HW=O@Q\F]QUL%"@C
M+FO_ $';OC?_ +LJ]L6]$O1/#_R2L/WNA_< KA,OGGMEEQN1-YO?H*OGQFW_
M "MNMARO]1'?[E,FYY[P/\4:^HO_ %K7T7%Y8:?)YI=FO5YN-_[0Y^P+_JJM
MVZ5K=\+G^17Z/,C^_2_)6*X#G/U;>SQ;C%N3#S5F&?8/AP7KCC&"RN_%-9CN
MV\6W7U;C."XI/=IA4</0A -!\-VY>B+6A>\-ZM$B;,M4&7<HOL5Q?CM.S(6Y
M#[#Y@A&WN3HNPE4=:(0+S1]+F#_5A?+EKD.<?J<?=_,[3DOZ/+W_ ,J4Z]6N
M*"(^?OR>M?QU?N15J^8>2.UO.4?4N[/%/V/_ .@;7\4C_<AKN,/T[>R'#9_J
M7=L^]HG/OT8W/]^B_=PK6<Y_2W=L>]M^1_J[>R?<A/%/R>@_L2_[Y5\ES^>7
MTN&9KQ2ZEU_T9-_>'?\ N+5K/-':B4B>6?\ (2X_?=[Y-&KZKR'Z$_FGW0^>
M_P"1?J+?R1[[DS5T3F5#IWY07CXT_P#=2KY#KO//;+[QR;R?PVORM8Z(H-VX
M/^E>W_O,GY,5=7R#Z]O9=XOGG^5?2O[;?!;ROHSY04$9<ZW>#8L*;NMQ7&AA
MQYK2NKF+#TJ#ZS;HIV6F <<)_5?5VBOJ;Z)AK_EP]AGVW)\EMMUQ^9$O-Q;)
M+9BD9Z%;X)QXS;1"K4D0=%UQ$0W$($Z^LGBM"4>Y[F^*P>2[K(8Q_#;'R%;;
M[%MEIR+)'BAO-MI;3E.W.<C/;,V#]2-&+?HI+ZY#ZJ42ESR]W*W7#C=ENU6N
MWVR';Y\^WB5D)URURRC2"$I<5Q[5PVW5U)"-5777JM$2D^0PW*CNQG=>T\!-
MGIT7:::+_P!=$-!Q' K]C;L:3(ND27(MEMM^/6Q1BNM#\V0GD)TWD[Y;GW6T
M014=  AW:$BJ*$MEL&/':+CD%UD/I)F7V<,M305'M1V8S,9EA-57H"-*731-
MQDNFJK1#GR+&,>RZVE9LHMD:[VHC%TH<QL7FE-OJ);214U3T4$%>23Z"HGWS
MG_\ ?&B96+H@H% H% H,??+':<EM,NQWR($VU305J3&=342%>J*BIU147J))
MU1>J=:B8B8I*MUL712=R/[-?[GQO<X^&YU-*5CLHNSBV7RB1-^B:C!N!KH@R
M!1/L;JZ(\B?K]47SB>'9+%MOG'/#?NZ)\)]?O2!#OUCN#R1H%SB2I"HI(TP^
MVZ>B>*[1)5Z5Z5AE1?;.Z74S''ARW$[WC!/>SI=X,B$DC;N[9/MD"'MU37:J
MZZ5%T5BBN2SCMFWKA5O >,.3+9FAW"%#M;EPX]E"V_%68XV$YV3!$D:8<1A>
MV),2$+5Q--V@KZ5K4Z?278[YNK5R?+^59-/GNOB:TZ.W:L=CO(UHR!V1:>P]
M:\RBMDX_B]S08T[415=6]RJ#K:JG1UHB#W52MK%\3VNILS1=LW7=4NEBO(%^
MR/(I]AD8D];@M#XQ;O,.=$?&.ZY%&4VFQHE(]PN FH^"KU\%J+;YF:45QYKK
MKICAI3?M;K<(3-R@2K=)$3CRV7([H&FX"!T5 D)-4U147JFM7F*LB8K%$&VS
MR[7U7;#"R[/',@Q:Q%O8LXP"MQDH-$TTOM4>9W4)K=J!*JJFE8ENFB)K5KK=
M'.SBNK$>JGVU;I*P_.\9BO2L+R^5/;CMDXW8\D:&ZMNJ*:HV$H%8DBJZ:(IN
MN=:]^&8W2R)QWVQ\-W=.W]J \?R \;;PC+Y7(EYO,Z3/C_/^/2+G+E,!'>0O
M:D6(CAO(D--2+N;M=GK)U1*P+,EW%%9:VR_AX;INF=O7/?[%M+/>[/D,!NZ6
M*?'N5N=^URHCH/-*J>*;@54U3TIZ*V<3$[FZMNBZ*Q-8=^I6*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!05QY_P KLF.Y-'AW8N/Q=GP1['XVV^;<+CMW."I%
M[(TX@L:_!WJ**N[K1,)1Q&(&,<.6J*3X9:S:\?;T=BH)M7-MJ+N1&D7<A"ZB
M;1UUW(O6@JE(SK!V[%.>L./<=0;=(M5JO>4V I<AMV[RFW79+5OM[,90%'F"
M! <!P%^R%M(-G6B5XX3WM$..^C11T=: ^P::$WN%%VJB>"IX458K,,>7*<>E
MV4)"19#A,2(L@@5T DPWVY+)&"$"D".-#O%"%5'5$5/&@Q^-8Y?+(]=)\J;$
M?N-_GN7.[JTPZVTCHPHT&.#"$Z2H(-Q6]ZDJ[UU5-NNB!D<.Q_\ %7%[5CY/
M>U2(,<&Y<S;M63+)-\B02:KH3SJFZ77Q*@@?SJ8QCTKA^Z95)MD9W)()P8T.
MZFV*R6F')@;@!S35!7>6J>_1,+"V7_0]O^+,_<QHAWJ!01L'_P M<TO-EZMM
MSVU(X.Y=4^=K"NPT1/=<BO"O_P!A6LWSX/79/V7?M]ZNZ71X[M-KM\_(>+;U
M"CS&<9E+<,;;E,@Z*6.\$3S(M]Q%Z,NB]'7W@&KY[IF+<D3YHI/YH^_9*(ZG
MTC#/&'(S"Q&@BX-GKHQC9;1&V(61--[6E$11!$9C0;.G_B@/I.HK\[%M\UGV
MV_L]QNE*M8"Y0*!0*!0*!0*!0*!0*!0*!01SSS]$64_%@^[MT3"1J(:P]R1Q
MY'1Q7LLLP=I%5Q%N$75-OCT[FNJ5[QI\L_NS[)16$>VGS#P9DRW2[OCTFR85
M>7@8MF23)+"#]G^T.26$7<PV[]::D6FJ;M-:S;^7W1$TFMT='W=:O$DN!G&%
MW26U MF1VN;.>549BQIT=YTU1%54$ -57HFO1*P+L.2V*S;,1V+5ACN2KS=+
M-C;7S-(&#<;G<K99V[B8B:11NDYF(;Z":*)& N+VQ)-JGMUZ5Y)=)G#YT2=(
ML[F;W-ZWW.(IC"D/M?.C<B,^T12(L@1 A;421MYOMD/K#M4-5W$M<P:Z0<4Q
MVX9GFF5W)Z*U>+[946YR"D1A;@WN5#C*C8-Z]SMQ@'=^R]V@Q\[,+U<TON>V
M6^OI:;'?K+:[5:6$:6'+ML\+6X^3X&WW%<>&>:MEO101&U3ZY"#K2<PS+$+C
M<[]F07J.S+DWYO&H;CUM<M+RP6IDJ&R;3(+)!7(L;N 1.=31173U=P<5XR3,
M</MCC Y-(N4Z]XN%UCR9(,.JW>5EPXB!"[;.FLHIHMLMF!-B:!Z%+4-WXJO=
MXG/9/9[V4]MZT3V1A6^]K'<NS$.1#9<%7W(:FRX)N]XFB!QQ=OJD6X5$06*X
M9LWR!F]MNDN-<ACV>T7&PVID2B1F%E2;PTC1NEW2(W$BM=U[9^Q#0>H?>2S\
MRBYOQZOML>%CESN+L&XVA@"=>>?6R7.6N^02BG:;..WL$6D4E]9531!H)#HA
M'.1_37@'WCRC[M9Z)2-1!0*!05%L]WL>3<J6+&XUVXZM5UL]["8X6/6^8U=)
M!0R/?%:E.M!'(G$U!Q!<)>O3T463+SK=L;M]GQJ%EUEM-UQZ[7^)"GR\BV);
M;<R3;QN2B,Q) =[8FTR2[4W'ZQ(FJ*1")N%<SM%TSW$68EEQ06)MNN46Q0+!
M)DRKUCD%@BDDU<$<(FA[A$H*0"'KEH.X:)E:ZBK1,XP.Y9-+D2;3<F8'SI:)
M6.W59#!2"]CEDA=QC:ZV@NAJ>F_<*[D_6Z$2R=YQ>7>H<&U/R66[3"N<.;[.
M#9JKL.W['FF'%(UU+OM@9%\%13;M]-$-HH*V/XQCV->;[&_Q?MD:V_.6,W&=
M</96Q:[\IV0[O=<VHFXRTZJM$]"R=$%!6;D/C?*HM]NMSCL,K8;Q<Q%N0X\/
M< [DZ@:DFFB#W#T15^#TUKY[S+DE]VIG-^[-T=/7/WOH_+.=XXT\8OWK;9Z.
MJ/N3)C<9O&\ON^-M*J0+A&CW> BKJN]L1B247W]09-??.NPP6_*S78XW71%T
M?RSX>UQFHNG-@MR3OMF;9_FM\8[FJ'D>06:]9C?K!#BNX_'EJLV%)<,'W9$!
MD0DNLJ"*(;T$43?KJHZ]-:UE^LOQ9<EUD1PUVQ/7$;9AL[=)CRXL5E\SQ4V3
M&ZET[(GKIXI:B26YD5B8SKVI#8.M[NB[7!0DU_46NCMNBZ(F.ES5ULVS,3T.
M:K*E H% H% H% H% H% H%!',_Z><>_X1OGX3M%$MDG9E @2WH;MNN[KC);2
M<CVJ<^R2^Z+C;1"2>^BUB7ZJVV:<-W=;=/@S+-)==;$Q=9MZ[[8^RK19?(F5
MOQKQD]K2''L-F>>;^:IS#K<Q]N']M[CBF*LN%HNP%:Z=-U:;)S++6ZZV(X;9
MW3$UFF_LGN;G'RW#\-EU9NNB-L3%(KN[8ZYJW%G/[8^C:C:KVG<0515L\_;Z
MW]MV=-/?K;1K+9_=O_X7?<U,Z&^/WK/^=OWNER!>KI N.+66'<_F&#?9S\6=
M?!!@W649AO2&VFEE-NLBXZ;>B*X!)M$D1-RIIG->C6\9SG3D/(+GCV81YD'&
M,7M]ZCRX\!D8]RGNW"ZQR5T71,NP8010^P8:KH;1"*Z*2RTS*,OM>3E@T_*"
M;BOW>)%/*'HT)J3'9E6J1-[#:*S[,A&\P@-$ZT:H)**[RT6@U;$"L$]_$X^<
MS(EVP^5.SIR')FBS\U3KVF2NJRZ8%JRKA,+(<CBNJ=34>J)09F]S<1EV(>/>
M-(+USL]_R)UFYVZW$R,9;? %B9=0@J^\PPD<U4(KB : CCSB#ZVM!@V/G*\P
ML'P2=9H<_(<1OLZS/V?)2;-HHC-GDOP'7U8&8*F40V2W#O17$+KTH-@XWN%V
MQAO+_FK#UD9$5[%J[X3CYPH$6V",41:DM+.D1@="4 "[W6Q#>JZ;$43H-=B3
MKKC>3YRU;%<CR>1;C,M%N)%$O9;['>:CBYT7X7L\LGBT54V1%_5"1^![8U'X
M:M%G@N.0V&END2,\RHJZR W"4V! IH2;A314W"J:^*+0E\<=0&;%9K[;8UY<
MM[3&7/M)-GNI*?DJ3[&YDW92DI.2556]VN[4O5ZZ4'<MEF;MG-5PF>URI<BY
M6#ON%+>)T6A2?H#3(= ;;!/!!'5?$E(E5:"2J(*".>(/\5S+_BZ^_*:)2-1!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0:'S;/DVSA_.IL,^W):L5P[3
MB:HHJ<<QW(J*FBIKJGOT3" /)Y88,[RYY?'> 2^>9MTCRE,4-%;6 RT@JG34
M41573WUHF74_^I]W"0[BF9VHB_P2+<8LIH?<<E,$!K^JC 4)3#YK+G<K-P'E
MMRM$Q^WW%CYN[,N(Z;#P;[G% MIMJA)J*J*Z+X+1$/,J9R#GMPBO09^4W>5"
MD K<B,_<)3K3@$FBB8$XJ$B^E%2B["V^XW"TS&KC:I;T&X,*JL2XSA,O JHH
MJHF"H2:HJIT6@V#^DWDG^>-\_E.7_?:(8F%DF16R5)G6V[S8<V8JE+DQY+K3
MKQ*2DJN&!(I*JJJ^LOC09#^D'/OYU7C^4)7]\I4I!_2#GW\ZKQ_*$K^^4J4A
MCPR3(F[PF0MW>:-_3PNHR74F?:^U]N0M_P #U/A?!Z>%$LM_2;R3_/&^?RG+
M_OM$'])O)/\ /&^?RG+_ +[0<$W/\[N<5R%<LHN\R$[IW8TB?)=:+:2$FX#<
M5%T5$5.GC43%28B=[XBYSFT&.$2%DEUC16]4;89G2&VQ15U701-$3JM1PQU*
M\%O4YOZ1.0/YUWG^497]\IPQU)X8ZGR?(.>N@33N4W<VS11,"N$E1453145%
M<ZHM.&.HX8ZG#;<VS.S-''M&17.WL.%O-J)-D, 1Z(FY4;-$5=$\:F(B-Q%L
M1NAW/Z3>2?YXWS^4Y?\ ?:E+$-Y%D#3KC[5VF ^\JJZZ,AU#-5755)4+5=5]
MVO.<=L[XAYW8K+M]L>QR_C9E/^O+A_"WOW=5^39^&/8K_3XOPQ[(/QLRG_7E
MP_A;W[NGR;/PQ[#^GQ?ACV0^8^49+$G#<XMYG,7(-=DQJ4\#Z:CL71P20DU%
M=OCX=*O%EL;H7MQVV[HB&4_I-Y)_GC?/Y3E_WVKKL=<<LRJ[O-R;M?+A/D-)
MM:>E2WGS$47702,U5$U76JS;$[U9LMG?#K_/U\_UG+_N[G[JHX+>J%/DX_PQ
M[#Y^OG^LY?\ =W/W5."WJ@^3C_#'L?!WJ\.HB.7"2:)U1"><7_K*G!;U0F,5
MD?NQ[&;#DKD9H!;;R^]@V"(( -REH*"G1$1$<Z(E7>E'[_2;R3_/&^?RG+_O
MM _I-Y)_GC?/Y3E_WV@QL/+,IMSSTBWWRX1)$E=9#K$MYHW%U5=3(#12ZJJ]
M:])R7SOF43;$N[_2)R!_.N\?RA*_OE5X[NM'!;U'](G('\Z[Q_*$K^^4X[NL
MX+>IU R[*VKDMY:OMQ"\*FBW 9;Z253;LT[J'N^"FWQ\.E3.2Z8I6:+1$0R'
M])O)/\\;Y_*<O^^U08Z?EN5762U,NE\N$V9'1$8D29;[SC:(NY-I&:JFB]>E
M7MR76[(F8*/W\;LL_P!?7'^%O_NZM\V_\4^U'#!^-V6?Z^N/\+?_ '=/FW_B
MGVG##@E9%D$T!;FW69) 5W"+TAUQ$7PU1"):?.O_ !3[4TAE0Y*Y%: 6FLOO
M8-@B" #<I:"@HFB(B(YT1*\AP3\\SFZQ3@W3)KM-A.*BG&DSY+S1**[DU W%
M1=%35.E3;=-LUB:%&*&[74401G2!%/!$=-$_ZZ]OZC+^*?;*.&.I]?/%V_R^
M3_=C_P#33^IR_BN]LG#'4_%N]V5%19\A47Q3O'_Z:?U&7\5WMDX8ZF0MF:9C
M963CV;(;G;H[A=PVHDV0P!'HB;E%LQ15T1$UKRNONNWS5-'=_I-Y)_GC?/Y3
ME_WVJA_2;R3_ #QOG\IR_P"^T'5D9UF\M]N5+R6ZOR6=.R\[.DFX&U=R;2(U
M5-%Z]*\[L=ETUF(F7I;DNMBD3,0Y_P"D?D/^=MY_E&5_?*G@MZH1Q3UG](_(
M?\[;S_*,K^^4X+>J#BGK<$K.<VG +<W)+K);%=PB].D.(B^&J(1K5;L5EV^V
M)[EK<M]NZ9CO=D>2^1P% #,+V("B((I<I:(B)X(B=RO1YN.5R'G\UDHTS*KQ
M(CEIN:>N$IP%T75-1)Q4Z+476Q=%)BL+6W3;-8FDNNWFF8M C;60W,&Q^"(S
M9"(GU$0Z\/Z7#^"WV0]?ZC+^*?;+Z_'C-/YQW3^'2/W=/Z7#^"WV0?U&7\4^
MV7X6;9F0J)9%<U%4T5%FR%147]O3^EP_@M]D']1E_%/MER0\^SNWM*S RB[Q
M62+>3;$^2T*DJ(BJJ"XB:Z(E>UEEML4MB(>5]]U\UNFO:['])O)/\\;Y_*<O
M^^U=1C5RS*5,G%OEP5PU4C-9;VJJO555=_6L>=-BG?;;[(9-NJS6[K[H[Y/Q
MLRG_ %Y</X6]^[JO]+A_!;[(7_K,_P".[_E)^-F4_P"O+A_"WOW=/Z7#^"WV
M0?UF?\=W_*7)'S/,(;Z2HF07)B2FJ(\U,? T14T7UA-%\*]+,..R:VVQ'<\K
M\^2_S73/;,N]_2;R3_/&^?RG+_OM>SP/Z3>2?YXWS^4Y?]]H/3;E'!.5LOO]
MHF8O>[% L]AFQ[O:FKC!?DR@GLM.LD1$+B 0$#QHB;=4UU14)$5"K,<785E^
M,S<HO><W&W72_P"22X\IR3:H[D1L6XT<8X-J!D6NU!Z+X]5U5:"&^195^S+D
MQSCJ[6>/#?F7X6+'EUUQ9F\-Q;,W:TD"D9R7')AQ7)B&VI&:[-5_4)3!P5?+
MQ?N/V'[L@NMQ)DR!:[DW!^:0N%NBO*W'EI#T%&>X*? %$3IJB:+1$I*HAP1Y
MD26KJ1)#;ZQW"9?1HQ/MNA\("VJNA)Z47K0&YD1Z0]$9D-N2H^WVA@#$G&]_
M4=XHNHZ^C6@YZ"NGDD^@J)]\Y_\ WQHF5BZ(*!0*!0*!0:1S%;W+IQ9ET-H(
M[CI6N48>V;$9%6FU/>I.*@BH[=PF2Z"2(7HKSR16V6/J8KBNCU*2^7?)[3BO
M*MGN4J8U;[,XU(BW24\*]L&GF21K>6B[$[R-:N+H(I\(D1:P,,TN<ARF[-9F
MF<L['H4^Q$N,-V-( ),&6T3;K9:&VXRZ.A(OH421:V>]VTQ$PURR<9\?8W<6
M[O8,:MUMN;2$+4N+';:=%'!421"%$7JBZ+5(LMC=#RMP8[9K$1$N+DK#8V9X
MI<H01&G<A9BR',=F$O:>BW+M%V'6GA5";5'-NJB7U>E+[:PC-CB^V8Z>CM5/
MXKM.98]GD6[6;%KPLS'W"',& 9[;[C#S.IM&LAQH)#I=T'VQWD2IH8Z]*T^F
MLS6Y)F[<Y'EN'5X]1==?6;86ZQS/,8RUN0-@FB_<XHJLNT/H46>P:?6/1WD%
MQM=>FI#I[FM;F+HG<["S+;?NG;U=+6\7Y$S&_P"42\;G82ML&UFTW>)GSK&D
M>S>TL=]I>V (I[DT^"O36J6WS,TH\K,U]UW#-M*;]J2:]64T^V<4\;66?'NM
MIQ6V0KE%+N1I3$5L'6S3IJ)(FJ+5(LMCH>%N#';-8MBKK7WBW'YTM^^X^K^,
MY6:*7SM97$AF\XB=/:6MI,OHJ^/>:+WJB;(WQLE%^"V9K'PSZE4,=9P&T'B]
M]M++D[F&/>&7[K:8[1.OD\V^I3FDB!HT(@".=E6A15)!VUK;)F+VELBR)B8\
M]?\ 78N/C.<8KF N_,%R;D2HZ[9< T)B;'+]:]'=0'6U_9 E;2VZ)W-[9EMO
MW2Z47E+CB;=6['$RFVO7AU[V5N"$ELGB?W;>V@HNN[7II4<=M:55C/CF:<45
M;=5WN4"@4"@4"@4"@4"@4"@4"@4"@4"@4$ /<;>8%,HO&50LIQ:/<+S!9M<D
MEM4AU%CQ#>-E=''31#'OFB_6%TW"NB42DG&L>N6 \4P<:A*#]XL%E]ECE$;,
M@=E1HZH) V:F2[C37:NNM$*L)>LANK5SY#B6Z'C&6X7:K&Y*@R,*9<N-[R*>
M&C[;CSL8'VD.6/8!8Y)IKOU\*++K0W7WXD=Z2S[/)<; WF-=W;,A12'7TZ+T
MHJYB(0$C,D$!15(E71$1/%56@XXTJ--8;E0W@D174W-/,DCC9#[HD*JBI0?,
M69$G,^T09#<EA5(4=9,7 W NTDU%535%31:""?.;] %_^,V[Y8U1,)OLO^A[
M?\69^YC1#O4"@CGFAIR%BT;-H@J4[")\?(!0$]<HD=5:G-Z^.A1'7OU=*S=)
M-;^"=U\4^[[:*W;JM9Y@S&U8%EV"YO$!VXW.4DVW2;9 03?FV1YH7C<%3(&_
ML#XL&.\T1=Y(B]:]])ANS67V=&R>R?VQ56Z:3$MHAW3$>>^/+BQ#]ICPI9.0
M9+<AM&9]ON$?:Z!**$0BZT2MO HDJ?!76O"ZR_2Y8KOCV3"VRZ'?XRRFX9%8
M78.1(+6:8\^5HR6.";4]L81%1\$5$^Q2&U!]M=--I:>A:\]1CBRZMOENVQZ>
MK<6RW6L98H% H% H% H% H% H% H%!'///T193\6#[NW1,)&HAA'<-Q%\3!Z
MP6XQ<14<UB,=4+QU]3TUZQEOCIGVHI".+/Y>[);;A;AG7R?=\3LKPR;1C4X8
MYQVS:^TBZZC:.O RJ_8Q,NF@[MVE9U^ONNB:1$3.^5>%)T7&L<@OA*A6>%&E
M-KJV\S&:;<%533H0BBIT6L"<ETQ29E:CDOECM626F58[Y&&9:YH=N1'-2'5$
M5"14(%0A(21"$A5"$D145%2O-+$8]@=AQNXNWB.<V?>76$A?.5UFR;C("*A(
M?9;.2X>P%)$(MNF\D12U5$T#+V:RV^PQ'(-L;5J,[*F3S$B(U61<I3LU\M25
M5T)UXR1/!-=$Z4&&G\>XQ<KXM_E,OK)<D19LF*$E\(4B7;]JQGWHPFC1N-;
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M7U(E^$GH5296GHJX)$R)$5D94AM@I#B,QT=,05QTM50 W*FXETZ(G6@2YD2
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MMFV^(FVW;MZ*[X[T7>I(O#-_@WW&I0M7"[S+K"EDQ>(V1$T4^)*[3:JU]A1
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M9MAEVV7')H#L9[$L@=:FG/<(D?B-7)0$C-I!T,0W[M1/X/CX5QW,.479,O\
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M-%X@NJ]17W/"@_?G#'E1A%E0M(J[HWV1K[$6Q6]0Z^JNTB'IZ%5*#E^>K/\
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M6UW4#<M<V/-;;7:X49T'D%5ZZ*H*NE+K9MWQ0=NJA0*!0*!0*!0=6Y6RVWF
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M[S!_S+QK^7I7_EU ^?O,'_,O&OY>E?\ EU ^?O,'_,O&OY>E?^74#Y^\P?\
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M/!4556LS4:F8OI/#?9T1ZNW?$JQ%>UVLZRC/K#;(^(9YB=GS&3>GUAX_>67
M8@N21:-Q7)D20#QL&VT#CNYGN(NFU-NM1@Q8[[N*RZ;:;XZ>Z>GOH3,[I9CR
M^3XT2RRL">L<2TY#B<6VL7*7;]A1[BTZP;;,M31MH^X:QW.X+@JJ+]<J+7GK
M[)XN.M8NKOZ/5]J;>I*EYOUCQR$MSR&YQ+3;1(6RF3WVXK"&?P15QTA'5?0F
MM:^RRZ^:6Q,SZEIFCJV#+\2ROVC\5K];KW[)L]K^;)C$SM=W=L[G9,]N[86W
M7QT7W*M?BOL\T3';%")B6:KR24"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4$/X;RIR=F<FWSXG&01<*GRC:2^/7Z-[0W%;>)DGCA)'WH2;556M^NO36B4
ME93%MLW&+U"O,E85HDP)3-PF"2-DS&<9(77$)45!4152UTZ40KGP[<6\@S3%
M_GO-YMW8QP+A;<-MKV/E8?:.W;HCA//N$1J:%#E-N- 0M[].YIT34F5HJ(:)
MG&!W+)I<B3:;DS ^=+1*QVZK(8*07L<LD+N,;76T%T-3TW[A7<GZW0B74Y"X
MK'D#'Y=GD71ZVOM0;A;;(["(P:;9N,0(Z^U-D1=Y4VDBJ*AZA$*:;BU#?X4;
MV*''A]YV1[.T#7M$@NX\YVQ0=[A:)N(M-27TK1"N\S'[#8/-]C'S%:X=L]OQ
MBX3)WL4=J-WY+DAW>Z[VQ'>9>DRU5:)Z%CZ(*!0*"+^0N*;)=6[CD]MC.+?@
M1)9P <48LTV%0R!QM$UU=$5!5%1ZKJM:#7\IPY9G-%OQQM[:?>Z+E_-\V*(P
MS=\$[/7%?N9_(6@RS!F;IC:HLEMN/>+$HHB:/QM'F@T3PW(BM$GOJE9^>/G8
M(NQ[]EUO;&V/N8&"?D:B;<F[;;=V3LG[VQV6ZQKY:(-YAKK&G,-R&_=1'!0M
M%]]-=%]^LO%DC)9%T;IBK!S8IQ7S9.^V:-8OB?BKE47*FTVVB\JS:[_HG0'M
M=L.47H30B[)K[A#[E8>7_IRQD_=NI;=_],^#/P_]^&<7[UE;K?\ ZK?&.]NM
M;%JR@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@Z5VO-IL,-;C>YS%N@";;12I;@
MLM(X\:-@*F:HB*1$@I04"\P^87K)>=K;A7-?M>,<4VZ8)1H\#[,+\,MPC.4T
MT1Q7/@D2"JLCN$14T+<6A=#^C#BJ_82QB\?'K7*PN3&!(;49IM6E9,=0=:>;
M];<J+N1T3W*OK;M>M%5/L<MM^\J?F4M>)1IKLKC_ #-YB.T+A='(DUY6&3=1
M/5[T5U?6)$ZAKX(>E%MZ_=%2@4"@AGGWBI[GC#[59;#?FH\2#=VI,O80NL/@
MR9QI J8;E1QE"<44\-Z;21%ZB3"*/,1Y;KE;KB/,G" N6S+;6:3+A:;>FPW2
M;359,44_\73[:UIHZFO3=JADQ*2/+AYB+;S19SM=T$(/(%J90[I!%%%J0TBH
M'M+&OUJDJ(8>($ON*BT1,)UH@H.&4LD8KY0@!R8C9K'!TE!LG4%=J$0H2H*K
MXJB+04$LGD]S'(>,KKD4\';1S!&O,V1"C.N[6Y49C8&S<BZ 9/ ZXP\B[514
MU7:2$):J6O+7YE)612DXHY74[?R);S6'$ES$5DYQLKM5EY"TVRATTZ_;/V7P
MB)A:>B"@4%5>6>"KYR]YBH+N507!XU9QQZ/'N<1W14>;1U$0M4]1X7Y0N"*H
MHF >E$(4)JC'#<RSOR=9VO'_ " CMTXLNCI.P)[0D0 !%HLJ*BZZ*FJ>T1]=
M=?6'75%,G>O9:;M;+[;(EYLTMJ=:IS0OQ);!(;3K1IJ)"2>*+15W*!0*#AE+
M)&*^4( <F(V:QP=)0;)U!7:A$*$J"J^*HBT%!+)Y/<QR'C*ZY%/!VT<P1KS-
MD0HSKNUN5&8V!LW(N@&3P.N,/(NU45-5VDA"6JEKRU^925D4I.*.5U.W\B6\
MUAQ)<Q%9.<;*[59>0M-LH=-.OVS]E\(B86GH@H%!4_DS@&]\O^8J9(S"&XQQ
MZ..=FTWB*YJHOMZ"(KJGJN@^^X[L5-I /BNJI1-4=<?\@9QY1LX7B_E!')W&
MLYPG;9<VA(VV6S+_ !J+XKLU7_"(_P (2]8>OVPG>O9;KC NT"-=+7);F6Z8
MV+\64P2.-.M.)N$P(=45%1>BT5=F@4$#^;?$<WS?BH<?PBW_ #C(=N<1RY,"
M>COLH*2(H#IH2(XK9'U]445=%\4)A ?)/#V;>5S(8?+O$,AV5B[(-M7R">YT
M64+:CC<@474XKI)J)?";+3JBH)43O6QX>YAQ;F7%F\@Q]SLSF=K=WM#A(LB'
M(5-=I::;@+15;<1-"3W"0A0A(=$% H%!4',?+C?.7N>L]N&<1W+=B[MGCCBU
MXBGW &5HTTR6B[4)1[+ZO-+IIN31?6$Z+5:EQ-RSF'EGS!>&.9T-</4__A%W
M]9UN*VZ2H#S)JFIQ#7X0_";+7HBH0T-Z\\>1'EQVI45T'XKX"ZP^T2&V;9IN
M$A(=45%1=45**N2@4$#^;?$<WS?BH<?PBW_.,AVYQ'+DP)Z.^R@I(B@.FA(C
MBMD?7U115T7Q0F$!\D\/9MY7,AA\N\0R'96+L@VU?()[G190MJ.-R!1=3BND
MFHE\)LM.J*@E1.];'A[F'%N9<6;R#'W.S.9VMW>T.$BR(<A4UVEIIN M%5MQ
M$T)/<)"%"$AT04'#*62,5\H0 Y,1LUC@Z2@V3J"NU"(4)4%5\51%H*"63R>Y
MCD/&5UR*>#MHY@C7F;(A1G7=K<J,QL#9N1= ,G@=<8>1=JHJ:KM)"$M5+7EK
M\RDK(I2<4<KJ=OY$MYK#B2YB*R<XV5VJR\A:;90Z:=?MG[+X1$PM/1!0*"*^
M6L5R'.83EA=PZSY/8(\F)+@M7.[2[<I.BT^+IFD9@U16U(!!-RH6Y571134E
MV^'L.F8=;;E&F8Q;\8*2^#@L6RZ2[N#R"&FXSEMMJ"IX;1Z4$>^:";A[5RPV
MVY4[>K4U<6;PV]DM@)".#;A&(,H93"M.HY'<5QE3735M00D]RA#=?+^_9'\-
MNHV(WY<>/D%XC2+U+EC<'[J^S*("GFZ#;0?9T1"$0'01T34O%1*5J(=.!=K7
M=%D);)T>:L1TH\I(SH/=IX/A-N;%7:2>D5ZT'Y%N]IG2Y=OA3X\F? 5!G167
M@<>8(DU1'0%5(%7T;D2@[M!4KRX_H@Y-\6R'Y.=%IWK%6:9<8''=GF6FW%=[
MBU:X*L6X'FXY/*K+:*B./*@#HBJOK+Z**HPY+S?DERV6>%*QV?A,*X7J!#E7
MZ/=;>\X#+SBH0(C2FJ;D].W1*#%V>_YGC7)<&TX]-NW($2;8KC*DVF9<X8(R
MY'F00!\3<%H?51T@VZZKO]ZIDA-.+7W*KPY)'(\5=QP&D!8YNS8LWO*2KN1$
MC$2CMT3X7CK4#JQ[M,+E*X6,Y*^P!8(,UF&JIM1XYLQMQQ$\=5$6Q7]2@BXW
M\AO/%PY:YDUWB7=G()EJ0HDE&6RC+ECT 4(=BZJ+"HV*^A$3W*);5(QVXOYQ
M%Q(,KOT>WQ;(=P%]J8'M!R#F[-SA&T2&@CZHH0Z:4&P\87F[W6Q7"+?)?SC<
M+'=[C95N:@#1RFX$@FVW7 ;$01Q0VBYL%!WHJHB)T0ANM H% H% H% H(YY7
M_P :X]_XN@?)I=$I&H@H.I<[7;;U!>MEWALS[=(3:_$E-B\R8^X0&BHM1,55
MNMBZ*2H;C'!_*]LS:U,Q+%)B,VZZ-G%OLAI4C(D5_<V^8MN(: 6U%)!75$7Q
MK76XKHN<;AY9FMU/S.BOIW+=?T@9)CGJ<@8K)BQ@^'?;#OO%NT3Q-QML!E,I
MZ?68(4_75F\<QOAU7SKK?/;WQMC[T;0/-I9)^81L::L)?-DFY!;6[ZLQ$C]M
MQY&D?V*PA;=%W:+_ &?37E&HBM&OCFV*<ORNFJQE93=% H(SFV7DYWD6-ED>
MWV!;9"B3+0P+EPF#).'+E1WT>(4@$(N",?[6AJ.I+ZWI7RF+N*NQB3;D^9Q4
MBF[?/W))=::?;)E\!=9--IMFB$)(OH5%Z+7JRU4LK\O\HN1&\3M5SC0\7RSY
MRNHHC)>T0V&'(ZR&&Q1=A:K*1&573:GBG1-=5DT5MV6+JN5U')K;]5%]:5V^
MS_5-C5HY7Q8 ;M%V@9=:F4$0A7AKYMN"- FB",N(),FNGZ^,/OE6PI='K=!P
MY;-TQ='KV3[8^Y!F8\ZY:.<-7YNP1(+.%E-AO6F8\KLIUQP&QEHK[!JT.U6]
M&E02]U?'1-=EUO!EBVCG-5SGY6IMLFW=XK0X]DMDRFVLW6Q3F)L5YL'%6.ZV
M]L[@[D$^V1(A)X*E;6)B=SJK+XOBL2TK,<RS:QYC:L<M86!8M]-P+:5PDR&I
M ]ACN$KH@"IH1H0-[==>GIKSNNF)IL8^3)?;?%L4VI)#?L'N:=S1-^W7;NTZ
MZ:^BO5EL//S'$;5+<@72_P!MA3FMO=BR9C#+H;A0AW 9HJ:HJ*FJ>%5FZ(Z7
MG.2V)I,PS#;C;S8.M&CC3B(0&*H0D))JBHJ=%14JST?5 H% H%!7S.N-<IS:
M\1,AO?&N.7:]C%6,[+>R*Y12;$'W=C8=B,B**MJ!JNB+N)1ZH**I*:<0MKEG
MQ>T6MZ"S;'8<5ID[?&?<EL,* HBM@\Z@FX(^"$2:K1"H?+ETX[<SOD0;O.R*
MQ/VL'W';3%FA%LN0ROFMCVMAM\HSJQWWHR--/ B^N"(J=5HLN7:E96UPEC-)
M'CK':[+ KJ+8;$VBB].B)THJ[#SS4=IQ]]P6F&A4W735! 0%-5(E7HB(GBM!
MP0KE;KE!;N=NF,2[:Z*FU,CN ZP0"JHI"X"J*HFB]=:#\MMUM=YB#/L\V/<(
M)JHC)B.@^TI"NBHAMJ2:HOCUH(-\YOT 7_XS;OEC5$PF^R_Z'M_Q9G[F-$.]
M0*!0*!01H"_B7R\36BA8>0V.X&GP&[_:FM#33HB+)B(B^ZI,+6=]3#Z[/Y9^
MZ?>INGM276"N@+S262YW2T8O,;M[\^P6RX//W<H31NR65<CDVR?V%%=1G4B1
MW9T^#NZ5N>5WVVWW1,TF8V/+)#$^7++?F-ZX8CD+LVU6VZ2&W\'CWEJ3'&2F
MQ1E!$<DHB*G<1"%K=NZJ2)HM>G,<473QV4FGFI]E2R>M9.M$]2@CSF>V6.YX
M>@WFVW>X.QY+;]K<QV.]*N46< 'VWVT8$R$43<!JHJ.A:+XUF:2ZZV_9,1UU
MW45NW(ZXHXVME^QEB^JN68OR@#49;SD4\9,"4Y-)@5<:!B4"1WX@&BB+9,J*
M)_;+K6;JM1=;?3X;K.B-^SNVQ/>K$5[66S7+>2,'@0[+E=ELV9A>9C=ML=[U
M6"Q[88&Z/M\(Q?V[6VG#W1S)%V[=!54KSPXL66:VS-E(K,;_ &3]Z9F7'P)?
MHN/!_15?8MMMV1VBWPCASX9B'SM#5761-1,1/NMFV2&*[OA:IXU.NQS=/S(F
M9B9GN+=FQ,60E?1M3QXX["9N@[2!VZ"X400144U-&B O@ZZ=:UN/AK\5:>I:
M6H\1Y3EV;8VQE&1%:?89[>Z$S:1?1QLP,P<%TG7#1?!--OZM9&JQV8[N&VNS
MK1;,RW]UYF.VKK[@M-#IN,U0135=$U5>GC6)$56<;$V%*51BR&GR%-21LQ-4
M3W]JK28F-XYZ@*!0*!0*!0*!0*!0*!0*!0*!0*!0*!08V^OWV/ [F.Q(\VX]
MUD>Q,?*,UV2<1'2W@VXNX0U(1V]5Z:IXT$#8KP[<;-F,&\IQEC]L9:N S'KI
M%R.Z/R 7N;E?2.; MF?IVDNB^&M$U3;F[\"+A>1R;K%]OM;-KFN38.Y6^^P$
M<U<:WIU'>**.OHUHA5K@Z;@;V?XA)M]SR"[9!=/G!QRR9'+;%VQR&;2PT#RL
MA&!9/>AMML,O[T%6TUT4M4$M*X=%73G7:UVPXS=RG1X;DUU(\,)#H-*\\7@V
MVAJFXE] CUH%RN]JLS RKQ.CV^*9BR#TMT&&U=/X((3BBBDNG1*#N(J*B*BZ
MHO@M! 61?I?8;_PC.^4.T3T)]H@H% H%!IN*+\P7Z\88?JQ4(KQ9$\$]DF&J
MO-"G_P!:?4OVIC6NT_\ UY+L71YK>R=\=T^^&SU7_;CMS=/EN[8W3WV^Z71Q
MZ]6?$;[=L)NDZ/!;62EPL(/N@TAQKDI.$T&Y4Z@\CJ(GN*->>'+9@R78KIB-
MM;>R[H[IJ]<^&_/CMS6Q,[*74Z[>GOBGVMTNMLA7JVR[3<6T=@S6C8?;7T@:
M:+I[BIXHOH6MCDQVY+9MNW2U>+)=COB^W?$M+L&=VFQ17<;S6\1X>0V9Q8;S
MDMP6EE,BB$Q)'5>O<;(5+W"W)6NPZRS''R\MT1=;LV]/5/?'VMIGT5^6?F8;
M9FR_;LZ)Z8[I^QOK3K;[0/,DAM."AMF*ZH0DFJ*B^^E;2)B8K#43$Q-)?=2@
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M_P"LTV^ 3+1!048\RW%L',/,QCMDER2MS.;6?M1[B*(2-W2($@&=P_7 JML
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M:);N1&+>KS8^I)?A+(11:?-A535$71=/1J*JFA#J5:[P)AO(>#X&U9N2K_\
M/M\[[KS:[B?6*R:ZHS[0>AN]=3U)/5W;4Z(E$RE"B'!,B,3XDB#*'?&DMFR\
M'ZYMP5$D_51:#R^PCBG,8ECR?/>/KB]&Y XOO+[=SB-D@&4%H%3NM(OB0$T^
MCK9ZBXWTTU3:9=9W@CS89)RYG-KPR1BC;;*VPWKQ<HSW5J4POK/H#BBB,'J
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M!-==.FI*;\,01Q2S(+MS?%(C.CU^%6[L?JIUEB0-JCR_7HH)U]%$*SY= O\
MD?)N<^SV/-<GAVZXQXC$BPW\;+"BI\W172BC'-X$51(U<[@_"W^&O4BRUT05
M&(P*B0*C8(H.%O-%04Z$7I5/2M%6O<@WFX6'%)<^UDC=P-Z'"8?44/LE/ELQ
M.Z@DBB2MH[O1"3153KTH,78;GD$F!FUE.["5RQN>=MM^07%IGUA=M<.X"_(;
MCC':7M%+(%0!!%$$UZZT'-QS<KQ=8MTERKA(N^/+)!,=N\YAB-)EQNRVKCJ#
M':8 F5=W]D^T*F/K>L*B9!"'G;O^41^.)>.Q<8.5BDQ(<B?E22VP")("8FQA
M8R@IFI[1]9#1$W>]1,++67_0]O\ BS/W,:(=Z@4"@4"@4"@@C,,GA^72\_.O
M:=F<>96^\26"'L67 O&TGC<B-N& ^S/Z*KH;D1MQ=R="5*V^##=K(X8\]O3U
MQZ_7'N>5UT6;9W)!XRY2QCE:RO7C'.^R<1WV>?;YH"W*CN**$.\0(Q421=1(
M25%^JBHF'JM+?I[N&]:R^+XK#=JQ%R@PV48ICN:6=VPY1 ;N-J=(3)AQ2%1<
M;743 P43 T]! 2+[]>N/+=CNXK9I*)BK5V.#N)XUH6RM8O%]E[RR1D&3SDX7
MR1$5P9IN+)$M!1-PNHM>\ZS--W%Q3X>S<CAA&W+\?/N*<69E8UF]Q<Q6;.CV
M^<5S;;FS;9'>0U[S-P-$-!4@!G[.+BCW-4)%K.T?RL]]+K8K2NS9$]WV[%+J
MQ##<-<U%:)UZMF<9!+N>(LC'6#DTQIV6Q%FN*?=BR)S+:@FH]MP>\2::JFO@
ME>VNT432<<1Q=7C3[D67=:R<6_6.=:_GR%<XDFR[%<^<F7VW(NP?$NZ)*&B>
ME=:T4V71/#,35ZU+-?K%D<3YPQZYQ+M 0E;65 ?;E,[Q\1WM$0ZIKX:TOLNL
MFET3$^LB:LA5$E!T;Q&N<RVR(UGG#;+DXB)'G&PDH6E0D555HB!"U35/A5>R
M8B=L5@:KQSA%_P 'AOVRXY&-[MANRI3#"0 AFW(G2G9CQ*8NN*2*;I:#IT2O
M?49K<DUBVD]M=T45B*,ER%:+)?<,N]KR*/+E6AYI%?:MC3K\Y":,7&SC@P)F
MKC;@B8;17JGA5,%]UM\3;2OKW)G<A;B7 <<RJ;='N1+1>L@N\<IL2U_CA93C
M0FK2,M1CN,B]$9:]I>;1LW2^V>CU41:VFJU%]D1P3$1LKPW;:T[=REL5WMMS
M3R]89=<6N=LQ")\Q7=]K_ NS+FM6Y7!(21M^*V]V2:/;L)%:71%U1-:Q<.NO
MMOB;YXH[(K[4S9#2,'Q#.\WRA,F!T,#+%4N%B65"*+<Y4B9O:!UK8\P37LP=
MM5U)-RKIMV^-9NHSX[+.'S\5)Z8V?>C;+=,[LO.=IQ"]2,?S"/>I(17-D8;,
MC%T4.N]8KS$E [R!]KU874O#T5AX;]/=?'%;3^+9W[-W>F8E%_%\^XPLO;<X
M:BS+[$6-(/,8%VF3(L0I&C:,FZ_*:?0)JEKZHAJ0H2%HFBUL=5;;-G_;-/PT
MB/#H5C?L2QEW*&?8OBUZO5WXTE(U AOO*^S<;?.ACL M">'NM/=KP4]C2J@Z
M].E:W%IL=]\1&3?/5,3]RTW3$;D<8;F=QXVR^/(RB7#N]IS=Z3<+@Y:;8Z3\
M.6U#:1'(S<3ONN1E!D&R38NBJAZ]2K/SX(RV?#LFS9MG?MZ:]*-R6;AS;Q)(
MMMP8>S2-:W?9GE(G#6%.;1 )%)EN4 DKHZ>H.PE4M.B^%:RW1YHF/AK]L?8G
MBA&?$F4W,\_89R2]9>-IO).+AC-]?MSL64T,1#-N:,5I";D*J.O,CJ*;$1.I
M(NN?JL41CK;%M8\U*]?17H1&_:LJXIBV1-CO-$51#7;JJ)T37T:UHWHBK".8
M9^8YG.P];+;XSUI+;='HU]C3W&]6E-%!EMH2<1#VMN:+ZA+U\-*V&;2QCLB^
ML[=WPS"D75E*KABTV3AKH (I$NBKT1-5Z)6O7:79.7./\CNX6*S71R1=3+8D
M=84UK:2@KB(9.L"(:BFJ;E36LJ_2Y++>*8V=L*Q=$MVK%6*!0*!0*"K'&SM^
MEY%:9.773E<,D6YE[7%>@/L8NXJ2"V*NZ)ZD0AVZ[W!T3W*)6)S>2<+"\CF-
MRG8)Q[7-=&;&'N/L*W',D=;'5-QAIN%->JT0@#@>S7U+WC][N6+YE"&1!5YV
M[WK(AN5L(GHVN]8JNJ:]Q5]34-154UTTHF5G:(1ER/DN16V?<6;-<2MC5AQR
M=DI;&F'AER(I:-L/=]LU1G0"W]I0<7<FACIU)97.+O-C66W7)J]2+"#Z+I$M
MT5B;=9DMUG<Q%C!):>!5UW$:=K70==P"A+1#9[ 5Y.PVL\B!IO("B1UNS<?J
MR,Q6A[R-]5]5#W;>J]*"MD"_Y1?O-]9OQFQ@\:]@L%SB6S?+;F>W0VY#NR4G
M; .VA_\ LRU5/=HGH6DH@H% H% H*P<JXYE;F:7:X/6N?<$<47+1-BM./@W'
M;!"$0-M%[:MEN54Z=?6ZZZU\YYSI-9=J^.VLV]%'TODNKT=NDBRZ;8NZ8FF]
M.*VUK-,&MHI/%V>4>-+A7AA4/MW!@447P5-.J&B[DZ=-16NW^7&?!;MVTB8N
M_P!T=/M<-\R=/J+OAV5F)M_VST>QD,2O[E_M:E-;2->X+A0KQ#3_ ,*6SHA[
M?= T5#;7TBJ5ZZ;-\RW;LNC9='K]-L>IX:K!&*_9MMNVVSUQ]_1/K9ZLIB(
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M3Y'QFN)<?\O8).QNS-0(5N8O<M7AD[(K01UDN-.LAO#5-SB NX$_7KXD47,
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M'! M5KM4-+?:X3$& .NV+&:!EE-WCH (@]?J5-UTW369K(A7FK@VU7NP/7/
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MD7%O-1QYD6-7.Q6J-SI%M$EJVO/QF#-[U-$<AOO"1M;B7:8(6H;MR*J> W-
MX\\T!\<<92N&,NPN7)R:VMRK5!B( M"[[8IJC4MEQ-Z$A.J*[ +>/HUZJ*+"
M>4'B_(.-.,GOQI:.)><@F+<BMSBJAQF.TVTT#@+T%Q=JF2>*(J(O5*(E8&B"
M@U[.</MF?XE=L.O#C[-MN[!1WW8CI,O"BJBHHD/CHJ)J):B2="1154H/,;,N
M'EXASM<0Y)<D0[).)3L6:V]LG $1707U9U]<154[[(DCH+H0$J:(X79[F=>8
M;5AEMQWDIMO+<98,)>%\A1G%E#VG434$F"BJXVZ'_AOHCFX1)"VCHHA,>&8K
MC7G%XM@'?I2VOE?#B9MD_( ;[KLF)KJV3PZCW$<!"\2U%T27H)*A$;EQ\>LK
M..6*VV"/(D2V+;&:B-RIKJOR719! 0W7"ZD2Z:JM%62H*4^;KRX76X7"9S#A
MHO75W07<DLKI./FC; H/?CZKN5M!'1QH5]5.H]-4$M$HHXF:S^':I>6^7N['
M<EC@A9=QE/TDN*"IM(P8)4&9'-/5$VT!\==G5?6(F75\O?(]HQ_D6ZX#E=H1
MCC?/GOFNZ8[*WNM0Y3I[8ZHAHAH@&7:55T(15"55($6A*Y_"7EWL_"=YR6Y6
MB]3)T.]."$*WO$H,QXH*ABC@HNCKPDI"CJHGJ=$1-Q:E9E-%$(H\P'"\;FS"
M_F,9SEOO5O<*99G]Y^RK)VJ.V0T/0A)/5W[=P>(_7"1,2\^L2PBX6;-7,(N-
MT?X[Y?M;ZMV6Y/.FS"DOK\!AUYM=62<1?L+X;FW$5!4>NXBS(<GYIR]B_(F/
M9)GEG6R<I8XH(E]!M&@NC$8D1LW$:^PO=%-HW&EVF"[%'I06JLW"W'O-]\PS
MS#XK,DXVY+(;C?K=;U5DWYT<E0D%P5%6G$>$@=,4^RCZR:$NY2M5HJ(*!0*!
M0*!009SI9LQS:X6?$H.(6R_V&%,9O1,3[X,%;@$=EUEUAR(D<C5L%?$D<1Q4
M0T%53T*3#8^$K%"LUEN)6_"K5AL65(11:LET&\L2B:16R,G!9902 D4-O6A+
M!>8&TSKE)Q5RYV>_9#QPP<Y,FLN+$[[<[)<!I()N-1W&W7605'MXMFFBJ)+K
M0ALG!<+)(& M,Y&S<(@E-F.62!>G.]=8MH-XEB,RSU)5<$/0I*HCH*]4H2D9
MUUMEHWG20&FQ4S)?!!%-56B&IX?GK&5N@R5N>MKDN Q>K6+YMN+(MDLB%MQ>
MVI;#31-[9?!W#HJ]= [5FS.+>\LO^*,P9<=ZP,0I#DN4TK#4@9[LME%80]"(
M *&8[]-I?6ZCZRAV\IR[&L)M)7W*[DS:K0!@R4N0JHVCCBZ"/1%ZK05D\N/Z
M(.3?%LA^3G1:=ZS.%_D=CWWLA?)PHJRLV;#MT1^?<)#<6#& G9$E\Q;:;;!-
M2(R)41$1/%5I,HF8B*RQF.Y?BV7,O2,7O$2[LQB0)!0G@>[9%JJ(:"JJFNBZ
M:^-5BZ)W*69+;_+-6:JST:WF5VP2V066\]DVQF!)<TC,W965!UT$U7M@]KN(
M4ZKM3HE!S'?L-MMC;R\KA;HV.I'9!J]BXR,1(KAH#2"^B[>VI$B#HNFJT'!D
M60X+B4F--R:;;[5,F&9Q9$OMMNNN,MHV1"2IN51 T!5] KIX4&0LEUQO(V$R
M#'9D.Z,/(L?YR@N-/H2,DNK2NMJOP"4M05?577IK0=!C),&>Q\LRCW"W'C<,
MI$DKR!-+&:,"-J0YW4Z"6[>)EKKXHM!D!M>/7.'#<2##EP TE0%5EMQH5=]=
M'&]15$4M==PT'<.#!<5]3C-$LE162I-BO<5M$0=^J>MIHFFOA0?'S7;/;_G7
MV)CYTV=OV[M![1L_6]S3=I[VM!\3)-H<DLV.>Y'.5/;==9M[R@1/-1U#N$C9
M?"$%,-RZ=-4H.KD 8O%MTV[Y0W!"UQV4.?,N -=D6&%4T[A.)IM%254U\%7I
MXT'<M]HM5I V[5!CP6W%0G BM R)$G1%5 1-5H.Y01SRO_C7'O\ Q= ^32Z)
M2-1!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!055S#&,DRS,[MFV:<8X[?;7
M&BQ;/[/<LJ;1N _&==/<+GLB"TKR26][1CKJ@JA==*)60Q"!\UXO:+=\TLV+
MV6*TU\S1GO:F(FP43L@[M#>(>"%M37W*(5IY8Q[*9.;Y4^]CV87;,Y)L+Q;?
ML?D.A9;<"1FA%'R!T&F%&2CA/]\%[@KZONT66JB#)"(P,TQ<F"V"2'&TV@3J
M"FY11?!%7PHJQ^2W^+C%DE7N6V;[<?M@W'9V]QU]]P666AWJ(HIN&((I*B)K
MU5$H.M8,H;O$6Z%*B.0;E8I)0KQ!U]I)I\8[4M$ F47N(;+[3@[4U];31"U2
M@^,,RUC-+0[=X\*3;VVIDR L:<':D(4)\V%(PU50W*&NTO63P71>E!!7G6R[
M&H?$MRPZ5<F6LGN)09<&V$J]YUAJ8&XQ3331-A>GT43"Q-E_T/;_ (LS]S&B
M'>H% H% H% H% H(5\R'$UZY/QRU.8R,=V_V.44EJ-)(6D?9=;4# 751=I(N
MTAW*@].OHK;<LUENGR3-VZ7AFQS?;2&F<*<5<U<60;M>([-F>D7AUGVK%YTA
MX3[<,30'&YL='6VW3[A(HJR::(&I)X)E\PUF#4W1OBG3^Q3#BNQVT;GF?F%3
M +03N585>+=D1FC,&WN=IR!*=74E[=Q85UK1!125"%#T^LK#P<OG-=2RZ)C[
M?8];\D6Q66:X8YHMW,$"YFU;';/>+,;(W" XZDEM E(:LFV\@-[T+MFG4!5%
M3P\*\]=H;M+=$3-8DQ98R16$H5KGJ4"@4&(R?&;)F-BF8YD,5)EIG"@OLJJB
MNHDA@8$*H0F!(A"0KJBIK7ICR78[HNMWPB8JU/%^$N.L6":C5K^=G[@(-RI%
M[+YS<)IK51;3VA"00155=!1-5\=:R<NMRY*5FE.K8B+8AJ_)'EZQ2\8Q/:P*
MSP[+D:NL2H[+!NP[=)*,^#RL/L,$C*BX@J**32[5T7T5[Z?7WVWQ-\S='ME6
MZR*;&I<<</<JP\FDY7*G-81*"%\W,M-C&O#DL''0>/O#T 6Q4!V[3WZJO5$\
M<O5ZW#?;%L1Q[>Q6VV8;3R5-YWQ#!;S<XMYLUU:B,@KL^%;),2Z,QR<$7GVV
MEDR62)IM2<\$31%71=-%Q-/&GR9(B8F._9[HE::Q",^&.0\Z3+)4+&Y%UY(L
M:P%D76*]<69!Q'^ZV++C<J<Z "1HKNK'<373<B)I6RUVGQ19$S2R:]7A'O4L
MNE+V6<WS<5QRXWB?@.10I41K5KVYF*L+O$H@".R8DF0(-J9(BDJ?J>%:K%HX
MONB(OMGVU]DQ#TFZG0TS"O,7>H^0#:>4F[?'MTZ._(A7&SQYBJR[&4%-IUI2
MD$0J)ZBX.FFGK)UU3,U'+8BVN.M?73]BMM_6D*[>8/B*U6R;</QFB2I$-HG0
MMC)Z37R$=1;9:<V*1&OJCZ-?36!;H<UTQ'#/;T+<<,)@OF&@9)?QQ_*;+^*C
M\IIU^V2I$UJ3&>1C13;<-!:[;NTMR#ZPJB+H6OC[ZCEUV.WBMGB[D1?5*TK(
MK%#MDR]2+C'&U6]@Y<R4+@F#<=L5,C)05>B"BK6MC'=,Q%-LKU:3A/..#9Y>
MTQ^U+-AW-YLWX#=RBG%&8RUU,F%)5UT1=RB6TMO7336LO-HLF*WBNI3U*Q=$
MI)K!78"RYQAF27"5:<?R"W72YPM5EPX4IE]YM!5!52%LE5$15VJOH7IXU[7X
M;[(K=;,1/J1$Q+.F . 3;@H;9HHD))JBHO145%KQ2UNT\<<>6&X,W:Q8E9;9
M=8^[V>="MT6-(;[@J!;'&VQ(=PDHKHO5%5*][M1ENBEUTS';**0V1P.XV0;E
M#<BCN'H2:IIJGOUX):%CO%,3&\A?R2/DU^F3IAMN7!J9*9<9E$RUV6^\(QP4
MM@Z;="3PK+R:F;[>'AM]G[58MHW^L19 N%<&WS&>05S*2QCJPR<%QFWQ6[BC
M4 R1Q'W(+3KY--&]O3=ZN@Z>KMU77;9M9;?CX(XOLV]KSBV:IZK4O0H%!A,N
MNMZLEAE7.P6R/=KC'VDD.9.&UL*WN3N&<DVGD! '4NH==/105RXRXTE8_D&/
M_C!Q=C[F0%+.Y!E7XQC(N9,I([JRT86-J^;2.!N(2%"73X.NE$K*Y&U=W\>N
M[./N"S?G(4D+6\>B"$PFB1DEU14T0]JT0K?PQ8;W!SRP/6?'<OL#C$&4/)<W
M*7GG(-RFJT@M%'5YYP'G/:/7%UA!'MZI]=T)E:.B&H9=GK&*R2C);WK@L6 _
M>KJ3)MA[-;(BH+CB(:HKAKJNQL?':75%T0@Y\WS>#A.+O90]#E7.,"(3;$!I
M72)%!7-YE\%MM!%2)QQ43T)J:B)!M%!6A<NQK+/-]CWXN7)FX_-.-W&WW'L*
MJ]F6S(=WM%JB>LFO6B>A9>B"@4"@4"@4'R8 Z!-N"AMFBB8$B**BJ:*BHOBB
MU$Q5,33;"N]ZSW(^/\@NF+8RZS^+UG?$HL2>VKI@#K0/$R)H8DC(J:HWXDB>
MG1-*X+7<YR:#/\G'%;8GI]?1'JZGT'1<GQZ_!&?)-+YCH]73V]:41LXY1;[;
MG>,/)8\FGPV)/='[+'?%UL3[$QL=J.BFNW?T,?0O32NK^5\ZVW-CG@OF(GU3
MZKNOWN3G+\FZ[!DCCLMF8]<>NWJ]TL/+YC^:)+EHO&/2_GR J#=VHALNL-H0
MH8DR9&*N;Q5#$=J$B>-:_/SS'I[HLRVS%W31G8>1W9[>/'?'!.ZM:]Z1[9<8
M=WMT6ZV]SNP9K02([FBIN;<%"%=%T5.B^"UT&.^+[8NMW2Y_)CNQW3;=OB:.
ME<<4Q:[R5F7:R6^?,5$%9$J*R^XHCX)N,%71*\K]-BOFMUMLSZXAZX]5FQQ2
MV^ZV/5,PR3$:/%CMPXS(,Q&0%IEAL4!L&P3:(B*(B(*(FB(E>T6Q$4C<\+KI
MNFLS691;D&.9=9,IN5RP:P19<&[1V%DHX\S%$);&\4(11154451214ZKX+XU
MS^JT>6,LW8K8F+HCJC:Z+2ZO#?AMMS7S$VS--DSLEDL8Q'-\>L%NC6^_@#K3
M(D_:;E$:D1P>/UG ;=C$T8CN5=OK'I67I]-GQ8[8MOZ-TQ$Q[8IXL74ZO3Y<
METW6=/FMF8FG1LFO@PEUN6<SLKE6FXWP,86#;VGP:MY-R&96]QW60*RF1(4!
M!VF/73IUK U.?4?-X9NX*1T;8G?MVPSM/AT\88NMM^96Z?-LF-VS9/L9;#>2
M(WXM6\\F^<"F;3!RZ_-\IV))V.D N@ZPRH:&B(7HTK-TFOCY5LY.*O7PS2>^
M(8>LY?/S;OE\-/P\45C9NI,U=Z7RA;I,H8&(15R.8+:ORNR\$9I@-VU$,W4U
M0R5/5#;X=5T2K9>9V1-,<<<^RCSQ\KOI7+/RXZ-E:^SH;/CM^BY+:&+O$!QD
M'5-MV.^FUUIYDU;<;-$5?6$A5*V&#-;FLB^.EK]1@NPWS9/^O4Y+O?['8&FW
MKW<8UN:=+8T<IT&4,D\4'>J:Z>G2IR9K,<5ONBWM5Q8,F6:66S=V15WF7F9+
M+<B.X+T=T4-IULD(" DU0A)-45%3P6O6)B8K#RF)B:3O?=2@H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MLQVA4W77"0 $1355(ET1$1/36#$5>K'V/)<<R>.Y+QN\0KS%9/MNOVZ2U+;
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M/FRVX\_*B/N2E:/3NNQ2%0:0==REN]X572A")O+?9<6#.&K]-R6[.95*;?\
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M%3UU1%5$K28M)%U\6\=NV>O]C+FZD;D*<3>9KD&Y9I'L^71UR&V71M\VV++
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M:I8!M%Z.6NB.;4(%]*%H:BM4ZX[R&?(?$M_Y*X*QR"G*UW0(UXBFL=J2U/:
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ME:?S9BL7%H/EQQBVRL*8C=QQ6%BDR0N(O::%DW&5%K:O<[C1>L2]53ZXAP<
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M-$BM2C;>-[89M-QC<,A$NFY-JDMER;(X6*VAR[SP-UL7&6&F&=B..O27!:;
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MC@V<[N$ZSR74;?NMP?A7*$VWXD9JY_A2(*)X"B*O@E#8N?$"2W%8;FO#(F
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M(M!MUJN#5VM<*ZLB0,SH[4IL#TW"+P(:(NFJ:HBT';H% H% H% H% H% H%
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M]UR8K!-RF)Q2$8?9[+AKL-(ZEH:"6BIJFNM!N5 H% H% H% H% H% H% H%
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M['!0QU3WEUH/L1$1011$%$T1$Z(B)0?M H% H% H% H% H% H% H% H% H%
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M49]Y$38T$EDFR(U333N-_;$]_4E)HFCRA<2Y#QIA%RN>61_8+]E,EN:=J5$
MHL9D%1D' 3X#BJ9DH?6IM1="140B5B*(*#HWNT0L@LUQL-R!7+==(KT&8"+H
MI,26R:-$7T:B2T%",9RSD[R89/<\6R:S/7[C6XR"?ARF]667270!D1WMIB#J
M@(HZP?N)U1-"4MO;WQ);<FYYY]:\P4RP'C6%6:/[/:D>ZNSG18-@%0MH=S3N
MD9F*;4T%M%+15H2N514H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!\@ -C
MM;% '55VBFB:JNJ^'NJM!]4"@4"@^5 %,7%%%,45!)4ZHA::Z+[^E!]4"@4"
M@^3 ' 5MP4,"30A)-45/?1:#ZH% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
H H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>tm2227887d1-bc_cyto4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-bc_cyto4c.jpg
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MHDIUJ)]1D53X\ ,&@00
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M7:8"H\,ZC]M\^SZ5MUC3DR3>(IR?XYR4%!<3#.BU-NDX9J2?R)Z.()P6X"
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M[9K?"F6;(L=>-FXV>YDTF01$HVU+3REK(R2XDT+X]TZ>B0)P6D"
M
M    !3>X?4UMSMGF*<'R-JY+O*D,.$J)';=8TRO2=Y3J#^/W03@E>Y^[.'[0
MVB'>\R=D-09TGP;!Q63?4;O+4YQ(C*A40?$$.M@F;V+<;%+?F>,K=<LESYWA
M5OMFRX?AWW(ZZH.M.^VH!(P   4MN#U4[/;<WAW'[I<WKE>8RM$R+:6?%>'6
M7 T..&I#9+(RHI!+-2?*1 G!(]KM\=NMWVI!8;<E+N,1/,EVJ6V<>8TV9DG6
M:#,R4BID6I"E$1F1&=3 P6,"
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MI#1]YMTD*41'0TK*A\4J(P$T
M
M
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MGK\MULXKR([Y1T&VE):O53/4BOR)&8(P7*"
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MX-G&FJ.).J5.)DMLY%#^3H8&\WH"H
M                                          _FWUA?G&M?.UJ_7!>%
MW]?WP;8S[>%[$?!$+&Z0?S=L-^N?]*RP1*[P0 *ZWXS*9M_M#EF5VY9M7*'#
MY,)XB,S;DS7416G"IY4+=2HOC F&+.EW%-F3L%\W&WKE6Y;"IWFFS1[P[ZFM
MYMI#\EPFC.KRJ/M<=)Z.WRU!,KJV>Z?L#B[F'N]M1G\>7C4>2]R<?M[92$,L
M26S2N*\^<@UD7>U(2MK45$GQI4$8M7 @
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MCDNM.T]/H F6[@5
M
M
M            '\V^L+\XUKYVM7ZX+P_I("C^>_5O^<WBWSM9O9SH+0^_5MMG
M==JMP[=O5@NJ%"N<Q,E]U@C(HEZ;/F&H_P#(D$1KIV&HED? R("$!S+<:W[K
M;_X%FL!')7-=QY$Z+Q]0F,R4(>;*O:DE$9H/RI,C!+3'7S\#UD^^6+[ G@K#
M/^S_ $@W'=O X.<1\K8M34YR0T4)R$M]2?#/*:,]9/((ZZ:]@+8M)]/?2U/V
M1S2=E<K)6;RW,M;MK**U$5&4E3LB._KU*=74BY%*4\H*S+.G48RK-NKN/B%[
M?4=H7/Q^QMD2C3RH<YN*XZ1'7AWY+BJ_%!,:FL^H[;_$[CL-D,#S7'C,8U;E
MSK$3#2$>#<A)UI)FA%I2I*30HB[4F8(A47]WW9X[6,9GD!$1RY4^+ ,^U26X
MK*G2^,1F^?QZ?$!,MD@J
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MGZH$-GX5,D7##<=N$LE)E2K9"??2YZ<G'8Z%*)7 N-3X@J[H
M
M#^;?6%^<:U\[6K]<%X7?U_?!MC/MX7L1\$0L;I!_-VPWZY_TK+!$KO!#(._7
M5MFFT^Y=RPFS62US;?"9BNMR)A2.<HY#"'5$?+=2G@:J%P!:(0+)M]<JW\Z?
M=T%WRUP;>6,NX\\T5O)ZJT39RTK-7-6YZ7E),J4X5J!@Y'2'L)A.[$#(+_G;
M;MP@6QY$&#:VI#D9!/.MZW'EFRM+E2+02.))X'75V$)E\<<ARNG?JZAX;C,M
MYW';E<8-J<8=54W8%[)K0EVE"4IA;Q*2KM,T5\ID!KA_1@%0
M
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MJTTXE)M\1+O;^R):J_'!;>?T'!4
M
M
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M+E^W68YYMUD]IFQHIK)Z'<G8SS<)YZW/+CN&T\I)(43J7$K10^*4U("6QP5
M
M            &=.M2R7F_;/,0;%;I5SFE>8CAQH3+DEW0EI\C5H;2HZ%4N-
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MI##*?0;:224E_@(%7W
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MKC)?D0TI1$9C-.GK-MHT(4;AU+N4J:C!$MY J
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M8\0C'N;US7:]1T\^VV&?*E272XD3=FCIM[*RIPH;R6J'Z )WF^@5
M
M
M
M
M                                        ?XI*5)-*B(TF5#(^)&1@
M,E[0[<9AL=U#Y#9+;9)DK:K*V37$NL=I;L6(:36_&2\M)&23:,W8_>_9)5V&
M"S6H*@             9T(S]#]4!DC:;;7,,ZZA\FWOW"LDNS6RWO*1B\&Y-
M*9<</E^&CK)MPJT:83J5P+U51&7$C!9K<%0
M
M
M                                     >*\6FWWZTSK'=F$R;7<H[L2
M;'7Z5QA]!H6D_CD9@,U]+^![A;/9AFNW=]M<AW!WW_'V'(2))QG'&Z-\32=2
M6\RILU%2B5-FD$RU""             !'LZNM[LF'WJZ8U;G;MD,>(X=JM["
M24MV6HM+14,R+22S)2_\DC 4ETB[,W?;;%[GDV915Q\XR9\SDLOGJ?CPV%*T
M(6=3[[BS4ZNA\2T5XD"9EHX$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6\RIAEY,HW"2IDET69$;9ZM:$]I C!8X(
M
M
M
M
M
M
M
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MA6WELQK.YL*?>H&II#\!"DEX9)T:2ZM1)YCB4\%+)!5X5U'52A*PP0
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MYBT\]B=_M]\;CF29!VZ4S*Y9G6A+)I2M-:<*]H#N@
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M&E25$1D? ^((=4
M                                            1O-<_P .VZM;5ZS6
M[,VBVO/)BLOO$M>MY25*)"4MI4HSHDSX%Y 'NN.3V"T8\YE=SGMQ<=:81+<N
M#M4M)8<(C2L^%2(]1>0! ?RD]BO?U;/]-?R@)P2K-MRL$VYC,2\VOL6S-RC-
M,9#ZC4ZZ:::C0TV2EJ(JEJ,DT+R@A[,1S;$\]M17O#KO&O%LU<M3\5>K0X1$
M>AQ)T4A5#(]*R(Z (M<M_MFK/D"\7N69VZ/>FW.0\RIQ1M-ND9D:''R2;2#(
MRHHE+*A]H)P3:\7ZRX_:9%^OEPCV^RQ4<V1/DN);80@Z4,UJ.G$S(B]$^! A
M%\+WEVOW#G.VS#<FAW2Y,I-Q<-!K:?-">U2&WDH4M)>4TD9%Y0,$Y
M
M
M
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M):
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MK=GK[<($=N/(N\I"6WI*FRIS%I1PJ?Q3,_1,SJ9D.P
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M0DS(JJ6LR215.G$P'V:=:?:0\RM+C+B26VX@R4E25%4C(RX&1D _8
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MLLH(S))&I:S))5,R+B8#T)4E:4K0HE(41&E1'4C(^PR,!_H
M                   #^;W4_AF\2+-"W#W?O++DN9<SMEEQR(9*8A13:==-
M1\OU,EJY:?2FLS+TR^!$1>%_]4.0>9>EFWP4KTN7UNRVU-.TR)"):B+XZ8YD
M8*QK4E@UZZ9[?%Q:Q;E;77.TKG0XS+N77/Q+465*)I!.R-"7DT94LZZF]6DC
M*I4X@E-';9:=X.MB[VG*H[=WQG'(*D1K=([\<T18S2:*29%J3XA];E.ROHEV
MC>1&'>_P(;U;VX_B!G LOF"XO6^*V:B;CS"8:D15I+C^XJ>6A'Q#\@#[[>[0
MX7=^D/*\YNMK9?RM97&XP[RLM4IDK<HB0A"JEI29M+U%Y=1U\@&.E"\NS6]9
M9L)L[@+\IQ295TN,22HU'5;<!]IB&1F9&1DA$I2$EY-!<.P$K,ZE,/Q;8_</
M:/*=N[:W9'RD.HDM1*MD\FVO1*&YQ[RG$2%H<4?%1=M01#5&?[X[7;77*+:,
M[OWFJXS&/%QF?"396IG6IO5JC,.I+O),J&=01@]6WF[^W6ZWG+W WGSOYHY'
MG#^*RXO*\5S.5_K3+6K5RE^EK2G'R A.                 'S0^PXXXRVZ
MA;K5.:VE1&I&KB6HBXE7XH#Z                _#KS+"26^XEI!F224M1)
M+4?853\I@/V                 ^;3[#Y*-AU#I(4:%FA1*TK+M2=.PR] !
M]
M
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M&[C:;\Q<'ER;S%8M9VTIADB<HEFVJ2<122Y!4/7SJM?LBX< E0
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M2HS(^!EQ*HP1-KK,VB5(8-^-?8ECDN<IG(I%M--M4>I2:DLG#<,NZ9_N=?\
M'08- 1I,>9'9EQ'4/Q9"$NL/MJ):%MK(E)4E1<#(R.I&0(?4
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MDZ#<H\N.F[2YC+[4:6ZI@E(7%4ZHTJ0E)T4;9)+5QXUJ82L
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MA<I3KY*;21EY5E0!U(RG5QV5O-<AY2$FXQJ)?+49%5.HN!T/A4@'U
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M3:"I4ZJ+R .PR:C:;-:.4LTD:FZD>DZ<2J7 Z /V
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MD9[Q<V+I9UJ<TZ8S[23[RC.IE4$8LQ?W>7]H_P!9/ZP!,MO@J
M     C-B4R>5Y2E&+':'4KA<W(S;CH*\U8.BB6T9NK\.7J7JO96B?+0),
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M;NW-SEL-WIF%'L%TC,\\T-N-+;GZ)!$@DMZ]=4&K2I)D1\*D0MX$
M        (SA:V5L7GDXLK%"3=IA+94W&:\>LE)K/_BQF2N?VZE]\Z<?(8"3
M
M
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M^G6[<XO&\U3(NQ*1RFKA#./&-)K(EFIQEQY1&2:FFB#J?#AV@8NA^CWL_O\
M)/V-;^B ,3]'O9_?Y)^QK?T0!B?H][/[_)/V-;^B ,3]'O9_?Y)^QK?T0!B?
MH][/[_)/V-;^B ,3]'O9_?Y)^QK?T0!B?H][/[_)/V-;^B ,3]'O9_?Y)^QK
M?T0!B?H][/[_ "3]C6_H@#%H/8K9R-LCB4W%(MV7>6YEQ=NARG6"C*2IUAAC
M1I2M=2+D5K7R@B96<"   <6S^ZWSM>_/YV[S'SFO<YX$G_%^'Y9<WQG-[FOF
M5T\KAI[>(#M                                      #PP[+9[=(=E
MV^WQHDI^O/?89;:<<J>H]2DI(SJ?'B ]$J+%G1UQ)K#<F*Z5'6'D)<;47;12
M5$9& _,*!!ML<HENBLPXJ3,TL1VTM-D:N)F24$1<0'QGV:SW13:[G;XTU;/[
MBJ2RV\:*_L361T[/( ]Q$1$1$5"+L(!B#^\-_LX^O?\ 5X+0V^"H
M       #@YJP[*Q2ZL,Y >+.K842<A+E?Q/B1\SU>B*>0]1E\0R/B Z\-*D1
M(Z%R#E+2V@E2CTD;IDDJK,D$2>]V]TJ /N          .?<+[9+2M#=UN46"
MXX1J;1*?;94I)<#,B6HJD \?NTP[WPVS^6Q_EP#W:8=[X;9_+8_RX![M,.]\
M-L_EL?Y<!PHN08^UEEQNSF?0I%MDPXS#&.JE0R9BN-+<-3Z5$O69NZJ'7]CY
M>&DEW?=IAWOAMG\MC_+@@]VF'>^&V?RV/\N >[3#O?#;/Y;'^7 /=IAWOAMG
M\MC_ "X![M,.]\-L_EL?Y< ]VF'>^&V?RV/\N >[3#O?#;/Y;'^7 /=IAWOA
MMG\MC_+@/TC,,2<6EMN_VY;BS)*$)F,&HU'P(B(E\3,!V@   <#-V'9.*71A
MC(3Q1Q;-"R$N3_$RU$9K]7HCL[O>,NW@9& [C)&3+9*<YRM*:N\"UG3TW=X<
M>W@ _8                                #G7BP6'(6&XU_M<2ZQFE\Q
MIF=':DH2NAEJ2EU*B(Z&95 >LXL4XIP38;.$;?).-H3RN5ITZ-%*::<*4I0!
MPK+M_@6-3E7/'<6M%HN2R-*YEOM\:*^I*NTC<:;2HR/R\0'OON-8YE,0K?DU
MGA7J E1.)BW*,U+9)9=BB0\E2:EZ- 'VL]DLV/0&[58+=%M5K9KRH4%EN,PC
M4=3TMM)2DJGZ! .7,V_P.XWE.17#%[1+R!"DK1=GX$9V82V_2J)Y;9K(T^0]
M7 !W9,:/,CNQ);*)$5]"FWV'4DMM:%E125)41D9&7 R,!QK!A&%XFZ\]BV.6
MNQO22),ARV0H\-3B2.I$LV4(-15]$!W@&(/[O+^T?ZR?U@"TMO@J
M        X5IAW]B_W^5<KXW<+-*7%.S6A$9ME=N2VSI>2MY*C4]S5^J%K(M/
M87 !W0    'Y6E2D*2E1H49&25E0S(S\M#J7 !EV1TD7.9'N612\T?=W=D7Y
MJ[P,U-"B<8B,*T):Y25$1'RU*5I09)U)0@J(2"<6GHK<AJ(RS*?\1*0VE#TD
MD$WS'"21*7H*I)J?&GD!#,=SZ2;C>49%D-TS)^5NE/O4>Z6+,#2IMR%%BG1#
M7+;4FAZ5K[K:B35#>G22: G%IFWLRX\"+'GR?&S6FD(DS.6EGG.I21*<T)[J
M=1\=)<"!#-^3]*$G,)V;9+D65O7#-KM(8>PR]*)3*K2U$43K;9);,B+O&;9\
MOL21++OF8)Q:'QZ#<K98K=;KS<3N]UBQVV9ET4V3"I+J$DE3IMI,R2:C*ID1
M@AG[+^E9[.;UG6393D[USR*[H:1A$U:3:\S(843Z$:6^%"61-U;H>C4KTZS!
M.*WCL&:0L)LMC;S%*,F@+@HN&228;3IS&F74\Y!LN+-*5/((T:M1JJ=2X\00
MFH                #@XM"R""S<TY#?6[\Z]<9+T!QJ*W#*+"69<J(HFU*U
MJ:H9&XJBE5XD [P
M
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M= 3BM)*4H2E"$DE"2(DI(J$1%V$1 A_H
M          BNYOP;9C[1W/V(Z SIT _!MDWMX?L1@%I:U!4
M  !$,75BAY;F:;)=)$V_E)A^Z*"^\\ZS#>\*7)2RAPM""6V1*5RZU/M] !+P
M               0W=-6'IPJ:>=W619L:YT3Q-PB2'XCR5^);Y22<C]\B4YI
M2=/(?D[2"9                 (;B*L//*LT+'KK(G7WQD;W20GI#[S4.1X
M<B;0TAWN-DI!5,F^%?C$1!,@
M        &(/[PW^SCZ]_U>"T-O@J                C>?N6UK#;RY>,??R
MJVHCF<C'HD9,V1,21EZFAA9D2SKQI\3AQ =R ;1P8IL1SALFRV;<12";4RG2
M5&S0FI)-)=VA=@#T          "D=\>FVR;XW6U76ZWR5:G+5'<BMMQ6FW$K
M2XO69F:^PR!,2JK]'YA_OQN?\GC_ /2"<3]'YA_OQN?\GC_](&)^C\P_WXW/
M^3Q_^D#%Q8W0YB<G*)^-'>LB9:@Q8\M-Z=@QTVY]4A2TFRR[J[SC>BJTTX5+
MXE1B[7Z/S#_?C<_Y/'_Z0,3]'YA_OQN?\GC_ /2!B?H_,/\ ?C<_Y/'_ .D#
M$_1^8?[\;G_)X_\ T@8GZ/S#_?C<_P"3Q_\ I Q/T?F'^_&Y_P GC_\ 2!B?
MH_,/]^-S_D\?_I Q/T?F'^_&Y_R>/_T@8O9:.@S$K3=8-U;RZXN.09#4I#:H
M[!)4IE9+(C,C[#H!BUN"H  (SN$NV-X9>'+SCTC*[8EDCD8]#C)FR)9:TT0A
MA1D2S(Z*_4J D4?1X=KEMFRWH3H9-.@T)IP3I+LIV4 ?0
M                             !B#^[R_M'^LG]8 M+;X*@
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ML\[HB9&=BG*N6I)/RFR=,];;AD6E:>Z=*$14H F0
M
M
M          Q!N3^?5B/UM]9<!;>;?!4               !P<FDW>.Y94VK'
M47]#US8;GK<D,QO-T51*USDD\1FXIK@1-MT6>K@8#O                 .
M#BTF[RD7<[OCJ,=4U<Y34-+<AF5XZ*DT\N<9LD6@WJG5M??33B8#O
M         X.12;O'FV)%LQU%\8>G)1<):Y#,<[9'Y:ZRTI=(U.F1T1H;HKO=
MH#O                                             (KN;\&V8^T=S
M]B.@,Z= /P;9-[>'[$8!:6M05                <2T3+](O5]CW.S-V^TQ
MGF$V>Y(D(>7<&U,I-QQ;24DIHVU^ID2C.M*]@#M@               X67R\
M@A6%^1B]E9R"\I6P3-KDR40FG$*>03BC=6E9%H0:ETIQI0N(#N@
M       .%99>0/WB_,W:RLVVUQY#2;/<&I*'W)[)LIUN.-I2DVC0HM!$HSJ7
MQ.T.Z                                             Q!_>&_V<?7
MO^KP6AM\%0               '*R5B_RK%.CXM,CP,A<:,K?,F-'(CMNU+BM
MM)I-14KY0'1CI?3':3*6ER22$D\XVDT(4X1=XTI,U&1&?86HZ>B ^@
M         .+&C9.G)Y\J5/C.8FY&91;[>ADTRFI23/FK6[6BDJ*FE-. #M
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MX+E\'/<2M686QAZ-!NS//:CRDDA]NBE(-*R(S(C(TGV&9>@8*I"
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MD5>8:.[Z #M@
M
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MF\J5?7%2F.;9E.1UE9SY!48)+)$M',+U2CO$^!^B9A)P
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M33U'TO>!;%K%DG4M-D^I*WR21.K0DT(4NG$TI-2C(C/L+4?QS!5^P
M                             &(/[O+^T?ZR?U@"TMO@J
M     AF,/8<YG.;M6.Y29>4M+MONG@/.R7(\19QC\*3*'2Y2-;=5+Y/:?IN-
M $S               !#=S%8@C'XIYM<9%KM)W. EB1$<?:<5-5(24=LSCD:
MM*UF1*KW:>FH7$!,@                $,VY>PY^+D)X;<I-S81?K@W>%2W
M9+RF+JE2?$L(.41*)"#II2CN>@9U 3,
M
M
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M4VC&)&,)1>YJ)J),1$,KA*+1S+@UH,^:V_PTNGQ5I^( E8
M (GF"[.BZ8KYTQ>1D+Z[HE-OG1XB):;4^;2S*6ZM1D;*"IIYB>PS+X@"6
M                                          (KN;\&V8^T=S]B.@,Z
M= /P;9-[>'[$8!:6M05                1C'EP%9+E*(V,.V:6E^+XR^.1
MV647=1QRTN(=;,UNDRGU,S<]+V%Y0$G               !%]PW+>WBDM=SQ
M9W,X7,C$YCS$9B:X\9OHTJ)F0:6U<LZ.'4^&FH"4                 (OC
M3D!>0Y2B+BSMCDMRF"F7AV,PPB[K-@C)Y#C1FITFR[FISB79Z)$$H
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M<6@C,BI7L_PEV@.C%.2J,RJ8E")9H2<A#2C4VERA:B2HR(S(C[#,B ?4
M           '%C/Y2K*)\>7$AHQ!$6.NVS&W5G-<F*4LGT.-F6DD)22-)D?^
M'Y$.T               #D92]DD?'Y[^'Q8LW)4-UMT6>XIF*MS47!Q:",R*
ME3X>7A4NT!U&C<-I!O))+II(W$I/4DE4XD1T*I5 ?L
M                          !B#^[R_M'^LG]8 M+;X*@
M  .):I>1/7Z^QKI:&(5CC*C>9+FU))YV<2VC-\W&B0DVN4JB"J9ZNWL =L
M             '%R>7D,*W-/8S:F;S<#E1T.Q)$DHB$QENI)UTEFE9&IM/?)
M-.-.'$!V@                '$QF7D4MJY'D=H8L[K5PDLV]$>24LI,!"BY
M,E9DA&A;E3JWQ,O1XT(.V
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MXEYEQ!_)(6@S2HOBD8(>@            !B#<G\^K$?K;ZRX"V\V^"H
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M0$J?ZL=BL)V5]R/N/<G.>?/.7C?'O(?IX/PG+T:&VZ?NRJ]OD!,2_I6"@
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MJ8R39J)')>>(R]5015,JF?8 FZWFFE-I<<2A3JM#1*,B-:Z&K2FO:=$F="]
M!"-O-UL?W(3D*[3$FP$8U<W;+<%7)+#252V3HOEFR\Z1IJ9<54[>P$O=;TV3
M\(=Y-C)9<J_^;XGC,6<EDN%#8UKY<AN-I+0MTR,EKU'4B+@7"I"6
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MW>:U2I^,*D,3[8;:+Q:IK9MR(KCVO02C*J%$KEKTFE1]G$B/@",%C @
M      !B#^[R_M'^LG]8 M+;X*@               (O8$V[W6Y6N+E#UWG*
M7!*=CSDAEUJSF4<R0EMEM)+:\0GU17,,]1E4O* E                (OGJ
M;>NRL)N63O8G'.=")-RCOM15N.<].B-K=)14>5W%)+B9?$J E
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MW%G#)"C7>\7N!ID,2FG&E$A3:TI01*2HT&DU-ZJ?)^0QBT""
M&(-R?SZL1^MOK+@+;S;X*@               (5N$UA+CV(GF;4AQQ&00E8X
M<<I9DF\DESPZG/"\"01:Z\[U/]D FH                "%[=(PM+>3JPM$
MA"%Y#<5W[Q12TF=Y,T>*-OQ?'09DG3RO4_V/E 30               $*SI&
M$JO&&*RQN0NY(O"3QDXY2S2FY&RX1&[X;NDG1J_=NYZ/"H":@
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M\%^-DBI4(LHE.MR4-2'RB)Y"FE.GRU$EHR2?)(BKV]M3"9
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MN(+8-C6BXMW>U0;LTVMIJ?':E(:=2:'$I?02R2I)D1D9$?$C(%7L
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MA6C'S4R@IE3(C:,Y'J=#+MU .M%-2HK"EL>&6;:#5&JD^4>DJHJ@S2>GL[O
M!]@    &<.KZQ6,\/M^:RBR!6561XXN+*QUU;7)G3C2E+CZDMN$A)J0A.HJ+
M4>E"3JH$PIW8/:&=:=U(>%;HN9!&R/&$1,IQE$"0:[$DG3YSB7D\E9(4;FMM
M2M:4K-*T=M-1,KMZN;%CKV!1\QNY7Y5YQUU18\>.NJ94W.FZ4H<?43;J4-DI
M"2YAD1E72D]2RJ1"B-C]H;K W3M>%;LN9'&O,!J+F6-)M\A2K2F0HTON^*2;
M+FATG"-M;FM)*6@T5.J-1,RT%U8V'&)>W/NJR)-\7(QEQ4BSIQYTV7$37R2A
MMUY?+=2VV@T\75)[I&9)[RB(R(9RV<VBO3&YEEPS=]S)8TR:TSFN/>;I"E0$
MSSTNO*G(4RX:'TJ02%N:DF2TDDS[R03+3'5+C^*W+;-_(,J3>W6L96=QMS6/
M.&T^4PT\MMQ:C;=0A"*F:G5I[B:F7$Z&1#+>U.TE\5N!8<2WA=R:.WE319A8
MUVR2M3!7$S);J[@E3+II>[B.8Y5*D*TZN"JD2WA#D2U9I<XZ\:*+#1"C&WE6
MM@SF*U+_ (MI3ZJ1,U-1:N[WCI\4JD0               .#FCS[&+W-V+CY
M94^EKN8^:F4%+,U$6@SD5;(ODN]Z #MLF9LMFIODJTIJUP/0=/2]WAP[. #]
M@                         #P6ZQV6T.S)%JMT:$_<'E2I[L=E#2Y$APZ
MJ<=4DB-:C_9*J8#W@*+N.]^00^I>T;)-VZ&JP7"(N4[<%<WQB5)@2)5$T7HI
MJ9(O2=@)P7/&LUHA7";=H<"/'NEQ)I-PF--(0](*/KY1.K21&O1S%Z=1\*F"
M'M             8@_N\O[1_K)_6 +2V^"H               "-6-QM6590
MA&+JM#B%PN9D1MQTIO%6#,E$IHS<5X<O4O52X5[OEH$E               !
M&LX<0U9V5N8P>6)*;#_\M2AAPVSYZ=,G3([OJ!T<J7>*E2[*@)*
M        C6&.-N,7CEXNK%21=9B5,K;CM^.42DUGEX8S(R?[=2^^=./D,!)0
M                                       5WO;NI;]GMOKAETI*7KA4
MH=FAJK21<'DJ-I!T,NZDDJ<7Q](DZ<: F&=^C[:>YWVYSNH'<#7+O5U>?785
M22+6M;RE%(FF5.&HS4VU2E$ZC(J&D$RV8"H
M                                                          "A
M>JC9%.[>#JN%E8)6<8ZER3:=!%KE,F578AGY=9%J;]!9$7 E*!,2K'9O?"?G
M73UG^'W60ZG/</QFZ%'D$:BD2(;<)U##I&7>YK2B2VL^WTBN)J,$S#9 *@
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M9N&V^:4*X$9=XR[:@.RR2B:;):^:LDD2G*$6HZ<3H7 J@/V
M             *2S7JKVDP'*+CB&0R9Z+S:UH;EI9AJ=;)2VTNE11'Q[JR!.
M#@_EM[%?[7<_Y OY8#!3F,;BXUNCUM8KE>*./.6AR%)CI5(:-ESF,VB:2NZ9
MGPX@G>;N!4             8@_N\O[1_K)_6 +2V^"H               #@
MVB)>F<BR"3/R%%SM4A44[78TQF65VLD-&3I*>0HUO<]5'"YA%I["X .\
M           #AY7$O,RVM-6*_HQR84N,M<]R,U,);*74FY')#RDI(WB]3)7:
MFM2X@.X                 X.*Q;S%9NB;UD*,B<<N4IV&ZW&9B>#BJ47+A
M*)E2B6IFAD;BJ*5Y2 =X                                       &
M(NMR9<,JW#VZVIAN\M$XT/DDJJU2+I**$TI22XGHY:]-/V1@M#:%FM,&PVB!
M8[8WRK=;8[,.(U^Q9CH)M!<*=A)(%7M
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MU))1(-1:S(S)->)D5*G3XE2 ?Z Q!N3^?5B/UM]9<!;>;?!4
M   !$LX582>Q@KWDTK'%G>XGFQN)+*&5RFT63<!XC2KFM.U/4UPU&1<0$M
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M_P FZ7@Y,0[U:GY)OL6USPQ$TVPT9$31.(+6HB,]2N/Q $M
M  !#]T$XVO#)B<LR*3BUD-V+SKU!EG;Y#2RD-FVE+Q$="6HB0HJ<4F?QP$P
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MRWN^I9D562<+L\H(TM3@@             8@_N\O[1_K)_6 +2V^"H
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M@1,7O+%^SC)+MD"F57-EA3L>WVQ]33+:G5D@E=TB4[H)'89U41\ 3,-D@J
M                                ##^^A%)ZTMMFGZK;:.Q&VDS.B=$]
M]Q-/C*[P+1J;@!4
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M5B[, (]B3TI]%Y5*QKW-&FZRT-(UQUG<&R-.F>?A^PW_ $'._P ./D 2$
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M<<AI<U%4W4M&2S+37L\H#IM<WE(YQI-[27,-!&2=5.-".ITJ _8
M                 X&<V.5DV$Y)C<!XH\Z\6J=;HT@S,B;=EQULH69EQ+2:
MB/@ Q-L4CI7MV'GC^[,6W,;C6R9,CWIRYFZ\VZIM]9-J8>94MDT$C2CN*XJ2
M9]AD9EIQ7WMQ^2?[L[9^#3S'[MO5_-?@>;XG_5W.=HU</W'F5^)4$:5^@@
M           8@_N\O[1_K)_6 +2V^"H               #B6I&7)OU]7>W;
M>O&5*C>YIN(EXIJ$$T?B?%J6>@S-S]SY?R/;Q =L              43GO3B
MSNAN%<,ESF_/7+%3M+L#'[$22;*VS)">6M]%.ZO3^Z)-1:C735W4)!.*3X=A
MVYN#[9V3%(N10;]D]N?CMO7.[,O)8*VI=2;K".6HUJ4AJJ&EK[>%:>0.)N+L
M"C=/<6#?\SO;T_ 8%ND1X^)D7*0U/?1RN>E:>WNJ4YJ5WTK2BAFG@0Q2C9C
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M9(M4>!=<;6CFE,FQD<LI*E&9)0JB2<-24ZC6I?8E1D!BNX$
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MIEE9*/F*6==3BB[?(-W+W9N4XR\OMG9]&2OQ;HF9CJQ.GEG\EHC9<,
M
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MW)%O9-YZ:<DL&S:-,=)VE/)+U$S9[Y\RO,]5XTI\<PD8
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M&>>O5ZDI?R/#M\@(Q7Z"             !B#^[R_M'^LG]8 M+;X*@
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M5"^(1F ]0                           ,0;V_GK;=?63V8^"T:FWP5
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MI"T+*J5),N!D9'4C!5]
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M=C4JSW-,B)YUO4B&4:/=G#CERW([Q*,WTM)]349D6E52 2L
M  $2W**Q'B$PLCQF5E]IYD;G6&!$*X2'E>(;T*2PI2243:J.*.O!)&8"6@
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M#0WW4]PI23H5/(0$J4ZC^GN'L/[F?"7YV]^?_':^;&3&Y7@?#4II<<U:N?\
M$I0$Q+^HX*                .1E$K((6/W"7BMO9NN1--&JWV^2]X5EYVI
M=U3ID>GA7]:I=H#I152%QF5RVTLRE(2;[2%<Q*'#(C4DE4+41'PK0J@/J
M            #BQIF2KRB?"E6UAK%&HL=RWW5,C5(>EK4LGFULZ>ZE!$@R57
MC7R_(AV@        '.OMMD7>TR;;%GO6R0^DDHG13H\T9*)54G\6E!BO6YKH
MFF)FF9WX9K%R+=<53$51&].I4^987E.,8O=+^QGUZ?>@,F\AE;E$J,C(J&9'
M7RC@YK*W;-JJN+M<X0]%E,Y9O7J;<V:(ZTNG;=M\FG6Z)-7N%?$*DLMO*23A
M&1&X@E4+C\49Z,C=JIB?&KTPP7-H6J:ICP*-$K/A1UQ(<>*Z\N2XPTAI<ASB
MMQ2$DDUJ^*JE3':HIPIB,<7!KJZU4S$88ON+*./E4O(H./SY>)6]FZY$TV1V
M^WR7O"LNN:B(R4Z9'IH53_Q< '59-Q33:GDDAXTD;B"/425&7$B/RT,!^P
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M-;^B ,5@[,=)5NV=S=K-(V4O79UJ,_%\&Y#1'292"(M6LGE]E/0!$RT@"
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M265%:'D$M-2(SH=#!#U             ,0;D_GU8C];?67 6WFWP5
M         <;(&\J<7:3QA^"PA%P95>RN#;KAN6PB5SD1S:4G2\9Z="EU3VU
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M]-AR;,\^VK'H\5E;3[$<FB)Q,A:E&2U&NIEI+L^/0@[8
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MRAZ[W#7 \?CSDAEUJSGX<R;2VTA)+:\0GU16LSU&52\H"5
M  B^?)MJK(R5TR9[$X_CH>BYQY+<1:W>>G1'-;I&1I>/N*3Y2,!*
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M-3LY:8Z"+T3JNOQB!,(5T1VJ5;MC(TJ0C0W=+G.F1JE34TDT1J_Z3*@):,!
M                                                 Q!U)?GA;1?^
MG/Z>D@M&IM\%0!BC<C/^JAW>Z_[>;77M$YI@RF1K;$BVITH,)Q*304I^5'HV
MH]1*HXZ:J*+T2!;0BF49_P!;6&7NT6#*KTBV.W][PEKF/QK"<%U\Z4;.0F.I
MM"C,Z$3AI_P<0-"UMF=Y-YK1NI&V9WXA-(N]UB+E66>A$9I9\I#CA<87J"VU
MI:<(C21&E:=)\3H1$PU8"            &(-R?SZL1^MOK+@+;S;X*@
M          (5N$>%$_B/NRF2(CAY!"]SJ8ZY2$O7C2YX=ISPQ&1H,M52=[GH
MF FH       .1E?W+7SVOE^LK%:M2ESLSR*+V(^";&_WI_V4Z.*Y-CRX6(#.
M  "$V?\ .0MOWIR?9I#:RW;]BMOSHY)7Z.DZB%[<JPI3>4*PJ6_+1[H;CY^.
M0J4OEWFJ/%-M^*(J(2>FA->I_L?* F@               (5G1X45XPSW63)
M$:XG>$%C+3"Y24/W/DN:6W2CD:33HU'ZM1/#M\AA-0
M         5KO_<+U:MH,GN>/7YK&+O#98?8O<A3B$,I;E,J<35IIY9J<02FD
M)2V>I2B+RU!,,I8CC76YF6,1LKMV4R(L"<RF3;X\Z8TQ)D,N%5"THY:B22BX
MIYBDU*A]A@G0XF)WKJ\OK61SK-F3J[YA3KB+YC<QUH[@T;25*KX=YA33J5:%
M$FBSU&7Q@-#873[N?)W<VQMF67)IMF]$MV#=6V"HUXF,JAJ21F9D2T&A=/)6
M@(E: (          !%=S?@VS'VCN?L1T!G3H!^#;)O;P_8C +2UJ"H
M         "&8F6&>['-SQY4A62>*A%E*7CDFTE_PJ38Y7.]3IRC+5R>%>WR
M)F               "%;L.84U@TY>X2Y",5)Z)XM4,Y1/<PY+9,T.%ZK3FZ*
MTX>B FH                "%8<YA*\KS=.-+D*OZ)T8LI2\<LVDR_#)Y1-<
M_P!3(N72O)X>CY $U                               !F'K@AVFY;=V
M"VRG7COLN]-,V"(QH2EZ4ZTXV9O+7Z5M*5\:<34:2X$9F1,*Q=_N^[LG'C?:
MS5A>4DUS"A'!4F";VG]RY_.UD6K_ .^<K_X 3BJ;$-J92=J;OO/@V82K7EV%
MR#:O=F)KD.-N-.(/4S*9>XITJU%J;HHR-/DJ9+^B>T^5R\YVUQ;+9Y$5PNMN
MCOS=)$E)R=&EU22+@1&LE&1>0@43(       &(/[PW^SCZ]_U>"T-O@J
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M<XB67\?_ (N9EZOVU7WJEQKP,PDH
M       ,0;V_GK;=?63V8^"T:FWP5    8HS[);)BO4UFMPOTKPD-V!#80YR
MW':NJAP%D5&DJ/L2?&@XE^8B[.[@?5MD6ZJ]FVXIX:OZJG0_#)MO]6OYK+^8
MC'UX;GVEW@YC\,FV_P!6OYK+^8AUX/M+O!S'X9-M_JU_-9?S$.O!]I=X.8_#
M)MO]6OYK+^8AUX/M+O!S'X9-M_JU_-9?S$.O!]I=X.8_#)MO]6OYK+^8AUX/
MM+O!S/A,W@VZ=B2&F[S5:VUI27A995,TF1=K(B:XP3&4N\',LWHZ^"5_VWE^
MM,#I9+R_:\3_ -I]9'=CGEH$;SR0   #*_5UL_E^23,=W8VY8=EY;BNA#\6,
MGF2E,1WO$QW6$<=:F7369H(C-6K@7 $PXV/=>V,L02BY]B=U@9)'(VYC=L2R
MZR;R.!]V2ZPMNO[$]1I[*F"<$#W!W/SWJ_F6[;K;;&9%MQ)B8B5<KE+4:DDM
M"32E<IQM/+:0A*U*)HE+4M5*5,B(#4V_A6*P<'Q&R8A;5&Y#LL-F$VZHJ*<-
ME!)4XHJG0UJJL_BF"KO ,0="/W8[F?\ A/9$H%I;?!5_/;>[.8FVW6/[MYT1
MR=%L[<-UR*RI*'%DY;":(B-7 J&NH+1J6*K^\"Q,TF3.&7);QE1M!R6")2O(
M5229E4_B&!@AV0S-\>L*[VRRL8Z]A^V$-],B1(D$YR#,NZ;JGG$->(=2E1DV
MVTBA5[W[(AJ;>Q;&[7A^.6O%K(V;5JM$9J'$09U5H922:J/RJ5Z91^4SJ"KK
M@                                                 #$'4E^>%M%
M_P"G/Z>D@M&IM\%0!AG+<RS7I<WWS/+Y^.KOV$YTZF2U,UJ829F9N)0B1H<2
ME;*EK0II::J30^!4,%M:+;C;P9IU<O6/;;!L07;X4>>W<)<I;RI7+<2A;"77
MG4M-I99;2ZX:JU-1TIQX&-2T[1"S'<GJ^9O+\!:,0VQ:?M?G4VW$)>4AAY"=
M3BZDMU;SYJ,D_()_5,;S7@*@           ,0;D_GU8C];?67 6WFWP5
M            <3(IF41'+.6-6V/<6Y%Q89O2I,@XQQK:HE<Y]LM*N8M-"THX
M5K^J0=L       '(RO[EKY[7R_65BM6I2YV9Y%%[$?!-C?[T_P"RG1Q7)L>7
M"Q 9P  0FS_G(6W[TY/LTAM9;M^Q6WYT<DK]'2=1Q,<EY/+*Z^Z:VQ[:IBXR
M&+04:1XGQ%L1IY$ASNIT.+JK4WQI3M =L               '$OTS*(TRRMX
M];8\^%(F$U?'Y$@XZHL+0HS=:225<Q6HB+3_ /Y(.V
M         "LNH+ +GN;M+D.)611%>9"&9,!M2B0EUZ(\A\FC-5"+7H-)&9D1
M&9&? $PRQCO5CN[MS88& Y)MRN1?++';M[#TA,J&ZIMA!-,FXR32M1T27>0H
MB7Y 3@_6%6G>^Q8ONGOW<+))8S7+F68-CLJ(3JWW3GS&B>?3$22G$H::_<=9
M<:5.I<5!HOI;V\O6VNT-MLV1L'$OLZ0_<YL,SJI@Y)DE"%4,R)1-H1J+R'4O
M(")7."           17<WX-LQ]H[G[$= 9TZ ?@VR;V\/V(P"TM:@J
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MIX/>IXD/NQU6[62'FV&V[SS'5)0FML>(JJ.A5,1.S+T<'O.O"\!RV0
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M$[R\PW+;C*)1&:U,NF2%%0C+O>C4!UV4N(:;0\OF.I21..4TZE$7$Z%V5/R
M/V                          ///@0[I!E6RX,ID0)K+D:5'7Q0XR\DT+
M0KXBDF9& PODW3-G.V%WDQ]N=XH6*6"X+-]J)=+U*L,DT]B27X4E)>-)%3F4
M36G80+8K VCZ65V6WY#FETR^/D^?7^US[?:KQ'<<DP8ST]A;*I!OFKFOK[U#
M5W:)KP,S(R&*U]@-C[?L=BDBSMSO.E[N;Y2KM<>7R4*4A.EMIM%5&2&RK34=
M3,U'PJ22(F5L@@           !B#^[R_M'^LG]8 M+;X*@
M .#:(UW:R+(7YN0HN=L?5$.VV-,=EE=K)#-'24ZA1K=YZO5"YA%I[$\ '>
M             !P<MBWB7:VFK)D",:F>+BFNXNQF9A+:)Y.N.2'U)21O%ZF2
MNTJ]TJT =X                !P<6C7>,S<RN^0HR);ERE.1'6X[,7P<8U$
M3<(R94HEJ9H:3<7WU>4@'>
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MK*(\5I#$=LJ(::22$)+MX)30B ?0
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M6P[EC!S\I>QYXKFDX4)F2S'3=7N6LBAN)<29N).NK0CCP]&@"5
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M0^!E3MJ5 '?MOAO-T3P;2H\3DM^'86@VU-MZ"TI-"J&DR+A0^P!Z@
M        0VVHQ0MR[XJ):)+.8^;(1W*]+8=3%?AJ6X3+2'3/EJ4@TJU$DJ_%
M.AT"9          "&;M?!QD?SHK]LD<[:7IJ^1T]E^JM\J18_P#2&U_.D?UI
M(V[/ET\D-*_YE7+/.Z(S,( B>YAXT6"7L\PM<B]8SR"\XVN&RY(D/MZTT)#;
M1I49DJBN!E2E?( DT7E>%8Y"#;8Y:.6V9&DTHTE0C(^RA /L
M              .!G5YG8[A&2Y!:V2D7.TVJ=/A,&1J)Q^+'6ZVBA<3JI)$
MQ#LOTNM;[8LK=7</+9[EPOTF0II,4VW)!\AY3*UON/)7WE*0K2A*2HFAUXT(
MM,N_MUA>0].W4Y8=MK%?7;SB.70GI<J(M)H-+26I!I6ZTDS23C:X]2=(BJ@S
M+AQ UPV\"H             Q!_=Y?VC_ %D_K %I;?!4               !
M#L91C"<VS15HL$FVY I=O\_WEZ*MB/<E%'/D&P\H]+Q,HJA>@BTJ/CQ,!,0
M              1#<=.-JL,?W4V*5D%M3<8)MPH49<MU$GGIY+QH;,C)#:Z&
MM793MKV )>                 AVWB,81&OY8O8)-@9.^3SN34N*N&<JX:D
M\Z6VE9GK:=X:%IX&1<"*@"8@
M   Q!O;^>MMU]9/9CX+1J;?!4
M                                                   &(.I+\\+:
M+_TY_3TD%HU-O@J ,*/;P81L'U,[@7!Z/)O%IR R1=%1VDE.@3M9.NH;YJD(
M<:4H]7!9?(_L>)9Q^HGJ@P+>&P6[!+' G1+.JXQYMTODYAHW6&F241^&80ZH
MU+HL^*EH\J>Q6HA$-%[3]36U>>7NT[=8BU=DSBBJ;B*G1VFV^5!8-1ZUH=4=
M=*/V/:",%\ @           !B#<G\^K$?K;ZRX"V\V^"H
M"-9<ZAIW']>+KR4UW:,E#B$1W/-:C2O_ ,P/GF1I)K]DWW^]P] PDH
M .1E?W+7SVOE^LK%:M2ESLSR*+V(^";&_P!Z?]E.CBN38\N%B S@  A-G_.0
MMOWIR?9I#:RW;]BMOSHY)7Z.DZB-8<\EY%\4G&%8QIN\Q*DK1'0=Q41IK<"\
M.9U)_P#9.=\]/'R )*               "-92ZAJXXV2\77D*EW%*43D(CK*
MTF;2_P".&;YDI-"[E6^]0_U#"2@                           I[JE;Q
M]>Q.6JR9,D[8AN*9+A)0N0W)7,8;86E+BD)4275(-:=1514B.H)AFW;SKH8Q
M7!K5C-^Q%R==+)#9M\>5#E(89D-QD$VVI:%-&;9Z4I)6G41GQ(B]*1."([>=
M45BQ_=',-WLLQ^5,R?)VVX4:+;W6VXL6 T3)$@S<XK691VB-6DO2U^2H0P;J
MVEW)@[LX/"S>W07;=%FN/M(BR%)6XDXSJFC,S1PXFFH*IG(D1XD=V5*=0Q%8
M0IU]]U1(;0V@M2E*4JA$1$53,P&/]U.L0TY[8,2VDDQYML\:U&O=Z=:YS#YO
M.H;Y<4S,JI01JJYV*,RT\"J9;!;W4=OBO93%H,FU0F[EEE]?7%LL1_4;)&T1
M&XZXE!I4M*-:$Z$J(S-1<2!$0K?%]_-X\+W-Q_;[?NR6^)&RTFRM5QMU$FR]
M)6;;:%FEUQ"DI<HTM/!2:DJJBIJ&#[YIOWNWE6ZMYVLV&L]OEOXRVXN\7&Y&
M1ZWHRTH=0@U.MMH23BN3155*54ZI(J@8.YM/U01\HVWR[)\YMZ;7DF!(-5^@
M1:H0\2B63/*0ZHU(6MQ"FC0I1T53CQH0P5;^4YU%,XNSO/(Q6T*VH?FG$3%1
MK)\FB=-G5S.::RJLC:YIMZ=?R%. )P6GO%U->Y7#L,G[=V]%XRC<%MMZPQ99
M&:&672;*KJ&UI,W-;J6DHUD6K54^[0R(AR, WXW5L.[,':#?:T0(=QOC27K+
M=+;W4&MTEFVE='%H6A:FU-$:22I*RH>HCJ0P7ON;\&V8^T=S]B.@AG3H!^#;
M)O;P_8C +2UJ"H               "-V%]QS(LG:7C)V=#+\9*+V?(_\W)4<
MCYOJ??\ 4:\KU3]3RD020               $;SR2_#QF2_'QD\P=2Y'I84F
MP1O$;Z"-9>(]3]2_=>/['R=H"2                 (WCTE]^_9,V[C)V5M
MF4RAN[J-C_S<N0GU;U+O^I\&_5./^,B"2          "B^K/X*6O;JV>O#J[
M,\[V2QW-2]!RF0                  &=>L>U7V\[<VR#C6+SLDO/G5IZ(_
M:F9#\NWN--.*3(24="SH9EH5J*G>\BJ&1,*A3U"=8B;&5L_!E,.Z$WRO/1X[
M=.?733F<O]QYE>/[GH_R 3A"-;5Y_P!1.T]HG6ZS;/7*X3KM,<N-WN\^SWA<
MN5)=/M6I!)*B2["(O*9]IF8#>>'W.ZWK$K!>;[".VWRXVZ'+N=N4A;2HTM]A
M#CS)H=[Z30M1ITK[Q4X\051[>/<9G:G;F]9NM@I4B VAN#$49DEV7(<2TTE1
MEQTDI6I=..DCH"89?M,'K#R+"[9O)8LO\?<+DXF5%PUMMAMI4!Y>E*M#A)9.
MI4/0?>)!ZM>O@"="3;Q;O;L73,,!V7PYQ&(YQD42++RF0@VI*X3\@E:V$+0;
MJ=#1-N.J4A1J6G30RXU#Z;2;B[G8+OK)V$W2OI90Q,CF_8[TXDD/:TQSE)JJ
MFHTK;2M*DN&HR6DM*J=H1.UYIOQU&Y7F]RVSR[W+XKB9Z++"821%,-9NDP2E
MDFIJ=2R:U&HS2BI$2?*!J71TK;R7;># 9,C)E(<RFQRO!7"0TE+92&UH)QE\
MT)(DI4HM2%$DJ534J5H1$PI7^\-_LX^O?]7@F&WP5                <K)
M?=)YBG>X_P #[IN4?FSSMSO <ZI4YW(]4TTKZ3B Z,?Q'AVO%Z/%:$\_E5Y?
M,IWM.KC2O94!]                <6-[KO=//\ &>;O<9X9GS9R>?YT\94^
M=SM7J7*IIT:.]VU =H          0S=KX.,C^=%?MDCG;2]-7R.GLOU5OE2+
M'_I#:_G2/ZTD;=GRZ>2&E?\ ,JY9YW1&9A ')R;W3>89WN-\#[I^7_Y9YWYW
M@.;4OW;P_JFFE?2<0'3:YO*1SM/.TES-%=.JG&E>-*@/V
M           .9D;=W=QZ[-8^M+=^7#D)M;BR2:$S#:43)J)9*30EZ:ZB,O1
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M98_!?>5/D*M1VUMUM*;89EX=+W-4HS>(JZS3W?0 =H
M                     &(-[?SUMNOK)[,?!:-3;X*@
M
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M&E=6KX@(C4E/4YE/4);+C=;3@-E\9MP_8U^=IWA6W=',0\F5ZHI1&6EJA]G
M$0\/0#\&V3>WA^Q& 3+6H*@               .#98MY8ON0OW#(476W/O1S
MMEG3&985:D)9+6VIUM1K=-U1\TC<(C21T+@ [P               .#F4:[S
M,?D,6/(D8K<E+8Y=[<CLS$M%SD:D<J0:4&;A5;*I\#54N(#O
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MM"X$=>RAU =^V^&\W1/!NJD1.2WX=]:S<4XWH+2HUJJ:C,N-3[0'J
M        !#;:O%#W+OB8EWDO9CYLA%<K*M]U45B&E;ALNH:,N6E2S4K4:3K\
M0JG4)D          (9NU\'&1_.BOVR1SMI>FKY'3V7ZJWRI%C_TAM?SI']:2
M-NSY=/)#2O\ F5<L\[HC,P@")[F%C1X)>RS"Z2++C/(+SC=(;SD>0PWK30T.
M-$I1&:J)X$=:T\H"31>5X5CD+-QCEHY;AF:C4C25#,S[:D ^P
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MKO'3O<M9?_ "6A>NA/C\GVDMD0R=G.RK@2&4G51\]ZWH;_TC29%\8$0LO?\
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M)3JF[MJ3XEI!RB(R0DZ4)ON>@9\0$T
M         !B#>W\];;KZR>S'P6C4V^"H
M                                                          ,0
M=27YX6T7_IS^GI(+1J;?!5YI]O@76&];KI%9G6^2DVY$22VEYEQ!]J5H61I4
M7Q#(!0V4=&.QN227)<>W3,?>=.JRL\KE-ZC\J6I"'VT_&0DB^("<7.LG0YLA
M:I"7YOGB]MD=?#W":A#9_$/P;,95/_B Q7SC&(8OA=M3:,3M$6SVU)U./#:2
MT2E=FI9I*JU?Y2C,P0[0            #$&Y/Y]6(_6WUEP%MYM\%0
M         $,S\L3-_$_=39I%X>\_0_,2HL=V1X.YT<Y,ITVS(FVVRU:EK[I>
MAZ 3,       '(RO[EKY[7R_65BM6I2YV9Y%%[$?!-C?[T_[*='%<FQY<+$!
MG  !";/^<A;?O3D^S2&UENW[%;?G1R2OT=)U$-V]3BB6\E3BEFDV9!7^X>=T
MRH[L;Q=SJCQ$IKFF>MISNZ%H[ITX%P 3(               $,S@L3.[X?[I
M+-(NMP\[H\P2(T=U],*<32S)]U;9D3:"21U-=2\M.%2"9@
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M4HD)2E"4+<4]Z92C7Z"0,5^;F_!MF/M'<_8CH(9TZ ?@VR;V\/V(P"TM:@J
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MTE(25./>*GD =.*M]V,RY*:*/)6A*GF"43A-K,B-2=1$1*H?"M.(#Z@
M          X467?5Y9<84BQML8ZU#C.0L@*0VMV3)4MSFL*8(M:";+29*4=#
MU</+0.Z          (9NU\'&1_.BOVR1SMI>FKY'3V7ZJWRI%C_TAM?SI']:
M2-NSY=/)#2O^95RSSNB,S" .+ETN]P<;N,K'+,C(;VVU_$[,\^W$;DJ-1$:%
M/.D:$E0S/O>A0!UV5.+:;6\CENJ21N-UU:5&7$JEVT/R@/V
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M/=[?%C8]'5&+'YK$A3LB4E;1G(-YHT))O0NB4T,]1?&XAVP
M  <7)Y>30[<T[BENCW.Y*E1VW8\M\XS:8JW4D^X2B2JJD(J:4^4_\!AV@
M        5GM'_K^?_?1</VQ#C;-[5[_DJ=W:O9L_\=*S!V7"  !Q,;E91*:N
M*LIM\6W/-3Y+5L1#D*DD];D*(F'G#4A&EQ95U(\G#XQ!VP
M                         8@WM_/6VZ^LGLQ\%HU-O@J
M
M             #$'4E^>%M%_Z<_IZ2"T:FWP5 $'S3>/;#;R6BWYED\.UW%:
M"<*$M2G9!-JX)4;3*5K))TX&::& BWY5&P'OVC?R>9\P!."WF76WVFWV5:FG
M4DMM7HI452/C\0$/V             Q!N3^?5B/UM]9<!;>;?!4
M      !Q<A]UNNT^Y0[=R_.#/GWSH3^KS7WN=X7D?_A'I=',[G;4!V@
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M$            (KN;\&V8^T=S]B.@,Z= /P;9-[>'[$8!:6M05
M      <6TIRQ-YOBKXY 58%.L'CB(9.E+2R3)$^4LU]PU&[71R_D>WB [0
M             .)EJ<N78WTX,Y;VLDUL^&7>$O+A<OFIYNLHYDNO+U:*?)4K
MP =L                !Q+,C+DW:^*R!VWKLBGV_<XB$EY,E$8FBYGBS</2
M:S<KIY?"G^ @[8       ,W=1_PH[-?/%\]9B#N;.\NY]/2QU:X=D9%P  >.
M[?2J=\[N_M#$QK$JZ9/@*PWYV?\ 9;PYVT?45;MY6C4MH<]<
M  $"W<W;QC9O%?=1DQ//H=>3$@P(I)5(D2%I4K2G6I)$1)2:E*,Z$1>4S(C)
M9M5_>#V0E*)&"2C14])G<6R,R\E2\.=/\()P7IL-OG$WSM%WNT2RN65-IDMQ
M5-.R$R3<-QO7J(TMMTIV B86V"        &(/[PW^SCZ]_U>"T-O@J
M          X.:H;<Q2ZH=R \5;-@]60I6RT<,JEZIK?]3+T*J =>'0HD<BD'
M++EHI*/29N]TN^>@B3WNWND1>@ ^X               (U":06<W5TLG5*=5
M!BDK$S<8-,).I=)6A/JI<ZAIJKNGI.G9P"2@         "&;M?!QD?SHK]LD
M<[:7IJ^1T]E^JM\J18_](;7\Z1_6DC;L^73R0TK_ )E7+/.Z(S,( C^<(;<Q
M.ZH>R(\2:4S161I6RT<,M1=_7(]3*OI>]Z/ R.A@.XQ3D-4<YQ:$T>X'KX>F
M[O#CV\ 'T                          ',R.^0\8QZ[9+<=7F^S0Y%QEZ
M"JODQ&E/+TEY3TI.@#%$'JBZG\[Y]YV^P!E_&R=4TPY'MLV<DC3QTKD$ZE"U
MI(^]H2GXP+80L/:#=+JAR/<6S6;<7"_-.'2?%><KAYKDQ>7RXCSC7JKCJDIU
M.I0GB7&M 1H:G!              Q!_=Y?VC_63^L 6EM\%0
M   $4QY-K++\N.)E+]XN!K@>/QYV2T\S9S\.?+2TR@B6UXA/JBM9GJ,JD E8
M               (MGZ+6NQL>=\F?Q.*4^$I-SBR6X;CCA/IT1C6X2B-+Q^I
MJ3Y2,!*0           5GM'_ *_G_P!]%P_;$.-LWM7O^2IW=J]FS_QTK,'9
M<(  $4P1-K3'O?FO*7\J0=YFG)>D26I9P9!J2:X"#:))(0Q\BVKBFOQ@$K
M                                     !B#>W\];;KZR>S'P6C4V^"H
M
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M)FC)O<G=I%V3[H+AYY.4^[(\+=:H\1&;YI%H;;[NE".Z5> "9
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M1L'XY*5%2>7(X>KUKW^]PXUX& D@
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MFE/(-BW7UXQ;F7O^-3UL,-*P1D;(
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MHG6I;&MJ_P #G5AA>%>=O/7*DQ97CO#^#KXAI9Z>7S7NRG;K!.\_I("@
M           #A9)+R&(Y9BL-D9O*'[DPS=5/2413A05DKFRT$M*N8IOA1M-#
M57M =T       '(RO[EKY[7R_65BM6I2YV9Y%%[$?!-C?[T_[*='%<FQY<+$
M!G  !";/^<A;?O3D^S2&UENW[%;?G1R2OT=)U'#QJ7?Y97;S_9&K*;%RDL6T
MF9*)13("-/*F*T)3RU.U55M7>33B8#N                X.0S,AC3;$W9+
M(U=HDB<3=WDNR41S@1.6NLA"5I4;BB.B=">/']4@[P
M         (KN/@-GW0PRYX-?WY,:TW7D>(>@K;;DI\-(;DIT*=;=255-)(ZH
M/A7XX#&U^V+Z-<9NSMCO.YUV8ND=?*D,-RXD@FW".AH6MBVK2E1'P42E5+R@
MMC+0.P^PNUVVTE[.-N+]/OT6]PSB(E2)427$4SS4N&IM4:.UWB4WI/O'3B5*
M@B97D"            $5W-^#;,?:.Y^Q'0&=.@'X-LF]O#]B, M+6H*@
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MV+LY8-I[9BR;SL_&CLXS?3*2;T5QY:7'&ZM]XGU*4A2*&E23H9'VD")6&"
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M"2SXIEIS41F:FC,M52J7^/B.^\ZZK).):;2\HEO$DB<61:24HBXF1>2I@/V
M                         /P\;1-.&^:28))\TUTT:*<=5>%*=H#&.7]8
MMO5D,NS;6;?,Y+;X*C2Y='6U&3Q)/2:VV6&E&ELS]*M:N\7R) M@L[I_ZB,0
MW=GR+#(L+>,YW 0MTX-$+0\T@]#BF7-#:B4FO?;4FI%Y5<:$3#08(
M      &(/[O+^T?ZR?U@"TMO@J                X%GC7=K(\B?FY&BZ6Q
M]43S;8DQV&5VHDLGS$J=;,W'>>HR<+FD6DN"> #O@               X.7Q
MKM)M3:+/D2,8E)E15KN3D=B6A;)/)UQS1(-*2-XO4R41ZDF=2X@.\
M#SW#_4)7[RY^U,4K[,\B]OM1RL\[??<?:_\ ,<]=6/EM.I]*O]N4F%F   'C
MP[X9FO:!SV28[>Q?4_3/0T-K>C^N.9>@]P\0X&*1KO&9NJ;OD:,D<<N<IR*Z
MW'8B^"C*47+@F3!F2S8XD;B^^JO> =\
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M_;N;;,9CDD>'%N;LR3&4U;T.ML:&%$23)+SKJJG7CW@)6N"
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MG41K#4,H3?>3E"LHU7B:;BE.1W?-JZIK;BY!%I*/V:7.^5>/D 24
M       $8RM#*[AC1NY4K'33<D&W"2Y';*[+Y:_XF9/D:E:O3:6N]0OU2"3@
M                           I_JBRJ\8?L?E%VL3JX]R<1'@HE-F:5LHF
MR&V'%I,N)*T+4E)\*&=03"H]G>D+9_(=L<>R+(DRKO>+_;V+B]+:EK8;CKE-
M$OE-H9,DU:-6A6O4>HCK3TI$XOATQQ)&VV_NY&REIN:[GAL"*=SC*=,E*;D-
M.14$1Z2)).$B2;3QI(M2FRX%2A"6PP5            17<WX-LQ]H[G[$= 9
MTZ ?@VR;V\/V(P"TM:@J                C&/-Q$9+E2V,H7>I#DB*<BQ*
M?9=39S*.1):2VWWV^<1<VCG;VEY3,).               "+[A-17L4EMS,I
M7AD<W(YJR%IYB,M@R?;,DDY)(VRYIER^/;JH E                 "+XTU
M%;O^4K8RE=]><ELG(LZWV'4V=1,)(F$H:+4WK+U2CG$^WT3,)0       #-W
M4?\ "CLU\\7SUF(.YL[R[GT]+'5KAV1D7  !X[M]*IWSN[^T,3&L2KID^ K#
M?G9_V6\.=M'U%6[>5HU+:'/7              !E'KR=G)V^QAC4ZC'WKX@K
MJMKT4L.&T1_J<PR(^%2^(0+0LF%AO3,> MNLVW%G,).&2O.3J8A&;&FG,7)7
M1TG/14:R62O0,$:57]"KBO,N?Q;8Z^[AS-Z0=B6\1D1DI"R6=#[%FVE@UE\8
M$RUJ"J/YUD7N1PK(LI[IJLMMF7!"5^E4N,PMQ*3^.I)$ R9AN[_6AN!CT7*L
M1Q*R7"P3#<3&F&<:/K-AQ32Z(D7!M?!:5)]+Y 6T)KNKOON=C4G;_:[&+7"/
M>7*8$&1?2?TNQ(4F0DFW&T$AQ2/W5#IFHUJ2E":EJU5(C!]]G][]QRW6G;'[
MT1(:<K0RI^U72WEH;D<MGQ!I,B/2HEM:G$J0E)EI-*DU[!,(G-WYWWW/R[+X
MVQ<&W(Q7"M1/.S$)=?FZ5.)2:349D9N\I:FD))/=+BJH)P7/T[;S_ALP0[],
MBMP<@MTA4"\1&#/D\TDI<0ZT2C4HD+2K@2C,R42BJ=*F1,,^?WAO]G'U[_J\
M$PV^"H               "*;F%BAX'?BSB*].Q(XJO.T2,E];SC&HJDDHQD[
MVT]*94[3.@"0VTXIVZ(<%*D0C9;.,A9*2HFM!:",E]XC(J<%<?1 >H
M         $+MC>%%N??EP8;Z,\.UP?.TY29)1W()N.E'0A2CY&I*DJKH+5\4
MZ'0)H       "KM\?I1BWWRV_P!;?'GMN^13WHYI>BV#YU?<GGAR!XUZ0
M!U-@?N-G^V\S]9L>TV'Z?ZIZ'FMO>HCNQTI-NA[DO<#?2SN*].Q$XY%=8D9+
MZWG&36DJ)*,:7?34]*9?X!WWGDHB\GPK'AR-+'+1RDG4C)&DJ$>KCV>B ^P
M                         C.X]NN5XV\RVT68E'>)]EN,6WD@Z*\2_%<;
M:H9=AZC(!E/I(WJVBP?;=W%,GN+&-Y1&FR'K@J8VMOQ9.*]37S$I,C-":-&E
M1ZBT]E 6F'P@93C6ZW6?C61;9(.1:[/;WBOMX:;6PW(4RQ);6Z=4I4::/-1R
M4HN\="]+0P-YMD%0            !B#^[R_M'^LG]8 M+;X*@
M    (?C1XW[M<S*U8[*M=])=O\^7M^(<>/=#..HV%,/U,GB929MKH1:5'3RU
M 3                $1W%]SWF*-[IK!*R.W^<8*6H$*,<QU$E<A*67S02DT
M0THR4M5>!>0^P!+@       >>X?ZA*_>7/VIBE?9GD7M]J.5GG;[[C[7_F.>
MNK'RVG4^E7^W*3"S   #QX=\,S7M Y[),=O8OJ?IGH:&UO1_7',O0>X>(0_;
MT\;.+?O<UCLK'&2OD\K@U,B'".9.)22>F-$9GS&G>&ASA6E*%0!,
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MG41?"EP%IO\ X#%W<7)-ZF)DI>CLQ?.3Z=!+N*.29\Q#_P BXOO*T\?( E
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M5N'D$-W<:'E5^1;O#S; S5,J(2GFG"=<0I]TTEZ4N*2],0(F6G00
M    BNYOP;9C[1W/V(Z SIT _!MDWMX?L1@%I:U!4               !P[/
M$R%B]WZ1=;PS<+1(=8.S6YN.EER VEDB=0XX2C-TUK[Y&HBH0#N
M       XF6P\BGV*1&Q6\,V&]K6T;%SDQDS6FTI=2:R-E2T$>M)&@N]PK4!V
MP                '$LL/(H]UOC]WO#-QM<B0VJS06HR8ZX+*6BUMN.$M1N
MFI1ZZF14^,? .V       #-W4?\ "CLU\\7SUF(.YL[R[GT]+'5KAV1D7  !
MX[M]*IWSN[^T,3&L2KID^ K#?G9_V6\.=M'U%6[>5HU+:'/7
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MW^Q3"]L\1L]PFW".\ZUF5FG)>1"D+8E(4R2$)6E9FA%%&3I42YV'V AJX$
M           #$']WE_:/]9/ZP!:6WP5                0K%E80>=YRFP2
M7W<N2Y;?=9'=5*4TTOPQ^$Y1/%RBU-5KR#_SO( FH               (9N<
MK"TX]&/.Y+\6R^<[>3+D54I*SG>)1X9)G$(UZ5.:2.O=]$!,P       >>X?
MZA*_>7/VIBE?9GD7M]J.5GG;[[C[7_F.>NK'RVG4^E7^W*3"S   #QX=\,S7
MM Y[),=O8OJ?IGH:&UO1_7',O0>X>(0G;56$*B9%[AY+\I@K_<2O:I*I2S1=
M]:?%-H\41&2$GITDUZGZ%3J FP
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MQQ*::2I4"(P;&P;%HN$8;8<0AJYC%E@QX)/4H;BV6R2MPR]%:JK/XI@JD
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M7R6R1JI4Z5I4%7N             8@W)_/JQ'ZV^LN MO-O@J
M     A6X3>&N/XE[K[=)GNIR"$K'U16I+I1[L1.<AYTXQD26T][4;OJ?E47H
M!-0       <C*_N6OGM?+]96*U:E+G9GD47L1\$V-_O3_LIT<5R;'EPL0&<
M $)L_P"<A;?O3D^S2&UENW[%;?G1R2OT=)U$+VZ;PUM&4>XVWR+>E60W%5]*
M2W(:Y]X,T>)?;\09ZFU]W2IKU/\ 8D7$!-                0K.F\-7=L-
M/*K=)G7!%Y0K''HS4EQ$:X\ES2ZZ<<R2E&G47JM4^6G"I!-0
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M:PU&4YJO'+9(A7U<Z.>2RWV)+3<N24<N6ME;W<6E*.!\KA7C\E4PF@
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M>H6!3K4=,LS41&V;CQ*0DJ&9]XC[!WWGG:9-:F6U.-\IPTI-3525H,RXIJ7
MZ=G !^P                         !4&]/3MA.]'*N=XY\3)H$-^);I\9
MPFTF:ZJ:*01H6:T-N&:B(J'WE<>()B6;K)T\],6/P?-&Y&Y<-[,(KCK=P.W7
M6-'829+,DHY;B'%)4DJ$LE*[03C*S-G<$Z5,/W M;V Y*C(,XEID-69I<TIY
MM&F.XX\I!1VTH0?)2YWG/)4BXF")Q:D!              Q!_=Y?VC_63^L
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M (>5\V#P:. ^SL_*?DX[*>]&/_#ROFP>#1P'V=GY3\G'93WHQ_X>5\V#P:.
M^SL_*?DX[*>]&/\ P\KYL'@T<!]G9^4_)QV4]Z,?^'E?-@\&C@/L[/RA].&R
MAE3W)1_X>5\V#P:. ^SL_*F6'81B^ 6A5BQ&!YNM2GER51^<\_ZJX24J5J?6
MXKB22X5H+TTQ3&$,]NU3;C"F,(2 690    !$K_M;MME4@YF1XC:+G-4K6J7
M)@L./J,_1<-&L_U3 =#',+P_#VELXI8+?9&W"(G2MT5F*;E.S6;:4FH_BJ =
M"Z6BTWR(JWWJ!'N4!1DI468RB0R:DG4C-#A*34O)P ?2WVZWVF&U;K5$9@V]
M@C)B)&;2RR@C,U&24((DE4S,^! /2 YUXL%AR%AN-?[7$NL9I?,:9G1VI*$K
MH9:DI=2HB.AF50'GFXCBEQ@1;7<+%;I=L@D1084B(PZPP1%I(FFUH-*.'#ND
M ZS333#2&64);9;22&VT$24I2DJ$1$7 B(@'[ <56(8DN[>?UV&W*OI+)WSH
M<-@Y?,25"7SM&O41%2NH!V@'FN%NM]VANVZZQ&9UO?(B?B26TO,K(C)1$I"R
M-)T,B/B0#_+;;+;9H35MM$-BWVYC5R8D1I##*-:C6K2ALB255&:CH7:8#RN8
MUCCUW1D#UGA.7YHB)NZ+C-*F)(DFDJ/&G67=.GINP![9D.)<(KT&?';E0I"#
M;D1GT)=:<0HJ&E:%$9*(_*1D ^-JL]HL40H%D@1K;!)1K*+#9;CM$I7:>ALD
ME4_+P ?&^8YCV3P_-^26F'>(%=7A;A':E-:J4KH=2HJ_% <K&]MMOL.?5*Q7
M%[79YBB,E2H4-EE\R,J4-Q*253CV5 25UII]I;+R$N,N)-#C:R)25)45#(R/
M@9&0#PV>P6''F'(U@M<2U1G5\QUF#':C(4NA%J4EI*2,Z$15 ?2ZV>T7V(<"
M]P(UR@FHEG%F,MR&C4GL/0X2BJ7DX /1%BQH49F%"91&AQD)9CQV4DVTVTV1
M)2A"4D1)2DBH1%V .%DN 8/F6D\LQRVWI;9$3;L^(S(<01'6B5K2:D_J& ].
M.XEBV(Q50L5LD&RQ%T-QFWQFHJ5F14(U\I*=1_%5Q =D       %495TU;*9
MMD$W*<GQCQU]N*DN3)?C[BSK4A"6R/0S)0@J)21=U) G%:X(         &=M
M]-T=^L6R%S%=M,$=O<"XPVS@Y''BRI11I#NI"R6:/4DJ09$I/,,D\2K7B"8=
M_IDV>F[1X"MG(-*LSOT@[C?5DHG#;532TP;A&9+Y9549_LUJH9E0P)74"
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M+=O)Y$V^6""S'\P2I"WB),IQMY,ME*"Y)H-)$G6GO=XB.@$M8@J
M   BNYOP;9C[1W/V(Z SIT _!MDWMX?L1@%I:U!4               !Q;2K
M+%7F^)OC<!-@2ZP6.+AFZ<M3)LD;YRR7W"43M='+^1[>(#M
M   XF6*RU%BD*P=NWNY+K9\*B\*>1"-'-1SM9L$:Z\O7HI\E2O !VP
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MQVQYYCTN4X]E]HR!Z!D3*C);27HNIE"V5]JDK-"RJKC5)^2@(EJ($
M ,0?WAO]G'U[_J\%H;?!4               !Q,P9D2,8NC,6_>YB0IA6B_F
MEE90Z&1\PTO^IF1%P/4 ZL4E)BL)6_XE9-H)4FB2YIZ2JNB")):NWN\ 'V
M             !'8<>6G-+G(7DI2H:X48F\5T,$<-6I?\9U)]5,GJ&DM7=[I
MT^($B       !5V^/THQ;[Y;?ZV^//;=\BGO1S2]%L'SJ^Y//#D#QKT@   #
MJ; _<;/]MYGZS8]IL/T_U3T/-;>]1'=CI3?,VI#V+W-J+D!8K(4U1&0&EE91
M#U%ZH:9%&S_8][T?1'?>>=IDC)ELE.<Y6E-7>!:SIZ;N\./;P ?L
M                  1/=*;/MNV6:7&U+6W<X=ANDB$XU7F)?:ANK;--.-24
M14H _G/%VIP1.Q&*[N.2WI]P]T2(>;04/E1BW*D/-Z$I06IM:D(:61JXGS*E
MY 777B6 [8[/]5&%P,/?\^6_(;7+=@FY+*0];);K+Q$ZE3)I);;K*5-I2ZE7
MIC41F9%0C>;9!4             8@_N\O[1_K)_6 +2V^"H
M  ")XZBT)S'+U0LHD7>Z+7 .Y8^]+0^Q9S*.9-)9821&QXA)&XK49ZSX@)8
M              "*[@)M"[)&*]9-(Q2*5PA*1<HDI$)QQY+Z5(C&XLC(TO&6
MA2/DB.G8 E0       //</\ 4)7[RY^U,4K[,\B]OM1RL\[??<?:_P#,<]=6
M/EM.I]*O]N4F%F   'CP[X9FO:!SV28[>Q?4_3/0T-K>C^N.9>@]P\0B>!)L
MZ8]]\SY1(RE!WJ<<MV5+1-.!*-2>9 ;-!%RVV.&EI7%->WB E@        "'
MY[N;B>VS,%_*GI#+=Q4XB*<:*_+,S9))JU$PA>GTQ=HV;&7KO8]7>5FJ(05?
M59LTTM#;ERGH<=.C:56N<1J,O(DC:XC:_;+_  1[X5Z\.OCO4-MEE-[A8]:)
M<Y=SN#A,QD.VZ8R@UF1GQ6XT24]G:9C'<R-VBF:IB,(XX3%<2M,:"X
M                   Q!O;^>MMU]9/9CX+1J;?!4
M
M       &(.I+\\+:+_TY_3TD%HU-O@J ,Q6#:[/L4ZC<LE-06YNU&Y#$IR\W
M J+4RHV7%<DZ*(VU\Y:DD:DJ2I"OV7I25 WNQ=1T?$RZ7DXB]-L4>XFJ%?FX
MCZFW8OB3D-J\74V$L\Q7,-2J*3Z0Z4H"7]#;)!=MEFMUM?=YS\.*S'=>X]];
M3:4&KCQXF505>X            !B#<G\^K$?K;ZRX"V\V^"H
M   "'YV>,\[%O='?Y-B<\^1/,Z(LM4,I]PHLFH;I)(^:VY4]31\%4(!,
M    <C*_N6OGM?+]96*U:E+G9GD47L1\$V-_O3_LIT<5R;'EPL0&<  $)L_Y
MR%M^].3[-(;66[?L5M^=')*_1TG41# ?<WHR0L;OTF_)*_3_ #J<N4J7X&XU
M0;\)K41<MIKNZ&BX)KV\0$O               !#\U/&?.F)>?\ ()-EF>=D
M'98L:6J*BX3.4LBC/(21\U!D9GH.A5IQXT,)@
M    "O-\L$C[D[77_$'IS-M=FH:7#G25:&&Y3#R'6=:O(E:TDV?:=%<",P3"
MB<AV?WPD;.;?W)M;3V\6VDYURUQTKCJ-=M;7R6VTK*C;BC;8871:JK15*^_P
M!.+I]-^ ;PO[FY/O-O!&\W7:[6XK1&AK2TAQQ)N,+UDVRH^6AM,9"")7>5JK
M\4R):F!            "*[F_!MF/M'<_8CH#.G0#\&V3>WA^Q& 6EK4%0
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MI.M5:&1:B[*@.[ )E,&*F-'.)')ELF8IH)LVD$DM*#07!.DN%/( ]
M         (G;U63\(=Y)C&I<6_\ F^)XS*7(A(A3&-:^7';DZCUK:,S-:-)4
M(RXGPH$L       !5V^/THQ;[Y;?ZV^//;=\BGO1S2]%L'SJ^Y//#D#QKT@
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MS2@U&MS0:DDJI)XGW:T,ABT."             !B#^[R_M'^LG]8 M+;X*@
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MUMNOK)[,?!:-3;X*@
M                                           Q!U)?GA;1?^G/Z>D@
MM&IM\%0!@].[]@V,ZH<_N.03YU\Q^\&\V^Q!YNN%+=<9=)+C#ZFFW.62.6E:
M%*HBE/*D%MY<A=;FQ1E7Q=S+XG@%_+ C!HB.^W*CM26J\IY"7$5X'I652_7!
M#Z             ,0;D_GU8C];?67 6WFWP5                <#)Y-WCN
M60K5CB,A2[<X[<Y:Y#$;S=%42B7.23Q'S%-=G+;HL]7 P'?       !R,K^Y
M:^>U\OUE8K5J4N=F>11>Q'P38W^]/^RG1Q7)L>7"Q 9P  0FS_G(6W[TY/LT
MAM9;M^Q6WYT<DK]'2=1P,6DW:2F\>=L=1CO*NDIJ$E$AB3X^(DTFW//D$7+4
M_4ZMK[Z:<3,!WP               <#(Y-W8FV%%LQQ%]8>GI1/EKD,1SMC!
MMK(Y:4O$9N&1GHT-T511@.^                           "E^K"';9FP
MF5INLMV%$:*$X3[+?.]5*<PEI*D529H4M2249'5)=ZATH9,*$V?ZT\%PK;^Q
M8?D^/74I=EBHA^)MA1Y+;W+X$LR?>8-)J+BHN/$$X- ;0=2F"[U7N=8<6M]V
MAS+?%\<\NYLQFFC:YB&J)-F2\9JJLNU)?'!&"XP0            BNYOP;9C
M[1W/V(Z SIT _!MDWMX?L1@%I:U!4               !P;+*O+]]R%BX8\B
MU6YAZ.5LO"9++ZKJA3):W%--I);1M*+E$3AF:B*I< '>               !
MP<SE7F%CTF18<>1E5S2MDFK(Y)9A)=(WD$I1NR$J07+35PJEQTT+B [P
M            #@V.5>7[QD#-QQY%H@L26DVVZ(DLOJNC9LIU/*;;22FC09<O
M2X9F9%4N #O        S=U'_  H[-?/%\]9B#N;.\NY]/2QU:X=D9%P  >.[
M?2J=\[N_M#$QK$JZ9/@*PWYV?]EO#G;1]15NWE:-2VASUP
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M?X#[ '1BE)3&93,4A<LD)*0MI)I;4Y0M1I29F9$9]A&9@/J
M  #BQF,I3E$^1+EPUX@N+'1;8;;2RFMS$J6;ZW'#/2:%)-&DB+_!\D':
M   !5V^/THQ;[Y;?ZV^//;=\BGO1S2]%L'SJ^Y//#D#QKT@   #J; _<;/\
M;>9^LV/:;#]/]4]#S6WO41W8Z4\RIG)9&/SV<.E1862K;(K=*N#:GHJ'-15-
MQ"#(S+36E/+Z([[SSJLDZ339/F2GB27,4DJ)-5.)D1^2H#]@
M             #D97&N$S%[W$M+3;]UD0)34%A]*%LKD+96EM*TN=PTFHR)1
M*X4[> ##&%[1]:.W:)$?"5-6>WR7ER5VYN9;'X:77"HI2&9)NH34B(N!>0O0
M(%M"X=IHG6,UN!:%[JSF'L"+Q/G9MM-F)1UBNDQ3PC27?W;E^D/X_"H(T-.@
M@             8@_N\O[1_K)_6 +2V^"H               "/6:)=6,DR.
M3,R,KI;9*XAV^Q$PRTJTZ&:.)-ULS6YSS,G"YA%I\G !(0
M 1_,(URE6MANUY&G&)!3(BUW!;+,@G&D/)4N-I?,DD;R2Y9*+B5>!'V )
M     #SW#_4)7[RY^U,4K[,\B]OM1RL\[??<?:_\QSUU8^6TZGTJ_P!N4F%F
M   'CP[X9FO:!SV28[>Q?4_3/0T-K>C^N.9>@]P\0CV)1+K#9NJ;MD99(X[<
MY;L9U+#,?P4=:BT0:,F>HV*4-:^^=>("0@         "B][/A6V2]NIWK+0Z
MN3\F[R0QU:X7H.4R                           Q!O;^>MMU]9/9CX+1
MJ;?!4
M                               &(.I+\\+:+_TY_3TD%HU-O@JX649I
MB>$Q6)V77F)98<ESDL2)SJ6&UNDDU:"4JA:J$9T 9DM^YO3+G6Y>76_+\9Q>
M+&@K)V-F,^1&?3=UJ,DFI)+910R+_P"HL%G@W8S7I2P;&V[IAN)XAF-[=DML
M%:XO(2:&5)4I;RE-M.\$Z230Z>F[>%#&EKBR3&;C9;=<([7(8EQ6'VF.!\M#
MK:5DGAZ!'0%7O             8@W)_/JQ'ZV^LN MO-O@J
M   CF6,2'G+ J/DWN;)N[1ENMZ8ZBN:")=8'J_$C=[:M]_N\/B!(P
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M$$            (KN;\&V8^T=S]B.@,Z= /P;9-[>'[$8!:6M05
M       1NPL.-Y%D[J\F.\(>?C*19#Y'_E!)CD7*]3[_ *M3F^J?J>4S"2
M              C>=QW96,2F6<F5A[BEQS*_IY%6:/H,T_QGU/U3]SX_LOU
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M5*=0^]&8;O>YSW68M[FO,WCO!]V0GG^+\/K_ '=*?2<E/I?V0)B']3@4
M            13<Q>*-X'?EYRX\UB115>=G(QR">)C47I3B^J]M/2_J\*@)#
M;5156Z(J :C@FRV<8UZS4;1H+17F=^M*>FX^CQ >H               $+MA
MX5^$^_)@K?//"M<%5V;4<GPY05..E'-!*]0U&I*JZ.]_C 30       %7;X_
M2C%OOEM_K;X\]MWR*>]'-+T6P?.K[D\\.0/&O2    .IL#]QL_VWF?K-CVFP
M_3_5/0\UM[U$=V.E)]SW,2:P&^KSM;S>(E'_ /-5Q3D$\3.M/I3B^J^FIZ7]
M7A4=]YY)XILG%8.,9G'-M'),]5=&DM-=7'L]'B ^P
M       S=U+[C;UX2F5;</Q-%]PR\6N2E^\1(TY^5;U$VI#ZGEQUFALDI43C
M;BB27;^Q,P3"A=G]^^HC'<#@VK%=OIF7V5IR0IF^N0+K/4ZI;RE+3SF5&A6A
M1FGAV4H"<$SVXD=0&ZG4/C.?YKB4W$[+8(KT>4E<6;;89Q^5))/=F*,W75K?
M))Z/D2*I$2:@-L J             ,0?W>7]H_UD_K %I;?!4
M    !$,<]S_NTS'S;C<JUWO7;_/-^?B<B-=3\.KDFP_J/G$PFK:^!:5'3C4!
M+P               1+<0K =BCED>/2LE@'<8)-P(,4YKK<A4A)-2#02DT0R
MH]:UUX)KP/L 2T       'GN'^H2OWES]J8I7V9Y%[?:CE9YV^^X^U_YCGKJ
MQ\MIU/I5_MRDPLP   \>'?#,U[0.>R3';V+ZGZ9Z&AM;T?UQS+T'N'B$0V^/
M'SBWWW.XW*QIDKW/3.9FQ/!',FI4DG9K1543C3QD6ATO34["H EX
M  HO>SX5MDO;J=ZRT.KD_)N\D,=6N%Z#E,@
M ,0;V_GK;=?63V8^"T:FWP5
M                                                 !B#J2_/"VB_
M].?T])!:-3;X*HSGV XSN7C,K$LLBG*M$I3;BB0KENMN,J):5MK+BE14I4O(
M9EV&8#(]UZ9>GK;O*[HK<K-H\6R34I<L5@7*./<([9JIK<42UK<2=#(E<M)
MMB]$# .A.%,8EKR9J6EE9+\-)N$A3*Z=A+)*$F9?$KQ TMI1S85':5&T^&-"
M39T%1.@R[M"+R4!5]             &(-R?SZL1^MOK+@+;S;X*@
M       (GFR[*A[&?/&,2<D6J]146]V)#1-\V2S)9MSW349<EMJG>>+BFH"6
M        Y&5_<M?/:^7ZRL5JU*7.S/(HO8CX)L;_ 'I_V4Z.*Y-CRX6(#.
M"$V?\Y"V_>G)]FD-K+=OV*V_.CDE?HZ3J(I@RK.I.1>9\8D8P2;Y-3.3*B(A
M><9A:.9<&M!GS6W^&EX^*]("5@               B>8KLJ+GBWG7&).025W
M1";;-C0T2TVJ1RUF4MY:C(V6R(M)N%Y3(!+
M   4WO5L+M9N-;+K?\H;9LE[*.US\N)7+<C1X:TN*4LEK2T9<M*FS4XG@D^W
M@0)B5%P5] EE@1+3<I4:Z7""PU'E7(XU\4<EUMM*5O&<=LVZK,M1Z.[4^ )T
MKGV(R#IMDS[G9=C2C(N1L)EW0F8<]EU3#:R0DU/3FDFI)*7P02_+6@(E>((
M           17<WX-LQ]H[G[$= 9TZ ?@VR;V\/V(P"TM:@J
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M?',.V          *+WL^%;9+VZG>LM#JY/R;O)#'5KA>@Y3(
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ME!O6,S;OT]:B<8QPW8N?F<K<R]75N1A.&.]T.R-AJ@
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M.HXN.QLGC%="R>=%G&[<9#MH.&RICDVQ>GD,NZE*UNH[VI94(^' !V@
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ME5XPQ66)D'<D7E!XRJ.4HTE<C9<)/-\/W21I-7[KW?U*@)L
M              "';I[?0]T\#NV!W"8[;XEV\/S);"4K<1X62U)*B5<#J;1)
M_5 9">Z2MBV<B8Q%6[!JRB0]X9NT-'#=E\ZAGH4VA2E)/@?IJ MBN_I_Z>L/
MVHO%RRO%,J<R-N?&<M;O[@IEM33Z%K+4R9]]*F]*DGV>4$3*_P $
M    (KN;\&V8^T=S]B.@,Z= /P;9-[>'[$8!:6M05                0O$
MRPHLRS@\=0^G)52H1Y4MTI)-*?*(DH_*-[U,R)HN/)X5[?( F@
M     (5NPG"5X/.3N&W(=Q3FQ#EHAE+4\;A26S9H4'U:A.Z*Z?U0$U
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MW$UWC95E#>-WITGI"D2)<A1R&4Z#2XF8XXMM:2.AHX>CY2,$2M $
M,0?WAO\ 9Q]>_P"KP6AM\%0               '!S1]R-BMU?:L!Y2XA@S+'
MT\JLSB1<OU?N4\IZJ_&,^ #KPU*7$CK7'.*M3:#5%/29M&:2J@S09I[O9W3H
M ^X               (W"?<5F]UCGC)Q6D08JTY7ZA28:UN$<;N^J^HTU=[A
MWO)PU!)        5=OC]*,6^^6W^MOCSVW?(I[T<TO1;!\ZON3SPY \:](
M  ZFP/W&S_;>9^LV/:;#]/\ 5/0\UM[U$=V.E-<W?=C8I='V,>/*W$,U+'BY
M/\<+41&CU>J.SO=XC[.!&8[[SSML&:F&E&WR3-"3-GAW.'I>'#AV< 'T
M                      'QE-Q7HK[4Y#;D)QM:9*'B2II32DF2R62N!I,J
MUKPH Q/E?4WLC"R!=EPG:FU9#!;D(BKO;\6)#C&I:]&MM!175*0?R)K-!GZ
M+8+LPK/MFI&\=[VSM&,6ZQYKCZU)ML]F%%:.611R5()AQIM*D+02EI4CY)!&
M9'341$+R!              Q!_=Y?VC_ %D_K %I;?!4               !
MQK9)R=V^WN/=H$6/CS"HQ6"8P^IV1)2MJL@WVC0DF]#G=111ZB]#RAV0
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MLX@7?U<!0                     8@ZDOSPMHO_3G]/206C4V^"H PW?\
M$5]2>^^XEGS*_P J!CVW[3C-GLL)3:7%$T9MJ<03I+21&M&IU>A1GK2FI$1
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M,BDY5'<LY8O!B36WKBPU>U37EL&Q;%$KG.LDE*M;J>[I2="/_&0=L
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MZEMS-M\<O3UXPY,$[HM;SA/:;B3L362U((D<Q!R'6EFDB,]/'BFA"6O@5
M         17<WX-LQ]H[G[$= 9TZ ?@VR;V\/V(P"TM:@J
M  XMI?RER\WQJ]1(;%B9=8+'I$9U;DA]E3)&\<A*B(D&ERI)T^3_  F':
M            !Q,MD97%L3[V%0H=PR(ELE'C7)Y<>,:%.I)TU+;2HZDWJ,N'
M;_@,.V                 XEFD96[=KXU?H4.-9F7VTX](BO+=??CFT1N*D
M(4DB0HEU(M)]GQJF';       !F[J/\ A1V:^>+YZS$'<V=Y=SZ>ECJUP[(R
M+@  \=V^E4[YW=_:&)C6)5TR? 5AOSL_[+>'.VCZBK=O*T:EM#GK@
M       RQUSJE)P/%3D)?7BI7YD[\F-Z8VR:7H(^)=I:]->&JGEH"80B!D_3
MI9]]H\NPR[+ VKEX ];[B3*.4P](?F.DXS(1I)U;ZV=)*2LC<4FA'4$I;T/I
MCKA[D2K"T^S@[U^+W/-OU,TM$EP])F?:LFE,$O\ 4 EK$%0       &(/[PW
M^SCZ]_U>"T-O@J                XV61[G*QRY,6:]HQNYK9,HU]<8:EHB
M*(R/F&R^:6UD1>11T =2,EU$=E#SO/>2A)./Z21S%$155I+@53XT(!]0
M           <&)%O*,NN4M_(D2;(Y#CIBXR49E#D1[4O5).0E7-63M-))4G2
M6DZ>4!W@       5=OC]*,6^^6W^MOCSVW?(I[T<TO1;!\ZON3SPY \:](
M  ZFP/W&S_;>9^LV/:;#]/\ 5/0\UM[U$=V.E.LN8N<G&[BQ9KZC&;FMJD:_
M.L-2T1%$9'S#9?-+:RIPHHZ#OO/.NR2B:;):^:LDD2G*$6HZ<3H7 J@/V
M                       (YN#:;C?\"RFQ6A6F[72T7"% 5JTTD28KC39Z
MO)WE%Q ?SH1NMBMKZ?F-G9]IE6G.K/?D2[DI<<DID$U,6ZM3I\%I=;29,FA:
M>Q!4/R$77%CV<VG?GJTQ3+-O[4^S9,8M[YWB[OMDRZ\@FI"$J6E*CHG4\AIO
M5WCJ=>Z7 C>;8!4             8@_N\O[1_K)_6 +2V^"H
M   ")8YYC/,<P.W9-*NUWUP"NU@?EI?C6A11SY28[!)(V"?3ZHNIGK450$M
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M9CX+1J;?!4   !G*[_#QE/SC']8ACY]M7U=?L_IA]!R'H;?+/]522CFLH
M   /A,_U21^]K_:F"8UNETX?!\[[8R/6VA[38?I_JGH>;_[!ZGZ8Z5NCOO.
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MT_9J]'B3+X?W?GW'YC[9Q_8Y@2V&"H   #^4>Y/YS=]^^X_9Q N_JX"@
M                 Q!U)?GA;1?^G/Z>D@M&IM\%0!E[?7IIMV99NQE^%Y<U
MAVX5\2IGP;CJF4W%<=GU1;/*6EU*R:1ZKH2LC253(CJ9DQ*O<*Z/&XV56C&=
MT=P(=P8MJ3N%NPF$^X;K\93BE+-")"D&VTM:%<TVFCKQ[R3X@G%N)*4H2E"$
MDE"2(DI(J$1%V$1 J_T            !B#<G\^K$?K;ZRX"V\V^"H
M        ")9QYCYV,%>LFE8XOSW$.VMPY:897.81+Y<!XC2KFM.\=37#50N(
M"6@       Y&5_<M?/:^7ZRL5JU*7.S/(HO8CX)L;_>G_93HXKDV/+A8@,X
M (39_P Y"V_>G)]FD-K+=OV*V_.CDE?HZ3J(I@OF31D/F3)962EY\G><%3):
M9IV^:9H-VWM:4IY33'#0R==&KMX@)6               ")9B=B\Z8H5WR:5
M8)7G1)VN%%EE$1=))-+(HCZ#2?.;,CU<NI=XBX]@"6@
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MY-*Q"T\R-SK] EE;Y#*O$-Z$I?4E1))Q5&U%3BDS(!+0
M$2Q4[$>1Y<=KR:5>KCXQCSK:9$LI+%J=)@B2S':))<E*TEK4FIU54_1 2T
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M^6W^MOCSVW?(I[T<TO1;!\ZON3SPY \:](    ZFP/W&S_;>9^LV/:;#]/\
M5/0\UM[U$=V.E*]R$8\Y@]Z3E=GD7_'N01S[/"87*DR$)6DR2VTT:5*,E$2N
M!E2E1WWGDDC<OP[/);-IK0GEM&G0:4T*B32?90O( ^H
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MLQ\%HU-O@J    SE=_AXRGYQC^L0Q\^VKZNOV?TP^@Y#T-OEG^JI)1S64
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M?VW;@E+\PUQT%:T<M?\ &Z/'J,R]+1KO<3^,82(
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M$F/<SQC#S+/JK+*VRU+(R[RRIY:$"(A670#\&V3>WA^Q& 3+6H*@
M       ([8I$MW(<D:?QHK.PT]&*/>M;"CNQ&P573)KOIY5":]5X^@ D0
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M]0-GWU]R_FFSR;3Y@\?SO%.-N<SQWAM.G1V:>0=:^B"8A_4 %
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M<%EP  0;>3X,<E^=?_M$#/E_,A6K4TOA_P!R5A]KH?K"!YV[VYY96C4[0Q)
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M(5(<D\];9-'5Q*4Z=)*5V:?1'9R64C+6^I$XZ<7%S^=G-7.O,=71@E@WG.
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MN3R)$HI3QOJ-QM.@J&9%0J G%/00    _E'N3^<W??ON/V<0+OZN H
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M<OP4_P 7,9Y?@V'GF?4F7D-GI69GWD'7RU($1*LN@'X-LF]O#]B, F6M05
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M1D7=(Z]A\*COO/)/%Y1QF384:F=">6I1F:C30J&9JXUIZ(#Z@
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MLGLQ\%HU-O@J
M              #^4>Y/YS=]^^X_9Q N_JX"B+[B9O;]M\+NV;76.]+M]H;0
MZ_'C:><LG'4-$2=:DI[5D?$P&<OR_MMO>S?/\$3YN"V#V6SKUVHERT1[C9KW
M;HZSH<M3,9Y"/BK2V^:Z?YJ5'\0$8-(XME>.YK9(V1XK<6;I99A&;$N.9FDS
M+@:5$9$I*DGP4E1$HC[2!#L         *1W8ZH]O]G<H1B636V\2[BN*U.)V
MVL176.4\I:$E5Z4RK55!U[OZH)P0;\OG9[ZB9+_)8'T>!@E6W'5UMMNAF=LP
M:P6N^1KM=>?X=Z='B-QD^&CN25:U-2W5%5+2B*B#XT^.!@OT$ #$'4E^>%M%
M_P"G/Z>D@M&IM\%0!@RY[/7/J#ZD=QK3F>0/6AC&E(*!&2@G7U05F28Q,(6H
MDH;T:7%J(N*EEPJJH+8IA^C\P_WXW/\ D\?_ *0,6O8D=,2(Q$2HU)8;0T2C
M[3)"237_ ! J^P            #$&Y/Y]6(_6WUEP%MYM\%0
M   $/SL\;)[%O=#CLF_K.^1"M+D2(<PK=/,E\J:\9&7*:;H>IWCI,RX )@
M     #D97]RU\]KY?K*Q6K4I<[,\BB]B/@FQO]Z?]E.CBN38\N%B S@  A-G
M_.0MOWIR?9I#:RW;]BMOSHY)7Z.DZB(8![G-&2%CF/2<>05^GE<TRXAPO'7
MC1SIS1&9\QI[NZ'>&JG9P 2\               $/S4\;*ZXD5]QV3?):KJD
MK/,C0SEHMLOE+-,EY9&7*01%37QXTX<*D$P
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MP\KQV3E5EYL4GK)!B'<)#JU2&R;4EDC*I(49+4=>"2/XP"8
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MD*N1V*4U+:YY)HGF&TXX1*T]A& GH(        8@_O#?[./KW_5X+0V^"H
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M2I4^)?$'?>>=1I3BFD*=03;II(UH(]1)49<2K0JT]$!^P
M          !'-P+? NV!93:KK+\!:YUHN$6;.TFOD1WHSB''=)5,]"3-5"]
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MQ9< <7*&,ID6YI&(2X<.YE*C+>=N#2WFCAI=2<A!)09'K4WJ))^CZ':0=H
M %9;I?=)MW[>(_62.-M#S+/?=W9GE7^XLT=EP@!Y[A_J$K]Y<_:F*5]F>1>W
MVHY6>=OON/M?^8YZZL?+:=3Z5?[<I,+,   /'AWPS->T#GLDQV]B^I^F>AH;
M6]']<<R]![AXAQ,98RMAFXEELR',?<GR'+6JWLK82W;5&7(;=)Q2M3J2KK47
M#]<P[8       ,U[A_G,L?>*C^F'!WLIZ:>__A8_XO8[@LN  "#;R?!CDOSK
M_P#:(&?+^9"M6II?#_N2L/M=#]80/.W>W/+*T:G:&)(
M     ,0;V_GK;=?63V8^"T:FWP5
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M1U/B=3]$%7W             8@W)_/JQ'ZV^LN MO-O@J
M XN0-Y4XY:?<N_!8;1/95>RN#;KAKMA$KG(C\I2=+QGIT*75)>4@':
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M)-"DG6O&OH@B96@"        &(/[PW^SCZ]_U>"T-O@J
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MY6C,;(2UKARUOHG1D2&U1U+)!R'6UH4EQ2-2352O&AT!$XM* @
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M[AXA"]N#PTXN0^XPY1L>?KAYX\9XO5YV)2?$\OQ?'EUIIY?J?['R@)H
M  #->X?YS+'WBH_IAP=[*>FGO_X6/^+V.X++@  @V\GP8Y+\Z_\ VB!GR_F0
MK5J:7P_[DK#[70_6$#SMWMSRRM&IVAB2                      #$&]OY
MZVW7UD]F/@M&IM\%0
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MMY0K"YTB<CW0W$KZ<E<EPV;P1H\2RWXDBTH3W=)-^I_L?* F@
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MMU]9/9CX+1J;?!4
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MY/\ JUJAR)SW^9&:4ZK_ !) 9,Z#;(Y.MV<;CW$^?=+O<46\Y"N*M32/%O\
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MRRMX_:V+A!DS":OCS\CPZXL(T*,WFDZ3YBB422TU_P"D@[8
M              (?NE@$'=# ;W@T]TX[=U9)+,HDZS9DLK2\RYIJ522XA)J*
MI5*I5X@,@6AGK;VHMZ,!L5L\[V6WD;-KG-M1I[2&#X))IU9I42$_(I>35/93
M30@6T+AZ9]E,TPRZ9!N=NI)*1N'E">4XUK0\XQ'4M+KG-6WW-;BT([C9Z$)0
M5#\B2)EHX$            (KN;\&V8^T=S]B.@,Z= /P;9-[>'[$8!:6M05
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M=?63V8^"T:FWP5
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M            "*[F_!MF/M'<_8CH#.G0#\&V3>WA^Q& 6EK4%0
M     $7QUN C)LJ7%R=Z\RUOQ?&6-R0T\W:%$P6EMMI!$IHGB/F&2_3=I )0
M          *AZH/@+RKZW_TE%&&]V):.>\FKV<\+>&9O   BVXB;<K%)977*
M7L-@\R/S,@C2&8;C)\]&E).R$J01.*HV9&7'50!*0                $6Q
ME-O+(<J7#REZ^252V/&6=V0R\BT.$P5&&VVTDIHG"[]%\3/CVU 2D
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M^:34OE.&2B2A:U))2B)'I>!:'"D6BYYKOYLUM;GS9SF,?QZV(N=JDJ-:>>U
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M2E>P=]YY)XI-%&9)A)H8)">4@R-)I10J%0^)4(!]0
M      !A&^XO,ZE>JS(,7OUUD0,4PIMQ#3459)>2S"<:96EG54DK=?<UJ<T'
M1)4\B06U0VQDV/P\KQRZ8Q<G'F[?=XKT"8N.LFWN3(0;;A)50R(S29EV JQ;
MM=C]VZ>.JJ-M;;+H]<,0RF,I9-O&1+4RIAYUA;B4T1SFG&31K21509\"U:06
MUPW0"H             Q!_=Y?VC_ %D_K %I;?!4               !'K+(
MFNY+DC#^->:HK*X?AK_S&%>=]3/>5I;]43R*$UZKV_(\ $A       !0N_\
M]W.TGMO*_:,C2S6J'.S?;HY93,:"   >.\?2F?\ .[W[0P'DZ7_@+Q7ZX?TE
M*'6L]B&3(^33[>>4^S%^9'M3*X..%E#WC(B3MQN,-<M)O)K)K([M6?W3T>'
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M-3;X*@   ,M9_P!16ZUCW5R#;G#L5MUW.S):>0;IO$^<=UEAW6HR?0GM?27
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MF>RU-BY%-,XZ,5J*L86R.>N
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MLEXNK(37<4I1-2W'65I5RU_QPS?,E)H7=U-=[C\8C"2@
M           P7T];A6+IPS[.=K]SE+M+$B:@X5X6TM;=8YN)0;G+2I?+?;6A
MQM=-)<:TKP+3I::NO4YL3:("K@[FD&2DD&M$>%S)4A9EV))MI*C(S/\ 94^+
M0@1@HOI.5<-P=[MR-ZV8"X&-W%M^!%2X7$W9DEB0E%2J1K0VPDW:>59>B"9;
M.!4           !%=S?@VS'VCN?L1T!G3H!^#;)O;P_8C +2UJ"H
M       "-6!UM>1Y.VC&%69;;\;F7Q3;""NYFP5'24WWU\DB)JKG$NP@$E
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MW6U/N*]P-F\T>=_.GG#^-2Y7-\+X/E?ZT\[IT\U?I:5KQ\@$/Z+ J
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M.TES-%=.JG&E>-*@/V                          ,:;W8+NEM)N^[O\
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MXI)&MNNK2HRXE4NV@#]@
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MP  0;>3X,<E^=?\ [1 SY?S(5JU-+X?]R5A]KH?K"!YV[VYY96C4[0Q)
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M;F!4             ?RCW)_.;OOWW'[.(%W]7 4
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M97E<1)(84P@M/@8.FB32:2T]W@HO_I^GM;MTY:GQ;NFN>S3TR3..B'0O]_\
M<WX3IWZ=XC;>2MMZ;Q>$]Z/9HZJ$[(D.D1ZI*JUXU,C,N&K2D4HHZ^-^_.C>
MCYOT3Q0C^';>6#;'J1Q3&K*^N9+/%Y<N\W%]6N3*GO/.FMYWB>DU$1:4^1-.
MTZJ/-=OU7LK55/S1AQ0KAA5#M]1_PH[-?/%\]9B"FSO+N?3TIJUP[(R+@  \
M=V^E4[YW=_:&)C6)5TR? 5AOSL_[+>'.VCZBK=O*T:EM#GK@
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M=O R,=]YYW62HRV7,-VB4ES3I5?#TW#AQ[> #]@
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M^SY%/=CF>=O^HJ[\\ZD]OON/M?\ F.>NK'S6G4^@7^W*3"S   #QX=\,S7M
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M-W_@FSS[W;O[!>&SE?.H[T<ZM6J5+;>?<!BGM/;_ &*V.Y>[=7+**=22#$L
M "-[0_G)9?\ >W&]>8$9WTU/>4CM-.#@,@
M "*[F_!MF/M'<_8CH#.G0#\&V3>WA^Q& 6EK4%0               $0Q=6+
M'EN9ILMYD7"^E)AGD%N>D.O,P7CBD3*&6UEI;);9:E$@SJ?;V4()>
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MHEI2LN9+E2W*UFS3K5+:3U&A!JI2O'TZPIIJS=4W+D]6W3^'%".SHC6B>W>
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M[SR0Q]/AVM#1L(T)TLF1)-!4X)H7 J=G !]
M                    &(/[O+^T?ZR?U@"TMO@J        R)@O[KEWWS7;
MUXAPH[57*^M?Z=ON4\R7"50  <-'PO[9?/EP]AF+6_-I]K6SWHKW)']4-4CM
M/F#B6I_*W+]?6KS$AL8VRJ,6.R(SJW)3Z5-&<DY*%))*-+E"1I[2[0';
M   !0N__ -W.TGMO*_:,C2S6J'.S?;HY93,:"   >.\?2F?\[O?M# >3I?\
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MP8Y+\Z__ &B!GR_F0K5J:7P_[DK#[70_6$#SMWMSRRM&IVAB2
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M#.W8Y:H=GMYK-TXEOCM1&3<41$:]#24IU&1%4Z#'7<JKG&J9F>,B,'2%$@
M  #Y2(L:6@FY3*'VR/42'4DM)*+A6BB/CQ ?MMMMI"6FD$AM!40A)$E)$7D(
MB[ 'Z       !^7&VW4*:=02VUE1:%$2DF1^0R/M ?XTRTPVEEAM+32?2MH(
MDI+R\"+@ _8#YOQX\IOE26D/-5KH<22TU+XAU ?I"$-H2VVDD-H(DH0DJ)))
M<"(B+L(@'Z ?)^-'E(Y4IE#S=:Z'$DM-2\M#(P'U(B(B(BH1=A  #XOQ(DE2
M%26&WE-G5LW$)6:3.G94CIV /L
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ML5L=R]VZN644ZDD&)8  $;VA_.2R_P"]N-Z\P(SOIJ>\I'::<' 9
M                    $5W-^#;,?:.Y^Q'0&=.@'X-LF]O#]B, M+6H*@
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MN  #QW;Z53OG=W]H8F-8E73)\!6&_.S_ ++>'.VCZBK=O*T:EM#GK@
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MCO0T6.NZ[BQHV3IR>?*E3XSF)N1F46^WH9-,IJ4DSYJUNUHI*BII33@ [0
M     *NWQ^E&+??+;_6WQY[;OD4]Z.:7HM@^=7W)YX<@>->D    =38'[C9_
MMO,_6;'M-A^G^J>AYK;WJ([L=*?9/'R&789T?$YL>W9$XW2WS9C)R8[;FHCJ
MMM*DFHC*I=O#MX]@[[SSIM$X32">42G221.*26E)JIQ,BJ="J _8
M                                    #$']WE_:/]9/ZP!:6WP5
M    9$P7]UR[[YKMZ\0X4=JKE?6O].WW*>9+A*H  .&CX7]LOGRX>PS%K?FT
M^UK9[T5[DC^J&J1VGS!$,;58#S/,2MN32[M>27;_ #Q8'Y?B(UI/PZN2F.QI
M+D$^FKB^)ZE%7A2@"7@       H7?_[N=I/;>5^T9&EFM4.=F^W1RRF8T$
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M!9<  $&WD^#')?G7_P"T0,^7\R%:M32^'_<E8?:Z'ZP@>=N]N>65HU.T,20
M                     8@WM_/6VZ^LGLQ\%HU-O@J
M
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M?.[O[0Q,:Q*NF3X"L-^=G_9;PYVT?45;MY6C4MH<]<
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M%]5[:>E_5X5 2&VIBIMT1, E%!)ELHQ+UDHFB06BO,[]:4]-Q]'B ]0
M  ,T;3_=-NI]^%T]>4./<[4N-:[5?>E: QLX  *[W&^Z[:_[Z(O[50RVNW#%
M7VJ.]#18Z[KH7;"PK\)]^5!0^6>':X*;LXHI/AS@I<=..2#5ZAJ)2E5T=[_&
M F@       *NWQ^E&+??+;_6WQY[;OD4]Z.:7HM@^=7W)YX<@>->D    =38
M'[C9_MO,_6;'M-A^G^J>AYK;WJ([L=*3;H(Q%S ;ZC/&GGL0..7G5N,4@WC:
MUIII*+ZKP5I/N_J\*COO/)3%Y/AF?#D91]">41D9'HH6G@KCV>B ^H
M                                      #$']WE_:/]9/ZP!:6WP5
M      9$P7]UR[[YKMZ\0X4=JKE?6O\ 3M]RGF2X2J  #AH^%_;+Y\N'L,Q:
MWYM/M:V>]%>Y(_JAJD=I\P1^S3+H_DF1QIF.%:[?&7$*WWWG,.'=B6S5Q1MM
MES&^09<OU7TW:G@ D        *%W_P#NYVD]MY7[1D:6:U0YV;[='+*9C00
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MJ.U713[U32=3,FW45^)0%H;C2I*DDI)D:3*I&7$C(P5?Z
M
M           ,,[ER&LTZY,1M,(SDGC[ML:>)-7"0J 3ET73B1$2"7WJ=AU\H
M+;S<P*@                  Q!N3^?5B/UM]9<!;>;?!4
M !%LS.VD[CAW'%G<F4=YBE#<9C,RO-<@R7HN"^<HN6AFAU<152:\ $I
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MQ6QW+W;JY913J208E@  1O:'\Y++_O;C>O,",[Z:GO*1VFG!P&0
M                  !%=S?@VS'VCN?L1T!G3H!^#;)O;P_8C +2UJ"H
M           ",8\JVJR7*DP\:>L\U,B+XZ].QFV&KLHXY:'&G4&:G2:3ZD9K
M(M)\" 2<       %([]_=+M;[?J]9&GFM4.?F^U1R]"3CGJ@   (YTI? I9?
MGB=[*<'5L=A?(>3'M3_<8[86)2SO&+/9E YL;78(L9J8Z\HWT$E9-/*2DR;.
MCAG7@2:C.WTK 1'+-Q;+A]QAVJ?%G2YTYM;T=J QXA1H;.BN!*(^'QAH9G/4
M6*HIJB9F>",71RN0N9BF:J9IB*>&<$7G;U85(D-6JY6.[.RG*.,PI%N2IQ7
MR)26UKJ?#5Q(O1&C7M6Q,]6JFK'@FET*-CWXB:J:Z<.&*NE!]R<VQ.XQL?:A
M8[-MSD:\Q)CYR+<F-S8[)+)QM/'OF>I/=\HYN>S=FJ*,*)IPJB=-.&AU-G9.
M]1-<S735C1,:*L<)E,9&ZFW]L;\;*Q6Y0VFE),I#MI0TE*J]WO*45#KV#H3M
M'+T:9MU1]+FT[,S-<X1<IGZW1+>_'#C>-*S7TX>CF^(\ ?*Y=-6O5KIIIQJ,
MW[M:PQZM>'=8?V:[CAUZ,>\GMENT6_6F%>H)+*'/91(8)PB2O0X52U$1G0_U
M1U+5R+E$5QJF,7(O6IM5S15KIG!G[ /N?_\ %2O7E#YE5KGE?1KNOV1S)0(8
M0  <BW?"_A?[W<?8CHZ>RO54>W^F6OG_ $=SZ?ZH7^/H#P**8P=L]T>6%"Q9
MZQS"E,>.O#L9IAN[KY!:7FW&U&ITFR[AFLBH?ZH#O7CZ4S_G9[]H8M1K@ED/
M:_<*S;7[*XO9<!M#=VWAS?GN,6Y@M;JW4R7F6Y$HZU)IM".XBI%P4? M:AZ+
M,6*KU^J:YPMT;L(8HG"-&M.K9;,>Z<\>E[C;C2U9-N_DRC0I2#YDN5+<I2%"
M*E4MI/22UDFE*</2(&I555FZHMVXZMNG\..4]G3.M^[!8/<WXOJ(ZB);;>2M
MMZK/9U=Z/9HZJFU'CM&9ZI*JTX5,C,^.K4H*Z^OA8L1HWY^;]$\<N?CN.W;?
M"[-[P;P-E9]K[.2I>*8I+42&%,(+5XZ=JHDTFDM7>X*+_P"GZ>]RY3EJ?"M:
M:Y[571"(C'3+EXAN/!W-ZI;3>K)">CXY#L,ZWVF:^DVRG-,.N&M]M)D5$:U*
M0G_-XT.J2O=R\V<I,3.GK1,\2(G&IW^H_P"%'9KYXOGK,04V=Y=SZ>E-6N'9
M&1<  'CNWTJG?.[O[0Q,:Q*NF3X"L-^=G_9;PYVT?45;MY6C4MH<]<
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MCKNNXL9_*591/CRXD-&((BQUVV8VZLYKDQ2ED^AQLRTDA*21I,C_ ,/R(=H
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M%                               &(/[O+^T?ZR?U@"TMO@J
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M_.O_ -H@9\OYD*U:FE\/^Y*P^UT/UA \[=[<\LK1J=H8D@
M        H#JZVIG;F;8G*L;//R/&'57.(RE.IU^-RS3)813CJ4DDN)(O3&@D
M^4$P^'23O4SN;@C6-W9Y)9EBS+466@S[TF$@B0Q)(CXF="T._P"653IK(@)A
MH8$
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M@                           "*[F_!MF/M'<_8CH#.G0#\&V3>WA^Q&
M6EK4%0               '&M,3)6+Q>Y%XN,>799+K*K##9C\EV*TEDDNI=<
MU'S#4Y51'0J%_@(.R       "D=^_NEVM]OU>LC3S6J'/S?:HY>A)QSU0
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M*IWSN[^T,3&L2KID^ K#?G9_V6\.=M'U%6[>5HU+:'/7
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M+@:DC4N;/HBBJJFO'J_RX=*>M..F&@1QV0
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MGR_F0K5J:7P_[DK#[70_6$#SMWMSRRM&IVAB2
M PKO/M?GFP6YZ]\MH8)O8PZ;DJZ0V4*<9B*?KXEI]E!DHXKG[HE2>#9\.[I0
M9EH7YLIU.8)O TU;.85BS33ZK8I:R]5415,XKIDDG2[>[0EEY4TX@B87<"
M
M                   ! MT-XL$VBM/G/+[@3<EU)G!M3%'9THR\C352X5[5
MJ,D%Y3 8RD/;H]:N<6ZMM78MK;+(43CZ34;$=I9D;JC=70GY2DD24I0FB*EP
M2DU*,MJ;M:PW&V,// V8"&\4. JT';T52@X3C1LJ14CKWDF=55J9\>T%7=
M                 !B#<G\^K$?K;ZRX"V\V^"H               "%;A%A
M9OXC[L(,B:\600O<ZJ,W*<Y%WTN<AUPXQD24)+5J-WU/]D7 !-0       <C
M*_N6OGM?+]96*U:E+G9GD47L1\$V-_O3_LIT<5R;'EPL0&<  $)L_P"<A;?O
M3D^S2&UENW[%;?G1R2OT=)U$+VY1A:&\H3A<&1!1[H;B=]*2B2V;UX,T>)>;
M\29ZD*[NDV_4_P!CY0$T       !2&Y7PLV'VH=]=<'C-N^=3W>F7L]B^FK[
MW1#[CS[I@  X>8_<M=_G5S]81.IEM=N.5<6 ?<)B_M1 ]C-CZ3D_(M]VGF>!
MSWJ+G?JYY<S.BPL[QAGNK@R)ER*\(/&7([<I:6+ER7*..G',DD@D:J\VJ/+3
MA4MMI)J       "&;O\ P39Y][MW]@O#9ROG4=Z.=6K5*EMO/N Q3VGM_L5L
M=R]VZN644ZDD&)8  $;VA_.2R_[VXWKS C.^FI[RD=IIP<!D
M                17<WX-LQ]H[G[$= 9TZ ?@VR;V\/V(P"TM:@J
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M5,BY9J?]3(C+B>H!U8IJ5%84MCPRS;0:HU4GRCTE5%4&:3T]G=X /L
M #-&T_W3;J??A=/7E#CW.U+C6NU7WI6@,;.  "N]QONNVO\ OHB_M5#+:[<,
M5?:H[T-%CKNNCL.1+5FESCKQHHL-$*,;>5:V#.8K4O\ BVE/JI$S4U%J[O>.
MGQ0D0       *NWQ^E&+??+;_6WQY[;OD4]Z.:7HM@^=7W)YX<@>->D    =
M38'[C9_MO,_6;'M-A^G^J>AYK;WJ([L=*;YF])CXO<WH>/EE,A+7<Q\ULME+
MJHB-LU2"-LN'>[Q>0=]YYVF34IIM2V^4LTD:FJD>DS+BFI<.'Q '[
M!DC:SLS7[[;SZZD>GO:J>[2QTI^,"X  (%DWPO[0^VTKUIL9?]&YR*5:X:U'
MFF0                             8@_N\O[1_K)_6 +2V^"H ^$N9#@,
M*DSI#<6,FA*>>6EM!&9T*JE&1<3$3."U-%54X1&,N=[J\6^KEO\ Y6S\N*]>
MGA9OMKOR5>Z3W5XM]7+?_*V?EPZ]/"?;7?DJ]TNN1DHB4DZI/B1EQ(R,7:[_
M $!D3!?W7+OOFNWKQ#A1VJN5]:_T[?<IYDN$J@  X:/A?VR^?+A[#,6M^;3[
M6MGO17N2/ZH:I':?,'&MD;)VK[>Y%VGQ9&//JC'8(;#"FI$9*&J2"?=-:B<U
MN=Y%$EI+T?('MNWTJG?.[O[0Q$ZE:M4L*81;[#F^"8WMS@V+0;CN5/1*<R3)
MY<<E-VN&<UXD+4M1'5PVM&DZ'0J$FJS+3SJ8BJ(IB-+@V8IKMQ133$U;\X:M
M*TLKP?:S:^S6G;W'L6BYKNO=4:(+<MHG7E.+KJER>-&F4T,THJ14+MH2EC+5
M333&$1C+<KM6[411%,553NQD>VTVKV0PAN5G=HBY=G]Y<_BEN2T2E2)KGI8\
M1E)=QE!JHI9(_4XH0'4IMTZ=,G@VK-'Q1%54\_$_W'MHL!V]QFZ;G;W6VWHF
MSBUMX^RTDH<%*^+<6.R1T<?52AG4Z<>/IEG--N*8ZU13E[=NF:[D1R;T<2.[
M.1YBM_;3>G,:C8E:+W99DVQ6:,V3:DV^IMMN.T(C-;AI-6I7:5*$2=(K:[>K
M#0PV(GQXGJQ3$Q.$?FLS?_[N=I/;>5^T9$YK5#9S?;HY93,:"   >.\?2F?\
M[O?M# >3I?\ @+Q7ZX?TE*'6L]B&3(^33[>>5BY/'R>5;FVL3FQ;?<_$L*=?
MFLJD-G%2X1O(2E*DT6I!&E)GV#,WG9 4UG^46K#MU+=?[LDW&X]@>3'90G4X
MX^Y(4E"$>@:JF5?0J/.YW,46,U375O43[\7ILCEJ\QDZJ*=^N,>3!];)9'WG
MW=VMVG41G(R.;:;2[7D6YBM4&:#[7CX:4TU:O\JA)FS9F9^YS.C#5&]3'Y[M
M>JMZ]$1]KE=./:JWZI_+=JU_Y @3MUIR,MRU!V[;JW&<BSV>09(\5H(S\5*J
M=-%.)$?"G^34U***LY5XMWX;5/9IX>.=WZJZZ<C3X5KXKM6BJJ-[^6G=^GQE
M2KEO1<EV6RK<MVU]N<)%PN""-MRXN-F1\IJI<$%_B],KCI2*U559^KJ4?#9I
MUS\W%&[HA>FFC9U'7K^*]5JCY>.>/=PRX>YF6)DX_<\#V[A-^YRQQR*_7!LB
M\,RVA148:5QU+4KTRN)F=?\ *,:V?S.-NJS8CX*(^*=[D;6SLKA=IOYB?CKG
MX8WYXY7#C_W"6OVHC^QDCT-GR*>[',\W?]15WYYU)[??<?:_\QSUU8^:TZGT
M"_VY2868   >/#OAF:]H'/9)CM[%]3],]#0VMZ/ZXYEZ#W#Q#C8Y&R>,U<"R
MB?%GO.3Y#MM5#85&2U;U&7(:<)2UZG$E74NO$!&-\_@<SGVEF^LJ&YD_/HY8
M5JU2H_:?!YN18UC6ZF^$IF+A>(V>&C$+ \K3":BQ([:$W"2DS,E+=)"5H2=:
M\/)I2.GFKT45U6[/:JF>M._R0I3&C&7:B1+QU-7A&09 AZS[!6=XW;;;73-A
MZ^O,&?J[_$C3'29?\Q=[4I.*9IR=/5ITW9US\OZI[7(^%]OMYZA+R[MCMBZ=
MFV>LQIBY/D\5)-HE(;(B*%"(B).C25.' RXGW*$NU%%.5I\2YIN3JC@XY)GK
M:(U/;?,H4RXST\].4=N+<82#8OV0M$9Q;-&['5FZ7IY2C,ZJKJ)79W_24HMX
M_P"?F-4ZH^;]#'>A_FP>$6S;K>#<C$;4Z[(C0;?8C7*D*U///OL+===5Z!K6
MM1T\G8)SMZ;MFBJ=^:BF,)?C</\ .98^\5'],.#)E/33W_\ "?Q>QW!9<  $
M&WD^#')?G7_[1 SY?S(5JU-+X?\ <E8?:Z'ZP@>=N]N>65HU.T,20
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MTG7]]2/YM9_E@-![I.O[ZD?S:S_+ :#W2=?WU(_FUG^6 T'NDZ_OJ1_-K/\
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MNDZ_OJ1_-K/\L!H?-V'U_P"5H5$D/+M$%X]"W4.66"I'D,R6Q_&"[:U3^IQ
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MWGW 8I[3V_V*V.W>[=7+**=22#$L  "-[0_G)9?][<;UY@1G?34]Y2.TTX.
MR                            (KN;\&V8^T=S]B.@,Z= /P;9-[>'[$8
M!:6M05                <:TO90Y>+VW>HL-FQ-.LEC[\9UQR2\R;)&\<A*
MDDE!DY4DZ3[/\)AV0       4COW]TNUOM^KUD:>:U0Y^;[5'+T)..>J
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M  #QW;Z53OG=W]H8F-8E73)\!6&_.S_LMX<[:/J*MV\K1J6T.>N
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MVECI3\8%P  0+)OA?VA]MI7K38R_Z-SD4JUPUJ/-,@
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M +A+7[41_8R1W[/D4]V.9YZ_ZBKOSSJ3V^^X^U_YCGKJQ\UIU/H%_MRDPLP
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M!MY/@QR7YU_^T0,^7\R%:M32^'_<E8?:Z'ZP@>=N]N>65HU.T,20
M
M
M!P\RR>%A6)WK+;BDUP[+"?G.M$>E3G(;-9-I.AT-9D22^*8#$C&Y'51?]O;I
MU!P,GB0\8M\M1-8RB,T:51$.H:<4E"F5:FT*5IJMWF42LZEPU%M#8>TN?-;G
M[=6#.&V4QW+K',Y49!F:6I+#BF'T),^.DG$*TU\E 594W)_/JQ'ZV^LN MO-
MO@J         .;>L@L&-Q43LBNL.T0G'"9;DW"0U%:4ZI*E$@ENJ21J,DJ.E
M:T(Q6JJ*=<X,UJQ<NSA;IFJ>*)GF<+\*^UOOWL'V5A?-13QJ/FCWMK]MS?\
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MS>[=7+**=22#$L  "-[0_G)9?][<;UY@1G?34]Y2.TTX. R
M            #.?5!O)E^$2<5V\VV6VSG&8R"99F.(0ZJ.TMU$=HD(<2I.IU
MQ>DE*2>DDGPJ9&1,0B&([C[R;1[WV3:;=Z_,959,K::5;;HAM*%LOR5+;;-*
MB;;4=7D&TI"ZT(TJ33L,EI'<WX-LQ]H[G[$=!5G3H!^#;)O;P_8C +2UJ"H
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M  'CNWTJG?.[O[0Q,:Q*NF3X"L-^=G_9;PYVT?45;MY6C4MH<]<
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M+'2GXP+@  @63?"_M#[;2O6FQE_T;G(I5KAK4>:9
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M4.N&2C/CY3)*2U[='4IQPTM#*V)M6\>K\3N;?[N[/,7*5NSNCF<6[[BOM+5
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M$;R;:;D7"1:L)R!F[W"(SXF0PTT^V:&=24:C-UM!>F41<# P3H$
M
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M:^PL/QZ'E+WB,FCVR&U>I&HG.9/;CH3(7J(B)6IPE'7R@J[@
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M@1U*.!!]ST]56T-HAWO,LI6U!G2?!QSBR67U&[RU.<2)LJ%1!\0\*G@3X=/
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M '@",3]'E_Q'^TG^\ ,3]'E_Q'^TG^\ ,3]'E_Q'^TG^\ ,3]'E_Q'^TG^\
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MEWG";:]"N$V/X.0X[*?D$IG6ERA)=6HB[R2XD!BLH$
M
M                                                 \EUMD&]VN;9
MKHR4BV7&.[#FQU5)+C$A!MN(.E#HI*C(!D9[HQS1B+,PFR[F/Q=J9\M,R19G
M&%K=,TFE5%)2XEM:B-">-4D9D2C34B!;%JK$<6M&$XS:L3L39M6FT1T18R5'
M59I07%:S(BJI9U4H_*9F"KM     /A-AQKC#D6^8CF1)32V)#=33J;=2:5%5
M)D95(_(8"*[?;68'M9#F6_ [3YIB7!U+\MOQ$F5K<0G2DZR773*A?L3(!,0
M   $'W#V@VZW6\V^[ZS>=_-'/\W_ ,:EQ>5XKE\W_57FM6KE(]-6E.'E 3@
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MJ1^0P$5V^VLP/:R',M^!VGS3$N#J7Y;?B),K6XA.E)UDNNF5"_8F0"8@
M                        *BWYV*MV]5HMQ(N*[)E-B=6_9;PVDU\LW-)K
M0M*5(,TJ-"%$HCU)--2\I&3$H?MGTU9!9MQ6MTMU<P7F64V]KD6E)MJ2TS1"
MFR6I3AF9Z4J5H2E*2)1ZZFH#%HT$     "";E;/X'NVQ;H^<07)S5J6ZY")J
M0]&TJ?))+J;2DUJ2"[02F[#+<9AJ.R5&F4);;*M:)05"XG\0@0^@    " 8M
MLSM_AN;WK<.P0'8^59!XKSI*7(>=0YXZ0F4]1M:C0FKB$GW2X=A< 3BGX(
M      0#;/9G;_:+SI[A8#L'SQX?Q_-D/2=?A.;RJ<Y2M-.<OL[03BGX(
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M4GL/0X2BJ7DX /K!@P;9$:@6V,U#@QTZ&(L=M+33:?02A!$1%\8@'H
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MK72:T)(]-2KIK0!)P
M
M
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M.AE0^(#V              #SS9T&VQU2[C):B14&1+?D.):;(U'0JJ69$53
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M*,B+B8#X+O%H;.&2Y\9)W$B.WDIYLO$$9),N34^_74GTM>T@'M
M     !\3EQ"D%$-]LI2BJE@UIYAE2O!-:]A /L               #\.O-,-
MJ>?<2TTGTSBS)*2\G$SX #3S3[:7F'$NM*]*X@R4D_)P,N #]@
M     ^)RXA2"B&^V4I152P:T\PRI7@FM>P@'V               !^'7FF&U
M//N)::3Z9Q9DE)>3B9\ !IYI]M+S#B76E>E<09*2?DX&7 !^P
M51E74KLIA.03<6R?)_ WVW*2W,B> N+VA2T)<(M;,9:#JE1'W5&"<'JPCJ#V
MAW&OJ,9PS(O.=[<:<?1%\%/CU;9*JSUR([:.%?V0&"S00     .=<K]9;._
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M>02R(S+RE4$/8
M
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M66G$ZB)152I1&52,C >^)+B3XZ)<%]N3%=(S;?96EQM1$=#HI)F1\2 ?8
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M=7IKW,3/M*\?RS&W6K5D5D=<)_D2FYK)50XDBU(4:5%Q+@:5%Q(B481O*?\
M6NCGYVA^QK."5@WSJ+S2X9[D^%;;8O;+FYB;IQI:;M=6H4V<^BI+3#C'12M)
MI4FI:J\.RI$",%W8+D5TRO%K??;W896,W64@SEV2?0WV%I4::5(DU2HBU)/2
M1T/B1'4@0D0    #SR)\&(HD2I3+"U%5*77$H,R]$B49 /W'E1I:#<BO(?;(
M])K:42TDHN-*I,^/$!]0   0K=#=#&MH\:1E65(E+MBY3<(BA-I>=YKR5J3W
M5+05*(/R@,-W/J$P.7U3V;>1INX>Y&!#7&?0IA!3-:K?)BEI;YNDRUNI^3[
M6PT-K;3;S8AO-;KC<\01,1&MCR(TDI[2&5:W$:RTDAQRI4!&"PP0     /\
M%*2A*EK424)(S4HSH1$7:9F \B+O:G%I;;G1UN+,DH0EU!J-1\"(B(^)F ]@
M    #'/4EU-;<WK#<ZVGAM7(LH:?7:5+<CMIB>(@34DZ?,)TU:?4E:3T M$/
MET[=4.VN-X+A>V%P:N9Y(E96TUM1FU1N?,F+Y??-XCT^JIJ>D"8;+!4
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MYV,W_'\5D9 T[99R?'X[DRVW7+6<C62&8RT(2?*]241I7WB4DS-*:\2):&!
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M]SSS*8=PVZ\#4K:RMLW>6Y%I&*B8K9]TS17U3_""):<!
M
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M1&=3[03BN#;O"+?MOA=IPFU2'I=OM#:VF)$G3SEDXZMTS5H2E/:LRX$"$H
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M>*[98O S+$K8QFUN0XJ:\[&ARI*'RDN.-J\0V3A&HDF@R4E9T_4 E<P(
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M4M)'P,TDNI5 9SPCHEQ;"<OLF7Q<IN$J39)C,]J,ZPRE#BF%DLDJ-)U(CIY
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M:$^FJ"<7JV^VLP/:R',M^!VGS3$N#J7Y;?B),K6XA.E)UDNNF5"_8F0(3$
M  !2.2['76^]0F.;S-76.U;+)%1%=MBFUF^XI+<E%4K+ND7JY=OH G%=P(
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M<F[*_-N5VO;Y2[W?+L_XJ?,?3J,E.N$E)'0UK,N[\D9F9F=0$^!
M   "!739_#+QN3;-UYK4@\NM#)1X;J7C2P3:4NI+4U2AG1Y8)3T$
M       X.:X?9<^Q>XXAD*'%V:Z(0W+2RLVG#2AQ+I4479WD$ 85A]EP'%[=
MB&/(<19K6A;<1+RS=<)*W%.G51]O>68#O                @5KV?PRS[DW
M/=>$U(++KNR<>8ZIXU,&VI+23TM4H1T90"4]!               (7N=M;B>
M[EACXWF+;[MLBS$7!I,9XV%\]MIUE)FHB.I:75< $KM\%BV0(MMBD918;+<=
MDE'57+:22$U/RG0@'I
M
M                    %4YUT[;9;@9(>7W:)+A9*X@FI%RM<MV$Z\A*";(G
M-!T,R06BI$1FG@=> )Q2C;O;/#=K+&JP87 \%"==.1*<6M;S[[YD236XXLS,
MSH1$1=A>0B!"7
M                                                   #F9%CUFRR
MQS\;R&(F=9;FRJ/-BK,R);:^WBDR4DR[24DR,CXEQ 4M;^D#:>&] 3)?O=TL
MUL?\5"L%PN*GK8VX:C5P9)">!F?$M7>^2K4P3BOP$
M
M                    X.3X3A^:L,Q<NL4&]L1E&N.B?';D<M2N!F@UD9IK
MY:=H#_<7PK$<)BNPL1L<&R17U$N0W CMQ^:M)4)3AH(C49$="-50'=
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>!@TEL5NY^&K"7,P\S^8^7.>@>"\3XRO(0VO7S.2SV\SLT^3M!$K-!
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M[G_ _P#X=X[G>.\1_P#J[&C1R/\ *KJ\E.)$PN\$
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M,>Q/W ^#\_7.':_&>>.;R?&R$,<S1X%&K3KU:=15]$@,&PP5      !4N_\
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MCQD./+TZ.>TAW16M-:252M"K2H*ON
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>]SLYNM_GP\SM=PELGBJX$=Q1&FV\>0M>C3H*.9J-1G2A::ANT%0
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M,13;'W"Y:;@:CY"7.49\TGE$HEEY>]0-WE6A5[?*"H
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M16%2#0<A3:#=-LZHUFDM6D_0KV J^P
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M;TV165/D]?6I#S*ER>8E9)?)HU>D-U*4\.YQ)8(EHT$
M
M
M    "-[@8A&S["K[ADM]45F]0W8?B4%J-I:T]QS34M6E1$K34J]@#.K^QV_>
M6XOCFT><W7&F]M,>>ADY<[:F4JZRX-N22&630XE+9*T429T3V$=5<=1;%<&^
M6W-[W,QJS6:PR(L>5;K[;[N^N<MQMLX\,UFM*3:;=,UGJ+21D1?%($0YG4%M
MCF&Y5MQ7W$R+9'O&-WR/?$^>5R&XR_"H7I2?AVG%'51IJ7=X5X@0Y-FVKW4R
MS<7'L_WHNUC4WB!/KQ^PXPW***<J4DDJ?><F4<J6E)DDJE5)=G$E!>X(
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M<[#^#C +XB_P;I *25XF<AYUYII;:TDVW4W5$LTKX<#JLT\1BU."
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MB_R^=/5WR>5O8S=+C%CVS<OS,NR.,*=<?CO65*ED<E"FT)))NDC@VM54U[#
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M,:Q?=B\8U$V_QV1$EN0,91.<ESU0$Z&VWUS"224F7IC1Z/I:TH,6DP0
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M'%.L6R*Q":=<XK6B.VELE*^*9)J8(=
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MT:%7CY""Y 0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+29FI)I(JUK\<@$D
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M@.^
M                C5]W$V_Q::5LR;*[/9;B:$O%#N5PBQ'S:69DE?+><2K2
M9D=#IY '7NU[LUABE.OMQBVR$:R;*3->;C-:U$9DG6XI)5.A\*@/]M5XM%]B
M%/LD^-<H)J-!2H;S<AHU)[2UMFHJEY>(#V@   CE]W P+%Y)0LFRFT668HB4
M4>XW"-$=-)E4C)+SB3H ZUJN]IOL)%RLD^/<K<[7ERX;R)#*J=NE;9J2=/C@
M/:
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MU0'DO&;X?CUWM]AOM[AVZ\W8TIMD&4\AIZ0I:^6DFTJ,M1FH]/#R@.^
M
M     /+<KG;;- ?NEXF,6^V14\R3-ENH88:07#4MQPTI27Q3,!S\>S#$LN0^
MYBE_MU];BFE,I=KF,34M*<J:26;"UZ350Z5[: /)!W$V_NEZ]S=MRNSS,BUN
ML^:(]PBO3>;')2G4<A#AN:D$A1K+3W:'7L 24    !&5;B8*C*?<0K(H!9?J
M)'F3Q"/&:E-<XBY5=5>6>OXP"3 (IENYNWV"*;;S#);?9Y#I:FHTI]"7U)_9
M):(S6:?BZ: /3B>?85G<=R5AU^@WIIFG/*$^AU;6KLYB"/4BODU$0"1
M
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M+*Y*B.[J;.'>$IX4G13Y;BJ%V<RA.D7D)1 2LH$
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MNEN8T9M2$%7C1+J%$FODH"J9@
M                                    _FWUU?#7']HX7KT@%X:+ZZO@
M4C^WD+UF0"L/=T2? 5$]LY_[=($M%@@ 1'=/(+EBFVV6Y+9R+SK:;3-F0E*3
MK2EYEA2D+-/&I),M1E\0!@[IMV L74"SE&5YY?KEXJ-+0T90G6BE.R)"3=6^
M^Y(;>J1UH1:2J=>/D!:9=;IT<O6U'5'<-J+7<5W/'9,FX6R>2>#;A0F'9#3Z
MD5TI=0;9(6?DJI)5 G4_H2"H
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M)R^QR5;;V9>6;$H1K.A$1&Z@VWC(N!:Z 2M0$
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MTD1+)9<2JFNE23],6H$[S^E *
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MF5 1#._]WU>''\8S6P&NK,&?#G);X\%3F7&E'Z'$HI?X 3+9(*@
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MR5^IHJ9^@"(5=T$WAV9M;>[0ZYK*V7IQ3"3K5#4F.RJA>2FM*S^.9@2U8"
M
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M@8*@
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M<:J)5#+XH(9H_N^+PZY;\[L#CGJ$=ZW3H[7'T\A,AIU7H=C+0)EM8%0
M
M  %5]2?P%9U[6+_;H!,*"_N]_I/GGSS;?6Y )E5FQWYZ1>WF3>Q;@"9U/Z2
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MG6_H]#EQKA$CSX3I/0Y3:'X[R?2K:<22DJ+XAD=04?<
M
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MCT3;,^X=$(G1JFWJ/C1*R-3:CIP)1F"(8EV.W_R'ILFW?;O/\?ENV@I2I#T
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M-HS(B-28#&LS(^TRK),OCD8)EKT%0
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M>MNT$^[O),O/5XD/1SIP-B.TTP1U_?$.$!+4((
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MRVYZ'9(=T@WJ6XLB/PT.SH:3')Y1523CWAT)TI,^\HZ5))F!JA_2 %0
M
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MS85O949<-4!IQU=#_P#%(J"TME@J
M                                    JOJ3^ K.O:Q?[= )A07]WO\
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MLUMAVYQZIGK5$80R:JGQXFFO$%';
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M=OV=K]MK!A:-*I4".2[BZGB3DU\S=D*(_*7,4HD_Y)$0(E.0
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M;W![%A=O,E1[-$;CJ=(J<U[TSSM/(;CBE+/XX*I,
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M94-2B;2FJC_9'Q =<
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ML^)NZTT/5/E'S7N)=I(,^6D_V*2 E8@(
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ME%\<@3+5F.;<;?X?*<GXKB]JLTYXE$Y*@0F([QI52J=:$$HD\/2D=/B JDX
M
M                                  /,5O@)?\4F*R4JIJYQ-I)S4?:>
MJE:@/2   #XRXD2?'7$G,-R8KI$3C#R$N-J(CJ54J(R/B0!$B1($=$2"PW&B
MM$9-L,H2VVDC.IT2DB(N)@/L              /&_:+5*F,W&3!CO7".1%'E
MN-(6\V1&9EH69&I-#,SX& ]@
M                                              \;-HM4::[<X\&.
MS<7R-+\QMI"'W$F9&9*<(B49&:2[3\@#V                  #QKM%J<GH
MNKD&.NZ-EI;FJ:0<A*:&5"<,M1%0S+M >P
M
M
M                                >-5HM2[@F[*@QU75!:43C:0<A*=)
MIH3E-1%0S+M[ 'L                      'CDVBU3)3$Z9!CR)L8R.-)=
M:0XZV:3U%H6HC--#X\# >P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M              !5>ZV_6(;/7JP6G+&)7)OR)+B)\="7&F$Q=.K6G5K,U&LB
M22$GQ!."/X?U1XGDV=Q-OKKCM]Q2]70B79BOT0HOB4+2:FS-)+4I',)*M!T-
M)TIJKP P<FX]7F,H?NDC&\,R;)L5LCSC%UR>V027;FS93J6HG#5321&1^J&C
MAQ[*5&"Z,%S?'MQL6M^88O(.19[B@U-&XG0ZVM"C0MMQ''2M"B-)EV>4C,J&
M"$B
M
M
M  !\9<N) CKESGVXT5HB-Q]Y:6VTD9T*JE&1%Q,!S).7XG"D18DR_6Z/*G)0
MY!8>EL-N/H=](II*ED:R57NFGM >J[7RR6",4R^W*+:XBE$A,B:^W&;-9]B2
M4ZI)5^( 6F]V6_1CF6.XQ;G#)1H.1"?;DMDHNTM3:E%4![P
M
M                       '!R+-<5Q*1:XF1W1FW2;W(*':FWM1'(D*-*2;
M10C[QFM/^$!W@'!RK-<5PB+%FY7=&;5$FR$PXCL@U$ER0M)J2V5"/O&23,OC
M .\ X.6YKBN"6UN\9?=&;1;'GTQ&Y,@U$A3[B5+2CND?$R0H_P!0!W@'#RO,
M<8P:U>>\MN;-IM/-2QXN09DWS7",TIJ1'Q.A@.TVXAUM#K9ZFUD2D*]$C*I&
M _0
M
M
M                                     REU*16)F_NPT>2@G&570U*0
MKB1Z)D115+RE4NP$P\G449-]3.RCQ(-:B?:,R01&M1)FI,B+T?B F-2H8L+$
MK3[K+]LGO!(P%J!(D*DX-E!' -U;:=1I;;-QPGRJ1M)0N.IPM.E7Q0UGTQ;@
MY7N7M3#R/,64(N:94B&U*::3';E,1]))>2A%$EWC4V>@B35!T(@1*XP0
M
M
M                                                      "GNJCX
M ,V^=H_LQ@$PS-E^RN#P>D&'N2[#6_G90K3/\\N/O+<-$J4Q%2QI4K03;;#I
M(2DD\-) G'2^V:X3N/E=LVCW1:L#.X]FBXI#C3<8E/+-Y3Z6EFX]R4.(<=-9
M+0K6C6K4COIH1 )OTOY!MLUN7D-GMN)WK;W/+A$US<5F/N.VOEL&A2N4TZTT
MXVX7IR)U/=)2B2JAT EKT%0
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M20LB<TJ[E5EI5K46DP1*_ 0
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MQNEWQJT72]V]5IO,R&P]<;8OBJ-)6V1NM5J=22JI%\0%77
M
M                                     !RKCC&-WBX0+O=[-!GW6U*Y
MEKG2HS+\B*LS)6IAQQ)J;.J2.J#+L ?FXXKC%WN<&]W:R0)]YMADJVW&5%9?
ME1E$K41LNK2:VSKQ[IEQ <2][2[7Y)<UWF_X=9[E=G#)3TR3!8<><,NPW%*1
M5?9\E4!+(L6+!C-0X3#<:&P@FV([*$MMMH25"2E*2(B(B["(!]@
M
M
M                                                  13<K!HFY.#
MWC")TMR#%O#;;3DIE*5N()MU#I&1*X'4T4 1N^[+6N^[*-;*NW20U:VH<& 5
MT2A!R#3;GV7TJT'W:J-DB/XX)Q0Z\]*MCDLXI<,9R:Y8SFN)V]FTQLE@$GF2
M8\=OEIYS54D:M)J35*BJD]*M14H,7?VRV!@8)EL_<+(,CN&8Y[/9.(J\7+2@
MFF#TEI;:2:J'I0E-34=$\$D1&8&*X00
M
M       X!81B*9][N:;+$*?DC"8E^?)I)*F,(2M!(>\BNZXHC\IEV]A4#WV.
MQ6;&K5&LF/P&+;:(:.7&AQ4)::0GXB4^4SXF?:9\3 >5&(XPW?YF4HM,5.0W
M"*FWSKB32><_%2K43;A_)%6G;VD1%V$0#ZXYC./XA:6+%C%MCVJT1Z\J)$;)
MMLC/M4=.U1^52N)^4!^"Q3&BR-S+BM<8LF>BG;WKH39%(<B&I*^4M7R1527;
M\;L ?[C>+XYA]L19L7M<:TVMM2EIBQ&TM(UK.JE'3M4?E4?$ /%<<5DB,Q.V
M1_=0B*J FZDV12/"K4E9MFHNTJI*E>SC3M,!_F.8KC>(0%6S%[5&M,!;JY#C
M$1I+25.NGJ4M6DN)GZ)^3AV$ [
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M6E)40U2I*(C2H]/?54G%HDN!$5:_%!
M
M
M
M                                            _*UH;0IQQ1(;01J6
MM1T222XF9F?81 .98,GQO*X:[CBUY@WNWM.G'<EVR2S,92\E*5FVI;*EI)1)
M6DS36M#+T0'ZON1X]BT(KGDUWA66W&M+)3+E):B,&ZLC-*.8\I*=1D1T*OD
M=!EYF2RW(CN)>CO)2XTZVHEH6A952I*BJ1D9'4C(!^P
M
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M)DO\E@?1X&!^7SL]]1,E_DL#Z/ P/R^=GOJ)DO\ )8'T>!@?E\[/?43)?Y+
M^CP,#\OG9[ZB9+_)8'T>!@DN =86V>XV86O"K':K['NMW6MJ,]-CPT1TJ;:6
MZ>M3<QQ1%1!]B#X@8-! @
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MQ[S[Y^\XSO'^)\)X+15EMK1HY[]?25KJ+XP(F5M @
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M"&MOQEUM]IM]E6IIU)+;5Z*5%4CX_$!5^P
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MQV>N$N/ @YQ9I$V4XAB-';FM*6XZZHDH0DB5Q-1F1$0)P3\$
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MQV22F2:E7%#;BDD\V@ZFLE)-M=6R,B)53X<03@O8$
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ME%O:2TERWD;9*Y3IMJ-2E+KK+61'II\<P[(
M       #Y+BQER&I:V4*ELI6VR^I)&XA#II-:4J,JD2C0G41=M"] !D'I$^&
M'>WVS/V?-!:4@QGI[Z9]Q<IS"]Q+M(S6Z2)CDF[-*N"TH@RYSSKJC0<-,<SU
M*)>GF*67=!&+*$\KM;L#W:V]M5PD7#",4R"))AN&>MHDHG2("7*E0B)\E-K.
MG U)(R(%F@=Y+I!D=$6$K;Y:2=C6&&T1'VOQF=+FFE.]ZBLU$?Q?C@B-:OMM
MX<G&.H_9IV]$O3/QFV+C(DF1:4R[0_&;)/ ^QSL*E=7 ^/$!/<VC.7GKML$*
MWN*;?CPFRDO,'WVM-MD.FI1F="[JD]E.!E3B8&\^_0/+9MUDW"ML\DQI=MEP
MWIIN&1+0CEOH,E%3@2#:5Y0)<SHAL-PO6W^ZD>&ZJ%YY2S;8,DJ\IF0<621J
M29=^J.>V9][T*<0)5!OMMCN3L5Y@\[9S)NWG_P 9R?"R);?+\#R-6K6OCJYY
M4IZ )A_4 %                '+R-U;%CG/-W9JQ+;:-17>0EM;,:AD>M:7
M5)0:?1U*+XX#H1Z^':U.D^K0FKQ$1$LZ>FHGAQ[> #Z                X
M\:0I62SHQWMA]"(S"BL"4M%(C&I2JOK42C<-+G DDI)$5#XG7@'8 >15TMB(
M_BUS6$Q-6CGFZ@F]9]B=5:5^( ]"G6DM&\I:29).LW#,B222*M:]E* /C#N-
MON*5+M\MF6A!FE:F'$NDE1&9&1FDSH=2 >D          <K)77&+%.>:N[-@
M6VWJ*\2DMN,1J&7?6EU2$&7D[RB =)JIM(JLG#TE5PJ$2N';P]$!^P
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MUN"R\O$ZQ*1D+<,BE=UHI/?II[[IH] N) )"
M               "*[F_!MF/M'<_8CH"@N@;X'KW]\LKV! !,O#U_?!MC/MX
M7L1\$POPL3M>=;30L1O1NIM5WLT.-*5'43;I(-EL^ZHTJ(CX>@"K#>[.T&*;
M-[\;:V+$5RUPI\JV37SG.I>7S?.?+[IH0W0J(+R L_HZ"H
M "+9U,LT.':57NUSKJR[=H345JVM.O+9E+<]2?=)E23)E!_NAJJFG:1@)2
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MVU3V2IED@D62:E>NB4J425T);:--%:^_3@DC!.+<9$1$1$5"+L(%0
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M*3-**KTIKP*M#(8K5W-^#;,?:.Y^Q'00SIT _!MDWMX?L1@%I:U!4
M        !%,;5:3RG+DP<9D6:>B1$*XWMZ*AAF[K.,1H=9=29F\323Y:C/TJ
MN "5@               BFY"K0C$)BK[B\C,K:3D;FX_$B-W!]XSD-DE26'3
M2E1-J,G%&9\"29^0!*P               88ZE]X=P(;T'&LWQ:3C$2)DJ;G
M9+M;YB5*N%EB&ZVMI:&G3[ZD.-K4?,IJ[II3V@M$-!;$Y5?LRFY;D%XVZ3@K
M%P>@RH<S21O75+K"CYKCQ)1S30DD44E.DM=*FHE B5"=4^[.X41AW#\OQB1C
M=H*_)EXSD%OF)-<VVP];:TK2T[P4MMTG/3II4DJ21]X$PT9LYN1GFY!W6ZY+
MA:\5QA;<5_&9+LA$AR8T\2S6I9D:?)RU)THIWC*I@B5#=6>Z>X]IL^0XC=\7
M>LN-S9D5.'Y9#F)2ZZ<8VW'4NI:<,_5")TT^E-*:$I)\5 F%R[';FYMN&I3T
M["WK!M\BW,*QZ]29"'WYJD&2*J(E5+6COE0E$5#JM7 $2J?JRW1W&L5DRC$K
MEBSMLQ"Y.0FL4S.',2A\Y#"V9+J7&VW#/U3ENH3Z11)XFE0)A9>P.Y^<9^W#
M;DX8]9]N8]G939\CE2$O/S9,=3;-5)U5(EIU*I15#2=5G4$2O4$
M                "JMK=CK5M=E6895 NLB?(S"1XJ3'?;0A#"C?>?H@T\3*
MKQEQ] $XH-E_2-:+IEMSR_ \PNV"3;WS/.T>U&?(=-\]3I)Y;C*DH6KO*;-2
MDU["(N &*:8/T[;=X1M]=]O&8[MRM^1),K_-F*2<J4HTT2>I!$2";[6B27=/
MCQ49F8Q5?;NA[&&+C#8N^97B[83;Y"Y4/&'M*&DFM6HTFLE&DM78XIMI"E>B
M0&*S=Y>GS%=X&+4^[+?Q_(K$1)L]XMQ));+9*)1-J1W:I29:D:5)-)\2/M(Q
M$O'LYTY6':>]7'+95YF93F=S0IEZ]7*A+2TM1*42$FIQ6I>E.M:EJ,R*A4*M
M1,HMGG1]C^495=LIQC*;EB"\A)SS_ @D2XTGGJ)3I42MHR2XKO+0HUI-7&A=
M@&*X=L=M<;VGQ&+AV,(7X)A2WI$E\TJ?DR7::W73222-1D1)*A<$D1>0$,H_
MWAO]G'U[_J\%H;?!4               !&\_7;6\-O"[OC[^56U,<SD8]$CI
MFOS$DHO4T,K,B6=>]3XG#B [D VC@Q38CG#9-ELVXBD$VIE.DJ-FA-22:2[M
M"[ 'H               !%("K2>X-Y0SC,B+>$V^&J3E:HJ$1IC2EN$F,B21
MZEJ:TU4CY&I?$J$K ?S[Z9=C\4W5VGR:]9HY,ELVV7+@V*(W*=98A2$Q&7W)
M*&D&25.*-QLCUZB,D$1D"TRX.+6?=+<;IEM\3'FI61V7&<KDM7/'6'G"?D6U
M$2(^TTDD*U*;0XZ[W$<2UDI)=W@2EFS%\V;M&\=A)K'LGVGR][1;FK$<ER5;
M)LB0K0EJ2J<A4BCBC)*4Z23J))ZDF500WL"H         C.X3EM:PR\.7?'7
M\LMJ62\1CL2,F:_+3K31"&%F1+,CHK]2H"0QC0<=DVVC8;-"=+)I))H*A42:
M2X%3LH ^H                                   *VW&V2Q7<[),6RF_
M3+A&N&(O^)MK<%UAMEQ9/-/4>)UEU1EJ:3Z52>%03B\.[_3[@V\KD&X7U4JV
MY!;"Y<.]6Q:&I)-$K63:]:%I4DE&:D\*I,STF53J,7VV>V$PC99F>O'#E3KQ
M=-)3[O<5H=DK0@S43:="$)0BIZC(DU4?IC.A4&* 91T5;59'D$V]Q9MUL46Y
M.\^?:+8\RB&M9KYBM"7&5F@C5Q)-32GY$B+@!BM>=M!M_<-N6]JG[2@L,892
MQ'AH4HG&C;5K)U#M343NLS6:ZU49G6M3!"LL#Z.ML\'R>!E*Y]UOTFT+2[:(
MET=95&8<;4:T+TM--FI2%=Y/$DZN.GT"<6A@0Q!T8?##NE_VGL]P%I;?!4
M             !&D/(//W6/<LM#A6E*O=F:(^A:?$'_$-9*Y]2,^=I,M':?;
M2H24               '*R4T-XY=E+M)WUM,.0I5D2EM9S2Y:C./I=[A\WTE
M%\#KQ ?2P+YEBMCGFT[-JB,*\T*)M*H=6TGX<R:,T$;7I.YW>'#@ Z)$1=A4
M_P#S@  1$785/_S@ !0BK0NWM          $:BO(/.[@R6++CN%;F%*R\T1R
M1*+F*I#UI5SCY=3711:2J?9PU!)0
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M4UMO$;!MMH]*I*]*JZC*H)E_00%0
M       &(-[?SUMNOK)[,?!:-3;X*@               .#E,:[RF[4FT9$C
M'5MW.*Y,6N.S*\;%2:N9!23YD2%/<")Q%5IIP(!W@                '!Q
MN-=H\B^*NF0HOS;UQ=<@,HCL1_-L8T(TPE&R9FXI'%1K<[QZNP!W@
M        <'*(MYE>9O,^0HQ[DW2*]/UQF97G"&C5S8"><I/+-ZI4=15:=/ @
M'>                                             17<WX-LQ]H[G[
M$= 9TZ ?@VR;V\/V(P"TM:@J                XMIC9.S>;X_>9\:38WW6
M#L$5ADVGHS26J/)>69F3AJ7WDF780#M                XN5QLHF6-]C#9
M\6V9 I31QYD^.J7'2A+B3<)3:%MF9F@E$7>[0':               !4M\Z>
M\(RC<&[Y]DRY-W=NUJ59DVN8YS(\1+J#:<<C5XMF:#,DD7!*E*47%7 G%T-E
M]M;[M1C\K$)V0G?\>C/$K'3>:-N5&CK35UIQ6I233S#,VTI+NEY>-"$O)D.P
M6&99N._N)DRY%V6_:G;.FRS%F["92^@V5NL$?%LS;4X6DN&I1K*BN(&*0;4[
M;P=J,-BX9;;G,ND**XZZT]/6E2D<Y6LT-I21$ALC.I)]$S/R@AQ\JV/Q3--R
M+3N)DCLBX^:8;T-FPRE<VVFMXM).DVK@DR2:]1=BCTGP-/$G%T-I=JK3M!CT
MG&;'<9LZV/3'YL=J<X3B8R7E5)IDB(J)(J5XGJ557EH \68[)XOG.X6.Y]D3
M\B;[G6G6V+"^KFVUQU?%#IM*X)4D^*J>GHBOI>(Q>K:?:6R[0VJYV2P3YDJU
MW">]/9B2W"6S$2ZH]+3"2*I)).DE&9F:C+4 L $
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MN%E/N0N$BX:,AN*;\<ER0YR+P1H\2PWX@BTMH[NE+7J9?(^4!,@
M    !&\RP##]P(<2#F%H8NL:#):FQ$OIJ;;S*R41DHJ'I532M/8M/!1&0"(9
M-AVTEOW5QC,[PE=NW(NSJH5FD17)393518R]3;R6*MF26C[7::B2E-3(M()3
M#-,"Q#<.UMV;,K2Q=K>R^W*9:?+BAYI524E14452[JJ'WDF:3J1F0(?E&W^&
MMYB>?HL\<LO\(BWINFGU1,=O41$DO2D=%:#61:C31-=)4 ?3-,%Q/<.R*Q[,
M;6S=;4IQ#Z&GB,E-O-UTN-K29*0HJF54GQ(S2=4F9&'R+;S"BRV-G166,650
MH:;;#N!(HIF*G41);27=2=%&C42=6GNUT\ 'WS/"<7W!L+^-9?;6KG9WS)9L
MNU)2'$5TN-K29*0LJG123(Z&9=AF \RMN,'5D]LS(['%+([+#\V6F:2-)QHA
M5(D-I*B2TDI24GIJE)F14(S 2@
M      !B#>W\];;KZR>S'P6C4V^"H               "'[@MXNXSCI918I-
M^:*^P#M:(L5R9X.XU7R9;I-_N;37>UN*[I$=#K4!,                 $0
MPA.-E-RM6/V*59GU7E_SR_*C+C)GSN6WKE,FLSYC:BTD2TT(S(^ "7@
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MN&W(=Q,W8GC$0TRU/&X4EHV:%"]6X.DBNG]7@ FH           (U?=Q-O\
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M!Z;?NOM;=IL>V6O-[!.N,M:68L.-=83S[KJSHE"&T.FI2C/L(B 2\
M                         !B#^\-_LX^O?]7@M#;X*@
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M2[0?[;<?L5/^8B/VV]P1[X3UX7..:N
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MQX*L:M;%UD.SHS4YN3(**EF"M?J[Z3-*M2FT\4H\O^(P[0
M  #BX[+R.7YU]T5K8MG(N,ABT^'D%)\3;4:>3)<HE/+6Y56IOCIIV@.T
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M5_M=S_D"_E@,%ZXQD5MR['K9E%F4M5JN\9N9#4ZGEK-IY)*3J2?8=#[ 0ZP
M                                  ,0;V_GK;=?63V8^"T:FWP5
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M<HY ;TW&.=[\Y$ZK5:2U>(3'Y79(/N\LU]SMJ [0
M                        "*[F_!MF/M'<_8CH#.G0#\&V3>WA^Q& 6EK4
M%0               '%M+^4N7F^-7J)#8L3+K!8](C.K<D/LJ9(WCD)41$@T
MN5).GR?X3#M                XF6/Y5&L4A["X<.?D1+9*-&N3RX\92#=0
M3IJ6VE2B,F]1IX=H#M@           I'=CI<V_WBRA&6Y-<KQ$N*(K4$FK:_
M%:8Y3*EK2='HKRM55G7O?J G%!OR!MGOJWDO\J@?0 &)^0-L]]6\E_E4#Z
MQ/R!MGOJWDO\J@?0 &+B6;H-PEV[7QN_7"\Q[*T^VG'GHL^&Y(>CFT1N*D)5
M;R)"B7P22?)_A,G%V_R!MGOJWDO\J@?0 (Q/R!MGOJWDO\J@?0 &)^0-L]]6
M\E_E4#Z  Q/R!MGOJWDO\J@?0 &)^0-L]]6\E_E4#Z  Q/R!MGOJWDO\J@?0
M &)^0-L]]6\E_E4#Z  Q/R!MGOJWDO\ *H'T !B[6(=%NUN%Y1:,MM=WO[UQ
MLLIJ=%:DR82V%.L*)2262(:%&FI<:*+XX&+1H(
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MR]=->CO4[ 'ZM/G3S7!\^>'\]^':\Y>"U^%\5H+F\GF=_EZZZ-7&G;Q >P
M             '$8]UWNJE>).V^XCP;?@2;)_P Z^<-9\WFF9\GDZ*:=/>KV
M\ '; 1+!]LL'VXL,O&,,M?FRQSGW)<J+XB3(UO/-(96K7(=<654-H*A*IP]$
M!'X_3ULY%PV1@#6+M'BDJ8=S<A.R);RTS5-H9-YM]UY3S:M#:4]QPN'QSJ3B
M\^"].&SNW-Y1D.,X\E%[9(RC393[\M;.HJ&;1/+4E"C(Z:B3J^*!BM4$
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M\H\J-+0;D5Y#[9'I-;2B6DE%QI5)GQX@/TZ\TPVIY]Q+32?3.+,DI+R<3/@
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M9EHW!',/7.RXL5N$B=+1?)"<A1)<D.%'N?+;-QEHGR(DH2DTF1-=SCV@JF0
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M=+IO*F7M%6XMM,RH%P1%E-Q2=84PHI/?TFXM1LN50G45>!$8(7."
M        $1Q55A/)<N*U9-*O5R*7'.[6B1+*2Q:7>01)9CM:2Y*7"+6I-3JJ
MOQ@$N                                             8@_O#?[./K
MW_5X+0V^"H               "-;@G9RPN\G?[])QBS^',I=_@R/!2HB#41:
MVGM*M"JT(NZ?;0!W8!LJ@Q51I!RXYLMFS*-9.&Z@TEI6:RX*U%QKY0'H
M           !$[>FR?A#O)L9++E7_P WQ/&8LY+)<*&QK7RY#<;26A;ID9+7
MJ.I$7 N%0E@               (QN'YF]Q=X]T%_E8M9S9(I5_@2? RHB36F
MBVG]*M"C.B?2G6M $BC:#CLFTX;S>A.ATSU&M-"HHS\M>VH#Z@ "C.KWX"KY
M\\V_V6V.KLOU$>WF8[FI>8Y3(
M     Q!T8?##NE_VGL]P%I;?!4               !#&UX=^%9YM%TD'GI6%
M*G;,;\@XI6HY="D$R?J.OF]S67?I\0^(3,               '$S)5E1B-]5
MDDIR#CQ0)7G6:RMQIUF)RE<UQ"VN^E24U,C3Q] !],45:5XO9%6&2Y-L:H$4
M[9,>6XZZ]$-E')<6MWOJ4I%%&I?>,^WB ZX               (9"7AQ[H71
M$:Z2%YR5HC^.M"GY!QF[?SE<MY+*O424:S,C4GO?X3J$S
M                        !%=S?@VS'VCN?L1T!F[HKM7GWI\S*R<"\Y7B
MYPZJKI_C%KA-\:<:=X%I5_TY;HXKMOL[N=A69SV[3D<-^>_'M,KU.2^^_"3$
M-EI)\5.$XP2%)^1K4^ $K Z1]LFLCZ>,ALV4)?9LN9W&0;?(/E.JAM-LL:T*
M4E1%5QI9>E/L E3N[.T&*;-[\;:V+$5RUPI\JV37SG.I>7S?.?+[IH0W0J(+
MR /Z.@J                C6:NH9B6LW,85E)*ND)*8R6V'/!J-SA.H_P "
MY!][4GO%Y $E      &0^KB[;GV YL*%D-KEX?FD=FQ6["%M.KNSKZJ$I^.3
M;9F:B<5Q5S$HIH2:5*H"T.KTH7_=+,(5KND^_6;\'F/6TL<+%(2'4W&-)AH:
M;:=D\QHCYAI:(Z\XTF2E421@B7FZN+UN9C,>:Y;LCM2L,RJ![G6,+?:<7<I+
M[Y*2X_&)M!F;B>:7>YB4$1))1*,R(R8?GI.O>ZN4Q[2J5?+/'P#$8JL?G8E'
M0\BZM26&B;;=DDXU4EJ4C5P>T'51$DC*A"7NZM;]N1B-OEW2UY+:6L)OUL<Q
MQ[#YC;BITYZ:EQIYV-RT*4;B4.EQ)Q"4DDM6HS(C(AQ>DZ[[LY"5IM[MZM$#
M!<'2_9;UAZ&WF[RF03:TMNR"<:.AFZ6HM+I)X*3IU%P)E)NJ_(-QL+MB\ELF
M36B'A<RW.66;BUQ;<5*N$B9S$.*CFVA2C6EM2:46@DDDS49EP!$(9TFW7=N]
M+M./(O%HM6%X"Y)MN08>MIYN]J=>)XR<?)QHZ>K+4:=+J4U0:334@3+4V'N(
M<*_&C&#QG3>)B3JAAOSD:301W'U#M)_]DYWST\?("J2@               C
M61O(;ON,(5BR[ZIR4\2+NE$=96@R95ZN:GE$M.LC-NK7'M+T",)*
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ME49@B6>]YI,>5UI[=.Q7D/-ULI:VU$M-2F/<*D9@F-3<8*@
M  .)DDO(8B+9[GK0S=UO7&,S<DR)*8A18"S/G2DFI"^8INA4;*AJ]$!VP
M             '$Q^7D,I^\)OMI9M;#$]QJTN,R$R%3(24IT2'$I2GEJ4=2T
M&9F5 ';               !P\DEY#$\T>Y^SLWCGW.,Q=.?(3%\);UZN=+1J
M2KF+;HFC94-5>T!W                                 '.FW^PVY\HU
MPND2))5Z5F1(::6=:=B5J(_*0#W-.M/-I=96EQI952M!DI)E\0R ?L
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M-J>?<2TTGTSBS)*2\G$SX /# O\ 8KHLV[9<XDUPNU$9]MY1>7L0H_0 =$
M            8@_O#?[./KW_ %>"T-O@J                XF8/2(^,71Z
M+8?=/(2PK18#4R@IE3(N6:G_ %,B,N)Z@'5BFI45A2V/#+-M!JC52?*/2545
M09I/3V=W@ ^P               ([#D2U9I<XZ\:*+#1"C&WE6M@SF*U+_BV
ME/JI$S4U%J[O>.GQ0D0               .%F;TF/B]S>AX^64R$M=S'S6RV
M4NJB(VS5((VRX=[O%Y ':9-2FFU+;Y2S21J:J1Z3,N*:EPX?$ ?L  49U>_
M5?/GFW^RVQU=E^HCV\S'<U+S'*9                       1J\;B[?8[(
M5$R#++-:I23TJ8GW&+&<)7'@:77$G7@8#HV;)<<R)M3N/WB%=FDE52X$EJ4D
MB/T3:4H!U              !B#HP^&'=+_M/9[@+2V^"H
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MDGCP,SJ!C#U_DV]87XW?_<=^^A@,8/R;>L+\;O\ [COWT,!C!^3;UA?C=_\
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M*,B.C)N'V^0!EC\)/75[T?M:S\T!;0?A)ZZO>C]K6?F@&@_"3UU>]'[6L_-
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MU]F8'S8# _#/L]^,'&OLS ^; 8'X9]GOQ@XU]F8'S8# _#/L]^,'&OLS ^;
M8'X9]GOQ@XU]F8'S8# _#/L]^,'&OLS ^; 8'X9]GOQ@XU]F8'S8# _#/L]^
M,'&OLS ^; 8'X9]GOQ@XU]F8'S8#!Q,MW1V[O=B?MV-[OX[C=W<6RMF[M7&U
MS%-I;=2M:>4\]H5K02D<>RM02[?X9]GOQ@XU]F8'S8$8'X9]GOQ@XU]F8'S8
M# _#/L]^,'&OLS ^; 8'X9]GOQ@XU]F8'S8# _#/L]^,'&OLS ^; 8'X9]GO
MQ@XU]F8'S8# _#/L]^,'&OLS ^; 8'X9]GOQ@XU]F8'S8# _#/L]^,'&OLS
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M%U\;P+JAV;N4-%GR6/N3@O/;:F6VXJ6W/:C*625.,\]:E)T),S)")"R_R#X
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M<54+AQ^( _8  HSJ]^ J^?/-O]EMCJ[+]1'MYF.YJ7F.4R
M       #.&X^V._^[>57.UR,M9P?:V.\;,!BVFMR?.9TE5Q\F5HJ2CKW5O)(
MN'J?E!+C6OH*VFBLD5SO%\GR:46M+\:.U7T4H3'4HOU5F!B\UPZ%,4A/IN6
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M>JG$$2O+'DH18+4ANYG>FTPXY(O*E(<5-232:2#4U1"C=]/5'=.O#@"'2
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MFM1MD?)@=B:T+M!;>:]!4       !%=S?@VS'VCN?L1T!G3H!^#;)O;P_8C
M+2UJ"H          *1W8Z7-O]XLH1EN37*\1+BB*U!)JVOQ6F.4RI:TG1Z*\
MK559U[WZ@)Q0;\@;9[ZMY+_*H'T !B?D#;/?5O)?Y5 ^@ ,3\@;9[ZMY+_*H
M'T !BXMIZ*=FKM>;Y9DR<TB+L;K#*YLQ4%F)+\0T3Q*B.>"/FI170LZ%17 $
MXNU^0-L]]6\E_E4#Z !&)^0-L]]6\E_E4#Z  Q/R!MGOJWDO\J@?0 &)^0-L
M]]6\E_E4#Z  Q/R!MGOJWDO\J@?0 &)^0-L]]6\E_E4#Z  Q/R!MGOJWDO\
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M7&U&E15NL0CH9<>P$P[?3BZZ]L=@[KRU..KMJ#4M9FI1GK7VF8$K1!
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MB3+R4[* /J  *,ZO?@*OGSS;_9;8ZNR_41[>9CN:EYCE,@
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MEPTDW;GI;+<I1K]*1-*62SKY. #L ,0=6'YR.U'UK_I=0+0V^"H
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MS_07\N!B[&,[+;5X9>&;_B^*PK7>8Z5H9F1TJ)Q*74FA9%51]J3,@,4\!
M.)>4Y:JZ6,\?<MZ+*F0X>1IFI>5)5%Y1\LHAMGI)?,IJYG"G^ P[8
M                       I#J'_ "B?_P 7/P!__KWNA^E7_P"K^%^F?_;?
MN7_Q?(@F%'__ )1+_E[E 3H1+/\ ;+K;W1ML6T9W:_.MNAO^+C,^(QV+I>T*
M;U:HSK2C[JC*AG0#0_H%;&7(]MAQWDZ7FF&FW$U(Z*2@B,JEP[05>H
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M\=,KQ=O1JYT1&I2>6MRJ:.%4TT[ '<
M !CS,]P.LV%F&0P\6Q?Q&,Q[G,:LLCP#3G,@-R%ICKU&X1JU-DDZ^4%M#A_A
M)ZZO>C]K6?F@&AT.G;#]YG-_[ON3N?CDBUN7:UR&Y,U32&6#?K&0A*4I4JAF
MEK_$!+9X*@       (KN;\&V8^T=S]B.@,Z= /P;9-[>'[$8!:6M05
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MDSR=U').5XNII-ON<O13RU!.#M?EU;*?[/?/Y$S]$ C _+JV4_V>^?R)GZ(
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MB'D2<KF3GKPR[C"X;+<6QIC)2^S+):C6^J1K,U)6DM)(TTX?$XAVP
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M2I;J1RK&,LZB-K9N+7N!?(;"[6R](MDIF8TAWSJI6A2F5+(E4,CH8)AO4%0
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M)EE7=>HE25$:="B46D^!$M+[F_!MF/M'<_8CH*LZ= /P;9-[>'[$8!:6M05
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M1I;)E9HXL*-9=_3Z4#0U<"H             Q!T8?##NE_VGL]P%I;?!4
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MWAQ;HW9R+;)+><JM$4I]V4Q)3%<MY/+Y32'5>H&M*ZF9)[WQ])T"9@
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MV^BV-?G2U>/?C\WD(>7)]10VI*M;9DGBKCV B'AZ ?@VR;V\/V(P"9:U!4
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M1'0JE4!^P !1G5[\!5\^>;?[+;'5V7ZB/;S,=S4O,<ID
M     '.R"1:XMANDJ]I)=E8AR';BA1:DG%0TI3I&7E(T$? !_/39[?+>;$+;
M<+'M+@LK)-ODSI+]JBR($VYR(3;J]7*.3!)M*O3$I6I!\3X4!:87SMAOMU"Y
M7GEFQ_,-KG[%C<YQQ$^[+M=UC)80EE:TF;CY\M-5)2GO>B",&HP0
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MR8*H=K\?D[N+(*ZPC9DLOLQCF/$YW()F\2B4E\^Z:$]Y7^$!)@
M      $8PQ$!'N@\!D[N3:KU,5)YTAF3YM?/1KMR.21<M+'D;75:=7$P$G
M        %9;I?=)MW[>(_62.-M#S+/?=W9GE7^XLT=EP@  1;)D0%9#BJY>4
MNV*2B6]X.SMR&647=9LF2F'&W2-3I(+OD2.)'Q] !*0
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M?+?=)3!5?8A2V9+C9=E5):6HR_5 =@!B#HP^&'=+_M/9[@+2V^"H
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M0)Q7MT\;+YAM#[H_=9E/NE\\^!\'WI"N1X3Q&O\ =U*]/SD^E_8@B97>"
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MQ[*>LG;NYXS=X5ZMQ+LS)S+;):EL$ZB6Z:D<QE2DZB(RJ5?*"=YO(%0
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M(ODN[P 6("        $5W-^#;,?:.Y^Q'0&=.@'X-LF]O#]B, M+6H*@
M           (Y8727D63-EC)V<VWXVJ]FEA)7<U,%ZJ1M'K5RBHUZKQ\A )&
M               "-9ZZAG%Y2W,77F*.9'K8&T1W3>]711>F49-GRC]4X]FF
MOQ0$E           !7>"_=_N+\]V_P!BF.3D_47N6GF=K.^FL<E7.L0=9Q0
M 1K'74+OV3MIQ=5C-N4SKO"D1T%=U&PGU<C9,UJY9$3=7>/D]$B"2@
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MGSR8&"P<"ZG]G-Q;C#LEDO+L:_SU<N+:I\9YAY:S*NDEDE;1G\0G ,%P@@
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M Z*7F9.[>YTB.XEZ.\E;C3K:B6A:%SEFE25%4C(R.I&0+2W$"H
M     #@HE7D\S<A*QY";"5M2ZC*O$LFXN5SS+P7AM/-(B2?-YFK1Y*5 =X
M             '.OSLUBQW)ZW6U-YN#<5Y46T+=0PF6Z39FA@W'2-""</N:E
M%0J\0'TL[LM^T0'I\$K7.<C,KE6Q+B'DQ75-D:V2<;(DK)LZHU)*ATJ0#V@
M       (AD6(7V\W)4Z!EMPL\<T)04**ELVR-/:JJBK4QH7\M<N58TW*J8X(
M=++YNW;HZM5JFN>&<4$8L68NY]*P\\ZNA1H]L;N12=+6LUN/<K294I2G$<N+
M-Z<Q-KQ:L(IQWN%UJK]B,M%WP:<9JZN&G@Q3_&<4O5BGN2[EE,Z]L+94TF)+
M2VEM*S4E1.%H*M2))E^J.K8R]=NK&JY->C5+CYG-6[M.%-NFB<=<)6-YSP!P
M8\J\JS";#=QY#%B1!9<8R@I+*G)$CF*)44XY)YJ2;(]9+4K2>K@ [P
M                      #X38<6XPY%OG,ID09;2V)+#A:D.-.I-"T*+RD9
M&9& H3)NC39.^N'*M,*;C%PKK1(L\M:2)PN)&3<GGH27Q$$G]3M!.*/_ (!.
MH;"5<S;+>)^=%1^Y6S)FUOM)07R!*<*8FA_Y+2/^<#%9FT%TWWD2KM;=YK/;
M(C41#!VB[6E:33+4HUDZ2TD\NAIHD_W-';V +6!       .?+OMD@2D09URB
MQIKM.7&>?;;=5J.A:4*41G4^S@ Z #$'5A^<CM1]:_Z74"T-O@J
M       X641+[,C6]%@OC=B?;N$1V8\[';E%)AH<J]%23AD25/%W26GO)\@#
MN@                .%C,2^Q//'GV^-WOGW.2_;>5';C>"@+T\J&KEF?,4U
M0ZN*[RJ\0'=          %9;I?=)MW[>(_62.-M#S+/?=W9GE7^XLT=EP@
M<*]P[_)NUA?M-\;M=NC27%W>W+C-R%7%DV5$EI#BU$IHT*[^I!&9T]#M#N@
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M(R[4F1^6@*IF       "*[F_!MF/M'<_8CH#.G0#\&V3>WA^Q& 6EK4%0
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M2/F&R\9(65.%%< '3BI=1&90^\4A]*$DZ^2203BR(JJTE4BJ?&@#Z@
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M2AD",6=^ARWLVG<_<6UQU*5'@L%&:4X9&LT,S%H2:C(B*M"XT($RW2"H
M           "-HC.>[UV7[IE+:.TI:+#ZL:4*\09^/H7JW']RX]W]7L"2
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MCT]B.Z\U!D^'4:W'EMF26TJ06DC61\?C5()F
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M8Y,^(4&4^F1((S-<A+D5EQ)\T^\>LR54Z=A5!,PA^U.[%I/>/>'="PVV2SM
MFT+N%TMS;*22]);-AII?+,R03TA92'")1EW5KU=@"R^A2#,9VKO=R=95&MUT
MO\E^W,&9FCE(88:4I'D,M23;K3M0"):A!       (KN;\&V8^T=S]B.@,Z=
M/P;9-[>'[$8!:6M05                1#%TXL66YFJRV:1;[Z<F&607%Z.
MZRS.>**1LK9<6>EPD-GI4:"*A]O;4PEX               (;NFG%5X5-3FM
MDDY#CO-B^(M4&,[,?<7XEOE*2TR9*,D+TJ50^PO+V )D           "N\%^
M[_<7Y[M_L4QR<GZB]RT\SM9WTUCDJYUB#K.*  "&X@G%"RC,SL-DDVR\'-C^
M?[@_&=89GR/#EH<86L]+B4I[JC01%J^/4PF0
M   ,;[UYK#VZZK,4RS<6(]*P:-:--F=2WSVXKZS<2X^AOL-QMPTFNG?))I47
M8D@6C4\_4OU([)YWM9<<5QF:K(K]-=85;U>"DQDPW674K-_F2V6C(]!+07+J
M9ZJ'W3,"(17<R_WG)Y/3UMW=(<IW<UA%KN<^X.ITNMM376T-H49F2^826.:^
M:J::$=3/5I#?0*@           ,0?WAO]G'U[_J\%H;?!4
M !%MR$X\O!KVG++3(ON.^',[A:83+DF3(;)23TMMM&E1F1T/@94I6I4 2"W%
M'*WQ"B-&Q$)EOD,*2;:FV]):4FD^*3(N%#[ 'I               !#[>G%O
MPE7I<2S26<N\V0_.-\5'=1$D1#<<Y+*'C/0M:#(S41%6E.)TH03
M  0S=KX.,C^=%?MDCG;2]-7R.GLOU5OE2+'_ *0VOYTC^M)&W9\NGDAI7_,J
MY9YW1&9A $3W,+&SP2]^Z^TR+[C?(([A:83+DF0^V3B3(FVVC2HS)5%<%%2E
M:\ $GBDV49DF4&TR2$DVTHC2I*:%1)D?$C(O( ^H  HSJ]^ J^?/-O\ 9;8Z
MNR_41[>9CN:EYCE,@                     Y63M79_&KRQ85\N^.P92+8
MY73IEJ943)U\E%TX@,6],_49MEM9@LC"<[:E6/)(<^4[.DE$<?.4XXOM=-I)
MN$ZW3EJ)Q/8DN/D(M,%AW5M^XO5E$S[;N))BXI:K')1E$PV^2<R)#CR'%OOH
M3QH:U,--Z^-4([/(-Y+^C>8YE>9[N[C0H*[;CN07-A<&.HBT\Q;LJ0I)FFB3
M6VEU&JG[,"6N 5 'DNEKMM[MTJT7B(U.M<UM3,N'(03C3K:RH:5)41D9& K;
M'>FW9#%+VUD5CP^,S=V%\V.\\]*EH:<(ZDMMJ2\XVE23XI-*",O("<4FSS:_
M =SH;$#.K&Q>&8JC5%6LW&7VC5343;S"FW$DJA:B2NAT*O8"'[P3;3!=LK>]
M:\&LC%GB25DY)-LW'7GE)(R3S'GE+<7IJ>DE+.E3IVF C.3=.6RF7W]W)\@Q
M&-(O<A?-DR&GI,5+SIGJ-;K4=UMM:E'Q4I:#-7EJ"<4]D8UCTNP'BLFU1',:
M-A,/S0IELX?AT$1);)JFDDI(BTD1</("$&P_I[V;P*]IR/%<4CP[VW7DRW7I
M,M31JJ1FT4IUU+9T,RJ@B.G#L!.*S00Q!T8?##NE_P!I[/<!:6WP5
M         1)M=J_"6\VG%7T7KS*E:\T\*V49<8Y5"M_BJZS<)1<[E4I3CZ "
M6@               X^6*B)Q>\JGVER_P4PI!R+(PTF0[-;)I6J.AI9DE:G"
M[A)/MJ ^F-G&5CMH5"MJ[+#.%&./9W6TL.0VN4G3'4V@S2A31=PTI.A4H0#J
M          "NX?PW7+[W6/99CDT^NJ[D<[M5_P#KZ?\ DG^E8@ZSB@  B<-5
MI/<:YH:Q9^/>2M<=3^8*BMHCRF3=628B9)'K6MLRUJ09<"I\0!+
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M.L0=9Q0  <6S^ZWSM>_/YV[S'SFO<YX$G_%^'Y9<WQG-[FOF5T\KAI[>(#M
M                           I'J0SW93%<?BVO=RV)R%<XUNVRQLLD[,/
M1W5/(6:V^215TFOF),_D=5#($PS1MSN]TA6/)HLP]LI5B=2M!LW:8\[>F8ZR
M.I.*:??=-.D^.IMM2O0($X2W!;\:PBY7MG<>W6^%+OLZ(VB+D+:4NNKAK15'
M*=XT2I*NU/:0*I*             Q!_>&_V<?7O^KP6AM\%0
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M8PZ-IRC&;^XXS8KS!NCK*26\W"E,R5(29T(U$TI1D5?1%*K==/:B8,76&-(
M          #_ !2DI2:E&1)(JF9\"(B 8%WDZ@.G.]Y9*=8VN8S24TLVI.0*
ME'9DRE([NM*H[;BWD\*)6Z1'3LX4!:(6OTW[R;(9JS)VXQ[$(^&72XL.<^RJ
M)N0Q<6B;,G4^)TI6\I*-54NI(]-:5(CH1,-*62Q67&K8Q9L>M\>UVF,1DQ"A
MM(8914ZG1""(JF9U,_*?$$.@             Q!T8?##NE_VGL]P%I;?!4
M             !Q4QLG+*US%3XIX:< FF[84=132N/.U&\;^O2;?+[NC1V\:
M^B':               !X;TU=7[1/9L4AJ)>G([J+=*DMF\RU)4@R;6X@C2:
MDI50S*H#]6ENY,VN"S>7VY5W;CM(N$IALV679*4$3JT-F:C2E2JFE.HZ%PJ
M]@          KN'\-UR^]UCV68Y-/KJNY'.[5?\ Z^G_ ))_I6(.LXH  .*Q
M&RA.4RY<B?%7B"X;3<.VHCJ3,;FDLS<<6^:S2I!IH1)T?K=X.T         X
MV66%W)\>G6%FZS;([-2E";I:W3CS6-*TKJTX7I3/3I/XAF,MJOJ515A$X;TZ
MD3&+.^Z&T&1X+M_D&76[=G-Y,VT1526&)%X=Y2U$HBHK1I.G'R&.QELU3<N4
MTS;HT\3'53A&N7>L>P=[NEDMMS>W=SI#LV*Q)<0B\.:24\VE9D5:G0C,8:\[
M335,>'1HGY4Q1QROBUPE6VV0K<N2],7$8:CJF25<Q]XVD$@W'%?)+534H_*8
MY54XS,LCUBH              "F^IW=6[;1;7O7^P)25_N4QFTVV0XDG$,.O
MMNNJ=-"JDHTMLKTD?#52I&7 $PSS!Z=^K/(+>SE,_<=ZWWR4@I2+:_=[BV^T
MHRU);5R$&TVHOV*#-*03C"V^E7='/<K/+-O=S*OY9A,AN,[/7IYKB%J=:4VZ
M:.ZM3:V3HX7ITJ^)4R):/!       *;R'I7V+R>^/Y#<\72FX2G3?EE%E2HK
M+KBCU*4IIEU*"-1^FT$FO;V@G%:EDL=GQJTQ+%8(3-NL\%!-1(49!-M-H(Z\
M"+RF9F9GVF?$^((8PZL/SD=J/K7_ $NH%H;?!4               !#MQ7,2
M;M]F/+[G)M<15ZMR+<N(Z^RIZY*=I&86<<C-2%J],E7<\JC*E0$Q
M         0[;Y>)++*"Q*Y2+D2<AN";V4IU][PUW(T>)CM<\BT-H/3I0WW"K
MW0$Q       !2VXGPK6GVD<]D*'C-N^=3W>E[+8WIJN_T/\ 1Y]U   1[.?N
M2NO[S_UB%:M3-9[<+PQ#[D[#[71/6$#Z;EO*H[L<SY[F_.K[U7.XN8.8<C*,
M+3D5SDPKXN=(+&HC#\EIJ5*\.KF(>0SW%I)'$N;PKP\ID>PU4S
M                     !B.U9EMGLSU3Y]=,WG,26;W5ZW7MIM<I=LDO+UO
MQG6VTK<;4==.M"3[I%Y%*H6WGEZJMZ]G=T\=L^&XM<6+C?#N3#IY"]'?8BVV
M/I4ETU.K:)Q1*)1:D-(47"OIDI("(:3V[WIVCR1ZTX-B65LWF]-14LL,I8DM
M+=3#9[Z_5&TI+NH-7I@1@M,$            ,0;V_GK;=?63V8^"T:FWP5
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MGY)1'Y/*!I:;!            #$&]OYZVW7UD]F/@M&IM\%0
M   '$R5_*V&[8>)PX<QQRXQF[NF>\M@F[8HS\0XR:$JU.I[NA*N';\8P[8
M              #BV!_*7W[P620XD6,U/<;L:HCJW5O6XD(-#CY*(B0X:C55
M)</^<.T          *SWH_U#$/OHMO[5X<;:O9M_\E/2[NQ^U=_XZNA9@[+A
M   XN1/Y2QYI]R\2'+YEQCMWKQSJVN5:U:O$.LZ"/4\GNZ$*X'QJ8#M
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M>%:^/I!+0.\=AM\3HCP<D,,DJ,Q9+@P:2).E^>T:W5)_RE<]>KT:F8(C6@V
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MLE)25*]I .G&6^Y'9<DM$Q)6A*GF25S"0LR(U))5"U4/A6G$!]0
M      <2-,OZ\JGPI%F:8QQN)'7#OI24*>D2#4OF,J8).I*6R,C)1JH=3I\0
M.V          (9NU\'&1_.BOVR1SMI>FKY'3V7ZJWRI%C_TAM?SI']:2-NSY
M=/)#2O\ F5<L\[HC,P@#C99)O</'+A(QRT-7Z]H:_B=H??1%:D+-1$:5.N$I
M*2H9GQ+C2@#K-*<4TA3J";=-)&M!'J)*C+B5:%6GH@/V  *,ZO?@*OGSS;_9
M;8ZNR_41[>9CN:EYCE,@     IC"/SC-U/:['_8ZQTKWIK?+4I':E<XYJX
M           K-W>;:2\7Z^;;W7((]OOT5;MMGVZX*.$;G,1I/DNN:4+U$K@2
M%ZOB$"<$,1T:]/KB$N-V*0MM9$I"TW*8:32?$C(R=XD8&+RW/I)Z:[)$7<+S
M;SMT!HJN2IEVDQV4E\5;CR4E_A Q=?8%O86SW/)\;V3D'+4R461?'VWI$J,:
MJNH9)MY\S2JG?KRZI^*!*\@0            Q!T8?##NE_VGL]P%I;?!4
M            !Q4NY7[K%LJCP2PGS>2FY1.NG<CN?.H:#;TDV3/*XUU:M7Q
M':               !X;RJ[HM$]=@;CO7U,=T[8U,4MN,J42#Y1.J;(U$@U4
MU:2K0!^K2JYKM<%=[;9:O*H[1W%J*I2XZ)1H+FI:4LB4:"74DFHJT >P
M      5W#^&ZY?>ZQ[+,<FGUU7<CG=JO_P!?3_R3_2L0=9Q0  <5EW*SRF4S
M(CP4X84-M4.4AUT[@J>:SYB7&S239-Z*:3)1G7X_ .T          *RZA_@3
MS7VN7^W2-[(>?1RJ5ZDSP_[DK#[70_6$#6N]N>65HU.T,20
M >&]Q[E+LUQBV>24*[OQ7FH$Q226EF2MM26G#29&1DE1DJE &59W45OGLVZ=
MOWKP%-XMK2B;;RNQJ4S&=34^^:M#C1J5Y$'R%4[4@M@]J.OK:0VB-RPY&E^G
M%"8\%2-7H:CFD=/_ (01@\4?JVW#W(?.U;([92KA*4K1YUNBS5$9KV&\37+:
M1\=<DOU03@TAMW$S:%AULC[C3H]RS.CSETE0T);CZG7W'&VT$E#94:;4ANNG
MCIKQ[052@    !^5K0VA3CBB0V@C4M:CHDDEQ,S,^PB >/SU9_JA&_AF_E@'
MHCRHLM)KBOMOH2=%*:6E9$?H&:3,!B;JP_.1VH^M?]+J!:&WP5
M      1C-VXCL.U%+RA>*I3=82FY+;[,8YCB7*I@F;_!12/2Z$]Y7DKV ).
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M\%+*%YRG=_E6]ZJ5<UE_CK9X:]/;P 2P
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M1D&4J;RI5]=7*8-VS*=CK*SF3!48)+)$M',+U2CO$^WT3,).
M              .-E&)XUFMG>L&5VN/=K0_^Z192"6DE%V*2?:A1?(K29*+R
M& S'D'0[:XUP7==KLUN6).K/5X5S7)2FAD9)0\TZPZDB[2U\P_B@MBX[71SN
MS<U>%R7>"8NV&=5MH5.EF? RIH>DMIXD=*U Q6]M=TJ;4[826;NQ#<OV2,&2
MVKK=S2\;+A?),LI2EM!UXI4:5+3Y% C%=X( &3NE;'<@L^[&\<V[VJ9 ASKB
M:X4B5'=8:?3XZ8JK2G$D2RHHC[OH@M*!8W/S?I-W&S^$K"[ADF-Y.LG\?FP4
MN+:7X=QYR*2W$MK[$R%(>3Z8C*I$HJ&8UOKM]TUYG=>G7.$W:$N#G.6R8MUM
M=LDD;#NBU+4XTEU"J:%O<U]*4J(J529T\@Q16]9/NAN%M/C'3G"V]NL;)K5)
M8BW">^RXW'Y$$U(:U:FTDV1:D<Q:U:2T^75P"=;J[7Y3LOG.VFZF(V:1DUFQ
M.UP+1?&(:5N/:X#2HRW3225FA+S3G=5I,DK+C2I .AM3:<LWHZD7=\[MC<S&
M\0LL8V;8U<4*;<>>3&.*A!&I*-9D:W'5&DC2FA)J8"(X;<\]Z2\FSW%_<5<<
M@M=]4ES%KE"0MQA2HYNE'4I:6UDHC0\GFI],E2:4.M0-:Z.CG:B][=[=3YN5
MPEP;UD\E,E=MD)-+K4-E'+92\A7I5J-3BS2?$B41'QJ1$2JC^\%A0X?X.O"1
MVF-?GK7RD)16GF^E=)%6E03#<P*@               (_G"&G,2NR'\B/$V3
M8/7D:7&63A%4O5-;_J:?0JKT>!D?$!V81$F''2F0<M)-((I2C2:G2TEZH9H(
MDF:NWNE3T 'W               !&H33"<YNKJ<G7*D*@127B9NL*3#22W*2
MB;27-3SO2U5P/2=/B!)0         !#-VO@XR/YT5^V2.=M+TU?(Z>R_56^5
M(L?^D-K^=(_K21MV?+IY(:5_S*N6>=T1F80!'<[;9=Q&[-R,C5B+)L]_)$.L
ML'#(E)/F<Q_U-)'Z4]7H^0P'>8IR&J.<XM":/<#U\/3=WAQ[> ",YKN3A&W3
M4-[-+NW:6K@IQ$-3J'7.8IHDFLBY2%TIJ+M&Q9R]R[CU(QP1,Q&M#_RF]BO?
ME&_@)?S$;'[=F/EYE>O"I>I/?#:O-MH[MCV+Y(S<;S(?AK9B-M2$*4EJ2A:S
MJXTE/!)&?:.AL_)WK=Z*JJ<(TJ5U1,+:_*;V*]^4;^ E_,1S_P!NS'R\R_7@
M_*;V*]^4;^ E_,0_;LQ\O,=>%B8SD]BS*QQ<DQF8FX62;S/"RT)6A*^2XIE=
M"<2E7!:%)XEY!IW+=5NKJU1A,+1.+K#&D 4QA'YQFZGM=C_L=8Z5[TUOEJ4C
MM2N<<U<             5IN?L)MENVCFY7:=-X))(:O<%11IZ"(J$1N$1I<(
MB[$NI61>0@3BH"1T,7NVK4WA^Z$ZWVY1GIB.QG$FDJF956Q*;2H^/_RR!.+H
MV'H3L3DU$_</-;EDKB:&IAA'A"/T4J==<DK-/^;H,#%IC#<$Q#;ZT)L6&VB/
M:+:1DI;<=/?<614UNN*,UN*IPU+49@JD(            #$'1A\,.Z7_ &GL
M]P%I;?!4               !#VSQX]T'R1DTI64>8T$YB'C*P40BE5*=X33P
M>-9\HW=7I:%3C4!,                <7+_ #<>*7OSO='K):O R?&WB*]X
M:1#8Y2M;[;M%:%ME5254.AEV /KC'@/<U9O-=Q<N]L\#%\%=GW?$/2V.2GEO
MK=H7,4XFBU+IWC.H#J@         "NX?PW7+[W6/99CDT^NJ[D<[M5_^OI_Y
M)_I6(.LXH  (?#/'CW+N9,9-*?R7S5'*5B:IFN%'C$ZHT2D1=/<<69Z5+U=E
M.''B$P          %9=0_P ">:^UR_VZ1O9#SZ.52O4F>'_<E8?:Z'ZP@:UW
MMSRRM&IVAB2                _Q24K2I"TDI"B,E),JD9'VD9 (Z[M]@3\
MCQCV+6AR74E<]=OBJ<U%V'J-NM2 =]AAB*TB/&:0RPV5&VFTDA"2] B*A$ ^
M@      Y63V"'E>-WG%KBMUJWWN#)MDMR.:4O)9F,J96ILUI6DE$E9Z3-)E7
MR& PSO\ =-&S.S6$'>HMSR*?D]R>*!CUM<E0E(=E+*IJ6EN"2S;;+BHDF1F>
ME-2-1&"T2TAT[;8L;&;6)9R2<B/<K@HKOD#LEQ#4:(\ZVA!,DI5"(FTI2E2C
M5Q74RX4($2SUU,W^PY#U%[5R;!=(EUC-+M;;KT&0U)0E?G91Z5*:4HB.AD=
M3#> *@               (UFKL9J';/$XPO*4+ND)"8K;+#_ (19N]V<9/F1
M)*.??U)[R?)3M()*           "H=DOI[NI]]\WUIL8;>NKE:.6[5?>6\,S
M>  !&<-=CN%?RCXPO&.7>9J'26RPSYR<(TFJXIY/IRD5].YWSIQ 28
M %+;B?"M:?:1SV0H>,V[YU/=Z7LMC>FJ[_0_T>?=0  $>SG[DKK^\_\ 6(5J
MU,UGMPO#$/N3L/M=$]80/IN6\JCNQS/GN;\ZOO5<[P9*XPC(,60[BJKZXN4\
M3-Y2U'<*SJ)D_5S4Z>M',+U.K7'T?(1[#52@
M       ',N^1X]CZ$.7Z[0[6VY^YKG2&HQ*IZ!NJ34!R/PF[;>_&Q_9.)\U
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M3FW>(T_5;"/-S*M>JX>K]O(_8M]\]7=&ZT4B
M         >5^Y6Z*YRI,MEETBKH<<0A5#^(9D _UBXV^4OE19;+SE*Z&W$K5
M0O+0C,!Z0        $5W-^#;,?:.Y^Q'0&=.@'X-LF]O#]B, M+6H*@
M          (SCSD->292B/BZ[-);D12DWQ<=AE-X,XY&EU+C9ZW>21\JKG9V
M%Y2(),               "+[A.P6,5E.7'%G<SB$[&)>/L1F)CCQF^V1+)J0
M9-GRC]5XGPTU 2@        !F_ /N?\ _%2O7E#Y;5KGE?3+NOV1S)0(80
M<BW?"_A?[W<?8CHZ>RO54>W^F6OG_1W/I_JA?X^@/ HOC3L%S(<I1&Q9VQR&
MY3"95Y<C,,)O"C8(R?0XT9J=)LO4]3G$NST2()0
M      #\N.-M(4ZZLD-H*JUJ,DI(B\IF?8 \?GJS_5"-_#-_+ /6TZT\VEUE
M:7&EE5*T&2DF7Q#(!^P            &(/[PW^SCZ]_U>"T-O@J
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MIRM/4B>M<G7_ "F'6Y'WNMJM?4#D;N&[<VB#9-J+,\3>29A#A,,O3W6Z'X2
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M_AZ]T?\ ^+GN?]S_ ('_ /#O'<[QWB/_ -78T:.1_E5U>2G$B87>"
M9$RQ1;H]:>/XM+,G[!MY#3<%QZU1XM+29>OT#/FNQDJ+T&Z MO-,YYA\'/\
M#[OAMR?=C0;S'.*_(CZ>:A)F1U3K)15X>4@5?SYW)V8L.R>^FV]@L$^7<(UP
MEVR<Z[.Y6M*_.7*TIY2$%2B"\@+XOZ4 H                XF3Q+[,C0$V
M"]-V-YN?%=F//1T2BD0TN%SHJ2<4DD*>+NDLN*?( [8       /RM:&D*<<4
M26T$:E*/@1$7$S,!!OPT[2^_2T?RQK_I&/Q*>%K?<VOF@_#3M+[]+1_+&O\
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M%O<C(?<GLFT>AIMQ2B-HTJ+69I(S,O\ 'L-5W0
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MVNZN-O,:PV(N':%R+1,4RX\Y(5SG93B5'J=4H^)(+A4$[S^A0*@
M      (]EL.[3&[.5IR0L;-FZ1'IBS88D>/C)-6N 7/,M!OU+OH[Y4X$ D(
M               #@8U%ND:1?5W'(DWYI^Y.N064L,L>;6#0@BA&;1F;AH.J
MM;E%=[L =\       %*;I?"=BGSC,_64/';>\RCDE['8GI[G+#]CSKJ@  YU
M_P#I%=/G1_UI0B=2]':CE6?MG\'V,^UT;ULA]&R'IZ.[#PVT?4W.]+U95&N,
MGS)YNR-..\FZQ7I>IEE[SA&1KUP"YQEH-ZI=]'?+3P(;SGI
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M3W<6E:."5$I)D7 $M(;F_!MF/M'<_8CH*LZ= /P;9-[>'[$8!:6M05
M          <6TQ,A8O-\DW6ZLSK/)=8.RP&HQ,N0FT-$3J''24HW36OOD9D5
M" =H               '$RR%DEPL;\7$[LS9+XM;)L7&3&*:TA"74FXDV36@
ME:T$I!=[A4!VP        &;\ ^Y__P 5*]>4/EM6N>5],NZ_9',E AA  !R+
M=\+^%_O=Q]B.CI[*]51[?Z9:^?\ 1W/I_JA?X^@/ N)9X621KM>Y%YNS,^TR
MGVEV2$U&*.N$REHB<;<<):C=-2N]J.E/C<"#M@
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MH8-I^IJ]G-!;[*YQS5P!3&$?G&;J>UV/^QUCI7O36^6I2.U*YQS5P
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M9>C$E9/ABL@L\BXWHISY8[.8CO/M0I/AU&XX\ML]+:5(+21KKQ^-4MAJID
M                             #(&ZG2[O%G6YERSNSYM#M[:W%)LQJ?F
M-2XL0RX,DXRU5*2,U'I2JG$_1!;%'_R3^I'\:_VTN_RH&+;$)EV/#CL/+YCS
M32$..5,]2DI(C.I\>)@J^X#YR([$N.[%DMI=C/H4T\TLJI6A9:5),C[2,CH
MY.,8AB^%P'+7B5HBV6W//*DNQ8+26&E/K2E!K-*"(M1I0DJ_$(!'[ULOM1D5
M[5D=\P^USKTXHG'I;T9"E.K(ZZG4TTN'Z)K(Z@8I?+M=LN%N=M$Z&Q)M3S?(
M=@O-H<CK:I30IM1&DTT\E $6Q7:/;/"+BN[XGBUNM5T6DT',CLI)Y*%>F2A:
MJFDC\I)I4![<OVYP7/FV&\RQ^%>O"F9QERVB6XW7M)*RHHB/RD1T,!TL=QG'
ML1M35DQ>V1K1:63-3<.&TEEO4KTRC))%51^51\3\H",W/9;::]7Y6377#K5+
MOBUD\[+=C(,W'2.NMQ--*U>B:TG7R@G%.DI2A*4(224)(B2DBH1$781$"&(=
M[?SUMNOK)[,?!:-3;X*@               (?N K'4-8[[H\=E9$@[[ *V(A
MQ#FG!GF:^3.=(C+EM,][6[\C7L.H"8                 (CA/N=.;E1V*P
M2K'(*\OE=WY<4XJ;A-Y;9KELJ,SYK:R,B)PJ5,CX )<       "E-TOA.Q3Y
MQF?K*'CMO>91R2]CL3T]SEA^QYUU0  <Z_\ TBNGSH_ZTH1.I>CM1RK/VS^#
M[&?:Z-ZV0^C9#T]'=AX;:/J;G>E\\\]SW_XL^Z#'Y5__ //X'FKP<8Y?@+AZ
MIR9SM%)Y;3/>UN\=->P;SGI<                               "+[CV
MS)KS@U]M6'/LQ<FF15LVY^22382XNA'K):'$FDTU(R-!_& 8SL'39U;8I!.V
M8UF<>TVPUK=3!A7>4Q'2MP]2C0TA@D)J9U/21 MC"XMBMM^HS%,V<NFZF7>>
M\8."\RB%YQD3*2EK;-M?+=;07 DJXU\H(EI($ "MMR;)(W7QJ7B6"YZG'+K'
MD-*NLZU+*7)0PI#J>0XEF0RILG%<:FKB23*GH$L01[RNQ[';P[(N6N'&O>)S
MHKUPN\ EK.XHBWJ/$=-Y3AJ/4VOEFC3I+17ND9'J++<OCT-?]WXRIE)DT<*"
MWIU$1F\B^M$L_DODR4JGH>@"-]32FGX<CIDDW:JK95E1MZ.6>@LB6XOB9E6K
M:V_DOB\*@E<'5NE;^_&SL>+7QJY,4D<.9Q7<VB1W"H9\2/R\01"5=3EKZCY5
MQNLO;R;R=LD6-?GACFP4:M*'CE=UXC=.K5/2_J<01#P] /P;9-[>'[$8!,M:
M@J                AV*MX>C+\U58+>_%R)<F$>33'FY"&I3Y12)A32G3Y:
MB2WW5<HB*O;QX@)B               "%;KLX:_@\YK/K;)NV+J>B>*@PFI+
M[RW"DMFR9(B&3ADES0HZ'3AQ] !-0        &;\ ^Y__P 5*]>4/EM6N>5]
M,NZ_9',E AA  !R+=\+^%_O=Q]B.CI[*]51[?Z9:^?\ 1W/I_JA?X^@/ H5A
M[.&MY7FR\<MLF%?W)L9632GVI+;,J3X<N4ME3Q\M221P/DD15XGVD9A-0
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MU6.N93LY!AQ;/>^6F:Y#2MM:G(NK2V\A9ZDK;YJNZ9?)5[#(P1*RP0
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MS_%>&Y9\OP?*[FOF4U<WAI[.(V&J[0
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M,VWD$9\32EQ*B2?E+B"J6             ,0?WAO]G'U[_J\%H;?!4
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M=6MDFD6_7X1Z]0F[MH]+X4FGUIU_Y//2S^K0$PDV!X?TW.[96QZ!;<:EXTN
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M(^ZG"DY!=I%OOGC9"L<A,/O,M39!1U$XV\ALC2M*4'J(ETX_',CV&JF8
M                           ,;[J;?[U[1;N7;>39:WG?;5D1:KS9VV53
M%DZO2;B'(S:DNN(6XGFI6P>I)F:3H7IBR)7.W=3_ %0W"U8MG..+P["8<IN3
M<G50)%K:+35)NDF<XMUYPD+42$(/14^-.TAHANZ'$CP(D>#$1RXL5M###?;I
M;;224EQ] B!5]P            &(-[?SUMNOK)[,?!:-3;X*@
M    (5N.>&<G&BS2=(@M'D%N*R'%<E-F]>#4OPK3GA2,S0H]52<]3[*F7 !-
M0                $,P)>&+G9?[DIS\R65\D%D:)"Y"R8NI--<QILGR(DH)
M.@RY54<>!^@$S       !2FZ7PG8I\XS/UE#QVWO,HY)>QV)Z>YRP_8\ZZH
M .=?_I%=/G1_UI0B=2]':CE6?MG\'V,^UT;ULA]&R'IZ.[#PVT?4W.]+R[B.
M84W[E/=I,?AZLCMR<>\.J2CG7H^9X5ESPQ'5"N_J)WU/]EY!O.>F@
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M$UXPK)\Q\R7^3=;N4R/Y]MK\I<AFW/DP1(;9:45&DK26HR34C,OB4()@
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MELK>FU,N,J0LC5S#7K2FI&6F@VK<5QVIAY[.UY2J(\"FJGAZTIP,SF
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MV_WGW1W?M^]F],!5EAV%E2++:763B*-PTK)M"(RU&ZVVV;JG#4Z>I2J%Q*M
MV("H             Q!T8?##NE_VGL]P%I;?!4               !"FE83^
M%F0AMR1^$3S A3S1JE^%\SG+,DJ(C_BVOG%Y/5*?$J FH
M.%FJ[$WAU_7E"W&\:3;I1WA;!O$Z4+DJYQH./ZI716G+[WH /MBBK.O%K&O'
M5+7CZK?$.U+>-TW3AFRCDFLW_5=1HTUYG>_9<0'7       !GRU_=1FOMW(_
MYA\WSOJ*^]+Z'9\BUW(=L:BX  (WD/W181]\$#UU(V<KY]OO4\Y7Y-WN5<S1
M@^E/G*%0582>Z=W3$<D'GY6B*=Q:4J6<8K:;R^2:25_%]6LCKH[W^,!-0
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MO$]V2EAR R32M#C;9H4;IJ4>@R294+_%L-5W
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M(,56]E2[$ZW+>4S9TO,-%>%&PHC8-#O?<Y9'S-+?'R^@9;#52@
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M]W+*Y4.Z6;;Y%L6T_9')$AZU,/)2TAO23B6VS>6HM=4MDJFKR5 EL0%0
M   $5W-^#;,?:.Y^Q'0&=.@'X-LF]O#]B, M+6H*@               (Y86
MG&\AR9:\F\\(=?C*;LGJ'_E!$P1&UZEW_5:<WU7]3RF82,
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M1WTO>X=T^WR!(@       5=OC]*,6^^6W^MOCSVW?(I[T<TO1;!\ZON3SPY
M\:](    ZFP/W&S_ &WF?K-CVFP_3_5/0\UM[U$=V.E-<W8=DXI=&&,A/%'%
MLT+(2Y/\3+41FOU>B.SN]XR[>!D8[[SSN,D9,MDISG*TIJ[P+6=/3=WAQ[>
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M3BG2HLUEP49U =0       &?+7]U&:^W<C_F'S?.^HK[TOH=GR+7<AVQJ+@
M C>0_=%A'WP0/74C9ROGV^]3SE?DW>Y5S-&#Z4^<HG#3:"W$N:VLHD2+V=LC
MD_B"I;:XT5@G5FF6F*1:T+<,]"EF?$J?$ 2P       %$]47TEV[^_JR^MRA
MUMF=NON3T,=>]ROR-I<   !\>D/X-[S]\ER_69&MM3S8[L*T+^'(7
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MIN=Z7US%U#7F#7C"LFUWF&A.EMASS8I6NEQ/G>E)C]DWWRU<!O.>DH
M                         (ON/+Q.!@E_G9RPF5B4:&X]=HJDZ^:RV6KE
MDFJ:J49$E)5*IT 9"M'7/:<>@Q<>Q':M;5AB$;%JCHNIMGRT<=)-IA.T,JU,
MB6H%L%I[%=4%YWNS=_'V<-\R62%!=E39_BG)YI?)Q"6D&LH["$:B-5"54ST\
M 1,-) @       !%=S?@VS'VCN?L1T!G3H!^#;)O;P_8C +2UJ"H
M       "*XVJT'E&6I@8S(L]Q3(BE<KT]%1'9NRSCD:'67DF9O$TD^6HU$6E
M7 !*@               1+<IRSM8A,7?L6D9E;"<C$[C\*&BXOO&J0V25)8<
M,DJ)LS)Q1F? DF8"6@        ,WX!]S_P#XJ5Z\H?+:M<\KZ9=U^R.9*!#"
M  #D6[X7\+_>[C[$='3V5ZJCV_TRU\_Z.Y]/]4+_ !] >!1/%EV=61Y:BWXO
M(L<Y$Q@KC=WHB(S5W<-@C2^RZ@S-XD%W#4KL/XIF E@
M          ,R[^;T[<;.[B6FYEAQ9-NHN$1-2FWO"*CP75.-(0;NAXS4NKE$
M$UV>4JD"8A7CG]X-()CGIVU-#:ZI;>5>3-LUE];RK3RE4$X-:[<9)=LOP:QY
M/?+<=INMTC%)DVTTK0;)K4=$T<(E>EIVEQ!5*             &(/[PW^SCZ
M]_U>"T-O@J    I; ?SB-W?G>P>P$#4M^;7['I<[_P"MRW+<_J72-MYH
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MK[3]35[.:$V^RN<<U< 4QA'YQFZGM=C_ +'6.E>]-;Y:E([4KG'-7
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M.]PX@/I87%NV.V.NV[S.ZN(PI=IJ@_!J-M)G'JWW/4O2=WAPX< '0
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MD]DVCT-MN&M)M&E1:S-)'P^(7'8:KN
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M8]?&K$MFY1G[BMZ,W+\7!09\V(DG%)Y:G:D1.)JI-.! .\
M   X>.P[_%D7I=[O;=X8D7!QVU--1FXQP89H028JS0H^8I!DHS<5Q.H#N
M     I3=+X3L4^<9GZRAX[;WF4<DO8[$]/<Y8?L>==4  '.O_P!(KI\Z/^M*
M$3J7H[4<JS]L_@^QGVNC>MD/HV0]/1W8>&VCZFYWI>[)(M]E>:/,=Z:LO)N<
M9ZY<V.W)\;!1JYL-&M2>6IVI4<352:<"&\Y[N
M         K7J"QNZY=LSF%@LC"I-UDP>9&C-EJ<=5&=1(-""\JE$V:4EY3!,
M,HEDC_X"=I]V+-8GF).T=^3:[NR1)0;T0TM^*<2::F275Z&UFLB,EJ5PIQ,E
M+MEMRXNZO5/>,NP2U3+9BDJP<F^IDH;0IYYE2.6^^EI:T)6:C)"*+4HTI,_*
MHB$ZFR@5        17<WX-LQ]H[G[$= 9TZ ?@VR;V\/V(P"TM:@J
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M]H#7O3RN^N;)X2K(R=*Z^;6R/Q'[J<<E**.:J\>+/+/CQ]$$2LP$
M    ,0?WAO\ 9Q]>_P"KP6AM\%0   %+8#^<1N[\[V#V @:EOS:_8]+G?_6Y
M;EN?U+I&V\T         .5DK%_E6*='Q:9'@9"XT96^9,:.1';=J7%;:32:B
MI7R@.A&*0F.RF6M#DHD))];:30A3A$6HTI,U&1&?81F8#Z@
M  XL:-DZ<GG2I4Z*O$UQ646^WH94F6W+2I1NN..FHR4E1&1)21</UP[0
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MR_I24-;:?J:O9S0FWV5SCFK@"F,(_.,W4]KL?]CK'2O>FM\M2D=J5SCFK@
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MJ'(\.9N+=6T9);2I!:2YE?\ $9EL-5-
M   8\M6]SNV?4EG%EW1S-U6#2R>596$.>/APWUN-*:;6TREQV.I#9+0:=*2K
MWE$9*)0+8+L_*-V$4Z4GW;6KGDG2ETS5K))\:5-%:?$!&"U&G6WFD/-*);3B
M26A1=AI452,$/V   #BSL/Q*Z3RNMRL%NF71)I-,V1#8>D$:/2T<6@U</)Q
M=E24K2I"TDI"B,E),JD9'VD9 .5:<6QBP.NOV*RP+6^^5'W845F,MPJUHHVD
MI,^/H@/M=[#8\@83%OULB72*A6M#$YAN2VE?9J)+J5$1_% >F%!A6V*U!MT9
MJ)"8+2S&CH2TTA/;1*$$1$7QB <^5BF+3KHB]S;';Y-Z;-)MW%Z(RY*2;?I:
M.J0:RT^3CP =<!B#>W\];;KZR>S'P6C4V^"H               "&[B>Y+DX
MV>76B1>&_/\ ;_,Z(L=Z4<:Z57X>2X3/I&V^]J6KNE6AD=2(!,@
M       $.P5.*%.RWW,6F1;)/GM_S\[)9>93+N7+;-R0T;IF2T*3I(E(HGAV
M>B$Q       !2FZ7PG8I\XS/UE#QVWO,HY)>QV)Z>YRP_8\ZZH  .=?_ *17
M3YT?]:4(G4O1VHY5G[9_!]C/M=&];(?1LAZ>CNP\-M'U-SO2^&X#>)K]RWNK
MM,B[:<@@*LGA6'I'A+L7,\/*<Y)EH;;[VIQ?<37B-YSTQ
M                !!=YI^5VO:[)[EA#I,93$AF];G>X9I4A:37I)PC2:M&K
M21EQ50@(5UL9O?A.9[90$Y]E-D+,9!26\DMTY42W+<6;RT57&7RTK)36C4I*
M32?Q.PB9A9V%RMJ8BG;-MV_CS"W:R'K?8%PD&K30C<4U$,JTKZ8R\H(3$
M     !%=S?@VS'VCN?L1T!G3H!^#;)O;P_8C +2UJ"H               "%
MXF6%%F6<'CJ'TY*J5"/*ENE))I3Y1$E'Y1O>IF1-%QY/"O;Y $T
M      !"MV&\*<P><C<)$AS%#>B'+1#*6;QN%*:-FA0O5:<W173^J FH
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M'77K;;XT-Y_]V<CLMM*7QKWC0DC/B?E >X!B#HP^&'=+_M/9[@+2V^"H
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M#NWGNZ7NA]V^'.XGYI\%X'FM26O$^*\1S*>)0FNCE(]+^RX^0$2N@$
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MTF7>I2OE!#48(        17<WX-LQ]H[G[$= 9TZ ?@VR;V\/V(P"TM:@J
M              XMI?RER\WQJ]1(;%B9=8+'I$9U;DA]E3)&\<A*B(D&ERI)
MT^3_  F':               !Q,MD97%L3[V%0H=PR(ELE'C7)Y<>,:%.I)T
MU+;2HZDWJ,N';_@,.V         S?@'W/_\ BI7KRA\MJUSROIEW7[(YDH$,
M(  .1;OA?PO][N/L1T=/97JJ/;_3+7S_ *.Y]/\ 5"_Q] >!<2S2,K=NU\:O
MT*'&LS+[:<>D17ENOOQS:(W%2$*21(42ZD6D^SXU3#M@
M           S%O!M3LANQO5!QO++[?(>XDJU(.+;K;RFXJH<?GNDLW'8;Q$K
M@NOJGD+@"4<RSHOV'PK&[EE5^OV4-V>U,G(F+:?@N+)LC(N"2@5,^()Q:$V7
M+$T[6XPW@LJ5,Q-N)R[7)GDDI:FD.*2?-)"&RU$HE$=$D")3P$
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M,C_P_(AV@       5=OC]*,6^^6W^MOCSVW?(I[T<TO1;!\ZON3SPY \:](
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MR"4XE9&HB42:-J[2,Z$ UB"H             Q!T8?##NE_VGL]P%I;?!4
M             !Q$MY;[KG'5O0/<-YO2EN.2'?.?G3G&:E&NO+Y'*X4IJU?$
M =L               '@O:;PNSST8\Y':ORH[I6QR:E:XJ91H/E&\ELR4:"5
M35IXT ?NTINB;7!3>UL.7I,=HKBY$2I$94HD%S3:2LS42#7722CK3M >P
M    &?+7]U&:^W<C_F'S?.^HK[TOH=GR+7<AVQJ+@  C>0_=%A'WP0/74C9R
MOGV^]3SE?DW>Y5S-&#Z4^<N(PWEI97+=DO0#PHX;283#:'2N)3R69N*<69\O
ME&BA)(BK7_&';       !1/5%])=N_OZLOK<H=;9G;K[D]#'7O<K\C:7
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MM^K%5>ZGW*W>3=J9#<"O7BGG7_"74N7XB*US2+0VWW=*$=Q-> "8@
MI;<3X5K3[2.>R%#QFW?.I[O2]EL;TU7?Z'^CS[J   CV<_<E=?WG_K$*U:F:
MSVX7AB'W)V'VNB>L('TW+>51W8YGSW-^=7WJN=QLO7B2<GPQ.07B1;KT<Y\\
M=@L2'F&ILGPZB<;>0V6EQ*4'J(ETX_'H>PU4R
M       $#W=VHQ[>/$'<3OZEQR)YN5!N+*4J?C/MGZ=&K@>I)J0HC\BO1H"6
M3[;T'*:R&\)R;)TP</:-)62>R;:I;IF?'Q#;B4H1P[-*C!.*1P.AO:MB8P]/
MSF7+AH62GHR%1&5.)+Y'7WM-?*9$!BV'%CQX<5B)$03<1AM#3#:?2I;0DDI(
MOB$1 J^P            #$&]OYZVW7UD]F/@M&IM\%0               $,
MW%/$R8QSW6WJ396?/]O\TKBR'(OBKF2EFQ%=-HCU-N=[4A5$G3B94 3,
M            !#\&5BRIV6^YN\R;M)\]/E?&I4AU\H5P)MLEQFDN$1-MI22=
M*453\7T F        *4W2^$[%/G&9^LH>.V]YE')+V.Q/3W.6'['G75  !SK
M_P#2*Z?.C_K2A$ZEZ.U'*L_;/X/L9]KHWK9#Z-D/3T=V'AMH^IN=Z7QS]S%D
M>Y?W47B39]>00$V7PK[L?QEU/F>'B.\HCUMN][4VONJIQ&\YZ8
M                      RMU%],N59[<;ME^"7^2V_*BH\1B)N*3'F2VSTF
M:%N/M--DM.DU$M--1&JO>!,2@&+=%^ZKN/6]RX;A2,<FJ:(WK&@G7TQ%5/U,
MG(\OEJIZ*. )Q6SL5TKGM-F,K.[[E"\COCD=R+&23"F$()[3K<<6MUU3BC).
MDBX$1>B=*$3+1X(        17<WX-LQ]H[G[$= 9TZ ?@VR;V\/V(P"TM:@J
M                B>,ILA95EYVW)9=XN9R(GG6RR)92(]I<\.7+;CLDDN2E
MU/JBRJ>I53^( E@               (EN4=B+$)AY'DTK$+3S(W.OT"65OD,
MJ\0WH2E]25$DG%4;45.*3,@$M         9OP#[G_P#Q4KUY0^6U:YY7TR[K
M]D<R4"&$  '(MWPOX7^]W'V(Z.GLKU5'M_IEKY_T=SZ?ZH7^/H#P*)8J=B/(
M\N.UY-*O5Q\8QYUM,B64EBU.DP1)9CM$DN2E:2UJ34ZJJ?H@):
M                ([G>(QLZQ&ZXK)DO0BN+"FV9\92D/QWR[S;J%)-)U0HB
M.E>\7 ^!@,0R.C/>$MPHD9&3O/V8XIJ<S@W")QAS2Y_%R85+\29'P+4GN][X
MX+8I1+Z&\XN;11;INH[*AJ41K:>BR7T\/+H7+H9D!BUEM[A5OVZPJRX3:W7)
M$*SQR83(>IS'5FHUN+,BX%J6I2J%V=@*I,             Q!_>&_P!G'U[_
M *O!:&WP5    4M@/YQ&[OSO8/8"!J6_-K]CTN=_];EN6Y_4ND;;S0
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M?X^@/ H[8'Y3M\R-#^,^96FI+*6+OKCJ.[)Y)5>,F3-9<O\ <RYO&GZI$$B
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M.WP  1V'(EJS2YQUXT46&B%&-O*M;!G,5J7_ !;2GU4B9J:BU=WO'3XH2(
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M[Y3)A+H2M1$2N\7?X<";)*5+ER+$>#9TU3VJNB"(QTR_TV;UU1W8Y$I4FR[
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M+G+<NU,EAY6]+[=[*21R#N)O&DXYQM-23R^_S-7Q/C!VP
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MQKKRW*4K3XE>(6,"         !B#JP_.1VH^M?\ 2Z@6AM\%0
M    $:S1MER';>?DZL6)-SAJ1*0ZPSXM9.<(1F^1DHG_ $NE/>/R )*
M  #QW;Z53OG=W]H8B=2M6J5 ;$?!-C?[T_[*='$<BQY<+$!G  !";/\ G(6W
M[TY/LTAM9;M^Q6WYT<DK]'2=1&L.;905^-G)U9/KO,U3AJ=8=*VKJDCMI<CT
MI1Z4TN=\J]X!)0       4MN)\*UI]I'/9"AXS;OG4]WI>RV-Z:KO]#_ $>?
M=0  $>SG[DKK^\_]8A6K4S6>W"\,0^Y.P^UT3UA ^FY;RJ.[',^>YOSJ^]5S
MO%D:&57_ !<W,I58W$RGS:LR7(R"O!\A56#2\1K7RR]4HUQ\I^0RV&JDP
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MZ7VRYDG3L)GDRL:Y=XB++2MA'G(R)9>;CY_:3]>QOO\ =[HWG/20
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M8]ZR)Z=D97F%(DM+@6HF&6E6I!,I)3)K;,U.:SHY5PB,J_J@)"
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M9M%N_"*\LLI>7=O,Z25AAR63CHC^)X3RCDGFDHU>H\S5IIP[0$I
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M,DI+R<3/@ -.M/-I=96EQI952M!DI)E\0R 8CZL/SD=J/K7_ $NH%H;?!4
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MNZN/;Q=5VWN6XS&FQ+<B5:8)M7)MII_FLREK4=&77DZ:+*G>_4 WG]& 5
M             13.3MA-6'SIBSV4I.]0BBMQXS4H[?(JO1<%DZI/+0QQU.)[
MR=7#M 2L                !%\/5;52\E\WXR]CKA79XIC[T9N,FZ/Z&ZSF
MS;,^8EPJ)YBN\>D!*        4INE\)V*?.,S]90\=M[S*.27L=B>GN<L/V/
M.NJ  #G7_P"D5T^='_6E")U+T=J.59^V?P?8S[71O6R'T;(>GH[L/#;1]3<[
MTOUFB[<@\=\XXR]DI*O<-,4X\=N5YMDF2^7<7.89<M#'R3J>\G5P&\YZ4
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M4/Q+W-^Z7,?,V.2;-="FL%>KI(AG%9N;W()2'F':F3R4)/2H^%%5X<:F$P
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MLS7[[;SZZD=6]JI[M**4_&!<  $"R;X7]H?;:5ZTV,O^C<Y%*M<-:CS3(
M       #P7N[1K#9;C?)A*.';(K\V02"JHVXS:G%4+T:) ?SKSB\[\;D;:7;
M?J[9:Y:,-*:42V8U;Y3["="I"8_!MG2@TH4K3K=4I:J'V%2I=HJZ9ON7@'51
M!Q^]34SMN=Q"2FTV\EJ<3#7%C)9U-DLB-M?-;)3B4U0I+E?3>E*[S3((
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M'1MYG>SG=Z;A#3K.W3LZ*5D2X2B;TDY*-!()?>*B#+@?>))IU<0):]!4
M  &&^L7=.[9>5ZVXPK6[C6')8FYW<&SHT<AR2U&8BZO*3;KJ34GRK\GJ9@M#
M1?3M*C0M@\)E3'D1XK5K0IUYY1-MI3K5Q4I1D1$")9NZH;K:[MU&[5/6J;'G
M,H5:T+<BNH>2E7G91T,T&9$=#!,-U J                X>3Q,AEQX"<=O
M#-E?;GQG9KS\=,HGX25^K1TI4I.E3A'1*RXEY '<       !X[M]*IWSN[^T
M,1.I6K5*@-B/@FQO]Z?]E.CB.18\N%B S@  A-G_ #D+;]Z<GV:0VLMV_8K;
M\Z.25^CI.HXF-Q<@B^=_=!>&;OSKE)>M?(CIC>$MZ]/)BKTJ5S%M<:N'0U5[
M ';       !2VXGPK6GVD<]D*'C-N^=3W>E[+8WIJN_T/]'GW4  !'LY^Y*Z
M_O/_ %B%:M3-9[<+PQ#[D[#[71/6$#Z;EO*H[L<SY[F_.K[U7._-ZAY%(NMC
M?M%X9MUKCR'%7F"[&3(7.94T>AMMPUI-HTJ+74B.OQBX[#5=L
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ME3[=QDQF8:VV5(0DF20S5)D2DJ5J[>]\0<F]<IKJQIIZL,L1@DPP)
M         1G</#(6X>$WS"K@Z;$:\Q5QO$)+4;3G!3;A)J5="TI52O&E &%;
M[MYU;8PQC&'>:%9#9,&NC%XQ:;$2Q*:2[#6:FBUU0Z;9&?!MY)&1<"[I$"VA
M>FP&T6Z2-P;KO7O8^A.6SXIP;=;$+:6MII>DC4LH]6FR2A!(;0E1GQ4:^]VD
M2TX"        $5W-^#;,?:.Y^Q'0&=.@'X-LF]O#]B, M+6H*@
M     .+:6\K1>;XN]OP7+"XZP>.M1$.HE-LDU1XI*EF:5*-SBC1Y.T!V@
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MGUU(ZM[53W:44I^,"X  (%DWPO[0^VTKUIL9?]&YR*5:X:U'FF0
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MAY C+ILYZ^-O8TY!9;BX\49M+K$HG%FN0<@E:U)6GNZ#*A4X>6H=T
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MC&O=Q&?DM%D%O.PE'3+6:+S5?A7%%$,C)*3U5-SU/]EY $U
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M"MUUX4W@T]6X,V1;\5YL3Q<J&N4V\ESQ+1LD2H9&[Q=T$>DOC@)J
M S?@'W/_ /BI7KRA\MJUSROIEW7[(YDH$,(  .1;OA?PO][N/L1T=/97JJ/;
M_3+7S_H[GT_U0O\ 'T!X%"L-5A2LJS<L:FR)-_3/C^ZF.^Y*6U'E^&3RDM)?
M(FR(VZ&?)J7D/L(B":@                           R?O/D&XV<]0V,;
M-X7>3L-HMT=B]W-S6IM$A;2E2%<TFS)3B"0A"$M=AJ,S5PXI+0E75KC6<RL0
M@Y_A&2.6*5@I2;E)896XRY)0YRB,TN(415;2A7J:T&2R49?$,B%E[+YG.W"V
MMQ?,+HA*+G<X9*FZ")*%2&5J9<6DBX$2U-FLD^2M )3L$   _G'N-.PS/.HO
M<)6X.;R</QBU**##?AI>DK7+@<B&;26FDN'0]#JUF2>!@LM)Q%CV'Z>\QS/:
MS-W\L7DCL.#;[NM23.&^:E-+-.DZH<2VXI5%$2DJ)/ !5.0[1R]N-D\2ZA+!
MDMR:W"G2(LZ>^;Q<LVKCJ6V2>Z2S45$<SF+4E=55*E" 3/<[,[QU![A;4[6J
MN#]HQ?(K1;[Q?F8AF@W),QA<IXJ&2B5RVV]+6M)I)2C,R,!UMKV)FPG5*K9F
MSW27-P'(8_,CQ)CG,-EU<14IM=$DE)+);:FS4E):DJ+5V<!O(EMW@#O5]DNX
M6;9C?)T?S<M+&+Q6%I)J,<DWE,H-+B%D33:6T$I*-*EF9J,Z\3&I<W1-N1>L
MQVZNMFR2:Y-E8O+0U'FR5FMSP,ELUMH6M9F9Z%(<(C,^":%Y 1*M_P"\%FPY
MGX.O"2&G]'GK7REI72OF^E=)G2M 3#<P*@#'VT.W=XW&\\Q\GF$QM-9\AN$Q
MZUMKT*N5Q):3,GU$=29:223XT[>'[)/&LVIN3.,_#$_B^A;4SU&5ZLVXQOU4
M4QC\M/%QRFMZO5VWWNSNW6W3IVG:BTFF-DF21DDVF4ELB+P4*A$6BA4X<#+B
M?<H2\M54WIZE&BF'-M6J-G4>/?\ BO5::*)WOYJMWXZNA?K\[#=8V%V%8;B7
M*(V3=\OC9&J-9HRCHM2EEZ>4OCY=1*_RO2WJJP_RK7MG=N]K#9LQ5$YW.SC$
M]FG?KG_QW:M?SNMULVQMFA;7;70CONZ-]/4A"J./*><+O3IRO(1<32DS(J%Y
M$D9B*JHLQU*--4K6[=>T:YS&8GJ6:-W5IW?BC,;;(MO]S=K)]YN"KQGF07&Z
M2LBNSBC4;CB87=0V1THV@U&1'3C\0J)+'39\.Y1C.,SCBW:MH?<Y7,4T1U;=
M%-,4T_5SRU,.L\,      "*;F'BA8'?CSB4]!Q(HJO.TN,I]#S;&HJFDXQ&[
MVT]*1U[#*@"0VTHI6Z(4%2EPB9;*,M9J4HVM!:#,U]XS,J<5<?1 >H
M &:-I_NFW4^_"Z>O*''N=J7&M=JOO2M 8V<  %=[C?==M?\ ?1%_:J&6UVX8
MJ^U1WH:+'7=="[8YA1[GWY$&8^O/"M<'SM!4J2<=N"3CIQUH2HN1J4I2JZ#U
M?$*IU":        J[?'Z48M]\MO];?'GMN^13WHYI>BV#YU?<GGAR!XUZ0
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M?6Y0ZVS.W7W)Z&.O>Y7Y&TN    ^/2'\&]Y^^2Y?K,C6VIYL=V%:%_#D+@
M          #-77+:[K<=E&Y%M;6Y'MEYAS+GHJ>F+R9#&I1$783KK7:"8>G&
M>ICID@X+"MT>X1K/:&XB4.8PJWR%FT9I[[*FVV%(</4?%1&9*/B9@82A?18A
MBY99NOEN.VY=KP2Z7%E%EBTT-)(G9+R6DH3W2-IIU%2+TNHB($RV "H
M .!FV&8_N%C$[$,ICJE6*X\KQ;#;BV5*\.\A]%%MFE146VD^!@/1BV,V?#,>
MM^+V!E4>S6MHH\-E:U.J2V1F=#6LS4?;Y3 8WZL/SD=J/K7_ $NH%H;?!4
M             !QLD5E:8\(\11;URO'1BN)70WDH*VFO^,FSR2,^<2?W/5W:
M]H#L@       \=V^E4[YW=_:&(G4K5JE0&Q'P38W^]/^RG1Q'(L>7"Q 9P
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MZ.0.Y0UYJ]R\>%(UW&.B]>/<<:Y=K/5SW&.6E6I]/=T)51)\:F-YSW9
M      !1G3#]*=QOO\O?[2,.KM'71W*>ECHW^5>8Y3(
M.#FV)6S.\2O&'WC45NO,5R(\XBFMLUEW7$UJ6I"B)::^4@&-HFV76OM3&/#]
MN;LB[8E'4X<%UAVU&A#:U&JA(NI$XT9U-1H09I(ZT,^T%M"U.GG83,\2RFZ[
MK[MW1-TW!N[)QVVB<\0<=MS3K4X[0DFX9(2VE+?<0C@1G6B2)EI,$
M (KN;\&V8^T=S]B.@,Z= /P;9-[>'[$8!:6M05                <6TS,E
MD7F^1[Q;6(=DC.L)L,UJ1SG9;2V24\IUO27+-#E4D7E+_"8=H
M    '$RR9D\&Q2)6'VV/=[^A;)1X$R1X-E:%.H2Z9NZ5TTH-2BX<: .V
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M,U^^V\^NI'5O:J>[2BE/Q@7  ! LF^%_:'VVE>M-C+_HW.12K7#6H\TR
M       ^$R)&N$21 FM$]#E-K8D,J]*MIQ)I4D_B&1T 8I?Z>^I?:2X3X&QV
M4%)PZ=(5(9B*D,,O-:BH7-:F)-K61$2#<:55="J1=A%L4SV5Z=MQ&=P6-WM\
MKV5URB$V:+3;^><M32U(4@E.K(B;239+6:&VJIU'JJ1E0R)EJH$
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M;K[D]#'7O<K\C:7    ?'I#^#>\_?)<OUF1K;4\V.["M"_AR%P
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MP!6+++)_<O>9-YID%P*\^+D.R/!W0C1XB(US2+EMM=W0VGNE7AV@)@
M "EMQ/A6M/M(Y[(4/&;=\ZGN]+V6QO35=_H?Z//NH  "/9S]R5U_>?\ K$*U
M:F:SVX7AB'W)V'VNB>L('TW+>51W8YGSW-^=7WJN=Q<O7BB<HPLK]>Y5LO"I
MLCS!;X\AUAF?(Y!ZVWT-D:7$I2>I)+,BK\>A[#53,       %9=0_P ">:^U
MR_VZ1O9#SZ.52O4K?"?N,QWVLA>QT#JW.W/*F-3NBB0  >+8/X6=XO\ TU[!
M?&':'E6_JYX4IURT*.*R               PQEK6^^_6]^;XAA^5NXSCN'O>
M&Y!3),&,E"%&VVHT12-3KCJDK<U+*A%Y2+21EGH_)/ZD?QK_ &TN_P J!BVQ
M"9=CPX[#R^8\TTA#CE3/4I*2(SJ?'B8*ON             Q!O;^>MMU]9/9
MCX+1J;?!4               !$-P#Q\F<?\ =!DLK&6_/D'P"X4OP1SYM5FU
M!=/2KF-/<=;7#5I[2H EX                ")85YA\9E)V3(I5^?.\OG=6
M)<KQ16Z83;9*ALITIY32"(C2WQH9GQ 2T       %*;I?"=BGSC,_64/';>\
MRCDE['8GI[G+#]CSKJ@  YU_^D5T^='_ %I0B=2]':CE6?MG\'V,^UT;ULA]
M&R'IZ.[#PVT?4W.]+\YR5A/W->?LAE8]_P">P?-GA)?@_.$_U3DP'>!\UI[O
M:F?DZ#><]+        <+-;A,M&&Y%=;>YR9\"V3945[2E>AYF.M:%:5D:3HH
MB.AD9#+9IBJNF)U3,(G4RGB.3=1^68W;LC9W,9C-W!KFI879K<M2.\::&9,%
M7L'HKEC+453'4U?S2QQUIC6[7,ZE/QIQ_L);_F IX>6_V_[TIPJX7"QC$M\,
M,9N3&-[C1X35WGOW>X)\TQ'N;.E$DG7*O-K-.HD)[J:)+R$,MR;%S#K48X1A
MKG4B*9C?=WF=2GXTX_V$M_S 8O#RW^W_ 'I3A5PI!L[ENZZMX)>#9]E:,CMW
MN:<O3"6X$2$2'_'LQDG5AI"CHG7\E3O=G :V<LV8LQ713U9ZV&N9WB)G'"6C
MQQ&0              $&WES2=MYM?DV96QI+URM<,UPT.%J03[JTLMK47E2A
M2R49>4BH!#(.*X7UG;DV"%F\+.784"\(\3$:>N2X:E,K.J5DS%:-"$J+BDN'
M#R MH7+L5MOU&8IFSETW4R[SWC!P7F40O.,B924M;9MKY;K:"X$E7&OE!$M)
M @       !%=S?@VS'VCN?L1T!G3H!^#;)O;P_8C +2UJ"H
M  "+8XW;TY/E:HN3O7F8J1%\;8W9#3S=H44<M+;;:")31/)]4,E]O: E(
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M\TR           Y.479ZPXS>KY'9*1(MD&5-:CG6CBXS*G$HX<>\::< &#<
MVXZEM_;(O<5.X[UM@3I+S<5E^XSF"/E+-+AML1$FVTV2JI2DJ=A\*4,RRVMJ
M^G7?+#=P+)DV4[B>>;!;W7%S;9X^Y/\ .2ME;:2T/))!T4HE=[T ,6K@5
M          &(.C#X8=TO^T]GN M+;X*@               (:TO$OPJOH1>)
M"LX\PHYMA.0\<5-L*6=)),&7+)PW#T:ZZJ<*<>(3(               '#S/
MS/[D;][H9KMML/F^5YSN$=Q;#T>+R5<UU#C=5)4E-5$:2,Z^0P'UQ7S6>,60
M[)+<N%E\!%\W3WW%ONR(O)3RG5N.=Y:EHHHU*XF9U,!UP       9\M?W49K
M[=R/^8?-\[ZBOO2^AV?(M=R';&HN  "-Y#]T6$??! ]=2-G*^?;[U/.5^3=[
ME7,T8/I3YRAL%>)?A/NR(UXD.YKYIB^.L:I#RHK,$GE\MY+!ERTK4HZ&HCK3
MR%7B$R       !1/5%])=N_OZLOK<H=;9G;K[D]#'7O<K\C:7    ?'I#^#>
M\_?)<OUF1K;4\V.["M"_AR%P            !G3K7QVYY!LJM=L<(E6BYQKE
M*CFLD*?CMM/M+0@C,M1IYI.Z>/!!T+@"8<G&<<Z(I>/VV1'>Q9++D=LTE=[D
MRQ</2E7Q"'WTK)S]E4NWLX :5M[5VG92U^=OP/.6-?-\/YZ\PRV9E-/-\/SN
M4XYI[7=%:5[WH +&!       /BN5%:>1'<?;1(<_<VE+22U?&29U,!]@&(.K
M#\Y':CZU_P!+J!:&WP5                <+*)=]AQK>NP6-N^ON7"(U,9=
MD-Q2C0UN4>E)-PC)2F2[Q(3WE>0!W0       >.[?2J=\[N_M#$3J5JU2H#8
MCX)L;_>G_93HXCD6/+A8@,X  (39_P Y"V_>G)]FD-K+=OV*V_.CDE?HZ3J.
M%C,N^R_/'GVQMV3D7.2Q;>5(;D^-@(T\J8KED7+4[4ZMJ[R:<0'=       !
M2VXGPK6GVD<]D*'C-N^=3W>E[+8WIJN_T/\ 1Y]U   1[.?N2NO[S_UB%:M3
M-9[<+PQ#[D[#[71/6$#Z;EO*H[L<SY[F_.K[U7.^=[F7^-=K"Q:;&W=+=)DN
M(N]Q7);CJMS),J-+J&UI-3IK5W-*#(RKZ'9L-5W0       5EU#_  )YK[7+
M_;I&]D//HY5*]2M\)^XS'?:R%['0.K<[<\J8U.Z*)  !XM@_A9WB_P#37L%\
M8=H>5;^KGA2G7+0HXK(              #$NY..=4%OWPR'/-K<;.$S((H*+
MA#.(;=QB-)23:Y+,EY25K21$DE\M)D1$"VA\O=)U_?4C^;6?Y8#0VQ".0J''
M.65)1M(-\N'[II+5V<.T%7W             8@WM_/6VZ^LGLQ\%HU-O@J
M              C^5S+A#;M"K=CAY&IVZ169""=89\"PLU:YWJ_IN33TJ.^=
M> "0                 (_C,J?)DWU,W'?,+;%R=:BO\QESSDRE"*3:,E5.
ML^[I<[W=X@)        "E-TOA.Q3YQF?K*'CMO>91R2]CL3T]SEA^QYUU0
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M>0Y?<G0G%EV)3<IDEW=2(Z"NYFRGU<E,J-:M!$3=7>/87HD024
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MI=P]!FGN]G=,R] !]P       9HVG^Z;=3[\+IZ\H<>YVI<:UVJ^]*T!C9P
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M*S1Q84:R[^GTH&AJX%0            !B#HP^&'=+_M/9[@+2V^"H
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M0.K<[<\J8U.Z*)  !XM@_A9WB_\ 37L%\8=H>5;^KGA2G7+0HXK(
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M14B4VX52J1T-*B[%)/BDZD?$$,:;V_GK;=?63V8^"T:FWP5
M   1_*X=PF-VA-NR,\<4U=(KTA9-,/>.80:M<'U?TO.KZ9'?*G !(
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M;+<!U[W4K6Z=I2GW&&N-H0GQ'TP)LD\_B?J.HST>3MI0),
M #EY*E"\=NR'+L=A0J'()5[)3:#A$;:JR-3O<+E^GJOAPX@/W8"05AM9-W,[
MT@HD<DW@U-K.:7*320:F2)L^;Z>J"T\>' !T0       9\M?W49K[=R/^8?-
M\[ZBOO2^AV?(M=R';&HN  "-Y#]T6$??! ]=2-G*^?;[U/.5^3=[E7,T8/I3
MYRC,5MHL\N#A94J0\=N8)6'&Y&-,5/-529RTESBYAD:-2CTG0^WAI"3
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MMQ]Z.J3;W,(MJ79VT3;5 \(X\4A1FQ)6O5J)".WF=E 3O/Z3 H
M      B&?IL"F<?*_P",R\F;\^03@-PHGC3@3:KY4]TM2>6TSQUN\=.KL.H"
M7@                (GA16(IF4>9L<EV!_SP_YS?F1/"E<I>AO5-85J5SFE
ME0DN<*F1\ $L       !2FZ7PG8I\XS/UE#QVWO,HY)>QV)Z>YRP_8\ZZH
M.=?_ *173YT?]:4(G4O1VHY5G[9_!]C/M=&];(?1LAZ>CNP\-M'U-SO2_P S
MDK%7&O/F.2LB_P#/87FWP<3QOFZ=1SE7![B7*:9XZGN.C47 ;SGI6
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M!]*?.46B+MWX0;DAO%GH]T\VQS>R]49E+$EKFJTQ$R"5S%*;/OF@RI_BJ$I
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MO_VBQZ#,>9*M.I.1@6  !P]O/SF7_O%7_3#8KF_31W_\*G\7L:4'!9
M         4%GG5+C>)[K63:FUV]=VN,NX1(%]N"7-#$#QCB$T2E*5&ZM!+U+
M(J$GLJ:JD1."9;VRL3Q7!;WN!?,6MV1W"S1B\*S-B,R'%K<<2VA&M;:U$@E+
MU*IV)J8$.3L)OSAV\UG>CV*&=CO5H0V4VP+-!DTTO@E;"D$DEM5+34DI-)]J
M2JFHF%P@@       !%=S?@VS'VCN?L1T!G3H!^#;)O;P_8C +2UJ"H
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M'>AHL==UW%C>Z[W3S_&>;O<9X9GS9R>?YT\94^=SM7J7*IIT:.]VU =H
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M#K;,[=?<GH8Z][E?D;2X   #X](?P;WG[Y+E^LR-;:GFQW85H7\.0N
M      \5XN<>R6B?>9=?"6Z,],?I0CY<=LW%=O#L2 QMTR1-RMX]TYO4!DEY
M-FQVU^7;8]K5K=0M,AC_ %6.G4E+33).-+-=#-:BXD:C4HBTK\ZA]J;_ +O8
M,WCN.WM%FN$*8W<V>8A1HD/1VUI::4XA1*:+4O7K)*N)%P!$*]Z.]T,NRVTY
M+@F>2'I>1X9(:93,E&;DE3#JG6U-.N'4UK:<946I1U,E%VT EIP$
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M9TI/TVDZ=@+0USCK$N-C]IC7"OCV8<=N5J/4KG(:22ZGY3U$8*ND
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M^X\SF4^1K\0$PEW3.B>WL/@R;D2TR#M^I!.>F\.IUQ3!E\0VC1I^)0"5K@@
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M#GQ2-)\06WFW 5             &(.C#X8=TO^T]GN M+;X*@
M    (4TC#"W9?6BWR2W .P()VYFW*\(=I\8>EDEF?A^9S>]0BUT\M",!-0
M             <+-"LBL/OZ<EC.S,=5;Y17:)'2ZMYV(;*B>0A+!DX:E(J1:
M#(_0 ?7$RM"<5L:<>8<BV K?$*U1GDN(=:ADRCDH6E[U0E)1I(R7WJ]O$!V
M       9\M?W49K[=R/^8?-\[ZBOO2^AV?(M=R';&HN  "-Y#]T6$??! ]=2
M-G*^?;[U/.5^3=[E7,T8/I3YRA4%&&%NI=G(MODHSP[/%*X7)3<HHCEN)Y?*
M:2M1\@UI74S)):OBG0Z!-0       43U1?27;O[^K+ZW*'6V9VZ^Y/0QU[W*
M_(VEP   'QZ0_@WO/WR7+]9D:VU/-CNPK0OX<A<           !XKO;(]ZM,
M^S3"K$N,=Z(^7_TWT&VK_$H!@O:W=N]](]ZOVU>YEAES+$Y,5/@S8.CFGJ2E
MKG,)=4A#K3R&T'3F)-"B,C[U2(MK65DO7SM]'M;QXG8+M.O:FS.,FX-L18B7
M%$=.8IM]U9Z3I5*4\?(HNT#!U>C/;_)[/:,FW+S!E<:[9S);DQX[J3;<..A3
MKIOF@Z&DGEO&:2/Y%)'V*!$M1 @         8@ZL/SD=J/K7_2Z@6AM\%0
M             '%R566(CP3Q%N Y*.=&*Y%<S=2@K::_XR;7)X\XD_N>KNU[
M0':       !X[M]*IWSN[^T,1.I6K5*@-B/@FQO]Z?\ 93HXCD6/+A8@,X
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MS&[GD^0PG"DP6$M&S"9D$=2=42E+6ZM)]Y)JTD1\=)G0P1,M0@@
M    8@WM_/6VZ^LGLQ\%HU-O@J                XF22LHBMVT\6M\6XN.
MW".U=4S)"HQ,VU9GSWFS2A>MQ'#2CA7]2AAVP                '%L,K)I
M+]X1D5OCP8[$YQJRN1GS?.1;R2DVW74FDN6LS-1&FI]@#M        I3=+X3
ML4^<9GZRAX[;WF4<DO8[$]/<Y8?L>==4  '.O_TBNGSH_P"M*$3J7H[4<JS]
ML_@^QGVNC>MD/HV0]/1W8>&VCZFYWI='(9>2Q/-7N;MT>X\^XQV;OXF1X;P]
MM7JY\AONJYCB*)TM\-5>T;SGNR       ",;C_!YEOM+<?8K@SY?S:>6.=$Z
MF==F_@QQKYU_^T6/09CS)5IU)R,"P  .'MY^<R_]XJ_Z8;%<WZ:._P#X5/XO
M8TH."R               SCOMTHVS=&^>[?$[K[FLW,D^*?TJ5&E+:226UJY
M:B6TX1$1<Q%:D7I:\03$J><Z4>IZ[ULU]W':>L!=U9.WFZRF3;<,E*)+"V2(
M^/:2M)&?E!.+2VQ>PF-;'V61&MSZKID-RT'=;T\@FU.$W72VT@C5RVDF9GIU
M&9F=3,^%")E;(( &:>HO:? \>VOW-SV!:D+S"]-M/2[O(,WGD<R7'2:&=7!I
M-"H>@B,_DC,$P@%Y7)1_=]Q>01:%,14R%&=#)L[\GLXEVJTE\8P3OO7?41/T
M?C),J,VB@P5:J5,G3OK)K+CIX:ZE7T/1 WU,<U]Z5TR-W11)MI*8+F(4I:B1
M[HG$K[?0;2WV)^)QH"5P=7"EM[[;.NQCI,3)C&W7N))2;DR:.^53+C\3@"(2
MKJ<SW?BQ7&ZX]@V,><MOI5C7YTNO@'Y'*YZ'D2?5D.)2G0V1*XIX=H(AX>@'
MX-LF]O#]B, F6M05                <.SR[Z_>[^Q<[(W;K5'>CIM%T1(;
M>7<6U,D;BUMI(E-&VOU,B69U+B7 !W                <',9F00+!(E8O8
MVLCO*%L$S:'Y+<)#J%/()Q7.=2I)&A!J652XTH7$!W@        &;\ ^Y_\
M\5*]>4/EM6N>5],NZ_9',E AA  !R+=\+^%_O=Q]B.CI[*]51[?Z9:^?]'<^
MG^J%_CZ \"X-DF9!)O%_8NUC:M=LC2&D6>XMR6Y"[BR;*36ZMM"2-HT*[A)6
M9F=/0[0[P   *8V(^Z#=S[\YWK30Z6=[-ON0I3OKG'-7
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M-6,;(ID70I:KYE\UKD2+LZV3*&F#,E&U':)2S22C(M2E*,U4+L+@")E=P(
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M1D^&HOE]E6J[KFR/,-OC278[%P?*.>MI]""-+B4H[R269<?CT/8:J9
M  K+J'^!/-?:Y?[=(WLAY]'*I7J5OA/W&8[[60O8Z!U;G;GE3&IW11(  /%L
M'\+.\7_IKV"^,.T/*M_5SPI3KEH4<5D
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M5J4NIFDDDDD]A.+0^YOP;9C[1W/V(Z"K.G0#\&V3>WA^Q& 6EK4%0
M        $:Q]I",DRAQ.3JO*W'XNNQFXPLK.9,%1HDM]]/.(^;1SB?:0"2@
M              C.?H97B\I+^4JPQLW(]<@2Y&9-D^>BB-4HC;+FGZGQ[=5/
MB ),         S?@'W/_ /BI7KRA\MJUSROIEW7[(YDH$,(  .1;OA?PO][N
M/L1T=/97JJ/;_3+7S_H[GT_U0O\ 'T!X%&<<;:1?\G4C*57QQ<I@W+,IR.LK
M.?)*C))9(EIYA>J4=X^4O*9A)@   4QL1]T&[GWYSO6FATL[V;?<A2G?7..:
MN                                      #$']X;_9Q]>_ZO!:&WP5
M&.MM<VRMZTWO:O;5A7NSNF0725.O3J3*+:K<M:&SD*50R-PS2HD%Z/HF9$.+
M;N5::*-<S/N?0\_E+45TYG,3_ETT4Q%._75P<G"L:XW&Q; V*)@& 1%9'NKD
M:M:$+]4E2I3E=4R8JM4MI/4:4FKT>/IUC8F8L1U:=-4N/;MW-I7)O7IZEFCW
M1'RT\>[@@MUNL6P-BEY_G\M61[JY&K0M:/5)4J4Y33#AII5+:3TDI1)]#AZ1
M 1$6(ZU6FJ2Y<N;2N19LQU+-'NB/FJX]W#+]V2R>Y[Q6_6_4IMO(6VZVJU'W
MH]HCJKRV&&ZGJD*K3AQK7C6IB::>K_FW=9>O>+ADLE'P[\[]<\,_RH1$OV>9
MQO#MKG.2QE6C%+G-GMXG9%F9/)C-1#4J2[2G>>U)^.1<"TT-6&FNNN[35.J<
M<'2JLY?+Y._9MSUJZ8IZ]6]CUM4<C68Z[P0 KG?OX',Q]KU?MTC7S'ER[.Q?
M6VN\EV*?<M8_:^)ZR@9:.S#G9GS:^]/.[ NUP!P,V0VO$[LE[(3Q1HV#UY$2
MV6O!$1E5W6_ZFFG950#L0Z%$CD4@Y9<M%)1Z3-WNEWST$2>]V]TB+T 'W
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MJ:YIZO6JX9ZT:N1/-\?I1BWWRV_UM\;VW?(I[T<TN9L'SJ^Y//#D#QKT@
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M2BE/Q@7  ! LF^%_:'VVE>M-C+_HW.12K7#6H\TR
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M$]2> Q?Z5WM)G0I\<S/L+G(_Z0ZL\!B]@J
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MAK4>:9                             !B#HP^&'=+_M/9[@+2V^"H
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MT,=>]ROR-I<   !\>D/X-[S]\ER_69&MM3S8[L*T+^'(7
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MW/*F-3NBB0  >+8/X6=XO_37L%\8=H>5;^KGA2G7+0HXK(
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MZ5\8=^!<(%TB-3[9*9FP7B,V949Q+S2R(S(S2M!F1\2IP,8JJ9IG"=$I>@5
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MACKWN5^1M+@   /CTA_!O>?ODN7ZS(UMJ>;'=A6A?PY"X
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M[<\J8U.Z*)  !XM@_A9WB_\ 37L%\8=H>5;^KGA2G7+0HXK(
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M^1BRSQ<\HLTF\:<@@*LOA8[LGP=THX3$MWE&6AMJJM3B^ZFI5&\YZ8
M  C&X_P>9;[2W'V*X,^7\VGECG1.IG79OX,<:^=?_M%CT&8\R5:=2<C L  #
MA[>?G,O_ 'BK_IAL5S?IH[_^%3^+V-*#@L@
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M?HD-FFJ*HQB<8:E5,TSA,83#.F ?<_\ ^*E>O*'R^K7/*^E7=?LCF2@0P@
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MDI*#,C$Q?N8ZY.K"V.F3X"L-^=G_ &6\.1M'U%6[>*-2VASUP
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MSZ4FMPN!T6FWI61$[,F.D5#>,J&1&5$E3AZ1!J*)O3-^_/P\_%!JT0F'2A\
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MR%P                           &(.K#\Y':CZU_TNH%H;?!4
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MMSMSRIC4[HHD  'BV#^%G>+_ -->P7QAVAY5OZN>%*=<M"CBL@
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M'9&1<  'CNWTJG?.[O[0Q,:Q*NF3X"L-^=G_ &6\.=M'U%6[>5HU+:'/7
M                         8@_O#?[./KW_5X+0V^"H Q]L[MQ"R=V^YEG
M]S0>WF,7RY2(=D>428AS4J)3TF36B30E.@B(ZZO+W:DKC6;453-54_#$OH6U
M<_59ZMJS3_FW**8FK?PWHC=^DS(KSU+7DDI)^T[%VE^A$6IE^^/LJ_4-+*3+
M]3_/])E^+,5<%$?BYWP;)HWJLS5'+%$3T[M6O[9#D-RW0N2MG-G%)M6%6I*8
MF595$3ICLQT]WP</30E&HB-)FD^]QXD@E*.:JINSX=OL[\[MT\BEBQ3DZ?NL
MU\5RK311.N9^:K=^+]7V^HQ)$38+8*(@\I-%+I="HMJV-+(B=DR72(]4A5:\
M?2\"(JZ4A55U?\JUK+-GQ\<[G9^#>CYN"(CY=W#+CJP+%=L]R=H\<MLI,S)'
MYMSG7Z>\HCFRG7HFE+KE3-1(-1+)M)GZ/:K49UBU3;N41&O3BV(SEW-Y;,7*
MHPHB*8IC>CXM4=*7]3?T@P;[\[3ZU)&?.=F.5J_]9\^Y_P =7/2X(T7K
M':Z4_@]N_P!\%Q_6:&]DO+]KR/\ V;U5/<IZ5O9*YD35BG.8DS$D9(EHSMS-
MQ6XW$4[4N#JFB-1%2O8-YY5T(WB#CLG,)!2]">>31F;9.4+5H-1$9IKV5(!2
M/4%"L]PO^V$3($,N61=^4<]$DR2QR4,ZU<PS,BT$1557A3MX#6O8:,>%HYFF
M)JHB=6/0Y$V1>.H^YN6&P.O6;8^U.DU<+FTDV7[T\R9>HL$9%I933RE\4RK1
M*8G&Y.$=E29G,3A&BC^K]'XR#()N:S4[%[%I1:L:M2"BY-DT4C\-"C5,E1XZ
MB/ON+[VI6K4M5>/IUE$SUO@HU%54USX=O1$:YX.*.-Z;[?8&U<"!L?L? 3.W
M G)]4<[KA0R<26N;-72AN&7>(E<$E3AITI5,SU/AIUK551:B+=N/BYN.7R4K
M'^G#'TQ(B5Y;O1EJZD1ZG9D^8ZKTRNU:8Z5GP+TRU?%J:6BU'#5*/AR]/S5U
M>^9_)W^E+X%++\\3O93@O8["<AY,>U$MI_NFW4^_"Z>O*'.N=J6K:[5?>E:
MQLX  *[W&^Z[:_[Z(O[50RVNW#%7VJ.]#18Z[KN-'<RH\GFM2V8)8>45E5N?
M;6Z=P5,-2B>2Z@RT$@B))I-)U =D!GC:S#H,NW'F^:3D.8[9'Y:K3;WCI&94
MEY2G7W2/@9ZO2EQ["] B'DMGY6FJGQKL_#1,X1O1ITS+V>T\W535X-F/CKB.
MM._.C1$),PQ/WEGINET2Y;]K;>X:X<-9FTY='&C_ '5WL,FB,O\ D=33N1%6
M>JZU7PV:=4?-QSQ-&JJG9]/5I^*_5KGY.*.-\;G<[ANO<%X9ABSM^W]O-+%Z
MO3"20E]*"(O#1J%333APX4_R:$JMRY5G:O"M?#:I[57#Q1N_#7-NW3D:?&O?
M%=JTTTSO?S5;OQU>R[79R.XUM-M,TB/-CHT72Z(XLVUD^"S-9>F?5_AK_E>E
MR7+F'_\ &RVB8US\OZ[M>K':M1,3FLU.,3V:=^J?_'=JU\:/C-@P_=? <?LR
MTN2F6+D]<GE*)4AUYZ(Y1Q[RD:M)Z2] :].7MV,W:HIUX58\.J=;:JS%S,9.
M]<KU3-.'!HJC1"1[X_2C%OOEM_K;XS;=\BGO1S2U=@^=7W)YX<@>->D    =
M38'[C9_MO,_6;'M-A^G^J>AYK;WJ([L=*>Y.O)6K!.<P]J&_DJ4$=N9N:G&X
M:G-15)Q31&LBTUI3RT'?>>=1KF\I'.))/:2YA(,S3JIQH9T.E0&=>IB+8IF:
M[01\F2RO'SN\M=R3+,DQ_#MH86LW3,R+01%55>%.W@.SL^:HMW>KKPACJUPY
M;[][ZI+V=HM!OV7I_LKY-RY;9&P_?'V#*C;94(TLI,N!?(]I]_2E%XBG)TXS
MINS_ '?U.UR/1D^3W+<&Y%L+L*3=JQBU-IB95E41-(L&*54JC1E),M3BJ&DS
M2=5'4B.FM91;MQ:CQ[^F9[-/#QR3..B'ZOM]B[:18/3YT^04RL^E)K<+@=%I
MMZ5D1.S)CI%0WC*AD1E1)4X>D0:BB;TS?OS\//Q0:M$/NZ[BW2_BS5GL[2\M
MWERU9&VV9*=G7*<ZHRYKM#-:8Z5F>E-:K.O'5J45?CSE>,_#;I]T1^9V>5*>
ME#X <1^N7]*2A@VGZFKV<T)M]E5^UG9FOWVWGUU(ZM[53W:44I^,"X  (%DW
MPO[0^VTKUIL9?]&YR*5:X:U'FF0                             8@Z,
M/AAW2_[3V>X"TMO@J                XJ8V4%ECDQ<^*>&G )INV%'44TK
MCS:F\;^LTFWR^[HT=O&O#B':               !X;TU=7[1/9L4AJ)>G([J
M+=*DMF\RU)4@R;6X@C2:DI50S*H#]VINXLVN$U>'VI-W;CM)GR8[9LLNR4H(
MG5MMFI1I2I532DU'0N%0'K       !GRU_=1FOMW(_YA\WSOJ*^]+Z'9\BUW
M(=L:BX  (WD/W181]\$#UU(V<KY]OO4\Y7Y-WN5<S1@^E/G+BL1LH3E,N7(G
MQ5X@N&TW#MJ(ZDS&YI+,W'%OFLTJ0::$2='ZW>#M        HGJB^DNW?W]6
M7UN4.MLSMU]R>ACKWN5^1M+@   /CTA_!O>?ODN7ZS(UMJ>;'=A6A?PY"X
M                       _FUU&[R;G[G66U7]5EEXEM>N6INR-NK-#\^4A
MM1F^LRTFHDH,R3I+0G49:E'Q(O$/Z*VMYMJR07GW"0VF*R:W%F1$7J:>)F8*
M,5]5,J++ZC]J5Q7VWT).UDI32TK(C\[*X&:3,%H;D!4               !#
M=QF\/=M]F+,X$BX1$WJWJMC<5N0ZINYD[_%G5>&,C)"%<5&ON>C7L 3(
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M*Q-4[+?<Q=9%RD%>W_/S4AYYY,2Y$TV3C#1.D1(0E))/2BJ>/;Y""8@
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M5YAYJO\ )NEX.3$.]6I^2;[%M<\,1--L-&1$T3B"UJ(C/4KC\0!+0
M '%RO+<>PBR/9%E$SP%FCJ;0])Y3KVE3JR0@M#*%K.JC(N"16JJ*8QECN7*:
M(QJU*[_*@V+]]7VON7T*,?C4<+5^^L_-^$_D?E0;%^^K[7W+Z%#QJ.$^^L_-
M^$_DMMIUM]I#[1ZFG$DM"J&54J*I'0QF;S]@(?N@6-'ALPLMR&3B]C-Z+SKS
M!EG;Y#:RDMFVE+R2,R)Q1$A7#BDS[.T@F "G]P'++'W9Q&;D)LIM4*!-E.N2
M.+:%,I6M"J'VF2B+27;6E.(\_G9HC-VYKPZL15.EZ3(Q<G)7:;>/6FJF-'&_
MR)$G[OST9!D"%V_;*WK-ZV6QX^6J>INO\8D<>#9>0NRG O*9Q335GJNO7\-F
MG5'S<<\1553D*?#M_%>JUS\O%'&^,^?<=X;BO&,86NW[;6]9-7:[-%H.8:*?
MQ>/PIHI^I3B?#2E5:ZZL]5X=OX;5.N>'BA>BBG9]/B7/BO5=FGY>.7KNUV?D
MOHVHVH0B&4-!-7B\-$9L6Y@SHI*5%Z9]7&IUK6O'54TY+MV9G[;+:,.U5\OZ
M[N3%:M13'W6:TX]FG?JG_P =W+SLON=AVUQ9_;G#89W'(I\1]4U)=]Q#*VE<
MZ5)4FG>T5-*?(7'@FA'AS-RWE+4V+4=:J8G'W:9GV,^4MW,Y>C,7IZM%,QAR
MXZ*:?;NQ6'MG\'V,^UT;ULAU\AZ>CNPXVT?4W.]*F< ^Y_\ \5*]>4/G=6N>
M5[R[K]D<R4"&$  '(MWPOX7^]W'V(Z.GLKU5'M_IEKY_T=SZ?ZH7^/H#P*'X
MF6-%D^8^9LADW>[JF1U7RV/RSDLVU[D$3;3+1D1,I6DM1I*M3^-0@D=X^E,_
MYV>_:&+4:X)8\V*P#(]T\)QI>X3A6_9G$DO.VZT:^6F[2DONNN292C,O46S4
MI''AP,B^24?H\[?ILW*O#TW*M_@XHXV&F,8TZDQNUVO74G>G<$P1URS;(69Q
M,?(,@CIY2KDIJE(D0J$7+H1>2E.\KAI2K6IIIRE/7KTW)U1P<<K=K1&ITLBR
M*5.E-=/?3VTW;4VULH^2Y+'(SBV:*9F2T(61U7*6>K4K5JU5XZ]2D4MVXB/'
MOZ<=4?-^A,[T/S?+Y:=D+3;]D]D[>5XW3O!$KO$EU;*W4U7/GK/AJIWD(5W4
MIXG1!$2E%$YB9O7IPHC=A!JT0B^W^V[NVO4?C4&Y71V]Y+=\<G77(;J\I2N=
M/?>=2O1JXZ")!$1JXGVG2M"SW\QXV5JF(PB*HB(XD1&%23=1_P *.S7SQ?/6
M8@Q[.\NY]/2FK7#LC(N  #QW;Z53OG=W]H8F-8E73)\!6&_.S_LMX<[:/J*M
MV\K1J6T.>N                            Q!_>&_V<?7O^KP6AM\%0!C
M7:G ,IW05>,>NTE4':6VY#/F7!AA1H>N<XW$GR#41U)M!)29_'X550T<6U:J
MN3,?PXOHNTL[:R?5KIC&_513$<%,</+.[CL+(<AN6Z%R5LYLXI-JPJU)3$RK
M*HB=,=F.GN^#AZ:$HU$1I,TGWN/$D$I1YZJINSX=OL[\[MT\CD6+%.3I^ZS7
MQ7*M-%$ZYGYJMWXOU?;ZC$D1-@M@HB#RDT4NET*BVK8TLB)V3)=(CU2%5KQ]
M+P(BKI2%575_RK6LLV?'QSN=GX-Z/FX(B/EW<,OK*E8YTZXY&Q+$HRLEW7R5
M1&TT9&Y,G3'#,CD2#(S4EE*C5I3JX\>/IUB9FG+T]6G37.[_ /(5IIN[4NS=
MNSX=FW[J8X(X]W!"*P]N+IAVZ>V&1Y?<EW;<#)KA<G[[*-566R:A>IL,EP+2
MWK,JD5/(5$D0QTVIHN435.FK'%OU9^B_E+]NU3U;5NFGJQ]6N>5/.IOZ08-]
M^=I]:DC8SG9CE:'_ %GS[G_'5STN"-%ZP   !VNE/X/;O]\%Q_6:&]DO+]KR
M/_9O54]RGI69N(FPJPF](R>\OX]851S3.O,.0<.1&;-1%K;>(C-*JT+L.M:4
MXC>>5=ZW''5;XBHCYRHILMFQ)4OFJ=;TEI6:S],:BXZO* I#J,QZ!EEXVSQR
MZZ_-MRORH\HFE:%FTIKO$2J'2I<*C6O1CA'&Y^;HBNJBF=6+F9)DEPSNX%L?
ML>2+9CEL0F+D^3Q4TBPHI52<:,:3+4M5#(S(ZJ.I$=-2BK55UO@HU%=<USX=
MO1$:YX.*.-Z[M=H>V4.#L?L?!1+SR6C5(D*HM$%"R+F3ISE*&X94-*3*A%3A
M30A4S/5^"C6F9BW$6[<?%S<<OS)?QOIRQYNW6UM>5[PY4NJ"42G9UQFO*H;C
MM#-:8Z5GW4UJH_BZE$T6HX:I)FG+TX1\5=7OF?R?Y9K-:]F;7/WBWBGE=MR[
ML5#,M+BVEN)HB#!07#53NJ4GNI3P*B",U(B*(ZU6LIIBU$W+DXU3NPAV>E+X
M%++\\3O93@O8[!D/)CVHEM/]TVZGWX73UY0YUSM2U;7:K[TK0&-G  !7>XWW
M7;7_ 'T1?VJAEM=N&*OM4=Z&BQUW71*WGCOX1;UX:_R9&3';H93L=7)-<2+&
M2MPVGVX]*(6X:C)2J\?B>4): SIMKB5WS>U-1L@=\-MW:9DEXH:%:%7"5SE+
M,W3(^#3=:?K<>)>0R.6KS%.%>BU3,Z/FG'FA[3:.:HRU<S;TW:HC3\L8;W'*
M27.YW#=>X+PS#%G;]O[>:6+U>F$DA+Z4$1>&C4*FFG#API_DT)6Y<N59VKPK
M7PVJ>U5P\4;OPUZ-NW3D:?&O?%=JTTTSO?S5;OQU>R[79R.XUM-M,TB/-CHT
M72Z(XLVUD^"S-9>F?5_AK_E>ER7+F'_\;+:)C7/R_KNUZL=JU$Q.:S4XQ/9I
MWZI_\=VK7^)\^V[5VV+@F"1?.N=W7O)2JBW5.K+O2I2O(1<32DSI3_)J8BNN
MG)TQ9LQUKE6[&4T45YVN;]^>K:IW=6E'[5ACV([KX.[<YJ[ED=V1=)5XG+49
MDM[PCA$E!'\BFM"]'XA4(M6UE9L9NUUIZU576FJ?9+<NYR+^3O13'5HIZD4Q
MQ=9+=\?I1BWWRV_UM\;.W?(I[T<TM+8/G5]R>>'('C7I    '4V!^XV?[;S/
MUFQ[38?I_JGH>:V]ZB.['2E>X_F$\(O)9/>Y..6$V4E-O<&0<.3&0;B2)3;R
M24:3-5$]AUK0=]YY)(W+\.SR7#=:T)Y;IJUFI-"HHU'VU+R@,Y]3^-V[,,PV
MBQB[\SS7=+Q*C2R95H<-I28^HB50Z5(J5':V=<FW1<JC7$1TL=<8S#SY/D]R
MW!N1;"["DW:L8M3:8F595$32+!BE5*HT923+4XJAI,TG51U(CIK64V[<6H\>
M_IF>S3P\<DSCHA^K[?8NVD6#T^=/D%,K/I2:W"X'1:;>E9$3LR8Z14-XRH9$
M9425.'I$&HHF],W[\_#S\4&K1#[NNXMTOXLU9[.TO+=Y<M61MMF2G9URG.J,
MN:[0S6F.E9GI36JSKQU:E%7X\Y7C/PVZ?=$?F=GE?&UVNT[$VF=O3O3.*^;M
MWPC2TTDTN+:6XFB8,%)=TJ)HEQQ):4I[J>[Z>:JIS,Q9LQA1&[&35IE+^E#X
M <1^N7]*2AK[3]35[.:$V^RJ_:SLS7[[;SZZD=6]JI[M**4_&!<  $"R;X7]
MH?;:5ZTV,O\ HW.12K7#6H\TR                             #$'1A\
M,.Z7_:>SW 6EM\%0               $*:3A/X69"VVY'X1/,"$O.FF7X7S.
M4LS2DC/^+:^<?D]4I\2H":@               X6:HL3F'7]&4(<<QI5NE%>
M$,$\;IPN2KG$@H_JE=%:<OO>@ ^N)ILZ,5L:,>2XFP)M\0K4EXG2=*&3*.22
MR?\ 5-6C37F=ZOIN(#L        SY:_NHS7V[D?\P^;YWU%?>E]#L^1:[D.V
M-1<  $;R'[HL(^^"!ZZD;.5\^WWJ><K\F[W*N9HP?2GSE"H*<)+=.[JB-R"S
M\[1%*XNJ3+*,=M)Y?)))J_B^K69UT=[_ !@)J       "B>J+Z2[=_?U9?6Y
M0ZVS.W7W)Z&.O>Y7Y&TN    ^/2'\&]Y^^2Y?K,C6VIYL=V%:%_#D+@
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ME^+V6LUQ'5B9JT<$1.$/SN)\*UI]I'/9"ASMN^=3W>EM[&]-5W^A_H\^Z@
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M"]CH'5N=N>5,:G=%$@  \6P?PL[Q?^FO8+XP[0\JW]7/"E.N6A1Q60
M                         !B#>W\];;KZR>S'P6C4V^"H
M   #@Y3,R&&W:CQVQM7Q;URBLW%#TE$3PD!9GSI:3<2KF*:H1DVGO*KP =X
M      'CNWTJG?.[O[0Q$ZE:M4L\=/OP0X[_ .-]GR!Q9<;+>7&[?68(;(
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MK3J3D8%@  </;S\YE_[Q5_TPV*YOTT=__"I_%[&E!P60
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MWXC'\?D5\+9HM:MF;9U-4A1F6A%-6KB?JE"0NW8B/ L:<=<_-^A$;\I;TH?
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M'6V9VZ^Y/0QU[W*_(VEP   'QZ0_@WO/WR7+]9D:VU/-CNPK0OX<A<
M                   5YNSLSB&\UNMULR]<Q$:V/+DQC@.H95K<1H/4:VW*
ME0$XI]&81%CLQ6J\ME"6T5XGI01$5?\  "&)>K#\Y':CZU_TNH%H;?!4
M           !#]PSQE,&RGE%\E6&/YZ@> ?A2%Q52)_,/D1G%-D9J;=/@M!\
M#+M,J )@  .+D678OB++,G)[O%M#$E1ML.3'4LI6M)5,DFHRJ9$*S5$:V.NY
M31VIP1[\-.TOOTM'\L:_Z17Q*>%B^YM?-#TV_=G;.[3H]LMF66N7<);B68T9
MF4VMQQQ9T2E*2.IF9B8N4SOK1F+<SA%4)D+L[QW;Z53OG=W]H8B=2M6J5 ;$
M?!-C?[T_[*='$<BQY<+$!G  !";/^<A;?O3D^S2&UENW[%;?G1R2OT=)U$0P
M%>-*+)RQN^RKX2;_ #TW;QDA<GP-RJ@WX36LBY;354Z&TU2FO P'SW:^#C(_
MG17[9(YVTO35\CI[+]5;Y5;6-=[W>MMJQN$;ULV[M$6+'O,TNX]<)##2"4RW
M_D$9?]97'2D<:SXF=IIMQC3:IB(JGYIB-6[EX'<O1;R%55RK"J[5,S3&]3$S
MKG=TNO=[O)R:26UFUA)@66 DF+Y?&"]1BL\24RRHC[RU<:G6JCKQ],HMB[=F
M]/V^7T4QVJMZ(X(W:??+6M6HLQ]SF?BJJTTTSKF>&>+=P0]5PN$;!XT7:[:Z
M*F1EDA.IUU5%)B)41:Y4I=*&LRXD1_$X4TI5>NN,O$9?+QC7/X?S5;NB&.W;
MG,S.9S,X41^/\M/%NX9?EYZS;,V9,*$E=_W$OZZD1U7*FREF9<QRAFI+25&=
M"KQ^/J429HR%&$?'=K]\S^2:::]H5]:KX+5'NIC\WCVABY#$S_-FLJD)DY I
MFVO3G$'5)+?:-TD%3A1M*B1PX<.' 8]F4W*<Q=BY.-6%./MCHU,NU:K566M3
M:C"C&K#V3A^.LW$^%:T^TCGLA0Y^W?.I[O2VMC>FJ[_0_P!'GW4  !'LY^Y*
MZ_O/_6(5JU,UGMPO#$/N3L/M=$]80/IN6\JCNQS/GN;\ZOO5<[D9:K&$Y-AQ
M7N_2K5=CFOE8K='E.1V;A(Y!ZVGVT%1U*4=XB70J_'H>PU4P 9 S"\9_$ZE<
MUL&VD(GLIR*U6V"BYN_ZO;8Y,LK=EN<#+ND1$FOR1]BCHD_16J+<Y6BJY/PT
MS.CAXF+&>M."83Y^-]-.-Q\2Q*.O+-Y<L62TI61NS9\UTS(Y,DR,U)82HU:$
M:N/'C76LM:FFK-U=:KX;=/NB.".-/9Y7YM%HL>P%CG;M;M3CR#=K(#-*E),G
M'U/N$6F#!32A$142M:2)))*A421$<U559JJ+5J.K13NQD[.F=;ZX[CKT)Z1U
M$=1$AN)=(C?-L%@=JJ-9(RCJVE+9\5RUG2A4U$K_ "_21<N8_P"18U;\_-^B
M8C?E2^^$K/MV,"G[N7XG;%M]!D1V,-QQ?!V2F0Z3:IL@NSBDST'\7N]WO+Z>
M3BW8N1:I^*J>U/0QU8S&+4_4/\">:^UR_P!ND<'(>?1RLE>I6^$_<9COM9"]
MCH'5N=N>5,:G=%$@  \6P?PL[Q?^FO8+XP[0\JW]7/"E.N6A1Q60
M                       !B#>W\];;KZR>S'P6C4V^"H
M ",YFVTXW9"=RE6*Z;O#4VXAR.UYP61JI;S\01DHG_V*.^>GAY0$F
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M/;S\YE_[Q5_TPV*YOTT=_P#PJ?Q>QI0<%D
M  17<WX-LQ]H[G[$= 9TZ ?@VR;V\/V(P"TM:@J (_F+.:/VA*,#DV^+>^<@
MU.W9#KD?D45J(B9[VJNF@I7UL/AUMO*S8BO_ #HJFG#^'#''VJ;SK)>HC [0
MQ>;C<L6DL2)L:WI;CQ9FLG);G+2H]:DE0C[1J7*KM$8S,/1Y/+[-S-<T4TW(
MPB9TS3O)2U;^I(G4&_><2-G47,),:=J-->-*GVT&3"]PPT9KV9AHIN^^E;8V
MGGP!C3:'[EY/ME-]<' HW^5]@S':CDCF3X7:X  .1;/ASVP^OW]&F,EGS:?;
MS-/:7H+WT?U0U(.P^9H]8V)+609&Z]DGG=EUZ,;-ETL)\TD3!5;JUWSYM>;Z
MKQ]#T0';F/G%B/R23J-EM;A)[*Z$F=/\0(F<(9VC=0>Y<G!D[CE@=O:P]27%
MIGOWIIHSY+JF%))M39+-1K0:4I)-5>0:GC588X:'-IS5R:.OU8PY70LF\V\=
M_P :3E\3;:(QCRVER$S9MY:AIY#95-TR?0@R10JDHRH9<>P3%VN8QPT+T7[U
M5/6ZL8<J%[+YWNQ<2R_(<1P)F[6V_7M^Y.27KBB&TAUU*4J:94Z@N:2=/%1>
MB*6ZZIQF(:^6N79ZTTTQ,3/"DV/;_;I97D%SQO'=O(EQN%G/3<76+NVJ(TJM
M-/B.7RC56I$25'V'Z!BT7JIG"(9J<S=JJFF*8T<:189O3E-YW.+;/*<:AV>Y
M)B.RWU1+DBX*:-M)*2A9-(TDHR.M#54BIPXB]%V9JZLPR49BJ;G4JB(T<+\;
M]_=+M;[?J]9&/-:H5S?:HY>A)QSU0   $<Z4O@4LOSQ.]E.#JV.POD/)CVK'
MSEB3(QJ2U$R;W(/FY'TW[3'7R:/HJBDKU/U7]SX_LAG;Z1@*3W4QLLNW.Q/'
MW)3D.-+A2O$NL\'#81J6M!?YY)T\?1[#[!YO:-CQ\U;HQPB8EZG9F8\#*7+F
M&,Q,8<KH7:[/R7T;4;4(1#*&@FKQ>&B,V+<P9T4E*B],^KC4ZUK7CJJ:<MV[
M,S]MEM&':J^7]=W)@M6HIC[K-:<>S3OU3_X[N7\W*Y0=MH,3;C;B(5PS:X%4
MB.BU-J67>E2E=E:=Y*5<"+B?=H1Q<N4Y2F+%B.M<JW8SN_!-NW5G*IS&8GJV
MZ=W5IW?B_P!99LVS-F5-FJ7?]Q+^NAF55RILI9D?+;J1J2TE1E4Z<?CZ4E,1
M1D*,9^.[7[YG\BJJO:%?5I^"U1[J8_-X)]@;QS&;]GNY4QM[,[K"D1(J#[S4
M/Q#2T-Q8R2KWN]WE%Y*\::E*PUV?"M5WK\_YE43$<6,:HW=,LM%^;UVBQEX_
MRZ:HF?YL)TU5;NB%A;9_!]C/M=&];(=?(>GH[L./M'U-SO2IG /N?_\ %2O7
ME#YW5KGE>\NZ_9',E AA  !R+=\+^%_O=Q]B.CI[*]51[?Z9:^?]'<^G^J%_
MCZ \"CF/L26K[DBWLF\]-.26#9M&F.D[2GDEZB9L]\^97F>J\:4^.8=:\?2F
M?\[/?M#%J-<$L=;59QE>6;88MLKM*2HE\\.^O+\J-!I9M,61+>5I;45-4AQ!
MEI,CJ7R/&JD>CS-FBB[5>NZOX:>'1S,-,XQA"P[Y?+3LA:;?LGLG;RO&Z=X(
ME=XDNK96ZFJY\]9\-5.\A"NZE/$Z((B5IT43F)F]>G"B-V$+:M$/]C1L:Z9,
M:7=+HMS+]Z,O<TJ4G4[/N<]U1'RFJD:TQTK,M2J54=#,M6E))FK.581\-NGW
M1'YG9Y7ZLUF@[5P;AOWOW<$3=PIJ-,:,FCB+>APCY<" W6ANF524HCH15XZ=
M:U*ZYO3%BQ'P<_')JTRANW%^SW+.I6Q97G< K1YXQZ9)Q^S_ /WR-:M:TM$Y
M4B/6M1+69JXG6M$E1);-^BW1E9IHG'"J,9XT1CUM*6]1_P *.S7SQ?/68@P[
M.\NY]/2FK7#LC(N  #QW;Z53OG=W]H8F-8E73)\!6&_.S_LMX<[:/J*MV\K1
MJ6T.>N                            Q!_>&_V<?7O^KP6AM\%0!C3;S/
M<I*T7K:K;.,I><WC(+I)E75:3*-;+>M;;9R%*H9:^Z9)]#XJC20XMNY5IHHU
MS,OHN>R5KKTYG,3_ )=-%,1&_55P+*E2L<Z=<<C8EB4962[KY*HC::,C<F3I
MCAF1R)!D9J2RE1JTIU<>/'TZQL3-.7IZM.FN=W_Y#C4TW=J79NW9\.S;]U,<
M$<>[@A\H$"S;$6:9N=N=,/(-U\@,T$2#);RWED6F'#33NH3W2<<)-"*A$5-*
M3B(BQ'7KTU2M777M&N,OEXZEFC=UJNB'UQO&W;>[)W]W]DML7EAOFV>SNU.-
M9XQG5M"&SK60=>ZGBHE'Y5GW9HHP_P V[KWHW;O:K?OQ5$9+)1C3/:JWZY_\
M=VI$V\BS?.=X=L\TOL0[/A]PFW!O%+0YPE>':B&I4I[AVO:DT*OI2X<.\K%3
M757=IJG1$XX-_P "QE\G?M43UKE,4]>K>QZW9CD3[J;^D&#??G:?6I(V<YV8
MY6A_UGS[G_'5STN"-%ZP   !VNE/X/;O]\%Q_6:&]DO+]KR/_9O54]RGI6MF
M33[V+W1N-?RQ9]3)Z,A-+*RAT,CYAE(]3I3@>KT>TC&\\JZ\1*D1&$+?.4I+
M:"5)/21NF22[_=H7>[>' !1'4HC(G;AMPUB2VV\E=O;C=L=?IRVWULZ4K56I
M4375V'V=A]@UK^.C#7BY^;ZW6HZNO'H?.3)QWIQQU%LMB%Y7N_E:]24JU.S;
MC-=49<UVAFM+"5F>E-:J/XNI11HM1PS*9FG+TX1\5=7OF7YLUFM>S-KG[Q;Q
M3RNVY=V*AF6EQ;2W$T1!@H+AJIW5*3W4IX%1!&:D1%$=:K64TQ:B;ER<:IW8
M0_5@L$F;)=WYWY=;MZ+>V;^.XZ^9G&M,8S(T+6@RJN2LZ4*FK53AJTI0B/XZ
MTTTS,^)<T8:HX/U<^U6J\=0UX;S;-FUVC9JT+4_8;"^KE'<3:K65*.I%RZ$?
MEI3NIX:E*B(FY.,]E2FF<Q/6JT41JCAXY2?I2^!2R_/$[V4X,ECL+9#R8]J)
M;3_=-NI]^%T]>4.=<[4M6UVJ^]*T!C9P  5WN-]UVU_WT1?VJAEM=N&*OM4=
MZ&BQUW71Z(Q)3FER?5DOB8JX,8D8KI8K$42UUE:D^JT=IIHON]TZ?$"0@,Y8
M-D]_N&-,[>X,DV[\_)F.W:\*(R:M\5R0OO$?E<47I?0\G'TOD,IF+E5OP+/:
MF9QJ^6,>=[7.Y:W1=F_>[,13U:?FG#FW<LOGS[;M7;8N"8)%\ZYW=>\E*J+=
M4ZLN]*E*\A%Q-*3.E/\ )J8WZZZ<G3%FS'6N5;L9<VBBO.US?OSU;5.[JTO]
MC1K1L[:';]?G57W<*^JTJ4FJY,N2LRHPP5#-+:3,M2J>AP]*D*::,C1UZ_CN
MU^^9X(XMW!!557M"N**(ZEJCW1'#/'NX9?JV6QO%VY.ZVZTE"\B6BD6*5%-P
M6U$>B-&17BZ?89E\7CZ91S;MQ9B<SF9^+>CY>*./=PRBY<F_,97*Q\&_/S<<
M\6[@A%K/=LJR+=_#<DR*-YOM]Q;N)V.VG^Z-1$1':+7P(ZN&JM3[?0)-!I6K
MEV[G+=RN,(JZW5CBPGG="[:LV<E=MVYZTT]7K3PSUHYDSWQ^E&+??+;_ %M\
M;>W?(I[T<TN?L'SJ^Y//#D#QKT@   #J; _<;/\ ;>9^LV/:;#]/]4]#S6WO
M41W8Z4VS5I]_%;FU&R$L4?-KN9":65%#HHCUF4BC=*%I/5Z/HCOO/.VR1DRV
M2G.<K2FKO M9T]-W>''MX ,U=5C.2R<DVIC8<ZAC*'[I,:M4ATR)#4AQ#"4N
M&:B,NY75V'V=A]@[>S9HBBYU^SA&+'7CC&#T.NXMTOXLU9[.TO+=Y<M61MMF
M2G9URG.J,N:[0S6F.E9GI36JSKQU:E%7X\Y7C/PVZ?=$?F=GE?&UVNT[$VF=
MO3O3.*^;MWPC2TTDTN+:6XFB8,%)=TJ)HEQQ):4I[J>[Z>:JIS,Q9LQA1&[&
M35IE^L5Q65)E/]1/42^W!?@M^(Q_'Y%?"V:+6K9FV=35(49EH135JXGZI0D+
MMV(CP+&G'7/S?H1&_+S0+-?.HJ\-9]N&VNP['68U3+!C\I9,G<2:(S\9-.I$
MEO21GQ.FG@GNFI:K55TY2GJ6]-R=<\'%!AUM>I-NE#X <1^N7]*2AJ[3]35[
M.:$V^RJ_:SLS7[[;SZZD=6]JI[M**4_&!<  $"R;X7]H?;:5ZTV,O^C<Y%*M
M<-:CS3(                             ,0=&'PP[I?\ :>SW 6EM\%0
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M>]ROR-I<   !\>D/X-[S]\ER_69&MM3S8[L*T+^'(7
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MVA7UJO@M4>ZF/S?*%"@;90)6XNXLKSEG=RJE"$F2U(4LN[%BI["H7!2BX$7
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M.@=6YVYY4QJ=T42  #Q;!_"SO%_Z:]@OC#M#RK?U<\*4ZY:%'%9
M                       &(-[?SUMNOK)[,?!:-3;X*@
M (MG"K>EFQ%<<6>RI*KS"3':8CLR3M\@S5HN"N<I)(2P?:XGO)U< $I
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M4]VE%*?C N  "!9-\+^T/MM*]:;&7_1N<BE6N&M1YID
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M:KHHU132C/WZ[^4HKKUS54\FZ7PG8I\XS/UE#G;>\RCDEN[$]/<Y8?L>==4
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M:^=?_M%CLYCS)13J3D8%@  </;S\YE_[Q5_TPV*YOTT=_P#PJ?Q>QI0<%D
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M=*7P*67YXG>RG!>QV$Y#R8]J);3_ '3;J??A=/7E#G7.U+5M=JOO2M 8V<
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MRUD+M5SM5]6>/M1KY4EWQ^E&+??+;_6WQFV[Y%/>CFEJ[!\ZON3SPY \:](
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M%*?C N  "!9-\+^T/MM*]:;&7_1N<BE6N&M1YID
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M=K2RG$^2R1HD>(-1SN=7FF1I]2T4T>7M 2        %-=3]PN-LVN7(M<V1
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M@80UKMM>\DR3!+%?<PMWFC)IT8G;G;>0]%Y#QJ,C1RGU*<1P(N"SJ"J5
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MW%LV.Y]MUYAQ*9XKSA=?,EWA<GE1'G6O5I3ZVDZG4(1WD\:T+B9 C!J<$
M                  #G7]Z3'L-TD0R-4MJ)(<CI(])FXEI1I(CX4XEV@,B=
M#$>&O:[/E.*(W'IAM2$&DE493"[IF7EKJ7P!:7CZ([G>+=M5N5+L\8YEP@.G
M+M<32MXGIB82U);Y39DI6I2$)HDZJ[" E4N\MUZD=\?,GNLVPN</S#XKP?FN
MPW=K5XWDZ^9SS?K3D)TZ:>7M\A,+3_*2ZPOQ1?\ MR_?1((P@_*2ZPOQ1?\
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MM>&!$1"2>[/KT]ZL;^ @?1(P)T.UA^6]:TG+;!'RK&H[&+O7&&W>WTLPB4W
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MY3D9+"F=4A+'!).+U>FKVD"8E>WZ/>S^_P D_8UOZ(!&)^CWL_O\D_8UOZ(
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M_1[V?W^2?L:W]$ 8ME0XY1(D>(2M9,-H:)5*5T))-:?J J^X
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M[L[SV6-C-KQ5EI-LM<=U#AO/QS6XUH0EUXR(G7#=6M:B/@E*:]J26N 5
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M;1:(%I2X;J8$9F*3IEI-9,MDC52ITK2H(>T
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MW     ?&1$B2TI3+8;?2DZI)U"5D1_$U$8#ZI2E*22DB))%0B+@1$0#_ $
M     'P>A0Y*T.2([3SC?I%N(2M2?+P,R.@#[@     #X1X4.'J\)':8UTU\
MI"45I6E=)%6E0'W       !^5H0XA3;B26VLC2M"BJDTGP,C(^TC ?B/%C1$
M&W%90PV9ZC0TDD)-1\*T21<> #Z@    /@]"AR5H<D1VGG&_2+<0E:D^7@9D
M= 'W         ?!4*&M\I2X[2I2::7C0DW"IV452H#[@    /RM"'$*;<22V
MUD:5H454FD^!D9'VD8#\1XL:(@VXK*&&S/4:&DDA)J/A6B2+CP ?4
M
M
M
M
M
M
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M;E:5[I\ # -R\7W+CW:3B[CSC5EG.6J=XAHV3*2R1&HDU,ZEQ[0$P
M       ''RK*K#A./S<IR>7X&Q6Y*7)DOENO:$K6ELCT,I6LZJ41=U)@&*Y5
M8<VQ^%E.,2_'6*XI4Y#E\MUG6E"U-F>AY*%E123+O)(!V
M 0ZS;IX'D.;77;JSW;Q.8V1I;]TMOAY+?*;:6VVH^:XTEI5%/(+N+/M^(8"8
M@               C.=;@XAMI9$Y%FUQ\UV93Z(B9/(?DU>=)2DIT1VW%\20
MKCIH [ELN4*\VV'=[:[S[=<&&I<1[2I&ME]!.(5I61**J3(Z*(C >H
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M,J/!W;3?,5RY3!RXUGR:!YOD2&$EJ-;1$XX1D1$9]XR,R(S*I$8&"UP0
M        S1U*[ZXO$VOO47;[.HK6;L28K335KFI*<C1*0EY)$VK45$DHE?$!
M,0EFRV].#7K!L+M-VS2!-SJ; AL2XC\Q"Y[L]:")2%I,]1N&KM+MJ!,+K!
M            X.49OB&$QX\K+[W#LD:4LVHSL]Y#"7%I+4:4FLRJ9%Q 91Q+
M?V%^5#E7GC/D?@K\$OS3SYQ>:>?RXM.556C57F]GQ06PT-:8UE>-9C;CNV*W
M6+>+8EQ3!RX3J7FB=01&I&I)F52)1< 5=@              9HZE=]<7B;7W
MJ+M]G45K-V),5IIJUS4E.1HE(2\DB;5J*B242OB F(2S9;>G!KU@V%VF[9I
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MXE R_.(4C.Y25L2X\^:A4]R0[*<2TA1+5J-2DF@DE\8"8:"!
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MV&AJO%LZPW-VY+N'WV%>VX1H3+7 ?0^32G",TDK09TKI.GQ@52$
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M=6>R&27NVX]:;W(=NMWE,0(+2H$M"5R)3B6FTFI39$1&I1%4^! G!=P(
M8>ZC-U=]IUBSO#KIM]X3;M,MZ&C)O"RTU@QYI%'?YBEFWZH2$<=-#U< 6@Z<
M]U=]H-BP3#K7M]XO;M4MF&O)O"RU4@R)IE(?YB5DWZF2U\=-"T\0);A!4
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MM+^A>W]XR+(,,LUYRRV>9LCFQR=N-KT+;Y#QF9&C2X9J+@7E,%$E
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M75?JK"82C5RW."RYJE%W^""H:0&DNF;*,[S#:6V7O<%DT79QUUN&^IA,5<B
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M'#7\3R@MCH;&VVVEP?::#.MV$0G(46XNID2D.ONR34XA.@C(W5*,N'H JFX
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M))"34?"M$D7'@ ^H
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M"(N!$1 /] ?%^+%DF@Y+#;QMG5LW$)7I/T2J1T ?8
M
M     !\VV&&5+6TTAM3IZG5(2234KT54[3 ?0!5&Z.UF:Y9D5HR[ L_GX=>;
M8V4=^&DER[7+:2M:TF[%-U#:E$:U$9K2JI4_8D8)>/:O92\8=FM^W,SC*597
MGE^C(@.2VXB($=F(@VSY:6T*41F?);X]VA)[#,S,#%;QQHZGTRE,H.2@M*7C
M21N$GCP)5*TXF"'^O,,2$<N0TAUNI'H<22BJ78=#J ^@#Y/QH\I'*E,H>;K7
M0XDEIJ7EH9& ^H#Y%&CI?5*2R@I*RTJ>))$X:>' U4K3@0#Z@ #XM18K#CCK
M##;;KIU=6A"4J6=:U49%4^)^4!]@
M                                                     !^7&T.M
MK:=22VUD:5H/B1I45#(_C@,X_DCQ(<*Z8YCVXF1V?!KNLU3,;9=;6R;:R)*V
MR6HO2FDM'%)U30E:J G%>V)8M9\(QJV8G8&C9L]I83&BH6K6LTIXFI:N%5*,
MS4H_1,$.T
M                                               .=>,?L.1,(BY!
M:X=UC-JUMLSX[4IM*C*E22ZE1$= '[M5EL]BB^!L=OC6R%J-?AH3+<=K4KM/
M0VE)5/XP#W
M
M
M
M
M
M
M
M
M
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M]CIGS(#!.MM=[=N]VW[C'P>X.SG;4AIR:3L9Z-I2^:B10W4)K4T'V 8+#!
M     (1N3NU@^TT&#<<WFN0HMQ=5'BK:8=DFIQ"=9D9-)49</1 5S^6;L!]7
MY/V.F?,@3@?EF[ ?5^3]CIGS(# _+-V ^K\G['3/F0&!^6;L!]7Y/V.F?,@,
M#\LW8#ZOR?L=,^9 8'Y9NP'U?D_8Z9\R P6=MSN;A^ZUDD9#A4Q<VU1I2X#S
MKK+L=12&VVW5)TNI29EI=0=>P$)>
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MS=BLPZFK[FSD+=RP^;<5*"\XB1X-N/\ QM*VR;3J2M1\4FO@"):2!
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M$)3ZX<=<HM,I32#>32E'#26HJ?'!5]P
M      9TW\R[J2L.808>SMB\YXRNV-.RY'A&Y.F><A]*T:EK294;2T=/B@F%
M5_A)ZZO>C]K6?F@)T'X2>NKWH_:UGYH!H/PD]=7O1^UK/S0#0?A)ZZO>C]K6
M?F@&@_"3UU>]'[6L_- -!^$GKJ]Z/VM9^: :&M=MIV67+!+%.SJ-X3+GXQ+N
M\;036A_4=2T),R+A3R@JE0      Y63OW:-C=YDV%OG7UF#)<MC.DEZY:&5&
MRG2=".JR25 &-?PD]=7O1^UK/S0%M!^$GKJ]Z/VM9^: :#\)/75[T?M:S\T
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MU$C\A,;5 *.PI"]*%*(ZN*=*OQ 1*U 0
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M78Q78':#";]$R?%L78MU]@\SPDQMZ2M2.<TIE="<=4DZH6I/$O*!BLD$
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M?MS:GK'A5K1:+5(D*FO1FENN)5(6A#:EU=6LZFEM!=M. (24
M
M
M
M
M
M
M
M
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MH0!(O%HB36;;*GQF+C())L1'7FT/.$HS2G2A1DHZF1D5" >T
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M^.7.VLS6K<],8;N#Q:F8BW4)>6GT4H,]1EP\A /4
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MJ9TX $F\6B%+9@3)\:/.DFDH\9YYMMUPUJTIT(49&JI\"H7: ]H
M   #S2;A ANQV)<IF._+5RXK3KB4+=7P[J"49&H^)<" ?&Y7RR6;E>>+E%M_
M..C/BWVV-9E2I)YBDU[?( ]R5)4DE),C295(RXD9& \T&Y6ZYM+>MLMF8RVL
MVG'([B'4I<21&:3-!F1&1&7 !X7<KQ9B0N(]?+>W*;6;3C"Y;*7$N)/2:32:
MZD9'PH ZZ5)6E*T*)2%$1I41U(R/L,C >-=WM*+@BTKGQTW1PJH@J>04A14-
M52;,]1\",^P .\6@KB5H.?&*[**J8!O-^(,M.O@W75Z4M79V<0'M     >.Y
M7:UV=@I5WG1X$4STD_+=0PWJ,JTU.&15X /Q(O=EB0F;E*N,5BW2#23$MU]M
M#+AJ(U)TK4HDG4B,RH8#SQLJQB:^W%AWN!(E.GI:99E,N.*5Z"4I49F8#K*4
ME*34HR))%4S/@1$0#X0I\&Y1REVZ4S,BJ,R2_'<2ZV9IX&1*09EP ?EFYVV0
MXEF/,8=>572VVZA2CH53H1'7L ?ZBXV]R:Y;42V57%I)+=B)<2;R4'2BE((]
M1$=>TR ?X]<[;&ELV^1,8:GR2K'BN.H2\X15](@S)2NSR$ ]0
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M.)YLXY45H/U2NGTW#M[0'VAS8=QC(F6^0U*B.5Y<AA:76U:3-)T4DS(Z&1D
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M%-1I#3RR01D1J-*%&=*F15 >N7+B0(ZY<Y]N-%:(C<?>6EMM)&="JI1D1<3
M"E13C%,)]LXBDDM,@EIY9H/L42JTH?H@/S'G09:E)B26GU)*JB:<2LR+XNDS
M ?Y$N-ON!O% ELRCCK-J03#B7.6XGM0O29Z5%Z!@/\;N=M>FNVYF8PY<&2U/
M1$.H4\A/HJ01ZB+CY2 >H
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M]ATRYLX\Y8LTO,FREBL!;YY!:DQUJ1SI.I9EW23K<JV7=H9:=7 G!JX%0
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MC.$]'>0EQEY)D:5H61&E1&7 R,CJ"KZ@
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M7"@#?=HDQYEI@3(DKQT21'9=8F__ #VW$$I+G_QD>H%7M
M                      9TW@_.7V-^O7L<@2\5WM%MO_6%,LMYC(F6J?@2
MX\R*[Q0ZTY+HI*J4X&0&\CUCV6VKD=3648@_BL)>-0\9B3HMM-*N2W)<?;2I
MPBU5J9&9=H)QT/K:=N,'SWJIW9M.862/=K?!MME.&R_K(FC5;XB#-!H4DR/3
MPK4#>2KIB-W'\CW5VQA2'9&)8=>VD8^3RU.^'9F\]2XR5J-1T;-HN'HF9GQ,
MP1+10(     %=[\9+=\/V?R_(K"M;5WB0%E$?;].RM]26>:FG8;9+UD?Q 3"
MH<<Z;MG+GL_C%^N3R[-?Y<.V7J5G;,PV)Q3I1-/*<)]]2FRUK7H22D\*E3O<
M0,7XZI<AL5SF8!LM>\B1;;)?I"+IE5ZDOM,**U0"/0:UZ4MZI#B5FBB:<Q!<
M/(!#@8'FZ<CZ2=PL2DSFI]VP6W7*QN26%DXV_";;7X-YM1<#;-!&V@_*38)W
MU-';<?ON#X/@MAVS7CFY^1,V]RP9[-F(MT:0ZRMM;LEIPU$2S614)LN_51&D
MC5I(R7]!<D9DQ\ N\>8_XF6U9Y*)$FA)YKB8JB4NA<"U'QH"C^>NW>57# ]J
M,RP2.:EW#<BS6V5C$<SH;CD^:Y9YB4^B:DDJE/V%/B@NM'9_-+GLSM5?L=Q2
M&S=<JNNY<O$,=1-4I,0I+D>(TAV0:#)1H+1Q))D9F?H5!$K?MNZ>YN+YK==M
M]R6K1-NSF.R<DQV]65M]IA7A"62V9#+RU'4C09DI)EP+RZNZ0AMFWYWH1C&V
M^XM^C8^K$,SO47'I%MC-R2N!*DN/-G))PW.6FO(6I***H6DCJ9F9$X)7<MS]
MXLORG.H.U<6QQ;%M\YX.2=\1)=DW*>T@W'6F^0XA+2"T*21GV\#KQ/20M':7
M/VMT=NK#G;44X1W=EPWHFK63;\=Y<=U*54*J>8VK2?H4!":  "BLFW$W6R/=
M#)-N-J&[-#]QUOBR[M-OK;[QR9D]HGV&&296@D(-"BU+57C7]4ES<CW.WM8S
M;;[;^WVVR6G)\IM4V5>FIW-F18DJ&2S-QM;#A&I!I1J2CCQ,B-7:8"#.=06^
MT;;[)=P7H>-JMN 7M6/WYI+<OF7)],IEA:F"YI<E*2D-<5:C49F="II!."Q[
MAN=NEEFZ-\P;;"+9XL'$K=!N%V?OB7W')<BY,HDLQVS86GEI-M=#7I50R,_0
M($,S83,EW#9#:O;ER2[#QO-LV?M^0NL+4T;L-#S)'&-::4)TW:_'20):L@;"
M;489GV-Y1B;ZL0O<9N1':M4&4AMN[-:4DI#S4CF*=)!'57+HKB1F=229$8LV
M=0V56W-]S\NNC.41K--VFAQ48?&=D(:7,OK,I$F6;:%\5*032V:)_P#OB&_C
M&3";]2.6VS<3:G:#+XL [K OF06]]VSMF1J>6IEU+\,C,Z:M9+9/CV@0Y&V=
MKMN2]0=C=VZPE6V#F%MRCS:!+EH1+F,26R2RTF$:C4I-3XN$G3WR49U)&H+'
MWKWKVRS+;?<C!<;OGC<JMMLE^-@>$F,\OP;[;+WJKS*&STK,B[JSKY*D"(AG
MJRW.8>UA].!N+.XW?)[5(2BO?1CURAMWA2R*G'0ILEG_ )W^$EJCI!_-VPWZ
MY_TK+!$KO!   **ZN<GO.,[-33LDI<!^[S8EIDW!HS2N/%DJ4;JM14H2DHY9
MG7L4"8?B3TU;-8V]BETLCSF&WFR36%0;U#F)9E3G20KU!U4KF(<-VFI2214R
M(R+NF9 8H1U';4;<P\FVWN4;'8C4[*L\M\?(7TI5JFM3WE+D)=[W$G#,S50$
MPMJ\YOLETZ6^W8U<I+.)VZX&_)M\*/$F26UJ2I/-5_%VGM)U4GTQE\0$:V6,
MMM=JS3'NH#=*XJ6_F&,Y*U%QB[)==1(@QK=,0TSR>PD$I'#AQ^,=#!*QMS\#
MW#W7R/!,J+!XF58W%Q-N3(CW2XE;XZ[M.)+KK>EE:7M9))&FJ$H,SXGW0$6B
MW3"-T9.P&#VNR>9=N)TJ_/W;$7'WW&$SX)*=Y2UG13A$ZI:D&?\ \RATXD0<
M&X*.'L_N7MU'E/HL]AW(59\7LIJ=7YP;5*5IM*5(,C2E7+4]6OIN/E 7!TV1
M46?<_<NTR;$6!SGF[7*8V^;>\4RQ';9-"IB'V_45\Q:BKRO2UH8(EIT$
M                                *>ZJ/@ S;YVC^S& 3"J^H/\ -DVV
M^><9]@J!,/3U1[6[>P_<;D$;'HK5ZR+.K5$O<U*5<R4Q,3)4^ASCQ)9I(S!$
M/CU![=81C\K9K#;+9(T+%[EFT5$ZUM$9,NIEN,-/$HC,S[Z"TGQ!,/9></Q_
M97J(VR+;6,=IM^<(N5NR.QQG'%1G6XC:%M/&VI:J&E3NHJ4(M'#M54AJ8$
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M,KF(;W94ZXI[(5/ONI9CO1S,W&"?H:*O'IHE2BKWP']#05
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MDYG,,I7.0:.X9?(T*NLS ;F!4
M!^'F6I++D=]!.,.I4VZVKBE2%%0R/XAD8#.2^DII%O?PZ!N'?HFU<J1XA[#T
M\I:22ISG&TB0JII1KXT-L^/$ZJX@G%;F<[;VG--MYNV:7EVNS2HL>"R['(EK
M99BK;4@DDO@=";)/$$/!N'M-;MP]LBVRFW%Z%!)N$UXYE"%NT@*0I)Z5<.]H
MX@E%+-TZ-%?[)?<ZS6]YJG&W4RK':[DIIJ"Q);IH=4TTGOJ10M/'X]2X 8KN
M!       *KW%V3B9ID</.,>R"X8;GD..J#Y\M9I5SX:CU$U(971*R2KBGB7Q
M:T3I)Q1Q/3%9DX-D^*N9-<Y%]S60Q(RK*Y/+>G2T1G.:AE)*[K;=?)Q/B9&9
ME0B&*1YET][997A4C#8]C@V7F-,M1;O!AQT3F#C*0I"TNZ"49GHTJJKO$9U[
M0,7JQO:)BP[D+W-DWJ1<KX]C[&-RD/-H0ATF%,+.29IXZUFQ4R[.)@/U@&S]
MLVVRS*+[C-Q>9L&4.E,?QDT)\'&F=JG8YD=4:JJJFE*&1=B4@/\ <NV=LV99
MLG,KG->+_P @FXP];DI0;3D6XDXEQ9J/CJ(G#(B[ ,42QKIBQO&++A5GA7B4
MLL-OCF2)D*:;)4R2X:2TN$7!)$E"4U3QX 8OE>.F2++EWZ)C^:7?'L(RR6Y/
MR7%8:6%1Y#TBG-Y+JTZF4N$5%)(E5+AV$1 8IK%V?L%NSS&\VM3[D)G%[&>-
MVZSMI)3!1*GI,UJ,UU21T^+Y0$;5TVXI)PS)<-N%QF/-7_(Y&7Q[BUH9E0+B
M^2"2;!T47<)!E51<249?% Q=+!=EEXYERL^R_*9^:YBW$.V6V?<&VH[<.&I1
MJ4EIEGNZE5[RSX]O94P,5K @ 1K/\&L6Y.(7/"\C0M5JNC:4.+95H>;6VM+C
M;C:C(R)2%I2HJD9>0R,JD KFQ=/TJ*]<)F69U=\IFO663CEK7+2VPU#A2VU-
M*5RFSHZZ25?NBSX^7R4)Q=!G8:T-67;6RE=Y)M;;3&Y\%WEMZI:FSJ272^1(
M_P#) Q?27L+B]UF;F.WF5(F0MS4P$W**1(;\*JV(6EE;"R(ZJ)2B<+41EJ27
M R Q<&T=.4IB_P"&Y'DN?7;(YV$.GYF:ELQVF$Q="4$T9-EJ-1Z2UNJ6I2J)
M[* 8OS?NFI#UUODK!\XO6%V;)W5R,@L5N-#D1YYXC2\MG49&RIPC[U*^@7=H
M1#%TSZ;L')>!0$K<7B. E)7#QZ0AM]B;*F%5<B6I1=]6NBZ:=-:D1$DZ 8NI
M>]C,1F9?B>:XVTSBUXQ62Z\1VF(PPB:Q(2E#C#Y(2BJ322DD?:6I5 ,7[P_9
M+&\7LV:X_->7>K1G%RF7.YQI2$I2GQZ22MI.CC0J=U7IB/B!B]^V&U\;;?$6
M<+=N;N16J"\XY:U7)ILW8S#IZN21E4C2DZFGAPK3LH1!',LZ>L<RZYYS<9UQ
M?:;S>V0;4_%:;;Y<0K8II;+C5>TR4TE5#X 8OMBVP=AQ.]8'>+?<I!G@EKE6
MB+'4A!)D^-)9NO.&7%*C4XI5$@8K;!    "G,QV#3>,MG9Q@V7W3!,CO#3;-
M^<M>AV/-)K@AQ;2S*CA)X:R5\6E=1J)Q2W:[;#']I\9]SEA6_*4^^Y.N=SFK
MYLJ9,>(B6\ZHB(JF22(B(N!%Y3J9D/SMCMK VRLESL<*:[<&+G=)=W=7(0E)
MI7-TZFR)/ TEI ?YN/M7C6Y&)2<4GI5;4.NLRXT^WI0U(CRXJC4TZ@]-#--3
M+CY#/L[0$6QOI]M,"VY@C++_ '#)\DSEEN+?<A>T1)),1T<MA,=+1&EOEE0_
M+4R*I4*@)Q?/"NG]O'\FM>499EMRS.7CL1VVXQ'N2&6V(,5]'*75*",W7#1W
M#<4?$NTCH5!BYF+=+UDQK(K)+<R:Y7+#<6G/W;%L1D$T46%.?7KUFZDM;A(4
M>M!'2BN)F=5:AB^=^Z7H%WG7Z'"S"ZVK <KN/GG(\0C)9-B1+-:'%FV^HM;2
M5J01FDB/R>0BH,5\1H[$..S$BMDU&80EIEI)42AM!$E*2+T"(J A]0
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M^1E"I#>AF1 FOK)Q)QU447</A51<2,R/M Q>K"MDG;#F#.>YEEMPS;*+?%7
MLDFX-M1VX4=VI.:&V>"G%I4:5.*/B5>'H#%;0( '%RW%K/F^-7/$[^T;UGNS
M"HTI"%:%DE7$E(5QHI)D2DGZ) *NP_I^D8_=K;<L@SJ[Y-'Q^"_:\:M\LFV(
M\./(:)DS637[LHD)(B-?H%P[I4)Q?N/TZV6/MQA&W*;U*5"PB^-Y%%FFVWS9
M#K4B3()IQ/823.295+CP(#%U[OL9C.09/F^07N2_*C9S:XUGN%N(DH2RW$2E
M*'&G"J>LC02RJ5",#%%;9TU2&KGAERR'/[O?_<'+;?QZ+)9C-L-1632:65:$
MZEJ/0@E.K69T21$1$!B]^3]/)S,FO&48%FMWP25DJB<R2+:S2Y&END9U>2E1
MI-MU6I55I5VG4B*IU&)^3)A#=DPG%8\F1[E<0N*KU(MCZ6WRNT]5*.S%*(B.
ME%%I2DDFE6FFFA 8NSENP^&WZY8S?,>CQ\3ON,7)NYQ9UHAQV5/)1Z9AY*$H
MU(71-:^3AY3 Q>K$-F<?Q=6?-RGUWFW[A7*7=+M!EMI)I"9QN&XPG3Q--'#*
MI\0,7WVMVIA[98NK#BN;U^L3$EV1:FKDTVI<-MXS4;*5%P-)*,U%P+B9^CP#
MBY7L#CN67[+KW-GO,IRRPMXX[#:;;)J,AAQ#K3[?HJ2MM*M)\ ,7RQ;I[Q_$
M[AMQ.M]SD*_!S'N<>(TIMLBEJO"'$O..F7I3)3JE%I Q7""    %29[L8UDV
M5JS[$,HN.$9M(C%!N-RM>EQJ9&0220E]E9D2E()*22HE%V%VT*A.+O;5;3V+
M:FTSH=ME2KK=[Q*5<+[?+BOFS)LM=:K6HB(B(JG0OBF9F9F9F'VVTVV@[:1,
MAB09SLY.0WR;D3RGDI0;3L]+:5-)T]J4\LJ&?$$/]W#VMQ;<?#[AA]T8\%%G
M<M:)D)*&I#+["R<:<0>FE4J+L/M*I>4!%,5V MMK:RV5E^0W#+,ES*&FU76^
M2=$1Y$%MOEH;82U4D*(M*C54ZJ21T[:DXO/A?3XC'<EL619+F%URXL19=BX?
M N*66V8#3S9-*-7+*KKA(2E)+.G87#@F@Q<VR=+=ALN0VR1[H[C*P6Q75>0V
M+"G4M%#BW)1ZDJYI%K6V@^*$&7QS.JM0Q?K)NF6)?+KDAVO,;K8\0S.85QRO
M&8B&%LRY1J);BFWG$FMKF**JR(E5^-0B&*\+? B6J!%MD!HF(,)EN-%93Z5#
M3*20A)?$(B(@0](                                    "M]U]G[;N
MCYDN";M-QW*L:?7)L-^MJB)YA;Q))Q*DJX+0K0FI5(^';0U$9+Q;9[*-X+DM
MUSF_Y+/R_.;M&3;W[Q<$H92W"0M*R:::;J22,T(-7>/TI4(N-1B[T#;:# W3
MNVZ:)SJY]VM;-G<MYI23*&V'$N$LE>F,ST]@(0C).GR===Q,@W&QS/KOBUTR
M-N*S.9MK;)IY<..U'2G4NI\>5J^.8)Q3C;':_'MJ[+)M-C=DS95PDKN%WN]Q
M<)^;-F/>G==61)J?H$1?X3,S,A-@     !X[M:K=?;7-LEWCIEVJXL.1)L5R
MNAUA])H6@Z&1T-)F7 !07Y*$-^-%Q:XY]D$[:V&\E]C"W7$$R:6W.8EE4A-%
M&T1]B=)&7D,CH9$XIU'V,Q!>X5ZW O[+-]>N,.-;+=:9\5AV%;HD1*2)#"%)
M455&DCJ95+C3@8&+DW'ITQEV\YE<+%-78;9F]E.QW6RP([+<-*B2242FT)))
M)<21&5*4/4HSXF!B]>1[ XSDVU-BVPG39"#QMJ*FS9 TE*)T=^&1))U%.!&I
M)&E1=GE[2(R&*PO,DB1BRL=N<]<R2] 5 E7,T)0XZI;1M*>-!&:24JNHR+A4
M$*?@]+6)0Y.VTMRZ29#^W!K\*I;;9>-+Q1S&2=IZ7E.*49:>VH)Q>USIJQ:3
MB=\QB5=9INW7)W\S@79CELR[?<GR0E/).BB-*213O%QKY#H9#%[<7V)3;+I>
M,HR[*9^7YG=;8Y8FKS.;:83#M[I*JVPPUW",S.JE&?'XFI51B_!]/UG/;W!M
MO?/,GP>#7B-?8DSEM\V0[$<D.$VXGL))\\ZF7H 8O+E/3UYTR/(,@P_,[IAR
M<O2E.5V^WH8>8F:4*;-:.86IEQ1*5J6DSXF9^4#%9^'8E9,$QBV8CCC)Q[-:
M628BMJ5K6?$U*6M7E4M2E+4?HF"'<  %/9SL0K(\PFYSB677'"[_ 'F&BV9
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MF9;F]\:9B2[S-::C$B+'](TTRR6E!&9$:N/&A=G&H6:"
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MN!8I<?/..8A)0P4>/,2M;B#<>2G6ZE"EF9),B\OD,R,8K\!
M
M
M
M
M
M
M
M
<                                  /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>tm2227887d1-lc_polar4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-lc_polar4c.jpg
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M ?_$ -X  0 !!0$! 0             ' P0%!@@! @D! 0 " P$!
M       ! @,$!08'$   !0(# @,-$PH#!00(!04  0(#! 4&$1('(1,Q% A!
M49&Q(C)2<M,55C<887&!H=&2LM(SD[,T=)1UE1875T(C0U-S5+0U-G9B@M3!
M)*15.(.C9BCAHL)C1(0E)F2UU98)PT6%I481 0 " 0("!0@'!P0" @,!   !
M A$#!#$2(4%1$P5A<8'1,E)R%?"AL4(S4Q21P2)B@I(UX:+2-"0&XB/QLD/"
M_]H # ,!  (1 Q$ /P#OX
M
M
M !S?RW6D2-%FH[I&;3U=IC;B2,RQ0MQ1&6);=I& LF.2)H$MEM:K74:E)29G
MQZ;PF7[8!4\D+0#P75\^F]V /)"T \%U?/IO=@#R0M /!=7SZ;W8 \D+0#P7
M5\^F]V /)"T \%U?/IO=@#R0M /!=7SZ;W8!<*Y'W)]*&ATK65O#6:3/C\[@
M+_M@%OY(6@'@NKY]-[L >2%H!X+J^?3>[ 'DA: >"ZOGTWNP!Y(6@'@NKY]-
M[L >2%H!X+J^?3>[ 'DA: >"ZOGTWNP!Y(6@'@NKY]-[L >2%H!X+J^?3>[
M'DA: >"ZOGTWNP!Y(6@'@NKY]-[L >2%H!X+J^?3>[ 'DA: >"ZOGTWNP"H[
MR0.3^G)A:RBQ21G_ +]-X3_[8!3\D+0#P75\^F]V /)"T \%U?/IO=@#R0M
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MW8 \D+0#P75\^F]V /)"T \%U?/IO=@#R0M /!=7SZ;W8 \D+0#P75\^F]V
M/)"T \%U?/IO=@#R0M /!=7SZ;W8!X?)%Y/Q<-LF7GSYO=@R/@^23R>D]=;F
M'GU"9W<1S0*[?))Y.1Q'7%VZG>),LIG4IA;#_P"W$<]>TPMBY)W)V/@MY)__
M .1F=W#GKVF'T7))Y/2NMMO'SJA,/_\ KB>:!]ER0^3^>TK84?G3YO=A(]\D
M+0#P75\^F]V /)"T \%U?/IO=@#R0M /!=7SZ;W8 \D+0#P75\^F]V /)"T
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M#%^!2 RP
M
M
M#G/EK^)V+_<%*^%4 E^-\79[1/2(!5       !=K_E[?[172 6@
M      *K_P"C[1("D              *D?W=OMBZ8#ZE_&7>V,!1
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M@,N ;BCT      55^XM?YNF I              #TN$@%S4/C)]JGI$ M0
M           !5C^[H\\!3/A,!X         @7EC>(JL?+*?_ !* '1EK_P!,
MT;Y#%^!2 RP
M
M
M   #G/EK^)V+_<%*^%4 E^-\79[1/2(!5       !=K_ )>W^T5T@%H
M          "J_P#H^T2 I              "I']W;[8NF ^I?QEWMC 40
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M42L_YLCWA$7 6]2\T7[/'FC/J:,TBLS]Z,L.GJQ>;1'W9;B,#,
M
M
M                                   .<^6OXG8O]P4KX50"7XWQ=GM$
M](@%4       %VO^7M_M%=(!:                JO_ */M$@*0
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MS--;<6<QA2\Q8YSSDP1<_,8[>\ISZ<X^[]CB;2_+J>?H]+LH>>>@
M
M
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M90[NB8$U5HC4E;:=I-O&6#K?"?6+)2.'F#S>KI\EYKV/4:5^>L6[6Q#$R
M
M
M                                         .<^6OXG8O\ <%*^%4 E
M^-\79[1/2(!5       !=K_E[?[172 6@               *K_Z/M$@*0
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M475*+S"'0T=I-NF6*UVSPX4>"R3,=&5/Y1\U1\\S'9I2*QB&&97 N@
M%5?N+7^;I@*0              ]+A(!<U#XR?:IZ1 +4              58
M_NZ// 4SX3 >         (%Y8WB*K'RRG_Q* '1EK_TS1OD,7X%(#+    Y;
ML&;]N;[O?551[R%.E]X[>7PEWLIV"#6C9UKJR)9_XL1Z33IR4BO[7F=?4Y[S
M*2S(C(R,L2/89&+L#6>3G.^S=8O32*0O!%#F]^* A1\-+J>"\B.#$FG.NV=<
ML<W?TZ8OV]#L[#4S$U]*?QRG4
M
M
M         <Y\M?Q.Q?[@I7PJ@$OQOB[/:)Z1 *H       +M?\O;_:*Z0"T
M              !5?_1]HD!2             .#A 8UVX(,60AMK&2^2BZAO
M:1'CS3&MJ;FE%HK,L14:C4Y\AW>.<794H_S37#Z*N$<O4WEK<&6--8MQVF]I
M)Q5S5'M/TQHS:9XLL1$*HJD           !49X5=HKI *8
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MM![NG.OG;%QK_)XE4#Q96O NM:=Q6?H#'K4Y].:^F&QM]3DU(GZ=+J ><>E
M
M
M                                           <Y\M?Q.Q?[@I7PJ@$
MOQOB[/:)Z1 *H       +M?\O;_:*Z0"T               !5?_ $?:) 4@
M           8^?6(<#J5JWCY\#*-JO1YPP:FM6G%,1EK\N;/J6)/KW$8_P!
M@]IE_B,<C6W=K=$<&:M'S%:;:<0EM))+$AHS,RRQ&%21[LOSQ"5,
M      5&>%7:*Z0"F               #[3(:3&=2D\Z\2P0CJCQ] 7K29X*
MS:(?4>EU29@>0HC1_E.;5X=J-[3V5IXL<ZC+P[>@QE$ZZ1R'BVYW-I8^80Z>
MGMJ58IM,LMP#95            55^XM?YNF I              #TN$@%S4/
MC)]JGI$ M0             !5C^[H\\!3/A,!X         @7EC>(JL?+*?_
M !* '1EK_P!,T;Y#%^!2 RP  YSU3F_;77"VK.;,ETBR(RKAJQ$98=\)&"(B
M%<Y2"RNEYBC':V-.6DV[>AQ=_J9M%>S][<QNN8 -:U!M=N\[,K-N*21NS8ZB
MBF>!826\'&3Q/@P6E.(FLXG(WK0V]%WYIA0:U*6:JNRSWOJZ5=>4Z$>Y=-9<
MPUY2<PYRAP-SI]WJ3'4])MM3GTXGK2(-9L@
M
M
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MWI=$CC.R
M
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MF6971,;==*M>$*97@RH %XS\0?[8@%F               "JOW%K_-TP%(
M            >EPD N:A\9/M4](@%J              *L?W='G@*9\)@/
M       $"\L;Q%5CY93_ .)0 Z,M?^F:-\AB_ I 98!"O*:KTN-8L:R:0YDK
MM]3F:'&PQS)C.*)4EP\#+J21U"_,6-_8Z?-J9GA7I:&]U.73Q[WTE6I=-B4:
MF0Z1 1NX4!AN+'1SFV4$A)= AV'!78   (SU<<?MAZU]4X#:ERK-J3;LU*.O
M72YADQ*1PECB1D1<[$PFG/6:]K)IWY+1;L=01I#$R.S+BN)=C/H2ZRZ@\4K;
M61*2HCYQD>(\S,8>HB<JHA(
M
M
M    YSY:_B=B_P!P4KX50"7XWQ=GM$](@%4       %VO^7M_M%=(!:
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MIS:>.N.A,8T6Z
M
M                                                      .<^6OX
MG8O]P4KX50"7XWQ=GM$](@%4       %VO\ E[?[172 6@
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MG2%9O*]9HE+8VIC)4HN:OJS],;%="D=2N97R&VVRP;0E!<Y)$72&6(B$/H2
M          O&?B#_ &Q +,               %5?N+7^;I@-?K5STZC?FEF;
M\P^".WUW^8^8+5K-IQ")G#4I-ZUR0HS82U%;YA$6=7HF8WJ;&\\9PQ3JPM2N
MFXR/'CA'YAMIP&7]!_-]2O?>1?1KYK#)EQIAJ2CFY<6U?[2](8+;*\<.E:-6
M&>I][TB6HFY6:$Z?,=ZSUQ;!J6I:O&,,L3$\&R-N-NI);2B6@^!23(R/T2%$
MOH      >EPD N:A\9/M4](@%J              *L?W='G@*9\)@/
M   $"\L;Q%5CY93_ .)0 Z,M?^F:-\AB_ I 4;SN>'9=J5FZY^V+2(CLM2,<
M,ZFTF:&R/;M6K!!>:8R:=)O:*QUL>I>*5FT]2 M&:+,IED,5.K&:Z_<KSM?J
MSJNN7(J"MX1GSCR9,2Y^(]+;'".$/+S,SQXI %4     #1K5F?83E DRH]W0
M]28&0RX$%6*4G%/ 6!9FC,O\2E#5W=.;2SUU^QO[+4Y;X]YTD.$[P
M
M
M                                  YSY:_B=B_W!2OA5 )?C?%V>T3T
MB 50       7:_Y>W^T5T@%H               "J_\ H^T2 I
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M;IC+&C2.I&5VB-':]S:0GSDD0R16(ZD*HL "M'ZY?[-?L3 40
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M)S%9S]/*Z#^WUV?A_5??HOMQQ>ZK[T.UWMO=EOXUVP
M
M
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M
M
M                                     'P<[S0$-732:G:-QVL_1;EJ
ME1N6L5=#,JGRWR=CNT\TK5(5N$H2E"6R)."BX/1!*E!;JNI=8OB7(K,^F,6Y
M+<I=#8ISYQT(<8;SF\X1$>=1J,MBMF! -[TNN"?=%@4*N511+J4EA29;B2P)
M3K#BV5*P_P 1HQ!#F+E7:NT"[;2>L6!3JG'J=-N&(3TJ7%-F&KB4A3:\CN8\
M<Q];LV@EU5&I[O%F>K;ZQ/Y1<X@0J][W>S;]<0!WO=[-OUQ '>]WLV_7$ =[
MW>S;]<0!WO=[-OUQ '>]WLV_7$ N%0W#AH:S(S$LSQS;-OF@+?O>[V;?KB .
M][O9M^N( [WN]FWZX@#O>[V;?KB .][O9M^N( [WN]FWZX@#O>[V;?KB .][
MO9M^N( [WN]FWZX@#O>[V;?KB .][O9M^N( [WN]FWZX@%1V"ZK)@M&Q)%M5
MS@%/O>[V;?KB .][O9M^N( [WN]FWZX@#O>[V;?KB .][O9M^N( [WN]FWZX
M@#O>[V;?KB .][O9M^N( [WN]FWZX@#O>[V;?KB .][O9M^N(!]LP74NH4:T
M8$HCV* >R(+BWG%DM!$9F>U6!@*?>]WLV_7$ =[W>S;]<0!WO=[-OUQ '>]W
MLV_7$ =[W>S;]<0!WO=[-OUQ '>]WLV_7$ =[W>S;]<0!WO=[-OUQ '>]WLV
M_7$ =[W>S;]<0"HS!=2:C-:-J%%L5SRP 4^][O9M^N( [WN]FWZX@#O>[V;?
MKB .][O9M^N( [WN]FWZX@#O>[V;?KB .][O9M^N( [WN]FWZX@#O>[V;?KB
M .][O9M^N( [WN]FWZX@#O>[V;?KB 7+41Q,1ULU(Q49&1DK8 MN][O9M^N(
M [WN]FWZX@#O>[V;?KB .][O9M^N( [WN]FWZX@#O>[V;?KB .][O9M^N( [
MWN]FWZX@#O>[V;?KB .][O9M^N( [WN]FWZX@#O>[V;?KB 1A>45S[0NI-2<
M4M(YNS:0Z6QGIE@UN$-)NNTFKKH4JBR72:)\B4T\DR,VW4'F0K ^' R':IJ<
MMHF&K,9C#GV;IEJ! DG%515S#QP1)B.LJ97YN*W$FG_,0[M-]IS'2TIT)ST)
M-TPTPJ=N27;@KZVDU5UDV(\-M9+2PVM1*5F46PUGE+@V$.9N=UWDXC@V=/3Y
M82?Q5SLD]$:7,RG%7.R3T0Y@XJYV2>B','%7.R3T0YAX<19E@9H,C\T1.)C$
MC.6Y69-%<3%E.$Y2UGAM/%31GS2\SS!Q=QM^3IKP;=+YZ)2:U$-]M+S+K2VE
MEF0M*R,C(QHLK[[WN]FWZX@ J>[B75M^N(!7F0W'7S6E2"+ BP-6![" 4.][
MO9M^N( [WN]FWZX@#O>[V;?KB .][O9M^N( [WN]FWZX@#O>[V;?KB .][O9
MM^N( [WN]FWZX@#O>[V;?KB .][O9M^N( [WN]FWZX@'VS!=2ZA1K1@1\Q0#
MX.GNXGU;?KB .][O9M^N( [WN]FWZX@#O>[V;?KB .][O9M^N( [WN]FWZX@
M#O>[V;?KB .][O9M^N(! /++B.-:#UA:E(,BF4_8E6)_&4 .A;7_ *9HWR&+
M\"D!E@ !S%I9_,]3_P"_*][-H>FK[%?AAY;5_$MYY2()8P  :YH%XPM7?I&F
M?PK@YV_X5]+L>'_>]"?!R75
M
M
M'BLV560B->!Y2/@QY@"'+?H6J]-N>;<E6I%*J=4GN;DZ@Y.<2<:!G+!F.UNC
M)!$19E;>J5M,$KQRSKYM:LW.NRVX4VEW<Z<MQ<UU;"X$MQ!MK624I5O$&6"B
M26!XD WNR[::L^UJ7;33QR$TY@FE/F64W%F9J6O#;AF4HS!"#N6LA!:/1E$D
MB4=P4K$R+;[JH!,,;XNSVB>D0"J       "[7_+V_P!H?2 6@
M    *K_Z/M$@*0              J1_=V^V+I@/J7\9=[8P%$
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MC(^ RVD**/0        $=WTR;5:8<YC\<CQ\U*S(=#8S_',>1AU8Z&N#M-4
M        #(C+ ^ )C(SEL7"Y1Y*84I9JICRB2DU'[DH^:7F;=HX>YV_=SF.#
M;T[Y242B41*2>*3VD9<X:+*^BX2 7-0^,GVJ>D0"U              %6/[N
MCSP%,^$P'@        "!>6-XBJQ\KI_\2@!T9:_],T;Y#%^!2 RP  YBTL_F
M>I_]^5[V;0]-7V*_##RVK^);SRD02Q@  US0+QA:N_2-,_A7!SM_PKZ78\/^
M]Z$^#DNJ
M                                                 +7OG3>.E3N.
M,=\#(U%$WJ-]E+A/)CFPV\X!]R)T*(:2ER6F#7CE)U:48X<.&8R 5&G6GFTN
MLK2XTLL4K09*29>89 /I2DI2:E&1)(L3,]A$1 /AB1'E-[V,ZAYK'#.VHEIQ
M+S2Q 49U2IU+9XS4Y;,*/B2=])<0RC,? 699D6("NT\T^VEYAQ+K*RQ0X@R4
ME1<\C+88"VC5:ES9+T.'.CR)<?XQ'9=0XXWCV:4F9I]$!>
M                                    #G/EK^)V+_<%*^%4 E^-\79[
M1/2(!5       !=K_E[?[172 6@               *K_P"C[1("D
M       *D?W=OMBZ8#ZE_&7>V,!1              %1E24;Q2S)*2;69F>P
MB+*8#6JA>%+B&;44U3)!?D-%U)'YJCV= 9ZZ-I9JZ4RU^5<E>FXDA2(3)\!-
MEF7AYJC_ -@V:Z%8XLT:588IQ@Y"MY+=<D+Y[JC/TAGBL1P98B(%%'C-K=42
M6VVTFI:N B2DL3,Q>(3Q<_U_4NXZ[+6[3IBZ922,RBM1\$.+1S%N*/$\3YQ8
M8#MZ>UI6.F,RWHTZUZ.,LK96IE:B52-3*_(X]3);B64R72+?LN+/!)FI.!*2
M9[#Q+$8M?:UF,UZ)A6^G$QT<4X#D-,      %PW\5=\\A6>(MQ8  R(]AEB
MI*C1U]<VD_0P >-Q]P>,9UU@_P#W:S2*S6)1,1*_9K%?BX;J<;J2_)?22_3X
M1CG1K*DZ=99%B\ZFW@4R"VZ7-4RHTGT%8C#.W[)8YT8ZF4C7I1W3),DW(CA\
MQU!Y>BG$89T+0QSI6AFXTZ%,+-%?;=(^P41F,4UF.+%,3"X%4   U#4.*9PZ
M=4$E[BM;2S_PKPP],AGV]^74B5+QF&CCT;2          !XI)*(TGP&(M6+1
MB2)PW*S*^K$J)-7BI)&<1P_RD]@9\\N8//:^C.G;'4W:6YH;N7"0UUUS4/C)
M]JGI$ M0             !5C^[H\\!3/A,!X         @7EC>(JL?+*?_$H
M =&6O_3-&^0Q?@4@,L  .8M+/YGJ?_?E>]FT/35]BOPP\MJ_B6\\I$$L8  -
M<T"\86KOTC3/X5P<[?\ "OI=CP_[WH3X.2ZH
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MJZ[(2\#-.TQ+5YUS:?:T:F7I6==;R<HMB6Y,.E6K;33ZVC>)+CB#>W;:%K/
MFR6XHD8YED68DI(C#KC1&W-/[9L9N'IC65UNT9$IZ5%DN2DS":6YE);*%)2G
M*E!IZQ19B,SQ!$I&!
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MAZ8PR2'6MVZM\\22G*;N_P #R$@MN'-)?HR"H
M                          YSY:_B=B_W!2OA5 )?C?%V>T3TB 50
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M+<LI1MNLIK5/0\K9*;,D2$<Y9<WSC'G9B8G$MUL-0^,GVJ>D0@6H
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M2K5?/;[#V.U#"5)<6G'A+ VVS5S309<P"75P*@
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MQ"2)*2/%7.)A^BU+1.;ID)NIK)VI(8:3,=3AE4^2")Q18$6PU8\P%%V
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M<+UO:O"5Q2J)2:&P<:D0VH;*CQ4EI))-1\]1\)^B*WO:TYF<HM:;<5^**@
M    N&_BKOGD*SQ%N+              HJBM&HG$XMN%P+;/*HN@(F,C+QKA
MKE/::1O$S6$YNH>V+PQYBB_VC!;0K+%;2B6IUFL4]JKJ6XE4-,TS<)+A=23O
MY1$HMG",VUS2W+/"6AKZ,QTJB5)41*29&D^ RVD.HT7H@          !D[<J
MAT>KM.J/")),FI'.+$]BO0,<G>Z6)YX;.E;J2]/,CDF9;2-*<.@0Y;.M0
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M\X!G&&&(K+<:,TAF.RDD-,MI)"$(26!)2DL"(B+@(@%0
M                                      6!42BIGG5"IT4JF9XG-)AO
M?X\'NF7-Z8"O(@P9:DJEQFGU)+!)NMI69%YF8C 56668[:68[:6F4XY6VTDE
M)8GB>!%LX0%.1"AS,O&X[3^3')O4)7ACACAF(\,< 'PQ3:=%<WL:(RRZ189V
MVT(5@?FD1 /B;1J14G6GZC3XTQ^/[@[(9;=6WMQZDUD9EM+F +Q24J2:5$1I
M,L#(]I&1@+&!1*+2W7'J93HL)YXL'7(S#;*EECCU1H21GMYX"_
M                                        '.?+7\3L7^X*5\*H!+\;
MXNSVB>D0"J       "[7_+V_VBND M                57_P!'VB0%(
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M/@Y+J@
M
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M]XV6/2Q'"W=,7SVMO3G,-_&DR@            "K']W1YX"F?"8#P
M ! O+&\158^64_\ B4 .C+7_ *9HWR&+\"D!E@ !R]ILPB5+U4BN&9-O7S<#
M:S3PD2U-D>&..W:/35]BOPP\MJ_B6^*7.FI.G%<T,EP*W;-RR-S47%M,K9S1
M9"#;(E97,BC2M.!^9VHVJVB_1,,,QCIAM=*Y0>I-E+8@ZDV^N7'6DC;F*;.%
M)6E18DI*B2;+A8=BDO/%>2)X2G..*<+"U:LS452X] E.)JC+1R'Z=);4V^AH
ME)0:L2Q0HL5$74K/A&*U9CBEE= O&%J[](TS^%<',W_"OI=CP_[WH3X.2ZH
M
M
M                                         .<^6OXG8O\ <%*^%4 E
M^-\79[1/2(!5       !=K_E[?[172 6@               *K_Z/M$@*0
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MR50JM$EIV&VXC'SE%@8YN\KFD3V2S:4]*6B/$B,N ]HX[:>@
M*L?W='G@*9\)@/         $"\L;Q%5CY93_ .)0 Z,M?^F:-\AB_ I 98
M<PZ7J2BHZH+6HDH3?=?-2C/ B(EM8F9CTU?8K\,/+:OXEO/*$.4OJ#:%VQZ/
M2+;J2*E)ITAYR6XP2E,)):$I+*Z9$E?!^09D-G3K,2PVGH6RKVUJU?IZ*!:]
M%3&MW(F.XXVRG<J2VG#\Y*E=3F(BX&\I^8'+6O%;,SP2CHGH=4=-:G(N*LU1
MJ34I4-<$X45"C9;0XXTZ:MZO*:CQ;PPR$7FF*7OS(B,))T"\86KOTC3/X5P<
MG?\ "OI=GP_[WH3X.2ZH             M&*I3)4MZ!&FL/3XWQB*VZA;S?,
MZM!&:D\/-(!=F9$1F9X$7"8"T:JM+><2TS-CN.K/!*$.H4HS\PB,!=@
M                                                         9D1
M&9G@1<)@-<INH-A5FK'0:/=-(J%<3FQID2H17Y9;OK_S+;AKZGF[-@#8P
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MSY:_B=B_W!2OA5 )?C?%V>T3TB 50       7:_Y>W^T5T@%H
M    "J_^C[1("D              *D?W=OMBZ8#ZE_&7>V,!1
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M)Z1 *H       +M?\O;_ &BND M                57_T?:) 4@
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MRPXPXRH\Q&2<JL4J49&K!2<3Q)RW?E)^(J^OHQ?LT 0<FSQ%6+]&(]FL"4J
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MF[6&R-1M.D'1Z=4UNO2J6P:MP1PG&DRD)21XDT\T^DC;X"/'+S"(1TN_ 5
M               '.?+7\3L7^X*5\*H!,,9"^+L]2?6)YGF$ JY%]B?0 ,B^
MQ/H &1?8GT #(OL3Z !D7V)]  R+[$^@ NE(5Q!LLIX[P]F'F +7(OL3Z !D
M7V)]  R+[$^@ 9%]B?0 ,B^Q/H &1?8GT #(OL3Z !D7V)]  R+[$^@ 9%]B
M?0 ,B^Q/H &1?8GT %5Y"_S?4GUA<P!2R+[$^@ 9%]B?0 ,B^Q/H &1?8GT
M#(OL3Z !D7V)]  R+[$^@ 9%]B?0 ,B^Q/H &1?8GT #(OL3Z "I'0O?M]2?
M7%S/- ?4I"SD.F23PS'S %'(OL3Z !D7V)]  R+[$^@ 9%]B?0 ,B^Q/H &1
M?8GT #(OL3Z !D7V)]  R+[$^@ 9%]B?0 6T^FM5&*Y$E-&IIPN=M(^89>:0
MM6TQ.86B9B<H]E4V;0Y*HLQ*E1E$HH\G R2HL-A'SC'1IJ1:&[6\64,JN<?0
M&9=KE[70W:-%74%-;Z6ZHF8;!GE);RB/#$^Q+#$QGT-+O+89-.G-*#'[ZO63
M).6JM.M.&>*6F4I2RGS"1@>)>>.Q&WTXC&&YRUCJ2YIO>[UUQ9$*HH2FLP"0
M;RD;$O-KQ(G"3S-I8*+F&.9N=#NYS'"6MJZ<5Z8X-[RJ[$^@--@,JNQ/H &5
M78GT #*KL3Z !E5V)]  RJ[$^@ 95=B?0 ,JNQ/H *[:5<6=+ \<2%9XBAE5
MV)] 6#*KL3Z !E5V)]  RJ[$^@ 95=B?0 ,JNQ/H &578GT #*KL3Z !E5V)
M]  RJ[$^@ 95=B?0 ,JNQ/H /M25;M&P^;S/-$#XRJ[$^@)#*KL3Z !E5V)]
M  RJ[$^@ ^'6$O-J:=;SMJ+!25%B1D TRK6K*B*5(IJ%/1SVJCX'G3VO/&?3
MUIIYF"^E$L"6)F:32:5EL4DRP,O/(="FI%N#3M68>+;-:329'@8R1*C8J,XU
M5::N!/:2_NOS3S3J26E:.9B1E@8Q7C$YAK7C$OJ/:%N0D/II](BPU26UM.N1
MV$-K-"R,C+%)$?-%.:6-S;<%KU>T)CE.J<9U,5M1IB3R0HX[S?Y."R(R)6'"
MDSQ'H-#<UO7IG$M#4TIB>AD+)M"J79681M174T2.^V_-FK0I#2D-+)>[09D6
M92C+#J> 8]UN:Q68B<S*VEISG,NM*-3'*K7V6B0:H\<B>?5AB18%L+T3'B=Y
MJ9Q5U]*O6E#(OL3Z YK.9%]B?0 ,B^Q/H &1?8GT #(OL3Z !D7V)]  R+[$
M^@ 9%]B?0 ,B^Q/H &1?8GT #(OL3Z "I'0O?(ZD^'G *9H7B?4GT #(OL3Z
M !D7V)]  R+[$^@ 9%]B?0 ,B^Q/H &1?8GT #(OL3Z "!.6.E1:$U@S29%Q
MRG\S_P#$H =%VO\ TS1OD,7X%(#+  #EO3M]45[5B4@B-;%[W$XDCX#-!MJ+
M'H#TU?8K\,/+ZGXEOBG[4#T6R]4-?ZLU<-UR7(%KYLS3[B3;8)HSVIAL'UVP
ML-X>SGJ4>P;,VBG#BP8F>++W!8.J&D5W3:EI-%D2;?J;2&T%'91-6@D$6*'6
MU)4>9*L5)7AM(^'KB$1:+1TI\S;] -/;RI5=K=_WPVN-5:PTMEME_+QA9OO)
M>=<<2GK.J0DDI/#SB+ 5O:.$$1VI:T"\86KOTC3/X5P<G?\ "OI=GP_[WH3X
M.2ZH      -&UAU'8TGT\J]\O0SJ"Z>32(\$EFT3KTAY#*"-9)5E(C7F4>'
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M.O\ CV39M/I\UZ1#3+04TG"6:OSAKZLGVDX$2-FP<'=[W7KN(TM**SF,]/\
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M4B8QIK;#A)FU.4WD)+2W$.R7%FDU(0MU+:&V6\QJ/89X%CE'!WT"H
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MU@2E0$         #F7E >/G0_P"D5_Q,8=S8_P#7U?-ZV*_M0Z:'#90
M          %-]AF2RY'DMI>CNI-#K3B26A25%@9*2>)&1ES!,3@8RAVI:UL$
M\5M42GT8I)DJ05.BLQ-X98X&O<H3FPQYHO?5O?VIF?/*(B(9<8T@
M            #5-3:/;%?T^N.DWI(*':TB"]WSFYLIQVFT[S?),R/JFS22T[
M#VEP'P .8=)^2Y2KEJ-M7W5-1)%]Z?416-L0'HTEEI3<5W!#9%*=43;*7&^J
M;;1E7AAP ME)&K%(I%VZ_:6TBMW)#IK= -RO4ZAN,R4S)\Q#F=&[?W?%\J51
MD=1O<_7=2>*00Z!!   (KY2?B*OKZ,7[- )@Y-GB*L7Z,1[-8$I4!
M   AFI?]1]'^B%_!R!YV_P#DJ_#ZWIM/_%V^/_BF8>B>9
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M9C-))#339$E"4EL(B(MA$,4S,SF6.9F>*J(         !<-_%7?/(5GB+<6
M              5%>YM^CTQ IB0      ',EW5J3<=Q3)\M1J:8=<CPF3VI:
M::4:-A<]1EF48]#HTBE(B'0B.6,0Q4:7)I<QFK4]PV*A$/>-.IV8D6TTJYZ5
M<!D,DUBT8G@M'3T3P=14;BE?70I<F,AQ,K=O;M:25AG02C+TQY?<5Q$PY>K&
M(E(#EEVZX>/%<G:+47^T<ESWK-FV\RK,40G#+]8I2BZ&. #-L,,QT):CMI::
M3P(01)(O0(!>U#XR?:IZ1 +4              58_NZ// 4SX3 >
M (%Y8WB*K'RRG_Q* '1EK_TS1OD,7X%(#+  #F+2S^9ZG_WY7O9M#TU?8K\,
M/+:OXEO/*1!+&  #7- O&%J[](TS^%<'.W_"OI=CP_[WH3X.2ZH      (2Y
M6\:JRM ;K124N+6@HCTM+6.8XC4ME;Q[-N5*2S+_ ,)'CL!,,CHKJ;I=5=-+
M:9M^N4Z&S3Z=%B/TQZ0S'D17F&DH6AQM:B41YB/JN!?7$9XX@2AS4V\[9O'E
M3:21M/IS-5KM'>>:KE0IZTO-%$6>=3&]1B2MVT4A2R(S).?#AQ!/4Z_!4
M  17RD_$5?7T8OV: 3!R;/$58OT8CV:P)2H"         !SQK#4M(96J=E52
MY[]CT6O69)XQWJ2PN4E:G'&W"2^ZWBECW/\ +YAXCL;6NM&C>*TS%^OZ<6*V
M,\70;#[$IAJ5%=0_&?0EQEYM1+0M"RS)4E2<2,C(\2,AR)C'1+*J"
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M9K E*@(         $,U+_J/H_P!$+^#D#SM_\E7X?6]-I_XNWQ_\4S#T3S(
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M7                1+R?/Z6N/\ NNO_ ,:L=#?>W7X:_8I3@EH<]<
M                $#ZQ:"Z)/6_<^HE6LUE^K4JG3JP^4&3(IG&G(C#DA25\
M742,SAIZIPVS5S=H)B62Y-5OZ>MZ<4B];*M*-;#]PL*5+;;=<FR,&GUMY#E2
M,75)Q1F))G@7. E,P(  !%?*3\15]?1B_9H!,')L\15B_1B/9K E*@(
M    $,U+_J/H_P!$+^#D#SM_\E7X?6]-I_XNWQ_\4S#T3S(
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M>T3TB 50       7:_Y>W^T5T@%H               "J_\ H^T2 I
M        "I']W;[8NF ^I?QEWMC 40             !6C]<O]FOV)@*(
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M*4HB&]LMG;2M-[S$VF,='"(<_>[RFI6-/3B8K$YZ>,RW4=5R0
M                     !%>L%<C+J=F:<R*-"K3-ZU)R/-8JB,\9N##94\\
MM)?K>MW?H@EI-[6=ISR>$T.^[(L>C18ZJM%@UR2:%JF,Q9BR;WD4UJ/JTF?
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MP%PW\5=\\A6>(MQ8              !45[FWZ/3$"F)      ,R26)G@7/,
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MM?;].,RE)HLQ.9)Y5);6V:7%$>);20:C!$.9=1X5+B<E'1F73FT-5%BJ49V
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M%7)0V1J6;)YEI4:2+$TXDK#$\,"/#%N-AJZ->:T='D36\3P2F.>N
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M'V#YZT'AT1FB\3UKQ:)?*94=>PG$X\XSP/TQ=94)1'P&1^< ]
M!45[FWZ/3$"F)  ,R+A/ !15*82>4E9E=BCJC](,B\BTRM5##BL-3;9_IG_S
M:?0(]IC#;6K#'.I6&P0;)8(R=JSYRE\.Y3U#1?[3&K;7F>##;6GJ;.Q'8BM)
M9CMI::3L2A!$1%T!KS.6"9RJ"$    /2X2 7-0^,GVJ>D0"U
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M63B..*0VM"664+P4LEF>"E$67+S>#'J>(;[2G2FM9BTV[&+3TYB<NWAX]M@
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MG02(HL9MLR_*))8]$89M,\6*;3*\%50       'I<) +FH?&3[5/2(!:@
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M-R5,X]432G)BT$K#@-23+S!@M.WQ/+%L^>/4MTI!&FL
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MU?US7!2+A0_9]?)Q+=O<64VIC!_>QCWN]-*C92I;>.3:2N8!,IY!
M")=9KQOFE5&T;'TX7#AW3=\N0TBKU)LWHT6-"8-YQ6[+KUGBG*7G@(0BZA<I
M"GT:/>]=O.D.VC N7[/W&VS1VBD,,M2TQE/)(W$YB49EL(R-)'CM$)=DB4
M   #G/EK^)V+_<%*^%4 E^-\79[1/2(!5       !=K_ )>W^T5T@%H
M          "J_P#H^T2 I              "I']W;[8NF ^I?QEWMC 40
M          !6C]<O]FOV)@*(               +QGX@_P!L0"S
M      !57[BU_FZ8"D              /2X2 7-0^,GVJ>D0"U
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M$J)Q25I(S(RPVD3#HD$     "*^4GXBKZ^C%^S0"8.39XBK%^C$>S6!*5 0
M        (1I]Y:T:@QZE=>G35!A6C&E28M"B59$AZ952@.J9==4ZTXA#*'%H
M6EOJ3,L.JV;1U+:6AI3%=3FFW7CJS]JD3,\$BZ<WDUJ!95)NYJ*J"JH(<*1"
M</,IF3&=7'?;QP+$DNMK22L-I;1I:^EW5YKQPM$YAM(P)
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MJ @         0S4O^H^C_1"_@Y \[?\ R5?A];TVG_B[?'_Q3,/1/,@
M         TBY;KJ<NI'9]CDW(N(\.^-066\BTME7Y;N&Q3IE[FUZ)[.'FZ^X
MM:W=:/3;KGJKY_+V0ZNWVM*T[W6Z*=4==Y\GD[96]6M2F6GIM=<:#G>ER:74
M'ZC4'SSR94A49S,XZL^$SYA<!<P4U-O71VVI$<9K;,]<SCK7TMU?7W6G-NB(
MM7$1PB,QT0V:T/Z3H/T=$^ 0-W;?A4^&/L:.[_&O\5OM9D;#5
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MOV)@*(               +QGX@_VQ +,               %5?N+7^;I@*0
M             ]+A(!<U#XR?:IZ1 +4              58_NZ// 4SX3 >
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MV;:''E9G7%N+4ZXXLR(B-3BUJ6K9PF-+6U9U;S:>,K1&&?&)(
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M#^DZ#]'1/@$"^V_"I\,?8IN_QK_%;[69&PU0
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M0XEILC4>!$:EF1;3%8B9X)6+%YV>2EXW#32ZA9?'&.Q/_&+]W;LE7FA>P:A
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M>*6TLK-9F98[$@)"!      BOE)^(J^OHQ?LT F#DV>(JQ?HQ'LU@2E0$
M                                              "#*CI%'IMXZH5>
MJUV!3['U1I*($R,_@U)8J+;!QB=0IPTH4G*XZYPYLZBYV()1QI-I;J(YJ/9L
MW4&_J%7J#I[&E1;3@4N2T[+=0ZP;!9DH:;5@EM*#4I:E*ZA);>J4"770*HHY
M2]3J5&T-O&I4B8] J+$9G<RXKBF7D9Y3*%95H,E%BDS+88)A%=A\LO2.DV/;
M-*N.HU21<,&E08M6?7%<?4Y-9C-H?6;JE&:S-9*/,?#P@8;M:_*YT<N^XJ9:
M]'E3U56KR&X<-+L);;9O/*RI)2L3P+$^$#"=00LJPJJ)I$]5$2TNM%&>.G(D
M8DR<HFSW1.&6!Y37AF\P!ROI=8'*(L"NU:Z*E:U$N&\KB?QK%SU&K*.448U)
M/<M(0@DMMIRD>1/#@1<"4D19,/*3\15]?1B_9H!$')L\15B_1B/9K E*@(
M       $,U+_ *CZ/]$+^#D#SM_\E7X?6]-I_P"+M\?_ !3,/1/,@
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MXH$9F*3RDY363#:6\QEB>&.&(Y%IS,RZL1AR]4>1E J%0ESSO!YLY3SCYME
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MMT@S))I/$O,!.&S\I/Q%7U]&+]F@"#DV>(JQ?HQ'LU@2E0$
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MF6E1YE;3X3 2';]KZ62E,UJUJ+;[RXZR7'J%,BPEFVX6TC0ZRD\#YI8&"&X
M   BOE)^(J^OHQ?LT F#DV>(JQ?HQ'LU@2E0$         "&:E_U'T?Z(7\'
M('G;_P"2K\/K>FT_\7;X_P#BF8>B>9          !'52K-2U!G2K8M-]<.W(
MRC9KES-'M6K\J+#/@-1\"W>!)<',QY&IJVW-IT].<4CVK?NKZW:T]&FTK&IJ
MQF\^S3__ %;]T=;=J-1J9;],CTBD1TQ:?%3D991Z9F?":C/:9GM,QTM+2KI5
MBM8Q$.7K:U]6\WO.9E?C*P@
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MV,!1              %:/UR_V:_8F H@               O&?B#_;$ LP
M             55^XM?YNF I              #TN$@%S4/C)]JGI$ M0
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M3I)/%L]B"!$))Y-GB*L7Z,1[-8$I4!
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M>,9TYR,TK21X[03Q=J@J  "*^4GXBKZ^C%^S0"8.39XBK%^C$>S6!*5 0
M      (9J7_4?1_HA?P<@>=O_DJ_#ZWIM/\ Q=OC_P"*9AZ)YD       !X9
MDDC4HR))%B9GL(B(!&TNH3]49#]&H#[D&QH[ALU6MM=2Y4#2>"X\0^8WPDX[
MS> MF./'M>V[F:TG&G'&WO>2OD[9=RFG791%[QG5GV:^[Y;>7LA(%.IT&DP6
M*;36$18$5!-L,-E@E*2YA?[3YHZM*5I6*UC$0X^IJ6U+3:TYF5T+L8
M                                   T;4RX]0Z!"@-Z;VFBZ*S.=6TY
MQF4B%$B(2G$G'EJ,C,C/81(V@(4:Y,=U7_=U-O[5FL4VDU2FRFIL>EV?!;AF
M:V5$LDOS5DIUS$RP5CCLX#(!U(      .<^6OXG8O]P4KX50"7XWQ=GM$](@
M%4       %VO^7M_M%=(!:                JO_H^T2 I
M "I']W;[8NF ^I?QEWMC 40             !6C]<O\ 9K]B8"B
M      "\9^(/]L0"S               !57[BU_FZ8"D              /2
MX2 7-0^,GVJ>D0"U              %6/[NCSP%,^$P'@        "!>6-XB
MJQ\LI_\ $H =&6O_ $S1OD,7X%(#+  #F+2S^9ZG_P!^5[V;0]-7V*_##RVK
M^);SRD02Q@  US0+QA:N_2-,_A7!SM_PKZ78\/\ O>A/@Y+J@#FGEM4ZHO:9
MT2N1XASZ3;]>B5"LQ",\BHV1UHC66!EESK2V9F6S."8;Y0>4QH=7*.Q5D7A
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M$VHR,T$9;#)& #7^4GXBKZ^C%^S0"8.39XBK%^C$>S6!*5 0
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MGXBKZ^C%^S0"8.39XBK%^C$>S6!*5 0         (9J7_4?1_HA?P<@>=O\
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M@             !Z7"0"YJ'QD^U3TB 6H              JQ_=T>> IGPF
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M^C%^S0"8.39XBK%^C$>S6!*5 0
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MVYKSU\,1V1!N=U6]8TZ5Y*5Z<9S,SVS+:AO.>
M           #D&\;YTKMN]:C4-)KE[Q74]).'7J?(@S%VC4I!F3:V9"VVB0T
M\9]3OVU92/',(2N--[&M:Y:@U85S77=5%EV\\P^[I559D=<(DQ74NL[IY#!<
M8BYDD:,CF;9M$CK8$     #G/EK^)V+_ '!2OA5 )?C?%V>T3TB 50
M 7:_Y>W^T5T@%H               "J_^C[1("D              *D?W=OM
MBZ8#ZE_&7>V,!1              %:/UR_V:_8F H@               O&?
MB#_;$ LP               55^XM?YNF I              #TN$@%S4/C)]
MJGI$ M0             !5C^[H\\!3/A,!X         @7EC>(JL?+*?_$H
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MS$0XNT 5     $5\I/Q%7U]&+]F@$P<FSQ%6+]&(]FL"4J @
M                                   !&>O-/GU/3N5$IM\,Z>R528QE
M<DB6=/;0E*\3:WZ7&C2:^#8K;P F'/<WD]Z]TU$9RH\H*5$;F.)8B+D5>IM)
M>=<VI0V:Y!9E*YA)VF"<M_TJT+UMLR^Z7<=WZK3KEMV&4@IE%?F5!]M_?1W&
MF\42'5(ZA:TN;2_)!&72(( ''NI=6LS3WE4G=NL5.XW9U6H++-MU&1%.=%B2
MF%H2L]TE+AFI)I</J4FI.\(\O58@MU,+=5Z:6:FZX:3-Z'PT/UVG5AJ77*O
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MI+ B(MA$1$.O$8<69R^A*
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M_N[?;%TP'U+^,N]L8"B              *T?KE_LU^Q,!1
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MQ%6+]&(]FL"4J @
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M0C<<42D+3@GF 8=> J  "*^4GXBKZ^C%^S0"8.39XBK%^C$>S6!*5 0
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MFN&:43(+S<EA1IX2)QI2DGAYX6I:LXM&)3E?"@
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M& H@             "M'ZY?[-?L3 40               7C/Q!_MB 68
M            *J_<6O\ -TP%(              >EPD N:A\9/M4](@%J
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M2C3CBGJL,=NT$9=$@@     17RD_$5?7T8OV: 3!R;/$58OT8CV:P)2H"
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MFEK'.:>>G'F"OC4TQ6/O?N-'+KP>8;(
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M3[5/2(!:@             "K']W1YX"F?"8#P        ! O+&\158^64_\
MB4 .C+7_ *9HWR&+\"D!E@ !S%I9_,]3_P"_*][-H>FK[%?AAY;5_$MYY2()
M8P  :YH%XPM7?I&F?PK@YV_X5]+L>'_>]"?!R75 $;:X:00=:[,;M294G*2[
M%F-U.#-;:3(2F2RTZT1.-*-.=!I>5BDE)YFT$Q+F=W3'5S1_%55TMLW5>U6-
MIR8=%@M51+2<<"RMQDN&HR+:>Y?[8$I.T"U8T$OBY.]MGV/$LV_VV'C4PBE1
M([AM-X;U+<J*V1X<]*\AGAP B728(1YJ_K):^BM"@W!=46?+B3Y90&&J8VRZ
MZ3AMK=S*)YYE))(D&778XX; 3A#?E\Z/?\DN7YK _P!>!AL=A\L3374.[*99
MU"HUP-U.J.[EEZ3%B%';/ SS.*:EN*2G9PD@P,.A 0  "A,?<BQ)$EIE<EUE
MM;B([>&=Q2$F9(3C@6*L," 0!I9K)J==>N->TZOFAPK>@P:(=9C4IE9R9K!K
M>B):2_)2LVUJ-M\S42$%@>!<PP3AFN4_=MJTW26[[:J-=I\2XY]*-R#1Y$MA
MJ:^A;N5*FF%K)Q9&:%$1I2>U)\X"&2Y/,V'3>3_9E0J$AJ) BTDGI,J0M+3+
M32%+-2UK69)2DB+$S,P)2:FLTA=)[_(J$95#W'&^^9/-G$XL2<YN[[')DR]5
MFQPP!#QFM4>122K\>H1G:$;)RRJ:'FU1#CI2:C=WQ*R9"26.;-A@ ]BUFD3J
M4BNPJA&DT1QHY+=29>;<BJ8(LQN$ZDS0:,"QS8X $*LT>I4MNN4ZH1I=%=;-
M]JI1WFW8JF4XF:TNH,T&DL#ZK'  I]9I%6IC=:I=0C3J,\@W6:C&>;>BK;3B
M1K2Z@S0:2P/$R, IM8I%9IS58I$^-4*0^E2V9\1YM^,M*#-*C2ZV9I,B,C(\
M#Y@"/G-4*[..34;9MKOG;<9Q:&YBY:67Y265&EQ<=K(K$B,CRYE=4.!?Q6V9
MFE.:L=>>/FAZ"OA5(B(U-3EO/5C,1V9G+)-:RZ;JB193M=99.4TEW<*2M;K>
M8L30X3:5Y5%P&6(VX\4VV(F;QTM:?"-US3$4F<?3H1M,U4OBN39%3MVH1Z?0
MT/.(IT549#V_9:4:"6\M?5)SF6.",,!X_>?^Q:U=:8I[,/5;;P'0C2CO(F;3
M'3T\/,WNW-;;)J=+A.5JIL4NM.EDF0EDYD;>2HT'^<RY22>&8L5<![1ZO;^+
MZ&I2)M:*VGJ>;W/@VXT[S%*S:L<)Z'S K%]WT<ZM6G5H%*M^-(=BTIMZ-QM4
M[BYY5..N$LMVVI1=3D(SPYG/4U=?<9OIVBM8G$=&>;';V07TMOML4U:VM>8B
M;=..7/5';/G;59-RKNJ@-5*0RF-4&W'8E1C(42TM2HRS;<21XGL,RS)QYAD-
M_:Z\ZVG%IC$\)\\=#G;S0C1U9K$YCHF/-,9AE*56Z-7&GI%$J,6I,1WEQ9#L
M-YN0AN0UAG:6;:E$E:<2S)/:0VFF\I=;HM<1)<HM1BU)$-]<.6J&^W()F2UA
MG:<-M2LJTXEF0K:0#VFUNC5DY14>HQ:@<%]<2:41YM_<26^O:<W:CR+3S4JV
MD \IU;HM8<F-4BHQ9[M/>5$GHBOMOJCR$=<TZ3:CR++FI5@8#VGUNC59V;'I
M51BSGZ<\<6H-17FWEQY">%IXD*,T++FI5@8#R!6Z+59$Z)2ZC%G2J8[Q:I,1
MGVWG(S^&.[>2A1FVO#\E6!@$&MT6J2IT&F5&+-FTQPF*E&C/MO.QG5%F)#R$
M*,VU&6TB61& ]A5NC5*9.IU.J,674*8M+=2B1WFW7HRW"-2$O(0HU-FHB,R)
M9%B 1*W1JA.G4N!48LJI4PT)J4-AYMU^,ITLR">;2HU-FHBQ3F(L2 (M;HTZ
MH3:3"J,635*;D[XP67FW)$;?%F1OFTJ-2,Q%BG,18@$>MT:94IE&B5&*_6*>
M3:I]/:>;7)CI>+,V;K25&I!++:G,18\P 8K=&E5251(U1BO5J"A#DVG-O-KE
M,(>+%M3K1*-:"46U)J+;S 'C-;HLBJR:#'J,5VN0VT/RZ8A]M4MEIWK%N,DK
M.E*OR346!@#5;HKU6?H#-1BN5V*TF3)I:'VU2VF'#P2XMDE9TH4? HTX& (K
M=%=J[MOMU&*NO,,IEOTM+[9S$1UJRI=4R2LY(,]A*-.&( FMT5=77;Z*C%57
MFV2EN4LGVSF)CFK*3ILYLY(,]F;+AB ][]T8ZN=OE48O?XF.-G2]\WQOBV;)
MO=SFSY,VS-EPQ >*K=%36$V\JHQ2KZV..(I1OME,.,2LANDSFSFC,67/EPQ
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M2=I(5YFS:G$C#JT$   BOE)^(J^OHQ?LT F#DV>(JQ?HQ'LU@2E0$
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M :?*6AE>/6D\2&\_GY"&C>(B>B<PO"^%
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M@ -6#:#%ZOZB-4M";SDPRIK]5);F=45)I,D&C/N\>H26;)FP+#' !Y]@+/\
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M5J&EE]4;BE>A+ITI1I0A>\2VX9F;9Y\I*YY&7,&EJZ7=SC,3YIRO$Y;$,*0
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MU;4G[K5U(Q+:+=Q[TL8_XL/.S&/4[?V(:D\64&P@       !5?\ T?:) 4@
M            !4C^[M]L73 ?4OXR[VQ@*(              K1^N7^S7[$P%
M$               %XS\0?[8@%F               "JOW%K_-TP%(
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M8:G08NB"%4>F-4S4U@FZPJ$R<9;,];#2FULH0>3(MQWJB4D\"+A PZ)!
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M &,;L5]$O4 ,8W8KZ)>H 8QNQ7T2]0 QC=BOHEZ@!C&[%?1+U #&-V*^B7J
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M;4MU^<Q'5+<0XPXR1-(6ALSQ61%CBXG8*S68XIS#+:!>,+5WZ1IG\*X.9O\
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M^C$>S6!*5 0         (9U%\<NGW^?V9CSN^_[FB]/X?_T==,P]$\P
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M?[LQS&TGS3\T;>CI3'\5F.99@;BH         JO_ */M$@*0
M  J1_=V^V+I@/J7\9=[8P%$              5H_7+_9K]B8"B
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M>GEJ&A=NVO2Z<\WAED,1&BD;.#%TTFL_14-"^XU+^U:9]*\5B&U#72
M   /%)2M)H61*0HC)23+$C(^$C(!I&L%Q56SM,+EN.@.)CU6EPE/0G%(2XE"
MTJ21=0HC2>P^ R&UM=.-35K6W"95M.(>Z/7'5KOTQMFY:ZZE^KU*&E^6\A"6
MDJ<-2BQ)*"(BX.80;K3C3U;5KPB2LYANXU5@
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M9")B)C$D3A<TRH.MNIITY69P_BT@]F\(OR3_ ,1>F.?J:?+/D;%;99D8E@
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M-6"N'G@.U 5     $5\I/Q%7U]&+]F@$P<FSQ%6+]&(]FL"4J @
M0SJ+XY=/O\_LS'G=]_W-%Z?P_P#Z.NF8>B>8             &!NNUHUU068
MZY#L&?"?1,IM1CX$]'DMXDE18[#(R,R4D]AD-7<[>-:L1G$Q.8F.J6WM=S.A
M:9Q%HF,3$\)ABZ-9%1:KD>XKJKSMP5. VXU3"..W"CQR>+*M9--&9&XI/4FH
MSX/0PP:6TM%XOJ7YYCAT8B/1'6V-;>5G3G3TJ<E;<>G,SCRSU-R'1<P
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M'B3LKZ.1[-0;_P#'OYRG!)HT5P
M<HT.CZUZU-W!J3;VI$RV8S%2G0;2M^(A!03;IKJF".4E23SFXM!YLY'Z! E.
M6BU]2=2M+;8O>:VEJ=5X:79:$%E3OD*-M9I+;@1FG$B!#?      !SGRU_$[
M%_N"E?"J 2_&^+L]HGI$ J@       NU_P O;_:*Z0"T               !
M5?\ T?:) 4@             !4C^[M]L73 ?4OXR[VQ@*(
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MF6XKO:^<65O4&W@X6/!CPEL&IM]U37SR_=G#<W.TU-OR\_WHS#8!MM,
M            <CW74[_Y.^LMYWU3;+DWA8U^%$D.2(&<GHDJ,A1&A:D-/9>J
M6O8I))41IP5BDR!9\615[^U_UTM346=9LFT;*L>/+)#\XG-[*?E-+;R)<<;:
M)9YE)/*A."$DK%6*B ==@J .;]:]>Y-GZAP;'T^L9-Y:F-0S?XQNC=7#8?2:
M]V@F4*>/,DB6Y@M"23APX["8AI6F^K3%+U?IU,U7T@@V3>]TOJ9IMT1X?%W'
M94@]WM-U*E*WJE);4XTZ?5*ZHL%&9$NQ05  !%?*3\15]?1B_9H!,')L\15B
M_1B/9K E*@(                            1ERA_$G>OT<OV:1O;#\>G
MG4OP.3QXD[*^CD>S4&__ ![^<IP2:-%<
M      '/<OD;:42ILN:U4+CA<<?=E.1H=7=882X^LUKR(2G B,S,$Y*%R-]*
MK=ET^72JG<K)4UYJ1%C%6'28)3*R6E)MI219<2VD!ET("     !SGRU_$[%_
MN"E?"J 2_&^+L]HGI$ J@       NU_R]O\ :*Z0"T               !5?
M_1]HD!2              %2/[NWVQ=,!]2_C+O;& H@             "M'Z
MY?[-?L3 40               7C/Q!_MB 68               *J_<6O\W3
M 4@             !Z7"0"YJ'QD^U3TB 6H          PM9B.-.%5(R34:"
MRRFDEB:VRX#+S4[1ET[\LJVC*-;PID^'62NJF1G*A39L=MBHLQ4FZ\A3)J-M
MY"$XFLL%FE1)V["'9T=2*^9IWIEKY5]F4>XI$654IZMB8C##I*(__>*4DB01
M<TU#;G5K$<6&*2DFQZ"_;U':B35I<J,AUR7.4CK-^^>91)YY)V)Q\P<V\YF9
M;41AGCX1 \  &MUZ]Z/0I14XTO3ZH:26J%"1O7$)5P*</$DH(^9F,L1>M9MP
M1,Q'%0I%_P!(J4YNFRF)%+G/;(R)R";0\KL6W$FI)J_PXXA:EJ\41,3P;*E?
M%*C&E)V(>449_P TEGU!GYRNF-/7KT99J3U-D&DS "!>6-XBJQ\LI_\ $H =
M&6O_ $S1OD,7X%(#+  #EO3J.<M_5>*2LIOWO<+1*/;AG-M./ICTU?8K\,/+
MZGXEOBG[40>2+5_"B-\U<[H-GOO(P<L'DBU?PHC?-7.Z!WWD.6'G)\MYRU-:
MKFMMU\I+E-IDF.J0E)H2LTRXFTDF9X=$+SFN2(Q+HC0+QA:N_2-,_A7!QM_P
MKZ7:\/\ O>A/@Y+J@"-]:-6X^CENTJX)-*75FZG5H]&)AMXHYMG):>=WF8T+
MQRDSAEP+''A!,-$U_MC1NK7A8M.O^TEU:NW?.[SPJO"?7#=9)LVR+?J:6@W$
MEO2P)6.&W "$F:=Z1:>:51Y#%C45NFKF9>.2C6Y(DNDC$TDIUY2U92QV)(\O
MF ANX  XFU'1I-0.5C5ZMK0[%J=M56DQE4QETU2FJ?-98CMDB7':-2R)24+6
M@U(-![S'A(S26ZFK7#=G)YI^O]@7%I=.C6W0Z,IV7=-9C,R6(#B"(MVPTP2,
M^=:=XTX:6\IDX6.."@';ED:A6;J/3'ZQ9-6;J]-C/G$??:2XWD?2A#AI-+J4
M*ZU:3QPP!51U/NMVQM/+FNZ.E*Y='ITB5%0O:A4A*#W1*PYAK-.(#D:8O4+3
MS3[3K7\K]KM9KMQU* =R4:=+WE)=AU$G'B:;CY4DC*E!-GM/ SQ1EP(%G9MV
M/O1;5KDF,XIF0S3Y;C+J#-*T+0RLTJ29;2,C+$C!5QQR=KCM.Y9MIR*_KA=3
MVH"GB=EVA/J,TJ:^^EY1-QS5(;W;I.))/4)=4:C/ @6E)/*VUFM"U[4KNE=2
M1,.Y[AHR9,!;+2%Q20\^MI.\<-PC(\6%XX)/F B(2%R;/$58OT8CV:P)2H"
M        !#.HOCET^_S^S,>=WW_<T7I_#_\ HZZ9AZ)Y@      $)Z@\F2PK
MUJ+-:@Q8M)K;UPP[BKDYR(4Y4YN*VM#D,TN.H)MM\U$MS+BDU%BI*CX"<I(L
MJP;2T[ILFCV;3&Z53)4IR>]&:-:D<8>)*5&6<U&18(21)+81%@6! AL@
M   (9T __P"R^EU?^T/.^#?_ -/B>G\=_P#Y? F8>B>8
M05RN;HN*T-')58M>IR*154SX329D-Q3+Q-N+/,DE)P/ \-H)AIFNVO<"G6_8
M;NGM_4U=2>K4%-?*FSX<IPH1M*-W?I2I>5O-AF-1$0$0G^C:F:<7%46J1;]X
M42K59\E&Q @5*)*D+)M)K5E;:=4H\J2-1X%L(L00VD  <D:S.ZIV9R@8NH6E
MM@3JPX='13JU,;;7*@U%AQ68D&EILE,N-&VC%1.'CE3U)%CF+0C^\[OY1E]W
MO:-W5S2&><.S'U3Z91FHTM+:YQFE27G7<IK/(IMM24E@74[<<3 =7Z,WK?\
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M]L/QZ>=2_ Y/'B3LKZ.1[-0;_P#'OYRG!)HT5P
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MV?4?;^Q/"BD?/XW= _6:'YE?[H/T.X_+O_;/J/M_8GA12/G\;N@?K-#\RO\
M=!^AW'Y=_P"V?4?;^Q/"BD?/XW= _6:'YE?[H/T.X_+O_;/J/M_8GA12/G\;
MN@?K-#\RO]T'Z'<?EW_MGU'V_L3PHI'S^-W0/UFA^97^Z#]#N/R[_P!L^H^W
M]B>%%(^?QNZ!^LT/S*_W0?H=Q^7?^V?4?;^Q/"BD?/XW= _6:'YE?[H/T.X_
M+O\ VSZC[?V)X44CY_&[H'ZS0_,K_=!^AW'Y=_[9]1]O[$\**1\_C=T#]9H?
MF5_N@_0[C\N_]L^H^W]B>%%(^?QNZ!^LT/S*_P!T'Z'<?EW_ +9]1]O[$\**
M1\_C=T#]9H?F5_N@_0[C\N_]L^H^W]B>%%(^?QNZ!^LT/S*_W0?H=Q^7?^V?
M4?;^Q/"BD?/XW= _6:'YE?[H/T.X_+O_ &SZD<\GQQMUN[W6E$MI=5-2%I,E
M)4E1*,C(RX2,<CP6<]Y,>\[7CT3$Z43[J:!Z)Y@               !JVH6G
MMLZGVR]:=V,N/4AYQI]26'5,N$XRK,DR4D!#OD2:%?NE3^?K]J"<MCL/DMZ3
MZ<77 O*VHTY%;IN^XJM^6MULN,,KCKQ09$1]0XH#*: 0 .7-6=0==Z]K<C1W
M1N=#M]4&F-U294J@TPM+R',,R\TAF1^;2:T()+31KS9C/J2V$LM:%G<L:'=%
M(EWCJ#0*A:K,II=8@QF&DOO1$J(W$(,J2R9*-.POSB?/(#H=&@@  $5\I/Q%
M7U]&+]F@$P<FSQ%6+]&(]FL"4J @         0U<>J-RTKE'6AI5%1%.V*Y2
M7:A-6MM1RB>;;J"BR.$LB).,5O9D/FCI:>VK;:VU9XQ./L]:DV_BPF4<U<
M   0=RLK1N6]]()5"M.FO56KJGPWDQ(Y$;AMMK/,HB,RX,03!>UH7)4.4MI?
M=L"FNO6S1:?5F:G44$6YCKD1)#;:5;<<5*6DBP+F@(Q5:-Z,ZR4JM:7V7<=B
MU&17#>OI;TEE=JS:=O3-YY!$X9.+<3BHDI2G SZDB5@H$NOP5     $9<H?Q
M)WK]'+]FD;VP_'IYU+\#D\>).ROHY'LU!O\ \>_G*<$FC17
M                               <Y\M?Q.Q?[@I7PJ@$OQOB[/:)Z1 *
MH       +M?\O;_:*Z0"T               !5?_ $?:) 4@
M !4C^[M]L73 ?4OXR[VQ@*(              K1^N7^S7[$P%$
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MBH-)8X\!D8RV]B%>M/&@7C"U=^D:9_"N#C[_ (5]+L^'_>]"?!R75
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M(\7EK,MG.&YM]KI:$3&G&,^?][0W.\U=Q,3J3F8\D1]C/#::@
M           .,];:1J!J3RG:79EI55BSZE0:(<VE7 >>/+D,O;7B;>:+>.D1
MK4A+6.4B2X?98EHX-TLO0[E!T*[*-6+AU>D5>AP9;3]0I:G):DR6$*Q6T9+5
MEZHMFT$9=, @  $5\I/Q%7U]&+]F@$P<FSQ%6+]&(]FL"4J @         <R
MWM_UL:<?V[(^!K [FC_T+_%_Q8I]N'30X;*                C+E#^).]?
MHY?LTC>V'X]/.I?@<GCQ)V5]'(]FH-_^/?SE."31HK@
M                          .<^6OXG8O]P4KX50"7XWQ=GM$](@%4
M   %VO\ E[?[172 6@               *K_ .C[1("D              *D
M?W=OMBZ8#ZE_&7>V,!1              %:/UR_V:_8F H@
M  O&?B#_ &Q +,               %5?N+7^;I@*0              ]+A(!
M<U#XR?:IZ1 +4              6SU*B3WVUNI-#Z3P2^V>5PB\__88F)F.
MQ+L&JQ#/(29S)<&&#;V'FXGE/TALUUYZV.:+?C\=!Y'\T=SFI>2:/3,L#] Q
ML1JUGK8YK*LAYEPL4.)47F&1B^85P]4XVDL5+21<\S(A.10XZAU6ZA(5*?/@
M0UM27GJZTNB,5M6L+1699.FTQ;#AS9BB<F*+*E*>L:2?"2?/YIC1O>;2SQ&&
M4%$@"!>6-XBJQ\LI_P#$H =&6O\ TS1OD,7X%(#+  #F+2S^9ZG_ -^5[V;0
M]-7V*_##RVK^);SRAJO:9:KZ4W+/KNE2W9="GJ-7%XR6WG$(49J)IV,X1Y\A
MF9(6A)[.QQ&Q%JVCI8L3U+-=\<J&M(53F*14(:WNH-]-*XHHB5LV.O-DE/;8
MEASQ/+2#,SU)3T+TCGZ?1YU<N1U+MT58B0ZA"]Z3#)*SFDU_E+6K UF6S86!
MGPC'>V>!$8;_ *!>,+5WZ1IG\*X.5O\ A7TNSX?][T)\')=4       !R#J/
M)U1T^Y2-6U"TXTYJ-P0ZA2X].K3Y(<=BSOS3)DIE;;1FRIO=-MJVK(\A["Q!
M9NUD:XZUW%=E)HEP:.3Z#19SY-3:PZN0;<9LR,S6HE1TEALYJB!&'1 (
M $5\I/Q%7U]&+]F@$P<FSQ%6+]&(]FL"4J @
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MUMJUZVE"*K2X:8\M+2R<02R4H]BBX>$<G=:D:FK:T<)EDK&(;J-58
M                                    !SGRU_$[%_N"E?"J 2_&^+L]
MHGI$ J@       NU_P O;_:*Z0"T               !5?\ T?:) 4@
M        !4C^[M]L73 ?4OXR[VQ@*(              K1^N7^S7[$P%$
M            %XS\0?[8@%F               "JOW%K_-TP%(
M    >EPD N:A\9/M4](@%J              *L?W='G@*9\)@/A2$++*M)*+
MG&6) +5RD4MP\5PF#5V6[21]' !\IHU)0>)06,2X#-M)],A.1>(;;;3E;22$
M\Y)$1>D('T   "!>6-XBJQ\LI_\ $H =&6O_ $S1OD,7X%(#+  #F+2S^9ZG
M_P!^5[V;0]-7V*_##RVK^);SRD02Q@  US0+QA:N_2-,_A7!SM_PKZ78\/\
MO>A/@Y+J@       .5]4+GUOU'UEJVC^DE:8M:FVO"C3*U57#R+==EM-O)+>
M);=<(B2\E*4-D6TE&I7!@2M;2N+7G1;4VT;(U9K\>[K1O9UR!3ZBV9NOQYB$
MI)/YQ;;;F.9;9*)>9)I4:B/$C!+K(%0    !%?*3\15]?1B_9H!,')L\15B_
M1B/9K E*@(
M    !QUJ52;!NCE8.4C6Z6B/:4:WXZ[6CS9*H,%Y]3B3-*W26WPK-_9F+,:2
M29GAE,MU,3=5"TBL/7#2=[0F;&17ZA6&HE?I](FKGQSIC[C;;JW3WKI(/=J<
MZG-M(LV79B [;!4  $5\I/Q%7U]&+]F@$P<FSQ%6+]&(]FL"4J @
M
M   !X1D? >(!B6.&.WG /0'.?+7\3L7^X*5\*H!+\;XNSVB>D0"J       "
M[7_+V_VBND M                57_T?:) 4@             !4C^[M]L7
M3 ?4OXR[VQ@*(              K1^N7^S7[$P%$               %XS\0
M?[8@%F               "JOW%K_ #=,!2              'I<) +FH?&3[
M5/2(!:@             "K']W1YX"F?"8#P        ! O+&\158^64_^)0
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M%6+]&(]FL"4J @
M       :WJ!>=/T\LRM7I5&UO0J-&5)4PV9$MU>));;(SV$:UJ2G$^#$!H*[
M+LGE*:>V_<^H5I\2>GQ^.4M!25'-C1I!YFU)D-);Q)U&5S(HC3M+$L03P1]3
M;1TDY.6L%GT.G6>\IZ]"=A4J\)4]4IR--S$V<=,=:"2C/O&BWJ59CSX<&('%
MU&"   17RD_$5?7T8OV: 3!R;/$58OT8CV:P)2H"
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M]Y;], XFW^\M^F <3;_>6_3 7"HR#AH;WZ,"69Y^8?F +?B;?[RWZ8!Q-O\
M>6_3 .)M_O+?I@'$V_WEOTP#B;?[RWZ8!Q-O]Y;], XFW^\M^F <3;_>6_3
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MF J,Q6TFK"0@\4*+9CS2X0%/B;?[RWZ8!Q-O]Y;], XFW^\M^F <3;_>6_3
M.)M_O+?I@'$V_P!Y;], XFW^\M^F <3;_>6_3 .)M_O+?I@'$V_WEOTP#B;?
M[RWZ8!Q-O]Y;],!<M1D%$>03R#)1D9K+@(!;<3;_ 'EOTP#B;?[RWZ8!Q-O]
MY;], XFW^\M^F <3;_>6_3 .)M_O+?I@'$V_WEOTP#B;?[RWZ8!Q-O\ >6_3
M .)M_O+?I@'$V_WEOTP#B;?[RWZ8"HN(V;39<801%FV[=N)@*?$V_P!Y;],
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MV9A*S66'-Q2 SH#!1+ULVH5EVW(%Q4R5<+!J)ZDL38[DQ!HZ[,PE9K+#FXI
M:1RD_$5?7T8OV: 3!R;/$58OT8CV:P)2H"
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M98\!=2:NIS$X2-RD_$5?7T8OV: (.39XBK%^C$>S6!*5 0
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M"B               "\9^(/]L0"S               !57[BU_FZ8"D
M         /2X2 7-0^,GVJ>D0"U              %6/[NCSP%,^$P'@
M    "!>6-XBJQ\LI_P#$H =&6O\ TS1OD,7X%(#+  #F+2S^9ZG_ -^5[V;0
M]-7V*_##RVK^);SRD02Q@  US0+QA:N_2-,_A7!SM_PKZ78\/^]Z$^#DNJ
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M.?+7\3L7^X*5\*H!+\;XNSVB>D0"J       "[7_ "]O]HKI +0
M      %5_P#1]HD!2              %2/[NWVQ=,!]2_C+O;& H@
M      "M'ZY?[-?L3 40               7C/Q!_MB 68
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MJ*C1:"U 1&?><9-1M(D.DHSRH):D]<KJ3,BRX["<I.D:95^LW)?#MTW6_5+
MNZF]ZXUJ;K=H@DXREIQQIS.HB4?5F1I06U6)[4D C&B<F"\#.V+7O:_$US2Z
MS)J*C1:"U 1&?><9-1M(D.DHSRH):D]<KJ3,BRX[!ETT"            &JW
M'IQ9EVW#0;JN"F<<KUL.F_0Y>_D-<7<-2%F>1IQ"%[4)/\XE0#:@
M         !JM@Z<69I?1WZ!8U,[U4F3)7.>C[^1)S27&VVE+S27'5%BEI!8$
MK#9P<(#:@                            &#AV99].K+MQ4^WJ9$N"0:C
M?JS$..U,<-9&2LSR4$L\<=N*@&<
M                                              !SGRU_$[%_N"E?
M"J 2_&^+L]HGI$ J@       NU_R]O\ :*Z0"T               !5?_1]H
MD!2              %2/[NWVQ=,!]2_C+O;& H@             "M'ZY?[-
M?L3 40               7C/Q!_MB 68               *J_<6O\W3 4@
M            !Z7"0"YJ'QD^U3TB 6H              JQ_=T>> IGPF \
M        0+RQO$56/EE/_B4 .C+7_IFC?(8OP*0&J:W64J_M,:_08R#554,<
M>I!IZ\IT,]\T23YAK-.[QYRC&SMM3N]2)ZFON-/GTYCK:#IY=*+SLNC7(1D;
MTR.GC1%@1%):,VWB(BX"SI5AY@[]HQ.'FFS"      1U6H7V]UDLNPDD3M*H
M1JNVOIV*3A%/=Q$*+S73P4D_R58X#%KWY-*9[>AM;;3Y]2(]+IX>=>C
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M5*RY<2V*,##;)^O=DP-(FM:5,5!ZU'C2E$9MA"9^\.4<-2#;<=0@C2X2B/\
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MI"#;=E.$9XN*2:W#(S[<_/!5G
M     <Y\M?Q.Q?[@I7PJ@$OQOB[/:)Z1 *H       +M?\O;_:*Z0"T
M          !5?_1]HD!2              %2/[NWVQ=,!]2_C+O;& H@
M         "M'ZY?[-?L3 40               7C/Q!_MB 68
M    *J_<6O\ -TP%(              >EPD N:A\9/M4](@%J
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MX\DX[4"IJS.O-DVA>]3BVV>7%1IX.9P@JW@
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M[$P%$               %XS\0?[8@%F               "JOW%K_-TP%(
M            >EPD N:A\9/M4](@%J              *L?W='G@*9\)@/
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M3(J&Z6XO>N(S93/>+7AAF5L+9M ;2
M          YSY:_B=B_W!2OA5 )?C?%V>T3TB 50       7:_Y>W^T5T@%H
M               "J_\ H^T2 I              "I']W;[8NF ^I?QEWMC
M40             !6C]<O]FOV)@*(               +QGX@_VQ +,
M          %5?N+7^;I@*0              ]+A(!<U#XR?:IZ1 +4
M        58_NZ// 4SX3 >         (%Y8WB*K'RRG_ ,2@!T9:_P#3-&^0
MQ?@4@,L UZ^K4B7Q9U;M*;@3%7B.QDK46)-NJ3BTYP'M0LDK+S2&32O-+1:.
MICU*1>LU[4$Z.5Z56K&AQ:HDVZ[05N4.KLJZ]$FGGN\%;3VFC(9^;B/2VQGH
MX/+SY6_"J   :);T/[><H*,VHB=H>F\ YCQ;%(.KU,LK23\U+99T\Y2!K;N_
M)I8Z[-_9:?-J9]UTH."[P
M
M                        #X>>9CMJ>D.):93AF<<424EB>!8F>SA >H6A
MQ"7&U$MM9$I"TGBDTGM(R,N$C ?0
M   .<^6OXG8O]P4KX50"7XWQ=GM$](@%4       %VO^7M_M%=(!:
M         JO_ */M$@*0              J1_=V^V+I@/J7\9=[8P%$
M         5H_7+_9K]B8"B               "\9^(/]L0"S
M   !57[BU_FZ8"D              /2X2 7-0^,GVJ>D0"U
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M?+7\3L7^X*5\*H!+\;XNSVB>D0"J       "[7_+V_VBND M
M    57_T?:) 4@             !4C^[M]L73 ?4OXR[VQ@*(
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MK:&([*>M0TTDDI26/,(BP'F9G,YEZB(Q&%<0D
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M(O,!,M,Y,>JE0TUT(=FM6M5KLXQ=,V(U&I#2G51VR@0WC4O*E6"34I6&SAQ
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MPG32I2<QEL5U.4!W("H
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MP%$               %XS\0?[8@%F               "JOW%K_-TP%(
M          >EPD N:A\9/M4](@%J              *L?W='G@*9\)@/
M     $"\L;Q%5CY93_XE #HRU_Z9HWR&+\"D!E@ !:52FPZS3)M(J+9/4^H,
M.Q);)\"V7T&VM)^>DS(369B<PBT1,8ES-HR[+I5+K.G=56:ZO9%1?I:U*X7(
MBEJ<C.[.8I.))\PAZ?FBT1:.MY:]9K,Q/4DL0HT[2:%]M=:+IOAPMY1[.83;
M5&6?6G.=_.3%IPV9D>YGMZU1#1WU^6D5[>ET]AIYM-NQT4.,[0
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MUBNBW?OMJ-&AV=;,CC)QZ-F-R8K,G,9)R[#<)!)S+4G(1]2C$S RZU!4
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ME:>P7*;9=$BT:(\HEOE&1@MU1%@1N.*,UK,BX,RCP!#90
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M%G_U9@'%G_U9@*C$=\GFS-!X$HL>B ^I,=Y4APR09D:CP,!1XL_^K, XL_\
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M&JV0
M   &L77IY9U\3*+/NFEIJ$NW97'Z,XIUYK<2<4GGP:6@E;4)/!>);. !LX
M
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M#1=%QL$6*$PZ>1XLJQQZE;R5M'YI$.UK6[NEIZ^#BZ&GSWB.K]SKT>:>E
M
M
M                                          '.?+7\3L7^X*5\*H!+
M\;XNSVB>D0"J       "[7_+V_VBND M                57_T?:) 4@
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M\CPS%STJ(C(^'A"?XJS$]72BW\59B4M#G.>    N&_BKOGD*SQ2MQ9
M     *3L9A[ W$$:BX%<"B\XRV@9?3;U1B?%G]ZV7Z%_JN@OKB]'$8YTZRB8
MB61BUN.Z9-2R.)(/\ASK3[5? 8P6TYACFDPS"]K#1E_BZ8Q**0
M    ]+A(!<U#XR?:IZ1 +4              58_NZ// 4SX3 >         (
M%Y8WB*K'RRG_ ,2@!T9:_P#3-&^0Q?@4@,L   #PR)1&E1$:3+ R/:1D8""=
M"-%G--KPOVKR6C3%>F][K8S?D4A1\=,D<S*:WDH/_&TH=#=;GO*UC]OG:&VV
M_=VM/[/,G<<]O@
M
M                                                          #G
M/EK^)V+_ '!2OA5 )?C?%V>T3TB 50       7:_Y>W^T5T@%H
M     "J_^C[1("D              *D?W=OMBZ8#ZE_&7>V,!1
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M&6O_ $S1OD,7X%(#+
M
M
M          .<^6OXG8O]P4KX50"7XWQ=GM$](@%4       %VO\ E[?[172
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ME?:YQ\\N>1\P:%Z<LM>U<+T45          !Z7"0"YJ'QD^U3TB 6H
M        JQ_=T>> IGPF \         0+RQO$56/EE/_ (E #HRU_P"F:-\A
MB_ I 98
M
M                                                           !
MSGRU_$[%_N"E?"J 2_&^+L]HGI$ J@       NU_R]O]HKI +0
M     %5_]'VB0%(              5(_N[?;%TP'U+^,N]L8"B
M    *T?KE_LU^Q,!1  &/J-+3+,I#"MS-06"7,,2478K+FETADI?E7K;##FX
M:'.+SF]S(_))6U"_-0KFC;BT3P9?,KB0         7#?Q5WSR%9XI6XL@
M          :/J6XMR%2Z6:C3#J$PFY9)/#.VVVMPD'YBC26(V]OQF>R&SMXZ
M9GLAA$I2A)(01)0DL$I(L"(AD9U>S'EP;RD4Z-\3J$)4R0R76H?8<0@ED7,-
M9+,CY^!!JQG3S/5*FM&:9[)24PLX]3BO)V)?,X[I<_$C4D_0,AS-2,U:-NF&
MQC38           >EPD N:A\9/M4](@%J              *L?W='G@*9\)@
M/         $"\L;Q%5CY93_XE #HRU_Z9HWR&+\"D!E@
M
M
M                                    '.?+7\3L7^X*5\*H!+\;XNSV
MB>D0"J       "[7_+V_VBND M                57_P!'VB0%(
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M* '1EK_TS1OD,7X%(#+
M
M
M            .<^6OXG8O]P4KX50"7XWQ=GM$](@%4       %VO^7M_M%=(
M!:                JO_H^T2 I              "I']W;[8NF ^I?QEWMC
M 40             !6C]<O\ 9K]B8"B      *;T=B0@VY#:74'PI61*+TQ,
M3A,3AC':$E.V#(7'YS:OSK?04>)>@8S1JSUKQ?M6;K-3BEB]&WZ"_21SQ/UA
MX'Z8RQJ5E>)B5)N9'<5DSY'?U:^H7T#&1;"N"   7#?Q5WSR%9XI6XL@
M          'VLR)I!F>!%FQ/T1 M6EOSUFU3TXIX%2E>Y)\[LC$6M%>).(XL
M]!@M0&=VV9J6H\SKJNN6KGF-.UIM+#:<KH55          !Z7"0"YJ'QD^U3
MTB 6H              JQ_=T>> IGPF \         0+RQO$56/EE/\ XE #
MHRU_Z9HWR&+\"D!E@
M
M
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M'*SO6SJSHK58%(K]/GSERX)HC1I3+SIDF2@S,DH49[ '55K_ -,T;Y#%^!2
MRP
M
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M42TZ?THE),C(]VKA+_, EMAAF*PU&CH)MAE"6VFT\"4(+ B+SB(!4
M
M
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M);<)I;Z8Y]6II*N;P@).9=;?:;?942VG4DMM9<!I46)&7GD ^P
M                  'BU9$*7@:LI&>5)8F>',(@$=LZF56/6:1!N.U)E$IE
M?D<3I<Y]YAU9OJ(U(2\TTI2F\Y%LQ]$ >U&N*3<U;MZW;2=JR*"^U&ES"FQX
MR<[S*'BP2Z9'L)0"0VU+4VA3B<BS21J1CCE,RVEB7. ?0
M
M
M
M             #!7)"NJ8F.5L56/2U(-7&3DQ>-9R/#+EZM&7#: UJKT.8_:
M]8INJ-QQ7;>GH:CJD1V2IQLFMQ)%BXI:RVJRD0#2(93&+BJ]CV?<TNZ+?F6_
M,5*XW**H<0F&@VXZ42"Q,MYB?49N9B"6-E7!1JYHM:EHTR4T[<TIZE4]%+0H
MCE-/Q)#:GC6V75))!-J,S,@'1*$FE"4GPD1$?H A]
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M. $I_M^(] H-,@R/C$:(PR[S>K;;2D_3($,B
M     ^'76V6EO/*)#3:36XM1X$E*2Q,S/G$0"%H5XVSJ9>U,J;E9A1;:MV4H
MZ)%=DMHE5&I*+=$\39JS$VC$R;(RQ49X@E::@Q;1HQW->=MWS*I%W./$MZGQ
M)Z%-.S8Z$L):7"VYS,DX;2 3';4JH3K<I$VK-[FJ284=Z:UAER/N-)4XG#F8
M*,P0R@
M
M
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M[ZVG(ZE9%&D\4.I2HMI<T@&P ,>="HBJB57538IU4N"<;+>_+_M,,WI@,@
M                            /%)2M)H61*0HC)23+$C(^$C(!B&K3M9A
MU#[%$@-O-J);;B(S*5)4D\2,C).)&1@*ZK?H*ZAWU73(BJI^^FPV;_K\N;TP
M&1
M
M
M
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M+-PU&/2ZW;4.GLQ'(7&TG@]%=:;0M:&U%E5O5&>T$NQ@0
M
M
M
M
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MS3 7MJ'RAT3J93+DI=JLTN&II%2K+#DIU^2RWL4IEGJ20XHMN*E&1'S $Q
M
M
M
M
M
M
M
M
M
M              AO4GE(V;IE=96;5*76:G63BHG&W2(2IA)9<,R(SR'B6TN<
M U;RR+(\$+O^I7P2>619'@A=_P!2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED6
M1X(7?]2O@'ED61X(7?\ 4KX!Y9%D>"%W_4KX!Y9%D>"%W_4KX!Y9%D>"%W_4
MKX!Y9%D>"%W_ %*^ >619'@A=_U*^ >619'@A=_U*^ >619'@A=_U*^ >619
M'@A=_P!2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED61X(7?\
M4KX!Y9%D>"%W_4KX!Y9%D>"%W_4KX!Y9%D>"%W_4KX!Y9%D>"%W_ %*^ >61
M9'@A=_U*^ >619'@A=_U*^ >619'@A=_U*^ >619'@A=_P!2O@'ED61X(7?]
M2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED61X(7?\ 4KX!Y9%D>"%W_4KX!Y9%
MD>"%W_4KX!Y9%D>"%W_4KX!Y9%D>"%W_ %*^ >619'@A=_U*^ >619'@A=_U
M*^ >619'@A=_U*^ >619'@A=_P!2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED6
M1X(7?]2O@'ED61X(7?\ 4KX!Y9%D>"%W_4KX!Y9%D>"%W_4KX!Y9%D>"%W_4
MKX!Y9%D>"%W_ %*^ >619'@A=_U*^ >619'@A=_U*^ >619'@A=_U*^ >619
M'@A=_P!2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED61X(7?\
M4KX!Y9%D>"%W_4KX!Y9%D>"%W_4KX!Y9%D>"%W_4KX!Y9%D>"%W_ %*^ >61
M9'@A=_U*^ >619'@A=_U*^ >619'@A=_U*^ >619'@A=_P!2O@'ED61X(7?]
M2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED61X(7?\ 4KX!Y9%D>"%W_4KX!Y9%
MD>"%W_4KX!Y9%D>"%W_4KX!Y9%D>"%W_ %*^ >619'@A=_U*^ >619'@A=_U
M*^ >619'@A=_U*^ >619'@A=_P!2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED6
M1X(7?]2O@'ED61X(7?\ 4KX!Y9%D>"%W_4KX!Y9%D>"%W_4KX!Y9%D>"%W_4
MKX!Y9%D>"%W_ %*^ >619'@A=_U*^ >619'@A=_U*^ >619'@A=_U*^ >619
M'@A=_P!2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED61X(7?]2O@'ED61X(7?\
M4KX"2M)-8[8UDIE4JEM1IL1%(F=[IL>I,'&?2^3:7<,AF9\"RX00D,
M
M
M
M        <^0?^LBJ?V:U_%(!+H,$ #&5>X:%0$)<K=2CT]"^L.2ZEO-ASLQE
MB,6IJTI[4Q"8B95J95Z76HQ2Z1-9G13/#>QW$N)QYV*3,334K>,UG),87HR(
M                                              !83*Y1*=(1$J%2
MBQ)3N&[8??;:<5CL+!*E$9@+\C(R(R/$CX#
M        494N+!95)FOMQHZ.O=>6EM!>>I1D1"8B9X)B)G@^850@5)GC%.E,
MRX^.7>QW$NHQ+F9D&9!-9CB3$QQ7 A                            #G
M3DM_SS6C^]I/\,R Z+
M
M
M                                '/D'_K(JG]FM?Q2 2Z#!#$W16DVY
M;E5KRTYRIT5Z22.R-I!J(O1,8=;4[NDV[(3$9E"-DV-"NV*F_+Y1WVKM9QD-
MM/&>XCL*/J$(01X;"V[1\_UM6VI:;6ET*4B(6]U41O26=$OVRR.'#W[;%;I9
M*-3#S#BNN(E&>4RV]$9=KN;:-XF)5U*1AT4VXEUM#J.M61*3YQEB/H$3EH/H
M2(TI5ZUN7KK<5@O*;^S]-M^!5(R"01.%)DR'&UF:N$R,DEL :U3;JU#O:^=2
MK(HM=CT)5N2*<FDSUPDS#0T\V:W4J0I;>8U8;#S; 2QVCM1UBNRJ5N?7[VBR
M*1;%>F46536Z0VTJ8W#;0><G2>Q;-1N<&56& #$V)<VOEW:>.ZH4:XJ=4)")
M532W:$FF$TV\U39K\;=IEM.YR6M+.*3W?"8"<M/KTIVHME42]J2A34&M1D2F
MV5F1J;,\24@S+A-*B,L00AF#K7=L/E&5FQ:X;!Z>'*8HE.>2V2'(]4?@-S62
M6Y^43V#J"+G@/C6'6N\;=U2MJT;,W'>&/5*)!NZ4XV3JB=KDPFFXJ58X(4;)
M*=Y_ "71IJ2DL5&1%SSV AIEHZBTR^*!6*U1FG&"I4J;3U(D9<RGH.)*41),
M^I,^ !%_)JUCNS4+OG1[\-DZN3*:Q1Y##>Y2]377G(ZBR\!FTZV:5&7/(!\6
M7K-=MV:^R[7;-@M.G&:FU2<K?YUYVCNH8=?)W\I"G#62<-F! )*U@U%/3"RW
MKA8A]\*J^^S3:1!,S2EV=+,T,I49;23B6*L.8 P%+IVNM!)%Q5VY:9<$3B[L
MBJ6ZU350U,J2RIQ+<1]#BU.&2R)'YQ)8EMX02P&B5W7YJ/%I%ZR;XI<F-+-U
M5>LAN"AN13^O23!.D\;I.-J).;>-X'M\P!:6?<FIM\79=*TW]3Z'2*%<TNCQ
MJ&Y367GGHL-XDD1.J?0K%9=3CE/: F"M7M2Z)=-N6G)0XN=<JI:8CJ,N[;."
MR;Z]YB>)8D6!8 AJM8OJN0M:8-D,+;[POVS+K"TF@C<.4R^3:#S<[#F E7T,
MO2MWY8#=PU]2'*DJ=/C&;22;2;<:2MM!8%S<I$"&NVE?NI4S7&99%WQX%/HK
ME!76:?389F^\T12R80;SYDDE+4G$U$@LI>:"6%J%ZZKW>W?EVV16(5&M^QID
MJGT^DOPBEJJCM,:2])4\\:TFVE6;(C=EYX#?FM7J2SI/1-4Y\9PX=5B4Z2N&
MP:5.(743;1E+,9;$*7M\X$+;69>H-.MRH799%TQZ-&HE/D2Y,%ZGHG<9<92:
MRP<4ZC)L+#K3 :A3+YOZQ-*T:LWW<#-TM56DP)-*MZ-3VZ<LJA4TM*::WZ7'
M,Q8N9.L+G^8 RT&'KG$D0:I6[[MY%3D*;<EV@Y W,9#3AEF;;E$^;QJ26."M
MV9&H@2Q-P73J-7-8[DL>A7I M&C4.FTZ8T<J S,4\[,2HUEF=>:PPP$"M=%R
M25ZE,V9=5R/0;:H]J1ZS/J$#_=>-5"7,7#2X>3.:4D:"4E!'AB>W$A(W'0>N
MW'<FF5*JMTO%*J;CLQMN49IWCT5F4XW'<<)&PEJ;2G,0(20       #0=7[K
MJ-JVEC13)NMU>2S2J?(469+#DHS)3QES3;02E$7-/ 9=*G/:*]JMK8C*!8EC
M6RPRXF7 :J4N09KF3IR$R)+[BNN6M:R,\3YQ;"Y@]'31I6,1#FSJ6F<Y;OH[
M59-I7:W8*75O6S6([\NC,N*-9PI$/*IUE!JQ,VUH7F21GU)IP+88Y&\T(I,3
M'"6YHZDVC$N@1SFP^5F:4*47"1&9>@ BS1Z_:_>=AUVX:TMM=0@5>M08YMH)
M"29I[ZVVB,BX3(D[3!+0HUVZNW1HA"U7I-V1:/*ATB=.J,!5+;E)E/0W'C29
M+4ZC=D:4$G DGSP'Q)N[5^W=!INJM1NV+4ZC4*93)=,BE2VXZ8;L^3'0HS43
MJM[@ETRP-)<\!FZW=FJNDK5$N6[JS!O"QZE*BP:LI$'O9/@*GJ)#3R-VZZAQ
MLEJ(EDK P$TW!->IM"J=1CX<8B1'WVLQ8EG:;4HL2\\@0@_DTZOW??T>;2-0
M=P==XG&KM*D1VR90_2YN*<<I;,6W$FE1ESP%'3#6:[KZUHJM$?W"-/Y%/DS;
M<;0W@ZXU#F'#WYN<)DXMM9ES, 2FR[[GA6;;%6NFH(6[#I$5V8\RUAO%H92:
MC).8R+$\ 0U'4W5ABQK#@W13()U2LUY^#3K<I1JR&_4*J9)80LRQP26.9>',
M(!AJ5!UJIU5I\NN7[0)LA]ULZI:RX!16VV7#+,F-(2^IU2TEUIK;P4"6GM:U
M7K Y0M4M&JJCKTX;J,.WV3)HDO,3ZC#.1'4IWFDM:%(P/FF NM:]:+MM;4"W
M[4LTV$P(TJG%=4AYO>F95:03+$=!_DJ-!+<,^'# !/\ 49S%,I\NI2CRQH;+
MDAY7.;:2:U'T"!"#+4J>NNIM 8U)M^X:5;U*J1KD4"UI5/5+;=AI6I+2I4HG
M$K2ITDYOS:#RD8)47+ZOZ[=4KILJF7;3;*E6RN*W2:-.A)E.U=#S1.+?)3KK
M:C:S=06Y(S+F@+J\;HU#GZO%I]0KO@6G3XUO-UA^7)@MS">DJDDPI"=ZZU@6
M!XEM/@ 3';3-3CT&"S6*HW6ZFEO_ 'BJL-)CM2%&9F2TMI4LDEA@6Q1@AE0
M    !RC5)1:CU=^ZJ^DID#?O-T&GN]5'CPVW%(0O(>Q3CA)SJ4HN;@0]!2O=
M5Y8X];LUCNXQ'I6^[.R)?VSM1M,&HP$[R7&9(D1Y<5.UQIULL$[4XY588D>
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M2$N+))9EDDC/ E'MPQ!"N     YTY+?\\UH_O:3_  S(#HL
M
M
M
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M&4P$9:C1+@U7:I4)[2:I4O59B93BEW ZF-Q&/'A24NO;N83V)MJ22\I9,=N
M);R6CM*NK72[Z_?-LL52WW:126*5+F-DXV;[*5)=)!XXXES0'Q,J<.U>4Q(R
MT^2[3FK%@QTH@,[_ '*$U.22,4)/-EV9=A& VS1&V:Q0HEUU.H1ETVG7'7IE
M6HU&=V.18CV"2-:"Q)"G32;AH+@QYX"4P0      #2=5+.EWI:JX5*<0U78#
M[52I*W=C9RHIYB;7AP)<+,@SYF.(R:=YI:+1U*VC,8<\/WS3*6ZY N./*H]:
MC]3*ITB.ZI:5_P"%3:5)61_DJ2>T=^NZT[1G.&A.C:)X)*TBM:KUBXTZA5>(
MY3J3#BN1;=B2$Y)#QR\N^E.(X4)-*$H;2>W S,^8.5N]Q&I,1'"&UI:?+'3Q
M3F-%G>*+,DTGP&6'1 <T6W)O[2"EW9IXFQJG<3]4JE3J-LU>F&PN"\W55FXE
M,E;CB%,J;4H\W4GL!+<Z3IW7+8Y-DC3U2"F7(FWYD9QA@\R53933BU-H,\,2
M);F4CYH##7E:%SR.2BQ:,2EO2+G8H]':52FR(WS=B/Q7'4$1F19B)"N:"%E<
MWV[UMIM$L:-9E1M:UF)L*9<5;KRF&%J9IZTN[B,PTXZI:G%)+JCP(B\\$I'G
MZ9QX2J]7(%7KDVHSX<YMNF2ZG(D0,\EM1$E$=:LA8&?4<X! ]3TQU2HNEVFE
M9L2"N+J'#I3EIUZ,KJ5MTVJI5BZO;_\ #.$APO\ T A)ULZ;2;/UDM_O- 6F
MSJ+9#=$;G8%D.4W-<6:5'V:B5G/SP&P:UZ2TG4^TZK'.'O[H*!(CT1U<N3%:
M0^ZD\N=++B4*+-V:% -,N_D\M-Z;TR!IVVBG7O0I]*N*+QJ5)DQI%2I)$9M*
M5(<<R)<Q4DLI$6.&.P!J=X0:KJC<=K2XNE-3H.H4&LTV97[@F(C(C-PH)GO4
M(E)>,W$F67*1(VD0)9FM:3W#<M0URSPW(DJK2:15+-J!X%GJ%*B*<:6V?,P=
M)*#/S0&$7IMJ#5].*;<UPTM;NI5SWC2J_<41!%FB0H;ALM->8AEE*3_S )NG
M:2TR94*I5%5VNK=JC,IER ]5)#M.24QI31D48U9,J25U*>8"$;Z?W5J-IA:-
M/TOJ6G=5K=PT%LX%*J=.<C=Z9L9"CW#JY#CB39Z@TDLE-F98>@"5KK>S,OIJ
MJ6J_I34YEZMYF;/NN*N.49EU1%NI7'$N(<9)M1YE-J2?!AS0%XQHXNX]7(4O
M4JBLW%2H5F18+E3EHWK"ZLU)1O#29X'F-.8^#@ 3W2J53J'38M'I$9N'2X3:
M6(D5DLK;;:"P)*2YA$"%X      .7+DHTS3&HRJ?4XSIVL_(=>HE380IYM++
MRS<XNZ2"-2%-FK*1F6!IYH[NGJ1JQGKZW7I>-2,]?6M*;#G:E/';EL,NG"D&
M3=4K#K:VHT:,>US UD1K<4GJ4I27">)X$+7O&E&9X]BUK1I],NJ(D9J%$8AL
M%@Q';0RV7.0VDDEZ1#@S.9RX\SF580A"^J=*N>W]2K2U<H%%?N.GTF%-HM;I
M, T<>3&FFEQ+[*'%)2O*I&"DYL?]A+S3FEW-=.J]>U@K-$D6W2)%'BVY1J94
M<A3W6H[ZY2Y#K;:EDV1J<RI+-CL!#*61;E:IVLVIU?FPULT>KIHY4V6K#(]Q
M>&3;F7M5;# 1_8UP7WIS)OV@1].JW6JI5[GJ56I$M@HS-.<:E-LH:-Q]UY)I
M+%LS4>0]@#9[$T+D1;&A4Z[*W5*?<TB;/K585;]2?@-*F51[>*09LY<Y-I)"
M",^<9EP@EC:_I1/N;5&\X<^(\Y:E8L6)08]4D*-PU3&I#RDF:S/,;B#R.9N?
MM 1RK2[5*O:-7U6+OICC^H]88I]"IT!O!3O>VC.-()98G^F6E;Q@.M*E18%>
MH;U"K#2GJ?,8)B6REQQE2D&18D2VE(6GSTJ(P0A_3_D\6S:=_71<[U--$-RH
M0Y=JFFHSG5M-LPVFW=ZE3QDH]ZE6!.9]GF; &AU'3._8MMW==-"I2ROBW[[F
MW3:T9>!',BN.)2XA.WK7FC5Y^ #,T;2NYJ#.T4==A+DU"#/K-8O2<C \DZK1
MMXM;AX]F>[+M2!+=;PT*BUFT;NH].K]9D5&X(#\>*BKU.1-A,R5*)YE1-.&9
M)(G$I+9^3B0"UM34_4%$*DVG5--:P5W1DL0ZC+-<9NC$3>5"Y"96\,S0:2SD
MDF\3/J?- :'J+3*[J17J4BB::5*U]5*=5(RTWJI<=$.-$8>(W'3E,N9I"%MI
MV-J;V\ #8:-HQ2KBUPU,N2_;68J-'F]Z3H,V:V2T+-J(2'MV>..Q2<#!#H)E
MEJ,RW'803;#24MM-IV$E"2P(B\PB(!]@    .=.2W_/-:/[VD_PS(#HL
M
M
M
M          <^0?\ K(JG]FM?Q2 2Z#!  H284.:C=S([4ALN!+R$N%T%$8K:
ML6XQD?;$>/%;)F,TAEHN!MM)(27H%@0F*Q' 5!(
M             #7F[+HK5\2-04DZ=P2:8U15F:\62B,/KD)RHPV*-;AXGCP
M-A          'PMEEQ1+6VE2D\"E$1F71 ?8
M        #Q24K(TK(E)/A(RQ(!XA"&TY6TDE/.26!>D ^@
M              '.G);_ )YK1_>TG^&9 =%@
M
M
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M][DL-L2E$<LG-R;><FLF)+ZD^JP 5*_K-:=O2*T4EB?)I=M.M1[CK$5A+D*
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MBHWS92@W#5L+*74I-6T^ !L;[[,9ER1(<2U'92IQUU9DE*4(+%2C,]A$1%M
M:!2-=-):]6H]OTBZHDJJ2W>+Q&TI=2T\]P9&GE()I:CPX$K,P%Q%UGTOFW"5
MJQ;DC.UPY"H:6$I=-M4E&)*:)[)NC66!]22\0%O6-<]*:!6Y=N56Y&F*U!<)
MF7$)F2ZIMQ1$9)4;;2DXX&7- 2"VXAYM#K9YFW$DI"N>E18D8#G;DM_SS6C^
M]I/\,R Z+
M
M
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M-.9!\T!T+IQ<L.\+#MVYJ?#.GPJG 8?8@JV[E)H(MV1X%B2<,"/FD"&T
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M%54'W=4+DO76MK2^'<$ZU[?IM#76Y+])6EF;-?4\VRA!.J2K!M!.&:B26T\
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M%EV[5%M =,HQRIS$1*P+$BX"/S 0YUY+?\\UH_O:3_#,@.BP
M
M
M
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M8D9'L,C(!$ODW:9(G./Q6ZE$I+SW&7K>BU.6S2%O&K,:CC(61$1JVFDC)/F
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M%+);[;9-$:24>"2REP$ SX#G3DM_SS6C^]I/\,R Z+
M
M
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ME-W9^!M]?5KO<P#RF[L_ V^OJUWN8!Y3=V?@;?7U:[W, \IN[/P-OKZM=[F
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KA=-F$294<UQ63-MU'"E1<TC =-@                           __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>tm2227887d4-lc_persis4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_persis4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#_FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXP+6,P,# @-SDN9&%B86-B8BP@,C R,2\P-"\Q-"TP,#HS.3HT
M-" @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/2)U=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P
M.$,X(B!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C,T0D(X.35%.#A$03$Q
M141!1#9".31!0D8S0S,T0CA!(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED
M.C,T0D(X.35$.#A$03$Q141!1#9".31!0D8S0S,T0CA!(B!X;7 Z0W)E871O
M<E1O;VP](D%D;V)E($EL;'5S=')A=&]R(#(U+C0@*$UA8VEN=&]S:"DB/B \
M>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#HY
M93 V939B.2UF,3@X+31C-#@M.&(P,RTY8S%D8C@U.&%E8S(B('-T4F5F.F1O
M8W5M96YT240](GAM<"YD:60Z.64P-F4V8CDM9C$X."TT8S0X+3AB,#,M.6,Q
M9&(X-3AA96,R(B\^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^4')I;G0\+W)D9CIL:3X@/"]R9&8Z06QT/B \
M+V1C.G1I=&QE/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z
M>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP
M #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4      !#\X1^)
MR+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0 ! ,# P,#! ,#! 8$
M P0&!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1$1$1%!04
M%!04%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@$, =G P$1  (1 0,1
M ?_$ .@  0 !! ,!               ( @4&!P$#! D! 0$  @,! 0
M       ! @8#! 4'"!   0,# @,$ P<+#@D(!P$1 0 " Q$$!1(&(3$'05$B
M$V$4"'&!D;$R<A6AP4)2LB/4E587-]%B@I+2,U-SL],DE!88HL*3="4U=389
MX4-C-%4F)PF#HU2T148X9(3$M7;P\>)$98665Z2EP\5'$0$  0("!P0'!@4$
M @$%  ,  1$" P0A,4%Q$C(%43,T!O!A@<$B<A.1L9(C%#6AT>%B)$)2XF/Q
M%5."HK+2)4-$!__:  P# 0 "$0,1 #\ G\@(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @X)H"4'47/XG[$=R&YQYI]
M->Y2M-)KT.-;M5*D=P/:FPJJUDDT-.\)IV$2IU. )&HJ:Y(<ASC4ZN?)6L[2
MD.:O' &H]*E2'(D)X<01WIJ5QK-*D\!W*U1P7'2:$DGE1(GM)T*HG.<3J^!5
M(FKM11 0$! 0$! 0$! 0$! 0$! 0$'6YWB )H/0I$Z2:*/,KS-">P*57>:C4
MG40.0JDP&L@<3[G>KI%+7N>*U(H>/<KIC0E(ERY[^52.\A2M38-?PX.+@.%5
M*LE37R5((64ZD-3N''BL8K0KI&O+N!/$=RL%%8J#SJWO2$=3GO+Z-=P'/GR2
MJT/,KP#C[JFDT.0]U"=0H.WC5*BJ.M>))]U6M2D0[54$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'#Q5
MI"#RRN<R-X;V-)^ *;8)T0A)O7J3OS'[UR;[*_=ZO9S![8@UI&EK6GN(^HOI
M&4R&7OP+:QIE\_SW4<UAYB[AI-MNE)[IIOAF]]DQY+S&_2$,/EW J-7F1Q-J
MZFEM*D]RTK/Y2<OCS&R6XY+,QCX,7Q+3/2?>6YLKU6OL;?W[IK%M2(R !72"
MMBZCE<.S*1=;&F7AY#-XN+F[[)GX;:?<ZNIW4W>6>WX-D;8N18P-<8B\Z#5P
M<YIXN#".7VRN0Z?@X>7^KB:7%GNH8]^9C PZ1Z_MV:/O7?#=.NM&V<I87\.:
M-_:.E8;N*1L+0&$U--4SZ\.X+@Q<]DL6R8X:?;_)V<')9W"NB9Q.*-L4_JVY
MOO?L.P-K',Y)OG7Q91D =HU24J>(:\?47@Y/*3F,;AMU/:S>9MP,+CNV0CQB
M;CK3U>FEO["Y=8XMQ#F/ B;1IJ.%3%J^0MLQ8R.2^&Z.*?;_ %:M@XF?SL<5
ML_3MG5JF?<O$FS>N^RZ9&QR/TA##1\C'"&K@.RCI)#V=RX(S.0QYX9MX?M_E
M#M3E\_@:;;XOILI3WS]R2.V;J^O<)9W63;Y=^Z,>:TT%'4]  6H8]MMM\Q;R
MMIP[IFV)NUKU'4GCS' K@T1+D=BJ" @(" @(" @(" @(" @(" @(.J3274)X
MT[DU)2)T(U^T+N[<6#SF.M<1>OM8GMF+VL#>-/+IS![UY^/=I?./-?4,?+XE
MD8=W#'Q=GJ[5TZ#=3[G--FV[N&Z\W(QG7;RO !='P ;0- J#Z5G@XFR7:\K]
M9NS$3A8MW%=&F-RV=8-U[@Q/4K&8['7SX+*2:V#HF@$$/\K56H[:E88UUT7N
MOUW/XV#GL.RRZELS%?\ [63=:NI.5V?A;+'X<AF1R#&O=<D-.EAU T:YCA6K
M>]<F+B3#TO,75\3)X-MN'S7[>QA6+Z;]7<IC(<_%G7B]D;YL=L'Q.9QY5=YH
M;R_6KBMMOF*O%P>C]4Q<.,7ZT\79HI]]/X-X;6N<]A=HQ7&\7M]?LX-=Y(-%
M#H;5Q^]\/@7;LFEOQ-ZR<XN'EHG'GXK8^*?OU-"Y_J?OOJ3N-V#V,QUK9-<6
M-T%CPX4^4Z1\;-(.DD"JZEU]UTT?/<UUK.]1Q_I931$;M/KF9C0][^EO6BTA
M%Y9YA\U\*$V[I(6M';S=*X?X*1AWP[=W1NK6QQ68M;NS1_7[FV>E%]NVXPI@
MWBPC*P/?&YQ#!4-<0/WL:3P"[6%-VUMO1<3,S@TS'/%8V>[0V&'>$4^!<\:W
MO5K#0?7?J7F\%?V^U]NO]6N;EH=-<>$DAVG2 'MH./;J73QK[JTAH7F;K.+E
M[K<'!T77;?\ RQ^UZ9]8[:U9FK/-NDORW6+4OA='3Y7RG2EIY?:K",.]T;.C
M]5LL^I;BSQ]FBGWT_@D-ML9-FW[#Z; ^E!!'ZWIH1YND:OD\.:[=E::7T++<
M?T;?J<U(KO7:&O,\^U9U['9B'<J" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @Z+C]YE^:[XBEO,3J0P
MPV"BW/U6W'@Y: W3#%$YW(/>&-!Y'XE]$Q<;Z64LN[&C8.%]7.XML]D/7TOS
MDW3??^5VGF'^19W/GL:YQ+8]+2\-=XBSY1'<N'J&#^JR]N)9KT,NGXTY;,W8
M%^J:S&YQT9\/67(@]QI3Y-= Y*]4\%:QZ7%,_B>S[EVZQ=)-UVFZ)-W[7B?<
MME^^$6XD=.Q^ISR:,CH*U^V77Z9U+"NPOIXFAV>J=,Q/J_6P],T]-CV[!]HC
M(V=[:[:WO:21/#FP^M/!\P.<>&MTLP[QR"XL[T.VZV<3"F)]-S/)]<^.,+&M
MFV?7_P"7B]I[,OOY\';6TKG8N?R9F%I\#A(']QIQHN7R_A1;%TSS15P>8\29
MBRR-5UT>]N/;U])M/I3C[W$6/KDL,#C';Q,+]1\QYY-+>]:]CV?6S4Q=-(;)
MAW?2R\4C5#6%W[3FX\;+##EMM&Q?*0&B6%["=7NSKV[>@X=\5LOK3U_T>'=U
MV^RZ(Q,.;:Z/3XDA]N9<9W#6F5+/+-PP/+*4H2/=/QK4\?#C#OFW71M.'?Q1
M%W:N\8H3Z5PQ-6='8J" @(" @(" @(" @(" @(" @(.MP\84E47/:'C9+O;;
MC)!JBDE<U[3Q\)?""O.Q[IFZCYAYJLB<U@Q.J9]]K%=[86ZZ9[SQFY,:UYQ]
MUHO&$ AFIQ)='X0P<N-*K"Z)MFKR.IY>[I><LQ\/ENT^KUQLV:8];U]3,Q:[
MAWYM[,V;P^"Z?:$$$'Q-\D.' GM]*N)=Q2Y^LX]N/G<#$MFL73;]]K;/6#IO
M?;WP5G=X>CLG8QMI$[5XV#42T:&/)/BY+LXN'Q1H;=Y@Z1?GL&)P^:WT[):C
MVQU2WYTS=%A]P6<[K%I+1'>MF\T"NH^7J>UI^4%U[;[K=;3,GUS.]-F,/&MG
MA_NK7V5FDZVXMX;XLMV=*;_,X:4B.:WECF82 ^-YB)+7!CG $5Y578NOK;H;
MOG^HV9KIE^+ASHFV=\3PZIHQCV:+2WM\+E<FV(/O'@5-*N/EN?0+#+QM>1Y/
MPK;<"^^(TS[JO5N;KKNC;U]<QNVVYEE \-]:D@E#'</MO- 5G&NVPYL]YDQ\
MM?,?1FD?ZIB:?;6C-MB]5+3<^V)MQY>-EA!;%WFN^0QH#] -7/=\:Y</%XHF
M9>[T[K%F9R_UKHX8BM?5_%ZX^K_3Q[V1LS<!D>X-;26+F33[=7Z]M')'6\E,
MQ$8EOVQ_-K_K?TXR6\6VN[-K 74\<8)A9J,DD?ATF,,8ZI[>+@N'%LF8K#7O
M,W1\3.1;C8.F8C5VQZM&OVL%VCUGW=L>6#"[NM)Y;2,@%UTV7UIK=7']\D8#
M0<EQ68MUNB7@=/\ ,>:R4QAYFV9MC_=$\7\9T^FM*+ 9VQW#C+;*XZ0RVUPP
M/;4@D:A6ATDBOOKO6S6*OJF7S%F/9&)9.BY=HR7.J1R7)&IV7:B" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!('$H*=;1VH.=0*!4
M(%0@5"!4(%0@5"!4(%0@5"!4(%0@5"!4(!< ">Y!T3N:89>/'2?B4MG2LQH1
M)Z=NIUZR8IQ$C/CC6^9[]OAI>2G_ /HXD;F0^TMLT0>K;QQ41%VPZ;HLH*#D
M/LO3V-73Z#FJUP[M3M=<RUW#&)9'Q0P+V>IY;SJ(+F:OG31/<]U*UH*>\O3Z
MU;$9>CR^AXEU^/-TZ)NAO)O7[9UKF[_ [@'T?-:RR0M+A<3AXC>6UHRW(%:=
MZUR.C8TX<7V?%7='O;'/5\"S%G#OFD^V?<T9U?W!M??6[\9#LJW$L_F-9-/"
MR2(%[BVAI)'&.7I6Q],P,7+X-TXLT_C[Y:WU3'PLUC6684<4Q,5G3%/7J;*Z
MM]/[S)],<'>00E^6PUO$9!X:G0PM XO X$^E>/T[.6V9F^)U72]OJ>3G$RUL
MQS6:8WT67I1U[Q6'P\>VMY,\B.T&B"=[97Z@7/<ZK(X'=I XN7:ZCTBZ^_CP
MM-=W\W2R'6K+;>#%^&GJG^3"^N6[]M;TSN/EVS(V6WA\KS'1PR1@%I?7@^-A
M[0O1Z3EL3+V71B.AU?,86:NL^G.J8V3ZTL>GU/['8MKN'WEO"GH6C9SOKJ-W
MR\4PX93$>)%*-')=*M79EV5"J%0@5"!4(%0@5"!4(%0@5"!4(%0@5" 7M':@
M:F\ZH&H(E34$*FH(5-00J:@A5UR.'=R[5-J[$7O:#%=[[:(Y&8_RD*\['TWO
MF?FFGZK W^^UM/?VSK;>'3IENR,29&TMA)9\*.\W2 .)<T?"5V;K/@];:>J]
M.MSF3X:5F(K&_P#@B%B/6F;AQ=G<EP-O>PL\L\=)\YNH#WPO/USI?%\KQ6YB
MRV=E\:.SXM*7NZNJF+V%D,7B\M!2UO+9LYO-4G@\9931'%(3\GO7H78D64A]
MISW6\+)7V68FB+HK73]T1+6_6#J;TZW5M.:QP\C+W+R.88'"">%["'M+CJDA
M:#P'VRX<6^V8];5>O];R&:RMUF'/%?HIHNC;';:]?1K95[D.F&<L[Z(L^EW2
M/L07-(<V2!C Z@>*<?MJ*V63].7/Y=Z==B=/Q+;XI]29X?7$VQIUL!Z?;UR/
M2+<M[A<Y 1CI7AEP'GY 9J(>-#)2=5>32N&RZ;):_P!)ZC?TG,78.+'PS.GU
M:].B)U^IFO5?JQL3<^T)<;A+ADN1FD:[0()XW :7@^)\+!V]ZY<3$MNM>WUW
MKV3S.6NLPKJW3ZKH^^V%SZ"8BTS>P[G%9)A?8WCWL>T5:2&RZN8H>84P;:VS
M#O\ E?!C%R/#?'PW3/WLOAZ ].;>XCN(\=('QN$C*W$QXM-1S>NQ]&UZ-OE;
M(671=%DZ-,?%=_-UYSJ[MO8^>;M+*VYM+.V@C,5X72R5::@#1'"\\*?;*?5B
MS1L99GKV7R6/]#$CAB+8FNF>W9%L]C5'6W?^P]W8NVM=MAEWE!*UQN&130N8
MT!U122%FJM1VK@QKK9U-/\Q]7R><P;;<'XKJZZ3%-?;;%>QN#H;A[W$;"LXK
MXN,EQ]_8'4!:V0 @<''DNQ@Z(TMS\N96[!R5MM\Z9T[JZ:>QLN'5P+VZ:<N-
M5V*ME=VH(E34$*FH(5-3>]%-3>]!R@(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(*7D!O'DI(\SKFVC?I=(T.'$MKQHLHBZ30,OK4UK*T>^K-
MD]B<4*_7;/\ AF_"G!/8<4'KMG_#-^%.">PXH/7;/^&;\*<$]AQ0>NV?\,WX
M4X)[#B@]=L_X9OPIP3V'%!Z[9_PS?A3@GL.*#UVS_AF_"G!/8<4'KMG_  S?
MA3@GL.*#UVS_ (9OPIP3V'%!Z[9_PS?A3@GL.*#UVS_AF_"G!/8<4'KMG_#-
M^%.">PXH/7;/^&;\*<$]AQ0X-[:4_?F_"IPSV'%#J?<6LGA,K2T\P3V*1$QL
M-$RQFPV5LS&9N7<5I:Q1Y24U=.WGV>GT+O7YK&OP^"9T.M;E\.V^;XC2O>2M
ML/F+5]CD1%<6LHH^-Y-#3B.2ZN'-]ET76UB7/?;;=%+F/[?V'L;;%V;[#64%
MK=D4$C:@T/9S*[6/G,?%BETU<&#EL+"FML1#S9_IGT^W),ZZRV/@DN9"2^;B
M2XDUXU/I7)@Y_'PM%LRPQ,E@XM>.V)5[=Z<[ VO*)L/8V\-P""V45#A3WU,;
M.YC%T7S-# RF!A1\%L0S!UQ9NU-,K=)%"">"\^+)=SBA@^;Z6=-\Z\S7V,MO
M.<:NDXU<33O/H7IX6?S&'RW2Z.-DL#%YK8EU8OI'TQQ#@^WQEN7@ZFDU%#W\
M"%GB=0S-^NZ6.%D<MA\ML0SJW=C[>..""1C(8Q1L;3PHO*NBZ[>[\1$;G<V\
MM0\DS-Y4I53@GL7BAV>NV?\ #-^%7@GL.*#UVS_AF_"G!/8<4'KMG_#-^%."
M>PXH/7;/^&;\*<$]AQ0>NV?\,WX4X)[#B@]=L_X9OPIP3V'%!Z[9_P ,WX4X
M)[#B@]=L_P"&;\*<$]AQ0>NV?\,WX4X)[#B@]=L_X9OPIP3V'%!Z[9_PS?A3
M@GL.*#UVS_AF_"G!/8<4.HWEL#43,I6IX]B<,ZJ+Q*G3L#=1>T5^22>!]Q8:
MH2;H5>MVO\(WX5*P<<=IZW:_PC?A2L''':>MVO\ "-^%*P<<=IZW:_PC?A2L
M''':>MVO\(WX4K!QQVJ77%N[@) ??Y*Q,)-T2QK.[/VEN6[M<AE;2*YNK1VN
M&5W'2:@]_P"M"XKL.V9JZ&9R6!CW6W8EL776ZI[%^8^UAB;';O;'&QH:UM>
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MVTQ'?H'Q!>-;S^U\<Z!^X1[4K.M$31TYS7IC%??*].[5+[I@Q\<;T#;>SMG
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MP.X\IB[R QO=)*QU"WF'EM10^A9U1Z\.W1/:L<*$$#ZJQG4X,?N[MR770_\
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MY+"!4J" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MK-IKH;J97G35W+(>:76Z6*$'C+(QE/0XT1$P^G#F[?V?8V$+=$9AC=(#]OI
MKQ45?K3<L%[?MBQS"UK2&N?0\W<.VJA1K+KKM87$0R!\=V33S#PK4N/N=J(C
MG8$MR,#"*%KZ$>X59U.''[N[<EWT/_WUQ/S1\07CV<[XST']PCVI7=:2/S=9
MK^+;\87IW<LONV%SQO0<LVGRCZ7.^,KYSCS\<OTYD9_Q[-S*.FK*]2MM1NX-
M=?15^!R]KHT_F2T7SQ3]/9ON^Y/*)C@ UHHT ::=O!;;69?&-"M\-2QWV336
MJ:2KAD6@EW%SS6M>U*)5P1I: 6&IY-'*ONJJ[H6N:RCB2>?%$=B @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M@Z#'YDM)\Z37 LWS]R<6WMPX?<5J+O"W;+VU/*>*NGZH!6[4?'XA>D! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M.8<>R1AY+G=\U_(RC&L=0_!^HI)";4H=)<F,<14D.]*Q9/+D8Y(XY"]Q#P.
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MLOER?S+O8T[S=-<&W?/W)M0FH;[BW]\IV.Y 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MZYN99'N\3JO<17W-5%@R>J("W ='P+>(<.=?=16[,AN&^AZ561@>6SS$Q22
MC5ITUYTJH-/8J_N<5DX[N)[W4.J5A<=+P34UK4*HN>XMT?25W.[%VOJ7K5=3
MF/X@'N\+2J+9%'Y8#B2Y]/$YQ)/PE09[TQ?)Z[DFPDZG6DE-)TFONA%AA-R7
M-O+@/#G2>8\$N))''THCQ& />YTG'NJ*HJCU=T4K)K5[XI&FH<UQ'U*HC;.P
M^K^ZMOS1XJ:=U[9W#FQT>YL9:TC3S+'D_"I16Q]X]58MH60?M]_GY.Z&F8CP
MZ*@GFYCP>07-?@761$S%(E(NJU%#U3W#/CKS!92(Y+'9.422QNE;$0=>OY6@
MG@3WKB5597.RK1MUBK2V^C+TP/++O6^ZI,. :.#0/=U(,$B#_/D/G&5PD-)#
MP)&KW2B-K;^R5Y9;,VYC1*^DD9>_B02-;Q0GM49-7V]Y=VLOGVDKHYP:U::'
MWU6+++?><&X,-D,3N.W@9<,A<;.ZCCC8_6&FE3&QI/'O<@L6U=]9O;(,4=98
M0ZC3J .EO+[%Q[$5(3\X[).GEON^:4OR,;71MMW5/WPN>&^+33['[58B/U]O
MO<F0W"W<DEP]MW$:P,U L !) I0#M^U60IONHFZ+Z:2ZN3$^9_-YCB+N5.>B
MO8@QO(7UYDYA/<TUT X #X@.]!EVSL5NW;>:LL[CIK>WCU N+YX 2P\#5KG=
MQ[D&U^HO6G+XO(XY^$N8K@.C9Z[$SRG#75Q=XM#J<AR4H,OVKU+._+2WMX9#
M%EHQ5T&NE:<3QTL'((+)UFZN7>/Q$FT[4Z[^=KHKAP(\(>US:?(/;Z4@:$VK
MT^EW=)<7N0O1:6$9U3W+V!S075-.,C*\>"R1F,.Z\-TRM[W$;-FER5W>PR6T
MUT9'PL:V5I:2(WB5IY]A45G_ $HZCYC<Y=M;,R^7 &^9Y[J. !/ ?);2E/ME
M!@'4K?M]G[MV(L+DG$6I!CDC=IU'36M  ?LCVJC!L'#CK,768R]Y/<7,+B;:
MS$DC0^KJ<7!Q X$GBU!=[7?F0LKD7.'QT6/F(+#/][FDH[@>)C!0=.*W5EL-
MG)L[#.Y]U<O>^Y</#K,C];JBAYGT(-T=5M]7VWK3&P8$&#Z4MWNNI-8=Q :W
MAJ;P^4>2#1EMN3<%G;S0VMZXQRR&25CP'ASB "3JKW!$<W6ZKK)XV:RR5I#+
M([2(YXVQPN;0\>#&"M>':BK[L^(QX.0'G4_<-6^>7N[G?[FA>8^>/EE*SJ)^
MB+:U?M+G^6MEHG6^^EP^9/!6>FVU$3J+-<NGM[-LI;:EOFN:!S-7-X^\NGE>
M5V/)WAK_ )_=##@W3&"'<N ;3FNVWM<L7+IRN//*ES#0_LP@S/JH[5N*U>.-
M;"TK_D0@UXR N>'2<&U"(Y-AJF/B+H>?'C0GNJ4%QAE,4D99X71N!8YO \Z]
MB#;?4K,7%[LC:S//<TFUB$H;45=HXU<*516GI6ZX^(/=P-$1T>IQEAXGOTDF
ME?A0=EO$Z)CCV(/1#(X7$$@%'![:<?2BM@=5WF:XQ,[^#G6D(K6OR8F(-?VE
M_-C[UMW; "4"FH@'M!Y$'N1'GO?6+Z[==2G4]QU$\$'<*.:.%".XH,\Z62:\
MU+8EVB*:,AQIJK1KCR]Y2589EV.;>W4#F@AKC0<E1Y/.F%CZMJHP&K6^E$4Y
M&\O,E<,GNJ5: T   <.'91!ZL'QS5B/^DI]0HK+NLLHFW<:<=,,'\BQ$:[/.
M@Y(KMQX>V^B,;BT%PJ&FE?@4G4X,QW=VY*KHBVN]L3\T?$%Y%O.^-= \?'M2
MNZR?H]S'S&_=!>G?RR^Z8?/"+N)9_08S[OQKXIG)_.NWON^3G\JW<XMFYG^V
M>VOH -&4-ZWR->BFO2:?+X+:?+'>7>QJ7FN:X-N^?N3"V<-S_1X_M3I]>_6>
M73_U?!?1)UOF&BC)$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$7=_P#L<83?&Y+C<#\W
M=6KYZN,<;XP*N))YP/[^]4C0\FV?8;V'B[AMUE\C>9$-<"+>8PO80"#0CR6'
ML0K*2.VMK8;:&*AP^"M&VMC$ &LC':!2I4&I.L'LR[7ZIW!S D..W 2TNNXB
MUNO2.%28Y#V#L5&'; ]C#;&WLPS,[DOILO)$?O=O(YCXN1Y_>8SV]Z"45O$V
M%@B8"&1@-:.R@%!10=R @(" @(.'<E)6$!^NA_\ $*_^9]=?2NG^$?.>J>.M
MW(MWE/6YJ<?OCJT]TKYY?S2W^SE@:2SE\GM':L&:IIK5I^3V50;(-R<ATV9
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MB?RK?;]R8L?)A_6CXE]*?-G:@(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MW<[_ '-#\Q\\?+*4W4/]$6UOF7'\M;+1>M]]+K^9/!6>FVU$'J%_K&V_B_\
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M#!9O$9ZV;=XB?UB$"FLL>P_^L:TKZA+YZNZ @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M#92K=+R/3]]<@PQ["YI<"!QI1!0YE.90=>I@KSJ$!K@!S0-0K7F41Z;$CUJ
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M7)ON+ZS+18=J@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MK9"1L#2S2WG45KV+[,UAWH" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MZ*2&5\,C0\!H>W6QVEX #FT/:B,K0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MZ_B5HBU[3WY@=YVLEW@YO/BB?H>1QH4H,F:[4*TIZ%!R@(" @(" @(" @("
M@B=[5_23#Q].]]=3\WD;[-[DC=8MP,=W,X6>)MILC:Q/BM8&$-JYKG![WUK7
M@!VF4)#],OT;;._V'C/_ '2)&+0WLU;>P?4[(;]ZR;PQUOF<WE]P7-ABW7\4
M=TVTQUI''Y;(1)K#/#((^''2P<>\LNS9^(MNE_M<9?:&VH&V&U-Y[=;FG8F
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MB6/X.E"KI;[1O6!W$9X5_P SL?P=*%0^T7UB_P"WQ_4[#\'2A5Q_>,ZPM_\
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M]T@\3L_+Y39O5CY;_D</33[9*"@Y&XN&F)]N6:A\JG #]L41<(\ECX&MBFD
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M_'$&&2@;))IX.;[J,GT8]FS]!6Q?]F,^[>C&6U$00$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MF@TYCB$%YZ>8IF7W1'8R.TPNG <ZM#0D"M:$?422$IL]M.WML;"Z"8^0UFD
M.%34 <:,HH(G;Q8VTR]Y:U&K4X-'=Z3R5@6"T9_W4O":N=Y@K3^,[%EM1T0F
MN)M&_P#2,X>^45*38>V8)ML67EO \UC7G41S<UI(X-6"K'UYVL,=@+#+L=J?
M\A_&M:EY^U'VO>K5$?+8:[K'2L(J\DGN%8R51WWY<S<URY[3J\D@CL_>F\DC
M4,[Z4;9FW9EXK-@ AB/F3 U T@AI^Q=WJ2),]3=GQ8C'6\P(\A\#]$9/ :6@
M&@T#M4X]%!"[*EK,KDXR2UCH2(SR'[X5FBW&*5^!>P@5#O3]NFU6Y^FU/[)Q
MM/,,;_)L6\^7^[G?[FA^8^>/EE+[J)^B':].6BX_EK9:)UOOI<'F3P5GIMM0
MYZDM)R,!!%1%R_9.73RG*[7D[PU_S>Z&HI26OXT:X3/)/<"Y=YO"5G2#;]IE
MK&U)(H]K7.+B.!K2OR2N.63R^T=M7'XW"6F2MG--S&)&N=4&NDQ-')H/:K B
MW'X<K8EOB.IM>TUUCFL]C%W4+=RF2H)!>:.Y<2[@D:E;*Z"Q>;F R1K7.J!Z
M!4.6-Q"9EKM9SL4)6!CP8@:MJ0.';X5BLP@1NJ$0[OR\(^0UIX]E2TK.$EC<
M#7/VW<>&NF0@"G9I"J/9; 29"P9I(;4 T]("@F)TGVICKK"7D+8F 2V[B^20
M '46M' AI6$LH1MZI8*XVYD[JSD8/%)JC KQ!(/:&]A64)+"(29LK;N90C1I
M([/E#ZJR1U1Q.CW1Q;1HJ2:=["BM@=',.<QFO+#*^4\R$.[FN8:C@>]8R)7;
MSZ<W3MIMG)#K:>!K@QQ)((TG@/+HH(0YF)UKE[J%U-+8I!Q]Q9(MMLUWT-([
M[+CI [JJBD$_25P_01K:WQ$<.#0@DKT!V\_(X.^NC4QUT@CM%&G[4K!DR??6
MT+/(X6^;C(I)[QC-48 :XC2TD_);5$1-<R6%UUC[QACO(KEPDC<*'PBA-#Q6
M0R'%1TN[>HXU"QG4X<?N[MR7O0__ 'TQ5>/A'Q!>/9SOC70/W"/:EAU@_P!P
M,KW:6?=!>E?RR^WM<;9?3#6?'[!?F#J=O^5?O>G;.B%NR;J[^V9_M%OW"W[R
M'%,3$W1]\N#&FM$E(_L/FCXE]CC4Z<ZW:J" @(" @(" @(" @(" @(" @("
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MACVND->7$?K@HL)L9#:5KC[.UM+9K8X(F!K0 *_&L58[U$Z86.YMESPEH-[
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MSJ[^V;_M%OW"WSR-%,3$W1]\N+$G4DU'R9[@^)?7H<#M0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$&"=9>H4W2KIMF]^V]@W)S8GU738R2&!LGK5W#;&KPUY&D2
MZOD]B+#YV=?/:,O>NMI@[2[V_%A!A)+B5KHKEUSYOK+8VD$.CCI3RT91"?7L
MV?H*V+_LQGW;T8RVHB" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(*)?D^X54E CKH?\
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MCWMB<'E,+>/DN&W%YY1<U@X>%PJ#Q]"TW@FW6[57SKS5L+7(92SCX@3D4KZ
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M47]$6U_F7'\M;+1.M]]+K^9/!6>FVU#WJ'7Z2MN'#ROA\3ET\KRNUY.\-?\
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M+HG=/O:SWM92XW&W%EDR89/DMU58-9!I\L KM]5FR[ K$Z*Z'O=-S'U8T=C
M=OP%V;L135Y-2XCC2L;@%JN0LX\>V'K8UW#9,MOX#%.R]QY+ZDN'A8WB:U !
MI0]Z^D32V-#2,QF)MTW,EN^F>3BB,L$C'2]D/C,G[41U7FW=4RUN)]*;[>+L
MXH_FZV'G.*:TEBV3PV2P\FB_A?'4>%[F.:/A<T+M_4LQ+)FV8F/4]G*YF+KZ
M5:<NXM65R,I=XC(\5]&I?-L?O+M[;87C8$3O67REU(V@M<SL-2.*]CHMM<:K
MH9^Z8PIHV]A)\6;EC)Y&Q,!\4A<UH'#O)6\71,-,OXILF8TRW##)M<VGD^LV
M<L;F\7NF8?=K1RUC'S6;C%B+;)INEXF'A74FZ=;5.]<?M^TF,F&NX[B1[RZ1
MD<D<C6U)X#02?A6R8=TS;$W130]3ILX]^O57UM*WK71[KI(TM+M%*BGV([U\
MVSTUQ;F_W]S.Y*7H@:;UQ/I:/K+6[>=\?Z#^X1[4L>L/#I_E_FL^Z"]._5.Y
M]O::V\^F)MOFK\_9^W\^_>X>)TUKU"V=_M!GW)6Y^3X^._V?>RMG2E0SDSYH
M^)?3W*[%4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%JW)MK!;OPMSMW<UC%D\)>
M>7ZU93@F.3R9&RLJ 1R>QKO>007]M;ICL'I]B]G3;+P%KA9;^XOF7CK5KFF1
ML3("P.J3RU%&4)4^S9^@K8O^S&?=O1);41! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%NSN=Q&V<3=9W/7;+'$V;==S<R
M5(:"0T !H)<22 UK023P'%29B(K+&ZZ+8K.IA>.ZT;6O,C9V%_8Y7"1Y&5MO
MCK[+63[6TGFD-(V"2KM#G_8B4,KRY\%PVX]LS1P1F;9FDUAL5<[LB @(" @T
MA[5^\MS;%Z/WF<VGD9,7E_7;.W%Y"&F1L<KSJ +@:5IS188KA>BO77+X?'Y;
M\_F3A]?MH;KR?HEC]'GQM?IU>N"M*TK0(52.Q5M=V6+LK._NSD+^WMXH;J_<
MP1.N)HV!KY2QI(:7N!=I'*J(M68WYL?;M]'C-P;FQ6*R4M/*L[^^MK6=VKEI
MCED:XUKW(+[%+%/$R:%[9(9&A\<C"'-<UPJ"".!!""-$V[^J?7C?^XML],MP
MMV7TXVA<?1^2W'%;LNK^_OV$A[(0^@:P%IH6N;X:.).H-!6R>FO3?J!L;-W4
M^?ZDWV\MMSVKHH<9E+5@N(;HRL<V87/F/<X!@>TLH!X@>P(-HHB'?M0=1NKV
MW.K>/P73C/38^UL]K/W#-CV1Q213&UGO'W#GA[':OO%OP!X>'A0FJ,H28Z9;
MVM.HVP=O[UM-(;E[1DT\3#5L5RVL<\0/ZR5KV>\C%JKVG>I>[-LVNWMA].;S
MU+?&Z9II?6V-8]]KC+"(RW$E'-=IKV.I\EKZ<46%T]E'>>YM]]'[+.;MR#\I
MEQ>7=L;R4-$CHXGC0'%@:"0#2O-"6UL_NO:VU88[C=&<Q^$MY21%+DKN&S8X
MB@.ETSV TJ.2(]&'SF$W#9MR. R5KE<>XT;=V,\=S"2.P/B<YOU4%=QEL7:7
MMIC;N^MX,C?Z_4;265C)I_+&I_E,<0Y^D<3I!H@MMMO?9=[F7[<L]QXNXW#&
M2V3$PWMO)>-<VNH&!KR\$4-?"@OR#&LAU$Z?XG)?0V5W7AK'+@Z3C[K(VL-S
MJ[O*?('5]Y!D;'LD8V2-P?&\!S'M-6EIX@@CF"@J00<ZA]>.J^Q.OFZ+ZWR,
MV0Z:[5O\;!F<$(XS&RPOH&-+F^"K3K<=+]?RRT&H-$942XW7N%C^FF<W5MN]
M#V'!W>3Q.0AHYI'JCYH965%#]BX5",6$>SOO7+Y[H#@=Z[POI<EDA!DY\A>O
M#3-)'9WUTQO!H:"1'&UOIHBRU/TWBZV>T?BKWJ(>I4^Q\$^^FML+@<-:ME$3
M+<C]^DUPN?Q-"'EVKGX11J+J2#Z6X?J1@MOW6,ZFYVUW'EX+V08[+6L0MW2X
M[RXO+\^,,8!*'^9JIJX4\1*,6ELUU1ZJ=9^H.8Z=]#KRWV]M7;<GJ^XM\7$3
M;E[I@XL<RV:X.;Q+7AE!5VG5K8*5*N,_1?VB-NPNRFT>M5QF,RRKW8[/6+#8
MSN/%S0727/E ]@;'P^V'-"K?FW)LY<;?Q4^YK>&TW'):0/RUK;.\R"*\=&TS
M,C=4U:'U XGW3S1%S01:O]S=4.M_6'=_3S9F\';$V=L@-MKVYL[=LV0O+IY,
M;B'.+'- <V0#3(   :.)X%;0Z8;+ZN;+SE_9;QWNS>FRY+4'&3W5N+?*0W@>
MVH>6A^N,LU>)TKC7L:@VJB"#QS9;%VV0ML3<7UO#E+T/=9V,DK&W$S8AJ>8X
MR0YP:.+M(X(+;8[WV7D\M)@,;N/%WF=A)$V+M[VWENV%O/5"QY>*4XU:@OR
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M6'6$UZ?98_K6?=!>G?&B=S[=70TG@'_Z*MA^M*^"9Z/S[M[J3*ACM74#9Y/
M#(-^Y*W'RC%,2_V?>Y;)K*54;@=%.1;S7TQV'<B" @(" @(" @(" @(" @("
M @(" @(" @A=_P"81_J?8?\ G.2_D[=&4-^^S9^@K8O^S&?=O1);41! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!HK\S'6/_
M /G9D/Q6S\+77^G=_N>=^FQ?_DG[/ZGYF.L?_P#.S(?BMGX6GT[O]Q^FQ?\
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MM^._V.;"G2E7B,UB,U"VYP^1MLA;D<9;2:.=A/NQN<%](H[BYH" @(" @("
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MDF&L\&N$?H18;?V#TZ/3GH+'LF"$ORL>&NGW[(VE[Y,C=PODF I4NH]^AOH
M1&+^Q[@LIA^B-OB]P8VXQ]T^_OC)9WT+[>0QR/ J62M::'W$):[Z:Y_<OLJW
MF?Z=[RVGF<QL:ZR,N1VUN3"6WKS3',UK-$H!: 2V-A+:AS7:N!:0Y%UK]@;3
M=GM =:]M]2LEMN_VSTPV-'++@QF(_5[S(7TI!$@B)JUNH1NJ-3?O=-57>$B^
M=:\)FK_K_P!%,G8XZZNL;87-\;Z\A@DD@@#O*IYLC6EK*_KB$(9-[5F+R>:Z
M![NQN'LI\AD9OH[R;.TB?/._1D[5[M+(PYQHUI<:#@!5"%IZA]+,IU-]FG$[
M-LHO)W-:XC$W>.M[G[R?7;*VCK"_730Y[2^/Q4TN/&@J@QK;?M097 ;8M=O;
MRZ;[J_.+C+>.SEL+3'N?;WEQ"WRVR1RDZFMD+=1I&ZGV)>A1DWLV=/-V8 ;N
MZC]0;48_>F_\A](7&+J'&SM&.D?%&:$Z7$S.JVM0T-#O%4 2WRB(Z]+<)FK/
MVGNKV8N\==08F]M[!MG?RP2,MIG-CAJ(Y7-#7$4-=)1=BS^UETRW+<'']6^G
M-E+<[JQEO<8?.6EHQTLMUB;Z*2$GRV<7F,2O:=(U:7UY,%!#+/9VLMU[7]F3
M#V\&'D;O"QLLS/887(,=:ODNS?7DUM'()-!8V0EG$T\+JH3K6.+VLY\? <?N
MGI5N^PW>QNE^,MK$7%NZ6GATS/=$_2X\B(3PY:D*/3[,FP-Y8O*;ZZI;[QAP
M.8W]?B\M\"[]]MK<2335D',.<Z;2&N =X:N )0EAL&W^I?LM;WSN1V9MFZWK
MT:W).;U^*Q@<^]QL[C]C&UKW> $MKI+7L#=3FN"+K=/5?KM<]9.G^7Z=;$Z;
M[NGS.;9%"^:\Q[8(( R:.7471R35'@IXM [:H427Z98?([>Z;;.P&7A]7RV*
MP>,L;^WU-?Y=Q;6D44C-3"6G2YI%6DCN1BRI!'O)^TGG]D9S*83J+TRW##';
MW=Q'B,K@;=N0M+VT9*X12 R/B:UQCTEP$CC7F&\@6C&NGV)WEU@]H2TZ[9;;
M5YM+9VV\;)C,##E&>3?7SI&7$0<^(\0*74KBX>$4:T%W$@-E[AZQY/$]?=L]
M&K##1WMEFL8_)W^4$SA+;4%T0"P-T@#U=M=3N.L4[*BC;R(CKU2PF:O/:>Z0
MYBTQUU/B;*WOVWE_%!(^VA<Z.:@DE:TM:344U%%V+S[7.(RN;Z%YW'X6QN,C
M?ON+!S+6SB?<3.:V[B+B&1ASB .)X(0R^^Z:[2ZC].MN;8W_ (DY''6EO8W0
MLWS7%HZ.ZAM?*!)MY(G@M$CVEI-./)!B7]T'V=OR-_\ [GE?PM"K/=H]/]J=
M)MKY#$=.L+ZI9N?/DAC1<3S&>],+&4\RYDE<-8B8SG0=R(U4SVL+*SA=:;BZ
M:[RQNYHZ-?B(\:+AKI7&@$<KGQ%S:_9&,5'(%%H\W0/9&^,KU.WGU\Z@8A^V
M\AN>!F.P^ F_ZQ'8L\@:IV\"UP;:PM <T.)U$M'"HE)!$$! 0$! 0$! 0$!
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M @(" @((7?\ F$?ZGV'_ )SDOY.W1E#?OLV?H*V+_LQGW;T26U$00$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MC+RZ;D+BZTR/<]A;)&9GL!T]A:N/"B*5=?*V63;%T:][<2YW>$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MKN+8-R^;#,#79$2N<0V,L(HX QU\1[BJC/MT^TEN''[K;-M^^]9Q :/.BK,
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M57T8]FS]!6Q?]F,^[>C&6U$00$'3=1S36LT-M,;:XDC<R*X#6O,;W AKPUW
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M(DJL[+IMFJM<N<!K86ZFU< WLY\UAK'7"Z2(.C#OO1^PX(.'/(<(W\0@ZGN
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M-->WBB.P5IP0;,V\SS^F65B/_-ROE_P&A(HK6P-&T1%((9P[^*"H.!\8'%%
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M$!!"[_S"/]3[#_SG)?R=NC*&_?9L_05L7_9C/NWHDMJ(C"NKF0RV+Z;;DO\
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M)2]$>&]<43]K]8+R+>=\9Z!^X1[4KNL?Z/,N[L+6_=!>I=J?;KM2..&(^CH
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M X.IHXMXM)H:"C="((" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MO-O,'@5[436'KV71=$3$U7%5F(" @(" @(" @(" @(" @(" @(" @(" @("
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MT9TF7C]]+?LZH,VZ!])-X=,\AOC+;OR6.O;O>&19E1!B&S,MX9G.G?-1LP%
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M!V!8H[-=.RJ#@FOH04NX \:U16<[T(& V^&G[%]3^Q8@PIAI6O&J(Y+N- $
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MX[/,=\97SR_FEO\ 9RPZVR-IQ6+)4#0$M*!Q\HD\"@O^X)/,M,<]OR0RE?2
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M<S:/V?=761V\;J/SFX.X-Y9/:Z0 F6QF =4@G4[R3IX^+M0K#Z%HQ$! 0$!
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MUF8=\XI\^?NH+W(L=MV33KM[6&S:(_\ 2OA!C@;SKQJ?0NW?CX5UL1P3\/\
M=ZZ_[6-)[5/6GH[!U)L+;,X*<8?J/@G-N-NYZ,F-[9(G:Q#*YO$QD\CQ+'<1
M]DUS*9OZ,TNTV7:X+K:M3Y7KQ!N7I%O/8&_HI,3U>M+*ZP]UAFV\CW7ET^-S
M(Y(&PM>*/X%WV(K4'06E>A;DILQK;[-.'6M>QAQ5BFU)/:^[]L[UQQRVULG#
MD[%KS%*^$D.CE;Q+)&. ?&\ @Z7M!7BXF%?AS2Z*2Y8FKV9K#8[<.(OL%EX!
M<8S(POMKJ%W)T<C2TT[CQJ#V'BN&8K%$NMBZ)B=4H[].LQD.G_\ ;+H%NJ=T
MDV.L;Z_V?>RG_K6,DBD>6 _;-%7Z1R^^#DP+K63PUMEY>#=.'Q85VR)IN;TZ
M??[A;6_V1C__ '6-=BSEAZ.#R6[H9&LG*(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MI(M%MCKJWOWZBYS3YK[V6,4<[C]YY?"L\QBX>),W1$Q,^N*?<1$PV,NDR$!
M0$! 0$$;,HZVQW6+><&:TPY_)NLKC#R2D-]8Q#+.*)C8*TJ(YV3B0-^RXE>_
M@Z<"VFJ*UWU_E1A&N5KV#U(V)@^NE]8OSEI8PY?#QVEY(7:;:XRT-RTV['S
M^7YK(72-J[[8-K4:5EF<"^[ B8BM)_AM2L<24ZUYR-![_P!M83J!U:DL]RV[
M9+3:N+MGV-J*Q/N'Y1\QDE>]A:YT<8A:QK*Z0XNKSHO.S-WQ4>9CVQ?B:?\
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M)LI\%:>O6[.4OMNMFG;+<RY'=$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%$
MHJP\:=_;P4J(&=:GPQ]1KN:=NN%@J]O86 \N17T?I_A7S_J?C;6 Q]8?9NFN
MG6EQLDNNHZLFD$H <]G!QIZB:5/I7S_$YIIVM\LT6Q5<!U/]FYP).R#H'8)0
M/_O%<=)95AS^<OV;@T:=DGW#(/P%*2M85#J3[.%..R2:<OOH_ 4I)6%3>I'L
MW/%1LLFG9Y@^/U%*25@_.3[.!)']BR!]J90>/]22DI6%?YQO9OII;LP\>?WP
M?@24E:PJ;U&]G,#ALPFG=(!P_J24DK#@]1_9S[=EGOKYH_ DI)6'(ZC>SDZI
M&RB >WS1P][U)*25A3^<?V=*Z?[&.=WTE _^\DI)6'/YQ?9S::?V+-/XT?@2
M4DK"H=1?9S' [+=Z/OH_ DI)6''YQ_9SK_N61WDR@_4]22DE8<'J3[.-:'9C
MO=\T?@24DK#AW4GV<F__ ":6CO,@-?\ ^B2DE8/SD^S@XU;LQPIQ_?1^!)22
ML!ZE^SA7_<LBG;YH_ DI)6''YR_9QJ/^Y;O3]]'X$E)2L'YR_9PXTV6ZO\:/
MP%*25A2WJ7[.)Y[+=7^.'X$E)*P.ZD^S@/\ Y+=_EA^ I22L*#U-]F_\B7?Y
M8?@*4DK#J=U1]FYH+CLIU!S^^C\!2DE85LZH>S>]FH[(+FGE24#_ .\4I)6'
M+>IOLVD?[EN%.('F@_\ WBE)*PK_ #F^SB>#=EG1V@R"OP^I)I70Y;U)]G!P
MTC99(KP'FCE_4DI)6'(ZD^SBTZ1LIU1_TP_ 4I)6%?YR?9R;SV8:N[/-'X$E
M)*P#J/[.E=#-EEI/?*#_ />24DK#EO4?V=/L]F'5_&BG_N24DK#EO47V=>+6
M;+(<>)K*'<?ZDE)*P'J5[.7)VS"">8\P?@24DK .I'LY T&S#0\ /-'X$E)*
MPY;U']G0.=79KJ=@\T?@24E*PX'4?V=6DM.S7:7<CYHK_P"Y)25K#@=2/9R%
M2=EN-/\ I13X/4E*25A:,QF=H9QOK>R\=]%XL M?!755_.M1'%]B0/DKZ!Y>
MI].=_N?/_,W-&[WM]=001TCVR*^(,N"?2#-;46A=;[Z7'YD\#9Z;;6C&;QZ5
M[<_HN_, <MD9CYEM,'Z-,/+3_P!7F^R!/-=+*Q/#+G\F^&O^?W6NX=3O9O)%
M=E$$]GFBI]_U%=O2WW0J;U.]G </[%.U<C24#_[Q2DE8<_G/]F_6"[99!Y-'
MF@\N_P#H*4E*PJ/4SV<!35LAP^U(F'/^HI25K"H=2O9O<?%LQPX<Q*!_]XI2
M2L'YR/9R)I_8T_Y0?@24DK"IW4GV=#Q&S'<.?WT?@24DK#C\Y/LXCB=E._RH
M_ E*25A4[J1[.0XC9;J?QH_ E:25A3^<CV<W#5_8MQ([/-'X$E)2L.6]1_9T
M(X[,<\]_F@4^&R2DK6'/YR?9S''^QCO\J/P)*25@_.3[.)X?V-+Z=GF 4^&R
M2DI6' ZE>SHX$?V.-?XSA_[DE)6L ZD>SJP#_N8:GG]\'X$E)*PK;U']G0U_
M[EG_ "HI_P"Y)22L.&]2O9UH2=F'_*C\"2DE84NZE>SJ/&-F'1]D?,'X$I22
ML*/SG>SD!7^QCM/9]^'X$K24K#C\Y_LXG_Y,=_E1^ I22L'YS_9P'/9;O\J/
MP%*25A2[JC[-_P"1CO\ *C\!2DE84#J=[/,S_(L]G&*Y?PBE,@.EQY&GJ0^-
M2[4X,QW=VYFO1@QNWSC7L;IB/%C?0:47DV<[XOY>K&?M]J5O60UZ=98TIX&\
M/V07J3J?<+M2+F)_ZE%[_P :^8YGO)WM!QN:5QVY^DC:?^?Q_<E>_P!"YKGK
M=)YY3/C^Q]SZRVZ&U2[5D@@(" @(" @(" @(" @(" @(" @(" @((7?^81_J
M?8?^<Y+^3MT90W[[-GZ"MB_[,9]V]$ECEP!DO:UM*"OT/M(EU!JH9+EXJ>[A
M<!=?7B^QYLZ<UNM;9WKM6TWMM3*[5O9GV\&3@,(N8J&2&0$/CE:#P)8]K7@>
MA=W!Q)P[XNC8]"8JC+M[*=1-W;JS_2K&0XR+<VW*09C=)GE]38UQT&>&U\D/
M=(*\(R\-U_9:5L&).'99&)-:7:H_JXXF9T)0;4VY8[0VUB=KXTN=8XBUALX7
MOIK>(6!I>^G#4XC4[TE:]BXDXETW3MER1%%X7&H@(" @(" @(" @U_O[I]N+
M?-ME,1_;"?&;:RUL;.XQ4-C:34CD9HDI-(WS/%Q//AV+N8&/;AS$\-9C;66,
MQ5?-M8/=.)GGDW!NF7<$,C V&&2RM;,1.!J7 V[6EU1PH5Q8E]EW+;P^V5B)
M9(0"*'B#S"X%1;S6Q]G;5ZYY>:UPUIB[G)8RTN\&V*,1PR.US-O7PM^2)01'
MK$8%&D'[)Q.PX.-??@16:TG3[G'$1$O+=Y/=N!ZDVE]TGP,6X-VR8ZX_M+BQ
M/':Q26 ?$+>2X>][&^8UY=Y-?&1J X+*ZW#NPZ8L\,5T3ZR=>AEGY].LF-JW
M.]#\L0WB^7&7@O:CGP9%;NKP_7\3P73_ $>!/+BQ[8I[SBGL</\ :MQF,8X[
MHZ>;OPSF@EYEQS?+;I^5J=+)$0 "*^%7_P!9,\M]D^T^IZF"';F7ZERX_J5N
MC(LL]T7,;+W$PV5E8R6MC%*P.AC>+BWE?<%K2-1E>>/R=- NS]+"PZV1;$QM
MKMIZ:&'TXNTS&E[\/L[>.8L9>K_38VV)ZGXF]O,9N7#6C3'B\RZQF(D>V-QH
MUTX#7EI(%3P+7C4? SF6^EB5LW_:Z>)E[HGZF'HN[.UNGI5U?P?4VSFMO*=B
M=WXVL>:V]=>&X@DC(:]S0ZA=&'>&M 0>#@#SX+,2+M[LX&8MQ8[)C7#8RY7:
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 04OIIXBO<@@'UV97?U^">3"?A*^D]
M/T9.7SGJT5SUJ'3[5L>9N',&EIDD+CZ2XKY[?S2^@6:H7=@ Y.;I])6#)4&L
M!XO:3[H05NI1Q#V\N51S040!G,R-]\A EGC:\-U@@G34$40=S#"?DO;7W0@[
M0Z,>$O;\(HHJETD  :)F5[?$$0?<6S&<)F<>7B'ZJHZ[>ZMI6$NFC#P2*:QV
M>^H.SUBT 'W^,D]@>VOQH*Q+!Q<96-'(%S@*H'K%CIXW,'I:)&_JJCQNO('.
M<631F)@J7:Q04]*"OUFS- ;J$@BO"1OZJ '0R-)A>#$WY3FD%0=$M]8Q"DD[
M0!S.IOZJM)50_+8QHT&X9YG( N;7XT'5](X]CR'SL!H#34WM]]*([8\ACGFD
M<P<:\.+?U4',]]9QD!SN?N?JH/#)F\<UQ&O@#0GAPK[ZM!UR9*TE#HV5+B/#
M0 _74%RLVM\ANH@'LJ:(.YK8ZZ7.;Q]/!!7IC#20YM!Z4'5#H#^+V\3SJ$%;
MY8XWTUM->?$(.YABJ1YC:>Z$5V5C+:%[?VP4'$DT  !E96O+4*CWD1QZQ;L8
M7.F94"HJX5I\*H>;;L>6.F9J%* N 0#=68XNGCX&A\8K\:@J$EM3]^C YU+@
MBAGL7-IZQ%Z!K;7XT'@N[ZV9+''#<1%AU:Z/:>5/2E$;*V>^.?!.=$]LD8=4
M.:0?L&]RWWR]'Y<[_<T+S)IOC=*5W43]$6UPX$^"XIP_Z:V6A];[Z7'YD\%9
MZ;;4..I7^MK1U=)$7;P^S<NGE>5V/)WAK_F]T,/<QCJ'6VO,\0NXWEV1M8[4
M-;:GD":*#JF# \-UMX=E0JKN^]@5<]M3PKJ%412R2(CC(T%I(I45X(/0U\/R
M@]AK^N"@>9 T NE:.^K@@X$UN3QFCIW:@JKHN+R!DC-,T>GD:N'!1'?Y]E2I
MN(C7EXV_JH#9X9#1DS'4[&N!*"KUFS:")+B(=]7M'P\4'5-=V36%S;B$D_):
M)&DU^%4<0W%L?#-*P24!#7. -#[Z#M,]FT5\^.O=K;^JHJKS( -;IF-:>57
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MU@)<*<'=A7>Q;<&VE)NF9BNJ-O;\3FLS$W32(^[^:1*ZCN" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M0^*5A#F.8X5#FD<"".16NNTK0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MH%WH;RWQT@QES?7%LRT;6262.A["2X!2+IMG0+AULV3<V5F<NYI#XR_UD#D
M',:/JE8JCK=1Z+VS<:T-U#Q]%5FD.S)%KL]:$<>!'O4*#)-A6T=]NKU1]:&>
M+W>Q22$NK[I[%]#LOVL<][. J""&@ K"51&WU9-QVZ+FR!)B: 0/2YH/UUE"
M2Q:V!-E?MC%0)'#C\T+*4=EAX+''%O ^9+]TDB4_0/;<DUO>7K8:S7$3F-D-
M>3FM]Y8*UQUFPK\9<7,TC"'N+FN=WZ:?JI!+3CA2+&D<1HJ7?LEFCI>R1N6M
M2]O N<17TM161XNV=>9B2RC;7SI6"C>//2WZZQD2V;M:^QW3[',T!MLUE7\>
M-:-')8JBUO.W\G=+V#@ *4/I 64(P:Y)%K?,H!25XY]FI9H/#&7[#2I>SG[E
M$&X.E-N^YEF;&ZCRVA=PX!8UHK<6\]DP7FU))I'-=/ "\$.%>%3RKZ%BJ*&1
M;IN+Z$GBW6*=]"LH1?L*/O\ :4X<1P6,ZG!C]W=N2^Z'@'>V)!Y:1\07CV<[
MXWT'Q\>U*_K, .G>7 Y:&_=!>I.I]MNU(N8GA8QGW5\QS'>3O:#C<\N+;#QY
M_>6VL;<2.@9/>M9K8 XC4T]A7O\ 0^:YZ_2=&)*8&S]LP[8L196\[[B,\2^1
MH:?@"W!M4RR9$$! 0$! 0$! 0$&O.NF!W/NCI-NC;^S6/EW)D+9D-E%%,VW>
M^L\9D;YCW,: 8PX&KA4<$6$?>D/L,X7%>KYOJU=#+Y 4>W;UD]S+&,\P)YAI
M?*1]JS0WTO"+5Y>K/L.6TLDNX>C5\<=?1N\]FWKV5WE:V^(>JW1)?&ZH&ELM
M17[-H0JDAT2M=XV/2O;5EO\ -P=WVUO)%DS>R">YU,GD:SS) YVL^6&>+4:]
MZ)+/T00$! 0$! 0$$+O_ #"/]3[#_P YR7\G;HRAOWV;/T%;%_V8S[MZ)+'/
M9R_IN7ZJYSF+[=EXQKJZSIB<Y[6ZNT 2\%U\'7=/K>;D],WS_<O7M/YGZ$Z&
M[LF:[3-=PP6$8XC5ZW<1Q/'#_HW//O+V>G6<68M^UWKYT,WZ<X?^S_3_ &M@
MR*/Q^)L;:3TR16[&O/ON!*ZN8OXL2Z>V991J9,N!1 0$! 0$! 0$! 0$! 0$
M! 0$! 0$&#=5MG7>^-LQX>PL[:YOH[J*YM[BYO9L;):21-?IN+>>"WN7"9I(
M: 8]):75X<#RX6-?A3Q6_P =3CQ.*GPTJCMANBN_.J%MD\?OC)PY#$8W*W&(
M#XLDZU?;/LI1&^X9##BV,N96MKH\Y[&NJ?"RM1ZN)GK\*ZWAMMTQ$SKV['!3
M$NUTIO\ Z+)#FNLWLEY./&YQAW1TKFETVUTW5Y#0XUHQQU.MIB./ENJQQK35
M\H879;#S$<6!\-VVS^7I3<XN"_!Y=,=G\NQ*SIWU0V;U0Q/TKM._$[F!IN["
M6C+NV<[D)8ZFGH<TEI["5Y$UB9B8I,;':PL:W$C1]FU<[_?&R\7=RV&3W'B[
M*^A($UK<WUO#*PD @.8]X(X&O$+EMP<2Z*Q;,QN<M8>O$;DV[N#SOH'+V65]
M7T^L>HW,5SY?F5TZ_*<[3JTNI7G0K&_#NMYHF"JYK!1 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$%$OR??00)ZZ_[_ .1^9]=?1\AX1\^ZGXVU%&Z;2ZGIS\QWQE?/K^:6
M]V<L/'=0F>)S*4>.(6+)G72#IID]VYXWKW!EC; .>X\1X>7?W=R"2=KL427@
MJ6BWC=4F@\1^!8U94:?Z^=*LKA[S^U-GIDQ<S6LDH "TTIZ%81'J2S9;6L[P
M=7FNU/KQ')9527NVKM>XSD]MCH)=#7R T[1J/:DR0FGLS:-UM##6=G#<T:QK
M2^Y94&H[ 10K!:J>IVQ8MT[4N61W^N_:#*VNJIH*T)(X_"D"%4^#N[/*FVO'
M "W?30>-"/?(6=6-'%S;.-RR5CFB0.(Y=B@WW[/739F8FNLS=O\ Z/;'2P"G
M$O94<P>T*2RA)Z# 7,MHW&WUQ))C?L8W/+FM!X<C4?46)M1EZS= ),)<W&X,
M3+K@DJ\L! (\P\>QO>LHE)A'RVL&-C?:.:'%C27DT)H%E5*-K=&>BDN^\@V^
MOYC#B;5XHT'B:UY<'#L[E)E:)=R['BP3VP8N1]I9QC28F.T!XY\0P %8ZU:N
M]H'I9;Y':T.XK!@=<0T%RTAO'B./(=_>D2(A96VMHG1NTU=0@'APK[RS1YV6
M\,CF"..MQ+1C7<*H)K='.E3-M;&%U>OTWM^!,^M"6M8YXY@=Q':L59GC=JX[
M*2RV5TQES:.:?,#VAU1^R!6(B]UBZ0VVT<U<Y+&Z?HV=^IL=&@<&L X -',G
ML651K!A&G30&G8."J*)XHKFW,3C0U!I[B#)>F.S+O<6Y6>40R*V:#(\]C0]H
M^NDR)>X;&W>,QGJMO-&8 &M=&0>-#[P6*M0]7^C&1S8EW58W4;3;QE\L+00:
M,#G<>2J(XBQ?CK:_$I'F%S6N Y>%U%D/-B,,_)>7:VS^,TK*,[WDT'H[4F43
M<Z:;%&U=H6<SKNE])&V7A6K#(UIY@>FG K"6;(]X[+.Z-K7=BZXU%T<DD4YJ
M2YXC>T#B">92$E!'<&U;O$9R?$WLE'6DLC6CO#7.97M[EE5'EO[?7=-F;X9F
M$:'>@TJK4;H]G3I\W.;F?D;XULXBZ9W+Q2:V5'$'[98S*PE?<X%L$;;*]G>Z
MQ%1#;EQ+6@FKJ @@<37DL=8T!U:]GVTN+V;<>V;_ ,J20%TMNXD.J7O<2-+6
MBG$=JRB9)1D?CG8RXGQ,CRZ8.<)7=IJ2?KJRC:W3^V;:;=DB9\D.TBO.@C:M
M\\O]W._W-#\Q\\?+/WI==1>/2+:P_67'\M:K0^M]]+A\R>"L]-MJ&O4MP&6M
M0[Y!B_QW+IY7E=GR=X:_YO=#7MQB)\@]T%F ?-+:@\N!KZ%W:MY2BZ1[1N-N
M6-K?W-SI+2PL()J' U'+W%A(S[J)M1VY=JSVTEVPON1J)(<7$%['"I(/<J(4
MYS;-[C<I#:7YTNMY&. ';0AWI[U:BS7UMYN29H>62M):Q_=2O<K$C;?1C8,N
M0W*W)R3Z8XY(W:S6CB*TX<3]BI,D)?9&*ZQ44;;FX=)!<>(P@NH 1R / !8J
MC#[0/3.*VN_[58&<NMYPT3Q<BQP8UO'@WF058E&C<;CS%;W+9'Z]9+Y#Z: =
MJRF1ZMM8&XS%_:8JV=SE/E-^<ZI29$]-I[$NMI;9Q]M:R%MTZ)OGR,.FCB.\
M4/8N.62S[ZZ,0;[VU<N-R(<E#K>V5_'6214&C2?L>]40LW'M.7:N4^C+M^M]
MM6,-/%HXUK1958K;DH'3>1)$-,[31C^[A3W58$F^@OL_R9:/^V&?E^]@>9#
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MSMXT&F,NC<?V5J0/=7OY;X<KBW=M(]/M=J[FA(1>.Y! 0$! 0$! 0$! 0$!
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M7/7MQ%<75_/))& &UED/ =]7%96Y7#B)B(BD^IG?BZF<RY?:^X-HQPWI8S+
MED\>EH+VNU#N/9WK5,YTW$LOK9'PNW9B1=&B46=QVEM:9Z]M[)NFW:]P#10
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M/_JL6/\ 0YK<M@1L;)P>[_9GL*#!Y79V/+0'!T;\?:'L'%SM!)^JI^AQ;?\
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MAU!Y#FOY A8=0I?;&)$1&FDEL4T)%+Q'((" @(" @(" @(" @(" @(" @("
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M))Y+&&3K-R<9?OA=$/5Z5+R/B-0D03*,WMF;:Q^;VU:9N,4FMWESRW32FEH
M^23V]ZSAA+7OLZ8^VL<JV5K1J:PD.X5[#QX!)1*J5N0W#YC&RMT0^*-S=6H'
ME2O%8QH5W9C*2B&WAE=2)QT/>RH%> '$E*567DQ%JV2]N&70:6$NT$\RRO/B
MH:*(8^TAL2TVIU @R5@"+7(Z7$&E 6,8#2C6CF5EL=?,]W=N; Z'U.]<4.56
M"A]X+R;.=\9Z#^X1[4K^LNH=.\O7B=#?N@O4G5+[==J1=Q-?48J<Z'XU\QS,
M?F3O:%B\TKCMKCU(VF'<_7X_N2O?Z%S7/6Z5'YDIFQ$>$5%:<NU;@VF7<B"
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M?\Y&T-NG7\@%'!KS]YXCAPYKL9FW"LNFVVV:QMK[J>]C;66T%T68@(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M]V='=GNJZ+)[HCO9X^PQ8\Q"0\B*AD[N:]_I_P -F+?V6_>[M^N$@UY#D$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M&MNMNTS29CMT?SU.:="544L4\;)H'MDAD ='(PAS7-/$$$<""M;F*.16@("
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MTI01XWSUVSNXL7!96T7EO:TB1[@1XJ\.3W?$K1)8'MS,.,CGWLP$KW%TD9-
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M$'T&:3O0:^\MS)F73'4DC(<VG#B/_P R#95GFI\WC&SW3?OT3/++N KX0:\
M.];[Y?G\J=_N:%YCYX^64D>HA#NDFV T\-%QJ'_I;9:)UOOI</F3P5GIMM0_
MZBM8<C:U&K[W[E!J<NEE>5V?)WAK_F]T,4 (X4YCP^\NVWE6P:6$]IX416T=
M]%C]D[8F(\0C<TCT-CA"@UC*W5I:.??Z54=DD]VVQ-B)#ZL3J?$.%3P[?>04
M6L C!<[F@N^'UMRMC(P^)LK34<$6&8=81&_=#G$:7.M[8N%:\?(9W(C ;2:Y
MLWB:SD,4GVW,T17FE\^>[<^61SR:$EQ+OC0>MCVB0.Y:""TCAR1&T>IF3EO=
MM;8:97:!&\:23V,CYJ*U<ZA:0X M/*G!5'48@Z)T78[D:\._DBNV%GEQAIH>
M^@IQ2I1F6"A,NW)YY*E\4A#'D\N("]WI>-='%%=%'6Q\/BHPZ]<^61T^HF>M
M"3Q/PKQ+KJS5V(AU1RW;(7!EPYK'?OC*D@CW*K$=,VJ68R..MQ%'./\ RH/7
MB91992VNFN+?*=5Q!(KP/<@V-UTNI9MP6C0\^K&WC(8.53"P\O=16I'Q-<P@
MBCN8IP51WX>:[M,E ^VG> 7<>)H?>)6,ZG#C]W=N2JZ)\=ZXHNXNT_">"\BS
MG?&N@>/CVI8=9*GIWEJBAT-J/V07J1M?;K]2,N) &/B)Y4*TK%MKB2^>XW/+
MV[>H>HFTG4\/K\?#E7PE>KTJVEUSV.D37$E,B%P=IT\@./!;!#;)EWJH(" @
M(" @(" @(-+>UI!=7'L][TCM&N=*([&1P9P/E19&V?(?<#&N)]"+#0>W=C;,
MO_8@R6?P^%L9]T^J75S?Y5UO&^^;-:9$F3[\6E[0V%GA (&GW247:L5UDN@V
M;]D:""XEPUOU'QMJV.*%@MX<X<C#<:0=+1YTD;V.XNXLTGB06\!M2D]F#=&9
MW?T.VIF,](^XR0BN+-]U+Q=-'8W,MM&\GFXZ(VM<X\2X$E$EMY$$! 0$! 0$
M'AS&%P^X<=-A\_C[;*XFYT^L6%]#'<VTGEO$C=<<K7-=I<UKA4<" 4$(O;@V
M7M+9^/V1+LO;V.P%W=W-^R9^'LH+&272R#2UQMV,+J:C0'O4E=[U^S+_ &;O
M-_8EF?;:$G:<%A;1WS6$7.3\Z%[Q'Y@H^5K=;2!5W-=6V;9Q)W/)MFR[,S.B
ME-'K;=VB#F_:UW[DSXX-NX&RQ43JDAK[L6]P:=U")!\*V/%^')V1_NNF?O>C
M'-*0:\=R" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(""Q[EAWC-! -G7N,LKD/)N79:TN+UCF4X!C;>YMBTUYD
MD^XN7#FS_7$SNFGNE)KL8?L/:'4W:$5MB;O.8*\V^V\O;V[9%B[R*\<<C=S7
MLK8Y77[V-I),X,K$ZC:5J>*[.-BX6)IB+JTC;%-$4[&,1,-F+HLUHW'M7;>[
M\:_$;HQ=MEL=(#6"[C;( 3]DTD5:X=CFD$+DP\2[#FMLTE)BJ,^[/9%R>WK^
M3<W0W<US@LG'5\6)N9Y&-IS+(KJ,ZP#2@;*'5[7T7I_K,/&BF/;6?]T:)]/2
MCK7Y>)TQHECF-]ICK'THR$6W^M&VI+J/BV.\E8+2XD:WPET<\0=!,!Z&\>UZ
MXK^GW3'%@W1B6]FJ[T^QP<>-AZ_BC[)_JD%L/V@NEW4 0P8S,-L,K-0-QF3I
M:SEQ')A),<A]$;W%>5Q4GAG1/9.AS8>:P[]%:3V2V@LW;$! 0:]ZJ=8MI])\
M8R?-2.N\Y> C$X&U\5Y=R$Z11O'2S5P+R*=U3P7<RV4OQYT:ML]C&ZZ(:FP_
M3'=/5/)0]2O:-N68W;MF?/P>Q'2>KV=K&>+7WA<X>(CY37>-W)Y:T>6N]B9K
M#R]O!@Z]MW\O3^;CIMN7+=N_MC[TW38['Q.Y[.'8F)L'760@QUT+.WNKD2MA
MAMC+&Y@,,; 7Z(W:75%>2UO&F_$GX*W=M-+IXF+&)=PVS6([&"=*-W[=Z;8C
M9&<;N".UQF7FDQNY\2^Z,T($@N'0W8A+G^4Z-T;&N<UH#F.X\5W,[%]F9NF8
MGA_AJ8\485T3JB=:5UGD-M;PQ<CK&ZL<[A;EOES>4^*\MI&N'%K@"YI![BL;
M;ML2]*VZVZ*Q-6G=S>S!MWZ2?N?I7EKOI[NOQ$2XM[O49*\=#[?4W2TD#PQN
M#/UA7K8?4;J<.+$7V^O6QFSL64=7>L_2,^K]:=J_3^VXJ [SVV ]K6#@7W$-
M&M'NN$/H#ER?I<#'[F[AG_;=Z?S3BF-;<NQ^INQ.H]D+S9V;M\C1NJ:U#O+N
MXN0/F02:9&\32I;0]A*\W&R^)A32^*,XNB66KKLFO=V=5)-GR7+K_96X;G&P
M7$%FW*6C,8ZVEENYH[>'R_,OXY*/DD8P:HV\^/!=S"RWU-5]M>S3_)C-U&2;
M9W'>[A9<OO-N93;Q@+ QF7%F'3:P:F/U2YN11M..HMY\*K@Q,.+-5T7;J^^(
M6)7Y<2B @(" @(+9E]R;=V_Y/T]E[+%>L:O5_7KF*V\SRZ:M'FN;JTZFUIRJ
M%G9AW7<L3*5>7'[UV;E[R/'XK<6,O[^;5Y-K:WMO-,_0TO=I8QY<:-!)H.06
M5V#?;%9MF(W%87U<2B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @((_;O]DWIWN_-3YW(7%Y'=3N+GMB$.FKC4_*83VJU'DQ/L<]
M*L=<QW<C)[SR7A_E7+8=#M)!IX6 \:(-[X7"8O 6,6+P]NVSL8&@,@CX,  H
M.=5!I#?WLF["WUG+C/7=U=6M[=$>9Y/E!E0*#BZ-Q5%ZZ;^S1L+IK?-RN/C?
M?Y5@'DW-T&:HR!2H,;6=Y2HVCG\!B]S8JXPV6MVSV5S&YCV'CS!%1Z1501VN
MO8CZ<7-_ZR+^]BM7N+_5QY :VOV(!BY#W51O+873S;W3G!LP&V[<0VD>ISY"
M '/UN+S72 .9/8@RIKJGP"@ HW5P!4'<*TX\_0@("#AW)25A ;KI3\X5_P#,
M^NOI73_"/G/5/'6[D6[L@7<U1Q\QU/A*^>7\TM_LY8< .(Y\%@S<BH-.PHC)
MMD2"/=>(#>?K+/C17;OIS9-U7QTZ?%S]\H+&W30<:HCEX HY![\'(69FP>"1
M]^96GNHL,HZI1MCW49&U^^6\!K^P086>/ GGSJB.L1@&KG<.Q!6UW-I-0>/%
M!G72N]%KN1S=.H30:/3Q>T]_H6=G-"L7ST+69J^%0"Z:0T]UQ5Q(F)TH\4$]
MS:MEC@F<V*4%LC!R+3V%<:O)'%Y9>_[8U1'NQI+<A:%I =YK::N K7M6>'-+
MH%]ZA/$N<A(<QSFV-L"8S5M0VA66-%+M)KABAX"G<N)71-R1'75S6E[?E-Y(
MK:FXO,N^EF)O)C5\4[F#W!$W]5!JD\D'6:E$5,:[217FBJV M'%!E_31Q_M?
M8T'V,O\ )N21T[R(=NC)D<A.[C[Z"Q #5J!-?2B.Q[2!4<N1HBMG="W.&Y[@
M_P#0C3\)4&M9@/.=4]H^)5'6]C''@.* \:SI/>$'--)T@507;;48DS]BTGB9
M6&GN."*R#JXXG?%VVE P.9\$TB#"">!09KMS_5#_ '_N6K?/+_=SO]S0O,?/
M'RRE-U$_1%M?YEQ_+6RT7K??2X/,G@K/3;:A_P!0VAV1MN%?O?\ C.71RO*[
M7D[PU_S>Z&( %IX? NXWIV!VOB>Q$;+WK/$-H[<M_LO*<[A2OBCB16O?!1M:
MHCL :X4!H$%!%#II5!==N0.GSEC$.;I6@!)6%^ZFZO[773''@V*W'P0L08=I
MKR1%?(4K0]Y0  7!O$EYIP]**S_J+$8,5MR(CE$YU!S\4<:(U\&@\_JH.:!O
M=7T(*@VG+M097BKL#;%Q9-;Q>]U7=U"#W^A>MD[/RK[O5[V%\Z88L*=O,%>1
MK9NJ;@T\**CS2'E4H.ZSB\ZXCB;S<ZGU$5GG6,D;BMH>UD$/\BQ!K=QJ2WN0
M=EB:WL/S@I.IP8_=W;DJ^B/^^F)^:/B"\BWG?&>@?N$>U+#K+^CS+_-;]T%Z
MK[=?JE&?#C^@1>X5J6+;\<OGF-SR]N#'_B-M+_/X_N2O1Z;&F7L]([R4R&<F
M?-'Q+VH;:[%D@@(" @(" @(" @LF\&;:EVKF(-Y36]OM6XM)H,O+>2-A@%M,
MTQOUO<0&U#J UY\N*#7G1'IETPVML+)X386;EW9LG<$T[[IUW=V]_;N,D0MY
MHFFVCB8 6MH]I&KO19: W=[$/3K;-W-N/-=1W;>V.V=H=!?V\+96-D/AB;>2
M3L87'DTF GT%%JEYL3';4Q&SL+C-CR03;3M+5D6*FM)6W$,D+?LQ*PD/+C4N
M=7BZI1BR% 0$! 0$! 0=%Y>V>.MGWF0N(K6TCIYEQ.]L4;=1#15SB *D@((K
M>U1G=D93<?2WU_(6F0P\.2NSD6V\S)PV!QM=>L1.)#2P/KZ*TXK@QZ\$T=?,
M=W/9HKN9?U(FVY)T[OO,=#);S6VG "V(<YU\6TL_5/+XF02:?+\OXJKRH]3H
M8E.&7A]EYM[E-S=6=VY(B2]O<['C7S>$U.-$H-*4YB5IY?"MSSWPX>%9V6U^
MUZ.%7:D>O(<P@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M9OM^.7SO&GXY>O!\>HNTB.7K\?W)7?R$4F7L]'[R=R8K.;/F_67JPVYW+)!
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MD\&Z8X;KYB?8QCBE<![*MIGG-EZF;^W%O!X(<;>6Y-M9D^B)QG+1Z&O"P_\
M93;W=EMJ\';+/=M] NCFU0TXG9^/=,SBV>^8<A*'=X?=F4M/S:+J8F=Q[]=T
M_=]S*+(AL6&&&WB9!!&V*&,:61L :UH'8 . 73F:LENSEUMR.U-CN6>R997K
M7,-MD7Q"*9K::AHF-' 5%>"SLBZM;:Z.Q):XZ S[0MNG.!Q^,DQL.4O(9'75
MK;.@9<3/;)(27L91SB&]XY+N9Z+YQ9F:T8V4HMN^/9HVEF\B-T[$NIMA[WA<
M98<IAJQ0/?S^^V[',;Q/RC&6U^RU<ER8/4+[8X;_ ([>R4FR-C&F=7>L'1Y[
M;+K=MPY_;+"&-WQMYH> WD'7,(#&CTU$7H#US?I<''TX-W#/^V?=Z2G%,:VT
MF9OI#UAVF,G<7&*W'M6S>+R87V@QVLK&/:'SQSZ3"X-<[]\:W@>Y='@QL"^F
MFV[[V=8F&MNB^W>AN:SVY9L'8[?OLSC-PSW>#-L+:2XALX66[H)8 TEPC;('
M%KF\-2[N;Q,Q;;;6;HB;=/\ %A;$)$KQG*MN>S+,#C9,F^RO,@V(M;ZKC8'7
M=R[6X-JV-G$@5J>X+.RSBFE8C>DL'M^M.&NKN\L+;;6YY;VP,;;VW9AYR^%T
MS!(P/ Y:FG4/0NU.4NB(GBMT_P!R<392Z3(0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'#N2DK" O73CU"O_F?77TKI
M_A'SGJGCK=R+\[!ZU/4_9N^,KYY?S2W^SEA0!H! [>T\5@S<AI-'4X'F$'?&
M\1W$3VB@:> 65LTF$E>=ST%Q!(&\7QMK3W%WL_WGLAA8L;7$\5Y[-V50>S&R
MB/(6KZ5TR--!P6=EO%=$"X;HN/-RA?R!:T@'C3FN[GXIB4KLAC;H6>I/$GT!
M>>R5AO8>?>@IKS%:DHK(]ERBWR<LSJ#3":5%1\H+N9*WBQK88W:(JM.3+GW]
MS(3\I[B!^R*XL?O)(>1I[#V+@9*7<2@[+-Q%W >P/;4>^L\.:71/9*/7N!Y?
M>MC<:,;&UP]^J[W4+N+$B?[8<6%J]JU \JFO<O.<JB0'GR"*X94C1SU<*HC-
MMUDVVU<-8DU<:2UY<',I3ZBBL$?6FKZBHH?6E4%;7.TZ1P0(^+B2>2(S/IG(
M(]R>8\Z6^1<"OI,+PK$55C-^ ,A<UXCS"H.C5V#@$%==(!',]J(O.V)"S*QR
M-%'MJ6D<#R/:O2Z=;$XT1*7Z(5;J>7Y^\DK1Q<W[AJ\^[6JTU#FU/.JQ'('/
MTHKC@TAQ/ =B(ONT,BRPSD5R\5:&N;2M/E4'<L[+)NF@Z-RR-?G<A<L%&S3/
M>T>ASB4Q+."Z;9V"V-(#"X\25@K--M'5B'GN)^Y:M\\O=W._W-"\Q\\?+*4W
M47]$6UOF7'\M;+1>M]]+@\R>"L]-MJ('4(#Z0MSVB/\ QG+HY7E=KR=X:_YO
M=#$2YQ(!XA=UO2O2*F@HX\#7BHC*;US;C:-M*X>.%TC13T%H7HQ;7+3/9/\
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M]ZY#J!T:VON/,2F?,.@EL[^9U=4DMC/);>8X]KGMC:]Q':426TD00$! 0$!
M0=%Y>V>.MGWF0N(K6TCIYEQ.]L4;=1#15SB *D@((3>WOF\+E\1L=N)R-K?N
MBN<B91:SQS%@=';TU:'&E:=J,H6;&W;\5['N[8F4\_.;ECM(-/RR/Z$\MIPJ
M2('\!7@?@[G1+:XT3V5G^#RLMR73VW2G/M[&#"8#%89OR<=9V]F.WA;Q-C[2
M?M5UL2[BNF>V7I0N2P40$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!X\KB<9G,=<8C,6D5]C+MG
MEW5I<-$D4C#QTN:>!'!96W3;-8FDC"_S&='/R&PO]2A_<KM?K,?_ 'S]K'AC
ML9U:6EM86L%C91-@L[6-D-O!& UD<4;0UK6@<@ *!=29F9K+)W* @(" @("
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MH?V([EYUVMDM H*@'TJ#L!X(K@T(\1Y(+C@8S+EX&@5!(X>BH7-@SPWH[]V
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M0P:/\&B\2;N*:]KLQ-8>U11 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MA<#O*D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MAO#X0A1WY';61QCY(;I[!<PN+)(!JUM<.!!J$*.J7 WT< G8!,TTU>77P:N
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'5/0QT<:
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MGE /;K=^J@H,MRT<9Y:\OWQWZJ#CS[DCA/+SH?&[]5%<">YK0SRC_P!([]5
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M%F\ROGB-KH8FU<"!QYA06C>6WIL/JG>P.@F_>^0IPIWGN5F*#"K8AN4L'EH
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M]_9VU=538,AV5B?I@06,5"V1S:OT]FHUX5"QD;:S>Q;-N(%K :SVK*AVGY1
MIVN4&C<E V&\N8J??&L(=^U6:/$X-=MGB*%KAQ]Y%>@.:V>W:YO[XT!I'?I"
M(D%TOVM<MVUD97D:[R%X8-(- YC>VJP9-*[NLI\9>3V]PT"1KQQH*4)%.55E
M"2LFD.R\=:5=$>STA4>2T;_WD8TC30N]/_-E-B[&5;1Q\V4F;;VX!>'5(-.0
M<!7C3O6,I#<'53%38S;&#9*T&D#:N%/M6]U5(9-"3EK99&D4K%(10>A9,#'M
MB.%E%!JXFM/2KM'BM"&Y&Y!YG10^\DJW+TAQ#<QN:Q\T5CA<":<.P]H(6*MK
M]?=L6[,A<S 5EABB(?7F#"T]ZBRBDZHCN3V"\( _8A9,5^QFDWMM3O"QG4X<
MQW=VY+_H?_OKB?FCX@O'LYWQKH'[A'M2PZR?H_RWS6?=!>O9KA]MOU2T#@C_
M *.@]PK<L./AA\;S,_FW;U>.X]1=I?[0C^Y*\WJ.BR&R^6M.+=[$MXAP!]"U
MU]!G6[4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00N_P#,(_U/L/\ SG)?R=NC
M*&_?9L_05L7_ &8S[MZ)+:B((" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(.#R4D0%ZZ_I!R'\7]=?2LAX-\ZZIXZW
M=[T4[RGK<_"I\QWQE?/;^:6_V<L+=?-;I#G#Q \*K!D]^P<._.YF"Q+7:3('
M<!PH'5[BDB9F\</CW;,PV-MKICYK5FCR&N!?R[118K*$N\K0V^=O[=S#$& \
M#PKS6<(Q]K [;M"TC[4=Y5VCLLG>8,<&_8O-1VA$37Z4X/'S[9L9<@!$)+:E
M7<.))[UQU9-7^T%MMF.L+>YLX3(P.=JD8*C33AQX*P2CYC*2YBV-> C<">XU
M' K/8Q=D;##DLCK\+7L&D]_B*BMJ]&-MWF3OV9,P/-K9.JZ0 T!IJ'&E.Q8R
M0W=U'DM=PXR6WQ=E/))%;_?G.8"#(":TTN=WI40]OXY;:_OV.C<'ZBW33[4D
M+*$>:>VEDP[&M8?, !H1RX*[1=L!'7+VL@::T:VGI H5)$V]A8F"YQ%SA[R-
M[9KKP#4* %PI[OU%@R1GZZ;0O]N9AT+K=PMG2%T<E'4(+CVD!90DM3V5H]^?
M,C6U!D;I<>[A593J2JB2*>UREU&8'_?I7>66CF2\]Z5$Q.A&W;W;."CSF7M"
MTW%'-8YK@\@.>. <&_&L%>7JUA[O<;<EE+.'R81%1L9!#C1Q-: .[^]144[:
M*1ENVV<PZXG&M1^N)6:+CH?1I X?9*#IR8I#$?UP^,*B\].(/6MT-A(=1TPK
MI])"DB95[A[*3IS#9NE8;EO V]?OA#I.ZG<L:LD)M\6HQ&>N\?Y;F-:3I#A3
MA6GH6<,%CMH@_:MR\-YR?_Y%9UJZ;)Q-A9QL-7MDCJW]D5)$O>DFQ\:-JP9.
M]K&^>ID/ >$AI',>E82K#NL^%9!@3<6K'FVC>&QFG#Y#SV>XLHGM$=K4"6\L
M.!HTG73OT'G[ZJ.ZX-=PSO<:1&(AG>3Y;?KJ[!M3H7BKS(96Z9:6LKVMC<Z1
MS6DBFM@-:5X<5C,T(22ZF8? 9_!0V&(QUP)H(GF6,,;^^4J--'.//O2ZZLZ9
M6(0AS=A>8B]R-ID+>2![6.8V.9I:ZH?3D:=RL(ML<4IPCX2W[X36GHUU^)7:
M-R]..&UFL/-K0/@C8MZ\O]W.]H?F/GCY92\ZB#_PBVO\RX_EK9:'UOOI<'F3
MP5GIMM0ZZD"N1M_XK_&<NGE>5VO)WAK_ )O=#4DX(E(:"3YCN Y\UWH;RDGT
M!QWT;F+;+9!_JME<E@+W^&C7/;7F*<AWK!8=/M$V)=;S96U;YL'F3:)!QJT/
M8 >'#C5(24;K)C?IBR:UM"PM)]YX6:.R1SF[FD>*M:7O!<>0XN[4V#9702V=
M<9N)CF.<P<#PX"H<I=K5*W-X3$''6LL0:;H$1S0-H7\!740L%A"3>MM+C]V9
M2"2-T56@L:X4J2ROUUG"2L)@G.W7!S3KK730UI17:/7:-DFOK%D+#(ZH#P!4
MBH [%)1-KI=!9X';+X,U87+Q>6Y$+8XP2'.: *ZW-X<%C5E,(\]?=O7\-^R[
MML;<1V<A!,OED"@#.WDK"2U'"?-RT%"2T,+37F/$%D.(K9]ON=KGM)BXD.[.
M+".:;!G_ $GL;RZS3H((7/>&N+@P$D-U-J5C(DWO#&8?=6TK?!QVMS+DK:$,
MJ&-(#VZ:\B3]CW*,D.L_C+["9:>RR%M+;:(WM;YC2WBX<.=%E#"CQV5O)]"3
M,:*R4)%.XE6ND6R6"XAO99'0N(DT:" >8%*()8] ]K96UPL&X+BS+8Y-+FM<
MUP<X%@/#A0\^]82R9UU*Q=SNRWR5SCX3%((*B%X(<?+BH>#=7<H3K0JFM;FV
MN;RQGB+;AETXNJ#0 "E./;59U1>L8W5?6Q_7!8SJ<./W=VY+WH?PWKB?F_6"
M\>SG?&N@_N$>U+'K(:]/\M\UGW07L6:WVV_5*/N$-,=![A^-;MA1\,/BN;G\
MV[>[<6:]1MI?[0C^Y*\SJ<?!#9_+$_FW>Q+J,#2WW%K#Z-*M5! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 01(]MJ7&07W2Z;-",XEF2OC>"=GF1>4&6^K4T@U'H
MHBKALW&=0+_:^+O-D/O6;3FA#L2VQNO5K805-/+B$C T5KPTA9:&.E??H#K5
M_"Y;\8'^>30A] =:OX7+?C _SR: ^@.M7\+EOQ@?YY- ?0'6K^%RWXP/\\F@
M/H#K5_"Y;\8'^>30'T!UJ_A<M^,#_/)H#Z ZU?PN6_&!_GDT!] =:OX7+?C
M_P \F@/H#K5_"Y;\8'^>30'T!UJ_A<M^,#_/)H#Z ZU?PN6_&!_GDT!] =:O
MX7+?C _SR: ^@.M7\+EOQ@?YY- ?0'6K^%RWXP/\\F@/H#K5_"Y;\8'^>30'
MT!UJ_A<M^,#_ #R: ^@.M7\+EOQ@?YY- ?0'6K^%RWXP/\\F@/H#K5_"Y;\8
M'^>30'T!UJ_A<M^,#_/)H#Z ZU?PN6_&!_GDT!] =:OX7+?C _SR: ^@.M7\
M+EOQ@?YY- ?0'6K^%RWXP/\ /)H#Z ZU?PN6_&!_GDT!] =:OX7+?C _SR:
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M-X]T1NYC<2>08H@*.+GT&H.X54E89HHH@(" @(" @(" @(" @(" @(" @("
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M69B%87-(  =4^(N[&4[>]<4)J04DMI8,OF;;@UL,C33B#XR\GL]"R1L[8G#
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MMTVG2''@.Y?2<O@19AQ$-=S&9F+Z.TW=T^$0FXD,0XM9K=I^"M$^G;6M'?\
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M! 0$! 0$! 00N_\ ,(_U/L/_ #G)?R=NC*&_?9L_05L7_9C/NWHDMJ(@@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@X<*@A0A 3KGPZA7_P SZZ^DY#PCYWU3QUN[WHMW5?6IR.R1WQE?/<3FEO\
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MA71;?$SIBKT&PY(Y([@DTU D5*^E8-\<$4U4:]F,O==>!IU%[CQYE9S=V.3
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M3BV6@X- =05)[RL\'K4S?\44M2[!K#G:'1:YV_8RY+<+?])EK@R&M='A]\?
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MY89ST:PIRN[(Y2"6P$.//@0?0L&2;.(A]5M&-:*Z:<%C5DRFQMY'2-E:"(Y
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MEOR>8:VJ+*7']VSH5^0N,_:/_=HE3^[9T*_(7&?M'_NT*G]VSH5^0N,_:/\
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M9V/;%)ZIZM+% 9&U^U)<ZO%&6Q-G^[9T*_(7&?M'_NT8U/[MG0K\A<9^T?\
MNT*G]VSH5^0N,_:/_=H5/[MG0K\A<9^T?^[0J?W;.A7Y"XS]H_\ =H5/[MG0
MK\A<9^T?^[0J?W;.A7Y"XS]H_P#=H5/[MG0K\A<9^T?^[0J?W;.A7Y"XS]H_
M]VA5%SVSNDNS-DXS:$NP-LPXV:\GOFWSK"-[B]L;("P.XNY%SJ(L-Q=#.@?2
M3/=)-I9C<>S;*ZSEY8MEOKBXC>)7R%S@2X:AQX=R),M@_P!VSH5^0N,_:/\
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M7!YD\%9Z;;44=[7&"9=VT5_KAR I);7<;PS30N XT+N?'@5T\KR.QY.\-?\
M-[H;,'7JRQ.T,9B(9&Y.[BCCADD<XO>UD0C XNX\@5VXAO;,L9U%9DIL7D,1
MD'1B*2+S;;S'\M8)% 0.Q9V6Q.S8D2R[J+UF.)Q=G*Z2C(V5(#B-3B& UXKB
MHRJBEU8W1GNJ4GKEUDS-C[8AS;,.D<UK6@DD!SBT=O8LF+&L#)MS;UM#>26C
MKC,1\&3,+ YC-( %2VO?VJS)#:N$]I#<-A>6D33*+!ITO89'TTN=Q)\=.T]B
ME&56X&9*#<$MOO8W\S+!D;9B6RN# [Y7B[^:[%F8FVWAI#&8EJ+*]>\T[=-^
M9KB>7"2Q&VCA;,\-:'1^6YP!=0=_)=9=3#,7MC:N<RMSF[F\;D"\F:.TN")G
M:B1X?&TA9(L69WED[Q\F'Q\0Q>):=/J=J#!&=/:6QD-/$5Y*#8G2'?&7M\K;
M;;NKB2YQUTYK/*D>]^G66LX:G4'P*2L.GJYOG*76;N-O6EQ);XZT-&LCD<TF
MH%?DN [.Y*#4MQ;"XE\V9SI"\U)D.H_563%M/H9NH[#W(W+^O-L\<*BXC)>W
M6T!U!X2!S/:L99PE1M+VC\)NJ[N; :0]E1#,7:M7(<.WF4IH*UE?\'U!G^F)
M67MPP6;7$AIU<C7TD)%D]A+JRG5O:D>Z[?%^L,&2?3@3P#:CLIZ>]2:]AI1A
M]H#/S=0<[?SXHAF.PG[\14A[F'RR.'I5A)AI^ZGQ(N["YPK9+.X+V"9K'!O'
M4/M U4;0ZI;ER]EA-O65I>RPQ3V,+YG1R/87N(-=1#A7EVI*-,^9/YS9HY'"
MZ;Q$Q)U"OIYH.JXNLM,]YFOYGL=4.!D>:U[ZE!S81O%_ =1/B'%)U.''[N[<
MEAT0K_;;%5X^'ZP7CV<[XUT#Q\>U*WK.?_#K,_Q;>'OA>QA\T/MTZI0IL9?O
M#?==\:^G8')#YIBV_F7;V2=.I-75#:_^?P_$5X?6^[CVO;Z)'YEWL3S9V>XM
M)AN*M4$! 0$! 0$! 0$! 0$! 0$&#YCHUTHW!D[G,YO9N(O\K>/\RZO+BSBD
MEE?0#4YQ;4GAS0J]^U^FVP-E7<U]M';6.PM[<1^1/<6-M'!(^+4':"YH!(J
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MT:A4#M/8@SV*X8.EOD5#0^X8:>_(HK7HXNT,HWLU%4=;FN:>:"E[2?$#R1%
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M*:#D@R&&1QP#HG//E!I=H[*T/%>Y99$Y.9EP\7Q48T[Q<&]B\)RAH&CCZ"J
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M/%O,JCD4/AJ-(04O>QITD\^ X(.Z,$- *"I 0$! 0$! 0$! 0$! 0$! 0$!
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M^)%95M^31MO,@GB:<._PN08KK C::>\B//("TU8@X+W.;Q[$'47FAHJ*@-7
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MM/V0,AN+I/CNI^V-VR6VXKK'NR<&+=;F)A<P//E-N63!S2=/!VCW1VH5;/\
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(/G3[%_\ ]0>8_P!F9/\
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M1\BZLH([Z4@:"V%[?>#20/A1%\S$V-QV)AO\;!'],FL>1,C Z)LHXG2TM ^
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MR6"N;C:EQG-EY&*X&4R=JYS7VL\;F"-M2TQ^)KG>&1S=78?":F,0A=OEV/\
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MGN+0VS.Q4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M/C^2">URW[R_-<.=_N:#YDIQ1NEO[J)QZ2;8!/)EQ3WY;;FM#ZWWTN'S)/\
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M( ^:LV*_XT'U^WKSU!83J<./W=VY+WH?_OKB?F_6"\>SG?&^@_N$>U*SK?\
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M/KKP>N]U'M>ETOGN]CZ0L(\/N+1&QNQ 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MM-XY""1I;HN9 YO9P)";&+>G2"=MEMN]R?K)9>P.T6S7'AXM1X4X\QWKN9+
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MHX.=\JG-:.]QWH" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MD*^8_4W;PVEO3)XR(ET+I'RQ]HHY[@.P=RS8-N^S%M]]Y/>9,-\(+!7CR+9
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MRL/ @TKP'%5=3%KG(6^0Q>2LW1N%89&AQ YN:X=Y4A)0PPVP9,AUXM)KA_\
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M%$.&F8-:[_!<Y:2]5?D00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MM='ZQ*99_#*]Q)+>'$\32B(]]M=Y"UEC?;WLT;X.,?WQ] >?845(C8^^;H;
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MO+C4!:35U21S!'"J#E\CC\H\#R [$&1=.&NFWKBV<@)F.->VC@@=3I"_>^3
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M=22;(Q-N36*)TOPNN'%=F;8^E$[4JQMU:4[EUAP7 L)[D5GVT7:L+(>7$C_
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M3("X$U\+:<FE*E'7-CL4ZW%]8RROLHG%EQK<TO+A05;1H',CFE4H]5WA\(,
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MW>T/^S8O@'ZB5DT'YN]H?]FQ? /U$K)H/S=[0_[-B^ ?J)630?F[VA_V;%\
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MTV2_L/K9^NJ\_-OEM0IM>Z#.T>JC]1/T^2I_H8_5ZAQ5IB4]@_ISEZUCVI<
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3^U*+I5LC<PU!X'L[$'8@("#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>tm2227887d4-lc_tumor4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_tumor4c.jpg
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M%!04%!04%!3_P  1" +4!V@# 1$  A$! Q$!_\0 Z  !  (# 0$! 0
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M2U-N%'46MM*B1J1K.JDF1T+L!:)0!
M
M
M                                     'PFSH5MB/3[C):AP8Z36_)D
M+2TTV@NU2EK,B(O5,P'\@SH-SB-3[;):F09"=;$J.XEUIQ/?2M!F1E]0P'\G
MW"!:HCL^YRF84%@M3TJ2XEEI">^I:S(B+ZI@,78<UPW*EN-XQD5LO;C)5>1;
M9L>8I!=GA$RM5/K@,XI24I-2C(DD53,^!$1 -;@[B;?W.Y_$MMRNSS+QJ)'Q
M='N$5V3J/L+E(<-=?K -E
M
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MWSAMGOV/]V R-ONMKNS2GK5-CSF4*T+<BNH>2E5*T,T&9$=# >L
M
M
M                                                       !5CJ
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M2#(E+TI,SH1J+B"-N
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M =MOG-?/7B>X 5/0!VV^<U\]>)[@!4] ';;YS7SUXGN %3T =MOG-?/7B>X
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M ';;YS7SUXGN %3T =MOG-?/7B>X 5/0!VV^<U\]>)[@!4] ';;YS7SUXGN
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M&0
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M%ETD!@
M&&R;$L8S.WHM666B+>;:VZF0W%G-)?:2\A*DI625D9$HB6HJ^J8"-\SV VI7
MA^0(L6!6CX[5;9A6SD0F4O>-&POE:#H5%:Z:?5!:L#TJ;3,8-MY:[EDF+LVG
M<,SFLS)CS+93_%W)*C0E3A5/2:4HH5>R@$MUVOV5QO;&7>;VS)DWS+K](=?N
M61W0TN35M+7K2R2B*B4EPU4]FKB? DI2*OXYLGC;.ZT;=NR2Y5DO1M.M7N#
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M%E;4&4<[^^93/O(<[VE0+#5ND'Z.V&_G/Y5E@2F\$
M
M     5*RSZ>F"^0W_@%T!K@MJ#(
M          "/-V<7W-R>W6YC;++6\2G,/+7.D.L)D$\T:*)01*0NE#X@J"LW
MPWJHPG$+WE\K=]F5&LD-Z>[&:@,I6XEA!K-*34S0C.G=!=CX[?XKU3[@899L
MSA[O,PXMYCE*:BO0&5.-I,S*BC2S0SX ;$[;28KNEB\>ZM[G9@WES\E;*K:X
MU'3&\70@EDX1DE"*ZC-/K B2 0
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M6;C\,=!);OO[YE,^\ASO:5 0I[T ^<G)O(9_"V 670@&0
M    &J[F^;;,?(=S^".@*"]"OGKD>0YOMT<&Y=) 8
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M)-Y+)DZ;).<PD>%IT\0&R@
M                             J5EGT],%\AO_ +H#7!;4&0
M                                   !'._OF4S[R'.]I4"P\/39YBL%
M\F(_EK E*@(
M     #ECA_TM(7[<._**P;X.IP,           I=_B$?V/@?]9N7M<<&H2IT
M9>8"P?UFX_#'026[[^^93/O(<[VE0$*>] /G)R;R&?PM@%ET(!D
M          !JNYOFVS'R'<_@CH"@O0KYZY'D.;[='!N720&
M
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M);[F&Q^%Y+DLU=QOEP@FN;-=))+=6EYQ!*5H))5HDNX")2
M           :CC><MY%F6:X@F$J.O#9%OC.2S<)923N,%N:2B1I+1H)S1VG6
ME?4 9#-LNM6!XI=LOO2C*W6F.N0MM'%UU9<&V6R^R<=6:6VT]U2B(!]\6FWR
MY8Y:[CDL!NU7V7';?G6QEQ3R8SKI:C9YBDH-2D$>E1Z2\*M. #+@    *E99
M]/3!?(;_ , N@-<%M09
M    $<[^^93/O(<[VE0+#P]-GF*P7R8C^6L"4J @
M                                  .6.'_2TA?MP[\HK!O@ZG P
M      "EW^(1_8^!_P!9N7M<<&H2IT9>8"P?UFX_#'026[[^^93/O(<[VE0$
M*>] /G)R;R&?PM@%ET(!D                   !JNYOFVS'R'<_@CH"@O0
MKYZY'D.;[='!N720&
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M?0#YMLF\N'\$8!96U!E'._OF4S[R'.]I4"PU;I!^CMAOYS^598$IO!
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MC+P0$S      "I66?3TP7R&_\ N@-<%M09
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MJ2?$C'->LLX
M     .6.'_2TA?MP[\HK!O@ZG P          "EW^(1_8^!_UFY>UQP:A*G1
MEY@+!_6;C\,=!);OO[YE,^\ASO:5 0I[T ^<G)O(9_"V 670@&0
M          &J[F^;;,?(=S^".@*"]"OGKD>0YOMT<&Y=) 8
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MADN@'S;9-Y</X(P!*VH,HYW]\RF?>0YWM*@6&K=(/T=L-_.?RK+ E-X(
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M&>KV*#*N'TW8Y?,1V.PK',DA.6Z^0()HF07J<QI:GG%DE6DS(CHHN (E,
M            $3Y/U%[;8A=Y-DOA7IF9%DE!4MJQ75^.N0I1(2AIYN,IMPU&
M=$Z%'J[@*V[!MPL?W#A2I^/MW!MB&Z3#Q7.W3+6LUJ3J\%$QII2BH?:DC($;
M4     _BE)0DUK,DH21FI1G0B(NTS,!5&/N[9K)N!O4O"KE OV99+=<>M>%0
M(LEJ0F7<7K+'CI</EJ5]X8<)2I"_8I)"B,R,!87;G"(FWN(6_&8[RIDIK7(N
MER=_GIMQE+-Z5)</M-3KJU*X]A4+L(!M0      J5EGT],%\AO\ P"Z UP6U
M!D                                           !33K9R%^X9%@^VQ
MN&BT/)?OER9XDE];1*;829E3@6ATO^=7N$.+JLLXL5UT<'=]#T$:[6XL$[KK
MMO\ AC;=\(E!'U"(B+@1%P(B+N$1#TF9KME^K<6*W'9%ED4MMBD1'" 2)HU?
M9;?;-MT5B=DQ.Z839T67V5:,\S+;Q"E?$DN&WD,".H_ 9=;<;COFA)<")1O(
M3QXT;2/=M'EG)BMNG>_*WJ'I]NAU^7#;]-L[/"Z(NB/9$T76'+>O-9W'O<_&
M=O,MR2UFE-SL]EN-PA*<3K03\2*X\V:DGVEJ252 <\_3;WU_#+9[P1]T#=#T
MV]]?PRV>\$?= 4=,@8                                        ?E
MQQMI"G75DAM!56M1DE)$7=,S[ 'G@7.VW5HW[7,8FL)/2IV,ZAY!*[QF@S*H
M#U /$W>+0].7;&9\9RY-UUPT/-J?33MJV1ZBI]0![0 !RQP_Z6D+]N'?E%8-
M\'4X&           4N_Q"/['P/\ K-R]KC@U"5.C+S 6#^LW'X8Z"2W??WS*
M9]Y#G>TJ A3WH!\Y.3>0S^%L LNA ,@                   -5W-\VV8^0
M[G\$= 4%Z%?/7(\AS?;HX-RZ2 P
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M@@               "K>_GTH>G?^L7GVID%6D!
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MRSZ>F"^0W_@%T!K@MJ#(
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M^X <QNK*%#MW4#E\.WQVHL1OXMY<=A"6FTZK7$4=$I(B*IF9@W#JJ#
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M1T!07H5\]<CR'-]NC@W+I(#
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M6GY4WA,'-;;)R=Z3X@S 9<4X:Y1GI)I+B4FV:C5X-"7V\.T!)0
M             (MWR_LS"?VWQCY1; 2D     ^4B1'AQW9<MU#$5A"G7WW5$
MAM#:"U*4I2J$1$15,S 0A&9?ZB;JW<IS2V=B;5(2[:X3B=)Y1,CK.DA]"B(R
MM[:TGRVE$92#HM7@DD@5KNT.T6W-JWJW.\4L+2DXC/LJ<9;DN/RF[?XW:6)3
MBHZ'W'$H4;JU*2HBU)[$F1<!B++8FL0\M^?)?;%MUTS$;HF9I'@LL-O"
M  "I66?3TP7R&_\  +H#7!;4&0
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MS<?ACH)+=]_?,IGWD.=[2H"%/>@'SDY-Y#/X6P"RZ$ R
M    U7<WS;9CY#N?P1T!07H5\]<CR'-]NC@W+I(#
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M/24.*;(ZJ9U-KX]SNA=B+*CS8S,V(X3L60VEYAU/L5MN$2DJ+U#(Z@/J
M          (MWR_LS"?VWQCY1; 2D   #^&9)(S,Z$7$S/LH @V6X_U#WARU
MPW'&=BK1(4W=)K:C0>438ZJ*BLJ*A_%[2R,GG".CZBT)\$E& F^/'8B,-18K
M2&(K"$M,LM))#:&T%I2E*4T(B(BH1$ B/;+ST[X>4<>^08P"8        5*R
MSZ>F"^0W_@%T!K@MJ#(
MP^4Y38<+L,W)LFFMV^RV]LW9,ET^!%V$E)%Q4I1^"E*>*CX$ JO8K%E/5YE+
M.99DS(LNP]ED*.P6 U&V[=76S-)NNFD^)'Q):R.B2JVV==:P:W+<PX<2WQ&(
M$!AN+!BMI9C1F4DVTVTV1)2A"4D1$DB*A$0,M W]\RF?>0YWM*@6'AZ;/,5@
MODQ'\M8$I4!    '+'J^^D3F7YL^2H@-PZG P
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M<WVZ.#<ND@,
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M1%0@1Z@$/[9>>G?#RCCWR#& 3        "I66?3TP7R&_P# +H#7!;4&0
M                                    &'RG*;#A=AFY-DTUNWV6WMF[
M)DNGP(NPDI(N*E*/P4I3Q4? @%5[%8LIZO,I9S+,F9%EV'LLA1V"P&HVW;JZ
MV9I-UTTGQ(^)+61T256VSKK6#6Y;F'#B6^(Q @,-Q8,5M+,:,RDFVFVFR)*4
M(2DB(DD14(B!E]P$<[^^93/O(<[VE0+#P]-GF*P7R8C^6L"4J @   #ECU??
M2)S+\V?)40&X=3@8
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MT%33S$GX14(B62B+@0_143$Q6-SHZ4E#G0#YR<F\AG\+8%)=" 9
M           :KN;YMLQ\AW/X(Z H+T*^>N1Y#F^W1P;ETD!@
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M3M_TK;&;:7IO(L9Q=!WV.K7$G3WWYRV%%Q)327UK0A1=Q:4ZB[X"90
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MOPZ+#CR?5;CLB?&+8B7K&2Z)NF8[4M= /G)R;R&?PM@=J\4NA ,@
M           -5W-\VV8^0[G\$= 4%Z%?/7(\AS?;HX-RZ2 P
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MY^8[^EX/NP#(6;<# \CFE;<>RFT7:XFE3A1(%PC2GS0CV2M#3BE4+NG0!L8
M       "K>_GTH>G?^L7GVID%6D!
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MTHM9=OL$<-2@:W+=1X\>)':BQ6D,16$):88:22&T-H+2E*4IH1$1%0B(&7T
M          !RQZOOI$YE^;/DJ(#<.IP,
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MHJG34?!)5/2DB3W!]3=;Q5QZ ?.3DWD,_A; ++H0#(
M #5=S?-MF/D.Y_!'0%!>A7SUR/(<WVZ.#<ND@,
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MFKE9+BV3T.:P>IMQ!F9'VT,C(R-*DF1&DR,C(C(:5DP !5SJXZG+OLT5KPC
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MQW?CL=$8\>/$CM18K2&(K"$M,,-))#:&T%I2E*4T(B(BH1$.0Z=]
M     '+'J^^D3F7YL^2H@-PZG P
M               Y8X?]+2%^W#ORBL&^#J<#              CG?WS*9]Y#
MG>TJ!84]Z ?.3DWD,_A; ++H0#(                   #5=S?-MF/D.Y_!
M'0%!>A7SUR/(<WVZ.#<ND@,
M                  U?<:U97?,'OEGP>XM6G*IT54>VW%]2T-LK<,B4K6VE
M:TGHU:5)29I50R[ %9]MMB^J#:BUR+7AUXPB.4UTY$Z8^4U^7(<XZ>8ZJ%4R
M21T2GL+B?:9F9JL)TVMM^^T*7<5;O7:P7&"MMLK8BQ(?2XATE'K-PW662TTI
M2E?K=TC9\*V^P[;JW/VG#+2S:8,J0Y+D(:U*4X\Z=3-2UFI1D7L4D9T2G@5"
M!'\N6WF&7?+K5GEQL[+V6V1#C5MNGA)=;0Z1I,E$E1)70E*T<PE::GIH9@-<
MW3@;X37;9^Z"Z6&W,(2]\;?'R7U+6LS1RN5RF7BH1:]5:=P%03A>R'55@5^R
MO),>R+#D7/,IA7"]J>.:ZA3Y.OO5;2<'P"U2'.'U 6L)CWBV9=WEV_MMEO%P
M;MN;6HV9L.\Q$J-ANXI;)+Q)29DODK.M.)**B5=RADJC>Y[>]76:6)>!97E.
M-P,;EM^)W:]P$/N7&3$]BLM/*0DS<+V1%RJE4C,JF1C8L#@6$V3;K$;5AF/(
M4FU6IGE-J<,C<<6I1K<=69$1&IQ:E+50J5/AP!&Q@    *S==7F4C^7(7M,@
M%A@^@'S;9-Y</X(P"RMJ#*.=_?,IGWD.=[2H%AJW2#]';#?SG\JRP)3>"
MT/=C*L_P['8][V_Q#]=IK4M!7.SMRDQ)!0#0LUN,&I*M;A*)!$@DF=#[# 5J
MQ[-NE7(MXF<ZSBV73;K==AQJ8[:,MYUK@?&26^64HR6KD$XE)$1+<-LE4)6G
M5Q!5H=M</Q3#L>=9P^6NXVZ\395[DW5R2F8N9+N#G,=?-U%$JU'0BT%2A C<
M &F;D6JWSK&JX7S++EB>.6E+LRZ2K7+1;C6VE/ W9.@W4I1Q/2VM.H^VO8 B
MVQ[M9-MILSAF:[E1)5PM,E4EF^7"6M#-[8CR)*RM+BHBR1SW%L\LI"4F3B3\
M.BJ*!7[W=R/<&[; R-P;;=EX5,:B.75<*TNLSGGXKSB?$T'-(J-GH4E;IQZU
M/P4KT\3#.Y>JZYIO.UMH=]NEAQ^W8L>0K58Y*H$F1-ESEPF^8\@M9H92TI26
MR,DJ4KPM1$1 C27IV0[A].^'7:[VJ;EV9-W**LI4%ELU<RSWC0[*6V2VD$:V
M(RZ&2?9*X4J(K+V7$LE>W3CW9_'I4:XEE,K))&5/H9)"L<DV-<-FWFZ3AN&M
M+RVVU1J:4FV;GVIG1$6<;CSL[ZM-G[?+Q&\8RC'+K>8+$N\1U,,W%.DD<Z(I
M22UM_>R54NXI/? 7A! !#SFVV^*G%*1O;(0@S,TH_5JSGI(SX%4T\: (MVNS
MC#-M\$@X)GMX@XKE^*MKA7RV7:4W%D.2&UJ4J4R3ZDJ?;D&?-0XUJ)6JA<>
MZW+CNYMSB9+)YF5VJV^W9NUHO.38SG4S ,9R2]3[Q9<<>L4&2ZB))4DD/K*8
MGF-&^:3=Y7>42NU1CGV1,6Q$N5;%(3]AUGR6QV9,'*\D7E5V)U:SNKD./;U&
MVJFE')C$2/![_:8VK8 '.7>IU$7_ ! ,4?ORDMVLIV/*B+D<&B;T())D:N!$
M3^KCWP5T:!%'?\1K<),+&<8VPB2>5(O,D[O=4E6A0XE6V270C,TJ=4I? NUH
M! ?4CGVREZL6V2]E[U(7D."1F[1K5#D0UG&C$EYB1J>02=:7DK6=#J:G*\:
MJQ?5UF\'<CI"Q[.;<1)C7R=:I:FB.O*>-MY+S5>^VX2D']0!6G);WU(6'IRQ
M:)=K@TUL/?VT08YVYB*[(2SS5N$U(4:$NI-2D+47WPB533JH= '0OICQ; \5
MV6QMC;J6[<L?N32KDJYR$$U(DRI!T>4ZV2E$VM!IY1H(STZ*55349$6_XAOF
M%B_M#!^#R@%<MP8DO:)?3CU"6F+6(O'[+%O/*-25.O0(S9+0M1<"-Z(X;2?4
M;.I J3,?G,]177$N^1GT2\(VRC<RW/LF2V7505$ELTN)*BM<M]3J3[J$<# 1
MWTB9A<L!V1W]R^S^#=[7#MSD!RA'RY#B)K3;E#J1Z%+)=#[: C<^C;ISVMW4
MVSNV<[DVH\COERNLF(AU^5*;4RTRVV:C(V74&;BUK4HUJJ?93NU#P]'DBYX9
MNWO-L[%G+E8M:X5X=;29ZFSDVB<B"AU/;I4MMT]5.VA5[" :UT2]/>W>\=IR
M>][B1I%VB6F0W"M]J3)?BQVW)+9..2#..XVLUT0E)%JTT[2/A0/9TB9)==M+
MGOY M+ZGH&,62XW6+'<+4A4NRK>0RLT]\RX*[_=["!68Z+]B]OMZL:R[<+=:
M">4WE^[K@-G*DR4+09,-R'75&RZV:E.&^7A*[-/#N@CW=)45[;/JNW(VDLLM
M]_#VV9Z6HRUZTDN!*9\7<7W#6AMQ;1JX5U .@8   ,;D/]@77^IR/:E -2V+
M\R.VO[*V/Y.8 ;^       #&7_(\>Q6VN7C)[K$LUI:,B<G7!]N*P1G4R(UN
MJ2FITX%4!S4R3(OW@YGDV7W-U-PES+G+:C.+(U):MS#RD06VDK(C0V<<FG"\
M$M6K6?%0]8ZEER1EI68C@^]^ANFZ')H/,FVW)DFZ>?FB)Y:3LC;NV;>^O<LC
MT2DJ-!SVW1&DHLK%PA.,&EM*4IEO1CY[9.$DC424I95I-1DC5P(JCN=#?=?A
MB;M[Y?ZKTVGT_4LEF"(BV*;(W1-(K'OX<-W!:T<YZH     (?VR\].^'E''O
MD&, F        %2LL^GI@OD-_P" 70&N"VH,@
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MD!@
M                5FZZO,I'\N0O:9 +#!] /FVR;RX?P1@%E;4&4<[^^93/
MO(<[VE0+#5ND'Z.V&_G/Y5E@2F\$    5+W.W0RK<K,,JV[PC92#N19,-5XC
M?)]\D1HZ2E+3J6W&)_29'P\$T+UG2M"X K)=)N&;<3(KNZFW\"\X<ZLIF/Y!
M@DB>[+M<>XL.M+=6A+Y&LU),O!4:BH2C+20(M$ T/<_:^-N?%M$29?KE9F+1
M,3<4-6XH;K,A]LOO7C+,Z-*:=2V?AH2M%-7'M(J![;?M_ U6N9ED^1F-\LKD
MERUW>\M0T/,>.)2A9):@QXL>NE.E*S9UD1J+511@,'ENRUBR+"%;=6:Z3L2Q
M!]4@YENLJ8:D/(E.\]3=9T:4;2"<,U)2QRR36A>#0@'XN^T$NYR+9?&,YOL#
M-H$-^TRLJC-VM,R=;I+_ #^0^QXCXJ7+5_-+:CH6GMJ9F9F&YXAB=EP;&;9B
M6/-*9LUI9*/%0XM3KAD1FI2EK49FI2E&:E'WS 9L!5O?SZ4/3O\ UB\^U,@J
MT@(  #P3;'9;E)CS;C;8LR9#/5$D2&&W763K6K:EI,T\?M0'O   !6SJJZ6R
MWX8M^1XU<&K5G]E9.-%>DFX465&UFXEEQ2-1MFA:E*0XE!^R,C+L-(14QMI_
MB"WFVHPZ[9U"MUA4A,5^Z\^*<OD$5#/QF/%\;-5"]EK):NZH!LA]+^?99U&6
MC.-R'(%XVTQF%'M]N8D.^,ORVK?$Y37.CN(4G[[(4J0ZE2C+B::F"I=W8Z=-
MO<TVXR3&<:Q2PV?(I\-:;3<H]MB1G&IC1DZS]]::2M"5+025FG[$S[>P$5\;
MZ8=])?2_(V7NBK6Y>H61-7.R%XZI3*;<I"E.MFOE\#)Y:UI*GV1@J;[1L3<)
M_2O'V.RI4=%]*T+B&^TKG,-3T/*D1UDHTD9DAS1J,D]^@#R=(FV&Z6T&#73"
M]QEQ%PVIOC=@\3DG)Y;4A/W]LZH1I22TDM/;Q6H$9#JUVERS>?:UG$<,\6.[
MM7:+/44UTV&S99:>0JBB2KC5PN% &$W"Z>[UF_2O8-HW?%OUXQVW6DX#ANF4
M5-SMS*67/OFFII4VIY!'I^RJ _71]T_WS8K$;VC+O%599?9J7'SAK-Y"(45O
M2PC6:4U/4MU1T+ND U/I>Z7<HV]Q#<G#=U&X;MJS9F-"2BWR#?4;"&I3;IU4
MVG0HN<DT'QX\>X T3$MA>LC8H[OBNT-^M$[#[A)5(8DR#CDI*U)2@G^3+;4;
M;AI2DEI2:T\.[V@)=Z:^F*X[/V/);WE=P8NNY66L.,S9+*EJ8C-.:EFT3BB(
MW%+<,ENKT%Q(B+LJH/WT<;&YQL=C636O."AE+NTYF3$*"^<A/+:9-!ZC-":'
M4P&N=/O3/F>";C;FWG/FH#^)YG&G0668LE3KCK$V6IQ25IT(-)&T9D?&H*T/
M&NGCJSV#NU]MFR%[M-PQ&\O)=2Y,\72Z6@C2VMQJ4A6AQ!'I/EK4E7"I'P(@
MEOI=Z:\@VHN^0;D;D79N\;F9.EQJ6MA:G6F&7WBD/:G5$GF..N)0I1DDB3IH
M5:F"+-    QN0_V!=?ZG(]J4 U+8OS([:_LK8_DY@!OX    #0<OWEP'#;@=
M@EW!=UR]2:L8K9&5W.\.&=#(BC1R4I%2.NIW0FG$S :ZJ?OQGY**T0X>UV/.
ME5JXW1+=ZR)23J9&4)"O%(YGPJ3KKQE]K7L#*V#8O!;7<49!?VY.99<DO"O^
M3O'<GR5WV65TCQZ=PH[**$ T7J,VIP*_2L7R:?:C1?[GDM@L=RN$.3*@NR;?
M+F(8=:>.*ZT2S-L]"5JJM)<$J(8NLMNWQ$N3@U.7#6<=]UE?TS,?<FK$\0QK
M!;''QO$K:U:[+%U&U%9U'5:SU+6M:S4M:U'Q4M:C4?=,;<>9F9K+-@@
MA_;+ST[X>4<>^08P"8        5*RSZ>F"^0W_@%T!K@MJ#(
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M>;='+;&RVWLC^,\97D'->M@            #ECU??2)S+\V?)40&X=3@8
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M H+T*^>N1Y#F^W1P;ETD!@
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M8_E#T6QE(B,O%"83*F)2A@EI,FR(D)(M/>!J5O2(B(B(J$780,@
M     Y8]7WTB<R_-GR5$!N'4X&
M      %4LGMN=[+=0F0;O0<3GYEA&6P6XLSXF1XQ.A+;0P2JM)J9D1QZD9D2
M32KV54@KP;LYEFG4=8&-LL#VZR"T0[A,CNW3(<HA_%T6*W'62ZI,E.D9UH9T
M5JTU(DG4%W-MZ@-F\GG8A@=]VY(Y^9;6KCNVV.HB)V9'CI8)5"J1*62H[:]%
M?"+41<3(C)$L%DO4#N9G.*3<+P[:;);?G5XCKM[TB?&4Q A*?3RGG2><2@O
MU&2#=Y9$=#5V4,437LEMNG:C;2R88MQ+UPBH6_<Y#=30N9)6;KNDSI5*35H2
M="JE)=T"4@@CECA_TM(7[<._**P;X.IP,             ".=_?,IGWD.=[2
MH%A3WH!\Y.3>0S^%L LNA ,@                   -5W-\VV8^0[G\$= 4
M%Z%?/7(\AS?;HX-RZ2 P
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M;SBR;=+2LD\QQ9<2X5H DH        !5O?SZ4/3O_6+S[4R"K2 @
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MR.79(S:^4HW*+TK+2>FM#X=H"P8       *E99]/3!?(;_P"Z UP6U!D
M                   !SOZ@-OY^TFYEVOCK"SV_S*4NX0KB@E*:BW!\S<?8
M<I729JU*3PXHTT]BHBZS7Z2<UL3;]4?%[QZ3]01TO/,9/]K)2+NV*;KO96:Q
M_"&FL_[RT3T8R>95[%UKPT&7J*34C'JEV.ZV:3$Q+]!8NJ:3+9SV9;)M_P 4
M?:/:QBFKIEMTCX'AD<[KD]Y4<1++%%ML-K\!Q;RRJ2221GJK[ JJ52A5[C0:
M*Z;HOOBD1N?-/5_JO!."[2Z:Z+YOV771NB.,1/&9W3PI7CNZ6;;85$VZP2PX
M3#<YS5FB(8<?(M).OG5;SA%W-;BE+IW*CV9\0;2   #&9'?(V,8]=\DFM/2(
M=FA2;C(8BI)<AQJ(TIY26DJ4DC69)HDC47'ND KSZ;^VWS4R[]'1/QT%HA_9
MKJ)QC;S+=SK]>L=R)^'FE]=N]K1#A,K=;CN/R722^3DALDKH\G@A2B[>(+,+
M#;?=4^$;CY?;L,M&/9'!N-SY_)E7*''9B(\78<D*UK;E.**J6S)-$'X5 2B<
MP0             <L>K[Z1.9?FSY*B W#J<#
M                        #ECA_P!+2%^W#ORBL&^#J<#
M CG?WS*9]Y#G>TJ!84]Z ?.3DWD,_A; ++H0#(                   #5=
MS?-MF/D.Y_!'0%!>A7SUR/(<WVZ.#<ND@,
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MJ7 !@T;:[<MJ2M&(61*TF2DJ3;8A&1EQ(R,FP&T        J5EGT],%\AO\
MP"Z UP6U!D                       !X+S9+/D5MD6:_0(]SM,I.B1"EM
MI>967:6I"R,CH?$N\ @Z?T8["S9;DINS2X:7#U'&C3I!,D9G4])+4LR+U"53
MO M92=@&U&WVU\1R)A%C8M9OD29,HC6]*>(N-''W5+<45>.G5I+N$"-R
M                     <L>K[Z1.9?FSY*B W#J<#
M             ,5,R?&[?(7$GWF#%E-TUL/R66G$U*I52I1&52,!\/UTP[YP
MVSW['^[ /UTP[YPVSW['^[ ?:+E.,3I"(D*]0),ITZ-,,RF7'%'VT2E*C,P&
M6           !RQP_P"EI"_;AWY16#?!U.!@             1SO[YE,^\AS
MO:5 L*>] /G)R;R&?PM@%ET(!D                   !JNYOFVS'R'<_@C
MH"@O0KYZY'D.;[='!N720&
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M**&E"R4789:2I0$36         JWOY]*'IW_ *Q>?:F05:0$
M                    8S(LBL>)669D62SV;99(#?-F3I*M#3:*TXGW3,SH
M1%Q,^!<0$0(M&4[_ )HF92Q+Q;9HU:XF,.:HMWOZ$]CEQTGJCQ#/BB.E6MPO
M"<H5$@J6;I"AVW%)T"WQVXD&- >:CQF$);:;;0RHDI0E)$1$1=A$"-9V+\R.
MVO[*V/Y.8 ;^         BW?+^S,)_;?&/E%L!*0      P67V6\Y!8G[78<
M@DXQ<W5-J:O$)F/(>;)"R4I)-R4.-GK(M)U3W> " \-QW>"^[@YWBLO>.\E"
MPN9:V&'"MEFU247"WLSEDY_NG@T-PT%I[GJ@JS((      "I66?3TP7R&_\
M +H#7!;4&0
M  !RQZOOI$YE^;/DJ(#<.IP,                               I7NYT
M99SN!N1D.9VK(;4Q;[Q)*2PS+\9)]!&VA)I5H:6G@9&145V U5I?H [D_.:Q
M^O+]P J>@#N3\YK'Z\OW "K:-M^B;/,-S_&LLN.1VIV#9+C&N#[44Y/.6B,X
M3AH3K92GPJ:>)@57@!D          '+'#_I:0OVX=^45@WP=3@8
M    $<[^^93/O(<[VE0+"GO0#YR<F\AG\+8!9=" 9
M :CNF^Q&VSS%R0ZAIOXEN*=;BB2G4N*XE)5.G$S.A *"=#<F/&WK<\8>0USK
M-+:9YBB3K<4]'HE-3*JCIP(@;ETI!@
M                &G[LJF)VKSA5NU>/EC]U.+H]GS?$G=&GU:]@"F_3CO/@
M6T^P.7/O7",SGY393\&UK(SDRG5QF6X="H>II*R/53@DM1GV\34PUCIIZ<8&
M^4'),PSF=/9MZ7CBP9$5:$O/W!PN:^\M3J%ZB1K1PIX2E'QX 3*3>@2YW!G]
MX&)N.&]:H$B%*8,JZ$/N\]EPR+C_ #B66^[]B!*Z0,@
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M3!?(;_P"Z UP6U!D
M         <L>K[Z1.9?FSY*B W#J<#
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MNMOI\F[8G8FX5WF-FQ)N;KK\R:MI2DK4@Y$IQUS2I2$J4G50S(C/L(!NP
M "I66?3TP7R&_P# +H#7!;4&0
M                 !RQZOOI$YE^;/DJ(#<.IP,
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M*NB\PW>Q_*F;#D619# ND:4PW,@2Y\QMU!K4E1)6A3E2JE1'Q[@YKE.O ,
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M<?OG>(!-^UVZ.+;OXLG,,/.2=G5(=B?[XR<=WFL4U>"9GP\(N-0&Z
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MNK4LE4JD_8F0\5N&RVZ;K;8B9WS3?XM3=,PLD/*R      "I66?3TP7R&_\
M +H#7!;4&0
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ML]@&WLMN9B<*9"<9C^),,O76Z38S<?P:(0Q+E.M)(B0DDZ45(N!< &]@
M         ",\WW1EP[Z6WFW,!O(]RWD)<?CN*4FV6>.Z54RKH\CBV@R\)#*?
MOKOV)4.H#V;?;71<2ERLJO\ .7DNY-V02+SE$M))7RR.I1HC1>!&C(/V+39%
M7M6:E<0&TY-DD'$[.]>[DQ-D1&5(2MJV0I-RE&;BB06F/$;==41&?$R3P+B?
M ! &!;G6FU;H[G7^=8,J9M653K,Y97SQ>^??$0[4Q$=-1>)U;)+J%%X=._V
MJRP(      "I66?3TP7R&_\  +H#7!;4&0                      5YVW
MSG+-P^HO/T1+J\6VN%LHM+-M29$PY<S432EG0O"HIJ0?;V:06BPP(@/?7,\I
MQO=?92R6*Z/0;5D-WEQ[U%:,B1*9;=@DE+E2/@1.+[.^"PGP$
M     8'*,WQ#"8\>5E][AV2-*6;49V>\AA+BTEJ-*3695,BX@-7_ '^[*?/Z
MQ^_F?N@6A^_W93Y_6/W\S]T!1LN+9UAN;MR7</OL*]MPC0F6N ^A\FE.$9I)
M6@SI72=/J C80   <L>K[Z1.9?FSY*B W#J<#
M         ")-U>F_;'=^;\<9)$DQ<AY*8Y7>WOFR_P MNIH)2%DXTJE>U3>J
MG"M* M53]R^C*9M\P>16'<"UQX;*M<?X^>*RODI-*):?U+0M=>S^;!:L/L-U
M$;O6W<C&<&NV1N7['[G=8UKE,S31<5$B2ZEG6U*\)RB=52^^&GU 68=(P8
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M +#!] /FVR;RX?P1@%E;4&4<[^^93/O(<[VE0+#5ND'Z.V&_G/Y5E@2F\$
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M!&H^X0"-TYCNON:9M[=V<\*Q)9D1YCD\=1W%]I1$9.6^U*H9$9'5+DQ22_\
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M4329]NSQFLNFUDN*KO9;==E-DTJ?%8E&T1ZB0;S:5Z:T*M*T'<OFSW@
M                #ECU'_27R;RG!^#Q@;AU.!@
M                      !A,QL<7)\1O^-SG_%H5XMTNWR)/#[TW*86TI?&
MA>"2M0"C?2QN=BFQN3Y=M[N#+BP_'GVG(V1Q7$RX+BHJ5D23?9UU;6E>MI78
M1ZB50SH#4IXW7ZH-EX>W]^9ME\BY+<I\-^#$LT4EN<YR2VILN89I)*6RK59F
M?9P*IF1 E$)=&F5[9;9V._W_ #++[?;;QD#C#,>V..*-UF-"-SPW"2DR(W%.
M'0OM4D?=!973Q#.\/SZ"_<\-O$>\P8SWBTAZ*HU$ATDI7I41D1EP41@RV$
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MRVJ';7[A,O+\]V'':CKD.\MH];IMI2:U54HZJJ?$P5;8$
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M6:4F1 J9K;;;?9[?&M5JC-PK;";2Q$B,()MIIILM*4(2FA$1$0(]0
M     "I66?3TP7R&_P# +H#7!;4&0                    !6;J^N,O((N
M$;+VATT7+.[RPF6:?"T08JT$:EEWB<<0Y_\ 1F"PL?;;?$M-NB6JWM$S @LM
MQ8K*?8H9902$)+U"21$"/4 K-U(>>OI[\N3?;K:"PLR"
M ".=_?,IGWD.=[2H%AX>FSS%8+Y,1_+6!*5 0   !RQZOOI$YE^;/DJ(#<.I
MP,                               J)O=U0;A;=;UQ\!L-K@/V%OXO)Q
M$AEYR5*\=T*7H6AQ))]EH11)^$7&O81J(?SJ,ZJMP-HMQUX=C5JM$BW-PHTK
MGW)F4Z\I;^HSH;,EE))*E/8G]4"(1+Z?.\/Y$QKWK/\ Q\"C:]LNM3=',MP\
M8Q.ZV2Q%;;U<HT"4N%'F(D(;D.$VI:%.3%I+374=4GP("B]8,@
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MZGK)R6?1;'+;X1Q]LS[J.O\ A?\ Z.Q[R9"^#H'8/46<
M      '+'J/^DODWE.#\'C W#J<#
M            #&Y%9VLBQ^ZX^\ZIEFZPY$!QY!$:D)E-*:-1$? S(E5 5 _R
M][/\_)/Z-;_& :J?Y>]G^?DG]&M_C %3_+WL_P _)/Z-;_& *IXV'V-@[&62
MZV>'>';RNZRDRW)#K*8V@D-DVE!)2M=>Z=:]T$F4L@@
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M)6.-=X^69Y<96>YO&5S8MVO9(\6AKXG_ +A!;(H\8B,^!DE3G?68YKU=)X
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ML&V<(K);5]J2GN<QE?J'X2IG$N\D%X+3@@ K-U(>>OI[\N3?;K:"PLR"
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MR9"^#H!AG                      !RQZC_I+Y-Y3@_!XP-PZG P
M                                    ""NK^X3[9L1?I=ME/0Y29%O2
ME^.XIIPDJEM$9$I!D=#+M!801MOUO6+#L%L6+WK'KG=;I:HJ8TFXG*;5SE),
M_"JY578=.(+1M/\ F!X?\SKG[XC_ , %#_,#P_YG7/WQ'_@ HPN8]=>.Y#B-
M_L%KQJYV^YW6VS(,*>4EI)QWY+"VFW2-%%%H4HE>#QX< *)"Z%[M=+OM'>'[
MM.D3WVLBE--.RG5OK2V4*$K2DUF9DG4I1T[YF"2LV"
M K-UU>92/Y<A>TR 6&#Z ?-MDWEP_@C +*VH,HYW]\RF?>0YWM*@6&K=(/T=
ML-_.?RK+ E-X(  #7,]PRU[B8=><(O3TB/:KY&5#EO0U(1(2VNAF;:G$.)(^
M'=08#(X]9(N-6"U8Y!6XY"M$./;XSCYI4ZIJ*TEI!K-*4D:C))5HDBKW &2
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M6[%X[A<2T0FU&M_351$N6ZY4C]B0"5H4&%;(C-OMT9J' C()N/%CH2TRVA/
MDH0@B))%WB(!Z            54W3DV[;C)95RV\W!L$%[)[]$BY%BMZ-J<S
M FW)Y+,FX-I9F17F"(_OK[;AJ2:JJJFH]3ZUZ6T75;[;\T71?;LYK9B)F.R:
MQ.SX][E8=3?CBD;DO[-8[B=EMMVG6+*H^:Y!=Y29.39''>CN\Z2ELD--DW&4
MM#+;39$EIJO!/:9F9F/8-%H\.DPVX<-O+99%(C[=N^9XR\%]\W36=Z3!S&
M             5*RSZ>F"^0W_@%T!K@MJ#(                   #6MPLL
MC8)@^09A*IR[-!?EH0?V;R$'RF_JK6:4%]4!$O1[B$C'MH8^07/4N^9C*>OD
MUYPOOJFW3Y;&H^Z2D(YI?]H8+*?P1 ^=2^J]O++FC;^!C;N'DM'Q6Y<%**4;
M?+3JYE'4\=>JG#L!=B*<RV]ZN\YR7$<JO5NQI-SPN4[-LY1WS;:-UY3*E<Y)
MN*-15812AEW078W7Q_K@_)F(_P#27[N";%AL<5?%X]:%9.EE&2JA1CO*(O\
MW=,XVD\\FN)^ 3FK3Q[ 1DP   8^^WJWXW9+ED-V<-JU6B*_/G.I2I:D1XK:
MG7%$E)&9F24F="XF A+TS=@/R_)_1TSW(%H>F;L!^7Y/Z.F>Y 49_">IK:#<
M+)X.(8M=WY5]N/-\48<A264J\796^NJW&TI*B&U'Q,"B7@0     1SO[YE,^
M\ASO:5 L/#TV>8K!?)B/Y:P)2H"    .6/5]](G,OS9\E1 ;AU.!@
M                        !K67X)@V:Q#:S2Q6^[QVD&279S#:ULH*IF:'
M5%K;[O%"B 4BWHVMZ1+#XP=BSA^S7M-21:[0H\A82HNU*DFJJ3+O.2T@UM1!
MT^9+?K#O-B5NQBZSF[3<;W#C3(R7%1$28KSR6W.>RAQQ!^ 9GI,U=G ^Z"RZ
MP@P          #ECA_TM(7[<._**P;X.IP,             ".=_?,IGWD.=
M[2H%A3WH!\Y.3>0S^%L LM5ZV_/K,\F0/Y"@6'1;"_\ T=CWDR%\'0##.
M                   #ECU'_27R;RG!^#Q@;AU.!@
M                        &,R#';%E=ID6')+>Q=+-+))2(4MLG6EZ%$M)
MFE7=2HB4D^TC*I (^]&S8KYBVS_H+^[!:GHV;%?,6V?]!?W8%3T;-BOF+;/^
M@O[L"IZ-FQ7S%MG_ $%_=@5;WB^)8SA5J39,3M4:SVI*U.^*Q&R;0;BR(E+5
M3BI1D154?'@",R                   "LW75YE(_ER%[3(!88/H!\VV3>7
M#^", LK:@RCG?WS*9]Y#G>TJ!8:MT@_1VPW\Y_*LL"4W@@
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MZ 89P                      <L>H_Z2^3>4X/P>,#<.IP,
M
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M88QMY@EAPMA\Y16>(AAV4HJ<U\S-;SA%W"4XI2B3W"X#[A$4=.VD4
M                           !4K+/IZ8+Y#?^ 70&N"VH,@
M         *L8L1[J=8&1Y*LN=C^U\$K/!/V2"N+FMI9&782B6N7Q[? 3]8O!
M:<$             %9NE[SD[^_M<_P#"YP+*S((      ".=_?,IGWD.=[2H
M%AX>FSS%8+Y,1_+6!*5 0   !RQZOOI$YE^;/DJ(#<.IP,
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M]H+"%]EI-PF;^X=,NREKNDC(XSLY;Q4=5(<DDIPUD9%11J,Z@LNMH,
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M/C?D_&W);\?\4U^+^,:"YG*YGA:-5=.KC3M%1Z@
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MW.YQU<%-/2U52VHNXI#9-I7_ !B,"4O CECA_P!+2%^W#ORBL&^#J<#
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MVG3:G%J<5N7%=S6716)AU<VS;-)=7<+_ /1V/>3(7P= Y+Q,X
M          J]NSN_G^89_)V7V2?;M\JVI(\MRY9:BAF9D2F63,E$2DD=#41:
MS75*=.A2AB^^+8K*771;%9:2]T?8[<U.7/(LPOMSRA\R<?NRW&C-;Q%36HG4
M.N'V%2KU?5'"_NIKN<?SY[&4L>X^YW3MDMNL>Z=X=S#:B\/%%B90_J7-M[RN
MSG*6:EFDB*JD*4OP?"0=4F@^5CRQ>\UE\7>*X25)6E*T*)2%$1I41U(R/L,C
M'F;?T                                          8;+I5T@XI?9MC
M2:[U&MTMZVH2@G5'*;86IHB09'J,UD7@TX@*D[4=<L9UUNP;R6\[;-0HV5W^
M TODDI/ _&8OA+09&7A*:U<?L$D#5&_[I]9>V>$1E1<1>3F.0N()32(+E+>U
MK*I&[)H9&95XH;)1]Q1I,$H^/2=NUGV\C><7;.5,N6QE^$U:HS#"6HK1.H?Y
M[2*D:E%0FS/6M1\0)6+MMKMEFA-VVSPF+?;FC6;42(TAAE!N+-Q9I0V24EJ4
MI2CH7$S,P1ZP                   5FZZO,I'\N0O:9 +#!] /FVR;RX?P
M1@%E;4&4<[^^93/O(<[VE0+#5ND'Z.V&_G/Y5E@2F\$              !^7
M'&V6UNNK)MILC4M:C)*4I253,S/@1$0#EADNZ^\^=9IC6XOC<:9(PQZ8K'I1
M%';)]$FB#<:2<1LC2HD$:>>CZQ#@9-=BQW<LSM>V:'TIU'68//Q61RSNK=$3
M=X?]:+A;5]3^,SMN; _FEU=N^Y<U,OQS';)">N%S)QJ6\A#;C$*.E+2B;0GB
MX2$]W49>$?.B8F*P]6OLNLNFVZ*3&R8[%3K[D7ZSYYFMZF-OQKO+O<Y4B+.-
M'C;,=MY3<9IPD+<27*92AJB%J2E25$1\#'K'4XO\S;NX/O/[?9--&BNBV8C+
MS3S[JTX=_+3XU3?TBY5BV*HW4O=WN<.U8["59WYTM]264%*4F:EQ6HZ:M1(0
MA*4U,UDHB\*H[CI\7QACF^T/F?J^_37]2R3IZ<NSFINYOS4_'OJV1W<%VWYY
MD6[=SQB]P]ILF@VZ+ RF1#<<<;5:B>HZY"9)R4Q#?)_4TXZRGPB,U$DED/-G
MQS=$4>E9;)NW/3"O>9YWF]@W,VMQ9=[Q7$XDYLI-S<<L*KPN[):;4U \;9JI
M+)-$XI;J4-+50DKJD,&.;:U,5DV[TK6+?;"9UT:QG*/&L(S)9?V#DS7B"W#+
M@?BTDS5%DD9D>DV'U&=*T'*>5)P#"Y=9\9R#&[C9<Q:8?QJ<V3-P:EKY3)H4
MHM-5ZDZ3)6DTJ)1&2J4X@*VX5@F%7/<3*['E^=7+)<2Q&7;%6"T7N[1GH,A4
MB(B6:I.AMM4KDO'X!.+4DJ%J)1CJ--T?1:?)YN+#99?VQ;$3[.SV/-=EONBD
MS*U@[=X0   'S>89D(-M]M+K9]J%I)2?6,!"N4[<9CC.8W/--LH%ONELR%$<
M[_B\E_XL<*9$;)AN5#?2TXWX31(0ZTZDJZ242JU(>F>I?2^+K%MM;YQWV;KJ
M5BD[XF*Q[-NSO<O3ZF<5=E8EDMMMOLK8R^9N7G_BL._.6X[)9[%;7ERF(5O=
M?1)>-]]:&^;(=<:;J;:$H2E!$6KM'.]/=!Q=(T\XK+IOFZ>:ZZ=E9I39'".Z
ML^+&?-.6ZJ7![*XX                                           "
MI66?3TP7R&_\ N@-<%M09             'PD38</3XW(:8UUT<U:45I2M-1
ME6E0'P^.K/\ E"-_3-_= 'QU9_RA&_IF_N@'HCRHLM)KBOMOH2=%*:6E9$?>
M,TF8"MO6/>)URQ_%-H;&NEZS^\1XJDEQI$C.(,S6DOL><XRJI\*(5]8L+$V2
MT0L?LMNL-M1R[=:HK$&(W]JS&;2T@OK)20(]X              K-TO><G?W
M]KG_ (7.!969!       1SO[YE,^\ASO:5 L/#TV>8K!?)B/Y:P)2H"    .
M6/5]](G,OS9\E1 ;AU.!@   !0[=KJ_A7QO,=KLFP!NX6;GS+2<AJZ&PZ2XK
MRD-R$ZHCI$M*D)<27VQ=T@:HIX5QGIMZ[2F2X5L<>1*7#U'R3?;2I"7-'9J)
M*U)KWC!I:G:_K#A;?8QC^ 8SM^TS#BZ&9,MZYFMR1)>67-D*),1%%+49JI4Z
M%1)'0B!FCH6#(                      *<]2>S._>=[E.7S ''SQKQ&,P
MRENZIA)2ZWJYA<I3J*<3K6G$&HE$!],W5@1&=91^I\>M?C +6'CZ?++N/<M\
M[7CMYRA^RWC&Y[<NY62[S):'Y34-PE28[*"2XVXHT$=4K4G4@S4DS(C,A+IB
M#   /A,A0[C&<A7".U+AO%I>COH2ZTM-:T4E1&1E]4!X;/C&-X[S?U?LT&U<
MZG.\0C,Q==.S5RDIK3U0&44E*DFE1$:3*AD?$C(P&$@87AUKG'=+9CULA7,S
M49S8T*.R_59U5]\0@E<3[>(#.  #ECA_TM(7[<._**P;X.IP,
M *U]<$I]K:"W0DNJ9@7+(8$2YN)K1,7E2'JJ[E"6T@^/=H)*PWJ#$BP(4:!!
M0EJ%%:0Q&;1[%+3:22@BIW"(B'XMU.6_+ENR9/JNNF;O&9K/Q>UVQ$1$0] X
M[2A'5L1?O==]6W0Z_P#7'Z>]!_\ \?'XW_ZY=!J_]V6T;*]2N]=WW$PG#;CD
M_.QN3<(-M?A>(6Y&J(:TMZ.8B,3A>#PU$K5ZH]]<*8=(09
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MWEP_@C +*VH,HYW]\RF?>0YWM*@6&K=(/T=L-_.?RK+ E-X(
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M(Y=2XM)7K(C51!4J= :X.FH,           Y8X?]+2%^W#ORBL&^#J<#
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MEDMK?)MUMMLR'#:^T8C^*MH3]9*2(<MR(6EZ;/,5@ODQ'\M8)*5 0
M                                !BLGM3-^QN\V.0_XK'N<&3"=E4(^
M4B0RIM2Z&9%X)*KQ,! NTFV?37M*EF?"R6QWK*6Z*._7*XP7'D+[\=OF:&2[
MQI\/OJ,%;WG;NP&Y=J.SYI><=ND4JFPXNY1$2&%**FIEY#I+0?\ JJX]VH#
M].VTF&[7NY:]@V6MY18[T_$-IMMUF0N'XJE[P''(ZS0M2N;75H1P(N $IR!
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MBQF1:3P*3@334E3OBLZX1+M)G.O)2;DIZ3&D2%+<49:5*>7K.G>H-"2
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MNF ]N'YUB6?VQ5XQ"ZLW2"VLV7C;U-NLNE]@\RZE#C:J<=+B".G'L ;"
M                             ^;[[$5I<B2ZAEALM3CKBB0A)=\S.A$
M@W?C<FR2\2B8GA651_URR>[0;+;'K1=2:E0UONZEREE$>2\;;2$*U(2HM9T2
M9\1FZZD529I%4:9IM]E^"XJ[FEOW.S*\+Q=KXVO=MN-\D)8N$&"CFRVT&R;:
MF7%(2HVCJM)'P4E1#AV:B9NI+P6Y9F=J8XNX^\&3I0]B6UQ6^TS&T.V^\Y3>
MHD1!MN$2DN+B6Y,]TBH==)FD_J#G.0V;#+?NTW=9-PW!O=D?MBV.7$LEB@2&
M2:?-23YJY<F0XM=")2=)-)(ZUX4H W@    !4K+/IZ8+Y#?^ 70&N"VH,@
M            A[JH\P&;?U:/\,8!8;3LQYGMOOV:LWP!D$EFLWRB)A.'WS+I
MU#C66$_-4@ST\Q3*#4ALC[ZU407JF A?HYQJ7;]K7LRN^I=_SBXR;U-?<*CB
MVS<-INOJ*-*W2_[0%E88$              !6;I>\Y._O[7/_"YP+*S((
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MC&+K<;39KTK(&(ZOBR)<;9(9B.2E>"T3TAO6A"-1EJ4I9<.[4!\/U!W'*/\
M'A;H7[]?]//U*=;/'_&Z5Y?Q83?+\7KX.DCUTXZM0Z_^YFO<XGG35[,4ZR-F
M[GCMLEY)=I%LR1V.V=VMK-HO$MMB614=0AUB&XA:-1'I4E1U+U1V#E,X75CL
M4KV%^GK/O)Q^_&?P !_#ZKMF*T;G7AW_ %,>O?\ \81 M'Y/JLVHK][1D#GJ
MIQV[$7_6C$!1^%]5>V:?80,C<_U;'-+^6A(%&HR]PV=^LW7BMHN%YL6"V.V,
M7&Z6]//LEPN4R;(?92A;C:DO>*MMLJUI;4G4M95/P1Q\^2;8V/#DNFV-C\/9
M2GI\RZR(;G7B[;?9*W+B.8TX^]=Y$&9$;)]I^$J4XMTFU%K0\V;FGPDJ*E*#
M.#+-U8E,5\W;VW>E5@GY!R7]&I]V'*>>C^>E5@OS>R;]'(]W H_/I68/\W,G
M_1S7XP!0]*O"?FWDWO!C\9 H_I=5.%GQ+&LFI_48Q?\ +* H>E1AW<QC)C+O
M^)Q"_P"680%#TJ,0[F+9,?\ _20B_P"6:!1IF-0+?OTU<=P,U?GR[>_<I\*P
MXR<V1#C6J);I*XB-;$1Y)'*=Y7-<<4I1EJ(D&22X\'-ENBZD.-DR3$TA],7W
M1SS <DR/;.%"9S2TV)V(];;MD&0Q;7,BQ[@P3Q17WI27'9/+42C0LD&I+9I)
M1GP')Q7S=;67FLGFBK<%YYN]<B-;%[VWQQ"R/0V]<YE\=;,^S4:/BY!G]3@/
M*V_+*<[FMH*];]V:&:B/G(L-KM<<RKW$N3Y$[L[A\L!_/U#PJ0_S[KO7DUP)
M14=9_6F/ :77M\&W(BZ:_P 0R ?0MI>F!P]=Q8L]X=.AJ=O5X<N[BC+C4U3I
M3QF8#Q;CX#M1<\&D67;0L-Q[*&GXLJRW)AZ':O%),1Y+J'TO1&75:D:>"3;4
ME?L5<#$F*I1'=WQ_>G++?#Q[+\VVX?QI2VRR"-;KG,AR+E&2HC4PXXIETD-N
M$5'4M)2:DF::I(QX+<%MLU>.W'$35:5&:X0VA*$9%:DH21)2E,V.1$1<"(BU
MCD/(]<#)L;NL@HELO$&;*,C43$:2R\YI3VGI0HSH0#*     *E99]/3!?(;_
M , N@-<%M09              !#W51Y@,V_JT?X8P"PVG9CS/;??LU9O@#()
M*(>LB]SIF+8SM/8U_P#CFX%XCPDH[AQH[K9GJIQ(N<MCZQ&"PL+C]D@XU8K9
MCML1R[=:8K$&(CO-1FTMHKZM$@C(@               K-TO><G?W]KG_A<X
M%E9D$     $,]1N[UQVOQ:#;\59*5N#E<CXLQN-0EZ'#TDX_H5P5R]:$I(^&
MM::U34>/)DMQVS==-(MBLSV1"Q%90]BW39C\@U9%NM)D9EFT_P"_7&3,D/<A
M#BB]@@DJ2I9)+P:K,RX>"E/8/S_UK]PM7ERS;HZ8\<;KJ1-UW?\ -6(B>RE>
M_@[S%HK8CYMLOWE'31B9Z;WMJ_(PS,H7WZW3H,A_E<Y!<"4E2S4@C[-39IIV
MF2NP_'TC]PM9AR1&KIEQS.V:1;=;X<M(FG9,5GM@RZ*V8^79*5NF[=V\;BV*
MZ8YFS91]Q\0?*!?F]*6^>DS4EN024\"-1H4E>CP:EJ*A*(A^@\.6S+9%]D\U
MMT1,3VQ.Z72712:)N'E9  !RQZOOI$YE^;/DJ(#<.IP,    (4ZH\AW-Q3:^
M5D&VCZ(SL-PCO<A+7-EM0%D:5.QS55*30HRUGH,R2>HC3I!85[MG5W):Z;Y5
MODW%;F[4=16&-)6HSD.,/)4:9^KM-3;1*0:CX\TDJ/V0+1.'21D^Z>8;<'?=
MQI:9L!Q[DX[+>;TSWX[-4../.$=%IUEH0HT:STJ-1JJ1@DI_!
M          !13KGF2[SN-@.$NOJ8M#D<GZD?@D]/E^+J69=AFA+14KV5/O@U
M"S>ZF86C8G9V;<[2TW&19X;5KQN%PTG*4@F8R-/V1(IS%EW4I4"*!;%;$9!U
M#W^]W.Y7ARWVR&KGW:]O-G+??FRU*62$DI:"4I5%+<4:N'#[8@:F:-MP^T9#
MTP]3UEQ([GX]:;K(AP)$A*38:EVZ[+)I*W&M2J*9</5[(_"1P.A@F^'2 &0
M         <L</^EI"_;AWY16#?!U.!@               !S-ZV_/K,\F0/Y
M"@;AH^SGT@\2_:6/\* EUJ!@                       !1+_$(_MC _ZM
M<O;(X-0LSTV>8K!?)B/Y:P24J @
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MR+/_ $E)^Z!#T#>G+\BS_P!)2?N@#T#>G+\BS_TE)^Z /0-Z<OR+/_24G[H
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M$?VQ@?\ 5KE[9'!J%F>FSS%8+Y,1_+6"2E0$
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MN)O'CUQS*X83:[3>Y\ZTSV[5=+C%MSKMMC27&T.T=D$>E*22XE2E&"I$!
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MY>V1P:A9GIL\Q6"^3$?RU@DI4!
M     1]OE9;'D6T^46?)+TG';)(BI.7>G&C?3&2T\VXE1M$I)KJI))TDHC.M
M"X@L*?8IT7XAF]@7E&+[N-3L?:6ZVY</B);+25,$1N5-Z<@R))'Q/L!:O7CW
M1!BF6M//XKO);KZQ&42)#MKM[$U#:U%4DK-BYK))F781@59C_+R_]Q_^"?\
MF %4Z]/?3\WL/%O[!9 =_=OKD5:G/%#A):3$2Z1$2/&'R,SYIU/@"3*:@0
M                 !6;KJ\RD?RY"]ID L,'T ^;;)O+A_!& 65M091SO[YE
M,^\ASO:5 L-6Z0?H[8;^<_E66!*;P0               !5W-)TS%RWRP.98
M[G<K_N*IR3ARX<"3+CSTW6S1K43*I#3:VFO%GF5<SG+3I;\(N!@JQ^.6UVRX
M]:;.^[SW[?"CQ'7BK1:V&DMFKCQXFFH(R8           *MY:Q;[1N!<9.T<
MW+F-U;MD<)RZV-46X)QM]"7&&9<B4;T=,4X_BB%&EU#QJU:=/'@"K2 @
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M2:D=#+OD"P\/3-$B1MC<+<CL-LN2+>AQ];:$H4XO6HM2S(BU'ZI@2EH$
M<L>K[Z1.9?FSY*B W#J<#    #\.NM,-+>>6EMEM)K<<69)2E*2J9F9\"(B
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M%*/N<3,J@CEWAJ4HZL8*$))*$YNX24D5"(BN*Z$1 WP=3P8
M   <S>MOSZS/)D#^0H&X:/LY](/$OVEC_"@)=:@8
M    42_Q"/[8P/\ JUR]LC@U"S/39YBL%\F(_EK!)2H"
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MA_!& 65M091SO[YE,^\ASO:5 L-6Z0?H[8;^<_E66!*;P0
M
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MB,J$HS29I)2UT51*4HK]ZZ)T;#TO31@Q[>-UW&Z[M_A'"'2YLLY+JRM8.]>
M     1SO[YE,^\ASO:5 L/#TV>8K!?)B/Y:P)2H"    .6/5]](G,OS9\E1
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MWQ6HQN'WUFVDC5_SC 9F3&CS([L26RB1%?0IM]AU)+;6A944E25$9&1EP,C
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M >_IZWXM._.'G?(T-=LOL+2F]6RCJV6%NN.DURGW&VTNDI#6H]'L3.A@)>
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MWZ/BNX&.Y-89]BDNQ;DDS<F-N<IMQ*UHH499<Q)I4A23,J*(R,P9JZ+ R
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M(_EK!)2H"
M                K-UU>92/Y<A>TR 6&#Z ?-MDWEP_@C +*VH,HYW]\RF?
M>0YWM*@6&K=(/T=L-_.?RK+ E-X(
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MGPJ7$$6$                      %2LL^GI@OD-_X!= :X+:@R
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MEO>(TI=DM&2O&32=.*3^^JX>S-":GRS(&MRVH,JS=+WG)W]_:Y_X7.!969!
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MC'Y)2[-=6$R8CZ>ZA?:2B[BDG5*DGQ)1&1CSMLL
M                 -#WI@YE<MKLD@[?+D-YB]'05K7">*+))9/(-?+=-2-*
MC02J'J(%A1?]WW7!^&9=_P#;"O\ '0:V'[ONN#\,R[_[85_CH&P_=]UP?AF7
M?_;"O\= V+-]*5@WML4#*$[ROW-Y;[T,[,F\3CN+J22E[GFA1OO:4G5OAPX]
M\&96)!                    %9NNKS*1_+D+VF0"PP?0#YMLF\N'\$8!96
MU!E'._OF4S[R'.]I4"PU;I!^CMAOYS^598$IO!
M               !J^2;=X=EU]QW)<CMOCUYQ1]<O'WU/OH1&D.:-3A--N);
M6K[VFAN(52G !M #S7"!$ND"5;)[9/09K+D:4R9FDEM/)-"TU29&52,RX& Q
MF'X?CF XW Q'$H16[';8E:(,(G'7N6EQQ3JBUO+6LZJ6H_"48#.
M                                *E99]/3!?(;_ , N@-<%M09
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MD.=[2H%AX>FSS%8+Y,1_+6!*5 0   !RQZOOI$YE^;/DJ(#<.IP,
M                        *@=3NQ.]V[&;%(QF8B1@[4:/XK:Y-P4S';EM
MDLG'/%S\#6>H_#I6ATKW :B4+M='/42RVEIE41MI!42A%TTI(O4(@6K<-K>E
MO?O%]QL7R.\R6&K1:[E&EW!2+B;RCC-.$IQ!(IX6M)&FGJ@E5]P9
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MQ@"B=NEGJ+W WDS"\V++FK<B% MIS6#@L.,KYO/:;\(UNN5*BS[@,S"UP(
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MX2'+.]#;B>(,K8(TR$NFK5K<<K[ J S,+$@@
M     ^,N7&@1'YTQU+,.,VMZ0\LZ)0VVDU*49]XB*H"C>7=?MX1>I+.#XQ#7
M8FEJ1'E75;RGWT).A.&VTILF]7VM5'ZH-48'T_MR?FS8_6E^[@464Z:=Z<OW
MGM5\N>4V-BT-0'(R;<]$;?0U(0^ETUF1O*7JTF@O8GW0283H"
M         *S==7F4C^7(7M,@%A@^@'S;9-Y</X(P"RMJ#*.=_?,IGWD.=[2H
M%AJW2#]';#?SG\JRP)3>"
M                                             *E99]/3!?(;_P
MN@-<%M09            5GW0W]R+*,B<V@Z>F2O.9.DIN[9*BBH-K;2>EPTN
M&1HU)[%.'5*3HE.M9T(M&];*;!8_M)&>NLIY5^W!N>IR]9-+JX^MQT]3B&C6
M9J2@U5-1F>M9\5'V$0F7XZJ/,!FW]6C_  Q@"&T[,>9[;[]FK-\ 9!);P
M          T'>3=&U[0X%<<ON&AV6V7B]H@K,R\:GND?*;X<=/ UK,NQ"3,%
MAH'3#M?=<:LD_<K.35(W)SI?QA<GGJ\V/$=/FM,4/V)J,^8M)4IX**> !*?0
M0 5FZ7O.3O[^US_PN<"RLR"       CG?WS*9]Y#G>TJ!8>'IL\Q6"^3$?RU
M@2E0$    <L>K[Z1.9?FSY*B W#J<#
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M(@$W+APH\=Y)+EMI41+;0E15(Z'Q!8:3_A[_ -CYY_6;;[7(!971!D
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M?>6P;J[BYA!R-RT-28[JDJ?5*4T]#D1VTIU,H31*W]7$^RH)5:H$
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MG?KJEP%O!C7*LMKE6Z&U--M;9OHBRU39+Z4+)*B0AO50E$1^ 9]A@<'0P&0
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M7#9^[R<@ZAL4OTU"&YEUR9B=(0R1I:2[)E<U1()1J,DD:N%5']4%EUH!@
M            !S-ZV_/K,\F0/Y"@;A9S%>CK8R;:+->IMIF/NRH<62_&5/D)
M84MQE"U>P4E9$9GW%@S5/^-8KC>&VEJQXK:XUHM+/%$6(VEM&H^U2J<5*/NJ
M49J/NF",N T?>?S/;@_LU>?@#P$*7] /G)R;R&?PM@&I=" 9
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MM,@%A@^@'S;9-Y</X(P"RMJ#(
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M_P DRHN3)7Q=?7V^$M7&G<*B2X$0(VT   %9NE[SD[^_M<_\+G LK,@@
M  (YW]\RF?>0YWM*@6'AZ;/,5@ODQ'\M8$I4!    '+'J^^D3F7YL^2H@-PZ
MG P                                A/J&3L%>+9 Q?>>ZL6R5(U/V:
M0A2TW"/4]"G&E-MN:4*I0^8DVU4XD9IX%A"\C_#YM#THGK?GTAJVJ\)++UL0
M\]I/B7WU,EM/9_\ +!:MYV PWIUVXS.;C&)9$5]W5;\8ARUW!*VY+?BQGXPU
M'0;2&TTT'KTFI="/PM-025FP0  %:%[%;V6C<G,-PL.SNU0IF4R5*-R;;O&Y
M#4!"S./&)3A+)*6T$A!Z*:M!&?80+5$.58[O<UU481:KCF5ND;BOV1YRT7]%
MO0B)'B$W<S4VN/HHM1DEXM5/LR[P+P;UU)1LAP:];*[K9&Z5T=Q:8U#R^YPV
M3:0M2E,.*6EM/L2<)$C27 JT*G&@$)IW"WMV]QO;FZY;%R*WSDK@N*M+$:4V
MX[*DO-F3#:$(5KJI1EJX>"53.E#!*-:Z0<-G8=LC:2N;)QYU]??O2V%ITK2W
M)TH9-7^LTTVOZBJ 2E:X8'@UVF.W&ZXS:9UP?,C?ER8$9YY9D1)(U+6V:CH1
M$7$P1S.PAAB+U6VZ-&:0S&9S5;;++:20A"$7!1)2E)4(B(BH1$#?!U2!@
M            !S-ZV_/K,\F0/Y"@;AT6PO\ ]'8]Y,A?!T PS@  T?>?S/;@
M_LU>?@#P$*7] /G)R;R&?PM@&I=" 9                             $
M!=9OF O_ /6;=\,:!817_A[_ -CYY_6;;[7(!971!D
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MZ'K2DS,N/#B ]H"LW75YE(_ER%[3(!88/H!\VV3>7#^", LK:@R
M
M                 #'WJQ63)+>Y:<AML6[VITTJ=@SV&Y4=:D*)234VZE23
M,C*I5+@8#5_W,;/?W?8U^AH'N(%5>>C+;O;_ "G:%^YY-BEGO5Q*\2V2F7*W
MQ9;Y-(:8-*.8\VI6DC,Z%7N@U*S=@V_P+%)B[CBV+6BR7!UHX[DNV6^-#>4R
MI25FVI;+:%&DU(29IK2I%W@9;&     C_=K>+#MG,>5>LGDDJ8\2TVNT,J(Y
M<QU)5TH3W$$=-;A^"FO?,B,M$&X?M+G/4#?HNY^_J5P<59,GL7V_;-;;:6E'
M5*Y*3,E$2B(M6KPW.[H01(,JUT>/'B1VHL5I#$5A"6F&&DDAM#:"TI2E*:$1
M$14(B!E]    0]U4>8#-OZM'^&, L-IV8\SVWW[-6;X R"2W@      0/G6W
M'43>LLN=SPW=!BQ8S(6A5OM*X3;JF$$VE*B-9M*,ZJ)2NWN@J&\_+J?P#+\%
MQ"9NLB9)SJ8] B26H+"41U,+CH-3A*8J9'XP79W@78D/]TO5A_?/&_1[7N()
ML2[D68M[2;6)R7/9Y7*X6.VQV[A*1I:5<+DEI+9DTFA$2GW>PJ>#6O80"*.F
M# [Y<WKMO]N(GF9OFQFY;6EIX0[4JG+Y9'Q3S$DDDEW&DIX^$H"5DP0   !6
M;I>\Y._O[7/_  N<"RLR"       CG?WS*9]Y#G>TJ!8>'IL\Q6"^3$?RU@2
ME0$    <L>K[Z1.9?FSY*B W#J<#
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M(D/N-<#["T< 6J7B(B(B(J$780( .6.'_2TA?MP[\HK!O@ZG P
M      YF];?GUF>3('\A0-PZ+87_ .CL>\F0O@Z 89P  :/O/YGMP?V:O/P!
MX"%+^@'SDY-Y#/X6P#4NA ,@                            " NLWS 7
M_P#K-N^&- L(K_P]_P"Q\\_K-M]KD LKH@R
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M=!%9NNKS*1_+D+VF0"PP?0#YMLF\N'\$8!96U!D
M
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MG*\6E1>6I\E&@J26FC54D*]C4&6Z    Y8]7WTB<R_-GR5$!N'4X&
M                         $%=0_3YC>]C,%[XS;LF<0&E,VZ:HDK2^PI1
MJ)AYNI+4@E:C0I)^"9JX'6@+$JERNAO>YB4;#!VB4Q6A2FYJDMF5:5HXTE?J
M^Q!JJ?NGKI +;._Q\XSJXQ[KDD(E':[?"):H<5U:32;JG'$H4XX1&9)+024G
MQ\(])I,S*U8(          #ECA_TM(7[<._**P;X.IP,
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M3JRI19]P&J+2= /FVR;RX?P1@$E;4&0
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M   Q]]LMOR2R7+'KLV;MJN\5^!.:2I2%+CRFU-.))23(R,TJ,JEQ(!"7H9;
M?D"3^D9GNH+4]#+8#\@2?TC,]U JS^$],NT&WN3P<OQ:T/Q;[;N;XH^Y-DO)
M3XPRMA=4..*2=4.*+B0%4O @   #&WC'<?R)IIG(+5#NK+*C6RW/CM2DH494
M,TDZE1$9EW@&'_=EMM\SK'^C(GN0!^[+;;YG6/\ 1D3W(!EK-C>.XZEY&/VB
M%:42#2;Z8$9J*3AHKI-1-)36E3I4!E    <L>K[Z1.9?FSY*B W#J<#
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M=T*:?,TZVT).AT+A4&H?SH!\VV3>7#^", 2MJ#(
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MUNY=O%,EM>98U:LJLKG,M=WBM3(RC]D2'4DK2HNXI)^"HNX9&0^KNK9@
M                   '+'J^^D3F7YL^2H@-PZG P
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M L,'T ^;;)O+A_!& 65M09
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MR[J]CV]([,UCI\P],VI*4F<XRE1&2B9<N$A3=3,SK4CJ7J&0_7CUB4V @
M                   .6/5]](G,OS9\E1 ;AU.!@
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M,BJ9]T^([=\[9(!H^\_F>W!_9J\_ '@(4OZ ?.3DWD,_A; -2Z$ R
M                      ("ZS?,!?\ ^LV[X8T"PBO_  ]_['SS^LVWVN0"
MRNB#(                             Y([+;WY!LA=+I=<?MT.XO76.B*
M\B?S32E+:]9&GE+0=:]\&YA,WI_;D_-FQ^M+]W!*'I_;D_-FQ^M+]W HLITR
M[X7[>^Q7VYW^VQ+=(M,MJ,T4'F\M:'6]?'FK6=2,NX8),)T!
M        %9NNKS*1_+D+VF0"PP?0#YMLF\N'\$8!96U!D
M
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MY);6234ZZC2:EDE9$M9U=452UEI.OM&'+;ELBZW=+X+U#09=#GNP98I=;/\
MZ3'=,;70.%!AVV&Q;[=';B0(R$M1XS"$MM-MH*B4H2DB(B(NPB'F=:^X
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M%DLUNQVSP+!:&2C6JV1VH<)A/$D,L()"$U/MH1=H^B.O>\
M         '+'J^^D3F7YL^2H@-PZG P
M   HQU)'DVRO438]][9;O'[/-:;;<-54LJD-Q50GXRUI(]*E,46VI5>/81Z#
M(&H:%=>IC&KIU%XUO4=FG,VBSVU<&5;-3*Y*GEQ9C-4*U$DTDJ0GB=#H1\ 6
MCU6C*[_U2=3>+7QFUJA6.QO1'_%24IQ,:V6Q\Y2U/.))):W7#-%2(N*DI[E0
M3<Z- R  #1MR=W,$VEB09V<3UP6KFXMB&;4=Z2I:FDDI5>2A5"(E%[+O\.Z
MK2YDUMZH.H/"KEARD1L1V\=1<I$Z:ZTQ.ENM/(DD3,12N:;>MEM.K3PJHU4\
M$C-;FT=25,BWRV1PF61+M"KBNY2XZ^+3QH>9HE9<2.B6EI[/LS[X)"R>36:/
MD6.7>P2VR>C72'(A.M*I129#2FS(ZD9?9 BO?0M='[ALF]$=49MVJ]S8;!&=
M2)"VH\HR+O%J?48++4]W^LK)MMMQ[]A$'&8$Z+9W6FFY3S[R'%DXPVZ9F2>!
M4-= 6BKNTEX=R+J+Q?('FDLO77*&9[C*#,TH5*E\TTD9\3(C50%=9@8
M           >:1;X$M9.2HK+[A%I);K:5J))<:541\.(#EUA_P!+2%^W#ORB
ML&^#J<#  T?>?S/;@_LU>?@#P$*7] /G)R;R&?PM@&I=" 9
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MB                     K-UU>92/Y<A>TR 6&#Z ?-MDWEP_@C +*VH,@
M
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M*X<2*O= A9X$                         '+'J^^D3F7YL^2H@-PZG P
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MQ5V&*>:UG_\ ,-_]N/\ C?\ Y>/,\E#_ ##?_;C_ (W_ .7@4/\ ,-_]N/\
MC?\ Y>!0_P PW_VX_P"-_P#EX%#_ ##?_;C_ (W_ .7@4/\ ,-_]N/\ C?\
MY>!0_P PW_VX_P"-_P#EX%#_ ##?_;C_ (W_ .7@4/\ ,-_]N/\ C?\ Y>!0
M_P PW_VX_P"-_P#EX%#_ ##?_;C_ (W_ .7@4/\ ,-_]N/\ C?\ Y>!0_P P
MW_VX_P"-_P#EX%#_ ##?_;C_ (W_ .7@4/\ ,-_]N/\ C?\ Y>!0_P PW_VX
M_P"-_P#EX%$M[ =4'[\\DN>/?JK\0_%T'Q_QGXP\=UT>;:T:/%6*>SK74?U
M286$!     !XX5HM5M6\Y;H,>&Y(/5(7':0TIQ15.JS01:CXGV@/8
M                  K-UU>92/Y<A>TR 6&#Z ?-MDWEP_@C +*VH,@
M
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MEN'Q)3E$5-+= :W+;@RK-U(>>OI[\N3?;K:"PLR"
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M/O/YGMP?V:O/P!X"%+^@'SDY-Y#/X6P#4NA ,@
M     *\]76&WJ[X;9<^QEA4F_;?7)%[2PFIFJ(@TK?,DEVZ%--N'_%2H28K%
M#?L93;W</'-R<=CW_'Y*5ZTI*9"-1&_%?,JJ:=21U(R/L/L47$N ZB^R;)I+
M@76S;-)9V\WNTX[;9%XODQJ!;(J36_*?42$)(O5/M,^X1<3&8MF9I#,157_:
MO;BQ=2^?Y9NIG=E<E;>MH19\6BNNR(9O*846IXE1W&UGH(CU>%IU.&7$T\.V
MQV<MM'866\L43-Z(/3M\S?\ B=U_&QY&JGH@].WS-_XG=?QL"IZ(/3M\S?\
MB=U_&P*GH@].WS-_XG=?QL"IZ(/3M\S?^)W7\; J>B#T[?,W_B=U_&P*GH@]
M.WS-_P")W7\; J>B#T[?,W_B=U_&P*GH@].WS-_XG=?QL"IZ(/3M\S?^)W7\
M; J>B#T[?,W_ (G=?QL"IZ(/3M\S?^)W7\; J>B#T[?,W_B=U_&P*GH@].WS
M-_XG=?QL"IZ(/3M\S?\ B=U_&P*M*W>Z7MB\7VOR[(K%BOBEYM=JE2X,GXPN
M3O+>:;-2%:')2D*H9=BDF0%4-] /G)R;R&?PM@%ET(!D
M               !6;KJ\RD?RY"]ID L,'T ^;;)O+A_!& 65M09
M
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MN7BMFR67/?QZ=<H\>Z-/62+';.,XLB<-3C<-"D$2:GJ)1 E(= 09
M  !RQP_Z6D+]N'?E%8-\'4X&                 !RQP_Z6D+]N'?E%8-\'
M4X& !H^\_F>W!_9J\_ '@(4OZ ?.3DWD,_A; -2Z$ R
M           &1&1D95(^T@%?,SZ1<$OEZ=R?"KI<<!R!\S4\[8W.7%4M1U-7
M)(T&@Z]QIQ"?XM>(DQ4\6)MO1K8IL]F;N5FU_P X:C*);,*;(6TP9EW%FIQY
MRE.'@.("+8C<12-RQUKM=MLENBVBSQ&H-KA-I9B0XZ";::;05"2E*2(B(A1Z
MP                   1SO[YE,^\ASO:5 L*>] /G)R;R&?PM@%ET(!D
M                            !6;KJ\RD?RY"]ID L,'T ^;;)O+A_!&
M65M09
M                     >:X3XEJ@2KG/=)B#"9<DRGE>Q0TRDUK4?J$1&8#
MF9F^;7G?#)I&:90MP[ VZZUC%A-1E'CQ$+-)+4E)T4XHR\,S]DHN/@$E(Z37
MZZ<<\EF_C/8^G>D/2MFOB=1J*^5$TBW=S3QK/Z8[M\\=FW'G;K<;11SA1SCD
M9J)DV6^61G7B2:4+M[PZ'^YRUKS3[WV&[T_TZZSDG!CI_ABO^;?7OK5[L-W*
MR[82Z.7S#%IDX]<"4S<<=FN+5!\86DR:>(B41I,C(JJJ1_8ZJ**GL>@UDYOE
MN^J/B^)^KO3-O3+XRX:^3?--OY;M]*\8GAQV37MFQ\'I[W6WCDL7[J(RUQFT
MZB?C858UI1';+M(EK1J:(R[*IYBS+_:$.V?/JK&89@6';>VHK-AEFC6>!P-Q
M,='WQU22H2G7556XKC[):C,&6Q@    *S="OF4D>7)OM,<%E9D$
M         !7KJ1W8O5L.!LYMGJD[HYA2.DV%47;X+M24\I1>P6HB5I5]@@E+
MX434L)$V9VGLNSN$Q,5M>EZ:=)%XN.FBY4Q9$2UGW225-+:>XDN_4S$I!!
M                           !RQZOOI$YE^;/DJ(#<.IP,
M                                     .6.'_2TA?MP[\HK!O@ZG P
M                .6.'_2TA?MP[\HK!O@ZG P -'WG\SVX/[-7GX \!"E_0
M#YR<F\AG\+8!J70@&0
M          !'._OF4S[R'.]I4"PI[T ^<G)O(9_"V 670@&0
M                   %9NNKS*1_+D+VF0"PP?0#YMLF\N'\$8!96U!D
M
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MU2]U<P(Y$E4@B)<&&[12&"3]@M223K25-"22V1%I.HE8($
M                !RQZOOI$YE^;/DJ(#<.IP,
M                          .6.'_2TA?MP[\HK!O@ZG P
M     .6.'_2TA?MP[\HK!O@ZG P -'WG\SVX/[-7GX \!"E_0#YR<F\AG\+8
M!J70@&0                                                    !
M'._OF4S[R'.]I4"PI[T ^<G)O(9_"V 670@&0
M        %9NNKS*1_+D+VF0"PP?0#YMLF\N'\$8!96U!D
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MX9$2UT-;CCBSHAMM">*UJ/@1%]4Z$1F"(,],:PQFX]ZO. 97:\'EJ2F-D\F
M115)<.B%UU:#(^WP'%'WB,%HL/9[Q;,@M4*^664B;:;BRB3"EM'5#C+J24E1
M5H?$C[#X@CV@.6.'_2TA?MP[\HK!O@ZG P                 .6.'_ $M(
M7[<._**P;X.IP, #1]Y_,]N#^S5Y^ / 0I?T ^<G)O(9_"V :ET(!D
M                                               1SO[YE,^\ASO:
M5 L*>] /G)R;R&?PM@%ET(!D                               !6;KJ
M\RD?RY"]ID L,'T ^;;)O+A_!& 65M09
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M #1]Y_,]N#^S5Y^ / 0I?T ^<G)O(9_"V :ET(!D
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MX?P1@%E;4&0
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M:E9 \\E*92KL1$3Q/$DSH2?!)HJ_S>D^Z9G]+=?*<00
M                <L>K[Z1.9?FSY*B W#J<#
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M+BE15XI41&0,,R T?>?S/;@_LU>?@#P$*7] /G)R;R&?PM@&I=" 9
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ME)*:@B-/JZ34!"<016;KJ\RD?RY"]ID L,'T ^;;)O+A_!& 65M09
M                                                          %9
MNC7^Q]Q_VNF^UM@LK,@C"97F&+X-9WK_ )==8]HM+/LI$E>G4JE="$E52UG3
M@A!&H^X0"M$W=W>/J#EO6#8BVNXO@Q+-B?GUS2;3JTD>E7BU*Z3[:$WJ<[#,
MV@:2CM)TXX)M4HKQH7D&;NU7+R:YD3D@W5\5FRE1J)JIUXD9K/NK,$JF$$
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M*TN,N8Q>%MN(,E)4E5O>,C(RX&1D!"F/0#YR<F\AG\+8!J70@&0
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M??EJ3D=SDE21 <.E8:&S_FTD1)XD1$M---$$DB)*R8(JQTL^>'J(_:5/P^[
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M#)J\Z2E)3HCON+XDA7'30&JK?] /FVR;RX?P1@$E;4&0
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MR_-GR5$!N'4X&
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MIAF?T;LA_8>9\D+!E4OH!\Y.3>0S^%L LNA ,@
M                             !F1$9F="+M,!4[>/J";W B9)L_M!CLG
M,YTV(];KK>XZR:M\4GB-I2D+,C2Y0ZD2U*0@_L34,W71&\F8C;*%MG[7O%TS
MWV?FEXV^?O-GF0_$IZ(DN.ZZRSS6W5.$494@_!T\=2-/JEVC%N6V=TI&2V>*
M\VV6Z>'[MXZG),/EF['2KE3(;Y$W*BO4KRWFR,Z'3L,C-*NX9CRJW0
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M@%A@^@'S;9-Y</X(P"RMJ#(
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MW-#B_7,>Q=(NFET<-GXOB'[CXL<9L-\?5=;=$^$3'+]]SI@._?(@
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M;Q.ZLRN5$A-/ID$['Y:5<PU)6NGA&I-/4!&_ @
M ##Y!B6*Y:RS'RJQ6^^QXZC<CM7.(Q-0VM14-2$OH623,N%2 1%O;M1M;:=H
M<VN=KPBP0;C$L\QZ+,C6J$R^TZAI1I6AQ#1*2HC[#(P6'CZ?]J]L+SLSAETO
M&%6&X7.5;T.29LNUPWWW5FM1:EN.-*4H_5,P)3/CV'XEB*'V\4L%NL3<HTJE
M(M<-B$EU3=22:R80C4::G2O94$9H   '+'J^^D3F7YL^2H@-PZG P
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MG=="Z&9_1NR']AYGR0L&52^@'SDY-Y#/X6P"RZ$ R
M                                 @WJVS2XX7LM=5V=Q;%TOK[%DCO-
MG1Q)2]2G=-..I33;B2IQ*M>X"P_&V> VK;?#K=C-L:2EQEM+EPD$1:Y$Q9$;
MKBS[M3X)[R2(NPAT^2_FFKK[[N::MN'C80+:H;6T/5'C_P"KR2B8QN7&D1;K
M;&BHRF:P2EI<0@N!??.6?9PUKIP,=I@OFZW:YN*ZMO@N".0\H
M                   *S==7F4C^7(7M,@%A@^@'S;9-Y</X(P"RMJ#(
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M[ZO7=5EC)?6-RX(]Q<0
M $<[^^93/O(<[VE0+#P]-GF*P7R8C^6L"4J @   #ECU??2)S+\V?)40&X=3
M@8                                                <L</\ I:0O
MVX=^45@WP=3@8                    <V^NKSUQ_(<+VZ0#<+H9G]&[(?V
M'F?)"P95+Z ?.3DWD,_A; ++H0#(
M                   "$NJ_!KEG>S%VBV9I4B[V=YF\Q([956YXIJ)TDTXF
MKE+<-)%Q,RIW06&/VIW&M6YN'0<@@/(.X$VAJ[PTF6N-,)/WQ"BX&1&=5(.G
M%(ZC)9-DT=??;RS1NQF22-2CH1<3,^PB'B80'CTM&\W4_9IN/GXUANV<9YZ=
M<VZFP[/D$M"4(67 ZKT:?MB:695(=I@LFVW:YV*WEMV\5PQR'D
M                    !6;KJ\RD?RY"]ID L,'T ^;;)O+A_!& 65M09
M                                   !C[[>K?C=DN60W9PVK5:(K\^<
MZE*EJ1'BMJ=<424D9F9)29T+B8"$O3-V _+\G]'3/<@6AZ9NP'Y?D_HZ9[D!
M1F\0ZH-G,ZR2!B>-WA^3>[FM3<-A<*4RE2D(4X=5K;))>"D^TP*)B!
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MS!K#$QG%+>W;;+"(R8C-5/BHZJ4I2C-2E*/BI2C,S':/"S8
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M9#^P\SY(6#*I?0#YR<F\AG\+8!9=" 9
M                        %=LXZ4[7-R%_--J<BE;?91),URT04\RW/J,Z
MG5A*F]&H_9$1FC^)428B=Y-)WM==Z9=X\K+XNW"W=>>QU="E0K3%)AR0V?LD
M*41M)(O]=*R_BC$8[8W0S%ML;H6!V]VZQ/:_'&,7P^"4.W-'S'G%'KD2'S(B
M4\\X?%:U4^H1<$D22(AY&FU                                K-UU>
M92/Y<A>TR 6&#Z ?-MDWEP_@C +*VH,@
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MD<LN8Y%;4HU%P\,S.JS[JJCW)^9Y;X"     "LW1K_8^X_[73?:VP65F00
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M1TM.NM/&I*6H[)DLC921'J[#/@!5, (
M            *I=0*4WWJ1VBQFZIU6*.Q,N;2%E5I<M',<(C*E#/5&:X>KZH
M\669BV:,WS2V4S#J'7@"&-EVBL75=N78;4>FSW*S1[M-805$(G$N*9:J<-2O
M&7EE_K#ML,ULAS\<UMA:X>9MJNYL.ZW#;;,;?8D.N7N58[FQ;6XYFEY4IV(Z
MEHFS(RHHUF6GCV@.;?[H.J;\C9+[Z<]V!O8Q4SIYZ@;A)7,N&&W>5+<IS)#]
M'7%:2))54I9F="(B JZQ@P
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M^@'SDY-Y#/X6P"RZ$ R
M                                                *S==7F4C^7(7
MM,@%A@^@'S;9-Y</X(P"RMJ#(
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MEG8L&*VR/:;1'*C46*@D)KW5*/M4H_LEJ,U'W3!EF
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M=*X=O09J;;,CXI->HO /BE*$$?A:B':1%(HYU*11884
M                             !6;I)_MC>+]KI7MCH++'=23J,=WXV0S
M"8HF[5X^Y DR%\&FJOL$:E'PIX+YJX_:GW@(64RF^1<9QJ\9%-=)B):H<B:\
MZJE$I8;4OL.E>SL[H(@/H=LDBT[(%-?0:$7J[S;@P:OLFTI:B5+U-4=0++(9
M_P!'NV>XV873-;Y=;['NMW6AV2S"D0T1TJ;:0T6A+D-Q1%1!=JSX@54CVRM$
M;'^IBP6&$M;D.U9:F#'6\9*=4U&FFTDUFDDD:C)/&B2^H#3J\#
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MR9;C&2R[K!L%VBW*79)!0[LS%=2ZJ/(-.K0O29T/M+_6)2>U)D1&9
M                    !6;KJ\RD?RY"]ID L,'T ^;;)O+A_!& 65M09
M                          &NYKGF([=V1S(<SNK-IM2#T)<>,U+<<,C,
MFVFT$I;BS(C/2A)G3CV (!=ZX]O%.J5;,6R6X6Q!F1SVHC!(423HHTD;_9_K
M:?5H,3?;$TF7EC%?,5B)HEO;#?';?=UA9X?===R93KDVB6@X\YI/VQMJ,R4G
MB55-J4GN5J-O'1(H( -0R[=3;G T*/+LGM]J=253BO/I5*,OXL=&IU7_ #4
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MCR_:M=CC\J5CUHDSJG.>A1G).K@KFK:2:Z^K4S'Z/= R8
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M2BUM$\I:6CH7^R2D"5BP0
M       $<[D[>YIF<Z#*Q;<*X88Q%:4U(BP8[<A#ZU*U$M1K6@R,BX J*\=Z
M5\UQ)VY/8WO%=;:[>)*IUS4Q;V2-^2LS-3BZOGQ.I@53!N?M3C6[6'*Q#*^8
MM*30]$N3.E,F/*;2:2>09D::F1F2DF5#(S+O&1$/N=*V8WJ$SC>:[QWN^X*T
M;9+L28Q1UNM,J(VT.2%R7M1)(OLFSXT/A0@6JQ=DLMKQNSP;!9(R(=HMK#<6
M%%;KI;9:224EQJ9\"XF?$^TP1[P'+'#_ *6D+]N'?E%8-\'4X&
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M0@(N,K;G(KE=LNDQ$%>X=U;\36TPEPJ&F.V2FZ$HR\(GG:5IJXT!F5K00
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M?;_2?I>.D8YNR3%V:_?,;K8_3'MVS.RNSL=3J=1YD[-R[(][<$
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MVE0+#P]-GF*P7R8C^6L"4J @
M                  .6.'_2TA?MP[\HK!O@ZG P
MYM]=7GKC^0X7MT@&X70S/Z-V0_L/,^2%@RJ7T ^<G)O(9_"V 670@&0
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MJ=WL.WAL"KYBKZTNQU$U<K7))*)D1TRJ274$:BHJAZ5I,TJX\:D9%SGJU&^
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M^$5GV.AG3YC\W%]EL+LUQ0;4YNW(??:65%(5,4J3H47<-/,TF0]U?E^4E @
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M4DN&GP22E1Z4F>HS6I5/N/3]!AT."W!ACELM^U9[Y=/DOF^:RL<.>\8
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M'NK6?YNYFCTQ;*H+KK'B_BR6R62TEX:ZZS4GU@$D @
M                                   Y8X?]+2%^W#ORBL&^#J<#
M                #FWUU>>N/Y#A>W2 ;A=#,_HW9#^P\SY(6#*I?0#YR<F\
MAG\+8!9=" 9
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M2JT;5'>03B%U.G TF1CW1ZVU.^;R;3XWJ*]9I9HSJ/91_'F''R_^B;4I?_5
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MCV;B0B[AW.>V5*%Q_G)$6O$P-@;_ %PWJM(N)8[J(R*AJ=T_8U*JYG^MW?\
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M25I,B.A&?,UT+4K1IJE''GX\<611R[;8MBBVH\K0
M                                           #ECA_TM(7[<._**P;
MX.IP,                    .;?75YZX_D.%[=(!N%T,S^C=D/[#S/DA8,J
ME] /G)R;R&?PM@%ET(!D
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MC.5P;G>YG,\5A,*4;CG);4ZNA&DNQ"%*^L"4;^"
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MN5I?/3S$52MMTB(U-NH512%IJ54J+U>PR'9O"V(
M
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M*-:K,HC3\7VX])T4@S/0M1)2DD'X22(]7A+41=C;;%L4AS(B(BD+(#0
M                         #S7"WPKM E6NYQT2[=.9<C3(KR26TZP\DT.
M(6D^!I4DS(R :%^X+93Y@V/WBS]R"U/W!;*?,&Q^\6?N0*LE8=H=K\7NL>^X
M[B-JM=YB:_%IT2*VT\WS4*;7I6DB,M2%*2?J&"-T
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M[@4?:+U[;<RY3$5&-7M*WW$-)491*$:U$DC/[_ZH%%KP9
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MG[WC_P (%3_+\P_YXW/WO'_A J?Y?F'_ #QN?O>/_"!4_P OS#_GC<_>\?\
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M<"IZ"NRGX1?/?K/XN!5]8W0YLO%D,RFI%[YC*TN(K,9,M2#(RK_N_J 564!
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MA@&V6#[76V5:,$M?Q5;IC_C<EGQB3*U/:$MZM4EUU1>"DBH1T ;:
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MHCJ?VQ&"U;5C6-V7$+%!QG'8WB=DMC1,0HO,<>Y;9&9D6MU2UGV_9*,$94
M            1?F?3MLYN%D$C*<OQOXQOLI+;;\OQZ?'U)903:"T,2&T%1*2
M+@D%JDUEEN.RW'93I9:2EMM-3.B4E0BJ?'L!'[              $5V?IPV8
ML.4LYK:<9\7R:/)5.9G>/7!S3)<,S4OEKDJ;.IJ/@:*>H"U2H"
M                                                         ^$J
M%#FDTF9':D)8=1(9)Y"7"0\T>I#B=1'123XI47$@'W ?!F%#CR)$MB.TU*EF
ME4M]"$I<=4VDD)-Q1%51I26DJ]A< 'W
M
M
M
M
M                                 &)R?);+AV/W#)\BE)A66V,F_,DK
MJ>E)4(B(BXFI1F24I+B:C(B 0.OJLFQ[:WE\[:W)8VVSNE99*M#9J)APZ(>5
M'[C:JE17-TG4J&=2!:)_LEZM>26>#?[))1,M%R8;E0I3==+C+J24D^-#+@?$
MCXEV&"/>         @K+>H]VP[C7K;3'\"O65WJQ-1WYJ[5RUD3<EAI\E$GP
ME$DB>0DS/[(%HW3;3<:_9X[<F[U@MYPXH*65,+O*"0F3S362B;H1<4:2K]4!
M@,^W[B8QEI[?XCC-RSG-V6"ES[;:22EJ&RJAI.0\HE$@U$HC(M)]I5,JE44>
MW:[?&T;BWBYXA<+-.Q3/;,A+UPQR[))+W)5I^^LK*FM!:T<32GV1&1&1U HE
M,$  !\Y$AB)'=E2G$LQF$*=>><,DH0V@M2E*,^!$1%4S 0.UU)W')'9$K;#;
M:^YEC45Q3*[^URX,5Y39T5XL3Q&IVG>\$^^0+1*D?.;:U@B<^R6-)QFW-0SG
M7&)=FS9E1$H(]2'&RJ>JI421<55*A5.@(AE?59-3;?UP+:W)3VU_G#R8T-DK
MQ:M.>4?LY=..KFZ?5!:)ZQS(;/EEBM^2V"4F99KHPB3#DHJ1*;<*I5(Z&E1=
MBDGQ2=2/B",H   "(LWWDRO$\FF6&U[6Y'DD**31MWFVMI5$>-UI#A\LZ'70
M:M"OXQ&"T:W;NIN:YFF-X5D6V]^QR=D\DHL!VXZ$%0C(EN::$9I1J(U&780%
M&X[G[V6C;NZVO%(%HG95G=Y2IVWXY:$$M_DHK5YY1_S;?@J\*A]AG2A&9"C&
M8%O_ !,FS!.W>8XQ<L&SB0RJ5;K;==*VIC*2-1FP\DDZE$25&9:*>"=#,R,@
M*)C!   ?"9,BV^)(GS74L0HK:WY#ZSHA#3234M2C[A$15,! C'4O>;["D9'@
MVUN09%@T=3B2OZ%-13?0RHTK<CQUDIQU)&D^SCW#(CJ0+1*6 ;F8IN/AC.=V
M"2INQK2Z<@Y9$RY&7'KS4/%4TI-%*F9*,J<2.@(BA?5)*NC<V\X-MID.481
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M]C?*)?<?N;9,S8;QZB(EI(SJDS0LB/@=4F1D1\ *)#!
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M6J1<\0E.&["6ENXVV8@F)L9:ZZ>8V2E%15#HI*E).AE6I&!1OH(
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MD.I(T+0X@Z+;<0JBD+2?:DR]7L,C!&P
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M.&DD1K[C#,N8TFB4G(:.*DG*%VG1"O\ I&8'!9D$
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MHV@,,X1UR/6^TZ8T'-K*Y)FQ4>"VI\F%O*5I(J:E+AFX9_QE<>)D"\%LP9
M       &D9[M1AVYDVQR<RCO7"'8''GXUJ-Y2(+SKY-EKD-)IS#1R_ (SIX2
MB,C(P$$["1(D#J<WEA06&XL*.AAJ/&80EMIMM#B22E"$D1)(B["(@:G<DSJH
M\P&;?U:/\,8!(:'LMU+;(63;?#<3N^6-PK[ MD2%,8?B3D-M/MMDE25/G'Y5
M"/[+7I]4"866A3H5RAL7"W26ID"2A+L:5'6EUEUM952I"T&:5),NPR,$?<
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M&F]'6%9%M]L_*=RZ.];7;K<7[NS!D)4AUF)XNRT2EMF6I*E\E2M)\=.G@!+
M]%$5.0VG.MUKFWKR7);_ "&7Y2RJHF$(;E&E!GV)-R0HC)/#P"^U("7EZGF&
M<1WIV9W&MNF-='[G\67-Y/@&[$0_'3I49%V&W(?0HS^Q,B!86S!D
M 8^]0+)<+>XC(8\63:HYIENIG(;6P@XRB=2ZKF$:2Y9IUZC[*5 05OUO-M7<
MMLLAQ.S7F!F&19'">MMGLMD=;NKZY;Z32TYIC&X2>4NCI:J'X/#C0%B&X=-^
M'7W ]F,8QO)4*8O++<B1(B+,C4QXY)=D):/O*2EPM1=Q52 E6OI:WPVNVOL.
M66?.K]\4W&;?GY49GQ29)U,FTVWJU1F'4EX23*AG4%F%S,3S3%,[M2;WB%WC
M7BUJ/0;\59*T+(JZ'$G12%4,CTK(C]0&6=          &@;S;F0MI\!N.5OI
M)^Y4*)9()U-4FXOD9,MD1<3(J&M=/L4GW06%/-R]M)NWV&;8S\E4<C<#*\L1
M>LLFN\7E2Y!I6EE1_P#RB69'W-9K,NT%3=UP9!,M.S;5F@*43V1W:+;WFT$9
MJ6PVAR49%0NZMELJ=VOU02$\XQBUHQ7%;9B%NCH39[;#;@H8-)&A:$(TJ-9'
MP,UG52Z]IF=016GI-2G%MR]Y=M(:Z6.TW?QBU1:G1M!/R&#H5.TVTL)4?\4@
M:E;$&0
M09U9X=?LNVF4_C+#DN]XU<HN018K!*4\YXHEQM>A*3(S4E#RET+B>GAQH"PU
MS(>KK;.Z;<2'L;EO3,]NT%46WXNU%DJF(N<ELVR;51O29(6KBI*CU$7@U,R
MHD?IYP*=MOM#CF+W9'+O*&G)=R:J1FW(F.J?4V9EPJV2R;.G=2!*3P0
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M,#VZVV><O>/6:[LY'EMZ;9=:B1F(9&E+9*=0FJUI6XDN%-2DTKX5"[ELP9
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MX[K-#22UJ:=;9TJ,C,M5.Z#4+AQ%/KB,+E))$I3:#>0783AI+47=[#!E]@
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M*6<@W9WMSR"1.6:;>/%+;+29*2\GQB2ZHTJ+A0T\I?\ SB!96K!
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MUPW#L>P'&X&)XM$*%9;<@T,-$9J4:E&:EK6H^*EK49J49]T$9X
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M'LKB6SUOF,6%4B=>+JLGKQ?+@LG9DIQ-3+49$1)21J49)(N[4S,^(%4C@@
M        (QW@V<B[N'C'C5V<M98W<DW1'+92_P \TZ? .JT:?8]O$%JW7+,6
MLF;8Y<<4R.,4NR71DV);!F:3--24E25%Q2I*B)25%V*(C!%>XW2GFUKMCF)V
M/>>^0< 7K;18BBDIU$5TZK:3(3)01$JIUTM)2=3\'B8+5.>W6WF,[78K$Q#%
M&%,VV+5:W75$M]]]=-;SJB(B-:J<:$1$5"(B(B($;4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                       BC=CJ&V]V:N,"TY:<YRX7
M%@Y3+,".3VEDEF@E*-:VR*JDF1$1F? %HT.-UR;(/NDV[\<1D'_M782327]&
M\M7^@"B7L!W;VZW/8<=PB_Q[HZR6I^&6MB6VG@6I;#R4.$FITU:=->PP1NH
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M<I2J5H=*@,H
M
M
M
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M\P&IATPPG*&,VQ"QY=&CKB,7N#'GMQ73)2VRD-DO29EP.E>WN@PSP
M
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MW!_=K>CN!Y"AZ)'><8C$Y&;<GH;<;)2S6E1^"ZA2M*#[>^"T3("
M"/\ =?>3#MFK7!NV7^-*8N+ZHT5N"R3[BEH3K49ZE(21$7?4"T9S <XL>Y&(
MVW-<;-X[+="=.-XRCE/$;#RV%DI-3H9+;47 S!&R             -2W(W&Q
MS:O%G\ORDW_BIAUI@TQ6^<\IQY6E))29I+UU$ \NUFZN*[P8X]D^(^,E;H\M
MRWOHFM$RZE]IMMTRH2ED9:74&1DKN@-W
M
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M+Z
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M1;T2H_CJVF$.(<?4@S07+2UJHHJ$=0673P&
M
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M?9:2KW@8;"
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MTLKX!  E:<$
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MID"-(D$HBH1DXXVI52IWP&P(0AM"6VTDAM!$E"$E1))+@1$1=A$ _0
M
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MN -;'2@&
M
M
M
M                             !1?JCVLWLW<W>:8L6,2'<5ML:/!M,]3
MK"(JDNT=??6I3G@GK6:3+V6E!< :A=+%\?@XGC=HQBVE2!9X;$"/PTF:([:6
MR49%W54J?J@RRP   ,5D\21<,:O,"(CFRY4&4PPW4BU..,J2DJF9$53/N@*@
M]&>T.Y.WV<9#=LSQZ19[>]:SALO2%-46^<EI>E))6HS+2A1ZB*GJ@U*Z8,@
M
M
M
M
M
M
M
M
M
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>tm2227887d4-fc_antibody4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-fc_antibody4c.jpg
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M .   0 !! ,!               ( 08'"0(#!00! 0 " P$!
M   !!0,$!@('$  ! P," @0&" \*"@4* 0T  0(#$00%!@<A$C%!$PA187$B
M%#>!L3*RLW05=9&A0E)R(S-SE+0U%C88"<'18I+2PR0T5A>"PN)#D]-5978X
MHE.#5"7PX6.C1&2$I(5&)R89\4659E?$U*6&1R@1 0 ! @,& P4&!@(" P #
M   ! @,1,00A<1(R,P5!48%AL<$B$Y&A0G(T!O!2@B-#%-$5X6+Q4Q:2TB3_
MV@ , P$  A$#$0 _ )_
M
M                                                "\.*@4JGA K5
M                         !3F3P@*I6G6!4
M
M
M
M
M              +T 8PW&WAMMO,M!B9\1-D7SVWI/:QS,B:B<RMY:.1? >8J
MQF8\DX,@83(MS&(LLLR-867T$=PV)RHY6)(U'454Z:5/<QA.#S$XQB^\A(
M          %%6B54#P?STTXNHX=*0WK)\[*R21UM#]L[)L3>9>T<G!JTZ$Z1
M&V$3.#WD6H2J      "R-Q]PH-N\?9W\^/DR#+R=;=(XI&Q*U6MYN95<BUZ#
MS-41,1YIB-DSY/0T#K"+76GH]00V;[%DDLL*6\CTD<G8NY:U:B)Q,DTS#Q%4
M3C[%SHM3Q#T$@
M
M
M
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MMDKN"SA7HDN)60M^B]4 ^:RU)I_)R=CC,M9WLW_5VUS%,[Z#'*H'IHM0*@
M
M
M
M
M     $6^\I^E]A\V_P Z\Q4<U7I[GN<H2$T5^A^ ^(VR?^K:;%WF8+?*CAOG
M<NLMU&7J-YUM8;&=K%541RQ+STJG16E##3,Q,X-BJF)H>KB=MM:;N/75^J\I
MZ!97BJ^PA>U97]@J^;V<56MC9X%7B[I,E5&$L--<S#Q->[.9G;^R;J''7_IV
M.@>U)IX6.M[BW<Y:-?1KEX5HG,B\%ZCS]3"7N*,69=C]:W^K]-319>59\OBI
M$MYKEWNI8G-YHW.ITN2BM5?$9:HV1/FQTSX2L[O.U[#32*JHG:7553A]3&:=
M54Q5Z-J(B:)WK4T[I[6^\-M9VLETF-TC@XHK&%SN985DA8B*K8T5.TE7I<Y>
M#46E3:JHC%K4U3@^[4_=WR>&Q,^4PF39DY;6-99K1\782.:Q*N6-R.<BJB<:
M+3Z)CQFE[BF'N]WO7F3O[JXT?E[E]U'%"MSC)9E5TC&L5$?$JKQ5.-6UZ.*&
M;#BIXH8YG"K!E?</5S-$:6O,ZYJ2W+*0V4+NA]Q+P8B^).*KXD->N<,F:B,9
MVHZZ4T3K#>6\NL]F\N]EA$]8WWLZ++654JL4$2*UJ(U%2M*(AFX(B-N;%Q8S
MLR7=?]V9B6JOQ.?Y[I&U8RZMT;&YR="*YCE5OEHIYF7J%K;5ZIU%HC746C\I
M+(F/N+KY.O;"1ROCBN*\C9(EZO.Z>7@Y#W;F*\7BY$TX8>K-FY^W<VXEIC[2
M/(MQR8Z62=7K$LW/SLY:41[*4I4P3L^]FB8PP]L(RZ+T:[5^JOS89>)9NY;A
M?2EC[1/M%57S$<WIIX3+;C&B?1CKJPKCU2GVVT*_;_!3862_2_[:Y?=).D:P
MHU'M:WEY5<[HY?"*JB(83W$W#U'N!J5=%Z.?)\EK,MK&RW<K'7DC>#WO<E%2
M)*+XJ)53';IFK;.6#W7/#&S-[5CW9N:R1^5SZ1Y!S:K';P))"QW@YGN1SJ>&
MB'N</!XC'Q6C>6NN]B-06\D%REQBKE>9G(KO0[MC:<['L6O)(B+Y>M%5!%43
M.$IFF<,82?TUG[+4^%LLYCW5M;R))$:M%<QW0YCJ=;7512*MDHIG&'K)6G$E
M*H&#N\O^CN%^/N^"4PU\]+)3RU/=V 5?[M[7XW=?"*;ESPW-6WG.]9?>=15?
MIM%6E4NTJG#C]K-.>;=#<B(X/5X&!TUK7>AL4]Y>IC-*8ID=E:M<CGQ\T+$:
MO)$BISO^O>Y>O@;-=.W&<V"*L-D/DW V5R&A<3^<-AD4R%A;O8EU2-;>:'G7
ME:]%1RHK4=2O0J&+CX7OAXG9B=:;B[BX[';>XJ9S;QK7_*>55ZQR26C*(WM7
MIQ1&IP=3B]3)-,3N8XG![UYW:+Z/'OELLY%<95K>9L$D"QQ/>B<&H]'JJ>#F
M5#Q.S)[C;F\_8C5^6PVK$T5D)GKC;SM8H[6557T>[@JJ\E:TYN56N1.'6>Z/
MGHQGR8ZOEJP9MW5X;<ZD<BK5;*3C] P79PI;%J(FJ(E&+1-YK'+6C]O](N6!
M^6N/2;ZZ8]T:]C&Q&T<]*JV-/JJ<5Z#/53C$>3#$Q$SO9"N.[/>,L'26V>BF
MRK6JYL+K=60O?2O+S\ZJE5ZZ>P>)V9/6>:Q-';DZKV_9D\':HZ594?;P6<WG
MI:WS7<G.QO'KJBL3@[@3C-5.,9[$1$15AX82OK'=W_4FI(5S6L,ZL&9NT[22
M%S%N96J[BG:/<]J5_@MX(*HB)V(IF<-JQ,ICM4;*ZRA=#=)VC$;/#-#5L%W:
MJM'->Q5\2HY%Z%XHO0IZMU<57#.29IPIQ2]QE\S*8VSR,2_:;R&.X9]C*U'I
M[9YJC;,/-,XQ$HM8=?\ \?J=7RW<>3I<1IYXJ=OE,_>F[LF,/-+%$1.@E+$/
M>,6FA(*</_$(.*?8O,=4_-$;WN(V3+Z.[XU%VYBKU7EUP_PD-BYX;F"B<<=[
M%W> F]'W$LYU3F2&RMW\M51%Y)9%IP\-#!:VU3O;%>$41+[,9H#6V\DKM7:F
MR:8_%7#G?)T3VNEI#S+1(8D5K6LZN95J[I/>&R//Q8HEY6O-E,OH3'KJ'&Y!
M+^PM5:ZXDC8MO<056C7^:Y:I5>E%14/,US#WPX[V6-B]<Y'5FG[K'YB99\IB
M)&1K<OXOE@D:JL5R];DHJ*IEJB,,88Z9\WO;H:_;H'3RWD36S9B\<L&-MW>Y
M5]*J]U/J6)Q\:T0P53..QDIB/%@G2>W>L=WIY=2Y[)NCQ\CU:E_<HLKI5:OG
M-@BJB(QJ\*\$\M#+PQ&>;Q-4SED]W47=TR>*LWY#2V66_O+=.T2TDC["9_+_
M -6]CJ<W@1:>4\XS"<(E[FR.Z63RMW^9>IYW37[&.7&WDWW5_9>[AE5>ES4X
MHJ\5Z%,FRJ,8>-L3A+.Z+6AC>U20
M
M
M
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M:J-6G%5=T&2S3MP\WF[.S%,^O!%,<YIAR)
M
M
M
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M1V6Q5MGEPS+7$0YVUG;"D"Q<CVW"*E&HJHC5=6G0O233,RB8P932M#R*D@
M
M
M
M
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MYJGBG%)-M:)7I/*50
M
M
M
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M*D]AA+"UG3HDBMHF.3R*C:@>SR_1 JB42@
M
M
M
M                                         !2B(1@*D@   *  %.L
M                    @"0    #QD , )   (P 8 2
M
M
M
M                                                       %4\(
M                       J@             %4\(
M                   !2J>$"H
M
M   *53H (J*!4         Z *50!5 /+SFIM.Z9ABN-0Y6UQ<$[NSADO)F0-
M>].-&J]4JH';A\]A=0V29'!9"WR5@KG1I<VDC9HE>SW2<S%5*IU@>@
M     /@S&;P^G[)V2SM_!C<>QS6/NKJ1L,2.<M$17/5$JH'3@]3Z=U-%-/IW
M*VN5AMWI'/)9S,G:QZI5&N5BK1: >J
M
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M(F9P6SH7<[ ;@7%W!A+>[A=8MC?,MW&QB*DBJB<O(]_@/<1L>9G:ODA(
M      <7I5*$#%&2W_T9B<C>8JZL\DZXL9I+>5T<,+F*^)RM56JLJ*J53AP/
M-$\40]3'"^=.\AH6G]2RG^@A_P!>>H1@?K(:$_[GE$\?80_Z\E"X=/;S: U'
M<Q64&0=9WLRHV*&^C6#F<O!$1]595>I.88"_T5%6G6G2!4
M    *]8'FMS^&DS*Z?CO(I,RV%;F2S8O-(R)JHWF?3W/%4X*3$8QBB9VX/2(
M2         *.Z")G8+!W.W'BVXM<?>/QC\DV_DDBY8YFP<BQM1U55S7UJ13M
MKBGS3.RF:O)>F-O$O<;:7SF=EZ3#'/V2KS*WM&(ZE>%:5/<QA.#S$['UD)
M
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M=+$]SN+UB7E7G7CY].H"Q/VDWZ&Z*^<YOQ=P%^_L_P#CW?(/GG(=/_9@2E
M         $8^_JE>[W?5_P!IV*_])X&/OV;'Z"ZW^=K?\6 FZ
M
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M06[XX'45CW(Y\BHM.5R+] GQVH\$CF<RL17)1RHBJB<:+X*GEZ<@
M
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M#=ZK8_4&H+32V&U(EWF[ZY2RM;:."5ROF5W*B(O+T5Z^B@&9D55Z0*@
M
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MRQM1?,5&JC9*]/TS)%6-$8YO-4?-BS,G!$\!XA*I(
M
M              ,)=Z_<EVV&RV>RUM(YF7RC4Q&+5B-<K9[M'(KE1R^Y1B.K
M[ $3/V=FW#\EJO/;EWL*I98:!,=C7OC1S'W5UYTJM>O%'1L:WH^O ^C]HMMP
MZRU#@-S[.!_HV3B^2<G*U&I&VXMT5\-53CS/8KNGZT"4O='W)_O+V3P5[<RN
MDS&&;\CY-9'-61TEHU$;)1O0US%3EKX ,Y@:C^_)P[QFH5\%O8?B[0,D[$]S
M_4&]V*@W)W@SE[:XJ^A;%B+1O&^FMX42*)ZNDJD<2(WS&HWBG$"ZMX.X%IG
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MU J
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M\>'3T@5Y4(B,!4D
M                                                #R@:T_VA^XZ9
MO7N)VYM)FOL],P>E7T:-5')>WS&N1.;H5.RY/(H$H^ZW::%VQV7T[B)\_B8<
MODH4R^4I>PHY9[UJ/3F1SZHYK.1BIX4 [^\W::#W0V:U'@F:AQ#\G90KE,7(
MZ[A>YES9(K_,:U]5<YG/&GV0$3?V>FXZ8#<3*;?W<B-LM56Z36K.6M;ZQ1ST
M\ZO!%C5Z4ZUH!LS;T :D._+_ ,Q>H?BUA^+, V?;2*J[6Z+5>*_(F/\ I6S
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M/
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M .0_XQAT>4_UL^I\/Z4MR7D
M
M   >1JC4&/TII[*:ERLK(,;B;6:\N99%Y6(R%BNXKXZ4 TY8+36K^\WO/D+;
M#.BCSFH[FZR4LMW*]8+:W15>JN<J*]6L14:B(VO@0#./_P";GW?3HU-@:)T4
MEO/_ .G ?_FZ-X*+74V!IUHLMY1?_4 8,U3I#6'=HWAQMGF98)<[I^YL\M;W
M%I(YT$\/.CVJBT:[E=RJU45$7Q ;C=):CQ^K],XG5&*E;/CLO:PWEO*RO*K9
MF([A7CP7@!JH[\O_ #%ZA^+6'XLP#9]M'ZK=&?,N/_%F >_J/]'LM\2N/@G
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M'5:)X&JY0(F_LX=4V5AK75>D9UY;K+V,5Y:JJHB*MD]4<U*]+J2U\B ;(>9
M(P]_:6)O=]O&O>UKGY.Q1C7*B*Y45]41%Z0+!_9L?H+K?YVM_P 6 FGD+*#)
M65UCKMJOM+R%]O.U%HJQRM5CDKY% U"8.*_[N7>AM;29J,BP&;2V<U\RMC=C
M[Q>1BR2-KP2*5'K7P >AN)=W?>1[TT]AAI9<EB,GE8\;CU5R1JW%VBHDJLJM
M$1&MD>WP@;:\=90XVQML=;(J6]G#';PHO3R1-1C?I(!]0
M
M               +4W%U,S2>C\KFN;DN(XEAM.*(JW,WF1T\BK7V#'7.$/=,
M8RP/W=M/KE=57>HIT[2'$1*UCUXUNKJJ5KX4;S+[*&Q$113@Q53Q58I0ITU,
M4/3D2,.=X?3?RII6+/PLK=823FD<B<?1IZ-?7PHU>5?HF&J<)Q]/M9*=L8>K
MQ^[CJIMSC\AI&XFK-9.],LFJJ*O82+1[4^Q=Q]DVJHQC\NQ@C9._:MG=K0^:
MT9JI=>:;8],;-.V][:%.9;6\K5W.B=$;EXUZ.-#!1,TRS51%5*[,+WD< ^Q9
M\NXRY@R36TD]#1DL+W^%M7(K47P+T'N9AXA8&M-:Z@WFS-C@-.XY[+&%ZNMK
M-'<SUD=P6:=S?-:UJ>PGAJ1%N>+&<D\>$80DAHC2\&C]-8_ P.21UM'6>9$I
MVD\B\TC_ &5Z/$>[E6,[&.B,$6K;+3[;[KW.2O;5\CK"]NNUMJ\CWP7/,G,Q
M5X+5C^9*\#Q8JPIX9\F2]MGBCS21V\W&Q^XD>1N,?:2V;<?+'$Z.=S'/=VK5
M<CO,JB)PITDS&QY\4?-O7L7>V%$<BK\I7W7]\%CEG<F]/S0EPG%RKXD(\CQ8
M3[Q^F4O]/V6I865FQ<O873DZ?1KA:(JKX&OI_&,<[*XG^/8]YT3"P]C<3<ZK
MU^_4.25;AF)C[>65W&MP]O9Q)7HX(BJB>(ST;(F?&?>Q5;<(\(]R5*HJGB'I
M&?O$Z2R%MGX=86\3I,;=PQP7,S$KV%Q#5&<W@1R4HOAX'BB>"O'S9*OFIW+G
MTMWA]--P]M;ZEAN;?)V\;(I9+>+MX958E.=O*J*VM.A4,M>&.,,5.,O(U5NQ
MF-R$?HK;K&7-+^L5W>R4;(L+O=)P54B;3W3GKT<#Q53.#WQ1$K.VA5=-[LVN
M+R3FQW4;[O'R)5*=OR.:C4\KDX&>W5$T32PUQ/%Q)+Z[L9LMH[.XZU:K[B>R
MF9$Q.ES^551$\M#5N<K:LU135$HQ;3[D6VW=WDOE&QEN[6_9&US8%:V5DL"K
M2K7JB<4<OC-B*HFW$-::<*L6><YJ2WU;L_E=16T:P07V-N'MA<Y'+'RJYBM<
MJ<*IR\3%>IPAFLS\T,:]V1S79+4-%1?Z/;UI]DXR_A89YY?5WG'-1=.U5$X7
M73Y(S7CGG<S_ ()WPRSM@J+M[I[XG'[:F>O/[&&G)=4_"&7Q,=[2F.7N$4MA
M7-7<]4JG]7O:\?X2'JSTT7YQN?:D/K[2%MKC35W@IU2*=R)-97+N*17$?N%7
MQ+T.\2GBJG&,7JF<)P1QTSK+66R^2NL)EL>K[*1_/-C[A7,C5Z<.U@E1%2CD
MZTJB]?$]4UXT_,\U1%,[%TY?O!9K4$'R-HS!OMLK=IV4<RO])G1SN'VIC&TY
MO KEX> 31,PG'!C/&XC(8+<+%XG*T^4K?(VGI*([GI))(UZHKNM4YN/C,NGF
M)G9Y2PW\O6/>FX8V4 HM.%?#P AS8.9_?;"E4JNHGT3_ .(<1I=E&'L3?VS*
M8S>A"4"]"@85W[T&[,8ANK\=%7)XIG+>HU/.ELZUYN'2L:KS?8U\!BJ^6K'P
M9*-L8>*W.[WK]D4S]#9*=$9*KIL.][DX/7C) B^/W;?9-F?FC%KY3L7=OAMS
M=ZNQ\&<P<7;9O&L<Q]JGNI[9?.5K?"YJU5$Z^*&O'RSC#/G&$L>[>[WW.D,>
MS36J+*:[L[/[5;2QJC+N!B+]SD8^G,C>JJU3H,LS$[?%CX9B</!<.K.\;8OQ
MTUMI*QG;?S-5C+Z]1L;8E5/=-8BN5SDZJ\#Q,3+UC$//V*VXR-QEF:ZSD#H[
M6%'/Q;9T5))YY:HZ>B\>5J*O*J]*KP,L84TX,<[9Q9=W+T4FN-*W&'8YL>1C
M5+C'3.Z&SQ]"*O4CD7E7RF"J/'R9J9P8!T'N/F]I[V[TUJ3&RR6/:*^6Q<J,
MG@F6G,Z)7<'-?1%Z:+THIEIJXZ<9S>)IP7SG^\AA66#TTUCKF3)2-5(I;Q&1
MPQO7K5$<Y7*G4B=)XJV>J8EX^Q^@\KD\\NX.H(WI QTDM@Z=%1]Q<S5YIJ+]
M2VJT7K=T=!FB(HIPCQ>*MM6*[M\MMKW55E;ZAP</;9G',='/;-ISW%JJ\U&^
M%[%JJ)UF#EGBC-DSC!8>WV^D^E;!FG=4V4MY:VGVJVN(O-N86-6B1R,DIS(W
MJZTZ#+CQ1BQX8;'MZM[QEE-CIK/2-E/'?SM5K,A>(UB1<W!7,C17*YR?4UX&
M*8XF3)\FQ&W5^_)MUUG;=T4$:.^2VSHO:S2R51TRH[CRHBKRJO2JU,\?)3A#
M%/S3$KO[QWZ!VW@7(P>\D-6J<)IWMJWRU;OBP[MUKC/;;*W+36+[O2F8<K)&
M+YK72P>:YT;^A)&]"M=TI]$VIV1OG%JQ&UDS-]Y'!QXYWR!C;F3)O8O(MXC8
MX(G^%W*Y5=3P(89AD6UL_H;-:JU/^?\ J5CUL8IG7D4L[>5UW>*JJCFM^L8O
M&O1T(G69*8BB'F9FI)*[MUN+6X@3IEB<Q%\;FJG[IBKC&,/9+W1.%42AWH#5
M;MLM8W-UE+*29(HYK"]M6JC)F+SHM41U$X.:G2>K57R8;B[3C7CO29T?JK%;
MG:9O+QMF^&PFDGL)[69S7/5O*B+S<O!.9'<":Z'BBI':]Q^J]C]9)D+1BRXY
M5<RVN'HJV]W:.6O92*G!'IU]:+Q0BBO".&7NJF)VLHV_>4THZR26XQ=]'?42
MMLQ(WL5U.J3F3AY4)G"'B-K%V:RNK]\=506^.M.SLX*QVUNU5=;VD3E3GEF?
M1$YEZ_#T(*:8QQE-56$80E%I73UII7 V&!LO.M[*)&+*ONI)%XO>OC<Y54]5
M58R\TTX0C$CF_K!<M4K^<-/^D>=+LB?ZOO>M1MP_I2X0
M
M                        5: 1([_FYOYJ;6P:)Q]UV68U;-V4[(I$;(F/
MAXR\[.E8Y/<5 Q_^SHVYCBL=1;HWD=99WIA\6KX^+61T?-)&]?"JHQ:> ">Z
M= !>@""?[1;;5;S#:>W0L8WNDQSUQ642.)%;V$Z\\4DCTXI1R<B5\(%V?L_M
MS&ZEVSO-!W]TDF6TK.JVL4DO-,['W"U:K6=*1QN7D]D")W?DX]XO4/Q:P_%V
M ;/MI%__  NT6G^Y,?\ BS +@U'^CV6^)7/P3@-3_=*5/UI< M>'IF1^!F V
MY550-.N\5KJ;93O)9G,LM4@R&-S3LUA73HDD4]N^3MH7\."HYJ\4Z47I G9L
M9WRL#O7K/'Z&L]-W6,RUQ:37=W<S31O@:^VCYG-C1OG*BKT5 M;]HRO_ .%.
MG_G=/@7 >A^SN]2&23_?]U^+VX%J_M)OT-T7\YS?B[@(Q;);M;K]W3'6NN<7
MC/3MNM4RS0S6MQ5;.>XLU[-R\[.,4S.9%2M.9OA0"1V;_:287Y$=^;FB[K\X
ME:G*F0GC]":ZGG*O9+SJE>CH C'M]HG<CO5[NOR&56;(/O[EESJ?-N;R6UM:
M(J5:BI1K4Y4[.)C>/@ V_8?$V.#Q%AA,:SL\=C;>*SM(U6JMA@8D;$5>M:-Z
M0(#]]SNRYF7,W6\F@[.2^@N6=KJK'P)S312QHB)=1M3SG-<GNT1/-Y:@>#LS
MW^\IHS3T&E]S,-<9_P"3(DM[++6CVLO7,8M&LN$DHUW(WAS>Z7KX@?/O=W\L
MKN!IV[T=MUA9L#8Y:'T:_P C=/:^_5DG!\<*1*K6HY%IS>Z\ %W]QWNSYG'Y
M2'>/7EBME''&J:7QERSEG<Y__M;V.2K41/N=>*]/12H3QR6.MLMCKO%9!O:6
M5]#);7#$X5CF:K'(B^-% U#[J;;[A]U?=B/+81T]G9VMTZ]TIGHT[2&6WYN$
M<BK5JN:B]G(Q_3Y% DEIS]I%ATPK/SKT;<NU"U*/=C9HTM'K3@J)*O.VJ]*<
M0(][V;P[K]Y+'WFJKK%?)^W.D5C<MM;U]%AFNW]BQ[Y'T[69WUJ>Y2M$ DU^
MS8I^8NM_G:W_ !8";M -<W[13;?T#4N!W-L87);Y6%<9DW1PTC;<6U71/DD;
M]5(UW*G-U, ^']G;MY'F-;9[<*^B:^WT_;,L[%'L552[O57[8QW15L;'-7[(
M#9,B4 J
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M'V<JTZ0/+73.GUOOE3Y*LDR?:=MZ:EM%V_:_7]IR\W-XZU$;"=KU42A J2
M
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MLMK&UC;#;6T2(V..*-$:UK43H1$2B(!W2Q1SQ/@F:CX9&JR1CDJUS7)145/
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MNW[]OMC-.6EW"^#*YAKLQD(I'(Y6R7=%8B<O5V2,=3Q@9U
M
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M,]=<53$>4,<1ABOE$I7QF-Z5
M
M                                                 "$G?0W1WVT+
MK/$XO;>ZR%KIO(8M5N'6-DEPU;CM7M<J2I&]S7(VG6@&&M@>ZMN9NCKFPU[N
MQ:W=KI2.6._N[G*O5U]DG,HZ*-C7JKN5RHG.YW"B4ZP-GL4,4$3(86-CAB:C
M(XV(C6M:U*(B(G0B(!S
M
M                        !3E1>H!RIX %$\ #E3HH1@8JT1.@D
M               *<K>BB .5O@(P%20
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M3A+O:E.M5\H0Y
M
M
M
M
M        45S4XJH%G;B[AX#;; 3:@SDBO55[.PL8ON]S<4X1QI[;NI#Q57%+
M>T>BN:JYP4?_  P1BM#ZPWHO8M9[L3266G%7M,-I*!RQM[+J<^BU1/&OG*:D
MSQNF_P!BSI*/I6(^>,Z_XPEFO%8C%X.S9C\+90V%BRB)!;L1B+3K6G2OC4G9
MX0I[ERJY.-<\4^<OMXD^KP4I^\#'V*55%5>KP(3CL,,=D9K>U?HO2FM;"2VU
M/913Q-8JI>*B,FA:U*JJ2=*(B<? >9BGQAL:;4W+,_VY8E[O>5U)::^R>D-)
M9"7/[56"R<][=M5$MW(B\B0.7IJY*<."IQH3:JJFKV+'O%JW-BFY7'#<E*MM
M:\?*;?BXUR)
M
M                                                   "K0"B+4#X
M\CF,1B&-ERU_;6$;UHU]U,R!JKXED5*@>6[7VA6>[U/B6T\-_;)_. 4;K[0K
M_<:GQ+O)?VR_S@'J8[,XC,,=)B,A;7\;%H]]K-'.U%\:L<M /M5: 5
M
M                                                           !
M\.2R%MB[&YR.1E2&RM(GSW$J]#8V)S*OT$(JG!ZHIFN>&,Y1FT;8W>]>M[K=
M+5,3G:1QDKK;2>)EXPO[)?NJUHCOKE6G%?(:54\57L=E>B-!9BS1U)YIWY,[
M55?WNI/8/4Q@I?8$(  %*\?)Q5? GA7Q B(8'UGJ3.[OZD=M/MQ,L>%B=_\
ME/J!O&)(VNHZ-')TM1>%$]TI$Q-4[%]9MTZ.CZ]^/F_#2D'HC0^$V^P-KIW3
M\79V<"5DD=199Y5]U+(J=+E4W*:8IC"'):K4UZBY-=7BN5KE551>G]P]-5R
M
M
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M+'551.>-U'MK3AS(!<:+7R 5
M
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M.5*HJ\50R-$1* 5
M
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MLK)[:9J2131.1['L=Q16N2J*B@=H
M
M                           %%2J 1VU8SY=[S>#M73+);:?PSKY(56K&
M3*YS5HGA5'(:=[-U6D^3053XU2RU6O$2KE"  +X.M>H&#$&ZFXF6^4HML-O6
M+>:WRR=E<31KYME%(G%7.2M'46JKU(><>+8M])I:<)O7=E$9>UDG:7:C$;6X
M'T2WI=Y^^Y9<SEGI66:7IY45>*,;5>5/9-NW1PPHNX:^K57,<J8RAD-$5%ZN
M7]TRJSQ=A
M
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M,M4I]5'7CY: 3_P6=Q.I<3:YS!W<=]BKQB26US$O,US5]I47@J+T >B
M                                        4JGA (J>$C *^R,0J 3R
M@5J )
M          !1RT2I$B.4,$EGWI<QZ0G"\P+I;>O6SS&\/9133KC^XZVB>+ML
M8>%7QEE[Q=8E62H$ %6JC7M5?<HJ*OD)B$51,Q."/6E,O;[+[PZ@?KNW<W':
MKEYL1J16]I'$U[W.Y5<J51/.1KO!1"+<Q3.UT&KL_P"[I:?HS\U$;:?_  E=
M;RQ3P,G@>V2&1$?'(QW,QS5Z%14Z44W(G%Q$Q,3A.;LHWJ3K0E#F
M
M              %*IX2-H*J(2*53Q_3 (J*J^(@4Z51>;AX"-DFUS/0
M                                     $8@2  C$"0
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M!%1>@@5)
M           %'= $=MV>;2F^FA-83S*W'9:%^&NN%&L1BJY*KT><LC4-2[LJ
MB74]MGZFDNT>,;66J<53P+3Z!YPP5Z@  ,4P\756E,%K3#S8+4%LEQ8RHO*Y
M.$L3Z<'QNZ4<@F(9;%^NS/%1.$L/:9UAJCN^9J+2&N))<IMK>/5N'SJ-<Y;5
M%7W*KQHB?5,ZNE!17P[)6NITEO7T_4M;+GXHR2ALK^SR%K#>V$[;BRN&-D@G
MB7GC>QR516JG34W(G%QM5,TSPS&$P^KF2E27D1:@5
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M.1QLR5BN+=W.U4JJ>5.CK*FNBJB<)C"5I1<IKC&F<8>FUR.XH>&14
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MX.Z1NX]ZKM7GYU=R-=+IRYD=7S&\9+9:^#W3/H(!+L
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M(D
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M5.M%-V*L7&W+55NJ::HPF'I-ZTI0EC<@
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M83DZC3ZBF]3C&;(*+S)7H0U8G%M2Y$@
M        HY:(!B77FN+J>ZDPV(E[.TBJVXN(UHZ1W6U%ZD0L]-IXB.*K-M44
M8,>5=UKQ7I+!E./A]@"X]*ZOO]-7+&JY9L8Y42>V<JK1OUS/ J&O>LQ<CVO%
M5$2SG97D%_;Q7=J])+>9J/C>WH5JE',3$X3FU9C!]!+R
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M\\+TZ4K3@Y.- -B6W&M;3<+1>(U;9HC&Y"%%GB;54CN&>9*Q%7ZUZ*B 74
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M)
M   "@<>7BBU7AU 1HW T[EME=:S;FZ6M77FALN]$U3B(DXV[W+59V-3J7IZ.
MGRFI7;X9XO!UVBOTZRU]&K97&4^;*V!S^(U1BH,W@+IMYC+EJ.CF9Q5%7ZER
M)T.3K13S%459*Z[;KLSPUQA+TJAX*\:!&  Z^GCXB83$/FO\=896RGQN3MH[
MRPNFK'<6TJ<S'M<G'@O0O@43&*::YIF)IG"81[N;[+=V75EN[$7:93;[.RHK
ML ]Z>E0.<M.:-OA3J5$H[HZ3Q37].<)7]-JCN=J=G#<H_%YI:6%XR_M8+V)'
M-AN8F31MD:K'HCTK1S5Z%X\3?QQ<--,Q,P^H(
M                                                     X/DY$5S
MU1&-17.<O0B)Q4C:(![[[IW6Y&K)K:SG7\T\1*^'%P)3DED;YK[AWUW-3S?
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M]N-4KCKGY#OWTLKA?Z*]5X,D7ZGQ(XT-59XHXHS8JZ<676JJIQ6I50U7(D
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M#S'^<JKU 6MW,=;I!D<QM_=S4;=-^4\9$[F5SGL1&S(B]"-1J-=XU F0
M                                   +/W3U7^9.@,[J5M5N+.V<EJUK
MD:]9Y52-BMKTJU7<U/$9[%OZER*?-@OU\%N:O*&MU\DLTCYIW]I<2N66:1>E
MTCU5SG+XU554[:,*,(\G&XS5\S(>RFW/]Y>MX,7=*K<%CVI?9=4X\\+'(C8N
M/_6.\U? G$T-9?\ HT>V<F[I+$7J_9XM@]K:V]E!#:6D38;:!C8X8F)RM8QB
M4:U$3H1$.0F>*<9S=9$81A&3Z*(2  #CRHO'KJ>9C$8([R>UMMJW3$VKL;$C
M=28")TRN8GG7%FSC)&ZG2K4JYGT"U[=J9MU<$^*LU^GBNB:O&$)$5'-14Z')
M5*\#J8\W,I$=TK6,^.U7D-&32.] RT*WELQSD:QES B(Y41>*N>VB</ 4O<[
M433%4>"X[;=F*IIGQ3+:M3G(G%T*I(
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MBCZ=F.&CWL[,HJ<R<57K0V7/.0
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M45RKU/I1#G^[VHBJ+D92Z'MEV<)HGP2?;[E"C7*H
M          !1R(M*^$"CN;ZFB#8B<54Z DKXR!4D>=G[62^PM_:1)666![6)
M_"5.![MSA5$O5$[4<TYFHYKO=1\%3QIP+]NYJ$@  JB5ZZ4Z^@#-&W^JDSEA
MZ#=+_P")V;4217+QDC3@CO+U*4NIL\%6,92UKE&&U>B+5*FLPJ@
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M?D/0\G"Q/MBQ/<L+XU1?&J ;.T7B!4
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M",4G,GA$"J*GA)%0
M          40 !;6J-#Z3UC EMJ;#VV28G%KIHT61JKPJCNGZ9YFF);-C57+
M-6-$X(D]X/;/3NU;L'<:-DO+-,E).D\3KE[F-[-O,G(E4H:%^B*9B7;]FUUW
M44UQ7A,1[(8JT]=YK/Y_%X*YS-[%;9"YCMI)&3.5S6R+151%5$,%-.,K[586
M;=5<1&28.'[K6VF/EAN,HV]S=Q#Q7TZX<^)Z_P )G1],L(L4XXN!O=]U%<81
MA3&Z/^&6L/@L+IVTCQ^"L(,=9QHC6PV\;6)3V.GV3/$8*.Y=JN3C5.+U26,
M
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MB!R2,<UZ<R+5M>I2NJIFG-94U15D^KG1?">,7I6O0GA)@5
M                                      "@<$:M*K[I?I 18[XZ4@TD
MG4DMU[Q#2U7@[+]M?Y-T>]'?07Z=:<^<+?WZ&I;G"IU>MC'3U_EELQI7BI;X
M/D13Q$BH
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M1$1&$1DZP]@%Q:,U/-I?*MF<YS\;<+RW<-5I1>AZ)QXH8ZZ.*%=KM)_L4?\
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MAZNA3F-5I:K$^QTNFU5-Z/*63$=540T\&XY$@
M                              (K=\C[CI/[[=>\0T=5E#L_VUG7NA';
M0/Z=:<^<+?WZ&K1S0ZK5]"O\LMF1</D0
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M<PO>[_-N^IKT>0UNX:.*OGMY^+8T&KFCY+D[/!,5$HB(<ZZ)4"G6A U>Y_\
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MNL+V,<]]#)VEK<22HJKV:*E6JE.A54#/"
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MNQN6IQIU\CNEJKY.HY+46)M5X>#JM/?B[1CXK\-=L@
M                                   BOWR/N.D_OMU[Q#1U64.S_;6=
M>Z$== _IUISYPM_?H:M'-#JM7T*_RRV9%P^1
M                                                 !1:]0%0,*]Y
M+<J;0NCTQ6)F[+4.H5?:P2-HKH;=$^W2HG4M%Y6U\?@+#06/J7,9RA7ZZ_\
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M$M+J9/Z9(U:\L:_4U\*FQ9H\72=IT453]2O*,F(FIRU:G2;<[76QLVR= ,,
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MCF2>:M>A*EGK[/';F?'P5VBO<%R(\/%L ;7BBK5>!R4.J<R0
M                                        (K]\C[CI/[[=>\0T=5E#
ML_VUG7N1UT#^G6F_G"W]^AJT<T.JU?0K_++9D7#Y$
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MN7K0#(<,T4\3)X9&RPR(CHY&*CF.:O0J.3@J*!V
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MN8=99KXJ(E=IB90
M       BOWR?N6D_OMU[Q#1U64;W9_MK.O=".V@?TZTY\X6_OT-2CFAU6KZ-
M?Y9;,2Y?(@
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M265D1N,O7UQ\KUHD5P[ICKT<KUZ/&5.OT_%''&<9M>Y1CMA(I.*%"U520
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MK?8J2[O.SR6&R4;Y+=D#*.G<Z&7@CFM1:*B\ -I*<$3KX=(%.= *U10*@
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M:)(Y7);WMW!'7J:QR41/%Q*CN-.%[T6G;:N*SZS'V,UIX^DK5F
M                                          $5^^3]QTG]]NO>(:.J
MRC>[/]M9U[H1UT#^G.F_G"W]^AJT<T.JU?0K_++9D7#Y$
M                                                          %%
MX)7P ?!G..$R7CM9_@W'JCFC>\U\LM>6RU/[UM(?'T]XX[#53_9G<Y'31_>C
M>GDO%?9H<YX.BG/%6I(   %0* %H(1*L?NT\J"4>" 6Z=$W)U/3@GRG*O#[,
MZ33=*G<YW4]2K>V':4XZ8PJ]/]!MN/\ V33C[G-.^776^6-SU^M#$R-7N?\
MR_E_C]W\.\[FUTZ=T.+KZM6^5\;!>M[3'WZ3WBFKKNA4S:+JTMA9R+K@#6MF
M_6GD/^(Y/QT[2.A.'DXV=EZ,?-L"FKV\E?KE]LYJ,G2>+@2'C  5]L!Y>H"@
M"@!>A1")0I[Q_K6RZ_\ N]JO_J&E_H9_LJ'6]64OMC?5/I?XHGOW'-ZOJU.C
MTG2AD(U&T                **E0+/U_I1NH\8Z6V:B9:S17VR]'.G2L:^%
M%IP\9DMU\,^Q:]NUDV*\)Y9S8&<U['.9*U6/:JM<QW2CDZ44W7>;)C&'$D
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MOX^6MG [^GO;T/E3H:BITHG6;=JC#:Z_M.B^G3]6N/FG+<QT;#H@ !5O2O@
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M]+6,\QS7+T@>1MUW[=7X-D=IN/BX]16#4\[*V7);7J)TU=&B)&]&IT<J<SE
MGCIO/6FJ,%C]0V$<T-CDX&75M'<L[*9(Y4YF\[*K1:>,#U0
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MU)%>^^C+?MV52I[AG2RCW3/5''\YWWOVE9W/J^D-_M71_JJ][.95K8
M                                              (K=\G[EI/[[=>\
M0T=5E#L_VUG7N1VT#^G6G/G"W]^AJT<T.JU?0K_++9D7#Y$
M
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MA+[3.H[#5&&MLQCI$?#.U.=GU4<B>Z8[QHIR=VW-JJ:9:55.$O9/#P
M $ 2+%W3U/BM/:3O8<C"R[?E(Y+*"P?T2]JU6NYD3ZE$6JFQI;$W:\/!DHHX
MFMS-8V[TSG'P1N5KX'I/9S-KQ96K5ZN*='B/5ZW-FYLV>3S5'#++VG,W!G\;
M'>QJB3\&742?42(G%/(O2AT=J[%RF*H;MN8F'K&9["07PUX)TD)R9]V2V_\
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M^M:1^]WOOXRW[;E4J>X9TLH]TSU21_.5[[]I6=SZOI#?[5T?ZJO>SF5:V
M                                                 "*_?)^XZ3^^
MW7P:&CJLH=G^VLZ]T(ZZ!_3K3GSA;^_0U:.9U6KZ%?Y9;,BX?(@
M
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M )A=W;9]-L=*^G92-6ZNSC6S93F5%6"/ICMVTZ.6OG_P@,U)T
M   41.@#&6\&QNB=ZK"UM-5LN(KW'\ZXW(V<JQS0+)3F1$6K7(ZB5JE?&!"S
M<GN2[D:59+>Z/FCU=B6\>QC1(+]J=/W)R\KD3PHZJ^ "8O=MV\OMM=I<'@,J
MLK<Q,UU]D;>=RN6">XHJPMXK1K*40#*EY=VUC:S7MY*V"TMV.EGF>M&LC8BN
M<JKXD0#Q=):YTCKK'MR>DLS:Y:S<B/5UM(CGM1>CG9P<W_"0"X0
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M9TLH]TSU1Q_.=][]I5]SZOI#?[5T?ZJO>SF5:V
M                             %%4"+'?)^Y:3^^W7O$-'591O=G^VLZ]
MT(ZZ!_3G3GSA;^_0U:.:'5:OH5_EELR+A\B
M                                                "CO<KY 2^#-?
MD3(_%9_@W'NWS1O>+G+.YKRV6]:VD/CR>\<==J>A.YR>EZT)Y?OG.^+H95)
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M8&?#K;;D:UM>3*O;VF"QDJ4=;L<G">1%Z)%^H3ZGIZ0)5IT
M      !C???2NM-;[89K2NA+BVMLWE&-@>^\5S6.ME6LK&N;T/<B415X :Q\
MMI+=;9#/,N;ZSR6ELK;/1T61M7/;;O=2K52:.L;UIU<0)R=S_=7<[=/#9NYU
MK+!>X;%/BM,?E&Q]G<37%.:1)*+1W*G70"3G4!2J 5J   41[7*J-5%5%HM.
M-%\"@5      !K.?ZP7_ #TOXRIVW^.-SBO\D_F^+8,GN&?8,]ZAS+IU0
M  $ 2"@0^[T?K*B^:;7WTA>:#I^LJ/7=3T_Y2CV!]36C?F]GOW%#KNO7O7F@
M_3T?EADA30EO-<.\'K3U;\YS^^4[/2]*G<X_4]6K>M[37Z2X;X];?"M,]WEJ
MW?!AM\U.^/>V?)TJ<*[942-<&\WK;UK\Z/\ >,.VTG2H_*XS5=6O\WPA-W2O
MZ+X/XC![PYVYS5.@MY0]A#PR^*I H2*^$@4 KQH!0D4\),/-2,W>T_K6D?O=
M[[^,MNW95*KN&=+*/=,]4D?SG>^^:5G<^KZ0W^U='^JKWLYE6M@
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MDQ64Q^:QUME<5<,N\=>1MFMKB)>9CV.Z%3]WP ?8
M                                 *.]ROD ^#-_D3(_%9_@W'NWS1O>
M+G+.YKRV6]:VD/CZ>\<==J>A.YR>EZL)Y>'RG.N@ER"5 !( 5 H 7K")5C]T
MGL>V$3D@%NIZR-3?.4OOSI-+TX<[J>I.]L.TG^B^%^(VWP33CJ^:=\^]UUOE
MC<]?K0QLC5[G_P OY?X]=_#O.YM=.G=#BZ^K.^5\[!>M[3'WV3WBFKKNA4S:
M+JTMA1R+K@#6MG/6I?\ _$;_ ,=.THZ/HXVYUO5L#F^[2?9+[9S,9.EG-UDH
M"0ZR!7CT 4)   \(1*%/>.]:F6^+VOP#2^T71]5#KNK*7VQGJGTO\4_QW'.:
MSK5.CTG2I9"-1M                    <7(JHM*5\8&&M\MN79JP=JW#PM
M=F;%G]-C;P=/;,3I\;F=*>+@;%FO"<)=-V3N'T:OIU\M67LE&I%14JG1TH6&
M</H'@J>4!*0G%$1MVC7OC>V2)RQRQJCXY$X*US5JBIXT&95$3$Q/+*6^TVX4
M6L\"D-](U-0X]$COHF\%>U.#96IX'==.LK+E'#+YGW30_P"O<QCDG)D)*KQZ
MO&85,P;O?H%9&KK3$Q(DK$1N6@8G%S4X),E.FG0XN-!J?P3Z-BU7AL8*]DO&
MW$  E G'R)TD$,P]WELJY[+.C6D+;6/M4\KUY2I[CRQO8+TPD0434      H
MM?8ZR)$/=Q'2OUQG7W"<LOI3N9$ZN"(GTCJ]-TJ</)OVXV+9-E[ F#R=76$2
MLG56A&95SK["QI'E'+5]NG!DZJM$1/ ^OT2KU6CIJQJC-KW+<9PM_2&M-<;.
MZJDNL>R3&Y6%4BR>)O8U:V6-:.5DC')5.9.*.3BG244S.36QE-/;'O*:"U^V
M"POKAN U/(J,^3KQZ-CE>JHU.QF6C7<RKP:M'>(\(C;3CX.O?/<5<?9KH["R
MJW(7;47)3L7[E;K_ )M/X3T^D;=BWCMEU79.VU7*HNUQ\L9;_!'-*42G0G4;
MV+NIPF,)G:J1@] P $;8Q<HHIKB6.WMXW2W$SFQQ1,2KG/>M$1$3K4B9B,WB
MJN(IF:MD)=;6Z!AT1@&MF1'9V^1LN1F3J7JC1? U.'E*Z[7Q2^9=SUU6IN?^
MM.2_&K1.5>GQ)P,2I8;W-[R>@-OFSV%I<-SVI6*K$QEB]'-C>BJU>VE2K6<J
MIYS?=>("%NLM>[@[SZBMX\FZ7(W3WN;B<%8M588N?JCC;[I:)YSW<>%0).[$
M=V.VTTEKJ_<*%ESJ=*366(54DM[)?J724\V27K\#0)-HB\:K7P 5
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MU[7EX(Q.-$1? !)?;/2UQHO0F#TQ=31W%QCK?LY9H45L;G/>Z1>5%HOU0%V
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MM6N7AX0E,O;/9?1.UEK3 VO;9>1O+<YBZI)=25Z41U/,:M/<M R&B4 J
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MXP[;2=*C\KCM5U:_S?"$W-*_HO@_B-O[TYVYS5+ZUE#V#&S3F=9*%?; I[
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M:(G%59 EM7E\/N@+]P^0CREA'>PT[)[I&-Y>C[5(Z/A[+0/O
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M3/5)'\YWWOVE9W/J^D-_M71_JJ][.95K8
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M=%0:[JRE]L9ZI]+?%/\ '<<YK.M4Z/2=*ED(U&T
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MK7YTD]XP[;2=*C\KC=5U:_S?"$W-*_HOA/B-O[TYVYS5+^WE#V$/#+X@%2
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M(]%Y;=6Q*C^%:I1OU(&5<7?VF4L+;(V$S+BRNHVS0SQ*BL>UZ5JBIY0/L
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M T+MSBG!\\[UW&;U?!3RT_>S :[G
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M^M:1^]WOOHRV[=E4JNX9TLI=TSU21_.5[[]I6=SZOI#?[7T?ZJO>SD5:V
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MO0G "06U^EK[16@L'I?)/BDOL; Z*=\"JL:N=(Y_FJY$7ZKP 7>
M                                            *.]ROD ^#-_D3(_%
M9_@W'JWS1O>*^6=S7ELKZUM(?'T]XXZ_4]"=SE-+UH3R\/E.=\5_+D$J$@
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MKN&=+*7=,]4D?SE>^^:5G<NKZ0W^U]'^JKWLY%6M@
M                                7H BMWQT^T:2^^7/P:&EJLH=G^VL
M)^ICY([:"_3G3GSA![]#3M<SJM9$?Z]<^QLQ3H^B7+Y$J
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M%T?50Z[JRE]L9ZI]+_%/\=QSFLZU3H])TJ60C4;0
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MOWHPCY=S*D5M#%$V"%J1PL3E8QB(UJ(G4B)PH8,<7/SC.;NI1*)[ %0
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M5](;_:NC_55[V<RK6P
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M0/J1:@5
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MDH0I[QWK5RWQ>U^ :7NBZ/JH==U92^V,]4^E_BG^.XYW6=:IT>DZ5+(1J-H
M                         "BM1U*I6G0!4 !2B 5    $8.\K^F.'^;%_
M&'F]IHV2EAGR^0VHV2E>>E]K=8ZQQBY?!6\$MBDCH.:6=L;N=B(J^:O&G%#%
M5>BF=J)>U_<'N5_W*U_"F?O'G_9I\D']P>Y7_<K7\*9^\1_LT^0?W![E?]RM
M?PMG[Q,:FGR'B:IVNUCH[&)F,];016*RL@YHIVRN[26J-\U/(>J+T53L2LWK
M\IE2S-W;?TORGQ#^=::NHY42D^:*     4Y43A0!R-\'C (B)T(!4"E$ J
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M-*SN75](;_:NC_55[V<RK6P
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MXR0O15:O3RO;TM5.M%0#W4Z
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MO*7K"69.[=3\[\I7H2P6O^E::6IC"'F4H*H5\("0
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MGU?2&_VOH_U5>]G(JUL
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ME&VK[![JPW*(G%]NY>*^-B\4\8&;/$
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MGJLSAX-.JG"5W&MB\!(
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M^M:1^]WOOXRV[=E4JNX9TLI=TSCM)'\YWWOVE9W/J^D-_M71_JJ][.15K8
M                                         HJHG2!&+O&]X==,K<:$
MT-<I^<;D5F6R4?'T)J\%C8O_ %J]?UOE CQM)LMJG>#*R3Q2/M-/QRJN5STR
M+(KI'+5S8^94[21>OP+T@3\T+M[I;;G#1X32UBRV@1$](N'4=<7#T^KEDI5R
M\5\2=2 70B4J!4 O0!C+>G<QVV.E69*U@2ZSF0F2QQ%N]/M:SO2JN=3J:G&G
M68ZZN&-BU[;H)U5R8RIIVRPCEMF=V-Q;>UO]>:IB2\;6:''K&CFVW:I[E.6B
M(M.E#2JIKKS=18[AI=-LM4[)V//M.ZYJ*QN8;VSU1!#=V[TD@E;"O,Q[5JBI
MQZCQ%J8EEK[S3,<,T[)7KIK7FX^VVN<7H[="^CS> U$KHL3FFHC7LE3@C5Y4
M2O&B.14ZTXFU3=F)PE5:C0V-19JKL1A-&<))I3A1>C@;4N2<P*.2H%F[A[8Z
M5W-PK\/J6S:]Z(JVE_&B-NK:1/<NC?T\%^I7@H$!=TMI=7;-YV!+V1\N-D?V
MF&U!:UC:Y[%Z%5%K'*G3R_0J!)SNZ=X)-;-BT7K*9L>KH&\MA>N\UM]$Q/<J
MO_7(G%?KD\?2$D*HJT J
M                         H[W*^0#X,W^1,C\5G^#<>[?-&]XN<L[FO+9
M;UK:0^/I[QQUVIZ$[G*:7JPGEX5\9SJ_E4)   D  !1")5C]TGE0(G) +=/U
MD:G^<I??G2:7IPYW4=2=[8=I/]%\+\1MO@FG'5\T[Y][KK?+&YZ_6AC9&KW/
M_E_+_'[OX=YW-KIT[H<77U:M\KYV"];VF/OLGO%-77="IFT75I;"CD77 &M;
M.>M/(?\ $;_QT[2CH^CC;G6]6P.?[O)]DOMG-4Y.EG-UDH *^,"G$!U *?3
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MA+DY:(:*I(
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M6(1L>5@9YO;,Z&7#&=2.^JIP1WE S$BU J
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M*>7G0PW>2K=**LDV3D%<$@
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MX[='RU*C7S\T,M=T^-T>T</-]7D;UR>17M*ON75](6/;.C_55[V<"K6@
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MLLP&:QVH\-8Y[$RI-C<C RYMI4ZXY$J@'I
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M?;^EZRW;/*QN63*  /0P'Y>Q7QR#WZ&*[R3NE%62;*=!R"N
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MG,=<0>C7KK5MQ=,1:KVLRJ]55?&BH<WK+G%>J\G1:.WPV:8\60T-.&X$@
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M^Y2+26-*K551WG>!$ EBG0!4
M                           #B^O"@$ N\;I%VEMS\DL34BQ^<C;DK-65
M\U9*ME55^N[1'+3P'5]NN<=K"?!RO<:."YL\4G-HM70ZST!B<BUR>F643<=?
ML3BK)K9J-XUXK5O*ZOA*J_;^G<F/-:6+GU*(GR7T8&PH2*KT@4 )3]X@"0")
M63NSJ^/1&@LMEVR]GDIHUL\92G.MS-YJ.1%Z>1%YE\1FL6^.N(8=1<X:)1?[
MNNE)]3[H8J9$=Z+@E^5+R1J5:CHU\QKD7J>[@6^ON?3M8>,JG0T?5NQ/DG^B
M]77UG(PZLZT U>Y_\OY?X_=_#O.YM=.G=#B[G4JWROG8+UO:8^^R>\4U==T*
MF;1=6EL*.1=<H[H4B1"WO9:3=C-9V&JH8FI8YZ#L9E2JJZ[M*(JNZD16*RGA
M.F[7<XJ?I^,.<[G;PJX_-DKNXZNCU#H"/"22\V3T\_T65KE5SW02JKXGJJ^'
MBGBH:VKM<%>/FSZ2YQ4X>,,O>R:<-V8PER"5/"   /W0**H1.;R=4:BLM)Z=
MR>I,@O\ 1L= ^5&51'/D5*1L;7I<YU*'JW1-RJ*8\7F[7%%.,H.Z#P=_N/N3
MC<?<.?)=Y:^6^R-PVG.V-K^VED5%X<.%3H+]<6K.,;,'/V*)N7L)VX[6R%B(
MB42B(G"B<.@XQV+D2                                 $#X\K^3+WX
MO+[Q3U3S0F,T(EZ7?9.]\IV:Q@   ,Q=WG\NY?XLWWZ%1W/DIWL%W)(;K*&6
MHB]OE^GL_P 7@]X='H.EZRW;/*QP63*  /0P'Y>Q/QR#WZ&*[R3NDG*4V$Z#
MD%:J                                                      %'
M= $6N]WHJ22VQ&O;.%.6U7T#*N:SSN21?M4CW^!J^8B+]<7?;+V&-,^BE[E:
MF<*H]7E=U[743K>\V^OYFLEC<^^P[7417H_C/&B]*N1?/\AL]PLS$\40U=!>
MB?EF4D*HB\>"%7&W8M)G"<?!6H>A% > @57PDB@"J)UA&*P-X]=0:$T3>W3'
MM^6<DQ]CBH5K5TDJ<KW\.-&-6M?#0V-/:^I7AX1FUM3=^G1CXSDC-W?-%.UE
MN18)<L6;%87_ ,2R#WUHYS%^U(JIT.5]'<? I::^]PV9\\H5NAM<5[V9M@*+
M5*G)NJ5(D:X=X/6GJWYRG]\IV>EZ5.YQ^IZM6];VFOTEPWQ^V^%:9[O+5N^#
M#;YJ=\>]L^3I4X5VRG%7+PX4X$R,#=Z?1+]0Z%9J.PM^TR>G9.WDY&<TKK)_
M"5M>IK5I([[$M.VWN"YAX2J^XV>.WQ>,,,]VC7<.$U#/I#(3-BQV?5K[)SJ(
MU+]B4:WF7_K&^:B=:EKK;/%3QQX*O1W>&KAGQ2VHJ>ZJB]:+X2EB<5W,82J2
MA7P$"@ D*T =(%O:XU?8Z%TO?:EOG-3T5G+:1+TS7+T5(V-3KJJ5\B*9+5N;
ME<4PQ7;GTZ)J0HT#IR_W*W&Q^*G;VKLG>.O<L[SG-;;H_M9JKTHB^X3RH7E^
MY%FU.W)1V:)O78V9MC=M#';1,MH&<EO"QL<+$Z$:Q.5$]A$./F<=KKHC#8[P
MD                                        #HO+N"PM+B^NG<EM:QO
MGF?2M&1M5SE]A$ U@:DR-_N=N7>WL;JWFH\HD%M(QKE1L4DG91.1O%:(Q$54
M V8:7P%EI;3V,T[CXVQ6>-MX[>-C*\OF)Q5*^%:J!ZP      (Y]['^KZ"^>
M_P";0T]3X.K_ &__ )?R_%EQ>KR)[0G-6J$#!'>&_2C;'YS_ )^(\5^"^[7T
M;_Y?@E0;[B D    !;NN]+6FM=(9C2]XC%CR5M)#&^1O.D<RM7LY*=:L=1R>
M0#7+MKJ*ZVSW0PV6O.>W^2[Y;+*HK.:1+:1W83)R_7*U?8 V=1N:]C7L6K'H
MCFKXEXH!R
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M[^'>=S:Z=.Z'%U]6K?*^=@O6]IC[[)[Q36UW0J9M%U:6PHY!URCEHU51*KX
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M?+]/9_B\'O#H]!TO66Y9Y6-RR9@ !Z& _+V*^.0>_0Q7>2=THG*4V4Z#D%<
M                                                       \K4>!
MQFJ,->X#,PI/C;^)T$\;D1>#DX*E46CFKYS5ZE0]45S15C#Q71%=.$M>FL=*
M:DV?UPM@L[HK_'2I=X?*L3E2:%%JR1$X_8O;Q.NL7J;]O;XYN4OVYL5[LO:E
MEM3NMBMR\2BR<EGJJT8GREBT7IIP66&O%T:KU?4]'C*?46)M581EYK;3ZB+E
M.,Y^3(?D-9M*IP)0!*J?3(%%Z*DCQ]2ZFPFD,+/G<_=-MK*!%HBK]LEDIPC8
MWI5RDTT355A#Q77333BA!KW6^?W3U6R[=%))VKTM,#AXZN[-CU\QC43I>[I<
MO[AT5JS38HFJ7/7;M5ZOAA-39/;"#;/2,=E,J29_(JVZS$_#[JK>$+:?4Q)P
M3QU.7U>HF]7C&3IM)IXLT8>+)C:HU$7BO6:C<5(D:XMX/6GJWYRG]\IV6DZ5
M.YQ^IZM6];NFOTDPWQZV^%:;%WEJW?!AM\U.^/>V?)TJ<*[94D=-S;07=M-:
M7<;9K:=CHIH9$YF/8].5S7(O!45%$3,;81,1,82U];R;97VUFKUCM'/7 WDB
MW>"OD\UT=%YEB5R?5Q+U]:'6Z/44WK>WPS<GJK%5FYL\<D@-E-Y;;75E%I_4
M$S;?6-JSE:KE1K+^-G#G9_Z1$]VSV4*_4V/ISC&4K'37N.,)SAF!>'E\'6:.
M+?P5ZB4 %?; XKT^/I&)@^3)Y3&X;'W&5R]U'9XVU:K[BYE<C6M1.-$\+EZF
MIQ4F,9R>:IB$*=X-U;W<G,L9;))!I?'/5F*L?JI'N7E69Z)TO?\ 4IU'0::Q
M%J-O-.:@U-^;D_\ K&7M2:[N&TTFA-/OU%FXN75&=B8Y\+THZTM/=-B\/,[@
MZ3V$ZBAU^I^I5PQE'WKS0:;Z=/%.<_<SBB4*Q9J@
M                     QCWA-32:5VCU)?VT_H]_<0)96;Z5K)<.1JMIXV<
MP$1>ZAIV',[NV5S,Y6MP=G-D(^M'2)2%J+X/NG-[ &P= *@      CGWL?ZO
MH+Y[_FT-/4^#J_V__E_+\67%Z4\-$]H2K5"!@CO#_I1MC\Y_S\1XK\%]VOHW
M_P OP2H-]Q 2     HO1X -<O>6TW'IK>'/-M&O2WRG995CWK6LURU'2<E.I
MKDX 3?V7U-#JW;'368CG=<2K9QV]U*]*.6YMD[*6M? YJ@7YT\4
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MTK(DG:(E?L0,E=SW,)?[5OQ?U6)OYX57[\O;)[X"08
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M87<_2U](J(Q;^*W>YRHUK6W#D8JJJ\*)4QZRF:K,O>EJX;T-CJ+5*G&NP5(
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M QL<,;49'&QJ-:UK4HC6HG!$0IEP[0
M     ! ^/*_DR]^+R^\4]4\T)C-")>EWV3O?*=FL8   #,7=Y_+N7^+-]^A4
M=SY*=[7NY)#=90RU47]\OT]G^+P>\.CT'2]9;EGE8W+)F  'H8#\O8GXY![]
M#%=Y)W23E*;*=!R"M
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MNY>GYIV+FQI;=F/EAD)&-Z>LU,(;F*M4K0(5)
M                   $1>^_[C1'WV_^#C N?N70M;MWF+A/=R9:5CO)&QM/
M; DF       !'/O8_P!6T%\]_P VAIZGP=7^WO\ +^7XLN.Z4\B>T)5JA P1
MWAOTHVQ^=/Y^(\5^"^[7T;_Y?@E0;[B D      BUWVFI^;.DE\&1N$^C;J!
MW=R;]"M3?.Z?B[ )/@
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MB,66[:SM+*%(+2".W@1:I%$QL;$5?X+41#1FJ9S;L1$9.]&MX<. 2J
M                               $#X\K^3+WXO+[Q3W3S0F,T(NMWV3O
M?*=DL84( "H&8N[S^7<O\5;[]"I[GR4[VO=R2&ZRAEJHO;Y?I[/\7@]X='H.
MEZRW;/*QN6+*  /1P'Y>Q7QR#WZ&.[R3NDG*4V4Z#D%:
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M@;R001LBB9U(QB(U$]A$.0F<9=;$81@[TH1 K1"0 43IZP
M                             $1N^^UW9:)>C5Y4EOD5U."*L<=$KXP+
MA[EEVQ^@\Y8U^V091TKD\4S$I[T"3        $<^]C_5]!?/?\VAIZGP=7^W
M_P#+^7XLN+U>1/:$JU0@8([PWZ4;8_.?\_$>*_!?=KZ-_P#+\$J#?<0$@
M  $5^^U-'^;NDH>9.T]/N'\G7RI!2H'U=R9%31.I:IP7+\%\/VA@$G@
M
M    0T[XOZ=:9^:9_P 8.E[3TZM[F^[=2C=/P1SE^XR?8N]HN*<U55RME.UO
MJYTM\VVWP:'$:CJU;Y=E8Z<;EW&%G     HG@ Q=OOMJFXVBIK>Q8BZAQBK>
MXE>M\C$\Z'AQ^V-X(GUU#<TFHFU7[):>KT_U:/;#7ZYLC'OCE8L<L:JR2-R4
M<QS>"M5/"BG835&S!RD1GBN?06O]0[<9Z//Z=E1)53L[RSDJL%S#6JQR(G1X
M6N3BA@U&GIO4X2RV+]5F<831V][P.@]=00P3WK,)J!_*V3&WSDCK(Y:)V4BT
M:]%7H2M?$<O?T==N?.'2V-71<CREE=CT5*\U?H?N&C.S-NQ.+ES='&I&(\34
M>KM-Z4M/3=196WQUNJJD:S2-:Y[FI56L;TN=XD0RT6JZYV0Q5W:*<Y1,WD[R
M5UJVVN-+Z'26QP$JK'?91]8[FZCK[B-O3'&[ZKZI4X<*E_I.W\,Q54H]5K^*
M)IIR1[1$:U&M2B)U(74QMA3QA$2S'W=]L9->:NBS62MU?I3!2)-<.>VL,]TW
MSHX*KP6BT<[P<"M[AJ(LT\%,[96.AT\W:N.J-E*=[.M>M3E,'4.5$7I)
M                                   $#X\K^3+WXO+[Q3W3S0FG-"99
MW<SO-9[IWU*>%3L,%B=N[ZQG\5!@';N^M9_%08).W=]:S^*@P0S#W?'J_.Y:
MJ-2ELWH2GU:%3W*/DC>P7D@_ 44YM1&+?"16:\F1&M7^CPU56HOU"'1:"/[7
MJW;/*QQV[OK6?Q4+'!F.W=]:S^*@P#MW?6L_BH,!Z&!F<N=Q2<K.-Y!T-3Z]
M#'=CY)W2\SE*:B="'(JY4
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M/(
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M=!R"N
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M<RTZ7+3BJ\5*6NY57.-4K>BW31&$0]0\/82
M                       6)O-IM=6;7ZGP3'I'+/922QRN3FY76])N'C7D
MI[($'>[=JQNDMV<-+<RLM[++-?B[Q\G0B3T6-OB59&L0#8X@%0      1S[V
M']6T%\]_S:&GJ?!U?[?_ ,OY?BRXO2GD3VD$YJU0@8([P_Z3[8_.?\_$>*_!
M?=KZ-_\ +\$J#?<0$@    *+2G'H UH[[:F366[.H\E"K'6[+EF+LY(E5S)(
M;:D+'_X5:\ -A&W6 =I?0NG\!(UC9["PMX;CLT1&NF2-.=W#K5U54"YP
M
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M<@K@
M    1E[X_P"0--?')?>(7':^>K<INZ<M._X(C(=)*@3A[IWJDB^<KWW[3E>Y
M]>?1TW;NC&^?>SB5GBLE20     !0 !3E3Z) IRI6I'#!BK3QGH45E51:JGB
M\)&$"O*E*=0%0!(
M    XO:U[%8]J.8Y%1S52J*B\%14 UF;N:7O=N-T\QCK57P+;WB93#W+T1%5
MDS^VC>B)PHU]6IY -A.VNL+?7>A\+JB!45U[;M6X9S-<YD[$Y9&NY>"+5*T
MNP      $<^]C_5]!?/?\VAIZGP=7^W_ /+^7XLN+TIY$]H2K5"!@CO#?I1M
MA\Z?S\1XK\%]VOHW_P OP2H-]Q 2     L/>'7#- ;=YS422]E?L@=!C.7E5
MWI<_VN)4:Y>/*KD>J>! (*[ Z.GUUNMA+>>/M;"PF7+Y1ZM1\?+"Y9.5Z>"1
MZ\J>-0-DK:(E$X(G10"H
M                             (:=\7].=,_-,_XP=+VGIU;X<WW;J4;J
MO@CG+]QD^Q=[1<4YJJKE;*=K?5UI;YMMO@T.(U'4JWR[*QTXW+N,+.
M   .*LK3BO C 5Y4ZA$0%*C 45E>M215$HE*@*<:U]@8"H
M                           ! ^/*_DR]^+R^\4]4\T)C-")>EWV3O?*=
MFL8   #,7=Y_+N7^+-]^A4=SY*=[!=R2&ZRAEJ(P;Y_IY+\6@]Z='V_I>K=L
M\K&Q9,H  ]# ?E[$_'(/?H8KO).Z43E*;"=!R"N5
M                                        $9N^/^0--?')?>(7':^>
MK<INZ<M._P""(J'22H$X>Z=ZI(?G&]]^TY7N?7GT=-V[HQZ^]G(K/%9!(
M
M  "@1C[X.W#\QIVTW!QD?->X&L.3:QM7OLIEX/5>E>S=U>!R@6%W0MS8L'F[
MO;G+3)'C\T];K$/>Y$8R]1//B1.C[:G&M>E$0";(      (Y]['^KZ"^>_YM
M#3U/@ZS]O_Y?R_%EQ>E/(GM"58H0,$=X;]*-L?G3^?B/%?@ONU]&_P#E^"5!
MON("0   "@02[V6YT6JM5Q:,Q<R28;3;U6[<U:LER*I1W4GW)*M]D#,G=)VX
M?IC1LVL<G!V>8U+ROMT<B<\>/9]S2J+_ )Q?/HJ< )$@
M                                                      0T[XWZ
M<Z9^:9_Q@Z7M/3JWN;[MU*-U7P1SE^Y/^Q=[1<4YJJK)LIVN]76EOFVV^#0X
MC4=6K?+LK'3C<NXPLX
M                $#X\K^3+WXO+[Q3U3S0F,T(EZ7?9.]\IV:Q@   ,Q=WG
M\NY?XLWWZ%1W/DIWL%W)(;K*&6HC!OG^GDOQ:#WIT?;^EZMVSRL;%DR@ #T,
M!^7L5\<@]^ABN\D[I)RE-E.@Y!6@
M                            C+WQ_P @Z:^.2^\0N.U\]6Y3=TY:=_P1
M&3H.DE0)P]T[U20_.5[[]IRO<^O/HZ;MO1CU][.)6>*R5)       "J
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MR5WUTSOI<0-D%O!%;1,MX(VQ01-1D4;$Y6M8U*(B(G4B(!V@
M                                                          0T
M[XOZ<Z9^:9_Q@Z7M/3JWPYONW4HW5?!'.7[D_P"Q=[1<4YJJK)LHVM]76EOF
MVV^#0XB_U*M\NRL=.-R[S"S@
M                      0/CROY,O?B\OO%/5/-"8S0B7I=]D[WRG9K&
M S%W>?R[E_BK??M*CN?)3O:]W)(;K*&6JC!OG^GDOQ:#WIT?;^EZMVSRL;%D
MR@ #T,!^7L5\<@]^ABN\D[I)RE-E.@Y!6@
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M&>U5Q.,8J?2(P2P1WAE3\Z-LO%D^/^GB,=?@O>V;+-^?_7#[I2GKQ-]Q*I(
M4541:*!C[=K=G3VT^GWY7)O2YRURUS,3B&.1);F9/>L;TN<O1Y0(!N?KG?#<
M%.:N0U/FI$1*5["VMVK_ -&*)M0-@^UFVN(VLTK;:<Q:]M/]VR-\Y$1]Q<N3
MSGKX$ZFIU(!>X
M                        "&G?%_3G3/S3/^,'2]IZ=6^'-]VZE&ZKX(YR
M_<9/L7>T7%.:JJR;*-K?5UI;YMMO@T.(U'4JWR[*QTXW+O,+.
M                                               ! ^/*_DR]^+R^
M\4]4\T)C-")?=.^R=[Y3LUC    9B[O/Y=R_Q9OOT*CN?)&]KW<DANLH9:J,
M&^?Z>2_%H/>G1]OZ7JW;/*QL63*  /1P'Y?Q7QR#WZ&*[R3NE$Y)L)T(<@K@
M
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MKT\6,JY4 VX8;$6>!Q&/P>-C[+&XRVALK2*JNY8;>-(V-JO%:-:B ?>
M                                   %*<0,1;X;'8G=C%)<6ZLL=763
M5^3LBB41[>GL9J=+57H7J @[9W^X&R>MY&Q=KA=4X]W+/;R(JPW$72G,B\)(
MGIT.]D";FSW>$TKNA!'87*MP^KF,19\5,]$9*O0KK=[J<R*O'E]TGC S&BU
MJ  Q9OGMG<[FZ2BL\5,V#/8F=+_%/D6C'2M146-R]7,G!%\)BNT\4+;M>MIT
MUW&J,::HPEC"TW1WCQ-NS'Y_;>]O,I!YDMY;,<C)>5.7GI6G&E>!JX3$;87L
MZ72USQ478BGRVN_^^+<E/_\ 5V37_!4C'V'^AI__ +8^R7#3VD=Q-V]=X?5N
MO\-^;>EM,N6;'XR5%;<2S*J.1:+5>*HBJ[HX'NBB:IV[(8[^KL:2Q5;LU<=5
M><I-))54\'A\INN0\78!15IU<0,'[R]X_3.W$5QA<(YF9UIRHC+2-R.M[9ST
MX.G>G6B<>1.*^("&,<>X6]VM^5%ESFJ+Q$1[W>;#;0-Z%7ZF*-*@3KV6V6PV
MTN%5C7-OM37J([)Y1S:*O!/M4=>*1HOT>L#*@
M                                                 !#7OB_ISIGY
MIG_&#I>T].K?#F^Z]2C=5\$<I?N,GV+O:+BG-559-E.UOJYTM\VVWP:'$W^I
M5OEV5CIQN7<8&<
M            ")'SWD7;VL\'_61O97[)JH3$X3"8S0AEC=#--#(U6R1R/8YJ
M\%14<J<3LXG&%A&3K"520(&;>[O9/==9O(_YMC8K?RJ_S_W"F[G5LIAKWI9\
M\92-5&C?NS?!K&WNNEEY:,<GB[->14.A[=5C;P\I;EF=C%JHI9LP )'KZ3MW
MWFJ,+;1M5SI+V!*)Q6B/157V$,%Z8BBJ?8\U[(303FK14X'(1BKW(]
M                                                      1E[X_Y
M TU\<E]XA<=KYZMRF[IRT[_@B,G0=)*@3A[IWJDA^<KWWS3E>Y]>?1TW;NC&
M^?>SB5GBLE20     "V]?:/QFX&CLUHO,(JX_-6LEI*J5JU7)5KN"HOFN1KN
MGJ U1WFF-[^Z#N.[-6MG) ^V62&WR[(?2,;D+!7-<J*Y$6C7)R\R+RN:O#J
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MO55R+4"%'[//;Z?-[@9G<B^AD=8X&W?:V=Q1JQ/OKQ*/:M>/,V->;HZP-EH
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MJ1_7TK1J<$ZD O&@
M                              AIWQ?TYTS\TS_C!TO:>G5OAS?=>I1N
MJ^".<OW&3[%WM%Q3FJJLFRG:WU<Z6^;;;X-#B;_4JWR[*QTXW+N,#.
M                                                    ! IUJ0(X
M;R[?W.*R=QJS%Q<^(OG]I?-C156"=WNG.3ZQZ]?4I?Z#5173%$YPV[=?@Q-T
M\2V9Y"1]6,QE_F;Z'&8R!UQ?7"\L<;$5>'URTZ$3K4\5UQ3&,Y(F<(2WT'I*
MWT;IRVQ#7))=<9;R9.'/._BZGB3H0Y347_JUS4T:IQE<Z=%3 \+#W1T.NM<$
MC+*B9FP59K%7<$>JI1T;E_A)T>!3<TM_Z5>W)DMU82BO<6]Q9W$MI=Q.AN87
M<LL,B*U[7)U*B\3IHF)C&&]%6,.L]"BJB<56B>,)9UV3V]NK:X9K+-0K$KF*
MW%6\B*DE'I19G)U(J<&_1*37ZF)_MT^K5NW,=C.I3-8)
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M(8*"=C$RV=1<SD9$8YCU==>=$QW-Q561\K0,]@
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M6,:E&M1O!$1$Z$0#F
M                                $-.^+^G.F?FF?\8.E[3TZM\.;[MU
M*-U7P1TE^XO^Q=[1<4YJFK)LHVN]76EOFVV^#0XF_P!2K?+L['3C<NXP,X
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M8E0
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M;&YL<D=G;NY[AR*[K:U%X ;L88HX(8X8FHV*)J,C:G!$:U*(B>P!V
M                                          \?,:7TYJ%DD6;Q-I?I
M*Q8GNN(6/>K%ZN=4YD3R*!C[(=VO9>_C?'^:\-H]W^>MI)6/2O@J]R?2 B)W
MN]E=&[4XS2MWI9UZZ3*WEW%<MO9TG8D<4*/:C$1C:+4#UNZ5L1H;=/0V3SVJ
M%ODO;/+S6K&6DZ0PNBCC8J(YJL=5>*U6H$I['NW;+V+&,32L%P]G1-</E>]?
M+YZ)](#(>*T[@<$QL>&QEK8-:QL:+;PLC=R-2B(KFHBK[('J
M
M       (:=\7].=,_-,_XP=+VGIU;X<WW;J4;JO@CG+]RD^Q=[1<4YJJK)LI
MVM]76EOFVV^#0XF_U*M\NRL=.-R[C S@
M                                  ! 4& $@   *(H#R$ 2
M                                                      1E[X_Y
M!TU\<E]XA<=KYZMRF[IRT[_@B,G0=)*@3A[IWJDA^<KWW[3E>Y]>?1TW;>C'
MK[V<2L\5DJ2      45*@>7F]-X#4MHMAJ'%VN5LU1S>QO(63-1'I1W+SHM*
MHG2@&-F]UON^,<U[=O<1S-7F3[6_@J?X0&3</@L/@+5MEA,=;8VT2B=A:1,A
M8O*E$JC$2JT\('H@<'MYTY52K5X*B]"HO4H&.=0=W_9?5=_\IZ@T/B;R_P"5
M&+.MND:JB+6BI%RHH'O:0VTT#H&#T;1FG+##1\SG<UK"ULE7^Z^V+5_'[("Z
MP/-S.G\%J&&.WSV,M<G!"_M(HKR&.=K7TIS-21%1%HM *XC!87 6[K3!XZVQ
MMJ]RR/ALXF0,5Z_5*UB(E0/1   *.15Z.GP@>%C=%Z1P][\I8G 8ZQR'G4NK
M:UABF1'^ZH]K47SNOP@>\G0
M               0P_:#_D/0?Q^^_%F@>_W O59GOGVX^"C E@
M
M           (:]\7].=,_-,_XP=+VGIU;X<WW;J4;JO@CE+]RD^Q=[1<4YJJ
MK)LIVM]76EOFVV^#0XF_U*M\NRL=.-R[C S@
M
M                                                  ",O?'_ "#I
MKXY+[Q"Y[7SU;E-W3EIW_!$9.@Z.5 G#W3O5)#\Y7OOVG*]SZ\^CINV]&/7W
MLXE9XK)4D
M                          0P_:#_ )$T'\?OOQ=H'O=P+U69[Y]N/@HP
M)8@
M                       "&O?%_3G3/S3/^,'2]IZ=6^'-]VZE&ZKX(Y2_
M<9/L7>T7%.:JJR;*-KO5UI;YMMO@T.(U'4JWR[*QTXW+O,+.
M
M
M   (R]\?\@::^.2^\0N.U\]6Y3=TY:=_P1&3H.DJ4"</=.]4D/SE>^_:<KW/
MKSZ.F[;T8]?>SB5GBLE20
M                                     !##]H/^1-!?'[[\7:![W<"]
M5F>^?;CX*,"6(
M                                  AIWQ?TYTS\TS_C!TO:>G5OAS?=
MNI1NJ^".DOW*3[%WM%Q3FJJLFRC:[U=:6^;;;X-#B-1U:M\NRL=.-R[C"S@
M
M
M             ",O?'_(.FOCDOO$+GM?/5N4W=.6G?\ !$9#HZE G#W3O5)#
M\Y7OOVG*]SZ\^CINV]&/7WLXE9XK)4D
M                                                0P_:#_D/0?Q^
M^_%V@>]W O59GOGVX^"C EB
M                                            (:]\7].=,_-,_P",
M'2]IZ=6^'-]VZE&ZKX(Y2_<9/L7>T7%.:JJR;*=K?5UI;YMMO@T.(U'5JWR[
M*QTXW+N,+.
M
M                         (R]\?\ (.FOCDOO$+CM?/5N4W=.6G?\$1DZ
M#I*E G#W3O5)%\Y7OOVG*]SZ\^CINW=&-\^]G$K/%9*D@
M
M "&'[0?\AZ#^/WWXNT#WNX%ZJ\]\^W'P48$L0
M                                                         !#3
MOB_ISIGYIG_&#I>T].K?#F^[=2C=5\$<Y?N,GV+O:+BG-4U9-E.UOJYTM\VV
MWP:'$W^I5OEV=CIQN7<8&<
M
M                                     1E[X_Y TU\<E]XA<=KYZMRF
M[IRT[_@B,ATDJ!.'NG>J2+YRO??M.5[GUY]'3=NZ,;Y][.)6>*R5)
M
M          $,/V@_Y#T'\?O?Q=H'O=P+U69[Y]N/@HP)8@
M
M      "&O?%_3K3/S3/^,G2]IZ=6]S?=>I1NJ^".<OW*3[%?:+BG-559-E&U
MOJYTM\VVWP:'$W^I5OEV5CIQN7<8&<
M
M                                             1F[XWY!TU\<E]XA
M<=KYZMRF[IRT[_@B+U'22H$X>Z=ZI(OG*]]^TY7N?7GT=-V[HQOGWLXE9XK)
M4D
M                   0P_:#_D/0?Q^^_%F@>]W O59GOGVX^"C EB
M
M               (:=\7].M,_-,_XR=+VGIU;X<WW;J4;JO@CG+]RD^Q=[1<
M4YJJK)LIVM]7.EOFVV^#0XF_U*M\NRL=.-R[C S@
M
M                                                      ",O?'_
M "!IKXY+[Q"X[7SU;E-W3EIW_!$;J.DE0)P]T[U21?.5[[]IRO<^O/HZ;MW1
MC?/O9Q*SQ62I(
M                              AA^T'_ "'H/X_??B[0/>[@7JLSWS[<
M?!1@2Q
M                           $->^+^G.F?FF?\8.E[3TZM\.;[MU*-U7P
M1RE^XR?8N]HN*<U55RME&UOJZTM\VVWP:'$W^I5OGWNRL=.-R[S S@
M
M
M        ",W?&_(&FOCDOO$+CM?/5N4W=.6G?\$14Z#I)4"</=.]4D/SC>^_
M:<KW/KSZ.F[;T(]?>SB5GBLE20
M                                          !#']H/^0]!_'[W\7:!
M[O<"]5F>^?;CX*,"6(
M                                       AIWQ?TYTS\TS_ (P=+VGI
MU;X<WW;J4;JO@CG+]QD^Q=[1<4YJFK)LIVM]76EOFVV^#0XC4=2K?+L['3C<
MNXPLX
M
M                    C-WQOR#IKXY+[Q"X[7SU;E-W3EIW_!$5#I*E G#W
M3O5)#\XWOOVG*]SZ\^CINV]&/7WLY%9XK()
M                                                    $,/V@_Y#
MT'\?OOQ=H'O=P+U69[Y]N/@HP)8@
M                                                "&G?%_3G3/S3
M/^,'2]IZ=6^'-]UZE&ZKX(Z2?<9/L7>T7%.:JJR;*-K?5SI;YMMO@T.)O]2K
M?+LK'3C<NXP,X
M
M                            C+WQ_P @Z9\=Y+[QI<]KCYZMRF[IRT[_
M ((C)Q0Z/-0)P]T[U2Q)_O*]]\TY7N4XWY]'3=NZ,>OO9QH5BR5)
M
M         $,/V@_Y#T'\?OOQ=H'O=P+U5Y[Y]N/@HP)8@
M
M   %:@45:)X?$!#7OB\=<Z97_=,WXP=)VF?DJWN<[K']RC=/P1TE^Y/3^"XN
M:<U35DV4;7+3;G2WS;;?!H<1J.I5OEV5CIPNXPLZE4 J
M
M                                                       %*\ *
M*XB<1&;OC*GR!IE4_P"^3+7_  &EWVKFJW0INZ<M._X(CHE$.BA0)P=T]:;2
MQ4_VC?4_C-.4[CUI]'3]OZ,>OO9Q15*Y8N0
M                                                    $,/V@_Y#
MT'\?OOQ=H'O=P+U5Y[Y]N/@HP)8@
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MNZ2[;VS&QOVM5;N92R(QW.BFHVW(D
M
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MOF7V/>O(KF>:^-Z=+)&+Q:Y/ I07+55NK"I?6[E-R,:7O&-D
M
M  !##]H/^0]!_'[[\7:![W<"]5>>^?;CX*,"6(
M                                                      /'U/J+
M'Z3P>0U%EY>RQN.A=/.O6J-3@UO\)R\$/=%N:ZHIC.7BNN**9JG*&O[</</5
M&\&IHYKF.5;=TBQ83 PU>V)K^A%:G!\CD3SG+['!#K;.GIL48^/BY2]J*K]?
ML9*TIW6,I?6C;O6.9^2I9&M<RQL6-GFCKTI*YZHVOB;T&M<[A'X:6Q1V_'FJ
M7-^JAI7H=J3(>7L8?WS#&OKQQX6>=!3AAQ'ZI^E/[2Y'_00_RB?^PK_E>?\
MKZ/YO<K^J?I3^TN0_P!!#^^/^PK_ )3_ *^C^8_5/TI_:7(_Z"']\?\ 85_R
MG_7T?S2ZINZ;IM6*D&I[]DB)YO/!"K:]5?.%/<:X\$U=OIGQ84W#VEU9MM+%
M/E&MNL7(_EM<Q9*Y(^;C1KOJHW='3TF_:U--[9A@T;NGJM;<<4B.[EO?=ZI1
MF@M5S]KJ"WB5^,R3U3FO(8T\YK__ $C$X\WU3?&4W<-'].?J4Q\JU[?J^/\
MMU3\T)'M7F:BE.N50
M
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MT=-?FS<PGQS\FPBWFBN8([B![9()6MDBD8M6N8Y*M<BIU*BU.1VQ.$NMS=H
M
M             AA^T'_(F@_C]]^+M ][N!>JO/?/MQ\%&!+$
M
M    $7N^%JA8K# :/@E3^E2OR%]#1>;LXJ,A5%\"N5Z*A=]JLXU\<^"E[I>X
M:>%Y'=<T78^@9#7M[$V6_6=V/Q?.G&%L;4=+(B=%7\R(B^)38U]Z>/AA@T5J
M(HXIS2-X%9M66$'D"( ]% %.( ;480^++8;&Z@Q=U@\O;I=8V_C6&X@<G2CN
MA47J5%XH[J)BN:9XH\'BJB*HX?- JY9?[;;B2,M).:_TOE:12K7ED["1*5ZU
M:K5XUZ3HYCZUC;^*'/X_2O;/PMDF.O8<E86N0MW(^"ZB9-&Y."*V1J.1?IG&
MU4S3.$NPIJXHQ?2>7H
M                                                  = %.9 ',@#
MF2E:\ ',@#F0!5 ',G#Q@.9 %4 <R* YD\("J .9OA 50!S-\(#F;X0',GA
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MD#W1-^DU#F=53A=J=+I9QM4[E_HY%-9LG,@"J .9 %4 <R=->GH 50!5 %4
M<R *H YDZ %4Z ',T!S( J@#F0!5/" JGA 50!5 ',@#F0!S( YDZU (Y%Z
M',GA 50"H                                         (8?M!_R'H/
MX_??B[0/>[@7JLSWS[<?!1@2Q
M         4YD <R>$!S)X0%4 50!S( YD <R>$!5 ',@"J>$!S)X0',E: *H
M YD\(!'-7H4!5 %4 52M %4 <R>$!5/" YF^$!S( 1R* YD4!S-7H4!5 (7=
M[Y?_ ,0L*G3_ .$(M/\ XB0Z7M4?).]S?<^>-S+>P#&)M/@E:E%?VRN5.%56
M1R57QFKK(GZLMS28?39,X]*&JV,5*^$&*M>!"<2OB"3P< %>L(Q$I5%Z*<44
M20A%W@V-9NQG4:B-YF6[EHE*N6-%5?*IT.CZ=,.>UFVY5*<&V[JZ TRKEJ[Y
M,M*JO3]R:<I?C"Y.]U5F<:(W+GJAA9BJ?1 50!S)T@.9OA <R=-0%4 <S?"
MYF]-> #F0!5*TKQ 50!5 %4 <S?#XP',GA <R?1 <S:TJ JG0 JGA <R</'T
M *IX0%4 <R *HO0 YD 50!S(!4
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M5:Y.**B]"H!R                                        "&'[0?\
M(>@_C]]^+M ][N!>JS/?/MQ\%&!+$
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M56GFNZ*=0&<- :SLM?:4Q^J+&%UO'>-5)+=ZHKHY8W*Q[:ITHBHM%ZT N8
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MH[[8WFKPZ0.6E]@LE=[CNPF6GB_-NRNIW33QJO/<16SD58F(O%'+S-:JKXU
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M!>JS/?/MQ\%&!+$                        XHY56E .0
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MRF-[=>O-@[_%ZWL\)I^YC7#7[;9GI,W!\#GHD<CG(E:\SFN>E/#0#LW$[O\
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M>YF8G*UTLZJ]R-\3:\J+UT O<
M                        MS7DBQZ3R2HE5<QC$3QOD:W]T"V8V>CZ'U59
M^Y6*YN;9$3@B*K(VT^F!QB;V6@]61.X<EW>L^FU .+GI_=_J>)O!T5Y=-7Q<
MTK5_="5&+Z/H[5EHOFNM[^>-6^#M)&*GT4<$.%NUUAHS5]H].5T%Q);JWP+(
MR-O^,!W0M6TT1K.%W!T<US$B>-;6%B?3 YVJHW1&K(5]VQUSS-\'-;QA+Y[5
M5M-'ZQM7<'03S.Y4\$K&.0(=^%?\E8#5T2IRK;2.HB?^F@:J>^ XXN/Y-TIJ
MVU=YKHF]FJ>!TEE$G^,!V8A.PTAJIDO!8H7,7RICHD Z<:Y&:.UC;IP<Q)I?
M8ELHZ>T!PPSO0-+ZMA?P= SM53Q36R.0"N(C?B\!JRW<G*L,-NJ)]]M&K^Z!
M].!:VVPVJX51$[&UAJG@7Y-C Z=,49I35$2I1S;9KE3Q+C8J>T!33SUM].ZJ
MAI18K*.=O"G"7'HJ+](#KTTY;#$:KB<WE6&TMYT3J5)K17U [M)1MQV.U&R2
MB=E8V<J^#S[-7 -&IZ/A<_&[ICL+-W_]O0!I9R,PV?A7@KL79S(B>!<<UO[@
M'#0]<?;9MCTY5^3K2[I_!?;+Q^D!313'6-GJ-7MY$^3[.Y1.CA)!,^OL@=^W
M_)#:9)%1&JF-Q\CD^R@D50*:":YF.S"O2B+86#D5?B:HOM =NBI8X=/Y")OW
M1N/MYW4_A6O_ )@/EVX>ZU6]65O)S8RSO/ E)&O6OT@*[:JD$M_</2C'6-O/
M3^"LMPZHS$;=^FK\FX%GU[+1WL.[9?W2Y[7.,58YX2INYQR8>,LD; 3IZ%JF
MVKY[;N5]/%RHA@N1\TXMBU/RQ"\M$-]'2[C5*)+C(;I/&BM<E37CQ9YC+>XZ
M!YK>YN9%2C7XJ&Y\O--(ZI,2BMVZ!<D<]PYW!9+&";_!6XG6OT%%.?HFKXJ:
M!7DOW-=P22QB>GD;<35]L\QEZ)J<="M[*_Z*)=8QDU?L)7M7VSTAPT CH[Z2
M5[:+<8U;FOB2X5*D1X)JG8[-"U3)SW*I3MK1\Z>-%OI%J3&>U%4;-B.V_P"G
M:QX"9.A8[Q5\DEW*I:]NJPKJW*KN-/\ ;IWI&;+)V-GA4=P2ZT]:.8GA[*:1
M%]\4=V/GG>N[4_)&YZ6VZ+'F955*)=V'I#5\/+<O8IXE[A3;SF^7&S*WE2[L
MKJ=%\*>F\O[A"7U:.5K]8W\R4I-!>O;3K3Y1>@'5H94BU/<QJG&:"[5/\'(2
MK^Z!TZ'C6'45K,J<+RUO_.3K6*_DZ?H@<]",=%GHY7)1+V&]F:[K=R7*,K[
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M<2I[0'6WG=KM;OE7E3-+:<W_ ,&KJ 95
M             !##]H/^1-!?'[[\6:![W<"]5F>^?;CX*,"6(
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M7P]A&C@*XEJKKEMTBIR7&1R<7C7L(&)])0*8R3M-PGRI[B2^OF-7[W9P-_<
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MT6(!]X
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M<B^R@'M
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M '5^%?Y(#]1[>_\ W5^%?Y(#]1[>_P#W5^%?Y(#]1[>[_=7X5_D@/U'M[O\
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M8N7W#_2$[-&N3[-*>0"DVI;BRBR\<\$;)\7C[>Z8U*HQ9IV/1&+_  4>RGD
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M1U<YG'ZGEI0#WL%?2Y3$663F8V-]W$V?D9541)$YD3CXE ]$
M                                               MG7ZJW2MY*U*K
M"^"5$^PG8[]P"V;M$FTGJJ[:O!F6DNV+UTB="]/: 3M9=:,U==HGVQ<A<S([
MKK"^-6_0H!TRM=+I'6=^_C)/>OX_>71M1?I ?1?/6\TUK&]3HFOZ)]C;NB8G
MTF@==R]M]IK6EY$GF27[9F>2%('(O_1 YW21WFF-;7Z)YZWCI&KXK>*&5OT%
M50*]DESI;6E])YSKATM57C]QA:J?050ETS.]+T_KJ^;5>U<V%J_%H6,3Z 0K
M<.3(X/7-PB>;(^%$7P]A!$G[@'?(K<C@];7;.B:2.=/%V=K _P#< I U,CIW
M6=V[B^>/GYNE5[.RCE;]-0.JV1;K3FMKV7SG/@;!S+U^CV3:?0Y@.$-;_!:U
MNF?YVV@A3_L+1$_= [%<S(XG6D\?%LMO9^6L=FQ5^F!W6C&Y+&ZTE?Q[:WMW
MIU^YL&2)]-0.G$)\I:?U;>S\7OLHX47IX1X]DB?3<!3%5N<-JVXI5?DFUMT7
MP]E8*[VW@<,>JY+&:P5B48[&6<#%^QLEK]-0.[%L9E+'5CF^<EQC;!JUX\6V
M2JOTP&!1,IC]1W4OG/?C;.-%Z:IZ$C_; I@>:[L<Y<2>=R8.RME7RV7:*GT7
M =6"7TZRS[X_<I@+.T3[)MJ^OO@.>F7,RMAJ!.5.9^%QT#Z_7):S(J?1 [=*
M1IE(<Q+/Q6;$V$2IU(BV[T7Z: <='_\ B$65GDXK'A[&VIXI+=SU^F!U:;K<
M13]?9:8M;=?*K9'?N@<M&R+E6WC.7S4T_86B^-R1RHOM@4T.WY4]/8]M9%PU
MK9*B^!JSQT_Z*$3(COO]>2RV&FGN=7T:*S;&OL2I_BEQVZG'BCV*KN%6'#/M
M7MW?K-$9JVYIYLDTD2K_ -*A%^K&K<FQ3A3OVK]TK(MR]S6^YML!#;5Z>*J]
MZ_34TFW.R,%-(/\ 3GS1NZ6Z?@M?^G(TF"I71K/3)G(_BD>(AM./4BR2QJGT
M&B,RJ=GJKHM%NKZ%K_.2WQ20)X/MD[T5/^B33M15L5T8]9KZS:J52VPKHJ_?
M)WN_<(C:3L<-%3^E30Q(E.PP;K94_P#B7$YDQ@:+<EW/#$]*R6V(]$2O@;=2
M1T^@(S*LD>-^I%CATZSH>D$L2^2VNI4;] L^W1MJB?!6=QG93,)&;/KZ19Z7
M\%GI]CE3QW,[E7Z/*4MW#BG>N+<SPQN>GMZ])LG9PIT6.*EB5?X4MZYR_20Q
MLKAH.3TC)V,"I1UKB;FW6OA;>JB?2 YZ$:V3-6UL]*MQV.NK=J+U*E\YGM)0
M#CHF-7ZAMK?IBQUM?]GUTY[Z2/VF@=NCG]KEL/ G19V^4<OB6:^<B?2:!UZ+
MD;)F\3 SIL[+(QR>5UXCD^D!70W+)FK"U>E78ZRR,2>)4O6)[3J <=&PO=G[
M&U=]SQC<HD:>#^D]G[2@<]-*UVI<;91\&6#\S)R^*2Y6-/: X:4F234&+LZ>
M?9R9IRKXI;A* <M(R.=G,9:*B)Z N9C1/$ZXC>GO@*:3;S:CL[1U:8Z3+,C:
MO526)/\ '4!I^-':OMK%/<8^[S,[$ZD1TC8T^DH''3\R/U586;6T2WR6<E\B
M.7E3VU KIR1':FQ]G3SK.^SBU\4KFN3WP%=/U;JRRL'<6V=WF%:WP*](7)[\
M!@8E=J]F/_\ 9[+(96:)O@X0T^$4!AVL=JNWLX^'89G+W'*G0B=BQB>^4!C)
M4=J^SLZ5?'F<S.[Q(Z-*>VH%<,C4U38VM.-OELR]6_?(6O1?HN KAVM35\&.
M7C':Y/*2-3P.?#%(GOU I91UU3#8)]SCSU]=,;X$CM(E3WZ@<;=S?SGM;2/J
MU%?SO;XDM6I7Z+@.>.Y$U;!9NXR,SV1N/\&2S54 K:M5=7PV3D1619N]N$3[
MY:I(GTP*1QHNM(\:G"%N9FNVM_A,LF2JOT7 =:<KM7NL6]*Y_P!+5.K[79LX
M_P#2 1W*IJE<?R]&I5N4^Q=8*E?H@90
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M0K]1:0-^A&@'J
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M)^:[=.JQJO@8M>('5MUN!I;+[EWV)M,A&Z2/TQ+21WFQSJLJO=V3EZ>"*OD
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M_<?2>Q[/LN?HYJ^:!GEJU1%4"H
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M)XE1S7(C41?93H5.H#U@
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M-\5O%%*_M)&,:U\B\%<Y$HKO9Z0.T
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MHF32.>UJ^!51>94ZJ@9-
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MG*KZ)S*B=2KTT JD;$>LO(G:.1$5]$YE1.I5 =G&DBRHQ$E5**^B<U/!7IH
M[-B2+*C&I*J45]$JJ>"O2 2-G:+)R)VBIRJ^B<RIX*@$BC1ZRHQ.T5.57T3F
MIX*@4[*-)%E1B=HJ<JOHG-R^"O30"O9LYUEY$[6G+ST3FY?!7IH [-G/VO(W
MM:4YZ)S4Z:5 Y@
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M96->VJ*B.1'(BIU\0.8
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MMH
M
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M1@[ D
M
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M&RM(+*T9V5K;1LA@C3H;'&B-:B5\")0X['&<77881@^D)
M
M
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MS&LU4WJMF3I-)I8LT^UEI$HAHMX
M
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MD<DMY>2^=<7$M*<TCNNG4B<$.>O7Z[LXS+H;-BFU&$+O1*&NSJD@
M
M
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M6I1%=R(E5IUJ:M54U9RV::8IRAZ"(B)1"'I4
M                              / U?K#":(PS\[GYG0V#'LBJQJO<KY.
MA$1 /.P6Z.W^H;=+G&ZBLE:Y:<D\K;>2O@Y95:OT /4GUEI"V2L^H,='PKYU
MW BT\2<X&/-4]X+2>-Y\?I))-3Z@559%:6;'+"UWADDI[G[&H%BXW<'>72-R
MNH=50-SV#OE62^Q5MRI/8HJ\$BY4ZD7HX@9FT?NGHC6T+7X?*Q-NUHU^/N7)
M!<M>OU/(Y4YE3^#4"\P 'AZAU=IO2EL^[U#E;?'Q-;SHV9Z=HY/X,:5<[V$
MPCJ'=O6.OY78G:V"7%8=CE](U+>-1CGHWH2%JHY$15Z^*^0#T=*[[W& 1FG]
MV[27&Y&#S&YZ.-7V=PB=#G<B+RN5/K:^P!E6PW T1D8F36FHL<]DB58CKF)C
MZ+_!>Y')] #G?:ZT9C8G3WFH,?%&QJN5/28G.IXFM<KE]A /-TANAHW760O,
M;IF^==W%BQLLKEC<QCHU<C>9JN1*I5: 7F
M                                HJ(O2B 5H@ ",W?'5?D#3*=7ILJT
M_P !"Y[7SU;E-W3EIW_!$4Z25 G#W3O5)%\Y7OOVG*=SZ\^CINV]&/7WLXE9
MXK(HG@)%:(G0@
M
M                                                    *(O2!#3O
MB_ISIGYIG_&#I>T].K?#F^[=2C=5\$=)?N,GV+O:+BG-559-E&UWJYTM\VVW
MP:'$W^I5OEV5CIQN7<8&<
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MJ<K6M2:-$1$0"2@
M                1E[X_P"0=,^.\E]XA<]KCYJMRF[IRT[_ ((C=1T<J!.'
MNG*G]TD/SE>^^:<KW/KSZ.F[=T8]?>SB5BR5)
M
M
M              J J!17-3BJ@.9M*UX$3. AKWQ>.N=,JG1\E3?3N#I.TS$T
M51[7.=VCYZ)]D_!'27[D_P"Q7Z9=1L5%639/M<J)MUI;YMMO@T.(U$Q%RK?+
ML['3C<NY7-3I4PLYS-3K 53AX^@"H
M                       89[SWJPD^.V_M/ ^+"_D;'?%8/@VD#[0  "J=
M(%I;+^NG6GWA/?,)%S]Z'U<L^/0^TX#KQ_Y.L_O$?O$('T@  %6]*>5/;"5I
M['>N;7_V#OAXR4)(@
M              **ZA XN>UB*YZ\K4XJY5HB>R!P]+M?^OC_ ([?WR<!&COB
M212X#3*QR-?2\FJC7(OU#? 77:N:K=\5-W3EIW_!$KJ.C4";G=1FBCVFA221
MK%7(WO!SD3ZIOA.3[CUJO1T_;^C'K[V;_2[7JFC_ ([?WRNP6.+MKY2,15%J
M2*@
M
M                                     <'.1. %I:[W+TCMUCVWNI[U
M(%FJEK:,3GN)E3ZR-.*I7A7H/%5<1FW=)HKNIJPMQBC=G.^!FYIY(].:=M[>
MQX)!+?R.?<5ZU5K*LX]1J3JO)U=K]N41U*L=W_PM[];'<I.B''I_![+H,?\
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MXWHCF/:J.1S52J*BIU*;,2YO#PEW)Q"
M                         89[SWJPD^.V_M/ ^+"_D;'?%8/@VD)?:$
M"J=* 6ELOZZ=:?>?\9A(N?O0^KAGQZ'VG <,?^3[/[Q'[Q"!]   !R3I3RI[
M82M+8WUS:_\ O;OAXR4)(@
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MW%35;+D2
M
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MZA.I?$;&GNS.R5;W[ME'#-VB,*J>:/BF"G0;KAE0
M                                !AGO/>K"3X[;^T\#X<-^1\=\5@^#
M:0/N   *ITH!:6R_KIUI]Y_QF$BY^]#ZN&?'H?:<!UX_\GV?WB/WJ ?20  #
MDWI3P53VPE:6QOKFU_\ >W?#QDH21
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MY*+V<K4>VJ=2T4XV:>&9I\G815Q1B^SI"0
M
M
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MMK$=^Z6\3C#Y/=M\%<T^4O1)8@
M                  PSWGO5A)\=@]IX'Q87\C8[XK!\&T@?:  !(G2@0M/9
M?UTZT^\_XS"1<_>A]7+/CT/M. Z\?^3[/[Q'[Q"!](  !5.EOE3VP+3V-]<V
MO_L'?#QDB2(
M       $:>^->*W3.F\<B+]MR#YU=U?:HE2GL\Q<]IC^Y*F[K/\ ;B/:\7NH
MV,#,'J3)<C5NY+J"W[54\](4C<Y6<W31744V>X3\T>K!V^/EJ2%ZZ]?A*U8^
M2H2 /;  .@@4IP\"$PB=J'7>=Q=I8[F-N(&<LF5QT%W><?=2HY8JIX/-:A>]
MOG&UZJ/71A=]$I]@[NXO=H-)W%U(LLSK1S5>[I5&2O:WZ"(ASNMZU6]?Z+HT
M[F234;@
M
M                                       $+.]_ZQ,-\TI^,2%?JLWT
M#]N=&=[+.P7JHP7V,WPKCW;Y59W/KU,DGI6*   %0* <F\5))R0D[P7K7S?W
MNW^#0TKG,[KM?Z>$XMM?5]ICYLM?@FEI1RP^;ZSK5;UTGMI@
M                                       !AGO.^K"3X[![3PA\.%_(
MV.^*P?!M(2^X  ]L"J=(%I[+^NG6GWG_ !F$BYN]#ZN6?'H?:<!UX[\GV?WB
M/WB ?20  #DWI3RI[82M+8WUS:_^P=\/&2A)$
M                                 "+W?(_)NEOC,_O&EYVGFF5)W7EA
MU=U3]%,_\?B^"<9=?S0Q:#EJ9Z\!7++PARH   "  IU#Q1X(C=ZGUBXKQX:'
MX:0O.W].=ZDU_5C<DIW>?4UI+XM)\/(<_KNM5O7VBZ-.YE U&X
M
M
M                      !"SO?^L3#?-*?C$A7ZK-] _;G1G>RSL%ZJ,%]C
M+\*X]6^56=SZ]3)![5@ 4    <F])*)R0D[P?K6S?WNW^#0TKG,[OM?Z>E.+
M;7U?:8^;+7X)I:4<L/F^LZU6]=)[:8
M                      89[SOJPD^.P>T\#X<+^1L=\5@^#:0/N  .L"J=
M*>4"TME_73K3[Q_C,)%S]Z'U<,^/0^TX#KQ_Y/L_O$?O4('T@  ').E/*GMA
M*TMC?7+K_P"]N^'82A)$
M                B1%[OD?DS2WQF?WC2^[5G4I.Z\D;W3W5/T4S_P ?B^"<
M9=?S4L>@Y:F?/ 5OFL8RAR H 0!T>P0!(H1&:/#U1'[U/K%Q7S-%\-(7F@Z?
MJI==U8W))]WGU,Z2^*R?#R%!K^O7O7NBZ-.YE TVX
M
M
M             !"SO?\ K#POS2GXQ(5^IS?0/V[T9WLL[!>JG!?8S?"N)M9*
MSN?7J9(,BL      Y-)@G)"3O!>M;-_>K?X-#2N<[NNU_IZ4XMMO5_ICYLM?
M@FEI1RP^;ZSK5;UTGMI@
M           !AGO.^K"3X[![3PA\.%_(V.^*P?!M(2^X   JG2@%I;+^NG6G
MWG_&82+G[T/JX9\>A]IP'#'_ ).L_O$?O4 ^@@  ')O2GE3VPE:6QOKFU_\
M>W?#L)0DB
M     1(B]WR/R9I;XS/[QI?=ISJ4G=>6-[I[JGZ*9_X_#\$XR:_FI8]#RU,^
M> KEA'@J$J@4Z '5Y2!5P(<1&:/#U1'[U/K%Q7S-%\-(7G;^GZJ77]6-R2?=
MY]3.D?BLGP\A0:_K5;UYHNC3N90--N@
M
M
M   0L[W_ *P\+\TI^,2%?J<WT#]N]&=[+.P7#:G!?8S?"N)M9*SN?7J9(,BL
M  %0*=8 #DW]XDG)"3O!>M?-_>K?X-#2N<SNNU_IZ4XMMO5_ICYLM?@FEI1R
MP^;ZSK5;UTGMI@
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MOZ]6]>:+HT[F4#3;H
M
M                                                 $+.]_ZP\+\T
MI^,2%?J<WT#]N]&=[+.P7':C!?8S?"N)M9*SN?7J9(,BL      Y-)@G)"3O
M!>M?-_>K;X-#2N<SNNU?IZ4XMMO5_ICYLM?@FEI1RP^;ZSK5;UTGMI@
M                                              !B'O*V5S=[67K[
M:-7I:7$%Q-R\5;&BJQ7?1<@'AZ:N[>_T[B[RTD26V?;1-:]J\*QL1JM7QHJ
M>H0 2!"K.*I1>'6O4B>%0+4V)9\I[HZWSUE]LQ;4;!VZ>Y61[DHC5Z%]PI(N
MSO,V5Q=;93S0,5[+.Z@FN*)54CJK:^2JI4#SL#>6^1PF/O;21)+::"/D>U:H
MJHVBIPZ_$0/OZ0 "J>$)5;15XK1$XJO4B=*JOBX$H6KL%&[(;FZ\U!:)VF)D
M7L&7*<6K(^5KD1/8:H$CP
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M9FSR&X]U=7>6RMW-?6+\A(^6Y2QD:QL2/[3SFU5KG-3P*!G\
M
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MJOZ7<U/8Z ,M@
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M*]RN5W3$Q:<U.GW/A V91L2-$8U$:QJ(UC6I1$1.A$3Q <P
M
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M1.1/ !])   *M7SD\J 6KL2JINSKYB+1E%7E3HJDS.-"1(\
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MO^N<YS%55\:J!]N4:C,5>HVB-2WE1$1*(B)&M$ TX]WK_F3T/_Q'#\*H(;G
M &NG]I)B[*WU+HK+Q6S&7]U9W4-S=-2CY&0R-Y&N7KY>9:>4"1/<<S5YFN[S
M@EO'J_Y/N;O'P5XTAMY/,3Z8$C.5*U Q5N-WB]I]I\Y%IS6^8?89:6!+ID3;
M>65%B<JHB\S&JE5IT 1HWM[_ %I>;3^2TSM197-]ELA$ZU^6[V-(K:&.9JM>
ML<=>=SZ+YM:(@'B]Q[NWZBM]11;QZ[LI\=;VT:NTU:7*.CGN)IVJCKE[7>=R
M(Q5Y>9/.5U>H#8,B4 Q]O3NIA]G-O\KK;*\LDUM&L>,LG.Y5N;V1%2*).NBK
MQ=3H0#6AM!MOK?O;;P7NHM5SRR8?MTO=49BBI''%_F[2#J15:G(QK?<MX@;7
M\'@<1IG$6. P-G'C\/C866MC9P-Y8XX8THUJ)['%>E>L#T@
M
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MTX#ACOR?9_>(_>(0/H   *ITH!:NQ7K=U_\ 8K\,PD2/
M                                        (D1>[Y/Y,TM\9G]XTONT
MYU*3NO+#J[JGZ*9_X_#\$XR:_FI8]#RU,]T\!7>:QC*%0*H0 %"07P$"@A'A
MZHC]ZGUBXKYFB^&D+SM_3]5+K^KZ))]WGU,Z1^+2?#R%!K^M5O7FBZ-.YE T
MVZ*!K8_:1(O]XFCW*G#Y'EHO4M+EW0!*/N3*B]W+2U%3@^]1:+7CZ5(!(0
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M<G2C*HQOB0#+@
M
M                       A9WO_ %AX7YI3\8D*_4YOH'[=Z$[V6-@?53@O
ML9OA7$VLE9W/KU,DF16 %0* 5 H!R:3!.2$G>"]:^;^]6WP:&E<YG==K_3TI
MQ;;>K_3'S9:_!-+2CEA\WUG6JWKI/;3
M                       ##7>=]5TWQVW]IX'PX;\C8[XK!\&T@?:   $Z
M4 M39?UTZT^\?XS"1<W>A]7#/CT/M. Z\?\ DZS^\1^\0@?2   53I0"U=BO
M6[K_ .Q7X9A(D>
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M
M
M          0L[W_K#PWS2GXQ(5^IS?0/VYT9WLL;!>JG!>#EE^%<3:R5G<^O
M4R29%8 5 H!4"@')I,$Y(2=X+UKYO[U;_!H:5SF=UVO]/2G%MKZOM,?-EK\$
MTM*.6'S?6=:K>ND]M,
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MBHYCV/2J.:J<%147@H'8
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M443,XNX_;VJMT4\$U83,SL2"V"X;4X+[&7X5PMXX-/N41]><-K)1D5J@
M <FDP3DA)W@_6OF_O=O\&AI7.=W7:OT\)Q;;>K_3'S9:_!-+2CEA\WUG6JWK
MI/;3                                                    ##7>
M>]5TWQVW]IX'PX7\C8[XK!\&T@?:   53I0"T]E_73K3[S_C,)%S=Z'U<,^/
M0^TX#KQ_Y/L_O$?O$('T^V  J 3I0"U=BO6YK_R+\,PD2/
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M(V6+16!9(Q:M>W%V:.1?"BI%5 +HM[2WM(6V]K#'! Q.5D43$8QK4ZD1M$1
M.X !14J!;69V\T%J.ZDOM0:6Q&3OI6HR2[O+&WGG<U$HB+(^-7<.KB!UX?;7
M;W3]S#>X/2F'QU[;U["ZM;"VBG95*+RR-C1Z>PH%T(WC4#D!147I3I \7/Z1
MTKJN%MOJ?"6&8A9S)&V_MHKCDYTHY6+(U5:JIUM U2=\+;[;O06\"Z<VRB6&
M.:UADR>'B<Z6.UOYG+2*+FJY.=G(_EYEHKNKH VB[4X_*8G;;2>-S2N7*6V*
MM([E'M[-S7)$WS'-7H5B4:OD O$
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M:<!PQ_Y/L_O$?O$ ^@@  %4Z4 M78GUNZ_\ L5^&82)'@
M                                        $2(O=\C\FZ6^,S^\:7W:
M<ZE)W7DC>ZNZI^BF?^/Q?!.,NOYJ6/0<LL]=96K&/!R *!4"@%>K]P@<?W1"
M/#U1'[U/K&Q7S-%\-(7G;^GZJ77]7T23[O/J9TC\5D^'D*#7]>O>O-%T:=S*
M!IMT                    !Q>SG8YG,K>9%3F;P<E>M% BEI3N583"[X7>
MZ&>SLVHL.V;Y3QMCD$22Z7)2/<Y5N7TY7LCX*S@E5ZDH!*Y$HM>M>D"H
M
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MR *M$ XHZO4I*,546J5(2J
M   B1%[OD_DS2WQF?WC2^[3G4I.Z\D;W5W5/T3S_ ,?B^"<9=?S4L>@Y99ZZ
MRM\UC'@Y     !0B$>'JB/WJ?6-BOF:+X:0O.W]/U4NOZOHDGW>?4SI'XJ_X
M>0H-?UJMZ\T71IW,H&FW0                     "B-1.A *@
M
M       QOW@(^UV7ULSIKC)OI44" 7<ZE2+?/ \?NMM<,^BRO[@&T4
M                                           "%G>_]8>%^:4_&)"O
MU.;Z!^W>C.]EG8+U4X+[&7X5QZM9*SN?7J9(/:L      Y-))R0D[P7K7S?W
MJW^#0TKG,[KM?Z>E.+;7U?:8^;+7X)I:4<L/F^LZU6]=)[:8
M                         M/7^O<'MY@WYO-R.5JN[*UM(J+-/,[H8Q%^
MFO0ACKN11&,MO2:6O45\-+"GZP6Y%]6YQ>DK**P>M84N[A[)E8O0KDJB&E_M
MU>$.LC]N6XY[DX[E?[]MV?[+8K\*?_*(_P!JORA/_P">L_\ V3]BG]^V[/\
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MIUI]X_QF$BY^]#ZN&?'H?:<!UX_\GV?WB/WB$#Z0D"#B!5."H!:FQ7K<U_\
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MKDK"WR%C,VXL[IC9H)V>Y>QZ514]@]N1KHJHF::LX?4'@
M                   !TW%S;VZ(MQ,R%%Z%>Y&='E5 ,<:C[P6S>EH[IV5U
MACW36;ECGM;:5+F='MZ6HR+F6H%P;?;@X+<S3T6K-,I<+@;A[X[.XNHG6[IN
MS7E<YK'HCJ(ZK:J!=H B1%[OD?DW2WQF?WC2^[5G4I.Z\L.KNJ?HIG_C\7P3
MC+K^:ECT'+4SV5JP\E0D   "@4(A'AZHC]ZGUBXKYFB^&D+SM_3]5+K^K&Y)
M/N\^IG2/Q63X>0H-?UJMZ\T71IW,H&FW0
M
M            !8&^#.TVBUDSPXNX]Z!KI[I<W8[ZZ1ZDE=-']&%Z_N ;50
M                                               (6=[_ -8>%^:4
M_&)"OU.;Z!^W.C.]EC8+U4X+[&7X5Q-K)6=SZ]3))D5@!4"@  !R0F"<D).\
M%ZU\W]ZM_@T-*YS.Z[7^GI3BVU]7^F/FRU^":6E'+#YOK.M5O72>VF
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MY5E;6KGHB\:(C6_1 O/?S2V2U3MW>6^)C6:_LGLO([=O3(V*O,B>/E6H&/\
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MN5$7HJG0*<V2WG"0&PCWOVIP'.Y7<L<C6UXT:DKD1$\2&Z^;]Z_65[V20I0
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MW0
M                                         !8^\;.TVKU>SPXNY]XH
M&M7NMO<W?;0E.N[D:OD6WE_> VQ
M                 0L[W_K$POS2GXQ(5^IS?0/V[T)WLL; ^JG!?8S?"N)M
M9*SN?7J9),BL.H"H%   #DWI))R0D[P?K7S?WJW^#0TKG,[KM?Z>$XMM?5_I
MCYLM?@FEI1RP^;ZSK5;UTGMI@
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MAY"@U_7JWKS1=&G<R@:;=
M
M %H[IQI)MMJMB]>*N_I1.4#65W7..^V@_CLGXO*!MC
M                                A9WO_6'A?FE/QB0K]3F^@?MWH3O9
M8V"]5."^QE^%<3:R5G<^O4R29%8 5 H   <FDP3DA)W@O6OF_O5O\&AI7.9W
M7:_T]*<6VWJ_TQ\V6OP32THY8?-]9UJMZZ3VTP
M              O0)$:^]-^4M$_&)O::5FLSI=K^W.6YZ?%;:FJZ:5 @ $)C
M-;F3_3O1?Q^+WX_'#S=_3W/RRDSOIZIM5?$E^$8=/I>K2^7Z7JTHW:*_13%_
M>W>_4NKF<K:OFE[QB8PD /#UC^B^6^+N/=OFC>R6^:-Z2&QOJJTS\67X1Q3Z
MOJRJ=5U99"-5K 'GY[A@LFO_ +I/\&X#7 ONW_9N]\H2F+W8/5R[X[-[30AF
MH    >!KC]#\Y\2G]XH&NYON4 FOW</57COO]Q[\#+('%W41(CMWL/R=H[YS
ME^#0M>W\U6Y9Z'.I:B]/L(;4YMGQ @)#J//@F5JZE_2;2'SE%[]#-3R2R4\E
M6Z4J=W_5AJGXA+^X<UX*_MWZFC>C'H;]$\?_ -I[]36JS?5+O,N!3RPJ 5(D
MC-Y6IOT>R7WAWM$QF]T<T,^[!>JG _8R_"N-U\X[U^LK_CP9+"E
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MPTA>]OZ?JI=?U8W))]WGU,Z2^*R?#R%!K^O7O7FBZ-.YE TVZ
M
M                             +:W#C[70.J&>'$WWTK=Z@:P>ZYZ]=!_
M')/Q>4#;&                                                 !"
MSO?^L/#?-*?C$A7ZG-] _;O1G>RSL#ZJ<$G\&7X5Q-K)6=SZ]3)!D5@
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M7T23[O'J9TE\5D^'D*#7]:O>O-%T:=S*!IMT
M
M                >#KAO-HK4C?#B[Y/HV[P-7/=<]>N@_CLGXO*!MD
M                                             A9WO_6'A?FE/QB0
MK]3F^@?MWHSO99V"]5."\/+-\*XFUDK.Y]>ID@R*P <   "H%6DDY(2=X+UK
MYO[U;_!H:5SF=UVO]/2G%MMZO],?-EK\$TM*.6'S;6=:K>ND]M0
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M?%9/AY"@U_7KWKS1=&G<R@:;=
M
M     'B:R_1#4'S;>? /"8:M>ZZM-]M"+_[](GT8)0AME
M                                   A9WO_ %AX7YI3\8D*_4YOH'[=
MZ,[V6=@J?W4X'[&7X5Q-K)6=RZ]3)!D5@   5 H!5I,$Y(2]X+UKYO[U;_!H
M:5SF=UVO]/2G%MMZO],?-EK\$TM*.6'S?6=:K>ND]M,
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MQHU>+6NX\CEZ5 D4J\R\$Z.FO #BD36N5R-1'/\ =N3I6G15>N@'8G0
M   (D1>[Y/Y,TM\9G]XTONTYU*3NO)&]U=U3]$\_\?A^"<9-?S4L>@Y:F>^L
MKEA&4*A(!7@!0@.HD4(C-'AZHC]ZGUBXKYFB^&D+SM_3]5+K^K&Y)/N\^IG2
M7Q63X>0H-?UZ]Z]T71IW,H&FW
M
M     !XFLOT0U!\VWGP#PF&K'NR.Y=\M!N_W@J?QHY$"&VD
M                                    "%G>_P#6'AOFE/QB0K]3F^@?
MMWHSO98V"]5&"\DOPKB;62L[GUZF23(K     * <FDDY(2=X/UK9O[U;_!H:
M5SF=UVO]/"<6VWJ_TS\V6OP32THY8?-]9UJMZZ3VTP
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M6SCY+G%Z9559*]S>+)+E4HK43@J,3V0)W,8C$1J<&HB(B)T(B <@
M B1%[OD_DS2WQF?WC2^[3G4I.Z\L;W5W5/T3S_Q^'X)QEU_-2QZ#EJ9[\!6K
M",H<O*$J   !>@"A"/#U1'[U/K%Q7S-%\-(7G;^GZJ37]7T23[O/J8TE\5D^
M'D*#7]:K>OM%T:=S*!IMP
M
MPMN-WH=L]K=43Z0U3'E&9>"**=%@LG2021S-1R+')S(CJ5HZG0H&-]3=][:7
M(X'*8RQM,M)->VEQ;1N?;=FB.FB<Q%7SEX54"#^V&K8]O=<Z?UE<6;\A'A+G
MTJ2RB>D3Y/-<G*CW(J)[KIH!,'_\X3A:_H!??_M"#_5 9PV'WPGWRQF5SL&F
MIL#AL?.VT@FN)VW'I,U*R<BL:U$[.G*[Q@9@
M                       "%G>_]8>&^:4_&)"NU,[7T#]N=&=[+&P?JHP7
MV,WPKCW;V4JWN?7J9)/:K '2    *IPZ.(,T)>\%ZU\W][MO@T-2YS.Z[5/_
M /FB4XMM?5_ICYLM?@FEG1RP^;ZWKU;UTGMI@
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M$D^[SZF=(_%9/AY"AU_6JWK[1=&G<R@:;<
M
M             (R=\O:%^N]#-UIA84=J?2C72N1*\T^-5:S1(B(JJK?=M1.N
MH&N%JHM'MZ^**!7H2G4!W6EE=Y*\ML;CXG3Y"]E9;6L#/=/FF<C&-;6G%54#
M;OL]M]9[9;<X+1]LQ$EM(&OOI$3E62[E3FE>[IXJ[A[ %]@
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MG&$2MNT?J[>_X('-]RAX?5_%./8'U5X/[&3WZGN'RSO7ZNO^/!DPE2@
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MCEG<Z5O_ $7H<QJZHJNU3[72Z6GAM4Q[%_FLV0
M
M                #A+%%-%)#*U'Q2-5LC7<45KDHJ+Y4 U3=Y#::7:3<N]Q
MUI$K=+YCFR.!D1%Y&12.7G@JO"L3JHB5KRT7K Q&!)#N7;:KK/<Y^K<A!VN!
MTA&DZ*M%8[(SU2!KFKT\J(Z1%3H5H&RA
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MA3#8U$UK8VM9[AJ(C?(G!"U?*Y<P@
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M)T(AR56W:ZJ-FQV)T<214
M
MO0!A/O/[2+NQMI=08^-/SHP?-DL&^E7.D8VLD'3P25J46G'@@&K*7M(D>V2-
M[)8U5KX%:J2(]JT5O+TUKPH!M6[LFVK=M=I,/87$:-S>68F5R[T6OV^Z:CFL
M151%1K6THU>A:@9C3H
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MN<4[(C*%_P :*C$1W29%:Y
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M<UT9NGH[15Q#K94M-,WBMN-/8:='>FVS745RN3H8QZ+5&=*>V$F0
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M
M                                         "B] $-=2]UM\_><Q&?L
M;9J;>9)[\_D?-7LXKVT<BNMV\M:=H]6RIS\%\Y )DL2B4]KH Y
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M+&QQIT1L1&M3R(AZP:TS,YNT(
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MKUT3K(P%>7QDBM*  *4 HK*]:C $:J(E5K0C <B0
M
M                      %%2J4 IR]=>(%42@%0 %%6@"O"M "+5 *@
M                                        "GAX@4IX. $->^+^G.F?
MFF?\8.E[3TZM\.;[MC]2C=/OA'.7[C)]B[VBYHG:JKDS,-E&UR*NW.ETZ/\
MPRV^#0XB_P!2K?+L[$_VXW+M:RG2M3 S8JTXU J
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M!YUW;ZHN+E[DBLYEX-N$>M6M=]1R)TI0#88G0 Y4K7K J
M
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M/MHW.<YR\5556JJ!<@
M     0T[XOZ<Z9^:9_Q@Z7M/3JWPYONW4HW5?!'.7[E)]B[VBXIS5-7*V4[7
M>KK2WS;;?!H<3?ZE6^79V.G&Y=Q@9P
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MI0;)?\N-[]CD_?..3[MUYW0Z/MO0A%5/<IY5]LJ5FFOW</57COO]Q[\#+(
M  C)WP?ZGI%/_3WGP<9<=LYJMRST&<HU:?\ TCPOSA:_#-+>YR5;EO<RG<V8
M'(.5  %%Z +!WK]5>J?BO\XP2MNS_J[>_P""!Z>Y0QOJ_BG'L!ZJ\']C)[]3
MV^5]Z_5U_P >#)A*F                  !QD:CF.:Y.9JI1R+UHO2!"C6/
M<<FS6ZK[[3^29C=MLFY;[)(OGWEO.YWVR"!%]TC^E'+[D"6>A-!Z6VZT_;Z:
MTE8,L<;;HG-1*RRR=<DK^ESU\*@7,
M
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M31NAE1DC4<B/8]$<U4KQ10/1
M
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MQ=GEK"3M;&^A9<V\E*<T<K4<U?H*<?51-,\,YNMIKBJ.*,GV50\O2H
M                                7H BSWNOZWI'["[]IA6Z[P=M^U_\
MGHP+I#]+M/\ SE:?#-*^CFAUNJZ-?Y6Q_K4Z%\<5)  !B_O$>IW4WWJ#\8B-
MO1]6&YH^K'K[D#I.AWD4Z>ET%/@G_L;ZI]+?$T]^XY;4]27.:GJ2R$:L-8)
M !Y^>_(63^*3_!N UP+[M_V;_?*!+/8#U-9?RWWP1[HYHWO-?+*$3OZF_P"Q
M=^Z?2HSA\_GDG=+9AMM^@&FOFZV^#0^=:KK5;Y=WI^G3N72:S.UL[G^LC5GS
MI<^VA]#TG0C=#B=3UJMZ4&R7_+C>_8Y/WSCD^Z]>=SI.V]&$54Z$]GVRI62:
M_=O]5>.^_P!Q[\#+(    C)WP/ZII#[_ 'GP<9<=LYJMRST&<HUZ?_2/"_.%
MI\,TM[G)5N6]S*=S9><@Y4  47H L'>OU5ZI^*_SC!*V[/\ J[>_X('I[E#&
M^K^*<>P/JKP?V+_?J>WROO7ZNO\ CP9,)4P              JT IT^0"&G?
M.V4UYJW(8G6NE'WN?M8ECL)].,=SI:R2NHVX@9P3E=6DG@Z0+D[O/=&Q.@EM
MM8;ALCRVLU1LEKCUH^RQ_7P3BDDJ+TN7@G4!*9&\:@<@
M
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M5Q&UN6U7</R4SUB6.5MNU.RAC<J\51.5SD^R DX
M         PQWH<S=8G::_AMJ<N5N;?&SJO2D4RJYRM\?FEAV^CBO1[&AKZN&
MS+!'=;TY#DM6934=PQKV8.W8RW1Z55EQ=51'M\:-:Y/9+O7U<-,4QXRIM%3C
M5,I:)Y2D70!4"@%? !0"B\5X@1+[TF#MK'6.-S5O'RR9>S7TUW#D=+;O[-O#
MAQ5O3X2Z[?7,TS2I==1A5BSOW7\K-D]I;"&>5TLUA<7%KS/7F5(VOYF-3Q-:
MM$*7N-'#>E;]OKXK,,S4Z/8*[Q6+D2
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MO@?U/2/W^\^"87';.:K<L]!G*->G_P!(\+\X6GPS2WN<E6Y;W,IW-EYR#E0
M!1>@"P=Z_57JGXK_ #C")6W9_P!7;W_! ]ON4/#ZOXIQ[ ^JO!_8R>_4]P^5
M]Z_5U_QX,F$J8            "E0(U;_ '>UP.V$CM-:-CAU#K1KT2[C1];2
MT8BHKDD>WID5*HC$7AU@9@VHW,P&[.C+'5^ D3DG3L[VTK]LM;IB)VD+T\*+
MT>% +UIQJG2!4
M
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M<YJT158JT7B!I]VQ6TT3WH\&S-SLL[3#ZK6&\GE=YD:1W+HU55\2@;DD5:T
M+U>4#3KWHK^35?>0U9%8(ERY,C'CK1+=>U[18T8Q.7EZ555H!MMCADMM%,MY
M45LL.+2-[5Z4<RWHJ+[*!+5MW+/^9S%?89+X)X0VS@1+_:(>HJP_XALOQ:Z
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MJN;(_AX0-K^&Q-G@L1C\)CT5EAC;:&SM6N7F<D5NQ(V(J]:T;Q4#[@
M                       &".]LG_X60_.]E_.%GVWK>DJSN71G?#&_=(2O
MYZ>'_P /_G"R[C&VE7=ORE)6A5+8      )(S1C[V']=TSX.RG]^6_;\I5&O
MS9)[I24VTN/G";A["%;W3JK#MG3G>SZ52U
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M7ZIR\&@;*- ;?:5VUT]!IG25BVRQ\-%D<GG2S2THZ65W2YZ^$"Z0
M
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MX633TBUT[;*R-\[%E=)?7J\'MD=PYV-:J^'S@-F@
M          !@CO;>JN'YWLO:D+/MO6C=*M[ET9WPQQW1^C6O_P!/_G"S[CG2
MK>W>*2E4*A;'E) @/)P0![8"I(< >*,?>P_KFF?O4_ORW[?E*IU_@R3W2O5G
M<?.$WM-*WNG5;W;.EZL^(52V5
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ML;'&U%6JT:U$1.('=1
M
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M-3U)9"-6&L$@  HJ*OD L?+;.[:YS(RY7)Z<MIKZ=>::5JRQ<RIUJV-[6_2
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M=Y:T FIW8N['/M0[\]]57;Y-:WMNL'R=;R*EI:02<58ZE.T?QZ5X)Y>($G
M
M
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MP_KNF?O4_ORW[?XJK7^#)7=+]6EQ\X3>TTK>Z=5O=LZ7JSVA5+54
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M;0:KRS&LOLHUB=L]&HJ<%^I5U?.5.GK NA$HB(!4
M
M
M              #CS)6@%45%6B=0%0  "B\4 \#+Z'T=J"X2\SNG\;DKQ%:O
MI%U:0S2KV?!J*Y[5541.I5H!ZF/Q6-Q-JVRQ-G!863%5S+:UB9!$CEXJJ,8B
M)Q\@'UI5$HO2!4                               P1WMO59#\[67\X6
M?;.O&Z59W+HSOACCNC]&M?\ Z?\ SA9=QSI5_;LI24*I:@#_ ,J  !  %Z"3
MQ1C[V']=TS]ZG]^6_;\I5.O\&2NZ5ZM+CYPF]II6]TZK?[;TO5GM"J6JH
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MHKW3/1:OBB:^O;*].#^;AX>H#9Y&BHB(Y>9R)Q=T57P@<P
M
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ML<SEDZZNE@3AX/N8$K--ZJT_J_'1Y;362@R>/D_SUN]'\J_6N3I:Y.M% ]H
M!16HO%4JH%.5%Z4(B1R)    40#KY&JZM%KX0@;]TZ.E*DIVNP@    !\]S>
MVEFZ%MU<Q0.N'I#;ME>UBR2NZ&LYE3F<O@0#Z$Z ,0;I=W?;W=O46%U)J>*1
MEYBW<MRVW5(TOK=/<PSKT\J+QX<>H#*6+Q>-PV/ML5BK2*RQMHQ(K6T@8D<<
M<;$HB-:G0!]E$K4"H
M
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M9TO5GLJELJ                                      *(
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MI1.94]U3K NVB
M
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MZ26=W%'<6\B=#HI6H]KO910-=/[2C]-]#_-5S^,H!,#NN^H/0WS:SVU R\
M                                     ,$=[;U5P_.]E_.%GVSKQNE6
M=RZ,[X8X[H_1K7_Z?_.%EW'.E7]N\4E"J6H ]H 0*@4)!>@'BC'WL/Z[IG[U
M/[\M^WY2J=>R5W2_5I<?.$WM-*WNG5;_ &SI>K/:%4M50
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M1?<,3H\*]?@ S,B41$ J
M
M                                    =<T39F/BD:U\3VJU\;T1S7-7
M@J*B]**@$%=_.X.W-9.ZU5LU/!8S7<G:7.E[I4BM6N=7G=;2_4)7_-N2G@5$
MX 1<@F[RO=TR#HHFYS3+(6/D6)6OFQRQ/<K5?R^?#15;T](&=MKOVB&I,?);
MXS=/"Q9:P1&1/R^-18+Q*5YI)(U562+XFHP">FA=?Z0W'T_!J?1F4BRF)N.'
M:Q+Y\;TZ62,7BQS>M% P1W^>/=WR'SICOA5 Q7^S7_).N?C%K[QP'K?M'=59
M&PT3I325LJ-L,O?2WEZO'F<MDQ$C;P6E*RJJHOB ^O\ 9Z;;8S%:"R>Y-Q;*
MN?SERZQMYI$;2.RM:+]J6G,G:.<O/QX\J 3.Y7<?'UU U@?M"-'X'3>Z^)S.
M(M6VMYJ/'.O,JV-$;&^XCF='VE$1/.<B><O6H$\.[?ZB=!?-,'[H&MCOILY^
M\?J=E:<WH;:^"MO&@&SO9;1NG-#;9Z;PNF+&.QL'6-O=3-8GGRW-Q$V2661W
M2YSE7I7JX=" ?9NSAK//[9:PQ.0ACGM;G#7Z+',U)&(]MN]S'T=5*L<B.3QH
M!K#[C\UQ:=Y'3]M%*YL<L.1AG:U51KVMM97(CD3IXM10-I.O=&V.X.C<SHK*
MSSVN-S=L^SNI[56MF;%)T\JN1R?10##VTO=;VG[ON;NM=6F3N9;WT=;2.^S4
M\$<-LR1:/5CD;&U%>GFKS+T= &4;O=G:ZP1KKK66%8CJTY<A;R?1Y'J!K<[]
MV3T;GMU\=G]'Y&RR;;[%QMR$]@]DC5FB>YK5>YG2Y6T3CQH@$^>ZW//<]WW;
M^:XD?-,[%L1TDCE<Y:2/1*JO'@B4 B!^TH_3?0_S5<_C($P.Z[Z@]#?-S/;4
M#+P                                       P1WMO59#\[67\X6?;.
MO&Z59W+HSOACCND?_>O_ -/_ )PLNXYPK^WY2DH52U.JH !QH0'E KUDBA!X
MHQ][#^N:9^]3^_+CM^4JK7^#)7=*]6EQ\X3>TTK>Z=5O=MZ7JSVA5+54
M                                          45:)4"S-S]QL/MCI.Z
MU+EZ2/9]JL+)'(U]S<N3S(V^+K<O4@&O',9C6^\^NVSSM?E-39>3LK&PBKV4
M,2+5(XT7@R.-/.<Y?*H$ZME-C\)M/ATD?R7VKKQE<EE7-JK:T58H:^YC3Z+N
ME0,L    #HO/ZI/][?[U2:>:'FK*4$-N.-KF?G!_M'<:C*G<Y.QXKU9[MOV2
M>V:TL\Y+D[IGY8W$^.6GM3&CWG*WNGWPV>U9U[X]SO[V'W?1'S@O^*1V7\>Y
M[[I^'>M1>E3>\&I*R]R?R5COCT/OD-S3M>^G98_U.V^],]ZAPE6;K*<H?2'H
M  >9GL!B-2XB[P6>LX[_ !-ZQ8[FUE2K7-7Q\%14Z45.* :]M\-D<IM+F$FM
MNTO=&7\B_)>27SGPOK5L$[FTH]/J'=#O*!G_ +LF_$NJ(HMO=877/J*UC_\
M![Z5R(Z[@C;]S<J^ZE8B=/2Y ).IT          '5/<06T4D]Q(R&"%JOEED
M<C&,8U*JYSEX(B)X0(/=XCOA27*WVAMHKBD#D?;9+5+>E5JK7QV?M=KX>CP@
M93[G.Z.K=PM"S8[5-G<RK@%9;66HI47L[Z&E&MYEXN?'2CG)T^V$DP
M
M
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MA+'MTX7H5W<(QLSZ.[NC_P#WK3_=_P#.%IW'\,JWM_XH24_\E*E:B> D
M@ 'BC'WL/ZYIG[U/[\M^W^*JU_@R5W2O5I<?.$WM(5W=.JW>V=+U9[*E;*@
M                                            #HO;NUL+2>^O96P6
M=M&Z:XF>M&LCC17.<J^!$2H&MW>G=#(;N:U=>6K9EP=J];33V.3BJM5>7M$8
ME:R3+]*@$N^[MLK;[;:=3,9NW:NM\LQ'7LBT<ZU@=1S;9B]5.F2G2H&;DX
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M]TOM!.S%8C&8+'VV)P]I%8XRT8D5M:0-2.-C&]"(B ?:
M
M
M   "*7?RVJS>X.V=CJ'3T+[N^T?-->SV,3>:22TG8ULKVHG%>S1B.HG54".W
M<P[S^G=J[>\V]U_(ZUTU?W'I>-RZ-=(VVN)$1CXY4;548ZB.1R)P6M0-AV.W
M)V^RUOZ5C-58B[MTXK+#?6[VIY51X&&.\+WIMN- :)REAA,Y;9O6&3MI[3%V
M6,F9<]E+(WLUEFD9S-C1G-S4=Q6@$-NXMHC-:KWOM]5M@63$:<CFO,E>/1R,
M[:=JMB:UR)3G5R\W+7H10)==_BOZNV0KT_*F.^%4#%?[-?\ )&N?C%K\&X#)
M7?LVNO=>;3QZBPULZZS6DKA;U8H^97.L)6\EQRL:BJYS51CO)4# '<<[QVG=
MOF7^VFN[V+&8/(SI>87)RMY88KN3S98YGIT->B,Y7+1&T6O2!/;([K;:XG&N
MS&0U=B(<:C%E2X]-@<CF-2OF(URJY? C4JO4!JO[VN]^-WOW);DM/L5-+X.W
M^3L3/(SDEG;SJ^254K7E<Y:L14JB=(&R_NW>HG07S1!^Z!K:[Y__ #)ZE\ME
M^+Q@;5]"?H3IOYKLOQ=@%->?H-J;YIO_ ,6D U8=RG_F:T[]CD_Q28"=7?7P
M>2SO=XU)%C(NVDLI+7(7+4Z4M[65'R.]A.($/^XEO!H_;;669P.L;EF,MM2Q
M11V.5FHVWCG@57=G,]?<-<B\'+YM>D#85F]Y]J=.8J7-976.(CQ\4:S<T=Y%
M,][4X_:V1N<YZ^!&HH&K#O3;WV&^>XWRYA;1UKI[%6Z6&+=+5)YXT<KG32)]
M3S*OFMZDZ>(&R?NIN1>[SM_3C3&-1?8E>!$7]I1^F^A_FJY_& )@]UWU!Z&^
M;6>VH&70             :]N_NBIN1IRJJK?DI>5JJM$^W.Z$Z@+ VO[J^X&
M[>E(M8:=S&*L\;+-);I!>]OVR/AI6O9HJ?5(!>GZA.[O]H<#_P#-_P D!^H3
MN[_:' ?0N_Y(#]0G=W^T. _^;_D@/U"=W?[0X#_YO^2 _4)W=_M#@?\ YO\
MD@/U"MW?[0X#_P";_D@/U"=W?[0X#_YO^2!3]0G=[^T. _\ F_Y(%?U"=WO[
M0X#_ .;_ )(#]0G=W^T.!_\ F_Y(#]0K=[^T. _^;_D@/U"=WO[0X#_YO^2
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MCKV&&R;FY5?I=;5GFP.1>%K(M*NJG0]WU7#H F B<./2!6B> "H
M
M
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M]=TS]ZG]^7';\I5.O\&2NZ7ZL[CYPF]II6]TZK?[;TO5GM"J6JH
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M[M^DMF[!E\K6Y?6UPQ/3<W*Q*LKTQVZ+7D8E:5Z5 S8W@G[X%0
M
M
M                   #'.]S-SG[:YQFT?8)K)8E2W[=%[18*+VJ6_%$2>GW
M-7</9H! ?9SOJ;@[/1OT7N=B;K4.-LW2-B2Z<^#+VTB.5%8Y\R+SMYJUYTJG
MA S!J/\ :.:,M\6KM,:6O;S,21.5C+R1D5O%-3S4DY4YGMKT\M (M:#T5N7W
MLMWW9?,)/<0W]TV?4.;2)?1+.T:M>S97S$HU.2..H&W7$8JRP>+LL-C8FP8^
MPACMK6)B41L<34:U$3R(!]P                          :_^_P",IKC2
MK^IV/D1/8D<!F/N(.5VREW7JS]^B?Z*W DZ                       P1
MWMO59#\[6?\ .%IVSKQNE6=RZ,[X8X[H_P#]Z_\ T_\ G"Q[CG2KNW92DITE
M2M@D %% >V   \48^]A_7=,_>I_?EOV_*53K\X9*[I?JTN/G";VFE;W3JM_M
MG2]6>T*I:J@                                            &".]C
MJYVG=K+C$6[FI>:CGCQ[4YE;(V"O:2R-I];1J>R!@GN?Z-BSVX%YJ:Y8C[?3
M5NBP>=16WETG*Q:)TIV?/[($[$14 J      #HO/ZI/][?[U2:>:'FK*4$-N
M/ZKF?C[_ &CN-1E3N<G8\5[,]VW[)#6EGG)<?=,_+&XGQNT]J8T>\Y6]T^^&
MSVK.O?'N=_>P^[Z(^<%_Q2.R_CW/?=/P[UJ.]TIO-25E[D_DK'?'H??(;FG:
M]].RP_J=M]ZC]ZAPE6;K*<H?0B42@>E0     P]WF-&OUAM3E?18EFR>%5N5
MLVI1%K;HO:55>KD5SE\@$8NZ7JU<'NC%B72*F/U';26SF*_DB2>%JS1R*BK1
M7+R\B>4"?M0*JM .N6>&!DDLSVQPQ-5\LCU1K&,:E5<Y5HB(B 1IR??0V\M=
MSK'1=BQ;S2[Y'6N2U2UR)!%=JO+&D:?51HO![_'PZ.(27CEBGB9-"]LD,C4?
M'(U45KFN2J*BIP5%0#E10"< *@
M
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M#96<4=O;0MK1D4348QJ5JO!$1 /I
M
M
M                                  $#_P!H(W_Q[1#_  V]VGT'(!E/
MN(>I2\_X@O\ X*W DZ                       P1WMO59#\[67\X6G;.O
M&Z59W+HSOACCNC__ 'K_ /3_ .<+'N.=*O[=E*2O_P"@J5JH2 %>GR@4HH%:
M@44",?>P_KNF?O4_ORW[?E*IU_@R5W2O5I<?.$WM(5O=.JWNV=+U9[0JELJ
M                                            :V^\C?27>\VJW++V
ML=N^*&&BU1J,@;5J>1U0)[;7X:TT_MYIG$V+.2UAQUN]C5^NG8DKO^D]0+N
M       Z+S^J3_>W^]4FGFAYJRE!#;G^JYGYP?[1W&HRIW.3L>*]6>[;]DGM
MFM+/.2Y.Z9^6-Q/CEI[4QH]YRM[I^#9[5G7OCW._O8?=]$?."^VTCLWX]SWW
M3\.]:CO=*;W@U%E[D_DK'?'H??(;FG:]].RQ_J=M]Z9[U#A*LW64Y0^D/0
M    #7)WFL(N%WBU URHJ9)(LFU4ZNW;2GT6 2CQF^ND-N-E]%ZEU]DE].R.
M/MV06D5);RX>U.15:RJ<&T\YR\ ,U8?+X[/XNTS.(N&W>,OHF7%I=1+5DD<B
M5145 .O,X#"ZBM66.=L(,C9QRLG9!<QME8DL:U:^CD5*H!Z#8V-1&M2C41$1
M$X(B)P2B=0'(
M
M
M                   (*_M!F_\ BFA'^&.]3Z'+^^!DSN'^I2\_X@O_ (*W
M D\                       P1WMO59#\[V7\X6G;.O&Z59W+HSOACCND?
M_>O_ -/_ )PL>XYTJ_M^4I*E2M5"00 !7B0*$@!&/O8?US3/WJ?WY;]O\53K
M_!DKNE>K2X^<)O::5O=.JW^V]+U9[0JEJJ
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M:]9[A\BKZ/#)(B*Z.V8O%L:+X0,G@
M
M
M                                      0:_:$-I=: ?X?E%OT&Q+^Z
M!D?N'^I2\_X@O_@K<"3P                      #!'>V]5D/SM9?SA:=L
MZ\;I5G<NC.^&..Z1_P#>O_T_^<+'N.<*_MV4I*%2M0D*  '0 J0"DB,?>P_K
MFFOO4_ORW[?XJG7LE=TKU:7'SA-[2%;W3JM[MO2]6>T*I;*@
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M$D>ZOI#":9VBPM[C+&*"]S#'7=_=HB=M.Y7*C5>_I5$1*-3J S:
M
M
M
M  @_^T*;3^[Q_AER;?H1P+^Z!D/N(>I6\_X@O_@K<"3H
M      #!'>V]5D/SM9?SA:=LZ\;I5G<NC.^&..Z/T:U_^G_SA8]QSI5_;LI2
M4*I:GE(%0 #J H2"\0>*,?>P_KNF?O4_ORW[?E*IU_@R5W2_5I<?.$WM-*WN
MG5;_ &WI>K/:%4M50
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MV2L)\9M-H^QN8G0SQ8V'M(WI1R*Y.;C]$"_@
M
M
M                                              $(OVA?N-NOOV4^
M"@ OWN'._P#P7OF^#/WR_1BMP)0                       ,$=[;U60_.
MUE_.%IVSKQNE6=RZ,[X8X[H_1K7_ .G_ ,X6/<<Z5?V_*4E"J6JO6!0    %
M!XHQ][#^NZ:^]3^_+?M^4JG7YLE=TKU:7'SA-[32M[IU6]VSI>K/:%4ME0
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MT@
M
M
M            (1?M#/N>W7W[*?!0 7SW#'5V>R3?!G;M?HQ0@2D
M              8'[VWJLA^=K+^<+3MG7C=*L[ET9WPQSW1__O7_ .G_ ,X6
M/<<Z5?V[Q24*I:BKQ( D* *  "@1C[V']=TS]ZG]^6_;_%4Z_P &2NZ7ZL[C
MYPF]II6]TZK>[9TO5GM"J6RH
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M*Q7QND<BQ1)6E$>USD>E? !L'
M
M
M                                     (1?M"_<;=??LI\% !>O<*=7
M:7+-\&<N5^C%$!*@                      !@?O;>JR'YVLOYPL^V=>-T
MJSN71G?#'/='_P#O7_Z?_.%GW'.E7=N\4E"I6RI H \9( 5(%%)/%&/O8?UW
M3/WJ?WY;]O\ %4Z_P9*[I7JTN/G";VD*[NG5;W;.EZL]H5*V5
M                                  /AS&*M<YB;[#7K>:TOX)+:9*(J
M\LK5:JI6J52M4 UC7MOG-I=Q9(8N>'+Z8R".B1'T62*-W,U.=.E)(U1'4\(&
MRS2.I<=K#3F-U-B9$EL<E R>-S:T17)YS>-%X+5 /;      !T7G]4G^]O\
M>J33S0\U92@AMQ_5,S\?D]H[C494[G)V/%>T?NV_9)[9K2SSDN/NF?EC<3XW
M:>U,:/><K>Z?@V>U9U[_ (._O8?=]$?."_XI'9?Q[GONGX=ZU%]TIO>#467N
M3^2L=\>A]\AN:=KWT[+#^I6WWIGO4.$JS=93E#Z0]     HJ^,"!W>TW!9J?
M7<6E;"2N+TPUS)W(OFOO9Z*_H54<C&HU$\"U SKW3="NTKMTN>O(^SR>J)DO
M']-4M8D5L"*BIP=Q<J^P!GT
M
M
M                                !4 !"+]H7]SVZ^_93X* "\.X0ZNU
MF;;X,U,OT8F 2M                       8([VU/[K(?G>R_G"S[;UHW2
MK.Y=&=\,<=TCHUK_ /3_ .<++N.=*N[=XI*%4MCR@% JI  .(%%)/%&/O8?U
MW3/WJ?WY;]ORE4Z]DKNE>K2X^<)O::5O=.JW^V]+U9[0JEJJ
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MM#9P0VEJQ(K6!C8H8V\&M8Q$:U$\B)0#N
M
M
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M[<R,3P)&[D7Z:%5W*K&],+3MU.%F)\V<T0K5DJ
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MU5F.2ZS$JIQC7E\RW1:5Y8T7^-4#+H
M
M
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M 5
M
M
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MWE9$Q>F.!J^Y3PNZ5.<U.KJO3['1:;2Q:CVLLIT&BW50
M                                *5 QAO+LQ@=VL,D,_+8ZDM$5V+RS
M6U<QWUDB)[J->M.KI0"!5Q!K[9?6W9N67!ZIQCT?'(VJPS15X.3ZF6)_7^^!
M-79OO':;W+9#ALMR876+6)SVDKT2"Z<G!76[W=*UX\B\4KU@9M157I^@!R
M45J+TH!3D;X",!56HO2, 1J)Q0D45C5Z@*HB)T$8!RM\!(K1 !& $BU];:^T
MOM[AY<WJJ_9:6S4=V,-4=/.Y$]Q%'6KE7AXO"! O>;?;46[5VEGR.Q>D;=_-
M9XACE<^63H1]PJ4YW?6LI1/+Q R]W=>[<Y76>X.XEIRM;RW&#P$R>RV>Z:Y.
M/A9&OE7P 2]3H J
M
M
M                            *42M>L#77WV=J5TIKBVW#Q,%,'JJL>0Y
M$HR')0M1*\$1&I*WCX7.YO !]'<?VN_.76=[N1E($?A]-)V&+<]/-?D9VKS.
M;U+V;.E%Z%5 -AC43J J                      I4"E$ 42E*< .#K>!Z
MU?$QR^%6HJDXRC"''T6U_P"HC_B-_>&,HX8/1;7_ *B/^(W]X8R<,'HMK_U$
M?\1O[PXI3PPY-MX&+5D3&KX4:B+](8R80[*(0D1$3H
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MBQ&@Y(]1:Q=%FM5HB.MXN2MG9K3ZA'>[?7ZM?83K D(@%0
M
M
M
M 6%O'MU9[I[=YK1URQOI-U"Z7%S._P U?Q-5T+ZKT<?-5? J@-FMNK7:S;O"
MZ.A1JW=K"DN4G8GW:^E1'3/5>OCYJ+X$0"_0
M
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MD5A;MXR2M2L\KEZ72R+YSE7Q\ +G
M
M
M
M
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M7(J^%0,Z:<T=IC2-KZ%IC%6V+M:JY66T2,557I57=*U ]NG"BJ!4
M
M
M                                                   *@  %*]"
M5                       45:="54!S>("H    HJT LNQW?VNR>3APV/U
MAB;K*W$OH\-G%>1/F?-7EY&M1:JZO"@%Z@
M                                                   * 4H!6@%%
M8URHKFHJIT*J 5 I1 '*B 5
M
M
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M;"
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M5BTIS4Z0)/:?RJ9W XS-I$L#<E:07B0.5'*Q+B-LB-54Z:<U /1
M
M
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MC9/_ )F-*_\ $[?QAP2W-!
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M?WK&_BD0);3MO_T#TO\ -%A^+1@7&
M
M
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MK_Q.W\8<$MS00
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MHL/Q:,"XP
M
M
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M TT;)_\ ,QI7_B=OXPX);F@@
M                                    :4M<_P#,+F_^+)OQ]00W6@
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M%^1,;\5@^#:!J>[[G_,KJ/[UC?Q2($MIVW_Z!Z7^:+#\6C N,
M
M
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M2O\ Q.W\8<$MS00
M                           -*.N/^87-_P#%DWX^H(;K@   !J/[\BO7
MO%ZAYJT2VL.6OUOHS/W0-GVTB)_=;HJBU3Y#QM/P6,"\51%Z0%.H"%?[2![V
M[=:2C:Y4C?EY>=M5Y5I!PJGB AYL]8=X^[PN0?LO\N?(C;EJ9#Y'>YL7I/)P
MYD1>GE R+\B]_/\ _>__ $C_ -\"V]6[2=[W7L=K'K/ ZCSC+%7K9MOD=+V2
MRTYU;5>%:)4"<W<DT3JS0&S<^"UGB;C"Y=V;O+AMG=MY).QDBMVM?3P*K74
M@OWSO^8[4?EM?@V@;:<%^1,;\5@^#:!J>[[G_,KJ/[UCOQ2(#:=M_P#H'I?Y
MHL/Q:,"XP
M
M
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M%C)K_(W4DS9(EFA=$SEA:G'E57K[KB!9_P"T=7_\,],?.[_@5 N7]GXO_P"
MR?.][[;0,?=_S8[/ZC] W9TO9.OF8NV6SU#;6[>:9L+'*L=QRIQ<UJ+RNHG!
M./0!A[8OOOZLVHP5CHG5.*;J+36-YH[.3G6+(00I[F%'.\U6M6M.9*HG #U-
M==[_ 'EW\G7;7;/"?(]OFYO1&LL.:7(SP2\.SDE55;&VB+SN;3S:U6@&"MG+
M^;;[??2S\JQK;C#YV*RO6-<CT;(V?T=_G)5%1'+T@;JI.,3_  <J^T!IGV45
M/UF-*+_^\[?IW#@EN;"
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M3@OR)C?BL'P;0-3W?<_YE=1_>L;^*1 EM.V__0/2_P T6'XM&!<8
M
M
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MI,%]#8P,F9.J\W:->C:HZJUJ!?(
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M?L+Z)8;VUQMG!<PNIS,EC@8U[5IUHJ*@'N@
M
M
M
M
M                   !2@%?:     "E *@$   *4 J@  !1?$ H!4
M
M
M                                                 "BJB $<B@5Z
M0         "E4K0!4"H            4540!4"H
M
M
M
M
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M*K1>/&@&<0
M                   %Z .GTJW1:+,SA6OG-Z?H@/2K;_KH_P".G[X'8R1D
MB58Y')X6JB^T!R
M
M
M                                  %'51. &I?O$:DO-_.\TNG,*LMS
M9PWT.F,6D42)(D<,RMG<UM?.H]TCJKU ?!MGD;_NS=Z!F)RDKI;;%9*3!Y)T
M3FM[:QNU1K'N5>"(J.CE5/$!MV8]DC&OC<CXW(CF.:M45%2J*BIU <@*.K3A
MT@8[U5OQM#HJYGL=1ZPQEID;:B3V*7#)+ABJE:.8RJI[('7I??[9S6-S;V.
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ME$6JKPX@97AD9-&V6-[9(WI5CV*CFN1>A45."@<P
M                                      #KGX02*G3R.]H#2'_^6>JM
MPY]+8+)W3\IE,M-9V,3[M\4:RRSN:U%<YR(U*]:@9I_4U[V/_4?_ -\A_P!<
M$O,U#MGWN]DK%^4GDS=GBVQ++<WV)OEO88HV+3[:Z%[^7BO6$,Z]U[OLY?4&
M?L]OMX+B*6?(.9;X;4C6-B59UHUD-RC:-\^GFR4KS+YW2!/4   5   %4
M "J    !5  %*IX0*@<7N1C'.^M15IY$ AEHCOZP:QW#PFA&:/DM5S&4BQ2W
M:W*.[/M9.SYZ(G&G30"9R>,"H     *H J@
M
M
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M^>OY+MEE'\IZ?;,JO='#5&3Q->JUY$56N:WJ55 GF@
M                                        !US_ '"7[!WM :8-K/\
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M!#8NQK,Y"Z=+!\B3.B6.5\2ISHUM:JRON0+V
M
M
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MK7(;1:TL[V-);:7$W7:1NXHO+&KD^F@&O#]GKZ]9_F6\]_$!M-
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M*O%0/<
M
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M=R_!28/N\Z7<]Z/7*=OD41$5.5LTBM1JU^P UO=X?_F-UY_Q%<?#(!N7Q_\
M4+7[S'[U +2WB]5>L?FF[^"<!KH_9Z^O6X^9;SW\0&TT
M                                           ZY_N$OV#O: T<6FF+
MO6FZ+M)6,T=O>9K,RV,$\U>S8^:X<U%=RU6B 287]G'NG5434N&5*]/](_D
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M\'_SGI_QO<_CD@&W@
M
M
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M:_>8_>H!:6\7JKUC\TW?P3@-='[/;UZW'S+>>_B VF@
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M$_XWN?QV0#;P
M
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MZKT7:7D.7=;/LE?<73IV=C*K7.\U43CYJ<0,S)T 5
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MJJRY;'56\J?5^Y<GLH!ZN*[^V_%CB5L+[%V61OJ4BR,EH^.1$I1%5C/-<OC
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MN?MG9OY?Z[)QK3H VY
M
M
M
M                                               %%Z. 'SI86:/2
M1+:))&KS->C&HJ+X:TZ0/H:BIT@5 Z9K:&>B3Q,E1M5;SM1U*^"J*!6*".!.
M6&-D<:JJJUB(U*KUT1 .Q0/DGQ>.NZ^EV<$_-Q=VL3'U\O,BU [(;*UM4Y;6
MWC@;2E(F-9PZ:>:B ?0 4#IFMH+A$;<1,F:G0DC4=2OEJ!TV^+QMF[FL[*"W
M<JU5T,3&+7_!1 /L  4<B.16JE47@J+T*B@?"[#8F21LLF/MGR-]P]T,:N2G
M@7EX ?5'"R)O)$QL<:=#&HB)T^! .T#4-D?^<V^_XWG_ !QP&W.:UM[GA<0Q
MS-2J4D:CTHOE Z[;'6%E_4[2&W1*T[&-D=*]/N43I ^E$H@%0.B:UM[EG9W,
M+)H_K9&H]./B=4#KML;C[.GH=I#;HB43L8VQT1?L40#ZDK3CT@=<UO%<)RS1
MME;6J(]J.1/84#YX<3B[5>:UL;>%RKS*L<3&KS)U\$3B!]B)3I .2M .A+*U
M1_:]A&DU5=VB,;S<R]=:5J!]")1*
M
M
M
M
M                   " 5WW0=W)^\3=;G,3&?FS+J67,L5;O[?Z(^X65%5G
M)[JB^YJ!/Q%J!4
M
M
M
M
M                  IRH 1* 5
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*Y>*D8[1WXW*X[,6C+_%7,=Y92U[.XA<CXW<JT6CDX+14H>IC!$3B^PA(
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MHE0.';1T<JK1&\7*O!$1.M5(Q'-KD<U')T+T$BH
M
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M$-]T->3Z^U"^\B5S<'9*Z#%PK5$5B],CD^N?2ODX'FC;5C+W7LIPA)79U/\
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M7*,//:^#NX(GY[7OS<_X5AMQTYWPUOQ1N2C9P:A@EDAS)  !A3O*?HOBD_\
M?T^">89GYXW,M$;&/MNME8=>:<;GWYM^/59Y+?T=MLV9/M=./,LC>FO@,]48
M1#!3...]=CN[#!3AJB2O56R;3X8AZ61JW9W6&W\:Z@QMWZ996J\[[VQ5\%S
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M$ (M0*@
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MO2NIL9J[!VN=Q3U=:W+5JQW!\<C5HZ-Z=3FKP)F,$1.+VB$@
M
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MRNY.*JO-PK7P&6:L6.(P7T>7H
M
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MD7CD1%7[&-$7Z)ALQQ5S/\NSXLER>&C>SCDK"WQ.BKW%VS>6WL\9-!$W^#'
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MXF,9A(QO!.BAX>U0(EZH]?#OG>T]MAXT_-._X/>HY8W?%+/K7R_N$QXO"I,
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M99%1K&M1*JKE7@B(1,X#Y['*XO*,63&7L%XQ.*NMY62HE?#R*I. ^Q/$
M
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M^!R_O'E+VM+[M:-UAEDPN$FN)+YT;YD;+;OB;R1]/G.2A,1XHQ>WK#5=GHW
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MHYYW0D"8&5%#?SUF-^+6OMJ-/U)WX_<B]R;X^*5=O]PB^P;[0\4NP   HJT
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M]]'D;&UOXFN9'=PQSL8ZG,C96HY$6BJE>)ZJCAJP1&3ZB
M
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M=(R9?1W]D_GB55;YU%X<2)A,2L->[GM\O^<R7X4G\@E!^KIM[UOR*^+TK_(
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MQLX<?96UC!7L+6)D$2N6KN2-J-2J^1"9G&<4/H
M
M                                         '%41$5?9^@!'/O"Z?S^
M8U-BY\3BKN_A9CU9)+:P23-:_MGKRJK&K1:*G \6XPN8S_&&3U5RX,]Z?C?'
M@\7%,Q62Q6ENQ['(J.:](FHJ*B]"H9:IQF9>(C8],\I      $8 2
M                    47B@%L8O0.E\5J6_U;:V?_CM^Y72W#W*]&*]$1_9
M(ON>>GG?O"GY8PCQ*OFF)GP7.B(G0!4                      !Y&I--X
MO56&N<%EXW/L+I$21&.5CT5CD<BM7PHJ'F:8EZBJ8R=N#P>*TYC8,1A[=MK8
MVZ*C(F<>*K57.5>*N5>E5/4[7B(P>D$@  !2B 5       IU@          "
MUKK0&E[W5<6LKRS[?-0QMCB<]RK$UT:KRR<G1SHBT15]LBF.''#Q)VYKIH,
M)        "Q-U=2:CTKIA,UIN-LMY!<Q,GBDB69JP251RJUJHO!:<44\53+W
M3$(_2W&XV]F8L[2XC7T.!WNV1.@LK9KO=R.K6KJ)PJY57H0]TTQCC.;'5,X8
M0E5@</9Z?Q%GA;!.6TL8FPQUZ5Y>ER^-R\5/554U3C)$8/2/*0
M    !3C7K MG5FA=-ZT?8+J&V=<MQTJS0,1ZL:O,E',>B=+5IQ(PVXGA@N**
M"*"-D,+$CBC:C(V,3E:UK4HB(B<$1$0F=J,'8$@                    '
M2            '3=6\-U#);7#.T@F8Z.5G%*L<E%2J>)2*J8JC"4Q.#P='Z'
MTYHFPDL<!:]DV=W/<3/=VDLCDK3F=PX-1:(B'K%YPVS/FN1$HE$(2
M  !& $@
M
M                *(G0
M
M   "A$@2
M
M
M
M
M
M
M
M
M
M
M
5                        '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>tm2227887d1-lc_poten4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-lc_poten4c.jpg
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M8W.3)#14-57R0X.CPT0E_]H # ,!  (1 Q$ /P"_P
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MQ;<(TRM:>7>;=[.WVBC[ 'N
M
M
M            58Z^?S/63_S+%_J$\$PA[H!_.3DWWC/^ML F70@%0
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MNTC!5^@
M
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M *XP"842Z0?TB<-_UG_X5+!:74X%&(RG)K+AF/7'*<ADE$LUK95(EOJXT27
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MS"> 0
M
M                                   "K'7S^9ZR?^98O]0G@F$/= /Y
MR<F^\9_UM@$RZ$ J *I]>&7SK+MM9\7A.*:1DD\_/*2=-<6 @G#;/U&XMI7\
M4$PA7HBVML6;Y?>LKR2&W/A8LW&\C#D()QA4V8;FAQ25$:5<I+*C(C[%*2KN
M($RO_DF+X_F%EDX[DMN9N5FEH-MZ(^DE)H9&1*2?:E2:^%:3)23XD9 JY$9M
M8YNV&YEYL=ME.-S,8NSB+;.(R)XO*O:X[W J$JA(7[(+K[]15H7NWTOP\Q;C
MD5TC6^W9<RV1<4(<CI7)21]I$EEYQ7\4@5C>@[H)S$[9GU]PQ]S3&O\  *5&
M09\#EVY1G1)>DVG7#/\ @@F48[RS)V\'4=>;=:%$MZYWIK'K4HS,VB3'6B A
M=2[$&:#<,_69@F&>Z/,B?P_?J#9YU8Y7IB98YC:^&AXBYR$F7TW-82CZ($G6
M?F/XT;USK8RYK@XS%8M35#JCG4\P^9%Z26[RU?P (7JZ>L)3@.SN*V);?+GN
M0TW"Y$947YN?_G#B5>DT:R;]A) K*3@0     (#WJZ4L&W=F.Y#'?7CF8ND1
M/7.,VEUF2:2TI.0P9HU*(B(M:5I5Z:\ 3$JE9;T3[U8\IQRSQH62PT5-*[=)
M2T]H])M2N2=?WJ#4"U4*3[9F^VU_;;N$:Y8ODL0R=94M+T&4CCP6VKPJH?<I
M)T,$NA723OY==VK'<,<RYQ+V88^EMQ4Y*4H.;"=,TDXI*:$3B%%I69$1'5)]
MM04F$+?W@?\ MCAWWLD?U@@3"5.@;\SU[_\ ,LK^H0 1)U\_F>LG_F6+_4)X
M$*X=&FWUASS=AUS)(C4^V6"W.W)$&0@G679/-:8:)Q"JDI*>8I=#]TD@6ET<
M_%S%;;.+)$6B%&N<..XRFY-1FTR$1CHI:"6A.K2>@O"7H!1QZO=\<S+,IV0Y
M!)4RJ]W%<NX23(W#:1)>-2S))$9F2$J\*2+L*A$#(Z/6#J?Z7L6LL''K!D[<
M&SVYE,>)%:M=U)*$(*A?_"<3/M4H^)GQ/B"E)4.W\G;=W7="\7C:Z0A_%+ER
MI:$M1WHC3<EQ!<]"&WVVU$DUD:_:T\5"X M"]:?C_>'H_0BWZY&273'4M)2@
MSYDF5;5$A:2]*GE1S33LJKT KTJ!;6[F9'LUFB,JLD5AZXL-NPI4*X-J-"FG
M#(G$'I-"T*(TE0R/@9<:E4C++9PNN';G,K)+QG<[#IL6W71A<.>4%QN?'6VZ
M6E1F2_+N(+C4M.I23[./$$42IL;B?2_<%,9#M#"M\J\6\N8;SKDAZYQE++2:
MU-S%J<;K4TZB22>TDG0$35K771BEZO\ M;;KS:6G),;'KB4NYLM$:M$9UE;9
MOFDNTFU&DC/N)1GV5 A4G8KJ*R/8U5PBVZUQ+O9;JXV]-B2#6R]K9(TD;3R*
MZ:D?$E(47HIQJ6F%A[IU3]/>]%GC8QN[C=QMT-$AN6E1F<B.T\W5-2?B+;D%
M4E*2>EKBFH(HL1M%B>S%IM7Q_L_#MI6Z<@F7+E;G#D.+2DR5RW7'%+<(TGVH
M6=2/M($))!    "'NJC\P&;?Z-'_ *XP"842Z0?TB<-_UG_X5+!:74X%%0>O
MW)Y5OPO%L48<-MF]SY$N4E-2YC=M;;(DGW4UR$JIZ2+T M"$ND3-MG=NKW?<
MJW+N:(%\0VQ&QU3D.7,T(<YAR7$''9>)*CHV@C.AZ341<#,$RFKJ#WSZ<MTM
MK[U8(^1HG9&RT<O'JVVXMNHGM44DD..Q4I1S"(VU&I1%I4"(A"'1+DTFR[WQ
M+*VL_*9'!F0GVS/PZH[2IB%4])<@TE_"/T@F61ZY<4O5KW:1E,AIQ=BOL&,F
M%+H9M)>B(Y3K%>PE%0G*>A=?2"(>K:+K4OFWV-VO#L@QJ/>;+:64Q(<J(\<*
M6EA'M=9*2XVX9%PX$BO?QJ9BB3D[I=(&^F50[YGMM=MF3H81#:5?#=AQ5DE1
MJ3K=AOFRK3J,B4^:>'T -JUV+8]C6+V.+:<0@QK?8$%S8D>$1$P9.^,UI--2
M/575JKQ[05<RNK[](G,O]6?^%1 7A?KIL_,5@OWL1_CK!64J @ <O^LW\_\
M?_\ 1K=_4V@7A='I!_1VPW_6?_BLL%93>"',OK9<0O?>>E"B4INW0$K(O<J-
MHU4/Z!D8+PLOTCW7\7>FF3D#S9K:MKUWGDBAEK1&(UF1'ZS095!65";+$NNZ
M&XUO@W"2MV\9;>&69<U1&I7-N,DDN.F7'@G6:O40+.N^(8?CF"6")C6+0&K?
M:82$H;::2236HB(C<<41$:W%4JI:N)F"BBW7+M;8,3OMBSC'(3<!O(?,1KO&
MCI)MDY<?0M#Q(3P)3B5J)=*$9HKVF9F6A)/0+ET^Z87DV'RUJ<BX[,CR8!J.
MO+:NA/&IM/H(G&%K]E9@2I??+;E&TFY3L><V;.38O=$2F%RD<Q+CL5XGF7C)
M7!:'-*5D?8I)@E;+$?[P*.:6V<\Q!:%E3FSK(^2R/TZ8TDTT^C(,$4;9MC:N
MC/<R^29F.VF&O*KF^Y+=LUY.0T[S'5&XI+$9YPXZB(S,]#&HB+U$!M;MUA9-
M)QG8F]MP7#9?O3T:SDM-2,FI"];R>!=BVFUH.O<8(A1CIKO&V6.;GQLCW4EH
MB6.TQ795O-V,_,;7<B6VADC;CMNGX4J6XDU)H2DEWT!:5T\SZD>ES.\7NF)W
M_*D2+7=&%L.I7:KHHT*47@<16)P6VJBT*+B2B(P5I*BNP632<2WEPN[QEFE*
MKI'@R>/ XT]917JEWT0ZHR]8+2Z[ H
M
M
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MXN19*N4P=OM\M<UEQ4DEDIM-5L<M7B+C18)VKP J
M
M
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MNVUS3GVX1L.96AM2+5:65$\W!YA:5NN.)\*GC29I(D52DC/BHS\)$RM>"H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M             #Y/R8\5'-E/(9;K36XHD)J?=4S(!]0
M
M
M
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M%D1FA:>"J'V&1D1$PD,$
M
M
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M.N)93/H\TRR\L_"F2Q)(G&DG7^4U*(N\B350%%M2,C(C(ZD?88*@
M                                #FIUIY=<,IWK=Q9M:EP,9CQH$*.1
MEH.3,;;DO++T*4;B&S_@$"\+*S,5Z6L1PQ>SM]N>,PKVN&<.=/DG&.>BX<K2
M<IUY1ZFW26>M)+<33VI43P!7:RW3_P!-UKV;NDG)[/E[V01[Q!\LMI++;,-U
M!K0ZV\DT..U-.E1)/52BS F4]2)46(DERGVV$*.B5.K2@C/T$:C($//\=6?^
MT(W\\W[X ^.K/_:$;^>;]\ _J;Q:%*)*9\8U&="(GFS,S/Z(#V@
M
M
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MQ;\0R%#:+S:[K ;EI963K9*6XTZ5%%V^%9 .P8*
M
M
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MN=0 4
M
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M15P\-L,*RLNTYYQ&4H<=T]G,<XK72O#4HP0V0
M                   8G),8Q_,+-)Q[)[<S=+-,3ID1)*=2#]!EV&E1'Q2I
M)DHCXD8"!U]$.QBIYS$Q[HB.:C45O3./RY$?N:F@W:%_RE?6":ITQ7$L:PBR
MQ\=Q.V,6FS1OY*+'30M1TJM:CJI:SIXEK,U'WF"&:   !R_WU_2PNOW\M7V*
M*"\;G4 %
M
M
M
M                '+_?7]+"Z_?RU?8HH+QN=0 4
M
M
M
M                                                <O\ ?7]+"Z_?
MRU?8HH+QN=0 4
M
M
M
M                     <O]]?TL+K]_+5]BB@O&YU !0
M
M
M
M                                                    !R_WU_2P
MNOW\M7V**"\;G4 %
M
M
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M3(S2MM:>.E:%$:5%W&0*L\
M                   Y?[Z_I877[^6K[%%!>-SJ "@
M
M
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M-'5'N\%!G4DF]5B1] ]+/[8+2NP"H
M                        #E_OK^EA=?OY:OL44%XW.H *
M
M
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M23B2(B["HRJA M*_8*@
M              .7^^OZ6%U^_EJ^Q107C<Z@ H
M
M
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M)2:EJ+N4LT]P(E/@(
M             <O]]?TL+K]_+5]BB@O&YU !0
M
M                                                    !&^[=^WB
ML<>U+VBQ:%D\EY;Q75N?):C$PA)(Y1I-R3'KJ,U5I7L!*"+AU ]4=KS2T[>3
M]N+&UF%\8=EVNV^<0KG,L)=6M7-3/-I-$LN'1:R/AZR!-(2WM?E745><E7$W
M3P6VXYC)17'$7"%,8D.G*2I!(;T-S'SH9&HZZ.[M!"9 0
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MN.MKO;)ZF;G/<<FOMJ+L4WSE*2VK]\VE)^L"J500
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M[%%!>-SJ "@
M
M                          "*M]MVW]G<<BY&EF+(CNN+96S(61.K<H1M
MH9;)Q"EF?BU4(R215.A"1SHRC?\ W$R;<^)NL<XH.06M1)LS,<JQXD8M1<A*
M55U)6E:R<U>WU'7AP*%Z+V=//4)=-[)$AF3 @PE0(^NXL,.&3Z'3-))4AMQT
MU*:5Q\1)H1\#.M*RI18 0
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MH *
M
M                   .575)>L[N>[EWAYQ<(TQ=N6;5HCVYY+L*/"6=6TH2
M2C-#AD572<HO5V^'2"\(7!+;]K?Q]_'VR?DR\Q^.GF"^+?*TK6GCYFKP\K37
MFZ_!HKJX AV!L_QM\4P?C[R_QWY=KXR\GK\MYG07-Y7,\6C573JXT[04>T
M
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MN&YWE<V#!E3KIYVR3W"7'<F?7%ML,E()1,DI1DI')TZB(DEP4"TK\@J
M         #E_OK^EA=?OY:OL44%XW.H *
M
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M692\"
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MX%0           '+_?7]+"Z_?RU?8HH+QN=0 4
M
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M
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MR_WU_2PNOW\M7V**"\;G4 %
M
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M-:S(C,R0DU&>EM/!)</691M8   (IR3\^V&_>^5]AE">A"5A"0
M                        ?Q2DI2:E&1)(JF9\"(B 5+W&ZRW"R)>$[(8^
M>7W[6IA-Q-#LB,XZBNHHT>/1Q])4KS-:4\*EJ3Q!:C77-PNNUAL[JYB#2XB4
M\PXB849:C36M":0^;YGW:2X@;&^[(=6\'/K\W@6X5K3B^<..''C4YB(<F2DZ
M&QH>JMATSX)0XI6H^!*U&23(F&R[\[C;YX3=[1%VFPUK)[=*C..W%]V#,F&R
M\ES2E)*C/LDFJ>-%$8$(6N_4GU<6"VR;S>MLH$"U0T<V5,D6FZ-M-(+AJ4HY
MM"+B":0\6,=5?5)FD!RZ8EM[:[U;F7E1G94&V7-]I+Z$I6:#4F<9:B2M)T]9
M 4A)VT^[O4UE&X%HL6X&WK%BQ&7YGXQNJ+9<(RF>5%=<:^N/RG$%J=2A'%)U
MK0N/$$,-<NJ'</;;>=.WN\-KM$3$W7=+5]ML>6PI4209E'F$;TEY)MD94>22
M:I,E$1F::&31;1MQMYM#K2R<:<(E(6DR4E25%4C(RX&1D"J'>HC?>!LEBJ),
M9#,[,;H:F[);'S4;9Z*:WWB0I*N4BI<"41J49$1EQ,B8AG=DLBW)R_!XF4[E
MPK?:[E=J2+?;+<P^PIJ$HOK:G^>^\>MSVY)*FE-*^(S(A*1P0  "MF\O5'+Q
M/+D;8[66'\;=P3434A!DX[&8>4G431-L&2W5D7B<HM"4%VG6NDF(:'/ZE>I'
M;%R-=-WMNHJ<6DNDA<B&AQA:-78DGD/R6DJ[TH<21J[*]Y$T6PPK,\?W QFW
MY=C$GS5FN3?,969:5H4DS2MMQ/N5H41I47I(%42;]=2L#:6;$Q'';6K)-PKB
M2%1[6@U<IE+QZ6S=)LE+4M9^T:055=M2X:B8A%5RZ@NK'!XGXU9WMM"+$R-"
MI1,LO,J9;/TK1*D*9KV:GFS(C!-(67VIW3QK=[$H^5XVM2$FKD7" [3GQ)22
M(UM.4X'P,C2HN"DF1^HB&\ A5OJ!ZJ_Q!R:V8/MXN%<L@3)0G(9#Z52&(J%&
M2283H6@C>,SJKB>BE#*I\"8A:0$             "/=\< N6Z.UU^P2T2F(=
MQNOE.3)EZ^2GRLUB2K5RTJ5Q2T9%0NT$PAS;SI@RW#]G<_VXG7BW/W3+M'DI
M;)O^7:T())\S4V2N[W*3 JASY@.Y/RFL?[,O[0":GS =R?E-8_V9?V@"J<^F
M7IPRG9"^WVZY!=;?<6;K$:BLH@&\:DJ;<UF:N:V@J4] (F5E00  #GCT^;:X
MU\Y'*\-W4M\>X7.W(G.6V!=$$XQ*DE);43I-.U)W4PI3J"54C29JIPJ1:5Y/
MR9;;?(ZQ_@R)]J!5]X>WV!6^4S.@8M:(LV.LG(\EBWQ6G6UI.I*0M+9&DR[C
M(P&Q@            .7^^OZ6%U^_EJ^Q107C<Z@ H
M
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M6.[FXFWE:,W+&E72*5U.X1KDB'Y4W"YG.4XV2"13VVK@"-CH<"H
M  #E_OK^EA=?OY:OL44%XW.H *
M
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MN"Z+(CANB)K'%=-?>MZZ>1)OY9=R_P#=%=/NESX$*TAX[^&>6_\ R&/]F/\
MB'Y9=R_]T5T^Z7/@04@_AGEO_P AC_9C_B)I96IQEMQ:#;6M*5*;/M29E4R[
MNP5?/;HB)F(VOV"H  *6_P!X0T^=IP)Y/_-42+FASPU^N+1&-'B[N"5\._Z
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M]Y&E*N_30J@B836"            '+_?7]+"Z_?RU?8HH+QN=0 4
M
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M%\5*I[==?\$J>L4UT688C#9X[OR6Y9=DU-TZC)XK8ZHZ?Y4KCCO0
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M8?;;O9\5LUKR">NZ7V)#8:N=Q</4I^4ELB=76A<#56GJ!5HW4G^8K.OO8O\
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M107C<Z@ H
M                                                      (PR#J)
MV8Q6]3<>O^61X5YM[ALS(BV)2E-N$1'0S0RI)]O<8)HQOSJ-@/EM&^YYGV@"
MB0\/S7%\^LJ,AQ"XHNEF6XME,MM#B$FXT=%%1U*%</8!#V7[(;%BUL>O61W*
M-:K3'*KLR8ZAAHC[BU+,JF?<DN)]P"NE\ZJ+KF5R=Q7IUQ63F-Y*B7;[*:7&
MM<;5P):B<-LZ>MY315[-0)H^-GZ7,ISVY-9-U&Y?(R64E1.LXS;G5L6UG]Z:
MDDW3@=#)EM'\-0%4!]2VW.R;2%9;M!E%D:D1B2S=L3CS6C-6BB.=%2:C/65/
MKC??[8N-2,F&G]/& ;99%>_QBW9RFUVC&;:X7*LDN8VS)N#R:*TK2:B4A@O=
M'VK]JGO,B9=0+'+L\^SP)F/.L/6)YAM5M<AZ?+'&TER^5H\.C3333A0%'O
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MU\"452D_%J,Z:2)E;D%0           '+_?7]+"Z_?RU?8HH+QN=0 4
M
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M9=1DR^],R]1@TN+#'L6Q'AU[WO&!M   BG)/S[8;][Y7V&4)Z$)6$)
M                                           $.;O_ #B_CN#^1OXI
M^(O*_P"?_&?+YOF^8OVNOCIT:03"._\ \.K_ /=K_P!R!L/_ ,.K_P#=K_W(
M&QG\(^=]^-EI_'KXA_%'GE\;^4Y7/Y%#KHT\:UH!L6(!
M          T;>2U8Q>]KLHM>8SBMF.2(*RF7(T*=*,:3)33VA!&:N6X2%Z2[
M: 0IUTV]2^);/V:X;<9J:Y-KC3WI%JR"TH.3'6AVFHE(5RW-)FG6A6C5XJ*2
MF@+3"P/SS=@/[?D_@Z9]J!%&[[;;Y[<;LSIUNPBXNS95N:3(E(=BOQB2VM6@
MC(W4)(^/H HD8$             #4-Q-SL*VKL[-\S:XE;X,AXHL8DMK?=<=
M,C51#;25*,B(C-1TH7T2 >C =P,7W,QY&48A*7+LSCKD=+SC3C"N8R=%%H=2
ME7"OH ;.   #E_OK^EA=?OY:OL44%XW.H *
M
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MI/E\,6S[T[9\?Z&?&@Z8   "*<D_/MAOWOE?890GH0E80D
M
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MR_WU_2PNOW\M7V**"\;G4 %
M
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ME*PA(     BG)/S[8;][Y7V&4)Z$)6$)
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MMM(;0GPI3V)(!V&!0
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M:5'^P5$_0%<V6<DQ,]$1'F6T^",5LQ'3,S/EELPP-D   !%.\W_/L(^_3/\
MC($PB4K"$@   -7S/&;YDC4-%DR-_'E1U+4\N.A3AO$LDD1'1UNFFA^GM$C0
MWMELH?N4>\O9_*<NL5*FXTQ451O-H62B,DJ\U4B,E*_9$U11M>)85D^/W4Y]
MXS&5?8AM*:*$^TI""6HTF2ZF^YQ*A^Y[Q%1O(A(
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MQ-JVGI(R=UQ>>DE>*E?K9U!$NCH*@  Y?[Z_I877[^6K[%%!>-SJ "@
M
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M3T@2DH$   Y?[Z_I877[^6K[%%!>-SJ "@
M
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M=ELPY#;[L![RTQ#:B4;3VA+FA5.P]*TG]$3,3"EM]MTS$36DTEZA"X
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MKO46)!GQ;A=[[D1/-R5-0%I6E!',/FN*5RTMIH2M)<?:D!5TJ!0
M  !R_P!]?TL+K]_+5]BB@O&YU !0
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M.ZC,S+Q**I@-O               !R_WU_2PNOW\M7V**"\;G4 %
M
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MXV=9)7>3:"(R+]L9+KYF*>52VRV)K'51+@QL@
M   -+W!L.=WUF C!\C1CSK"G#FK<92]SDJ).@BJE5-)D?[(S8KK(]Z*N=K<.
M?)$=S?P=?:A6Z%OE:]PK'MZYGR7)E\C/2FIB8K1--I80\LR4DVJF9\D^STC=
MCNILF[AW/-Y/GK-1;@[[;?$S6D=%>SL2M@N*;IV6]*F9EF#=]M!L+;3"1'2T
M9/*-)I7J)">PB/O[QJY+\<Q[-M)=W1Z;58[ZY<G';3=1) UG8
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M^_EJ^Q107C<Z@ H
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M?V3X$-VS]Q=X_4\SJ9CZGA_HS^%R<!I/3
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M0]HQ/.9WXMY7C\YB=%@/,D^S.5'H_P I#Z'2))N-^)I6E25=GMJ$9,NG(*
M          .7^^OZ6%U^_EJ^Q107C<Z@ H
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MJON1/JCVU#B&5.(;6Z>MPZ)+2@C,7LLF^:0UM3J<>GLX[YI#0?G)[2?VL_\
M<<GW@V/E<G4Y7U[2?%/FED;#OOMKDEXAV*TW)UVY3G"9C-JBOH)2S(SH:E((
MB[.\5NTU]L5F&7#SC39;XLMNVSV2DD:SL@  TC)]W=NL1-3=WOT<Y::D<.*9
MRGR,NY2&25I_CT&>S!?=NAS=1S/38/>OBO5&V?0I/EFX5WR'<"1GD=U4>8B6
MA^V$9\6&HRBY"*=G!*2U>DZ^D=FS%%MG"^;:G6WY=1.:-DUV=E-R^&$Y5"S7
M%K9DT&A-SV26XT1UY3R?"ZV?\%9&D</)9-ETQ+ZCI-1;J,5N2.F/Y6?&-M
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MZ7 H            Y?[Z_I877[^6K[%%!>-SJ "@
M
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M8G;Y)Z4\#1>H
M                              !JNX^ V?=##+G@U_?DQK3=>1YAZ"MM
MN2GRTAN2G0IUMU)54TDCJ@^%?9 0%\P;9[^V\E^ZH'P $U/F#;/?VWDOW5 ^
M  5/F#;/?VWDOW5 ^  523L]TYX1LG<KE=,5GW69(NC"(TA-S>CNH2AM>LC0
M3$=DR.OI,P)E+P(  !"&]?3%@.\+YWZ8\[8,I;;)"[U#2@TNMME1/F6ET)S2
M78HE)52A:J$1 F)5NMG1+C]UO)VB!N]:9LA)J-46)&:>F:$%4SY*9QF7KX\
M35:#93IZV^V<9<N%@4N[9#*0;$F_2S0IWEZBU-LI06EM&I/$BJHZ>)1T!$RF
M $            .7^^OZ6%U^_EJ^Q107C<Z@ H
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M )N9]N"J*-BQK#<;P]$AO'87DD2S2J07->>U&V1DG^56NE-1]@A+.@
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MB[QHWX;[8K,/2X.8:?/=PX[JSY6W#$WP
M
M!SGW9S7<_J8W:N.V6!K</%[:^^Q%MS;IL1'&H2^6Y.F+[%$I?M-1>$C2E*=9
MGJ+;GNZ;,"O6U_5-(P>_.QI-XM5LD'(<@K6N.HY,1F2@D*=;;5P2ZDCJ@N->
MTN($[GGV@S/<W8K?QK <[4MBW9/<4,W6VJ=)V)S;JY]8FQU$HTE]<4G4HO<Z
MDJ+47A$NB0*@           .7^^OZ6%U^_EJ^Q107C<Z@ H
M
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MM]FBE$MS"6&2XG3BI1^E2CXF?LCEY<U^6[BNFLNU@T^/#;PV12'M&%L
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M2$D=#IV"LWW3OE>S!CLFMML1/9$,H*LX
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MG4 %
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ML]L<5+?,1Y@G'DTJ7*;2:UU]6DC%K;YLFL;U+\=M\<-T5A<T864
M          !!_38ZVN!F:$K2I99!(6:2,C/2I*=)T]!T.@W=7OM\3S/(9CAR
M_P!.4X#2>F:9D>[.W6*DM-XR&(F0CVT6.OS3]?0;;!+4FO[Z@S6X;[MT.=GY
MEIL/O7Q7JC;/H1^YU!73(E*C[9X1<[ZHS-!3I*>1&2KLJ9MDLJ5^F<0-CY:+
M??NB')GG5^79I\5U_;.R/#RP_/XM]1>:>*^9%"PRW.^VB6Q/,DHKZ%(,U<"]
M$D./#9NCB\/#H.XYEG]^^,4=5N_P_K*L9ZU#C9;<X<&Z2;VQ$=..=UF*UNR'
M&O"XLCJ?AUZM/B.I<:\1U,=>&-E'A]9$1FNB+IOILK/2^>$Y&6)95:\@<CHE
MQX;Q')BN)2M+C"_ XFBB,JFDSTGW'0PR6\5LPKI,_<Y;;Z5B)]'2Z+6V5!G6
M^+.MJT.6^2TA^*XV5$*:=22DFFG<9'4>>F)B=KZ]CNMNMB;=T[GJ$+@#R72W
MM7:VR[7(6XW'FLKCNK95RW20ZDTJTJ+B1T/M$Q-)JQY+(OMFV=TQ16_=[8G
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M3"W2GK?YI&ZDTDE%-">TC,_H")AYOFO*M!IL/'@U,9KJQ'#PTV=>](XAY(
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M4           !R_WU_2PNOW\M7V**"\;G4 %
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M?(BN*-Y#5#J:".6OC7]Z8C8\_K=-R&W!=.#-ENR4]F+HV3/;_AQ^*5Q5X@
M$']1&Y&6[??BW^*\M$7XQ\]YOF,MO:O+^7T4YB54IS%=@M;%7T?[,Y)I.9=]
M\Q;-W!P4VS&_CKN\4*X3=WL[GY3;LSE3FU9!:F7(\*04=DDI;=2XE1&@DZ3J
M3BNTA>CZUB^V]#CTM^EMMGN\DQ-T<4[XITUKT0FO8G=[.\YS9RRY'.;DV],%
MZ03:([+1\QM;9$>I"2/L48K,/G?W;]MZ'0:*,N"V;;N.(]Z9V3$]<K*"CY$
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MD">ATD!0           !R_WU_2PNOW\M7V**"\;G4 %
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M+"Q,*JI$@S_YZM!E0FT=D=-*<-1$24HJ3,KM J
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M.X^WFU^1[2W?XJGSK,B?DU)"(I.O38L-UHRUI54B5SJ4[*@A&WY-NNKY7?\
M>3/VL$[%J+GF$7;';&/DVXLS2_:+;&*[.I,G'9$\FDH4AKL):W7:DGL+C4Z%
M4P54RVWP[)^KO=>9N5G[2V-O+4ZEI$-*E$TIML];-O85P,RH>N0M-#XG[4UE
M0MN= (\>/$CM18K2&(K"$M,,-))#:&T%I2E*4T(B(BH1$"KZ
M             (=ZJ9D^#L!FSUM,RD*C1V%FFM?+R)C#+_89<.4M=03"%NC#
M&< E;59%?4Q8DW-T/RF;BZ^A#LJ-'Y'UA*"41FAM9:CU)]LJI&9Z:$3+\]%=
MKQB\;+YK#S*-#EXU\;K<N#=Q2A45+3<)A1N+-S@G01:M?#3VU("6F]#RV&]Z
MLSC6%;J\6.U2U13<K52&[A'**I?[[EJ7^V!*_P""H JYM!U:W'=#="/MX_BS
M-M9>\Y6>B8MY1>3;6X7ULV4%XM%/; FC3,IZ[[MCN3WK'T83'D(M,^5 2^=P
M6@W"BO*:)1I\N=*Z:TJ":,1^L(O'R#C?A)SX.!1G=O\ K/>SK<#'L:D8'"B/
M7NX1X2KD4LW76N<LD$LJQTF9I+L\1 470!4           !R_P!]?TL+K]_+
M5]BB@O&YU !0
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MESLV4X?^+D.%!.8S*TR4\QWG-MZ/KR4EV*,^'H!$PL("
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MR1B3V(*R=J2VJTE!N<5V4<HE%R^4A#ZC4NO81$8&U.H(            <O\
M?7]+"Z_?RU?8HH+QN=0 4
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MSCBM)7X(I1M7SPMY_P"E6_[B1[X8/I6#M\Z.[AT/'CFJ
M
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M%%!>-SJ "@
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M+XQ^+_,?%*'5^5\OYG3S.4R]3F<P]-:>U/M'(YCI[<O#Q7Q92N_R,5]M>E8
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ME%7B1*,>HT]DV8[;9Z(;%L4AJPSI '8H?.&B
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M4&E-\STJ5>T5'+/>[\[^;??F9]E4/>:/]S9XH;ENZ&@C;6 '8H?.&B
M
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M6A"C*I$9%[HC Z%^@5            <O]]?TL+K]_+5]BB@O&YU !0
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MJ=.(Y4ZG41ONN]+'Q7).&BH
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MI877[^6K[%%!>-SJ "@
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M4N<LBJ9?\H.CGU,V9+K8MMI$_##[IRG[0Y?J-)BRWQ=Q7VQ,^UUO8Y?LB/\
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M7)3[Y<IPTJ46EQ:B[4%Q&#-K<N:WANG8B;YE)(TE
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M*MPVIZ1MX\1W*Q7*+S%MZ;5:+G%F3%-3$.+)IEPE*TI(N)T+L!%70(%0
M       '+_?7]+"Z_?RU?8HH+QN=0 4
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MI<S1JUJXZ2.G?4;6GS=S=Q4K/0T=7@^8LX*S;'33J79M&+6*R$2H,1)/E_\
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MSG.8BVF9Q^34N72JE<:=O$<;/W?%_AUX>UBFG0VH:Z
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MIR&C1P/ED1\U9JTIXE[DP2M)\T#)OE!"_P!B?Q<_DW?^UO1V?\W_ /6>W_>
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MH0(HLR"            '+_?7]+"Z_?RU?8HH+QN=0 4
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MXV7).2^;IZ6*9K+,C&@
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M?4DCX'1UNE1U-)$=SEGL];Y+_J)?=%F&V)FD]Y6.OW'2(<5\4
M
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M;:XLG(\CR F"N\!N!,N*&2Y"^<M+<)Q"TIYR*$:CI0Z=H(HBKYR76%_NB_\
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M+,#F/-
M                                                   #"9A#O-QQ
MBZP,?=0S>),=;49QPS(B-?!5#+L,TU)*NX^(S8;K;;XF[<M;,1.U6?YO^XO^
M0B?=*?W!Z'ZCA[?,V^^M/F_[B_Y")]TI_<#ZCA[?,=]:VW;3:;<+$,P@WB0<
M9BWI);4_2\3AK86DZHTII6JB29>@R(QJZK68LF.;8K52_);,46&'":H
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MMQ/I^R[&;,WRK7:,0ND*(@^)\MBVNH(U'WJ.E5'WF"%*NEWJ,PC9.PW^UY5
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M]G1#9[[E>Z^5;G79"GF6XLDI4]2*)<NETD(>423I2NA+BE$GLU%W'Q$K^ J
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MQVS2V8F=USH".:^'@
M
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MZ1*B^:-QGET0Z\LM="50Z>D$2N2"H  .7^^OZ6%U^_EJ^Q107C<Z@ H
M               ^$R9$M\1^?/?;BP8K:GI,EY1-M-M-D:E+6I1D1)(BJ9F
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MY[K]7,QERW3'5$TM\T4A+0UG!
M
M
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M.;VMO6EV*=DS.&USY%J4YS6GF2,DJ=CN42:B(S+4A1:DU]T7$$3"<@0
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MJ<4I1T+O4HS%+[YONFZ=\OD\S5[Q1
M
M
M                             #4=T,'C[D[?Y!A$APF"O$533#ZBJEN0
MVHG6%J(N)DEU"%&7H(!SAQ_<K>GIBG7O 9$1MAB4MQ4FT79EQZ(I:DFUYF,M
MM;1F2TD7C0O2JA5K0%][ ;?;_9_MCAMWPO#%QH35ZD*DOW0VUKGM+6TAFC"M
M>A'!/!7+-1'Q(R HMAT3;-9#B$2[[CY9$<M\^^L(A6B')2IN24+63SKSB5<4
MDZM+>@E<:)U=BD@B96[!4  '-'9+$+3OOU&WYW/E')AZ[C?94%:U(\TM$E#:
M(]4FE1)3S25I3[E%.P%Y7\=VCVK>MYVMS";$=O-)HY!6V*E)$=.RC9&1\"XE
MQKQ!10G)<9A;'=6]BMN%.J:M:;K:W8T8UFM3,:Z&AM^,:S,S-)I<6E)JXZ#*
MM3XF7Z'2@%            '+_?7]+"Z_?RU?8HH+QN=0 4
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MDC90M^O+0M6HC)2N%.'NB&U;I;[L<WQN7BR9BK;AJJ
M
M
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MX,S_ "BB1)Y"M6A2JTK[-#H,M^*^SWHI5:;9C>RHQ*@
M
M
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MH
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M$JD9D"(5'VGQGJKWBQ=>6XSN>N);D2G8)M7*ZW!I_FLI0I1T9CO)TT65/%]
M$[&X3-ENMBU(\W"W&1='VR-28S%XE*-1E[G3,CM-F9_OCH!6&0VAZILWL>;I
MVKZ@8GDKLMY,1B\N,HBO-27#(FTR4MT:4TY4M#S:2+B1G5)ZDBBY0*O)=;I;
MK);9=XN\E$.UP&5R9DIX]+;3+234M:C]!$0"@-KZD\YW*ZD,;*T7>;:L$EWF
M' B6-IU3;3L(GB3JD(2=%+=J:EUK2NGL(%J.A(*J5Y#N_O#U!;DW';W8JXEC
M^(V8U>=R$CY2G4-K)LWUO)2M:$J54F6VJ*67B5PKH+,?EUEZJNG6$WG19PYF
M^+Q7$?&\::](G);0I1)+FMR]2TMJ,R3K9<)23[:$!LE;+:O<:T;JX-:\VLZ#
M9:G(4F3#4K6N-*:4:'6E'0JZ5%X3H6I-%4X@JW(
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M]?IHQS$VQLE?+93<EL<M@
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MU?'W[#F^-N+_ ,V@RX-P8;,_=S6W6G#(O8C-U!:5S05
M        &@;W8+*W*VJR?"X"B3<;C%2J"2STI5*B.HE,H4HZ4)3C24F?=4$P
MK[T<;A83A^(W7;;+)4?%LX@760[,B752(+DC6E"2HI[15QO0:%-UU$1$?8?
MF5I?QTP[Y0VS[MC^_!5[+??;)=EK;M5RBSG&R)3B(K[;RDI/@1F2%'0@&0
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M5)E[)&*W6S;-)WDQ1Z!5
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M1*2J9T+CV A1S^[UBN*F[@3.QIMJU,]_%3BI:N'=P)''V06E>8%0
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M)*JU[AIZO78\N.;8K5COR6S%%BQPVN
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M[=%4Q%7J%4
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MNXB(8&-^@
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MKP40ZN+03?BX^GH9[<5;:I?(R,B,CJ1\2,ARF!_0
M
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MK&^>*F_;T<,4IVNB \XT
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M2TH7V&I)GQ+U'Z!LW:>^VR+YC9*\V3$5;0-90
M
M
M  <B]^EWI6[.7_'2&6GCN\T]$12EQ]7.572I9)49D5*ZDD?JI0;&:<DQ;Q[J
M;/$R(V&N/M#:=>DMH:;)U>HE:%>T,BXGJ[.'I%[+)ONB+8K,CL)MWM[C>$V&
MWL6_'+78[OY=KXQ3;$&MLI.@N:2'G2YJT:JZ36=:=HHQMS
M
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M2C(DD53,^!$1 /XAQMU!+:42T'V*29&1TX=I /T
M
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M*3,/-R](J@
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M-L[X1,4FCW"B
M
M               <Q=\IDQOJIN\9N0XB,J^6S4RE:B0>MJ'JJDCIQT)K[!>@
M*K4ATZ!4
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M24KA0J=Y#:LTU]V.;XW0O%DS%6VC54
M
M                  <O]]?TL+K]_+5]BB@O&YU !0
M
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MTR]&:8C"NRU$=P;+RUQ27=):(B4="[-9&2R]2AY358>ZR3'1T-"^WAEMPU5
M
M                                              <O]]?TL+K]_+5]
MBB@O&YU !0
M
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MO'F6D
M                                                   #E_OK^EA=
M?OY:OL44%XW.H *
M
M                       -(O\ M+@V375Z]7:WJ<N$C3SG&WG6B4:$DDC-
M*%$5:$0W,>LRX[>&)V,D9+HBC&_D'VU_LUW[J?\ ?C)]0S=?H3WMQ^0?;7^S
M7?NI_P!^'U#-U^@[VYN]AL5KQJU,6:S,%'M\8E<MNIJ.JU&I1FI1F9F9GWC3
MR9+K[N*[>QS,S-99(8T "N&2;"9Y?;_<KPY=;:^<V0X\EQYR0APT*4>@C23"
MB31-"TDHR+L(=_%S#%99%M)V>+UMJW+;$48OYMN<_P!H6G^>D_!AE^IXNJ?1
MZUN^M?I'3AG;:TN-W*U)6DR4E27Y)&1EQ(R,HPCZGBZI]'K.^M69@MR6849F
M:\4B8VTA$A]*=!..I21*62>-*GQH//73$S--S4EZ!5
M
M                            Y?[Z_I877[^6K[%%!>-SJ "@
M
M
M
M                                                           #
ME_OK^EA=?OY:OL44%XW.H *
M
M
M
M                               .7^^OZ6%U^_EJ^Q107C<Z@ H
M
M
M
M
M   Y?[Z_I877[^6K[%%!>-SJ "@
M
M
M
M                          ""^H_J(A[(6F)#ML5NYYK=TJ<M\-XS*.RP
M@])OOZ#)1IU>%"",M1D?$M()B%5&^KKJ3MK,;+;C$9<Q:6Z;49<FTJ:MCRT\
M5-MR$$A2C(B/@3QF":+J[(;QV3>K#D9';6O)7.*LHMYM:E$M4>2225X3X&IM
M9'5M="KQ+M(P1,)*!   .7^^OZ6%U^_EJ^Q107C<Z@ H
M
M
M
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MD]BOEU;/JU^\ H?.3V*^75L^K7[P"A\Y/8KY=6SZM?O *'SD]BOEU;/JU^\
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MY/8KY=6SZM?O *'SD]BOEU;/JU^\ H?.3V*^75L^K7[P"A\Y/8KY=6SZM?O
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M7A[3,P*).!
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M\?+R-^#7/A %3]7O>/EY&_!KGP@"I^KWO'R\C?@USX0!4_5[WCY>1OP:Y\(
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M>/EY&_!KGP@"I^KWO'R\C?@USX0!4_5[WCY>1OP:Y\( J?J][Q\O(WX-<^$
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MI<YBF7:D@U*,J:Z=H)== 4
M
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MF5PP5                    <O]]?TL+K]_+5]BB@O&YU !0
M
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M^KF"97#!4                   !R_WU_2PNOW\M7V**"\;G4 %
M
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M\WM>2W7$[7,R!QQ#[ER?BMKD*=:))(6:S*M4DE-#]0#<@
M     &+R#'+#E=K=LF2VZ/=;0\:%/0IC:7F5*;42TF:55(Z&1&0#RXOA&(83
M'D1<0LD.R1I2R=DM0&4,)<6DM)*42"*ID7 !G@                    &F
MW+:7;*\WM>2W7$[7,R!QQ#[ER?BMKD*=:))(6:S*M4DE-#]0#<@
M
M
M
M
M
M                                                !%._V],#9+"_
MCU4=,^_W!PXEDMRU&E#C^DU*<<,N/+;+BK3Q,S)-2U5(F(4J1O\ ]6M]MDW<
M&US)WXJ6]9^9EP[5%5;6"2=5),U1UZB1J\2E*4:>&H^P%J0M)TP=1ZMYX4S'
M\E99B9S:&BD/>7+0Q,B&HD<YM!F9I4A2DI=3V54DT]NE)686'!
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M3UEPR7<XT6#:4LQU'Y3FH;JXI;:U:W"JI7BX5H7 @6HZ0 J
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M+FY@6>I9_&I+"Y-LNC"$LIFH9H;C;C2:)2ZE-5D:")*DD? C3XA,+6 J
M          #SSY\*UP9-SN+Z(MOAM+D2I+JB2VVRTDU+6HS["21&9@.<F<]7
MFYN2;C.NX1>WK+A:I346VP$,L*4N.E9)-UTW6U*UNU-1E7PD9)[J@O1T?D2&
M(D=V5)<2U&80IUYU9T2A""U*49GV$1%4%'/[+NK/>C<S,7,:V3BNP;>M:V[<
MQ#AMS+E)9;[7G3>0XELC(M7A2G07ME'V@M1Y;?U/=16T&4QK5NW$=N,)9)=?
MMESBLQ)*HRU4-R/(CH01G4C(C5K36I4] HO]8;W;LELEMR*T.\^U76,S-A.T
MH:F9""<09D?8=#XEW JR(              CS>?=VQ;,X8]E-W;.5+=7Y6TV
MUL]*Y4M25*2FO'2@B2:EKIP+TJ,B,F%(V]_^K;<E4[(,*;FILD%2C=9L5J;?
MBLF7BT:W&7EK423+PFM1TXT!-(33TN=4UZW'OGY/-PR97DCK3CUHN[+:8_FC
M82:W&76D$2"<)!*6DT)2DTI,C(C[1,)7ZA]\8>R&(-7)J.B=DUV6N-8X#IF3
M1K;21N/.T,C-MHE)U$GB9J252KJ(B(4R3O\ =6URM$C<6'-G_BC%<TNSF+5%
M.V-EJ-)IJJ.HE)29Z5*,STG2JJT!:D+7],O40G>NTS+7?F&H6<69"7)K<>J6
M)49:M)/M)4:C29'1+B:F1&9&7!5$E9A/H(             &G[K7R\8SMKE6
M08^K1>[9;)4JWKY9/4?:;-2#T*(R5Q+L,@'/WYV?4O\ T[_NB/\ :07H^$CK
M ZBX>GS=W:8UUT<VUQ45I2M-3)5I4"BY/3=N3E>9;0R,\W,DDEQJ5-<*>N.B
M(U\716T*-PB;2E)I29.541=Q^@%95GR_J\WDW&RM>.[,0W;? =6M%MC1(:)U
MVDM(*IN.\Q+R4<"U4;26@NU1TJ":,?"ZH.I#:;)8]NW1CO3HRM+K]IO,)J&\
MY'-1I4N.^RVV9]ADE1ZT5[@*+^8;EEGSO%K5E]@<-RTW>.F3'-9$2TZN"D+(
MC,B6A1&A9$9^(C!5G
M
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MYY/@"]K][K?@SLDI<FU3+&<I]/!"I$J/$DO$CL\!..J2BO'215!+K8"@
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MM98V8.50%K>E,RC>*Y0URDK0HS0MYU.E9+6G4VHT=W=0$2L,"
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M@'1S>GK1O[CS"%FB/=F9UOE$5?$A45Q]!'3_ -:RV"TNHH*
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MF8$
M                                              YR=>4-<?>*V2CJ
M;<NP15I.E")2)4I!IKWTH1_1!:%X=E'6W=G-OE-J)22QRT(,R^F1":2HOH&1
MD"LN<73NPNY=1^*E#,G".[2)*5%4R-IEMYY1E0C]RDS!>75<%
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MA7(VMZKF,;LDA:X$?(9N,.5457X2Y"XI$YIJ1F5$.4[E)+T MT.G@*
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M$Z>MQ9VZ.T]CRJ[T.^&3L.Z+0DD)7)B.&V;A$FA%S$DE9D14(S,BX B4H @
M            <Y>O*"Y'WAM<PZFS,L,92%4H1*;E2D*36O&A$D_H@M"P_3GL
M7M<]LM8IMZQNW7NY9)#\[<Y\UAN4\9R#,TMMN*(U-$VG2FC9IHHJ^VX@B952
MP9#FTO5G#Q_'7EE;XV4?B^A)KU&NWSI7E=#AD9DHTH<(SK[I->!]A;H9?KEA
MKB[W$^NNF;9H3Z*E3PI6\SP/OXMGQ A?K;&0P>UV&R^87ECL%L=YM:)Y?DFE
M:J^BG$%'-GI-B/3.H+#4LE7E.S'W%'6A(:@R%&9T(Z5I0O69 O+JJ"@
M         *V=;.>N8GM*6.PG>7<<MDE .GMB@LESI)D?KHVT?J68)AXNAO V
M<>VL?S)]HBN>62G%H=,BU%!@J4PTGTE5PGE^LC("5H 0K7U-=3L;:AA>'X@;
M<O<&4UJ=<66MFVLNI\+BR[%/*(ZMMGP+VR^%$J)B%?NG+IOOV[E[;W.W*-Y>
M(.2%3#*6I2I5YD$O4JIJ\7)-5>8X?M_:I[U))F71-"$-H2VVDD-H(DH0DJ))
M)<"(B+L(@5?H
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MQ!GS=V,@B.0XCL54#'6WT&A;Q/FE3LE)*H>@DI)"%=BM2O0")E=X%0
M        <_?[P"\O/Y]BF/*-7EX%G7/0D_:DN?*<:49>ND5-?H M"Z&TEG;Q
M_:[#+.VDD^4LL!#E*<73CH4XKA7VRS48*OGN]G2=M=M<CS4DDN1:XIG#;5Q2
MJ6^M+$<E%]+S7$:O4!#D6]?I\[(%Y+>33=[D_*\]-\]J<1*=4YS%\[2I)F2S
M]L1&7 &18&/UQ;QQ([46+"L#$5A"6F&&H+J&T-H+2E*4ID$1$1%0B($477Z>
M=PK]NCM9:\RR5,=%WF/2VWDPVU-,Z8\A;2:)4I9EP25>(*RE($
M
M                                  ,#+PC"Y\X[I/QRURKF:M9S7X4=
MQ\U$=:\Q2#56OK 9XB(B(B*A%V$                   #X2(,*6:3EQFGS
M172;J$KI7MIJ(P'T:9:8;2RPVEII/M6T$24EW\"+@ \[MKMC[BGGX3#KJO;.
M+:0I1]W$S*H#\?$MG_L^-_,M^] ?MJUVQAQ+S$)AIU/M7$-(2HN[@9%4!ZP
M            !^'F69#:F9#:7654U-N))23H=2J1\.T!Y/B6S_V?&_F6_>@'
MQ+9_[/C?S+?O0'J8CQXK?*C-(9:K70VDD)J?J*@#Z /*Y;;<\\<AZ(RY(,R,
MW5MH4NJ>!>(RKPH ]0                # 2<&PF;..YS,;M4BY*5K5,=@Q
MW'S67'4;BD&JOKJ SR4I2DDI(B214(BX$1$ _H#!S\+PZZS?C*Z8];)MQJ1^
M<DPH[S]4]AZUH-7"G#B S3;;;+:&FD$VTV1)0A)$E*4I*A$1%P(B(!^@
M            'E>MMND.\]^(RZ\=*N+;0I7#LXF50'J >*Z6:T7R/Y.]6^-<
MHE:\B8RW(;KZ=+A*(!\+/C6.8\3A6"SPK43O\J4&,U&)5/IN4E-0&4
M           82XX9A]XF?&%WQ^VSYY4,I4J&P^]X:4\;B#5PIZ0&899:CM(8
M8;2TRV1);;01)2E)<"(B+@1$ _8# R,'PN7/.Z2L<M;]S-6LYKL*.M\U_3<Q
M2#57UU 9X                !YI%O@2UDY*BLON$6DENMI6HDEQI51'PX@/
M0E*4I)*2(DD5"(N!$1 /P\PQ);-F0TAYHZ5;<22TG3B7 ZD \OQ+9_[/C?S+
M?O0#XEL_]GQOYEOWH#U,L,1FR9CM(9:*M&VTDA)5XGP*A /H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MCC;C;\F$HR=:0:*'JTI4M/"BDD?JJ31.0(
M
M
M                                                        !I6Z
M&U^-;N8TC%<J7*1;$2FYI'"<2R[S64K2GQ*0LJ46?< @#,^BO9ZPX?D%]@OW
MDYMLMLR;&)R6TI'-C,+<1J(F"J54E7B"U5/]@L%LFY>[6/83D2GTV:Z>=\RJ
M(LFGB\M!?D(TJ4E9%XVTU\/8"97@C=#FR\60S*:D7OF,K2XBLQDRU(,C*O\
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M>PYI (D,7F&W)6TD]1-/4TO-5[S;<)2#]@%6S
M
M
M
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MG%.F!*T8(
M
M
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MQ^@@P(:C_=_1W4X-ELI2:,.W9II"_2MJ,E2B^@2T@F5O@5
M
M
M
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MG:PVT8(E.H(
M
M
M                                                     !7WJ\VF
M<W)VS<NMHCF_E.*FNX0$H*KCT4R+S3">\S-"2<21<34@B+M!,,=T5;B(R[:E
M.+RG25>,0=\DM)G52H+YJ<C+IZ"\;1?P )63!                    #G;
MGD25U0=4R\=M*E.8I95)MS\UHZH;M=M69RGB452JX\MQ+2N_4@%MT.AD6+&@
MQ6(4-I+$2,VAF.R@J(0VVDDI2DNXB(J$"K[
M
M
M
M                    //'@P8BE*B1FF%**BC:;2@S+UZ2(!Z
M           'GCP8,12E1(S3"E%11M-I09EZ])$ ]
M
H                                                  #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>tm2227887d1-pht_ipsc4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-pht_ipsc4clr.jpg
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M .$  0  !P$!               ! @,$!08'" D! 0 " P$!
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ML]PM/,#W_6KSWBY]E9O#Y40B@(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MQT;-%;PL%61M:7&KBT4J5#2KAM$ "@010$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MWN$;6DVC@Q[:'UB0R@.A0;GF=S==LQF,])B!B]JX?'/<S&19>)[[B\;"UM9
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MZ$T%%UMVKRZ\KMH^5ZY92E.RJY4**>H*D0J.] J.] J.]!% 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M-4$5((" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MMEAD$D;M6N;KHMN<RK37"Y:MC%% 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M]6R(AX39JME>1W$#M6/#O-JMTWAA].85JD\%G68EKF)1;7M4R0F6"19 @("
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MD7:T;(ZM>'=L#&U^!Q+*5;%:0$ ]_AARY')F)LWU92HIQT[55GLSE%K@:BM
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M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M(I98W\;[V:VPUL*SW4O,^GUMO$ZKS7@*NY%GHK\S5OM\KHL$388F0L%&Q@-
M'"@%%V,='%SF5._NH[*RN+N4TB@C=*\_N6"I^187G$)I'5S[%<\S)LI)4W%_
M(Z;UN/AD_@M/M TKEWMU=G57$+UO(PGG)))JL,=&_*<%I^C\:A*5S"XU1#4M
MTO=)D(8:^K$P/ \KC_:1G#"-.E1H'ZGSHS11L$8% @A0BCF&CV$.:[MT-3\2
M,+.BVI?<P12,<">1KC7]TROSJ6J9PBUK2YCBT^(TFIKHB4-OPOR>YC?4_B&,
M86QO&@-R^H?3M/J.;Y%<U4S&5'DWZ8;\T\5>K&(<K.4[> 62911 @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M@QDSH6N=Y2 UQ\BQMIG,LO)+KN-O(+ZR@O+=Q=#<QMFB)^PE:'M^(JNT6A>
M: 'TK'Q1"E/&)&.C<.8.!:0>!:X4*3&8(G$N?SX/-X-\K;*$7^.<[F:T_38X
M]@\BYNS3U=+5NCLDM<E;W,I@<V2&Y;H8)11Y/;RC2H5:U5^EEZ:$%O?VK&);
M92QM+& <0>(*SF<L<83/HXUJ-.Q8I#J B<HQMC<7"1W+0:+8T3"FYQ8RH;6A
MH#V%83+.*HU#F]SB"2?(M<U\_1EC#CN>W;#N3J!9[4BR%QC,66MM3<VYISWT
MSG,8*T^R+%WZ\3_;:-DXAL&(ZE[8V8S$VV1B=<9G(-,EU=G7E8V=\0/P,5O5
MPYFO1S=F9=VLKB&[M8KB!W-#,T/8?(52K3R]%65VLD)7 ZT[D2U+<.W[ZYN8
M<MB7-;D(AX4C'G25A[_-15=E/,LZK^7NU]U]/9R"++6S[-Q/+X@!\*O;J5SK
M:)KU=2FZ+0R+'1R-!83R<6$]H[QY$BS9%4K8Z2E]=%/F985*%S:<*J$I6@-'
M*%CEKQU*T[J'1,MN$SVQM<&L=SM(J3W%/-AIQE28\R%P<W0<"IVSFC9$8:=U
M*W@W:F">^+F=D;P.9:-9])OA\O,?\)=#VS5YHG\/YL+RP&W,E@<+80;DRV0N
M<MCI;)]P8)C^+NX7QM+6T' A[ET9T?//WJ.R9EUKI]OO#;ZQLDV*:8G6I:R6
M \6<0/1ZJC9K\JC>&Z,/$+35KE,LH0HR5)IV?7#R$):.B8GJT.\V_EL1=3S8
MV/VW'3.,CH*\LC*\>3C7X%SK:9RZ>K?'BMXLG$Z5MK<-=:WSM60S@L<6]@:T
MZG4%:+5PN5OE?$ MH3J5KB<,YKE)&SD:6@ZE93.41&$71^(*< .Q0E.12@'P
M*$C0TOY7DM [5-9+)"0T/#!SM' K.98^5 /<^/F.CM!Z%7E/D6CFW.0RD6$L
MWF%SF>//*.+8A4:>6M%;U0K[=GEAM6'VOC\8\W#0^:[=].>8AQKPTT'8NA%'
M+OMFTL\UIH.[C\"VPT)U((" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(""!-$$H<7&G<B$>;6B)3(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" 4$*]B"1[BW@@F:^
MHJ4$W% 0$! 0$! 02.<0%*$S34 J$HH)2ZAH@#34]J 7  D\$$H>#J*?"I0B
M74H4$>8:>5!&M"!7BH2B@(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M_9YI9Z)C14"@TTIQHK*M56  ",D40(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @@31!YWR/OA]+\;?W%A-89HSVTCX92VTB+>9CBW2
MLXTJ$,+./WUNDDKBV.US+RS24LM83R?;?A]$&]=,^O\ LKJCE9L1MVVR,5U
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MFO8WCF+F &K0.TE$0X%LWKAE'XR'&]'.EE_<[0A%()C[/;"E &D,,A!#F@?
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M<RE#DGO!6EM![S?3ZYAA;#/=Q W4D8HZ5S7/:TN(I6C0 H2]I1_1IW*4)T!
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$E
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MOH\A5V+1+GS5,'-';4]M-5FUST5FFH4,D4! 0$! 0$! 0$! 0$! 0$! 0$!
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M'A7T((>K2M-$0B.45.B)1K7AQ0*FGE010$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0*50$! 0*(%$!!"@0.4'
MT((<C.X('ALXTXH)J(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M]GK9^2>0([261D<DA<: ,#B"23H*(8:5[QW6G";+VQFMO8_-'';W=:F6RCA
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MKYT$',J*5T.A\RA*D;5HH6:$=M3KYU* 6K1)XI)+^-4%<-IYD$1P0$! 0$!
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M6^+M)+JXD$;0#R@G5SNP =JTWV1#=2DS+1L4R<0/N+AG+>7KW7$XU%"_7O\
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M*HDL1 4@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M61WH) 9YR@^L&(QUKB+"VQEA&(;.TC9#%&!1H:T::(,D@(" @(" @(" @("
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M+&RN!:]\3GN<0\^M](GBH2W=L=32OJ@4IY$0JAM!]1! LJ:UI]5 \,5J37M
M01Y @AX=#4'3N0.36I-4$/"_=&O>@>%QH=#V=B"(CII6OH0/#&HKIW(')P%=
M!P0"RO$_V%!.--$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$CY"TT#2X]H'<@@)0
M6\W9VZ\$ 2@D@#AVH)Z^1!% 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MVP[39W4=]!%<PR$PS /8?H^FHKQ6F5;JOFN%3Z]:+7&<F%4&HJID14P"D$!
M0$! 0$! 0$! 0$! 0$! 0*A!*Z1C1S.- >U $C#P*"9 0$! 0$! 0$! 0$!
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MTJD4F95XE:20MRV8L\,16W<U\MX[B&AE"UI^V]96/I9EIW7F*YAT>,4)%*-
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MPX/O6JNO;B/XZNQ1N#AHK<N!A44 @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(//7OH@?\"LI_+;#^':@A[EO]2-I_+[K[F-!Z&0$! 0$! 0$! 0$! 0
M$! 00/!!(YP:YQ\G%1@A3>"YK2P:5XJ?!$]7B[K9N/-Y?J-F,//D+F+'X=[8
MK6&&5\;&O,;7AX#2T$@NKJN3NVXE]&]FX=+:/-,1UK\'H#H3D<SDNF^.O,S-
M)<3N=,R&:5Q<]T,;RQM2:FM05;XUO-&7D?>*13?-8=08X^&VO'Y5<ER*](Q+
ME'O"Y#,X[I]<3X6>2VD?<1,NYH'N9(VW->>A;0C3M&JI\F9B(P[/M.NE]V+.
M+] MP9C'=0+;!QWT\V-R,,K[JWFE?(WQ(2SD<T/)H?7=]'CV]BT:=DY>D]WX
M%::?-]GP^YZ^A8?7-0:G0#ZJZ<3T>!QU77<H2(" @(""C)4 $<:I#*.[Y^Y7
M^<;EI&@D> /MCHO0:,X=/6VS930=A]4^T_H: U[:TN%5Y$S$U:]D1"XZN<QW
M';.K1XL;6G?^+%5.B;>!6,L-TYH.HFU*=N4AH3YG+=R[9UXGXHW>E[I;J-#I
M4KA*"HH0*00$! 0$! 0$! 0$! 0$! 0$!!#M*#RO[]G]6>+_ .\6?<H.H^[2
M!_P.V<:"OLTVO_S,R#K" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M"1P/,.ZG%0//7O2?D>V>[VBY_@FJ]Q)B+=5K2\Y3D<CJ=@/R+M[+1,=%VSM^
MX !F.H/_ /:UC_\ GEQ:SUA5RXD>'H'SKLRM:Y>O?=\I_P /+<=OM$W^*N%R
MO6YMW5:T5.&I%/$%D" @(" @(" @(" @(" @(""!H@U?J)N.#:>RLWN"9WAL
MLK5[^;N<X<K3\)0AY?\ <DVS/?'=O4O+M$U[F9O!MIW:R'Q)73W!YOW3O#/E
M0>Q6T-=!_;4H5 *:#@H2(" @(" @(" @(" @(" @E<T$<.&J"A-$V1KHWM!8
M?IM(!!!6,QT3$SESC$M;#-EX80UEO'=SQQ-;V!CZ:=RXT]';U9F&3!!J >_B
ML,PM8Z(D4^E\(X*6GQ2@UX&CN(/<C)@,U@77;S>V9#+BGX5G#GIIYE+*&L31
M20$MG8Z-P.H.O]I0W1:,*8D82*.'FKJB?-"M#:W=[(([:)SA6A=2@%>W59ZY
MQ:&%K1AP?$![=Q0->143^N.VC7?-5>UX\3]'./!1M*-VX#.N: :"35G;4DZK
M5:)K29F"LYEZV<]L4+G/?1K&%[G'4 +R.Z<[)^]NMTAE=AVSX,-)(\4-W<S7
M; ?L)G<X/P%7M$='&W3UEM;>%:*U+1"UFA;,)(I8VOB>*.:\5:14<1JL;Q&"
MMIRY[A@QL-P(JB 75PR-I[ V9X^ 4T7'V8R[^F>C)<!P6.8;9A#LXHQA,':#
MM(4,FN9G .N2ZZL*,N#]-G"OP*6<2UI['0.\.5AB</I!VGQ\%#+,*?.P\'#X
M1Z$/-"O!9WEXZEM&X_9NIRT'I6,7AEYH;+'C/T/B;Z44-\;>61TX[ UIHW7R
MT*W\:(FROLL\Z[,N[EV\O$,SW3W$5^9W.>>5W\3G)![]?(O4;]=8UU^]7KUE
M:Y&]FMMT6]R)'@P''D.8]U>7P(06@#LUX+*='R9PSM;$=7L+IW#+#M''MG:6
M2N\>1S7<:27$CV_""%R(Z6<C?.9;8/HK;XJZF0[ARU\I2T1,$3,-*W1!;Q9O
M'20L$=W,9C(YHIS-:&ZN(XG4KG;L0Z7'M/9(TU&NE.*INGA$4[$R82TU^12A
M:9+'PY&W\"4 .&K)*<"$2TV\QMWC9'"XC<]G"*5NH [*]JAEE9E[:T<X<_;K
M]5&683,YI"&1@O)^CRBHKYT3F&<Q. FDE;<9 !L3#S-B.I--0IB8CNB;-EN0
M&V;VM :P1N;RGN(/!9Z*S-^C19Y$MZF_O@*M+H9_-0UK2B]Q$5\C5B60MF_^
M=H&@D@7L8'=J6K3HB/I_BU[.SW4".T]BXUG'\544(40(J00$! 0$! 0$! 0$
M! 0$! 00/!$J)^N2$>+2^JP__!UN#R6W^.U:.1Z71]L_]S7[WB#&WMSC9K#*
MV?JW-@]EQ&1]E'I4>@E<6L_-^+ZOR-'FXL_;#W5M#>."W=A[;)86XCG]HCC?
M-"#^%B>Y@<YKP>!!-%W-=XF'R+D<:VJT]/%DLAF++#VEQ?Y2=D%K'J992.4:
M]Y6RUXB,M''TWV6\L1EXLZB;K&^-Z9'.0M(QS2+6SYN+60T82WR.<WF7"Y&[
MS6?5?8N']&F/X[/0?NU_U>.-:TO;GT_AG+I<6<P\5_R+]?\ CXR[3"T!OGU5
MV7G)E54($! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!Y[]]'^HG*?RVP
M_AVH(>Y=_4A:?R^Z^YC0>A4! 0$! 0$! 0$! 0$! 0$$#P04)NT+(CQ31C\$
M/2L45>%^K(KU8W?IS'VF.C>_^+Q+@<KU?B^L>Q1GC5^[^;MON[[XL+K;1V;=
MSMCRN+F<RUCDHTS6\Q$H+>^CG/;Z%?X5HBN'C_?.+:.3:^.F?Y0[@)32O%C?
MD70F8>8G,V<&]X[?5DS$VNS\?<-DRM[*Y]WR:^%!%RU#A33GYM/M50Y5XQ$/
M5>R<.UML6F.F8<NZ(<AZKX, $M]FN*%W9K%H54T>IZS_ )#7R\>/NG^3VM""
M 23QU79\'RE54@@(" @(*;^![P:HF'S]RW\Z77;^&=]T5Z#1V=/6VS95/Z!]
M5?\ N:'Y+A5N5WAKW*W5W_:2S)X^P6M1_P"S"V<9EJ[,+TZTZA;2I^LX?-P<
MIYGH8[7NJ/04'E*X2C*<&J0A%2@0$! 0$! 0$! 0$! 0$! 0$!! Z5/D0>5_
M?L_JSQ?_ 'BS[E!U+W:/ZC=G?R:;_K,J#JZ @(" @(" @(" @(" @(" @("
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M#*X2YN7MPV-%LV"R8XB)SIK=DI+@*!VKCQJK&R^8ES_^/\*EM5K>,3\'.P*
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M4HT\AR4+@!KI1VNG8IYGH8[7NB,.\_$%<-1E5%:J(0BI0(" @(" @(" @("
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MB>]_%'?[MZ>XJ4<T4MR[F;W@/:@];0@1QL8>#6@>@!!60$! 0$! 0$! 0$!
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M+F>S)MMVV7F=D[.43R7\9QDCB#X<;FQM8T^9X<5ZCG9BKAZ)S9VWZ7*:ASG
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MN5>;=N2,\%M _@+B,\[?("YK&M'>B7OILI=0@^K74_,B%4&O#@@F0$! 0$!
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MV3=!9Q@<><RMDH/1&A#I5G&(+2")HY1%&Q@'9RM: $%X@(" @(" @(" @("
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M6;:D3F1ND@DO/#]<,O+>4N!(UHUP\,'TJ1ZHZ0=2L7U1V58[DL7L;<>M!?0
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MQ(K3TK.M&F]V[X"U=8X>SM7?2CC%?[H\WSKJZXQ6'%VVS:991;6H0$! 0$!
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M\MQ/6Z;']$5^Q!7R_=ZWT&GH3\%CL[,=8C8* 4@H#TZJ4+6^:/"CD/THY&R
M^8CZBRAKO#>[27QK>*:M>=H-?-_R*5&T=58_N>)42P8+QVX??^T\PQQ;'-<B
MVE=V!A<T$>3BK/&V>688<C5]3CV^RLO4$3FCE/ '0#ZJ]17K$/F\]Y7+2W4U
M"(3U"D*A J$"H0*CO0$! 049'\K*@CF/ %!;W=W!:6\ES=RL@MHQ62:5P8P
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M$! 0$! 0$$#P*"D!0 E2>#BGO!2-CM]M3.^@R_8YY/  2PKF<SL]/[%WM^#
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M9[N_O1LJ&Y-X+OI.9>QMKZ"2@@?=W]Z/]:NT_P#BF_?('[._O1_K5WYVS[Y
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M0(RKW.CE@[.=0,ON)S:VU@QMM;O(KZWK5I\(72X>O,Y>>]YWS$>7[7HD  U
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M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MV@-:QH:QH[ ."].^?WOE=MJ>W1&N$RA(@(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M$"MQ#&#QY:D_&U,'U%6/:4[Z&YOGD?7-8W0^2H 3"/J,E:;=Q-N\.,//(/\
M.5</\(E,-<VRRS(V1-Y(FB)@X-: !\28:;=4Q.G%3C"*QA#6FNJ,D:]O!!0N
M;JWM+=UQ</$4;14RO(Y13O"7[$U\^/L2=-MK7>^MR?TMRMOR[5L29,;!+PEF
M<:!_*-2*!Q'-WJ[P^/YIS+C>Z<Z*Z_IQW[/1\;6AP%*4^B!V+T/2(P\6KMX*
M4)D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!! \$%$ZR.'+7N4HRTWJ%
MT_Q^]\6^WFC;'DH&N?87K:LDCE%"-6$&E114]VF+PZ7!YEM%XGPZ.!V%]E,%
MD3MC=T9M<I'ZD%Q)3PIV#Z):YOJD_P!G%<';JFLO=?NJ[HB:2V0.;R@@T8>#
MB>/F6EFFJ.Q ^= 0$#C\B(\J/?W=H/ HG"E-;0W+#%.P21'BQVOP(F)Q.6MW
M6UYHGNEQ,O+77V5YX^8NJ/C48;8VL5*Z\LCRW]O)#Y>7F'PMJF&Z+HLNK=XJ
MQ[:=U:'X"L)9^;*IS CF;\-0?G4&40>^OH0R@7 ]_P ")*>1WP402E[6ZN<&
MM'>6T^5$Q.%%UW"_U8N9SNZ$.>3\.BG")NN8,;F+X?@X!# ?\K(0V2GVM5.&
MF=C/XK;UK8'QI?XS<'C(\5U\@.@HI:IMEF0.72FG=7L1KDH.S1(81'4J?2EF
MO9&;,%N7-NQ=BYMK67*3_@K&%GTB]V@("VZ]>5BWR4S]CL?2;9+ME[:%K=AL
MF6NG":\F/%SA4-![Z:KO<35Y(G[7A?<N7]:^,](=$;$&T(THK^7(QU3TKQ4)
M10$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 02OI35,"B0*NTHB9K\&
M,S.&L<[83XO(P1S6L[:%CVAP\AH>T=ZU;=?GC#;IY%M=LQ+SYN;8&Z.G=])?
MX.%^3VDYQ?);-<'26['#UN4./,?6)=H5R-O%FKVO"]SU[*16WJ4\3G<=EHN>
MTG:Z2M'QOJV1A[BQU#\2Y=Z8EV<1:,PR@X4()[CP2%>TXG"&G8I9""* 4$-$
M Z]U?A3 E?&R321H<W[$CF^51A.98RZV[C+DEPB,,A^NC)'Q-*89UMB6-DVE
M,PDVU\Y@[I&U^4%&WZBW.W<XTU9/!)_? G_!"83]1*<-N!NGAPGRU/U$P?41
M&#W [0B",?9<Q^<)@^HJ#;.6=^,O&LK_ )MK7C[E,'U%Y!M*T80;N9]P[MU<
MT?$0F&,[&6ML;8V8I;6\<9^R J[X34IAIFV5V1V]O:4PUQ.)*=BEEDT]"A"4
MN:-7&@X@#6J35$U\W1KVX<E/SPX'"L\?/Y(B*VB8:NC,OJ<SNP <=5GJI.4V
MVQIKF7<>F>Q(-DX*.S<T2Y"X?[1?7%27.D-*"M>#0 O0Z='EB'A>?S)W[)F.
MS?&LXDBBNN6G HH2B@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @D<WF(-2*(RB<(>'ZQ=S&A[%.6O"G)&T]Y)X=]%#.6L
M;FV)MW=ELZUS5FVX!)#9Q5DS#^YD%'#X5HVZHOX+G'Y=].,3V<8S_33>^RW.
MGVU*[.89A/+:3&,S,96@HXEI-!Y2N+MXDQV>JXWO$7Q%HB/S8&QW?9/F]DRH
M=C+WA)#=,?$&/'$!S@ =>XJE-;1X.SY:WCS5G,_!L,$T4[2^-S7LXM+34.'D
M(6+#R[/&%2IIS4JSLIV'N4]#..Z)T [>TZ429^#&9M/IC(>\*(,;/@@7-"RQ
M++R[/@B*GAP\J,NAYM"L<RQF:_%'F<1Y?)Q41,L<QX2A3R"OE )664YE&H/
M4\Q(3*4*^?X3]5$FA_LJ@>2I]!I\2  .)K5.J9K866&,^?X(Z=]>X*)Z,?-;
MQA#@.8MT[!VK&6<=5K?7MI80.N+R9L43-7O?4>8#O/F6&99^5B]O[;R_5*_J
MYK['9T#QSS?0=<EIH  [UJ$$G@NCIXWU(B9<_D<^O'B8CK,O2>,Q=GA[&WQM
MA"VWM;=C8XXF4  8.4<.-5WM6J*1B'A-^ZVR\VMW9%D?*6D$G3BIF,RUYRN
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M<;;ND8PZW%&&TI4>3BNG$8AY_P 59$B @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MHAJ>PJ&6$2:=Q\@XHQF"GD/P%9PQ"._3RG129*>4?"AF4I[JU<>"Q^HB)O\
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MQM:VG92GH6,V917"<L836I493E.!0 *4(H" @(" @(" @(" @(" @(" @("
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M-HIZHRF4H0<#V*,"'K!2E$%$(H" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @500J$"H""* @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M" @(" @(" @(" @(" @(" @(" @(""!-$ =QXH(H)>;RA!$&O! )H@A4TJ$
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M]!"OE4H 0>!4!77R(DJ@ U010$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M.5VQ=1O9 _23P[IK_4IV\IA)]*(:OT5]7WO>H=>R7* TU_\ >G(EU?WO!_\
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MNL>S>C%K<.@P5_[*<S'&>5T@N+IS9-=>$;--$'I3#],=A[>Q<&(L-N6'LT+
MPNEMHIGNTH7%[VEQ.B#@\G1_>6P?>!L=Q=.,6^#8&2]D;FQ&\>%&!,3,0TD
M4:>Y$NJ=7^NF"Z4PV%G);R9;<V4<]EEAK/U[AQ8&G5C0YP!YQ2HU1#E[/>UW
M!@I;>?J%T[RVVL-</$,>0N;6XAC#W^L&DR-H?5:X^A!Z7Q&5LLWB[7+XR9MQ
MCK^*.YM;F,A[)(I6AS:4KV."#+C@.S3@@B@(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(""!X(*;AZQ/IIZ$,/$USBV=;_>OOL?F0;K;&TVL(L7$B$B.V
MU!I_SSN?CQTX:(EZ]?M7;+\>[%.Q%H<8^,Q/M_9V<A86\M*!O%!P'I1T?WST
MSZOYZ\QEJV/IEEWE[&-GB(92-Q%(R_G!YR*^J@ZOUGWT.G?3C-;E\1L5]%"Y
MEB'4UN' \@ /'@B'A4;)S_3O9NS>N\,4S+^3*3764,@)/@%T#H!2@(!+9JZZ
MH/HWBLI:9O'6N7QCVSX^_C9-!*T@M=&\$\P(XH/'^=M;>Z]]&UMKB)DL1MXS
MX<K.=G"/B'54)>J,WLO9F3QEU;93"V#K5['"4OMXXP&M[0X $4X\5*'E[W2)
M78_JIU%VO@Y/'V-97%^ZPF:_Q8FB&]9';AKP:>M$YSD'J#J)?W>-V1N&_L9#
M#=VMA/-#,/IM>UA+2*Z:>9!S/W2]UY_=W2J/+;COWY#(.NKAIN)0 [E9*]H!
MH -*(2[JYQ<WB!YT&*W)=C';>RN1DB;<,LK.YN'PR#F9(V&%SRQP[00*(.<>
M[WORVZB[*NMPVN%M<(V/(SV@MK*(0QO,4<3N8M!<2X\_&J#S[[I=G87W53J-
M'>V\-U&UL+V^.UCVMYI90:!P/<B7JO>/3K8.XL#>X_/86QCL'1N\2X$44)C%
M".;Q&@$4![T0\Q>Z3D-Q7/3SJ)@;<R2V^-9 S$2$.),LS;H2!I/[VS@B5C[G
M>4V/CY]Q8S>LME9;[=.QH9EG,CG(:YP<QGCD$NYBVH&J#O?77HS9=3MFR8[%
M6EI:;DAFCGL,DU@B+*$U]<#4$%$-,ZG9[<?1_P!VV#!Y>_9+ND6<&&MKJ(DA
MW(UC#ZQ/'PVNU09SW9^DNWMM=.\/G[O'Q7&Y,W;"]O;VY G>[QWND81S@\M&
M.:/54)3^\1T-9U'VJ^?:F.ACWG9N8_'W$1CM7.(ECY@Y[N4:-#J:A2-GQ^YK
MCI?TCL<[U,D;;7^&L/#OASMD+Y8.9L;&O87-<7M#  ":DHAQFU]X[KIN2U.X
M]E=.'76SV\Q;--:W4MS,V(DR.B+)F!PIH*,.J#L/1CK;A.KN-FFM8Q89VQ/+
MDL5*X>+&[O#3J B766.#A6J(3H" @(" @(" @(" @(" @(" @(" @(" @(,5
MF,C;87&7V6O7MCL;""6[N)"0"(X6E[C4^0(/%6T,-NGWK-Z9?<&Y,C=XW8.,
MG$%M86#S;U\)K6^J7"3F#Z<Q\Z#<.H_NL6&V]N76YNF.4RUGN'!1/R%O')<^
M*)?9VF5PY1$"XD#U17BH2ZA[N6^]R;YZ=LNMTV\MMN+&7,V/NO:(7PF4L:R5
MDG*_4BDH;4::*4-ZW=U'V5L2V%QNO.V6,+A6."YN(HI7]Y:Q[@XCS!!;;.ZL
M=/\ ?;I(-K;@L\A=QNH^S;/&+GE[_#YN;E_=4H@RNX=Z[8VJ^R9N+*6^,DR$
MCH;-MS*R,2/92K07$5(Y@@U/.]?.DNW<C^B<GNO&QWK=)8X[F*0L<"!1W*\\
MOI0;UB,YBLYCX\IA[V&_Q\[0^*ZMI&31D.UIS,)&B##;OZC;+V' +C=6<M,9
M')3P63S1LD?I4<K7$$U'<@L]G]7>G6^I70;6W%8W]X 3[&RXB]ITX_@N;F\O
M!!O#7AS*G0GL[4'$_>LEE@Z);A? YT<A;&"YCN5U"ZA((X(.-="_=QV;U#Z7
M8/=V<R69&4R#9O';;WC6,'A7$D3='1/-*-':@ZUMKW7-A;7S=CN#'Y',275E
M.V>%D]XR2(O:01S 0CN[T'5-R[LV[LW&NR6Y\M:XC',:XFXOIX[<.+0/58Z0
MM#CY!5!QKJ3UDZ<[WZ9;NQNW=R65YD&60>+6*9GCEGC,^@TN)=3MH$%E[J]K
M;7?N^^QW\XML?-)=MEN&N\,B,L9Z[7&H% B68Z-6O2?I=LW+Y7 [P.4V^^X9
M[=E,C>PS-BD:7-:&O:V-HKS'CQ1#E^Q_>/?+U\W-:[AWE">F38+MV$=)) +$
MO;<PLA#)*"I+"^GK:H/7D.8QUQC(<PV[C&+FA9<,N^=K83%(T.:><Z4((-:H
M.?W'O!]';3*.P\F[\<^\:_PW%ES"^-KNXO:Z@H?*@Z)89&SR=E%?X^ZANK*<
M!T-S ]LD3A6FCFD@H-5WAU7Z?[%?[/NG<%CC[I]'-MGSQ"X##H'&,NY@*@ZT
MH@\H^^3OC:>^=G[3R&U<K;9:W9>7C)G6LS)7PN#;<TD:PGE-#S>L."#V=M=U
M=MX>NCO8K?3_ -DU$RM]X;EL=H;=O]RY1P9:8Z!\\A=H*,%?F1#QUTLZ<[J]
MY&\OM_\ 4O*7]KMPSO\ T786DAM&$O)+@T/:\EC &4U[>)097J]T#EZ58%O4
M?I/E\G!<XAXDO(+BY;/&^W-3S<HC;]<&]J#T3T<W\WJ1T\PNZ!R>VW%O&S(,
M9V7<30R8'4@>MS:(.0^^+NV^@V_A^GFW9G?IS<MU&)H(23,+:)WB!P#2" 'Q
M@501]S[=F1M\=FNE.Y97-SNV[B<V\,Q_#^S&0.>XAQ)-9)21Y$'=^I3S%T\W
M262!DOZ(R!C=S4/-[-)0@H0\?>[CT)VSU9V1?;CW-D<LR]CREQ9-%K=>&P"*
M&!XJ'QO_ ,YWH)^LG3'.^[LRQZD=.=Q9,XQMS!'=65_.V?UVNY@WE\./U7!I
MJB7KWI[N9^\=E87=#N1HR-LV5S6@@<U2UW$GM'>B):5U9ZXV_2S<6V=OW&,D
MO7[CEEBBF82&QF-T3=:?OO:@ZZUU0.<4=VM[J^9!7::M!K6O:@B@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @@4&.S#[]N/NG8N(39%MO*ZTB
M<0&OG#"8VDD@ %U!J4'!?=WZ/;JV=G-T[RZ@6K8MS9N\_B])HI^6U8!RN!B<
M\ GF<-36B)>@W-=Q#>'<.U$/-#.CN_-L^\5_Q VC91_T+R(!RYDFB'KRES7D
M1<[7^J'$MT*)5NFO1[?&VO>%W=U#RUI'#MO,27QL9FRQ/<]MQ.7L)8UQ<-#V
MA!OOO#;)W#U!Z;7NV-LVHN,M-+&^)CI&0BC0[ZZ0M;V]Z(;9TZPV1VWL7;6
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M" @(" @(" @(" @(""F]O%W<@\F=>>FV^-M=2+3KCTUM)+RZ@;$<O8P-+I)
MQ@MB0UM3K&0.'8B4\GO@2R8YV/Q^QLD_=188FV57%GCN% 2!%7Z1^BB%][NO
M37=,&=SW6+J)#):;AS,CY;*PD:6&.$1<G,6.U!()'H1+4^BNS,GU*ZQ;KZ@;
MWP\WZ+ADD;CK6_B<QA;+S48.<:M:34>=0/48Z:;" H-N68T_S8T4H>9]N[<R
M_1[WF[N+&XZ;^AF[&^M)%&XVT3G3/=&"X:#D:XU4)5LK@LV[WP[3+"RG=BA"
MS^-B)QA! 97U^"D>E-[[1Q^]MK9+;.6B$MI>, 8TBE)6'F:=:\"$0\]^ZU>;
MRV3F\]TAW587(M,9-=/QN1DB>R!XBG##R..A#^;F90_14)>BMZX>ZW!M/,X:
MT(;<Y"TEMX7/T:#(PMJ5,C1_=TZ9YGI9T_BVQG9(Y;V.>:4/B-6ELLCGC@3]
MDB'7"P ::&M4&O;V;)+LS<,+ 7328R]8R-NKBYT#P /.@XI[GN+R6$Z89"UR
MUG+9W)S-S*(9VF-WANA@ =0@&E04&A^ZA@,YA^J/4&YRMA/:07(A;#)/$YC)
M"))"0TF@)H42]A"E*5\GEH>]$-=WQMAF\-JY7;DA<P9"%T0D::%C@06GTD*!
MY,V#O3J/[MK;W9>]MLWV:VZV=\F/R<(?R5)_SG(\$%H4AU,ZP;KZ_85G3[IU
MM"]9!D)F27>1N&.<QL<9^N 8 T5/TB[Y4'=L1T;@;T*AZ5Y@!]R[',CN9FD%
MC+QH:\EIU%!(WX$'">G_ %*ZA^[I#-L;J#MF]R.U;%[V8K)VO,&-8][I1RGD
M>'<Q?V%$I-^;VZA^\O+9;*V7MJ\Q6TKF1CLED[@/+#$QS9.9SN5C6D&/0$G5
M$.T]2.GN^,=T?LMO=,<E/8[CP4,?A.MR6ON&14?(W3BYQYN6G>B7/,![T]SA
M]OQX'?VS<F_=\3)(9+=T9:VXK]$N#XR6\U>7M4"K[J73_==GN7<?4;.8V3"6
M.>(%ECI&%GX-I<0X @5^EQHI'K1C T4HB$R @(" @(" @(" @(" @(" @("
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M?9\-NI[GQ7LGJ0@W7-&7%QTHSG!<B7:_>#ZC;,Q_2G+VC\I#/<Y*(6UE;Q2
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M(H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M/>&L'%[M #PXGRHA3@R-C=N(@N(I9!HZ.-[7N![]"@OVO!T03(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M]I VZJT:M;$YH<:D4&FJ)9O9^\<%OGI;N3.;=VV=O6ABN+=H= VV;,&,#A(
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M%!K\:D7*($! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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ME-5( >10(TU0$$*((H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MHJH2]^,-6U[.Q2A,@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MH(:^5$FOE0-?*@:^5!&GE*@0IYT"GG01IY2@4\I0*>4H%/*4$-?*@C3RE!%
M*"%3W*1#7RH&OE0-?*@4\Z@1IY2@A3SH(@>= IY2@4\I0.4TH#H@D=%S#EYB
M!VT009"&  &M.)H@-@#34'L 'F""I1!$:(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(($@(.6=?M^.Z==,,SG+9Y&
M0>PV]B0>4^/(T\M#0]R#SQ[E_3"*]9E.J&>8+F\EG;;X=TK*EKX@)))&DD\>
M:/X$'M)K*^L"2.!'$>=2*\8H/.:]R@3(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""23Y*%!Y,]^^_FBV%A+
M //@7-X][XP:5,(9R_=E!V#W?<-;8;I#MBUM!ZG@.D)(U)=(X&OP!0EU1K>5
MO*I0FX(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @E(0>/??T93:NVG=]S<?)$@]"=%!_\ @LVQ74&T=7_I
M7(ET!$" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(('L\Z#Q_[^PIM7;0_^)N/DA0>@>BFO2W;'\D=_"N1+
MH"($! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 00/9YT'C_W]_\ 9;;7\IN/DA0>@NB?]5NV/Y*[^%<B6_H@
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$!! ]GG0>/_ ']_]EMM?RFX^2%!Z"Z)_P!5FV?Y*[^%>B6_H@0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$!!#M0>/O?V_V5VS_ "FX^2)"'H/HG_59MG^2N_A7HEOZ($! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0.U!X]]_7_93;/\ *;CY(D(>@^B?]5NV/Y*[^%<B6_H@0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!
M+S '7R!!X_\ ?U_V5VR/_B;CY(4(>@NB;A_PMVQ_)3\<KT'0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M2/):WU>*"B)"7<IH':<P/V).A0>0_?R>'[4VYR'F(N;FO(*D&D-$'?NC,WA=
M+]M,=02-M#4$TT\1_8@Z&V3F=1!40$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M7@]9^299>7HZ7;3-DC;*R421R-#Q(T@L(<*@M/:"%A+6NJ@GRK&!&H[U(("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M",1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00(J@
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M 0$! 0$! 0$! /!!+6A\@XH(M.B"* @(" @AS-X500:YI!H:H)@@(""!('%
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M[=MKL_\ +F%IVV%K7_H6J+=Y:[>IFO";0A8H1;&&_P!E$$Z @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @D>_E!X5
M&I\R"UBO+:=SXX)FR/8:2!KP[E/EH4$6WMN9?9Q+'[0!7P>8%]!K]&M40KF4
M@5-!IIYT2B):BM$ RTT(]*" EKV:=_8@B9#RUH#I6GE49,+$Y.P%Z+!]U V]
M<TR-M#(WQRT4]8,K4C7BI%VUX T U[.]!-XM*Z<.Q!'Q"=10>?O1(9#72AIQ
M\Z(4)KN*$&2=[(HQ3UWN#6Z]Y-$%*')V,\@CM[F&:0U(;'(QQH.)H"4%V9""
M!VD501$AJ012G:@>*36@X $^6O<@E,O*"3V"M.U,F%O#D+:Y>]D,T<KXR1*&
M.#BP@TH:'B@N1+IV((B4$T[4%1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! /!!BLS<.@M26FCSH%LIW:;]FL$ZZ\25:4I%C"$.&J
MR0B#1P?4APX%$MJQ5PZ>W:XG4:?!HJENZ]KGHR2P;A0"D$! 0$!! \"@US-W
M)+Q;AQ &I^16*0I[I8<"E0-0MRN("CQ%>RG?;W,;FFC"1S_"HMV;*=VXQ&K
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M(ZM:PO>UK14D UKIJI&8CZ%YYFUNF& =?V_M&R;^2\OW5=R21N=.X!FO'\(
MB'H:/6A' A!4'D0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 4 I! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0662M?:;9S.WL6=9:[US#4GL<Q[FO%) :4/<K,3E2M64E2-%G$0U9
M$EE7$JD4;II6Q,%2>U8Y;HI$MMM+?P(61@5( KYZ*I,]5NM<0NQ6FJP9HJ 6
M0(" @(" >"# YRS)Y9XP2[@[X%NUV5MT=& ];B1HMZH>591$)Z(T)\W:5$Q!
MT75C:NN)@&BH!!)]*U6LWTK#;XVAK0!V!5Y6X3J$B H! 3J"D$!!3D;S"B0B
M6H7UNZWG+"/5.HKY5<HYVR)6VM->*SEA7[4#7N1ET =""->Q0=&4PMNY\IF<
MVC6C0^5:;6RW4UXELS 1Q6B5R$U5"0DJ42"O:A"*A(@*,@I! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00/$*!XKZS_ -9F9\\?^,N]Q/2Z>CLW
M+W:/]I\K_(7?PL*K<W^:OO[O43>"Y:HB@(""':$$ :J91":H6.4I0ZITX++"
M,IE"1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M!!(X5]"E"0-=Y%"4>4]FI[40B&"M7<4$>0<0$#DUJB4' $$#B4%I;8NPM)9I
MK:SAAGN#S3S11L8^1W>\M +CKVH+EL7*?F1"<, X!$J4T#9XW0RL;)$_1S'@
M.!'E!T*"RL\'B<7S_HO'6MD9*EYM88X27'4D\@%40R#&D  ZG[+O1*)CKQ4]
M$=4.2DG-V.T0R<C7$DZ'@H2@]I)U'&E#Y4 1"E#Z4$Y;P--1P1&92'Q-0 /)
MY$2BV.AJ>)XH@\-NIIJI$S!10)T2(" @(" @(($T%4$.840350$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!!*XGL%42QU_B8+OUQZL@[0LXMAJM6)89
M^%O6FG)5HX&H"V1=IMIR1X6\<X!S"UO::A)NB-,LS:8Z*U&HYGCM6N;-T:\,
MBTB@[%@VIJA 0$!!"H010$! 04I8V/:6NX44Q*)KE@KS"N)=+;>NX_6=BSB[
M1;0L#C+T&AA()] 6R+-%M,KB'"7<I:)AR1^<<%C-V==+.6MG%:L#&"A^R6N9
M6*TPNAH5@V83J000)HHRE"H[2GF1A$?$H\PBL@0%C(@?C2)%C?6$=Y& X\KN
M_@ML6PPFL2UR?'W5N\M,9(' C73T+;6W14V:IST6_A3&E(W_  %99:OHROH,
M7<W#@YP,<?ET439E&F<MDM;=EO$&,&G>J\NCA<+&9$%$2(K(0)[E&1+JL>J<
M(4![5E!,(BE:+)'E3J 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$$CB0*@5([% \6]9_P"LS,G][^/F7>XGI=/1V;E[M'^T^5[O87?PD*K<W^:M
MO[O4$;JA<M53ZH(5/<@5\J"#G4("#'9#,XS$Q>+D+J*V;Q'C/;&3Y@XBJPO;
MHRK7,L/9[^VK=S"&')0AY^B9'!C3Z20J\7ZMTZYPV9KP[UF4(/!PX$*W$Y5\
M*C22-4$4$.U!% 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00\W%!A]R[
MFQ>TL)>;ASDO@8JQ =<2M:7D!SQ&-&_NG!!RS]JWHU^N)*@T(]GD^H@C^U9T
M9K3],2_FLOU$2@?>MZ,C_P"L3?FLOU$0C^U;T7_7$WYK+]1!#]J[HQV9B;\U
ME^H@F_:LZ,?KB;\UE^H@E_:MZ,"O^N)J?R67ZB"(]ZWHN>&8F)_DLOU$$?VJ
M^C/ZWG_-9?J()?VKNB_ZXF_-9?J((CWK.C!_^L3?FLOU$$/VK.BX_P#K$U?Y
M++]1# />MZ+_ *XF_-9?J(!]ZWHM^N)OS67ZB"(]ZOHR17],3?FLH^9!2/O9
M]% 2#FY&T[[:3ZB WWL>B9J[]-O+1Q/L\FGQ(80_:SZ*4US<@/:?9Y*?(@F_
M:NZ,FA;F)3Y?9I3IW\$$Q]Z[HQ2OZ9E&M*>S2_404G>]GT4#J?IN6O=[-+]1
M,F$SO>PZ*TYOTW+Y:6TGU$$![V/172F:E\G\6E^HB4Q]['HMH/TU+^:RTI\"
M(#[V710?2S4H XDVTOU$$&>]CT4>ZC<V\^:VDX_ @C^UET3-:YQWD_ 2?'H@
MB/>NZ+.U;FI".PMMY'#X@B4P]ZWHP?\ ZS-^:R_41 ?>KZ-<?TS,/)[++]1
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M-BC+<?; \QX0L'?Y%%IZ-&ZTX83]$XKF/\0M^/\ FF?46K,JWFGXMEML)B#
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M[(Q=V1XS-(SKJ/25RMU,=79X^[/1T$&JINDB@(" @(" @(" @(" @(" @("
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MCS_N5^]W=I)U(H>Y<9Z5'B@B@(" @(" @(" @(" @(" @(" @(" @(" @("
M@(($T04W2L! )H2B,I9'!H))H&CUCQT4,L2\4=7;ZVO>I&;DM7>)&"QO,- 2
M.8+T/"GY?R=+1T9_H/%&_<N1+P'D63BVH[?%A7&]S\?X\5G^K+T%S$FCCKP]
M72B\UANZH^3UO/51A.94I)'1D<NH\J83$J@)H">U3@R*<(0)#6EQX)$Y3,)
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M_'.=86(:3SB\M^4#AS>("N#[57ZEXB._^:QR[8JQ^W]KV>9M);_(RW G=<W
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M?S.[.T+";9;(KA4.JQ9'RHA$<%EX)B$C@#4'5IX@=JUS#-KV=P<KYFY_$O\
M RUH YH!Y.9K.RK>]M5LKTZM%^L3#==G;IBW)CFN(,=]!ZEW$[0AP[1WZ+J:
M]OF<?;J\K9VFAH%8F5;">NM%A"45D" @(" @(" @(" @(" @(" @(" @(" =
M0@E<2-1V(.*^\!N?'GISN/$F.?QSX#>;D:6>I=1$Z\WD48CQ[-6VOFI,-5P.
M]-O,P&)B?+*2VTA93P7#6.,-.K:]H7G.5[CJUW\O7^S_ !4OVEIAL^.WUM.Q
ML8;V[N)&Q7,SXF-Y'NHZ-M35H!5RG)U>3S=66CC6SA?1=2MGY*2/%VE\_P!H
MO'M@CYXY@WFD<&CBP #55=7NVN]\1G^S_%TMWM]XI/6/[?\ !J[]^;>MKB:-
MTTGB,D<UPCB>[G#-.ZE/.5IY?NE=5O'M]G^*IQ_:=EXS$QW^W_!D+63";OQT
M]\;N6"UQ<GBNF!="^)\7K:4\_8K\Z:\^BM75?1;$S#0^EV)CWX,_N/+RWK+J
M#(>R,AGF<]S;>!@>T.]9U=9':573Y7MG&U]*9_-A._;>W687^\WY#:\&,GP^
M1NK5N5S$<,X;/(UA%PV1[J!I':U>0M[52UL_S6=7+V1V;MC]J6%T^X9--<NF
MFG9=&8S.Y_%C#V@@ZFM'GM70K[7KVU\D_?W8UY5IG,M?VU!>9_>N^]MY/)WD
M^-V[+C66<,ES*X/-Q$^5Y<'$C1\8IY%AQ?9-59_#XK>[E7FO7XL?U M[K;>)
MRF<P]]=VUS+=1&=D,SV-/C7+(S2CF]CEIY'L^NVQ6T\N\1B&TXC9-A>7%V;R
MZNI+B\\&9]SXKC-6)S.0AQ-10 #BK>OV737-)\/M8:^5LF^6*PN&GRVX]WX6
M_P G?3V6$R%I!9MDGD(<R2SM[HAX+CP>\JA;VCC:]L8B?!;MR-EH[J6YNGF(
MW)=O=D+BZ=$2&NMV7+Q'1H^Q(H5Z")M2L17&'(MNF9F&4VSLO#8ALV-A?//8
MWC?"D@NY3*QK:<M& U 41;+"D1,LA#TEV*U[KEN/8)^5H\4AA=ZI)^P\O>LN
MZY].N,-8ZHWN,M-K9W&BXC@N3:O9#;EP!^B0*-"QLI;(ZS#;]K9#'Y";GQ]R
MV?PVL#J.#^7FKJ16HX+.J=$=>C%V+?\ \,65(;_[A .4FI^B%E'=<F/F_!D-
MYD#&Y5O=;2 ^AA6-U6_J8'I(YHV%LHDT#<+CR23RC2S8L:]V-?4EN;VQ/7.R
MD\>(1G:LX+P]M.;](1NY"X]O:MT]E[P9S>#XSB\L>=KFNLIG\Y/$.A-*$5[U
MIE2VQ\S&]/"P[=Q9[.5P!J"?QKDAAKKA/N TZM[-TU]GO?3_ !>=;/+.,NC&
M&=S[VN,P/^8=PTX<RPKLZJ&^.K4>E#.?9N#/;R/''_G7*-DS!KCYF5WZYDF]
M]CEH/+XEW4'C].U4WVTW3VE;V5\LU9+>N'ML@UMQ=,#Y+.*;V=]?6'B!I<>'
M[D+3N]LIM_\ BPV<FU9Z.<],L7;9#"V^1NFFXOX[F1MO/-ZX9RB@XU(X]BJ1
M[=]/I3&4TY][1'F_N;=,=W;5DP>WXY+&:#(S_H^UDYGAS*0R2U=^#_YM<&O_
M !N=DS-IKV^,_P"#O5YV;=?@MKO&2X/.[?BS$T4D\M]<SW#V:QL\5LKP YP;
M7C3@M?N'$_:<6OV2PT?3V;IS\&$WYA[6PN8\KM.Y9XT]W Z?$1O#8+A_.TZ-
M9ZK7 ZU(^EW5JGLO+KR[?2O$Q$?AX_YL.9KO6N*3&&U=-]PMR6#-L ZVR5O=
M74=]8S4$D3C.\_6D@BA!!!^/1<3_ )%QYX_-O6(^7Y>W7^F%O@3>-%<X\?[Y
M:UG\!'N;<C\+<7#[:"XR<[WOBXES+*%W81]BL^/R?H\6/)\)S_:O:*V^K,SC
M'1;Y'IGC]J38O*6U_/+.,A;1\CJ_72-[>91[;S;6W1'VQX,?</I6GM+,7^_L
M@,E>61N(8(;:<PQQ2LE<7  :\S(WKTGN'NDZ\8_E_BKZ?;8V5Z3_ &I;/?9N
M;*::_!NQ#<P6L;[6/E<YUP)#2DGAG3D76XWN<6TQ,]\?9_BY7/\ :K:[5Q,=
M9^W_  7=SNB*TA]INL1D(;9E ^0^#05( YJ2JIK]SK-\=>_V?XM%_:[Q7/3^
MW_!MC]V;;L'^RWE^R*X82V1I9(XAS=""6L<NKL]QI%6O7QYF<+?)[HVU<V$E
MU;W[706\C6SNY9 0Z0.+: MKKRE3'+U36)ZM>[1;LP(W5MEQ%+WC2A+)!5Q(
MT/JK5^[U?;_'XJO[>S:&;NVQ9AL4U\T3Q-:'-:V3EHX UJ&]Q64\_52,]?X_
M%>IIGIEH.Y<WBLUUGZ9/Q5T+CV:;(,D]5P(+K"X</I@=ZO<;F5W=F^NK$O1[
M#S4)U(XG@KDMZ=IJL:SD3+,$! 0$! 0$! 0$! 0$! 0$! 00/!!89,!\+V.:
M',<TAWFH4QF$?4M6<PTJZV]BCR@R.@>[5K>4$?*J&S5#M:.=LF%J[:8<!X=V
MTM\K1]5:/)$+<\S9"B-HW0-?'@K]L_[Q::Z6^_NF/"?R8O<>V[BTPM[<23Q&
MC:!K"XGXVA5M^K$+?%]P\]HZ2Y&V. QP,FD<]KP*M.H!Y2O-WCJ]M3=,5S":
MWM+9KFM@):.4Z^E*U+;[RN# ZI'COHT<Q_LKY5N\K3]:QX9:QW--(6M:'4J>
M#C3O6$TZX;:VS&96KV1Q<SVES7MT#CY17YU6V4\LK,?-#;-@XW])9&Z!G E<
M&!I=7M![5V>%3S/+^YW^E$V^#HAVE=\6S1./=4_478C3F7 K[G$QXJ&0VO<P
MV,\DLT8+8WZ#R#S+'?I\M6?&]P\VS'7O#BH8UK!')+5LG8VNE._X5Y>\?-+W
M$7F:UF$S+&TYVNA+@X\#P(2%FW)O%<2N!;AW*!._UM1Z/2LNZK7?:9!%0\QF
M>X%A<!KP'I6'58B\+9UO%&#*YS@:-+?.XCR^51Y6<]6P[*Q[LAN*&(ST,CI*
MEQ-*-A<1\BO<*,[HC[_[G#]TM]'CVO'AC^^'3_Z'7)?5D\9\Y_M+T$Z9R\E_
MW2WE[3^2#]I2AI,EPP-%:BI[!7N6&W7,0UZ/=;6OB8_L<3N8A#<W$9E-"9!Z
MO#Z(7G+QU?0-%YW1YI^Y(RSMA('L)YPYH)X<5HFL+M\Q"Z%N>4\LQ;ZW#5;J
M0UTOE-X3P169SJDBFOUOI6CR2TUF1K8P&O<35PJVJSB<-TQ$MCV)/,[=>))<
M2>=S===.0Z+J^V;,[?P_P>=]]I7]OT_U?REZ/;H 3Q)U7K]<OF=U99B*@%((
M" @(" @(" @(" @(" @(" @()7=JB.Y+3\C^6S?;_,%<HY^SNMHM96?;#Y5G
M;M+73O#,9W\7#YG_ "!:-:WL84]JLPI@6*911 B56V_*(OMA]RM=FS1W9;<'
MXR,?N?G*UT;=["'1]3WA6)[*](S+,C#VN7Q++>Z /.UP#CJ1ZQ\BT>>8E9G5
M$QAI.2V#E+:3^*N9/%2O$@CX0K--ZELXC%LVIG97\C+>E.]PHMT[U:O%F6S8
M7I^YCVSY-S'TU$314<PX'4*M??E>U\;'=O%Q&V*SECC:*-;0#0!5)G,K\=(:
ME\A5QS-C*83\K<1_FW?*%IOV7-7989V[MK.2YN;Q[88&T)D> >SL'%94IYFG
M;>*3ESJ]ZP;-L9C&V6XO"W1TL0+J?](6J]3CSA0ORXB53'=6]H9!XB\6:V<]
MU&&5NA/EY25A?CS#*G*B6[03Q7, N8'>) ZA;(TBA!6F(PM3;S1E6&AIY-/2
MHEC#*X$5GD'?HM-NRWK6=[3VR4]TBSU]6O9T4K2@GCJ#H=> 6=Z]&JMNK:7Q
MV\\?))RN:!0M=2A53,PO>6+1U8:ZVCMVZ=S/@8QY-3X7*VOQ!91>6BW'URJV
MFU=OV;O%@A:7M% 7\KC\BB;RRKQ]<,PV6*,!H( &G9YE#=F(8S.2"2!A&K0X
M<"%G2&O9;HP IZU/*K%94+3F6?Q1 Q5T.\OU[/Q;56OZG2U>EIV8W!B<'&)<
MG<-A&I+2.<T^U"Z-->8<K?M\LM,DZT[0AE>P,O)QV/9%&X4\[Y6GT46RG&F8
M5XY<1T9G"=1MJ9MWA6UUX,QX1SLY7'TCF'QK"^C"S3D1+;.8 "NI/"NI^=5)
MJMQ>$3J:4'H6RK3;NSV-_FN7T_*JE^Z[K]+ ./'4 55F.RKYXK9D\(TFY)(T
MIW\=%JO/18I>)7N0V_B\GZUY TR<.84K\BQK>896I$L&>GN'+^8R/I7Z(.BR
M^K+3]"K.8W;N*Q9YK> <_P!D0TG3T+"UYENI2*LJ".:H^EP[ M$Q+?%H56NX
M@UJI$W-Y$%-[Z'7@-5A-9E.<-.W+U.VGM?3(W9,@):(H6\[ZCT@?&KFKCVLI
M;>36K58_>*V*]XC++YH)IS&&/E\_XU;K<*WV-$<ZOVMWV]OG [GB$N)NQ,T\
M6$<CQ2O8?,J]],U6=>^+]FR,?4T[>*K8ZK?@J=M5DA% 0$! 0$! 0$! 0$!
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MONME:U16(9W9DT\5[.8R00&#0TTY:_.NAP]N.SB>X:J7B8EO;;[(- _".%.
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M=]Y'>67N+EL\C<7SGV>$DM'*-!5H)'!=K1QZUAP>3R+7:APX4^#178Z.;/5
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MY/\ 7%J RZY@&EX IS:$UT7"Y&GR3T>AXF^;QU=-:3P*H^+HIED@0$! 0$!
M0$! 0$! 0$! 0$! 00.H049'F-KGF@8T%SSY M5[,JURX_BK@Y[=F3SH)-K!
M6ULWN[JEQ%/[I<W=;S.SJKY8;0XB-A<WBUJT0V2K6]C"^/Q9AS%W  K9#"<J
M,\/L<C"VO(ZNE5A'J;*/+75"G]/LM3_F_D<O:>W>G\FC:V?H-_M'D?Y"[^%A
M5#W+M/\ 'BVZNSN]XV4Q?@N*\TVEB)FQTF&O>@N42(@H$ @( -1KQ00+>9I!
MJ"5(EB:6-+*U%>U0F%2E>'$(*3I@#RM!>_M#>"SB$9&S-(Y7 L/<5$PF,*AH
M:.' =JAE@(JVAU!X@BH/G3L3&6#R&U,)D'NDE@$<IU+HB8S_ (-$\^&OZ<2Q
MS<)G<$_VG;^3D?R>M[).26. [*FJSIMG+5?1#?-D[K.Y;*3VF/P<A;/$=Q%W
M<W CX%T==\PY6W7Y9;4/(K,*TIQP4)10$! 0$! 0$! 0$! 0$! 0$! 0$!!(
MX./!!Q3W@<)>#IQN:^.4F,)$#C9\K?#HZYBTKQTJL+WBL9F,PQM$S&(Z2UC9
MVVMQ9/9^ NL;NF;$P>SAOLD5M!*WB02"[7LJODO(W<+]Q>;4MGS6\?M^]U8U
M;L5^:.W\FNVNU]T?TFM(#NV9KW9"Y$<WL=L>4LMB2[A]=2B]%N]SXL<2:^2V
M/E_E]KFSIVSOCYH\?YL]NO9VZX(+%TN]KBY9)?V@HZSMFT<Z=@!J-1R]@6CV
MOE^V?6B9U7FW7'S?9_XF7+U7C5,3.>L?WFR]I;BGPS7G=]S':.FF:^V;:P"K
M?$<'-$@U%>-1WJA[IS.!2^?IVB?O^V?_ )EKB:YPS73S;MEBLEGXXRZYNA=N
MC?>SFL\@: 0UTA)-!7O[5[7VOF_N>-C$Q&7%Y6O&^?N_Q=$!(=J:D5 !UH%T
M&N6J.+@X@$ Z"M!V+3+F,M@ZE\H))/?Z5-5G2RS@"-?E*SE9:Q=4\>5M/KW?
M$5JE0MW7V%KXSS4EQ9VGLY@5E5MT]V<)(! X<374]ZVK34[G\<_M]<GX56MW
M4+=UWB?RMOH^=;*L]7J;!W><K8N0U>\_'R><K3*C?NN<7^5C[53#/5ZF?;YR
MMJXU[+'^-O%-*5/G6F>ZEMGYE/'$^V1UUJ3\*RAAKGYFS,=Z="MJ_#7,M^62
M4[FGY%IMW4MOJ4K"IN6:T'-4**L:=VTDT''M]8=ZL1*_+4=Q8^RO[MIO;:&X
M,8!8)HV2 &O<X%:+=U3;'S+/%8;$6=[!-96%M;R@^J^*&-C@.W4-"5EC3U-!
MW=U-PV0W;MB]M;*_=;XF2X-X?9)QRB1UN10%@K] \%OE9M.9B71+C.V6XL$S
M+6+9&VMQ#*Y@G:Z%XJT5!;(&GXEA9ALG+3.CSV_T5@H1SBZD:6$Z@BGI6#37
MP;IO$C]-[,J1RG*DM=QK_%+CLXK9"[;O#,Y@?A65%#0:>E8W5]O=RKI&PNP-
MXX:TRV3\G_U"Y6K77K*O:.N?M;GOAKO!V^#HTWT/-J::2,</C4UU5B^?N7YM
M/EA#?6)L-P9O V5\/P+A<DS-<8Y(W"%Q86O%' \PTHN5[[S(BN?].?[ESBZ\
MS/W-8W5C]Y8*UQT=MD+?-V#+^V,,5URPW+/P@]5K@ '>=[EY_P!MY'&W[:^?
M7?.8Z_C]ZUR--J:^\3W4O^(&9V"V:+<VV[JV9D;NL5S#)!<QUE#6@$12/<.'
M:%V/<_\ C%N5YK:;UK'7I;*OQ.;&J)\T2H9+<=EDI(<VZD,<N4QT@@YFF<,B
M]HYB8VDN^N'8N-L_X]R>-QIB?G\T?TQ/^#.GN.O;M[3'EF&;W;OK [CP%_A\
M1++/?GEB,3896D'G!U+F #Z)[5Q^%[=RM.VLS$Q^#H;^1KM$0V7:!C=)G8G@
M- R,]?6/$O/:.*I>Y:ME[VB9A;T4I%(F&JY6C=TYNE"TW>,'EIX#S5='5:*<
M"T?"*J=]?_[-)^V?[F\[K).WLC0<6M[?W;>]<#3Y;[Z+U\Q6S3MFV>?E@N7X
M_*-M("YO)&862&M-?6+2NE[AII6]<?!LX=JS6<M0NH<A![PNS(\G=-N;AMQ=
M$R"-@!!Q4I'8%[?_ (KCZ4X_U3_<I\N(R]81:.%-0=?-HO7T<Z55O ^=;&"9
M$B @(" @(" @(" @(" @(" @(""ROR!%(2*@,/R%3'9CXM)W!^BIW#FE:R2,
MD.T=Y/(N1R,/1\.;0TZ22S:XB%]6]]'?47,=[,J?B6_8*^:JQ93KEC-P2-_1
M-RT,H.7Y54W1T7^-3K#G,9IR.I0^H1_>$+BQ$Y>HB,59.U)))=JX1O\ NE;J
MK77!IH/^9<LI:DKM8M.'*SYEC4FF5A>>&YDH!H:G[D*MMA;UUZ,QM%\3+V7F
M=]+E';V-5SB1.8<KG5Z2WCQ(CP-1Z5U;=)<2*9A:Y*1@L;@-87UC.@T[UHV]
M:M^BF+Q][EW*[U0T?9$\.RBX.,6EZJD8JR5L][W4=PYW$*U1INNXOI1#_FN7
MX*+:UI'. :VO^;^HHGLUVUY65P6>'1W$M;3X0M%H7-.O"]VP8FYFWJ=.9]3_
M .R<IXV8VQ_'@I>X=-4_QXN@>+!]D3Z"NSGJ\_'6$DTL?([E'8?D6W9'RLM<
M=7*IR7S/ %/QA^(+@6CJ];IM'E7MLYY(YQ3UV465477[>+1W256^)592DCD/
M[ZY:,LNZ/8SRL(^,*,$0SFP03NO&.I_EI#Q':URZGMT8V_A_@X7OL_\ Z_\
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M>6[BK6OXKL^%8SQ-4^"S7W#;'B?\=NH?$7D53V&/^VL/V6OX,O\ N.SXH?\
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MJ=&/<RM-J7]ENO=V8?/G+=XF;9648CC8YM"T.E<YY=KQ]1J#UK'#R!C031@
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MLW_AP_[4@?\ I^X/_?6;_P .'_:D#_T_<'_OK-_X</\ M2!_Z?N#_P!]9O\
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M"KX'"0D#B2"QM/A63&TQ,LQ'%:2M$C&-\.1H<PK)LFD*.1M+5]A=ET+"&P/
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MFE8IHK2.D8CX.N=)-K74+XMROH+,S0L9J2XN$S=*=E*]Z]/[3FV)G^.KYO\
M\BY.NMII%>O^3T+R F-_$DT[^WO7JK4C,='@JQGJN@LQ))&)&.8X>J1J$%I^
MBK(?^[1\ !H"  @G&*L.VW97[4(E XNQ[+=G]X$0#%V/^CL_O @C^BK#_1X_
M[T('Z*L/]'C_ +T(D_15A_H[/[T('Z*L/]'C_O0@?HJP_P!'C_O0B#]%6'^C
MQ_WH00.,L6N!]G9IP ;10+:YQMB+:4FV8:M<[4<-"I'R@S^S=P[OZH[KQFV,
M7-D+DYC(CP[<%X:&W4@J30:?(@]&]+/<@N9/9\UU*R @Y1S?H2U89'&M".:8
MO;0@:%OAGSH/7VT]C[9V/CFXW:V,BL+.@+F1M#7.(XEQ'$GBH2V>,$%SB*5[
MU*%1 0$&!W#]&'SO^0+=16V]F![2K2A'=/#^,'G6JRQ1F-P<8/,?F6NC?L[,
M*Y;X4:=VM[JKX4'G6[7W:M_2&KGL]/SJW?LYE;QYG0\#_L5<4X<LWRN7,_K=
MJOZ<N=]_F^=="CEV"MDM<%>U95QAEGJAW@=JU8;)F'$MRDNSE]7MG>?C73U=
MG+VL=;BMQ$/W0T](47126Z=1(8H?T=X4;8^9CJT''E I\"TUGJVV[-&&HJK*
MMT14,A!!+](AGKZY7^#C9)FL:R0<S'74(<T]H+VA1LZ:\QWQ+&G79C[8;EU4
M@CM\E:-9&(_P;A5H[ >"J<6]ISF5GDUBLQASXZ\>PU'G5RW6%:L8MEZ"Q#G2
M;+VYSDNI"Y@KV-#(Z!<BWK=CU4C/5-V:+9/@K^(.*AE:.G0\OH4M=8GQ669I
M^C+T'_-$'Y5.ON7[.$EO @Z:_(5TJQT4)[MGV%%%+G6<X#J,=0.%14M(6C;.
M(6=<9E9;L8V'<-[$T 1-<V@;P%6A;-<YA6VQB6%K2J1/5G7L@MUF"*P$/D0;
MGTVMHI\K=B6,/+;9[FAPK1WB1BOP%:-TX6M<1+ [C8R+.W[(QRM$SZ :?7%9
M:>O=IVYB>BVQ9+<E9D&A\>'XY&K9MB,,M5IB7H"]_*Y_WQ_W97)GNZ.(QE;K
M=/9H\TY-%C$]$S"/!WH/QJ,L6D]1G$XJW96C#)J/*M].["_IES#A4]ZNQV5:
MM^VE;POVUD9'L!> :$BO>JLV^8BLY:#V'RJWTPRO&,(J&L4B!^)8R;NF$1PI
MV:5"V>!;TY=VZ;V%K<](MT2RPL=+&+CDD+:N!;!S-H?(=5PMFRWU8C+O<776
M=,S,=<N%.:8WO':7.X>1=C3UAQ8C-IRZW[O,A.\Y&.-1[,[3T%<WW#TNI[1.
M;3G[?Y/5K>"X<O2PF4)$! 0$! 0$! 0$! 0$! 04Y7<C'/\ L037S!8V[2F.
M[C.S3[3<YG(R'FF?>/CKY&@47)O+NZ*]&V-X56G#9;NDF=RL)'$FE%E+*>R[
MAL(2P%[>=[A4@Z46RM5>UEO<V_LX$L!-*^LWN6-HPSK.426DDC@>"P;! 06>
M1B\7'7,7?$YWP:HFKG=F0^WCKI4$'SMJ/F1OA7%0T'M/'X49BA @(" @("E*
M%>*":U];,8^,-U\6O^ Y&JSHA\6&1LT0]8?2'>I:)A-)=3SCPRSD!-202?F6
M4RPBJ+6 - \I;\0/SK7,LX:UNZ[N'P6N%LG$7>1D$0<.(96A-/2LJ1F46MB'
M2]O86UP&-CQUH/P<?%U*%Q[UUM5<0XFV_FG++MX+<THH" @(" @(" @(" @(
M)2VI0 VCB[O01#:((H" @@30(-7W[ALYN+;=UBMO9=V#RLM/ R+ 7<CAV$-(
M-"@\OYI_47IN_P +J5NW,.Q[_5;F<'<27$52>+V3R6Q82!4!G-VHEZGVC<P7
M6U\)/:WTF2M9+"V,61F!$ERQT+2)7 DGF>/6=4\2B&D=>[&S9TKS\[8&MG_B
M]9*#FJ;N*JT;_1+*L9E<;5>W^C.%H14V-L#7R0M"\CR=<S9U]6N<-MQ9;X+G
M5^BZBN<;7,0J[:8E?RO;X,FOUI5J])PQB.K6GO'.=1Q7#VZ9ROUU=&1Q#V\\
MK:]E5>T:YA7V4PRI(IR@TJ:+I33,*M8:U(]I<[4<5Y_=JG+H5U2R>)<"^8 @
M_P#*NAQ-4Q+1NIB&2<X#MX*[?6KQ5KMRYOM$HYN+W?*N-OTRN4U3*[Q;V^*\
M5[*_ 5MXVJ8B&.W7AE^9O?V?,NE-9PJ^66MSR-\60@]JY&W3,RO:]4RN<=(W
MVM@KQ6[1JF)8[=>&<+V\*KHVI,PJ15KMP]IF>:Z@KD[M,KU-717QSQ[6-1JT
M'BLN-IGS->S7B&;Y@X<0NU.O$*DU8+).:+IYYA4 !<?D:I6M>N9C*%BYHN8S
M7MI\2<;3.65Z3$,_S-=ZVG;\2ZGDE3PP.0>/:WFHX-'PM!7+Y&F9E<U:\PI6
MSV^/'J.-%KT:9B6>S7B&Q%S=37L 77BDJ&.K"Y-[/:J$TT"H\K3*SKIF%"T>
MT3Q'F%2ZE*JMHU3EG;5,0V*H'$KN:Z=%/#$Y5X,D57 <>WS+E<O3.5G73*QM
MWL\6,%PXJOHU3$MM]71L8(["-%V*5F(4)JQ.6>/$9J*T5+D:YE:TTRQS9 7<
M1H51UZ9B5F^KHV6%[?!CUXM"[--<X<ZU>K%Y:1ID8#H*?55/D:9F)6=6O+'<
M[>>@/<J6G5,-FS4V6,MY6U(X#L79UTG"C-5AF)!X3!6@)/D5?EZIG#?IIEB0
MYO-J11II6JY]=4Y6)U2V2%S2QOFT79X^O$*5Z]5AEW 1,UT>\ @?N05KY6N<
M=&>JDRQ/,VI];1U= ?+75<.NNWF6IU3AB.I[@=G0$'0WV*.GER%NO1Z-<^52
MFO5JW4)S?^,_2@?\YD*_^'SKI4JTWAWEJMM"9 0$! 0$! 0$! 0$! 0$$A::
MC71 H*C5$)P*(D0$!!9Y/\CF\K2/B*B4PQD7T&GOJ55LN51D_%@+&&4M0L?R
M&'][:HAU8,EI:3$=WSA39E*]:UAB:'-TY1QXJOEIB<2D&MI>#ZWPWZ>9JG+7
M6<V:K9RR-MF!KSRM8.5M4R[E*QY4+N>7V:?G<2SPR2"=""U36:9ZM>^D^3Y>
M[!;FN=IW4%M!>3QQW$3 ]PE8#6K*4:1754.=.G'7#9[73F1?IYL=/[W+<D["
M>V.;81\T8XN#0&D?"O);)U9Z8?2='G\OS]UD;JPCT;%4=S&BGRJOA81]JB;0
M0VY(?V$ !#NBZ6Y>3'0,9]*G"M/*D1FT,+US#L/3*[REVUGZ0%88@WV=SQ0E
MI!X'M7L>!VA\O]\UQ&W\V:@N)627+6O</XQ*.-- XKKWGHUZM.=4?=",\SC&
M^CR26D$>BI44RPV:[Q'1AL]>[9GQT%K?W#([CPV'DE%3ZH%:$57(Y^,?Q\70
MX%=T6Z9<MS!V\+JEDT.IIS$ #3NI5>7V8>WXWULQYLX8QUQCV"@BYO,T'YU7
M=),VY@ 'A1<>\4HB1TTLC7,8&L%16G:/@41'5-?4Z=TROLK,\6URYWL,,]L;
M;[&I>:T7JO;Y?,O^0XB_Y-R?(]F0R(8XM:ZYD)%?(U=_9*EQJYJD=-,7.YG$
M@CO2D]%RU(\O1C<Q>X#]&"RRT[(9I2][/&%6&E!Q%3V]RH\K&%/V^O(^I\N>
MW^#EF=_HO&YK<>63R-=1TD;0(Z4[.WXEXW=$9?0.'')^I/U/-C'C^##^/8-^
MBP4\RKX=E WEN&@QQ:^4* -Q,\#DC%#H=.8 'R&E%-LM41.9SV=5Z0Y+.F[;
MC2XC#1RPO<VGJ F5M2/*O5^T>'\>+Y]_R3Z.9GIYNO\ <]$CF+FG7EKIW+UE
MH?.JY701DB@(" @(" @(" @(('N04I(JM<"='"E*5XH,)@]I[=VV^[EPF.@L
MYKZ5\]V^%@89))7<[BZG>35!GN1OP((AJ"9 0$$"@P6X?HP^=_R!;J*VWLP
M5I0CNJP_C&^<+598HR^?XP>9WS+71OV=F%<MT*-.[";BLY;BUCDA',Z-WT1Y
MZ+=2V&'(KYJ]&HMBF?)X+89#,'4 Y>TCSK;;9T<NFBWF=/LL=+C-ESPS?C'1
MR/([N:I5")S=WYIY=4N6#M\WSKIU<6Y4'CH.U;):X!J":T ('H*U>;"9I,]0
M]H'#37SU6=43F'$=R?SY?#_GW_*NC12NL+-KI+J%HU+GAH])6.[HPTQEOO5*
MTGLI,=%<M+"T/:T]_!4Z6ZKEZ8ASOAIY NEX.?'=%8LQ!!-G:&6OO+([?_G[
M%_RN#^$:HV_I?A++5'^[^,.E=<88HKK$OC;0R1.YO/54>)XKW+KV<D[U?GLY
M\=WH'"G_ ,E[>_>G?<1+D7];KU]"<'2BWXZ-..ZI;P/N9F01D![S0$JO:V$Z
MH\TX9#-8.YPEQ'#<.;(9&ES2VOS@+&E_,W[M7DAKV7K^C+RH_P D:_ K&ONI
MW[.$\*>8_(5TZ]G/GNZ)T8P\.9W9[%(2VL,AYJ5U#''@J/*MBDRZ7#IYMD0P
M74.P_1N\<Q8\W.(90T.(I4>&T_.MG%MYJM/,U^6V&KE;\=5:L]!;)8HK$%(Z
M3T6M676X<A#)P-D]P/GFB5/D2N\>,M2WG"+;=.6@!J&74K0:=SRMFB>C#?5C
M<;_.5G^_P_PC5MV3T:=?>'H&]_*KC[=_W97*GU.IX+=;I[*WBR&,PU[E?$-J
M 61_2))]/ 'O5>;X7:Z_-&6/Y7-=RO\ I-)!IY%-9S+1>N&D]1],9;_OBNZU
M2_9S&G:K?@JYQ;#KW3[;=SD=CY;(0R -9SAS2.ZJYU[Q%L.IKT9KER'O':WB
MK])S#G[.Z*R:Q! J)1O\/N1!]8#^S1;/Z4W]+T#TM:7='MT_NFW)^"W7G]GZ
ML/0\7]"?O< ?^,>3]DX_'1=O3V<./5/WNK^[R*[W>?\ X9WSKF\_TNG[/ZOS
M>KV_17#EZ6$ZA(@(" @(" @(" @(" @(""C.PO9(TGU7-+?A"QMVEE7NXUM@
M?H[)YK$2CDG9.Z<,/'E+1J%R+1,._JM$PVVH;3NI\JUY96B>Z61G,TBNO$+*
MT]DYS"ZAO8_##)G\CFZ<U#\RW5M$1U5;4MGHI7=P)J10:L[2- M=YB>S92LQ
MW2!O+0#L6N&Y%$)72-:X-)]8TI\J ]H>PL/ \P=]J:HF)<UDA-I>WEB13PWE
MT;?(XAWSHW1,)^T^A&>8$,@*@R(D1 I!#)HAE#2M?0B<KW V_M.?C=Q9;M+R
M>XD<OSHU6;]J->*-6 ZGN*)2G0&NOTJ? L)RAK]OR7/4O&6\HJR&T=*WM <'
MOU\^BWZ.D]53DS\KK#2!2GTNU=BD='&M/55;HIR0B@(" @(" @(" @(" @("
M @(" @@>"E#4NH>.W;E=L7=CLC)PXC/R4$-]< F-C>WZ+)#_ (*A,/.5ATEZ
MIV6X+6US69V]N'=3X'WMM<9F2ZO7,$3V,=)"VXL961D&0 !A'%!Z?V_%D8,1
MCXLH^%V2CM8([UUMI";AL8$O(WE8 WG!IZH\P0<Z]X"UO_\ A=N&9U\#;D6Y
M;!X3:_E<6G.-118WC,-VF/GAJVWKFY&!Q-)GT]C@I0GLC;Y5P]VKJ];QM<8;
MSMF>=]O+S2O/KCB3W#RJYIUQ$*O(I$2S5S,\6\M'NJ&'6I6V:1A7K6,M!EN;
MKQ'_ ,8>/6--3]5<^^J)EV=>J)AG=LW,SII@^5[O5!XGMKY5OUZH4.1KB&R&
M20\)' U/:?JJS%,=U&*PY]+=77B/K.^E21J?JKG7U1,NQ35EG]K7-PZ2XYY7
MN%!VGO5VFNN.BMR:1AL<D\I:?6=\)6SR0I16&AWMW<^VW(\9]!(ZFI["?*JM
M]=74UZXF&3VY<3ONI"Z5Y'(="3VD>51KU0U<BD1#:?%?0>L[@>T]WG5CZ<*'
MEC+0[VZN/:I@)G@<QH*GN\ZJWU0ZNG7&%W@;FX.1:'S/(%.)/E6>O7##?KC#
M<3)*=0YU//\ VU;\D.;Y8:+D+FY;>S 3/ J=*GZJJWU5EV->N/*N<%=7+LB
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M@5R.0[?XS)Q\S5T9G"KP[2@>P?(GE="[1-Y86XR38[F*KV6S9#)&'.K4EM*
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MFWCW[RWMA:&LY36O#L4VB9F%3T]%>JS0(" @(" @(" @(" @(" @(" @("#
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M,<Y9=H(]30-'UH\B,4>.B @4^-$P@> 6,,Y6&5R]GB+8S7D@:[4PL/TG$4H
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M[AH8R)KFN\-M-=6]]55Y/)B_2%SB\2=?678V-HVBYF<NJG4@@(" @(" @("
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MR?&&+;KCK#1MG%9=<L+""QMH;2W:&PP,#&]AT\R[>' RNPVBE"9 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$!!(\GLX]B#C77]^YO^&VXFR16PQ7\7H\<WC<HN
MHJ?7TXT^M1NT>N&L[>#C@,5S?Z'!_!M7+W=WL>+V;UM>G@2?;CY MVOTJO)[
MLU=?DTWVCOD**M>\.?R:2'[9:)=W5V9O:_X^<_N&_*5NHY_)[MJ'T1Z?F6VZ
M@YS+]-WI5.7>U=FP[5^G<^9JW:N[G<ELC_HE;94V@7_Y?<_OLGRE5[.II[,I
MMG6YD_>Q]TU9T:N5W;6>'PK:Y_BT"]_*Y?MS\BK6=C3Z5[@OYQ;Z%GK8;O2W
M3ZT+=/=R?%H61_+9O.57L[>OM"XP/\Y-^U"RIW8\GT-U^M6Z'&\6E[A_G*3S
M-5>_=UN+V4\+_.</V[OD*BO=/*[-V[/1\RM^#DM*SO\ .EQYF?<-5:_=U>+V
M4,=^6P_;CY HJW<CTM]^L'I^1;W$GNT_<G\Y-_>V?=%:+]W2X_99XW\NA^V^
MHE>[=L[-\9P5JSCRU?=/XZ#S._Q5HLZ'%8:S_*H?MFK"O=9W=G01P]"L0XTM
M6W/^4P?:N^Z6JZ]Q>[!L_&#T?=!:H=+9Z70+3\FB_>V_(K,.!;NU_<WTX5A=
MT.-V:XSZW^SM6J%G:Z)!^+9YA\BLPXTL+NK\DB^V/R+7M\%KC=VKCZ1\X6AU
M;^ET&T_)8?,%:UN#L]4L/NC\FA^W^8J-G98X_=JWUP]/R%5/%U;>E<=0/]B;
M7^68K_KT"N1V</9ZI8;>']=/2C[?(?\ V^X6ZCF;WHIJW.<F0$! 0$! 0$!
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MZ!6X[.'L]4L/O#^NGI1]OD/_ +?<+?1S-[T4U;G.3(" @(" @(" @(" @("
M@(" @(" @((4 ""FZ&)QU:$%-UI!2O(/C1,RQF<M(Y,3=PTY2^,M%-=5C?LR
MT=+.%XO(,LKF;&7=6NM'OMVN^R,;BWXZ*A:7O*S6VN,-C:X2 ..C#]$DU^+1
M898X3$BO*75/>!_;3)F5*Z=2UN 3PC/D1HWQFN6UX\M]AM^7M8WY L7#B,67
M'&JQEM\8<NL_Q \Y^4K%Z3B]EPBS;NISG\%)]J?F6%IZPW:^\-0V(2-Q7A+O
MK64'PK925;W.N<?BZ:2"0VIJ=5M4M=,423N(MY">P'Y$:]E.C9,.1^CK<?\
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MC;_*Q./W8^Y_^WG[K?W/6/\ E!YUVO!\TCQ50H! 0$! 0$! 0$! 0$! 0$!
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M<W?.8>I(FTY?[.Q;G.5D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0#7L02EO\
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M899-%E"$" -40AR@ZT%?(L?*RRA3LIZIXCRJ1,UO:>*E"(\B!12A%8I%(("
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M+@%E%53;?,/5T?TAYEL5592@0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M08W*CEL,@\?2-O)3SAA2>L,]?2\2\P;QP=_M?.?I&!O):WW+)"0?5YN4%W-V
M#TKF;J]7ON!SZVK%9+/=T8:T7L9J?5YXP"%3S,2[?_;XV_/'AU9./<V)?0.F
M(-.'*X_(%G.QJV<;8M[G=N.C!$#72R@>KZI ^.BU3MDU<6_BU+(927(/8ZY/
MJM=K&W4T/F2MIO*YLB-%,R[3T?VU/B(X[V\:UMY>1OD<WB1&"WE![B*ZKIZ*
MX?._=^5]6^(^UV.!Q%6GLI3S*_AYZ$MQK%(TBHH=#YD9Y\O5YKZH8&ZPV9&Y
M( [V:[Y8YWLU+9 *-T%3RT'%<W=67LO:O<HG%9_E\&'Q^[@(VMO6%S6GE#XZ
M'2FAKVJA,S$Y>L_9Q>/J0S$6Y<4_3Q2T4^N:[Y@GU5/9QMBA<[HQ;"?!YIGT
MTH"!_A44_59ZN-?Q:KELM<9&1KW'DBBK2-IXD:BOPK&<WG+I?+IKU[NF])=J
MW-G)%G;QG*;R2-L+#]*C75U'9Q[5T]-</GWN_*\\XC['=XP>7OU.JZ$O+4[I
MG#U2#VT"AE/=Y\ZN[>O1?C<MFTED$[XKMS#1P;J6FG$C14=L/6>T<GR])_CL
MT[&;J>R-AN6F2$Z->VE21Y#0ZKG3::O:_3KLCY>[/1;FQ$I!=(Z-Q%2.4FA]
M 4?54MG&V*=QN?%PM)8XRR=C6@_/1/JLM7%OXM7RV=FR(<?Q5H-34:@ :F@U
M*QS-I=*(IJKU[MPZ7;>N7WEKN69M+<W,$5F'5YW?A6 OIV--2-==%>TT>&]W
MY?GS$?QT>E(F\*]BZ<=(>/\ %61(@(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(""7L6%B'G;WE/IX3SR_<KL\'O+A^X]H>?Q]$KN^#S<]V4VU_M'
MB?Y7!_"-6N?T9^Z5G7^M'WPZ][Q?Y5M_^3#_ !ERO;N]G8]S[0X8NO'=P]7J
MEEMK?[28?^66_P#"M5??V3I_7_&'NVU_$P_:#Y%Y6W=[JO9<I *00$! 0$%.
M3ZGRJ81+Q9U:_K&W!^_M_@F+T7!]$/+^X^MI1[/.KL]W+AUOW>/]N'_R=_R%
M4/<?TOQ=7VS]5K'5C_;[.?R@K=POT?Q5^?\ K_@TM68]*C;U.S>[A_MAD?\
MNV3^'@7,]Q=CVOO^'\X>I1Q*X$/3(K($! 0$! 08#>(KMS)>6W?\@6WC^N%;
MD>B7A*M=?2O54],/'[NUCL]'S+.>S37].?N>BND']5.=^TE^Y<N%RO7#T7"_
M1G\'G:3Z;O.?E78KZ8^YP>7ZAN@KZ5O_ *6%_0]3>[FPC9]Z3]==D_X#5YCE
M^MZGVW].?O\ Y.R-% %2=5% 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M.!%R?C8%YCE^IZKV[]/\78F\ J3J(H" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("!
M1! MJ@AR?4]" 6U^"B"--$$"U #33SH%#Q0.75 (/U% <OPE2'*>WB."@"WA
MY/G4AR]W% +:A #3VT\B@ VG#BI$.0=G?5!!U 0.']I!BLEN#!8>1@R^5LL?
M(^O*V[N(H"1Y ]S:H86UKNW:UXQSK7-V%S&T@.,-W!(*N^C]%QXH,VV9K@'
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M_%!<NNL;( V2>&O'D<YM1YPXU""87>+80UES RGUK9&5^"J"W=,+IWA6X$C
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!3D#B13NX\:(-
MZL;=P^4VCE;Z_P ?'<WMI XV\L@-65<VI%"$','V^-VCT/V;FL586XO\E;X/
MVF<M+S+X\$;W/)!XDBJ)8G*;[ZNNV_N;>5AE\?;X_ Y1MA961@D#)62WHM?P
ME7\6\W8YJ(92ZZF]0]B9#(VNYKFUROB[=.>LQ'%(T17,KPQD('.#R@\0?6_=
M*$LGTPWUU(R6Y\7;9NUOKO Y:R?<3WD^,N[6*UGH^1K1+(QK"UP#0WC6O%2A
MWUCB6\Q^HI0J*$B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(($ @U00 I3R<#VH)'PL?H]@>.WF *"F+*UK^(CI]H/
MJ((BSM&\(&>AH^H@JB-H%  !W#1!,  @B@(""D^%DGTVAWD< 1\B)2-LK05K
M S7O:T_,B#V.U!YA;Q@CM#&@_(@JAO+HT:=W!!.@(""! /%!)X8H!2H' '@$
M%-UI;$\Q@C)/;R"OR(!LK0FOL\=>_D;7X:()VPL8*,8&^8 ?(H2J4%*44H
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MM;:F0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!
MC\UBK?,XVYQ=W7V6Z88Y0TT/*2.U!K5YT]P%YM/%;,D,S</AVVL5F&N;XG)8
MM#(JN+2"*-%=$2MG=+-L'!9;;K'7#,?F;IM]>.;(SQ/&9.+CU26$4+V_8HA-
ME.EVU\QD6Y._CFFE_0[MOOC+QRFQ>7<U:-!Y_6/K BBA*79_3#$;0O()[7)7
M]XRTB=!8VEW+$^&")Q<?4$<3''Z1^DXJ4-Z9&6\345J@J(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" HD2\OE6,1,)2F)AI7B%LS+'$(".AT- L<2RS&$W+70FJ2A ,%>&O
M>D9B,&(3<I["G5, '>B$RD$! 0$! 0#J%$BBZ(EX-=%E#+(V  \W:DS+7%>J
M9C* BJPPV3)X8(U[%-8PQMU0;"!6AXI;,HB,(^& *);JF.B8MTT4QT)3*, I
M! 0$!1(D>SFIY%->B)C)RD!88ZLH"P/&NBSRC$(", !1U1B$P;3R!$I3&":E
M(S!,1*3PC6O8LLIZ)PP\P=S#3N6+%.%*44! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 00(!XA!#D;W<4#D;W((T"!RCC35!&@0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$"@0 *(" @(" @(" @40$! H$! H@A0((
MH" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @A4!!$$'@@(" @(" @("
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M.* UQ/'T()D! 00<>4502E_F0.?R<.)0!(3V:]R!S]^B"(=4T[#P/8@F0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MC0:%QJ> X?&@F#P1]+YT$[34:&JE"=0D0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M:>!03(($@<4$:A 0$$"YHXFB ' \$$4! 0$! 0$! 0*A 0$! 0$! 0$!! N
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MZ 48UL@U0:UTJQ=O@?>ZR>W[!H98XVTALX&C3U8L.W7SDZE![;:*!!% 0$!
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MEP'W/,_CMK]',_F\Q.(L=97TLMQ)'&YQ#6LYJEL37&OH1#D,74SIWF_>4O\
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MM^D703K/M]F^-O0PX>^R,1N;FZL+IS9+9[&&-WB1^)R1TI]@.]$-3]V#+YG
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M3#<1]/MS&W;^'=C;JE-:_@CS'3R50APKW'FVHZ;Y!\7+[9)D)!=%OTN9KY
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MV\,(R[.7R[PZ5MQ)&Z&'1X+86LB86@\YKS.<@Z/=V-G?6[K2]C;<6LOJRQ/
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M(ODC(-O>P.\*YB+=?5?1W=VA!R=GN:;)?<$9#<.X+[&-/X*REO(F@ &O*ZD
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M8B.;[;10EU_K[@LKN;I!N?!X*TDO<K>10,M;2-I=(\MNH7F@&N@:3YE*&/\
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M"I!_=!$+E 0$! 0$! 0$! 0$!!*YI/ T[T -(%.SRJ!&G;Q4AP&GP(&IX\4
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M%\1YAYT$/!(X>;3R('A.![#6NG=750E'PS7L(\JE"=C>4'R]G8@F0$! 0$!
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MNH+K;DC9;2.W+ Q[HY1,T/#@2=1V(,UU%Z:[;ZE[8.V-S1O=;,UAN8J-EA<
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MTL=&\: <G+S ]AH>*(< =[FFT8YY&XO<V8L<<\DMLHWL< UW$--&T^!$NO\
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M1$O7+/HAW&O:>%$0KH" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MS72CVCE->]!E]M;<QNUL1:8+#1"#&VC.2)@ U[*FE!73N0EFVCE%$$R @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @@XT0<\ZQV^QKG8N2=U" =M6#DEO
M&DCF<YKO4:VHU))0<+VGUURMMAH,1T<Z9Y/+;+L6^!97(CI5K/5) 9S BH4)
M:G[KMY?W/O%;YN<ABS@[V^L)9;K%N%'1%TUL\U%!J7"OI4DKJTQMCDO?IR[,
ME;LN1'X$D/.*T<S!,<T@=X("(=6][VSM[OH?F1<-J89K>1CB/HO9('#X:(.>
MY7+7V/\ <ELI[-Y9/+:OMW!I_P G)=RL<W^Z!1+K7NR;?QNWNCFW7XZ)L=QD
M(W7=X\"GB3%W)6OD:QH4#B_4BSM+3WP]F26L+(G3&S=*]HIS2"<5KYJJ4/:+
M75:.(\_%!Y ]^<@V>T#_ /%C[I$O5.*TP5E7_1(JG_V0H$0\O^Z^[DZL]7!2
M@&9R!J1P_CI%/C0:UT Q]E>^\[ONXN8&RS6L5Y);%XJ8Y#<L87-[JM<X>E0E
MO7ONVT1Z66MV6_AH+^$P/I6A>X U/=ZQ4H2=;GOE]TNR>\U>ZTQ=3WT+ B72
M_=O:!T1V<:5K;S</)=3(AP[W(N;VW?8+CS"[8\^<4^HB5MUS']+O>EV5L?+C
MQ]NV[;*=MJ[4.=<RTEJ#WA@0>PI;:WN;.6PF96U>PL>TC0L/'1$/'ONN&3;7
M5OJ7LFP);M^WE?[+:EU0T6TL[6Z4IS4=J@R?NRX;'WO6SJWD[J%C[VSOIHK>
M5P!<R.>Z<]P!\\;4&S>^V".D5CS'FYLY:APYJ ?Q>Y!-*(.K]'+"VL>D^SH+
M&%MO#)A,=*X1M #WRVL;GO/E<34HEYHZ)[>PT/O:[W8RV ;CX;BYMAQY9)A#
MSNI3365R(=*]\ZTM+GHW?WDL+99K6:V]GE=J6>)=V['T\[20@LNHDLLONBA\
ME9'C$0 "M"0P$-'P !!N/NUMIT)P4;#S<L5X!3LK-(?G1+DON.BL&\''F:?:
M:5;QISG@@I>])93=/.J.RNKN/'A0RRFWRLC10CV22&1@)[><.?\  B%7WBLF
MSJIU2V+TMQ,GC6T<QOLARFK6QSM@,;J#N',B7KVR@BM+=EK;M#(86AK&C2@'
M (A=BO:@B@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @I25YJ5[:T[
MT'BWI_RY[WU]S9"^]:XL89#; Z@%EA';@?WI1+V<6\U:4!IQ^.B(:@_IIL^7
M=T.^W8YC=R0@^'>MIS D%I[*\#1!H7O1[]_H3TLRL5F^F7SD$F-LV?7GV@""
M0M\H$@0<JS_0\VGNLPV%K"YV?M2=P/<&^N;A\;6N\NK8HT2[+[M^^';WZ5XB
M]N9O&RF/!L+\$ZB6+45_N7!!PGWA,_C=K>\GLW/Y9YBQUE;QSSN:T/KRO!T!
M(1#J>1][WI!8V,UU:WMS<7(8YT,'@AI>]W 5YT'/?=@P6?R&_-Z]<=QVGZ*Q
M.;ANC:&<'F:W)7D=X[EKQ:/# /H0>A6=9^EKWLB&Z;-TSCR!H+B2>%-6H/,O
MOGW$5YNGI_<0N;/:S/A,1['M?,?F-5"5[TQDFZ.>\KE]B2R>%MC=4+KO&AWJ
MM-Q/;LN0>[Z4;H@I0Z![W&^+C ;!@VOB9!^G-TRMLH8VZ$QN>&R?"'$(. 6V
MTH]B]=NCFUHF!D[++%7EY^_W&1N7'X!0(/H6Y@%*<.!]*#RM[]=S,SIOB[*,
M@V]U>U>WLYHPT ^CF0>A]C8ZTQFU<5C;$&.SMH>6)O#U2XGAYT$V\-G;<WOB
M&83<EBR^QK9FS> X"@<P. <*^0H.4=?=[Q=%.E5M8[3;[+?7,D>*Q#&T!B:Z
M*1]?1X=/2H2Y=M'W8=B;HVO9[DWYN2:;>N8M([RXG]LC!MKBX8)"VCG$^H3R
MG4<%(S'NT[BS6V^HNZ.BF5RKLIC\*V:?"W<CN<NACE:UG*:NIS1NYJ \$0P?
M0L ^]IOT'4>!<?\ YA$KN7_^?6+^1G_[&$0]CH" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(%$$O(WXJ()@*(" @(" @(" @(($ BAX((>
M&WMJ?.@F0$! 0$$I8#6O:@!H""- @B@(" @(" @(" @(" @()2QKC4BJ"(:
M:CS((H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MOX(-(VKF1[R77S#9:05VSM/'V\LK)AS W(A$A(::C\>^E?2B&1ZP#E]\GIT
M.4"VQ>G=3(7*#V=4T%-:&I0>=O?+VG>[DZ2R7EA&)Y\1<-N98B2"ZW(/B<M
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M$0F8YSCQ! TJ.TH*B @("!1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M([:ZE8O;\V1ZF9HWVX,DX2.LV1VS8[>E1H86-%3W \J#K3&EIUIKV!!.@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M#J#6FAHB44! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M(<KM#=0M[O:C)63X6_BF89@YP+96E@+CRZ,+:BO'4]DH>@&4YB/KNY!40$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 02.C
M81R\NG! #!4:<."E 8V]@IVJ$H>$VM7<:4]" Z.O#0#@@@65H1Q';Y>""5L0
M)X:5KZ40BZ)I]4MJWC3RH(.#OL=$2G$?]M$'A4.GH1*9K0W@*()D! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0.U! U
M0-4$0@AI52@/]G<@AYD$RA*![$$4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
:! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>tm2227887d1-bc_icar4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-bc_icar4c.jpg
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M%!04%!04%!04%!04%!04%!04_\  $0@",09+ P$1  (1 0,1 ?_$ ,\  0
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MAC#21S@N(%0T8G,5/JUL@$&_]K^]?;GO'!?7/;[*/R<.->V.\=):W%KL<\5
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M_7.G_EKU]>'BL_3/]HZOQ:?2?[,'?]S.XD!$<.?RSP#JX7]R#^Z+?3U>*_\
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MR9W89>>](0$! 0$! 0$!!:WG5GSKB]GO'1Q?*V7(W$! 0$! 0$! 0$! 0$!
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MENTT4%1H(" @\O\ QB<5SL5CQ/N]Q>(RY3@E\+BZ#&EQ;;NDCFCE<!J612Q
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M3;9+%7/F!EZUD[@>I &BZ-N&SNTNB>.\<T14-34T?XE8;<;':89QL[9&!CG
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MT#C_ ,0SZR^F]?\ ;U^SY;V?W=ONRBZ'.(" @(" @(" @(" @(" @(" @("
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MSCWQ6W'LXQR?A%ZZ=Y9;&=E:M>QI=IIZ%[G%[$P[)<L7C>$YR_N&V\>/F#=
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M.[#+SWI" @(" @(" @(+6\ZL^=<7L]XZ.+Y6RY&X@(" @(" @(" @(" @("
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M63\&_P"Y/UE7;LF=V&7GO2$! 0$! 0$! 06MYU9\ZXO9[QT<7RMER-Q 0$!
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M7VMHZYMY*=CP+&6=;F)SI+L&C&2T#:_)13?9NW1.UPN+P7-O'M#]ER/9.W0
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M?D(XKRQRLC(H&8XPS.DE:7W=D-XE;"T#S#HX^SX@.$?[0_[PS^R?BG_>H/\
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MXOE;+D;B @(" @(" @(" @(" @("#3LG^7W'W95XVG9:*4B @(" @(" @("
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MR/8]PE'7T.\"JRKYPP5U;W3[N+0>6'5W,(KX=5T3&%L6KNXP[+RX\^1H; P
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MWN>K?G66[3105&@@(" @(" @(" @()9/P;_N3]95V[)G=AEY[TA 0$! 0$!
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MW5::85)+J0MD,KP ![-#HL,X<^UP13/ELFN<\$DD%OJ5NY;E1N&%FTV]'/\
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M$! 0$! 0$! 0$&G=VOZJN<_T?RW\"E0>0O[MK]"\V_?<'[F$'NY 0$! 0$!
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M6BE(@(" @(" @(" @("#LO'/T#C_ ,0SZR^F]?\ ;U^SY;V?W=ONRBZ'.("
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MYZM^=9;M-%!4:" @(" @(" @(" @ED_!O^Y/UE7;LF=V&7GO2$! 0$! 0$!
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M#V^[487MY@YYG#(/;8QF1P,[[*T >\$L:VM7.B::#4&BMZG_ /3DN]5]O_\
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M52M%I5-JA6JJIE$**F7(:TT4+(4--5,2B#0?*I 5" 25"$6ZUJJU*!T HK1
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M9_=V^[*+H<X@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#
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MAL.,DF,_ELK0==5YN\Q7F6]6;(#C6NI6=K;"RR#F ;7.IH?4M](A@7DDG?\
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M^XGQ7)X;1SKB5N"OI86-$[8R0&LBFO9V5^C3>= $'L% 0$! 0$! 0$! 0$!
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MK8O;*8VF9HT>6C=KZU,W8W7"+W.<:GH>@^14O5,2CJLKKA:HDT*M$(%C2/9
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M3DW'(;W+<E+'Q6F6S<T5S-:12MVR-MVPPP1L+Q[)DV&3:7-#MKG AW- 0$!
M0$! 0$! 0$! 0$&G=VOZJN<_T?RW\"E0>0O[MK]"\V_?<'[F$'NY 0$! 0$!
M 0$%O<]6_.LMVFB@J-! 0$! 0$! 0:OW Y[@>W'&KKDV?E(MX!M@MF4,UQ,?
MHQQ@TU)\>@ZE(/(G;WAV?^)KN)><[YO%+%PVSD#9&1N+(GB,[H[&)^CCH:RN
M;0@'JTN:KWHJ]NVEI:V%K!8V,$=M96T;(;:VA8V.***-H:QC&- #6M    H
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MV?+>S^[M]V470YQ 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M^7C/+NRBS:" @(.R\<_0./\ Q#/K+Z;U_P!O7[/EO9_=V^[*+H<X@(" @("
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MB@1$11*(\5%M3$"!Z%,3$%-D6E;_ &?Y);_BV?XH6L>?MWJNI5$!!HW-^[W
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M@()9/P;_ +D_65=NR9W89>>](0$! 0$! 0$!!:WG5GSKB]GO'1Q?*V7(W$!
M0$! 0$! 0$! 0$! 0$&G9/\ +[C[LJ\;3LM%*1 0$!!PCO+$./=SN ]Q,I"7
M\7L)'6.1N=I>RV>]SO+D?2M!63<#3[3TT7J>K?+BVTG=Y?M3QY==[V=RM[FW
MO(([JTF9/;2M#XIHG!\;VGH6N:2"/D7F667%>G++,Q54)$! 0$!!V7CGZ!Q_
MXAGUE]-Z_P"WK]GRWL_N[?=E%T.<0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M?K*NW9,[L,O/>D(" @(" @(" @M;SJSYUQ>SWCHXOE;+D;B @(" @(" @("
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MY7JHN(" @[+QS] X_P#$,^LOIO7_ &]?L^6]G]W;[LHNASB @(" @(" @("
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M-=QP^9&P:"OH3RJMV64(F@MK2=]HX.FH7;C4U^=4G)E$ZL\,5#<Q%KRZ O\
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M<]PJ(H_#H/MWF_95[#X5P[#\#XU8\8P<>RRLF!I>0 ^60ZOD?3JYQU*HLV!
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MH/V%AR3,[./9M5BYN9P=M=.T<]H!^5<<OB+6XPTKW!UKM:ZFTDA6_(RP&PR
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MG=AEY[TA 0$! 0$! 0$%K>=6?.N+V>\='%\K9<C<0$! 0$! 0$! 0$! 0$!
M0:=D_P ON/NRKQM.RT4I$! 0$'/>Y7(NW9FQ_;[G3'3_ ,Y?8M(61/EVR;VQ
MQFL0+V/+W48YHZ@UH%V<&G)UWT^''[&_'TTW^7,[KX3;>"YD?QSF5YC+63Z4
M,EN)WFG2KXIK<&E3]JNJ?]POSK_RY;_V^?&W_#8^#_#3Q+B^3BSF;O)N1Y:%
MXFB-RP0VPF!W>88@YY<ZNOMO(]2RY?>VVF),->+T==;FW+M:\YZ(@(" @[+Q
MS] X_P#$,^LOIO7_ &]?L^6]G]W;[LHNASB @(" @(" @(" @(" @(" @("
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MB/.\AV^R5MD([Z7,XH3&>6".&:)UL[R+JT=L<Z5LAJ\BK![/B X1^J#WO_\
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M;E,G*^TO<JXN8N,7M\YSKG'Y"K&QVS&N=*]K6R200; [R2)!(T-<'M0>Q4!
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M&?67TWK_ +>OV?+>S^[M]V470YQ 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MW9,[L,O/>D(" @(" @(" @M;SJSYUQ>SWCHXOE;+D;B @(" @(" @(" @("
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M-Z=-%KY-<Q[QXBW;Q3!-]&/M!]2!B^0Y?U[?>OF.3]=^[,K)F(" @(" @("
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M*Z-O5X->]Q_JY]?:Y]NTS_HOO]I?Q._^"HO^X3_]NJ_@]?\ R_Y6_/['^/\
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MMKZ=*5*TFTE;ZV]6 RWG&[8^!H,8^G7I1=5[=&?6WNPV6OL/CHS)*3"7 NV
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MMEPZ8.W1]/3JO0UN%=V!>V2<NVDNC&KFGI1=FMF'3Q_U8+D'(K2R>RWMXJR
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MYS_1_+?P*5!Y"_NVOT+S;]]P?N80>[D! 0$! 0$! 06]SU;\ZRW::*"HT$!
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MM_\ %9_958?R#GOXZGX=/H?FW^I^M_\ %9_958?R#GOXZGX=/H?FW^I^M_\
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M'[F$'NY 0$! 0$! 0$! 0$'S=^%?_P"L_EOXC-?N\2#Z1(" @(" @(" @("
M@^>?=?\ _N&<1_?.$_<$2^AB($! 0$! 0$! 0$!!\\_CW_KO[7?O:'_\11+Z
M&(@0$! 0$! 0$! 0$'D#^\2_J@Q7_P![1_XA0=/^#W_Z;N!_O:[_ (?<H.X(
M" @(" @(" @("#F?Q$_U#]R/Z.Y/^#/0<,_NXOZD,_\ TKO/_P .QR#U^@("
M @(" @(" @("#P!_=E__ ,T?_P" ?_F2#W^@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @("#4N:]K^W?<9D+.<\9QV>=; MMI[VW9)/$TD.+8YJ"1C21[0:X ^*#(
M<3X7Q'@F+_,G#,)98'%%_G/M<=!';L?*6M89)-@!>\M8T%[ZN( J4$<CPOAV
M8SEER;+<>QE_R3&!K<;F+JRMY[ZV$;B]HAG>PR1[7.<X;7"A)*#.(,-:<2XI
MC\]><JL,%C[7E&18(<AFX+2"*_N(ALHR6X:P2/;][9HYQ^B/0$&90$&J=S[2
M[R';7F5A80275]=8/)P6UM QTDLLLEG*UC&,:"7.<2  !4E!Y:_N_P#A'-.&
M8CE\7,..93C\ES=0NMF9:RN+%TK1& 2P3L9N ]2#V@@(" @(" @(" @("#P#
M\-G;SG^"^+7D_),YQ3,8SCMQ#EA!E[W'W5O92&6:,L#)Y(VL.X [:.U0>_D!
M 0$! 0$! 0$! 0>%.YG >=7_ ,=?%^76/&,M=<3M[C$.GST%A<R8Z,10T>7W
M+8S$ TZ.J[1$O=:($! 0$! 0$! 0$!!X4^-C@/.N5]X>W.3XOQC+9O&V-O$V
M]O,987-Y! 1?[R))(8WM80WVO:/35$O=:($! 0$! 0$! 0$!!Y8^/#B?*N7]
MK,9CN)8/(9[(1Y-DK[3%6DU[,V,-/M%D#'N ]=$'1?A5PN8X[V X5AN08ZYQ
M68M;>Y;=8^_ADM;F(NO;AX#XI6M<TEI!%1T*#L2 @(" @(" @(" @Y[WXQN1
MS'9;G^*Q-I-?Y2\P.1@L[*UC?//--);O:UD<; 7.<XF@:T5*#C7P#<3Y5P[L
M]F\9R[!Y# 9*7DMU<Q6>5M)K&=\#K"P8V1L<[&.+"YCFAP%*@CP0>IT! 0$!
M 0$! 0$! 0>(/[O'@G..%?[1_P">7&LKQWW[\R>Y?G>QN;#S_)_.'F>5[Q&S
M?LWLW;>FX5ZH/;Z @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MBS>(L<Q##-;0Y"WBNHX+IGE3L9,P/#9&5.UP!U%=%*%\@(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""C=W,-E:SWER[9;V\
M;YI7^AD;2YQ^8!!Y7^'[C4'>3E7(^^'/+<9&1M^ZRX[C[H>;;VK8FB31CJM<
M(F21LCTH';G?3U%)UZKWIT>J9[:VNH'VMU"R>UE;LD@D:'QN:? M<""%=1C.
M.<5X[Q&SFQW&<=#B[">XDO)+6V;LB\^:F]S6]&UVCV6T \ @X+\)/_\ ,C^D
M$G^6J:K;+' 9G#X/XQ>X-WF\A;8VU?@K:)D]Y-';QF0P8EP:'2.:"XAI-/4G
MR?#T1C.6\5S5S[EAL[C\C>;2_P!WM+N">78WJ[;&]QH*]5=5Y_\ B=M+:_[E
M=C[&\C;-:7.<EAN(7ZM?')>8QKFGU$&BIM\+1/\ #/=W/">5<Y[&Y:5SI,%>
M/R.$=(?:DLY2UKG = "UT$H \7N37Z%^K=/B5YK/Q/MG=X[%EQY%RB1N#Q44
M6LI-UI,YH&M1'N:".CG-4[5$<5[?<+M^WOQ-<2XC &F3'\>I=R-U$EW+9323
MOKZ#(YU/50*LG5:]F<[Y9"WX1\1G!>?\RM'W/!8[+W=DWE^?'#<L]X!<&?MH
MG313="2/HU<-)O<G9Z.LKSA7<+%VV1LI,?R/%131W-M,WRKN.*XB(>QPKNV2
M,-#X."LHS5[>6V.LKG(7L@AL[2)\]Q,[Z+(HFE[G'U "JD>&_P"8EWW8[7=S
M.]-Y;O.?O<J<G@:C[Y'88O=YK&D5]GRI',H#]*%OH6>,S*^</679WF@[@=MN
M/<G>_?>W%LV'(&NOOEL3#,2/#<]A</40KRJUO*E#C?/^\/);#G4/:_MGQV/D
M/,A:B_R$EY-[O9VD!H1OU:7&CFD^T*;F@;B:"MJ9&4XAR_N[>1Y['\RX1#89
MS'V;KO#SV=VU^/R$U'!D >XN\MQ< "7OZ&I '6>IT><..<F[S0_$;R[,8_A-
MK<]P+C$Q197CKK^W9#;6HCQX;*V<S!CB0R$[0\GVSZ#2G7*W3#TOF>?<UXWV
M_P 7GLEPFYO^<Y"9MD[C&+E;<MBN'^:X.DGB\UK8@R/<Y_M4+@#Z5?*N'.\_
MW@^(#A%@_E/,>W%@SB=NYIO6V5^V2[@CD<&@N<R24:5H2(Z>FBC-3B.PMYMC
M\EVYE[@X>/WG'R8F7+VUO-[!<UD#I?*DINH:C8ZE:'TJ<H8/M#W!GY[VQMN:
MS8V#'2O]\K8VQ/DCW661HH2*C=MJ4E+'+.+?$QS;N#AH+/@/!QF.;ETC\C%Y
MQBQ=C;A](G2S2^6'/D =1F]O30DZ*ODG#;>U??#-\EYED.V?<;CPXUSJRC-Q
M##$_S+>>-H#G-;4OHX-<'M+7N:YM344UF4L9CG7<Z?C'=7@_!8\5;W<7)/,\
MS(2N(FMZ.+?O8 IX:ZI;U1A1[R]ZH^T69X?;WMG'-A<_-=C*7CB\R6T%GY%7
M1L8#O<1,=/5ZTMP29:+GN_'>S$XP\Z/; 6W;IA;(YUY<[<E[NXT$DC&NW1!U
M0=8'!OB2-5&:G$=PXSSG <HX5:<^LYC#Q^YM'WTDL_LF&.'=YPDI4 QECFNI
M7HK91AQS&=ZN\O/[:YY'VOX#:W/#8)9(K6YRMVV*[O/)< [RF"2,-/A]LVNF
MXD$*,U.(R79'O-W"[J96Z.2XI:8[C5BZ:UOLA%=M-Q!>QAKFQ/MY'>;K7KLI
MZ]$ER68=V5E1!YJ^+J2.&/MU+*]L<4>?8][WD-:UK0PDDG0 !4V6U=Q'<+@+
MB&MY5ARXF@ R%J22?_6*V48:9\1W"_Y[]I,[:0QB3)8M@R^/TJ1+9 N>&^MT
M1D8/64LZ$[KKX?\ F@YSVHX_E))/,R%G",9D2=7>\V0$1<ZGB]H9)_RDEZ%<
MTY8S_:?\4W'^,C[[@>WEH,K?M!W,]]<63#U:O=:M(_XKE7O4_#&]U;=W=GXD
M>.=JLE(3Q# 6XR.4LVN+1-*8C<OW;2#[;#%%Z6ASB#JEZU,Z1ZBL["QQUE%C
MK"VBM<? P106L+&QPLC H&M8T  >H!74>4N<8FR[.?$OPOD/%XF8[#<S>VQR
MEA"&QV^^XF;;S$,% UE9(9J?MVD^I4O2KSK%S\0]W%Q+OKV[Y_RFS?=\"M+<
M6TIV>=''=LEG<Y^S]LT20RCQ=LTKM2]R=GHC'Y'@W<G#17EC-C^287>R:,TC
MNHXYF'<PN:X$LD:?!P#FE6[JL#WI[:6W=/@5_P =(:W+1#WO"W#J#R[V('8"
M3T:\$QO]3J]0$LR2X>:#WZY-F^TEMVCMH+A_=V\NSQ6X8X.$WNK:1NE<[PD(
M/D/J:@ASRJ9Z+8ZO5/:_@&.[9\)QG$K#:^2V9YE_<M%/>+R0 S2FNM"[1M>C
M0!X*\F%;7'?A;_\ TJ[O_P!(3^[W:KJFO22NJ(//^0[]<UY9R;*<:[(\0CY)
M#A)/)R6=OIQ;V7F EI;'5T0(JUVT^95U*ANW4US]%L?5N_:_N%RSE5UE\!SO
MB<W%>2X5L$DPWB:RN(KC>&O@E%0:&,@[7/'_ !NH$RHL:*_OUSKG.<R.+['\
M/BY!B<3)Y-UR+)3^[V<D@\(@715K]K]\+B-=H"C/T3CZLGP3OKF[GF[.V7=7
MC7\U.97+/,QLD4GG65V*$@,=5U-VUVPM>]KB"VH=H4I8O^\7?*'M'R/C%AD+
M%L^$S#+N7(W8+C/$RU#-HB8T4<YQ=3VC3Y.J6X1)E+VU[B]W>7<BC/*.!#C_
M  G(6\ESCK]TVZYC H8VS-+JU>#T,3$EI9&,R'>SFO*^3Y3C797BT'((,%)[
MOEN09*?W>P$X<6F.*CF%]"#[0?KU#=M"6?HG#)=ON\^:R?,Y.V/<OCPXQSL0
M&ZLFPS-GL[V%H+B8G NH:-<X#<X4:[4$425%CLBLAI/=CN'8]L.$9'E-V&R7
M<;?(Q=HX_E%[*"(H]-:5&YU/M05%N$R9>3.==O;[A?%.WN8Y*73<\Y7R9F6Y
M'<RFLHEF+7QPG\6'G</V[G>%%2Q;+T1\3_(KOCG9C/R6,CHKK(F#&-D::$1W
M4@;,/^5$'M^=6V[*SNV/LOQ+'<.[8<;Q-E;LAEFL;>\R+@T!TMY=1-DE>\]2
M:G:*_:@#H%,[%<8X):Q<!^+7E/%L2UMK@.28\WK+)M&1B8QQW6YC1I[+_/#0
M- UQ"K.Z;V5>_F&R/:OG^%^('BL+G6PECL.76D6C98GTC:]WXQGWLDZ![8SU
M*7IU)UZ+2UN8?B9[T6M[ UTW:?@;&3L\QKFLO;Z6CP'-/7<YHJ#_ .;C_P".
MG>I[1ZK5U! 0$! 0$! 0$! 0$! 0$! 0$! 0$'FG,_%X+7F?).&<:[7\KY;=
M<7OIL=D;O!VIO(A+ \L)(B:\M!(TW(-O[8=]L]W$Y-_-[)=JN6\.M_=Y;G\\
M9^PEM;+=$6@1;WL:-[MWLBO@@[.@(" @(" @(" @TKNIW4XEV=XE/S+F4TL>
M-BD9!#!;,$EQ//)4MCB:YS6EQ#7'VG 4'5!P&+XV+_$209;N)V@Y/Q+@%[*R
M&RY1-'),P^;4L=)%);P!H+07TCED<0#M#D'J;$9?&9_%VF:PMW%?XF_B;<6=
MY X/BEBD%6N:X=04%Z@(" @(" @(" @P/->68[@O%,MR[+ASL=B+=US.UE-S
M@V@#172I) 0>=L3\9&7S^.M\Q@NQ_.\IB+MN^TO[+'27-M*RI&Z.6)CFN%01
M4%!W#M=S_(=Q>/R9O)<2S'#9V3.@&+Y!;OM;MP;_ .<#'M:=I\"@W= 0$! 0
M$! 0$!!R/O/\07%.RU[QO%YFVFR65Y+<BVMK*SEA$T4>YK/.D9(\.\LN=M!#
M=2"$'7$'F3F'Q@P0<KON(]H> 9?NE?8=Q9F;W#E[+*%S2 X1R1071D+3[))8
MUM?HN*#HO9GOWQ;O)'D;&RL[S <PPA#,YQ?+QB&^M233=MZN94TW4::]6A!U
M9 0$! 0$! 0$&A]W^['&^S/"KOFO)0^:VMW-BM[* M\^XGD-&QQAQ]/4] -2
M@V;B^=AY1QK#<FMHG06^:L;7(PP2$%[&7<+9FM<1I4!U#1!QON5\3+.!=PIN
MW&'X#R'FN<M["')W X[![X8X9G.9[4<8<\4( )(IJ$%MQ7XEN3\DY)BL!<]D
M^<X6WR5U%:RY;(XR:*SM6RO#3-,\Q@-8RM7&O1!Z#0$! 0$! 0$!!Y\[G?%7
MB>'\PN^VW N(9CN1W#L(H[B_Q6$B=[M;1R!KCYL[(YG@M;)&7%D+F#> YX=5
MJ"CVS^+'%<KYG9]M.XG#\MVT[@9)CI<7CLTUQMKH5(8V.>2.W?ODV2;-T+6.
M+2UKR\M:0W7O3WZXEV3M,4S,6E[FN3<AE=:\>XYB8O.O;R=NUN@) :W>^-GB
MXEWL,=J$'-.+_&*R/D6)XYWG[=9OM9)R";W?"93+"27'2/H ?.FFM[1T='/8
MUQ;&]K-X=(6-JY!Z?0$! 0$! 0$!!QSO1\17&.S^0QG%VXG(\K[@YR,S8;BF
M%B,UU+'5[6R2$5+6.=&]K=C'O)::-(!(#GW'?C+9:<CQG'>]G;K,]JFYR0PX
MC+Y8OEQKWL W&:6:WM"QH<]C7/:Q[6;P9"QE7 .M=\>\^ [$\*;S3D-G<9""
M:]AQMK96FT2R3SM?)3<\AK0&1/=4^BGB@Y?^MAR[^P#N)_)$_P#V2#T-QK+S
M<@X[B<[<8ZYQ%QD[.WO9<5?L,5W:/N(FR&"=A +9(R[8\'H0@RB @(" @("
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M_.9\6R7!\7VDQSH\WW+RN9L9<=@K/=<7UL=CVMD,<0<0^43-ABC=1TGF$M!
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ME@7963=:7%[D9L/&>L=D;I[2TCPK,V9X]3JH/22 @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#
M%\DX[A^6X*^XWG[87>(R,1@NH'$MJTD$$$4(<T@.:X:@BJ#C%I\-V7P<+,;Q
M3NGR;#\?C+O*QK9A((VN^UC<QT0;KKHS[*KXK9;WVU[/\5[9&^O,8^YR7(<H
M:Y//9.3WB]GUW%I?0 -+O:( J33<30*9,(M9[B'".-\%LKJQXY:&W9?7,E]?
M322/GGGN9C5TDDDA<YQ^=,(;$I! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MW]T+"VH\?KH.Y< [?\4[8\7L^'\,L&X_"V0JU@)=)+*ZF^65YU?(\BKG'ZU
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M=+( ^UD<\Z N-LTT 1#5_A=Y)DN4_%;S_/Y'C]QQ2[REO+-<8*\;)'<Q5D)
MG;(UAWZ:@M&J)9//QGL=\<&-S0F=!QCN3$?>6^\[(S-<UC>^XW!K0QDHW,;4
M] @N/B)%SWB^*3M[V9MWROPO']F6S,+/)C+2ZDSYHY'@DEL36@L]6@J@V?XU
M^U'<'F=AQ?E? \<[/Q<3E=<7?'(F"5[V@@A\,%"97$>R6,:30: ]$0U^]^-'
MM#SO!7_;3OEQ7.\-N,K$^QSL+X3/!;-<*%VYNRZ:[Y+4EOK0>E.R."X-QWME
M@L=VURTN:X/Y;Y\-?33-N'&*=Y>YNYK(Z;7EVYCFAS75#M:A!T% 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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E @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>tm2227887d4-lc_ipscmacs4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_ipscmacs4c.jpg
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M<R0E_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M                                                      HE_P 0
MB\?L'3>^4GM<+8'_ !"+Q^P=-[Y2>UP8'_$(O'[!TWOE)[7!@?\ $(O'[!TW
MOE)[7!@?\0B\?L'3>^4GM<&#K=L>VM=-P<^L&%S8=3T$5ZJFTKJQE<^5T:.:
MJ\R,6!NO1WP8+@!4                             \O)+_;\5QZZ9+=7
M]7;;12S5U4[@B]73L5ZHFNG%=-$3NJ!2;_B$7C]@Z;WRD]KA;!;_ &PSRAW-
MP.QYO;V)#'=:=))J9'<_45,;ECFBYM$UY)&N:BZ)JG$*NN  5&W9[9USVTW$
MON#P8A!<8K/+'$VM?7/A=)UD,<NJL2!R)ISZ=(6P6;PC(7Y=A>.97) E+)?;
M7171]*UW6-B=6T[)U8CE1.9&\^FNB:A5[P
M
M
M
M                                    \2Z9GA]DG\FO606VW5/^9K*R
M"G?_ (LCVJ!]]NNUKO$'E5HKJ>OI?\_2RLGCX\?/1JJ ?8
M!6;Y"NRGIB^>O8?:X3B?(5V4],7SU[#[7!BJCVIMH,4V;S"S6+$7U;Z*OMJ5
MLZUTK9G];U\L?BJQD>B:,3N!:$@=ESLV[>;Q;?W+)LMEN++C27B>VQ)0U$<,
M7414M+,FK71/7FYIG<=>\$3*;OD*[*>F+YZ]A]KA&+W<-[(.U&"Y1:\NLLUW
M==;1,E32MJ*J*2)7HBIXS4@:JIQ[X,4^!
M  !5;MT;@_H]MS0X-1R\MQRNI1:IJ=*6^A5LK^CBG/*L2>%J.0)A32U[5UMR
MV1OV[$;7.CM-[I+8J<>5*9\3DF?_ #L],W73OA99/L#[B*C\@VOKYO%<GNW9
MFN[Z<L-4Q%7O_<GHU/LU[X1*\(5 ,H^U1\?^;>J:?V' %X:2;,?$]M]_NU9O
M8$(4EW
M
M
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M ^\8S*Z&MI52.Z6BI5J55+([HYD:JHYCM%Y)&\%\"HJ(1,)%"
M            !Y>1Y%9L2L5?DN0U;*&S6R%U165,B\&L;W$3I5SET:UJ<7.5
M$3BH&;>]/:TSW<FNJ;;C%5/B^%(JL@HZ218JVIC3ASU,[%1WC?YJ-R,1%T7G
MTYE+Q"O3G.<Y7.55<JZJJ\555"7J6#),@Q6XQW?&KI56FYQ*BLJJ*9\$FB+K
MHJL5-47NM7@H%\.S/VM)LYN%+M]N4Z*+**C2.SWQC6PQ5TB)_D9F-T:R9=/$
M5J(U_G=$=ISE9A;D*@              &>_;^^,G&?R&GLN<+0F'L#?$]>_]
MY:KV!0!$K3A !5C=_ME?!3N+><!_0KW7]R/)?_B'NIY+UOE5)#5?Y+R.7EY>
MMY?/KKIKX G!83 <J_3G";!F'DGD'NY0P5_D76=?U/7L1_)UG(SFTUZ>5/,"
M'1@1EOKNY\"N$QYA[C^[G65T-!Y%Y3Y'IU[)'\_6=3-T=7T<O=Z0F'']G[M+
M_#K>+Q:?T7]P/<FFCJNN\O\ +NLZR3DY>7R:#ETZ==5!,.^WFW,^"+;^OSKW
M+]V/(9:>+R#RCR3G\IF;#KUO53:<O-KYSB"$:[-]J^R;G4>4W7(K/%AUFQ6G
MIZJKKZBX>61N;4ND8B:>30*BZL1&HG,KE71$U!,(JSOM^/AKIZ/;C&HJBBC5
M6PW6]/D3K53AS)30JQ6M[VLVJ]U&A.#GK!\X!G$-4Q<HQ6U5M$KONB6Q]312
MHSP+-)4HJIT]":^#I!@N-MONYA.Z.)NS#'*Y([=3(Y+G#6<L$U"]C.=[:A%<
MK6HC?&YT<K53BBA57C<_MV6&Q7&>S[;6AN0/IW+&^]5DCH:%SFZHO4QL3K)&
MZ_5JYB+W-4T4+8(UMW;]W+BJFON^-6*JHM4YH:5M92RJWNHDDE1.B+X>0&"V
M6R>_^&[VVZ9UG1]MR.A8DERL-2YKIHV*J-ZR)Z:)+%S+R\Z(BHNG,UNJ:D3"
M6 A &[_:WV[VLK:BP43),GRJF565%OH9&QT\$B=+)ZE4>C7(O!6L8]S?JD0)
MP5SN/;]W-EG5UIQNQ4M-JND=4VLJGZ<-/'940)W_ *D)P=-B/S@-7Y5'#GF)
M1+1N5$EK+),YLC$[Z4]2KD?_ #[08+@8-G^);D6&+),-N4=RMDB\CU9JV6&5
M$15CFC=HZ-Z:^=<G1HJ:HJ*%72@5*PWMM_I;N%:,$_07R/W5N<=K]T/=;K>K
MZR7J^LZKR)G-IT\O.GFA;!^&]?;8I\,R"KQ/;BUTUZKK<]T%=>*Y[W4*3LX.
MCAC@<QTB-7@Y_6-35%1$5/&!$/*VE[;V099E5HQ+*L1@FJ;S50T-/5V.1\:L
MDG>C$58*E\FK45=7+UR:)JO$&"Z(5   #*SM5;@_"!O+>YJ:;K;/8E2R6W1=
M6<E&YR3.3H14?,LCD7NMT"\+T[<[-TM)V<:/:R\1I%47>T2K=%<GC15UR1TZ
MJNG2Z![VHG\1 KBSEP3)+QL[NI;;U41OAN.,W-U/=:5//+'&]U/5P]SBYBR,
M"S7VAK:2Y45-<:"9M10UD3*BFG8NK)(I6H]CFKWE145 H_<#*/M4?'_FWJFG
M]AP!>&DFS'Q/;??[M6;V!"%)=I45%/24\M552L@I8&.EGGE<C(V1L3F<YSG:
M(B(B:JJ@52W*[=&%8W5S6G K6_*JN%7,?<Y)?)+<CDX:QKRODF1%^Q8U?J7*
M%L$0/[?>ZRU'-'C^/-I-4UB=#6NDT[OCI5HG_(!@DS;WMZX[=*N&W;BV%]CZ
MQ4:MWM[W5=*U5[LD+FI*QOA8LB^ &"W-LNEMO5OIKM:*N&NM=9&V:DK*9[98
M98WIJCF/:JHJ+X JY+=_</X*=NKSGWN;[K^Y'DO_ ,/Z_P EZWRJKAI?\KU<
MO+R];S><7733P@17LQVLK3ND_))K[8XL0M&-43+A5W*HN25475ODZO146F@Y
M?!Q557@B:A,PC?/>WU1TE;-0[;XVEPI8U5K+O>'OA9(J+IJRFBT?RKTHKY6N
M[[4"<'%VKM_;CPU*.OF,62MH]4UBHO*Z*33N^/)/4I_R 8+3[*]H[!=Z8WT5
MLZRTY53Q];56&L<U9%C3@LD$C=&RL37BJ(CD[K4334B83"$.=S;.\3V[L4V1
MYC<XK9:HO%1\FKI))%XI'%&U%<]Z_6M15^@!3_,/G 9TJ)(,"Q)GDK55(ZZ]
MS.5[TUX*M/3*G+_/J%L'+VWM^[F13HZ[XU8JJEU3FCI&UE+(K>.J(^2HG1%Z
M/J 8++;-]JC;W=VI98T1^/9;(GW*T5[V.;4*B:JE-.G*DBHGU*M:_I5&JB*H
M1,)T"
M
M
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M78Y$MUZ<FB+,YK$=%4:)T=:WSWV;7:<- K,)K"
M
M
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M\;6*[H357*FJJO2O$*/9 _*JIJ>MIIJ.KC;-2U#'0SPO35KXY$5KFJG>5%T
MQKO%/5X#N!7TM ]S*[&+Q-%32.14<V6VU2M8JHNBZHL:!]&DO:UG95=F[+*J
M+7JYF6J1FO!>5]THU37Z84A47L/V^FK-\H:B=O-+;[575-,OULCDCIU7_$E<
M@6EI<% #(3?>&.#>G/V1-Y6K?KC(J:JOC25#WN7CWU55"\-$=W,@J;!V8;S=
MV3*VJDQRFI.O<[1_-<8XJ17<R\>;[MP7IU\(5X6=>R64XQA.Z6.9;F$<TUAL
M\TE7-'2QMFF69D$GDZM:]S4\698W=/<[X6E>7Y=6RGI>^>LH?; 5P/EU;*>E
M[YZRA]L P0MVG.T9M9O)M_2V#'(+FR_4-QAKZ66LI8HH^K2.6*1JO;,]4U23
M733BJ($Q#^>P!>*B#<'*<?:Y?):ZS-KY6_4K)0U443%7CTHE4_N EH(%0
M
M
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M+N;5B:>-] &*;@@
M
M
M              'Y.I:9\[*I\+'5,2*D<RM17M145%T=IJG!5 _4"J/;VL5'
M6;86/(',3W1M=Y93PRJG'R>LIY>M8GFNBB=_@A:%"<0N-19\ML-WI'*VKH+C
M1U4#D714D@G9(U47CIQ0+-(NVE1R56PEXG9KRT5;;YY-$U\5U2V'CWN,B!2&
M8@7;4XU4LK,<L]7&BI'445-*Q%Z>5\37)T>:'S5R[>56V#9NVTZHBOJL@I(T
M37141E+5R*[3N^=1/HA,,[K50ON=THK;'KUE9414[=-$769Z,3IT3N]T+MD<
M]HY+C@N3V^'7K:NTU\$>B<R\TM-(U.'=XJ'S8QA]&I'8ZJ63]GK%8FHJ.II+
ME$_7NN6XU,G#Z#T"DNUWTJVT6S&?S/1%1V/W*#BO+QJ*62)./FOZ.[T AD$%
MVL_9HH7V_8C!J=^NK[<E0FNG152OG3H\#PI*1;_8;5E%DK\=OM/Y79KI ^DK
MJ;G?%UD,J<KV\\;FO;JB]+7(H0B'Y(/9V_8W_P SNOML)Q/D@]G;]C?_ #.Z
M^VP8GR0>SM^QO_F=U]M@Q/D@]G;]C?\ S.Z^VP8JL=LK:#;K:G]"OT!LWN1[
MK^ZGNA_I575=;Y+Y'U7^M32\O+UK_.Z:Z\>X$PY7L9?'_8/4UQ]ARA,M0 H
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MB^1WJ^[8U\RI3W-GNO9V.7Q4JJ=$94,:G??'R/\ ,C4$H5[5'Q_YMZII_8<
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M]R[.,BN%VQY',MUE@N$JS\\S%YZB9'R:N5&^(Q%U5%57=UH)6N"H
M
M
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M*R-OA75555XN<JZJO%>(5>D
M
M
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MRN\%0     *0?.&_V<?GO^KPM"'NQE\?]@]37'V'*$RU "@
M
M
M
M
M                         'YSP054+Z>IB9-3RHK9(I&H]CFKTHK5U14
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MY0F6H 4
M
M
M
M
M         *0?.&_V<?GO^KPM"'NQE\?]@]37'V'*$RU "@
M
M
M
M
M                                               !2#YPW^SC\]_U
M>%H0]V,OC_L'J:X^PY0F6H 4
M
M
M
M
M                          *0?.&_V<?GO^KPM"'NQE\?]@]37'V'*$RU
M "@
M
M
M
M
M    !2#YPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H 4
M                           !_$LT4$;IIY&Q1-\](]4:U.YQ5> '\4]7
M25;7.I)XYVM71RQ/:]$7P\JJ!^P      /F6X4#9_)754*56J-ZE9&I)S+T)
MRZZZ@?2
M
M
M
M           "D'SAO]G'Y[_J\+0A[L9?'_8/4UQ]ARA,M0 H
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M)X7\ELJGMYF2/5JZ.1')JG2@6EI>%
M
M
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M&>_9!_\ <3AOYS_]*JPM+4X*
M
M
M                                       4@^<-_LX_/?\ 5X6A#W8R
M^/\ L'J:X^PY0F6H 4              5QWF_7:7U-!_>4\B[4?&SU:7KG9C
MX*.M4CXY5U(   6.V9_4F+U3/_?0]=[+_!1UJGDG:?XV>K2D$ZIRH
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MR*G2BHH5?V
M
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M6Q6EV]QFMPO![!B5PN/NM566BAH'7#JU@ZUE.WD9XBOD5-&HC?/+T:A5TH
M
M
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MGHK7QO1'-<U>E%1>"H!&.6=G/97,T>Z[X?0PU3^*U=N8MNGYE^J5U*L?,O\
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MP0K1MKO=N)M)3W"EP>X0T,5T?'+6];30U*O="CFLT65KM-$<O0$X.Z^6;O\
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MS-<US=45%1=45 J_0
M
M
M  4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %              %<=YOUVE
M]30?WE/(NU'QL]6EZYV8^"CK5(^.5=2   %CMF?U)B]4S_WT/7>R_P %'6J>
M2=I_C9ZM*03JG*@           H)\X'^N.'?DRH]D(%H3%V%?B4J/RY6_@:<
M(EU7:^_]NV9?FS_U6D!"EW8R^/\ L'J:X^PY0M+4 *     S:[:\6067>>K>
MM=5LM%ZH*.OI8$FE2G18XO(WHUO-RHNL"J[1.[X>)>%G^QIGE%EFSE!8NM:M
MYQ1[[=6P:^/U+WNEII-/K58[D1?KF."LK#!   QTW;J;16;I9I5V%6K9YKW<
M9*-T>G5NC=4O5',T^I=TM\ 7:X8915EMP_'[=<-?+Z2VT=/5<R:.ZZ*!C'ZI
MW^9%"BB7;OV^GM&<VS<2EB5;;D5.RCKI43@VX4+>5O,OV<",Y4^P<%H2#V$=
MT*.LQVX[57*=&72V327*RL>Y$ZVCJ%19HV)W5CEUD7OI)]BH)7'"H  S?[;>
MYU+F6XM+A]IG2:U8?'+3U$C%U:ZY5"M6H35."]6C&1^!R/0+0F_L'XM>*# ;
MQEESGJ'45YJFTUGI99'K"RGH>9))8V*O*G62O<Q53_-@E,N2]GO9S,+Y69)D
MF*P5][KW-?65CYJICI',8UB*J,E:U-&M1."!&+RODK[ ?L33>N*ST<&)\E?8
M#]B:;UQ6>C@Q3"$,:[U\9-P_+DWLMP7;*!10KM\X(E%D..[BTD:I#=876FY.
M1/%2II/ND#E7ZY\;G-\R,+0[;8W>]EE[)][O-1,U;W@<=1;*5LG%725"HMN5
M4^MYYFQ>8Q03&E#O8CPA^5[M5&75[734>+4SZM97ZNYKA6\T,/,J]*\JS2:_
M7-0$M(0JQYWG^.'<'_>6\^SY@O#6K"_U.Q[\F47L=@49G=J[<2Z9UO#?:">=
MWN+B]3-9;71ZJC(UI7=74/TUTYI)6N57?6HU/J4"\+*]G[LC[>MPJS9?N%0+
M?L@O5-%<8Z.>1[*.EAJ&I)$SJXW-ZQ_(J*]9%5-5T1O#52)E9*R;<[?XVK'8
M_BMHMCV>=DI*&GADUTTUYV,1RKX54*N)[3]Y@L>Q&:5$\J1+5424$*<%5\E;
M*R!&HB]]'KKWDU7N!,*&]D'_ -Q.&_G/_P!*JPM+1K=ZPS9/M;F-AIF=;5UU
MGKHZ6/1%YJA('.B3CWWHT*,R>S;D-/B^^6$W:K>D=.ZO\A?(Y41K?=*&2BU5
M5X(B+-Q7N!>6M04 (4W][1%NV)DQ^&ILKKY/?%J7.ABJDIGP0TJ1^/HL4G-S
M.DY415;T+W@F(>_LIO-;-[<=K<CM%IK+524-5Y ]*Q8W(^9L;)7=6Z-RZHU'
MMUU1.D$PS3W]^.O/ORY7?AG!:&KF%_J=CWY,HO8[ H]P#+/M=V">Q;]Y,^1G
M+3W5*6Y4CM-.=DU.QKU_G62)] +POMV:\FI,IV/PNKI7HKJ"W16BH8BIS,EM
MB>2JCD3H54C:]/ Y%"LI6" #(/?3)Z7,=W\QR&A>V6@J;E-'23,5%9)!2Z4\
M<C53N/;&CD\T+PU1VPL<N,[;XCCU0SDJK99K?2U+5147KXJ9C9-4754U>B\
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MYV',MN>0[1U-HN<KI_T<N4E#0R/555M')%',R/5?K'/>B=YNB=P*RLT$
M
M
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MR"]U#[Q<J9R>/ Z=C(XH7=U%;'&Q7(O0]7(%93<$
M
M
M                        !2#YPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H
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M]HL]IQ^VT]GL=%!;K52,2.FHJ6-L,,;$[C6,1$0*OM R5[2?QZYU^4W_ &C
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MC&*G2CG<[VKT.0(Q3H$
M
M
M     I!\X;_9Q^>_ZO"T(>[&7Q_V#U-<?8<H3+4 *
M
M                   ,E>TG\>N=?E-_VC O#4#;+XML._(=L]B1!1U0
M           #\JFGCJZ>:EF36&=CHI$[[7HK5_N*!D#<[?DVQVZW431=7?\
M$;I'44RRM5(YVT\B2PR:<-8YF<KO"UP7:'X1VN-E<OM\,];?&8W=7-3RFVW=
M'0]6_3BC9].J>W7H5':]]$Z K@]#)^U/L9C%%+5/RNGNT[&JL5%:4=6S2NTU
M1K58G5M5>^][4\(,&>V[NYF2[_;C-NT=#)S3K';,=L=.BS2,@YUZN-$:FKY7
MN>KG*B<571."(@6:1;![;/VIVNLF)U?*MX1KJR\.8NK?+:I>>1J*G2D:<L2+
MW4;J%926$
M
M
M      "D'SAO]G'Y[_J\+0A[L9?'_8/4UQ]ARA,M0 H
M
M                     JKN+V*;7N#F][S2;,:B@EO52M4ZC90LE;&KD1.5
M'K.W7H[P3BLMC=F;CN.VC'V3+4,M-%34#9U;R+(E+$V)'*W5=->7734(>H
M               1MNQL7M[O'1QQY90NCNE,WDH[W1.;#70LUUY$>K7->S55
M\21KFIJJIHO$)Q59OGS?=\CE>[&LTI*B!5UCCN-))3O:FJ<%?"^9%X:\>5/,
M"<7X6CYOS*99F^[V96^DI]?&6AI9JMZMX="2NIT15X^9X08K+;1=FW;?9Y[;
ME9Z9]TRCE5CK]<5;)4,1R*CD@:U$9$BHJIXB<RIP<Y4",4P!
M
M
M                                               4@^<-_LX_/?\
M5X6A#W8R^/\ L'J:X^PY0F6H 4
M
M
M
M
M                            *0?.&_V<?GO^KPM"'NQE\?\ 8/4UQ]AR
MA,M0 H
M
M
M             !&/: K-PJ#;"YU.US:I^9-FI$HVT$+:FHZM:AB2\L;FO14Y
M.;7Q>@)A3?\ 2SMU>E\E]Z8?:P3H?A69OVX+?25%?7-R.GHJ6-\]3426J!K(
MXHFJY[W*M-P1J(JJH-#P<6WN[6.;R5,6'WF[7N2B1CJME!04TZQ-D54:KN2G
M737E73S G"'2_I9VZO2^2^],/M8(T)7[.U^[4-PW)@IMUXKTS$5HZETKKA01
MTL'7HU.JU>V%BZZ]":@G!;\*@
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M3LF1&RMBJ8VRM1Z-5R(Y$=QT<OFA#T
M                                                         #E=
MS?BVS'\AW/V)*!3SYO?^F,\]36W\)4!:5[0J
M
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MX9U61[;[B5"390K'.LEY<C6+6MB:KG03(U$3KFM17-?]6U%U\9-7%9A;H*@
M    4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
M              *M]JKL]YYO-D&/W/$)+>RFME'+35*5\[X7<\DO.G*C(I-4
MT"8E('9EVOR7:/;F7%<J?2ON;[E45J+12.FBZJ:.)K?&<QBZZL7N E\G:^_]
MNV9?FS_U6D!#._9G;/X7=P*#!?=3W'\NBJ)?+_)_*^3R:%TVG5=;#KS<NGG^
M 6E:#_AY?_D?_P D_P#F 1B?\/+_ /(__DG_ ,P!BYG-.P3FEEM<]PQ#(Z7)
M:F!BR+;I:9;;42HGU,2K-.Q7=Y'O:GA!BKWM]N#F.SV8QWZPRR45SHI5@N5N
MFYFQSQL=I+3U$:Z:IJBIQXM=Q31R!+6O"<NM6>8E9\PLKE=;;Q3,JHFKHKHU
M<FCXW:<.:-Z.8[PHH4<!VCMWUV<VYJ+W0(Q^2W&1+?8HY$YV-J9&N<Z9S5Z6
MQ,:KM%X*[E1>D)AG!@> 9_OSG$]#:WON%ZK'.K;Q>:^1RQ0L<[1TT\FCEXJN
MB-1%<O<0++>X_P#-_P"$04K4RK*[K75JM\=;8RGH8D<NG!$FCJE5$Z.E-?!T
M!&+Z;MV =N9J566+)[W15NB\LU;Y)6Q(O<UCBAIE7_'!BJ3O)L7FNR%WIX+[
MR5=IJU5;7?:/F2GE<SBK%UT='*WI5B^:U7)Q"8E<'L<[^7+<&W5.WN85*U63
MV2G2HMMQD766KM[%;&Y)57STL+G-3FZ7M<BKQ:YRD3"U85<9NEN7C^TV&UV8
MY"Y70T^D5'1L5$EJJN37JX8]>Z[355^I:BN[@&7F=;@[C[_9K$^N\HN=QK)E
MALF/42/?!3M>NJ1P1)KQT3QWKXRZ:N7AP+K'[>=@>>JHX:_<_()*&HE1'/LU
MF2-\L6O'1]5*CV<R="HR)S>\Y0C%);^PELLZ-6-J[\QRIHDC:RGYD7OIS4RI
MK] (Q0)O1V+LCP&U564X/<'Y+8:-KI:VADB2.Y4\+>*O1&*K9FM3B]6HUR)]
M2J:JA,2X[LY]HF^;/7ZGM5TJ):S;NNE1MRMSE5_DJR+QJ:9/J7-UU>U.#TZ?
M&Y50F8:ATM33UM-#64DK9Z2H8V:":-4<Q\<B(YKFJG!45%U10H_4   \^^7N
MU8W9ZZ_WRJ916BVPOJJVJD\['%$G,Y>&JJO>1.*KP3B!E[OUVB,IWJO4E#2O
MGMV"PR(VUV%CM%E5J^+-4HQ=))7=*-XM9T-XZN<7B$B;3]A_+,LH(+[N%<'8
MK;JA$DAM3(NMNCXW<461'JC(-47@CN9Z=#F-",4XP]A+9>.)K)*R_3/1/&E?
M64Z.<OA1M,U/[@1BC/<OL&34%OGNFUM[FN-1 U7I8[ND:32HB:JD53$V-G-W
M&M?&U%^N0)Q5OVRW2SG8[+W5]I66!\$RP7S'ZOGCAJ$B<K7Q31KQ:]O%&NTY
MF.^BBDM6,%S2R;AXE:LRQZ19+5=84FB1VG61O159)$]$541\;T<QWA0*.A
M40[?&X/E5WQ_;.BEU@M[%O-U:U>'E$Z.BIVJG?9'UCO,D0+0J]EF 7;$\=P[
M(ZYJI1Y?035]+S)IRK!520JSPZQI#+YD@2TM[+^XOPC[/V2NJI4DO5G;[C79
M==7+-1M:C'NUZ5DB6-[E^N50K*8P@ I=\X1_0^!^J;E^#IPM"$.S1V?K/OK^
ME'NM>*FT^X'D'4^2QQR=9Y=Y3S<W/T<O4)IIWPF93[_P_,/_ &QN?K>G_A",
M3_A^8?\ MC<_6]/_  @Q<AFG8#O=%0RUF"93%=JJ-KG,M=R@\C?)IQ1K)V2/
M9S*G!.=C6Z]+D3H&*KUAOV:[29JVXVU\]DRRQU#HJB"1%8Y'1NTD@FC73F8[
M31[5X*@2UEVPSR@W-P.QYO;F]5%=:='ST^NO4U,;EBGBUX:\DC7-1>ZG'NA1
MUP    QKW-^,G,?RY<_9<H7=7L7E=5M5O98*^YZTD=+<'6B^1O7E1D-2Y:6?
MG\$2NZSS6 EK2%  !1CM^9VDM9C.V])(JMIFOOES8BZMZR3FIZ9%\+6I,J^!
MR!:%+)898']7,Q8Y$1%5KDT71R(Y."]]%"S9#;+XML._(=L]B1!\W5
M
M                     '*[F_%MF/Y#N?L24"GGS>_],9YZFMOX2H"TKVA4
M
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M!\WW@    !2#YPW^SC\]_P!7A:$/=C+X_P"P>IKC[#E"9:@!0
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MPTM/>*R&"%B:-9''*K6M1.\B)H"&J>V7Q;8=^0[9[$B"CJ@
M
M            'FW_ "&QXM::F^Y'<(+99Z1O-45E4](XF(JZ(FJ]*JO!$3BJ
M\$ J-NQVW<#K+-?,3PZRUM\CN5'4VY;K.]MOIT\JB=%UD;',DE>C>;71[(U7
MHX=(6P5][-V_=#L7=;W4W&R2WBCOD=-%(ZGG;#) E,Z1VJ,>QR/YNLZ.=NF@
M3,- -K-_=M=WF+%BMR6*\L;SS62O:E/7M:B:JJ,YG-D1.ZZ)SD3NA7!)H0
M
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M_</W2\M\OA9!KY9Y)U?)R22:_P"1=KT=P+1#RNQE\?\ 8/4UQ]AR@EJ %
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MOC2N;W>9D3>5?!*$R@3?WXZ\^_+E=^&<$PU.VR^+;#OR';/8D04=4
M
M                 !^554T]%335E7*V"DIV.FGFD5&L9'&BN<YRKP1$1-54
M#*CM";ZWK>?+)GLF?!A-MF>S'[9Q:WJTU;Y3*WAK+(G'CYQ%Y4[JJ7B$/!(!
M]=JNMRL=RI;Q9ZN6ANE%(V>DK*=ZQRQ2L75'-<G%%0#4SLU[UMWHP5:VX\D>
M7V5[*2_01IRM>][56*H8U."-F1KN'<<UR)P1 I,)F"
M
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MI%&OA:$2SHW]^.O/ORY7?AG!:&IVV7Q;8=^0[9[$B"CJ@
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MOUKJ87Q<=%FI5;4,?P[K6LD1->XY0K+2,*@
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M]^7*[\,X+PU.VR^+;#OR';/8D04=4
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M;')[KN_4W[JU6CL%KJ)'S?4I/5JVGC9YKFNE5/XJA66CX5
M
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MU$JKT)RQH[EUZ7:)TJ$MAX88J:&.G@8D<$36QQ1MX-:QJ:(B>!$0*/[
M"D'SAO\ 9Q^>_P"KPM"'NQE\?]@]37'V'*$RU "@             " NTOFW
MD-KI<)H9-*FXZ55RY5XMIHW?<V+_ !WIKYC?"=-N3*[54W9U1HCE:3>=_"F*
M(X=:KQV#G0 !]5MN-7:+A2W2@D6*MHI65%/(GU,D;D<U?IH4KHBNF:9U2M35
M-,Q,:X7XP_)J3,,:MV146B1UL2.DC1=>KF;XLD:_Q7(J'FF9L39N31/ [6S=
MBY1%4<+W#'?8           %!/G _P!<<._)E1[(0+0F+L*_$I4?ERM_ TX1
M+JNU]_[=LR_-G_JM("%+NQE\?]@]37'V'*%I:@!0    &=W;HV[K+'N'2[A4
M\2NL^3P1P5$R(ND=PH8TB5CE3@G/"V-S._RO[P6AU78^[1U@L%GBVISRM;;H
M89GOQR[5#D;3(VH?SOI9GKP8O.YSXWN\5>96JK=&\PF%Y6/9(QLD;D?&]$<Q
M[5U:K5XHJ*G2BA5_0'!;L[M8KM%B]3D&0U4?EO5O]RK2CT2IK:A$\6.-O%>7
M73G?IHQ.*A++;!\<O&[NZ-NLO*LUPR2YK-<96(NC(I9%FJIE[R,9SO\ H!9L
M*UK6M1K41&HFB(G!$1 HIYVY]I)[U9Z#=6R4ZRUEEC\AO[(TU<M YZNBGT3N
M1/<YKU^M>B]#0M"%.RCVA*7:.\U6-99(],$ODC99*AK5>M!6HB,Z_E:BJK'M
M1&RHB*OBM5.A44F8:26RZ6V]4%/=;/60U]LJV))35E+(V:&1B]UCV*J*GF!1
M]8'';E;G8CM3CD^29;6M@A8BI243%:M55S(G"*"-517.7O\ 0U.+E1.(&4N?
MYED.[^X5?DU7 ^:[WVJ9%0VZ#656,54BIZ:)$35RHWE8FB>,[CTJ%VH&PFV2
M;3;86?%)N5;PJ.KKU(S14=7U.CI$14Z4C1&Q-7NHQ%"LI+"  !!O:JVFFW4V
MQJ$M$"SY5CSUN=GC8FKYD:W2>G;WUD9Q:G=>UJ!,*"[#[OW#97/8<A2)]39:
MEJT5^MS=$?+2N<BJK$=HG61N1'LUT[K=41RA:6IF&YOBNX%C@R+$+G#=+5.B
M:20KX\;M-59+&NCHWIW6/1%"CH /,R#(K'BEHJ;]DEPAMEGHVJ^HK*EZ,C:G
M>X\55>A&IQ5>" 9;=H[>N7>K.?=*B9)3XI:6.H[#2R\']6YVLD[T35$?*J(J
MIW&M:G2FJEXA<3L7[35.";?SY;>X%AO^7K%41PR-Y9(;;"B^3M5%35%D5SI5
M^Q5G=0*RXSM\;@^1V2P;:44ND]SD6[W5K5T5*:G58Z=CD[K7R*]_FQH$PYCL
M#8$E9?,BW'K(]8;9$VSVQSDU3RBITEG<B]QS(T8WS)%!*^05  &2W:-V^^#;
M=[(;%3Q=5::J7W4M"(FC/(ZY5D:UG!/%C?SQ?X 7A?7LE;BKN!L]:XJR;K;W
MC2^XMP5RZO<RG:BT\BZ\5YH58BN7I<UP5E$7SA']#X'ZIN7X.G"8?#\WE_:/
M^9/ZP!*[X5 (OW[VAH-Y, K,?<C([_2:UF/UKN'55C&KHUR_YN5/$?YO-TM0
M)B66=EN^3;:YE37:BY[9E6.5JKU4K51T513O5DD4K.&J+HYCV]U-4"[6O:[<
M2S;J81:\TLJHR*M9RU=(KD<^FJX_%FA?IW6NZ%5$YFJCNA0^;L0   !C7N;\
M9.8_ERY^RY0NV4"BK_;EP;](=K*7+::+GK\3K&RR.1-7>0URM@F1-./^4ZER
M^!JA,*L;7[UOPS8S<K;]9^2X7A(5L355=5]T-*2OT7N:0-:YNG=U4+8)?[ >
M"=;6Y-N35Q^)3,;8[8Y4U3K).6HJ51>XK6I"GF.7Z)$KT!5D/O[\=>??ERN_
M#."\-3MLOBVP[\AVSV)$%'5
M                                        K-VZOB4I_P N47X&H"8>
MYV,OB L'JFX^S)02GT(  '@9=F^(X%:G7K,;Q36>W-U1LM2_E=(Y$U5L4::O
MD=I]3&U7> "G6Z/;LK*I\MEV?M2Q*]>J9?[G&DDSG+P1:>D35J+KYU95=KW8
MT"V#B<1[,F^6^-U;ENYUQJ;/0U.CG7"]J^:XOB5=4;!2*K5C;]:C^K:B>=14
M!BX+M =GV_;*7[FB2:XX17+_ /";TYJ*J.TU6"HY$1K)4[G<>WBWZI&DQ*&0
MD ^^R6.[Y)=J2Q6&BEN%WKI&PTE'3M5\DCW=Q$3N=U57@B<5X :G=G/9:'9;
M!4ME6L<^5W5[:N_U<7C,ZU$TC@8[1%5D355$[[E<[NZ!293 $
M
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MBR0U3XU1W?:QS_-4+8O.QWL:[\7RJ9%662GL5*Y='5ERK*?D;IT^)3/GE_\
MU8,5XMB.S[C&R%JF\DE]U<KN#$9=+Y+&D;G,1>9(86:NZN)%T54YE5RHBN7@
MU&E9E+X0     !2#YPW^SC\]_P!7A:$/=C+X_P"P>IKC[#E"9:@!0
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M7*Q[8GN:J+,[BBHG$+PU$VT:YFW.'L>U6O;9+:CFJFBHJ4D>J*@4=0
M
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M$$
M                                                 "D'SAO]G'Y[
M_J\+0A[L9?'_ &#U-<?8<H3+4 *
M              \^Y6&QWE$2\6RDN"(BM1*N".?1JZZI]T:[AQ \RDV_P*@F
M2HH<6M%+4-\[+!;Z:-Z:*B\'-C1>E$4#HFM:QK6,:C6-1$:U$T1$3H1$ _T
M   ?-6V^@N4/DUQI8:RG5=5AJ(VRLU_BO14 \-FW6WT<WE,>)V9E1JKNN;;J
M5'\R]*\R1ZZKJ!T4,,-/$V"GC;%"Q-&1QM1K43P(FB(!_8       '\30PU$
M3H*B-LL+TT?'(U'-5/"BZHH'.S;=;?5$O7SXG9I9ETUD?;J5SN'1Q6/4#W**
MWT%MA\FMU+#1TZ+JD-/&V)FO\5B(@'T@
M
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MGVM5<51C$<[OCJ7+@
M
M  %(/G#?[./SW_5X6A#W8R^/^P>IKC[#E"9:@!0
M
M
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M;MT135QL>_O+,WZ=BY7-4<3VS8M<
M                               YK/<[QW;;%:_,,IJ%I[50-151B<TL
MLKUY8XHFZIS/>[@B='=541%5 H=F?;KW0N];*W#J*AQVTH[_ $?GB2NK%:B\
M.L?+]SXIW&Q)IWU"V#B'=L#M$.<YR9@C$555&I;+7HFO<36D5?IJ$X/\^5]V
MB?VR_P#++5[4!@?*^[1/[9?^66KVH#!W^R/:;WOR_=C%,9R+*?++)<ZYL%;2
M^Y]NAZR-6N54YXJ9CTZ/J7($3#0\*@
M    *0?.&_V<?GO^KPM"'NQE\?\ 8/4UQ]ARA,M0 H
M
M
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MZB\I7Q]=(U$C7JNN?JNO=Y> )6_"H
M                               "B?S@.65+[OB6"QR*VC@II;W4Q(O!
M\L\CJ:%RI]@D4J)_'4+0_KLM=E;%<MQ2GW&W*IGW&GN3WK9++UCX8?)XG*SK
MYUB<U[E>]J\C.9&\J:KS<VB"96AB[/NR4,;8F8%95:WH5]''([Z+GHJK]%0C
M%_?P!;*?L#8_6,/\D&)\ 6RG[ V/UC#_ "08OMM&S6U%@N5->;+AMHH+K1OZ
MVEK*>DBCEB>G#F:Y$U1>(1B[D
M"D'SAO\ 9Q^>_P"KPM"'NQE\?]@]37'V'*$RU "@
M
M
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M]SJ5=$LW(_$6^O3TPB383_6[Y][I_MI#A.Q_GW>2GQNZ[7^9:Y:O$FX](><
M
M    "@?S@&/5,.9XGE7(JT=;;)+7UB(JM22BJ'SZ*O0BJE5P[^B]X+0M%V9+
MW07W8O"YZ!S52CH4M]0QO2R>B<Z%Z.3N*JMYO,5%[H1*6@@
M                          %(/G#?[./SW_5X6A#W8R^/^P>IKC[#E"9:
M@!0
M
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M1+-R/Q%OKT],(DV$_P!;OGWNG^VD.$['^?=Y*?&[KM?YEKEJ\2;CTAYP
M
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M#?[./SW_ %>%H0]V,OC_ +!ZFN/L.4)EJ %
M
M
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M][I_MI#A.Q_GW>2GQNZ[7^9:Y:O$FX](><
M                                       " NTOV?KQOK^B_N3>*:T^
MX'E_7>51R2=9Y=Y-R\O)T<O4+KKWPF)0#_P_,Q_;&V>MZC^$)Q/^'YF/[8VS
MUO4?P@Q/^'YF/[8VSUO4?P@Q/^'YF/[8VSUO4?P@Q=?M;V+<GV_W"Q[,ZS**
M"LI;-5-JI:6&"9LDC4:J:-5RZ(O$&*Y@5
M        4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
M
M
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M
M       C;='?C;7:*-K,MNFMVD9UD%EH6I4U\C>XO5HJ(QJ]QTKF-7N*$X*V
MWGYP>%M0YF/8*Z2E15Y9Z^X)'(Y.YK%% ]&_SBA."?>SGO#<M[,(K\JNEM@M
M=11W6:V-IZ9[Y&.9%3T\Z/57\=5694^@$3#DZOMA[?6+<B^;>Y=1U-HBM-:^
M@BOS%\JI'NCT1RRL:ULD6CM6^*V1.&JJ@,%@J&NHKG1P7&VU,59053&S4U5
M]LL4D;TU:YCVJJ.14Z%0(?0                                   !2
M#YPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H 4
M
M
M           'D9/E%@PRQ5F2Y/7QVVR4#.LJJN95T:G0B(C45SG.5=&M:BN<
MO!$U HON;V[<LN=7-0[74$5DM+%5L=UKXV55?*B=#TB=S0Q)]BY)/-3H"V"L
MU5N!F%;FB;AU5T?)F;:B*M2Z\D2/2H@1K8W\B,1GBHUO#ET"RR&V_;LS>T5<
M%)N50PY#9W*C9[A1Q,I+BQ.ZY&,Y()-/K.2/^,%<%ZL.S+&\^Q^DR?%*^.XV
M>L;K'-&OC,>B(KHY&KQ8]NOC,=Q0*O;EEB@B?-,]L<,;5?)(]4:UK6IJJJJ\
M$1$ @;<7M?;/X'UM)0W!V57EFK?)++RS0-<GU]4JI$B=Q>K5[D^M"<%7\A[4
M7:!WEN+L<VWH)[/#-XJ4./125%?R*OGI:OEYF(GU\:1(G="<'NX'V&\[R>I2
M];J7QME94.ZVHI('I<+I*YW%>LE55B8JZ^>YI?,!BF3-.Q=MK5[=U./8-2+;
M\NA5M307VMF?/-//$U4ZNH=YU(Y$54=U3&HUVCN5=-%(Q9Y9+C-_P^]U>.Y-
M;YK9>:%ZQU%)4-Y7(O<<B]#FN3BU[55KDXHJH%WE  +,]EGLWW/<2^4><9;1
MNI]OK;*V>&.=JM6Z3Q+JV.-')XT".3[J_H=YQ./,K2)EI(%    \^Z6*S7KJ
MO=>AAK>HYNIZ]B/Y.?3FTUZ->5#$S&4LW\/:4Q5AJQC%E9?-WK&/LZIIQUX3
M@\_]!<-_$5%_,L_@,7Y1D_=4<T,OYMG/>U\\N#W<QG'K1BK*JUVRGI*E:N)B
MRPQM8[E5KU5-43HX',=I,AE[.5BJW133.U&F(Y73]F\_F+V:FFY755&S.B9Y
M'U;7XKC=TPVCK+C:J:JJWR3H^:6)KWJC97(FJJG<0^^X-WY:]DZ:J[=-4XU:
M9CNL??\ O#,VLY531<JIC"G1$]QV7Z"X;^(J+^99_ =!\HR?NJ.:&@^;9SWM
M?/+T;99+196R-M-%#1-F5%E2!B,1RMUTUTZ=-3+L92S8Q]G3%..O",&)?S=Z
M_A[2J:L..<7WF4Q0    >9DGZNW?U%4_@G&%GOA[G4JZ)9N1^(M]>GIA$FPG
M^MWS[W3_ &TAPG8_S[O)3XW==K_,M<M7B3<>D/.
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M/>6X6G*$VFO=4^:P7ELLMA;(Y7)2U\;72OC8J^=9,U'KIT=8B:)JYP): A4
M                                 !2#YPW^SC\]_P!7A:$/=C+X_P"P
M>IKC[#E"9:@!0
M
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M:BKHB2-?P[X5Q6-AABIXHX((VQ01-1D43$1K&L:FB-:B<$1$Z$"']@
MCC>W]38_5L/VDAR/:KX..O'1+KNROQD]2>F'V[0?J)0_?*C\,XR.S7P-/+5T
MRQNTOQU7)3T0[HZ9S0      #S,D_5V[^HJG\$XPL]\/<ZE71+-R/Q%OKT],
M(DV$_P!;OGWNG^VD.$['^?=Y*?&[KM?YEKEJ\2;CTAYP
M                                                 ,^^W_>:F;<#
M%L><Y?)*&S.KXV?4I)754L3UZ>G2E;W M"U_9NQ:W8GLEAM+;XVL=<K;3WFL
MD:GC25%SB;4N<Y>ZJ(]K$\#43N!$H[[=7Q*4_P"7*+\#4 A\/8&^)Z]_[RU7
ML"@!*TSFM>US'M1S'(J.:J:HJ+THJ!#*JXVNGVZ[4;+;9&]30V?+Z9:&")%7
MDIG5K)&1(B<51&.ZO3NA?@:K!0
M!2#YPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H 4
M
M
M             &*5_K:BY7VYW&LYO*ZNKGJ)^L\_UDLCGNYM.[JO$/H\\
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MT2S<C\1;Z]/3")-A/];OGWNG^VD.$['^?=Y*?&[KM?YEKEJ\2;CTAYP
M
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M"'NQE\?]@]37'V'*$RU "@
M
M                                                        !&&Z
M': VQVEBDBR6[-GO;6\T=AM_+4U[E5-4YF(J-B1>XZ9S$7N:A.#*3(Z^ANN0
MW>Z6RF=1VVMK:FIHZ1ZHYT,$TKGQQJK41%5K51NJ(%WF   ':;28/5;C;C8[
MB%/&LD5?61^7*B*J,HHEZRH>NGUL;7:>'1 AL2%    K_NELG+FF9UF0-QRW
M7%M1' SRNJCI72NZJ)K-%65.;AIHAPN]LEO*[F9JL5511HPPKV>#3HQ=SNG/
M;MM9:*;]-,UZ<<:,>'1IP<9\FF?]CK/_ #-#_ :GY9OGTZ_^3_)M_F>YO0I_
MX_\ %S^1;/67%9H:>]8M:89:AJR1(VEI)-6M71?.M70U6=JWCDZHINW*XF?X
MYGQMKDJ=W9NF:K5NB8C^"(\3W8.S>^HACJ(L/LZQ2M;(Q>IHDU:Y-4[ALZ-W
M[XJIBJ*Z\)_^G^365[QW/35-,T4XQ_\ /_%_?R:9_P!CK/\ S-#_  %OEF^?
M3K_Y/\E?F>YO0I_X_P#%8S;O'G8IAEIQ]U)%0NH8WL6DIT8V)G-*]^C4C\7C
MS:\#OMVV[UO+44WIQKC7C./#QN WE<M7,S759C"B=6$8<'$Z<V37     CC>
MW]38_5L/VDAR/:KX..O'1+KNROQD]2>F'V[0?J)0_?*C\,XR.S7P-/+5TRQN
MTOQU7)3T0[HZ9S0      #S,D_5V[^HJG\$XPL]\/<ZE71+-R/Q%OKT],(DV
M$_UN^?>Z?[:0X3L?Y]WDI\;NNU_F6N6KQ)N/2'G
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MCEA1[=461ZHBRJU53@C4Z%5Q6963"
M    %(/G#?[./SW_ %>%H0]V,OC_ +!ZFN/L.4)EJ %
M
M                                    #X[M=K98K95WF\U<5#:J&)T]
M75SN1D443$U<YSEZ$0"CVZG;NNLU7/:MI;=%36^-RL;?[G&LD\J)JG/#3*J-
MC3NM67F54Z6M7@%L$%S]J'?RHJ4JY,WK$E1=>6..FBBZ57_)LB:SN_6A."2=
MONW+N78*J*#.H*?*K1JC9I$CCH:]K>C5CX6MB=IWGQ:N^N3I",%[=O-QL3W1
MQJ#*<0K/*K?*O5S1/3DJ*>=J(KH9X]5Y'MU\**G%JJU44*NK
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M=,YH      !YF2?J[=_453^"<86>^'N=2KHEFY'XBWUZ>F$2;"?ZW?/O=/\
M;2'"=C_/N\E/C=UVO\RURU>)-QZ0\X
M                                    #X+Q9+-D5OEM-_M]-=+7.FDU
M%6PLJ('Z=&K)$<BZ>8!"E]['.PU[F?416*>TS2:J];;63QLYE[K8Y72,;IW$
M:U$\ 3B\FA[#^QM)+UD\5UKF:HO55%=RLX=S[A'$[C_&!BF#"-JMNMN(W,PK
M'*.T2/;R254;%DJGL3ZE]1*KY7)PZ'/4(=@
M            I!\X;_9Q^>_ZO"T(>[&7Q_V#U-<?8<H3+4 *
M
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MZ0\X
M       55[7V]NXFTEQQ2GP>X14,5U@K9*U)::&IYG0/A1FBRL=IHCUZ F(5
MI^6;O_\ C^F][J/T(+8'RS=__P ?TWO=1^A P/EF[_\ X_IO>ZC]"!@?+-W_
M /Q_3>]U'Z$# ^6;O_\ C^F][J/T(&!\LW?_ /']-[W4?H0,'>;+=J;>?,]U
M,5Q>_P!YIZBS72M;3UD+*&EB<Z-6N71'LC1R='<4(F&@@5
M                     4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
M
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MU/QZD\N
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M]WT=))C&3.MM+'<XJJ%JN=3RSI$CU56HY8Y%=SHOB+KS-Y1+00*@
M                          *0?.&_V<?GO^KPM"'NQE\?]@]37'V'*$RU
M "@
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MU?VN?^K<IZ-?-3_<? 7EOIVW?SL_H ^DLWZ5'/5_:?5N4]&OFI_N6!/5'E@
M    $%;\?TO:/4TGX0\S[7_G6^K/2]+[(?E7.M'0FBS_ -$4'J:'\&AZ)EOR
M:.K'0\\S/YM?6GI?:9#'       1QO;^IL?JV'[20Y'M5\''7CHEUW97XR>I
M/3#[=H/U$H?OE1^&<9'9KX&GEJZ98W:7XZKDIZ(=T=,YH    $?;S?J3+ZI@
M_OJ<KVH^"GK4NJ[,?&QU:E<3R)ZV   '=;0?KW0_>ZC\"XZ;LU\=3R5=$N:[
M2_ U<M/3"RI["\?
M                  9[=OZX5DNY.,VIZK[GTMC2J@3ZGKJJKG9+IX>6"/4+
M0N#V?Z6VT>R6!16E$2E=9:.:3EZ/*9XDEJ>XG'KG2:A$I("  !EEE$M-;.UI
M4SXZJ(VGS:%\+8E:B=>EP8LK4^I1.LYFZ= 7X&IH4
M                4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
M
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MX[*D-?"B,NMFE>U:JCF7N.1-.9COJ)$31R=YR.:FP:[!(80
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MNMH/U[H?O=1^!<=-V:^.IY*NB7-=I?@:N6GIA94]A>/@
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M[!ZFN/L.4)EJ %
M
M       "']Q,$P7'++D>X-_K:^.FHXZFZ5;(Y86M<]RJ](V:PN75[U1C-=>*
MH<G?[,96]<JN555XU3,ZZ>&<?1=98[3YJU;IMTTT84Q$1HJX(P])2WLT;9.W
MTW2NN092QS\>MC'UUR5J->U]35*YE- G6M>W1-'/35%\6/0Z#]+3%CV-$S1&
M&$33KCDGC[K0_JJO;>VJB*YF<<*M4\L<7<37E&QFV5JSZ'':>R0NHGS4L:O>
MR-)-*CDYN#&M9PYN'B' YW.YK+YV,M3=JV9FF,9V9J^]AP[+O,EDLKF,E.8J
MM4[415.$;44_=QX-I-EM[.FWEGAZBTI54,*\593^2Q(J]]>6G34Z+,=G;5^<
M;EV[5RU1_:YW+]HKMB,+=JU3R4S_ '%W[.N WVW3VJZRU]305+>66)\L'FHJ
M*D&J*B\45.**1E>SEC+W(N6Z[D51W:?[4YGM'?S%N;=RBW,3W*O[E*]P]M]R
M^R5GE/FF&ULLN-32NBM=WY>>-\3_ !EHZ^--&ZJB>8_EYV:.31O4N9UKK[&;
M\XOO985J+?I09/0L9[LV.1R+)$Y41.MB7ZN%7<$=TIT.1%TU*S"6 @
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M7+3TPLJ>PO'P
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MT5-4Z%1>"HO%%X*$/2      !2#YPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H
M4
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M*L=.DE36)3S=8D3*>-51O*G5.;QD1&:IXJ] 1,K[[9=FW:C:U(:JSV=MQO\
M%HONY=>6JJT>GU46J(R%?#$QJ]]5"N*6P@ \C*<9L^9X]<,7O\+JBS72):>L
MA8]T3G1JJ+HCV*CDZ.XH$,_(RV _$%3[XUGHH3B?(RV _$%3[XUGHH,3Y&6P
M'X@J??&L]%!B?(RV _$%3[XUGHH,7MXAV7]G,%R2@RS&[//37NV/=)1SOK:J
M9K7/8Z-=6/D5J^*Y>E 8IB"      *_73X[8_P HTOVD9Y7F/]W'7IZ(>IY?
M_2SU*NF5@3U1Y8        05OQ_2]H]32?A#S/M?^=;ZL]+TOLA^5<ZT=":+
M/_1%!ZFA_!H>B9;\FCJQT//,S^;7UIZ7VF0QP    19NYE^18Q4VJ.QUGDK*
MEDSIDZJ*7F5BL1/\HQVFFJ]!Q/:3>68RE5N+-6SM1..B)XN.)=KV;W;E\W3<
MF[3M;,QAIF./BF$;_"QN!^-_]FI?0CD/J/>'O/Z:/[77_3N0]W_57_<\V]YU
ME61T:6^\U_E-&CTE2/J8(_':BHBZQL:O=7NF'F][YK-4;%VO:IQQU4QT1#,R
MFZ<KE:]NU1LU88:ZIZ9E_=GW RZP4$=LM-Q\GH8E<YD74P2:*]5<O%\;EXJO
M?+9;?.;RUN+=NO"F.Y3/3"F9W-E,Q<FY<HQJGNU1T2^_X6-P/QO_ +-2^A&5
M]1[P]Y_31_:QOIW(>[_JK_N2=M#EF091[L^[M7Y5Y)Y-Y/\ <XHN7K>MYO\
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MBB&PWSN?+9/)3-N/O8Q]Z=,_9WFOW/OC,YS.Q%R?NX3]V-$?;WT+GG;T,
M.ZV@_7NA^]U'X%QTW9KXZGDJZ)<UVE^!JY:>F%E3V%X^
M                                               H=V^\ON#<JQ'#
MZ:=\--0T;KXJ1N5NM143/IXGZI]5&D#^54XIS*%H3'V+KIF5_P!K:J^9=?ZN
M]-FN,E+:XZV3KWP4U*QC5^ZOUD7F>YR:.<J(C4TTU4(E8X(
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MSC\]_P!7A:$/=C+X_P"P>IKC[#E"9:@!0
M
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MY55'%,O7,]@
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M $TL#'2)]!^H?-U      4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
M
M                                                 %6.W#N;^C&
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M\RURU>)-QZ0\X
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M*/(.JIX:;D\KZKK=>I:WFUZEG3T P=_V,OC_ +!ZFN/L.4$M0 H
M
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M?,GDE]+7GQRH+V)_6*Y>HO\ M6'F?9'XBOJ>.'I?:[X>CK^*4]GJ#S
M   K]=/CMC_*-+]I&>5YC_=QUZ>B'J>7_P!+/4JZ96!/5'E@     %9-V/C
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M>GIA$FPG^MWS[W3_ &TAPG8_S[O)3XW==K_,M<M7B3<>D/.
M
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M?]@]37'V'*"6H 4
M
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M_P!M(<)V/\^[R4^-W7:_S+7+5XDW'I#S@
M                                      4U[>E;DE'\'_Z/5%=!S^[/
ME/D#YF:Z>0<G/U2IKIJ[37PA:%-?=K<G\87S^>J_Y02>[6Y/XPOG\]5_R@/S
MFR'<*FC6:HNMYAB33622HJF-37@G%7(@2^7],\P_:&Y^O*C^6!.W9^L&]CMU
ML*N]VM>4KBSZR.>:OJJ>X^Y[J9\;E1[I'MZM6+JBHY5T"):6!0
M( [1W:+NNQ519*6CQF.\,OD-1)#73U3H(XY*96M='U;87*[3K&.UZQ.]IW0F
M(1ILQVR\BW"W/M6(95;;59[#=NM@IYX$GZ]*SE5T#'22S*S1ZIU>G5ZJ]4TT
MZ F87*"JBWS@>26Z>X89B<$C7W.BCK+C6,1=5CCJEBCAU3ONZJ1?H>$+0KYV
M<+;577?/!::D8KY([I%5O1$UTBHT=42+]!D;E"9:+]I3')<JV-S6UT[.>HBH
M?=")J)JY5MLK*Q4:G3JJ0JU-.G70*PR7"[7[9#)J?+]I,.OM/(DBRVNF@J51
M472JI&)3SMX=Z2-P4E7/YP+)*>+',0Q!LB+555;/=I847QFQTL2P,<Y->ARS
MO1J_8J$PJ5LEC<N6[MX988V*]E1=:66H:W77R:E>E1.J:=&D4;U"9:]55-#6
MTL]'4-YZ>HC?#*WOLD:K7)])0HQ9R&RU>-W^Z8[7II76FKGH*E--/NM-(Z)W
M!?"T/HT,["N34]VVCJ\=ZQ/+L?N<S'PZIS)3UJ)/&_3O.>LK4_BJ%)=OVL,D
MI\;V(RETLB,J;K'%::1BKRK))62M:]J<4U5(DD?IWFJ"&5C6N>YK&-5SW*B-
M:B:JJKT(B!=LMMUCSL2P'&,8D32:T6JBHI^.NLL$#&2+]%R*H?-TP     4@
M^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
M
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M +53YW?,GDE]+7GQRH+V)_6*Y>HO^U8>9]D?B*^IXX>E]KOAZ.OXI3V>H/,
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M_$6^O3TPB383_6[Y][I_MI#A.Q_GW>2GQNZ[7^9:Y:O$FX](><
M
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M7'<7/:+*[E2N;A.,U#*RIJ)&Z1U5;"J/AIF:\':.1KY>E$8FBZ<S03+34*
M    4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
M
M                              13VB]S/@KVJO-_I9NJOM8WW,L:HJ(Y
M*VJ:Y&R-U[L3$?+_ ((3"NO8,VS5S[UNO<X==.:SV)STUU5>5]5,W7C]9&UR
M=]Z!,KP!54/)/UBN_JVI_"N/!<]\1<Z]73+WG(_#V^I3T0\PPF8   %M</\
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MHEUW97XR>I/3#[=H/U$H?OE1^&<9'9KX&GEJZ98W:7XZKDIZ(=T=,YH
M !YF2?J[=_453^"<86>^'N=2KHEFY'XBWUZ>F$2;"?ZW?/O=/]M(<)V/\^[R
M4^-W7:_S+7+5XDW'I#S@
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MFJKJH0^X      %(/G#?[./SW_5X6A#W8R^/^P>IKC[#E"9:@!0
M
M                                        &=W:_P SN&Z&\5JVLQ?6
MKBL<L=L@@8OBS7FO>Q)>*=QGW.+CYUS7]\+0O9M[A=NV\PJR87:]'4EGI64Z
MR\J-667STLJHG0LDBN>OA4*NE J'DGZQ7?U;4_A7'@N>^(N=>KIE[SD?A[?4
MIZ(>883,   "VN'_ *I6'\G4?X!A[MNSX2UU*/PP\+WG\7=Z]?XI>T;%K@
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M6;D?B+?7IZ81)L)_K=\^]T_VTAPG8_S[O)3XW==K_,M<M7B3<>D/.
M                                                          !!
M/:/[0E9L/^C/DEABO?N_Y=S];4NINJ\A\FTTY8Y.;FZ_P::!,0@C_B$7C]@Z
M;WRD]KA.!_Q"+Q^P=-[Y2>UP8'_$(O'[!TWOE)[7!@X+<?MI[EYS9:G'K31T
MF,6ZM8Z&LGHEDFK7Q/U1S&S2*B,16KHJL8CN\Y.@)P?AV.=J[AF^Y]%EM33.
M_1?$96UU14N31CZ]J*M+$Q>ZYK])G:=#6\=.9H):8A0
M                 !2#YPW^SC\]_P!7A:$/=C+X_P"P>IKC[#E"9:@!0
M
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MS/$^PR&.    #B]V/B_N_P#X;V5$<[VC_P!?<_E_'2Z'L[\?;_F_!4\78O\
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M(_$6^O3TPB383_6[Y][I_MI#A.Q_GW>2GQNZ[7^9:Y:O$FX](><
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M\X;_ &<?GO\ J\+0A[L9?'_8/4UQ]ARA,M0 H
M
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M9/LE7.F_7AW*=,\^KI<DCMT=QEX>4.MLG>_T2BY?^2C]/\)318[TWGZ6Q/\
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M &TAPG8_S[O)3XW==K_,M<M7B3<>D/.
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ML@75CV+PZ%T5%14T<UR(K5X*B*@5>F
M     !2#YPW^SC\]_P!7A:$/=C+X_P"P>IKC[#E"9:@!0
M
M                                >)F.4VW"<5N^6WAW+;K/2RUDZ)P<
M_JVZM8W[)[M&M\*@9_\ 9>Q:Y[T[[W'<O*6)4TEGJ'WZX.<BK$ZY5,CEI(FZ
M]",<BR,3N)$B!:6C85 /BN]TI;+;*NZUCN6FI(W2O[ZZ)P:GA5>">$Q\SF*;
M%JJY5JIC%D9;+U7[M-NG75."!,%M=5N!G4]]NC>:EIY?+:M%XM5VOW&%->YP
M_P 5IY?NG+U;RSTWKFJ)VI_[:?VX(>H;VS%.[<C%FWKF-F/^ZK]N&5B#UAY.
MK]G?QNTWJFW?]F>5[W_V\=:WXGJ>Z/\ 43U;GC6!/5'E@!Y]ZLMNR"W36NZ0
MI-23)Q3H<UR=#FKW')W%,7-96WF;<V[D8Q/[8QW65E<U<RUR+EN<)C]L)[BO
MTL61;0Y2U[%6>BEXM7BV&KI]>*+T\KV_3:O?1>/E=5.8W+FL8TTSS54^6/!R
M:_4Z:LOOK*X3HJCGIJ\D^'EU3]8+];LDM<-UMDG/!*GC,73GCD1/&8].XY/_
M .Z<#U')YRWFK47+<Z)\$\4]UY=G,G<RMV;=R-,>&...X],S6&  (>W[_P!4
ML?WRH^UC. [8>9:Y:O$[_LAY]WDI\:0<%_4VQ>HH?M$.JW1\':ZD=#E=[?&7
M>O/2Z VK5       .+W8^+^[_P#AO941SO:/_7W/Y?QTNA[._'V_YOP5/%V+
M_5*M_*,OX" UW9+X2KKS^&EL>UOQ=/4C\523CLW&@    Y+<[]1+S][C_#,-
M%O\ ^!N<D=,-[N'XZWRST2JZ>*O:    ^VTMN;[E3,LW6)='/Y:58%5LO.O#
MQ5331?"9&6B[-RF+6.WCHPUL?,S:BW5-W#8X<=22;/LMD-TE\LR6N;1]8O-(
MQ%\IJ7+W>9=>5%\/,[S#L<MV6S%Z=J_5LX_S5>3PRY#,]J<O9C9L4[6'\M/E
M\$),L6VN(6#ED@H4JJIO_P"TUFD[]4[J(J(QJ_Q6H=CD]Q93+:8IVIXZM/V<
MT..S>_<WF=$U;,<5.C[>>76]!O6B (8^ +_ZA_V/_OSSSZ._^W]'^3T/ZP_^
M/]?^+_/@"_\ J'_8O^_'T=_]OZ/\CZP_^/\ 7_BC^JQ#R;-FX=Y9S<U3%3>6
M]5I_E4:O-U?.O1S=',<I<W;L9W]+M?O13M8<>'!CXW4V]Y;>2_5;/[LU;./%
MCPX>)('P!?\ U#_L7_?G5_1W_P!OZ/\ )RWUA_\ '^O_ !/@"_\ J'_8O^_'
MT=_]OZ/\CZP_^/\ 7_BF6&/JHHXM=>1J-U[_ "IH>@TTX1$//JIQF9?V65
M  !!6_']+VCU-)^$/,^U_P"=;ZL]+TOLA^5<ZT=":+/_ $10>IH?P:'HF6_)
MHZL=#SS,_FU]:>E]ID,<      !'&]OZFQ^K8?M)#D>U7P<=>.B77=E?C)ZD
M],/MV@_42A^^5'X9QD=FO@:>6KIEC=I?CJN2GHAW1TSF@      'F9)^KMW]
M15/X)QA9[X>YU*NB6;D?B+?7IZ81)L)_K=\^]T_VTAPG8_S[O)3XW==K_,M<
MM7B3<>D/.
M            $9[];J1;0;;W'*V-9)>)%;0V2"3BU]?4([D5R:IJUC6ND<G=
M1N@3#,&RV+</>S-I:>W15.1Y?=7OJ:N>5Z:\J:<TDLCU:R.-NJ(FJHU.#6]Q
M LFJ7L([T1T+JME;89:A&<R4#*RI2=5^M17TK8M?-DT\(1BY/:7<[-NS'N+7
M6C):"JBH$5:;),;D<B*KE8CHIX^*L5[=6N8]JZ/8NB+HJ*$ZW-81AF;=HO<^
MII8IVOO-WEFNE[NLZ*L--"KD5\CFIQT17-CC8G=5K>"<4&I=6S=A;9RAM\<%
MVJ+K=:]&IUU8ZI;3M<_NJR.-FC4[R*KE\*A7%7[M%]DJ7:JTOS;"ZZ>ZXA"]
MK+C35B-6LHNL<C&2*^-K&R1JY4:J\C7-U37F354)B74=@W<FKI,@N^U]?.K[
M9<('72T1O75(JNGY4G8SO=9&O.OWOPKJ)7U"H
M           "D'SAO]G'Y[_J\+0A[L9?'_8/4UQ]ARA,M0 H
M
M                                   *8=O+<U*2UV?:JVS?=[@K;M?6
MM5>%-$Y6TT3M."H^1'2*B]'5M7NA:$S]ES;/X,]I;52UL/59!>T]U[QS)H]L
ME2U%BB=KQ18HD8U4^NYN^$2F@( (4WLRA99J?$J%ZKR*V>X(WNO5/N4?#O(O
M.J?Q3SKM5O#:F,M1RU>*/'S/1>RN[\(G,U\E/CGQ<Z0=O<73%<;IZ.5B)<:C
M_2*]W=ZUZ<&:_8)HWS=5[IU.Y=W_ */+13/G3IJY>+O:G*[ZWA^LS,U1YL:*
M>3C[^MU1O&D5^SOXW:;U3;O^S/*][_[>.M;\3U/='^HGJW/&L">J/+  !Y&2
MXY;<IM4MJN3-8W^-%*W3K(I$Z'M5>ZG]U.!@9[(V\W:FW<U<$\,3QPS\CGKF
M4NQ<MZ^&."8XI0-;J_(-H\H?25C%EH)53KXF_P"3J8-51LD>O0Y..GAX*>8V
M+V8W+FIIJTTSKC@JCCCN_P#27IU^SE]\Y6*J=%4:IX:9XI[G_6%A+5=:&]6^
M"YVV5)J.H;S1O3I\**G<5%X*AZKE\Q1?MQ<HG&FIY5F,O78N3;KC"JE]AD,<
M A[?O_5+']\J/M8S@.V'F6N6KQ._[(>?=Y*?&D'!?U-L7J*'[1#JMT?!VNI'
M0Y7>WQEWKSTN@-JU0    .=RW,[7AM/35-TAJ)8ZIZQQI3-8Y45J:\>=[#4[
MRWI:R-,57(F=J<-&'CF&VW=NN[GJIIMS$;,8Z<?%$N3^'3$O25Q_FH/1S1?5
MN4]&OFI_N;SZ2S?I4<]7]KG\WW7QW)<7K[)0TU;'5574]6^>.)L:=7,R1=5;
M*Y>AJ]PU6]NT67S65KM44UQ-6&N(PT51/I3Q-KNKL[F,KFJ+M=5$Q3CJF<=-
M,QZ,<;S]M]R+'A]CJ+9<Z>KEGEJWU+74S(W,Y'1QL1%5\C%UU8O<,7<>_+&2
ML3;N15,S5,Z(CBB.&8XF5OS<=_.WXN6YIB(IB-,SQS/!$\;L/ATQ+TE<?YJ#
MT<W_ -6Y3T:^:G^YH/I+-^E1SU?VNBQ+<&S9E45--:X*J*2E8DDBU+(VHJ.7
M3AR2/-ONW?-G/533;BJ-F,=.'BF6IWCN:]D:8JN33.U.&C'QQ#K#>-&  .+W
M3K*2'"KI335$<=1/&Q(87O:U[U25B^*U5U7H7H.=[07:*<E<IF8B9B,(QUZ8
M=#V?M5U9VBJ(F8B9QG#5HE60\:>R   !T^W?Z[63U2G]Y3<[D^-M=9IM]?!7
M>JM0>W/$P     *_73X[8_RC2_:1GE>8_P!W'7IZ(>IY?_2SU*NF5@3U1Y8
M       05OQ_2]H]32?A#S/M?^=;ZL]+TOLA^5<ZT=":+/\ T10>IH?P:'HF
M6_)HZL=#SS,_FU]:>E]ID,<      !'&]OZFQ^K8?M)#D>U7P<=>.B77=E?C
M)ZD],/MV@_42A^^5'X9QD=FO@:>6KIEC=I?CJN2GHAW1TSF@      'F9)^K
MMW]15/X)QA9[X>YU*NB6;D?B+?7IZ81)L)_K=\^]T_VTAPG8_P ^[R4^-W7:
M_P RURU>)-QZ0\X
M                  4F^<(NTK:7 [$QR]3+)<:V=G<5T3:>*)?H))(%H='V
M!L;HZ3;S(<J6-ONE=+JM"LNB*[R6A@B>QNO<\>:35/,!*VP547^<#QFCAKL-
MS""+EK:N.KME=*C>#V4ZQS0(JIW4ZR7I[GF!:'K?-\VBG;:<WORM1:N6HHJ%
MKU3BV.)DLJHB_9+(FOF("5T@JYC<BV4=YV]RJU7"-):.KM%=%,Q=-='4[^*:
M]"ITM7N+Q S)[+%P?;=_<*G8JIUM5/2N1.ZVJI9H5UU[GCA>6KH4
M                           4@^<-_LX_/?\ 5X6A#W8R^/\ L'J:X^PY
M0F6H 4
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M>.B77=E?C)ZD],/MV@_42A^^5'X9QD=FO@:>6KIEC=I?CJN2GHAW1TSF@
M   'F9)^KMW]15/X)QA9[X>YU*NB6;D?B+?7IZ81)L)_K=\^]T_VTAPG8_S[
MO)3XW==K_,M<M7B3<>D/.
M                        %$OG"/Z8P/U-<OPE.%H2IV%?B4J/RY6_@:<(
ME9D(4\^<#_4_#ORG4>QT"T/N[ /Q;9-^7%]B0 E;4*O#S3]3LA_)E;['>!EC
MV;/CUP7\IL^T>%Y:U!0                                  !2#YPW^
MSC\]_P!7A:$/=C+X_P"P>IKC[#E"9:@!0
M
M                   JQVX-S?T7V_IL"MT_)>,L?_I:,=H]ELIG(Z373HZU
M_+']DWG3OA,/6[%^V7Z$[7-RBX0\E]S%[:]RN14>RWQHK:5BZ_7(KYM4[DB=
MX$K(A !!>\^2R7*Z4V)6_61E*YLE2UG%7U,B:,8B)T\K7?3=X#S3M1GINW:<
MM1IV=?=JG5'>\?<>E]E\C%JU5F:]&UJ[E,:Y[_B[J4\)QJ/%,=I;7P6JTZZM
MD3ZJ>317>:B<&IX$.UW5D8R>7IM\.NKEG]L'$[USTYS,57.#53R1^V*+[]A>
MZ-5?+G56^>=*">KGDI4;7<B)"^1SF:-ZQ-/%5.!Q><W7O2N_751,[,U53'W\
M-&.CA=ID]Z;KHL44UQ&U%-,3]S'3AIX'G_H)N[Z9J??'_O#%^4;WXZO^3[65
M\WW1Q4_\?V/BFVMW(J*E*R>%9:M%:J5#ZN-TB*SSJ\ROUX:<#'J[/[RJJVIC
M&KCVXQY\613V@W=33LQ.%/%L3AS8/M_03=WTS4^^/_>&1\HWOQU?\GVL?YON
MCBI_X_L/T$W=],U/OC_W@^4;WXZO^3[3YONCBI_X_L3K:8:FGM5#!6*JU<5/
M$RH57<ZK(UB([5W'7CW3TS+4U4VJ8J\Z*8QY<-+S3,U4U7:II\V:IPY,=#[#
M(8X!RF=X119E;>J72&ZTZ*M#5+W'+TL?ITL=W>]TH:/>^ZJ,]:PU5QYL^*>X
MWFZ-ZUY&YCKHGSH\<=U$N$9E<MOKQ-CF1,D;;$DY)X7>,ZFD5?\ *,[[5Z51
M.E/&3P\)NK>ES=MZ;%^)V,=,>C/''<_ZQW>ZWKNRWO*S%^Q,;>&B?2CBGN_]
M)[DL?"=@GXYC_FYOY!W7S_(^\CFGR.&^0Y[W<\\>5&>\&56#(Z:TLLM:VK=3
MOF69&M>WE1Z,T\^U.G13C>TN\,OFJ;<6JMK"9QU]SC=CV:W?F,K5<F[3LXQ&
M&KN\3LL2W"PVWXQ::&LNL<573TL4<T2LE56O:U$5-48J'0[MWUD[66MT57(B
M::8B=$^1SV\=RYR[F;E=-N9BJJ9C3'E>U\)V"?CF/^;F_D&Q^?Y'WD<T^1K_
M )#GO=SSQY7O6>]VN_TBUUHJ6U5(CUC61J.:G.W1531R(O=-GELU:S-&W:JV
MHU-9F<K=R]>Q<C9G6^\RF*  (DWX_HBT>J9/M#A.U_Y5OK3T.Z[(?FW.K'2@
ML\S>E@  ![^*XO?,KJ9Z"RJUJ,8CZETDG5QHQ5T3F1-57CWD4VN[]WW\Y5-%
MKOXSA#5[PWA8R=,5W>]A&,I.M.Q%,WE??+J^1?JH*-B,1/\ K).95_Q$.RRW
M9"F--ZY,]RGRSY'&YGM=5.BU;P[M7DCRN\M&WV'V7E=1VJ%\S>*3U"+42:IW
M463FT7^+H=/EMRY.QYMN,>.=,^'Q.9S.^<Y?\ZY.'%&B/!XW2HB-1$1-$3@B
M)T:&Y:9RFYC'/P:\,8U7.6./1J)JJ_=6&BW]$SD;D1Q1TPWFXIB,];QXYZ)5
MB\CJ_2\G^([^ \9]E7Q3S/9?:T<<'D=6G_,2?XCOX![*OBD]I1QP_B.*6552
M)CGJG%4:BJNGT"L4S.J%YJB-<O[\CJ_2\G^([^ M[*OBGF4]K1QPZ;;VEJF9
MK97.AD:U*A%55:J(B<J^ W.Y;=49VUHGSFGWU<IG)7-,>:M&>U/%@     *_
M73X[8_RC2_:1GE>8_P!W'7IZ(>IY?_2SU*NF5@3U1Y8        05OQ_2]H]
M32?A#S/M?^=;ZL]+TOLA^5<ZT=":+/\ T10>IH?P:'HF6_)HZL=#SS,_FU]:
M>E]ID,<      !'&]OZFQ^K8?M)#D>U7P<=>.B77=E?C)ZD],/MV@_42A^^5
M'X9QD=FO@:>6KIEC=I?CJN2GHAW1TSF@    <WGENO5UQJIHL?<YET>^)8G1
MR]0[1LB*[Q]6Z</":?>]B]>RU5-GS]'#AP\;;[HO6;.9IJO>9IX,>#B1%^@F
M[OIFI]\?^\.#^4;WXZO^3[7>?-]T<5/_ !_8_E^ ;M2L=')-.^-Z*U['7!%:
MK5X*BHLG%%(G<V]IC"9G#_\ 3[5HWQNF)QB(Q_\ S^Q\U)MCN7;U>M!&ZE63
M1'K!6,B5R)T:\KTUTU/C;W!O*WYD;./%7$>-];F_MVW//G:PXZ)GQ/K_ $$W
M=],U/OC_ -X??Y1O?CJ_Y/M?#YONCBI_X_L=1M_BVX%IR)E9D4TS[:D4C7-D
MJ^O;SN3Q?$YW?WC=;FW?O"SF(JOS.QA/[^/@Q:7?.\,A>R\TV(C;QC]S#PX)
M9.Z<,
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MP>IKC[#E"9:@!0
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M>JN3EXKHU/[AQ>]]]U9^*:=C9BF<=>/D=INC<M.0F:MO:FJ,-6'E<2<XZ(
M ):V'_I>[^IH_P (=WV0_.N=6.EPO:_\JWUIZ$ZGICS0    'X5G^J5'WM_V
MJGSN^9/)+Z6O/CE07L3^L5R]1?\ :L/,^R/Q%?4\</2^UWP]'7\4I[/4'F
M      !7ZZ?';'^4:7[2,\KS'^[CKT]$/4\O_I9ZE73*P)ZH\L        (*
MWX_I>T>II/PAYGVO_.M]6>EZ7V0_*N=:.A-%G_HB@]30_@T/1,M^31U8Z'GF
M9_-KZT]+[3(8X      ".-[?U-C]6P_:2'(]JO@XZ\=$NN[*_&3U)Z8?;M!^
MHE#]\J/PSC([-? T\M73+&[2_'5<E/1#NCIG-
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MQ^>_ZO"T(>[&7Q_V#U-<?8<H3+4 *
M
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M>SU!Y@        5^NGQVQ_E&E^TC/*\Q_NXZ]/1#U/+_ .EGJ5=,K GJCRP
M       @K?C^E[1ZFD_"'F?:_P#.M]6>EZ7V0_*N=:.A-%G_ *(H/4T/X-#T
M3+?DT=6.AYYF?S:^M/2^TR&.    "/MSLZN^%^Y7N7#33>7>4=;Y2V1^G4]5
MR\O(]GUZZZG*[_WO>R'L_9Q3.WM8[6/!L\4QQNJW#NFUGO:>TFJ-C9PV<.':
MXXGB1_\ #IEOI*W?S4_HYROU;F_1HYJO[G4_264]*OGI_M>)E.YE^RZV):KE
M3TD5.DK9D=3LE:_F8BHB:OE>FGC=XUN\-_7\[:]G7%,1CCHB?',MEN_<5C)7
M?:435,X8:9CQ1#]<;W3R#%[3%9K?34<E+"Y[FOG9*Z361RN756RM3I7O'TR/
M:#,92U%JBFF8C'7$XZ?YH?//=G\OF[LW:ZJHF<-4QAH_EEZWPZ9;Z2MW\U/Z
M.9WU;F_1HYJO[F#])93TJ^>G^U(FV6;77,X+C+=(:>%U&^)L24S7M14D1RKS
M<[W_ %IUNX=ZW<]37-R*8V<-6/#CQS+D]_;JM9&JB+<U3M8Z\.##BB'>G3N8
M
M                                                        !2#Y
MPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H 4
M
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MHA'!R#K0   L/LDB?H=(O=6MFU_Q(SUCLI\'/7GHAY1VJ^,CJ1TRD@Z]R(
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MI[/4'F        !7ZZ?';'^4:7[2,\KS'^[CKT]$/4\O_I9ZE73*P)ZH\L
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MT+J
M
M          %(/G#?[./SW_5X6A#W8R^/^P>IKC[#E"9:@!0
M
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M(WAFHS68JNQ&&UP=[![!L&O
M
M                              *0?.&_V<?GO^KPM"'NQE\?]@]37'V'
M*$RU "@
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M +53YW?,GDE]+7GQRH+V)_6*Y>HO^U8>9]D?B*^IXX>E]KOAZ.OXI3V>H/,
M     ("J-WL[CGEC924ZL8]S6_Z/)T(NB?5GEM?:7/15,133ZL^5ZC1V;R,T
MQ.U5ZT>1^?PPY[Z4IO6TO\LK]39_T:?5GRK?3.0]*KUH\CDI[[?JC)4RN2F3
MW42:.H1$B?U7/$B(GBZZZ>+WS15YN_5F?U$T_?QB=4X:&]HREBG+?IXJ^YA,
M:XQTNM^&'/?2E-ZVE_EF]^IL_P"C3ZL^5HOIG(>E5ZT>0^&'/?2E-ZVE_ECZ
MFS_HT^K/E/IG(>E5ZT>18$]4>6
M
M  IMVU]XLOPF^8EB^%WBHLM6V*2]UT]'*L<DB.>ZGIV/1%\:/5DRN8]%:Y=.
M'BA:(2CV4=QMPMS]OZS(\]EIJCJJYU#;:J&!*>>9D$;72R2\CNK7QG\K>2-O
MG7:Z\ B4\!                                        *0?.&_V<?G
MO^KPM"'NQE\?]@]37'V'*$RU "@
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M7+5XG?\ 9#S[O)3XT@X+^IMB]10_:(=5NCX.UU(Z'*[V^,N]>>ET!M6J
M   <7NQ\7]W_ /#>RHCG>T?^ON?R_CI=#V=^/M_S?@J>+L7^J5;^49?P$!KN
MR7PE77G\-+8]K?BZ>I'XJDG'9N-       ?A6?ZI4?>W_:J?.[YD\DOI:\^.
M5!>Q/ZQ7+U%_VK#S/LC\17U/'#TOM=\/1U_%*>SU!Y@
M
M                               %/.V]LUD&5Q6O<S&*1]PELU(ZWWNC
MA17SMHV2.FBF8Q.+FL=))UFG%$5%TT1RH6B7/]BW?7$L?L%3MAE]?#:*GRQ]
M99*ZJ<V&FF;4HU'P.D=HULB/;S-YE\;FT3BB:B87@AFBJ(F3P2-EAD1'1R,5
M'-<U>**BIP5%"K^P                                      !2#YPW
M^SC\]_U>%H0]V,OC_L'J:X^PY0F6H 4
M
M B#<WM+[4;7)-2W2[)=<@BX>XEIY:JI1_1I*Y')'%IW4D>CM.A%"<%+-VNTM
MN)OU3S838[''08O4/CD?;::-:VLDZJ5KXWS5#FHC$:Y&\8VL3N.54/E=NT6Z
M9JKF*8CAE]K5JJY5%-$35,\$*\U5+44-3-1U<:PU5.]T4T3N#FO8NBHOF*7I
MJBJ(F-,2K53-,X3KA^19   O'V#,<]RI[[>ZZFTK;S1M6@F<NCF4=-,U'^*J
M=$SY&KKKT1IT\QJZ-X45YN<M3&,TT[4SQ:8T>'%L;F[ZZ<I&8F<(JJV8CCT3
MI\&"[1M&J      K]MC\9M5_XW[93RO<'^SJ_G>I[^_UE/\ (DS<_*4QG&I4
MIW\MSN'-34>BZ.;JGW21/XK5X>%4.RW_ +P_29:<)^_7HI\<][IP<=N'=_ZK
M,QC'W*--7BCO]&+E-DL6ZFGGRJK9X]0BT]OU3HC:NDCT\U4Y4\Q>^:+LIN_9
MIG,51KT4\G#/BYV\[5;PVJHR],ZM-7+P1X^9,!W[@0               !#V
M_?\ JEC^^5'VL9P';#S+7+5XG?\ 9#S[O)3XT@X+^IMB]10_:(=5NCX.UU(Z
M'*[V^,N]>>ET!M6J       <7NQ\7]W_ /#>RHCG>T?^ON?R_CI=#V=^/M_S
M?@J>+L7^J5;^49?P$!KNR7PE77G\-+8]K?BZ>I'XJDG'9N-    !YF17?W L
ME;>>I\H\CC67J>;J^;1433FT=IT]XPL[F?TUBJ[AM;,8X:F;DLM^IOTVL<-J
M<,=:*OA]_P#I[_;?^X.)^L?_ (_U_P"+MOH__P"W]'^3^)M^>MADB_1_3G:K
M=?+-=.9-/\P4J[7[43'L?Z_\5J>R&$Q/M?Z/\G"X)F?Z%7&IK_(O+O*(>HZO
MK>IY?':[77D?KT=XYK=&]/T%RJO9V\8PUX</)+I=[[K_ %]NFC:V,)QU8\'+
M#O?A]_\ I[_;?^X.H^L?_C_7_BYCZ/\ _M_1_D]?&-XOTCOU%9/<7R;RMSF]
M?Y5UG+RL<_SO4MUZ.^9V0[3?JK]-KV>SM<.UCP8^C# S_9G]+8JN^TVMG@V<
M.'#TI2B=JXL
M                                                         J5V
MV]R<[V]_07]"K[4V7W1]UO+O)5:WK?)_(NKYM47SO6/T\T+0H'=KK7WRXU%V
MNDJ3W"K>LE1,C&1J]Z]+E2-K4U7I5=.*\0L^BUY+D=CX62\5MM37F_T.IEI_
M&Z-?N;F\>('J_";N3^V-\]\ZOT4(/A-W)_;&^>^=7Z*!)G9ZS_.[GO5A=!<L
MHN]90U%Q8R>EJ*^IEBD;R.X.8^145/-0$M2 H
M            I!\X;_9Q^>_ZO"T(>[&7Q_V#U-<?8<H3+4 *
M
M          JWOOVQK'MW756)8'30Y!EE*KHJVLF<ON;1RIP5B]6J.FD:O!S6
MN:UJ\%=S(K4)B%1[_P!J7??(9WRSYA54,3E7DI[8R*A8Q-471%A8UZZ:=+G*
MOA"V#[L7[7&^V,U#)'Y'[M4C=.>BN\,=2Q^G?D1&3)_@RH#!=;8;M08IO*K;
M%5PI8LY8Q7NM4C^>&I:Q-7/I9%1%=HGC.C<G,U/KD17!683K++%!$^:9[8X8
MVJ^21ZHUK6M35555X(B($*][F]L?:G!.MH;%4+F%^9JU*>UO;Y$UW_25BHYF
MGWI)%[Z($X*NW;>+M)]I"XRX_AU/54UGD5&2VVPM=2TK&NX?Z76O<BZ*G2DD
MK6+W&A;4E';'L&4T74W/=>\+._Q7K8;0Y61]_EFJG(CE[RI$UO@>$8K7X[MM
M@.)V9,?Q['+?16CQ5?3-@8_K7,UY72ND1SI')KYZ1SG>$^5VS1=IV:Z8JCBF
M,8\+Z6KURU5M4533/'$X="#.T'V2;-N5_P#S-@:4MAS&*/EGIN1(:&O:Q/%1
MZ1I]SE1$T21&\>AW<5+444T4Q33$1$<$:E:KE5=4U53,S/#.M13+=H-SL&JI
M*7)\5N-%U:JGE*0/GI7:+IXE1"CXG?X+RP\2UX9E]\J6T5FL%QN%6]41L%+2
M3S/55Z.#&*HB8DF,%IMD.Q1D%TKZ;(=W8_<NQPN;*S'62(ZLJM%U1L[HU5(8
MU^J1'=8O1XG22K,KTVO',>LBM6S6FCM[FQI UU)3Q0*D2::,U8U/%\5.'@,:
MC*V:*YKIHIBJ=<Q$1,\LOO7F;U=$455U33&J)F9B.2'IF2Q@ !YF15D]NQ^[
M7"E<C:JDHZB>!RHCD22*)SFKHO!>*&'G;M5K+W*Z==--4QRQ$LS)6J;N8MT5
M:JJJ8GDF85]^%_._3T?K>'^2>5?4N>]*/5CR/5/IK(^C/K3Y3X7\[]/1^MX?
MY(^I<]Z4>K'D/IK(^C/K3Y7-VG)+M9+L^]VZ5L=P?UG-(K&O3[JNKO%<BIQ-
M/EL]=R]WVM$X5:>#C;?,9&U?M>RKC&G1P\3^LARB]934Q55ZJ.OE@9U<2-:V
M-K6JNJZ-:B)JJ]*EL[O"]FZHJNSC,1A' C)9"SE*9IM1A$SC/"ZW#]QLJ2Z6
M*P-J8F6M:FEH^I;!$GW%TC8U3FY===%Z>DWN[-]YKVMJSC&QM4TX;,:L8AHM
MY[DROLKM[9G;V:JL=J=>$RL4>M/)@               !#V_?^J6/[Y4?:QG
M =L/,M<M7B=_V0\^[R4^-(."_J;8O44/VB'5;H^#M=2.ARN]OC+O7GI= ;5J
M@      '%[L?%_=__#>RHCG>T?\ K[G\OXZ70]G?C[?\WX*GB[%_JE6_E&7\
M! :[LE\)5UY_#2V/:WXNGJ1^*I)QV;C0    ?E4TU/60/IJN%E132IRR0RM1
M[')WE:Y%12E=NFNF::HB8G@G3"]%=5%454S,3'#&MY7Z'XE^(;=ZS@_D&#\L
MRGNJ/4I\C.^9YOWM?KU>4_0_$OQ#;O6<'\@?+,I[JCU*?(?,\W[VOUZO*?H?
MB7XAMWK.#^0/EF4]U1ZE/D/F>;][7Z]7E/T/Q+\0V[UG!_('RS*>ZH]2GR'S
M/-^]K]>KROVI<:QRAG9545GHJ:JC76.>&FBCD:JIIP<UJ*G!3Z6\AEK=454V
MZ*9CABF(GH?.YGLS<IFFJY75$\$U3,=+U#-80
M
M                        _B::*GB?//(V*&-%=)(]4:UK4XJJJO!$0"-;
MUVB-D;!.ZFN.<6M9V.Y'LI)5K>5W'5%6E;*B*FG'O!.#XJ3M/;"ULR00YQ0M
M>O0L[*BG9Q5$XOEB8U.GO@P2/8\CQ[)Z3W0QN[4=XH==/*;?41546O>YHG.3
M4(>F                                     I!\X;_9Q^>_ZO"T(>[&
M7Q_V#U-<?8<H3+4 *
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M8V<<<8PUX)%.M<F
M
M           #GLXS2P[>XM<LPR6?J+1;(EEEY=%DD>J\K(HVJJ:OD<J,:FO2
MO'1.(&7^[V_6X&]E[?3U$\]+CLDJ,M>+T3GK"B<WW/K&LT6>9?KG)T^=1J<
MO$/KQSLH[\9+!'5P8I+;Z65&JV2Z304+T1VG3#,])4T1=5UC_N@Q>K<NQIO[
M01K+#8J:X(U.9S:2OI>;ATZ)-)&JKX$!BC6&3<S9?*8ZAC;GB&44R<S.L8^F
M>^-5[K7IRRQN[RHYCO"!HWV;-_J7>O&YH;DQE)F]F:QMXI8_%BF8_5&5,**J
MKRNTT>WZAW@5NI683@$                                   *0?.&_
MV<?GO^KPM"'NQE\?]@]37'V'*$RU "@
M                                                   4$^<#K:J3
M,,.MST=Y%3VRHJ(57SO6U%0C)-.'3I$S7CW@M"GH6   #07L UM3)MYE% _7
MR2GO*30JO1SSTL2/1/H1M7Z(5E;@*@ ".-[?U-C]6P_:2'(]JO@XZ\=$NN[*
M_&3U)Z85W/)GJX   2/LE^N4GJ*;[>,Z_LK\9/4GIAR7:KX..O'1*Q!ZP\G?
M+47*W4FOE=7#!IT];(QG1_&5#XUW[='G51'+,/M18N5^;3,\D2\NHS?$*77K
MKY1:IP5K)V2*BZZ=#%53!KWKDZ-=VCUHGH9U&ZLW7JM5^K,=+E\JW*PJIQ^[
M6ZEN:3UE51U$$$<<4RHKY8G,:G-R<J<5[YIMX;]R567N44UXU54U1&BK7,3'
M%@W.[]Q9VG,6ZZJ,*::J9G33JB8GCQ5V/)7K    >UA_ZVV'\HT?X=AL=V?%
MVNO1^*&OWG\)=ZE?X96U/=GA0             "+MR*+<2HOE._$75:6U*1C
M94IIFQ,Z_K)%75%>WCRJWB<5ORUO&J_$Y;:V=F-4X:<9[O%@[3<=W=]-B8S.
MSM;4ZXQT81W./%Q_N7O;_G+CZZ9Z(:#]/OOCK]:/*W_ZC<O%1ZL^1Y]SQ#=:
M]-C;=J6KK6PJJQ)//&]&J[37363AKH8M_=F];^'M*:JL-6-43XV58WENJQC[
M.JFG'BIF/$^JFL6\M'3QTM*E?#30M1D43*EC6M:W@B(B2<$0^UO*;YHIBFG;
MB(U1M1Y7QKS>YZZIJJV)F=<[,^1^WN7O;_G+CZZ9Z(?3]/OOCK]:/*^?ZC<O
M%1ZL^1+.W\.108ZR/*%E6Z];(KEJ'I(_D54Y?&15.ZW-3F*<O$9C';QG7.,X
M.&WS5EZLQ,Y?#8PC5&$8NH-TTH
M
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M7A:$/=C+X_[!ZFN/L.4)EJ %
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M+\7*ZXB8F*9PT3$\N.&J<=&$\3(OV9MT43,3$U1CIB8Y,,=<8:<8XUC3,88
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MX=AL=V?%VNO1^*&OWG\)=ZE?X96U/=GA0
M
M
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M      4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
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M\)=ZE?X96U/=GA0
M
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MSC\]_P!7A:$/=C+X_P"P>IKC[#E"9:@!0
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MW>T&=NT3155&%43$_=C5+LSH7/
M
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M_P!@]37'V'*$RU "@
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MA9/:947/[.J<47RG1?\ PLII^SL8;PM_S?@J;?M%..[[G\OXJ5G#V1XX
M          R;[3<<T6_.<-G75ZUZ/1555\1\$;F)Q[S50K3,3J?68F-:)BR
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MP)ZH\L
M
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M:&1EJJ:;M,U>;%48\F.E!7Z";N^F:GWQ_P"\/,_E&]^.K_D^UZ7\WW1Q4_\
M']A^@F[OIFI]\?\ O!\HWOQU?\GVGS?='%3_ ,?V/B@VMW(I9UJJ6%8:E==9
MHZN-DB\W3XR/1>)CT=G]Y45;5,83QQ7&/2R*^T&[JZ=FJ<8XIHG#H?;^@F[O
MIFI]\?\ O#(^4;WXZO\ D^UC_-]T<5/_ !_8]3&\-W.HK_;:NZ3SNMT-1&^J
M:ZNZQJQM<BNU;UBZ\.X9N1W7O.C,457)G9BJ,?OXZ.3%A9[>>[*\O73;B-J:
M9P^YAIY<$VGH[SD
M
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MA$ZIB>'N)/.T<8
M
M
M    *'?. 8G5QY!B><LC5U#4T<EEGE37E9+32OJ8FN[FKTFD5O\ %4+0LEV7
MLAMV1;&8A+0/:KK=2):ZR)O3'442K&Y')W%<B-D\QR*$2E\(
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M7A:$/=C+X_[!ZFN/L.4)EJ %
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M;E..%48Z7PF,R0   M%MC^HEF^]R?AGGM6X/@;?)/3+Q??WQUSECHAUIO6B
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MD3NH=EN+(7LG:JINS$S-6.B<>"'';\S]G-W::K43$13AIC#AEVIT3G0
M
M
M                                            !R&Y^(8CG&#W>P9P
MZ.''9872SUTKVP^1NB17-J6R/\5CHE\;5W#N.U:JH!FQAF[^0=GG-;S1;<W^
MERK$9)^21)H9V4-:QG!LJ1OZM\<K4\7G8NB]][= O@GZC^<)HUIV>7X%*E4B
M:2=1<VK&J]].:F14U[W'S0C!^_\ Q"+/^P=3[Y1^UP8'_$(L_P"P=3[Y1^UP
M8.GVZ[:UKW!S>R87#AU102WJI2E;6/KF2MC5R*O,K$@;KT=\(P6J"
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MJFKN;@4F5I0@     "D'SAO]G'Y[_J\+0A[L9?'_ &#U-<?8<H3+4 *
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MU7,&F;D   +1;8_J)9OO<GX9Y[5N#X&WR3TR\7W]\=<Y8Z(=:;UH@
M
M
M                                                     *5]OC<*
MXT5+C^VM!,Z&BN+'7>\(U519HXI.KIXUTZ6(]LCU3ZY&KW M"&=C>R?E>\-H
M;E59<XL=Q*1[XJ6KDB6JJ:ET3E8]8H4=&G(CD5BO<]/&3@BA,RG6/YOO$D8U
M)<SN+I$3QW-I8&M5? BN=I],(Q?U_P /S#_VQN?K>G_A!B?\/S#_ -L;GZWI
M_P"$&+I=O^Q;C&W^9V;,Z/**^LJK-4)514LL$+8Y'(BIHY6KJB<0C%9X(
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M8B-:G0U$T1"\1$:E)F9UO])0
M
M
M                        !G]\X!8JJ#.\5R96KY%76A]M8_ZE):&IDF<G
MFZ530M"U79HN-NN>Q6$36U6]3#;VTLS6]RHIGNBFU3N*KVN7Z(1*5P@
M                                  %(/G#?[./SW_5X6A#W8R^/^P>I
MKC[#E"9:@!0                                               "@
M?;+W@JLTRFEV9PU[JNAM]3&RZMI=7NJ[N]W)'3-1OGDA5=-$Z9%TZ6(1AI7C
M4M+V?-GJ/9K *:R/1DF2U_+69#5MT7GJG-X1-=W8X4\1O?XN^J)5F4KA
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M5.,S+M*J*:+<TTQA$0N6?H!X
M
M
M                                     $%=J6#:B\X1#BVY=^AQVON+
MI:K%[E+#-.Z*LHT8CW(D+'JK-)FLD:NFK7<.*(J$PI=LAVBLBV$N5?8>2')<
M+GJ'/GHX97L:DJ)R>44DKV:MYT1O,U\?C(B<&KQ"TPM?;NW/LI64[9:R.\6Z
M?1.>">C9(J+W='0RR(J?2"N#[/EM[%>F[GZP?_*!@?+;V*]-W/U@_P#E P>U
MB/:RV@S;);;BEBJ:]]WNLR4](V:C?'&LBHJ^,Y5X)P!@G$(
M                      4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
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MM:ES?62FF?\ R4ZEHSVIXL
M
M
M                                  %>^U!L!DF^?Z*_H]<Z&W>X/NAY
M3Y?UR<_EODO)R=5&_HZAVNO?0)B5>_D [D_M-8_IU?H 3B?(!W)_::Q_3J_0
M 8GR =R?VFL?TZOT &)\@'<G]IK'].K] !B[':CL8YW@&XN.YE<K_:*FALU6
MVJGIZ=:GK7M1KDT;SPM37CW5!BNN%0
M    %(/G#?[./SW_ %>%H0]V,OC_ +!ZFN/L.4)EJ %
M                             ^*\7>VV"U5M[O%2RDM5OADJJRJE71D<
M,35<YR^8B 9HU=1DW:\WZ:V))*6Q.=U<#%XI;[)3.5=5XJG6/U5R\>,CN'#0
M^==>SJUSJ?>BC'7JC6TKL5DMF-6:@Q^RT[:6TVV".EHZ=B:(R*)J-:GF\.*]
MU2U,81@^54XSB] LJ
M
M
M                                             !X>19GA^(>3?I9D
M-LL/EG/Y'[J5E/1==U7+S]7U[V<W+SMYN7HU3O@>'\,^SW[P<:]^:#T8&!\,
M^SW[P<:]^:#T8&!\,^SW[P<:]^:#T8&!\,^SW[P<:]^:#T8&#Z[;NIMA>:^"
MUV?-;#<+G5.ZNFHJ2Z4<\\KUX\K(XY7.<O@1 .M
M               I!\X;_9Q^>_ZO"T(>[&7Q_P!@]37'V'*$RU "@
M                                      48[;6]+[A61;+XM,Z1D3XI
MLF?!XW6SKH^"C3EXKRJJ22(GU7*G2UR$3*U,)L[*NS$>UF",N5TA:F7Y"QE3
M<9-/&BA\]%!KQ\ZBZKX3%L?^2?:<$^;R<?\ -KY,&3?^Y_X^+SN7B_EU<N/<
M3V9;$
M
M
M                                   51[:6U>X&YGZ$?H+9);Q[E^ZO
ME_520Q]5Y3Y%U6O7/9KS=4_H[P6A5'Y*^_\ ^Q-3ZXH_1PG$^2OO_P#L34^N
M*/T<&+\YNR[OY3QK*_"*Q6IIJD<M+([C]BR9R_W 8HZR+$\GQ&L2WY59JVRU
MKD5S(+A3R4SW-3ZIJ2-;S)QZ4X!*QW9HV!SFIS'#MTK?/;*_#Z2L2HJ*BEK&
MOE8C&JCF.B5J.;(U7)JQR(H5F6BX5
M    4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
M                        !%?: W?HMF]OZN^HYC\CKN:BQZD=HO/6/:OW
M1S>.L<*?=']Q>#==7($Q"GG9,VDK=S<YGW(R]KZVU6^=U6^:IU>M7<'O5RO<
MKO/>-JJKW]>ZAKK\^UK]C&K77U>"G^;\,3QPV5F/94>VG7JHY>&K^7\4QQ2T
M7Z#8M8
M
M
M                                         !R&Y>W&-;IXG6XIDM,R
M6&H8Y:.KY46>DJ=/$GA<O%KFKWO/)JU>"J@% ^R]G5]VBWO=MY=Y%2V7FXOQ
MV\46NK&7**5U/!*Q%T\9)ON:_8N7O(%Y:5A0
M          !2#YPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H 4
M                              /PK:VDMU'47"OF934-)$^HJJB5R-CC
MBB:KWO<Y>"(U$554#,3<O,+]VH-Z(:*RI*N/Q2>16&FT5%BH&O1'SN:O!))E
MT<NO=5C%7@8F:S$6+<U3IG5$<<SJB.5FY7+S>KBF-'#,\41KF>1HOMQ@UKVZ
MQ"VXM:HFQQ4D34F<WCSRZ)S*JKQ7O:KQ7N\2,I8FU1][375IJGCGR1JCN0C-
MWXNU_=T44Z*8XH\LZY[LNK,QA@
M
M
M
M ?A75M';:.HN-PG934%)&^>IJ)7(R..*-JN<]SEX(B(FJJ!DW17C].NT92WZ
MSL5&7_,HJR@9RHCDCJKFDD?,BHU-4:J*Y5T[ZA=K6%
M                 %(/G#?[./SW_5X6A#W8R^/^P>IKC[#E"9:@!0
M                                     ICVW-[5H*1FSN,U/^G5S63Y
M1+$OC1T[M'PTFJ<463A)(GUG*G0]0M$/?['>RWZ*65V;7RGY;S7)]P:_I9P5
M-$_B(JI_&5WUJ&BR\_J[\W?_ %V\8H_BJU55=[S:>_+=YB/TECV7_LN837W*
M==-/?\ZKO0M>;UH@
M
M
M                                               !5_M@[S;@;1?H
M9^@M?%0^['NGY?UM/#4\_DGD?5:=<UW+IUS^CI"8A5_Y9N__ ./Z;WNH_0@M
M@?+-W_\ Q_3>]U'Z$# ^6;O_ /C^F][J/T(&#B<YW[W<W'H5M>79/45=I<NK
M[? R&BIWZ+JB2,I8XDD1%Z.LY@8)[[&6P]\JLHIMV,HH9*&Q6MCG8_%4L5CZ
MRJF8Z/KFM=QZJ)JJK7:>,]6\NO*H1,K]A4
M        !2#YPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H 4
M                           1]O1NG:]H,!N&6URLEKT3R:S4+UT6IKY4
M7JX^''E317O7N,:O="84$V%V^OV].Y4N6Y%))5K)6/K:JLE1%26J<[K))%3H
MY8M45$X)S<K4X<#1;SOUU33EK4_?N:Y]&C]ZKQ1W6^W;9HIBK,W8^Y;U1Z5?
M[M/CGN-,Z"AI;914]OHHTBI*:-L4,:=QK4T3S5[ZFWLV:;5$441A33&$-+>O
M57:YKKG&:IQE])]GR
M
M
M                                               <GF.YV [?2TD.
M:7^ELLM>U[Z-M4YS5D;$K4>K=$7HYD ^_$\RQ?.K6MZQ&Z0W>U-E=3NJJ955
MB2QHU7-XHG%$<@'Q9EMM@FX7D7Z:V*FO7N=UOD/E2.=U7E')UG+HJ>>ZMFOF
M <K\FS8K]A;9_B/_ )83B?)LV*_86V?XC_Y8,3Y-FQ7["VS_ !'_ ,L&+U['
MLEM%CE1'66;"K/3UD2\T52M'%+*QVNNK7RHYS5\**#%WH0
M                      4@^<-_LX_/?]7A:$/=C+X_[!ZFN/L.4)EJ %
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M]H
M
M
M                                 "B7SA'],8'ZFN7X2G"T)4["OQ*5
M'Y<K?P-.$2LR$                                          *0?.&
M_P!G'Y[_ *O"T(>[&7Q_V#U-<?8<H3+4 *
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M$4;>UCAQQAH3<=8Y0
M
M
M                                                HE\X1_3&!^IK
ME^$IPM"5.PK\2E1^7*W\#3A$K,A
M         "D'SAO]G'Y[_J\+0A[L9?'_ &#U-<?8<H3+4 *
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M8,EB@
M
M
M                                   %$OG"/Z8P/U-<OPE.%H5XP7?W
M=K;2R.QW"<A]R[,Z=]6ZF\BH:G6:5&M<[GJ()'\48WAS:!.#IOE?=HG]LO\
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MYHT],+K&4Q
M
M
M                                         "B7SA'],8'ZFN7X2G"T
M/4[)&R&UFX6U<U^S+'(;K=VW:JIFU4DM1&Y(8XH7-;I%*Q."N7N F4\?)7V
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MSWHTX0ZKM%E*,KEK%JG53M=^=&,K G=.%
M
M
M
M    *)?.$?TQ@?J:Y?A*<+0E3L*_$I4?ERM_ TX1*S(0
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MT_VTAV?8_P ^[R4^-QO:_P RURU>)-QZ0\X
M
M
M
M      *U]J7L]YIO=7XU58I76NCCLT-7%5)=):B)SG5+HG-Y.HIY]43D7770
M)B7:=FW:K(=G=O)<2R:IHJNXON-17)+;9)98.JFCB:U-9HH7<VK%U\7Z()3
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MT:J9N4W?E\K,S:IV=K7K\;!S6\,QFHB+M6UAJU>)[!L&
M
M
M
M
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M8SQ=QZAFL(
M
M
M
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M&8N1A3'F]V>/DC@[K3RS_P!$4'J:'\&AVN6_)HZL=#B<S^;7UIZ7VF0QP
M
M
M
M
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MCYATE%,4TQ3&J'.5U355-4ZY?H65
M
M
M
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MX:<%<G#75>.G0NGTBU5-$UX:(G!2:Z8JV<=+[SYK@
M
M
M
M                                                         XW=
MC$*[/MNLBPVV3PTU=>:5:6&HJ>9(F*Y[55SN1KEX(G<0"(=I>QMMWM]407K)
M7KEV1P*U\3ZN-([?!(G%'1TVKN94[CI7.[Z-:H3BA3YP)$3,,.1$T1+94:)_
MUZ!,(Z[&7Q_V#U-<?8<H3+4 **^=M.LEIMA+O#'YRLK;?!+QT\5M2V;Z/C1H
M$PS%"[:K'*=E)CUHI8U58X**FB8KN+E:R)K4UTTX\ ^:NG;OIV3;,4$CE5'4
M]_HY6:="N6FJX^/@T>H3#.FVULEMN-)<8M5EI)HZAB(O*O-$]'IQT73H"[9/
M/JR6W8+D]P@X34EIKYXUUT\:*FD<G%/"@?-C&'T:D=CNG9#V>L4D:JJZH?<I
M7Z]".2Y5,?#P:,0*2[C>^G94[-;@1R*J-;CMUE3EZ>:*CDD3IUX:MX@AC^%V
MLO9FK9*_8?!IY->9EO6G35=?%III(6]Q.XQ I+M<^RK]!L)O^8>2>7^X=#/7
M^1=9U'7=0Q7\G6<C^773IY5\P(5#_P"(;_\ CC_SO_Y>%L#_ (AO_P"./_._
M_EX,' ;S=K==WL$J<8BQE<>J'3Q.;.VX>6K)&O-UC>7R:#E31-%75>G33NF+
M=L1<KHJG]R9GOX3'C95F]-NBNF/WXB/#$^)6 RF.   %ROF_[N_](\LL+W:Q
M^11UT#-.AW6LBD77P_<_I&--B/;1=X=F:?#$QS:>=]_;S[&;?!M15X)CPZ.9
M?,R6(    "*\Y[1NSFWM3);[_DT$EVA562VVWM?75#'ITMD2!'-C=X)'-"<'
M!T?;AV.JJA(9Y+M11KTU,]#S1IQ[T,DC_P#D@P33AFXN#;AT;J_"[]27F!B(
MLS*>3[M%KT=;"_EDCU^S:@0^K+\QQK [#4Y+EEQBMEGI4\>>9>+GJBJV.-J:
MN>]VGBL:BJH&>>\_:.SG?JZ/PK!Z:HMN&2.5&VZ->6JK6M5/NE8]J\K8TZ>K
M1>1/JE<NBI\;U^BS1-=<Q33'"R+-BN[7%%$;54\"9NSOV3J&RI39?G$:55?H
MCZ:F<BHQ->.K4714;W.94YG=SE3SVDHB[G]-4318X(U55];BI[FN>'0W-R;6
M0T4S%=[AG731R<=7=U1P:5P(HHH(F00,;%#&U&1QL1&M:UJ:(B(G!$1#?TTQ
M3$1$81#05535,S,XS+^RRH!_$TT5/#)43O2.")KI)9'+HUK&IJJJJ]"(A,1,
MSA")G#2I-D&Z-RK]S_T^H7.1E%4-;;H7*K4\BB56I&O>ZQJN5Z=]RGH-G(4T
MY;V,\,:>7['(W,U,WO:1P:N1<ZS7:BOMJH[S;G]90UT+*B!W=Y9$UT7O*G0J
M=Q3@;EN;=4TU:X=917%=,51JE]Q\UP
M
M
M
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MHJUZXY/L3*:%M@
M
M
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MB:IQUDU_N@ADT%VPNS=BEQK:C"['.WDJJ2ST25+./BSOA:^5./>>YP?.7<
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M?I*>:UT315-,ZX=K35%41,:I?446
M
M
M
M             *"?.!_KCAWY,J/9"!:$==C+X_[!ZFN/L.4)EJ %'Q7BU45]
MM%?8[DSK;=<Z::BJXOKH:B-8WM[O2UR@8][E[?WK;#-+IAM\C5*B@E7R:H5.
M5E32N5>IG9]B]O'P+JB\44+IQV$[7E9M-BS<)R*R/OEBI'R26J>GG2&I@29R
MR.B<CVN:]BO<YS>+5;JO2FFA$PC#?+>N^;W97'?KE3-MUKH8EIK1:8WK*V")
MSN9SG/5&\\CU\\[E;P1$TX!,0F/L-[75=]S>?<NX4ZI8\<9)!;I7IXLMRJ&<
MB\NO2D43W.7O.<P(EH8%68?:[VJK=O\ =&OR"G@7]&,MFDN5#4-3Q&5<B\U5
M JIP1R2.5[4^L<G>4+P\3L^]H.[;&72X:6]+QC=X2/W0MRRK#(V2'F1DL+]'
M(CD1RHY%;XR:<4T103#W^T+VH[EO504F,VJUNL>*4TR54\,DW75-5.Q%1BR*
MUK6M8SF71B:\?&5>":"(<5V?]KZS=?<RT6%(%DL5)*ROR";3Q&4$#T<]JJO=
ME72)OA=KIHB@EK:B(B(B)HB="!0   .+W*Q"Y9C:J2AMDL$4T%1USUJ7/:U6
M\CF\%8QZZZKWCG=^[MN9ZU31;F(F*L=./%/%$NBW'O*WD;M5=R)F)IPT8<<<
M<PAG).S%<<LH?<^^.ME1$B\T4G6U#98W?7,>D&J+W^XO=.=R.XMXY.O:M5T1
MQQC5A/+&S]KH<]OW=V<HV;E%?<G"G&.2=K[%2=_.S\_8Y]G?77E*Z._>5>Y\
M,,?6.8M$D/.DLCNIZ>O;R\L:]WZ/<V)OS'_EBF)_AJF>FF'$WHLX_P#BFJ8_
MBIB.BJ?$X_:';1V[.94>%4ER2W7*L;-+'++#UD'5TT2RNU<U_,BJC51/$4^U
MR:XC[D1,]V</%+Y6XHQ^_,Q'<C'QQTKI8=V1JC"F*^V36^:XO;RRW"HEF?.K
M577E32G1&IX&HFO=U.-WENS>>=T55VZ:/1B:O#]W3^VAU^[MY[MR>FFBY57Z
M4Q3X/O:/VTI?VYVWN^)W*MJ;Q+1U-+5TRTW50.DDUYGM54<DD;$T5$4^VXMR
MW\C>JKKFF<8P^[,\<3PQ#X[]WU8SUJFBB*HF)Q^]$<4\4R\7/.SMCF0=;<,6
M<VQW9VKEIT15H9'>%B<8_-9P^Q/4,IOFY;T7/O1X?M><9C=M%>FC[L^!$E#D
M>Z^QU>RW7*&1;.KEY*.JUGH)4XZK!*U?$7NZ,<GV33>5V<KGZ=JGSN.-??:N
MFY?RLX3J\'>3KA^[>!;D0QVNO9%27:3@MIN2,>V1R\-(7N3EDU[B<'?8G*9_
M<U5$3MTQ<HY,>>'09/><3.-%4T5<N'A<YOKM5C,VU^75UHHGTMTBME3)3Q4S
MU1DDB,7E:K'<R<5X>+H<=5N?*6+E-^FG8FF8U3HTZ-7?X,'5T[WS=^W-BJK:
MBJ.&-.C3K[W#BRT.A:(   )2[-] ^X;Y8/$U'*V&YPU+U;]2E/K)JJZ+HFK4
M3Z)\KER*(QGCB.><%Z+<US,1Q3/-&+6L^KX/RJ:JFHJ>2JK)HZ>EB3FEGF<D
M<;&]]SG*B(GFEJ:9JG"(QE$S$1C*(<O[1F&V'K*:PM??[@WAS0KU5(CO#*Y%
M5W^ UR+WS>9?<UZYIK^Y'AYFKO;RMT:*?O3X$0U.8;R;P5$E!:(YVVQR\DE-
M;FK34;$73A-.Y>/#CROD\Q#>4Y;*9.,:L,>[IGO1]C5S>S&9G"G5W-3PL]VR
M=MU;+?[MW*.HR.Y.5[+=2HJQ0T\:>,]\CM%<JN5&M1&HG3Q70R<IGOU-4[,8
M4T\,\,OAF,K[&F-J?O3P(_-FP@ !/VP,^+9515N"97;*2OFI^:LM4E1$U9>J
M<OW:-LFB.3E<O.FB_5.[QS.]XNVIB[;JF,=$^)N]WS1<B;=<1/$[N^]FO!+E
MS26B6KL\R\6MCD\H@37OLFU=_P#K$-;:WW?I\["KP='D9ES=EJK5C".+IV;\
M\LDR5F,W.GKWQKK$Z*1]#5:]S3F56I_.FVM[ZL5QA73,>&/V[S KW9=HG&F<
M? ^!,UWZV\T2\-KGT4?GEN<'ED"Z?_O'%?\ %E/I^ER.9\W#'N3AX/L4]OFK
M/G8X=W3X?M=98NU-YR/)K!_'J;=+_>AF]%,*[N'T*N?RQY&3;WKZ5/-^WC29
M8M[]M;]RLCO+*"H=TP7%JTJIYLCON?TGFHN[KS%O]W'DT_:V-O/6:^'#E=O)
M=K;';9;PM5$ZUP1/J)*MCT?$D4;5<YW,U5141$-?%NJ:MG#2R]N,-K'0H?G.
M55.:93<<AJ-6MJI%2FB7_FZ=GBQ,^@U$U\.JGI&5R\6+441P=+C+]V;M<U2G
M;LS9MU])68+72?=*;FK;5S+TQ.7[M&G\5R\Z)]D[O'-[\RN$Q=CAT3XFYW7?
MQB;<\L+#'+MZ                /CNMSH[+;*N[W"3JJ&AA?45#^\R-JN71
M.ZO#@G=/I;HFNJ*8URI75%-,S.J%!LLR.LRW(KCD5?PGKYED1FNJ1QIXL<:+
MWF-1&IYAZ5E[,6;<41P.*O7)N5S5/"\8R'R6A[-&;>76NJPFNDUJ;=K56WF7
MBZFD=]T8G\1ZZ^8[P''[[RNS5%V-4Z)Y71;LOXTS1/!J3Z<RW8
M
M
M
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M+U1QW"T5<-=0R^<J*=[9&+WTU:J\4[J=PYJNW51.%482W5-=-48Q.,/L/FN
M
M
M
M
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MM<U514\PYZJF:9PF,);B)B8QA^Q5(
M
M
M
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M1>ZBGG$S<L5S$3--4<3LHV+M,3,8Q*,\G[-F&7?GGL,\]BJW<48Q?*:;5?\
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M31]^/#S>1M;&\:*]%7W9\"8&/9(QLD;D?&]$<Q[5U147BBHJ=**:*8P;5_1
MKU:][W5>\TM"ZJ5<,JE2STC>;[DDS'>)4HG1]TD56\WUCDU\Z=1<W7AD\</O
MQ]Z?)S>%HJ,]CF,,?NZOM6%.7;T
M
M
M
M                        !2#YPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H
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MBKTKHJZ)]! /]
M
M
M
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MKFBK7#?VKD7*8JCA>H?%]
M
M
M
M       !2#YPW^SC\]_U>%H0]V,OC_L'J:X^PY0F6H 4
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MFJ^661R,8UK>*JYRZ(B(3$3,X0B9B-,OT(2
M
M
M
M            I!\X;_9Q^>_ZO"T(>[&7Q_V#U-<?8<H3+4 *
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M;UROL;TS'FU:8\;*R%_VEO3KIT),-0V
M
M
M
M       %(/G#?[./SW_5X6A#W8R^/^P>IKC[#E"9:@!0
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MCOL
M
M
M       *0?.&_P!G'Y[_ *O"T(>[&7Q_V#U-<?8<H3+4 *
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MJK]QD7S'+RJO<:Y3=;UROMK.,>=3I\K6Y"_[.YA.JK0N<<"ZP
M      /XFFBIX9*B=Z1P1-=)+(Y=&M8U-5557H1$)B)F<(1,X:5&,YS^X9+G
ML^7T4SX5I9V>XR]#HH:5VL*Z+T*JISN3ZYRGHN5RE-JQ%N>&-/?UN.OYB:[N
MW'>7+PK**7,L8MV14FC4K(D6>)%UZN=GBRL[_BN1=.^G$X+,V)LW)HG@=78N
MQ=HBJ.%[YC/N
M
M
M               4@^<-_LX_/?\ 5X6A#W8R^/\ L'J:X^PY0F6H 4
M
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MB(DJ,54<J/:J*JHFG-JG<//]XY*JS=G")V9TQY'79/,Q<HC&?O)(-2SP
M  $=8KNQ;,GSV^X;"UC66]/_ (=5(NOE*P>+4)WO%<OB:=+453:YC=]5JQ3=
MGAU]SB8%K-TW+M5'%J[O&D4U3/       0QVB\V]P,59C5%)RW._<S)N5?&9
M1,TZQ?\ K%TC\*<W>-_N;*^TN[<ZJ.EJ=Y7]BC9C75T*D';N83SV:LV]S;S4
MX772:4=UUJ+?S+P;5QM\=J??&)]-J)W3F]]Y7:HB[&NG7R?8W6[+^S5-$ZIU
M<JTIQKHP
M
M
M          "D'SAO]G'Y[_J\+0A[L9?'_8/4UQ]ARA,M0 H
M
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M'E&/72GKVHFKV1/TE8B_7QNT>W_":AS][+W+,X5TS#;V[U%R/NSB]LQWV
M
M
M                                                          I!
M\X;_ &<?GO\ J\+0A[L9?'_8/4UQ]ARA,M0 H
M
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M8NG=8Y%:OA0UEZU-JN:*M<,ZU<BY3%4<+U#XOH
M
M
M                              "D'SAO]G'Y[_J\+0A[L9?'_8/4UQ]A
MRA,M0 H
M                                      YS.,4_37':C'7U\MNIZIS%
MJ)8&M<]\;'<W)XW<5437Z1E97,>PN17AC@^%^U[6C9QP1+\EFP?C^L_FHC>?
M/KGH0U?RJCTI/DLV#\?UG\U$/GUST(/E5'I2?)9L'X_K/YJ(?/KGH0?*J/2D
M^2S8/Q_6?S40^?7/0@^54>E+M=N-HZ;;>X5=9;[S4UE/71)%/23,8V-7,=S,
M?JWCJW5R)_&4U^=WC.9IB)IB,.%F9;)Q8F9B9G%)!J6>   ' ;Q9LF$855U=
M/)R7>OUHK;HOC)+*B\TB?>VZNU[^B=TV>[<K[>]$3JC3+"SM_P!E;F8USHA2
M!555U7I/0W'@'J8W?JW&+[;[_;ETJ[?,V9B:Z(Y$X.8NG<>U5:O@4^-ZU%VB
M:*M4OI:N3;JBJ.!?JQWBBR&ST-[MS^>BKX63PKW41Z:\J]Y6KP5.XIYI=MS;
MKFFK7#MK=<5TQ5&J7H'R7   "MVX^S6Y6=9=7WYTMO2D<[J+?$ZHDUCI8M4C
M33JN"KQ>Y/KG*=7DMY9>Q:BC3CPZ.'G:#,Y*]=N35H[G(Y3Y-.XO^=MOKB3T
M(S?G>7_BYOM8WRR]W#Y-.XO^=MOKB3T(?.\O_%S?:?++W</DT[B_YVV^N)/0
MA\[R_P#%S?:?++W<?30=G?<^UUU-<J&IMT-;22LGIY6U$FK9(W(YJI]R[BH5
MKWQEJZ9IF*L)[GVK4[NO4S$Q,8PM;2.JG4D#JYC(ZU8V+4QQ*KHVRJU.=&JJ
M(JHBZZ*J'%U88SAJ=+&.&G6_"Z6>U7RE=0WBB@KZ-W%8*F-LK->^B.1=%\*%
MK=RJW.-,S$]Q6NBFN,*HQA#V5=FG%+IUE1C55+9*MVJI [6II%7ITY7*CVZ^
M!ZHG>-[E]]W:-%<;4<TM5=W915IIG9Z$73X7O5M-,^KLKZE]N8O.^:V.6JI7
M(GU4E.Y%Z$Z5?%]$W$9G)YN,*L,>[HGG^UKIL9C+Z:<<.YICF=7BO:@J(^6F
MS.TI*B:(M=;O$>FG#5T,BZ*O?Y7IYAA7]Q1.FU5WI\K)M;TG57',FO'-Q\)R
MJ%TMFO-/*]C%DEIY7=3.QK4U<JQR<KM$[KD33PG/WLE>M3]ZF?$V]O,V[D?=
ME3G<W,I,YS&OO:.7R!'>3VUB_4TL2JC.'<5W%Z^%RG>9'+>PM13P\/*Y7-7O
M:W)JX.#D2WV9<VY)JS!*Z3Q9>:MM/,OU:)]VB3S41)$3P.4T>_,KHB[')/B\
MG,V>Z[^NW/+"RAR;H       ')[D9A%@V(7"_*J>6-;U%NC=]75RHJ1IIW4;
MQ>Y/K6J9N2RTW[L4<'#R,;,WO96YJX>#E<]L=GDN;8BV.XSK-?K2Y*:O>]=7
MR,758I5_C-16JO=<U5,K>F4BQ=^['W:M,>.&/D<Q[6WIUPDTU#8@       '
MQ4-VMMRFK:>@JHZB:W3>2UK&+JL4R-:_E=X=')_>Z44^E5NJF(F8PQC&%*:X
MJQB)U/M/FN
M
M                                         "D'SAO]G'Y[_J\+0A[L
M9?'_ &#U-<?8<H3+4 *
M
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MB<WUJ<(E3Z]? ;NG=LSE)N_O:_Y?VT\C63G8C,>SX-7?_;0EHTC9@
M'RUMRH+;Y/Y?4QT_E<[*2EZQR-ZRHEUY(VZ]+G:+HA>FBJK'",<(Q[RM544Z
M^%]118
M
M                %(/G#?[./SW_ %>%H0]V,OC_ +!ZFN/L.4)EJ %
M
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M?/+/$B>.OWQJH_S55.X>=[QROL+TQ&J=,?MW'89._P"UMQ/#&B7=FM9H
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MGD5.YS-31?LFJ;#/9*K+51$Z<8\/"Q,KF8O1,QP3_P!'<FN9@
M
M                                     4@^<-_LX_/?]7A:$/=C+X_[
M!ZFN/L.4)EJ %
M
M                 0[VA\V_1W$TQZCDY;I?^:%W*OC,HVZ=:O\ AZI'X45W
M>-[N?*^TN[<ZJ.G@\K5;QO[%O9C75T*AG<N7  'WV.\5N/7BAO=N?R5M!,R>
M%>XJL77E7OHY."IW4/E=MQ<HFFK5*]NN:*HJC7"_>-WZBR>Q6^_VY=:2X0MF
M8FNJM5>#F+IW6.16KX4/-+UJ;5<T5:X=M:N1<IBJ.%ZA\7T   "I':+S;W?R
MIF-44G-;+#S,FY5\5]:_3K%_ZM-(_ O-WSM]S97V=K;G77T.8WE?VZ]F-5/2
MA@W[4@':;69%;<<S&BEO=-!56*M7R.X1U4;)8VQRJG++H]%1.1R-=KWM4[IK
M\_9JN6IV9F*HTQ@R\I<BBY&UJG6N+/MY@-5JLV,6IRN7F5Z44#7*O\9K$4X2
M,Y?C575SRZJ<M:G]V.9YD^SNV51JLF-TJ:KS?<^LBXK_ !'-X> ^T;RS,?OR
M^<Y*S/[L/,FV!VJET5ME="NJJO5U=7QU_C2N_N'VC>^:C][P1Y'SG=]B?W?#
M+RYNS9MQ*B<GE\'!4UCJ47I[OCQN/K&^LQ'%S/G.[+/=>9/V7<,=KY-=KI&N
MG#K'4\GC=_A"SAX#[1OV]PTT^'ROG.ZK?!,^!Q>X&PE@PG&:[(Y,CG5*9J-I
MZ:2G8JS5#UY6,14D;IJO3P71-5[AL,IO:Y?N11L1I[O P\QN^BU1-6T@<Z1I
M@#T;'3UUPN=+:J"J2DJ*Z5D,3Y)'0Q=8]>5G,YNNFJKIJO0?*[5333-4QC@O
M;B9F(B<,4M?!!OK2+_HM9,O/YY8;HK.CHUYI&FD^8Y*=<?TMI^CS,:I_J?XF
M(=I2AT<V>[JU/$:UMWCF1$_B^4NTZ.\/U.[JN"GU?L1['.1Z7K?:<W:6M_XY
M?U2Z=#*G77_'YO[H_P#\ZKT>A/\ _9'I'Z9]I.@U22GNZL9X[U?:&2MT\+_)
MEX?X0_3;NJX:?6^U'M\Y''ZOV'PP[YT:JVJHY5<Y-4ZZUJQ43P:,:/EN2JU3
M_4G];F8UQX'^_*2W*I.-5;[<J.X-2:EJ&)P[VD[1\ER\ZIJYX\A\SO1KB.:?
M*Y#<+=C(MQX*"FN\-/2T]"KI$AI$D:R25Z(G.Y'O>NJ(BHWCPU4SLGN^WEIF
M:<9F>-BYC-UWHB)X'!FR821-I]TY]M:ZN=+2NN%JN$;4FI&R)&K9HU\21JJC
MDX(KD5.[JG>-5O#(1FJ8TX3#.RF;FQ,Z,8E,,7:EQA=>OL=>SHY>1T+]>_KJ
MYNAHIW#<X*H\+:QO6CT9>C#VG-OY%TDHKK#PU5700*FO>3EJ%7^X?*=QWXX:
M>>?(^D;TM<4_MWWWP=HS;.7EZRHK(.;IZRE<O+YO(KO[A\YW-F8X(YUXWE9[
MO,]"'?O:J;EUOJQ.<NB-DI*M/IJD*HB?1/E.Z<U'[OACRKQO"Q/[W@E]\6\F
MV,R*K,DID1."\Z2Q_;L0^4[MS,?N2^D9VS/[T/1BW*V]F549E-K14XKSUD,?
MV[D/E.2OQ^Y5S2O&:M3^]'.\K-]TL:QW%+A>+5=J&ON+8N6W4]/413N?/+XL
M:\K'+JUJKSN\"'WRN0N7+L4U4S$<.A\[^:HHHFJ)B9X%(III:B:2HG>LD\KG
M22R.75SGN75555Z553T*(B(PAQ\SCI3)V=,V]P,J?C5;)RVR_<K(>9?%96LU
MZM?^L36/PKR]XT.^<K[2UMQKHZ&VW;?V*]F=572MN<0Z<      !23>?-OTU
MS6JFI9.>S6W6BMVBZM<R-5YY4^^/U5%^MY>\>A;LROL+,1/G5:9<AG;_ +6Y
M.&J-$/MV(S;]$<TAI*N3DL][Y:*JU71K)57[C(OF.7E5>XURGSWKE?;6<8\Z
MG3Y5\A?]G<PG55H7..!=8       A3M'9M[AXS%BM%)RW&^:^4<J^,RBC7QO
M,ZQWB>%.8Z#<N5]I<]I.JGI^QJ-Y7]BC8C75T(+V=S9<(S6DJZB3DM%?I17+
M5?%2*54Y9%^]NT=KWM4[IT>\LK[>S,1KC3#39*_[*Y$SJG1*[Z*BIJG0>>.P
M
M                                                "D'SAO\ 9Q^>
M_P"KPM"'NQE\?]@]37'V'*$RU "@
M
M                               .1R?;'!\RN#+KDEK6NKHXFP,E6IJ8
MD2)JN<C4;%*QO2Y>X9UC/7K-.S15A')'D8MW*V[LXU1C/?>+\ NT_P"S_P#M
ME=Z.??YMFO3\%/D?+Y?8]'PSY3X!=I_V?_VRN]''S;->GX*?(?+['H^&?*?
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MTMX3KIT)0-.V(
M
MI!\X;_9Q^>_ZO"T(>[&7Q_V#U-<?8<H3+4 *
M
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M9O+*^WLS$:XTPS<E?]E<B9U3HE=]%14U3H//'8
M
M              Y+<3<K#]K<>DR3,:]*.B:O)3P-3GJ:F;35(H(]45[E^DB<
M7*B<0*@Y+\X'=7U3V8?AU/%0M72.>[5#Y99&]]8H$C1B^#K'^:%L'T8G\X#4
M+5Q0YQB,:4+W(DU99IW))&W7I2"HU1_#N=<T&"X>%YMC.X6/4N48E7LN-FJ]
M49*S5KV2-\]'(QR(YCV]UKDU^@J!5T       *0?.&_V<?GO^KPM"'NQE\?]
M@]37'V'*$RU "@
M
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M=7/B1/N,B^:U.55[KFJ<#O7*^QO8QYM6GRNLR%_VEO"==.A*!IVQ
M
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M*$RU "@
M
M
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MDU+8
M                                     #E=S+[+C&W.6Y% [DJ;79Z^
MKIW<4^[0T[W1IP[[D0#&P/HU7[*-HAL^P>'QQHG65<-173/;]4^JJI9$5>"<
M4:K6_0"DO#[:-GI[GL'>:V9J+)9JRWU].J]*2/J64:JG!>/)4N0$,R:6IGHJ
MF&LI9%BJJ=[9896^>;)&J.:Y/"BH%VT]@NK+[8;7>XT1([E24]8Q$XHB5$39
M$T_Q@^;T0     I!\X;_ &<?GO\ J\+0A[L9?'_8/4UQ]ARA,M0 H
M
M
M
M
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M\')??FO]&!@?#/O#^\')??FO]&!@?#/O#^\')??FO]&!@?#/O#^\')??FO\
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M5\\E54/:RKD:U'22N<Y41$T35>"!64W!
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M5944T*O75W)#*YC=51$U71 NTN[&7Q 6#U3<?9DH4E/H0
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MG^\M+[ KPF%+M@OCKP'\N4/X9H6EKP%
M                     "'NU1\0&;>IJ?V9 $PRC"[;T/F
M                                     <KN;\6V8_D.Y^Q)0,; ^C87
M9CXGMOO]VK-[ A#YR[@
M         !B[F?ZX9#^4ZSV0\/HTE[&7Q 6#U3<?9DH4E/H0
M
M  "A7:_[.=WI;[7;L831/K+1<5Z_(Z"F:KY::IT\>J:QJ:K')IS2+TM?JY?%
M7Q2T2JEBV8Y5A-Q]UL1O%79KBK>K?/12NB5[%X\KT1='MUX\KD5 L_'(\GR+
M+[I)>\HNE3=[M*B-?5ULKII.1OG6HKE71J:\&IP0"Y_8T[/=WM-PCW<S6B?0
MR,B?'C%NJ&\LR]>U6/JY&*FK45CG,B1W%=5=IIR*I6979"H     %(/G#?[.
M/SW_ %>%H0]V,OC_ +!ZFN/L.4)EJ %
M                     "K';Y^)ZR?[RTOL"O"84NV"^.O ?RY0_AFA:6O
M4                                                  (>[5'Q 9M
MZFI_9D 3#*,+MO0^8
M      !RNYOQ;9C^0[G[$E QL#Z-A=F/B>V^_P!VK-[ A#YR[@
M                                        !B[F?ZX9#^4ZSV0\/HTE
M[&7Q 6#U3<?9DH4E/H0
M                                  !&&3]G79/,*J2NON&4+ZR5>>:>
MDZVWO>Y5U5SW4<D*N5>ZJA.+]<4[/VS.%5<=?CN'4,-? J.@JJE)*Z:-R+JC
MF/JWS.:Y/KFJB@Q24$       *0?.&_V<?GO^KPM"'NQE\?]@]37'V'*$RU
M"@                                                 !5CM\_$]9
M/]Y:7V!7A,*7;!?'7@/Y<H?PS0M+7@*
M                     $/=JCX@,V]34_LR )AE&%VWH?,
M                                     Y7<WXMLQ_(=S]B2@8V!]&PN
MS'Q/;??[M6;V!"'SEW
M         #%W,_UPR'\IUGLAX?1I+V,OB L'JFX^S)0I*?0@
M
M              4G^<%HJRL^#KR2GEGY/=KGZICGZ:^Y^FO*BZ:Z!:$0]CFV
M7&FW[L,U11SPQ)37#622-[&IK1RHG%41 F6FP4
M                            *N]O&EJ:O:&RQTL+YY$R2E<K(FJ]R-2@
MKDUT:B\.(3"FNPUIND6]&!RRT-0R-E[H5>]T3VM1$F;Q553@%I:V!0
M                                            B'M1PRS["9I#!&Z6
M5U-3\L;$5SE_TR!>")Q"897>XMX_%]3_ #,G\D+MKP^8
M                                 !R^Y;7/VYS!C&JY[K)<D:U$U556
MDDT1$ QX]Q;Q^+ZG^9D_DA]&O.S;'Q[0X!'(U62,QNSM>QR:.1R4$**BHO0J
M!\Y=L                                                   QJS*
MSW=V7Y YM!4JU;E6*BI#(J*BSO\  %VCG8Y@GIMA+##41/AE2IN&L<C58Y-:
MR54X+HH5E/(0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MLU/,ULD4L;D>Q['IJUS7)JBHJ+JBH$/[
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MW"UU;$EI:VED;-!*Q>AS'L545/,4(?6
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M%UI&*C9V1JK)X7.UT;-#(C9(U71=.9J:]S4(=4
M
M%#>V]O3755Z39_'ZIT-KH&15&2OB<K5GJ96I)%3N5.F.-CFR.3H5[DU35@6B
M%8]N=L<RW5OJX]A=!Y961QK/4RO<D5/!"BZ<\LCN#455T1.E>XBA+W-U=A]Q
M=G4I)\PHH?<VN>L5+<J*5*BF=,B*Y8U71KFNT151'-35$737108NP[+&]MRV
MNSNBL=?5.=@V15$=)<Z61WW*GGF5(XZMFOG58NB2:>>CUUU5&Z"8:A!0
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M_>VY8-G%%@-VJG289DU0E-'#([5M)<9O%AECU\ZDCN6.1.CBCOJ>(F&DP4
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M'HUR)T.;KRN3N+P"CUP
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MRM<]NB=*.:BM5.\%VS@?,
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MQ=6JB]]%0+MGL.OJ91B-@R9J:-O-MH[BB:::)5P,FZ%Z//!\WM@
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MV22WK9;W*G>KGX]=*JAB1VO""9&5;>/>YIWI] *2LH$
M
M  #Q\MFDI\5OM1"[EFBM]7)&[1%T<V!ZHNB\.D#%H/HT][%\4<>P5D<QJ(Z6
MKN+Y%3NN2JD;JOT&H@4E*FZ44<VV6:0RM1\4EANC'M7H5KJ.5%0(8W!]&J79
M(GDJ.SSADDFG,C+A&FG#Q8KE5,;_ '&H%)36$
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M!=M+BD\E5BUCJ9=%EFM])(_3@G,^%BK_ 'P^;V
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MS(U<U?H*B*"&107:W=G.>2HV-P2233F2U0QIIP\6+5C?[C4"DI/"
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M%,B_:($2N8%0
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M[[DJF/T^DU5"89A!=M+B<,E-BMCIYDTEAM])'(FNNCF0L1>*>% ^;V
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MR+"[6WLYPR4^QN",E31RVJ&1$UU\615>W^XY I*4 @
M                     %=^VQ#)+L/<'L;JV&X4$DBZHFC5EY->/A<B!,,R
M@NU.[*VVMDP3:2P72DIF+?LGHH+O=;ARIULC:MB301\W%49'&]K4;T:ZNZ54
M*2_'M8;:67.=I;[>9J1GZ18Q2R76VW!&HDS(Z1%EGB5VFJQNB1_B:Z<VCNE
M0S MUPK+3<*2ZVZ9U/<*&:.II*ABZ/CFA<CV/:O?:Y$5 NV<Q*^MRC%;%DK&
MHQEYM])<6L;YU$JX&3(B>!.8/FQJO\4D-]N<,K5;+'5SL>U>E'-D<BH'T:"=
M@9[%VAOD:.19&Y)4N<S7QD:Z@H4153O+HH4E:::6."*2>9W+%$U7R.[S6IJJ
M\/ $,10^C2CL,PR1;(N>]-&SWFMDC77I:C(6?WVJ%)65"
M                         ?#>[O0X_9KC?KF_J[;:Z6:NK)/K8*:-TLB\
M=.AK5 Q_W-W$OVZ69W+,+_,YTU9(Y*.E5RNCI:1KEZJ"-.A&L1?\)=7+Q50N
MMGV<>R)AV0X509SNA3S7&>^1I56RSLGEI8(J*1-8I)'4[F2.?(GCIH]$1JIP
MU")E^O:&['N'6;#+EFNU\,UMJ['"^LK[+)-+5034D+>:5T;IW/D:]C45_%[D
M<B::(N@(E3_;[/LBVTRN@R[&*E8+A1/19(M5ZJH@5?ND$S4\\QZ<%3N=*:*B
M*$M?\6R&ARW&K1E-LU]S[S1P5],CO/)'4QMD1KO"G-HOA"C*'M Q21;VYZV1
MJM<MZK'HB_6OD5S5^BBHH7A97YO-[$?N+&KD21R65S6:^,K6^7HJHG>35 B5
MX JQVWAECGW<SZ>%W-%+D=X?&[OM=73*B\? %UO/F^89&V#.:A4^Y25E!&U=
M?JHXIE=P\QZ!$KFA4
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M\&SRM8YVJ="-1555[B!=L^B(B(B)HB="!\P
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MGAK9K91VY51=45:2!D2KKW?.A\WN@
M        !&':*Q>7,-D\SLM.Q9*KR!:ZG8G%SI+=(RL:UOA<L/+]$)ADB%VM
M79PR:W95LEA=7;Y&O]S[936BKC:NKHZBV1MI7M>G2BKR(]$7ZER+T*@4E]N_
MUVI++LIGM76O1D4MDKJ)BN736:OA=2Q)YJOE:@(9$!=LCM=;JBS[987:*MJM
MJZ"Q6NEG:J:*DD%'%&Y%3CIQ0/FRNWSQV3%=X<ULKV=6R.[5513LTTTIZQ_E
M,/!-/^;E:%X6H^;\R2G=;LRQ"1Z-JHIZ:[4\:Z:OCE8L$JIW?%5D6O\ &0(E
M:;=3(H,3VVRO(JB1(FT%JJY(E5=-9UB<V%B*O=?(K6IX5"K'$/HU>[+F.2XQ
ML3A]'4,5E364K[G*B\%5+C,^ICX=S[G(Q I*7P@
M                  $<[_0U4^RF>QT:JDWN)6N71.95C9$KI$T\+$<$PR("
M[839B[T%\VEPFY6R1)*1]EH8M6JB\LM/ V&5BZ=UDC',=X4#YR^S=*[4%BVV
MRZ[7-S6T5-:*YTB/5$1ZN@>UL?'@JO<J,1.ZJZ 8WA]&MO9RIJBDV,P2*I:K
M9'6J&9J.T1>KG5TL:\.XK'-5 I*A7;$QV2P;\WZ=6<E->H:2Z4W#35LD#89%
MX=^6&0+0[GL$9)3V[<>_8U4/1CKY;$EID73QYZ"5'<B=W7JY)'>8U0B6@E=7
M4MLH:FY5TK8*&CBDJ*F9ZZ-9%$U7O<J]Y$15"K%N_P!U??;]=+W(BI)<JNHK
M'HO%46HE=(NO^,'T:*]AO');-LP^[SL5K\@NM560JO#6"!K*1O\ RX9 I*RX
M0
M                     % NVOLE<K9D4N[N/TKI[#=$C9D+8D5RTM:Q$B;,
MY$Z(YFHU->Y(BZ^?0+1*N>V>ZF9[27YV08;6-@J)6=364T[$FIJF'5'<DK%T
M71%35%:J.3N+TA+WMW.T#N)O.E)3Y7/3TUHHG]=3VBVQO@I$G5%;UKDDDE>]
M^BJB*]Z\J*O+IJNHP>_V7]F;ANKN!15M72JN%X_/%67NI>GW*1T:\\=*FOGG
M2JGC)W&:KWM1,M3 H
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M>)4UT2\\$#-?/<KM)).XC4T7SR F6F 4
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M.T-Y;;9J2&BIU5$1SDA8C5>[3ZIZZN<O=55"CV@
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M*R%+2TM#30T5#!'34=.QL5/3PL;'%'&Q.5K6-:B(UJ(FB(@0_8
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M6-L4,;==>#6HB<5755[J\5"'W@
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MVB.WLFT6KJE59:JH<W54669ZJ]VFJ\K=>5O<1 J[(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M          #XKQ<6VBT5]V=&LK:"FFJEB1>57I#&K^771=-=- *=_P#$(L_[
M!U/OE'[7"V"Q.R.[=/O1ALF84MJ?9XV5LU!Y)),E0Y5@9&_FYD8SIZSHT")2
M0$
M
M
M
M
M   /#S3]3LA_)E;['>!B\'T:2=A7XE*C\N5OX&G"DK,A
M
M
M
M
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MS08+5X]D=BRRSTN08W7PW.S5K.LIJRF=SL<G0J=]'(O!S7:*U>"IJ%7J
M
M
M
M
M                             \/-/U.R'\F5OL=X&+P?1V^ X?GV[-RM
M^WN*I)6QT[IJR*GED5E%2-EY&S5$B\48B\K&N=HKG>*U-5T0(6._X?>6>YRR
M_IG;O=;D54I?)9_)^M[C>OYN;E^RZGZ 1BJQFN&9#M_DU?B644ODEYMST9-&
MBH]CFN1',D8Y.#F/:J.:O>\(66$[#>?5MAW0EP:25SK/E5-+RP+JK65U!$^H
M9(G<36)DK'?7>+WD"LM&PJHEVT=^Z^:Z3[/8I5N@MU*QOZ4U,+M'3S2-1Z4B
M.3_FV-5%E^N<O*O!JZEHA3VS6:[9#=*6R6.BFN%VK7I%245,Q9)9'KW&M;QZ
M.*]Y.(665M/8/W=K[:RLK[E9;762,YFV^>>>61CM/.R/@@D8BZ_6.>%<4)[E
M[29WM+=8[5FEL6E2H1745=$[KJ.I:WSRQ2MX*J:IS-71R:IJB:H$N@V&WPO^
MRV5Q5U/))4XI72,9?[/KJR6'7198T7@DT:<6.X:^=7@H)AJY;+E07FVT=WM<
M[:JV5\,=51U,?%DD$S4>Q[=>XYJHH44<^<(_IC _4UR_"4X6A6;9CXX=OO\
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M75-55FOG0B6@H5
M
M
M
M                                              \/-/U.R'\F5OL=
MX&+P?1H+V!,;I:3;[(\J6-$N%TNOD/6+HJ^34$$;V:+KPU?42:IX$\ 5E;@*
MLY>WI2L@WBM4\<:M\JQZE?(_N.D965C.GOHUK0M"/>RO\?\ A/JFH]ASA,M3
M[Q<H;-:*^\5":P6^FFJY4U1NK((UD7BO1P0*,7+S=JZ_7>OOESDZVXW*HFK*
MN7ZZ:H>LCUXZ]*N4/HNMV!,#M\E'DFY-7"R:X1U"6.V2.1%6!&1,GJ5;KT*]
M)8FZ].B*G0Y0K*[051?VAL$H=P=HLFM%5"V2MHZ.6Z6F1417QUM#&Z6-6KW.
M=$=$Y?K7*$PR2"[3?L69/49%L=14E2]9),?KZNT->[77JV\E5&FJ]*-;4(U/
M F@4E#'SA'],8'ZFN7X2G"85FV8^.';[_>6S>SX0F6PP4<KN;\6V8_D.Y^Q)
M0,; ^C3+L2?$52?E.O\ MVA23MM_$55_E.@^W<"&9H7:O]F'$Z/$=C\2@IHD
M9/=J-EZK9$1.:6:Y(DZ.=ITJD:QL3[%J!24O!#,GMGX9<L<WIN-^GC=[D91#
M!76^HT\57PP1T\\>OUS7Q\VGUKFA>$08)N+F>VEY]WL)NTMJN+F=5,K$9)%+
M$JZ\DL4C7,>FJ:IS-X+Q310+-8GV_<NHDCAS/%Z*[,3@ZJMTLE!-I]<K)$G8
MY? G(@1@F7%NUUL!FU=1RY#$ZPWR)%CIJB]T<<C(U<J*J1U4/7(QJJG2_D3@
M$8+&T%PH+K1PW&UU4-=;ZEJ24]732-FAD8O0YCV*K7)X44(?2
M
M
M
M
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M).Y(TJ6-5=&21ZHY53SS4Y5[FA$PU1"@
M
M
M
M
M   'AYI^IV0_DRM]CO Q>#Z-).PK\2E1^7*W\#3A25F0AGOV_OC)QG\AI[+G
M"T(K[*_Q_P"$^J:CV'.$RU<"C)+M!;:U6UVZ5[L+H5CL]5,^XV.331CZ"J>Y
MT:-7NK&O-$[PM4+P^_L\;XUFR.7R7&:!]=B]V8RGOE!$J)*K(W*L<T7,J-62
M+F=HCET<CG-U37F03#0JT]I/8V[VZ*Y0YO;:>.1O,L%;+Y)4L5$XM=%,C7ZI
MX$T7N:A7!5WM2]JJQYG8JC;?;:5]5::M[4OE]<QT3)HXG(](*=KT1RM5S4YW
MN1-431-6KJ$Q"H=JM5QOESH[-:*9]9=+A-'2T=+$FLDLTSD8QC4[ZJH6:^;0
MX#%MCMQC^$L<V2HMM,GETS.+9*R=RS5#FJJ(JM61[N77CRZ('S5=^<'LT[Z3
M!<AC8JTT,EPH*B3ZE'S-@EB3S52.7Z06A2BR76HL-ZMU\I$1:JV54%; CO.K
M)3R-D;KX-6A9K5@^^6U^>6&GOMJR2@IU?$V6KM];4Q4U72OT17LFCD<U4Y5U
M3G3Q'::M54XA3! ':L[3.'/PZY;;X%<H;W>+RQ*:Z7&B<V:CIJ-5UE8V9JJU
M\DB)R:,U1K5754=H$Q"@P6:9=B3XBJ3\IU_V[0I)VV_B*J_RG0?;N!#,T+MD
M]LOBVP[\AVSV)$'S=4!G?NYVI>T/B6;W[#9:ZALD]JJY(&.HJ")W/ KN>&1/
M*_*.$D2M<G@7OA;![G9H[5]RCRBX63>;(Y)[?>&Q+;+Q6JUD%'4QJ[5C^1K6
MQQRH_P _IHU6IKHBZH)A>>GO-GJZ+W2I+A33V[1%\LBFC?!H[31>=JJWCKWP
MJH5VX<KVOR"XV&CQ2:@N.8TCYW7JY6[DDTIW-8D<,T\7BR.1R*J-57*SCYWF
MXEH5@PS'Z[*\ML>-VUCY*ZZ5U/20I'JCD661&J[5.A&IJY5[B)J%FT(?,
M
M
M
M
M                            #Q\MAFJ<5OM/3QNFJ)K?5QQ11M5[WO?
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MYY+&Z.EBA7GIK=%(G*]&.5$YYG-7E>]$T1-6MU15<XK,K,!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
4                       /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>tm2227887d1-pht_myloid4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-pht_myloid4clr.jpg
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M$P;P@9&Q4A2AP=%"<C,T%>$C4Q;Q8H*20R2R-:+"TE0E8W.#X@?_V@ , P$
M A$#$0 _ ._@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                               2=4_Q?N_]0X"1UKPB_N4J4ZB>#='7
MBTZ$FB<D23;HJ.C;HB#1Y\:\8RXNO92I&I">L_Q?NK]8J'H            '
MG.CDHOBG7@4I2/JC5QX1Y=+3^_4<?!",4HR2K1KL2YE6FI,R]@     ILO(L
MXMBYDW[BM6;47.Y=E1*,(JKJV3$3,Z*;6BL:S.D-;V_7;T]EJL=+>?*KDK<<
MMQ:L.;=*5[*]AL9[;EBNNCG*_,FRME^'%N+9-B[&];A=LM2MSI*,XNL9*7;X
MFNF)B=)=)$Q,1,<I5!"0 !Y.DI.+X]*13PE,\DCZGP?*791U'$XIX*DN?9R[
M"K3Q4^+U"4&Z*O<0/&LNU2Y<U2E")GR.*?W^R/#VE24.J?XG_3Z@A&L_Q?NK
M]8"5N;Y\EV*LJD)3+I4E%*G4F1RX$0]"I              "27#BNYD:"Q;F
MW5H>T=.EJ>O94<7%3X.7&<Y=BC%5;?@B]BPWRVTJP]WO,.UIUY;=,+#M'U:V
M=O/+6GZ7ESM9[_B\;(B[<IKC\/>^'M,C-LLF*-9C@UG;^_;3>6Z<=N/E/!GM
M?HIS,-OD2$@     2RETQ;Y450AYR=51-M4[*NI'%5IP0494_&IP7!K]4>DT
M\WK%^ZGS]A.HF" "#;[.+('C*4E^"VUQKP0$4W6C:5'5I$P3J]@/%/CU4YU2
M;YC0C248S;BG!5B^37:")B4\6WSX,"$U5I43]I$I24FGP[.4:-+ZZB."$_5/
M\7[O_43P$*S_ !?N_P#4!)%\5)UBO9S$:^)H]P             0?(#RE2-6
MN-?PFPF(B.:EOZII>++IR,RQ9GV1N7H1;^B31,5O/A*U.2D>,)L;4-/S.&'E
M6;].RS=C/CW>ZV)I:.<2JC)6>4Q*K@Y."KS[2%2< !)-+IXJJX!$I&YJB47]
M5?\ V%.D*H35G^+]W_J*D)OB7/GR:)0F(2\9JLG25&J5X50Y''P(2G1^[P7T
M$<?%*:L_Q?NK]8E![[X./#Z (2X4=6J\.3D1JGF]24             23:I2
MM*\"!+1KE637+JJ#31&MSN^[_P!1(=4_Q/\ I]0$C4J<&T_I2*=4O2W\"JZ\
M.=*,E"<D2R<ER2?M"7G*=RG+I7?S*9] A&*4HI\*=B7!E7-$S+V;HF^X#QK1
M=3]WA6O<AIY'#35,I2HNF-5V,#T56N/ "('G<IPK+I^@:(><>M22IP570CBJ
M]:=RN).D:>/ 2)%QXMI-^\U3O'/@3KYJ@E
M
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M,FW2B]W@VS==QM/P;=7'@XOL-<EM]CFFO"W/ZG<[KUNC]WC4X".;W[Q>Q*
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M>N0BDX]RE1+M.T[;CI."+3$3+Q;YES9:[ZU:VF(];7[U358\]2RVN_S[J_\
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MB7M/RMO_ ,SM(B9]JDZ2VT:MU@
M
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MX'+CMCO-9>_;3<TW.*N2D\+0\M[?[(:Y_4<C_-LKVO\ -KZUON']-D_AG[G
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MG'/90
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M=#XU.7V_#+7UO5M_QVV3^&?N<"VO@CW=/ZAZ(^;_ !EVOZ%_\*]O_M+_ /\
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M:9@
M                                                !*_PO^G81*7S
MRU;^U=0_K>1_G9'I.'W(]4/FG>_SK_Q3][I#[.6)8U#9>N8.4E/'R<FY8NVY
M*J=N=OI:=?:<MWBTURUTYZ:O5?E#'%]GDI;E-I^R8<];CT*_MO7=0T#(@U+
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M2^<PX]GE7G2:K7LE]\Y[O&#IF+QXO1ODW>=6*^"9UZ)UCU2Z"3KQ.?>B(@
M
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M\,_<^>\?]'?[3]8]&CG#YKCQ^GD[Q]-?]AM!_J5K[QY[NOYUO6^B.U?TF/\
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M +5'^E[7_P GF_?LG4=CY7^K];ROYZ][#ZK_ /Z6FMA_[:Z#_7;'[]&ZW?\
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M
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MD(IRC)=C;5"SW'>3@CV>;+^7NS4[AEMUS,4KY?\ #]3=?_+'L'^FZI_+6O\
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M-$I/VKB<'O\ %./-,/>^P;Z-WLZVGG'LS]38BY&"Z!$
M
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MU_"-G_>[?A<O_LC#_J3]A_RO8?9N"?\ X=?KD_WNWX4?['Q?ZMOL@_Y8,/\
MW@G_ ""_7']ZM^%/^R,7^K9E_ISZ.6/3[7,C6+6IRS?F,?Y9VW;Z*/J3KS=>
M1@[K?SGKI,:-]V?Y?KV_+-ZVFVL:<62^HFQ[>_=#MZ+/,^2A&[&\[JAYG52+
M5&N'#B8^TW,[>TS$:MGW/MT;W%&.;=.DZM4S^R[B2MRBM?G[W*EFG93\9FUM
MWJTUTT<?7Y)QQ^_+?^'CQQL7&QD^J-B$+2EWJ$5&IS\SK,R]$I6*UB(\%60K
M6K5]*P->TW+TC4;4;V%EP=J];DJQ?5X=K+E+S2T6CP6,^&N;'-+\I:-E]F'
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MQ])F.3I.R]F_MT6B+]46;)CP7*G%FO=$F
M
M                     (-)TJN7()1"$$DJT7/F!$   Y8]6O5/>.B;^U73
MMOZI<Q=/Q8V;7DP4+D7<=M.;I*+HZLZC9;/%;#%KQQU>3_,'?MS@WEL>&_3$
M1'T\6FM2U34-8S99VJ9,\S4<IQ\RY<;N79NE(P2X\%RH;_'3'2)T]F(<-N,^
M7<7ZKZWGPGQ^FO@Z>] /3_*VYI.3N+5[+LZEJO2K-B:I<MXT*^[-=\GQ]AR/
M<]U&6T5CE#UWY7[5;:XIO?A:_P!S=4*^"5.1I7:2]"0 A1/Q B ( D0:3XL
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MHO8($4DN27T$HA$A( H!"B[@:H=*KU45>^G$(3!(
M
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MT8^/"-JS"K=(0X156^PULSK.LNDI2*5BL<H51"L
M
M
M
M                     "7II6CI5U!"*5%^N2A$A(
M
M
M
M
M
M                            2N5'QY A!W(UI7CV$:ZAUKZ7V$QQ)%)-
MT7'L=.PC5"<E+S\RG%Q:[V$^";K\']1&J$4($20
M
M
M
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M4W;0(N232X\>Y$(3!*53B^0(XI@
M
M
M
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M.+NNUR3$1>-91N.S;O!'5;'.GFRI2B^*::K3Z3:M+JF"0
M
M
M
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MM7GP
M
M
M
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MOLF[VL=5Z</..++;;35*OAW\S:0TKT)
M
M
M
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MY2V]&59/C5=YV$0X5Z$@
M
M
M
M                $M7U/N0$BN<6EQ:[* UA!SG5<*)IU*=?01#47K].\]OZ
M;%?Z.\R+G)<5UJ,NE?4V<C\SVF,$1_S?JEWGR=$3N+SX]$_?#4FDQC1.BY]7
MU</J/*;3K.D._P!Q,LD=NQY*=./;W<2.,M3$VU8QJL;=6TN7&C[7V%=)F-?2
MV^WF6\O1#SI;&C&4GY<<F]Y+YTA5<%_A-GKGRY:9VO'SEYG\V1'YWASZ8U7S
M=_I[H&\K:EJ%N=K-C[UG.QWT74Z4H^R2IWFRWW;,.ZC2T:6\VL[;WG<;&?8G
M6OX9^G!I[='I%E[<5F]'65<PK]SRFYV>F<'W\&T^!YWW?L\;&*VUZHM.CO\
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M4/3B4[7J'HWD-J4KER,TNV#@TZ^PZ?Y>M:-W51WNL3V_)KY1]KJ6"44DG6G
M]?FWB\4B-(T.N2:YI/P0)3.O#C2KX^)(G
M
M
M
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M^IMGS-#LW^7D7ZOV.+7WZ&9\WXIG:1:/W9_4Q>P7_P Z8_%#)M%O/)TO!O\
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MN575*B5:U[>XWSF7J
M
M
M
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MYDHV+71&ZJU?!5:X(P.U]IMOJVRS/177@Z+=_,U]KTTM2M[:<9U9CHWH5MO
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M
M
M
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M<96HB9F(CG+6>*I[^W'\S=3>B:;*L(NJA)5[4Z<70\XQUMWC?=<_R<?#T?\
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M94HO:>V]IQS3:TB?)XSWW+%]]DM'+J9?5?\ 1&U:0ZHI>!(F(
M
M
M
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MVK2Z)R4
M
M
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M1I@
M
M
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MPF"0
M
M
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M-UAW.++'^7:+.?S[3/@G3)2:^M<(MN2X\*-/]<R-9\6+P>Y(
M
M
M
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MS>/=[[7.QSZ1[EN-6;F[<^
M
M
M
M  %KUZ5V&D9TK'\:K%UPISZNETH8NZUC#?3GI+*VFDYJ1;EU0Y!TI*M)<9.4
MO>\.H\*S<WON=FF%&T[=.%48TPT&69U4&IP@VTNWN$1IQED89E=?1R\X;ZAT
M34%<QKD;J?NU4?A7UG8_+=NG<Q'A.K7?,U==C/HM&CI52ZX]2K]/ ]7>/Q.H
MHU?57B4Q"K5B.ZMGVM6<L[!I8U6VE*,UP\R2XJM&N*.5[UV.NYCXN+V<L<O3
MHW7;NXSA]B_''*BVQO"Y*[^8]Q?S;5K+Z(W)^ZKK7!)O\9_=,;L_>YU_+[KV
M,D<-9_>9'<.VQ$?%P>U2?T+CKFR-+UJ<LBU7$S7SNVDN+7XR_6,_N/R_@W4]
M7N6\X8NT[MEPQTS[5?)CRQ-_;;5;$UJ6%;Y17Y1]*_8OWONG/_![IL?<]NL?
M3DVO7V_=<_8M+WCZA8%ZU<P-Q:?=Q/-B[=[W7)2[*THB_'S3@M$XMU2U/#C&
MJU_9<D3UX;Q99M"UW%VQK4L?'R(Y.A9+7OJL?+4N3:?:NTT_;NX4V&YZ*6ZL
M-OJT;'>;2VYP1:T=.2/TMM6[T+L83M-3MS2<))U3354ZGJE+5M&M9X.'M$UG
M28XO1)OC7ZRM3**7>2/.Y<A:BG.2BG[J;:7O/DN)"='HG7P\ A$
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MX<KEV*?!SMW()</!-G>?*MYC/-?#IG[X:3YMI$[2EIYQ:(^V)=%'ICR@
M
M
M
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M;8Z3EM&DVX1ZGG_S9W"N2]<%)UZ?>];<IVC@0
M
M
M
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M:/>]IW.TXY::1Y^'VLFZH\JKG0V6K4IB0
M
M
M
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MP\^^K]R$Y.$E6B@^7/N.I[+L\^UP?#S3U2T7<-QCSYNND:0R(WK6@  !K_U
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M*MR/X:\)'L7:NX1O,.O[T<WCG>^V?D<\TCW+<:_L9N;IH
M
M
M
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MX]E&ZU,:^VRTYUE:G%>.<,HA.U=CUV[D;D.^$DU]PQYUCFMS&CV)0
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MV!]G_P SYG<$6OYM3'=?V=9GH_RE,^W]7ZW(_.6G3B\_:_4WL=\\W
M
M
M
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M^Z1O<^M/<KPK^UGQO'.
M
M
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MZU7&<Y-)-2IS:IQ+ZQP\)>P
M
M
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MNZ]%N%X>4]_[+&SR1?'K\.WZ)\FRUQ2.DT<HB
M
M
M
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M(2
M
M
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M9V,VS?$F/9KX^EH_F?>UP;2<43[633AZ'2*JTF^#[4>GO(T2$@
M
M
M
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MR:49TYVV_94U.\[;;%/57C5C9]M-)]GDW^G&23BZQ?POL:9JF$FJN\@T1(U
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M
M
M
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M?#E;R<7W7L6;8^U/M4_%'Z_)GBI14Y4X&^<TB0D
M
M
M
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MLTN2FTE-+V21[=MMQ\;#7)YQ#PO>[>=OGOB_#,_X+O&G2NXRV%IHF
M
M
M
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M8R;W+:OG]W!F2X<.TW#1H@
M
M
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MVUTVXI*$>244J)+V'J<5B(TCP>0S:9G6?%ZI4*E*(
M
M
M
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M-'&:S*J3JDQ$*420
M
M
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M4>O%OR=9SL1=.F3[XGJWR]W*<]?A7YQ'"7F_S3VNF&8W&*-(M/&/2W(=>X0
M
M
M
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MYQHZ>7%)\CUEXRB$@
M
M
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M>M3;E/J:#^S9_:N\_P"M0_?3-]W?E3U. ^4O?S_Q3]\NA#0/00
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M<-)RVYVC@\X^:.ZUS6C!CG6M>?K;@5:*O,[&'"HD@
M
M
M
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MF-23JFHTZ>SF;;:=DVVWG73JGTN>WOS#N]U&DSTQ/A#/4DE1<$C?N;1(2
M
M
M
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M_=L_);C2ON7XU_9]3.S?.;
M
M
M                                                          Q#
MU(=^&QMPW,>OFK$N))<73MI]!J^YS/Y;)IST;GLD5G?8NKEU1]/M<Q:,[:Z&
MO=HEP\5P/$LDSJ]JW.K+\2%EVGP2[_:RQ$:-'DF8E:M5A;C55]U5X)^':5UG
MBS,.LPNGI1HF?K6MZKAXF2\7&^7MSR91JU)N=$FEX'1]K[?DWL]%;S2(C6=&
MO^8MUCP8*6M'5/5.GV-V:;Z>:%A]+R83S9II_E>$*_M50[?:_+.UQ1[4=4_H
M^QYSF[UGOPK/3#*L?#Q,.'E8MF-FW'E&"HOJ1TN+#3%7II6*QZ&GODM>=;3J
M]E%+DB["VI,O+Q\&U<RLFZK6/;7OSD^E*GCVLLYLU,-9O>8K6/%7CQVR6Z:\
M9:XC\YZAZR[DHNSMS"ETKJJG.CX_X3^X>>5^)WS<ZZ37!2?MT\76>SVS%I.D
MY;-E6;5K&A"Q9BH6;<5&,4^"BE1(]%ICBE8K6.$<G)6O-IF9YR\L_4<73K$K
M^;>C8M17QS:3KX+FRUGW./!3KR3TQ"O%@R9;=-(UE9M#WA@Z]J-S P[=[IMQ
M<U?G%*,DFOJYFH[?WS!O,ML>/CIXMANNV9-OCB]YCCX,H.A:D I\O_1[O^2N
M?>)CG'K4VY3ZF@_LV_VKO/\ K4/WTS?=VY4]3S_Y2]_/_%^N6X=XZ*]R;;U;
M05EW=/N:EB7<;Y^UPG9\R+77%UX4[>)H\5^B\6TUXO1J6Z9B7%WIAZ\ZSZ-Y
M^;LS7+ZW9M#!R+EFWG8ER5R]9Z).+N6)3JIVY/CTS?/DSJMQL*[BL7K[-M/I
MJV.7;Q;Q=0[=^T!Z3[EL1N8VX\;#OM5^5U!O$OQ['57.'[EG/Y-CGQSQK]C"
MM@O$\M66?I!V1Y:NK<>F]$E6,_FK5']-2Q^7R?AG[$?!R?A8SK/KUZ3:#&3S
MMUX-R:=/)QIO)N=7LMIT+U-CGM/NZ)C!?RT:KW1]LO:N'YF-M#0\_6LKI<[=
M^_'Y3&2CS<JIRHO9])L,?:+_ +\Z>I<KMYF=)8-C:S]H[[06'EY>AY./HNU+
M4KEKHQ;WRL9WH+C9ZXUO2=/%1,R:;7:3$6XS]O\ @OS%,4Q$QQ\U']FS8GII
MNS5M>T7>V!>O[YP+L_\ R_,FX6I6(OHN-133G=A*O77ES15W#<9<<1..=*SX
MISY;5XU9EZ-Z9O;T<]8]4]++V#EZGLG5U/,T_48P?R]J"K.%YRY1?36W<BN<
MJ,PMW;'N,$9-=+1]-%G):+U;4V1Z%Z/L3U)UW?FC:A?MXFKVI6H:%%)6++NS
M5RXZI\56-8)_#5F%GWMLN**3'&/%8MEZJZ2VU"U;AU.$5'K;E*G:WVOQ->LO
M11BN00F     "64(RX-5)1HBHI<B$M*?:;_X?X__ *EC_>F;CL_\WZG%_-_]
M%_U1]TMG;/\ ]DM!_P#3\7_,1-=N/YEO7+IMA_3X_P"&OW+ZN1CLY$D0<4^8
M%NU72,#5\=X^=:5R#32E1=23[GS,+=;/%N:=-XU_4R,&XR8+=5)T8%?TO<>R
M;\LS1F\W1W\>.U\*Y.J[*=Z.#R;'>]IOU[?6^+QJZ>NYVW<*].7V+^;*MO[N
MT[<%JEE^5FQ_C,6X^E\.;5>:.J[9WK!O:\/9MXUGZ<6EWO;LNVG7G7PED*:E
M54I4WL:M4CY<4N1.GB+9J.@:/JL&L[%A=?XZX3^M49K=UVW;[G^92/N9F#>9
M<'&EI:XWOL6WIFV]7U#2,N[:Z,>7F6OQH5HX]2XO@SD=[\N_EZVRXK=/#E_B
MZKM'=_C;G'3+6+>US:.T90=JT^'&,4Z<#S[-K-GIVYF=99AC6[3M\>XL3+17
MM,2M>J0BHSY478(O,2S<$LQ]")75N#5[<*JW.S"5VG+J4FDOJ/0_E2UOB6\M
M'-_-U8G;XY\=70)Z,\O
M
M
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MZ=&SE;I6K;J8,Q$QHL0A&"CQ;;?>RH3T5:]H$0        &D_M-?\/\ '_\
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MGCYRV:=*Y(
M
M
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MZCIUBE9\*LZ=KJI5TXU=.TW\.8>P
M
M
M
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M '<_X0_N.X_$?[=V'^G!^A;TW_U';_=S_7']PS_B3_M[8?Z<'Z%O37_4=O\
M=S_A#^X[C\2/]N[#_3A']"_IM_J.W^[G^N/[AN/Q)_V]L/\ 3A#]"_IO_J.W
M^[G_  A_<,_XC_;VP_TX/T+>FO\ J.W^[G_")_N&X_$C_;VP_P!.#]"WIK_J
M.W^[G_"(_N.X_$?[=V'^G"/Z%_3;_4=O]W/]<?W#<?B3_M[8?Z<(?H7]-_\
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M\U^9^U4P7C/BC2E^<>5O0VSUQ?#MX?=.M<0G
M
M
M
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MX<_IH=I\KVF-Q_TS^IK?F?2=AQ_%'ZW2<8]34FJ/F>J2\@\'J
M
M
M
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M;K%2C:ZN_I;X_27_ )2QQ7XNG+59[_>9BFK8RY'?5Y.51*D
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M3Q\Y_P &UCK'%
M
M
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M:_%7)5,O;=FVN"=8KK/I8&]^8-YNHZ9M%:^C@S:":X<ZI\3=ZN=XP]20
M
M
M
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M]J(J4(@
M
M
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MZN$NVJ?(VG<=GC[KMXW&WGVZ\OV3Z6'L\U]GFG#E]R?IJKMF[E>N8<K&2_\
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M2L1Y/!,ENJ\V\YU514M@
M
M
M
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M_&ZK\'#PIKQG\7^#:\*T?#MX4[CJ8<4G)
M
M
M
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M56?#3E_P=+1E2->:7"O*IS3TZ8XO1.O@2I1
M
M
M
M                 #S<H]4>U\: :N]7/4_(]/\ &P;&!8A?U+/4Y1N7DW"W
M;MT][I5*\73L-EL=G^8M.O*'+]^[U_;J5TC6UO#T+=H>5A^O6PK^-K5GY#4,
M3)4'?QVY*W?@E*-R%>]5JBN]9V6:)JL8+5[YLIC)'3/W2OOIIZ4Z?Z>?-9,,
MJ>?JV7"-JYFSBK?Y&$JJ'2I/M+.[WEL\\>3.[1V3'V_7IF;3/CZ/)L:2\*F
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MKIKQ>ZG%UX\B#5%3BTJ.M24PF
M
M
M
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M_#M;68B='J<[K'CF*WM'5IRU7^#BZ=+JFN#5*->!:9:=-<@(@
M
M
M
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MM1Q=5PK&HZ==C?PLF"N6;T.*E&7;P,2U9K.DMQCR5R4BU>4K@4K@
M
M
M
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M;K8*SDO&DSR]3S;YH[K3/:,&.=:UYSYRVS&O7Q[N?TG7Q&D.(F>.CU)0
M !!I,"27!<%Q;[/U2!I/U7]&-4WIKT->T7+MVK]RVK&1:R/A5M<&XTKV=AN]
MCW&,%9B8<5WWY>MOLD7I.DPN&9NG0/0W:FC;;RG=U#-5IJW:L\Y)/JG.5:]*
MKR+>/;WWN2;5X,G-OL/9=M3'>>J6<[0W=I>]-$AK>CRD\>;Z)V[B<9VY1?&#
M7>J\S7YL4XK:2WVRWV+=X_B8^3)DN"7@66:B$@
M
M
M
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MB:UUF/&9^D?H8&\^8=WNJS6UNFL^$</\6<=$75M<:49N]'/(QC&/(D3
M   0:3IX.H2DE&/2Z]G)\VF!KGU)]*=/]0OE\B>7+!U/&71;OQ75%PEQ::X,
MV&RWT[>WH<WWCL>/?Z3,]-H\5AUK5M*]!-G:?I.F6I:EJ&?=N>2[SZ8W;Z2Z
MY3IR5*<$9&.D[[-,S.C"W6XIV/:5I2O7,_?]3)/3#U(AZ@Z7?OW;#P]1PIJ&
M5:B^NW[RJI1?.C]IC;S9SM[:2V79^[1O\75II,-A0;<57G3F8#?(JO;S B
M
M
M
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MW?H9IM8=FFA-22HZU521.
M
M
M                                           "1RHZ<^TB9X"U9&NZ
M+:SHZ9>U"Q;U"='#&E=CYCKRX=A=^%>U==)T6+;C%6T5FT:N<O7C4-\X^\(6
ML>6;CZ4K</S;/#E=2N7'2O4[?"M>%&='VZ,'PM;<WFGS-?>QN/8ZHKPZ=/TZ
MMW:+HD]T[.TK%WS@6\G-G9A/(MW(]71-?"Z]C:YFBMD^'DF:.\P[?\SM:1N*
MQ,Z,IT_3<32\2UA8-FW8Q;*I;MVX],4EW)&/:TVG66RQXJ8ZQ6L:1"N*5P
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MD<UQB.3T>)CDJ4ZDI1
M
M
M                                     )7))I=Y(\I7[<(2N7'T6X)R
MG*7!))5;J^XC1$S$:Z^#"=&]6]BZ]KTMOZ;J77G]3MVI2MRC9O2C7A;N/A)\
M&9=]EEK3KF.#2[?OFTSY?A4M[7Z)]4M$[B])/4/+W[D9%C%ED0R,U9%G6/,]
MR%IRZJMU]WH7#IH;W%O\,8.B?)PF\[!OLF]ZXY=7GPT_;Z'4UC'_ "-JSD25
M^[:A",YM)N4XQ2ZN/)MHYC5ZG%8TB)XZ*E1:GU-U?_3L"N>;T(
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MUA?T>A(
M
M
M                       D<DNU5H!8]S[BT_:VB9NOZDY2Q,.WU7%#FWPB
ME%=[;27B7<.&<N2*QXL3=[JNVPSEMRJU_L?U<TGU-OYNV+VGWM,R<C'O>5U3
MC-3L3CT-U2X2I/D;#<["VUTMS<]V[OV+N-[8>F:S,?H^DL8V?]GO4M W7C:K
MG:G:O:5I]SS;$;<&KMZ*5(J5?A:X<5W&9N>[1DQ36(YM1L/E.<&Z^+:VL5GA
MYZ-^N,Y/E2O"C7 YWGQ>B:SX/:":^)<?#D2A.
M                                             $DHU55S7*A I\BS
M=NV;]NW+HN3A.,)?BN2:37L9,<)B5-]9K,1P<L[7])?4;#W_ (63F8T["Q<K
MS\K67/\ (SM1E*O2ZUDY=QU6XW^&<,1&G+D\JV?8][CWL3.O"=9OX:>3?V3Z
MB[)Q=?M[:RM8LPU=R47;;I!7DZ*$I?"I/NJ<[^4R37KTX/0K=VVM<OP9O'5'
M#Z_)F$9PDN$DUX&-K#:PCU1IS)$4TU5<4P(@
M
M
M                                               $LFNE]U.P#6_J
M]OS.V#H./F:9CJ_GY5Y6+,[G"W;X-UE]7!&?L=M\>VDN?[YW.VQP1:L<9ECO
MISNR[ZQ[;U[;N[\9?D%"U=NX_N1G"XJII]DHN)E;O#^4RUMCEK.T[VW=L&3'
MN*Z>'!D&P?2'0=A9]W4\3*NY^HWD[<+V3TKIMM\DHKN1C;G>WS\VP[7V'!L+
MS:LS,S]/\&RH\C7NC3
M                               $D_@?!OAR7-@<V:W]G[<N?O6_F6,V
MS^8,O)^:EF7)OS[?5+J<%;[9=TCH\7=*5Q=,QQT>:Y_E;/?>SDBT=$S$Z^+8
M^Y/6+:&S]8AMW-GD7\NQ""RKUB'5&U5)+J[WWI<C78]AES4G)6.#I]UW_:[3
M)\&\SU1$-AXF9CY^)9R\6XKMB]!7;5Q?A1DJHUTQHZ&MHO&L*M5IQYD*D0
M
M
M
M       /.7.M%6G&I&GB0I<G.P<>["SDY%NS<EPA"<U%R[J)TJ512\\8A;ME
MI6=+3$3/FT7]H'<N\=$R=+Q=&R+V!I-ZU.=W,QN$IWXNG3*:^'@;WMF##>)F
M_-POS5O-UAZ(Q3,1/EYLL].[.3O[TUQH;_PUE.]*Y&T\A-7+EB%%;NM\U)\>
M)A[R:X-Q/PY;CM=+[[8Q&[KU3/GY>$LWVUM?0MK8/YOT##CB8CJYJ-7*4N^4
MI5J867+;).MF[VNTQ;>G3CC2%_+3+
M                                             @^3[")3#2.]_02Q
MNG=$MPXNJO!LY3B\_'E#K;Z>V#HEQ[I&ZV_<[8J=.CBNY?*]=UG^)%NF)YO7
M>?JKIGI3>T[9NE:;/.E@XMGS9.?1&U9Y156^,FD4[?87W,3DF>:KN7?,7:^G
M;UKKI$-F;5W!A[IT'#UW!A*%C+AU^5<IUPGVQE3A5/@:[-B^%>:SX2ZC:;JN
MYQ5RUY6C5?$J5\6664F
M
M
M                          "24NG]0)8E?]1-G6-<_NW>U6W#5G)05J7P
M]<GPCU<DWW&3^5R6IU1'!K+=TVU<OPYM[31/K+LO?NI[[NZAB865J.!D*VM-
MGCMRA82X-.G!>][S;-[L,V"N*8MS<#\P=OWV7=:TCJKX>C_']3?VV](RX[7T
MK2]T*WJ&I6,:W',G>2G&5V*YT::J<_DM'7,UY/0=K@M^6I7-[5HCCKYLDA;A
M&*A&*C"*244DE1<DJ%KTLV(C31/1<J$*D0
M                                                   )'"#I[JX<
M4@-<;X](=M[YU''UC/N9&)GVHQMW;N/1>=;AR4TT^2X)FPVV^R8:=.D3#0=Q
M['@WUXR7UB88IZB[[O>D&#H>T-H85O\ *8\KD,C)K**A;DHNOXTY5JVS*VFU
M_-S:]I\6G[OW.W::8\&"L3P\?*&>^F>]KV^MK6M9R<=8V;&Y<Q\FU%MP<K4J
M=4&^QIU,'=[>,.3IB=6_[/W#\[MXRS&DZS'UPS2VVU7L[$^9AMQH]
M
M
M                                                         $&T
MN8%)G9MC Q+^9E7/+Q\>$KEV;5:02K6G@36LVG2%&2\4K-K<H:SVOZY;9W7N
M-;=LV,G&E><X8N1>45;N.-4U5<57L-EF[=DQTB[F=E\R;?=9YP5B8GS:^S?L
M_;EO[UNYD,ZU/1+N6\V6:W)9*3EU=#7*L>R1L([G7X'3,<7/9/E?-;>SDZM:
M:ZND;%KRK5NUU.:MPC%2?-T5*G.3[7%Z36.F(CR>W2JUJ^'97A]1$<!,2D
M
M                  )'"+YJM./$@8YNC8^VMY6;-C<&&LE8[<K%Q2E"[!R^
M)*<*2H^U&5@W.3#,S2>;7[WM^#=UB,L:Z?5+7'JYK.H>F.U-*TG9.-'3\"[<
M=J>1&*GT45:>]^%.O&;,[8XJ[C+/Q/V.<[[N+]NVM:[>.F//373[5S]#-Y[B
MW=H.?/<#5Z>!D1LV,[HZ?.C*/4^22?0^%5S+?<MO3#>(IXLKY=W^?=8;3F\)
MC2>6O!M:$G+CPIV-.IJXU\74O0D
M
M
M                          !!NGL E<FI)=Y$S!I+$]_;QCLK:V;N&6-\
MU>Q_+MVK%7&+NWI)1ZGS457WC)V^+XN2*\FK[IOHV>WMEF.K3Z?8U]Z;^J61
MZG7]5VKN/3[=NU=QY2A<QISI.U<X2@ZI--)\US-EO]A&TFLUG5SW9N]_W/KQ
MY*Q$3'A]RKV=Z#:-M?<L=>>HW<ZWBSE/"Q)PC%0D^3E).KZ>PM[CN5\M.G32
M&1L?EO%M<WQ.J;>,1I'U?8W!&"XM\:]C[#4:.NU>E.TE"(
M
M          %%J.EZ?JV-/#U+'MY6-/G9O14X_4RJE[5G6)T6LN&F6O3>(M'I
M:X]6[&L[>V!/&V-8^3MV[BCD0PH^7.&.U[SM]*X,V&RFM\VN2=7/=[KEP;.8
MVT:>B/)BOV=]4W=DVM76N7;][0;23P[V5U4C=KQ4)2H^GIXOQ,KNT8HM'PVI
M^4\^ZR4M\:9Z8\9\V\L34,+.ZGAY%O(C%T;M24DGW.C-',3$\8=Q3)2\>S,2
MK N
M
M
M"64E&-:-KP \IWX0C^4]Q-T74TN+X)?2./A")F(C6>#5/KKO'<6T= P+FW9>
M3+,R';R<Y+J\J$8J?+L<NQFU[=AQY,FEW*?,W<,VTP1.+G:>:W^C^M:EZE;0
MU;3=ZP6I85N]&S9R;T.EW(2BVZOME&7PNA<[ACKM\L3BE8[#GS=PVMJ[J(MK
M]WI9YL_TUVKL:61=V]C.U?RZ*]?N3E=GTIU44Y<D:_/NLF7WI;_8]KV^SF?A
M5TU9?'JI[U.KMH8S:(I=I(B0
M                                                  #SN0ZXM47L
M?)U[PAB'J%HFL:GLG5=+V[*./J5ZVO)C:I;JE*LH1:I1M5XF5MLE:Y8F_)JN
MZ;?)EVEZ8?9M,-0^@>U=YZ+K^9J6K6,C3=&>.[=^QE=45<NQ:I)*335*-N7)
MFY[EGPWI%::3+C?EC9;O#EM?+K2NFFD^/I_6W?I&]MKZ_G7],TC4[&5G8S:N
MV8275[KHZ5HI4\#17PWK&LP[C!W#;Y[S3'>+3#(.KCRX=_ LM@F
M
M
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M.-*QI"M*58
M                                        "2=>Q/Z")-5LU[2[FLZ)
MJ&E0O/&NYN/=L1R(NK@[D7%/O+F.W1>+:<F/N<4Y<5J:Z=4::M!^F'HKNS;>
M\<76];E9Q,#2?,<;UJ<6[\6I1X*+=(OXGUT.AWG<,>3%TUYV>?\ 9NP;G!NH
MOETK7'KI,:<?L\&S<'UBV1J6Y'MO&S)?,NZ\>U?<)1L3O1X."E3ZJFIMLLU:
M=<QP=3B[]M,F;X46XZZ<ITU];8E3!;\34E5<4!$
M
M
M                            !*Y*/-I>UA#SG.$55M*-*R=?=27%L<T\
M-.+6T/6K8]W<L=M1R+GG2N>1\VX_S?S>2C)UKQ[.!GQV[)./K\G.T^8=I.XC
M%$\>6O@UKZE>C.]-P;VR-4TN,,O U&<:9-R:3QE"E4TW5K\6B-KLNXXL>&:V
MCBY?N_R_N\^ZZZ3K69YZ\F_]"TW(TK1--TR]=>3>P\>%FY>N>\[DH1Z6W]1S
MV6W5:9C@]#V^.<>*M9G68C1=(MT;?/P3_5+?)D<7L2@
M         "%4N;("J)"J 50"J B   0JN\"(
M               A5 1   (50"J B!"J =27-D:B)(     !XW[,,BQ<Q[JK
M;NQE":7!N,DTZ$Q.DZJ;5BT3$^+0.A_9VN:9NVUJ=[5%>T/%R5EV;:C3)DXS
MZX1E+E1-)<#>9.Z=6'HT<'MOE:<6Z^)-_8B=8CQ7[.^T'MW"W3<T'Y.]<P+-
M_P"6OZDFNF,^KH;Z>?2I<&RS':K_  NO7TLW-\T[>FY^#I.FNG5X<]/O;AM7
M(7+<+D)*4)14HR7)I\FOH-1H[")B>3U"0
M
M
M                     "T:_JN-H6EYNLY;IB8%J5^]3FU!5H_K*Z4ZYB/-
M8W&>N'%;);]V&I-B^NMO>>X[6VM0TJ.%9SXW(8=V%QRDW%.L9II4JNTVVX[;
M.&D9(ER';?F:N\S_  ;4Z>I26OLZ8EK=$-5EJ\Y:+;OO)M82A2[\?5&#E7BH
MOM*O[I/P>B(XK=?E/'&Y^)U3%8GJT;WMM55./"B?>C2:<7=<GL
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MY'JI]!H[5Z;3#N<.6,M(O'*8U7 I7@
M
M
M                ,"]5-V:GLO9F7K.F6E<SU<A8LRE%RMVW<;_*27<O$R]K
MAKER166E[SO<FSVMLE(ULU_Z.>H>N[_NZIMO=D8:AC/'\QY$;:A'HG6,H3[U
M^*;+N.TIMXBU)XN=^7N\9>X=>'-75FFT_1O9NS]9EKNFVKT\M5^7>1/S(VE+
M\7@J,P<_<,N6D5EN]EV#:[3)\3'KKZ?!L:*[:UX<.'(U\<G0IDEV$B(
M  'G<DHVVY.B2JWX$2EJO=WK7H.A7+FG:'%ZSJ4*J;A+IQH2X\)7$N/'\5,Y
M_?=\P[>=(]J76]L^6L^ZB+W_ ,NGZ9:US/6OU!S+CE8O8F!CO_$V[/F/]U-G
M*Y?F;//NQ$.RQ?*FSI[W5;]"7"]:-_X=V,KU_$R\=.KM3Q^F3_PXRX?43C^9
M]Q7WHB3-\J;*_N:TGUZMD;2];=$UJ_9T[7;2T?4;TNFW.4NO%G)OX5.5.E_M
MN'B=1V_OF'<SI;V;./[E\LY]M$WQ^W2/M^QM>W+JBY<TW5/L:[SH==7'HS56
MER[V2+5KFX-)VY@O4-9R[>)B0X=<VZR?'IC%+BVZ&/FSX\-=;SI#*V^TR[B\
M4Q5FTM+;@]?M1R+DK&U]/C;L1?Y/,S5U2=.U6TU3]T<AN_F:E=8Q1]<O0-E\
MGQPG<6^JO[6,3]8?4B[<<XZA8BO^[CCQC'[]333\R[F?)NX^5MA'.+?:O.B^
MO&Z<*[%:_I^-J.'+A.[C)V+L?%*LHO[AL=O\TSKIDK]C6;KY/PVC7!::SY6;
MDVEOC0-Y8KNZ-DURK='?Q+E(W[5?QHU::\4=AM-[BW$:TGZG ;_MF?9WZ<L>
MJ?"63VVW&KYMO[IGM8A<<E-)5HUV?>!S:[WGZP;>VK?E@8[>J:O%-2Q<9IP@
M^ZY.ONOP2;-%O>\X-MP]Z?0Z;MOR]N=Y'7[E/.?U-5:AZX[^S+DGAPQ=/LRY
M68VG=FE^WF_U#E<WS-EF?8B(AVVW^4MI2/\ ,M-Y^Q38_K-ZC6'6YE8N3"J<
MHW<?L[4G&2+5?F;<1ST7K?*FPF.'5'UM@[3]>=,U"Y'"W3C?FN_RCEVVYXS?
M?+DXG1;3YBPY>&3V)_0Y7N/RGFPQU89^)7R\6W;5ZWD6H7K4U.S-*4)P:DFG
MQ337>=16U;1K$ZPXJU;1.D\)<I;KT'3-P^MNMZ5JEMSP9KS)*TU"?6H1[>\Z
MW'EFFSK,/(]UL\6Y[Q>M^7_!6OTMV6TG+&R%5<%*_P :)M+A0Q8[AFGDV7^W
M]G^[K]I^BO9']'O_ ,O_ -1/Y_/YH_V_M/3]J'Z*]D_T>_\ R[_6'Y_/YG^W
M]IZ?M/T5[(_H]_\ E_\ J'Y_/YG^W]IZ?M1_19LC^C7_ .7?ZQ'Y_/YI_P!O
M[3T_:?HKV1_1K_\ +O\ 6)_/Y_-'^W]IZ?M0_19LG^CW_P"7_P"HC\_G\T_[
M?VGE/VH7_2_9D,3*N0Q<A3L6;EZW-W>J-8IOP*L>_OU:64Y.Q;.M+3$3U=,^
M+3$5;G"-SIBNI>ZFERCP.BCD\YTKTQ]/%-T6_P 1?N2=3ICR_0>7;_$7[D(Z
M8\CR[?XB_<C4Z8\DOEVOQ%]0XHZ8\DWEV_Q%^Y">F/(Z+?XB^J(-(\ON0\N/
MXD?J&J.GT0AT6OQ%]1)TQY)NBW_W:_<D*NF/(Z+?_=K]R#ICR.BW_P!VOW(.
MF/)+Y=K\1?4.*GICR3>7:?X"^H<5736? \NW^(OW(1TQY'EV_P 1?N0=,>2'
MEVOQ%]0U.FODCT6_Q%]40:1Y?<=%O_NU^Y">F/(\NW^(OW(U1TQY'DVOQ%]0
MU3T0>7;_ !%^Y".F/)+Y=K\1?4.*.F/)-T6_^[7[D*NF/)#HM_B+]R@C2/)#
MR[7XB^H<4=,>2;R[7_=K]R.*=*^27HM?B+ZB4=,>2;R[?XB_<D:IZ8\DOEVO
MQ%]0XHZ8\DWEVO\ NU]41Q5:1Y)?+M?B+Z@HTCR3>7;_ !%^Y&JKICR2RA;H
M_=CP5>7<3Q4STQKPCZ<&UML^GFU-8V[I^J9>->EE9=MNYY=UQC\3\#GMSW#)
M2W3#O]AV3:YL&.UXGC'FN:]*]D_T:_\ R_\ U%O\_G\V9_M_:>4_:A^BO9']
M'O\ \O\ ]1'Y_/YG^W]IZ?M1_17LC^C7_P"7?ZQ/Y_/YH_V_M/3]I^BS9/\
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MJ:7K^=9^7R\VPIW;7%14TW%M)\>-*FDSXXI>8AVO;=S;<;:F2T:3:&4%EL0
M
M
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MM_(9_P#5KWW(E5?#UJ,O\N_\,N:;7\5#Z/OG:>$>IXU$:1'T\4P
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MB)X3I*(F--8G5[Q=5QYU?WPK3!
M
M
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M-T\34.O3@
M
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M-W@TB(LX6W:MY$S,X[<]?'Z]>"SNG)<X_C?%U&1$Z\?!K.&GICS0*D
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M2_59E;?!3!2,=(TB.$+G%-+BZOO*%]$
M
M
M          -3Z]ZM; TK>,-"U.%N5[$3\W5I68W88M^3HHN=*KN;7(V6/99[
M8^JOV.8W'?-GBW<8;\_Q:<I]:^ZGZG;!Q-)O9E[7<3(Q[EN?3;MS5R=RJ?NQ
MBJUJ8^+:9>K32=67G[ULJXIM.2LQ/E.NKG+TBQ[^L^JF!E:?:=G'LWKV9-17
M3Y5A52@WXJB2[3I=]/1M])>;=CI;-W*+TC2L3K]3L*-91I^%VUX'':<=7LL\
M6FOM#;.S-=T##US3[,KV5H\I>?"%:_+WDHN5$N/0UU&[[5FK3)TVY2XOYJV$
MY\-;UC6:3Q]4^/U<V(^C'J_HNAZ9_=?=.5Y&-;;>!GR4I6^FXVY1FZ<*/DS+
M[EL;6MUX^34?+W?L6''\#/;32>$^#,=?UCT%P<>]J.7'3\W(N=5V-JQ'S;]R
M<NZ*:J8&/'NK6B(UC1O-UN>T4K-[]$Z_7+4GH1&5[U0QIV;4I6;6-DRFXIR5
MM3ATI2?*/9S-YW2(C!/&-=8<7\JUUWT6B/9B)AV#%KI5.1QL2]CTT3$@!8MV
M:2M<VWJ>DJ*G<RL>Y;LQ?"MQ1;@F_;0Q\^/XF.:^<,O:9O@YJW_#+CS%Z[#^
M7O1<+UINW<A)4DI0;3X?0>([K%-+VK/.)>_]<9*Q>O&)XKY9N+R+JYMVY)?N
M37T]^/7'WL')5B6R\' SLW*M:E9C>M0M]:A-<FY4X4?>=9W7)DPUK-=5C)P]
MUFD=%V_BR5RQ@6XW>UTJJ]]&SG;;W+>NEI6XZIYI<W(E)N;E6=*)/E1&%69\
M9U9>.FC'\N3N5MVG6[-JW:CVNY-J,5]+9LMOBF]XK$<V=%HI'5/*.,ME^JFT
M9Z!MO:>9&UT+"L1P,]U^"Y./6D_;-W#O.^[&U=MCF/W(TG]#A_ESN49MUGK,
M_P RW57]/ZM& 8=Z,91X\'R:Y'G%ZNVR5E;-ZS4L3!;?#JN4[^1O>RTUO,^;
M7S'&5ZT;1-"OZ1@WLW3[4\B=FMR<JOWNSDS!W.\S8\TQ%M(8]NK7G*Y6K&#I
MT)0T_'MX\)*LHPC1MOODZLU^2]\D^U;6%5:S/-;LRXI55:>WD44KI+8XX9)Z
M0:)+7-Z.Y*TKN#I^+>EDN7P]=^/EVTN=76K.Z^6MK\3+:TQPB'._-.Z^#M8K
M$^U:T:?5Q89E8%_1]3R])RX]&5A7KEBY&O"L)-+CPK4YW?X)PY;4GPETFVSU
MSX:Y*SK%H7? O*,HJO'A1FDFLZ\%C+7@P[;F+B9^XKUK.LJ_BUO-VWQBVI<.
M3.QWM[X]K6U>$\&/DUTX<V;1T/;MJ77#3;74N*3J_JXG,WW>:T>_*S'5YILJ
M\DJ1]U<NE<DER2,>9UXVYLG'1CV=>@H7)MT4?BKV&5BIQAL\<<87#9>E9NC^
MH,,/.CT9DL2=V<$ZT5R*E%/N;1]'=KVWP.SXZ?O:ZR^1_F#>_F_FC/:.-:UZ
M8^J(_P 6U>'%(A=TCP       >67_H&=_5KW[PFO./6MY?Y=_P"&7-5O^+A]
M'WSM/!XW'*/IXI@   !'Q"?2@$  !PHZ\FJ?7P$<X3$SX>3L+T-U3'U+TPT6
M$)=4L*,\.]%4]VY;N/\ 49Q7<JS3/.OB]J^6\M<FPI$?NZQ/VN4]UZ)E[;W3
MJ^A9MIVLC'R+MRW!_A8]V3G":;^)--\CK-MEKDI'3X0\E[AMLF#=6K:..L_7
MK_AZEIE%QI[O&L81C3C*4N48+FV_ R..FLPUL<9Z=-)CP_9Z_6JL_3]0T?*>
M'K.)>P<NBE"SE0<'*+2XKC1IIUX,HQY:W]V=63GP9,,].2)K/I^K_CX.D_LW
M;9EI^V\O=&5:<<K6KK^7<J56)9;44NVCEU'+=VW'7?HCE5ZA\I;/X>WG-,<<
MD_HCZ2L/J1Z0^HV]MXY^O6/DEILU'&P87LB2FL:$7S2MM*LFW0R]GO\ #AI%
M>/IX,'O/8][O-Q;)'3III'M>''T>EM;TUT/<.@[*P=M[JC9N9F)&>,OEYN["
M6-7W4VU'BDZ<N1I]YDQWRS;'R=;VC;9L&UKBS::UX?4Y$W]MW^Z6Y=;V^XNW
M9QKOF85.W'O/K5'PJDGTG7[7+\3'%H\GC7==K&UW&3'/#C[/JG_!VCA:IC:-
MLK#U;,ZOE,+3;.1?\N/5+HMV8R=(KFZ'%7I-\DQ'C9[=3-7#M8O;E6D3PX\H
M6;8WJCM#?UW)Q]NW+L;^)"-V5K(M*S)VY<*P57U)/@R_N=IEP5B;<I\F)V_N
M^WWMIKCUUKYQHU]Z[^I&XMORCM'3<5X-C5;$JZY*3;G;I2Y;M)+W9][,[MNT
MQWGJM/+P<_\ ,W=<V"OP:1I%XXV_5#2VS/4'<FP+698VU*PK6=.-R_\ ,0=Q
MJ5N/2J4DNPWV?9X\NG5X.$V'>-QL:S7%II/G_P ?L;]]'/43<V]\#<5_7I8\
M[NE]#Q79MN"3E;<N*KQXHT._V=,,TZ?WGH?8.[;C=X\ELDQK7EI&C5+^T)ZE
M75<B[F"H2ZX>[8DFDN'!]7,VM>UX.?%Q]OFG>S-HUCAK'NM8M<92[92<E3X:
MOWG]TVE8Z8T\')VUF9G776?\?O0*D        !_#+V/]Z3',\)^O[F^]C_['
M:3_D/_>9R>[_ )MGJ?9OZ+&OIBMJ      (2P+?_ /M1L]=]V7^=B;?8>Y=R
M7>_ZO;?7]\,H^TIN9>7I>TK,^$OY_F13;2=OW;<94[^:+/:,.LS>6;\X;OV:
M8(GC,ZS]7)@6V;7K+HVF06U<34;&DYB61;G9LV:7.I44DY*M'$V&XC:WM[<Q
MK#G]G'<\../@1>*6X\H4&\\7U/U.S:U;>^#F2LX<7;AEY5J$8VH7)<56%%Q=
M.PN[3\O2VF.>+%[CC[AFK%MS2WL^.GA]/0WAZ$;RQ<GT]OXN?D]5S;?7"[<E
MV8O2[EM]]$JQ-!W+!-<W#]YWWRUW"M]CI:W\KGZN;G^[D[AWIN_.UW2<:YF:
MMD94\N$+45-V[=N:5O@UP2HCHJTQX<58MPAYW:^?=[JV;%K-IG7A'A'!FOYU
M^T3.'3=MZJX-M3B[-CI<>U)=*=/IXF#.+9<]6[KN>^3^[:?1I]/O8CMG4=6V
M#OC S]5Q[N%DXN0KF?:OKIEY%^73-N*YQ2FY?09V:M,^+2.,:<&FV67-L=U2
MV2LTF)]K7\,S^K5NO[0NZXV=M8>W\2YU2UA^=<C%_%BVW&477]DZ</::/M.W
MFU[6F/==S\V;^M=O7%$\<G'ZOI]K4>T[/JUI.F_,[,Q=0M:?F=-SS\>S:Z;B
M@Z)+J3X<>9M=Q^6R6]N8<?L*]RP8]<$7Z9]'--NVUZN:OIT+^\,//N:?@5O>
M=DV;2Z$Z)NL56C&#\MCM/1/,[C'=,V.+9L=IK3E/CZ?I#9OH/J\-P[-U?8N7
M><;UFW<CC-\6L?)37NKM47QX/M-7W/'\/)&2(X.L^5]S^8VM]O,^[R]4J)?9
M:QXVE:CN"E(N*E\JI3H^]]:XER>]3,>Y&C%GY)BW&<L\]>7^+8.X]ZZ)Z2;=
MT;1]0E/.RXQMX]JQ:71<E:MT4[J7=%<EVFMQ;:VZM,QP=/N]_B[7AI2^MIY<
M/O5V'Z@>F>X,=YL-2T]MQ3NK+C;C>CX35R/-?26K[;/C]G25[%W389Z]?57T
MZN;_ %<U/:>I;QMYFQ^CRK2C"]<QX.%J>9YE8N%*4_;1.HV-,E,>N3D\Q[]F
MVV7>5G;Z<--=(\=>#K;;<LZYH.FO5*_G!XUIY/5P;O='O57M./RZ=7#D]BVO
M7.&O7[VG'UKU'X5V\%Q*%^$P2
M
M
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M1A9^Y9,L:<H;;MORQMMI;JGVY]+:\8I2ZFN)JW7:ITJ((1
M
M
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MK:]*]&29C6MK1""G'G%U;XRDWU2<OV3+FBW$^7T]:%5V49 C6)">!6(T1P.
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MN*E]8<_W'>8=QN,/PYUXNR(?"O8CDI>O1R3$)
M
M
M
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M#]#OIG_J&Q^[N_PA^>W'XI/[!V__ $H/T.^F?^H;'[N[_"'Y[<?BE']@[?\
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MC]W=_A$_GMQ^*3^P=O\ ]*#]#OIG_J&Q^[N_PB/SVX_%)_8>W_Z4'Z'?3/\
MU#8_=W?X1/Y[<?BE']A[?_I0?H>],_\ 4-C]U=_A$?GMQ^*4_P!A[?\ Z<'Z
M'?3/_4-C]W=_A$_GMQ^*3^P=O_TH/T.^F?\ J&Q^[N_PA^>W'XI/[#V__2@_
M0[Z9_P"H;'[N[_"'Y[<?BD_L/;_]*#]#WIFN6@V/W=W^$/SVX_%)_8>W_P"G
M!^A[TS7+0;'[N[_"'Y[<?BD_L/;_ /3@_0[Z9_ZAL?N[O\(?GMQ^*3^P=O\
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M)))+L1AMTB$@
M
M
M                                              ATKN03J=,>X&I1
M=R 47<@%%W(!1=R 47<@%%W(!1=P$:!!0!0"%%W!)1=P$:!!0"5I5KW 03C*
MJ3Y<.9*-1TX+EV<R$\T*>\N=77Z G1%4JZ<V3HC75/0@0HNX)1H$% % % (4
M7<$E%W 1H$% % % % % (47<$HT""@"@"@$*+N"4:!!0"%%W!)1=R 47<@%%
MW(!1=R 47<@%%W(!1=P-4.F/<N'@#5,$
M
M
M
M                          !+*+?)\0A0VI8?R]^=JXGCJ4_,EU-T?X7&
MO E3&D0\YW-/6-CRN7U'&E.*QY]<O>FW[JK6KJ$3:ND:O?KQ_G(1=RF6XRZ;
M74^,%S=.7!A.M>KF8TL65^^K-SJO=2\Z/4Y=+]CX(:%9C65:0K
M
M
M
M
M                    !YRDTW157!)$P2M=G+C\CF7OD9VU9G=3Q6EU7>A5
M<HKE[Q.G%9C)K69TY);V5".%@W/S=<DK]RW&-A*-;'7^%)<ETE45XSQ46R>S
M69KSF/J5/FK\X0L>1)N5J5Q92BE!)22Z7VUE6I1IP7=8B^FGAS0PK\;V1F16
M++'=JZH.[))*\TJ]4:<7S[29A%+ZS:---%R*5T
M
M
M
M
M        'G<J^%%2G-E4(X^"W68:NL7+=Z>.\YRN?*.,;BM*'^+ZU6K:[>DC
MAJMQ&7IG737P_P 4+D-;^5PU9N8RRHSA\\Y1FX2A^&K:3JGW5*HFO'53,9=(
MXQKX^7U/7IS_ )Z,D[?YNZ&W&D_.\WJ5&G7IZ:%$=.GI7)ZNKPZ=/K,7\X+(
MRGERLRL.XOE%:4E-6Z<>MMM-U_%)F8T16,D3/5IIX?XKB0N
M
M
M
M
M                  \KM6NFO2WR:Y\!")C7@Q_&LXGYIU.W'6;M^Q=N9#NY
MWFIRQGVP4UPBK?W"YI.O)BUB)I;V]8\_))>Q\-Z7I<+FM7K5BU>LRL9JO)2R
MVOAA*3^+K[5VE43I,\%%ZUZ*^WPUCCY^A6RMV7KMF_+4+BR8V)Q6E*XE;E!R
M7Y5V^^/PU*(GV=-%^=/B1[7'3W4ND6;%O4-3N6M2N9LYWUY^-<N>9'%GT_Q<
M4OA[Z"W)3BK$6MI;J]'DOI0R0
M
M
M
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M<E+/OW+,K4<F]TJER$GPFDN'41?KTC68T,%L<WOTUF)UXS,<_5YLC+;,
M
M
M
M
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M@
M
M
M
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MQ,5B*Z&WQS6]YF_7K/+\/H9&6V8
M
M
M
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M,GIX-.7!JG=P*<G5I&LZQX*MG?!.7+&.-+1;V_3+,2PV8
M
M
M
M
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MB8G75&TRY;WR1?'T16>$_B]+*"PV(
M
M
M
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M5ODG)DZZS/LQ^'T,H++8
M     !Y.<^II)-+Z_O$2:2FZI?B_= G5>TD      DZ^+78N83HCU57!<>YD
M:QJ"E5T0-$Q*                      "1R2;7.G$(3)\*A*(
M
M
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MU>B\?IAMI2KR-4ZU$
M
M
M                      I[BXNCYJO<ZQY+Z1H:Z-<:7N*=_:^XLU;*N8OR
M5^Y!:5Y<%+.2?QI=*JGWT?@;&^.>NG^9S\?)S.'<1.VRV_+].DS[.GO_ *$=
M2U^=C;6U\U;,GERS;MJ/YK\M-Z>GQ3Z>E]/33N1-,4SDO'Q-.'/\2K/NIK@Q
M6_+]75,>SI[G[%VN:M.&_P#&TF.VYS5S$ZY[C\N-+:HWY3G1OFJ<RU3'_D3/
M7RGW?-E6S_\ NQ3X7.O\S3EZ-39NJRU/4]?M7-NST%XF5Y;R)1C!9G=<]U*O
MW>93GK,5K[?5Z/)/;\W7DRQ\+X>EO>T][TLX,1N0     (/EQ(D8KZ@-_P!R
M=P/_ /8+W#FJ]+,C;_S:^MK^XSIMLD_\LN$$W3DN1Z+I'I?-SL?T%H_2[2%)
M=49W,M-=E'D3K4X;NG]1;3T/=_E6/_Y=2.?O?_*7.'JOMB6T=\ZEIUN'1A9$
M_G,%I*CM7VI=*I^+*J^@ZG8YHS8HGQB.+R_O^RMMMY>L<K>U&GE/']$_<K?1
M3<;VWO[ E=ET8>J+Y'(;X55YKRV_!2HRSW+!\7!,UXS"_P#+.\G;;VNL^S?V
M9_5^IVA;<7^H^]/B<0]SYIY-)5;IQ7WR4-:^MNYEMS8F<X3Z,S4_YA9@G23\
MU/KZ6N5(U9L>VX9R9H]'%S?S)O8VVRMYW]F/K<9*+A'AR7"G9[?:=W$>3P>T
M3[SKK[/^V%H6QK>IY$>G/UJX\F<_PO*7NVHUY\$<1W3<1DS:1RA[E\K[&=MM
M(FT>U;BVY#X554\#5.K3@ ))INE'1KC[2)Y(<A?: W3^?=[3TFQ/JP]#A\M&
MJK'YB24KCB_IC'Z#L^TX(QX>J8]YXU\V[[X^Z^'$\,7W_3@U.G*M.'>_8;K3
MCIXN(TGS;G^SGN:>F[JR=N7Y4Q-8MUM=<N*R+%9144J+WDW7O-#WC#U4B]8Y
M<WH'R?W#HW$X)Y6C],.L%1+N2.1>NH@0;2Y@*KD!+-TIQHZHB8U&FOM(M/8-
MGW>+SK+7W?#M-YV>-<WU.+^<8_\ 2_ZH<X[!_P!N-M\:I:C8<4U2G5-<*G3[
MS3X-]'EG99G\[B_BK^IWL>>OH=!R1.B-4)3C'BV-$PCU1[R ZE]? )0ZEWD(
M14DR4C:2J^00B!SEZ^>FNX=9UJWNG0,6YGVW9A9S,>S1W(NTW[])-<*/L1T?
M:]]3'6:6G1YO\U=ES;C+&;%6;<-)T\-%F]%/2O<*W3A[GU["NX&!ICE?QHWE
MTSO7I*45PK6D>I]B+W<M]CMBZ*3JPOEOL6>FXC-FK-(KR]+J"VNBO5S;KQ.6
MCD]4>G5&E:J@2*47V^))*+DDJM\"F9"JI7L)$0-.^O6Q-9WAI.GYFA67DYVF
M793EBJCE<M7(T:C5KC7L-QVO=UPWM%N$2X[YG[7DWF*LXXZK5\&E=A^DF\-7
MW%B_G'3+^!I>-=A=RLF_%024))J,:NM>'8C=[ON&*,736=9EPG:_EW=7W%?B
M4FM:SK,_9].3L:W1+A\,4DN7"BY'&O;--'HYQ5/$A.AU+E4IF4(.<4N+2]O
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M$6TE5\$@(-Q7%NE"24Q
M
M
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MO@GCR=OVOO&'?5UI/M?A\6=&&W(
M
M
M                   *>_3HGURZ8-4DZM4CVNHB>*)TTXM-:'I6Q[.RMV8]
MC>-_+TB_E7'J>I2OSZ\.=?@B^RO_ &C<6R9/BTGHX^7FX[;[?;5VN:L9YFLS
MQM^%Z:SI>R)[-V9BY.[KN)I>/>M_FO45<FIYLE^-PX>U\$,.7)&7),8]9GG'
MD;G;[6VTP5G/-:1/"WXE]OZ?M7]*V!J%S<=V&Y(X<;=C0%=DK5RWY<TIN/)U
M57]%2Q6^3\MIT<-?>\F=?%@_N%;3EGKZ>%->?#G]FLGIQA;8Q-:W/<T#<,]<
MS+V6I:C9N7)3^6G67NJO/BVJKNH4[FUYI6+5Z8\#M&+!3+FG'EG):;<8G]WZ
M?X-F& Z0     "$N3(D8MZA?[%;A_J-[]X9&W_FU];7=S_I<G\,N#ER/1GS<
M[)] _P#A?HO^5RO_ *B9PW=/ZBSW?Y4_^NI_U?\ REG&Y-%Q=Q:'J6AY*3MY
MUB=J5.?4X\']#-?COT6BWDZ#=[>NXPWQSRM&C@K4L'+TK4,O3<R"CE8=V5B_
MWJ5IT?U4/1,=^NE;>;YUW.*^')..W.LZ.A/LQ[E<K&K[5O2<O(:S\.O)0N-0
MN17^%Q.:[W@Z+Q;\3T_Y,WD32^#\'']3?NH9V-IVGY&I9;Z,7%M3OWI=T+:Z
MFSGJUZIT\WH63)%*3>>41JX&W!K%_7]>U'6\E]=_-ORNQ?[%NB^X>B8<71BK
M3R?.>^W$[C/;)/.\_K;M^S1M=W-0U3=V3!>3C1CAX,I<O.N>]=H^^*]U^TY[
MO&>=(QO0/DW8>U?/;P]F/UNFCFGJ   DFJ^[V--$>(Y_^TMNB&/I6!M#%G2]
MF2^;RU'FK5NL8I^$FW]1T79L'M3?ZGGOSEOHIBK@K[UN/U-!;5T&]N;<^E:%
M;CUO-R(VFTN"M1:E<;\.E'0[G-\+%:?*'FO;=G;<;FF*.4VX^KQ=TYNDXF7H
MU[0G%+$O8[Q%#NMN#A'ZC@(M,7ZGT+?#6V*<?AII^AP5JVEWM%U3,T:_&2OX
M5V[8GU?A>5)I/_"2J>B8\GQ*5L^<MYMK[?-;';]V73?V<-SQU/:N1MS(FI9&
MCW'*S'L^7N\5_P!ILY3N^&:Y.O\ $]:^4-]&;:SBGG3[FZ7<48]+I7BDEV41
MHYG1W<1RU<W?:/WM<NYF/LG"NN&+:C'(U56^<Y2KTVY+NIQ.F[1MJS$Y)YZO
M+_G'N=JZ;>GKEI'1-%U+<6IV=%TG&EDZADUC:M*JI3CU-]D5S9T6;-7'7JM.
MCS[;;3+N<D8\<>U/AY?X-RV/LRZ[+"C=R=;Q;6;T=3QXVY37F/G'KJE1\OA.
M?GO43/+@[N/DK+TQ_FQ$Z<O3].#6&\-D[DV'F+ UO'\O'RD_)RK#<K%]Q[*\
M%5>RIN-ONL>XC6O.')]P[7N>WVZ<FNEO+E+PV#_MWMS_ -0QOWZ*MU_(MZEC
ML_\ 6XOXJN^#SU]$.$/4_P#XB[I_]2R/WQZ!L?Y%/5#YZ[]_79?X[?>\MG[)
MW#OK4/S;H=GKA;5<C(NR:Q[,6^<G1\7V)<1N=UCP5UF>*KMO:\^_OT4CV8\?
MW6Q]=^SCN'2](O9V#J5K4,C'@YO#C!VY2455],I/BZ&KQ=XI>T5F--74;OY-
MS8\4WK?JM'@TLXR4W"::FFX2ZN=8<&I>*? Z")B8T\)<!,VBVDQ[OAZF=[3V
M'O3U0R(7[5R<]/Q81QOSGF2?EVX6W3R[5:UHGR1J\^ZP[76/&72[#MF\[M,6
MF?8CAK/ZF0;U] M=VMH]W6,+-MZM8QD[F59MVW:N1@N;3JZT[3'V_=Z9+=/2
MVG<?E/)ML4Y*6Z].,^J.;3[?5&2C)Q7"49Q^)-&[FNKA(X<8=[;'U">J[1T3
M/N\9Y&'9<WWM1Z:_2><YXZ<DQZ9?1_;\GQ-MCMYUAH;[4/#6-#79Y$_WQTO9
M.5GF_P [^_C]4L<^SCQ]2[?]1R?_ '3)[Q_3QZVI^3OZ_P#Z;?J=7ZW_ &-J
M7]5R/\W(X['[\>M[+N?Y5OX9^Y\];;7EVVZ445S]AZ7CB..KYJCG.GT^GV^3
M/MC>E^ZO4&F3BP6-I5M>7/4<ERZ:KLMJM7X]AJ]QOL6W];INU]CW6_X\J1RF
M?U>EF.O_ &;MQ:9IMW+TO4;.I7K"<YXO0[$Y)<Z2;DGP^LPL7>:3;VJMWN?D
MW-BI-Z9(M/E]/1]K2733JA.,HOX)I_$FC?\ -YW:MHGEQ=E>A.JY&J^G&FSR
M;OF7<25[&4WS\NW)J"^B-#A^YXNC//I>[_+.>V;84FW[NL?5#'_M,\-GZ8__
M -M7^;D7^S?SI:OYS_I*_P <.?O3/_B)M7_U3'_?HZ;??R+^IYMV7_[#'_'7
M[W;>X=3CHNAZCJT^,,+'NY#2YUMQ<OOG XJ=>2*^;WS=9OA8;7_#&K@;4<_)
MU7.RM4SKDLC,RIRNY%R?Q2D^-&W^+R/1L=.C'%=->F'SKN=QDW&:V2W.T^/V
M>KZW0.S_ +.^@:CH&)JFN:ED7LC-M1OQ6 XV[45<58Q3?56AS&X[O>MIK6.3
MTOM_RAM[XHOEM,S;CP4^Y_LT9%FU<R=H:B[T^E4PLZ*4I/LI=7#[A=P=ZC_R
M56-[\F:1U8+:_P#+;]O%D?H%Z=9>V\7/W#KF-+%UC,D\:QCW/BMX]J5&W3\:
M2X>!B=SWD9;1%>3;?*O9[[3'.3+'M6\/)0^I'HAN+>6\,K7M/R\:WB9"M1<+
MTI=2451\D_H+NT[I3#BZ.EC]X^6LV]W4Y>J.F8AS;DV9X^3?Q)R3E8N3M.46
MWU.VW%]/AP.KI:+Q$Q&G!Y-EQS2]JZ\:_J;'V9Z*[@WMH%C7M.R\:QB79SC"
MW>;ZJVWX)^WB:C-W.F*TUF-76]M^6,^[PQEBT5UU^MT_Z=[=S-I[1TO;^?<C
M<R\*TX7'!UA5S<N#HN\Y+<98R9)M$:/6NU[2VUVM,5N=7'_J57](&XZ.C^>G
M25*TX([C9?R:O$>]Q$[[+$\/:6W0-N[@W7G1TO0L2[J%VW+J=J/"U;<N'6Y/
MW8\BO)N*8.-F-M-EN=Y;HQQU:?9];<&T?0/>NC:[I&MYV1A0^2RH7KN/"[*<
MO+BN/%PY\32;CN>&];5KKQ=QVWY5W6#/3+:U?9\&Z_4G:MW>6SM2T/'O2L7[
ML/.L2C)Q4KENLE&5.<9<FC1;7-&/+6TN\[KL[;K:WQ5G29AS+LKT2W;NRF3D
MP_,^EQ;@[^7!QE*C:DH6^$G1U7&AU>X[KBIRC67E';?E?=;F?;CX=?/QEL>?
MV8=.6)*WCZ[=6<N$+URTO*3IQ]Q/]4U?][MK[KII^2,73I%YU\_^#2F]]EZM
ML36_S5JG1<=R'F6,F%7;N6V^E-5Y.JY&_P!KNZYZZQ&FC@^Z=KS;+-\.W'7E
M+9/V;-RY.%N/+VO<N2E@:A8ED6;;^&U?QTG-T\4S4]WV^M/B>7ZW5_)N^O&2
M<$^[,3,?4V1ZP^ENL>H69I>1I>18L0PK5R$_F.I5<W7L1JNW[V-OKJZCO_9,
MG<9ITVZ>ES)N_;&9L[7;^WLZY;O9>-&W*X[->BDUU+G[3KMOG^-3JJ\C[EL+
M[++.*UNKI7K8'IKJ_J'#-EI658QI8/1U._)T?F>$48V\WU=O;ILV7:.R9.X]
M4UM%>ET?Z.>GFJ>G^GZOB:K>L7KFH9%N]"6.VXI0M]#3K[#EM_NZY[Q,>3U+
MY?[3D[?BM2\ZZS$M,_:05-_64N7R%K[[.@[1_*^N7!_.7#>5_A7#[,/^UNN_
M^FK_ #\"UWOW*^M=^1_Y^3^#]<.B-W;CQ=I;:SM?S*.UAVW*%O\ 'NRX0BO;
M)I',X<4Y;Q6/%ZCO]W7:X+9;?NPX;W!K^I;DU7*US6+SO9N3)^=U?#&%.$(?
ML8^!WV#!\.L5KRCF^?M]O<F[O.;)QM;EZF?;#]#MS[QP+>JWKEO2=*OI_+7;
M\'*]./8U!T]U][9K=UW2F.>F.,NF[=\L;C>4B]YZ*^GG_P 'MO/T&W1M? N:
MMB7K>L85F,IY2L)V[D%'M4.+:7;Q*=OW6F6W3;V57<?E7<;7'UXYZX\?-K/2
M]6S]%S<?5])R98^H8[C<MW[?#BG2G[5\G$VV6E<E9K+E=KN,N')&2DZ6CE]S
MN#86[<;>FV,'7;5(7K\.C*M=MN_"JFO955]C."W>'X&2:^$/?>U[Z-YMJ9=-
M)F.+3'VI>.1MNO=D_P#]LWW9/WG!_/'_ (O^K]30F#A9VI9<-.TVQ/*S,J2M
M6L:W5RN-OP^Z=#:U:QU6G31YSAQ7RWC'CUULW-I7V:=Q9>+&[JNJ8^G7Y<?E
M81=_I37+J70E)=O,TF3O6.+>S&KO,'R3FM6)ODBLL!W]Z=ZSZ?ZC9Q=5<;N'
ME=;Q<RU)N,^CG%IKGR,_:;NNXB9CP<[W;L^3M]XZ_:K/N^7ZU5Z,:ID:9ZDZ
M$L>3A'-O/"OP:^*U>BZ?=2*.YTUVTRN?+6:V+?X]/WO9^J7;IPSW<
M
M
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M+J2Y1Y-]*[Z]HW>/)6E9M;JCPA/:<V"^;+&/#..T3[4^?&?^.GI;2-<Z0
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MY^7OZ_%_$[I.!?0
M
M
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MU=*E8:;<*M<*5X=*5>KM)W%<,4KT3Q\4=NMO9R9/S$1%-?9T^GEIS9X83=@
M    0G\+(D8MZ@_[$[B_J-[]Z9&W_FU];7=S_I<G\,N#NQ>P]&?-\NR?0/\
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M>9O>S_S9]3B/G#^DC^)H+TJ_XC[5_KT/WLCHNX?R+^J'FWR]_7XOXG=1P+Z
M
M
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M_P#IU_B:$]*Z+U)VM&M6LZ%*.O.+.C[C73;WEYU\OUTW^+UNZC@'OH
M
M
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MP5$WXEV^[S7K-9MS86/L^SQ7B],<1,3&C-3%;<
M
M
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M*_[SC&K7\8J<>KL)W5<<4KTWZI\8\CM6;=6R9(S8XI77A/GQ_3ZVS#7.B
M
M
M
M
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M-?=B==/V>IM@UCJ
M
M
M
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MCQ;P-.[8
M
M
M
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M%_S>?K;B-6ZT
M
M
M
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M;A$:J+Y*4C6TZ0],>["_;5ZU-7+<TI0G%U3B^331&DQ.DIB8F-8XQ+W"H
M
M
M
M
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M[J;3EM-HTGR=)VNN.NUI&.W773A,\Y988S9@
M
M
M
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MP3?.K75])HMU68RVUGJ>@]IO2^TQS2O1$QR\F6&,V@
M
M
M
M
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MUIVFCW$4^+;HY.VV'Q?R]/C>_IQ9&66<
M
M
M
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MSXI)OIX]QSN[F?C6UCIX\GHG:JQ7:8XB_7'3[WFRTQFT
M
M
M
M
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M\3%O.MR"ZY]2E+M;E5U[3F]U%XRVZIUEZ3VBV*VTQSBB:TTX1//FS$QFU
M
M
M
M
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ML:\NG3]#:>+;LV;:LV8*W9MI1MPC1**2HDDN2-3K,\^;JHK%8B*\H502
M
M
M
M
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M-4ZQ.DER21(B
M
M
M
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M27(A*(
M
M
M
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MCV(*U8M14+=J*2BHTI3D:B9F9UEV%:],1$<(A[0BH1Z:\%P52E4G)
M
M
M
M       0J^X N0!NCH#1([MM<)3C%]E6E]\G243,1S>4\[$MTZ[\(UX*K1,5
MMY*)R5CQ><M5TZ*K+)@E[2>BWDCXM/-#\\:9_28?6.BWD?%IYH_G33OZ3;^L
M=$^1\6GFFCJ.%+X;]M_X13TRGXE?-[1R+$TNFY%U_9(:2JB\3XIU)2Y.J[UQ
M1"=4:ON^Z0J1" D
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M;#LNUWV+/DMGMK6>4?KAMQ02HE1)<DE3ZC4:0ZR'H2D
M
M
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M1<F_80E%.J)$0
M     !*XIU\0,1]0=EV=];=R- R,F6+YDHW+5^*ZE&=NC58\*KAR,K:[F=OD
MB\1JU?<^WUWN"<4S-=?%HCU*V%LK:NB[7V_KNOW,7*QK>1%S^7=^-VW=FG<N
M=*DNA1ERYF_V>[R9;VO%(F' =X[7MMKCPX\F6U9C7E777C^C1L.WZ*Z9F;ST
M[>N/JER6%9MX]R&,TW.<K4*0:N5X*E/=-;^?GX-L<UC69=)3Y?I.ZKN(O,Q$
M1P^KS;>:N<&N'%MJO-&G=AJ]B4
M
M
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M]A@W4Q.6O5T\E^LVH6H0M6XJ%NVE&W!<$E'@J>PL3,S.LLVL1$:0J D
M
M
M
M      4&;JN)@I^=.L_Q5Q=2JM=5F^6M>;'LO7,S)<HVEY5IK@TZR9E5QUCF
MU]]S:W);57JDW)RD^<I<RYK'@Q)F9YHA(     $?8$(!(       N81($@
M!*Z.K:=>QK@3HGJ\E7AZGFXCBH2Z[4?P)=B?'@46I$^M=IGM6>+(,37<7*:A
M.?DWN71)<_$QK8IJV./<TLNR:?%--/DT6F1"8)
M
M
M
M                                          I<G*LXT'<OS48)<*\W
M]!,1JIM>M>;',S7\C(3CBQ5JTZIRE\;7L,JN+1K<FYF>2UUD_>;K*M7)\V_$
MNL.9UG4) @                  !'Q"$ E&@1J@$@$LXQDJ3553F"-%;A:M
ME8;2@_-L=MN7!I)_@E%J1;FR<>>U638.J8N?&EJ5+E.-N7!\.9BVI,-E3+%O
M6N!0N@
M
M
M
M     "#=%W@6?4=<L8GY&V_,R>Z/PJO:WX%RN.98N7<13@QF_?OY=R5W(N>9
M)?##BTO94RXK$-7DO-DO<^TJ4 2$                    $?8$(!(   0)
M0C1/FD_H($>N46IPDX37PS3::3Y\1/&%46FLZPO>G:^ZJQG*BX*-]/@_;W&-
M;'XMABW/A+(824HUA*J?X2XHL:,[U/0)
M                'C674U5T[Z<"G5*FR=2P<+JGEY5FQ!*K\VY&-/K:+D4M
M;E"S?-2GO3$++>]0]CXTNB]N'!MRXJCOP_79>C;Y9_=E@Y.Z;2DZ6R5CZX>$
MO4[T_;I_>;3Z_P"7@3^5R_AE37N^RM.D9:S]<*W'WSL[)I'&UW#N2E\/3?@V
MRF=ODB-9K*]'<-M/+)7[87FSF8V5#KQ;]N\FJQ=N:DG]398F)CP9E,E;<8F)
M>EMSI[S2X>-?ND0N<7L2@
M
M
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MO_EW\I;3C>\R,;D&I6Y\8R335'RHUS-5RYNLB=8UCB]TZA*(
M
M
M                                               \;UZW8BYW9*,(
MJK;$0B;1$,2U#5;F?)PM_D\;C2/;*G:S,ICTXM3FSS:=%O44DN-:<NQ%UBPF
M(2       /@@A*[E.-.':^SZV-:QS3P3I/C+\%?AM]"^MDZ3X&BQZIO':NBU
M>J:O8MS5:VK4O.N)KFJ1[2[3!DORAB9M[M\/OWAA^I^N6T<6%=.P\O4)]C:C
M9B_H=&9U.VY9YZ0TV;YCVM(]G6S&,SU\U:4O_+-%Q+-NC]Z]*=R5:\'W+AV&
M57ME?&TM-?YKR3_+I&GIU6/(]:M^7Y5LW\;%BWP5JQ&K7^$JT+]=ACCGK+"O
M\R;RVFDQ7]:WW?53?]UNNLW(U[+<(Q^]0N1LL/DQ+=\WL_\ D_1#P?J9OUOC
MKM_]K7_K*OR>'\*G^];V/_(]+?JAOZWPAK5U^U)_?(_)X?PI_O>^_P!3]"NQ
M_6/?UB2E<S[>0ESC<M0:^\6[;#%/@R:?,6]KSMK]4+UB>O&YH27SNFX66GQG
MT]=N;]G31?46+=LI'&+2SL?S/F_?I6?I].3(=/\ 7G1+KIJ.D9&+#AU3L3C<
MCQ[:2JS%MVV_[LZPVF/YEQ6]^FD><<F8:5ZC[(UGICBZO&U?GRLY,':=>Y-\
M##R;7)C]Z/L;C!W7:9O=O&K)K=V-Z/F8[5^UV3MM3B_8T8TSZ);*)BT:QQ1<
MFG1Q:EW,1,"+5././AS !(   1YA') )/N/O"$*4Y-U[RJ)%1B95_ NJ]8E2
M#XW8/E+Z.PMVK%EW'DFC+,#4;.?94[;2N+XX=J9B6KI+;8LL7A6IME"\B
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M(OCG6%[BVVZTX<BTRTX
M
M
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MJ-K/M.4?=NQX2MNC:IV\.\PK5TG1N,66+QJKJHI7D0
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M8E=%).J[BVR4Q*
M
M
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M3]IH.Y[7JIUQ'&.;O/E?N<8LGP+3[-O=]?'[/N=2IIOQY'*UUF'JDIRI
M
M
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M?+I\$1:G5"]CRS269X^1;R;$;MJ2<)+O3IX,P9C26YK:+1K"HK]9"H
M                         )6TN;H!J3[0&ZY:#LZ6DXESHU'6I/&332E'
M'7O7'W\4NE&U[9M_B9-9Y5<E\S[Z<&UZ*S[63@Y,;?O=_P %?9[W4=C,<7CV
MOLZ3SCZ:@0           "+YD*IYH$J4]B_?Q;MO*Q9NUDXTHW[%R+I2=KC"
MOTHIO2+UF)54O:DQ-.$UTG[/U\'<^Q=QPW9M?3=?A17,NQ!WX*GNWH>[--+]
MDOJ."W.+X62:O?.V[R-WMJ98YS''U^+)BPV(
M
M
M                            ,=U[4W!?(X\J3G_&W%^#X&3BQZ\6#N<V
MGLPQ]*B2[C(:Q$A*- C5 ) !(CSXD(4.IZIINBZ?/4]8R%BZ?:3;O2X.;_%7
MXWT%5:3:T5JIS9:8:3:\Z1'BYZWUZH:KNV4].P>O3]O<:8MIN-R[3D[LDJ\>
M?3W'18-A&/C;F\W[KWS)NHFN.>FG@P%<DWRI^U7T>!L^'@YN?5I^N?/U(D
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M;I^U?>6,F/@R\.7HMHR^,DTFG6+Y,Q&V3@
M    'G<7"JY]GC0)AR/Z_P"X):OON6G1E7%TBU&RE_\ $N>\W]3.N[5BZ<75
MYO'_ )JW?Q=U\/\ T_I^MJLW#CT? )0"             (JL4WRI[S?X-.[Z
M2)Y)B=(F?)T9]F;7[EW$U7;=V58X[AF8]>Q7>$HKP5$SFN\8_:BSTSY-W6N&
MV'\/'[709S[T(
M
M
M    +;JF>L#'E<3_ "T_=MQ_5*Z5U6<V7HAB+E*3=VZZM_29K2S.J"Y< @"0
M !&@1J@ZM-+GV 6?<.Y-(VOIES5-7O*,.*QL=->9?N?B17<^\NXL5\MN#'W6
M[Q[?'UWGER_8YIW=O'6=XZC+,U.[Y6)!TQ<&'\19MUX4[W3FSJ=MMJ8:\.;R
MSN'<\F^MK.L5_1IK^SFQ]OWJJOT%Z.37VF->') J4   !%<PF%YVK_:<Z_\
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MR]"H
M
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M^NIC;NO5BM'H;+M-NC>8Y_YH^GUN[ES. J]]1*@
M
M
M                            Q[<.<XPC@VY4N7%U7*<7TKL+^*NO&6%N
M<LQ&D>+'DERYQ[F94M6B0D   $F^GAS[%_T[D3$(46IZK@:/IV1JNHW5:PL9
M-W92X.32X02[Y<BJE>N>FO-&7)7!2;WY0Y>W=N[4=Y:O<U3-K#$MKR\'#_!L
MV:\(I/@V^=>9U>WV\8:>EY)W'?WWF>>J?9CE'TX?X,?K'LBJO\4OZ-=K'@@2
MI D   !.BF4:M/BE];_@D)UG7Z?L7G:U(ZI/JDE^2EWF/FXLO;QI++N#XJ7
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MV3$:IA<-&SOE<F,)M+'O-*C7*3=%3N+.6NK*V^3IGBS"O;V&(VR(
M                    &&^JE[R/3O<M^+HXX-U?71&5M*]66L>EJ>\6FNSR
MS'X9<1>[TQ4>7X)WFNO%X/$1%8B$ @                5NC7?)UC3;T:)P
MR\=UYIMW4F6\ON6]4LC:WZ<M+1SBT>GT/H!6CX<GQ//'T0G)0
M
M
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MEENCYCS,2/4Z7H+HFJU?#E(P<D:2W.#)U471*BH6U]$
M          &#^L"?Z,]ST5?YE/A]*,S9?SZ^MIN]?T.7^&7$RKP7:CNM7@M(
MG2->:(7                !4:?T_/X5.7S./T_RL2WE]RWJE>P\;UT\Z_?#
MZ!KE'Z/O'GKZ)\'J
M
M
M   "#[^XA+&]Q9<ET84'1S]^=.Q)\C)Q5XZSR:[=9-/9A8J4;[EP1DM<B0D
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ME?\ FC[]?^#OYM.7@CSU]#HN:7)-OP)0G
M
M
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M7A6[DFNM>[-=U$85XTEN\-^NJX)U57P+4+R)(
M &(;\WYHNPM-AJ.K.<KE^YY>+CV56[=DDJJ/@JF3M]M?-,Q5K.X]RQ;.D6OX
M\H\VM=3]?-D:]M_4\#)M9>/DY./<LPLNVI1E*4:*DJ]E39U[7EK>L\X<MF^:
M=IFPWI,3%M)CUN:>%(I5Y+G\7+DT=5+RZ\Q-N'+]/U^B4 I
M   %TVYFXFFZ_IF?J'4\+%R+5V_&W3J<823=$^?+D6LM9M28CG,,S9Y:8L];
MY.-:S'+Z<?4Z0U#[1^R<?(C'"Q\W,MRX2NJVH1BNU\7QHCE:]GRS6=9^IZC?
MYLVD7B*ZSZ6U=$UK3]Q:9C:KIEY7L/+CU6KB3?)\4ZTIR-7DQ3BMTVYNJVVX
MKN,<9*3PE=RAD
M
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M<Y2A8SIPM=3?NQ<(SHO#B<EW:NF;ZGK7REDF^RT\K3#=!IW:
M
M
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M:W>=F]:OI<8M3E[")C6JJDZ69W9FKEJ-Q<I)/ZS TT;RLZQJ] J
M               #FS[3F UJ>@ZCV7[-[$^F'O\ _O'3=EOIU0\U^<,/5DQ3
M^*)C[.+0;=6;^(X/.NKJXH$@                  !&FJ:SQ=9_9[PWC>G\
M,A__ #V1.ZOHI;_]TY'NM]<^CU[Y4Q].QB?-MTU#L
M
M
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M
M
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MRKEF3]VXETQ\46<L<&;M+:6F&4*-*^+J8D-FF)
M !9]PZ19U[1=0T?*5;.?8N6.GE\4:+[J+F*_1>+1X,;=[>N?#;'/*T.$=1T_
M*TG/R=*SK?EY6%=E8NP7/J@VOJ=*KP.^QY(O6)A\_9L5L62<=HTFLZ?3T?L4
MI<6@                 BW&CD_AC\13.I,QS]/'TLO]+MLW-U;YTO3?+4\.
MQ<67G.KI&S9HZ<.]]-##W^:,6*?"9C@WG9-A^9WE:S&M*SU3ZO+[G;<(T5'W
MU7TLX?1[F]0
M
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M90EY<TNJUCI>[#O3?-G']QW?QKZ1RAZ]\L]KMM,/5D]^_P"CT-P.*9J77I@
M
M
M                                          "'>0,*U2YYVH7IKG%]
M*?L1G4C2&FSSK92)LK8Y5@T E'P"$*T2?>".+1WKUJG7K&DZ-;DI0P\=W[D%
MV7;_  3IX)T-]VW'[%K.%^:<_P#F8ZQRK''ZVHJN7O/FS;PXO77B@2
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MF'3Z::\#H7CIVH#6'KA_LKA_UVW^]F;3MO\ ,GU.3^:/Z:/XH_6T1V(Z)YL
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MI14-4ZYZD
M
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M7;[#8=OOTYZ^ESOS%@^+LKZ1QK[7V.-XM=+_ &S:D_QGS.VGG+Q.LQ,3/F!
M             #TL8TLV]9PK:?7E7;=FBXO\I)07W"F]NF)GT+F.GQ+12.=K
M0[[T;!AI>EX.F07NX=BW8X<O<@HO[IY[>W5:9?0N''\/'6OE$+B4KP
M
M
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MW]0#)]M7$\%VVU6$VJ=M**ABY>;:[2?8^M>BRS
M    46I8EK/P,G O).WDVYVI)\O?BU^J5TMTVBT>"UEQQDI-)\8<$ZQI][2-
M5S=(O\+F#>G8?"C?1)QK3QI4[[%;JI6WF^?=UCG%FM3EI,_311%UC@ "/M"4
M @        <6P1QEGGH]H,];]0M(MW(UQ\*<LR^GQX6DZ+PK*2-=W#)T8I]+
MH_EW:3EWM=8X5UGZ>6KM&+3K54=6OH1Q+VM.2D
M
M
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MU*S"F'K%I7FUV7K;Z)+ZN)UW:LW7BF)_=>1?-6TC#NHO'+)^IJ<W#C@
M       (\6I4Y4X_M2(C657.MM/"/V\'1WV;=N>3@:GNF^E*[E36-BR?X,+;
MZI->UM'+]US]5HIY/3/D[:37#;-;][_%OY/WEWTJ:%Z"G)
M
M
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M5P5%XL#:8 "':@-8>N'^RN'_ %VU^]F;3MO\R?4Y/YH_IH_BC];1'8CHGFP
M 0^.W[5]\*6!ZM_:N;_E)?>,W'[L-=E]^5$^PN+$A     "/,)YH!";@NF3_
M  7^J4VY$^'KC[VZO0*XWB[AL/EUV+OW'']0TO<_>AWORS?7XD>G_!N/FWW)
MK[QI792    "][9E_.<F/["+^Z6,W)G;3G+([?P_48S90G
M           'E=AU1^AKZP3R:M]=]JSW#LRYG8EMW-1T2:S+,5SG:I2['Z8U
M-EV[-\+)ZW+_ #)L?S&UUK[U./[7(Z3YRXQCPAX5_P"E#LXY:O&(F9KK;ST0
M)            >N-BY6=D8^#AP<\O)NPLVXKME.24:?M:E%[Q2)NN4QWRVK2
M//\ 3P=U[.V_8VMMO3M"L4IB68PN-=MSG-^QR;."SY/B7FWF]^V6UC;8:XH_
M=AD!99H
M
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M    +QMK_3;_ !_Q:^^6<O)E[2?;GU,GCPX+Q,5M$P2
M        #POV;%^U.Q>@IVKL7;N1?%.,E1IHF)F)U4S6+1,3REQ#ZB;7>S-W
M9^B*KPZJ_A3:YV;SZHKZ*T.XV6;XV")\8>&=XVGY/<VQ?N^]'UL4,UI0
M       ;?^S[M&UKFYYZ[F04L+15YEF+XQEDW*]#[O=75]PTO=L_3CBD<Y=M
M\J[#XV:<EHUK3E_%_AJZMMIJM>/<NY'*/6?2]"
M
M
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M]OZAI?!W4IJ%*-4 D  7C;7^FWO\FOOEG+R9>T]^?4R>/+Z3%;1,$@
M                   \[E:*G>F_9VDHUES;]IO3HV=1T#6(Q_C;5[$N2?)N
M+\R-?97F=)V2WLVJ\U^<\?3./)'/C#0IT+SL          (\FFX^X^93/.(A
M7PZHCS=:?9ZTB&%Z>6<J2_+:AD7LB4^UQ=(Q7T=)R/=;]>;3R>O?*>+X>QB?
M&TS+;222H:EUR(
M
M
M +1N+^S)^$X??+F*=+,;<^XQ5/L[N!FRTX0E%!$H!)S"&%^K%IW?3W4Z+^+O
M6)T[TIF9L[:9H:7OL?\ I7]&DN97S.J>63/% (       "$PRS:U7@7U1O\
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MD(T0"0![0A>-M+^>9#KRMQ7W2SEY,[:1[4SZ&31?#ZS%;).$@
M              EFZ1=.P#0WVF[:6W]!DY5:S;O2^YNPU^H;WLT?YEH]#@OG
M+3\OC_BG[I<U'4O+0       "/B$H!":->4I<./ 1SU55XS$.TO1FW&UZ8[<
M4.3QFZ]];DSA=[K\:WK>X=@B/R&+3\/ZV>&&WH
M
M
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M3<OU3B=_73-/IXO;?EZVNQI'X>#8J=>RC\37NB1)0
M
M
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MOYVPG_\ "_5-ELW-=X_G5]336K.NK9O^4?WC=4]UR.6?;E1]A5*WX)0I
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M1ZK\H;F;X;8YYUMK]NC>T:5<NU\_H-$[I.$@
M
M
M                      >.1%7+-R#Y2BU]:)CA*FT:Q+ H)137=5?5P,^&
MAGG*8!1A&H$@"TE*<8M<))U;Y4<:4)CGJFL:\/6Y$W)A/3MQ:K@4Z5CY5R$8
MRJFDG5<&==@MKBK/H>-[S'\/<7KY66OVE]B>L"      #Y!+*ML_V7D_MW^]
M,;)S9N+^5/K;VT;^Q=._J\#G<GOR]$V_\JOJ5A0O@!<P+_LO^V[O]7?WT8^X
M]QLNW?SI]38JY&NATC',Z>\EEW%I]G#GA</*E=G-7/&J2H2/#S=__P#<:?\
MNY_K 1\W?_\ W&G_ +N?ZP$/-W]_W&G_ +N?ZP#S=_\ _<:?^[G^L \W?W_<
M:?\ NY_K /-W_P#]QI_[N?ZP$?-W]_W&G_NY_K 2.YZ@5X6=/IP_#G](&36/
M.\F'S%%?Z5YG3RKVT Q[>_\ 9=O_ "\/O,R=O[WU-5W+^7'K8$9[G@!V 8/O
MK^U</_(_JFSVKFN\?S:^IIC5O[6S?\I(W&/W8<CE]^5&^:]A6M3S0"
M $4VDWPY?JD:Z21/'UQ^MU=L3 >E[*T+#:I)8RO35*-RNOJ;.2W5NK++V#MN
M+X6TQU]#(#'9X  BPB$.37TO[@&5;<CTZ9%\G.3E]=#$R\VVVL>Q]:[EIE@
M                        A6G,"P[MW+@;2V_F[@U"XH8^';ZDJ\93?"$(
MKM;?!(O8<4Y;Q6/%A[W=4VN&V6T\*PX;UC4LS6=4S-6S_>RLV].[>=:T<Z2:
M7@JT1WN.D8Z13R>!9LUL^6V:_'JU_3_Q416L@         !'D$\F7^F6\'LG
M=^%JUZ3AIMU_+9_;6Q=HFZ=\9*,C!WNWC-BGSAN>S;^VSW-;S/L3PGTQ/TU^
MMVOC7[.3:AD6)QG9NQ4[=R+34HM5KP\#AYC3@]SBT6C6.2I"H
M
M
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M*51XHYS#-]-M>3A68=BBG]?$U]N;>XHTK"L*5P
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MQY:9*Q:DZQ/BKRE<
M
M
M !#JY^ (8AKEEV=1DW\%R*?W:&7BG@U&YC2ZW)4]U%UB@2C4(T0"4?:$-2>O
M.E>=I.CZ[:AU3Q;MS$OR[5;G[\77GS1MNVY8K:8<A\TX)O@IDC]V6BWTKA'X
M4NDZ#1P4_J0"D      ^02RK;7]F9/[=_O3&R<V=B_ESZV]M&_L73OZO YW)
M[TO0]O\ RJ^I6%"^, @+_LO^V[O]7?WT8^X]QLNW?SI]38IKH=($@
M   8QO?^R[?^7A]YF3M_>^IJNY?RX]; NPSW/ #L P??7]JX?^1_5-GM7-=X
M_FU]33.K?VKF_P"4?WC<8_=AR67WI43YKV%:S/- (       9]Z.Z2M2WKCY
M-V'58TR,LJ3YQ37NQ\.?(U_<,G3AF/-T?R]@^)NHMX4X_3P=(UK*4N]U7T\3
MF?)Z=?G(%(!&@1J@$D+?G7;=I?ASC%_0QX2FD:V9_%=,4NY)?4C7M]"8)
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M3,
M
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M9NGW&O.M2[Z=L7^,CC=UM;X+<8X>;V3M?=L._P ?52?:CG$\X9H8C<@
M
M
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M/P:GYW-YG]Y]>_I7_97ZQ'P:'YW-YG]Y]=_I/_9C^L/@T/SN;S/[SZ]_2O\
MLQ_6'P*'YW-YG]Y]>_I7_97ZQ/P:GYW-YG]Y]=_I/_9C^L1\&A^=S>9_>?7O
MZ5_V8_K#X-#\[F\S^\^N_P!)_P"S']8?!H?G<WF?WGU[^E?]E?K#X-4_G<WF
MILW6-3U"VK&9>\RTI=2C1+WE5)\%XE=<=:SK"SDW&3)&EIX*$N+  [ ,'WU_
M:N'_ )']4V>UY.:[O_-KZFF-7_M7._RC^\;C'[L.1S>]*C['["N5KS0"
M  /7'Q;^;DV,/'CU7\JY&U9BO>;N3HJ?0V4VOT1,JOA6RS6D1[T_IX.O=&TN
MWHFCZ?HUOE@V(VI/MZZ5DZKQ..R6ZKS+V?!BC#BKCC]V%:N5*U]I0N@2  'O
M+F$+_MNP^F_?I\;HNZB,;++8[.NFLL@5>->_@8\-@F)
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MU5NJ7:NPX_>;*V"=?W7L?9^^8M]'3KI>/#S]38ZE7_KYT-;#HTZ=21$
M
M
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M/%LF.6I$:SHS73+'R^%9M->\HU?95OC^J8-IUF6ZQ5Z:1"M*%X
M          !37LFUCVYW;\E;M03E.[)T@DEQZF^1,<>2F;16-9X0YL]4_6^[
MJGG[=V7>E;PO>MYNJ1K&=RO#ILJG"+[9'2;'MVGMY/L>:]^^8IM_D[?QYV:+
MK3J7%1:YU[^<J][.@CT<GG<\.7Z?OU]/DBWW?"2KM/ER0"D
M         ]L/+R-.RK&;@W9V,NQ+S+.1:;C.$H\%1KBH]Y1>L7C2W&%>&\X;
MQ>LS%HY3Y:?IT\W3OI1ZUX>XW;T#<]R.+K_*QDR]VSD=/"BDZ4F^Y\SE=]V^
M<?M4XQ]SU?LGS%3<:8LT].3]%O\ BW0KBBDJ/Z$:6)=K/!/%MUJJ<>'$E*8(
M
M
M                                        $2,7W)C=%VUET5)^Y)_3
M7B96&=>#6[JG*5FZNSMY?49$\& $)   #ROVK&39N865'JQ<RW*SD1I5=$E1
M_3Q(ZII,3!-8M6:6Y6C1R;N?0<G;.X,S0LB%/EKK6/-\5.Q/WK<Z^*K7N9V&
M#)%\<3#Q[>[:=MFG',<IG3TQX?H6CDY+M7#Z"^PM-$ @    3#*MM?V9D_MW
M^],;)S9V+^7/K;VT;^Q=._J\#G<GO2]#V_\ *KZE84+X              P
M     8/OK^U</_(_JFSVKFN\?S:^IIC5_P"U<[_*/[QN,?NPY'-[TJ/N*Y6D
M @    $4INXO+BYMI0C&/%RD^"27?4B9B*S*J,<VM&O&/IX?I=5[$VVMI[5P
M]+<4LR\OFLYJC?FW4G&+?[%.AR.XR_$O,^#U_MNV_*;>*1SGC]K(HQ:K[$OJ
M+#-1"0!1A&H2E4:=C_,YN/;:K!/KE[%WE%YTJO8*ZV9PDDJ=B,!ND20
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MJ)"0
M
M                                          4.JXJS,&[9:K*G5'VQ
MXE=)TE:RUZJRPJ//BN/*CYU7,SIX\6DB.$IB   1H$:I)<$W3J;Y+NX4$SK&
MB=>4M:>LNT[FLZ1;W)@PZ]3TN/1F1BO>N8DG5/\ P6C9;#/\.W3/*7,?,G;_
M ,Q@G+6/:KS]3GU]*C#H]Z-*U[Y=IT>G'6)X/-YTZ8TX\/T^7K"0   !"895
MMK^S,G]N_P!Z8^3FSL7\N?6WMHW]BZ=_5X'/9/>EZ'M_Y5?4K"VO@    >(
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MQ3-'FV67%K,QP\W<['OFTW6D4MI:?">$L[K&E:\'R?M,)NQRBN;"4P
M
M
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M\24(VK;OW;=B"I*Y+I?L(LKK'5[+.K%B%BU"U!4453ZE0P-6\K72'L0J
M           (-I+P00UGOGUFVILV5W#A=_.6N03I@XS347W7)\5'L-EMMADS
M<^$.;[E\P;;9Q,:]5O*'.&[O5+=V\KL_SAD_*Z:W[FGX[<+:CW2:XS\:LZ/!
MLL../.7FN^[YN-W:>N>FGE#"^'2HI\%7A6M.HV$:>#GYX\IUC[O6$@
M               !'VA* 0    "*= F.!P(3P0)4@$8\6EU]+?P^((XHP?'S
M$W;N-U33I6<>*:?8T^1$Z>,:PJK/CRG]?^$^#9VRO7'=.UE;Q-4D]:TF*2\F
M\VLB*KQZ;CKV<J\#4[CMV/+K,>S+JNW?,^XVT=.37)6/N^GU>ET;L_U"VOOC
M'Z]'RXK)C&N1I][\GD6V^R47SX]J.:S[:^&=+0]-V'==MO:ZX[<?+Q9F8K;
M
M
M                                   "#7%!*U:Y@O+PY2MJM^U[]OZ.
M9<QVTG5C9Z=56)*2E)+N33_;/F9D3JTR8)   !X*3C+LIR"%AWCM;%WAH5W1
MLAJUEM^;@Y/XE]<%7]MR9?PY[8;:QX\&%OME7=X9QSSYU];E?4,#,TO-OZ9J
M%N5G.QINW>M25$IP=$UX/L?:CK*VK:(M5Y%DP6P3..W"T>'Z_KY:^*F*UL
M31"J&3[7:EIF7%<^IO[ACY>;+Q?RK-\:2ZZ/IK?+Y:".=R>]+T;!_*IZE66U
MX                    !@V^J_G/$3[+5?NLV6S<UWC^;7U-,ZI-3U3,DN3
MN/[QNJ>ZY++/M2HGS96L3SD(  #FBZOB0ET#Z1;'>@::]S:K;<=7U&WT8=N7
MQX^)^/)=DY_>.=W^ZZ[=%/=>D=A[9.WQSER>];W?^6/VRV;2BI6M.<N_Q-9I
MIP=*!(   'R?L)0O>W<)RE+-N+A%]-KV=ICY;_NMAM<?[S)C&;$
M    !*ZT?:^X"UZOK6EZ!@W-2UC)AB85I/JG-T7#N17CQVR6TK"QGSX\%>O)
M:(AS-ZA^O&J[@E=TS:JN:;HW&/S=:9.17AS7P)]U:G3[7M<4]J_-Y;W7YGON
M-:;?V*^?C/\ A+3S3<I.5>INKKQ=9<ZF[B>#B9XSK,?3]@2
M    !&K(5:R@2I (T83H@$      D     "/L"4 @ BN9"8GB]L3)RM/RK>9
M@WKEC,M.MB[;?3->UE%JQ>.FRYARWQ7ZZ<)=!>G'V@(W5:T??E+5Z,E;M:Q:
MXVI-\$KL5\+_ &2X'.[SM>GM8^7D]([1\T1;3'N.?+J_:Z L7K619A>L7(W;
M$XUA.#4HM/E1KAQ-!,3$Z3S>@5M%HUCC$O9*BIS(2B$@
M
M
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M3M7K<JKCSJN::[CD[X[4G2T/7,&?'GI%\<ZQ*Z)=_,M:,A,2
M
M
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MP1JR';VG.W#YZXJ7+B]R/<N_Z3%RVXMEML6GM2O_ $1189R8
M)9-JCJDNT3(Q+>^^],V+HD]5U22=V7N86+!KS+USV=B[S)VVWMFOI5J^X]RQ
M[+%-\GU1YN.-T[LU;>>LW=;UNYUWIU\BRG^3LVZ\(Q7)47-G:X=O7;TB*O$M
M]W"^]SS>\ZQ'+P^GZUF<FH\'PY_27_%AVM,P>)*G1
M (\4PGD@$            CR">2 0        1K2J_!?Q1_!7^"1H<(^G"/J9
MSZ:^IFI>GVH+XLK0;TJY>#7C25*W+;?)T^LUV\V<9XX>\Z#M'?+[#)$3QI,_
M?XZNPM'U?3]=TVQJVE7HWL'+A&Y:NI]ZY/MJCC;TFENF?![1AS4S4B])UB5P
MA)MT;XI<8E*_$O0
M
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M;:;>,%-(\?%X?W7N%]_FF]_=KRCT?3]+&>-51?!6G^%S,OUM3X\(^G^"!*
M            $7S(53S0)4@                     $? )]" 0      K6
M/35<T^K\+W?U/ F)TG5.O#3Q\_'[/NCP;0]'?4V>R]4AI&IW'_=C/NQA)2?4
M\>].M+D>-.EMKJ--W#9_%CJKSC]+KOE[O/Y2_P *_P#*G2(]$^CT3XNNK4E<
MBIJ2DFDU*/%-/BJ/V'(O7XG6-7L$@
M
M
M 0=:.G/L DN6H782A<5825&B8G1$QK&DL*S\*>G9#LS_ (JYQM3[*]QFUMU1
MJTN3'T3HIU6BJJ-=C["I:  $4$2@$G'LI7C2O+P!'!+%3C)24EU?A*BI3M27
M<R-..J>J8XM1^H?I+;RU>UW:5I6K_&YF:5^!<[6[7<V^/2S;[3?33V;\7(]V
M[%3)$Y,,:3SF&D9VYPNRMW(.%V-4[4ZQ<6N::?%-=IO8F-.'%P%JS6TQ;G'Z
M/U_7"2E.?T4?45*=-/I])31;B^H2FNGBGQ\B[BW/.QY]%S\9?>IW,3QX3R17
MIB=8UU^GWKSC[IO>[#-Q87*?AVVXO]8LSAK+*KG\]55_>?$_HES]VBC\O"[^
M8KY2F_O5A_T2Y^[1'Y<_,U])_>O#_HES]TA^7@_,U])_>K#_ *)<_=(?EX)W
M-?2?WJP_Z)<_=(?EX3^9KZ4/[U8;37RMQ=SZD3^7A3.YKZ63:3>M9^GV<V%M
MQC=3:A/BU1TXT,>]8C@S\<ZQKQ5OEQ_%7ULMZ*^!Y<?Q5];&AP0\N'!]'/VC
M24Z,<UO7,;3,^>)=QY3<(QFY1DDGU+AP9D4Q=4,'/FKCGCJH7NK#7_RES]VB
MO\O"W.XB//[3^]>'_1+G[I#\O!^9KZ4'NK#?#Y6:?C-$_EX1.XKZ4LMSXG2^
MG$DY=D93X?30?EX1.>NGT_4M>9N#4,RMM2C8L<G&'&5/:R[&*L,:V6;3S6Q4
M7[+]M^J7=9GFLQ'CKK*/ZW80J%&M$N/5]PDI'5PU."57S[O^LA$S$<N/T^W3
MTMB^GWI;G;HN6]4U;KP]NQEQX-7LBC_BX)I)*G&4OJ-;NMY%(TCC+J.U]FMN
M/;MPQ_IGT1^OSY.@\3#Q=/QK&!@68XV%CKILV8)=,5X][9SLS-IUEZ+2E,=8
MK2-*P]:2X.M7VM]W@0(A4   $>'L7:^X((0N7;D;-M+S+G!-\NE]K\"==$Q$
MS.C,M-PHX&-"Q&E5QF^UMF!>VLMWBQ]%=%<4KH            'G/@U3G]PB
M4N5_7O?T]=UM[2T^[71M,E7*<'PNY27+A^#;??\ A'5=KVO33KGG+RGYH[E\
M7-&"ONTGCZ9_PG@TY.3GTU;JDUP_?&]B9<):9M.L\_1]Z 2
M                                    A2/&L:Q2Z7%?#3M)B9A$UC29
MGE'T_4Z?] ?4&6L::]H:M==S4]+A_,KTW[U[&JJ+CQ;C6AR7<MK%)ZZ\I>L_
M+'=OCXXPWGVJQP],-WJ:K1\.-#21.KN-$Y*
M
M
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M4*0      $? )0"$7S(53S0)4@        "/M"?6@$     B^9"J>:!*D
M              (KF0JCF@2I135''\!K@N\$3X>$KKMO7LS;&N8&N8-Q^;@W
MHW'!<.JU3WH2[ZQ["QGPURTFLLS8YYVF:N2D^[/'U?\ #P];N;1-3Q-:TS$U
M;"?5C9MJ%^RWW27+CVIG!Y*32TUGP>^;?-7-CC)7E:%T*%\
M
M
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M>?K_ &M0MUK7L?#]KWFYB)UU<7,^?A])^I J0    "/L"4 A'V!/J0"
M (^T)0"            1?,A5/,JP:R>)*$ @            "/,)YH!   BE
MQ\5[R]I,(F/V_<Z;^S?NB>;H67M?)N==_29]6+U/WG8N=B7-]+K7VG)=TP=%
MHMYO5_E/?3EQ6PSSI/#U-Z&E=R
M
M
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MMMJ/U<#O\%.BD5\GSWO-S^8SWR3XS^W_ (+<7F,
M           "/()Y(!                  1C1-)<Y/W2F36M>;8?HGKD]$
M]0M-@Y*./J;GB7>YQE%R3_=11KNXXNO%-O)TWRWN)P[Z(\,G[/\ !V.Y-KW>
M=5]1QCVF>7!Z@
M
M                                                #50+%JVC+(KD
M8JIDT]Y<D^WD7:7T8>;!U<88VE.+=NY&DH\)5YU,N)UAK+5TD"    BPB$.0
M )/ODH*T]Y/I:Y23::^HC37@1KX*#4]*TG7<=X^LX%G.MUX.Y;75^Z2J7*WF
MGNRC/AQY:Z7B)8!K7HAMO.G.[H>1?TJ\^5J35ZS]->*,_'W')7GQ<SN?EG;V
MC_*UQRP+5?1?>6G1E=PXVM0LQ;K\NUUN/?TSHZLV5.X5MS<_G^6MSBXUF+1Z
M&&:AH6O:9.4=1TW)Q5"E7=LS[?'I2,RN6EHX6AH\FVW..9BU9C3T:_L6U37*
M+BWSK+WJ>!<UB/'5B1\2.$1]/+T_4F:[><OQNT:ZJIB?% E2$2FO./6RS;_O
M;2U>/;U7/O&-F_FU9^W_ )%V*1Y?09+ 04NF3?&D1,QXJ8M&ND:ZPJ<7"S,V
M=,3&O9$YOA&U;=SBO&*;+5LF.OBR:8;7G2*SK/H_X_>RW2O2O?.IR4H:>\2U
M*GY7*DH*C[>E\?:8]][AKSXMO@[)N\D^[%8\_P#C^EG.C^A&%#IGN'59W9?A
MX^%'I3?=URHTN_@:Z_<YY8XTEO\ #\LTB=<MYGT0V'H>S]L;;26CZ78M75_C
M[Z\V\WW]4ES-?DRY;\;3P=+@V6WP^Y6-?.>:_2E6CNU?<NSZ%R+#,U0\%P7@
M$!*3P(0!(  C4(T.8.27W4EPK;_!CV@7;2](EDSCE947&S&G1;?"O<6<F3P9
MN#!-IUGDRJ$8PCTQ5$N22HC%;/31,$@              &#^K>I_FKT^UR_%
MJ,[EAXT)-TH[](+[YF[*G5FK'I:3O>?X6SR6]&GV\'$]7PZOC=:_X1W4\YAX
M5$ZQ$^?ZY"$@      (^T)0"
M        #15:;ESP=4P<ZVVI8N39N]5:?!<BW]Q%O)7JI,><+V#)\/+6_P"&
M8^__ (._<?(AD8]K)C\%ZW"XJ=TTFCSVT::OH>MNJ(E4A4
M
M
M                      ! M&IZ/:S%YMI*WD+E)<*JG)EVN288N;!%XX<V
M+7+=S'N.Q>3A>3:?5R?L,NO&-6JM6:\)0)0       AS5 A'I7=]T1P#ICS[
M?I)B=$:0*B=5P??5IE,QJF(T1E/KBX77YL7P<;GOI_6F(C3DJF9F-)XK3F;:
MVQGIPSM%P[RES<K23^M4+],^2O*TPQ+[3;W]_'65CO\ I9Z?7O\ ]R*VF_\
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M                      1?,)E (  $?:$H!     (T9"K24"5(
M         2W5^2N/M47]X<TZ1XN[]E7_ )S:&BY$GU2N85A.3XMT@E^H>?[B
M-,LQX:O?^WWZ]M2T\YK#(RRSP
M
M
M   4.=IV/G6^FXJ3C\-SDU])56TPM9,<7CBQ7.PLG DU=C6U^#<7%4\3+I>)
MYM5EQ="EJFNJ+5"[P68C7DC6J7B4H E%!$H!(    ',(1B_! 0:KS2=.U@U*
M=CXKG3N^JA.HAT1[/J($4O\ K)@83O6OY[T>]RK!5:Y>Y-)&;M=9I:-7/=UX
M9\<LXN12N-I*/PJOM29A5=+,Z)5RX-^+Y"5$\T.""$R()0"4>01S0"0
M#?T!"-FW=RKBL6(MW7P:[%7M;$VB%5:S:=(9/INC6L6/7?I=R'QJ^,5[$8E[
MZMIAV\4CBO)9T982                 !I'[2TFMI:<NR6<DU_@,W79_P"=
M]3B/F^?_ %:QYV<N]B.LGG+RC7AJ!
M              C[ E (       2S_BY>R1,3Q46]WZ>;N'TN;GZ>[>E+BWB
M0^XV<%N^&:WK>^=IX[/'_##,3%;8
M
M
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MV$\T @                       2S=+;]C$1Q4VGV?M=Q>EJZ?3W;T>?\
M-(_?9P>[_G6];WOL_P#1XOX89@8K;
M
M
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M1\WS_P"M3^.'+<5[O[:K.LGG+R:(Y^F91"0       "-6$ZH!
M             C1A.B 0         (T83H58-4 @    $+G&W*G<(YHO[LNX
M?2]UV!M[QQ(_?9P>[_G6];WKM']'B_A9@8K;
M
M
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MGI_$Y@<>FB9U>NLR\IB-(C5 E  !H  (\PGF@$
M                         @_@?L'BC29J[<]*IQEZ=[=?#CB12?BI2^]0
MX3>?SK>M[SV:8G98ICETLU,1MP
M
M
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M7:^:\8VDX.(NJU:3FOPWQ98F]F77%6/!7+@DER*5U%*@
M          :&^T_.F@Z#;KQEGSX?M;7_ %F^[+_,MZG!?.4Z8,7\;FI]5%7O
MXG30\NB9Z82E2
M      C[0D2J$TX2[1]';GG>F>VKE:OY=I_1<FCAM[_.MZWMWR_/_P#+\7J_
M7+/C";\
M
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MGXS=?N%$Y)78VU(5]G$Q["_)6HPX4X)5H43:9YK]:Q7DJ"%0
M                  YY^U%>_FFV[/;&]?N_]A(Z+LOO6]3SCYVMICQ1_P S
MG>4:3?BJ?N3HXY/.KQ[7U)25                    $?$)]* 0      !J
M                        $4J\>PB4376)=B^A-U7?3/18]MJ-RW]5QO\
M5..[I'_L6>V_+E]=AC;*-6Z,
M
M
M                   ( !0:#QNVHW82MR7N234J\53M5"5,QJU=Z2R>+F;A
MT>YPN6LCS%"O"B;BZ=W,VO<(ZJULY#Y>M-+YL4^$MJJ,>=%4U6KL-$P2 0H@
M(@                              '-?VG;\?SIM[&;;I9OW7'LI51K0Z
M3L]>%Y>9?.=HZ\43Y2T)[TN?9P.B>?S$H!2 1\ E (  $? )]" 0
M                $:,)T0"                   1X\R)1,:PZU^SO>5[T
MZL6TW7'RKUJ2;K2CBZ'(=UC_ #WL?RK;791'E:8;:-2ZT
M
M
M                                            &IM ?YH]5M6PI>['
M/ZI6UV4E2XOO&UR1U;>)\G&;/_)[IDK^-MA+@:IV:(
M                .5?M*Y'G;TTW&KPQ\%JGC<FW]U5.I[173':7E/S?:;[F
ME?*K33I1/\*5>HWG@XC7A'GH@2I
M          (^(3Z4 @!       "9-UJ4SR51S=.?9KR7+:>IXD9<;6<[G3_E
M(KC]/2<OW>O^;#U3Y0R:[6T>5F\C1NY
M
M
M                              !J7>;_ #1ZC:)JGPPR%;BY/A\,O+:J
MO"1N-M[>"U)\'%]SB</<,67SX-LIU--#M$20
M        'GUOJIV<7]TB4^+D#U]S%D>I.?&%)+&Q\:W'Z;?7*OC7@=GVNNF#
MUZO&OF?-_P"_;_EK'W:_X-94HG4V<.4T"0
M                           #D$Q.G%T+]F+)K_>'";7'Y>[%=OX:?WSF
M^]1/5%GHWR7>.C)7U2Z+.=>D
M
M
M                        UCZP8<Y:3@:G:7Y;$ONLOQ5)-K_M)&QV5])F
M/-ROS%CGX5;QSK+/=&S8:CI.%FV_>A?L0N)^/2C"RTZ+S'E+HMMDC)BK:/&(
M7$ML@                                $CCV_1]TI2X>]3\Q9V_]=O)
M\8Y#L\6VWY'NU5.SAP.[V->G#5X3WO)%][DGTZ?9ZF*>TS&F0)0
M                                            !V>!,<U,SPU;G^S=
MF>3O#-PN/\YPI2Y\*VIP=*=O!FB[Q76D6]+N_E*W3N[U_%6)=4G*O5@
M
M
M                                                      8UO73_
M ,[[8U'$2XJWYMOQ=KWONT+^WMTWAK.Y8/C;:]?0LOI9J;S]I6K'^-P9SQ^G
MNC'X54O]PITY9E@]@S_$VD1XUX,\@I=/O<WQ,%T2<(
M             "GO7%:M7KM:=$).G[55%8XZ(M.D2X%UO+6?K.HYU7+YG)N7
M4Z=+;E.O'ZST'%&E(]3YYW-^O->WG:?O\5%S+JQS0"
M                                 !'M(5>*!*E'DNKQ7WPB8X?9^IL/
MT2S?D/4O2(J5%FJ[8EXN46TO^R:SN5==MJZ?Y=R]'<8C\6KLPXQ[2
M
M
M                                                    #RE"-R$K
M4E[DHN+78T^#1$:QI*+1$\&J?3ZY^8MVZ[M>[)J$[L[UGJX5Z'V=]5(W&\B+
MXJW]#C>SV^!NLN">''6&V(2ZH\J/EQ-0[-.
M       ,<WIJ'YJVKKFH+@\?#OS3K3CT_P#67L$:Y*PP.X9?A[>]_*LN$_=<
MI.,7[S;Z9=K?,]!TT> 3QF?3,CB^R)!:-/ \'R!" 0        17,A5'- E2
M                                      $5S"80" "*[28YJZ<U]V7J
M$=*W;H>HUI*UG6(MUHJ7)=#;\./$Q,]>O#:&;VK+.+<8KSP]KB[PZXKF^VB]
MIP3Z 13KQ7(E"(
M
M
M             U'O=/;F_=*W%;5+&4XQR*=O0^B7W)5-MM_\W#:/PN+[G_ZN
M^QYHY6X3]/K;8MRC*,9Q^&24E['Q7W#4NSB=7H$@
M          !K+UWU'\V^FVJ=+Z99D[6+[?.G0V/;:=6>',?,^7HV%_\ FTC[
M7'O)]2]UI<)TK[LNRG>WR.UF>&KQB*=7+FGR<7(P+T<;4<>YA94U&Y&U.#AU
M1?PM5YIE-+]2NV"^+A?7CQ^GH2OAP*E$ZI0@           $7S(53S0)4@
M                                     FA>=B=O(CPE:E"[%^-MJ2^\
M4VC6)A52W3,6\M)_8[YT7*6I:/IV?6KR,>S=D_V4K:;//;UZ;3#Z'VV3KQ5M
MYUA=$J*B["B%Y$D
M
M
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MF WH2
M
M
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M9(M'B]2^3LVNVO29Y6G3U-Z)U2?>:1WB(
M
M
M                                E<4Z][5"1JSU4TR]@Y.G[NT]?SK%
MN0MWI+P?N2;_ .S])M=A>+:XY<?W_#..U-S3G6>+8>B:G9UG2\;4[$JV\B"G
M3N?)KZ&C69*=%IKY.HVV>,V.MXY6A<BAD
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M>?ZG*\I54J.JYQ^DZ^>;R/E'T^FB4*0               !%<PF$ @
M       !%*35(JLN'0EVOL(F8KQGP55K,QP=P^GF@1VKL[2-'E_I%NQ&YDM?
MA7KBZIOPXLX/=9/B9+6>\=IVOY;:TQ^,1Q]?BYY^T/H'YLWM:U:TJ6-7QU<G
M+FO-L>X_96M3H^TY>K%-?)YQ\V[6<>YC)'*\-1FZ<8       BO'D0F&X_LW
MZL\3>&9I,GTVM0Q'.,>QSLRJJ/V-FD[O29I%O)VORCFFFYMB\+5^G%U6E1)=
MB.6>L(D)
M
M
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MU,3>4ZL%H;KL^XZ-]COX:]/ZO\7<QPKW4
M
M
M                                 "1Q=6TZ57'Z 1S:Q]3]OY-F5C=^
ME-V\W!E%WW"M>B+3C)I=W)^TVFRR1.M)Y2Y+ONUM6(W./WJ<_4S/:VNX^XM'
MQ]3LTC.<>F_:33<;JYKAWF#FQ?#O,.@V6[KN<47CGXKZG55Y>TL,U$D
M                      U7Z^:P]-].\ZQ"?3=U&Y:PXQKQ<;DO?IX=)LNV
M8^O/'H<O\S[CX.QMISMP<AOJCT]2YOB=IPF7B^DTX3Q5VDZ;D:QE_*8RZ(Q_
MC[O8H^/ZA:RWBL,C!CG);2&1ZOJ6+M[ 6@Z.TLGGDW%SAU<*MK\)KD6*4F\]
M4L[-DC%7HK]?W,/72EPK5NL_%][,V9EJ^'/QU2S2N)*:7M79T]W:OK&OH.KQ
MX:^?-GFS/6'>VS(PQ+65^=='C2FGYS<I1BG1JW=KU1KV+BC5[CMV++K/*72=
MN^8=SM-*Z]=?*WZO6S+U ]>+&Z-H6M'VY;OX.?J=;6JNYSM6$O?A"2KQER[.
M!A[7MDTR=5])B&[[I\SQN-OT8HM6UO>_9#22CT1A"WQC'\#L?A[#?SQGT//I
MC2(BO/Q_6SGTDVZMR[\TS&N0Z\/%DLS([NFQ[T?^TDN)K^X9/AX9GS=%V#;1
MGWU:Q[E8U^G^+M2#K%.E/!]AQ&KVU"YV4]I$QK"J.;CSUTT&.C>H6;D6H]%C
M4X6LN"2I'J:Z9KVUBJT.T[;EZ\,>C@\7^9]M.+>S/A:-?V_2&MC:.7   "/M
M"?6@$                          CQ<6E+XZ+@1J3:8CA/-T#]F;0O,NZ
MYN6Y#I:Z,&PZ<DO?DX\/'I?$YONV332GUO2?D_;Q/7FT_P"7]?\ A^AT6HOB
M_I5#GGHRAU;3+6KZ9FZ;D).QF69X\Z_BW$U7Z"NEYI:)CP6,^*,N.U)Y6C1P
M9JFG7M(U7-TG(BX7-/R)6.E\'2W)RXU\&=[CMU8XMYO -UAC!FM6(TZ9T^SU
M_3@HWQ=2\QIX@     1BZ--_@LA56>,3Y$;URS*%Z"75CW%>@US4K4NJ/W28
MB)B8GQ1%[5C6.<6U=Z[:U6&KZ!IFI*76\K&LW)25/BE!=7U,\^RTZ;S7RE]!
M[3-\7!2_XHA>BTRP
M
M
M                /#)LV\BU+'O04[-Q2C=@^*<6J-/ZQ"FU8M&D^+3N)/)]
M,=UW<*3E+;NH33A.?&,%+BGWUC7B;K2-SC_YH</37M6YZ?\ Q7GGZ^3<5J[;
MO0A=MR4[5Q)PFG5--531I(B8UB7<Q:)B)CE+W)2
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M$WW9\FEYI/BX3YOVW5@KEB/=GCZG-+K1-\GR.I\='E?A$^$\D
M                    "*^&JYMT_P +\$BW&%4>[,_37P=H>CFA_F'T^T>Q
M*/3?RK;S;]?B=S(?7Q]BH<1OLOQ,TS')[AV';_!V5(TTFT:S];/S!;U!\@.2
M_M";<CI6]8:O9CT8^MV%>FTO\=COIG],N#9U?:<O5CFL^#R7YLVOP]S%XC2+
M\9]<-2&[<4        =;?9_UC\X^G]C"N2ZK^EW[F*T^+H_?B_\ M''=TQ=&
M?AXO8_E;<_%V41;G2=&V8NJX\S5:.L1
M
M
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M
M
M
M$LHUIX.HU0Q#>FRL3=6)U)JSJ=E?S?([6UQZ9>TR]MN9Q3Q]WQ:?NG;*[RG#
MA:.4L8VAO?)TG*_NIN[KLY-A^78RKW%45%&,Y/FJ<I&7N-K$U^)C:?MW=;X[
M?E]SPM'")^GWMHIQFE*,D^I-Q:XIQ-2['TP]DDHT[ (@
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M9=^$%^PZJQ_[-#O\%_B4K+Y\WF+X&XRT\K3^U:R^Q
M           !LST&TF6J>HV+>DJV--L7<F?[9KIA]TU7=+].WT]+J_E?!\3>
MQ/X(U=A1HHJG(XU[+*8E"$N,6O!A,*++PL?,Q<C"RHJ>/E1E;O1?)QFJ4^D5
MX3JMVI%JS6?%PGN71<C;FX-3T&^^F6#D7(VW6O5!OJB_J9WVWR_%IU/ -[M[
M[?<Y,4^O]/!:FZ\:4+\<F',Z\4"4     C1D*M)97Z:ZU_=W?6AZE*:M6)7U
MCWUWVKRZ7_VJ&)O,<Y,,UCUMQV7<1M]WCM/C/3]KN0X35[J$@
M
M
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M\1^8Z]&^OZ9_5^M@1L7/             1]@3ZD @ CQ3"4 @
M&^/LQXB>K[ASFOAQK-A/VS<F<]WJWL5CTO0/DVG^;EMZ(C];I:/;[:'-:/3D
MP2 0:3YH#F#[2.V7BZY@;FL6WY&H6_ELF:7NJ[9^&M.].M? Z;M.;6O1Y/+?
MG#9=.2N>/WN$M(N3<DU&B.@G1PLVFTZS&B4*     1]H$'<G9<+L.,[<U<@W
MS4H4DONE,QK,QZ%43,6CT3$N\=FZS:U_:VDZO"?6LC&MN;YOK2Z9U??5'!9\
M?1DFOI?0&QSQGP4O'*87]*A89H
M
M
M                            !*XQ?,G5&BFS=/PM1QIX>=8C?Q9\)6YJ
MJ?BNYBMIK.L<UK+BIDKTWC6&L=4],\_2\AZMLK+E8OJ3IC2DXOFW12Y/_"1M
M,>\KDCIRPY/-V.V&TY-K:8GR287J;KFA7E@;OTRY%PX2R(KI?MY4EP[B;[2E
MHUI93B[WFP3T[FDQZ6:Z5OK;&L4^4U*W&<E_%76K<T^[WJ+[IA9-KDISAT&W
M[KM<\>Q>&0VKL;D5*VU<B^4H--?<X&-+91,3RXI^OL?#[I&L*N*'6VUP=.\:
MCT)         !(I55>/,3P(XO&]DV<>#N9-V%BWSZIR451>V@B)GDHM>M.-I
MB&'ZUZH;:TKJACY'S^3RC9L\(U_;M&=399+<>4-%NN^;;#PB>J?*&*7-6]0]
M\5LZ;CRTS2[G.Z_<BX_LIM*3_P $R_AX,,:S[4M-.YW^_P"%*_#KYLBVUZ7Z
M-I5RWF:HUJ6=1RK.OEJ54ZT?Q?28F3=WF-*\(;79]APX9ZLGMV]+//*A&'1%
M4BN$8K@DDJ<*=A@NDC@Y@^TCKBS-QZ;H%I]4,"R[UV%>"O7I4?T]"1U'9\73
M2UWEGSAGZ\V/''*O./2TH;YP8     $4NII+E(0GGR\5;H^EW=<U;!TC&K\S
MJ-V%B-%7IZVO>7@BW?)&/'-I\&3M=O.?/6E?WOIKZG>6DZ9BZ1IF'I>';5K&
MP[4+%J$>2C!)<*U//[VZK:R]^P8:X<=<=8TBL:+@4KX  EG1Q?UD3R'('K_&
M,?4?*<4DWC6).G;)\$_NG9=L_D0\<^:JQ&]X>4?;R_6U@;5R8    (\4PGD@
M$   !'BV$\T @    $?8$^I (   "/%,)0"     =$_9@A'R-Q3HJ^;85?#I
MJ<SWKC-8]#TOY,CV<L^F/N=!PBJ)]K1S[T2'H   8#ZK;9CNC8^J8=N/5E8T
M7EXM:U\RRG*B\9*J,W99IQY8EHN][.-UM+UTUF.,>N'%M92XO@_PHR[^T[B)
MB>,/#N.O'GX_K"4      1JON=)'CJEU)]G'75F[1R=&N3_+:5?:MP=.%FZN
MI4_PJG)]VQ=.7JC]YZS\I[J<FUG',^Y/V1+=,:M*O,TWB[2$P2
M
M
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M.O,X^'KZ<J
M
M
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M4PN*=7P7#O*5Y,
M
M
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MN+D^#E0T#O-'H2
M
M
M                                      $KE%.C?/E] Y(8)ZJ[YL[)
MVEE9]F:EJN2GCZ;:KQ=V?#JIW0YLS-EM_CY(B.31]Z[C&RVUK_O3PCUN+KD[
MER=R5R?F7)OS)7*U<YMUE5]\F^)W/1I$1#PVU[7M,S.NO'Z_I^I)5%6DJ=2H
MTE.L(C24E4-)1J<!I)K!5#236$4FV^E5JJD3JJB)MK$>,.D?LU[6^4TS4=VY
M$&KVH36)B\.*LV'[[X]CEVG+]WS1-XI$\(>G_)VQ^'AMFM[UN'U0W\:%WX
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M::=.I5<7W.+YG!7QS2TQ+WK;;BF?'%Z3K$KJ4,D
M
M
M
M   \;E52C=>-.-$QHF'/GJIZ>>IN_-R/+P\/%CH>''RM.M3S%%N+^*<HTX.3
M-_LMY@P8])YO/>]=KW^^S]58CHCE'5^EA'_+_P"J']"PO_&1_@F?_=-OZ?L:
M#_:^_P#PU_[D/T >J']"PO\ QL?X(_NFW]/V'^U]_P#AK_W'_+_ZG?T/"_\
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MR5NZ^$HM47!I(TN_S8,LQ;'S\7:_+^RW>UQSCSQ&GAI+;O-_6:QU28A(
M
M
M
M
M
M
M
M
M
M
M
M
M
M       !*Y)47>!XPR%.W.[TR2A54<>+IW=X1JEEEPC:MW7"?3<:2BHNJKWK
ML!,Z)_/CYRLTEU./5U4]WZQH:EN\ISG!1DG;?2W)43]C[0E[@
M
M
M
M
M                   !+)M+@3!*AA<SUCWI7K=J.3&4O(A&3<6E\-6UP\1I
M"W$VTGAQ0N7=0^7L2A:M2R'*'S$7)J,8/C)Q=.+[B=(U4SU],3$1J]7/(67&
M,86UAN#<KC?O^95-))=A'#17[75PY&/<RY7;ZR(VXV5.F.X-N4H]\DUP8F(1
M6;:SKR5A"X
M
M
M
M                                        "27/A12IP;)@E;+./<6'
ME6Y9KN2N2NTOU5;75^"NSW>PGQ6N/3,:O.]B2GAX=IZE*V[4[<OF%TMWE#CT
MNO!]1.O'DHM7V8B;<I5$[3N:A"\LAJ"M./RJZ:2JT^I_A=A$<(7)CVHG7ZC$
ML2MY&5-Y3R%<NJ2M.E+*7#IX<4)G@BD:3/'75<BE=
M
M
M
M
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M#K@WTIJO=VDZ""N1=:<:<Z)A*;KC7I_"[@A&O&@$0
M
M
M
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M"NE>J8CS6\V2,5)O/AQ:A_YH-GT_LC5/W./_ /JFZ_LF7SC]+A/][[3\%_\
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MM-8T\O2WK;<G&K\?OFAAWD/4D
M
M
M
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M.X;^,_LUY,WY>[#;8VG+EF)O^INJ*YOO=33.R3!(
M
M
M
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M*.9'\^6I3G/R\KH25(R=(JG9'@,OQ.FO5RTX)VDX/BY?AS[6OM\^;+BPV(
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M%V=OWS63&KJGH2
M
M
M
M#QFJ-R7.G%=KIW$QHCC'%BFGZKE7=#U7*EMRYCSL7+\;>FN%M/*<?PDEP?7X
MEZU.,<6NIEM..\_#TTUX?B0R=6S(:+H>2MLW+US+O687M/Z;;E@J5?RC3X)0
MI^"55I$S,39;OGM&+'/PM>J8]G\/I5][,O\ ]Y\?3_S3.Y8ECRN2UKIAT0?5
MPM=3]Y5\"BM8Z-=?J9-LD_'BO1PT][R]!H>=D96IZS8NZ/+388V0H6LN48*.
M8G'^,73Q=.7$BU=(CB;?):U[Q-.G2>?XO2R,M,T     "$_A9$C%O4'_ &)W
M#_4;W[TR-O\ S:^MKNY_TN3^"7!\>3]AZ++YPCQ=D>@?_"_1?\KE?_43.'[I
M_46>Z_*G_P!=3_J_^4L2^U+_ &'MU?\ [;?_ ,PS+[+_ #+>IJ/G;^1C_BG[
MG.&FZ?FZOG8NFZ=;=_4,NY&UCVJ53E+B_P!=LZG)>N.O5/*-7EN#!?<9(I2-
M9M/T_P 716W/LU:3#!4MT:A>NZC**E.UAR\JW;;[*M-RIW\#F,O>+]7L1P>G
M[3Y+PUKKFM,V]'@P;U;]'+>QL6SK>BY%W(T6<U9NV[W&Y9N/X7UJC:D_ S=C
MW&<]NBT<6A^8/ER-E2,N*9FOC^K]+7FTLF]A[IT;)QI.%^WFV)0DG1I^8G]3
M[4;;=>UBMKY2Y?MF2:[O',<^JOWN^5.72IOAUI.*[N%3SOQ?1<<8U>R9&L#S
M3DFWQ=7P55P"='G=C;O6[EF\E<LW(RA.+7!Q:::?MJ(YZJ)K$\)\7">^]MSV
MKN_5=!:DK>-=E<Q.Q>3<?F0:[^#I]!Z!LL_Q<$>;Y^[OL[;3<7Q^$3[/JGBV
M']G3<KTK=M[0KMRF+K-M^5QYY%I52^KK-9W;#U8^OQATGR;ONC/.&9TB\:_]
M3J?)R(8F-=R[\W&Q8A*[<DZ+W;:<F_N')Q6;3$0]=O>*5F9Y0X)W/K=S<VX=
M6UZY6NHY$[G%_P"*3Z;?W$>B[?'&/'6D>3YU[CNIW.XOD\+6_1_@VW]FK;'S
MVN9NZLF#\K38/%QJK@[]ZG72O;%)?6:7O.?2L4CQYNS^3-C-LULTQPKPCUS^
MQU,<GH]9<A_:,_XA.B_^2M5^NAV?9H_R9EXU\X1$[R/X5[^R[1[@W%54KA6&
M_P"5D8W>HB*5];/^2?YN;U1][-/M&[4CJ6T[.XL:W_.]$N5NS@O>>+>=)U?@
M_>-?VG-%,O3/*70?-VR^-MXRQ&ML?W3S<V;5UV]MG<>F:Y8K7 OPN7()M*5N
M4J3C['%\CJ=UB^+CM6?J>6=NWMMON:98G2(GCZO&/5H[TQ,FSFXEK+QI^9CY
M%N-RU*/;&2JG])Y_:LQ.D\WT-2\7B+1RESM]IG<:=[3-I6)UC:KJ&9"+YN58
M6X27_:1T?9,/&<D^')YK\Z[WA3;QX^U/ZFL_27:_][=\:9@7(^9IV(WFYM5[
MKM6FFE+]M*B9M.XYXQXIB?'DY7Y=V=MWO*U_=I[7+R_:ZO\ 4;<\-E[1S]:B
MJW[<8V<:%55W+KZ8TKW<SC]G@G+EB)>Q=UWU=GMK9)\.7K</YF7D9V9>SLV[
M*]F9,I7+UV;;E*[-]K?8>@XZQ2G#A$>#Y\S9K9[3>TZS,\V]M@?9YM:MI.-J
MV[LN_C/*@KEK3\>D)JW))J4YR7"5'RH<YNN[S6TUI#T;M7RC3+BKDSS,3;CT
MJG>WV<\7#TR_G;/S;]V_9@[CP<EJ;G%)MN,TE65%RH4[;O$S.F2%[N7R?CK2
M;X+3K''I<_6[N1B9,+]F<[&7CS3C*#Z;MN[;?"E.*=4=+:*WIZ)>:8\E\-HF
MOLVK+M?THW?>WMLW U7)E_/[+EB9R=&Y7K-$Y</QJIG!;_!\+/,1R>^=DWWY
MS:5R3SCA/KCQ^MGIA-V
M
M
M
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M#6/UNASG'HP
M
M
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M!I79@
M
M
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MATOEYD3K\]J_#MQCE/W/'-ACM^8Q\/WZ_?#OZU*EM=ZBG]P\[GF^CXY0]P
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ML;%M8=BUB8MN-K%L1C;M6X_#&$51)+PH<A:9M.L\WL=:Q6(B.4*L)
M
M
M
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MIR0
M
M
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M0
M
M
M
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M3VB^SG+FC!2:VZO:F?'U-H& Z0
M
M
M
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M/7%%8Z)F9\5/;LVZODR1FQQ2NOLS'.?6SPQ&[
M
M
M
M
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M;KQ)0F"0
M     !Y7')5Z7[U*KAP0(8GN7U'V?M#(MX6O:M:Q\RXE3'2<[J3[6H\EXF3B
MVV3+[L-9N^Z[7:SIEO$2O.A;@TC<F$M1T3,MYN#)N*N6G5*2_!99R8[X[:6C
M1E[;<X\].O';JA>"AD
M
M
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M=E:RK.'=N6KL7249*-4T^RA?PQKDB&%W#)--O>T<XK,N+5O_ 'U1?_<VJ?\
MC+W\([S\GA_!'V/ ?[OO?]:__=9%;^WTVZ;EU1*-*UR[W;W>]R(_*8/P1]BN
M.[;S37XUO^ZQ_?[?;X?WEU.CK1O)O=G^$51LL7C2$QW;?3RRW_[I7?1/5SU"
MT6Y&]:UJ]D0;4KEK.;R4Z<*>^ZQ5/Q3%R[##DG3IZ?4S-I\Q;W;SKUS?QTMQ
M^]T;Z7>KF!O^,L#+LQP-RV+?7/%5?+NVTZ==IOCT]Z[#F=[L;8)UYP]3[)W_
M !=PCIGV<FFNG[&S8RG*3X)0=&GVM=M35Q+J'L2
M                                    'E-*O'N7WQJF'"GJ'#4[.^==
MCK,9QS)9=QIW'Q=E2:MR@Y<'%KL/0-C:LXJ]'"?%\_=ZKDKO;?%C6=>#;OV7
M?SH[^OW'%K1)PL]+?"+RJRZNE?M:5-'WOHZHTG67:_),9(C)'[G#3Z>ITF<V
M]+
M
M
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M,2M5WF&TQ$7B9]:^%EEA(
M
M
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M4?-_DY]Q;WW'!:=-&5V#6W<,,:^/']+N)<N)P4/?$24
M
M
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M4/ZI?_S;.0I[T>M[!G_EV]4OGY<KYTZOI2E)UI7C5\#TBG*/4^:LD3K;UR[
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ML:6M.GH:P](/^)FVOZT_\U,W._\ Y%W(?+G_ -EB]?ZI=QKD<!#WU$D
M
M
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M@9J\B[;<G-VLB"JJ-_C(V/;-[;+[-N;1?-/9J;2:Y<4:4GP]+ ME;D_NIN/
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MB_4TQZ/_ /$O;/\ 6G_FYF^W_P#3W<%\M_\ V.+U_JEW(N1P$/?D20
M
M
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MTUO[OH=$VZ4?!<WR.<>D2XL]<&OTG:PZ^]U6^E5Y_DT=WVR9_+UT>$_-<_\
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M[WT/[?I_4/-8?3#BCUQ_XH:W^VL?YN)W?;/Z:/6\'^9__L+_ %?=#;GV7/\
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M[LKY<_\ L<7K_5+N-<C@8>^HD@
M
M
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M^XWB-K/G+E?EO'-]_CTCW>/U.WU7M.$A[PB2
M
M
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M$Q ATKO9(EZ(TIQ:YA"/16O'F0E!05%X*E1H'0J43:[>#)U(X)J+F0'35\_
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MI\:RHJ>!R_==[&3V*<H>I_*G9[8(^/DC2UHX1Z&^XJD4N[O-"[^4P0
M
M
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M>^6=;3JZ?9]MV^TC3%2*_>R+I7?Q1CMBG)
M           !+*/5[.X"@U#2<#5<:YA:GCV\O#O<+EB]%3@TU2G@5UO:DZUG
M25O+CKDCIO$3'I:RU3[.GI_GW97<..5I[E7\E8NULQKW1DG3ZS:8NZYJ>.KE
M=Q\I['+:;:369\I6FS]F/:L;BEDZMFWK2Y6X]%OA[>)?OWK+,<HAA5^3-IK[
M5K3#--N>CFP=L7(Y6%IBR<ZVZV\O-D\BY%^'4Z+ZC7YM]FR<[-[LNQ;/:3U4
MI[7G/&6=^4E&B?)455P^HP6^]2=)I*KJ^UA"8)
M
M
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MK4H2\R-YMMIJ7%NB?3Q[C1;JT3EMI'3QY/0.V4FFUQQ-NOA[W/5E1C-D
M
M
M
M
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M->?/]K,3%;4
M
M
M
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M$]/+333ZF5&.V0
M
M
M
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M#19K5M>9K&D.XV./+CP4KEGJO$<61%EG
M
M
M
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M$Z5HN9I]WNYW$Q-O!UW9^T1L*36+=75.K8,:5X<J&$WOBF
M
M
M
M
M       0DE)-/D^83$J7+P</4,6_@YEJ-_$R82MW[4U6,X35&GX.I56TUF+1
MSA:R8ZY*S6T:Q;A,--^IN@[2V'LB.%IFT[>?I^3FQG=M0=UJU=2=+LI*3G7\
M'G0VVUSY<N7JZM)T<;WG;;;8[3II@B];6Y<>>G/S]#"-SZ]HT(;$<=A*Y&>)
M;NV;,XW:QBY*ENVTTY<NK\HFS8X<<Q&7_-TXM%O=UBC\M$[?]WEQ^R//Z^*N
MQ-PZ;'U7U1K8G\XA9R;<YJ%QW9.%GJ;</XM>8O=32XEN<6NVT^+XPOX]W$]Q
MO_ZWA/KY<YCEQY?3A:-%U[2GL'=KM[%A''^9LN<*7W:<I3I[SDW./EO\2A?O
MCGX^/_-\&%MMS3\EGB=MPUCA&OG^KT*77MP:2ME[14M@PE;_ )TK=J:OJ"Z+
ML.I1<7U/S/B]YOP*L..?C7_S5.YW6/\ *X8_+\-9CCKY_KEE5[7L"7J[IZ_N
M1UY?DVH+(49^<NJS534.%NB^'C]/$Q*XI_+6_P WQ;.VZI'<J_\ K\=(]?+G
MY>ACNC;ATNWC;VZ/3Y4\NY*\K<;KBJWE%PGU-N-&^M]'<96;'QQ_YO@U^#=X
MXC<:;;7A/GRUY3]\Z/#+W!ID?3/382V'#Y99UU)M7_)=$GU1G%];<^7.G<3&
M*?S4_P";X>A8OO:3L*?^MPZO3IZ]>?HXLBUS<&C1WOM%7M@N>7/%P7"4HW5<
MMQN22BE%5B_+^*L^/>8^+%:<%Y^+PUG@VVYW-/SF&)VWA3CQX>7HX-WZ5L/:
M>C:SE;ATW2[6-K&9*;OY,>JK\Q^]1-M1K2ONI&AON<F2L5M;6(=QB[;ML6:<
MU:1%[<Y^G!DBA%))+@N7$QFQ3@"0
M      (50%)^<M/5SR7F6%>Y='F1ZJ^RM0*O]4 J]H$).BX<^PB1@VZ/5?96
MT\KY#4=0=_4/PL/#CY]V"?;-*B7U_09F#99<D:Q'#TJXK,O/;WJ[LW<66L"S
MDW<'-FOR-G4;:QG<_:-MI_63FV66D:\X]!T3#.TY]O*A@\=%,ITZI,J0B
M
M
M
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M^XY[),=4]/)W^VK?X=9RZ=<1Q]:\Q5(\V^?%\RWIHR83A(
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MC<BY-]K4NPYK>XHIDB8Y3#'R5B&QS 60D
M
M
M
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MW;;;#!\.;]7'5G48TI7L22,&.3>S*9*@0B2
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M
M
M
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MV.P[/M]GDMDQQQNS:B7)&(W2(
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M?_TMDT._]ZOJ_7+'S\VW#5L<
M
M
M  $O5'O7UDZ(U2N[!=OW1H:PE=ZG*A5TJ>I*[[K3L]@TA3U)7?F^1.AU2@[L
MWS^X1HCJE#S9>))J>9(:&LGF2\1H:H^=<(T@ZI15ZY0G2#JE,KTJ<:5(T3U2
MBKWL$PGJ31O1[:(B83%DZG!NE57VD:2JUA&J9"40
M                  !1YN-CYMJ6/EV(Y./-)3LW(J<'1IJJ=5P)K,Q.L2HO
M2MZZ6B)AJ;U<P-[6HZ'C;'T#&SL&Q*4KL/E[=[R[J:Z8],J*%MJM91[3:["V
M/VIRVT<CWZN[K\.-MCBU8YQIK](;+Q]*Q)W<;4<S3['YWA:AUY/1%SC/I75&
M,J5278:RV28UB)G1U-<-+3%[5CJTYZ<5U@FHOGSY/VE$LB9U>H
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MGVZ=[_FMDT>^XS7U?KEB[B=);75VV^U&KB)8W5"92B^U?63HG6$R=2$@
M
M
M                            23GTDQ"F9T>;OIK@BKI4S9YN[+Z!HIZD
MO6V2C5 D              1JT_$"97&AH:HJ[+MK]9&BKJ>RO193TJ^I.FFD
MUR92E$)
M                       \W=2*M%/4\W==>%2K11U)'<?*3XB$:I6Z]M24
M(   D<A?:3_XFP7_ /C,7[]PZSM/]/\ 7*OQ:_T:KDDN549N1E8V;V(J6->A
M%4<;4OWK,"W-F5YNI]A+_P"T=#3_ *)97_91S>X_F6];57]^6*[ _)[EU.QV
M3\Y_5=D8R;+']IM__P .,=]^IXW[RZ;KM'\[ZI4.5=.ET7(OQ1U%UW&V+H5U
M42CS@OOFKRPV.-OWT9BOD-=_K]O_ .EM&CWG.OJ_6Q-U[S9IKXY,)'J:)$RN
MR[.13,:IZGI&]W_?&B8LGC<3=")A7%GH4J@
M
M
M)7.*[2=$:O*5_BU'FNTG11-DG6Y*KYE40IUU2R)0E
M    3K@E3F!,KLH\&4S"J+/2-V+K5T(F-%46>B:?(A5JB0D
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M5ZIDZA(
M
M                          "64XQ]I,0B9T>,KU5PX%6BCJ>=7VLJ4:I0
M(^P"                        !&K 580?2$IE.475-OP(F$Q.CVC>3Y\R
MF87(L]$TUP*52(
M                 !N@'F[L*TKQ)B%,R\)W)-\Z+P*HA;F4I5H@38"K[P(
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MD*@
M
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M57VP7&7'P(ZJS.FO$FLZ:^"=REV<?ODZH>I(
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MH.N2E)5>HV^'_P#*VT<UW*OMU]7ZUK-:);D2X*K7T&J8^B+\/K)1(_;4"
M   "4(U=:]I&B7I"\UPEQKR*9A5%GO&2EVE,PN1*8A(
M
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MUE[I-\N7>%1RY@0     "*X<@/6%UI*O(IT5Q9[1DI*J*9A7$ZIB$@
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M@T^'#Z3L,66N6D7KQB7%YL%\-YI>-+55#G)<(I>+?)%W58T>D'U*O#Z"1,
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M,*HEZIIKP*%Q$
M
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MCAS(F$Q.BHC)3546UV)3!(
M
M                          $KDHKBR=$3.BGG<<O!+D5Q"W,ZO-5IXDJ
M)  0CV5"1<1J*6_FV;::@^J7=Q*NF5FV2(6^[F9-Y4KT0Y)+G0KBL+%LEI>*
MBHKAQ[77G7VE:TCP[J>WB$H@    !%)A)1D"*YT&HQS?$W';F0DZ==RVJ=ZJ
MZHRMK_,CZVJ[MPVUO7"S^G=]J>H83=8+IN6X=B5.+,C>QIHU_9+^_5G5%VFM
MU=+H4&L&B-$-30HAJ:%$-31"G<-0HR1"C"   HN;56!"+G"75;;C)>/!D:)U
ME6V]3N*D;ZK%?A(HM7R7JYI\5PMW+5U)VG7MIR^^43$PR8F)Y(O@Z$:I
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MY.#K]PC0B=%3&<94[RB878G5.0J
M
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MS71E5O%H5%:NG!T[BG5<"4(!(  C%N+J00J;=Q223?$HE=B7H0J
M
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M E(   %*CX!"HA>XJ,N;*)A=BSV*58
M
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M6QD6K\$TZ3[O$LS#+K:)AZ!6   $4Z- 5%NXGP[D42N5EZE*L
M
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M8$7Q)0A%RMR4[;Z9IU37>4S&I$Z<ESQ<N-Y*-WW;J["U,:,REXGFJGP?@0K
M(!)1<^T(13HZB83$Z*FW/J7%\2B87:R]"E4
M
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MZ*J,E)51;F-%Z)U3$)
M
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MT5?P7WE%JKF.^G"5U=>'BJEMER@   .*=41H*JS+JCQYHHF-%VLZO0A4
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M?4=@XK6$Z=>($0  "2<E&+KSHZ$Q")G12MN3JRJ(T69G5 J  !'C5)+@^WN
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M^O!5]Z["%U   "$\).,EW5XD3"J)T52:DJHH781(2
M
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M>UKN(5H!(!$E#UMR<>91,*XE4%"Z
M
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M32KW-DTM-91>E;UZ;1JUWN/8^1I\9YFE+SL*/O7+'.<5VT7:;7!N8Y6<EO\
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M1EN5VLO4A4
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M86M&4$I  'I"XXLB4Q*I3JD^\MKR(
M
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M+C'ZRBT:<61CR>"O33KWHH7T   "HLS372^PIF%=9>Q0N
M
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MQJG(5  ":#H^8(5<755+<KT(D)
M
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MS!WG%?A+,K5ZU>MQNV9J[:DJJ2\3!FLQ/%O:VBT:QQ3-!*7@0A#A4E"5UJ!
M(0"$./T$Q*!HJ0E: D@Y0E"[VQX$:(CAQ7FW-7+<;B=>I)LM,V)UC5,Z_6!
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MR]A1,+F.VDZ+CV\/A+?'5DA( 1Y!#WLR;HO:4S"Y67L4+@
M
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M4JKFN*?CW"$2N6+>=ZRG157"21:LS,4]4/<A4  )X2<9+MJ-")52?"I:7T0
M
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M_P!1HNCW[-P7X/YMQ5P[.2^\)S8-)_R__P I4_D=]_\ Q/\ ^%1;/]1TE_\
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M646A<QSI.BYN-"ADI0 $5P J;,NJ-*4IP*)A=K+T*50
M
M                       \;\E3I[651"BT\%.5K8  BVNSFE5^ %DG<\Z[
M*;?)N*^@O5C2&#:=9U0\>TG52BN1$I3Q3(5(\:$B/$C5.B**52:C"44J2ZNV
ME*$$*#6=*LZYIU[3\E)1N1:M3[87*5BZ^#+F/):EHF%K<8*YZ36S3FW=PZEM
M34L_3YVI*YCRE8S+;Y.<:TNP7XLEQ1NKZ;FNKA\.3+VW)-)CA/TU8]KNI9FM
MY,[V3?E#*MRE<M*CZ7;Y_69N+'6D:0YW>;B^XM,VGC')9Y?-9MOS<.[&3?N7
M;55P\2YK$,2L3:-5FS)96,[498\IN<G"54^#"Y68A;,W&P<2_9RLFTI2L+\A
M:C5)-]LZ<RG5?BW5P28=W(OWL_-LWH*_;L\'%\)2G\,.GG1?<"J:Q6$FCN[<
MRH1OJ-N:@WF97PQMJM9I/M_7)6YF-%KUSYG'E=E#55=TW(NK(3C9I=C9MU2M
MP;X]4J_<"]@K$O'9TLS)PIY5RRX:+=OR5S'S'UW*N7!KM7#B%>YK%.$SK/@V
M%BXV/84K5AIX\/>MW9S4DTUV)<>!.C6S,ZK3ER<;4[MB[T9%RL+4VFE[O;0A
M=K/'2>:P:ABX>H1MW]6Z\>]C1Z[MVQ)*Q=2_&7XQ#(Q6Z)T\V.83R\S*G;T^
M_P!>!*,^B[;X2;_$:YOVAE]/1$:RH=0VK>RI=+M*#@X3A=55<N2ASBT^SQ&L
M*\>XBL:3XLOTS5)Z3?P7/#A8M.?3*-B*BH)JG7+MKXC6&->)O/!4;FU/$TW0
MLC'R7+)NY-V-K3,:/\;>R)RX47:N]DJ=MBF]^'#1AN9M_P"1MRUK5<2U"]<A
M6[)35R4&E\+78RQ>9AN-IDF;:1.NG-I+/OSS<Z_?=%&Y-Q4>:Z48\\6[UB%/
MY,NN5M+C%5H5:<=%462=#I62E%+A*O A<CBBY6X^\O=@U\/Q<1/!,UG713WH
MN]%R_!C^*J%JTPNUB5&[*7O)M4XNJ+4Q#)B9Y(6KD[%U7;?*JK'E6A1$S$\%
MV:1:-)ENG8.]83A&W9L6;6;;HNJ[[W13M53,I?1S.]V4VGA+=.DZQI6O6[MN
MY>C=N2M267:3=IMI?%#JY_09U9B7)YL-\=M=%IM3T.SMV-G$N26IV[LKNGY"
MY*DN-NXO8/%7U=5O:C3REFFFZA#4](QIX%FT[<X1CE8]RCA5M]2IS;[> B%B
M\S6VD,8U;:UG#S+T=.C*U"]25EI^Y%OFEW)%6BOXDS&BY6L:V\%:?JL7+J24
M;U/>A+V=M0L3Z%%?PKF!&3NM.W%=%OM4J\F^[Z2)51JS3T7WYINVM>R<#-K9
MTO490BKS3?1?5>+BN-'WFNWN#KXUYPZ?LV]C!DF+>[9U)9O6LFU&]9FIVY*J
M:[4^1HYX3H] K,6C6.2:O']=%"H*D)6OJ")A)0E" 0A1@0:?U!"7M*M5.B%&
M2(/BFI<.XA"JTZZY0=F?QQ;=/!\N)19?Q3K&BNH4KR $5P8$RDDU[0*I--5+
M2^B!K?U4V9J&YL;#U#18*YJVFR;A8DU%7K4Z=44WPJN9S'?NUVWF.)I[U75_
M+W=<>UO;'EX4OX^4M6K9^ZM4=S&U7'_-&DX_'-U'+:A:A;BZMQKQ<J<%0X';
M=AS]<SD]BL<;3,\G;3W/;8HBV.?B7GW:UYS+:&G>J>P</&QM,Q,V\[>-;A8Q
MG.S<C&70E&*4W%*KI3B=Y3OFSI6*5M-IK'#A/%Q6;Y?W^2\Y+5C6TZS[4>/.
M=%4[V;D:E"Y>LQR]<E'JP=-K6QA6YU_*WYK@Y2X>/<8E\V3)GBUJQ?+^Y3]W
M'Z;V\Y^WR6*UQTQ36L]../>M^]>?*L+I+%CM[%R-9U&Z]0UNY'IC=:HO,G\-
MJU%<(QJ9]L,;/';<99^)FGQ],\JU\H8=<D[F]<-(Z,?TXSYO+'R);>TC%T^-
MMYFN9K<X8ZI6=^X^J<I/\&$:\9,MX\T[+!6D1UY\FMHCSM/.9\JQYSP+8XW.
M6UI]G'7A,^4>CSGT)MHSU#SM76H9+RKMK+5IS7",7"%&HKN3*NQ_%US1DOUS
M6^G[3N7P],<TKTQTZLCM9V-=O7,6W<4[]AQ5Z*[')55?H.AIFI>UJUGC7FU5
ML=JUBTQPMR52G%UX\N9=6SJ5:=H$.N-/"K7U CB.232KQ; BVEQ?8->*7F[L
M%7@W3CR;*>J))C@L6OZWFZ.L:_8QEEXUZZK-WWNB<)2^%*O#B:CN6_R;6:S6
MG56TZ<_%L-GM*Y]8M;IF(U>#R=+W-8NZ;<E<Q=0C\-J^G;R+5V'%3@G\72^U
M&/.?!W+';%;6E_PS[-HF/&/./3'-<C#EVMHO'M5\XG6)CRE1X>'B:Q.]AZS8
M>/N#!HI9=C\E.XN/3>MRC2J?;W&+@PTW4VQYXZ<].=J\)F/"U5_)DMAB+XYZ
ML5O">.GG$J?5,?-Q?*LZQD/\FZZ=N*VDI6KG9&_%<*25$WVF+NL6;'$8\M^,
M?R\_C$^5X\O#RED8,F.VML<<_>Q>$QYU]+WO;\TG1,=6-SWXX6I17O6[:=V-
MV/9<MJ*;Z7S-EC[S3'[.Y]C)7373W;?\U?1/Z%FG9\N>9G;QUU]/#3T3KXM=
M[NT&]N#4Y;UV3<CJ^/?A;AGX=IKS[<[:48M0=&TTEPYG.=Y[=.[O.XV\]7G'
MZ'6]JWE=KBC:;J/AS77IGPG7TI-G[&W-J>OX6K:]A2PM,T^Y\RU=I&Y=NKX8
M]'.B[S%[)\OY:YJWR1I$*^Z=XVV';VQX;==[1IPY1'GJW\>HO,0"FN23F^[@
M7(Y+5IXO-NI*E "*K7@!X9=Y6;$N-)23BNWB^!,1Q49)TA9X1='U/B^9?8,)
MT1JE'F0E/%-(A4F1*2GU$20F12J1HPE,!KSU2V]9R\3$W'95-3P)=$H5I&_C
M7.$K<GR37Q1J9VSO-;:-'WG;TOBZYYPU1G=<K3>/%J=M5MTDGR?!5\%P-]-=
M/6\WR<8X>"RZEEYF/&SJ>.FN5N_"2ZDRN=%NO'VM>*F_/&%J&1'&GA-791D[
MEZ+I"$:<WV<>XHY*IC3P6S(O86'"6+ILJ2G[UVXWU57<NYL:JHC3FDM[:SL_
M!E>M9*QIY#3BIQ=V*E'E6E>#[@K^-.FD<E+K-R^M4>GY6-*-IVXQ6=;XVZ)<
M8PCS2?:@KK:'CD:S?P,JUI]I_+Z?&/RUJW"OG7+TOBG-_>)55PQT=4+%J.BX
M][4[-W*7F8N%)>4TZ6XW'QIXU[R%RE]*LJLZLG#YK C%64XV\G&FE1=W2^WZ
M"6),2K<K5\:6,W=R(6L7&]^_5*WTKG1,E36DVM%88)IN^'N/)RX8F&XXD+GE
M6+U]KRY03YIOM*6UR[*,58UGC+QU#-S-8G?TS0;CPUBR]Z33<;D^Y5[!*WBQ
MUQS[3(L/2L;2-,A<UFY"UEY44WC6&N#[9/VD:K%K6O/#DQ[.^16=-824;,8Q
M5(\E+G4V.+C2)]?WO0?E[7\KK/C:5;A7E;E'J7#MH1:'5UEDFG:A)*5Q-5@G
M'I?L?)=IB7HRZ6TEK;U%U*.+MOR[73'*N4MW:<'TRDW3VEG<^_\ 8\PMQW&3
M^*6GK4:.$XJE>$8U_P"E#%UA=G75-'RU*?0G=2_C%R2?M*X78C@\H]-_JC;B
MX2['+DB(XQP7(J\U&ZG24KEM+\.#X%,SHKB$R<XJ4I+K@^'OLM]2YTP](6IQ
M]V,:QDN/2ZT*N*K1-;@ZQA*TY*,FFGP]U\RJ%'4ONW=:OZ%F1N6&IX#E^5M/
MBH/O15,J+16\<6X-+UW45?M:C@Y"OV;Z3NXUSC;Z(\5T=SJ7*V:3=[.LUF55
M^<M1=W*NN<UBWY^=)6TZV:]_>BOBT<XZ1$>A<- UR.W<[Y74X=.D9S\U*2JH
MS[+B7:N]%<:J;TB8C3BS'5<NSF85F6)&W>PKL7+'R8/@Y=W3S1+%TTG1:</4
ML#(D\/)MK#RIKAU233FO%=X3%9B-57>N^5_-<ZSV4ZZ<:+MB^U$J(EBNMVYX
M=S&RH7/-QKTO==:=+[O:6K<632M;5TU;;V%ZS9&V<&&E:XI9]F/"S=7%J*_!
M??3O,++LZWXQS=#L^\WVT=-HZJNA=#UO$U[3[6?BJD9QK*-4VJ^!I<E)I;27
M<;;<USXXM5<Z>'B4,A*$)*$J4&FP(48$KX!"5DPB2E?85*4LFX_E%PG!U7L1
M$FOBNMFX[EJW/LDJU+3,K.L:IPD  >MF2C)I]I3,*ZRJ2A<
M
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M3QWRC\+\'V^PM67\,Z\%:0O  ":'!@A5IU52TOH@
M
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M+CLY2K\,_<7TE%DTGILNQ0RP !%<R4*JWQB6I7J\DY"H
M
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M+@
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MJA%DUYJHMKP
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M<"E?  $T>9$D*M<4F6U]$
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MEDH$) (IT"%7'X4_ MROPF(2
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M@NB5UVY]5FZDNVAI]Q>-UB^+$:7I.D^K7A/U</TNCQX(Q3.#GCF.'V<8^O\
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M-BW*59J*^-_C-A<M.M6::%+'P[EV[8A)7W"L6EU<? JU:W)'-<;F1K-Z#NO
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MBRVRT D !"LMNL46Y7XY)B$@
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MN''EWE4*95NGM?*I=J;37<6Y7\?NJDA=  'K8^,ILJHJ2A=
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ME>KR>A"H
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M5WM.MJ#[XHLSS9D<A\PE ")*%3:^'ZBW9=J]"E6
M
M              "6?PLF$3R4DN;+JP@0E$E"*Y_2$K'+XY?MG]]EQ@SS3Q[
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M*4I*$&!*_A84^"IT_P#BY^TB5W%R592O  #TL_QA3*:\U44+P
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MCV_VJ^\42RZ\H1?,)0 CW@5%GX2BRY5ZE*L
M
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MOF$H 17:2A46?A+=EVKU*58
M                                                          )9
M_"R81/)22YLN+* $24)TN)"5DE%1NW**B4N'TLNL*><HK]<E(BF9(3$)3+F%
M29)5 G2(5)J)\PE%+@U3@^=2-318=?VE@Z[9<>A0O+CUJJ;:Y&1BSS3@UV[[
M=3<1RXM3Z[L?4M-G)66W%<4U7L=#<X]U68</NNSY,<\&(9EK(MMVL^UU0Y5:
MY,S(M%N30Y:7K.EH6CKR\>ZU@3\Q2I^2D_=I])4LQP5[MX]VUYURVK>13IN6
MTJKV\2%>L::^*R6,C1,!96EY4^K,RE/Y97(KIGPX0ZNPE77VM=><\DNC9$+.
MK7\;RO*619JJ-TBXH*)F?'R3:QH>G0O0RLZ]U.73&S8BZRG)^"#(QVM2--45
M@XEG!RK^?A6Y8MIJ'R=GWJTY.;7&O>)6^KCJM.H[=LZM:^;VMD1A<NP75I.0
M_+LJ,.<8/@DWXD<F17/KP\?)IK>]AX]VYIFHV[MN=B2Z+<^4:_@KO5>TGIK;
MFZS8=,UUABEK2L;'H\EPLQBZ]4ZOI[>2XF-%.;;WGJY,UVSMG)UV]:OXEM/'
M5(K.S+L,7%;KP48M.4V^SI1KM[W39;'^;-[S^&M>J?U+/7&NC9N)L'/CASAB
M9V#<FXRA=LN$ZKO@_>JOJ.=O\\X*V_I[Q7SU^[P4Q%;1KPGT:\5GN;%S<'3K
MN'D8RS,&^G)2L7.N"JZIQ4J.-/ W^R^:.V9ITZIQV\KQI^GC#"MML<Z6]WU<
ME'H>FQMXV2^F[;L8T72,XMSI%*C5>+53:;S/BMTQ2T6B9YQ.L?:Y_OGMVQX8
M\9UGU:Q#$]>M7=U[;CO; N?*ZSMW)A#6+=C^,A94F[&0DNQ2X2X<.+[#5;G=
MUQ;JFVS1[.:)Z;>$^=/K=#L.V3L[6KSI?E7U_3ZN'C.JX:CNC298O]^,:V[6
MMZGB?+ZGB.*25^#2\RWPXJ=*G+5V&7J_)Q.N+';JK/HG]V?355;%.LTF=?'T
M?2>>GFU"Y7,J]=S+ZK/(ZFWW.3JJG<16*Q6/1I'U,V>,1PY0KM,T:62EU+JZ
M>4?$KDBJ[Y.AXV+:4KZA&3['S*=54QYK+DX3Q9)P7F6[GPQ[B]759O6-=7GY
M3C-+R5*Y"C2]I7K$>"F:S9<].U_5])61'$OJU#*?Y:TTG3R^"?$MY*5R<;1J
MLY-OBOIU1QA:L[-R<^?G7;DYQDZ\>5>WI7(CHB.7)<FD54[5JS27E.G/WG2K
M]A,KNO)5Z-I63J]QNS"L5+\HH]D?!%.FJ[ES5K&C;FV\#$T'3/SM:L++<%[T
M9U5+B?"M.PO5JYK>;F;SIKP7MZL\A7;6K7(RCD=,\*Y#\&<E\%.[Q8LUM*=-
M_9+VE0U&S#3K\(PS[75/!OI)PC-KL?<,?!?G/\.W'DQC3-OZAINB7KF7'ISK
M=^4$GQI<KS+LKF7/7)EB8X1X)W@V+-^&=&VIY?ETDTN,IKC0@M?A,+NKTKF(
MLR\HV+]Z/DTMI</%^P,6.%N/)2OY+0=(OYF7<E-V8OINM?%<FZ1KX-A7%9R9
M8K7DM\\[4[5R'S%%)]#E"U2BZU6BISX!D36M9FNG@NCSX7K;E<@I0@E^57./
MT(ACVC3DVOZ#Z+J>=O/&SL=>9A6??=U_%$P=WDTITMSVK#:V>+>$.TZ+G3F<
M^[^4KYA2DD0A*^0$CK0J4I.-2$($H2LE"5\_$E"5A"67P/P_7")5.!_%S_;M
M$2N8^2J*5X  >ECXRF55>:J*%U32N34Z)QIU4XNCY=A5HIU4TLR^HUZK->BY
M+C*BK#D_8NTG1;FTJ;(U3)LVY3C<QDU;LS3G<I&LY4;Y<G^"(JM7RS$<X\'@
M]8RUD0M^=A*,LN5AQ=VLW!0KTI4^/]0KZ.'*5N=Q/5IK7WM.?H^]0/<6I^1"
MZK^G.4L/*R7+SVH*Y8DU%ITXVTE[\BY\*-9X3ST^GI6)W=M(G6GNVGGY?J\W
MAE;HU2Q#)E')TJ/DQT]QE<R>E)Y37F=?#@I?XE_A"N*)TX3XHON[1U>U3A%/
M'\7GZ_W4RW-JKSK6,[^E1M7-4NZ?3YEN]*U;M]2C&/3_ !Z?Q0Y=/$?!]G7C
M[NO+Z<"-YD^)$:TTF\U][CIIKI'_ #>CR4=K>&M2Q+&1*_HTKMW3L[,K#,<K
M?FXMQPA*+Z>-E+^-G^"RY.WB)TTMSB.7G^OR6*[[+-(G7'QI:WO>,3PG^'\4
M^"?(W9K5J&3)7]'C*S;TR4>O*:BI9S7F]?#A%_\ R_XY$8(UY6_>_1].*;[[
M-$3.N/\ \?[WXO>^W]R?%[1W3J_ST+$\C2HP>JY& X1R6[OE6K77&"5*>?VS
MCR42/@QIRGE$\E<;S+UZ:T_F6K[W'2(X?]7G'@H(;VUQX,,F63H:NRTO,SI.
M.9)V_.Q[G1"<9=/&PE_&3[&7?RU>K32WO1'+Z<6-_<,W3KKBU^':WO3IK$\)
M_@CQE)F[VW#8^;=O(T1*RM,=OKRI)IYM%<4^'!2K^1?;VDQMJ^5O'P\OIQ1D
M[CFB+:3CX?#_ 'OQ<]?1/[J1[XW#'-M6'D:'&S+5,C!=<J76[-FTYI+_ .*I
M?&N5"8VM>G72W+7DIGN6;JB-<>G7-?>GE$<O6M2]2=SK#MY'S.WW*>FY.8W\
MW.GFV;G1%\OXM?A=M2].SKY7]Z(87]XS]$3U8=>BUO>GG$Z?8\<KU)W3:N9#
M^:V]2W^;O+_G<G)/*5;CY=M?<\"J-E3A[-_WO!1D[SN*ZZ3B_<_>G][FPB&/
MIBU#'E\KHBZM8U!\-2OJ-96FVZ.3YOGXF;/7%=/:Y1^ZT4UI-ZSIB_F7_P#)
M;R]:S1Q]*>F6OYMHB_\ (\CEJ5[EY_?7[ADZWZIXV][\/H8?PZ='NX_Y5O\
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M2RHY#YA* $24*BU\/U%NR[5ZE*L
M
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M6Y7JO0I5
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M(KQ1;E>A.0J
M                                                HI*DG[2ZL(
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MK+L1[EU/V,FQ'O0N7WRVR$ D B$*N'PI>!;E?CDF(2
M
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M#SG5]$4JN4DJ=M I\EV^%*/=PI["AEH   %5:32Y4X%$KE7H4JP
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MEUY<I+C&,:)]E2;)I[RO?,MLB4  $T>8%6EP2\"VO(D)
M
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MR?81KZ4Z0=,&GU17+BE2CIR(T]*/J0<+;EU."\).E:C68.G7P>T>7_62J3A
M   4<^$Y>UEV%B>:4 !%?$B)%OU!5R+4OQDT_H1<JQ\O-X%2VBBE*9!4G"4T
M00F1"I-VB4IH\R$PG"I,4B;L7?QH2EI'U3Q\C)UFUB6J]5WX[G9;BDGQ-WLI
M]EP'?ZVMEB(:PR5@Q;M^9+@VO,@N#:X5-I#CKUTG1XK!E?3C-6[^.N,.MT:9
M*B-84=W!CB.=[+C&Y=<7&S;3]R*?:_'N&BY-O!3:3;C.[F.Y.4LB45%-<5&#
M";QP4NLPS<2%G/Q'%7;+_*1E^%#Q)5X_;X*##U;!U"=V5E)14JW[%Q_DV^V/
M@%=\=H5<EB0P+]NQAJ>GSF^G'G+JBX=B4N:2(6[6GAHLF#I^!BY"A@P=A7I]
M:MMUA;DN:^DADVM;36W-D\L+RL*#C:7E76[ER4>"ZJTX$PQNJ;)<JQ>P<"[D
MPM]4O*E.W.7)-*J"JMIF=&&6->TS=&/=P]3A'2]QQBO-P)*MJ_#LE%OD^TLS
MCXZMW6<F#2==:^+%,O8^CRNW+N/F/!S(55RW-5A)RY4]I#98MW6T+9=V[D6+
M4K5^*O1CRE#\+VERK.K.K%=0TW*A>48XDU'LYLF(4W@QM/R;DU95IP['6+=/
MN%^/):C65R>D9*AY-BS.:DZ2G!45>XN=.M="VL2N^+L_7KMB-I6NBPZ=$KKX
MJO.B[2FV6*QHIXSS9/I_IU=PX3OW,A7[\8^9Y4U[C2Y_28TY)GU)G/CKS7K3
M]-NRLJ]*VHI.G0E1+V%N8U6L^[TY/36<"W'$M9$[D;4(NDDUQ*ZU:C\Q-K,.
MU#4)X5F63.[.UC1]V,8KWKOAX%=8U7\6+XCWVSN#(O7[=J#N:9C3E6QE=3D^
MO]DNU,2IW.VICAL:]F.U"-S5;+N7X)NSDXW!3IR<D1#23I;@U_N++RL1WKUN
M4;<;S5[H2K.4WW_0&VV]>N-%9MR$\OR;UV'\YNQ]]3^!1?*GB%G<STSHN^K7
MLG!Q7C6Y0A.;<+]R3K^37&GTA9I''5AEF2OWYO!E%0A_%02I2':2V5N4,CTW
M3/FKMOYV?1:MJO2OPB&%FM,>ZN>58L05ZW.RK=A?Q<UVDK%>M/HT--R,>>/F
M*5K+7\3)KW7[ 6MYH7(W:.%N45D6JKIB_C2Y<"K3AJMZVTU\&?[*]-](]0-+
MZ]-W);Q-QVEU2TG(@HTDN*XJC:X=A@9=U\*T:PZ+9=NIN8B:VTMY>;:'I%Z8
M;[V9NK(U#5IV;.F782C=A8NN4+DN%)*/)?286]W>/-7AS;KM/;<^VR3-XTAO
MB3344VFZNC1J/%ULS"!*V@R!*R4)0AYRYA3*4F$)62B4A*$&$/;3U[LY][(L
MKQ*R7-E*\@  GMJLB+)JJRVO
M
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M1)1.-'V_J 3X2;E=N/EP2^A,IE5C\5;R^DA=0"0">'%@A5+D6EZ$0D
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M4L.&'E0O*T[EMUA.J^)=R\.PCQ8V;'%>$-C6L6Q;P+"3C>M6X)MQ?%OQ]A+
MFNG%8=?N9T-*OW=)MQOW)_\ RESDEVL+N.(F>+",O1\#7<:UCZUBJ.9:5+>7
MB^Y*,7]^A#-QY[4G@\+NAZK@XEJQ>=O4L&,DK.?=73<C!/A&ZNU]S)7*YJS,
MSXK7+'>#J#5F<[$[G\9B7U6U<K^*^RI-;-CBWMNE?]!NV,[,>'J\+4$ZK'=K
MM:Y*9;^%5?S[Z8C@R%Z#C793MK%JVVEW/VLSL'1CCTM9_<;>*AGMV=N?3A1A
M:R%_BKJK!KP\2Q97&^UCBNN'H^7;<;NHRA[B?EX\>+4N^7AW%I8OO>'!;-Q;
MCTW3J:;C]>5JU^,NN=OX81IQ7M(E&&9F.J5[T335E:-@WL6VXV)03_*.LXR[
M>OP95IKP8N6\^"W;UT;&NZ9:R87I/Y>[6<;?"C(B-$[;+-9:XR,'4;V3&W=C
M"[C756*?X(;&N3I32L3P+4;5FW%5E^6N=R\ 3;J9+IVIWK^FVY1LSG;5QVH=
M?)AA9HT6#6YRP=85Z[<MSFX+HQ;:]Y)JCJ^PEG88UA-MC688M]8UUP\AR:AT
M\7"3XMM_<(1FP^RN6Y(V7-P5R$H.C=RO.H6,%=%OT['LQ@W&S^6N53EX=A*N
M_#BNT;L<2RHN+E(A9GVE+Y^1D7D\R5(?XNTN1*618&VM=U;'N96-8E=LVET>
MZG1)>PM7S5I/%D8]K;)&L56+*LY&#=\N[U6YP=&I5;^Z78F)XPM3BTG28T>"
MUIX]^%^U*5C(M-.WEV*PFI<_B7)E[IBT:24F:6C1N38_VFM9T)0T_=UAZQ@V
MVH?-P73DP78YKE.B-9F[72W&L\73[7OEZ>SDC6&_MO\ K!Z<[FQX7L#7+%J4
MDJ8]^3M78R[NE\C2WV>2DZ::NFQ=PP9(UZM&88^=B9UM7,/+MW[3X]5N49*A
MC6K->=656];>[9[M\:KD$CY 2A#SES01*#)A2DD2B4BX,E"2XZ1;"F5=C6W9
MLPAX%,LBE=*O6/)/O13"0E*:/>![6E[S?@4RKJ]BA<
M
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MCD$ 2F1(J+2I$MRNU>A2J
M
M*2XJ29=A9E($  "DU"VY0A<M_%;Y]O#M)B5K+&L*./PJG+L*Y6(3HA*9<PJ3
M+F$IZD)3!**YE*7I'D%29<B$IES G7$E*9I-\N/()144N7,@1:;=>I]2\2F(
MT52ENVHY%N=FXE*$X]+B^335"8G2=54UZJS$N6?4S:&5HNN9'19I@7GUVNFM
M$Y5;.DVN;JIQGB\L[OLIV^69T]F6JLBW++<W&,GD1JN"IQ7*AG-+68B-?-<;
MD;<;5JQ>MN=JY;Z;O9Q]I"B+1KP6G3\&WHEV4[+4O-G[[N^_2V^SCR"_?):_
M-7W,?3[T;MUR5Q*34''\']<**S,,?QYPMYD[>36*E[L)M5MR_;+L(T9%I\EO
MS<=3GD84%<?DM7HV5[T%7C5-\D2NUX<(Y*O3<NYF6UCZOI&-D8GPV=5QI?+W
M\=_@MNM'QYA3FI&G!?\ "Q<>Y@IY.?\ -:BF^N[:CY;5M<NK\?VAB9.K31:]
M7T&UJMU7K=MK/MQ7RL^IIRFNV7@^XE?QYNB-)\5)+:NJ/'QIZKDRP\B,NIW,
M632IW4\0J^-^%<\C%S<F5K*OWIK!PHTMW;EREVY3L]WL(6IM6>&G-ANHW97-
M0<LO%G1?Q61U^[3V=H;.DQ6CPA+3Y-S=I1F^RGF??"F8M/BJ%JUK!E"6)\Y'
M+BJW(PCTVYKQ1"B<6O-D&-N):W<QL?/Q,IR;7D*[>K:73WP9+'OM[1QCDNEV
MW&\LFV[<(68)MJ/O3?2O'N[ L1/'10Z=-Y6%;G@3N^0VE;MWN,E)<Z^!*J\Q
M7GR7N["WA8[N7LAN-V/5;B^4;BYT78@L]4VX0PO,:U/-M9F='K=K_1I/X(^-
M.0;"E^F.#TTW;V'8SIZA#(D[5_A.,WU4D^[N01?<S,:+[8Q[2N*ERD(OX*<P
ML6XPJL^_#'MQNQZ(6^KI5JO3U?\ 3Q+D<(XK7PN'">*RZ=@Y>L:W9TS QNO*
MOW5"Q9C\#;XI.7B4WF*QU2S<<=>E:1QEL?4_1OU'V]E86?\ *0GD4\Z5S%GU
M*VX\5'VF'3=XLFM==(;;)VG<8;Q:(=0^FVK:YK.U<:[N'#EAZG#\G<C./350
MX*5/$Y_<TK6_LSP=SL<E[8_;CBS%J-*47MH8^C-E"E.3:?@1HA"2JJ-M+N3H
M5(2TIRE)45*5(T@>-S'Q[O\ '6;=WN\R"E3V517&L>*G2/*$5&,$H02C%+@E
MP27L1!*64U51H%.J#Y>!(D(4I2K0080\WS)4)+D7<=NS'G*7'V=H\$3&O!<X
MJD5147%+CW%#*X:   !4VHI*M.-2BTKE8>I2K
M  !)<2<74JA3:%*UQ*UI  !'Q78FPF%KR+;AE-OX+D>J/M7,N5EAWC2R")T1
MJB4JDRY!*9-]@2GBV0E$2E,N93"7H2J11"4ZY!*;MK3B!&/'GV!5S3/BUX=Q
M3(1C%.JX?2$QP:]]5]K7=;T665AVU\W8K)27.B[#.V.6:VTEH.]['X^*;1'&
M(<LZK9N8LW9O0<)7).-V*7:CHXGJY/-(]FW1,<5'IV([61*Y)25F472G)OLI
MW$ELD*?4].QM4M67<A*%ZS-IRA+I;7CWD)Q9)KKIXO?'N05CY2_.U&W:]VRW
MPFUW!3;FI-5Q;%JQUX:K==%<X]_<%>.9\5MBK&5@7;;?5<MM_D[G\;&2_"@_
MN4"[,1X+3<GD67CZECQ<[Z5(ROP5R"ERYL,FO+C&J]6+UW.LRNY.%9T+6(27
M3J>.ZV[\>^5KD^ 8UZS$\.*_7,;#4+>19O7+S?3%W;;I:E)\VH=B?<&-QUT8
MQG;9R+]^6;HMI6]5E)J<9-JWT5_%Y$LRNXZ8TEZ?W9O6,FQDYF1?Q[ME)RA8
MG6+N+\&/AXD%L]9C2.2LRL;.\Z>K9\Y69J+\NS&YQDVJ4N4YL+59K,:,(G>C
M/)=R_@NWEU]V=R<GU1#8Q6=(A-:>"NJ=FU&W)</+Z?,JW[2$],Z/=ZQ8PYPN
M87S4<J/&Y;MQ]R7AX!1-->;(L37[6LYN/;R\3)5Z4OR$;]]RA5+\1\"K5BWP
MS2=8X+C<@[EK+]U0LQ3;Z>-SAS"Q284.G78Y6'U:=*[Y*:73/XNKM=>[P"[:
M=87Z5J&+C]>1=]V<4NB+]WJ\.[Q#$UF9TAA>K?\ FV13,M^9C6IJ5J')=45\
M09\=580L[>Q[VJ?G:U<I?HE<BW[M%X<@N6S7TTE?K>+;ZE:M32JZO]4,>TS*
MXW8*&*XX_3'RW1W&Z=3)A;F)T8QGY7GW;-V,(1<XTGP<G6O.I7T,C',=,<>+
M8R]&-_Y>VX:U:Q+*Q&XO'LV6W=G"7%S9@_G<=;=+:QVG<6Q1DCFW/Z#9F\=.
M=_:FO:?.&#CP5S'RY+AQX=)K-_\ #M.M?%T_9YSTCX=XX1XMYT3K[J[^\U3H
MT&D^+2\*(0B4)+@EXDZ(2-55&-(1K*$DI?$DUW.C7U,JT4SQ>4;5B#<K=JW"
M3[8Q2?UHB>/C*8X>$#?T>TE2EZJI-<B$)76H0@3"$K*D)*T=>P*4V%#JNW+K
M7NP]U>UE-E6*..LJXA?  $5SH!615$D6Y7H1(2
M
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MHL1AVOC)]M2F5^D<-'L0K  $]N-9KP*93$*LH7@
M
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M"$I*'G+M"F4I,"#)4I:IU7A7ZB4)+?Y7(A"G"/O-]E%V$3*(XRN7#LX)$,A
MA(!&@'O:@TF^''D43*Y6'L4JP
M
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MI&LJH+@  F2=4"%7'A%>PMRO0B0D
M
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M?;5]Y1*]2ND/9LE4@0D FBJR2\2)(5<51)%M>A$)
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MRIX0$H  'M9C7BUR? B5585!;70
M
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M6^)F^QTU&/0NE171&BMP79%<#0NT>K7"B 15%0)1   )92)0 2%2D E?,E"
M0EDZ4YJK2X$#6/JIZ.:%ZBZ;=GTPP]QP3^6S8JG5+L4TN<7WF=M-Y?!/#DQ-
MSM*Y./[SB^_LWU*],M[X4L/ R<76L2]_,[UB$IV;D>JC:E%=,HM<ZG65S;?-
M37G&G&'.SBRXLG!]"]&R,C+T?!R\RWY.5>Q[=W(M?BW)174OK.'O&EG5U]U6
MKDJ"4(/M"$H0ED2B4G81"$&5(2A"&-!9%SS7\%KA'QEVBR:1U3KY*]\RE>0
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MW*YCKPU5(7  !%+BO$(5=M4BD6Y7X3$)
M
M                \+UNO$JB5NT/$K6T D CPHT2*',LN+5^"Y<))=S[1"Q>
MOB\8M->"Y%2A%!*9<P)T0J3+L"02EZ1\2$PF7,B4IB$IT3"0)3KL F(2B$@$
M&JJCX5I]\2KKPE9-VZDM(VOJNH-T\K'GT]CJTTJ/Z2<5=;PQMQ?IQ6EJCTAT
MF.5K-O45'\E@V'>N3Y_E\KC2O>D;/=WTCI:+M6#CU-[5=74U3I6O]6V1?UCU
M/TG=>3&W/1M*P6H1D_RGSRG)VY4[HJ3*HOI711--;:J#U>CKV;A8&C[;G=MZ
MI>O*X[D.$(0C\4[CY=,49.TBO5K+7=PZ[5BE><N=MW;ZL[6P<S9FSLF4\G(E
M77]=A_'9%Q\'&,ERC5LW./#.2W79R>?<3BB<&+_JEA&R-F:WO[7HZ+I$.N<E
MU963-NEJSS;G)]OA4R\V>,5=6NVNRMN+],1]?^/^+M#T\]*ML^GV+;6%CQR-
M6<5&]G7%6;[7TUY*O<<QGW-LL^AZ!L]ACV]8X:RV&TFN)B-HB   0;H!!NI*
M$'R\0A(3"$21*W4E!7@! (&)$M:D0#Y/O*D/&4+<W%SA&;C\+E%-Q^EIDQPY
M(3-\/#N(0D(0AVDB#)0DDT0B4O83"$K\>7:2I>4W*Y2Q'X[G"J[%WDHGCP7"
MW;5JVK<>"2XTX?>*%^(T1"0 !-&/4TOI(DA5QCTJA1,KT0B0D
M                   0:3X 4UV'2Z]Y<B5F8T>9*  !&E:I\4UQ[@+3*T\:
M]<@^"E[UI]G'L*H8TQI,IHUX5YOB_:2A,@E-'F$IT0J3 1[2E*?L1*I%$"8A
M*:),)3KF$IER(2B J-4H@13Z4Y=ZK]12EJ;UIS87K>DZ'*:\N_<E=OJO'HCV
MFPV5>,RT/=K:Q%?K7STETKY';MS.E'HEJ%YW(JE&[4%T0?L:+6[OU9&7VS#T
M8M?Q,^7->W]4Q);6.;4GI-M&_A:_NS=FHXMS'R-1SKV-A1OJESR(2]ZXE^+<
ME3I]A>RY.JL1'@Q<&/IO-O-9/534-=UK<\=K:1"-W'G9<;T[L5TXM?BNN3\.
M)L-K$5IU>+1]RF]\G1$>S/Z&H=S>I&+M70X[#V!?=G"M-QU358?QN5??QNJX
MI5[3-P[><L]=VES[V<=?A;?A'BP/:&TMP;VUB.F:1CO(R+DOYQ?JW"W%OC.Y
M)\DO:9N3/7%766MP[/)N+Z1Q^GT\78/IYZ)[:V-"WE7K4=2UM1K/,OQZJ2:5
M4HM4278SFL^]ODGAR=[LNV8]OZ9;1C'IX/@DE1=B,-MTZHN"($0 $*LE"4(2
MRYDH"8"K E;J2A  2A!L@$$(=M>WO)0M^K:7INLXDL#5<2UFX=Q>_9OP4X?1
M7D3%YKRX%HB>:ET?0-'V_8^5T7"M8./6LK=E4%KVMS416(Y+F4I2E2$&!YOG
M4A2@5(2]OA3B$(6+;OWJ_P"+M\5W-O@)*QK*OIS[.1"^@0  #UM6ZRZBF558
M5"5"A=1
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M[L^,[GX3YT*9E7CC3BJB%Q!( $HT;Y<R4/>S"GO-<:<RW,KM8>Q2K
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M
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MA[D*P
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MN13,IB-56E0H7@
M
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MFVH1Y+GXLMSS7HC2$Y*0  "'O:APJUVE,RN5A[E"X
M                  /.Y#J3:YT*HE3,*5\/:5Q*T   $)14O=:337)D3JC3
M5;[EN6-)I\;3?"2XM-]Z+L3KP8\UZ?453]CY/L9 B!/U!4F3[2G1)]XA*>,J
M+B$IT^X)13X@12KXD)')+GRIU.7))+FV^R@U5-'^H/V@,'2,J>D[/MPSLRTW
M"[GW&WC1DN=*.LVN\W>S[7.3C?DX;NWS53#><>&.JT>/@T_J/K'ZBYUV5R[K
M]S'A)MPMVXP@N/8N"=%XLWE>WX(C3H<-?YCW^29F,DQ'E&GT^U5Z-ZV^H>E7
M?.>J_G'%B_?QLB$)Q;?*K24N/M*<G;,-^4:2O;;YFWV&>-^N/*SH3TS]6M'W
M_&>#**P=QV8*=[#DTXW(_C6I<FD^#1S&[V5\$Z\X>F=G[[BW\373IO'A/CZF
MQ^M)5Y\_&C79[37Q+HV ^KN];VS-G7<[3[SLZODSC8P9],9-7&U)NDDTZ1J9
M^PP1FRQ$QK7Q:#OV_G9[2;UMTWMPK.FOTX.;EZU^J323W#.KZJKR,=-?]@ZC
M^U[>?W7EG^YNXS;AD_16/U.D?2#>>5O+9EK.U"[YNKXTY8N;-I)N<>*E2-%T
MR7)T.5WVWC#ETCD]5[%W&=[M8O;GREL$Q&\:']>-];OVAJVF6-NZG+!L95J5
MR[&$+4^*=/PXR-YVO:8\VO7')P'S3W3=;.](PWFNL>4?KB6HUZV^J4$O_N*Y
M3CQE8QO_ -(W,=LV_P"%Q,_,O<=?YL_97_\ :C'UN]3I2BI;BES7!VL>-?;2
MWR']KV\^&BNOS+W&9T^+/UQ73[F?;*^T3G_/VL+>>/"6%<:MO4+":NQ;X*4H
MUXQ[VC7;KM,5C7'S=/VSYNFUHKN(X3^]'G]O)T?8OV<BU;NVYJ[;G%3M7(^]
M"49<5)-'-3PG1Z9$ZQJ]B4(KC)5[PERQZD^J>_\ 0M[ZKI6DZW<Q\#&N)6;2
MM6)**I6GO6VZ>)U.RV&"^*+6KS^]Y1WCO>\P;RV.F28K'AI7]FO+F\?3WUGW
MC>W?IF'N75Y9FDYD_E[UJ=NU%1G<=(R;44TJOO&[[9CKBFU(XPH[/\R;JVYK
M3-?JK:=.3JJ3C&KI2*2Y=OL.4U>M2QG?NY8[5VEJ.N*73?L6Z8_)MWI\(\Z\
MF^)D;?%\3)%6O[ANORVWMD\H<K?IJ]4')O\ O#<BI\>E6+#Z5W*MMG7_ -JV
M^D:\WCMOF;N.NL9.$\N%?V-V>@F[MR[NTO6LO<FH2SK^-E6;5ERC"-(RM5:I
M!(Y_N>WIAO6*<I=_\K;_ #[O%DMFM-IB8TY>7H;BZD:MV"1LC5"5L" 0@^PE
M"5M((2-UK0DU0X#12EDU%5EP2YDHE+8M?,24Y\+4>*7?[43-H*1JKN:[DN5"
MA?D   A&*ZFDNT:IA5P@HKQ+<RO1&B8A(
M
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MX!#UM6^KWG\/9XD3*NL*E*A;70
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ME8>Q2K
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M;C#><MIM,6C[-/J;C5'7OX&F=F$@  GMQ\Q\2-4Q&JJC%122Y(HE=B-$2$@
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M=85!0N
M
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MC=R&N^$5V>TCJ\%<4\95:KR["%Q )  $\:4 FC;<Y5[$4V51&JH2X4*%U$
M
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M!\42A-&#?!?^PB4Q"HMPZ%QXOO+:[$:/0*@
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M5)2?&C\"-5Z*1#W^Y4A* 2  )TE0":%MR=>Q=A1*J(5"22HE1%*XB$@
M
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M9C835:.Q:C"7'GQ21:ODM>?:F99&':X<7N4BOU+GP2HN7+Z"ADZH58T0I<W
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M'(^Y[!HD   )N"7%<0)K=MS:?X!3,RJB%2DDJ+D4KD(D)
M
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M+JEVRES;[R-5RM8AZD*Y"4($)  !<>00J(6JI-LHU7(J]4DE1<BE6B$@
M
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MSN[    !-1@0HZT ]867S?(HF5<5>Z22HN12N(@
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M5@
M
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M>T+:7%KB1,JXAZE*L
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MIC!17!<2E=B$Q"0
M
M                         ><K2?@51*F:O"5MQ=:.GL*EN8T2\B5* 2
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MWQEP7<4=2N*O90C'BEQ*5>B8)
M                       $KBI<T$:/*Y9ZN**XE3-7DXT=*4H5+: 0@$@
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M4GR=%X$&CWC:7"OU%,RN15Z))<$4JT0
M
M                                            (-)JCY >-RTGQ15$
MK<U>?EM<RI1HD)            318$U0DJP%6!$@><N;)0@           (I
M5X >D;5:=Q&JJ*O>,%%4[2B97(C1,0D
M                                 !*X1ES)U1,/"5FG+D51,+<U2./2
M5*=$H            >JY$)0JR0JP%0(2? (2            !,H5(-'I"SQX
MD3*J*O=14>2*=5S1$A(
M
M                                     'F[*[.!5U*.EX2MR3?:5:J)
MA+1HG75"            C5@0            ">,>KD-31/&S6M?O$3*N*O:,
M%%U11,JHC1,0J
M                    !+**E]!,2B8U><K/:N95$J)J\G!JO@5:J=$@0
M                     $0A%0DR-4Z/>-G\9D39<BKT2222Y(I5(D)
M
M
M                 $&D^:J!)*U&7<3JIFKSE8?8ZDQ*F:I';DBN)4Z(*/%5
MY#5"9I=P'F              !%+C0":G@!#I;&IH]%9D_ C55TIHV(I>]Q93
M,JXK#TC%17!)+P(F4Q"8A(
M                                  @TFJ/BF$)7:M\J4)UE'3#R=AKE
MQ*^I1TI'!U9*G0Z>'("#H!*              !,E5<@#B^X"*A)O@-31.K#K
MQ? IF5453QM15*I,IU5]+THER1"I$
M
M                                                           E
M<(R3X<R=4:)?*CXDZHZ82.P^QCJ4]"3RI%6JGI2N$Z\F3JC24*-<T-30H^X!
MTON)"C 48#I?< Z7W$:ATR[N!&IHF5N3YIHG5.B;R9>PIU3TIE8X^]6G@R-5
M72]%:BN\:IZ83))%*I$
M                                       -5 D=N+)U4Z0DE83Y-D]2
M.E([,EXDZJ>E*[<DJT)U1HATS[F-4:(49(=+[B0HP%& Z7W$!1]P"CY49&IH
MCT3_ !6-324WE29.J=$RL2?-E'4JZ4ZLQ2XU^L:IZ83*"7C[2)G55$)R$@
M
M
M                                     0Z4^:"$.B/<3J:(]$>X:FD'
M1'N&II"'2NY#4T1Z8]PU-$.E=R&IHBJ+@B$H@
M
M         )>E=R)U1HCTQ[AJ:'3'N&IHATKN0U-#HCW#4T1Z8]PU-$.B*XTX
MD&B8)
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>tm2227887d4-lc_lnp4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_lnp4c.jpg
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M%!04%!04%!3_P  1" *-!J$# 1$  A$! Q$!_\0 [  !  (# 0$! 0
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M 0 "$0,1 #\ [^
M
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M,MM-!'U-OM^8WNEHX$57)'!"^-K&(KE5=$1.ZH)7P$
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M=3Z(+[7J?1#VIUCZ#M6/9/5GI_O5YCY?;J?1!?:]3Z(>U.L?0=JQ[)ZL]/\
M>KS'R^W4^B"^UZGT0]J=8^@[5CV3U9Z?[U>8^7VZGT07VO4^B'M3K'T':L>R
M>K/3_>KS'R^W4^B"^UZGT0]J=8^@[5CV3U9Z?[U>8^7VZGT07VO4^B'M3K'T
M':L>R>K/3_>KS'R^W4^B"^UZGT0]J=8^@[5CV3U9Z?[U>9GXIN+DMTRN'&<@
MM$=ODEB?(J<LD<K>5BO15:]5U1=#T:'K?49NIC)S:17&/GB=['A>;7]3Z?*T
MLY^3F3>(F.*8W\.!9Q:U1
M                                               %/;2_:?O/\.6_
M_=<(2N$(
M      %(=F+YNYS_ ,<7_P!5C"97>$
M                                    !5&P_P W[G[,_DF%/]V/,WZ7
M<A<_>OS].CW96N7!3                            %4S?;I!["7W.\I]
MOUB.CXJYU_19Z7C0M8N"F
M                                               "GMI?M/WG^'+?
M_NN$)7"$*,[2F_5SV,MV/U5JL\%VGO4]1$]*F5\3(V4S&.X(Q-55RR)W>X$Q
M"SMO,IDS?!<=R^6F2CFO=OIJ^2E:Y7MC?/&CW-1RHBJB*O#@$*1R7M-7FQ=H
MFGV4BL%++:Y:ZVT#[HZ:1)_^\:>&=7HQ&\O>+-IIW=/+"<'280
M                    ./\ MD;R;D[9Y)B]OP:^/M%+64<]55,C@IYNLE9,
MC6JY9XY.")W.CR0RB'6ULFDJ;=1U$RZRS01R2+IIJY[$5>">6H8LH
M             %(=F+YNYS_QQ?\ U6,)E=X0
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MV_6(Z/BKG7]%GI>-"UBX*8
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M6\'.3JT1G'I7D1&Z]"(@8I$         I#LQ?-W.?^.+_P"JQA,KO"
M
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MZ*-KTU_PHU&K[Z(XJP9&],\<S];ZP']8[=OV+8?<,8S/,T^E-/.6^A=IXWH
M         "J9OMT@]A+[G>4^WZQ'1\5<Z_HL]+QH6L7!3
M
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MO_JL83*[P@
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MXMT8,@          JF;[=(/82^YWE/M^L1T?%7.OZ+/2\:%K%P4P
M
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M0)Q=18UC=EQ"PT&,X[2-H;);(D@HZ5BJJ,8G'BKE57*JJKG.<NJJNJ\0Q;4
M       !2'9B^;N<_P#'%_\ 58PF5WA
M                                      51L/\ -^Y^S/Y)A3_=CS-^
MEW(7/WK\_3H]V5KEP4P                           !5,WVZ0>PE]SO*
M?;]8CH^*N=?T6>EXT+6+@I@
M                                                 I[:7[3]Y_AR
MW_[KA"5PA                                8]=0TESH:FVU\3:BAK(
MI*>J@?YV2*5JL>U?*5%5 (O@>U> ;9,KV8+9(K.VYK&ZO6*2:595@Y^KU69[
MUT;UC]$3R0)@      "O,RV+VCS^MDN>68G1UUSE32:NCZRDJ9-$T17RTSXG
MN5$X(KE50G%Z8;LAM/M_6)<<2Q2BH+DQ-(ZYR/J:EB::+R2U#I'MU3IY7)KW
M08I^$              *0[,7S=SG_CB_^JQA,KO"
M                                               JC8?YOW/V9_),
M*?[L>9OTNY"Y^]?GZ='NRM<N"F                            *IF^W2
M#V$ON=Y3[?K$='Q5SK^BSTO&A:Q<%,
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M>?[C;G\=6_S 'UP;S_<;<_CJW^8 ^N#>?[C;G\=6_P P!]<&\_W&W/XZM_F
M/K@WG^XVY_'5O\P!]<&\_P!QMS^.K?Y@#ZX-Y_N-N?QU;_, ?7!O/]QMS^.K
M?Y@#ZX-Y_N-N?QU;_, ?7!O/]QMS^.K?Y@#ZX-Y_N-N?QU;_ # 'UP;S_<;<
M_CJW^8 ^N#>?[C;G\=6_S -AV<\;RK'<0OLF7VA]CNE[R.Z7J.VR2Q3R1P5K
MV.8CG0N<W75%3^[IQ!*WP@
M                            *HV'^;]S]F?R3"G^['F;]+N0N?O7Y^G1
M[LK7+@I@                           "J9OMT@]A+[G>4^WZQ'1\5<Z_
MHL]+QH6L7!3
M
M
M                                               *HV'^;]S]F?R3
M"G^['F;]+N0N?O7Y^G1[LMQNAN]B^U5%2RWED]==;BKFVRST+6R550L>G,Y$
M<YK6L;KWSG*7?)R+9LX0I]*3:=Q7N+]J[&KK>:6T918*[%XJZ1L%+<JF2&HH
M^M>NC&2OC5%C5R\$7E5->Z>K-T%Z1COMMLBU8Q= G.><   (WG6=8[MUCE1D
M^35"PT$"HR.*-$?//,_@R*%FJ<SW+T)^SP-F7ES><(95K,SA"C:;M@6MM4V2
M[X3=:"PJO?W!LL$\T;%Z'R4[5:J(G[;1ZZ'0MU=>(QQ;YT]HAT5:;K;K[;*2
M\VBH95VROB944E3$O,R2*1.9KD7RT4YDQ,3A+SS&#,(0
M %4S?;I!["7W.\I]OUB.CXJYU_19Z7C0M8N"F
M
M
M
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M'Q5SK^BSTO&A:Q<%,
M
M
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M9Z7C0M8N"F
M
M
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MVZ0>PE]SO*?;]8CH^*N=?T6>EXT+6+@I@
M
M
M
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M35;'&G%SG.57.>]R\7.<JJKE4KE[S><9<Z9QG%O#!
M*IF^W2#V$ON=Y3[?K$='Q5SK^BSTO&A:Q<%,
M
M
M
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MN=?T6>EXT+6+@I@
M
M
M                                                  %4;#_-^Y^S
M/Y)A3_=CS-^EW(7/WK\_3H]V5KEP4P  :#./F;D'P=5>HN-V3YRO9AC?>EP9
MV0?MJM_L&N]2+5UIYB>S#F:;OW]$BGNJ                      53-]ND
M'L)?<[RGV_6(Z/BKG7]%GI>-"UBX*8
M
M
M
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MM^L1T?%7.OZ+/2\:%K%P4P
M
M
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M
M
M
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M4S?;I!["7W.\I]OUB.CXJYU_19Z7C0M8N"F
M
M
M
M           51L/\W[G[,_DF%/\ =CS-^EW(7/WK\_3H]V5KEP4P  :#./F;
MD'P=5>HN-V3YRO9AC?>EP9V0?MJM_L&N]2+5UIYB>S#F:;OW]$BGNJ
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M
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M?K$='Q5SK^BSTO&A:Q<%,
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MMC/PXGN2<)AO.W5]BE/\.47J-0$0F.V^[&V>,;,87-?,MM-(MNQNTLK*=U;
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M#]GG]9S>_P!DS>[G!,[SK4,0
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MIF^W2#V$ON=Y3[?K$='Q5SK^BSTO&A:Q<%,
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MMVQRYX_09"GAE)%<Z:6!4ZZJ=)R<SV-:YR(O'E"9=>!B
M
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M8_<;#29)6-N5%#<Z:6G=RU595S\B.D8U'.8DB([E"9=;AB
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M'1\5<Z_HL]+QH6L7!3
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ME=:H)9YKQ&L3J"1:=8VR,C<CU<Y6NDY=>7EU1=%T"<%L!
M
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M]Y9KK&QM/5)+_!)SM=JUTG[3O58J\.;734G!T($
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M9I-O"EV6<I[0        !5,WVZ0>PE]SO*?;]8CH^*N=?T6>EXT+6+@I@
M                                                   '%_:]5^5;
MT[2;;7%[DQRX55*M3$Q5;S+<[@RDD5=-.+8X]&KW.9?)#*'5F1X%BF48?58'
M<[;"F,U-.M(VB@C9$V!B)HQT*(W1CHUT<Q43O50,7EM]M[C&V.-Q8IB,$M/:
M(I'SHR>>6I>LLNBO=S2.73737E;HW7CIJJ@<R[A?KU8#\&1^HUX9<#L&2..:
M-\4K$DBD16O8Y$<US7)HJ*B\%14#%_+?>^U+M)N5E^V>#Y"E)A62+1ONM Q[
MG14S'O2=M/.J-<[\PJZIR:NZIR([55<@9P[LH\7L^S?9YN]!B$K98[/CMPN3
M+G#HCJNL2BDG=5<R:\7N1%;Q71O*B<$0,5 =GBP6NL[(&YKJB&)9*YM[DFFF
MTY4?1VV-\#E7N)$]O6)Y"ZJ$SOH]C62W&#L'9+"V5R+%=5M-.Y%\Y35-;2RR
MM_ Y)9&Z?X0.%(<OL%KC[!-EE9#$V2D;0W*%S].=:FJN7)(YB]URMG>G^+J#
MA6MCN'Y#O#V9\#Q^ER6HQQ]11T++I<:7G=/-;Z6-\#X.]>S7K$1G-S.T\E%Z
M A4>PN&V?;[M?93AM@ZWWIM%GE@IW5#^LE=K'0O<Y[M$15<YSG+HB)QX(B!,
M[SN,,0
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M=OJ'U=!2U4B(DD\,<KT;P:CGM1RZ:Z\.(8LD
M    "J-A_F_<_9G\DPI_NQYF_2[D+G[U^?IT>[*URX*8 :G*+;/>,;N]IIE1
M*BNHZBFA5RZ)SRQN:FJ_A4RI.%HEKS*[59B.)SMA&Y5)@&+T6)9-8;S!>+4D
MD-2D-'UL2Z2.5%:_G1%313JWIMSC$QNJ[EYDY=8K:LXQ\S:TO:/P&MD6&BIK
MI4S(G,L<%,R5VB=W1LJKH1.GO&^RC55G>B>1DX96U6X&\%OS&UVJNH\>L]KF
MI)ZJX0^#J^>5SU1K&JJZ^?-6;A7+V<=V9>G31-\Z+83$1'"Z 5$5%14U1>"H
MISG;?,<442<L3&L;TZ-1&IK^(#[  ><M/!/RI/$R5&KJWG:CM%\E-0/0
M           !5,WVZ0>PE]SO*?;]8CH^*N=?T6>EXT+6+@I@
M                                          '.G:IV7R7<.BL.;8 J
M+G.(2K-34NK6/J(>=LJ)&Y_>]9%(Q',:[@[5W=T128E7.3=H'M 9IB=5@%HV
MCN]IS&Z0NMU=>$BJTAB;*B1ROB9)3QI$KD<NCWSZ1].J]PG!T;L?AV5X-MQ:
M[)F]YJ;WE"\U17SU=0^LZATNG+31R2*Y59$U&MZ=.;54X*@1*F,YQ+*JOMFX
M3E-)8KA/C-);XXZJ]14D[Z")Z15J*U]0UBQM75[>"N[J>2#@7INUF%\PC!KE
M><7L==D63.;X/:+;;J2>N>M5*BHV25D#7*D4>G.]5TUTY==7($.7MKNR=59K
MMKD^1;HQSTVYF8++/;9[BQ[*JW2-D61LTS%T<CYY.,K535(^":*JAEBF/9GD
MW#FP^_[&[J8Y>+=34--54%IO=31U+*22AE1T$E.RJ<SJW=6KN:!S7Z.8NC>#
M4U(E4-AJ-Y-GMO,YV"GV\NMZJ\ADJX+3?+?#-/1K%<8&TDSFNCB>US58WG9W
MR*U7+S<N@2O+&NSY=J?LJUNTE<L<&67BG?<:EG,B1LN:SLJX(GO;JG>+#%$]
MR*J<%TU30(QW5#UM=O3D6SMK[-?U:7>&_4E8R"HO4T4C:-:2"H=/'K(Z-(VH
MBJUO6=;R<K=45>;@2[HP#%8\&PC'L/B>DJ66@IZ)\S4Y4DDAC1LDB)P\^[5W
MXPQ<[X-B654G;-S;*:NQ7"#&:NWR1TMZEI)V4$KUBHD1K*AS$C<NK'<$=W%\
M@)X'580
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MDTA\+GEY.O=%&YD;N:1&*UB-:Y&JY5>]> 3O.VPQ
M         *HV'^;]S]F?R3"G^['F;]+N0N?O7Y^G1[LK7+@I@  T.;JJ8;D"
MM56N2WU6CFKHJ+U+NA4-V3YRO9AC?>EP7V057ZZK?HNB+0UVJ)W?S1:NM/,3
MV8<S3=^_HD4]U0                     "J9OMT@]A+[G>4^WZQ'1\5<Z_
MHL]+QH6L7!3
M
M
M                                               *HV'^;]S]F?R3
M"G^['F;]+N0N?O7Y^G1[LK7+@I@  T&<*B89D"KP1+=5<?\ V+C=D><KV88W
MWI<%]D'[:K?[!KO4BU=:>8GLPYFF[]_1,I[J@                     %4
MS?;I!["7W.\I]OUB.CXJYU_19Z7C0M8N"F
M
M
M
M          51L/\ -^Y^S/Y)A3_=CS-^EW(7/WK\_3H]V5KEP4P  47F.Y^1
M9A=[G@6UM!35T=(U]+?K[<=5H8E?WCHXT15YU\\B\%\I-.)YIS[;7V.#A6+(
MZMRJ9<9FHF8BV]6-^>RJW#=BL_VGO3,QQ&:U7.\0121+13K,B.CD\^V-7HU$
M<J)IJJH>C-UVIS*X6M$QV(9UTW5LSA%+4^?''NNB=L=SJ#<2AJ8Y*9]KR6UO
MZF\6>?A)#(G[9NO%6*O!%-67F1>/G<W7:&VFM&[M5MO2GIN<P
M         !5,WVZ0>PE]SO*?;]8CH^*N=?T6>EXT+6+@I@
M
M          !',^RKY#83?\P\$\/]XZ&>O\"ZSJ.NZABOY.LY'\NNG3RK^ #>
M451X91T]7R\G7Q,EY-==.=J.TUT3734#W    $5PC,OEC\H_\R\"]X+Y6V'^
M%Z[KO >3\]YQG+S<_G..G[I0)4
M
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M?K'.EP8S@DDD#WN:]R=U>\;Q\HUUW,R'2S?M]7VQ_=M&"_3W*J
M           JF;[=(/82^YWE/M^L1T?%7.OZ+/2\:%K%P4P
M
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MRLOF-WNQSXMG>,RQQWO'JF5E5R1U"*Z&:&HC:ULL3VIP<C4_85JJ%C!
M
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M^AS:QCACV&7#<*&HD2*"HCDD7H:UR*O ]5-1EWG"MHF7GMD9E8QF)B&2;VD
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M\*K-DO\ Q%_XXO?\@$RM,(
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MO%*S.-OF?5#VA=E;G74UMH,TMU175DL=/2P,>_FDEE<C&-3O>E55$.@[V"S
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M*74"-9E9[0W$,@<V@ID<EMK%14AC145('^4!S+_9^?,_,?A.G]SJ&4NPPQ
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M_<VN/YOFQPP^?%;1>U%
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M]&+U:JO3R\=5U()6S:<5QBP32U%BLE!;)YDTFEHJ6&F>]-=>^6-K57\80VX
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MO]; F^)WB_7NUK69'CLV,7!)71I;:FII:UZQM1JI)UE))(S1RJJ:<VO (;T
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MIGMXJU..FIC:]K;[&V9:T82FQ@U@
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M.R'X,K?<[P.6/[/SYGYC\)T_N=0REV&&(
M                             !7._OV*9]\!UWJ+@F$XLO\ L>W^QH?4
MVA#.    %6;)?^(O_'%[_D F5IA
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M875-+RR1N1S5TQZ-%T5.'2&7 [P#$
M                    <SU/95N%14S3ID\+4E>Y_+X(Y=.9573^%.7.BGC?
M/K>Z=IF9\I'\/[71UMI%H+=1T*NYUI8(X%>B:(Y8V(W73N:Z'3B,(P7W*IL4
MBO%$0RB6Q$,QR?,K#4TT.,8/597!,QSYZBEK[?0MA>BZ(Q6ULT3G*J<=6HJ
M1KZQ=V?N<N?QW8O];"5>;T9QN17XG00W/:^OM5.V_6*5E3+=K1.UTT5SIWQP
MHV&I<Y%E<B,1RIRM5=7*B A8?UB[L_<Y<_CNQ?ZV ^L7=G[G+G\=V+_6P+"Q
M^ON=SL]+7WFTR6.YS-<M1:IIH:F2!4<J(BRT[GQNU1$=WKEZ0AL@,>O_ -!J
M?\E)^]4QMO2PS.]GL(QM9]GN/>Q6_OG'ET?F:]AS>J?RF7V$O/8ZH    *HV
M'^;]S]F?R3"G^['F;]+N0N?O7Y^G1[LK7+@I@   ?#(HF*KF,:U5Z5:B(O\
M<"<9?80                      53-]ND'L)?<[RGV_6(Z/BKG7]%GI>-"
MUBX*8                       *UWUQ;<#,,!FLNVEW?9,H?54\L=='63V
M]R0QN59&]=3HKTU3N=T)AR?>-A.U_26BOJ[EN+4S6Z"FFEJX5R.Z2(^%D:N>
MWE<W1VK45-%Z0G&$W_L_/F?F/PG3^YU!+L,,0
M                                 "EM^,BKO>BYX)/21):,CMLM-X<R
M1?"&),CHY%1BMY4Y=4Y>*ZE9ZXZXMH;UK6L6VHQ6CJ;J:NNI:TVFNS*1;6YM
M=,MBGIIJ&"GM]LABA2=DCG2ND5-&HK%;IHK6JJKKT]PW=3=:6UU;3:L5V<.V
MT===55T-J16TVVHGM+'+ KP   59LE_XB_\ '%[_ ) )E:80
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MZB:!8J;GZOEB5$1>_<Y=5U\DWY5YO7&7<ZKUEM5D>4M$1.,[R=FYU0#'K_\
M0:G_ "4G[U3&V]+#,[V>PC&UGV>X][%;^^<>71^9KV'-ZI_*9?82\]CJ@
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M[^^<O2ZNFJZTC,ICAL\/1=75Z.^EZJMEWPQVHWNE"[2^/GX
M           :/-/F=D/P96^YW@<L?V?GS/S'X3I_<ZAE+L,,0
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MR55;5SIKH^>>5SGN5-5T37E35=$350)<!PE=O^H1'[)I/^7HPRX'=H8@
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MUDIJ6&&14Y5?'&UCM%[FJ(AE7*I6<:Q$?0POG7O&%K3/TL@VM0
M              :/-/F=D/P96^YW@<L?V?GS/S'X3I_<ZAE+L,,0
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M>4O:_A3,\K(-K4
M#A*[?]0B/V32?\O1AEP.[0Q
M                    *[R38O:K+KM57S(L?;772L>R6IG=55C$<^-K6M7D
MCF:Q%1&IT-"<6_P[ <2P&FJ:/$K?[WT]8]LM0SKIY^9[4Y476>214X>0$)*
M  4WEL-\P+<B3<2AMDMVL=UI6TES93HKI8>1L;==$UT_@6*BKPZ4X<%.-GQ?
M)S_*Q&U$QA/R^A4M97-T>LG4UK-Z7C"V&_&]S0P9;A=]X,MQ^:@M%3;<5L-0
ME;/75C>1TKVN8Y6-TU35>3E1&N7IU4PFUM5F5PK,5K..,M,YF9UEGY<UI-<O
M+G'&>'Y8+R.XN8
M               &CS3YG9#\&5ON=X'+']GY\S\Q^$Z?W.H92[##$
M                                                         _&M
M:W7E1$U75=$TU5>Z1$1"9F9?I*
M              .$KM_U"(_9-)_R]&&7 [M#$
M
M                                        $?S'-L:P&T-OV6UJ6ZS+
M/%2OK',>^..2H7E8K^K:Y6M5>"N5-$[H$.WCW*J<7VCN.>8-5T=:J^"LI+NW
M_/:*&*KJ8X'U2I!S=8V)KU=HFO'IUZ%)A5>SV[.9U^Y]JPVMW$M>Y]IO-%65
M5;/;;<E!+:GTC&O8YSHHHV.9(YW5]]J[71>][HEU*$-'FGS.R'X,K?<[P.6/
M[/SYGYC\)T_N=0REV&&(
M
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M!"<@<)7;_J$1^R:3_EZ,,N!W:&(
M
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M2(B:JO=4)P0#^S\^9^8_"=/[G4)EV&&(
M
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M,]IZ!ULANU2WEH9)$G='X+9UIEU>C6(O,L7-YWN@X'](0Q
M
M                                                 !%]P,#L>Y.,
M5.+7]T\5),^*>&JHY.HJJ>HIWI)%-#)HO*]KDX:HH$1V^V*MF$9(N7W/*+_F
M.1QTSZ&AK<CKG5JTE/,Y'2-A14317JB:JJKY6G'4G%:P0C&?;?XON9CS\7R^
ME?5V:26.H=#'+) [K(5U:O/$YKN&OD@4KDO8_P!B+;CEXN-)8JEE5245340/
M6X5;D22*)SVKHLNBZ*@3BAO]GY\S\Q^$Z?W.H3+L,,0
M
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M4=N_M (*.WT\5+21U-+U=/ QL4;>;'XW+HUJ(B:JJJ&7 [T#$
M
M                                                     #G;>/M(
M9!AU^OF+;=8FN2W#%:)MRRJZ3O='06^*2/K6M<C=%>Y6*CO/M\A$54=RDX);
MA6];LAW%J-MK[9)K3<7VFCOMCN#E7P>X4TU/"^HZM')JG5ROD:U4<Y'(Q==%
M311@MP(:/-/F=D/P96^YW@<L?V?GS/S'X3I_<ZAE+L,,0
M
M                           0K=S/%VRVXR#.6TR5DUIIVNIZ9RJC'SSR
ML@B1ZMX\O/(U7:=S4#G*UY3VE*2LRB@O&5T%5D\^$P9G9::.&G9042.N#6OB
MYD@5'O2"&5J<W,U5<G??MPR=';29O+N/MOCF;5%.VEJ[M2))501Z]6VHC<Z*
M7DU55Y5>QRMU55T#%-        .$KM_U"(_9-)_R]&&7 [M#$
M
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MIP13;E:J+VPP=3JSWFRM;GQDQ2U9F)XN#=6N>Q;P
M')&[^UVXM=FV?U&R]ZM5S3-**GM^>8E55$+:VGD;3(R*5J/5.1%BEZQO,]O%
M_0YJIH9)9LIM1NI#FL.Y>\E71LNMJL[<>QVRV]6N93TJ*BN?(YFK57373OWJ
MO,NJIHU B7180T>:?,[(?@RM]SO Y8_L_/F?F/PG3^YU#*7888@
M
M                                 A&\%9AU#MKD4^X%/+4X<M.V&[14
M[>:;JIY61(YB(K5YF.<UZ*BZIIJG$#E+!^SKAFY$OA&'[[7"[XVM(EMFLD;7
M1W)EH:]94HY$EJ45D2.<KD:ZDZOFU5&AEB[/QG'+1B&/VW&+#!X-9[33QTE'
M#KS*D<::(KG+Q<Y>ESEXJO$,6U        X2NW_4(C]DTG_+T89<#NT,0
M
M       "C>R_\T;Q\)+ZA$<[0][*A>Y?Y2_3\6J\CHKZ
M            HVJ_6:HO@U?<TAS?[GY<2B9WZ_3^7W++R.DO8
M         #D3M*V7L\V[**S*[QF-PQ;=ODA>Y^.S255>Z2.!C(>MIVKI$O5-
M9R_G8.9-%UXZJ90V/97S/?S([I44V:0UMQVT932.M61WNB90W"61KVI"C521
M72(]JO5SOSNBIIUGDD2ZJ"&CS3YG9#\&5ON=X'+']GY\S\Q^$Z?W.H92[##$
M
M                                          $9W"RNP8/AEXRG*('U
M-@MT*/KJ>*)L[Y&2/;$C$C>K6NU5Z)HY40#A^Z;<Y'OG>Z:_[.[4IMM1-E25
MF6U=5-;$D:NNCXJ>'D8W_&IXI/\ &#)W+@EEO>.8?9K'DEV??+[0TS(:^[2*
M]7U$K==7JLBJY?(U<NJABD(       '"5V_ZA$?LFD_Y>C#+@=VAB
M
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M_/F?F/PG3^YU#*7888@
M
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M#;8LAQG('0,I:BHMSY>HDBG9$B,5\<G!')Q5$55\H+L"'"5V_P"H1'[)I/\
MEZ,,N!W:&(
M                    !1O9?^:-X^$E]0B.=H>]E0O<O\I?I^+5>1T5]
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M];H$\+U         "C:K]9JB^#5]S2'-_N?EQ*)G?K]/Y?<LO(Z2]@
M               %!T>991)VMKAA#[I,N)Q8RVNCM*JG4)4JZ).L1--=>^7N
MA/ F6^N;9K@& S9%@%G9?,A954\+*"2FJ*UJQ2N5'NZNE?&_@B=/-H@(<GWC
MM0]I^OM%?0U^W%-!0U---#4S)9+RQ6121JU[N9U4J)HBJNJIH$X0F_\ 9^?,
M_,?A.G]SJ"7888@
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MX345O7=;:%EB_/5362NY8GL9WS>&FB<$0)X']) P
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MSLA^#*WW.\#EC^S\^9^8_"=/[G4,I=AAB
M
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MJ(%A!#A*[?\ 4(C]DTG_ "]&&7 [M#$
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MNPPQ
M                                                          '"
M5V_ZA$?LFD_Y>C#+@=VAB
M                                4;V7_FC>/A)?4(CG:'O94+W+_*7Z
M?BU7D=%?0                           %&U7ZS5%\&K[FD.;_<_+B43.
M_7Z?R^Y9>1TE[                        #1YI\SLA^#*WW.\#EC^S\^9
M^8_"=/[G4,I=AAB
M
M         .$KM_U"(_9-)_R]&&7 [M#$
M                                           HWLO_ #1O'PDOJ$1S
MM#WLJ%[E_E+]/Q:KR.BOH                           "C:K]9JB^#5]
MS2'-_N?EQ*)G?K]/Y?<LO(Z2]@                       !H\T^9V0_!E
M;[G>!RQ_9^?,_,?A.G]SJ&4NPPQ
M
M               #4Y+D^/8=9Y[_ )1<H+59J;3KJRJ>C&(KET:U.ZYSEX-:
MW55[@$2PG?7:7<6YNLN'Y137"[-1RMHGLGI9I$9Q<L3:F.)9-$35>37AQZ G
M!M\[W-P/;.BAK\YOE/9X*E7-IF2(^6:56:<W5PPM?(]&ZIJK6+IJFO2$,K#<
M\P_<&U+>L,N]/>+:UZQ22TZJCHY$37ED8]&O8NG'1S4X 2(#A*[?]0B/V32?
M\O1AEP.[0Q
M                     *-[+_S1O'PDOJ$1SM#WLJ%[E_E+]/Q:KR.BOJ+9
M;N3@F"+$W+K]26J2?C%#,_65R>2D;$<[3ATZ:&RF7:^]&+**S.\V6.93CF76
MYMVQFYT]UMSETZ^E>DB([IT<B<6KY2IJ8VK-9PF$3$PVYB@   -'E.98MA-O
M]]<KNU/::!5Y6RU#^57.\AC4U<Y?*:BF=:6M.$0F(F=Y@8?N7@>?I*N'WZEN
MKX$UFAA<K9FMZ-5CD1K]./3RZ$WRK4[Z,$S68WTK-;$
M*-JOUFJ+X-7W-(<W^Y^7$HF=^OT_E]RR\CI+V
M &CS3YG9#\&5ON=X'+']GY\S\Q^$Z?W.H92[##$
M
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M
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MNBGEO2:SA+?6VU&+=F#( HVJ_6:HO@U?<TAS?[GY<2B9WZ_3^7W++R.DO8
M                     KG>[:OZX\$FPKWV]Y>MJ8*KP[P?PS3P=RKR]7UL
M/3KT\X3#EB]=@/WHL]PNWUA==X!33574^\W)S]1&Y_+S>'KIKIIKHH3BE7]G
MY\S\Q^$Z?W.H)=AAB
M
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MH<:L6(=N^BQW&:&*V62CJ8/!:*!%2./KK"V5^B*J]+WN=^,)X'] 0Q
M
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M_<ZAE+L,,0
M
M/B6&*>-T,\;98G>>C>B.:O=XHO #]8QD;&QQM1D;$1K&-31J-3@B(B="(!]
M<)7;_J$1^R:3_EZ,,N!W:&(
M                                 !1O9?\ FC>/A)?4(CG:'O94+W+_
M "E^GXM5Y'17UR!VE,+DQ3-X-PJ9B-Q[)DBH;N].B&Z1-Y89':)HC98V<FO[
MI#N]79_[DO=I[\"KU1%145-47@J*=U[4OVLW>O>SSG6FII)[YM[,]TC:*G[^
MNMSWJJN6G:YS6NB55U6/5-.YW3D:O1;?VJ[[R9N3CNPZ<Q[?;:/):=DUORVW
MQ2.3OJ6MF;25#%_<NCF5JHJ'#MD9E=^)>*:6C@>>1[][1XQ3/FK<JH:J=J*L
M=%;Y6UM3([N-9'"KN*Z:)KH@II\RT[D$4M/ YBW/W7OV\-1'1+2RV7;^EE2:
M"U3+RU==(Q=6OJVM56HQ%3F;'QX\5.[I-%&7]JV^]V5D[.[**\$3R$0ZSU+7
M[,&'SY'F%9N94L7WBLD<UKL3G(ND]9+HVHG9PT5K&ZQ(J>2IP.L<_'[$/#J+
M\#K2>&.HADIYF\T,K71R-7H5KDT5/V%.)#PS&+G*DV2W0DVTK-F:ZXVF'#X/
M"/>Z[02U+JZH8Z5U13Q2QK$C(VMD5%E5%=KT-\DZ$ZBGE(S(B<>T\L9,[$TG
M>2')-M]RLXQ7"*&_/L])>\9O=ON59U-14R12T= UJ.5'+!JLSUYEY=$;T=\:
MJ9E*6MACA,3'*SO2UXC'#&)B>1:F:6:JR/#LAQZA?''6W:V5M!323*YL39:J
MG?$Q7JUKE1J*Y-=&JNG<//2VS:)^=NM&,3"HY-ELPMV,[<5N.7&@@W%V^IEI
MHUJ%F=:ZN*>/JIXG/;&DB-<W7E=R:\>YTGKG/K-K8Q.S;E>>,JT5KAOUY&XM
M..;U9'?Y+SG-QM]EL]/055'28W9IYYH*FHJ8W1I+5ND8FJ,UYF\NJHNGX]<V
MRZQA6)F>.6RL7F<;81\T-A@^"YG@^R5+@MOK*%N;4-%54])7(^9:%E3/-+)&
M_G6))-&I(G_9=*=!&9F5OFS:=Z91ETM3+BO#$*WP#:WM";=4U6VSOPJJNMRE
M=472]5TMTGN%5(]>95EF\&151%7@WH/1FYN3>=W:PXMQHRZ9U(WJX\>,\SHR
MTI=$M5"E\6!;TE/%[Y+2<RTWA7(G6]5SHCN3GUY>9-=.DY\X8[F\]L?.HV]X
M'O6Z.\XPJ8[FF,7.>HDM=QRA\[ZR@CJ6\O(YC87M5&?M.0]E<S*W)W:S\S1:
MN9NQN3'S_P#@38;(\;Q_ *S#+K2OSW V31QRW'K6T-9!6+(L\#EC:Y[6_G'(
MQ43H\@GUB+6MM1N61Y&:UKLSNU;F@PW=W)[C>+YGETI+9'/9ZFT6C&+/5U3[
M;UU3&]JU%6CVHCWHK^"HUVB?@-=KY<1$5CAWY9UB\SC;DA+MH,.N>W^V]@P^
M\RP3W.U121U$M(Y[X'*^>25.1TC(W*FCTZ6H:\^\7O-HX4Y5)I2*SP0RMS<,
M9G^#WC%D=''65<*NM]1+KRPUD2\\,FJ(Y41'HFJM3734C*OL6B65Z[43#3[,
M;>W3;S%JFDR.LBN667>NJ+K?;C Y[V3552[CH^1C'*B(G[9J<=3+/S(O;<WH
MW(8Y5)K7=W^%8IH;5&U7ZS5%\&K[FD.;_<_+B43._7Z?R^Y9>1TE[
M                 #1YI\SLA^#*WW.\#EC^S\^9^8_"=/[G4,I=AAB
M
M                                                 .$KM_U"(_9-
M)_R]&&7 [M#$
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M[+0X]8J9E':+="VGI*:--&M8Q/[JKTJJ\57B5JUIM.,N=,XMD8H
M        "C:K]9JB^#5]S2'-_N?EQ*)G?K]/Y?<LO(Z2]@
M         !H\T^9V0_!E;[G>!RQ_9^?,_,?A.G]SJ&4NPPQ
M
M                                         '"5V_ZA$?LFD_Y>C#+@
M=VAB
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M^?:70='14=NI8J&WT\=+10-1D%/ QL<3&)T(UK41$3\!SIG%YWN0
M           HVJ_6:HO@U?<TAS?[GY<2B9WZ_3^7W++R.DO8
M            :/-/F=D/P96^YW@<L?V?GS/S'X3I_<ZAE+L,,0
M
M                                        *1RO-]Q\OW,N6U>U-90V
M-,;HZ>LRC)KA3K6NAFKF\]/300*YK5<YB\[G.\OH5-'$MCM9N#E]7F&2;5;E
M-HWYGCT4-PH[I;FNBIKE:ZI=&S)$Y7*Q\;E:R1.C5>'1JH6Z$.$KM_U"(_9-
M)_R]&&7 [M#$
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M&6#Z_L_/F?F/PG3^YU!+L,,0
M
M              *#V53J=\=^*>I_VBMQLLJJO2M-)2S.@Z=."-7^Z$R_.7K^
MV5ST7!M-@"-N2MU1%<ZZ*K4=Y*Z.C5$\KR@<"EZZU?V@"UM2M))4^"+*_J/\
M[Q]/S?,O+TR:]'DA.XQ]JME.T7]?MAW0W0LKG\D[I+O=Y*VUO=RLH7TL2K%2
MSJJZ(C&=XP&+NT,0
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MN9$Q$QPK(-#8        4;5?K-47P:ON:0YO]S\N)1,[]?I_+[EEY'27L
M                    85UL]HOM(M!>Z"FN5"KD>M+60QU$2N;T+R2(Y-4[
MG #1?5EMM]#K'\64GK0&XL^.X_CL4L./VJCM4,SD?-'04\5*U[D31%<D36HJ
MHGD@;(
M                                                         %2Y
MGM3DTF=_6?MAD,&/9754;+;?*.X4JUEMN5/$NL3I6M>Q[)8TT1'M7541&\$Y
MN8EL-L=KZ_$+K?<RRZ]?*3<#)EA;<[HV!*6GAIJ9O+#34T**[DC;W5UU>NBJ
MFH%E!
M                   4;V7_ )HWCX27U"(YVA[V5"]R_P I?I^+5>1T5]
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M9C#%=)Y'H  %&U7ZS5%\&K[FD.;_ '/RXE$SOU^G\ON67D=)>P
M
M
M
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MML-F,(AG2LQOSC*>&EL  %&U7ZS5%\&K[FD.;_<_+B43._7Z?R^Y9>1TE[
M
M
M
M                                  HWLO\ S1O'PDOJ$1SM#WLJ%[E_
ME+]/Q:KR.BOH   <M=NC[.;#\+IZA(>74;T+%U%YZW89O8=^R2X_#E3[GIR=
M/WK#KSS\=&.ZZ8/2X             'C5T=)<*6:BKH(ZFCJ&K'/3S-22-['
M<%:YKD5%1?+)B<!%\:VOV]P^N?<L:QVBMUPD146IBCUD1%Z4:YRJK=?\'0SM
MFWM&$SBPK2M=Z$N-;,    %&U7ZS5%\&K[FD.;_<_+B43._7Z?R^Y9>1TE[
M
M
M                          1C<#/L>VSQ>JR_*'RQV:D?%',ZGC6:3FGD
M;$S1J::]\Y *;\=O8K]+N?M!_H@G \=O8K]+N?M!_H@8'CM[%?I=S]H/]$#
M\=O8K]+N?M!_H@8'CM[%?I=S]H/]$# \=O8K]+N?M!_H@8'CM[%?I=S]H/\
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M:#_1 P/';V*_2[G[0?Z(&#<]E_YHWCX27U"(YVA[V5!]R_RE^GXM5Y'17T
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M5?3USZQM*BM21T3X$8KM57HYE"8=@>+9L5]!;9^0_P!&$8GBV;%?06V?D/\
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M-47P:ON:0YO]S\N)1,[]?I_+[EEY'27L
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MSO;WY=?+6Q5-E]\?>GP'PI&MZWP?PWK.715\[UC-?PAE+K4,0
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MK.7^%Y47FY=.]_"IHIF;/!$]EMM7:X9A0VV."Y#FF0Y_:;EN3F,5/BM[DM5
MZ"\3(Y\+.;19.;75W>]S0]N;F16*S%:[L<3RY=)F;8VG<GC^:&KSG,\QP7?V
ME;'D5SGPC&X+)'>Z*HJY7P/I:MC:62IFCYD8Y_.YKW.5//+J99=*VR=[[4XX
M?1NHO:T9N_N1$8_3C"WNT=E-WL>#QV7&:V6@RG(JEM+05-.]\4T4-.BU%1*U
M\:HYO*QFBJG[H\NFK$VQF-R'HSIG9PB<)EMNS[=;G>]G,4NMYK9[A<ZFGE=4
M5E7(Z>>1R5,K45[WJKE5$1$XJ1J:Q7,M$;V)D3,Y=9GB66>9N      HVJ_6
M:HO@U?<TAS?[GY<2B9WZ_3^7W++R.DO8
M
M
M
M       %&]E_YHWCX27U"(YVA[V5"]R_RE^GXM5Y'17T  <_]IG_ &AMG_Q
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M9;=/YJO86N>5Z      *-JOUFJ+X-7W-(<W^Y^7$HF=^OT_E]RR\CI+V
M
M
M
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M9!      !1M5^LU1?!J^YI#F_P!S\N)1,[]?I_+[EEY'27L
M
M                #75&06&C_P!+NE)!TK^=J(F<$Z?/.3H-D9=IWHEC-HCA
M:^'/,&J*R"W4^36F6X53D934D=?3.FE>Y=$:QB2<SE5>"(B&<Z?,B,=F<.Q+
M'RM,<,8Y4A-#8
M
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M\N)1,[]?I_+[EEY'27L
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M\^]<_P#HV$VNDU=P\)KNNT;Y?52-_9_N'/M[W^[U?[BUNQEW[M6ZO576$_\
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MTD]0[7\76:?W#F9O_8O7UY\_LQQ13+_#CVWHI[O:"O\ QX]F;<["DQ3'L=W
MVYDLMOCHY);[3LD?'S*KFM<U415<JGTKW!]X-?UGZU&JS9S(K2)C'#<QF<=Z
M(5[K[0:?31E3E4BLS9V*79QP
M
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M^#5]S2'-_N?EQ*)G?K]/Y?<LO(Z2]@
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M-E5WJ5CZ(9S&,C:C(VHUB=#6IHB?B0YM[VO.U:9F9X9>B(B-R'Z:T@
M     BM^^?NVWP_#_?:?</\ JS?UG\NOUV4OWG[W)Z?<=6'U560
M
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MC9)$1.959W="-7KZ:C,QB)C<PW43U)G9&7-HF,R/].ZZH145-4XHO0IH<P
M                  !1M5^LU1?!J^YI#F_W/RXE$SOU^G\ON67D=)>P
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M*SCWL1]6"_C8D
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M2B9WZ_3^7W++R.DO8
M
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MSOU^G\ON67D=)>P
M            !^.<UC7/>Y&L:BJYRKHB(G2JJ!7^([X[4YY?/DWB.34]TO2L
MDE2EBCG:JQP^?<CI(VM5$U[C@G!8(0       AN0;F8WCF;8UM]5I4U&392D
M[Z"GI8DE;'%3-5SY9U5S58S1KM%1%\Z[R )D           -#F&:8Q@-E?D6
M7W%EKLT<C(7U<C9'M225=&MTC:YW%?* \L*SW$-Q;3)?<+NL=WM4,[J26IB;
M(Q&SQM8]S%21K'(J->U>CN@2,
M
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M,[]?I_+[EEY'27L
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M3K%BZS1$T[[AP")5=M!_^YW: W#W;E_/6/&N7#L7DX.C7J5YJF2-R>7J]/\
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M1$X(B)3T83+HP(
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M_7Z?R^Y9>1TE[
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ME-K76WWFC@KJ?CJJ,J(T?RKT<6Z\J^6&*B^QU\SL\_XXN_N>C"9=%A
M
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M+"JU$;>")YY*I$TXJUC-0F77%Z_V/</8TWJ;@Q4AV,OL L'LFX^[)0F5^A
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M\CI+V
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M(['7S.SS_CB[^YZ,$NBP@
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MGY<2B9WZ_3^7W++R.DO8
M                  ^9(V2QOBE:CXWHK7L7BBM<FBHOX0*SP/L_[9;:WM+_
M (A;ZFBKFQRPL:^NJYX&LF5%<B12R.9W.Z@3BLX(      TE+A^,4635V94M
MK@BRFY0LI:ZZHW_.)8(D8C8U<J^=3JV<$\A -V            $=S;",?W!L
M,F-Y-%-+:I9(YG,IZB6EDYXEYF]_"YCM->YJ!B;>;:XCM;9)\?PRC?16RIJI
M*^=DL\M2]]3*QD;GJ^9SEXMC8FG1P EH
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M?<TAS?[GY<2B9WZ_3^7W++R.DO8
M
M
M        !@WJS6S(K176&]4S:RT7."2DKJ5ZJC9()FJQ[=6JBIJB]+514[@$
M/V^V5VSVLJZVNP.Q^]-5<8V0UDGA=95<\<;E<U-*F:5$T5?VJ($XI\$
M :FT8OCE@K+G<+):J6WUUZG\+NU330LBEJIU5R]9,YJ(KW:N<NJ^2OD@;8
M          (GG^V>$;HVNFLV=6OWUMM)4)64\'A%13<LZ,=&CN:FEB<O>O<F
MBKH!G8;AF,[?X_38MB-"EML-(LCJ>D226?E=,]9'JKYWR/75SE7OG*!O@
M                        4;V7_FC>/A)?4(CG:'O94+W+_*7Z?BU7D=%?
M0   JK*.SYM]DMRDO$4=59;I,JNFJ+5-U"/<O2KF*CFZ_@1#SVR*SNNUD=<:
MC*KL[EH_U;KUQ'8/ ,1N<=[9%47:\PJCH*RYR^$.C<G%%8U$:U%1>[H37(K6
M<6.IZWS\ZNSN5KQ1N+0-[C@                    *-JOUFJ+X-7W-(<W^
MY^7$HF=^OT_E]RR\CI+V
M
M
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M
M
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ME>YK7IH[3G>Y$U3AJ9TR:5G&(>K2]3Z/37\IE9<5MQ[O=E*S<[
M
M
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M3A]]R^LC6>GL=#47!U.CN195IXW/;&CE1=%>J(U%TZ5"%2,[0V01VS&,ON6
M5%OV\R.JH*!M[FN$:544EQT:V9*)84>ZGY^#)'/8Y[-'\B(J(I."7Y!N?=OE
M968-MYCK<HR"T4\=3D$]17-MEOMR5+>:GBEG6&=SII&HKTC;'YWBJIW C<_:
M-MM)M$NZ-79)(YHKJEBGLS:ELS?"VUB4TJPU,4;TE8UJ.D:YD??\O+PZ08+
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M$KE1?/<CW\%3HZ <"Z @
M
M
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MMZVZS^X[499)<K3-'G&[>2T,EUH*;\^^UV=U3"R.*9\>K=(:>)W6/Z$Y].E
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M3</=U>_M%;4Q8QBTO!6R6^RJYE1-&Y->:.:I5RM7_!4"[ @
M
M
M
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A1_@,'O-U6NG@W(G+KS=]S?N^;ON;7FXZ@24     /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>tm2227887d4-lc_2lnp4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_2lnp4c.jpg
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M%!04%!04%!3_P  1" )O!J,# 1$  A$! Q$!_\0 Y@ !  (# 0$! 0
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MU>LMK-U7S;1$3C&SQH7L?07SD
M
M
M
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MOYMWO=WQ.8IF9^\UY/,E=\O]DOR^?5;I<U(
M
M
M
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MD
M
M
M                                     51L/]'[G[\_JF%/]V/4W\;N
M0N?O7Z^GB]V5KEP4P  0;=_;]-S<!N>)QSI2UTW3GM]2[56QU5.]'QJ[3CHN
MG*NG@4W9.9Z.\6:LVG/K,(-0[F[V6^S)9[QM=65^9PL6%EPI:JG^29Y&HB-F
M?)SZL15XN9_(J>#=.5E3.,7X.RPC,OAPUX>6,/A\29[/8KEF*XDL.<71]TRB
MY5<URK]7K)#3/J-/]'A555.1FFOBZ)JJFG.M6UOFQA#9EUM%?G3C*-[.XAD>
M.9[NO=KU0/I+??[S'5VB=[F*D\#5G57-1JJJ)X[>W0VYUXM2D1Q0PRZS%K3/
M'/<8N88?E>Z^Y5':,BH);?M'C#V5RM>]B.O-Q:GXM.5JN5(HU5>WM37^<FBE
MZY=,8\*>Q"+TF]HB?!CLS_1Y385E6VV[O[78';GW'",P>C,ML\+VM6DJU=KY
M[$QSFZ^%7)Z[O532?25OE\VVVNSO',FM\:[)V]]>1XWH5;OAA%]RFT6.^8E#
M'4Y;B%UIKW;*29Z1LJ/-WHZ2'F7@BO1J::^IIX3TY%XK,Q;9,8-.;69B,-L3
MBC%51YSNYGF&UMWQ2KQ+$L.JEO%6^Y20OGJ;E&B)#'$R)SM6,5/9^'7[FNR)
MKETMA.,VX&$Q:]HQC"(X7A9(]P=FKUF%KM6&U65XWD%TJ+]8JJVRQ-=%4UK6
MM=3U*2*BL:BQIXZ:_P!\6FF;%9F<)B,)*Q:DSP8Q,XIML;A-YP?"'4V2<C<D
MO%?5WJ[Q1.1\<516OUY$<G!>5C6(OKZFK49D7MP;(X&S*I-:\.W:P\/Q:_6[
M?#<C**VB?%8;S3VAELK55JMF=2TC(Y41$553E<FG%";WB<NL<<8HK68O:>K@
MM8\S<          %15O[^;=[W=\3F*9F?O->3S)7?+_9+\OGU6Z7-2
M
M
M
M                              *HV'^C]S]^?U3"G^['J;^-W(7/WK]?
M3Q>[*URX*8        8MRHOE*WU5O\XGI/.HGP^=4C^E41=1JMYXGZ+RO;KJ
MU=."DQ.$BM?L27_>/G'_ ,:3] >CT_\ VU^1J]'UY^5*L,PA<-\]UR.^9!Y[
MTO\ 7U:E=T>CS_YG2-G+S\_C]NO*WU#5?,YW%$<C*M<.-*C6S
M    *BK?W\V[WN[XG,4S,_>:\GF2N^7^R7Y?/JMTN:D
M
M
M
M                   51L/]'[G[\_JF%/\ =CU-_&[D+G[U^OIXO=E:Y<%,
M                            5%6_OYMWO=WQ.8IF9^\UY/,E=\O]DOR^
M?5;I<U(
M
M
M                                           JC8?Z/W/WY_5,*?[L
M>IOXW<A<_>OU]/%[LK7+@I@                           "HJW]_-N][
MN^)S%,S/WFO)YDKOE_LE^7SZK=+FI
M
M
M
M     %4;#_1^Y^_/ZIA3_=CU-_&[D+G[U^OIXO=E:Y<%,
M             5%6_OYMWO=WQ.8IF9^\UY/,E=\O]DOR^?5;I<U(
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M!M0
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M]7!'4TLK)Z:5J/BFB<CV/:O%%:YNJ*B^L!Z
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M[S5S+UYLX)Z:&                  5%6_OYMWO=WQ.8IF9^\UY/,E=\O\
M9+\OGU6Z7-2
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M[$,%[T6U-1BMN\PFO]U9<KN[KSS]:KDKD5S])Y'HW57+XK-&^L#B=MAB
M
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M9[G Q[>DV1(G:MFD35[%7CZR!$+0V"_<I@/S'0_F6@E8P0
M          %4;#_1^Y^_/ZIA3_=CU-_&[D+G[U^OIXO=E17>+H76_>I*I_\
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M5;I<U(
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MA[YA^/-!&QUJ&(
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MS%,S/WFO)YDKOE_LE^7SZK=+FI
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M%91><&6V8OB-W2**Y0U,$C9;?'6<Z5#VK+S(JL1'<J-#)V$&(
M
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MO#[#>Z=:2[VZTTE-6TKE:YT<T42-<U58JHNB^HH1*;
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M=[W=\3F*9F?O->3S)7?+_9+\OGU6Z7-2
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MM>ZWMCGF;,^1$B9*DGBM:C=4?['C]T)F%I!
M
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MOR^?5;I<U(
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M=W8LEM.+P-I;514%!;Z*"#V+:66MIH':*FNNK'JKE7M[5#&-JG+I043?^'S
M]L+4=&RGJ6.TXI-)D#6N?]U4>Y/N*$\:O=[[S<JONO[)4M5SI%*E3SH[7LM[
M/-J?P)_V;EY?6!&U9W?I8VQMVNN-I@Y*VUUE6V@2)%1[4A\T?&QNFO8K&Z A
M?>Y.Q6+[L918KYF-555-FL4;DBQZ-_3I*B=S^;J3JBZJFGBZ-Y57^=IP",5.
M=P']VV3?/B_%( F76H8@
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M5 F(=ZX'6U-RP;&;C6+S5E9::"HJ'<>,DM-&]R\=5[5#%(0
M               *HV'^C]S]^?U3"G^['J;^-W(7/WK]?3Q>[*URX*8  -!G
M*(N&9 B]GR=5?F7&[)]97EAC?9+@SN@_OJM_O&N_-%JWIZB>6',TWAOT2*>Z
MH                     !45;^_FW>]W?$YBF9G[S7D\R5WR_V2_+Y]5NES
M4@
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M/>GLFJG%0F71H0
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MO=WQ.8IF9^\UY/,E=\O]DOR^?5;I<U(
M
M
M
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M0Q2    "HJW]_-N][N^)S%,S/WFO)YDKOE_LE^7SZK=+FI
M
M
M
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M3$12,,?C6J>=N    !45;^_FW>]W?$YBF9G[S7D\R5WR_P!DOR^?5;I<U(
M
M
M
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M=8S+'%>\>J9F57(RH:KX9H9XT:V6)[4X/1J?R*U5"Q0@
M
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MZ#!= 0
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MFGKZ-"X0AQ!_S$O[OJH&7$[?#$
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MF*9F?O->3S)7?+_9+\OGU6Z7-2
M     X@_YB7]WU4#+B=OAB
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M=\YU'Q= RAU/A?T.Q[YLHOB[ Q;P
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M@W6+;E_M1=FVG]C\FLO,Q\GGUYMOFE(G(FO*LG4=XR^!- A.0
M     #77Z\TN/6:NO=;JM-0PNF>UOLG<J<&IKX7+HB&O,S(I6;3Q//J,^N3E
MVS+;*QBJ2@O&^654'[665U!06J3FEHK1(UJRSQ-71-%?&Y>.G:LC->U.&AR*
MYFKS(Y]<(CJ?#^BKY>=O/44]-E\VM>*O5CY.[">[<YLF<V!;A-3^:7.EE=2W
M"F37E;,Q$75O-QY51>Q>Q=4\&I[]+J/34QPPF-KM[LU_M>5SIC"T3A,==+SV
M.J     !5&P_T?N?OS^J84_W8]3?QNY"Y^]?KZ>+W96N7!3 ".Y_]!LD^;*O
M\RXV9?A1RM6=X%N25<;*_NQQ[_N'_G7GOSO#EP]/ZN$^-+T*QK?XBL1^9ZK^
MO-EO53RM>7^)KR2]\3CCJ.]!N%-<&H^KH[-:66A9.+F4LD;5F6/7L3J*J+IZ
MICF?AZX=6<70IZ^V/4C!:.8184^@I9<Y6@;;(*R&6DENCHXX65J*J0JUTJHB
M/U5>4\F7S\?FXX]9Z;\W#YV"J\%_B<W4^;[/\4ISV9OX>G+/;>/*_$7^+M,3
MO+HM/==KKA:V_P#YHCR:&*WJQ-970O8JRM33BJ<R1ZH8Z79>)V<UNS]M/&[D
MH]:%W"O.Z>Y5YV0DH*2VNJ8[??I\@YY:>>ZT3'Q*ZC; U'-Y%YD57JK571>S
M@9SS(I6,S'K8=3KL(YTVM-,.OCU>LG'=GEH(,*NE@6*H@RFSWBLARR*K>R1[
MKK(Y'2R-<Q$:L;^'+IZGWUTZK'G8\4QP<C;D8<W#CB>'E6OD7T?NOO.H_-./
M-7;#?*L>ZW^X;$/\BM_^85)Z=9ZZSSZ7U5>11%M63#\]N>[,&B4]HW'O5COB
M*BZ?)UXG?'SN5-.$;TU35?9.0]EOG5YG5I68Y8AYZ_-^=_W6CY9[^!WDG?ME
M49SE<;^K:,0;18M0JNO+Y]-,E35N;X-6*U(U4:3YLUCI3CWC51C6T]2,._W'
M:YR'1         %15O[^;=[W=\3F*9F?O->3S)7?+_9+\OGU6Z7-2
M                                X@_YB7]WU4#+B=OAB
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M"GN1\/B<K>N]*ZKFY>77F95/!CNS\/C2\[[@
M         X\_X@?T/P[YSJ/BZ!E#J?"_H=CWS91?%V!BW@
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M         %15O[^;=[W=\3F*9F?O->3S)7?+_9+\OGU6Z7-2
M                           X@_YB7]WU4#+B=OAB
M
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MU.0G=F]:Z[G<VLUYN&WKX]YCO'=MM'S>=:)YV/8P[Z1G;<@
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M'%<*)'(LL$C(T:K7M1>"HO C*U&5F3A2T6PZDHIG4O/S9B5F'H;0
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MRXW9/K*\L,;^#+@ON@_OJM_O&N_-%JWIZB>6',TWAOT2*>ZH
M         !45;^_FW>]W?$YBF9G[S7D\R5WR_P!DOR^?5;I<U(
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MRE\K_)'G7_M#H>:]7SK'YJK_ #74EY>7J\OLUUTU]8'$_18,0
M                        #09?)F\=MB=@5/:JF\==J3QWR>HIJ9*;D?S*
MUU-#,Y7\W)HBMTTUX]@$(?-WC9-.I9L&?IV<URNR_P"&WF,UB=L,HM,;)1W/
M)-_V8)E*5]HPN*W.M%>E:^EN%T=.D'FTG.L;74+6J]&Z\J.<B:^$16(V0F;3
M.V6/AN*[F95@>)OO,5BIJ2DM-"VU+1U=8^1],^FBY5G22E1&R:(W5&*Y.WB5
MS?.Z;ZV:36T5YN.WKX.[NK>=-'%HM$SSL-GQI%18SN_B?4_9&GQNL\\T\\^5
M:VOAY>EKR=/H4;]=>=W-S>L9;FW5?0\_G6BW.PV=;'OL=Z[RIK.;S8F.;CV<
M.\G^(29O);979[3VJFO'7<D$=CGJ*FF6FY&<JN=4PPN1_-SZHC=--./:6-P6
M_                                              %$]X3+-K(5H\)
MS7#*_.[Y6T[JZEM5FHO.JZEI>ITEJ$F:^.2%'.16HZ-VJJFB\ F%86&RY)DV
M+_*V$4C=T< M=5+1UFW>XU/$S(K35PHUTD--62-<B.1CF<K7N5$9HG%=0ET)
MM!E6.9)C<M+CN,5&&I9:A:&OQJJHF6YU)4JULKD;'&B,5KD?S(]J>-VA"P0@
M K7O 9/D6&[.Y9DF*<S;]14K/-96(CG0MFGCAEF1%14UBC>^3BGX(3"JZS83
M9VFV;DS2DG?'D<5I7((-Q&UL_P H.N/0\X;5K,LB(O/)QY/7X:.X@Q:"KR>]
MWBD[LN[&9KTYDKJJW7:ND:D42R7B)L$$TFB(UO5;!U->#>/J!*P.]>K;GBF)
M873JC[OD^4VNCI*9J_C5CC>Y\LB)Q\6/Q>=VFC>9-0B&JWU[IWVU9M'F'[7?
M(?3H8:#S+Y-\\UZ#Y'\_4\[A[>IV<O@[01+E'O ]VC["K/9[M^U'R_\ *U3)
M2]'S#S'I]./GYN;SF?FU[--$#*)?I)A?T.Q[YLHOB[ P;P
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M2YV^JMKU<Y.9%8VJCC5R>NW@$)*
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M5-(^HJZJH=VR332JY[U^ZNB>!$ E8'$'_,2_N^J@9<3M\,0
M                         KK=/(XXK97X>D#W.O5MJ*>>I5'-9%'6,? C
MF.5O*]R>,KFZZIXNOLD*_O?>TZ'F85YW.QX\-F'?=S=>[(UG.QMS>;AQ8[<>
M\^-K<GADH+=A2T\C9;1:X(J>J1CWQR14+8J=RR/1O(QZ\S%:Q7:N\;35&N&Z
M-[3KN?C7F\W#CQVX]XWINR-'S<+<[G8\6&S#OK(+ X8
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MBHNFJ)KIPUT50G%980X\_P"(']#\.^<ZCXN@90ZGPOZ'8]\V47Q=@8MX
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M*JIZFB^#0SR;3$\V6.\LFF;E1J*1A..%HZ_57H>M6@
M  %15O[^;=[W=\3F*9F?O->3S)7?+_9+\OGU6Z7-2
M        *_W1W3Q3;VR72.XY!;[7E/R955EFH:V9C)9I61R)#RQN5%>BR-Y=
M/#V!*(=WS?6S[C89CL&39%;)-S+GY[YU98'QPU*^;U%0K-*=%54_T>-LGW.(
M)A=X0        <0?\Q+^[ZJ!EQ.WPQ
M        "+YAA_[5^9?Z;YIYIU?^RZO-U>3_ !V::<AP=[;I]NYGS^;S<>+'
M;AUXZCM;LWG['SOF\[G8<>&S'K3U3#\/_93SW_3?._.^E_V72Y>ES_X[]=><
M;IW3[#S_ )_.YV'%ALQZ\]4WGO/VSF_-YO-QX\=N'6CJ)0=YQ0
M                                     -7D&1V'%+7+>\EN-/:K1"K&
MS5M9(V&%KI'(QJ*YVB)JJHB <^8?WG;#7;NYO8\BRRS4^WMOBIG8Q7NDBB9/
M(]K%E1)^;2315=]P)P=)T]1!5T\5532-EIIV-EAE8NK7L>G,UR*G:BHNH0]
M       .//\ B!_0_#OG.H^+H&4.I\+^AV/?-E%\78&+>
M                 #!O7^I[A[VF_-N @^P7[E,!^8Z'\RT)E8P0
M                           JC8?Z/W/WY_5,*?[L>IOXW<A<_>OU]/%[
MLK7+@I@!%MRW.;MYE3FKHY+56JBI_P!P\UYO@3R/9HOQ%/&CMJ\V61$VNQI$
M33_157^61YY<OP8=W>/XB_*GAL<Y5UQ56]Y#"%:NBNM-:UVGA3DJ%T-<>LAT
M_P#\_,\:.XZ!/<J@                    "HJW]_-N][N^)S%,S/WFO)YD
MKOE_LE^7SZK=+FI                           %9[L8)MYFU!645_H;+
M49K56VHH<>GNG12I9+*R1(>FK]7HB2NU\5%XA*);+[/8=LQ@N/W//:&PV_/+
M4ZK9590YT3%YJNHJ$C1M5,V-558)&Q_<X F5\-<U[6O8Y',<B*UR+JBHO8J*
M$/Z       !Q!_S$O[OJH&7$[?#$
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MIOS;@(/L%^Y3 ?F.A_,M"96,$
M*HV'^C]S]^?U3"G^['J;^-W(7/WK]?3Q>[*URX*8 17<W]W65_--;^8>:\WP
M)Y'MT/XBGC1VU>[+_NNQGWK_ %CSRY?@P[F\?Q%^5/#8YRK;E_$?@WS56_\
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M;)E]DI,AQVK976BM;SP5#->.BZ*BHNBHYJIHJ+V&FU9K.$[6RMHF,8;8Q2
M            J*M_?S;O>[OB<Q3,S]YKR>9*[Y?[)?E\^JW2YJ0
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M]6.[0>:7*BG756MGBYG(G,B*K5:Y4714UU140A-0.(/^8E_=]5 RXG;X8@
M                              H_<:[[W8I<K7+;<BL#K5D60T]DMU--
M:*ATU+#7OD6)TLB5J)(L;6(CM&MYEX\ E:>)TN6T=K6+-+E176\=5SFU-MI7
MT,"0JC>5O3DFG7F1>;5W-]X(;T
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MVC"8>YM:@
M Y][RVYE+CK\>V^H<&IL_P KR1[ZBVVBNA2HIX?-N"2]/E<YS]5=IRJWE:CE
M5R)VDPC*=\C'Z'"[RW<+&IK?N);JIUIJ<)UYEJ7R,54>O5;JR%>+9.9KM.&G
M/S(#!8O=JI;Y%M_55]]Q.GPI]VNM3<*&P4</FL45'+'"V->DJJYJNY%UYD:O
MAY431 2N,( *=[U5TJK1W?\ -JNC<K)I*:FHW*BZ?BJZM@I94^^R5R!,(!%E
MV[U#M73W6W[:V>;9ZDM$<;\<JZR5+Y4V-E/ROD5C&=%O/#XZQKS/TX:*H'SE
M]UQC+<C[ME#B=,VGP2Z5U9>:&@1B1Q0NM--%)!&Z)J\J.C<][>"Z-5%TU0"3
M][36BP7',EIDY;KCV4VBOM\S4TD;(DCF*B.\"+S<4XHNB< 0PM[N];;]E\RC
MP^JQB:\2/HH:_P [CK&T[42=\C.7E6)_9T^W4$0Y0[Q/>4H=\[+9;328[+97
M6FJDJG2RU3:E)$DCY.5$;%'IIVAE$/T<POZ'8]\V47Q=@8-X
M              '/FZ6.W-,LJZ^EM\OF%2Z!C)V,58WSR,:FB+X7*[@?/=\Z
M7,]HM:M9YLX</7E7-;E6]),Q'!."R]J;/56?%^C7TCZ.MDJ)'RLE:K'JG!&J
MJ+ZR%FW+D6RM/A:.;.,NIH<N:9?#&$XIP=Q[P !%\RP>WYK%215]1-3I1N>Y
MBP<NJK(C477F:O\ -.;K=!351$6F8YO4>/4Z6N?AC,Q@Q\.V\MF%U-354%5/
M4/JHVQO2?DT1&KS<.5J&&BW;32VF:S,X]5CIM'7(F9B9G%,#JO<
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MS53J.CZL#6.E5-5U>O%W::<R<NV,XVQY([[;3GQA&$1'+_1;YY6\
M    "HJW]_-N][N^)S%,S/WFO)YDKOE_LE^7SZK=+FI
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M41M<CXW=J*KW+Q^\I=MU95LO2TK>,)B.[*H;RS*YFHO:LXQ/>;HZCG
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MWGZNOCT[;QZKP8\:.VEAUGL
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MN::6"*21VB)JYS$55T3AVA#*        X@_YB7]WU4#+B=OAB
M                     "K-[?\ Z=?[<63^O"86F$
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M<U/6U+>+/.YW2,Z:+ZR2?WE-=/G9F/4=/4?^'0<VVW,MP<D.@SW*H
M              J*M_?S;O>[OB<Q3,S]YKR>9*[Y?[)?E\^JW2YJ0
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MEH_*.X][+BEBFC;+"]LD3TU:]BHYJIZRH!]@
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MU$U7[N@8O8       #B#_F)?W?50,N)V^&(
M       *LWM_^G7^W%D_KPF%IA
M                     %*;S[ UV[=^H+U2YO<<790TGF;J2A8Y[)5ZKY.H
M[EGBX^/R]G@"8ES7M]W?<@S;/MQ,+EW*O-'%@U514L58WJR.JDK6SJKG,6I;
MR<O1\"KKJ$XNP=H-MJC:O%'XS59!59)(^KEK/E&M:K9425K&]/19).#>37V7
MA"$^"       ''G_ ! _H?AWSG4?%T#*'4^%_0['OFRB^+L#%O
M              "+91MKM_FM7#7Y=C5NO5;3Q]""HKJ>.=[(N97<C5>BZ)JJ
MKH!HOL"V4^H-C^ P^2$XL/)MNL'QRS6ZGL-BI+;3_*-)%T:1G1C2.:=.=J-:
MJ(B.U77@<3>>3E\VMN;&,VK&.$;,7@U5*X1.$8XQQ-O<-E=IKM4>=77#K575
M7*C.O54S)I.5.Q.9Z*NB:G7IEUI&%8B(ZW ]E:Q6,(C"&)]@6RGU!L?P&'R3
M8SQ3FT6BUV"VTUFLM'%06JC9TJ6CIV)'%$Q./*UJ<$3B$,T
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M5F]O_P!.O]N+)_7A,+3"
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M6JUC'-7FCX\.":ZIRAT<$.//^(']#\.^<ZCXN@90ZGPOZ'8]\V47Q=@8MX
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MX<^NI.BW=K/;*Y^?,3A$]3J3'%'71KMY:+V*VGT\3&,QU>K$SMGK+:+BI0
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M]):AC)'<L;V-\9O#31.&@)V/T:#$
M%6;V_P#TZ_VXLG]>$PM,(
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MVWCU7@QXT=M+#K/8
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M21):RK?$U6QM7E1K6QQHJHQC4X(OA G80X@_YB7]WU4#+B=OAB
M                      #F_=C*MP[O?;;::?$;>REQ3(Z:\TU5)>WH^L@H
M'2=-KHTH%2%96/1R^._D[/&.1G[WTN3>:7MA:.M/>=7)W7J,VD7K7&)Z\=]=
M6!Y#?<HL#+QD%GALE7++(R*DIJU;BQT4:HU']58*=457(Y.7D\';Q.AI\^F?
M2+TG&L_]'AS\B^3>:7C"828WM
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M23:(GXQZ^OVHBH3BML(<>?\ $#^A^'?.=1\70,H=3X7]#L>^;*+XNP,6\
M                       "MMQ<QL$*P65]2JW"CKZ.HJ(VL<Y&QQO21WC(
MFFJ)X.TK6]=?DQAEX_.K:LS\4XN7J]12,*X\,3";6+(+5DE$M?:)NM3(]8W*
MK58Y'-[45KM%3M.WIM5EZBO.I.,/?E9M<R,:MF>IM
M
M                     '-N3]SC9*MK[ME5^K[K1^>5$]PKZA]=!!3QOJ)%
MD>NKX-&MU=PU<$XN<LZQKNA8S4?).*5&29QD+W=.&CLU7$M,Z1>QJU+J54=K
MZL+9 GA?HI:TY;91-Y%CT@B3INXN;HQ."\$XI]P,66       !Q!_P Q+^[Z
MJ!EQ.WPQ                                !5F485D-SOU;74=.U]-,
MYJQN61C55$8U.Q5U[4*!O+<^ISM3>]*\$]>.HN^[]ZZ?*T]:6GACK3U4YQ*W
M55IQZCM]:Q&54/5ZC45'(G/*]R<4U3L5"U[JT]\C35R[QA:,?[IE6MY9],[4
M6O39.':ANCJ.:
M      "I-U^[IM_O)>:*^Y=+<65M!2^90)0SQPLZ74=)XR/BDU75Z^$)Q<V[
MA[/]SG;/JT]_R>[U-WCU1;/;*R"MK.9/P7-9!RQK_P!Z]@3PKY[IS,:;M?._
M$;/<K-C\MVJI**&\S-GJIF+%"G6YF11-1KM-$1O,G#V2A$KT"       ''G_
M ! _H?AWSG4?%T#*'4^%_0['OFRB^+L#%O
M I?/]NLFOF45=SM%'&^BF;%H_JQQJKFQHCE5%5%[4*5O/=6?G:B;TK&$X<<=
M1P]5I,R^9-JQP)UMOC]?C>-MH+G"V&N6:221&.:_5':<JJYNNO!#O;ITM]/D
M<V\83C+WZ/*G+R\+;4N.N]H
M
M   _/3>#$]TJ;<.XWW?.T9)E.U<=9436Y+#6QK2P4G5<Z)71LCD9&B1^*Y'M
MA<O\_P!4R2;NW91LY3;_ .05>$.AQ_$:VP4U+8Z6ZRI!4+6<U/UHT=42O5\J
MN:]5Y9':IV< 2[E#$        X@_YB7]WU4#+B=OAB
M
M           !RSWML9WTO\]M?MY\I5F"1TO+?K39:EM/5S3=5RNU8U.I(CH^
M5J(ULB(O'D]4F',LUPV,MRX-;\?Q^Z8WFEMR:VRY5)DLG4?YC&[635_XN)K$
M56N=K!$OK:(&3]-;;<K9=Z**X6>L@K[=,FL%522,G@>WU6OC56JGW%#!E@
M     <>?\0/Z'X=\YU'Q= RAU/A?T.Q[YLHOB[ Q;P
M /*JJ8**FFK*J1(J6G8Z::5WL6QQHKG.7UD1 *F6^7215DBN-0L3UYF*DTFB
MM7BFG'U"L6SLS'PI^5R9S+8[96C:*ZGN5KHZ^DF2HIYXF/9,U=4<FG;JOKEE
MKLAU:[&:9)
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MZ0H#)
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M-4\(3@GX0X\_X@?T/P[YSJ/BZ!E#J?"_H=CWS91?%V!BW@
M      *IJHHDWZMM@1C?D6;$;A7RT.B=%U7'<Z*)LJM_G(Q[FHOJ*IH]!E]&
M&'HZ]1:K6M8U&-31K4T1$[$1#>S?T
M
M               !QKM/N/B?=\W"W)P7=-\MFK+M>Y+M;+]+!+/%64DZN6+G
M?"Q[NQW.BZ*WF<]%5JIQ,GSWD=Z=O=XL3H]J=LGORW,;W<:3S'S>FE9'3.C?
MS*[J3L9XSFZM56<&M5RN5$3B(AU_9J*6VVBWVZ>7SB>CIH:>6?C^,?%&C%=Q
MU7BJ:ABS0 $&S3:ZRYWE.)9)?IY9Z7$IJFJI[(]K'T-3/41(QLDS7)JKHG-:
M^/CHFG9Q4"J=X)[?EN^FUN+8?&VHSC'+FV]Y#<J;BZ@L<.G6@J)&]GG">*UC
ME\*</QB:DL[;."#*^\;NSE=SC;45&,):L?L#I41RTL+H)'U/3UUY>>1O-S)Q
M\9R=B@?W'HH<.[V618]:XVTUHS+%8,BJZ6!$;'\I4M8ZEZJM31&JYJ2*]43Q
MG+JO'4'$\*COJ['4M1+32U=R26%[HWZ4+U3F8NB_A>L#!0N"9O8MQN_/;\SQ
ME\LEDN?6\U?/&L,B^;XW)3OU8NNGCQN">)^@(8@
M    _CD1R*U>**FBIZRD3&*8G!4GF%)]MO[(=/\ _+O[*_*OF?,[_P ;\H]#
MJ=37G]AXO+S<OATU.3^CZ3H=FW?=3]4U/2[%>\MPZ[E
M                                            Y6[P%<S;7?W;K>G(
M:*>LP>EH9[)730LZWF=2[SE62\O8CE2IU3PN1BZ<40)A,;[WN]@*.R5%9%D/
MRP]\3N2TP454LT_,U?Q:I-"QC=>Q>HY$!@Q.YKC%ZQS9Y:F\TSZ),@NM5>K=
M12(K5BHIXX8HD1J]C7=)9&\$U:Y%\()=!A !'LZQ2/.<0O&(3UU1;:>\T[J.
M>LHU:D[8I-$>C>=')X[=6.U3L50*NWDBV^VRV#K,*JZ&">EGMRV3'+*R-JU%
M9<I8NE"Z*-J*Y9$D<DKY&ZN1?&]EVDJ]R>PWA+1W;MG<TUJ$KZE*K(:&9>9D
MB6.ECE2FFUUYVL2;IN;[%W+]Q0E,N]'3TV.V?"MR+9"RGO\ B>1VY*>JC:C9
M5H*A7Q3TJ:::QR:MU9JB:!$)/N3WD-LMJ<A;B^75%9%=7TT=8UM-2NG9TI7/
M:WQD5..K%X P<D][+?O;W>#'L=MN&354M5;:V:HJDJJ=T#4CDBY$T5575=0F
M(=ZX7]#L>^;*+XNP,6\                    !5=5_$C:?]A[G_P#-Z )6
MH$
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M59\B?LCYAY_S)T?.OE/J]+F_G<GC:>H>'V_3].ORO;[%G]"WR+8/<\0
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M<%; Z]=:GD9-'SWRY/;S1N1R:M=.J*FJ=BF2<5MA
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M/%5T53&QZ/BG@>DD;VZN[6N:BH#%9(0
M                                      #RAIJ>F1R4\+(4>O,](VHW
M5R^%=$350/4#CS_B!_0_#OG.H^+H&4.I\+^AV/?-E%\78&+>
M         I:;_/2?Y3O\)4[;7%G:N*B_\'3_ /=,_P"JA::>#'([%=D/<S9
M                                              HWNO\ T1O'SDOY
MB(YVA\&5"]R_PE_'\VJ\CHKZ                            H2Y_Q06;
MWF_XA4G,G\3\.HH&I_V#*\2?[;K[.FOX
M          <0?\Q+^[ZJ!EQ.WPQ                         !_'.1C5<
MO8U%5?O$3.$8IB,95%\H4OVQ?MOS+\A_LS\C:Z+U?._/_.?8?S>3PZ]IQ/UO
M3=6?D=C](U'4CY5O'<<8
M                                <>?\0/Z'X=\YU'Q= RAU/A?T.Q[Y
MLHOB[ Q;P                   /*J;4/IIFTCVQ5;F.2"21JO8V147E5S4
M5%5$7M35 *O7;W.'+S/NMJ5Z\7*E-4(BKX>'6.;.@I/'+R>S1U5D6B"OIK92
M4]TFBGN$4365,T#%BB<]J:*K&.<Y43UE<IT8C",'JB,&:2D
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M%9&B-:KE3FT:B(G@/H2BL@
M                                 !QY_P 0/Z'X=\YU'Q= RAU/A?T.
MQ[YLHOB[ Q;P
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M/4         *$N?\4%F]YO\ B%2<R?Q/PZB@:G_8,KQ)_MNOLZ:_@
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M]7WL,DR*Z71FS^V=QS7&[+(Z*KOC)7PQRN9VI$QD$O:GC,17<ZM5%Y$!@L3
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MISHF=K?G9<H
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MJ> F8%HF(
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M-N=$RWY^LMFUYLQ#:G1>
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M *(WCYR7\Q$<[0^#*A>Y?X2_C^;5>1T5]
M 4)<_P"*"S>\W_$*DYD_B?AU% U/^P97B3_;=?9TU_
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M.UX\R-UUX]H3BGP0
M                                         07=7;2DW.Q^FMOG\MFO
MEJK(+MC]]IFH^:BN%*JK'*C55.9O%4<W5-?NHB@0ZAVCS_)LIQ_(-W\LH[W;
ML3G2OLMCM-"M%32W%B:1U=4Y[WJY\?:QC41J+V:)JCB5UA        !B72U6
MR]V^HM-YHX;A:ZMBQ55%51MF@E8O:U['HJ*GW4 A6,;';28;=DON-XC;Z&\-
M<KXJQ(UEDB<OABZKG]-?^[T"<4TN=IM=ZI'4%XH:>XT+U17TU7$R>)53L562
M(Y%T^X$/FU66SV*E\QL=OIK91<RO\VHH8Z>+F=VKR1M:FJ_< CF6;4;;9U61
MW'+L7MUVN$2(QM940-ZZL3L:Z1NCG-3P-<JH@$DM-GM-@MT%HL=#3VVU4K>2
MFHJ.)D$$;===&L8B-3BNO! ,T
M                      !1O=?^B-X^<E_,1'.T/@RH7N7^$OX_FU7D=%?0
M                           %"7/^*"S>\W_$*DYD_B?AU% U/^P97B3_
M &W7V=-?P
M
M
M                                            *-[K_P!$;Q\Y+^8B
M.=H?!E0O<O\ "7\?S:KR.BOH                           "A+G_ !06
M;WF_XA4G,G\3\.HH&I_V#*\2?[;K[.FOX
M
M
M
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MI.9/XGX=10-3_L&5XD_VW7V=-?P
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M4# ]-O8KW7<_@#_*!@>FWL5[KN?P!_E P/3;V*]UW/X _P H&!Z;>Q7NNY_
M'^4# ]-O8KW7<_@#_*!@>FWL5[KN?P!_E P/3;V*]UW/X _R@8'IM[%>Z[G\
M ?Y0,#TV]BO==S^ /\H&!Z;>Q7NNY_ '^4# ]-O8KW7<_@#_ "@8'IM[%>Z[
MG\ ?Y0,#TV]BO==S^ /\H&!Z;>Q7NNY_ '^4# ]-O8KW7<_@#_*!@>FWL5[K
MN?P!_E P/3;V*]UW/X _R@8'IM[%>Z[G\ ?Y0,#TV]BO==S^ /\ *!@>FWL5
M[KN?P!_E P/3;V*]UW/X _R@8'IM[%>Z[G\ ?Y0,#TV]BO==S^ /\H&!Z;>Q
M7NNY_ '^4# ]-O8KW7<_@#_*!@>FWL5[KN?P!_E P/3;V*]UW/X _P H&!Z;
M>Q7NNY_ '^4# ]-O8KW7<_@#_*!@>FWL5[KN?P!_E P/3;V*]UW/X _R@8'I
MM[%>Z[G\ ?Y0,#TV]BO==S^ /\H&!Z;>Q7NNY_ '^4# ]-O8KW7<_@#_ "@8
M'IM[%>Z[G\ ?Y0,#TV]BO==S^ /\H&"_K/=:2^VB@O= KEH;E30UE*KTY7+%
M41I(S5/ NCDX!#-                                    YXJ.^KL=2
MU$M-+5W))87NC?I0O5.9BZ+^%ZP3@\_3;V*]UW/X _R@8'IM[%>Z[G\ ?Y0,
M#TV]BO==S^ /\H&!Z;>Q7NNY_ '^4# ]-O8KW7<_@#_*!@>FWL5[KN?P!_E
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M$_#J*!J?]@RO$G^VZ^SIK^
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MU53^4"J]DM@,;V,^7?V>N==<?E[S3SGS_HKR>9=?DY.E&SMZ[M=?40)F5M!
M   4_3=WC&*;>MV^++I7KD#I))?DY5A\SUFH74*I_F^?@QW-[/M]8)Q7 $
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M&)M9MQ:]I\+HL)LU745MOHI)Y8ZBLY.LY:B5TKD7IM:W@KM$X 3,
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MF6YT[6-*12,(V)&:V:A+G_%!9O>;_B%2<R?Q/PZB@:G_ &#*\2?[;K[.FOX
M
M
M
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MFCFRQ02(OBS5;FJK9'I[)K$\5OAXE?U6NF_S:['@S<_'@AT]V<$[#DO*
M              "A+G_%!9O>;_B%2<R?Q/PZB@:G_8,KQ)_MNOLZ:_@
M
M
M
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M &#*\2?[;K[.FOX
M
M
M                                                  %&]U_Z(WCY
MR7\Q$<[0^#*A>Y?X2_C^;5>1T5]   #EKOT_NYL/SNW\Q(>74;(6+<7KK<C-
M[CO[I+C\^5/Q>G)T_@L-^>OCQ8[KI@]+@                     *$N?\
M%!9O>;_B%2<R?Q/PZB@:G_8,KQ)_MNOLZ:_@
M
M        #"JKQ:*'5*VOIJ947E7K31QZ.[=/&5.)G%+3LAC-HC;+3U&XFW]&
MO+5Y79H':JW26XTK%U3M3QI$[#;&FS9V5M\DL)S:1QQ\K35&]NTU*FLN7VYR
M:*OXJ;K+P]:-'&V-#GS]"6$ZC+CZ4-6_O&;-,E9 S)6S3R:)&R*DK7\RN71$
MYD@Y477U5-GZ=J.CV8[[#VO*ZJTCG/6
M
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M\0J3F3^)^'44#4_[!E>)/]MU]G37\
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MEYD=J\MU?=[6SMO2.3&>XQ75>^E7R^>;C-@3CJE-;*1--?!JUD:K]\\>;_\
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MYUK6X>#JRX/O'DY=-'/-K$?.KLAV,?7U3
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MP>-Z  !0ES_B@LWO-_Q"I.9/XGX=10-3_L&5XD_VW7V=-?P
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M_P!XG_\ ROYJK>\WX.?&JZ\/MRG
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M0D1K9  "A+G_ !06;WF_XA4G,G\3\.HH&I_V#*\2?[;K[.FOX
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MVWIK7-KLS;Q_RED>C53?7_*/AJ>0>+V/=OY/3_XJ=YMY^H^^S/+D]&JF^O\
ME'PU/('L>[?R>G_Q4[QS]1]]F>7)Z-5-]?\ */AJ>0/8]V_D]/\ XJ=XY^H^
M^S/+D]&JF^O^4?#4\@>Q[M_)Z?\ Q4[QS]1]]F>7)Z-5-]?\H^&IY ]CW;^3
MT_\ BIWCGZC[[,\N3T:J;Z_Y1\-3R!['NW\GI_\ %3O'/U'WV9Y<GHU4WU_R
MCX:GD#V/=OY/3_XJ=XY^H^^S/+D]&JF^O^4?#4\@>Q[M_)Z?_%3O'/U'WV9Y
M<GHU4WU_RCX:GD#V/=OY/3_XJ=XY^H^^S/+D]&JF^O\ E'PU/('L>[?R>G_Q
M4[QS]1]]F>7)Z-5-]?\ */AJ>0/8]V_D]/\ XJ=XY^H^^S/+D]&JF^O^4?#4
M\@>Q[M_)Z?\ Q4[QS]1]]F>7)Z-5-]?\H^&IY ]CW;^3T_\ BIWCGZC[[,\N
M3T:J;Z_Y1\-3R!['NW\GI_\ %3O'/U'WV9Y<GHU4WU_RCX:GD#V/=OY/3_XJ
M=XY^H^^S/+D]&JF^O^4?#4\@>Q[M_)Z?_%3O'/U'WV9Y<GHU4WU_RCX:GD#V
M/=OY/3_XJ=XY^H^^S/+D]&JF^O\ E'PU/('L>[?R>G_Q4[QS]1]]F>7)Z-5-
M]?\ */AJ>0/8]V_D]/\ XJ=XY^H^^S/+D]&JF^O^4?#4\@>Q[M_)Z?\ Q4[Q
MS]1]]F>7)Z-5-]?\H^&IY ]CW;^3T_\ BIWCGZC[[,\N3T:J;Z_Y1\-3R!['
MNW\GI_\ %3O'/U'WV9Y<GHU4WU_RCX:GD#V/=OY/3_XJ=XY^H^^S/+D]&JF^
MO^4?#4\@>Q[M_)Z?_%3O'/U'WV9Y<GHU4WU_RCX:GD#V/=OY/3_XJ=XY^H^^
MS/+D]&JF^O\ E'PU/('L>[?R>G_Q4[QS]1]]F>7)Z-5-]?\ */AJ>0/8]V_D
M]/\ XJ=XY^H^^S/+D]&JF^O^4?#4\@>Q[M_)Z?\ Q4[QS]1]]F>7+SE[L%IJ
MEB;7YGD5;!%(R9*>IJ62Q*Z-=456N8J'JTT:737Y^1ILG+MAASJ9=:SARQ$2
MU9E<W,CFWS;VCJ3:9A>YI;@
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MMQ>NMR,WN._NDN/SY4_%Z<G3^"PWYZ^/%CNNF#TN
M  H2Y_Q06;WF_P"(5)S)_$_#J*!J?]@RO$G^VZ^SIK^
M
M
M
M                  !1O=?^B-X^<E_,1'.T/@RH7N7^$OX_FU7D=%?0 !BW
M&Y6^T44MQNM5%14$"<TU34/;'&Q-=-7.<J(A$S@F*S,X0Y#[XN=8=F&"6:@Q
M:]T=WK8+HDLT%'*V5[8^C(WF5&^#53R9]HF(P6/<])R\V9M&$8,SN?Y[A>([
M9UUKR>^T5IN,MXJ)HZ:LF;%(L3X(&HY$=X%5JIJ3D6B*\+'?%+9F=$UC&,.^
MZSHJVCN5)#7V^HCJJ*H:DD%1"Y)(WL7L5KFZHJ'KB<5>F)B<)>X0
M           !0ES_ (H+-[S?\0J3F3^)^'44#4_[!E>)/]MU]G37\
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ML5W2N5ZL]DHKI;;K8$@=<:*\4GF4S$JN;D\3G<OX'X6G:@3@L<(
M
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M\3H\RQGKI:*UTT<3:N-(ID=3R.B<CFHYR=K>&CE E0
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M9J3(,?JFUUGKFJ^DJF-<UKVM<K%5$>C7)Q:J<4%JS6<)VD3$QC#9F*0
M*$N?\4%F]YO^(5)S)_$_#J*!J?\ 8,KQ)_MNOLZ:_@
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M<\#TDAE:CXY&KJUS7)JBHJ=J*@8N=]G_ .)??+_W+\74)=%A
M
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M;?$O6T<O#B]E2J-]21B!,NM;U_J>X>]IOS;@Q4AW,OW 6#WS<?CDH3*_0@
M                     4;W7_HC>/G)?S$1SM#X,J%[E_A+^/YM5Y'17T
M4%WEO_';<?/S?\#3S9W$Z>A^ER)D8M[^IVH!!>[?5OM^#9[7QMYGTM^ND[6^
MJL4+'(G]XV::,>#KO+K_  HY&V[L-BH'[=TF?U4:5.799+5UMXNLOCSR*E5+
M&QB.7BC6M8G!/"=;6VGG\SBJX6DC&G.G;9,X-M,<QW),CSJS)+1W"^4+H+E0
MQ.:VBDD8G-UUCY>$JZ:<R+ZO#531Z:UJQ6>*6[T45F;1QHGW:[;;JW8_&&UE
M)#4-=%-S)-&R1%_'2)QYD4VZR9C.EJTL1.5"'X1C-!:-W=U=G;4^:@PV]VJ"
ML93TKD1:22MAY)NBKT<C.9)G:</ GJ&>9>9RZ7G;$II7"]JQLPB?EQ>V\UOQ
M#&MM;7L-C%O;=LMNC(*:P6UC46>)Z.3FKI7(FC-%1RJY=->/@11D3:UYS+;(
MV]XSHB*<R-L[._\ $UN>R5N%;J;85D5&N:93:L?2WS8O3H]:QJL8YJW&-ZM?
M&GC(Y/'T[/OI.5A;+M'@QCM[AF<%ZSMG#9W6\V(KDO.ZFY-^K*+]F+S7>8MG
MPR5KDJ8&0Q(WSJ5>1C%ZJKKXFO;Q]?#41AEUB.&.'A[B<KAO:=FS@[OQN@:B
MCI*OE\ZIXY^7V/58U^FOJ<R*>%ZE#["V^@FS/>-DU+#(V+*IFQM?&UR-;X_!
MNJ<$/;J/!IXKS9/A7\;N0JC>B@K:?>W+,QLJ<MUP:V66_4K6(G&*"2.*5FG9
MIR2*O9X#U9$_^**SLM,P\^;'_DFW'6(GMX]A9O>"O-/G5FQ?"K+,DMNR*"IR
M2OD;V_)=HI_.41R>!)7JUO;VH>;31-)FW4X/CEZ,["V%>KP_%"8]VG]QN'>]
M9OC4QKU?K;<J=/ZJO(M<\KT      4)<_P"*"S>\W_$*DYD_B?AU% U/^P97
MB3_;=?9TU_
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M'JJ_A:A$M%L__$OOE_[E^+J!T6$
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M=13]1J+IX41=%]<,52=S+]P%@]\W'XY*$ROT(
M%&]U_P"B-X^<E_,1'.T/@RH7N7^$OX_FU7D=%?0 !07>6_\ ';<?/S?\#3S9
MW$Z>A^ER)D8M[^IVH!#NZ[&R;%\RBE:CHY,DKVO:O8K7,C144SR-GQO-K_"C
MD>>,VW=?9)E7B-@Q9,XP-L\M38*FGK8:&LI&U+UE?!+'*CD<U'O=HY/N^'1.
MS><O.^=,\VW&X%(OD_-B.=7B;_"\:W'O64WO<3/F-LTU7;G6BQXC35'G,5/
MJI)U9Y6JC'RJ[5.#>Q?!V&O,OEUK%*\/#C,LZ4O-IM;@X,(A$ML:O?';K!+7
MAC-KFW&>W,>QM:Z^T=.QZOD<_56=-^FG-_.-N=&3F7FW/V]9JRO2TK%>;LZ_
M]&XQ3"=R<5MV<[G7.FI[MN]E,3&T=GIGM924;8=600MD>[1S6(YKGZKQ1FFN
MJZFF^92TUI'!6&^E+1C:>&T_"(0[;2AW9P!:R\5VT\U_SF[N=)>LFJK]2,GG
M5SM48QG1>D<:</%:[_R:;<VV7?@BV%8V1A+#+B]>&:XS.V<4QR.R;A8_N/0;
MQ8YC"7M]TL4-JR+&FU<45522HY)M89GIR/Y5T8NC>.BKX>&JEJ33F3.'#C$M
MEJVB_.B,>#!L-N\9S*\[G7K=K,+.W&DJK9#9;58^NRIJ.E%)U'S3OBT;JKDT
M:W3L^YJL9EZQ2*5G'AQQ32LS>;3P<&"Y3R-ZI]H,.R'&,HW-N-[I/-J3(,@E
MN%IDYV/ZU,[GT?HU55O;V.T4].=>+5K$<4-.72:S;'CGN0QZ3;^ZU6^&9Y#=
MZ!'X=?<?IK4R=7L5)9$5B2,Y47F3@B\50F<R/116-L3B12?23/%,1W4+VFVD
MSNQVK*VYE DMPH;+)BV&JCXW<]!_I,JOU:Y=%D?*Q/&TT1#;G9U+3'-ZN,\K
M7E9=JQ./)'(M/8[&[SB&U.-8WD%/YI>*""2.JI^9K^1SIY'HG,Q51>#D[%//
MJ+Q?,F8V2VY-9K2(GBA8)H;0     *$N?\4%F]YO^(5)S)_$_#J*!J?]@RO$
MG^VZ^SIK^
M              .8^ZQ?[%17+<ZS5ESI*>\5F;W1U';YIXXZF9O!-8XG.1SD
MX+[%/ $RDVYO=]R+--R:?<W$L_GPV]06YEJ_$6]*QZQM?(YRH]:F'1'(_14Y
M5[.T&+:;>[4[J8GDT%YRG=NMRVS1QRQRV2HMK*:.1TC=&.63SF54Y%\;@WCV
M:@;;:7:--K:W,JM+Q\JIEMWEO*,\V\V\VZSGNZ6O5EZFG-[+1OW ([O_ -V^
MR;Z):JUUT6P9%:T= RYLIDK$EI'JKNC)'U857E?XS%Y_%U=P7FX")2O,=K(L
MJV?EVFCNCJ*)]NH[6RZN@2=S6T*Q:/6))(T57=+BG.G:!)\,QW]D,/Q[$_.?
M//D&V4=K\\Y.EUO,J=D'4Y.9_+S<G-R\RZ>JH0HGO.S2YQD>WNPU ]VN5W)M
MRR!(UT<RT6_5[]>*=NDCV_XT03#H^&&*GBC@@8D<,349'&U-&M:U-$1$3L1$
M"%;0;1M@WOJMY?EA7+4V=+-\B^;:<JHYB]7SCJ\?8>PZ7WPDW'VC;N#FNWN8
M+>%MRX'73UZ424W7\\Z[Z9_)U.K'TM/-^WE?V]G #VWNVK^V/!)L*^5OD7JU
M,%5Y]YOYYIYNY5Y>GU8>W7MYP0PMZ-FF[O;?4F"?+2V9*2IIJI*_S7SOF\UC
M?'R]/K0^RY]=>?@")63<K?1W>W5=IN,+:BWU\,E+5P/XMDAF8K'L7UE:JH$*
MJVVV0J=OMK;]M;+DS[O;;HE?';JR2D2!]%!<8>FL?(D[TDY7JZ3M9JKEX($X
MI/M!MY]E.W5FP'Y2^5_DCSK_ -H=#S7J^=5<U5_FNI+R\O5Y?9KKIKZP0K;<
M#NK6#-=V;3NM0WE]EK*6JHZV[VYE*V=E;-0R,<U[7]6/I.<UB,>O*_7MTUUU
M)Q3*^;/_ +1;S8_NQ=+TLM%C-%)2VK'/-OQ;:F5)$=4.G65=5_&>QZ7:UO'@
M!9X0J7 -I:3:3+<]S.+(F,Q3*IOE2HL]1 VGAH)F.?*^3SETRMY/QDFJ=-B(
MW3^:$H+LA<;?=N\7O;<;55PUUOG2S+!5TTC9H7HD#FJK7L56KHJ*G!02Z4"
M
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M)<_XH+-[S?\ $*DYD_B?AU% U/\ L&5XD_VW7V=-?P
M                                              !$(-JMMJ;(ERVF
MQ2UQ9,M0^L6ZLI(FU/G,JJKY>=&Z\[E<JJ[MU74"7@      QW4%"^M9<GTL
M+KC&Q8HZM8VK,V-5558C].9&ZKV:@9             8MSMEOO-OJK3=J6*M
MME;$^"KI)V))%+%(G*YCVNU145% TN+;?X1@[JIV'X_06-]:C$JW4%/' Z5(
MN;D1ZL1%5&\SM/N@20
M                                 ,>OH*&ZT-3;+G3QUENK(GT]723L
M22*6&5JM>Q['(J.:Y%5%10-!BVW.!X1/45.(8Y;[)45;&QU,M#3QP/D8U=4:
MY6(BJB+QT DX      ,>FH*&B?/+1TL-/)5/66I?%&V-TLB]KWJU$YG>NH&0
M            &CR?#<4S6CAM^76:CO5#3R]>""NA9.QDJ-5G.U'HNBZ.5 ,J
MPX]8L6M<-DQNW4]JM%.KE@HJ.-L,+%D<KW*C6(B:JY550-D
M           4;W7_ *(WCYR7\Q$<[0^#*A>Y?X2_C^;5>1T5]   #F/ON?N]
ML7%?];)P\'_AY#M[H]9/(\6K\&&9W*=?LJN/SW4?%Z<QWMZZ.3OITO@_&Z0.
M,]@                    "A+G_ !06;WF_XA4G,G\3\.HH&I_V#*\2?[;K
M[.FOX
M
M
M                                        %&]U_P"B-X^<E_,1'.T/
M@RH7N7^$OX_FU7D=%?0   YB[[BI]GMB3PK=DT3_ /IY#M[H]9/(\6K\&&;W
M*?W57+Y[J/B].8[V]=')WTZ7P?C=('&>P                    !0ES_B@
MLWO-_P 0J3F3^)^'44#4_P"P97B3_;=?9TU_
M
M
M
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M;_B%2<R?Q/PZB@:G_8,KQ)_MNOLZ:_@
M
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M._V9'*M+:+]74M(BKKRQ>(]&IZVJJOWQI_!F.N]&_(_\M;<=J1*ZCU*\
M               !0ES_ (H+-[S?\0J3F3^)^'44#4_[!E>)/]MU]G37\
M
M
M                         QKC7TUKM]7<ZQW)244,E34.]2.%JO<O\B <
M?TEGK\?[OV";W0PN=D^/7R;-+FC$YGS6^^5CXZR).S@^GDB5SO48H9)O@590
MY'B^[&>R6NZ9);<RR6IH*2+&WHVOJ;1;V14%/)#)UZ?1J(UZZI*GB^KV!#66
M+ \%K+U;J7[-MRJ+K5,3%K*^Y/920HKTUDF5MX<[IM]D[E:JZ=B*O "X=S,0
MOF6VVHJK+N%<,.HX*29DSZ!*5:;5BN5\LLCV)*WE1.5>G,SET\"Z@:+NN5T%
MRV0QFLI[1!9F/2I8Z&EZO2G=#4R1+4ZS*Z15F5O.Y7N5=5]30$M'#;;+N-W@
M\W;FM/3W&Q[:VVU4MHMM>C):*.>\T[ZRHJW12:L5Z,:V/G>G!$X<4U J2U7.
MAQ_:S>;/=M$AL=ORG*(,=QZLIM8H(+>V:*E6IAT7\6Q?.IWQZ*U&*O!&Z(@2
MG>]FVN!X;A.%XIA%FI*'-ZK(+328S<((HTNBSPSMDGJ7S(B2/1&(YTKGNY=7
M(J^ (AMZ+#[+NAWC\UO62TS;E8\'H+39*&WU"=2BFK*ADE<]\D:^+(L"RKHU
MZ*B.=S::M:J!7U%<JNQ[$YM5XG-'8[?GFX-;;[+54J)!%16RX5L5O<^+ET:S
M1D$FBMT1NNJ::($I?O)MY@N)6_;3%L#LE';,RFR>UQV&II(6-N+8*-RRU51)
M*B))(QC$YIG/<NJJBKQ"(9UCPC'MT]_MP\GRNABO%AQ1+;C]IMU8Q)Z%]6RE
M=-422PO16/="Z=S8T<BHG.KNW30-=F^/T^V.X5TS+*L7M.7[:9Q46FQHZ6.)
MU?96I&VDC@B@G:Z.2F<J([DA5J^%4\7B'0]_N46.XY<[PUC4AM-%/5I'IHQ&
MTL3I--&]B:-\ 0K;NU6UEIV6Q>JJI4?<K^R6]5]3(J(^>KNDSZE7+ZKN5S6_
M<:$RKG<;&KSA^Y>UE=D.456X$%TR&&AI\<O;(H_-9'ZJMSIXZ%L$3G4NNNLL
M3^75--.U Z6O+[?%9[A)=HF3VIE-,ZN@D8DK)*=(U61KF.X.16ZHK5X*$.8\
M IJ3;KNM5FZE!:**GSJIMMSO-/<F4L/7ADN4\JTZ,?R<W38Q\?B>QT3U GC>
MEDV$RO),*LF-W>DQ>V6J>2AO%VRNADJKOD=PJ6RMJI9TJ9Z>F2*2=>"R<\G*
MU5:FK08I3A]DLFYV[^X^1YG1TUXBQ*K@QG';7<(V5$%% R!)JF=L,J*WGJ)'
M?YSEUY6\J+H!I\\V_P 3R;=#;':2S4<=%@UFH[SEESM= JQT\E-52MB8QO35
M.6*6::1'(W@K'JUN@'MCZV'"]UMZ<HQ^VT=IL&'8];8:BEH(64U/+51TD]P>
M[EB1&\S&(UCN'J)ZH%;U^UV/XSW28[E7VV"Y[@9=3VU:6OKXTEJ8JB]UL<D4
M-.YZ*Z%(VS.>K8]-7\[E15<H3QKHR"+Y5[Q&W]@<KIHL*QRZ9#._17<TE<L=
MLB56IKJ[Q9'-3M[?4"&CV+P[#-Q]O)]SMP+5;[_D&>5E;57"JN4454M/ E5)
M24]' ^1%6-D;(VM:UG*J.7U40$F*V;$LPW2W(R#-Z2CJL=V^;28WC]!<TCFH
M;=104J35<RQS<S$61VGXQR:HQNFH%8VEM!2=VG<.\8E2)24^Y.45%LQ>F8CF
MHENK*V*VT\*(JJJ(R)DVC?O)H@3QNRZ&DHK#9Z:AATAMULIF01JO8R"FC1J:
M_<:T,7-.RV)X_!ME?=_[_9X+MF%WEO.66^2XQ-J'T4<,]140,IN=%Z2N<SJJ
M^/1RJY./BIH3+3X7M%G6XNU<*72FQ579[3,NU\S:J=47>_R^?Z3HK8W4T$4,
MD+%2)C&SN;%R\./$)Q2V]X=8<][P]EPV].=<,<P#$XJF6WSOYFU=75U36,94
ML_[2-&112O1>#G(U')IP4A%9+C:L2;WELOQ"&"@Q&FI*.R6^.B8R&C=>X:%]
M/.Z-K$1K5CFJ(VOY4\95"4H7'4H,K[ONUW27I8S;JF_7>+BBMGMM RFAD5/5
M6IF>J^N$,K9S&L3W)I,PW0SZW4%]NEZO-QH8_E6&.I9;[1;I5IX*1C9VJD2(
MUJO?HC5=S:N!+YL>-8OE6^.4V6_T---A^T=ELUHQNR5G+-04Z7*D6HDJ%BE5
MS5<R)C(D>_\ !3U4U A&%)AE'M9O]N'8[52?LE<*ZOI[#1)"V2CDAM-/_HDD
M<;^9K8W5,[I&(B:,7V+4T1 EN\OQU^V?=\Q#'</IJ2R9EEBV'%KC?6-913I)
M<T:M2Z6JCC<]K55'M5ZHY6(NJ<40(2G']D;V[)<0NEUM6,8G9<*F?4VZAQ=M
M14UM2]T*PHR>MJ(:5>GXW,]O3<KU[5\(,6AN]CCVXW/JZK/<9M68X=NKD=+1
M6Z_S,BFN=OK*MB,I:.6&H:[GIX^DJQNB=XB(KEXZ- MK?#(OV5VAS2^-=R30
M6FJBIWZZ:5%4Q:>%?O22-!#G_<':G$,-V!QG&K324]1N?D=78:.S7U[&3W)]
MS?-3O>Z*9=7MABA8]C&M=R,9HGAU4E):NDS/</?/-*RWVO'[]0X,E#9K+;\F
MJJB.&A?64[:FHJHZ6&EJ&R22KJQ)'.8Y&MY454["&OW VYKL$V8J-O$KJ=]_
MW3S.CAG6VTZTM!1S76IBE?%20*YRM@CCI=/&7U54#H7#=O\ #\!H?,L5M-/0
M/D9''6US(V^>UBQ<RMDJI].I,_5[W<TCEXN7U0A4EKMV/[A[Y;BW;.Z>EN%E
MV\I[=:['17)(Y:.E2LIG5=;5/BEUC1SE1&]1R<&-[>' E4MDJZ6U;.;@Y)@'
M)8+;N'FS;!8ZZGUA;3662>.C9+'JOXM$:L_*B*B1Z^+IH@2L+>3;S!<2M^VF
M+8'9*.V9E-D]KCL-320L;<6P4;EEJJB25$221C&)S3.>Y=55%7B$0V&/X98]
MS>\!N'E62TC+K9,42V8_:;?5-2:B?5QTRSSR2Q.16/="Z9S8T<BHG.KO9::!
M7-JJ)_L1MMML<[;-C^[.Y,]LB?1KYNE+8[C6S,?'3Z<&HYE(L;&IVM=H$I]N
M?A.%X[FVS..;?62AL^5Q9'!6-?;H(XJE+!;X)%KTF<Q$<YCV\C5=(JJY=>*K
MJ$/K;_ <8W.W6W2W#RZVP7N@I+TF,VBVW"-M30M=9Z6.">;HRHYCW*YW*QRM
M7E\?3M4"0(C<C[U'-2HCJ3!\3Z5=(W7Q*^\U/-%$O@XP,5Z XEW!     *-[
MK_T1O'SDOYB(YVA\&5"]R_PE_'\VJ\CHKZ  */W]^D6V7SXO^",\FHVU6/<_
M@9WBK )>03M0" ]VS_5>:?[2UO\ U8QI]D\KU;\\/+\2%K7O+,7QOD_:&]4-
MK63_ #;:VIB@<[_)1[D5?O'MK2UMD8JW-HC;+-H;I;+I1MN-MK8*RWO17,JZ
M>5DT*HG:J/8JM7^4QFLQ.$IB8EI(]Q]O)G<D.6V61_\ -9<:5R_R)(;/17ZD
M_(QY]>K"105$%5"RHI963T\B<T<L;D>QR>JCFZHJ&IFUD&5XM4W)UFIKW;YK
MNU5:ZWQU4+ZE')VHL2/5VOWC+FSACAP(QAMS%(             "A+G_ !06
M;WF_XA4G,G\3\.HH&I_V#*\2?[;K[.FOX
M
M
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M]YO^(5)S)_$_#J*!J?\ 8,KQ)_MNOLZ:_@
M
M
M
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M,P           4)<_P"*"S>\W_$*DYD_B?AU% U/^P97B3_;=?9TU_
M
M
M
M                              HWNO\ T1O'SDOYB(YVA\&5"]R_PE_'
M\VJ\CHKZ  */W]^D6V7SXO\ @C/)J-M5CW/X&=XJP"7D$[4 @/=L_P!5YI_M
M+6_]6,:?9/*]6_/#R_$A=QZE=                    H2Y_P 4%F]YO^(5
M)S)_$_#J*!J?]@RO$G^VZ^SIK^
M
M
M
M !1O=?\ HC>/G)?S$1SM#X,J%[E_A+^/YM5Y'17T  4?W@OQ-VVXKI/%I*>^
M(DTJ\&MYT9IJOKZ*>34<7*L>YN&N;''-5@$O(:HG%>")VJ! N[4BOL675;>,
M%1DE<Z%_@<U&Q\4&GV3RO5OSUF7'4I'=7:>I70                   *$N
M?\4%F]YO^(5)S)_$_#J*!J?]@RO$G^VZ^SIK^
M
M
M
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M-_Q"I.9/XGX=10-3_L&5XD_VW7V=-?P
M
M
M
M      *-[K_T1O'SDOYB(YVA\&5"]R_PE_'\VJ\CHKZ   'R]C)&\LC4<WU'
M)JG]\)Q?UK&,3E8U&M3P(FB!#^@                     4)<_XH+-[S?\
M0J3F3^)^'44#4_[!E>)/]MU]G37\
M
M
M
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MZK?65?,RYRIYL_-G;X-N'AB.TZ=.N^I@
M
M
M
(       ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>tm2227887d4-lc_3lnp4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_3lnp4c.jpg
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M%!04%!04%!3_P  1" *T!H(# 1$  A$! Q$!_\0 ]  !  (# 0$! 0
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MP].$_]H # ,!  (1 Q$ /P#OX
M
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MJT$
M
M
M                              KG7WQ*7]]!SNHJ!,-YIEXMK.^@Z9\$
M:!"5
M          "GN=1X@+V[&C_#& 3"X00
M
M
M                                                         "N=
M??$I?WT'.ZBH$PWFF7BVL[Z#IGP1H$)4 YF\Z.L><-R,][T8J3\I_)9U/?N'
M(_FLV\RY<OKOX/H=$$X.@[IK*K=MBM7 ADI"Z3 E3TL&K(3AQ65.DDU8'ACE
MPQP!"F>;1S@JOKJFY_E:C1J2J@' W1Q77'2=*=QG',2RV9=QT/1!,POP$
M                                XUT3UJU-NOG+7#95?KJY=K,/UEN/
M3#8CH;;1"?4EDDJ0TE?2DDBQS8GT<093#LH&(                      *
M>YU'B O;L:/\,8!,+A!
M
M
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M+$$;CJ$$         "GN=1X@+V[&C_#& 3"X00
M
M
M
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M"=KZ, Q         %/<ZCQ 7MV-'^&, F%P@@
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MNT/7V7J<V,J*S$SC]6Z\.O\ =_,TN3.;-HM%</KG!88LBK@
M
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M[=C1_AC )A<((
M                         51H/]GZGV9_1(%/]V/0W\;N0N?O7Z>GB]V5
MKBX*8                                J*;X^:=V.KX&\*9F?S->+]$
MKOE_PE^/]=5NBYJ0
M                                                     *YU]\2E
M_?0<[J*@3#>:9>+:SOH.F?!&@0E0
M    "*7UIK8^I<&-3;XH[=7APW>,16W''6C;=-.4S)3*T*VEPEC@ WM&H],M
MZDPJ%18R8=)IS+<6%%;QRMLM))*$EF,S/ BZ)@,X      ><B/'EL.1932'X
MSR3;>9=22VUH46!I4E6)&1EPD8"I*AS6] JE,X_(LB(A_,:LD9Z7$9Q/_P!3
M'>;;P]++@"<5@6G8]H6)3U4NSZ+$HL)9DIUN&TELW%)V$IQ?KEF6/"LS,$-^
M               "GN=1X@+V[&C_  Q@$PN$$
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M9J24LW\Q*-+:DI,DD:<$G_"X1LS<BV76)G;+#+SHO,Q&\M$>9N
M  5%-\?-.['5\#>%,S/YFO%^B5WR_P"$OQ_KJMT7-2
M
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MG:O3W&VC0^V[BI.*,2Z3#UQ .H00
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M^B5WR_X2_'^NJW1<U(
M
M
M
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M\T[L=7P-X4S,_F:\7Z)7?+_A+\?ZZK=%S4@
M
M
M
M                                    51H/]GZGV9_1(%/]V/0W\;N0
MN?O7Z>GB]V5KBX*8         /XM"7$FA:24A18*2HL2,CZ!D8##^2*3^H1_
M:4>H)Q'O'AQ(F;BK#;&?#/ND)1CAP8Y2+'#$0/8                  5%-
M\?-.['5\#>%,S/YFO%^B5WR_X2_'^NJW1<U(
M
M
M
M                                     %4:#_9^I]F?T2!3_=CT-_&[
MD+G[U^GIXO=E:XN"F                                *BF^/FG=CJ^
M!O"F9G\S7B_1*[Y?\)?C_75;HN:D
M
M
M
M                             "J-!_L_4^S/Z) I_NQZ&_C=R%S]Z_3T
M\7NRM<7!3                                %13?'S3NQU? WA3,S^9
MKQ?HE=\O^$OQ_KJMT7-2
M
M
M
M                     !5&@_V?J?9G]$@4_P!V/0W\;N0N?O7Z>GB]V4_N
M6ZK=LZE.URZ*DQ2Z4R9$N3)62$YE;"271,SZ!$6(N5:S:<(4V(F=B+6AK?I;
M?54*B6U<3$JKK)2FH3B7&'7$I+$S;)U*<V!;>E&V^1>D8S#*:3&U8(T,
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MA;E;?FP;L6IS
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MPV;EICN)2-SK@
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M^I"_,6*IU=_*ZSBR/RV=34?M<KCOVX;P6MRP
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M:(\[: *BF^/FG=CJ^!O"F9G\S7B_1*[Y?\)?C_75;HN:D
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MUW_4A?F+%4ZN_E=9Q9'Y;.IJ/VN5QW[<-X+6Y8
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M0#E-TV\,:'W3B== .4W3;PQH?=.)UT Y3=-O#&A]TXG70#E-TV\,:'W3B==
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M$   T=,^TM=_U(7YBQ5.KOY76<61^6SJ:C]KE<=^W#>"UN6
M
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M ')EIMX'4/N9$ZT <F6FW@=0^YD3K0!R9:;>!U#[F1.M ')EIMX'4/N9$ZT
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MWT9"^#H'I6%O
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M3NQU? WA3,S^9KQ?HE=\O^$OQ_KJMT7-2
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MZ)"GNJ                         *BF^/FG=CJ^!O"F9G\S7B_1*[Y?\
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MJWQ[MIO]W 8G(S5/*K?'NVF_W<!B<C-4\JM\>[:;_=P&)R,U3RJWQ[MIO]W
M8G(S5/*K?'NVF_W<!B<C-4\JM\>[:;_=P&)R,U3RJWQ[MIO]W 8G(S5/*K?'
MNVF_W<!B<C-4\JM\>[:;_=P&)R,U3RJWQ[MIO]W 8G(S5/*K?'NVF_W<!B<C
M-4\JM\>[:;_=P&)R,U3RJWQ[MIO]W 8G(S5/*K?'NVF_W<!B<C-4\JM\>[:;
M_=P&)R,U3RJWQ[MIO]W 8G(S5/*K?'NVF_W<!B<C-4\JM\>[:;_=P&)R,U3R
MJWQ[MIO]W 8G(S5/*K?'NVF_W<!B<C-4\JM\>[:;_=P&)R,U3RJWQ[MIO]W
M8G(S5/*K?'NVF_W<!B<C-4\JM\>[:;_=P&)R,U3RJWQ[MIO]W 8G(S5/*K?'
MNVF_W<!B<C-4\JM\>[:;_=P&)R,U3RJWQ[MIO]W 8G(S5/*K?'NVF_W<!B<C
M-4\JM\>[:;_=P&)R,U3RJWQ[MIO]W 8G(S5/*K?'NVF_W<!B<C-4\JM\>[:;
M_=P&)R,U3RJWQ[MIO]W 8G(S5/*K?'NVF_W<!B<C-4\JM\>[:;_=P&)R,U3R
MJWQ[MIO]W 8G(S5/*K?'NVF_W<!B<C-4\JM\>[:;_=P&)R,U3RJWQ[MIO]W
M8H7JY9%S6%IM<EXT?5"\7ZG1X:I,9J7+@+84LE)+!:6X#:C+;T%$ Z(!
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M>FI1=*!$NE:1'D0Z3 B2\.-,1V6G\'7)!;Q""2K!U[](O:7KU],KA/:"&:
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M#!D            J*;X^:=V.KX&\*9F?S->+]$KOE_PE^/\ 75;HN:D
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M_=N]^IK-=-E1.YX?;AOQ;G*    5SH5XL*5V35?K24"96,"
M                                              57SD_$5?7T8O\
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M:0Q.=-R-4&6CQ:3)CK-"S;,S,\BL"4G$^ QXL_*\W>:O3E9G+K%D[&EM
M %13?'S3NQU? WA3,S^9KQ?HE=\O^$OQ_KJMT7-2
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M7BPI79-5^M)0)E8P(
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M %U6Z+FI
M           -#9EKQ[,MV-;L60N4S&<DNI><(DJ,Y4ER29&1;-AN&1 -\
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M > AO++^QUO?1D+X.@!O
M            57KI\UV3]^+7^LFP3"U 0     *YNWQNZ<=C7!U"*"5C @
M       51H/]GZGV9_1(%/\ =CT-_&[D+G[U^GIXO=E:XN"F   T%\?8VX/H
MZ5U%0W9/I*\<,;[)<&<T'QU4_L&=U(6KK3T$\<.9IO#?1(4]U0
M  !&;VT_M/4.GLTVZZ>4QJ,YOHCR%K8?8<,L#4TZTI*TF9<.![>B-E,RU)QB
M6%J1:,)8%CZ46/IX[)EVY 654F$2)=3F/NS);B4[22;KRE&1;>!.!"<S-M?;
M**9=:[$U&IL        5%-\?-.['5\#>%,S/YFO%^B5WR_X2_'^NJW1<U(
M
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M36HS4^3'@PEK5L=DS%DVPVG#'$UJ,B2 V*5)6E*T*)2%$1I41XD9'P&1@/Z
M                         *KUT^:[)^_%K_638)A:@(     %<W;XW=..
MQK@ZA%!*Q@0         *HT'^S]3[,_HD"G^['H;^-W(7/WK]/3Q>[*UQ<%,
M  !H+X^QMP?1TKJ*ANR?25XX8WV2X,YH/CJI_8,[J0M76GH)XX<S3>&^B0I[
MJ@                        "HIOCYIW8ZO@;PIF9_,UXOT2N^7_"7X_UU
M6Z+FI
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MB*OKZ,7^>@$PM0$
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M WA3,S^9KQ?HE=\O^$OQ_KJMT7-2
M                               5SH5XL*5V35?K24"96,"
M                                          8-:^9ZAV,]U-0"#Z!>
M)2P?H.#U%()E8P(    57SD_$5?7T8O\] )A:@(
M                   :RXZ["M:WJO<U3)9TZBPI-2F$RDENFQ$:4\YD29D1
MJRI/ L2 5U'UU8EQVI4;3V]G8SZ$NLNHHN*5H669*B,G]I&1X@G!Z\MO^'5\
M=Q/Z\# Y;?\ #J^.XG]>!@<MO^'5\=Q/Z\# Y;?\.KX[B?UX&!RV_P"'5\=Q
M/Z\# Y;?\.KX[B?UX&!RV_X=7QW$_KP,#EM_PZOCN)_7@8'+;_AU?'<3^O P
M.6W_  ZOCN)_7@8'+;_AU?'<3^O P.6W_#J^.XG]>!@<MO\ AU?'<3^O P.6
MW_#J^.XG]>!@<MO^'5\=Q/Z\# Y;?\.KX[B?UX&!RV_X=7QW$_KP,#EM_P .
MKX[B?UX&!RV_X=7QW$_KP,#EM_PZOCN)_7@8'+;_ (=7QW$_KP,#EM_PZOCN
M)_7@8'+;_AU?'<3^O P.6W_#J^.XG]>!@<MO^'5\=Q/Z\# Y;?\ #J^.XG]>
M!@<MO^'5\=Q/Z\# Y;?\.KX[B?UX&!RV_P"'5\=Q/Z\# Y;?\.KX[B?UX&!R
MV_X=7QW$_KP,#EM_PZOCN)_7@8'+;_AU?'<3^O P8U0U]A4F!*JE3L&](E.@
MLN29DIZC$AIIAE)K<6M1OX$E*2,S,#!:\9]$J.S*:QW;R$N(QV'E61&6/Y00
M]0    %5ZZ?-=D_?BU_K)L$PM0$     "N;M\;NG'8UP=0B@E8P(
M %4:#_9^I]F?T2!3_=CT-_&[D+G[U^GIXO=E:XN"F ".W_\ 8:Y/HR7U%0V9
M?A1QM6=X%N*5<:*^+&WO^X7U58]^=X<N'I_1PGPTO0K&;^\5:/T/*_IQLMZ*
M>-KR_P!S7BEM[SO&]KCU%Y)].9C5%?@PT5*Y;F=9;EKB-/\ \TTRP[TJEK+
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MQ_KJMT7-2
M            5SH5XL*5V35?K24"96,"
M                       8-:^9ZAV,]U-0"#Z!>)2P?H.#U%()E8P(
M57SD_$5?7T8O\] )A:@(
M0?6?Q/:@_=JL_ '@(;RR_L=;WT9"^#H ;P
M                 $'UG\3VH/W:K/P!X"$JHOS/3^QF>II 9P    "J]=/F
MNR?OQ:_UDV"86H"     !7-V^-W3CL:X.H102L8$         "J-!_L_4^S/
MZ) I_NQZ&_C=R%S]Z_3T\7NRM<7!3 !';_\ L-<GT9+ZBH;,OPHXVK.\"W%*
MN-%?%C;W_<+ZJL>_.\.7#T_HX3X:7H5C-_>*M'Z'E?TXV6]%/&UY?[FO%+^1
M:E"L7G+W&NY'4P8-]TJ JASGCRL+D4YLF7&#6>Q*NE-1$9ECLZ)D(F)OIXP^
M[,X_2]\3%,Z<?O1'U)MJ%JW1[)=HU,@-)KUS5V:S"@T2(\DGS0X>"WE&25DE
M""VXJ+;^4:,K(F^,SN1&^WYF=%,(VS*"6E4Z;3><UJDNI3&(:%P*.2%2'4-$
MH^)QSP(UF6(].9$SIZ8<,]MYLJ<,^_T=I@:X5>DZBWGIYIO:LYJHU=FM-UFJ
M.1%$\F'#BMJ(UN+1TI9B6K!.;'9Z9##(K-*VM;<C#!MS9BUJUCAQ:6W;/L[6
M'4C4F9JJ>:KT2H+I-,IA2%T\X].:-Q+3V9A32G<R4DK%9J27H8&,[9ELJE>1
MLF,?I8Q2,RUN5MB</H_JG/-EJ<M^V+@M]N0FHVU;5:DTNW*LAM#)2(39)46Q
M"4D>4U>NZ./I#3JHCE1._,8RVY$[DQO1.$+=N+[/U7L.1U)0\M=L-\JSYKWB
M(M#_ +J9\/D#T:OTMN-HTWHJ\2CIM.DQJ/?FH=*;QK-B:E5"KH<09DX<%4M3
M4ILN@:5)4E2L2X$CV8XVBL[+4B/JW'FB/LS;FVF?KW?J8&J;A7KIUJ)J\LE.
M0JS5XE'MEY9&G_PBF*-O,DCX$NND:C],C$Y/V<RE.#=GCDSIY67>W#LXH_KB
M[>'(=$          %13?'S3NQU? WA3,S^9KQ?HE=\O^$OQ_KJMT7-2
M                                                          :F
MVK=IMJ49BA4A*TP(ZWG&TN*SJS27EOKQ4?\ IN*P ;8
M 57S@INHL#3R2_IBF0JODM12#C(95EA<7>-Y2EN.M+;RD69"V,SN\)!)+ S!
M,*M36N<7YNQ3S;G<H&]P-1LP\WR+\GYM[OBE;[UOZ3>_[SQCI<F7: _AUKG%
MGS=3G[J>6H&]PQW,//\ (OR?FWN^XUOO6_I-[_O/&.ER9=H#]_+/.(\W1R>;
M<[E"WN"#)F)F^1>(9MZ3W&M]ZS])OC_VGC'2Y,-H"T.;[-U&GZ>1W]3B?*OF
MX@H_&6VDF<'BS)LJ2MMUU;F8C-2UOY7=X:R46P@)6H"
M        !@UKYGJ'8SW4U (/H%XE+!^@X/44@F5C @   !5?.3\15]?1B_ST
M F%J @                                       !!]9_$]J#]VJS\
M> AO++^QUO?1D+X.@!O
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M_P )?C_75;HN:D
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MNIJ 0?0+Q*6#]!P>HI!,K&!    "J^<GXBKZ^C%_GH!,+4!
M                           "&ZNQ9,W2>^X4)E<F9)MVKLQX[*3<=<=<
M@O)2A"4D9J4HSP(BX0&YM!IUBTZ"R\A3;S=.B(<;61I4E26$$9&1[2,C ;D
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M4S,_F:\7Z)7?+_A+\?ZZK=%S4@
M                            %':/Z7Z9UVP(-6KEF4*IU63*JBI,Z;2X
M<B0ZI-2DI(UN.-*4HR(B+:? "93GD8T>\GUM=QH'601B<C&CWD^MKN- ZR!B
M<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN-
MZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^M
MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&C
MWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B
M<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN- ZR!B<C&CWD^MKN-
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M.#U%()E8P(    57SD_$5?7T8O\ /0"86H"
M                                !6>M.C=*UEM]BCU.=(B+A*6]"2VK
M_9C?<RD2WD)P4O(DE9"):2Z8\<03$M!>?-MMFZM.:3ITBJU!%.M_?'1SDNI=
M02GEYD;\D(;4X3*,6VBS%L]=G/:!B7IS;K:NO3FE:=IJM113Z!OU4<Y+Q.I)
M3SF9&_R(;4X3*3-#73%L]=G/:!B7IS;K:NO3FE:=IJM113Z!OU4<Y+Q.I)3S
MF9&_R(;4X3*3-#73%L]=G/:!BLVR[2@6-;,"U*5(DR:;34K;B+G.$\^EI2U+
M2V:R2C%+9*R(Q+'*18F9XF9#?                      "#ZS^)[4'[M5G
MX \!"547YGI_8S/4T@,X    !5>NGS79/WXM?ZR;!,+4!      KF[?&[IQV
M-<'4(H)6,"         !5&@_V?J?9G]$@4_W8]#?QNY"Y^]?IZ>+W96N+@I@
M  -#?'V-N#Z.E=14-V3Z2O'#&_@RX+YH/CJI_8,[J0M76GH)XX<S3>&^B0I[
MJ@                        "HIOCYIW8ZO@;PIF9_,UXOT2N^7_"7X_UU
M6Z+FI
M        *YT*\6%*[)JOUI*!,K&!
M            "J]"_FN]OOQ='UDX"96H"    &#6OF>H=C/=34 @^@7B4L'Z
M#@]12"96,"    %5\Y/Q%7U]&+_/0"86H"
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MV =_>L_DD_YCI_6P#O[UG\DG_,=/ZV =_>L_DD_YCI_6P#O[UG\DG_,=/ZV
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MBF^/FG=CJ^!O"F9G\S7B_1*[Y?\ "7X_UU6Z+FI
M                                          *YT*\6%*[)JOUI*!,K
M&!               /PTZT\VEUE:7&EEBE:#)23+TC( :=:>;2ZRM+C2RQ2M
M!DI)EZ1D -.M/-I=96EQI98I6@R4DR](R &G6GFTNLK2XTLL4K09*29>D9 /
MV                       "J]"_FN]OOQ='UDX"96H"    &#6OF>H=C/=
M34 @^@7B4L'Z#@]12"96,"    %5\Y/Q%7U]&+_/0"86H"
M                          $'UG\3VH/W:K/P!X"&\LO['6]]&0O@Z &\
M                                     59S</$Q;/\ ;OK"2"96F"
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MHU(06PL2;/@]$:\O[.9A&^Z>J_\ ?T/+MX67;#'YI="#W*H
M           J*;X^:=V.KX&\*9F?S->+]$KOE_PE^/\ 75;HN:D
M                                                      P*+1:7
M;U.:I-&CE$IS*G%M,)-2B)3[BGEGBHS/:M:E</1 9X              ANJ-
MO71=-F3:)9U1*D7#(<CG$J9R'XG%]V\A:G"5'(U+-)$9DV?2K]:K89@*.TPT
M>UDI&B4^TYM6.EW3.73W*(^NI3&UTIJ.X2EH-M@EMI-K U$AI1H>V$X9 G$T
MPT>UDI&B4^TYM6.EW3.73W*(^NI3&UTIJ.X2EH-M@EMI-K U$AI1H>V$X9 8
MFE^CNL=&T4J-K3*N=+NNH'3UT1]=2F-KI34=PC6V;;!*;2;73+)#2C0_C@X9
M 8IAS7M/K^T]LE<"_'C5(D)C*@0URG7EPV6TK2<8V3Q9:R*/',RH\^;%6T@)
M7F"                       57H7\UWM]^+H^LG 3*U 0    P:U\SU#L9
M[J:@$'T"\2E@_0<'J*03*Q@0    JOG)^(J^OHQ?YZ 3"U 0
M                            @^L_B>U!^[59^ / 0WEE_8ZWOHR%\'0
MW@                                    "K.;AXF+9_MWUA)!,K3!
M  "#ZS^)[4'[M5GX \!"547YGI_8S/4T@,X    !5>NGS79/WXM?ZR;!,+4!
M      KF[?&[IQV-<'4(H)6,"         !5&@_V?J?9G]$@4_W8]#?QNY"Y
M^]?IZ>+W96N+@I@ BNIOBZNOZ)F]06->;X$\3VZ']Q3QH[:O=%_%=;/8O](L
M>7+\&'<ZQ_<7XT\&QSE6U+]X^QOHJ;^9(&N/20ZG_P ?F>-'<=!#W*F
M                   J*;X^:=V.KX&\*9F?S->+]$KOE_PE^/\ 75;HN:D
M
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MV.KX&\*9F?S->+]$KOE_PE^/]=5NBYJ0
M                                  "N="O%A2NR:K]:2@3*Q@0
M                               JRQ/'/JW_ ,.?5[@)6F"     !5>A
M?S7>WWXNCZR<!,K4!    #!K7S/4.QGNIJ 0?0+Q*6#]!P>HI!,K&!    "J
M^<GXBKZ^C%_GH!,+4!
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MS/K2H\34G$B_%AAG9N$>;B<>&>'^C/+IC/+F-W>^;^J_!XGH
M  !44WQ\T[L=7P-X4S,_F:\7Z)7?+_A+\?ZZK=%S4@
M                                            %<Z%>+"E=DU7ZTE
MF5C @                                   !5EB>.?5O_ASZO<!*TP0
M     *KT+^:[V^_%T?63@)E:@(    8-:^9ZAV,]U-0"#Z!>)2P?H.#U%()E
M8P(    57SD_$5?7T8O\] )A:@(
M       1Z_;@DVG8MSW3":0_,H=)GU..R]CNENPXSCR4KRF1Y3-&!X& BD1>
MO$N(Q+3)M%*7VT.DDXU3Q(EI)6'^\>F"7MNM>?UNT?<U3^, &ZUY_6[1]S5/
MXP ;K7G];M'W-4_C !NM>?UNT?<U3^, &ZUY_6[1]S5/XP ;K7G];M'W-4_C
M !NM>?UNT?<U3^, &ZUY_6[1]S5/XP ;K7G];M'W-4_C !NM>?UNT?<U3^,
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M!=JQS(#R)+!/526ZT:VE$HLR%+,E%B6TC$VU%K1AN=A,941..[V96@/,V@
M            J*;X^:=V.KX&\*9F?S->+]$KOE_PE^/]=5NBYJ0
M                                                     "N="O%A
M2NR:K]:2@3*Q@0          #'A3H-3BMS:=):F0G<=U(CN)=:5E,TGE6@S(
M\#(R/TP"%.@U.*W-ITEJ9"=QW4B.XEUI64S2>5:#,CP,C(_3 (4Z#4XK<VG2
M6ID)W'=2([B76E93-)Y5H,R/ R,C],!_8DR)/83*@R&Y459J)#["TN-F:%&A
M1$I)F1X*(R/TP'N                   "K+$\<^K?_  Y]7N E:8(
M%5Z%_-=[??BZ/K)P$RM0$    ,&M?,]0[&>ZFH!!] O$I8/T'!ZBD$RL8$
M  *KYR?B*OKZ,7^>@$PM0$
M  (/K/XGM0?NU6?@#P$)51?F>G]C,]32 S@
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M7-2
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M->+]$KOE_P )?C_75;HN:D
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MI 9P    "J]=/FNR?OQ:_P!9-@F%J @     5S=OC=TX[&N#J$4$K&!
M     JC0?[/U/LS^B0*?[L>AOXW<A<_>OT]/%[LK7%P4P  &JK]LT"ZH7R=<
M5.8J4+',34A!+(E>BD^$C_ ,;5BVUNR<_,RK<JDS640IVA6E%,EIFQK9BJ?0
MHE(WV=Y*3+@,DK49?Y!KC)I&\]]^M=5>,)O*PTI2A)(0DDH26"4D6!$1= B&
MYRG]                         5%-\?-.['5\#>%,S/YFO%^B5WR_X2_'
M^NJW1<U(                                      !J[D<ELV[5W8$E
M$*<W"DJC3'2Q;9=2THT.++HI2>"C <$V;3N;%7;:@574;4NOMWU)0:J^A<R0
MK"82C)>1:(KQ+1LZ11.*Q+H] &6Z[TM9NEM6Q16J(^N5140(J:=*<,U+=BDR
MDFEJ,R29FI&!GB1 Q:G4&MWE1*(TJP[?3<-R3I*8<9E]Y,:)%);;BSE25F9'
MN6\A$I*.F49D1;3 5QS8:C=<^BZ@,WI555BOTV]ZO3I$LU+-G&*S%0:6$K_F
MV<V8T(+ B(P3*XZ]5F*!0ZG7918QJ9$?FO%_H1FU.*_R)!#B_32185UT.@(O
M+G"7A3[_ *RRE^92X=R+CPVGI"U&VRE2V7$(7E-)&VI[,2MF!< ,G8<RX+8M
M"+!@7!<$6"O<DVP]5YC++\@F4I2I9J=4C.K@-:B+A,&+"Y3=-O#&A]TXG70$
MI2I*TI6A1*0HB-*B/$C(^ R,!_0         !5?-L\15B_1B/SU@F5J @
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M7'1ZH2X\"#?%&D393B&(T=N:TI;CKJB2A"2)6TU&9$1 G!/P0
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M$*%0JK;]5J%1>JLMV*\B>;)I2EMO.1IW3:#QQ]$&42^C=%^9Z?V,SU-(,&<
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M)Q:B(S(\,<!Z=/U5I<B_+RZ86XYGMR\VIZWU6HIR,R^->#"([40DHZCD@
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MRDT"A4N? DT.?(=D.S29R+(T;K!&[<6?"71(&<0^BM%^9Z?V,SU-(,&<
M      *KYMGB*L7Z,1^>L$RM0$                            *KE?O(
MTG[CU/ZW@ E:@(     %66)XY]6_^'/J]P$K3!      JO0OYKO;[\71]9.
MF5J @   !@UKYGJ'8SW4U (/H%XE+!^@X/44@F5C @   !5?.3\15]?1B_ST
M F%J @                 4EKM?FJEF-37K<L6FW+IVU252*_4JG/C1FT&I
M3R'V%,/.H4XG=$@]B#S9\I8GL!,.::70:U8<^CZFS- Z51*=*EQ#B52;6'WH
MD)R8ZE#3JXSDEPF.G4G*IYI*4*PPR@E] P8@#\,LLQVTLQVTM,IQRMMI)*2Q
M/$\"+9P@/XRPQ'1NX[2&F\3/(VDDEB?">!8 ,>)2*5 ?>E08,>+)DGC(>8:0
MVXX>./3J21&K:?1 8USUGO<MNLW#N.,_),&3/XMGW>\XJRIW)GRJRYLN&.4\
M/0 ?.*]-=N776'36K?('R!\DU.!%W/'./;S>3VEYLVX8RX<&&!@SP?3(&
M       @^L_B>U!^[59^ / 0WEE_8ZWOHR%\'0 W@
M "N8'CYN'[HT/ZSJX)6,"     !5>E7VVU<^\K'U/!!*U 0     *LYN'B8M
MG^W?6$D$RM,$    (/K/XGM0?NU6?@#P$)51?F>G]C,]32 S@    %5ZZ?-=
MD_?BU_K)L$PM0$     "N;M\;NG'8UP=0B@E8P(
M
M    &HNI%-=MBMMUEU;%(7 E)J#[1F3C<8V5$ZI)EB>))Q,L '*=J6/SAKJT
MQA6/:EX6Y+TAJL%=/A7$Y$EL515&=S,*;..ZRG!6[S)(CZ' Y_"!DZOMFA1K
M7MNCVS#<6]$HT&-3H[KIXN+;B,I92I9_QC).)@Q;0      <6\_2B46EVG:3
MU,IT6$\]4I!.N1F&V5++<$?3&A)&>WT090[$HOS/3^QF>II!BS@
M!KZ)1*3;=)B4*A1$0:1!0342(T1DVVV1XY4XX[-H#8
M           *KE?O(TG[CU/ZW@ E:@(     %66)XY]6_P#ASZO<!*TP0
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MX&1\(#]---,-(990EMEM)(;;01)2E*2P(B(MA$1 /V
M   KF!X^;A^Z-#^LZN"5C @     57I5]MM7/O*Q]3P02M0$     "K.;AXF
M+9_MWUA)!,K3!    "#ZS^)[4'[M5GX \!"547YGI_8S/4T@,X    !5>NGS
M79/WXM?ZR;!,+4!      KF[?&[IQV-<'4(H)6,"
M
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M-0"#Z!>)2P?H.#U%()E8P(    57SD_$5?7T8O\ /0"86H"
M    !#M5XL6;IS<<.=!J=3AOPUMOT^@%FJCR%&1&B.6!XK/\'  XGB4?3>U'
MZ<TNQ]7:$Q*EL1HB9!E#CN2'7"2V@B-M!*-2CPREM,&3Z$@Q     &KN2/59
M=NU>)0GBC5M^%):ID@SRDW*6TI+2S/ \,JS(\<# ?.>_+9UBMG6+31C6*NMU
MVI/U*"NFNM/G()M@I[1*29FTUABK;P&#-]+ 8
M          "N8'CYN'[HT/ZSJX)6,"     !5>E7VVU<^\K'U/!!*U 0
M *LYN'B8MG^W?6$D$RM,$    (/K/XGM0?NU6?@#P$)51?F>G]C,]32 S@
M  %5ZZ?-=D_?BU_K)L$PM0$     "N;M\;NG'8UP=0B@E8P(
M
M             &-4')C,"4]3V2DSVV7%Q8ZE$A+CR4F:$&HS(B)2L"Q,P'+-
M[7+SG;UH$^PJSI70X'?'&>@M/2:U =6UOD&@WVFN-&I2VLV=)I29I41'@#+<
M=,6I3ZG2+7HE*K4OY0K,&!%BU&?M_P!HDLLH0Z[MV].LC5^,&+;@     #C7
MG^3H4JT;01%DM/+14I&=+:TK,OT!<)$9X RAUY1?F>G]C,]32#%G
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MW;XW=..QK@ZA%!*Q@0
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M\G'D1ACQF=J,S-PY<XX<38CT/.          "JY7[R-)^X]3^MX )6H"
M !5EB>.?5O\ X<^KW 2M,$     "J]"_FN]OOQ='UDX"96H"    &#6OF>H=
MC/=34 @^@7B4L'Z#@]12"96,"    %5\Y/Q%7U]&+_/0"86H"
M      !R=KA3M/KKYR%"M?5RH1XEC1;/=GQ4SZA\F1TU&1.>9S$Z;C19S0VD
MR3FVY-I&18 RA0=/:TY+0>@7BBI0W-<"N1B2[)54"<K9-MS%(0HV3=-S*2$H
M41FC#@4"7TM!@     ,&MTF+7J-4:%.-90JG%>A23;,DKW4EM3:\IF1X'@H\
M-@#Y\ZNZ,VAHSK3I=3+07,7&J=0A29)SW4/*SMU!I!930VW@6 ,L7T4!B
M      *(UI(CNN)B6/\ X>UU=\>7-VM=MKVT3(BN"?@6'^QGU5 G*VE=J\1Z
M6P                   !7,#Q\W#]T:']9U<$K&!      JO2K[;:N?>5CZ
MG@@E:@(     %6<W#Q,6S_;OK"2"96F"    $'UG\3VH/W:K/P!X"$JHOS/3
M^QF>II 9P    "J]=/FNR?OQ:_UDV"86H"     !7-V^-W3CL:X.H102L8$
M
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MKMR<=UC.&^_=G\GW'G^]'=\>W7Z?)O\ '=9B_P#2[.'#@"O)WB,-Y,AL9
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M2:E8&ZTA)F1$9X8C.F?2\X1.Z]>DZ\T6JS(R\K,Y5IWL+1LXXA,AO=P
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M \%),RV&-]+UO&-9B8^9HO2U)PM$Q/SO89L    %5ROWD:3]QZG];P 2M0$
M    "K+$\<^K?_#GU>X"5I@@     57H7\UWM]^+H^LG 3*U 0    P:U\SU
M#L9[J:@$'T"\2E@_0<'J*03*Q@0    JOG)^(J^OHQ?YZ 3"U 0
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M1&2DF6)&1\)&0(<4\ZZ)$B:\:/)B,-L)5*B&HFD)01G\IM<.4B!E#M<&(
M   (-=-NZH5*K*E6I?,*@T@T(2FGR*$FI.$X1=,K?',8Q)7H9-@):3O-UU\J
M5,_95']Y *WU I5YTRM,Q[LN6-7JDJ*A;4R/34TU"6#<<)+9M%(?Q,E$I6?-
MMS88;-OES=K5?:]-/:3>M3J<IFTKGC4&<AC.]*D4Q-32MG.DC039R&,IXF1Y
MLQ\&&&T3E;2FU8G>;KKY4J9^RJ/[R'I;4@M"@:DTJI.R+QO.'<5,4PIMJ%&H
MJ:6M#YK0:73=*6_B1))2<F7;FQQV;2$T <W2?]X>_P!=7^<Q5YVJ=;:NS3_[
M(T[_ .VZNX.]I?11\M]9-%Z&OT]M)1ZGM '\4I*$J6M1)0DC-2C/ B(N$S,!
M7MVZ@V!4+9JT&%=M$=ER(SC;+15.&1J6I.!%B;I$//J:S;*M$;9AY]32;95H
MC;,*!WU.[<4CNM3OC JGJ&?S>TJOJ&?S9^IT92M2-.H]+A,/7?0TNM,-(<3\
MIPSP4E!$9;'?1%ORXPK$3P+=E5F*1$\$()7-;*G%JTN/1G:3+I3;AE$E%G>)
MQOH*);;Y)5CZ*1PM1UCFY>9-8B,(^:>^X6?UCG4S)K$1A$\$]]([.U<HM0@R
M'KPK5'I$M+V2.TY);B9VB0DS427WE&>T\,2'0T.HOG5F;1&Y+H:'47SJS-HC
M<G>6#3*M2ZW#14:-.CU&GN&HFY<-U$AE1H/*HB6V:DG@98'M'1=%F  "N8'C
MYN'[HT/ZSJX)6,"     !5>E7VVU<^\K'U/!!*U 0     *LYN'B8MG^W?6$
MD$RM,$    (/K/XGM0?NU6?@#P$)51?F>G]C,]32 S@    %5ZZ?-=D_?BU_
MK)L$PM0$     "N;M\;NG'8UP=0B@E8P(         '.?-XM"U[BMBJ2J[2(
ME1D-3S;;=DM)<4E&Y;/*1J+@Q,<K29=;1.,8OFONEH-/GZ:]LW+K>>7OQ$_=
MJN#DPT[\&*;[F;]0>[U?+X%T]CZ+H:>3!R8:=^#%-]S-^H'J^7P'L?1=#3R8
M.3#3OP8ION9OU ]7R^ ]CZ+H:>3!R8:=^#%-]S-^H'J^7P'L?1=#3R8.3#3O
MP8ION9OU ]7R^ ]CZ+H:>3!R8:=^#%-]S-^H'J^7P'L?1=#3R8.3#3OP8ION
M9OU ]7R^ ]CZ+H:>3!R8:=^#%-]S-^H'J^7P'L?1=#3R8.3#3OP8ION9OU ]
M7R^ ]CZ+H:>3!R8:=^#%-]S-^H'J^7P'L?1=#3R8.3#3OP8ION9OU ]7R^ ]
MCZ+H:>3!R8:=^#%-]S-^H'J^7P'L?1=#3R8.3#3OP8ION9OU ]7R^ ]CZ+H:
M>3!R8:=^#%-]S-^H'J^7P'L?1=#3R8.3#3OP8ION9OU ]7R^ ]CZ+H:>3!R8
M:=^#%-]S-^H'J^7P'L?1=#3R8.3#3OP8ION9OU ]7R^ ]CZ+H:>3!R8:=^#%
M-]S-^H'J^7P'L?1=#3R8.3#3OP8ION9OU ]7R^ ]CZ+H:>3!R8:=^#%-]S-^
MH'J^7P'L?1=#3R8.3#3OP8ION9OU ]7R^ ]CZ+H:>3!R8:=^#%-]S-^H'J^7
MP'L?1=#3R8.3#3OP8ION9OU ]7R^ ]CZ+H:>3!R8:=^#%-]S-^H'J^7P'L?1
M=#3R8.3#3OP8ION9OU ]7R^ ]CZ+H:>3"HT4:E4+G*T6GT:&S A)BN+*/'03
M:,RH$C$\"Z)CPQ6*ZB(CY;BG6T^5D=?95<NL5CDSN1&'W;NB!U7T<
M                               &NKYU,J%4SHF!UDHCYTXE88<:W:MU
MCCB6&? !\]VU<W-&D4I^L+J:.<6A+ZW%NJJ15GOF)Q60\2_19=[@9X[<.']*
M#)W]9AUP[/M\[G^TITV'\L]#_;MPC?\ _P!YF!B_5Q6E;5W-08]STN/58U-E
MHJ,)B6C>M(EM(6VAPT'TJC2EQ>!*(RVX\)$ JCFVD1%JX1%@1:E7'@7N8$RD
M/.+4^C0V^SC9MY\DODK)M/=JP)?!T,IGCZ0$-=>;=.\U^L-D2>()LAWBQ$9Y
M>EI>+.!E_I$G #?5]7KPU_MK3/2A.DUNHKQRK9@KKJY$=4A;3Z8<;(1X/-8&
MK%>/#P .:.<3>.OUS46BL:Q6TU0J:Q*<7376HRHYN/FW@I)F;SN."=O 0,H?
M2JB_,]/[&9ZFD&#.              &BJME6;799SZW;M,J4Y220<J9"CR'3
M2G@+.XA1X%T-H#"Y,M-O ZA]S(G6@&#4=)[)DFT=.H=,IF3-O"C4^.C>8X89
MLB4XY<#P_"/%J=-.=A]KDX/=IM5YG'&O*Q?JGZ4V/&0M-0H-+J:E&1MJDT^,
MLT%T23G2KA&6FT\Y43&..+'4ZCSTQ,1R<&9R9:;>!U#[F1.M#UO&V%(L^TK?
MDKFT&@4ZE3'$&RN1!AL1G5-*,E&@U-(29I,TI/#TB ;H          <WSO\
M?9/_ 'J_SC'SC,\.>-]#R_!CB7%IK]E(_P#WK_5#%QZI_;QQSVU1ZU_<3Q1V
MDN'6<H   !5<K]Y&D_<>I_6\ $K4!      JRQ/'/JW_ ,.?5[@)6F"
M!5>A?S7>WWXNCZR<!,K4!    #!K7S/4.QGNIJ 0?0+Q*6#]!P>HI!,K&!
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MXSKHSK%IH6N<AN15CJ4$Z2IHH!$4?C[6<CX@A"?7?QMH,GTL!@
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MJ?[T%&[#7\ DCF3^Y^7 H&I_R#*\2?RW7V.FOX
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MD24I(O0(BP!#D'_S _L?9WTG(^#D#*'6M%^9Z?V,SU-(,6<
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M==(GK?JL.JLLRXB'G($AJ4E"CJ31D2C:4HB,R]$&4.XP8@
M    U51MJAU:04JHPTOR"22"6I2R/*6)D72J+T1IODTO.,PT7R,N\XVC&7ZI
MENT:CNK?IL1,=UQ.1:DJ4>*<2/#IC/HD)IDTI.,09>12DXUC!LQM;P
M            57I5]MM7/O*Q]3P02M0$     "K.;AXF+9_MWUA)!,K3!
M "#ZS^)[4'[M5GX \!"547YGI_8S/4T@,X    !5>NGS79/WXM?ZR;!,+4!
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M#UJ09Q+Z247YGI_8S/4T@P9P
M    "JY7[R-)^X]3^MX )6H"     !5EB>.?5O\ X<^KW 2M,$     "J]"_
MFN]OOQ='UDX"96H"    &#6OF>H=C/=34 @^@7B4L'Z#@]12"96,"    %5\
MY/Q%7U]&+_/0"86H"                 !7VN=+=K6D-XTJ/&FS),NFO-,1
M:6TJ3,<=/#(3;23(U]-AF21[4XD"8<SVQ5;2APZ3"G<U>M-U%E+#;\OY&>>2
M3R<"4YO7H^<RQZ;%6T$NV08@    #7UVD1K@HE2H,U:VX=5BOP9"V3)+J6I+
M:FE&@U$HB41*V8I/\ #YZZJZ)6KHGK/I?2[5F5"9'JE0@R9"JFZPZM*VZ@T@
MB0;#+)$6'HD8,L7T:!B                                T-ZSI=,M&
MM5& Z;,R-#>=8=(B,TK2DS(\#(RV#SZFTURK3&V(>/6YEJ9%[5G"8B7+_*YJ
M+V]=]K8ZV*C[0S^=VGSWVOJ^?/U=YUE27G)%*@R'E9WG8[2W%'T5*01F>STQ
M<\N<:Q,\#Z3E3,TK,\$,P9MH   "J]*OMMJY]Y6/J>""5J @     59S</$Q
M;/\ ;OK"2"96F"    $'UG\3VH/W:K/P!X"$JHOS/3^QF>II 9P    "J]=/
MFNR?OQ:_UDV"86H"     !7-V^-W3CL:X.H102L8$         "C>:_]D:Q]
M)'U!H<[0^#*A>Y?[2_C_ *:KR'17T   !0]:MS432S4.N7WI]1DW5:MV&V_7
M[?2ZF-,8G-8IWS"C)1*)68S46'1/'H&/;%Z9E(K:<)KLEYIK:MYFN[$[7[ID
M;5O5"]Z#<%Q4QZP['MMXYB*5QHW)U1E%AE2^3>0B:]%*B,N$MN.R)G+I68B>
M5:>Q"8B]K1,[D1];=:_V?<-Y4*WH=NPSF2(5=@S9*"4E.2.RO%:^F,N AKR+
MQ69QX)9YM9M$8<,=M,-1ZE=M,M*<Y8M,.JW2^11J>UG0VAI;N);]9K,BRMET
MV'1/ AKRXK-HY4X0RO,X;FU6K?-RI3FE;]KSI!R+]EN_+<FYU&9R#K^"E)>)
M9GCD2:C1_J[?7#T^LSYSE1LV8?-P-/F(Y&$[=N/S\*?Z53KXEVC&CZB4XX%T
M4\^)R7B6EQ$LF4DE,E)I,]KG"HO1](>?-BO*^SL;J<KD_:VIL-3-R5#B:ROZ
M@RM0;STN>NFI1WL;8C.U9F+#I3"59D[IG<O$;F)$HW#5P]#':.GCE<CDQ?#A
MW-KPX9G+FTUB>#=V?4Z1LBN7+<-%^4+KMP[7JF^6W\F*E)G'NDDG*YO$-MET
MV)[,O0'@S*UB?LSC'8>NDS,;L82A>F]HW!0]4=4*_4XAL4FORX#M*D&I)D\A
MAA25F1$9F6!GT1MS+Q.72(VQCVV%*3%K3PX=I'+BD:E4JZ:XW5M/X]^FY)4]
M8M=2U#),!E?3-L2%+1G032C]?CBK#'HXC.L4FL86Y/"B9M$[,>!.]'+$FV#9
MJ85:=2_<U5E2*Q7WFSS-G.G+SK2@_P"*@LJ/3,C/HC5G9D7MC&R-R.*&653D
MUW=NWLK &AM          !0E3_>@HW8:_@$D<R?W/RX% U/^097B3^6Z^QTU
M_                                      !BU)N0]3I;,20424XRXAB
M69$HFG%(,DN8'L/*>T!RE>MN<X*T+4J]TIUWBSD4>*].>B<0ALK<:CH-Q26S
MZ?%PR+!"3(LRL"Q(&3IJR:BFL69;M73-74DSZ9"E%47&R87))^.AS?*:(S)!
MKQS&DCV8X Q;T      ?/KG@ZVZ=ZH4.@4:S:@[,J%(J$AR<VY&>CDA)M[O8
MIU"2/IBZ ,HAWO1?F>G]C,]32#%G
M -4JY[:0I2%UF"E:3,E).2R1D9<)&68>6=7D1]^OE0]4:3.G[EO)EGQ)D2>R
M4F#(;DQU&9)>96EQ!F1X'@I)F6PQOI>MXQK,3'S-%Z6I.%HF)^=[#-@    J
MN5^\C2?N/4_K> "5J @     598GCGU;_P"'/J]P$K3!      JO0OYKO;[\
M71]9. F5J @   !@UKYGJ'8SW4U (/H%XE+!^@X/44@F5C @   !5?.3\15]
M?1B_ST F%J @                 1K4!JGO6966JI7W[6IZXYE(N&(_Q1^&
MC$OTJ'C]89<&(#CB_P"1:UIT1JOVASB;GN>IQ9L(G+=9KZY4B;'=DMMO(9)I
M98+2VI2R-25)/###:#)W8#$     :ZOUABWJ#5*_);6[&I421.>:;PSJ1&:4
MZI*<3(L3).S$P'SPU,UOM_6_6;3&JV_3IE.9I51@Q7D3]T2E*<J#2R-.Z6LL
M,/1!E@^D ,0                               &NKU);KU%GT9YQ3+4]
MA<=;J"(U))PL,2(QJS<OSE)KPPT9^5&;EVI.YRHP5-YN5%[=RO:FQQO8].=*
MM?#F7SY[$+CAQDPX<>&E1J3';0T2CX3)"23C_D'<K&$1"TTKR:Q' ]QDS
M 57I5]MM7/O*Q]3P02M0$     "K.;AXF+9_MWUA)!,K3!    "#ZS^)[4'[
MM5GX \!"547YGI_8S/4T@,X    !5>NGS79/WXM?ZR;!,+4!      KF[?&[
MIQV-<'4(H)6,"         !1O-?^R-8^DCZ@T.=H?!E0O<O]I?Q_TU7D.BOH
M          ()=^E=)O.JIJTVMURGO):2P3%+J+D./@@S/-NT$99CQVF-U,V:
MQAA$\<,+4QX6B1H#;Z%I65T749I,C(CK3YEL]'8,_6)X*]ACYN.&>RM@>9M
M                %"5/]Z"C=AK^ 21S)_<_+@4#4_Y!E>)/Y;K['37\
M                                  %4:KZFQ;/NZQ['J[41%MWV57B5
MBI3)'%2BLPX[1D:5F:4EG-[+BH_0P!*LF=!.9NR\ATY]*=)"B5NW+C,T*P/'
M!1%*+$@,9=-4U%/;IT1NDDT5*0RVF"4;+N"CD@B;W>7I<F7#+ALP!#*
M '"'/7TQL&Q;<MJI6C0(M(G5"HR$37XR5$IU)-9\%8F?1/$&4.X:+\ST_L9G
MJ:08LX                              59_\R/\ \#_^]P2?_,C_ / _
M_O<!5,KOLXR]OOD[>[Q6\R;_ "YL3QPQVX8CY[F<CESMVK[E\ODQLV)W:G+A
M\B,]Z_>I\DYW,ORE\H\8WF<\^.YZ7#'@%MZKP]7C#AGMJKUGCY^<>".TW?\
M\R/_ ,#_ /O<=5S$YM;OM^24]^WR=\NYUY_D;?\ %-UCTF'&.GS8<((;H
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M'8UP=0B@E8P(         %&\U_[(UCZ2/J#0YVA\&5"]R_VE_'_35>0Z*^@
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M]OOQ='UDX"96H"            %5\Y/Q%7U]&+_/0"86H"
M   !55>T<B7+K3#U+K:(%2H,:W?D$Z+.C)DF<DI;D@GRWA*1@27,O!B"<4M3
MIIIRA25HL^B)6DR-*BIL0C(RX#(]V"$H      &KN0ZRFW:NJW4DNX"A23I*
M3R8',)I6Y(]X9(]?E]<>'H[ 'SGOQ[71[6+30]<X[<>K%4H)4E+1P#(X_'VL
MYGQ!:T^N_C;09OI8#          :RHW%0:0^F-5*C'B2%()Q+3SB4*-!F9$K
M SX,2,8S:(1B_M.N&AU=U;%+J#$QY"<ZT,N)6HDXD6)D1\&)A%HG88MD,D@
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M^]!1NPU_ )(YD_N?EP*!J?\ (,KQ)_+=?8Z:_@
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MDQ#4EN2^X\DE;Q!8D2U&1'@8PRIF98UE<@]#8
M             JRQ/'/JW_PY]7N E:8(     %5Z%_-=[??BZ/K)P$RM0$
M          *KYR?B*OKZ,7^>@$PM0$                 "C-?ZUK?:,69>
M=B5NWZ98M&IA/U-FKMONSES$NN9MT3;#B3):5,H01K+IL<<"V@F%<UZ[^=G9
M=K4^_+OK5KQ;5=>@E5#986[)A,3WFVDN.H)LDF23<22MTM9ECB1&"=QUR#$
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MAK^ 21S)_<_+@4#4_P"097B3^6Z^QTU_
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M1X?C&,VB-LLHK,[(?I"T.)S(42DGP&D\2_R"8F)V(F,'Z$H
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M4E8GF,_1'JT^=.9$S+V:7/G-K,SPI(/4]@
M "K.;AXF+9_MWUA)!,K3!    "#ZS^)[4'[M5GX \!"547YGI_8S/4T@,X
M  !$[^LYV](E"C-2TPSH]>I5>4I2#<WB:5*3(-HL%)P->7*2NAZ!@)8
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M\S?UKUS?7Q6+5BO)QV?.F [[@    *KYR?B*OKZ,7^>@$PM0$
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MK]#TZB6T>HNB,6V;0,H5.8NYSY,GR&)&5*&G)S##1N,9C(C4O>*,CX>FV +
MU0YS6G.D=RHM6ZFJDNIKBMS2.%';>:W3REI3TRG4'CB@^@!@Y/U=UFM#6;6G
M2ZIV@B8B-3*A"C22GM(95G<J#2RRDAQS$L 3@^B@,0                !6
M=?T[K=5K,RH1WXJ69#AK0EQ;A*(L"X2)LR_RCE9NDO:TS$PXV=H;WO-HF-WY
M<"365;LVVX$B+.<:<<=>WJ39-2DY<I)VYDIV[!Z]-DSEUF)>S29%LJLQ/"DP
M]3V@   *6+7*<9$?R*UM_P#YA76Q6_:]N;]?]%<]KVYL=E9UI5U=RV_#K;C!
M1UR=[BRE1K).Z=6WPF1<.7'@';TV=YW+B^&&/?=K39TYN7%YC#'OMV/2](
M        (/JQ4JA2K27+ILER))*0RDGF5&A>51GB6)>B/!KKVKE8Q.$XN5UI
MF6IDXUG"<84O0[SNQ^MTUEZM35M.2F$.(4^LTJ2IQ)&1ECP&0X>5J,V;Q$VG
M;"KY.KSIO6)O.V-]U +6OH     JSFX>)BV?[=]8203*TP0    AVK4*94M*
MKYIU.CNRZA+M^K1XD2.A3KSKSL)U"&VT((U*4I1D24D6)F DM(0MNE06W$FA
MQ$=I*T*+!1*)!$9&1\!D S             %<W;XW=..QK@ZA%!*Q@0
M    *-YK_P!D:Q])'U!H<[0^#*A>Y?[2_C_IJNY]HGV'63X'$*0?_6+ =%?7
MSCHL)VE,2J')(TRZ/-F4^0@^$EQY"T_YL!=,FW*I$NQ2<:PV$.L-VQ=-JW;(
M/"'0ZO&E3E<.6*K%IU7XB7B->JIR\N8ACFQC5]#6G6WFT/,J);3B26A:3Q)2
M5%B1D?H&0I[DOV  /*5)8A1GIDIQ+46.A3KSJSP2EM!&I2C/T"(@B,1\[6ZJ
MJXZK7+K4G(5>J4J<TD^'<J<-#?Y4I(Q<=/3D4B'7RXPJ_DB*Y4JA0Z,R6+U4
MJ]/AMI+A,UR$J/\ (23$ZBV&7,F9.%9?1C81>@1"FN0ITM>XIT]5WIH#W)>W
M/^3EW8<AO$OTNX.1Q,DFYN2<Z7-CCAMRCU>8G'DX_:X&KSL88[RNM:[Z5<NF
M^F5_3Z2_2X[]SP9Y4[-QF1Q9I2U),B2E.*EI3F2G#HX#?I\O"]JX_=EY\^^-
M*V_]56\OKG'V36+(N6D1J1<+<FH4J=$9<?I3K;25OQUMI-:C/I4D9[3Z!#&F
MEM%HW:[>%G;/KA.Y/DR\[9U-G65I)I7;=N0&*G>%S4]MNFLS'N+1&FHS>\=>
M?7LZ5*>@1D9C+,RN7F7F=R(ECEWY.72(VS$=I):5JY=E+N\[(OF'2')\^GRZ
MA0:K07W7H;[D%DWG6'&W3-Q"B21GB9ECALX1IG)K->57';NXMT9DQ;DRU6G%
M^:S:Q4%JI*I--MRSJS$E14UQAQQR>W(2E;)OL-*=PRI=(TI)6WI<<1GG967E
M6PQF9AADYELRN.&$2CNK5@:8:9Z,(LQ-.8J-[U!M$6B2D,8U:;55*2:I!*3G
M<26;%1EGREZT;,G,OF9O*QW-_@B&O-I6F7R=_>X9ET+9L2LP+3HL*X7N,5R/
M"8;J#QF2C4^E!$O$RQ(SQZ/1'/MAC.&Q[(V*?:UAU'NBK74S8L"WS:MB=(IZ
M*)5)+Z:S/7%VJ4RA!I2@EXY49BX>B/7YFE8CE8_:CZ&B,RUL<,-QO;JU<N2F
MQK-H-%MQ)ZE7DDU-T.H.FVU!2T@UON/J01&I*,JL"29&> PIDQ/*F9^S7ZV5
MLR8PC#=ECR[KU(2W==GZ@4.&VE= FS:=7Z'QA=/<P862VG-_BI"RVX9C+'#@
MX!$UIN36=_9*8FV[$PIC2'4O0.B:;T"E7;;3<ZXHS+B9TI5!3,-:E/.*2>^-
MI6?!)I+''TA[\_*SIS)F)W/&_J\>1F9<9<8QO<V>\O&7?\*SJGIS&MZCPX6G
M%]?HFELQSA.Q9DMM+\;%M&5"2=)?3)-&)&1XF/#&7-HMC/VJO7RXCDX;);MF
M_P"I5'6!_3JE1F%4FC4LJC7YSF<WD/R%$4=EK!1)(S(\ZLQ'L(8>;PR^5._.
MXRY?V^3\RPAH;%"5/]Z"C=AK^ 21S)_<_+@4#4_Y!E>)/Y;K['37\
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MEY2U%BA>)$LS/_I%1OU'F6F9Y4;JYY?7^76(CD3N<2XQ;E,
M               1K4"SHVH%F5FS)DE<.+68YQ793224XVDS(\4DK89[ $E
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M[T%&[#7\ DCF3^Y^7 H&I_R#*\2?RW7V.FOX
M              **YPEXV)9-9LRKWK<E<H>"*NB##HA*4Q+WK+#+ARDEPFSO
M$+9]!1F"8<O=]>A7ECU*]M7Z@)=^6>Y$>M*@.P)+\V"Y3H:HLR9MDO-*80:'
M'?\ 346"E^F#%N@     !\S><MK!J!J/!IM)O"RW;9@4N<^N%,<9E-%(4:<F
M!&^A*3Z4LW2@SB'TDHOS/3^QF>II!@S@
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MU_ )(YD_N?EP*!J?\@RO$G\MU]CIK^
M        #67'5'*';U6K3+)R7:;"DS&XY<+BH[2G"1_UC3@ X@3J9SDZA2OE
MKE2I,*/-M=Z\8,?B--0TMMAY33T!#KD8S*0U@G$C4>T\,=AF#)VG8U136+)M
MNK)F.5%,^E0915!YLF79!/QT+WJVR4HD*7CF-)*/ SPQ!BWX      X\_P#,
M#^Q]G?2<CX.0,H=:T7YGI_8S/4T@Q9P
M       #\//,QF7)$AQ+,=E*G'77%$A"$(+%2E*/ B(B+$S,!IN_2SO"&F>[
M8_LP#OTL[PAIGNV/[,!")&N%$8<=04):R;4HB4E]OIB2?"7X17;]=UK,QR)W
M%FIU%:T1/+C=3?OTL[PAIGNV/[,6)63OTL[PAIGNV/[,!MXTJ--8;E0WD2(K
MI9FGF5$XVI/HI4DS(R >H        "M-:JQ5:+0:>_29CT)YR9D6XPLVU*3N
MEG@9IZ&)"M]?Y^9E959I::SRM[BE9_=[3Y>=G6B]8M')W^.%769>5V3+LHL2
M76ICT9Z8RAUIQY:D*2I9$9&1GM(Q5]!K]1;44K:]IB;1OK5UAU?IZ:;,M7+K
M$Q6=YTX/ICY< (;>&H/>A.8A=ZUPU[?M;[C%"I_'6$=,:<BU[Q&"]F.'H8 (
M]RV_X=7QW$_KP3@TUR:S5A^$V=&MVO6V^ETMY)K]-3&9=0:5=(V:EN8JQ+'#
M#@%8]X=?G:3)K?*G"9MALQWI6;W?T&3J\ZU,V,8BN.W#?ACVQK)7V3E+K5'J
M]RIZ0F6K?IZ)3C)GFQ4Z25-X$>!$0\?NYUGJ-9;,C-G'DX8;D1MQX'K]XNK-
M/HZY?FHPY6..[,[,$AY;?\.KX[B?UXN:G8-O;.IW?-6&:1WFW11]\E:N/U>F
M<4AHW:35@MS>JP-6&"=FTP$\!  J&^/D<]0XO?P;A6QQ$^(_SFXW^;IL=UM_
M#A_HX[!0>MO,^T*^MX^:Y'V=N&/T?+9CN+YU3Y[V?;U3#SO+^ULQP^GY;<-U
ML](L/_\ (?DW>]ZW'"^1]]CP=/O,,VW##=\/X]N(]GNU_P![S>/F>5]C'Z<>
MY_U>3WD_[/G,//<G[>'T8=W_ *++%R4X               ! -<*U<%N:27A
M7+6-:*[!IKSL5YO:MHBP)QU.P]K:#4X6SH F'%==G56VN.RZIK/==20EJWZQ
M;]*^4)K2J_3*LI)2T,)-;A(6VI+J4YD*3L+$N$$OHF#$     ?Q2DH2I:U$E
M"2,U*,\"(BX3,P'%/.NEQ)>O&CRHC[;Z4RHA*-I:5D1_*;7#E,P90[7!B
M                                     \WY$>*WO9+J&6B/ UN*)"<3
M],\"$3,1M8VM%8QF<&,FL4A:DH1/C*6HR)*2>;,S,]A$1$8Q\Y7AAA&=2?O1
MV6:,VT     1VQ;/@V%:L"TZ<^[)A4_?;I^1EWJM^\M\\V0DEL-PR+9P )$
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M62<^))E=*GI3R](#.'TDHOS/3^QF>II!@S@
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M1*)+*3P_ 8YN1U#D969%XM;&LX[8_M=//]X-1G9=J6K7"T8;)_N6*+$K8
M#6UJWZ/<+#<:LQ4RV&E[QM"C4DB7@98]*9= QX]5H\G4UBN;7E1$XO9I=9G:
M:TVRK<F9W'C1+6H%N*>71828BI!))XTJ6K,2,</7*/@Q,:])U?I]+,SE5Y..
MW;W6>JZPU&JB(S;<K#9L;@=!X    'A*A0YS9,S8[4EDCS$V\A+B<2Z."B,A
MKS,JF9&%XBT?/&+9EYM\N<:3-9^:<'HTRTPVEEAM+3*"RH;01)2DBZ!$6PAE
M6L5C"(PAC:TVG&9QE^QDQ                1#52Y:I9^G-S7/18*:E5*7
M>DQH;B36VI24\*TI,C4A)&:U$1EBDC 431K"U_NN+;5R2JGIY/CPFH[U'=32
MDREPV<$J2B*[Q<R;RD1$6[,B(RV EU*"     !K;BH[5Q6_5;?>=4RS58<B
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ML%:DO5K>&RMQ#9F2W&VB:7L218GM/#^%EZ'F\],[L1N*_/6U[8VR\J;4C?\
ME"W[+O"C7Y;<*YZ"XI=/F)/I'"RNM.(,TK;<3B>"DF6'#@?"6)&1C?6T6C&'
M9T^HKGTB]=DM^,GH        4;S7_LC6/I(^H-#G:'P94+W+_:7\?]-5Y#HK
MZ    Y:Y])?_ *<T'Z7+J#@\NHV0L747IK<3-YCOBDJ/TY)^#QA.G\%AUYZ>
M/%CNNF!Z7                         4)4_WH*-V&OX!)',G]S\N!0-3_
M )!E>)/Y;K['37\                                      &MN%Z7'
MH%5D0'6F)S4.0N*_(PW+;J6E&A3F.S*1X&K'H .$M,V-+BL^ [5><#<-KUMX
ME+JE$I=0<I\2-*4LS<0TVTE2#22C/!;9Y5<) R=UVWQ8K=I'$Y[E5B<2C<7J
MCZS<>E-[I.5]:SVJ4X73J/HF8,6T      '"'/7U.L&^K<MJFVC7XM7G4^HR
M%S6(RE&II)M9,58D71+ &4.X:+\ST_L9GJ:08LX
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M: ^?.KNLUH:S:TZ75.T$3$1J94(4:24]I#*L[E0:664D..8E@#+!]% 8@
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MN*?VW0FK:HL:B,S9U1:B[S+,JLIV?-7O'%.'O'WC-:\,V5.)[$D1<! AM0
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MCM2P:V8         H2I_O04;L-?P"2.9/[GY<"@:G_(,KQ)_+=?8Z:_@
M                                  U-TFLK8K1MJ0APH$K(MUKC#:3W
M*L#4U_#2711_"X '&FG.KO-Y3:E.B:B::Q5W>PVI%4G,VE3SC/NDL\%M$RRG
M C3AL-I/JF3M"@2*;,H-+ET9@HU(?B1W:?&)LF";C+:2II!-D1$C*DR++T.
M&+8@     #Y]<\'1+3O2^AT"LV;3W8=0J]0D-SG')+T@EI)O>;$NK41=,?0!
ME$N]Z+\ST_L9GJ:08LX
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M31$I:6$()1D6S$P90[I!B
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MU2B?Q3NL"2<9C+P8^N4#.(?22B_,]/[&9ZFD&#.
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M:,W=,GZZORJ<4..B6X[,J$R8\VF2Q-C&1Y$*(W,2V$9X),U8[27T"!B
M-7<DBJQ+=J\NA,E)K;$*2[3(YEF)R4AI2FD&6)8YED188D ^<]^7-K%<VL6F
MC^L5";H528J4%%-::8..3C!SVC4HR-UW'!6SA(&;Z6 P
M                        0?5BG3ZI:*XM-C.RY/&&5;EE!N+RD9XG@G$]
M@\&NI:V5A$8SBY76F7:^3A6)F<8V*6H=G78S6Z:\]1)K;3<IA;BU1W"2E*7$
MF9F9EL(B'#RM/FQ>)FL[85?)TN=%ZS-+;8WI=0BUKZ (U=-3OFGN1BL^W8%<
M;<)9RUSZJNE&THC+*221"EY\=N)XIPPZ("/=\>M?@!0_VH>_N<$JKUKJ=]SX
MU'*[+;I]&2VX_P 4.%5EU,W3,F\^8EP8N3+@G#UV./0PV\O7[*J_UQ$85^GN
M(7IG*N&)?%)D6_2HU2JZ#D<6A29BH++F,9TE9GTQWS3@DU*+]&K$RPV8XEX]
M)AYV/EO.9U=$>L5^GM2Z([X]:_ "A_M0]_<XL"YMA1:WJI*JD>/7K.I--I"S
M,I4V-7W9KS:229D:6%4Q@EXG@6&\3Z/I A^+IT=TXO6K*KES47CU46A#2G^-
M2V<4-E@DLK+R$[/P -+YN&C'@S[^J'QD$XJGU&YN-05<*>3RA(;MU,9M.14W
M$]_F6:_]Y>-?13T<!X<_*O:V,./J]/F9F9C6-S!FZ9<W$BGSDZF4%#M--E)P
MDHFK(]^2MI_[*\E7K3/UVP9:?+M69Q9Z/)S,NTS:-S!9?FX:,>#/OZH?&1['
M5Q2&S]*K"L*<_4;3I/R?-DM<7?=XS)?S-9B7EP?=<(MJ2VD6((3(
M  5K5M =):W655V?;C9SG5FZ^EEY]AAUPSQ-2VFG$HQ,]IX%MZ.(U3E5F<<'
M,OU7IKVY4UW?I6'#AQ*=$8@0&&XL*,A+4>.RDD-MMH+!*4I3@1$1= AMB,'1
MK6*QA&Y$/<&0       "C>:_]D:Q])'U!H<[0^#*A>Y?[2_C_IJO(=%?0
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M&1D8(<B_^8']C[.^DY'P<@90ZUHOS/3^QF>II!BS@
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MEDRJ1!W+:%M&TXLLJ,3)1>NX '1@(<7<[;Q\Z.]DQ?K-H&4.T08@
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M*T1YFX     4)4_WH*-V&OX!)',G]S\N!0-3_D&5XD_ENOL=-?P
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M"XM/B17<-XRRVVO#:69"2(\/R Q9(
M                (KJ.TZ]9E2;90IQPSCX(01J4>$ALSV$.+UW6;:.\1&,_
M9_-#L=36BNKI,[GA?EE0JJ;4<I_[&_P?^C7Z@^9^8S.;/8E](C/R^='9=2#[
M,^/@   *TUIHU5K5!I[%)AO37FYF=;;"#<4E.Z66)D70Q,5OK_(S,W*K%*S:
M>5O<4K/[O:C+R<ZTWM%8Y._QPJZS+,NR'=E%ERZ+,9C,S&5NNK96E*4I61F9
MF9;"(5C0:#44U%+6I:(BT;RT]8=8::^FS*US*S,UG?=.#Z6^7@
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M3DL.TE1&LHSR7<A+5/7ES9<,<IX>@"<78@,0
M                       %9ZP6)7;X8I+=$-@E0EOJ>XPX;>QTD$G#!*L?
M6F/%JLFV9$8;SD]8:6^=%>3AN8HCIWI!=UL7E3*[5#B<1B;_ 'NY>4MS]+'<
M:3@1H+^$LNB//D:6]+Q:<'CTF@S<O-BUL,(QW_FE?0ZJQ    *,U9T2N&_[K
M*OTRH0XT8HC48VI)NDO,TI9F?2(46'3>B/'G9$WMC#EZG26S+\J)AL='-(:Y
MIQ5JE4*K.B2FYD=+#:8IN&HE)62L3SH3LV"<C)FDSBRTNEME6F9F-BXAZW2
M                       4;S7_ +(UCZ2/J#0YVA\&5"]R_P!I?Q_TU7D.
MBOH   #EKGT>+F@_2Y=0<'EU&R%BZB]-;B9O,=\4E1^G)/P>.)T_@L.O/3QX
ML=UTP/2X                        "A*G^]!1NPU_ )(YD_N?EP*!J?\
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M$1 A_0
M                                           !%[VTYLK46)&A7E2&
MZFW"6;L)TUNL2&%JP)1M/L+;=1FP+-E66.!8\ #WLVQ;2T^I'R'9U+:I5--Q
M3SC;9K<6XZHB(W'775+<<49$19EJ,P"@6):-L4"1:U$I+,:WI:GURJ<K,^RZ
M<O'?$LGC7B2\>F2>P!'+6T*TGLNNHN2V[:9B5EDEIBR%O29*8Y.8YN+MONN(
M9Q(S+]$E.S8"<5B @
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M4TZL0)CU-J<1I9N-ID1\IF:#/;E,E%L/'\)CU9=^5&+BZC)\U;#>6 -CS
M                    H2I_O04;L-?P"2.9/[GY<"@:G_(,KQ)_+=?8Z:_@
M
M
M
M
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M)',G]S\N!0-3_D&5XD_ENOL=-?P
M
M
M
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MZPL2WI=I6;0K9GSCJ<VDPF(<BHJ)1*?6R@DFX9*4H^FPQVJ,&*0@ "C>:_\
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M7 H&I_R#*\2?RW7V.FOX
M                     B6JE-GUG3"]:/2V%2JG4*#5(D*,WM6Z^_#=;;0G
M'HJ4HB(!6'-!LVZ+%TH>HMW4MZD5557E2$Q9)$2S:<:8)*MAGL,TF"97X"
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M3+81J($PL_2NFSZ-IA95'JC"HM3I]!I<2;&<V+:?8AM-N(5AT4J29&"$M
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M9:VKT&;3F[:HC,5J7%?=?3.4J.I\U;M"6%-F1[TL,72Z()Q=! @
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M^6Z^QTU_
M
M
M                                             'X=>:80;C[B6VRX
M5K,DI+'TS$Q&(U<JZK7A9N.5N!'RF1*WTIEO SX"/,LALC*O.R)[#";UC?AJ
M9.J>FD3,4B\**E23P4@JA&4LC]-*7#/_ "#9&ESI^Y;L2PG.RX^]'9:B3KOI
M#%QWMVPE93RGNC<>V^ENT*Q+TQMC09\_=EA.IRH^\V5H:K6!?E1DTJTJP52G
MQ&C?D-ICR6B2T2B1F);S2$GM47K3,:\[29N5&-XPB>)GEY]+SA64R'E;@
M            %&\U_P"R-8^DCZ@T.=H?!E0O<O\ :7\?]-5Y#HKZ    YCY[
MGB]H7TL7P=P=OJCTD\3Q:OP8XV9S*?%54OIN1\'CC'K;TT<7?3I?!^ET@.,]
M@                       "A*G^]!1NPU_ )(YD_N?EP*!J?\ (,KQ)_+=
M?8Z:_@
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M%+<G[>$3CN3]VUHPPESM3IM1I<ZN7FS6>5&/V<>[$.B1M2
M
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MQ)_+=?8Z:_@
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M4WQ^C_\ ZX_A<_\ \WZ:/GGO%^\R_$GMRZC%V<@
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MQY'^43[-S(VVK'TM%NL\BNV>UWVLD<[FU"S\2MBMO889-ZVPUCP8XY77,/\
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MU_
M           &IN:XJ?:="F7#5"=5 @I2MXH[9NNF2EI065!;3VJ(;<K+G,M%
M8VRPO>*QC*GY/.KL5DC)BA7#(5E,TY83*4YN@1FN01E^(C'3CJK-YU>S_1XY
MUM."6HE<[>E(QXE9M7>/ L-\:&<3Z..4G!MCJBV_>&$ZZ.;+3RN=]5.F3"T_
M?Z&1QZ8O\>*$Q/\ ^(;8ZGKOYGU?U83KYYOR[#3R>=O?R\>)V;&:Z;$M[QIW
MI?0Z7=[?3_R#;'5&5OWGZF$ZZ_-:Y7.DU=E&62F4F"G$^&#4%GAT"4>\<_R$
M(MU;DUV1:W%->[@RKJKVWZQ]%OZL5?.!U=D$1+KS,,\ID9QZ,MP\3X/YUH^
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M\K6:JELO'"*S&[&'"ZW'5:
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M_ )(YD_N?EP*!J?\@RO$G\MU]CIK^
M
M
M
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M@HW8:_@$D<R?W/RX% U/^097B3^6Z^QTU_
M
M
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MZTMZ5%@,UA%/,Z4X_.0EQ"425+22\"4>8DD9D:5;-@)P6N"
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MM\T;&S)RHRXPC?6</,W             "A*G^]!1NPU_ )(YD_N?EP*!J?\
M(,KQ)_+=?8Z:_@
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MKF?*%<>=FLR)AH0VIQ+$IQ"#4ELDIQ))$G8DN#T=H$K>!
M
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MC4S             %"5/]Z"C=AK^ 21S)_<_+@4#4_Y!E>)/Y;K['37\
M
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MCKA^C)OP=8(4]S,O$!0.R:C\,=!,K]!
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M.<2Y_P"(QDFX3Q+224JWBRD$188YG"+\(G8L3GB_8ZP_OQ2/@\P$0Z+!
M                        "C>:_P#9&L?21]0:'.T/@RH7N7^TOX_Z:KR'
M17T  %'Z^_:+3+Z</_,V/)J-M5CZG\#.\58 EY N$@$!YMGS7>GWEF_FMAI]
MD\;U=>>'E^)"[AZE=                      !0E3_ 'H*-V&OX!)',G]S
M\N!0-3_D&5XD_ENOL=-?P
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MN#'(18@ASOSB%<HNIFFVA+![R#,F=\ETMEA@5.@DLD(4>W^<)+Y8'_"R;#V
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M
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M^]!1NPU_ )(YD_N?EP*!J?\ (,KQ)_+=?8Z:_@
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MM.Z6VV*Y&<EO26&G$O)1QB2XX@LZ#-)GE,C/ "5K@@
M                                                        &ANB
MRK1O:,Q#NZB0JW%C+-V.U/80^EMPRRFI.<CP,RX< &;0J!1;8I4>AV[3V*71
MHF?BT&(VEEAO>+4XO*A)$19E*4H_3,!L0     !Y2(T>8PY%ELH?C.D:7674
MDMM:3X24E1&1E^$!^F668S*(\=M++#220TTVDDH2E)8$22+ B(@'[
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M_&WLKE0A#:$MMI)#:")*4I+ B(MA$1$/2K\SB_0
M  *$J?[T%&[#7\ DCF3^Y^7 H&I_R#*\2?RW7V.FOX
M
M
M
M                                           HWFO_ &1K'TD?4&AS
MM#X,J%[E_M+^/^FJ\AT5]                                4)4_P!Z
M"C=AK^ 21S)_<_+@4#4_Y!E>)/Y;K['37\
M
M
M
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MO^'O'FO6CVXJ7Y6.MAZC7AD^"M-TE_P]X\UZT>W%2_*QUL/4:\,GP5INDO\
MA[QYKUH]N*E^5CK8>HUX9/@K3=)?\/>/->M'MQ4ORL=;#U&O#)\%:;I+_A[Q
MYKUH]N*E^5CK8>HUX9/@K3=)?\/>/->M'MQ4ORL=;#U&O#)\%:;I+_A[QYKU
MH]N*E^5CK8>HUX9/@K3=)?\ #WCS7K1[<5+\K'6P]1KPR?!6FZ2_X>\>:]:/
M;BI?E8ZV'J->&3X*TW27_#WCS7K1[<5+\K'6P]1KPR?!6FZ2_P"'O'FO6CVX
MJ7Y6.MAZC7AD^"M-TE_P]X\UZT>W%2_*QUL/4:\,GP5INDO^'O'FO6CVXJ7Y
M6.MAZC7AD^"M-TE_P]YOK,T(MJRKBBW)"GS94R&3I,MOFUN\7FU-&9Y$),^E
M4?1&S+TM:6Y42Z/5WNQI]'GQG5M:TUQPQPWXPX/G6H/8MP
M
M
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M ]Z57:)72F*HE1C5%-/E.4^<<1Y#Y,3&"(W&'#09Y7$9BS(/:6.T!L
M        !J;FN:A6=0Y=R7--13Z)!)!RICA*4E&]<2TC8@E*/%:TI+ NB VQ
M'B1'Z/X@     !J+IN>C69;\ZY[A?5&HM-03LR0AM;QH;-1)S9&TJ49$:MN!
M -EQJ-_Z9'K-]ZXOYK^/P^M],!Z@
M
M
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M_3H)J/)U/^2&IC])EG BT/C&1AMR/E2V\Y(-6\<2X>&9"4I/H88[ U&2Y_\
M3\4>7A1\Y_E]=Z?K0'1((
M
M
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M2W$R)3JC+UN=:6VF\<"4H\H$+EXK&_\ 0H]9N?6E_-?Q.#UOI AZ@
M
M
M
M                                      "/*[T._IO-Q?O]^27,G#QO
MY(XRC-CT-WOLO#_"X.B D(                   (G=G>)\NVEWV[KY:^4%
M]Z>^WOSAN%XY,G29]WFR[S\6T!+            1/3?O$[TX_)QNN];C$O=;
MG>X<9XRYQG-O_P!)FWV?'-^+9@ E@            ",Q.\GO\J7%N+<H/R?'
:X_CCQWY,WB]UES?]CO,V.3I<_KMH"3 /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>tm2227887d4-lc_4lnp4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_4lnp4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#@6AT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-RXP+6,P,# @-SDN9&%B86-B8BP@,C R,2\P-"\Q-"TP,#HS.3HT
M-" @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#TB>&UP+F1I9#ID,&4U9#$R82TY8S$P+31E86$M.39F-2TX
M93)F-#%B,C@V9#0B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z,S(Q045&
M13$X.$1!,3%%1$%$-D(Y-$%"1C-#,S1".$$B('AM<$U-.DEN<W1A;F-E240]
M(GAM<"YI:60Z,S(Q045&13 X.$1!,3%%1$%$-D(Y-$%"1C-#,S1".$$B('AM
M<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@,C4N-" H36%C:6YT
M;W-H*2(^(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X
M;7 N:6ED.F0P935D,3)A+3EC,3 M-&5A82TY-F8U+3AE,F8T,6(R.#9D-"(@
M<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#ID,&4U9#$R82TY8S$P+31E86$M
M.39F-2TX93)F-#%B,C@V9#0B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F
M.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O
M8F4 9,     !_]L A  $ P,# P,$ P,$!@0#! 8'!00$!0<(!@8'!@8("@@)
M"0D)" H*# P,# P*# P-#0P,$1$1$1$4%!04%!04%!04 00%!0@'" \*"@\4
M#@X.%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!3_P  1" +1!N0# 1$  A$! Q$!_\0 Z  !  (# 0$! 0
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M Q$ /P#OX
M
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MH)$J*M5;)'"YS5T6=4Z*@,4E\-SG/X+P57N5R^]D::JNO1KG(B?41- 2M((
M
M
M
M                   !5?B3_45G7P8_^.P)A.,+_0['O@RB_%V!#>
M                                             -'FGZ'9#\&5OXN\
M"#^&S]16"_!C/X[PF5J!
M
M
M                                         *K\2?ZBLZ^#'_QV!,)Q
MA?Z'8]\&47XNP(;P#F6S>*.\W/Q"R\,R8_2QVIESK+6ES;/(M1_ND4KD?M5N
MWSG1]4]10G!?F<9#)B.%Y'E<4"54MBM=;=&4SG*QLKJ*G?.C%<B*J(Y6::Z!
M"J/#7SU=><Z#(:JZV>GM,EEFIHHTI9'RMD;4MD<NN].BIW?^$)F%ZA
M                         P[O=*.R6JNO5P<K*"W4\M95/:U7.;#3L61Z
MHU.JJC6KT0" <1\YX1S4R[NPY*UCK(M.E<RO@; [2K[WNU;M?(BHO<OUZ] G
M!980           #1YI^AV0_!E;^+O @_AL_45@OP8S^.\)E:@0
M
M
M
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M\-GZBL%^#&?QWA,K4"
M
M
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M1*=!      &CS3]#LA^#*W\7>!!_#9^HK!?@QG\=X3*U @
M
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MF:3)G-FT6B,./A6"6-60
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M:QJ:ZKT1/*&+-      !H\T_0[(?@RM_%W@0?PV?J*P7X,9_'>$RM0(
M
M                  JC@?\ 1^Y_?G\TPI_NQY&_.ZT+G[U^7IS>O*URX*8
M                           JF;]>D'WDOXN\I]O;$<WP5SK[%GG>%"UB
MX*8
M                            57XD_P!16=?!C_X[ F$XPO\ 0['O@RB_
M%V!#>                                 !CUU%2W.AJ;;71I-15D4E/
M4Q*JHCXI6JQ[=6JBIJBJG10(C@7$7'/&+ZR3!;##:);@C6U<K))IY'M8YSFM
MWSR2.1J*Y>B+I^\@$V               T>:?H=D/P96_B[P(/X;/U%8+\&,
M_CO"96H$
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MS?KT@^\E_%WE/M[8CF^"N=?8L\[PH6L7!3
M                                                           "
M <WXY>,MXFRW',?IO2[S<:!\5%2HYD:R2:M<C4<]6M15TZ:J$PAMBY*Y2M-D
MMMJDX;O<DE#2P4KY&W"V(USH8VL5419NQ= -A\K7)_S,7S\H6OW8!\K7)_S,
M7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7
M)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8
M!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H
M6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,
M7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7
M)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8
M!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H
M6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,
M7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7
M)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8
M!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H6OW8!\K7)_S,7S\H
M6OW8!\K7)_S,7S\H6OW8#7WWDKE*[62Y6J/AN]QR5U+/2LD=<+8K6NFC<Q%5
M$F[$U F7"&.7C$N)L2QS(*;T2\VZ@9%6TJN9(L<FKG*U7,5S55->NB@E/P@
M
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M5VD3-DJ;%:CD77H]W8AE@[%#$
M
M
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MAD\='%54S]O<Q)00MA8K-$U\Y&ZKJIE;,F:Q7B1%(B9GC2TU,P
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MZG"
M
M
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MVCK-WHE1%/LTW]T]K]-==-=JKIKH&+W
M
M
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MRFP:W2T,EV;"RM=+4SU.YM.KU8B=Z]VFG>.[ 8K!"
M
M
M                                                         %4<
M#_H_<_OS^:84_P!V/(WYW6A<_>OR].;UY6N7!3
M      %4S?KT@^\E_%WE/M[8CF^"N=?8L\[PH6L7!3
M   &)=+5:[W03VJ]45/<;75-V5-%61,J*>5J*BZ/CD1S7)JFO5 /J@M]!:J.
M&W6NEAH;?3-2.GI*:-L,,;$[&L8Q$:U/61 ,D
M
M
M                                                          *H
MX'_1^Y_?G\TPI_NQY&_.ZT+G[U^7IS>O*;9CG&*X!:'WS+;E%;;>U48QTBJL
MDCUZ(R*-NKGNZ]C44N=*6O.$0IL5F=Y#L-\0O%F<7B.P6FZR4UWGU]%IKC3R
MT2SJGDB69$:YWJ-1=5]0W9FFS*1C,,[9=HWUI'F:P   P;S>;5CUKJKU>ZR*
M@M5%&LM55U#TCBC8GE55_>3U5)B)F<(3$8JEMWBIX;N-SBMR76II8YWI'#<:
MRCGIZ%SG+HGVY[41$5?*[1#USH\V(QP;)RK1&*YF/9*QLD;D?&]$<Q[5U:K5
MZHJ*G:BGC:GT                  *IF_7I!]Y+^+O*?;VQ'-\%<Z^Q9YWA
M0M8N"F
M
M
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M^L>.8PG!Z(G%L2$@ "J9OUZ0?>2_B[RGV]L1S?!7.OL6>=X4+6+@I@
M
M
M
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MPS&,]8R[3:9XL<.RMD\S< 53-^O2#[R7\7>4^WMB.;X*YU]BSSO"A:Q<%,
M
M
M
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MF6739K$)B:FP JF;]>D'WDOXN\I]O;$<WP5SK[%GG>%"UBX*8
M
M
M
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MV+/.\*%K%P4P
M
M
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MS?KT@^\E_%WE/M[8CF^"N=?8L\[PH6L7!3
M
M
M
M                   "J.!_T?N?WY_-,*?[L>1OSNM"Y^]?EZ<WKRM<N"F
M #09Q^AN0?!U5]Q<;LGRE>K#&^]+@SP@_KJM_P!XUWW(M72GD)ZL.9INW?T2
M*>ZH                     !5,WZ](/O)?Q=Y3[>V(YO@KG7V+/.\*%K%P
M4P
M
M
M                                               JC@?]'[G]^?S3
M"G^['D;\[K0N?O7Y>G-Z\K7+@I@  T&<?H;D'P=5?<7&[)\I7JPQOO2X,\(/
MZZK?]XUWW(M72GD)ZL.9INW?T2*>ZJ+9MR)B/'M'#5Y17I3.JG+'14<3'U%7
M42)]C%#$CGN[>JZ:)Y5-N7E6S)^[#5F9M:1C+08ESE@F77J/'('UMIOU0U7T
M=!>:.:@DJ&M35>Z61-KE1$UTW:^L;+Z:](QWX^9C7/K:<.'YXP8N4\_X!B&3
MU^(W-+E/>K:D+JN.AH)JIC$J(FS,7=&B]K7H94TM[UBT883\["VII6TUW<8^
M9M\'YCX_Y#K)[7C=S<Z\4S>\FMM7!-1U21]FY&3M;N1%[=NNGE->9D7R]^&S
M+SJWWF+F7-V X/=UL%TJ:JKO,4:3U=';*2:N?30JB*CY^Z:J,1477JNNGD%,
MB]XQC>Y$VS:UG"?LF?L3''<CLF66>EO^.UL=PM%8W?3U46NUR(NBHJ*B*BHJ
M:*BIJAJM6:SA.^V1,3&,-=<,YL-MS.T8'5.E3(+W3SU="QL:K$L5,USG[GZ]
M%T:NAE&7,UFW!")M$3@]LUS&S8!C-;EN0ND;:+>L*5#H&=[)_O$S*=FC=4U\
M^1NHR\N;VV8WT7O%(QG>8]-GMAJ\NBPJ%9UO4UM2\LUB5(/15>UB?;.S=J]/
M-(V)V=K@QP3M1C@DY@R          "J9OUZ0?>2_B[RGV]L1S?!7.OL6>=X4
M+6+@I@
M
M
M                                                  !5' _Z/W/[
M\_FF%/\ =CR-^=UH7/WK\O3F]>5KEP4P  :#./T-R#X.JON+C=D^4KU88WWI
M<&>$']=5O^\:[[D6KI3R$]6',TW;OZ)%/=51F.Q1WOQ09K4W5J3RXQ9K;36)
MLJ;D@CK8TFF?&B]BJYSFJY.O70]]_NZ>N'#,XO%3[V?;'\,1@L_+L-Q7+FVQ
MV34Z2.M-9'7VZ=)7T\L53'JC=LL;F.T77JU':.Z:GER\RU,=GA>F^76V&/ J
M[!?VG.5/@^S_ (I3GKS?T].K/VO'E?J+_1]C%\0E+2V?+^+,RMT;8LC9DE/;
M'31HC99Z*I:JOC>J:*YJ;=-%[-R^J8Z:<:WK.]LXMV?N6I/#CA]4HY;[]F=I
MY@Y-JN(K!'FD%7+2MOTE7+';XZ.XTD;X^XBFDD3ODUW;FHU-%3ZIG-:SEUVY
MV>+AW&,3,7MLQCQ]7Y<B:^%EMK@XSDI*.JDEND=SK'WVBGA6F?15\KFN?3I$
MJNVM:FU6]>NJ^NB:=7CM_1&'4;,C#9^F>5&^8KCDUJ\0> 5N(V9M_OT=HN"4
M]K?41T;9&N;*CU[V54:FUJJ[KVZ&W(BLY5L9PC&&.;,QF5PC'?1[GK+N9[IQ
M1?J'+..H;%C\KJ'TRZLN])5NAVU].YFD43U<[<]&LZ=FNOD-FEIEQF1A;&=W
M@^9IU-KSESC7#>X?GA85LRN_LYLIL4;6*E@9A27%M'LCT2J;)"U)-^W?V*O3
M=IZQY9I'BIMP[6'U/3M3XV*\&'7A ,.K.<<WXHJ^2I,_EM,EGCN,UMHXJ&FD
M;6MM[Y7.?4N<WKJK71-1K=$1J+VZGHS(RJ9FQLX[W#/#Q--)S+TVMK#?XN/A
M2"?EC-<XM'%V*8S6QV3*<]HI:Z]7AD+9G4E-1,5)7P,?YNZ1S'JFOL=/JF'B
M:TF\SNQ5EXV;16(W)M&+*H+CR;A/-6*8-DF7OO\ B-PH+E7)4STT%/42)3P*
M[;.L;>O=.:CFN:J*NO4B8R[95K1&$Q,,HFU;Q69QC">L@%!S3=<WI*W+:KEB
M#"*WO9EL&)Q4+*F!L46J1^F2/B<KED5/.ZKM3JGJ&ZV1%)V=C:XY[#57-VXV
MMK#YMSZW0W#/($W)G'UKRJL@;37*7?!<(8T5(TJ87;7*S557:Y-')^Z>'/R_
M%WFKTY5]NL2GQI;0    53-^O2#[R7\7>4^WMB.;X*YU]BSSO"A:Q<%,
M
M
M
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MO"A:Q<%,
M
M
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M!]Y+^+O*?;VQ'-\%<Z^Q9YWA0M8N"F
M
M
M
M               %4<#_ */W/[\_FF%/]V/(WYW6A<_>OR].;UY6N7!3  !H
M,X_0W(/@ZJ^XN-V3Y2O5AC?>EP7X0?UU6_[QKON1:NE/(3U8<S3=N_HF4]U0
M                     "J9OUZ0?>2_B[RGV]L1S?!7.OL6>=X4+6+@I@
M
M
M
M                                          !5' _Z/W/[\_FF%/\
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M(/O)?Q=Y3[>V(YO@KG7V+/.\*%K%P4P
M
M
M
M                JC@?]'[G]^?S3"G^['D;\[K0N?O7Y>G-Z\K7+@I@!'<_
M_0;)/@RK^XN-F7VT=5JSNTMU)5QPK^K''O\ 8/\ NKSWYW;RX>G\G"?&EZ%;
M5'[0^,? E3_'E-EO)3U6&5^HKU)9N99+F>8\E/XFP.Z_FY!:J%ERRC(6PLJ*
MAC:G_4T\#)-$1SD5'*_7R^MUPRZ4IE^,M&..]#HWO:U]BLX8;\O-<8Y>X]OE
MGN-ER2OSW&ZNJ;2WRRW-(&U,$,C5_P!ZAG73HQW56?4_<;>5F1,3$5G@F$;&
M928PG:CAQ:"L^4/..<\XP^TYW7XS9;#36ZHHZ>D@IYVZU-+"YZ?;6Z]7.5W:
M;/N4R:VFL3,XM<6O?-M7:PB,.+B9:7WDGA_.\:LV:9(N8X1ET_O737"HIXJ.
MKHKB[39N[K5'L<GK^KV:==<UIFUF:QLS7=^ANB;Y=HBT[43]KQK;QFF?<H9M
MC$&=OP6UX@VE2AI:>"G?+4MJ(ED?4R.F5JJQJM[$Z=?)Y416E*SL[6TG&UKS
M&.&":\ YQ?>0..J>]9&K9KG!5U-"ZOC8D<=8RF?HV=C41$1'(NG3RHIJU&7%
M+X0SR;S:N,O'D_$<XJ&W?*[!R#<;!145!)41V:FIJ:2'?2PN>J[Y$5WGJWKZ
MAEDWI&%9K$[IF4M.[%ICD0S@ZS<E9KBF+\B7CDJYR0U<KJFKL:TM*L$L=+5/
MB=$LB-1VV1L?54ZIJ;=1:E;32*1U6G(B]JQ:;3]781OA#EO.+CS#=L8RVZ2W
M''[M4W>CL3)6QM2"JM4W>;&JUJ*J=RJ]OK&S49-(RXFL83&&/TL,G,O-YBT[
MDXX?1+;>*'E?+,2N%DQS":^2W5D;676]54*,<Y*22H;211KO:Y$1SWZ].O0P
MT>56V,VC'@C[6>IS+5PV?E&.'7=+G.>P         53-^O2#[R7\7>4^WMB.
M;X*YU]BSSO"A:Q<%,
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MURIK-47"FAO%8USZ.WR31MJ9F1HKG.CB54<Y&HU556ITT S0
M
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M'CUPN$]IH+M1U5UI?^TT,%1%+41?Z<;7*YOU4 V8
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MF>BMUL]LJ$A8YB+]C)(USE_SD(R?NYE:<43CU9A.9.U2;<<QAU(F':YR'0
M       %4S?KT@^\E_%WE/M[8CF^"N=?8L\[PH6L7!3
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MO<.!W0&(
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M,C8U/(UJ=$-<S,SC+9@]JJFIZVFFHZN-LU+4,=#/$]-6OCD16N:J>HJ+H(G
M8EDL=HQNUT]DL-%%;[32(Y*:CIV[(HT>Y7NVHG9JYRJ3:TVG&=]$1$1A#"H<
M,Q6VT%RM=!:*:GMUY?++=*9D:)'4/J$5)72)Y5<B]29O:9QF=Y$5B'G-@F'5
M&.T^(S66D?C-*K'4UJ6-/1XW1OWM5K.Q-'+J3XRVUM8[IL1AAAN)":V0
M     JF;]>D'WDOXN\I]O;$<WP5SK[%GG>%"UBX*8
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M(EKLZ_;JXR_Y:J?N-Z!P.IP@
M
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M8Y9V8]CUHL$<BRLM5%34+95Z*Y*:)L2.^KM#!LP
M        %4<#_H_<_OS^:84_W8\C?G=:%S]Z_+TYO7E:Y<%,  $!SS!L-FL%
M^O4E@M[[NVCJ9VUCZ6)\G>MC<Y'JJMZKKUZGIR;VVXC'<Q>?,R<N8F9K&+B7
MPMTE+D?+5':K_#'<[9+15;I*2L:D\2N9'N:NU^J:HJ=I9>D8BN3C7<G&',T^
M32;[L0_H)9L;Q_'8WPV&V4MMCE761M+"R%'*GJ[434J=K3;?EV*9=:=K&#:&
M+,                    !5,WZ](/O)?Q=Y3[>V(YO@KG7V+/.\*%K%P4P
M
M !XQTM+#*^>*"..:7_6R,8UKG>7SE1-5 ]@   !^.:U[7,>U',<BHYJIJBHO
M:BH!\PPPT\;8:>-L4+==L<;4:U-5U71$Z=H'S-34]2C4J(63(Q=S$D:CM')Y
M4U1=% ]0
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MQ=Y3[>V(YO@KG7V+/.\*%K%P4P
M
M
M
M           JC@?]'[G]^?S3"G^['D;\[K0N?O7Y>G-Z\K7+@I@  J3E#E6T
M4+JS ++;JK)LGKJ>6"JMUM[::.5FU72R:*C5T=V?OZ&J=1XNT8;LP[&EZ+MG
M4V[S%*<<\/4<U<58'G/"V70YY>,5KKC0T]/-"^&CDADDC;,FUSW-8KU7:W7I
MT_=/?J>E\S-ILS2(AMR^A-+C_P#/.^]\\;CL["\WQW/K-'?,<JDGIE79-$[S
M9H941%6.1G:UR:GBI>+1C#F:G2YFGOL7C"?M2(S>4
M !5,WZ](/O)?Q=Y3[>V(YO@KG7V+/.\*%K%P4P
M
M
M
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MCF^"N=?8L\[PH6L7!3
M
M
M
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M7U/(OJ]% E8
M
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MA,
M                  JC@?\ 1^Y_?G\TPI_NQY&_.ZT+G[U^7IS>O*URX*8
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M' \H)DQ_Q6Y&RD1$I+O@,-[N<#-6][5V^XK21.=U5-4BU;KIY?WQP*G_ /\
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M%HF)^=[FYK
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MQ\HR\)\U+27&]U-$ZZ8[DMOC2%E9#'N5S7L8R-B=&/TTC8K58J+NU:X#H<(
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M=%;0YJW6AT5/^T1?QT*YHYCQ].='VNYJ8_\ E?FS]BTSZ,HX   5AF[V-O\
M(CG(B]W'VKI]B?/>FYB-5/4A=>B8F=/'5EG<?/:ZNJ]KD7[2G8NOV2'L]WIB
M<R_4Z[S=-1,9=>JL$NRI@  !0U9_VRH_VC_XRGQK.\I;JR^HY7:1U(6AQ_\
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MZ@0CQ \ZYOQ+>+/;L5Q'\Y*>XTTE143[:AW=/9)L1OVAKDZIUZ@B%5_W>_\
M4^>??-M^YU 3+M$,0     .+<]3E[@/DB_\ -$3\5][,M>D%=C7OFZ)U0VF8
MU&S,2L92N65--[DB=)HKG=%10G?;7B*V\L<J\J6WQ!7:?&9;730NL\5GH[F^
MHFM](_J_:E*RHC6;9+(NR:9JZOZHU$1 .O0@   .8KGBV3R7*LDCLM>YCIY7
M-<VEF5%17JJ*BHTSQ0N3B>@KK=B[Z>X4LM).M5*Y(JB-T3]JM9HNUZ(NG0QE
M*<D   PKM1R7"W5%'$Y&R2MVM<[7:BZHO737U#7F5VJS#7F5VJS"&_F+=/\
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MQCRSV5E'G;@            *IF_7I!]Y+^+O*?;VQ'-\%<Z^Q9YWA0M8N"F
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MC=#=.ZO4ZRF7F6B:VVL=R."LRZ?2G1.FR--:]*X6C#AGNHA;!]+44
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MX3@R[1SQQ1?KI1V6TY!Z1<Z^5E/20>AUL>^61=&MW/@:U-5\JJB P6,$
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MH                    "J9OUZ0?>2_B[RGV]L1S?!7.OL6>=X4+6+@I@
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M5%.W6T6B)B<8ER[5FLX3N2^C)B
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M9(69->X<AN4CEE2Y4U$EMC="_16-2!)9M-$\N_KZA[8G&,7NB8F,8;TE(
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M7JB]=5\A.369G:EETEFTR<F-/6<9QQM/S\2^#V*R
M JF;]>D'WDOXN\I]O;$<WP5SK[%GG>%"UBX*8
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M%FF>U8HW;FHD;WJQ%U7M1NI] Z M,Z6,>.5+Z9C#4?1"?%A<4
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M-JK.5^2ZRQ1)!9*B-TMLA1G=HRD?7/="U&?8Z,5$T\@3+N0,0
M -+/B&+U,\E346BEEGF<Z261T35<Y[UU<JKIU554G$9UNM-LM$3X+7214D+W
M;WLA:C$5VFFJHGET0@9@  !XUE,VLI*BC>NC*B-\3E3M1'M5J_XS5G9<9F7:
MD_BB8Y6S*S)R[Q:."8GD17Y/K?\ \0_]Y?Y17/A[*[J?E]+N^N\SBCY?0E5'
M3-HZ2"D8NK*>-D357M5&-1J?XBQY.7&72M(WJQ$<CA9N9.9>;3PS,\KV-K6
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MW-=5X+6SN:FC5EEI7JB>MN:H3@\?[O?^I\\^^;;]SJ 2[1#$
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M]0KN7G4S>EHM28M&SP<U9<S(OD]#S6\36=K>GG0N$NJC
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M7#?ZL0Z'1VGKGZBN7;>MV%4_*YDW_0TOM;OY9\U^,-9Q4Y)[*\_#>EX[<O\
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M;?N=0$R[1#$
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M[U;-VWT/TY_<Z;_.TV;?9=?5"9=QAB
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M4MNBT>7I,F,K+C[M?EC*NZK4WU&9.9??EGGL>4
M              YNR3+O$SQ/77:^7JVV7.N.VU,]1#)#4QVRXT="Z1SHF/?(
MV)JJQJHU=(I573V7:H3N-_QAXK^*.3:ZDL<%5/8LFK7)%3VNZ1HSOI5[&13Q
MJ^)RJO1K7.:]R]C08+R"      *1YQY8X:X[NMJHN3L?]^:^MIY)J"7WMI;A
MW<+'[7-W5#FJW5WD0)A3G]WO_4^>??-M^YU 3+M$,0
M                                         Y0YP_6+<?\ 94WW!A3^
MDO+S]'V/FW3GZNW4C[$F\./]=WO[UB^Z'JZ([>W4=#W<\I?J1]KHDLR\@ "/
M9S39A68I<J; *REM^7R,8EKK+@BNI8WI(U7+(B1R]%8CD3S%ZF5<,=W>95PQ
MW=YSG7\5^+BZ5;:ZY9%@M76-TTGGH4DDZ=FJNM2JNGDU)ME::TXS3&49FGTF
M9;:MEQ,_/$+7XELO/5IKJ]>7;_9+O:G0,9:X+-&L;XIFN\Y7ZTE-YNWHG5?W
M#*\TP^[#9?8P^[&"UC4U
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M^;[8W):=%>Y/0TKG]SHLFKU\S;[+KZO4)EW(&(
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MI\\^^;;]SJ F7:(8@
M               !SMRQQ[F609M6W2SVJ2JH)8X&QS-?$U%5D36NZ.>B]%3U
M"LZ[29N9G3:M<8W%&Z6Z.U&=J9M2N,;G%Q-]PAA>3XO=;K47ZW/HH:BGC9"Y
M[HW;G(_54\QSO(>GHW39F5:TVC#<>SH/19V1>TYE=G&%UG=6T
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M9W\/G_\ #3J-)G9&'C*S7'>Q6>>]XP
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MXY=;5!S-;J6MN<]/(^V/JK=)<'-@1^CT1S(W[4W>0)A3G]WO_4^>??-M^YU
M3+M$,0
M          !AW>M?;;37W%C$D?24\U0UB]CEB8KT1=/5T,,RVS69XH:LZ^Q2
MUN*)E3&(\<0\BV)N991>:R>]W%\KZ:2"1J,I4CD<Q$1JHO8K==J:(B=$]4X.
MGT?I%/&7M.U/U*MI.C:ZS*\=FVF;6XIWMU+N'K]=;K9+A;;O4+6U-DK9*%E>
MJ[N^B8B;55R^R5.O7U-#W='YMKTF+3CLSABZ71&?>^7:EYVII;9QXUBG3=P
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MJQ$77RA,NY Q
M           #G/D3],[M_M&?<F'P?WC]H9O5C_UA]<Z$_19?4G[93/A/_P".
M?^Z?SQ:_<?\ Y_Z/#5[WK_XOZ_!6R?35$
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MN]_ZGSS[YMOW.H"9=HAB
M                         /Q[&2,<Q[4<QR*US7)JBHO145%")C%5,O#U
MTH9*JFQ3+*NS6&M<YTUM1CI$9O31VQR2,[4Z=FNG:JG&GHZU9F*7FM9X%=GH
MC,IC&3FS2D\&_P FZG>)XK:\-LT5EM2.6%CEDEFD5%DEE?IN>[1$371$3]Q$
M.CD9%<FFS5U])I*:;+BE-[[9;P]#V
M                        1S.\(L7(V*7##,F9+)9+GW/I3()%AD7T>>.H
M9H]-=//C:!Q_SE8O#79,_JK1<+!D>4YQW%,ZYT=BF58Z:.*GCBB215TT<L36
M.T:U>WKIJ&4+3\*5)PDL.15_%5-=+9>=:>ER&SWN3=5P=VLBQ+M17-VJJR)J
MCO)HJ($2Z0" "CO%AC%;DO$LDM)0R7..Q7*BO-=;86JZ6>BI7.;4-:B:=D<C
MGKZR*$PA?/&>\;<D<5VK#>-;I07G,+U76IN'6VUN8^JH)H:B-RROAB\ZE;'
MDC%5[6[470$)+6WNU\7>(^]7K+ZR.T8MGMCHVT-ZK7MAH4N5I<L3J9\S]&L<
ML3N\3<Y$7]W0#]PFHH.3>?LOSZQ3^G89:<:@PRGN].J+25=3/4^G5'H\J(J2
M)%[%7(JIJOE14 B-Y\'/ARQUL+\@O]?:65"N2!U?=:2E216:;D:LL+==-4UT
M!BA/@HH+=:^6>3;9:)>_M-$QU-03[VR]Y3PUSV1NWMZ.U:B+N3HH3+N,,0
M                                                         YSY
M$_3.[?[1GW)A\']X_:&;U8_]8?7.A/T67U)^V4SX3_\ CG_NG\\6OW'_ .?^
MCPU>]Z_^+^OP5LGTU1
M&ARO"L7SBDHJ'*K<RY4MNK(KG11R/D8D=93M>V.1%C<U55J/=T7IU[ .-,UF
MXQO&<9'2\?< U>?K:[E-#D-^@JKA#"^OWN=4,C;"V9-=ZKHY53U49HJ*&3H'
MPTW3C6ZX9<)..\<DQ*6"X209'CU0Z5\]+<HF-:Y'+,JJJ;4:B+HWL5%1'(J!
M$KH" "C/$98;@E1@')-':Y[W1X%>VW"\6RDC2:H6WS(U))XH^U[H71L<C4_=
MZ(BJA,(OFF=8WSSEO&U@XMEFO,F/Y+19-?;W'2SPT]NHK>UZNBEDGB8B23*N
MC6:+U;U SXLHM'!/,.?5>>OEM>%9VZAN]AOJPS3T:5E/ L-732NB:]62N=H]
MB*FFWZB ;#B>R,Y&R/E/D>\VZ9N%9\VDLEEHZQCZ:2KL]#2/I99U8NR1K*A7
MJK-VCM-?6 T><\:^#CC:KI*'-[/06>JKHW34L<LESD5\;';55%B>]$T7U0;J
M#?W>_P#4^>??-M^YU 3+M$,0
M
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M9U1;;>QU)1SO<U[I((*Y\<;E<Q&M55:U%U:B(OD"9=QAB
M                                            $<N.!XI=JV6X7"W]
M]63JBRR=].S541&IT;(B)T3R(<'4] :'49DYF9EXVMOSM6C[+.OD=,:O)I%*
M7PK&]N5[#-LF,V/'._\ >:E]&])V=_\ ;))-W=[MO^L<[33<O8>O0]%Z;1;7
MB:[.UACNS.]CAOS/&\^KU^?JL/&VVMG>W(C?ZD1Q-L=-X
M                           $&Y5O')]DQZFJN)\>I<ER)];'%54-=/'3
M1,HEBE<^5'23TZ*Y)&QMTW_9+T]0.;L*;XQ,!DR)E@XRL_O?D%RJ+VM#47"B
M>RFK:Q&][W;F7)CEC<YN[8Y5T[$5$#+<6[X;,9SG'[+E%7R39([1FE]O<]UN
M,L=3352U*U+&N1Z)2R2-B8U=6,CUUZ*OE")7:$      45SSCWAVO-WM$O-5
M?%1W2*FD;:VRU=32JZG635ZHD"HB^=Y5"85'_=[_ -3YY]\VW[G4!,NT0Q
M
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M7M<]E.UDK'.:Q-7:;V-1=$ZZ&=,ZEIPB7JTO3&CU-_%Y69%K<6[UX2LW.P
M                   X>YHO6>7G/>4JVDY#N^.47'_O*ZFQ>SU4U')/:JM8
M&UE6UL4L>[NN]WJ]6N]DU%5$VHIE"QO#@Y+9R9G^,S9[6\BNIJ.V5-OOT]<Z
MOITI94D<Z+SI)MDK7N\[;(J.33HU4T")=-A      %.\^<08-RU26.GS;(9+
M!%:Y*B2C?%-30=ZZ=L:/1?2&N1=J,3V/JA,.??!+;*2R\K\EV:WSK4T%NC=2
M4M2JM<LD,%<^-CU5NC5W-:BZIT"9=R!B
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M[G4!,NT0Q
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MC\,KIH;4QU!',]$1SVTM<^)'*B=$54;J$R[C#$
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MOBM[);G%;E="Y^YRHV1R;O.\H3"E/[O?^I\\^^;;]SJ F7:(8@
M
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MS<=Y7Y+Q]DRU#+3&Z@;.K=BR)2USXD<K=5TUVZZ:A,NY Q
M                                                    #S=3P/E;
M,^)CIF]&R*U%<G[B]IA.769VIB,>-G%[1&&.X]#-@
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M*9577U%0$*H_N]_ZGSS[YMOW.H"9=HAB
M                                            *-\+_P"B-X^$E^X1
M'.T/:RH7N7^DOS_!JO(Z*^@  !S[Q%;J3+N8>4,UO\25MXL5U;8[(LZ;THZ2
MGW_ZIKM4:YVU%U3U_54]V=.SETK&],8R\N5&U>UIX)P6?>N,<:O69V7/526A
MR.RJ]&U-$YD2U43TT[JI\U5>SMZ=%Z]IYJYMHK->"6^:1,Q/"JSQ3T%#3X]A
MKH*:*)S\IMS7JR-K55%W]%T3J>C2[]N;+1J-ZO.K]J]Y['9ZFDJ:&:@@=25D
M3H*J'NF(V2)Z:.:Y$3JBH>.)P>IQM4)<;-F]3X7*#*&0<?W*YQR-N#I'K54E
M%,QU1):4?IHCY7*B)YVG7K[)S3K[DT\=,?>CY;3F[UO%1.Y\ON_+@=DV6S6W
M'K116.ST[:6UVZ&.FI(&=C(HFHUJ>NNB=5\IR+6F9QET8B(C"&>0E4%SH>-^
M L/R*ZW3?<4R"JGJ*F*N2.IK;E55+=&TJ*C$W-731$<FC=553TQMYUHB.#ZF
MF=G+B9:CBGC',*;@NDPZX7BJQ>[W"9]5*^F;NJJ.CJ)$<ZE8KE3NWJS5-R=6
M*[LU,\[-K.;M1&,?;\['*I,9>$[G6^9JO#MC5NP_DGEG&K4LKJ"W5-KBB?.]
M99GJL$CG/>]>USG.5R_NF>IO-Z4F?G^UKR*Q6UXCCC[$?XKR_C[ JWD6S<KS
MPT&9U5VJ9;E[Y,61]=02^="V+5KM[%:O1FOE0SSLN]XK--VN')QHR[UI-HM.
M$X\O$EWA+N=758%>K7,R6"BL]]KJ2W4E1KWE-3N5LJ0*B]FQSW:IY%-6LC"\
M3QQ#/33]V?FF?M7Z>)Z@        !1M5^TU1?!J_BTAS?]GY<2B9WM^G]OK6
M7D=)>P                   (GR5:\UO>$W2U<>76*QY=5=PRANM0FL<#/2
M(UG7_5R]5A21K?,]DJ=6^R0*2L'@WQNLK67WEW)[MR!?51%D2KJ)8*5->JMZ
M2/F5$7L^W-3_ #?($XK^QG#\5PRA][<3LM'9J)=%=#0P1P(]4Z;GJQ$5SO\
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M3<O[H)=R!B
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M5/6W0H$XM7_=[_U/GGWS;?N=0"7:(8@
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M4#X([94V3E7DJS5M1Z766Z):.HJNJ][+3UKXW/\ .Z^<K=>H3+N8,0
M
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MS;?N=0$R[1#$
M                        4;X7_P!$;Q\)+]PB.=H>UE0O<O\ 27Y_@U7D
M=%?0        !!\MXIQG-+HV[W>HN<54V)L"-HKA44D6UBJJ>9$Y&Z]>TVTS
M9K&&$<C"U8EHV>'[!HWM>VMOFYJHY-;Q6*FJ=?\ I#/Q\\4<D(\7'S\LK4/.
MV               %&U7[35%\&K^+2'-_P!GY<2B9WM^G]OK67D=)>P
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M/D57:N7<Y%=UZA,NY Q
M
M    5KS9D6'63&*:@R[&)LR2^U3;?:\:I*1M;4554Z-\FK&OT1FQC'.61%U;
MVH$PH3$\=NN34EYQS J&I@I+$M-/=N&^4*?TRB9'4H]T$ENJGJ^:%NC'I'KJ
MB.ZNT30)7WPY=*"6TUV/4^ S<=U]FDC2OLBP0QT;Y*A':34T].B1U#';%19$
M1%U3J$2LH(      HKGGPUT/.=WM%VJ\BELKK3324K8HJ5M2DB22;]RJZ6/3
M3L"8E4?]WO\ U/GGWS;?N=0$R[1#$
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M+7ROR7;;M5+6W6CC=3UU:KG2+/40USV22*Y_G.WN17:NZKY0F7<@8@
M
M                                      (ER#QUCW)5HI[1?UJH%HJE
ME=;KA;IW4E;2U,:.:DD,K=5:JM<YJZHJ:+ZNBH&#QQQ-C/&*7*:S5%PN5VO"
MPK<[Q>:IU=73MID<V)KI'(U$:Q'NT1&IV@3L       "BN>?#M7<U7>T72DS
M&7&6VNFDIG014;JM)5DDW[E5M53Z:=FFBA,2J/\ N]_ZGSS[YMOW.H"9=HAB
M
M            *-\+_P"B-X^$E^X1'.T/:RH7N7^DOS_!JO(Z*^@
M                  *-JOVFJ+X-7\6D.;_L_+B43.]OT_M]:R\CI+V
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M$<]&N=N>BNU<B*H3+N0,0
M
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MVAS4Z)TZ@B55_P!WO_4^>??-M^YU 3+M$,0
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M7/;,]%T37<]%771 2[D#$
M
M           "+<A<@XYQGC4^3Y+*]M+&YL%+2P-[RJJZJ37NZ>"/5-\CU3HG
M8G555$15 KK!L%S#.,PHN8>6X$M];01R-PS"F.1\=IBG31T]2[[.JD;IK_D>
MHBHC6$O'AM66_F/FVQU*-CN+KI;;I&BKH^2DK*158YJ*B:M:J:*J*NBKIT\H
MEI;1;;CF/+'B&IL;JTI*BIL]LQZBNR/>QL-S?;9F;FOBU<BP/<F]6^<U4Z 5
M=]$_Q(_.O_\ >EW_ )(3BSO[O?\ J?//OFV_<Z@$NT0Q
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MB!,NY Q
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M
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MF/(7;[^R)6W5^K5UK$K7I,NK/-75^[V/3U F7<P8@
M
M                                   !17//'/.>;7>T57$V918Q;J6F
MDBN,$M=64:S3.DW-<C::"9':-Z:N5 F%1_W>_P#4^>??-M^YU 3+M$,0
M
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M3$X3,[\_*%OGE;U&U7[35%\&K^+2'-_V?EQ*)G>WZ?V^M9>1TE[
M                     %.\^0<^34EC3@JICIJM)*CW[65+>NL:MC[G3T]C
MT[=_L/JA,.??!*EY;ROR6W(G(_($C<EV<FS1:Q*Y_?*G=HC/9[O8IIZG0)EW
M(&(
M                                                          45
MSSAW/V37>T3\.Y+%8K;!32,N44M2ZG62=9-6N1$AEUT;T[4"85'_ '>_]3YY
M]\VW[G4!,NT0Q
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M/MJPZRUU<]-):NKDZRS2=O5R]B:]$T3R%4S<R<RVU+E6M-IQ2XU,0
M          HVJ_::HO@U?Q:0YO\ L_+B43.]OT_M]:R\CI+V
M                K'.^4;S:,QMO&^!X^W),WKJ-UUJV5-5Z#06^W-D[I)ZB
M5(Y7*KWIL:QC=?+ZFI+)XVY,K<ONE_Q+*+(N-YUC+X??*UI4-K()::J:KH*F
MGF1K-\;T3KJQ%:O10(YXA+CSO;Z.PKP=2>E54DM2EZ3NZ27;&C8^Y_[6J(FJ
MJ_V/U00H'P1OO$O*O),F0MV7]\2NNK-&II6+6O69-&>:FC]WL>GJ!,NY@Q
M
M                                                   *<O?)'(>1
MY_>L!XCMUGD=BD5._)+[D4E3Z(VIK&]Y%201TFCW/V(JO?JK6]BIJB;B4AXG
MY&K<]MUVH\@MB63-<9KGVG(K4R3OHF3M:CV2PO\ LHI6KN8J^NG7M4()X@;7
MXC[A>+._A"M]%M3*:1+JWO:&/6H63S%TJT55\W_)Z A5?]WO_4^>??-M^YU
M3+M$,0
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M(                  *-JOVFJ+X-7\6D.;_ +/RXE$SO;]/[?6LO(Z2]@
M                         *,PU&?2CY-=4Z^E)8[&E#K_ ,,K%[W3R:=X
MB!/ \9%EC\6EV?;&JZ9..$=.U$56K6)=OM6NO15V:::?7!P*9^4GQU?%'_[M
MA]T"=Q(/"+@/)N.9]F^3\A6"IL\M^A2?OIV-CCDJ9JITTB,1KET]EKH"77X8
M@
M                                                     %&<"(D>
M;\U05".2Y)ELDLFYVY?1I8&K3^5=$VH[3UOW.A,M-C#;]-RAXEI<(<C+\^EL
MD-@ETC[M+Q'9IT;TF18]4G5F[>FWU>@%=>@?WA']ITW\''O< G<3OP@\/YYQ
M);LKI\XH8Z&6ZST4E$D51#4[FP,F1^JQ.=IHKT[0B72P0
M                                                         *-\
M+_Z(WCX27[A$<[0]K*A>Y?Z2_/\ !JO(Z*^@  !RUXZ4_P#T<V'X73\7D/+J
M-Z%BZ"\M;J,WP._JDN/PY4_B],3I^U8=.>7CFQUW3!Z7
M      4;5?M-47P:OXM(<W_9^7$HF=[?I_;ZUEY'27L
M          !5^><99!<LOH>2..[Y#8,WI:)UHK?3J=:NWU]N=)WK8IXVN8Y'
M1O\ .8]BZ^3L"63QKQK<L6NU^S3,+PR_Y_DRP,N-?#!Z+24]+2-VPTM+$KG*
MUC=55SE75ZZ*O4"QP@
M
M             *IRGB&]U&8UN><;YA+A617B"*FR!%H(;K15R4J;897P3/C1
MLS&^:CT=['IIVZDI%QKQS;^.+/5T<-9/=KU=JN6Z7^^5FU*BNKZA?/D<UOFL
M:B(C6,;T:GKZJI":
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M]/[?6LO(Z2]@
M
M
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MWUK+R.DO8
M
M
M                                                     !1OA?\
MT1O'PDOW"(YVA[65"]R_TE^?X-5Y'17T   .6O'1^KFP_"Z?<)#RZC>A8N@O
M+6ZC-\#OZI+C\.5/XO3DZ?M6'3GEXYL==TK-#'40R4\S=\,K71R-7L5KDT5/
MWCTN Y\Q.HY'X)HZC!Y,.KLPPNEJ)I<<O%F="Z9D%3(Z=89X'.1R*U\BIN7I
MZFJ'2S-C/G:VMF>'%X,O;R?N[.,<&#>8]1<J9==,HS+*Z.;'K-56:>U8]AKI
MV32.<]JN])J.[=M215U:C5ZHCO6ZZ[SETB*UW9QQF6RD7M,VMN1AN1UT0XGR
MKE+C[ [1ADO$]XKZRWL>STE*FE@A>Y[W/3J]5VIU[5-V?EY>9>;;<;K3DWS*
M4BNQ.YU&\QC'N2L7I<]YBOME96\EY#'#':\7I)&S>C4].O=Q0K(QRM>NBM<[
M3R,[>IHO:EMFD3]V.%Z*UM&-YC[T\'60#C>OY$Q"X5F79-Q/?\FY$N:N].R"
M>6&-&1+V0T\6U6QL1/\ )ZK^YT-^;%+?=K>(K'!NM67-HW9K,VGJ=E/\BILR
MQCD^W\RT6)UE\MEWQZ"V7:T4KXW7"VU&_OUT8Y4W(B>:[;Y=316:VRYI,X83
MCU6VT3%]J(QW,&PXXLN59%RO?N6[Y8)L6ME7:X;-;K;5O8M94=U(CW3S,8J[
M?8[6H[R:>H1FVK7+BD3CNXII69O-IC#<P9_B,QJ_95A5JM^/4$MQK8;];JJ6
M&!$5S8(7/WO754Z-UZF.FO%;3,\4ISJS:(PXX^U8N74M178I?:*DC66JJ;?5
MPP1-]D^22![6M3UU5=#SUWX;I<Y63CW-:?%>"*.:R5+*K'+TM3?(E:FZDA5^
MN^3KT30Z%LVLVS)QWXW'DKEVBN7&&]O\DK,XSQN^6CE3EB\W*AEIK7>JJU26
MJJD31E0R""9LBL7R[5<B*>;-O$TI$<&+=2LQ:T\>'V*TO'&&2W+&^26S,9:+
MI)G3\CQ=UP>RG@K70HWN6M>]R(B2ZJUJJO:>F,ZL6KPQLX2T^*F8MSL8^IB<
MP9MGV5TV$6V]8-58O1-RFTI4SUM3!,LU8DBHR*G;$JN<S17.63L[$)R<NE=J
M8MC]V6.;>TQ7[N'WJ\7'\SWRSBV#&.3LGR:_<=R\@8EE$C*ZDJ*)6OJJ"K5%
M[Z-T6]KE8]RZH[L[/7(IG3;+B(MLS7ZV4Y41>9FNU$_4LG@C$:^Q07V\UF(T
MF%T]VGC][;/ JOJV4L*.1JU3M[T5RJNJ)T5/*>?/OC,1M;6#=E5PC>V5P'E;
M@ !1M5^TU1?!J_BTAS?]GY<2B9WM^G]OK67D=)>P
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MMJ8Z>&GE=*]9FOCWJ].]BB7HO3HBA$K;"
M                     .2,P\0GB4LN6W^S6+B2HN5CMUQK*2V7%MHN\K:F
MD@G?'#,CXEV.1[&H[<SS5UZ= RP:7Z2_BJ^9>I_(MZ^N#"#Z2_BJ^9>I_(MZ
M^N#"&NO?BW\1>,T"W3).+&V>V-<V-U;<+;=J2!'OZ-:LDSVMU7R)J#![VWQ5
M>)B\T$%TL_$CKA;*IO>4U;26J\3P2L7IN9)&YS7)ZZ*#!E?27\57S+U/Y%O7
MUP80?27\57S+U/Y%O7UP80?27\57S+U/Y%O7UP80?27\57S+U/Y%O7UP80T=
MZ\97/.-UE+;LBXXIK1<*[3T*DN%%<Z6:?5VQ.Z9+(US_ #ET\U.T&#>?27\5
M7S+U/Y%O7UP80?27\57S+U/Y%O7UP80?27\57S+U/Y%O7UP80?27\57S+U/Y
M%O7UP80?27\57S+U/Y%O7UP80TM)XQ^?*^^5&,4/&U/59+2(YU79H*&YR5T+
M6:;ED@;(LC43<FNK?*@,&Z^DOXJOF7J?R+>OK@P@^DOXJOF7J?R+>OK@P@^D
MOXJOF7J?R+>OK@P@^DOXJOF7J?R+>OK@PA\3>)WQ24T,E14<.3PT\+722RR6
M>\L8QC$U<YSE5$1$1-55080UF/\ C!\0664TM;BW&4-\HX']S-46RWW2LB9+
MHCMCG0O>B.T5%T4&#;?27\57S+U/Y%O7UP80?27\57S+U/Y%O7UP80?27\57
MS+U/Y%O7UP80?27\57S+U/Y%O7UP80UU[\6_B+QF@6Z9)Q8VSVQKFQNK;A;;
MM20(]_1K5DF>UNJ^1-08,FW^*?Q-W:BI[G:^(GUUNJV-FI:RFM-XF@EB>FK7
MLD8Y6N:J=BHH,&1])?Q5?,O4_D6]?7!A!])?Q5?,O4_D6]?7!A!])?Q5?,O4
M_D6]?7!A!])?Q5?,O4_D6]?7!A#1W;QE<\V"Y4EFOO'%-;+Q7[?0;?6T5SIJ
MF?O']VSNHI)&N?N=YJ;475>@,&\^DOXJOF7J?R+>OK@P@^DOXJOF7J?R+>OK
M@P@^DOXJOF7J?R+>OK@P@^DOXJOF7J?R+>OK@P@^DOXJOF7J?R+>OK@PAI:3
MQC\^5]\J,8H>-J>JR6D1SJNS04-SDKH6LTW+) V19&HFY-=6^5 8-U])?Q5?
M,O4_D6]?7!A!])?Q5?,O4_D6]?7!A!])?Q5?,O4_D6]?7!A!])?Q5?,O4_D6
M]?7!A#XF\3OBDIH9*BHX<GAIX6NDEEDL]Y8QC&)JYSG*J(B(B:JJ@PAK,?\
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MA^%T^X2'EU&]"Q=!>6MU&;X'?U27'X<J?Q>G)T_:L.G/+QS8Z[I@]+@
M        :',</L.=X_58UD<"U%LJMJJC'NCD9(Q=S)&/:J*CFN35%,Z7FDXP
MQM6+1A*$V;@ZW4U]MM_RC)+UEU19)$J+)!>:ITL%+4-TTF1C=$<]-.CGZFZ<
M^<)B(B,>)AXJ,8F=W!:AYFT    %&U7[35%\&K^+2'-_V?EQ*)G>WZ?V^M9>
M1TE[                                       !3WBH_4!FWWM3_CD
M3#!\(/[.V&_^)_\ FM6"5WA    <7>//^N.*/OFZ_=+:&4.T0Q    !Q!C?[
M?UW_ />?_)VAEP.WPQ   #!O7]3W#[VF^YN Y*_N_/T/S'X3I_Q=0REV&&(
M  <Z>-O]157\)T'\=P3"Q> OU*8#\!T/W%H)6,$   !Q!XL/VD>*/_"__-W!
ME#M\,0    <0<)?MK<B_^-_CD 93O.WPQ   "*\F_JVS'X#N?XI*!07@&_4]
M>_\ F6J_$* )EU.$   !RQX^?U/63_F6E_$*\)A?O&7ZML.^ [9^*1!"5
M #B#FW]M;CK_ ,$_')PRC>=OAB
M                      YT\;?ZBJOX3H/X[@F$W\-GZBL%^#&?QW@E:@0
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M3[A(>74;T+%T%Y:W49O@=_5)<?ARI_%Z<G3]JPZ<\O'-CKNF#TN
M             HVJ_::HO@U?Q:0YO^S\N)1,[V_3^WUK+R.DO8
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MJ]-% S@
M
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M^WUK+R.DO8
M
M
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M1,[V_3^WUK+R.DO8
M
M
M
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M81U(^4,HOXR8GBC'E^4K5\-/ZC<.^]9OQJ8\^K\K;JL]/Y*O46N>5Z
M*-JOVFJ+X-7\6D.;_L_+B43.]OT_M]:R\CI+V
M
M
M
M                      4;X7_T1O'PDOW"(YVA[65"]R_TE^?X-5Y'17T
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MORRK6*Q$1O0WA@R      HVJ_::HO@U?Q:0YO^S\N)1,[V_3^WUK+R.DO8
M
M
M
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M65U=4JBRSU,VF]ZZ(B(G1$1#32FS&#SYV=.;;&4P,V@
M  "C:K]IJB^#5_%I#F_[/RXE$SO;]/[?6LO(Z2]@
M
M
M
M                        %&^%_P#1&\?"2_<(CG:'M94+W+_27Y_@U7D=
M%?0   YC\;GZO;%\+)^+R';Z(\I/4>+5]K'59G@I_55<OANH_%Z<QZ6\M'4[
M*=+VOTND#C/8                     HVJ_::HO@U?Q:0YO^S\N)1,[V_3
M^WUK+R.DO8
M                                        #%JKE;J%%6MJX:9&HCE[
MZ1D>B+T15W*AE%9G>A$S$;[456?8+1;O3<GM--LTW]]7TT>FO9KND3374VQI
M\V=ZL\DL)S:1PQRM/4\S<4TFO>YA:W:.V_::EDW7_JE=T]?L-L:+/G\$\C"=
M1EQ^*'E9N:N,,AO5)CMER&*MO%<]T=+3Q0U*H]T;5>[SUB1B=&JNJN34F^BS
MJ5FUJX1'41749=IPB=U/CQ/0
M
M                                *-\+_P"B-X^$E^X1'.T/:RH7N7^D
MOS_!JO(Z*^@  !S!XU)H:O";-;Z:>&2NAN39I:1)&=^D:PR-1W=Z[M-5[3J=
M':C+RLR9O:(W$7T6?GU_^=9LS?!C+#2\;U]NGGB9<)+K/4MI.\8LW<K# Q'J
MQ%U1%5J^0QZ1U&7FYL32<=Q-='G9%<,RLUW721S0
M!1M5^TU1?!J_BTAS?]GY<2B9WM^G]OK67D=)>P
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MQ.M"ZN0
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M)Y?MCV=#+U9FQOS6/I:;=(Y-=^6MF\7&#IIZ)CU^GZKJKJ>G8FB>5-*AVO\
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M6).B)54RHCE1/(CD5'?5/5E7VJXN'TCI8T^=-8WIW8ZDIV;7-
M         HVJ_::HO@U?Q:0YO^S\N)1,[V_3^WUK+R.DO8
M                                          !@5%\LM&NVKN5+ [56
MZ2SQL75.U/.<G89Q2T[T2QFT1PM-4<D\=TB:U66V:+5%5$?<:5%5$[=$[S5?
MJ&V--FSO4MR2PG.I'XHY6HJ><.)*37O<NM[M&[OM4BS=/^K1W7UNTVQH<^?P
M2PG4Y<?BAIZKQ*<+TNY/SE[Z1NGF0T=:_77U'=QM_P#WC;'1NHG\/UQV6$ZO
M*CA^UK)/%-Q;JJ4:W.O\[:GHU"]=?W-[F?7)MT=F5[::UZMBNIK;M8F>I#&?
MXH,<E<C;;B.35BJY6HY*&-K51/*W29RK]5$/)F5T^5&.9J,FF''F1'VMT6S;
M=KE7G^F6,_Q(7F1&^@\:WB1515_WB1M-V=G;$[M/!;I+HFO;:S)^B]9^R6^N
MGU=M[)O],8,5_/?)]4G_ '?QFV!5;JGI-UB7KZNBQQ?O'BS?>+H'*[;65GFT
MM;_UBW*VQH-?;>R>6U>S#'EY@YUG1WHN*V.D71-OI-1)-U\NO=S-U/%;WR]W
MJ_\ />W4R[=>K?'1'2$_@K']788TF?\ B&JU727&J!JN3_5Q5+U1/+MWK)_A
M4\&9_P!@= Y?:US[]2M>O:&VO0.OG?G+CE[#&??O$#4KJ_,[?1(KE54IK=!+
MHGJ)WT*__3RGCO\ ]D]$QVNGS;=6T1]EI;X]W-5._FUCJ0QG4_,%5M=6\F5;
M53=JRFHH84\[UV.;_%/!F?\ :.FB9C+T6,<=LWK;$_:W5]V,R>VS^2O\6,_%
M<TJ4VUW)&1R-5JM<V&LD@:NO;JB/5%3]T\E_^U+_ (-)EQU9F>M#='NO3AS;
M_8QI.,J>I1??#)<@K5<U&N[^X*Y-$\GL.SUE.?;_ +3Z3Q^[E9%8YEOSMU?=
M?3<-KS_5'8>2<-X.Z19:FGJ*J1RHKGS5,JJNG315:K5/'?\ [/Z:M&$6I7J4
MCKXM\>[.AC?K,_U2S(>*>/X/866-=%U^V2SR?QY%.7?_ +!Z>OOZB?HIEQ]E
M'IKT!H:[V7'+:?MEGPX!A-/ILL-$NW73O(62=OJ[T=J<_.]\>F<V)BVJS-WB
MML_^N#T5Z(T==[*KR1/VL^'&L<I].XL]%%HFB;*:)NB>IT:<N_3W25^VU&;/
M5S+]EZJZ+(KO9=8_IAGPTU-3_P"HA9%TT\QJ-Z)Y.B'-SM5G9WE+VMU9F?M>
MFM*UWHB'J>9F              BS?UX\;_Z5?^+N/T+_ -8^SM7SJ?8H/O-^
MHR>I;K.JSZ X8
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M6T_J_P#67;Z#_6T_J_\ 67](+7_5E%_L(OXB'NOOR^_5WF68I
M   4;X7_ -$;Q\)+]PB.=H>UE0O<O])?G^#5>1T5]  %'>(#KD'&+%ZL6^JJ
MM\BJC6:?XSR:C?KU5CZ'[3.YJP27D$[4 @7AL5?>C,F?8-R6MVM\B:MC&GWI
MZKU=.=OE\R%VGJ5T                   "C:K]IJB^#5_%I#F_[/RXE$SO
M;]/[?6LO(Z2]@
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M\F+[^Q6*X]7"(Q:K9>9>T6O>U]G>VIQ^U=9Y7H
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M/4%O.TY3X5U/'')/8/>G+?BG>_P"?^2/4%O.TY3X5U/'')/8/>G+?BG>_P
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M$$\\<=0[9'-+1MC1S6*O^>OK:]-=OHT8S6+8VC@_BP\=.&,QA"^#Q/2
M         HVJ_::HO@U?Q:0YO^S\N)1,[V_3^WUK+R.DO8
M
M
M
M                              !1OA?_ $1O'PDOW"(YVA[65"]R_P!)
M?G^#5>1T5]  %'<__I'QA\.K_%8>34;]5CZ'[3.YJP27D$[4 K+@AM4_$.1F
M4.J5KKW=$IE3M[U86[-/JZ&6EPX>-Z>G>VR^9'7;OPM/I7<'XVRGV]_&ZN97
M(GLTJ?39U?O_ ,[JG;Y-#JZW'QT_1]BI:/R4?3]J595>\0;67S'TDITSA]@J
MJMT21?[TMO1KFZK*C?8(_P"Q5W;Y#32ML(G\./UM]K5QPX<$9\,/ZD<6_P!E
M-]W>;=9Y6S5I/)51?&*F@A\2W)U<^6"''Z>T6UEYFF5C*=M0K(T1)%=HW7H[
MM]<RO$^(I'#C)3RMNI'78_B+L.6U&.R96VZ4MUXJM$E%<*C#88TI'5%-#LU7
MTQFY7-5R[D8C=-"=+:NULX86G<Q_@:B)PQWZQNX?Q>G+])Q#=,?MG)-ZLE1>
M<HRJFI8<:M4=34PSU<\\2.@B5D,B(U&[DWN1#')\9$S6)PB-]EF37#&=W'>2
MO@#B)W&&.5%5='*N47US:FY0->]T%*Q-5CIH]SG:]VCEW/\ *IAJ,[QEMS>A
M.3E[$;N_*WSRMX           *-JOVFJ+X-7\6D.;_L_+B43.]OT_M]:R\CI
M+V
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M<F8SRSC#<LQ19_>Q9Y:1[*N-(9F30Z;D<U'/3L<UR:.7HH$Q
M
M                        !JB::KV]@
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M^#5_%I#F_P"S\N)1,[V_3^WUK+R.DO8
M                                $5Y-_5MF/P'<_P 4E KKP@_L[8;_
M .)_^:U83**^&_\ 77XA/ARB^[7($KOY-_5MF/P'<_Q24(<,<"7"LX.?QSR;
M42/^3[DB.KL>32.5>YI:^EN-3#3RN\B(UC&/3R[4FT#*5[^+546[\.*BZHN7
M4FB_]9$$0^/&E3P5>/\ 'M+4QMEII\KHXIHGIJU['Q2-<U47M1470$/;Q"\$
M<16SBC(LFL]@H\;OMAIEN%LNEL9Z'(VIB<U6,7NU:UW>+I&FY%T5VK>N@(E:
M'"&3W6_\,8GD^5RJERFMC9:^KG7SI&0[FI.]R^61C$D<OK@E6WA?@GS6]\@<
M\7&-R29?<W4%B[WV3+1;EV,VZ^151D;O7B!+-9XK+/<:^\8YC&)7>_YM;;I6
M6R&P4*->^2&@<C'UDLJ(K885<NU-R*N[H#!\V;Q<8=76RY07:PW:U\@VVJ9;
MDP18>_NM55S;MC*=J(U7(FU>\5S6[/*GG,W#!NN/_$/3Y3G/R;9?B=RPC,JB
M!U5;**YJV2.KB8USW;'HUB[MK7N3S5:J-=YVJ: P03Q&6BUW_GOA*S7JCBK[
M5635\551U#$DBE8JPKM<U>BIT!".^+/C7C;CO#K1EN"6^FQ;/Z:ZTS;,^T+Z
M+43>R5^V*-4W*Q4:[>C=471-?.T4F$^\6LE?-X::^:Z,2*YR+:'UL:)HC9W5
M,*R-T15[':^4(A"_#Q<*OAGD>;AF]RO_ #6S*CI\BPJKF7S$GFIT?- BKTU5
M&N9_I1ITUD"927+/VX,%_P"49_X]T".!8'B3SI^ </Y!<:1ZMO-SC2S6A&=7
MK57#6/5G;YS(^\D3_1!"B>)<7J?#CSGC6'UKWMLO(N.4T52]RJL3;_1LW2M1
M5ZKI(CVM3R=^WZA.^[/#%S-X%?U*5'PY6_<:<)ETR$
M
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M27D$[4 @/AL_JO-/^9:W^+&-/O3U7JZ<[?+YD+N/4KH
M  %&U7[35%\&K^+2'-_V?EQ*)G>WZ?V^M9>1TE[
M                                         BO)OZMLQ^ [G^*2@5UX
M0?V=L-_\3_\ -:L)E%?#?^NOQ"?#E%]VN0)7?R;^K;,?@.Y_BDH0H/ASCJW\
MJ>#:S897HULE9#='V^I=_P#9ZZ*ZUCH)>G71'HB.T[6JJ>4)G?4O<>0[CE5@
MXEPW*6N@SO <UI;%>Z:5=9E9!)''!*[MU54C=&Y=>KF*OE"5V^-F&HJ<9P&G
MI*A:2JFRFEC@JD:DBQ2.AE1K]JJB.VJNNGE"(;BM\-.69DZ&BY:Y8NV6XU%(
MR9]CI:.*SP3.C=N1)EBEEWIK_FHY/(J+U!BV?B>R)N"\+2XKC$#8;GDBT^)X
M_;Z=$;I'4M[M\;&IIHB0-=&WL1%<T$+/XYPZEX_P7'\-H]JQV>BBII)&)HDD
MZ)NFDT]6217O7]T(41X2::G3(>9*M(F)5.RNIB=/M3>L;99G(W=VZ(KE70)E
M\8M0T3_'+FT[Z>-TT.+0U,4BM17,F5MMA61JKV.6-SF:I]BJH#@>_.2)%XD^
M#*B+S)WS5T3Y&]'+&G=IM54\GGNZ>NH(:CQ/XW;LPYLX:QF[K*EMN<EP@J5I
MY%AEV*Z%?->WJU>G:$PBV?<66'PQ\A8?RO;F2Y!@\U:VV7FFO:-KY[<^75[*
MBFD5J*BM1KWL5>J.;IN\_H-];?C)DCF\/E\EB>DD4E1;7,>U4<US75D2HJ*G
M145 B&!S?QO79EPKC.58PUT>>X-1T5[L-1#_ *Y6P0Q23Q-]552-LC4TU5[&
MHG:"%=X9R-0\J^)[BS-*1&QSUF%S1W&E8NJ05T+[HR>/KUT1R:LU[6*U?*$\
M#;>(S)[MD?..#X1CF/5.71X0C<JO5CH7M8^299&=RV1ST<B)&B1N75O5)=/+
MT$(SXBLSY-R_'K-D\_%5WQ2X81<([S2Y!45$=1% QJIO:YK&,<B.>V)VJ+]B
M"'8N%Y10YKB5ERVVJGH=YHX:V-J+JK%F8CG,7UV.U:[UT#%0?@5_4I4?#E;]
MQIPF73(0
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M29.Q\,[$D8[ZK7(H0Y_\)_\ \U_^>+I_]4)ET6$
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M6D.;_L_+B43.]OT_M]:R\CI+V
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M*CN]>GG]B]G0)5QX%?U*5'PY6_<:<$NF0@
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M]W"V>X=43,XLRME-897;V66[Q^DLA<O:D;U1W3][ZIY)R;1VLK''2N3G1_\
M>F-NZKN/NFX3S++*ZGGY8R=ERL],])6V*V1^C4\KVKJG>N1&JJ>1?+ZZ$QD3
M/;2B_2N5E5F-/39M/XIW9^A>%)2TU#30T5'$V"DIV-BAAC3:QC&)HC41.Q$0
M]41@KEK3:<9WY>Q+$                   "C:K]IJB^#5_%I#F_P"S\N)1
M,[V_3^WUK+R.DO8
M                'G/!!502TU3$R:FF8Z.:&1J/8]CTT<US5U145%T5% C&
M,<9<>8772W/$L8MMEN,T*TTM50TT<$KH'.:]6*YJ(NU7,:JIZJ(!*P
M8\%!0TU1/5TU+##552HM3/'&UDDJMZ(KW(B*[3R:@9             :7)L1
MQ?-*".U9;:*2]6V*9M3%2UT+)XVSL:YB/1KT5$<C7N37U%4#VQ[&L?Q.V1V7
M&;936BTQ.>]E'11-AB1\B[G.VL1$U5>U0-H
M
M \*VG],HZBDW;._B?%OTUTWM5NNFJ:Z:@49X?..>9^*;=1X3DM1C%5@=$E5)
M'/;G7!]W=45$JRMU6:..'9JY=?-UTT[0F5]!      %8LXFFJ.<9.8;O=6UD
M-':DM&/V=(%:M&K_ /6RK+O5'*[=,G1B=)/6"5G!            -#F7YZ_F
M_4_)[[U_G5NC]#]_O2/>_;WC>\[ST7[9KLW;=OV6FO0"O?#]QCEW&MKRE<UJ
M;;4WK);Y47QZ6=T[Z6/TEC-S46HCC>GG([1.O33SE"97 $
M          !1OA?_ $1O'PDOW"(YVA[65"]R_P!)?G^#5>1T5]
M                  4;5?M-47P:OXM(<W_9^7$HF=[?I_;ZUEY'27L
M
M
M
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M[OHVIC/MFVS)B)C=^?Y\96N>U;@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M/[MST:NO1W:$PGD<C)8V2Q.1\;T1S'IU16N35%3]T(?0
M
M
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ML:XXX&J[PM+49Q>[C-=I+74S(VCLE$UU?-;J*>96S(S8K8TD[=-4TZ@2CD;
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M.>(;C7%<%H/>WWOIJ_(LBM\$\KX7)20K3V^:2.1[T[WO9)/MB^<J>5=>@9N
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M"NO7KM"(="4M.RDIH:6-56.!C8F*[JY6L1&IKIIUZ!#U
M
M
M                                                           !
M'+'A-EQ_)<FRRB69]XRR2DENLDST>W_N^#T>%D:(U-K6MUZ=>J@:BQ<1X9CG
M(M]Y0M5/+%D^10)37!=Z+3[=8W/<R-&IM=(Z)CGKN75>OE"4Z"$(SCC.CS:K
MI;DW(;]C5TI(G4[*W';@ZA>^%[D>K)&.9+$]-4U171ZIZH'U@7%V,<>RW*NM
M3JRX7Z\O8^[WZ[U+ZZXU2Q(J,225^GFM1>C6M1 /?D/CFQ<E6FDM=ZFK**:V
MUD5SM5TMDWHU=1UM.CDCFAD5KT1R(Y?9-5/6U1 -/B/"V)8=E7Y[TM1<;EE<
ME#);JNZW:J6MJ*EDLD;UDE>]J+O1(F,:C5:QK.C6IJH3BT]7X=,/J*FZLI;W
MD-MQJ^54E=>,3H+DZGL]3-4+K-NC:SO6MEU\]D<S6JG331$!BF59QSC%7>,0
MO#8'4J80E2VPV^FV144:55.E+YT2-Z]W&FD>BIM"&3!A-G@SFKY"W3R9!5VV
M*RKO>BP1T4,SIT;&S:BHKGN5SO.4" R>'#"W/KJ."\Y!28A<ZB2LK\,I;DZ&
MR2R3OWRM6)K.]2-ZKYT;9D9ZP3BG%7Q]CE7D>+9+W3X*G#8*NEL%'3[(J.&.
MNA93O^U(W[&-B,9HJ(U/($,#+^-8\LNT=XBRK(L=J4IVT=1%8KAZ+!/"Q[WH
MCXY(Y6H]%D=]LC1LFGV71 -[B.)6#!<=H<6QFE2CLMO:YM/#N=([5[ED>][W
MJKG.>YSG.<J]54"$XCB]VL?-_)%_FHGI9<KH;!4TMQ1?M2SVV&HI)8EZKYR)
ML=Y.@2U]7X=,;KTFH*[+,MJ,5J%7OL5DO4KK6Z-S]ZQ*W9WW=^39WVF@,5KV
MVVT%GMU):;73LI+;0PLIJ2EB3;'%#$U&L8U/(B(F@0ALW%%D=R')R31W2[V^
M\5;:9MTH**M6&W5_H3%9!Z3#M57[$5=$1Z-]5%U74EJ[AP;8Y\BNV1V/),BQ
M>:_3)57NAL5P;2TE54HB-69S'PR.9(Y$\YT3V:^4&+:9GQ)C>;6BQ6VNK+G0
M5V,O9)8K];ZQT=VII&1I$KDJ)$D5ZO:B=XLB.W+U7J$,.7A7&*O%I\3NURO%
MWI:VOI;I<JZY5SJNLJIJ%\;XF222-5J1(L3/M<;&I^^$XI+?<)LV19'C637)
MTZUN*3553;(&/1M.Z:L@[ASY6*U5<K&JNS14T5?*$/S&L(L^*U^1W.V/G=7Y
M17NNERGG<U[DF6-L361Z-32-C6>:U=?+U CL'"F&T^"V/CMKJQV.6&X0W6!K
MYFNFJ*B"J?6:5#U9Y[72O5ST1$U]4)Q?F7\,6#*\I9FE/>;WC62+3-H*RNQZ
MN]!?5TD;E>V*?6.1'(BKT5NUW9UZ(#%^Y-PKBF2V''[(M;=;74XO*M18[];Z
MUS;M!*]%25WI,[9E>LNNLBO1=5!B_<6X5Q#$+S<\BM<UPEO]YM_O9<KI652U
M55,U9'2.F?+(U7+,JN1-RKHC6M:C4:U$!BD^%XC9\#Q:UXA8&O;:+3#W%+WS
MD?*K=RN5SW(C45SG.5570(>5DPFS6#)LFRZC69]YRM]&^Z/F>US$2W0>CP,C
M1&IM:UJKT55ZJJ@1G(N%[)>\KK<TM=^ON+7ZZPP4]ZFQ^M92LKF4K=D2SLEB
MF17,9YC7LVN1.Q0G%$^5>-*C*:KC#C;N;G<\+AN57<LBO$U1/-41I04<JP.G
MJ]V]))99UV+KVITZ- F.&\-X_B-_=E=1=KSE&3-@=14EUR2N6X3TM*]VYT4'
MF1M8CE[5V[E_RNJZC%\S\)X;4X1>,!G?6/L=^N<EZN[UE9Z1454U6RL>CW]W
MIL<^-K53;[%--08O?/.([#GEYMF227.[8_D]IBDI:6]6"K2BJUI9EW/@>YS)
M&NC5>NBMU1>Q0,.]\'XG?<8M6.37"\4]59:Y;O;<CAKWNO<5>]SG/F]*F27<
MK]ZHY'-5O9HB:)H,61AW#.(X3E$^:6Z:OK<GK*!;9<+G<ZI:RHJF.F;,Z661
M[=RR*K(V=%1C6,:C6H#%[XMQ19,/RJ]939;I=V,OM54W*ML4E:K[2E=7/WSU
M#(-J+O>J?9/5$^Q1 AHK1P!CV/2^CX_D^3VG&$J'U<6*T-T6"UQNED61[(T9
M$D[8W*JZQI/MZKY0G%NLMXII<MNM1<URK)++'6PMIKA;K1<O1Z*HC8BMZQOC
MDV.5JZ.="K'+ZH$JL-ALV'X_1X_C]&E'9;5 D%%1P[GJV.-.Q%<JN<Y>U5<J
MJY>J]0ASUQ?X?%ON$,O.9W+)<:R'*JFON.7V"WW"2AIJM:RKF<V.JA5KE15A
M<UCMBL54Z*$XK>RCB##<FQRR8TV.HLE/C,D,V-UMFF6DK+?)3L[MBP2:/^QZ
M+O1R+VKUZ@Q>]AXXALMNO%!59)?K[+>J=:2HK;Q7)4RQ1JU[?]W8R..&)WVQ
M556Q==$UUT0(;S$\8M>%XU:L4LC7MM5GIHZ.E[U4=(K(DTW/5$1%<[M<NB=0
M-/R'QM8N2:"WTMVJ:ZW5MHJV7&T7>TS^BU])5,:K=\4BM>G5'*BHYJI^\@&M
MP[AG$<)RB?-+=-7UN3UE MLN%SN=4M9453'3-F=++(]NY9%5D;.BHQK&-1K4
M"<6AD\.&%N?74<%YR"DQ"YU$E97X92W)T-DEDG?OE:L36=ZD;U7SHVS(SU@8
MIQ5\?8Y5Y'BV2]T^"IPV"KI;!1T^R*CACKH64[_M2-^QC8C&:*B-3R!#TI,'
MLE)F5WSI%FFO=YHJ:V5#9GH^".EI%>YK(F;4T1SGJY^JKJH$ I?#7@]+$VT>
M^U_FP=DZU+,'EN*NL*.[SOMBPHQ)'1[_ #^[?,K-?($XI_+@MBFS2W9T])4N
MUIMTUHM\#7-2EB@J)&O>YL:-U1Z[$9KNTV]- A#[YC5ZSGF"RU-UHI:;!,!9
M[Y44DVB,N5^JV*R-[&ZZJRCCU7<J)]L=IU1%"5JA
M
M
M
M
%   ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>tm2227887d4-lc_5lnp4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_5lnp4c.jpg
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M%!04%!04%!3_P  1" *;!M$# 1$  A$! Q$!_\0 X0 !  (# 0$! 0
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M
M                                                         JSO
M(N<W8O.E:JHON9(FJ<."O:BA,--:^ZYL)/;**>;"Z9TLL$3Y'=HK.+G,157A
M/XP8LOZJ^P'S)IO9%9Z^#$^JOL!\R:;V16>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'
MS)IO9%9Z^#$^JOL!\R:;V16>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'S)IO9%9Z^#$
M^JOL!\R:;V16>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'S)IO9%9Z^#$^JOL!\R:;V1
M6>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'S)IO9%9Z^#$^JOL!\R:;V16>O@Q/JK[ ?
M,FF]D5GKX,3ZJ^P'S)IO9%9Z^#$^JOL!\R:;V16>O@Q/JK[ ?,FF]D5GKX,3
MZJ^P'S)IO9%9Z^#$^JOL!\R:;V16>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'S)IO9%
M9Z^#$^JOL!\R:;V16>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'S)IO9%9Z^#$^JOL!\
MR:;V16>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'S)IO9%9Z^#$^JOL!\R:;V16>O@Q/
MJK[ ?,FF]D5GKX,3ZJ^P'S)IO9%9Z^#$^JOL!\R:;V16>O@Q/JK[ ?,FF]D5
MGKX,3ZJ^P'S)IO9%9Z^#$^JOL!\R:;V16>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'S
M)IO9%9Z^#$^JOL!\R:;V16>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'S)IO9%9Z^#$^
MJOL!\R:;V16>O@Q/JK[ ?,FF]D5GKX,3ZJ^P'S)IO9%9Z^#$^JOL!\R:;V16
M>O@Q:G*.[#L108S>JZDPRFBJJ:@JIH)$J*M5;)'"YS5T6=4X*@,4RV$<YVRN
M JY55?<.@35>/!(&H@)6*$
M
M
M                                        "J^\G]!6=?!C_P -@3"Q
MK+_T>W_JT/Z-H0S@
M      &CS3Y'9#\&5OM=X$5V"^A3 ?@.A_0M"96,$
M
M
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MP'X#H?T+0F5C!
M
M
M                                JOO)_05G7P8_\-@3"QK+_P!'M_ZM
M#^C:$,X#^7]OSZS[7][?(LYO\%34VFU9+DO:(:%D<E2[M+JVF;R-EDB:NCI6
MJNKTX:_8#/B7;N=WTMK<TV\R?$K7:+_#<;U;JFAI9:FFHF0-EGC5C5>K*Q[D
M;JO'1J_8",&P_P#I^?(_,?A.G]KJ"7GW8MV=Q<TWUS3&LHO]1<[%245QJ*6A
MF;$D<4M-<J>"-6<K&JW1DCFZ(NBZ\>A 2=\[=G<7;O)\4H\*O]19Z6IHYJJH
MB@;$K9)63(UJOYV.YD1/N5X>@"$V[YF?YCM]@-CK\,N\UGK:R[-IJFHID9UC
MH4III.75S7*B<S47@$0I2KRKO>;IX-)N58JR2Q8A9J3K(H:.5M'55[:./_B*
MEJ(U'S*JM<Y4U:Q5U;&U5X!/ \-O=^N\QO!9H-N,(6%^1TZOENN9/9'$^.A<
MC4C;*Y6+'&[FYTYVL61Z:<J(K7.480V6S6\N\V![Y0;0;K72>[PUE6VV545;
M(E3+!45$:24TT,^G.K'\S.#ETY':Z(H)A?F^D'>,O5]M.-[,RTUHL%12OEN^
M03NA8YDZR*SJE=(V61J(WE<BPQ<W%>/ (ASGN/<>]-W<*FSY+?<Z3(K5<9UB
M5CI9:VE66-.=898JJ)BM1[>;E=$J+P7BU40)X)7_ +V[I7UG=GCW-PZKDLMU
MNU+:*N&6+E=) E?)"LD:*]JIJB/5G,B?8"(4'AV8=[C?7$:>+"K@MNM-BC6G
MJ[ZLS**IN=8U5?IVCE15<UJM;I'RM3ASN55U">!.>Z)OKG^4Y;=]L-QJN2Y5
MM'32U-#6536I5Q2TDK8IJ>5S417^KYD5VKDY5373303#L4,7"F\>_P!N[@O>
M5O&.XK5RW6V4[:2BM6*NC1]/+45]KA6/R(VI(]R5$W6HB.YG:<NJ-#*(1?<3
M+>]ULO7V?,,UR21T5X>KF4C98:J@;*S1[Z::G8UL;%Y5_P"[\&O*[5. X&_R
M'->]CNQBUQW7QA[\4P"V1255';:&=*:HGIZ9JNEF8JM22=$1JJO,J-731C57
M4' N;N@[TY'NSBEYM^7S)69#C4U.Q]Q1C8W3TM8Q_5+(UB(WG:Z&1%<B<4TU
MXZJI$PJ"\;V;W=X3<ROP79&Y,L&,T/7/BKV.[.KZ2!Z1=KJ*CDDE:CW.3D9"
MW71R<%5%4)P:R\[F=Y3NQY?:*3<B]-RO'+DBS=6^5:R"IAC<U)FPU$T4<\<L
M:/3U2<OE)JCD!M7+WNMT,FQ;;#%\EV\O<UL;>[A"J5M,C4?+234DL[$U>U51
M%T:[AH$0J&3(^^!N[AB[@X[626/%+72\U/#1S-HJJX=DCTGJ&:-1\JN5KEZ6
MQJODL;J$\"W.YWOAE&Z=GOE@S6H2OOF/K3RT]R5C(Y)Z6IYV\LB,1$5T;H_5
MZ<4<FO%-5(F%:Y5OAO1OENI7;9['U[+)8J%\[4N,:I#)+!2N2*2KGJ%:^1D:
MO5$C;$U'>4W5%7H)P:7(MP.\[W8\FL_[?WYF5X[<U<_JY)G5M+4LA5O71LGG
MBCGBD8CT5."-XIP>FJ X)=(;Y]X"DVXVHM><8VR.MNN5,IUQJ.H1>KY*J%*C
MKY&HJ*K61JGDZ^J<U.C4(B'/V+6'OK9MC=-NE:,P<QM6SM5ML\]3'!+4PKJK
M7LI%@[)ROZ6I*YNJ:+T:!/ SN\'N=O\ ;?0[:Y?)=Y[0EVM,'NU98X8F4[;Q
M2JDE2R5NCOZ1LC$Y57ARNT] 0Z#W9W?I[!L%6[GXY4=547:VT[\?E7E<]E3=
M$8V)W*NK5?#SK(K7)IY"HJ> (P<T4%;WC<Z[LMURYN4/K+=/-=GW=E9U"2RX
M[2T3HZA&.=$JNYGMF;RHY%X<%\1/&KKNW63O 7>GOKME;Q#:J.*>D2]=>^!J
M.>Y).J72:*151$1^O*$RZ?[TN_N58%=+)MIMJUO[<7]L<CZQ6,E?!'42K!!'
M"R1%9ULKT=Q?ZE$3AY2*TQB%:9[:^]AL9CU/N5<=PDOM'#- V\6UTCZN&%9W
M(UJ.CJ(T:Z-7*D:NCY'(JIIXT)X%LYIWDZVD[MENW@QRCACO]Z?%;HH)=98*
M2OZR2.=RM545S6=3(L:.Z=6JNJ=)&"K<"Q?O7;A8=1[HXUNK#)6W#K)H+---
MK$G5/5JL?&D#Z=DBJW^C6/E37BJ<0G@=I6);LMDMJWY&-OJTL"W-L.G5)5]6
MWKD9IJG+S\V@8M@      #1YI\CLA^#*WVN\"*[!?0I@/P'0_H6A,K&"
M
M
M
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M=D/P96^UW@178+Z%,!^ Z']"T)E8P0
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MF_DVJY4731>A#WZ'KW+U6;&7%9B9<_K#J#,TF3.;-HM$8<O&L$L:L@
M
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MHB(&+*      !H\T^1V0_!E;[7>!%=@OH4P'X#H?T+0F5C!
M
M        51L/\G[G^N?U3"G^['F;]+M0N?O7Y^G1[<K7+@I@
M               "J9OIT@_4E]KO*?;VQ'1\5<Z^Q9Z7C0M8N"F
M
M                %5]Y/Z"LZ^#'_AL"86-9?^CV_P#5H?T;0AG
M                        !B72V4-ZME;9[G"E1;;C!+25E.JJU)()V+'(
MQ5:J*G,URIP74",8'M3M[MDVM;@MBALZW%6+6OC?+,^3JN;D17S/D=HWG=HB
M+IQ F0              &CS3Y'9#\&5OM=X$5V"^A3 ?@.A_0M"96,$
M
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M3-].D'ZDOM=Y3[>V(Z/BKG7V+/2\:%K%P4P
M
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MW^D \\&\_P"XVY_'5O\ 2 >>#>?]QMS^.K?Z0#SP;S_N-N?QU;_2 >>#>?\
M<;<_CJW^D \\&\_[C;G\=6_T@'G@WG_<;<_CJW^D \\&\_[C;G\=6_T@'G@W
MG_<;<_CJW^D!@7O<_>B[V6XVENR-RB=7TL]*DJWFWN1BS1N9S::)KIKJ!96T
M-BNF,;78ACU[@[->+;::.FKJ;F:_JYHXFH]BN8KFJK5X:M54"$T
M
M            %4;#_)^Y_KG]4PI_NQYF_2[4+G[U^?IT>W*URX*8  *([V]+
M53;3LJXFN?16Z[T%9<XV\>:D8Y['(J>%.9[%/;H_.8<L2\VI[S'DF/M7?25]
M%7T4-RHZB.>@GC2:&I8Y%C=$Y.9'([HTT/',8/2C^#Y_CNX=OKKIC,LD]!05
MLUMDGD9R,?-3HU7+$NJH]BHY%1R<%,\S+M2<)84O%N&%4[!?2=O?_B"+\*J/
M5J/-Y?8:<KO[]GM0V/>4O%LJL4@VWAMR7O,LNE9!8+:FO-')"]KG53G-5',2
M)-51WAZ%\GF,=+$Q;?QPBNWN?2G/F)KN[9ML^7S--W;*F+$*K(MI<FI64>XM
MNJI+A75RO>]UXIYW<S:MKY.+]$<B+IX/!KS&>JC>PO'>S]7S,-/]W&D]]'U_
M.Z&/ ]:C=_/R&8[/7"=>2W091''/,[A&Q\K$ZOF5>">I=]H]FG[V\?I>;.[Z
MG9[4O/?F)]5N!LQ24R<U6N2]H:U/5=13=3),OV$;TC([R_83F]]7L]J61W:?
MR-HSZBF7EK:?-+OVB)>#V\[8%:JIT\43A]@:K;6?TPC(V6Z4L7NXVZWWG#,S
MCN%-%76>OS&ZU$,,[&RP21L? K'<KD5%1'Q\R>BA.JG"T=&#(V3TI^UE8 B-
M[QN[:(FB)2V%$1.C3L,9&9YFGTIIYRWT+N/&]           53-].D'ZDOM=
MY3[>V(Z/BKG7V+/2\:%K%P4P
M
M
M
M      "J-A_D_<_US^J84_W8\S?I=J%S]Z_/TZ/;E:Y<%,  &)<[9;[S;ZFU
M76F95VVLC=#54TR<T<D;DT5KD\2DQ,Q.,$QBIMO=EL%/1R62VYGE=OQ.;GZW
M'J>Y,;1\KUU5C46%51B^%-5U\9Z_W4[9K69Y<'F_;Q'!$S$<F/RE:^+XO8\,
ML=)CF.4C**TT3>2&%G2J^%SEZ7.<O%54\MK3:<9VM]:Q6,(:G$=NK'AE]RG(
M+5-52UN75C;A<V5+XWQ,E8LBHD*,C8K6_E%]4KOLF=\R;1$3^%%:1$S,<;RM
MVV=@H,]N.X\T]7<,DKH6TT+JV2.2&B@:G*L=*QL;%8CD]5JYRK_*HG-F:17B
M(I&]O<;"S[;_ !F[W:U[BW">X6^]XBR6I@K;.K4J):=J*]\$C%BE65CDYDY&
MIJO,J>$G+S+1$UXK(M2)F+<<-+]8K O[#?\ XDK_ %HV?MK<M?"AAY>O)/@V
M[C*6NP'O X]=L9J*.Y-H*5U/)))64<]MGBF>KUBEIWSL35[>1W%J+IKQZ2,+
M9,Q,3'/BG&N9$QA/-,/7$ME[-C61Q9;<K[><IO\ 1POI;957ZJ95=C@DU1R0
MHR.-$5R+HYR_Z"+Y\VC=B(B/F*Y6$XS,S/SL7)]A\?O]^N.06N_7O%ZN]M2.
M_0V*J9305S>*.=*Q\4GEN1=%<B_R$TU$Q&$Q$X;,2V5$SC$S'83O$\5LN$X]
M0XQCT'9[5;V<D+%7F>Y7*KGO>[AJY[E5SE\:FF]YO.,[6RM8K&$,&T8'9[-F
MF19W2RU+KQDT=)%7Q2/8M.QM#$D,?5-1B.15:WRN9[N/B)G,F:Q7BA$4B)F>
M5*#6S          "J9OIT@_4E]KO*?;VQ'1\5<Z^Q9Z7C0M8N"F
M
M
M
M                                  51L/\ )^Y_KG]4PI_NQYF_2[4+
MG[U^?IT>W*URX*8                            JF;Z=(/U)?:[RGV]L
M1T?%7.OL6>EXT+6+@I@
M
M
M
M %4;#_)^Y_KG]4PI_NQYF_2[4+G[U^?IT>W*URX*8
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M93DM1E615MCJ:^Y76I16(LTU/5(L43%5>6)G(B,3_0WH0RXG;@8@
M
M
M
M         "J-A_D_<_US^J84_P!V/,WZ7:A<_>OS].CVY6N7!3
M                  %4S?3I!^I+[7>4^WMB.CXJYU]BSTO&A:Q<%,
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M7W^.K&/\-2?H:T)XG4X0
M
M
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MSD5OE)HJ*&*7
M
M
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MD\**>68PG!OAGD)  %4S?3I!^I+[7>4^WMB.CXJYU]BSTO&A:Q<%,
M          "GN\U2Y[=MJ+AC6W=IGNMZR":&V5*4[HV.AH955T[U61[$Y7HS
MJ7>@]=?&$PF6UF$T^W.WF.X7 C>:TT<<=4]GJ7U<FLE1(GH/E>]W\H0EX
M
M
M
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MP
M
M
M                                           "J-A_D_<_US^J84_W
M8\S?I=J%S]Z_/TZ/;ELM[-N5W+P.LLU&K8L@I',KK%4N_P"[K*=4<C==4X2-
M18UU^^U+QI\WR=XE4*6W9Q<5T%7)4LDBJH'4ESI)'4UQH94Y9(*F)>62-R>@
MJ</&A;Z7BT8PZU9QC%ZM=<Z"Y4608]7/M>1VUW/0W"-$=IKZIDC%X/C=]TUQ
MAFY5<R,)1:D6C"5^XGWLJ*FI6TNYUCJK;71HC?=2TQK74,VG2Y6-7K8U7[WE
M=]DX&;U?>L_=X7@MIYC8E51WL=E8HN>ENE;73*GDTU-;*WK57Q?E(F-^VX\\
M:+-GB:XR;*<W*WWR[<JFGQZP4<N+8;4(L=9/,YBW2M@=JCHU1BN; QR+QT<K
MO1.GI^K]V<;/3EZ?#AE7=-304=/'2TS$C@B:C(V)T(B'9B,'L;S ,(GW5SFD
MQ6-JNQRV/CKLJJ4]2V%B\\-.BZIJZ5[4143H;JIS];J(RZ81MEY\[,W8P=LY
MEB]-EV'WG$I7I!3W6BFHFR(FJ1]8Q6M=HFFO*NBZ%:R[[EHMR.3>N]68Y5+W
MO:?=W)L)LN/76OL]+784M%-CO8Y*A\5?66_DCCGJW/B;U2)$CT1C&N\IZJO!
M$/7Y;+B\S&.%MOT\C1Y.\TB)PQCM)=>L S3)L\VXSBZ/ME*_%DN*WJDIYJA^
MJUK&-C;3JZ%.?EY?*5_)Z"&FN96M+5X>'#ZF=J3-ZVY,?K;?>W!+ON3MQ=<0
ML4U-3W.N= Z*6M=)' B0S-D7F=''([H;PT:8Z?,C+S(M/$G.I-Z36.-',GVU
MSBW959MQMNJJWKDU%:8K'>+5<UE91UM+$O.BMEC:YS7H[U.K4X(FJF>7F5W=
MRV.&./ B])WMZNW8UURVVW>S;',U_;&]4%-=,DMS;;9\<I)9UM%$C'M=ULDB
MQN>Z1VBZJC'=/\B9US<NEJ[L3P3CCQL;4O:MHF=L8?,E>78=GM5L_38-AEQH
MK?E3:"BMDUQGDFC@9'!&R.H6)[(9'ZN1JM:JQIP77@IJR[TC,WK1P,\RMIIA
M7:@.#[?=X;;^S4F.X[^Q%):H%19E:^XOGF<J^7)(]U-J][O&J^@FB<#?F7R;
MSC,VQ^AII7-K$1$5P[,]QT'5P+54L],DKX%FC?&DT2\LC.=JIS,7P.375%/
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M]BSTO&A:Q<%,
M
M
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M*N=?8L]+QH6L7!3
M
M
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M(/U)?:[RGV]L1T?%7.OL6>EXT+6+@I@
M
M
M
M             %4;#_)^Y_KG]4PI_NQYF_2[4+G[U^?IT>W*URX*8  -!G'R
M-R#X.JOT+C=D^<KV88WV2X,[H/TU6_\ 4:[]$6KK3S$]F',TW?OZ)%/=4
M                   JF;Z=(/U)?:[RGV]L1T?%7.OL6>EXT+6+@I@
M
M
M
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M[8CH^*N=?8L]+QH6L7!3
M
M
M
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M/U)?:[RGV]L1T?%7.OL6>EXT+6+@I@
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M]%410EM@O$&0V&UW^FC?%376DIZZ&*33G:RIB;*UKM%5-41W'10AL0
M
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M7.OL6>EXT+6+@I@
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M.B*KG.U7BNFB*H(=$[9?1MAWP';/:D08I4
M
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M(      !5,WTZ0?J2^UWE/M[8CH^*N=?8L]+QH6L7!3
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M(E+$V)'*W5=->7734(;0
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MZ
M
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M-'#;K70V^FD66GI*>*"&5515>R)B-:Y53@NJ)J&+,
M
M
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M&%SF*BZ.5[G<OATU\!CH\JLXS:,<>".;%EJ;VC"*_3SX?+L.HSF/:
M  *IF^G2#]27VN\I]O;$='Q5SK[%GI>-"UBX*8
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M+I:9,>R_&JIE%D%BFF95=0^:-)H9(YHT:DD4K%YF/Y6Z\> 0G
M
M                   5/WDZ^]6W9V_5=DJJJA>CZ)EPK[?S)5P6Z2LA9521
MJS5R*D2NU5$X-U7T0F',5FN]TRC<&U[J6>Z7B6ZWS-:/'\"ITZ](*G&;4C&5
M\L\?*UJ1/A>QTG1Y7.NG!RH2[U#$
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MZ5ZZJW7CT] 1*_0@
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MS6RT^18M<(KG9JKF2&JAU1.9B\KFN:Y&N8YJIHYKVHY/"@&X
M
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M         JF;Z=(/U)?:[RGV]L1T?%7.OL6>EXT+6+@I@
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M<(
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MA.#J';',9=P<!L&:34C:"6]4K:IU&QZRMC5SE3E1ZM;KT>(,4L
M
M JC8?Y/W/]<_JF%/]V/,WZ7:A<_>OS].CVY6N7!3  !%LZM=M?B]^KW4<"U[
M*"I?'5.AC=*US8G*BHY45=4-^3,[\1\[5>L3$S@X4[I;&5N\5%25C6U%++0U
MBRP3(DD;N6/5-6NU3@O$M'6<89'!RPYFFI7?V0_H;2T5'0Q]314\5-$JZK'"
MQL;=?'HU$0J,SBZ\1$;'N0D                    !5,WTZ0?J2^UWE/M[
M8CH^*N=?8L]+QH6L7!3
M/"NHJ.Y453;KA RIH*R)]/54TK4?'+#*U6/8YJ\%:YJJBH!0U'W.]I:6Z05<
MT]ZKK)33)44^+UE?UMG8Y'<R)U75I(K47P.E77PZA.*_VM:UJ-:B(U$T1$X(
MB($/T     *)[Q&U^>YQ3>[6*Y_78G:[3;*OW1M=')4LBK=$=(O.D$\35U:G
M)Y37!,(=W!OH>O?^):KVA0 EU.$
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MC/PWA$K4"
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MEUEXJLT>FNG+ZE0F)1SN#?0]>_\ $M5[0H 2ZG"
M                          4AEN\>3V')+E9Z.DH'TU',L43Y8YED5$1%
M\I6S-37CXB@:_P!XM1D:B^76M,*SAPQ/]SZ#U?[N:;4:>F9:U\;1CP3']JQ-
MO,FK\MQMEXN4<,52Z:6)64[7-CTC5$3@]SUU_E+/U1K;ZO3QF7B(G&8X/E*K
M]<:*FDU$Y=)F8PB>'_I"5G8<8
M A>ZV ,W-P6Y8AVY]LJJI89Z&XQMYUIZNDF9/"_EU3F3F8B.37HZ.(%3TNT>
M_.97['DWDR^S5N(8W<J>]145DIWQU-=5T*JL"SN=!"C$U75Z,54Z41.AR$NC
M @     #COOB3[Y>X.50PTU%YDNKMO:*E5@[9UG:*94T3GZW_F>5/4]'H!E"
M\.[9]!6"_!C/PWA$K4"
M     H'?B>>+([:V*1S&K0HJHURHFO6R>(K'6\S&9'8[:H==S,9M>CVY9NP4
MTTM;?4ED<]$BIM.9RKIY4GC-G4\S,V^AMZCF9M?L1VUXEC6H  0//MT*# :R
MCHZR@FK'5D;I6NB>UJ-1KN71>8Y^JUM<B8B8QQ<;K#K2NDM$369Q@P'="@SZ
MLK*.CH)J-U'&V5SI7M<CD<[ET3E&EUM<^9B(PP.K^M*ZNTQ%9C"$\.@[(
M           !5&P_R?N?ZY_5,*?[L>9OTNU"Y^]?GZ='MRM<N"F  "F=R-UN
MT5EPVYPBS/RG()(7T]UZMW)1TC)4Y%;+*BIH[C]\FB^CP-$ZB:6^[PS#N:7J
MN+Y?E,ZVY2=G+/84+MUM3N-LODL.=0V!E]6GADBDHX*IKIF1S)H]6M:B*YW+
MT::GMU'6N?FUW;5C#YO^K9E]5:#'[F9:)_5AA]CK3 -P[!N+9UNEE>Z.:%W5
M5]OG3EJ::9.EDC?]2]"GEIF1>,8<S6:/,TU]VWT3Q2EAL>(
M       !5,WTZ0?J2^UWE/M[8CH^*N=?8L]+QH6L7!3
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MFO<]RJKD1NC00].X-]#U[_Q+5>T* $NIP@
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MGK_WF=Y7=W>"(PQQV?1"1'3<L
M A^Z.?4VV6$7+,)Z*2Y24G4PT=M@7EDJ:JJE9!#&CM'<J*]Z<SM%T371%7@!
M4=C[P&X%%74]+N'A]+01IE$.*7A]NJ>N2W25]-3S4;WKS2)+S.F5KU9HU$3Q
MZ(XG!T8$      <:=\7#]Y'6G*LMBRBF;M R.VMGQE9INT.?U]-"BI%V?J_^
M85LG]-T)KT\ RA>_=L^@K!?@QGX;PB5J!
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MKHV0U-5 L21TC&\STEE21[7*U5:C$Y$<NJ]&G$=4=_;L'NW'_DOV(=-%E7@
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M!.,I#W!OH>O?^):KVA0!$NIP@
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MM]':;S'\_GOUTBMC\0R&T-E1[EKKG200TK.1JNT<]E1(J*NFB>3TGJ>5,@
M                                 *ZWUH;/<=JLAI;_ &.XY%:7,I^T
MVRR-YKGR]IB_+4R*BISP?TW%--&+KPU"8<[[(8=LYE.74UYGW2NV3W>CN$=T
MI\/R*1:"J2[4S&PQ35$4KU6IFA:QK4=&O#1$7AJU29=FAB 8MRJI*&W5=;#
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MO3IKV-[8_P"DT_I$7[03#5=P;Z'KW_B6J]H4 )=3A
M                     (ID^&W/(J^.MHLSON.Q1PMA6BM"VY*=[FN<[K7=
MKH:E_.J.Y5T>C=&IPUU50CU7M1>JFEE@EW&R2OCD:K74EP]R7TLFO@D;3VZ"
M14\/DR-7T3Q:[3?N,B^5CAO1AB]NBU,:?/KF88[LXM%#L56131RI?FL5CFN1
M\=/H]-%UU:KG.35/!JBIZ!2<GW2O2];>4B<)B>]Y/I73-][*WI:ODYC&)CON
M7Z$C\U]^_>CEW\ZR?_A)]#?/TNQJQU6/VY:&LOEPR"59'2]ONRTRU"(Y$3D3
MLD%,SE335/(UX](0W ')NY'RYOGZROX*'QKKG^9F=)]IZE_A9?17=LG\AH?U
MF?\ "0OWNU_#CI2^?>\W\V>C"Q"SJN
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MJQKN?@R17\$\'B"8EUWW;/H*P7X,9^&\(E:@0
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M.J+S<']51TKJ&OA61Z^#FEIV-3[*KH86T^96,9C@91G4F<(GA64>=N
M       JF;Z=(/U)?:[RGV]L1T?%7.OL6>EXT+6+@I@
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MW0_L\GR>]O<,SCAAM^F5?ZSU_P"\SO*[N[P1&&..SZ(2(Z;E@
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MF=93Q*O5=5K_ ,NKG_TGH^@&4.BN[9]!6"_!C/PWA$K4"
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M%2NCFKJBZ++ITG%K[O:"LQ,9?#'ZK?W.S;W@UUHF)S."?TU_M3 L#@
M                                    *6W+V<W*S7*)+YB^[=SPZU/A
MBB;9:.FDFB:^-%1TG,VL@35_A\@)Q0ZC[KVX$^2XQ?<NWCN.3T6,W>BO<%LK
MJ"16/EHIFR:-<^ODY%<B*SGY5TUZ%!BZ:"      .(>^-/L'SY1#-32>?;JK
M;V:IUN'5]7UE.J\$?V7_ )7F3BW_ ,X,H=%=VSZ"L%^#&?AO")6H$
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M45-%\/@7HTXQD:F\YGD\R,+88QALE&EUF;.;.3GUBML,8F-DPGIT78
M   %4;#_ "?N?ZY_5,*?[L>9OTNU"Y^]?GZ='MRM<N"F $5W-^CK*_@FM_0/
M->;WD]A[=#_(ITH^U7NR_P!%V,_JO]8\\N7WL.YUC_(OV4\-CG*TK/XBL/\
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MOIT@_4E]KO*?;VQ'1\5<Z^Q9Z7C0M8N"F
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M7>\FOUJCR;'</I\<DJZ=MXFI)*I:F.B=*U)W1<U8]O6)'S*W5JIKX%!P+Z"
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MD[1R]=U>OE=7KRZZJO1S*3EY-,O'=C#%.5D4R\=V,,6S-S>
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M^]AW>L?Y%^RGIL<Y6E5Y7>,Q%K>+F66L<Y/$U5E34UQYR'2M_ OTH7V>Y50
M                   %4S?3I!^I+[7>4^WMB.CXJYU]BSTO&A:Q<%,
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M24B-R"H?'+)"E-50S<7=F8[RFQ]7ZM.G^0)B'7?=L^@K!?@QGX;PB5J!
M                                    *YS[<>X8A>8;924<-1'+2LJ5
M?*KD<CGR2,T\E>CR#DZS76R;Q6(QX,7'UNNMD7BL1$\&/VL[;O.:W,UN25=+
M%3=AZCDZI7+S==UFNO-XN0V:+5SG[V,888=MLT.LMG[V,1&&'UXIP=)U
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M2^UWE/M[8CH^*N=?8L]+QH6L7!3
M        *HW;N=TQ>MM^36G<2TXI5+'V5F/Y3)"RS7+D?S:\RN9/%(G6:.EB
M5VC=.9NB!*D;VRCR;*+I4Y=D-7M5-GL%-!=TEI+=>L>O#8:9*5C[=>GL<R+G
M@1."JQR+QT50EUM9+=0V>RVZT6Q56VT%+!2T:J[G58((VQQ^5X?)1./A#%G@
M    !07>.R'?6T0LI-K;!37;&:FV5?[0550UCGPZHK5Y5=41+_1ZKP:X)A%>
MX-]#U[_Q+5>T* $NIP@
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MV=CDGIJGE69&=1_2M2'U?2NG2$PO?NV?05@OP8S\-X1*U @
M                    ")Y'N#9\9N*6RNIZJ6=8VS<T#(W,Y7JJ(FKY&+KY
M/B/#G:RF5;=F)^7TO!GZVF5;=F)^7TLW&,OMN6,J7V^&>%*56)(E0UC57K-=
M-.1[_O39D:FN=CNX\#;I]37.QW8G@Y6_/4]0  KW.]MJG,+Q#=(;@RD;%3,I
MEC?$LBJK))'\VJ.;]^<K5Z&<^\6B<.#!R-9H)S[Q:)PX,/M9NW^"SX6MQ6>M
M96=NZCEY(UCY>HZSIU<[77G-FCTDY&.,XXX-FBT<Z?>QG''#ZL4U.BZ8
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M5_M'#4-HW/DX*J\JU,$K_P"CU3R')]L)A%>X-]#U[_Q+5>T* $NIP@
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M0]'VPRA>_=L^@K!?@QGX;PB5J!
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M7O\ Q+5>T* $NIP@
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M959!VQ9.T4S45'=FZW_F>5_]/T>AP#*%X=VSZ"L%^#&?AO")6H$
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MRUW+*R*-SG,76L5-'(FG% G%+.X-]#U[_P 2U7M"@")=3A
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MI(R[3:9FUIXY8Z701DWG,M:;WG@QGD^9,#W.H
M                                                           !
M2F[V+7ZBS["]W<>N]IMZV%7VB]09!*E/2OMU?(WK'PR*YB),U.?1%<G-PX\.
M5Q*N.\CL(RX66_YWM[D-%C=!?:>!^76RKGCI;/<HJ>5E3#4-DT5C)NL8U47[
MO7U2*YW.3$NI;.G+:*!-472FA35.C^C0,6:  UMWQ^RW]UN=>**.L=::R*YV
MY945>HK8&N;',W14\IJ/<B?9 UV88#AV?T<%!F%G@NM/2R==2K,CFRPR<-71
M2QJU[%73CRN37P@9F,XKCF&VF*Q8M;*>TVF%5<REI6(QJO=ZI[EZ7.7PN<JJ
MH%%]YO:*S[@]GO\ <<W_ &9J++;*KJ+;K'_Q?+K+]W-$O%4Y>#5"8:/N#?0]
M>_\ $M5[0H 2ZG"
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M2M0(
M
M                           #E_?ZVX)DF]^ 8_NK<(*; 8[1<ZV6"OKU
MMM&ZKYFL9S2I)"J.71--'HJZ:=&J!,*<VIQ;;',ZBNH=T=RJ"+;3"[S<+=B&
M&5EX@I&5$"3K.VJ>]\K%?"Y)>5CX_5:+HY$31Q+O^G2!M/$VFY>S(QJ0\BZM
MY$3R=%3P:!B]      YT[S>VVSV9]GO&XF7?L_D%KME5[B4'NE04/:M-9$_)
MU<;WR:O1&_DU3Q=(3#1]P;Z'KW_B6J]H4 )=3A
M          4#7Y5DD=?51LNM2UC9I&M:DKD1$1RHB=)\?S^L]5&9:(S+;9X_
MG?4\GJ_33EUF<NNR.)<N)U$]7CENJ:F1TM1)"CI)'KJYRZKQ55/IO5>9;,TN
M7:TXS,;7SWK&E::F]:QA$2W)TW.
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M.BN[9]!6"_!C/PWA$K4"
M
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MNE=_<_)J6V57[/T_:7P=;IJY/):UR._*:)Q"8:/N#?0]>_\ $M5[0H 2ZG"
M                            #3Y+CE+E%N2VUE9<*&))&S==::ZIME1J
MQ%319J22-_*NO%O-HO\ (!$?,S8?G'EW_P U7O\ O83BJVLB;!5U$#7.<V*1
M[$=(Y7O5&N5-7.<JJJ^-5Z3X=J?.WZ4_:^PZ?S5>Q'V+#L>UMGO=HH[K47S)
M:::JC1[X*#(KM14S5Z-(X(*ED;$X=#6H?6^I_P"'E]%\QZT_E9G92K&-O[9B
ME?)<:*[7VOEEA=3K#=[U<;I3HUSFOYFQ5<\K$?JS1'HG,B*J:Z*IUG+2L
M                                               !Q[NG;]J+WW@,
MP@W?K*6*AI,4I(<?;<*I:5C*F99'*L.CFZO155S?$JJN@9-!W;+1M/>7XIF^
MYN<TM_W*9V6WXMCE;6,:EL[)(E-11QP:HKYO(8YFJ:<SD717^6"7<(8@
M <0]\:#8/GRB::ID\^W56WLU-I<.KZOK*=%XHSLO_*\R\7?^<&4.BN[9]!6"
M_!C/PWA$K4"
M
M                                   Y^WMP[=.JW&QK/-L+C9*"X6JV
M55OE]W)N1%2JD15Y6<CD5-$Z=0F%)S[.=XVHV_NVV<E^Q']EKU6/N%=&E6J3
M+.^J96*K9.IU1.LC;P\7 )Q=QVV!]-;J2GD5%?##'&Y6KJU58Q$71?%P#%E
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M64T#>2-JJKE1/LKQ.UD9-<FD4ILKL<G.S;9MYO;;+(-S2
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M]5SP6^A:!V7:
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M;1/CB>B+$USW2S1.:J/5%\EK@F&5W!OH>O?^):KVA0!$NIP@
M
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M4,KD6=CW2IK'&Z--/'IT!,0ZW[MGT%8+\&,_#>$2M0(
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MQ2031<R1IS.T<]J)JB<>DSIJ*7G")>W1=?:/5YGD\JV-I^:8[2;GH=X
M                                   " ;@[*;9;IUE'<,\L?NM5V^)T
M%))VNLI>2-[N94TIIHD75?OD4)Q<^6+8;9RY;[Y3MI5;?TT>+66TTUQH:]E=
M>VU,E1.D'.U\CK@L:M3K':(V-%X=(3BZ_AACIX8Z>%O+#$UL<;=571K4T1-5
MX] 8OL     .=.\WN[9]ONSV"XX1^TU1>K95=1<M(_\ A.;6+[N&5>"KS<'(
M$PT?<&^AZ]_XEJO:% "74X0
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MPT%$VWO>E/3L2-G,ZFDU71/"IXJUBNHPCY<"IQI\K(Z]I7+K%8W)X(C#BLZ
M.H^A                                         4-O7D6Z5QS_ !/:
MG;"]4^-5=ZHZVZW&]SPMJ'MBHU1&QL:]CT1%7IT35=4XHB+J3"LL=W$[R6\E
M')MQC;J>QUM@J*FTYON,UG)&^HIYWQ\M&UK6\LBQHUSNK:CM5U3JDT5278%+
M"ZGI8*=\BROBC9&Z5>EZM:B*Y>*]/3TAB]@     HGO$;H9[@]-[BXK@%=EE
MKNULJ_=&Z4<=2^*BU1T:\ZP02M31J\_E.:$PAW<&^AZ]_P"):KVA0 EU.$
M                      !K*[(\>MDZTMRN]%1U2(CEAJ*F**3E7H7E>Y%T
M4#19#G-H@M4TM@O%!57)JLZN&*>&=ZM5R(Y>1KE5=$.3UKJ;Z?3SF4VQA]KI
M]6Z>F?GQ2^R<?L16U;BWF6Y4L=RJ*>&WND:E3*]K8VMCU\I5<JHB(B>$JFBZ
M\U.;GTI:8PM,1L6;5]3Z?+R;7K$XQ$\:??MIAWSAMGLVG_'/H*C-I15U#<J=
MM7;JF*KI7JJ,GIY&RQJK5T71S%5%T4#(
M                           !#\BVIVURZY.O.48K;+O=7,;$ZLK*6.:5
M61\&MYG(JZ)X *?V<VRL[MP,^FR+;ZWVRAQR^0NP6O=9HZ%>HBDE>V6GFZIG
M6\JLC<DB.=IPX\0F72 0     !QWWQ,FWI;8<JQN'&:)VS;X[:Z?)%1>V-D[
M132HB+VI$_YA&Q_\OT+_ -H,H7AW;/H*P7X,9^&\(E:@0
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MBHJ="H:FQZ@         %&U7\35%\&K[6D.;_L_+D43.]OT_Q]JR\CI+V
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MX];:6T6J)7.BH:"".EIV.>Y7.5L<36M155=5T3BH&P
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MTZ#=IM1Y6)G##!NTVH\K$SAA@D9ZWK
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MS3*^SQ/4         *-JOXFJ+X-7VM(<W_9^7(HF=[?I_C[5EY'27L
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M'(&LBJ+A40N=))&LZJL#7)*V1'<T:(B/YDY?O2<&[[O-CN&\>5[H;F6VYW[
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MKVKIY37(J*G!2T*ZGX0
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MMQJFJXJV6*1]0]KF]2KE1$:BIQYFM\9OTN1;*B8GC;]+D6RHG'C2D]KV@
M                                  !1O=?^2-X^$E_01'.T/>RH7N7_
M !+]/Q:KR.BOH   4/=[!N'M5N%?LUP*PIEF)9>Z*IOUEBE9!74U="CF]; K
MU1'-?SZN31R^/3@I[8M3,I%;3NS79+S36U+3:L8Q/$^[=#NQNCF]BOM_M-3@
M>"XW-VUEN?5(ZON-4W16MF;"NG4]&K7)X^GP1/D\NLQ$[TSS0F-^UHF8W8CZ
M_P"C9]X?#\DS&R8M2XU0/N$]!D-#75;&.C9U=-#S\[UZQS4T37P<3#3WBLVQ
MXZS"<ZLVB,.6$TW*NV86C$ZN3 K0Z\95/I!;X=8VQ1.D719I%D>Q.5B:KIX5
MT\!KRHK-OO3A#9>;1'W8QE63>[=;)MKI\?KJE9MQ:J;W;GRGF5:CW=1%<CTD
M5.;JD5>33[WCZKB>C]U/E,8[W9A\S3Y"-S"=NW'Y^58FU5RSFOQ*GAW%M3K9
ME- O8ZJ17QR1U:1(B)4L6-[_ .DZ7(NG'P:'GS8I%ONSP-N7-MW[VU-S4V.2
MJ2'>"MS^JS[.]J:[)J^EE5N,4*W.BIZ"VTR="L@=UB.E5>*R.7I.I/DMS=K?
M#EX)X7@CRF]-IICR<,?+%TEA-]R'(K+[H9-CDN+7+KGQ^Y<]3%5OZMJ)RR=9
M$B-T=JO#T#GYE:UG")QA[*3,QPQ@A&VN)Y#9-T]TK]=*%U-:+]5T$MIJG.8Y
ML[(8'->J(URJFBKIY2(;<R\3ETB-L8_:UY=9B]IGCP^Q&,@GW'M627N&^;;4
MN?5$DW68;D,-/0-;3Q.;Y,52Z5$>SJW?=>'P+X396*36,+;O+'"BTVB>]QY-
MB?;,8#7;>X6VWWJ9M3DUSJJB[WZ>-W-&ZNK'\SD8NB<&M1K?175?":<_,B]L
M8V1P1V(9Y5-VN$[=O.L,T-H         HVJ_B:HO@U?:TAS?]GY<BB9WM^G^
M/M67D=)>P                                        *HW+W9O.+9O
MA^W6'V)+_E&22]JK8WR)%'26B"1$GF555J*Y6I)R:NT16\=>#7$HGWGZVTV:
MBLMXRS;JDS+;UKWP91=GZ,N%M9,^..!]/)&Y)6HJN?S<NB*O*WF:J@A?= M*
MZAI74+D?1+#&M,]%U1T2M3D5%7IU30(9   !!,YVSCRR[VS*K/>ZS%\TM$4M
M+1WRW-AE<^DG<UTE//#4,DCEC5S4<C7-\EW%/"!E[?[>6[ :6XK%755XOE[J
MEN%\OMR<Q]75U*M1B<W5M8UK&-3ECC:WE8G! )@         C>4;?8-FSH'Y
M=CMNO<E,BI3RU]+%/)&U>EK7O:KD1?"B+H!NK;;;=9Z&"V6BC@H+;3-Y*:CI
M(V001,UUY61QHC6IQZ$0#*        \NS4W_ -RS^:GI&OR=.2&?E+<LO1$1
MJ(B)HB<$1.C0V1&#!^@
M                         #EOO%[)[G9SF%)E=G6'+L+HXHDFV_J[A4VY
MCY(D57OB5CXX^9_WRO:[HX.0)B4+V%S/'-O][<FM638G5;:.S-EFMN,X]/3S
MRPI5P,2F?&R9(DYDEF?SI*J<J\VKG!,NV Q   "F++)#9.\QEE+<94AFRC';
M55V5)'(C9FVV6>"H8Q5TU>Q7->K$U7E7FZ GB1FR8Y5[HWK?E^,WV2R4.07.
MT6FVY+1<TKXZFR4,$=4L75RQ*Y$<G5ZMD3I7[ $-N7<LS>\T4MMN^]EUN%NG
MY>NI*NBJ)X7\CD>WF9)=%:NCD1R:ITH$XNE=ML-\WN"6+"NV^Z/N+3)2]NZK
ML_6\KE7FZOGDY>GHYU#%*@   !\R1LEC?%*U'QO16O8O%%:Y-%1?L@<)P7/?
M?NO9)E>(X?A;LBPJ]7">Z6">*CJJJ"/KM&1JCJ331R1MC9)$_3BQ.7AQ<9;5
MX]U?;K*,3QJ^Y;G]&VESK-+G-=J]LC&MJF0RKS-9-IZE5D=))R?<\W'CJ@1*
M_0@  4YD>T-WN-ZJZRS.M]';)7-[/3:R1<C6L:U4Y(X5:G%%Z#*)$TV_Q"3$
M[9)#7LIGW221RNJJ=%<Y851O*Q7N8QRHBHJZ=!$B7D   I;)MGGUE]K*JQV^
MDI+7*K'04\#88(VKU;4?HQK$1-7HYR^-5U.'J=%?,S)M&R>XX6JT-\S-FT;)
M[B8;;X-#B-)4RU5%3,O,\KF]MC9&LZTJMCTB65K4=R<[5=RZZ:\3W:+(ME4F
M+<O<>[19%LFDUGEQ^Q.3W/>  (C?,'2]7*6X]NZCK4:BQ]5SZ<C4;T\[?%XC
MP9VD\I;>Q>'-TN_;>Q;3&L?3'J6:F2H[3UTG6\W)U>GDHW33F=XC?D9/DHF,
M<6[(R?)Q,8XMT>AZ
M!1O=?^2-X^$E_01'.T/>RH7N7_$OT_%JO(Z*^@        ""9?M7:<SNK;M6
MWN^6^9L38$@M=QDHZ?1BJO-U;$5.9=>*FZF;-8PPB>S#"U,>5HF; X^Q[7IE
M&5*K5141;U.J</'P,_W$\E>9CY..6>=;!YFT               HVJ_B:HO@
MU?:TAS?]GY<BB9WM^G^/M67D=)>P
M        *4WDV]S^JRW'-V=IW4<V:X[!/;ZFT7-W+35]OJ%5RQH[5J->USG+
MQ>W77U2<NBDP@.1VKO.[X4/[ 9CB]LP'"*Z6+W?ND=7#75<D$$K95C@;%/+Q
M<K4Z6HB_?Z:HHX'4=)2P4-)!14K$CI::-D,,:=#8XVHUJ?R(@0]@
M
M                          !2TV=YW?\ O$)M[CLU+08;B5!%<LIZ]B/J
M*]]?$J111NY7*Q&+(QZ<JMXM75531H2U^[F3YK@VY>%7>Y^YUVVDO]TM^/R6
MFHIV/JZ&[RODE@KHWN:KN9JMYM47@C-$:CE1P%\A    1[+L#PW/:.*@S*R4
MEZI:=ZR4[:R))'1/7358W>J;KIQY537P@;*RV.SXW:Z:RV"@@MEHI&\E-14D
M;888VJJJO*UB(G%5557PKQ4#/
M                                      *-[K_R1O'PDOZ"(YVA[V5"
M]R_XE^GXM5Y'17T                           !1M5_$U1?!J^UI#F_[
M/RY%$SO;]/\ 'VK+R.DO8
M
M                                        "FMS-E\AO^6T^Y&V66RX
M9GL=*EOKI^H;5T==2M7F8R:%^K=6KT*YKTX)Y.J(H3BT6+;$[B7;+;'F.^.>
M)ELV,S)66.R4--'1T$=:W163R=7'"CW,5$<W\DBZHGE::M48N@@@
M
M           4;W7_ )(WCX27]!$<[0][*A>Y?\2_3\6J\CHKZ
M                 HVJ_B:HO@U?:TAS?]GY<BB9WM^G^/M67D=)>P
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MC8Y%=.J*J:,X:)H$2GH0
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M6@8+*VXW3PO=BUU=YPFMDK;?15'8ZB26"6G5LW(V31&RM:J^2Y.*!"9@
M  HWNO\ R1O'PDOZ"(YVA[V5"]R_XE^GXM5Y'17U^.<UJ:N5&IXU70#]145-
M4XHH     ?BJC457+HB=*KP0#\:]CTYF.1S?&BZH!]
M"C:K^)JB^#5]K2'-_P!GY<BB9WM^G^/M67D=)>P
M                                      K#>_9:U[WX_;L?NMTJ+5#;
MJSM[)J5C)'.<D3XN54?PTT?J$Q*R:2G;24D%(URN;!&R)'+TJC&HW7_0$/8
M!AW>WLNUJKK5(]8XZZGEI7R-35S6S,5BJB+X4U @6R6SUMV3Q6LQ6UW*>ZT]
M9<);FZHJ6,C>U\L$,"L1&<-$2%%_E"9E9(0  *JK=CK56[WV[>]UUJ&W6W4[
MJ5EJ2-G9W-=234FJO]5KI,KOLH$XK5"  ! MX-KJ#>##)<,N5?-;:66HAJEJ
MJ=C9)$= JJB:/X:+J$PDN)8_#B6*V+%:>9U13V*WTELBJ)$1KY&44#(&O<B<
M$5R,U70(;@   JK:#8ZU;077+;K;;K47*3+:B&JJ(ZB-D;8'0/J'HC%9THO:
M%Z?$$XK5"  !56<;'6K.-S\3W.J[K44E?BG4=GH(HV.AF[/4.J$YW.\I-5=I
MP"<5JA   BFY6#4FY.#WC"*ZKDH:6\1QQ254+6OD8D<K)45$=P756: -M<&I
M-ML'L^$4-7)74MGCDBCJIFM9(]))7RJJHW@FBOT E8  !56#['6K!]S\LW.I
M+K45=?E?7]HH)8V-AA[14-J%Y'-\I=%;IQ"<5JA   JK>C8ZU;T?L][IW6HM
M?[/5$M5#V:-DG6NFZO5'<_0B=6G0$Q*U0@  :?+<?ARW%;[BM1,ZGI[[;ZNV
M2U$:(Y\;*V!\#GM1>"JU'ZIJ!&MG]KJ#9_#(L,MM?-<J6*HFJDJJAC8Y%=.J
M*J:,X:)H$RGH0                                             $>
MR# L%RRIBK<IQBTWRL@9U,-1<Z"FK)61:J[D:Z:-ZHW5571 -1YF-GOW?8U\
M34'K(,3S,;/?N^QKXFH/608N5>]]@N$8SE6TE/C>-6JST]RN%;'<8K?0T](R
MI8R>W(ULS86-1Z(CWHB.U]4OC#*'57F8V>_=]C7Q-0>LACB>9C9[]WV-?$U!
MZR#$\S&SW[OL:^)J#UD&)YF-GOW?8U\34'K(,7*O?0P7",6\WG[,8U:K+VVX
M54=9[FT-/1]<QO9M&R=2QO,B<RZ([QAE#JKS,;/?N^QKXFH/60QQ/,QL]^[[
M&OB:@]9!B>9C9[]WV-?$U!ZR#$\S&SW[OL:^)J#UD&+E7OQ8+A&)8KBE1BN-
M6JQ5%1<)XZB6V4-/1/D8V!%1KW0,8KD1>.BAE#JKS,;/?N^QKXFH/60QQ/,Q
ML]^[[&OB:@]9!B>9C9[]WV-?$U!ZR#$\S&SW[OL:^)J#UD&+F'OO8%@N)[?X
M]6XMC%IL=9/>$AFJ+904U'*^+LLSN1SH8V*K=41=%#*'25HV;VADM5#))@&-
MOD?3Q.>]UGH%<KE8BJJJL/%5",69YF-GOW?8U\34'K(1B>9C9[]WV-?$U!ZR
M#$\S&SW[OL:^)J#UD&+FWOL[?X%BFU5GN.+8M:+)<)<@IJ>2KMEOIJ.9T+J*
MM>L;GPQL<K5<QJJW735$\090OK$MGMI*G%;%45&!8Y-436^DDEEDM%"][WO@
M8KG.<L*JJJJZJJA#<>9C9[]WV-?$U!ZR$8GF8V>_=]C7Q-0>L@Q/,QL]^[[&
MOB:@]9!BYY[YNW>W^+;0P7/&<4L]EN*WBDA6LMMOI:2=8GQ3JYG60QM=RJJ)
MJFO@#*%Q;=[1;3UNW^*5M;@F.U-94V>WS5%1-:*&26262EC<Y[W.A57.<JZJ
MJ](0DGF8V>_=]C7Q-0>LA&)YF-GOW?8U\34'K(,3S,;/?N^QKXFH/608J2[V
M>VNW.-[(7N[8]B%DM%UBJ*!L5=06VDI:AC7U<;7(V2*-KD1471=%XH$PF&R6
MU&UMVVAPFYW3"+!77&KL]'-55E3:J*:>65\35<]\CXE<YRKTJJ@E/?,QL]^[
M[&OB:@]9",3S,;/?N^QKXFH/608GF8V>_=]C7Q-0>L@Q4]WIMLMML>V'RR\6
M##K':KM3>YW9Z^AME)35,?67.EC=R211-<WF:YS5T7BBJ@3#<=W_ &KVPO.S
M.&72\858;A<ZJWLDJ:VKM='//*]7N3F?))$YSE]%5!*R?,QL]^[[&OB:@]9"
M,3S,;/?N^QKXFH/608GF8V>_=]C7Q-0>L@Q55WD]K]L[%LAE]VL>&6*V76FI
MX'4U=16NCIZB)SJN%JJR2.)KFJJ*J<%Z F#NV;7[9WW9#$+M?,,L5SNM33SN
MJ:ZMM='45$KFU<S45\DD3G.5$1$XKT E:OF8V>_=]C7Q-0>LA&)YF-GOW?8U
M\34'K(,3S,;/?N^QKXFH/608JV[P&U>V%FV9S.Z6?"K#;[G2V]\E-6TEKHX)
MXGH]J<S)(XFN:OHHH3#3]UG;+;;(=A\3O%_PZQW6[5/NCVBOKK925-3)U=SJ
MHV\\DL3G.Y6M:U-5X(B("5P^9C9[]WV-?$U!ZR$8GF8V>_=]C7Q-0>L@Q2''
M\5QC$Z:6BQ:R4%CHYW]=-3VREAHXGRZ(WG<V%K$5VB(FJ@;<      %&]U_Y
M(WCX27]!$<[0][*A>Y?\2_3\6J[YI600R3R>HC:KW:>)J:J=%?7\^LHS._[M
M7*JR+(+A5)8IIY?<.QPSR4]-34K'JQBN;"K.>1R)JYSM5+5IM+2E=G"Z>5E1
M$+!V#W R#%<\MF$5USJ;CB&0-DIJ"DK)'5#Z*MB;UC.JDDYG]6]J.:K.;1%X
MGCU^FK%=Z&K/RXB,8=CG!>$   .*M],YON;;@7S$>WU%)AF.21T2V^EE? E9
M5.B9+)).Z-6N<C'+RM;KIPU+!H--7=WIVR]^1EQAC*)8/F5ZVDOMNNMAK:A<
M;EJH*:]V*::2:FF@J)&Q+(QLCG<DC%<CD<W37H7@>G5:6MJ3/&V9N5$P_H"B
MHJ(J="\4*LYC] UUVO\ 9+$M(EYKX*%:Z9M+1]>]&=;/(NC8V:]+E\1,1,[$
M8LNLJZ6WTD]?6RMIZ*EC?/43R+RLCBC:KGN<J]"(B:J1$8I>=NN-#=Z&GN=L
MJ(ZNWU3$EIJF%R/CD8[H<U4Z44F8F."3%E$ !H$SC#%NON&F0VU;SS<G8.UP
M=?SZZ<O)SZ\VOW/29[EL,<)P1O1C@WY@D  >534P4=/-5U4C8:6G8Z6>9Z\K
M&1L17.<Y5Z$1$U4"%^>7:GYX6KV4STS;Y&_)/,PWZ\L)79[S:L@MT-WLE9%7
MVNIYNHJZ=R21/ZMZQNY7)P71S5:OHH:YB8G"643$[&<0D HVJ_B:HO@U?:TA
MS?\ 9^7(HF=[?I_C[5EY'27L
M
M
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M141>*=("U6BU6*WP6FQT-/;+53(K::AHHF4]/$USE<J,CC1K6HJJJ\$Z0,P
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MS?\ 9^7(HF=[?I_C[5EY'27L
M
M
M
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M;]/\?:LO(Z2]@
M                                                       UU3?[
M%1HBU=TI*=%UTZVHB9ZGI]4Y.@SC+M.R)8S:(XV725=)7TT=90SQU5),G-#4
M0/;)&]OC:YJJBI]@QF)B<)3$Q.Q[$)
M
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MF;"BR5E:]$ZZJJI.,D\J^%SE^TFB="%4S<R<RV]+EVM-IQ2LU,0
M        HVJ_B:HO@U?:TAS?]GY<BB9WM^G^/M67D=)>P
M
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M>;KV%A'A>@
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MD.;_ +/RY%$SO;]/\?:LO(Z2]@
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MGW^BL1]=HGZFZO4.OG;;+CG[C%=?.\!4\O69O0T:<>;LUMIY.GH3\K">2_\
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M+Y3IO-U["PCPO0
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MZ1.:L(              !1O=?^2-X^$E_01'.T/>RH7N7_$OT_%JO(Z*^@
M!REW[$__ "/C?PE)^B/)J-D+)U%YRW8;7N._1)<?ARI]KTQEI^]:NO//QT8[
M;I@]+@                     *-JOXFJ+X-7VM(<W_ &?ER*)G>WZ?X^U9
M>1TE[
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M<_)I-*1$\24GF;0
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MC:K^)JB^#5]K2'-_V?ER*)G>WZ?X^U9>1TE[
M
M
M
M                   HWNO_ "1O'PDOZ"(YVA[V5"]R_P")?I^+5>1T5]
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MB9WM^G^/M67D=)>P
M
M
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M,1"U#SMH  HVJ_B:HO@U?:TAS?\ 9^7(HF=[?I_C[5EY'27L
M
M
M
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M_L_+D43.]OT_Q]JR\CI+V
M                                             \*VMH[;1U%PN-1%
M24%+&^>JJJA[8H8HHT5SWO>]4:UK43555=$0#XMMSMMYH(+I9ZR"X6RJ;UE-
M6TDK)X)6+PYF21JYKD]%% R@
M
M                                       "C>Z_\D;Q\)+^@B.=H>]E
M0O<O^)?I^+5>1T5]   #E+OU_(?&_A*3]$>74;(63J+SENPVO<=^B2X_#E3[
M7IR=/WK5UYY^.C';=,'I<                     !1M5_$U1?!J^UI#F_[
M/RY%$SO;]/\ 'VK+R.DO8
M                                   .4<]P/%=SN]Q%C&<T+KM8H,.;
M50T:U%13M9,RK<B.:ZGDC<GJW<-=%#+B3'O)YADFV]AP&GPFX/M,57D%#::E
M(VLE5]#U3TZI5F:]=-&IQZ?1"(7Z$.,]_-Z-X<*WKK*+#*]9<7QFU4=[NEB6
M&!T<U(LK&5',Y8W2<>M354=Y#4YDTT#*(=4V?++?E>$4V98]-ST%RM_;Z*1=
M%<WFB5R-<G%$<QWDN:O0Y%0,5;=U3-<HS_:.ER'+[B^Z7E]=60.JY&1QN6.)
MZ(U-(FL;PU\03*HMD6=X7>O"ZC-X-X9K).ROGHV6U;+1U,2NA;'(CNL1T>C5
MZS3EZM=-/"$RLS8G=?.;OF65;.;K-II<\Q-K:EETHVI%'6T3U9^4=&U&M1=)
MHG-<UK45KTU:U4\HB7QWM;]<%PBT;9V!^F2[C72GLE*Q%5%2E21CYWZI]SJL
M4;_]EZ@A<%HI\;P6S6#$(JRGH:>G@AM=GIZB6.*6?LT;8T;&URM5[U1$5>5-
M=5"'U3YOA=7>GXU29':Y\CC5S9+1%6T[ZUKF>J18&O61%33CY('U<\TPZR7.
MGLMYR&V6Z\U>G9;=5UM/3U,O,NB=7%(]KW:KT:(!@[FWBXX]MMF-_M$W9[M:
MK'<ZZ@J.5K^KJ*:DEEC?RO16KRN:BZ.14\8'.VVF.=X[</;FS[@VS>9U+7W2
M*2>"T5=EI)(&OBF?$C7SHKE5%Y-57J%Z>@,EC]V_=S(]SK-?[7FE+#3YGB%>
MMKNTE(G+!,OEM:]$U5$=S1O:]&^3PU3371")411=XS<[%][,CK,JN:UNT%NR
MNLQ:O@6&!C*!DD\[*61'LC:_R&0*Y55R\S6.U\I44)P=+=X')[WB.S64Y/C%
M:M#>:&GADHJV-K)%8LE3$Q51'M<U=6N5.*!$)%M?=KA?MM,,OEVG6INMSL5L
MK:ZI5&M62HJ:.*21ZHQ$:G,YRKHB(@0Y=WPWSW3M&Y5]N&WU8]-OMM7VB#+*
M1D<3XZF>MG57M<]\;G(CM>SKHYNBM54X\0RB'8=LN5'>+;1W>W2I/;[A!%5T
MD[?4OAG8DC')Z"M5%#%RM<=O,/V][W6V:X?;EMON]2WVNNVE143]?4.HJM5<
MO7R2<O'CRMT3T RXG688@
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MH*N:VW2DC<KXVU%/HJJQ5X\JHY.D]67?>C%Q=1D^2MAQ)^;'F
M         HVJ_B:HO@U?:TAS?]GY<BB9WM^G^/M67D=)>P
M
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M5B-5T3%3AI&$2\]Q?XNMG/@R]^T:L'$Z+"
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MK&R#*O-J1,\<)X:&T     "C:K^)JB^#5]K2'-_V?ER*)G>WZ?X^U9>1TE[
M
M             !SI_P#S6_\ V/\ ^V!/$^^]SC65Y!C.'U.)V.KO]59LAI[C
M4T5"Q9)>IABD771J*J(JZ-UTX:@A]T?>%W/J:NGIYMB\D@AED9').KUT8USD
M17+K3-3@BZ\53[(,'I1XGDL?>]N&7OM52F+2XPVDCNZQN[*M0CXOR:2='-Y*
M\ <3U[S^UE^R^R6K.L A5VXV&S]JM[843KJJC<OY:G3HYU3U;6+TISM1-7@A
MD]TC%<CP[9NCM&4VR>TW5:ZLG6CJV=7,D<CTY5<Q>*:Z<-02P>YUB>2X;M+/
M:,KM539[HMXJYTI*V-T,JQ/B@1KT:[3@JM7102MO</,*3 ,'O^95FCHK-1RU
M+(W<$DF1-(H^E/5R*UG3X0A6_=3Q"KQO:6CO5XYGY'F51+DMUFDXO>ZO5%A5
M5]&)&/T\#G."9:WO#XGDN1Y[LM<+%:JFXT5DR>&LN\]-&LC*6G;4T;UDE5/4
MM1K'+JOB!#;]ZS&[]EFR=[LN-6ZHNMWFJ*%\5%21K+,]L=7&YRM:W55T1-5!
M"7W:UW&39FNLL=+(^[/QB6C91M:JRK4K;UC2-&IQ5RN\G3Q@5;MKA^4VWN=U
MF&W"T55-E<E@R6F99Y8G-JEGK):]T+.K7CS/21G*GAU0'&G'=TL%TL&R.*6#
M([?+07.GIJB.LM]7&K)&<]5,[E>QR>%KD71? H)0?N\8EEFUF?;A[;U-JJF;
M>/J_=K%+NZ-_8^6;D:^!LJ\'/ZM\3=/'$\$LON\8GDN.9]O57WVU5-NHKUD\
MU9:*BIC=''54SJFL>DD2KP<U4>U=4\8)5[WM-E<RK[P_<#;"W35]1D%%[B9A
M:Z&/K)IXV.9)#.K&\7\8HVN5.CJV+T:A,2WFZV)[B7C87:W:"QV:L]T+O3V.
MW93/'&Y\5OIZ"F@;*E2YNJ-1)N5W%=-(W=(0MV#N^[)T\$4"8)9I$B8UB/DH
MXGO=RIIJYRMU55\*@Q5EA6WMZVE[S%SCQ2P3Q;4YI:V/EEHH=+?;ZZE8YS6O
M<U-&>5'(C4_].@&9N+_%ULY\&7OVC5@XG180
M                                                 %!=\WZ +_\
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MVN3K;;=,:J*VCEX>5#4TO6,7@J]+7($0SM@OH4P'X#H?T+02L8(
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MRST_FJ]A:YY7H      HVJ_B:HO@U?:TAS?]GY<BB9WM^G^/M67D=)>P
M
M          4MGNR.59!N;%NE@V>NPZ^MM3;+,U;33W=KX6RNE56]HE8UNNK?
MN%7AT\= G%<=)'40TD$-5/VFJCC8R>IY$CZR1K41S^1O!O,O'1.@(>P
M0C=;;*U[MXK^Q][N%906F2J@JJOL#HV23MIU5R1.61CTY5=H[@FNK4 F=/3P
M4E/%2TT;8J:!C8H8F)HUC&)RM:B)T(B)H!Z            !25NV.S"3=VR[
MJYAN$N1?L]V^.TVA+-3T'54]?#-"D2SP3>5R)+KS.C57:> )Q7:$
M
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MBHNBM54X!# Q;%K!A5AI,8Q>A9;K%0]9V2BC<][6==(Z9^BR.<Y=7O<[BOA
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M
M
M
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M:^F25]1/45+^LGFGETYY)'(B)JNB)P0\U:Q6,(:<W-MF6QE*#-I
M           HVJ_B:HO@U?:TAS?]GY<BB9WM^G^/M67D=)>P
M
M
M
M                              *-[K_R1O'PDOZ"(YVA[V5"]R_XE^GX
MM5Y'17T   .6^^_\B\<^$9/T1W>J._MV'BU>R&T[E/T57+X;J/:].:^MO/1V
M.ZG2][]+I XSV                     *-JOXFJ+X-7VM(<W_9^7(HF=[?
MI_C[5EY'27L
M
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MD?%'55,4$DZ\L+)9&L<]R)KHU'*FJ_8"'L^2./EZQZ,YE1K>9435R]")KX5
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MP
M
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M6R.DQV5VM)47&ZL=(RHFC1423JH8TC8UZ*UJ\?"$,'/,(QRCRG MA\;IG6;
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M12Z(K]$1$3F:K57T3T9-]ZO"Y?6>EKD9\Q7O9C&.Q*PS<Y0
M      %&U7\35%\&K[6D.;_L_+D43.]OT_Q]JR\CI+V
M
M
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M!.E (#W;/^E9FG@3):W1/^S&-/LGLO5UYW^7T(7<>I70
M   *-JOXFJ+X-7VM(<W_ &?ER*)G>WZ?X^U9>1TE[
M
M
M
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M2'-_V?ER*)G>WZ?X^U9>1TE[
M
M
M
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M^U9>1TE[
M
M
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MIF           "C:K^)JB^#5]K2'-_V?ER*)G>WZ?X^U9>1TE[
M
M
M
M                                 HWNO_)&\?"2_H(CG:'O94+W+_B7
MZ?BU7D=%?0 !1V__ ,H]L/AU?P6'DU&VJQ]3]YG=%8)+R"=* 0'NV?\ 2\T_
MQ+6_@QC3[)[+U=>=_E]"%W'J5T                   "C:K^)JB^#5]K2'
M-_V?ER*)G>WZ?X^U9>1TE[
M
M
M
M     HWNO_)&\?"2_H(CG:'O94+W+_B7Z?BU7D=%?0 !2_>.MM>W'K'F5NA6
MHDQ*YQ7"HA;Q5:9R<KU3["\O\AYM1'!$\BP=2YE?*6R[<'E*X?2E%DO=LR*U
MTUYL\[:FWU3>>*1JZ_91?$J+P5#&)QAAF9=LNTUM&$P\,GR2UXE9*N^W>9L5
M+2L<Y$541TDB(JMC9KTN<J:(A%IPC%EDY-LV\5KMEJ>[I9:^W8'/=[G"M/59
M)<:F\-A<FCFPS\K8]47QHWF^PILT\3%>'C8==9M;Y^[7ABD17F6Z>APP
M               *-JOXFJ+X-7VM(<W_ &?ER*)G>WZ?X^U9>1TE[
M
M
M
M                                    HWNO_)&\?"2_H(CG:'O94+W+
M_B7Z?BU7D=%?0 !\2Q13Q/AG8V2&1%;)&]$<US5X*BHO!44)B9CAA2]S[O<=
M)7SU^WN45^(MJ7+)/;Z;66C5_C;&CF<OV.)Y9T_)."P9?7,S6(SJ1F8<?&];
M)W?J5;G3W?/LCKLPGI'I)2TE;Y-&U[5U15B5ST=]CH)KD1CC,XHSNN+;LURJ
M1EX\<;>=<C&,C8V.-J,C8B-:UJ:(B)P1$1#TJ_,XOH
M  %&U7\35%\&K[6D.;_L_+D43.]OT_Q]JR\CI+V
M
M
M
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MRTGA0Y\3CJ/ER*/FS$]?4P]'VK+T.DO8
M
M
M
M              '\YWZ<[N73EU73EUTT]#FXZ?9*P_,T[7R0@
M                !:7=[Y?.=;^;EU[/5<O-S:Z]2[U.G#73[[AIZ.A[-)YR
M%M]U/:%>Q;['9!W'VT
M
M
M
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>tm2227887d4-lc_6lnp4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-lc_6lnp4c.jpg
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M%!04%!04%!3_P  1" +*!H(# 1$  A$! Q$!_\0 Y0 !  ,! 0$! 0$
M      8'" 4$ P(!"0$!  (# 0$!              $& @,%! <($  ! P,"
M 00)#0L'"P($ @L  0(#! 4&$0<2(3$3"$$BTQ24E587&%%A,M)4=+055746
M-U=QT;(CD[.DU#9V.(&1L4(SPS6A4G*2)#2%M68H6&)S0U.#)0G!@D>B8\7B
MH^2E)V<1 0 " 0$!" P,!00" @,! 0 ! @,1!"$Q05&1$A0%<;'!,E)R$S-3
M%086\&&!H=&2HL+2DS0UX2)"LE2"<V0V(T-B!_'B16,D_]H # ,!  (1 Q$
M/P#?P
M
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M
M
M
M      !7._OU*9]\QUWYEP3"587^QV/?-E%\'8$.X
M                                \-Z_P>X>]IOS;@*LZJ_U 83[VJ/A
MDX3*X0@
M
M
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M9.$RN$(
M
M
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M8=KZG(&+N       \-Z_P>X>]IOS;@*LZJ_U 83[VJ/ADX3*X0@
M
M
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MU_@]P][3?FW 59U5_J PGWM4?#)PF5PA
M                                         %2/WZLR/<C+34N8BKPN
M5\:*J=A53ET*=/M1BUW*6^9=H]E,VF[>OSOYY^K1\D5/Y2,CWHQ>!/+![J9?
M25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)
M//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:
M/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI
M_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1C
MWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>
M!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+!
M[J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?
M25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)
M//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:
M/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI
M_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1CWHQ>!/+![J9?25Y)//U:/DBI_*1C
MWHQ>!/+![J9?25Y)=G%=VK5E%Z@LD5!/33U*/6*1[F/;K&Q9%1=.5.U:I[MA
MZ^Q[3EC'%9B9U^:-7@V_V?R[+AG+-HM$:?/.BPRR*P
M
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MO:;\VX"K.JO]0&$^]JCX9.$RN$(
M                                    JC8?]G[G[\_NF%/]F/,W\;N0
MN?M7Y^GB]V5KEP4P                           !45;]?-N][N^!S%,R
M?O->Q]R5WQ_LE^S]^JW2YJ0
M                                                5SO[]2F??,==
M^9<$PE6%_L=CWS91?!V!#N                                 !\JFG
MAJZ>:DJ6\=/.QT4K-53B8]%:Y-4T7E10(9@FSVVNV=35UN#X_#:*NN8D=5.R
M2>:1T:.X^!'3R2*UNO+PMT3F]1 :IP              !X;U_@]P][3?FW 5
M9U5_J PGWM4?#)PF5PA
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M2
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M[6Y_V,7SQA:^[ /.UN?]C%\\86ONP#SM;G_8Q?/&%K[L \[6Y_V,7SQA:^[
M/.UN?]C%\\86ONP#SM;G_8Q?/&%K[L \[6Y_V,7SQA:^[ /.UN?]C%\\86ON
MP#SM;G_8Q?/&%K[L \[6Y_V,7SQA:^[ /.UN?]C%\\86ONP#SM;G_8Q?/&%K
M[L \[6Y_V,7SQA:^[ /.UN?]C%\\86ONP#SM;G_8Q?/&%K[L \[6Y_V,7SQA
M:^[ /.UN?]C%\\86ONP#SM;G_8Q?/&%K[L \[6Y_V,7SQA:^[ /.UN?]C%\\
M86ONP#SM;G_8Q?/&%K[L!YZ[=+="KH:FD;LU>VNGBDB1RW"V:(KVJW7^V]<#
MO]7_ !>^89L[BF,Y)2K17N@II4JZ17LD6-TM1+*B*Z-SFZ\+TUT4$K*"
M
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M=\?[)?L_?JMTN:D
M
M
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M1GT59)+5Y1'113T;FM2.%*"%L+5:Y.5>)&ZKJ3;),UBO$B*1%IGC3 U,P
M       J*M^OFW>]W? YBF9/WFO8^Y*[X_V2_9^_5;I<U(
M
M
M
M                 *HV'_9^Y^_/[IA3_9CS-_&[D+G[5^?IXO=E:Y<%,
M     /X]C9&JQ[4<QR:.:Y-45%["HH'C^*+3[@I_R+/O$ZC[T]'24G%WK!'!
MQZ<?1,:S73FUX43734@?8               !45;]?-N][N^!S%,R?O->Q]R
M5WQ_LE^S]^JW2YJ0
M
M
M                                               51L/^S]S]^?W3
M"G^S'F;^-W(7/VK\_3Q>[*URX*8                            J*M^O
MFW>]W? YBF9/WFO8^Y*[X_V2_9^_5;I<U(
M
M
M
M     *HV'_9^Y^_/[IA3_9CS-_&[D+G[5^?IXO=E:Y<%,
M             5%6_7S;O>[O@<Q3,G[S7L?<E=\?[)?L_?JMTN:D
M
M
M
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M'W)7?'^R7[/WZK=+FI
M
M
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M9D_>:]C[DKOC_9+]G[]5NES4@
M
M
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M4S)^\U['W)7?'^R7[/WZK=+FI
M
M
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MJMTN:D
M
M
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M &2_9^_5;I<U(
M
M
M               ?*JIJ>MIIJ.KB;/25#'0SPR(CF/CD16N:Y%Y%14714 I?
MT7-KX\KMMYI+31PXS0VJ>TS8PZE;-!4NGD<_OB2:1ZO65NJ:.=J[D3MN0)U6
MY8+#:,7LM!CM@I6T-FMD+*6AI6*YR1Q1IHB<3U5SE]5SE557E554(=$
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MN^/]DOV?OU6Z7-2
M
M                                                        %<[M
M[S8WLY1VFLR*WW.X_'52ZBHJ>T0PU$RS-:CD16RS0\^NB<.JZ]@)T5UZ8N'>
M0><>**?]<!H>F+AWD'G'BBG_ %P&AZ8N'>0><>**?]<!H>F+AWD'G'BBG_7
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M4R<Z:QKIS=.Z[Y;W*
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MM2(MWW.W_DA-CT.\               9TZSG[8[&_OQ;OA$ 3#180
M                                   SIAW\9&XO[M6_^BC">!HL(
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M*IUYY_9/][[EG4V+O,OB=V'=+6Y8
M                                     "N=G/\ "<D_>.Z?AM/+L^]/
M9E6/9[S>7_>R=M8QZEG                      *XLWUTY-\T4'X:GEKYV
M>Q"L;/\ NV;_ &Z+'/4LX              !G3K.?MCL;^_%N^$0!,-%A
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MWFKU8LG/K%D^-#:    "HJWZ^;=[W=\#F*9D_>:]C[DKOC_9+]G[]5NES4@
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M=V'=+6Y8
M                 "N=G/\ "<D_>.Z?AM/+L^]/9E6/9[S>7_>R=M8QZEG
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M',<U>RBIJBH!^P  "N+-]=.3?-%!^&IY:^=GL0K&S_NV;_;HL<]2S@
M        &=.LY^V.QO[\6[X1 $PT6$              /E)54T4T--+,QE14
M<700N<B/DZ--7<#575=$Y5TY@$]534W1]\S,AZ9[88>D<C..5_L6-U5-7+IR
M(@"IJJ:CA=4UDS*>G9IQS2N2-C=51$U<Y41-570#]2RQ01/FF>V.&-JODD>J
M-:UK4U555>1$1 $,T-3#'44\C9J>9K9(I8W(]CV/35KFN35%1475%0#]@
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M9/@C^(FXE\2+,DK./OWI8G</!KKIHU>VYB9R1Y+F\/.U^9/,GRG.X--/G>K
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M9+RO35H0K+J.T$5KMVXUL@<]\%%?N]HGR*BO5D+'L17*B(BJJ)R\@3+6(8@
M#A7_ /WVQ^_D_-O*IUYY_9/][[EG4V+O,OB=V'=+6Y8
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M&Y!\W57YEQNP^<KV88WWI8,ZH/UU6_WC7?FBU=:>8GLPYFS=^_T2*>ZH
M       (WF>!8EN#;H[5EUM9<:2"3IJ?B<^.2*733B8^-6N:NG)R*;*9+4G6
MLZ,;4BV_#PX1M7@NW;JF;%+4VDK*U&MJZR222HJ)6L551'22N<NB:\R$WRVO
MORBM*UWH3(U,P      %15OU\V[WN[X',4S)^\U['W)7?'^R7[/WZK=+FI
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M$RU.$  #A7__ 'VQ^_D_-O*IUYY_9/\ >^Y9U-B[S+XG=AW2UN6
M
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M;>53KSS^R?[WW+.IL7>9?$[L.Z6MRP
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M5K45H):0"  !7%F^NG)OFB@_#4\M?.SV(5C9_P!VS?[=%CGJ6<
M     S1ULK5;[[>]F['=H$J;5<\PI**NIG*YK9:>HDBCD8JM5%1'-<J<BZA,
M)MZ*^P'D33>$5G=P:GHK[ >1--X16=W!J>BOL!Y$TWA%9W<&IZ*^P'D33>$5
MG=P:GHK[ >1--X16=W!J>BOL!Y$TWA%9W<&IZ*^P'D33>$5G=P:GHK[ >1--
MX16=W!J>BOL!Y$TWA%9W<&IZ*^P'D33>$5G=P:GHK[ >1--X16=W!J>BOL!Y
M$TWA%9W<&IZ*^P'D33>$5G=P:GHK[ >1--X16=W!J>BOL!Y$TWA%9W<&IZ*^
MP'D33>$5G=P:GHK[ >1--X16=W!J>BOL!Y$TWA%9W<&IZ*^P'D33>$5G=P:G
MHK[ >1--X16=W!J>BOL!Y$TWA%9W<&IZ*^P'D33>$5G=P:GHK[ >1--X16=W
M!J>BOL!Y$TWA%9W<&IZ*^P'D33>$5G=P:GHK[ >1--X16=W!J>BOL!Y$TWA%
M9W<&IZ*^P'D33>$5G=P:GHK[ >1--X16=W!J>BOL!Y$TWA%9W<&IZ*^P'D33
M>$5G=P:HGNAU;-D+%MGF=\M.(4]-=;98KI6T-2V>K<Z*HIZ.62-Z(Z9456N:
MB\J: U3GJV?45@OS8S\-X)6H$   !G3#OXR-Q?W:M_\ 11A/ T6$   !5&P_
M[/W/WY_=,*?[,>9OXW<A<_:OS]/%[LK7+@I@!R\DN<EEQZZW>%J/EH*2>IC8
M[F5T4;GHB_RH95C68AADMS:S/%#.N(8%<=Q<6I<HR/,+XM7>&RR5%-3U*,IT
M8Y[F\",5KDTT3FYCJVM%)TB(W%=I6V2O.FUMWXWHMO5HQ.S525MHO-UH*QJ*
MUM12R0PR(UW(J(YD2+HIE;:K6C2=U,;-$;UK<KKX:MZP3=VW82E]K[U8KW;9
MJIT=SEZ=\4T2O5%8O)I_9^IV3SY8BV/G::3#T[-:U,T4UF8F.%?YSG;
M                5%6_7S;O>[O@<Q3,G[S7L?<E=\?[)?L_?JMTN:D
M                 '#N?[2V+_0K?P&%4ZQ_==C[&?\ MJZFS_I<O9IVY=PM
M;E@                     '"O_ /OMC]_)^;>53KSS^R?[WW+.IL7>9?$[
ML.Z6MRP
M                %<[.?X3DG[QW3\-IY=GWI[,JQ[/>;R_[V3MK&/4LX
M                  !7%F^NG)OFB@_#4\M?.SV(5C9_W;-_MT6.>I9P
M          #.G6<_;'8W]^+=\(@"8:+"
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MG7GG]D_WON6=38N\R^)W8=TM;E@
M                                    *YV<_P )R3]X[I^&T\NS[T]F
M58]GO-Y?][)VUC'J6<                      KBS?73DWS10?AJ>6OG9[
M$*QL_P"[9O\ ;HL<]2S@              &=.LY^V.QO[\6[X1 $PT6$
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M:T:]B6-^L,EJS72L1;?TK$.T6=S0
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MHTF;6FVY'92@W.L               9TZSG[8[&_OQ;OA$ 3#180
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MI
M                         "-9I@&)[@VF>SY5;8ZVFJ(74RS:='4LA?)'
M(]D<S-)&(YT3%<C7)KHFH'JK,0Q:NMSK346>C6@626H;"V"-B1U-0CVR3Q\+
M4X)7=(_61O;=LO+R@?"TX'A]FL46.45EI%M$=/1TCX9H8YEFBML;(J;IW2(J
MRNC;&SA=)JJ: ?BP8!B&-0U,-KM,#5K'5BU,LS$FF>RXU#ZJHB621%<L3Y'N
M=T>O#ZP'YM.WF&V.]UF0VRST\-UK9(95F2-J] ZFI&T#.]T5-(4Z!B1JD7#J
MG.!)P
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MMCF,L?'8+736YLO]IWO&UBN^ZJ)JI5+7FV_+L4QUIWL:.N8-@
M         "HJWZ^;=[W=\#F*9D_>:]C[DKOC_9+]G[]5NES4@
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M_P"F W#_ +UO^A_TP&X?]ZW_ $/^F W#_O6_Z'_3 ;A_WK?]#_I@-P_[UO\
MH?\ 3 ;A_P!ZW_0_Z8#</^];_H?],!N'_>M_T/\ I@-P_P"];_H?],!N'_>M
M_P!#_I@-P_[UO^A_TP&XYMKW)ZPV,[N8/@>YS<<6V9:^KT=9XYW2HRC@<]>V
MD>B-7B5O]5>34#3H0
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M]VK?_11A/ T6$   !5&P_P"S]S]^?W3"G^S'F;^-W(7/VK\_3Q>[*URX*8
M.#G'[&Y!\W57YEQNP^<KV88W[V6"^J#]=5O]XUWYHM76GF)[,.9LW?O]$BGN
MJ                      5%6_7S;O>[O@<Q3,G[S7L?<E=\?[)?L_?JMTN
M:D
M          S-UMO\8V=_>ZE_.1!,-,A
M       !G3>#^)?8W_C7P= EHL(
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M5.&6*1$159(Q>5KDUYCPTO%HUAS-IV;)@OS+QI+O&;S
M    *BK?KYMWO=WP.8IF3]YKV/N2N^/]DOV?OU6Z7-2
M                                                   9FZVW^,;.
M_O=2_G(@F&F0@                                    SIO!_$OL;_Q
MKX.@2T6$
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M? YBF9/WFO8^Y*[X_P!DOV?OU6Z7-2
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MXE]C?^-?!T"6BP@
M       ,Z=9S]L=C?WXMWPB )AHL(                             ,Z
M;]?7KU?OG.\?@403#180   $'WG^I[<']VKS\ F!#A]6SZBL%^;&?AO"96H$
M   !G3#OXR-Q?W:M_P#11A/ T6$   !5&P_[/W/WY_=,*?[,>9OXW<A<_:OS
M]/%[LK7+@I@!%=S?JZROYIK?S#S7E[R>P]NP_J*>-';5[LO]5V,^]?[QYY<?
M>P[G6/ZB_93PV.<JVY?Q'X-\U5OX%0:X\Y#J?_S\GC1W&@CW*F
M           J*M^OFW>]W? YBF9/WFO8^Y*[X_V2_9^_5;I<U(
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M*[P@  <+(L-Q?+9;;-DEKAN4MGJ6UUL=.BJL%2Q45LC-%3E31 .Z
M     "A^LCL'6[T6ZDFMUQC@N5J8UM#120P1MD?+4Q=,^2K6*29K6P=+PQ-[
M5TG"J\W*3$OQEG5O;>]FZ#:NGOB.BLSYYZ.H6WT$#Y^%LJTL3GLA7H7(Y8NF
MJ(V])*B/XO9KH-4JV)VD79W$EQ]:]*U:IT55+&E/!$L%0Z)J3LZ>)C'U#>DX
MN!\O;(S1O,@)6B$                   SIO!_$OL;_ ,:^#H$M%A
M                                       B.Y^55N$8'>LJMR4SZVV1
M,EABK4J'02.=*QG1JE*R23B>CN%G"U>V5->UU HW8WK 9YG5+EL>54E+:JBQ
MT%TNM(ZYQ53)7=%4O1C7][TL<?>](B=[S</%.YS=>'770F8>;8OK$[@;A[C3
MXQDMK@MUJK)II:5\\54Q6LAH(Y4IJ-R4L:*KE_VM5JW\71/T371NHF&J0@
M *?WKVZR7.LAVPN5@CA?2XKDU)>;NLTJ1.;202Q/>K$5.V=HQ>0)A< 0
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MI$PFII;             *BK?KYMWO=WP.8IF3]YKV/N2N^/]DOV?OU6Z7-2
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M-89.*"1T3]6KKIVS5"$G    &=-X/XE]C?\ C7P= EHL(
M                              #Q6NT6NR4[Z2T4<5%2R335+X8&(QBS
MU,BRRO5$_K/>Y7.7LJH"BM%KMM175=!1Q4U5<YDJ;C-$Q&OGG;&V)'R*GLG(
MQC6ZKV$0#V@               /)=+7;KU;JJTW:ECK;96QN@JZ2=J/BEB>F
MCF/:O(J*G.@'W[W@[W[UZ-O>W!T71:=KP:</#IZFG(!\+7:[=9;=2VFTTL=%
M;**-L%)20-1D443$T:QC4Y$1$YD ]8               #.F_7UZ]7[YSO'X
M%$$PT6$   !!]Y_J>W!_=J\_ )@0X?5L^HK!?FQGX;PF5J!    9TP[^,C<7
M]VK?_11A/ T6$   !5&P_P"S]S]^?W3"G^S'F;^-W(7/VK\_3Q>[*URX*8 1
M7<WZNLK^::W\P\UY>\GL/;L/ZBGC1VU>[+_5=C/O7^\>>7'WL.YUC^HOV4\-
MCG*MN7\1^#?-5;^!4&N/.0ZG_P#/R>-'<>VPU,./=:',*.[.Z"7+;/;JBPOD
MY&S)01=%-&Q5YW(K'.T3U#O6CG;/73^F9U46G\N>VO\ 5$:?(L3<#<FP[<TU
MKEN\<]75WFNAMMOMU$D;ZN669=.)C)'LU:WDXEUY-4]4\N+#.373@>G)EBFF
MO#*N\%_B<W4^;[/\$ISU9?T].S/;>3%^HO\ )VG@ZQ<\&193MI@%IF8_)IK_
M !7-\;':R4])3QN1TCT;JK6KQ:HO9X5,=FC2M[3O::-V?=M2(W]=?FE-[RW%
MM[*6]XI;LBNUKEQVLDH+TRTSNH)NGT<SHY=6KTD2Z.Y.9VAHK-L4Q:8C=XVV
MT1>)C7D5EM1F.*X[M1DM'GD%NN&,8#=ZFU6RNBI85AN'1L1[$BB<G"Z=ZN5-
M?ZW$FO94].:EIR1S==;1JTX[Q%)UWJSHD6T.V<UTO[]XLSL]-:KQ5M5N,XY#
M!'%':Z%W*Q[VHQG^TN15XG::HGW=$PS9=(YE9UCAGC_@RQTUGGVC=X/B_BO@
M\3T@            5%6_7S;O>[O@<Q3,G[S7L?<E=\?[)?L_?JMTN:D
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MUX4<K>+35=/5!+1(0   &=-^OKUZOWSG>/P*()AHL(   "#[S_4]N#^[5Y^
M3 AP^K9]16"_-C/PWA,K4"    SIAW\9&XO[M6_^BC">!HL(   "J-A_V?N?
MOS^Z84_V8\S?QNY"Y^U?GZ>+W96N7!3 "*[F_5UE?S36_F'FO+WD]A[=A_44
M\:.VKW9?ZKL9]Z_WCSRX^]AW.L?U%^RGAL<Y5MR_B/P;YJK?P*@UQYR'4_\
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MX_#)0F5^A    9TW@_B7V-_XU\'0):+"
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M76IAB1=5_P U5!HGX0 4]UJ/J S;WM3_  R )A-]LOJVP[YCMGP2((2H
M    !X;U_@]P][3?FW 4AU,OJ L'OFX_#)0F7AZL?[8[Y?OQ<?A$X):+"
M                   #,W5)_P 8WB_>ZJ_.2A,M,A    9TWZ^O7J_?.=X_
M H@F&BP@   (/O/]3VX/[M7GX!,"'#ZMGU%8+\V,_#>$RM0(   #.F'?QD;B
M_NU;_P"BC">!HL(   "J-A_V?N?OS^Z84_V8\S?QNY"Y^U?GZ>+W96N7!3 "
M*[F(J[=Y4B<JK::WD_\ H/->7O)[#V;#^HIXT=M7NRZHNUV-:>Y5_.//+C[V
M'=ZQ_47[*>&QSE77'EZQ^#HG+I:JU5^YP5!KCSD.I_\ S\GC1W&@3W*F
M                 J*M^OFW>]W? YBF9/WFO8^Y*[X_V2_9^_5;I<U(
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M55T_F C_ -.++_FS_P"HGMB=$:I%#*V>&.=FO!*UKVZ\^CDU0A+]@
M                      /#>O\ ![A[VF_-N I#J9?4!8/?-Q^&2A,K]"
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M#G*YTRIZBHYW\_K$X:S:W.EGUEDIAPQL]9UMKK;Z%]'L5D
M      !45;]?-N][N^!S%,R?O->Q]R5WQ_LE^S]^JW2YJ0
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M^/H^#C[;773DXP0VB$ 'DNL;Y;76Q1M5\CZ>5K&IRJKE8J(B 5A\0WKW!/\
MZBF3%:5O8Z.@I8WHK7MAC:YJ\BHJ-1%0Q9.==LEH+-4MI:J.9\CV)(BQM:J:
M*JM_K.3EY"=$/[:,CH;S.^"ECE8^-G&JRHU$TU1.3A<[U1HEV"
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M_P")'?+YSN/_ #><,I;##$ I[K4?4!FWO:G^&0!,)OME]6V'?,=L^"1!"5
M %3]8'=&[[88=238Q1LKLOR*X06.P12_V3*JJ1RI(]%T14;PZ(U535RIKR:A
M,*CRJ]]9+82BM^XN<9;19QB:U,%/D]ECI(J5U,VH=P\=-(R*-5T5>%J]JG$K
M=6*G,&L89HZB&.HA=Q0RM;)&[14U:Y-471>7F"'[ \=V<YEJKGL56O;3RJUR
M+HJ*C%T5% JKXSN/NR?\H_[YDQ6W2*KJ2!SEU58V*JKSJO"ABR?8
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MYR?Y#7&&D<#W7ZUVJ\:3>=%@M:UK4:U$:U$T1$Y$1$-SEOZ
M        !45;]?-N][N^!S%,R?O->Q]R5WQ_LE^S]^JW2YJ0
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MO\'N'O:;\VX"D.IE]0%@]\W'X9*$ROT(   #.F\'\2^QO_&O@Z!+180
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MUG<AS/I5C'RW0>%0^V-7E\?A1RP\_2L/AUY8=9%1R(YJZM7E14Y45%-STOZ
M  4ILUDEALMDN$%VN,%'-)5<;&3/1BJWHVIJB+V-4*)[/;9APXK1DM%9FW#V
M%_\ :38L^?-6<=)M$5X(^.5D_3W#/EVC_+-+1ZTV3TE>55/5.U^BMR'T]PSY
M=H_RS1ZTV3TE>4]4[7Z*W(?3W#/EVC_+-'K39/25Y3U3M?HK<A]/<,^7:/\
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MB2M,X+X>IKUO$UG7>GQZKH+RH0
M       "![U5EUMVU65UUCJ:RCO$%!))0U-L8LM8R9%3@Z-J.:JJJ\BZ+S:A
M,*$PKK3V*VVNVR91MMD[\LBHH8+K>:.UP3S5-3&QK))%D>ZG<J2*BO77FYM
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MU1K4X7\JKR)_5.'3VGZMO:*QFC6?BM]#V3U;M$1K-.T[A9G.
M        R>N#Y'E.Y^X==L1G];AU?3W**',[1<*)DM(^X.8Y>^*5SG2:H_A5
M5XHVKKS.X51$,EU;.[4Q[56.OIJJ[SY#DM\K'W2_WVJ3@DJ:J1$3D:KGJUK4
M3DU<JZJJZ\NB$2L8(    !CSJQ_Q([Y?.=Q_YO.&4MAAB 4]UJ/J S;WM3_#
M( F$WVR^K;#OF.V?!(@A*@  #BY9EN.X-8*S*,JKV6ZQT#4?4U4FJZ<2HUK6
MM:BN<YRJB-:U%55Y@*DQ'K:[3Y;?Z+'O_N=CGNCD9:*R\TC:6CK'.=PM2*5D
MDB)Q+R-61&IKR<^B!.B]0@    '@K++:[A-T]93I+*B(WB57)R)S)R*GJ@?N
MAM5OMJO=0P)"LFB/5%<NNG-SJOJ@>P#@7++J"UULE#-3U$DL7#Q.C2-6]LU'
M)IQ2-7F7U#RY-IK2VDQ+S7VBM9TF)>NS7ZEOC9G4T4L70*U'),C$UX]=-.!S
MO4,\6:,FNC/%EC)O.A-/#3QK+42-BB335\CD:U->1.5>0W3,1NRVS,1OO.V[
M6I[D8RNIW/<J(UJ2L555>1$1-3#RE>.&'E*\</8;&P \-Y_P>X>]IOS;C7E[
MR>Q+7E[R>Q*CBM*\O6V_X=2?^S'^ A9J=['86*G>QV'J,V8         S-U2
M?\8WB_>ZJ_.2A,M,A    9TWZ^O7J_?.=X_ H@F&BP@   (/O/\ 4]N#^[5Y
M^ 3 AP^K9]16"_-C/PWA,K4"  !&=Q/V%R+WA4?@*>3;/,W[$N?UC^FR>++&
M117RQNNA_P!RIO\ VF?@H?0Z[T/L%.]CL/09,P !#';3[?O<KULZ:N5572HJ
M6IR^HB2HB'#GJ+8I_H^U;Z7>CK_;H_\ 9]FOT/SYI=OOD?\ 2:KNI'J+8O ^
MU;Z4^\&W>D^S7\)YI=OOD?\ 2:KNH]1;%X'VK?2>\&W>D^S7\)YI=OOD?])J
MNZCU%L7@?:M])[P;=Z3[-?PGFEV^^1_TFJ[J/46Q>!]JWTGO!MWI/LU_">:7
M;[Y'_2:KNH]1;%X'VK?2>\&W>D^S7\)YI=OOD?\ 2:KNH]1;%X'VK?2>\&W>
MD^S7\)YI=OOD?])JNZCU%L7@?:M])[P;=Z3[-?PGFEV^^1_TFJ[J/46Q>!]J
MWTGO!MWI/LU_">:7;[Y'_2:KNH]1;%X'VK?2>\&W>D^S7\)YI=OOD?\ 2:KN
MH]1;%X'VK?2>\&W>D^S7\)YI=OOD?])JNZCU%L7@?:M])[P;=Z3[-?PGFEV^
M^1_TFJ[J/46Q>!]JWTGO!MWI/LU_">:7;[Y'_2:KNH]1;%X'VK?2>\&W>D^S
M7\)YI=OOD?\ 2:KNH]1;%X'VK?2>\&W>D^S7\)YI=OOD?])JNZCU%L7@?:M]
M)[P;=Z3[-?PGFEV^^1_TFJ[J/46Q>!]JWTGO!MWI/LU_">:7;[Y'_2:KNH]1
M;%X'VK?2>\&W>D^S7\)YI=OOD?\ 2:KNH]1;%X'VK?2>\&W>D^S7\)YI=OOD
M?])JNZCU%L7@?:M])[P;=Z3[-?PGFEV^^1_TFJ[J/46Q>!]JWTGO!MWI/LU_
M">:7;[Y'_2:KNH]1;%X'VK?2>\&W>D^S7\)YI=OOD?\ 2:KNH]1;%X'VK?2>
M\&W>D^S7\)YI=OOD?])JNZCU%L7@?:M])[P;=Z3[-?PGFEV^^1_TFJ[J/46Q
M>!]JWTGO!MWI/LU_">:7;[Y'_2:KNH]1;%X'VK?2>\&W>D^S7\+H6;;_ !"P
M5[+G:;:D%=&CFQS++-*K4>G"NB2/<B*J+IKH>G9^JMEP7Y^.FEH^.9[<O-M/
M6^U;13F9+ZUG@TK':A)3J.2
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M1$1-$3D1$-C<
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M7YL9^&\)E:@0
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M[M-'!=::XY'?KU3I314#*9KVO;&]CWHKM'N5-7->[31&\O(-YLH(
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M'AO7^#W#WM-^;<!2'4R^H"P>^;C\,E"97Z$   !G3>#^)?8W_C7P= EHL(
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M--W>>:T8DVU5S*WOM958CD1G1\/LDTY^)?5,,6S<RVNK#'L_,MKJDA['K
M      %'[A-:N6UZJB*ND/.G_P"Y85O;?.S\G:5S;(_\L_)VDFVD1$9=]$TY
M:?F_^J>SJ[^KY.Z]G5W]7R=U91V'7   #,W5)_QC>+][JK\Y*$RTR$   !G3
M?KZ]>K]\YWC\"B"8:+"    @^\_U/;@_NU>?@$P(</JV?45@OS8S\-X3*U @
M
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M'YCN?P24(4%U!OJ>O?[RU7P"@"9:G" #.G7%_8[ _P!^+1\'K F&BP@
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M#DMBQIJ7:E=TE%+5U-36,@>BZH^-D\CVHYO]5RHKF]A0G5;H0
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M$\C8M)8WO:[BC1C^1RZ:Z&24C
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MYM?I>+',(EL5S;<'UC9T:QS.C2-6KVR>KQ*<WJ+V2OU=M49IRQ?<F-.;IO\
MRO1MO6D;1CYG-T^5,3Z&X(                    #*J]:FT[<[J9[A^Y=T
MJKC:Z:O8N.RT%$Q8Z*'@59*:7DBD<Y%5NC_QB+ZK>8)T7CMANSA^[UHK+WAL
MM1+0T-3WG.M5"L#DEZ-LG(BJNJ:/3E"$Y     #'G5C_ (D=\OG.X_\ -YPR
MEL,,0"GNM1]0&;>]J?X9 $PF^V7U;8=\QVSX)$$)4
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M_5=]\\G0<'@PY_JO9? A+6,:QK6,31C41K43L(G(A[72B-']"0
M
M      $"WMI,@KMI,RH\621U]FM52RE9!_;/16?C&QZ*B\3H^)K=.77FY0F&
M+K_?^K%7[,4..X5994WC=3T5/;X::AJTO#+RCXT>Y]4C&LDU?Q<C7KKKVK47
M1$)W6^L:CNL..6>&^OZ2]QT5,RY/UUXJIL34E75.?5^H8NH    (KN;]6V8_
M,=S^"2@4%U!OJ>O?[RU7P"@"9:G" #.G7%_8[ _WXM'P>L"8:+"
M                         /S)%',QT4S&R1NY',>B.:J>NBF%Z5O6:VB)
MB>"65;36=8W)>3XHM/N"G_(L^\>+U=LOHJ?5K]#=TG+X=N67M.@\X    (KF
MEQK:!E$M'.Z%9%DX^!=->'AT_I*5[4;;FV>,?DK377G:Z?([75F&F2;<Z-=-
M.ZX^-7JZU=[I*>IJY)(7])QL<NJ+I$Y4_P J' ZCZTVK-MN.E\DVK/.UC_3:
M7OV[9<5,-K5K$3N=N%A'U15@   SIO!_$OL;_P :^#H$M%A
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MC\"B"8:+"    @^\_P!3VX/[M7GX!,"'#ZMGU%8+\V,_#>$RM0(
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M6+C[9[T=6^E^S?\ ">?C:CR@_0ZWN Z5BX^V>]'5OI?LW_">?C:CR@_0ZWN
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MX!0!,M3A !G3KB_L=@?[\6CX/6!,-%A
M             ",9BVUN91_&;YV)K)T7>Z,77V.NO%_(4WVEC99C'Y>;QWVG
M,T^+775V.K9RQ-N9$<&^Y&.,Q]+U2K12U;JK\9T;9FQHS^S=KKP\O-J<+J6N
MP1ME/)6R3?\ FTYT5T[V>+=WGOVV<_D;<Z*Z;F]KQPGQ]/5@   ,Z;P?Q+[&
M_P#&O@Z!+180                            Q-OS<]E;+N?=JRT[CY%A
M.;U21196S%V5$E/-)$U.%)5CD@1)4;IQ(U[FZ\[4?Q:F4+KZKU5M?-@=93[7
MU%?7T<%PD=>KI=F*RMJ[E-&Q[Y9%7GU:K433U.RNJJ1*[@@    &/.K'_$CO
ME\YW'_F\X92V$YS6-5[UT:U%5RKS(B!C,Z*@MMZW1W 967[%;A2V2P1ROAMM
M//"R62H2/G<]SXWJFO-R:>IV-3ATR[3M&M\<Q6O!\:LXLVV;7$Y,5HI37^6-
M-=>RF.W66UF666>6Z4[::\VVIDH+A''_ &:RQ(B\3>5=$77FU7E3U#W;'M$Y
MJ:VC28G273ZNVNV?'//C2U9YL]F'HS/-[;AE+3OJHI:RXUS^BM]NIDXIIGII
MKHG81-4_GY$4SVG:JX8C7=F=Z&>V;;39HC6)M:V]$;\N5CNYL5TO4>.WVSU>
M/7>I:KZ**M3M)D1-51KE:WMN1=.33L:Z\AHP[;%[\RU9I,[VKS[/UE%\D8\E
M)QVG>UX4\.D[                                 (7NE+)%BKGQ/<QW
M?$2<355JZ<OJ'.ZPF8Q;G&YW6$Z8OE51B=96/R:T-=42.:ZKA145[E145Z>N
M<39[SY6N[PPX6S6GRM=WAAHLMBW   !G3?KZ]>K]\YWC\"B"8:+"    @^\_
MU/;@_NU>?@$P(</JV?45@OS8S\-X3*U @         9NZOF$XGD^,W.KO]I@
MN%3#7+%%+,BJYK.AC=PIHJ<FJJ<G9,5;Q.L/F?LGU?LVT;->V6E;S%]-V/\
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MRO2"%-&\3Z"H55Y=><\=:17:(B/AN*A.S8L'7V*N.L5CFSN1XMVBSJOI
M                                      " ;WU%SI=HLRGL];%;KDVU
MU"05D\C86,5S>%4Z1^C6JY%5K7*J:.5.5 F&0\.P_JP28O:7U6].16ZK?31N
MJJ"&X-H8X9W)Q2,; ^B<K4:Y53V2Z\^JA.ZW;964L=GM\=#.ZJH64T+::JD=
MQOEB2-J,>YVB:JY-%5= Q>X    17<WZMLQ^8[G\$E H+J#?4]>_WEJO@% $
MRU.$ &=.N+^QV!_OQ:/@]8$PT6$
M        4_N+L-YP<EDR/Z>9-C_'#%!\76:N[VI$Z)%3B1G"O;.UY5"=7!H-
MB*S"ND=299DF4+6\*/;=JI:M(.BUT6/1J</'Q]MZNB%,]IL&;+7'Y.DWTYVN
MD:Z;SL=6Y*5FW.GF[S[5>U%SR:G?8ZBZ7FQPU6G%=:"1:>IAZ)4D3@D5%TXE
M;P+ZRJAP>I-CVFFVX[7Q36L<[=YLQ_39[]MS8YPVB+1,[G#\</!3]53O>HBG
M\ZF;2=$]K^C?<]6NX5UT5.'F4^HJQJT.$  #.F\'\2^QO_&O@Z!+180
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M:=[987]/4.X7M75%T=(J+_*AHKL>*LQ,1NQ\<M%=BPUF)B-V/CGZ4F/8]@
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MWF_X!4G,G]3\.)0-I_[!B\2?[;K[.FOX
M             "-;@0W&HPR\P6FP4N4W%].J4V/W#HDI*Q^J?BI>G5(^%>?M
MET R9D3L]Q*TS7[(^K+A%#9:96=]UO1VFH9 Q[D;TDC:=97M8W75[^'1J<J\
M@9-E65W%9[>Y88:?BIH5[WI5:ZGCUC;VD2L[56-YF\/)H&+W    "*[F_5MF
M/S'<_@DH%!=0;ZGKW^\M5\ H F6IP@ JS?7;"[[J6+&[59ZRFHIK+D-#?9WU
M?2<+X*2.=CF-Z-KEXU65-->3UPF%IA
M                   #.F\'\2^QO_&O@Z!+180
M       Q-N5<-O+/NIEM<N_UWPR_5M2QEVL]MM%Q='&Z"-&QL?)3-1DJL;R-
M?RKIR:Z!DO/JX76TW;%KK-:-QJ_<F!EP5C[K<Z:JI):=_0QKT#6U2(Y6Z+QZ
MIR=L$2N8(    !CSJQ_Q([Y?.=Q_YO.&4MAAB
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M8V@$"S;:Z@S7,\'S.JKYJ6JP>HJZJEI8F-='4.K$A1R2*[E1&]"FFGJA*>A
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M.)0-I_[!B\2?[;K[.FOX
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M+Y#E>/YI=*5\N08QT_Q/4-ED8V/OIO!)Q,:Y&OU3_.1= ).
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M16-9G1^F2,E8V2-R/C<FK7M5%14]5%01.J8F)WGZ)2
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MV?+-]HVK)3R<;1>)K6=_2-=WY>=W7CZQO72F.L\[F1NS\.PDA>7'
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MO8;-AK&#:[X:3K3FZZ>#*VSM+(
M      !0M9L_EL]743,=2<$DCWMUE=KHYRJG]0K%^K,LVF=Q5;=69IF=[E6Q
M@UEK,=Q:AL]P5BU=.LZR=$JN9^-GDD3151.PY#N;)BG%BBMM^->V[VQX;8L4
M5MOQKVY2(];V  "#[S_4]N#^[5Y^ 3 AP^K9]16"_-C/PWA,K4"
M!1O5?_9&\?.2_F(CG;#WLJ%[%_I+^/\ =JO(Z*^@        "#Y;M3C.:71M
MWN]1<XJIL38$;17"HI(N%BJJ=I$Y&Z\O.;:99K&FD<C"U8EPV=7[!HWM>VMO
MG$U4<FMXK%35.7_YAGY>>*.2$>3CX^65J'G;               "A+G_ !06
M;WF_X!4G,G]3\.)0-I_[!B\2?[;K[.FOX
M              ")WS-=LL5O6F2Y%8;)D3Z=J:7&MHZ.M6E<Y5;_ &SVR+&K
MFKIV-4 \?GGV>^T'&O'-!W8&B:PS0U,,=13R-FIYFMDBEC<CV/8]-6N:Y-45
M%1=45 /V    (KN;]6V8_,=S^"2@4%U!OJ>O?[RU7P"@"9:G"
M                                       #GWRVON]JJ;='+T#YVHUL
MNG%PZ.1W-JGJ'-ZSV.=KV:^&)TYW#\L2]&S9O)9(OOZ(&[:ZY*U49?$8[3M7
M)"JZ+ZOLRB4]B[5M$^4C<GP?XNY/7$3&G-GE0#S"[Z_^0-S\3L_73Z:KFKUP
M8?EN/Q-M%_R*IRB[4VO?%]EIE@?4=(O2-UC;)(B<#7-C]FOL=3XE[28<ENL<
MLQ29C^7=TGP*KGU=>L;/7=B-_MRL;;:EJ:6"X-J5>JN?$K5>U6\B([FU+3[&
M8[5KEYU9KNUW_P#4Y?7%HF::3KO]Q.CZ(KX                        1
M3<;;VP[HXG5X;DKJAEHK'PR3.HY&Q3<5/(V5NCG->B<K4UY )6       !CS
MJQ_Q([Y?.=Q_YO.&4MAAB 1#*]M\=RZKBN-8M1176%$8E?02)#,K$YFN56N1
M=->?37USQ;1L>/-.LZQ/'#F;5U=BVBT6G6MHX:SI+V8EA%APNGFAL\;W3U*H
MZJK*AW25$JIKIQ.T1-$UYFHB&>S[-3#&E>'A;=DV+'LT3%-^=^9WY2,]3W
M                                             @^\_P!3VX/[M7GX
M!,"'#ZMGU%8+\V,_#>$RM0(         %&]5_P#9&\?.2_F(CG;#WLJ%[%_I
M+^/]VJ\CHKZ                            H2Y_Q06;WF_X!4G,G]3\.
M)0-I_P"P8O$G^VZ^SIK^
M  HWK&;28EE&&9/FB8O%>\^H;1+':ZASIUE:V%'.1611R(U[HT<][6\*\2\G
M+S!,,LW^IZI%3M-3T6&VRJGW;?2TT=!2,AN4M:MU56H[INE1:61CGZ\3&\2*
MBZ,:BZ:$[K_0/&&5<>-V:.X4K*&O90TS:JBB_LX)DA:CXV\J\C':M3E#%U0
M  !%=S?JVS'YCN?P24"@NH-]3U[_ 'EJO@% $RU.$
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MWF_X!4G,G]3\.)0-I_[!B\2?[;K[.FOX
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MVK$ZQN3_ %3/!N*GMN2N3-:U9UB?H=0[;Q
M 8FWYHMD\AW<[QI[/DC\HDK[?:<IR#&IXZ*VPU->]D43*J66"H:LJ-TU1K6<
M6FG$KD=H90OCJXOVV@PFMLNV]LJK1!9KG4T-[H;FU4N'QC%PH^2=5Y7*]J-X
M5T31J</"WAX4(E<(0    #'G5C_B1WR^<[C_ ,WG#*6PPQ
M                             .3D]XJ,>QZYWREMM3>*FWTTE3%:J%BR
M552Z-JN2*)K455>[F1$0"BO2<S'[#<X\75'< G1&)]RLSDGDD2HNL".>YR0.
MDD:YFJZ\*IV%3F*ADSY8M/\ /._QJ9?:,L6G^>>5V[7UALRLE#':UVNR[*E@
M5_\ ]^H:2>HIJCC>K^TD2)R+T?%T2\O(K50L6Q6FV&)F=9W>W*R;!:;8*S:=
M9W>W*UMK=R;ON+3W.:[83>L,=;WPLBBOU/)3.J4E1ZJZ)'L9JC.'MM/50]KW
MK!" "#[S_4]N#^[5Y^ 3 AP^K9]16"_-C/PWA,K4"         !1O5?_ &1O
M'SDOYB(YVP][*A>Q?Z2_C_=JO(Z*^OR^1D;>*1R,;ZKE1$_R@?U%141475%Y
M45 /Z    /XYS6-5SU1K4Y5<JZ(B ?F.6*9O'"]LC%YG,5')_.@'[
M           %"7/^*"S>\W_ *DYD_J?AQ*!M/_8,7B3_ &W7V=-?P
M                                  $-W8NN.V7;?)KEEMO?=<9AH94N
MENBTZ2:GD3@<UJN<S1>VY%XD5.=%U QO1[;[!56VMSWAL=]R/),:L;:5UQP2
MKKX:=[."=K8Z.I5L+G)&Q955BMY%37A?KJH9-TV"J@KK%;*VE@2EIJFD@FAI
MFZ<,4<D;7-8FB(FC473F#%T0   !%=S?JVS'YCN?P24"@NH-]3U[_>6J^ 4
M3+3UPI._Z"JH>E?3]]0R0=/"O#+'TC5;Q,7L.375%"&??1/_ /\ J^<>-/\
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MKKNUF.+XWKVKK&F7%-(B=9^E,2_."
M  !CG-]M<VOF>Y9;=F,JL-RHY+]0Y/D.-7)[HZZWWJFD:]'ZM8JNA>K-5[9/
M\U$U353);?5SL[;=19G677(Z;),]KK_4?3.>@BDAI:6XP-;$M)&DD<?$D6B]
MNUJ(NNG8U")76$     QYU8_XD=\OG.X_P#-YPREL,,0
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M=0;ZGKW^\M5\ H F6IP@
M                                          #(EPV"SV[;@;A;EXE6
M5&+;@45[[YQ*NE5$HKE0R4[4DAD:O$G"Y45$<K=.PY%3E:9:IOU4K;FM);=P
M+GGEBJ+!?;YE-9=9:2H@D@C5U4QCWN@637CB1ZN:U[7.1=.=0B6A @    &/
M.K'_ !([Y?.=Q_YO.&4MAAB
M              (;N[2U-;M/G=%10OJ:RIQV[PT]/"U9)9)9*&9K6,:U%5SG
M*NB(G.!Q>KU0UULV5PN@N5-+1UU/;F,GI:B-T4L;N-W(YCT147[J!,K,"
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MYG<9<_6_-XH6,:&U0ES_ (H+-[S?\ J3F3^I^'$H&T_]@Q>)/]MU]G37\
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M@ZVR[9&3%GK%<V&W-MIO3Q3'9TEX]MV:N*:VI.M;QK#M%H<X
M
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M%O1=+94,J[=75M;4T=5"Y'Q2P3729\;V.3D5KFJBHH3+9@8@
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M*!M/_8,7B3_;=?9TU_
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MJ<W-JIW>H>J<NQQDRY[1;-FMSKZ;T<41V-9>/;=IKEFM:1I6D:0[1:'.
M
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M3TMREBC:KG*JJJ-:B:KRJ$RVF&(
M                !DW=:1S=P;XB1*Y.EC[9/_8C*5M\?^>WPX% ZRC_ /Z;
M]GN0^N&[IYC@MMFHL=VVNV94]5.Z::KMKE;' ]&,;T;M(9.543BYSM=41_XY
M[/<=_J.(\E;QNX]]_P!Z]Q,EMDENN.V=^PJG1S)4O55,]D?$UR(D6J0Q+J[7
M_.[!Z.LK3&&9B=-V'JZVF:X)F)TG6'(P_)\CJ,ML,$]PKGP2W&C9(Q]3*YCF
MNG8BHY%=HJ*G.A7=GRWG+7^:>^CA^-5=ES9)S4B;3WU>&>-K4NKZ
M 4;U7_V1O'SDOYB(YVP][*A>Q?Z2_C_=JO(Z*^H?N9M[:-S<2J\8NVL3GJD]
MOK6:])2UD6JQ3,T5->%5Y4[**J&W%EG';G0RK::SJQ#=[7?L,R"?#LR@[UOE
M/JM+4I_N]?3HNC9X7)R=MSJSV3>RA:\&T5RUUAU<>2+0_+XV2L6.1J/8[D<U
MR(J*GKHIZFQS(+#2T,BRVFIK+4]5U7O"KGIVJO\ HL>C?\AIMAI;?AA-(DFL
M-)62I-=9ZNZ2M75JU]5/4M14_P#2]ZM_R"N&E=Z$Q2(=-C&1M1D;4:QJ:-:U
M-$1/61#<R?2QV;(,[R"/#L+AZ>ZR:+7USO\ =K?3KIQ32N7D5R(O:L3E53R;
M1M%<5=9:LF2*PW%MW@5EVVQ2AQ6R-UAIFJ^IJGI^-J:E_++-(O+JY[N7UDY$
MY$*KDR3DMSI<NUIM.J5&IB                 %"7/^*"S>\W_ *DYD_J?A
MQ*!M/_8,7B3_ &W7V=-?P
M  $5W+RJWX3@.0Y5=:#XTM]LHI99[;HU4J&N3@Z)W$UR(UZNX7*K51$UY% R
M=<F[GYQ;+!+6=6^T5MFMD#'8\QU8V)(:2721D?"V:-59IHO1O;P_^GG#)M"U
M.J'VNB?5T[:.J=3Q+/2,TX89%8G%&FG)HU>U#%ZP   !%=S?JVS'YCN?P24"
M@NH-]3U[_>6J^ 4 3+4X0
M                                           !C[=#*]DWYGN!BU'A
M63Y->[XVDI,NK,:AZ2&&MM[DDBDA5SE5D\;D;QN1G JMY4=J[4R6?U7;?C%N
MPZ[LQNP9'972W-\MPGS!K4N=9.^)B]*KFM8BL1%X4T:G+KV550B5Y!     ,
M>=6/^)'?+YSN/_-YPREL,,0
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M;_@%2<R?U/PXE VG_L&+Q)_MNOLZ:_@
M            ('O7+=(=I,S?9J..X7%;35,BHYHVS,D:^-6O18W<CU1BN5&K
MKQ+R:+S AG/!=O\ .*G#K)/;NLRRCHGT<+H:*.*"J;3M5B*D/22U[7KT?L-'
M-3ATTT30,FOK9')#;:.&:J[^FC@B9)6Z(G3N:Q$631%5.W7MN=0Q>H    17
M<WZMLQ^8[G\$E H+J#?4]>_WEJO@% $RU.$
M                                                          9&
MMR[[U&[>Z,^S%/9;58H;Q%#=K??7/=T]>VF9K5L:QJO;TS5:_G1J\FFJ\09-
M ;8>=?XHK/.W\4?'7?/^P_$72]!WKT;?9]+R\?'Q<W8T#%.0     QYU8_XD
M=\OG.X_\WG#*6PPQ
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M=S^"2@4%U!OJ>O?[RU7P"@"9:G"
M                                                  ,BR[8[=[F[
MP[A-R'(LHQ'*Z"LBC2%MYHZ9M=1O8YT<M+%)2=(D"</:IQO1->=.8,E^;4;<
MV';:S5MJL%_N>0TU75=]2U-XK(JZ:-_1M9P,?%'&B-T:BZ:<ZA"?!     ,>
M=6/^)'?+YSN/_-YPREL,,0
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M-;(        H2Y_Q06;WF_X!4G,G]3\.)0-I_P"P8O$G^VZ^SIK^
M                                  BVY-SQFS8%D-VS*B;<<8HJ*6>Y
M6]\;94J(HTXNBX'Z-57JB-3BY-><#'2K=[+:H-RLLZN^+4^TTJ0U4W>D4#KQ
M3T%2Y$9,YKINV5$<U>%8&?\ JX$Y4,FX;-46VKL]OJK,K%M$]-#+;UC3A9WL
M^-'1<*<FB<*IH@8O:    (KN;]6V8_,=S^"2@4%U!OJ>O?[RU7P"@"9:G"
M
M                     ,1[R6/:F\;HY#18UM/>]Q\OIY63Y966VXUE'24T
M\[$<UB+$R9%?PIRMX6IKJB*JHNAE"\.K$W;),'KW[;6FLL")<98<BL5SEEEK
M*.Z0,9')')TSE5.U1NG-ZZ(Y'(A$KL"     8\ZL?\2.^7SG<?\ F\X92V&&
M(
M    !1O5?_9&\?.2_F(CG;#WLJ%[%_I+^/\ =JO(Z*^@  !EKKT?5S8?G=/S
M$AY=HWH6+J+SUNP]O4=^J2X_/E3\'IR=G[UAUYY^/%CNM%W>L=;K37W!C>-]
M)3S3M9S\2Q,5Z)_+H>NL:SHK\SI"F.K1C-IKMO:3<*ZT\=QS#*Y:JMNEUJFM
MFG72IEB9&U[T5R,:UB=KKSGMVR\Q?F1N15XMDK$TYT[]DIJ]L<=Q>LS+,["L
MM!)>[//!7VBGX([<Z6.)52H2)K4TE5$T5VO97LJ:HS6M%:SP3\K?Y**S-HX8
M1GJWXUCESV4QF6Y6BBK))8I>D?44T4KG:3/TU5[5U-NUWM&6=):MEK'DHW$:
MPG&:>T[K[K;.66>>W8?>+7#6P14JI_L$M?%PR][HNK8]4F7AT3L-]0G);7'2
M\[\3IV=$TKI>U8WM(GL:ZF\ECP3&-NZ#9G%;1!=,WN;(:2Q4<$,3JV)Z.3BK
MIGL:BL1-%57KS_<U&"UK7\I:=R-_Z#-$13F1OSO?3\CR[FK-B>Z6W%=5TOT]
MO-MLGQ?68Q#&^JKW/1KD=<HV/:YFKG(K5=(J+R?RHP_S8[1WL:[_  =@R;EZ
MSO\ Q=UUM@:F&Z[E[C7U:%F*U=<ZC8N$/C=3UE.R!B-[[FCX&,UE5==6*O*J
MZ\Z*L;1&E*QO_'W$X=VUIWOB[ORNEUM)EI]MK74-C?,Z+(;8](8TU>]6K(O"
MU.RJ\R$;'&MY[$FTSI37XX[;\Y#OE>ZNP76E?M3F-.R>CJ(G3RT#&QQH^)S5
M>Y>DY&IKJI$;-'AUY?X)\O/@6^;Z4'P3)*BQ[?["T,-#0U;+Q=W4DLM;3,J)
M8&K(O;T[W<L4G+[-O*;LM(MDR3Q->.VE,<<?T2FB9IO1F&Y.<83A=59[9:\7
MFI4^,KA3R2R(VJBXF1(UBJCE<K7JYR\R(:O)XZTK:VNZV<^]KVK&FX\T._F3
M6C;;([AD-NIJC<"PW]^(Q0TG$VBJ;@[3HI$1SN)&<J\2?^GUR9V>)O$1/\LQ
MSOD1&:8K.L;L3I\OPEX\US?K!;:T>/W+(JJQ7&AOESH[?4]Z4LS)*-]2[58^
MV<B.:K4<B.Y]4%*8KZZ:QI$R7ODIIKI.LQ#J97N]DERW$O>$8ID&/8I;L:9"
MVONV0R-Z2IJYV)(L5/&Y[$5K$Y'KZO\ (13!$4BTQ,Z\29RS-IK$Q&G&E>R^
MYUPSQF0V2^OH*C(<6JV4E5<+/)TMNK(9FJZ*>!=571R-7B3L?Y#5GQ<S28WI
MXV>+)SM8G?A:AYFX  4)<_XH+-[S?\ J3F3^I^'$H&T_]@Q>)/\ ;=?9TU_
M                                         0/=&3 +_C%ZV_S#([?9
M_CNB?"YM364]/41MEUZ.9K)7M5>%[>)->1530)9BJ;'NI?[%%M9DF].%+MHQ
MD-%4W.GK*9;K/;J=6\$:M5J=OPM:BZR\NG*]W+J2V99J*@MMHM]NM6BVNDIH
M:>B5KD>WO>*-&1Z.3D5.%$Y0Q>T    17<WZMLQ^8[G\$E H+J#?4]>_WEJO
M@% $RU.$
M                               9IO6);^;6Y_EF0;/6:U97C6;U;+I5
M4-QF;35-%7<.DJ\3YZ=',<JJJ:.=R:)HFFKB4^V(V\R?"K3?[WG4]/-G&976
M:]WF*BU[UIW2HB,@C5==>#EU7U]-7:<2B5L!     ,>=6/\ B1WR^<[C_P W
MG#*6PPQ
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MZ?F)#R[1O0L747GK=A[>H[]4EQ^?*GX/3D[/WK#KSS\>+'=:8/2X
M     ''RC%['F=CJ\<R*D;66JL;PRQ.Y%14Y6O8Y.5KFKRM<G*BF5;36=81:
ML3&DH/CNPV&6"]V^_P!16W>_UMH1/B9E]N$EPAHE;[%8(WHB-5O]7U.P;[;1
M:T:;D:\4:-5<-8G7=GLS,K0/,W     H2Y_Q06;WF_X!4G,G]3\.)0-I_P"P
M8O$G^VZ^SIK^                                          K;.M@M
MI=R[VW(LVQ[XTO+8&4C:GOVNIM(8E<YK>"GGC9R*]W+PZA.J,^B#U=O(W_\
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MD_VW7V=-?P
M    *JWKV(QW?&EL]+D%RK;<RRR3RP.H.B17K4M8UR.Z5C^;HTTT"8E:H0
M  "L-GMD,?V9^/\ XBN-97_2&HBJJGOWHOQ;H>DT1G1,9R+TB\^H3,K/"
M JK>/8C'=Z*K'*J_7*MM[\:DJ):1M#T6DBU3H'.23I6/YN]VZ::<ZA,2M4(
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MO"J<@3JL\(   #G7^SP9#8;I8*F1\5-=:2HH9I8].-K*F)T3G-U14U1'<FJ
M0S9K:"R;*XQ5XM8:ZJN%'65\ES?-7='TJ2RPPPJU.B8Q.%$A:O-V5"96($
M !569;$8[FNZ>-[KU]RK:>\XS'2Q4E%!T7>LB4=3+4M63B8K^5TRHO"Y.0)U
M6J$   !R,JQ^FRS&+WBU;*^"COE!56RHFATZ5D59"Z%SF<2*G$B/U35 (QM!
MM19MF\4?B-BK:JOHGU<M<L];T?2\<S6,5OXMK$T3HT[ 2GP0
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M=>U_E E-BM%-C]DMMAHGODH[52P4-.^94=*Z*FC;$U7JU&HKE1O+HU/N =
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MD_VW7V=-?P
M
M
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M4G,G]3\.)0-I_P"P8O$G^VZ^SIK^
M
M
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M+S?#79_O)NKB\*)W[5XG0/H7<VE5!+#+%HOKN:B&['?F8JV_^4L+4YU[1_\
M&.Z\5KRZHWQEMMXG9K2X)B=PK;QKKRWNXTTM,U'>NUL#WI]TFU/(ZQX4_-!6
M_E)B>*/GGX2M_JT_4;AWO6;X5,>;:_.V[+9L_FJ]A:YY7H      H2Y_Q06;
MWF_X!4G,G]3\.)0-I_[!B\2?[;K[.FOX
M
M
M
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MA8J/&\?I^];/;VK'2T_$Z3@:YRO5.)ZJJ\KEYU,;6FTZSOLJUB(TAUC%(
M  %"7/\ B@LWO-_P"I.9/ZGX<2@;3_V#%XD_VW7V=-?P
M
M
M
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M/ZGX<2@;3_V#%XD_VW7V=-?P
M
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MP\];7Y]J7KS;5X%FGG;0
M                                                  'SEJ((58V:
M5D;I%X8T>Y&JY?437G)B)E&KZ$)         %&]5_P#9&\?.2_F(CG;#WLJ%
M[%_I+^/]VJ\CHKZ   &8^NY]7MB^=D^#R';ZH\Y/8>+:^]CLO9U*?JJN7SW4
M?!Z<QZV\]'8^E.R][\K2!QGL                     4)<_P"*"S>\W_ *
MDYD_J?AQ*!M/_8,7B3_;=?9TU_
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MXHY7,MV+Y+6R(J(BLH8VL57=C7IU=_\ LGEOBPXXUOFQ5CX[PW1?).]CO/\
MIEYI.LC<9%_^W[<7R5.+A3OG2EY-.==6/T_H]<Y]NL.JJ]]MF#Y+UGM2WUP[
M5;>PW^6-.V\SM_\ <6I5$H=L7QHJKHZINL3=43U46%G#_.>/+U_U'BB9MME9
MT\&MK?VZZML;#M]M[#/RVAYG;Q[X3HG08?9Z5=%U[XJW2\O8_LY4/#;VP]GJ
M_P#OO;L8[]VK?7JGK"?Z*QV;1W'F?N+UAZQ%X68Q;U5FG:QU3M%7L]L^7E_R
M'BR^WO4&/>C-?L5K]ZU?I;8ZBZPMPXX^6?HEYI<BZP53Q:Y;;*+BTT[VH(I.
M'3GTZ:)?\IXK?_9'4\=[L^6>S-8[5F^/9W:YW\E8^1YY&[SUBJM;N7.S5R*K
M:6WT\6J(G86-6:?S'@R?_:&R5\WL>OC9=/NV[;=7V9RSWV?DK_%YGXWGE2J+
M6;EY"[ME<[O:IDI>?U.!_)_0>2__ -IS_1L>..S:9^[#='LO7AS7[3S.VW[X
M1OQCEF15JHBHJ2W%RM[;GT16JJ:_=.?D_P#M3K&9GF8<%8\6TSR\^.TW5]E]
MF_JODGY8^AYUV<PR1R.JVU=6YK>%'3U4CE_R:'DO_P#:'7,[TXZ]BGTS+?'L
MSL7#%I_U2]<6TNWT/L;,URKIJKYZA_-_I2*<N_\ ]A]?7G]1IV*8X^X]%?9_
M8*_^OY[3W7OAV]PB#E98:-=%U[>)).5/]/7^8YV7VTZZR1I.TY/DGF_VZ<KT
MUZGV.O\ ZJ\CWPXOC-/IWO9:"+1=4Z.EA;RK]QIR[^T'6=^^VG-/9R7_ !/5
M78=GKWN.D?Z8^A[X**CIM.]J>*'35$Z-C6::\_,B'.S;;M&;<R9+7[-IGMO3
M7'2N]$0^YXVP  ?;J[_M/N9\XT?YN4_775'[/L?^U'<?*MK_ %F;QE^'K:@
M
M          !_'O;&USWN1K&HKG.<NB(B<JJJJ!S:G),>H]>^[O14^C>->EJ8
MF:-37E[9R<G)SFR,=YWHEC-ZQPN14[F[<4>J5.7V6-S4XE8ZXTO'IZS>DU7^
M1#;&RYIWJ6Y)83FI']4<KDU.^.TE)Q=+EUO=PIJO1/=-_-T;7:_R&R-ASS_1
M+"=IQQ_5#D5763V7I>)%R5)7HB*C(:.M?KKZCD@X?\IMCJW:)_I^>/I83M>*
M.'MN5/UJMI8N+H*BOJ^'33H:-Z:Z]A.D5G^4S]5YN'2/E:K;?AKORYU1UML
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M_P"*"S>\W_ *DYD_J?AQ*!M/_8,7B3_;=?9TU_
M                                           '(R'*L<Q.D979+<Z>
MUTDK^BBFJI$C:^3A5W"W7G71%71#;CQ7R3I6-6%[UK&LSHAE3U@=G:37I<KI
MG:-XOQ,=1-R?_3B=R^MSGJCJ_:)_IGYFB=JQ1PN/5=:'9NGXNBO,]5PZ:=#1
M52<6OJ=+&SF]<VQU7M$\'SPPG;,7&X]5UNMK*?7HJ>[U6BHB=#2PIKZZ=+/&
M;8ZHS3Q<O\&$[=C^-QZGKDX8U?\ 8\>NDK=5T65U/$O#V%[623E]8VQU-DX;
M1\["=OKQ2YS^N-'*B=XX<CE<B\M3=X8--.;D6!?_ ,B+=5Q7OK3\E+3VF5=K
MFV]$?+:(>63K69;.FM)C]DI=6ZM6IN\,O;+ZS'L7^0\ML."N_P"5GL8<GX6Z
MM\EO CLY*_2\TG62W+J4<D-1AM$U4319)YY7HO9T5LZM_G:>6^7!3_T[3;L8
M_IT;HIDG_P!F&/\ 6\\F]NY]2J\6=8I1(KD_W9G2:-[.G3,7_*<ZW6D1WNP;
M7/9K2.UD;Z[+,[^T88[$Z]QYG;F[@U:_[7O%;J=G$KN&FHJ+D3L(B\#%7^53
MRY.NMIK'_CZKSVG_ .5M/Q-L;#CG?VND=B(^F'F=D]WJ-%K=ZZERIQ:][21T
MWLO]"13P6]H>M_Z>J;1V;3/W(;Z]7;)_5M<?)I'=EYGR6.K3ANF[=YK$X58J
M.O"Z+KSIVZOY%]0\67VB]I/_ %=6UKN\-+6[5J_#@;8ZMZM_JVF9_P!5?HEY
MI;'M15(J7#+9ZY'(C5[YN:/U1.7U$/%;V@]L/Z=CK7L8I[MY;XZOZGX<NO\
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M+\LS[X]S>NO\7)R'K?8_2UY8/I_A/R]1?EF??'N;UU_BY.0];['Z6O+!]/\
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MU9;5G6)MOM!&Q
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MF_X!4G,G]3\.)0-I_P"P8O$G^VZ^SIK^
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MMHXFPI(K-4:KN%$UTU70TY,U\G?3,ME,=:[T:.T:F8
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M_P!&,;/O3V7JZ\[_ !^)"[CU*Z                   !0ES_B@LWO-_P
MJ3F3^I^'$H&T_P#8,7B3_;=?9TU_
M
M
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MTNB0            H2Y_Q06;WF_X!4G,G]3\.)0-I_[!B\2?[;K[.FOX
M
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M@
M      #S7"XV^TT-1<[K5PT-MHXW3U=952-A@AB8FKGR2/5&M:B<JJY=$ X^
M,Y[@N:/J8\.R>TY"^C1CJQMHKZ:O6%)=48LB4\C^'BX7</%SZ*!(0
M(G'N3ATVX4NUL->LN;4]O2[U%O9#,YL5&KVL1SYD9T3557-T:K]>5.3E0"6
M          #B9+F>'X93P5>89!;<?I:EZQ4T]VK(*&.21$XE:QT[V(Y43ET0
M#VV:]V;(K;3WK'[C2W:SU2.=2W"@FCJJ:5&N5CE9+$YS7:.:K5T7G0#W
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M-I_[!B\2?[;K[.FOX
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M)&CVM555%X6/IN1O];C]<";==G^&/.?^$_\ .*("T-I_JLP?]W[5\"B EX
M
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M>DM]OK:F@2Y4L-9WO.E,_22+IF.X'I_G-T4"I^HK_#=CGONY_#I0-'@
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M3\.)0-I_[!B\2?[;K[.FOX
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MH!:.T_U68/\ N_:O@40$O
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M3]YF\58!+R"<Z 0'JV?X7FG[RUOX,8V?>GLO5UYW^/Q(7<>I70
M         *$N?\4%F]YO^ 5)S)_4_#B4#:?^P8O$G^VZ^SIK^
M
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MM7 [V4<T%+&Q[5]='(J 28
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MK6QZHOJHWB^XILV>)BN[PL>NLM;Y^;6=8I$5Y%N'H<,
M  "A+G_%!9O>;_@%2<R?U/PXE VG_L&+Q)_MNOLZ:_@
M
M
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M^SIK^
M
M
M                                    4;U7_P!D;Q\Y+^8B.=L/>RH7
ML7^DOX_W:KR.BOH                           "A+G_%!9O>;_@%2<R?
MU/PXE VG_L&+Q)_MNOLZ:_@
M
M
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M#;BV2M+<[5Z]@]FZ;-M%<\Y+7M7737XXT[JUCVK<
M
M
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MHB:^RYU N$
M
M
M                 *#L.N3];K+[FO;4V!8E;;$UG.C:N^3NN*O]9RQ,1OW
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M5D\:5M+2Q+,USF<B/57H]R?^H"R0
M
M
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M./HJ2&."+7BX(FHQNJ]G1J(@'U
M
M
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M= Z2!8.CY4='-QH_I.QIP]E FP
M
M
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MOLG :%
M
M
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M_%/P.YDX?5 O
M
M
M
5                        '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>tm2227887d1-pht_reprobw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-pht_reprobw.jpg
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M )K_ -A0X?(?QP?[3]H_YK_V%#A\A_'!_M/VC_FO_84.'R'\<'^T_:/^:_\
M84.'R'\<'^T_:/\ FO\ V%#A\A_'!_M/VC_FO_84.'R'\<'^T_:/^:_]A0X?
M(?QP?[3]H_YK_P!A0X?(?QP?[3]H_P":_P#84.'R'\<'^T_:/^:_]A0X?(?Q
MP?[3]H_YK_V%#A\A_'!_M/VC_FO_ &%#A\A_'!_M/VC_ )K_ -A0X?(?QP?[
M3]H_YK_V%#A\A_'!_M/VC_FO_84.'R'\<'^T_:/^:_\ 84.'R'\<'^T_:/\
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M7U6B% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH*65P_$YV;A<EFX./D\AQQD/'Y4T222XYF #F)F!*%@H!*T%V@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'C,J*SNP5
M%!+,38 #J2:"GQ_,<1RW<_=>?C9W:($ORTT<VPGINV$V^^@NT"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@K9W(8'&0'*Y+*AP\4$
M*9LB18H]QZ#<Y N:#W"SL'D8!E<?DQ9>*Q(6;'D66,D=;,A(H+%!2R^9X?C\
MB'#S^0QL7+R+?+P3S1QR2;CM&Q6(+7.FE!=H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H%!2P^9XCD9YL;C^0QLO)Q_P"OA@FCE>.Q
MMZE4DC736@GRLK%PH'RLV>/'QHQ>2:9UCC4>99B *"+ Y3C.5C:;B\V#-A4V
M:3&E290?(E"106Z!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!082RQ0QM+,ZQQ(+L[D*H'Q)H*G[ZX?\ VAC?Z:/_ .6H)(>3X[)D$./F
M032F]HXY$=C;4Z DT&6;G8/'0'*Y#)BQ,52 TV1(L48)Z79R!0>8/(8')P#*
MXW*AS,4DJ)L>198]PZC<A(N*"S0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*#\2?QG^]_<//^^O:_P!#O;V8V+A\D,63
MDUB8J)\KD<@P8\4P6Q*1A>YMZ'>"?PBQK'S_ .L7TGY3^$[G?9_OCZ>>X<S(
MDR7EBR)<D(G^L8XC9HW6.P:&968&-KVL=3H:&=?T']M\WC>YO;O$>Y,,;<3F
M,+&Y#'6^ZT>7$LRB^E]&HRVE H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H%!^&<_Z(?57Z_?6SF,KZM1\I[>]BXGS+\0R;&C&+%*L>/C
MXQ)>-'=6[CN4):S:7Z&JY7C>)Y?^&/\ B>X#V5[3YK(Y+V]SV1QF/FXDA :;
M%Y.;Y<I,BV0RQL2\; #PZ7-#[C]Z^[_=?"^Q_;7)^[/<.0,;A^*@;(R9#^(V
MT5$'B[L0B+XL0*,OYA<C[Z]S_4SZ]^U??7N6!\9.9YCC9>%QFOVHN,AY'L1)
M$2!N56CD5F ]4@8]2:-OZL48*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0? _XH_K1/]-/:L/MGVLS3?43W7?#X>" %Y\>*0]M\@(H)
MWW/;A'BYN+["*+F/@G\ <<L7O?WM%D B=./@64$W.\9)!N?MHNL_KS!R_P!7
M/XJ^-^CON'F9>(]FP-BPX(!VQGO8"YDLB*WI::5R<='(-CM'@10SXT/N_P!E
M-_##]??96%],^=S<V/F&PSE<=E.DF1)%D97R[X\X@2-9$E'X/RP0=1J :'U_
M1*C)0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0<K]2?9O
M]X7L3G?97SO[N_?6,<7Y[M?,=K<P.[M[X]W3IO%!^,?=O\#?#>R?;?)^[/</
MU.^7X;B8&R<J0<'=MJZ!4'[Q%W=B$1?%B!1JG\#OTBY3,]RR?5[,=\;@>,&1
M@<.K* V;/,ABE?J;)$K6-NKFP/I:AK<>Y?HQ]6/K[]=>43ZEQ\GP'TXP&RSP
MTZ!&@&'CR+%"F/JT:S3AA*[,I.C?T0 *XK-X'E/X5_XC_;7M_P!F<WE<APG-
M_NY\S$E*AY\/.RGQ9()U0!&<%&>-MHVW4T/K^BM&2@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@_G]]<Q+C_QK>T9\J0#
M';E/:\D3-Z52)<F$-<FVFY6-Z-9\=[_]<#9?]T/9JW&X\EDD#QL(!?\ EH8_
M0GT+BGA^C/L!,B_<_<'&L+FYV-C(R?\ DD:>%$U] HA0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#Y)]>?KS[=^B?MWYC(V9_NW/1AP
MG"!K-(PT[TUM5A4]3U8^E?$@N8^#?PU?2#WC]0/>X_B+^J\CO/D2',X'%F79
M)D2E=D>24T"01+I MO58,/2!O+KG_P"*?ZK<7[Y^J7'_ $?Y3F7]N_3K@,N,
M^Z.3[4\IER=N]R(H$D=Q$A[<0V6[C%CZ0K 8X+ZR>_OI5R7UF^F_+_3S.1_8
M/M3!X;"EECQLJ!<=./Y*>>1>W-$DKE8W5RRJVXGQ:]%Q_17V?[P]N^_?;N%[
ML]IYO[P]O\AW?D\SM2P;^Q*\#^B=(W%GC9?4HZ>5&&\H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H-1[J]R<?[/\ ;7+^ZN5W_NWAL2;.
MRA$NZ0QP(7(4>)-K"@_ ?TE^K'TX]P_5_F/K9]<_<*87+X[[/:W!G$SLV/'%
MB$<''@E0+ AVQ@G<7+2$!@"33#^#WZC^S/9OU)]R_P"\G)_)?[R]G!X7\C(F
M[^3-E^A/R8WV7W#63:/C0UT'UZE?^('^(GC_ *2>U\3"XW+X1WP\GW2ZLV6Q
MQHFR,@,5*WCA.Y8X^O<N=P#:#'-^YO:/,?PC?5SVQ[P]Q2XWO[C.3$CPY^;#
M)'EK\NT:Y#1H\TH2>-9$,3EW&OA0^OZ+PS1Y$,>1"VZ&55DC:Q%U87!L=>E&
M6= H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H/QM_&W[J
MY3G>6]F_0_V\]\[GLB',S80;=QYYOE<*-K:[=_<=A\%/A1K'ZM]F^U>+]C^U
M>(]H\,FSC>'Q8\2'2Q?8/5(UOVG:[M\2:,N(^N/UQ]M?13VT>1Y$KF^XLU67
MA.$5K29$@_;?J4A0GUO]PN31<Q^=?X=?I1[T^K'O]/XBOJN[&#OC-X'$D3MG
M)GB%H)43]C'@L##XNR@ZBY8NOV[1DH% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H/RM_%I]"?=WO?D>%^IOTXC.1[LX&-(
M,G C94R)(H)C/!-!NLK21.SW4F["VW46)<U\I]P>U/XC_P"*'W1[<XWW[[6?
MVE[=X0LF7FR8LV!"BS.@R9U3*=FEE81@1JEU^Q2S47X_>W'8&)Q7'XG%X$8A
MP<&&/&QHAT2*%0B*/L  HRLT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@\8A5+&]@+FP).GP%!_,SWI]-_XC?>OU'S?J+RWL'.S,N?,
M&5C8&;$F1BQX\37@QVC9[-&B@*5.C>-[FC;[3[6^H'\:4WN+A</F_:@Q_;\F
M;BP\C(..AC$>&TJK*01)Z=J7Z=*)Q]Q]R_PR?1#W?SN=[F]Q>UOG.;Y.4SYN
M5^\.1A[DA !.R+)1!T_9442OS+]8/X6%POJ_[4P_IM[)RF^FTT7'GW"T,^1/
M$)&SYERMTL\[RK_JXCOL86&HUHM?MCV?[/\ ;OL+V[A>T_:>%^[_ &_Q_=^3
MP^[+/L[\KSOZYWD<W>1F]3'KY49;R@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@UW/\#Q7NCA,_V[SN/\WPW*0/B9V-O>+N0RC:Z[XV5U
MN#U5@:#Y#_\ N@_P[?\ ZF__ -SY7_\ JZ+7P3^&G^&K+Q_??,<E]4O9V5BX
M/%-#F>V)\F::!4RH,G>C+V)EWV"J;27'PHNZW'U@^CGU9^GWUJ/US^CO'#G(
M\N8Y>7QL:B6:+(GC,.2CP JTD4P);=&=RECTL&(S7,\M[#_B _BF]\<'D_43
MVT_LWV?PX,<K30RX8B@E=6G,4>2S2R32A%4';L%A>WB/C]ZPQ1P11P0KMBB4
M)&ODJBP&OPHRSH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H%!^0>2^FGO_P!P_P 9^'[WY/@,H>P^/FC.+RS -C*N%Q9,9!W ^K)&FFC&
MC7C]?49?S2^I7TX_B(^H'U-Y'W]R'L3/S$?,W\=@Y<2RXR8./)_J^.T;.+IM
M WKIN)8GJ:-OK7 >_P#^-?\ >G&8>=[17'X;YB"')V<;!&L>+O57MMD](5+]
M.E$X_:=&2@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%7D>0Q^
M*PIL_+)&/" 7*C<;$A=!]IH.;_O(]L_TYO\ 1'^>K$I_>1[9_IS?Z(_STA7@
M^I/MHEANG&VPN8C8W\M:0J1OJ)[;1MK22WO;^KZ?;K2%8?WD>V?Z<W^B/\](
M4_O(]L_TYO\ 1'^>D*?WD>V?Z<W^B/\ /2%9CZB>VR2-\UP+V[?^.D*#ZB>V
MB0O=DN1< IX7MYTA7I^H/MT)O9Y@OA>,Z_9K2%8#ZC>VV-E:<D^41_GI"I#]
M0?;H4L7E%M2.WKK\+TA7J^_O;[@,&F .NL9'^&D*Q/U"]MC_ -+(?(".Y_EI
M"L/[QO;5K[YO]$?YZ0HOU&]MN=JM.6ZV$1O_ "TA63?43VVNZ[S73J!'_CI"
ML/[R/;/].;_1'^>D*Q;ZE^V%ZO/>X _)8WOY4A67]Y'MG^G-_HC_ #TA3^\C
MVS_3F_T1_GI"@^I'ME@2'GL#8GM$?RTA3^\CVS_3F_T1_GI"G]Y'MG^G-_HC
M_/2%/[R/;/\ 3F_T1_GI"G]Y'MG^G-_HC_/2%/[R/;/].;_1'^>D*?WD>V?Z
M<W^B/\](4_O(]L_TYO\ 1'^>D*?WD>V?Z<W^B/\ /2%/[R/;/].;_1'^>D*?
MWD>V?Z<W^B/\](4_O(]L_P!.;_1'^>D*?WD>V?Z<W^B/\](4/U)]L 7,DP'_
M *H_STA4:?4[VNXNKS]+_P!2>GZ:0J0?4GVR1??./'6(_P ](4'U)]L$7#S$
M'I^4?YZ0J_![PX;(XK*YF-I/DL-UCF)2S!G*@6%]?Q"D%)?J+[;8,0\WI%S^
M6?YZ0K$_4CVT 3NG-@381$DV\M:0KV/ZC^VY "&G6XOZXBMOMN:0H?J-[9%_
MS)M-/ZL_STA7G]Y'MG^G-_HC_/2%/[R/;/\ 3F_T1_GI"LG^HWMN.VYY[FVG
M:-]?OI"L_P"\#V[M#;Y=K>/;-M?/6D*Q'U$]MM;:\QOH+1$WMY:TA7C_ %%]
MM1G:TDM_(1DZ_II"O?[Q/;9;:KS,?\F(GX^=(5Z_U"]O(5!,Y#]&$5QK]](5
MDOO_ -OLS(K3%EZ_E_XZ0J)OJ-[90>J2;K:W;-P;VUUI"A^H_MH*7+S!0+DF
M(]+V\Z0KV/ZB>W)0&C:=A\(CXTA4A]_^W@F_=-MZ_P!6;_HO2%1O]1?;2&QD
MF)^$1/4VMH:0K(_4+VZ "6G"G6_:-OY:0K%?J)[<8D*T[$ L;1'H.IZTA4D?
MO_V]*H='E*G_ .=^7WTA0>__ &X382R$];;//[Z0KQOJ#[<6QWS&_2T9/\E(
M5Y_>#[=_I3WOMMVC>_7I>D*D'OS@#;U3"_G'K_+2%>-[]]OJ+EY?/^K_ ,=(
M4_W]]O\ 7?+I:_Y?2_GK2%8CZ@>WB RM,5)M<1'P\]:0HOU ]O-J&FVDV!,1
M Z$^?PI"O#]0O;JE@6GNO7\H^'WTA7G]X?MS6SS&UCI&3U^^D*Q/U&]M#J\_
M^B/\](4/U']M#]N;0V_J_P#'2%#]1_;0ZO/_ *(_STA7C?4GVP@W&2:UK_U1
M_GI"O/[RO;-R-T]QH1VCH3]](5[_ 'D>V?Z<W^B/\](4_O(]L_TYO]$?YZ0K
M8K[MX=^*7F0T@PFE[ )2S;Q?P^ZD%8>_. /1I;>'Y?7]=(5XWO[VZC*KR2!G
M-D!34D:Z:TA67^_7 _TI?]'_ (Z0I_OUP/\ 2E_T?^.D*PD]_>WXEW,9B/&T
M1/\ AI"LQ[[X B^Z7_1G^>D*\_W[X"]M\MQU';_QTA7@]^^WC<]R6PU)V?XZ
M0J.#ZB^U\DR"#(=S$0'LGB?#K2%#]0_;8E['<E,NEU$=[;NE]:0J4^^^  )W
M3&W@(R3_ "TA6*?4#VZ^@>4-XJ8]1^ND*S_WZX'^E+_H_P#'2%8?[_\ MSNQ
M8_=D^8F)$<12S&WVFD*JP?4_VMD32P1O/W(3:2\) N3;0WU^ZD*LO]0/;B$!
MY9 3YQ_XZ0JO/]3O:F-D+C332I(ZAP3&=H5NA)OH#2%6(OJ![=FC$J/*8ST/
M;\OOI"O%^H7MYI#&#.2MKGM';K\;TA7H^H'MUD+H\SVM<+'<Z_"](5G_ +^<
M!:Y:8:7UC/\ /2%>+[]]O.+I)*1YA+_X:0KT^^^  )+R@#4GM_XZ0JK-]3/:
MV/VC+),$F(5'$1*W.@N?"D*LCW[[?()#RV'4]L_STA0>_.!-[&;3SC_QTA6/
M]X'M^S$F<!=3>(C_  TA6/\ >'[<MNWS$>)[?E]](5E_>#[=L&W3;3T/;-OY
M:0KQ_J%[=C)#--IU(B)'\OQI"O!]1/;3"XDETU-XS_/2%8CZC>VB;!YB>@M$
M=?UTA7G]Y'MG^G-Y?U1\/OI"A^I'MD$#?/J+W$1M_+2%#]2?;(_;G)/0"(DD
M_#6D*\'U*]LF]GGTT/Y1Z_II"O?[R/;/].;_ $1_GI"G]Y'MG^G-_HC_ #TA
M6R7W9Q#\3#S0:3Y&>0Q1G9ZMPW=1?_)-(*W^_7 _TI?]'_CI"O#[[X$ G=,;
M> CU_EI"A]^<  "6F%["W;\3IYTA7O\ OWP'3?+_ */_ !TA7G^_? :^J;3_
M .=G^>D*]_WZX'^E+_HS_/2%>'WWP %R\MAU/;_QTA5;&^I7M;+9U@EE8H2&
M_+-M/OI"C?4GVX&15&3)OZ%(2P^_72D*L-[]]O(NYWE4?&/_ !TA1/?O .H9
M6FVGH3&1<>?6D*2>_O;T2&1WE"+JQ[9T'Z:0JOC?4OVMF(),>:5T)(#=H@>G
MK2%2+]1/;;7VR2W\NV;D^0UI"O/[Q/;NPR,9T4,5]41!N/OI"L#]2O:X"-W)
MB'%[B(FP_P K72D*F'U!]N$H-\UW%U_+.H_3\*0KU??_ +?9BBM,2.I[>GZ;
MTA1_?_MY.KRDD[;",DW_ $TA4$7U)]N2O(ELF/M$JS20E5N/+6D*CD^J/M.*
M6&%YIN[.=J*(B2#_ )6NGWTA5EOJ'[:6(S&63MCJ=G^.D*]B^H/MR9=R22D?
M^K_QTA7I]_\ MT-M,DF[0$;//IXTA7LGO[V]$C2222*BB[,4L /TTA7D?O\
M]NRKOBED=?-4N/Y:0K/_ 'ZX'^E+_H_\=(5B/?WMTMM$DA8>&S73[Z0K+_?K
M@?Z4O^C_ ,=(4_WZX'^E+_H_\=(4_P!^N!_I2_Z/_'2%8O[]X!%W$S$#K:._
M^&D*B/U%]MJ2K/,".H,1OK]](4;ZC>VU-B\U^O\ 5'Q^^D*Q/U)]L@@!YR3X
M"(_STA3^\GVR>CS$>8B-OY:0I_>1[9_IS?Z(_P ](4_O(]L_TYO]$?YZ0K8<
M?[OX;DX,W(Q6D,>!$9\C<EB$ )TUU_":0;ZHI0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#0>]59_:_(JHNQ1+#_
M -HM7$U\.8%25/4=:TB.::''B>>=UCA0%G=C8 "@JX',\=RBS?NW)3)[!*R+
M&U[-8$#[]*"\VI.M_CYT'E!'//%C1--.VR);;F/Q-AT^)H)2"/\ ATH)=IA9
M =20' \+'SH)-R1E[:2-HPMYCPH,9V<FP 4_A()+,10>LA3;VG;M:!C:QN>N
ME!%+D&"5P(A8:!VM>]K].E!,LRR1OU>%K;68$$,03<#K08!BS!F(?8MEZ:*O
MGT\*#ULA(5 +"SL%5M2;L.MZ"O+"LC;_ ,+L H*$@VT_EH,))&67:5NFTDL/
M\F@DW$Q-VD#R$#:Q)L-=3I\*#S\6B6W= +Z7H/';8"00]C:ZG0F]M":"+&R!
MD1E]I4AF0@^!4V-!,"#TH%!DJ[MQW!=H+>HVO;P'QH,:!0*!0*!0*!>] H,&
MD"Z=6_5]Y\*"(JTEB23?0$"P'Q%_Y:"<*%Z?>?$_;0>F_AUH/&L5-^GZ*#LN
M%C9OI[SP+#7(B(\@ T1_P5!R*GTE=H.[HQ\+517SN7X?BT4\CE1XZ 7'<:S-
MKK84%OYB.>.-T/<QV&Y'#=>EK'QTH, H*WL21<GRM0>(C.0!X]+T&1V#*.&7
M3Y@KO[8/J"?T@/*@MSQJ(T1KBUR%N"0=+6H('+=D68E2 #N'B--*#".5L/M$
M1 Q,.B!18>>@H)B )"+)\ON#Z?BNO4?9_+01EY)'!6R@^H*MP+$=1;J=:"7)
MD2(,BDKV@#?Q_3Y4$4<CV>5'5F9-W777P^V@PB(]%XPNW: A-RUM6:^FI- V
MR/("EG=O5IY]3I0"@;>=[J)BJC(!*6:P)0#I0>H0;+,"9@=JH26N1U%_L-!!
MR$[0VBQP8Y94>2);[K=L7))TZ6H).^7A#!]@-E(71F)UO<]0:"'/S(H(M\NZ
MQ(B8H22=VES038P5&6[;R 0%_"#OL+G[J#(2B(M$P"3HPV."264C4VZ6UH+!
MGD0A6DU*A@ +>D:4'BRE'!DW;];VUMNMKI01OFX4159<H=_(!52#K<$6T'2@
MD/H=E>:S6VL0+#R'\E VI;;\P"-!X]!_+03#0>G(M<WN% _P4'@62ZA)B20;
M'S8>%CTT%!B7ELRLX\F!%KG2]!X\DFW\<8-OZL#P&OC08M,-Q "C<UR2;C[;
M?&@A8$D+M]>U>O704 %F%^M[W)%E4>=!$/Q64_\ M"+'RT\J!8  #I\*!0#?
MPH.ZQ?\ N\AW6USB#Y=&J#0&U]1TUO5&+112NCNH9XCNC8C521:X^Z@:.#^T
MM[6^PZT&2EC>_F;?90>T$<XF,9$%A)\: (_020!,R@.PM<D#S^^@AA5=C8VH
M!-V) !MY=#05</B</B\B2;'W%YS=D(O;XT&$.%BGE?WA'DG?(NL(.V]S<7H-
ME)&&!)<JUKZ'R\:"M+G<?BW;(M%"U@KR+8-IUH+,<J9%I('_ "]MMZV(;=KX
M@] *"MR,<1B[QBWRK^ VZ[>H%!CBB%;3R*!)-8[;#T^2B@+B L>ZR.CM8QI<
M:-H+DMX7H(#@0),^1*G<>=0LCG]G;TL/+2@R7LXK)$)1&&8+'&UR#N\0>E!9
M9GQ8W<KMB ).M[:_\/"@K-FQ"5L2&528K,K)H66VC$?$'I033,)L1HY)643J
M4# 68'I<6M0:;@H,CB\Q\:?<\3 +&]]PT.A-_&@Z6:Y0H-=W4>.WQM\:#1MP
MF8<!,2/+[$*2=S:5#DCP!)H-SCDB)$9M[*-K,!;4>?E02DMN4 74WW'RH,7[
MA&B@]/'7]8H(]K,1>$#4WUT^_P Z"-_3<- 3?U>DW&FIZT&/H$UC&RWNNQ>A
M(N;GSO>@Q<Q7(92I 46(O>WG00$+N]/I#= #;4=#K08+8G6VXFYOT^_[:#QM
MP&Y3:/H6OI>WZS08!&MJ"#^T?$C_  #X4'H4+H!;X=*!0>7!-K7H.[#*GTZX
M]F]*C,<F_P#[6IZ- K!U#+T.HJCF>?\ ?_MOVYDG$Y#(/S*A6=44L%#&WJ(Z
M>=!M</F..SPD^-DQ2PN 8R)%)U(!T^^@OK&H(8W9A< G4BYN:#.@T?+Y/(SY
M!X[B[ID(JR/(RD)M<D"S>/2@M<=C9D&,(LZ3YC)ENI*Z*+]=>E!KN&Q^0Q.2
MS<6:#;ANS$2? ^%Z#HAT%NE!I>8AY(0YF7#DH$1 L$#"QN1J?MH)N!DR$X:
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M22*#T,6C+QC>!^T#<6/2@UD'*OD/#(N.QPIY7B@G.A)30DCJ*#:&^@ ))(4
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M H% H% H% H% H% H% H% H% H% H-#[T57]L\@K6MM0^K0:2*:N)KXIDKL
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M5$+QSG(5T:\8.MSH/,6H+ 558V &[6PZD^)H*N=DY,:E<"!,G+7_ -%))V0
M1UW;6H.?Q_>ZI(Z<SQV3QXC;8TH0Y$!8=;2QW%ONH-P/<?"O&DD.9'*)&V*%
M-S?XCJ/T4%ELE)4$2H3)*/PBPZ"][^'PH*V'G'(/JA:/'0%2S'3<O737^6@G
MES8E#/&I>1ALC !%W/36@IIC29F/W<X_L[98R1H1_1M>WWF@L-B1;",)6[B@
M,K)JH"DJ2U^M_P#!0>2Y B0A48R '<B':"5N=R_'2@UV)R<,\44ZAXE61N\^
MDC%MA(70M<DVO07#E9DR["M@4NZ.C"3?H1M"]0!YVH->V8\LQCA8S'U;C<(
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M%!#\VDDG9XQ#+(-'R&%T6WD#]E!D,>. F[=[(Z-(;V'V:T"@4"@4"@\%R=?
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M"VFNFM!0)&Y!!&6<LN[=Z=VMKG=Y"]$229D>,S8BH [*72(BY!/ZJ*DQ<P2
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MK0HNYV6Q5M-H%P0PU'Z*"+)Q!(G;+$0-=XRQ)%QJ2?C:PH,QCY$)[L+@*PT
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MNUA8!QZ"BQ6L"O2X-QX>-!KLS CRU+SA1([ZR$ E=S;G]'36@EBA@QY(S?<
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ML9#,4[4S+=BHW'XZ?S4&<S19,"S1G;C,EGO:Y/G\*#6Q2S8S=OLJT;FT1V
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M?O'>C6%PM!CD S8K+(+SR"ZNQ(^'AT'W]*":>*!\,QR @KNCC?H1Y'4B@Y?
MXX0<@<QL]UBDMN25@=[#R'6YMX4'5X$>8"[Y3BQ9BB#0A6-P&U.NM!)FRP0
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M#4"WQH(9=\CQW&XRJO;4, MF\#0<[N_>ON+LV<8_&ZM&+V+'Q/F:#=S3'&E
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MU!4/N'!S(%3C9%CR"AB>%B=68Z=1K>@G$[<!Q$F9)#)%)-'(=X"MLDVG;<>
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MBMVWVL0AL54]=+7_ $4$4L?8LDO]8VJV-]!UH(S:^G2@[#V7_P!4>Z/^@/\
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M=6" W /Q-J"16B<;X>DEV6XL/1^B]^OQH/DW.YN/DS<A;(4922%MC#J5-M+
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M .O6YT_P>=!E KQ]QFNX6X5M UFUT^&M!KI,=U*JP9F-RRL ;F@MB-XX@\*
M):QC ^PW^-!+C2O$Z;S'O<F[6 *B]P1:Y\*!D&66<K$;(':T@76P^'A07<5L
M>Z.X+QJ0#8'TZ];:"@MY$4&3#(8"O:T9?20HN=NECY&@JP3F)YOEX4>61;:@
M';\1]EJ"Q+C2R 1P F>74[006^X]?CI05(XY,/=)W#$_X0&Z @]-IMI]M!L\
M7E\B'*41RJ^/,;3%4%Q&P(8$6L 0=1XT'V7CW4XT Q!$BQ*JS+(Y#%I1W#HH
ML22Q\=#0220C(C[;*P1KZ&Q8#P_301C#&(!)&6=5%V UZZW \*"OCOR"94AF
MD27"DOVK#:44%K#J23;2@G:6+'C8@70>HIU-K::=;WH)%F7+BNT3&,GTWN#;
M]5!FKQ=KLQ$K?32][7&A/7PUH+<4\;2D.OJC4(2MM=+@G[ :#.?(E+E5T4 :
M*;BW@;B@A5RMW#_F=/,V/4WH,;D]:#R@4'<1!F^GD 4__5#6WD+WJ#0MZ4LI
MV@:#[*HJ+Q^*F8,QEW3$;0[:GSH-![A;Y2>'F,2-V@#&//B5#9T(/KMXE?Y*
M"_#EK-BQ/Q:_,!MJH$ U6YN223TH)7,LTADD-E="I]0.XWT-K#;;[:#7\ES"
M8, Q\*1I76X92255 -6;]-!R,W/<XW(-+#!'D11?B[UD8L!;T$Z]+Z4&^7FG
M?@UY2/T&15 %OA>Q%[7O0<;C8<W*9W>RXA,9)"]PI#;WL-M[@V%[T'T3$QH\
M#%@QQM,J1]M1TN1J0/T4$?N/%X^7BG&6!W@A*Z;KW\-/*@^&2YR8"2X^*I4N
M65B+&P)]-_*@TT*RNTA*_C (<FQ]6ENGCZ:"W,C/=8ULQW7WV(9R>I^V@AC+
MQ$$?E.I VZ7*D^5M:#T94AD==MX7-C< :=;_ '4'B]P.99#M9OP.?Y?T=:#8
M8R12QD3J'>S6*BQ7R/QH(_FPD[0'>Z%0'L ?#PH)Y(H98D53M[+$11#5M-;;
MM+]308B+(@QY)$1[ECL91;0WOK065V H&/YK*!<B^P-U/VT%=BPDD38\L<B[
M =5VE2;-X:4&Q;F>1PE.1%(H8D*)H2!=Q<$^DBU[WH._]H<V^7C'+R(X5E,@
M$TK,1(\;$6L#\?&U!U$?%QOSIY/'Y-AD3[=^, '38NI6]_'8*"Q&T)68XP:(
MQ@QONO8!3^O6@ACR(FQC-'.KS*N[MC2X.@:WD:#5F/ R^36:3'<926D7(4M9
MKBQT/7I;I07<W(GQS$F-#N:ZJ^VW]6?+[#02Y*Y<<<D\$JAU%PKBR&W@3?H:
M#W!;)7C$RLR1U/=+-&-K* V@O<'372@W2!%A*1OHZF_[6K6&MAI0:J/)7(9H
MXB5$9.^,@@7M;J;V^R@DF=84W./P]2OJ)N;#04'M[Z]+^% (N+'I0*#NQ_W>
M\<//-?\ DEJ#FG2-%,NW?(NH/B2*HYK!]Q9W*\F^!%"8(H[B5R-"OVF@WN;Q
ML&7QTW'E0T<B[2#_ "_"@XW YC]P\B/;G,S&/8[?)9<@_'&U@!<^5J#IBD.4
MC1!V9') D#6]%M2OQ-!96,)&AC)1;;%+V+;387O:@UF3P^%\_%*DD:X\@8.
M26+&UK:VMXT&M]Q8:S8.1\GEH+#TMN 7<!T!!T-!\\@D?-ERU^;_ -9+_DJ[
MD-(0= "04-OMH-Q#['R.7BCRYGD#/_7&2VX=1X#Q\Z#N,#CGQ.+S,1LUP X*
M%-95"G\(!Z D@ 4')^Z8$XW)',#'NP4$HVAOUOIX_90<-[GS\K-ED,\@$O;N
M5ZV#:C[+"@Y&''EB0-N96;< ]K!2;Z@G6UZ"Z4ED24JH21AM'78P'D+=:"E%
M*^W7TD7!6WEY:4$C6=#8Z 6 ;KK08HJXZN)KLS>L,= HL+T%N'*(6[#N$:A;
M C46_1]U!AB2AF*2H@WW%VM?7R^-!,N&)G[S/MD#7$(!.@OJ?"@VJ18XW9K,
MCB([#$?QEBHU /@"/&@HNCSN\BK^8[J0#TU\/*@NKRCQQ/CPQ[%FM#(I >Y4
MZD::$_;0;/AO<?*C.7%Q3&BQ1NDDQ4+Z""6NW@0"=10?8O;3XF9PL+G,^:9
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M78"RQZKN!(.GI%!NUSH9)IIL?+66!?00URJ2(;&Q-A06)H8<]#!EQ6C5D=9
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MY8#M1%)ED8'TF_A>@].=))BK@ACVD8%)%VEV+:DD==;B@I\A"RYDF-AZ1NP
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M/WB]!Y,K&02%[0@DLJ$W 4C_ (&@FQX<W*BW8Z=R)"-S)9M@/33PTL* 8IV
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M7QL//3K:@N&YED<L65R"K-^, "UC\-+_ 'F@S&H() L"1\:#&@4"@4'=XO\
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M"X12$'3Q\/NH-?F%8I5B^79D.XKN])"D]-">EZ#72O93&HVHS[5MIHIN;VZ
M"U!BK1.8\>4-'&UBDA\ +=-3Y4%Y\<8P@,FTQL=^T"[;#TN+Z?IH) LSP?+H
M@+/M82J RH+"X;7]=!A$G?/S#@"4-L54%_2!?4?9:@LP$Q;\B06]6C 6+>%!
M$0')8H7,IM&1J!IKI?K0>R1S17(D4CIJ;VLOQ\Z"7'BR9U.03O*J+Q^+*#K]
MXH)YI]) J&0J-J7&YEW"U[T%7#<!>VMV-_5:^AU\/+SH+D$T;N(F!:%3<]-5
M(L=:"UD!GE@AQ$08\0+$ C:2=3=M; 4&4#P9:0K*5AEBDL7C6PN %%SK>@W_
M !&>,%'::(2X9VLQ1K,CB7<-3<$&P/2@[5.?X[YG'AF:0SR>I'MNB4R"X!(/
MD:"?$X#'6.25W[F3D,SODJ39@Y)&G0]:#/D(,WY=8>/-Y3(/F'DT6RJ+G2Y!
M)M07H^Y!C@Y!N0BJ4&OJM8B_CK058>5X],I..0;,AA?8H]()OU/F;4&QD<0Q
M-)8D(I:PU)L+Z4&./.N3'W4!"DVUH/;2=T6L(0.GQH)*#%U##6_W&U! I8ON
MT?;TOZ7'^ T'=<#(&^GO.$W!&3"#==;[X? U!R)D>1G:2!H%6ZIN8-N'F+?X
M:HDC:-DVD@!NFEM0+D _=082%%CDD;T(%[@1?5^'S^Z]!X7WD,H >0'>FVQ!
M4[>GZ*"+(*AD-CW"!M5-!8:&Y'B*"AC831\H\VW=&VYEC)-QI^+32@LY4$CV
ME3:>T"9 URNPC^6@X*3W,W%Y#RXJ!X5"HI9+%T9B;W!U)T_FH+3<ERO.K/,R
M]O"C2[[>@OX CJ:#YSG2Y'S'9Q!OBB<7E8:7N =Q(^'04&PX]<?)EB,X#N-C
MJ&.T>G;H!'X$-<,==:"GSG%Q<?G9 E0_++*Y]+$QE="NT$=;-XF@YS)?&%BA
M9G!OL*VU&H-B3>U!AO[L:L+AI&O<V(%M>GZJ#;18Z&%_FIMRD?DVZ J+;0?C
MXT$N-"LJCN,'1$%V%@UO"QH(U)?:A!7'5K)IN(-^EAYGQH(D6>/.EGDC!Q3J
M5^T_X;T&:I+VE"6**/4J^H%AKXCSH*ZD[W=S=KV*@V-SY@4&P2.5E.0YZ L@
M)L/*@2R@Q(LB@.A]) )Z7/WBYH)%EG2*,Q@V9K/<6%QXD:^=!LXV>:58F.R9
MM0(^C#0CJ=.E!#/&4DGR RA93N9==%8-^$]/"@RQ)OF P"$,B$(UP B@]#<&
M@LP\A\F&AQY69[7:108[@ZV)-_'X4'1\+S/)9N?AF3+:+'#)CK$3NC9#8:C_
M (:T'T2/ P\8Y$T"A-VT2R'TD[;VUUTZVH(9)V[O;2Q386W$^D-X&@DP788A
MB=-Q!NL@.A^(H(XUA17R%1DDD 0>8-["PH+ <=K>["P&ZX&EC^N@\>Q2X;TD
M7N#8V^T]*"*#(25=-+';8];CSH)Z!0*#M/F8\3Z<13RW[0SSO8:[1M;6H.?B
M8_ESAQ)'DAB@'AMMX'IH:H]>=#-V58]Y1NV 7NOC05!%# ),P1COK&60+^'0
M7Z>=^M!FKM*24!FQCM<NIVJ575K@]#>@J\KC')Q2@4/(BLT7I!-FUU/C]]!#
MP_']S";N#8Q8D"UK,?'3I\/*@PF38HC:T:HUD4';Y W%K6H()?=G"X$4L2MO
MGU!MXD&QZF@Y=LKFN9D:?%+KB=5#: *--#X"B.4Y:3&0R+'^9)9Q-)N( >VY
M;'Q&GJHKAI1)D.%&V1@U@U[6!\+&@RS..BBFC$=UE8 2F4#8-QL2+7Z4&$N(
M5<M'*2B!7.T7UMM\?"]O"@QR(V=#LVON (:+]D@7)-J"3'NMH[%D<#KUN?/X
M4&PDCCR6N+HMSO?HH*C0[=;ZT&#R-E9"JJ -%=;@672PU_104 65NT3Z"1>U
MCJ*"S),9#VS)V^WHK+Z1:UM;4#ORM&N5IOC:PTT M;I]]!X)GDF661+[] W3
M7X4$Z!UG9++)$;,ZFX6X^R@LXF5E+*YBCV@;C'NZ"]@5H)\@-)$TF,"J/ZG%
MK*#H+6O?[:#$90QC!(H5D8A94O<7(L0*"_B/%A[6C<K/$_?B64J=[+Z@"O3]
MG44&]BS]^2)LTG'FE&YNRNUN[)*5)]) ! %_Y:#Z%@008W'X\TB*D_;[2';J
M(PUUU%[_ -*@DD"Q//DQ@2)J787O?Q%OC022+:&9C'ODCO)CVZ[KZZ$_&@)/
ME'%A7*3=,P"OL_""?&U!4BRH),B2*9%=\=P%*W8@$>9&AH+;;<R"2,73<"MV
M&H\C04(8,KBNP@G.3"S!75U ('G<$4&VH% !!Z&]J!0=AR6(,[Z9<?C,#9\\
MWVZ=.Z>M3T<SC8O([E.1*J+&0J)$204'0FXZU14YSW"G#9$$4V.TL4IT9=3?
MX"@RGS.0D=&4*N.0C&X]95@; _&XM00Y.,C]R"2=6WJ P)+*V@]"Z#S_ %4&
M30QXZP+"  B@$:DD:CK\!0:B'-P<?FFQYYBL[V&JVC(\KT&Y2/&DED?N*5C
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M[&7("; Q(VW!Z?$4%J@QW(7M<;QI\?.@\,@$HBL;D$W\-*#M/9?_ %1[H_Z
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M#+;] O009$0ERI9(BPW2%2"WI"W!6@GDFCQH67;OF !+$7U'E]E!)@&?,BE
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M,* 21X]?+]%![0=C[+_ZH]T?] ?_ ).2IH^P5EHH% H% H% H% H% H% H%
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MOWT1I.?Q,2-F:&00Y4R+=6"@$E;#:2#X"U%<?%F0".1,H#OEG5 ^XLS[]JJ
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MM.&D+ZEOLZG6][_902XT+O$T<)';1R"#Z3M.HO:@A>3'.-)Q\Z]Y)@5!L&0
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M"D%3YT%;E,/B)^-AR=TBYTB%I=NTIN!_I;@0;?;0:;T6CB8!!*"@\&Z "Y(
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M06LH'_C-:_QH,MXE15V;/5Z!8>DWUT\^MJ#''5,8/$K[[,=M[VW=2?NH,9%
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M5ACFC28.LE@BDKNN"MC:_4Z#XVH+F2F<O97#V_E[>YOT5E_#IH?Z)H+<J]P
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MK;6VACI\;T%=^]+-&'B5\7;N=GU(D'0@?X:"-9A&;O( "3M4#2US^N@L/)&
M R;MY7K^S?QH(\@;G!<D(+6"CJ:"2*7TEV&VQU#>7QO0>]T%"P!(&O2U!FZN
M+K<;O,'</TT %O&QTL?A]E H% H!T%^OPH.YQ+M].X21M)S3<?<=*GHY]F/<
M5$!9V!('AH+U1X5CR8=LBW1QJIH/8H8X$V1*%7R%!4SL2.3'9'%X0K*5&EMP
ML6!'B*"OBXXA$<B9'>QF41IO-P;'0@T%UD$T&@W-Y=-:"EWHQ,F,-RO+=U9
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MXL*JXWJ;$6'HT^P&@[O@N#X_B8XY<55FE161,EP%<*QL01]U!LVR)=ZL!:%
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ME/5@.FX>-Z"9<I()7&2VQ+6+1@"Y\+?HH/5"R%5E.TRJ@!'06_$1Y>JU!X^
MPR'DQSVI)'+;A86N-  ?CK>@A+.S%)KNP;<JN?4POI?P-J#'/G;C%BWWE#M=
M8QK<Z:_9091R).HGC;<C#0^%Z#E?=OMI.5$8Q"L>9&>XY;U"UQJ 1YT'.-[6
MY["B5'._O?UKNP*N=;Z#H .EZ#GN8]K\AP,4>?G(LN(6%I8CN&XZ@'RO:@TL
M31_.!)5[6-9T-A=0]STOXT%[+,>?LC:PQH(TB#MI(;DW.E!2''R2RIA81$LT
MOHC7=IN)\? :4$1PIH(YFR087CLLA;6Y8!0!^N@UBP1B-IY&5O0"".NE]:"#
M$6:6[H6<%@ .IO\ #R%%?2O:OMJV1!EY$0D=57(,+V ])_I>&X^ \*(Z3W;[
M8&;%%-PV,HY.,AL^.-;%OF )-F[3=M+'3RH-._L_F<7B8<N8,#$_=>-2-$8>
M)'P\*"+&BR%BS,_#B?)>+8.VZ;E*L?2P!'A0=Y[6BG''EYH#!&7+@[=K@"^K
M?;?]%!N84FS<DY;H1%%L1=S-^*U[;;VTO:_G0309*7>:0?EJ/0'&N\'72@JO
M+/>3N?F&3<X7IIT4?KH(HIRTD>.+12(N]XC;=M%@/CJ*##)[^7C[L4M$=WJM
MHS!?#[Z"%\Q>.>TT;$R$ *FHUTO08X;P9_(2R+ZD@-PO50Y L?M%!MZ"I#F9
M+9[X\N,1CH+I*3U'^,WH+K-<D@;0? =*#&@4 WMIU\*#L?9=_P!S^Z/Z7[O?
M3X]N2IH^P5EHH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M,4S78E2WV*3I]]!+L  538+8J0;]/TT"]C:W6YO\:#V@4'B+M%B2Q)O<T'M
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MI_1037@Q(EB#>IF]*$^HFP%!0,.1))&L=UC75F<>?7[Z"W%BQXX;>P=22RW
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M\,^5BMD9<T<B2K(QB4(T9(8[+@^GRJ4<]_=QR_\ S_ _TTG]G5J1[_=OR_\
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MW"V-P5(TH*Z7A;%QI'1\E+NL94["%\P/*@RE7%[:Q3O>[;B%.ESX >5!)'(
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M&_AUH/&OM-C;X]:"(6]-[W8EP!H=/ _IH(V=H7<L?4UMK6)4>=!BQ,CW0A6
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MI<@EB%(Z>5C]U AS%R5.VY5;B(]%])N2Q/2_A01Y$\;B.9P(3*+ ;O0S#06
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MLSV(&WJ#8FQH)FGRH)8XG@::)AK/$0;-?Q4A=+:W%!/(TNS= %=NH#$@$?:
M;?HH*DG,8,!*Y3_+R#JDFA\M#T-!:Q\B/)B$L?X6Z7_Q4$M O;^>@4"@==#0
M  HL!8#H!05,[,Q,7LKEDA9GVIY;AKK02Y!0(=[$*= + W/W@T%;&5F5EO8
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M>&'M[!'8[6.[I8D7M07I<..*1Y;+)EY+(K]T;K*+A55;:!;B]!K,B+G%+3Y
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M-QX&-(9 GI#$W)(.H)^%!+"&_+E#DQD-W+%=EO.PN/T4!^Z^1%%LVQ!=SZZ
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MSL>+U9F%E&S2D+N1A;=NL;@ 6U_5I0;Z@4"@4"@\M<$-J#UOY&@A19$W!$4
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MC\C-PUA[SY'STBSAAK"T*Z$N'O9[_LB@FX?%S(5&5CQQ2<?QL;QQ#_TD89+
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M?\)'PH*^9G8>3EQXLLVUXR'=64A"P%PK 'H;>-$;G 67(QEFQ3$[.22P8NC
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M6%H3,&$/K];LE]I%_P (L*#6\AP_&<A'A9<F.QSABK ,QR8D,S)ZC8^IFO\
M=06?;N+-A83_ # 1>0U&2%((D _!NL--/*@JP\%GR>Y'GS^WF\-+'W'E=1Z?
M3I&"MFT)ZWH-A/F09O(S?+9:2,'C22".6Y?8"!N!.EE('IH.6]R^T)YLA\^'
M.5IIW1&C:ZD&S,=1I:PH-[Q6/!P^#QL#\G%)C 27">F20MY6!.AH*<WN6/C.
M5"YT#QP&<RR3,"TORKD*"@&O6Y-!T$LF.G(1+.LDN1(3+CJ"0#&Z [F&E[4&
MD]P9TZ1SX\,J@RQ!8"@WOH/42--+=*"O[<YJ&?CWX]79<_!0+*KE4>W@RBWA
M\:#;0C&3)2!@YF^5C];L2I0%K:7MNN"2:"#/Q!/V\LL(YX90P9/5W%7H+7L+
MWUH+.1CB79.\KC&C7<8!T8^%SUH+,$L,T*-#K&;;?A;6@D#*Q(5@2OX@#J/M
MH 96) ()'4 ]*#V@4 $'I003*LKB(DW'J/D+>=!V/L9H?W5[L[=K_N]B[^']
M7+4TQ^3/XAN;P/;/\86#[DY0LO&</R'MWD,UHUWN(,1<::0JHZG:IL*RZ9\?
MH+E_XVOH6W%YB"/DN4WPNAXYL$!<@.-IC8RL$VL#9MWAX'I1(^4_P'>S>>;W
M=[D^HCX3X?M>3CY.+Q&=66.:?(RH9R(F-@PA6#:Q'3<*+KH/=?UW^M'U:^J?
M)?3/^']\?C..X8SIE\S*D+M*N,_:EG>3(258XMY"QB-"Y_%?6RB-C]._KK]7
M?87U9POHY]?A!FS<R88N)YN!(8VWY+&/'8- D:212NIBN45U;KT(H19_BC^O
MWO\ ^D/U&]K\9[:RHQ[?R<*+.Y/ :"&1Y[9<B.BR2(S)N1-OIZ=:&8Y/WW[R
M_C4]J<(/JMRD^'QOMH%)\CV]C08DQPL>9UV+D1O$TMO4JLPF9U\=NM#CZWB_
M7[/]Y?PT\]]5_;BQ\9[JXG'F@RX HGBQ^1QS&6VB4$,K)(DBAKV#6-R*)'P3
MV=]:/XN?K%P,\'T^[4N1P<IGY7F(8>/QWF,H!AQE7)41Z!&:R+N-_4;6!+,?
M6OKG_$5[M^D?!^UO8G&1P\S]7^5X[&DY;+:(-%!-(HB+)CQ65I)90_;3\*@:
M@@@43,?.^?\ =O\ &W]*^(7Z@^[LJ#/]OH\3\GQ\D7'SI"LA 43)BQH\:W;:
M6B>P-KFB\?HGVW_$-[5Y[Z)YOUF>!X,3BH95Y3BMP:6/D(=JC&5[6/<:2/ML
M1^%U) U )'YY]B?4'^,'ZWRY_O/V+R/'<1[;P<AX(,":+%CQ'D"J[0(989I9
M"%9=SNX )T(\"\;;Z5_Q'_5WWE_$5Q?T_P#=$</#<1(V5B<M[>7'BW0YG'\7
M,\H68AI-IR83(!O/I.VY%"*WUC_B3^K_ +(_B Y;V'[5:'D>)A?"Q>*X-\6)
MGERN0XZ!HU,@42M_K$P;:'%_PW%#,?1_IAR?\3OM?BO>O/?5[$FY^7!PHI_;
M7 84>!++EYLS/=(WX]255"JJX:]@VX#34G'SCBLO^.GW_@97N[!S8_;6-#+-
M\KP&7B8^!.QA.J1P9.-)(PN-J_,/KYVHO'TC^$KZ\^YOK#QG.\5[S6&7GN .
M-(G(X\8@^9@R^X/S$3T!T:/J@4$,--"23<?&_IY_$/\ Q*?4CW%S?L+VD^!G
M\]*6DQ>4RL>""#C,/&D9996"1V<L7B12X>W]$DW!8CP/XBOXC/I=]0^1^F?O
MF&#WC[DG*87%X92&*V?G(K8DD,N/%%W(W,B;D:WD"A!H1-[^^K?\5WT*]R<+
MR_U%Y/ Y/A^:9Y5XK'BQFPV3'9.[C[XX8Y8G59%LP8WO>[V-#C[/_%']8O=W
MT\^G/M?W;["RTP,GFLV))&G@BR+XTV)).%VRJP!N%U%$S'R?G?J/_%U[E^G"
M?5_A,G#]N^R\#%3)^5@CQI,_*BQ[1RYCI-!("C,'?8"B[/V2+,2\6_9WUG_B
M;^OGMI<#Z:X_'<'F<)$(_</N67MJ,O)D),<<"31RK&Q0;GVJ===R J"(ZS^%
M'Z\_4#WY[G]P?3?ZDE<SG>&QI,R+/[44$R_*Y$>+/!,L"K&Q#2+M8*#^*]]+
M#<:7WW]>?K#]2?JQG?23Z -!@1\0T\/(<S*D,CR'%819$K/D)(D<*.P1=B%V
M.H/J  B7V3]<_K+],/JKQOTI^OYQ^2Q^<,$?&<Y D*,AR7[,,@>!(EDB,@,;
M]Q ZGU7L+,(Z/^*+^(KW-].N7XOZ<_3>%)/>W+1QSRYK1#):!,B0Q010Q,"K
M32,I_&" MO22UU)F/DWU=S_XJ?:7TGY7#^K;X//^TO<20XN1D0]CYSC)VE2>
M/>V-%$I#,NPW[B^ 9=+EX^W?P2?]Q6)_\3S_ /SUHFOT71'X\_\ K@?_ ,A_
ML[_XGD?_ 'N*-8^^_0+_ +E/8/\ \#P?^16B:_-O\=?O7+Y//]J?1_@R9LS+
ME7D\_'C.KS3,<;"BT/B3*Q4_Y!HN/F_U(]G3?PJ?63V![JX7>_$_)X<V2ZDV
MFFQ8UQ.4C6]M94;N? R_"U#Z_:?UPS,7D?H1[UY#!E6?"R_;^7/C3IJKQ2XY
M9&'P((-$Q_-3B,'*]L>Q?:GU8XI;<AQGN[,QFEZ6DPL;C<W%%]?'O4:?I?\
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M.#&IBC7<Q,>X%@"19;;=/.]%0'EAF228:1RM*N,&AQDVQFP8H6W7/I'C0;;
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M\G&SX>1P6,L@O%.DIW;HW(-_#5;6H-@,#'Q)I,W&0I(]NZBZ*1>Y-O.@O W
M(Z'6@BBQX8&=HDLTS;I"/$VH):"OD22",[/0;VUMJ/AK0=I,Q/TRXQHR 5Y!
M]NFA($]K_;4]'!C+=LA\;:9IT7O2@7 VCPJC&>5,;&B>0K&0^\!V"JJM\?&@
M0Y4+R.6)W2[94*J2K"X8 'I0>OE(DI[UGA"+L*"Y))OZK?M7)H*^5D8SLD>T
M%[ F-OQ 'QZ6.M$88V1 TNXR$WN%%CM#'3;?0@_$T%C*BFDGC8*^Y+D*& !5
MK==#J#:BJG[P9"!.WY[DI$MQ<D-TT^SK07Y%QH(0S L0+]I3U<CJ108Y4JX^
M'(5)?([=E3:2"VM@>AM<VH(^#+RXK8DT;IEXXA,SG: S2@L%0_Y.VU!L1.6A
MW1I(A5@.VVDA ^-CU\[4%?:).7CS,O'2)P$CC0'>3KJ2; 'X4&I?FLI\S)XK
M,"XW+/E&+ F<%G$<@90\:=/\D^KQH-HO[MY <HN'COBX.QV=90V,&G20I*;^
M(MM]5!@O)\?QBX;)BSIVXE@:''"RR*[.1Z[:.+]"=:"Z<N>!X)?E9QW6D^90
M0JLLC[21XZ  6H,./PTE,ON/)[\>1R)BQOW?*P>*(-)MB%@HLS 7;[Z"3+&+
MAR#(Y&>*')#*T4,SC9M7Q  N+_909O'E(F1.N*7GR-C)"K+HJC3RO05)9EP^
M3@GY1<A>_&T:8\(#0,H0!]P!%C<V&M!S<7M(>WLO,YJ"$SPY,J-BX<.Z6>)6
MW.O<-M-0%-!MN3Y?DH'QN/DX@P9.7&&D8G>H91ZI%\A08<7'@X>/C"=UR<PN
MK8HC]4RD$F0E3X F][T%W.Y+"P\K&Y'-VODVED6-H09'BCMLLUS^ _#QH*7"
MR9&5(KYV8^//)+(N*&*&<K-Z0P))M?RMI>@B>&8Y'(X:Y*/D!S$Q9;F*PLK$
MBPMIX"@U47&21X,BV&1R\\BP94\*FRX[%"AO8EKD'[/&@Z?% 6[YA0V*18[E
M&0DZ@K=K7U\+4$P:-Y-AA(()4'IUOK^KK0><<TC8H6:W<1F1K:]#_-018K8N
M).^%'<%W+JIN;%M3:PL!02PX4&)/E9D>[?D[6E6]Q= ;6'WT%;B\2T\W)"=W
M3+U$+6LEM+:4&TH%!!C8D6)&8XBVTL7)8DF[==30>R;6;J04&YD\_+I0=7[$
M=?W/[N=5&[]VNS#4B_;ETM4TQ^6OKMQ^%RW\:/#\7R>.F7QV=RWMG&S,690\
M4L$QQ4D1U.A5E)!%9=,^/I7\4/\ ##[>QO:[_4/Z6<2G$<QP &1R?&<>ICAG
MPXO4TT<:Z++#;>=MMR[K^H"AFNZ_A,^O+_53VQ+[8]QR1CWM[=C19&15C&9@
M"R).%6P#*?1*%%OPG]JP)N/R/]#O9/(Y7U4Y_P!B<A]0.1^G/N6 9&-\[ARR
M8\N9D8LX63'=EG@))L9%!8WVFC6OIO(?3#Z>'ZQ<'[?]U?6_E_<'O_"R<!./
M.5A9/)DRF?NPXHRER)^T=QW$,0%W7HC#^.3.BXSZP^R>2FC[T.'QD&1)#H=Z
MQ9\SE==-0+4,?H+Z[?5;Z>YWT ]Q\K@<_A9F/[AXN3$X>**9&GGGRU"*BQ7W
M[DW7D4K= #NM:B8_/GT>XK.P_P"#/ZH\CDQ&/%Y+(R7PF;_TD<,6-$SC_)WA
MD^U31?7U+^ 6*,?2/G9POYK^X\A&;S5,'"*C[BQHFOE7\2CGV+_%?[6]]^X8
MGD]MM+P_))(07408$JQSA!K=HS'W-O\ E#SHN?'Z%_B%^K/TYC^B/N3L>X./
MY*3W!QTN#P^-B9$>1)/-E)M5E6-B;)?>S'06UUL"3'YN^G?L;W)E_P %WU$R
MX(90O)\C'RF%CVTFPN*EQ7R)1I>P[4OCUC_27U]/_@Y^KOT[X7Z2R>VO<7/\
M=P?+<-F94\\7(3QXC38^0PE69#*P$FI*$+J-HN-1<:^5?2WW9Q7OC^."#W5P
M8_\ I1R.=RS83[2G<BCXC*B$NTZCN;-^NNNM#QL_>$4<W\?F,DJ[E'*\.X'^
M5'Q.*ZG[B :'C]:?7SZA\E]+?I5SOO'AX4GY;%6&#!$HW1)-ES) LCCQ";]U
MO$BU$Q^8?I_[-YGZT_3K)^JGUA^L7*0^VM^3^\>#P,E,2''3&=@RS MV4>0#
M<B"#\++UO:BHO_K>_P#UQ[\_Z-QO_*9%#4?\"\,;?5#W]D$?FQX9C4W_ &9,
MR[:?:@H:J_5#_P#CJX#_ .)\!_R,%#QU7_UPC_J?V'_TGDO^3QZ&'\97_<-]
M./\ I.%_^3)*&/J'(0QX_P#!@B1"RGV#CR$7OZI.-1V_6QHGKB_X ?\ NV]S
M?_'#_P#>D%%UP_\ "I__ !5?4S_HW.__ ):Q:&_'RSZ7>S>0F^NGN7V1R7OS
MD/IW[@$N?BIRV'*^/+ESQY2L<=G6>$D2@=U;L0Q46N2**^A^Z/I9]/?[S^&]
MK>]/KIS'.>]HGPTXULG#R>6*RSSDPXPG3(G,3EK-M-@-P/C1&/\ $E./9/\
M%I[4]Z<\C'V^)>%Y,2LI95Q\*<)-ML-60QE[=;D>=#/C[9_%U]0_9;_0?E.,
MQ.8P>0S?<QP4X>#&R$G,R19<.2TRB)[E%2(G?^'=M!ZVHF+'\$G_ '%8G_Q/
M/_\ /6AK]%T1^//_ *X'_P#(?[._^)Y'_P![BC6/O/T*R(,3Z&>QLK)D6+&@
MX##EFE<V5$2 ,S$GH !>B:_!>!C?4_\ B&^N7N+WY]-MB<MQV4.4X[*RGCC3
M%Q<>18<(#NJR]P(JFVWJK-1KXZSZP?2/^*SG/:D_-?4S/QN;X3VW'-R)1)<5
MIHD5/S700PHQ&T787\+^%$X^@_2WZA_[Y_P<^]^ RY=_+^T.(S>,E!-V.&\#
MOB-]@7=$/_5T/7S/V/[5_P!Z/X*??$L:=S+X'W4W,XPMT^7P\".8_"T$LIH>
MJ?\ "IC<M]2_KO[<Y'F7^9Q?9?$*\0(]*8W&P+AXJ#XK)*C_ '&BZ[S^#8A?
MKQ]2&-[#%SB; DZ<G'X"B:J\W])/H']?_?O-CZ3^\IN!]US&3.RN*SL&1,*>
M9I")3CI/V)D.X[G2S;;Z*!H T7L[W)]7_H!]</;_ -+LWW4/<O%9N;@X>9Q>
M/E29^)V,^80E42=0T$R7W;5"^%[J:#]Q^^_JI]/_ *9_(?[]<W%P_P"].]\A
MW8YI.[\MV^[;LH]MO=3KYT9==#+'/%'/"VZ*50\;>:L+@Z_"@SH%!S_O?_Y%
M>2_XB?\ *+5Q-?"90Q*2H]D2Y8#7<+5I%5 ,J!IL VS)#^9(^H 'A;[*"7(;
MM8[S*=^1$I4,.N[IX4'N,AABM*06ZW5=I*J.I&M!&$[)=70"(OW2^VVM_P"E
M<Z?"U!7Y+D<:-#CR,$9BI$EP8UNPL78V4 ].M!H\Z8KAR3P.TK2*908D=CL-
MW) !L+ WZ:4'%Y_/9<KO$9)2FPN6L%.T];ZV)'_&H.:S)U1(LF$&4NFY-2"0
M'(]08"VHU%!/*/EL<,Q=7-NXJIVTNZ#TL" 1Z7;Q;4>.E!IY^1RI8.P3$(!)
MMU]?3I:YT-@!<T&^XCA,_D^-?(*2(4]5RJQQB--3ZB^N@_HT&C,<*Y+QI<S%
M_P MG]3*3X K?70=*"IDF6':'ZD%B&+(68Z&PUH+^!\P\C0H@=W7:8SZF)MT
ML=0:#8B68Q30SPJN2MU0Z#;*I&A N0+"U!<7#EEQ8H82920$E5$;<)-I8WTU
MUTH)N*^13!WY32KD3,Q(2Q(4>=V4W^[I019>*8O7"[*^3ZH%9;2&^@T7<+$:
M]:#8PQG'X^,JXDYIRT>7)(0T:XS"X,=[7?3;I<??09Q\G+)BOAL_:3'<.LVT
MR%R+G86L-?OH*R9+B8S)+<,=]X_4+#5A<$FUJ#IL+C4YR&+-3LQ0"-H\C%>4
MF0]N.P8"--(F+^HWOU^%PWF1F9>!D"/(P7_=T444<90EUC<7VLHM?;H!N-!0
MR1QV#-)FY>^7'R18]J4&9%(N^C$ CX"@V>#DI)@H8B8DAT[;7E&P@%!N.MAU
M;R_E#'D5,<D<<<87DI8&:.6.P&]5((5F !T-!L,/&[,,7(Y[*<Z&*TI0V7:1
M>Q&HO\:#:<5W.2Q>Z6$+N"4:/U;==#KI>U!=3 !S#R.6H$D&]("K$WC)O<CP
M/PH-E#F3SYD213;<:1"CQ[==PT# ^%!M%#X>(=S-DO&MR3^)J@]).9A[HBT+
M2I=2PLRD^8-Z"QM98PY'IO:]_P#">M [.]@RC<5&I Z7_P -!<AQ]R[D/XUM
MN/13>Q_5>H,SBH[!1?<NKR?&P_\ #54;' W,H%OZ3M8?H H,^4O'[#YEENTA
MD@T;3UF6(>-O&H/E,N+-E*^_:DI4*'72RWNUZTC!),6/CPF&3V8SMF<W#EF-
MM"+=:"ST*PB,M("%T)-KW!L;:VH,8FE>6R+LN@)$GI-AI;?;SN:#5RYN/&Z"
M60Q[U8%+D]2?41\*#8?/Q18BS!2\2J+,0;O\2=0:#69&4^8C1X#"-NWZQ* M
MXGN"H:U]UO\ )H)HN/#8XC2TL9],BOJ06U)%CI<T%#.S9>-X^09(,*0D",!P
M=ZKJ;D:@G[#0?.^8]PS9&8),;9%BRRB)<-59Q)$;!F)8EMQZZT&ERILC&P"J
MRNSO8-NVAP"MP 03>]];T%&%!-+&LAOF.PL5!)52 1^V/UT$H@F3(97L[R'\
MMK@@DC6]A:@J9K9"2!@!="3(C7)-M/1^CQH)E@:1E3<1+(UDC*[=!TO<@4%^
M%9RSN 9TCT1M!'Z1;Q.AH,%P<N9)960.QN2M[D6'P\ATH+.#QA&,<]G6X&XP
M%O7VS>QZWTM:]O$?>&$<LD.09NY>0D@NUMPZ6MY_<:#J/;'N.#'SHVYC>89&
M4-(%N=R]"0220#Y7H.B]S>XH)%?!QWBD"ON7,B>Y %WVZ>8]-_"@XN/DLJ-N
MZT@[3#Y4XR2,64 W.X686L=!XF]J#ZKQ$;Q<1QSP'<W;#]L@*&#ZCJ#<Z: F
M@L;<7B<67D)89(UGO/R&,CF60EOPL!T/3R%!P'(>[XN8YG#*1O#@X_>3'#26
M:\PLK2*NS1+?X[4'U&.?()C#Q;0'M.QN"$%QH3XC2]!K\O>7*10=V [A.LBL
M0Z=1JM_UT'BI$Y1V:1HVV$1G\*V!4>%Q<T$+PG&6+!B#9$S[Y4F<@%;,#9B1
M9M--/"UZ (>W*$=)8R+O(&LR:'6Q!)%O"@MQQ( SJ5<EKH?AY?;02M&'D5V4
M>G56OZOY/\-!GO7?LN-UMQ%Q>W3I0>[DT]0O^T#86-Z!X[=+@$ZLJZ @:7(O
MUZ"@4#Q_P4"@[":W]V^/N+;?WD-VS\5K-4'&%(T#1S&ZL]T,AUVGH-:HKN\T
M;A%!)LP9DU)%M+W.EJ#7.QA>(-(G>/\ 5,A?=?R%[G=IX4&>;ER<<D$ (1&"
MC3PM8$"USTH),>?]XXD19R90^ZP%B=I-O^%Z"O+R*\=EQQ98V=QR;:&Z!&-]
M-!8_'I02PA<C,RM\4A>8QM'D*FU!&5 50UVU%B6^W2@F(BCY+), =VA&UX4)
M"23;;@:@W-O.@]C0Y>6D>0BX^9&C,TG55 (-E8VW;@? =103\0T\R#YF:7(,
M4[QF2%2L3LK,=Q)N;>K;]UZ"'#QN+DY;)Y>>>.+G&C, C216V1J+G8CZ7(ZD
MT&I/U"XG]Z18<\7RV"3VXYBRM*).A8J@(U\*#?X.=B%VGXW!7*Q,=IDGR(PK
M26B0,-H%S=B3K:@BQYY8X\-\M+8>25RTGRWC+LI8D(R&QN =&H-G'(&;YO*
MA0"13$XW/(/!A\+?"@HR9V(^%EQ1P_,[Q*<3$D0H7$5K[;&VAUH(L.:&4)@8
MHEGS99 W(29 >\: >D.X%B.MMM!;YJ49$?;F3(Q46>.,2XJAHAN %CTH)9Y(
M,%A-R[EL%&V8LR&-8P(]-S!B"6N+F@K8IP^;X[/"YD<N-E2LL+8S'O;0;QEA
M:RWVT%/@N$EQR,K/A5LZ8[8)I'(:RFP2U^H%!)SGMS%Y?%ES<F68OC2W[>&
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MYC#8^_\ #8 :7\K"J,N4XW%YO&^7E<JCBP>/H"-=>M!)C8"8>/&BSRG#B(=
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M,D%_G.SW-^^.2_\ 4K;IXT*^D8T"8N/#BQ7[<*+&E]3M0 "_Z*(EH%!S?O\
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M1KTU\*#UVWA5A*O?1@?PVT\Z#5YL"EU,D<?S36:Z*"-MK6TL#TZ41Y#-#BQ
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M"?I\:GHY-'8DM+91<)LO?4ZD_95&#QAW C7NAE*+&EM#:X/V:4$.UHW<D[5
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MT/&R6_T<M33'W&LM% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M ^88@%@Q^_72W6B-VF*F/!#'""QD7?ZB6"+K<G^36@KMCXPD9Y)!O9 (&"@
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M1AQ?NZ'<2@X]P#Y$QRWJ:8^U5EHH% H% H% H% H% H% H% H% H% H% H%
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MAM.O@#058X7P(T3""R<G"!(ZD6WAM#H+7T%!MOE<989,@PI!+E,&G68;0XU
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MM% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M!)!7QM]]!G&\4Y-F*'\3A@02;>'WT%W&A21BRR&.50;@V'[.W]76@BD#0W1
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M !)">@?^6@[;+@.3].N*B";[\@Q^RRSD'].E3T?.><Y3CN&E$V=?YIPL<&!
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MNQZ&PZ6L+T$^%$A!*%IIM?SI; @ZVZ:&QH(<S.^0(S%42JVR.<J=3;\3 6\
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M-;<67744%;W"89U@X_#>'$Q(I5.3#L-VN1:U@=*"J&XX\EC\+CHLV$LW=:4
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M;04<7GI<O+;%,+I.ZRB-BOY1>(:DM<]3TH(@942*+(01NT;]V9V-I&*$D:^
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M>"%FD'YHZ,=-/MH-1RF=\U(!&?RP+$#_ (:T5-[9XL<OS>'@O)VHY)%5Y#X
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M8VV-MOQO04,'*F9LGOI$9"[[5B6R!59E(UN;V%!-D0R384;W#Y&PJIO;5K7
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M)C+W$4VW*WX===106I())A%$?3&A]1'D- * DH9AC&$[3N20^ "CQ^!H+8
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M!!&@V[Y!UMY4$<DT&$F1/F3.F+E)W&VV0H4]5OL;I0:_AN6XGW-#ERPRNF/
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M(!!-R- 3XB]!ON+]HYDVV18?0.L;$7 !T#?'QH+/^Z>3W<A,,B3L$*DEAZG
MUZ>5!0S^-FQMHEB,3(" BC<6;:01K;4@]:"CBY6S)<Y,8F$=E*:@*UKL2/"@
M[OB^-X_DN*@FUR!M=DQ?PR,Z^&X ^GRH).4]L3O)BS8 6"*R]P@!7C9%&M[B
M]SI0;S"Y#]XPSK+",/'QIPN2)?49(GU!#:6+.;_HH*GNG&3"6/D<6%A*9%C[
MUB0UUN!H#<D^-!>X?ELOD3!/D]QC#((8E*E&$A!N69>JW'E0=1A8F?%@,QR)
M$G%[.#W')=M2+]38T%EEQ$B:>+\K,R3O?M+9V[;6MM-QXZ:T&I;W%)D93_+8
MDR=A^VN]=NXE;^L6T/WT'2RYSKA/GQ1-)^6O^J*%LVX@:'X7N:"KA<=@Y4:9
MDW&IB30BYCT"VTUW:>%!?BFPLS+.!,YE9+L(V4D6\!NM;3PH+F/E019$G'B-
MH^PH<-MM'M/D>E_A4$''?)83OA8*JN*"TC,&O9VL3>]!-EX&)R;JN7 )$A(9
M&)TOU!%!:FQX9X3!,H>(BQ4^5!G&B1(L<8VHHLH'@!0>EE6US:_^#6@U61-W
M7NHV@7 M5&KSKHJ(&]/]'Q^TF@T^;,$C,=_4P\/*@Y'DLSU$*/419?LH/H7L
M:"+(^E/NB&2X63.QPQ'6^['M4]&LX^8JKP;7 0&/<_B ?CY51*S-<PI%OW#J
M1< >-!FH^79H8B%(3:64WN&UZ??05BKEQ%AL%BC+2O<C:]Q8:?#7I00Y42R1
MA&?\MVNY2S68GIUOTH,)XUC$: +V8%MWV&VX \O.@R+Y>PF,!V5E61@2I&\B
M[#34 6TH)6Q8CG+DV_UB->W(1YD'J/#I04<QTG"NFY88[[6 L 3U%OC05\;C
M<2/.BSH<561]6F'4/J>G0_=1%KDW^1Q9$C?M%@?EY1J5=B39AY'SHJ%&GS8$
MQS*5F)#.+ [MH%[>'6@U_NC R,GC'B11O5S(SD$L2!<G6@XOA.+[_*X\<JAR
M"961E-W"MJ&(Z+J*#J\WVWP<:IWHVA,IVCL>L*+ZL?@M^M!2]P^S5P^+R,W%
MW3YD;!D47)9.A%A0<=A^W.8Y$C)A7=#CW[L4ME9776U_C>@V'M+D9\'F<;&F
M&^"5C'L'42DL@:QTW"^T? T'T1XHX9=^-"_:DD,H?%M."P<GU$[2">FEZ"G[
MCA1<)$:5]W(,G;QW3<XF!]((-M"?CI0;7B<[+S^/E;DU*Y&+>.<[[C?$UU?T
M^=KV\10>386;/C"7*R%,XF1S'(/2D1)%F \2"H^ %!GF<9A2QC)CA09*A=P;
M7U"UKC7P%!)F3YG:=H(TFE5- 05.ZX TO:P!-!2PN/,^8.5FEV,4*JI%PLNI
M8ZGPL0/*@M/< HR"-@9"L%@0-S$[@WA>Y.E$(L" 1N7.V2R@D$D+M&H_G-%9
MX<2OEMD+&>V$"Q2-Y$W](^-!GCQPY$4Z*I12S^K\.C7Z>76@RFQWRF4%MO:-
MU87ZVT/QH+,,7:3:3N;]IO,T$3AX!)+<R22$*B@>9L/T4%A;[1N_%;7[:#V@
M'IIUH N!J;GSH!-A<]*#QE5QM8 CR-!V&1&9/IOC*'V <D"6M?0!KU!Q(:/*
M[D+(1)CR6WFQ#"P((JB&:$B.<V W6VZ"P H/,=@&3&9$V%2=?Q?HM0>Y$IQB
MEC=4 W]"2!ITH-3GPJ<N,) PM<F^I-^M@.E$:+][9D4C8F3.XBDE,0QP;F,O
M<#K:Y UM174R1+ D.-+.=D..[B1&"L[7%]#?36@K\<).3Q$S(Y'BR2.RS6V;
M.WX.G0GQTH)L'(E7*GBY!3-F8Y58Y8T"JT+FQ91_24GU4&PC[^-'%-F6GF<O
M' \6T!XW:T>XGQ  )M]M!%DYL?'Y'SG) K T9B<0,)?4" %(T(.M!YA9DLN+
MF3W^4P\)WCVH;RJA 8ERUA^B@DR,AY7XS'[<3+FY"HDLJAA<>KT@ZFPZ?$T'
MG(<;/&LANLLJ3F2"4CU;">C*;B@AE?*Y#(R+HK[(RV'C1$72=+;22-+'RH,V
M/RTF+)([XD6.N\Q;2T1+-:0FU_ T$?+>W.,YC9))%N64=PY*^B5E\5)(Z"UZ
M"N?;O'28>! ,9EXY0TL;HRAR^ZPW6ONH-AF<;&V1PL. T>*T&27G4613':[$
M^-M-:!G9&=B?*Y,<*R<5"Y9LF(@36:^W<GZJ"CQ61F>X\!Y>"E^4Q86;7).Y
M@Q))-SYVH+BXTS1,.10YVV/<O:%@^H'7RH-7F^U8N.:?-Q[009J""5 VVR.1
M96\-#I07LR/$;@QCSXXQP$:'%CD]4;2#\!#CINM0>>U\G.S,:23)BB@DB*QX
M\2^O\)L?LZ4&:XO%_,9.-'&B\HHF?YFY%XG(!!(_HD]:#'BHFR,!TBQ@N(DK
MP022L29%4ZR:C0=;4&QOD 1&&>-F4;4=DMJ?,@G2@JXG*1-/,D,9,^,+9>H(
M+#3;>P\!>@U/(X!]Q9F*4>2*'CI 3*([)-$W<#JWJUN2/21\:#<0X./C@=J%
M%8*%N!Y"@T>3Q46)+/)Q.*%S)F$DC0N8R7'4Z@@T&>3#RV1#\D,A\2:9543A
M0V@8 Z7TO<^-!O<6/LP)%O[A0;2_F:"1E!921<B]CY7H,J ;Z6^^@KB)H\DR
MESL<=#T%!VF6K1_3/C4\#R$FH\!MG(-3T<7D9*XVYY;B+;I87NU^E4:B:8.!
M-AQ&5]QL Q4V(UOUZ4%CC,IHX8L?*!$A>UK@[MY\=/*@DRW,$+I"3&4+/L #
M7"@$?IH(#ERM&Z+"DCZ%MMQU.@&G6B--RL#S<:[1"7MI(IE\+(;[K>)M15#V
MTRIFSXF*6; $7<468()AT"EOA^+XT'6<2O91AZMC&X9]  --+T%[(/;VB-;,
MQ_$!?7_'0:G"@DR,EF*")8W8CP8@W!(^%$6XOEVWB5W=Y!;\TZ$*Q8  _ T5
MXIDG&U91+,I/=,:Z"][*/CK054GR+1AH.]EE.RXE&PJER-6(N2>FE$>+V9<?
M+P8)DABEB6-)8%8A!,KJR#?UV@J:*FAQSCO!A-(LL4$(A8S*2W<30-Y:4%S&
M9(8LA@&1H66*69]2X U?:+VZT$&'^\._)B8Y1^)1MUIO5(1*";*;>=!8QLC!
MBA:,6AADR%B#(O;,KR-?8K-JVNG2@K\7+FQOF2\D\<\A=FDGD3:8MOX8U0WW
M6O\ B!M09961VAV%>6<Y,4KLY%F2,J21I<7-Z#1\"D7MG%^<:3?Q\D)>>($V
M5@6NQM^N@MY6#QG*P0<BT[6Y">*7!R,92K*I2]Y03K0;7-BDR'R,>9Q/((B,
M-W'I4JMC>U[DVO0:Z#!7 QL9(4 D>[NBV9A(PL? :41I.<@AP)4S,Q$9V0)(
MO=90=[JHC5;$7_I45L>'Y'%Y'#^7?%DQ0WHBADO<Q1D!=;>7AXT%O,SY(X3$
M,-H1#(8NYHQ*,+[@? 'XT&29*Y,(P,61H9I8T65D7<XZAC<^)Z4%++E'$X$S
M0S.[1G8[6W%&4JJD[>I#%1;QH+&1D<CR''.O'ZE5U:0%6)47L01XGK0;#,,.
M1QS)E*'D,?KC O9P+G0VZ$4&H7#SLE8%<*$W&24ZE3?I<GRHCHL5G:(%_P#Q
M=+:6%%34%=XIWG+=S\@K8+T(;S^-!F8Y%@:.-_S=I".W@2-+T$$4LL&.@F/=
MF*C>Z:J9+"_V"@I&4%Y5 !0D BW0CK8T1W?L-RW ^[E+$[>->P/0#M2U-7'V
M^LM% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H.=]]DK[2Y,@;B(UT'_K%JXFO@$=V4%(@6N?S!< 6'F;UI&??[R0
MSXQ/S$ 996T*Z>5A05Y)DCCAQ)<AE=I#/&JB[+?0@_"@D*RI)E233F6%658D
M0$!3UN21U-! \<C/-"Y6>$ '8][=R0:*'Z7^V@AQW5H8VCCDB;>(WB%O48R"
M"2;]+:6H/.2$Q*M$ZR=L%V8 BS'=<BUM5)W>1H(\24SJY#*P0!5[8T-O%C?R
MH(1BY>+D39;1AQ)<74ZZ 6!(%[7(_3]]!DT.+/G+&R.TH5GD %XR&LIL/O%^
ME]/*@DB@@W2&.%8G%UN+7L>FNE5%/D<9YN,EQ')EE:Q! (MZ@1KX6MUHKB^,
M]J90Y!<H1AXHW20!'#1DJ;D694-[::V'V^,'990S<*&3*P4CD8CN20N"'8 >
M!!T-S00<3R65GIM<10S7/<"W4DW\ =>FE!+EXV)F13C.C3MH'0SE@'",FTWO
M:Q-["]!Q7(XB8L$#8\OS$3(KI*Y&XJ"5:P%M-.EC0=3BY8QL&$X;(T;(JQXY
M/:<&^TG<P.GP\Z#89 &%E#)R<MEBE&PX4A#*^FXF,+KH2NFTWH+*R1<ACKCB
M9E3)4.'A <6C(/X6MU++I\*"08$0A8=W,SHY&21\8+OD&VX! ]-A<^%!9Q?:
M<0FEGS$DEQ\@J855W[B[>MRO1C?KN(H-MC<QAS<?_P#3":;C$E5A&Y#LZK&P
M6X<*-3N7K;X7H(FXZ'#&(\?*S97*(>]$A529XAM#+8M:P_XQH-GS6?[;*0-R
M"LV9CLC+$B$.O=.W<R@@$??02X,.5'Q?;Q$@CD97:$HSF(DWM?=Z@+'6@EX^
M'E(L?*3EHQDK)MC"QG1VL%;TFP \!Y_;07XN'A^7DAD9NW.NTJIVE1Y ]14&
M.<J((\%V=<5E";UU8*-/43]E!KN%QRO)9,$:CY,+NW;BTHD!VBYT'0=+51M,
MKC\YL!L;#SG3(+%DR)-6 /AI;I4$V'#FX\$<.1*<B0#U3BPN3X$-K;[Z"[01
M3-&BAY#HO0>=Q:U!JI&4LS ;4ZV\A5&FR).[,S#47L/L%!SG)SL"X8^N^U=N
MGX?TT'*94G<E/DN@H/J7TU?O?2[W0S#_ .J$%AUZ&"U3?HIID@JPF4I$C:,0
M03N^WXU1ZJLKK(K[E8G>AZ6MX&U!A)$SIZ"$EO?<P[EOLU%!(G8QX5CS9.W"
MBBTCC\5_ 4$?^KY;#)785C1HXK-Z=E_([;G[J"%X7F95(0I%M!.C*]C>]AT/
M3K08O$(@CNN\@.7$=R0!J"%M8@ T%/$RP9XQ"7FNK;)[D+J=JZ-<GI0>-'GR
MY&0KQ(N-??"S!=WGJ#Y4$L?;6*"+?H'"JN.5*78VO=03I?QM0.7A&7AR8I42
M7 ="1N! )MNN?AUH(,";#@[<98*4!NIZ_<+=/T_"@O[.[&\R'OQE2T43?A)M
MT5K7%Z#GUP,#C<Y,J%!CN8G=HVC=S&T@"@';?1NA])H.@BQRTB3R(+%?0@ ;
M86Z@-< C3^C08961)!&0YWJ QDD(*"PU\+F@K+F8C;I8(?F(3'ND>(JA5CH+
M[]@N1YM<>6M!JL*'B(^;E"8XQY\I(<K$<B-F;</4 W0-H"+7H.@C[4D8QL5>
MW"I(8H=BVZV&FI-]:#C^:]SNW*_N^& 29&+(3'+D.2JFWXMH&MO"S4%_BI,K
MEI \LZQ9V,6,?;-DD=DT9XSKZ? W(O0="F:YB9,V%1/,%CE,*LJDA1N_$3H3
MY[=*"F\4?(PO#Q\K1+*P+RJH:PMN-M+6^.M!AD)RT'RV)A!4Q5/YL?J>8QKY
M2#:+D_"@N09*-B)/DHQ,Q)Q\:V^3XC6PZ^)(_30>9N02T0WK KL/2R[I+>)Z
MZ:]+"@G[ *,XE)@9;;56YVG7XDW%!#D-%$/RWV (?38AE &EAH1?XT%/C3RR
MY$DV9)')A3@+!BQ_C&H%V!46LH-_4;_"@W8C4,&%]!8"^EOLH(WF=9Q$$NI
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MP_O %KK^[7&[X=N6LZ8^X5EHH% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H%!S/U"_^0[E?^(G_ "J5<-?GWN'L&*^C
M'H*TR8SHU\9F_"+J222#?PH+NYDQ&DV[G4':@UZZ 4&N20Y&*)0I@GF!5D06
MUZ7^^B)I8)\C;D9$O:>,_F*+#<0+6-O.BH)XXDBR'B';60;I3?<P"^-CTUZ4
M&,V,\T?Y1]2;',K*+.'%M  !H*#+&00QB)D&Z,E7E;HP;4'[QK0>8\1.Z-F
MQWTB9+W'J.GWF@I\OAR-A--'*0L2,LL8-G(8V.I\_&@U6-C\EE<4)(966-&)
MQX2Y%HP+VW#7J:#0)E9J37@9HF1&[K@AM[Z6#7H-]'PL?R\>;FREY!&H8,
MI9A<Z?8*HVD+QXF'',+.9;$LO[6[^84&O.#Q&-DS2D=G(D4JH;\-V!U_74%J
M##E1(,.3(.Q8RK1@"WFI!MX40GDX_'B^2R)MZKM6S'<XT&A_EH/,.#&R"1"L
ML8QK)'-N(#@ZG3X=*JI'G3%+/)B^E6:SA5W$^!^^HBSB-\WCIG^N) .X^/\
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MT) U:P'CXFVMJ"LKYB02F+9-*FU(["P(TZ_8#06X!*(E$UN[^UMZ7^%Z#,R
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M*^"^$_*MGXFYVR$%Y0Q,;!=0;'2]!;]QXF1GX/R\&2T"BS*5-@YZ[2102\/
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MF#'+R"F3)<$_+PD@RL7]1#;2!9:"KG<ER$!XWFN%XIICR;1PYL,S6:*&0>(
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>tm2227887d1-lc_macro4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d1-lc_macro4c.jpg
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M%!04%!04%!3_P  1" -N!U$# 1$  A$! Q$!_\0 Z@ !  (# 0$! 0
M      8'! 4( P(!"0$!  (# 0$               $# @0%!@<0   % P(!
M!@0."@X'! 8#$0 ! @,$$04&$@<A,4$B$Q0(46'1%7&!D3*24]-4M)465A<W
M0E+2(Y.S=)15=:&Q8G*B,W/4-39V5Q@XP8*R)#2DI4/C987"8X,EM2;PX?&C
MA,0G1\-DQ2CB1$5FIG=(AA$!  (" 0,!! 8(! 0%! (#  $"$0,$(3$205%Q
M$P5A@<$B,A3PD:&QT4(S!E)R(S3A@A46\6*R4R22HD-$PM(U8W/_V@ , P$
M A$#$0 _ ._@
M                   1"[_TB_Z)?[)"4,(
M
M               !EVO^D(_[\!,1"0
M
M
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MQBF9F?\ [0!)@                 !$+O\ TB_Z)?[)"4,(
M                      5[F&^&UV WD\?RR_%;[NEI#ZHQ1)DBC;M=)FIA
MEQ/&G)6H)PQ\>W_V?RFX,6JRY5'<N$E9,QV)#4F&;CBO6I2<EIHC,SX$5>)\
M ,+*!                #"@W:V7)V8Q;I;4IVWN]FFI963G4OZ26;:S36BR
M2I)FD^)5+P@,T  1;Z1<-^6WT=><O_G+JNT>;>HD?Q75]=JZWJ^J]9QIK_9
M>MMSW$+QD\_#+;=&Y&3VMM3T^W)2X3C3:%(0HS-222=#<07!7. D@"/YCF^+
M8!9_/V7W%-LM76HCI>4AQTU.N5TI2AE*UJ.A&?13R$9\@#<QY<:5$:GL.$J(
M^VE]MTZI(VUIU$H]5#+@=>(" 0M^MH+A?TXS#RR(Y=UN=2VFCJ8ZW#/22425
M()E1F9T(DN<>8#"Q@                                 !EVO\ I"/^
M_ 3$0D
M
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MW>PS#[9MQ?IUNQ^VPYK+31LR8\-AIU!F^V1FE:$$9<#IP,1+.DSE? I;8
M              B%W_I%_P!$O]DA*&$
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M+U,<-V;+M<54ITZF:WDMDAQ1UXU-1&8,4Q
M       9=K_I"/\ OP$Q$)
M
M
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M;-<TMXRRI>+1F$@%;,  $"WK^J[(OY%KX0V(EG3NMP4MP
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MP                                &7:_P"D(_[\!,1"0
M
M
M                             !4>RGU78[_(N_"'!=#3OW3T2P  !S%W
MK+0SD&9;16&0>EBZW.5!=5RT1)D6YHS]10ZG"MXUO/LC^+0Y49M2/I_@J(\K
MN%TV.LVS:#,LC7E2K.4;E4<<ED\DC+E/_>'R27[WT!M^$1MG9Z>.5.9G5%/7
M.%F]VS%++=V]W<-G-+587I[=O<9;<6TOLZ5RT$1+;-)EP(O1Y^ U>7>8\+>N
M&QHK'WX],R\][Y&)VC%;=W<=M;9YRO\ *E-.%&:^_KAGUIOFI;A\>M74ZU]:
MW4U4*@GCQ:;3MO/1COQX_#KWETOAUD=QK$;#CC[I/OVBW1(#KR3,TK7%80TI
M1:J'0S34AS-EO*TS[9;M8Q$0HS#)2LN[U68W.:9J9Q6V^;K6TLS/JCU--K4G
MP$HU/G_KC>V1X\>L?XI:U>NVWT1AI-D/\S.Z7_F'_P 1:&?(_H4_3T8ZOZMV
M9W*?ZE9'^M$_!T!\P_''N8\+\$^]?.>XU/S#$[CC=MO#UAE3R91YTBDHWFFT
M/(6ZE.E;9_?$)4WZ[D5S\@Y^N\4M$S&6Y>LVC&<.;=KL+M&WW>AGXG9#=7;X
M-DZ+LA6MUQQUB.XM:C(B*IJ49T(J$.ENV3?1Y3[6GKI%-N(]C:R$E=N^>TU/
M(GFK3;4G"0LM1(,H!N%0E5I1;RE%3GXC".G%Z>LL\9W^Z'SLLLX'>7W0M$-!
MLVYYN5)6TWP:ZUN8SI,R+A7[\Y3TQ/(ZZ*2C5TW6AL^[A(+']P-TMN636FUV
MZZ+FVMA5:-M]<XRKQ<4$QQYZ#'E1Y4I?Z&6CI:U?I_>Z/'-;8  (%O7]5V1?
MR+7PAL1+.G=;@I;@                 B%W_I%_T2_V2$H80
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MJ6TMZS-2]"2351\IG3E,!Z        \BCL$\<@FD%(,M)NZ2UF7@U<H#U
M                               &7:_Z0C_OP$Q$)
M
M
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M-:4]D,='6UK>V?W.BQSFV  "!;U_5=D7\BU\(;$2SIW6X*6X
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M]K+V2?* >8[C[67LD^4 \QW'VLO9)\H#(@VB<Q+9=<01(0JJCU$? !(Q"0
M
M
M                                      !SQM]F-UQ##[7C=SP3+'9U
MO0XV\Y&M*G&3-3JU]!2EI,RHKP"V+0U[:YF4F^E5_P"8&9?$Y^ZAY0Q^%)]*
MK_S S+XG/W4/*#X4GTJO_,#,OB<_=0\H/A2?2J_\P,R^)S]U#R@^%)]*K_S
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MY=AUUQRVX)EC4Z>AM#+DFTK0R1I=0L]2DK49%1/@";0RKKF)=#BIL
M
M
M
M
M
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M2DI=B)<-UN5;9):XLQE2DIJEQ/!:>.A7 S!*> @
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MSL&W%7DN1Y5A5[@IM668M*2EV(EPW6Y5MDEKBS&5*2FJ7$\%IXZ%<#,!/ 0
M
M
M
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MCC^&7M):J/,REH.(1DGETNNJ74_M4\P)=#@@
M           !PGWSWI&3;V[>;>2GEMV1^/#69(,RHY=KBY%=61'PJ2&$4,&4
M.WX-GM5LM3%C@0V8]GC,E%8@MH23"6$IT$V2*4TTX4!B@6V^P^W&U-UN5[PZ
M ]&N=T2MJ0Z[)=<03#CI.]4AJI-DE)D6D]&HBX:N)U)RY<[JG^:K<S\FOO\
M\:B@F>RUN^_BUGNFSKF2R(Z//-BFQ50IA)+K2:DNDPXUKY="M9*,O"D@1!M9
M!RK=KNCV7'K/?7+)D$ICS7Y[);J7&(MNN1MF23:-*E:HS)-:=1$9*H9TJ!/=
MSGGNSU@VDW^VHP6Q27Y;\Q^RS+E=91EJ?DRKPMG43:>"$I)HJ)(S\9F?$$Y=
M)]^"_2;-L@N#'KIOUVA6U]25::-I2[-\'$C.,14\8(A1V#[Q95BFP\*V6[:8
M[[M1$8<C9%>9SBFVIKTEY1R5$3:#H@EKZHG#UTTE6AEI(EU%M]8=F-U-H(,;
M'L<C-X!=5=I>L9)-CJIK*B2LG>J41]8A2.*M72H1U,C!"AN];F#6'X5] >+8
M@Y;\*81;FU9*[VAV#%2EU,E+2%=6XHW*I2:UJ<4LR,^B9J AT=W?L?LV+[.X
MI9+#>&;_ &UB,XZB[1J]2\Y*?<DNZ".BB)+CBD$2B)14Z1$=2!#/WHRV1@NU
M6695#7U<^!;G>PN?:2GZ,,*])Q:3 :SN\XLUB.S&'6Q""3(D6]JYS5<JE2;D
M7:G-1\:F1N::^ O !+C[ XRL(Q;$-[XRM",8SJY6G(%D5*VBZDTRXI7B;Z>G
M]TX)3EU+WG+U-3MPUA5@=ID6X,^)C-MT55][FK(Y"S(O^SZDE)6?,2A"%>=W
M#'K=8-Z]YL6@(-%JMS=JMT=!&:5$PRTXTDJI,C(])<I<03*_,<QG ]F<,>@6
MA+5AQ"V&_.D.27EK0T3BC6XM;KRE*/P%J49\A A3.P93-Q=W\_W[C178.'W=
MAFPX[UR3;7-:B=2AR0:3YO\ =TT,R^R-/*DP2V&[[R\([P&TN=PE=6C)''\,
MO:2U4>9DK0<0C)/+I==-=3^U3S .AP0
M
M
M                                         "C\=WXO-[W]O6SCV)O1
MK9;&W%-WHU+-?WILEDZXC1I2T[72V9*^UY:\"<+P!
M/AYYJ.RY(?63;+236XM7 DI253,_0(!36%]YS;[-\HBXU!CW*"BY]K\Q7>X1
M%1X%P[ ='SCNJX*T\_[()6?$R[%)ZK>F#?($E5VZP[6EF4RX<KJ/XSJ=*CUZ
M*=+36@(0VQ[Z[?Y)N'>-N;'/*=<K%!5<;G/84AR$VEM9(6WUJ3.JTZNE3D!*
M.8MWE\+S^\R<6Q5,B'>)46:_C-RO4=R+:KBJ$:FUJ:>*IJ0A:3U4YDGS@/G8
M7<'.LDO>9XCN#*CRKOCCT0XSS<15O==9E-&I2TLJ-6IC47WEWE6GB9$!*\ 0
M  #D;ON[99%>H-AW/Q9ER3*Q@G&;HVRG6ZW&-9/-2$IXU2TLE:^!\%$?(2@3
M#:6/OS[6/8BU<;\S/C98W'+M5E9CFXER4E/'JGB/J]"E<AK-)ESD!A^=T_.M
MYMSKOD^89=-<+;MUUT[/">9;T]K>>-9MQGM"7%-1T50JIF5333B2@)43@FY>
M+;4]ZO<?)\O=>:M2[ED4-*H[1OKZYVYZDEI3S40?$$SV2_O#]YG'MX<4:VLV
MMM]QN<^^RXQ2G%L&WUB&'"=0RTT2E+6M3B4&=4D1$GGYB(AO]X-HLGQ#N?6'
M$8+:WKC8);%XR=B.9NF;;W:''RZ/KDLNOH,S+AI1JY"J!'=I+IWAMH9/=48V
M^:6I>6^9(]D.Q'%<(TSF$(0J4;FCJM.M/7DHEZC/FU5 QU9EEVGR^_=R5=F<
MB/KOB)3F1V6V&DS>.*A_5H2CEJXV;KJ$EQ5J+PB3U:O;OO*;;X]W9YNWE[-U
MK,(ENN=IC6A$=U2)9SC>-MSK20;2$_?OOO6*)7!1D1U(A!A;W<BQ2]XUL^],
MO++D9%^NCUSM\=TC2?938890[I/B76&T9EX4Z3Y# E..\]99%_V%S>!&2I;K
M<)N=I1RZ+=):F+YC^Q9,"$GV@ND>];585<HID;3]DM_ CKI6B,A"TF?A2I)I
M/T 0H#8G#6MP>[9G>&N$1KNUWO3,8SI1,I/5.1U'7AT74H5Z0D:[8#(+CO5G
M6'3[VRZ3&TF.G$FI?(RU9#+<7#):N0C,X[&OCR+!*6;&?YCM]?RBW_\ YT$+
M&[R/U%YU^K'/]I(@9FP7U*8#^HX/XE("M>\HRB^[C;(8DQTYLG)/.;B$GTDQ
M+>IEQY7(=.B:C(_$)'2 @                        :++\RQG K$_DN77
M)JU66,:4N2GSH6M9T2E)%4U*,^0B(!X83GV([BV1&0X;=&KK:5+4R;S52-+J
M>5"DJ(C2HO 9 -U<+C!M,"3<[E(1&M\-M;TJ0ZHDH;;;+4I2C/DH0"%O[T[9
MQ<$8W*E7]AG#)2C;BW%PEI)U9+4WI0BFHSJD^!$ ANY&_;EHVYA[F;9L6[),
M6<-Y<^[2Y*V([*&"H31(;2ITWG5_>TEIHD^*J%Q!*V\9O/RBQRTW\V#BG=(;
M$PXRE)6;9R&TN:#4G@>FM*D"&U   !QYWV=N,C?E8YO%BL=<F1C:$QKIU2.L
M<8:8?.3&?TERH0XMPE_:U(^2ID3"0P._1M0YB:;K<(\]G*4L5=L"&#42I))]
M:B14V^K-7(I1ZJ<J:\ ,/3NDYEO+N)\H<NSJ>XYA$AU?F&,\RVDU27734YU#
MI()PV64EU95,RJ="]:H"7/NT.Z6)[2=XS<3),Q=?9MDI5ZM[2HS)OKZ]R[,O
M)(TIY"TM*X@GT2SO$=XVS;W6*W[5;4VVXW.9=IS#DEUQCJU/=553;#+9*-2C
MUZ5J4HB)))Y^4B(AUULU@[NV^U^,X7)-)S;9$_WW0>I':Y#BI#Y)/G(G'%T,
M$.6N\E_G"VB__P"<_P#CTD&4=EU][C!;EG>R]RCV:,N9=;+)8O,:*TG6XX4<
MEMND@BXFHFG7%$1<3I0N4$0H#&^\IMO"[K,S;FXK=;S5-FG6%BTHCN+0ZN6E
MUMJ23VCJB21.$XLE*)6HCH1\#,G"6[-O[F;,]U21EUEL17*[OW)V]IM4]+E6
M[0ZAIDW4MMJ0NGWKKJ?:&:N02B6%FO>XV[SK8"[6B[53N)>;<JWRK U%?ZA$
MQPB2<AMU9+;)I*OOJ"-TW"H1<O$086?W,<9R'&=E8Y9 VXP=VN$FYVV,\1H6
MU!>0TVCHGQ(EJ;6ZGPDNO.!*4]YZRR+_ +"YO C)4MUN$W.THY=%NDM3%\Q_
M8LF!"3[072/>MJL*N44R-I^R6_@1UTK1&0A:3/PI4DTGZ (4!L3AK6X/=LSO
M#7"(UW:[WIF,9THF4GJG(ZCKPZ+J4*](2-=L!D%QWJSK#I][9=)C:3'3B34O
MD9:LAEN+ADM7(1F<=C7QY%@E)MEY<:!W@]_9TQU+$.*Y"?D/+.B4-MI>4I1G
MX"(JF"%</[J8/W@<ODS-T,QC8UM!8Y=+-ARG%LRKLXV52D3#16B./ O12FAU
M49+JK ]S=JLJ>3B^WM\M\URWQ>M1;+=T4LQ&5(:JE!)224)-:$\/"(0JKO*,
MHONXVR&),=.;)R3SFXA)]),2WJ9<>5R'3HFHR/Q"1T@(
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M(:4R50GDO$V;A&:25I,Z5TG0!O
M
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M>,83&E-J:<<2@S.9.)"TI,DN*4MMI1^N1XJ"1=H@
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M?CS!126PRW,<D,H024$X:S1Q*E:EX1(KS E[EX;WAF-N<ISR9F%GE8Z[=_\
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M_%4+W(!7>Q=NM]IW#W?MUKB,P;?&NT)$>)&;2RRV@F7>BA"")*2\1$ O0
M
M                                                         !$-
MR]P[9M;B4K,[U;Y]QM,%;2);=K;:>?;0\LFR<-+SK):"4:2,]52KR4J YV:[
M^^UY7E]2\5O2+8;22;N"$0U3%K*G06SUZ4DDN-%=>K]Z#+#IO#,HCYKBUJRR
M'!EVZ'>(Z9<6)<4-MRDL.5-M2TM..I+6FBTT6?1,JT/@#%O0
M             !1W>]^H+)OY2!\.9$"XK'_0EM_)6/Q:1(SP
M                                     !X3(4.X1G(<^.U*B.E1V.^A
M+K:R\"DJ(R/TP'Y"@0;9&1#ML5J'#;X-QX[:6FDEXDH(B(![K0AQ"FW$DI"B
M-*DJ*I&1\#(R,!@KLEF<MQVA=NBJM)E0X"F&SCT,Z_Q9IT\OB 9,2'$@1VX<
M%AN+$:+2TPPA+;:"\"4I(B(O0 >P#GV9_G(MO]BG?AB@2Z"!
M                                   -/EO]5;Y^KY?XA80()W</J3Q'
M\G>^%/ +3                                              %*;-?
M6?O+^N(7XET!=8
M
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M)(!.\II;>2[3T3;U$1^(!N[1D%BR!@I-DN4:X,F1&:HSJ':$?VQ),S+TP&R
M                4=WO?J"R;^4@?#F1 N*Q_P!"6W\E8_%I$C/
M                                                 '/LS_.1;?[%
M._#% ET$"                                               :?+?
MZJWS]7R_Q"P@03NX?4GB/Y.]\*> 6F
M                *4V:^L_>7]<0OQ+H"ZP
M
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M8O)3P<0KD4E9'PY.("TL-R%.5XQ;+]H)IZ6PE4IA)U)J0GHNM\_K5DH@&]
M             !RSWQ[]N*U@=\LD7$VG]OW"MZI64'/90ZT[VIH])13/K%=(
MB34BYZB$NE['_0EM_)6/Q:1*&>
M                        .?9G^<BV_P!BG?AB@2Z"!
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MVB/,>CH+4JAF>ELC4?.=>!%P#D:HUWFL>AQ]L[*1:?5.1KM@
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MQ,SY00RP  K3C6GC 9NS#2TX5V@TZ69EQN,J-XV7I;BD'Z@)E8((
M      !1W>]^H+)OY2!\.9$"XK'_ $);?R5C\6D2,\
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MM\>]/')N&/RY5C5)49J-;4-1&UQ/B9(;6ELO$D$RO($
M      I39KZS]Y?UQ"_$N@+K   !Q3W[_P"EL)_)[A_MQQW?EG:WU.'\S[U^
MM!=NU%M5WB\34?WJUWMBW5^Q0IO((#?J)1(=]+0+]W^KHM[8S^R6OJ_TM]?9
M./VPE7>A>=W#[P&,;;Q5F;,1,&W.H(Z]6_<W2==7XJ,J:,_0%7"CX>F;^_\
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MO>*_0(!:^.V5C'+!;+#%/4Q;8S,5"Z4-74H))J,N/%1E4P&S
M   !1W>]^H+)OY2!\.9$"XK'_0EM_)6/Q:1(SP
M          &IR6_V_&;-)N]SJJ*R5#;21&I:E<"21'PXF*]EXI7,MGB\:_(V
MQKIWLH/'-R;);\JDW678&&8,Q;/5]21&Y%ZI)HU(J1$=:U5R#D:^52+YFN(G
M]CZ!R_[=Y$\:*QL\K5S..O7M_#HZ/9=;?:;?:/4TZDEH47.E15(QVWS>8Q.'
MV"                    '/LS_.1;?[%._#% ET$"
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MXQ9#Z],UE1Z6VW%*.A%7@0@=$6/^A+;^2L?BTB4,\
M             !7&]KT%.%+8E/\ 5R'9#1Q&RXJ6M%3,J5Y*5J?,-+FX^'.7
MI?[;B_YZLTC.,Y^B.RA,>P_(,FF)B6R$XHN@;SZDFEIM#G%*E*.A4,N)>'F'
M&UZ+WG$0^E\WYSQN-29FT3/7I'MAUO:X2;9;(5M0>I$-AJ.E1\IDT@D$?[ ]
M+6,1A\2O;RM,^V66)8                    .?9G^<BV_V*=^&*!+H($
M                               "AE0(66[ZW.W961.Q+<TGS;;7E5:7
MI:;,NB? ]1*-PRY_2!+]WBL5CQ&7CN08NPU:L@*:E+;,-)-$ZA-#J;:*$=#H
MD^''50P%[(-2D)4HM*C(C-/@/P A]         -/EO\ 56^?J^7^(6$""=W#
MZD\1_)WOA3P"TP   85VM%MOMND6B\1D3+;+1U<B.Z54J3R^B1D?$C+B1\2
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M*WG(-26%NLH<:-"U))1I(T.KH>D^-/1&AQ=\:KYGLW^5HG;3$=U2=WO:??W
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M$N@+K
M              5IOMMO==U< >Q*SRX\*:Y*CR2?EZ^J)+"C,R^]I4=3KPX#
M:XVZ-5_*6KR=,[:>,/#8';"[[28*YBUZF1ITQ<]^:3T/K.JT/(;21??$H.I:
M#YA/*W1MOY1[$<73.JGC/M6D-1M@
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MBU&7*9<*EJIP >N'1+_!QJWQ,HD%*OK2%%+?2>HE&:U&GC0JF2321F W@
M        -/EO]5;Y^KY?XA80()W</J3Q'\G>^%/ +3
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M-D</%#>-R^3&UOIC-I-75LMI4KK'%<B2/3I+G,^:G$9Q2?'R]$9ZX;H8)
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MIJ4LSZQ[CX3X)],:G$U3,_$MWEZ#^X.?2L1Q-/2FOO\ 3/L^KU^E= Z;Q0
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MJ(P'/SL:/%[XUN;C,H9;/"W3T-I)!5[8KC0B($NAP0
M            #%N-PAVF#(N5P=)F%%0;K[JJF24)XF? ! +5C6/YCE</=&S7
MEY]ALNJ*(E.E'6-I-!D9G0R(B/BF@)62"            &GRW^JM\_5\O\0L
M($$[N'U)XC^3O?"G@%I@
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MC2?KR2HDT,S/415,B(JF,M=)U1,V1:?+I#H$:"X
M        <"]WF2JXIR;*'CK)O^2W*4\L^51K76IGZ*C&_P :/NS+R?S;;_\
M)K'IA?PM:<P A^A'JB)G,2AG=#NB\>Q3=FQDDELXSDMPF1T\GWMUA)DCT"-@
M_5'+GI+V^N?*L2E.V[)PL?M4=1U6J(E:U'SK<^^*/TS4(B%GURFXE'0 ?#S2
M7V7&%\4.H4A1'R445# ;C9R4Y+VTQ];JC4XRR[$,U<O^Z/N1R+TB;!,IR"
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M2^4S-53,P0VH            #3Y;_56^?J^7^(6$""=W#ZD\1_)WOA3P"TP
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MEZ1MD0A:F0  >CR ,[90Z[;VPR]:<FYFG]Z=RDF7[ "P
M     %'=[WZ@LF_E('PYD0+BL?\ 0EM_)6/Q:1(SP
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M%VK+!:R*!<W;XVRA$]V(S&-A;R2HI:-4A!T5RTTE0$MC_BJV]_1EY_ 1?YT
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M;D(2XGE2:FS41**O$@%.=[WZ@LF_E('PYD0+BL?]"6W\E8_%I$C/
M                   !%\]RYC#K ]<#,E3W?O4!D^.IT^<R\">4Q1OVQKKE
MT_EO MS-\:Z]O6?9" ;.XB_,??SR^D;LN2M2H!N5,S4LSZQXZ^$^"?3&GP]4
MS_J6[R]%_<//K6(X>GI37W]_L^K]ZYQTWB@
M <^S/\Y%M_L4[\,4"700(                            #.G$^0!7V26
M?(,KOUFNV(Y*PS9[:]IN4=EXU$I2%D:BHT2DJ4:>B:5F5 2L$$
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M-T+QF-GN6%YV79]T<*>\W9"PNB52$),TM2DD7!1+(J+4GAJZ7!*T@2ND$
M                    I39KZS]Y?UQ"_$N@+K
M
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M\UR'U3]PM3L:,GJY;2SUN&HR3P+@ [#L?]"6W\E8_%I$H9X
M             \WWV8K+DF0LFV&DFMQQ1T2E*2J9F83.$Q$S.(<^&<S>//2]
M<C&X'"I5+3&2=><O7NGX?] XW7D[?_+#Z+T^3<+_ /W[?V?^'[W0<>.S$CM1
M8Z";CL(2TTVG@24(+2DB] B'8B,/G4S,SF7H)0
M   /";$9GPY$&01G'E-+8=))FD]#B32JAEQ(Z& Y5PG;3%ML.]G%LN)M2&H,
MG$GY;I2I#LI9NKE&DZ*=,S(J)+@0A+K$2@
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M>' U4J9<" >H                       *4V:^L_>7]<0OQ+H"ZP
M
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M;CR75FZ:36HD]!/[ #H<$*.[WOU!9-_*0/AS("XK'_0EM_)6/Q:0&>
M                    *8WCR]^2\U@ECJ[,D*1V[JCJH]?K&>!\]24JOB',
MYFV9_P!.O>7M/[>X%(SR]W2E.WTS[?J_>G^!8@QAMA:MY:5SW?OTY\BXJ=,B
MX5X]%/(7J\XW-&J-=<//?,N??F;YV6[>D>R$H%[F
M        .?9G^<BV_P!BG?AB@2Z"!                            "ML
M5O,3<^7<49-BJ8QX_*24%<Q)N'J6:M1=-":*3U:36GB7$@2LD$
M      -/EO\ 56^?J^7^(6$""=W#ZD\1_)WOA3P"TP
M                           !2FS7UG[R_KB%^)= 76
M
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M        4=WO?J"R;^4@?#F1 N*Q_P!"6W\E8_%I$C/
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M*XD="X& N           :?+?ZJWS]7R_Q"P@03NX?4GB/Y.]\*> 6F
M                                        *4V:^L_>7]<0OQ+H"ZP
M
M                                               '-U[_ *9N'Y2]
M^,,2,       !$D(YG7]6WJ>^H'PY@;&B/OPY/S:?_C2\)G]:<=/QS/Q WN1
M/W7G/DT1/)C,>GV0E0Y3W(  -=+*M\Q[\M7\&=$2/2Z?UX,N?S4CX2X S1(
M       O7;C^J$']\]^.6($K <E]\*3BUGR/!<CNV>7/!<@MR9Q6>;:;:5Q=
M5UR4MN\3?9T=%1IYZU!*E]F;[8,>RK&K!B^].5KM<R]QG5V(\=[-"F/2Y*.L
M0ZYVI6E+QGI6NAT(^00/Z."4        *.[WOU!9-_*0/AS(@7%8_P"A+;^2
ML?BTB1G@                       ^'GFH[2WWUDVRTDUN.*.B4I253,S!
M,1GI#GR6[-WASU$5A2TXW;U'11<B8Y*+4OEH2G:</_J'&G/(VX_EA]$UQ7Y-
MPO*?ZVV.GT?^'[W0$2+'@QF8<1LFHS"";:;25"2E)4(AV(C$8A\\M:;3,SWE
M["6(                 _G/N;AVY#=^W:Q6T3L2*P9KD:KJZY/OL*//9.,^
MI;:3:6\DT']NE::B$ND]@-P=ULDO#F/YN6*>9;?;D]D/';HS<)AN-*;;3UB&
MWW#)&FM5:>42.A00UM\R&PXQ;UW;)+I$M%K:,B<FSWVXK"3/D(UNJ2FI\W$!
M^V2_V+);>W=L=N<6[6MW^*FP'VY+"J<M%M*4GAZ(#-??9C,N29+B68[*3<==
M<,DH0A)5-2C/@1$0#1*SO"48ZG+EY';48JJNF]+ELI@GI4:#H^:R0?2(RY>4
M!!MT][8^#8A"S3%[>WEM@D]:Z_=H<N.FW,QV$U,SD&O0:UGT&D),S4KAR@E9
M-@N[606.VWUAIQAFYQ69C;#Z=#J$OMDX25IYE$1\00HZ9_G(MO\ 8IWX8H$N
M@@0                         ,&ZWBU6.)VZ\3&8,/42.N?63:-:N0B,^
M<Z (AA6"O8_D%YR3SRNXQ+T?6QVR/4C0XK62C54R.A'1)ES E/00  #X==:8
M:6\\M+;+:36XXLR2E*4E4S,SX$1 .3MT;RUN+FNC$H;]P5':ZA*V$J=4^3=5
M&I"$D9DDN/'G!+:[1;9Y.K+(5\N]ND6RW6Q?7UEMJ86XXDCTI2A9$HRKRG0!
MT^"         !I\M_JK?/U?+_$+"!!.[A]2>(_D[WPIX!:8
M                                 I39KZS]Y?UQ"_$N@+K
M
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M!;;N3:^]A$8W.OD"_7M6)/*8E6N*<)I,?M)D2%(,^*M53J ZT!
M                K.[W7"-T;Q.VWGMS.UVEPY1OI)+2.MCGU2M"JJ,Z=8:3
MU(H?-S E8D&%'MT*/;X:.KBQ6T,,(J:J(;224E4ZF? N<$,@  ?#SS4=I;[Z
MTMLMI-;CBSHE*2XF9F8#G3.\\O.YMZ3@V#I6=J6O1(?+H]HH=#4I7V+*?V02
MMO;[;FT8';DML)2_>'4TFW RZ2SY=*:^M27@]4$)F           #3Y;_56^
M?J^7^(6$""=W#ZD\1_)WOA3P"TP
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MYQM-=DSGTC+4Y.Z=<1CUG"UQIML
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M5@LN,6J/8\>@,6RT1"-,:%%03;2",S4=$EX3,S,^<!L0'/LS_.1;?[%._#%
MET$"                        $7S^_7[&\=7<\<MI72XI=0CJ#2M:4-JK
M59I09*,BH1<#YP&7C""F6^/D$ZT-6O(+@RA5P2EM*7B5]JM="4?(7!0#>@ #
MX>>9C,KD2%I:8:2:W'%F24I27$S,S <YYQG-[W2O2<'P=*E6=:J/OE5'7DD^
M*UG]BTG]G]@$K@V_V_M6!VHHL0NNN3Z4G/FJ(M3BRYD^!!&? @0EX
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M.-32C1784JL:X0Y4B.E#LUM*2);J"29)KR>NJ9J,7<:]/C_<CI/[/<IY-+_
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MCT]C6Y6F=?CB9FN?7VNT!PW;
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M@QFH<1M+,5A)-M-)X)2E)4(B'8B,=(?.[6FTYGK,O82Q
M    <^YUW4,7O>43=P\!OERP7<.<ZY)E7>W/K=:?>=4:UJ<:<4=-1\N@R+Q
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M((2T              :?+?ZJWS]7R_Q"P@03NX?4GB/Y.]\*> 6F
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M:3,G<)9[P^0O=X9MX\9*&S\ASEIDN6KJB0CK-),$=5&>JI&6G7JKQTBS7Y_
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MI]M^ZSI]Y;:/4B+.=;[/K+D-33#;*5T_=D9 )B2221)25"+@1%S  A
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M$Q#QZ>MMC1,*3I>D?;ITD:2K^YXCK\#'A];YW_=<V_.8F<QXQB/8MH=%X\
M                               <^S/\Y%M_L4[\,4"700(
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M^ZPVM]O^+<4DC6FG'@9E4A.48>PA+X:9:82:&6TMH,S4:4$22J?*="\(#[
M'D_&CRD$W)90\V1ZB2XDED1\E:&1^$3$X1,9>A$22)*2(DD5"(N!$1"$OEUE
ME]'5OMI<;,R,T+(E%4N)<# ?1D2B-*B(TF5#(^)&1@/-B-'BH-N,RAELSU&E
MM)((SY*T(B\ F9RB(P]%)2M)H61*0HC)23*I&1\I&0A+X989CMDU';2TT7(A
M"22DJ^(@R8>@
M       (5)+[^[^_5^V \@'[3@ _    1;<TO_Q;9C^H[G\$=!,.<MD_JKQG
M\F/\:L<3D?U'U7Y+_L]?NG]\I^-=V42V*_S&[I_JRT?B&AW-'].'ROY[_O;_
M /+_ .F'4@O<. $OTRH _  !^D0 8 9 /P!^TX /P!*;)_1Z/WROVP&Q
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M1)985)>9:6XW&09$MQ2$F9(29\*J,J$ Y4P?+\AS+O91;AD>(SL.ELXF^PW
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M/5#):T&YUI(-HNDVHM)KU<.061KMX^6.BN=E?+QSU2 5K
M         &&U=K6_<I%G9F,N7:(VAZ5"0XE3S3;U="EH(ZI)5#TUY1EXSC/H
MQ\HSCU9@Q9   C]CS;&,DO=]QVRSNTWC&G&F;W&ZIYOJ')!+-LM;B$H77JU?
MQ:E<G$66UVK$3,=)[*Z[*VF8B>L=T@%:P
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M5$MQB0RK2M!J30CYE).A529'0N0:F_3.J_C+:T[HVU\H3(4+P
M                $.D%]_<_?*_; >= "@!0 H 4 17<XO\ \6N9?J.Y_ W0
M3#F[9/ZJ\9_)3_&K'#Y']1]6^3?[/7[I_?*?BAV$5V(_S&[I_JRS_B6QV]']
M.'RSY[_O;_\ +_Z8=2D0V'#?M "@!0 H 4 * % "@!0 H DMF_X%'HJ_; ;
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M;\*##ML9N% 81'BM%1MILB2DB] ATHB(C$/%WO-IS:<S+($L0
M                           <^S/\Y%M_L4[\,4"700(
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M                   !I\M_JK?/U?+_ !"P@03NX?4GB/Y.]\*> 6F
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M0W$DI(J$1$EFA$0VN?\ U(]T-7@?TY]\K_'.=$
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M5AXCE<S;R;S?9:;3^G9NA8U
M    !S[,_P Y%M_L4[\,4"700(      !ILKR&/BN.S\@DIZQJ$V2R;(Z:UK
M42$)KXU*(@%2VR)O;F4!.3QKXS:(TM/7P+=0DDIM7%/V"J$9<AJ/B"7K:]]U
M6FUNQ<PMSJ\C@RNQR6XQ)22D\?OAD? C*AE0N7TP$QS#*LQMTW'?DK8EW.W7
M(R5.=-"U&VA1HHE1IX-=$S/6OAZ@#[O=IS^1G=KN%IN26<2:2GML0U$53(SU
MU13I&KA0^8!ZL[=M-;@KSTKI(4XMLT>;S+[W53?5\5:N*2+B2=/ P&UM6%8Y
M9KY/R.WQ":NUR-1R7M1F57%:UFDCX%J5Q,$-S'A0XAN'$CM,&\K6Z;2$H-:C
MYU:2*I^B ]P   >$R9%M\5Z=.>1'B1T&X\\X9)0E"2J9F9@.<,JRK(MY;^G%
M,2;<:QYI1*<6=4I6E)T-Y\RY$D9]%)_M\A*\,)PBSX-:4VVVI)Q]?2ES5)(G
M7ETY3Y:$7,FO $),                     T^6_P!5;Y^KY?XA80()W</J
M3Q'\G>^%/ +3             8MPMMNN\1<"[0V)\%W^,C2FT/-*]%"R,C]0
M!BV?&<;QXG"L%G@VHGOXXH,9F-KIR:NJ2FOI@,N;;X%R;0S<8K,MIM9.H;D-
MI=2EQ-:*(ED9$95X& _94"#.-DYL5F2<=PGHYO-I<ZMU/(M&HCTJ+F,N(#]D
M0H<M3*Y<=I]<99/1U.H2LVW4\BT&HCTJ+PD \)UDLUT?C2KG;HLR3"7UD-Z2
MRV\XRO[9M2TF:3\:0'C=\;QW(2:*_P!HA74F#,V"G1FI.@SY33UJ54](!E/6
MVW28B8$B(R]!02"1%<;0MHB;IHH@R,BTT*G#@ ^YD*'<8RX=PCM2HCE.LCOH
M2ZVK29**J5$9'0R(P'LE*4I)*2(DD5"(N!$1 / X,$YI7(XS1W%+?4)EFVGK
MB:KJT$NFK34ZTK0![J2E:5(6DE(41DI)E4C(^4C(!BQ+7;($54&#"8BPEZM<
M9AI#;1ZRHJJ$D1'7GX ,2TXOC-@==>L5E@VMY\J/.0HK,92RK7I&TE)GQ\(#
M*N=HM5[BG!O,&/<8*C)2HTQI$AHU%R&:'"45>/@ ?5NMMNM$1NWVF&Q @-5Z
MJ+%;0PRBIU/2A!$DO2(!@R<4Q:9=$7N78[?(O39I-NXNQ&5RDFCUM'5(-94Y
MN("%;R81?<V^C_S$AI?R=S.SY#<NM<)ND"!UW6FBOKE%K*B><$PG5NQS'K/*
MD3K3:(4";+,SER8L9IAUXS/4?6+0DC54^/$P0];G9+->VVV;S;HMQ:963C3<
MQEN0E"RXDI).)41&5.4@'S=[#8[^PF+?;9$ND9!ZD,SF&Y+9*\))=2HB,!DP
MX4.W1FX5OCM1(;):68["$M-(36M$I21$1>@ 0X4.W1D0[?':BQ&Z]7'80EIM
M.HS4=$I(B*IF9@/<  4ILU]9^\OZXA?B70%U@   B$K;FR2]R86Z+DB6600+
M8=F9C)6V4,XZG''34I!MFO75U7$G"+DX"Z-TQK\/3.5,Z8G9Y^N,&*[<V3$<
MHRS++;(ENW',7H\BYM2%MJ8;7$)TD$R2&T*21]:JNM2N8+[IO6M9_E*:8I:U
MH_F+CMS9+GN):-S'Y$M-^LL)VW18Z%ME$4T_UFHUI-LUFHNM.E'"+DX!&Z8I
M-/22=,3>+^L)>*5R(8_MS9,;S/)\Y@R);EVROLWG%EY;:HS?9$:$=2E+:5%4
MCZ6I:O2%U]TVI%9[54TTQ6\VCO9X[C;68ENA;XT/)&GFI=O<Z^V7:"YV>?$=
MX54R[15*T(S)2334B.E2(3IWVU3T1NT5VQU1&U]W7'TWVW7_ #')+]FTFSJ)
MRUQ<@F%)B,N%0R7U1(+4JI$?%5#IQ(Q=;EVQ,5B*Y]BFO$KF)M,VQ[4DW(V@
MQC<Q=OGW)Z9:LBM!FJU7^T/=EGL:N.DEZ5537C2E2^Q,JF*M/(MKS$=8GTE;
MNT5V8F>DQZPTV.;"6*U9-#S#)<@O>97ZV&9VAR_RRD,PU']FTTE*2)?/4ZE6
MAD6HJBR_*F:^,1%8GV*Z<6(MY3,VF/:K'(L#M&X7>HO]GNK\N$Y%Q5B?;KE;
M7U19D28S)C(0\RXFM%$E:BXD9<1M4VSKX\3'^)JWU1LY$Q/^%:V';&X]C&2E
MFEVNUURW+FD&S#NM_D]J7%;41I,F$DE*4U(S*O$^)TI4ZZFSDVM7QB(K'T-O
M7QJUMY3,VGZ67N'LSBVX=PA7]^3.L66VU/5P<BLK_9)S;?$R0:Z*)2>D?-4J
MG0RJ8QU<BVN,=)B?266WCUV3GK$QZPPL/V)QK&,F+-;O=;KEV7MH-J)=<@DE
M+7&;.I48224DG@9\>-*G2E3&6SDVM7QB(K'T,=?&K6WE,S:?I2/Z.;)])/TH
M]HE_*#S9YF[-K;['V?K.MU:.KUZZ\_64\0J^-/P_#TSE;\&/B>?KC!FNW-DS
MNX8Q<KO(ELOXI<V;S;DQ%MH0Y(86E:4O$XVX9H,T%4DFD_&&O=-(F(_FC!LT
MQ>8F?Y9RTNX&RN-Y[>H65)GW''<PMZ.ICWZQR"BRC:X]!PS2HE$1&HN8Z'2M
M. LU<BU(\<1,>R5>WCUO/EF8GVP\<+V/Q_%,D^6ESN]VRS+D-J8BW:_RNU+C
M-+(TJ2PDDI)%2,R,^)\3I2IB=G)M:OC$16/H-?&K6WE,S:?I?>=;(8QFM_8S
M"-/N6,YFP@FO/UAD%$DNMI+22'JI42R)/1YCI0C/25!&KDVI7QQ$Q[)-O&K>
MWEF8GVP8)LCC.%9!(S"1<+EDV92$&R=]OT@I<AII7 T,T2DD$9='G.G C))F
M0;>3:]?'$1'L@U<:M+>69F?;*S!JMI5MRV*QV9N4WNA O%WL]Z6_&D7.';Y*
M6H4TX>@D)>0;9F:5$@DN)U447@,ZC;CDVC7X3$3#4GC5G9YQ,Q+]S/8O&LJR
M3Y:6NZ73$\P6@FI5XL$GLCLEM)$DDOI-*B5P21<U:%6M U\FU:^,Q%H^DV<:
MMK>43-9^AE[?;,8MM_=)N1M29U^R^Y))$W(KV_VN<I'#H)5I224G0N0JF1$1
MF9$0QV\BVR,=(B/2&6KCUUSGK,SZRL8:S91#%=N;)B.499EEMD2W;CF+T>1<
MVI"VU,-KB$Z2"9)#:%)(^M576I7,+K[IO6M9_E4TTQ2UK1_,;:;<V3:S%V\3
MQ^1+DVYMYV0EV>MMQ_6^9&HC-IMI-.'#HANW3MMY2:=,:J^,&%;<V3!+AD]R
MM$B6\_E=S>O-Q3+6VM#<A]:EJ2R3;;9D@C6="4:C\8;-TWB(G^6,&O3%)F8_
MFG):-N;)9<_R+<:+(EKO>3,QH\^.ZMLXB$0VFVD&TE+:5D9DV6K4M7'P!;=,
MTBGI!73$7F_K)MYMS9-M+?=+;8I$N0Q=[G(O,E4U;;BTR)2&T+2@VFVR)!$V
M5",C/EXAMW3LF)GTC!JTQKB8CUG)BNW-DQ'*,LRRVR);MQS%Z/(N;4A;:F&U
MQ"=)!,DAM"DD?6JKK4KF"^Z;UK6?Y2FF*6M:/YB+MS9(FY,W=%N1+/()]L*S
M/1E+;.&4=+C;I*2@FR7KJTGB;AER\ G=,Z_#TSDC3$;//UQA"LA[N>-W7*;A
MEN/Y%?\ #[G>5&N])Q^=V1N6M2M2EJ+2HR4HS,SXZ:\=-:UOIR[16*S$6QVS
M"B_$K-IM$S7/?#;X+L3A&W65O9?C:IJ+C(MRK5(:D/I?:=)QYN0Y(6I3?6J>
M6MLC4I3E.8DD5*8;>3?97QGVY9ZN-37;RCV8;["MN;)@EPR>Y6B1+>?RNYO7
MFXIEK;6AN0^M2U)9)MMLR01K.A*-1^,5[-TWB(G^6,+->F*3,Q_-.3Z.;)])
M/TH]HE_*#S9YF[-K;['V?K.MU:.KUZZ\_64\0?&GX?AZ9R?!CXGGZXPC67;#
MXWD>3.9I9;O=L0RN0DD3KEC\GLIRDE0OOR#2HE'P+B5*\]1;KY5JU\9B+1]*
MK9QJVMY1,UGZ&QV[V;Q7;F9/O<1Z;>LKNA4N617E_M<]U/ S1KTI)*3,BX$5
M3H6HSH0QV\BVR(CM$>D,M7'KKF9[S/K+39#W?[!<LIG9EC.07O#+[=3U7==@
ME%'9EK/B:W6U(41J,^D9D=#.ITU'49TY5HKXVB+1'M87XM9MY5F:S/L2#;G:
M7&=M3N$RVO3;KD%W4E5VO]W?.7<)&CUJ5.&22))5Y"+C]D9T(5[M]MF,](CT
MA9IT5UYQUF?64-E=V3%TWFX7+&\FR/%K?=WCD72S62X'%AO+49FKHZ#,B.I]
M$S,B+@FA"^.9;$1,1;'K,*9X=<S,3-<^D2E>WFR^&;7WB\W?$BDL%>FHK#T%
MUQ#D=I,-)I2;70)S4JIJ6IQQ9J5Q%.WD7VQ$6]%NKCTU3,U]7/\ W>]H8&88
M?<LFM^0WK%<B*\SX,B?8I9QCD14=6M#;R#)25:5+4:3*AEZE.CR^1-+168BT
M8CNYW%T1>LVB9K.9[.D-NMK\5VQMTF%CS;STR>YU]UNTYSM$Z8\5:+><,BK2
MIT))$GB9TJ9F?,W;K;)S+IZM-=<8ASEL1M- S6UY;DL._7C%\EC95=8!W2QR
MSC+>ADW'<)EU)DI*DI6M2D\".I^@.GRM\TFL8BT>,=W-XNB+Q:<S$^4]G1.W
M.U>+;91)C=C*1+NES63UVO5Q=.3/EN)K0W7#(N!:CH22(N)GRF9CF;M]MD]>
MT>CI:=%=<=.\^K(P/;FR;>>?O,LB6_\ *&YOWF;VQ;:]$B334EOJVVZ(*G E
M:C\8C;NG9C/I&$ZM,:\X]9RU>XFS>*[C3(%[EO3;+E=K*EMR*S/]DGM)XF2-
M>E1*21F? RJ53TF53&>KD6UQ,=XGTEAMX]=DQ/:8]8:S%-AL<Q_*&LVOEXN^
M895%1U<"?D$DI114\>+*"0DDGQ.AG6E:E0QE?E6M7QB(K'T,:<6M;>4S-I^E
ME9YLECF;Y!&S"/<KGC.8Q6R83?+%(*+(<:+D0[5*B41%5/,=.!U(B(1JY-J5
M\<1,>R4[>-6]O+,Q/M@P?9/'L.R%W,9MTNF4YBXT<=N]7Z3VIYAA7 T,$24I
M01EPYSI4B,B,R#9R;7KXQ$5CV0:^-6EO*9FT^V6LO?=[L,K);CE>*9'?,+NE
MX4;EW18)91X\ETS,S<6V:%=(S,U'0Z5,SI4S,9UY=HK%;1%HCVL+<6)M-JS-
M9GV)/MSM3C&V;,Y5G7+N%YNRR=N]\NCQRI\M::Z>L<HDJ%J.A$DO'4^(JW;[
M;,9[1Z0NTZ*Z\X[SZR\\+VBQ'"L$?VYCI?NV,RE/G):NJFWEN)E>O2HVFVDT
M\%$U+PALWVO?S[3]"->BM*>'>/I08^Z]CZ(CE@B9GE47"7E&;F+M7(NP]6HS
M4;1$ILSZLS/BDZF?AKQ&Q^=MG/C7R]N%'Y*N,>5O'V96).VQQ.3MX_MA"CKM
M6*OQ3A$W!-*'D-FK4I25NI<(UJ5TE*62C,S,SXC6C=:+^<]9;$Z:S3PCI#?8
MY8XF,8]:<:@+<<@V:%'MT5Q\TJ=4U$:2R@UFE*2-1DDM5$D5>8A7>TVM,SZK
M:5BM8B/1H]N-N;)MA8Y%@L$B7)AR9KUQ<7.6VXZ3L@DDHB-IMHM):"IT:^,9
M[MT[9S*O3IC7&(2\4K@                           $3>+[\Y^^5^V"7
MQ3B 4X@/V@#\,@"E>4!%-T"(MM,S_45S^!N@F'+^QSNG;3'&CY#C</PBQPN1
M/^I+ZW\GK_\ !US]$_OE9%15XNDC&P=#[QVZ9EQ+S9:/Q+8[.C^G#Y;\]C_Y
MM_\ E_\ 3#JHB/TALRX4&DA"7[02% 'Y0 (@'[0 H _*<0"G$!^T ;^T?\$G
M]\K]L$,\            !1W>]^H+)OY2!\.9$"XK'_0EM_)6/Q:1(@C.*8VC
M=5]M-KC$VBS,34HZLJ%)5->(W"+[:A%Q!*R@0     (3N7E=DL>.W&V3Y%+A
M<X4B/$C((U+-3K2D$HZ<$IJ?*8UM^VM*S$SWAU_EG W\G;'PZYBLQF?2$?9W
MEQ.UXQ"[.IV7<VF4,'!)"D*2MM!$9J49:=-2YC,4?G-=:1ZRZD?VYS-F^:S7
MQC.?*>R(=7N/NZ]J<+S?CAJ\;<8DUY"+USJBY?)P&M_J\CZ*NSGY?\H[?ZN[
M]WV1^]:&([7XUBG5R6VCFW5)%JF2")1DKG-M/(GQ<_C&_JXU-?;N\K\P^<<C
MF3B\XK_ACM_Q34;3B@                                        #E
M/>O?/=2Q9YF-CV\<MT6T[<66'?;ZBX,&^Y..8M%&6U$9:")"ZZ@2NM>\V VK
M$L;RS+;S&Q^+DT-F;!1,6::FZTEU2",B.NG5Q!"D[=N3A&4]Z^'D&,WAF\6A
MC$'(STF%5TDO=K,])E2M:&1@E8.1W_)-Q<S5@V*7!=HL\-A,FY3"2:'5D9).
MG#I4Z:4DFI5/E :V\Q,OV6?@7MF]O7O&I#Q,W"%(KJX\>B2C41&9$=%$9<>7
M@ D,S?['3L?;K3#D/795";@/IT$1FK2=5I-14(N/ :\\BD6\9GJZM/E7)OH^
M/6N:?\<=NZ=?+>P_;/?@5^0;#E-)DNZ6/6J&MDG9#4R2TZF(\3!J)#I)HE1D
MHRY#,C%&W?77CR]74X/RO?S/+X49\<9ZQ'?_ ,%76#<=98A>+#E=\FR;E/-:
M8<Z.WUBV4*+CTUJ;49&?-S%R"C\[J=3_ +8YW^&/_JACJRO&3VREX-*F7&=/
M>,W69KC*$H2XEQ+J$\7E*TU3QY0_.ZT_]L<[_#'_ -4,W%=]W;!CL:R7.SNR
MYEO91&BOLK)+:T-)THUU*I4(B*I"^N^EHSF'(W?*^5JOX6UVS]$9?&V>2XLQ
M.OF09HZUYVN\@G$15,&ZVVA)Z]53(RK4Z%X*>,5QRM7M;=OD7.K$3\.>JV3W
M5P="2,[B1)IPHA7(+8W4GM,-"_R[DT_%KM^J6.O>3;U!T5=2(_Y-9_Z!;$Y:
M4UF.DL=S>_;EOEN:U?O67#_T"488ZM^MN4\DR0KT(SG^DB!#'=[P>W[?K#FN
M_O(Y%_MK2 Q%=XW!DG0H-T5XR9C_ .F00#'?[R6)I_X:U7%P_P#UA,-_[+JP
M$>R/O%N3K3)AV"V.V^X/))#,YQU"^K(S+49()/+2M./ !2TF]WF<3J9<^0^F
M0=7TN.K42SK7B1G0^()RZDP"1AF(8]%B0&WD2GVT.S7U-+4XXZHJG4Z<A5H1
M%P 2KY;V'[9[\"OR 'RWL/VSWX%?D /EO8?MGOP*_( ?+>P_;/?@5^0 ^6]A
M^V>_ K\@!\M[#]L]^!7Y #Y;V'[9[\"OR 'RWL/VSWX%?D /EO8?MGOP*_(
M?+>P_;/?@5^0 ^6]A^V>_ K\@!\M[#]L]^!7Y #Y;V'[9[\"OR 'RWL/VSWX
M%?D /EO8?MWOP*_( D#+S<AEM]E6MEU)+;47.E15(_4!#[ :?+?ZJWS]7R_Q
M"P@03NX?4GB/Y.]\*> 6F
M       *4V:^L_>7]<0OQ+H"ZP               8:;3:D7)=Y1!CIO#K79
MW+@32"DJ9(R/JS=(M1IJDCTUIP&7E.,>C'QC.?5F#%D
M                       P[;:;59V%1;1!CV^,M:G5LQ&D,-FXNFI1I;(B
M-1TXF,IM,]Y8Q6([,P8LF';K3:K0VZS:8,> T^ZJ0^W%:0PE;RR(E.*)!$1J
M,B*JCX\!E-IGNQBL1V9@Q9
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MFM"")/*9$EESA3CTE$"4[PO-[-G%M.X6I2D.-*T2HCM">:7S$HBYCYC!"2@
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MZXA?B70%U@
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MN(!\G<X_2*/SZ5[B ?)W./TBC\^E>X@'R=SC](H_/I7N(!\G<X_2*/SZ5[B
M?)W./TBC\^E>X@'R=SC](H_/I7N("3V")=84$V;O(*1)UFI)I6IPDH,BH6M:
M4J5QJ?$A*&U             <^S/\Y%M_L4[\,4"700(
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MBY3 6\
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M9*X<]0%MXS?HN3V&!?H9&EF:T3F@^5"RX+2?[U1&0(;8
M    !S[,_P Y%M_L4[\,4"700(
M
M
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MC_H2V_DK'XM(D0)G(25N4[<O-5R*$[;6K4ETXBR3VA$MUPS/]Q11=($K,!
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MFX2? 2J5(@%1[N8$I,B)GF+V\G;Y!DHD7)I&I2I#;>DTJT5,JI--#TE4R/Q
MEK<@WOM^36!_'L>M,UW([FTJ+V9;:30V:RTK.J5&:J%6G1+QT 67MQCDG%<-
MMEGFF7;FT&Y)21U)+CIFLTE^]KI!"5                     .?9G^<BV_
MV*=^&*!+H($
M
M
M                                      T#B?OBO1!+YTD :2 -) &D
M@#20!I( TD :2 ?BVD.(4VXDE(41I4E1$9&1\#(R,!QCAG=E5:N\G.[1%,\
ML)HR&VJ4FK3G:%J[)&J94/JG4+J7.EKCZX$Y=GZ2!!I( TD :2 -) &D@#20
M!I( TD :2 ;:W%2/3]T8(98            #E?OD;HV"'@M[VT=AW)5]F%;W
MVI;<-Q5N)/:FG**D%T2.B?5$)=,V/^A+;^2L?BTB4,\
M       !"\OVNQ+,M;UPBG&N2O\ ^/BT;>KS&JI&2O\ 6(!4,G!=TMJWUW'$
MI2KE9T'K=;9+41I_]9'4=3\9HJ"4NQ'?^RW%:8.6L>9Y_K52$DM48U\E#+BM
M'IU+PF MV),B3XZ)<)]$B,X54.M*):#+Q&0(>X   /RA5,Z<3Y3 ?H
M              #PFQBFPY$,W%LE(:6R;S1Z7$=8DTZDGS**M2,!RKA& M[>
M=[*+:6[[=;^3^)/R>U7N3VM]!JE&G0A6E-$%2M/"(2ZQ$H
M
M
M
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MZQB!E             *.[WOU!9-_*0/AS("XK'_0EM_)6/Q:0&>
M                  "&9=M?B.8H4Y.AIC7$RZ,^*26WJ_NJ%1?^L J*7@6Z
M.U\A<[#ISMTM)'K6RPE2M1%[9&,U$9EX4U!*4XGW@;1--,#+HJK3.3T5RD:E
ML*5X3334C]D$+>@W"#<XR)ENDM2XKA50\PM+B#(_ :3,@&2
M            Y]F?YR+;_8IWX8H$N@@0
M
M
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M1-B(=63:)<AIM+%3.A&HT.J41'^]]&@(6FE25I)23(TJ*I&7$C(P'Z
M               Y]F?YR+;_ &*=^&*!+H($
M
M
M
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MGE$VAE"#-53\)4X4YP0[DLD1Z!9K= DK-V1%BL,/.'RJ6VVE*C],R 9P
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M
M
M
M                    %5[(?57C?\B]\(=&%N[9I^%8(Q9@       *@[S7
MU173\HA_"$#1YO\ 3^MZG^U__P#(4]UO_3*C+9D7T7Q\]L76$TWD>-V^X6SF
MK)FLM-JT%]L7:G5?^S'*UV^'6U?\58_;_P )E[+9QOS\Z-G?X>VU;>ZLS/\
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M!DV]SO=]OB^=$8-YMZYOMG4-7$GNHU%KT:I!EJTUI7G 7J"
M
M
M                            !5>R'U5XW_(O?"'1A;NV:?A6",68
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MJ3L)C:5$:3ZR?P/@?_&O E>((
M
M
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M68/G!"$=K\\QWM&AQ+E='5(KZVGKA,5PQMLS&,+KC^M5^^_T$#![
M              ",[B9C'V^P:_YK*9[0S8X3LPV"/3UBFRZ*:T.E3H0"G=EM
M],\RO-(V%[D6BW0)=^L$;+,>?M*W324.41+ZEXG355:4J+I)/F,$O??G?_(=
MLK]8,;QO&WY9S[E;HESO\QI96QEFX.*033:R-.M]1),R*O1(C,P'0((
M    '.^^'>&R/;O,L>P_&\9>D,3KI;8%VR&<TM-O0BXNH3U3"B-/6.Z5U.A]
M'G!+H@$         "I>\!N]=-HL.=NM@Q^5?[X^T^N*33:E0XJ8Z4J6_+<*F
MAM.HJ%4M1\"!*!Y-O[N!YNVTL6$VJV2L]SJRNW^2NX&ZB$Q'AQ3D.DA#:M1F
MHR-*:J 6MLKN3]+.W%GS5R(F#.EI<9N$-M1K;:E1UFVX2%'Q-)F6I->8P0L
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M@"U@
M
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MUO-,MH<5X5)21&?JB4,@
M
M
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MTN-GRH61*2=./(8#]-ML])F@CT>LX%P]#P &A&OK-):S*AJIQIZ(#Z
M    'R2$$LW"26LRH:J<3+T0'T          /E2$*,C4DE&DZI,RK0_$ ^5,
M,K<2\MM*GD$9(<-)&I)'RT/E(!Z
M
M
M                 #'2^A!:32Y4N!T;69?[(#Z[4W]JY^"<^Y .U-_:N?@G
M/N0#M3?VKGX)S[D [4W]JY^"<^Y .U-_:N?@G/N0#M3?VKGX)S[D [4W]JY^
M"<^Y .U-_:N?@G/N0#M3?VKGX)S[D [4W]JY^"<^Y .U-_:N?@G/N0#M3?VK
MGX)S[D [4W]JY^"<^Y .U-_:N?@G/N0#M3?VKGX)S[D [4W]JY^"<^Y .U-_
M:N?@G/N0#M3?VKGX)S[D [4W]JY^"<^Y .U-_:N?@G/N0'ZRK42E$1D1GPU$
M:3Y"+D,B,!Z@                            .*^\1.FL=X>X,L276FBV
MPNCA-H6I*=9.2:*H1TJ7A!,+R[LL\T]W7!;E<'EN=7:.ND/N&:UFE"W#,S,Z
MF? @$0R_=F-OG@V06S8C,V[;+LS3DC)YKD5TI";:4=\U-QC6BA.K6E):N%"K
MQ 4)#NMUNG=WV)PAV?*9M&9Y <&_/,O+;>=C(D5ZLW4F2B(S57@?,0@7MW47
MY=IO^[VW+<J1)QK#<E.)CZ)3JY#C$9[K?O76.&:C)/5ERF)%<3-V\BQLM\-^
M8+;4VZVF\P\4LD.7J-AJW1G"0I.E)E0UGTS/[80)<KO);DX'F5UQW=6SVI;/
MR5?S&V%97'E&VTRT\XF.ZIXDU55DT*,BISE42,.R]X+>^//VMEY9:["C&]T)
MI%!."I]4J+&X&:'271.O2I*B4DU%S (EB6[6X-EO$"9A<.!-NV\V67E45^[J
M=)IJ)"2B/$.K53)"="W#)*3J1B$LPN]/OC!L,_*+I9; JS8GDJ<4R-+*Y!/R
MY!O*;4N,1EI0A)(Y5'4S/D$H3[NZ3Y4W?'?<G7W7&$7ACJ&W%J4E"5)4=$D9
MF1>D!+;W&;(P_O?V2! 6I-KW%QV0JYQ=1F@YUF)Q:'M)\",VDDC@ Z'!
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M()MMY4=Q1-/$A/ M:2YN )6X"
M
M
M
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M6BE="%]6:C2D!T""
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M%F5$NQ82EM$ZGPDLSY1)+HH$
M
M                                                           T
MYSKS4Z0B_9/_ $@@[?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E
M .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?
M>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]Y
M%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J'
MY0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .
MWWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O
M>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%Z
MA^4 [?>O>1>H?E ?G;[U[R+U#\H!V^]>\B]0_*)#M]Z]Y%ZA^4 [?>O>1>H?
ME .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [
M?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]
MY%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J
M'Y0#M]Z]Y%ZA^4 [?>O>1>H?E .WWKWD7J'Y0#M]Z]Y%ZA^4 [?>O>1>H?E
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M/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_*
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M .WWKWD7J'Y0#M]Z]Y%ZA^4!^]OO7O(O4/RB$';[U[R+U#\H!V^]>\B]0_*
M=OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]
M>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+
MU#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R
M@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =O
MO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\
MB]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#
M\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@'
M;[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7
MO(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]
M0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H
M!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[
MU[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(
MO4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_
M* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V
M^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[
MR+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4
M/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_*
M=OO7O(O4/R@';[U[R+U#\H!V^]>\B]0_* =OO7O(O4/R@';[U[R+U#\H!V^]
M>\B]0_* =OO7O(O4/R@-E%<?<82N0WU3QUU(+FX\ 2]@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!Y\MWMA^Q5Y #SY;O;#]BKR 'GRW>V'[%7D //EN]L/V*O( >?+=[8?L5>0
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M^XEIM9FM9T26DRX@,X
M
M
M                                              !$+O\ TB_Z)?[)
M"4,(
M                                            !EVO^D(_[\!,1"0
M
M
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M-9A= ,0                !$+O_ $B_Z)?[)"4,(
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M(A(
M
M                                            JO9#ZJ\;_D7OA#HP
MMW;-/PK!&+,                       !7V]_U5Y)_(L_"&AE7NPO^%:@S
M:P                 B%W_I%_T2_P!DA*&$
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M9^1)R)12K79W"2AJ'#4:EH,DDDC(W"45",^""3SF8(E;X
M                 #+M?](1_P!^ F(A(
M
M
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M+5RM48_EO'_FCU^O^"UQOO-   K[>_ZJ\D_D6?A#0RKW87_"M09M8
M          1"[_TB_P"B7^R0E#"
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MFO0DR&&T)3',BJ1H)U!]82OM#+Q@CT=9D1$5"X$7(0(?H
M                 #+M?](1_P!^ F(A(
M
M
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MJ\D_D6?A#0RKW87_  K4&;6                 $0N_](O^B7^R0E#"
M                                     1_$<,LF$P9D"QH<2U<)K]SF
M./+-UQR7*,C<6:C\.D@$@                      $'V_VJQK;>9D,^Q.R
MWY62R^W7!R:XAU1+)3BDH0:&T'H2;JZ:M1\>4!.
M             !EVO^D(_P"_ 3$0D
M
M
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M
M
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M>4^U@W?9^_7^W/VB\Y]<Y=LE$29$=4:(DEI2HE$54H(RXD0(FTRM<$
M
M
M
M
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M=I,HN#UPAW5D\FPB?,6IQ[LCJC3*@&XKUW4+2I315-75\I\@)7("
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M/)L(GS%J<>[(ZHTRH!N*]=U"TJ4T535U?*?( N0$
M
M
M                                                   I2P=WQ%CW
MVNV]?RGE23N2'DILBV=.A4AM+9I6_P!:>MI!)JVWU14Z/'H\2<KK!
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MHX/XE($JT[R3R;#N7L?E["NJF1\B.UO+2725$N*F&W2,RY:(UD1?NC ATB"
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M#;I&9<M$:R(OW1@0Z1!
M
M
M                              */QW8>]V3?V];Q.Y:])M=T;<0FRFA9
M+,G6R0EEQ>O2;3)EJ;+3S)Y*5,G*\ 0
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M\"G&5(_UBY@2Z+!
M
M
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MXX:C41F('01WJS$=#N,8C+E+KF_NA*&8VXV\A+K2TN-J*J5I,E),O$9 /H
M             %=X#MU-V^RG*UVF4TK!,CD%>(EJ/63T&Z.\)1-E0T&R[1*R
MXD:5<"*G$!8@      KS ]NI=BRS*]P,FD,SLNR9\FFUQS6;,.T1J)C1&S62
M3,R(M;JM):E>@)%AB                       &!>KU:<=M<J]7R8U M4)
M!NRI<A9-MH07.9F T.W&X^-;J8PUEV)K><LSSSL=M<AOJEJ4PK2HR34^!\Q@
M(?)[RVU$//E;=2+A(1>$3$VM<[LRSMI7!7)&.3ZWK/$"<+/.]6<C41W",1HD
M%!477(X2U4(F3X_QAU*B.4$(C,W@P6)N1;MJ.WG(S.XM.OIB1R)U#"64&X9/
MJ)704:2JE-*@(]$[RVT\W.7,!;N3[=S1(?@IN#L=;=L7,BH-QUA$D^B;B4ER
M G#1;-[]R-UMSLSL4<H[6(6N-%?QE52*5+;4Z\TZ^HM1GI5U9*2FE2295Y0%
M] @                   !7> [=3=OLIRM=IE-*P3(Y!7B):CUD]!NCO"43
M94-!LNT2LN)&E7 BIQ 6(      *\P/;J78LLRO<#)I#,[+LF?)IM<<UFS#M
M$:B8T1LUDDS,B+6ZK26I7H"188@
M
M
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M*M#*@)69W<UK<V-P1;BC4M5J9,U*.IGR\Y@+/!
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MQ;=TH6IL]22?41<4GSB1O>V]Z_\ 1V#^RN7NP@.V]Z_]'8/[*Y>[ ';>]?\
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MOI94IY#BE5-]UPU4TE2A) 6N
M
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M\2E$CPJ0ZNG@!*T&G6GVD/LK)QEQ)+;<2=4J2HJD9&7*1D"'V
M    " [X_4QN#_9VZ_ W &L[N/U%X'^J6?\ 2"5H@@
M               4=EV10V=SK4VNQ07G(G;6EDN5#3VDWNJ)"W=1]!2=/1)S
MCX!#)=[9ZFTJH15(CH1U(JEX2$L7T             ^>J;TZ="=)'4DT*E0#
MJV]?6Z$];2FNA:J>"H#Z ?AI2:B49%J+D53B0#\ZMLEF[H3UAE0UT+53P5 ?
M0"LN\1]1^>?JB1^T0#<[0_55A/ZCMWP9L!-
M                     !I\M_JK?/U?+_$+"!!.[A]2>(_D[WPIX!:8
M                                          I39KZS]Y?UQ"_$N@+K
M
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MA1$I*DF5#(R/E*@#9[/2GW<*:@/JU^9I<RSLK,S,S9M[ZV6ZUKR)21 )Z
M            " [X_4QN#_9VZ_ W &L[N/U%X'^J6?\ 2"5H@@
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M+"!!.[A]2>(_D[WPIX!:8
M       I39KZS]Y?UQ"_$N@+K
M
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MUYQ7 DH06I1GZ!$ WFTEN>@8+;Y$DC3*NZGKP\E7*2KBXJ01'X]*R 3<
M           $!WQ^IC<'^SMU^!N -9W<?J+P/]4L_P"D$K1!
M  _%*2A)J69)27*9\"(!I9^8XI:TZI]YAL$1T/4^@SKZ!&9@(O<-[]N(!*TW
M54QU/_916'EF?H*4E*#]D BEP[R5B:-2;;:),CAT%O+0T5?&1:OVP2TQ[Z[@
M71246'&6>GZW4U)DF?H:%-D J7,Y&2S,@DSLM8=C7J2277&GFS9,D:22C2@^
M1-"X AO-O,2SC*$34XK,7!B-&@I;O7K80I9UTET.4R($IXK8+-9]/.>2MN$?
MKDN+?>/^%P 9D?NT-4(Y60J(^=+48C+U5.%^T VS?=TPIAHWIMVN"DMD9N.$
MY':;(BY3.K2J%_K A[_0_M' M2[S)><>M;*=3DU<LU-D1<.5JA>H0)?4O'=D
M;%C",J<@-3+*M24,/H-UY;CBC,B21:BX\#KJI2@#TOMRVOQ'&;9D\/&HT^WW
M12$Q=,=!JHI)JJKKDF9&5.3P@-CE69JPV)8GL:QGM4:\&E2DL-]3U:5$E1)H
MVGUYZN?@ T6_5QS)%K.TVFWFYC$F.3MTN#:%+6A3;NK0HTG1":)36I<:T 2;
M"[K@R-O(2&I$1NTHA)3<&G%((^LZLNN)Q)\349UKPX\P(1;N^I,T90]!2M-A
M<F([#JKIU$2]5/'I-%?2!*Z00                    Y\[UV5YI:-O<@LE
MDPR1>\=N-GD>=,@:E1V6X'&G2:<42U\"U=$@2L_:"I[4X34J'YCMW#_[V;!"
M:                                              #3Y;_ %5OGZOE
M_B%A @G=P^I/$?R=[X4\ M,    !X2IT*"@G)TEJ,V9T);RTMI,_149 /MB0
MQ*:2]&=0\RKBEQM1+29>(RJ0#T
M    %*;-?6?O+^N(7XET!=8
M
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MT               " [X_4QN#_9VZ_ W &L[N/U%X'^J6?\ 2"5H@@
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M,ZD"5QVFSVRQ0&K9:(R(D%GUC+94*I\IGSF9\YF"&:
M   K+O$?4?GGZHD?M$ W.T/U583^H[=\&; 30
M                       :?+?ZJWS]7R_Q"P@03NX?4GB/Y.]\*> 6F
M"K=Z]SY&!6F+;;$CK\MO2C:MR-/6=4@C)*G=''4JJB2VGG5QXZ3(P@]D[M\W
M(T>?-S\@G2+Y+3K=CQG$*<:,^))4\\ETCIR:4())<QF0# R3:'+MI&GLQVPO
MLI^'#+KKA;7])N&PWQ4I:4$EMY*2+I$:",BXD NK;3.XFXF*1K^R@F)9&<>X
MQ4G4FI+9%J(OW)D9+3XC+G 2\   %6VC<*_3M_<AVT>3'^3MKL,:[1E);44G
MM#SK:%$I>JAIHHZ%I!+9;WYG=]O=K,CS*PI95=[4RTY%3)0;C)J<D--'J2E2
M3/@L^<"$>R1[O#7IJQ77;.9BL:S3+1$D3V[\F=VCS@Z2ENFV4=M:2:T*;TU.
MM:^(!6F#9OWL<_DY/%LTS"&',4O$K'KB<MJXH2Y+A'I6MGJTN5;/[$U:5?N2
M Z)7N=GF]>,7+:O!\>=Q_P"768MW%J\R9;<I=K*7;F8[IFR:*.I;/6Y2K9GR
M<@#'N^3]Z_ +5)R?)+1B.66*WI.1<8%B<N#%R*,V57%M'(0E!Z4D:C+0M7@(
M#HNC!<SLNX6)6K,L?<-RU79DGFB70EMJ(S0XTLB,R);:TJ0JG.0(2$
M                 %*;-?6?O+^N(7XET!=8
M
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M#W<7@R)=V=1+RB[+*1=YK::(U$5&V6Z\2;:3T4^'B?. EX
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MN_7-F7'-WLB6G&B0PA_3K0@C;.B3))%Q!.4P26E)),S49%34?*?C.@(?H
M                 "LN\1]1^>?JB1^T0#<[0_55A/ZCMWP9L!-
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M0C.E>49;M4Z[36?1&G;&RL6CU2D4K0
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MWA.R5VF0E#+<EI2S53D))*J9B1+-H/JJPG]1V[X,V"$T
M                 8ESNEOLT)VXW22W$A,E5Q]T]*2KP(O&9\Q$)B)GLQM>
M*QFTXB&BL&XF'Y-+5 M%R0Y-*II862FUK(N=!+(M7I<1G;7:O>&MIYFG=.*6
MBTI0*VV         -/EO]5;Y^KY?XA80()W</J3Q'\G>^%/ +3   !4V]^VE
MPS.!!O\ C*NKRZPJ-V'I43:GFR42]"5'2BTJ+4W7A6OA 1?&^\O"@L>:=QK3
M,MN0Q")N2XPR6AQ2>52VEFA;:CX=$B47H<@#69=OA=]Q&W,)VKM$MV3<D&Q)
MGNI)+B65]%>A*5*2VDR.BG'%%0O!R@+>VJP!G;K$F+*:TO7)Y1RKG(3ZU<AP
MB(R37CI01$E/AI7A4!-@   4[NGM%DU_S"S[H;:7YG'MPK/&5;E]N:-Z!/@K
M4:^I?))&I)$:E=(DJ/CS&23(E&+QM)O?NP["LV]&0X_%P*-(:F3;)BC4OK+@
MN.=4-O/3$I4A!GQ/09^A6AI#HA*4H2E"$DE"2(DI(J$1%R$1 A6VTVW%TV_G
M9[*N4N/*1EF3S\AA)CZZM1YJB4EMS6E/3+GTU+Q@EIMYML\\S'+,"S+ +C:X
M%WPM=S<)-Y2^XRXJXML-%1+"3,Z$VNM3+E("&@O.V_>/SR&]CN8Y[9++B\Y'
M47-.-07CF/QUD9.-$Y),C02R/29I5R<QE4C"Z<2Q:S83C=LQ/'F.SV:TL)C1
M6S.JM*>)J6?"JUJ,UK5SJ,S!#<@                       I39KZS]Y?U
MQ"_$N@+K   !Q3W[_P"EL)_)[A_MQQW?EG:WU.'\S[U^M!]D'5;7=XBQVMY9
MM6^^QH\8ZF=%-7R$U*CI(^<B>6TGTO"+^3_JZ)GV?9+7XW^EOB/;]L)=WOI\
MK,]W,0VVMR]2V&V&4I+CIFWB0E%#+]XAH_3%/ CPU6O/Z87<^?/;6D?IE&^Z
MS#8MW>)E6^*1IC1&KJPRDSJ9(:5I21F?+P(6\V<Z,^Y7PHQOQ[UY]XW$=Z-Q
M,DM>%8&\]%PF5!)R^/J<3%A=<IYQ)I>=(NL<+02:LIU>'3SCG\39JUUFUOQ9
MZ-_EZ]NRT5K^''5RY PM.WG>1QK#$RSG^:<CL32YAHZKK%K>BNJ,D550M2SH
M53X#K3L^)HFWMB7)C7\/?%?9,/Z:#RSU(     UZ;Y:%7M>.%,;*^MQDSE0#
M/2\<5:S;)U)'34G41I,T\A\#&7C.,^C'RC./5L!BR '\[=^+(WDW>NF8XZK0
MU>+G8;>M?$J)EPX31GPX\"4/2\6WCQL^R)^UYODU\N3CVS'V+ [C^0/6Z_9?
M@,\S;?6VW<6HZ^&AV(X<>07@J?6-U_>C6^94S%;0V/EM\3:LJJW-6O=+>G<*
MZ:C=MMDBW1]*TGP)BRQ51V5)I]BIY+9_ZPV]/^EJK'MQ^UJ;O]7;:?9G]BZN
MXA_1.;?E%O\ ]B0-'YGWK];>^6=K?4GN ]UFRX5N+](,R^+OT@E2'VX<R(@M
M,N2=>O)SK%=)-5TJCE.M:D-?;S9O3PQAL:N%%+^><JB[\URQM^^XO;(A,KRF
M(Q)<N;C=.M1%>-OL[;IEQXF3BDI5R$=?LN.[\MBV)GT:?S*:YB/5U+LW;[E:
MMJ<-M]W)2;@Q:(B76UEI6V75$:6U%S&A)D@_0'(Y$Q.RTQ[76X\3&NL3[$X%
M"]_,O#LC?V'WKF3\ULJKM,M3\J-+:<TI?2MXZIEL&HM.HRHM!\BDJX&5:CU.
MRGQ]6*SC+RVN_P #;FT9PZBR'>'N^[\XG(PR\WXK&_.-M4==VC]G>BOH42DN
M(>7J82K@:3^_<2,RY#')IQ]^BWE$9]SK7Y&G?7QF<>]+MI=F&MGL>R,\*OBK
MY+OC#<BV=O2CL:9+#3O4J^\K3J0X;B==%E5*2H9<HIW\CXUH\HQA=HX_PJSX
MSG**=W+O$9+NQDE[QC,(-O@7"%%3,@HM[3[!F3;O5/I<)]]XS,C6W0BI3I5\
M5W+XE=58M694\3EVVVFML(SOEWJ\PVYW&GX;BMOM,N!;&HY27I[4EUTY#S27
ME$2F9#2:$E:2IIX'46\;@UV:XM:9ZJN3SK:[S6L1T75N/NLUB.SSVYUI0R^[
M(A1)5G8D:EM..7#J^J)1(4@S(B<U'11<"/B-'3H\]OA/Z8;V[?X:O.$7V4W7
MSC<C;3(\XRJWVV.B(<EJU,0V'VVGBBQ^L<4Z3S[IJ2:E$CHFGUJO2MY.BFO9
M%:S*KC[[[-<VM$(AW:MZ;]N1<\FC2\>L=K<MMO3)CG983L9QUPUF1(<U/.:D
M\.!%07\SCUUQ'69S/JIX?(G9,](C$>CEG.LQW"OF[4?+,FL'FW.VY%O=:L?8
MY4?4[&ZOLZ>SO+4\?6:4\"555>B.MJUTKJ\8G->O5R=NR]MGE,8MTZ.\-M]S
M<GE;97/.MX;46*RK6](.1&.)*@TB,H;4A9,REK<4I:E*2FA](^!<1Y_=IK&R
M*ZY\LN_IW6G7-MD>.%!O=Z[>3.[W*B[38<A^VQ>GU797[C,)K50EOJ:6EM&J
MGK23PY-2N4=#\CJI'^I;['/_ #VV\_Z=?M2_9SO57?(\Q:V]W/M#-FOTEXX4
M66PAV,29J3TE'D,/J6I"UJ+2DR5ZZB=/&HIY'!BM?.DYA=Q^;-K>%XQ*J._#
M];%F_L[&^'31N?+?Z<^_[(:GS+^I'N^V4TOO>/WMEV;Y2;>80MG;RWM$E-ZG
M0WY*WFV.BMXS0M"$MEI/5I)6GC5?@HKQ-43B]OO>Q?;E[9C-*_=]JUN[MO\
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M(4.GAA6G&,?L3CCUHMK$-YW^,<:01*,CXTKRD7B$S:9[L*:ZT_#$0VPA8
M      -/EO\ 56^?J^7^(6$""=W#ZD\1_)WOA3P"TP
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MSI'2G&IJ+#D<G777\.DY]&7'XVRVSXEXQZNS1Q';
M          !_.G8EWM%BNMQ7Q=F7RX/K7SJ-2T\3]4<3ES_J/J']M5_^):?;
M9<G,-9WWZ)'SSEZGI5 8/=;DJM\W?YEDS;['<4RFR2=-*EL2CJ7@/H$.YHG-
M(?(OF5<<F\?2G> -=ELEE8(J)*(TFGHH(Q<YGIA.!*0  9VRII3MY!8(_P#A
MY=T9,O 2+E)H7I)H L                     ! =\?J8W!_L[=?@;@#6=W
M'ZB\#_5+/^D$K1!#PFS8ENBNS9[R(\1A)K=><,DH2DN4S,P$-P#<)K/9U].$
MQU5KMJX[<1Q5>L=ZPG-2U%S$>DJ$ G)^(!KSL=F5="O:K?'.\I3H*X&TCM!)
MIIH3E-7)PY>0!L
M      5EWB/J/SS]42/VB ;G:'ZJL)_4=N^#-@)H
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M"P@03NX?4GB/Y.]\*> 6F
M       *4V:^L_>7]<0OQ+H"ZP
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M%9C3WI2W"ZI25K4UI22>L6@S(S(]5./("%B@
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M$@[;:&2>1_V[Q&^Z9^'4X:OV!I6V6MWEZ;3Q-6F/N5B$G%;:
M        :?+?ZJWS]7R_Q"P@03NX?4GB/Y.]\*> 6F
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M<JGE%I;3Z:S(@%D879"QS$[-9*47"B--N_RNDE.'Z:S,!O0
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M4K,J<:DGAR\@(;L            !67>(^H_//U1(_:(!N=H?JJPG]1V[X,V
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MZ[3Y36)GW-ZE*4)2A"22A)$24D5"(BX$1$0Q7/T
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MQ8:2XD3##;7'P]%)<13,S+I5I6L8B,-@(9
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M2/DY.@TZ)T?=I:Q?K,0F/T-;9_-YG\*_[H*?CW]K+PA&=WX=FP;:F99;!&3
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MO@J6_(=4;T^X/F2I,J0OBIQU1$53YB(N"2X%P!#?
M  " [X_4QN#_ &=NOP-P!K.[C]1>!_JEG_2"5H@@,J\#Y &ELF*V7'9MQF6A
MCLWG13:Y+*3^]$MK5TDIYJZN)<@RFTSW54TTI,S6,>7=NABM
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M(TF1\2,C+E(:;T;Z
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M^Y /,-C_ $9$_ -_<@'F&Q_HR)^ ;^Y /,-C_1D3\ W]R >8;'^C(GX!O[D
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M_JK?/U?+_$+"!!.[A]2>(_D[WPIX!:8
M                 I39KZS]Y?UQ"_$N@+K
M
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M+BMDXTDS6S+BJ.IM26%J:=17G(EI.A\Y -J       "4X_\ \ ?\HK]H@&U
M<D]\>5B%ION"W^^9K=<+OL#MOF:99;?YP>4;R":<X]:UHZ*C3SUJ"5);1W7'
M+!E./6;&MV<S[!,O49]=I5CKD:'*?E24&M+R^T&24NF=%JIP(0/Z1B4
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M0T;4B-<3:=0JI*):6TD9&1\AD? $KE!
M             T^6_P!5;Y^KY?XA80()W</J3Q'\G>^%/ +3
M                                  %*;-?6?O+^N(7XET!=8
M
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M>Y&/NVS<)>'625=(:2P^&=UN;3^M])$P9OI2TDEUT&NO#EH(']21*
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M54/,J):3]3D/Q#4F,/15M%HS$YAEB&0
M /Y/9I$V(BWN4>QDR]S;QURCD,76+;7[5K,SK5=R-*J5K_V9^B(2[*[F[.1M
M8M?59+"QF'+7(CF@\77#4M:2;7QEIA+4A*OM"X<_ 22Z7!          Y][U
MV&Y3>]O<@R"TYI-L=EMEHD><,>CL-.QY_'5]\6L]2>!Z>! E9VT!4VIPDC.O
M_N.W<?\ [V;!":  #7V^RP+7+N$R&WU;MS>*3+IR*=)!(U4\9%Q ;
M                                    :?+?ZJWS]7R_Q"P@03NX?4GB
M/Y.]\*> 6F                                              *4V:
M^L_>7]<0OQ+H"ZP
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M>.YR]N]P+YD&.0L7N^5V>"QC>(I8<TI?E(492I32*F9$5-'6*$)?T$$L0
M    $!WQ^IC<'^SMU^!N -9W<?J+P/\ 5+/^D$K1!          CF48-C67L
M&U>8:5OT,FI;?0?;,^<E%RT\"JD,Z7M6<PUN1QM>^OCLC,*;N.W6X&V\I=XP
MF<N;;R.JVFBJYI+C1QDR-*R\:?V!N1MILZ7CK[7G;?+^3Q)\N-;RK_AG]/X2
MD>([\VV:M-ORV.=MFD9([4@C-@U<AZR/I(.OH^D*[\:8ZQUAM\7YUKV3X;(^
M';Z>WZ>];\:3'F,-RHCJ'XSI$IMUM1*0I)\Y&7 :COQ.7J"0
M               ' E]N?=NR.[RL?V.V7/<?(6EF4J2TW)AP&G#/B:W'EI.E
M>4S))>,0E:'<V9NENNFY]AO.-VK%;C:;E!C2+19",X[2^I=,TFZIQTW#+[;6
M9> 2.JP0         *R[Q'U'YY^J)'[1 -SM#]56$_J.W?!FP$T   !\N+0V
MA2W%$A"2JI9F1$1%X3,!KK+D-ER*.Y*L<UJ<PRLVG5M'4DK(JT.M/" V8
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M<0LB4A:3Y2,O&52,C!"0@             "E-FOK/WE_7$+\2Z NL
M
M                         !H,FQ=C)UVCM4A;3%IN#-TZE*2-+SD>NA"Z
M_8\>(V=&^=7EB/Q1C];F<_@5Y<Z_*<1KO%\>V:]HGZ&FO6W\VXY2]E=LR.5:
M)[T5$$TL,LN$3"%:]-725RJZ0OU\N*Z_AVI%HSGU<[E?)K[>5/(U[K:[36*]
M(K/3OZ_3U;;'<?O=HD//77))5[;<02&V9+3#26U5KJ(VDI,SYN(IW;:7C[M(
MK^MO\+A[M-IG9NMMB8[3%8Q^J$B&JZK1P\98B93<\J4^MV7<(\>(AI1$2&6H
M]3,DF7$]2CU'4;%MTSKC7CI$S/ZW-U<&M.5?D9S-XK7'LB/XSU8-\PZ3.O)9
M#8;P]8[RM@H<MUIIJ0T^PDS4DEMNE36@S/2OTN)"S5R(K3PO7RC.?9AK<OY9
M;9N^-IV3JOCQF8B+1:/3,3ZQZ2\%;>6].(W+%8\M]#EW-;ERNSFER4^\ZHC<
M<69T(S41::<A$,OS=OBQLF(^[VCTA7/R77^4OQZVG.S\5^]K3/>9]_9*8,1J
MWPHT!C@Q%:0PV7[AM))+]@AIVM-IF9]7:U:XUTK2.U8B/U(Y8\$M]DM]^L[;
M[CUFOC\A\X:B))1TRTFAQMLRXZ:<G@&UMY5KVK;'WJQ'7VX<GB?*=>C7MU1,
MS3;-I\?\/ETF(^AH3VH??Q=S$;ADTV39FVC9M['5M-$T1'5LW3;HI[1]BE2B
M3XN!4V?S\1L^)%(BWK^GHYG_ &]:W&GC7W6M2(Q6,1&/9G'6V/9G'T=L6%!C
M'#A1H9K-TX[2&C=,B2:M"23J,DD1%6G(14',M;,S+U.JGA2*YSB(C]3W&*U!
MW"Z:OWROVP'R      (]GO\ 47)_U3/^#.""%&=W#ZE,1_D'_A3PZ.G\+RG.
M_JRM(6-%5>U_^:C<;]06S]I@<[;W>KX7]&'2M!@WG[0  ?E"K4!^@
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MR:4MN%JK4C)7K2YR,$ND2.I$9<A\00_0
M         !I\M_JK?/U?+_$+"!!.[A]2>(_D[WPIX!:8            #B7?
M'&9E]WJW!NUG+_YEP_%[5E-C=(C4I$FTRVGE&1$9&9FUUA$1<] 90N7=_.59
M7LK9F<2=T73=55NLEGH=5-HO!$J2:BX'1M@G4K/AI/E!$-1W8+1!L&1;OV*U
M-DQ;K9DO8H35."&8[1MH+A3D)) 2B67;3X]MMNWLS,A29MWR:]7Z8Y?<BNSZ
MI,Z8MMAK3J4=$I2G4>E*4E0N6O*"77(,0  13-\[MV -VVYY RMK&)4@H=QO
M9'5FWN/4)AR0FG196O[VIVM$*-->"C-(2AEYF2RW(CN)>CO)2XTZVHEH6A95
M2I*BJ1D9'4C(!S+WG<4A9SN=L]B%PH46\HRF&:S*O5K<@1R0X7C0K2LO&0)A
MO]NMUUV?NUR,LOU$W_!84NRW6,Z?2\YVBL9EI9G]D[]YKXU@*^V!PZ3@^_L.
MSW(C\_/[<%<KZXY3K5W*X7=F3(UF7*I*UZ*^!) F5Z.KVU[M^W<E\UJMV-1'
MGI"&7'%29DJ;),U]6V;JM;KKAE0M2N!%Q,DE4B.[0=VC%,@L.)7[(LE@^9[A
MF]^G9.W8::>P1YQIZMI2?L5436G*2=)&1&1D!*Z@0             *4V:^L
M_>7]<0OQ+H"ZP   4IO%WB;;L]D]JQ^XV-ZXLW&,B8[.9?)LF&E/J9.K9MJ-
M5-->4J\@WN/Q)W5F8G#1Y'+C5:(F,KH:=;?:0^RLG&7$DMM:3JE25%4C(RY2
M,AHMY36X?>(M&!;DV7;8K0Y<Y]T.&F1+;D)91&5/?ZI"5(-M1J,DT</B7 R&
M]JXDWUS?.,-';RXILBF,Y27<O=ZR;;OVRT*@3+]EE[-2;1C]K;ZV4\2."EJ^
MU07AXF?&A<#I5IX\[,SG$1ZRMW;XUXC&9GTA&K3W@%1\BMN-[CX;<\'?O2TL
MVF=-4W(@NO+H26U/())(49G2E#I]E06VXOW9FEHMA57E?>B+UFN5T#1;P
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MC.SV&&VS-MN*TET^L<6="+4;*TI)-3KRD1<1=&JTTF_I"F=M8O%/64K%*X
M%?;K;I1]KHMAE/VQ=R*^71FTH2AXF>J4\E2NL,S0NI%IY. V=&CXLSUQB,M;
M?O\ A1'3.9PL$:S9
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M1V7NPW51<8,DR2HU<E$*Y%^+G\0U=FFU.[N<3YAIY,?<GK[)[IP*71
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MJ<QMC$JWR&%769;C;B,E2G6.+,^"/&)%_P"SYUVIPDZ4_P#<=NY?R9L$)H
M #\,B41I454GP,CXD9& YDR6W.[.[DQ[U#CI>QR<:G6V5)+JR0LZ.-<E"4V?
M213FIXP2M_;&\YK>H<^;ES+3<5UQM=G>:T$3K+A*,S+09D:::=)\X$IZ"
M                                  !I\M_JK?/U?+_$+"!!.[A]2>(_
MD[WPIX!:8    "$7G=C"[+(5$7,7,D-GI<3#1UJ4F7-K,TI/TE&-FO&O:,X<
M7?\ .>-JGQF?*?HZ_P#!L,=W!Q7*'2C6R:133*I1'TFTZ=/M25P5_JF8QOIO
M3O"_B_,^/R)Q2W7V3TE)Q0Z8   "CK/CMV5WH<OO4RU2?DU-Q2)";N+L=SL+
MSI/-ZV4NFGJU*TUJ@CK0$^B!;([=YO W-:QS*+=+CX+M,J[HPV?);=2S/5>Y
M!]2XA;B22YU4<UET5*T&HBX 2L#8JQ7NT9GO#*NUME0(MSREV5;7I3#C#<F.
M9*HZRI:2)Q'[I-2 DWGL5[NFZ.S%PMEME38%KO$UZYRHS#CS,5I;+1)6^M"3
M2VDS(R(UF0$+N!"*9/MCMYFD]NZ9;C%NO5Q993&:E3HS;[J6$*4LD$I9&>DE
M+4=/&8#2?0%LI\P;'^8L_<@G**9QW8]N,G8M]GLN-6>P6IR03M]N,**VU<U1
MF2U(8BJZLR0;JZ=8Z:JI01DDCU52,K=QO&['B%CA8WC<)NW6.WH-J'#9KH0D
MU&H^*C,S,U*-2C49F9G4^((5+NQ8KW<=[]DKM;[;*EVJTR+^JZ3H[#CL>*E^
M)'2V;[B$FELEFDR3K,JF7 $J\R?;;,WM\Y>#0;7)5M+F=YMF;7NY(:=5!:>M
MC;JY,1UPDFWJER&FEFDU:O64\)$I\BTWJ%WJ;OEKEIG+QQ&!]F3<FHKJX[DI
M%Q:=..VX2=*GC2DS)LCU'X 1Z*=L.87F_9[)W)WCVMW O-U@2%%AN/PL?<?M
M%JBE0T.T><9-R49E52U(H1E4OL=!+JC ,[^7UME7+Y,W[%^S/]G[)DT'S;)=
MZ"5]8VCK'-2.EIU5Y2,&*6@             "E-FOK/WE_7$+\2Z NL   '+
MV]>*1\Y[P&/8E)-*47;$;I';<452;>-,LVG*?N'"2OTAUN-?PTS;V6C['*Y%
M//=%?;6?M6-W=<N<O^T=L*\+ZJ[8SUMBO).J*K3MLZ!:S/GZGJU*,^>HU>7K
M\=LX[3UCZVSQ-GEJC/>.D_4YCOC3V17'%=W)R5=HSG<%I=N-==2;1;741HB>
M/$J467H$0ZM?NQ;7'\M/VSW<JWWIC9/\U_V0[/=V_P ;>SQG<AUEQ>4QX)VM
ME]3BC:3&4HU42V? CJI72+[8QP_BV\/#TSEW/A5\_/UQA2?>+N;&XV0XML?B
MM)N3KND>[7F0UTDVR''0HC6XHO6KTNZZ<M"(J56FN_Q*_#K.RW;&(^EH\NWQ
M+1KKWSGW.E!RW34#O-GVY]CW3PW"-NWV#=R2'*0<66TVN.EXC/\ WEQ6A3FE
MA!*<TH41'IXD?(?1X^K7;7:U_1SN1MV5V5K3U:[,;QO'L4FWYOD>7)SO"7)3
M47)+>[;X\!^,4@Z=?'4Q7@2N!)-5*F14XZDY:ZZM^:Q7QMZ=6.RVW1BTV\J^
MO1/]T;_N8XYCEAVHB-FYD#BCGY4^SVF';8A)):7-/K34LJFG41IX4I51&6OI
MKKZS?T]/:V-UMG2*>OK[%7;C3-]-C+5&SR7N$UFMD:F,L72S3;7'M^IIY5"-
MM;2G%%QX=%2:5(Z*+@-K3&G?/CX^,^W+5W3NT1Y>7E'LPP>]1 R2X9!MK<X&
M0G$M5QNT-FU6]4)EPX4Y2TJ[8;AJJ[P4C[RKH]'EXC+A36*WB8ZQ'Z0QYL6F
MU)B>DS^DO7?YG-<>G;+,]O;RO.HMXD)CSGXZ(#,N8MR/U/6,L'I;26I*5:5<
MA5J0<7PM&SIXUPGE>=9U]?*V6=N'*[P>S]D+<RX9Q$RFW1'F"OF.*MC4.*AN
M0XEHB9=15PR):DI)705QJ=>)#'5&C;/A%?'V3E.V=VJ/.;>7MC"8Y'N)D=CW
MDV\C]O/Z-\Z@.L-P7&6*MW)*.L;7UA-]:6OK&4:3<IQ,44U5MJMT^]6?V+[[
M;5VUZ_=M'[45WBWMRS#MY<=L%ED]5A-O.W'F?WEAQ-+G)4@B4XXA2T:6B):=
M"DU,^(NX_&K?5,S^+KCZE/(Y-J;8B/P],_6G&YV:9/%W)VZV[P^<<&3?);T^
M_NI99?45IA)U+1]^0X2.M(G")9%4C27'PZ^G76==KVCMV][8W;+1LK2OKW]S
M4SV=^=P\LR"#:;Q]&V&69\HMKEJMK<^9<Z&=7BZ]:2)LZ:B-!IX&1&1G49Q\
M'76)F/.9^GLPGXVRTQ$^$1]'=A[>YCN5C.\<G9S<&],95'D6SSM:+XW&;AR$
MI2HRTNMM43Q)*ZD9J,C(NE0QEMUZ[:OB4CQZXPQU;-E=OP[SY=,Y;G9G.,KG
MY9GFV^?7#SADF,3R>M\M;+,9;]IE)+J3T,-MIZ)$E9JT_P#:$7,,.1JK%:WK
M'28_:LX^RTVM2T]8G]C"+<W)[ANUG+=KD*<V]VYLBG+E;V6F3.;>#;6\2.M6
MV;J:$E:*(41:F^3B)^#6-5<_BO/[&/QK3LMC\-(_:BF!R-[=V\7^7MDW4@6N
MYR#>=BXI$ML61&C:%K2AB0XX9NI-5.52%&1<2-7 7;8U:K>,TF?IRIU3MVU\
MHO$?1A>&VETS:[X= E[AVA-ERPM;<Z*VMM;:]"C)+J2;6X2=::&:35P.O-0:
M&ZM(M/A.8;^FUYK'G&);#-;Q>+!BMUN^/VMR]7R*PI5OM;1&I3\A1DE!&14/
M21GJ53CI(QCKK%K1$SB&6RTUK,Q&94W'POO*WNQLY1,W-8L%^?CE+3C*+/&.
M'&4HM:6''W#4K@1T6:FUT.I5415&[.S16?'PS'MRTHU[[1Y>>)]F&TVQWPDW
MK9"X;EYC'2BX8\4MBYH8+JDR'H:4J1H3Q)"G-:$4Y-5>88[N-X[HI7U9:>3G
M3-[>C08Q;>\;N1CL?< L]BXEYT:[=8L:CVMB5'*,Z1+9Z]YVJ_OB:'R+H1D?
M[D67G1KMX>/ECO.5=(W[*^?EXY[1A#-[[IN;EW=Z\]9BVYBT^TS2A9'8%PD=
M7=5G(CE&DLNN*-;*$'J51%26JI>M(A?QJZZ;\5^]GM/L4\FVR^C-ONX[Q[4R
MS"];E;6=W)V_IR_SKDJ56UVV7/S;$C=E@R>S-E%ZG2ZVYI+7]]6G4>KQ$*-=
M=>W?CQQ'7U7;+;-6C/EF>GHW^:Y]EV%;F;</S;EJVZRULK5<H:F(Y$U=7$_>
M7>N)!.)):G$='7I(DJ%>O56^N^(^]7K]2S9MM393,_=MT^ML-^LZR?&XN+XI
M@<LH6;YA=F8$"2;34CJ8J#(Y#NAY*TF2=;9'5/!)F?"@QXNJMIFUOPUAERMM
MJXK7\5I>69/;U9'FZ<'PJ5\E,5AP4/W#.),%$UV3(41$;4="M+5>D6K@FE%&
M1E0B-KC56GE;[TY[&SXMK^-?NQCNB7RCW<VCW.PW%<PRQK.,7S-]<)#KD%F!
M+BOD:$DJC1JX:G$TU+42B)7 C*HN\-6W7:U:^,U^E3Y[=6RM;6\HLB>=8WGT
MKO86:#;LW[!>)UFD2[-=O-45_P W6\USJ0^I6HD/TTK^_+/5T_$0NU7I'&F9
MKTSUZ]^W53MI>>3$1;KCIT[=^BS-P,\SZZ[A6_9C;&;&@7], KIDN3RF$O\
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MSCMW:7*KLKXQ:?*,]W:0X;N
M                  A:_7GZ)@/D      1W/OZBY/\ JF?\&<!,*([N'U*8
MC_(/_"GAT-/X7D^=_5E:8L:*K=K2_P#VJ-QO[/VS]I@<_;W>LX/]&'3 K;H
M      !0 H   "1V+_@C_E%?M$ V8           /-J1'?4XEEU#BFCTNI0H
ME&E7@53D,!!=\?J8W!_L[=?@;@#6=W'ZB\#_ %2S_I!*T00
M   ^7&VWFULO(2XTX1I6A9$I*DF5#(R/@9& J?,=B['>-<['%^:KD9ZNI+C&
M6?[WE0=><CIXAM:^1:O2>L.'R_D^K=/E7[E_;"'PLYW(VOD)M>6PUW"U5HVX
MZ>LZ>%I\JU_>J_8%OP]>S\,XGV.?'-Y7"G&^OG3_ !1^G[T[5OS@B83$DU2E
M2':DY#0S5QHR^V4HTI,O!I48I_+;,XPZ4_.N+%8MY=_3'5,<5S&Q9E!5.LCY
MK2V>A]EQ.AUM1\2)2>/+X2,R%-Z36<2Z/'Y.O?7RUSF&^&#9
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M22M\EETS(C2E1(/A4B\=2<K\!"LN\1]1^>?JB1^T0#<[0_55A/ZCMWP9L!-
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M\K3&(Q,,.;MK/C6)S.8=3CDNL
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MW.\_LK>MM,UQVW9"IV[3K-<H,9@X<M)*D.QG&TIU*:(BJHZ5,Z"19O=P^HO
M_P!4L_Z0%H@@                  &/,@PKC'7$N$=N5&<*BV7D)<09>,E$
M9 B8B8Q+D?<O$9.+95.8;B&S:7W#>MRT)5U74KXDE)GSIKI,=GC[8M7K/5\Y
M^;\&VK?,UK]RW;$='O@N0Y1@"EY%%M#LFT3"[.ZXZVZEE6@R51+A%0E>/B,=
MU:;)QGJN^7;>3PZS?X<VI;],KNQO>_#KX:&9[BK/+50M,HR-G4?,3I4*GC41
M#0OQ[U],O5<;YMQ]W3R\9]D]%C1Y,>6TE^*\A]E7%+C2B6DR\1I,R&NZ[U
M                             !67>(^H_//U1(_:(!N=H?JJPG]1V[X,
MV F@      H#>[%I>/WF%N18"-MU+J.WFG[%Y%-#A^)9=%1>4$HQ9;;+W"N\
MB%M\Q\GH.EJ9=YW7.DLY"TG5!&2JZ"4I6E!>B?, FF)3<KVQR^'AV4R/.=IR
M!S_<KB:UNK2^?0(B-9F9$9Z24D_#7P@+P)Q!K-LE%UA%4T5+41>&@(?0
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MN(Q%8304+P
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MN/9WBN4$E-HN+;DA15*,L^K>]@JAGZ0U+4M7O#OZ>3JW1FEHE(Q@V
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M -WO+MIC>PF+1-WMLCEVG),=G0CNRESI$A-XBR7DL.MS$/.*)Q2C7JJDBY_
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M?!N+!2;?):EQC,TD\PXEU%2Y2U(,RX"9B8[HB8GLR!"0
M                                !$3]<8)* % 'Z _#*H  CN?_ -0\
MH_5$_P"#."!S%W=9AP]J\8<.IMJ8>):2\':7>/I#JZJYH\+\PV>'*O/N_<NH
MYT0F^M-Y.FE>7CZ@R\95_%IC*LMGI*9?>AW%>0DTI58;=0CY:)Z@O] T-W]1
MZKY;;RX]9^F?WRNRW;LX)=<\F[:PKGUF6P$*6_%ZIPFS-LB4M"'33H4M!&1J
M(C\/@.E#J)L7  ,J@% "@#] ?AE4 (J    &50&]LO\ PBOY0_VB!#8@
M        (#OC]3&X/]G;K\#< :SNX_47@?ZI9_T@E:((
M         &MO./V7((_9;S!:F,_8]:DC4FOVJN4O2,3$S'9A?76\8M&855D/
M=\M$@SDXS/=@2*ZB8D'UK)'^Y41$I/IU&W7E6CI;K#@;_D>FT^6N9UV^CLCI
M73>;;4R*>RJZVA/#4[66SI\2T'K0?[[U#&>-6SM]V6O\3YAQ?Q1&VOM]?X_L
ME,L:WYQ>Z&B/?$+L\HZ%K41NQS5^^254_P"L5/&*K\:]>W6&]Q_G7'V3BT^%
MO9/\5G0;C N;"95NDMRHZN1QE9+3Q] :KMQ,3&89()
M      4%WJMK\,RO;C(\SO<)U_(;!9Y!6R0B5)90W0]?2::<2A?$_LTF"5D[
M0$1;4X21<GF.W?!FP0F@       .5N\&N8K/"2^1E&1$9[*?,:3J:O3U5 1/
M \LR3$;D].QYDY)K;T28QH6XVI-2H:B1SD?(8)6A$[QMTC.]7?+"E-"XI94M
MM=?0< 2&%WC<2>+_ 'ZWS8Q_N";>+_:0"$DB;V;:RR07GGJ'%?8/QY"*>(U=
M6:?X0#?P<[PRY&90K["=,BJ?WY"?]HR ;=+UNNC"VT.,38RRHM)&AY"B\!EQ
M(P'A<K#9;Q"1;KI 8E0&S2;<=Q!&VG05$Z2YJ$ UN0X)BV4L08UZ@$\Q;CK$
M0A:VB0FA$:>@9529$7 !#MZ-ND95:G<@A&ZN^VN/ICQD'5#K9.$M14/[(DFH
MRIR@EAX'NUA-LPR!!NTSS?<;6P4>1"4TX:S4W4JH)*3(]7H\O*"&CV=QR\W7
M*9NX:%JM]ADR)/50>*3D$Z2J&:>32DU5K]L7 $K Q[%,JMN=7R_W&[G(L<\E
M=CA:E*TDI54$:3+2GJRZ)&7+ZH#SPK'L^M,[(7LBNY369BC.TDI:G4MJJHR5
MI,BTE0T]$O  QL2M&Z-NQ:^L7VXHDY"\:U69;BTO:%Z#XFHRII-5-*3Y 'U:
MF-UHVW4YN8XAW.2-78-:HZU$C4G@I7\4:J:M.HZ>$!^7"5NI$VUB/LL(>STE
M$4U*$LN*)KK%])*4_>S7IT5)/#E >F4WK<JVX;:9EHM:).3NJ;3=6&T=>3=4
MG6B$JX\:$=*D0#\SC)\^LD''W+!9BFS)II*Z()!NDVYI2?5]$^C4S5TCX< $
M;W(C(R;=?%L-NSRDX\Y%.8XP2C03CU7^C4N<^J2GTP0\=WL%Q?&L::R/'HJ+
M/=[=(9[,[&,T&NJN0RKQ,J5(^4!;V/RW[A8[;.E$929$9EUVI4Z:T$9G0O"8
M#8@        -/EO]5;Y^KY?XA80()W</J3Q'\G>^%/ +3             45
MFFV&Y&/;BS]U]EIUN\YWV.S'RG&;WUB84TXJ20RZTMFAI=))4XFGC4]1ZC29
M+57C -\-Y9=LM.ZC=CQG;ZW38]QG6NT..S9]P<BGJ2V;J^@VV9UJ9&2B\"N8
M-MWD]F\HW4M]ADX1-CV_([8Y-A2'Y2U-H5:;Q%5&F(JA"S49D22)-.0U<2,"
M):O??N]W?<"-A$'"93%LCV)E5CNRW7%-*78GDL(4A.A"M1H)G@GAZXP(E.MR
M]N[GDTW;<\=3&CV_$,AAW66RXHVR3!B-+;T,DE*JJ*I$23IZ("/WO =R;1OT
MUN?AC=KGX_>[?#LN0QK@ZZU)C1V)"7'76"06E2C;06BIGTN4J<0&#$P7=O:?
M(\G?VLAVG(L,RN>[>O-%TDN0)-NN4DB)XT+2A:'&5&DNCZXB(BX4-2@UUZV.
MW$O6U>06B\WN/==P<IO<.^3R4\\W:8:(\IMWLT0EDI1(0A*J'H(U'R\E0,K$
MW]P6][E[2Y#A..J83>;IV+LRI:S:9+LTYB0O4I*5F70;53H\H$+ MS"XMOB1
M7:=8RRVVNG$M2$D1T]0$*VE;>WY[O#0MT$*C_)J/BAV!:#<5VKMASG)%21II
MHT++CJY>8$L_>K:V!NY@<[&'E)C79LRF6*XGP5%N#)&;2ZD1F25<4+IQTJ.G
M&@$(5?MK]SLRPC"KK=+C MF]N"R.TP+JE2Y-NEJTDTZEZB$*2F2A*#=THX*(
MZ%0P'H[9^\/GMVL<;)'K?@6+VN2B9>',?GOR;A<C:X$PA6A!-,K(SU$I1GR'
MQH S,PV]SVP[FN;M[5%;Y\^[0F[9E..79Q<5J4W'IU+[#[:5Z'4DE*.F6G3Z
M(#'M&U6;9Q.RR_[QS68R<EM"L=@XK9I#KL*!!49K-Y:UDE+DK6HU)7HZ/&AT
M/2D-3:;'WG\1Q5O;BS)QVZ1X4<K=9<VD27X[S$-">K:4]$)I>IUI!$1&DS+@
M5=?$S'1H-]\0R6Q[8[1X>G)Y5QS LYLD9&57 U/O><)")FE\R4HU:6W%EH3J
MKI215,^($)'D.";S[OKM6*[FQ;'8L#M\QB=?SM$E^8_>%1%:D,MH<0CJ6%J+
M4HEF:BX<M &TW/P'<ES=3&=U=MV[7.F6RW/66?;;NZZPGJ9#IKZU"FBXF6M5
M>/,5"54!XS< W-V\W!R/-=J6;;?+#F*VY=]QFZR'(3C-P:2:3D17TH<31RIJ
M<2LN7DYJ!L]L=M<PBYU?=W-S9<-S-+S$;M,&U6KK%0;=;&EDYU1..D2G%K4A
M*E'2A'JI4E< W&P6"WO;3:7'L)R)3"KS:^V]I5$6;K)]IG/R$:5*2@SZ#B:]
M'E E9(( %*;-?6?O+^N(7XET!=8   *LN+F %O\ VAJ4U-/<D\>6<)Y)EV K
M9U\BI*+57K-?6?8\E!MQY_!G_#G]K4GP^-'^+'[&/?.\9M[8;M>,?D)N,K(K
M1,3;_,\*+VB9+>4@UF<9M*^DE)%TE+TD1F1<XFO$O:(GIB46Y=*S,=<PV>W.
M]^&;E7.;8;8W/M.2V]!NRK'>8W9)J6DF237I2IQ)D1J34M>HJE4ACNXU]<9G
M$Q[89:>339.(S$^R5D#5;2G\M[RFW&&76^6&Z%<'KY8GXT5RW18Z'7Y*Y;2G
MB..1N))24)3]\4LTD52+B9D-W7P]EXB8QB6ELYFNDS$YS#<W3?# K)@]GSR[
MOR(=NOZ"59[>XP9W&2I7(A#"#54^0ZZM/$NEQ*M=>->UYK'I^I9;DTBD6GU_
M6UN,=X7"L@OT3&KE;[SB=YN1DFU,9+!. 4Q1TH3*R6XDS/46G495J1%4S(9W
MXEZUS$Q:(]DL*<NEIQ,369]J0[B;L8GMHF U?#E2[M=5*1;+-;&#ESY!HIJ-
M#9&DJ%4BJI1<>05ZM%MF<=H]5NW?77C/>?1J,,WWP[,,B1B#L*[8UE3R%.Q;
M/D4(X$E]""4:C;HIQ)T))G356A'0N!TSV<6U*^728^AAKY-;V\>L3]+ZR[?G
M <(R.9BE]7,3>HL=B0U'CQS?5*5+426V8Z4*-2W#KR:2*G.(U\6]Z^4=C9RJ
M4MXSW,,WSQ+,<C/$'H%VQC*S;-^/9LDA^;Y+[9$9F;2=:R50BKIK6E3(J$=&
MSC6I7RS$Q[8ZFODUO;QQ,3[)9^XF\6&;9N0X-[7)G7ZXD9V^PVIDY=P?21TU
M);(TD15X$:U)KQI6ATQU<>^SK':/666WD5U])[^R&NP;?C"<XOGR60S<<?RE
M2#=9LM_B]AE.MD1J,VR):TJX%JTZM5*G2A&,]O%O2/+I,>V&.OE4O/CUB?9+
MVS'?/ <#R.3B^2/R&+I'M[=T;2VSUI2$O/E';88)*M:WE*/@@DTTD9F9$1B-
M?&O>OE';.#9R:4MXSWPUV']X?!\NR=G#G85WQS(I:35;X>00NQ*E$1*5][-+
MCA<22=->FO(53X#+9Q+TKY=)CZ&.OETO;QZQ/TMQN!O+B>WERA6&<Q<+QDUP
M;-^+8;)%.=.4R1F76&C4@B29D=*JXT.G(8PU<>VR,QB(]LL]O(KKG$YF?9#X
MP+>K#]P+M)QR&U<+-E,1OKW[#?(JH,XFBI59)U+2=*E4B57GI0-O&MKC/28]
ML&KD5V3CK$^R7YGN]>&[?W6/CLQ$Z]93*03K-@L<8YT[JSK11H)24IK3@2E5
M/EI0-7&OLC/2(]LFWD5USCK,^R'KM_O)AVXDZ79;:4RU9- 03LS'[S'.%<&V
MCIT^K,U$I/2*NE1TJ5:5*K;Q[:XS/6/;'8U<BNR<1TGV2GSSA,LN/&E2B;2:
MS2@JJ/25:$7.8UFRY3VBW@>NV^6;><8>028MZ?@P;-&>BN**V-$I9:9*#52,
MBJJGX>)CK[^/C37&.F?K_BY&CD9W6SGKV^C^"X\\WUPK KTWC+S5POV4K03R
M['8(O;IC;2BJ2G"-2$IJ7'2:M5.-*&0TM7&O>/+I$>V6[MY-*3X]9GV0R]O-
MY<,W)E3+79U2K?D5O3KG6&[,'#N#2*D6HVS-1&1&9$K2HZ5*M*D(V\>^OK/;
MVPG5R*;.D=_9*P1K-E5FVSF +W&W,1BK4UO*$2X/RL7*,NSK>-,CJ>ST4? B
MZS5P+F&WN\_"GEVZX:FGP\[^/?IEH4=ZK;>9;HLVQP;W?9DE#CJ[3:H)29L=
MIMQ3>M]).DA!*-)FDC<KIXTH9"S\CLB<3,1[Y5_G=<QF(F?="68SO7A>88=<
M\SQQ,Z>Q9^C<K0U&4JZ-.<#)OJ"/I*,CX:%&DZ'QJ1BF_&O2T5GU_4NIR*7K
M-H]/UN<MC'<%S?<G);QEV+76\95<\E>E6B[2(CRHMN;BJ.0RV^LG"2RXDTDD
MT*2? DIY. Z?)\Z:XBLQ$1'ZW,XWA?9,VB9F9_4L/N?28\/;7+9<MU#$6/D]
MQ=??<42$(;1#B*4I2CX$1$53,QK?,(SLK_EC[6SP)QKM_FG[&_E=Z;!"-Z19
M;%DN065A2DNWRU6LW+>75^O/K'G&CHGE/HBN.%?UF(GV3*R>;3TB9CVQ"=V;
M=;#<AP"=N39):YN.6V-*ES2;122UV%HWGFE-J--'"27!)G0ZD9'0R,:]M%ZW
MBD]Y;%=];4F\=H0*=WK-MX\1N?;8%\O<,H[4NXR+7!2^U;TO()9)E.*=0A"B
M2?2)*E:>0^(V(X.S.)F(]\]VO/.UXS$3/NCLV%S[R^V\6'"E6)%SRQR9&*:N
M)CT,YC\9@S4FLDEJ;2T9&E1&E2M7#DI0QC7A[)GKBOO96YFN(Z9M[DOP[='$
M,\P^1FV-R5R+3$2\<QI2-$EER.CK%MK09\%$DR,J'0ZE0Q3LT6I;QGNNU[JW
MKY1V0![O6;;G;H]PM$"^7W6P<N;'M4%,AR SJ4DE2S-U+;==!JIK,]-#.E1L
M?D=F<3,1[Y[^YKSSM>,Q$S[H[,^3WF=M/-5MN-B\Y9++N32I"+-9(9R[BPVV
MK0LY#1J036E1&725TN5-2XC&.'LS,3B,>L]F4\S7B)C,Y]([IAMQNCB6Z=F>
MO6+/N:(CIQY\.6WU$J,Z1:B2XBJBXEQ)25&D^)5J1D5.[3;5.++M.ZNV,U0J
MY=YO!&)LJ+CUHR#+F(3BF)=PQZVG+AMNHXFGK7'&B/T4U(^4CH+XX=\=9BOO
ME1/,IGI$V]T)+CF]&%Y=AMRS7&^V7*+::IN%K8C*5<VW"H9([/6IJ,CJ6DS(
M^-#X&*K\>]+Q6>F?U+:<BEZS:.N/UJB[INY4N_1[_9;VW>+A>KE>YUR.]267
M'8:&DQHJ$LN2%*,D.))'!JG!-*#<YVF*XF,8B.S3X.Z;9B<YF>ZQ]AY^VT7;
M#SA@1RH&%QY$MUQV\+2AQM39DIY:U&I1$@J5J9\@UN5&R=F+=_H;/&G7&O->
MWTM*]WK-NR6_(A6G(KCCL99H?R:';%+M:"2=%*-Q;B%D1?R8S_(W]9B)]F>K
M#\]3TB9CVXZ+)<W$Q7Y"2-QX,SSCBL>&Y<#DPRUK4RR1FLB0HTF2R,C2:54,
MCX'0:WPK>?A/26S\6OAYQUA7,[O4[=1X[<RV6Z^WV$49B7<)=I@%(8@E(:2]
MHDNJ=0A*T)476$DU:3J7*1C9C@W]9B/?/=K3S:>D3/NA:>'9CCV>8_$R?%YA
M3;1,)75NZ5(6E;:C2M"T+(E)4DRH9&7C+@9&-39KM2WC;NV]>RMZ^5>S>BM8
M                                            B9D=02:3 -)@&DP#
M28!I,!K[[;"O%DN5H4HDIN$5^(:CY")]M3=?X0#BS9^]-8I$E[294M-MRS%)
M4F'U$A1-]ICF\MQ#K)G0EI,E<-/*5#YQTN/LKC$O'?-N'L^+YUC,2LVXWRRV
MB([/N<^/$B,I-;CSKB4I(B]$QM3LI'JXE>/MO.(K+"[K=NGY3F6=;R&PN-8+
MP;-EL1.EH6^Q!)&MXB/[$S(N/AJ7,8X^VWE;+W_#T?!T13U6;9_H-^F2Z)LW
M8_I?ZE7G'04CK-.A.NAG_N_6:3+K.KZ=/7<XP;N<K6TF(#28!I, TF :3 -)
M@&DP#28!I, TF WEG_X9?\H?[1 AL             $!WQ^IC<'^SMU^!N -
M9W<?J+P/]4L_Z02M$$                            /PR)1&E15(^!D?
M)0!#LDVMPW)M3DJWHBS5$?\ O<0B9<,SYU$DJ*_UB%M-MJ]I:/(X.C?^.L9]
MOK^M6%PV?S?#WEW+!;TZ^A)5-EM2H[^GETFDC-#A</3\ V?CTO\ CAQ)^5;]
M$YX^R<?X9_3'['S:=\LGQ^05MS6TJ>4G@IPB.-((N2NE1:5EP\7HB9XU;1FD
ML:_.=FF?'D:YCZ8_3[7K+[QL@KD78;*VJT)50R>=44A:?"1I+2GT-*A,<.<=
M9ZL;_P!QTB^*TF:^W/V8^U<^,Y%!RJRQKW;M11I!'T%^N2I)T4D_0,:-JS6<
M2]/IVUVTB]>TMN,5P                   "LN\1]1^>?JB1^T0#<[0_55A
M/ZCMWP9L!-        :+)L.QS+XZ(U_A(DDT=67>*'6S/ETK30R(^<N0 QG#
ML=Q",N-882(Q.G5YWBMUPRY-2U5,R+F+D ;-^VVZ37M,1E[5Z[K&T+KZ-2,!
MI)FWF"ST*1)QVW]+URVH[;*_9MDE7[(".3=B]NI9U;@.Q/$P^LB_AFL!'YO=
MOQAY2E0[I,C5]:E1-NI+U2(S]4!I)/=RO$8M=HR=*G"/HI=8<CD7^LVXY_L@
MEY*V[WTM*DE;LB>E-H*B"3<'3;(BY*(>H7[ #Y3<.\59M>N._.2GAJ-IF1ZA
M(XGZ@ K>;=2RHK?,:TH+E=DPY,;]G@G]@!3=]O<S(+Q)O4XFRE25]8I+:$H0
M7@+214.A>$!>6']X"TPK-#MV1Q'NVQT]6Y(BH032DI.B3)!&5#IRT(!+XV_6
MWCZM*I,EC]TZPHB_@FH!N(N[FW,M1);O["%'[<EQDB]$W$I+]D$-U'S/$):B
M1%R"VO+/D2W,86?J$L!LF[C;WJ=3+9<KR:'$*_:,!D@   @NY.WS>9PV9<)\
MX.26[IVZ<2C10ZD>E2D\2+G(RY# 5OBN"Y1G=SZ[-[\=SLEDF/15PTO*6;C\
M9>BM-)%H53UW*9 ET VA#2$M-I)#:")*$)*A$DBH1$1> $/H        !I\M
M_JK?/U?+_$+"!!.[A]2>(_D[WPIX!:8
M      -!E.&8_F7F7S_'5(^3]UBW^UZ'%M=7<(.KJ5GH,M1%K5T5<#YP&_
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M_P#EC[5' Z4M_FG['00YSH@
M      (M3B _=(#\TG4!^Z0#2 _*<0 R+D 0'<+93;3=(VGLTL+4V>PGJX]Q
M:6Y%EMIK4B)YA2%&1'R)55/B GKW06V]SK8F!+;ER++*N?5&2D,7"?*>9(_"
M:$N))7H*J0$1$+Q@V^%;(;%NMT9N) BH2S&BL(2VTVV@J)2A"2(B(BYB($YZ
MY5?9;+L>SO+=KC9W8JMVU-+5<6$R'5.)):$$XI+1J-HEFBFO06HJG7E,$+8T
M@&D T@&D T@/PTGS /W2 :0#2 :0&YM'_#+_ )0_VB 9X            " [
MX_4QN#_9VZ_ W &L[N/U%X'^J6?]()6B"
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MS41T+Q@.V00         -/EO]5;Y^KY?XA80()W</J3Q'\G>^%/ +3
M                                        %*;-?6?O+^N(7XET!=8
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MRL<:S9                                            1FG)Z
M  4 -/. <0 !CS)\&W,]HN$EJ(P9DDG7W$M(U'R%59D5> "HK-8=A;=NU=<T
MM=[@?2"^RIV;'\XMJ;;[024N.I:U4):R,M7'[*M"J)%P194::PB5#>;D1G*]
M6\RHG&U4.AT4DS(Z&5! ]0          H V]IX1U_OS_ -D@&>
M   @.^/U,;@_V=NOP-P!K.[C]1>!_JEG_2"5H@@
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MNR&XWVZ6]/%5.8!T'M!7Z*<)KR^8[=\&;!":
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M9GH(]3:>E2HMG;::>'IG*J-58OY^N,)&*EH
M
M     (W3D] @2 @         17<G!H&X^$7C#KA1*+BP:8[ZBKU,I'39=+GZ
M"R29TY2J7.)2_E]CFW60Y!N)%VU)A4>_.3U6Z6A15[.;*C)]:B^U;2E2S\1"
M&67]6<=L%MQ:Q6['+.UU-LM<=N)%;YR;:222,SYS.E5'SF#!L@'[0P'X
M     VUJ_B%_OS_V4@,X            !1/>?N^Y\' ,AAX?CL&ZXK*L-S+(
M;E*EE'?B-FPLE&TW7IF2#-7H\ $E[N'U%X'^J6?]()6B"
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MT/U583^H[=\&; 30
M  >,N*Q.BOPI2.LBR6ULOMU-.IMQ)I454F1E4CYC 5-_A<V)^:G_ %"Y?SH
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MUJ9)1(.LAURE"4?K: ):
M
M         CZ2Z)>@"7[0 H 4 * % "@!0 H 4 0.V[38U:]T;MNK';(KW=H+
M,);6DB0VX@S)UY/[IQ"6D'P^Q/[8P$\H 4 * % "@!0 H8!0 H 4 ;*V?Q*_
MWY_[*00S0            $!WQ^IC<'^SMU^!N -9W<?J+P/]4L_Z02M$$
M                                                      "LN\1]
M1^>?JB1^T0#<[0_55A/ZCMWP9L!-
M
M
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M!N -9W<?J+P/]4L_Z02M$$
M                   "DN\_G6'V#:K*\:O5ZB0;_=K1(.VV]]TD/O\ V/02
M?+Q*@)3G: R/:G"3+D\QV[X,V"$T
M
M
M                                                      %1[*?5
M=CO\B[\(<%T-._=/1+                        ! MZ_JNR+^1:^$-B)9
MT[K1M_\ %N?O_P#T4BEN,L            ! =\?J8W!_L[=?@;@#6=W'ZB\#
M_5+/^D$K1!
M        I[O+8UCETV@S&\7*SPIEW@VB1V&?(C-/26.?[TZM)J1QX]$P$MV@
MX;5833]!V[X,V F@
M
M
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M7@?ZI9_T@E:((
M          %9=XCZC\\_5$C]H@&YVA^JK"?U';O@S8":
M
M
M
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M-0$(VNW+MNZ=BG7ZUPGX+$"YR[0MJ2:#6IV$HDJ66@S+2JO !-P
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M;E8O$R_&5.KLTTW$L*D-]2Y5I9H55)F=.) ),
M
M
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MUJUVYYY4IV.R:C2IY:$H-?2-1U-*$EZ0IOLM><VG+.M8KVC#>#!D
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M81/YH!E<.%XPO#L;AX\N[S[ZJ(2R.Z79Q+TUW6LU??%H0@CI6A43R AOP
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MQ9W&$K2;J"L+!&I!'Q(CIPJ0"^P0
M
M
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MN"
M
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M#99I12$GP.I^I4@,.EVG4/M(>;.K;B26@_"E15($/L
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M& M($
M
M                                                     /*-_$-'
M^X3^T ]*"4% "@ 95$)*"4% 'Z14$)?A%0 IQ ?H#\,J@!E4 IP "(2/T0/P
MRJ 4$H?M.%!"7Y02@IP$)>3)46\7[O\ ]!(#V
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M]W6!D&1;O9+N9*L-PL-@^3-GQMANZL'%>>F0FVNO4E!F=4)4V:25SB275 (
M
M
M                                               ?#;?5H2@CKI(D
MD?B+@ ^P                         !\H02#69'76=3](B+_0 ^@
M
M
M
M
M
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MR!#<89E=JSG%;1EUE6:[9>(S<MBOKDDX7%*O&DZI/T &]
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M<S(.T7OK$]0J;%,C5%4@RJ2C2HE)/5QK2@(3\
M
M
M
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MG#FKB2DN.,O/-)74C)EQY9HY>:@(7H
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MTX:O& WS&U]I=SWNZX+E,<Y,"Z8W+N-\ADXXTE]^:M<Q:'#;4E1D2EDDRKS
M*SEX1C\+87<',H[3J,BQ?+V;=CTPI#U844I'%MI.O21*U<> "\L;W3PG;7O7
M;AWK/KRW:HL^SVUIE]XEJZQXV&%F1$A)GR<0$H[P.=XSN+'V6R?;RXHN;AYW
M"CVR6T2DGUB%H)Y)$HB.E*:N D=> @
M
M
M
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M91&B1V^"6VFDDE*2] B 98
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M6:*%T4I222)/+QJ"5G@@
M
M
M
M
M
M
M
(       !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>tm2227887d4-fc_carm4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2227887d4-fc_carm4c.jpg
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M .0  0 !!0$! 0             & 0,$!0<( @D! 0 # 0$! 0
M   ! @,$!08'$  !! $" P0$ Q *#@8&!0T!  (#! 41!B$2!S%!$PA182(4
M<8$RD:&QP=%"4G(C,].4%196&&*"LM)SD[-T-9620U-C@R0T5(34=397&>&B
MM"47.,*C1&15-_#BI$4F1G8)\<2%M2C#9:5F)Q$!  (! @,$!@<&!00" P$!
M  $"$0,$(3$205$R!6%Q@9$B$Z&QP=%"4C/P<A0T%0;A8J(C4X*2-1;QTK+"
M0R1S_]H # ,!  (1 Q$ /P#W\@(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(,6?(T*MBM3LV8H;=TN;3@D>ULDQC',X1M
M)U<0.)T092#587<F%W"Z\W#VVVG8VR^E=# X>'/'\IOM :_"."#:H" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(+%R[4QU66]?G96IP-+YIY7!C&-'>XG@ @OH" @L5+E2]"+-*9EBN7/8
M)8W!S>:-Q8X:CO#@04%] 06([M.:U/1BG8^Y5;&^S UP,D;9N;D+F]H#N5VF
MOH07]1Z4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0:[.9FI@<=)DKO,8HRUH9&.9[WO.C6@>DE
M3$9E6UL1E!W]1\C::\T(*T3M#R,E<][PX=@>!RZ<>W@M.AGUS* 3;ER&X]QX
MO/Y:G)6S>W]"RKX1-=KSS&3D.NKP1IJYI[-._56BL85F\Y2'*]0MU1OJV:1]
MZQLI>RQ'1B8ZPQY;K$6AY +2[V7\QU':HZ<)Z\]JSM7+-V4V8T:QE.0,<UBF
MYW/+SQLT.CAZ.\GM*F:Q)US#L&)R4&7QU;)UM1!98)&!W CN(/P%8S&);1.8
MRS5"4>WSO#';!VIDMW9:*:?'XQC'S15@UTSO$D;$ T/<T=KQVE;:&C.K>*1S
MEAKZT:5)O/*&?M[-U=R8+&[@I->RGE*T5R!DH#9!'.P/:' $@'0\>*IJ4FEI
MK/.)6TM2-2D7CE:,MDJ-4+N]2\'1ZD8[IA+!9.=R5-]^&PUC#5;&P2'E<XNY
MM2(W=C5U1MK3HSJ\,1./2X[;ND:\:/'JF,^C]N":+E=@@(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M>SUK"_.6]/##>JJX@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M_P#NL/[@+Q[<Y?14\,-NJKB @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MC3\U8]-<^UOU6Q[$ZQF&H8II-1A\9X#99GN+GOY?223\Y;L/6V" @(" @("
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ML5O$Q$S,</>Y=>+3>DQ/;Q]6)][H0[%S.I5 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$!!SKJ& <SB 0"/!GX%I>.UOUHXE:T[7-K<X4C@;X;
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MXI(#XT(:7CED#3PYAQ02M 0$! 0$! 0?,DD<,;I97B.)@+GO<0UK6M&I))X
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M2&$Z):EJ\XF":S'-L%140$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M&J#C-:L<?/D,2[7_ +MNV*S>;@?#YS)&?@+'C1$K&8_R$CTS5@/A-B-!Z$1
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MZV> 'X'QN;]$K2G;ZF6ISCUMRLVH@(" @(" @(" @(" @(" @(" @(" @("
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MY^ _V=4_D6*$N.]:/]XYOY@W^48I1VN_J$O/^VCKU$Q!/;X[?^R3J4.\7_\
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M6E^3]=X+V/:?LFH.V] >G<NR_+*<>*[OR[N#%7<K<9H#*^:_7=X+>';]S\,
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MUDDKFC4B-KB"X@>A!DCL0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MV+5>I&9K4S((00TR2N$;=7'0#5V@XGL0+%JO4A?9MRL@KQC5\LK@QC1ZW.T
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M-]ZE9)]JX.^@5:)B4KBD4U050$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M)72Q8RI#.X:&Q*YLKS\/*W4_&5(RX:[FO\:Q)X]GL#].5K1Z&M[@@R!VCX5
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M@Z?8.*ML$=J2I/&#S!DKX9&@^D!Q/%!C^X;;_P WQO\ 8UD#\G[;_P WQO\
M8UD'GGK#5ZC5NHM>;9$5AF,=!7;@Y<,Z..!D^@\83F(M /B<7&3@6>I!Z/@M
M1>[P>]6ZIM^%'[R8Y8PPS<@\0M'-V<VNB"X9Z4FL;[5?PW@L>/&CTY7#0_7>
M@H,#'SFQ7P\.@,K VH[E<'Z>Z66@G4=OLQZK:GAESZOBB/VYIJL72(" @("
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M6Z:$^SJ@Z-N#RW;!W5TRP?3'/ON7*6VF<F#S1E8S)UB. <)&,#3[.C'#DT<
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MCX;>S[7T/]T?J:?[MOKA[&7HOC1 42" I! *#;Q_>V?:CZ"A9R;S"_[FTO\
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M![G35W00N,GW.2/G:'N( )#F:^R-%"T)ZI! 0$! 0$! 0$! 0$! 0$! 0$!
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MU1BF70RV:^8W?@=3X0FK9*!@^2/>F%K^'<26!>=OZ\*V]CHOQI6?8[2O)8"
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MFH/F21D3#)(>5C1J2@B&>SL%0-M66OD?*[P:%*(<T\\G='&WO)[7'L:.)00
MNR5C<61DS9C=?J1UXX88270U8[$?BNB8?KCV<[_KO@4C-1+,VY3_ "GO'#U.
M7FBI^+E+&O<(&^'$=/X1^H^!$.TH" @(" @(" @(" @(" @("#D6Z?,]T1V5
MGK^V=R[HCHYK&2>#=K.KV7>'(0':<S8RT\#W%!+MB]4NG_4NM+:V-GZN997T
M-B.!Q;-$'=A?$\-> >XENB"7H" @(" @XID_-KY?\/D+6*R.\(H;U*:2M8B-
M>T>66%Q8\:B+0Z$=R"<].^JNP^J]"YD]A99F7HT)A6MRLCEBY)7-#PW25K2>
M!UX()D@(" @(" @(" @(" @(" @(" @H1J@CVV]B[1VC9R5W;N(K4+^8L27,
MI<C9K8LSS.YW.DE=JX\>QNN@[@@D2 @(" @(" @A.?\ ][1_LP?]H*@GDMJ5
M!!1!5 0$!!>J_+/VJ+01?TUC_P"<'^1D4)312" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @("#RWYDO]S-Z_P YA_\ V54W/Z$^SZWH^2?^0I[?J03R
M2?TYO/\ F5/^6>N+8^&WL^U[_P#='ZFG^[;ZX>QEZ#XT0$! 0% =Q4Y&WB^]
ML^U'T$6<G\PO^YM+_:,/\G(L-?P/7\H_F8]4N+]!?\CWW_/F_P @]4\OY7]<
M?:[_ .Z_U-#]R?L>P6_)'P!=3YE5 0$! 0$! 0$! 0$! 0:K-Y&>I'%4Q[1)
MEKI,=-A^2W0>W*_]BP<3Z> 4PK,HC!2BQ]S(5XGNE(F;XTTAU?)+X3>=[O62
MKQ)$80#J1ORYM7)5,?%2CLTO<WY6PZ1SV/<ZK, (F/ +1J-2=0F42DNQ-TNW
MMM+&[J=4]Q_*0D>*H<9 UK)',!#B!KJ!JD)2% 0:;==XX[!36&R/C<9(HP8C
MI(2]X]ENG'4]BY-YU_*F*>*<1"M\XX(([);H<.:#*24]>+8N9]C3U.<Y[=?7
MH%SZ>UU(CXM6TRB*3VRN8S<^?DMNQ>2O3PY!K/$B?#('0SL':6A[201WM*\[
M>WW.W^*+S-?9P];._57M964W9N#"BO/';]X:Z0B2"S&PM<T-UTU8&N!]87GU
M\VW%9S,Q:/4R^;:$CR&"P>7HR9Z?'L9D+-5MA[@2.9_)S-+PT@/+?2X+[*D]
M58MWPZIY-I9;.^O1R%=AFL5@R0QMX%\<C 'M'KTXA73+!AS6-I6[+7RGW:T_
MQXW<KN=DFFCV/9IS#LU!3"O5$2Q]PP9C<&)=#C*P96#XYS#:>877(XSS&'1O
M%C7^ER+9RTFR,;D<1:R63R%)]#&MBEF=7>"6Q$$.#(0\D^RT.YB-!QT5)MB)
MF>4'+BNV,Y7RLOO>0YVQZ:5JCXWF.)A[SP(<\][N[L"^0W.]^?;.<5[(<MK]
M33Y3)X@20T*4$4UNP0'R<I8(6<2''@"2=. 6.CK]&K7'?'T\%,LFH['2SNKV
M8*T+VQMDYVR%FG-V-(<1Q(X\$^;:+VKF8Q,]J8LV+*5)V@A>3KP'AS$_0<5M
M&XU8Y6GWK]4][#PV4;:W95Q-*22?'\LXMNDD<YKW1L+O8T(TY2!Q[UV;'=ZN
MIKQ29S&)RFEYFV&W>QK,KEN37E;8;$W5Q<0&1,X N).FI[%]*Z4MV!_2&3_@
MH/HO5;)A/55(@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M5B<MR5"O6CI316XV@%L\<8TYN4C1VI!'>@Z<@(" @(" @(" @(" @(" @("
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M21Y[R3V>@<%\[KZLZMYM)J7FTY218,Q 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$%B[3K9"I/1NQB:I9C=#/"[Y+HW@M<#\(*#
MSMD=K[EV3NME-D$F0PV2>8:,P< )CRE[6ZD@-L -TT=IXG<=2B6TJW*]P.-9
M_,Z,\LL3@62QN':V1CM'-/PA!L=I@LSF=;];+%1D'[5LK"B$DOX^EE*QIY"$
M3P$AS026N8\=CV/;HYCAW.:=4&N8-R8<@0G\O46Z>&9)&U\C&WT%YTCFT])Y
M7%!G1[Y=#[%NED8)6\'1S49)#_9Q<S3\14!)OL2#EKU<A+(?DQQ4)6N)]',\
M #XRI&')/N?+.(9%^0ZSC[=NPYEF^YO["-NL<9];W'3T(,S&XNCB8GQ4HR'3
M'GL6)'&2>9_V<LCN+C\X=P09T8U>T>L?14"([7V;G-PP37V6X<=B+=RW,VRP
M>/<E!G<WV6N 8SLT!=S'U*1(Y.G-";)4L.RHYNUZ;FY+)6)GB6?)WQJV)DKB
M>8LC&KW?6ZD #35!T8#0 #@!W(*H" @(" @(" @(" @(" @("#P#1W_M#IOY
MTMZ[EWKDV8K"L;:K&U(U\@\:6*'D;RQM<[CH>Y!=ZE;FB\WG6+:.T^FT%BSL
MW;,ALY7/R1.CA:R21CII?:TT;RQAD8=H7./8@D'F&W[F+?7_  _2C<F[[VQ.
ME'N<$ERYC9'5'VFRQN<XOF )Y2]HAU^2SMTU00'INS85+SC;<I]/,]9W!M>*
M.2*#*Y"U)=FDL"E()6-FF <YK7>RW0<OH09_FO@S72#K%D]Y[;8(:'43 6L?
M=(!##+(P5[(X=LG*&2#UE!ZJ\LNP6=.^C&VL2Z+PLC>@&6R?I-F\!)Q];6<C
M-/4@D?5;I)M+K)M^OMK>/O7Y-K6F78O<IS6D\:-KFC5P!X:./!!'>FO03970
MN#/Y3I[7OV\GDJPYZM^YXPE?5:]\4;7.: SF<="Y!S[8GG"Z6;@P>X#OZK%L
MO-T99H[^W[?^,26FAG*[3EC:'O)!C<QP]'<4$:\@F,OMP&^-Q"N^MM[+92)N
M+:[@QQ@:\OY/2&"1C-4'L- 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M0G/_ .]H_P!F#_M!4$\EM2H(" @(" @O5OEGX$6@B_IK'_S@_P C(H2FBD$!
M 0$! 0$! 0<)WIYB,SM[J5E>F6UNG.5WCEL13K9"U+C;->,"&VT$$LE&H +@
MWM1+?["Z];>WAN$;'SF(R>R^H)A]X9MS/P>!+/$ 2Y]65I,<S6@<>4Z^I$.K
MH" @(""-[UW]L_IUB/R]O7+U\-BC((8Y[!.LDK@2&1L:'.>X@'@T%!$^E77;
M:76++;@Q^TJUYM7;WN[9[E^$U1,ZSSD>'$_V^4!FO,\#77L0=00$! 0$! 0$
M! 0$! 0>6O,;_N1O7^=MU_LZJKN?T)]CT/(__(4_ZOJ07R2?TYO/^8T_Y9ZX
M=CX;>S[7T']S_J:?[MOKA[&*]%\:("@%(* 1)W(AMXOO;/M1]!%G)O,+_N;2
M_P!HP_R<BPU_ ]?RC^9CU2X?T/ED9#OAK#R@W6EVG?K7D'TUGY?ROZX^UW_W
M9X]#]R?L>R(>$,?VK?H+K?,OM 0$! 0$! 0$! 0$! 006*/WFY=RQ<9,S6NV
M(JTDAU#:\,AC\!@[&M<T<=.UW$JT2B5N%WB,,NA;XCWOY7=HU<>!5D+<F0HU
MK$=6>W%#;E&L<3WACG#U:_ @R&V#-&'QR^+$X:M>UW,TCT@C@@M3-KD$31QO
M]3F-=]$*,I::[7I.MXL1U8(I#=CD+V1L8\1P-=*\\S0#PY0D(6W8?\KXJ(-L
MOIO-B:U ]C&2#EE) #F/X:$<5R[O:UW%.F9F,=S.:]4(M:V&V">.F_=,%2Q9
MU,-4QBJ7COY6-F'SERTVFO2,5U9]M8E$5M':S*>P<SBXC7Q]S&MC)YGE\%@2
M/<>][N<DGX5PZOE6MJ6S;4B9]2DZ4SSECY+8>Y,C+7,UFAX41T=X9F:[E<X$
MD!P/<.Q8?T;4S'Q5^E7Y,][H5JS6JL\:S*V&+Y+2\\3IW #M/P+ZMU3.&J.Z
M=MS6'XUUMDED:"2JYA<X$C4 L(U^<BO5"WXV,AUEQ6093D'M.@F+A6<!W/#]
M.3X0>"(X=B_-!BMU8V7'Y*!DT1+?'A#VR<CNUKXY&ZC0_6N"+1.5JMM_'8/%
MY&&@UY=/!())97!SRUL;@UHT  :W7@ %G>/AGU3]29Y(E6.M: _WMG[D+\[C
MD\YSWJ8/^\\*?2__ -"1>MY3^O/[K?1\3/Z4_P"Z\O\ /)?H-5/,_P"8GU0C
M5\27Y#^CKO\  2_N"O,GDQ?'2R(G*7INYE&*/^SE!_\ 17N^25^.\^B/K;Z'
M.6^B]J>\[[*[8/S'Z?27U3J2_I__ $AD_P""@^B]5E,)ZJI$! 0$! 0$! 0$
M&)E;[<7C+N2<PRMIP2V'1M(!<(6%^@)].B#SMMGS4;KW1BJVY,;T8W-;VK8Y
MW?E7'RUKFL<3BU[HXFEKGZ$'AP0=EZ=]3-H=4L#^<.S[ALU8Y'5[E:9CH+=6
MRSY4,\+QS,>/1V>@E!+T! 0$',.I?6O$=/LMCMIX_#Y#=F_LQ%)9QNV<-&'V
M'5XOE33/>0V*,:'VG>CL0.F?6O$]0<OD-I9'#9':6_L1"RUD=LYF,,L"M*0&
MS0O82R6,D@<S?F(.GH" @(" @(" @(" @(" @(" @(/E[&R,=&]H<QP+7-<-
M00>!!!0<"ZD=/AL8R[PVI&1MISP[.81OR( \@&Q6'UH!^6SXQP[/;VNY^9\%
M^?9/V2Z8F-6,3XNR?O:)KFO:V1AYHW@.8X=A:X:@_,78Y54&@WG&9-N6M/[6
MZ.0_ UW_ $K33\3HV\XO#EBZGK" @*04 @(" @VV"V_<SL_+#]RIL/W>TX>R
MWU-]+O4JVM%6.KJQ2./-U'&XVGB:K:E&/DC'%[CQ>]WV3CWE<DS,\WE7O-YS
M++4*"#2;JX8F/OUNT@1Z1X[>"M3G[)=&W\?LEZV7RS 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'RYC'Z<[0[E(<W4:Z$=
MA'K"#1YW9VW=Q/$^2IM]]8-([T)=!9;Z-)(R'</0=0@@..Q4&#W;F\77MV+L
M<%6F726N4O893*\,YV-;S<..I&J#?*$""H<X<-=/@0.9WI*D44 I'W%PD:?6
M/HHEF]-'-_-&M7'%]6Q<KR>CG9:EU02Y 0$! 0$! 0$! 0$! 0$! 0$!!#LK
MTHZ99S(6,MF=GX>_D[;N>S<LT8)9I':::O>YA).@[T$@PNW\%MRI[AM_&5<5
M2UU]WI01UX]0--2V,-&J#1[WZ9;!ZD5H:F^=OT\W#7/- ;+/ND>IU(;(TM>
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M$>3R%EP?+-:#!XKG.: #[1.G#L0<7V-RV_-SU1L3M#YJ6 PU:JX\2R*1K7N
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M5(GF"W3B=P>+%2D=%D*_"WC;33!<@=Z)(G<1]L-6GN*#=H" @(" @(" @("
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M0Z]^NON_]%,9_'V%U?QWH>'_ .KQ_P G^D_77W?^BF,_C["?QWH/_5X_Y/\
M2JSSK;M)T=M7&M'I\:PG\=Z$Q_:\?\O^ED?KF;N[?S7QNG<?&G5?X_\ RM?_
M %./^7_2?KF;N_1?&_QTZ?Q_^4_]2C_E_P!)^N9N[]%\;_'3I_'_ .4_]3C_
M )?]*A\YN[M#_P#A?&?QTZG^/_RG_J4?\O\ I=1J>9#/RU*\KL'3#Y(HWN E
MET!<P$@?-6L;K/8\N?(L3,=?T(KOWJKF=]5*V-MU(*52"7Q^2$N<Y\FA:"2[
MLT!/8J7UNN,8=.U\NKMK]?5U3C@U/0T_XMO<>FXW^0D6_E_*_KC[7#_=/BT/
MW)^Q[+K#2O$/0QOT NI\VNH" @(" @(" @(" @("#G\5AD$5T\72RW;PAB;Q
M<]QL2=GJ])[D&C:Z]5FB]XH.:]T8AC8R6)^KFG4Z.U:/B[5;*J]->?6B,MFE
M9@:#RATC&\G,> !<''M*1Q3/!BB\(""^*3WM_P!_FGBD C/V( !(T3*%]^0K
MFO!XF18PN,A^]EHX$#Z\)D8$4].QF; ?F:;#%7AC8)Q7)=SN<\Z"1P[- K0B
M8?%'I_B(LA-E:%H26I^8O\-WBQZR'5Q:T2$-_:J5>EL7;2G.H==D#?1R.^F]
M3DZ7RS9>*Y@;_/<#3J(I-&LU]/#C\],D4B$:W+L;(2WI7XBK6L8FU/':, ;'
M%8@DB:UHB:]V@$/#F]GB./!5E=,7V!MS;T<V1>ZU)2@CCE,?%\LIT:&MYO2X
MZ E!J\=OBE:N6,?DJ4V*NUB6.BD>RP'R!H=R-='IJX@\!HB,LG*Y27'Q16<G
M8DI,L.+*M"E#[S;D+1S'7X!Q=IP"E'%3%Y09JG)8Q-H9BC\BQ4M1^[S@.UX
MZ <=#IJAQ7,;F*T+G8>^70R1ZLKFR.4OB/ -<3PY@.'K3"(GL8@PNU'VCC:V
M2=%<CT::<5QI>W7L:&NU^8O)MY5MY[)CVJ_+JRZFT<-6O,R$HENVHFED)MN;
M*U@/$D-Y0-?65IH^6Z&E;JB,SZ>*8TXB<OBYM,V;<UG'6!4;+RF2!L >P.:.
M74<KFZ:A8;GRNFM?JB>GT85MI1,Y:^UL[*S02UV9"MI*QT;G20R-< \:$@->
MX$C5<5O)9[+_ $*?)]+?[<P5+;U*'&TM7^TUT]A^GB32\ 7NT[/4.X+W=OMZ
M:%(K7_Y;UK%8Q",T7 5 ]Q !?*XD\ -97+H637I__2&3_@H/HO593">JJ1 0
M$! 0$! 0$!!I]U@NVOFVM!<XX^UHT#4DF%_8 @\C>7?S$[&V#TEP.R,KCL_<
MW53]Y#L;C\/;G=))+8DD8R-_*UA)#A]<@ZKT8VCO/.=0-S==NHN,?@,IGJ\.
M)VUMJ9P?8H8B AW-/IJ&S2. +F]W'4!!Q[8VY>EFR-Q;ZK>8K OO]7)\U9GC
MGR6+DS!O8^0CW./'ZQRLY0W@UC>4<1\0=!\HLCCD.J_B8.;;1DW)[S%@;$'N
MSZD$T1,<7(T!@Y0/DLX#L003;.P,S!YBCT9$0_\ #?:V;GZE5 .(:V[$T05R
MT\"UM@G3XT'M;N0>:-U9J#HAYB,IU%W97GCZ>;[P]6@_.UX9+$5')8[@&6&Q
M-<YHD8-6NTT^84#:^<@ZX>8G$]0MHPV)>G>Q</:HC.6()*\-S*9 Z&.N)6M<
MX,8[5SM-/G(/3" @(" @(" @(" @(" @(" @(" @P,Y6DNX7)4X1K-8JSQ1C
M]E)&YH^>5>DXM$^E:LXEY:VH\/V[08.#X&&O*T]K9(G%K@?6"OI[^*5]:,7E
MN51B(-)G-L8_.:32$P7@.5MF, D@=@>#\I7K>:M]/6M3U(9=V/G:I/@,9<C'
M8Z)VCB/M7:%;QJ1+MKN:3SX--8Q>3JNY;-.:)WH=&[Z(U"O%HEO%ZSRF&*6O
M':QP^%I'TE*^5 "3H 2?0 4&=5PN7NG2K2FD'V7(6M'QNT"B;1#.VI6.<I!C
M]@9&;1^1G94C^P9]UD^=[(^:LIU8['-?=5CE&4QQ6W\5A@'4X=;&FALR>W*?
M@/=\2QM:;<W'?5M?FV:JR405""S:MUJ-=]JY,R"M'\N20Z ?5*1&>28B9G$<
MV;MO:6[.H!;)09)@-JO^7F;#-+=AGHK1.[ ?LW</0L-;<4TO\UN[[W1T5IXN
M,]WWN\;5VC@MF8MN)P-;P*^O--*X\\TTA[9)7GBYQ_\ U+Q-75MJ6S:65[S:
M<RWBR4$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 08>1RV,Q$'O65N0TJXU^Z6)&Q-X#4Z<Q&I^!!$[/4+WW6/:>,FRFO 9"QK2
MH-]8DD'._3T1L.OI0:]^WL[N4\^Z[YMU''F_)E<.J8X=AT<T'Q9M"/[8[3U(
M)11Q=2A%''#&T"(!L36M#(V =S&#@% S4%'DM8YP&I:"0/@&J"RZ.O>A8][0
M]CVAS'=C@'#7@5(UT^&>.-=X</L7\#\WL4#"DJV8?OD3F^O34?.1"R@1\TCG
MLC:7<A ) UXD:]R)9]?%6)2#*/!C])XN^((-O7K0U6\D#.74ZN=]<XGTE!@Y
MC;^)SOA/R$&MNOQJWX'N@N0.[C',PAP^#73U*1KV?GQ@-!6ECW3C1V0V"RGD
MV-[@) /!ET'V08X^E!G4=_;=L3BED)7X;)GMHY5AJ2=FOLN?[#_VCR@DX<"
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M,@UU.77T 2AH/[4E!)6D. <T@M(U!'$$%!5 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0<@ZL_TY%_LF?^47I;;P
M3^W8\;??J5_;M<SV-_N\S^'D_<L5MM^FRWWZL^J$C74X1 0$! 08V2_HV]_-
MYOY-RK;E*U?%'K7^B?\ EV$_A+W\DY<,?R_[=[UI_F_9]CT4N%Z@@(" @("
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M6O\ 1/\ RW"?PE[^2<N&/Y?]N]Z\_P W[/L>BEPO3$! 0$! 0$! 0$! 0$!
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ME-FL]!#(T\T4L=R\/E"*&$\T4;SV<TC]#R^@+IM.(>)2N9=2"Q=@@(" @("
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M5V()5T_!]_R9T.GAP GNU/.JRF$]54B @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @("#B_4CI[N!FX9]Y;2K-R++\<;,SA^9L4I?
M WE9/ XZ-+N4:.:>U>MM=S6*]%^&.4MXFMJ],\,<I0J#&;ZOR"M0V=D&V3PY
M[W+5KM/I=(X\1\"[9U=*(S-H]A\JL<[0DL/1WJ%-7]XL;AQU2V1JVE'5=-"#
M]BZ5Q:[XPU<T[[3SPK.#.EW3[T8S%#=VTR[\Z\)(VFPZ',8W6U3([ YP YV>
MOF"Z=/4T]3PSQ[I/E1;P3[)6J60H9)GB8^S'99W^&X$CX6]H^8M9B8YL;5FO
M.,,G0ZZ:<?0JJK&)J9O>.4?@]GL8XP$#)YN8<U.H#]:-/ODA[FA5U+UTHS;V
M1WMZZ<1'5?W=[IM'H'L]L+3G+-_,WR/NUF:S)"USN\MCB+0T>KBO,MO]2>6(
M6^=,<HB&TBZ(]+XN4G;T4KFG4.FFGE^<Z0A93O=;\R/GW[TAH;%V9BP/<,!C
MX".QS:T1=_9%I/SUC;7U+<[3[V<ZEIYRWS&,C8&1M#&-&C6M&@ ]0"Q4?2 @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(,'+9.+%4W6I
M&.E>2(X*\?&265W!K&CTDH-#2P$D]QF=W&6V\X-?=X1[5:BUWUD+3VN^SD[3
M\"#=\J@4TT0$! 040$'S-%%8C\*Q&V:+["0!P^>@P_<)ZX_[NMOA8.RM./'@
M^ <QYFCX"I%18R<6@GHMF'9SU)1\WDET/ST'TW(=OB4[D?K,!(^:TE ][J2O
MC+GF.2-QY/%8Z/Y0Y2-7  :_"@S/4H%$&JR-X5[M9C?;=$#)X0!)<7#0'1H)
MX#L0?9RTA:##CK<A]49T^>I%EU[.RD"OC71:_73%K/F\Q/T$%LXS-VS_ (]=
M;!%WQU]7OT^V=H!\Q!L*.+HX_P!NO%K,?E6)/;E/[8]GQ(,P\>)XJ!5!1!5
M0$%- 1H1J#V@]A"#4Y'!5[<,L0B9+6F:63TY0'QO:>T:'Z"#782Y9VM)%CK4
MTD^VI7-BJ33.+Y:,A.C8I'NXNA/8QQXL^2>&A4B=(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @Y!U9_IR+_9,_\HO2
MVW@G]NQXV^_4K^W:YGL;_=YG\/)^Y8K;;]-EOOU9]4)&NIPB @>M 0-4&-D?
MZ-N_S>;^3<JVY2M7Q1ZU_HG_ );A/X2[_).7#'\O^W>]>?YOV?8]%+A>F("
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M3D6 =KA")&_-82B<-;-MB[!KXC;$6G;XM:5NGSD1AN=A4W4]W8<R2->Y]N(
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M7IP/P(-H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MX'E+'>L=H^>@R$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$!!R_JSB;3O!SD$9E@95FI6&MT+VF3VHRUG:[5VK3R\>S@N
MW;ZE:UF)G#S=YHVO-;5C.')=J,EQF);0R4,U6\)'RFN^";Q/#(8 [1K#PU&F
MJWVLQT8<N^I;YF<3C$-Y[U!_??Q>Q^#74X>F>Z?=)[W!_??Q>Q^#0Z9[I]TG
MO<']]_%['X-#IGNGW2>]0?WW\7L?@T.F>Z?=)[U!_??Q>Q^#0Z9[I]TGO<']
M]_%['X-#IGNGW2Q<E<K#'6FN,C720R11\T$[>:1["&M!,8&I/8JVY2M2MNJ.
M$\^Z6\Z'8C(R35+4L#Z\&,-ET_CM,;W/G'(QK6.T=V:DG31>=UQ&CT]KVOE6
MG<3?L=\7([A 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M[-1IH@]KCL050$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M!!3E""A8B%/#04,:#Y\/U('AGT(*>&?0@>&4#PSZ$%1$?0@>$@J(T%1&@J&
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M &@'8$$W0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MK@__ )7]Q#__ %3_ /96H.-]8KUO%]".A&2Q])V3OU+^ GJ8YAY76)F5-61
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M @(" @(" @(" @("#45;'-EIHM>PO^=H@VZ @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @HYK7-+7 .:X:$'B""@MUZM:I'X56%D$6NO)$T,;J>_1
MH""Z@(" @(""CV,D:YDC0YC@0YKAJ"#V@@H+<%:O5C$-6%D,0.HCC:&-U/J
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MF.'^$C0>WD! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M=_BZU!-%9@CL0/$D,S6R1O'8YCQJ"/A!73#Y^8F)Q*XI0(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(/"713_ ,[^_OX;,_NXD'NU 0>-/+YL
M'/\ _C?UGCW5M^_3VQN".]6CLW*LL-:U%8NN!$<CVAK]6.)]D]G%!'O+'T-W
MCA>M=V7>N-NQ[?Z=QW*NV[%R%[:DLMF9S6.JN>.5[>4NEU8>TH))Y=MC[EAZ
MX]9)MR8+(8_!YQMZ"O>MUI8(+#)[KM?"D>T-?JPZCE[D$-V#O#J-Y/[>XMB;
MBV)D-RX'(WC8V_D\<2()7:<C2'AD@/.T,YF\'M(XA!)^CO2KJ"W9O67JGO3$
M38_=&_,5E(\9@Q&[WMS+$4LI)AXN:7O+61L/M$#73B$$I\K&V-S8+RU;CPN<
MPM[&9F9^7,..N5Y(++Q+5:UG+&]H<>8\&Z#B@YYT7Z*;OW9Y8-\[#R>(M8/<
MMO*&[AZ^6@DIF2:O'$^/A*&^R\M+.;L&J#74.MW5C"=+#Y?)NF.8DW^RA)@Z
MUX1O='[L_6,/\,1GF(C):'-?R'@[71!*,WY5]UL\K&,VA3B;+U$Q5]^Y7X]C
MVN#IIVF.6I&_4-+Q$&Z'70N;H.U!BQ>8WKSN;!X?IATYZ?9'"]1\>*M/)Y:]
M7$M6..!@B>Y\<\;6QAQ&KG/=[/=J@ZAYK=A7=Q] '7<M9CM[LVA'6RS\BQK8
M6S3PM$=OD' -;('.<&^H!!'O(QLZ:OLS.=2\KS39G=EYS([DWM2OJ4R6EW,>
M)\24O)^U00"[E]V="_-ANG=5[9^1SN,WE)[KBI:+'\CX[TD#_$9(&/:3&6:/
M;P(0?/53I_G>C77#-]4K6PV]1.FFY3-:NUC VR:L]DAT@(+)/"<UXU8\MY7-
M.FH*#J/E]SC=\[RFW#BNB5+8VSJE,G&[CFKQ09%UQY+'MC(C9SQN9J/8'L]Y
MXZ(/1VXJ$^4V]EL96T%F[2L5H>8Z-YYHG,;J?1J4'A?RRG/T(=V>6G=FT<GC
M[.YVY!]O-S1.9!2 I&-O.TLT<'%@,;FOT.J!TXZG]4/*[A,ETFW'TZR.:R+[
ML\VWLE3#C5F?.T-#@6QO$C"YH?HP\PXM/%!V/R=](]T]/=N9_=&]JKL?N'=]
MIEK\ER<)J]>/G</% /LO>Z1Q+#Q: ->.J#,\[&W\_N7HJ<;MO%6\QDORM4D]
MSQ\$EF;PVLF!=R1@G0:C4H(UUZVMN?*^4C;&W\5A+U[/018(38JM6EEML,,0
M$G-$UI<.0_*U'!!]]7-K[FR'D^P&WJ&%O6MP15,.V7$P5I9+C'1!O.'0M:7@
MM^NX<$',.KW3KJ#?\NG1N2+ 7KV,VQ )-T[=\.1EEA(;RNE@TY] &O:3R^QS
M:H(MU/GS'5=FR=P]/.C&2VOM/"7 R2Q2QX,EIW-"YVK*T37&.)L9TD>.)U[T
M'8.N6V][]-^NV$\R.U-OV=S;?-1D.;Q]-I]X@(KNK.YF@.<&OB<"'ENC7#1W
M<@DO2GJSUOZT=3:F:Q^!GV?T7I0.-^+)5XWSW+ :X!L4SV-<27D<WA\&M';J
M4$>\HVT]U[?ZH]4;V>P60Q5*]8F=2LWJLM>*<&],X&-SV@.U:0>'<@U?47#[
MZ\OGF"R?7#";:M;JV+N.&3\IQT 3-7DF:P2LD+6NY/NC&O8XMY2.&NJ#YZ>X
MG?/F&\P6*ZVYK;5K:NQ=M0Q_DQE\$2SR0!QC9&2UO/K(\O>X-Y0!IKJ@@VTN
MHF=Z8>8WJ]NK$;4M[NJ1V+L>7J8YP;9K5S<:6S@%KM6APY7<.':@Z'Y?,!O3
MJ=UOW+YB-R8.Q@,)-4FK8&K9#FOD=+&V!K6\[6E[61-/-)R@%YX(-WY(-K;G
MVS5ZA-W+A+V&=;RE>2H,A6EJF9C1/JZ/Q&MY@-1Q""$]#NGG4=M/KSCH,1D,
M)E\[6FAP-F[!+398D?+9T$4D@:#S!P',#PYM4'.MBOR6,Z8[BZ-5>BEZ_P!4
M)F6C=STU-OB5XW#7Q'/EC+PYC6\L;8W^T[3EXE!T#"=&=X[Z\G;MH1XBYC]Y
M83,V,G5Q.0@?4L61&22QK9@W[Y'(2P][AH@CN\NN.^=S= LATNRO3G)X^?;U
M.ECMP[CLAT%.M'3DC9'S1R1M<)7\C6\G-VZE!O[72#<?5/R>=,[>T(/?-Q[:
M%NY!C20UUF":U,V5L?-H"\<K7-:?E<1VZ(,/$=2#GHZ>S\'Y:*EGJ+'X$&3D
MMX^*&@TM+6S2/:Z%AC!&I]M^C3VZ]X>\L76BI8VG4@J1T(8(8XV4H=/"@:QH
M C9R@#E;\D:!!EH" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(/
MB:*.>&2"9H?#*TLD8>PM<-"/C")B9B<PXE)Y>8G7YA'G'Q8AW-X+1"'66:@\
MHYB>4\OITXKB_AN//@^F_KD]/A^+Z&6S=_4'I9R5>HE([DVA&1'#N[$Q:V88
M^QINU6\>'#5[.'PK7JM3Q<8[W'_#Z&ZXZ,]%_P EN7_3/V.HX'<>"W1CHLMM
MZ_#D<?,-63UWAP^!P[6D=X<-5M6T3QAY.KHWTK=-XQ+:*S)$MV=1=N;2#H+<
MQM98MYH\;6T?,?07\=&-];R/5JN;5W%:<.<]SUMEY5K[KC6,5_-/+_'V.%;K
MZ@[DW<706YO<L2[A^3*KB&.']]DX.D^#@WU+RM36MJ<^7<^\V7E6AM>,1U6_
M-/V1V?6B! F=X31I6B.C@  USAV-'J;WKGY^I[/+CVK_ ,/:KJ,:0^[2&P/O
M$A^[C[%W8'_2=\U4GA.5XXQCM23;6[<_M&8/PMKEJEW-+CY=9*DFO;[&HY2?
MLF$?&MM/4M2?AEYN\V&CNH_W(X_FCQ?X^UV_:75K;^X3%2R.F(S+_9;7G</!
ME=_>I> .OV+M'>I>GI;JMN$\)?#;[R36V^;5^.G?'./7'[0Z NU\^UV8SV&V
M_3ER.;O08^E TR236)&Q@-'HU.I^ *LVB.;73TKZDXK$S+E4W4#?74Q\E#I/
MCCC, 28YMZY>,LC(['&G7<.:0^ASAI\"QZ[7\/+O>M&UT=MQUYS;\E?_ -I[
M&M_5XL>_0LDSS9L40TVI'0\EIY^OY0"6#F/?W++^&X\W?'GL=/@^+Z'<JM:*
MG6AJ0-Y8*[&Q1-[=&,:&@?,"[(C#Y>UIM,S/.5Y2J(" @(" @(" @(" @("
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M;]:.00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!X2Z*?\
MG>W]_#9G]W$@]VH""(;DZJ].-GYBKM_<^Z,=BLS=+1!2M6&1R>W\DO!/L-/<
MY^@0>:_+KO3>V?ZV]7\5D=S6[^.Q[+APU?(6'V*-1S;KFQN8PG0,:-.SZU!/
M^@V\]WXS:.Z<WUCW]MW.04\AI2OT,E2FAKQN:=&2S0EL;/$=IX4;O:'8@XAT
M4WWO_K!U'L[SW5U:9M;%X?*LEK;-]Y97AOTXR^62)D#I8]8FQ1^U)H\]I*#Y
MWAU2WAU=ZZ9G9^%ZKP=/>GV&:X8[,5+D45:UX): 62B1C9WRO=P'B:!HX:H/
M96=WKM3IS@J5G?6XZN/C;$R'WR[(V-]F6-K0][&:ESB3[1Y0=-4&QVSN_:^\
M\8,QM3+U<QC">4V*<K96M=IKROY3JUVGUK@"@T=_K#TKQN,ES-K>6(_)D-EE
M"6Q%<AG#;<AT;"1$YYYS]CIJ@V6[>H&R=B4(LEO#.T\-3G_R=]N5K'2Z<3X;
M.+GZ \>4%!E;;W?M?>.+&;VMEZF7Q1U!M5)6RL:X#4M?H=6N [6NT*#26^K_
M $LHX>SN"?>.'.&IRBM9N1789V,G<"X1?<G.)>0">0#71!D/ZD[)EV?-OG'[
MAQL^VVL=X63=:BCJF8#V8G2.< UY=HWD/M:G31!RORZ^9!G6>/*5=P18W 9^
MM8$.+Q45OGL6XO#<]\C(I2U[@W3CR @=Z#*\O.5ZF9');W9U WE@]U5X,@!B
M8L);K7'U8RZ0'Q!7XQ,< T-CD]K5KNQ!.LOULZ28'.#;>8WEBJF;+O#?4DLL
MUC>#H6R.!+8R.\/<$&%UIZL4.E?3R_O"M-1N940B7!XVS9;$,@\O9JV'0ETF
MC'\_W,'AQ[$$4VMUCN=4^AV1W-M_,X7;W4+\FV)Y:\UR-\&+E$CV1R6?$/-&
MUP;J'2MTXZ]B"1>7V_O._P!,Z-G?NXL;N7/B:P)<GB;,%V 1-=[$;YZ_W-\C
M!\HM]2#;5^MG22UN#\UJ^\\3)G>;PQ5;:CT=)V<C9->0NUX<H=KJ@DV?W3MG
M:L$-K<^9I8:M8D\&";(6(JK))=->1KI7-!=H.P(-%:ZN=,:6YXMFVMUXR+<\
MQ#68YUAGB<[ODL)UY0\Z\&D\Q]"":(" @(" @("!H@(" @(" @(" @(" @("
M @(" @(" @(" @(" @((WG-U_D_(0X/%4W93/3M\3W2-P8V*+N?*\\&@]RA+
M74MT[OR,)GH[?KSPM>^)SV7F:!\9Y7#BWN*D9'Y:WW^C,/X]'^]0<.\Q=S<5
MN#;KLOBACFQR6O#?%,+ <7-9J"6@<NFG>OIO(N=_8\?S'\/M;7R^7]RU-JY)
MN)P[<A$^^7/FEL"N0[PF>SHX'7NXK#SO]6O[OVM?+_!/K=<_+6^_T9A_'H_W
MJ\!Z;&GW3N^M:JTI]O0,M72\58O?F<TAB;SO ]G3@/2H&\V[N2MN&&;DB?4R
M%1_A7Z$PTE@DXZ!WI!TX'O4H;I 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!ALQ6,CNNR4=*!N1>-'W!$
MP3N'9H7Z<Q^:J],9RTG4M->G,X[NQY&ZE[;P.?WCN6/,8^*T1D)0V1S>65HY
M&=CVZ.'S5X-_';UR_5?+OY72_=C[4!?M/<FVXW3;2SSW5(^(Q.5'O$)'V+9!
M[3?4LYF(AZ$5F92RH;SHN>1D7O+O\H',[A(.!:.'8.[U+.LRUM6%[6[]A%_9
M.^HK9MZ%<1Z5=;WV$/\ 9.^HF;>@Q'I4_P >^QA_LG_43-O0C$>E;L-LNA?X
MS8@QOM<P<_4.'81P[=56V<<<+5B,\,HG^:&>W Y[]V9Z5U7G<W\E8T>ZP<H/
M /?\HZCM5XG*DUF$JVYM[!X&U3BPU"*H#8@:7L;K(?NK>UYU<?FJS'4\%O5/
MU/:4E6O++'/)$Q\T6OA2.:'.9KV\I(U'Q+Z+#\=BTQ&,K@&BE55 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!X2Z*?^=[?W\+F?W<2#W:
M@MSR^#!+-REWAL<_E':>4:Z!!X(\K_3'9_7O</47?75;'C<-XY!C(ZUI\C&,
M=:,DCG:1/8=6M:UC!KH!J@R_*AB:F ZO]8L#0#A0QE&W3JB1Q>\0P7',8'./
M$D =J#[\G&R]K[YZ7]2MN[LQD63PLV4KS2TY"YC'200N>QQ,;FG@X:]J"UY)
M^F&PMYU=UY[<^$AR.8PV0]SQEN1TK70U[,$L4C &/:"'-<1Q!0:GI;TAZ;9O
MS3[ZZ?Y7;\%G9V"CL2XC%.?,(Z\D$T(8YKFO#R0''M<4&DWCG\=O;S,[QM[]
MV=ENH.$V])8Q>,VQB@YW@PU'"!DDC6N:1'KS//*>+R-=4$T\N>/SV"\Q-V;:
M>R,[LOI9N.C8CL8S*UY/ @E@@$K-9':M'W1KA&==>5W+J@C'E4Z&;#ZNY3?-
M[>T-BU%@<G&VA3@G=7A$MB6>1TKN30EX\, <>Q!@;JS6-WCYE=Z6]^;.R_4+
M";>?-B\7MG$ASQ!#5>V&-\K6N:6QCBX\I]J0@G5!-?+S0SN Z\9J3:VR<]L[
MI?N+&V1)C<M!*(()J\/B,U>=6_+#FQDGFY7::H-+Y.^C73CJE4WU8WWA6YC\
MFWXH:$4DLL<47CB9SY&MB>P>(>4>T>.B#/\ *OM/;V[-M]9MA;FI-RFTJ5R"
MS7QL[GAC9ZQM!C]6.:>;[DS7TZ<4&U\A>RMK9;\X=Z9#&QS[HP5YE;$Y)SGB
M2"&Q ]LC&@.#2'#[)I04\GK:#(.N7OU]V&QYF=[WE87".2M$3=YYFN((#F#5
MP.G:@YY8H]#'],MUU.G/3;=&[JS!-([J3DH6<M6S'Q:\R LTB;\H^SS.U]KU
M!)L?AL9NOR-VL]N* 9',;-FNMVQ<F<\OI-DLPL(9HX CE<6@.!T'8@F'378V
MT\1Y.MP[TQN+CK[GW#@+K,UD6N>7V6UYY6QAP+BT<H^Q:$'/Z.ZLMM+R*/.$
MF?5DR^>GQ=F: ECQ6G<Y\K0YNA;SB/D.G<2@FFX?+%TLQOE=&[(,:QF]X,'!
MFSN%LD@E?/(UD[F%O/R<FCN0 -X<#VH.<]4-V9;>?E,Z:7\[*ZSD:6<GQCK<
MAYI)64V2QQO<3]<&<K=?4@D?FCZ)]-NGG1G:VZMI8?W'<EJW3AO90S32SV?'
MJ23.?*9'NU?SL#@X::(/<6P[-B[L?;-VW(Z:U8Q-&6:5YU<^1]=CG.)/:23J
M@D* @(" @(" @(" @(" @(" @(" @(" @(" @(" @(&O<@U=S<>#H.Y+5Z)L
M@[6 \[OC#=5.%9M$+$&[MNV'!C+S&N/ <X<P<?6X )B3JAN6/9(P21N#V.&K
M7-.H(]1"A9](""&Y?:^X/RW;S6VLE#2FR4+(+K;,1D+?"'*UT9;V'3TJ$M]M
M["5]NXFOBJ[G2MA!,DS_ )4DCCJYY^$J4-H@@O5%K78>BU[0YIN-U#@"/O;^
MXIF8Y)B&MV%GH,;6IX4P.<[(7+/+(SE:R/E#0-1WZGT*,Y3,.F*56AW/@)\U
M'4LXZU[EF,;+X]&R1SL#B.5S7M[VN' HF&/MO;N3H9&_G,[;BMY>^V.%QK,,
M4+(8=>4 'B3J>)*"3(@0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0>4][,Y-];B![[[G?V4<97S^KX[>M
M^L>63G::7[OVRAW3KIML3<^WY,QG\+%D,I/D\E[Q:FDFYW-CM/:P'ED X :=
MB[^J8B(CN?+_ ":7M>UHS/5;MGO2UW1CI6UP=^:];D=P/W2QV]Q^^J/F6[TQ
MMM/N^F?O7!T5Z6%YB&UZIF U=$)9R\ ]A+?%U'S%/S+<U?X?2[OIG[VGJ;!Z
M W\H_!T*F&M9IA(?CX+SI+ <WY0Y&SDDCO XK6U-:M>J8F([\,XT]"9Q&,^O
M_%]Y[IQT5VS1;?R^W(&,ED;7JUX3:FLV+$GR(H8F2<SWGT#XU;1IJ:ML5]O=
M$=\RC6IHZ5<VCZ^/J0A[NA3_ ':K7V!=_+V1DBAPF$LQRUI<A)/(86&.5UAT
M36->/;<]PY?0N^WEVM&9FU>FOBF./3V\8QEQ5W&WF/#:)GE$YC/MSAF3['Z>
MYKI7G=W0[,AP609C\J:L0MR69(IZ+)6"02,>!KSL.@T[EPZM9T]7IZNKEV8Y
MNCY=+:,VZ<3B>V>QN=JN=)3VXYY+GO;C2YQ.I)/A:DE>-;Q3Z_M?<Q/_ /GS
M_D__ %>TU]$_(1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0>$NBG_G?W]_#9G]W$@]VH"#QO_X#>8+I+U%SV2Z"9'%_FCNJ<SSQY0M+
M:?.]S]'Q/XN,1>[PWQDDMX$()-T'\OW4/IKOS?V?W5?IY6MN.G)!4R44CA8L
M6)9C*Z26+PP(]23P#G(-MY7>B>]ND.V]WXK=YI&UF[;9Z/N,[IV\@A<SVRZ-
MFAU/K09'E4Z,[SZ.8G=-+>)IF?,9".W3]QG=./"8UX/.71LT/M=G%!C=.NB>
M]MK^9'>W5/*&E^:N?BL,Q_@SN?:UFEB>WGC,8#>##]<4&CZH^7_J=A>J,_6C
MH%E*M7<.2!&:PEXAD,TCVAKWM+P6/;)RASV/(T=[33Z FG1O;'F*_.');LZT
M;DJ>ZV:8I4]I8UK'58WAW,)RYOLL?VM]DN+N\\ @U?E9Z+;UZ/NWP=X&D?S@
MOP6L?[C.Z?[G$9R>?FCCY3]T;PXH(YU-\O\ U2P'5*SUGZ 92M7SV5#ORUA;
M[@R*5\@ D<"X<DC)"T.<QY:6N]IKO0$UZ/[4\Q!S.8W3UFW+4=%?I>Y4MIXY
MK7589&DD3ES?98[CH>4N+N\\ @UGE1Z*[UZ-T]X0;R-(R9N]#:H^X3NL#PXF
MR@\_-''H?;'#B@L>6_H7O+IED>HLF\C3]RW98:^C[A.Z9_@\]@NY^:-G*=)6
MZ=J"+= .B_7GHKU"N89LF,L]*<C:ELY*^'M=9F;'&\5S'&[22-VKFAXT(]:#
M8=&_+7N[;F#ZL;<WO/4K4]^<T6/L8Z9UA\;'FP>=[71QZ$>*T\NO'B-4$*VU
MT+\U>%V7E.BU;(8&CT]G;:URQ/C6)V3 N,48 YV"5VFI>S5@)XE!T38'E]WC
M6\M6X^B^ZYJ=#-Y22T^E<IS.LUV^*Z.6(O)C8?ELY7:-/#L0:/ICTF\P>-Z4
M;QZ2[PCQ46 =B9J.T6QS,>\VK$CGO,LL8+O#]KAS,U0;[9/EIR,_EQM=&M_3
MP5<Q-;L7JM['O-F.M8+P^"0<[6<VFFCVZ?))XH.;R=%?-_D=HQ=%;^8PT73F
M(,J',-D#IG4HG\S6$Z>,YHT&C"P'ZTNT03KK'Y8LUENCNRNE_31U63\V;@L6
M;&2E-8S\T;_%E)8R35SY'DZ=PX:H))YD>C>\NJ?2; ;,VJ:?Y:QMJI/9]\G=
M##R5ZLD+N5[8WDGF>-/90=IVAB[6$VI@L->Y??,=CJE.QX9YF>+7@;&_E) U
M&HX<$&Z0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%'.# 7.(#0-7$\
M $',MR[SDRD<E#'-=#3YM'6 XA\K1W:#L:5I$,+7RB(&@U X=FOK5F:O H-O
M@MQ7L#.'0N,E(G[M5)]DCO+=>QRB8RM6TPZ]5LPW*T5JN[F@F:'QN]1"R=$+
MR)$!!\22"*-TCODL:7.^ #5$3.'.LSE3GBQMV("DQ_B5F'LYAJT%Q[=="O2K
MH5KZ9>3;<VMZ(:V+"0V<E6M^\14Z=0%TC.+9''B08P!H23P*SU*SU1,0UTK1
MT6BT\VR@R=ZCHZ">1I)X1D\P)^U=J%O.G6W.'-75M7E*7;?S4F6AE;/&([-<
MAK^7Y)U' A<.MI]$\'I:&M\R)SSANE@Z1 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0>6^H;!%O[/ \
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M'37M*XMUSCU/8V'@GUIRN-Z0@(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M7X-=+[7%>JEHMCGA/1W.P@ZKB9B @(" @(" @(" @(" @(" @(" @(" @("
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MB-Q$SA?4\EU:TFV8F8['5UU/ $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$!!X2Z*?^=[?W\+F?W<2#W:@(" @(" @(" @(" @(" @(" @("
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MQCA9D8QVH8X?);KIH7 GX%QQM^//@^GU/.XG3G%?BGW.ZA=KY95 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0>$NBG_G>W]_"YG]W$@]VH"
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MZO/$_@=>4\DC#\EPTU*"2H" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MNU<"!\.NI7)N;1,1#UMC2U<YAT!<+U! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%#ZT',MF%M
MJ/<&:&A_*V=ORQ2 Z\T%9S:D1^9"5Z>KPZ:]U8^]SQVSZ7WOZR^KLK./A)$T
MM8U(N4:GGN/;7&G\8FWC.I7]N2+\D#G,+?,4':_XATYV6Y_..P23\-'#UQNU
MX>A3&9T?3>SMX5T_V_;L="V75=3VAA() !*:C)Y-.POLZSN/S9%76G-Y]?\
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M@(];6OT6DSC1MZ9B/=Q(CXG1EY[<0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M8S#8AFKR.AEBEC.I:]CV$$?20;Q 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M;TZN[*S.;WM8@L9"EE'TZ[ZT#:[1"V)C@"UO:=2>*#T"@(" @(" @(" @("
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MT=]UC/MS(LL31@.GIO\ N=F+7[.-W'XQJ/6O)UM"^E/Q0RM68YI0L%1 0$!
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MA\0'%^H#!KQ)"#5],.INW>K>UV;PVK'<CP\D\M5GY0@]VE<^#0.(:7.]G4Z
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M,$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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ML<G<%Y3$0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M3B" X:D<0002$'"=K^2;"4,]C,EO;>N6WAA<(]K\5@KH\.LSPR"QK]9)?8!
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M88Z<W(YS)HYBZ/V>8&0DC4@=FB#=](\#B-Z^3G=K=U5F9;\T+>3M[:=,Y_\
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M">UI]"BT8G@,A0+-JK7O5WU+3!)!(-'-/=ZQZ"%,3,3F!M^BVZ[&U-QR]/\
M+R%V,R#S)B)GG@R9W$-'H$@[OLOA6'F&A&I3YM><<QZ-7SJ1 0$! 0$! 0$!
M 0$!!#^HG3#9G53#P8+>]!V0QE:PVY#"V62 B=C7,#N:)S3V./!!X8Z@='.G
M>!\U&S^F>,Q)BV9E&4S?QQGG>9#-XG/]T<\R#7E'R7#U(/2&Y\/T\\H>QLWO
M_8.UG69[DU.I<I.O3-\4%[FL//,)@WEYCV-XH-7T\\U68WYGK&0EV7:PW2W'
M86SE,CN2=DTI]ZI,:^6.%X8V-S=26,^N>?1KH@BDWG"ZG7<;9ZA;=Z52S=)*
M$QAMY.W.Z.VX!P;SC1O*P:D<WL.#2="4'2M[>:##;?Z+87K-MO#OS6/S-J*D
MW&3SBE+!*\2"1LC^24!T;HRTC3CVH.<;H\Y._<'%BMW1=*KM?IA;;#XF9R+I
M(9+$DS.8BLX-Y&C7F$9D;]T UX:Z(.K]5O,AM[IULK;>Y\9CI\_E-YMC=MC$
M1.$3YO%C8_FE=[?*&^(P$ $EQT'I00O;7F>WUA-\X78O7+81VI9W*YC</DZ4
MIL5V^,[DC$P)=I[1#7D/]D]K4&PZT^9S+[+WQ!TMZ9;6=O#?I8R:W7U>8HFO
M;X@C#(O;>_D]MQU#6#MU0<-VANW)[X\ZV!W#F\!:VOF7TQ6R&"OC[O!8KX^1
MKM#H.9COE,=IQ"#TMTLZ_NZE=3]Y].3M_P#)@VD9@,E[T)_>?!L^[_>_"9R:
M_*^44'UL;K\[>76G=_2)V ]Q9M5DS_RP;0D%CP)61?>?";R:\^ORR@YIN3S=
M[RR^X<MC>B73V?>&#VY*8\SFG>*Z-S6$AQB;"/9!Y7<A<27 :\J"WO;S*2=2
M/+YF-P;&VQ>LWYS-AMSUX+(9-@B83)[V]S&ZOBT^2[V/G:(-'Y5=[YW(]'=T
M;:W1M>]E]G4,=E\A)N:Y:>^OD21I)CVN>USF.#2[VN<Z?8H)AY9>H/3#;/0'
M/;YQ6WY=F[2P^0MOR%::Z<K9FECBA(<)3'#JY_.R*-FF@X<>)*",'SF]270.
MWU#TFM.Z0,?R',&203<O/X?/XW+X0]KAIRZ:^SS=Z#K'43S+X3:G1W"]8MKX
MP[BQ&;MUZ<%22<49(S.V7F\0EDNCHW1%KFZ? 4',=T><C?N$BQ>[H>E5ZOTP
MM-A\7,Y)TD$EA\S>8BLX-Y&C7F$9D;[>FO#5!ZNVYG\?NG 8S<F)>7XS+58;
MM1SAH[PIV![0X:G0C70A!RC>/7]VT^N6U^C0V_[VW<<<4AS7O0C\#QC(-/!\
M)W-IX?V8[4%>HW7UVP>KVR^E@P'Y0&[O!UROO0A]V\:P8/O7A.Y]-.;Y001W
MJ1YC]STNHD_23HYM ;OWO1C$V2EM3>[TJ^C0]S"=6DD-<WF<7M <=.)0;7HU
MY@(^K-C<>R=V;:GVWOG;T,GY8P\Y+Z\T0/A2<CBT$:./*YCM>!!!*#EOEYZD
M["VKTIZH[XV)L27!Q[?LBU=Q\^5====>&'D:V9T#?"8P:AHY7(+ESSD=0\QL
MVON_8_2BY8Q=7G=N'*VI))L;6$;O:CBEB8PO(:0YS^71NNFA0=AP7F-V=E.B
M<G6N]#+2QE5CX[N+!;+8;>C>(_=HR.4/+G%O*?L3J=.*#CV+\Y74(8?(;XSO
M2>ZSIT]CCALU4DD,0E#N1C;$SV%I8Y_L&1C-&GTH/1G2#J&[JIT\PN^W8[\D
MG+LE><?XWO'A^%*^+3Q UG-KRZ_)0;#J1O&KT_V)N#>5LM$>'I2V8P[Y+IM.
M6)AXCY4A:WXT'YQ=++FYNE&[^F_7/<4A=AM^9#(5[TG$O->280SR/UTUU+_$
M9]J@_1?J5U%P/2W961WOGRY^.H,;X4$):9;$TI#8HH]3H2]Q^9Q[D'BWJEYB
M.HO4GH[N&'<W36WA=F9_P!M_<U<R256F.PUX;8=(T!W-R. D9RC7N0;C>>6.
M-\@.V*[7!KLH*E$-.@YN:[+*6C7O(C01S8,/D?RM7 ;;W(R?\YK-2M'DLM-)
M>KX]]^1@$C?%$@:T"0EG-RAGK03+SO9W+8C9&%Z;8O;MFML6M[A/!NP2E]/G
MK1RQ14BTM]IP:T2:F3N[.]!O^G6RMP=3NA-_96W-K'H[<LQXZK/GW0B:;-T1
M$9))@^-L$A$A/:7N]EQ&NB#E_6KHSY=^FG2B6AALU%>ZOXJ:"N'U+AENSY#G
M'CM?4C>[PF@%Q&C0YN@XD]H=.ZKY?=%#R/51O,RLW3D:&/I61;X3N=)9:Z(2
M<W'G,;&\VO'7MXH.4=/V^22_B]N[>W>R=VZ;-."/+Y9[[T./-Z4 2-=(UX:W
ME>[D+@P,&G;WH/T#V_BL9@\'CL/A6AF'H5HJU!@>90*\3 V/1Y)+O9 XZ\4&
MQ0$! 0$! 0$! 0$! 0$&IW+N/$[3PEO<&;F\''TV<\A U>XG@UC&][G'@T+3
M3T[:EHK7G*8C,X>1-T[TW?U9MR3Y"P_%;1:__%<7"XAKFM/ OTT\1_I<[V1W
M!?3Z&VIH1PXV[V_"GK6:&(QN,:!4@:UX[97>T\_&?I+>9F64VF6;KJH0(@0-
M"B1$" @((UNK,W\:^O#3=X39&E[IM =2#IRC7@KUC+;3K$\VWPUR>_C*]NPW
MDFD!YM!H#H=.8#UJLQB5+1B6<H48#KUL9=F/%1QINCYS<^M#M-=/1ZE;'!?$
M8RSU500:3-T[5>:'<F&D=6S>.>V>.:(\KCX9U!X=X^>%;A,=,\I:TMV3R>M>
MF6^:W4':=3.Q 1W0/ R-<?VNU& '@?L7?*;ZBOE=SH3I7FON4M7$I@N900$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$!W77\'+N
MD T;.QL@^$>R?H*T,[<T2S?^2L^W'T%2_)Z'E_ZD^I:H#2JSUZGYZSAZ6I/Q
M,?(/=%8AE;VM&H^(\5$M-.,Q,-@UP>T/;\EPU'QJ7/,851 @(")$%J4Z.A_A
M6#YZF.:+1\-O5+9K=X!KIQ*#5Y^&7W:G/X;O!\<M\70\NIC=PU5;<FE.;.V%
MCIK]MSA%SUH+;I)GG4-T#6Z#7O.O<D<DV\3KZA(@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @A6\1ID:Y
M]-28?,<TKNVW;ZX>9O.<>J6FJ-D%2%C'GPP.$3B>4:GCIH0HO/Q2K2OPQZD@
MPL#XY)W&)H]EHYFD'OU[]"L;6RZ*:<Q,\6;DS_B,I+2--#V>L>A16>*UZ3-4
M<\1G>[YNH6O4Y?ER>+%]FWYH3J1T2KXD?V;?FA.I/RY4\5GV8^(ZIU)^6^3+
M&3IKJ>\:$_256D1A0EA[(C\.@;\]1A(YUCPWL:\QL+7 MYB[@1H>U6B91B)-
MJM S&/ [&"QI\ ;HNG<>#W.;:^./:Z.O,>R((CU-Z>X?JELG+;)S;G15,E%I
M':C =)7G8>:*9H/ EC@#IWC@@\M87IQYU.G.)9TYV9E<1?VE"'PX_-R20MEJ
MPR$\&-F;XK=-=0 '<OUI03?8?E:M; Z,;XVG6O5\CU"WM5E9?R+@Z*H)2UPB
MC:XM+^4%SG.>1JXGL03WRU],]Q])NF,.T-TOK29:.[9LN=2>Z6'PYRTM]IS6
M'7AQX(/-OG=P&"W3U!V)4VQ;@N[WS+GX.YCZSV22!OC,$#Y.4^RX.D>WVN.@
M0>I=U=&,!NCHZ.D$K_=L=!CZ].E<B:"Z"Q3:WPYPTGC[;>9P[P2$'FO_ ,&_
M-^S9YZ'MR.$/3OD]T_+_ (K?%%/GY_"Y=/&Y?5RZZ>SS:(,SS-].,3TF\J6$
MV3C'FU#C\Q4?<M/'*^S9E98?-(0.SF<> [AH$&HL]*_--U+Z?[7Z=SY?$2]+
M;E&A:9F@6P66UA$R2&&Q$!XCS$"![ Y7$#4H.D];?+3N#=&S.F>S.GLM-E'8
M\I%F3(2.A,D?+$"]H8Q_M.<QSB/6@[3U4Z9XSJOT^R6Q,O*:S+L;#6NL:'NK
MVH"'Q2M:=-='#B.]NHX(/->!Z>^=?:6%CZ7X+,X9NU88W5:6ZGRM=8K5WZC2
M,.;XPY0?8U82WL!X!!TGJET;ZMYW;^R\ML[?,C>I.SXXVW)YG25:.7+.5Q,T
M;"YH=S-^N!#@3S((#_X)==NLW4;;&\>M5;";8QFU)8Y&U\,_Q[5P0R"4-YVO
M?R\SFCBY_LCL;J@D'5_H#U&@ZGLZW]#,G7J;M?&&93#72(X;#PSPRYKG L(D
M8 'LDTXCF#M4$IZ0;?\ ,I9W<_>/63/4:.(%)U*+9^,:R6)TA=S"9[V>PUP/
MUP<YQ'L\ @UOEJZ'[SZ2[@WUD]TRTI*VX[+9\>*4KY7!C9II/N@<QFATD'9J
M@D'F<Z,Y'K-L6IB]O.KP[HQ5V.YC;%M[HXPQP+)F<[&N+>9I![.UH0??1CHG
M)L+HG/TVSLT8R^:AO_EZW2)>WQLBUT3C&YP:7<L?+IJ.T(.';&Z'>:7IYC,U
MTGVO>P,&PLN^=TFYY])9FMGC\)_)!]\#WL 'M-(:>PH.@]$_+_O#9W1?>O2G
M=TU*&;<#[9H7J,K[#&BW6;$#(',81RN8#IWA!H.@O27S ;!P&Z.F.YX<6S8<
M^.R3,3;BG9++-DKK!&UVK?;9%VDA[=0@W?2+RTY?#] MR='NHD]86,[:FGBM
MXU[IVP$QP^#*/$:P\S)(N;E[QPUXH.>1]'/-_C=H2=$:&2PTO3R1CZC<^96L
ME93D>7.B#=/&#3J=1RDZ'EYM$$[Z@>5S*R>7/$]&MA6ZT^7IY*OD[V0R#G5X
M[$P\0SR>PU^FI> UNGR0@E/4GHYNW=GESQG2O%R4V[GJ5,97EDFE>VKST@P2
M:/#"=.'#V4'1^D>U<GLCIKMG:69=$[*8BC'5M.KN+XC(S77E<0TD<?0@FB".
M;ZW/#L[:V1S\NADKQEM5A^OL2>S&W^R/'U+HV^C.KJ14>8MITYS7GSE]QER6
M4>Z5\K^+BUSN8G7]D>*^GUIC/3'*$)%]%8 @("#1[GQN2R=.*+'2<KF/UEB+
MO#YP>PZ^I;:5HK/$;/'0V*U"O7MR>-9C8&R2>D_3T6=IB9F8&2JC;=-K%)DN
MXH9[43,O/D@[W.1[8YO=V0,9"YK7$%S2.;0M7Y[O[3_%:G5SS]&.#VZ1_M4Q
MRQ].>+(ZH2:U,%B#H)+N3BF?"[@XP4F/F<[3T!W)Q4;.G7N-.OIS[N),XI>W
MHQ[VAU.NO>OT-XBW'7KP.>^&%D;I/EN8T-+OA(4S,R+B@.SB@(" @T6YL7/<
MK17J!+,ICW":N]G!^C3S: ^D$:A;:5XB<3RD>@>EW4"MOW;[+$A;'G*0;#E*
MPX$2:<)&C[%_:/0=0OGMYMIT;X[)Y)3I<0(" @(" @(" @(" @(/$?5G_P \
MO3_[3'__ -9!U'SO?_(#+?SVC_*H-MMC=SNGOE3Q.\JU-MR;"[8@MPTR"&/E
M$0#>;E^MYCS.T[M4'FK(YKJ!U%Z!9[JAO;K V 6V30-V+3BJ0UY>24,;7>W4
M2<SNW1K=>70Z]J#1;GT_43V__P#G-)P_;64':?,9_P"37;G\UV]_),0:3?U/
MI-N'H]T7VKO[-W=K;GLXZI+M3<5:LZ6"&9\<4<C)7\&!NO(XZN!;H':H+4F_
M>M'0KJ9L[9^^=U4.I6UMQSQP5]8V29*-DTK81)S$>('@D.;JYS7\>\(+>RLA
MCMD>>'>QWI9BH',,G.'MW'B.+2U'#)$T/>0!S,:YHX]O!!\29K$9[S^4;V$N
MPY"E'695=8K/;+%X\&.>)&<S202TG0Z(+GETS.(V]YH.KT.>OU\9+8DNQP"Y
M*R />R^)'-!>0-0T\VGH08W1JU!N;S1=9[&V[D=N')8W*-QMVN\/B>Y\\;&N
M8\<".;O"#;>1O=FUMK[/WE@MQY.KB,[C\D;%^*]*RO)X,<7AN=]T+2X,<QX.
MG9\:"5'>/2+>O0GJY?Z08%^(I05)XLM/[BVBRU9\)S@YI:YW/RM))/=S>M!I
M_*YD\<_RI[EQ3+D+LG%7W!++2$C3.V-T#M'&/7F#3KVZ:(.,;0QN3R7D8W8<
M:'.%+<QN7&LXGW:)E7G)'H:2UQ^!!WS'=3.FD?D[Y'9.ERQ[<DQ#\298S8_*
M+HS"(_!UYN8RGG[.SVD'G[/X[(8_R*8)]]CF,O;M%NES?75GMG:UPU[BYKB$
M'<O,8?\ ^3C;O\VV_P#R+$'=>@.G_@ML7_8]7]P@\V]=+M3"^<[IGELO,REC
M&5ZA?<G<&0M'BSLU<XZ #F(!)X(+'73/8//>;KI(W"9&MD?<9*,-QU65DS8I
M9+KGM:\L) );QT]"#8;SVELW?W7O/S=(NH-S876C&,>S,5K%9\=*V^(-C>Z-
M[BWFYF\I<UO,'#VM$$A\N_5S?^=WUO;I1U&EQ^<S6W*TTL>Y\9&QHD$3VPN8
M]T;6M>T\P+7:!VH(=J@XKT,_\M77G[9O\F4'7.B)/ZDN:X]F.S@_E$'$:5"]
M=\B=^6DUQCI;K-JXYO8R -CC+G>H.>U!V[=O4#8>1\EGN>+S%**S)@Z6,CQG
MC1LL^^PR0LDA\$'FYN9CG=G9Q[$'3O*)P\O6S=?[E9_[5*@Y?YZ=VV[&)VOT
MBP9=-F-SVVVK%2(Z/?#"\1UV'TB29W_40<JZH;8\R.4Z0TMG;JZ;XK%[-V5%
M';ARF.L>)?ABIQECW_Y1('<X)=)RLX]J#=]4]X9'JGY*MNYZ-YGO8')4Z.X2
MS4Z/ILDK-E?ZCSQ.)/>Y!-.JV_MBY/R;4J.)S%+WJUC,5CZV-9,PV/>JSH1-
M%X0/,'-,;B=1Z^\(,K;N^M@;#\H_3V_U+VS-N?:UR,59*L-:&VV*=TLYC>YL
MSV!NNCFM<TZH-+YKLIT4RW0/%7MJ#$-R-B2H[;<-!M=MR*%P)E86Q>TUK6DB
M1KN'-V\4&!YEFY=GD]Z>,SO,,J'8GW@/UY_\BEY>;7CKRZ:H.^W^JV$Z.=#-
MH;RW%0O7\6,=B:<K<;&R66-T]5O*]PD?& W5NFNO:0@X1UXVYY<L[TPRG6S9
M]RMC>H.5?%EL;?JWG#(2Y&:1KG0R0>*[E</:YPUHY2-=?2$[H=6L73\K.U-[
M]<<!8W91R/AU,@P5H;;Y#XLL=>S*R9S .8,;[>NO,=>]!$O,_E^AV9\NU+([
M5;AH[%A])^W(*;:[+<+7'FFC<R+VVAL?.)0>'-V\=$'HCH S*Q]%MC-S0D&0
M&)K<XEUY_#+?N6NO][Y=$'2$! 0$! 0$! 0$! 0$!!Y?\Q.YY-Q;IQO3RA*?
M<<?I;RA:>!G>-6@Z<#X<9U^%R]_R[1Z:SJ3V\G13X8RB;(XXHV11-Y(HP&L:
M.P-'8O28OI$" @#MXH(]CL1EZ^<FO6;'/4=S\>;4R!WR1R]VBO,QAK-HFN$A
M5&0B1$"#XEAAG;R3QME8#J&O:'#7XT3E]@     #@ .  1 @=VB @('SQZ"@
MN]-=YNZ4[T='=)_,_/.;':=QT@>#[$H [V$Z._8GU+FW>A\ZG#Q0W\=?3#V%
M')'+&R6)XDB> YCVD.:YKAJ"".!!"^7Y.=]H" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(""*[T@UCJV@.+7.C<?4X:CZ"F%+.?9O_
M "5GVX^@JWY._P O_4GU+=(ZU8_@(^>LX>CJ>)8RC=8V/^Q)!^-1+32GC@QL
M_,PP.^4WBS[5(-6O:SE+G50$2(@0?/@R6;-*M%IXDUB-C-> U)[RI3/@MZI3
MBMLVPXZW++6-[VQ N/S3H%KEX/2W=/;F)J:.$/BR#Z^7VS\SL^<F5HB$;ZG@
M-P] -&@%MH ' ?>WJLM(7>F'] 6OY]-^Y8D(E-5*! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!#MZ-TL
MT7?916&_,#"NW:]OL>=O.SVM/1&L,(^ ?/47YRC3\,)/B_[:?M?IKFEV59-W
M_)9?@'T4A,M-J>]2H^2UI^M'S I0<C/L6_,""HX=@ ^ :(F&#,297_"5I')C
M;F^%*JC_ )#O@/T$%=J_TU3^TLG]RNC<>#W.?:^/_N=$7FO8$! 0$!!R/:_E
MMZ6[4ZAY/JA3I6+>[,E:FOB:[-XT-:Q9)\1]>,-:&DZG0NYB.XA!UQ 007JS
MTGVQUEVJ-G[LEN0XIMJ*Z'XZ5L$_BPM>UHYG,D'+H\ZC1!*=OX6IMO!8W;V/
M=(ZCBJL-*LZ9P?(8J[!&TN<  7:#B=$&Q0$! 0$! 0$! 0$! 0$! 0$! *#S
MSU\SC\YN'$;"IO\ N4!%S(Z'@'O'L _:LU=^V7T'ENGT4G4GV(:9K&QM;'&.
M6-@#6-'<UHT 70*H*(*H" @( [1J-4&@P^P,WO;&Y6Y/E*?A>]6*./GM5#9F
M:8M62/8\.:8P"?9#=>(U7Q_F/F/S-6:UI2:TG'Q1G/?ZGL:&G&G6)F;9F,\)
MQZO68W9UWI\_&XS+L@NS7(Y*U3.PR2R2RF >(YDS9N,9<TZCD]DZ+3RK<Z7S
M>F-.M+6SCIY<.SCQA&[BUZ]75,Q'9./L;]?6/($! 0$! 0-=#P[4&A=^6-G9
MN/>&TSRSQDF]3&ICDC)U<'-':QW?WM/$+;X=6O1<>C-@]1L%O_'^\8YWN^1A
M ]]QDC@9HB>&HT^4P]SA\>A7SFYVM]"<3R[TI@N0$! 0$! 0$! 0$! 00+,]
M&NG^?Z@8WJ?D\<^7>6)$8HW18F8U@AYN36)K@PZ<Q[6H-MO[8&UNIFW)MJ;Q
MJ.NX.Q)'++ R62 E\1YFGFC<UW ^M!F8O:.W\1M:MLNK3:[;56H,<RA.3,QU
M4,\/PW^)J7 MX'5!QZAY-.@-#)VLD-O2V!9CDBCIV+4TE:N)6EI,+=0YK@#H
MTEQY>Y!)IO+ETFL=/V=,)\3-)LV.\<I'1=;L%S;1!:7"3GY].)]G71!(=S]*
M-D;PV/5Z=9^@^QM.FRM'7IMFEC<UM(!L/W1C@\Z =YXH,?<'1CIQNG8U#IWG
ML,RYMC%Q1PXR&1[S-7$+>1CHYM><. X:\W'OU01;I]Y6^CW3;.Q;FPF+GN9V
MMJ:5W*67W75B1IK$'Z-:0#P.FH[D&XZJ= .F76*6I;WIC'R9*FSPH<C4E->S
MX)/,8GN;J',UXZ.!T[M$%G;/ERZ0;.W%A]U;;P Q^:P5;W.A-%-,&B/D<PN>
MSGY7O<'GF>X:E!KNH?E<Z.]3MQG=6Y\1+^6)>3WV2I.^NRUX8#6F9K=03H-.
M8:.]:"0;*Z%],.G>Y+6Z]FX08K+7*PHR^#+*8!7;RD-;$YQ:WBP<0-4$:W_Y
M4^BW4?<$FY\[A9*^9L/$EV?'S.JBQ(-!SRL +2XZ<7- <>\H.B[>Z?[-VKM,
M;&P6'KU-JF&2O+C@WFCE9.TME\4NU+R\'VG.))00'9'EAZ2=/<GFLIMO'V8I
M,[0FQ%R&6U))$RC9TYXH@='-'#0'F)""7["Z4[%Z:;9M;/VGC!!MV[-+8M4;
M$C[;)'V&-CD#O'+]6N:T M[$',W^2_R_R9[\N';\P:7^(<8VU**/;KR\FO-R
M_L>?1!TS?72C8G4;:M;96Z,6)MLTY89ZM"L]]1D;JS',C#? +-&M:X@-[$#<
M_2G9&\-CUNG>?H/L;3ILK1UZ;9I8W-;2:&Q?=&.#SH!WGB@D&W-O8K:F"Q^W
M,)$8,1BX&5:4+GND+(HQHT%SR2?A)00_JGT1Z>=8ZM2#>V.=-8H<WN=^M(:]
MJ-DFG.P/;KJQVG%K@0@CVW_*QT2VQ;V_D</MXP9+;4WO6.N"Q,)73\XD\2;1
MP$A!'#F&@'#L0;#J=Y=>EG5K(Q9K=6+DCST3!%^5L=.^G;=&WY+7O9P=H. +
MAJ!PUT0;CIOT9Z>=)\;:QNRL2*?OW](7)'NFMV- 0/$E>2=!KP T'J0:[;_E
M^Z6[7VKN+9F&Q,D&W]U:'-US:G>Z70:<'N>7-X?8D(-S@>E&R-M;"GZ:8>@^
M'9]F*Q!-2,\KW&.WKXH\1SB\:ZGOX(-$[I[MKI/TEW#MOI_M)V=Q_@6K4>U7
MS&<WIYV!KXRZPXZAP:-6Z]WL\4'@[+X':&6IWL%T]Z';DH]3,HQM4C).FLU<
M7S/:9#6#F@ZZ L:Z4^PTZH/?_0S8N0Z:]*=L[+RTC9,KCJI]^,9YF-GFD=*]
MC2.T-+^77OT07,ST5Z>;@Z@4.I^7QTEK>&,,)H6WV)O"B]W!\/EA#^3@7$_)
M[>*"<7J57)4K..O1B:E;B?7LPN^2^*5I8]I]1!(00+9O0SIGL3 9K:VW\/IM
MS<.GY5QEJ:6W!+[!CX-F<[EU:=#RZ=@]""%8GR;] \0[*.CV_):.4B-9QM6I
M9'5XBX.+:[M0YAX <VI=IPUTU0=-H=,MD8_8<73)N)CL;)AKFFW%6BZPPPN>
M7Z%TA+B0XZ@ZZ@]B#F6W_)ST&V[GX]PUL#+;GAD;/!3O6'V*C)&'F:?#=\KE
M(X"0N"#I74;IALWJM@8]M;WHNOX>*=EJ.!DTE<B6-KF-/-$YI[''@@VDVS]M
MVMJMV3>Q\5S:XILQSL=9'C1NJQ,#&M=S:DZ!HT.NNO'M0<8I>2KR_P!+,#+_
M )"L6&AW.,?8MRR5.!U#2W4.<T?8N>0@[?DMM8#+X&;:^3QM>SMV> 4Y<6^)
MONQKM #6!@  #0!RZ=FG!!Q?#>37H)A-P,W#!@);$L4C9H:-NS)/3:]AYFZQ
MNXO (^3(YP0=[:UK&AC &M: &M'  #N 050$! 0$! 0$! 0$! 0:S<.;J;;P
MF0SU]P;4Q\#[$FITYN0:AH/I<=&CUJ^G2;VBL=J8C+Q7@IK>9OY3=F2/->RU
MB20D]P>[F=IZM?9'P+Z_IBL16.4-M2>QO5#$0$! 0$!!@Y6KD+<,3,=;]TE;
M('2.T/M,'=P_^A4Q,0O68CFSN.@!.I[SV:E0J(@0$! 0$! 08N0Q]?)U7U+(
MU8[BUP^4QW<X*8G"T3B<I3THZOV^GTT6S-[N?)MPNTQN4XN]U:3IH[O,/?Z6
M?!V>?N]E\SXZ<^[O_P 6MJQ;C#U/7L06H([-:5D]:9HDAFB<'L>QPU#FN&H(
M(["%\[,3'-SKB @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @("#6YVD+V,GBTUD8WQ(OMF<?G]B(GDY+FS_BL0]+_ *2K?D[O+O'/J6,:
M[F@+?L'?./%9P]/5CBNW&>)6D:.T#F'PA3*FG.+-/%(Z)[9&_*:=1]15=DQF
M,-[&]LC&R,^2X:A6<,QB1KM2]O>P_.(U"$PJBJJ"B#)Q3>?/8=AXZVFN_L03
M])$V\%O4Z^M7BB"#=4/Z(H_SQO\ )O42M"YTO_H"U_/IOW+$@E-5*H@(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @B&]?\HQGP61_U6+LVW;['G;SL]K38_P"]Q?;'Z*:G.4:7*$FQ?9+\
M+?IKFEVU9-W_ "67X%$)EI5=D( 42F!2A@S??7_"M(Y,K<WPI54?\AWP'Z"#
MZVK_ $W4_@[/T6KHW'@]SGVOZGO=#7FO8$! 0$! 0$! 0$! 0$! 0$! 0$!
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M!!NJ']$4?YXW^3>HE,/OI?\ T!:_GTW[EB02FRE @(" @(" @(" @(" @("
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MML"D"8YH"6-'*X2'7B2._1!Z20$&-D<A4Q5"SD[\@AI5(GSV)7=C8XQS./S
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M @["@(" @(" @(" @(" @(" @(" @(""S;LPTJL]RP[EKUXWS2N]#(P7./S
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MC=PT^%?(P,G:WMY7$:.;^U<"%\CJTFEYK/8QF,3AMUF@0$! 0$! 0$! 0$!
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M>SL<>7T!!S[8FY*VR-Z;=W?/7=9JX"_#D9:L3FQND; [F+6N=[()])0>R/\
MF*[3_0B]_6%- _YBFU/T(O?UA304_P"8KM/]"+W]84T%?^8IM/\ 0B]_6%-
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M2\TM%H[!Y*V]%:P61R>S\F.2]C9GAC3]<UIT)'I!&CAZE]9J3%ZQ>.4H2-8
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MV7847A;6I'OD\20_'([ZBVKR>!NYSJRDBLY!!!NJ']$4?YXW^3>HE:'WTO\
MZ!M_S^;]RQ(1*;*4" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(""*;S^7BS_?)?Y-=>W[7#N_P^M'L:=&Z
M_P!\/T5?6\4L-#PPW]6803MD/%O$.T[="N5W0R[=V&2%T41+G/X$Z: !1$)F
M6N5E! 0%"S!D^^/^$K6.3GGF^%*'S)\AWP%$OG;ATR^*/I=*/_5/77K^&7'M
M?%7VND+RGMB @(" @(" @(&J @(" @("!J@(" @(" @(" @(.#=?-HSU)ZG4
M;#L^[U"R#+-:/E1@\L<A]0UY'>K1>[Y;KQ,3I6[>0B=*W#D*D-R ZQ3-#@/0
M>\'X"NRT8G"%_L[% PZ^*QU2U+=K5VQVIM>>0:]_;H.P:]^BM-YF,2,Q5! 0
M:'.;8AS5B.T+!KS-:&2>SSAS1V:<1H0MM/5FL8&XJ5HJ5:&G#KX4+ QNO:=.
M\K*TYG(YSNRR;.=LC75D'+"SX&CC\\KT-&,42TJV! 0-$!$9$2=J AD09..M
MOH7Z]QAT,+P3]J>!'S%6]<Q,#KNH.CF\6D:M/J/8O*0(+<\++,$M>37PYF.C
M?IP.CAIP4Q.)R-7@MOP8)LWAS.GDG(!<X<H#6]@T'T5IJ:DW&X60PMLT7;AZ
MM8*A&-8<61;G/</!^ZGY_*%.M;HV]I[^ ]5KY9(@(" @(()O+H]T\WYDL?FM
MP86%^>Q5F"[0S%?[A=9+6>U[ 96:%[=6Z%K]1H@G: @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("# S6(HY
M_$W<+DHQ+0OPO@G8?L7C34>L=H]:M2\UM$QSA,3AXN_)=_9&Z,CL7+G5]:0N
MHS'@)8G<6.'J>WC\*^NIJ1JTB\-K\8ZH;92Q6+E*ID(?=[D8EBU#@#J"".\$
M=BF)PM$S"Y##%7B9! P1PQCE8QO  *$3.7VB!$OB:)D\,D$@UCE:6. ]#AHA
M#2XC;$.*N&Y[P9G-!;"WEY>4.X'7TG17FV6EKYC#*W#8=5PUN1IT>]HB:?7(
M=/H*(YJTC,N;#@MG6JB! 044)50%*! 0$2F6RK9?7LT7'7PG"6,?L7\#\]9W
MAAJQVI2LV @U&9V_!FI8999G1.B!8[E =S,)UTX]A5HMAI6_2VS6AC&L;\E@
M#6@\> &@55&-DK(I8^S:/]KC<1\)X#YY4QS36,R[EY:\%)BNG3,A,-)<S:EM
MC^";]R9^Y)7S_F-^K5QW+:L\78EYK(0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0</W6WP]RY('A]WYOF@%8SS?1;?CIQZF3ZU+G$0(*(
ME5$,3(MYJVOV+@?I)+;2GBU"HZQ!W#:<?A;<QC"-#X#3I]MQ^FMXY/G=Q.=2
MWK;E2YQ!!NJ']$4/YXW^3>HE:'WTO_H&W_/YOW,:0B4V4H$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$
M3WH1XN+'IDF^=&NO;=K@W?X4<QY]A_J?]-::WB8:'@;Q<KND1 @(D1 B6#,/
MNK_A6D<F-N;X4JOF7[T_[4_01*UM\Z93$'^^2#YL;UUZ_AEQ;7Q5_;O=+7E/
M<$! 0$! 0$!!Y&S6P\?U4\V.^-K;CRF7K8?&[=Q=^I!B\A/1#9W>'&XZ1G30
MAQ[D&YSM7<'E@W#MK,8_<F3S_1W/9"'"9[$YZ<WI\7/:U$%FK.0'!A=P>P\/
MCTT#L_4?JQM+I=6H.W"^Q8R>6F]VPV$QL#KF2NR@:D0P,XD#O<= $&FV!UXV
MGOS<<^S74,IMG>,,'OC<%N*H:%J:N#QDA!<X2!OUW*=1V]B"1;$ZE[:ZANSL
M6 =.RWMO(28G+U+<7@3Q68N)]G4^R[ZT]Z!M7J3MS>6X]T;7P9GEO[/LQT<S
M,^(LK"S(TN\..37VBT#VN'!!B=2^DVW.JD&-K[ANY2FS%OEEKG$7I:#G&9K6
MN\0Q_* Y>&O8@\T]<>A6T=DXG"8+9N8W+-O_ 'EDH<-MZ.QG+4D49>0ZQ9D:
M"-611ZD^LA!Z_P!OXB/ 8/&X.&:2Q#C:T-1EB=Q?+((&!G.]Q))<[34H-D@(
M" @(" @(" @QLA0JY2C8QMZ,2T[<;H9XW<0YCQH1\]6K::S$QS@>3J^-L[-W
M7E=DW271Q2&6A([Z^,^TP_MF?/"^KF\:NG&I'M0WBR! 0:ZM#F&Y:U-9F8[$
MN:!6A'R@>[Z>OI5YFO3&.:6Q5$" .T?"@Y/FM?RQ?U[?'?\ 17J:?AA+!5Q\
MO>R-I>]P:QHU<XG0 #O)*B9B(S/),1,SB.,RT&X,Y9K2P8C#M$N8N<6'@6Q,
M/UQ]:TI$3QGD\;?[R]+1HZ7ZEO\ 3_BT63?GMNR1/9F)+UV8%TM4L+V::=H!
MUX>C0+AU]]I4U*Z,\+:G".W'=,^UU[;R;S"-'4W=;_,IH_%>L\.J.VM?9W,G
M'LS=_'C-8[*FQ.-?$JD: .;VLT)TU^)>%J>7[_2CKC6FUX_#V3^WJ?=;+SSR
M?>UBO\/%-.>'5^*L^G''VY]+>XW<%2YCI;M@B!]4:W&'ZTCO /I[EZOEV^C=
MZ>8C%HX6CNG[GC^=>7SY;J3U3G3F,UMWQ][1QR9W<<4V5??=AL+'J:S6#VG-
M;]<XC3@O6O>FE69MV<Y?$:&GN_,+9I,TK:<4K'.6NQ^4S&5MQ8FYDW5V/#A7
ML\G*9N4]FH(X_&OG]2M_,:5U-#4G3IQB8QQS'[=[[/9;J/)=Q;:;_1KK:W":
M7S\,UGLGT^S/9/9,SK'5[-6HR"W/[Q.PNUF/:X$DC7XEZ.STM33TXKJ6ZYCM
M^I3?:VEK:TWTJ?+K./A[I[64>P_ NQPNN8UYEQM.0]KH6:_$ %Y5_%*&6J@@
M(,:_>@QM.6[9.D<0X#O<X]C1\*M6LVG$";>7[:]L1Y'?N486V,L3!1:1_P"S
MAP<]XU'8YP ;ZFK@\SUHX:<=G-+N*\0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!P[S(;)
M_*FWX=[8UFF8P!!G<T>T^FYPUU]/AN/,/42O5\NU^F_1/*WUMM.W8XYCKK,C
M1ANLX>*WVAZ'C@X?-7NS&%+1B<,I0J(,7),O24I68UXCNG3PWN[.WC\!T4PM
M7&>*[6;8;6B;;<'V@T"9[>#2[O(1$\UU0@0:+=^OY$=I_=H]?@XJ]>;73YH"
MM70H@J@(" @(" @()#LUY;EGM[GPN!^(@JEN3/4Y)TLG,(" @TM^G?W7F\?L
MC"-\2_?E:)R.R-HXDN([ UNKG):\:=9O/8VI&(ZI>U,%AZFW\-0PE$:5,?!'
M7B[B1&W34^L]I7R-[S>TVGM8S.6P5$" @(" @(" @(" @(" @(" @(" @("
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M=^G[V]7.ONYNI;_N^TNGS'[4VD[MADR+_:R%EA'!Q&OA ^@H/1* @(" @("
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MF>*XB!!!NJ']$4?YXW^3>HE:'WTN_H&W_/YOW+$A$ILI0(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((!
MN"P;.=L::&.LR.LPCT_?'_/<%Z.C&*/)W%LZGJ:_'C6)[P=0]Y.JKK>(T(^!
MN(#K$WU</F+FGF[(Y+BA(@("!W*$L.S]]/P!:5Y,K<UI644>"6. [2#I\.B#
M5\SA3<Z+@^+5[/MHG<X^@N^>/M>='"/4ZK!*V>".=GR)6M>WOX.&H7CS&'T$
M3F,KBA(@(" @(" @X3O7R[9/<G4G*]2]M=1,QL[+Y:G6Q]N+%0P$.AJ- :"^
M0%Q!(YM$2W>PN@6 VAN,;XS^:RF]M^,A-:OG]P3B=]:)P/,VM$T!D7-KH2.*
M(5ZI]%I]\;APV_=I[EL[.ZBX"-]:CF:T3+4,M25W,Z"Q7D(:]A/K0:'#^7/(
M1;^VYU3W3O[*;AWQA9)C:FGA@BHS5YXRSW>"LSV:\;>8N]C4D]J")^94[,ZO
M9[9'1W"VH,OO/\OQVLDRE(V9^+Q=0.]^?9Y"?#YFZ,Y':$E!Z@KP0U8(JU=@
MBKPL;'%&W@UK&#E: /0 $&)G*-K*8:_C:5Q^.MW*\M>#(1M$DE=\K"T2M:[0
M%S2=1J@CO2[IUB>E>R,9LK$3/M0T ]T]Z9H;-9L3/,DDT@;PYG.*"8H" @("
M @(" @(" @\^^8:8V-R;2Q?UNLDWQND:W_T5]!Y7&*7LAI'?*/PKH%$! 040
M50"".T((GOG'F6K#DXQJZN?#FT^P<>!^(KJV]L3@05=J34]B B,")$#UH"(P
M(D09F)INR&2K5&C422#G]3&\2?F!4O;IB9'6SVZ <.P!>6A0@CM" @CNZI+=
MHT-NXT<U[+S,B:T=X<\,:/@+CQ^!;Z6(S:>4#U'L_:V/V;MZG@,>W[G7;K-+
MI[4L[N+Y'>MQ^=H%\OKZTZMYM*6]6 (" @(" @(" @(" @(" @(" @(" @("
M @\S>;_&4,T>E6'RD(LXS(;NJ5;E=Q(;)!,TL>PEI!T(.G!!LMY>5[9&$PEO
M</1Z.QL7?V(BDN8C)XNS8\.26%I=X-B&61[)(I-.1P(^H@E&P>N.'RG0FCUA
MWI,S%UJ]-[\\6 N:RW6>8)&QM U)?(/8;^R 01F7S/9/$5L?N7=_3'.[=Z<Y
M*:**+=%F2O*88[+N6&:S4C)DB8[4'74Z:H.A9?JUB\)U+VQTYN4)RW=U*>YA
ML^QT9HR2UP7N@/'FYRW1S=.!U""[NOJGC]L]0-H=.(L?8R>>W:;$K17=&UE.
MG4 ,EB;G();V@!O'@@GH0>"MKL\K^7SV_P#</7&YC_S@R>[,D,>VW8M-F93B
M<UC26UW:-8YVNCG]NB(>P>EVSNG6SMK15^E]>O#M7)2.R,,E.=UF"9\S6M,C
M9'/?KJ&CL/<B4U0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!:LS"O6
MFL'B(F.D/[4$_24Q&9'A?:#G3QY*Z[Y5FTYQ^:7?37V5HQB&^IS2-58B @("
M!H3V<4 M:YKF/&K' M</2#P*)<NR5)^.O34W_P!K=[!]+#Q:?F+>)RZXG,98
MJE(@H@J@(*(*H" B4UV74,5.>XX:&=_(S[1G_2LKRY]2>.$G )[ J,5$#@.+
MCHT<2?0!VE!(.@6TH=Y[NO[WRS/%QV$D;'C87?)-H\6.]!$;?:^V(7!YAK=%
M(I'.S>_PUP]5+YUSB @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(.1=11_\ B0^DUX^/QN65N;W=E^G[6!6.M>(_L0B+\Y7448]YGB5G
M^EOM#XDEKISB6HBE=#()&=H[O2.\*KJF,QAO(Y&RL;(PZM</F>I6<4QB7VBK
M3Y!G)9<1V/ <JR[-.?A4Q\?C9"I%]G/$WYKPD+7G%9GT/0"W?," @@W5#^B*
M/\\;_)O42F'WTN_H&W_/YOW,:02FRE @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @Y7-8,OO=PCE=/--)
MIVZ%TA:/G +UZ1RAX.I;.9]++K1F."-A[=-3\)7':<SEVUC$1#+@E#"6N^2[
MO]!5)AI6<,M4:" @("#"F<'R$CL[!\2TCDRM/%;4JB# Y1'9D@/R7^VT>KO'
MSUUTG-?4X[QB_K3K:LQEP%+7Y43#"?\ !.+/H!<&M&+R]3;SG3AN5BZ! 0$!
M 0$! 0$! 0:3$[/VK@LKDLYAL+2H9G,/,N4R%:O'%8LO.A)ED: YW9WE!NP@
M(" @(" @(" @(" @("#SSU_!BWKM*RX?<?#<WF]8E!T^>OH/+/TKP-0[Y170
MA1 "#6U<A>GRUNC+2,5*!NL5HZZ//#XCKW:+2:Q%8G/%+9+-!W>CNU]"#68?
M&6L:RPVU==<=/(9&EVNC1\9[3WK2]HMRC V$L45B*2"=O/#*TLD;Z6NX%9Q.
M.(Y7F,5-A[SZDNIC/M02]SXSV'X1V%>G2_5&4L!: @(" @(" @G.R<2887Y:
M=NCYQR5@>WP_KG?'V!<.O?,]*&RW7-?@Q#WX_F#BX-F?&-7MB/;IIQ6>C$3;
MB,#9+<D*]B2V9/<GD>[B774N^N+=>.BTU^G/#F)4N86M@TFYKK-1$@YX,1 ^
MQIZ'Q1Z-/]G(%&ZMT;:?2/4:^82(" @(" @(" @(" @(" @(" @(" @(" @(
M/./FK_I3H]_^>M!!V;J+NW"['V3G-S;@M1U,;1IS/<^5P;SO\,\D;=>USW>R
MT!!YPV7FCT5\GN.S^X\%%D\A?>+-'!9*/6!UG+W/\5$X<UW*T!S9"=.ST%!C
M=?\ ;W6R'H1NG-;\WYBWXU].)UO:N-P\4==X?-'R0Q7))3*"TZ$$-XZ()-UO
MP=[_ ,#=C=2<&W7<O3AF(W#3(',YU=D,4=J/]M&>8_:H,WI!=I]6>MV].L=-
M_O&V<+2J;6VK*X<'%\;;5V5AUX>VX,^-!Z*D>V&-\KSHQ@+G$ G@!J> XH.9
M[ VWT-W5MRUG-A8/#9#;N=L6'7;,=)FD]CG+)Q()V!X(<#JT@:=W:@Y[Y2XV
MXK_Q0V?B)'2[(VYNRU3VR22]C('-#I(HWGM:QVG =FJ#TB@(" @(" @(" @(
M" @(" @(" @(" @(" @(" @("#&R,;I<?;B9Q>^&1K1ZW-("M7FF'AK9?LT+
M<3N#X[#@X>CAI])?97;:O-)%1B(,3)VK%.E+9JP&S.S3EB&O>>WAQ.GJ4Q"U
M8S*]5DEFK0S3Q^#-(P.?$>):3W)*)75"&NRV.L9%E=M>VZIX4G.\MU]H?%IQ
M"M$X7K;#8_/]:JHT&Z<.[(5A<K-UN5@=6CM?%VD?".T*]9PUT[8X($#J-5JZ
M540(" @(""B#(IU)K]J*I -993H/0T=Y/J 49)G$9=/K5XJE>*K"-(H6AC?7
MIW_&L<Y<<SE",W)FYLX^&+Q@]K]*;(]0WE[B".'PDK2,8=%<=*=1^((V"4@R
MAH\0CL+M./SUDYV%F[!K8>[,#HX1%K3ZW^S]-3'-:D9EZ'\O6)9B^EN*E:-)
M,D^>_)\,DA8W_J,:OG-_;JUI]' U)^)U)<#,0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$!!Q[J$_FW-*T<?#AB;\>A/TUE;F][9Q_M^
MUK!(8J$$GV);\S4A1V+XS:89NH/$=AXJ6"A <"T]A!!^-!IW4+320&:@=A!'
M%1AV?,JSJ$4L,;Q*.7F.K6]_K2&&I:)G@RU+%KLHSA%)W<6GZ(42Z=&></O;
M<8EW!BXW<0;,9(^U/-])(YK:TXT[>IW5;/FQ 00;JA_1%#^>-_DWJ)3#ZZ7?
MT#;_ )_-^YC2"4W4H$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MP'M1O](](/>%>EYK.82YGD<;<Q5DU;C.5WUD@^0]OI:>]>C6\6C,#$5P0$!
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M>8L/P (.F; Z?[7Z9;8J[2VC4-7$UBZ0E[C)--/)QDFFD/%\CSQ<[Z2"3H"
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M'G]DWZ85HMAI6\PA][!Y3'$F> NB'9-'[;#\SL^-:1,2VBT2UVH^-2N(&NI
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M+;C>4QV97 H6+Q'M6YG<CN\Q0_<V_/#EQ;B?BQW/2VE?ASWRDBYG8(" @("
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MHBA_/&_R;U$IA]=+?Z!N?S^?]S&D$INI0(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(-3F,#7RY9*
M9'5[<0+63L /LDZEKFNX.&O%:Z>K-&&KHQJ>M'[VU):E<VW9 R^ 0[D\%K>;
M4AO$ZGTK?^(SPQS<L[7''/)B24?'D92\4M\=[8_$#02.<Z:Z>I1%L<>Y/1GX
M>]LSLJ4MY/RH_0CE/W"/L[%/\3Z#^#X8ZFM]R-5OA^*7^&YT>I:!KRN(UX?
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MS:'CQ)(8WUE9Z^M&CIS;M[&]?AC+V7C<=1Q%"OC,9795Q]1@BKUXARL8QO8
MOE+6FTYGFPF<LI50(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(""U9C\:M-%IKSL<W3X00@Y4T$#0]HX'X0KL6\VI"9,PR33A%&]Y
M^/V1]%1*U>:?*K001O?1(VW9T&NKHP?@YPICFI?DY.M7.Z5TY:!B[3^]TY!/
MP-"SLWT^29*K00$!!!NJ']$4?YXW^3>HE,/OI=_0-O\ G\W[F-()392@0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M;E'LD:Z"33E=WZ%?3[;=UUHQ/"W[<F^8OZVIQN7Q^5C#Z<H+_KH7:!X^+O\
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M3K^::-/RC;T<]NO;X;![+-?5Q]:\W<;W4UN$\([A/EP@@(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @H]K7M+'@.8X$.:1J"#P((0<>WGY=-F[DFER.$>_
M;N6D)>7U '57./$DP$@-U_O;FKT]'S#4IPM\4-:ZDPY7DNC'67;^ON!JY^HS
ML,,K1(1W>Q/R.U^!Q7I4W^C;GF%LTGT-#-ANJU3_ "C95U^G:Z."1X_ZA<NB
M-?1G\4'37O5CPO5:P=(=D7F$\ 9()&C_ *_*DZ^C'XX.FO>V=7ICUPR@!9B(
M,=&3H76)8(W#7OTYGN^<LK;S0KVY/@AO(/+OU0M-#KVY:-8GM8QTSW#X>5C!
M\]83YEI=E9.NO<K9\NW4VHTR8[<U.VX?VN0S1$_!S->$CS+2GG63KKW-%:Z9
M=<,8"Z3#P9",'0&O+!(X^O3F8[YRWC>:$]N#X):M^'ZJP.Y)MCWWN],=>5P^
M:SF'SUK&MHS^.#IKWKD&W>KE]PCJ[-M0N/8Z>(Q#YLKF!1.XT8_%!TU[VYK]
M'.N%SC,RE0:>(#YXB?F1M>L9WVA'?)FC8P^7SJQ8_P JW%CX&]^CYG._ZL0'
MSUE/F.E'*).JG<D.#\KM9T[+.\MQ3Y-K3JZI4:8&.]&LCW/=\.@"PU/,YQ\%
M<$ZO=#NF#P.'VUC8<1@J<=#&P?>X(1H-3VDDZEQ/>XG4KR+WM><VG,L9G+8J
MB! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M0S>C=+E5_IC</F._Z5,*686U[!@R\;-=&3M=&[UG34?/"F45YN@*K000OJ-;
M\/'U:0[9Y>=WVL0^J5:K+4G@YPM&+:8//7<!9,];22*303P.^2\#LX]Q'<5$
MQE:+8<BW=Y?(=Y;MMYS:&?I8NEE9W6[F,RH>R:":9W-*(#&TMD822YH)!'8L
MYAM%HEU?%] 8=IX*C!L3.2ULS!&YM^W=UG@OEYYB7Q@Z1AI^1R?)'I/%0NCF
M:QFZL"TC=FW'6*;>/Y2Q@]]@''Y1;]\9\:C"V5_;V[;D6CMK9]_A,X''SN]Y
MA;I]:89B)&?M'!#@WF=WGDL_4IX[*48H9V3^+[U6D)B=RL<.7PWCF!.OI*$0
MUV,W?EL=7N;>QER"B76'S22\'W")6MX,:_V&CA\KE<?@1,PTWY2CLY$UL=%:
MS^X'<'M@YK=C7TR3.):P>GB $.288KI=NG,Z2;DOMPE!W;0QI$MMP/<^PX%K
M?V@**Y2Z7H_TVMXB+!Y#;U6]2B>9@^T#+.97 !SS*3SZNTX^UHI0WNW=F[4V
ME"8-LX:GBF.:&O-2%D3WM'8'. YG?MB@WB @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @_/#J/T[S
M&Q=\?FM9G@N2Y&1EBC9B<YK3';G<R/Q&N;JUP/R@-?4OT?9;Z-70ZXCP1Q]D
M=C\B\S\LMI;KHF8SJ3F/;/:]K])-D7.GFQ<?M?(VH[=^N^::Q- '"'GGE=(6
MLYP'$-YM-2!KZ OA=]N8W&M;4B,1+]+\MVD[7;UTIG,Q]LY3A<3TA 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0." @(" @:(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("!H$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$$-WH\&U58/E"-Q/P$_]"F%+-+B&O=E:;8_E^*TZ^H<3\Y3*L<W3%5J(-#NK
M;YSU)C(7B.W XOA<[Y)U&A:=/2IB<*6KE _S'W+S%ONS-!]=XK-#\]7ZH9=$
MM?DL!E\0T/O5BR$_VYI#X]?07#L^-3$HFLPUVG-W:_/4JJ5=QLQLH?4RT<$C
M>YL[=-?06ZD*."T9A-JO5C$'&-):_(9EFK'UZ3=8R1V.=([2-H/VQ^!9SP=%
M<S#FVZFU=U3?E3-TZ6)CA)>U]$"&8>CQK9#2\^H #X57*^$?Q..W;FK3*VRG
MV,]CXW^W9ML\&O"1W-MGEYN'< 4,MEDXYL*TU=YX&QCFN<>:W,SWNHYYX$BQ
M&#IK\2&6XVSF+F"J!NSLC%'B^;G-4,CM5BXG4Z]CVZ_;H83S$]4IR6P9W$/;
M)V>\XUWO$;CZ?#=RR-']DF48;B3J3@HFE\E:^V,=KS5?H/IIDPWF'W+@L^TN
MQ%Z*R]O%\37:2M'[*-VCA\84H;5 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0>//,A_\ZMO_ ,!C
M?^V/7V/E/\GJ>WZGP/GO_D-#V?\ Y/8:^.??" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @("#E/4GK=3V7N&AL3;6!N;SZBY&(VXMNXQS(S!4!T
M\>U/)[$+">S7B?@0:?;O7[)0[MQ6R>J^R;NP<MN!QBV_=GL17\;<L-XF 6(
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MDZ NX:E!O-4%4 H*:^I U05U0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'#M]>8S';"
MZT;>Z49;#N-#/10.=N'W@-CKR6WOBC:^(L["]H'-S=Z#N'<@X=M[S&X_<O7K
M)=%<;AG/KXQE@2[@]X;R.L4XVNEC$/)KP<>37F[M4'<=4%4% 4#7U(&O>@J@
MIJ@:H.6]?>I&<Z7;+I;CV]7JV;UC,X[&/CNM>^(0W9>1[@(WL/,!\GCH@ZEJ
M@:H*ZH&J"FJ!KKV(*@_-0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MM<QD6&$=@CE9!6CDB;+*7#4/<W0!!W,=B"J @(" @(" @(" @(" @(" @("
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M .Q,IB,-JH2(" @(+4M>O8Y?'B9+R'F9SM#N4^D:C@@NH" @(" @("!H@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @UNXL;+F-OY;$UWMCGOT[%6*1^O(U\\3HP7:
M<= 3Q01+HCL/)=,>E>V=AY>S!<R6$KO@L6:G/X#W.FDD!9X@:[31X'$()^@(
M" @@_4?:>\MR5L;:V+NZ;:F>Q,SYX@866\?<$C.0PW('$%S!VM+7 M/%!S_"
M=&NHNYMX8'>?7#=5'-NVG,^WM[;^"J/IX]EQPT%J=TI+Y'M'R6]@*#NX'I[4
M%4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!".L&R\AU%Z9;FV1BK$-3
M(YRDZI7LV>;P6/<YIU?R NTX=P0;_:>(GP&UL'@K,C);.+Q]6E-+'KR.?6A9
M&YS==#H2W4:H-P@(" @YKU%V=U-RF6J[EZ9[U;@<E6JNIS8/*5A=PMIKG\XD
M>QI;)'*#P\1I/L\-$&BV!T>W57WR.JO5K<<.Y-]UJ;\;AJ^.KFGB\;6F^^^
MQQ+WOD['.?W(.S!!5 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
I! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>lg_svbsecurities-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_svbsecurities-4c.jpg
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M ,<  0 # 0 # 0$            '" D& P0% 0(! 0 # 0$! 0
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M9\C/I6-Y'%_B>U"4]Y/9X:B;C!\/3BG[7<_&UX::)P45-$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M(<UW8OSJ]+4M-;1I,/V7%EKDI%ZSK$\I>RN;J(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M/7[\SL0_*<_^'5CL?>E4=R]VOK4GPCYZ8Y^5*+_$,5I?W94N/WH];999IL1
M090]2WZ]LW_'_P#T8UH-O\N&5W?S;>M-G0#\Z<S_ !"D^.>HN^Y0F]L]ZWJ7
MJK?P2?[T_P"U*JH7D\F+5=^&5'WU_P!L5IXY,9/-8W$=YZK;#IH-BQVI\#,,
MEO%='!,T_=*6B9% )9QY'N)Y&>Z>T*#?#UY=9Y1"QQY_AX-(YS*N4<59<*GD
MA9)55D[B>5@=+*]Q.I.@U))*F\E=QE)FV&W^=T.X6'W*LQ>[4]O9>*![ZJ6@
MJ61-:VH82YSG1@ #O*X9,E9K/&.23AQ7B\3,3S:BYI\SLA_)M9\0]4-/>AJ,
MGNSZF,ZTS&M,^C+]0UG_ !VX?XAZH]W\R6FV'RH0#U@[>9YD^[HN>.XW<KI;
MA:J2+VJCI99XO$8^4EO,QI&HU&JE[3)6M-)GQ0-]BO;)K$3/!5V^X[?L8KOD
MS([;4VJX<C9?9:R)T$OAOUY7<KP#H=."GUM%N,*NU9K.DQH_+'8+YDM>VUX]
M;JBZ7)S'2-I*2-TTI8P:N/*P$Z!)M$1K)6LVG2(U=.W9K=D.:?S)O7 C_P!A
M/Y?K%X^-3SAT^GR?MEK9:&/CM5#'(TLD93Q->TC0AP8 01YEG9YM97E#*+?_
M /77G?Y9J_C"M#@^77U,KN?FV]:QO^7[_/YU]9;OW:A0M]X+'MGZO8N^JI=H
M*ZCM_:39FP1T=M;'5YO=F.^2Z20\T<$8]4U,P[VM/!C?A.\P*E;?!\2?1"#N
MMS&*ND<Y9KY)D]_R^[U%^R:X37.[53N::IJ'%SO,UH[&M'<UH '<KRM8K&D,
MY>\VG6>,I*PGIAWDSNCCN5NL7L%LF =#5W604;7M=V.:QVLA'GY-%PON<=><
MI&/9Y;\8ATEVZ+M[[92/JH*2WW,L!)IZ*L'BG3N F9$"?=7B-YCEUG898\I0
M7?+!>L9N<]FR"WSVRZTQTGI*J-T4K3Z'#L/<>Q2JVBT:P@VK-9TGA*R?3'U,
MW3#KK0X)G5<^KPNK>VGH:VH<7R6Z5YT9Z[N/@$GUA\#M'#4*%N=O%HZJ\UEM
M-W-)Z;<O[-#@0X @Z@]A\JIF@<1NMN%0[6X)=LTKF^,:*,-HZ4DCQZN4AD4?
M#4Z%Q'-IV-U*ZXL?7:(<<V6,=)LRES3-LEW!R"JR;*JY]=<ZIQ.KCI'$S7U8
MXF=C&-[&M"T%*12-(97)DM>=;.PV[Z>]U-SJ,73&[/R69Q+8[G72-I:=Y!T/
M(7>L_0][&E<LF>E)TF7;%M<F2-8C@[NMZ)M[:6!TT,=JK'M!T@@K='G3CP\6
M.-O\9<HWF/TNT]OR^A!F3XGDF%W:6QY5;)[3=H@'.IJEA:2T]CFGL<T]SFD@
MJ76T6C6$*]+4G2T:2L1TL]1=UQ"_4& 9?6OJL,N4C:6@FJ'%[K?42'2/E<>(
MA<[1KF]C??#0:ZPMSMXM'5'-8;/=32>FW+^S1-4S0B#B=RMML=W3Q2KQ3)82
MZFE^Z4M6S3QJ:H:/4FB)'OFZ\>YPX'@NF/)-+:PXYL5<M>F69N[FQN;[/W1\
M%\I755BD>107VG:XTDS=> <?]F_RL?Q\FHXJ]Q9JY(X<V:S[>V*>/+S1FNZ*
M(" @(" @(.WP/=W<7;6I;/B-]J*.G!!?0/=XU&_3CHZ"35GN@:^=<KXJWYPD
M8L]\?NRO%L?U=8WN)/3XUF4<>/9;*6QT\O,?8*N0\-&/<=8WGN8\\>YQ/!56
M;:S3C'&%WM]]6_"W"5FU!60@\,T451$^"9HDAE:62,<-0YKAH01Y"$)8][EX
MK)A&?Y'BCQHVUU\\$/G@YN:(^ZPM*TF.W56)9#+3HO-?*7*KHXB#ST57/05E
M/74SN2II963PO\CXW!S3]$),:OL3I.K9#$;]!E.+67)*9S70W:BIZUI'9]WC
M:\CW-=%F;5Z9F&QI;JK$^;[J\O8@S@ZW,I^6]W8[%$\.I\=M\-,6@ZZ3U.M0
M_P!WE<P>XKK9UTIKYL[W"^N33RA6I3E8("#3#HZQ 8QLQ;[A-&&UN1SS724]
MYB<1##KYN2,.'URH]W?7)ZFEV&/IQ:^:PBAK 04[Z_\ YL87^/UGQ+%9;'G*
MG[G[M5#U;*(0$&H72/1,HMA<9Y=-:EU94/[^+ZN4?^"H=U.N26HV4:883DHJ
M:(" @(""">KZC;5["Y&XZ?V62AG'I%7$W]QQ4O:3_P!D(.^C7#+,%7K," @F
M3I4F?#OWA_)_M):F-WUKJ.8%1MS\N4S9S_W5:H*@:D0$! 0$'BGABJ(9*>=@
MD@E:YDC'<0YKAH0?2%ZK::SK'.'B](O6:S&L2JYF6-RXO?ZFV.U--_.T<A^'
M \GE]T>]/G!7Z7LMU&XQ1?Q\?6_$>Y[&=GN+8YY<Z^FO]</6^"IRK$! 0$']
M1ODBD;+$XLD80YCVG1P<.(((\B^3$3&DOL3,3K'-8K;C-VY5;_9*QP%[HV@5
M TT\5G8)6^GL=Y_2L!W3M_T]^JON6Y>CT?@_7NQ=WC>8^B\_]E.?ICS_ !=T
MJ1IA 0$$.;T=/.&;RTWM-<UUKRJ!GAT=\IF@R<H)(CF9P$C!KV$AP[BI.'/;
M'ZD3<;6N7GPGS46W"Z6]W-OWS3NM#K[98]7-N=H#JAO(.]\0'BL]UNGG5KCW
M-+^.BBR[/)3PUCT(:EAE@D=#.QT4S#ROC>"US2.X@Z$*4AO/07*XVJH;5VNK
MGHJIOO9Z:1\,@T\CF$%?)B)YOL3,<DOX?U5[UX@Z-C<@=>J)F@-)>&"K:6CN
M\0Z2CAY)%&OM<=O#1+IO<M?'7UK,[;]<&'Y!-#;MP*!^-5LA#?E&%SJJWEQ.
MGK</$C'I#AYU!R;.T>[Q6>+N%;<+<%I+?<*&[44%QME1%66^I8):>JIWMDCD
M8[L<US=00?*% F)A:1,3&L/>7Q]4OZZ]QZBCH;+MC;YBP5X^5;R&G0NAC>64
M\9T[B\/>1^]:K/98^=E-W++II2/6J7M?@-PW-SJSX9;G&)UQFTJ:C3F$--&"
M^:73]ZP'0=YT5AER12LRJL.*<EHK#5[#,*QS ,>I,8Q:B90VNC8 UK0.>1^G
MK22OTU>]Q]\YW:L]>\WG66KQXZTKTU=,O+V]"YVR@O5#46JZTT=9;JQCH:FE
MG:'QR,>-"US3KP7V)F.,/DUB8TEEMU&[31[1[BU%GMP<<<N48N%E<\ZED$CB
MUT)/>8G@MU[VZ'O5]M\OQ*Z^++[K#\*^D<O!W'17GT^,[I?FG/+I:<JA= 8G
M$\HK:9KI87Z=FI ?']D%RWF/JIKY.VPR].3I\+-(%2M&RIZE-R)]R=UKQ6QS
M%]DM,CK59XP3R""F<6N>!Y9'\S]?(1Y%?[?'T4AEMWE^)DF?".3Z_2ULU3;L
MYT^:^Q&3$<?8RKN<?$"HE>[2&GU'<XASG_O6D=Z\[G-\.O#G+WL\'Q;\>4--
M:6DIJ"FAHZ.%E/20-$<$$31'&QC.#6M:.  5%,M-$:/:00=U,[16S<W;RXUD
M=,W\[+#3R5MFK&@"4B%I?)3DCB62-!'*>QVA4K;Y9I;T2A;O!&2DSXPR\5\R
M[4_ICSRHS_9ZQW&OD,UUMO/:;A(XZN?)2$!CW=^KHRQQ\^JH-S3IO,-5M,G7
MCB9Y\D3=?OS.Q#\IS_X=2-C[TH?<O=KZU)\(^>F.?E2B_P 0Q6E_=E2X_>CU
MMEEFFQ$!!E#U+?KUSC\H?^C&M!M_EPRN[^;;UILZ ?G1F?XA2?'/47?<H3>V
M>];U+UUOX)4?>G_:E54+R6+-;^&U/WU_VQ6GAC)YNNVLVXONZ^96_#K*>0S$
MR5=6\%T5+2,.LDKAYNP#X3B!WKEER1CKK+MAQ3DM%8:=;:;.8)M5:XK?C%L9
M[<&@55WG:V2MJ']A<^734#7L:W1H\BHLF:UYUF6GPX*8HTB$BKB[OAYI\SLA
M_)M9\0]>J>]#QD]V?4QG6F8UIIT9?J'L_P".W#_$/5'N_F2TVP^5'M6 4-/9
MN=<'Z[&_D>B^WF5WL_E^UG.X?-]CU>BDZ;YT?GMM=]HU?=Y\M\[?\WV-+51M
M((,DM_\ ]=>=_EFK^,*T6#Y<>ID]S\VWK6._R_?PC.?K+=^[4*#OO!8]L_5[
M%V*BHBI8):JH<(Z>%CI)9'=C6,!<2?, %5KN>#(G=O/ZW<S<&]Y?5O<8:N=T
M=OB<21%10DL@8->S1HU/[XDK1XJ=%8AD<^2<EYLL5T9['6S(S-NEE=*RKH:*
M<TV/T4S0Z)]3%H9*A[3J'",D-8#PYM3W!0MYFFOY866PV\6_/;V+YJI7@@AC
MJ&V7M.[F%U?)3,;F-JADGL5>UH$ID8"XT[W#B62Z<NA[#HY2<&:<=O0A[K;Q
MEKZ8Y,LWL=&]S'@M>TEKFG@01P(*OV7:B=*^>S9[L]:9J^4S7:RN=9ZZ1QYG
M.-*&^$YQ/'5T3F:^4ZJAW-.F\^EI]GEZ\<><<'!]>,U6S;"QPPEWLLM[C]I
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M=:[GJ:J0RR'N!/8!Y@. \R_3<6*N*D4KRA^&[C/;/DMDOSM.O]>C_#U%U<!
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ME/,WRLE:6N'T"H43IQ6,QK&C'#+L=K,1RB\8Q7M+:NTU<U'('<-?!>6AWH<
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M;E5U.VU_MTS^:FH+N33-^I\>GC<X#S:C54^^C\\>I?\ ;9GHF/2\77ACSJO
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MBGQ;<[<O5_R_,/\ :.X_%R1@K/Y:>]_]?\1]^ODBY:5B1 0$!!UN!89/EUT
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M(VB6.JOU61I&6-=S-IP3P+Y2.73N;J>Y<-QFC'7TI.UP3EOZ(YM36,9&P,8
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MM.W61Q](:/.H]]U2OI2L>QR6YQIZUY-FMA\.V9MCXK.PUV0530VXWVH:!42
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M=OD'#RK#]W[C\6?AT]V.?IG\'ZE_KO9_IZ_'R1^>T<(_;'XS]T</-)BSC9B
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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2(" @(" @(" @(" @(" @(/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>ft_svbsecurities-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ft_svbsecurities-4c.jpg
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M1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4
M9,     !_]L A  $ P,# P,$ P,$!@0#! 8'!00$!0<(!@8'!@8("@@)"0D)
M" H*# P,# P*# P-#0P,$1$1$1$4%!04%!04%!04 00%!0@'" \*"@\4#@X.
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!3_P  1" "(!Y\# 1$  A$! Q$!_\0 V0 !  ,! 0$! 0$
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M.OV@J)@/'H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB=E(9+2Q+C&HD>(:29F:32HTI=1T$9D:>!T32SX.G-8Y+VWW'4BD\U^BJN
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MYJ>EZ8#&;H
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M<<D*IVB7&CKPJ]#6=/\ BFL0><VQFVUF6/1]UWVA:_C=\[?>Y,%W;6/7;/\
M2J.HKD^093?%?&PQ$G2VS/B6DTFRT7X$J*GU"_/_ (^'%C[9FV/?+(C_ ,O<
M9\W9%M]W_MM_'V)KL5_:E[_KD?\ >N#'_D'S6>$^Y])_$/DR^-OO0JYW!BT[
MGR;G*)1QHET4\Z2"JK2ARIT(S+B-G%CG)L8LCG-E/8^:W&>W#YI=DNY6Y*S]
MZQYN]>--Q7508TI^9I/L6W$(;0:O9J5K,R+ZB'SV/R'--T:IB(^WH?89?Y7M
MHMG1;=-W96(B/Q0W9RTS)F3KO)(-,*$VYVCM*(-UXM)(+V5H9J^@:_G>:VW!
MH[;IC[H?/?Q?;7Y-UU:?#;$\?3/8LO<^^_(\2E$TK3+G_P!AL4Z2[0CUG^!!
M*X^^@^<\IV_5W$5Y6\9]WM?9?R#>?M]I=3YK_ACU\_957V$X/\XP*]S%MUFS
M^%N.G'^Q#U%I_=KJ@_J&]O\ ?]+=66UX6_-_J_I'%\IY3Y3U]AENF/BO^7_3
M_6>#ZMD;[V4F=CCZJ)>+Q<4C_9HHEPOK,M)_T)B+S[;UMMRQV<)]R?\ B>\I
M=?@GM^*/'M]WW)CNW_B/._KD?\JD9/DW_*M\)_!]#_)?^#=XV_C"DBQV4G%6
M,MAFHTLRUQY.GI;-)(4VX5.BIG0_IH/LOW-O7G#=VQ6/3WP_-?V-_P"UC<V]
METQ/HY4G[>A95URM&5[27*0ZHOF4;PK$]'1^,*0U1=/<LN/UU+V#YW#L_P!M
MYA;$?+.J8_\ 3/#U/L=QYC&\\HONGY[=,7>.JWCZW1V1_P 5)GYP=_(,"OY_
M]>/\8_&Y<_B7_$N_SG_MM<+>'$5,/(RZW(-*5&E%Q)'#2YT(=X>_[)G[Z>\7
MO)-[6.C=_I]\,S^3^6Z9_<X_]7CV7>[[D58=ONZ.26^'+5P990V\X@OA;9;(
MNU=,NC4LS_5,B&G=&+R_#==';/WSV1ZF%9=G\WW-EMW9$1/HB.<^,_C2&@TV
MBWHM'R-#))MAL'$-@N!=DI.@RKT\2/B8^"G-?.3J5^*M?6_68VV.,/1B/@II
MIZ.3SRYXOTT,?F2'^6D#1VGR>MF[WZGJ;EM5WVY.T0D.SK(9G&:):5.Q/ZF5
M2,C,9DQ=7M:T3;3L8/YPG-LG-P+>K;Q5O5*\&?S]5H-LXIR.T/LZ]C^+[737
M7IX]&KB-3:ZM/Q,C=Z-7PKUWUQ')LXY4L6NTYMV3E%@A6N]W%)DI3[C90^RD
MJ61G]HDN]LX?[4Q6PW1;EF.R5O/9-V&)[8HCO)?O7C-LQ^1MAE-Q:MDYJ4Y+
ML3\M:66'FI.DUL$M9DDG"<U*2D_M:N'$AUNL4S.J'&SS1$:9::W W<P3;?'Y
M-^R"[QJM-J5$M[+R%RY3I%\+;+9&9F9G0C532GI49$*=F*Z^:1"_DRVV1698
M5Y7[%>-S>8/[[2VC./;I,O(KP^5="9$HW#:1J/\ 7*><U$72:4J]PT]Q,68Z
M>ID[:V;\NKUKJWCYIMP-JMW%X;*LUL5B+#T*0<LVI"ITBVO]FMU32NW2V2R_
M&M$9MF6I/0*V+;VWV5KQ6LVYNLOI3@O^:SM%N;8$7NY-6/([ ZT2TW"2F.^A
MM"B,_P"F++4THJ'7BE23(^@R%6-=DTXQ*Y.B^*S28>>)1,<M_,U;8>TCJY&/
M,9);T69;*U+(R)YGMB0X9J-31+[1)+,S(V^)U(:U9G%\7.C%I$9?@Y5>I Q&
M^\U^8;^=G<?SE8/XE!&Q@^C][#W'UON]STH&.W'G;SI8G=<7W?8SN*EQ$/((
M\63'G)(]*)]N0B.I!&=2U)0VTO\ HOK&OM;HFRG<Q=Y9-M^KO;*VJWJPK='&
M(=XM]SBQ[OV*#NUG==0W(BR*$2R-"E:C;U?87T*+Z:D6=DQ7631IXLUM\54A
MSC[V8NWA,G;''KDS<K_=W6?FI1'"=1$BQW4OZ7%H,R)Q:T(3HK736M*E6SM<
M4ZM4\E7=YHTZ8YNQR/85-Q[;:XY/<&E,N91,)V&A94-4*&DVVW*'^R6IVGO3
M0^@QSN[ZW4[G6RLI97O4CR'_ *7KU_FW*_C\$6=Y\D>*KL?GGP_H^SFNVSN6
MU&X=NW?P@E0K==)B91NL$1)AWIH^U/A2FE_2;A$=:J)9'PH0\VV2+[=,O=UC
MG'=KM^TN5R32%RM\)LIPB)Q^SSG5DG@1&M]A1TK7AQ'6[^3UN=G]3U/189#:
M5#S1_H$S3^#1_P".,"QM_J0K;GZ<N)R<_H$L/\)N'\<='6Z^I+G:?3A?(JK;
MSCYKL?NFW>_C><Q8](5U<AWRV.FG\4J5"[-+S9G2AJ)QLEJ+W++WC7VUT78Z
M,3=6S9DU>MNC"-UL$S_'8^26&\Q3C.MDN3&>>;;D17*54V^A1D:5)/\  ?21
MF5#&9?CNMFDPUK,MM\5B69MV^;^_V?<Z/8-I3A9#8XZ&H<EMQE4AJ9<'7#JF
M.XRM"S(B-#:32HTFJO RI6[BVT3;6[@HY=W,7TLXPLOFV7-<Y=;FY<FT,W%2
M[6J8RT>IM#YR636E)GTI)52(Q#MOJ)]U]+CZ$*Y$8$&7MWDBY49I]:;T9)4Z
MVE9D7A&.!&HC$F\GXH\$6RCX9\4TYP+;;HVQ%]=CQ&6G2DV^BVVT)459;1'Q
M(B,1[:9ZD)=W$=.41Y#5H;VVR=QQ1(;1>E*6M1T(B*(P9F9GT$0DWGS1X(MC
M\D^+,&:/9;S%;V7R3A<%=UFS7G3M,8EM,I3;H"=#2C6^IM"*H22CU**JE4XF
M8NV4Q6150OU9LDT6+=-K.=N]6^3:;N=VG6R8VIF7$D7VWN-.MK*AI4E4PR,C
M$,9,$36/P3SBW$Q2:_>XW*_DUTVDWU/#<G;5;RN[CF.W>*XI)DU.2O\ L<ZI
M,TJ_&EV:5)4:32LS*I#K<6Q?CK'BXVUTX\E)\$DY]?TC8U^9"_C;XXV?RSXI
M-]\\>#0Y;!;;[C[.6"!)L<&VWN58H#D6_0XK3,QJ4J(A1.*6VE*G$FHZK0LZ
M*X]!\2J=:ZV^>/:N="R_''#C1D_:/=',>6O<J5@^8J=3BR)AQ,@M:C4MMDU&
M1)FQBI^QTN?"7XQOZ=)E>RX[<MM8YL_%ENPWZ9Y-J<PTAB7L-F<J*XEZ,_:C
M=9>;,E(6A:D*2I)EP,C(ZD8SL'U(:FX^G/@SYR(7NS6FTYLFZW&+!4[(MYM%
M*>;9-1)1(KIUJ*M*BWO(F9BBGL9B(FK7OWRQ#_*"V_\ 3&.N,_1/<TM=O>SQ
MSL8D]EFUMKR^R_V:WCLOQ+ZHY]H@X$U!-K=2:3,C)*TM&9ET)J?01BWM+M-]
M)[5+>6:K*QV.1R;[V8PO"H^V.17)FW7ZT.O?*2EN):1+B2'%/:&UK,B-Q"UK
M+1TZ:::T.G6ZQ3JU0YVF:-.F>:\=T]ZL)VNQF7>+C<XLB[=BL[59VG4.2)4B
MADA)(09J)&K[:^A)?30CK8\5U\T6LN:VR*L:<E^)W3*MX7\ZE)6N'CS$F5)F
M*KI7.N*%QT(,_:I27'5_T/U#1W5T193O9FSMFZ_5W/1,9#:>:_+S_.SMWYRO
M_P#$IPV,_P!'[F'M_K??[WI0,=N.)F7^*&0?FV9^06.K.<.;_EE@WD/_ $O7
MK_-N5_'X(U-Y\D>+(V/SSX?T>AHR6R\R^61^UQN8>([>'([4 CNO:+EJ0EDC
M-AXDU-RB>GH&SN*]/@PMM3J\?2]"_G.W'F%D[Z)_PC)I=Z6S6WT.I:+IC4LU
MQ;#-@OJ27:N,P765F1<$ZC2T9_051Y,3VNHF.QU1RZ8UY_\ ^1\%_A-Q_)QQ
MH[+G+,WW*&O+-_(]O_@S/Y,AGSS:4<GW#QZ\\MJ_Y\<__.3*_P C<1K9/H>J
M/<QL7_(]<^]->=?9Y<=UC>7&F3;6E34;)B8+2:5D9(CS*IXD==+2SKTZ/I,1
M[3+^F4N\P_KCUJ8Y>[[<LFYE<8R"\.D]=;C.DR)CY%I[1Y<-\UK,BX$:CXG0
M6,T1&*8A5P73=EB97WSW[@>#LEAVVA.D3]S<.[75)'\11HYFW'0?T+<UJ^ML
MA5V=G&;EO?9.$6J=P3:/FWLV/QY&!1;E:K#=TMW)IN)=X,(G2D-(-#BVE2D+
M2HT$G@M)*+H,A8ORX9GXOP5K,6:(^'EXH+NKM[O3A=PBY?NE#E1[G=7B2Q>'
MID::\X_%0G3J<C/.FE24DG3KIP+AT'27'?9=%+467'DMFMS=DG>N_2^7!G>+
M$HD6Y7Z-"9>N4&2E9M)>8=2Q./2TM!D39DMTN)? 5?:0S.E'4TRUNM/2UQS1
M_EWYEHN[K%VL.X:[5;,F0Z2X,)LE1XTN$IM)*2A,EUTUN(6E2EEK^RHJ%0C'
M6?!HXV\G&WW'4K%U*H=SAX;LG8\)<N,&#;K1N*Y(93;&+6EN.\^1N%VYOLLZ
M2-!-ZC[12*Z])5XB3:W7S=Z$6[LQQ;Z4@Y$?F7I9>O$DOY=\[=\ :S/3_:S'
M::"/];J]W#57VU'.\IKCP=[&NB?%GCE888D\Q\)J0VAUH_FU4.))23I'>,N!
MU(6]Q]-3VWU?O>CWR:S^7QNY;_X!CUEMTAYR<J)$7,E!(N!%\VH7_P#'>&ON
M?I,3:_5^]OS=#"V=P]OLAPUXDZ[K#<;BJ7]E$M'XR.L^G@AU*%?@&7COTW1+
M8RV:[9AY=8QN-?L(Q'.<!:0MMG*F8\242CHJ.[$D$;GPG^S;-QI?X/P;5UD7
M3%W<P+<DVVS;WMM\DV"?=O:Y_*I36BXY9*-]*CH1^!AFIE@O?Q7VRR^A1#-W
M=];Z=S5V=E+*]ZO_ /W!/_3K^[7_ )>)ME^KU(=_^GU^Y:&*_P S!_\ S)NO
M\3D""[ZWK3V_0_TRI3D0N]IM-VS95UGQX*78]O)HY3R&24:5R*Z=9E6E19WD
M3,115V,Q$S5M?[Y8A_E!;?\ IC'7&;HGN:NNWO51S72XL[ESRV7"?;DQ72MI
MMOLK2XVHBNL0CHI)F1\2$^VBF2/MV*VZFN*?MVJRY&;]8[5M[D;-TN<2"\N\
MFM#<E]ME2D^%9*I$M1&95(3[N)FZ*=R#971%LU[VI/OEB'^4%M_Z8QUQ1T3W
M-#7;WLT<^+K;^VF+O,K2XRY>4K;<09*2I*H;YD9&7 R,A=V?S3X*&^^2/%W.
M4NY89&V0LC5XEVQF>4B?VB);D=+Q$<MS34G#)71T#C<Q=KFCO:S;TXJNY-[V
MZ29*3<;*2B.I&3T0C(R_HA6I=Z5JMOH22/(8ELMR8KJ'X[J26T\THEH6D^@T
MJ34C(_H'"1^@#%'*I_.-W4_NG_XLD:6X^G;]NQE[7ZMWV[6UQFM1FOGB_0NQ
M^>X?Y&0+FT^?U*.]^GZW^<M6)V;.N5V+B5_9[:U755RCOEPU(,YCAH<09D9$
MMM1$M!^Q1$&>Z;<M8-O9%V&DL09M9\NVHO&4[771PTQ'GV?%MT/L9*(R^UBR
MF_W2%'3Z%&1\>C3LF+XBYE7Q=CF;9;MY*_T'1/SE._?I&7N_G:VS^FRERR/V
MN-S#Q';PY':@$=U[1<M2$LD9L/$FIN43T] O;BO3X,_;4ZO'TO0OYSMQYA9.
M^B?\(R:7>ELUM]#J6BZ8U+-<6PS8+ZDEVKC,%UE9D7!.HTM&?T%4>3$]KJ)C
ML88Y[L;7:]P,<R^,DVDW>WJC+=1P,Y-N=KJJ70>AYLB_<C3V=U;9AD[ZVET2
M^/E'A7'<;?Z[[B7W\=*@,S;Q)>(OQ?CKDLV4I(N@BTNNF@O9IX= ]W,Q;CTP
M\VL3?DFZ4BY\L:<M^28AGL*K;LF.[;7WD<-#L)PI#"OW1D\NA_M!QL[JQ-KO
M?6TF+D1Y5F)VY7,;+SF\))R1%1<<@EF1?BRD2U=BE)>[2J15!?M?H$FX^#'2
M/!'M?CRZI\7HH,AM "H.:1)*V#S0E$1EX>.=#X\2F,&0L;?ZD*VY^G*D^0!*
M?E6=+H6OQ%N+53C31(X5%G>\X5=CREKN^VEF_62Y6.2HT1[G%?A/*+I)$AM3
M:C+B7L5[QGQ-)JTKHK%'FML3F;G+[O9)AYLVY"A$4BP9!\*E=B1N)4AXDEQ4
ME*VT*U)(ZMF9IK7CLYK.K9P86"_I9/B\'HXC-L-<M/SY&0VU5D[/MOF)3&/#
M=E^R[37II^$8^BZM*-O7;2M>#SJYCMP$;Z[OPK=@R%W&WQ4,V.QZ",O%R''5
M*6ZE*N)$M:]*3/\ 6I)1T&O@LZ=G%B[C)U;_ (?!I+FGL+>*\L=MQAI?:-V5
M5FMR'/V11$$SJX^_344]O-<M?%>W-NG#3NHCG)G@>$YCM!?/O5CMNO"U7^4P
M3TV*T^\EHH,(R2AQ:36FAJ49:5%0SJ7$=[J^ZV^*3V.-G9;=9-8KQ4UNKA^7
M<JVZT>_8),?C6">:I%CDJ,UM.,$HC>@R2K1PD'0C)72DTJJ2NBQCNC-92>:K
MELNP7UMY-Z;4[D6C=;"+=F-HHWXE)M3X>K4J-,:(B=94="K0SJDZ?$DR5[1E
MY,<V74EKXLD7VUAYSV/#+;N%S+2\/O#CC5KN>271,M3!DETVFGI#RDI,R.AJ
MT::^RM1KS?-N*L=S%MLB_+2>^6K.:?82TWK;&'=,)MC<.Y8+',HD**BG:VE/
MQ/-$1<5*0=7DF=3/X^E2Q1V^:8NX]K0W.")LK;^E$N2G>HY<=6T&1R*R(R5R
M,7?<49J6T55O1*G^PXN-_M=1="4D)-WB_5'K1[/-^B?4V:,YIJ\WY_0OGGYD
MF_D5";#\\>*'/].[P5=R._H7?_/<S\C'$V[^?U*^R^GZVE!37F2M].9_<3:/
M=+[I(LUL=Q8BAS693S4A4R1!=)/;:%$^EM*B6EYLCT'T$8OX=O;?96O%G9]S
M=COI3@OIQ6TFZN.M7N8W9<DL#S1+3*EHCODTE95HHW"-32T^TCTJ2?N,5?CL
MFG&)6_@OBO"8>=V30<6MO,;&A;/.*?LK%]MR;*<9Q3B2E=HSVB6':J-2">U$
MA7'AT5+B>M;,SC^+N8UT1&7X.56E>>O<#Y7B5GV[A.D4J_O>/N2"/B4*$HC;
M2HO<X]11?UHQ3V=E9F[N7M[DI;%O>HO;[:7FOMF/L7+;N+<;78;VVU<&CB7:
M%!)]#J"-MQ3:Y3:RJ@RIJ21T%J_)BF?B[%3'BS1%;>4^E#MVMM][<6>9S+=B
M%*1)N3R(K=WD38TYUQYENJ$J7'>=41DA'PZJ<$\.@28\ED\+467'DMXWM7;D
M9^C<ODKN.5+<)=R=CVR-=BX5*=%NL1IXS(NC6I/:)+]BHA0QV:,]/MR:.3)K
MV]?MS.26TVZ_;&Y/9;O'1+M=POTZ-,C.%5#C+MO@I4D_K(PW<S&2)CN-G$3C
MF)[V4MT<0R;8G-<FP9I]SY)>8W8L/.%5$ZTNO)>94=*%K0XT1*,NA:%?K3XW
M\=T9+8EG9;)Q73;V2U9R%?HYR7\]G_%&!0WGS1X-#8_)/BU>*+18H_\ <$_]
M.O[M?^7C2V7ZO4R]_P#I]?N7AR]8MC,S97"Y4RRP)$EVW(4Z\[%9<<4>M7%2
ME),S,5L]TZYXK6WMCIQP6O L-CM3BGK7;(D%Y:="W(S#;*E)K6AFA)&95(5Y
MF9YK,6Q')@_GU_2-C7YD+^-OC4V?RSXLC??/'@T.6P6V^X^SE@@2;'!MM[E6
M* Y%OT.*TS,:E*B(43BEMI2IQ)J.JT+.BN/0?$JG6NMOGCVKG0LOQQPXT9/V
MCW1S'EKW*E8/F*G4XLB8<3(+6HU+;9-1D29L8J?L=+GPE^,;^G297LN.W+;6
M.;/Q9;L-^F>39G,3N.Q@NS5YO]NDH5.N[";;8WFU$9+>N"323C:BJ1Z&M;R3
MZ#TC/P8]5\0T]QDTXYE@O:';/?R\QGLUVAA2V624Y;7+I$GQ;>XHR[-QQLNW
M?:6I/V*FDM->%:D8U,N3''"YD8L>2>-CM;G;3\SS]C<R;<^'/N-FL#:W52IE
MSA3U1FG5(2M24-R7'*&9)U:4]!5/@0YQY,5:6]KO)BS4K=V-,<D>X/WCVYE8
M5->U7/%'],=*C^)5OFFIQJE>)Z'"=1^U3I+W"EN[*75[U[99*VZ>Y2/*Y_.@
MNG]VORABSN/I?<J[;ZT^MW^<C::5B.2P]Y\02N+'FR6CNZX_PJBW5LR4S*3I
M+X>UT\5?U0JUJL<[7)JC1+O=XM,ZX03E0NDN^<R,"]3S2<ZY%=IDDT%I2;LB
M.\XNA>PJJ/@)-S%,=$.UFN6OBFG/?A4R)EUBSYADSM5SAE;)3R2^%$R(M;B-
M9TX&MM?P^_LS]PCV=_";4N^L^*+FG=D-YL1W'P:TR6[I&9R&)%9CWJV/.(9?
M:E-()"U$A1D9MK,M2%%PIPZ2,BI9<4V7>A?PYK;[8X\50\Q7-?)P7([58=KI
MT"Z2X?:N9$IQ!2X>I6E+4?6VI)ZTT6I>A94X%6M2*Q@VVJ*W*VXW6F8BU-=Y
M;Q?L@Y4+Q?<G@MVR^W*UPI<RWM:M+*GI;"THHNJB,DF6HCXD=2$>*(C+$0ES
M3,X9F>=%7<AZIJ<9W$5;4H7<4KA'$0]7LU/$S)T$NAD>DU4KQ$V\YPK['E<Z
M&S_.)><FW"5BVZ4>TXY:GVW6(DEE#T?LK@VM.EN0Y(?<21&1+36B?BI[QYEV
ML1;6WBZQ;N9NI=2%J[X8;L/,PJ\7[-H-IB.>$==BWB,EEBX*?TJ)KL7&M*W5
M&O[*#-25'TETB##=DU1$+&:S'IF;J,T\A?S+U+R+L26=I^1K\70S)HG_ !<?
ML-7LU:>UT_1J%S>4TQXJ&QKKGP1;=*+-V/YH7,H?BJ5;"O*,DB$E-$OP9KIN
MOH:K0JI-3K)>Y21)C_W,5/11QECI9J^FKT$L6X^"9)86LFM&0P'K*ZWVQR52
M&VB:32IDZ2U)-M2?UR5D1E[1DSCNB:3#8MR6S%8EE6^\W69W#>=.*[6QH608
MK*E1K7;V93*R.0^HR0Z\VZVI*DH-1G12M2="=5.(O1MK8LK=PEGW;NZ<E+>,
M+!YU,*G9/M,U>K<TI^3B\Q-PDH;(U'X)Q"F7E:2/H0:D+4?L2E1]%1%M;Z7T
M[TV\LFZRO<A7)EO7C,?$_2[)KDS;;K;Y#SUD5+<2RS(C2E]JII"UF1=HEU2U
M:?UQ*^&M%"3=8IKJA%L\T:=,M#;D[QX+MCCLF^7JZQG92&U';[4R\A<N6\1?
M"AM"3,Z&="4NFE/28J8\5U\TA=R9K;(K,L1\HN-7?.]\UYQ,0I<6R>*NUSDT
M/LSF3TN-M(KQ^)2G%N$7N08TMS=%N.C*VELW9-7<]'!D-L
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MG\G\:['=\?V'B]'AGDNT[/M&JZM-/M\!#BR:+JI\V/J6Z7$V$V5]$,<N6/\
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MP(B(B(4+[YOFLM''CMLBD)2.$@
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M*4TC6\O\R_:Q=&G5J]-/=+Y[SCR7]_-LZ]&FOZ:\_7"(^A'_ /O_ /\ 3_\
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M84KQ#RG3+02ED5-5.D>Y<FNZKS%CZ=NE.1$E
M                5!OQL/$WQB62+*O;EE*RN2'4J:CID]IXE+:3(R4XW2G9
MBQAS=.O!6SX.K3C2BV8<<HD1B*2M9,-H:)5*5T))-:?@$$K$/V'CT
M                              4UM?R_P]L]PLHSYB^NW%[)?$ZX*XR6
M4L^*E%*.BR<4:J&6G[)"QDS:[8MIR5<6#1=-U>:Y176@
M                   $?SG%V\VPZ^8B[).&W>H3T%4I*"<4T3Z#1J))FFM*
M]%1W9=IF)<7VZK9CO1K97:>/LUASF(QKHN[MKFO3O%.,E'41O(;1ITDM?1V?
M34=Y<G4FJ/#BZ=M*K%$*<
M
M
M
M
M
M
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MH:,$*P
M
M
M
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MA!_@$=G"V92Y/BOB$#V!_P 6-W?\TIWY%T=W\X\7&/E/@WP*B\
M
M
M
M
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M_P DG/U!YDX6T>XOBNJC&P/^+&[O^:4[\BZ.K^<>+G'RGP;X%1>
M
M
M
M
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M;6;;PMK,97C,"<[<&%RG)AOOI2A>IU*$FFB>%"T"*Z[5*:RW3%$*W)Y9<'W
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M%(-:-/29:N@QU.2KFW%$5]*[1$F
M
M
M
M
I                                                   ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
